diff --git a/meta/CD012685StatsDataOnly.rm5 b/meta/CD012685StatsDataOnly.rm5 deleted file mode 100644 index 607e524..0000000 --- a/meta/CD012685StatsDataOnly.rm5 +++ /dev/null @@ -1,776 +0,0 @@ - - - -Exercise training for advanced lung cancer [Data only. When citing this record quote "Cochrane Database of Systematic Reviews 2019, Issue 2".] - - -Dr -Carolyn -J -Peddle-McIntyre -PhD -Postdoctoral Research Fellow -c.mcintyre@ecu.edu.au - - -+610423907620 -
-Exercise Medicine Research Institute -Edith Cowan University -270 Joondalup Drive - -Joondalup -6027 - -Australia -+610863043987 - - - -
- -
-
- - -Dr -Carolyn -J -Peddle-McIntyre -PhD -Postdoctoral Research Fellow -c.mcintyre@ecu.edu.au - - -+610423907620 -
-Exercise Medicine Research Institute -Edith Cowan University -270 Joondalup Drive - -Joondalup -6027 - -Australia -+610863043987 - - - -
- -
- -Dr -Favil - -Singh -PhD -Academic Researcher and Clinical exercise physiologist -f.singh@ecu.edu.au - - -+610405230214 -
-School of Medical and Health Sciences -Edith Cowan University -270 Joondalup Drive - -Joondalup -6027 - -Australia -+61863042369 - - - -
- -
- -Dr -Rajesh - -Thomas -MD -Respiratory Medicine Specialist -rajesh.thomas@health.wa.gov.au - - -+610400607009 -
-School of Medicine and Pharmacology -University of Western Australia -Hospital Avenue - -Perth - - -Australia -+610893461335 - - - -
- -
- -Prof -Robert -U -Newton -PhD -Co-Director, Exercise Medicine Research Institute -r.newton@ecu.edu.au - - -+61419907774 -
-Exercise Medicine Research Institute -Edith Cowan University -270 Joondalup Drive - -Joondalup -6027 - -Australia -+61863043443 - - - -
- -
- -Prof -Daniel -A -Galvo -PhD -Co-director, Edith Cowan University Health and wellness Institute -d.galvao@ecu.edu.au - - - -
-Exercise Medicine Research Institute -Edith Cowan University -270 Joondalup Drive - -Joondalup -6027 - -Australia -+61863043420 - - - -
- -
- -Dr -Vinicius - -Cavalheri -PhD -Lecturer -v_cavalheri@hotmail.com -vinicius.cavalher@curtin.edu.au - - -
-School of Physiotherapy and Exercise Science, Faculty of Health Sciences -Curtin University -Kent Street - -Perth -6102 -Western Australia -Australia -+61 8 9266 4043 - -+61 8 9266 3699 - -
- -
-
- - - - - - - - - - - - - - - - - - - - - - -
- - -Exercise training for advanced lung cancer - -

-Review question -

-

We looked at the effect of exercise training on fitness level, muscle strength, quality of life, shortness of breath, tiredness, feelings of anxiety and depression, and lung function in patients with advanced lung cancer.

-

-Background -

-

Patients with advanced lung cancer often have many symptoms and accompanying diseases. This, combined with side-effects of cancer treatment, leads patients to become less fit. This is concerning as fitness level is a measure of whole body health, and is critical in a patient's ability to participate in life activities and tolerate difficult treatments. Exercise training has been shown to improve fitness, muscle strength and quality of life in survivors of several types of cancers. However, the effect of exercise training on these outcomes in people with advanced lung cancer is not clear.

-

-Study characteristics -

-

We looked for all research studies (randomised controlled trials) published up to July 2018. We found six studies which included 221 participants, with an average age ranging from 59 to 70 years. These studies included different numbers of people, ranging from 20 to 111.

-

-Key results -

-

Our results showed that, compared to those who did not exercise, people with lung cancer who did exercise were fitter and had a better quality of life. We did not find any difference in muscle strength, shortness of breath, tiredness, feelings of anxiety and depression, or lung function. No serious harms were reported in people with lung cancer who exercised, but only three studies talked about harms.

-

-Quality of the evidence -

-

The results of this review are not clear, mainly because of the small number of studies found, the small numbers of people in those studies, and because the studies did not seem to have been carried out to a high standard.

-
-
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -Exercise training versus control - -Exercise capacity (6MWD) -Favours control -Control -Favours control -Favours exercise training - -Within-group difference (pre-intervention SD) - groups not balanced at baseline - - -Post-intervention mean (SD) - - -Within-group difference (pre-intervention SD) - - - -Disease-specific global health-related quality of life -Exercise training -Control -Favours control -Favours exercise training - -Within-group difference (pre-intervention SD) - EORTC-QLQ-C30 (Global) - - -Within-group difference (pre-intervention SD) - EORTC-QLQ-C30 (Global) - - -Within-group difference (SD) - CRDQ (Total score) - - - -Physical functioning component of health-related quality of life -Exercise training -Control -Favours control -Favours exercise training - -Within-group difference (pre-intervention SD) - EORTC (Physical Functioning) - groups not balanced at baseline - - -Within-group difference (pre-intervention SD) - EORTC (Physical Functioning) - - -Within-group difference (pre-intervention SD) - SF-36 (Physical Functioning) - - - -Dyspnoea -Exercise training -Control -Favours exercise training -Favours control - -Within-group difference (pre-intervention SD) - EORTC-QLQ-C30 Dyspnea (higher score = worse) - groups not balanced at baseline - - -Within-group difference (pre-intervention SD) - EORTC-QLQ-C30 Dyspnoea (higher score = worse) - - -Within-group difference (pre-intervention SD) - Medical Research Council scale (higher score = worse) - - -Within-group difference (pre-intervention SD) - Borg Scale (higher score = worse) - - -Within-group difference (SD) - Likert scale (higher score = worse) - - - -Fatigue -Exercise training -Control -Favours exercise training -Favours control - -Within-group difference (pre-intervention SD) - EORTC-QLQ-C30 Fatigue (higher score = worse) - - -Within-group difference (pre-intervention SD) - EORTC-QLQ-C30 Fatigue (higher score = worse) - - -Within-group difference (SD) - CRDQ (higher score = better) - reversed score - - - -Feelings of anxiety -Exercise training -Control -Favours exercise training -Favours control - -Within-group difference (pre-intervention SD) - HADS anxiety - - -Within-group difference (pre-intervention SD) - HADS anxiety - - - -Feelings of depression -Exercise training -Control -Favours exercise training -Favours control - -Within-group difference (pre-intervention SD) - HADS depression - - -Within-group difference (pre-intervention SD) - HADS depression - - - -Lung Function (FEV1) -Exercise training -Control -Favours control -Favours exercise training - -Within-group difference (pre-intervention SD) - FEV1 (% predicted) - - -Within-group difference (SD) - FEV1 (L) - - - - - -
- -

Forest plot of comparison: 1 Exercise training versus control, outcome: 1.1 Exercise capacity (6MWD).

- -iVBORw0KGgoAAAANSUhEUgAAA3YAAADwCAMAAAB7cgbnAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA -AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC -QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA -AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA -mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz -AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z -zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm -MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm -zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ -M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ -zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM -M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M -/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ -ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/ -/2b//5n//8z///9BjlLGAAAtVElEQVR42u19C3QcV5nm31JXVT9kqaskET9ij2Vp4MxwgFnhOLZk -xaSdh70OG4ZlgJ0ZNgmzJ8AAh7NncnJO2LMHWA6ThEl2lgnMDF4GT4BweAzZOBsggK0kSHJiJVZm -gezZBLXl2NhKYqlKstUqdVe3e++tW1Vd1VXdXf1Qq1v5v8TqW7f++9//3rr/fVV9VQEREAhEY9GG -VYBAoNshEOh2CAQC3Q6BQLdDIBCVItikdsXpn9EalfQk1QKlozXquwIrGc4ZqfYk65pJxfV0366e -d5aoKyIx3vYPd1C7pCS0h8i/5dZqoz7LqIRbp4zNO9qNjtbcfN+5p64W9b6/ffbY/q6C2EPXrnFF -3QzfK1OTrwW/3UPqEy4Pz/6O/mu90eFA+TK2H2qhMjb3JFOL8EI4Fu8gwY74WKfAd5KeLa7/i8ej -Iegh5yMalZTv4vnIJEDnfr6LnpcOChJPu0FdDjp5obNma5anw9LIKOlG7+L364YcCQuiwDKJREgm -un2NxgkZHj9Ba4CWUYbJyH7+oEprICIcMUSkENAYfgQ+sJH8k2RSS3fJtGrCYIV1eXpEKtTQ1TQ4 -MV9QRt5dxnArlbG53a5LSC/tUZ/dpYG267lbdoY7dsbyJ4ULsLT7tQ279abeN9Xx6u590LVzquPd -VCb7/HAyzaYlRC62Mxre2VWrNRl4mVk1Fb1H1/aZS8NqimUyv0jydtrXIKhh+DqdS/ft7Ijs3A77 -fnY8maLPQGQTwx83ZV4htgPQ+tDrZPvOezqmdpCYJy/lw7r89p1Tyd1dpq6mgauM6WTq/a1cxuZ1 -uzgZ0paDncSpQmQF2g38EJyeBttibVqCK7Al+y961ApMbxpVYQgSTGZmzi73QUicJudqxDBIwPJK -DAJxNzjDEQuMhsFBoX0NgjjUOyyyGkgQE1W4qxOy5HhuE+RMGSkfBL1tDjJL387lw7p8GhIcGc8/ -xHQ1DcShHr2MHzLL2NUJx6ot4zAr48palrE93JxO1wejMzMgvutc4tFtE1MvrbTH//cnt338/r5z -2T6YIWdn+oD0c12JoU2f6aIVug/0bu8slRmYpif7ts0wUXLi1zT6GT1pDbiw7dT99PfGLNF2/anC -TM7m7WtkPf1q4NUtvxqAmfZtP/gBPJM99sXHnjr+e8Sqs9Q4XWIG5B/odhlVB4HfI6Jns7rVVliX -v45V46+ZrqZpC2YZf22W8Vz0qqrLuI2VsX0ty9jck8wknCNrJ+n7w7Hh70ttMEmn4uMAk+Z5efZf -B4f/DQ1NgMyKQ2SecukJgDxZe1GD8Db99ymQZTjnUZWTa7FU4CbSJzi9jP8ySuZXh+Dc77tk3gbt -9sPrmCjrd21hsohidRtwRK493GV82SXzVmcZ7eW6runK2Nxutx/eRqfkc+PXTswBDzcPQJhY3HuD -eT76gfZ7iccBnYgOzMbDROamfrAGcMMXgcT03wRCrdZExt+Q1XiU5NU/BSdcmRj2NRzBve2sBvp7 -4zT7VH+hhPwG/Mx+/DxM9ZJyGFbnw/ToJi0eobp64s00D8qXsadYGS86y2gv1/NFyti7ZmVsbrd7 -7sQlunjieOA4OPPC8tKpBYicuGw50MLkYvTZyzQ088LS9ucuERk1SWTM0+NbWeD0qaT6wmKt1lzs -DG+KvbBA8koeOmVpi0xczQKGfQ0HqRy9BgaTi889AwsT2wsnTvGN4Y+M2CPOHD+0eHLBHdbLEJlc -pLouEV3Ng3wZL9WjjFFWxsU1K2MAiT8IBI52CAS6HQKBQLdDINDtEAgEuh0CgW6HQCBKuN1kTuCE -Dg16Iw6JeLxoYrlD4IXopA9Jn4jH4yT/eLWKTHuIAj50rFCzTe1Y1Lt41eavdQo839HLMlaryHcS -ZD7OyzAZD7nOGyE1WkE1RuK95Lc3HrFZ4X19rEgtxws5YgeTjVEiRwd7BhV6woKQ0+pwfatuFuur -PI5nMr87Mvblp3974NTuqx0PFZZ4xnDz0uLlpev/W6a8pE/0AXznCL8JqlRk2tMHoxff8o1vHbGd -mpmhT3maR6/mi+gwutr8u65ZvPz0bxN6xv/j+svLFef7gPr5G2Db24/8aOOnnjQTFkjefPWM/2p8 -Y9O5FEBw8xsrRgR9wnVmxlPWiG3bf+RD5+9LHXr65CtU8MwDWY3Tn0SA3ve/dP7gq3NaY582Xcfl -cYx2GvwBjIweNlhqer+h6XymkD4E6P7JeGuMwwZwN0kTHl0xpQFiofAkZXzF4hYHzeC/GRw5iT+o -lbTnxOOQ0ZlVd/H7czJoYYEPqwZ/rmxhTHsIpHfDAS8R3R6dI6dz+dT65J8m/40YGYc9WQhl8p2H -jTAO7yW/nQYPjNZ+VIjp1doTDkmCwbj3h5/DNeTvNXDRORD08h8DOcxpJm8tHMoTlQQYGSTFeC/8 -d3qU3ZSD7q+wMxbPcO2w3spjc7t2GIyojLFkRnXvjnyGFqCXtGf6RJbFWxMusMSD4TG7titP7CHO -tfuUwtrSYp7/ZjavjlR3SXvUr4KmM6umOqb2byeNMJXco7PHnh9O+ihM3p4/BC//ZvboHLmuULpz -z2fqkz8H7w71GmHG+6ow3zCx9m9I1Yfh7jwPLHht9Av62YuXhkxen0/sOpnrgZ7cyYIXUFwM/Vbc -sSfCGXnE9zxxxToXoM+WZonxnxYiMrT3tmnpP2FnTJ7hGmK9lcfmds+cgN2Hoo6H6FcgcQbgCUiR -FkHfumLx1qb1rv/SCdjzufzajozkg6T5aHCaNTydg5ZwcNCUaVgpaY801DMsgcEeS4O6tXODzmmz -8eeKw26PROrdDZs9y+2dS/BwffKfFmDoHR2akXGu4nwnhrTM2J7xjDY0cTHPAwvBNHsrhcJBpQQV -npTgInD2NaZ+gU6oy8KMyVvTYPCMJRGEAfqcOUyMR3ZvhdCi8BZhB6c/OmjyDNcS66w8NrfbdeGz -J+DaLfaze0EiFo6MZ7XMBG13/0yPj+ttS+/kL0yRFO+xNVoJbiOtTuKMBkhkSdT1DoFASXveINX7 -BvnNwQc+QNpa7J1f7CBW6LrKUxLt9sjEEjds9ojvyJ5266wu/02PTE3ArpiRcaDifDkI7hV2fXpv -kIT0nGkd04rcZVbk3gqva2JAk0Njp61j4800Umho74RErqOex7B+eQ2cO7mre+I2SKZ2Jch4sJCe -UWc+uKzPxCyOxRpinZXHfgNBuuHClEGXHgd9jjZBeWoAH98b2/tpY+B28NakhQsfImWaAGNGJ8uQ -IEJ53pnBf7M4cnK5AnOB9ITFrNJgGT7ySgWlMeyh+L/wiGdxLT4e4/LVKX9pYXYKGHmrgPflK98g -mcIH4RtkfGu38cBuL19dxQ367rA47F6OyqowcY1m5hGwZyAln1zOGXVGx+t+VZrmcsy6t625262z -8th8KBRXpVly3cf1DrunR1+WDlBu27fhWriVLUEcvLVQXJL+kJQiALM9bBtpCo6RDvvm7fm5gc5/ -szhy4kA52ttze7/MJlgDs/EIaXlv7fdfGNMeej0OwJznXEW3h/Z3bfC2/nrlHyZVFyTKwc378pXv -RTKaXSQGD5PKy/PAvgcD22wT0cr6aB720zlZwSa5OPxcJBc0eWvHYKrP2nOP8pq4l4eQMBvWWYOp -12Bi8nZ6xuQZrvEscz2Vx+Z2v5yMcbHJ38HXx7fCsYmlJ+gOyMkk7boTY3BCJzMV8NYun0zyN0w+ -DcrER9m0su2WZxUYfU5to+ObPvdm/LeIYHDkpKWT82WGO/i8vn/+wtL2k4uwZ+JyBY3NtIfSr7Iv -elEYTXsmrobwiUvZeuXfcTzGX3phATx4X77y5SbgWQ64EzDxio0HRmqfMyvSxuvzh+lxGE+weUse -PfufVZTn9vcavDXl2VvawJSZC0bVKQUut22PvTBDRGEThId/qHcKBs9wTbG+yuOHbydv2DD0qznf -KoXw6Q03n/Ta92vsm1tbHsKPBzfc/GxtL0U6+U+Hy8r0/vHhlqmTdVKegA+Zt2yaveLf66AnsHk2 -d9HrzLteex2dyT+6r34Nsrn5mnT0wFxdZJoF5W399z9qgfIguxyxvhBvhRkVPgqNQKDbIRDodggE -ou4IYhUg3qQw7oR1rUHWONohEGs62ili/q8r2h4BIOZ/rPOWHA2Y/yqGYYShG3Qug1jcrAJbSsiX -zsfzvKWMBUVvBSDa9bgFPWvT07x8KUSHuAIetVlYcvf1yJsuFhimiK6y2+vDWW5LVgHc9l67Sabh -UZZz5ZtBYYOtwu8Uh+PmG4xSUtCHfJl8PM+LNkWipwJbSzf1iD7y9TbP0qI4xfUCuryusOSF18Pu -wrqE6NJqd2+7rOhdv6LSTC03XvGJQvyvCuWLYrRObmd0eqLVv9GqNy9cYaeveDWgKq+QV0JF9Ih3 -C4ol5as1sNjgZCgoPzUokswr+4o7KYeji0VKJvoxzJZK9FOOJkCxtl7xfbu1uM/X5n0RWM9mdXB6 -hyeWbCuOKabZHpQqG5KrIYvlBBWltHyFLdw9cVYU72Irhf2Bovh1lHKZe4cKi1zEMA9xpbgusVAp -TicbN8lUyrmUzz69ZohKhX2/MRFavXyKzUZd8WItteO9eqKTDsV1Lj/DVMTSl4WlLDTMs+we9aig -k6yy21mbBIrXOshnD10PVLwhI9YtH7Z5IPrUL9bJECu1o93bl4suh/AxcBqOJZrrNde8uWw5mccj -GrOlIrobg3vXy3WJV2UMrFRprUaI9tKszVwrX5VKfr9EqaLoYjn95TWt58lm19pl3Vbi2heL87pm -ZOW3ji6RqzSK31pSanM3Z+aVVWrRKWaBYZVoxZGugaOda9ovss0VswvWg8XWRWLJfYCK1lzl0xuC -vuWrWtsppQpbkH/Fq9Ki1ihioQViyZyVIjchi1WRV525LHAmRtQLq0D8qYPbIRo2Pa/kGrXE9Xyz -En9EBb2uOfyuyfXhJLO+fvcmWI63wgK1jlJ4PZt+tEMgEOh2CMSbYJKJQDQz1pBnh6MdAtEso52f -py+dUQ6SnicTz0b0MokMxfc4nfw1N5mseDLnk/OKv+eNXWLF8vfgu4nVZVxCysWMsyK8+XaF/Don -9U9x0et88e2ggHWpIN+uaSeZjsf8Cplf9itoMrfEkpqKkslK+JCDqVb2ya6ifDvv/N2750qVGZeQ -cjHj8mYoHjXmMqywpkSHqX74dh5KbbJN8nRmGSt+5HeGp9Sn0dfL7ZyEYnrBFSMXaxQrHIrEPMfU -3oo8KGm+ON+mpFhTJZTmeCueIr5vNRZTINZ+Gf1VWOVMPx/FaYk7rWVsLH+7fLH2S1X/0a6AUGx1 -56L9ZQ2uoahE9Xi8qqA48dzp2ZV0gSI4nhgurUCsbPbnfhZZLH261u5cLCyFx9gIBUUuY7pSnAnr -ulY2pUhAaIzbia5g8Qfb3V7nTaEsJ+ISNmkuNudRyvTlriVnVQ9HuYz15++lIrxKWcRFCplxrBTe -fLtKmX6++HZFdOAzmau/tlO8arrgHR82gXINs6qZYv7XmL6W4X2JHlPU2icw+VxLrUULPFysem3n -YsZBCb6daxQstkWjFL6KowTfzqW0FDcPURe3s1dxYcfntXYTzRc4KGIla6PqLp+/RJWT/kqLi341 -K6vcLIvP9UrlLHpL+ODbuRl/6whda29CW7G9IqX4NlJxtnkR/msFS/siR/4WGJWT/kq/waA8R81F -kasD306pRLh8zoaEL75djYw/RBWjXZ5bpYcU2/smGZfLjGLUr/wsVMxvsnsw8ZxySukbd05+l28a -WzGeWPm2WyBXLP86Z+wtVbzUxfl2rpzLMAMr5Nvh2m510NAPbSETD9aktus150e+3apOMlcLyMRr -rN81uT6cZDbK7yraIEHUpbLrIYVXrYVHOwQCgW6HQLwJJpkIRFNhrah3ONohEGs52hV/rtmLYecI -e/Hs7E/ol+fZFeYI7s/G+eDbKSW+21AqXZEiu7/zVrOh+VQeYsVYhl58O1OF68t6Lr5dca3eT/+J -xWSRb9dck0xPnp3teU0/PLsCFHDH/PHtbFJKJYYX8Qv3d95qNtSWSClfilJ8O0OF68t6Lr5dCa0u -vp1LadN+3664KT+qRE29qHe2C1Cp24k2t7F93U4B+3c+mRCIJb6kqHjdnqvqma3qn2z2yVcRyyZX -xDKCtXRVVV+1cpOQklpFPwWu0qSGobhhFd0uXyvqXbD4EGDR6hRnZDlSjetRFD88O7+Tv7r3O/6K -UHdD6/BFlSJfVV7lAiNWye1c97TtI4f1zgHROe/xQXap8M5sAd9O8fFMZhWPDvq3qugc0/EkZm1P -L1byfbuideatVfR4L4ziZxKn1P6MN6KU25mepFQ2mfbtSf57UtGdSKxsbVe1VUo1D25UurarsI48 -v2/nY4C3f99O8XjsudhM3HVq3X7mrqsJ3M7ehiuctpXf/2wVFFsv1f+7mTWuVX2oKL0iFf0sqkvI -IqpHm7NT83xNluL5K1bUJivrK13Ms1XqapVa/URZG2sqSa0UKYuvGWZ5WUS91naOGUUB/c6MKrhM -Zb94V9kX6Krk21X8mTvf37fz/fG4Onzfzh/fzpmmBN+u2IfwSlRWMVlEvVAD385/60ae3VoA+XYt -MslcreUJ8uzWxu+aXB9OMmvde/Api17XQCDfbj2OdggEAt0OgUC3QyAQ6HYIBLodAoFuh0Ag0O0Q -CHQ7BAKBbodAoNshEAh0OwQC3Q6BQKDbIRDodggEuh0CsY6hjXV13BlsC0W6JHkt8g8giQqxrlCG -XS6/9N5MRpsjoe55FvMHSrD9K3/OodshEKvgdtoz78tkdz3hea67PcgFX9qEbodA1MvttMxVw8cz -82XTdgfbPvVPwYu4tkMgaoGsxr4SahdWXv3u68Truk33KvILr8/+l9OvtPGRnNgjN8jt4jrMo56w -7YT+cyQMWo4XcpMgM8kY3wXQIZnygpDTqOzB5h9Ae6I8H9ZACwt8tKeB+Y6RfKOTALGDfFh1noqS -SpY7BJ7UIa3lDv2qa5083zEJMY5UaXTMW+cxomsMeqO8ENE8y0YvlRbhOetIj7DyyGdPUtK43gjJ -VFclRwW+k4REQQj3gK1xtMa2SSwX2hZYmfnPs3Pz3cy3/P3Ov36+/fRvA0K4Kza5Ss7XnveumZk+ -GJ0xj3ZvtYJ9QIPy9Xyqbf+RD52/L3Xo6cmXZ0jcmQeyGneZlfG2l84ffHVOI7IXV964v8mvSJs2 -9vnJ17Od2Q3yvkSmcfl+L5OcPfklTRw8pfynac12ojdwLank7YvzwtCrAXHvPLcz92MSLe6UHzt9 -T+A/nghk5x887KlSnCa67tba/uy0/J4Dp2jZ/mzmlck3MvmykasKX/35q19iRzMzM996+qSWz4O5 -N80+9+czwmDqyY++8OqRwXlq3ealI48OLqTU62SFy2RmWDtodvTNwPwXgtE7XlxcWFl6nUSoVf5b -uryw8NDXuFB44dKXGzDJ7OSFTuBJvwiTpN87aPbKO4aDIMDIIKThvfAgjcluykG34bZ/Px2WRkaX -afC1of5mvzRL6WunoR2SqbmrINDAfNU0JwAZicZl7vCy/cQ7svTv45CYhjCp4ESChAnSMN1JIh7m -cnCvUKRPZ7qWDs9l4JxetsMXp8lldZbtM6lNGfNIvnFiwZYHxc1XdOsOX3wZ7oavpja9DHqfcDeM -TBPJ7gmZS6ktNM4ltkDu4fm6qMoFcrAl0YC1XWxnNLyzKw2kj9z3s3Qy9X7z+sI0uXBk0L0CGfi0 -EJGhvbdNSxsm3Q0vmwqCkGr+KxP+nEC/bSb80Ynzjc14B6nEdCAsRB3Tl5MX6N/jIEmQI/+Rn+P6 -RQdpF6lv0G6XHzrtrc/SFTr07ONm2Z51ly10yDzqGxI4Wx4Uk5eMwBTzzX7SJ+nZy/RPFqJcVGsh -t9slB9SUuLJj659u6AZj/ljxv563bIn1r8ylli/JuxrgdiokThuOo0JXJxyz3E4iHjUQphdmYjyy -eyuEFoW3CDs4fSk3DJKp4DJkm//KnH8xdQ/5mX1xaGtD81WX4R9h7/DPo9c68k3qtbeX/rlC6tKE -HgpAOPLDvlCfEPNSuHf475muCy/uEc2y7aGvP52dspftwtTQNjbYDU2cAVse+ghp3LVSD0GELkGX -IEQPeTg6QO0Z5g9f23o73puUpZ8G537T8aWNPXTko+s2f7/dV/Ff2vHWFW05IG+SGreTSfrBK2y1 -/rlMB4wYsbQbPHcy2T1xG5nA7EqQIW8hPaPOfHBZny1NgNV7m6mbGlIC/o79ZBqZbU9s74t3kN+3 -T3vlO8CuyAT9uZ3Vqj7mLGiJ1NzK0oq3zluZLlKUP7XKRmek0ml7HuSIDVjhlCCBLQ/7jk9seIpc -xt79I1P6G6CVyY+lxmkLSdxq6m41SCOXHkhlO/q3b95ozjpL/HZfteV7O7rn0isPKBdX9f65l9vJ -k0b0ITj3cn6WSxxLSqaWc4/kJft5aZqsO/SZ5Vut5HBdS1yRQOOz1C7nPqJY3uTCOZBlYlaA/pxj -JhrXYkDlhjnPSYRd17dKl+02tnujvwk8n4fNus/DFxbI9bs08uMFPYJbSicD7TBOww9DC4OTF8ms -8/cf27q5t7uIyLs2x051zKWXP6FclFbfILfbhaD/JtJbTuidYyq/O8LDBojymriXh7AwG9anIamX -YULT+8zI+EVZjXfQ4AY42eyXIcL39pMyhoTZATadahC6b0vSsU6AqZe88p2AqQFSzwIMTMFP6L0Y -Afpv1r1EzcCJWc97rIauMK9NkTBJ41m2sNAThu/rt4Ky8LqezMzDZt34Ep3aiPAruk9GTpHrLA3P -QxgGBoCDlsfcHUtqZu6t27dufJdZYvrnlo1btp/qOKsGbuCkRpnieEolDqOks+tTA8IlUDv5pBoD -YSeM6tEQG/xXWe3OtIUWQOu8AsIZCXrIBDOW7NAnJD1LORDmOSI79rkXm/0jFT2qFlgJ0HLkQpca -mK+gL6lGoTOVS2WcDZlWsrxNo/GyKAS4sxKJ0e75O+BHd4HauwRdK+EFL51MV+9yuo1cNZJmdkCj -1y9fNqp58j0ZCC/qQW6EXk1Z5NtoHuPpfPaGdaEh/YfE0GsaIdeyS6X2sObR9PD1xZ/JA9l0ToN2 -rr2BT4QVc7uSkDfre3/l0Zm+IAGiedphCW/pSar1UdRibrfmCxz/O1SquOJLLhyWsa03EXgIFL2j -E31ypC560O1Wze0QCHS71dpSQSAQ6HYIBLodAuEFpUl0/KgVyoJuh0DgaIdArH8E7cOimP/rDPkd -V0VXGoV9ad6IVkQ69HqL2IQLZGhipSBVPpGh1P1Bey+9DgNLWaPnp+A2L2LV3a5miF6OaG+8ot6Y -i4lYIW89RfTSH7GkiBFiP6Jdrqg1+v/odRUtXZplcde8OsQybsfGBb3xsbYpWkE6DrDhxziRH0j0 -I8WSN12Bhc3hQ4FyjdnZ2lm6Qqeq0SEsbQqga9Wpi61HJ/Wm0REsloKNC+aQkQ8y/ys4kR+njBmf -46qItvmnYs4ZSziPbQJper6Z1mNSKLp7mJKVRnXlva6ENTjYIRoyyVT89W2iUmrYET1nZ6LzVyzT -kTpmgopnXnYRa40mlhjwRcV1XixeCDBHbgRidd1ONFuoUt4TlbrPhWuYQJZOwnyocJ1ZXqPHDhEC -sXpbKmL5Bl3BWsuj7SrVOJgjkbdDeOsVK1Gct1rB5rG6veWbV0ewvK+4GrjivawSbYsne9DLQcQK -vFTxSlRkGBKrWiDjkIZogtFOtO622dZDRtCYsTkXSrYj27a+93qqSGZ0o8PKIb+8M7Jzj0+m4qLb -/KX0FndEy2CWDh3S3yxEdP1UrESEmnVAbUnrY4Wv2ghUX0XVnq5PJlXnpuB98Dp7XeFOdzXVq1j3 -XqvXUfvVrYMV/mqj4ofDFIJGeJ3/ObSyKt6MaORCqDmuSj2s8KciWH+1YoOvpli5WnS9dei6rWQF -PgqNWC+DVQvVRhBrCVF9A6vDCKG8GScf6HaImmdlNQ12687n/NQGTjIROMVseG3YbiAonr2PeR+u -ol7J9ViV4roJZiMBeOXqyZUzU/rk1+HjXY2aaZoUKrxv57M2AmIZTy3kvlbldl7811LPnBThyjl0 -lU2DXFVEs8JrkqkoivWjGI9GK2a0YgxPxlkoOGOkdeoiZ+wnTb1KUW9HT0G82bZUPMjYBdQ7cD4N -4CblFegSHaw8/X87663UbLPM1Lk0b4+9tAGHO0QLuF2ZUcdBYHVw60Tfw5Qnc04s4V4Fz3aW5dch -EK3mdopXSy+7jHQF3cdK1Vs/rney+F4eIxCtsbYTCdiPz8cdjQR6UxfFIqcKD7yWlPmVoU+fcaRx -nwSkzK1ryK2adbDoSOGr4YuK646pUnLUcW+MKqLHEKZUNVt1ncMBr4mhf9Gytu+EbHYqHK2vdm/F -BrYUkfD35ZOglyvZ6WlW0y3KsAMnKc8xRDoS2Rh7YL1dTAGPu3CK9U7LAmMq4dfhXLPJUbtTDI2u -pvaSqvaMekv4y7bNY/AwpoLmVNM8YRznJ4xWCtsZUTR2VkS7mGjXAKZeM6177mlEiYXGlBzj8lZY -wuhxzY+eMB8SITQJWgi0KB/V2EhF/sVjIZAEPsy+fKkd5I+AJdF1kFeJTFwXmozwkUlv7WMHeSEG -IQ0mvbSrPHdwjGnvoOeiPXAkaoRpHsSm/ZIubdghR4SozAZTljXTz/QJgmpq5iUqG4rFK1jbNTeQ -X7e+kJTTkWXgb4ZnBOg+mua786cCFyAZSYfZt4GDf9X1CYBuPn1Un6E9cryTjCxkbPnbC3BNKB0q -0sBvejQdUYF/Bm4i2jkjraW96yfaozfqB91KWuiGhSX5L5+iYd2K9kcgFv4/y8xKZse2xdSTIhvU -RnUNTL+OK7MLXUboQkeSNFThwhVYN25XDb8O0ZSLuzj1FTUM8jC8rsGTT8DKICRsnwxOSBDUpGnW -rIXBi+RUKgGDIXI0I40Y36G9VYLQNExrRbUrwxDcD5knIHWapbVp36+qLL8UB3IKOHUrv4uGFfrd -2mkJMok5dt6wI8PBSNiugenXcUYK7zVDpEQQTkjzxYreHsbLj1gT9I3OzJAf+R+5tq0zl18/NfU/ -Yd/H4f5gFvpIPPnX93GA1x9MzZ3VBxxyjv29/8Zp/RSVYEI08i9O6ck8tN95ceb8V7K3f8pL+1eF -BySmva+v72wWelfO3W+GDc2gSxt2XEdOvZo14qgA028e9dlDbX8N7Q6TWnu0Q6wrbAH+l2TtFIqR -wWRcBjmnx5r789Ly7A8v6aFx2fgru3YtAiTyYW/tmwP83xItXFdnEe1fN7SPjo6mAdJtO6ywodlh -x0T+lF2/J0habR1NMhHrClf+3/QN5Odbg2TpFBqAfjINHB+T+4yzYUkKsBA/1UtOpQZgKmWlHWft -+uRLMMB5a89x03Q599i7v2mlHVPl7XntH2aOGNLgWAQmtfMrMg2LESbwXH9vyG4Hp4EasvUCpn4v -rOyA7jF0O0RTIvLRTbQRXhxLAMyn+DRZDx2PbzLb5c9VLhllDf/BS78gi6sU976MlZbr0H/O3iSs -nPXWHl3aSHdkOsenrbSjXXnt1/JdTMV8jHswCtd3SL/YSsO7WZ7wlHopYrdjNMaLl1kvcJVdvxee -TwttxdwrgFsOCMQqQVpZxi0VBKKB6MwFryy242iHQDQJcG2HQKDbIRDodggEAt0OgUC3QyAQ6HYI -BLodAoFAt0Mg0O0QCHQ7BAKBbodAoNshEAh0OwQC3Q6BQNTB7eSyEQgEojLY+Xae768OrRRERJax -1hCImuB4/4rXi6Rd77vePYq1hkDUe5KpRTn6Lmo5ciAis5dOHwvxY2Y8jZiP8tF5gDGOD/VgFSIQ -lcL+LhXjXZptP/3njlQA7tvwmw2fC8z0jUJf8rH/+v2sEU8jrhyDDckT8J0NS099I4t1iEDUMtqx -91d/bBASAn2XNEwbr67+rP6aaSOe4CEO5IcAhNTY21NYhQhEpXBsqYxaP0JK/+E0+kNDxg+Lp845 -ngYtlm7bMId1iEDUvrabkEG+jf20ecQTDLBXUnPJ1yNLWIUIRB1Gu1y3LMoByK2EpfkACEucMdoZ -8fxr0l33cuLun0LoFyNqVxrrEIGofbTLpPh0BkCRhJXnrfdd5+P5jXBvjFt5AaDjRr5zEasQgahl -tEMgEA2B7XZ5vDoNePccgcDRDoFowbUdAoFAt0Mg0O0QCETj3K5ZmXZycxkuN4UKRMu4nZgjV5w+ -h5ljGy0CufxSnITlO+k+5xZrt7OqTc+4/r8q5Mb4Tv+pxFxxdQa2lNOx2dtiLSLwnbL+KGpcUAE6 -pLpU6RaPKor7qZ08ri6bKF71zjOiydxOVjOgXT1EQpnden/LDQDMn/wLgIGv0/sEeyzJam8akHRd -0cD+xUv++301U1yXgT3llAx5W9wpzL4W2E5VjY4udEmgqHUZZfbUrmK3z8pErAO361c52PC47m8T -/fTnsSsAH1t4COCKyIh3ZLC6k44LtK+NhQ4Yo4McFmJ6zJ0wH72TcvXiRn+s6kcEJF7U4+J7/yi+ -9xBohlxXCOQo5fWZ+rSQQP7KUSHCXKCf5yD+S4FJ3GmmM/v7GJWmduX13akRHfZj1TTd4BGSRJyq -a9iXkKRFgzwf7kgCt9zvGAyJzXomB0GOMAuMbJk96gEuPMZMiTGrI7zBUNSTh2huvZ8SBFZNPeED -tA68yqlFeaMqe8J3CqKlYjZMz/ZEOBIHKs+HxsDkOhqW6OWzxSFaz+1SvQCXb9CDP9YftfwPGRh7 -hAuOgRbUe1fSv15130IXk75yYTJpzANDs1fob+A+kLjDvO0OfOg+7h490MfflzW66FGqp3vhsNBN -DtsvgLjw5Ne2W/piX9mwTDQupPQ4YhNP/jw+S9sd1W+mA9OGaBKc+jp7oVewjnMXPtLFDAcIHtV0 -265cGGVFGOsTNTCfKZWHiY84HjDtDjKb2x4BUUiFbDc4mT1dz2nyjTY7YNvX0sI2MzcIXniSWHD5 -e6koe1x86edP7kl6l/Me/jXDa66RD0eXLRUPno9sI3HzGokj04T0P5Ds7l1IC/dalujlK4hDtJbb -ZV8h4xwLvl2f2r08ArdwcPQWuO4VU+aMTr1jIdpS9ZEiIemtJiHBx06bnDwdinT6IT3w4YR0xp7t -hzmQP0x+pyUIc3BH2tKX+ZM5Mv6YccwmuFdKhJh+Mx0U2JDX90UFMk9Yx2ekkb2msMkXtOLOZdOR -sJ0e/4pjQvvhGekYGDbmuYdg2RPMqOqK3Q7tVkhotrKPpABW5kBmua2MwB17vcv5UEJSWKKfhsGs -VT2fOc2K4z4/duuKxXW0KoCWxRmHaH7Yn1Lh9ZbOeAgsHD6/5bw0ue/8FtUg3OWpdywUp+MXlc2f -M7l6RgxTROLy6QzG3oQhR8cdzZ7EijPsMNSYwhMpPVenNZY+eVMqtOLQb8vWZpsxxu1IqWaejF+o -5zHqtNnGPbQVa/I9GUhyZtJ8fF4dOdB6tetS+imtN5PdM+pZTrOQAJM3ZjNDo04VRpwmpgMb5kyu -o/NysDhES452gfyOghxgjrj9LyXY1fZtvuiynkwZoU22drzznDyZ/ZFvNxQ6N8UnSMJUPpgfIyZk -Z5xuk2Yx/1g6PVfw1idxMdWh367asM2AIIO08BHjQBoHIxdLu7NYbfliMXt2Lb8W7SjMIGAd9epl -77oy97ixgZO7+DvwLuftVk77Aj+5nBea1fMx4ril1368ZHEdHfCKQ7SK2wVfsoJhtkBr33mQXvCj -7frR+KS3DrUftrO9BVgZgP6vE0lV/mt6uB2m2L0CYQdstydZ0UCKWMEj+Re6BI/2huxxwaPkzz3Q -r7rS5UHsssVzg92FchOazTabETs0uesRw+uSiwBHHe9RE/pg+7ihMwxHyQRvQpX1yQGz56AkXXDc -3eCOQj8Z/cZZh5GEl0jZM8dUYy2anVNt6y9HOTut2slyISo+zrxwAF4i+QyxuJAqCWQJ3amBeLBw -S9YjDtEqbsfvzXfVbHx7cmyQ/D09Pl143gElJTxq6MmkeI0skI53bvqG7rbc+z7LdjI1wdGkMzH+ -2gQLPt8lfCJ/Q2HhE5cj9jiejpbfENKKK53Dblt8Ymy6UC7YYdiWdizeFKXjquwC6Dfukguk+d/u -GNXnM0K7ETwrCZ98nhjXtVHfcWT2fFPluxyj3dlP8itnLYbiYuggKfvivs2PsrPHN7A68Sjnvdqd -Rk7RpREa4q/SjyLhm0k+L7K4DaKw/ziYXEcHvOIQrbK2kzdfNnZUtH/3SGW3jo980uultfHaby1R -m+INukOlbbhQUOpjtyZXp1gIdDsLv/y3xqtROvhKbhx3rgTaFzmPE3cert1AUVsSGvR6spy5n2gc -hm77jmexBHxdGqKObodAIBq9tkMgEOh2CAS6HQKBWDO3q/yTd8gfQyBscGypiHKgZynXdokz9/Ti -AOPBxKaCNGF27zq/j+76Bl4hIstV77oTm7SubC50RmJPfC2EK9xnRSCaerSj3LaljlSo0+Tb0Qel -0nx/YRqDUJb3o6Fyueyumh1GbVolXhwC0QxuR/l2K3OQ2Gfy7XQsZMDkm0k8H1YtNljczmcjElGd -EyeENZgP244Fi/DG+Gg0jjfGS1EQfjkmHNC5aro845uZPDJgfLsyvDgEopXdjvLtKJ42+Xb6cBML -gsk3S0bT8vstNhiFxWcTn07N6Zy4We6b8DhnHV+ZXbAIb4yPRuMWDc5ednbh3ltmKf/MkGd8M5NH -BoxvV4YXh0C0sttlGatuu2Ly7ejTihu1hPWtu6AsqT91JLe4a6FdEKYPLyckfgU+JVjHeX5eno9m -5+yFUzM6/8yQN/lmll5qUxleHALRylsqjBrXm14EJ/fO4pvJV2eh86JJs3MR3hgNTN68YhDextNu -whufthHezFA+vY1vZuf9efLiEIj1MNoxbtsb9FPKNt4YhcE3k5ZnI3/Mdlq8CG/MQ6T22P32Y6eW -QBE7DHkn38ywqQgvDoFYD25H+XbqXyn0Kfywg6Zj8s0OqlLgYQ/e3YQGK5MgGaw5frAT7Mdg8scM -PponDHmDb2az6WhZXhwC0cpuR/l04m8+QD9g3uvkkxt8s89KXHLBg3cX7ADlemHZYM29MXEr2I/B -5I8ZfDRPGPIG38xm0+1leXEIRCuv7Wrg260a8jbl4ebFIRAt63bV8u1WFaLm+jx6AS8OgWhpt0Mg -EI1e2yEQCHQ7BALdDoFANNzt8Pt2CET93U7MQW+YUgjw+3YIRIPcTufbyalwJ37fDoFolNtRvp0a -Bnkfft8OgWiU2zG+ndw1ht+3QyAa5XY6307etDyH37dDIFYTbr4djN2QelN/3w6BaORoZ3zfbgTe -3N+3QyAa6XaUbxfSoKcdv2+HQDTK7SiPrqNToA0Qv2+HQDRmbYfft0MeH6Lhbofft0MeH6LxbodA -IBq9tkMgEOh2CAS6HQKBQLdDINDtEAgEuh0CgW6HQCDQ7RAIdDsEAt0OgUCg2yEQ6wT/H8DCw2g0 -DFIEAAAAAElFTkSuQmCC - -
-
- - - -
diff --git a/meta/CTCAE_v5.0.xlsx b/meta/CTCAE_v5.0.xlsx deleted file mode 100644 index cd14d02..0000000 Binary files a/meta/CTCAE_v5.0.xlsx and /dev/null differ diff --git a/meta/PRISMA_2020_flow_diagram_new_SRs_v2.docx b/meta/PRISMA_2020_flow_diagram_new_SRs_v2.docx deleted file mode 100644 index c2f37fa..0000000 Binary files a/meta/PRISMA_2020_flow_diagram_new_SRs_v2.docx and /dev/null differ diff --git a/meta/PRISMA_2020_flow_diagram_updated_SRs_v2.docx b/meta/PRISMA_2020_flow_diagram_updated_SRs_v2.docx deleted file mode 100644 index 7da3004..0000000 Binary files a/meta/PRISMA_2020_flow_diagram_updated_SRs_v2.docx and /dev/null differ diff --git "a/meta/RevMan5.3_\344\275\277\347\224\250\346\214\207\345\215\227.pdf" "b/meta/RevMan5.3_\344\275\277\347\224\250\346\214\207\345\215\227.pdf" deleted file mode 100644 index 14dc28e..0000000 Binary files "a/meta/RevMan5.3_\344\275\277\347\224\250\346\214\207\345\215\227.pdf" and /dev/null differ diff --git a/meta/meta.qmd b/meta/meta.qmd deleted file mode 100644 index d433233..0000000 --- a/meta/meta.qmd +++ /dev/null @@ -1,212 +0,0 @@ -## 研究设计 - -Efficacy and Safety of the first line chemo-immunotherapy plus radiotherapy for ES-small cell lung cancer: A Systematic Review and Network Meta-analysis - -评价**免疫检查点抑制剂联合铂-依托泊苷加胸部放疗** 与**免疫检查点抑制剂联合铂-依托泊苷**治疗广泛期小细胞肺癌 (ES-SCLC) 的疗效和安全性。 - -### 纳入标准 Inclusion Criteria: - -Population: ES-CLC Patients ,18+ years 们将包括经组织学或细胞学证实的 SCLC 的成人(18 岁或以上)以及根据标准化诊断系统(例如退伍军人管理局肺研究组分期系统)的广泛分期疾病的临床证据;根据实体瘤反应评估标准 (RECIST) 1.1 版的可测量 ES-SCLC;东部肿瘤合作组 (ECOG) 体能状态评分为 0 或 1;或其他公认的分类(Horn 2018)。我们不会对患者的性别或种族有任何限制。 - -Intervention:至少有一个干预组是 chemo-immunotherapy + TRT\ -Control:chemo-immunotherapy 铂类+依托泊苷 +免疫抑制剂, - -anti PD‐1 (for example, nivolumab, pembrolizumab/lambrolizumab, pidilizumab, or tislelizumab) or anti PD‐L1 (for example, atezolizumab, avelumab, or durvalumab) plus platinum‐etoposide plus TRT - -主要结局 - -总生存期 (OS):从随机分组到全因死亡的时间 - -任何不良事件和严重不良事件 (SAE) 的总体发生率:根据美国国家癌症研究所不良事件通用术语标准 (NCI-CTCAE) (NCI-CTCAE 2010) 评估的严重程度,包括治疗相关死亡的百分比。我们将严重不良事件定义为导致以下情况的不良事件:死亡;危及生命;需要住院治疗或延长目前的住院时间;导致持续或严重丧失工作能力或严重干扰正常生活机能;或导致先天性异常或出生缺陷。不会导致死亡、不危及生命或不需要住院治疗的医疗事件,如果它们使参与者处于危险之中或需要医疗或手术干预以防止上述结果之一,则可能被视为严重不良事件。 - -次要结局 - -无进展生存期 (PFS):从随机分组到疾病进展或任何原因死亡日期的时间 - -客观缓解率 (ORR):根据实体瘤缓解评估标准 (RECIST) (Eisenhauer 2009) 或免疫相关 RECIST (Wolchok 2009) - -与健康相关的生活质量 (HRQoL),通过经过验证的量表衡量 - -反应持续时间:从第一次出现有记录的、客观的、确认的对治疗的反应到研究者确定的疾病进展时间(根据 RECIST)(Eisenhauer 2009),或任何原因死亡的时间,以先发生者为准。 - -我们将纳入随机对照试验 (RCT)。为了限制发表偏倚,如果未发表的在线数据和会议摘要提供足够的数据来分析和评估可能的偏倚,我们还将纳入它们 - -### 排除标准 - -- 患者接受了除了铂类和依托泊苷和免疫抑制剂PD-1、PD-L1和放射治疗以外的药物治疗的研究 - -- 如果没有脑转移, 患者接受了预防性脑部放疗的研究 - - -- 无对照组的单臂研究 - -- 未完成的论文 - -- 病例报告 - -### **Researcher Agenda** - -## 检索策略 - -我们在2018年7月7日检索了PubMed、Web of Science、Scopus、CENTRAL、Embase(通过Ovid)、 - -我们将使用 Cochrane 高灵敏度检索策略、敏感性和精度最大化版本(2008 revision)进行 MEDLINE 检索,如 Cochrane 干预系统评价手册(第 4.4.7)(Higgins 2011)中所述。 Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, Noel-Storr A, Paynter R, Rader T, Thomas J, Wieland LS. Chapter 4: Searching for and selecting studies \[last updated September 2024\]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/h - -### PRISMA - -### **数据提取和编码** - -1. 研究特征。 - -2. 计算效应大小所需的数据。 - -3. 研究质量或偏倚风险特征。 - -## meta分析 - -```{r} -#devtools::install_github("MathiasHarrer/dmetar") -library(dmetar) -``` - -## 附录 - - -广泛期小细胞肺癌 AND 化疗 AND 免疫治疗 AND 放疗 - - -### PubMed - -``` -#——————————————————广泛期小细胞肺癌——————————————————————# - -#1 extensive stage OR extensive disease OR extensive OR advanced - -#2 "small cell lung carcinoma"[MeSH] OR Small Cell Lung Carcinoma OR Carcinoma, Small Cell Lung OR Oat Cell Carcinoma of Lung OR Oat Cell Lung Cancer OR Small Cell Lung Cancer OR Small Cell Cancer of the Lung OR SCLC - - -#3 (small cell OR oat cell ) AND ("lung neoplasms"[MeSH] OR Lung Neoplasm OR Pulmonary Neoplasm OR Lung Cancer OR Pulmonary Cancer OR Cancer of the Lung) - -#4 #1 AND (#2 OR #3) OR ES-SCLC - - -#_____________化疗_________________________# - -#5 ("Drug Therapy"[MeSH Terms] OR Drug Therap* OR Chemotherap* OR Pharmacotherap* OR Therap*, Drug) - -#6 ("Antineoplastic Agents"[Mesh] OR "Antineoplastic Agent*" OR "Antitumor Agent*" OR "Anticancer Agent*" OR "Antineoplastic Drug*" OR "Antitumor Drug*" OR "Cancer Chemotherapy Agent*" OR "Antineoplastic*" OR "Chemotherapeutic Anticancer Agent*" OR "Cancer Chemotherapy Drug*") - - -#7 ("Cisplatin"[Mesh] OR "Cisplatin" OR "cis-Diamminedichloroplatinum" OR "cis Diamminedichloroplatinum" OR "cis-Diamminedichloroplatinum(II)" OR "cis-Dichlorodiammineplatinum(II)" OR "cis-Platinum" OR "Dichlorodiammineplatinum" OR "Platinum Diamminodichloride" OR "Diamminodichloride, Platinum" OR "Biocisplatinum" OR "Platidiam" OR "Platino" OR "Platinol" OR "NSC-119875") - - -#8 ("Carboplatin"[Mesh] OR "Carboplatin" OR "CBDCA" OR "cis-Diammine(cyclobutanedicarboxylato)platinum II" OR "Paraplatin" OR "Paraplatine" OR "NSC-241240" OR "NSC241240" OR "NSC 241240" OR "JM-8" OR "JM8" OR "JM 8" OR "Blastocarb" OR "Carbotec" OR "Carbosin" OR "Ercar" OR "Nealorin" OR "Neocarbo" OR "Platinwas" OR "Ribocarbo" OR "Carboplat") - -#9 ("Oxaliplatin"[Mesh] OR "Oxaliplatin" OR "1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II)" OR "L-OHP" OR "Cpd" OR "Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1)" OR "Oxalato-(1,2-cyclohexanediamine)platinum II" OR "Oxaliplatin, (SP-4-2-(1R-trans))-isomer" OR "Oxaliplatine" OR "1,2-Diaminocyclohexane Platinum Oxalate" OR "1,2 Diaminocyclohexane Platinum Oxalate" OR "Platinum(II)-1,2-cyclohexanediamine Oxalate" OR "Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II)" OR "ACT 078" OR "ACT-078" OR "ACT078" OR "Oxaliplatin, (SP-4-3-(cis))-isomer" OR "Eloxatine") - -#10 ("lobaplatin" [Supplementary Concept] OR "Lobaplatin" OR "1,2-diaminomethylcyclobutane-platinum(II) lactate" OR "D 19466" OR "D-19466") - -#11 ("Etoposide"[Mesh] OR "Etoposide" OR "Demethyl Epipodophyllotoxin Ethylidine Glucoside" OR "Eposide" OR "Vepesid" OR "Etoposide, alpha-D-Glucopyranosyl Isomer" OR "alpha-D-Glucopyranosyl Isomer Etoposide" OR "Etoposide, alpha D Glucopyranosyl Isomer" OR "Etoposide, (5S)-Isomer" OR "Etoposide, (5a alpha)-Isomer" OR "Etoposide, (5a alpha,9 alpha)-Isomer" OR "NSC-141540" OR "NSC141540" OR "NSC 141540" OR "VP 16-213" OR "VP 16213" OR "VP 16 213" OR "VP-16" OR "VP16" OR "VP 16" OR "Celltop" OR "Eposin" OR "Toposar" OR "Etoposide Teva" OR "Teva, Etoposide" OR "Eto-GRY" OR "Eto GRY" OR "Etoposide Pierre Fabre" OR "Etoposido Ferrer Farma" OR "Etopos" OR "Exitop" OR "Lastet" OR "Onkoposid" OR "Riboposid" OR "Vépéside-Sandoz" OR "Vépéside Sandoz" OR "Etomedac") - -#12 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 - - - -#______________免疫治疗_________________# - -#13 "Immunotherapy"[Mesh] OR immunotherap* OR chemoimmunotherap* - -#14 ("Immune Checkpoint Inhibitors"[Mesh] OR "Immune Checkpoint Inhibitors" OR "Checkpoint Inhibitors, Immune" OR "Immune Checkpoint Blockers" OR "Checkpoint Blockers, Immune" OR "Immune Checkpoint Inhibitor" OR "Checkpoint Inhibitor, Immune" OR "CTLA-4 Inhibitors" OR "CTLA 4 Inhibitors" OR "Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors" OR "Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors" OR "Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor" OR "Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor" OR "CTLA-4 Inhibitor" OR "CTLA 4 Inhibitor" OR "PD-1 Inhibitors" OR "PD 1 Inhibitors" OR "Programmed Cell Death Protein 1 Inhibitor" OR "Programmed Cell Death Protein 1 Inhibitors" OR "PD-1 Inhibitor" OR "Inhibitor, PD-1" OR "PD 1 Inhibitor" OR "Immune Checkpoint Blockade" OR "Checkpoint Blockade, Immune" OR "Immune Checkpoint Inhibition" OR "Checkpoint Inhibition, Immune" OR "PD-L1 Inhibitors" OR "PD L1 Inhibitors" OR "Programmed Death-Ligand 1 Inhibitors" OR "Programmed Death Ligand 1 Inhibitors" OR "PD-L1 Inhibitor" OR "PD L1 Inhibitor" OR "PD-1-PD-L1 Blockade" OR "Blockade, PD-1-PD-L1" OR "PD 1 PD L1 Blockade") - - -#15 ("Nivolumab"[Mesh] OR "Nivolumab" OR "MDX-1106" OR "MDX1106" OR "MDX 1106" OR "Opdivo" OR "BMS-936558" OR "BMS936558" OR "BMS 936558" OR "ONO-4538" OR "ONO4538" OR "ONO 4538") - -#16 "Ipilimumab"[Mesh] OR "Ipilimumab" OR "Anti-CTLA-4 MAb Ipilimumab" OR "Anti CTLA 4 MAb Ipilimumab" OR "Ipilimumab, Anti-CTLA-4 MAb" OR "MDX 010" OR "MDX-010" OR "MDX010" OR "MDX-CTLA-4" OR "MDX CTLA 4" OR "Yervoy" - -#17 "camrelizumab"[Supplementary Concept] OR "camrelizumab" OR "SHR-1210" OR "SHR 1210" OR "carrelizumab" - - -#18 "atezolizumab"[Supplementary Concept] OR "atezolizumab" OR "immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MDPL3280a heavy chain), disulfide with human monoclonal MDPL3280a kappa-chain, dimer" OR "anti-PDL1" OR "MPDL3280A" OR "MPDL-3280A" OR "Tecentriq" OR "RG7446" OR "RG-7446" - -#19 "pembrolizumab"[Supplementary Concept] OR "pembrolizumab" OR "MK-3475" OR "Keytruda" OR "lambrolizumab" OR "SCH-900475" - -#20 "pidilizumab"[Supplementary Concept] OR "pidilizumab" OR "CT-011" OR "CT 011" - -#21 "avelumab"[Supplementary Concept] OR "avelumab" OR "MSB0010718C" OR "MSB-0010718C" OR "bavencio" OR "MSB0010682" OR "MSB-0010682" - -#22 "durvalumab"[Supplementary Concept] OR "durvalumab" OR "MEDI4736" OR "MEDI-4736" OR "Imfinzi" - -#23 "tislelizumab"[Supplementary Concept] OR "tislelizumab" OR "BGB-A317" - -#24 "toripalimab"[Supplementary Concept] OR "toripalimab" - -#25 "Serplulimab" - -#26 "Adebrelimab" - - -#27 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 - -#____________________放疗__________________________________# - -#28 "Radiotherapy"[Mesh] OR Radiotherapy OR Radiation Therapy OR Targeted Radiotherap* OR Targeted Radiation Therap* OR radiation OR irradiation OR radio-chemotherapy OR chemoradiotherapy OR radiation treatment OR 3D Conformal Radiation Therapy OR 3D-CRT OR Intensity-Modulated Radiation Therapy OR IMRT OR Image-Guided Radiation Therapy OR IGRT OR Stereotactic Radiation Therapy OR SRT OR Stereotactic Radiosurgery OR SRS OR Stereotactic Body Radiation Therapy OR SBRT OR Volumetric Modulated Arc Therapy OR VMAT OR Adaptive Radiation Therapy OR ART - - -#__________________结果__________# - -#29 #4 AND #12 AND #27 AND #28 - -#30 randomized controlled trial[Publication Type] OR randomi?ed[Title/Abstract] OR placebo[Title/Abstract] OR drug therapy[MeSH Subheading] OR randomly[Title/Abstract] OR trial[Title/Abstract] OR group[Title/Abstract] - -#31 animals[MeSH Terms] NOT humans[MeSH Terms] -#32 #30 NOT 31 - -#33 #29 AND #32 - - -``` - - - - - - - - - - - -### Scopus - -``` -TITLE-ABS-KEY ((("extensive stage" OR "extensive disease" OR "extensive" OR "advanced") AND ("Small Cell Lung Carcinoma" OR "Carcinoma, Small Cell Lung" OR "Oat Cell Carcinoma of Lung" OR "Oat Cell Lung Cancer" OR "Small Cell Lung Cancer" OR "Small Cell Cancer of the Lung" OR "SCLC") ) OR "ES-SCLC") - -TITLE-ABS-KEY ( "Drug Therap*" OR "Chemotherap*" OR "Pharmacotherap*" OR "Therap*, Drug" OR "Antineoplastic Agent*" OR "Antitumor Agent*" OR "Anticancer Agent*" OR "Antineoplastic Drug*" OR "Antitumor Drug*" OR "Cancer Chemotherapy Agent*" OR "Antineoplastic*" OR "Chemotherapeutic Anticancer Agent*" OR "Cancer Chemotherapy Drug*" OR "Cisplatin" OR "cis-Diamminedichloroplatinum" OR "cis Diamminedichloroplatinum" OR "cis-Diamminedichloroplatinum(II)" OR "cis-Dichlorodiammineplatinum(II)" OR "cis-Platinum" OR "Dichlorodiammineplatinum" OR "Platinum Diamminodichloride" OR "Diamminodichloride, Platinum" OR "Biocisplatinum" OR "Platidiam" OR "Platino" OR "Platinol" OR "NSC-119875" OR "Carboplatin" OR "CBDCA" OR "cis-Diammine(cyclobutanedicarboxylato)platinum II" OR "Paraplatin" OR "Paraplatine" OR "NSC-241240" OR "NSC241240" OR "NSC 241240" OR "JM-8" OR "JM8" OR "JM 8" OR "Blastocarb" OR "Carbotec" OR "Carbosin" OR "Ercar" OR "Nealorin" OR "Neocarbo" OR "Platinwas" OR "Ribocarbo" OR "Carboplat" OR "Oxaliplatin" OR "1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II)" OR "L-OHP" OR "Cpd" OR "Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1)" OR "Oxalato-(1,2-cyclohexanediamine)platinum II" OR "Oxaliplatin, (SP-4-2-(1R-trans))-isomer" OR "Oxaliplatine" OR "1,2-Diaminocyclohexane Platinum Oxalate" OR "1,2 Diaminocyclohexane Platinum Oxalate" OR "Platinum(II)-1,2-cyclohexanediamine Oxalate" OR "Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II)" OR "ACT 078" OR "ACT-078" OR "ACT078" OR "Oxaliplatin, (SP-4-3-(cis))-isomer" OR "Eloxatine" OR "Lobaplatin" OR "1,2-diaminomethylcyclobutane-platinum(II) lactate" OR "D 19466" OR "D-19466" OR "Etoposide" OR "Demethyl Epipodophyllotoxin Ethylidine Glucoside" OR "Eposide" OR "Vepesid" OR "Etoposide, alpha-D-Glucopyranosyl Isomer" OR "alpha-D-Glucopyranosyl Isomer Etoposide" OR "Etoposide, alpha D Glucopyranosyl Isomer" OR "Etoposide, (5S)-Isomer" OR "Etoposide, (5a alpha)-Isomer" OR "Etoposide, (5a alpha,9 alpha)-Isomer" OR "NSC-141540" OR "NSC141540" OR "NSC 141540" OR "VP 16-213" OR "VP 16213" OR "VP 16 213" OR "VP-16" OR "VP16" OR "VP 16" OR "Celltop" OR "Eposin" OR "Toposar" OR "Etoposide Teva" OR "Teva, Etoposide" OR "Eto-GRY" OR "Eto GRY" OR "Etoposide Pierre Fabre" OR "Etoposido Ferrer Farma" OR "Etopos" OR "Exitop" OR "Lastet" OR "Onkoposid" OR "Riboposid" OR "Vépéside-Sandoz" OR "Vépéside Sandoz" OR "Etomedac") - -TITLE-ABS-KEY( "immunotherap*" OR "chemoimmunotherap*" OR "Immune Checkpoint Inhibitors" OR "Checkpoint Inhibitors, Immune" OR "Immune Checkpoint Blockers" OR "Checkpoint Blockers, Immune" OR "Immune Checkpoint Inhibitor" OR "Checkpoint Inhibitor, Immune" OR "CTLA-4 Inhibitors" OR "CTLA 4 Inhibitors" OR "Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors" OR "Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors" OR "Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor" OR "Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor" OR "CTLA-4 Inhibitor" OR "CTLA 4 Inhibitor" OR "PD-1 Inhibitors" OR "PD 1 Inhibitors" OR "Programmed Cell Death Protein 1 Inhibitor" OR "Programmed Cell Death Protein 1 Inhibitors" OR "PD-1 Inhibitor" OR "Inhibitor, PD-1" OR "PD 1 Inhibitor" OR "Immune Checkpoint Blockade" OR "Checkpoint Blockade, Immune" OR "Immune Checkpoint Inhibition" OR "Checkpoint Inhibition, Immune" OR "PD-L1 Inhibitors" OR "PD L1 Inhibitors" OR "Programmed Death-Ligand 1 Inhibitors" OR "Programmed Death Ligand 1 Inhibitors" OR "PD-L1 Inhibitor" OR "PD L1 Inhibitor" OR "PD-1-PD-L1 Blockade" OR "Blockade, PD-1-PD-L1" OR "PD 1 PD L1 Blockade" OR "Nivolumab" OR "MDX-1106" OR "MDX1106" OR "MDX 1106" OR "Opdivo" OR "BMS-936558" OR "BMS936558" OR "BMS 936558" OR "ONO-4538" OR "ONO4538" OR "ONO 4538" OR "Ipilimumab" OR "Anti-CTLA-4 MAb Ipilimumab" OR "Anti CTLA 4 MAb Ipilimumab" OR "Ipilimumab, Anti-CTLA-4 MAb" OR "MDX 010" OR "MDX-010" OR "MDX010" OR "MDX-CTLA-4" OR "MDX CTLA 4" OR "Yervoy" OR "camrelizumab" OR "SHR-1210" OR "SHR 1210" OR "carrelizumab" "atezolizumab" OR "immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MDPL3280a heavy chain), disulfide with human monoclonal MDPL3280a kappa-chain, dimer" OR "anti-PDL1" OR "MPDL3280A" OR "MPDL-3280A" OR "Tecentriq" OR "RG7446" OR "RG-7446" OR "pembrolizumab" OR "MK-3475" OR "Keytruda" OR "lambrolizumab" OR "SCH-900475" OR "pidilizumab" OR "CT-011" OR "CT 011" "avelumab" OR "MSB0010718C" OR "MSB-0010718C" OR "bavencio" OR "MSB0010682" OR "MSB-0010682" OR "durvalumab" OR "MEDI4736" OR "MEDI-4736" OR "Imfinzi" OR "tislelizumab" OR "BGB-A317" OR "toripalimab" OR "Serplulimab" OR "Adebrelimab" ) - -TITLE-ABS-KEY("Radiotherapy" OR "Radiation Therapy" OR "Targeted Radiotherap*" OR "Targeted Radiation Therap*" OR "radiation" OR "irradiation" OR "radio-chemotherapy" OR "chemoradiotherapy" OR "radiation treatment" OR "3D Conformal Radiation Therapy" OR "3D-CRT" OR "Intensity-Modulated Radiation Therapy" OR "IMRT" OR "Image-Guided Radiation Therapy" OR "IGRT" OR "Stereotactic Radiation Therapy" OR "SRT" OR "Stereotactic Radiosurgery" OR "SRS" OR "Stereotactic Body Radiation Therapy" OR "SBRT" OR "Volumetric Modulated Arc Therapy" OR "VMAT" OR "Adaptive Radiation Therapy" OR "ART") - -AND ALL( -"randomi?ed controlled trial" OR "randomi?ed" OR "placebo" OR "randomly" OR "trial" OR "group") - - - - - -``` - - - - -### ASCO - - -``` -extensive stage small cell lung cancer AND radiotherapy -extensive stage small cell lung cancer AND radiation -extensive disease small cell lung cancer AND radiation - - -``` - diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2022-safety-and-efficacy-of-shr-1316-combined-with-chemotherapy-and-sequential-chest-radiotherapy-as-first-line.pdf" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2022-safety-and-efficacy-of-shr-1316-combined-with-chemotherapy-and-sequential-chest-radiotherapy-as-first-line.pdf" deleted file mode 100644 index 8fd3c69..0000000 Binary files "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2022-safety-and-efficacy-of-shr-1316-combined-with-chemotherapy-and-sequential-chest-radiotherapy-as-first-line.pdf" and /dev/null differ diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2023-dares-a-phase-ii-trial-of-durvalumab-and-ablative-radiation-in-extensive-stage-small-cell-lung-cancer.pdf" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2023-dares-a-phase-ii-trial-of-durvalumab-and-ablative-radiation-in-extensive-stage-small-cell-lung-cancer.pdf" deleted file mode 100644 index 713fdba..0000000 Binary files "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2023-dares-a-phase-ii-trial-of-durvalumab-and-ablative-radiation-in-extensive-stage-small-cell-lung-cancer.pdf" and /dev/null differ diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2023-role-of-consolidative-thoracic-and-prophylactic-cranial-radiation-in-extensive-stage-small-cell-lung-cancer.pdf" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2023-role-of-consolidative-thoracic-and-prophylactic-cranial-radiation-in-extensive-stage-small-cell-lung-cancer.pdf" deleted file mode 100644 index e84ef86..0000000 Binary files "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2023-role-of-consolidative-thoracic-and-prophylactic-cranial-radiation-in-extensive-stage-small-cell-lung-cancer.pdf" and /dev/null differ diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2023-updated-safety-and-efficacy-results-of-shr-1316-combined-with-chemotherapy-and-sequential-chest-radiotherapy.pdf" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2023-updated-safety-and-efficacy-results-of-shr-1316-combined-with-chemotherapy-and-sequential-chest-radiotherapy.pdf" deleted file mode 100644 index 662f69d..0000000 Binary files "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2023-updated-safety-and-efficacy-results-of-shr-1316-combined-with-chemotherapy-and-sequential-chest-radiotherapy.pdf" and /dev/null differ diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2024-a-phase-ii-exploratory-trial-of-adebrelimab-in-combination-with-chemotherapy-and-concurrent-radiotherapy-as.pdf" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2024-a-phase-ii-exploratory-trial-of-adebrelimab-in-combination-with-chemotherapy-and-concurrent-radiotherapy-as.pdf" deleted file mode 100644 index f23e06d..0000000 Binary files "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2024-a-phase-ii-exploratory-trial-of-adebrelimab-in-combination-with-chemotherapy-and-concurrent-radiotherapy-as.pdf" and /dev/null differ diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2024-jcog2002-a-randomized-phase-iii-study-of-thoracic-radiotherapy-for-extensive-stage-small-cell-lung-cancer.pdf" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2024-jcog2002-a-randomized-phase-iii-study-of-thoracic-radiotherapy-for-extensive-stage-small-cell-lung-cancer.pdf" deleted file mode 100644 index cb67347..0000000 Binary files "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2024-jcog2002-a-randomized-phase-iii-study-of-thoracic-radiotherapy-for-extensive-stage-small-cell-lung-cancer.pdf" and /dev/null differ diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2024-overall-survival-of-adebrelimab-plus-chemotherapy-and-sequential-thoracic-radiotherapy-as-first-line.pdf" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2024-overall-survival-of-adebrelimab-plus-chemotherapy-and-sequential-thoracic-radiotherapy-as-first-line.pdf" deleted file mode 100644 index a7100c3..0000000 Binary files "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2024-overall-survival-of-adebrelimab-plus-chemotherapy-and-sequential-thoracic-radiotherapy-as-first-line.pdf" and /dev/null differ diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2024-real-world-outcomes-in-extensive-stage-small-cell-lung-cancer-(es-sclc)-treated-with-consolidative-thoracic.pdf" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2024-real-world-outcomes-in-extensive-stage-small-cell-lung-cancer-(es-sclc)-treated-with-consolidative-thoracic.pdf" deleted file mode 100644 index a8fd002..0000000 Binary files "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/et-al-2024-real-world-outcomes-in-extensive-stage-small-cell-lung-cancer-(es-sclc)-treated-with-consolidative-thoracic.pdf" and /dev/null differ diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/jeremic1999Role of Radiation Therapy in the Combined-Modality Treatment of Patients With Extensive Disease Small-Cell Lung Cancer A Randomized Study.pdf" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/jeremic1999Role of Radiation Therapy in the Combined-Modality Treatment of Patients With Extensive Disease Small-Cell Lung Cancer A Randomized Study.pdf" deleted file mode 100644 index d72859a..0000000 Binary files "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/ASCO/jeremic1999Role of Radiation Therapy in the Combined-Modality Treatment of Patients With Extensive Disease Small-Cell Lung Cancer A Randomized Study.pdf" and /dev/null differ diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/Cochrane 614.txt" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/Cochrane 614.txt" deleted file mode 100644 index 4644ce3..0000000 --- "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/Cochrane 614.txt" +++ /dev/null @@ -1,52 +0,0 @@ -Search Name: meta -Date Run: 18/10/2024 01:36:59 -Comment: - -ID Search Hits -#1 extensive stage OR extensive disease OR extensive OR advanced 96865 -#2 small cell 31026 -#3 oat cell 173 -#4 MeSH descriptor: [Lung Neoplasms] explode all trees 12253 -#5 Lung Neoplasm* OR Pulmonary Neoplasm* OR Lung Cancer* OR Pulmonary Cancer* OR lung malignan* OR Pulmonary malignan* OR Cancer of the Lung 38920 -#6 #4 OR #5 39206 -#7 (#2 OR #3 ) AND #6 20946 -#8 MeSH descriptor: [Small Cell Lung Carcinoma] explode all trees 644 -#9 Small Cell Lung Carcinoma OR Carcinoma, Small Cell Lung OR Oat Cell Carcinoma of Lung OR Oat Cell Lung Cancer OR Small Cell Lung Cancer OR Small Cell Cancer of the Lung OR SCLC 20747 -#10 #1 AND (#7 OR #8 OR #9) 10992 -#11 MeSH descriptor: [Drug Therapy] explode all trees 186545 -#12 Drug Therap* OR Chemotherap* OR Pharmacotherap* OR Therap*, Drug 648676 -#13 MeSH descriptor: [Antineoplastic Agents] explode all trees 19873 -#14 Antineoplastic Agent* OR Antitumor Agent* OR Anticancer Agent* OR Antineoplastic Drug* OR Antitumor Drug* OR Cancer Chemotherapy Agent* OR Antineoplastic* OR Chemotherapeutic Anticancer Agent* OR Cancer Chemotherapy Drug* 71935 -#15 MeSH descriptor: [Cisplatin] explode all trees 6421 -#16 "Cisplatin" OR "cis-Diamminedichloroplatinum" OR "cis Diamminedichloroplatinum" OR "cis-Diamminedichloroplatinum(II)" OR "cis-Dichlorodiammineplatinum(II)" OR "cis-Platinum" OR "Dichlorodiammineplatinum" OR "Platinum Diamminodichloride" OR "Diamminodichloride, Platinum" OR "Biocisplatinum" OR "Platidiam" OR "Platino" OR "Platinol" OR "NSC-119875" 17334 -#17 MeSH descriptor: [Carboplatin] explode all trees 3335 -#18 "Carboplatin" OR "CBDCA" OR "cis-Diammine(cyclobutanedicarboxylato)platinum II" OR "Paraplatin" OR "Paraplatine" OR "NSC-241240" OR "NSC241240" OR "NSC 241240" OR "JM-8" OR "JM8" OR "JM 8" OR "Blastocarb" OR "Carbotec" OR "Carbosin" OR "Ercar" OR "Nealorin" OR "Neocarbo" OR "Platinwas" OR "Ribocarbo" OR "Carboplat" 9287 -#19 MeSH descriptor: [Oxaliplatin] explode all trees 1827 -#20 "Oxaliplatin" OR "1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II)" OR "L-OHP" OR "Cpd" OR "Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1)" OR "Oxalato-(1,2-cyclohexanediamine)platinum II" OR "Oxaliplatin, (SP-4-2-(1R-trans))-isomer" OR "Oxaliplatine" OR "1,2-Diaminocyclohexane Platinum Oxalate" OR "1,2 Diaminocyclohexane Platinum Oxalate" OR "Platinum(II)-1,2-cyclohexanediamine Oxalate" OR "Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II)" OR "ACT 078" OR "ACT-078" OR "ACT078" OR "Oxaliplatin, (SP-4-3-(cis))-isomer" OR "Eloxatine" 6771 -#21 "Lobaplatin" OR "1,2-diaminomethylcyclobutane-platinum(II) lactate" OR "D 19466" OR "D-19466" 87 -#22 MeSH descriptor: [Etoposide] explode all trees 2163 -#23 "Etoposide" OR "Demethyl Epipodophyllotoxin Ethylidine Glucoside" OR "Eposide" OR "Vepesid" OR "Etoposide, alpha-D-Glucopyranosyl Isomer" OR "alpha-D-Glucopyranosyl Isomer Etoposide" OR "Etoposide, alpha D Glucopyranosyl Isomer" OR "Etoposide, (5S)-Isomer" OR "Etoposide, (5a alpha)-Isomer" OR "Etoposide, (5a alpha,9 alpha)-Isomer" OR "NSC-141540" OR "NSC141540" OR "NSC 141540" OR "VP 16-213" OR "VP 16213" OR "VP 16 213" OR "VP-16" OR "VP16" OR "VP 16" OR "Celltop" OR "Eposin" OR "Toposar" OR "Etoposide Teva" OR "Teva, Etoposide" OR "Eto-GRY" OR "Eto GRY" OR "Etoposide Pierre Fabre" OR "Etoposido Ferrer Farma" OR "Etopos" OR "Exitop" OR "Lastet" OR "Onkoposid" OR "Riboposid" OR "Vépéside-Sandoz" OR "Vépéside Sandoz" OR "Etomedac" 5006 -#24 #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 692433 -#25 MeSH descriptor: [Immunotherapy] explode all trees 12295 -#26 immunotherap* OR chemoimmunotherap* 16896 -#27 MeSH descriptor: [Immune Checkpoint Inhibitors] explode all trees 295 -#28 "Immune Checkpoint Inhibitors" OR "Checkpoint Inhibitors, Immune" OR "Immune Checkpoint Blockers" OR "Checkpoint Blockers, Immune" OR "Immune Checkpoint Inhibitor" OR "Checkpoint Inhibitor, Immune" OR "CTLA-4 Inhibitors" OR "CTLA 4 Inhibitors" OR "Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors" OR "Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors" OR "Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor" OR "Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor" OR "CTLA-4 Inhibitor" OR "CTLA 4 Inhibitor" OR "PD-1 Inhibitors" OR "PD 1 Inhibitors" OR "Programmed Cell Death Protein 1 Inhibitor" OR "Programmed Cell Death Protein 1 Inhibitors" OR "PD-1 Inhibitor" OR "Inhibitor, PD-1" OR "PD 1 Inhibitor" OR "Immune Checkpoint Blockade" OR "Checkpoint Blockade, Immune" OR "Immune Checkpoint Inhibition" OR "Checkpoint Inhibition, Immune" OR "PD-L1 Inhibitors" OR "PD L1 Inhibitors" OR "Programmed Death-Ligand 1 Inhibitors" OR "Programmed Death Ligand 1 Inhibitors" OR "PD-L1 Inhibitor" OR "PD L1 Inhibitor" OR "PD-1-PD-L1 Blockade" OR "Blockade, PD-1-PD-L1" OR "PD 1 PD L1 Blockade" 3093 -#29 MeSH descriptor: [Nivolumab] explode all trees 993 -#30 "Nivolumab" OR "MDX-1106" OR "MDX1106" OR "MDX 1106" OR "Opdivo" OR "BMS-936558" OR "BMS936558" OR "BMS 936558" OR "ONO-4538" OR "ONO4538" OR "ONO 4538" 3376 -#31 MeSH descriptor: [Ipilimumab] explode all trees 585 -#32 "Ipilimumab" OR "Anti-CTLA-4 MAb Ipilimumab" OR "Anti CTLA 4 MAb Ipilimumab" OR "Ipilimumab, Anti-CTLA-4 MAb" OR "MDX 010" OR "MDX-010" OR "MDX010" OR "MDX-CTLA-4" OR "MDX CTLA 4" OR "Yervoy" 2060 -#33 "camrelizumab" OR "SHR-1210" OR "SHR 1210" OR "carrelizumab" 343 -#34 "atezolizumab" OR "immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MDPL3280a heavy chain), disulfide with human monoclonal MDPL3280a kappa-chain, dimer" OR "anti-PDL1" OR "MPDL3280A" OR "MPDL-3280A" OR "Tecentriq" OR "RG7446" OR "RG-7446" 1705 -#35 "pembrolizumab" OR "MK-3475" OR "Keytruda" OR "lambrolizumab" OR "SCH-900475" 3671 -#36 "pidilizumab" OR "CT-011" OR "CT 011" 14 -#37 "avelumab" OR "MSB0010718C" OR "MSB-0010718C" OR "bavencio" OR "MSB0010682" OR "MSB-0010682" 464 -#38 "durvalumab" OR "MEDI4736" OR "MEDI-4736" OR "Imfinzi" 1426 -#39 "tislelizumab" OR "BGB-A317" 326 -#40 "toripalimab" 213 -#41 "Serplulimab" 46 -#42 "Adebrelimab" 31 -#43 #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 33855 -#44 MeSH descriptor: [Radiotherapy] explode all trees 10137 -#45 Radiotherapy OR Radiation Therapy OR Targeted Radiotherap* OR Targeted Radiation Therap* OR radiation OR irradiation OR radio-chemotherapy OR chemoradiotherapy OR radiation treatment OR 3D Conformal Radiation Therapy OR 3D-CRT OR Intensity-Modulated Radiation Therapy OR IMRT OR Image-Guided Radiation Therapy OR IGRT OR Stereotactic Radiation Therapy OR SRT OR Stereotactic Radiosurgery OR SRS OR Stereotactic Body Radiation Therapy OR SBRT OR Volumetric Modulated Arc Therapy OR VMAT OR Adaptive Radiation Therapy OR ART 90446 -#46 #44 OR #45 90545 -#47 #10 AND #24 AND #43 AND #46 614 diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/PubMedSearchHistory851.csv" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/PubMedSearchHistory851.csv" deleted file mode 100644 index 1a69e67..0000000 --- "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/PubMedSearchHistory851.csv" +++ /dev/null @@ -1,34 +0,0 @@ -Search number,Query,Sort By,Filters,Search Details,Results,Time -33,#29 AND #32,,,"(((((""extensive""[All Fields] OR ""extensively""[All Fields]) AND (""stage""[All Fields] OR ""staged""[All Fields] OR ""stages""[All Fields] OR ""staging""[All Fields] OR ""stagings""[All Fields])) OR ((""extensive""[All Fields] OR ""extensively""[All Fields]) AND (""disease""[MeSH Terms] OR ""disease""[All Fields] OR ""diseases""[All Fields] OR ""disease s""[All Fields] OR ""diseased""[All Fields])) OR (""extensive""[All Fields] OR ""extensively""[All Fields]) OR (""advance""[All Fields] OR ""advanced""[All Fields] OR ""advancement""[All Fields] OR ""advancements""[All Fields] OR ""advances""[All Fields] OR ""advancing""[All Fields])) AND (""small cell lung carcinoma""[MeSH Terms] OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""carcinoma""[All Fields] AND ""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields]) OR ""carcinoma small cell lung""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""oat""[All Fields] AND ""cell""[All Fields] AND ""carcinoma""[All Fields] AND ""lung""[All Fields]) OR ""oat cell carcinoma of lung""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""oat""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""cancer""[All Fields]) OR ""oat cell lung cancer""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""cancer""[All Fields]) OR ""small cell lung cancer""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""cancer""[All Fields] AND ""lung""[All Fields]) OR ""small cell cancer of the lung""[All Fields]) OR ""SCLC""[All Fields] OR ((((""small""[Journal] OR ""small""[All Fields]) AND (""cells""[MeSH Terms] OR ""cells""[All Fields] OR ""cell""[All Fields])) OR (""oat""[All Fields] AND (""cells""[MeSH Terms] OR ""cells""[All Fields] OR ""cell""[All Fields]))) AND (""lung neoplasms""[MeSH Terms] OR (""lung neoplasms""[MeSH Terms] OR (""lung""[All Fields] AND ""neoplasms""[All Fields]) OR ""lung neoplasms""[All Fields] OR (""lung""[All Fields] AND ""neoplasm""[All Fields]) OR ""lung neoplasm""[All Fields]) OR (""lung neoplasms""[MeSH Terms] OR (""lung""[All Fields] AND ""neoplasms""[All Fields]) OR ""lung neoplasms""[All Fields] OR (""pulmonary""[All Fields] AND ""neoplasm""[All Fields]) OR ""pulmonary neoplasm""[All Fields]) OR (""lung neoplasms""[MeSH Terms] OR (""lung""[All Fields] AND ""neoplasms""[All Fields]) OR ""lung neoplasms""[All Fields] OR (""lung""[All Fields] AND ""cancer""[All Fields]) OR ""lung cancer""[All Fields]) OR (""lung neoplasms""[MeSH Terms] OR (""lung""[All Fields] AND ""neoplasms""[All Fields]) OR ""lung neoplasms""[All Fields] OR (""pulmonary""[All Fields] AND ""cancer""[All Fields]) OR ""pulmonary cancer""[All Fields]) OR (""lung neoplasms""[MeSH Terms] OR (""lung""[All Fields] AND ""neoplasms""[All Fields]) OR ""lung neoplasms""[All Fields] OR (""cancer""[All Fields] AND ""lung""[All Fields]) OR ""cancer of the lung""[All Fields]))))) OR ""ES-SCLC""[All Fields]) AND (""Drug Therapy""[MeSH Terms] OR (""Drug""[All Fields] AND ""therap*""[All Fields]) OR ""chemotherap*""[All Fields] OR ""pharmacotherap*""[All Fields] OR (""therap*""[All Fields] AND ""Drug""[All Fields]) OR (""Antineoplastic Agents""[MeSH Terms] OR ""antineoplastic agent*""[All Fields] OR ""antitumor agent*""[All Fields] OR ""anticancer agent*""[All Fields] OR ""antineoplastic drug*""[All Fields] OR ""antitumor drug*""[All Fields] OR ""cancer chemotherapy agent*""[All Fields] OR ""antineoplastic*""[All Fields] OR ""chemotherapeutic anticancer agent*""[All Fields] OR ""cancer chemotherapy drug*""[All Fields]) OR (""Cisplatin""[MeSH Terms] OR ""Cisplatin""[All Fields] OR ""cis diamminedichloroplatinum""[All Fields] OR ""cis diamminedichloroplatinum""[All Fields] OR ""cis diamminedichloroplatinum ii""[All Fields] OR ""cis dichlorodiammineplatinum ii""[All Fields] OR ""cis-Platinum""[All Fields] OR ""Dichlorodiammineplatinum""[All Fields] OR ""Platinum Diamminodichloride""[All Fields] OR ""diamminodichloride platinum""[All Fields] OR ""Biocisplatinum""[All Fields] OR ""Platidiam""[All Fields] OR ""Platino""[All Fields] OR ""Platinol""[All Fields] OR ""NSC-119875""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields] OR ""CBDCA""[All Fields] OR ""cis diammine cyclobutanedicarboxylato platinum ii""[All Fields] OR ""Paraplatin""[All Fields] OR ""Paraplatine""[All Fields] OR ""nsc 241240""[All Fields] OR ""NSC241240""[All Fields] OR ""nsc 241240""[All Fields] OR ""jm 8""[All Fields] OR ""JM8""[All Fields] OR ""jm 8""[All Fields] OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR ""Ercar""[All Fields] OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR ""Ribocarbo""[All Fields] OR ""Carboplat""[All Fields]) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR ""1 2 diamminocyclohexane trans 1 oxolatoplatinum ii""[All Fields] OR ""L-OHP""[All Fields] OR ""Cpd""[All Fields] OR ((((((""platinum""[MeSH Terms] OR ""platinum""[All Fields] OR ""platinums""[All Fields]) AND ""2""[All Fields]) AND ""ethanedioate""[All Fields]) AND ""1r 2r""[All Fields]) AND (""1 2 cyclohexanediamine""[Supplementary Concept] OR ""1 2 cyclohexanediamine""[All Fields] OR ""1 2 cyclohexanediamine""[All Fields])) AND ""1 1 1""[All Fields]) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""oxalato""[All Fields] AND ""1 2""[All Fields] AND ""cyclohexanediamine""[All Fields] AND ""platinum""[All Fields] AND ""II""[All Fields])) OR (((""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR ""Oxaliplatine""[All Fields] OR ""oxaliplatin s""[All Fields]) AND (""sp 4 2""[All Fields] AND ""1r trans""[All Fields])) AND (""isomerism""[MeSH Terms] OR ""isomerism""[All Fields] OR ""isomer""[All Fields] OR ""isomers""[All Fields])) OR ""Oxaliplatine""[All Fields] OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""1 2""[All Fields] AND ""diaminocyclohexane""[All Fields] AND ""platinum""[All Fields] AND ""oxalate""[All Fields])) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""1 2""[All Fields] AND ""diaminocyclohexane""[All Fields] AND ""platinum""[All Fields] AND ""oxalate""[All Fields])) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""platinum""[All Fields] AND ""II""[All Fields] AND ""1 2""[All Fields] AND ""cyclohexanediamine""[All Fields] AND ""oxalate""[All Fields])) OR (((""cis oxalato""[All Fields] AND ""trans l""[All Fields]) AND ""1 2 diaminocyclohexane platinum""[All Fields]) AND ""II""[All Fields]) OR ""act 078""[All Fields] OR ""act 078""[All Fields] OR ""ACT078""[All Fields] OR (((""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR ""Oxaliplatine""[All Fields] OR ""oxaliplatin s""[All Fields]) AND (""sp 4 3""[All Fields] AND ""cis""[All Fields])) AND (""isomerism""[MeSH Terms] OR ""isomerism""[All Fields] OR ""isomer""[All Fields] OR ""isomers""[All Fields])) OR ""Eloxatine""[All Fields]) OR (""Lobaplatin""[Supplementary Concept] OR ""Lobaplatin""[All Fields] OR ""1 2 diaminomethylcyclobutane platinum ii lactate""[All Fields] OR ""d 19466""[All Fields] OR ""d 19466""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""demethyl""[All Fields] AND ""epipodophyllotoxin""[All Fields] AND ""ethylidine""[All Fields] AND ""glucoside""[All Fields])) OR ""Eposide""[All Fields] OR ""Vepesid""[All Fields] OR ((""etoposid""[All Fields] OR ""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR ""etoposide s""[All Fields] OR ""etoposides""[All Fields]) AND ""alpha d glucopyranosyl""[All Fields] AND (""isomerism""[MeSH Terms] OR ""isomerism""[All Fields] OR ""isomer""[All Fields] OR ""isomers""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""5s""[All Fields] AND ""isomer""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""5a""[All Fields] AND ""alpha""[All Fields] AND ""isomer""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""nsc 141540""[All Fields] OR ""NSC141540""[All Fields] OR ""nsc 141540""[All Fields] OR ""vp 16 213""[All Fields] OR ""VP 16213""[All Fields] OR ""vp 16 213""[All Fields] OR ""vp 16""[All Fields] OR ""VP16""[All Fields] OR ""vp 16""[All Fields] OR ""Celltop""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""Toposar""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""teva""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""teva""[All Fields] AND ""Etoposide""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""eto""[All Fields] AND ""gry""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""eto""[All Fields] AND ""gry""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""pierre""[All Fields] AND ""fabre""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""etoposido""[All Fields] AND ""ferrer""[All Fields] AND ""farma""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""Lastet""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""vepeside sandoz""[All Fields] OR ""vepeside sandoz""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]))) AND (""Immunotherapy""[MeSH Terms] OR ""immunotherap*""[All Fields] OR ""chemoimmunotherap*""[All Fields] OR (""Immune Checkpoint Inhibitors""[MeSH Terms] OR ""Immune Checkpoint Inhibitors""[All Fields] OR ""checkpoint inhibitors immune""[All Fields] OR ""Immune Checkpoint Blockers""[All Fields] OR ""checkpoint blockers immune""[All Fields] OR ""Immune Checkpoint Inhibitor""[All Fields] OR ""checkpoint inhibitor immune""[All Fields] OR ""ctla 4 inhibitors""[All Fields] OR ""ctla 4 inhibitors""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitors""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitors""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitor""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitor""[All Fields] OR ""ctla 4 inhibitor""[All Fields] OR ""ctla 4 inhibitor""[All Fields] OR ""pd 1 inhibitors""[All Fields] OR ""pd 1 inhibitors""[All Fields] OR ""Programmed Cell Death Protein 1 Inhibitor""[All Fields] OR ""Programmed Cell Death Protein 1 Inhibitors""[All Fields] OR ""pd 1 inhibitor""[All Fields] OR ""inhibitor pd 1""[All Fields] OR ""pd 1 inhibitor""[All Fields] OR ""Immune Checkpoint Blockade""[All Fields] OR ""checkpoint blockade immune""[All Fields] OR ""Immune Checkpoint Inhibition""[All Fields] OR ""checkpoint inhibition immune""[All Fields] OR ""pd l1 inhibitors""[All Fields] OR ""pd l1 inhibitors""[All Fields] OR ""programmed death ligand 1 inhibitors""[All Fields] OR ""programmed death ligand 1 inhibitors""[All Fields] OR ""pd l1 inhibitor""[All Fields] OR ""pd l1 inhibitor""[All Fields] OR ""pd 1 pd l1 blockade""[All Fields] OR ""blockade pd 1 pd l1""[All Fields] OR ""pd 1 pd l1 blockade""[All Fields]) OR (""Nivolumab""[MeSH Terms] OR ""Nivolumab""[All Fields] OR ""mdx 1106""[All Fields] OR ""MDX1106""[All Fields] OR ""mdx 1106""[All Fields] OR ""Opdivo""[All Fields] OR ""bms 936558""[All Fields] OR ""BMS936558""[All Fields] OR ""bms 936558""[All Fields] OR ""ono 4538""[All Fields] OR ""ONO4538""[All Fields] OR ""ono 4538""[All Fields]) OR (""Ipilimumab""[MeSH Terms] OR ""Ipilimumab""[All Fields] OR ""anti ctla 4 mab ipilimumab""[All Fields] OR ""anti ctla 4 mab ipilimumab""[All Fields] OR ""ipilimumab anti ctla 4 mab""[All Fields] OR ""mdx 010""[All Fields] OR ""mdx 010""[All Fields] OR ""MDX010""[All Fields] OR ""mdx ctla 4""[All Fields] OR ""mdx ctla 4""[All Fields] OR ""Yervoy""[All Fields]) OR (""camrelizumab""[Supplementary Concept] OR ""camrelizumab""[All Fields] OR ""shr 1210""[All Fields] OR ""shr 1210""[All Fields] OR ""carrelizumab""[All Fields]) OR (""atezolizumab""[Supplementary Concept] OR ""atezolizumab""[All Fields] OR (((((""immunoglobulin g""[MeSH Terms] OR ""immunoglobulin g""[All Fields] OR (""immunoglobulin""[All Fields] AND ""g1""[All Fields]) OR ""immunoglobulin g1""[All Fields]) AND (""antib technol j""[Journal] OR ""anti""[All Fields])) AND ((""human s""[All Fields] OR ""humans""[MeSH Terms] OR ""humans""[All Fields] OR ""human""[All Fields]) AND (""antigens, cd""[MeSH Terms] OR (""antigens""[All Fields] AND ""cd""[All Fields]) OR ""cd antigens""[All Fields] OR (""cd""[All Fields] AND ""antigen""[All Fields]) OR ""cd antigen""[All Fields]) AND ""cd274""[All Fields])) AND ((""human s""[All Fields] OR ""humans""[MeSH Terms] OR ""humans""[All Fields] OR ""human""[All Fields]) AND (""monoclonal""[All Fields] OR ""monoclonality""[All Fields] OR ""monoclonally""[All Fields] OR ""monoclonals""[All Fields] OR ""monoclone""[All Fields] OR ""monoclones""[All Fields]) AND ""heavy""[All Fields] AND (""chain""[All Fields] OR ""chain s""[All Fields] OR ""chains""[All Fields]))) AND ((""disulfides""[MeSH Terms] OR ""disulfides""[All Fields] OR ""disulfide""[All Fields] OR ""disulphide""[All Fields] OR ""disulphides""[All Fields]) AND (""human s""[All Fields] OR ""humans""[MeSH Terms] OR ""humans""[All Fields] OR ""human""[All Fields]) AND (""monoclonal""[All Fields] OR ""monoclonality""[All Fields] OR ""monoclonally""[All Fields] OR ""monoclonals""[All Fields] OR ""monoclone""[All Fields] OR ""monoclones""[All Fields]) AND ""kappa chain""[All Fields] AND (""dimer""[All Fields] OR ""dimer s""[All Fields] OR ""dimeric""[All Fields] OR ""dimerisation""[All Fields] OR ""dimerise""[All Fields] OR ""dimerised""[All Fields] OR ""dimerises""[All Fields] OR ""dimerising""[All Fields] OR ""dimerization""[MeSH Terms] OR ""dimerization""[All Fields] OR ""dimerizations""[All Fields] OR ""dimerize""[All Fields] OR ""dimerized""[All Fields] OR ""dimerizer""[All Fields] OR ""dimerizers""[All Fields] OR ""dimerizes""[All Fields] OR ""dimerizing""[All Fields] OR ""dimers""[All Fields]))) OR ""anti-PDL1""[All Fields] OR ""MPDL3280A""[All Fields] OR ""MPDL-3280A""[All Fields] OR ""Tecentriq""[All Fields] OR ""RG7446""[All Fields] OR ""RG-7446""[All Fields]) OR (""pembrolizumab""[Supplementary Concept] OR ""pembrolizumab""[All Fields] OR ""MK-3475""[All Fields] OR ""Keytruda""[All Fields] OR ""lambrolizumab""[All Fields] OR ""SCH-900475""[All Fields]) OR (""pidilizumab""[Supplementary Concept] OR ""pidilizumab""[All Fields] OR ""ct 011""[All Fields] OR ""ct 011""[All Fields]) OR (""avelumab""[Supplementary Concept] OR ""avelumab""[All Fields] OR ""MSB0010718C""[All Fields] OR ""MSB-0010718C""[All Fields] OR ""bavencio""[All Fields] OR ""MSB0010682""[All Fields] OR (""avelumab""[Supplementary Concept] OR ""avelumab""[All Fields])) OR (""durvalumab""[Supplementary Concept] OR ""durvalumab""[All Fields] OR ""MEDI4736""[All Fields] OR ""MEDI-4736""[All Fields] OR ""Imfinzi""[All Fields]) OR (""tislelizumab""[Supplementary Concept] OR ""tislelizumab""[All Fields] OR ""BGB-A317""[All Fields]) OR (""toripalimab""[Supplementary Concept] OR ""toripalimab""[All Fields]) OR ""Serplulimab""[All Fields] OR ""Adebrelimab""[All Fields]) AND (""Radiotherapy""[MeSH Terms] OR (""Radiotherapy""[MeSH Terms] OR ""Radiotherapy""[All Fields] OR ""radiotherapies""[All Fields] OR ""Radiotherapy""[MeSH Subheading] OR ""radiotherapy s""[All Fields]) OR (""Radiotherapy""[MeSH Subheading] OR ""Radiotherapy""[All Fields] OR (""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""radiation therapy""[All Fields] OR ""Radiotherapy""[MeSH Terms]) OR ((""target""[All Fields] OR ""targetability""[All Fields] OR ""targetable""[All Fields] OR ""targeted""[All Fields] OR ""targeting""[All Fields] OR ""targetings""[All Fields] OR ""targets""[All Fields] OR ""targetted""[All Fields] OR ""targetting""[All Fields]) AND ""radiotherap*""[All Fields]) OR ((""target""[All Fields] OR ""targetability""[All Fields] OR ""targetable""[All Fields] OR ""targeted""[All Fields] OR ""targeting""[All Fields] OR ""targetings""[All Fields] OR ""targets""[All Fields] OR ""targetted""[All Fields] OR ""targetting""[All Fields]) AND (""radiate""[All Fields] OR ""radiated""[All Fields] OR ""radiates""[All Fields] OR ""radiating""[All Fields] OR ""radiation""[MeSH Terms] OR ""radiation""[All Fields] OR ""electromagnetic radiation""[MeSH Terms] OR (""electromagnetic""[All Fields] AND ""radiation""[All Fields]) OR ""electromagnetic radiation""[All Fields] OR ""radiations""[All Fields] OR ""radiation s""[All Fields] OR ""radiator""[All Fields] OR ""radiators""[All Fields]) AND ""therap*""[All Fields]) OR (""radiate""[All Fields] OR ""radiated""[All Fields] OR ""radiates""[All Fields] OR ""radiating""[All Fields] OR ""radiation""[MeSH Terms] OR ""radiation""[All Fields] OR ""electromagnetic radiation""[MeSH Terms] OR (""electromagnetic""[All Fields] AND ""radiation""[All Fields]) OR ""electromagnetic radiation""[All Fields] OR ""radiations""[All Fields] OR ""radiation s""[All Fields] OR ""radiator""[All Fields] OR ""radiators""[All Fields]) OR (""irradiance""[All Fields] OR ""irradiances""[All Fields] OR ""irradiant""[All Fields] OR ""irradiates""[All Fields] OR ""irradiating""[All Fields] OR ""irradiations""[All Fields] OR ""irradiative""[All Fields] OR ""irradiator""[All Fields] OR ""irradiators""[All Fields] OR ""Radiotherapy""[MeSH Terms] OR ""Radiotherapy""[All Fields] OR ""irradiate""[All Fields] OR ""irradiated""[All Fields] OR ""irradiation""[All Fields]) OR ""radio-chemotherapy""[All Fields] OR (""chemoradiotherapy""[MeSH Terms] OR ""chemoradiotherapy""[All Fields] OR ""chemoradiotherapies""[All Fields]) OR (""Radiotherapy""[MeSH Terms] OR ""Radiotherapy""[All Fields] OR (""radiation""[All Fields] AND ""treatment""[All Fields]) OR ""radiation treatment""[All Fields]) OR (""radiotherapy, conformal""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""conformal""[All Fields]) OR ""conformal radiotherapy""[All Fields] OR (""3d""[All Fields] AND ""conformal""[All Fields] AND ""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""3d conformal radiation therapy""[All Fields]) OR (""radiotherapy, conformal""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""conformal""[All Fields]) OR ""conformal radiotherapy""[All Fields] OR (""3d""[All Fields] AND ""crt""[All Fields]) OR ""3d crt""[All Fields]) OR (""radiotherapy, intensity modulated""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""intensity modulated""[All Fields]) OR ""intensity-modulated radiotherapy""[All Fields] OR (""intensity""[All Fields] AND ""modulated""[All Fields] AND ""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""intensity modulated radiation therapy""[All Fields]) OR ""IMRT""[All Fields] OR (""radiotherapy, image guided""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""image guided""[All Fields]) OR ""image-guided radiotherapy""[All Fields] OR (""image""[All Fields] AND ""guided""[All Fields] AND ""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""image guided radiation therapy""[All Fields]) OR ""IGRT""[All Fields] OR (""radiosurgery""[MeSH Terms] OR ""radiosurgery""[All Fields] OR (""stereotactic""[All Fields] AND ""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""stereotactic radiation therapy""[All Fields]) OR ""SRT""[All Fields] OR (""radiosurgery""[MeSH Terms] OR ""radiosurgery""[All Fields] OR (""stereotactic""[All Fields] AND ""radiosurgery""[All Fields]) OR ""stereotactic radiosurgery""[All Fields]) OR ""SRS""[All Fields] OR ((""stereotactic""[All Fields] OR ""stereotactical""[All Fields] OR ""stereotactically""[All Fields] OR ""stereotactics""[All Fields]) AND (""human body""[MeSH Terms] OR (""human""[All Fields] AND ""body""[All Fields]) OR ""human body""[All Fields] OR ""body""[All Fields]) AND (""Radiotherapy""[MeSH Subheading] OR ""Radiotherapy""[All Fields] OR (""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""radiation therapy""[All Fields] OR ""Radiotherapy""[MeSH Terms])) OR ""SBRT""[All Fields] OR (""radiotherapy, intensity modulated""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""intensity modulated""[All Fields]) OR ""intensity-modulated radiotherapy""[All Fields] OR (""volumetric""[All Fields] AND ""modulated""[All Fields] AND ""arc""[All Fields] AND ""therapy""[All Fields]) OR ""volumetric modulated arc therapy""[All Fields]) OR (""radiotherapy, intensity modulated""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""intensity modulated""[All Fields]) OR ""intensity-modulated radiotherapy""[All Fields] OR ""vmat""[All Fields]) OR ((""acclimatization""[MeSH Terms] OR ""acclimatization""[All Fields] OR ""adaptation""[All Fields] OR ""adaptations""[All Fields] OR ""adapt""[All Fields] OR ""adaptabilities""[All Fields] OR ""adaptability""[All Fields] OR ""adaptable""[All Fields] OR ""adaptational""[All Fields] OR ""adaptative""[All Fields] OR ""adapte""[All Fields] OR ""adapted""[All Fields] OR ""adapting""[All Fields] OR ""adaption""[All Fields] OR ""adaptions""[All Fields] OR ""adaptive""[All Fields] OR ""adaptively""[All Fields] OR ""adaptiveness""[All Fields] OR ""adaptivity""[All Fields] OR ""adapts""[All Fields]) AND (""Radiotherapy""[MeSH Subheading] OR ""Radiotherapy""[All Fields] OR (""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""radiation therapy""[All Fields] OR ""Radiotherapy""[MeSH Terms])) OR (""art""[MeSH Terms] OR ""art""[All Fields])) AND ((""randomized controlled trial""[Publication Type] OR (""randomi""[All Fields] AND ""ed""[Title/Abstract]) OR ""placebo""[Title/Abstract] OR ""Drug Therapy""[MeSH Subheading] OR ""randomly""[Title/Abstract] OR ""trial""[Title/Abstract] OR ""group""[Title/Abstract]) NOT 31[UID])",851,1:17:26 -32,#30 NOT 31,,,("randomized controlled trial"[Publication Type] OR ("randomi"[All Fields] AND "ed"[Title/Abstract]) OR "placebo"[Title/Abstract] OR "drug therapy"[MeSH Subheading] OR "randomly"[Title/Abstract] OR "trial"[Title/Abstract] OR "group"[Title/Abstract]) NOT 31[UID],"6,466,132",1:15:12 -31,animals[MeSH Terms] NOT humans[MeSH Terms],,,"""animals""[MeSH Terms] NOT ""humans""[MeSH Terms]","5,267,115",1:14:46 -30,randomized controlled trial[Publication Type] OR randomi?ed[Title/Abstract] OR placebo[Title/Abstract] OR drug therapy[MeSH Subheading] OR randomly[Title/Abstract] OR trial[Title/Abstract] OR group[Title/Abstract],,,"""randomized controlled trial""[Publication Type] OR (""randomi""[All Fields] AND ""ed""[Title/Abstract]) OR ""placebo""[Title/Abstract] OR ""drug therapy""[MeSH Subheading] OR ""randomly""[Title/Abstract] OR ""trial""[Title/Abstract] OR ""group""[Title/Abstract]","6,466,132",1:14:25 -29,#4 AND #12 AND #27 AND #28,,,"(((((""extensive""[All Fields] OR ""extensively""[All Fields]) AND (""stage""[All Fields] OR ""staged""[All Fields] OR ""stages""[All Fields] OR ""staging""[All Fields] OR ""stagings""[All Fields])) OR ((""extensive""[All Fields] OR ""extensively""[All Fields]) AND (""disease""[MeSH Terms] OR ""disease""[All Fields] OR ""diseases""[All Fields] OR ""disease s""[All Fields] OR ""diseased""[All Fields])) OR (""extensive""[All Fields] OR ""extensively""[All Fields]) OR (""advance""[All Fields] OR ""advanced""[All Fields] OR ""advancement""[All Fields] OR ""advancements""[All Fields] OR ""advances""[All Fields] OR ""advancing""[All Fields])) AND (""small cell lung carcinoma""[MeSH Terms] OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""carcinoma""[All Fields] AND ""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields]) OR ""carcinoma small cell lung""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""oat""[All Fields] AND ""cell""[All Fields] AND ""carcinoma""[All Fields] AND ""lung""[All Fields]) OR ""oat cell carcinoma of lung""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""oat""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""cancer""[All Fields]) OR ""oat cell lung cancer""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""cancer""[All Fields]) OR ""small cell lung cancer""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""cancer""[All Fields] AND ""lung""[All Fields]) OR ""small cell cancer of the lung""[All Fields]) OR ""SCLC""[All Fields] OR ((((""small""[Journal] OR ""small""[All Fields]) AND (""cells""[MeSH Terms] OR ""cells""[All Fields] OR ""cell""[All Fields])) OR (""oat""[All Fields] AND (""cells""[MeSH Terms] OR ""cells""[All Fields] OR ""cell""[All Fields]))) AND (""lung neoplasms""[MeSH Terms] OR (""lung neoplasms""[MeSH Terms] OR (""lung""[All Fields] AND ""neoplasms""[All Fields]) OR ""lung neoplasms""[All Fields] OR (""lung""[All Fields] AND ""neoplasm""[All Fields]) OR ""lung neoplasm""[All Fields]) OR (""lung neoplasms""[MeSH Terms] OR (""lung""[All Fields] AND ""neoplasms""[All Fields]) OR ""lung neoplasms""[All Fields] OR (""pulmonary""[All Fields] AND ""neoplasm""[All Fields]) OR ""pulmonary neoplasm""[All Fields]) OR (""lung neoplasms""[MeSH Terms] OR (""lung""[All Fields] AND ""neoplasms""[All Fields]) OR ""lung neoplasms""[All Fields] OR (""lung""[All Fields] AND ""cancer""[All Fields]) OR ""lung cancer""[All Fields]) OR (""lung neoplasms""[MeSH Terms] OR (""lung""[All Fields] AND ""neoplasms""[All Fields]) OR ""lung neoplasms""[All Fields] OR (""pulmonary""[All Fields] AND ""cancer""[All Fields]) OR ""pulmonary cancer""[All Fields]) OR (""lung neoplasms""[MeSH Terms] OR (""lung""[All Fields] AND ""neoplasms""[All Fields]) OR ""lung neoplasms""[All Fields] OR (""cancer""[All Fields] AND ""lung""[All Fields]) OR ""cancer of the lung""[All Fields]))))) OR ""ES-SCLC""[All Fields]) AND (""Drug Therapy""[MeSH Terms] OR (""Drug""[All Fields] AND ""therap*""[All Fields]) OR ""chemotherap*""[All Fields] OR ""pharmacotherap*""[All Fields] OR (""therap*""[All Fields] AND ""Drug""[All Fields]) OR (""Antineoplastic Agents""[MeSH Terms] OR ""antineoplastic agent*""[All Fields] OR ""antitumor agent*""[All Fields] OR ""anticancer agent*""[All Fields] OR ""antineoplastic drug*""[All Fields] OR ""antitumor drug*""[All Fields] OR ""cancer chemotherapy agent*""[All Fields] OR ""antineoplastic*""[All Fields] OR ""chemotherapeutic anticancer agent*""[All Fields] OR ""cancer chemotherapy drug*""[All Fields]) OR (""Cisplatin""[MeSH Terms] OR ""Cisplatin""[All Fields] OR ""cis diamminedichloroplatinum""[All Fields] OR ""cis diamminedichloroplatinum""[All Fields] OR ""cis diamminedichloroplatinum ii""[All Fields] OR ""cis dichlorodiammineplatinum ii""[All Fields] OR ""cis-Platinum""[All Fields] OR ""Dichlorodiammineplatinum""[All Fields] OR ""Platinum Diamminodichloride""[All Fields] OR ""diamminodichloride platinum""[All Fields] OR ""Biocisplatinum""[All Fields] OR ""Platidiam""[All Fields] OR ""Platino""[All Fields] OR ""Platinol""[All Fields] OR ""NSC-119875""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields] OR ""CBDCA""[All Fields] OR ""cis diammine cyclobutanedicarboxylato platinum ii""[All Fields] OR ""Paraplatin""[All Fields] OR ""Paraplatine""[All Fields] OR ""nsc 241240""[All Fields] OR ""NSC241240""[All Fields] OR ""nsc 241240""[All Fields] OR ""jm 8""[All Fields] OR ""JM8""[All Fields] OR ""jm 8""[All Fields] OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR ""Ercar""[All Fields] OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR ""Ribocarbo""[All Fields] OR ""Carboplat""[All Fields]) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR ""1 2 diamminocyclohexane trans 1 oxolatoplatinum ii""[All Fields] OR ""L-OHP""[All Fields] OR ""Cpd""[All Fields] OR ((((((""platinum""[MeSH Terms] OR ""platinum""[All Fields] OR ""platinums""[All Fields]) AND ""2""[All Fields]) AND ""ethanedioate""[All Fields]) AND ""1r 2r""[All Fields]) AND (""1 2 cyclohexanediamine""[Supplementary Concept] OR ""1 2 cyclohexanediamine""[All Fields] OR ""1 2 cyclohexanediamine""[All Fields])) AND ""1 1 1""[All Fields]) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""oxalato""[All Fields] AND ""1 2""[All Fields] AND ""cyclohexanediamine""[All Fields] AND ""platinum""[All Fields] AND ""II""[All Fields])) OR (((""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR ""Oxaliplatine""[All Fields] OR ""oxaliplatin s""[All Fields]) AND (""sp 4 2""[All Fields] AND ""1r trans""[All Fields])) AND (""isomerism""[MeSH Terms] OR ""isomerism""[All Fields] OR ""isomer""[All Fields] OR ""isomers""[All Fields])) OR ""Oxaliplatine""[All Fields] OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""1 2""[All Fields] AND ""diaminocyclohexane""[All Fields] AND ""platinum""[All Fields] AND ""oxalate""[All Fields])) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""1 2""[All Fields] AND ""diaminocyclohexane""[All Fields] AND ""platinum""[All Fields] AND ""oxalate""[All Fields])) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""platinum""[All Fields] AND ""II""[All Fields] AND ""1 2""[All Fields] AND ""cyclohexanediamine""[All Fields] AND ""oxalate""[All Fields])) OR (((""cis oxalato""[All Fields] AND ""trans l""[All Fields]) AND ""1 2 diaminocyclohexane platinum""[All Fields]) AND ""II""[All Fields]) OR ""act 078""[All Fields] OR ""act 078""[All Fields] OR ""ACT078""[All Fields] OR (((""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR ""Oxaliplatine""[All Fields] OR ""oxaliplatin s""[All Fields]) AND (""sp 4 3""[All Fields] AND ""cis""[All Fields])) AND (""isomerism""[MeSH Terms] OR ""isomerism""[All Fields] OR ""isomer""[All Fields] OR ""isomers""[All Fields])) OR ""Eloxatine""[All Fields]) OR (""Lobaplatin""[Supplementary Concept] OR ""Lobaplatin""[All Fields] OR ""1 2 diaminomethylcyclobutane platinum ii lactate""[All Fields] OR ""d 19466""[All Fields] OR ""d 19466""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""demethyl""[All Fields] AND ""epipodophyllotoxin""[All Fields] AND ""ethylidine""[All Fields] AND ""glucoside""[All Fields])) OR ""Eposide""[All Fields] OR ""Vepesid""[All Fields] OR ((""etoposid""[All Fields] OR ""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR ""etoposide s""[All Fields] OR ""etoposides""[All Fields]) AND ""alpha d glucopyranosyl""[All Fields] AND (""isomerism""[MeSH Terms] OR ""isomerism""[All Fields] OR ""isomer""[All Fields] OR ""isomers""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""5s""[All Fields] AND ""isomer""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""5a""[All Fields] AND ""alpha""[All Fields] AND ""isomer""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""nsc 141540""[All Fields] OR ""NSC141540""[All Fields] OR ""nsc 141540""[All Fields] OR ""vp 16 213""[All Fields] OR ""VP 16213""[All Fields] OR ""vp 16 213""[All Fields] OR ""vp 16""[All Fields] OR ""VP16""[All Fields] OR ""vp 16""[All Fields] OR ""Celltop""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""Toposar""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""teva""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""teva""[All Fields] AND ""Etoposide""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""eto""[All Fields] AND ""gry""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""eto""[All Fields] AND ""gry""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""pierre""[All Fields] AND ""fabre""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""etoposido""[All Fields] AND ""ferrer""[All Fields] AND ""farma""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""Lastet""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""vepeside sandoz""[All Fields] OR ""vepeside sandoz""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]))) AND (""Immunotherapy""[MeSH Terms] OR ""immunotherap*""[All Fields] OR ""chemoimmunotherap*""[All Fields] OR (""Immune Checkpoint Inhibitors""[MeSH Terms] OR ""Immune Checkpoint Inhibitors""[All Fields] OR ""checkpoint inhibitors immune""[All Fields] OR ""Immune Checkpoint Blockers""[All Fields] OR ""checkpoint blockers immune""[All Fields] OR ""Immune Checkpoint Inhibitor""[All Fields] OR ""checkpoint inhibitor immune""[All Fields] OR ""ctla 4 inhibitors""[All Fields] OR ""ctla 4 inhibitors""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitors""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitors""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitor""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitor""[All Fields] OR ""ctla 4 inhibitor""[All Fields] OR ""ctla 4 inhibitor""[All Fields] OR ""pd 1 inhibitors""[All Fields] OR ""pd 1 inhibitors""[All Fields] OR ""Programmed Cell Death Protein 1 Inhibitor""[All Fields] OR ""Programmed Cell Death Protein 1 Inhibitors""[All Fields] OR ""pd 1 inhibitor""[All Fields] OR ""inhibitor pd 1""[All Fields] OR ""pd 1 inhibitor""[All Fields] OR ""Immune Checkpoint Blockade""[All Fields] OR ""checkpoint blockade immune""[All Fields] OR ""Immune Checkpoint Inhibition""[All Fields] OR ""checkpoint inhibition immune""[All Fields] OR ""pd l1 inhibitors""[All Fields] OR ""pd l1 inhibitors""[All Fields] OR ""programmed death ligand 1 inhibitors""[All Fields] OR ""programmed death ligand 1 inhibitors""[All Fields] OR ""pd l1 inhibitor""[All Fields] OR ""pd l1 inhibitor""[All Fields] OR ""pd 1 pd l1 blockade""[All Fields] OR ""blockade pd 1 pd l1""[All Fields] OR ""pd 1 pd l1 blockade""[All Fields]) OR (""Nivolumab""[MeSH Terms] OR ""Nivolumab""[All Fields] OR ""mdx 1106""[All Fields] OR ""MDX1106""[All Fields] OR ""mdx 1106""[All Fields] OR ""Opdivo""[All Fields] OR ""bms 936558""[All Fields] OR ""BMS936558""[All Fields] OR ""bms 936558""[All Fields] OR ""ono 4538""[All Fields] OR ""ONO4538""[All Fields] OR ""ono 4538""[All Fields]) OR (""Ipilimumab""[MeSH Terms] OR ""Ipilimumab""[All Fields] OR ""anti ctla 4 mab ipilimumab""[All Fields] OR ""anti ctla 4 mab ipilimumab""[All Fields] OR ""ipilimumab anti ctla 4 mab""[All Fields] OR ""mdx 010""[All Fields] OR ""mdx 010""[All Fields] OR ""MDX010""[All Fields] OR ""mdx ctla 4""[All Fields] OR ""mdx ctla 4""[All Fields] OR ""Yervoy""[All Fields]) OR (""camrelizumab""[Supplementary Concept] OR ""camrelizumab""[All Fields] OR ""shr 1210""[All Fields] OR ""shr 1210""[All Fields] OR ""carrelizumab""[All Fields]) OR (""atezolizumab""[Supplementary Concept] OR ""atezolizumab""[All Fields] OR (((((""immunoglobulin g""[MeSH Terms] OR ""immunoglobulin g""[All Fields] OR (""immunoglobulin""[All Fields] AND ""g1""[All Fields]) OR ""immunoglobulin g1""[All Fields]) AND (""antib technol j""[Journal] OR ""anti""[All Fields])) AND ((""human s""[All Fields] OR ""humans""[MeSH Terms] OR ""humans""[All Fields] OR ""human""[All Fields]) AND (""antigens, cd""[MeSH Terms] OR (""antigens""[All Fields] AND ""cd""[All Fields]) OR ""cd antigens""[All Fields] OR (""cd""[All Fields] AND ""antigen""[All Fields]) OR ""cd antigen""[All Fields]) AND ""cd274""[All Fields])) AND ((""human s""[All Fields] OR ""humans""[MeSH Terms] OR ""humans""[All Fields] OR ""human""[All Fields]) AND (""monoclonal""[All Fields] OR ""monoclonality""[All Fields] OR ""monoclonally""[All Fields] OR ""monoclonals""[All Fields] OR ""monoclone""[All Fields] OR ""monoclones""[All Fields]) AND ""heavy""[All Fields] AND (""chain""[All Fields] OR ""chain s""[All Fields] OR ""chains""[All Fields]))) AND ((""disulfides""[MeSH Terms] OR ""disulfides""[All Fields] OR ""disulfide""[All Fields] OR ""disulphide""[All Fields] OR ""disulphides""[All Fields]) AND (""human s""[All Fields] OR ""humans""[MeSH Terms] OR ""humans""[All Fields] OR ""human""[All Fields]) AND (""monoclonal""[All Fields] OR ""monoclonality""[All Fields] OR ""monoclonally""[All Fields] OR ""monoclonals""[All Fields] OR ""monoclone""[All Fields] OR ""monoclones""[All Fields]) AND ""kappa chain""[All Fields] AND (""dimer""[All Fields] OR ""dimer s""[All Fields] OR ""dimeric""[All Fields] OR ""dimerisation""[All Fields] OR ""dimerise""[All Fields] OR ""dimerised""[All Fields] OR ""dimerises""[All Fields] OR ""dimerising""[All Fields] OR ""dimerization""[MeSH Terms] OR ""dimerization""[All Fields] OR ""dimerizations""[All Fields] OR ""dimerize""[All Fields] OR ""dimerized""[All Fields] OR ""dimerizer""[All Fields] OR ""dimerizers""[All Fields] OR ""dimerizes""[All Fields] OR ""dimerizing""[All Fields] OR ""dimers""[All Fields]))) OR ""anti-PDL1""[All Fields] OR ""MPDL3280A""[All Fields] OR ""MPDL-3280A""[All Fields] OR ""Tecentriq""[All Fields] OR ""RG7446""[All Fields] OR ""RG-7446""[All Fields]) OR (""pembrolizumab""[Supplementary Concept] OR ""pembrolizumab""[All Fields] OR ""MK-3475""[All Fields] OR ""Keytruda""[All Fields] OR ""lambrolizumab""[All Fields] OR ""SCH-900475""[All Fields]) OR (""pidilizumab""[Supplementary Concept] OR ""pidilizumab""[All Fields] OR ""ct 011""[All Fields] OR ""ct 011""[All Fields]) OR (""avelumab""[Supplementary Concept] OR ""avelumab""[All Fields] OR ""MSB0010718C""[All Fields] OR ""MSB-0010718C""[All Fields] OR ""bavencio""[All Fields] OR ""MSB0010682""[All Fields] OR (""avelumab""[Supplementary Concept] OR ""avelumab""[All Fields])) OR (""durvalumab""[Supplementary Concept] OR ""durvalumab""[All Fields] OR ""MEDI4736""[All Fields] OR ""MEDI-4736""[All Fields] OR ""Imfinzi""[All Fields]) OR (""tislelizumab""[Supplementary Concept] OR ""tislelizumab""[All Fields] OR ""BGB-A317""[All Fields]) OR (""toripalimab""[Supplementary Concept] OR ""toripalimab""[All Fields]) OR ""Serplulimab""[All Fields] OR ""Adebrelimab""[All Fields]) AND (""Radiotherapy""[MeSH Terms] OR (""Radiotherapy""[MeSH Terms] OR ""Radiotherapy""[All Fields] OR ""radiotherapies""[All Fields] OR ""Radiotherapy""[MeSH Subheading] OR ""radiotherapy s""[All Fields]) OR (""Radiotherapy""[MeSH Subheading] OR ""Radiotherapy""[All Fields] OR (""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""radiation therapy""[All Fields] OR ""Radiotherapy""[MeSH Terms]) OR ((""target""[All Fields] OR ""targetability""[All Fields] OR ""targetable""[All Fields] OR ""targeted""[All Fields] OR ""targeting""[All Fields] OR ""targetings""[All Fields] OR ""targets""[All Fields] OR ""targetted""[All Fields] OR ""targetting""[All Fields]) AND ""radiotherap*""[All Fields]) OR ((""target""[All Fields] OR ""targetability""[All Fields] OR ""targetable""[All Fields] OR ""targeted""[All Fields] OR ""targeting""[All Fields] OR ""targetings""[All Fields] OR ""targets""[All Fields] OR ""targetted""[All Fields] OR ""targetting""[All Fields]) AND (""radiate""[All Fields] OR ""radiated""[All Fields] OR ""radiates""[All Fields] OR ""radiating""[All Fields] OR ""radiation""[MeSH Terms] OR ""radiation""[All Fields] OR ""electromagnetic radiation""[MeSH Terms] OR (""electromagnetic""[All Fields] AND ""radiation""[All Fields]) OR ""electromagnetic radiation""[All Fields] OR ""radiations""[All Fields] OR ""radiation s""[All Fields] OR ""radiator""[All Fields] OR ""radiators""[All Fields]) AND ""therap*""[All Fields]) OR (""radiate""[All Fields] OR ""radiated""[All Fields] OR ""radiates""[All Fields] OR ""radiating""[All Fields] OR ""radiation""[MeSH Terms] OR ""radiation""[All Fields] OR ""electromagnetic radiation""[MeSH Terms] OR (""electromagnetic""[All Fields] AND ""radiation""[All Fields]) OR ""electromagnetic radiation""[All Fields] OR ""radiations""[All Fields] OR ""radiation s""[All Fields] OR ""radiator""[All Fields] OR ""radiators""[All Fields]) OR (""irradiance""[All Fields] OR ""irradiances""[All Fields] OR ""irradiant""[All Fields] OR ""irradiates""[All Fields] OR ""irradiating""[All Fields] OR ""irradiations""[All Fields] OR ""irradiative""[All Fields] OR ""irradiator""[All Fields] OR ""irradiators""[All Fields] OR ""Radiotherapy""[MeSH Terms] OR ""Radiotherapy""[All Fields] OR ""irradiate""[All Fields] OR ""irradiated""[All Fields] OR ""irradiation""[All Fields]) OR ""radio-chemotherapy""[All Fields] OR (""chemoradiotherapy""[MeSH Terms] OR ""chemoradiotherapy""[All Fields] OR ""chemoradiotherapies""[All Fields]) OR (""Radiotherapy""[MeSH Terms] OR ""Radiotherapy""[All Fields] OR (""radiation""[All Fields] AND ""treatment""[All Fields]) OR ""radiation treatment""[All Fields]) OR (""radiotherapy, conformal""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""conformal""[All Fields]) OR ""conformal radiotherapy""[All Fields] OR (""3d""[All Fields] AND ""conformal""[All Fields] AND ""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""3d conformal radiation therapy""[All Fields]) OR (""radiotherapy, conformal""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""conformal""[All Fields]) OR ""conformal radiotherapy""[All Fields] OR (""3d""[All Fields] AND ""crt""[All Fields]) OR ""3d crt""[All Fields]) OR (""radiotherapy, intensity modulated""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""intensity modulated""[All Fields]) OR ""intensity-modulated radiotherapy""[All Fields] OR (""intensity""[All Fields] AND ""modulated""[All Fields] AND ""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""intensity modulated radiation therapy""[All Fields]) OR ""IMRT""[All Fields] OR (""radiotherapy, image guided""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""image guided""[All Fields]) OR ""image-guided radiotherapy""[All Fields] OR (""image""[All Fields] AND ""guided""[All Fields] AND ""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""image guided radiation therapy""[All Fields]) OR ""IGRT""[All Fields] OR (""radiosurgery""[MeSH Terms] OR ""radiosurgery""[All Fields] OR (""stereotactic""[All Fields] AND ""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""stereotactic radiation therapy""[All Fields]) OR ""SRT""[All Fields] OR (""radiosurgery""[MeSH Terms] OR ""radiosurgery""[All Fields] OR (""stereotactic""[All Fields] AND ""radiosurgery""[All Fields]) OR ""stereotactic radiosurgery""[All Fields]) OR ""SRS""[All Fields] OR ((""stereotactic""[All Fields] OR ""stereotactical""[All Fields] OR ""stereotactically""[All Fields] OR ""stereotactics""[All Fields]) AND (""human body""[MeSH Terms] OR (""human""[All Fields] AND ""body""[All Fields]) OR ""human body""[All Fields] OR ""body""[All Fields]) AND (""Radiotherapy""[MeSH Subheading] OR ""Radiotherapy""[All Fields] OR (""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""radiation therapy""[All Fields] OR ""Radiotherapy""[MeSH Terms])) OR ""SBRT""[All Fields] OR (""radiotherapy, intensity modulated""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""intensity modulated""[All Fields]) OR ""intensity-modulated radiotherapy""[All Fields] OR (""volumetric""[All Fields] AND ""modulated""[All Fields] AND ""arc""[All Fields] AND ""therapy""[All Fields]) OR ""volumetric modulated arc therapy""[All Fields]) OR (""radiotherapy, intensity modulated""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""intensity modulated""[All Fields]) OR ""intensity-modulated radiotherapy""[All Fields] OR ""vmat""[All Fields]) OR ((""acclimatization""[MeSH Terms] OR ""acclimatization""[All Fields] OR ""adaptation""[All Fields] OR ""adaptations""[All Fields] OR ""adapt""[All Fields] OR ""adaptabilities""[All Fields] OR ""adaptability""[All Fields] OR ""adaptable""[All Fields] OR ""adaptational""[All Fields] OR ""adaptative""[All Fields] OR ""adapte""[All Fields] OR ""adapted""[All Fields] OR ""adapting""[All Fields] OR ""adaption""[All Fields] OR ""adaptions""[All Fields] OR ""adaptive""[All Fields] OR ""adaptively""[All Fields] OR ""adaptiveness""[All Fields] OR ""adaptivity""[All Fields] OR ""adapts""[All Fields]) AND (""Radiotherapy""[MeSH Subheading] OR ""Radiotherapy""[All Fields] OR (""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""radiation therapy""[All Fields] OR ""Radiotherapy""[MeSH Terms])) OR (""art""[MeSH Terms] OR ""art""[All Fields]))","1,360",1:11:53 -28,"""Radiotherapy""[Mesh] OR Radiotherapy OR Radiation Therapy OR Targeted Radiotherap* OR Targeted Radiation Therap* OR radiation OR irradiation OR radio-chemotherapy OR chemoradiotherapy OR radiation treatment OR 3D Conformal Radiation Therapy OR 3D-CRT OR Intensity-Modulated Radiation Therapy OR IMRT OR Image-Guided Radiation Therapy OR IGRT OR Stereotactic Radiation Therapy OR SRT OR Stereotactic Radiosurgery OR SRS OR Stereotactic Body Radiation Therapy OR SBRT OR Volumetric Modulated Arc Therapy OR VMAT OR Adaptive Radiation Therapy OR ART",,,"""Radiotherapy""[MeSH Terms] OR (""Radiotherapy""[MeSH Terms] OR ""Radiotherapy""[All Fields] OR ""radiotherapies""[All Fields] OR ""Radiotherapy""[MeSH Subheading] OR ""radiotherapy s""[All Fields]) OR (""Radiotherapy""[MeSH Subheading] OR ""Radiotherapy""[All Fields] OR (""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""radiation therapy""[All Fields] OR ""Radiotherapy""[MeSH Terms]) OR ((""target""[All Fields] OR ""targetability""[All Fields] OR ""targetable""[All Fields] OR ""targeted""[All Fields] OR ""targeting""[All Fields] OR ""targetings""[All Fields] OR ""targets""[All Fields] OR ""targetted""[All Fields] OR ""targetting""[All Fields]) AND ""radiotherap*""[All Fields]) OR ((""target""[All Fields] OR ""targetability""[All Fields] OR ""targetable""[All Fields] OR ""targeted""[All Fields] OR ""targeting""[All Fields] OR ""targetings""[All Fields] OR ""targets""[All Fields] OR ""targetted""[All Fields] OR ""targetting""[All Fields]) AND (""radiate""[All Fields] OR ""radiated""[All Fields] OR ""radiates""[All Fields] OR ""radiating""[All Fields] OR ""radiation""[MeSH Terms] OR ""radiation""[All Fields] OR ""electromagnetic radiation""[MeSH Terms] OR (""electromagnetic""[All Fields] AND ""radiation""[All Fields]) OR ""electromagnetic radiation""[All Fields] OR ""radiations""[All Fields] OR ""radiation s""[All Fields] OR ""radiator""[All Fields] OR ""radiators""[All Fields]) AND ""therap*""[All Fields]) OR (""radiate""[All Fields] OR ""radiated""[All Fields] OR ""radiates""[All Fields] OR ""radiating""[All Fields] OR ""radiation""[MeSH Terms] OR ""radiation""[All Fields] OR ""electromagnetic radiation""[MeSH Terms] OR (""electromagnetic""[All Fields] AND ""radiation""[All Fields]) OR ""electromagnetic radiation""[All Fields] OR ""radiations""[All Fields] OR ""radiation s""[All Fields] OR ""radiator""[All Fields] OR ""radiators""[All Fields]) OR (""irradiance""[All Fields] OR ""irradiances""[All Fields] OR ""irradiant""[All Fields] OR ""irradiates""[All Fields] OR ""irradiating""[All Fields] OR ""irradiations""[All Fields] OR ""irradiative""[All Fields] OR ""irradiator""[All Fields] OR ""irradiators""[All Fields] OR ""Radiotherapy""[MeSH Terms] OR ""Radiotherapy""[All Fields] OR ""irradiate""[All Fields] OR ""irradiated""[All Fields] OR ""irradiation""[All Fields]) OR ""radio-chemotherapy""[All Fields] OR (""chemoradiotherapy""[MeSH Terms] OR ""chemoradiotherapy""[All Fields] OR ""chemoradiotherapies""[All Fields]) OR (""Radiotherapy""[MeSH Terms] OR ""Radiotherapy""[All Fields] OR (""radiation""[All Fields] AND ""treatment""[All Fields]) OR ""radiation treatment""[All Fields]) OR (""radiotherapy, conformal""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""conformal""[All Fields]) OR ""conformal radiotherapy""[All Fields] OR (""3d""[All Fields] AND ""conformal""[All Fields] AND ""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""3d conformal radiation therapy""[All Fields]) OR (""radiotherapy, conformal""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""conformal""[All Fields]) OR ""conformal radiotherapy""[All Fields] OR (""3d""[All Fields] AND ""crt""[All Fields]) OR ""3d crt""[All Fields]) OR (""radiotherapy, intensity modulated""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""intensity modulated""[All Fields]) OR ""intensity-modulated radiotherapy""[All Fields] OR (""intensity""[All Fields] AND ""modulated""[All Fields] AND ""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""intensity modulated radiation therapy""[All Fields]) OR ""IMRT""[All Fields] OR (""radiotherapy, image guided""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""image guided""[All Fields]) OR ""image-guided radiotherapy""[All Fields] OR (""image""[All Fields] AND ""guided""[All Fields] AND ""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""image guided radiation therapy""[All Fields]) OR ""IGRT""[All Fields] OR (""radiosurgery""[MeSH Terms] OR ""radiosurgery""[All Fields] OR (""stereotactic""[All Fields] AND ""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""stereotactic radiation therapy""[All Fields]) OR ""SRT""[All Fields] OR (""radiosurgery""[MeSH Terms] OR ""radiosurgery""[All Fields] OR (""stereotactic""[All Fields] AND ""radiosurgery""[All Fields]) OR ""stereotactic radiosurgery""[All Fields]) OR ""SRS""[All Fields] OR ((""stereotactic""[All Fields] OR ""stereotactical""[All Fields] OR ""stereotactically""[All Fields] OR ""stereotactics""[All Fields]) AND (""human body""[MeSH Terms] OR (""human""[All Fields] AND ""body""[All Fields]) OR ""human body""[All Fields] OR ""body""[All Fields]) AND (""Radiotherapy""[MeSH Subheading] OR ""Radiotherapy""[All Fields] OR (""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""radiation therapy""[All Fields] OR ""Radiotherapy""[MeSH Terms])) OR ""SBRT""[All Fields] OR (""radiotherapy, intensity modulated""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""intensity modulated""[All Fields]) OR ""intensity-modulated radiotherapy""[All Fields] OR (""volumetric""[All Fields] AND ""modulated""[All Fields] AND ""arc""[All Fields] AND ""therapy""[All Fields]) OR ""volumetric modulated arc therapy""[All Fields]) OR (""radiotherapy, intensity modulated""[MeSH Terms] OR (""Radiotherapy""[All Fields] AND ""intensity modulated""[All Fields]) OR ""intensity-modulated radiotherapy""[All Fields] OR ""vmat""[All Fields]) OR ((""acclimatization""[MeSH Terms] OR ""acclimatization""[All Fields] OR ""adaptation""[All Fields] OR ""adaptations""[All Fields] OR ""adapt""[All Fields] OR ""adaptabilities""[All Fields] OR ""adaptability""[All Fields] OR ""adaptable""[All Fields] OR ""adaptational""[All Fields] OR ""adaptative""[All Fields] OR ""adapte""[All Fields] OR ""adapted""[All Fields] OR ""adapting""[All Fields] OR ""adaption""[All Fields] OR ""adaptions""[All Fields] OR ""adaptive""[All Fields] OR ""adaptively""[All Fields] OR ""adaptiveness""[All Fields] OR ""adaptivity""[All Fields] OR ""adapts""[All Fields]) AND (""Radiotherapy""[MeSH Subheading] OR ""Radiotherapy""[All Fields] OR (""radiation""[All Fields] AND ""therapy""[All Fields]) OR ""radiation therapy""[All Fields] OR ""Radiotherapy""[MeSH Terms])) OR (""art""[MeSH Terms] OR ""art""[All Fields])","1,688,880",1:11:28 -27,#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26,,,"""Immunotherapy""[MeSH Terms] OR ""immunotherap*""[All Fields] OR ""chemoimmunotherap*""[All Fields] OR (""Immune Checkpoint Inhibitors""[MeSH Terms] OR ""Immune Checkpoint Inhibitors""[All Fields] OR ""checkpoint inhibitors immune""[All Fields] OR ""Immune Checkpoint Blockers""[All Fields] OR ""checkpoint blockers immune""[All Fields] OR ""Immune Checkpoint Inhibitor""[All Fields] OR ""checkpoint inhibitor immune""[All Fields] OR ""ctla 4 inhibitors""[All Fields] OR ""ctla 4 inhibitors""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitors""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitors""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitor""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitor""[All Fields] OR ""ctla 4 inhibitor""[All Fields] OR ""ctla 4 inhibitor""[All Fields] OR ""pd 1 inhibitors""[All Fields] OR ""pd 1 inhibitors""[All Fields] OR ""Programmed Cell Death Protein 1 Inhibitor""[All Fields] OR ""Programmed Cell Death Protein 1 Inhibitors""[All Fields] OR ""pd 1 inhibitor""[All Fields] OR ""inhibitor pd 1""[All Fields] OR ""pd 1 inhibitor""[All Fields] OR ""Immune Checkpoint Blockade""[All Fields] OR ""checkpoint blockade immune""[All Fields] OR ""Immune Checkpoint Inhibition""[All Fields] OR ""checkpoint inhibition immune""[All Fields] OR ""pd l1 inhibitors""[All Fields] OR ""pd l1 inhibitors""[All Fields] OR ""programmed death ligand 1 inhibitors""[All Fields] OR ""programmed death ligand 1 inhibitors""[All Fields] OR ""pd l1 inhibitor""[All Fields] OR ""pd l1 inhibitor""[All Fields] OR ""pd 1 pd l1 blockade""[All Fields] OR ""blockade pd 1 pd l1""[All Fields] OR ""pd 1 pd l1 blockade""[All Fields]) OR (""Nivolumab""[MeSH Terms] OR ""Nivolumab""[All Fields] OR ""mdx 1106""[All Fields] OR ""MDX1106""[All Fields] OR ""mdx 1106""[All Fields] OR ""Opdivo""[All Fields] OR ""bms 936558""[All Fields] OR ""BMS936558""[All Fields] OR ""bms 936558""[All Fields] OR ""ono 4538""[All Fields] OR ""ONO4538""[All Fields] OR ""ono 4538""[All Fields]) OR (""Ipilimumab""[MeSH Terms] OR ""Ipilimumab""[All Fields] OR ""anti ctla 4 mab ipilimumab""[All Fields] OR ""anti ctla 4 mab ipilimumab""[All Fields] OR ""ipilimumab anti ctla 4 mab""[All Fields] OR ""mdx 010""[All Fields] OR ""mdx 010""[All Fields] OR ""MDX010""[All Fields] OR ""mdx ctla 4""[All Fields] OR ""mdx ctla 4""[All Fields] OR ""Yervoy""[All Fields]) OR (""camrelizumab""[Supplementary Concept] OR ""camrelizumab""[All Fields] OR ""shr 1210""[All Fields] OR ""shr 1210""[All Fields] OR ""carrelizumab""[All Fields]) OR (""atezolizumab""[Supplementary Concept] OR ""atezolizumab""[All Fields] OR (((((""immunoglobulin g""[MeSH Terms] OR ""immunoglobulin g""[All Fields] OR (""immunoglobulin""[All Fields] AND ""g1""[All Fields]) OR ""immunoglobulin g1""[All Fields]) AND (""antib technol j""[Journal] OR ""anti""[All Fields])) AND ((""human s""[All Fields] OR ""humans""[MeSH Terms] OR ""humans""[All Fields] OR ""human""[All Fields]) AND (""antigens, cd""[MeSH Terms] OR (""antigens""[All Fields] AND ""cd""[All Fields]) OR ""cd antigens""[All Fields] OR (""cd""[All Fields] AND ""antigen""[All Fields]) OR ""cd antigen""[All Fields]) AND ""cd274""[All Fields])) AND ((""human s""[All Fields] OR ""humans""[MeSH Terms] OR ""humans""[All Fields] OR ""human""[All Fields]) AND (""monoclonal""[All Fields] OR ""monoclonality""[All Fields] OR ""monoclonally""[All Fields] OR ""monoclonals""[All Fields] OR ""monoclone""[All Fields] OR ""monoclones""[All Fields]) AND ""heavy""[All Fields] AND (""chain""[All Fields] OR ""chain s""[All Fields] OR ""chains""[All Fields]))) AND ((""disulfides""[MeSH Terms] OR ""disulfides""[All Fields] OR ""disulfide""[All Fields] OR ""disulphide""[All Fields] OR ""disulphides""[All Fields]) AND (""human s""[All Fields] OR ""humans""[MeSH Terms] OR ""humans""[All Fields] OR ""human""[All Fields]) AND (""monoclonal""[All Fields] OR ""monoclonality""[All Fields] OR ""monoclonally""[All Fields] OR ""monoclonals""[All Fields] OR ""monoclone""[All Fields] OR ""monoclones""[All Fields]) AND ""kappa chain""[All Fields] AND (""dimer""[All Fields] OR ""dimer s""[All Fields] OR ""dimeric""[All Fields] OR ""dimerisation""[All Fields] OR ""dimerise""[All Fields] OR ""dimerised""[All Fields] OR ""dimerises""[All Fields] OR ""dimerising""[All Fields] OR ""dimerization""[MeSH Terms] OR ""dimerization""[All Fields] OR ""dimerizations""[All Fields] OR ""dimerize""[All Fields] OR ""dimerized""[All Fields] OR ""dimerizer""[All Fields] OR ""dimerizers""[All Fields] OR ""dimerizes""[All Fields] OR ""dimerizing""[All Fields] OR ""dimers""[All Fields]))) OR ""anti-PDL1""[All Fields] OR ""MPDL3280A""[All Fields] OR ""MPDL-3280A""[All Fields] OR ""Tecentriq""[All Fields] OR ""RG7446""[All Fields] OR ""RG-7446""[All Fields]) OR (""pembrolizumab""[Supplementary Concept] OR ""pembrolizumab""[All Fields] OR ""MK-3475""[All Fields] OR ""Keytruda""[All Fields] OR ""lambrolizumab""[All Fields] OR ""SCH-900475""[All Fields]) OR (""pidilizumab""[Supplementary Concept] OR ""pidilizumab""[All Fields] OR ""ct 011""[All Fields] OR ""ct 011""[All Fields]) OR (""avelumab""[Supplementary Concept] OR ""avelumab""[All Fields] OR ""MSB0010718C""[All Fields] OR ""MSB-0010718C""[All Fields] OR ""bavencio""[All Fields] OR ""MSB0010682""[All Fields] OR (""avelumab""[Supplementary Concept] OR ""avelumab""[All Fields])) OR (""durvalumab""[Supplementary Concept] OR ""durvalumab""[All Fields] OR ""MEDI4736""[All Fields] OR ""MEDI-4736""[All Fields] OR ""Imfinzi""[All Fields]) OR (""tislelizumab""[Supplementary Concept] OR ""tislelizumab""[All Fields] OR ""BGB-A317""[All Fields]) OR (""toripalimab""[Supplementary Concept] OR ""toripalimab""[All Fields]) OR ""Serplulimab""[All Fields] OR ""Adebrelimab""[All Fields]","499,997",1:11:11 -26,"""Adebrelimab""",,,"""Adebrelimab""[All Fields]",23,1:10:58 -25,"""Serplulimab""",,,"""Serplulimab""[All Fields]",60,1:10:51 -24,"""toripalimab""[Supplementary Concept] OR ""toripalimab""",,,"""toripalimab""[Supplementary Concept] OR ""toripalimab""[All Fields]",369,1:10:45 -23,"""tislelizumab""[Supplementary Concept] OR ""tislelizumab"" OR ""BGB-A317""",,,"""tislelizumab""[Supplementary Concept] OR ""tislelizumab""[All Fields] OR ""BGB-A317""[All Fields]",416,1:10:34 -22,"""durvalumab""[Supplementary Concept] OR ""durvalumab"" OR ""MEDI4736"" OR ""MEDI-4736"" OR ""Imfinzi""",,,"""durvalumab""[Supplementary Concept] OR ""durvalumab""[All Fields] OR ""MEDI4736""[All Fields] OR ""MEDI-4736""[All Fields] OR ""Imfinzi""[All Fields]","2,025",1:10:29 -21,"""avelumab""[Supplementary Concept] OR ""avelumab"" OR ""MSB0010718C"" OR ""MSB-0010718C"" OR ""bavencio"" OR ""MSB0010682"" OR ""MSB-0010682""",,,"""avelumab""[Supplementary Concept] OR ""avelumab""[All Fields] OR ""MSB0010718C""[All Fields] OR ""MSB-0010718C""[All Fields] OR ""bavencio""[All Fields] OR ""MSB0010682""[All Fields] OR ""avelumab""[Supplementary Concept] OR ""avelumab""[All Fields]","1,146",1:10:15 -20,"""pidilizumab""[Supplementary Concept] OR ""pidilizumab"" OR ""CT-011"" OR ""CT 011""",,,"""pidilizumab""[Supplementary Concept] OR ""pidilizumab""[All Fields] OR ""ct 011""[All Fields] OR ""ct 011""[All Fields]",40,1:09:58 -19,"""pembrolizumab""[Supplementary Concept] OR ""pembrolizumab"" OR ""MK-3475"" OR ""Keytruda"" OR ""lambrolizumab"" OR ""SCH-900475""",,,"""pembrolizumab""[Supplementary Concept] OR ""pembrolizumab""[All Fields] OR ""MK-3475""[All Fields] OR ""Keytruda""[All Fields] OR ""lambrolizumab""[All Fields] OR ""SCH-900475""[All Fields]","10,992",1:09:46 -18,"""atezolizumab""[Supplementary Concept] OR ""atezolizumab"" OR ""immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MDPL3280a heavy chain), disulfide with human monoclonal MDPL3280a kappa-chain, dimer"" OR ""anti-PDL1"" OR ""MPDL3280A"" OR ""MPDL-3280A"" OR ""Tecentriq"" OR ""RG7446"" OR ""RG-7446""",,,"""atezolizumab""[Supplementary Concept] OR ""atezolizumab""[All Fields] OR (((((""immunoglobulin g""[MeSH Terms] OR ""immunoglobulin g""[All Fields] OR (""immunoglobulin""[All Fields] AND ""g1""[All Fields]) OR ""immunoglobulin g1""[All Fields]) AND (""antib technol j""[Journal] OR ""anti""[All Fields])) AND ((""human s""[All Fields] OR ""humans""[MeSH Terms] OR ""humans""[All Fields] OR ""human""[All Fields]) AND (""antigens, cd""[MeSH Terms] OR (""antigens""[All Fields] AND ""cd""[All Fields]) OR ""cd antigens""[All Fields] OR (""cd""[All Fields] AND ""antigen""[All Fields]) OR ""cd antigen""[All Fields]) AND ""cd274""[All Fields])) AND ((""human s""[All Fields] OR ""humans""[MeSH Terms] OR ""humans""[All Fields] OR ""human""[All Fields]) AND (""monoclonal""[All Fields] OR ""monoclonality""[All Fields] OR ""monoclonally""[All Fields] OR ""monoclonals""[All Fields] OR ""monoclone""[All Fields] OR ""monoclones""[All Fields]) AND ""heavy""[All Fields] AND (""chain""[All Fields] OR ""chain s""[All Fields] OR ""chains""[All Fields]))) AND ((""disulfides""[MeSH Terms] OR ""disulfides""[All Fields] OR ""disulfide""[All Fields] OR ""disulphide""[All Fields] OR ""disulphides""[All Fields]) AND (""human s""[All Fields] OR ""humans""[MeSH Terms] OR ""humans""[All Fields] OR ""human""[All Fields]) AND (""monoclonal""[All Fields] OR ""monoclonality""[All Fields] OR ""monoclonally""[All Fields] OR ""monoclonals""[All Fields] OR ""monoclone""[All Fields] OR ""monoclones""[All Fields]) AND ""kappa chain""[All Fields] AND (""dimer""[All Fields] OR ""dimer s""[All Fields] OR ""dimeric""[All Fields] OR ""dimerisation""[All Fields] OR ""dimerise""[All Fields] OR ""dimerised""[All Fields] OR ""dimerises""[All Fields] OR ""dimerising""[All Fields] OR ""dimerization""[MeSH Terms] OR ""dimerization""[All Fields] OR ""dimerizations""[All Fields] OR ""dimerize""[All Fields] OR ""dimerized""[All Fields] OR ""dimerizer""[All Fields] OR ""dimerizers""[All Fields] OR ""dimerizes""[All Fields] OR ""dimerizing""[All Fields] OR ""dimers""[All Fields]))) OR ""anti-PDL1""[All Fields] OR ""MPDL3280A""[All Fields] OR ""MPDL-3280A""[All Fields] OR ""Tecentriq""[All Fields] OR ""RG7446""[All Fields] OR ""RG-7446""[All Fields]","4,205",1:09:31 -17,"""camrelizumab""[Supplementary Concept] OR ""camrelizumab"" OR ""SHR-1210"" OR ""SHR 1210"" OR ""carrelizumab""",,,"""camrelizumab""[Supplementary Concept] OR ""camrelizumab""[All Fields] OR ""shr 1210""[All Fields] OR ""shr 1210""[All Fields] OR ""carrelizumab""[All Fields]",773,1:09:22 -16,"""Ipilimumab""[Mesh] OR ""Ipilimumab"" OR ""Anti-CTLA-4 MAb Ipilimumab"" OR ""Anti CTLA 4 MAb Ipilimumab"" OR ""Ipilimumab, Anti-CTLA-4 MAb"" OR ""MDX 010"" OR ""MDX-010"" OR ""MDX010"" OR ""MDX-CTLA-4"" OR ""MDX CTLA 4"" OR ""Yervoy""",,,"""Ipilimumab""[MeSH Terms] OR ""Ipilimumab""[All Fields] OR ""anti ctla 4 mab ipilimumab""[All Fields] OR ""anti ctla 4 mab ipilimumab""[All Fields] OR ""ipilimumab anti ctla 4 mab""[All Fields] OR ""mdx 010""[All Fields] OR ""mdx 010""[All Fields] OR ""MDX010""[All Fields] OR ""mdx ctla 4""[All Fields] OR ""mdx ctla 4""[All Fields] OR ""Yervoy""[All Fields]","6,227",1:09:13 -15,("Nivolumab"[Mesh] OR "Nivolumab" OR "MDX-1106" OR "MDX1106" OR "MDX 1106" OR "Opdivo" OR "BMS-936558" OR "BMS936558" OR "BMS 936558" OR "ONO-4538" OR "ONO4538" OR "ONO 4538"),,,"""Nivolumab""[MeSH Terms] OR ""Nivolumab""[All Fields] OR ""mdx 1106""[All Fields] OR ""MDX1106""[All Fields] OR ""mdx 1106""[All Fields] OR ""Opdivo""[All Fields] OR ""bms 936558""[All Fields] OR ""BMS936558""[All Fields] OR ""bms 936558""[All Fields] OR ""ono 4538""[All Fields] OR ""ONO4538""[All Fields] OR ""ono 4538""[All Fields]","11,290",1:09:06 -14,"(""Immune Checkpoint Inhibitors""[Mesh] OR ""Immune Checkpoint Inhibitors"" OR ""Checkpoint Inhibitors, Immune"" OR ""Immune Checkpoint Blockers"" OR ""Checkpoint Blockers, Immune"" OR ""Immune Checkpoint Inhibitor"" OR ""Checkpoint Inhibitor, Immune"" OR ""CTLA-4 Inhibitors"" OR ""CTLA 4 Inhibitors"" OR ""Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors"" OR ""Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors"" OR ""Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor"" OR ""Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor"" OR ""CTLA-4 Inhibitor"" OR ""CTLA 4 Inhibitor"" OR ""PD-1 Inhibitors"" OR ""PD 1 Inhibitors"" OR ""Programmed Cell Death Protein 1 Inhibitor"" OR ""Programmed Cell Death Protein 1 Inhibitors"" OR ""PD-1 Inhibitor"" OR ""Inhibitor, PD-1"" OR ""PD 1 Inhibitor"" OR ""Immune Checkpoint Blockade"" OR ""Checkpoint Blockade, Immune"" OR ""Immune Checkpoint Inhibition"" OR ""Checkpoint Inhibition, Immune"" OR ""PD-L1 Inhibitors"" OR ""PD L1 Inhibitors"" OR ""Programmed Death-Ligand 1 Inhibitors"" OR ""Programmed Death Ligand 1 Inhibitors"" OR ""PD-L1 Inhibitor"" OR ""PD L1 Inhibitor"" OR ""PD-1-PD-L1 Blockade"" OR ""Blockade, PD-1-PD-L1"" OR ""PD 1 PD L1 Blockade"")",,,"""Immune Checkpoint Inhibitors""[MeSH Terms] OR ""Immune Checkpoint Inhibitors""[All Fields] OR ""checkpoint inhibitors immune""[All Fields] OR ""Immune Checkpoint Blockers""[All Fields] OR ""checkpoint blockers immune""[All Fields] OR ""Immune Checkpoint Inhibitor""[All Fields] OR ""checkpoint inhibitor immune""[All Fields] OR ""ctla 4 inhibitors""[All Fields] OR ""ctla 4 inhibitors""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitors""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitors""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitor""[All Fields] OR ""cytotoxic t lymphocyte associated protein 4 inhibitor""[All Fields] OR ""ctla 4 inhibitor""[All Fields] OR ""ctla 4 inhibitor""[All Fields] OR ""pd 1 inhibitors""[All Fields] OR ""pd 1 inhibitors""[All Fields] OR ""Programmed Cell Death Protein 1 Inhibitor""[All Fields] OR ""Programmed Cell Death Protein 1 Inhibitors""[All Fields] OR ""pd 1 inhibitor""[All Fields] OR ""inhibitor pd 1""[All Fields] OR ""pd 1 inhibitor""[All Fields] OR ""Immune Checkpoint Blockade""[All Fields] OR ""checkpoint blockade immune""[All Fields] OR ""Immune Checkpoint Inhibition""[All Fields] OR ""checkpoint inhibition immune""[All Fields] OR ""pd l1 inhibitors""[All Fields] OR ""pd l1 inhibitors""[All Fields] OR ""programmed death ligand 1 inhibitors""[All Fields] OR ""programmed death ligand 1 inhibitors""[All Fields] OR ""pd l1 inhibitor""[All Fields] OR ""pd l1 inhibitor""[All Fields] OR ""pd 1 pd l1 blockade""[All Fields] OR ""blockade pd 1 pd l1""[All Fields] OR ""pd 1 pd l1 blockade""[All Fields]","55,201",1:08:53 -13,"""Immunotherapy""[Mesh] OR immunotherap* OR chemoimmunotherap*",,,"""Immunotherapy""[MeSH Terms] OR ""immunotherap*""[All Fields] OR ""chemoimmunotherap*""[All Fields]","470,605",1:08:34 -12,#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11,,,"""Drug Therapy""[MeSH Terms] OR (""Drug""[All Fields] AND ""therap*""[All Fields]) OR ""chemotherap*""[All Fields] OR ""pharmacotherap*""[All Fields] OR (""therap*""[All Fields] AND ""Drug""[All Fields]) OR (""Antineoplastic Agents""[MeSH Terms] OR ""antineoplastic agent*""[All Fields] OR ""antitumor agent*""[All Fields] OR ""anticancer agent*""[All Fields] OR ""antineoplastic drug*""[All Fields] OR ""antitumor drug*""[All Fields] OR ""cancer chemotherapy agent*""[All Fields] OR ""antineoplastic*""[All Fields] OR ""chemotherapeutic anticancer agent*""[All Fields] OR ""cancer chemotherapy drug*""[All Fields]) OR (""Cisplatin""[MeSH Terms] OR ""Cisplatin""[All Fields] OR ""cis diamminedichloroplatinum""[All Fields] OR ""cis diamminedichloroplatinum""[All Fields] OR ""cis diamminedichloroplatinum ii""[All Fields] OR ""cis dichlorodiammineplatinum ii""[All Fields] OR ""cis-Platinum""[All Fields] OR ""Dichlorodiammineplatinum""[All Fields] OR ""Platinum Diamminodichloride""[All Fields] OR ""diamminodichloride platinum""[All Fields] OR ""Biocisplatinum""[All Fields] OR ""Platidiam""[All Fields] OR ""Platino""[All Fields] OR ""Platinol""[All Fields] OR ""NSC-119875""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields] OR ""CBDCA""[All Fields] OR ""cis diammine cyclobutanedicarboxylato platinum ii""[All Fields] OR ""Paraplatin""[All Fields] OR ""Paraplatine""[All Fields] OR ""nsc 241240""[All Fields] OR ""NSC241240""[All Fields] OR ""nsc 241240""[All Fields] OR ""jm 8""[All Fields] OR ""JM8""[All Fields] OR ""jm 8""[All Fields] OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR ""Ercar""[All Fields] OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR (""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields]) OR ""Ribocarbo""[All Fields] OR ""Carboplat""[All Fields]) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR ""1 2 diamminocyclohexane trans 1 oxolatoplatinum ii""[All Fields] OR ""L-OHP""[All Fields] OR ""Cpd""[All Fields] OR ((((((""platinum""[MeSH Terms] OR ""platinum""[All Fields] OR ""platinums""[All Fields]) AND ""2""[All Fields]) AND ""ethanedioate""[All Fields]) AND ""1r 2r""[All Fields]) AND (""1 2 cyclohexanediamine""[Supplementary Concept] OR ""1 2 cyclohexanediamine""[All Fields] OR ""1 2 cyclohexanediamine""[All Fields])) AND ""1 1 1""[All Fields]) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""oxalato""[All Fields] AND ""1 2""[All Fields] AND ""cyclohexanediamine""[All Fields] AND ""platinum""[All Fields] AND ""II""[All Fields])) OR (((""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR ""Oxaliplatine""[All Fields] OR ""oxaliplatin s""[All Fields]) AND (""sp 4 2""[All Fields] AND ""1r trans""[All Fields])) AND (""isomerism""[MeSH Terms] OR ""isomerism""[All Fields] OR ""isomer""[All Fields] OR ""isomers""[All Fields])) OR ""Oxaliplatine""[All Fields] OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""1 2""[All Fields] AND ""diaminocyclohexane""[All Fields] AND ""platinum""[All Fields] AND ""oxalate""[All Fields])) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""1 2""[All Fields] AND ""diaminocyclohexane""[All Fields] AND ""platinum""[All Fields] AND ""oxalate""[All Fields])) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""platinum""[All Fields] AND ""II""[All Fields] AND ""1 2""[All Fields] AND ""cyclohexanediamine""[All Fields] AND ""oxalate""[All Fields])) OR (((""cis oxalato""[All Fields] AND ""trans l""[All Fields]) AND ""1 2 diaminocyclohexane platinum""[All Fields]) AND ""II""[All Fields]) OR ""act 078""[All Fields] OR ""act 078""[All Fields] OR ""ACT078""[All Fields] OR (((""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR ""Oxaliplatine""[All Fields] OR ""oxaliplatin s""[All Fields]) AND (""sp 4 3""[All Fields] AND ""cis""[All Fields])) AND (""isomerism""[MeSH Terms] OR ""isomerism""[All Fields] OR ""isomer""[All Fields] OR ""isomers""[All Fields])) OR ""Eloxatine""[All Fields]) OR (""Lobaplatin""[Supplementary Concept] OR ""Lobaplatin""[All Fields] OR ""1 2 diaminomethylcyclobutane platinum ii lactate""[All Fields] OR ""d 19466""[All Fields] OR ""d 19466""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""demethyl""[All Fields] AND ""epipodophyllotoxin""[All Fields] AND ""ethylidine""[All Fields] AND ""glucoside""[All Fields])) OR ""Eposide""[All Fields] OR ""Vepesid""[All Fields] OR ((""etoposid""[All Fields] OR ""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR ""etoposide s""[All Fields] OR ""etoposides""[All Fields]) AND ""alpha d glucopyranosyl""[All Fields] AND (""isomerism""[MeSH Terms] OR ""isomerism""[All Fields] OR ""isomer""[All Fields] OR ""isomers""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""5s""[All Fields] AND ""isomer""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""5a""[All Fields] AND ""alpha""[All Fields] AND ""isomer""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""nsc 141540""[All Fields] OR ""NSC141540""[All Fields] OR ""nsc 141540""[All Fields] OR ""vp 16 213""[All Fields] OR ""VP 16213""[All Fields] OR ""vp 16 213""[All Fields] OR ""vp 16""[All Fields] OR ""VP16""[All Fields] OR ""vp 16""[All Fields] OR ""Celltop""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""Toposar""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""teva""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""teva""[All Fields] AND ""Etoposide""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""eto""[All Fields] AND ""gry""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""eto""[All Fields] AND ""gry""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""pierre""[All Fields] AND ""fabre""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""etoposido""[All Fields] AND ""ferrer""[All Fields] AND ""farma""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""Lastet""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""vepeside sandoz""[All Fields] OR ""vepeside sandoz""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]))","5,063,906",1:08:13 -11,"(""Etoposide""[Mesh] OR ""Etoposide"" OR ""Demethyl Epipodophyllotoxin Ethylidine Glucoside"" OR ""Eposide"" OR ""Vepesid"" OR ""Etoposide, alpha-D-Glucopyranosyl Isomer"" OR ""alpha-D-Glucopyranosyl Isomer Etoposide"" OR ""Etoposide, alpha D Glucopyranosyl Isomer"" OR ""Etoposide, (5S)-Isomer"" OR ""Etoposide, (5a alpha)-Isomer"" OR ""Etoposide, (5a alpha,9 alpha)-Isomer"" OR ""NSC-141540"" OR ""NSC141540"" OR ""NSC 141540"" OR ""VP 16-213"" OR ""VP 16213"" OR ""VP 16 213"" OR ""VP-16"" OR ""VP16"" OR ""VP 16"" OR ""Celltop"" OR ""Eposin"" OR ""Toposar"" OR ""Etoposide Teva"" OR ""Teva, Etoposide"" OR ""Eto-GRY"" OR ""Eto GRY"" OR ""Etoposide Pierre Fabre"" OR ""Etoposido Ferrer Farma"" OR ""Etopos"" OR ""Exitop"" OR ""Lastet"" OR ""Onkoposid"" OR ""Riboposid"" OR ""Vpside-Sandoz"" OR ""Vpside Sandoz"" OR ""Etomedac"")",,,"""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""demethyl""[All Fields] AND ""epipodophyllotoxin""[All Fields] AND ""ethylidine""[All Fields] AND ""glucoside""[All Fields])) OR ""Eposide""[All Fields] OR ""Vepesid""[All Fields] OR ((""etoposid""[All Fields] OR ""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR ""etoposide s""[All Fields] OR ""etoposides""[All Fields]) AND ""alpha d glucopyranosyl""[All Fields] AND (""isomerism""[MeSH Terms] OR ""isomerism""[All Fields] OR ""isomer""[All Fields] OR ""isomers""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""5s""[All Fields] AND ""isomer""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""5a""[All Fields] AND ""alpha""[All Fields] AND ""isomer""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""nsc 141540""[All Fields] OR ""NSC141540""[All Fields] OR ""nsc 141540""[All Fields] OR ""vp 16 213""[All Fields] OR ""VP 16213""[All Fields] OR ""vp 16 213""[All Fields] OR ""vp 16""[All Fields] OR ""VP16""[All Fields] OR ""vp 16""[All Fields] OR ""Celltop""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""Toposar""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""teva""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""teva""[All Fields] AND ""Etoposide""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""eto""[All Fields] AND ""gry""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""eto""[All Fields] AND ""gry""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""Etoposide""[All Fields] AND ""pierre""[All Fields] AND ""fabre""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields] OR (""etoposido""[All Fields] AND ""ferrer""[All Fields] AND ""farma""[All Fields])) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""Lastet""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields]) OR ""vepeside sandoz""[All Fields] OR ""vepeside sandoz""[All Fields] OR (""Etoposide""[MeSH Terms] OR ""Etoposide""[All Fields])","31,608",1:07:57 -10,"(""lobaplatin"" [Supplementary Concept] OR ""Lobaplatin"" OR ""1,2-diaminomethylcyclobutane-platinum(II) lactate"" OR ""D 19466"" OR ""D-19466"")",,,"""Lobaplatin""[Supplementary Concept] OR ""Lobaplatin""[All Fields] OR ""1 2 diaminomethylcyclobutane platinum ii lactate""[All Fields] OR ""d 19466""[All Fields] OR ""d 19466""[All Fields]",225,1:07:31 -9,"(""Oxaliplatin""[Mesh] OR ""Oxaliplatin"" OR ""1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II)"" OR ""L-OHP"" OR ""Cpd"" OR ""Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1)"" OR ""Oxalato-(1,2-cyclohexanediamine)platinum II"" OR ""Oxaliplatin, (SP-4-2-(1R-trans))-isomer"" OR ""Oxaliplatine"" OR ""1,2-Diaminocyclohexane Platinum Oxalate"" OR ""1,2 Diaminocyclohexane Platinum Oxalate"" OR ""Platinum(II)-1,2-cyclohexanediamine Oxalate"" OR ""Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II)"" OR ""ACT 078"" OR ""ACT-078"" OR ""ACT078"" OR ""Oxaliplatin, (SP-4-3-(cis))-isomer"" OR ""Eloxatine"")",,,"""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR ""1 2 diamminocyclohexane trans 1 oxolatoplatinum ii""[All Fields] OR ""L-OHP""[All Fields] OR ""Cpd""[All Fields] OR ((((((""platinum""[MeSH Terms] OR ""platinum""[All Fields] OR ""platinums""[All Fields]) AND ""2""[All Fields]) AND ""ethanedioate""[All Fields]) AND ""1r 2r""[All Fields]) AND (""1 2 cyclohexanediamine""[Supplementary Concept] OR ""1 2 cyclohexanediamine""[All Fields] OR ""1 2 cyclohexanediamine""[All Fields])) AND ""1 1 1""[All Fields]) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""oxalato""[All Fields] AND ""1 2""[All Fields] AND ""cyclohexanediamine""[All Fields] AND ""platinum""[All Fields] AND ""II""[All Fields])) OR (((""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR ""Oxaliplatine""[All Fields] OR ""oxaliplatin s""[All Fields]) AND (""sp 4 2""[All Fields] AND ""1r trans""[All Fields])) AND (""isomerism""[MeSH Terms] OR ""isomerism""[All Fields] OR ""isomer""[All Fields] OR ""isomers""[All Fields])) OR ""Oxaliplatine""[All Fields] OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""1 2""[All Fields] AND ""diaminocyclohexane""[All Fields] AND ""platinum""[All Fields] AND ""oxalate""[All Fields])) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""1 2""[All Fields] AND ""diaminocyclohexane""[All Fields] AND ""platinum""[All Fields] AND ""oxalate""[All Fields])) OR (""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR (""platinum""[All Fields] AND ""II""[All Fields] AND ""1 2""[All Fields] AND ""cyclohexanediamine""[All Fields] AND ""oxalate""[All Fields])) OR (((""cis oxalato""[All Fields] AND ""trans l""[All Fields]) AND ""1 2 diaminocyclohexane platinum""[All Fields]) AND ""II""[All Fields]) OR ""act 078""[All Fields] OR ""act 078""[All Fields] OR ""ACT078""[All Fields] OR (((""Oxaliplatin""[MeSH Terms] OR ""Oxaliplatin""[All Fields] OR ""Oxaliplatine""[All Fields] OR ""oxaliplatin s""[All Fields]) AND (""sp 4 3""[All Fields] AND ""cis""[All Fields])) AND (""isomerism""[MeSH Terms] OR ""isomerism""[All Fields] OR ""isomer""[All Fields] OR ""isomers""[All Fields])) OR ""Eloxatine""[All Fields]","25,231",1:07:20 -8,("Carboplatin"[Mesh] OR "Carboplatin" OR "CBDCA" OR "cis-Diammine(cyclobutanedicarboxylato)platinum II" OR "Paraplatin" OR "Paraplatine" OR "NSC-241240" OR "NSC241240" OR "NSC 241240" OR "JM-8" OR "JM8" OR "JM 8" OR "Blastocarb" OR "Carbotec" OR "Carbosin" OR "Ercar" OR "Nealorin" OR "Neocarbo" OR "Platinwas" OR "Ribocarbo" OR "Carboplat"),,,"""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields] OR ""CBDCA""[All Fields] OR ""cis diammine cyclobutanedicarboxylato platinum ii""[All Fields] OR ""Paraplatin""[All Fields] OR ""Paraplatine""[All Fields] OR ""nsc 241240""[All Fields] OR ""NSC241240""[All Fields] OR ""nsc 241240""[All Fields] OR ""jm 8""[All Fields] OR ""JM8""[All Fields] OR ""jm 8""[All Fields] OR ""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields] OR ""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields] OR ""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields] OR ""Ercar""[All Fields] OR ""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields] OR ""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields] OR ""Carboplatin""[MeSH Terms] OR ""Carboplatin""[All Fields] OR ""Ribocarbo""[All Fields] OR ""Carboplat""[All Fields]","21,716",1:05:05 -7,"(""Cisplatin""[Mesh] OR ""Cisplatin"" OR ""cis-Diamminedichloroplatinum"" OR ""cis Diamminedichloroplatinum"" OR ""cis-Diamminedichloroplatinum(II)"" OR ""cis-Dichlorodiammineplatinum(II)"" OR ""cis-Platinum"" OR ""Dichlorodiammineplatinum"" OR ""Platinum Diamminodichloride"" OR ""Diamminodichloride, Platinum"" OR ""Biocisplatinum"" OR ""Platidiam"" OR ""Platino"" OR ""Platinol"" OR ""NSC-119875"")",,,"""Cisplatin""[MeSH Terms] OR ""Cisplatin""[All Fields] OR ""cis diamminedichloroplatinum""[All Fields] OR ""cis diamminedichloroplatinum""[All Fields] OR ""cis diamminedichloroplatinum ii""[All Fields] OR ""cis dichlorodiammineplatinum ii""[All Fields] OR ""cis-Platinum""[All Fields] OR ""Dichlorodiammineplatinum""[All Fields] OR ""Platinum Diamminodichloride""[All Fields] OR ""diamminodichloride platinum""[All Fields] OR ""Biocisplatinum""[All Fields] OR ""Platidiam""[All Fields] OR ""Platino""[All Fields] OR ""Platinol""[All Fields] OR ""NSC-119875""[All Fields]","93,067",1:04:57 -6,("Antineoplastic Agents"[Mesh] OR "Antineoplastic Agent*" OR "Antitumor Agent*" OR "Anticancer Agent*" OR "Antineoplastic Drug*" OR "Antitumor Drug*" OR "Cancer Chemotherapy Agent*" OR "Antineoplastic*" OR "Chemotherapeutic Anticancer Agent*" OR "Cancer Chemotherapy Drug*"),,,"""Antineoplastic Agents""[MeSH Terms] OR ""antineoplastic agent*""[All Fields] OR ""antitumor agent*""[All Fields] OR ""anticancer agent*""[All Fields] OR ""antineoplastic drug*""[All Fields] OR ""antitumor drug*""[All Fields] OR ""cancer chemotherapy agent*""[All Fields] OR ""antineoplastic*""[All Fields] OR ""chemotherapeutic anticancer agent*""[All Fields] OR ""cancer chemotherapy drug*""[All Fields]","1,444,622",1:04:27 -5,"(""Drug Therapy""[MeSH Terms] OR Drug Therap* OR Chemotherap* OR Pharmacotherap* OR Therap*, Drug)",,,"""Drug Therapy""[MeSH Terms] OR (""Drug""[All Fields] AND ""therap*""[All Fields]) OR ""chemotherap*""[All Fields] OR ""pharmacotherap*""[All Fields] OR (""therap*""[All Fields] AND ""Drug""[All Fields])","4,491,336",1:04:14 -4,#1 AND (#2 OR #3) OR ES-SCLC,,,(((("extensive"[All Fields] OR "extensively"[All Fields]) AND ("stage"[All Fields] OR "staged"[All Fields] OR "stages"[All Fields] OR "staging"[All Fields] OR "stagings"[All Fields])) OR (("extensive"[All Fields] OR "extensively"[All Fields]) AND ("disease"[MeSH Terms] OR "disease"[All Fields] OR "diseases"[All Fields] OR "disease s"[All Fields] OR "diseased"[All Fields])) OR ("extensive"[All Fields] OR "extensively"[All Fields]) OR ("advance"[All Fields] OR "advanced"[All Fields] OR "advancement"[All Fields] OR "advancements"[All Fields] OR "advances"[All Fields] OR "advancing"[All Fields])) AND ("small cell lung carcinoma"[MeSH Terms] OR ("small cell lung carcinoma"[MeSH Terms] OR ("small"[All Fields] AND "cell"[All Fields] AND "lung"[All Fields] AND "carcinoma"[All Fields]) OR "small cell lung carcinoma"[All Fields]) OR ("small cell lung carcinoma"[MeSH Terms] OR ("small"[All Fields] AND "cell"[All Fields] AND "lung"[All Fields] AND "carcinoma"[All Fields]) OR "small cell lung carcinoma"[All Fields] OR ("carcinoma"[All Fields] AND "small"[All Fields] AND "cell"[All Fields] AND "lung"[All Fields]) OR "carcinoma small cell lung"[All Fields]) OR ("small cell lung carcinoma"[MeSH Terms] OR ("small"[All Fields] AND "cell"[All Fields] AND "lung"[All Fields] AND "carcinoma"[All Fields]) OR "small cell lung carcinoma"[All Fields] OR ("oat"[All Fields] AND "cell"[All Fields] AND "carcinoma"[All Fields] AND "lung"[All Fields]) OR "oat cell carcinoma of lung"[All Fields]) OR ("small cell lung carcinoma"[MeSH Terms] OR ("small"[All Fields] AND "cell"[All Fields] AND "lung"[All Fields] AND "carcinoma"[All Fields]) OR "small cell lung carcinoma"[All Fields] OR ("oat"[All Fields] AND "cell"[All Fields] AND "lung"[All Fields] AND "cancer"[All Fields]) OR "oat cell lung cancer"[All Fields]) OR ("small cell lung carcinoma"[MeSH Terms] OR ("small"[All Fields] AND "cell"[All Fields] AND "lung"[All Fields] AND "carcinoma"[All Fields]) OR "small cell lung carcinoma"[All Fields] OR ("small"[All Fields] AND "cell"[All Fields] AND "lung"[All Fields] AND "cancer"[All Fields]) OR "small cell lung cancer"[All Fields]) OR ("small cell lung carcinoma"[MeSH Terms] OR ("small"[All Fields] AND "cell"[All Fields] AND "lung"[All Fields] AND "carcinoma"[All Fields]) OR "small cell lung carcinoma"[All Fields] OR ("small"[All Fields] AND "cell"[All Fields] AND "cancer"[All Fields] AND "lung"[All Fields]) OR "small cell cancer of the lung"[All Fields]) OR "SCLC"[All Fields] OR (((("small"[Journal] OR "small"[All Fields]) AND ("cells"[MeSH Terms] OR "cells"[All Fields] OR "cell"[All Fields])) OR ("oat"[All Fields] AND ("cells"[MeSH Terms] OR "cells"[All Fields] OR "cell"[All Fields]))) AND ("lung neoplasms"[MeSH Terms] OR ("lung neoplasms"[MeSH Terms] OR ("lung"[All Fields] AND "neoplasms"[All Fields]) OR "lung neoplasms"[All Fields] OR ("lung"[All Fields] AND "neoplasm"[All Fields]) OR "lung neoplasm"[All Fields]) OR ("lung neoplasms"[MeSH Terms] OR ("lung"[All Fields] AND "neoplasms"[All Fields]) OR "lung neoplasms"[All Fields] OR ("pulmonary"[All Fields] AND "neoplasm"[All Fields]) OR "pulmonary neoplasm"[All Fields]) OR ("lung neoplasms"[MeSH Terms] OR ("lung"[All Fields] AND "neoplasms"[All Fields]) OR "lung neoplasms"[All Fields] OR ("lung"[All Fields] AND "cancer"[All Fields]) OR "lung cancer"[All Fields]) OR ("lung neoplasms"[MeSH Terms] OR ("lung"[All Fields] AND "neoplasms"[All Fields]) OR "lung neoplasms"[All Fields] OR ("pulmonary"[All Fields] AND "cancer"[All Fields]) OR "pulmonary cancer"[All Fields]) OR ("lung neoplasms"[MeSH Terms] OR ("lung"[All Fields] AND "neoplasms"[All Fields]) OR "lung neoplasms"[All Fields] OR ("cancer"[All Fields] AND "lung"[All Fields]) OR "cancer of the lung"[All Fields]))))) OR "ES-SCLC"[All Fields],"36,976",1:03:44 -3,(small cell OR oat cell ) AND ("lung neoplasms"[MeSH] OR Lung Neoplasm OR Pulmonary Neoplasm OR Lung Cancer OR Pulmonary Cancer OR Cancer of the Lung),,,((("small"[Journal] OR "small"[All Fields]) AND ("cells"[MeSH Terms] OR "cells"[All Fields] OR "cell"[All Fields])) OR ("oat"[All Fields] AND ("cells"[MeSH Terms] OR "cells"[All Fields] OR "cell"[All Fields]))) AND ("lung neoplasms"[MeSH Terms] OR ("lung neoplasms"[MeSH Terms] OR ("lung"[All Fields] AND "neoplasms"[All Fields]) OR "lung neoplasms"[All Fields] OR ("lung"[All Fields] AND "neoplasm"[All Fields]) OR "lung neoplasm"[All Fields]) OR ("lung neoplasms"[MeSH Terms] OR ("lung"[All Fields] AND "neoplasms"[All Fields]) OR "lung neoplasms"[All Fields] OR ("pulmonary"[All Fields] AND "neoplasm"[All Fields]) OR "pulmonary neoplasm"[All Fields]) OR ("lung neoplasms"[MeSH Terms] OR ("lung"[All Fields] AND "neoplasms"[All Fields]) OR "lung neoplasms"[All Fields] OR ("lung"[All Fields] AND "cancer"[All Fields]) OR "lung cancer"[All Fields]) OR ("lung neoplasms"[MeSH Terms] OR ("lung"[All Fields] AND "neoplasms"[All Fields]) OR "lung neoplasms"[All Fields] OR ("pulmonary"[All Fields] AND "cancer"[All Fields]) OR "pulmonary cancer"[All Fields]) OR ("lung neoplasms"[MeSH Terms] OR ("lung"[All Fields] AND "neoplasms"[All Fields]) OR "lung neoplasms"[All Fields] OR ("cancer"[All Fields] AND "lung"[All Fields]) OR "cancer of the lung"[All Fields])),"144,865",1:03:27 -2,"""small cell lung carcinoma""[MeSH] OR Small Cell Lung Carcinoma OR Carcinoma, Small Cell Lung OR Oat Cell Carcinoma of Lung OR Oat Cell Lung Cancer OR Small Cell Lung Cancer OR Small Cell Cancer of the Lung OR SCLC",,,"""small cell lung carcinoma""[MeSH Terms] OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""carcinoma""[All Fields] AND ""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields]) OR ""carcinoma small cell lung""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""oat""[All Fields] AND ""cell""[All Fields] AND ""carcinoma""[All Fields] AND ""lung""[All Fields]) OR ""oat cell carcinoma of lung""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""oat""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""cancer""[All Fields]) OR ""oat cell lung cancer""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""cancer""[All Fields]) OR ""small cell lung cancer""[All Fields]) OR (""small cell lung carcinoma""[MeSH Terms] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""lung""[All Fields] AND ""carcinoma""[All Fields]) OR ""small cell lung carcinoma""[All Fields] OR (""small""[All Fields] AND ""cell""[All Fields] AND ""cancer""[All Fields] AND ""lung""[All Fields]) OR ""small cell cancer of the lung""[All Fields]) OR ""SCLC""[All Fields]","141,911",1:03:19 -1,extensive stage OR extensive disease OR extensive OR advanced,,,(("extensive"[All Fields] OR "extensively"[All Fields]) AND ("stage"[All Fields] OR "staged"[All Fields] OR "stages"[All Fields] OR "staging"[All Fields] OR "stagings"[All Fields])) OR (("extensive"[All Fields] OR "extensively"[All Fields]) AND ("disease"[MeSH Terms] OR "disease"[All Fields] OR "diseases"[All Fields] OR "disease s"[All Fields] OR "diseased"[All Fields])) OR ("extensive"[All Fields] OR "extensively"[All Fields]) OR ("advance"[All Fields] OR "advanced"[All Fields] OR "advancement"[All Fields] OR "advancements"[All Fields] OR "advances"[All Fields] OR "advancing"[All Fields]),"2,133,954",1:03:09 diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/citation-export CENTRAL 538.bib" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/citation-export CENTRAL 538.bib" deleted file mode 100644 index 462320b..0000000 --- "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/citation-export CENTRAL 538.bib" +++ /dev/null @@ -1,8564 +0,0 @@ -Record #1 of 538 -@article{NCT0240292015, -author = {NCT02402920,}, -title = {Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer}, -journal = {https://clinicaltrials.gov/ct2/show/NCT02402920}, -year = {2015}, -accession_number = {CTgov NCT02402920}, -publication type = {Trial registry record}, -keywords = {Carboplatin; Carcinoma; Cisplatin; Etoposide; Etoposide phosphate; Lung Neoplasms; Neuroendocrine Tumors; Pembrolizumab; Podophyllotoxin; Small Cell Lung Carcinoma}, -abstract = {PRIMARY OBJECTIVES: I. Safety of pembrolizumab (MK 3475) plus chemotherapy (chemo)/radiation for limited‐stage small‐cell lung cancer (LS‐SCLC). II. Safety of MK‐3475 plus radiation for extensive‐stage small‐cell lung cancer (ES‐SCLC). SECONDARY OBJECTIVES: I. MK‐3475 will improve progression free survival (PFS) compared to historical controls for LS‐SCLC and ES‐SCLC. OUTLINE: This is a dose‐escalation study of pembrolizumab. Patients are assigned to either Part A or Part B based on diagnosis. PART A (LS‐SCLC): Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 and undergo radiation therapy twice daily (BID) 5 days a week for 3 weeks. Patients also receive cisplatin IV over 2 hours or carboplatin IV over 30 minutes and etoposide IV over 4 hours on days 1, 2, and 3. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy, 4 courses for chemotherapy) in the absence of disease progression or unacceptable toxicity. Patients who achieve systemic disease control and do not exhibit severe (grade > 3) pembrolizumab related toxicity during/after completion of 16 courses may receive 16 additional courses of pembrolizumab in the absence of disease progression or unacceptable toxicity. PART B (ES‐SCLC): Beginning after the completion of chemotherapy, patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy) in the absence of disease progression or unacceptable toxicity. After completion of study treatment, all patients are followed up at 30 days and then every 12 weeks.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01598022/full} -} - - -Record #2 of 538 -@article{Arriola16, -author = {Arriola, E, Wheater, M, Galea, I, Cross, N, Maishman, T, Hamid, D, Stanton, L, Cave, J, Geldart, T, Mulatero, C, Potter, V, Danson, S, Woll, PJ, Griffiths, R, Nolan, L, and Ottensmeier, C}, -title = {Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC}, -journal = {Journal of thoracic oncology}, -volume = {11}, -number = {9}, -pages = {1511‐1521}, -year = {2016}, -accession_number = {EMBASE 612224681, PUBMED 27296105}, -publication type = {Journal article}, -keywords = {*biological marker; *cancer combination chemotherapy; *carboplatin; *carboplatin/ae [Adverse Drug Reaction]; *carboplatin/cb [Drug Combination]; *carboplatin/dt [Drug Therapy]; *controlled study; *etoposide; *etoposide/ae [Adverse Drug Reaction]; *etoposide/cb [Drug Combination]; *etoposide/dt [Drug Therapy]; *ipilimumab; *ipilimumab/ae [Adverse Drug Reaction]; *ipilimumab/cb [Drug Combination]; *ipilimumab/dt [Drug Therapy]; *small cell lung cancer; *small cell lung cancer/dt [Drug Therapy]; Adult; Aged; Aged, 80 and over; Agitation; Alkaline phosphatase/ec [Endogenous Compound]; Anemia/si [Side Effect]; Antibodies, Monoclonal [administration & dosage]; Antibody blood level; Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; Antinuclear antibody/ec [Endogenous Compound]; Article; Autoantibodies [blood]; Autoantibody; Autoantibody/ec [Endogenous Compound]; Autoimmune disease/si [Side Effect]; Biomarkers, Tumor [*analysis]; Brain disease/si [Side Effect]; Cancer radiotherapy; Carboplatin [administration & dosage]; Chemotherapy; Clinical article; Clinical outcome; Clinical study; Clinical trial; Colitis/si [Side Effect]; Controlled clinical trial; Diarrhea/si [Side Effect]; Drug combination; Drug efficacy; Drug safety; Drug therapy; Dyspnea/si [Side Effect]; Etoposide [administration & dosage]; Fatigue/si [Side Effect]; Febrile neutropenia/si [Side Effect]; Female; Follow up; Headache/si [Side Effect]; Human; Human tissue; Humans; Hyperglycemia/si [Side Effect]; Hyponatremia/si [Side Effect]; Infection/si [Side Effect]; Ipilimumab; Lung Neoplasms [*drug therapy, mortality, pathology]; Lymphocyte count; Male; Middle Aged; Multiple cycle treatment; Muscle weakness/si [Side Effect]; Neoplasm Staging; Neurologic disease/si [Side Effect]; Neuropathy/si [Side Effect]; Neutrophil count; Outcome assessment; Overall survival; Pharmacokinetics; Phase 2 clinical trial; Priority journal; Progression free survival; Rash/si [Side Effect]; Response evaluation criteria in solid tumors; Retrospective study; Safety; Sepsis/si [Side Effect]; Side effect/si [Side Effect]; Small Cell Lung Carcinoma [*drug therapy, mortality, pathology]; Small cell lung cancer/dt [Drug Therapy]; Thrombocytopenia/si [Side Effect]; Thromboembolism/si [Side Effect]; Treatment Outcome; Treatment response}, -abstract = {OBJECTIVES: Our aim was to evaluate the safety and efficacy of ipilimumab combined with standard first‐line chemotherapy for patients with extensive‐stage SCLC. METHODS: Patients with chemotherapy‐naive extensive‐stage SCLC were treated with carboplatin and etoposide for up to six cycles. Ipilimumab, 10 mg/kg, was given on day 1 of cycles 3 to 6 and every 12 weeks. Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0, and immune‐related response criteria. The primary end point was 1‐year progression‐free survival (PFS) according to RECIST. Secondary end points included PFS according to immune‐related PFS and overall survival. Autoantibody serum levels were evaluated and correlated with clinical outcomes. RESULTS: A total of 42 patients were enrolled between September 2011 and April 2014; 39 were evaluable for safety and 38 for efficacy. Six of 38 patients (15.8% [95% confidence interval (CI): 7.4‐30.4]) were alive and progression‐free at 1‐year by RECIST. Median PFS was 6.9 months (95% CI: 5.5‐7.9). Median immune‐related PFS was 7.3 months (95% CI: 5.5‐8.8). Median overall survival was 17.0 months (95% CI: 7.9‐24.3). Of the patients evaluable for response, 21 of 29 (72.4%) achieved an objective response by RECIST and 28 of 33 (84.8%) achieved an objective response by the immune‐related response criteria. All patients experienced at least one adverse event; at least one grade 3 or higher toxicity developed in 35 of 39 patients (89.7%); in 27 patients (69.2%) this was related to ipilimumab. Five deaths were reported to be related to ipilimumab. Positivity of an autoimmune profile at baseline was associated with improved outcomes and severe neurological toxicity. CONCLUSIONS: Ipilimumab in combination with carboplatin and etoposide might benefit a subgroup of patients with advanced SCLC. Autoantibody analysis correlates with treatment benefit and toxicity and warrants further investigation.}, -DOI = {10.1016/j.jtho.2016.05.028}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01209420/full} -} - - -Record #3 of 538 -@article{Fang23, -author = {Fang, M, Wang, L, Gu, Q, Wu, H, Du, X, and Lai, X}, -title = {Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world}, -journal = {Clinical & experimental metastasis}, -volume = {40}, -number = {5}, -pages = {423‐429}, -year = {2023}, -accession_number = {EMBASE 2024905902, PUBMED 37584783}, -publication type = {Journal article}, -keywords = {*Lung Neoplasms [drug therapy, radiotherapy]; *Small Cell Lung Carcinoma [drug therapy, radiotherapy]; *cancer immunotherapy; *cancer radiotherapy; *extensive stage small cell lung cancer /drug therapy /radiotherapy; *partial body radiation; *small cell lung cancer /drug therapy /radiotherapy; *thoracic radiotherapy; Adult; Aged; Article; Blood toxicity; Bone marrow suppression; Cancer combination chemotherapy; Cancer patient; Cancer prognosis; Cohort analysis; Esophagitis; Female; Follow up; Human; Humans; Immunotherapy; Local recurrence free survival; Major clinical study; Male; Median survival time; Metastasis; Neoplasm Staging; Oligometastasis; Overall survival; Patient safety; Progression free survival; Radiation pneumonia; Radiotherapy dosage; Randomized controlled trial (topic); Retrospective study; Stereotactic body radiation therapy; Survival analysis; Survival rate; Therapy effect; Treatment Outcome}, -abstract = {The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive‐stage small lung cancer (ES‐SCLC). The CREST trial reported consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for ES‐SCLC with intrathoracic residual after chemotherapy. In this study, patients with ES‐SCLC who received immunotherapy were assigned to receive either TRT or no TRT. TRT significantly improved progression‐free survival (PFS), local recurrence‐free survival (LRFS) and OS with well tolerated toxicity. Further sub‐cohort analysis, TRT significantly improved LRFS in patients with oligo‐metastasis and without liver metastasis.}, -DOI = {10.1007/s10585-023-10227-5}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02609242/full} -} - - -Record #4 of 538 -@article{Senan20, -author = {Senan, S, Okamoto, I, Lee, GW, Chen, Y, Niho, S, Mak, G, Yao, W, Shire, N, Jiang, H, and Cho, BC}, -title = {Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: the ADRIATIC Study}, -journal = {Clinical lung cancer}, -volume = {21}, -number = {2}, -pages = {e84‐e88}, -year = {2020}, -accession_number = {EMBASE 2004598791, PUBMED 31948903}, -publication type = {Journal article}, -keywords = {*apoptosis; *cancer patient; *cancer staging; *chemoradiotherapy; *immunotherapy; *small cell lung cancer; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal [administration & dosage]; Antibodies, Monoclonal, Humanized [administration & dosage]; Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Antineoplastic activity; Article; Brain radiation; Cancer survival; Chemoradiotherapy; Controlled study; Double blind procedure; Double‐Blind Method; Drug combination; Drug efficacy; Drug safety; Drug therapy; Female; Follow‐Up Studies; Histopathology; Human; Human tissue; Humans; Lung Neoplasms [*drug therapy, pathology, therapy]; Major clinical study; Male; Middle Aged; Monotherapy; Multicenter study; Overall survival; Phase 3 clinical trial; Prognosis; Progression free survival; Radiotherapy; Randomized controlled trial; Research Design; Small Cell Lung Carcinoma [*drug therapy, pathology, therapy]; World Health Organization; Young Adult}, -abstract = {Limited‐stage (LS) small‐cell lung cancer (SCLC) remains an area of high unmet medical need. The standard‐of‐care therapy comprises curative‐intent platinum‐based chemotherapy with concurrent radiotherapy (cCRT), which can be followed by prophylactic brain irradiation and then observation. However, most patients will relapse. Durvalumab (antiprogrammed cell death ligand‐1) has enhanced the efficacy outcomes after cCRT for patients with unresectable, stage III non‐small‐cell lung cancer. Recently, durvalumab combined with platinum‐etoposide demonstrated a significant survival benefit compared with platinum‐etoposide as first‐line treatment of patients with extensive‐stage SCLC and has also shown antitumor activity as monotherapy and combined with tremelimumab (anticytotoxic T‐lymphocyte‐associated antigen‐4) in pretreated patients with extensive‐stage SCLC. ADRIATIC, a phase III, randomized, double‐blind, placebo‐controlled, multicenter, global study (ClinicalTrials.gov identifier, NCT03703297), is designed to investigate the efficacy of durvalumab, with or without tremelimumab, as consolidation therapy for patients with LS‐SCLC without disease progression after cCRT. Approximately 600 patients with documented histologic or cytologic LS‐SCLC, World Health Organization/Eastern Cooperative Oncology Group performance status 0 or 1, and no progression after 4 cycles of cCRT will be randomized (1:1:1) to treatment (durvalumab 1500 mg plus placebo every 4 weeks [q4w] for 4 cycles, followed by durvalumab 1500 mg q4w; durvalumab 1500 mg plus tremelimumab 75 mg q4w for 4 cycles, followed by durvalumab 1500 mg q4w; or dual placebo q4w for 4 cycles, followed by single placebo q4w) within 1 to 42 days of completing cCRT, stratified by stage and receipt of prophylactic brain irradiation. The primary endpoints are progression‐free survival and overall survival. The secondary endpoints are overall survival and progression‐free survival rates, objective response rate, and safety and tolerability. Recruitment began in September 2018.}, -DOI = {10.1016/j.cllc.2019.12.006}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02077476/full} -} - - -Record #5 of 538 -@article{Paz-Ares19, -author = {Paz-Ares, L, Dvorkin, M, Chen, Y, Reinmuth, N, Hotta, K, Trukhin, D, Statsenko, G, Hochmair, MJ, Özgüroğlu, M, Ji, JH, Voitko, O, Poltoratskiy, A, Ponce, S, Verderame, F, Havel, L, Bondarenko, I, Kazarnowicz, A, Losonczy, G, Conev, NV, Armstrong, J, Byrne, N, Shire, N, Jiang, H, and Goldman, JW}, -title = {Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial}, -journal = {Lancet (london, england)}, -volume = {394}, -number = {10212}, -pages = {1929‐1939}, -year = {2019}, -accession_number = {EMBASE 629540114, PUBMED 31590988}, -publication type = {Journal article}, -keywords = {*cancer staging; *small cell lung cancer; Adult; Adverse drug reaction; Aged; Antibodies, Monoclonal [*administration & dosage, adverse effects]; Antibodies, Monoclonal, Humanized [administration & dosage]; Antineoplastic Agents, Immunological [*administration & dosage, adverse effects]; Antineoplastic Agents, Phytogenic [*administration & dosage]; Antineoplastic Combined Chemotherapy Protocols; Area under the curve; Article; Cancer patient; Cancer survival; Carboplatin [administration & dosage, adverse effects]; Cisplatin [administration & dosage, adverse effects]; Controlled study; Drug Administration Schedule; Drug combination; Drug safety; Drug therapy; Etoposide [*administration & dosage, adverse effects]; Female; Human; Humans; Immunotherapy; Intravenous drug administration; Lung Neoplasms [*drug therapy, mortality]; Major clinical study; Male; Middle Aged; Overall survival; Phase 3 clinical trial; Progression‐Free Survival; Randomized controlled trial; Response evaluation criteria in solid tumors; Side effect; Skull irradiation; Small Cell Lung Carcinoma [*drug therapy, mortality]}, -abstract = {BACKGROUND: Most patients with small‐cell lung cancer (SCLC) have extensive‐stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive‐stage SCLC (ES‐SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum‐etoposide) in treatment‐naive patients with ES‐SCLC. METHODS: This randomised, open‐label, phase 3 trial was done at 209 sites across 23 countries. Eligible patients were adults with untreated ES‐SCLC, with WHO performance status 0 or 1 and measurable disease as per Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were randomly assigned (in a 1:1:1 ratio) to durvalumab plus platinum‐etoposide; durvalumab plus tremelimumab plus platinum‐etoposide; or platinum‐etoposide alone. All drugs were administered intravenously. Platinum‐etoposide consisted of etoposide 80‐100 mg/m2 on days 1‐3 of each cycle with investigator's choice of either carboplatin area under the curve 5‐6 mg/mL per min or cisplatin 75‐80 mg/m2 (administered on day 1 of each cycle). Patients received up to four cycles of platinum‐etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks in the immunotherapy groups and up to six cycles of platinum‐etoposide every 3 weeks plus prophylactic cranial irradiation (investigator's discretion) in the platinum‐etoposide group. The primary endpoint was overall survival in the intention‐to‐treat population. We report results for the durvalumab plus platinum‐etoposide group versus the platinum‐etoposide group from a planned interim analysis. Safety was assessed in all patients who received at least one dose of their assigned study treatment. This study is registered at ClinicalTrials.gov, NCT03043872, and is ongoing. FINDINGS: Patients were enrolled between March 27, 2017, and May 29, 2018. 268 patients were allocated to the durvalumab plus platinum‐etoposide group and 269 to the platinum‐etoposide group. Durvalumab plus platinum‐etoposide was associated with a significant improvement in overall survival, with a hazard ratio of 0·73 (95% CI 0·59‐0·91; p=0·0047]); median overall survival was 13·0 months (95% CI 11·5‐14·8) in the durvalumab plus platinum‐etoposide group versus 10·3 months (9·3‐11·2) in the platinum‐etoposide group, with 34% (26·9‐41·0) versus 25% (18·4‐31·6) of patients alive at 18 months. Any‐cause adverse events of grade 3 or 4 occurred in 163 (62%) of 265 treated patients in the durvalumab plus platinum‐etoposide group and 166 (62%) of 266 in the platinum‐etoposide group; adverse events leading to death occurred in 13 (5%) and 15 (6%) patients. INTERPRETATION: First‐line durvalumab plus platinum‐etoposide significantly improved overall survival in patients with ES‐SCLC versus a clinically relevant control group. Safety findings were consistent with the known safety profiles of all drugs received. FUNDING: AstraZeneca.}, -DOI = {10.1016/S0140-6736(19)32222-6}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01998359/full} -} - - -Record #6 of 538 -@article{NCT0522364722, -author = {NCT05223647,}, -title = {Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer}, -journal = {https://clinicaltrials.gov/ct2/show/NCT05223647}, -year = {2022}, -accession_number = {CTgov NCT05223647}, -publication type = {Trial registry record}, -keywords = {Carboplatin; Etoposide; Lung Neoplasms; Small Cell Lung Carcinoma}, -abstract = {Studies show that adding ICI therapy to standard chemotherapy prolongs survival in ES SCLC. The survival benefit, however, is modest, and there is a need for more effective therapy. It has been hypothesized that there is a synergistic effect of combining ICI with radiotherapy. In this randomized phase III study, the main aim is to investigate whether concurrent thoracic radiotherapy of 30 Gy/10 fractions improves survival in ES SCLC patients receiving carboplatin/etoposide/durvalumab. It is currently not possible to classify the patients who benefit from ICIs in SCLC. In this study, biological material (tissue, blood, feces) which will be analyzed for potential predictive and prognostic biomarkers. Prophylactic cranial irradiation in ES SCLC is debated, mainly due to the potentially detrimental effect on cognition. Thus, frequency and timing of brain metastases and cognitive function will be assessed before, during and after study treatment.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02367398/full} -} - - -Record #7 of 538 -@article{Paz-Ares19, -author = {Paz-Ares, L, Dvorkin, M, Chen, Y, Reinmuth, N, Hotta, K, Trukhin, D, Statsenko, G, Hochmair, MJ, Özgüroglu, M, Ji, JH, Voitko, O, Poltoratskiy, A, Ponce, S, Verderame, F, Havel, L, Bondarenko, I, Kazarnowicz, A, Losonczy, G, Conev, NV, Armstrong, J, Byrne, N, Shire, N, Jiang, H, and Goldman, JW}, -title = {Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial}, -journal = {Lancet (london, england)}, -volume = {394}, -number = {10212}, -pages = {1929‐1939}, -year = {2019}, -accession_number = {EMBASE 2003873320, PUBMED 31590988}, -publication type = {Journal article}, -keywords = {*cancer staging; *small cell lung cancer /drug therapy; Aged; Alopecia /side effect; Amylase blood level; Anemia /side effect; Antibodies, Monoclonal [*administration & dosage, adverse effects]; Antibodies, Monoclonal, Humanized [administration & dosage]; Antineoplastic Agents, Immunological [*administration & dosage, adverse effects]; Antineoplastic Agents, Phytogenic [*administration & dosage]; Antineoplastic Combined Chemotherapy Protocols; Article; Asthenia /side effect; Carboplatin [administration & dosage, adverse effects]; Cisplatin [administration & dosage, adverse effects]; Constipation /side effect; Controlled study; Coughing /side effect; Decreased appetite /side effect; Diarrhea /side effect; Drug Administration Schedule; Dyspnea /side effect; Etoposide [*administration & dosage, adverse effects]; Fatigue /side effect; Febrile neutropenia /side effect; Female; Human; Humans; Hypertension /side effect; Hyponatremia /side effect; Leukopenia /side effect; Lung Neoplasms [*drug therapy, mortality]; Major clinical study; Male; Middle Aged; Multicenter study; Multiple cycle treatment; Nausea /side effect; Neutropenia /side effect; Open study; Phase 3 clinical trial; Pneumonia /side effect; Priority journal; Progression‐Free Survival; Randomized controlled trial; Side effect /side effect; Small Cell Lung Carcinoma [*drug therapy, mortality]; Thrombocytopenia /side effect; Triacylglycerol lipase blood level; Vomiting /side effect}, -abstract = {Background: Most patients with small‐cell lung cancer (SCLC) have extensive‐stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive‐stage SCLC (ES‐SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum–etoposide) in treatment‐naive patients with ES‐SCLC. Methods: This randomised, open‐label, phase 3 trial was done at 209 sites across 23 countries. Eligible patients were adults with untreated ES‐SCLC, with WHO performance status 0 or 1 and measurable disease as per Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were randomly assigned (in a 1:1:1 ratio) to durvalumab plus platinum–etoposide; durvalumab plus tremelimumab plus platinum–etoposide; or platinum–etoposide alone. All drugs were administered intravenously. Platinum–etoposide consisted of etoposide 80–100 mg/m2 on days 1–3 of each cycle with investigator's choice of either carboplatin area under the curve 5–6 mg/mL per min or cisplatin 75–80 mg/m2 (administered on day 1 of each cycle). Patients received up to four cycles of platinum–etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks in the immunotherapy groups and up to six cycles of platinum–etoposide every 3 weeks plus prophylactic cranial irradiation (investigator's discretion) in the platinum–etoposide group. The primary endpoint was overall survival in the intention‐to‐treat population. We report results for the durvalumab plus platinum–etoposide group versus the platinum–etoposide group from a planned interim analysis. Safety was assessed in all patients who received at least one dose of their assigned study treatment. This study is registered at ClinicalTrials.gov, NCT03043872, and is ongoing. Findings: Patients were enrolled between March 27, 2017, and May 29, 2018. 268 patients were allocated to the durvalumab plus platinum–etoposide group and 269 to the platinum–etoposide group. Durvalumab plus platinum–etoposide was associated with a significant improvement in overall survival, with a hazard ratio of 0·73 (95% CI 0·59–0·91; p=0·0047]); median overall survival was 13·0 months (95% CI 11·5–14·8) in the durvalumab plus platinum–etoposide group versus 10·3 months (9·3–11·2) in the platinum–etoposide group, with 34% (26·9–41·0) versus 25% (18·4–31·6) of patients alive at 18 months. Any‐cause adverse events of grade 3 or 4 occurred in 163 (62%) of 265 treated patients in the durvalumab plus platinum–etoposide group and 166 (62%) of 266 in the platinum–etoposide group; adverse events leading to death occurred in 13 (5%) and 15 (6%) patients. Interpretation: First‐line durvalumab plus platinum–etoposide significantly improved overall survival in patients with ES‐SCLC versus a clinically relevant control group. Safety findings were consistent with the known safety profiles of all drugs received. Funding: AstraZeneca.}, -DOI = {10.1016/S0140-6736(19)32222-6}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02618002/full} -} - - -Record #8 of 538 -@article{Wang22, -author = {Wang, L, Lei, X, and Wang, X}, -title = {Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: a Retrospective Observational Study}, -journal = {Computational and mathematical methods in medicine}, -volume = {2022}, -pages = {2848220}, -year = {2022}, -accession_number = {EMBASE 2018389473, PUBMED 35586668}, -publication type = {Journal article; Retracted Publication}, -keywords = {*Lung Neoplasms [diagnosis]; *Small Cell Lung Carcinoma [drug therapy]; *cancer chemotherapy; *cancer recurrence; *drug efficacy; *drug safety; *observational study; *retrospective study; *small cell lung cancer; Adult; Anorexia; Antigens, Neoplasm; Article; Biomarkers, Tumor; Body Weight; Body weight change; Cancer patient; Cancer prognosis; Cancer radiotherapy; Cancer resistance; Cancer staging; Cancer survival; Carboplatin [therapeutic use]; Cisplatin [adverse effects]; Complication; Controlled study; Diarrhea; Drug combination; Drug therapy; Fatigue; Female; Gene expression; Hand foot syndrome; Human; Humans; Hypertension; Immune Checkpoint Inhibitors; Immunity; Keratin‐19; Leukopenia; Lung development; Major clinical study; Male; Metastasis; Prognosis; Programmed Cell Death 1 Receptor; Protein expression; Protein urine level; Radiotherapy; Randomized Controlled Trials as Topic; Randomized controlled trial; Receptors, Death Domain; Statistical significance; Survival rate; Survival time; Thrombocytopenia}, -abstract = {Background. Relapsed and refractory small cell lung cancer (SCLC) accounts for about 15% of all lung cancers. The prognosis of patients is poor. The 5‐year survival rate is almost 0. The average survival time of patients who refuse to receive treatment is only 2‐4 months. For patients with extensive‐stage SCLC, the current first‐line treatment regimens are mainly platinum‐containing double‐drug chemotherapy. Poside combined with cisplatin/carboplatin and irinotecan combined with cisplatin/carboplatin are commonly used clinical regimens for the treatment of patients with extensive‐stage SCLC. Although SCLC is very sensitive to radiotherapy and chemotherapy, most patients will develop recurrence and metastasis after initial treatment. Therefore, it is necessary to study clinically effective therapeutic drugs for relapsed and refractory SCLC. Objective. To investigate the relationship between programmed death receptor‐1 (programmed death receptor‐1 (PD‐1)) and programmed death receptor‐ligand 1 (programmed death‐ligand 1 (PD‐L1)) inhibitors and Lung Cancer No. 1 efficacy and safety of Lung Cancer Fang No. 1 in the treatment of relapsed and refractory SCLC. Methods. 80 patients with refractory SCLC were selected and randomly divided into control group and treatment group with 40 cases in each group. Among them, the control group received PD‐1/PD‐L1 inhibitor chemotherapy, and the treatment group received PD‐1/PD‐L1 inhibitor chemotherapy combined with Lung Cancer Fang No. 1 treatment. The differences in immune and tumor marker levels, clinical efficacy, and prognostic complications between the two groups before and after treatment were observed and compared. Results. Before treatment, there was no significant difference in clinical improvement between the two groups. After treatment, the clinical symptom scores and body weight changes in the treatment group were significantly improved. The clinical symptom scores in the treatment group were lower than those in the control group, but the body weight changes were higher than those in the control group. The difference was statistically significant (P<0.05). Before treatment, there was no significant difference in the levels of tumor markers between the two groups. After treatment, the levels of CYFRA21‐1, CA125, and VGEF in the treatment group were significantly lower than those in the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the immune level between the two groups before treatment (P>0.05), while the differences in CD4+, CD3+, and CD4+/CD8+ after treatment were significant, and the treatment group was higher than the control group, with statistical significance (P<0.05). After treatment, the clinical efficacy of the two groups was significantly improved. The DCR90.00% of the treatment group was significantly higher than that of the control group, 67.50%, and the difference was statistically significant (P<0.05). The analysis of complications after treatment showed that fatigue, anorexia, hypertension, hand‐foot syndrome, diarrhea, leukopenia, thrombocytopenia, and urinary protein in the treatment group were significantly lower than those in the control group, and the difference was statistically significant (P<0.05). Conclusion. PD‐1/PD‐L1 inhibitor chemotherapy combined with Lung Cancer Fang No. 1 has a good and safe effect on SCLC patients. It has a good curative effect in improving the clinical symptoms of patients. It can stabilize the tumor, inhibit the development of lung cancer, improve the body's cellular immune function, adjust the level and expression of tumor markers, improve the body's material metabolism, and restore the balance of yin and yang in the body.}, -DOI = {10.1155/2022/2848220}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02403676/full} -} - - -Record #9 of 538 -@article{Qi21, -author = {Qi, WX, Xiang, Y, Zhao, S, and Chen, J}, -title = {Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab}, -journal = {Cancer immunology, immunotherapy}, -volume = {70}, -number = {11}, -pages = {3199‐3206}, -year = {2021}, -accession_number = {EMBASE 2011042078, PUBMED 33796915}, -publication type = {Journal article}, -keywords = {*cancer chemotherapy; *cancer immunotherapy; *cancer staging; *prognostic nutritional index; *small cell lung cancer /drug therapy; Adult; Advanced lung cancer inflammation index; Aged; Antibodies, Monoclonal, Humanized [*therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Article; Assessment of humans; Cancer patient; Cancer prognosis; Cohort analysis; Controlled study; Female; Follow up; Human; Humans; Inflammation; Leukocyte Count; Lung Neoplasms [*drug therapy]; Lung immune prognostic index; Lymphocyte monocyte ratio; Major clinical study; Male; Middle Aged; Multivariate analysis; Neutrophil lymphocyte ratio; Nutrition Assessment; Patient identification; Phase 2 clinical trial; Platelet lymphocyte ratio; Prognosis; Prospective study; Randomized controlled trial; Small Cell Lung Carcinoma [*drug therapy]; Systemic immune inflammation index; Systemic inflammation response index; Treatment Outcome}, -abstract = {Background: The present study aims to investigate the prognostic role of systematic inflammatory and nutritional indexes in extensive‐stage small‐cell lung cancer (ES‐SCLC) treated with first‐line chemotherapy and atezolizumab. Materials and methods: Prospective cohort population involving 53 patients were identified from NCT03041311 trial. The following peripheral blood‐derived inflammatory and nutritional indexes, including neutrophil–lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), lymphocyte–monocyte ratio (LMR), systemic immune‐inflammation index (SII), systemic inflammation response index (SIRI), prognostic nutrition index (PNI), advanced lung cancer inflammation index (ALI), and lung immune prognostic index (LIPI) were evaluated. Results: The optimal cut‐off values of the ALI, LMR, NLR, PLR, PNI, SII and SIRI were 323.23, 2.73, 2.57, 119.23, 48, 533.28 and 2.32, respectively. With a median follow‐up of 17.1 months, the 1‐year OS and PFS were 56% and 8%, respectively. Multivariate analysis showed that PLR was the only independent prognostic factors for OS among ES‐SCLC patients treated with chemotherapy and atezolizumab (HR 4.63, 95%CI: 1.00–21.46, p = 0.05). K‐M analysis showed that the OS and PFS for patients with high PLR (> 119.23) were significantly poorer than these with low PLR (≤ 119.23) (p = 0.0004 for OS and p = 0.014 for PFS). In external validation set, prognosis of patients with high PLR was also significantly poorer than these with low PLR in terms of OS (p = 0.038) and PFS (p = 0.028). Conclusion: Pre‐treatment PLR could serve as a valuable independent prognostic factor for ES‐SCLC who receive chemotherapy and immune checkpoint inhibitors. Further, prospective studies are still needed to confirm our findings.}, -DOI = {10.1007/s00262-021-02926-3}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02384695/full} -} - - -Record #10 of 538 -@article{NCT0304387217, -author = {NCT03043872,}, -title = {Durvalumab ┬▒ Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)}, -journal = {https://clinicaltrials.gov/ct2/show/NCT03043872}, -year = {2017}, -accession_number = {CTgov NCT03043872}, -publication type = {Trial registry record}, -keywords = {Carboplatin; Carcinoma; Durvalumab; Etoposide; Lung Neoplasms; Small Cell Lung Carcinoma; Tremelimumab}, -abstract = {Primary objective of this study is to assess the efficacy of durvalumab + tremelimumab +EP treatment compared with EP and the efficacy of durvalumab + EP treatment compared withEP in terms of OS.All patients will be randomized in a 1:1:1 ratio in a stratified manner according to theplanned platinum‐based therapy for Cycle 1 (cisplatin or carboplatin) to receivetreatment with durvalumab + tremelimumab + EP (Arm 1), durvalumab + EP (Arm 2), orstandard of care‐ EP (Arm 3). Arm 1 and Arm 2 patients receive the treatment untilconfirmed disease progression while Arm 3 patients receive up to 6 cycles of EP andprophylactic cranial irradiation if clinically indicated, at the Investigators'discretion.Patients who have discontinued treatment due to toxicity or symptomaticdeterioration, clinical progression, or who have commenced subsequent anticancer therapywill be followed up until confirmed disease progression and for survival.Targeted population are adult patients (aged ΓëÑ18 years) with histologically orcytologically documented extensive disease (American Joint Committee on Cancer Stage (7thedition) IV SCLC [T any, N any,M1 a/b]), or T3‐4 due to multiple lung nodules that aretoo extensive or have tumor/nodal volume that is too large to be encompassed in atolerable radiation plan. Patients must have WHO/ECOG performance status of 0 or 1.Tumor assessments will be performed at Screening as baseline with follow‐up at Week 6 ┬▒1week from the date of randomization, at Week 12 ┬▒1 week from the date of randomization,and then every 8 weeks ┬▒1 week until confirmed objective disease progression.An independent data monitoring committee (IDMC) comprised of independent experts will beconvened to confirm the safety and tolerability of the proposed dose and schedule ofdurvalumab ┬▒ tremelimumab in combination with platinum based chemotherapy at two earlystages of enrolment.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01598264/full} -} - - -Record #11 of 538 -@article{Goldman21, -author = {Goldman, JW, Dvorkin, M, Chen, Y, Reinmuth, N, Hotta, K, Trukhin, D, Statsenko, G, Hochmair, MJ, Özgüroğlu, M, Ji, JH, Garassino, MC, Voitko, O, Poltoratskiy, A, Ponce, S, Verderame, F, Havel, L, Bondarenko, I, Każarnowicz, A, Losonczy, G, Conev, NV, Armstrong, J, Byrne, N, Thiyagarajah, P, Jiang, H, and Paz-Ares, L}, -title = {Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial}, -journal = {The lancet. Oncology}, -volume = {22}, -number = {1}, -pages = {51‐65}, -year = {2021}, -accession_number = {EMBASE 2010392424, PUBMED 33285097}, -publication type = {Journal article}, -keywords = {*area under the curve; *cancer staging; *small cell lung cancer; Adult; Adverse drug reaction; Aged; Antibodies, Monoclonal [*administration & dosage, adverse effects]; Antibodies, Monoclonal, Humanized [*administration & dosage, adverse effects]; Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; Article; Cancer patient; Cancer survival; Cancer therapy; Carboplatin [*administration & dosage, adverse effects]; Cisplatin [*administration & dosage, adverse effects]; Clinical trial; Controlled study; Dehydration; Deterioration; Disease Progression; Drug combination; Drug safety; Drug therapy; Enterocolitis; Etoposide [*administration & dosage, adverse effects]; Febrile neutropenia; Female; Follow up; Heart arrest; Hepatitis; Histopathology; Human; Humans; Immunotherapy; Interstitial lung disease; Japan; Liver toxicity; Lung Neoplasms [*drug therapy, mortality, pathology]; Lung embolism; Major clinical study; Male; Middle Aged; Multicenter study; Multiple organ failure; Neoplasm Staging; Overall survival; Pancytopenia; Phase 3 clinical trial; Pneumonia; Progression‐Free Survival; Randomized controlled trial; Respiratory failure; Sepsis; Side effect; Skull irradiation; Small Cell Lung Carcinoma [*drug therapy, mortality, pathology]; Sudden death; Thrombocytopenia; Time Factors; Voice; Young adult}, -abstract = {Background: First‐line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide) showed a significant improvement in overall survival versus platinum–etoposide alone in patients with extensive‐stage small‐cell lung cancer (ES‐SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum–etoposide versus platinum–etoposide alone. Methods: CASPIAN is an ongoing, open‐label, sponsor‐blind, randomised, controlled phase 3 trial at 209 cancer treatment centres in 23 countries worldwide. Eligible patients were aged 18 years or older (20 years in Japan) and had treatment‐naive, histologically or cytologically documented ES‐SCLC, with a WHO performance status of 0 or 1. Patients were randomly assigned (1:1:1) in blocks of six, stratified by planned platinum, using an interactive voice‐response or web‐response system to receive intravenous durvalumab plus tremelimumab plus platinum–etoposide, durvalumab plus platinum–etoposide, or platinum–etoposide alone. In all groups, patients received etoposide 80–100 mg/m2 on days 1–3 of each cycle with investigator's choice of either carboplatin area under the curve 5–6 mg/mL/min or cisplatin 75–80 mg/m2 on day 1 of each cycle. Patients in the platinum–etoposide group received up to six cycles of platinum–etoposide every 3 weeks and optional prophylactic cranial irradiation (investigator's discretion). Patients in the immunotherapy groups received four cycles of platinum–etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks. The two primary endpoints were overall survival for durvalumab plus platinum–etoposide versus platinum–etoposide and for durvalumab plus tremelimumab plus platinum–etoposide versus platinum–etoposide in the intention‐to‐treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered at ClinicalTrials.gov, NCT03043872. Findings: Between March 27, 2017, and May 29, 2018, 972 patients were screened and 805 were randomly assigned (268 to durvalumab plus tremelimumab plus platinum–etoposide, 268 to durvalumab plus platinum–etoposide, and 269 to platinum–etoposide). As of Jan 27, 2020, the median follow‐up was 25·1 months (IQR 22·3–27·9). Durvalumab plus tremelimumab plus platinum–etoposide was not associated with a significant improvement in overall survival versus platinum–etoposide (hazard ratio [HR] 0·82 [95% CI 0·68–1·00]; p=0·045); median overall survival was 10·4 months (95% CI 9·6–12·0) versus 10·5 months (9·3–11·2). Durvalumab plus platinum–etoposide showed sustained improvement in overall survival versus platinum–etoposide (HR 0·75 [95% CI 0·62–0·91]; nominal p=0·0032); median overall survival was 12·9 months (95% CI 11·3–14·7) versus 10·5 months (9·3–11·2). The most common any‐cause grade 3 or worse adverse events were neutropenia (85 [32%] of 266 patients in the durvalumab plus tremelimumab plus platinum–etoposide group, 64 [24%] of 265 patients in the durvalumab plus platinum–etoposide group, and 88 [33%] of 266 patients in the platinum–etoposide group) and anaemia (34 [13%], 24 [9%], and 48 [18%]). Any‐cause serious adverse events were reported in 121 (45%) patients in the durvalumab plus tremelimumab plus platinum–etoposide group, 85 (32%) in the durvalumab plus platinum–etoposide group, and 97 (36%) in the platinum–etoposide group. Treatment‐related deaths occurred in 12 (5%) patients in the durvalumab plus tremelimumab plus platinum–etoposide group (death, febrile neutropenia, and pulmonary embolism [n=2 each]; enterocolitis, general physical health deterioration and multiple organ dysfunction syndrome, pneumonia, pneumonitis and hepatitis, respiratory failure, and sudden death [n=1 each]), six (2%) patients in the durvalumab plus platinum–etoposide group (cardiac arrest, dehydration, hepatotoxicity, interstitial lung disease, pancytopenia, and sepsis [n=1 each]), and two (1%) in the platinum–etoposide group (pancytopenia and thrombocytopenia [n=1 each]). Interpretation: First‐line durvalumab plus platinum–etoposide showed sustained overall survival improvement versus platinum–etoposide but the addition of tremelimumab to durvalumab plus platinum–etoposide did not significantly improve outcomes versus platinum–etoposide. These results support the use of durvalumab plus platinum–etoposide as a new standard of care for the first‐line treatment of ES‐SCLC. Funding: AstraZeneca.}, -DOI = {10.1016/S1470-2045(20)30539-8}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02210221/full} -} - - -Record #12 of 538 -@article{Bozorgmehr22, -author = {Bozorgmehr, F, Christopoulos, P, Chung, I, Cvetkovic, J, Feisst, M, Krisam, J, Schneider, MA, Heussel, CP, Kreuter, M, Muller, DW, Thomas, M, and Rieken, S}, -title = {Protocol of the TREASURE study: thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial}, -journal = {BMC cancer}, -volume = {22}, -number = {1}, -pages = {1011}, -year = {2022}, -accession_number = {EMBASE 2019285222, PUBMED 36153496}, -publication type = {Journal article}, -keywords = {*Lung Neoplasms [drug therapy, radiotherapy]; *Small Cell Lung Carcinoma [drug therapy, radiotherapy]; *cancer combination chemotherapy; *cancer radiotherapy; *small cell lung cancer; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols [adverse effects]; Article; B7‐H1 Antigen; Biocompatible Materials [therapeutic use]; Cancer patient; Cancer survival; Clinical Trials, Phase II as Topic; Clinical trial; Comprehension; Controlled study; Drug safety; Drug therapy; Feasibility study; Female; Health care quality; Human; Humans; Immunotherapy; Maintenance therapy; Major clinical study; Male; Multicenter Studies as Topic; Multicenter study; Overall survival; Phase 2 clinical trial; Radiotherapy; Randomized Controlled Trials as Topic; Randomized controlled trial; Translational research}, -abstract = {Background: Recently, the combination of the programmed death‐ligand 1 (PD‐L1) inhibitor atezolizumab with first‐line chemotherapy has demonstrated to improve outcome for patients with advanced small cell lung cancer (SCLC), leading to approval of this regimen. At the same time, accumulating (pre‐)clinical data suggest synergisms of radiotherapy and immunotherapy via the radiation‐mediated induction of anti‐tumor immunogenicity. Combining the recent findings, the TREASURE trial aims at further enhancing response to upfront chemo‐immunotherapy by the addition of thoracic radiotherapy (TRT). Methods/design: The TREASURE trial is a randomized, multicenter, phase II clinical trial (ClinicalTrials.gov identifier, NCT04462276). One hundred four patients suffering from extensive disease (ED) SCLC, with any response to the standard of care induction chemo‐immunotherapy will be randomized to receive atezolizumab maintenance therapy with or without TRT. The primary endpoint of this study is overall survival (OS). Secondary endpoints include further measures of efficacy, safety, and the collection of biomarker samples. A safety interim analysis will take place after n = 23 patients receiving TRT have been observed for three months after the end of TRT. Discussion: This trial will investigate whether treatment efficacy can be improved by adding TRT to atezolizumab maintenance therapy in ED SCLC patients with any response after chemo‐immunotherapy. Safety and feasibility of such a regimen will be evaluated, and biomaterials for a translational research project will be collected. Together, the results of this trial will deepen our comprehension of how checkpoint inhibition and radiotherapy interact and contribute to the evolving landscape of SCLC therapy. Trial registration: Clinicaltrials.gov identifier: NCT04462276 (Date of initial registration: 8th July 2020), https://clinicaltrials.gov/ct2/show/NCT04462276 Eudra‐CT Number: 2019‐003916‐29 (Date of initial registration: 30th March 2020), https://www.clinicaltrialsregister.eu/ctr‐search/trial/2019‐003916‐29/DE}, -DOI = {10.1186/s12885-022-10074-9}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02468163/full} -} - - -Record #13 of 538 -@article{NCT0561796322, -author = {NCT05617963,}, -title = {Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax}, -journal = {https://clinicaltrials.gov/ct2/show/NCT05617963}, -year = {2022}, -accession_number = {CTgov NCT05617963}, -publication type = {Trial registry record}, -keywords = {Durvalumab; Small Cell Lung Carcinoma}, -abstract = {Small Cell Lung Cancer (SCLC) is a rare tumor, accounting nowadays for 10‐15% of all new lung cancer diagnosis. Approximately one third of patients present with limited disease (LD‐SCLC) confined to the chest with a median survival from 18 to 24 months and a 5‐year survival rate between 20% and 25%. A platinum‐based chemotherapy combined with etoposide and a concurrent thoracic radiotherapy represents the standard of care for LD‐SCLC treatment with a median PFS of 12 months. However, sequential radiotherapy may be preferable for patients with poor performance status or having comorbidity predisposing to a worst tolerability. Clinical evidence supports the immunogenicity of SCLC and the involvement of immune activity in SCLC development and prognosis. Several immune checkpoint inhibitors got the approbation in first and further lines for the advanced SCLC in the last decade. The most important results have been achieved in the first‐line setting for patients receiving a combination of platinum ‐ etoposide chemotherapy and an anti‐PD1/PDL‐1 inhibitor compared to chemotherapy alone. However, despite these were the first positive results after a while in this setting, the modest absolute benefit showed (3 months) have to be taking into account. The possibility to enhance the immunotherapy efficacy in SCLC field with the radiotherapy administered as part of the standard treatment for a LD‐SCLC seems to be a great opportunity. In the PACIFIC trial, the sequential administration of durvalumab in patients with locally advanced, unresectable, stage III Non‐Small‐Cell Lung Cancer (NSCLC) whose disease had not progressed following platinum‐based concurrent thoracic CRT showed a dramatic overall survival improvement compared to placebo, with manageable toxicities. The ADRIATIC phase III trial, is currently recruiting LD‐SCLC patients not progressing after the concomitant CRT (NCT03703297). Patients are randomized to receive durvalumab, durvalumab plus tremelimumab or placebo as maintenance treatment. In this trial, only ECOG PS 0‐1 patients able to receive a concomitant CRT are eligible. However, in our clinical practice, LD‐SCLC patients may not respect these criteria due to the aggressiveness of cancer and comorbidities. Thus, DURVALUNG study aims to evaluate the efficacy of durvalumab maintenance treatment in frail LD‐SCLC patients who have not progressed following platinum‐based concomitant or sequential CRT.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02497282/full} -} - - -Record #14 of 538 -@article{Wu21, -author = {Wu, Y, Zhang, T, Liu, Y, Wang, J, and Bi, N}, -title = {Anlotinib combined with durvalumab in a patient with recurrent multifocal brain metastases of small cell lung cancer after definitive concurrent chemoradiotherapy and palliative radiotherapy of the lung and brain: a case report}, -journal = {Annals of palliative medicine}, -volume = {10}, -number = {2}, -review groups = {Gynaecological, Neuro-oncology and Orphan Cancer}, -pages = {2379‐2386}, -year = {2021}, -accession_number = {EMBASE 634596568, PUBMED 33725780}, -publication type = {Journal article}, -keywords = {*brain metastasis; *cancer patient; *cancer recurrence; *chemoradiotherapy; *palliative therapy; *small cell lung cancer; Adult; Advanced cancer; Antibodies, Monoclonal; Article; Brain; Brain Neoplasms; Cancer staging; Cancer survival; Case report; Chemoradiotherapy; Chinese; Clinical article; Clinical trial; Double blind procedure; Drug combination; Drug therapy; Female; Human; Humans; Immunotherapy; Indoles; Lung; Lung Neoplasms [drug therapy]; Maintenance therapy; Male; Overall survival; Phase 2 clinical trial; Progression free survival; Quinolines; Radiotherapy; Randomized controlled trial; Remission; Sample size; Small Cell Lung Carcinoma [drug therapy]; Synergistic effect; Whole brain radiotherapy}, -abstract = {The brain is a common metastatic site of small cell lung cancer (SCLC), but systematic treatment options are limited by the blood‐brain barrier. Currently, the optimal treatment regimen remains controversial, especially for patients already treated by brain radiotherapy. Anlotinib is a novel oral multitarget tyrosine kinase inhibitor which has shown significant improvement in progression‐free survival and overall survival in third‐line or beyond therapy of advanced SCLC in a randomized, double‐blind phase II study (ALTER1202 trial) based on a Chinese population sample. Emerging data has also suggested that immunotherapy, such as the programmed death ligand 1 (PD‐L1) inhibitor, has a relatively high response rate in brain metastatic SCLC, although there is a lack of large sample‐size studies. Integrating anlotinib and immunotherapy for recurrent or relapsing brain metastases (BMs) of SCLC has not been previously reported, but it is possible that these two treatments may have synergistic effects and provide even better outcomes. Here, we present a case of stage III SCLC who developed lung and BMs after concurrent chemoradiotherapy (cCRT) and achieved radiographic locally complete regression following whole brain irradiation (WBI) with a simultaneous integrated boost (SIB) technique. Durvalumab was delivered as maintenance therapy. Asymptomatic multifocal recurrence of BMs occurred after the administration of the second dose of durvalumab. After administration of combined durvalumab and anlotinib, the BMs achieved near‐complete regression and no severe toxicity was reported. This suggests a potential synergistic effect of combined durvalumab and anlotinib in previously treated BMs in a patient with SCLC and may provide a direction for future clinical decisions.}, -DOI = {10.21037/apm-20-2390}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02261734/full} -} - - -Record #15 of 538 -@article{Bozorgmehr22, -author = {Bozorgmehr, F, Christopoulos, P, Chung, I, Cvetkovic, J, Feisst, M, Krisam, J, Schneider, MA, Heussel, CP, Kreuter, M, Muller, DW, Thomas, M, and Rieken, S}, -title = {Protocol of the TREASURE study: thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial}, -journal = {BMC cancer}, -volume = {22}, -number = {1}, -pages = {1011}, -year = {2022}, -accession_number = {EMBASE 639100703, PUBMED 36153496}, -publication type = {Journal article}, -keywords = {*Lung Neoplasms [drug therapy, radiotherapy]; *Small Cell Lung Carcinoma [drug therapy, radiotherapy]; *cancer combination chemotherapy; *cancer radiotherapy; *small cell lung cancer; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols [adverse effects]; Article; B7‐H1 Antigen; Biocompatible Materials [therapeutic use]; Cancer patient; Cancer survival; Clinical Trials, Phase II as Topic; Clinical trial; Comprehension; Controlled study; Drug safety; Drug therapy; Feasibility study; Female; Health care quality; Human; Humans; Immunotherapy; Maintenance therapy; Major clinical study; Male; Multicenter Studies as Topic; Multicenter study; Overall survival; Phase 2 clinical trial; Radiotherapy; Randomized Controlled Trials as Topic; Randomized controlled trial; Translational research}, -abstract = {BACKGROUND: Recently, the combination of the programmed death‐ligand 1 (PD‐L1) inhibitor atezolizumab with first‐line chemotherapy has demonstrated to improve outcome for patients with advanced small cell lung cancer (SCLC), leading to approval of this regimen. At the same time, accumulating (pre‐)clinical data suggest synergisms of radiotherapy and immunotherapy via the radiation‐mediated induction of anti‐tumor immunogenicity. Combining the recent findings, the TREASURE trial aims at further enhancing response to upfront chemo‐immunotherapy by the addition of thoracic radiotherapy (TRT). METHODS/DESIGN: The TREASURE trial is a randomized, multicenter, phase II clinical trial ( ClinicalTrials.gov identifier, NCT04462276). One hundred four patients suffering from extensive disease (ED) SCLC, with any response to the standard of care induction chemo‐immunotherapy will be randomized to receive atezolizumab maintenance therapy with or without TRT. The primary endpoint of this study is overall survival (OS). Secondary endpoints include further measures of efficacy, safety, and the collection of biomarker samples. A safety interim analysis will take place after n = 23 patients receiving TRT have been observed for three months after the end of TRT. DISCUSSION: This trial will investigate whether treatment efficacy can be improved by adding TRT to atezolizumab maintenance therapy in ED SCLC patients with any response after chemo‐immunotherapy. Safety and feasibility of such a regimen will be evaluated, and biomaterials for a translational research project will be collected. Together, the results of this trial will deepen our comprehension of how checkpoint inhibition and radiotherapy interact and contribute to the evolving landscape of SCLC therapy. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT04462276 (Date of initial registration: 8th July 2020), https://clinicaltrials.gov/ct2/show/NCT04462276 Eudra‐CT Number: 2019‐003916‐29 (Date of initial registration: 30th March 2020), https://www.clinicaltrialsregister.eu/ctr‐search/trial/2019‐003916‐29/DE.}, -DOI = {10.1186/s12885-022-10074-9}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02466990/full} -} - - -Record #16 of 538 -@article{Wang22, -author = {Wang, L, Lei, X, and Wang, X}, -title = {Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: a Retrospective Observational Study}, -journal = {Computational and mathematical methods in medicine}, -volume = {2022}, -pages = {2848220}, -year = {2022}, -accession_number = {EMBASE 638042730, PUBMED 35586668}, -publication type = {Journal article; Retracted Publication}, -keywords = {*Lung Neoplasms [diagnosis]; *Small Cell Lung Carcinoma [drug therapy]; *lung tumor /diagnosis; *small cell lung cancer /drug therapy; Antigens, Neoplasm; Biomarkers, Tumor; Body Weight; Body weight; Carboplatin [therapeutic use]; Cisplatin [adverse effects]; Human; Humans; Immune Checkpoint Inhibitors; Keratin‐19; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic; Receptors, Death Domain}, -abstract = {Background: Relapsed and refractory small cell lung cancer (SCLC) accounts for about 15% of all lung cancers. The prognosis of patients is poor. The 5‐year survival rate is almost 0. The average survival time of patients who refuse to receive treatment is only 2‐4 months. For patients with extensive‐stage SCLC, the current first‐line treatment regimens are mainly platinum‐containing double‐drug chemotherapy. Poside combined with cisplatin/carboplatin and irinotecan combined with cisplatin/carboplatin are commonly used clinical regimens for the treatment of patients with extensive‐stage SCLC. Although SCLC is very sensitive to radiotherapy and chemotherapy, most patients will develop recurrence and metastasis after initial treatment. Therefore, it is necessary to study clinically effective therapeutic drugs for relapsed and refractory SCLC. Objective: To investigate the relationship between programmed death receptor‐1 (programmed death receptor‐1 (PD‐1)) and programmed death receptor‐ligand 1 (programmed death‐ligand 1 (PD‐L1)) inhibitors and Lung Cancer No. 1 efficacy and safety of Lung Cancer Fang No. 1 in the treatment of relapsed and refractory SCLC. Methods: 80 patients with refractory SCLC were selected and randomly divided into control group and treatment group with 40 cases in each group. Among them, the control group received PD‐1/PD‐L1 inhibitor chemotherapy, and the treatment group received PD‐1/PD‐L1 inhibitor chemotherapy combined with Lung Cancer Fang No. 1 treatment. The differences in immune and tumor marker levels, clinical efficacy, and prognostic complications between the two groups before and after treatment were observed and compared. Results: Before treatment, there was no significant difference in clinical improvement between the two groups. After treatment, the clinical symptom scores and body weight changes in the treatment group were significantly improved. The clinical symptom scores in the treatment group were lower than those in the control group, but the body weight changes were higher than those in the control group. The difference was statistically significant (P < 0.05). Before treatment, there was no significant difference in the levels of tumor markers between the two groups. After treatment, the levels of CYFRA21‐1, CA125, and VGEF in the treatment group were significantly lower than those in the control group, and the difference was statistically significant (P < 0.05). There was no significant difference in the immune level between the two groups before treatment (P > 0.05), while the differences in CD4+, CD3+, and CD4+/CD8+ after treatment were significant, and the treatment group was higher than the control group, with statistical significance (P < 0.05). After treatment, the clinical efficacy of the two groups was significantly improved. The DCR90.00% of the treatment group was significantly higher than that of the control group, 67.50%, and the difference was statistically significant (P < 0.05). The analysis of complications after treatment showed that fatigue, anorexia, hypertension, hand‐foot syndrome, diarrhea, leukopenia, thrombocytopenia, and urinary protein in the treatment group were significantly lower than those in the control group, and the difference was statistically significant (P < 0.05). Conclusion: PD‐1/PD‐L1 inhibitor chemotherapy combined with Lung Cancer Fang No. 1 has a good and safe effect on SCLC patients. It has a good curative effect in improving the clinical symptoms of patients. It can stabilize the tumor, inhibit the development of lung cancer, improve the body's cellular immune function, adjust the level and expression of tumor markers, improve the body's material metabolism, and restore the balance of yin and yang in the body.}, -DOI = {10.1155/2022/2848220}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02464706/full} -} - - -Record #17 of 538 -@article{NCT0446227620, -author = {NCT04462276,}, -title = {Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease}, -journal = {https://clinicaltrials.gov/ct2/show/NCT04462276}, -year = {2020}, -accession_number = {CTgov NCT04462276}, -publication type = {Trial registry record}, -keywords = {Atezolizumab; Lung Neoplasms; Small Cell Lung Carcinoma}, -abstract = {This is a multicenter phase 2 clinical trial to investigate the treatment efficacy and feasibility of combining thoracic radiotherapy (TRT) with the IMpower133 regimen in the upfront treatment of ED SCLC patients. Patients with a response after induction therapy with carboplatin/etoposide and atezolizumab will be included into this study to subsequently receive atezolizumab maintenance therapy and will be randomized to receive TRT or not. This trial aims to i.) increase the efficacy of combined atezolizumab‐ and chemotherapy by adding radiotherapy and ii.) determine the safety and tolerability of the combination of chemotherapeutic, immunological and radiological treatment in the first‐line setting of advanced SCLC, and iii.) to collect tumor tissue as well as blood and stool samples for separate biomarker research project.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02134241/full} -} - - -Record #18 of 538 -@article{Welsh20, -author = {Welsh, JW, Heymach, JV, Chen, D, Verma, V, Cushman, TR, Hess, KR, Shroff, G, Tang, C, Skoulidis, F, Jeter, M, Menon, H, Nguyen, QN, Chang, JY, Altan, M, Papadimitrakopoulou, VA, Simon, GR, Raju, U, Byers, L, and Glisson, B}, -title = {Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer}, -journal = {Journal of thoracic oncology}, -volume = {15}, -number = {2}, -pages = {266‐273}, -year = {2020}, -accession_number = {EMBASE 629576355, PUBMED 31605794}, -publication type = {Journal article}, -keywords = {*cancer staging; *chemoradiotherapy; *induction chemotherapy; *small cell lung cancer; Adult; Adverse drug reaction; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; Article; Asthenia; Autoimmune disease; Cancer patient; Cancer survival; Clinical article; Controlled study; Drug combination; Drug safety; Drug therapy; Female; Follow up; Human; Humans; Immunotherapy; Incidence; Induction Chemotherapy; Lung Neoplasms [drug therapy]; Male; Maximum tolerated dose; Middle Aged; Nomenclature; Overall survival; Paresthesia; Pharmacokinetics; Phase 1 clinical trial; Progression free survival; Prospective Studies; Prospective study; Radiotherapy; Randomized controlled trial; Rash; Side effect; Small Cell Lung Carcinoma [drug therapy]}, -abstract = {INTRUDUCTION: Radiation and immunotherapy have separately been shown to confer survival advantages to patients with extensive‐stage small cell lung cancer (ESCLC), but failure rates remain high and combination therapy has been understudied. In this single‐arm phase I trial (NCT02402920), we assessed the safety of combining pembrolizumab with thoracic radiotherapy (TRT) after induction chemotherapy for SCLC. METHODS: Patients with ESCLC who had completed chemotherapy received TRT with pembrolizumab. The maximum tolerated dose of pembrolizumab was assessed by 3+3 dose‐escalation; doses began at 100 mg and increased in 50 mg increments to 200 mg. Pembrolizumab was given every 3 weeks for up to 16 cycles; TRT was prescribed as 45 Gy in 15 daily fractions. Toxicity was evaluated with the Common Terminology Criteria for Adverse Events v4.0. The primary endpoint was safety of the combined therapy based on the incidence of dose‐limiting toxicity in the 35 days following initiation of treatment. RESULTS: Thirty‐eight patients with ESCLC (median age 65 years, range: 37‐79 years) were enrolled from September 2015 through September 2017; 33 received per‐protocol treatment, and all tolerated pembrolizumab at 100 to 200 mg with no dose‐limiting toxicity in the 35‐day window. There were no grade 4‐5 toxicities; 2 (6%) patients experienced grade 3 events (n = 1 rash, n = 1 asthenia/paresthesia/autoimmune disorder) that were unlikely/doubtfully related to protocol therapy. The median follow‐up time was 7.3 months (range: 1‐13 months); median progression‐free and overall survival times were 6.1 months (95% confidence interval: 4.1‐8.1) and 8.4 months (95% confidence interval: 6.7‐10.1). CONCLUSIONS: Concurrent pembrolizumab‐TRT was tolerated well with few high‐grade adverse events in the short‐term; progression‐free and overall survival rates are difficult to interpret due to heterogeneity in eligibility criteria (e.g., enrolling progressors on induction chemotherapy). Although randomized studies have shown benefits to TRT alone and immunotherapy alone, the safety of the combined regimen supports further investigation as a foundational approach for future prospective studies.}, -DOI = {10.1016/j.jtho.2019.10.001}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01999481/full} -} - - -Record #19 of 538 -@article{NCT0647947324, -author = {NCT06479473,}, -title = {Radiotherapy to All Residual Lesions After Chemoimmunotherapy}, -journal = {https://clinicaltrials.gov/ct2/show/NCT06479473}, -year = {2024}, -accession_number = {CTgov NCT06479473}, -publication type = {Trial registry record}, -keywords = {Lung Neoplasms; Small Cell Lung Carcinoma}, -abstract = {Trial design: To enroll 150 patients diagnosed with extensive‐stage small‐cell lungcancer to receive first‐line chemoimmunotherapy with or without radiotherapy to allresidual lesions.Primary endpoint: Progression‐free Survival Secondary endpoint: Overall Survival,Objective Response Rate, Duration of Response, Disease Control Rate.Randomization: All the enrolled patients would be randomly assigned to chemoimmunotherapygroup and chemoimmunotherapy with radiotherapy group using random table method.All enrolled patients with accordance to the inclusion criteria would first receive 4 to6 cycles of chemoimmunotherapy (etoposide and cisplatin & carboplatin withAdebrelimab). Then patients who were evaluated as partial response or stable diseasewould be assigned randomly to receive radiotherapy to all residual lesions followed byAdebrelimab maintenance or only Adebrelimab maintenance up to 2 years.Chemoimmunotherapy: Etoposide 80‐100mg/m2 day 1, 2, 3 and cisplatin 75‐80mg/m2 day 1& carboplatin AUC 5 day 1 and Adebrelimab 1200mg day 1 q3w totally 4 to 6 cycles.Immunotherapy maintenance: Adebrelimab 1200mg q3w to 2 year or disease progression &untolerated toxicity.Response evaluation: After 4 to 6 cycles of chemoimmunotherapy, patients would undertakeresponse evaluation according to RECIST criteria. These patients who were evaluated aspartial response and stable disease could be included into the study and receiverandomization.Radiotherapy to residual lesions: Patients assigned to chemoimmunotherapy withradiotherapy group would first receive PET‐CT and cranial contrasted MRI to ascertainresidual lesions. All residual lesions would be irradiated in a hypofractionated manner.Radiotherapy should be completed in two weeks. The suggested dose fraction for differentlesion was as follows:Thoracic lesion: 40Gy/10f Cranial lesion: Hippocamps‐sparing whole brain irradiation of30Gy/10f with or without simultaneous integrated lesion boost of 40Gy/10f Hepatic oradrenal lesion: 40Gy/10f Osseous lesion: 30Gy/10f or 40Gy/10f Dose constraint to organsat risk could be referred to QUANTEC criteria (30Gy/10f) and Timmerman's sheet (40Gy/10f)Follow‐up: Patients should be follow‐up every three months right after the completion ofthe final cycle of immunotherapy to 3 years after that. Then follow‐up every half year isallowed to 5 years. After 5 years, follow‐up every year is appropriate. In follow‐up,chest CT and abdominal ultrasonography should be implemented. Cranial MRI should beperformed every half year. Bone scan should be undertaken every year for all patients.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02729222/full} -} - - -Record #20 of 538 -@article{NCT0498585121, -author = {NCT04985851,}, -title = {To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS}, -journal = {https://clinicaltrials.gov/show/NCT04985851}, -year = {2021}, -accession_number = {CTgov NCT04985851}, -publication type = {Trial registry record}, -keywords = {Antibodies, Monoclonal; Lung Neoplasms; Small Cell Lung Carcinoma}, -abstract = {Target subject population Adult patients (aged ≥18 years) with histologically or cytologically documented extensive disease (American Joint Committee on Cancer Stage (8th edition) IV SCLC [T any, N any, M1 a/b]), or T3‐4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. Patients must have World Health Organization/Eastern Cooperative Oncology Group performance status of 0‐1, weight > 30 kg and adequate organ and marrow function. All patients are suitable for firstline platinum‐based chemotherapy. Duration of treatment Unless specific treatment discontinuation criteria are met, patients in Arms 1 and 2 will continue therapy until disease progression, as per investigator assessment. Investigational product, dosage and mode of administration Durvalumab 1500 mg will be administered for all patients via IV infusion concurrently with EP q3w starting on week 0 for 4 cycles. Non‐PD patients who completed the 4 cycles of Durvalumab + EP will be randomized 1:1 into Arm 1 and Arm 2. Eligible patients should begin continuous treatment in 3 days after randomization. ‐ Arm 1: Durvalumab 1500 mg monotherapy will be continued q4w. Anlotinib will be administered according to prescribing information in general use. The dose is 12mg, QD, PO, 14 days‐on and 7 days‐off. ‐ N.B. If a patient's weight falls to 30 kg or below (≤30 kg) the patient should receive weight‐based dosing equivalent to 20 mg/kg of durvalumab until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500 mg. Anlotinib is available at three dose levels, 12 mg, 10 mg, and 8 mg. Dose reduction may take place whenever toxicity that is not controlled with optimal supportive care is noted during the study. If a subject subsequently tolerates treatment well at that level in the judgment of the investigator, the dose may be increased to the next dose level. If a subject cannot tolerate treatment after dose reduction to 8 mg, treatment will be discontinued. ‐ Arm 2: Durvalumab 1500 mg monotherapy will be continued q4w.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02297208/full} -} - - -Record #21 of 538 -@article{Komaki17, -author = {Komaki, R}, -title = {Thoracic radiation-YES}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {11}, -pages = {S1663‐S1664}, -year = {2017}, -accession_number = {EMBASE 620147920}, -publication type = {Journal article; Conference proceeding}, -keywords = {*immunotherapy; *mediastinum; *non small cell lung cancer; *skull irradiation; Adrenal gland; Aged; Body weight loss; Bone; Brain metastasis; Cancer center; Cancer prognosis; Cancer recurrence; Cancer resistance; Cancer staging; Cancer survival; Cancer susceptibility; Chemoradiotherapy; Chromosome 3; Chromosome deletion; Controlled study; Diagnosis; Drug combination; Drug therapy; Gene amplification; Gene deletion; Gene expression; Genetic marker; Genetic transcription; Human; Human tissue; Immunohistochemistry; Liver; Low drug dose; Major clinical study; Male; Molecularly targeted therapy; Overall survival; Paraneoplastic syndrome; Pleura effusion; Positron emission tomography‐computed tomography; Prognosis; Prospective study; Radiotherapy; Randomized controlled trial; Relapse; Remission; Smoking cessation program; Somatic mutation; Spiral computer assisted tomography; Systemic therapy; Treatment failure; Tumor suppressor gene; United States}, -abstract = {Small cell lung cancer (SCLC) accounts for 15%‐20% of all lung cancers, and the overwhelming majority (>95%) are associated with tobacco exposure. The incidence of all types of lung cancer, including SCLC, has been declining in the United States with the onset of tobacco smoking cessation programs, although this trend took nearly 20 years to become evident among men. Overall survival (OS) rates for patients with lung cancer have also increased by about 5% since the advent of low‐dose spiral computed tomography (CT) scanning to detect early lung cancer. The prognosis for patients with SCLC continues to be poor but has improved with the advent of smoking cessation campaigns, more effective chemotherapy agents and radiation planning and delivery techniques, and the use of prophylactic cranial irradiation (PCI) for those who experience a complete response to therapy. Consolidation with chest radiotherapy has improved OS among patients with extensive‐stage SCLC who achieved a complete response to chemotherapy. SCLC often presents as bulky symptomatic masses, and mediastinal involvement is common with or without pleural effusion and extrathoracic disease. Extrathoracic spread (i.e., extensive‐stage disease) is also quite common, being present in 80%‐85% of cases at diagnosis. Brain metastases are present in approximately 20% of patients at diagnosis; roughly half of these metastases are symptomatic and the other half are detected by imaging. Predictors of poor prognosis include poor performance status, older age, and being male. The pathologic subtypes of the disease (small cell carcinoma and combined small cell carcinoma) all carry a similarly poor prognosis. Current guidelines of the U.S. National Comprehensive Cancer Network recommend the use of positron emission tomography (PET), CT scanning, or fused PET/CT scanning of the chest, liver, adrenals, bone, and other areas of concern in the diagnosis and staging of SCLC (NCCN guideline‐SCLC 2017). Thoracic radiotherapy has also become important for improving OS among patients with SCLC who achieved a complete response to chemotherapy. In one prospectively randomized study of 498 patients with extensive‐stage SCLC (WHO performance status score 0‐2) who achieved complete response to chemotherapy, patients who received consolidation thoracic radiotherapy (30 Gy in 10 fractions) had significantly better 2‐year OS rates than did those who did not receive thoracic radiotherapy (13% vs. 3%, P=0.004). Thoracic radiotherapy further improved thoracic‐only failure rates (19.8% vs. 46% without, P=0.001) (Slotman B et al, Lancet Oncol 2015;385:36‐ 42). However, many patients with extensive‐stage SCLC do not respond to the standard etoposide/cisplatin chemotherapy (Fig 1). Those patients may need to receive molecular‐targeted therapies or immunotherapy with the consolidating thoracic radiotherapy. Several histologic and immunohistochemical markers have been evaluated for diagnosing or monitoring treatment response in SCLC, including transcription thyroid factor‐1 (positive in >85% of SCLC cases); cytokeratin 7; deletions in chromosome 3; Leu‐7; chromogranin A; synaptophysin; myc amplification; and p53 mutations (present in ∼75% of cases). Deletions in tumor‐suppressor genes are also relatively common and include fragile histidine triad (FHIT) (80%); RAS effector homologue (RASSF1) (>90%); TP53 (>75%); retinoblastoma‐ 1 (RB1) (>90%); and retinoic acid receptor‐beta (72%). However, to date no biomarkers have been validated for use in diagnosing SCLC. Moreover, mutations that are often present in non‐small cell lung cancer (such as epidermal growth factor receptor [EGFR] mutations and anaplastic lymphoma kinase [ALK]) are rare in SCLC. Several clinicopathologic features have been linked with worse prognosis, including poor performance status, significant weight loss, high lactate dehydrogenase levels, large numbers of metastatic sites, and the presence of paraneoplastic syndromes. Because SCLC has the among the highest rates of somatic driver mutations, and because more than 95% of patients with SCLC are former or current smokers, immunotherapy seems a reasonable approach, as high mutation burdens correlate with good response to chemoradiotherapy and sensitivity to immunomodulators (Peifer M et al., Nat Genet 2012;44(10):1104‐10). At MD Anderson Cancer Center, an ongoing phase I/II study of patients with extensive‐stage SCLC has been proposed to the NRG as a prospective randomized study (PI J Welsh) (Fig 2). Use of thoracic radiotherapy to consolidate a site at which SCLC is quite likely to recur is reasonable, given that recurrence considerably reduces quality of their life as well as OS. In summary, in most cases SCLC presents as extensive‐stage disease, for which outcomes are very poor. Consolidation with thoracic radiotherapy for patients who achieve a complete response to chemotherapy can improve 2‐year OS rates. However, less toxic and more effective systemic treatment is also required to derive the greatest benefit from consolidation thoracic radiotherapy.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01451690/full} -} - - -Record #22 of 538 -@article{NCT0635016224, -author = {NCT06350162,}, -title = {Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC}, -journal = {https://clinicaltrials.gov/ct2/show/NCT06350162}, -year = {2024}, -accession_number = {CTgov NCT06350162}, -publication type = {Trial registry record}, -keywords = {Carcinoma, Small Cell}, -abstract = {This phase II trial compares the effect of adding radiation therapy to the usual maintenance therapy with Serplulimab versus Serplulimab alone in patients who have already received Serplulimab plus chemotherapy for the treatment of extensive stage small cell lung cancer . Immunotherapy with monoclonal antibodies, such as Serplulimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x‐rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to Serplulimab may extend the time without extensive small cell lung cancer growing or spreading compared to Serplulimab alone.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02687763/full} -} - - -Record #23 of 538 -@article{Murray17, -author = {Murray, N}, -title = {Immunotherapy of small cell lung cancer}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {1}, -pages = {S65‐S67}, -year = {2017}, -accession_number = {EMBASE 615338292}, -publication type = {Journal article; Conference proceeding}, -keywords = {*immunotherapy; *small cell lung cancer; Adverse drug reaction; Antigen expression; Cancer stem cell; Carcinogenesis; Cell surface; Chemoradiotherapy; Clinical trial; Cohort analysis; Controlled clinical trial; Controlled study; Cytotoxic T lymphocyte; Death; Diarrhea; Driver; Drug delivery system; Drug therapy; Excitement; Gene expression; Gene frequency; Gene inactivation; Gene mutation; Gene overexpression; Hazard ratio; Human; Literature; Maintenance therapy; Major clinical study; Monitoring; Neutropenia; Overall survival; Paraneoplastic neuropathy; Patient history of chemotherapy; Phase 1 clinical trial; Phase 2 clinical trial; Phase 3 clinical trial; Probability; Progression free survival; Radiotherapy; Randomized controlled trial; Side effect; Somatic mutation; Squamous cell carcinoma; Systemic therapy; Therapeutic index; Tobacco; Toxicity; Treatment failure; Tumor syndrome}, -abstract = {Immunotherapy of Small Cell Lung Cancer Nevin Murray MD, British Columbia Cancer Agency, Vancouver, Canada The general principles of cytotoxic chemotherapy for advanced SCLC and NSCLC have many similarities and have advanced minimally over the past two decades.1 The success of cancer genomics research in changing the care of patients with NSCLC with a driver mutation suitable for targeted treatment has been a powerful incentive to discover such molecular targets in SCLC. Although comparative genomic profiling shows some similarities between SCLC and NSCLC, for SCLC, the abnormalities identified to date are mainly tumor suppressor genes.2 These loss‐of‐function alterations do not provide the clear opportunity for rapid clinical translation offered by an activating mutation in a known receptor tyrosine kinase. A considerable number of targeted agents have already been tried in SCLC clinical trials without notable success.3 In contrast, there is a growing body of evidence for immunotherapy as a promising new treatment for both SCLC and NSCLC. Immunotherapy investigated for SCLC includes interferon, vaccines, antibody‐drug conjugates and immune checkpoint inhibitors. Interferon and vaccines have been studied in phase II and III trials without sufficient activity to change practice. Although preliminary, the data emerging from trials of antibody‐drug conjugates and immune checkpoint inhibitors has generated more excitement and are the focus for this abstract. Antibody‐drug conjugates: The components of an antibody‐drug conjugate include an antibody directed at a defined antigen on cancer cells, a linker, and a cytotoxic agent. This package represents an effective mechanism of targeted drug delivery potentially resulting in decreased toxicity and an improved therapeutic index. Rovalpituzumab teserine targets the Notch pathway with a monoclonal antibody portion directed against the cell surface available Notch ligand delta‐like protein 3 (DLL3), which is over‐expressed in SCLC tumor‐initiating cells but not in normal tissue. Rudin et al.4 have reported a phase I study including 74 patients with previously treated SCLC. The confirmed response rate in 56 evaluable patients was 16%, but in 26 that showed high DLL3 expression, the response rate was 31%. Response rate was 13% in second‐line and 25% in the third‐line setting with some durable responses observed. A phase II trial for third‐line treatment of patients with DLL3 expressing tumors has begun and if positive will be the first approved agent in this setting. Sacituzumab govitecan is another antibody‐drug conjugate of a topoisomerase I inhibitor linked to an antibody to the Trop‐2 epithelial antigen.5 In a phase I/II clinical trial enrolling 33 evaluable SCLC patients with a median of 2.5 previous chemotherapies, the response rate was 24% and the median overall survival was 8.1 months. Dose limiting neutropenia was 34% and grade 3+ diarrhea was seen in 9%. Immune checkpoint inhibitors: Since immune checkpoint blockade is more active in hyper‐mutated tumors, SCLC should be a good candidate disease for this treatment because of a strong association with tobacco carcinogenesis and a high frequency of somatic mutations. 2 The most advanced trial evidence is available for a cytotoxic T‐cell antibody (CTLA4) and data for two programmed death (PD‐1) immune checkpoint inhibitors is emerging. After a randomized phase II trial of ipilimumab and phased chemotherapy showed a modest improvement in progression‐free survival as first‐line treatment of advanced SCLC,6 a large phase III placebo controlled trial was performed in which 1,132 previously untreated patients were randomly assigned to receive either etoposide and platinum for four cycles alone or together with the CTLA‐4 antibody ipilimumab.7 The trial was negative with similar response rates and no difference in the primary end point of overall survival (hazard ratio 0.94; 95% CI 0.81‐1.09). Immune checkpoint blockade with PD‐1 or dual CTLA‐4 and PD‐1 inhibition may be a more effective strategy. In a large phase I/II trial including 180 previously treated SCLC patients, Antonia et al.8 reported a response rate of 13% (7/80) with nivolumab 3 mg/kg and 31% (14/45) in a cohort of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg. The activity of nivolumab alone or combined with ipilimumab was seen regardless of PD‐L1 expression and not related to platinum sensitivity or line of therapy. The responses were durable with one‐year overall survival of 27% for nivolumab alone and 48% for the combination arm. These results have led to two phase III studies among patients with SCLC evaluating nivolumab, nivolumab/ ipilimumab versus placebo in the maintenance setting after first‐line therapy and nivolumab versus placebo in the second‐line setting. As part of a phase IB multi‐cohort study (KEYNOTE‐028), pembrolizumab was evaluated among patients with relapsed SCLC with PD‐L1 positive tumors.9 Of the 135 SCLC patients screened, 37 (27%) had PD‐L1 positive tumors. The response rate was 29% in 24 evaluable patients. The median duration of response was 29 weeks and durable responses were observed. There is an ongoing phase II study of this agent as maintenance therapy after the completion of standard first‐line therapy in extensive stage disease. A phase I trial is evaluating pembrolizumab with conconcurrent chemoradiation. Adverse events associated with checkpoint inhibitors is greater with CTLA‐4 combined with the PD‐1 antibody combination but were generally manageable. The proportion discontinuing therapy for toxicity was usually less than 10%. The literature contains anecdotes of autoimmune syndromes such as limbic encephalitis.8 Immune para‐neoplastic syndromes are expected in a small proportion of patients with SCLC and an increase in their occurrence with immunotherapy requires close monitoring. However, this concern is currently insufficient to impede further trials with these promising agents. Conclusion: Over the past 20 years, almost all phase III trials of systemic therapy for SCLC have failed to improve outcome and advances have been restricted to improved application of radiotherapy. Like squamous carcinomas, the SCLC molecular battlefield is complex and bleak with little opportunity of even temporary respite by identification of mutually exclusive oncogenic drivers that can be treated for patient benefit. Ironically, this hyper‐mutated genome and greater neo‐antigen expression may enhance the probability of success with immunotherapy. One senses that the likelihood is high for approval of antibody‐drug conjugates and immune checkpoint inhibitors for SCLC after the current roster of clinical trials are reported.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01734320/full} -} - - -Record #24 of 538 -@article{NCT0645541024, -author = {NCT06455410,}, -title = {GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma}, -journal = {https://clinicaltrials.gov/ct2/show/NCT06455410}, -year = {2024}, -accession_number = {CTgov NCT06455410}, -publication type = {Trial registry record}, -keywords = {Carcinoma; Nasopharyngeal Carcinoma}, -abstract = {Platinum‐based neoadjuvant chemotherapy plus concurrent chemoradiotherapy (CCRT) is the standard of care for patients with locoregionally advanced nasopharyngeal carcinoma (NPC). Gemcitabine plus cisplatin(GP) has been demonstrated an effective chemotherapy regimen for NPC patients in previous studies. Three cycles of GP neoadjuvant chemotherapy resulted in 10% of complete response rate, and GP neoadjuvant chemotherapy added to chemoradiotherapy significantly improved recurrence‐free survival (85.3% vs 76.5%) and overall survival (94.6% vs 90.3%) among locoregionally advanced NPC patients , as compared with concurrent chemoradiotherapy alone. Therefore, GP has been established as the highest level of evidence‐based neoadjuvant chemotherapy regimen in the 2020 National Comprehensive Cancer Network (NCCN) guidelines. Recently, immune checkpoint inhibitors, such as anti‐programmed cell death‐1 (PD‐1) monoclonal antibody has shown promising efficacy in NPC patients. Clinical trials have shown objective response rates of 20.5%‐34% in patients with recurrent or metastatic NPC patients receiving anti PD‐1 monoclonal antibody immunotherapy including pembrolizumab, nivolumab, camrelizumab, and toripalimab. GP chemotherapy combined with anti PD‐1 antibody were hence considered in treating locoregionally advanced NPC. Concurrent radiotherapy might cause T‐cell dysfunction, and larger‐volume elective nodal irradiation might hinder immunotherapy effects by directly depleting memory T cells. No survival benefit was observed when PD‐1 blockade was added concurrently to the CCRT phase for treating head and neck cancers. On the contrary, several studies have demonstrated that administration of immunotherapy in the neoadjuvant setting modified the primary tumor into an antigen source for T‐cell expansion and priming, thereby resulting in stronger effects than those of adjuvant therapy. Currently there were 3 trials exploring the addition of immunotherapy to chemoradiotherapy, the preliminary results of which were recently published. These trials had different trial designs, with two trials utilized anti PD‐1 inhibitors in all treatment phases including neoadjuvant, concurrent and adjuvant phases, The third trial, which was conducted by our team, gave anti PD‐1 inhibitor only in the neoadjuvant phase, and promising efficacy was observed in our study. Adebrelimab is a recombinant humanized IgG4 monoclonal antibody with specificity for PD‐L1. In a phase III clinical trial of extensive stage small‐cell lung cancer, the addition of adebrelimab significantly improved the median overall survival compared with the control group (15.3 vs. 12.8,HR 0.72, P=0.0017). So we hypothesize that GP neoadjuvant chemotherapy combined with adebrelimab could further improve the survival of patients with high‐risk locoregionally advanced NPC (diagnosed with T4 or N2‐3 disease). Therefore, we designed this phase II multi‐center randomized controlled trial to evaluate whether GP neoadjuvant chemotherapy combined with adebrelimab plus cisplatin‐based CCRT improve the complete response rate of high‐risk locoregionally advanced NPC patients compared with GP neoadjuvant chemotherapy plus CCRT.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02709188/full} -} - - -Record #25 of 538 -@article{Palumbo19, -author = {Palumbo, G, Carillio, G, Manzo, A, Montanino, A, Sforza, V, Costanzo, R, Sandomenico, C, Manna, C, Luca, G, Piccirillo, MC, Daniele, G, Cecio, R, Botti, G, Totaro, G, Muto, P, Picone, C, Esposito, G, Normanno, N, and Morabito, A}, -title = {Pembrolizumab in lung cancer: current evidence and future perspectives}, -journal = {Future oncology (London, England)}, -volume = {15}, -number = {29}, -pages = {3327‐3336}, -year = {2019}, -accession_number = {PUBMED 31432705}, -publication type = {Journal article}, -keywords = {Animals; Antibodies, Monoclonal, Humanized [administration & dosage]; Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Carcinoma, Non‐Small‐Cell Lung [*drug therapy, pathology]; Docetaxel [administration & dosage]; Drug Evaluation; Follow‐Up Studies; Humans; Lung Neoplasms [*drug therapy, pathology]; Mice; Nivolumab [administration & dosage]; Prognosis; Receptors, Estrogen [*metabolism]; Small Cell Lung Carcinoma [*drug therapy, pathology]; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays}, -abstract = {Pembrolizumab is a humanized monoclonal antibody against PD‐1 capable of enhancing antitumor immune activity. The KEYNOTE‐001 study showed that pembrolizumab has activity in advanced non‐small‐cell lung cancer patients and identified programmed death ligand 1 (PD‐L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non‐small‐cell lung cancer: in second‐line setting PD‐L1 ≥1% (KEYNOTE‐010), in first‐line setting PD‐L1 ≥50% (KEYNOTE‐024 and KEYNOTE‐042) and in first‐line setting in combination with platinum doublets, any expression of PD‐L1 (KEYNOTE‐189 and KEYNOTE‐407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene‐addicted patients, in combination with radiotherapy or other biological agents.}, -DOI = {10.2217/fon-2019-0073}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02090124/full} -} - - -Record #26 of 538 -@article{EUCTR2019-003916-29-DE20, -author = {EUCTR2019-003916-29-DE,}, -title = {- TREASURE- Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-003916-29-DE}, -year = {2020}, -accession_number = {ICTRP EUCTR2019‐003916‐29‐DE}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trade Name: Tecentriq® 1.200 mg Pharmaceutical Form: Concentrate for solution for infusion CONDITION: Small cell lung cancer extensive disease ; MedDRA version: 21.1 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: The objective of this study is to investigate the treatment efficacy of combining thoracic radiotherapy (TRT) with the IMpower133 regimen in the upfront treatment of ED SCLC patients.; The study is designed in an attempt to increase the efficacy of atezolizumab maintenance after induction with chemo/atezolizumab by adding radiotherapy. Primary end point(s): The primary endpoint is overall survival (OS), defined as time from randomization to death due to any cause. The primary endpoint will be evaluated as a time‐to‐event variable using a Cox proportional hazards model. Secondary Objective: Additionally, with this study, we aim to determine the safety and tolerability of the combination of immunological and radiological treatment in the first‐line setting of advanced SCLC.; Furthermore, we aim to collect blood, stool and tissue samples prospectively for the separate translational program. Timepoint(s) of evaluation of this end point: at study end / after LVLS SECONDARY OUTCOME: Secondary end point(s): • 1‐ and 2‐year OS rate; • PFS (according to RECIST 1.1); • Response rate (according to RECIST 1.1); • Intrathoracic tumor control (defined as rate of intrathoracic progression and time to intrathoracic progression; progression defined according to RECIST 1.1); • Safety in terms of ‐ Incidence, nature, causal relationship and severity of Adverse Events according to NCI CTCAE v5.0 ‐ Frequency of abnormal laboratory parameters; • Feasibility in terms of: ‐ frequency of treatment withdrawal (either due to adverse events or other reasons) ‐ completion of radiotherapy; • Cancer related quality of life (FACT‐L); • Collection of biomarker samples for separate biomarker research project Timepoint(s) of evaluation of this end point: • all secondary endpoints will be finally evaluated at study end (after LVLS); • 1‐ and 2‐year OS rate: additionally at 1 and 2 years after LPI ; • Safety will be evaluated continously and after LVLS INCLUSION CRITERIA: 1. Fully‐informed written consent and locally required authorization (European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol‐related procedures, including screening evaluations. 2. Age = 18 years. 3. Histologically or cytologically confirmed ED SCLC as defined according to the Veterans Administration Lung Study Group staging system. 4. Measurable ED SCLC according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 5. ECOG performance‐status score of 0 or 1 at screening 6. Any response after four cycles of standard chemo‐immunotherapy (carboplatin, etoposide, atezolizumab) defined as CR/PR or thoracic SD with CR/PR of extrathoracic lesions a per RECIST 1.1 7. Thoracic treatment volume considered treatable using acceptable radiation fields as judged by a radiation oncologist 8. 28 ± 7 days or less between last administration of chemo‐immunotherap}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169480/full} -} - - -Record #27 of 538 -@article{Stanley23, -author = {Stanley, DN, Harms, J, Kole, AJ, Dobelbower, MC, McCann, C, Levine, L, Russell, K, and McDonald, AM}, -title = {Daily Adaptive vs. Non-Adaptive External Beam Radiation Therapy with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC): a Prospective Randomized Trial of an Individualized Approach for Toxicity Reduction (ARTIA-Lung)}, -journal = {International journal of radiation oncology biology physics}, -volume = {117}, -number = {2}, -pages = {e41‐e42}, -year = {2023}, -accession_number = {EMBASE 2026580829}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer adjuvant therapy; *chemoradiotherapy; *dyspnea; *external beam radiotherapy; *non small cell lung cancer; *prospective study; Adult; Adverse drug reaction; Cancer center; Cancer patient; Cancer size; Cancer staging; Cervical lymph node; Clinical trial; Conference abstract; Controlled study; Coughing; Doublet chemotherapy; Drug therapy; Dysphagia; Eligibility criteria; Esophagitis; European Quality of Life 5 Dimensions 5 Level questionnaire; Female; Follow up; Heart; Human; Immunotherapy; Incidence; Intensity modulated radiation therapy; Low drug dose; Major clinical study; Male; Mediastinum lymph node; Metastasis; Multicenter study; Outcome assessment; Pneumonia; Positron emission tomography‐computed tomography; Primary tumor; Quality of life; Radiation pneumonia; Radiotherapy; Randomization; Randomized controlled trial; Response evaluation criteria in solid tumors; Side effect; Volumetric modulated arc therapy}, -abstract = {Purpose/Objective(s): Radiotherapy (RT) with concurrent chemotherapy is a standard treatment for Stage III NSCLC. However, radiation pneumonitis incidence increases rapidly with volume of lung irradiated, and esophagitis increases with dose to the esophagus. Both conditions can have adverse impacts on patients’ quality of life. Daily online adaptive RT (ART) may allow for reduced normal tissue doses due to smaller margins around the target, as well as target size reduction with tumor response. This prospective, randomized controlled trial tests the hypothesis that the proportion of study participants who experience score ≥3 PRO‐CTCAE cough, dyspnea, or dysphagia will be at least 20% lower with daily ART than with non‐adapted RT. Materials/Methods: Enrollment goals are 244 subjects at up to 10 cancer centers worldwide. Eligibility criteria include stage IIIA‐IIIC (AJCC v8) NSCLC; baseline grade 0‐2 dyspnea, cough, and dysphagia; and no contralateral hilar or supraclavicular/cervical lymph node involvement. Subjects will be randomized (1:1) to CBCT‐based daily ART or non‐adapted RT using IMRT or VMAT delivering 60‐66 Gy in 30‐33 fractions with concurrent platinum doublet chemotherapy. Adjuvant immunotherapy with durvalumab is permitted. Follow‐up for study participants will be for 1‐year post‐completion of chemoRT. Study endpoints include: frequency of PRO‐CTCAE score ≥3 cough, dyspnea, or dysphagia from randomization to 30 days post‐chemoRT; patient‐reported quality of life (FACT‐L and EQ‐5D‐5L questionnaires); percentage of lung receiving ≥20 Gy; mean doses to lung, heart, and esophagus; primary tumor response on CT or PET‐CT (RECIST v1.1); local disease progression; and incidence of grade ≥2 pneumonitis within 1 year. Stratification factors are the treating institution and the presence of contralateral mediastinal lymph node metastases (associated with increased volume of irradiated lung). Interim analyses for futility and superiority will be performed when the primary endpoint data have been collected for 50% of evaluable participants. Results: This study opened to enrollment on 20 October 2022 and is expected to be completed in approximately 3 years. Conclusion: This prospective, randomized clinical trial rigorously evaluates the impacts of daily online ART on radiation pneumonitis, esophagitis, and quality of life in patients with advanced NSCLC. It will collect standard tumor response and disease progression metrics to assure that reduced margins do not have an adverse impact on outcomes. Online ART is emerging as an innovative approach enabling increased sparing of normal tissues. The results of this clinical study will support evidence‐based clinical decisions around ART technologies.}, -DOI = {10.1016/j.ijrobp.2023.06.739}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02611676/full} -} - - -Record #28 of 538 -@article{Neninger07, -author = {Neninger, E, Diaz, RM, De La Torre, A, Rives, R, Diaz, A, Saurez, G, Gabri, MR, Alonso, DF, Wilkinson, B, Alfonso, AM, Combet, T, Perez, R, and Vazquez, AM}, -title = {Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial}, -journal = {Cancer biology & therapy}, -volume = {6}, -number = {2}, -pages = {145‐150}, -year = {2007}, -accession_number = {EMBASE 46641614, PUBMED 17218777}, -publication type = {Journal article}, -keywords = {*active immunization; *small cell lung cancer /drug therapy /radiotherapy; Adult; Aged; Animals; Antibodies, Anti‐Idiotypic [*therapeutic use]; Antibodies, Monoclonal [*therapeutic use]; Antibodies, Neoplasm [*therapeutic use]; Antibody Specificity; Antibody response; Antigen antibody reaction; Arthralgia /side effect; Article; Binding Sites, Antibody; Blood toxicity /side effect; Cancer Vaccines [immunology, therapeutic use]; Cancer chemotherapy; Cancer immunotherapy; Cancer radiotherapy; Cancer staging; Cancer survival; Carcinoma, Small Cell [*drug therapy]; Chill /side effect; Clinical trial; Combination chemotherapy; Controlled clinical trial; Controlled study; Drug fever /side effect; Drug induced headache /side effect; Drug safety; Female; G(M3) Ganglioside [immunology]; Human; Human tissue; Humans; Humoral immunity; Hypertension /side effect; Immunohistochemistry; Immunotherapy, Active; Injection site abscess /side effect; Injection site erythema /side effect; Injection site induration /side effect; Injection site pain /side effect; Injection site reaction /drug therapy; Lung Neoplasms [*drug therapy]; Male; Mice; Middle Aged; Multicenter study; Paresthesia /side effect; Phase 1 clinical trial; Randomized controlled trial; Tissue section; Treatment Outcome; Treatment response}, -abstract = {1E10 is an anti‐idiotype murine monoclonal antibody (Ab2 MAb) specific to an Ab1 MAb which reacts with NeuGc‐containing gangliosides, sulfatides and with antigens expressed in some human tumors. Preparations containing this Ab2 were capable to induce a strong anti‐metastatic effect in tumor‐bearing mice. We conducted a Phase I clinical trial to evaluate the toxicity and humoral immune response elicited by 1E10 vaccine in patients with small cell lung cancer (SCLC). Eligible patients were those who after received chemotherapy and/or radiotherapy had partial or complete response to treatment. Patients received four biweekly injections with 2 mg of aluminum hydroxide‐precipitated 1E10 MAb, then other six doses at 28‐day intervals, and later the patients who maintained a good performance status were reimmunized. Six patients with limited‐stage disease and three with extensive‐stage disease were enrolled in the study. Most of the patients who received at least four doses of 1E10 vaccine developed strong specific antibody responses against 1E10 MAb and NeuGc‐GM3 ganglioside. Antibodies able to react with lung carcinoma tissue sections were detected in sera from vaccinated patients. A prolonged survival was observed in several patients treated with the anti‐idiotype vaccine. No evidence of serious adverse effects was found.}, -DOI = {10.4161/cbt.6.2.3574}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01742151/full} -} - - -Record #29 of 538 -@article{Iivanainen23, -author = {Iivanainen, S, Baird, AM, Balas, B, Bustillos, A, Castro Sanchez, AY, Eicher, M, Golding, S, Mueller-Ohldach, M, Reig, M, Welslau, M, and Ammann, J}, -title = {Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA)}, -journal = {BMJ open}, -volume = {13}, -number = {4}, -pages = {e063242}, -year = {2023}, -accession_number = {EMBASE 2024156126, PUBMED 37076159}, -publication type = {Journal article}, -keywords = {*Carcinoma, Non‐Small‐Cell Lung [drug therapy]; *Liver Neoplasms; *Lung Neoplasms [drug therapy]; *cancer therapy; *clinical practice; *feasibility study; *home care; *information system; *outcome assessment; *patient monitoring; *telemedicine; Adoption; Adult; Article; Cancer patient; Cancer staging; Case report; Child Pugh score; Clinical article; Cohort analysis; Delivery of Health Care; Drug therapy; Feasibility Studies; Female; Finland; Health care personnel; Health care quality; Human; Humans; Informed consent; Intravenous drug administration; Liver cell carcinoma; Male; Monitoring, Physiologic; Multicenter Studies as Topic; Non small cell lung cancer; Organization; Professional standard; Randomized Controlled Trials as Topic; Randomized controlled trial; Regulated cell death; Small cell lung cancer; Spain; Treatment Outcome}, -abstract = {Introduction Digital patient monitoring (DPM) tools can enable more effective clinical care and improved patient outcomes in cancer. However, their broad adoption requires ease of use and demonstration of real‐world clinical utility/impact. ORIGAMA (MO42720) is an interventional, open‐label, multicountry platform study investigating the clinical utility of DPM tools and specific treatments. ORIGAMA will begin with two cohorts that aim to assess the impact of the atezolizumab‐specific Roche DPM Module (hosted on the Kaiku Health DPM platform (Helsinki, Finland)) on health outcomes and healthcare resource usage, and its feasibility to support at‐home treatment administration, in participants receiving systemic anticancer treatment. Other digital health solutions may be added to future cohorts. Methods and analysis In Cohort A, participants with metastatic non‐small cell lung cancer (NSCLC), extensive‐stage SCLC or Child Pugh A unresectable hepatocellular carcinoma will be randomised to a locally approved anticancer regimen containing intravenous atezolizumab (TECENTRIQ, F. Hoffmann‐La Roche Ltd/Genentech) and local standard‐of‐care support, with/without the Roche DPM Module. Cohort B will assess the feasibility of the Roche DPM Module in supporting administration of three cycles of subcutaneous atezolizumab (1875 mg; Day 1 of each 21‐day cycle) in the hospital, followed by 13 cycles at home by a healthcare professional (ie, flexible care), in participants with programmed cell‐death ligand 1‐positive, early‐stage NSCLC. The primary endpoints are the mean difference in change of the participant‐reported Total Symptom Interference Score at Week 12 from baseline (Cohort A) and flexible care adoption rate at Cycle 6 (Cohort B). Ethics and dissemination This study will be conducted according to the Declaration of Helsinki, and/or the applicable laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The study received its first Ethics Committee approval in Spain in October 2022. Participants will provide written informed consent in a face‐to‐face setting. The results of this study will be presented at national and/or international congresses and disseminated via publication in peer‐reviewed journals. Trial registration number NCT05694013.}, -DOI = {10.1136/bmjopen-2022-063242}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02558930/full} -} - - -Record #30 of 538 -@article{Melillo21, -author = {Melillo, G, Chand, V, Yovine, A, Gupta, A, and Massacesi, C}, -title = {Curative-Intent Treatment with Durvalumab in Early-Stage Cancers}, -journal = {Advances in therapy}, -volume = {38}, -number = {6}, -pages = {2759‐2778}, -year = {2021}, -accession_number = {EMBASE 2011255644, PUBMED 33881745}, -publication type = {Journal article}, -keywords = {*cancer immunotherapy; *early cancer /drug therapy; Antibodies, Monoclonal [therapeutic use]; Bladder cancer; Cancer prognosis; Cancer staging; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [drug therapy]; Chemoradiotherapy; Clinical outcome; Health care quality; Human; Humans; Liver cancer; Long term survival; Lung Neoplasms [drug therapy]; Lung cancer; Multiple cancer; Non small cell lung cancer; Overall survival; Progression free survival; Review; Treatment outcome}, -abstract = {The introduction of immunotherapy has fundamentally transformed the treatment landscape in cancer, providing long‐term survival benefit for patients with advanced disease across multiple tumor types, including non‐small cell lung cancer (NSCLC). In the placebo‐controlled phase 3 PACIFIC trial, the PD‐L1 inhibitor durvalumab demonstrated significant improvements in progression‐free survival and overall survival in patients with unresectable, stage III NSCLC who had not progressed after platinum‐based chemoradiotherapy (CRT). These findings have led to the widespread acceptance of the ?PACIFIC regimen? (durvalumab after CRT) as the standard of care in this setting. Moreover, the PACIFIC trial is the first study to demonstrate a proven survival advantage with an immunotherapy in a curative‐intent setting, thereby providing a strong rationale for further investigation of durvalumab in early‐stage cancers. Herein, we describe the extensive clinical development program for durvalumab across multiple tumor types in curative‐intent settings, outlining the scientific rationale(s) for its use and highlighting the innovative research (e.g., personalized cancer monitoring) advanced by these trials.}, -DOI = {10.1007/s12325-021-01675-0}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02298865/full} -} - - -Record #31 of 538 -@article{Cheng22, -author = {Cheng, Y}, -title = {EP14.01-010 CAN: a Phase II Trial of Combination of Niraparib and Anlotinib in Patients with Recurrent Small Cell Lung Cancer}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S530}, -year = {2022}, -accession_number = {EMBASE 2020097751}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer combination chemotherapy; *cancer patient; *cancer recurrence; *small cell lung cancer; Adult; Advanced cancer; Aged; Angiogenesis; Cancer chemotherapy; Cancer staging; Chinese; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Drug combination; Drug safety; Drug therapy; Drug withdrawal; ECOG Performance Status; Exploratory research; Female; Histopathology; Human; Informed consent; Maintenance therapy; Major clinical study; Monotherapy; Ovary cancer; Phase 2 clinical trial; Phase 3 clinical trial; Prospective study; Young adult}, -abstract = {Introduction: Small cell lung cancer (SCLC) accounts for 14% of all lung cancers. Despite immunotherapy approved, SCLC is still associated with a poor prognosis and many patients relapse and develop drug resistance. Subsequent therapies are limited and the overall survival for recurrent SCLC is around 26 weeks. Anlotinib is a multi‐target receptor tyrosine kinase inhibitor that can significantly inhibit angiogenesis. The ALTER 1202 trial showed anlotinib monotherapy has a longer median PFS compared with placebo (4.1 vs. 0.7 months) in patients (pts) with SCLC who had received ≥ 2 prior lines of chemotherapy. National Medical Products Administration (NMPA) has approved anlotinib in the third‐ or further‐line treatment for SCLC. Niraparib is a highly selective PARP1 and PARP2 inhibitor approved in advanced ovarian cancer. ZL‐2306‐005 trial is a phase 3 study evaluating the efficacy and safety of niraparib as first‐line maintenance therapy in Chinese pts with platinum‐responsive extensive stage‐SCLC (ES‐SCLC). Although the study did not reach primary end points, niraparib showed a modest effect in prolonging the PFS of platinum‐responsive pts with ES‐SCLC. Methods: CAN study is a prospective, open‐label, single‐arm phase II trial aims to investigate the efficacy and safety of niraparib in combination with anlotinib in recurrent SCLC pts. Eligible pts with aged 18‐75 years and ECOG performance status 0‐2 must have histologically confirmed recurrent SCLC who had received ≥1 platinumbased chemotherapy. Each patient has evaluable target lesion according to RESCIST v1.1. Prior anti‐PD‐L1 treatment is allowed. Pts will receive niraparib (300 mg or 200 mg QD) and anlotinib (12 mg QD, Day1‐14), 21 days for a cycle. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of informed consent. The primary endpoint is ORR; secondary endpoints include PFS, OS, DCR, DOR and safety. Exploratory analyses are planned. The study will enroll up to 62 pts with a Simon's two‐stage design. In the first stage, 19 pts will be enrolled. If there are ≤3 responses in these 19 pts, study will be stopped. Otherwise, 43 additional pts will be enrolled for a total of 62.Registration number : ChiCTR2100046269. Keywords: SCLC, Niraparib, Anlotinib}, -DOI = {10.1016/j.jtho.2022.07.946}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02488711/full} -} - - -Record #32 of 538 -@article{Owen22, -author = {Owen, DH, Durm, GA, Wei, L, Pilcher, C, Ferguson, S, Benner, B, Jukich, M, Sukrithan, V, Konda, B, Savardekar, H, Spakowicz, D, Schwarz, E, Norman, RO, Wesolowski, R, Carson, WE, Kaufman, J, Alahmadi, A, Memmott, R, Shields, P, He, K, Bertino, EM, Presley, CJ, Carbone, DP, and Otterson, GA}, -title = {EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: a Randomized, Multi-Cohort Phase 2 Trial}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S544‐S545}, -year = {2022}, -accession_number = {EMBASE 2020098435}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *small cell lung cancer; Adult; Brain metastasis; Cancer patient; Cancer recurrence; Cancer research; Cancer resistance; Cancer survival; Clinical article; Clinical trial; Cohort analysis; Conference abstract; Controlled study; Drug combination; Drug therapy; Exploratory research; Female; Gastrointestinal tract; Human; Human cell; Immunotherapy; Male; Microbiome; Monotherapy; Myeloid‐derived suppressor cell; Nonhuman; Null hypothesis; Ohio; Overall response rate; Overall survival; Phase 2 clinical trial; Progression free survival; Randomized controlled trial; Response evaluation criteria in solid tumors}, -abstract = {Introduction: Treatment options are limited for patients with extensive stage small cell lung cancer (ES‐SCLC) after progression on first line chemo‐immunotherapy (CIT). Temozolomide (TEM) is active in ES‐SCLC and has been shown to have an immunomodulatory effect for patients with advanced cancers. Immune checkpoint inhibitor (ICI) therapy combined with TEM has demonstrated promising activity among patients in 2nd and 3rd line after CIT (NCT03728361, reported at this meeting). Two different dosing regimens of TEM monotherapy have been explored in ES‐SCLC but the objective response rate among patients treated after first line CIT remains unknown. Methods: NCT04919382 is a randomized, two‐cohort, multiple‐institution, open‐label phase 2 trial of atezolizumab combined with TEM for patients with ES‐SCLC. Patients who experienced disease progression after treatment with first‐line CIT are eligible. Study treatment consists of atezolizumab 1680 mg IV and two dosing regimens of TEM based on prior phase 2 trials: TEM 150 mg/m2 for days 1‐5 (cohort 1) and TEM 75 mg/m2 days 1‐21 (cohort 2) out of 28 day cycles. Patients (N=28 in each cohort) will be randomized to each TEM dosing cohort and stratified by presence of brain metastases and platinum sensitive/resistant disease. The primary endpoint is disease response rate by RECIST v1.1. Progression free survival (PFS) and overall survival (OS) will be assessed using the method of Kaplan‐Meier, and adverse events will be graded using CTCAE v5. Exploratory analyses include an evaluation of changes in myeloid derived suppressor cells (MDSC) and other immune subsets in peripheral blood induced by the different dosing of TEM, and differences in pre‐treatment gut microbiomes between responders and non‐responders. A response rate of 15% or less is the null hypothesis and an overall response rate of 35% or more would be considered promising. Based on these assumptions, this phase 2 design will require 28 evaluable patients in each cohort using a one‐stage design with 80% power and one‐sided significance level of 0.05. Conclusion: This randomized phase 2 trial will study the efficacy of atezolizumab and two different dosing regimens of temozolomide in patients with refractory/recurrent ES‐SCLC as second line therapy including in patients with brain metastases. NCT04919382 is currently enrolling at Ohio State University and will soon be opening at additional sites in the Big 10 Cancer Research Consortium. [Formula presented]}, -DOI = {10.1016/j.jtho.2022.07.979}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461481/full} -} - - -Record #33 of 538 -@article{Ruckdeschel81, -author = {Ruckdeschel, JC, McKneally, MF, and Baxter, DH}, -title = {Regional immunotherapy has a detrimental effect on the response to combined irradiation and chemotherapy in locally advanced non-small cell bronchogenic carcinoma}, -journal = {Cancer immunology, immunotherapy}, -volume = {11}, -number = {4}, -pages = {277‐282}, -year = {1981}, -accession_number = {EMBASE 11027695}, -publication type = {Journal article}, -keywords = {*adverse drug reaction; *cancer chemotherapy; *immunotherapy; *lung carcinoma; *non small cell lung cancer; *radiotherapy; Clinical trial; Controlled study; Drug administration; Drug comparison; Human; Randomized controlled trial; Respiratory system; Therapy}, -abstract = {Twenty‐one patients with stage III M0 non‐oat cell bronchogenic carcinoma confined to the thorax were randomized to receive either intrapleural BCG (107 cfu, Tice strain) or intrapleural saline 3 weeks prior to beginning combined irradiation and chemotherapy. Radiation to the primary tumor and regional nodes was given at a dose of 3,000 rad in ten sessions and was followed in 7‐14 days by CAMP chemotherapy (cyclophosphamide, adriamycin, methotrexate, and procarbazine) for a planned duration of 6 months. Isoniazid, 300 mg/day, was given to all patients for 3 months starting 1 week after intrapleural therapy. There were no significant differences in pretreatment prognostic factors or in response to radiation therapy. The patients receiving intrapleural BCG in addition to radiation and chemotherapy had a median survival of 18 weeks, significantly shorter than that for the patients receiving intrapleural saline (54 weeks, P = 0.017).}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00177753/full} -} - - -Record #34 of 538 -@article{EUCTR2019-003301-97-ES20, -author = {EUCTR2019-003301-97-ES,}, -title = {A Study of Atezolizumab plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-003301-97-ES}, -year = {2020}, -accession_number = {ICTRP EUCTR2019‐003301‐97‐ES}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: tiragolumab Product Code: RO7092284/F03‐01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Tiragolumab CAS Number: 1918185‐84‐8 Current Sponsor code: RO709‐2284 Other descriptive name: MTIG7192A, anti‐TIGIT, aTIGIT, PRO400402, 4.1D3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60‐ Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: TECENTRIQ® Pharmaceutical Form: Solution for infusion INN or Proposed INN: ATEZOLIZUMAB Current Sponsor code: RO5541267 Other descriptive name: MPDL3280A Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60‐ CONDITION: Small cell lung cancer (SCLC) ; MedDRA version: 21.1 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) ; MedDRA version: 21.1 Level: PT Classification code 10041067 Term: Small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: To evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in patients with untreated extensive‐stage small cell lung cancer (ES‐SCLC) on the basis of progression free survival and overall survival. Primary end point(s): 1. Progression‐free survival; 2. Overall survival Secondary Objective: • To evaluate the efficacy of tiragolumab plus atezolizumab and CE compared with placebo plus atezolizumab and CE on the basis of Confirmed objective response rate, duration of response, progression free survival at 6 months and at 12 months, overall survival rates at 12 months and 24 months and time to sustained deterioration; • To evaluate the safety of tiragolumab plus atezolizumab and CE compared with placebo plus atezolizumab and CE; • To characterize the pharmacokinetics of tiragolumab and atezolizumab; • To evaluate the immune response to tiragolumab and atezolizumab. Timepoint(s) of evaluation of this end point: 1‐2. Up to 43 months SECONDARY OUTCOME: Secondary end point(s): 1. Confirmed objective response rate; 2. Duration of response; 3. Progression‐free survival rates at 6 months and at 12 months ; 4. Overall survival rates at 12 months and 24 months; 5. Time to sustained deterioration; 6. Incidence and severity of adverse events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0; 7. Minimum serum concentration [Cmin]of tiragolumab and atezolizumab at specified timepoints; 8. Maximum serum concentration [Cmax] of tiragolumab and atezolizumab at specified timepoints; 9. Prevalence of ADAs to tiragolumab and atezolizumab at baseline and during the study. Timepoint(s) of evaluation of this end point: 1‐9. Up to 43 months INCLUSION CRITERIA: ‐ Age >= 18 years ‐ Eastern Cooperative Oncology Group performance status of 0 or 1 ‐ Histologically or cytologically confirmed ES‐SCLC ‐ No prior systemic treatment for ES‐SCLC ‐ For patients who have received prior chemoradiotherapy for limited‐stage SCLC: must have had treatment with curative intent and a treatment‐free interval of at least 6 months between the last dose/cycle of chemotherapy, thoracic radiotherapy, or chemoradiotherapy and the diagnosis of ES‐SCLC ‐ Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors version 1.1 ‐ Submission of a pre‐treatment tumor tissue sample ‐ Adequate hematologic and end‐organ function ‐ For patients receiving therapeutic anticoagulation: stable anticoagulant regimen ‐ Negative HIV test at screening ‐ Negative hepatitis B surface antigen (HBsAg) test at screening ‐ Negative total hepatitis B core antibody (HBcAb) test at scre}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169393/full} -} - - -Record #35 of 538 -@article{Cheng24, -author = {Cheng, Y, Wang, H, Min, X, Hu, D, Wang, Q-M, Li, B, Liu, A, Liu, C, Zhao, L, Liu, Y, Wu, C, Xin, Y, Zhang, X, Cui, H, Zhang, J, Ma, K, and Yang, L}, -title = {Adebrelimab with concurrent chemoradiation (cCRT) for limited-stage small cell lung cancer (LS-SCLC): safety run-in results of a phase III trial}, -journal = {ESMO open}, -volume = {9}, -year = {2024}, -accession_number = {EMBASE 2030949457}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *small cell lung cancer; Adverse drug reaction; Clinical article; Clinical trial; Conference abstract; Controlled study; Double blind procedure; Follow up; Human; Incidence; Infusion related reaction; Male; Median survival time; Parttime employment; Phase 3 clinical trial; Pneumonia; Radiotherapy; Side effect; Therapy}, -abstract = {Background: cCRT is the standard of care in LS‐SCLC, but LS‐SCLC still represents a significant unmet medical need with a median survival of 25 to 30 mo. Addition of the anti‐PD‐L1 antibody adebrelimab to carboplatin and etoposide has demonstrated survival benefits in extensive‐stage SCLC in the phase 3 CAPSTONE‐1 trial. This ongoing, 2‐stage, phase 3 study aims to evaluate cCRT with adebrelimab in LS‐SCLC. Methods: In the safety run‐in stage, patients with pathologically confirmed, unresectable LS‐SCLC were enrolled. Treatment consisted of four 3‐week cycles of adebrelimab (20 mg/kg, iv, d1, Q3W) plus carboplatin (AUC 5, iv, d1, Q3W) and etoposide (100 mg/m2, iv, d1, 2, 3, Q3W), with thoracic radiotherapy started on cycle 3 (60 Gy/2 Gy, QD, 6 weeks). Following cCRT, patients received maintenance adebrelimab (20 mg/kg, iv, Q3W) until disease progression or unacceptable toxicities. The primary endpoint was safety. Results: In the safety run‐in stage, 28 patients were enrolled and all received adebrelimab with cCRT. As of Oct. 31, 2023, median follow‐up was 29.4 mo (range 6.5‐33.3). Grade ≥3 TRAEs occurred in 27 (96.4%) patients; all events with an incidence of ≥10% were hematological toxicities. Four (14.3%) patients had treatment‐related pneumonitis and one (3.6%) had treatment‐related immune‐mediated lung disease (all grade 2). TRAEs led to treatment discontinuation in one (3.6%; infusion‐related reactions) patient. There were no deaths due to TRAEs. Confirmed ORR was 92.9% (26/28; 95% CI 76.5‐99.1) and DCR was 100% (28/28; 95% CI 87.7‐100). Among responders, median DoR was 20.1 mo (95% CI 7.7‐not reached [NR]; 11/26 responses ongoing). Median PFS was 17.9 mo (95% CI 8.8‐NR). Median OS was NR and the OS rate at 2 years was 64.3% (95% CI 43.8‐78.9). Conclusions: In the safety run‐in stage, adebrelimab with cCRT showed acceptable tolerability and favorable efficacy outcomes in LS‐SCLC. The randomized, double‐blind, placebo‐controlled stage of the trial is ongoing to further assess the regimen. Clinical trial identification: NCT04691063. Legal entity responsible for the study: Jiangsu Hengrui Pharmaceuticals Co., Ltd. Funding: Jiangsu Hengrui Pharmaceuticals Co., Ltd. Disclosure: J. Zhang, K. Ma, L. Yang: Financial Interests, Personal, Full or part‐time Employment: Hengrui. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.esmoop.2024.102771}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02685571/full} -} - - -Record #36 of 538 -@article{Levy16, -author = {Levy, A, Massard, C, Soria, JC, and Deutsch, E}, -title = {Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: single centre subset analysis from a phase 1/2 trial}, -journal = {European journal of cancer (Oxford, England : 1990)}, -volume = {68}, -pages = {156‐162}, -year = {2016}, -accession_number = {EMBASE 613098235, PUBMED 27764686}, -publication type = {Journal article}, -keywords = {*Chemoradiotherapy; *apoptosis; *durvalumab; *irradiation; *ligand; *programmed death 1 ligand 1; *radioimmunotherapy; Adenocarcinoma [secondary, therapy]; Adult; Adverse drug reaction; Aged; Aged, 80 and over; Antibodies, Monoclonal [*therapeutic use]; Antineoplastic Agents [*therapeutic use]; B7‐H1 Antigen [antagonists & inhibitors]; Bone Neoplasms [secondary, therapy]; Brain Neoplasms [secondary, therapy]; Breast Neoplasms [pathology, therapy]; Carcinoma, Squamous Cell [pathology, therapy]; Carcinoma, Transitional Cell [secondary, therapy]; Clinical trial; Colonic Neoplasms [pathology, therapy]; Controlled clinical trial; Controlled study; Disease‐Free Survival; Drug therapy; Eye Neoplasms [pathology, therapy]; Female; Head and Neck Neoplasms [pathology, therapy]; Human; Humans; Intravenous drug administration; Kaplan‐Meier Estimate; Liver Neoplasms [secondary, therapy]; Lung Neoplasms [pathology, therapy]; Lymphatic Metastasis [radiotherapy]; Major clinical study; Male; Melanoma [secondary, therapy]; Middle Aged; Mucosa inflammation; Neoplasms [*therapy]; Pharmacokinetics; Phase 1 clinical trial; Phase 2 clinical trial; Practice guideline; Radiosurgery; Radiotherapy; Radiotherapy, Conformal; Remission; Response evaluation criteria in solid tumors; Safety; Side effect; Skull; Small Cell Lung Carcinoma [secondary, therapy]; Squamous Cell Carcinoma of Head and Neck; Survival Rate; Systemic therapy; Tumor growth; Urinary Bladder Neoplasms [pathology, therapy]}, -abstract = {Purpose To assess preliminary safety and efficacy results of the anti‐programmed cell death ligand‐1 (anti‐PD‐L1) durvalumab in combination with radiotherapy (RT) in an expansion cohort of patients included in a phase 1/2 trial at our institution. Patients and methods Data from patients who received concurrent palliative RT with durvalumab (10 mg/kg every 2 weeks via intravenous infusion) were analysed in terms of safety (CTCAE v4.0) and efficacy (RECIST v1.1 and tumour growth rate [TGR]). Results Between 02/2014 and 04/2016, 10 patients received palliative local irradiation of 15 isolated lesions. Most patients (90%) had received one or more prior lines of systemic therapy for advanced disease. The median duration of exposure to durvalumab was 5.2 months with a median delivery of 11 cycles (range, 4–38 cycles). RT (conformal 3D RT, 79% and intracranial stereotactic RT, 21%) was delivered at a median biologically‐effective dose of 28 Gy (range, 6–92), in a median number of five fractions (range, 1–10) and over a median duration of 6 d (range, 1–14). Five patients (50%) reported an irradiation‐related adverse event (AE) grade (G) 1 or 2 and one patient had two G2 AEs. The most frequently reported AE (3/6) was G2 mucositis. There was no G3 or more RT‐related AEs. All AEs were transient, lasted less than one week, and were manageable by standard guidelines. There was no unexpected AE. On 10/15 in‐field (IF) evaluable lesions, the objective response (OR) rate was 60% (complete response, 2/10 and partial response, 4/10) and 4/10 stable disease (SD). All evaluated IF lesions had a TGR decrease resulting in a significant decrease in the TGR between the two periods (before versus after RT; p < 0.01). Outfields disease evaluation retrieved 10/14 SD and 4/14 progressive disease (PD). There was no out‐field OR, no abscopal effect and no out‐field difference between the two periods according to TGR (p = 0.09). Conclusion In this small data set of patients, concurrent palliative RT with the anti‐PD‐L1 durvalumab was well tolerated. ClinicalTrials.gov number: NCT01693562; EudraCT number: 2012‐002206‐52.}, -DOI = {10.1016/j.ejca.2016.09.013}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01248329/full} -} - - -Record #37 of 538 -@article{Senan19, -author = {Senan, S, Shire, N, Mak, G, Yao, W, and Jiang, H}, -title = {ADRIATIC: a phase III trial of durvalumab 6 tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer}, -journal = {Annals of oncology}, -volume = {30}, -pages = {ii25}, -year = {2019}, -accession_number = {EMBASE 628119291}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *cancer staging; *chemoradiotherapy; *non small cell lung cancer; Adult; Advanced cancer; Antineoplastic activity; Apoptosis; Brain radiation; Cancer survival; Clinical article; Conference abstract; Controlled study; Double blind procedure; Drug safety; Female; Human; Male; Multicenter study; Overall survival; Phase 3 clinical trial; Progression free survival; Quality of life; Radiotherapy; Randomization; Randomized controlled trial; Response evaluation criteria in solid tumors}, -abstract = {Background: Limited stage small‐cell lung cancer (LS‐SCLC), which represents ∼30% of newly diagnosed SCLC, remains an area of high unmet medical need. Standard of care, which has not changed for several decades, consists of curative intent platinumbased chemotherapy concurrent with radiotherapy (cCRT) followed by prophylactic brain irradiation (PCI) and observation. Despite good response to cCRT, outcomes remain poor, with median progression‐free survival (PFS)∼15 months and overall survival (OS)∼25 months. Durvalumab (D) is a selective, high‐affinity, human IgG1 monoclonal antibody (mAb) that blocks programmed cell death ligand‐1 binding to programmed cell death‐1 and CD80. Tremelimumab (T) is a selective human IgG2 mAb against CTLA‐4. D demonstrated a PFS and OS advantage over placebo in locally advanced NSCLC following cCRT. D and D+ T demonstrated a tolerable safety profile and antitumour activity in pretreated extensive stage SCLC. The ADRIATIC trial (NCT03703297) will assess if treatment with D±T is beneficial vs placebo in patients (pts) with LS‐SCLC who have not progressed following cCRT. Trial design: ADRIATIC is a Phase 3, randomised, double‐blind, multicentre, placebocontrolled international trial. Pts (N∼600) will be randomised 1:1:1 to receive D+ placebo T, D+ T, or dual placebo, stratified by Stage (I/II vs III) and receipt of PCI at the investigator's discretion (yes vs no). Eligible pts must have confirmed inoperable Stage I‐III LS‐SCLC; WHO/ECOG PS 0/1; and completed 4 cycles of cCRT with a response of stable disease or better within 1‐42 days prior to randomisation. Pts will receive the assigned treatment until clinical, RECIST v1.1‐defined progressive disease, intolerable toxicity or for a maximum of 24 months, whichever comes first. Primary objectives are PFS and OS for D±T vs placebo. Key secondary endpoints include health‐related quality of life, and safety and tolerability. Recruitment is ongoing (Table Presented) .}, -DOI = {10.1093/annonc/mdz071.007}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01957871/full} -} - - -Record #38 of 538 -@article{Schulz21, -author = {Schulz, C, Senan, S, Shire, N, Mak, G, Yao, W, and Reinmuth, N}, -title = {ADRIATIC: a phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer}, -journal = {Oncology research and treatment}, -volume = {44}, -number = {SUPPL 2}, -pages = {253‐254}, -year = {2021}, -accession_number = {EMBASE 636847770}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *cancer staging; *chemoradiotherapy; *drug tolerability; *non small cell lung cancer; Adult; Advanced cancer; Antineoplastic activity; Brain radiation; Cancer survival; Clinical trial; Conference abstract; Controlled study; Double blind procedure; Drug safety; ECOG Performance Status; Female; Funding; Human; Male; Multicenter study; Overall survival; Phase 3 clinical trial; Progression free survival; Quality of life; Radiotherapy; Randomization; Randomized controlled trial; Regulated cell death; Response evaluation criteria in solid tumors}, -abstract = {Introduction: Limited stage small‐cell lung cancer (LS‐SCLC), which represents 30% of newly diagnosed SCLC, remains an area of high unmet medical need. Standard of care, which has not changed for several decades, consists of curative intent platinum‐based chemotherapy concurrent with radiotherapy (cCRT) followed by prophylactic brain irradiation (PCI) and observation. Despite good response to cCRT, outcomes remain poor, with median progression‐free survival (PFS) 15 months and overall survival (OS) 25 months. Durvalumab (D) is a selective, high‐affinity, human IgG1 monoclonal antibody (mAb) that blocks programmed cell death ligand‐1 binding to programmed cell death‐1 and CD80. Tremelimumab (T) is a selective human IgG2 mAb against CTLA‐4. D demonstrated a PFS and OS advantage over placebo in locally advanced NSCLC following cCRT. D and D + T demonstrated a tolerable safety profile and antitumour activity in pretreated extensive stage SCLC. The ADRIATIC trial (NCT03703297) will assess if treatment with D ± T is beneficial vs placebo in patients (pts) with LS‐SCLC who have not progressed following cCRT. Methods: ADRIATIC (NCT03703297) is a Phase 3, randomised, doubleblind, multicentre, placebo controlled international trial. Pts (N 600) will be randomised 1:1:1 to receive D + placebo T, D + T, or dual placebo, stratified by Stage (I/II vs III) and receipt of PCI at the investigator's discretion (yes vs no). Eligible pts must have confirmed inoperable Stage I‐III LS‐SCLC; WHO/ECOG PS 0/1; and completed 4 cycles of cCRT with a response of stable disease or better within 1‐42 days prior to randomisation. Pts will receive the assigned treatment until clinical, RECIST v1.1‐defined progressive disease, intolerable toxicity or for a maximum of 24 months, whichever comes first. Primary objectives are PFS and OS for D ± T vs placebo. Key secondary endpoints include health‐related quality of life, and safety and tolerability. Recruitment is ongoing. Results and conclusion: Not applicable. Funding by AstraZeneca.}, -DOI = {10.1159/000518417}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02359497/full} -} - - -Record #39 of 538 -@article{Griesinger20, -author = {Griesinger, F, Senan, S, Shire, N, Mak, G, Yao, W, Jiang, H, and Thomas, M}, -title = {Adriatic: a phase iii trial of durvalumab +/-tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer}, -journal = {Oncology research and treatment}, -volume = {43}, -pages = {124}, -year = {2020}, -accession_number = {EMBASE 631302560}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *cancer staging; *chemoradiotherapy; *non small cell lung cancer; Adult; Advanced cancer; Antineoplastic activity; Apoptosis; Brain radiation; Cancer survival; Clinical trial; Conference abstract; Controlled study; Double blind procedure; Drug safety; Drug therapy; Female; Human; Male; Multicenter study; Overall survival; Phase 3 clinical trial; Progression free survival; Quality of life; Radiotherapy; Randomization; Randomized controlled trial; Response evaluation criteria in solid tumors}, -abstract = {Purpose: Limited stage small‐cell lung cancer (LS‐SCLC), which represents 30% of newly diagnosed SCLC, remains an area of high unmet medical need. Standard of care, which has not changed for several decades, consists of curative intent platinum‐based chemotherapy concurrent with radiotherapy (cCRT) followed by prophylactic brain irradiation (PCI) and observation. Despite good response to cCRT, outcomes remain poor, with median progression‐free survival (PFS) 15 months and overall survival (OS) 25 months. Durvalumab (D) is a selective, high‐affinity, human IgG1 monoclonal antibody (mAb) that blocks programmed cell death ligand‐1 binding to programmed cell death‐1 and CD80. Tremelimumab (T) is a selective human IgG2 mAb against CTLA‐4. D demonstrated a PFS and OS advantage over placebo in locally advanced NSCLC following cCRT. D and D + T demonstrated a tolerable safety profile and antitumour activity in pretreated extensive stage SCLC. The ADRIATIC trial (NCT03703297) will assess if treatment with D + T is beneficial vs placebo in patients (pts) with LS‐SCLC who have not progressed following cCRT. Methods: ADRIATIC is a Phase 3, randomised, double‐blind, multicentre, placebo‐controlled international trial. Pts (N600) will be randomised 1:1:1 to receive D + placebo T, D + T, or dual placebo, stratified by Stage (I/II vs III) and receipt of PCI at the investigator's discretion (yes vs no). Eligible pts must have confirmed inoperable Stage I‐III LS‐SCLC; WHO/ECOG PS 0/1; and completed 4 cycles of cCRT with a response of stable disease or better within 1‐42 days prior to randomisation. Pts will receive the assigned treatment until clinical, RECIST v1.1‐defined progressive disease, intolerable toxicity or for a maximum of 24 months, whichever comes first. Primary objectives are PFS and OS for D + T vs placebo. Key secondary endpoints include health‐related quality of life, and safety and tolerability. Recruitment is ongoing. Results: Conclusions:.}, -DOI = {10.1159/000506491}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02098150/full} -} - - -Record #40 of 538 -@article{NCT0276855816, -author = {NCT02768558,}, -title = {Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC}, -journal = {https://clinicaltrials.gov/show/NCT02768558}, -year = {2016}, -accession_number = {CTgov NCT02768558}, -publication type = {Trial registry record}, -keywords = {Carcinoma, Non‐Small‐Cell Lung; Etoposide; Lung Neoplasms; Nivolumab}, -abstract = {PRIMARY OBJECTIVES: I. To compare the Overall Survival (OS) for patients with Stage III unresectable non‐small cell lung cancer treated with or without nivolumab following concurrent chemoradiation. II. To compare Progression‐Free Survival (PFS) according to RECIST 1.1 criteria for patients with Stage III unresectable non‐small cell lung cancer treated with or without nivolumab following concurrent chemoradiation.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02046425/full} -} - - -Record #41 of 538 -@article{EUCTR2007-001256-39-IT07, -author = {EUCTR2007-001256-39-IT,}, -title = {A Randomized, Double-Blind, Parallel, Three Arm, Multicenter, Phase II Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Taxol/Paraplatin (Paclitaxel/Carboplatin) Compared to Taxol/Paraplatin Alone in Previously Untreated Subjects with Lung Cancer - ND}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007-001256-39-IT}, -year = {2007}, -accession_number = {ICTRP EUCTR2007‐001256‐39‐IT}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Ipilimumab Product Code: BMS‐734016 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Ipilimumab CAS Number: 477202‐00‐9 Current Sponsor code: BMS‐734016 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5‐ Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: TAXOL*1FL 300MG 6MG/ML Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Paclitaxel Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6‐ Trade Name: PARAPLATIN*IV FL 450MG/45ML Pharmaceutical Form: Solution for injection INN or Proposed INN: Carboplatin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ CONDITION: Men and women who are ≥ 18 years old with histologically or cytologically confirmed lung cancer (Stage IIIb/IV NSCLC or extensive stage SCLC) with ECOG performance ≤ 1, who have met screening laboratory requirements, and who are previously untreated. Subjects with specific underlying autoimmune diseases (particularly gastrointestinal) or paraneoplastic syndromes related to SCLC will be excluded ; MedDRA version: 9.1 Level: LLT Classification code 10062042 Term: Lung neoplasm PRIMARY OUTCOME: Main Objective: > To compare the immune‐related progression free survival (irPFS) of subjects receiving ipilimumab in combination with concurrent Taxol/Paraplatin (?concurrent?; Arm A) to that of subjects receiving Taxol/Paraplatin alone (Arm C) in Stage IIIb/IV NSCLC subjects using irRC as per the assessment of an independent review committee (IRC). To compare the immune‐related progression free survival (irPFS) of subjects receiving ipilimumab in combination with sequential Taxol/Paraplatin (?sequential?; Arm B) to that of subjects receiving Taxol/Paraplatin alone (Arm C) in Stage IIIb/IV NSCLC subjects using irRC as per the assessment of an independent review committee (IRC). Primary end point(s): The primary endpoint is progression free survival using irRC (as per the IRC assessment) in NSCLC. Secondary Objective: To compare: PFS for the NSCLC subjects in Arm A vs. Arm C and Arm B vs Arm C using mWHO; The irPFS and PFS for extensive SCLC subjects in Arm A vs. Arm C and Arm B vs Arm C using the irRC and mWHO, respectively; Overall survival in Arm A vs Arm C and Arm B vs Arm C in subjects with NSCLC and in subjects with SCLC; Immune‐related best overall response rate, immune‐related disease control rate, best overall response rate, disease control rate of Arm A vs Arm C and Arm B vs Arm C; To evaluate: The safety profile in each arm for subjects with NSCLC and for subjects with SCLC; The association between safety and efficacy in subjects with NSCLC and in subjects with SCLC; Candidate biomarkers of safety and/or efficacy in subjects with NSCLC and in subjects with SCLC; Health‐related quality of life for subjects with NSCLC and for subjects with SCLC. Blood samples for pharmacokinetic evaluation of ipilimumab INCLUSION CRITERIA: 1) Signed Written Informed Consent a) Willing and able to give informed consent; 2) Target Population a) Subjects with histologically‐ or cytologically‐documented NSCLC (squamous, adeno, large cell anaplastic, bronchioalveolar, and non‐small cell carcinoma not otherwise specified) who present with Stage IIIB/Stage IV disease (with managed malignant pleural effusion), or recurrent disease following radiation therapy or surgical resection. The cytological documentation of NSCLC may be from brushing, washing or needle aspiration of a defined lesion but not from sputum cytology alone. OR b) Subjects with histologically‐ or cytologically‐documented SCLC who present with extensive stage disease (e.g. tumor that is too widespread to be included within the definition of limited‐stage disease. Subjects with distant metastases (M1) are always considered to have extensive‐stage SCLC). The cytological documentation of SCLC may be from brushing, washing or needle aspiration}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01857352/full} -} - - -Record #42 of 538 -@article{NCT0562499622, -author = {NCT05624996,}, -title = {Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer}, -journal = {https://clinicaltrials.gov/ct2/show/NCT05624996}, -year = {2022}, -accession_number = {CTgov NCT05624996}, -publication type = {Trial registry record}, -keywords = {Albumin‐Bound Paclitaxel; Antibodies, Monoclonal; Carboplatin; Carcinoma, Non‐Small‐Cell Lung; Cisplatin; Durvalumab; Etoposide; Etoposide phosphate; Immunoglobulin G; Immunoglobulins; Lung Neoplasms; Paclitaxel; Pemetrexed; Podophyllotoxin}, -abstract = {PRIMARY OBJECTIVES: I. To compare the overall survival in patients with stage II‐IIIC inoperable node‐positive non‐small cell lung cancer (NSCLC) after image guided, motion‐managed conventional radiotherapy to the primary tumor and nodal metastases (arm 1) or after image guided, motion‐managed stereotactic body radiation therapy (SBRT) to the primary tumor followed by conventionally fractionated radiotherapy to nodal metastases (arm 2) both given with concurrent platinum‐based chemotherapy. II. To compare progression‐free survival between the experimental arm (arm 2) and control arm (arm 1). SECONDARY OBJECTIVES: I. To compare objective response rate (as defined by Response Evaluation Criteria in Solid Tumors [RECIST] version [v] 1.1) between the experimental arm and control arm. II. To compare the rate of local control between the experimental arm and control arm. III. To compare patterns of failure (primary, locoregional, or distant) between the experimental arm and control arm. IV. To compare changes in pulmonary function (forced expiratory volume in 1 second [FEV1] and diffusion capacity of the lung for carbon monoxide [DLCO] assessed at randomization and at 6 and 12 months following completion of radiation therapy) between the experimental arm and control arm. V. To compare changes in quality of life and patient‐reported outcomes assessed from pre‐treatment to 3 months following radiation therapy of each treatment arm. VI. To determine acute and late toxicity profiles of each treatment arm as measured by the Common Terminology Criteria for Adverse Events (CTCAE) v5. EXPLORATORY OBJECTIVES: I. To characterize and compare longitudinal quality of life and patient‐reported outcomes of each treatment arm. II. To collect biospecimens at baseline, after SBRT (for arm 2 patients), during last 2 weeks of chemoradiation, and after first dose of consolidation therapy, to allow for future analyses. III. To collect 4‐dimensional (4D) computed tomography (CT) planning scans and radiation dose to calculate regional lung ventilation and explore pre‐treatment 4D‐CT based ventilation to predict pulmonary toxicity. IV. To characterize clinical outcomes, toxicities and changes in pulmonary function and quality of life among patients receiving proton and photon radiotherapy. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo conventional IGRT and receive standard of care chemotherapy consisting of paclitaxel intravenously (IV) and carboplatin IV or pemetrexed IV and carboplatin IV or etoposide IV and cisplatin IV or pemetrexed IV and cisplatin IV and then receive durvalumab IV on study. Patients also undergo CT and/or positron emission tomography (PET)/CT during follow up. ARM II: Patients undergo SBRT and conventional IGRT and receive standard of care chemotherapy consisting of paclitaxel IV and carboplatin IV or pemetrexed IV and carboplatin IV or etoposide IV and cisplatin IV or pemetrexed IV and cisplatin IV and then receive durvalumab IV on study. Patients also undergo CT and/or PET/CT during follow up.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02500845/full} -} - - -Record #43 of 538 -@article{EUCTR2015-004861-97-DE16, -author = {EUCTR2015-004861-97-DE,}, -title = {A Study of Carboplatin plus Etoposide With or Without Atezolizumab in Patients with Untreated Extensive-Stage Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2015-004861-97-DE}, -year = {2016}, -accession_number = {ICTRP EUCTR2015‐004861‐97‐DE}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Atezolizumab (MPDL3280A‐RO5541267) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ATEZOLIZUMAB Current Sponsor code: RO5541267 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60‐ Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Tecentriq Product Name: Atezolizumab Product Code: RO5541267 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ATEZOLIZUMAB Current Sponsor code: RO5541267 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60‐ CONDITION: Small Cell Lung Cancer ; MedDRA version: 20.0 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: • To evaluate the efficacy of atezolizumab (Atezo) + carboplatin (Carb) + etoposide (Etop) compared with placebo + Carb + Etop in the intent‐to‐treat (ITT) population as measured by investigator‐assessed progression‐free survival (PFS) according to Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1); • To evaluate the efficacy of Atezo + Carb + Etop compared with placebo + Carb + Etop in the ITT population as measured by overall survival (OS) Primary end point(s): 1. PFS; 2. OS; Secondary Objective: • To evaluate the efficacy of Atezo + Carb + Etop compared with placebo+Carb+Etop in the ITT population as measured by investigator‐assessed objective response rate (ORR) and duration of response (DOR) according to RECIST v1.1; • To evaluate PFS rate at 6 months and at 1 year and OS rate at 1 and 2 years in each treatment arm for the ITT population; • To determine the impact of Atezo as measured by time to deterioration (TTD) in patient‐reported lung cancer symptoms in each treatment arm for the ITT population; • To evaluate safety and tolerability of Atezo+Carb+Etop compared with Carb and Etop; • To evaluate incidence and titers of anti‐therapeutic antibodies (ATAs) against Atezo and to explore the potential relationship of the immunogenicity response with pharmacokinetics, safety, and efficacy; • To characterize pharmacokinetics of Atezo, Carb, and Etop in chemotherapy‐naive patients with extensive‐stage small cell lung cancer (ES‐SCLC) Timepoint(s) of evaluation of this end point: 1‐2. Up to 31 months SECONDARY OUTCOME: Secondary end point(s): 1. Objective response ; 2. DOR ; 3. PFS rates at 6 months and at 1 year ; 4. OS rates at 1 and 2 years ; 5. TTD on each of the European Organization for Research and Treatment of Cancer (EORTC) Quality‐of‐Life Questionnaire Core 30 (QLQ‐C30) and EORTC Quality‐of‐Life Questionnaire Lung Cancer Module (QLQ‐LC13) symptom subscales ; 6. Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 ; 7. Changes in vital signs, physical findings, and clinical laboratory results ; 8. Incidence of ATA response to Atezo and potential correlation with PK, pharmacodynamic, safety, and efficacy parameters ; 9. Maximum observed serum Atezo concentration (Cmax) ; 10. Minimum observed serum Atezo concentration (Cmin) ; 11. Plasma concentrations for Carb ; 12. Plasma concentrations for Etop Timepoint(s) of evaluation of this end point: 1‐5. Up to 31 months ; 6‐7. Until 90 days after the last dose of study drug ; 8. Cycle (C) 1 Day (D) 1, C2D1, C3D1, C4D1, C8D1, C16D1, after Cycle 16, Day 1 of every eighth cycle, at treatment discontinuation, 120 (+/‐ 30) days after last dose of Atezo ; 9. C1D1, C2D1, C3D1, C4D1, C8D1, C16D1, after Cycle 16, Day 1 of every eighth cycle, at treatment discontinuation, 120 (+/‐ 30) days after last dose of Atezo ; 10. C1D1, C2D1, C3D1, C4D1, C8D1, C16D1, after Cycle 16, Day 1 of every eighth cycle, at treatment discontinuation, 120 (+/‐ 30) days after last dose of Atezo ; 11‐12. C1D1, C3D1 INCLUSION CRITERIA: ‐ Male or female, 18 years of age or older ‐ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ‐ Histologically or cytologically confirmed ES‐SCLC (per the Veterans Administration Lung Study Group (VALG) staging system ‐ No prior systemic treatment for ES‐SCLC ‐ Patients who have received prior chemoradiotherapy for limited‐stage SCLC must have been treated with curative intent and experienced a treatment‐free interval of at least 6 months since last chemotherapy, radiotherapy, or chemoradiotherapy cycle from diagnosis of extensive‐stage SCLC ‐ Patients with treated asymptomatic CNS metastases are eligible (only supratentorial and cerebellar metastases allowed) ‐ Measurable disease, as defined by RECIST v1.1 ‐ Adequate haematologic and end organ function ‐ Patients must submit a pre‐treatment tumour tissue sample during the study. Any available tumour tissue sample can be submitted. The tissue sample should be}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01804931/full} -} - - -Record #44 of 538 -@article{EUCTR2016-003795-49-FR17, -author = {EUCTR2016-003795-49-FR,}, -title = {Immunotherapy (atezolizumab) or chemotherapy as second-lin therapy in patients with small cell lung cancer (SCLC)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2016-003795-49-FR}, -year = {2017}, -accession_number = {ICTRP EUCTR2016‐003795‐49‐FR}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Pharmaceutical Form: INN or Proposed INN: Etoposide Other descriptive name: ETOPOSIDE Pharmaceutical Form: INN or Proposed INN: Carboplatin Other descriptive name: CARBOPLATIN Pharmaceutical Form: INN or Proposed INN: Cisplatin Other descriptive name: CISPLATIN Pharmaceutical Form: INN or Proposed INN: TOPOTECAN CAS Number: 123948‐87‐8 Product Name: Atezolizumab Product Code: MPDL3280A Pharmaceutical Form: Solution for infusion INN or Proposed INN: ATEZOLIZUMAB Current Sponsor code: Atzolizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60‐ CONDITION: Small Cell Lung Cancer ; MedDRA version: 19.0 Level: PT Classification code 10041067 Term: Small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) ; MedDRA version: 19.0 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) ; MedDRA version: 19.0 Level: PT Classification code 10041069 Term: Small cell lung cancer limited stage System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: To determine the activity of anti‐PDL1 antibody ATEZOLIZUMAB (MPDL3280A) in second line after progression following platinum – etoposide regimen Phase II component of the study Primary end point(s): Response rate in the experimental arm Secondary Objective: Duration of response; Progression‐free survival; Overall survival ; Quality of life (EQ5D – LCSS); Safety – AE (NCI –CTC 4.0); Reponses rate according to tissue PD‐L1 expression; Timepoint(s) of evaluation of this end point: 6 weeks SECONDARY OUTCOME: Secondary end point(s): • Overall survival ; • Progression‐free survival ; • Response rate in the experimental arm as assessed by panel; • Response rate (in the control arm); • Duration of response ; • Quality of life (LCSS); • Safety – AE (NCI –CTC v4.0); • Reponses rate according to tissue PD‐L1 expression: PD‐L1 expression status will be determined according to IHC (Ventana and Dako antibodies) and qRT‐PCR criteria. Timepoint(s) of evaluation of this end point: ‐ Time from randomization until death due to any cause.; ‐ Time from randomization to first observation of progression or date of death (from any cause). ; ‐ 6 weeks; ‐ 6 weeks; ‐ Time from documentation of tumor response to disease progression; ‐ During study treatment; ‐ During study treatment INCLUSION CRITERIA: 1. Histologically confirmed small‐cell lung cancer. 2. Extensive or limited disease according to the criteria of the Veteran's Administration Lung Cancer Group: (disease extended is defined as a disease beyond hemi thorax and supraclavicular lymph node areas. Tumor pleural effusion will be considered as extended disease). 3. Targetable tumor lesions according to RECIST 1.1. Tumor involvement encompassed into a radiotherapy field is eligible as target pending that progression is documented. 4. 6 slides of tumor tissue or paraffin block sent to IFCT for PD‐L1 immunohistochemistry 5. Previous platinum – etoposide treatment for at least 2 cycles. 6. Demonstrated progression of the disease other than brain metastasis or carcinomatous meningitis. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 48 F.1.3 Elderly (>=65 years) yes 65 years, 14 vs 11 months (p = 0.026). Race, sex and number of metastatic sites were not significant. Conclusion: Our single institutional result suggested benefit of both PCI and TRT in these patient populations who had any response to chemotherapy. Recently, the addition of immune check point inhibitor to platinum‐etoposide in ES‐SCLC have shown improvement in median survival from 10 to 13 months. Future trials are needed to evaluate the role of PCI and TRT in combination with chemo‐immunotherapy.}, -DOI = {10.1016/j.ijrobp.2020.07.1348}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02175266/full} -} - - -Record #48 of 538 -@article{EUCTR2016-001203-23-ES17, -author = {EUCTR2016-001203-23-ES,}, -title = {A phase III, open-label, multiarm study to assess the efficacy of immunotherapy together with standard of care in patients diagnosed with extensive stage Small-Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2016-001203-23-ES}, -year = {2017}, -accession_number = {ICTRP EUCTR2016‐001203‐23‐ES}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935‐60‐7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ Product Name: tremelimumab Product Code: MEDI1123 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: tremelimumab CAS Number: 745013‐19‐6 Current Sponsor code: MEDI1123 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20‐ Trade Name: Carboplatin Product Name: Carboplatin Product Code: 61703‐339‐56 Pharmaceutical Form: Solution for infusion INN or Proposed INN: carboplatin CAS Number: 41575‐94‐4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ Trade Name: Cisplatin Product Name: Cisplatin Product Code: 63323‐103 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: cisplatin CAS Number: 15663‐27‐1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1‐ Trade Name: etoposide Product Name: Etoposide Product Code: 63323‐104 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: etoposide CAS Number: 33419‐42‐0 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20‐ CONDITION: First‐line patients with extensive disease (Stage IV) small‐cell lung cancer (SCLC) ; MedDRA version: 19.1 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: To assess the efficacy of durvalumab + tremelimumab + EP treatment compared with EP in terms of overall survival (OS) and progression‐free survival ( PFS). Primary end point(s): 1.Overall survival (OS)‐ the time from the date of randomization until death due to any cause.; 2.Progression free survival (PFS)‐ the time from the date of randomization until the date of objective disease progression or death. Secondary Objective: 1.To further assess the efficacy of durvalumab + tremelimumab + EP treatment compared with EP in terms of ORR, APF6, APF12 and OS 18. ; 2.To assess the efficacy of durvalumab + EP compared with EP in terms of ORR, PFS, OS, APF6, APF12, and OS18.; 3.To assess the efficacy of durvalumab + tremelimumab + EP treatment compared with durvalumab + EP in terms of PFS and OS.; 4.To assess the PK of both durvalumab and durvalumab + tremelimumab.; 5.To investigate the immunogenicity of durvalumab and durvalumab + tremelimumab.; 6.To assess the effect of the treatment on changes in symptoms and health‐related QoL using EORTC QLQ‐C30 v3 and QLQ‐LC13.; 7.Safety objective: To assess the safety and tolerability profile of durvalumab and durvalumab + tremelimumab in combination with EP treatment compared with EP. Timepoint(s) of evaluation of this end point: 1. 34 months after the first patient has been randomized; 2. 23 months after the first patient has been randomized SECONDARY OUTCOME: Secondary end point(s): 1.Objective Response Rate (ORR) ‐the number (%) of patients with at least 1 visit response of CR or PR.; 2.Proportion of patients alive and progression free at 6 (APF6) and 12 months (APF12).; 3. Proportion of patients alive at 18 months (OS18). Timepoint(s) of evaluation of this end point: 23 months after the first patient has been randomized INCLUSION CRITERIA: 1.Histologically or cytologically documented extensive disease (American Joint Committee on Cancer Stage IV SCLC [T any, N any, M1 a/b]), including patients with T3‐4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. Brain metastases; must be asymptomatic or treated and stable off steroids and anti‐convulsants for at least 1 month prior to study treatment. 2. Suitable to receive a platinum‐based chemotherapy regimen as 1st line treatment. 3. Life expectancy =12 weeks at Day 1. 4. ECOG 0 or 1 at enrolment. 5. No prior exposure to immune‐mediated therapy excluding therapeutic anticancer vaccines. 6 .Body weight >30 kg. 7. Adequate organ and marrow function. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 477 F.1.3 Elderly (>=65 years}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01854662/full} -} - - -Record #49 of 538 -@article{Lu24, -author = {Lu, S, Dai, XR, Li, BX, and Chen, Z}, -title = {Results of a phase III clinical trial with anti-PDL1 treatment in combination with chemotherapy for extensive stage small cell lung cancer}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644913603}, -publication type = {Journal article; Conference proceeding}, -keywords = {*small cell lung cancer; Adult; Adverse drug reaction; Aged; Conference abstract; Controlled study; Diagnosis; Double blind procedure; Drug combination; Drug resistance; Drug therapy; Female; Human; Intention to treat analysis; Major clinical study; Male; Multiple cycle treatment; Overall survival; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Side effect; Survival rate}, -abstract = {Background: In China, small cell lung cancer (SCLC) accounts for over 15% of lung cancers. The morbidity of SCLC has been continuously increasing. SCLC is invasive, fast‐growing cancer that distinctly differs from other cancers. Approximately 70% of cases present with metastasis at diagnosis and the median overall survival rate is about 8 to 11 months with a 5‐year survival rate of less than 5%. Although being sensitive to chemotherapy and radiotherapy, SCLC patients are liable to relapse and often present with drug resistance. Here we study the combination of Socazolimab, an anti‐PDL1 antibody, carboplatin and etoposide to treat extensive stage small cell lung cancer. Methods: The study is a randomized, double‐blinded, placebo‐controlled multicenter Phase III clinical trial. Patients who have extensive‐stage SCLC are eligible to the trial. Patients are randomly assigned to the study group (Socazolimab + carboplatin + etoposide) or control group (placebo + carboplatin + etoposide) at 1:1 ratio, with a treatment cycle of every 3 weeks. There are 4 cycles of chemotherapy followed by Socazolimab or placebo alone until termination events occurred or for up to 2 years. The primary endpoint is overall survival (OS). The major secondary endpoint is progression free survival (PFS). Results: There were a total of 498 patients recruited for the study with average age of 61.9 amount which 449 patients were diagnosed with stage IV SCLC. All the analysis was based on intent‐to‐treat (ITT). The median baseline performance status score was 1.0. The median OS of study group and control group are 13.90 months (95% CI: 12.22‐15.34) and 11.58 months (95% CI: 10.64‐12.81) respectively, with a P‐value of 0.0316. The 24 month survival rate of study group and control group are 20.7% (95% CI:14.8‐27.3) and 5.9 %(95% CI: 0.8‐18.9). The median PFS of the two groups are 5.55 months (95% CI:5.06‐5.82) and 4.37 months (95% CI: 4.27‐4.70) with a Pvalue < 0.0001. The treatment related adverse event were similar in both groups. Conclusions: These results show that Socazolimab plus chemotherapy continued to provide clinically meaningful improvements in OS for patients with extensive stage small cell lung cancer.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02736430/full} -} - - -Record #50 of 538 -@article{Aisner80, -author = {Aisner, J, and Wiernik, PH}, -title = {Chemotherapy versus chemoimmunotherapy for small-cell undifferentiated carcinoma of the lung}, -journal = {Cancer}, -volume = {46}, -number = {12}, -review groups = {SR-CANCER}, -pages = {2543‐2549}, -year = {1980}, -accession_number = {EMBASE 11210215, PUBMED 6256048}, -publication type = {Journal article}, -keywords = {*cancer combination chemotherapy; *cyclophosphamide; *doxorubicin; *etoposide; *immunotherapy; *lung cancer; *small cell carcinoma; Aged; Agranulocytosis [chemically induced]; Alopecia [chemically induced]; Antineoplastic Agents [*administration & dosage, adverse effects]; BCG Vaccine [adverse effects, *therapeutic use]; Brain Neoplasms [secondary]; Carcinoma, Small Cell [*therapy]; Cyclophosphamide [therapeutic use]; Doxorubicin [therapeutic use]; Drug Administration Schedule; Drug Therapy, Combination; Etoposide [therapeutic use]; Female; Humans; Lung Neoplasms [*therapy]; Major clinical study; Male; Middle Aged; Nausea [chemically induced]; Prognosis; Prospective Studies; Vomiting [chemically induced]}, -abstract = {Thirty‐eight patients with small‐cell carcinoma were treated with cyclophosphamide, Adriamycin, and VP16‐213 + or ‐ MER. Response and survival of the six patients who received radiotherapy prior to entering the study were inferior compared with patients who received chemotherapy alone. Of 32 previously untreated patients, 13 had limited and 19 had extensive disease. Ninety‐seven percent of these 32 responded and 63% achieved complete remission (CR). All patients with limited disease had a response and 77% achieved CR. Patients with extensive and limited disease had 91/2 months (range 1‐26 months) and 14 months (range 31/2 ‐42 + months) median survival, respectively. The median survival for all complete responders irrespective of extent of disease was 16 months (range 6 ‐ 42 + months). Three patients with limited disease are disease free more than 34 + months and off all therapy 10 + to 18 + months. Eighteen of 38 patients required antibiotics for fever during neutropenia. Eight patients had MER fevers and nine had serious infections. There were four drug‐related deaths. MER therapy did not influence response rate, drug toxicity, or survival, but did add morbidity. This combination chemotherapy alone is an effective treatment for previously untreated small‐cell lung cancer patients regardless of extent of disease.}, -DOI = {10.1002/1097-0142(19801215)46:12<2543::AID-CNCR2820461202>3.0.CO;2-4}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00205992/full} -} - - -Record #51 of 538 -@article{NL-OMON5433121, -author = {NL-OMON54331,}, -title = {A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON54331}, -year = {2021}, -accession_number = {ICTRP NL‐OMON54331}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Subjects will undergo screening tests and assessments to determine eligibility, and those eligible for the study will be randomised to a treatment arm in the following ratio: 1:1 Arm A: Induction period (cycle 1 ‐ 4) Carboplatin & Etoposide (chemotherapy) Q3W (Intravenous administration) + BMS‐986012 420 mg Q3W (Intravenous administration over 60 mins) + Niolvumab 360mg Q3W (Intravenous administration over 30 mins) Etoposide will also be given on Day 2 and Day 3 of each treatment cycle (cycle 1‐4 only) Maintenance period (cycle 5 onwards) BMS‐986012 560 mg Q4W (Intravenous administration over 60 mins) + Niolvumab 480mg Q4W (Intravenous administration over 30 min Arm B: Induction period (cycle 1 ‐ 4) Carboplatin & Etoposide (chemotherapy) Q3W (Intravenous administration) + Nivolumab 360 mg Q3W (Intravenous administration over 30 mins) Etoposide will also be given on Day 2 and Day 3 of each treatment cycle (cycle 1‐4 only) Maintenance period (cycle 5 onwards) Nivolumab 480 mg Q4W (Intravenous administration over 30 mins) The dose of carboplatin and etoposide will be based on respective product labels for the treatment of SCLC PET‐CT SUB STUDY There is no intervention. The sub‐study is being conducted for exploratory purposes only. Subjects will receive one intravenous injection of the radiolabelled agent or tracer BMS‐986279, after a tissue sample (biopsy) is provided at screening. Approximately 37 MBq of the tracer will be injected. This is a limited dose of radioactivity. CONDITION: ; cancer ; lung carcinoma 10038666 PRIMARY OUTCOME: 1. To assess the safety and tolerability for participants randomized to ; BMS‐986012 in combination with carboplatin, etoposide, and nivolumab for 4 ; cycles (induction) followed by BMS‐986012 and nivolumab maintenance (Arm A) vs ; those randomized to carboplatin, etoposide, and nivolumab for 4 cycles ; (induction) followed by nivolumab maintenance (Arm B). ; ; 2. To compare the Progression Free Survival (PFS) as assessed by Blinded ; Independent Central Review (BICR) of participants treated in the combination ; induction and maintenance therapies of Arms A and B described above. Assessment ; will be based on RECIST v1.1 criteria; SECONDARY OUTCOME: 1. To estimate the Progression Free Survival Rate (PFSR) at 6 and 12 months in ; each treatment arm, based on Progression Free Survival (PFS) by RECIST v1.1 as ; assessed by Blinded Independent Central Review (BICR) ; ; 2. To compare PFS as assessed by investigator of participants treated in the ; combination induction and maintenance therapies of Arms A and B described above. ; ; 3. To estimate the PFSR at 6 and 12 months in each treatment arm based on PFS ; by RECIST v1.1 assessed by investigator. ; ; 4. To estimate the Objective Rate of Response (ORR), Time To Response (TTR), ; and Duration of Response (DOR) by RECIST v1.1 criteria by BICR and by ; investigator. ; ; 5. To assess Overall Survival (OS) of Arm A and Arm B and estimate Overall ; Survival Rate (OSR) at 12 and 24 months by treatment arm. ; ; 6. To characterize the immunogenicity of BMS‐986012 in combination with ; carboplatin, etoposide, and nivolumab in Arm A. ; ; ; Tertiary / exploratory ; ; 1. To assess disease‐related symptoms measured by Lung Cancer Symptom Scale. ; ; 2. To assess the bother associated with the side effects of treatment. ; ; 3. To assess associations of fuc‐GM1 expression in pretreatment tumor biopsies ; assessed using IHC and mass spectrometry assays with anti‐tumor activity ; measures. ; ; 4. To assess associations of PD‐L1 expression (CPS) in pretreatment tumor ; biopsies with anti‐tumor activity measures. ; ; 5. Fuc‐GM1 expression on CTCs and associations with baseline fuc‐GM1 ; expression measures; changes in CTC count during treatment (from baseline) and ; associations with response to treatment in each arm. ; ; 6. To explore associations with antitumuor activity measures in Arms A and B ; with changes in biomarkers during treatment such as the following: ; • NK cell‐mediated ADCC gene expression ; • Immune cell population in blood (ie, NK cell activation) ; • Shed fuc‐GM1 levels in plasma ; ; ; 7. To explore associations with anti‐tumour activity measures in Arms A and B ; with baseline biomarkers such as the following: ; • Fuc‐GM1 synthesis pathway (FUT1, FUT2, GM1 synthase, etc) ; • FcγR polymorphism ; • Tumour tissue‐based TMB ; ; ; 8. To explore whether pruritus is a histamine‐mediated event through a pre‐ and ; post‐dose histamine release assay. ; ; 9. To characterize PK of BMS‐986012 in combination with carboplatin, etoposide, ; and nivolumab in Arm A. ; ; 10. To characterize PK of nivolumab in Arms A and B. ; ; 11. To characterize the immunogenicity of nivolumab in Arms A and B. ; ; 12. To explore the PK‐pharmacodynamic relationship(s) of BMS‐986012 with ; select biomarkers and anti‐tumour activities. ; ; 13. To explore fuc‐GM1 and PD‐L1 expression in tumour tissue obtained at ; progression from optional biopsies. ; ; 14. Explore associations of the BMS‐986279 PET tracer uptake of the biopsied ; lesion with fuc‐GM1 expression levels by IHC and/or MS, and the heterogeneity ; of BMS‐986279 PET tracer update in tumour lesions, in a substudy of ; participants at select study site(s). ; ; 15. To assess SARS‐CoV‐2 serologic status that will support advancing the ; understanding of the impact of SARS‐CoV‐2 on study treatments and ES‐SLCLC. ; ; ; PET‐CT SUB STUDY Exploratory Objectives ; ; 1. Assess Safety of Fucosyl‐GM1 PET tracer BMS‐986279 ; ; 2. Correlate BMS‐986279 tracer uptake of the biopsied lesion with Fucosyl‐GM1 ; expression levels measured by IHC and/or liquid chromatography‐mass ; spectrometry (LC‐MS) at baseline ; ; 3. Characterise the baseline heterogeneity of BMS‐986279 tracer uptake in ; tumour lesions ; ; 4. Explore BMS‐986279 uptake of tumour lesion associations with anti‐tumour ; response to BMS‐9866012 treatment. ; INCLUSION CRITERIA: 1. Participants must have histologically or cytologically documented Extensive Stage Small Cell Lung Cancer (ES SCLC). Participants must present with extensive stage IV disease based on the American Joint Committee on Cancer, 7th edition guidelines. The following grades will be considered: T any, N any, M1a, or M1b, or T3‐4 due to multiple lung nodules that are too extensive or tumour or nodal volume that is too large to be encompassed in a tolerable radiation plan. 2. a. Archived tumor specimens, in the form of blocks or sectioned slides, are mandatory for all participants except those participating in the separate PET tracer sub‐study for whom the archived tumor specimen is optional. b. Participants taking part in the separate PET tracer sub‐study must provide a fresh tumor biopsy from any disease site (primary or metastatic). Mandatory minimum of 3 cores to be processed as 2 fresh frozen and the rest as formalin}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02715924/full} -} - - -Record #52 of 538 -@article{null18, -title = {IASLC 19th World Conference on Lung Cancer}, -journal = {Journal of thoracic oncology}, -volume = {13}, -number = {10}, -pages = {A1‐A4}, -year = {2018}, -accession_number = {EMBASE 2001540449}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Adult; Advanced cancer; Advanced practice nursing; Cancer patient; Cancer resistance; Cancer screening; Cancer staging; Cancer surgery; Cancer survival; Chemoradiotherapy; Chronic obstructive lung disease; Clinical research; Cone beam computed tomography; Conference review; Controlled study; Coronary artery disease; Cytology; Drug combination; Drug safety; Drug therapy; Dyspnea; Experimental therapy; Female; Human; Human tissue; Image quality; Liquid biopsy; Machine learning; Male; Mesothelioma; Molecularly targeted therapy; Morbidity; Mortality; Nurse; Overall survival; Pharmacokinetics; Phase 3 clinical trial; Physics; Pleura biopsy; Radiologist; Radiotherapy; Randomized controlled trial; Voice}, -abstract = {The proceedings contains 1978 papers. The topics discussed include: Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC;Brigatinib vs Crizotinib in Patients With ALK Inhibitor‐Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA‐1L);Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised‐Controlled Population Based Trial;IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive‐Stage SCLC;Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME‐Meso Trial;It's All In The Tissue;The Future of Targeted Therapy;Image Quality Characteristics and Nodule Growth Measurement, Medical Physics and Machine Parameters;Image Interpretation and Advances from the Perspective of the Radiologist;Deep Machine Learning for Screening LDCT;Multi‐Phasic Screening ‐ Can We Address Competing Causes of Morbidity * Mortality Such as Coronary Artery Disease and COPD;Expanding PROs in Daily Practice;PRO: To Medicate: Managing Breathlessness;CON: Not to Medicate: Managing Breathlessness;Molecular Testing 101 for Nurses;Structured Approach For Developing and Implementing and Advanced Practice Nursing Role in Lung Cancer;Diagnosis of Mesothelioma Based on Cytology Alone;When to Repeat Pleural Biopsies;Role of Chemotherapy in Mesothelioma with Minimal Bulk Disease;Role of Surgery in T0 Mesothelioma;Liquid Biopsies in Lung Cancer;Overcoming Resistance by Improving Treatment Compliance;Can Patient Groups and Regulatory Bodies Work Together to Make Clinical Research Easier?;Discrepancies and Sustainable Access to Innovative Therapies: Transforming Patient Experience in to Patient Voice;Surgical Considerations in OMD}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01790483/full} -} - - -Record #53 of 538 -@article{Gerber17, -author = {Gerber, DE, Urbanic, JJ, Langer, C, Hu, C, Chang, IF, Lu, B, Movsas, B, Jeraj, R, Curran, WJ, and Bradley, JD}, -title = {Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505)}, -journal = {Clinical lung cancer}, -volume = {18}, -number = {3}, -pages = {333‐339}, -year = {2017}, -accession_number = {PUBMED 27923550}, -publication type = {Journal article}, -keywords = {Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal [*therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Carcinoma, Non‐Small‐Cell Lung [mortality, *therapy]; Chemoradiotherapy; Cisplatin [*therapeutic use]; Combined Modality Therapy; Etoposide [*therapeutic use]; Humans; Immunotherapy [*methods]; Lung Neoplasms [mortality, *therapy]; Middle Aged; Neoplasm Staging; Nivolumab; Placebo Effect; Proportional Hazards Models; Research Design; Survival Analysis; Young Adult}, -abstract = {Radiation Therapy Oncology Group (RTOG) 3505 is a randomized phase 3 study of concurrent chemoradiation followed by immune checkpoint inhibitor therapy or placebo in patients with locally advanced non‐small‐cell lung cancer (NSCLC). Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy to 60 Gy with concurrent cisplatin 50 mg/m2 intravenously (I.V.) on days 1, 8, 29, and 36, and etoposide 50 mg/m2 I.V. on days 1 to 5 and days 29 to 33. Between 4 and 12 weeks after completion of concurrent chemoradiation, eligible patients will be randomized to the anti‐programmed death 1 (PD‐1) monoclonal antibody nivolumab 240 mg I.V. or placebo every 2 weeks for up to 1 year. The primary end points are overall survival (OS) and progression‐free survival (PFS), as determined by central independent radiology review. Secondary objectives include toxicity assessment, patient‐reported outcomes and quality of life, and OS and PFS in programmed death ligand 1 (PD‐L1) expressors (≥ 1%) and PD‐L1 nonexpressors (< 1%). Assuming a rate of 16.7% due to ineligibility and dropout before randomization, a total of 660 patients will be enrolled to ensure 550 patients will be randomized after completion of chemoradiation. This sample size will provide ≥ 90% power to detect a hazard ratio of 0.7 for OS with 2‐sided type I error of 0.04, and to detect a hazard ratio of 0.667 for PFS 2‐sided type I error of 0.01. (NCT02768558).}, -DOI = {10.1016/j.cllc.2016.10.009}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01455039/full} -} - - -Record #54 of 538 -@article{Nosaki24, -author = {Nosaki, K, Zenke, Y, Nomura, S, Sasaki, T, Niho, S, Yoh, K, Yoshioka, H, Hosomi, Y, Okamoto, I, Kaneda, H, Akamatsu, H, Okamoto, H, Sasaki, K, Sekino, Y, Horinouchi, H, and Ohe, Y}, -title = {JCOG2002: a randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644907585}, -publication type = {Journal article; Conference proceeding}, -keywords = {*small cell lung cancer; Adult; Brain metastasis; Conference abstract; Controlled study; Diagnosis; Doublet chemotherapy; Drug combination; Drug therapy; First‐line treatment; Follow up; Human; Japan; Lymph node metastasis; Maintenance therapy; Major clinical study; Male; Multicenter study; Overall survival; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Small cell carcinoma}, -abstract = {Background: Consolidative thoracic radiotherapy (cTRT) has shown a marginal improvement in overall survival (OS) and progression‐free survival (PFS) for extensive‐stage small‐cell cancer (ES‐SCLC). Consequently, ASTRO and NCCN guidelines conditionally recommend the use of cTRT. Despite the recent establishment of anti‐PD‐L1 antibody (aPD‐L1) combined with platinum‐doublet chemotherapy as the standard first‐line treatment for ES‐SCLC, the impact of cTRT in the era of immunotherapy remains uncertain. Methods: The JCOG2002 study, a randomized, multicenter phase 3 trial, initiated in October 2021 to assess the superiority of additional cTRT in terms of OS for ES‐SCLC following induction aPD‐L1 plus platinum doublet chemotherapy. Eligibility patients must meet criteria for the first registration including ESSCLC, no prior radiation or chemotherapy history, age 20 or older, ECOG performance status 0 or 1, and adequate organ function. Induction treatment involves atezolizumab + carboplatin + etoposide or durvalumab + cisplatin / carboplatin + etoposide. Responding patients proceed to the second registration, randomization (1:1 between 30 Gy in 10 fractions of cTRT plus aPD‐L1 maintenance therapy and maintenance therapy only). The cTRT targets metastatic lymph nodes in stations #1‐7 and ipsilateral stations #10‐12 identified at diagnosis. The adjustment factors include response to induction treatment (CR/PR versus SD), presence of brain metastasis (yes versus no), participating institutions, and aPD‐L1 type (atezolizumab versus durvalumab). The primary endpoint is OS, with secondary endpoints being PFS and safety. The study aims to enroll 240 randomized patients, with 330 in the first registration, providing 80%power at a one‐sided 5%significance level to detect a hazard ratio of 0.69 with 3‐year accrual period and 1‐year follow‐up. As of February 6, 2024, 239 patients initiated induction treatment, and 121 have been randomized. This trial is registered at Japan Registry of Clinical Trials as jRCTs031210393 (https://jrct.niph.go.jp/detail/jRCTs031210393).}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02736084/full} -} - - -Record #55 of 538 -@article{NL-OMON5049317, -author = {NL-OMON50493,}, -title = {A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease Small-Cell Lung Cancer (SCLC)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON50493}, -year = {2017}, -accession_number = {ICTRP NL‐OMON50493}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: 1. Durvalumab + Tremelimumab combination therapy + EP: Durvalumab 1500mg via IV infusion q3w, start on week 0, for 4 doses/cycles, and then proceed with Durvalumab 1500mg via IV infusion q4w, start on week 12 until progression. Tremelimumab 75mg via IV infusion q3w, start on week 0, for 4 doses/cycles, and last dose/cycle on week 16. EP (80‐100 mg/m2) via IV infusion q3w, start onp Week 0, for4 doses/cycles 2. Durvalumab + EP: Durvalumab 1500mg via IV infusion q3w, start on week 0, for 4 doses/cycles, and then proceed with Durvalumab 1500 mg via IV infusion q4w, start on week 12 until progression. EP (80‐100 mg/m2) via IV infusion q3w, start onp Week 0, for 4 doses/cycles 3. EP (80‐100 mg/m2) via IV infusion q3w, start onp Week 0, for4 doses/cycles (can be extended with maximum of 2 doses/ cycles). CONDITION: ; Small‐Cell Lung Cancer; Lung Cancer 10038666 PRIMARY OUTCOME: To assess the efficacy of durvalumab +tremelimumab + EP treatment compared with ; EP in terms of OS and the efficacy of durvalumab + EP treatment compared with ; EP in terms of OS and PFS; SECONDARY OUTCOME: ‐To further assess the efficacy of durvalumab + tremelimumab + EP treatment ; compared with EP in terms of PFS, ORR, APF6 (PFS rate at ; 6 months), APF12 (PFS rate at 12 months), and OS18 (OS rate at 18 months) ; ‐To assess the efficacy of durvalumab + tremelimumab + EP treatment compared ; with durvalumab + EP and the efficacy of durvalumab + EP compared with EP in ; terms of PFS and OS ; ‐To assess the PK of durvalumab and durvalumab + tremelimumab ; ‐To investigate the immunogenicity of durvalumab and durvalumab + tremelimumab ; ‐To assess the effect of the treatment on changes in symptoms and ; health‐related QoL using EORTC QLQ‐C30 v3 and QLQ‐LC13 ; INCLUSION CRITERIA: ‐Male or female >=18 years at the time of Screening. ‐Written informed consent and any locally required authorization obtained from the patient/legal representative prior to performing any protocol‐related procedures, including screening evaluations. ‐Histologically or cytologically documented extensive disease (American Joint Committee on Cancer Stage (7th edition) IV SCLC [T any, N any, M1 a/b]), or T3‐ 4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. ‐Patients must be considered suitable to receive a platinum based chemotherapy regimen as 1st line treatment for the ED‐SCLC. Chemotherapy must contain either cisplatin or carboplatin in combination with etoposide. ‐Life expectancy >=12 weeks at Day 1. ‐World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at enrollment= Grade2 pneumonitis within 6 months from the start of radiation therapy SECONDARY OUTCOME: Median overall survival; Median progression‐free survival based on RECIST 1.1; Overall response rate; Safety (all adverse events , all grades of pneumonitis , electrocardiograms , and laboratory findings including clinical chemistry test and blood test). INCLUSION CRITERIA: 1)Patients providing the written informed consent. 2)Patient with at least 20 years of age (at enrolment date). 3)ECOG performance status of 0 or 1 4)Patients with small cell lung cancer confirmed histologically or cytologically,and diagnosed as "extensive‐disease" depending on the degree of progression. 5)Patients without symptomatic brain metastases. For patients with brain metastases, use of steroids and anticonvulsants for at least 1 month prior to enrolment should be stable. 6)Patients with no prior treatment history for extensive‐disease small cell lung cancer. 7)Patients with at least one measurable lesion as defined in RECIST criteria version 1.1. 8) Patients with lung lesions suitable for irradiation. 9) Body weight >30 kg 10) Patients with life expectancy of at least 12 weeks at the time of enrolment. 11)The functions of major organs such as bone marrow, liver, and kidney are maintained and the following criteria are met withi}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02256594/full} -} - - -Record #57 of 538 -@article{CTIS2023-505989-29-0024, -author = {CTIS2023-505989-29-00,}, -title = {Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLphi 305)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTIS2023-505989-29-00}, -year = {2024}, -accession_number = {ICTRP CTIS2023‐505989‐29‐00}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: CARBOPLATIN, Product Code:SUB06614MIG, Pharmaceutical Form: CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: ETOPOSIDE, Product Code:SUB07337MIG, Pharmaceutical Form: CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: MYCOPHENOLATE MOFETIL, Product Code:SUB03360MIG, Pharmaceutical Form: CAPSULE, HARD, Other descriptive name: , Strength: , Product Name: DURVALUMAB, Product Code:SUB176342, Pharmaceutical Form: CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: DEXAMETHASONE, Product Code:SUB07017MIG, Pharmaceutical Form: INJECTION, Other descriptive name: , Strength: , Product Name: , Product Code:SCP1023586, Pharmaceutical Form: , Other descriptive name: , Strength: , Product Name: , Product Code:SCP1158234, Pharmaceutical Form: , Other descriptive name: , Strength: , Product Name: Tarlatamab, Product Code:PRD10282194, Pharmaceutical Form: POWDER FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: CISPLATIN, Product Code:SUB07483MIG, Pharmaceutical Form: CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Tarlatamab, Product Code:PRD10282188, Pharmaceutical Form: POWDER FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: , Product Code:SCP30321681, Pharmaceutical Form: , Other descriptive name: , Strength: , Product Name: INFLIXIMAB, Product Code:SUB02681MIG, Pharmaceutical Form: POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: TOCILIZUMAB, Product Code:SUB20313, Pharmaceutical Form: CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: , Produc CONDITION: Extensive stage small cell lung cancer (ES‐SCLC) ; MedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864 MedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864 Therapeutic area: Diseases [C] ‐ Neoplasms [C04] SECONDARY OUTCOME: Secondary end point(s):Change from baseline PROs up to disease progression or 12 months in disease symptoms of Cough Chest Pain and Dyspnea Secondary end point(s):Incidence of antitarlatamab antibody formation Secondary end point(s):Incidence of treatment emergent adverse events after randomization Secondary end point(s):PFS defined as time from randomization until the first documentation of radiologic disease progression or death from any cause whichever occurs first Secondary end point(s):PFS rate at 6 months 1 year and 2 years from randomization OS rate at 6 months 1 year 2 years, and 3 years from randomization " Secondary end point(s):Serum concentrations of tarlatamab PRIMARY OUTCOME: Main Objective: To compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS) Primary end point(s): OS, defined as time from randomization until death from any cause Secondary Objective: Compare the efficacy of tarlatamab plus durvalumab with durvalumab alone as assessed by progression free survival (PFS) based on investigator assessment per RECIST 1.1, Compare the efficacy of tarlatamab plus durvalumab with durvalumab alone as assessed by objective response (OR), disease control (DC), and duration of response (DoR) based on investigator assessment per RECIST 1.1 against baseline at the time of randomization, Compare the efficacy of tarlatamab plus durvalumab with durvalumab alone as assessed by PFS at 6 months, 1 year, and 2 years from randomization, OS at 6 months, 1 year, 2 years, and 3 years from randomization, and time to progression (TTP) based on investigator assessment per RECIST 1.1, Compare the safety and tolerability of tarlatamab plus durvalumab with durvalumab alone, Characterize the pharmacokinetics of tarlatamab when administered in combination with durvalumab, Evaluate the immunogenicity of tarlatamab, Compare the treatment effect of tarlatamab and durvalumab with durvalumab alone on disease symptoms, physical function, and quality of life INCLUSION CRITERIA: Subject has provided informed consent prior to initiation of any study‐specific activities/procedures., Age = 18 years (or = legal age within the country if it is older than 18 years)., Histologically or cytologically documented extensive‐stage disease (American Joint Committee on Cancer, 2017, IV SCLC [T any, N any, M1 a/b]), or T3 to T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. Patients with prior LS‐SCLC are allowed if the interval is > 6 months since the end of previous therapy and progression, in discussion with the medical monitor., Completed 4 cycles of platinum‐etoposide chemotherapy with concurrent durvalumab as first‐line treatment of ES‐SCLC prior to enrollment, without disease progression (ongoing response or stable disease) per RECIST 1.1. · Patients with 3 cycles of concurrent durvalumab are eligible, provided 4 cycles of platinum‐etoposide chemo}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02731211/full} -} - - -Record #58 of 538 -@article{Paz-Ares22, -author = {Paz-Ares, L, Reck, M, Peters, S, Borghaei, H, Herbst, R, Siddiqui, M, Cuchelkar, V, Bhatt, K, Chakrabarti, D, Wang, L, Morris, S, and Liu, SV}, -title = {EP14.01-015 IMforte: a Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S532‐S533}, -year = {2022}, -accession_number = {EMBASE 2020100199}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer combination chemotherapy; *drug tolerability; *maintenance therapy; *small cell lung cancer; Adult; Antineoplastic activity; Autoimmune disease; Cancer patient; Cancer staging; Cancer survival; Cancer therapy; Central nervous system metastasis; Clinical trial; Conference abstract; Controlled study; Drug combination; Drug safety; Drug therapy; ECOG Performance Status; Female; Human; Intravenous drug administration; Male; Multicenter study; Overall response rate; Phase 1 clinical trial; Phase 3 clinical trial; Progression free survival; Quality of life; Randomized controlled trial; Response evaluation criteria in solid tumors}, -abstract = {Introduction: Despite the effectiveness of PD‐L1 inhibitors in combination with platinum‐based chemotherapy as first‐line treatment for extensive‐stage small‐cell lung cancer (ES‐SCLC), most patients still have disease progression and prognosis remains poor. In the IMpower133 study, the addition of atezolizumab (monoclonal anti‐PD‐L1 antibody) to chemotherapy improved median overall survival (mOS) to 12.3 months compared with 10.3 months in the chemotherapy plus placebo arm (HR 0.70; 95% CI: 0.54, 0.91; P=0.007; Horn et al, 2018). Single‐agent lurbinectedin, a selective inhibitor of oncogenic transcription, has shown promising activity in many tumor types, including as second‐line (2L) treatment for SCLC (objective response rate [ORR] by investigator assessment, 35%; Trigo et al, 2020), which led to its approval in the US for patients with metastatic SCLC who have previously received platinum‐based chemotherapy. In the Phase I part of the 2SMALL study, the combination of lurbinectedin and atezolizumab showed promising preliminary anti‐tumor activity (ORR, 57.7%) as a 2L treatment for ES‐SCLC (Ponce Aix et al, SITC 2021). The current study assesses lurbinectedin in combination with atezolizumab as a maintenance treatment for ES‐SCLC in patients who have received atezolizumab plus carboplatin and etoposide as first‐line induction therapy without experiencing disease progression. Methods: IMforte (NCT05091567; GO43104) is a Phase III, randomized, open‐label, multicenter study of atezolizumab plus lurbinectedin compared with atezolizumab alone. The study consists of an induction phase and a randomized maintenance phase. Patients eligible for the induction phase will be ≥ 18 years old and have an ECOG performance status of 0 or 1 and measurable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria. Patients with central nervous system metastases, autoimmune disease or prior anti‐cancer therapy for ES‐SCLC will be excluded. During the induction phase, patients will receive four 21‐day cycles of atezolizumab (1200 mg intravenously [IV]) plus carboplatin and etoposide. Patients must have an ongoing response or stable disease per RECIST 1.1 after the completion of 4 cycles of induction treatment to be randomized into the maintenance phase of the study. In the maintenance phase, patients will be randomized 1:1 to receive either atezolizumab (1200 mg IV) plus lurbinectedin (3.2 mg/m2 IV) or atezolizumab (1200 mg IV) every 3 weeks until disease progression. Independent review facility‐assessed progression‐free survival (PFS) per RECIST 1.1 and OS are the co‐primary endpoints. Secondary endpoints include investigator‐assessed PFS, ORR, duration of response, quality of life and safety/tolerability. Keywords: Atezolizumab, Lurbinectedin, Small‐cell lung cancer}, -DOI = {10.1016/j.jtho.2022.07.951}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461496/full} -} - - -Record #59 of 538 -@article{EUCTR2018-004843-22-HU19, -author = {EUCTR2018-004843-22-HU,}, -title = {Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in 1L ES SCLC}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2018-004843-22-HU}, -year = {2019}, -accession_number = {ICTRP EUCTR2018‐004843‐22‐HU}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: PEMBROLIZUMAB Product Code: MK‐3475 Pharmaceutical Form: Solution for infusion INN or Proposed INN: PEMBROLIZUMAB CAS Number: 1374853‐91‐4 Current Sponsor code: MK‐3475 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ Trade Name: KEYTRUDA (pembrolizumab, MK‐3475) Pharmaceutical Form: Solution for infusion INN or Proposed INN: PEMBROLIZUMAB CAS Number: 1374853‐91‐4 Current Sponsor code: MK‐3475 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ Product Name: Olaparib Product Code: MK‐7339 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: OLAPARIB CAS Number: 763113‐22‐0 Current Sponsor code: MK‐7339 Other descriptive name: OLAPARIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150‐ Pharmaceutical form of the placebo: Film‐coated tablet Route of administration of the placebo: Oral use Product Name: Olaparib Product Code: MK‐7339 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: OLAPARIB CAS Number: 763113‐22‐0 Current Sponsor code: MK‐7339 Other descriptive name: OLAPARIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Pharmaceutical form of the placebo: Film‐coated tablet Route of administration of the pl CONDITION: Extensive Stage Small Cell Lung Cancer ; MedDRA version: 21.1 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: ; Main Objective: 1. To compare pembrolizumab (MK‐3475) plus maintenance olaparib (MK‐7339) with pembrolizumab plus placebo with respect to progression‐free survival (PFS) assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in participants with extensive stage small cell lung cancer (ES‐SCLC) with stable disease (SD), partial response (PR), or complete response (CR) following induction treatment with pembrolizumab combined with etoposide and carboplatin or cisplatin; 2. To compare pembrolizumab plus maintenance olaparib with pembrolizumab plus placebo with respect to overall survival (OS); ; Primary end point(s): 1. Progression‐free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR); 2. Overall Survival (OS); ; Secondary Objective: 1. To evaluate the safety and tolerability of pembrolizumab plus maintenance olaparib compared to pembrolizumab plus placebo; 2. To evaluate the change from Baseline (at randomization) and the time to true deterioration (TTD) in global health status/quality of life (QoL), cough, chest pain, dyspnea and physical functioning following treatment with pembrolizumab plus maintenance olaparib compared to pembrolizumab plus placebo; ; Timepoint(s) of evaluation of this end point: 1. Up to approximately 33 months; 2. Up to approximately 42 months; INCLUSION CRITERIA: 1. Have a documented new diagnosis of SCLC by histology or cytology from brushing, washing, or needle aspiration of a defined lesion. Participants who do not have histology samples (defined as core or incisional biopsy, or resections) will need to undergo a new biopsy to provide a tissue sample 2. Have extensive stage disease defined as Stage IV (T any, N any, M 1a/b/c) by the American Joint Committee on Cancer, Eighth Edition 3. Have at least 1 lesion that meets the criteria for being measurable, as defined by RECIST 1.1, and is appropriate for selection as a target lesion, as determined by local site investigator/radiology review. Lesions that appear measurable, but have undergone palliative irradiation, cannot be target lesions 4. Have provided archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated. Formalin‐fixed, paraffin‐em SECONDARY OUTCOME: ; Secondary end point(s): 1. Number of Participants Who Experience an Adverse Event (AE); 2. Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE); 3. Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30 (EORTC QLQ‐C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score; 4. Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Lung Cancer Module 13 (EORTC QLQ‐LC13) Cough (Item 1) Score; 5. Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Lung Cancer Module 13 (EORTC QLQ‐LC13) Chest Pain (Item 10) Score; 6. Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30 (EORTC QLQ‐C30) Dyspnea (Item 8) Score; 7. Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐C30 (EORTC QLQ‐C30) Physical Functioning (Items 1‐5) Combined Score; 8. Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30 (EORTC QLQ‐C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score; 9. Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Lung Cancer Module 13 (EORTC QLQ‐LC13) Cough (Item 1) Score; 10. Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Lung Cancer Module 13 (EORTC QLQ‐LC13) Chest Pain (Item 10) Score; 11. Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30 (EORTC QLQ‐C30) Dyspnea (Item 8) Score; 12. Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐C30 (EORTC QLQ‐C30) Physical Functioning (Items 1‐5) Combined Score; 13. Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Lung Cancer Module 13 (EORTC QLQ‐LC13) Cough (Item 1); Chest Pain (Item 10) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐C30 (EORTC QLQ‐C30) Dyspnea (Item 8) Combined Score; ; Timepoint(s) of evaluation of this end point: 1. Up to approximately 42 months; 2. Up to approximately 24 months; 3. Baseline (at randomization) and Week 18 post‐randomization; 4. Baseline (at randomization) and Week 18 post‐randomization; 5. Baseline (at randomization) and Week 18 post‐randomization; 6. Baseline (at randomization) and Week 18 post‐randomization; 7. Baseline (at randomization) and Week 18 post‐randomization; 8. Up to approximately 42 months; 9. Up to approximately 42 months; 10. Up to approximately 42 months; 11. Up to approximately 42 months; 12. Up to approximately 42 months; 13. Up to approximately 42 months;}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02068493/full} -} - - -Record #60 of 538 -@article{Taylor20, -author = {Taylor, JM, Rusthoven, CG, and Moghanaki, D}, -title = {Prophylactic cranial irradiation or MRI surveillance for extensive stage small cell lung cancer}, -journal = {Journal of thoracic disease}, -volume = {12}, -number = {10}, -pages = {6225‐6233}, -year = {2020}, -accession_number = {EMBASE 2008595783}, -publication type = {Journal article}, -keywords = {*brain metastasis /prevention; *neuroprotection; *nuclear magnetic resonance imaging; *skull irradiation; *small cell lung cancer /radiotherapy; Clinical research; Disease surveillance; Human; Radiation injury; Randomized controlled trial (topic); Review; Risk assessment; Systematic review}, -abstract = {The treatment paradigm for extensive stage small cell lung cancer (ES‐SCLC) is evolving. Prophylactic cranial irradiation (PCI) has long been considered a component of standard treatment in patients with extensive stage disease who respond to chemotherapy. However, in the modern era of magnetic resonance imaging, the role of PCI has become an area of controversy following conflicting level I evidence. Due to conflicting data and toxicity concerns, the routine use of PCI has declined. Recent improvements in systemic disease control with the use of immunotherapy and reductions in the toxicity attributable to PCI with hippocampal avoidance and memantine have reignited the discussion. As such, we present here a narrative review of PCI with a focus on historical milestones, randomized data, risk mitigation and future directions.}, -DOI = {10.21037/jtd.2020.03.80}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02202978/full} -} - - -Record #61 of 538 -@article{Zhang24, -author = {Zhang, P-X, Liu, F-J, Wang, D-Q, Zheng, S-Y, Guo, J-Y, Zou, Y-Y, Liang, Y, Zhao, Y, Qiu, B, and Liu, H}, -title = {A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644913801}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *small cell lung cancer; Adult; Adverse drug reaction; Conference abstract; Controlled study; Drug therapy; Follow up; Human; Human tissue; Intention to treat analysis; Major clinical study; Male; Middle aged; Multiple cycle treatment; Overall survival; Phase 2 clinical trial; Pneumonia; Progression free survival; Radiotherapy; Randomized controlled trial; Side effect; Skull irradiation; Therapy}, -abstract = {Background: In recent years, the use of immune checkpoint inhibitors has led to significant progress in the treatment of extensive‐stage small cell lung cancer. However, there is limited data on the efficacy of immunotherapy in patients with limited‐stage disease (LS‐SCLC). Therefore, we conducted a phase II randomized study to verify the efficacy and safety of Toripalimab consolidation following definitive concurrent chemoradiotherapy (CCRT) in patients with LS‐SCLC (ClinicalTrials.gov ID: NCT04418648). Methods: Patients with LS‐SCLC who had achieved complete or partial response after definitive CCRT (including four to six cycles of etoposide and cisplatin, and curative‐intent thoracic radiotherapy) were randomly assigned (1:1) to receive Toripalimab consolidation (240mg intravenously, every 3 weeks for 6 months) or observation. Prophylactic cranial irradiation (PCI) was recommended but not mandatory. The primary endpoint was progression‐free survival (PFS) calculated from randomization, and secondary endpoints included overall survival (OS) and toxicity. Results: As of data cutoff (November 30, 2023), a total of 64 eligible patients (intent‐to‐treat population) were randomly assigned to the Toripalimab group (n = 31) or the observation group (n = 33), respectively. With the median follow‐up of 25 months, PFS was significantly improved with Toripalimab (hazard ratio [95% CI]: 0.47 [0.22‐1.02]; P = 0.04). The median PFS in observation group was 12.3 months (95% CI, 0.04‐24.50), while the median PFS in the Toripalimab group has not been reached. The 24‐month PFS rate was 61.6% (95% CI, 43.0%‐88.3%) in the Toripalimab group and 34.8% (95% CI, 21.5%‐56.3%) in the observation group. The 24‐month OS was 82.7% (95% CI, 65.2%‐100%; P = 0.23) in the Toripalimab group and 59.1%(95% CI, 44.2%‐79.1%) in the observation group. There were 5(16.1%) and 3 (9.1%) patients in the Toripalimab group and observation group experiencing G2+ pneumonitis respectively. No G4+ toxic events occurred in either group. Conclusions: Our preliminary results suggested Toripalimab consolidation following definitive CCRT was effective and tolerable in LS‐SCLC. (Table Presented).}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02736447/full} -} - - -Record #62 of 538 -@article{ChiCTR240008558024, -author = {ChiCTR2400085580,}, -title = {Phase II clinical study of chemotherapy combined with immunotherapy for extensive small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2400085580}, -year = {2024}, -accession_number = {ICTRP ChiCTR2400085580}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: treatment group:Adebelizumab radiotherapy group;control group:Adebelizumab chemotherapy group; CONDITION: extensive small cell lung cancer PRIMARY OUTCOME: Progression Free Survival; SECONDARY OUTCOME: Overall Survival;Objective response rate;Disease Control Rate;Duration of Response; INCLUSION CRITERIA: (1) 18‐75 years old. (2) the physical status of the Eastern American Cancer Cooperation Group (ECOG) was 0 or 1. (3) ES‐SCLC subjects confirmed by histology or cytology (according to American Veterans Association of Lung Cancer, VALG staging). (4) the clinical stage is extensive cTanyNanyM1, including cT3 (multiple metastases of the same lobe), T4 (multiple metastases of the same lobe), NanyM0. (5) there is at least one measurable lesion assessed according to the RECIST v1.1 standard. (6) the expected survival time is more than 3 months. (7) have not received first‐line systemic therapy for ES‐SCLC or immune checkpoint inhibitors in the past. (8) there are no taboos of radiotherapy, chemotherapy and immunotherapy in patients. (9) adequate organ function: 1) Bone marrow function: absolute neutrophil count = 1.5x109 / L, platelet count = 90x109L, hemoglobin = 90g/L. 2) liver function: defined as total bilirubin level = 1.5 times normal up}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02741989/full} -} - - -Record #63 of 538 -@article{Peng23, -author = {Peng, J, Meng, R, Liu, X, Zhang, L, Wang, L, Feng, R, Feng, H, Huang, Z, Yao, D, Li, X, Liu, N, Tan, B, Li, S, Yu, J, and Meng, X}, -title = {A Chinese multicenter, real-world study of PD-L1 inhibitors in extensive stage small cell lung cancer}, -journal = {Journal of thoracic oncology}, -volume = {18}, -number = {4}, -pages = {S135}, -year = {2023}, -accession_number = {EMBASE 2023626786}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *drug tolerability; *small cell lung cancer; Adult; Brain metastasis; Cancer chemotherapy; Cancer patient; Cancer radiotherapy; Cancer survival; China; Clinical feature; Conference abstract; Controlled study; Drug safety; Drug therapy; Drug withdrawal; Female; First‐line treatment; Funding; Human; Immune‐related gene; Major clinical study; Male; Multicenter study; Outcome assessment; Overall survival; Phase 3 clinical trial; Pneumonia; Progression free survival; Radiotherapy; Randomized controlled trial; Skull irradiation; Smoking}, -abstract = {Background Based on two randomized phase III studies, IMPOWER133 and CASPIAN, immune checkpoint inhibitors combined with chemotherapy have shown improved clinical efficacy as first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC). This study will describe the real‐world characteristics and outcomes of patients with ES‐SCLC treated with standard chemotherapy with or without PD‐L1 inhibitors. Methods Treatment‐naïve ES‐SCLC patients treated with standard platinum‐based chemotherapy with or without PD‐L1 inhibitors (atezolizumab and durvalumab) were enrolled from 12 sites in China between Jan 2019 and Dec 2021. Analyses of baseline characteristics, survival, treatment‐related adverse effects (TRAEs), and subgroups were conducted. The primary end point was progression‐free survival (PFS) and overall survival (OS). Results 414 ES‐SCLC patients were enrolled, of those 208 patients received durvalumab (66.3%) or atezolizumab (33.7%) combined with chemotherapy and 206 patients only received chemotherapy. In this study, 60.1% of patients had a history of smoking and 24.6% had brain metastases. Of 414 patients, 256 (61.8%) received six or more cycles of chemotherapy (median, 6) and 213 (61.8%) received radiotherapy to any site. Median PFS in PD‐L1 inhibitors plus chemotherapy group or chemotherapy group was 7.2 months (95% CI 6.6–7.8) and 6.4 months (95% CI 5.8–7.0), respectively (P = 0.001), and HR for disease progression was 0.72 (95% CI 0.59–0.89; P = 0.002). The median OS was 20.6 months and 15.9 months, respectively (HR = 0.74, P = 0.020). TRAEs were similar in the two groups, with AE‐related withdrawal rates from 1L therapy of 6.3% in the PD‐L1 inhibitors plus chemotherapy group and 3.4% in the chemotherapy group, including one death from immune‐related pneumonia in the former group. Conclusions In this real‐world study, PD‐L1 inhibitors combined with chemotherapy demonstrated good efficacy and tolerable safety profiles. The clinical characteristics and treatment patterns were markedly different from those in the two RCTs, including receipt of thoracic radiotherapy (tRT) or prophylactic cranial irradiation (PCI). The OS benefit and radiotherapy subgroup analysis of ES‐SCLC patients need to be further followed up. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.}, -DOI = {10.1016/S1556-0864(23)00426-4}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02543514/full} -} - - -Record #64 of 538 -@article{Higgins21, -author = {Higgins, K, Hu, C, Ross, H, Jabbour, S, Kozono, D, Owonikoko, T, Movsas, B, Solberg, T, Xiao, C, Williams, T, Welsh, J, Simko, J, Wang, X, Mohindra, N, Hsu, C, Stinchcombe, T, and Bradley, J}, -title = {P48.02 NRG Oncology/Alliance LU005: chemoradiation vs. Chemoradiation Plus Atezolizumab in Limited Stage Small Cell Lung Cancer}, -journal = {Journal of thoracic oncology}, -volume = {16}, -number = {3}, -pages = {S499‐S500}, -year = {2021}, -accession_number = {EMBASE 2011421324}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *chemoradiotherapy; *small cell lung cancer; Adult; Autoimmune disease; Cancer patient; Cancer survival; Clinical trial; Comorbidity; Conference abstract; Disease control; Drug therapy; Female; Human; Immune‐related gene; Major clinical study; Male; Overall survival; Patient‐reported outcome; Phase 2 clinical trial; Phase 3 clinical trial; Progression free survival; Quality of life; Radiotherapy; Randomized controlled trial; Skull irradiation}, -abstract = {Introduction: Limited stage small cell lung cancer (LS‐SCLC) is treated with standard of care platinum/etoposide (EP) and thoracic radiation therapy (TRT) with curative intent, however the majority of patients are not cured and median overall survival is approximately 30 months. Addition of atezolizumab to chemotherapy in extensive stage SCLC has improved progression free and overall survival in a non‐curative setting leading to hope that addition of an immune checkpoint inhibitor to standard chemoradiotherapy could benefit LS‐SCLC patients. LU005 is a randomized phase II/III trial of standard concurrent chemoradiation with or without atezolizumab for patients with LS‐SCLC. Methods: Patients are randomly assigned in a 1:1 ratio to standard EP chemotherapy with concurrent TRT (45 Gy BID or 66 Gy QD) with or without atezolizumab beginning concurrently with TRT, and continued every 3 weeks for up to 12 months. Eligible patients have LS‐SCLC, PS 0‐2, adequate organ function, no concerning comorbidities (including no active autoimmune disease) and are eligible for TRT. Patients are randomized prior to their second cycle of EP and thoracic radiation begins with the second overall cycle of chemotherapy (first cycle of study therapy) in both treatment arms. Prophylactic cranial radiation (PCI) is recommended for patients who respond to treatment. The phase II/III primary endpoints are progression free (PFS) and overall survival (OS) respectively. Secondary endpoints include objective response rates, local and distant disease control, and quality of life/patient reported outcomes assessment. Translational science component includes blood and tissue based immune related assays. Results: This study activated in May 2019. 120 of 506 planned patients have been accrued as of 8/20/2020. Keywords: Limited stage small cell lung cancer, chemoradiation, atezolizumab}, -DOI = {10.1016/j.jtho.2021.01.872}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02267457/full} -} - - -Record #65 of 538 -@article{NCT0529842322, -author = {NCT05298423,}, -title = {Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)}, -journal = {https://clinicaltrials.gov/ct2/show/NCT05298423}, -year = {2022}, -accession_number = {CTgov NCT05298423}, -publication type = {Trial registry record}, -keywords = {Carboplatin; Carcinoma, Non‐Small‐Cell Lung; Durvalumab; Etoposide; Paclitaxel; Pembrolizumab; Pemetrexed}, -abstract = {Researchers are looking for new ways to treat people with locally advanced non‐small celllung cancer (NSCLC). The goal of this study is to learn if people who receive thecombination of vibostolimab and pembrolizumab (MK‐7684A) live longer without the cancergetting worse and live longer overall than people who receive durvalumab.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02391772/full} -} - - -Record #66 of 538 -@article{EUCTR2020-001863-10-GR21, -author = {EUCTR2020-001863-10-GR,}, -title = {A Study of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-001863-10-GR}, -year = {2021}, -accession_number = {ICTRP EUCTR2020‐001863‐10‐GR}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Anti‐fucosyl‐GM1 Product Code: BMS‐986012 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: anti‐fucosyl‐GM1 Current Sponsor code: BMS‐986012 Other descriptive name: BMS986012 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30‐ Trade Name: Opdivo (100 mg/10 ml) Product Name: NIVOLUMAB ‐ 10ml vial‐COMMERCIAL Product Code: BMS‐936558 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NIVOLUMAB CAS Number: 946414‐94‐4 Current Sponsor code: BMS‐936558 Other descriptive name: BMS936558 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ CONDITION: Extensive‐stage Small Cell Lung Cancer ; MedDRA version: 21.1 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: ‐ To assess the safety and tolerability for participants randomized to BMS‐986012 in combination with carboplatin, etoposide, and nivolumab for 4 cycles (induction) followed by BMS‐986012 and nivolumab maintenance (Arm A) vs those randomized to carboplatin, etoposide, and nivolumab for 4 cycles (induction) followed by nivolumab maintenance (Arm B).; ; ‐ To compare the PFS as assessed by BICR of participants treated in the combination induction and maintenance therapies of Arms A and B described above. Primary end point(s): 1. Incidence of adverse events (AEs) ; 2. Incidence of serious adverse events (SAEs) ; 3. Incidence of AEs leading to discontinuation ; 4. Incidence of deaths ; 5. Progression‐free survival (PFS) by blinded independent central review (BICR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria Secondary Objective: ‐ To estimate the PFSR at 6 and 12 months in each treatment arm, based on PFS by RECIST v1.1 as assessed by BICR.; ‐ To compare PFS as assessed by investigator of participants treated in the combination induction and maintenance therapies of Arms A and B described above.; ‐ To estimate the PFSR at 6 and 12 months in each treatment arm based on PFS by RECIST v1.1 assessed by investigator.; ‐ To estimate the ORR, TTR, and DOR by RECIST v1.1 criteria by BICR and by investigator.; ‐ To assess OS of Arm A and Arm B and estimate OSR at 12 and 24 months by treatment arm.; ‐ To assess associations of fuc‐GM1 expression in pretreatment tumor biopsies assessed using IHC and mass spectrometry assays with anti‐tumor activity measures.; ‐ To assess associations of PD‐L1 expression (CPS) in pretreatment tumor biopsies with anti‐tumor activity measures.; ‐ To characterize the immunogenicity of BMS‐986012 in combination with carboplatin, etoposide, and nivolumab in Arm A. Timepoint(s) of evaluation of this end point: 1: Up to 2 years and 100 days; 2‐4: Up to 2 years and 128 days; 5: Up to 2 years SECONDARY OUTCOME: Secondary end point(s): 1. Progression‐free survival rate (PFSR) [PFS by BICR based on RECIST v1.1 criteria] ; 2. PFS by investigator based on RECIST v1.1 criteria ; 3. PFSR [PFS by investigator based on RECIST v1.1 criteria] ; 4. Objective response rate (ORR) based on RECIST v1.1 criteria ; 5. Time to response (TTR) based on RECIST v1.1 criteria ; 6. Duration of response (DOR) based on RECIST v1.1 criteria ; 7. Overall survival (OS) ; 8. Overall survival rate (OSR) ; 9. Measures of tumor fucosyl‐GM1 (fuc‐GM1) expression by immunohistochemistry (IHC) ; 10. Measures of tumor fucosyl‐GM1 (fuc‐GM1) expression association with measures of anti‐tumor activity measures (eg, ORR, PFS) (IHC) ; 11. Measures of tumor fucosyl‐GM1 (fuc‐GM1) expression by targeted mass spectrometry ; 12. Measures of tumor fucosyl‐GM1 (fuc‐GM1) expression association with measures of anti‐tumor activity measures (eg, ORR, PFS) (targeted mass spectrometry) ; 13. Measures of tumor programmed cell death‐ligand 1 (PD‐L1) expression combined positive score (CPS) at baseline ; 14. Measures of tumor programmed cell death‐ligand 1 (PD‐L1) expression association with measures of anti‐tumor activity (eg, ORR, PFS) ; 15. Immunogenicity of BMS‐986012 measured by assessment of the presence of specific anti‐drug antibodies (ADAs) to BMS‐986012 (i.e. incidence of positive ADAs) Timepoint(s) of evaluation of this end point: 1, 3: 6 and 12 months ; 2, 4‐6, 9‐15: Up to 2 years ; 7, 8: Up to 3 years INCLUSION CRITERIA: ‐ Histologically or cytologically documented extensive‐stage small cell lung cancer (ES‐SCLC) and extensive‐stage disease (American Joint Committee on Cancer, 7th edition, Stage IV [T any, N any, M1a, or M1b], or T3‐4 due to multiple lung nodules that are too extensive or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan) ‐ Must provide a fresh tumor biopsy from the primary disease site (when possible) or from any metastatic site when the primary site is not available ‐ Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1 ‐ At least 1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (Response Evaluation Criteria in Solid Tumors (RECIST) v1.1) criteria ‐ Adequate hematologic and end organ function ‐ Must agree to follow specific methods of contraception, if applicable Are the trial subjects u}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02281212/full} -} - - -Record #67 of 538 -@article{Aisner82, -author = {Aisner, J, Whitacre, M, VanEcho, DA, Wesley, M, and Wiernik, PH}, -title = {Doxorubicin, Cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer}, -journal = {Cancer chemotherapy and pharmacology}, -volume = {7}, -number = {2‐3}, -review groups = {HS-HANDSRCH; SR-CANCER; Lung Cancer}, -pages = {187‐193}, -year = {1982}, -accession_number = {EMBASE 12157018, PUBMED 6282482}, -publication type = {Journal article}, -keywords = {Adult; Aged; Brain Neoplasms [prevention & control, radiotherapy]; Carcinoma, Small Cell [*drug therapy]; Cyclophosphamide [adverse effects, *therapeutic use]; Doxorubicin [adverse effects, *therapeutic use]; Drug Therapy, Combination; Etoposide [adverse effects, *therapeutic use]; Female; Humans; Lung Neoplasms [*drug therapy]; Male; Middle Aged; Podophyllotoxin [*analogs & derivatives]}, -abstract = {Small cell lung cancer requires aggressive combination chemotherapy. The three active agents, doxorubicin (A) 45 mg/m2 i.v. day 1, cyclophosphamide (C) 1.0 mg/m2 i.v. day 1 and VP16‐213 (E) 50 mg/m2/day i.v. days 1‐5 were given together. The combination (ACE) was given every 21 days without chest irradiation. One hundred and seventy‐four patients have been stratified for extent of disease and randomized on three sequential studies testing ACE vs ACE + MER immunotherapy (38 patients), or ACE vs ACE alternating with CCNU, methotrexate, vincristine and procarbazine (109 patients), or ACE vs ACE II (ACE with continuous VP16‐213 ‐ 100 mg/m2/day X 5 days ‐ 27 patients ‐ ongoing). The immunotherapy and the alternating non‐cross resistant combination have not proven beneficial with respect to response or survival. The ACE combination, regardless of additional treatments, has produced greater than 90% response overall. In limited disease the complete response (CR) frequency is 65%. The median survival for limited disease overall is 14 months and 18 months for patients achieving CR. In extensive disease the CR frequency is 40% with a median survival of 9 months overall and 13 months for patients achieving CR. Response frequency and survival are identical in the first two studies and 20‐30% of patients with limited disease are long‐term survivors with one late relapse (greater than 3 years). Patients who achieved CR had a significantly longer survival regardless of other factors such as performance status or extent of disease. Prophylactic cranial irradiation was demonstrated to be useful in prevention or delaying CNS metastases in patients who achieved CR. The third generation study of high‐dose VP16‐213 infusion seeks to increase the CR frequency. ACE chemotherapy without chest irradiation is a highly effective treatment for all patients with small cell lung cancer and compares favorably with all other studies with or without adjuvant radiotherapy.}, -DOI = {10.1007/BF00254546}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00028022/full} -} - - -Record #68 of 538 -@article{NCT0157918812, -author = {NCT01579188,}, -title = {Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer}, -journal = {https://clinicaltrials.gov/show/NCT01579188}, -year = {2012}, -accession_number = {CTgov NCT01579188}, -publication type = {Trial registry record}, -keywords = {Carcinoma, Non‐Small‐Cell Lung; Lung Neoplasms}, -abstract = {Lung cancer (both small cell and non‐small cell) is the second most common cancer in both men (after prostate cancer) and women (after breast cancer). It accounts for about 15% of all new cancers. Lung cancer is the world's leading cause of cancer death with more than 1.6 million new cases diagnosed each year. About 85 percent of lung cancer patients have Non‐small Cell Lung Cancer (NSCLC ) and are usually diagnosed with advanced disease and have few treatment options and a very low survival rate. Radiotherapy is the treatment of choice in the successful treatment of stage III NSCLC. However, the 5‐year survival for stage III patients treated with radiotherapy alone is less than 10%. Several types of chemotherapy treatments have been investigated, however, progress has been limited. Most patients die from relapsed disease. The peptide telomerase vaccine, GV1001, is under development for use as active immunotherapy in the treatment of cancer. Normally, the immune system is tolerant to self‐proteins and peptides, while being able to react to foreign pathogens. However, cancer cells are degenerated cells and many of their peptides and proteins are self‐proteins or peptides. By using vaccination, the immune tolerance towards a specific peptide or protein can be circumvented.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01531619/full} -} - - -Record #69 of 538 -@article{Gobbini24, -author = {Gobbini, E, Filleron, T, Thureau, S, Falchero, L, Le Treut, J, Bonetto, R, Bernardi, M, Benyoub, S, Stoffaes, L, Simon, C, Lamrani-Ghaouti, A, and Doyen, J}, -title = {215TiP A phase II study of durvalumab (MEDI 4736) maintenance in frail limited disease small cell lung cancer patients after thoracic chemo-radiotherapy (CRT): DURVALUNG trial}, -journal = {ESMO open}, -volume = {9}, -year = {2024}, -accession_number = {EMBASE 2030949449}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *small cell lung cancer; Clinical trial; Comorbidity; Conference abstract; Diagnosis; Disease control; Drug therapy; Female; Human; Male; Multicenter study; Non small cell lung cancer; Overall survival; Phase 2 clinical trial; Progression free survival; Quality of life; Radiotherapy; Sarcopenia; Skull irradiation; Survival rate; Therapy}, -abstract = {Background: Small cell Lung Cancer (SCLC) is a rare tumour subtype, and approximately one third of the SCLC patients (pts) present limited disease (LD‐SCLC) with a 5‐year survival rate between 20% and 25%. The standard of care (SOC) is platinum‐based chemotherapy combined with etoposide and thoracic radiotherapy (CRT). While immunotherapy is currently limited to advanced SCLC setting, NSCLC setting suggest that the combination of immunotherapy and radiotherapy may produce a synergistic effect. The relevance of a multimodal strategy including immunotherapy after CRT is therefore currently under investigation, but frail LD‐SCLC pts are often excluded from clinical trials. Thus, DURVALUNG study aims to evaluate the efficacy of durvalumab maintenance specifically in frail LD‐SCLC pts who have not progressed following concomitant or sequential CRT. Trial design: DURVALUNG is an academically‐lead, open‐label, multicentre, randomized phase II trial in previously untreated frail LD‐SCLC pts. Pts will be screened during the CRT and only those achieving a disease control (SD or PR/CR) after the CRT and presenting frail condition (ECOG PS 2, ECOG PS 0‐1 and older than 70 or did not receive a concomitant CRT due to comorbidities) will be randomized 1:1 to receive durvalumab every 4 weeks for 24 months or surveillance as per SOC. Prophylactic Cranial Irradiation will be allowed according to local SOC within 45 days after the end of CRT. 110 pts will be randomized in the study. A safety interim analysis will be performed after the first 15 pts included into the experimental arm for the Data Safety Monitoring Board. The main objective is to evaluate the progression‐free survival (PFS), per investigator, of LD‐SCLC pts on durvalumab arm compared to surveillance. The primary endpoint analysis will be a Cox regression analysis with 90% confidence interval (1‐sided). Secondary objectives are BIRC PFS, overall survival, quality of life, and toxicity. Ancillary studies will be conducted to determine biomarkers of clinical benefit from the durvalumab maintenance, the impact of sarcopenia on outcomes, and the correlation between radiotherapy plan and survival outcomes and toxicities. Clinical trial identification: EudraCT: 2021‐005920‐39 NCT05617963. Legal entity responsible for the study: Unicancer. Funding: AstraZeneca. Disclosure: E. Gobbini: Non‐Financial Interests, Personal, Other, Spouse of an AstraZeneca employee: AstraZeneca; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, AstraZeneca; Financial Interests, Personal and Institutional, Other, Personal fees: Roche, Pfizer, Merck Sharpe and Dohme, Bristol Myers Squibb, Takeda, Janssen, Sanofi. T. Filleron: Financial Interests, Personal, Other, working group: Janssen‐Cilag; Financial Interests, Institutional, Invited Speaker: Lilly; Financial Interests, Institutional, Other, working group: Roche; Other, Personal, Other, Consulting (compensated to my institution): Cellectis. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.esmoop.2024.102788}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02682738/full} -} - - -Record #70 of 538 -@article{Schild22, -author = {Schild, SE, Wang, X, Bestvina, CM, Williams, T, Masters, G, Singh, AK, Stinchcombe, TE, Salama, JK, Wolf, S, Zemla, T, Duma, N, Chun, SG, Amini, A, Kozono, D, and Watt, C}, -title = {Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer}, -journal = {Clinical lung cancer}, -volume = {23}, -number = {5}, -pages = {e317‐e320}, -year = {2022}, -accession_number = {EMBASE 2018357818, PUBMED 35613998}, -publication type = {Journal article}, -keywords = {*advanced cancer; *chemotherapy; *immunotherapy; *non small cell lung cancer; *stereotactic body radiation therapy; *systemic therapy; Adult; Antineoplastic activity; Article; B7‐H1 Antigen; Cancer patient; Cancer radiotherapy; Cancer staging; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [drug therapy]; Clinical trial; Controlled study; Drug therapy; Female; Gene expression; Human; Humans; Immunotherapy; Lung Neoplasms [drug therapy]; Major clinical study; Male; Multicenter study; Outcome assessment; Overall survival; Phase 2 clinical trial; Phase 3 clinical trial; Progression free survival; Protein expression; Radiosurgery; Randomized controlled trial}, -abstract = {Introduction: Treatment of advanced stage non‐small cell lung cancer (NSCLC) has changed dramatically due to immunotherapy. However, patients without Programmed Death‐Ligand 1 (PD‐L1) protein expression often benefit less from immunotherapy. This trial is designed to test if stereotactic body radiation therapy (SBRT) to a single tumor site can significantly enhance the outcome of patients with advanced stage PD‐L1(‐) NSCLC when added to systemic therapy including immunotherapy. Materials and Methods: Alliance A082002 is based on subgroup analysis from the randomized phase II PEMBRO‐RT trial., PEMBRO‐RT compared pembrolizumab alone or with SBRT and revealed improved progression‐free and overall survival (PFS and OS, respectively) in PD‐L1(‐) patients when adding SBRT (8 Gy x 3 fractions). In A082002, patients without PD‐L1 expression will be randomized to SBRT (8 Gy x3) plus systemic therapy vs. systemic therapy alone. The primary endpoint of the phase II portion of the trial is PFS and will require 100 patients. The primary endpoint of the phase III portion of the trial is OS and will require an additional 284 patients. This trial will clarify whether adding SBRT to systemic therapy can improve PFS and OS in a larger multi‐institutional cohort. Several systemic treatment options are allowed including either immunotherapy alone or chemo‐immunotherapy. Conclusions: This phase II/III Alliance trial A082002 will test whether the addition of SBRT to a single tumor site will enhance the anti‐tumor activity of systemic immunotherapy or chemo‐immunotherapy in patients with stage IV PD‐L1(‐) NSCLC. It is now open in the National Clinical Trials Network (NCTN).}, -DOI = {10.1016/j.cllc.2022.04.004}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02401843/full} -} - - -Record #71 of 538 -@article{Belluomini22, -author = {Belluomini, L, Dionisi, V, Palmerio, S, Vincenzi, S, Avancini, A, Casali, M, Riva, ST, Menis, J, Mazzarotto, R, Pilotto, S, and Milella, M}, -title = {Study Design and Rationale for Espera Trial: a Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction}, -journal = {Clinical lung cancer}, -volume = {23}, -number = {3}, -pages = {e269‐e272}, -year = {2022}, -accession_number = {EMBASE 2014337977, PUBMED 34470722}, -publication type = {Journal article}, -keywords = {*advanced cancer; *comparative effectiveness; *immunotherapy; *non small cell lung cancer; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; Article; Cancer patient; Cancer prognosis; Cancer radiotherapy; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [drug therapy]; Chemotherapy; Clinical trial; Controlled study; Drug safety; Drug therapy; ECOG Performance Status; Female; Host interaction; Human; Humans; Immunotherapy; Lung Neoplasms [drug therapy]; Male; Multicenter study; Pemetrexed [therapeutic use]; Pharmacokinetics; Phase 2 clinical trial; Platinum [therapeutic use]; Progression free survival; Radiosurgery; Radiotherapy; Randomized controlled trial; Stereotactic body radiation therapy; Translational research; Tumor Microenvironment; Tumor microenvironment}, -abstract = {Background: Improvement in radiotherapy techniques and expected outcomes, as well as in understanding the underlying biological mechanisms contributing to its action (immunomodulation in primis), led to the integration of this therapeutical approach in the current management of advanced non‐small cell lung cancer (NSCLC), not only in oncogene‐driven tumors, but also in non‐oncogene addicted NSCLC where the combination of platinum‐based chemotherapy plus pembrolizumab represents nowadays the pivotal strategy. In this light, we have designed a randomized phase II (ESPERa) trial to evaluate the efficacy and safety of adding Stereotactic Body Radiotherapy (SBRT) to pembrolizumab‐pemetrexed maintenance in advanced NSCLC patients experiencing disease response or stability after chemo‐immunotherapy induction. Patients and Methods: Advanced non‐oncogene addicted NSCLC patients with ECOG performance status of 0 or 1, who obtained disease response or stability after 4 cycles of platinum‐based chemotherapy plus pembrolizumab will be randomized 2:1 to receive pembrolizumab‐pemetrexed maintenance plus SBRT vs pembrolizumab‐pemetrexed alone. The primary endpoint is progression‐free survival (PFS). Concomitant translational researches will be performed to identify potential prognostic and/or predictive biomarkers, as well as to analyze and monitor tumour microenvironment and tumor‐host interactions. Conclusions: Although available data suggest the safety and efficacy of combining immunotherapy and radiotherapy, their systematic integration in the current first‐line landscape still remains to be explored. If the pre‐planned endpoints of the ESPERa trial will be achieved, the addition of SBRT to pembrolizumab‐pemetrexed maintenance as a strategy to consolidate and ideally improve the awaited benefit could be considered as a promising strategy in NSCLC undergoing first‐line therapy, as well as an interesting approach to be evaluated in other disease setting, as well as in other oncological malignancies where immunotherapy represents nowadays the standard‐of‐care.}, -DOI = {10.1016/j.cllc.2021.07.004}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02326326/full} -} - - -Record #72 of 538 -@article{Gu17, -author = {Gu, Y, Lv, H, Zhao, J, Li, Q, Mu, G, Li, J, Wuyang, J, Lou, G, Wang, R, Zhang, Y, and Huang, X}, -title = {Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC)}, -journal = {International immunopharmacology}, -volume = {50}, -pages = {263‐269}, -year = {2017}, -accession_number = {EMBASE 617260354, PUBMED 28711032}, -publication type = {Journal article}, -keywords = {*advanced cancer/rt [Radiotherapy]; *cancer adjuvant therapy; *cytokine induced killer cell; *non small cell lung cancer/rt [Radiotherapy]; Adult; Aged; Aged, 80 and over; Article; Cancer chemotherapy; Cancer growth; Cancer prognosis; Cancer radiotherapy; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [mortality, pathology, *therapy]; Cell Proliferation; Cell count; Cell culture; Cell expansion; Cell viability; Cells, Cultured; Chemoradiotherapy, Adjuvant [*methods]; Combined Modality Therapy; Controlled clinical trial; Controlled study; Cytokine‐Induced Killer Cells [*immunology, transplantation]; Female; Flow cytometry; Human; Humans; Immunotherapy, Adoptive [*methods]; In vitro study; Lung Neoplasms [mortality, pathology, *therapy]; Lymphocyte Count; Major clinical study; Male; Middle Aged; Neoplasm Staging; Overall survival; Phenotype; Priority journal; Quality control; Retrospective Studies; Retrospective study; Survival Analysis; Treatment Outcome}, -abstract = {Objective Cytokine‐induced killer (CIK) cells have important therapeutic effects in adoptive cell transfer (ACT) for the treatment of various malignancies. In this study, we focused on in vitro expansion of CIK cells and their clinical efficacy in combination with chemotherapy in patients with advanced non‐small‐cell lung cancer (NSCLC). Methods A total of 64 patients with NSCLC (enrolled from 2011 to 2012), including 32 patients who received chemotherapy alone or with sequential radiotherapy (conventional treatment, control group) and 32 patients who received conventional treatment and sequential CIK infusion (study group), were retrospectively analyzed. The time to progression (TTP), overall survival (OS) and adverse effects were analyzed and the phenotype of lymphocytes in CIK population was also determined by flow cytometry. Results After in vitro expansion, the average percentage of CIK cells was 26.35%. During the 54‐month follow up, the median OS and TTP were significantly longer in the study group than in the control group (P = 0.0189 and P = 0.0129, respectively). The median OS of the ACT ≥ 4 cycles subgroup was significantly longer than that of the ACT < 4 cycles subgroup (P = 0.0316). The percentage of CIK cells in patients who received ≥ 4 cycles of ACT was higher than that in patients treated with < 4 cycles of ACT (P = 0.0376). Notably, CIK cells were difficult to expand in vitro in some patients after the first ACT cycle but became much easier as the treatment cycles increased monthly. Longer treatment interval negatively impacted the expansion of CIK cells. Conclusions Systematic immune levels can be increasingly boosted by reinfusion of ACT. Conventional treatment plus CIK cells is an effective therapeutic strategy to prevent progression and prolong survival of patients with advanced NSCLC.}, -DOI = {10.1016/j.intimp.2017.07.006}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01394166/full} -} - - -Record #73 of 538 -@article{EUCTR2021-004155-16-DE21, -author = {EUCTR2021-004155-16-DE,}, -title = {Phase Ib study investigating dose, safety and efficacy of [177Lu]Lu-DOTA-TATE in patients with Extensive Stage Small Cell Lung Cancer (specific form of lung tumour)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-004155-16-DE}, -year = {2021}, -accession_number = {ICTRP EUCTR2021‐004155‐16‐DE}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trade Name: Lutathera Pharmaceutical Form: Solution for infusion INN or Proposed INN: LUTETIUM (177LU) OXODOTREOTIDE Current Sponsor code: AAA601 Concentration unit: MBq/ml megabecquerel(s)/millilitre Concentration type: equal Concentration number: 370‐ Trade Name: NETSPOT Pharmaceutical Form: Kit for radiopharmaceutical preparation INN or Proposed INN: Not yet available Current Sponsor code: AAA501 Other descriptive name: DOTATATE Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 40‐ Trade Name: Baize’an Product Name: Tislelizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Tislelizumab CAS Number: 1858168‐59‐8 Current Sponsor code: VDT482 Other descriptive name: BGN‐A317 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ CONDITION: Extensive‐Stage Small Cell Lung Cancer ; MedDRA version: 21.1 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] SECONDARY OUTCOME: Secondary end point(s): Phase Ib:; • Objective Response Rate (ORR), Duration of Response (DOR), Progression‐Free Survival (PFS), Overall Survival (OS); • Time activity curves (TACs), describing % of the activity injected vs time in blood, organs and tumor lesions.; • Absorbed radiation doses of [177Lu]Lu‐DOTA‐TATE in organs and tumor lesions; • Concentration of [177Lu]Lu‐DOTA‐TATE in blood over time and derived PK parameters; • Quantification of [177Lu]Lu‐DOTA‐TATE excreted from the body in urine from the start of infusion until the first whole body planar imaging; ; Phase II:; • Progression free survival (PFS) by investigator assessment, Objective Response Rate (ORR), Duration of Response (DOR) based on investigator assessment as per RECIST 1.1; ; Phase Ib and Phase II:; • Incidence and severity of Adverse Events (AEs) and serious Adverse Events (SAEs); • Incidence and severity of Adverse Events (AEs) and serious Adverse Events (SAEs) within 48 hours after [68Ga]Ga‐DOTA‐TATE infusion Timepoint(s) of evaluation of this end point: •Incidence and severity of AEs and SAEs ‐ from randomization until 30 days after safety follow‐up.; •ORR, DOR, PFS, OS : from randomization until date of progression or date of death from any cause, whichever comes first; •Time activity curves (TACs), absorbed radiation doses of [177Lu]Lu and concentration of [177Lu]Lu‐DOTA‐TATE in blood: week 7 day 3; •Quantification of [177Lu]Lu excreted from the body in urine: from the start of infusion until the first whole body planar imaging; •Incidence and severity of AEs and SAEs of [68Ga]Ga: within 48h after administration PRIMARY OUTCOME: Main Objective: The primary objective of the Phase Ib portion of the study is to establish; the recommended dose of [177Lu]Lu‐DOTA‐TATE in combination with; carboplatin, etoposide, and atezolizumab in induction treatment and; with atezolizumab in maintenance treatment in newly diagnosed; participants with ES‐SCLC.; The primary objective of the Phase II portion of the study is to assess; efficacy of [177Lu]Lu‐DOTA‐TATE in combination with carboplatin,; etoposide and atezolizumab (experimental arm) versus standard of care; consisting of carboplatin, etoposide, and atezolizumab (control arm) in; terms of overall survival. Primary end point(s): Phase Ib:; • Frequency of dose limiting toxicities (DLTs), incidence of adverse events (AEs), serious AEs (SAEs), and AEs leading to treatment discontinuation; Phase II:; • Overall Survival (OS) defined as time from date of randomization to death due to any cause Secondary Objective: Phase Ib:; • To assess the preliminary anti‐tumor activity of [177Lu]Lu‐DOTA‐TATE in combination with carboplatin, etoposide and atezolizumab in newly diagnosed participants with ES‐SCLC; • To characterize the pharmacokinetics (PK) and dosimetry of [177Lu]Lu‐DOTA‐TATE in participants with newly diagnosed participants with ES‐SCLC; ; Phase II:; • To evaluate the antitumor activity of [177Lu]Lu‐DOTA‐TATE in; combination with carboplatin, etoposide and atezolizumab (experimental arm) versus standard of care consisting of carboplatin, etoposide, and atezolizumab (control arm); ; Phase Ib and Phase II: ; • To characterize the safety and tolerability of [177Lu]Lu‐DOTA‐TATE in combination with carboplatin, etoposide, and atezolizumab in induction treatment and with atezolizumab in maintenance treatment in newly diagnosed participants with ES‐SCLC; • To assess the safety and tolerability of [68Ga]Ga‐DOTA‐TATE in; participants with newly diagnosed ES‐SCLC Timepoint(s) of evaluation of this end point: Frequency of DLTs: Within the first 6 weeks of [177Lu]Lu‐DOTA‐TATE treatment; Incidence of adverse events (AEs), serious AEs (SAEs), and AEs leading to treatment discontinuation: From date of randomization to 8 weeks following the last dose of study treatment; ; OS: Time from date of randomization to death due to any cause INCLUSION CRITERIA: Key INCLUSION CRITERIA: • Participant is = 18 years on the day of signing informed consent form • Histologically or cytologically confirmed ES‐SCLC • Presence of measurable disease (at least one target lesion) according to RECIST v1.1 assessed by conventional computed tomography (CT) scan • SSTR positive [68Ga]Ga‐DOTA‐TATE imaging positron emission tomography (PET) scan demonstrating uptake equal or higher than the liver uptake (uptake intensity score 2 or above in the visual uptake scoring scale) in at least one target or non‐target lesion • No prior systemic treatment for ES‐SCLC (except the first cycle of chemotherapy with or without atezolizumab of the induction period) • Provision of tumor tissue to support exploratory biomarker analysis • Life expectancy of >=6 months Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 87}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02694335/full} -} - - -Record #74 of 538 -@article{Delaloye18, -author = {Delaloye, R, Britschgi, C, Bihr, S, Bankel, L, Stahel, R, Weder, W, and Curioni-Fontecedro, A}, -title = {Pathologic complete remission after two years of adjuvant Ipilimumab in limited small cell lung cancer}, -journal = {Swiss medical weekly}, -volume = {148}, -pages = {15S}, -year = {2018}, -accession_number = {EMBASE 626874767}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer adjuvant therapy; *remission; *small cell lung cancer; Adult; Body weight; Bronchus; Cancer patient; Cancer staging; Cancer surgery; Case report; Chemoradiotherapy; Clinical article; Conference abstract; Drug combination; Drug therapy; Female; Follow up; Human; Immunity; Immunotherapy; Male; Maximum standardized uptake value; Mediastinum; Monotherapy; Pleura; Pneumonia; Positron emission tomography‐computed tomography; Primary tumor; Radiotherapy; Randomized controlled trial; Side effect; Skull irradiation; Stimulus; Tumor cell}, -abstract = {Small Cell Lung Cancer is an aggressive cancer with poor prognosis and even in limited disease the 5‐year survival is below 20%. To date, immunotherapy with immune‐checkpoint inhibitors for SCLC have made the greatest advances and preliminary data for pembrolizumab, nivolumab and combination of ipilimumab with nivolumab showed promising antitumour activity. We here describe the case of a patient with limited disease SCLC (cT4 pN1cM0; T4:10 cm with contact to the mediastinum, visceral pleura and infiltration of the main left bronchus), who was included in the ETOP 4‐12‐STIMULI trial. The patient underwent standard chemoradiotherapy and prophylactic cranial irradiation achieving a partial response; subsequently the patient was randomized to the investigational arm, with adjuvant ipilimumab. The treatment consisted of four doses of ipilimumab 3 mg/kg every three weeks and thereafter eight doses of ipilimumab 3 mg/kg every six weeks for two years. Follow up was done with FDG‐PET/CT scans every three months. The treatment was well tolerated and the patient experienced no side effects. On the FDG‐PET/CT scans, the primary tumor showed persistence three months after the last dose of ipilimumab, with a size above 7cm, low FDG‐uptake (SUVmax 4.1) and no other tumor manifestation. The case was evaluated at the multidisciplinary thoracic‐tumorboard for resection. Given the unclear metabolic behavior of the large mass and in order to reduce the risk of pneumonitis, the patient underwent a left upper‐lobe resection. The histopathologic analysis showed a necrotic mass with no vital tumor cells, resulting in a ypT0 ypN0 stage, and an immune infiltration. Based on these data, we assume that under immunotherapy an immune reaction occurred leading to the pathological findings as well as the still ongoing complete remission from disease 31 months after diagnosis. The CheckMate 156 showed no efficacy of Ipilimumab alone when added to chemotherapy of extensive SCLC. Based on the CheckMate 012 and 032, with improved efficacy of the combination nivolumab and ipilimumab compared to monotherapy, the STIMULI trial was amended to the combination of nivolumab and Ipilimumab after chemo‐radiation. This is the first report of a complete pathological response after adjuvant ipilimumab for limited disease SCLC. This case shows moreover the potential of a multidisciplinary approach in this setting.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01914772/full} -} - - -Record #75 of 538 -@article{Quoix17, -author = {Quoix, E}, -title = {Lung cancer vaccines: an update}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {1}, -pages = {S87‐S90}, -year = {2017}, -accession_number = {EMBASE 615338741}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Adjuvant chemotherapy; Asian; Bacterium culture; Cancer immunotherapy; Cancer patient; Clinical trial; Controlled clinical trial; Controlled study; Disease free interval; Disease free survival; Drug combination; Drug therapy; Epithelium cell; Exploratory research; Feasibility study; Female; Gene amplification; Gene mutation; Gene overexpression; Gene silencing; Human; Human cell; Human immunodeficiency virus infection; Immunological tolerance; Induction chemotherapy; Infusion; Innate immunity; Lung cancer cell line; Maintenance therapy; Major clinical study; Male; Median survival time; Melanoma; Molecularly targeted therapy; Multivariate analysis; Natural killer cell; Neoadjuvant therapy; Nonhuman; Osteosarcoma; Overall survival; Phase 2 clinical trial; Phase 3 clinical trial; Placenta; Post hoc analysis; Prognosis; Radiotherapy; Randomization; Randomized controlled trial; Relapse; Remission; Safety; Skull irradiation; Soft tissue sarcoma; Statistical significance; Surgery; Survival rate; Suspension; Systemic therapy; T lymphocyte; Testis; Tumor associated leukocyte; Vaccinia virus; Virus strain}, -abstract = {Treatment of small‐cell lung cancer (SCLC) has not been modified since decades: and consists in a chemotherapy (CT) with platin+etoposide+/‐concurrent radiotherapy (RT) and prophylactic cranial irradiation in case of a (near)complete response to therapy. Non‐small cell lung cancer (NSCLC) represents 85% of all lung cancers and around 50% are metastatic at presentation. Systemic treatment (platin‐based doublets) has been implemented for stage IV NSCLC but also for locally advanced and early stages as a (neo)adjuvant therapy to surgery or RT. By the end of the XXth century, a plateau has been reached with CT in stage IV disease with similar results whatever the drug used in conjunction with platin‐salt. Since the beginning of the XXIst century there have been tremendous innovations in the systemic treatment of NSCLC. First, adjunction of bevacizumab to CT for stage IV non‐squamous cell carcinoma and the use of maintenance therapy have led to an improvement in median survival time (MST) exceeding now one year. Second, targeted therapies proved to be of major interest for patients with EGFR activating mutations leading to a MST>2 years. Other targets of interest have been found such as ALK and ROS1 translocations, V600EBRAF mutations leading to prolonged survival with appropriate treatments. Third, immunotherapy represents now an exciting approach especially for those patients without targetable mutations/translocations. Lung cancer has long been considered as a poor candidate for immunotherapy because of low content of tumor‐infiltrating lymphocytes (TIL) compared to other tumors. On the other hand, in case of the presence of TIL the prognosis is better.1 The fact that incidence of lung cancer is especially high in patients who were transplanted2 or in patients with HIV infection3 is against the assumption of lung cancer being non immunogenic. There are two types of immunotherapy : the immune checkpoint blockers which aim at enhancing a T‐cell response directed against tumoral cells and abrogate the immune tolerance and the therapeutic vaccines designed to induce or amplify an immune response directed against tumor‐associated antigens (TAA). The immune checkpoint blockers in current development are anti CTLA4 monoclonal antibodies (ipilimumab), first used in the treatment of melanoma and now investigated in NSCLC and SCLC, anti PD1 (nivolumab, pembrolizumab) or anti PDL1 (avelumab, atezolizumab). All these molecules are now either at an advanced stage of development or already authorized.4 Therapeutic vaccines have already a long story beginning with Coley toxins at the end of the nineteenth century.5 The Coley's toxins, (cultures of streptococci) were infused in patients with bone and soft tissue sarcomas and some impressive regressions were observed. The hypothesis was that the immune reaction provoked by the infusion of the “toxins” present in the infectious material was able to destroy the tumoral cells. However, due to the reluctance of doctors to administer dangerous bacterial culture and the appearance of novel treatments of cancer (CT and RT), the Coley's toxin approach has been abandoned although numerous articles were devoted to this subject.6 Nonspecific vaccines using for example BCG to stimulate innate immunity have been disappointing as well in SCLC7,8 and NSCLC.9 Specific immunotherapy aims at the stimulation of adaptive immunity against the vaccine components and thus induces or amplifies an immune response against TAA. These vaccines are peptides (Tecemotide, MAGE‐A3), cellular vaccines (Belagenpumatucel), or vaccines using viral vector (TG4010). Tecemotide and TG4010 are a MUC1 antigen‐specific cancer immunotherapy. MUC1 is expressed at the apical surface of mucin‐secreting normal epithelial cells of various tissues and can be overexpressed and aberrantly glycosylated in some tumors and thus is an attractive target for immunotherapy. Tecemotide is a liposomal vaccine. In a randomized phase II trial,10 171 NSCLC patients who were not progressing after induction CT or CT‐RT received subcutaneous tecemotide plus best supportive care (BSC) or BSC alone as maintenance therapy. Median survival time (MST) was longer in patients receiving tecemotide (17.2 vs. 13.0 months) but this did not reach statistical significance. As in a post hoc analysis the benefit appeared to be more important for patients with stage IIIB disease, it was decided to perform a phase III study in locally advanced NSCLC11,12 comparing in nonprogressing patients after CT with platin‐based doublet and RT, tecemotide versus placebo. MST was 25.8 months with tecemotide versus 22.4 months with placebo (HR 0.89, 95%CI 0.77‐1.03, p=0.111). In the concurrent CT‐RT subgroup, there was a significant survival benefit in favor of tecemotide whereas in the sequential CT‐RT subgroup, survival did not differ between the two arms. A similar study13 was initiated in Asian people. This trial was prematurely terminated as the sponsor decided to discontinue program with tecemotide in NSCLC MAGE‐A3 is an antigen expressed in 76% of melanoma and in 35% of NSCLC. It is absent from normal tissues except for testis and placenta. This vaccine has been investigated in early stage of NSCLC as an adjuvant treatment. A randomized phase II study14 compared the MAGE‐3A vaccine to a placebo in 182 patients operated of a stage IB or II NSCLC with their tumor expressing MAGE‐A3 antigen. The randomization was on a 2:1 basis. The main objective was to compare the Disease Free Interval (DFI) defined as the time from resection to the date of recurrence (any type) or second primary lung neoplasm. Although there was a trend toward a numerically longer DFI in the MAGE‐A3 vaccine group, the main objective was not met. Nevertheless, even if these trends were by far not significant, the results appear promising to the sponsors and a phase III trial was launched (MAGRIT trial) with the same scheme.15 Unfortunately, the biggest trial ever performed with the inclusion of 2312 NSCLC patients is negative regarding as well the primary objective: disease‐ free survival (DFS) but also the secondary objective, DFS in the group of patients not receiving adjuvant chemotherapy or other subgroups. Belagenpumatucel‐L is a vaccine comprising 4 tranforming growth factor‐b2‐ antisense gene‐modified irradiated allogeneic NSCLC cell lines. A randomized phase III trial16 comparing this vaccine to a placebo was performed after platinumbased CT for stage III/IV disease in non‐progressing patients. This trial was negative with no difference in overall survival and in PFS. However, in a prespecified multivariate analysis, there was an improved survival for patients who were randomized within 12 weeks after CT and for patients who received prior radiation therapy. TG4010 is a suspension of a recombinant modified vaccinia virus strain Ankara coding for the MUC1 TAA and IL2. Feasibility of either upfront combination of TG4010 with cisplatine‐vinorelbine or TG4010 alone until progression has been demonstrated in a phase II study.17 Sixty‐five patients were randomized. Response rate was 30 % in the combined upfront schedule; MST was 12.7 months and one‐year survival rate 53%. Taking into account these results, a phase II randomized study18 comparing CT with cisplatin and gemcitabine to the same CT + TG4010 was performed. One hundred and forty eight patients with stage IIIB or IV disease were included. The primary endpoint was 6‐month PFS with the hypothesis that it will be at least 40% in the combined arm. This objective was met with a 6‐months PFS of 43% compared to 35.1% in the CT alone arm. There was a non‐significant trend toward a higher response rate and a longer time to progression in the combined arm. An exploratory analysis of the subgroups defined by the level of activated NK cells (CD16+CD56+CD69+lymphocytes or TrPAL) shows that a better outcome was observed for those patients with normal level of TrPAL and that the vaccine might be deleterious for those with high level of TrPAL. A phase IIB was then performed to confirm the role of the level of TrPAL.19 222 patients were randomly allocated to CT+TG4010 or CT+placebo. Median PFS was 5.9 months in the TG4010 group versus 5.1 months in the placebo group (HR 0.74, 95%CI 0.55‐0.98, p= 0.019). In patients with TrPAL values less or equal ULN, the HR for PFS was 0.75 (95%CI 0.51‐1.03) with a posterior probability of HR being <1 of 98.4% and thus the primary endpoint was met. In patients with high level of TrPAL, there was no deleterious effect but no benefit as the HR for PFS was 0.77 (95%CI 0.42‐1.40). As a conclusion, all studies with vaccines have been quite disappointing. To the best of my knowledge, the only vaccine still under investigation remains TG4010, but phase III trial is not implemented at this time. In each vaccine study some efficacy has been observed in subgroups of NSCLC patients but mostly in post hoc analyses. All vaccine studies have shown that there are no safety problems. The fact that nowadays, considerable interest has been developed toward checkpoint inhibitors, probably explains the disaffection toward vaccines. Hopefully it will be only transient and the already long story of therapeutic vaccines will continue.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01733871/full} -} - - -Record #76 of 538 -@article{Wu23, -author = {Wu, C, Zhang, Y, Zhang, H, and Liu, W}, -title = {Efficacy and safety of anlotinib combined with docetaxel in second-line treatment of extensive-stage small cell lung cancer}, -journal = {Chinese journal of cancer prevention and treatment}, -volume = {30}, -number = {6}, -pages = {368‐374}, -year = {2023}, -accession_number = {EMBASE 2026789742}, -publication type = {Journal article}, -keywords = {*cancer combination chemotherapy; *second‐line treatment; *small cell lung cancer /drug therapy; Anorexia /side effect; Article; Brain metastasis /radiotherapy; Cancer control; Cancer growth; Cancer immunotherapy; Cancer patient; Cancer prognosis; Cancer recurrence; Cancer staging; Cancer survival; Chemotherapy induced nausea and vomiting /side effect; Controlled study; Drug efficacy; Drug safety; Extensive stage small cell lung cancer /drug therapy; Fatigue /side effect; First‐line treatment; Follow up; Hand foot syndrome /side effect; Human; Hypertension /side effect; Hypertriglyceridemia /side effect; Hypothyroidism /side effect; Leukopenia /side effect; Major clinical study; Median survival time; Microcapsule; Neutropenia /side effect; Overall response rate; Overall survival; Progression free survival; Whole brain radiotherapy}, -abstract = {Objective To investigate the efficacy and safety of anlotinib combined with docetaxel in the second‐line treatment of extensive‐stage small cell lung cancer (ES‐SCLC). Methods A total of 117 patients with ES‐SCLC who progressed or relapsed after first‐line EP±immunization regimen were enrolled in Fuyang People's Hospital (40 cases), Fuyang Second People's Hospital (37 cases) and Taihe Hospital of Traditional Chinese Medicine (40 cases) from 2020‐01‐01 to 2022‐03‐31. They were randomly divided into observation group (59 cases) and control group (58 cases). Observation group:patients were given anlotinib hydrochloride capsule (12 mg orally, once a day, 2 weeks of medication followed by suspension for 1 week, every 21 days for 1 cycle) combined with docetaxel (75 mg/m2, intravenous infusion 1 h,d1,every 21 days for 1 cycle). Control group: Patients were given docetaxel (75 mg/m2,1 h intravenous infusion, d1, every 21 days for 1 cycle). The short‐term efficacy, progression‐free survival(PFS), overall survival (OS), and adverse reactions of the two groups were observed. The effect of different prognostic factors on the survival of patients was evaluated. Results The median follow‐up time was 12.5 months until November 1, 2022. The objective response rate(ORR) of the observation group and the control group was 61. 0 % (36/59) and 25. 9 % (15/58), respectively. The disease control rate(DCR) was 91. 5% (54/59) and 77. 6 % (45/58), respectively, with statistical significance (χ2 = 14.700, P<0. 001; χ2 = 4. 366, P=0. 037). Median PFS were 6.1 and 4.2 months, and median OS were 9. 2 and 6. 7 months, respectively, the differences were statistically significant (χ2=47. 331, P<0. 001; χ2=31. 101, P<0. 001). Univariate analysis showed that first‐line immunotherapy could prolong PFS and OS in observation group (P<0. 001), ECOG score =1 and brain metastasis were associated with shorter PFS and OS (P<0. 001). Subgroup survival analysis showed that in patients with BMS, median PFS(4. 9 months vs 3. 0 months, P<0. 002) and median OS(8. 2 months vs 3. 7 months,P<0. 001) after whole brain radiotherapy in the observation group were both longer than those in the control group. Common adverse reactions in the two groups were fatigue, anorexia, nausea/vomiting, leukopenia, neutropenia, etc. Hand‐foot syndrome, hypothyroidism and hypertriglyceridemia in the observation group were more common in the control group, with no statistical significance (P>0. 05). The incidence of hypertension in the observation group was higher than that in the control group, with statistical significance (P<0. 05). The occurrence of adverse reactions was mainly Grade 1 to Grade 2 in the two groups, with low incidence of Grade 3. No Grade 4 adverse reactions or treatment‐related death was observed, which could be controlled by symptomatic treatment or anrotinib reduction. Conclusion Anlotinib combined with docetaxel can be used as a safe and effective second‐line treatment option for patients with ES‐SCLC, and has a trend of improving prognosis. It is worth expanding the sample size to continue clinical research.}, -DOI = {10.16073/j.cnki.cjcpt.2023.06.08}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02623717/full} -} - - -Record #77 of 538 -@article{Doyen22, -author = {Doyen, J, Besse, B, Texier, M, Bonnet, N, and Levy, A}, -title = {PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial}, -journal = {Clinical lung cancer}, -volume = {23}, -number = {3}, -pages = {e252‐e256}, -year = {2022}, -accession_number = {PUBMED 34810130}, -publication type = {Journal article}, -keywords = {Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; Carcinoma, Non‐Small‐Cell Lung [drug therapy]; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms [drug therapy]; Lung [pathology]; Prospective Studies; Quality of Life}, -abstract = {Advanced non‐small cell lung cancer (NSCLC) remains a high unmet medical need. The first line standard‐of‐care therapy comprises concurrent chemotherapy‐immunotherapy with pembrolizumab. Concurrent irradiation with pembrolizumab has been shown to significantly improve survival benefit compared with immunotherapy alone in a pooled analysis of 2 randomized phase 2 trials. We present the rationale and study design of the "PD‐1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non‐small cell lung cAncer" (NIRVANA‐Lung) trial (ClinicalTrials.gov identifier, NCT03774732). This study is a national multicenter 1:1 randomized phase III trial testing in 460 patients, the addition of multisite radiotherapy in advanced NSCLC treated with standard immune checkpoint inhibitors (pembrolizumab)‐chemotherapy in first line. The primary objective of the trial is to compare the overall survival between the 2 arms at year 1 of the study. The secondary objective is to compare the progression‐free survival and cancer‐specific survival at year 1 and 2, as well as to determine quality of life, local and distant control in irradiated and nonirradiated sites at 6 months and year 1.}, -DOI = {10.1016/j.cllc.2021.10.008}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02398057/full} -} - - -Record #78 of 538 -@article{Horn16, -author = {Horn, L, Reck, M, Gettinger, SN, Spigel, DR, Antonia, SJ, Rupnow, BA, Pieters, A, Selvaggi, G, Fairchild, JP, and Peters, S}, -title = {CheckMate 331: an open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC)}, -journal = {Journal of clinical oncology}, -volume = {34}, -year = {2016}, -accession_number = {EMBASE 611756189}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *drug therapy; *small cell lung cancer; Adult; Adverse drug reaction; Antineoplastic activity; Brain metastasis; Clinical trial; Controlled clinical trial; Controlled study; Drug resistance; Gene expression; Human; Japan; Major clinical study; Monotherapy; Overall survival; Pharmacokinetics; Phase 1 clinical trial; Phase 2 clinical trial; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Relapse; Safety}, -abstract = {Background: Overall survival (OS) remains poor in pts with advanced SCLC, and treatment options are limited for pts who relapse after first‐line PT‐DC. Nivolumab, a fully human IgG4 programmed death‐1 (PD‐1) immune checkpoint inhibitor, has demonstrated superior survival and favorable safety over docetaxel in two phase III trials in previously treated advanced non‐small cell lung cancer (NSCLC). These results led to the approval of nivolumab in the US for previously treated metastatic NSCLC and in the EU for previously treated squamous (SQ) NSCLC. In a phase I/II trial (CheckMate 032) in pts with advanced/metastatic solid tumors, nivolumab monotherapy showed antitumor activity with durable tumor responses in pts with SCLC whose disease progressed after ≥1 prior therapy. In this study, responses were observed regardless of programmed death ligand‐1 (PD‐L1) expression or platinum sensitivity/resistance. Adverse event profiles of nivolumab were manageable and favorable compared to safety profiles of historical topotecan or amrubicin data. These encouraging data have led to a phase III trial, CheckMate 331, designed to evaluate nivolumab monotherapy versus chemotherapy in pts with relapsed SCLC. Methods: Adult pts with limited or extensive disease SCLC, disease progression or recurrence after first‐line PT‐DC or chemoradiation therapy, and ECOG performance status 0‐1 are eligible. Pts with symptomatic and active brain metastases are ineligible. The primary endpoint is OS. Secondary endpoints include progression‐free survival and objective response rate. An estimated 480 pts will be enrolled and randomized 1:1 to nivolumab or chemotherapy (topotecan in the US or EU, and topotecan or amrubicin in Japan).}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01718426/full} -} - - -Record #79 of 538 -@article{NCT0526948522, -author = {NCT05269485,}, -title = {Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer}, -journal = {https://clinicaltrials.gov/show/NCT05269485}, -year = {2022}, -accession_number = {CTgov NCT05269485}, -publication type = {Trial registry record}, -keywords = {Carcinoma, Non‐Small‐Cell Lung; Lung Neoplasms}, -abstract = {Trial title: Hypofraction radiotherapy followed by immune checkpoint inhibitors for locally advanced non‐small cell lung cancer: A phase I/II clinical trial. Trial objective: To explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors for stage III locally advanced non‐small cell lung cancer. Trial Design: To enroll 36 patients diagnosed with stage III locally advanced non‐small cell lung cancer to receive hypofraction radiotherapy (18 patients receiving high dose of 60‐68 (Gray, Gy) /15‐17 (fraction, f) and 18 patients receiving low dose of 48Gy/12f) followed by 1‐year maintenance of immune checkpoint inhibitors. Inclusion Criteria: a. 18‐70 years old; b. Eastern Cooperative Oncology Group (ECOG) 0‐1; c. non‐small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large‐cell carcinoma; d. wild‐type of driven genes; e. stage III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and Positron Emission Tomography (PET‐CT); f. surgically unresectable or deny of surgery; g. signature of inform consent. Exclusion Criteria: a. younger than 18 years old or older than 70 years old; b. ECOG>1; c. small‐cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large‐cell neuroendocrine carcinoma; d. mutant type of driven genes; e. non stage III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET‐CT; f. surgically resectable; g. no signature of inform consent. Staging Examination before Radiotherapy: a. ECOG scoring. b. Cranial contrast MRI and PET‐CT, or cranial contrast MRI (preferred), chest contrast CT, abdominal ultrasonography and bone scan. c. Bronchoscopy for centrally‐located lung cancer. d. Staging examination is mandatory after inductive chemotherapy & chemotherapy with immunotherapy. e. Pulmonary function test. Inductive therapy before radiotherapy: Chemotherapy or chemotherapy combined with immunotherapy is allowed as inductive therapy. Detailed regimen could refer to NCCN guidelines. Tyrosine kinase inhibitors are not allowed as inductive therapy. Randomization: Patients would be randomly assigned to high dose group and low dose group using random number table method. Radiotherapy CT simulation: 4‐Dimensional CT (4D‐CT) with intravenous contrast is recommended for simulation. Scan thickness should be less than 5 mm. Thermal mask or vacuum bag is recommended. Target Delineation: Considering hypofraction and involved field irradiation (IFI), only Internal Tumor Volume (ITV) should be delineated without the need to delineate Clinical Tumor Volume (CTV). Delineation of ITV: ITV should include pulmonary gross tumor and metastatic mediastinal lymph nodes. PET‐CT registration with simulation CT is recommended for patients with obstructive atelectasis. For patients with suspected mediastinal lymph nodes, Endobronchial Ultrasound‐guided Transbronchial Needle Aspiration (EBUS‐TBNA) is recommended. Production of Planning Tumor Volume (PTV): Low Dose Hypofraction Arm (48Gy/12f) PTV: PTV is produced by a margin of 5 mm added to ITV. Modification of PTV is suggested to respect anatomic boundary. High Dose Hypofraction Arm (60‐68Gy/15‐17f) PTV: Planning Tumor Volume (PTV) is produced by a margin of 5 mm added to ITV. Modification of PTV is suggested to respect anatomic boundary. For patients with ITV abutting esophagus, the technique of Esophagus‐Sparing Simultaneous Integrated Boost (ES‐SIB) should be utilized. PTV should be modified not to cover esophagus to ensure that the maximum dose to esophagus should be ≤ 45Gy. The dose to PTV in adjacent to esophagus could be compromised (D99% of PTV should be ≥ 51Gy). Dosimetric Limitation: 95% prescription dose should cover 100% PTV and 95% PTV should receive 100% prescription dose. Total Lung: V20<25%, Dmean<13Gy, V5<50%. Spinal Cord: Dmax<40Gy. Heart: V30<40%, Dmean<25Gy. Treatment Implementation: Radiotherapy is implemented every day. Cone‐beam CT should utilized every day to minimize set‐up error. Concurrent Chemotherapy: If patients have received over 4 cycles of inductive chemotherapy with or without immunotherapy, no concurrent chemotherapy is needed. If patients have received less than 4 cycles of inductive chemotherapy with or without immunotherapy, concurrent chemotherapy is needed to ensure 4 cycles of chemotherapy. Adenocarcinoma: Pemetrexed combined with platinum is recommended. Squamous‐cell lung cancer: Etoposide combined with platinum is recommended. One month after completion of radiotherapy, chest CT and abdominal ultrasonography should be undertaken. After exclusion of disease progression and grade 2 or more radiation‐induced pneumonitis, consolidative immunotherapy should be started. Durvalumab maintenance for one year is recommended. Follow‐up: Patients should be follow‐up every three months right after the completion of radiotherapy to 3 years after radiotherapy. Then follow‐up every half year is allowed to 5 years after radiotherapy. After 5 years, follow‐up every year is appropriate. In follow‐up, chest CT and abdominal ultrasonography should be implemented. Cranial MRI should be performed every half year for patients with adenocarcinoma. Bone scan should be undertaken every year for all patients. Primary Endpoint: Rate of radiation‐induced pneumonitis, esophagitis, myelosuppression (CTCAE V4.0). Secondary Endpoint: 1‐year local‐regional control rate, 1‐year progression‐free survival rate, 1‐year overall survival rate (RECIST v1.1).}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02382251/full} -} - - -Record #80 of 538 -@article{Shaverdian17, -author = {Shaverdian, N, Lisberg, AE, Bornazyan, K, Veruttipong, D, Goldman, JW, Formenti, SC, Garon, EB, and Lee, P}, -title = {Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial}, -journal = {The lancet. Oncology}, -volume = {18}, -number = {7}, -pages = {895‐903}, -year = {2017}, -accession_number = {EMBASE 616453405, PUBMED 28551359}, -publication type = {Journal article}, -keywords = {*cancer radiotherapy; *lung toxicity/si [Side Effect]; *non small cell lung cancer/dt [Drug Therapy]; *non small cell lung cancer/rt [Radiotherapy]; *pembrolizumab/ae [Adverse Drug Reaction]; *pembrolizumab/ct [Clinical Trial]; *pembrolizumab/dt [Drug Therapy]; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized [adverse effects, *therapeutic use]; Antineoplastic Agents [adverse effects, *therapeutic use]; Article; Cancer chemotherapy; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [*drug therapy, radiotherapy, secondary]; Chemoradiotherapy; Combined Modality Therapy; Controlled clinical trial; Controlled study; Disease severity; Disease‐Free Survival; Drug efficacy; Drug safety; Drug withdrawal; Female; Follow up; Human; Humans; Lung Diseases [*etiology]; Lung Neoplasms [*drug therapy, pathology, radiotherapy]; Lung toxicity/si [Side Effect]; Major clinical study; Male; Middle Aged; Multicenter study; Multiple cycle treatment; Non small cell lung cancer/dt [Drug Therapy]; Overall survival; Phase 1 clinical trial; Priority journal; Progression free survival; Radiotherapy [adverse effects]; Retreatment; Survival Rate; Survival time; Treatment response; United States}, -abstract = {Background Preclinical studies have found radiotherapy enhances antitumour immune responses. We aimed to assess disease control and pulmonary toxicity in patients who previously received radiotherapy for non‐small‐cell lung cancer (NSCLC) before receiving pembrolizumab. Methods We assessed patients with advanced NSCLC treated on the phase 1 KEYNOTE‐001 trial at a single institution (University of California, Los Angeles, CA, USA). Patients were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status of 1 or less, had adequate organ function, and no history of pneumonitis. Patients received pembrolizumab at a dose of either 2 mg/kg of bodyweight or 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks, until disease progression, unacceptable toxicity, or other protocol‐defined reasons for discontinuation. Disease response and pulmonary toxicity were prospectively assessed by Immune‐related Response Criteria and Common Terminology Criteria for Adverse Events version 4.0. The primary objective of the KEYNOTE‐001 trial was to assess the safety, side‐effect profile, and antitumour activity of pembrolizumab. For our secondary analysis, patients were divided into subgroups to compare patients who previously received radiotherapy with patients who had not. Our primary objective was to determine whether previous radiotherapy affected progression‐free survival, overall survival, and pulmonary toxicity in the intention‐to‐treat population. The KEYNOTE‐001 trial was registered with ClinicalTrials.gov, number NCT01295827. Findings Between May 22, 2012, and July 11, 2014, 98 patients were enrolled and received their first cycle of pembrolizumab. One patient was lost to follow‐up. 42 (43%) of 97 patients had previously received any radiotherapy for the treatment of NSCLC before the first cycle of pembrolizumab. 38 (39%) of 97 patients received extracranial radiotherapy and 24 (25%) of 97 patients received thoracic radiotherapy. Median follow‐up for surviving patients was 32·5 months (IQR 29·8–34·1). Progression‐free survival with pembrolizumab was significantly longer in patients who previously received any radiotherapy than in patients without previous radiotherapy (hazard ratio [HR] 0·56 [95% CI 0·34–0·91], p=0·019; median progression‐free survival 4·4 months [95% CI 2·1–8·6] vs 2·1 months [1·6–2·3]) and for patients who previously received extracranial radiotherapy compared with those without previous extracranial radiotherapy (HR 0·50 [0·30–0·84], p=0·0084; median progression‐free survival 6·3 months [95% CI 2·1–10·4] vs 2·0 months [1·8–2·1]). Overall survival with pembrolizumab was significantly longer in patients who previously received any radiotherapy than in patients without previous radiotherapy (HR 0·58 [95% CI 0·36–0·94], p=0·026; median overall survival 10·7 months [95% CI 6·5–18·9] vs 5·3 months [2·7–7·7]) and for patients who previously received extracranial radiotherapy compared with those without previous extracranial radiotherapy (0·59 [95% CI 0·36–0·96], p=0·034; median overall survival 11·6 months [95% CI 6·5–20·5] vs 5·3 months [3·0–8·5]). 15 (63%) of 24 patients who had previously received thoracic radiotherapy had any recorded pulmonary toxicity versus 29 (40%) of 73 patients with no previous thoracic radiotherapy. Three (13%) patients with previous thoracic radiotherapy had treatment‐related pulmonary toxicity compared with one (1%) of those without; frequency of grade 3 or worse treatment‐related pulmonary toxicities was similar (one patient in each group). Interpretation Our data suggest that previous treatment with radiotherapy in patients with advanced NSCLC results in longer progression‐free survival and overall survival with pembrolizumab treatment than that seen in patients who did not have previous radiotherapy, with an acceptable safety profile. Further clinical trials investigating this combination are needed to determine the optimal treatment strategy for patients with advanced NSCLC. Funding US National Institutes of Health.}, -DOI = {10.1016/S1470-2045(17)30380-7}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01396705/full} -} - - -Record #81 of 538 -@article{Rajappa19, -author = {Rajappa, S, Sharma, S, and Prasad, K}, -title = {Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: treatment Strategies to Improve Patient Outcomes}, -journal = {Advances in therapy}, -volume = {36}, -number = {3}, -pages = {563‐578}, -year = {2019}, -accession_number = {EMBASE 626253110, PUBMED 30693419}, -publication type = {Journal article}, -keywords = {*advanced cancer /disease management /radiotherapy; *non small cell lung cancer /disease management /drug therapy /radiotherapy; Abscopal effect; Antibodies, Monoclonal [*therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Antineoplastic activity; Cancer adjuvant therapy; Cancer growth; Cancer immunotherapy; Cancer radiotherapy; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [pathology, *therapy]; Chemoradiotherapy; Chemoradiotherapy [*methods]; Clinical practice; Colitis /side effect; Diarrhea /side effect; Drug safety; Female; Gold standard; Health care need; Health care quality; Human; Humans; Immunotherapy [methods]; Induction chemotherapy; Lung Neoplasms [pathology, *therapy]; Lung metastasis /drug therapy; Male; Maximum tolerated dose; Middle Aged; Monotherapy; Neoadjuvant chemotherapy; Neoplasm Staging; Overall survival; Pneumonia /side effect; Progression free survival; Quality of life; Radiation Dosage; Radiation dose; Radiation pneumonia /side effect; Review; Small cell lung cancer /drug therapy; Survival Analysis; Transitional cell carcinoma /drug therapy; Treatment failure; Treatment outcome}, -abstract = {Stage III locally advanced non‐small cell lung cancer (LA NSCLC) comprises the most heterogeneous group of patients, accounts for one‐third of patients with lung cancer, and is unresectable at presentation. Multiple treatment approaches have evolved over the past few decades focusing on timing of chemoradiation (concurrent vs. sequential) and sequencing of therapy (induction vs. consolidation). Concurrent chemoradiation (CCRT) emerged as the standard of care for the majority of the patients worldwide. Despite improvements in median and overall survival (OS) using the concurrent approach, the rate of distant failure remains high. Consolidation with chemotherapy or targeted agents, adding more radiation dose, or induction chemotherapy did not improve OS. With continued research on defining optimal radiation doses and schedules and integrating novel systemic agents, immunotherapy consolidation has renewed optimism. Synergistic use of radiation and immunotherapy can prevent micrometastatic disease and reduce local failure and may have an abscopal effect in addition to survival benefits. The PACIFIC study reported an absolute progression‐free survival benefit of 11.2 months with durvalumab consolidation after standard CCRT compared with placebo. The OS data with durvalumab consolidation are encouraging. Durvalumab is the only approved immunotherapy for unresectable stage III LA NSCLC. Improved survival confirms the definitive role of durvalumab as an effective adjuvant therapy after CCRT with no new safety signals. However, the potential mechanisms driving interaction between immunotherapy and chemoradiotherapy require definitive investigation. These mechanisms may help define the timing of immunotherapy initiation as neoadjuvant, adjuvant, or consolidation and maintenance therapy after progression. FUNDING: AstraZeneca Pharma India Limited.}, -DOI = {10.1007/s12325-019-0876-4}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01966832/full} -} - - -Record #82 of 538 -@article{Lew23, -author = {Lew, A, Berghmans, T, Andratschke, N, Dempsey, C, Flackett, L, Leonetti, G, Koller, M, and Faivre-Finn, C}, -title = {174TiP PRIMALung (EORTC-1901): prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small cell lung cancer patients}, -journal = {Journal of thoracic oncology}, -volume = {18}, -number = {4}, -pages = {S136}, -year = {2023}, -accession_number = {EMBASE 2023625630}, -publication type = {Journal article; Conference proceeding}, -keywords = {*brain metastasis; *cancer patient; *irradiation; *neuroimaging; *nuclear magnetic resonance imaging; *small cell lung cancer; Adult; Austria; Belgium; Cancer chemotherapy; Cancer growth; Cancer staging; Cancer survival; Conference abstract; Controlled study; ECOG Performance Status; Eligibility; Failure free survival; Female; France; Funding; Human; Immunotherapy; Major clinical study; Male; Meningeal metastasis; Multicenter study; Overall survival; Poland; Quality of life; Randomization; Randomized controlled trial; Switzerland}, -abstract = {Background PRIMALung is an EORTC‐sponsored study. Primary objective is to show that overall survival with brain MRI surveillance alone is non‐inferior to brain MRI surveillance combined with PCI in patients with SCLC. PCI is currently SOC in most institutions, but can be associated with neurocognitive toxicity and impact quality of life. 600 patients will be recruited from 50 EORTC centres in 10 countries. This study is currently recruiting and will play an important role in clarifying whether MRI surveillance is a viable strategy in SCLC. Furthermore, it will answer important questions about the role of PCI in the era of immunotherapy, particularly in ES‐SCLC. Trial design Key eligibility: ECOG performance status ≤2 patients with SCLC (Limited or Extensive‐Stage, stage I–IV) who did not progress after (≤16 weeks from day 1 of last cycle of chemotherapy to randomisation) completed standard therapy. Absence of progression, brain metastases or leptomeningeal disease after completing therapy. Trial Interventions: Patients will be randomised 1:1 to receive brain MRI surveillance with or without PCI (25 Gy in 10 fractions). Primary objective ‐ to show that overall survival with brain MRI surveillance alone is non‐inferior to brain MRI surveillance combined with PCI. Secondary objectives ‐cognitive failure‐free survival, quality of life and acute/late toxicities according to CTCAE v5.0. The trial was open to recruitment on 27/10/2022. Three countries open to date (Belgium, Switzerland, UK). Further sites in France, Poland and Austria will be open to recruitment Q1 2023. The first patient has been randomized on the 4th of January 2023. Clinical trial identification NCT04790253. Legal entity responsible for the study EORTC. Funding EORTC Lung Cancer Group, PHRC (France), KCE (Belgium), Swiss Cancer League (Switzerland), AstraZeneca, Ligue contre le cancer (France). Disclosure A. Levy: Financial Interests, Institutional, Funding: AstraZeneca, BeiGene, Roche, Amgen. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/S1556-0864(23)00428-8}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02543502/full} -} - - -Record #83 of 538 -@article{Rudin17, -author = {Rudin, C, Shen, L, and Pietanza, MC}, -title = {Keynote-604: phase 3 randomized, double-blind trial of pembrolizumab/placebo plus etoposide/platinum for extensive stage-SCLC}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {11}, -pages = {S2400}, -year = {2017}, -accession_number = {EMBASE 620148103}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *small cell lung cancer; Adult; Adverse event; Antineoplastic activity; Clinical trial; Controlled study; Diagnosis; Double blind procedure; Drug combination; Drug therapy; Drug withdrawal; Female; Human; Major clinical study; Male; Monotherapy; Nomenclature; Patient‐reported outcome; Phase 1 clinical trial; Phase 3 clinical trial; Randomization; Randomized controlled trial; Response evaluation criteria in solid tumors; Retreatment; Skull irradiation; Systemic therapy; Toxicity; Vascular guide wire}, -abstract = {Background: Therapeutic options for small‐cell lung cancer (SCLC) remain limited, with etoposide/platinum (EP) as the standard first‐line chemotherapy regimen. However, patients with extensive‐stage (ES)‐SCLC experience high relapse rates within months after initial therapy. Pembrolizumab, a humanized monoclonal antibody against PD‐1, has shown antitumor activity as monotherapy in heavily pretreated patients with PD‐L1epositive SCLC in the phase 1b KEYNOTE‐028 study. KEYNOTE‐604 (ClinicalTrials.gov, NCT03066778) evaluates EP plus either pembrolizumab or placebo as first‐line therapy for ES‐SCLC. Method: Not applicable. Result: Not applicable. Conclusion: In this international, double‐blind, phase 3 trial, adults with newly diagnosed ES‐SCLC, ECOG PS ≤1, and no previous systemic therapy for SCLC are randomized 1:1 to receive either EP plus a 200‐mg fixed dose of pembrolizumab intravenously (IV) once every 3 weeks (Q3W) or EP plus placebo IV Q3W. Randomization is stratified by the chosen platinum therapy (carboplatin vs cisplatin), ECOG PS (0 vs 1), and baseline lactate dehydrogenase concentration (≤ upper limit of normal [ULN] vs > ULN). Study treatment includes a total of 4 cycles of EP and 2 years of pembrolizumab/placebo and continues until documented PD, intolerable toxicity, or withdrawal of consent. Patients with a response after 4 cycles of EP plus placebo or pembrolizumab may receive prophylactic cranial irradiation. Patients who complete 2 years of pembrolizumab treatment or stop pembrolizumab for reasons other than PD/intolerability, but subsequently have documented PD confirmed by blinded independent review, may receive an additional 1 year of pembrolizumab provided that no other systemic therapy has been administered. Patients must meet the eligibility criteria for retreatment; patients in the placebo arm are not eligible for treatment with pembrolizumab at the time of PD. Tumor response is assessed every 6 weeks for 48 weeks, and every 9 weeks thereafter by RECIST version 1.1 by blinded independent central review. AEs occurring during treatment and 30 days thereafter (90 days for serious AEs) are graded per Common Terminology Criteria for Adverse Events, version 4.0. Primary endpoints are PFS and OS. Secondary endpoints are ORR, duration of response, safety, and patient‐reported outcomes. Approximately 430 patients will be enrolled.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01451672/full} -} - - -Record #84 of 538 -@article{Ross20, -author = {Ross, HJ, Hu, C, Higgins, KA, Jabbour, SK, Kozono, DE, Owonikoko, TK, Movsas, B, Solberg, T, Xiao, C, Williams, TM, Welsh, JW, Simko, J, Wang, XF, Mohindra, NA, Hsu, C, Stinchcombe, T, and Bradley, J}, -title = {NRG Oncology/Alliance LU005: a phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer}, -journal = {Journal of clinical oncology}, -volume = {38}, -number = {15}, -year = {2020}, -accession_number = {EMBASE 636606343}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *chemoradiotherapy; *small cell lung cancer; Adult; Autoimmune disease; Cancer patient; Cancer survival; Clinical trial; Comorbidity; Conference abstract; Disease control; Drug therapy; Female; Human; Immune‐related gene; Major clinical study; Male; Overall survival; Patient‐reported outcome; Phase 2 clinical trial; Phase 3 clinical trial; Progression free survival; Quality of life; Radiotherapy; Randomized controlled trial; Skull irradiation}, -abstract = {Background: Limited stage small cell lung cancer (LS‐SCLC) is treated with standard of care platinum/etoposide (EP) and thoracic radiation therapy (TRT) with curative intent, however the majority of patients are not cured and median overall survival is approximately 30 months. Addition of atezolizumab to chemotherapy in extensive stage SCLC has improved progression free and overall survival in a non‐curative setting leading to hope that addition of an immune checkpoint inhibitor to standard chemoradiotherapy could benefit LS‐SCLC patients. LU005 is a randomized phase II/III trial of standard concurrent chemoradiation with or without atezolizumab for patients with LSSCLC. Methods: Patients are randomly assigned in a 1:1 ratio to standard EP chemotherapy with concurrent TRT (45 Gy BID or 66 Gy QD) with or without atezolizumab beginning concurrently with TRT, and continued every 3 weeks for up to 12 months. Eligible patients have LS‐SCLC, PS 0‐2, adequate organ function, no concerning comorbidities (including no active autoimmune disease) and are eligible for TRT. Patients are randomized prior to their second cycle of EP and thoracic radiation begins with the second overall cycle of chemotherapy (first cycle of study therapy) in both treatment arms. Prophylactic cranial radiation (PCI) is recommended for patients who respond to treatment. The phase II/III primary endpoints are progression free (PFS) and overall survival (OS) respectively. Secondary endpoints include objective response rates, local and distant disease control, and quality of life/patient reported outcomes assessment. Translational science component includes blood and tissue based immune related assays. This study activated in May 2019. 50 of 506 planned patients have been accrued as of 2/1/2020.}, -DOI = {10.1200/JCO.2020.38.15-suppl.TPS9082}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02348876/full} -} - - -Record #85 of 538 -@article{Yaping24, -author = {Yaping, X, Ni, J, Ren, S, Xu, X, Hu, M, Xu, Q, Chen, Y, and Zhu, Y}, -title = {Preliminary results of a randomized controlled, open-label, multi-center phase II study of camrelizumab combined with chemotherapy followed by concurrent chemoradiotherapy and camrelizumab consolidation therapy versus standard chemoradiotherapy as first-line treatment for limited-disease small cell lung cancer}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644908221}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *first‐line treatment; *preliminary data; *small cell lung cancer; Adult; Adverse drug reaction; Aged; Clinical article; Complication; Conference abstract; Controlled study; Drug combination; Drug therapy; Esophagitis; Female; Follow up; Human; Human tissue; Incidence; Intravenous drug administration; Major clinical study; Male; Multiple cycle treatment; Phase 2 clinical trial; Pneumonia; Progression free survival; Radiotherapy; Randomized controlled trial; Side effect; Skull irradiation; Special situation for pharmacovigilance; Survival rate; Therapy}, -abstract = {Background: Immune checkpoint inhibitors combined with chemotherapy have significant clinical benefits in extensive‐stage small cell lung cancer (SCLC). However, for patients with limited‐disease SCLC (LD‐SCLC), the data on immunotherapy combined with chemoradiotherapy is insufficient. Methods: In this open‐label, multi‐center, phase 2 trial, we randomly 1: 1 assigned patients with previously untreated LD‐SCLC to receive camrelizumab combined with chemotherapy followed by concurrent chemoradiotherapy (CCRT) and camrelizumab consolidation therapy or standard chemoradiotherapy. Patients with ECOG performance status of 0 to 1, and adequate organ function were eligible. For thoracic radiation, 45 Gy in 3 weeks (1.5 Gy, BID) was given on the first day of the third cycle of chemotherapy. An etoposide plus platinumbased regimen was given 4 cycles in total. Patients who had a good response to initial treatment were offered prophylactic cranial irradiation. The primary endpoint was the 1‐year progression‐free survival rate. We assumed that the 1‐year PFS rate in the experimental group was expected to reach 65% compared to chemoradiotherapy alone group 45%, and planned to enroll 112 patients with 56 in each group. Results: Up to date, we have enrolled 40 patients. The median follow‐up was 10.6 months. Safety was evaluated in all treated patients. No Grade 5 adverse event was observed. Grade 3 or 4 treatment‐related adverse events occurred in 58.8% of the patients in the camrelizumab plus chemoradiotherapy and in 52.9% of those in the chemoradiotherapy alone group. The most frequent grade 3 or 4 adverse events were hematologic toxicities (70.6% vs. 58.8%). Acute esophagitis and pneumonitis of grade 3 occurred in both groups were 1/17 (5.9%) and 1/17 (5.9%), respectively. In the experimental group, only one patient was developed grade 3 immune pneumonia 1/17 (5.9%). The 1‐year PFS rate was 54.5% (95% confidence interval [CI] 19.5%‐89.6%) with camrelizumab plus chemoradiotherapy and 44.4% (95% CI 3.9%‐88.0%) with chemoradiotherapy alone. Among the 17 patients who received camrelizumab, the median PFS time was not reached, as compared with 14.35 (95% CI, 8.15‐20.91) months among the 17 patients with chemoradiotherapy alone. Conclusions: In patients with LD‐SCLC, the addition of camrelizumab to chemoradiotherapy did not increase the incidence of adverse events. Camrelizumab plus chemoradiotherapy resulted in an encouraging 1‐year PFS rate. Larger sample sizes and longer follow‐up times are required to validate our preliminary results.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02736125/full} -} - - -Record #86 of 538 -@article{Trédaniel22, -author = {Trédaniel, J, Barlési, F, Le Péchoux, C, Lerouge, D, Pichon, É, Le Moulec, S, Moreau, L, Friard, S, Westeel, V, Petit, L, Carré, O, Guichard, F, Raffy, O, Villa, J, Prévost, A, Langlais, A, Morin, F, Wislez, M, Giraud, P, Zalcman, G, and Mornex, F}, -title = {Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer}, -journal = {Cancer radiotherapie}, -volume = {26}, -number = {5}, -pages = {670‐677}, -year = {2022}, -accession_number = {EMBASE 2017122057, PUBMED 35260342}, -publication type = {Journal article}, -keywords = {*advanced cancer /drug therapy /radiotherapy; *cancer combination chemotherapy; *cancer immunotherapy; *chemoradiotherapy; *induction chemotherapy; *inoperable cancer /drug therapy /radiotherapy; *non small cell lung cancer /drug therapy /radiotherapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; Article; Cancer control; Cancer patient; Cancer recurrence; Cancer survival; Carcinoma, Non‐Small‐Cell Lung; Cetuximab [therapeutic use]; Chemoradiotherapy [adverse effects]; Cisplatin; Cohort analysis; Conformal radiotherapy; Controlled clinical trial; Controlled study; Disease exacerbation; Drug efficacy; Drug safety; Dysphagia /side effect; ECOG Performance Status; Esophagus disease /side effect; Feasibility study; Female; Follow up; Heart volume; Human; Humans; Hypersensitivity /side effect; Intensity modulated radiation therapy; Loading drug dose; Lung Neoplasms; Lung adenocarcinoma /drug therapy /radiotherapy; Lung disease /side effect; Lung toxicity /side effect; Major clinical study; Male; Medication compliance; Multiple cycle treatment; Nausea and vomiting /side effect; Neoplasm Staging; Nephrotoxicity /side effect; Neuropathy /side effect; Neurotoxicity /side effect; Overall survival; Patient compliance; Pemetrexed; Phase 2 clinical trial; Planning target volume; Primary tumor; Progression free survival; Radiation dose fractionation; Radiation induced cancer /side effect; Radiation pneumonia /side effect; Radiation safety; Radiotherapy dosage; Skin toxicity /side effect; Subdural hematoma /side effect; Survival rate; Systemic therapy; Thrombocytopenia /side effect; Treatment refusal; Vitamin supplementation}, -abstract = {Purpose: Roughly 20% of patients with non‐small‐cell lung cancer exhibit locally advanced, unresectable, stage III disease. Concurrent platinum‐based chemoradiotherapy is the backbone treatment, which is followed by maintenance immunotherapy, yet with poor long‐term prognosis. This phase II trial (IFCT‐0803) sought to evaluate whether adding cetuximab to cisplatin and pemetrexed chemoradiotherapy would improve its efficacy in these patients. Materials and methods: Eligible patients received weekly cetuximab (loading dose 400 mg/m2 day 1; subsequent weekly 250 mg/m2 doses until two weeks postradiotherapy). Chemotherapy comprised cisplatin (75 mg/m2) and pemetrexed (500 mg/m2), both delivered on day 1 of a 21‐day cycle of maximally four. Irradiation with maximally 66 Gy started on day 22. Disease control rate at week 16 was the primary endpoint. Results: One hundred and six patients were included (99 eligible patients). Compliance exceeded 95% for day 1 of chemotherapy cycles 1 to 4, with 76% patients receiving the 12 planned cetuximab doses. Maximal grade 3 toxicity occurred in 63% patients, and maximal grade 4 in 9.6%. The primary endpoint involving the first 95 eligible patients comprised two (2.1%) complete responses, 57 (60.0%) partial responses, and 27 (28.4%) stable diseases. This 90.5% disease control rate (95% confidence interval [95% CI]: 84.6%–96.4%) was achieved at week 16. After median 63.0‐month follow‐up, one‐year and two‐year survival rates were 75.8% and 59.5%. Median overall survival was 35.8 months (95% CI: 23.5–NR), and median progression‐free survival 14.4 months (95% CI: 11.2–18.8), with one‐year and two‐year progression‐free survival rates of 57.6% and 34.3%. Conclusion: These survival rates compare favourably with published data, thus justifying further development of cetuximab‐based induction chemoradiotherapy.}, -DOI = {10.1016/j.canrad.2021.12.005}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02471565/full} -} - - -Record #87 of 538 -@article{EUCTR2021-005034-42-FI21, -author = {EUCTR2021-005034-42-FI,}, -title = {Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-005034-42-FI}, -year = {2021}, -accession_number = {ICTRP EUCTR2021‐005034‐42‐FI}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: MK‐7684A Pharmaceutical Form: Solution for infusion INN or Proposed INN: Vibostolimab CAS Number: 2231305‐30‐7 Current Sponsor code: MK‐7684 Other descriptive name: Anti‐TIGIT humanized monoclonal IgG antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ INN or Proposed INN: Pembrolizumab CAS Number: 1374853‐91‐4 Current Sponsor code: MK‐3475 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ Trade Name: TECENTRIQ® Product Name: Atezolizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Atezolizumab CAS Number: 1380723‐44‐3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1200‐ CONDITION: Extensive‐stage small‐cell lung cancer ; MedDRA version: 21.1 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: 1. To compare overall survival for MK‐7684A in combination with etoposide/platinum followed by MK‐7684A to atezolizumab in combination with etoposide/platinum followed by atezolizumab. Primary end point(s): 1. Overall Survival (OS) Secondary Objective: 1. To compare progression‐free survival per RECIST 1.1 by blinded independent central review (BICR) for MK‐7684A plus etoposide/platinum followed by MK‐7684A to atezolizumab plus etoposide/platinum followed by atezolizumab.; 2. To evaluate objective response rate per RECIST 1.1 by BICR for MK‐7684A plus etoposide/platinum followed by MK‐7684A compared to atezolizumab plus etoposide/platinum followed by atezolizumab.; 3. To evaluate duration of response per RECIST 1.1 by BICR for MK‐7684A plus etoposide/platinum followed by MK‐7684A compared to atezolizumab plus etoposide/platinum followed by atezolizumab.; 4. To evaluate safety and tolerability based on proportion of adverse events.; 5. To evaluate change from baseline and time to true deterioration in global health status/quality of life, physical functioning, dyspnea, cough, chest pain for MK‐7684A plus etoposide/platinum followed by MK‐7684A compared to atezolizumab plus etoposide/platinum followed by atezolizumab.; Timepoint(s) of evaluation of this end point: 1. Up to approximately 37 months SECONDARY OUTCOME: Secondary end point(s): 1. Progression‐Free Survival (PFS); 2. Objective Response Rate (ORR); 3. Duration of Response (DOR); 4. Percentage of Participants Who Experienced an Adverse Event (AE); 5. Percentage of Participants Who Discontinued Study Treatment Due to an AE; 6. Change from Baseline in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30); 7. Change from Baseline in Physical Functioning (Items 1‐5) Combined Score on the EORTC QLQ‐C30; 8.Change from Baseline in Dyspnea Score (Item 8) on the EORTC QLQ‐C30; 9. Change from Baseline in Cough Score (Item 31) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ‐LC13); 10. Change from Baseline in Chest Pain Score (Item 40) on the EORTC QLQ‐LC13; 11. Time to True Deterioration (TTD) in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the EORTC QLQ‐C30; 12. TTD in Physical Functioning (Items 1‐5) Combined Score on the EORTC QLQ‐C30; 13. TTD in Dyspnea Score (Item 8) on the EORTC QLQ‐C30; 14. TTD in Cough Score (Item 31) on the EORTC QLQ‐LC13; 15. TTD in Chest Pain Score (Item 40) on the EORTC QLQ‐LC13; Timepoint(s) of evaluation of this end point: 1. Up to approximately 26 months; 2. Up to approximately 37 months; 3. Up to approximately 37 months; 4. Up to approximately 60 months; 5. Up to approximately 60 months; 6. Baseline and up to approximately 37 months; 7. Baseline and up to approximately 37 months; 8. Baseline and up to approximately 37 months; 9. Baseline and up to approximately 37 months; 10. Baseline and up to approximately 37 months; 11. Baseline and up to approximately 37 months; 12. Baseline and up to approximately 37 months; 13. Baseline and up to approximately 37 months; 14. Baseline and up to approximately 37 months; 15. Baseline and up to approximately 37 months INCLUSION CRITERIA: 1. Has histologically or cytologically confirmed diagnosis of ES‐SCLC in need of first‐line therapy. 2. Has ES‐SCLC defined as Stage IV (T any, N any, M1a/b/c) by the American Joint Committee on Cancer, Eighth Edition or T3‐T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. 3. Is male or female, at least 18 years of age at the time of providing documented informed consent. 4. Male participants are eligible to participate if they agree to the following during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention. The length of time required to continue contraception for each study intervention after the last dose of the intervention is as follows: ‐ Etoposide, cisplatin, or carboplatin: 95 days ‐ Blinded study intervention: no contraception measures • Refrain from dona}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02378141/full} -} - - -Record #88 of 538 -@article{NL-OMON5368122, -author = {NL-OMON53681,}, -title = {A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON53681}, -year = {2022}, -accession_number = {ICTRP NL‐OMON53681}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Intervention Group A: ‐ MK‐7684A ‐ 200 mg/200 mg; Q3W; IV infusion; until discontinuation criteria are met ‐ Saline placebo ‐ at Cycle 1 (and Q3W as needed beyond Cycle 1); IV infusion; as needed beyond Cycle 1 ‐ Etoposide ‐ 100 mg (may vary according to supplier/country); Q3W; IV infusion; up to 4 cycles ‐ Cisplatin ‐ 50 mg (may vary according to supplier/country); Q3W; IV infusion; up to 4 cycles OF ‐ Carboplatin ‐ 600 mg (may vary according to supplier/country); Q3W; IV infusion; up to 4 cycles Intervention Group B: ‐ Atezolizumab ‐ 1200 mg; Q3W; IV infusion; until discontinuation criteria are met ‐ Saline placebo ‐ at Cycle 1 (and Q3W as needed beyond Cycle 1); IV infusion; as needed beyond Cycle 1 ‐ Etoposide ‐ 100 mg (may vary according to supplier/country); Q3W; IV infusion; up to 4 cycles ‐ Cisplatin ‐ 50 mg (may vary according to supplier/country); Q3W; IV infusion; up to 4 cycles OF ‐ Carboplatin ‐ 600 mg (may vary according to supplier/country); Q3W; IV infusion; up to 4 cycles CONDITION: ; ES‐SCLC ; small cell lung cancer 10038666 PRIMARY OUTCOME: 1. Overall Survival (OS); SECONDARY OUTCOME: 1. Progression‐Free Survival (PFS) ; 2. Objective Response Rate (ORR) ; 3. Duration of Response (DOR) ; 4. Percentage of Participants Who Experienced an Adverse Event (AE) ; 5. Percentage of Participants Who Discontinued Study Treatment Due to an AE ; 6. Change from Baseline in the Global Health Status/Quality of Life (Items 29 ; and 30) Combined Score on the European Organization for ; Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC ; QLQ‐C30) ; 7. Change from Baseline in Physical Functioning (Items 1‐5) Combined Score on ; the EORTC QLQ‐C30 ; 8.Change from Baseline in Dyspnea Score (Item 8) on the EORTC QLQC30 ; 9. Change from Baseline in Cough Score (Item 31) on the European Organization ; for Research and Treatment of Cancer Quality of Life ; Questionnaire Lung Cancer 13 (EORTC QLQ‐LC13) ; 10. Change from Baseline in Chest Pain Score (Item 40) on the EORTC QLQ‐LC13 ; 11. Time to True Deterioration (TTD) in the Global Health Status/Quality of ; Life (Items 29 and 30) Combined Score on the EORTC QLQ‐C30 ; 12. TTD in Physical Functioning (Items 1‐5) Combined Score on the EORTC QLQ‐C30 ; 13. TTD in Dyspnea Score (Item 8) on the EORTC QLQ‐C30 ; 14. TTD in Cough Score (Item 31) on the EORTC QLQ‐LC13 ; 15. TTD in Chest Pain Score (Item 40) on the EORTC QLQ‐LC13 ; INCLUSION CRITERIA: 1. Has histologically or cytologically confirmed diagnosis of ES‐SCLC in need of first‐line therapy. 2. Has ES‐SCLC defined as Stage IV (T any, N any, M1a/b/c) by the American Joint Committee on Cancer, Eighth Edition or T3‐T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. 3. Is male or female, at least 18 years of age at the time of providing documented informed consent. 4. Male participants are eligible to participate if they agree to the following during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention. The length of time required to continue contraception for each study intervention after the last dose of the intervention is as follows: ‐ Etoposide, cisplatin, or carboplatin: 95 days ‐ Blinded study intervention: no contracept}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02715480/full} -} - - -Record #89 of 538 -@article{Gettinger16, -author = {Gettinger, S, Rizvi, NA, Chow, LQ, Borghaei, H, Brahmer, J, Ready, N, Gerber, DE, Shepherd, FA, Antonia, S, Goldman, JW, Juergens, RA, Laurie, SA, Nathan, FE, Shen, Y, Harbison, CT, and Hellmann, MD}, -title = {Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer}, -journal = {Journal of clinical oncology}, -volume = {34}, -number = {25}, -pages = {2980‐2987}, -year = {2016}, -accession_number = {EMBASE 611817285, PUBMED 27354485}, -publication type = {Journal article}, -keywords = {*advanced cancer/di [Diagnosis]; *advanced cancer/dt [Drug Therapy]; *advanced cancer/rt [Radiotherapy]; *advanced cancer/su [Surgery]; *cancer chemotherapy; *monotherapy; *nivolumab; *nivolumab/ae [Adverse Drug Reaction]; *nivolumab/ct [Clinical Trial]; *nivolumab/dt [Drug Therapy]; *nivolumab/iv [Intravenous Drug Administration]; *nivolumab/pd [Pharmacology]; *non small cell lung cancer; *non small cell lung cancer/di [Diagnosis]; *non small cell lung cancer/dt [Drug Therapy]; *non small cell lung cancer/rt [Radiotherapy]; *non small cell lung cancer/su [Surgery]; Adjuvant therapy; Adult; Advanced cancer/dt [Drug Therapy]; Adverse drug reaction; Aged; Aged, 80 and over; Alanine aminotransferase blood level; Alanine aminotransferase/ec [Endogenous Compound]; Amylase blood level; Amylase/ec [Endogenous Compound]; Antibodies, Monoclonal [adverse effects, *therapeutic use]; Antineoplastic Agents [adverse effects, *therapeutic use]; Antineoplastic activity; Antineoplastic agent/dt [Drug Therapy]; Arthralgia; Arthralgia/si [Side Effect]; Aspartate aminotransferase blood level; Aspartate aminotransferase/ec [Endogenous Compound]; Cancer adjuvant therapy; Cancer growth; Cancer radiotherapy; Cancer staging; Cancer surgery; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [*drug therapy, pathology]; Clinical trial; Cohort Studies; Cohort analysis; Conference paper; Constipation/si [Side Effect]; Controlled clinical trial; Dehydration/si [Side Effect]; Diarrhea; Diarrhea/si [Side Effect]; Drug efficacy; Drug safety; Drug therapy; Drug tolerability; Drug withdrawal; Erlotinib/dt [Drug Therapy]; Exploratory research; Fatigue; Fatigue/si [Side Effect]; Female; Heart failure/si [Side Effect]; Human; Humans; Hyperglycemia/si [Side Effect]; Hyponatremia/si [Side Effect]; Hypothyroidism/si [Side Effect]; Ligand; Lung Neoplasms [*drug therapy, pathology]; Lung infection/si [Side Effect]; Major clinical study; Male; Metastasis/dt [Drug Therapy]; Middle Aged; Nausea; Nausea/si [Side Effect]; Neoplasm Staging; Nivolumab; Non small cell lung cancer/dt [Drug Therapy]; Overall survival; Pharmacokinetics; Phase 1 clinical trial; Pneumonia/si [Side Effect]; Priority journal; Programmed death 1 ligand 1/ec [Endogenous Compound]; Progression free survival; Protein expression; Protein tyrosine kinase inhibitor/dt [Drug Therapy]; Pruritus; Pruritus/si [Side Effect]; Rash; Rash/si [Side Effect]; Remission; Safety; Systemic therapy; Toxicity; Treatment response; Triacylglycerol lipase blood level; Triacylglycerol lipase/ec [Endogenous Compound]; Vomiting/si [Side Effect]}, -abstract = {Purpose Nivolumab, a programmed death‐1 (PD‐1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced non‐small‐cell lung cancer (NSCLC). First‐line monotherapy with nivolumab for advanced NSCLC was evaluated in the phase I, multicohort, Checkmate 012 trial. Methods Fifty‐two patients received nivolumab 3 mg/kg intravenously every 2 weeks until progression or unacceptable toxicity; postprogression treatment was permitted per protocol. The primary objective was to assess safety; secondary objectives included objective response rate (ORR) and 24‐week progression‐free survival (PFS) rate; overall survival (OS) was an exploratory end point. Results Any‐grade treatment‐related adverse events (AEs) occurred in 71% of patients, most commonly: fatigue (29%), rash (19%), nausea (14%), diarrhea (12%), pruritus (12%), and arthralgia (10%). Ten patients (19%) reported grade 3 to 4 treatment‐related AEs; grade 3 rash was the only grade 3 to 4 event occurring in more than one patient (n = 2; 4%). Six patients (12%) discontinued because of a treatment‐related AE. The confirmed ORR was 23% (12 of 52), including four ongoing complete responses. Nine of 12 responses (75%) occurred by first tumor assessment (week 11); eight (67%) were ongoing (range, 5.3+ to 25.8+ months) at the time of data lock. ORR was 28% (nine of 32) in patients with any degree of tumor PD‐ligand 1 expression and 14% (two of 14) in patients with no PD‐ligand 1 expression. Median PFS was 3.6 months, and the 24‐week PFS rate was 41% (95% CI, 27 to 54). Median OS was 19.4 months, and the 1‐year and 18‐month OS rates were 73% (95% CI, 59 to 83) and 57% (95% CI, 42 to 70), respectively. Conclusion First‐line nivolumab monotherapy demonstrated a tolerable safety profile and durable responses in first‐line advanced NSCLC.}, -DOI = {10.1200/JCO.2016.66.9929}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01211438/full} -} - - -Record #90 of 538 -@article{Dempsey23, -author = {Dempsey, C, Flackett, L, Levy, A, and Faivre-Finn, C}, -title = {PRIMALung (EORTC-1901-LCG): prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small-cell lung cancer patients}, -journal = {Lung cancer (Amsterdam, Netherlands)}, -volume = {178}, -pages = {S89}, -year = {2023}, -accession_number = {EMBASE 2023807768}, -publication type = {Journal article; Conference proceeding}, -keywords = {*brain metastasis; *cancer patient; *irradiation; *neuroimaging; *nuclear magnetic resonance imaging; *small cell lung cancer; Adult; Belgium; Cancer chemotherapy; Cancer growth; Cancer staging; Cancer survival; Conference abstract; Controlled study; ECOG Performance Status; Eligibility; Failure free survival; Female; Human; Immunotherapy; Major clinical study; Male; Manager; Meningeal metastasis; Multicenter study; Overall survival; Quality of life; Randomization; Randomized controlled trial; Switzerland}, -abstract = {Introduction: PRIMALung is an EORTC‐sponsored study, endorsed in the UK by Cancer Research UK. Primary objective is to show that overall survival with brain MRI surveillance alone is non‐inferior to brain MRI surveillance combined with PCI in patients with SCLC. PCI is currently SOC in most UK institutions, but can be associated with neurocognitive toxicity and impact quality of life. 600 patients will be recruited from 50 EORTC centres in 10 countries, including 8 UK participating sites aiming to recruit 76 patients. Methods: Key eligibility: Diagnosis of SCLC (Limited or Extensive‐ Stage, stage I‐IV). Standard therapy completed prior to randomisation. Absence of progression, brain metastases or leptomeningeal disease after completing therapy. ≤ 16 weeks from day 1 of last cycle of chemotherapy to randomisation. ECOG performance status ≤ 2. Trial Interventions: Patients will be randomised 1:1 to receive brain MRI surveillance with or without PCI (25Gy in 10 fractions). Primary objective: to show that overall survival with brain MRI surveillance alone is non‐inferior to brain MRI surveillance combined with PCI. Secondary objectives: cognitive failure‐free survival, quality of life and acute/late toxicities according to CTCAE v5.0. Results: Open to recruitment 27/10/2022. 3 countries open to date (Belgium, Switzerland, UK). Conclusion: This study is currently recruiting and will play an important role in clarifying whether MRI surveillance is a viable strategy in SCLC. Furthermore, it will answer important questions about the role of PCI in the era of immunotherapy, particularly in ES‐SCLC. Further information: https://clinicaltrials.gov/ct2/show/NCT04790253 or contact: UK Chief Investigator Corinne Faivre‐Finn (corinne. finn@nhs.net); UK Project Manager Clare Dempsey (clare.dempsey@manchester.ac.uk); EORTC (eortc@eortc.org); Liz Hackett (eortcliaison@nihr.ac.uk) Disclosure: No significant relationships. [Figure presented]}, -DOI = {10.1016/S0169-5002(23)00627-X}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02562301/full} -} - - -Record #91 of 538 -@article{NCT0579884523, -author = {NCT05798845,}, -title = {The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer}, -journal = {https://clinicaltrials.gov/ct2/show/NCT05798845}, -year = {2023}, -accession_number = {CTgov NCT05798845}, -publication type = {Trial registry record}, -keywords = {Carcinoma, Non‐Small‐Cell Lung}, -abstract = {In recent years, the survival rate after diagnosis of non small cell lung cancer (NSCLC) has improved with advances in treatment. In terms of 5‐year average overall survival (OS) by stage at the time of diagnosis, OS decreases significantly from stage IB to IIIA NSCLC, with 68% for stage IB, 53‐60% for stage II, and 36% for stage IIIA. How to optimize the perioperative treatment strategy to reduce postoperative recurrence and prolong the survival of patients has raised great concern in early and mid‐stage NSCLC. Radiotherapy combined with immunotherapy is suggested for advanced NSCLC in preclinical basic studies and recent clinical trials. Stereotactic body radiation therapy (SBRT) at 8 Gy × 3 Fx plays an effective immunoregulated role and can further enhance the antitumor immune response promoted by immune checkpoint inhibitors (ICIs). Although little is known about the optimal SBRT dose and fraction pattern, 6 Gy × 5 Fx or 8‐9 Gy × 3 Fx have shown effectiveness in clinical studies.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02542496/full} -} - - -Record #92 of 538 -@article{Holmes93, -author = {Holmes, EC}, -title = {Postoperative chemotherapy for non-small-cell lung cancer}, -journal = {Chest}, -volume = {103}, -number = {1 Suppl}, -review groups = {HS-PRECNTRL; Lung Cancer; HS-HANDSRCH}, -pages = {30S‐34S}, -year = {1993}, -accession_number = {EMBASE 23019320, PUBMED 8380131}, -publication type = {Journal article}, -keywords = {*cancer adjuvant therapy; *cancer immunotherapy; *cancer radiotherapy; *non small cell lung cancer /drug therapy /radiotherapy /surgery; Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Cancer recurrence; Cancer regression; Cancer staging; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [*drug therapy, surgery]; Chemotherapy, Adjuvant; Cisplatin [administration & dosage]; Clinical trial; Conference paper; Controlled study; Cyclophosphamide [administration & dosage]; Doxorubicin [administration & dosage]; Human; Humans; Immunotherapy; Intrapleural drug administration; Large cell carcinoma /drug therapy /radiotherapy; Lung Neoplasms [*drug therapy, surgery]; Lung adenocarcinoma /drug therapy /radiotherapy; Multimodality cancer therapy; Postoperative period; Priority journal; Radiotherapy; Randomized Controlled Trials as Topic; Randomized controlled trial}, -abstract = {The Lung Cancer Study Group has performed a number of postoperative adjuvant trials in patients with resectable non‐small‐cell lung cancer (NSCLC). Adjuvant cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy was compared with immunotherapy in the treatment of 130 patients with stage II or III adenocarcinoma or large cell undifferentiated carcinoma. Careful intraoperative staging was performed in all patients. Disease‐free interval was significantly prolonged in the chemotherapy group (p=0.032). After 7.5 years of follow‐up, the difference in time to recurrence and cancer deaths remains statistically significant. Another study compared CAP chemotherapy plus radiotherapy with radiotherapy alone in advanced stages II and III resected NSCLC. Again, the chemotherapy arm had significantly increased disease‐free survival. In a third study, patients with high‐risk stage I NSCLC were randomized after surgery to CAP chemotherapy or observation. In this study there was no difference in recurrence‐free survival or overall survival.}, -DOI = {10.1378/chest.103.1_supplement.30s}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00194905/full} -} - - -Record #93 of 538 -@article{Paz-Ares19, -author = {Paz-Ares, L, Chen, Y, Reinmuth, N, Hotta, K, Trukhin, D, Statsenko, G, Hochmair, MJ, Ozguroglu, M, Ji, JH, Voitko, O, Poltoratskiy, A, Ponce, S, Verderame, F, Havel, L, Bondarenko, I, Kazarnowicz, A, Losonczy, G, Conev, NV, Armstrong, J, Byrne, N, Shire, N, Jiang, H, and Goldman, J}, -title = {PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: results from the CASPIAN Study}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S7‐S8}, -year = {2019}, -accession_number = {EMBASE 2003407744}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *cancer survival; *overall survival; *small cell lung cancer; Adult; Blood toxicity; Cancer patient; Clinical practice; Conference abstract; Controlled study; Drug combination; Drug therapy; Drug withdrawal; Female; Human; Immunotherapy; Incidence; Major clinical study; Male; Mortality; Phase 3 clinical trial; Randomization; Randomized controlled trial; Response evaluation criteria in solid tumors; Skull irradiation}, -abstract = {Background: Extensive‐stage (ES)‐SCLC is a recalcitrant disease associated with a median OS of ∼10 months following etoposide‐platinum (EP); new treatments that prolong survival are needed. CASPIAN (NCT03043872) is an open‐label, phase 3 study of durvalumab (anti‐PD‐L1), ± tremelimumab (anti‐CTLA‐4), combined with EP as first‐line treatment for patients with ES‐SCLC. Here we report results for durvalumab + EP (D+EP) versus EP from a planned interim analysis. Method: Patients with previously untreated ES‐SCLC (ECOG PS 0/1) were randomised (1:1:1) to durvalumab 1500 mg + EP q3w; durvalumab 1500 mg + tremelimumab 75 mg + EP q3w; or EP q3w. Patients in immunotherapy arms received up to 4 cycles of EP followed by maintenance durvalumab until progression. Patients in the EP arm received up to 6 cycles of EP and prophylactic cranial irradiation (PCI), at the investigator’s discretion. Investigator’s choice of cisplatin or carboplatin was allowed across all arms and was a stratification factor at randomisation. The primary endpoint was OS. Data cutoff: 11 March 2019. Result: 268 patients were randomised to D+EP and 269 to EP. Baseline characteristics were well balanced between arms. In the EP arm, 56.8% of patients received 6 cycles of EP. At the interim analysis, D+EP significantly improved OS compared to EP with a HR of 0.73 (95% CI, 0.591‐0.909; p=0.0047); mOS 13.0 versus 10.3 months, respectively. 33.9% of patients were alive at 18 months with D+EP versus 24.7% with EP. Secondary endpoints of PFS and ORR were also improved with D+EP compared to EP: PFS HR 0.78 (95% CI, 0.645‐0.936); mPFS 5.1 versus 5.4 months; 12‐month PFS rate 17.5% versus 4.7%; investigator‐assessed ORR (RECIST v1.1; unconfirmed) 79.5% versus 70.3% (odds ratio, 1.64 [95% CI, 1.106‐2.443]). The incidences of grade 3/4 AEs (61.5% versus 62.4%) and AEs leading to discontinuation (9.4% each) were similar between arms; the incidence of haematological toxicities was numerically higher in the EP arm. The durvalumab + tremelimumab + EP arm continues blinded to final analysis. Conclusion: The addition of durvalumab to EP as first‐line treatment for ES‐SCLC significantly improved OS (27% reduction in risk of death) versus a robust control arm that permitted up to 6 cycles of EP and PCI. Of note, this chemo‐immunotherapy regimen offers flexibility in platinum choice (carboplatin or cisplatin), reflecting current clinical practice for this challenging disease. No new safety signals were identified. Keywords: durvalumab, SCLC, CASPIAN}, -DOI = {10.1016/j.jtho.2019.08.061}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01998358/full} -} - - -Record #94 of 538 -@article{Karim23, -author = {Karim, NFA, Miao, J, Reckamp, KL, Gay, CM, Byers, LA, Zhao, Y, Redman, MW, Carrizosa, DR, Wang, W-L, Petty, WJ, Mehta, K, Faller, BA, Agamah, ES, Kasbari, SS, Malisetti, RK, Kumar, A, Schallenkamp, J, Alluri, KC, Gray, JE, and Kelly, K}, -title = {SWOG S1929: phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC)}, -journal = {Journal of clinical oncology}, -volume = {41}, -number = {16}, -pages = {8504}, -year = {2023}, -accession_number = {EMBASE 642931970}, -publication type = {Journal article; Conference proceeding}, -keywords = {*small cell lung cancer; Adult; Aged; Anemia; Caucasian; Conference abstract; Controlled study; Drug combination; Drug therapy; Febrile neutropenia; Female; Follow up; Human; Major clinical study; Male; Randomized controlled trial; Side effect}, -abstract = {Background: In unselected patients (pts) with extensive‐stage small cell lung cancer (ES‐SCLC), the addition of immune checkpoint inhibitors (ICI) to chemotherapy resulted in a modest improvement in OS. In a retrospective analysis of a study with veliparib (PARP inhibitor [PARPi]) and temozolomide in patients with SCLC, Schlafen‐11 (SLFN11) predicted PFS and OS benefit for the addition of PARPi. We evaluated whether the addition of PARPi (talazoparib) to standard‐of‐care maintenance ICI (atezolizumab) following frontline chemoimmunotherapy improved outcomes in pts with SLFN11‐positive ESSCLC. Methods: Participants with ES‐SCLC expressing SLFN11 (H‐score ≥ 1, evaluated centrally at MDACC) were randomized to maintenance atezolizumab (A) versus atezolizumab plus talazoparib (AT) following frontline chemotherapy and A. Randomization was stratified by Zebrod PS (0‐1 vs 2) and use of consolidation thoracic radiation. The primary endpoint was PFS, and secondary endpoints included ORR, OS, and toxicity. The primary analysis was done using a 1‐sided 10% level stratified log‐rank test. Target sample size was 94 pts. Results: From June 2020 to December 2022, 309 pts were screened, of which 204 of 259 (79%) with evaluable tissue were SLFN11 positive, and 106 were randomized (52 A, 54 AT). Median follow up time is 5 months. Median age was 67 (45‐84); 51 (48%) were females; 94 (89%) were white,102 (96%) were PS 0‐1, and 26 (25%) had radiation prior to randomization. With 80 PFS events reported, PFS was significantly improved with AT (hazard ratio [80% CI]: 0.70 [0.52‐0.94]; p = 0.056). Median PFS was 2.8 months (80% CI 2.0‐2.9) for A and 4.2 months (80% CI 2.8‐4.7) for AT. OS was not different (hazard ratio [80% CI]: 1.17 [0.80‐1.71]; p = 0.30). Median OS was 8.5 months (80 %CI 7.4‐12.7) for A and 9.4 months (80% CI 8.1‐14.2) for AT. ORR was 16% (5/32, 80% CI 8‐27%) for A and 12% (4/34, 80% CI 5‐22%) for AT. Grade 3 or greater treatment related nonhematological adverse events (AEs) occurred in 13% pts in A and 15% in AT. Hematological AEs occurred 4% in A compared to 50% pts in AT (Expected for T) (p<0.001). There were no treatment related grade 5 events. One participant on AT experienced grade 3 febrile neutropenia. The majority of grade 3 AEs were due to anemia (2% in A and 37% in AT). Only three pts discontinued treatment due to toxicity (2 in A and 1 in AT). Conclusions: This study met its primary endpoint demonstrating that maintenance AT improved PFS in SLFN11‐selected patients with ES‐SCLC. Hematologic toxicity was increased with AT as expected, with majority being grade 3 anemia. This study demonstrates the feasibility of conducting biomarker selected trials in SCLC, paving the way for future evaluation of novel therapies in selected SCLC populations.}, -DOI = {10.1200/jco.2023.41.16_suppl.8504}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02633171/full} -} - - -Record #95 of 538 -@article{Altorki21, -author = {Altorki, NK, McGraw, TE, Borczuk, AC, Saxena, A, Port, JL, Stiles, BM, Lee, BE, Sanfilippo, NJ, Scheff, RJ, Pua, BB, Gruden, JF, Christos, PJ, Spinelli, C, Gakuria, J, Uppal, M, Binder, B, Elemento, O, Ballman, KV, and Formenti, SC}, -title = {Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial}, -journal = {The lancet. Oncology}, -volume = {22}, -number = {6}, -pages = {824‐835}, -year = {2021}, -accession_number = {EMBASE 2012343891, PUBMED 34015311}, -publication type = {Journal article}, -keywords = {*cancer patient; *cancer staging; *drug tolerability; *neoadjuvant therapy; *non small cell lung cancer; *stereotactic body radiation therapy; Adolescent; Adult; Adverse drug reaction; Aged; Ambulatory surgery; Antibodies, Monoclonal [*administration & dosage, adverse effects]; Article; B7‐H1 Antigen [antagonists & inhibitors, *genetics, immunology]; Cancer radiotherapy; Cancer surgery; Carcinoma, Non‐Small‐Cell Lung [*drug therapy, immunology, pathology, *radiotherapy]; Cerebrovascular accident; Clinical trial; Combined Modality Therapy; Controlled study; Drug therapy; ECOG Performance Status; Fatigue; Female; Hepatitis; Human; Humans; Hyponatremia; Immune response; Immune‐related gene; Intravenous drug administration; Lung embolism; Major clinical study; Male; Middle Aged; Monotherapy; Neoadjuvant Therapy [adverse effects]; Neoplasm Staging; New York; Pancreatitis; Phase 2 clinical trial; Physician; Presbyterian; Primary tumor; Radiosurgery [methods]; Radiotherapy; Randomized controlled trial; Side effect; Stereotactic radiosurgery; Surgery; Systemic disease; Thrombocytopenia; Young Adult; Young adult}, -abstract = {Background: Previous phase 2 trials of neoadjuvant anti‐PD‐1 or anti‐PD‐L1 monotherapy in patients with early‐stage non‐small‐cell lung cancer have reported major pathological response rates in the range of 15–45%. Evidence suggests that stereotactic body radiotherapy might be a potent immunomodulator in advanced non‐small‐cell lung cancer (NSCLC). In this trial, we aimed to evaluate the use of stereotactic body radiotherapy in patients with early‐stage NSCLC as an immunomodulator to enhance the anti‐tumour immune response associated with the anti‐PD‐L1 antibody durvalumab. Methods: We did a single‐centre, open‐label, randomised, controlled, phase 2 trial, comparing neoadjuvant durvalumab alone with neoadjuvant durvalumab plus stereotactic radiotherapy in patients with early‐stage NSCLC, at NewYork‐Presbyterian and Weill Cornell Medical Center (New York, NY, USA). We enrolled patients with potentially resectable early‐stage NSCLC (clinical stages I–IIIA as per the 7th edition of the American Joint Committee on Cancer) who were aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0 or 1. Eligible patients were randomly assigned (1:1) to either neoadjuvant durvalumab monotherapy or neoadjuvant durvalumab plus stereotactic body radiotherapy (8 Gy × 3 fractions), using permuted blocks with varied sizes and no stratification for clinical or molecular variables. Patients, treating physicians, and all study personnel were unmasked to treatment assignment after all patients were randomly assigned. All patients received two cycles of durvalumab 3 weeks apart at a dose of 1·12 g by intravenous infusion over 60 min. Those in the durvalumab plus radiotherapy group also received three consecutive daily fractions of 8 Gy stereotactic body radiotherapy delivered to the primary tumour immediately before the first cycle of durvalumab. Patients without systemic disease progression proceeded to surgical resection. The primary endpoint was major pathological response in the primary tumour. All analyses were done on an intention‐to‐treat basis. This trial is registered with ClinicalTrial.gov, NCT02904954, and is ongoing but closed to accrual. Findings: Between Jan 25, 2017, and Sept 15, 2020, 96 patients were screened and 60 were enrolled and randomly assigned to either the durvalumab monotherapy group (n=30) or the durvalumab plus radiotherapy group (n=30). 26 (87%) of 30 patients in each group had their tumours surgically resected. Major pathological response was observed in two (6·7% [95% CI 0·8–22·1]) of 30 patients in the durvalumab monotherapy group and 16 (53·3% [34·3–71·7]) of 30 patients in the durvalumab plus radiotherapy group. The difference in the major pathological response rates between both groups was significant (crude odds ratio 16·0 [95% CI 3·2–79·6]; p<0·0001). In the 16 patients in the dual therapy group with a major pathological response, eight (50%) had a complete pathological response. The second cycle of durvalumab was withheld in three (10%) of 30 patients in the dual therapy group due to immune‐related adverse events (grade 3 hepatitis, grade 2 pancreatitis, and grade 3 fatigue and thrombocytopaenia). Grade 3–4 adverse events occurred in five (17%) of 30 patients in the durvalumab monotherapy group and six (20%) of 30 patients in the durvalumab plus radiotherapy group. The most frequent grade 3–4 events were hyponatraemia (three [10%] patients in the durvalumab monotherapy group) and hyperlipasaemia (three [10%] patients in the durvalumab plus radiotherapy group). Two patients in each group had serious adverse events (pulmonary embolism [n=1] and stroke [n=1] in the durvalumab monotherapy group, and pancreatitis [n=1] and fatigue [n=1] in the durvalumab plus radiotherapy group). No treatment‐related deaths or deaths within 30 days of surgery were reported. Interpretation: Neoadjuvant durvalumab combined with stereotactic body radiotherapy is well tolerated, safe, and associated with a high major pathological response rate. This neoadjuvant strategy should be validated in a larger trial. Funding: AstraZeneca.}, -DOI = {10.1016/S1470-2045(21)00149-2}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02284728/full} -} - - -Record #96 of 538 -@article{Jackson86, -author = {Jackson, DV, and Case, LD}, -title = {Small-cell lung cancer: a 10-year perspective}, -journal = {Seminars in oncology}, -volume = {13}, -number = {3 Suppl 3}, -review groups = {Lung Cancer}, -pages = {63‐74}, -year = {1986}, -accession_number = {EMBASE 17213297, PUBMED 3020703}, -publication type = {Journal article}, -keywords = {*adverse drug reaction; *bone marrow depression; *brain radiation; *cancer chemotherapy; *cancer combination chemotherapy; *cancer immunotherapy; *drug comparison; *drug therapy; *esophagitis; *fatality; *gastrointestinal toxicity; *lung cancer; *partial body radiation; *small cell lung cancer; Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; Blood and hemopoietic system; Carcinoma, Small Cell [*therapy]; Central nervous system; Clinical Trials as Topic; Clinical trial; Combined Modality Therapy; Controlled study; Esophagus; Human; Humans; Intoxication; Intravenous drug administration; Lung Neoplasms [*therapy]; Prognosis; Randomized controlled trial; Remission Induction; Respiratory system; Review; Therapy}, -abstract = {Over the past 10 years, four clinical trials have been conducted with a total of 528 patients with previously untreated small‐cell lung cancer. Trials I to III were randomized phase III studies testing the value of prophylactic cranial irradiation, immunotherapy, and etoposide, respectively. They were done in the setting of combined modality treatment with the same local chest radiotherapy (3,000 rad in 10 fractions) and combined agent chemotherapy using a nucleus of CAV (cyclophosphamide, doxorubicin, vincristine). Trial IV was a pilot study evaluating sequential hemibody radiotherapy in a combined modality treatment program with CAV. Overall, the best treatment results to date have been observed following the combination of etoposide with CAV in trial III, particularly for patients with extensive disease. This combination with or without other agents also appears to be a common component of many trials that have reported particularly good survival results in this disease.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00176219/full} -} - - -Record #97 of 538 -@article{Higgins20, -author = {Higgins, KA, Curran, WJ, Liu, SV, Yu, W, Brockman, M, Johnson, A, Bara, I, and Bradley, JD}, -title = {Patterns of Disease Progression after Carboplatin/Etoposide + Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)}, -journal = {International journal of radiation oncology biology physics}, -volume = {108}, -number = {5}, -pages = {1398}, -year = {2020}, -accession_number = {EMBASE 2008562505}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *small cell lung cancer; Adult; Brain damage; Brain metastasis; Brain radiation; Cancer patient; Clinical trial; Conference abstract; Controlled study; Disease free interval; Drug therapy; Female; Follow up; Human; Immunotherapy; Liver; Log rank test; Lymph node; Major clinical study; Male; Physician; Randomized controlled trial; Response evaluation criteria in solid tumors; Skull irradiation; Systemic therapy; Thorax disease}, -abstract = {Purpose/Objective(s): Chemo‐immunotherapy became the standard of care in the first‐line treatment of ES‐SCLC after the IMpower133 trial demonstrated an improvement in overall survival with carboplatin/etoposide (CP/ET) + atezolizumab (atezo). This exploratory analysis seeks to examine patterns of first progression after CP/ET + atezo in IMpower133 (NCT02763579). Materials/Methods: 403 patients with ECOG PS 0‐1 and no prior systemic therapy for ES‐SCLC were randomly assigned (1:1) to 4 cycles of CP and ET with either atezo or placebo, followed by maintenance atezo or placebo until disease progression (per RECIST 1.1), loss of clinical benefit or unacceptable toxicity. Patients with treated asymptomatic brain metastases were allowed. Prophylactic cranial irradiation (PCI) was allowed at the discretion of the treating physician. Consolidative thoracic radiation was not permitted. Patients were stratified by sex, ECOG PS (0 or 1) and presence of brain metastases (yes or no). Progression of disease was investigator assessed (per RECIST 1.1). Patterns of progression were summarized descriptively. Time to progression was estimated by Kaplan‐Meier methodology, and comparisons between treatment arms were made with an unstratified log‐rank test. Results: The number of patients receiving PCI in the intent‐to‐treat (ITT) population was comparable in both arms (11%). In the ITT population, time to intra‐cranial progression, defined as first development of new lesions in the brain or receipt of brain radiation without new brain lesions reported during the follow‐up period, was improved in patients receiving atezo, with a median of 20.2 vs 10.5 mo (HR, 0.66; 95% CI: 0.44, 1.00). In patients who did not receive PCI (placebo, n = 180; atezo, n = 179), a similar trend was seen, with a median time to intra‐cranial progression of 16.7 mo in the atezo arm vs 9.8 mo in the placebo arm (HR, 0.72; 95% CI: 0.47, 1.09). 59.4% of patients in the placebo arm progressed in initial target lesions compared with 56.2% of patients in the atezo arm. Progression outside of initial sites of disease developed in 53.0% vs 48.3% of patients in the placebo vs atezo arm, respectively. In the ITT population, the most common sites of progression in patients who progressed in new sites were the brain (13.4% vs 12.4% [placebo vs atezo]), lymph nodes (12.4% for both arms), lung (11.9% vs 11.4%) and liver (10.4% vs 10.0%). Conclusion: CP/ET + atezo delayed the time to intra‐cranial progression, indicating potential CNS efficacy in a disease in which brain metastases are pervasive. In both treatment arms, the most dominant pattern of progression was in initial sites of disease. This suggests a role for consolidative radiation to initial thoracic disease and sites of metastases to further improve outcomes in patients with ES‐SCLC receiving chemo‐immunotherapy; this is being evaluated in the NRG Oncology LU007 study (NCT04402788).}, -DOI = {10.1016/j.ijrobp.2020.09.020}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02201063/full} -} - - -Record #98 of 538 -@article{Tufman21, -author = {Tufman, A, Neumann, J, Manapov, F, Sellmer, L, Jung, A, Kauffmann-Guerrero, D, Kahnert, K, Mertsch, P, Borgmeier, A, Semrau, S, Rittmeyer, A, Ulm, B, Ulm, K, Flentje, M, Fietkau, R, and Huber, RM}, -title = {Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)}, -journal = {Lung cancer (Amsterdam, Netherlands)}, -volume = {160}, -pages = {17‐27}, -year = {2021}, -accession_number = {EMBASE 2013933099, PUBMED 34371299}, -publication type = {Journal article}, -keywords = {*Carcinoma, Non‐Small‐Cell Lung [therapy]; *Lung Neoplasms [therapy]; *advanced cancer; *chemoradiotherapy; *gene expression; *non small cell lung cancer; *predictive value; *protein expression; *tumor associated leukocyte; Adult; Article; B7‐H1 Antigen; Cancer patient; Cancer prognosis; Cancer staging; Cancer survival; Chemoradiotherapy; Clinical trial; Consolidation chemotherapy; Controlled study; Desert; Female; Human; Human cell; Human tissue; Humans; Lung; Lymphocytes, Tumor‐Infiltrating; Major clinical study; Male; Multicenter study; Overall survival; Phase 3 clinical trial; Prognosis; Randomized controlled trial; Retrospective Studies; Retrospective study; Tumor biopsy}, -abstract = {Objectives: Immune checkpoint inhibition after radiochemotherapy (RTCT) has become a new standard of care for locally advanced non‐small cell lung cancer with programmed death‐ligand 1 (PD‐L1) expression. However, little is known about the prognostic role of immune response markers in this setting. We analysed PD‐L1 expression and tumour infiltrating lymphocytes (TiLs) in tumour biopsies from the multicenter German Intergroup Lung Trial (GILT), which previously randomised patients with stage III NSCLC to RTCT with or without consolidation chemotherapy. Materials and methods: We retrospectively analyzed tumour biopsies from patients treated in the GILT trial. PD‐L1 expression was analysed using the Ventana SP263 assay and TiL score (low, intermediate, high) and pattern (excluded, inflamed, desert) were assessed. The primary endpoint of the biomarker analysis was PFS in patients with PD‐L1 ≥ 1% vs. PD‐L1 < 1% NSCLC. Secondary endpoints explored the prognostic relevance of additional PD‐L1 expression levels and TiL score and pattern. Results: Biopsies were available from 92 patients treated with RTCT. Patients with available tumor tissue did not differ significantly from the whole study population. PD‐L1 scores from 78 samples were available for analysis. There was no difference in PFS in the PD‐L1 < 1% vs. PD‐L1 ≥ 1% subgroups. TiL score was available in 66 patients. Patients with high TiL score showed favourable overall survival compared to the low TiL subgroup. This trend was most pronounced in those patients treated with consolidative chemotherapy. Conclusion: In this analysis, PD‐L1 expression did not correlate with PFS following RTCT. However, patients with TiLs > 10% were found to have longer overall survival, especially for those patients treated with consolidation chemotherapy after the end of RTCT. Further analyses to explore the prognostic and predictive relevance of TiLs in the context of consolidative checkpoint inhibition with durvalumab are required.}, -DOI = {10.1016/j.lungcan.2021.07.008}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02301394/full} -} - - -Record #99 of 538 -@article{Leal20, -author = {Leal, T, Wang, Y, Dowlati, A, Lewis, DA, Chen, Y, Mohindra, AR, Razaq, M, Ahuja, HG, Liu, J, King, DM, Sumey, CJ, and Ramalingam, SS}, -title = {Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive stage small cell lung cancer (ESSCLC): ECOG-ACRIN EA5161}, -journal = {Journal of clinical oncology}, -volume = {38}, -number = {15}, -year = {2020}, -accession_number = {EMBASE 636605875}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer combination chemotherapy; *cancer staging; *small cell lung cancer; Adult; Cancer patient; Clinical trial; Conference abstract; Controlled study; Drug combination; Drug fatality; Drug safety; Drug therapy; Drug withdrawal; ECOG Performance Status; Female; Human; Incidence; Major clinical study; Male; Phase 2 clinical trial; Randomized controlled trial; Response evaluation criteria in solid tumors; Skull irradiation; Systemic therapy}, -abstract = {Background: Immune checkpoint inhibition is now given in combination with chemotherapy for first line (1L) therapy of extensive stage small cell lung cancer (ES‐SCLC). We conducted a randomized phase II study of nivolumab (anti‐PD1) in combination with platinum‐etoposide (CE) as 1L treatment for patients with ES‐SCLC (EA5161, NCT03382561). Methods: Patients with measurable (RECIST v1.1) ES‐SCLC, ECOG performance status 0 or 1, who had not received prior systemic treatment for ES‐SCLC were enrolled. Patients were randomized 1:1 to nivolumab 360 mg + CE every 21 days for 4 cycles followed by maintenance nivolumab 240 mg every 2 weeks until progression or up to 2 years (arm A) or CE every 21 days for 4 cycles followed by observation (arm B). Prophylactic cranial irradiation (PCI) was permitted at the investigator's discretion. Investigator's choice of cisplatin or carboplatin was allowed across both arms. The primary endpoint was PFS in eligible and treated patients. Secondary endpoints included OS, ORR, and safety. Adverse events (AEs) were graded per NCI‐CTCAE v4.0. Results: This study was activated in May 2018 and completed accrual in December 2018. 160 patients were enrolled. Baseline characteristics were well balanced between arms. In the ITT population (n = 160), nivolumab + CE significantly improved the PFS compared to CE with HR 0.65 (95% CI, 0.46, 0.91; p = 0.012); mPFS 5.5 versus 4.6 months, respectively. Secondary endpoint of OS was also improved with nivolumab + CE versus CE with HR 0.67 (95% CI, 0.46, 0.98; p = 0.038); mOS 11.3 versus 8.5 months. Among patients who initiated study therapy, nivolumab + CE significantly improved the PFS compared to CE with HR 0.68 (95% CI, 0.48, 1.00; p = 0.047); mPFS 5.5 versus 4.7 months, respectively; in this population, OS was also improved with nivolumab + CE versus CE with HR 0.73 (95% CI, 0.49, 1.11; p = 0.14); mOS 11.3 versus 9.3 months. The ORR was 52.29% versus 47.71%. The incidence of treatment‐related grade 3/4 AEs was 77% versus 62% and AEs leading to discontinuation 6.21% versus 2.07%. Ten patients remain on maintenance nivolumab. Lethal adverse events independent of treatment were similar between the two arms (9 in arm A; 7 in arm B). Conclusions: The addition of nivolumab to CE as 1L treatment for ES‐SCLC significantly improved PFS and OS. No new safety signals were observed.}, -DOI = {10.1200/JCO.2020.38.15-suppl.9000}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02348824/full} -} - - -Record #100 of 538 -@article{Gronberg21, -author = {Gronberg, B}, -title = {ES11.02 Advances in Thoracic Radiation in SCLC}, -journal = {Journal of thoracic oncology}, -volume = {16}, -number = {10}, -pages = {S831‐S832}, -year = {2021}, -accession_number = {EMBASE 2015169385}, -publication type = {Journal article; Conference proceeding}, -keywords = {*small cell lung cancer; Adult; Cancer patient; Cancer staging; Cancer survival; Chemoradiotherapy; Clinical trial; Conference abstract; Controlled study; Drug combination; Drug megadose; Drug therapy; Female; Human; Irradiation; Male; Multicenter study (topic); Netherlands; Non‐inferiority trial; Overall survival; Patient selection; Phase 2 clinical trial (topic); Phase 3 clinical trial (topic); Radiotherapy; Radiotherapy dosage; Randomized controlled trial (topic); Superiority trial; Systematic review; Thorax}, -abstract = {Concurrent chemotherapy and thoracic radiotherapy (TRT) have been standard treatment for limited stage (LS) small‐cell lung cancer (SCLC) since the 1990's, but the optimal dose and schedule of TRT is debated. The Intergroup 0096 trial published in 1999 established twice‐daily (BID) TRT of 45 Gy in 30 fractions as the best documented schedule.1 However, BID TRT caused more esophageal toxicity than once daily (QD) TRT, and it has been argued that the biologically effective dose (BED) in the control arm (45 Gy in 25 fractions) was inferior, and population based studies show that BID TRT is poorly implemented.2,3 Results from single arm studies suggest that high dose QD TRT might be an alternative to 45 Gy BID, and such schedules are widely used. However, the first randomized trial comparing high dose QD with BID TRT failed to show that 66 Gy in 33 fractions was superior to 45 Gy BID, and numerically, survival was better in the 45 Gy BID arm.4 At this year's ASCO Annual meeting (2021), the first survival data from the long awaited CALGB 20610/RTOG 0538 trial were presented. Patients were randomized to 45 Gy BID, 70 Gy in 35 fractions (QD) or 61.2 Gy in 34 fractions (QD in 16 days followed by BID in 9 days). After a preplanned interim toxicity analysis, the 61.2 Gy arm was dropped in March 2012. The trial was designed to show superiority of the higher TRT‐dose. Survival data in the 45 Gy BID and 70 Gy QD arms were similar, and the trial was per definition negative, but 70 Gy QD appears to be an alternative to 45 Gy BID. Notably, there was no difference in radiotoxicity between treatment arms.5 A systematic review concluded that a shorter time from start of chemotherapy until end of TRT is associated with improved survival.6 Consequently, it seems reasonable that high dose TRT might improve survival if it is accelerated, i.e. the treatment period is reduced, and two trials published this year have investigated such TRT schedules. A Chinese study randomized patients to receive moderately hypofractionated TRT of 65 Gy in 26 fractions or 45 Gy BID and showed that the hypofractionated schedule prolonged PFS (median PFS 17.2 vs. 13.4 months; p=0.031). There was, however, no statistically significant survival benefit (median OS 39.3 vs. 33.6 months; p=0.14), though the survival data are not yet mature.7 A Nordic trial employed a different strategy. In this trial, patients were randomized to receive standard BID TRT of 45 Gy in 30 fractions or high‐dose TRT of 60 Gy in 40 fractions. There was a large improvement for the primary endpoint, 2‐year survival (74% vs. 48%; p=0.0005), and in median overall survival (37.2 vs. 22.6 months; p=0.012), though the difference in median PFS was not statistically significant (18.6 vs. 10.9 months; p=0.13). Final survival data will be presented in 2023.8 There are differences in patient selection, definitions of limited stage disease, target volume definitions and radiotherapy techniques between these trials (and the Intergroup 0096), and they are not necessarily directly comparable. However, it appears that with improvement in assessing extent of disease, using modern radiotherapy techniques and omitting elective nodal irradiation, there is now far less radiotoxicity from 45 Gy BID than observed in the Intergroup 0096. Furthermore, the high dose TRT schedules mentioned here are not more toxic than 45 Gy BID. It has been commented that a non‐inferiority trial is needed to establish high‐dose QD TRT as an alternative to 45 Gy BID, but one might question whether this is a priority. Not many randomized LS SCLC trials have been completed the last 20 years (e.g. the CALGB/RTOG trial took 11 years to complete), and it seems more appropriate to further investigate the accelerated schedules which seem to hold a larger potential for improved survival. However, it might be a good idea to await final survival data from the Chinese and Nordic trials. Another factor to consider before designing the next TRT trial is the potential role of immune checkpoint inhibitors (ICIs) in the treatment of LS SCLC. Two trials have shown a survival improvement of adding atezolizumab or durvalumab to chemotherapy in extensive stage SCLC,9,10 and several ongoing trials are investigating whether concurrent or consolidation ICI therapy improves survival also in LS SCLC. 1. Turrisi et al: Twice‐daily compared with once‐daily thoracic radiotherapy in LS SCLC treated concurrently with cisplatin and etoposide. N Engl J Med 340:265‐71, 1999 2. Schreiber et al: Utilization of Hyperfractionated Radiation in SCLC and Its Impact on Survival. J Thorac Oncol 10:1770‐5, 2015 3. Damhuis R et al: Population‐based Results of Chemoradiotherapy for LS SCLC in The Netherlands. Clin Oncol (R Coll Radiol) 30:17‐22, 2018 4. Faivre‐Finn et al: Concurrent once‐daily versus twice‐daily chemoradiotherapy in patients with LS SCLC (CONVERT): an open‐label, phase 3, randomised, superiority trial. Lancet Oncol 18:1116‐1125, 2017 5. Bogart et al: Phase 3 comparison of high‐dose once‐daily (QD) thoracic radiotherapy (TRT) with standard twice‐daily (BID) TRT in LS SCLC: CALGB 30610 (Alliance)/RTOG 0538. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 8505‐8505, 2021 6. De Ruysscher et al: Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in LS SCLC. J Clin Oncol 24:1057‐63, 2006 7. Qiu et al: Moderately Hypofractionated Once‐Daily Compared With Twice‐Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in LS SCLC: A Multicenter, Phase II, Randomized Trial. Int J Radiat Oncol Biol Phys, 2021 8. Gronberg et al: High‐dose versus standard‐dose twice‐daily thoracic radiotherapy for patients with LS SCLC: an open‐label, randomised, phase 2 trial. Lancet Oncol 22:321‐331, 2021 9. Paz‐Ares et al: Durvalumab plus platinum‐etoposide versus platinum‐etoposide in first‐line treatment of ES SCLC (CASPIAN): a randomised, controlled, open‐label, phase 3 trial. Lancet 394:1929‐1939, 2019 10. Horn et al: First‐Line Atezolizumab plus Chemotherapy in ES SCLC. N Engl J Med 379:2220‐2229, 2018}, -DOI = {10.1016/j.jtho.2021.08.743}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02336826/full} -} - - -Record #101 of 538 -@article{Doyen22, -author = {Doyen, J, Besse, B, Texier, M, Bonnet, N, and Levy, A}, -title = {PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial}, -journal = {Clinical lung cancer}, -volume = {23}, -number = {3}, -pages = {e252‐e256}, -year = {2022}, -accession_number = {EMBASE 2015688404, PUBMED 34810130}, -publication type = {Journal article}, -keywords = {*Carcinoma, Non‐Small‐Cell Lung [drug therapy]; *Lung Neoplasms [drug therapy]; *advanced cancer; *chemoradiotherapy; *irradiation; *non small cell lung cancer; *prospective study; Adult; Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; Article; Cancer patient; Cancer specific survival; Cancer survival; Clinical trial; Controlled study; Drug therapy; Female; Human; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung [pathology]; Male; Meta analysis; Multicenter study (topic); Overall survival; Phase 2 clinical trial (topic); Phase 3 clinical trial (topic); Progression free survival; Prospective Studies; Quality of Life; Quality of life; Radiotherapy; Randomized controlled trial (topic)}, -abstract = {Advanced non‐small cell lung cancer (NSCLC) remains a high unmet medical need. The first line standard‐of‐care therapy comprises concurrent chemotherapy‐immunotherapy with pembrolizumab. Concurrent irradiation with pembrolizumab has been shown to significantly improve survival benefit compared with immunotherapy alone in a pooled analysis of 2 randomized phase 2 trials. We present the rationale and study design of the “PD‐1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non‐small cell lung cAncer” (NIRVANA‐Lung) trial (ClinicalTrials.gov identifier, NCT03774732). This study is a national multicenter 1:1 randomized phase III trial testing in 460 patients, the addition of multisite radiotherapy in advanced NSCLC treated with standard immune checkpoint inhibitors (pembrolizumab)‐chemotherapy in first line. The primary objective of the trial is to compare the overall survival between the 2 arms at year 1 of the study. The secondary objective is to compare the progression‐free survival and cancer‐specific survival at year 1 and 2, as well as to determine quality of life, local and distant control in irradiated and nonirradiated sites at 6 months and year 1.}, -DOI = {10.1016/j.cllc.2021.10.008}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02346830/full} -} - - -Record #102 of 538 -@article{Salgaller02, -author = {Salgaller, ML}, -title = {The development of immunotherapies for non-small cell lung cancer}, -journal = {Expert opinion on biological therapy}, -volume = {2}, -number = {3}, -pages = {265‐278}, -year = {2002}, -accession_number = {EMBASE 34464808, PUBMED 11890866}, -publication type = {Journal article}, -keywords = {*T lymphocyte; *cancer immunotherapy; *dendritic cell; *non small cell lung cancer /diagnosis /drug therapy /etiology /radiotherapy /surgery /therapy; *radioimmunotherapy; Animal model; Animals; Asthenia /side effect; Bone marrow toxicity /side effect; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [*therapy]; Chemotherapy induced emesis /side effect; Clinical trial; Combined Modality Therapy; Controlled clinical trial; Controlled study; Cytokines [pharmacology]; ErbB Receptors [immunology]; Fever /side effect; Human; Humans; Immunotherapy [*methods]; Immunotherapy, Adoptive; Lung Neoplasms [*therapy]; Lung cancer /diagnosis /drug therapy /etiology /radiotherapy /surgery /therapy; Major clinical study; Melanoma /therapy; Mouse; Multicenter study; Multimodality cancer therapy; Nonhuman; Oncogene neu; Phase 1 clinical trial; Phase 2 clinical trial; Phase 3 clinical trial; Radioimmunotherapy; Randomized controlled trial; Review; Skin toxicity /side effect; Treatment outcome; Viral gene therapy}, -abstract = {Standard of care for non‐small cell lung cancer (NSCLC) (surgery, chemotherapy and radiation) may enhance patient survival but the enhancement is typically transient and quite uncommon with advanced disease. Researchers and medical professionals are using new approaches to improve patient mortality and morbidity. One of these approaches, immunotherapy, seeks to stimulate antitumour immunity above a threshold level needed for tumour regression or to induce stability in the face of progression. Among the most established approaches are vaccines involving monoclonal antibodies (mAbs) or immune effector cells. These approaches stimulate the humoral and cell‐mediated arms of the immune system, respectively. As the development of humanised or fully human antibodies has spurred exploration of radioimmunoconjugates and immunotoxins, mAbs have enjoyed a revival of sorts. Cell‐based therapies using the tumour cell itself as a vaccine component has resulted in disease stabilisation or regression. In addition, immune cells (e.g., T‐lymphocytes and dendritic cells [DCs]) are the focal point of numerous patient trials in which meaningful clinical impact was achieved. In general, there are many tactics under development for the treatment of NSCLC. This review primarily concerns immunotherapeutic cancer treatments that are either already in clinical trial or well progressed into preclinical studies.}, -DOI = {10.1517/14712598.2.3.265}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01769010/full} -} - - -Record #103 of 538 -@article{Bi23, -author = {Bi, N, Deng, L, Hu, X, Shayan, G, Zhao, L, Zhang, L, Jiang, W, Zhang, J, Zhu, X, Wang, Y, Ge, H, Cao, J, Lin, Q, Chen, M, and Wang, L}, -title = {30 Gy vs. 45 Gy Consolidative Thoracic Radiation (cTRT) for Extensive Stage Small Cell Lung Cancer (ES-SCLC): a Multicenter, Randomized, Phase 3 Trial}, -journal = {International journal of radiation oncology biology physics}, -volume = {117}, -number = {2}, -pages = {S56‐S57}, -year = {2023}, -accession_number = {EMBASE 2026576388}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *small cell lung cancer; Adult; Blood toxicity; Cancer patient; Cancer radiotherapy; Cancer recurrence; Cancer survival; Chemotherapy; China; Clinical trial; Conference abstract; Distant metastasis free survival; Drug combination; Drug therapy; Female; Follow up; Health care quality; Human; Human tissue; Incidence; Intensity modulated radiation therapy; Local recurrence free survival; Major clinical study; Male; Middle aged; Multicenter study; Outcome assessment; Overall survival; Phase 3 clinical trial; Probability; Progression free survival; Public hospital; Radiation dose; Radiation pneumonia; Radiotherapy; Randomized controlled trial; Sample size; Skull irradiation; Smoking}, -abstract = {Purpose/Objective(s): Consolidative thoracic radiotherapy (cTRT) showed potential benefit to extensive stage small cell lung cancer (ES‐SCLC). However, the optimum dose of cTRT is unknown. The purpose of this randomized trial was to compare the effect of 45 Gy in 15 fractions with 30 Gy in 10 fractions cTRT in ES‐SCLC. Materials/Methods: This phase III, randomized trial was conducted in 12 public hospitals in China. Eligible patients with pathologically confirmed ES‐SCLC who responded to 4‐6 cycles of etoposide plus cisplatin (EP) or carboplatin (EC) chemotherapy were randomized 1:1 to receive either 30 Gy in 10 fractions or 45 Gy in 15 fractions cTRT. The primary outcome was 2‐year overall survival (OS). Secondary outcomes included 2‐year progression‐free survival (PFS), 2‐year local control (LC) and radiation treatment related toxicity. The primary objective was to detect an OS improvement in 45 Gy cTRT group at 2 years from 13% to 26% assuming a two‐sided a = 0.05 and power of 85%, with a planned sample size of 186 patients. This trial was registered with Clinical Trials.gov, number NCT02675088. Results: Between January 15, 2016, and September 20, 2022, 90 patients were randomly assigned either 30 Gy in 10 fractions (n = 50) or 45 Gy in 15 fractions (n = 40) cTRT group. Recruitment to the trial closed early due to slow accrual since first‐line chemoimmunotherapy has become the new standard of care for ES‐SCLC. The median age of patients was 58 years, 87.8% were male, 76.7% had a smoking history, 95.6% received IMRT, and 58.9% received prophylactic cranial irradiation. At a median follow‐up of 39.9 months (IQR 27.2‐59.2), there was no significant difference in the 2‐year OS between the 45 Gy group and the 30 Gy group, at 43.4% (95% CI 29.3%–64.3%) and 40.0% (95% CI 27.9%‐59.1%), respectively (log‐rank p = 0.62; HR 1.13 [95% CI 0.69–1.84]). The 2‐year PFS was 12.1% (95% CI 4.3%–33.8%) in the 45 Gy group and 9.0% (95% CI 3.2%–25.2%) in the 30 Gy group (log‐rank p = 0.25, HR 0.76(95% CI [0.478‐1.22]). There were also no significant differences in locoregional recurrence free survival (log‐rank p = 0.75; HR 0.888 [95% CI 0.423–1.863]) and distant metastasis free survival (log‐rank p = 0.95; HR 1.015 [95% CI 0.624–1.651]) between two groups. No grade 5 toxicity was observed in both groups. Patients treated with higher cTRT dose presented with increased incidence of grade 3+ radiation pneumonitis (10% vs 2%) and hematological toxicity (20% vs 12.5%). Conclusion: This randomized trial did not find a higher probability of survival improvement in patients with ES‐SCLC receiving cTRT of 45 Gy in 15 fractions compared with 30 Gy in 10 fractions. In contrast, there was an increase in toxicity, especially radiation pneumonitis. Additional randomized studies investigating the role of cTRT in ES‐SCLC after a response to chemoimmunotherapy are warranted.}, -DOI = {10.1016/j.ijrobp.2023.06.350}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02611622/full} -} - - -Record #104 of 538 -@article{Kotsakis14, -author = {Kotsakis, A, Papadimitraki, E, Vetsika, EK, Aggouraki, D, Dermitzaki, EK, Hatzidaki, D, Kentepozidis, N, Mavroudis, D, and Georgoulias, V}, -title = {A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide}, -journal = {Lung cancer (Amsterdam, Netherlands)}, -volume = {86}, -number = {1}, -pages = {59‐66}, -year = {2014}, -accession_number = {EMBASE 53291846, PUBMED 25130084}, -publication type = {Journal article}, -keywords = {*HLA A2 antigen/ec [Endogenous Compound]; *cancer immunization; *cancer vaccine/ct [Clinical Trial]; *cancer vaccine/dt [Drug Therapy]; *cancer vaccine/sc [Subcutaneous Drug Administration]; *immune response; *non small cell lung cancer/dt [Drug Therapy]; *telomerase reverse transcriptase/ec [Endogenous Compound]; *vx 001/ae [Adverse Drug Reaction]; *vx 001/ct [Clinical Trial]; *vx 001/dt [Drug Therapy]; *vx 001/sc [Subcutaneous Drug Administration]; Adult; Aged; Aged, 80 and over; Anemia/si [Side Effect]; Article; Cancer Vaccines [administration & dosage, adverse effects, *immunology]; Cancer control; Cancer growth; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [*immunology, mortality, pathology, *therapy]; Chemotherapy, Adjuvant; Clinical article; Controlled clinical trial; Controlled study; Disease Progression; Drug efficacy; Enzyme linked immunospot assay; Fatigue/si [Side Effect]; Female; HLA‐A2 Antigen [*immunology]; Haplotype; Human; Human cell; Humans; Immunotherapy; Injection site reaction/si [Side Effect]; Local skin reaction/si [Side Effect]; Lung Neoplasms [*immunology, mortality, pathology, *therapy]; Male; Middle Aged; Middle aged; Nausea/si [Side Effect]; Outcome assessment; Overall survival; Peptide Fragments [*immunology]; Peripheral blood mononuclear cell; Phase 2 clinical trial; Progression free survival; Radiotherapy, Adjuvant; Telomerase [chemistry, *immunology]; Treatment Outcome; Treatment response; Unclassified drug}, -abstract = {OBJECTIVES: The immunological and clinical responses of patients with NSCLC treated, in the context of an expanded action program, with the cryptic hTERT‐targeting Vx‐001 vaccine are presented. MATERIALS AND METHODS: Forty‐six HLA‐A*0201‐positive patients with advanced NSCLC and residual (n=27) or progressive (n=19) disease following front‐line treatment received two subcutaneous injections of the optimized TERT572Y peptide followed by four injections of the native TERT572 peptide, every 3 weeks. Peptide‐specific immune responses were monitored by enzyme‐linked immunosorbent spot assay at baseline, and after the 2nd and the 6th vaccinations. Thirty‐eight HLA‐A*0201‐positive matched patients were used as historical controls. RESULTS: Twenty‐three patients (50%) completed the vaccination protocol and 87% received at least two administrations. Twelve patients (26%) without disease progression after the 6th vaccination received boost vaccinations. Three (7%) patients achieved a partial response and 13 (28%) disease stabilization. The disease control rate was significantly higher in patients with non‐squamous histology compared to those with squamous‐cell histology [n=14 (45%) versus n=2 (13%); p=0.03]. The median progression‐free survival (PFS) and overall survival (OS) was 3.8 (range, 0.7‐99.4) and 19.8 months (range, 0.7‐99.4), respectively. Patients who developed immune response had a numerically higher PFS compared to those who failed to mount any (6.7 versus 2.7 months; p=0.090). However, the median OS for the immune‐responders was significantly prolonged compared to non‐responders (40.0 versus 9.2 months, respectively; p=0.02). Toxicity was = 18 years; ·ECOG performance status <= 2; ·Life expectancy > 12 weeks; ·No prior systemic chemotherapy, immunotherapy or biological therapy for SCLC; ·Prior radiation therapy allowed to < 25% of the bone marrow. Patients who have received prior radiation to chest for the treatment of SCLC are not eligible. Prior radiotherapy must be completed at least 2 weeks before study enrolment. Patients must have recovered from the acute toxic effects of the treatment prior to study enrolment; ·Adequate haematological, hepatic and renal functions; ·At baseline, presence of at least one measurable target lesion (according to RECIST criteria); all radiology studies must be performed within 28 days prior to rand}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01834613/full} -} - - -Record #106 of 538 -@article{EUCTR2016-004309-15-HU17, -author = {EUCTR2016-004309-15-HU,}, -title = {Phase 3 trial of first line etoposide/platinum with or without pembrolizumab in ES-SCLC (KEYNOTE-604)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2016-004309-15-HU}, -year = {2017}, -accession_number = {ICTRP EUCTR2016‐004309‐15‐HU}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Pembrolizumab Product Code: MK‐3475 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Pembrolizumab CAS Number: 1374853‐91‐4 Current Sponsor code: MK‐3475 Other descriptive name: Anti‐PD‐1 monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Carboplatin‐Actavis Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: CARBOPLATIN CAS Number: 41575‐94‐4 Other descriptive name: CARBOPLATIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10 ‐ Trade Name: Carboplatin Pharmaceutical Form: Solution for infusion INN or Proposed INN: CARBOPLATIN CAS Number: 41575‐94‐4 Other descriptive name: CARBOPLATIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10 ‐ Trade Name: Cisplatin Accord Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: cisplatin CAS Number: 15663‐27‐1 Other descriptive name: CISPLATIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1‐ Trade Name: Etoposide‐Teva Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ETOPOSIDE CAS Number: 33419‐42‐0 Other descriptive name: ETOPOSIDE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20‐ Trade Name: Cisplatin Teva Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Cisplatin CAS Number: 15663‐27‐1 Other descriptive name: CISPLATIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1‐ CONDITION: First‐line treatment of extensive stage small cell lung cancer (ES‐SCLC) in combination with standard of care (SOC) chemotherapy ; MedDRA version: 20.0 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] SECONDARY OUTCOME: Secondary end point(s): 3) ORR as assessed by BICR per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ ; 4) DOR as assessed by BICR per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ ; 5) AEs ; ; Timepoint(s) of evaluation of this end point: Objective Response Rate/Duration of Response: Tumor imaging to be performed every 6 weeks (42 [±7] days) for the first 48 weeks of treatment from the date of randomization, then every 9 weeks (63 [±7] days) subsequently until documented disease progression, or the start of new anti‐cancer treatment. Imaging is to follow calendar days regardless of any delays in dosing. ; AEs will be monitored throughout the study INCLUSION CRITERIA: 1.Have a documented new diagnosis of SCLC by histology or cytology from brushing, washing, or needle aspiration of a defined lesion. Subjects who do not have histology samples (defined as core or excisional biopsy, or resections) will need to undergo a new biopsy to provide a tissue sample. 2.Have extensive stage disease defined as Stage IV (T any, N any, M 1a/b) by the American Joint Committee on Cancer, Seventh Edition. 5.Have ECO PRIMARY OUTCOME: Main Objective: 1. To evaluate PFS as assessed by BICR per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.; 2. To evaluate OS. Primary end point(s): 1. PFS as assessed by BICR RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ; 2. OS; Secondary Objective: 1.To evaluate ORR as assessed by BICR per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.; 2.To evaluate DOR as assessed by BICR per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.; 3.To evaluate the safety profile in each treatment arm using CTCAE 4.0.; 4.To evaluate the following patient‐reported outcomes (PROs):; a) Mean change from baseline at Weeks 18 in global health status/quality of life using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ‐C30) global health status/quality of life scale.; b)Time to true deterioration (TTD) in the composite endpoint of cough, chest pain, and dyspnea using the EORTC QLQ‐C30 and Lung Cancer Module 13 (QLQ‐LC13). Timepoint(s) of evaluation of this end point: Progression‐free Survial: Tumor imaging to be performed every 6 weeks (42 [±7] days) for the first 48 weeks of treatment from the date of randomization, then every 9 weeks (63 [±7] days) subsequently until documented disease progression, or the start of new anti‐cancer treatment. Imaging is to follow calendar days regardless of any delays in dosing.; Survival: Subjects to be followed until death, withdrawal of consent or loss to follow up during treatment, 30 days after last dose of study treatment, every 6 weeks (42 [±7] days) or every 9 weeks (63 [±7] days) per imaging schedule during PFS follow‐up, and then 8 weeks (±7days) in survival follow‐up. Updated survival status may be requested by the Sponsor at any time during the course of the study. 3. Have at least 1 lesion that meets the criteria for being measurable, as defined by RECIST 1.1, and is appropriate for selection as a target lesion, as determined by local site investigator/radiology review. Lesions that appear measurable, but have undergone palliative irradiation, cannot be target lesions. 4.Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. Formalin‐fixed, paraffinembedded (FFPE) tissue blocks are preferred to slides.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01894901/full} -} - - -Record #107 of 538 -@article{NL-OMON5218121, -author = {NL-OMON52181,}, -title = {A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGBA1217) Plus Tislelizumab (BGB-A317) Versus Durvalumab in Patients With Locally Advanced, Unresectable, PD L1 Selected Non- Small Cell Lung Cancer Whose Disease Has Not Progressed After Concurrent Chemoradiotherapy}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON52181}, -year = {2021}, -accession_number = {ICTRP NL‐OMON52181}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Ociperlimab, 300 mg/15 mL, 900 mg Q3W administered by intravenous infusion. Tislelizumab, 100 mg/10 mL, 200 mg Q3W administered by intravenous infusion. Durvalumab, 120 mg/2.4 mL (50 mg/mL) and 500 mg/10 mL (50 mg/mL), 10 mg/kg Q2W (or 1500 mg Q4W where the dosage has been approved by the local health authority) administered by intravenous infusion. CONDITION: ; Non‐Small Cell Lung Cancer (NSCLC) 10038666 PRIMARY OUTCOME: • PFS by the IRC, defined as the time from the date of randomization to the ; date of first documentation of disease progression as assessed ; by the IRC per RECIST v1.1 or death, whichever occurs first ; INCLUSION CRITERIA: Each patient eligible to participate in this study must meet all the following criteria: • Histologically or cytologically confirmed, unresectable locally advanced Stage III NSCLC (AJCC Cancer Staging Manual 2017, derived from International Association for the Study of Lung Cancer [IASLC]) prior to cCRT. • Have completed >= 2 cycles of platinum‐based chemotherapy concurrent with radiotherapy. For patients who are recovering from toxicities associated with the prior treatment, the first dose of study drug(s) may be delayed by up to 42 days from the end of the cCRT. It is recommended to screen the patients within 14 days after the completion of cCRT. • Have not experienced PD following definitive, platinum‐based cCRT. CONFIDENTIAL Page 23 • Agree to provide archival tissue (formalin‐fixed paraffin‐embedded block containing tumor [preferred] or approximately 6 to 15 freshly cut unstained slides) o SECONDARY OUTCOME: • OS defined as the time from the date of randomization until the date of death ; due to any cause ; • RR, defined as the proportion of patients who achieve a complete response ; (CR) or partial response (PR) assessed by both the IRC and ; investigators per RECIST v1.1 ; • DOR, defined as the time from the first determination of a confirmed ; objective response as assessed by both the IRC and investigators per ; RECIST v1.1 until the first documentation of disease progression or death, ; whichever occurs first ; • TTDM, defined as the time from the date of randomization until the first date ; of distant metastasis as assessed by both the IRC and ; investigators, or death. Distant metastasis is defined as any new lesion that ; is outside of the radiation field per RECIST v1.1 or proven by ; biopsy ; • PFS2, defined as the time from randomization to the disease progression after ; next line of treatment, or death from any cause, whichever ; occurs first ; • Safety and tolerability, defined as adverse events (AEs) (using NCI‐CTCAE ; v5.0), laboratory tests, vital signs, Eastern Cooperative Oncology Group (ECOG) ; Performance Status, physical examinations, concomitant medications, and dose ; modifications ; • HRQoL, measured via patient‐reported outcomes (PROs) using European ; Organization for Research and Treatment of Cancer Quality of Life ; Questionnaire Core 30 (EORTC QLQ‐C30), European Organization for Research and ; Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC ; QLQ‐LC13), and the 5‐Level EuroQol 5‐Dimension (EQ‐5D‐5L) ; • Serum concentrations of ociperlimab and tislelizumab at specified timepoints ; • Immunogenic responses to ociperlimab and tislelizumab evaluated through ; detection of antidrug antibodies ; • PD‐L1 and TIGIT expression in archival and/or fresh tumor tissues before ; study treatment or at disease progression/reoccurrence, and their ; association with clinical efficacy ;}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02719863/full} -} - - -Record #108 of 538 -@article{Shimoyama21, -author = {Shimoyama, R, Omori, S, Nomura, S, Kenmotsu, H, Takahashi, T, Harada, H, Ishikura, S, Mizutani, T, Ando, M, Kataoka, T, Fukuda, H, and Ohe, Y}, -title = {A multi-institutional randomized phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin as regimens for concurrent chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer: japan Clinical Oncology Group Study JCOG1914}, -journal = {Japanese journal of clinical oncology}, -volume = {51}, -number = {5}, -pages = {836‐841}, -year = {2021}, -accession_number = {EMBASE 634599812, PUBMED 33728436}, -publication type = {Journal article}, -keywords = {*Japan; *advanced cancer; *cancer patient; *chemoradiotherapy; *non small cell lung cancer; Aged; Albumins [pharmacology, *therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [pharmacology, *therapeutic use]; Article; Cancer staging; Cancer survival; Carboplatin [administration & dosage, pharmacology, *therapeutic use]; Carcinoma, Non‐Small‐Cell Lung [*drug therapy, pathology]; Chemoradiotherapy [*methods]; Clinical trial; Controlled study; Daily life activity; Deterioration; Drug combination; Drug therapy; Female; Functional Assessment of Cancer Therapy; Human; Humans; Japan; Low drug dose; Lung Neoplasms [*drug therapy, pathology]; Major clinical study; Male; Multicenter study; Overall survival; Paclitaxel [pharmacology, *therapeutic use]; Phase 1 clinical trial; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial}, -abstract = {Daily low‐dose carboplatin plus concurrent thoracic radiotherapy is the standard treatment for elderly patients with unresectable clinical stage (c‐Stage) III non‐small cell lung cancer (NSCLC) in Japan. However, a phase I study by Omori et al. suggests that weekly carboplatin and nab‐paclitaxel plus concurrent thoracic radiotherapy have comparable efficacy outcomes with more manageable adverse events. In December 2020, we initiated a randomized controlled trial in Japan to confirm whether the weekly carboplatin plus nab‐paclitaxel regimen is noninferior to the daily low‐dose carboplatin regimen for concurrent chemoradiotherapy in elderly patients with unresectable c‐Stage III NSCLC. We plan to enroll 166 patients from 50 institutions in 3.5 years. The primary endpoint is overall survival. The secondary endpoints are progression‐free survival, response rate, proportion of patients starting maintenance durvalumab therapy, adverse events, site of progression, Functional Assessment of Cancer Therapy‐Trial Outcome Index deterioration and Instrumental Activities of Daily Living deterioration.}, -DOI = {10.1093/jjco/hyab025}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02261771/full} -} - - -Record #109 of 538 -@article{Reinmuth20, -author = {Reinmuth, N, Paz-Ares, L, Chen, Y, Hotta, K, Trukhin, D, Statsenko, G, Hochmair, MJ, Ozguroglu, M, Li, JH, Voitko, O, Poltoratskiy, A, Ponce, S, Verderame, F, Havel, L, Bondarenko, I, Kazarnowicz, A, Losonczy, G, Conev, NV, Armstrong, J, Byrne, N, Shire, N, Jiang, H, Goldman, J, and Alt, J}, -title = {Caspian: os results from a randomised phase 3 study of first-line durvalumab ± tremelimumab + chemotherapy in ES-SCLC}, -journal = {Oncology research and treatment}, -volume = {43}, -pages = {115}, -year = {2020}, -accession_number = {EMBASE 631302360}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer chemotherapy; *small cell lung cancer; Adult; Cancer patient; Cancer staging; Cancer survival; Clinical trial; Conference abstract; Controlled study; Drug combination; Drug safety; Drug therapy; Female; Histopathology; Human; Immunogenicity; Major clinical study; Male; Multicenter study; Overall survival; Pharmacokinetics; Phase 3 clinical trial; Progression free survival; Quality of life; Randomization; Randomized controlled trial; Skull irradiation}, -abstract = {Purpose: Immune checkpoint blockade targeting the PD‐1/PD‐L1 pathway in combination with platinum‐based chemotherapy (CT) has demonstrated improved clinical outcomes in patients (pts) with extensive‐stage small‐cell lung cancer (ES‐SCLC). Treatment with durvalumab (D), a selective, high‐affinity, human IgG1 mAb that blocks PD‐L1 binding to PD‐1 and CD80, and tremelimumab (T), a selective human IgG2 mAb against CTLA‐4, may provide possible additive or synergistic effects. Durvalumab demonstrated durable clinical activity and had a manageable safety profile both as monotherapy and in combination with tremelimumab in pts with pretreated ES‐SCLC (NCT01693562; NCT02261220; NCT02937818). CASPIAN (NCT03043872) is a randomised, multicentre, open‐label, sponsor‐blind, Phase 3 study of Durvalumab ± Tremelimumab in combination with etoposide and platinum‐based CT (EP) as first‐line treatment for pts with ES‐SCLC. Methods: In total, 804 pts were randomised 1:1:1 to receive D 1500 mg + T 75 mg + EP q3w for 4 cycles, followed by D 1500 mg q4w until disease progression (PD), with one additional dose of T given post EP (Arm 1); D 1500 mg + EP q3w for 4 cycles, followed by D 1500 mg q4w until PD (Arm 2); or EP q3w for 4‐6 cycles with prophylactic cranial irradiation if indicated (Arm 3). Randomisation was stratified by platinum‐based CT in cycle 1 (carboplatin vs cisplatin). Pts had histologically or cytologically documented ES‐SCLC, WHO/ECOG PS 0 or 1 and were suitable to receive first‐line platinum‐based CT. The primary endpoint was overall survival (OS) for D ± T + EP versus EP. Secondary endpoints included progression‐free survival (PFS); objective response rate; landmark OS and PFS rates; safety and tolerability; pharmacokinetics; immunogenicity; quality of life. Results: Results will be presented at WCLC 2019 including OS, key secondary endpoints, safety and tolerability. Conclusions: Not applicable.}, -DOI = {10.1159/000506491}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02100799/full} -} - - -Record #110 of 538 -@article{De Ruysscher22, -author = {De Ruysscher, D, Ramalingam, S, Urbanic, J, Gerber, DE, Tan, DSW, Cai, J, Li, A, and Peters, S}, -title = {CheckMate 73L: a Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer}, -journal = {Clinical lung cancer}, -volume = {23}, -number = {3}, -pages = {e264‐e268}, -year = {2022}, -accession_number = {EMBASE 2014434722, PUBMED 34489161}, -publication type = {Journal article}, -keywords = {*cancer staging; *chemoradiotherapy; *drug tolerability; *non small cell lung cancer; *progression free survival; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; Article; Cancer patient; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [drug therapy]; Chemoradiotherapy; Clinical trial; Comparative effectiveness; Controlled study; Distant metastasis; Drug combination; Drug efficacy; Drug safety; Drug therapy; Female; Human; Humans; Ipilimumab [therapeutic use]; Lung Neoplasms [pathology]; Male; Nivolumab [therapeutic use]; Overall survival; Pharmacokinetics; Phase 3 clinical trial; Radiotherapy; Randomized controlled trial; Remission; Treatment response time}, -abstract = {Introduction: The 5 year survival rate for patients with locally advanced non‐small‐cell lung cancer (NSCLC) not amenable for definitive resection with historical standard‐of‐care concurrent chemoradiotherapy (cCRT) ranges from 15% to 32%. cCRT primes anti‐tumor immunity and also upregulates programmed death ligand‐1 (PD‐L1), providing a rationale for combining an immune checkpoint inhibitor with cCRT to improve outcomes. In the PACIFIC trial, consolidation therapy with the PD‐L1 inhibitor durvalumab improved progression‐free survival (PFS) and overall survival (OS) vs. placebo in patients with stage III NSCLC who did not have disease progression after cCRT. CheckMate73L (NCT04026412), a randomized phase 3 study, evaluates the efficacy of nivolumab plus cCRT followed by nivolumab with or without ipilimumab vs. cCRT followed by durvalumab for untreated, stage III NSCLC. Patients and Methods: Patients with untreated, stage III NSCLC will be randomized 1:1:1 to nivolumab plus cCRT followed by nivolumab in combination with ipilimumab (Arm A) or nivolumab alone (Arm B); or cCRT followed by durvalumab (Arm C). Primary endpoints are PFS and OS (Arm A vs. Arm C). Secondary endpoints include additional analyses of PFS and OS (Arm A vs. Arm B; Arm B vs. Arm C), as well as objective response rate, complete response rate, time to response, duration of response, time to death or distant metastases, and safety and tolerability. Recruitment began on August 20, 2019, and the estimated primary completion date is October 17, 2022.}, -DOI = {10.1016/j.cllc.2021.07.005}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02326388/full} -} - - -Record #111 of 538 -@article{Patel20, -author = {Patel, P, Alrifai, D, McDonald, F, Forster, M, and AstraZeneca UK, Limited}, -title = {Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)}, -journal = {British journal of cancer}, -volume = {123}, -number = {Suppl 1}, -pages = {18‐27}, -year = {2020}, -accession_number = {EMBASE 2007547197, PUBMED 33293672}, -publication type = {Journal article}, -keywords = {*cancer immunotherapy; *chemoradiotherapy; *clinical outcome; *non small cell lung cancer /drug therapy /radiotherapy; Antibodies, Monoclonal [adverse effects, *therapeutic use]; Antineoplastic Agents, Immunological; B7‐H1 Antigen [adverse effects, genetics]; Cancer patient; Cancer radiotherapy; Cancer staging; Carcinoma, Non‐Small‐Cell Lung [*drug therapy, epidemiology, immunology, radiotherapy]; Chemoradiotherapy [*adverse effects]; Human; Humans; Immunotherapy; Phase 2 clinical trial (topic); Phase 3 clinical trial (topic); Priority journal; Progression‐Free Survival; Review; Treatment Outcome; Treatment response; Tumor Microenvironment [*drug effects]}, -abstract = {The treatment paradigm of non‐small‐cell lung cancer (NSCLC) has rapidly changed in recent years following the introduction of immune‐checkpoint inhibition (ICI). Pre‐clinically, both chemotherapy and radiotherapy modulate the tumour microenvironment, providing the rationale for clinical trials evaluating their role in combination with immunotherapy. Standard‐of‐care treatment for patients with unresectable stage III disease is concurrent chemoradiotherapy (cCRT); however, only recently, the combination with ICI has been explored. The Phase 3 PACIFIC study randomised 713 patients with confirmed locally advanced, unresectable, stage III NSCLC, whose disease has not progressed following cCRT, to either the anti‐programmed death‐ligand 1 (PD‐L1) agent durvalumab (Imfinzi®▼, AstraZeneca UK Limited) or placebo. Patients with a PD‐L1 status ≥1% treated with durvalumab had a significantly longer median progression‐free survival compared with placebo (17.2 vs. 5.6 months, respectively; HR: 0.51; 95% CI: 0.41–0.63), prolonged median overall survival (OS) (NR vs. 28.7 months, respectively; HR: 0.68; 99.73% CI: 0.47–0.997; P = 0.0025) and long‐term clinical benefit (3‐year OS HR: 0.69; 95% CI: 0.55–0.86). Grade 3 or 4 toxicity was marginally greater in the durvalumab cohort versus placebo (30.5% vs. 26.1%). Based on these results, durvalumab has been licensed in this setting, and further clinical trials are exploring the use of ICI in unresectable stage III NSCLC.}, -DOI = {10.1038/s41416-020-01071-5}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02210967/full} -} - - -Record #112 of 538 -@article{Ai20, -author = {Ai, X, Pan, Y, Shi, J, Yang, N, Liu, C, Zhou, J, Zhang, X, Dong, X, He, J, Li, X, Chen, G, Zhang, H, Liao, W, Zhang, Y, Ma, Z, Zhang, B, Zhang, D, and Lu, S}, -title = {A randomized double-blind phase III study of niraparib versus placebo as maintenance therapy in extensive-stage small cell lung cancer}, -journal = {Annals of oncology}, -volume = {31}, -pages = {S1387}, -year = {2020}, -accession_number = {EMBASE 2008604057}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *maintenance therapy; *small cell lung cancer; Adult; Body weight; Cancer patient; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Double blind procedure; Drug safety; Drug therapy; Female; Gender; Human; Immunotherapy; Major clinical study; Male; Multicenter study; Parttime employment; Pharmacokinetics; Phase 3 clinical trial; Platelet count; Randomized controlled trial; Skull irradiation}, -abstract = {Background: Niraparib is a highly selective PARP‐1/2 inhibitor approved by FDA for the maintenance therapy of ovarian cancer. It also showed promising activity as maintenance treatment in platinum sensitive SCLC PDX models. ZL‐2306‐005 is a randomized, double‐blind, multicenter phase Ⅲ study to evaluate the efficacy and safety of niraparib (nira) versus placebo (pla) as first line (1L) maintenance therapy in extensive‐stage SCLC (ES‐SCLC) patients. Methods: Patients (pts) with ES‐SCLC, ECOG PS 0 or 1, CR/PR after 4 cycles of 1L etoposide/cisplatin or etoposide/carboplatin were enrolled. Prophylactic cranial irradiation (PCI) was optional. Pts were randomized 2:1 to receive nira or pla once daily as maintenance therapy until progression or unacceptable toxicity. Nira started with 300mg QD for pts with baseline body weight ≥77 kg and platelet count ≥150,000/μL, otherwise 200 mg QD. Stratified factors were gender, LDH level and PCI history. The primary endpoints were PFS by blinded independent central review (BICR) and OS; the secondary endpoints were PFS by investigator, CFI, QoL, safety and tolerability. Results: From Jul 2017 to Feb 2020, 272 pts were screened in 34 sites, of whom 185 were randomized and dosed according to protocol, 125 in nira arm and 60 in pla arm. The study was early terminated due to landscape changed by immunotherapy in ES‐SCLC. At the data cutoff: 20 Mar 2020, there were 167 pts discontinued from the treatment and 70 pts died. Median PFS (BICR) was 1.54 m (1.41, 2.69) in nira arm and 1.36 m (1.31, 1.48) in pla arm (HR 0.66; 95% CI [0.46, 0.95]; p= 0.0242). Median OS was 9.92 m (9.33, 13.54) in nira arm and 11.43 m (9.53, NE) in pla arm (HR 1.03; 95% CI [0.42, 1.73]; p = 0.9052). Grade≥3 treatment‐related AEs (TEAEs) was 34.4% in nira arm vs. 25% in pla arm. No patient had a TEAE leading to death. Conclusions: Niraparib has modest improvement in PFS compared to placebo in 1L ES‐SCLC maintenance with manageable and tolerated safety profile. OS benefit was not observed based on immature data. The value of adding niraparib to immunotherapy needs further investigation. Clinical trial identification: NCT03516084. Legal entity responsible for the study: Zai Lab. Funding: Zai Lab. Shanghai Science and Technology Commission (18DZ1910700). Disclosure: B. Zhang, D. Zhang: Full/Part‐time employment: Zai Lab. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2020.10.371}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02202193/full} -} - - -Record #113 of 538 -@article{Varlotto21, -author = {Varlotto, JM, Sun, Z, Ky, B, Upshaw, J, Katz, SI, Fitzgerald, TJ, Wakelee, H, Diehn, M, Mankoff, DA, Lovely, C, Belani, C, Oettel, K, Masters, G, Ramalingam, S, and Pennell, NA}, -title = {A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study}, -journal = {Oncologist}, -volume = {26}, -number = {6}, -pages = {523‐532}, -year = {2021}, -accession_number = {EMBASE 2010758095, PUBMED 33594771}, -publication type = {Journal article}, -keywords = {*cancer staging; *chemoradiotherapy; *heart; *immunotherapy; *morbidity; *non small cell lung cancer; *radiation pneumonia; Adult; Advanced cancer; Article; Cancer patient; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [therapy]; Controlled study; Drug therapy; Female; Human; Humans; Immunotherapy; Lung Neoplasms [therapy]; Male; Overall survival; Phase 3 clinical trial; Progression free survival; Prospective Studies; Prospective study; Radiation dose escalation; Radiotherapy; Randomized Controlled Trials as Topic; Randomized controlled trial; Treatment failure}, -abstract = {ECOG‐ACRIN EA5181 is a phase III prospective, randomized trial that randomizes patients undergoing chemo/radiation for locally advanced non‐small cell lung cancer (LA‐NSCLC) to concomitant durvalumab or no additional therapy, with both arms receiving 1 year of consolidative durvalumab. Radiation dose escalation failed to improve overall survival in RTOG 0617. However, conventionally fractionated radiation to 60 Gy with concomitant chemotherapy is associated with a high risk of local failure (38%–46%). It is hoped that concomitant immunotherapy during chemo/radiation can help decrease the risk of local failure, thereby improving overall survival and progression‐free survival with acceptable toxicity. In this article, we review conventional chemo/radiation therapy for LA‐NSCLC, as well as the quickly evolving world of immunotherapy in the treatment of non‐small cell lung cancer and discuss the rationale and study design of EA5181. Implications for Practice: This article provides an up‐to‐date assessment of how immunotherapy is reshaping the landscape of metastatic non‐small cell lung cancer (NSCLC) and how the impact of this therapy is now rapidly moving into the treatment of patients with locally advanced NSCLC who are presenting for curative treatment. This article reviews the recent publications of chemo/radiation as well as those combining immunotherapy with chemotherapy and chemo/radiation, and provides a strategy for improving overall survival of patients with locally advanced NSCLC by using concomitant immunotherapy with standard concurrent chemo/radiation.}, -DOI = {10.1002/onco.13725}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02265529/full} -} - - -Record #114 of 538 -@article{Owonikoko19, -author = {Owonikoko, TK, Kim, HR, Govindan, R, Ready, N, Reck, M, Peters, S, Dakhil, SR, Navarro, A, Rodriguez-Cid, J, Schenker, M, Lee, JS, Gutierrez, V, Percent, I, Morgensztern, D, Fairchild, J, Baudelet, C, and Park, K}, -title = {Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): results from the double-blind, randomized phase III CheckMate 451 study}, -journal = {Annals of oncology}, -volume = {30}, -pages = {ii77}, -year = {2019}, -accession_number = {EMBASE 628119084}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer chemotherapy; *cancer patient; *maintenance therapy; *small cell lung cancer; *visually impaired person; Adult; Adverse event; Cancer survival; Conference abstract; Controlled study; Death; Double blind procedure; Drug combination; Drug dose regimen; Drug safety; Drug therapy; Drug withdrawal; Female; Follow up; Human; Major clinical study; Male; Overall survival; Pharmacokinetics; Phase 3 clinical trial; Progression free survival; Randomized controlled trial; Skull irradiation}, -abstract = {Background: In pts with ED‐SCLC, response rates to 1L platinum‐based chemo are high but lack durability. Treatments (txs) that prolong response duration and improve survival are needed. CheckMate 451 (NCT02538666) is a global, double‐blind, phase 3 study of nivo+ipi or nivo vs pbo as maintenance therapy in pts with ED‐SCLC who did not progress on 1L platinum‐based chemo. Methods: Pts (N =834) with ED‐SCLC, ECOG performance status (PS) ≤ 1 and response or stable disease after 4 cycles of 1L platinum‐based chemo were randomized 1:1:1 (3‐9 weeks from last dose of 1L chemo or 3‐11 weeks for pts who received prophylactic cranial irradiation [PCI]) to nivo 1 mg/kg + ipi 3 mg/kg Q3W intravenously (IV; 4 doses followed by nivo 240 mg Q2W IV; n =279), nivo 240 mg Q2W IV (n = 280), or pbo (n =275), stratified by PS, sex and prior PCI. Pts were treated up to 2 years or until progression or unacceptable toxicity. Primary endpoint was overall survival (OS) for nivo+ipi vs pbo. Secondary endpoints included OS for nivo vs pbo and progression‐free survival (PFS) per blinded independent central review for nivo+ipi vs pbo and nivo vs pbo. Results: Minimum study follow‐up was 9 months. Baseline characteristics were balanced between arms. OS was not significantly prolonged with nivo+ipi vs pbo (HR, 0.92; 95% CI 0.75‐1.12; P= 0.3693). OS was also not prolonged for nivo vs pbo (HR, 0.84; 95% CI 0.69‐1.02), although not formally tested due to statistical hierarchy. PFS HRs vs pbo were: nivo+ipi, 0.72 (0.60‐0.87); nivo, 0.67 (0.56‐0.81). Rates of all‐grade (grade 3‐4) tx‐related adverse events were: nivo+ipi, 86% (52%); nivo, 61% (12%); pbo, 50% (8%). Rates of discontinuation due to tx toxicity were: nivo+ipi, 31%; nivo, 9%; pbo,<1%. Tx‐related deaths were: nivo+ipi, 7 (2.5%); nivo, 1 (<1%); pbo, 1 (<1%). Conclusions: In CheckMate 451, maintenance therapy with nivo+ipi (primary endpoint) or nivo did not prolong OS vs pbo for ED‐SCLC patients who did not progress on 1L chemo. Safety profiles of nivo+ipi and nivo were consistent with previous reports at this dose/schedule in SCLC.}, -DOI = {10.1093/annonc/mdz094}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01957856/full} -} - - -Record #115 of 538 -@article{Wehler21, -author = {Wehler, T, Wehler, B, Atmaca-Dirik, H, Topsch, J, and Ehrlich, A}, -title = {DOLPHIN: phase II trial of Cisplatin/Etoposide (CTx) + Radiotherapy (RTx) (RCTx) combined with Durvalumab followed by Durvalumab maintenance versus concomitant RCTx in patients (pts) with limited disease Small Cell Lung Cancer (LD-SCLC)}, -journal = {Oncology research and treatment}, -volume = {44}, -number = {SUPPL 2}, -pages = {254‐255}, -year = {2021}, -accession_number = {EMBASE 636847809}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *drug tolerability; *small cell lung cancer; Adult; Autoimmune disease; Cancer survival; Chemoradiotherapy; Clinical trial; Comparative effectiveness; Conference abstract; Diagnosis; Disease control; Drug combination; Drug safety; Drug therapy; ECOG Performance Status; Female; Germany; High throughput sequencing; Human; Major clinical study; Male; Multicenter study; Overall response rate; Overall survival; Parallel design; Pharmacokinetics; Phase 2 clinical trial; Progression free survival; Prospective study; Quality of life; Radiotherapy; Randomized controlled trial; Skull irradiation; Tumor biopsy}, -abstract = {Introduction: SCLC accounts for approx. 15% of lung cancers, of which approx. 30% of patients show LD‐SCLC. Since Takada et al. showed superiority of concomitant RCTx, this is seen as standard of care (SoC). 2 trials recently have shown an overall survival (OS) benefit for adding PD‐L1 antibodies to CTx in pts with extensive disease SCLC. For limited disease patients concomitant RCTx and Durvalumab followed by Durvalumab maintenance may therefore show better results for progression free survival (PFS). Methods/Trial design: This clinical trial is a prospective, multicenter, randomized, open‐label, parallel group phase II investigator initiated trial (IIT) to evaluate the efficacy and safety of Durvalumab in combination with Cisplatin/Etoposide/Radiotherapy followed by maintenance Durvalumab in patients with LD‐SCLC. Prophylactic cranial irradiation is possible in both groups. Eligible pts have LD‐SCLC, are eligible for radiochemotherapy, have ECOG PS 0/1, no active or prior documented autoimmune or inflammatory disorder, no systemic steroids >10mg/d prednisone equivalent, no uncontrolled intercurrent illness. After a Safety run‐in phase with 6 pts in the Durvalumab group and an interim safety analysis after all 6 have completed the 1st cycle pts will be randomised 2:1 to Durvalumab group vs. SoC (RCTx). All pts receive 4‐6 cycles of CTx and RTx of 60±6 Gy, 2 Gy/d), Durvalumab maintenance continues until progressive disease. The primary endpoint is PFS after 18 months. Secondary endpoints include overall response rate, disease control rate, OS, PFS at other assessments, patient reported quality of life and safety and tolerability. The trial began in December 2020 and recruitment is ongoing and planned at seven sites in Germany; an estimated 105 pts will be enrolled. Duration of the trial is estimated 30 months. Assessment of biomarker analysis of tumor biopsies will be performed for all patients by central lab by next generation sequencing (NGS).}, -DOI = {10.1159/000518417}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02359637/full} -} - - -Record #116 of 538 -@article{Reinmuth21, -author = {Reinmuth, N, Garassino, MC, Trukhin, D, Hochmair, MJ, Ozguroglu, M, Havel, L, Goldman, J, Chen, Y, Losonczy, G, Spinnato, F, Conev, N, Bar, J, Broadhurst, H, Byrne, N, Jiang, H, and Paz-Ares, L}, -title = {P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: exploratory Analyses Based on Extent of Disease in CASPIAN}, -journal = {Journal of thoracic oncology}, -volume = {16}, -number = {3}, -pages = {S500}, -year = {2021}, -accession_number = {EMBASE 2011422076}, -publication type = {Journal article; Conference proceeding}, -keywords = {*exploratory research; *small cell lung cancer; Adrenal gland; Adult; Bone; Brain; Cancer patient; Cancer radiotherapy; Cancer staging; Cancer survival; Conference abstract; Controlled study; Drug combination; Drug therapy; Female; Follow up; Human; Liver; Lung lesion; Major clinical study; Male; Overall survival; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Skull irradiation; Thorax disease}, -abstract = {Introduction: In the Phase 3, randomised, open‐label CASPIAN study, first‐line durvalumab plus etoposide and cisplatin or carboplatin (EP) significantly improved overall survival (OS) compared with EP alone in patients with extensive‐stage small‐cell lung cancer (ES‐SCLC) at the planned interim analysis (data cut‐off: 11 March 2019): hazard ratio (HR) 0.73 (95% confidence interval [CI] 0.59–0.91; p=0.0047). This OS benefit was sustained after a median follow‐up of more than 2 years (data cut‐off 27 Jan 2020): HR 0.75 (95% CI 0.62‒0.91; nominal p=0.0032). Here we present post‐hoc exploratory analyses at the updated data cut‐off based on the extent of disease at baseline. Methods: Treatment‐naïve patients (WHO performance status 0/1) with ES‐SCLC received 4 cycles of durvalumab 1500 mg + EP q3w followed by maintenance durvalumab 1500 mg q4w until disease progression (PD) or up to 6 cycles of EP q3w and optional prophylactic cranial irradiation (investigator’s discretion). Planned consolidation thoracic radiotherapy (TRT) was not permitted. The primary endpoint was OS. Progression‐free survival (PFS) was a secondary endpoint. Patients with M0 or M1a classification at diagnosis were included in the thoracic‐only disease subgroup and M1b in the extra‐thoracic disease subgroup. Data cut‐off: 27 Jan 2020. Results: At baseline, 151 (28.1%) of 537 patients had thoracic‐only disease, of whom 77 (28.7%) were in the durvalumab + EP arm and 74 (27.5%) were in the EP arm. Among 386 (71.9%) patients with any extra‐thoracic disease at baseline, 191 (71.3%) were in the durvalumab + EP arm and 195 (72.5%) were in the EP arm; across both arms, the most common sites of extra‐thoracic disease were liver (52.8%), adrenal gland (35.8%), bone (31.3%) and brain (13.7%). Durvalumab + EP improved OS vs EP regardless of the extent of disease (thoracic‐only HR 0.73 [95% CI 0.51–1.06]; extra‐thoracic HR 0.77 [0.62–0.96]); PFS was also improved with durvalumab + EP vs EP in these subgroups (HR 0.70 [95% CI 0.49–1.00] and 0.85 [0.68–1.05], respectively). Among patients with extra‐thoracic disease, 52.8% in the EP arm developed new lesions at first PD vs 44.5% in the durvalumab + EP arm (EP vs durvalumab + EP: lung 14.4% vs 8.9%; liver 11.8% vs 6.8%; bone 8.7% vs 4.7%). In the thoracic‐only disease subgroup, a similar proportion of patients had new lesions at first PD in the EP (36.5%) and durvalumab + EP (36.4%) arms, however more patients developed new lesions in the lung in the EP arm compared with the durvalumab + EP arm (20.3% vs 7.8%). TRT was administered concurrently with study treatment in 1.1% of all patients across both arms. TRT was administered subsequent to study treatment in a higher proportion of patients in the EP arm compared with the durvalumab + EP arm, regardless of whether patients had thoracic‐only disease (31.1% vs 7.8%) or extra‐thoracic disease (12.3% vs 7.3%). Conclusion: In CASPIAN, OS and PFS were improved with durvalumab + EP vs EP, regardless of the presence or absence of extra‐thoracic disease, consistent with the intention‐to‐treat analyses. Keywords: CASPIAN, Durvalumab, PD‐L1}, -DOI = {10.1016/j.jtho.2021.01.873}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02267493/full} -} - - -Record #117 of 538 -@article{Spaas23, -author = {Spaas, M, Sundahl, N, Kruse, V, Rottey, S, De Maeseneer, D, Duprez, F, Lievens, Y, Surmont, V, Brochez, L, Reynders, D, Danckaert, W, Goetghebeur, E, Van den Begin, R, Van Gestel, D, Renard, V, Dirix, P, and Ost, P}, -title = {Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: the CHEERS Phase 2 Randomized Clinical Trial}, -journal = {JAMA oncology}, -volume = {9}, -number = {9}, -pages = {1205‐1213}, -year = {2023}, -accession_number = {EMBASE 641752422, PUBMED 37410476}, -publication type = {Journal article}, -keywords = {*Carcinoma, Transitional Cell [drug therapy]; *Lung Neoplasms [drug therapy]; *Radiosurgery [adverse effects]; *Urinary Bladder Neoplasms [drug therapy]; *advanced cancer; *cancer inhibition; *cancer patient; *cancer radiotherapy; *head and neck squamous cell carcinoma; *stereotactic body radiation therapy; Aged; Antineoplastic Combined Chemotherapy Protocols; Article; Cancer survival; Clinical trial; Controlled study; Data analysis; Disease burden; Drug therapy; Female; Follow up; Health care quality; Histology; Human; Human tissue; Humans; Immune response; Lack of drug effect; Ligands; Major clinical study; Male; Melanoma; Metastatic melanoma; Monotherapy; Multicenter study; Non small cell lung cancer; Overall survival; Phase 2 clinical trial; Progression free survival; Radiotherapy; Randomization; Randomized controlled trial; Renal cell carcinoma; Response evaluation criteria in solid tumors; Stereotactic radiosurgery; Surgery; Systemic therapy; Transitional cell carcinoma; Treatment Outcome; Treatment failure}, -abstract = {Importance: Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD‐1) and PD‐1 ligand 1 have improved the outcome for many cancer types, the majority of patients fails to respond to ICI monotherapy. Hypofractionated radiotherapy has the potential to improve the therapeutic ratio of ICIs. Objective: To assess the addition of radiotherapy to ICIs compared with ICI monotherapy in patients with advanced solid tumors. Design, Setting, and Participants: This open‐label, multicenter, randomized phase 2 trial was conducted in 5 Belgian hospitals and enrolled participants between March 2018 and October 2020. Patients 18 years or older with locally advanced or metastatic melanoma, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, or non‐small cell lung carcinoma were eligible. A total of 99 patients were randomly assigned to either the control arm (n = 52) or the experimental arm (n = 47). Of those, 3 patients (1 in the control arm vs 2 in the experimental arm) withdrew consent and thus were not included in the analysis. Data analyses were performed between April 2022 and March 2023. Interventions: Patients were randomized (1:1) to receive anti‐PD‐1/PD‐1 ligand 1 ICIs alone as per standard of care (control arm) or combined with stereotactic body radiotherapy 3 × 8 gray to a maximum of 3 lesions prior to the second or third ICI cycle, depending on the frequency of administration (experimental arm). Randomization was stratified according to tumor histologic findings and disease burden (3 and fewer or more than 3 cancer lesions). Main Outcomes and Measures: The primary end point was progression‐free survival (PFS) as per immune Response Evaluation Criteria in Solid Tumors. Key secondary end points included overall survival (OS), objective response rate, local control rate, and toxic effects. Efficacy was assessed in the intention‐to‐treat population, while safety was evaluated in the as‐treated population. Results: Among 96 patients included in the analysis (mean age, 66 years; 76 [79%] female), 72 (75%) had more than 3 tumor lesions and 65 (68%) had received at least 1 previous line of systemic treatment at time of inclusion. Seven patients allocated to the experimental arm did not complete the study‐prescribed radiotherapy course due to early disease progression (n = 5) or intercurrent illness (n = 2). With a median (range) follow‐up of 12.5 (0.7‐46.2) months, median PFS was 2.8 months in the control arm compared with 4.4 months in the experimental arm (hazard ratio, 0.95; 95% CI, 0.58‐1.53; P = .82). Between the control and experimental arms, no improvement in median OS was observed (11.0 vs 14.3 months; hazard ratio, 0.82; 95% CI, 0.48‐1.41; P = .47), and objective response rate was not statistically significantly different (22% vs 27%; P = .56), despite a local control rate of 75% in irradiated patients. Acute treatment‐related toxic effects of any grade and grade 3 or higher occurred in 79% and 18% of patients in the control arm vs 78% and 18% in the experimental arm, respectively. No grade 5 adverse events occurred. Conclusions and Relevance: This phase 2 randomized clinical trial demonstrated that while safe, adding subablative stereotactic radiotherapy of a limited number of metastatic lesions to ICI monotherapy failed to show improvement in PFS or OS. Trial Registration: ClinicalTrials.gov Identifier: NCT03511391.}, -DOI = {10.1001/jamaoncol.2023.2132}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02580197/full} -} - - -Record #118 of 538 -@article{Tsuboi22, -author = {Tsuboi, M, Goldman, JW, Wu, YL, Johnson, ML, Paz-Ares, L, Yang, JC, Besse, B, Su, W, Chao, BH, and Drilon, A}, -title = {LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer}, -journal = {Future oncology (London, England)}, -volume = {18}, -number = {28}, -pages = {3133‐3141}, -year = {2022}, -accession_number = {EMBASE 638718398, PUBMED 35950566}, -publication type = {Journal article}, -keywords = {*adjuvant chemotherapy; *cancer adjuvant therapy; *molecularly targeted therapy; *non small cell lung cancer; Adult; Cancer recurrence; Carcinoma, Non‐Small‐Cell Lung [drug therapy, genetics]; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Clinical trial; Controlled study; Female; Human; Humans; Lung Neoplasms [drug therapy, genetics]; Male; Neoplasm Recurrence, Local [pathology]; Neoplasm Staging; Phase 3 clinical trial; Protein Kinase Inhibitors [adverse effects]; Proto‐Oncogene Proteins c‐ret [genetics]; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Review; Side effect}, -abstract = {Selpercatinib, a first‐in‐class, highly selective and potent central nervous system‐active RET kinase inhibitor demonstrated clinically meaningful activity with manageable toxicity in pretreated and treatment‐naive advanced/metastatic RET fusion‐positive non‐small‐cell lung cancer (NSCLC). LIBRETTO‐432 is a global, randomized, double‐blind, phase III trial evaluating selpercatinib versus placebo in stage IB‐IIIA, RET fusion‐positive NSCLC, previously treated with definitive surgery or radiation; participants must have undergone available anti‐cancer therapy (including chemotherapy or durvalumab) or not be suitable for it, per investigator's discretion. The primary end point is investigator‐assessed event‐free survival (EFS) in the primary analysis population (stage II‐IIIA RET fusion‐positive NSCLC). Key secondary end points include EFS in the overall population, overall survival, and time to distant disease recurrence in the central nervous system.}, -DOI = {10.2217/fon-2022-0656}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02462976/full} -} - - -Record #119 of 538 -@article{Rudin17, -author = {Rudin, CM, Shen, L, and Pietanza, MC}, -title = {KEYNOTE-604: phase 3 trial of pembrolizumab plus etoposide/ platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC)}, -journal = {Annals of oncology}, -volume = {28}, -pages = {v541}, -year = {2017}, -accession_number = {EMBASE 619623357}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *small cell lung cancer; Adult; Adverse event; Antineoplastic activity; Clinical trial; Controlled study; Diagnosis; Double blind procedure; Drug combination; Drug therapy; Drug withdrawal; Female; Human; Major clinical study; Male; Monotherapy; Nomenclature; Patient‐reported outcome; Phase 1 clinical trial; Phase 3 clinical trial; Randomization; Randomized controlled trial; Response evaluation criteria in solid tumors; Skull irradiation; Study design; Systemic therapy; Toxicity; Vascular guide wire}, -abstract = {Background: Therapeutic options for SCLC remain limited, with EP as the standard first‐line chemotherapy regimen. However, patients (pts) with ES‐SCLC experience high relapse rates within months after initial therapy. Pembrolizumab, a humanized monoclonal antibody against PD‐1, has shown antitumor activity as monotherapy in heavily pretreated pts with PD‐L1‐positive SCLC in the phase 1b KEYNOTE‐028 study. KEYNOTE‐604 (ClinicalTrials.gov, NCT03066778) evaluates EP plus either pembrolizumab or placebo (pbo) as first‐line therapy for ES‐SCLC. Trial design: In this international, double‐blind, phase 3 trial, adults with newly diagnosed ES‐SCLC, ECOG PS≤1, and no previous systemic therapy for SCLC are randomized 1:1 to receive either EP plus a 200‐mg fixed dose of pembrolizumab intravenously (IV) once every 3 weeks (Q3W) or EP plus pbo IV Q3W. Randomization is stratified by the chosen platinum therapy (carboplatin vs cisplatin), ECOG PS (0 vs 1), and baseline lactate dehydrogenase concentration (≤ upper limit of normal [ULN] vs > ULN). Study treatment includes a total of 4 cycles of EP and 2 y of pembrolizumab/ pbo and continues until documented PD, intolerable toxicity, or withdrawal of consent. Pts with a response after 4 cycles of EP plus pbo or pembrolizumab may receive prophylactic cranial irradiation. Pts who complete 2 y of pembrolizumab treatment or stop pembrolizumab for reasons other than PD/intolerability, but subsequently have documented PD, may receive an additional 1 y of pembrolizumab. Tumor response is assessed every 6 wk for 48 wk, and every 9 wk thereafter by RECIST version 1.1 by blinded independent central review. AEs occurring during treatment and 30 d thereafter (90 d for serious AEs) are graded per Common Terminology Criteria for Adverse Events, version 4.0. Primary endpoints are PFS and OS. Secondary endpoints are ORR, duration of response, safety, and patient‐reported outcomes. Enrollment is ongoing with a planned enrollment of approximately 430 pts.}, -DOI = {10.1093/annonc/mdx386.007}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01438423/full} -} - - -Record #120 of 538 -@article{Gomez-Randulfe Rodriguez24, -author = {Gomez-Randulfe Rodriguez, MI, Escriu, C, Mohammed, S, Shah, R, Fuentes, JDB, Cox, S, Monaca, F, Bria, E, Diaz, SS, Campelo, MRG, Crook, B, Talbot, T, Leporati, R, Balachandran, K, Newsom-Davis, T, Hughes, S, Cove-Smith, L, Taylor, P, Blackhall, F, and Califano, R}, -title = {Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis}, -journal = {ESMO open}, -volume = {9}, -year = {2024}, -accession_number = {EMBASE 2030949297}, -publication type = {Journal article; Conference proceeding}, -keywords = {*immunotherapy; *small cell lung cancer; Adult; Aged; Aggression; Clinical trial; Conference abstract; Controlled study; Diagnosis; Female; Genotype; Genotyping; Human; Lung cancer; Major clinical study; Male; Middle aged; Overall survival; Phase 4 clinical trial; Practice guideline; Progression free survival; Radiotherapy; Skull irradiation; Symposium}, -abstract = {Background: Extensive Stage Small cell Lung Cancer (ES‐SCLC) is an aggressive disease with poor outcomes. Although most patients (pts) initially respond to first‐line (1L) treatment, eventually all will relapse. Second‐line (2L) therapeutic options have limited efficacy. For pts with platinum‐free interval (PFI) ≥90 days, rechallenge with carboplatin‐etoposide (CE) is a standard option. A phase 3, randomized trial comparing rechallenge CE vs topotecan in pts with PFI ≥90 days, demonstrated longer progression‐free survival (PFS) in the rechallenge group (4.7 m vs 2.7 m; HR=0.57; p=.0041) but similar (7.5 v 7.4 m) overall survival (OS). However, this study pre‐dates the use of 1st line chemo‐immunotherapy (CT‐IO) therefore the efficacy of platinum rechallenge after CT‐IO is still unclear. Real‐world data could offer valuable insights for this strategy. Methods: We retrospectively reviewed pts with ES‐SCLC who received second‐line rechallenge CE after first‐line CT‐IO between September 2020 and August 2023 in 9 European centres. Demographic and clinical data were collected and analysed. Results: A total of 93 pts were included. Sixty‐six pts (71%) had PFI between 3 and 6 m. Clinical and demographic characteristics stratified by PFI are shown in the table. Consolidation thoracic radiotherapy and prophylactic cranial irradiation had been administered in 31 pts (33.3%) and 20 pts (21.5%), respectively. ORR was 59.1%. Median PFS was 5 m (95% CI, 4.3 – 5.7) and median OS was 7 m (95% CI, 5.7 – 8.3). Notably, PFS and OS were not different according to PFI (3‐6 m v > 6 m). [Formula presented] Conclusions: Rechallenge with CE is a valid 2L option in pts diagnosed with ES‐SCLC who progress after 1L CT‐IO. Our analysis shows similar results compared to previous studies. Furthermore, outcomes were consistent across pts with different PFIs, confirming its efficacy in pts with PFI > 3 months. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: R. Shah: Financial Interests, Personal, Advisory Board, Advisory board + speaker roles: BMS; Financial Interests, Personal, Advisory Board, Ad board and speaker roles: Boehringer Ingelheim, AstraZeneca, Roche, MSD, Pfizer, Lilly, Novartis, Takeda, Bayer, BeiGene, Guardant, Sanofi, EQRx, Merck; Financial Interests, Personal, Other, specialist advisor: Genesiscare; Non‐Financial Interests, Personal, Leadership Role, Steering committee member: BTOG. E. Bria: Financial Interests, Personal, Advisory Board: AZ, Roche, BMS, MSD, Eli Lilly, Amgen, Pfizer, Novartis; Financial Interests, Personal, Invited Speaker: AZ, Roche, BMS, MSD, Eli Lilly, Pfizer, Novartis; Financial Interests, Institutional, Research Grant: AZ, Roche. S. Silva Diaz: Financial Interests, Personal, Invited Speaker: Pfizer, Ipsen. T. Talbot: Financial Interests, Personal, Invited Speaker: Merck, Dohme. T. Newsom‐Davis: Financial Interests, Personal, Advisory Role: Amgen, Bayer, AstraZeneca, BMS, Boehringen Ingelheim, Eli Lilly, MSD, Novartis, Pfizer, Roche, Takeda. F. Blackhall: Financial Interests, Personal, Invited Speaker, Educational Symposium lecture: AstraZeneca; Financial Interests, Personal, Advisory Board, NTRK Advisory Board and guidelines for diagnosis: Bayer; Financial Interests, Personal, Other, IDMC Chair: AstraZeneca; Financial Interests, Personal, Advisory Board, Small cell Advisory Board Oct 2020: Amgen; Financial Interests, Personal, Invited Speaker, ESMO Satellite Symposium November 2020: Takeda; Financial Interests, Personal, Other, Consultancy for RETinhibitor development: Blueprint; Financial Interests, Personal, Other, Real world evidence research study design and analysis (EGFR): Janssen; Financial Interests, Institutional, Invited Speaker, Institutional payment for clinical trial activities: Amgen, Pfizer; Financial Interests, Institutional, Invited Speaker, Payment for clinical trial activities: Mirati; Financial Interests, Institutional, Invited Speaker, Clinical trial activities: BMS; Financial Interests, Institutional, Funding, Real world evidence research programme: Roche; Non‐Financial Interests, Personal, Advisory Role, Application of genotyping platforms in lung cancer: Guardant Health; Non‐Financial Interests, Personal, Advisory Role, Clinical trials of IMPs in lung cancer and translational lung cancer biomarkers: AstraZeneca. R. Califano: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, Roche, Pfizer; Financial Interests, Personal, Advisory Role: MSD, Lilly Oncology, BMS, Takeda, Janssen, Bayer, Novartis. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.esmoop.2024.102774}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02685569/full} -} - - -Record #121 of 538 -@article{Zhong24, -author = {Zhong, H, Sun, S, Chen, J, Wang, Z, Zhao, Y, Zhang, G, Chen, G, Zhou, M, Zhou, J, Du, Y, Wu, L, Xu, Z, Mei, X, Zhang, W, He, J, Cui, J, Zhang, Z, Luo, H, Liu, W, Sun, M, Wu, J, Shen, Y, Zhang, S, Yang, N, Wang, M, Lu, J, Li, K, Yao, W, Sun, Q, Yue, H, Wang, L, Ye, S, Li, B, Zhuang, X, Pan, Y, Zhang, M, Shu, Y, He, Z, Pan, L, Ling, Y, Liu, S, Zhang, Q, Jiao, S, and Han, B}, -title = {First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial}, -journal = {Lancet respiratory medicine}, -volume = {12}, -number = {5}, -pages = {355‐365}, -year = {2024}, -accession_number = {EMBASE 2030147452, PUBMED 38309287}, -publication type = {Journal article}, -keywords = {*Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; *Carboplatin [administration & dosage, therapeutic use]; *Carcinoma, Non‐Small‐Cell Lung [drug therapy, pathology]; *China; *Lung Neoplasms [drug therapy, pathology]; *Paclitaxel [administration & dosage, therapeutic use]; *metastasis; *non small cell lung cancer; Adult; Adverse drug reaction; Aged; Antibodies, Monoclonal, Humanized [administration & dosage, therapeutic use]; Article; Chemoradiotherapy; China; Controlled study; Double blind procedure; Double‐Blind Method; Drug combination; Ethnicity; Female; First‐line treatment; Follow up; Human; Humans; Intention to treat analysis; Maintenance therapy; Major clinical study; Male; Middle Aged; Multicenter study; Multiple cycle treatment; Neoplastic cell transformation; Phase 3 clinical trial; Progression free survival; Progression‐Free Survival; Randomized controlled trial; Response evaluation criteria in solid tumors; Side effect; Special situation for pharmacovigilance; Treatment Outcome}, -abstract = {Background: Penpulimab is a novel programmed death (PD)‐1 inhibitor. This study aimed to establish the efficacy and safety of first line penpulimab plus chemotherapy for advanced squamous non‐small‐cell lung cancer. Methods: This multicentre, randomised, double‐blind, placebo‐controlled, phase 3 clinical trial enrolled patients with locally advanced or metastatic squamous non‐small‐cell lung cancer from 74 hospitals in China. Eligible participants were aged 18–75 years, had histologically or cytologically confirmed locally advanced (stage IIIb or IIIc) or metastatic (stage IV) squamous non‐small‐cell lung cancer, were ineligible to complete surgical resection and concurrent or sequential chemoradiotherapy, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, did not have previous systemic chemotherapy for locally advanced or metastatic non‐small‐cell lung cancer, and had one or more measurable lesions according to RECIST (version 1.1). Participants were randomly assigned (1:1) to receive intravenous penpulimab 200 mg or placebo (excipient of penpulimab injection), plus paclitaxel 175 mg/m2 and carboplatin AUC of 5 intravenously on day 1 every 3 weeks for four cycles, followed by penpulimab or placebo as maintenance therapy. Stratification was done according to the PD‐L1 tumour proportion score (<1% vs 1–49% vs ≥50%) and sex (male vs female). The participants, investigators, and other research staff were masked to group assignment. The primary outcome was progression‐free survival assessed by the masked Independent Radiology Review Committee in the intention‐to‐treat population and patients with a PD‐L1 tumour proportion score of 1% or more (PD‐L1‐positive subgroup). The primary analysis was based on the intention‐to‐treat analysis set (ie, all randomly assigned participants) and the PD‐L1‐positive subgroup. The safety analysis included all participants who received at least one dose of study drug after enrolment. This trial was registered with ClinicalTrials.gov (NCT03866993). Findings: Between Dec 20, 2018, and Oct 10, 2020, 485 patients were screened, and 350 participants were randomly assigned (175 in the penpulimab group and 175 in the placebo group). Of 350 participants, 324 (93%) were male and 26 (7%) were female, and 347 (99%) were of Han ethnicity. In the final analysis (June 1, 2022; median follow‐up, 24·7 months [IQR 0–41·4]), the penpulimab group showed an improved progression‐free survival compared with the placebo group, both in the intention‐to‐treat population (median 7·6 months, 95% CI 6·8–‐9·6 vs 4·2 months, 95% CI 4·2–4·3; HR 0·43, 95% CI 0·33–0·56; p<0·0001) and in the PD‐L1‐positive subgroup (8·1 months, 5·7–9·7 vs 4·2 months, 4·1–4·3; HR 0·37, 0·27–0·52, p<0·0001). Grade 3 or worse treatment‐emergent adverse events occurred in 120 (69%) 173 patients in the penpulimab group and 119 (68%) of 175 in the placebo group. Interpretation: Penpulimab plus chemotherapy significantly improved progression‐free survival in patients with advanced squamous non‐small‐cell lung cancer compared with chemotherapy alone. The treatment was safe and tolerable. Penpulimab combined with paclitaxel and carboplatin is a new option for first‐line treatment in patients with this advanced disease. Funding: The National Natural Science Foundation of China, Shanghai Municipal Health Commission, Chia Tai Tianqing Pharmaceutical, Akeso.}, -DOI = {10.1016/S2213-2600(23)00431-9}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02660668/full} -} - - -Record #122 of 538 -@article{Varlotto22, -author = {Varlotto, JM, Sun, Z, Ky, B, Upshaw, J, Fitzgerald, TJ, Diehn, M, Lovly, C, Belani, C, Oettel, K, Masters, G, Harkenrider, M, Ross, H, Ramalingam, S, and Pennell, NA}, -title = {A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181}, -journal = {Clinical lung cancer}, -volume = {23}, -number = {7}, -pages = {547‐560}, -year = {2022}, -accession_number = {EMBASE 2019418789, PUBMED 35882620}, -publication type = {Journal article}, -keywords = {*advanced cancer; *cardiotoxicity; *chemoradiotherapy; *immunotherapy; *lung toxicity; *morbidity; *non small cell lung cancer; *tumor mutational burden; Adult; B7‐H1 Antigen; Biomarkers, Tumor [genetics]; Carcinoma, Non‐Small‐Cell Lung [drug therapy]; Chemotherapy; Consolidation chemotherapy; Controlled study; Drug combination; Drug safety; Female; High throughput sequencing; Human; Humans; Immunotherapy [methods]; Incidence; Lung Neoplasms [drug therapy]; Male; Phase 1 clinical trial (topic); Prospective study; Protein function; Radiotherapy; Randomized Controlled Trials as Topic; Randomized controlled trial (topic); Review}, -abstract = {ECOG‐ACRIN EA5181 is a current prospective, randomized trial that is investigating whether the addition of concomitant durvalumab to standard chemo/radiation followed by 1 year of consolidative durvalumab results in an overall survival benefit over standard chemo/radiation alone followed by 1 year of consolidative durvalumab in patients with locally advanced, unresectable non‐small cell lung cancer (NSCLC). Because multiple phase I/II trials have shown the relative safety of adding immunotherapy to chemo/radiation and due to the known synergism between chemotherapy and immunotherapy, it is hoped that concomitant durvalumab can reduce the relatively high incidence of local failure (38%‐46%) as seen in recent prospective, randomized trials of standard chemo/radiation in this patient population. We will review the history of radiation for LA‐NSCLC and discuss the role of induction, concurrent and consolidative chemotherapy as well as the concerns for late cardiac and pulmonary toxicities associated with treatment. Furthermore, we will review the potential role of next generation sequencing, PD‐L1, ctDNA and tumor mutation burden and their possible impact on this trial.}, -DOI = {10.1016/j.cllc.2022.06.005}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02465485/full} -} - - -Record #123 of 538 -@article{Antonia17, -author = {Antonia, SJ, Villegas, A, Daniel, D, Vicente, D, Murakami, S, Hui, R, Yokoi, T, Chiappori, A, Lee, KH, de Wit, M, Cho, BC, Bourhaba, M, Quantin, X, Tokito, T, Mekhail, T, Planchard, D, Kim, YC, Karapetis, CS, Hiret, S, Ostoros, G, Kubota, K, Gray, JE, Paz-Ares, L, de Castro Carpeño, J, Wadsworth, C, Melillo, G, Jiang, H, Huang, Y, Dennis, PA, and Özgüroglu, M}, -title = {Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer}, -journal = {New England journal of medicine}, -volume = {377}, -number = {20}, -pages = {1919‐1929}, -year = {2017}, -accession_number = {EMBASE 619258301, PUBMED 28885881}, -publication type = {Journal article}, -keywords = {*cancer chemotherapy; *chemoradiotherapy; *non small cell lung cancer /drug therapy /radiotherapy; Adult; Aged; Aged, 80 and over; Anemia /side effect; Antibodies, Monoclonal [adverse effects, *therapeutic use]; Antineoplastic Agents [adverse effects, *therapeutic use]; Aortic dissection /side effect; Arthralgia /side effect; Article; Asthenia /side effect; B7‐H1 Antigen [*antagonists & inhibitors]; Backache /side effect; Bacterial pneumonia /side effect; Cancer growth; Cancer mortality; Cancer radiotherapy; Cancer staging; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [mortality, secondary, *therapy]; Cardiomyopathy /side effect; Chemoradiotherapy; Confidence interval; Constipation /side effect; Controlled study; Coughing /side effect; Decreased appetite /side effect; Diarrhea /side effect; Disease‐Free Survival; Drug megadose; Drug safety; Drug withdrawal; Dyspnea /side effect; Emphysema /side effect; Eosinophilic colitis /side effect; Fatigue /side effect; Female; Fever /side effect; Hazard ratio; Headache /side effect; Heart arrest /side effect; Heart failure /side effect; Heart infarction /side effect; Heart right ventricle failure /side effect; Hemoptysis /side effect; Human; Humans; Hypothyroidism /side effect; Immunopathology /drug therapy /side effect; Intention to Treat Analysis; Interstitial lung disease /side effect; Interstitial pneumonia /side effect; Intestine obstruction /side effect; Kaplan‐Meier Estimate; Lung Neoplasms [mortality, pathology, *therapy]; Lung fibrosis /side effect; Lung insufficiency /side effect; Major clinical study; Male; Middle Aged; Multiple cycle treatment; Musculoskeletal pain /side effect; Myocarditis /side effect; Nausea /side effect; Neoplasm Staging; Overall survival; Pneumonia /side effect; Priority journal; Progression free survival; Pruritus /side effect; Radiation dose; Radiation pneumonia /side effect; Randomized controlled trial; Rash /side effect; Respiratory distress /side effect; Respiratory failure /side effect; Sepsis /side effect; Septic shock /side effect; Streptococcus pneumonia /side effect; Survival rate; Treatment duration; Treatment response; Upper respiratory tract infection /side effect; Very elderly; West Nile fever /side effect}, -abstract = {BACKGROUND: Most patients with locally advanced, unresectable, non‐small‐cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti‐programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum‐based chemoradiotherapy. METHODS: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression‐free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12‐month and 18‐month progression‐free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. RESULTS: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression‐free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12‐month progression‐free survival rate was 55.9% versus 35.3%, and the 18‐month progression‐free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events. CONCLUSIONS: Progression‐free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).}, -DOI = {10.1056/NEJMoa1709937}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01427861/full} -} - - -Record #124 of 538 -@article{NCT0631354124, -author = {NCT06313541,}, -title = {Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy}, -journal = {https://clinicaltrials.gov/ct2/show/NCT06313541}, -year = {2024}, -accession_number = {CTgov NCT06313541}, -publication type = {Trial registry record}, -keywords = {Carcinoma, Non‐Small‐Cell Lung; Immune Checkpoint Inhibitors}, -abstract = {This study is a multicenter, randomized controlled clinical trial to explore the preliminary efficacy and safety of treatment response adapted hybrid radiotherapy (LDRT and SBRT) in the first‐line treatment of immunotherapy combined with chemotherapy for advanced driver‐gene negative NSCLC, and to provide new ideas for the comprehensive treatment of advanced NSCLC}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02673017/full} -} - - -Record #125 of 538 -@article{NCT0347205318, -author = {NCT03472053,}, -title = {A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer}, -journal = {https://clinicaltrials.gov/show/NCT03472053}, -year = {2018}, -accession_number = {CTgov NCT03472053}, -publication type = {Trial registry record}, -keywords = {Carcinoma, Non‐Small‐Cell Lung; Lung Neoplasms}, -abstract = {This randomized, open label, multicenter Phase 2 study is to evaluate safety and efficacy of BIO‐11006 in Stage IIIB Non Small Cell Lung cancer (NSCLC) patients who are not candidates for curative surgery, radiation, or immunotherapy and who are also receiving Pemetrexed and Carboplatin as standard of care (SOC). This study will be conducted at ten clinical centers in India under an IND from US‐FDA and an IND from Indian FDA. This is a parallel 2‐ Arm study in which a total of 60 patients will be randomized. One Arm of 30 subjects will receive aerosolized 125mg BIO‐11006 BID using Pari eFlow nebulizer in conjunction with SOC chemotherapy (Pemetrexed plus Carboplatin). A second Arm of 30 subjects will receive only SOC chemotherapy (Pemetrexed plus Carboplatin). The treatment period will be three months and nine months survival follow up period (every three months). Primary efficacy endpoint will be Progression‐free survival (PFS) in patients who receive BIO‐11006 plus SOC compared to those who receive SOC alone. The secondary efficacy endpoints will include: a. Response rate at three months (4 cycles) per RECIST V1.1; (b) overall survival; and (c) patient body weight maintenance.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01567356/full} -} - - -Record #126 of 538 -@article{EUCTR2006-001173-14-IT07, -author = {EUCTR2006-001173-14-IT,}, -title = {Protocol H3E-MC-JMHO(a) A Randomized Phase 3 Trial of ALIMTA (Pemetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer - ND}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2006-001173-14-IT}, -year = {2007}, -accession_number = {ICTRP EUCTR2006‐001173‐14‐IT}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trade Name: ALIMTA*1FL POLV 500MG Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Pemetrexed Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500‐ Trade Name: PARAPLATIN*IV 1F 150MG LIOF Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Carboplatin CAS Number: 41575‐94‐4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150‐ Trade Name: ETOPOSIDE FIDIA*FL 100MG/5ML Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Etoposide CAS Number: 33419‐42‐0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ CONDITION: Previously untreated patients with ED‐SCLC ; MedDRA version: 9.1 Level: LLT Classification code 10041068 Term: Small cell lung cancer extensive stage PRIMARY OUTCOME: Main Objective: The primary objective of the study is to compare the overall survival of previously; ; untreated patients with ED‐SCLC after treatment with pemetrexed plus carboplatin; ; versus etoposide plus carboplatin. Primary end point(s): The primary endpoint of study JMHO is; ; overall survival; the experimental arm (pemetrexed/carboplatin) is expected to be; ; noninferior to the control arm (etoposide/carboplatin) Secondary Objective: The secondary objectives of the study are to assess and compare the following variables; ; between treatment arms:; ; overall survival among a subgroup of patients classified as ?sensitive? with; ; respect to the results of a prospectively defined set of biomolecular assays; ; time‐to‐event variables, including:; ; o objective progression‐free survival (PFS); ; o survival without Grade 4 toxicity (G4 SWT); ; o survival without Grade 3‐4 toxicity (G3‐4 SWT); ; o time to worsening of HRQoL (health‐related quality of life); ; (TWQ); ; objective tumor response; ; time‐to‐event variables and objective tumor response among the subgroup of; ; patients classified as ?sensitive? with respect to the results of a prospectively; ; defined set of biomolecular assays; ; changes in dimensions of HRQoL; ; the safety and adverse event profile (including Common Terminology; ; Criteria for Adverse Events [CTCAE Version 3.0, NCI 2003] grades; ; for laboratory and nonlaboratory adverse events) INCLUSION CRITERIA: [1] Histological or cytological diagnosis of ED‐SCLC, including malignant pleural effusion. [2] Performance status of 0 to 2 on the ECOG performance status schedule (Oken et al. 1982). (See Protocol Attachment JMHO.3) [3] No prior systemic chemotherapy, immunotherapy, or biological therapy for SCLC. [4] Prior radiation therapy allowed to <25% of the bone marrow. Patients who have received prior radiation to the whole pelvis or chest for the treatment of SCLC are not eligible. Prior radiotherapy must be completed at least 2 weeks before study enrollment. Patients must have recovered from the acute toxic effects of the treatment prior to study enrollment. [5] At least one unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors (RECIST; Therasse et al. 2000). A measurable lesion is defined as a lesion that can be accurately measur}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01848087/full} -} - - -Record #127 of 538 -@article{Trommer24, -author = {Trommer, M}, -title = {Radiotherapy plus durvalumab for the treatment of locally advanced non-small cell lung cancer-The DOLPHIN trial}, -journal = {Strahlentherapie und Onkologie}, -volume = {200}, -number = {7}, -pages = {646‐648}, -year = {2024}, -accession_number = {PUBMED 38635049}, -publication type = {Journal article}, -keywords = {*Antibodies, Monoclonal [therapeutic use]; *Carcinoma, Non‐Small‐Cell Lung [drug therapy, pathology, radiotherapy, therapy]; *Chemoradiotherapy; *Lung Neoplasms [drug therapy, pathology, radiotherapy, therapy]; Aged; Antineoplastic Agents, Immunological [therapeutic use]; Female; Humans; Male; Middle Aged; Neoplasm Staging}, -DOI = {10.1007/s00066-024-02231-9}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02710701/full} -} - - -Record #128 of 538 -@article{Paz-Ares22, -author = {Paz-Ares, L, and Schulz, C}, -title = {Durvalumab ± tremelimumab + platinum-etoposide in firstline extensive-stage SCLC (ES-SCLC): 36-monthoverall survival from the Phase 3 CASPIAN study}, -journal = {Oncology research and treatment}, -volume = {45}, -pages = {147‐148}, -year = {2022}, -accession_number = {EMBASE 640066496}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *cancer survival; *small cell lung cancer; Adult; Cancer patient; Clinical trial; Conference abstract; Drug combination; Drug therapy; ECOG Performance Status; Female; Follow up; Human; Immunotherapy; Long term survival; Major clinical study; Male; Overall survival; Phase 3 clinical trial; Randomized controlled trial; Skull irradiation; Statistical significance}, -abstract = {Background: Etoposide plus either cisplatin or carboplatin (EP) had been the standard first‐line (1L) treatment for ES‐SCLC, with limited alternative therapies for more than three decades, until recent progress with immunotherapy in this setting. The Phase 3, randomised, open‐label, global CASPIAN study assessed EP ± durvalumab (D) ± tremelimumab (T) as 1L treatment for patients with ES‐SCLC, and D + EP demonstrated a statistically significant improvement in overall survival (OS) compared with EP alone (data cut‐off [DCO]: March 11, 2019): HR 0.73 (95% CI 0.59‐0.91; p=0.0047). After a median follow‐up of 25.1 months (DCO Jan 27, 2020), the OS benefit with D + EP vs EP was sustained (HR 0.75 [95% CI 0.62‐0.91; nominal p=0.0032]), and D + T + EP numerically improved OS vs EP (HR 0.82 [95% CI 0.68‐1.00; p=0.0451]), but did not reach statistical significance (p≤0.0418) per prespecified statistical plan. At 24 months, 22.2% of patients were alive in the D+ EP arm, 23.4% in the D + T + EP arm, and 14.4% in the EP arm. Here we report updated OS data from the CASPIAN study, after a median follow‐up of approx. 36 months. Methods: In the CASPIAN study, 805 patients with treatment‐naïve ES‐SCLC (WHO performance status 0/1) were randomised 1:1:1 to D 1500 mg + EP q3w, D 1500 mg + T 75 mg + EP q3w, or EP q3w, stratified by planned platinum (investigator's choice of carboplatin or cisplatin). Patients in the immunotherapy arms received 4 cycles of EP + D ± T, followed by maintenance D 1500 mg q4w until disease progression. Patients in the D + T+ EP arm received an additional dose of T 75 mg after EP. Patients in the EP arm received up to 6 cycles of EP in total, and optional prophylactic cranial irradiation at the investigator's discretion. The two primary endpoints were OS for D + EP vs EP and for D + T + EP vs EP. Result: We present mature OS data for patients in the CASPIAN study, based on a median follow‐up duration of approx. 36 months. Conclusion: This updated analysis of OS from the CASPIAN trial will provide further insight into long‐term survival benefit with D + EP and D + T + EP vs EP in 1L treatment of patients with ES‐SCLC. Funded by AstraZeneca.}, -DOI = {10.1159/000521004}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02517584/full} -} - - -Record #129 of 538 -@article{Levy23, -author = {Levy, A, Berghmans, T, Andratschke, N, Leonetti, G, Koller, M, and Faivre-Finn, C}, -title = {Prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small-cell lung cancer patients (EORTC-1901: pRIMALung)}, -journal = {Journal of clinical oncology}, -volume = {41}, -number = {16}, -pages = {TPS8614}, -year = {2023}, -accession_number = {EMBASE 642928978}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *nuclear magnetic resonance imaging; *small cell lung cancer; Belgium; Brain metastasis; Common Terminology Criteria for Adverse Events; Conference abstract; Controlled study; Drug therapy; Failure free survival; Female; Human; MRI scanner; Major clinical study; Multicenter study; Overall survival; Poland; Quality of life; Randomized controlled trial; Therapy}, -abstract = {Background: PRIMALung is an EORTC‐sponsored study. Primary objective is to show that overall survival with brain MRI surveillance alone is non‐inferior to brain MRI surveillance combined with PCI in patients with SCLC. PCI is currently SOC in most institutions, but can be associated with neurocognitive toxicity and impact quality of life. 600 patients will be recruited from 50 EORTC centres in 10 countries. This study is currently recruiting and will play an important role in clarifying whether MRI surveillance is a viable strategy in SCLC. Furthermore, it will answer important questions about the role of PCI in the era of immunotherapy, particularly in ES‐SCLC. Methods: Key eligibility: ECOG performance status ≤ 2 patients with SCLC (Limited or Extensive‐Stage, stage I‐IV) who did not progress after (≤ 16 weeks from day 1 of last cycle of chemotherapy to randomisation) completed standard therapy. Absence of progression, brain metastases or leptomeningeal disease after completing therapy. Trial Interventions: Patients will be randomised 1:1 to receive brain MRI surveillance with or without PCI (25Gy in 10 fractions). Primary objective ‐ to show that overall survival with brain MRI surveillance alone is non‐inferior to brain MRI surveillance combined with PCI. Secondary objectives ‐ cognitive failure‐free survival, quality of life and acute/late toxicities according to CTCAE v5.0. The trial was open to recruitment on 27/10/2022. Three countries open to date (Belgium, Switzerland, UK). Further sites in France, Poland and Austria will be open to recruitment Q1 2023. The first patient has been randomized on the 4th of January 2023.}, -DOI = {10.1200/jco.2023.41.16_suppl.tps8614}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02633110/full} -} - - -Record #130 of 538 -@article{Rudin22, -author = {Rudin, CM, Kim, HR, Navarro, A, Gottfried, M, Peters, S, Csoszi, T, Cheema, PK, Rodriguez-Abreu, D, Wollner, M, Czyzewicz, G, Yang, JC-H, Mazieres, J, Orlandi, FJ, Luft, A, Gumus, M, Kato, T, Kalemkerian, GP, Fu, W, Zhao, B, El-Osta, H, and Awad, MM}, -title = {OA12.06 First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S33‐S34}, -year = {2022}, -accession_number = {EMBASE 2020097288}, -publication type = {Journal article; Conference proceeding}, -keywords = {*follow up; *small cell lung cancer; Adult; Cancer patient; Cancer staging; Cancer survival; Clinical trial; Conference abstract; Controlled study; Drug combination; Drug efficacy; Drug safety; Drug therapy; Female; Human; Major clinical study; Male; Outcome assessment; Phase 3 clinical trial; Randomization; Randomized controlled trial; Survival}, -abstract = {Introduction: In the phase 3 KEYNOTE‐604 study of pembrolizumab + etoposide/platinum (EP) versus placebo + EP as first‐line therapy for ES‐SCLC (NCT03066778), PFS was significantly improved with pembrolizumab + EP versus placebo + EP (HR, 0.75 [95% CI, 0.61‐0.91]; P=0.0023) and although the HR for OS favored pembrolizumab + EP, the significance threshold was not met (HR, 0.80 [95% CI, 0.64‐0.98]; P=0.0164). We present updated results with ∼3.5 years of follow‐up and outcomes in patients who completed 35 cycles of pembrolizumab. Methods: Eligible patients with previously untreated ES‐SCLC were randomized 1:1 to pembrolizumab 200 mg or placebo Q3W for up to 35 cycles plus 4 cycles of standard‐dose EP. Dual primary endpoints were OS and PFS (RECISTv1.1, blinded central review) in the intent‐to‐treat (ITT) population. No alpha was allocated for this updated analysis. Results: Among 453 randomized patients in the ITT population (pembrolizumab + EP, n=228; placebo + EP, n=225), median (range) time from randomization to data cutoff (September 21, 2021) was 43.3 (37.8‐52.3) months. 54.8% of patients in the pembrolizumab + EP group and 66.2% in the placebo + EP group received subsequent therapy (11.2% vs 22.1% received subsequent immune checkpoint inhibitor). Efficacy outcomes, including OS and PFS, were improved with pembrolizumab + EP (Table). Among the as‐treated population, grade 3‐5 AEs occurred in 78.9% of 223 patients in the pembrolizumab + EP group and 77.1% of 223 patients in the placebo + EP group. Eighteen patients completed 35 cycles of pembrolizumab (median [range] time from randomization to database cutoff, 42.5 [38.2‐49.5] months); of these patients, 14 were alive as of the last assessment before data cutoff. ORR among these patients was 100% (95% CI, 81.5%‐100%; 2 CR, 16 PR), and median (range) DOR was not reached (14.1 to 46.8+ months). From the time of completing 35 cycles (∼2 years), median OS was not reached (95% CI, 16.6 months to not reached). Two‐year OS rate (95% CI) from the time of completing 35 cycles of pembrolizumab was 72.2% (39.5%‐89.2%). Conclusions: Pembrolizumab + EP continued to show clinically meaningful improvement in survival and manageable safety versus placebo + EP in patients with previously untreated ES‐SCLC; 3‐year OS rate was ∼3 times higher among patients who received pembrolizumab + EP. Patients who completed 35 cycles of pembrolizumab had durable responses. Data support the continued exploration of pembrolizumab‐based combinations for ES‐SCLC. [Formula presented] Keywords: pembrolizumab, extensive‐stage small‐cell lung cancer, etoposide/platinum}, -DOI = {10.1016/j.jtho.2022.07.063}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461444/full} -} - - -Record #131 of 538 -@article{EUCTR2020-004656-14-ES21, -author = {EUCTR2020-004656-14-ES,}, -title = {A phase 3 study evaluating ociperlimab plus tislelizumab plus cCRT or tislelizumab plus cCRT versus cCRT followed by durvalumab}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-004656-14-ES}, -year = {2021}, -accession_number = {ICTRP EUCTR2020‐004656‐14‐ES}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Tislelizumab Product Code: BGB‐A317 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: TISLELIZUMAB CAS Number: 1858168‐59‐8 Current Sponsor code: BGB‐A317 Other descriptive name: BGB‐A317, BGN1, JHL2108 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 9‐11 Product Name: Ociperlimab Product Code: BGB‐A1217 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ociperlimab Current Sponsor code: BGB‐A1217 Other descriptive name: Humanised IgG1 monoclonal antibody against TIGIT Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 18‐22 Product Name: durvalumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: DURVALUMAB CAS Number: 1428935‐60‐7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ CONDITION: Previously Untreated, Locally Advanced, Unresectable Non‐Small Cell Lung Cancer ; MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non‐small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] INCLUSION CRITERIA: 1. Age = 18 years on the day of signing the ICF (or the legal age of consent in the jurisdiction in which the study is taking place). 2. Ability to provide written informed consent and to understand and agree to comply with the requirements of the study and the schedule of assessments. 3. Patient has newly diagnosed, histologically confirmed, locally advanced, Stage III unresectable NSCLC (AJCC Cancer Staging Manual 2017). a. Tumors of mixed non‐small cell histology will be categorized by the predominant cell type; if small cell elements are present, the patient is ineligible. b. Staging will be confirmed at screening by positron emission tomography (PET)/computed tomography (CT) and brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) with contrast. c. Fluorodeoxyglucose (FDG)‐PET/CT will be performed for the whole body, or sufficient to rule out distant metastases (eg, from skull base to knees), to exclude distant diseas PRIMARY OUTCOME: Main Objective: • To compare PFS as assessed by the Independent Review Committee (IRC) per; Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) in the; Intent‐to‐Treat (ITT) Analysis Set between Arm A (ociperlimab plus tislelizumab; plus cCRT followed by ociperlimab plus tislelizumab) versus Arm C (cCRT followed by durvalumab) in previously untreated, locally advanced, unresectable non‐small cell lung cancer (LA NSCLC); • To compare complete response rate (CRR) by the IRC per RECIST v1.1 in the ITT Analysis Set between Arm A and Arm C in previously untreated, unresectable LA NSCLC; • To compare PFS as assessed by the IRC per RECIST v1.1 in the ITT Analysis Set; between Arm B (tislelizumab plus followed by tislelizumab) versus Arm C in; previously untreated, unresectable LA NSCLC Primary end point(s): • PFS by IRC in the ITT Analysis Set, defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the IRC per RECIST v1.1 or death, whichever occurs first; • CRR by IRC in the ITT Analysis Set, defined as the proportion of patients who achieve a complete response (CR) assessed by the IRC per RECIST v1.1 Secondary Objective: • To compare overall survival (OS) between Arm A and Arm C; • To compare PFS as assessed by the IRC per RECIST v1.1 in PD‐L1‐positive; population between Arm A and Arm C; • To compare PFS as assessed by the IRC per RECIST v1.1 between Arm A and; Arm B; • To compare OS between Arm B and Arm C, and between Arm A and Arm B; • To compare CRR as assessed by the investigator per RECIST v1.1 between Arm A and Arm C and to compare CRR as assessed by both the IRC and the investigator per RECIST v1.1 between Arm B and Arm C and between Arm A and Arm B; • To compare overall response rate (ORR) and duration of response (DOR) as assessed by both the IRC and the investigator between Arm A and Arm C, between Arm B and Arm C, and between Arm A and Arm B; • To compare PFS as assessed by the investigator per RECIST v1.1 between Arm A and Arm C, between Arm B and Arm C, and between Arm A and Arm B; [More are listed in the study protocol] Timepoint(s) of evaluation of this end point: approximately 4 years SECONDARY OUTCOME: Secondary end point(s): • OS in both the ITT Analysis Set and the PD L1 Positive Analysis Set, defined as the time from the date of randomization until the date of death due to any cause; • PFS by IRC in the PD L1 Positive Analysis Set, defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the IRC per RECIST v1.1 or death, whichever occurs first; • CRR in the ITT Analysis Set, defined as the proportion of patients who achieve a CR assessed by both the IRC and the investigator per RECIST v1.1; • ORR in both the ITT Analysis Set and the PD‐L1‐Positive Analysis Set, defined as the proportion of patients who achieve a CR or partial response (PR) assessed by both the IRC and the investigator per RECIST v1.1; • DOR in both the ITT Analysis Set and the PD‐L1‐Positive Analysis Set, defined as the time from the first determination of a confirmed objective response assessed by both the IRC and the investigator per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first; • PFS by the investigator in both the ITT Analysis Set and the PD‐L1‐Positive Analysis Set, defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first; • Time to death or distant metastasis (TTDM) in both the ITT Analysis Set and the PD‐L1‐Positive Analysis Set, defined as the time from the date of randomization until the first date of distant metastasis assessed by both the IRC and the investigator or death. Distant metastasis is defined as any new lesion that is outside of the radiation field per RECIST v1.1 or proven by biopsy; • Safety and tolerability, defined as AEs (using NCI CTCAE v5.0), laboratory tests, vital signs, ECOG Performance Status, physical examinations, concomitant medications, and dose modifications; • HRQoL in both the ITT Analysis Set and the PD‐L1‐Positive Analysis Set, measured via patient‐reported outcomes (PROs) using EORTC QLQ‐C30, EORTC QLQ‐LC13, and EQ‐5D‐5L; • Serum concentrations of ociperlimab and tislelizumab at specified timepoints; • Immunogenic responses to ociperlimab and tislelizumab evaluated through detection of anti‐drug antibodies; • Evaluate PD‐L1 and TIGIT expression in archival and/or fresh tumor tissues before study treatment or at disease progression/reoccurrence, and their association with clinical efficacy. Timepoint(s) of evaluation of this end point: approximately 4 years}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02350579/full} -} - - -Record #132 of 538 -@article{Nesbit21, -author = {Nesbit, EG, Donnelly, ED, and Strauss, JB}, -title = {Treatment Strategies for Oligometastatic Breast Cancer}, -journal = {Current treatment options in oncology}, -volume = {22}, -number = {10}, -pages = {94}, -year = {2021}, -accession_number = {EMBASE 2013516017, PUBMED 34426881}, -publication type = {Journal article}, -keywords = {*Radiotherapy, Image‐Guided; *metastatic breast cancer /disease management /drug resistance /drug therapy /radiotherapy /therapy; Ablation therapy; Axillary lymph node; Brain Neoplasms [secondary, *therapy]; Brain metastasis /complication /radiotherapy /surgery; Brain surgery; Breast Neoplasms [*pathology, *therapy]; Cancer immunotherapy; Cancer palliative therapy; Cancer prognosis; Cancer recurrence; Cancer research; Cancer survival; Circulating tumor cell; Clinical Trials as Topic; Colitis /side effect; Conformal radiotherapy; Consensus development; Cost effectiveness analysis; Cytokine release; Disease course; Disease free interval; Drug efficacy; Drug safety; Endobronchial ultrasonography; Female; Head and neck squamous cell carcinoma /drug therapy; Histopathology; Human; Humans; Hypofractionated radiotherapy; Image guided radiotherapy; Immunotherapy; Intermethod comparison; Liver Neoplasms [secondary, *therapy]; Liver metastasis /complication /radiotherapy /surgery; Liver resection; Lung Neoplasms [secondary, *therapy]; Lung biopsy; Lung metastasis /complication /diagnosis /radiotherapy /surgery; Lung resection; Lymph node dissection; Lymph node metastasis /complication /surgery; Lymphocytic infiltration; Medical decision making; Metastasectomy; Metastasis potential; Non small cell lung cancer /drug therapy; Nonhuman; Overall survival; Patient Selection; Patient safety; Patient selection; Phase 2 clinical trial (topic); Pneumonia /side effect; Positron emission tomography‐computed tomography; Progression free survival; Progression‐Free Survival; Quality adjusted life year; Quality of life; Radiation Dose Hypofractionation; Radiation dose; Radiation dose fractionation; Radiofrequency Ablation; Radiofrequency ablation; Recurrence free survival; Review; Spine metastasis /complication /radiotherapy; Survival Rate; Triple negative breast cancer /drug therapy; Tumor associated leukocyte; Whole brain radiotherapy}, -abstract = {Oligometastatic breast cancer, typically defined as the presence of 1–5 metastases, represents an intermediate state between locally advanced and widely metastatic disease. Emerging research suggests that oligometastatic cancer has a unique molecular signature distinct from widely metastatic disease, and that it carries a superior prognosis. Owing to its more limited capacity for widespread progression, oligometastatic disease may benefit from aggressive ablative therapy to known metastases. Options for ablation include surgical excision, radiofrequency ablation, and hypofractionated image–guided radiotherapy (HIGRT). The phase II SABR‐COMET trial, which enrolled patients with oligometastatic disease of multiple histologies and randomized them to HIGRT vs. standard of care, found a notable survival advantage in favor of HIGRT. Other data suggest that HIGRT may synergize with immunotherapy by releasing powerful cytokines that increase anti‐tumor immune surveillance and by recruiting tumor infiltrating lymphocytes, helping to overcome resistance to therapy. There are many ongoing trials exploring the role of ablative therapy, most notably HIGRT, with or without immunotherapy, for the treatment of oligometastatic breast cancer. We believe that patients with oligometastatic breast cancer should be offered enrollment on prospective clinical trials when possible. Outside the context of a clinical trial, we recommend that select patients with oligometastatic breast cancer be offered treatment with a curative approach, including ablative therapy to all sites of disease if it can be safely accomplished. Currently, selection criteria to consider for ablative therapy include longer disease‐free interval from diagnosis to metastasis (>2 years), fewer metastases, and fewer involved organs. Undoubtedly, new data will refine or even upend our understanding of the definition and optimal management of oligometastatic disease.}, -DOI = {10.1007/s11864-021-00889-2}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02301361/full} -} - - -Record #133 of 538 -@article{Tjokrowidjaja22, -author = {Tjokrowidjaja, A, Lord, SJ, John, T, Lewis, CR, Kok, PS, Marschner, IC, and Lee, CK}, -title = {Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer}, -journal = {Cancer}, -volume = {128}, -number = {8}, -pages = {1574‐1583}, -year = {2022}, -accession_number = {EMBASE 2014864741, PUBMED 35090047}, -publication type = {Journal article}, -keywords = {*Carcinoma, Non‐Small‐Cell Lung [drug therapy]; *Lung Neoplasms [drug therapy]; *cancer prognosis; *non small cell lung cancer /diagnosis /drug therapy /radiotherapy; *predictive value; Additive effect; Advanced cancer /drug therapy; Article; Biomarkers; Cancer patient; Controlled study; Female; Hazard ratio; Human; Humans; L‐Lactate Dehydrogenase; Major clinical study; Male; Overall survival; Patient selection; Phase 2 clinical trial; Phase 3 clinical trial; Prognosis; Randomized controlled trial; Treatment duration; Treatment response}, -abstract = {BACKGROUND: The survival outcomes of patients with advanced non–small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) are variable. This study investigated whether pre‐ and on‐treatment lactate dehydrogenase (LDH) could better prognosticate and select patients for ICI therapy. METHODS: Using data from the POPLAR and OAK trials of atezolizumab versus docetaxel in previously treated advanced NSCLC, the authors assessed the prognostic and predictive value of pretreatment LDH (less than or equal to vs greater than the upper limit of normal). They further examined changes in on‐treatment LDH by performing landmark analyses and estimated overall survival (OS) distributions according to the LDH level stratified by the response category (complete response [CR]/partial response [PR] vs stable disease [SD]). They repeated pretreatment analyses in subgroups defined by the programmed death ligand 1 (PD‐L1) status. RESULTS: This study included 1327 patients with available pretreatment LDH. Elevated pretreatment LDH was associated with an adverse prognosis regardless of treatment (hazard ratio [HR] for atezolizumab OS, 1.49; P =.0001; HR for docetaxel OS, 1.30; P =.004; P for treatment by LDH interaction =.28). Findings for elevated pretreatment LDH were similar for patients with positive PD‐L1 expression treated with atezolizumab. Persistently elevated on‐treatment LDH was associated with a 1.3‐ to 2.8‐fold increased risk of death at weeks 6, 12, 18, and 24 regardless of treatment. Elevated LDH at 6 weeks was associated with significantly shorter OS regardless of radiological response (HR for CR/PR, 2.10; P =.04; HR for SD, 1.50; P <.01), with similar findings observed at 12 weeks. CONCLUSIONS: In previously treated advanced NSCLC, elevated pretreatment LDH is an independent adverse prognostic marker. There is no evidence that pretreatment LDH predicts ICI benefit. Persistently elevated on‐treatment LDH is associated with worse OS despite radiologic response.}, -DOI = {10.1002/cncr.34113}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02406837/full} -} - - -Record #134 of 538 -@article{Zhou22, -author = {Zhou, Q, Chen, M, Jiang, O, Pan, Y, Hu, D, Lin, Q, Wu, G, Cui, J, Chang, J, Cheng, Y, Huang, C, Liu, A, Yang, N, Gong, Y, Zhu, C, Ma, Z, Fang, J, Chen, G, Zhao, J, Shi, A, Lin, Y, Li, G, Liu, Y, Wang, D, Wu, R, Xu, X, Shi, J, Liu, Z, Cui, N, Wang, J, Wang, Q, Zhang, R, Yang, J, and Wu, YL}, -title = {Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial}, -journal = {The lancet. Oncology}, -volume = {23}, -number = {2}, -pages = {209‐219}, -year = {2022}, -accession_number = {EMBASE 2016678411, PUBMED 35038429}, -publication type = {Journal article}, -keywords = {*Carcinoma, Non‐Small‐Cell Lung [drug therapy, mortality, pathology]; *Chemoradiotherapy; *China; *Immune Checkpoint Inhibitors [therapeutic use]; *Lung Neoplasms [drug therapy, mortality, pathology]; *advanced cancer; *cancer patient; *cancer staging; *chemoradiotherapy; *non small cell lung cancer; Acute liver failure; Adult; Adverse drug reaction; Aged; Article; Cancer survival; Clinical trial; Comparative effectiveness; Double blind procedure; Double‐Blind Method; Drug efficacy; Drug safety; Drug therapy; ECOG Performance Status; Female; Follow up; Human; Humans; Intravenous drug administration; Major clinical study; Male; Middle Aged; Multicenter study; Neoplasm Staging; Phase 3 clinical trial; Pneumonia; Progression free survival; Radiotherapy; Radiotherapy dosage; Randomized controlled trial; Side effect; Voice; Young adult}, -abstract = {Background: A substantial proportion of patients with unresectable stage III non‐small‐cell lung cancer (NSCLC) cannot either tolerate or access concurrent chemoradiotherapy, so sequential chemoradiotherapy is commonly used. We assessed the efficacy and safety of sugemalimab, an anti‐PD‐L1 antibody, in patients with stage III NSCLC whose disease had not progressed after concurrent or sequential chemoradiotherapy. Methods: GEMSTONE‐301 is a randomised, double‐blind, placebo‐controlled, phase 3 trial in patients with locally advanced, unresectable, stage III NSCLC, done at 50 hospitals or academic research centres in China. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 who had not progressed after concurrent or sequential chemoradiotherapy. We randomly assigned patients (2:1, using an interactive voice–web response system) to receive sugemalimab 1200 mg or matching placebo, intravenously every 3 weeks for up to 24 months. Stratification factors were ECOG performance status, previous chemoradiotherapy, and total radiotherapy dose. The investigators, trial coordination staff, patients, and study sponsor were masked to treatment allocation. The primary endpoint was progression‐free survival as assessed by blinded independent central review (BICR) in the intention‐to‐treat population. Safety was assessed in all participants who received at least one dose of assigned study treatment. The study has completed enrolment and the results of a preplanned analysis of the primary endpoint are reported here. The trial is registered with ClinicalTrials.gov, NCT03728556. Findings: Between Aug 30, 2018 and Dec 30, 2020, we screened 564 patients of whom 381 were eligible. Study treatment was received by all patients randomly assigned to sugemalimab (n=255) and to placebo (n=126). At data cutoff (March 8, 2021), median follow‐up was 14·3 months (IQR 6·4–19·4) for patients in the sugemalimab group and 13·7 months (7·1–18·4) for patients in the placebo group. Progression‐free survival assessed by BICR was significantly longer with sugemalimab than with placebo (median 9·0 months [95% CI 8·1–14·1] vs 5·8 months [95% CI 4·2–6·6]; stratified hazard ratio 0·64 [95% CI 0·48–0·85], p=0·0026). Grade 3 or 4 treatment‐related adverse events occurred in 22 (9%) of 255 patients in the sugemalimab group versus seven (6%) of 126 patients in the placebo group, the most common being pneumonitis or immune‐mediated pneumonitis (seven [3%] of 255 patients in the sugemalimab group vs one [<1%] of 126 in the placebo group). Treatment‐related serious adverse events occurred in 38 (15%) patients in the sugemalimab group and 12 (10%) in the placebo group. Treatment‐related deaths were reported in four (2%) of 255 patients (pneumonia in two patients, pneumonia with immune‐mediated pneumonitis in one patient, and acute hepatic failure in one patient) in the sugemalimab group and none in the placebo group. Interpretation: Sugemalimab after definitive concurrent or sequential chemoradiotherapy could be an effective consolidation therapy for patients with stage III NSCLC whose disease has not progressed after sequential or concurrent chemoradiotherapy. Longer follow‐up is needed to confirm this conclusion. Funding: CStone Pharmaceuticals and the National Key Research and Development Program of China. Translation: For the Chinese translation of the abstract see Supplementary Materials section.}, -DOI = {10.1016/S1470-2045(21)00630-6}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02364834/full} -} - - -Record #135 of 538 -@article{Tachihara23, -author = {Tachihara, M, Tsujino, K, Ishihara, T, Hayashi, H, Sato, Y, Kurata, T, Sugawara, S, Shiraishi, Y, Teraoka, S, Azuma, K, Daga, H, Yamaguchi, M, Kodaira, T, Satouchi, M, Shimokawa, M, Yamamoto, N, and Nakagawa, K}, -title = {Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: the DOLPHIN Phase 2 Nonrandomized Controlled Trial}, -journal = {JAMA oncology}, -volume = {9}, -number = {11}, -pages = {1505‐1513}, -year = {2023}, -accession_number = {PUBMED 37676681}, -publication type = {Journal article}, -keywords = {*Carcinoma, Non‐Small‐Cell Lung [drug therapy, radiotherapy]; *Lung Neoplasms [drug therapy, radiotherapy]; Adult; Aged; Aged, 80 and over; B7‐H1 Antigen; Chemoradiotherapy [adverse effects, methods]; Disease‐Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Staging}, -abstract = {IMPORTANCE: Administration of durvalumab after concurrent chemoradiotherapy is the standard treatment of unresectable, locally advanced non‐small cell lung cancer (NSCLC); however, 20% to 30% of patients do not receive durvalumab because of adverse events (AEs) during concurrent chemoradiotherapy. In addition, radiotherapy and immunotherapy have a synergistic effect. OBJECTIVE: To investigate the efficacy and safety of durvalumab immunotherapy plus concurrent radiotherapy followed by maintenance with durvalumab therapy for treatment of locally advanced NSCLC without chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: The multicenter, single‐arm DOLPHIN (Phase II Study of Durvalumab [MEDI4736] Plus Concurrent Radiation Therapy in Advanced Localized NSCLC Patients) nonrandomized controlled trial was performed by 12 institutions in Japan from September 13, 2019, to May 31, 2022. Participants in the primary registration phase included 74 patients with programmed cell death ligand 1 (PD‐L1)‐positive, unresectable, locally advanced NSCLC. The current analyses were conducted from June 1, 2022, to October 31, 2022. INTERVENTIONS: Patients received radiotherapy (60 Gy) in combination with concurrent and maintenance durvalumab immunotherapy, 10 mg/kg every 2 weeks, for up to 1 year. MAIN OUTCOMES AND MEASURES: The primary end point of the rate of 12‐month progression‐free survival (PFS), as assessed by an independent central review, was estimated using the Kaplan‐Meier method and evaluated with 90% CIs calculated using the Greenwood formula. The key secondary end points were PFS, objective response rate, treatment completion rate, and AEs. RESULTS: Data from 35 patients (median [range] age, 72 [44‐83] years; 31 [88.6%] men) were included in the full analysis set of the evaluable population. The 12‐month PFS rate was 72.1% (90% CI, 59.1%‐85.1%), and the median PFS was 25.6 months (95% CI, 13.1 months to not estimable) at a median follow‐up of 22.8 months (range, 4.3‐31.8 months). Scheduled radiation therapy was completed in 97.1% of patients. The confirmed objective response rate was 90.9% (95% CI, 75.7%‐98.1%), and the treatment completion rate was 57.6% (95% CI, 39.2%‐74.5%). Among 34 patients evaluated in the safety analysis set, AEs of grade 3 or 4 occurred in 18 patients (52.9%), and of grade 5 in 2 patients (5.9%). Pneumonitis or radiation pneumonitis of any grade occurred in 23 patients (67.6%), and of grades 3 or 4 in 4 patients (11.8%). CONCLUSIONS AND RELEVANCE: Findings from this phase 2 nonrandomized controlled trial indicate that durvalumab immunotherapy combined with curative radiotherapy for patients with PD‐L1‐positive, unresectable, locally advanced NSCLC is a promising treatment with tolerable AEs and is appropriate as a study treatment for phase 3 clinical trials. TRIAL REGISTRATION: Japan Registry of Clinical Trials ID: jRCT2080224763.}, -DOI = {10.1001/jamaoncol.2023.3309}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02625509/full} -} - - -Record #136 of 538 -@article{Richards81, -author = {Richards, F, Howard, V, Shore, A, Muss, HB, White, DR, Jackson, DV, Cooper, MR, Bearden, J, Stuart, JJ, Sartiano, G, Rhyne, AL, and Spurr, CL}, -title = {Combination chemotherapy with and without the methanol-extracted residue of bacillus Calmette-Guerin (MER) in extensive non-small-cell lung cancer: a prospective randomized study for the Piedmont Oncology Association}, -journal = {Cancer}, -volume = {47}, -number = {12}, -review groups = {SR-CANCER; Lung Cancer}, -pages = {2827‐2832}, -year = {1981}, -accession_number = {EMBASE 11066875, PUBMED 6266642}, -publication type = {Journal article}, -keywords = {Adenocarcinoma [therapy]; Adult; Aged; Antineoplastic Agents [*administration & dosage]; BCG Vaccine [*therapeutic use]; Carcinoma, Small Cell [therapy]; Carcinoma, Squamous Cell [therapy]; Doxorubicin [administration & dosage]; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lomustine [administration & dosage]; Lung Neoplasms [*therapy]; Male; Methotrexate [administration & dosage]; Middle Aged; Mycobacterium tuberculosis; Prospective Studies; Random Allocation}, -abstract = {One‐hundred‐three patients with extensive non‐small‐cell lung cancer were entered into a prospective, randomized trial to determine the value of MER as an adjuvant to chemotherapy. Patients were stratified according to histology and performance status. All patients received CCNU, methotrexate, and Adriamycin with 48 patients also receiving MER. All patients had a performance status of 2 or less (less than 50% bedridden), 49% had prior radiation therapy, only one patient had prior chemotherapy, and all had extensive disease. Of the patients, 42% had epidermoid cancer, 21% had large cell cancer, 32% had adenocarcinoma, and 4% had mixed adenosquamous or undifferentiated carcinoma. The response rates and response durations of the two treatment regimens were similar. Of the patients, 18% had an objective response; in 4% it was complete. An additional 29% had a stable response. Median duration of response ranged from 21 to 23 weeks. Median survival rates for non‐MER and MER treatment groups were 21.5 and 18.6 weeks, respectively. The four complete responders have a survival of 24, 85, 86+, and 129 weeks. MER did not improve response for hematopoietic tolerance, was associated with significant morbidity, and was poorly tolerated. The value of immunotherapy in lung cancer remains to be established.}, -DOI = {10.1002/1097-0142(19810615)47:12<2827::aid-cncr2820471212>3.0.co;2-d}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00025651/full} -} - - -Record #137 of 538 -@article{Wang23, -author = {Wang, L, Zou, B, Huang, W, Shao, Q, Meng, X, Tang, X, Zhang, P, Hu, X, Zhang, Y, Guo, J, Fu, L, Zhao, W, Zhao, C, Yuan, J, Yu, J, and Chen, D}, -title = {Safety and Efficacy Analysis of Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Treated with SHR-1316 Plus Chemotherapy and Sequential Chest Radiotherapy as First-Line Therapy from a Phase II Trial}, -journal = {International journal of radiation oncology biology physics}, -volume = {117}, -number = {2}, -pages = {S58‐S59}, -year = {2023}, -accession_number = {EMBASE 2026576204}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer chemotherapy; *cancer patient; *cancer radiotherapy; *cancer staging; *first‐line treatment; *small cell lung cancer; *thorax; Adult; Aged; Anemia; Brain metastasis; Cancer survival; Clinical trial; Conference abstract; Drug combination; Drug megadose; Drug safety; ECOG Performance Status; Ex‐smoker; Histopathology; Human; Immunotherapy; Leukopenia; Liver metastasis; Low drug dose; Lymphocytopenia; Maintenance therapy; Major clinical study; Male; Middle aged; Neutropenia; Overall survival; Phase 2 clinical trial; Phase 3 clinical trial; Pneumonia; Radiotherapy; Thrombocytopenia; Young adult}, -abstract = {Purpose/Objective(s): CAPSTONE‐1, a phase 3 trial, showed that SHR‐1316 (PD‐L1 antibody) combined with standard first‐line chemotherapy could prolong overall survival (OS) in patients (pts) with ES‐SCLC. The CREST trial reported consolidative thoracic radiotherapy (TRT) of 30 Gy in 10 fractions provided a 10% 2‐year OS benefit and more intensive TRT should be investigated in ES‐SCLC. In the era of immunotherapy, the role of TRT also needs further exploration. Therefore, we designed this clinical trial to investigate the efficacy and safety of SHR‐1316 plus first‐line chemotherapy followed by TRT combined with SHR‐1316. Materials/Methods: Key inclusion criteria were pts aged 18‐75 years, with previously untreated histologically or cytologically confirmed ES‐SCLC, and an ECOG performance status of 0‐1. Eligible pts would receive 4∼6 cycles of SHR‐1316 (20mg/kg, D1, q3w) combined with EP/EC (etoposide, 100mg/m2, D1‐5, q3w and cisplatin, 75mg/m², D1‐3, q3w or carboplatin, AUC = 5, D1, q3w), followed by SHR‐1316 combined with TRT (≥3 Gy*10 f or ≥2 Gy*25 f, involved‐field irradiation), and then the maintenance therapy with SHR‐1316 until disease progression or intolerable adverse events (AEs). The main endpoints included ORR, PFS and safety. Results: From October 2020 to January 2023, 33 pts received SHR‐1316 and sequential consolidative TRT. Among them, 19 pts received high‐dose TRT (>3 Gy*10 f or ≥2 Gy*25 f) and 14 pts received low‐dose TRT (≤3 Gy*10 f or<2 Gy*25 f). The median age was 62 (range: 38‐73). Most pts were male (28, 84.8%), former smokers (22, 66.7%) with an ECOG performance status 1 (32, 97%). Ten (30.3%) pts were diagnosed with brain metastasis and 10 (30.3%) pts had liver metastasis at baseline. At the data cutoff date, 9 pts remained on treatment, the average number of treatment cycles was 9.2. 33 pts had at least one 1 post‐treatment tumor assessment. The confirmed ORR and DCR were 90.9% (30/33) and 100% (33/33) in all pts, were 89.5% (17/19) and 100% (19/19) in high‐dose TRT group, and were 92.9% (13/14) and 100% (14/14) in low‐dose TRT group. The median PFS was 10.2(CI: 5.8∼14.7) months in all pts, was 7 (CI: 3.8∼10.2) months in high‐dose TRT group and 10.4 (CI: 8.4∼12.3) months in low‐dose TRT group. AEs occurred in 27 (81.8%) pts and grade 3 or 4 AEs occurred in 20 (60.6%) pts. The most common grade 3 or 4 AEs included neutropenia (15, 45.5%), leukopenia (8, 24.2%), lymphocytopenia (5, 15.2%), pneumonia (3, 9.1%), anemia (3, 9.1%) and thrombocytopenia (2, 6.1%). Conclusion: SHR‐1316 plus chemotherapy and sequential TRT as first‐line therapy for ES‐SCLC showed promising efficacy and acceptable safety. There is no significant difference between high‐dose and low‐dose TRT groups in terms of safety and efficacy according to current data.}, -DOI = {10.1016/j.ijrobp.2023.06.354}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02623587/full} -} - - -Record #138 of 538 -@article{Mansfield19, -author = {Mansfield, AS, Liu, SV, Szczesna, A, Havel, L, Kzrakowski, M, Hochmair, MJ, Huemer, F, Losonczy, G, Johnson, ML, Nishio, M, Reck, M, Mok, TS, Lam, S, Shames, DS, Liu, J, Kabbinavar, F, Sandler, A, and Horn, L}, -title = {IMpower133: primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)}, -journal = {Cancer research}, -volume = {79}, -number = {13}, -year = {2019}, -accession_number = {EMBASE 628904910}, -publication type = {Journal article; Conference proceeding}, -keywords = {*adverse event; *cancer staging; *central nervous system; *drug safety; *small cell lung cancer; Adult; Cancer survival; Comparative effectiveness; Conference abstract; Controlled study; Double blind procedure; Drug combination; Drug therapy; Female; Human; Major clinical study; Male; Mutation; Pharmacokinetics; Randomized controlled trial; Skull irradiation}, -abstract = {Background Platinum chemotherapy (carboplatin or cisplatin) + etoposide is the current 1L standard of care treatment (tx) for ES‐SCLC. Despite high response rates on this regimen, patient (pt) outcomes remain poor. IMpower133 is a Ph1/3, double‐blind, randomized, placebo (PBO)‐controlled trial that is evaluating the efficacy and safety of adding PD‐L1‐inhibitor atezo or PBO to 1L tx for ES‐SCLC (NCT02763579). Methods IMpower133 enrolled pts without prior tx for ES‐SCLC; PD‐L1 testing was not required. Pts were randomized 1:1 to four 21‐day cycles of carboplatin (AUC 5 mg/mL/min IV, Day 1) + etoposide (100 mg/m2 IV, Days 1‐3) with either atezo (1200 mg IV, Day 1) or PBO, then maintenance atezo or PBO until PD, unacceptable toxicity or loss of clinical benefit. Maintenance prophylactic cranial irradiation (PCI) was allowed per protocol, while definitive thoracic radiation (TR) was not. Coprimary endpoints were OS and investigator‐assessed PFS. A key exploratory endpoint was outcomes by blood tumor mutation burden (bTMB) analyzed at prespecified cutoffs (≥ 16 vs < 16 and ≥ 10 vs < 10 mutations/Mb). Results Adding atezo to carboplatin + etoposide demonstrated significant improvement in efficacy (OS and PFS) in 1L ES‐SCLC (Table). Survival benefits were consistent across key subgroups and prespecified bTMB cutoffs. 44 pts (22 in each arm [per ITT]) received PCI, and 7 (3 in atezo arm, 4 in PBO arm) received TR. Gr 3‐4 tx‐related adverse events (AEs) occurred in 57% of atezo pts vs 56% of PBO pts; serious tx‐related AEs occurred in 23% vs 19%. Occurrence of CNS‐related AEs in pts who had PCI are shown in the Table. Conclusion Adding atezo to carboplatin + etoposide resulted in a significant improvement in survival in this 1L ES‐SCLC all‐comers population. There were no new safety signals, including in pts who received PCI or TR. Atezo + carboplatin + etoposide may represent a new standard regimen for untreated ES‐SCLC. (Table Presented).}, -DOI = {10.1158/1538-7445.SABCS18-CT199}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01978768/full} -} - - -Record #139 of 538 -@article{Mansfield19, -author = {Mansfield, AS, Liu, SV, Szczesna, A, Havel, L, Kzrakowski, M, Hochmair, MJ, Huemer, F, Losonczy, G, Johnson, ML, Nishio, M, Reck, M, Mok, TS, Lam, S, Shames, DS, Liu, J, Kabbinavar, F, Sandler, A, and Horn, L}, -title = {IMpower133: primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)}, -journal = {Cancer research}, -volume = {79}, -number = {13}, -year = {2019}, -accession_number = {EMBASE 628858708}, -publication type = {Journal article; Conference proceeding}, -keywords = {*adverse event; *cancer staging; *central nervous system; *drug safety; *small cell lung cancer; Adult; Cancer survival; Comparative effectiveness; Conference abstract; Controlled study; Double blind procedure; Drug combination; Drug therapy; Female; Human; Major clinical study; Male; Mutation; Pharmacokinetics; Randomized controlled trial; Skull irradiation}, -abstract = {Background Platinum chemotherapy (carboplatin or cisplatin) + etoposide is the current 1L standard of care treatment (tx) for ES‐SCLC. Despite high response rates on this regimen, patient (pt) outcomes remain poor. IMpower133 is a Ph1/3, double‐blind, randomized, placebo (PBO)‐controlled trial that is evaluating the efficacy and safety of adding PD‐L1‐inhibitor atezo or PBO to 1L tx for ES‐SCLC (NCT02763579). Methods IMpower133 enrolled pts without prior tx for ES‐SCLC; PD‐L1 testing was not required. Pts were randomized 1:1 to four 21‐day cycles of carboplatin (AUC 5 mg/mL/min IV, Day 1) + etoposide (100 mg/m2 IV, Days 1‐3) with either atezo (1200 mg IV, Day 1) or PBO, then maintenance atezo or PBO until PD, unacceptable toxicity or loss of clinical benefit. Maintenance prophylactic cranial irradiation (PCI) was allowed per protocol, while definitive thoracic radiation (TR) was not. Coprimary endpoints were OS and investigator‐assessed PFS. A key exploratory endpoint was outcomes by blood tumor mutation burden (bTMB) analyzed at prespecified cutoffs (= 16 vs < 16 and = 10 vs < 10 mutations/Mb). Results Adding atezo to carboplatin + etoposide demonstrated significant improvement in efficacy (OS and PFS) in 1L ES‐SCLC (Table). Survival benefits were consistent across key subgroups and prespecified bTMB cutoffs. 44 pts (22 in each arm [per ITT]) received PCI, and 7 (3 in atezo arm, 4 in PBO arm) received TR. Gr 3‐4 tx‐related adverse events (AEs) occurred in 57% of atezo pts vs 56% of PBO pts; serious tx‐related AEs occurred in 23% vs 19%. Occurrence of CNS‐related AEs in pts who had PCI are shown in the Table. Conclusion Adding atezo to carboplatin + etoposide resulted in a significant improvement in survival in this 1L ES‐SCLC all‐comers population. There were no new safety signals, including in pts who received PCI or TR. Atezo + carboplatin + etoposide may represent a new standard regimen for untreated ES‐SCLC. (Table presented).}, -DOI = {10.1158/1538-7445.SABCS18-CT199}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01981486/full} -} - - -Record #140 of 538 -@article{Courtney21, -author = {Courtney, PT, Yip, AT, Cherry, DR, Salans, MA, Kumar, A, and Murphy, JD}, -title = {Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer}, -journal = {JAMA network open}, -volume = {4}, -number = {5}, -pages = {e218787}, -year = {2021}, -accession_number = {EMBASE 634933452, PUBMED 33938936}, -publication type = {Journal article}, -keywords = {*advanced cancer; *cost effectiveness analysis; *non small cell lung cancer; Adult; Antineoplastic Agents [administration & dosage, therapeutic use]; Article; Cancer chemotherapy; Cancer patient; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [*drug therapy]; Clinical trial; Comparative effectiveness; Controlled study; Cost‐Benefit Analysis; Data analysis; Disease simulation; Doublet chemotherapy; Drug Therapy, Combination; Drug combination; Drug therapy; Female; Human; Humans; Immune Checkpoint Inhibitors [administration & dosage, economics, *therapeutic use]; Immunotherapy; Ipilimumab [administration & dosage, economics, *therapeutic use]; Lung Neoplasms [*drug therapy]; Male; Markov chain; Nivolumab [administration & dosage, economics, *therapeutic use]; Overall survival; Platinum [administration & dosage, therapeutic use]; Price; Probability; Quality adjusted life year; Quality‐Adjusted Life Years; Sensitivity analysis; Treatment Outcome; Uncertainty; United States}, -abstract = {Importance: Treatment with nivolumab‐ipilimumab combination therapy was found to improve overall survival compared with chemotherapy among patients with advanced non‐small cell lung cancer (NSCLC) in the CheckMate 227 clinical trial. However, these drugs are substantially more expensive than chemotherapy and, given the high incidence of advanced NSCLC, the incorporation of dual immune checkpoint inhibitors into the standard of care could have substantial economic consequences. Objective: To assess whether nivolumab‐ipilimumab combination therapy is a cost‐effective first‐line treatment for patients with advanced NSCLC. Design, Setting, and Participants: This economic evaluation designed a Markov model to compare the cost‐effectiveness of nivolumab‐ipilimumab combination therapy with platinum‐doublet chemotherapy as first‐line treatment for patients with advanced NSCLC. The Markov model was created to simulate patients with advanced NSCLC who were receiving either nivolumab‐ipilimumab combination therapy or platinum‐doublet chemotherapy. Transition probabilities, including disease progression, survival, and treatment toxic effects, were derived using data from the CheckMate 227 clinical trial. Costs and health utilities were obtained from published literature. Data analyses were conducted from November 2019 to September 2020. Exposures: Nivolumab‐ipilimumab combination therapy. Main Outcomes and Measures: The primary study outcomes were quality‐adjusted life‐years (QALYs) and cost in 2020 US dollars. Cost‐effectiveness was measured using an incremental cost‐effectiveness ratio (ICER), with an ICER less than $100000 per QALY considered cost‐effective. Model uncertainty was assessed with 1‐way and probabilistic sensitivity analyses. Results: Treatment with nivolumab‐ipilimumab combination therapy was associated with an increase in overall cost of $201900 and improved effectiveness of 0.50 QALYs compared with chemotherapy, yielding an ICER of $401700 per QALY. The study model was sensitive to the cost and duration of immunotherapy. Treatment with nivolumab‐ipilimumab combination therapy became cost‐effective when monthly treatment costs were reduced from $26425 to $5058 (80.9% reduction) or when the maximum duration of immunotherapy was reduced from 24.0 months to 1.4 months. The model was not sensitive to assumptions about survival or programmed cell death 1 ligand 1 status. A probabilistic sensitivity analysis indicated that, at a willingness‐to‐pay threshold of $100000 per QALY, nivolumab‐ipilimumab combination therapy was less cost‐effective than chemotherapy 99.9% of the time. Conclusions and Relevance: In this study, first‐line treatment with nivolumab‐ipilimumab combination therapy was not found to be cost‐effective at current prices despite clinical trial data indicating that this regimen increases overall survival among patients with advanced NSCLC..}, -DOI = {10.1001/jamanetworkopen.2021.8787}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02298520/full} -} - - -Record #141 of 538 -@article{Kanda16, -author = {Kanda, S, Goto, K, Shiraishi, H, Kubo, E, Tanaka, A, Utsumi, H, Sunami, K, Kitazono, S, Mizugaki, H, Horinouchi, H, Fujiwara, Y, Nokihara, H, Yamamoto, N, Hozumi, H, and Tamura, T}, -title = {Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study}, -journal = {Annals of oncology : official journal of the european society for medical oncology}, -volume = {27}, -number = {12}, -pages = {2242‐2250}, -year = {2016}, -accession_number = {EMBASE 619972285, PUBMED 27765756}, -publication type = {Journal article}, -keywords = {Adult; Aged; Analogs and derivatives; Antibodies, Monoclonal [*administration & dosage, adverse effects]; Antineoplastic Combined Chemotherapy Protocols [*administration & dosage, adverse effects]; Antineoplastic agent/ad [Drug Administration]; Antineoplastic agent/ae [Adverse Drug Reaction]; Bevacizumab; Cancer staging; Carboplatin [administration & dosage]; Carboplatin/ad [Drug Administration]; Carcinoma, Non‐Small‐Cell Lung [*drug therapy, pathology, radiotherapy]; Cisplatin [administration & dosage]; Cisplatin/ad [Drug Administration]; Clinical trial; Controlled study; Deoxycytidine [administration & dosage, analogs & derivatives]; Deoxycytidine/ad [Drug Administration]; Disease free survival; Disease‐Free Survival; Docetaxel; Female; Gemcitabine; Human; Humans; Male; Middle Aged; Middle aged; Monoclonal antibody/ad [Drug Administration]; Monoclonal antibody/ae [Adverse Drug Reaction]; Neoplasm Recurrence, Local [*drug therapy, pathology, radiotherapy]; Neoplasm Staging; Nivolumab; Non small cell lung cancer/dt [Drug Therapy]; Non small cell lung cancer/rt [Radiotherapy]; Paclitaxel [administration & dosage]; Paclitaxel/ad [Drug Administration]; Pathology; Pemetrexed [administration & dosage]; Pemetrexed/ad [Drug Administration]; Phase 1 clinical trial; Randomized controlled trial; Taxoid/ad [Drug Administration]; Taxoids [administration & dosage]; Tumor recurrence}, -abstract = {BACKGROUND: The human IgG4 monoclonal antibody nivolumab targets programmed cell death‐1 (PD‐1) and promotes antitumor response by blocking the interaction of PD‐1 with its ligands. This single‐center phase Ib study investigated the tolerability, safety, and pharmacokinetics of nivolumab combined with standard chemotherapy in patients with advanced non‐small‐cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients who had stage IIIB without indication for definitive radiotherapy, stage IV, or recurrent NSCLC were eligible. Regimens were nivolumab 10 mg/kg + gemcitabine/cisplatin (arm A), pemetrexed/cisplatin (arm B), paclitaxel/carboplatin/bevacizumab (arm C), or docetaxel (arm D). Regimens A, B, and D were repeated every 3 weeks for up to four cycles and regimen C was repeated for up to six cycles; nivolumab alone (arm A), with pemetrexed (arm B), bevacizumab (arm C), or docetaxel (arm D) was continued every 3 weeks as maintenance therapy until disease progression or unacceptable toxicity. Dose‐limiting toxicity (DLT) was evaluated during the first treatment cycle. RESULTS: As of March 2014, six patients were enrolled in each arm. The combination of nivolumab 10 mg/kg and chemotherapy was well tolerated. DLT was observed in only one patient in arm A (alanine aminotransferase increased). Select adverse events (those with a potential immunologic cause) of any grade were observed in six, four, six, and five patients in arms A, B, C, and D, respectively. Three, three, six, and one patient achieved partial response while median progression‐free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively. CONCLUSIONS: Combination of nivolumab 10 mg/kg and chemotherapy showed an acceptable toxicity profile and encouraging antitumor activity in patients with advanced NSCLC. CLINICAL TRIALS NUMBER: Japanese Pharmaceutical Information Center Clinical Trials Information (JapicCTI)‐132071.}, -DOI = {10.1093/annonc/mdw416}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01441224/full} -} - - -Record #142 of 538 -@article{Chen22, -author = {Chen, NB, Xiong, M, Zhou, R, Zhou, Y, Qiu, B, Luo, YF, Zhou, S, Chu, C, Li, QW, Wang, B, Jiang, HH, Guo, JY, Peng, KQ, Xie, CM, and Liu, H}, -title = {CT radiomics-based long-term survival prediction for locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy using features from tumor and tumor organismal environment}, -journal = {Radiation oncology (London, England)}, -volume = {17}, -number = {1}, -pages = {184}, -year = {2022}, -accession_number = {PUBMED 36384755}, -publication type = {Journal article}, -keywords = {Carcinoma, Non‐Small‐Cell Lung [diagnostic imaging, therapy]; Chemoradiotherapy [adverse effects, methods]; Humans; Lung Neoplasms [diagnostic imaging, therapy]; Lymphopenia; Prognosis; Tomography, X‐Ray Computed [methods]}, -abstract = {BACKGROUND: Definitive concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced non‐small cell lung cancer (LANSCLC) patients, but the treatment response and survival outcomes varied among these patients. We aimed to identify pretreatment computed tomography‐based radiomics features extracted from tumor and tumor organismal environment (TOE) for long‐term survival prediction in these patients treated with CCRT. METHODS: A total of 298 eligible patients were randomly assigned into the training cohort and validation cohort with a ratio 2:1. An integrated feature selection and model training approach using support vector machine combined with genetic algorithm was performed to predict 3‐year overall survival (OS). Patients were stratified into the high‐risk and low‐risk group based on the predicted survival status. Pulmonary function test and blood gas analysis indicators were associated with radiomic features. Dynamic changes of peripheral blood lymphocytes counts before and after CCRT had been documented. RESULTS: Nine features including 5 tumor‐related features and 4 pulmonary features were selected in the predictive model. The areas under the receiver operating characteristic curve for the training and validation cohort were 0.965 and 0.869, and were reduced by 0.179 and 0.223 when all pulmonary features were excluded. Based on radiomics‐derived stratification, the low‐risk group yielded better 3‐year OS (68.4% vs. 3.3%, p < 0.001) than the high‐risk group. Patients in the low‐risk group had better baseline FEV1/FVC% (96.3% vs. 85.9%, p = 0.046), less Grade ≥ 3 lymphopenia during CCRT (63.2% vs. 83.3%, p = 0.031), better recovery of lymphopenia from CCRT (71.4% vs. 27.8%, p < 0.001), lower incidence of Grade ≥ 2 radiation‐induced pneumonitis (31.6% vs. 53.3%, p = 0.040), superior tumor remission (84.2% vs. 66.7%, p = 0.003). CONCLUSION: Pretreatment radiomics features from tumor and TOE could boost the long‐term survival forecast accuracy in LANSCLC patients, and the predictive results could be utilized as an effective indicator for survival risk stratification. Low‐risk patients might benefit more from radical CCRT and further adjuvant immunotherapy. TRIAL REGISTRATION: retrospectively registered.}, -DOI = {10.1186/s13014-022-02136-w}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02499646/full} -} - - -Record #143 of 538 -@article{Blanco23, -author = {Blanco, R, Domine, M, Gonzalez, JL, Loutfi, S, Alfaro, J, Saldana, J, Rubio, J, Campos, B, Hidalgo, J, Barba, A, Marquez, D, Martin, M, Olaverri, A, and Nadal, E}, -title = {Pembrolizumab as first-line treatment for advanced NSCLC in older adults: a phase II clinical trial evaluating geriatric and quality-of-life outcomes}, -journal = {Lung cancer (Amsterdam, Netherlands)}, -volume = {183}, -pages = {107318}, -year = {2023}, -accession_number = {EMBASE 2026278866, PUBMED 37557022}, -publication type = {Journal article}, -keywords = {*Carcinoma, Non‐Small‐Cell Lung [pathology]; *Lung Neoplasms [pathology]; *advanced cancer /diagnosis /drug therapy /radiotherapy /surgery; *first‐line treatment; *geriatric patient; *non small cell lung cancer /diagnosis /drug therapy /radiotherapy /surgery; *quality of life; *treatment outcome; Aged; Anorexia /side effect; Article; B7‐H1 Antigen [metabolism]; Cancer growth; Cancer radiotherapy; Cancer staging; Cancer surgery; Cancer survival; Chemoradiotherapy; Clinical effectiveness; Clinical feature; Cohort analysis; Confidence interval; Diarrhea /side effect; Disease specific survival; Drug safety; Drug tolerability; Drug withdrawal; Ex‐smoker; Fatigue /side effect; Female; Follow up; Frailty; Human; Humans; Hyperuricemia /side effect; Hypothyroidism /side effect; Kidney failure /side effect; Major clinical study; Male; Multicenter study; Neoadjuvant chemotherapy; Nutritional status; Overall survival; Phase 2 clinical trial; Pneumonia /side effect; Progression free survival; Pruritus /side effect; Quality of Life; Spain; Thrombocytopenia /side effect; Treatment response; Very elderly}, -abstract = {Objectives: Since specific data on immunotherapy in older adults with advanced non‐small cell lung cancer (aNSCLC) are scarce, we designed this study to determine the overall survival (OS) at one year of first‐line pembrolizumab in patients older than 70 years with aNSCLC expressing PD‐L1. Secondary objectives included progression‐free survival, disease‐specific survival, response rate, tolerability, quality of life (QoL) changes, and geriatric assessments. Materials and methods: A single‐arm, open‐label, phase II clinical trial was carried out by the Spanish Lung Cancer Group between February 2018 and November 2019 at ten active sites in Spain. We included patients 70 years old and older with histological or cytological documented stage IIIB or IV aNSCLC and PD‐L1 expression ≥ 1%. Each subject received 200 mg of intravenous pembrolizumab every three weeks for a maximum of two years. Results: 83 patients were recruited for the study and 74 were finally analysed. Most were male (N = 64, 86.5%) and former smokers (N = 51, 68.9%). 24 patients (32.4%) completed at least one year of treatment, 62 (83.7%) discontinued treatment, and 30 (40.5%) experienced disease progression. The median follow‐up of our cohort was 18.0 months [range: 0.1–47.7] and 46 patients (62.2%) died during the period of study. The estimated OS at one year was 61.7% (95% CI: 49.6–71.8%) and the median OS of our cohort was 19.2 months (95% CI: 11.3–25.5). QoL tended to improve throughout the study, although the differences were not statistically significant. The main geriatric scores remained stable, except for a worsening in nutritional status (P = 0.004) and an improvement in frailty (P = 0.028). Conclusion: Our results support treating older adults with aNSCLC expressing PD‐L1 with pembrolizumab in monotherapy. The stability of most geriatric scores and the positive trend on the patients’ QoL should be highlighted, although our results did not reach statistical significance.}, -DOI = {10.1016/j.lungcan.2023.107318}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02623438/full} -} - - -Record #144 of 538 -@article{McCracken80, -author = {McCracken, JD, Heilbrun, L, White, J, Reed, R, Samson, M, Saiers, JH, Stephens, R, Stuckey, WJ, Bickers, J, and Livingston, R}, -title = {Combination chemotherapy, radiotherapy, and BCG immunotherapy in extensive (metastatic) small cell carcinoma of the lung. A Southwest Oncology Group study}, -journal = {Cancer}, -volume = {46}, -number = {11}, -review groups = {SR-CANCER}, -pages = {2335‐2340}, -year = {1980}, -accession_number = {EMBASE 11253686, PUBMED 6254629}, -publication type = {Journal article}, -keywords = {*BCG vaccine; *cyclophosphamide; *doxorubicin; *fluorouracil; *lung carcinoma; *metastasis; *small cell carcinoma; *vincristine; Antineoplastic Agents [*administration & dosage]; BCG Vaccine [*therapeutic use]; Cancer chemotherapy; Cancer combination chemotherapy; Cancer immunotherapy; Cancer radiotherapy; Carcinoma, Small Cell [radiotherapy, *therapy]; Drug Administration Schedule; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Lung Neoplasms [radiotherapy, *therapy]; Major clinical study; Neoplasm Metastasis; Prognosis; Radiotherapy; Respiratory system; Therapy; Time Factors}, -abstract = {From November 1976 to November 1978, the Southwest Oncology Group treated 254 patients with extensive (metastatic) small cell carcinoma of the lung with combination chemotherapy and radiotherapy with and without BCG immunotherapy. Patients receiving BCG achieved a response rate of 50% versus those patients not receiving BCG of 46% (P = .704). Response duration was 20 weeks for the BCG arms and 23 weeks for the no‐BCG arms; survival was 28 weeks for the BCG arms versus 29 weeks for the no‐BCG arms. An adverse effect in patients surviving more than one year was detected; those continuing to receive BCG had significantly shorter survival, 60 weeks versus 85 weeks (P = .019). Toxicities of the programs were not affected by the addition of BCG immunotherapy. It appears that BCG immunotherapy has no beneficial effect on response rate or duration of response in programs using chemotherapy and radiotherapy for control of metastatic small cell carcinoma of the lung. In addition, because of the adverse effect on long‐term survival, we do not recommend the addition of BCG immunotherapy as a treatment modality in this tumor type.}, -DOI = {10.1002/1097-0142(19801201)46:11<2335::aid-cncr2820461102>3.0.co;2-g}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00205976/full} -} - - -Record #145 of 538 -@article{Jazieh22, -author = {Jazieh, K, Khorrami, M, Saad, A, Gad, M, Gupta, A, Patil, P, Viswanathan, VS, Rajiah, P, Nock, CJ, Gilkey, M, Fu, P, Pennell, NA, and Madabhushi, A}, -title = {Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab}, -journal = {Journal for immunotherapy of cancer}, -volume = {10}, -number = {3}, -year = {2022}, -accession_number = {EMBASE 637445578, PUBMED 35256515}, -publication type = {Journal article}, -keywords = {*Carcinoma, Non‐Small‐Cell Lung [diagnostic imaging, drug therapy]; *Lung Neoplasms [diagnostic imaging, drug therapy]; *chemoradiotherapy; *image analysis; *non small cell lung cancer /drug therapy /radiotherapy; Adult; Aged; Antibodies, Monoclonal; Article; B7‐H1 Antigen [therapeutic use]; Biomarkers; Chemoradiotherapy; Cohort analysis; Female; Follow up; Histology; Human; Humans; Immunohistochemistry; Lung parenchyma; Lymph node; Major clinical study; Male; Middle aged; Neoplasm Recurrence, Local [drug therapy]; Overall survival; Progression free survival; Radiomic risk score; Radiomics; Retrospective study; Smoking; Training; Tumor mutational burden; X‐ray computed tomography}, -abstract = {Background The landmark study of durvalumab as consolidation therapy in NSCLC patients (PACIFIC trial) demonstrated significantly longer progression‐free survival (PFS) in patients with locally advanced, unresectable non‐small cell lung cancer (NSCLC) treated with durvalumab (immunotherapy, IO) therapy after chemoradiotherapy (CRT). In clinical practice in the USA, durvalumab continues to be used in patients across all levels of programmed cell death ligand‐1 (PD‐L1) expression. While immune therapies have shown promise in several cancers, some patients either do not respond to the therapy or have cancer recurrence after an initial response. It is not clear so far who will benefit of this therapy or what the mechanisms behind treatment failure are. Methods A total of 133 patients with unresectable stage III NSCLC who underwent durvalumab after CRT or CRT alone were included. Patients treated with durvalumab IO after CRT were randomly split into training (D1=59) and test (D2=59) sets and the remaining 15 patients treated with CRT alone were grouped in D3. Radiomic textural patterns from within and around the target nodules were extracted. A radiomic risk score (RRS) was built and was used to predict PFS and overall survival (OS). Patients were divided into high‐risk and low‐risk groups based on median RRS. Results RRS was found to be significantly associated with PFS in D1 (HR=2.67, 95% CI 1.85 to 4.13, p<0.05, C‐index=0.78) and D2 (HR=2.56, 95% CI 1.63 to 4, p<0.05, C‐index=0.73). Similarly, RRS was associated with OS in D1 (HR=1.89, 95% CI 1.3 to 2.75, p<0.05, C‐index=0.67) and D2 (HR=2.14, 95% CI 1.28 to 3.6, p<0.05, C‐index=0.69), respectively. RRS was found to be significantly associated with PFS in high PD‐L1 (HR=3.01, 95% CI 1.41 to 6.45, p=0.0044) and low PD‐L1 (HR=2.74, 95% CI 1.8 to 4.14, p=1.77e‐06) groups. Moreover, RRS was not significantly associated with OS in the high PD‐L1 group (HR=2.08, 95% CI 0.98 to 4.4, p=0.054) but was significantly associated with OS in the low PD‐L1 group (HR=1.61, 95% CI 1.14 to 2.28, p=0.0062). In addition, RRS was significantly associated with PFS (HR=2.77, 95% CI 1.17 to 6.52, p=0.019, C‐index=0.77) and OS (HR=2.62, 95% CI 1.25 to 5.51, p=0.01, C‐index=0.77) in D3, respectively. Conclusions Tumor radiomics of pretreatment CT images from patients with stage III unresectable NSCLC were prognostic of PFS and OS to CRT followed by durvalumab IO and CRT alone.}, -DOI = {10.1136/jitc-2021-003778}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02406547/full} -} - - -Record #146 of 538 -@article{Jabbour20, -author = {Jabbour, SK, Berman, AT, Decker, RH, Lin, Y, Feigenberg, SJ, Gettinger, SN, Aggarwal, C, Langer, CJ, Simone, CB, Bradley, JD, Aisner, J, and Malhotra, J}, -title = {Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: a Nonrandomized Controlled Trial}, -journal = {JAMA oncology}, -volume = {6}, -number = {6}, -pages = {848‐855}, -year = {2020}, -accession_number = {PUBMED 32077891}, -publication type = {Journal article}, -keywords = {Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized [adverse effects, *therapeutic use]; Antineoplastic Agents, Immunological [adverse effects, *therapeutic use]; Carboplatin [adverse effects, *therapeutic use]; Carcinoma, Non‐Small‐Cell Lung [mortality, pathology, *therapy]; Chemoradiotherapy; Female; Humans; Immune Checkpoint Inhibitors [adverse effects, *therapeutic use]; Lung Neoplasms [mortality, pathology, *therapy]; Male; Middle Aged; Neoplasm Staging; Paclitaxel [adverse effects, *therapeutic use]; Programmed Cell Death 1 Receptor [*antagonists & inhibitors]; Treatment Outcome}, -abstract = {Importance: Consolidative programmed death ligand‐1 (PD‐L) inhibition after chemoradiotherapy improves overall survival and progression‐free survival (PFS) for stage III non‐small cell lung cancer (NSCLC) and requires safety evaluation for incorporation of programmed cell death 1 (PD‐1) inhibition at the onset of chemoradiotherapy. Objective: To determine the safety and tolerability of PD‐1 inhibition concurrently with definitive chemoradiotherapy for NSCLC. Design, Setting, and Participants: This phase 1 prospective multicenter nonrandomized controlled trial using a 3 plus 3 design was performed from August 30, 2016, to October 24, 2018, with a median follow‐up of 16.0 (95% CI, 12.0‐22.6) months and data locked on July 25, 2019. Twenty‐one participants had locally advanced, unresectable, stage III NSCLC as determined by multidisciplinary review, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate hematologic, renal, and hepatic function. Data were analyzed from October 17, 2016, to July 19, 2019. Interventions: Pembrolizumab was combined with concurrent chemoradiotherapy (weekly carboplatin and paclitaxel with 60 Gy of radiation in 2 Gy per d). Dose cohorts evaluated included full‐dose pembrolizumab (200 mg intravenously every 3 weeks) 2 to 6 weeks after chemoradiotherapy (cohort 1); reduced‐dose pembrolizumab (100 mg intravenously every 3 weeks) starting day 29 of chemoradiotherapy (cohort 2); full‐dose pembrolizumab starting day 29 of chemoradiotherapy (cohort 3); reduced‐dose pembrolizumab starting day 1 of chemoradiotherapy (cohort 4); and full‐dose pembrolizumab starting day 1 of chemoradiotherapy (cohort 5). A safety expansion cohort of 6 patients was planned based on the maximum tolerated dose of pembrolizumab. Dose‐limiting toxic effects were defined as pneumonitis of at least grade 4 within cycle 1 of pembrolizumab treatment. Main Outcomes and Measures: Safety and tolerability of PD‐1 inhibition with chemoradiotherapy for NSCLC. Secondary outcomes included PFS and pneumonitis rates. Results: Among the 21 patients included in the analysis (11 female [52%]; median age, 69.5 [range, 53.0‐85.0] years), no dose‐limiting toxic effects in any cohort were observed. One case of grade 5 pneumonitis occurred in the safety expansion cohort with the cohort 5 regimen. Immune‐related adverse events of at least grade 3 occurred in 4 patients (18%). Median PFS for patients who received at least 1 dose of pembrolizumab (n = 21) was 18.7 (95% CI, 11.8‐29.4) months, and 6‐ and 12‐month PFS were 81.0% (95% CI, 64.1%‐97.7%) and 69.7% (95% CI, 49.3%‐90.2%), respectively. Median PFS for patients who received at least 2 doses of pembrolizumab (n = 19) was 21.0 (95% CI, 15.3 to infinity) months. Conclusions and Relevance: These findings suggest that combined treatment with PD‐1 inhibitors and chemoradiotherapy for stage III NSCLC is tolerable, with promising PFS of 69.7% at 12 months, and requires further study. Trial Registration: ClinicalTrials.gov Identifier: NCT02621398.}, -DOI = {10.1001/jamaoncol.2019.6731}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02233312/full} -} - - -Record #147 of 538 -@article{Gulley17, -author = {Gulley, JL, Rajan, A, Spigel, DR, Iannotti, N, Chandler, J, Wong, DJL, Leach, J, Edenfield, WJ, Wang, D, Grote, HJ, Heydebreck, AV, Chin, K, Cuillerot, JM, and Kelly, K}, -title = {Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial}, -journal = {The lancet. Oncology}, -volume = {18}, -number = {5}, -pages = {599‐610}, -year = {2017}, -accession_number = {EMBASE 615095391, PUBMED 28373005}, -publication type = {Journal article}, -keywords = {*avelumab; *non small cell lung cancer; Adverse drug reaction; Aged; Antibodies, Monoclonal [administration & dosage, *adverse effects]; Antibodies, Monoclonal, Humanized; Antineoplastic Agents [administration & dosage, *adverse effects]; Antineoplastic activity; Biological marker; Cancer therapy; Carcinoma, Non‐Small‐Cell Lung [*drug therapy, secondary]; Cell cycle G1 phase; Chronic obstructive lung disease; Clinical trial; Controlled clinical trial; Controlled study; Death; Disease Progression; Disease control; Disease duration; Drug Resistance, Neoplasm; Drug resistance; Drug therapy; Dyspnea; Dyspnea [chemically induced]; Endogenous compound; Epidermal growth factor receptor; Fatigue; Fatigue [chemically induced]; Female; Follow up; Funding; Gene expression; Gene mutation; Genetic marker; Histology; Human; Human tissue; Humans; Infusion related reaction; Infusions, Intravenous [adverse effects]; K ras protein; Lipase [blood]; Lung Neoplasms [*drug therapy, pathology]; Major clinical study; Male; Merkel cell tumor; Middle Aged; Monotherapy; Nausea; Nausea [chemically induced]; Neoplasm Recurrence, Local [*drug therapy]; Oncology; Patient selection; Pharmacokinetics; Phase 1 clinical trial; Platinum; Platinum Compounds [therapeutic use]; Pneumonia [chemically induced]; Programmed death 1 ligand 1; Pulmonary Disease, Chronic Obstructive [chemically induced]; Radiation pneumonia; Remission; Response Evaluation Criteria in Solid Tumors; Response evaluation criteria in solid tumors; Retreatment; Safety; Side effect; Thinking; Toxicity; Triacylglycerol lipase; Tumor biopsy; Tumor resistance}, -abstract = {Background Avelumab, a human Ig‐G1 monoclonal antibody targeting PD‐L1 and approved in the USA for the treatment of metastatic Merkel cell carcinoma, has shown antitumour activity and an acceptable safety profile in patients with advanced solid tumours in a dose‐escalation phase 1a trial. In this dose‐expansion cohort of that trial, we assess avelumab treatment in a cohort of patients with advanced, platinum‐treated non‐small‐cell lung cancer (NSCLC). Methods In this dose‐expansion cohort of a multicentre, open‐label, phase 1 study, patients with progressive or platinum‐resistant metastatic or recurrent NSCLC were enrolled at 58 cancer treatment centres and academic hospitals in the USA. Eligible patients had confirmed stage IIIB or IV NSCLC with squamous or non‐squamous histology, measurable disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), tumour biopsy or archival sample for biomarker assessment, and Eastern Cooperative Oncology Group performance status 0 or 1, among other criteria. Patient selection was not based on PD‐L1 expression or expression of other biomarkers, including EGFR or KRAS mutation or ALK translocation status. Patients received infusional avelumab monotherapy 10 mg/kg every 2 weeks until disease progression or toxicity. The primary objective was to assess safety and tolerability. This trial is registered with ClinicalTrials.gov, number NCT01772004; enrolment in this cohort is closed and the trial is ongoing. Findings Between Sept 10, 2013, and June 24, 2014, 184 patients were enrolled and initiated treatment with avelumab. Median follow‐up duration was 8·8 months (IQR 7·2–11·9). The most common treatment‐related adverse events of any grade were fatigue (46 [25%] of 184 patients), infusion‐related reaction (38 [21%]), and nausea (23 [13%]). Grade 3 or worse treatment‐related adverse events occurred in 23 (13%) of 184 patients; the most common (occurring in more than two patients) were infusion‐related reaction (four [2%] patients) and increased lipase level (three [2%]). 16 (9%) of 184 patients had a serious adverse event related to treatment with avelumab, with infusion‐related reaction (in four [2%] patients) and dyspnoea (in two [1%]) occurring in more than one patient. Serious adverse events irrespective of cause occurred in 80 (44%) of 184 patients. Those occurring in more than five patients (≥3%) were dyspnoea (ten patients [5%]), pneumonia (nine [5%]), and chronic obstructive pulmonary disease (six [3%]). Immune‐related treatment‐related events occurred in 22 patients (12%). Of 184 patients, 22 (12% [95% CI 8–18]) achieved a confirmed objective response, including one complete response and 21 partial responses. 70 (38%) had stable disease. Overall, 92 (50%) of 184 patients achieved disease control (they had a confirmed response or stable disease as their best overall response). One patient was initially thought to have died from grade 5 radiation pneumonitis during the study; however, this adverse event was subsequently regraded to grade 3 and the death was attributed to disease progression. Interpretation Avelumab showed an acceptable safety profile and antitumour activity in patients with progressive or treatment‐resistant NSCLC, providing a rationale for further studies of avelumab in this disease setting. Funding Merck KGaA and Pfizer.}, -DOI = {10.1016/S1470-2045(17)30240-1}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01367738/full} -} - - -Record #148 of 538 -@article{NCT0350958418, -author = {NCT03509584,}, -title = {Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients}, -journal = {https://clinicaltrials.gov/show/NCT03509584}, -year = {2018}, -accession_number = {CTgov NCT03509584}, -publication type = {Trial registry record}, -keywords = {Antibodies, Monoclonal; Carcinoma, Non‐Small‐Cell Lung; Lung Neoplasms; Nivolumab}, -abstract = {Nivolumab is superior to docetaxel monotherapy as second line treatment in advanced stage non‐small cell lung cancer (NSCLC) patients. However, the long term survival advantage seems to be limited to a 20% proportion of treated patients. To date, no definitive biomarker, including tumor cells or infiltrative cells PD‐L1 expression, has been demonstrated to predict nivolumab (or other PD1 or PD‐L1 inhibitors) efficacy. Ipilimumab has also suggested efficacy in the same patient population. Finally, the addition of ipilimumab to nivolumab has a suggested better efficacy over nivolumab alone in advanced stage NSCLC patients with an acceptable safety profile. In parallel, hypo‐fractionated radiotherapy alone has been suggested to elicit the immune system activity as demonstrated by the occurrence of an abscopal effect. Some case reports in melanoma but also lung cancer patients reinforced this hypothesis. Furthermore, preclinical and clinical data suggest that radiation may have a synergistic effect with antibodies targeting the immune checkpoints (PD1, PD‐L1, CTLA4) and improve antitumor efficacy. Moreover, it has been shown that fractionated radiotherapy delivered in combination with aPD‐1 or aPD‐L1 mAbs is able to generate efficacious CD8þ T‐cell responses that will in turn improve local tumor control, long‐term survival, and protection against tumor rechallenge. Therefore, the combination of single fraction or hypo‐fractionated radiotherapy with the anti PD1 nivolumab and/or the anti CTLA4 ipilimumab warrants further investigation. However, a large number of doses, sequences and schedules remain possible. In order to select the best combination, a mathematical modeling of immunotherapy in cancer and its synergy with radiotherapy has been set up. This work provides with mathematical formulas to link the drug serum concentrations of nivolumab and ipilimumab, and the dose of radiation therapy, to the immune response. In silico, the single and three fractions schedule have been found to have the same efficacy while activation of the immune response seems to be better using a hypo‐fractionated (less than 6 fractions) radiotherapy in vivo.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01599378/full} -} - - -Record #149 of 538 -@article{NCT0556821222, -author = {NCT05568212,}, -title = {Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab}, -journal = {https://clinicaltrials.gov/show/NCT05568212}, -year = {2022}, -accession_number = {CTgov NCT05568212}, -publication type = {Trial registry record}, -keywords = {Carcinoma, Non‐Small‐Cell Lung; Lung Neoplasms}, -abstract = {This is a randomized, non‐comparative, phase II study investigating whether: 1) the addition of durvalumab to investigator's choice second line chemotherapy prolongs survival versus investigator's choice second line chemotherapy in NSCLC patients with locally advanced disease progressing on durvalumab given after concomitant chemoradiotherapy; 2) whether the addition of olaparib to durvalumab improves survival over durvalumab alone after induction chemoimmunotherapy in patients relapsing after completing durvalumab maintenance therapy for stage III disease. After evaluation of inclusion and exclusion criteria and after consent form signature, all eligible patients progressing during durvalumab therapy will be in the Part A of the trial randomized to in a 1:1 ratio to investigator's choice single‐agent chemotherapy plus durvalumab (Arm A: experimental arm) or to investigator's choice single‐agent chemotherapy (Arm B: standard arm). In the clinical trial's Part B, patients progressing after completion of durvalumab therapy will be further randomized in a 1:1.7 ratio to investigator's choice platinum doublet chemotherapy plus durvalumab for 4 cycles followed by maintenance durvalumab plus olaparib (Arm C: experimental arm) or to investigator's choice platinum doublet chemotherapy plus durvalumab for 4 cycles followed by durvalumab (Arm D: experimental arm). Therapy will be continued up to disease progression, toxicity or patient refusal.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02467587/full} -} - - -Record #150 of 538 -@article{Ma22, -author = {Ma, SC, Bai, X, Guo, XJ, Liu, L, Xiao, LS, Lin, Y, Tan, JL, Cai, XT, Wen, YX, Ma, H, Fu, QJ, Leng, MX, Zhang, YP, Long, LL, Guo, ZQ, Wu, DH, Zhou, JG, and Dong, ZY}, -title = {Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice}, -journal = {BMC medicine}, -volume = {20}, -number = {1}, -pages = {120}, -year = {2022}, -accession_number = {EMBASE 2015598261, PUBMED 35410334}, -publication type = {Journal article}, -keywords = {*advanced cancer; *non small cell lung cancer; Adrenal gland; Adrenal metastasis; Adult; Article; B7‐H1 Antigen; Birch; Bone; Brain metastasis; Cancer patient; Cancer prognosis; Cancer survival; Carcinoma, Non‐Small‐Cell Lung; Chemotherapy; Clinical Trials as Topic; Clinical trial; Cohort analysis; Controlled study; Female; Human; Humans; Immunotherapy; Liver; Lung Neoplasms [pathology]; Major clinical study; Male; Mediastinum; Metastasis; Nonhuman; Outcome assessment; Overall survival; Pleura effusion; Prognosis; Progression free survival; Progression‐Free Survival; Randomized controlled trial; Scoring system}, -abstract = {Background: Organ‐specific metastatic context has not been incorporated into the clinical practice of guiding programmed death‐(ligand) 1 [PD‐(L)1] blockade, due to a lack of understanding of its predictive versus prognostic value. We aim at delineating and then incorporating both the predictive and prognostic effects of the metastatic‐organ landscape to dissect PD‐(L)1 blockade efficacy in non‐small cell lung cancer (NSCLC). Methods: A total of 2062 NSCLC patients from a double‐arm randomized trial (OAK), two immunotherapy trials (FIR, BIRCH), and a real‐world cohort (NFyy) were included. The metastatic organs were stratified into two categories based on their treatment‐dependent predictive significance versus treatment‐independent prognosis. A metastasis‐based scoring system (METscore) was developed and validated for guiding PD‐(L)1 blockade in clinical trials and real‐world practice. Results: Patients harboring various organ‐specific metastases presented significantly different responses to immunotherapy, and those with brain and adrenal gland metastases survived longer than others [overall survival (OS), p = 0.0105; progression‐free survival (PFS), p = 0.0167]. In contrast, survival outcomes were similar in chemotherapy‐treated patients regardless of metastatic sites (OS, p = 0.3742; PFS, p = 0.8242). Intriguingly, the immunotherapeutic predictive significance of the metastatic‐organ landscape was specifically presented in PD‐L1‐positive populations (PD‐L1 > 1%). Among them, a paradoxical coexistence of a favorable predictive effect coupled with an unfavorable prognostic effect was observed in metastases to adrenal glands, brain, and liver (category I organs), whereas metastases to bone, pleura, pleural effusion, and mediastinum yielded consistent unfavorable predictive and prognostic effects (category II organs). METscore was capable of integrating both predictive and prognostic effects of the entire landscape and dissected OS outcome of NSCLC patients received PD‐(L)1 blockade (p < 0.0001) but not chemotherapy (p = 0.0805) in the OAK training cohort. Meanwhile, general performance of METscore was first validated in FIR (p = 0.0350) and BIRCH (p < 0.0001), and then in the real‐world NFyy cohort (p = 0.0181). Notably, METscore was also applicable to patients received PD‐(L)1 blockade as first‐line treatment both in the clinical trials (OS, p = 0.0087; PFS, p = 0.0290) and in the real‐world practice (OS, p = 0.0182; PFS, p = 0.0045). Conclusions: Organ‐specific metastatic landscape served as a potential predictor of immunotherapy, and METscore might enable noninvasive forecast of PD‐(L)1 blockade efficacy using baseline radiologic assessments in advanced NSCLC.}, -DOI = {10.1186/s12916-022-02315-2}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02407027/full} -} - - -Record #151 of 538 -@article{Yao20, -author = {Yao, J, Wang, Z, Sheng, J, Wang, H, You, L, Zhu, X, Pan, H, and Han, W}, -title = {Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a two-center retrospective study}, -journal = {International immunopharmacology}, -volume = {89}, -number = {Pt A}, -pages = {107033}, -year = {2020}, -accession_number = {EMBASE 2008006746, PUBMED 33039958}, -publication type = {Journal article}, -keywords = {*advanced cancer /drug therapy /radiotherapy; *antiangiogenic therapy; *cancer immunotherapy; *non small cell lung cancer /drug therapy /radiotherapy; Adrenal metastasis; Adult; Aged; Aged, 80 and over; Anemia /side effect; Angiogenesis Inhibitors [adverse effects, *therapeutic use]; Anorexia /side effect; Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; Arterial thromboembolism /side effect; Artery thrombosis /side effect; Article; Bone metastasis; Brain infarction /side effect; Brain metastasis; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [*drug therapy, immunology, secondary]; China; Cohort analysis; Combination drug therapy; Diarrhea /side effect; Drug efficacy; Drug safety; Edema /side effect; Fatigue /side effect; Female; Functional status assessment; Hand foot syndrome /side effect; Hemangioma /side effect; Human; Humans; Hypotension /side effect; Hypothyroidism /side effect; Immune Checkpoint Inhibitors [adverse effects, *therapeutic use]; Immunotherapy [adverse effects]; Interstitial pneumonia /side effect; Kidney dysfunction /side effect; Leukocyte count; Liver dysfunction /side effect; Liver metastasis; Lung Neoplasms [*drug therapy, immunology, pathology]; Major clinical study; Male; Middle Aged; Middle aged; Myalgia /side effect; Nausea /side effect; Oral mucositis /side effect; Pericarditis /side effect; Pilot Projects; Priority journal; Programmed Cell Death 1 Receptor [antagonists & inhibitors]; Progression free survival; Progression‐Free Survival; Proteinuria /side effect; Pruritus /side effect; Rash /side effect; Retrospective Studies; Retrospective study; Risk Assessment; Risk Factors; Scoring system; Side effect /side effect; Thrombocytopenia /side effect; Time Factors; Treatment outcome; Treatment response; Vomiting /side effect}, -abstract = {Background: The synergistic effects of immunotherapy and antiangiogenic therapy in advanced non–small cell lung cancer (NSCLC) have been reported in both preclinical and clinical trials. Herein, we evaluated the preliminary efficacy and safety of combined immunotherapy and antiangiogenic therapy in patients with previously treated advanced NSCLC in a real‐world setting. Methods: We conducted a 2‐center, retrospective study of previously treated advanced NSCLC patients who received any anti‐programmed death‐1 antibody combined with antiangiogenic agent between May 2018 and March 2020. Results: In total, 57 patients were included in this study, and the objective response rate and disease control rate were 19.3% and 63.2%, respectively. The median progression‐free survival (PFS) was 4.2 months (95% confidence interval [CI]: 3.2–5.2 months). Bone metastases (odds ratio [OR] not available; P < .01) and ≥ 3 treatment lines (OR 6.8; 95% CI: 1.6–29.6; P < .05) were independent negative predictors of objective response. Additionally, liver metastases (hazard ratio [HR] 3.7; 95% CI: 1.6–8.5; P < 0.01), poor performance status score (PS) (HR 3.4; 95% CI: 1.6–7.5; P < 0.01) and ≥ 3 treatment lines (HR 3.5; 95% CI: 1.7–7.4; P < 0.01) were found to be negative predictors of PFS. Eighty‐nine percent of the patients experienced an adverse event. Conclusions: Metastatic sites (bone and liver), ≥3 treatment lines and poor PS were potential negative predictors of the efficacy of immunotherapy combined with antiangiogenic therapy for treating NSCLC. Further investigations and randomized controlled trials are needed.}, -DOI = {10.1016/j.intimp.2020.107033}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02190829/full} -} - - -Record #152 of 538 -@article{Reck19, -author = {Reck, M, Feng, Y, Kim, HR, Plautz, G, Kang, Y-K, Owonikoko, TK, Nghiem, P, and Sheng, J}, -title = {Analysis of tumour hyperprogression (HP) with nivolumab (Nivo) in randomized, placebo (Pbo)-controlled trials}, -journal = {Annals of oncology}, -volume = {30}, -pages = {v486}, -year = {2019}, -accession_number = {EMBASE 630606679}, -publication type = {Journal article; Conference proceeding}, -keywords = {*stomach cancer; Adult; Cancer patient; Cancer radiotherapy; Cancer size; Chemotherapy; Clinical evaluation; Conference abstract; Controlled study; Double blind procedure; Drug therapy; Female; Human; Immunotherapy; Maintenance therapy; Major clinical study; Male; Phase 3 clinical trial; Post hoc analysis; Randomized controlled trial; Retrospective study; Small cell lung cancer; Tumor growth; Tumor volume; Whole brain radiotherapy}, -abstract = {Background: Tumor HP has been suggested to occur in some patients with solid tumors subsequent to PD‐1/L1 inhibitor monotherapy; however, reports are based on nonrandomized, single‐arm studies. Previous post‐hoc analysis of HP with nivo was performed in the phase III ATTRACTION‐2 trial, which randomized patients with gastric cancer who received ≥2 prior lines of therapy to nivo or pbo. Using the pbo arm as a surrogate for natural course of disease progression, nivo was not associated with HP at≥20,≥50, or≥100% tumor growth rates. The current analysis expands this framework to assess HP in patients with extensive disease small cell lung cancer (ED SCLC) in the randomized, pbo‐controlled CheckMate 451 trial. Methods: CheckMate 451 was a phase III double‐blind study that evaluated maintenance treatment in patients with ED SCLC without disease progression after platinumbased 1L chemotherapy. Patients were randomized to nivo 240 mg, nivo 1 mg/kg + ipilimumab 3 mg/kg, or pbo, within 9 weeks from the last dose of 1L chemotherapy (or≥11 weeks for those receiving PCI or whole brain radiotherapy); HP analysis focused on the nivo (n=280) and pbo (n=275) arms. Tumor assessments occurred every 6 weeks for the first 36 weeks, then every 12 weeks until disease progression. HP was calculated as changes in size of the primary lesion (sum of longest diameters [SLD]), as assessed retrospectively among patients who had baseline and≥1 on‐treatment tumor measurement available (nivo, n=177; pbo, n=175). Results: Baseline characteristics were balanced between treatment arms in the analysis population. Median increase in tumor size from baseline to first on‐treatment assessment in the maintenance period was 2% with nivo vs 17% with pbo. Compared to the pbo arm, fewer patients on nivo had SLD increases of ≥20% (27% vs 46%), ≥50% (10% vs 22%), and≥100% (3% vs 6%) at the first on‐treatment scan. Conclusions: In this analysis, nivo was not associated with HP in the pbo‐controlled CheckMate 451 trial. These data are consistent with the previous analysis of ATTRACTION‐2, suggesting that reports of HP with immunotherapy may reflect some patients' natural course of disease.}, -DOI = {10.1093/annonc/mdz253.019}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02077482/full} -} - - -Record #153 of 538 -@article{NCT0492904121, -author = {NCT04929041,}, -title = {Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative}, -journal = {https://clinicaltrials.gov/ct2/show/NCT04929041}, -year = {2021}, -accession_number = {CTgov NCT04929041}, -publication type = {Trial registry record}, -keywords = {Adenocarcinoma of Lung; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Non‐Small‐Cell Lung; Ipilimumab; Lung Neoplasms; Nivolumab}, -abstract = {PRIMARY OBJECTIVE:I. To assess if stereotactic body radiation therapy (SBRT) improves the progression freesurvival (PFS, phase II portion) and overall survival (OS, phase III portion) of advancedstage non‐small cell lung cancer (NSCLC) patients with PD‐L1 tumor proportion score (TPS)< 1% who receive immunotherapy with or without chemotherapy.SECONDARY OBJECTIVES:I. To estimate and compare the rates of >= grade 3‐4 and all grade adverse events byCommon Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 between the arms.II. To summarize and compare progression‐free survival (PFS) per Response EvaluationCriteria in Solid Tumors (RECIST) between the arms.III. To determine and compare the objective response rate (ORR) per RECIST between thearms (including at both irradiated and un‐irradiated sites).QUALITY OF LIFE (QOL) OBJECTIVE:I. To assess the health‐related QOL in both treatment arms.CORRELATIVE SCIENCE OBJECTIVE:I. To evaluate changes in the peripheral immune microenvironment between the arms.OUTLINE: Patients are randomized to 1 of 2 arms.ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 andipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24months in the absence of disease progression or unacceptable toxicity or patients mayreceive standard of care systemic immunotherapy. Patients also undergo magnetic resonanceimaging (MRI), computed tomography (CT), or positron emission tomography (PET) throughoutthe trial. Patients may undergo blood sample collection and tissue biopsy on study aswell as echocardiography (ECHO) during screening.Arm B: Patients receive nivolumab IV over 30 minutes on days 1 and 22 and ipilimumab IVover 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in theabsence of disease progression or unacceptable toxicity or patients may receive standardof care systemic immunotherapy. Patients also undergo 3 fractions of SBRT every otherday. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergoblood sample collection and tissue biopsy on study as well as ECHO during screening.After completion of study treatment, patients are followed up every 3 months for 3 yearsand then every 6 months for years 4‐5 following randomization until disease progression.Following disease progression patients are followed for survival every 6 months for up to5 years following randomization.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02278503/full} -} - - -Record #154 of 538 -@article{Antonia17, -author = {Antonia, SJ, Villegas, A, Daniel, D, Vicente, D, Murakami, S, Hui, R, Yokoi, T, Chiappori, A, Lee, KH, de Wit, M, Cho, BC, Bourhaba, M, Quantin, X, Tokito, T, Mekhail, T, Planchard, D, Kim, YC, Karapetis, CS, Hiret, S, Ostoros, G, Kubota, K, Gray, JE, Paz-Ares, L, de Castro Carpeño, J, Wadsworth, C, Melillo, G, Jiang, H, Huang, Y, Dennis, PA, and Özgüroglu, M}, -title = {Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer}, -journal = {New England journal of medicine}, -volume = {377}, -number = {20}, -pages = {1919‐1929}, -year = {2017}, -accession_number = {PUBMED 28885881}, -publication type = {Journal article}, -keywords = {Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal [adverse effects, *therapeutic use]; Antineoplastic Agents [adverse effects, *therapeutic use]; B7‐H1 Antigen [*antagonists & inhibitors]; Carcinoma, Non‐Small‐Cell Lung [mortality, secondary, *therapy]; Chemoradiotherapy; Disease‐Free Survival; Female; Humans; Intention to Treat Analysis; Kaplan‐Meier Estimate; Lung Neoplasms [mortality, pathology, *therapy]; Male; Middle Aged; Neoplasm Staging}, -abstract = {BACKGROUND: Most patients with locally advanced, unresectable, non‐small‐cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti‐programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum‐based chemoradiotherapy. METHODS: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression‐free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12‐month and 18‐month progression‐free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. RESULTS: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression‐free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12‐month progression‐free survival rate was 55.9% versus 35.3%, and the 18‐month progression‐free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events. CONCLUSIONS: Progression‐free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).}, -DOI = {10.1056/NEJMoa1709937}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01426087/full} -} - - -Record #155 of 538 -@article{NCT0602043023, -author = {NCT06020430,}, -title = {Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy}, -journal = {https://clinicaltrials.gov/ct2/show/NCT06020430}, -year = {2023}, -accession_number = {CTgov NCT06020430}, -publication type = {Trial registry record}, -keywords = {Carcinoma, Non‐Small‐Cell Lung; Lung Neoplasms}, -abstract = {Radical radiotherapy is critical for locally advanced non small cell lung cancer(NSCLC ). Our previous sturdy indicated that patients who received induction immunotherapy and subsequent radiotherapy suffered higher proportion of pneumonitis.Grade 2 or more pneumonitis patients have worse prognosis. It is urged to optimize the radiotherapy dose and target volume for patients treated with immunotherapy and radiotherapy. According to retrospective and prospective studies, omitting CTV radiation is feasible for patients undergoing concurrent radio‐chemotherapy for locally advanced NSCLC. It is postulated that omitting CTV radiation for patients responded to induction therapy with immunotherapy and chemotherapy will have less pneumonitis without sacrificing the local control rate. Omitting CTV may also retain better immune function which will facilitate the immunotherapy.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02594444/full} -} - - -Record #156 of 538 -@article{NCT0654574724, -author = {NCT06545747,}, -title = {Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI}, -journal = {https://clinicaltrials.gov/ct2/show/NCT06545747}, -year = {2024}, -accession_number = {CTgov NCT06545747}, -publication type = {Trial registry record}, -keywords = {Carcinoma, Non‐Small‐Cell Lung; Immunomodulating Agents; Lung Neoplasms}, -abstract = {This study is a randomized phase III trial that aiming to investigate the role of dynamiccontrast‐enhanced magnetic resonance imaging (DCE‐MRI) guided hypofractionatedradiotherapy (hypo‐RT) in patients with locally advanced non‐small cell lung cancer(LA‐NSCLC) who are planned to receive hypo‐RT combined with concurrent chemotherapy andconsolidative immunotherapy. Patients will be randomized in a 1:1 ratio into two groups: 1. The study group will undergo adaptive dose‐painting hypo‐RT based on DCE‐MRI. 2. The control group will undergo hypo‐RT based on enhanced CT.The treatment‐related toxicity, local control and long‐term survival will be evaluatedcompared between MRI‐guided and CT‐guided hypo‐RT.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02739013/full} -} - - -Record #157 of 538 -@article{NCT0363178418, -author = {NCT03631784,}, -title = {A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)}, -journal = {https://clinicaltrials.gov/ct2/show/NCT03631784}, -year = {2018}, -accession_number = {CTgov NCT03631784}, -publication type = {Trial registry record}, -keywords = {Albumin‐Bound Paclitaxel; Carboplatin; Carcinoma, Non‐Small‐Cell Lung; Lung Neoplasms; Paclitaxel; Pembrolizumab; Pemetrexed}, -abstract = {This is a trial in adult participants with unresectable, locally advanced, Stage III non‐small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy followed by pembrolizumab monotherapy. The primary hypothesis of the trial is that within each platinum doublet chemotherapy cohort, the percentage of participants who develop Grade 3 or higher pneumonitis is ≤10% and objective response rate (ORR) by blinded independent central review (BICR).}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01662236/full} -} - - -Record #158 of 538 -@article{Reckamp22, -author = {Reckamp, KL, Redman, MW, Dragnev, KH, Minichiello, K, Villaruz, LC, Faller, B, Al Baghdadi, T, Hines, S, Everhart, L, Highleyman, L, Papadimitrakopoulou, V, Neal, JW, Waqar, SN, Patel, JD, Gray, JE, Gandara, DR, Kelly, K, and Herbst, RS}, -title = {Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A}, -journal = {Journal of clinical oncology}, -volume = {40}, -number = {21}, -pages = {2295‐2306}, -year = {2022}, -accession_number = {EMBASE 2019086396, PUBMED 35658002}, -publication type = {Journal article}, -keywords = {*Carcinoma, Non‐Small‐Cell Lung [pathology]; *Lung Neoplasms [pathology]; *advanced cancer /drug therapy /radiotherapy; *cancer immunotherapy; *non small cell lung cancer /drug therapy /radiotherapy; Acidosis /side effect; Acute kidney failure /side effect; Adult; Adverse outcome; Alanine aminotransferase blood level; Anemia /side effect; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols [adverse effects]; Article; Aspartate aminotransferase blood level; Cancer combination chemotherapy; Cancer patient; Cancer recurrence; Colon perforation /side effect; Controlled study; Dehydration /side effect; Diarrhea /side effect; Docetaxel [therapeutic use]; Dyspnea /side effect; Fatigue /side effect; Febrile neutropenia /side effect; Female; Gastrointestinal disease /side effect; Health care quality; Heart arrest /side effect; Human; Humans; Hypertension /side effect; Hypoalbuminemia /side effect; Hypotension /side effect; Hypoxia /side effect; Immunotherapy; Leukocyte count; Leukocyte culture; Limb weakness /side effect; Lower limb; Lung [pathology]; Lung hemorrhage /side effect; Lung infection /side effect; Lymphocyte count; Major clinical study; Male; Multiple organ failure /side effect; Muscle weakness /side effect; Nausea /side effect; Neutrophil count; Oral mucositis /side effect; Overall survival; Pericardial effusion /side effect; Phase 2 clinical trial; Pleura effusion /side effect; Pneumonia /side effect; Pneumothorax /side effect; Progression free survival; Ramucirumab; Randomized controlled trial; Respiratory failure /side effect; Sepsis /side effect; Side effect /side effect; Standard of Care; Thrombocytopenia /side effect; Thromboembolism /side effect; Treatment duration; Treatment response; Vascular Endothelial Growth Factor A; Vomiting /side effect; Wheezing /side effect}, -abstract = {PURPOSEResistance to immune checkpoint inhibition (ICI) in advanced non‐small‐cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular endothelial growth factor (VEGF)/VEGF receptor inhibition has yielded promising results in multiple tumor types.METHODSIn this randomized phase II Lung‐MAP nonmatch substudy (S1800A), patients ineligible for a biomarker‐matched substudy with NSCLC previously treated with ICI and platinum‐based chemotherapy and progressive disease at least 84 days after initiation of ICI were randomly assigned to receive ramucirumab plus pembrolizumab (RP) or investigator's choice standard of care (SOC: docetaxel/ramucirumab, docetaxel, gemcitabine, and pemetrexed). With a goal of 130 eligible patients, the primary objective was to compare overall survival (OS) using a one‐sided 10% level using the better of a standard log‐rank (SLR) and weighted log‐rank (WLR; G[rho = 0, gamma = 1]) test. Secondary end points included objective response, duration of response, investigator‐assessed progression‐free survival, and toxicity.RESULTSOf 166 patients enrolled, 136 were eligible (69 RP; 67 SOC). OS was significantly improved with RP (hazard ratio [80% CI]: 0.69 [0.51 to 0.92]; SLR one‐sided P =.05; WLR one‐sided P =.15). The median (80% CI) OS was 14.5 (13.9 to 16.1) months for RP and 11.6 (9.9 to 13.0) months for SOC. OS benefit for RP was seen in most subgroups. Investigator‐assessed progression‐free survival (hazard ratio [80% CI]: 0.86 [0.66 to 1.14]; one‐sided SLR, P =.25 and.14 for WLR) and response rates (22% RP v 28% SOC, one‐sided P =.19) were similar between arms. Grade ≥ 3 treatment‐related adverse events occurred in 42% of patients in the RP group and 60% on SOC.CONCLUSIONThis randomized phase II trial demonstrated significantly improved OS with RP compared with SOC in patients with advanced NSCLC previously treated with ICI and chemotherapy. The safety was consistent with known toxicities of both drugs. These data warrant further evaluation.}, -DOI = {10.1200/JCO.22.00912}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02466363/full} -} - - -Record #159 of 538 -@article{Gauvin21, -author = {Gauvin, C, Krishnan, V, Kaci, I, Tran-Thanh, D, Bedard, K, Albadine, R, Leduc, C, Gaboury, L, Blais, N, Tehfe, M, Routy, B, and Florescu, M}, -title = {Survival impact of aggressive treatment and PD-L1 expression in oligometastatic NSCLC}, -journal = {Current oncology (Toronto, Ont.)}, -volume = {28}, -number = {1}, -pages = {593‐605}, -year = {2021}, -accession_number = {EMBASE 2005974990, PUBMED 33498159}, -publication type = {Journal article}, -keywords = {*aggression; *cancer survival; *non small cell lung cancer; *protein expression; Adult; Aged; Article; B7‐H1 Antigen [genetics]; Brain metastasis; Cancer prognosis; Cancer staging; Carcinoma, Non‐Small‐Cell Lung [drug therapy, genetics]; Controlled study; Female; Follow up; Gene expression; Human; Humans; Immunotherapy; Lung Neoplasms [drug therapy, genetics]; Major clinical study; Male; Neoplasm Staging; Overall survival; Prevalence; Prognosis; Progression free survival; Radiation dose; Randomized controlled trial; Retrospective study}, -abstract = {Background: Studies have shown that aggressive treatment of non‐small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as anti‐programmed cell death ligand 1 (PD‐L1), anti‐programmed cell death protein 1 (PD‐1), and T‐Lymphocyte‐associated antigen 4 (CTLA‐4) inhibitors are now part of the standard of care for advanced NSCLC. However, the prognostic impact of PD‐L1 expression in the oligometastatic setting remains unknown. Methods: Patients with oligometastatic NSCLC were identified from the patient database of the Centre hospitalier de l’Université de Montréal (CHUM). “Oligometastatic disease” definition chosen is one synchronous metastasis based on the M1b staging of the eight IASLC (The International Association for the Study of Lung Cancer) Classification (within sixth months of diagnosis) or up to three cerebral metastasis based on the methodology of the previous major phase II randomized study of Gomez et al. We compared the OS between patients receiving aggressive treatment at both metastatic and primary sites (Group A) and patients receiving non‐aggressive treatment (Group B). Subgroup analysis was performed using tumor PD‐L1 expression. Results: Among 643 metastatic NSCLC patients, we identified 67 patients with oligometastasis (10%). Median follow‐up was 13.3 months. Twenty‐nine patients (43%) received radical treatment at metastatic and primary sites (Group A), and 38 patients (57%) received non‐aggressive treatment (Group B). The median OS (mOS) of Group A was significantly longer than for Group B (26 months vs. 5 months, p = 0.0001). Median progression‐free survival (mPFS) of Group A was superior than Group B (17.5 months vs. 3.4 months, p = 0.0001). This difference was still significant when controlled for primary tumor staging: stage I (p = 0.316), stage II (p = 0.024), and stage III (p = 0.001). In the cohort of patients who were not treated with PD‐L1 inhibitors, PD‐L1 expression negatively correlated with mOS. Conclusions: Aggressive treatments of oligometastatic NSCLC significantly improve mOS and mPFS compared to a more palliative approach. PD‐L1 expression is a negative prognostic factor which suggests a possible role for immunotherapy in this setting.}, -DOI = {10.3390/curroncol28010059}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02263948/full} -} - - -Record #160 of 538 -@article{Takayama22, -author = {Takayama, Y, Yano, J, Seike, R, Mishima, S, and Shoda, H}, -title = {Efficacy of Chemoimmunotherapy in NSCLC Patients With Brain Metastasis With or Without Prior Brain Radiotherapy}, -journal = {Anticancer research}, -volume = {42}, -number = {10}, -pages = {4805‐4812}, -year = {2022}, -accession_number = {EMBASE 2020563225, PUBMED 36191986}, -publication type = {Journal article}, -keywords = {*brain metastasis /radiotherapy; *brain radiation; *cancer chemotherapy; *cancer immunotherapy; *drug efficacy; *non small cell lung cancer /drug therapy; Adult; Advanced cancer; Aged; Anemia; Article; Asymptomatic disease; Brain Neoplasms [drug therapy, radiotherapy]; Brain [pathology]; Cancer patient; Cancer radiotherapy; Cancer size; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [drug therapy, radiotherapy]; Central nervous system disease; Colitis; Controlled study; ErbB Receptors [therapeutic use]; Female; Hospital; Human; Humans; Hypophysitis; Hypothyroidism; Immune Checkpoint Inhibitors; Kidney dysfunction; Liver dysfunction; Lung Neoplasms [drug therapy, radiotherapy]; Major clinical study; Male; Nausea; Neutropenia; Overall survival; Patient safety; Pneumonia; Progression free survival; Protein Kinase Inhibitors [therapeutic use]; Radiation necrosis; Rash; Retrospective Studies; Retrospective study; Thrombocytopenia; Treatment response}, -abstract = {Background/Aim: Many patients with advanced lung cancer develop brain metastasis (BM); however, few reports confirming the efficacy of immune checkpoint inhibitors (ICIs) plus chemotherapy in non‐small cell lung cancer (NSCLC) patients with symptomatic BM have been published. Therefore, we retrospectively evaluated the effects of chemoimmunotherapy in NSCLC patients who did or did not receive prior brain radiotherapy. Patients and Methods: A total of 103 patients with advanced NSCLC who received ICIs plus chemotherapy at our hospital from January 2019 to July 2021 were retrospectively enrolled. Results: Patients with BM tended to have shorter progression‐free survival (PFS) and overall survival (OS) compared with patients without BM. The maximum size of BM and the proportion of patients with symptomatic BM were greater among patients who received brain radiotherapy before chemoimmunotherapy. However, patients who received prior brain radiotherapy had better PFS and OS compared with patients who did not receive prior brain radiotherapy. Conclusion: Patients who received prior brain radiotherapy experienced a superior therapeutic benefit of ICIs plus chemotherapy, including those with larger and more symptomatic BM.}, -DOI = {10.21873/anticanres.15985}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02490025/full} -} - - -Record #161 of 538 -@article{Chen20, -author = {Chen, Y, Paz-Ares, LG, Dvorkin, M, Trukhin, D, Reinmuth, N, Garassino, MC, Statsenko, G, Voitko, O, Hochmair, M, Ozguroglu, M, Verderame, F, Havel, L, Losonczy, G, Conev, N, Hotta, K, Ji, JH, Broadhurst, H, Byrne, N, Thiyagarajah, P, and Goldman, JW}, -title = {First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): impact of brain metastases on treatment patterns and outcomes}, -journal = {Journal of clinical oncology}, -volume = {38}, -number = {15}, -year = {2020}, -accession_number = {EMBASE 636606022}, -publication type = {Journal article; Conference proceeding}, -keywords = {*brain metastasis; *cancer staging; *small cell lung cancer; Adult; Cancer radiotherapy; Conference abstract; Controlled study; Drug combination; Drug therapy; Female; Human; Major clinical study; Male; Phase 3 clinical trial; Radiotherapy; Randomized controlled trial; Skull irradiation}, -abstract = {Background: In the Phase 3, randomized, openlabel CASPIAN study, first‐line durvalumab (D) added to etoposide plus either cisplatin or carboplatin (EP) significantly improved OS vs EP alone (HR 0.73 [95% CI 0.59‐0.91]; p = 0.0047) in pts with ES‐SCLC at the planned interim analysis. Here we describe treatment patterns and outcomes for pts according to brain metastases. Methods: Treatment‐naïve pts (WHO PS 0/1) with ES‐SCLC received 4 cycles of D 1500 mg + EP q3w followed by maintenance D 1500 mg q4w until disease progression (PD) or up to 6 cycles of EP q3w and optional prophylactic cranial irradiation (PCI; investigator's discretion). Pts with either asymptomatic or treated and stable brain metastases were eligible. Brain imaging was suggested for pts with suspected brain metastases, but was not mandated at screening or during treatment. The primary endpoint was OS. Analysis of OS and PFS in pt subgroups with and without brain metastases was prespecified. Other analyses in these subgroups were post hoc. Data cutoff: Mar 11, 2019. Results: At baseline, 28 (10.4%) of 268 pts in the D + EP arm and 27 (10.0%) of 269 pts in the EP arm had known brain metastases; of these, only 3 pts (∼11% of those with baseline brain metastases) in each arm received radiotherapy (RT) to the brain prior to study entry. D + EP consistently improved OS vs EP in pts with or without known brain metastases at baseline (HR 0.69 [95% CI 0.35‐1.31] and 0.74 [0.59‐0.93], respectively); PFS was also consistently improved with D + EP regardless of the presence or not of baseline brain metastases (HR 0.73 [0.42‐1.29] and 0.78 [0.64‐0.95]). Among pts without known brain metastases at baseline, similar proportions developed new brain metastases at first PD in the D + EP (20/240; 8.3%) and EP arms (23/242; 9.5%), despite 19 (7.9%) pts in the EP arm having received PCI. Overall, 48 of 268 (17.9%) and 49 of 269 (18.2%) pts in the D + EP and EP arms received RT to the brain subsequent to study treatment; rates remained similar across the D + EP and EP arms regardless of baseline brain metastases (11 of 28 [39.3%] and 11 of 27 [40.7%] pts with known baseline brain metastases, compared to 37 of 240 [15.4%] and 38 of 242 [15.7%] pts without known baseline brain metastases). Conclusions: In CASPIAN, OS and PFS outcomes were improved with D + EP vs EP regardless of baseline brain metastases, consistent with the ITT analyses. Rates of new brain metastases at first PD were similar between arms, although PCI was permitted only in the control arm. Rates of subsequent RT to the brain were also similar in both arms.}, -DOI = {10.1200/JCO.2020.38.15-suppl.9068}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02348851/full} -} - - -Record #162 of 538 -@article{Schulz20, -author = {Schulz, C, Chen, Y, Paz-Ares, LG, Dvorkin, M, Trukhin, D, Reinmuth, N, Garassino, MC, Statsenko, G, Voitko, O, Hochmair, MJ, Ozguroglu, M, Verderame, F, Havel, L, Losonczy, G, Conev, N, Hotta, K, Ji, JH, Broadhurst, H, Byrne, N, Thiyagarajah, P, Goldman, JW, and Alt, J}, -title = {First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): impact of brain metastases on treatment patterns and outcomes}, -journal = {Oncology research and treatment}, -volume = {43}, -pages = {144‐145}, -year = {2020}, -accession_number = {EMBASE 640123312}, -publication type = {Journal article; Conference proceeding}, -keywords = {*brain metastasis; *cancer staging; *small cell lung cancer; Adult; Brain radiation; Cancer patient; Cancer radiotherapy; Conference abstract; Controlled study; Drug therapy; Female; Human; Major clinical study; Male; Neuroimaging; Outcome assessment; Phase 3 clinical trial; Randomized controlled trial; Skull irradiation}, -abstract = {Introduction: In the Phase 3 randomized, open‐label CASPIAN study 1st line durvalumab (D) with etoposide plus either cisplatin or carbopla‐tin (EP) signifcantly improved OS vs EP (HR 0.73 [95% CI 0.59‐0.91]; p = 0.0047) in patients (pts) with ES‐SCLC. Here we report treatment patterns and outcomes for pts according to brain metastases. Methods: Treatment‐naïve ES‐SCLC pts received 4 cycles of D 1500 mg + EP q3w followed by maintenance D 1500 mg q4w until disease progression (PD) or up to 6 cycles of EP q3w and optional prophylactic cranial irradiation (PCI). Pts with either asymptomatic or treated and stable brain metastases were eligible. Brain imaging was suggested for pts with suspected brain metastases, but was not mandated at screening or during treatment. The primary endpoint was OS. Analysis of OS and PFS in pt subgroups with and without brain metastases was prespecifed. Other analyses in these subgroups were post hoc. Data cutof Mar 11, 2019. Results: At baseline, 28 (10.4%) of 268 pts in the D + EP arm and 27 (10.0%) of 269 pts in the EP arm had known brain metastases; only 3 pts ( 11% of pts with baseline brain metastases) in each arm received brain radiotherapy (RT) prior to study entry. D + EP improved OS vs EP in pts with or without known brain metastases at baseline (HR 0.69 [95% CI 0.35‐1.31] and 0.74 [0.59‐0.93]); PFS was also improved with D + EP regardless of baseline brain metastases (HR 0.73 [0.42‐1.29] and 0.78 [0.64 0.95]). Among pts without known brain metastases at baseline, similar proportions developed new brain metastases at first PD in the D + EP (20/240; 8.3%) and EP arms (23/242; 9.5%), despite 19 (7.9%) pts in the EP arm having received PCI. Overall, 48 of 268 (17.9%) and 49 of 269 (18.2%) pts in the D + EP and EP arms received brain RT subsequent to study treatment; rates remained similar across the D + EP and EP arms regardless of baseline brain metastases (11 of 28 [39.3%] and 11 of 27 [40.7%] pts with known baseline brain metastases, compared to 37 of 240 [15.4%] and 38 of 242 [15.7%] pts without known baseline brain metastases). Conclusions: In CASPIAN, OS and PFS outcomes were improved with D + EP vs EP regardless of baseline brain metastases, consistent with the ITT analyses. Rates of new brain metastases at first PD were similar between arms, although PCI was permitted only in the control arm. Rates of subsequent brain RT were also similar in both arms.}, -DOI = {10.1159/000510995}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02519159/full} -} - - -Record #163 of 538 -@article{Zhang20, -author = {Zhang, Z, Yuan, F, Chen, R, Li, Y, Ma, J, Yan, X, Wang, L, Zhang, F, Tao, H, Guo, D, Huang, Z, Zhang, S, Li, X, Zhi, X, Ge, X, Hu, Y, and Wang, J}, -title = {Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors}, -journal = {Frontiers in immunology}, -volume = {11}, -pages = {1173}, -year = {2020}, -accession_number = {EMBASE 632160652, PUBMED 32587591}, -publication type = {Journal article}, -keywords = {*non small cell lung cancer /drug therapy; *prospective study; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm [blood]; Article; Asian People; Biomarkers, Tumor [*blood]; Blood sampling; CA‐125 Antigen [blood]; Cancer immunotherapy; Cancer prognosis; Cancer staging; Carcinoembryonic Antigen [blood]; Carcinoma, Non‐Small‐Cell Lung [*blood, drug therapy]; Chemoradiotherapy; Controlled study; Female; Genetic transfection; Human; Human tissue; Humans; Immune Checkpoint Inhibitors [*therapeutic use]; Immunoassay; Immunohistochemistry; Keratin‐19 [blood]; Leukocyte count; Longitudinal study; Luminescence; Lung Neoplasms [*blood, drug therapy]; Lymphocyte; Major clinical study; Male; Membrane Proteins [blood]; Middle Aged; Monocyte; Neutrophil; Observational study; Outcome assessment; Overall survival; Prognosis; Progression free survival; Randomized controlled trial; Treatment Outcome; Treatment response; Very elderly}, -abstract = {Background: Serum tumor markers carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cytokeratin 19 fragment (CYFRA21‐1) and squamous‐cell carcinoma‐related antigen (SCC‐Ag) are routinely used for monitoring the response to chemotherapy or targeted therapy in advanced‐stage non‐small cell lung cancer (NSCLC), however their role in immunotherapy remains unclear. The aim of this study was to investigate whether dynamics of these serum markers were associated with the efficacy and prognosis of Chinese late‐stage NSCLC patients treated with programmed cell death‐1/programmed cell death ligand‐1 (PD‐1/PD‐L1) inhibitors. Methods: We initiated a longitudinal prospective study on advanced NSCLC patients treated with PD‐1/PD‐L1 inhibitors in Chinese PLA general hospital (Beijing, China). Blood samples of baseline and after 6 weeks' treatment were collected. CT scan were used by all patients to evaluate treatment efficacy according to RECIST 1.1. Serum tumor markers levels were measured with an electrochemical luminescence for SCC‐Ag and with a chemiluminescent microparticle immunoassay for serum CEA, CA125, and CYFRA21‐1. At least 20% decreases of the biomarkers from baseline were considered as meaningful improvements after 6 weeks of treatment with immune checkpoint inhibitors (ICIs). Optimization‐based method was used to balance baseline covariates between different groups. Associations between serum tumor biomarker improvements and objective response rate (ORR), progression‐free survival (PFS), and overall survival (OS) were analyzed. Results: A total of 308 Chinese patients with advanced NSCLC were enrolled in the study. After balancing baseline covariates, patients with meaningful improvements in <2 out of 4 biomarkers (CEA, CA125, CYFRA21‐1, and SCC‐Ag) was ended up with lower ORR (0.08 vs. 0.35, p < 0.001), shorten PFS (median: 5.4 vs. 12.5 months, p < 0.001), and OS (median: 11.7 vs. 25.6 months, p < 0.001) in the total population. Subgroup analysis of patients with adenocarcinoma revealed that patients with meaningful improvements in <2 out of 4 biomarkers had significant lower ORR (0.06 vs. 0.36, p < 0.001), shorten PFS (median: 4.1 vs. 11.9 months, p < 0.001), and OS (median: 11.9 vs. 24.2 months, p < 0.001). So as in patients with squamous cell carcinoma, meaningful improvements in at least 2 out of 4 biomarkers were linked to better ORR (0.42 vs. 0.08, p = 0.014), longer PFS (median: 13.1 vs. 5.6 months, p = 0.001), and OS (median: 25.6 vs. 10.9 months, p = 0.06). Conclusions: The dynamic change of CEA, CA125, CYFRA21‐1, and SCC‐Ag from baseline have prognostic value for late‐stage NSCLC patients treated with PD‐1/PD‐L1 inhibitors. Decrease of associated biomarkers serum levels were associated with favorable clinical outcomes.}, -DOI = {10.3389/fimmu.2020.01173}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02144616/full} -} - - -Record #164 of 538 -@article{EUCTR2021-003266-13-NO21, -author = {EUCTR2021-003266-13-NO,}, -title = {COMBINATORY IMMUNOTHERAPY-2 (COM-IT-2)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-003266-13-NO}, -year = {2021}, -accession_number = {ICTRP EUCTR2021‐003266‐13‐NO}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trade Name: Pembrolizumab (KEytruda) Product Name: Keytruda Pharmaceutical Form: Injection/infusion Trade Name: Atezolizumab (Tecentriq) Pharmaceutical Form: Injection/infusion Trade Name: Nivolumab (Opdivio) Pharmaceutical Form: Injection/infusion CONDITION: Non small cell lung cancer, stage IV Patients are eligible if when they are planned to start immunotherapy according to standard routines and are not in need of radiotherapy Therapeutic area: Diseases [C] ‐ Respiratory Tract Diseases [C08] PRIMARY OUTCOME: Main Objective: The aim of the trial is to study the acute and subacute toxicity of adding extensive radiotherapy to immunotherapy in the treatment of non small cell lung cancer with stage IV disease Primary end point(s): Primary: Acute (<3 months) and subacute (3‐6 months) toxicity Secondary Objective: The secondary objectives are to study the effect and quality of life of the treatment in question. ; Specifically, secondary objectives are to evaluate: ; ‐ progression free survival and overall survival; ‐ response rate, duration of respons; ‐ Time to NeXT treatment; ‐ Health related quality of life; ‐ therapy response in non‐irradiated lesions, if any; Exploratory objectives: Investigate; ‐ biomarkers of treatment response ; ‐ immune response ; ‐ imaging to predict therapy response; ‐ ctDNA as a tool to monitoring treatment effect Timepoint(s) of evaluation of this end point: 3‐6 monts SECONDARY OUTCOME: Secondary end point(s): PFS; OS; ORR; DoR; TNT; HR‐QoL: EORTC QLQ‐C30 and QLQ‐LC29 Timepoint(s) of evaluation of this end point: 3, 6 and 12, 18 and 24 months INCLUSION CRITERIA: 1. Age >18 years 2. Written informed consent 3. Advanced NSCLC with clinical indication of starting systemic treatment with immunotherapy alone or in combination with chemotherapy (first or later lines) 4. Available core or excisional biopsy of a tumour lesion 5. Measurable disease according to RECIST criteria (RECIST 1.1) 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0‐2 7. Life expectancy > 3 months 8. At least 1 tumour lesion suitable for radiotherapy treatment 9. Adequate organ function based on clinical examination and lab values Hb>9 g/dL Neutrophils >1500 pr mm3 Estimated creatinin clearance >40 mL/min AST and ALT <2.5 x upper normal limit (if liver metastases: AST/ALT must be <5x upper normal limit) Serum bilirubin < 1.5 x upper normal limit 10. Women of childbearing potential (WOCBP) should use a highly effective method during the treatment period and for at least 5 months after}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02378090/full} -} - - -Record #165 of 538 -@article{ChiCTR200003555820, -author = {ChiCTR2000035558,}, -title = {Phase II clinical trial of acc006 combined with albumin bound paclitaxel and carboplatin in the treatment of advanced squamous non-small cell lung cancer}, -journal = {http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000035558}, -year = {2020}, -accession_number = {ICTRP ChiCTR2000035558}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: experimental group:ACC006 combined with albumin binding paclitaxel and carboplatin;control group:placebo combined with albumin binding paclitaxel and carboplatin; CONDITION: Squamousnon‐small cell lung cancer PRIMARY OUTCOME: Progress‐free survival (PFS); SECONDARY OUTCOME: Objective response rate (ORR);Duration of response (DOR);Disease control rate (DCR);Pharmacokinetic parameters;Incidence of adverse events; INCLUSION CRITERIA: 1. Patients with age >= 18 years old, sex not limited, inpatients or outpatients; 2. Patients with locally advanced, metastatic or recurrent squamous cell lung cancer (IIIB‐IV, UICC and AJCC TNM stages, 8th Edition) confirmed by histology or cytology (including non central lung squamous cell carcinoma or adenosquamous carcinoma with squamous cell carcinoma as the main component); 3. According to the criteria for evaluating the efficacy of solid tumors (RECIST, version 1.1), there should be at least one measurable tumor lesion; 4. Patients who can not receive surgical treatment and / or radical concurrent chemoradiotherapy; 5. Patients who have not previously received systemic anti‐tumor therapy for locally advanced, metastatic or recurrent squamous non‐small cell lung cancer (including chemotherapy, molecular targeted therapy and immunotherapy, excluding adjuvant chemotherapy or local regional therapy when the last time of administration is more than}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02436705/full} -} - - -Record #166 of 538 -@article{NCT0377548618, -author = {NCT03775486,}, -title = {Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)}, -journal = {https://clinicaltrials.gov/ct2/show/NCT03775486}, -year = {2018}, -accession_number = {CTgov NCT03775486}, -publication type = {Trial registry record}, -keywords = {Antibodies, Monoclonal; Carboplatin; Carcinoma, Non‐Small‐Cell Lung; Cisplatin; Durvalumab; Gemcitabine; Lung Neoplasms; Olaparib; Paclitaxel; Pemetrexed}, -abstract = {Adult patients with a histologically or cytologically documented advanced NSCLC notamenable to curative surgery or radiation with tumors that lack activation EGFR mutationsand ALK fusions are eligible for enrollment. During the initial therapy phase, patientswill receive treatment with Durvalumab along with the Investigator's choice ofplatinum‐based doublet therapy for squamous NSCLC (nab‐paclitaxel plus carboplatin orgemcitabine plus carboplatin/cisplatin) and non‐squamous NSCLC (nab‐paclitaxel pluscarboplatin or pemetrexed plus carboplatin/cisplatin) for 4 cycles. Patients who havecompleted 4 cycles and not progressed throughout the initial therapy phase will berandomized in a 1:1 ratio into the maintenance phase of the study to receive eitherDurvalumab plus placebo or Durvalumab plus Olaparib maintenance therapy. Patients willreceive maintenance treatment until specific discontinuation criteria are met, includingclinical disease progression (as assessed by the Investigator) or RECIST 1.1‐definedradiological Progressive Disease (PD), unacceptable toxicity, and withdrawal of consent.Tumor evaluation scans will be performed until objective disease progression as efficacyassessments. All patients will be followed for survival until the end of the study.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01795437/full} -} - - -Record #167 of 538 -@article{Zhang23, -author = {Zhang, Y, Zhang, L, Cao, S, Wang, Y, Ling, X, Zhou, Y, and Zhong, H}, -title = {A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer}, -journal = {Cancer medicine}, -volume = {12}, -number = {15}, -pages = {15998‐16010}, -year = {2023}, -accession_number = {PUBMED 37409360}, -publication type = {Journal article}, -keywords = {Carcinoma, Non‐Small‐Cell Lung [drug therapy]; Humans; Lung Neoplasms [drug therapy]; Nomograms; Pneumonia [chemically induced, diagnosis, epidemiology]; Retrospective Studies}, -abstract = {OBJECTIVE: Immunotherapy extensively treats advanced non‐small‐cell lung cancer (NSCLC). Although immunotherapy is generally better tolerated than chemotherapy, it can cause multiple immune‐related adverse events (irAEs) involving multiple organs. Checkpoint inhibitor‐related pneumonitis (CIP) is a relatively uncommon irAE that, in severe cases, can be fatal. Potential risk factors for the occurrence of CIP are currently poorly understood. This study sought to develop a novel scoring system for predicting the risk of CIP based on a nomogram model. METHODS: We retrospectively collected advanced NSCLC patients who received immunotherapy at our institution between January 1, 2018, and December 30, 2021. All patients who met the criteria were randomly divided into the training set and testing set (in a ratio of 7:3), and cases fulfilling the CIP diagnostic criteria were screened. The patients' baseline clinical characteristics, laboratory tests, imaging, and treatment information were extracted from the electronic medical records. The risk factors associated with the occurrence of CIP were identified based on the results of logistic regression analysis on the training set, and a nomogram prediction model was developed. The discrimination and prediction accuracy of the model was evaluated using the receiver operating characteristic (ROC) curve, the concordance index (C‐index), and the calibration curve. Decision curve analysis (DCA) was used to evaluate the clinical applicability of the model. RESULTS: The training set comprised 526 (CIP: 42 cases), and the testing set comprised 226 (CIP: 18 cases) patients, respectively. In the training set, the final multivariate regression analysis revealed that age (p = 0.014; odds ratio [OR] = 1.056; 95% Confidence Interval [CI] =1.011‐1.102), Eastern Cooperative Oncology Group performance status (p = 0.002; OR = 6.170; 95% CI = 1.943‐19.590), history of prior radiotherapy (p < 0.001; OR = 4.005; 95% CI = 1.920‐8.355), baseline white blood cell count (WBC) (p < 0.001; OR = 1.604; 95% CI = 1.250‐2.059), and baseline absolute lymphocyte count (ALC) (p = 0.034; OR = 0.288; 95% CI = 0.091‐0.909) were identified as independent risk factors for the occurrence of CIP. A prediction nomogram model was developed based on these five parameters. The area under the ROC curve and C‐index of the prediction model in the training set and testing set were 0.787 (95% CI: 0.716‐0.857) and 0.874 (95% CI: 0.792‐0.957), respectively. The calibration curves are in good agreement. The DCA curves indicate that the model has good clinical utility. CONCLUSION: We developed a nomogram model that proved to be a good assistant tool for predicting the risk of CIP in advanced NSCLC. This model has the potential power to help clinicians in making treatment decisions.}, -DOI = {10.1002/cam4.6244}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02592978/full} -} - - -Record #168 of 538 -@article{NCT0648449124, -author = {NCT06484491,}, -title = {IMPT Dose Escalation for NSCLC (HyDose)}, -journal = {https://clinicaltrials.gov/ct2/show/NCT06484491}, -year = {2024}, -accession_number = {CTgov NCT06484491}, -publication type = {Trial registry record}, -keywords = {Carboplatin; Carcinoma, Non‐Small‐Cell Lung; Cisplatin; Docetaxel; Durvalumab; Pemetrexed}, -abstract = {In this randomized controlled trial, the aim is to test the hypothesis that protontherapy dose escalation using a heterogeneous simultaneous boost on the primary tumor aspart of chemoradiotherapy for locally advanced non‐small‐cell lung cancer is safe, i.e.does not result in an increase in severe toxicity compared to standard‐dose protontherapy. Secondarily, the goal is to estimate the treatment effect size, if any.In the intervention group, patients will receive intensity‐modulated proton therapy doseescalation to the primary tumor up to 74.0 Gy or 64.0 Gy (RBE of 1.1) in 25 fractions,depending on proximity to the mediastinal envelope. In the control group, patients willreceive 60.0 Gy intensity‐modulated proton therapy in 25 fractions.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02733177/full} -} - - -Record #169 of 538 -@article{Hellmann17, -author = {Hellmann, MD, Rizvi, NA, Goldman, JW, Gettinger, SN, Borghaei, H, Brahmer, JR, Ready, NE, Gerber, DE, Chow, LQ, Juergens, RA, Shepherd, FA, Laurie, SA, Geese, WJ, Agrawal, S, Young, TC, Li, X, and Antonia, SJ}, -title = {Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study}, -journal = {The lancet. Oncology}, -volume = {18}, -number = {1}, -pages = {31‐41}, -year = {2017}, -accession_number = {EMBASE 613934515, PUBMED 27932067}, -publication type = {Journal article}, -keywords = {*ipilimumab; *ipilimumab/ae [Adverse Drug Reaction]; *ipilimumab/cb [Drug Combination]; *ipilimumab/ct [Clinical Trial]; *ipilimumab/do [Drug Dose]; *ipilimumab/dt [Drug Therapy]; *nivolumab; *nivolumab/ae [Adverse Drug Reaction]; *nivolumab/cb [Drug Combination]; *nivolumab/ct [Clinical Trial]; *nivolumab/do [Drug Dose]; *nivolumab/dt [Drug Therapy]; *non small cell lung cancer; *non small cell lung cancer/dt [Drug Therapy]; Acute kidney failure/si [Side Effect]; Adenocarcinoma [*drug therapy, pathology]; Adrenal insufficiency; Adrenal insufficiency/si [Side Effect]; Adult; Advanced cancer/dt [Drug Therapy]; Adverse drug reaction; Aged; Alanine aminotransferase blood level; Alanine aminotransferase/ec [Endogenous Compound]; Amylase/ec [Endogenous Compound]; Anemia/si [Side Effect]; Antibodies, Monoclonal [administration & dosage]; Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Appendix; Arthralgia/si [Side Effect]; Article; Aspartate aminotransferase blood level; Aspartate aminotransferase/ec [Endogenous Compound]; Brain disease/si [Side Effect]; Cancer staging; Carcinoma, Non‐Small‐Cell Lung [*drug therapy, pathology]; Carcinoma, Squamous Cell [*drug therapy, pathology]; Cataract/si [Side Effect]; Chemotherapy; Clinical trial; Cohort Studies; Cohort analysis; Colitis; Colitis/si [Side Effect]; Controlled clinical trial; Controlled study; Creatinine blood level; Creatinine/ec [Endogenous Compound]; Death; Decreased appetite/si [Side Effect]; Dehydration/si [Side Effect]; Diabetes mellitus/si [Side Effect]; Diarrhea/si [Side Effect]; Disease duration; Dosage schedule comparison; Drug combination; Drug dose comparison; Drug efficacy; Drug fatality/si [Side Effect]; Drug safety; Drug therapy; Drug tolerability; Drug withdrawal; Dyspnea/si [Side Effect]; Endocrine disease/si [Side Effect]; Endogenous compound; Esophagitis/si [Side Effect]; Facial nerve disease/si [Side Effect]; Fatigue/si [Side Effect]; Female; Fever/si [Side Effect]; Follow up; Follow‐Up Studies; Funding; Gastrointestinal symptom/si [Side Effect]; Human; Human tissue; Humans; Hyperthyroidism/si [Side Effect]; Hypertransaminasemia/si [Side Effect]; Hypokalemia/si [Side Effect]; Hyponatremia/si [Side Effect]; Increased appetite/si [Side Effect]; Infusion related reaction/si [Side Effect]; Interactive voice response system; Ipilimumab; Liver disease/si [Side Effect]; Lung Neoplasms [*drug therapy, pathology]; Lung disease/si [Side Effect]; Lung embolism/si [Side Effect]; Lymphocyte count; Maculopapular rash/si [Side Effect]; Major clinical study; Male; Middle Aged; Monotherapy; Multicenter study; Nausea/si [Side Effect]; Neoplasm Staging; Nephrotoxicity/si [Side Effect]; Nivolumab; Non small cell lung cancer/dt [Drug Therapy]; Open study; Outcome assessment; Overall survival; Pancreatitis/si [Side Effect]; Pharmacokinetics; Phase 1 clinical trial; Phase 3 clinical trial; Pneumonia; Pneumonia/si [Side Effect]; Priority journal; Prognosis; Programmed death 1 ligand 1; Programmed death 1 receptor; Progression free survival; Pruritus/si [Side Effect]; Radiation necrosis/si [Side Effect]; Randomized controlled trial; Rash/si [Side Effect]; Respiratory distress/si [Side Effect]; Safety; Side effect; Side effect/si [Side Effect]; Skin disease/si [Side Effect]; Skin toxicity/si [Side Effect]; Survival Rate; Survival time; Toxicity; Treatment duration; Treatment response; Triacylglycerol lipase; Triacylglycerol lipase blood level; United States; Vomiting/si [Side Effect]; Young adult}, -abstract = {BACKGROUND: Nivolumab has shown improved survival in the treatment of advanced non‐small‐cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety and activity of combination nivolumab plus ipilimumab as first‐line therapy for NSCLC. METHODS: The open‐label, phase 1, multicohort study (CheckMate 012) cohorts reported here were enrolled at eight US academic centres. Eligible patients were aged 18 years or older with histologically or cytologically confirmed recurrent stage IIIb or stage IV, chemotherapy‐naive NSCLC. Patients were randomly assigned (1:1:1) by an interactive voice response system to receive nivolumab 1 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks, nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 12 weeks, or nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks until disease progression, unacceptable toxicities, or withdrawal of consent. Data from the latter two cohorts, which were considered potentially suitable for further clinical development, are presented in this report; data from the other cohort (as well as several earlier cohorts) are described in the appendix. The primary outcome was safety and tolerability, assessed in all treated patients. This ongoing study is registered with ClinicalTrials.gov, number NCT01454102. INTERPRETATION: In NSCLC, first‐line nivolumab plus ipilimumab had a tolerable safety profile and showed encouraging clinical activity characterised by a high response rate and durable response. To our knowledge, the results of this study are the first suggestion of improved benefit compared with anti‐PD‐1 monotherapy in patients with NSCLC, supporting further assessment of this combination in a phase 3 study. FUNDING: Bristol‐Myers Squibb. FINDINGS: Between May 15, 2014, and March 25, 2015, 78 patients were randomly assigned to receive nivolumab every 2 weeks plus ipilimumab every 12 weeks (n=38) or nivolumab every 2 weeks plus ipilimumab every 6 weeks (n=40). One patient in the ipilimumab every‐6‐weeks cohort was excluded before treatment; therefore 77 patients actually received treatment (38 in the ipilimumab every‐12‐weeks cohort; 39 in the ipilimumab every‐6‐weeks cohort). At data cut‐off on Jan 7, 2016, 29 (76%) patients in the ipilimumab every‐12‐weeks cohort and 32 (82%) in the ipilimumab every‐6‐weeks cohort had discontinued treatment. Grade 3‐4 treatment‐related adverse events occurred in 14 (37%) patients in the ipilimumab every‐12‐weeks cohort and 13 (33%) patients in the every‐6‐weeks cohort; the most commonly reported grade 3 or 4 treatment‐related adverse events were increased lipase (three [8%] and no patients), pneumonitis (two [5%] and one [3%] patients), adrenal insufficiency (one [3%] and two [5%] patients), and colitis (one [3%] and two [5%] patients). Treatment‐related serious adverse events were reported in 12 (32%) patients in the ipilimumab every‐12‐weeks cohort and 11 (28%) patients in the every‐6‐weeks cohort. Treatment‐related adverse events (any grade) prompted treatment discontinuation in four (11%) patients in the every‐12‐weeks cohort and five (13%) patients in the every‐6‐weeks cohort. No treatment‐related deaths occurred. Confirmed objective responses were achieved in 18 (47% [95% CI 31‐64]) patients in the ipilimumab every‐12‐weeks cohort and 15 (38% [95% CI 23‐55]) patients in the ipilimumab every‐6‐weeks cohort; median duration of response was not reached in either cohort, with median follow‐up times of 12·8 months (IQR 9·3‐15·5) in the ipilimumab every‐12‐weeks cohort and 11·8 months (6·7‐15·9) in the ipilimumab every‐6‐weeks cohort. In patients with PD‐L1 of 1% or greater, confirmed objective responses were achieved in 12 (57%) of 21 patients in the ipilimumab every‐12‐weeks cohort and 13 (57%) of 23 patients in the ipilimumab every‐6‐weeks cohort.}, -DOI = {10.1016/S1470-2045(16)30624-6}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01297337/full} -} - - -Record #170 of 538 -@article{NCT0613941923, -author = {NCT06139419,}, -title = {The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC}, -journal = {https://clinicaltrials.gov/ct2/show/NCT06139419}, -year = {2023}, -accession_number = {CTgov NCT06139419}, -publication type = {Trial registry record}, -keywords = {Albumin‐Bound Paclitaxel; Carcinoma, Non‐Small‐Cell Lung; Cisplatin; Lung Neoplasms; Paclitaxel; Thymalfasin; Tislelizumab}, -abstract = {This prospective phase II randomized study is to determine the impact of thymosin alpha‐1on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patientswith locally advanced NSCLC by assessing the survival outcomes, treatment responses andtoxicities.Patients with locally advanced NSCLC who will receive concurrent radiochemotherapyfollowed by immunotherapy consolidation will be randomly divided into two groups(concurrent Tα1 treatment group and control group [in which Tα1 will not be used]), andthe overall survivals, progression‐free survivals (PFS), completion rate of immunotherapyconsolidation, toxicities/adverse effects, and peripheral blood immune biomarkers will becompared between these two groups.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02626899/full} -} - - -Record #171 of 538 -@article{O'Brien00, -author = {O'Brien, ME, Saini, A, Smith, IE, Webb, A, Gregory, K, Mendes, R, Ryan, C, Priest, K, Bromelow, KV, Palmer, RD, Tuckwell, N, Kennard, DA, and Souberbielle, BE}, -title = {A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma}, -journal = {British journal of cancer}, -volume = {83}, -number = {7}, -review groups = {HS-HANDSRCH; SR-CANCER; Lung Cancer}, -pages = {853‐857}, -year = {2000}, -accession_number = {PUBMED 10970684}, -publication type = {Journal article}, -keywords = {Adjuvants, Immunologic [adverse effects, therapeutic use]; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; Bacterial Vaccines [adverse effects, immunology, *therapeutic use]; Cancer Vaccines [adverse effects, immunology, *therapeutic use]; Carcinoma, Non‐Small‐Cell Lung [immunology, *therapy]; Cisplatin [administration & dosage, adverse effects]; Combined Modality Therapy; Female; Humans; Immunotherapy, Active; Interferon‐gamma [blood]; Interleukin‐10 [blood]; Lung Neoplasms [drug therapy, immunology, *therapy]; Male; Mesothelioma [drug therapy, immunology, *therapy]; Middle Aged; Mitomycin [administration & dosage, adverse effects]; Mycobacterium [*immunology]; Tumor Necrosis Factor‐alpha [metabolism]; Vaccines, Inactivated [adverse effects, immunology, therapeutic use]; Vinblastine [administration & dosage, adverse effects]}, -abstract = {Mycobacterial preparations have been used with limited success against cancer apart from superficial bladder cancer. Recently, a therapeutic vaccine derived from Mycobacterium vaccae has been given to patients with prostate cancer and melanoma indicating a possible beneficial effect on disease activity in such patients. We have recently initiated a series of randomized studies to test the feasibility and toxicity of combining a preparation of heat‐killed Mycobacterium vaccae (designated SRL172) with a multidrug chemotherapy regimen to treat patients with inoperable non‐small cell lung cancer (NSCLC) and mesothelioma. 28 evaluable patients with previously untreated symptomatic NSCLC and mesothelioma were randomized to receive either 3 weekly intravenous combination chemotherapy alone, or chemotherapy given with monthly intra‐dermal injections of SRL172. Safety and tolerability were scored by common toxicity criteria and efficacy was evaluated by survival of patients and by tumour response assessed by CT scanning. The toxicity of chemotherapy was similar in the two groups. SRL172 caused mild inflammation at the injection site. In the group of patients randomized to receive chemotherapy combined with SRL172, there was a trend towards improved response rate (54% vs. 33%) with more patients in the combined arm receiving radical surgery and radiotherapy, improved median survival (9.7 months vs. 7.5 months) and improved 1 year survival (42% vs. 18%). SRL172 appeared to improve sleep (P = 0.08) and improved appetite (P = 0.01). There was no detectable change in serum cytokine levels for gamma‐interferon and TNF‐alpha before and after treatment. In patients with NSCLC and mesothelioma, there may be a beneficial interaction when chemotherapy is administered in combination with SRL172. Confirmation of this effect and further investigation is underway in a randomized phase III trial and in laboratory models.}, -DOI = {10.1054/bjoc.2000.1401}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00299370/full} -} - - -Record #172 of 538 -@article{Spaas21, -author = {Spaas, M, Sundahl, N, Hulstaert, E, Kruse, V, Rottey, S, De Maeseneer, D, Surmont, V, Meireson, A, Brochez, L, Reynders, D, Goetghebeur, E, Van den Begin, R, Van Gestel, D, Renard, V, Dirix, P, Mestdagh, P, and Ost, P}, -title = {Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial}, -journal = {BMC cancer}, -volume = {21}, -number = {1}, -pages = {514}, -year = {2021}, -accession_number = {EMBASE 2011448873, PUBMED 33962592}, -publication type = {Journal article}, -keywords = {*cancer combination chemotherapy; *cancer immunotherapy; *external beam radiotherapy; Article; Cancer survival; Clinical protocol; Combined Modality Therapy; Disease burden; Head and neck squamous cell carcinoma /drug therapy; Human; Humans; Immune Checkpoint Inhibitors [*therapeutic use]; Melanoma /drug therapy; Neoplasms [mortality, *therapy]; Non small cell lung cancer /drug therapy; Outcome assessment; Phase 2 clinical trial; Progression free survival; Quality of life; Radiation dose; Radiation response; Radiosurgery [*methods]; Randomized Controlled Trials as Topic; Randomized controlled trial (topic); Renal cell carcinoma /drug therapy; Survival rate; Transitional cell carcinoma /drug therapy; Treatment duration; Treatment outcome; Treatment response}, -abstract = {Background: While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for various tumor types has led to considerable improvements in clinical outcome, the majority of patients still fail to respond. Preclinical data suggest that stereotactic body radiotherapy (SBRT) could work synergistically with CPIs by acting as an in situ cancer vaccine, thus potentially increasing response rates and prolonging disease control. Though SBRT administered concurrently with CPIs has been shown to be safe, evidence of its efficacy from large randomized trials is still lacking. The aim of this multicenter randomized phase II trial is to assess whether SBRT administered concurrently with CPIs could prolong progression‐free survival as compared to standard of care in patients with advanced solid tumors. Methods/design: Ninety‐eight patients with locally advanced or metastatic disease will be randomized in a 1:1 fashion to receive CPI treatment combined with SBRT (Arm A) or CPI monotherapy (Arm B). Randomization will be stratified according to tumor histology (melanoma, renal, urothelial, head and neck squamous cell or non‐small cell lung carcinoma) and disease burden (? or > 3 cancer lesions). The recommended SBRT dose is 24Gy in 3 fractions, which will be administered to a maximum of 3 lesions and is to be completed prior to the second or third CPI cycle (depending on CPI treatment schedule). The study?s primary endpoint is progression‐free survival as per iRECIST. Secondary endpoints include overall survival, objective response, local control, quality of life and toxicity. Translational analyses will be performed using blood, fecal and tissue samples. Discussion: The CHEERS trial will provide further insights into the clinical and immunological impact of SBRT when combined with CPIs in patients with advanced solid tumors. Furthermore, study results will inform the design of future immuno‐radiotherapy trials. Trial registration: Clinicaltrials.gov identifier: NCT03511391. Registered 17 April 2018.}, -DOI = {10.1186/s12885-021-08088-w}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02272688/full} -} - - -Record #173 of 538 -@article{Multhoff20, -author = {Multhoff, G, Seier, S, Stangl, S, Sievert, W, Shevtsov, M, Werner, C, Pockley, AG, Blankenstein, C, Hildebrandt, M, Offner, R, Ahrens, N, Kokowski, K, Hautmann, M, Rödel, C, Fietkau, R, Lubgan, D, Huber, R, Hautmann, H, Duell, T, Molls, M, Specht, H, Haller, B, Devecka, M, Sauter, A, and Combs, SE}, -title = {Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: a Randomized Phase II Clinical Trial}, -journal = {Clinical cancer research}, -volume = {26}, -number = {20}, -pages = {5368‐5379}, -year = {2020}, -accession_number = {PUBMED 32873573}, -publication type = {Journal article}, -keywords = {Adult; Aged; Carcinoma, Non‐Small‐Cell Lung [blood, *drug therapy, pathology, *radiotherapy]; Chemoradiotherapy; Combined Modality Therapy; Female; HSP70 Heat‐Shock Proteins [*blood]; Humans; Immunotherapy, Adoptive [adverse effects]; Killer Cells, Natural [drug effects, immunology, radiation effects]; Male; Middle Aged; Neoplasm Staging; Platinum [*administration & dosage, adverse effects]; Progression‐Free Survival}, -abstract = {PURPOSE: Non‐small cell lung cancer (NSCLC) is a fatal disease with poor prognosis. A membrane‐bound form of Hsp70 (mHsp70) which is selectively expressed on high‐risk tumors serves as a target for mHsp70‐targeting natural killer (NK) cells. Patients with advanced mHsp70‐positive NSCLC may therefore benefit from a therapeutic intervention involving mHsp70‐targeting NK cells. The randomized phase II clinical trial (EudraCT2008‐002130‐30) explores tolerability and efficacy of ex vivo‐activated NK cells in patients with NSCLC after radiochemotherapy (RCT). PATIENTS AND METHODS: Patients with unresectable, mHsp70‐positive NSCLC (stage IIIa/b) received 4 cycles of autologous NK cells activated ex vivo with TKD/IL2 [interventional arm (INT)] after RCT (60‐70 Gy, platinum‐based chemotherapy) or RCT alone [control arm (CTRL)]. The primary objective was progression‐free survival (PFS), and secondary objectives were the assessment of quality of life (QoL, QLQ‐LC13), toxicity, and immunobiological responses. RESULTS: The NK‐cell therapy after RCT was well tolerated, and no differences in QoL parameters between the two study arms were detected. Estimated 1‐year probabilities for PFS were 67% [95% confidence interval (CI), 19%‐90%] for the INT arm and 33% (95% CI, 5%‐68%) for the CTRL arm (P = 0.36, 1‐sided log‐rank test). Clinical responses in the INT group were associated with an increase in the prevalence of activated NK cells in their peripheral blood. CONCLUSIONS: Ex vivo TKD/IL2‐activated, autologous NK cells are well tolerated and deliver positive clinical responses in patients with advanced NSCLC after RCT.}, -DOI = {10.1158/1078-0432.CCR-20-1141}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02347612/full} -} - - -Record #174 of 538 -@article{Bozorgmehr23, -author = {Bozorgmehr, F, Weykamp, F, Overbeck, TR, Maguire, N, Buchmeier, EL, Hammer-Hellmig, M, Gauler, TC, Wermke, M, Troost, EGC, Ulmer, M, Mueller, A-C, Kokowski, K, Roper, B, Wehler, T, Hey-Koch, S, Consdorf, N-S, Behnisch, R, Christopoulos, P, Thomas, M, and Rieken, S}, -title = {1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data}, -journal = {Annals of oncology}, -volume = {34}, -pages = {S1060}, -year = {2023}, -accession_number = {EMBASE 2027888530}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer combination chemotherapy; *cancer radiotherapy; *drug safety; *small cell lung cancer; Adult; Cancer patient; Clinical trial; Comorbidity; Conference abstract; Consultation; Controlled study; Drug combination; Female; Functional status; Human; Immunotherapy; Maintenance therapy; Major clinical study; Male; Multicenter study; Phase 2 clinical trial; Pneumonia; Radiotherapy; Randomized controlled trial; Writing}, -abstract = {Background: Carboplatin/etoposide + atezolizumab (IMpower133) is now 1L standard‐of‐care for patients with extensive disease small cell lung cancer (ED SCLC). Thoracic radiotherapy (TRT) after induction chemotherapy has been shown to increase 2‐year overall survival rates. Alongside, evidence for synergistic immunostimulatory effects of radiotherapy and immunotherapy (IO) is increasing. Combining these results, the TREASURE trial attempted to improve response to chemo‐IO by adding TRT. Methods: The phase II, multicenter TREASURE trial (NCT04462276) randomized patients with ED SCLC, ECOG≤1, and response to IMpower133 induction to receive atezolizumab maintenance therapy (1200mg, Q3W, until progression/toxicity) either with TRT (10x30 Gy, arm A) or without TRT (arm B). Safety interim analysis was planned once 23 patients in arm A had been observed for 3 months after TRT ended, with the safety signal being ≥2 patients with grade ≥3 pneumonitis. Results: In 04/22, interim safety analysis showed only 1/23 patients with grade ≥3 pneumonitis in arm A. However, routine safety monitoring committee (SMC) review in 08/22 identified a potential imbalance in grade 5 severe adverse events (SAEs) between the arms (n=5 in A, n=1 in B), and thus recruitment was paused. Data review 3 months later revealed more SAEs in arm A (28 any, 16 grade 3/4, 6 grade 5) vs. B (9 any, 4 grade 3/4, 1 grade 5). Along with evaluation of further parameters, this prompted Coordinating Investigator and SMC to permanently stop recruitment. Of note, neither differences in clinical measures of comorbidity nor functional status were detected between arms. At the time of recruitment stop (12/22), 68 patients were included in the trial (n=34 in each arm). Conclusions: Although TRT‐IO combinations have not been the source of safety concerns in other trials, it was associated with more SAEs in TREASURE. SAE analysis did not indicate any new safety signal of atezolizumab or TRT. Observed SAEs were either known adverse effects or confounded, and not clearly tied to either IO or TRT. Thus, the factors underlying this unexpected outcome remain to be identified and will be focus of the final analysis of this trial. Clinical trial identification: NCT04462276. Legal entity responsible for the study: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Funding: Roche. Disclosure: F. Bozorgmehr: Financial Interests, Personal, Advisory Board: AMGEN, Janssen, Novartis, AstraZeneca, Novocure; Financial Interests, Personal, Invited Speaker: Novocure, AstraZeneca, MSD, Janssen; Financial Interests, Institutional, Research Grant: Roche, AstraZeneca; Non‐Financial Interests, Principal Investigator: AstraZeneca, GSK, Janssen, Amgen. F. Weykamp: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Merck Sharp & Dohme. E.L. Buchmeier: Financial Interests, Personal, Invited Speaker, and congress sponsoring: Takeda; Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Institutional, Local PI: BMS, AstraZeneca, Novartis, MSD, Janssen Cilag, PDC Line Pharma, Roche, GSK, Novartis; Non‐Financial Interests, Member: Political Party FDP. T.C. Gauler: Financial Interests, Advisory Role: Roche, MSD, BMS, AstraZeneca, Merck Serono. M. Ulmer: Financial Interests, Advisory Board: AstraZeneca, Roche, Novartis, Amgen, Lilly, Teva, Chugai, Pfizer, MSD, BMS, Merck, Mediolanum Biosciences, Servier, Eisai, Takeda, Boehringer Ingelheim. A. Mueller: Financial Interests, Speaker, Consultant, Advisor: AstraZeneca; Financial Interests, Local PI: SAKK; Financial Interests, Research Funding: DFG; Financial Interests, Writing Engagement: Servier. P. Christopoulos: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, Chugai, Pfizer, Novartis, MSD, Takeda, Roche, Daiichi Sankyo; Financial Interests, Personal, Writing Engagement: Gilead; Financial Interests, Personal, Invited Speaker: Thermo Fisher; Financial Interests, Institutional, Funding: AstraZeneca, Boehringer Ingelheim, Amgen, Novartis, Roche; Financial Interests, Personal, Funding: Takeda. M. Thomas: Financial Interests, Personal, Advisory Board: Sanofi, Lilly, BMS, MSD, Roche, Boehringer Ingelheim, Janssen, AstraZeneca, Amgen, Novartis; Financial Interests, Personal, Invited Speaker: Sanofi, Lilly, MSD, Roche, GSK, Pfizer, Janssen, AstraZeneca, Amgen, Novartis; Financial Interests, Institutional, Advisory Board: Takeda; Financial Interests, Institutional, Invited Speaker: Takeda; Financial Interests, Institutional, Funding: Roche, Takeda, BMS, AstraZeneca, Amgen. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2023.09.1219}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02613687/full} -} - - -Record #175 of 538 -@article{NCT0423816920, -author = {NCT04238169,}, -title = {Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC}, -journal = {https://clinicaltrials.gov/ct2/show/NCT04238169}, -year = {2020}, -accession_number = {CTgov NCT04238169}, -publication type = {Trial registry record}, -keywords = {Bevacizumab; Carcinoma, Non‐Small‐Cell Lung}, -abstract = {This is a prospective, multicenter, open‐label study to observe the effect of SBRT and immunotherapy combined with Bevacizumab or not in stage IV non‐squamous non‐small cell lung cancer (NSCLC) with previously failed after chemotherapy.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02079610/full} -} - - -Record #176 of 538 -@article{Bria22, -author = {Bria, E, Garassino, MC, Del Signore, E, Morgillo, F, Spinnato, F, Morabito, A, Iero, M, and Ardizzoni, A}, -title = {1533P Atezolizumab (ATZ) plus carboplatin (Cb) and etoposide (eto) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC): results from the interim analysis of MAURIS trial}, -journal = {Annals of oncology}, -volume = {33}, -pages = {S1248}, -year = {2022}, -accession_number = {EMBASE 2020168749}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *cancer staging; *small cell lung cancer; Aged; Brain metastasis; Cancer survival; Clinical practice; Clinical trial; Conference abstract; Controlled study; Deterioration; Drug combination; Drug safety; Drug therapy; ECOG Performance Status; Female; Financial management; Follow up; Health care quality; Human; Incidence; Major clinical study; Male; Multicenter study; Overall response rate; Overall survival; Palliative therapy; Phase 3 clinical trial; Profit; Progression free survival}, -abstract = {Background: MAURIS is a multicenter, open label, single arm, phase IIIb trial conducted in 25 Italian centers, that evaluates the safety and efficacy of ATZ + Cb‐Eto in patients with newly diagnosed ES‐SCLC, according to the new standard of care from the pivotal trial IMpower133. Patients (pts) with ECOG PS2, untreated asymptomatic brain metastases (BM) were eligible for this study and consolidative and palliative radiotherapy was also allowed. An interim analysis (IA) has been conducted roughly one year from the end of enrolment with a median follow‐up of 10.5 months. Methods: Patients enrolled in the study received ATZ 1200 mg + Cb‐Eto every 3 weeks for 4–6 cycles in the induction phase, followed by ATZ maintenance every 3 weeks up to disease progression, unacceptable toxicity or clinical deterioration. The primary endpoints were the incidence of serious adverse events (SAE) and immune‐mediated AEs (imAE). The secondary endpoints were 1 year survival, overall survival (OS), progression‐free survival (PFS) and overall response rate (ORR). Results: 154 patients (95 males, mean age 65.1 years, 6 pts with PS2, 19 pts with BM) were treated. At data cut‐off 28 oct 2021, 139 pts (90.3%) discontinued the treatment: 97 pts (63.0%) due to progressive disease, 17 pts (11.0%) due to AE. Safety data related to the induction phase and efficacy data at data cut‐off were analysed overall and by the number of induction cycles. [Formula presented] Conclusions: In this interim analysis, safety data observed in the induction phase seem consistent with IMpower133 results considering a patient population closer to clinical practice both for baseline patient characteristics and co‐treatments allowed. In terms of efficacy data, we found that PFS and ORR were also aligned. Survival data in relation to the number of cycles in the induction phase, according to the investigator’s choice, might reflect a biased population and they should be confirmed. Clinical trial identification: NCT04028050. Legal entity responsible for the study: Roche. Funding: Roche. Disclosure: E. Bria: Financial Interests, Personal, Advisory Board: AZ, Roche, BMS, MSD, Eli Lilly, Amgen; Financial Interests, Institutional, Research Grant: AZ, Roche. M.C. Garassino: Financial Interests, Personal, Other, several roles: AZ, MSD, BMS, Boehringer Ingelheim Italia SpA, Celgene, Eli Lilly,Ignyta, Incyte, Inivata, MedImmune, Novartis, Pfizer, Roche, Takeda, Seattle Genetics, Mirati, Daiichi Sankyo, Regneron, Merck, Ose Immuno Therapeutics; Financial Interests, Institutional, Other, several roles: Eli Lilly, Pfizer (MISP), AZ, MSD International GmbH, BMS, Boehringer Ingelheim Italia SpA, Celgene, Eli Lilly, Ignyta, Incyte, MedImmune, Novartis, Pfizer, Roche, Takeda, Tiziana, Foundation Medicine, Glaxo Smith Kline GSK, Spectrum Pharmaceuticals. A. Morabito: Financial Interests, Personal, Speaker’s Bureau: BMS, BI, MSD, Novartis, Roche, AstraZeneca, Pfizer; Takeda, Lilly; Financial Interests, Personal, Advisory Board: BI, MSD, Novartis, Roche, AstraZeneca, Pfizer; Takeda, Lilly. A. Ardizzoni: Financial Interests, Personal, Invited Speaker, Occasional fees for advisory board participation and lectures: BMS; Financial Interests, Personal, Advisory Board, Occasional fees for advisory board participation: MSD, Takeda, Lilly, Bayer; Financial Interests, Personal, Advisory Board, Occasional fee for advisory board participation: Roche; Financial Interests, Personal, Advisory Board, Occasional fees for advisory board participation and lectures: AstraZeneca; Financial Interests, Institutional, Invited Speaker, Financial support to my University for covering 50% costs of a no‐profit accademic clinical trial: Ipsen. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2022.07.1628}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02489033/full} -} - - -Record #177 of 538 -@article{Jelavic21, -author = {Jelavic, TB}, -title = {Place of immunotherapy in treatment of cervical cancer}, -journal = {Libri oncologici}, -volume = {49}, -number = {SUPPL 1}, -pages = {43‐44}, -year = {2021}, -accession_number = {EMBASE 635343948}, -publication type = {Journal article; Conference proceeding}, -keywords = {*tumor associated leukocyte; *uterine cervix cancer; Adult; Advanced cancer; Africa; Asia; Bioengineering; Cancer immunotherapy; Cancer patient; Cancer recurrence; Cancer staging; Cancer survival; Cell therapy; Clinical outcome; Conference abstract; Controlled study; Dendritic cell; Drug combination; Drug therapy; Europe; Female; Gene expression; Gram positive bacterium; Human; Human cell; Immunity; Immunotherapy; Incidence; Investment; Kidney cancer; Median survival time; Melanoma; Mortality; Non small cell lung cancer; Nonhuman; Organization; Overall survival; Patient selection; Phase 2 clinical trial; Phase 3 clinical trial; Precancer; Prevention; Protein expression; Radiotherapy; Randomized controlled trial; South America; Squamous cell carcinoma; T lymphocyte; Virus particle}, -abstract = {Cervical cancer is common cancer type, with global high incidence which ranks it on fourth place in women worldwide. Its' mortality is especially high in underdeveloped regions in the world, such as east Africa, eastern Asia and South America. Nevertheless, because cervical cancer affects generally younger women, many in reproductive years, in comparison to other solid tumor types, it represents big socioeconomic burden to societies globally. Therapy options in different stages of this cancer have not changed significantly for decades now, reflecting low investment in research and development of new drugs and treatment strategies for this disease. So, cervical cancer patients truly represent underserved population in terms of cancer care. Cancer immunotherapy has made major impact on treatment of many patients with solid tumors. Immunotherapy offered a new hope especially for melanoma, kidney cancer, non‐small cell lung cancer patients, but for many others also. Fortunately, cervical cancer represents a field of rapid and extensive immunotherapy research due to its' genuine ability to produce immunogenic response. It is well known that almost all of the cervical cancers are caused by infection with oncogenic types of human papiloma virus (HPV), and the virus particles themselves, especially E6 and E7 component represent potent targets for immune reaction. So far, research in this area branches in several directions: use of checkpoint inhibitors, cancer vaccines, immune modulators, T‐cell therapy, and therapy with dendritic cells. Pembrolizumab, an anti PD‐1 antibody, is first immunotherapy drug approved for treatment of recurrent/ metastatic cervical cancer whit positive expression of PD‐L1 based on the results of KEYNOTE‐158 study. In pretreated patients pembrolizumab elicited a response rate (RR) of 14.6% and a median overall survival (OS) of 11 months. This drug is still not approved in Europe for this indication. Results of treatment of cervical cancer with other checkpoint inhibitors, such as nivolumab, ipilimumab, and combinations of anti PD‐1 and anti CTLA‐4 antibodies have been reported also. The combination of ipilimumab and nivolumab in women with squamous cell cancer of the cervix showed great response that was better than with existing chemotherapy regimens. The response rate in second‐line metastatic disease was 36% with an OS that was not reached (>13.9 months). While prophylactic vaccines have made a major change in prevention of cervical precancerous lesions, therapeutic vaccines active in developed disease are still in research. Two phase II studies on Lysteria monocytogenes based treatments in cervical cancer have been reported. This gram‐positive bacteria serves as a vector for T fusion protein that includes a truncated fragment of listeriolysin O (tLLO) which is fused to human HPV‐16 E7 and elicits potent cell immunity. The therapeutic compound made this way via bioengineering is called Axalimogene filolisbac or ADXS11‐001. In these studies, in pretreated cervical cancer patients, investigators observed a median survival ranging from 6.2 to 8.3 months, and 12‐months OS in range of 35‐38%. Currently, there are numerous ongoing studies with combination regimens, such as chemotherapyimmunotherapy combinations, similarly to proven protocols used in other tumor types. Of special interest are ongoing studies in locally advanced cervical cancer that test concomitant whole pelvic radiotherapy with cisplatin and checkpoint inhibitors. Besides PD‐1 and CTLA‐4 inhibition, immunotherapy against other targets, such as TIM‐3, LAG‐3, VISTA, and TIGIT, is in progress also. A novel approach using tumor infiltrating lymphocytes (TILs) is being tested in HPV induced cancers, including cervical cancer. In cervical cancer TILs are connected with better clinical outcomes, and in limited number of patients infusion of specially engineered and expanded TILs induced promising treatment response. Altogether, immunotherapy has shown promising activity in cervical cancer. So far, we still lack results of big randomized phase III studies that are currently recruiting patients. If they show positive results, treatment paradigm in cervical cancer could be changed across broad spectrum of the disease, from locoregional to advanced stages. Proper patient selection for every modality is of paramount interest and novel biomarkers beyond PD‐L1 have been explored.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02288149/full} -} - - -Record #178 of 538 -@article{de Langen23, -author = {de Langen, AJ, Johnson, ML, Mazieres, J, Dingemans, AC, Mountzios, G, Pless, M, Wolf, J, Schuler, M, Lena, H, Skoulidis, F, Yoneshima, Y, Kim, SW, Linardou, H, Novello, S, van der Wekken, AJ, Chen, Y, Peters, S, Felip, E, Solomon, BJ, Ramalingam, SS, Dooms, C, Lindsay, CR, Ferreira, CG, Blais, N, Obiozor, CC, Wang, Y, Mehta, B, Varrieur, T, Ngarmchamnanrith, G, Stollenwerk, B, Waterhouse, D, and Paz-Ares, L}, -title = {Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial}, -journal = {Lancet (london, england)}, -volume = {401}, -number = {10378}, -pages = {733‐746}, -year = {2023}, -accession_number = {EMBASE 640294705, PUBMED 36764316}, -publication type = {Journal article}, -keywords = {*non small cell lung cancer; Adolescent; Adult; Advanced cancer; Adverse drug reaction; Antineoplastic Agents [therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; Article; Brain damage; Cancer patient; Cancer radiotherapy; Cancer survival; Carcinoma, Non‐Small‐Cell Lung [drug therapy]; Central nervous system metastasis; Chemotherapy; Clinical trial; Comparative effectiveness; Controlled study; Diarrhea; Disease‐Free Survival; Docetaxel [therapeutic use]; Drug safety; Drug therapy; Drug withdrawal; Ethnicity; Fatigue; Febrile neutropenia; Female; Follow up; Health care quality; Human; Humans; Intravenous drug administration; Line of treatment; Lung Neoplasms [drug therapy]; Major clinical study; Male; Multicenter study; Mutation; Neoadjuvant therapy; Neutropenia; Phase 3 clinical trial; Progression free survival; Proto‐Oncogene Proteins p21(ras) [genetics, therapeutic use]; Radiotherapy; Randomization; Randomized controlled trial; Side effect}, -abstract = {BACKGROUND: Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRASG12C. We compared the efficacy and safety of sotorasib with a standard‐of‐care treatment in patients with non‐small‐cell lung cancer (NSCLC) with the KRASG12C mutation who had been previously treated with other anticancer drugs. METHODS: We conducted a randomised, open‐label phase 3 trial at 148 centres in 22 countries. We recruited patients aged at least 18 years with KRASG12C‐mutated advanced NSCLC, who progressed after previous platinum‐based chemotherapy and a PD‐1 or PD‐L1 inhibitor. Key exclusion criteria included new or progressing untreated brain lesions or symptomatic brain lesions, previously identified oncogenic driver mutation other than KRASG12C for which an approved therapy is available (eg EGFR or ALK), previous treatment with docetaxel (neoadjuvant or adjuvant docetaxel was allowed if the tumour did not progress within 6 months after the therapy was terminated), previous treatment with a direct KRASG12C inhibitor, systemic anticancer therapy within 28 days of study day 1, and therapeutic or palliative radiation therapy within 2 weeks of treatment initiation. We randomly assigned (1:1) patients to oral sotorasib (960 mg once daily) or intravenous docetaxel (75 mg/m2 once every 3 weeks) in an open‐label manner using interactive response technology. Randomisation was stratified by number of previous lines of therapy in advanced disease (1 vs 2 vs >2), ethnicity (Asian vs non‐Asian), and history of CNS metastases (present or absent). Treatment continued until an independent central confirmation of disease progression, intolerance, initiation of another anticancer therapy, withdrawal of consent, or death, whichever occurred first. The primary endpoint was progression‐free survival, which was assessed by a blinded, independent central review in the intention‐to‐treat population. Safety was assessed in all treated patients. This trial is registered at ClinicalTrials.gov, NCT04303780, and is active but no longer recruiting. INTERPRETATION: Sotorasib significantly increased progression‐free survival and had a more favourable safety profile, compared with docetaxel, in patients with advanced NSCLC with the KRASG12C mutation and who had been previously treated with other anticancer drugs. FUNDING: Amgen. FINDINGS: Between June 4, 2020, and April 26, 2021, 345 patients were randomly assigned to receive sotorasib (n=171 [50%]) or docetaxel (n=174 [50%]). 169 (99%) patients in the sotorasib group and 151 (87%) in the docetaxel group received at least one dose. After a median follow‐up of 17·7 months (IQR 16·4‐20·1), the study met its primary endpoint of a statistically significant increase in the progression‐free survival for sotorasib, compared with docetaxel (median progression‐free survival 5·6 months [95% CI 4·3‐7·8] vs 4·5 months [3·0‐5·7]; hazard ratio 0·66 [0·51‐0·86]; p=0·0017). Sotorasib was well tolerated, with fewer grade 3 or worse (n=56 [33%] vs n=61 [40%]) and serious treatment‐related adverse events compared with docetaxel (n=18 [11%] vs n=34 [23%]). For sotorasib, the most common treatment‐related adverse events of grade 3 or worse were diarrhoea (n= 20 [12%]), alanine aminotransferase increase (n=13 [8%]), and aspartate aminotransferase increase (n=9 [5%]). For docetaxel, the most common treatment‐related adverse events of grade 3 or worse were neutropenia (n=13 [9%]), fatigue (n=9 [6%]), and febrile neutropenia (n=8 [5%]).}, -DOI = {10.1016/S0140-6736(23)00221-0}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02524300/full} -} - - -Record #179 of 538 -@article{Grohe20, -author = {Grohe, C, Paz-Ares, LG, Dvorkin, M, Chen, Y, Hotta, K, Trukhin, D, Statsenko, G, Hochmair, MJ, Ozguroglu, M, Ji, JH, Voitko, O, Poltoratskiy, A, Verderame, F, Havel, L, Bondarenko, I, Armstrong, J, Byrne, N, Jiang, H, Goldman, JW, and Reinmuth, N}, -title = {Durvalumab ± tremelimumab + platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): results from the phase 3 CASPIAN study}, -journal = {Oncology research and treatment}, -volume = {43}, -pages = {149}, -year = {2020}, -accession_number = {EMBASE 640123501}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *drug tolerability; *small cell lung cancer; Adult; Cancer patient; Cancer survival; Clinical trial; Conference abstract; Drug safety; Drug therapy; Drug withdrawal; Female; Follow up; Health care quality; Human; Incidence; Kaplan Meier method; Log rank test; Major clinical study; Male; Maturity; Overall response rate; Overall survival; Phase 3 clinical trial; Progression free survival; Randomization; Randomized controlled trial; Skull irradiation}, -abstract = {Introduction: CASPIAN is a Phase 3, randomized, open‐label, global study evaluating 1L platinum‐etoposide (EP)±durvalumab(D)±tremeli‐mumab(T) for patients (pts) with ES‐SCLC. D+EP demonstrated statistical signifcant (stat sig) improvement in overall survival (OS) vs EP (HR 0.73 [95% CI 0.59‐0.91]; p=0.0047; DCO 03/2019). Here we present ef‐cacy & safety results for D+T+EP vs EP (DCO 01/2020). Methods: ES‐SCLC pts (WHO PS 0/1) were randomized 1:1:1 to D(1500mg)+T(75mg)+EP(3qw), D+EP or EP. Investigator's choice carbo‐/cisplatin allowed in all arms (stratifcation at randomization). Pts received 4 cycles of D±T+EP, followed by maintenance D (q4w) until disease progression. In the D+T+EP arm, pts received an additional dose of T post E P. In the EP arm, pts received up to 6 cycles of EP & prophylactic cranial irradiation per investigator's choice. The primary endpoint was OS. Secondary endpoints included progression‐free survival (PFS), objective response rate (ORR), safety & tolerability. Final OS analysis of the ITT population was planned at 80% maturity for D+T+EP vs E P. Statistics: Kaplan‐Meier method & stratifed log‐rank test. Results: 268 pts were randomized to D+EP, D+T+EP & EP, respectively; baseline characteristics were balanced across arms. The median (m) follow‐up was 25.1 mo at 82% maturity. D+EP continued to demonstrate improvement in OS vs EP [HR 0.75 (95% CI 0.62‐0.91; nominal p=0.0032)]; mOS 12.9 vs 10.5 mo, respectively. 22.2% of pts were alive at 2y with D+EP vs 14.4% of pts with EP. D+T+EP numerically improved OS vs E P, w/o stat sig per prespecifed stat plan: HR 0.82 [95% CI 0.68‐1.00; p=0.0451 (p≤0.0418 required for stat sig)]; mOS was 10.4 mo & 23.4% of pts were alive at 2y. PFS & ORR remained improved with D+EP vs EP. For D+T+EP vs EP ORR (58.4% vs 58.0%) & mPFS (4.9 mo vs 5.4 mo) were similar, but 12‐mo PFS rate was numerically higher (16.9% vs 5.3%); PFS HR 0.84 (95% CI 0.70‐1.01). In the D+EP, D+T+EP & EP arms, respectively, incidences of all‐cause AEs of Grade 3/4 were 62.3%, 70.3% & 62.8%; AEs leading to discontinuation 10.2%, 21.4% & 9.4%; & AEs leading to death 4.9%, 10.2% & 5.6%. Conclusion: D+EP still demonstrate improved OS, supporting this regimen as new standard of care for 1L ES‐SCLC with fexible platinum choice. No additional beneft of D+T+EP was observed in this pt population. Safety fndings remained consistent with known safety profles of all agents. Clinical trial information: NCT03043872.}, -DOI = {10.1159/000510995}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02519174/full} -} - - -Record #180 of 538 -@article{De Ruysscher16, -author = {De Ruysscher, D, Pujol, J-L, Popat, S, Reck, M, Le Pechoux, C, Liston, A, Speiser, D, Coukos, G, Kammler, R, Dafni, O, Tsourti, Z, Roschitzki, H, Finlayson, M, Piguet, A-C, Ruepp, B, Maibach, R, Stahel, RA, and Peters, S}, -title = {STIMULI: a randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT}, -journal = {Annals of oncology}, -volume = {27}, -year = {2016}, -accession_number = {EMBASE 613912446}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *small cell lung cancer; *treatment outcome; Autoimmune disease; Cancer epidemiology; Clinical trial; Controlled clinical trial; Controlled study; Drug therapy; Follow up; Hazard ratio; Human; Human tissue; Lung function; Major clinical study; Organ; Overall survival; Peripheral blood mononuclear cell; Pneumonia; Progression free survival; Radiotherapy; Randomized controlled trial; Safety; Skull irradiation; Stimulus; Study design; Switzerland; Thorax; Time to treatment; Translational research}, -abstract = {Background: Preliminary results from trial CheckMate 032, targeting two distinct inhibitory immune checkpoints combining nivolumab, an anti‐PD1 IgG1 monoclonal antibody and ipilimumab, an anti‐CTLA4 IgG1 monoclonal antibody, demonstrate very promising 31% objective response rate (ORR) and 48% one‐year overall survival (OS) in pre‐treated advanced SCLC. This treatment option will be explored in a consolidation setting after curative‐intent chemotherapy, chest radiotherapy (RT) and prophylactic cranial irradiation (PCI) for LD‐SCLC. Trial design: STIMULI is an open‐label, randomised, two‐arm, phase II clinical trial. Inclusion is restricted to stage I‐IIIB untreated LD‐SCLC patients ( pts) with adequate organ and pulmonary function, and no history of auto‐immune disease. Hyper‐ or conventionally fractionated chest RT is administered concomitantly to 4 cycles of Cis‐/ carboplatin plus etoposide, followed by PCI. After completion of this standard treatment, non‐progressing pts are randomised 1:1 to consolidation (induction and maintenance) or observation. Induction consists of four 3‐week cycles of ipilimumab 3mg/kg plus nivolumab 1mg/kg, and is followed by maximally 12 months of nivolumab 240mg every 2 weeks. OS and progression‐free survival (PFS) are co‐primary endpoints. ORR, time to treatment failure and tolerability are secondary endpoints. A total of 325 pts are expected to be enrolled in the standard treatment phase, in order for 260 pts to be randomised, with a target hazard ratio of .70 for OS and .57 for PFS. The overall one‐sided significance level of .05 is split to .04 for OS and .01 for PFS, with power 78% for OS and 80% for PFS. A safety evaluation for pneumonitis will take place after the first 30 patients reach the 12 weeks follow‐up on the experimental arm. Safety will be monitored by the Independent Data Monitoring Committee every 3 months. Translational research will be done on formalin‐fixed, paraffin‐embedded tumour tissue, PBMCs, whole blood and serum samples at the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland. Up to April 2016, 7 pts have been randomised, and enrolment is ongoing.}, -DOI = {10.1093/annonc/mdw389.8}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01295673/full} -} - - -Record #181 of 538 -@article{Hummel24, -author = {Hummel, H-D, Paz-Ares, L, Blackhall, F, Chiang, AC, Dowlati, A, Goldman, JW, Izumi, H, Mok, TSK, Sands, J, Martinez, P, Anderson, E, Bharania, P, Yu, B, Yu, Y, and Pulla, MP}, -title = {214TiP Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): deLLphi-306 (NCT06117774)}, -journal = {ESMO open}, -volume = {9}, -year = {2024}, -accession_number = {EMBASE 2030948450}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *small cell lung cancer; Adult; Aggression; Alopecia; Antineoplastic activity; Brazil; Cancer inhibition; Clinical trial; Conference abstract; Controlled study; Disease control; Disease free interval; Double blind procedure; Expert witness; Female; Human; Immunogenicity; Immunotherapy; Interstitial lung disease; Life expectancy; Life insurance; Male; Medical education; Non small cell lung cancer; Overall survival; Parttime employment; Pharmacokinetics; Phase 3 clinical trial; Pneumonia; Progression free survival; Radiotherapy; Reaction time; Response evaluation criteria in solid tumors; Signal transduction; T lymphocyte; Travel}, -abstract = {Background: SCLC is an aggressive disease with poor survival. Despite initial response to chemoradiation, most patients with LS‐SCLC relapse. Between 85‐96% of patients with SCLC have tumor expression of Delta‐like ligand 3 (DLL3), a Notch ligand aberrantly expressed on the surface of SCLC cells with minimal expression in healthy cells, making DLL3 an attractive therapeutic target. In the phase II DeLLphi‐301 study, tarlatamab, a bispecific T cell engager (BiTE®) immunotherapy targeting DLL3 and T cell co‐receptor CD3, demonstrated antitumor activity and a manageable safety profile in patients with previously treated extensive stage‐SCLC: 40% objective response and a 6‐month overall survival (OS) rate (KM estimate) of 73% at 10 mg Q2W (NEJM 2023;389:2063). Trial design: DeLLphi‐306 is a randomized (1:1), double‐blind, placebo‐controlled Phase 3 trial examining tarlatamab (10 mg Q2W in 28‐day cycles) clinical activity and safety in ≈ 400 patients with LS‐SCLC following concurrent chemoradiation. Key patient inclusion criteria include age ≥ 18 years, histologically/cytologically confirmed LS‐SCLC, completion of platinum‐based chemotherapy with concurrent radiotherapy without progression, ECOG PS ≤ 1, chemoradiotherapy‐attributed toxicities resolved to grade ≤ 1 excluding alopecia, and life expectancy ≥ 12 weeks. Key exclusion criteria include transformed NSCLC; interstitial lung disease; active pneumonitis; non‐concurrent chemotherapy and thoracic radiotherapy during chemoradiation; prior DLL3 pathway‐selective inhibitor therapy; and history of severe/life‐threatening events from immune‐mediated therapy. Primary endpoint is progression‐free survival (PFS) per blinded independent central review (RECIST 1.1) with OS as a key secondary endpoint. Additional secondary endpoints include investigator‐assessed PFS, objective response, disease control, duration of response, time to progression, pharmacokinetics, tarlatamab immunogenicity, and safety/tolerability. Clinical trial identification: NCT06117774. Editorial acknowledgement: Medical writing support was provided by William W Stark, Jr, PhD, Amgen Inc. Legal entity responsible for the study: Amgen. Funding: Amgen. Disclosure: H. Hummel: Financial Interests, Personal, Invited Speaker: Amgen Inc, Bristol Myers Squibb, Boehringer Ingelheim; Financial Interests, Personal, Other, Consultancy (including expert testimony): Amgen Inc, Boehringer Ingelheim; Financial Interests, Institutional, Principal Investigator: Amgen Inc, Boehringer Ingelheim, Bristol Myers Squibb, AstraZeneca, Celgene, Merck, Novartis, Revolution Medicines, Daiichi Sankyo, Dracen; Financial Interests, Personal, Advisory Role: Amgen Inc, Boehringer Ingelheim, Bristol Myers Squibb, Roche. L. Paz‐Ares: Financial Interests, Personal, Leadership Role: ALTUM Sequencing, Genomica; Financial Interests, Personal, Other, Honoraria: Amgen, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Daiichi Sankyo, GSK, Janssen, Lilly, Medscape, Merck Serono, Mirati Therapeutics, MSD, Novartis, Pfizer, PharmaMar, Regeneron, Roche/Genentech, Sanofi, Takeda; Financial Interests, Personal, Other: AstraZeneca, Amgen, Ipsen, Merck, Novartis, Pfizer, Roche, Sanofi, Servier; Financial Interests, Personal, Speaker’s Bureau: BMS, Lilly, Merck Serono, MSD Oncology, Pfizer, Roche/Genentech; Financial Interests, Institutional, Research Grant: AstraZeneca, BMS, Kura Oncology, MSD, Pfizer, PharmaMar. F. Blackhall: Financial Interests, Personal, Other, Scientific Advisory Board: AbbVie, Amgen Inc., Boehringer Ingelheim. A.C. Chiang: Financial Interests, Personal, Other, Consultant: AstraZeneca; Financial Interests, Personal, Other, Advisory Board: AstraZeneca, Daiichi Sankyo, Janssen; Financial Interests, Institutional, Leadership Role: SWOG executive Officer; Financial Interests, Institutional, Principal Investigator: BMS, AbbVie, Amgen Inc., GNE, AstraZeneca. A. Dowlati: Financial Interests, Personal, Advisory Role: Ipsen, AstraZeneca, Amgen. J.W. Goldman: Financial Interests, Personal, Invited Speaker: AstraZeneca, AbbVie; Financial Interests, Personal, Other, Consultancy (including expert testimony): AbbVie; Financial Interests, Institutional, Research Grant: AstraZeneca, AbbVie, BMS, Genentech, Amgen Inc.; Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Personal, Advisory Role: Amgen, Daiichi Sankyo. H. Izumi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Eli Lilly, Takeda, MSD; Financial Interests, Institutional, Principal Investigator: Amgen, AstraZeneca, AbbVie, Takeda, Ono, Bristol Myers Squibb, Eisai; Financial Interests, Personal, Advisory Role: Amgen. T.S.K. Mok: Financial Interests, Personal, Invited Speaker: ACEA Pharma, Alpha Biopharma Co. Ltd, Amgen Inc., Amoy Diagnostics Co. Ltd, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Daz Group, Fishawack Facilitate Ltd, InMed Medical Communication, Janssen Pharmaceutica NV, Jiahui Holdings Co. Ltd, LiangYiHui Healthcare, Lilly, Lucence Health Inc, MD Health Brazil, Medscape LLC, Merck Pharmaceutical HK Ltd, Merck Sharp & Dohme, MIRXES, Novartis, OrigiMed Co. Ltd, P. Permanyer SL, PeerVoice, Physicians'Education Resource (PER), Pfizer, PrIME Oncology, Research to Practice, Roche Pharmaceuticals/Diagnostics/Foundation One, Sanofi‐Aventis, Shanghai BeBirds Translation & Consulting Co., Ltd, Shanghai Promedican Pharmaceuticals Co., Ltd, Taiho Pharmaceutical Co. LTd, Takeda Oncology, Touch Independent Medical Education Ltd.; Financial Interests, Personal, Other, Consultancy (including expert testimony): AbbVie Inc, ACEA Pharma, Adagene, Alpha Biopharma Co., Ltd, Amgen Inc., Amoy Diagnostics Co. Ltd, AnHeart Therapeutics, AstraZeneca, Aveo Pharmaceuticals, Inc., Bayer Healthcare Pharmaceuticals Ltd., BeiGene, BerGenBio ASA, Berry Oncology, Boehringer Ingelheim, Blueprint Medicines Corporation, BMS, Bowtie Life Insurance Company Limited, Bridge Biotherapeutics Inc, Covidien LP, C4 Therapeutics Inc., Cirina Ltd, CStone Pharmaceuticals, Curio Science, D3 Bio Ltd, Da Volterra, Daiichi Sankyo, Eisai, Elevation Oncology, F. Hofffman‐La Roche Ltd, Genentech, GLG's Healthcare, Fishawack Facilitate Ltd, G1 Therapeutics Inc., geneDecode Co., Ltd, Gilead Sciences, Inc., Gritstone Oncology, Inc., Guardant Health, Hengrui Therapeutics Inc, Hutch Med, Ignyta, Inc., Illumina, Inc., Incyte Corporation, Iniviata, IQVIA, Janssen, Lakeshore Biotech Ltd, Lilly, Lunit USA, Inc., Loxo Oncology, Lucence Health Inc, Medscape LLC/WebMD, Medtronic, Merck Serono, MSD, Mirati Therapeutics Inc., MiRXES, MoreHealth, Novartis, Novocure GmbH, Omega Therapeutics Inc, OrigiMed, OSE Immuotherapeutics, PeerVoice, Pfizer, PriME Oncology, Prenetics, Puma Biotechnology Inc, Roche Pharmaceuticals/Diagnostics/Foundation Once, Sanofi‐Aventis, SFJ Pharmaceutical Ltd, Simcere of America Inc, Summit Therapeutics Sub, Inc, Synergy Research, Takeda Pharmaceuticals HK Ltd, Tigermed, Vertex Pharmaceuticals, Virtus Medical Group, XENCOR, Inc, Yuhan Corporation; Financial Interests, Personal, Invited Speaker, Consultancy (including expert testimony): Qiming Development (HK) Ltd, Regeneron Pharmaceuticals Inc; Financial Interests, Personal, Officer: AstraZeneca PLC, HutchMEd, Aurora; Financial Interests, Personal, Member of Board of Directors: AstraZeneca PLC, HutchMEd, Aurora; Financial Interests, Personal, Stocks/Shares: Alentis Therapeutics AG, AstraZeneca, Aurora Tele‐Oncology Ltd, Biolidics Ltd, HutchMEd, Prenetics, D3 Bio, Lunit Inc; Financial Interests, Institutional, Research Grant: straZeneca, BMS, G1 Therapeutics, MSD, Merck Serono, Novartis, Pfizer, Roche, SFJ, Takeda, XCovery; Financial Interests, Personal, Sponsor/Funding: AstraZeneca, MiRXES, Daiichi Sankyo, Novartis, Roche, AbbVie, Pfizer, Liangyihui, Zai Lab; Financial Interests, Personal, Advisory Role: AbbVie Inc, ACEA Pharma, Amgen, AstraZeneca, Berry Oncology, Blueprint Medicines Corporation, Boehringer Ingelheim, Bowtie Life Insurance Co Ltd, Bristol Myers Squibb, C4 Therapeutics Inc, Covidien LP, CStone Pharmaceuticals, Curio Science, D3 Bio Ltd. J. Sands: Financial Interests, Personal, Other, Consultancy (including expert testimony): AstraZeneca, Amgen Inc., AbbVie, Boehringer Ingelheim, Daiichi Sankyo, G1 Therapeutics, Medtronic, PharmaMar; Financial Interests, Personal and Institutional, Research Grant: Amgen, Harpoon; Financial Interests, Institutional, Principal Investigator: Amgen, Daiichi Sankyo, PharmaMar, Genentech, Merck, Phanes, Legend, Loxo, Shenzhen, Chipscreen Biosciences; Financial Interests, Personal, Advisory Role: Curadev. P. Martinez, E. Anderson, P. Bharania, B. Yu, Y. Yu: Financial Interests, Personal, Full or part‐time Employment: Amgen; Financial Interests, Personal, Stocks/Shares: Amgen. M. Provencio Pulla: Financial Interests, Personal and Institutional, Invited Speaker: Bristol Myers Squibb, Roche, MSD, AstraZeneca, Takeda, Eli Lilly, F. Hoffman La Roche, Janssen, Pfizer; Financial Interests, Personal and Institutional, Other, Consulting fees: Bristol Myers Squibb, Roche, MSD, AstraZeneca, Takeda, Eli Lilly, F Hoffman‐La Roche, Janssen, Pfizer, Takeda; Financial Interests, Personal and Institutional, Research Grant: MSD, AstraZeneca, Roche, Boehringer Ingelheim, Takeda; Financial Interests, Personal and Institutional, Other, Honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Bristol Myers Squibb, Roche, MSD, AstraZeneca, Takeda, Eli Lilly, F Hoffman‐La Roche, Janssen, Pfizer; Financial Interests, Personal and Institutional, Other, Support for attending meetings and/or travel: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F Hoffman‐La Roche, Pierre Fabre Pharmaceuticals, Takeda.}, -DOI = {10.1016/j.esmoop.2024.102787}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02682729/full} -} - - -Record #182 of 538 -@article{Faivre-Finn19, -author = {Faivre-Finn, C}, -title = {ES16.01 Proton Therapy}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S53}, -year = {2019}, -accession_number = {EMBASE 2003406120}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer radiotherapy; *proton therapy; Adult; Advanced cancer; Blood toxicity; Cancer patient; Cancer research; Cancer staging; Cancer survival; Cardiotoxicity; Conference abstract; Consensus; Controlled study; Drug combination; Female; Human; Immunotherapy; Intensity modulated radiation therapy; Ion therapy; Light; Lymphocytopenia; Male; Multicenter study; Non small cell lung cancer; Overall survival; Phase 3 clinical trial; Physics; Preclinical study; Prospective study; Radiation dose; Radiation oncology; Radiobiology; Radiotherapy; Randomization; Randomized controlled trial; T lymphocyte; Tumor cell}, -abstract = {Proton therapy is an attractive option for the treatment of lung cancer patients due to the physical properties of proton beams. Proton therapy allows a focused delivery of radiation at the Bragg peak, with very steep decline of the radiation dose beyond the target volume. These properties offer the possibility to 1) reduce toxicity by reducing the integral dose and the dose to adjacent normal tissues and 2) escalate the dose to the target in some patients. In this talk, I will summarise briefly the physics/radiobiology of protons and the need for adaptation. I will also discuss the rationale for the use of protons in patients with lung cancer, including reduction in integral dose, cardiac toxicity and reduction in haematological toxicity. The clinical trial evidence supporting the use of protons will be presented in early stage and locally advanced non‐small cell lung cancer as well as in small‐cell lung cancer. Finally I will discuss future research directions, including preclinical and drug‐proton combination research, ongoing clinical trials, the model based‐approach and the need for biomarkers. References: Liao Z, Lee JJ, Komaki R, eat l. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity‐Modulated Photon Radiotherapy for Locally Advanced Non‐Small‐Cell Lung Cancer. J Clin Oncol. 2018;36(18):1813‐1822 Chang JY, Jabbour SK, De Ruysscher D, et al; International Particle Therapy Co‐operative Group Thoracic Subcommittee.Consensus Statement on Proton Therapy in Early‐Stage and Locally Advanced Non‐Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):505‐16. Vyfhuis MAL, Onyeuku N, Diwanji T, Mossahebi S, Amin NP, Badiyan SN, Mohindra P, Simone CB 2nd. Advances in proton therapy in lung cancer. Ther Adv Respir Dis. 2018 Jan‐Dec;12:1753466618783878 C, Pawelke J, Seidlitz A, Peitzsch C, et al; “Radiobiology of Proton Therapy”: Results of an international expert workshop.Lühr A, von Neubeck Radiother Oncol. 2018; 128(1):56‐67 Jin, J.Y., et al., Higher Radiation Dose to Immune System is Correlated With Poorer Survival in Patients With Stage III Non‐small Cell Lung Cancer: A Secondary Study of a Phase 3 Cooperative Group Trial (NRG Oncology RTOG 0617). International Journal of Radiation Oncology Biology Physics, 2017. 99(2): p. S151‐S152. Joseph, N., et al., Post‐treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy. Radiotherapy and Oncology, 2019. 135: p. 115‐119. Durante, M., D.J. Brenner, and S.C. Formenti, Does Heavy Ion Therapy Work Through the Immune System? Int J Radiat Oncol Biol Phys, 2016. 96(5): p. 934‐936. Lee, H.J., Jr., J. Zeng, and R. Rengan, Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non‐small cell lung cancer. Translational lung cancer research, 2018. 7(2): p. 180‐188. Dess, R.T., et al., Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non‐Small‐Cell Lung Cancer. J Clin Oncol, 2017. 35(13): p. 1395‐1402. McWilliam, A., et al., Radiation dose to heart base linked with poorer survival in lung cancer patients. Eur J Cancer, 2017. 85: p. 106‐113. Schulz‐Ertner, D. and H. Tsujii, Particle radiation therapy using proton and heavier ion beams. J Clin Oncol, 2007. 25(8): p. 953‐64. Gameiro, S.R., et al., Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell‐Mediated Killing. Int J Radiat Oncol Biol Phys, 2016. 95(1): p. 120‐30.}, -DOI = {10.1016/j.jtho.2019.08.140}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01996559/full} -} - - -Record #183 of 538 -@article{NCT0380190219, -author = {NCT03801902,}, -title = {Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial}, -journal = {https://clinicaltrials.gov/ct2/show/NCT03801902}, -year = {2019}, -accession_number = {CTgov NCT03801902}, -publication type = {Trial registry record}, -keywords = {Antibodies; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Carcinoma; Carcinoma, Non‐Small‐Cell Lung; Durvalumab; Immunoglobulin G; Immunoglobulins; Immunoglobulins, Intravenous; Lung Neoplasms}, -abstract = {PRIMARY OBJECTIVES:I. To evaluate if the addition of durvalumab to two schedules of radiation therapies (60Gy in 30 fractions or 60 Gy in 15 fractions) is safe.II. To evaluate if the addition of either monalizumab or oleclumab to radiation therapy(RT) (60 Gy in 30 fractions) + durvalumab is safe.SECONDARY OBJECTIVES:I. To examine if the addition of durvalumab to radiation therapy as well as the additionof either monalizumab or oleclumab is feasible.II. To assess toxicities associated with the addition of durvalumab to radiation therapyas well as the addition of either monalizumab or oleclumab.III. To obtain preliminary estimates of progression‐free survival (PFS), using ResponseEvaluation Criteria in Solid Tumors (RECIST) guidelines, in patients who receiveddurvalumab added to radiation, and either monalizumab or oleclumab added to RT (60 Gy in30 fractions) + durvalumab.EXPLORATORY OBJECTIVES:I. To assess the impact the addition of durvalumab to RT and either monalizumab oroleclumab to RT (60 Gy in 30 fractions) + durvalumab have on progression‐free survival,using Immune‐Related Response Criteria (irRC) guidelines.II. To assess the changes in circulating tumor cells (CTCs) and various immune parametersduring treatment with durvalumab and radiotherapy and changes after completion oftreatment.OUTLINE: Patients are randomized to Arm I or Arm II (CLOSED TO ACCRUAL).ARM I (CLOSED): Starting 2 weeks prior to radiation therapy, patients receive durvalumabintravenously (IV) over 60 minutes on day 1 of each cycle. Treatment repeats every 4weeks for 13 cycles in the absence of disease progression or unacceptable toxicity.Patients also undergo accelerated hypofractionated radiation therapy (ACRT) 1 fractionper day, 5 days per week for 15 fractions. Patients also undergo brain magnetic resonanceimaging (MRI) or computed tomography (CT) scan during screening and as clinicallyindicated, chest CT scans on study and during follow up, and collection of blood samplesduring screening and on study.ARM II (CLOSED): Starting 2 weeks prior to radiation therapy, patients receive durvalumabIV over 60 minutes on day 1 of each cycle. Treatment repeats every 4 weeks for 13 cyclesin the absence of disease progression or unacceptable toxicity. Patients also undergoconventionally fractionated radiation therapy 1 fraction per day, 5 days per week for 30fractions. Patients also undergo brain MRI or CT scan during screening and as clinicallyindicated, chest CT scans on study and during follow up, and collection of blood samplesduring screening and on study.Patients are assigned to Arm III or Arm IV.ARM III: Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over60 minutes and monalizumab IV over 60 minutes on day 1 of each cycle. Treatment repeatsevery 4 weeks for 13 cycles in the absence of disease progression or unacceptabletoxicity. Patients also undergo conventionally fractionated radiation therapy 1 fractionper day, 5 days per week for 30 fractions. Patients also undergo brain MRI or CT scanduring screening and as clinically indicated, chest CT scans on study and during followup, and collection of blood samples during screening and on study.ARM IV: Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over60 minutes on day 1 of each cycle. Patients also receive oleclumab IV over 60 minutes ondays 1 and 15 of cycles 1‐2, then on day 1 of cycles thereafter. Treatment repeats every4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity.Patients also undergo conventionally fractionated radiation therapy 1 fraction per day, 5days per week for 30 fractions. Patients also undergo brain MRI or CT scan duringscreening and as clinically indicated, chest CT scans on study and during follow up, andcollection of blood samples during screening and on study.After completion of study treatment, patients are followed up every 3 months for 1 yearand then every 4 months for 1 year.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01795839/full} -} - - -Record #184 of 538 -@article{Fleckenstein22, -author = {Fleckenstein, J, Pottgen, C, and Reinmuth, N}, -title = {Modern definitive radiochemotherapy—state of the art implementation and new consolidation strategies}, -journal = {Onkologie}, -volume = {28}, -number = {12}, -pages = {1071‐1077}, -year = {2022}, -accession_number = {EMBASE 2022100253}, -publication type = {Journal article}, -keywords = {*chemoradiotherapy; Cancer survival; Drug dose escalation; Esophagus disease /side effect; Human; Intensity modulated radiation therapy; Lung disease /side effect; Overall survival; Review; Treatment outcome}, -abstract = {Background: In locally advanced non‐small‐cell lung cancer (NSCLC), the addition of chemotherapy to radiotherapy and consolidation with durvalumab leads to a significant increase in overall survival and represents the most profound innovation of the last decade. Objectives: Analysis of new possibilities for the state‐of‐the‐art implementation of definitive radiochemotherapy concepts. Materials and methods: Evaluation of prospective and randomised studies regarding improvements in treatment outcomes. Results: Overall survival benefit of consolidating checkpoint inhibitor therapy after combined radiochemotherapy with durvalumab is 43% (95% confidence interval 38–47%) versus 33% (27–40%) in the placebo group in an updated analysis of the PACIFIC trial for 5‑year survival; stratified hazard ratio for death is 0.72 (95% CI 0.59–0.89, p= 0.0025). In the dose escalation studies, increased pulmonary and oesophageal side effects were observed, so no immediate clinical benefit could be derived from the increase in local efficacy. Improved imaging before and during therapy and optimised possibilities of dose application, especially by using intensity‐modulated radiotherapy (IMRT), allow selective sparing of healthy structures, which increases the ability to safely intensify radiotherapy also in connection with new immunomodulatory substance combinations. Conclusion: The integration of immunotherapy, the stringent use of fluorodeoxyglucose positron emission tomography (FDG‐PET) in staging and radiation planning, the widespread use of highly conformal radiation techniques (IMRT; volumetric modulated arc therapy, VMAT) and the consistent application of image‐guided radiotherapy have led to significant improvements in treatment outcomes.}, -DOI = {10.1007/s00761-022-01250-4}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02570905/full} -} - - -Record #185 of 538 -@article{NCT0377473218, -author = {NCT03774732,}, -title = {PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer}, -journal = {https://clinicaltrials.gov/ct2/show/NCT03774732}, -year = {2018}, -accession_number = {CTgov NCT03774732}, -publication type = {Trial registry record}, -keywords = {Carboplatin; Carcinoma, Non‐Small‐Cell Lung; Cisplatin; Lung Neoplasms; Paclitaxel; Pembrolizumab; Pemetrexed}, -abstract = {Overall survival (OS) of patients with advanced (stage IIIB/IV) non‐small‐cell lungcancer (NSCLC) remains short after the first line of treatment with a median OS of 12.2months in non squamous NSCLC and 9.2 months in squamous NSCLC . In this setting theprogrammed death 1/ligand 1 (PD‐1/‐L1) were targeted with nivolumab (IgG4) in advancedsquamous and nonsquamous NSCLC leading to an increase of the 1‐year OS rate ofapproximately 10‐15% in both histologies. Nivolumab, pembrolizumab and atezolizumab arenow considered a standard of care in 2nd line advanced NSCLC and in 1st line forpembrolizumab but but prognosis still remains poor in advanced NSCLC. Overall survival(OS) of patients with advanced (stage III/IV) NSCLC remains limited with a median OS of12.2 months in non‐squamous NSCLC and 9.2 months in squamous NSCLC if anti‐PD1 alone. Itis of around 16 months if pembrolizumab is combined with chemotherapy.Preclinical data indicates that anti‐tumor efficacy is increased when anti‐PD‐1/‐L1 arecombined with irradiation (IR). Radiotherapy alone can elicit tumor cell death which canincrease tumor antigen in the blood stream, favoring recognition by the immune system andits activation against tumor cells outside of the radiation field (="abscopal effect").IR may also reverse acquired resistance to PD‐1 blockade immunotherapy by limiting T‐cellexhaustion.Because of these preclinical and clinical data several studies analysing the combinationof IR and anti‐PD1 in NSCLC are ongoing. Among them, two studies are testing theadministration of IR and nivolumab in stage III NSCLC: the NCT02768558 phase III trial(RTOG), and the NCT02434081 phase II trial (ETOP). Antonia et al [2017] tested the use ofanti‐PD‐L1 after chemoradiotherapy in unresectable stage III NSCLC. Median time todistant metastasis was increased (23.2 months vs. 14.6 months, p<0.001). An increase ofOS is consequently expected.However, no study involving concurrent RT and pembrolizumab combined with chemotherapy inadvanced NSCLC is ongoing, which is the purpose of the present study, NIRVANA‐Lung.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01795425/full} -} - - -Record #186 of 538 -@article{Wu23, -author = {Wu, Y-L, Wang, Z, Dong, X, Li, J, Wu, L, Han, L, Li, X, Zang, A, Li, W, Wen, G, Lin, W, Feng, J, Wang, L, Wang, Q, and Zhu, J}, -title = {First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: a phase II study}, -journal = {Annals of oncology}, -volume = {34}, -pages = {S1681}, -year = {2023}, -accession_number = {EMBASE 2028553861}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Adult; Aged; Antineoplastic activity; Cancer inhibition; Clinical trial; Conference abstract; Controlled study; Drug combination; Drug therapy; Female; First‐line treatment; Follow up; Human; Intravenous drug administration; Male; Multicenter study; Parttime employment; Phase 2 clinical trial; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Side effect; Surgery; Systemic therapy}, -abstract = {Background: Adding PD‐L1/PD‐1 inhibitors to chemotherapy (chemo) has demonstrated efficacy and been approved for advanced squamous non‐small cell lung cancer (sqNSCLC) as first‐line therapy. However, the prognosis remains unsatisfactory. High expression of the epidermal growth factor receptor (EGFR) is prevalent in sqNSCLC. This study aimed to compare the efficacy of HLX07, a novel humanised anti‐EGFR antibody, plus serplulimab (anti‐PD‐1 antibody) ± chemo versus serplulimab plus chemo as first‐line option for advanced sqNSCLC. Methods: This randomised, multicentre phase 2 study consisted of 4 parts and assessed different combinations of HLX07 (at various doses), serplulimab, and chemo. Part 3 explored the preliminary efficacy of the three‐drug combination and is presented below. Patients with stage IIIB/IIIC or IV sqNSCLC that could not be treated with surgery or radiation therapy and had not received prior systemic therapy were enrolled and randomised 1:1 to receive intravenous HLX07 at 800 mg (group A) or 1000 mg (group B), combined with serplulimab (300 mg) and chemo (carboplatin and nab‐paclitaxel), Q3W. The primary endpoints were IRRC‐assessed ORR and PFS per RECIST 1.1. Results: As of 27 June 2023, 12 patients were enrolled and randomly assigned to group A (n=6) and group B (n=6) in part 3. The median age was 64 years. 11 (91.7%) patients were male. 10 (83.3%) patients had stage IV disease. With a median follow‐up of 3.5 months, investigator‐assessed unconfirmed ORR per RECIST 1.1 was 83.3% (95% CI 35.9–99.6) in group A and 66.7% (95% CI 22.3–95.7) in group B. Disease control rate was 100.0% (95% CI 54.1–100.0) in both groups. 2 (33.3%) patients in group A and 1 (16.7%) in group B had serious treatment‐emergent adverse events (TEAEs). 1 (16.7%) patient in group B reported a grade 3 adverse event of special interest (AESI) with dermatitis acneiform; no grade 4–5 AESI occurred. No TEAE leading to death was reported. Conclusions: First‐line HLX07 plus serplulimab and chemo conferred encouraging antitumour efficacy with a manageable safety profile in patients with advanced sqNSCLC and warrants further investigation. Clinical trial identification: NCT04976647 (released on 26 July 2021). Editorial acknowledgement: Editorial assistance was provided by Zhi Hao Kwok, Shiqi Zhong, and Chen Hu of Shanghai Henlius Biotech, Inc. Legal entity responsible for the study: Shanghai Henlius Biotech, Inc. Funding: Shanghai Henlius Biotech, Inc. Disclosure: J. Feng, L. Wang, J. Li, Q. Wang, J. Zhu: Financial Interests, Personal, Full or part‐time Employment: Shanghai Henlius Biotech, Inc. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2023.10.621}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02630455/full} -} - - -Record #187 of 538 -@article{NCT0649135524, -author = {NCT06491355,}, -title = {First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer}, -journal = {https://clinicaltrials.gov/ct2/show/NCT06491355}, -year = {2024}, -accession_number = {CTgov NCT06491355}, -publication type = {Trial registry record}, -keywords = {Colorectal Neoplasms}, -abstract = {Colorectal Cancer (CRC) is a common malignant tumor. Its incidence ranks third and secondamong men and women respectively, and its mortality rate ranks third. Data from the WorldHealth Organization's International Agency for Research on Cancer (IARC) in 2020 showthat more than 930,000 patients died due to CRC. Since 2000, the incidence and mortalityof colorectal cancer have been steadily increasing in China. The National Cancer Centerof China (NCC) reported that there were approximately 408,000 new cases of CRC in Chinain 2016, and approximately 196,000 deaths. Most of the patients are in the mid‐to‐latestage when diagnosed, and about 35% of them are in the advanced stage. They have nochance of radical surgery and can only receive palliative care.In the early days when leucovorin (LV) and 5‐fluorouracil (5‐FU) were used as the maintreatment options for patients with metastatic colorectal cancer (mCRC), the efficacy waspoor, and the median overall survival (OS) of patients was only for 8‐12 months. Sincethe introduction of effective cytotoxic drugs such as irinotecan and oxaliplatin in 2000,the combination regimens FOLFOX (5‐FU/LV + oxaliplatin) and FOLFIRI (5‐FU/LV +irinotecan) have become first‐line systemic Standard protocol in treatment. The use ofbiologics targeting key pathways in the development and progression of mCRC, such asepidermal growth factor receptor (EGFR) and vascular endothelial growth factor(VEGF)‐related pathways, further extends the survival of mCRC patients.In the latest version of CSCO colorectal cancer diagnosis and treatment guidelines, themain recommended first‐line treatments are FOLFOX/FOLFIRI┬▒bevacizumab or cetuximab (bothRAS and BRAF are wild‐type), FOLFOX/FOLFIRI┬▒bevacizumab (RAS or BRAF mutant).PD‐1 plays an important role in suppressing immune responses and promoting immunetolerance by inhibiting the activity of T cells, allowing cancer cells to evade immunesurveillance. Cells in the tumor microenvironment often express PD‐1 and PD‐L1.Consistent with the inducible expression of PD‐L1 by tumor cells, activated CD8+ effectorT cells often express PD‐1, indicating that tumor cells are resistant to adaptive immuneresponses. PD‐L1 has been found to be expressed in many types of cancer, includingmelanoma, lung cancer, urothelial cancer, and hepatocellular carcinoma. Its expressioncan also be induced by various factors such as radiation, which helps cancer cells evadeimmune regulation. Blocking the PD‐1/PD‐L1 interaction has been shown to treat a varietyof cancers. Clinical studies have proven that anti‐PD‐1 and anti‐PD‐L1 monoclonalantibodies can induce long‐lasting anti‐tumor activity against a variety of tumors.Anti‐PD‐1 monoclonal antibodies have been approved for the treatment of melanoma,non‐small cell lung cancer, small cell lung cancer, head and neck squamous cellcarcinoma, urothelial carcinoma, entities with high microsatellite instability ormismatch repair deficiency and colorectal cancer, gastric cancer, esophageal cancer,cervical cancer, hepatocellular carcinoma (HCC), Merkel cell carcinoma (MCC), renal cellcarcinoma, endometrial cancer, bladder cancer, primary mediastinal large B‐cell lymphoma( PMBCL) and classic Hodgkin lymphoma. A large number of clinical studies of anti‐PD‐1antibodies are currently underway, some as monotherapy and some in combination withmultiple drugs.This study is an open‐label, single‐arm, phase II clinical trial. The study inclusioncriteria are patients with unresectable mCRC aged 18‐75 years old and histologicallyconfirmed by multidisciplinary treatment (MDT). The patients have RAS gene mutations andare confirmed to be MSS. state. All patients received treatment with sintilimab combinedwith CapeOx and bevacizumab. After the disease achieved complete response (CR)/partialresponse (PR)/stable disease (SD), maintenance treatment was performed. The main purposeof the study Endpoints include objective response rate (ORR) as assessed by RECIST v1.1and adverse events as assessed by CTCAE v5.0. The secondary endpoint is progression‐freesurvival (PFS).This study mainly aims to explore the effectiveness of chemotherapy and bevacizumabinduction therapy combined with PD‐1 monoclonal antibody in the first‐line treatment ofMSS‐type initial unresectable metastatic colorectal cancer. The second is its safety andtolerability.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02733247/full} -} - - -Record #188 of 538 -@article{ChiCTR230007501123, -author = {ChiCTR2300075011,}, -title = {Consolidation therapy of Adebrelimab for stage III unresectable NSCLC after concurrent radiotherapy and chemotherapy (cCRT combined with or without Adebrelimab)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2300075011}, -year = {2023}, -accession_number = {ICTRP ChiCTR2300075011}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Adebrelimab combined with Concurrent radiotherapy and chemotherapy sequential Adebrelimab treatment group:Adebrelimab+pemetrexed/Albumin paclitaxel+ carboplatin/cisplatin,The dose of chest radiation therapy is 60‐66Gy/30‐33f. Consolidation therapy After four cycles of combined treatment, the patients received a dosing cycle of 1200 mg Q3W of Adebrelimab. Until PD or intolerable toxicity.;Concurrent radiotherapy and chemotherapy sequential Adebrelimab treatment group:pemetrexed/Albumin paclitaxel+ carboplatin/cisplatin,The dose of chest radiation therapy is 60‐66Gy/30‐33f. Consolidation therapy After four cycles of combined treatment, the patients received a dosing cycle of 1200 mg Q3W of Adebrelimab. Until PD or intolerable toxicity.; CONDITION: non‐small cell lung cancer PRIMARY OUTCOME: progression‐free survival; SECONDARY OUTCOME: Objective remission rate evaluated by researchers;duration of response;Disease control rate evaluated by researchers;over‐all survival;Progression free survival rates at 1 and 2 years;Survival rates at 1 and 2 years;The incidence and severity of adverse events (AE) and severe adverse events (SAE) evaluated based on CTCAE 5.0, as well as abnormal laboratory examination indicators;; INCLUSION CRITERIA: 1. Both male and female, aged 18 ‐ 75 years old; 2. The expected lifespan exceeds 6 months; 3. According to the International Association for the Study of Lung Cancer and the Joint Committee on Cancer Classification of the United States, 8th edition of the TNM staging classification for lung cancer, NSCLC with locally advanced unresectable (stage III) diseases; 4.According to RECIST 1.1, there are measurable lesions; 5. The Eastern Oncology Collaborative Group (ECOG) physical fitness score is 0‐1 points; 6. Has not received any systematic anti‐tumor treatment for advanced diseases in the past; 7. Cytological gene testing confirmed that the driving gene was negative (EGFR mutation, ALK fusion mutation, c‐MET amplification, ROS‐1 mutation were all negative); 8. Adequate hematological function: Absolute neutrophil count=1.5×109/L, platelet count= 100×109/L exclusion standard, hemoglobin=90 g/L; 9.Adequate liver function: Aspartate transaminase (}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02606446/full} -} - - -Record #189 of 538 -@article{NCT0230917714, -author = {NCT02309177,}, -title = {Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer}, -journal = {https://clinicaltrials.gov/show/NCT02309177}, -year = {2014}, -accession_number = {CTgov NCT02309177}, -publication type = {Trial registry record}, -keywords = {Albumin‐Bound Paclitaxel; Breast Neoplasms; Carboplatin; Carcinoma, Non‐Small‐Cell Lung; Gemcitabine; Lung Neoplasms; Neoplasms; Nivolumab; Paclitaxel; Pancreatic Neoplasms}, -abstract = {This will be a phase 1, open‐label, multicenter, safety study of nab‐paclitaxel based chemotherapy regimens administered prior to and/or in combination with nivolumab in Pancreatic Cancer, NSCLC and mBC. This is a six arm study assessing two treatment arms per tumor‐type/indication: ‐ Adenocarcinoma of the pancreas with 1 prior systemic chemotherapy (Arm A, Part 1 only); and subsequently no prior chemotherapy, surgery or radiation therapy for locally advanced or metastatic disease (Arm A, Part 2 and Arm B): ‐ Panc Ca Arm A: nab‐paclitaxel with nivolumab starting at Cycle 1. ‐ Panc Ca Arm B: nab‐paclitaxel/gemcitabine with nivolumab starting at Cycle 1. ‐ Stage IIIB or IV NSCLC with no prior chemotherapy for metastatic disease and who are not candidates for curative surgery or radiation: ‐ NSCLC Arm C: nab‐paclitaxel/carboplatin x 4 cycles with nivolumab starting Cycle 1 and continuing as monotherapy starting at Cycle 5. ‐ NSCLC Arm D: nab‐paclitaxel/carboplatin x 4 cycles with nivolumab starting Cycle 3 and continuing as monotherapy starting at Cycle 5 ‐ HER2‐negative recurrent metastatic breast cancer after one prior regimen for mBC, including an anthracycline unless clinically contraindicated: ‐ mBC Arm E: weekly nab‐paclitaxel with nivolumab starting at Cycle 3. ‐ mBC Arm F: q3weekly nab‐paclitaxel with nivolumab starting at Cycle 3. Enrollment in each treatment arm will be conducted in two sequential parts to allow for the evaluation of the DLT in Part 1 prior to expanding the treatment arm in Part 2. Part 1: Part 1 will assess the Dose Limiting Toxicity (DLT) of the nivolumab dose in combination with nab‐paclitaxel regimens in each treatment arm. Subjects who meet the entry criteria will be assigned to the respective treatment arm based on tumor type and indication as outlined above. Panc Ca Arms A and B, as well as NSCLC Arms C and D, will enroll sequentially in Part 1. The safety of nivolumab in combination with nabpaclitaxel, without gemcitabine, will first be assessed in Arm A in subjects with one prior systemic chemotherapy regimen for locally advanced or metastatic disease. Panc Ca Arm B may begin enrolling subjects in Part 1, if Panc Ca Arm A is deemed safe, based on DLT criteria. Similarly, NSCLC Arm D will begin to enroll in Part 1 after NSCLC Arm C is deemed safe to expand in Part 2. However, Arm D may be initiated, even if Arm C is not to proceed for Part 2, if the totality of data from Arm C and emerging data from this and other studies in NSCLC with nivolumab in combination with platinum chemotherapy doublets support the decision. Unlike the Panc Ca and NSCLC arms, the two mBC arms (Arms E and F) will be initiated simultaneously. Subjects will be assigned randomly between treatment arms of a tumor type/indication whenever both treatment arms are enrolling. An IRT system will be used to ensure the central random allocation of subjects. Part 2: Treatment arms deemed safe within each tumor‐type/indication may be expanded using the RP2D with an additional approximately 14 subjects (to attain a total of 20 nivolumab‐treated subjects) to further assess safety and tolerability, as well as explore anti‐tumor activity of the proposed regimens. Since the primary population for the pancreas arms is in subjects with no prior chemotherapy, surgery or radiation therapy, enrollment in Part 2 for Panc Ca Arm A will continue until 20 such subjects have been treated with at least one dose of nivolumab. Additionally, in Parts 1 and 2 overall, each mBC Arm (E and F) will enroll a minimum of 9 subjects with triple‐ negative breast cancer (TNBC), treated at the RP2D. For both Part 1 and 2, subjects may continue to receive their assigned treatment regimen until Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 defined progression or until unacceptable toxicity. However, the chemotherapy doublet will only be given for 4 cycles in the NSCLC arms; thereafter, nivolumab will be given as monotherapy.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01550706/full} -} - - -Record #190 of 538 -@article{EUCTR2018-000245-39-LT18, -author = {EUCTR2018-000245-39-LT,}, -title = {A Phase 3 study to investigate Efficacy and Safety of BGB-A317 in patients with Non-Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2018-000245-39-LT}, -year = {2018}, -accession_number = {ICTRP EUCTR2018‐000245‐39‐LT}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Tislelizumab Product Code: BGB‐A317 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Tislelizumab CAS Number: 1858168‐59‐8 Current Sponsor code: BGB‐A317 Other descriptive name: BGN1; JHL2108 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ Trade Name: Docetaxel Actavis 20 mg/ml koncentrat till infusionsvätska, lösning Product Name: Docetaxel Actavis 20 mg/ml koncentrat till infusionsvätska, lösning Pharmaceutical Form: Concentrate and solvent for solution for infusion INN or Proposed INN: DOCETAXEL Other descriptive name: Docetaxel trihydrate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20‐ CONDITION: Previously treated Non‐Small Cell Lung Cancer in the second or third line setting. ; MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non‐small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: To compare the efficacy, as measured by overall survival (OS), of tislelizumab with docetaxel in the second‐ or third‐line setting in patients with non‐small cell lung cancer (NSCLC) who have progressed on a prior platinum‐containing regimen. A comparison of the treatment arms will be performed in:; o The intent‐to‐treat (ITT) population; o The program cell death protein ligand‐1 (PD‐L1) positive population, where PD‐L1 positive is defined as =25% of tumor cells (TCs) with PD‐L1 membrane staining via the Ventana SP263 assay Primary end point(s): OS ‐ defined as the time from the date of randomization to the date of death due to any cause in the ITT and PD‐L1 positive population. Secondary Objective: 1. To compare the efficacy of tislelizumab and docetaxel as measured by objective response rate (ORR), duration of response (DoR), and progression‐free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in:; o The ITT population; o The PD‐L1 positive population; 2. To compare health‐related quality of life (HRQoL) between tislelizumab and docetaxel; 3. To evaluate the safety and tolerability of tislelizumab versus docetaxel Timepoint(s) of evaluation of this end point: as per protocol SECONDARY OUTCOME: Secondary end point(s): • ORR – defined as the proportion of patients in the ITT and PD‐L1 positive population who had a CR or PR as assessed by the investigator per RECIST v1.1 ; • DoR – defined as the time from the first occurrence of a documented objective response to the time of relapse, as determined by the investigator per RECIST v1.1, or death from any cause, whichever comes first, in the ITT and PD‐L1 positive population ; • PFS – defined as the time from the date of randomization to the date of the first objectively documented tumor progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurs first, in the ITT and PD‐L1 positive population ; • HRQoL – measured using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Lung Cancer (EORTC QLQ‐LC13) and Core 30 (EORTC QLQ‐C30), and European Quality of Life 5‐Dimensions, 5‐level (EQ‐5D‐5L) scale INCLUSION CRITERIA: 1. Able to provide written informed consent and can understand and comply with the requirements of the study. 2. Age = 18 years on the day of signing the informed consent form. 3. Histologically confirmed disease which is currently locally advanced or metastatic NSCLC of either squamous or non‐squamous histology. 4. With disease progression during or following treatment with at least one platinum‐containing regimen. ; • Incidence and severity of TEAEs graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI‐CTCAE), v4.03 Timepoint(s) of evaluation of this end point: As per protocol • Patients who received prior neo‐adjuvant or adjuvant chemotherapy but progressed within 6 months after last dose are eligible provided the target lesion(s) have not been previously treated with local therapy (radiation) or the target lesion(s) within the field of local therapy have subsequently progressed as defined per RECIST v1.1 • Anti‐EGFR treatment with disease progression as the treatment outcome is counted as a line of therapy. • Anticancer agents used for pleurodesis are not counted as}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01906863/full} -} - - -Record #191 of 538 -@article{Paz-Ares19, -author = {Paz-Ares, L, Senan, S, Planchard, D, Wang, L, Cheong, A, Slepetis, R, Nguyen, MH, and Vokes, EE}, -title = {RATIONALE 001: tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)}, -journal = {Annals of oncology}, -volume = {30}, -pages = {ii67}, -year = {2019}, -accession_number = {EMBASE 628119936}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *cancer staging; *chemoradiotherapy; *monotherapy; *non small cell lung cancer; Adult; Brain; Cancer survival; Clinical evaluation; Comparative effectiveness; Conference abstract; Controlled study; Double blind procedure; Drug efficacy; Drug safety; Drug therapy; Female; Gene expression; Human; Major clinical study; Male; Oncology; Overall survival; Pharmacokinetics; Phase 3 clinical trial; Protein expression; Radiotherapy; Randomization; Randomized controlled trial}, -abstract = {Background: In pts with locally advanced, unresectable, stage III NSCLC, cCRT is associated with better survival than radiotherapy (RT) alone, but 5‐y survival remains poor. Immunotherapies targeting PD‐1/PD‐L1 may be synergistic with cCRT, improving outcomes. Tislelizumab, an anti‐PD‐1 antibody, showed clinical activity/tolerability in solid tumors, including NSCLC. RATIONALE 001 is a phase III, randomized, doubleblind, placebo‐controlled trial evaluating the efficacy and safety of first‐line tislelizumab+ cCRT in pts with locally advanced, unresectable, stage III NSCLC. Trial design: RATIONALE 001 aims to answer important scientific questions by employing a 3‐arm study design (840 pts randomized 1:1:1) to evaluate whether the timing of giving tislelizumab earlier upfront with cCRT in addition to consolidation will improve outcomes rather than giving the anti‐PD‐1 as consolidation only (Table). Both tislelizumab approaches (Arms 1 and 2) will each be compared to a global standard of care, cCRT alone. Chemotherapy will be investigator's choice (cisplatin + etoposide or carboplatin + paclitaxel). RT will be given in 2Gy fractions (target dose of 60 Gy). Key eligibility: Locally advanced, unresectable, stage III NSCLC; stage III confirmed by FDG‐PET and brain imaging; Eastern Cooperative Oncology Group performance status ≤ 1; and no prior anti‐PD‐1/PD‐L1 therapy. PD‐L1 expression assessment is not required prior to randomization. Primary endpoint: Progressionfree survival. Secondary endpoints include overall survival (OS), OS at 24 mo, objective response rate, and safety. Blood and tumor biomarkers, including PD‐L1 expression and tumor mutational burden, will be evaluated for correlations with clinical benefit. (Table Presented) .}, -DOI = {10.1093/annonc/mdz063.083}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01957914/full} -} - - -Record #192 of 538 -@article{NCT0363260318, -author = {NCT03632603,}, -title = {PAlliative RAdioTherapy to Lung Cancer A Randomized Multicentre Phase III Study}, -journal = {https://clinicaltrials.gov/ct2/show/NCT03632603}, -year = {2018}, -accession_number = {CTgov NCT03632603}, -publication type = {Trial registry record}, -keywords = {Lung Neoplasms}, -abstract = {1. Background 1.1 Radiotherapy in lung cancer Non‐small‐cell lung cancer (NSCLC) is the leading cause of cancer‐related death in both men and women [1]. In stage IV disease platinum‐based chemotherapy yields a median overall survival (OS) of 8‐10 months [2]. When diagnosed, more than 50% of the patients have distant metastases. Forty percent have signs or symptoms originating from the thorax: dyspnoea, cough, haemoptysis, recurrent pneumonia or chest pain [3]. Palliative thoracic radiotherapy can relieve symptoms originating from intra‐thoracic malignancy and improves quality of life (QoL) in approximately one third of patients [4]. It is increasingly used in daily clinical practice as an alternative to chemotherapy in patients without local symptoms with the purpose of prolonging life and avoiding local thoracic symptoms. In addition, palliative radiotherapy is used to relieve symptoms before initiating systemic treatment (chemotherapy, targeted agents, immune therapy, etc). In this latter case, it is important not to delay the systemic treatment unnecessary with long schedules of radiotherapy. An optimal radiotherapy regimen will thus palliate symptoms with minimal toxicity and consider the patient's time investment, as well as be compatible with any additional treatments given. In a recent retrospective study of 159 consecutive Danish NSCLC patients who received palliative thoracic radiotherapy (2010‐11) median survival was 4.2 months. One third of the patients died within two months and 22% within 30 days [5]. This further underlines the importance of not subjecting patients to prolonged, toxic treatments in their final year of life. A recent Cochrane review [6] found that there was no consistent evidence to support that longer, more fractionated radiotherapy regimens gave better or more durable palliation than shorter regimens. Furthermore, there was no significant survival advantage associated with longer regimens with higher biological radiation doses. The most common acute toxicity is oesophagitis. It is often not technically possible to avoid high dose exposure to the oesophagus because of the target localization in proximity to the mediastinum. Radiation‐induced oesophagitis is most often a reversible condition. However, it compromises swallowing due to pain, causes weight loss and deterioration of the performance state (PS) and QoL at a vulnerable time for the patient, and it may impact the possibility of receiving further anti‐neoplastic treatment. The Cochrane review found that up to 50% of patients receiving palliative thoracic radiotherapy reported severe oesophagitis. The studies differed widely in terms of physician‐ or patient self‐assessment, timing, and the method used, and no overall judgement could be made. The review concluded that toxicity was comparable between different radiotherapy regimens. However, recording and reporting of early toxicity was lacking in the included studies. This absence of early toxicity data means that the current evidence is insufficient for clinical decision making in this patient group. 2. Study design The patients will be invited to participate in the study prior to initiation of palliative radiotherapy. After signing informed consent the patients will be randomized 1:1 between two different radiotherapy dose fractionations: 30 Gy/10 F or 20 Gy/4 F. Physicians and patients will not be blinded to the randomization. 2.1 Systemic therapy Patients can receive chemotherapy, immunotherapy and targeted therapy during radiotherapy. 2.2 Study sample size and time frame According to the Danish Lung Cancer Registry, 50% of the 4700 lung cancer patients diagnosed yearly are in advanced stage. Of these, one third is supposed to benefit from palliative thoracic radiotherapy and of these, 400 patients ( 50%) are expected to be enrolled on the trial each year. Since 1184 consecutive patients are required (see chapter 7) the study is expected to enrol patients over a 3‐year period. Given the declared support of all Danish radiotherapy centres, this is considered a realistic time frame. Following study closure, 3 weeks of follow‐up after radiotherapy initiation will be allowed for all patients, at which point data will be collected for primary analysis. Further analysis will be performed 1 and 3 years after the last patient is enrolled. Data will be kept in databases 15 years after the last patient is included. 3. Radiotherapy treatment planning 3.1 Target and organs at risk The gross tumour volume (GTV) is defined by the referring oncologist based on a planning CT scan, and if available, a diagnostic PET/CT scan. The oncologist will note in the CRF if the GTV fully or only partially encompass all active malignant disease in the thorax. The clinical target volume (CTV) is identical to the GTV, and thus not delineated. Spinal cord or spinal canal, total lung, heart and the oesophagus are delineated for all patients based on the guidelines in [5,6]. The heart is cranially limited defined by the division of truncus pulmonalis. The oesophagus is delineated from cartilago criocoideum to the gastro‐oesophageal junction. 3.2 Dose planning Patients are treated with conformal treatment plans, conventional or intensity‐modulated. 4. Treatment verification and quality assurance 4.1 Verification of treatment position Daily imaging must be performed and used for daily correction of treatment position. 5. Participants Patients with lung cancer stage III‐IV not suitable for curative treatment, being referred for palliative radiotherapy either alone or in addition to systemic treatment. 5.1 Evaluations during treatment and follow up 5.1.1 Expected side effects Palliative RT comes with a risk of side‐effects including fatigue, pain and soreness in the throat and chest, reddening of the skin in the irradiated area and dry cough and dyspnoea. 5.1.2 Scoring of symptoms and QoL Symptom scores on oesophagitis, cough, pain, dyspnoea, bronchopulmonary haemorrhage, performance status and QoL will be registered at baseline, end of treatment, 2 weeks, 3 weeks, 8‐10 weeks and 6 months after radiotherapy completion. If the patient has symptoms which need clinical assessment, the patient will get an appointment with a physician. All complication (side effects) will be evaluated according to the NCI‐CTCAE v 5.0 during all follow‐up visits or calls [7]. See appendix C for an overview of the CTCAE v 5.0. Table 6.1 shows the evaluation plan for the trial. Symptom scores on oesophagitis, cough, pain, dyspnoea, bronchopulmonary haemorrhage, and assessment of performance status will be registered during the patient on‐site visit at baseline, end of treatment, 8‐10 weeks after treatment and 6 months after treatment completion. At 2 weeks and 3 weeks, symptom scores will be registered by a phone call. Questionnaires for registration of QoL will be filled in on‐site by the patient at baseline, end of treatment, 8‐10 weeks after completion of treatment and 6 months after completion of treatment. In addition, two questionnaires for registration of QoL to be filled in 2 weeks and 3 weeks after completion of treatment will be handed out at end of treatment. During the phone calls at 2 weeks and 3 weeks, the patient will be reminded to fill in the questionnaire. The questionnaires will be collected at the on‐site visit at 8‐10 weeks after treatment. One or both phonecalls at 2 weeks and 3 weeks may be substituted by on site visits. After the end of the study‐specified visit, patients will be seen every 3rd month according to the guidelines by the Danish Health Authorities. Evaluation of toxicity will be performed at every occasion. End of study is 3 years after commencement of radiotherapy. 5.2 Quality of Life To examine the participants' quality of life (QoL) during follow up, they will be asked to fill in a QoL questionnaire. The EuroQoL 5D (EQ‐5D‐5L) questionnaire will be used. 6. Statistical considerations and planned data analyses 6.1 Sample size calculation for primary endpoint ‐ acute oesophagitis The primary study endpoint is reduction in early oesophageal toxicity, as assessed two weeks after completion of radiotherapy. The investigators assume that 50% of patients who receive the standard treatment (30 Gy in 10 fractions) will experience grade 2 or worse oesophagitis, compared to their baseline prior to treatment. A reduction in acute toxicity of 10%‐point with the experimental treatment (odds ratio between arms of 0.67) will be clinically meaningful and will justify a change of practice for this patient group. This corresponds to an expected 40% rate of acute oesophagitis in the experimental arm. With 90% power and a 2‐sided type 1 error rate of 5%, 1184 patients will be required (assuming 1:1 allocations between treatment arms, and incorporating a 10% loss to follow‐up). There are some clinical indications that oesophageal‐related toxicity will mainly be seen in patients with centrally located tumours (where palliative radiotherapy results in irradiation of mediastinal structures). These patients make up approximately two thirds of the palliative radiotherapy patient population. An incidence of oesophagitis of 70% in these patients (and 10% in patients with peripheral tumours) is consistent with the observed overall toxicity rate. Enrolling 790 patients with central tumours in the study will result in >95% power to detect a 15%‐point reduction of toxicity in this subgroup, from 70% to 55% (consistent with an overall reduction of 10%, assuming very limited effect in patients with peripheral tumours). Alternatively, there will be nearly 80% power to detect a 10%‐point toxicity reduction in the central tumour subgroup. Any such subgroup analyses will be completely exploratory. All sample size and power calculations for the primary endpoint are based on two‐group chi‐squared tests (continuity corrected) of equal proportions. 6.2 Non‐inferiority of overall survival Current best evidence indicates that overall survival should not be different with shorter compared to longer palliative treatment regimens, although the literature is not conclusive. The proposed study will have the power to test for non‐inferiority of the short (experimental) treatment arm compared to the standard treatment: Assuming a median OS of 4.2 months, inclusion of 1184 patients over 3 years (with one year of additional follow‐up) will give approximately 90% power to test that median OS in the experimental arm is at most 3 weeks shorter than in the standard arm (one‐sided significance level of 95%). Power calculations for overall survival are based on Cox's proportional hazards model. 6.3 Planned data analyses All analyses will be conducted on an intention to treat (ITT) basis. The primary endpoint analysis will take place once all enrolled patients have reached the primary endpoint assessment (2 weeks after completion of radiotherapy). A multivariate logistic regression model will be used to compare rates of grade 2+ acute oesophagitis in the two treatment arms, adjusted for stratification factors. Robustness of the primary endpoint to the timing of oesophagitis assessment will be examined in secondary analyses, comparing the two arms with respect to oesophagitis rates at 3 weeks after end of therapy as well as oesophagitis rates at 4 weeks after the start of therapy (two weeks after end of therapy in the standard arm and three weeks after end of therapy in the experimental arm). Significance testing will be two‐sided, with a 95% significance level. Analysis of secondary endpoints will depend on the follow‐up required for each endpoint; with most endpoints (QoL, response assessment) available at the time of primary analysis, and initial analysis of overall survival conducted one year after randomisation of the final patient. 6.4 Randomization ‐ Patients are stratified prior to randomization by treatment institution, performance status 0/1 versus 2, and histology (small cell carcinoma vs squamos cell carcinoma vs non‐squamos cell carcinoma). ‐ Patients will be randomized 1:1 between the two different radiotherapy dose fractionations 7. Complications All complication (side effects) will be evaluated according to the NCI‐CTCAE v 5.0 during all followup visits. 8. References [1] Jemal A, CA Cancer J Clin 2011 Mar;61(2):69‐90 [2] Wao H, Syst Rev 2013 Feb 4;2:10 [3] Beckles MA1Chest. 2003 Jan;123(1 Suppl):97S‐104S. [4] L angendijk JA, Int J Radiat Oncol Biol Phys 2000 Apr 1;47(1):149‐55 [5] Støchkel Frank M, BMC Palliat Care. 2018 Jan 5;17:15. [6] S tevens R, Cochrane Database Syst Rev 2015 Jan 14;1:CD002143. [7] Kong FM, Int J Radiat Oncol Biol Phys 2011 Dec 1;81(5):1442‐57.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01662253/full} -} - - -Record #193 of 538 -@article{Goldman21, -author = {Goldman, JW, Dvorkin, M, Chen, Y, Reinmuth, N, Hotta, K, Trukhin, D, Statsenko, G, Hochmair, MJ, Ozguroglu, M, Ji, JH, Garassino, MC, Voitko, O, Poltoratskiy, A, Ponce, S, Verderame, F, Havel, L, Bondarenko, I, Kazarnowicz, A, Losonczy, G, Conev, NV, Armstrong, J, Byrne, N, Thiyagarajah, P, Jiang, H, Paz-Ares, L, Voitko, N, Kazarnowicz, A, Ozguroglu, M, Hochmair, M, Burghuber, O, Cicin, I, Moiseenko, V, Erman, M, Kowalski, D, Wojtukiewicz, M, Adamchuk, H, Vasilyev, A, Shevnia, S, Valev, S, Insa Molla, MA, Ursol, G, Chiang, A, Hartl, S, Horvath, Z, Pajkos, G, Kim, S-W, Smolin, A, Goksel, T, Dakhil, S, Roubec, J, Bogos, K, Cornelissen, R, Lee, J-S, Garcia Campelo, MR, Lopez Brea, M, Alacacioglu, A, Casarini, I, Ilieva, R, Tonev, I, Somfay, A, Bar, J, Zer Kuch, A, Minelli, M, Bartolucci, R, Roila, F, Saito, H, Azuma, K, Lee, G-W, Luft, A, Urda, M, Delgado Mingorance, JI, Majem Tarruella, M, Spigel, D, Koynov, K, Zemanova, M, Panse, J, Schulz, C, Papai Szekely, Z, Sarosi, V, Delmonte, A, Bettini, AC, Nishio, M, Okamoto, I, Hendriks, L, Mandziuk, S, Lee, YG, Vladimirova, L, Isla Casado, D, Domine Gomez, M, Navarro Mendivil, A, Moran Bueno, T, Wu, S-Y, Knoble, J, Skrickova, J, Venkova, V, Hilgers, W, Laack, E, Bischoff, H, Fulop, A, Laczo, I, Kosa, J, Telekes, A, Yoshida, T, Kanda, S, Hida, T, Hayashi, H, Maeda, T, Kawamura, T, Nakahara, Y, Claessens, N, Lee, KH, Chiu, C-H, Lin, S-H, Li, C-T, Demirkazik, A, Schaefer, E, Nikolinakos, P, Schneider, J, Babu, S, Lamprecht, B, Studnicka, M, Fausto Nino Gorini, C, Kultan, J, Kolek, V, Souquet, P-J, Moro-Sibilot, D, Gottfried, M, Smit, E, Lee, KH, Kasan, P, Chovanec, J, Goloborodko, O, Kolesnik, O, Ostapenko, Y, Lakhanpal, S, Haque, B, Chua, W, Stilwill, J, Sena, SN, Girotto, GC, De Marchi, PRM, Martinelli de Oliveira, FA, Dos Reis, P, Krasteva, R, Zhao, Y, Chen, C, Koubkova, L, Robinet, G, Chouaid, C, Grohe, C, Alt, J, Csanky, E, Somogyine Ezer, E, Heching, NI, Kim, YH, Aatagi, S, Kuyama, S, Harada, D, Nogami, N, Nokihara, H, Goto, H, Staal van den Brekel, A, Cho, EK, Kim, J-H, Ganea, D, Ciuleanu, T, Popova, E, Sakaeva, D, Stresko, M, Demo, P, Godal, R, Wei, Y-F, Chen, Y-H, Hsia, T-C, Lee, K-Y, Chang, H-C, Wang, C-C, Dowlati, A, Sumey, C, Powell, S, Goldman, J, Zarba, JJ, Batagelj, E, Pastor, AV, Zukin, M, Baldotto, CSDR, Schlittler, LA, Calabrich, A, Sette, C, Dudov, A, Zhou, C, Lena, H, Lang, S, Papai, Z, Goto, K, Umemura, S, Kanazawa, K, Hara, Y, Shinoda, M, Morise, M, Hiltermann, J, Mroz, R, Ungureanu, A, Andrasina, I, Chang, G-C, Vynnychenko, I, Shparyk, Y, Kryzhanivska, A, Ross, H, Mi, K, Jamil, R, Williamson, M, Spahr, J, Han, Z, Wang, M, Yang, Z, Hu, J, Li, W, Zhao, J, Feng, J, Ma, S, Zhou, X, Liang, Z, Hu, Y, Chen, Y, Bi, M, Shu, Y, Nan, K, Zhou, J, Zhang, W, Ma, R, Yang, N, Lin, Z, Wu, G, Fang, J, Zhang, H, Wang, K, and Chen, Z}, -title = {Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial}, -journal = {Lancet oncology}, -volume = {22}, -number = {1}, -pages = {51‐65}, -year = {2021}, -accession_number = {EMBASE 2010392424, PUBMED 33285097}, -publication type = {Journal article}, -keywords = {*small cell lung cancer /drug therapy; Adult; Aged; Alopecia /side effect; Anemia /side effect; Area under the curve; Article; Asthenia /side effect; Backache /side effect; Brain metastasis /complication /prevention; Brain radiation; Cancer staging; Constipation /side effect; Coughing /side effect; Decreased appetite /side effect; Dehydration /side effect; Diarrhea /side effect; Drug fatality /side effect; Drug safety; Dyspnea /side effect; Enterocolitis /side effect; Fatigue /side effect; Febrile neutropenia /side effect; Female; Fever /side effect; Follow up; Headache /side effect; Heart arrest /side effect; Hepatitis /side effect; Human; Hyperamylasemia /side effect; Hypertension /side effect; Hyperthyroidism /side effect; Hyponatremia /side effect; Intention to treat analysis; Interactive voice response system; Interstitial lung disease /side effect; Japan; Leukopenia /side effect; Liver disease /side effect; Liver metastasis /complication; Lung embolism /side effect; Major clinical study; Male; Multicenter study (topic); Multiple cycle treatment; Multiple organ failure /side effect; Nausea /side effect; Neutropenia /side effect; Open study; Overall survival; Pancytopenia /side effect; Phase 3 clinical trial (topic); Pneumonia /side effect; Priority journal; Progression free survival; Pruritus /side effect; Randomized controlled trial (topic); Rash /side effect; Respiratory failure /side effect; Sepsis /side effect; Side effect /side effect; Thrombocytopenia /side effect; Treatment outcome; Vomiting /side effect}, -abstract = {Background: First‐line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide) showed a significant improvement in overall survival versus platinum–etoposide alone in patients with extensive‐stage small‐cell lung cancer (ES‐SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum–etoposide versus platinum–etoposide alone. Methods: CASPIAN is an ongoing, open‐label, sponsor‐blind, randomised, controlled phase 3 trial at 209 cancer treatment centres in 23 countries worldwide. Eligible patients were aged 18 years or older (20 years in Japan) and had treatment‐naive, histologically or cytologically documented ES‐SCLC, with a WHO performance status of 0 or 1. Patients were randomly assigned (1:1:1) in blocks of six, stratified by planned platinum, using an interactive voice‐response or web‐response system to receive intravenous durvalumab plus tremelimumab plus platinum–etoposide, durvalumab plus platinum–etoposide, or platinum–etoposide alone. In all groups, patients received etoposide 80–100 mg/m2 on days 1–3 of each cycle with investigator's choice of either carboplatin area under the curve 5–6 mg/mL/min or cisplatin 75–80 mg/m2 on day 1 of each cycle. Patients in the platinum–etoposide group received up to six cycles of platinum–etoposide every 3 weeks and optional prophylactic cranial irradiation (investigator's discretion). Patients in the immunotherapy groups received four cycles of platinum–etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks. The two primary endpoints were overall survival for durvalumab plus platinum–etoposide versus platinum–etoposide and for durvalumab plus tremelimumab plus platinum–etoposide versus platinum–etoposide in the intention‐to‐treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered at ClinicalTrials.gov, NCT03043872. Findings: Between March 27, 2017, and May 29, 2018, 972 patients were screened and 805 were randomly assigned (268 to durvalumab plus tremelimumab plus platinum–etoposide, 268 to durvalumab plus platinum–etoposide, and 269 to platinum–etoposide). As of Jan 27, 2020, the median follow‐up was 25·1 months (IQR 22·3–27·9). Durvalumab plus tremelimumab plus platinum–etoposide was not associated with a significant improvement in overall survival versus platinum–etoposide (hazard ratio [HR] 0·82 [95% CI 0·68–1·00]; p=0·045); median overall survival was 10·4 months (95% CI 9·6–12·0) versus 10·5 months (9·3–11·2). Durvalumab plus platinum–etoposide showed sustained improvement in overall survival versus platinum–etoposide (HR 0·75 [95% CI 0·62–0·91]; nominal p=0·0032); median overall survival was 12·9 months (95% CI 11·3–14·7) versus 10·5 months (9·3–11·2). The most common any‐cause grade 3 or worse adverse events were neutropenia (85 [32%] of 266 patients in the durvalumab plus tremelimumab plus platinum–etoposide group, 64 [24%] of 265 patients in the durvalumab plus platinum–etoposide group, and 88 [33%] of 266 patients in the platinum–etoposide group) and anaemia (34 [13%], 24 [9%], and 48 [18%]). Any‐cause serious adverse events were reported in 121 (45%) patients in the durvalumab plus tremelimumab plus platinum–etoposide group, 85 (32%) in the durvalumab plus platinum–etoposide group, and 97 (36%) in the platinum–etoposide group. Treatment‐related deaths occurred in 12 (5%) patients in the durvalumab plus tremelimumab plus platinum–etoposide group (death, febrile neutropenia, and pulmonary embolism [n=2 each]; enterocolitis, general physical health deterioration and multiple organ dysfunction syndrome, pneumonia, pneumonitis and hepatitis, respiratory failure, and sudden death [n=1 each]), six (2%) patients in the durvalumab plus platinum–etoposide group (cardiac arrest, dehydration, hepatotoxicity, interstitial lung disease, pancytopenia, and sepsis [n=1 each]), and two (1%) in the platinum–etoposide group (pancytopenia and thrombocytopenia [n=1 each]). Interpretation: First‐line durvalumab plus platinum–etoposide showed sustained overall survival improvement versus platinum–etoposide but the addition of tremelimumab to durvalumab plus platinum–etoposide did not significantly improve outcomes versus platinum–etoposide. These results support the use of durvalumab plus platinum–etoposide as a new standard of care for the first‐line treatment of ES‐SCLC. Funding: AstraZeneca.}, -DOI = {10.1016/S1470-2045(20)30539-8}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02667445/full} -} - - -Record #194 of 538 -@article{Viculin20, -author = {Viculin, I, Viculin, J, Boban, M, Boskovic, L, Vrdoljak, E, and Jelavic, TB}, -title = {The efficacy and safety of concurrent chemoradiotherapy in patients with non-small cell lung cancer-single institution study at department of oncology and radiotherapy, university hospital of split}, -journal = {Libri oncologici}, -volume = {48}, -number = {SUPPL 1}, -pages = {114‐115}, -year = {2020}, -accession_number = {EMBASE 633439796}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *chemoradiotherapy; *drug safety; *histology; *non small cell lung cancer; *university hospital; Acute toxicity; Adenocarcinoma; Adult; Advanced cancer; Cancer staging; Cancer survival; Clinical feature; Conference abstract; Conformal radiotherapy; Croatia; Demography; Drug combination; Drug therapy; Esophagitis; Ethics; Female; Follow up; Histopathology; Human; Immunotherapy; Major clinical study; Male; Middle aged; Neutropenia; Overall survival; Progression free survival; Radiotherapy; Randomized controlled trial; Retrospective study; Squamous cell carcinoma}, -abstract = {Backround: Lung cancer is most frequently diagnosed cancer and leading cause of cancer death worldwide. Concomitant chemoradiotherapy is the treatment of choice for patients with non‐small cell lung cancer, who are in good condition, with stage IIIB, IIIC and selected patients with earlier stages of the disease that is inoperable. Although randomised clinical trials have proved the benefit of this approach, in everyday clinical practice, due to multiple reasons, it is still underutilised. Based on survival benefit with consolidation immunotherapy with durvalumab after concomitant chemoradiotherapy, this has become new standard of treatment in western countries. The prerequisite for optimal results of this new strategy, that is still not reimbursed in Croatia, is properly conducted chemoradiotherapy part of the treatment. Objectives: Our goal was to examine the efficacy and safety of concurrent chemoradiotherapy as primary therapy in patients with non‐small cell lung cancer stages I‐III, treated at the Department of Oncology, University Hospital of Split from 2011. till 2018. Patients and metods: In a retrospective study conducted at Department of Oncology and Radiotherapy, University Hospital of Split, the comprehensive demographic and clinical data was collected on a total of 84 patients, treated with concurrent chemoradiotherapy as a primary treatment, in period between 2011., when we introduced 3D conformal radiotherapy, and 2018. Study protocol was approved by University Hospital of Split Ethics' Committee. Results: The median age of patients was 61 years, 75% being male. The most common histological types where squamous cell carcinoma (56%) and adenocarcinoma (32%). The median dose of applied radiotherapy was 55 Gy, with 30% of patients receiving 60 Gy or more. All patients got concurrent platinum and etoposide (PE) chemotherapy, five or three‐day regimens, and 69% got both cycles.The median follow‐up time of our patients was 15 months. Objective response rate was 69%. The median progression free survival (PFS) was 9 months (95% CI: 7.27‐12.57) and median overall survival (OS) was 17 months (95% CI: 13.47‐27.43). The treatment was relatively well tolerated. The most common acute toxicity was leukopenia, observed in 65% of patients. Radiation esophagitis, with a 39% occurrence, was the most common acute toxicity of grade 1 and 2, while the most common grade 3 and 4 toxicity was neutropenia (38% of patients). Conclusion: This retrospective analysis on treatment outcomes of patients with locally advanced lung cancer treated with concomitant chemoradiotherapy showed comparable results in clinical efficacy and toxicity with older randomised clinical trials that positioned the role of concurrent chemoradiotherapy in this disease, but are slightly inferior to the most recent trials. Possible explanations are: retrospective nature of the study, treatment in every day setting that differs significantly from clinical trials conditions, mainly by inclusion of patients with worse demographic and clinical characteristics. Nevertheless, these results are the first one reported on treatment outcomes of this approach in Croatia, and are again pointing out on importance of real multidisciplinary approach to lung cancer patients.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02205509/full} -} - - -Record #195 of 538 -@article{Jairam24, -author = {Jairam, V, Soulos, PR, KC, M, Gross, CP, Slotman, BJ, Chiang, AC, and Park, HS}, -title = {Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex}, -journal = {Advances in radiation oncology}, -volume = {9}, -number = {4}, -year = {2024}, -accession_number = {EMBASE 2030488982}, -publication type = {Journal article}, -keywords = {*sex; *small cell lung cancer; Article; Doublet chemotherapy; Drug combination; Drug therapy; Electronic health record; Female; First‐line treatment; Human; Major clinical study; Male; Progression free survival; Radiotherapy; Randomized controlled trial; Retrospective study; Sensitivity analysis; Systemic therapy; Therapy}, -abstract = {Purpose: The landmark randomized trial on chest irradiation in extensive disease small cell lung cancer (CREST) demonstrated that consolidative thoracic radiation therapy (cTRT) improved overall (OS) and progression‐free survival (PFS) after initial chemotherapy (chemo) in extensive‐stage small cell lung cancer, with potentially increased benefit in women compared with men. It is unknown whether similar findings would apply after chemoimmunotherapy became the standard first‐line treatment. In this analysis, we report national practice patterns and survival outcomes of cTRT according to patient sex. Methods and Materials: We included patients from de‐identified electronic health record‐derived database diagnosed with stage IV small cell lung cancer (2014‐2021) who completed 4 to 6 cycles of first‐line systemic therapy (platinum‐doublet chemotherapy or chemoimmunotherapy). We evaluated OS and PFS using multivariable Cox proportional hazards regression with receipt of cTRT as an independent variable and stratified by sex. As a sensitivity analysis, we weighted the models by the inverse probability of receiving cTRT. Results: A total of 1227 patients were included (850 chemotherapy, 377 chemoimmunotherapy). There were no statistically significant differences in baseline characteristics between patients who did and did not receive cTRT. Among women, cTRT was associated with superior OS (adjusted hazard ratio [HR], 0.67; 95% CI, 0.52‐0.87) and PFS (HR, 0.63; 95% CI, 0.49‐0.82) compared with those not receiving cTRT. Conversely, no OS or PFS benefit with cTRT was observed in men (OS HR, 1.03; 95% CI, 0.80‐1.31; PFS HR, 1.12; 95% CI, 0.85‐1.47). Findings were similar in weighted analyses. Conclusions: The survival efficacy of cTRT may be moderated by sex, with female patients appearing more likely to benefit than male patients. These findings reflect sex‐based survival trends with similar effect sizes to those observed in the CREST trial. Although the underpinnings of this association need to be elucidated, stratification by sex should be considered for randomized‐controlled trials studying cTRT in extensive‐stage small cell lung cancer.}, -DOI = {10.1016/j.adro.2023.101413}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02665611/full} -} - - -Record #196 of 538 -@article{Jiang21, -author = {Jiang, T, Wang, P, Zhang, J, Zhao, Y, Zhou, J, Fan, Y, Shu, Y, Liu, X, Zhang, H, He, J, Gao, G, Mu, X, Bao, Z, Xu, Y, Guo, R, Wang, H, Deng, L, Ma, N, Zhang, Y, Feng, H, Yao, S, Wu, J, Chen, L, Zhou, C, and Ren, S}, -title = {Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial}, -journal = {Signal transduction and targeted therapy}, -volume = {6}, -number = {1}, -pages = {355}, -year = {2021}, -accession_number = {EMBASE 2013950705, PUBMED 34650034}, -publication type = {Journal article}, -keywords = {*chemotherapy; *non small cell lung cancer; Adult; Aged; Antibodies, Monoclonal, Humanized [*administration & dosage]; Antineoplastic Combined Chemotherapy Protocols [administration & dosage]; Antineoplastic activity; Article; Brain metastasis; Carboplatin [*administration & dosage]; Carcinoma, Non‐Small‐Cell Lung [*drug therapy, genetics, pathology]; Clinical article; Clinical trial; ErbB Receptors [antagonists & inhibitors, genetics]; Female; Gene Expression Regulation, Neoplastic [drug effects]; Gene expression; Gene frequency; Gene mutation; Human; Humans; Immunohistochemistry; Immunosuppressive treatment; M2 macrophage; MAPK signaling; Male; Middle Aged; Multicenter study; Mutation [drug effects]; Nucleic acid base substitution; Overall survival; Pemetrexed [*administration & dosage]; Peripheral blood mononuclear cell; Phase 2 clinical trial; Polymerase chain reaction; Progression free survival; Progression‐Free Survival; Protein Kinase Inhibitors [administration & dosage]; Radiation pneumonia; Signal transduction; Single nucleotide polymorphism; Treatment response; Tumor associated leukocyte; Tumor gene; Tumor microenvironment; Upregulation; Whole exome sequencing; Young Adult}, -abstract = {This multicenter phase‐II trial aimed to investigate the efficacy, safety, and predictive biomarkers of toripalimab plus chemotherapy as second‐line treatment in patients with EGFR‐mutant‐advanced NSCLC. Patients who failed from first‐line EGFR‐TKIs and did not harbor T790M mutation were enrolled. Toripalimab plus carboplatin and pemetrexed were administrated every three weeks for up to six cycles, followed by the maintenance of toripalimab and pemetrexed. The primary endpoint was objective‐response rate (ORR). Integrated biomarker analysis of PD‐L1 expression, tumor mutational burden (TMB), CD8 + tumor‐infiltrating lymphocyte (TIL) density, whole‐exome, and transcriptome sequencing on tumor biopsies were also conducted. Forty patients were enrolled with an overall ORR of 50.0% and disease‐control rate (DCR) of 87.5%. The median progression free survival (PFS) and overall survival were 7.0 and 23.5 months, respectively. The most common treatment‐related adverse effects were leukopenia, neutropenia, anemia, ALT/AST elevation, and nausea. Biomarker analysis showed that none of PD‐L1 expression, TMB level, and CD8 + TIL density could serve as a predictive biomarker. Integrated analysis of whole‐exome and transcriptome sequencing data revealed that patients with DSPP mutation had a decreased M2 macrophage infiltration and associated with longer PFS than those of wild type. Toripalimab plus chemotherapy showed a promising anti‐tumor activity with acceptable safety profiles as the second‐line setting in patients with EGFR‐mutant NSCLC. DSPP mutation might serve as a potential biomarker for this combination. A phase‐III trial to compare toripalimab versus placebo in combination with chemotherapy in this setting is ongoing (NCT03924050).}, -DOI = {10.1038/s41392-021-00751-9}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02370254/full} -} - - -Record #197 of 538 -@article{Paz-Ares19, -author = {Paz-Ares, LG, Senan, S, Planchard, D, Wang, L, Cheong, A, Nguyen, MH, Slepetis, R, and Vokes, EE}, -title = {Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001)}, -journal = {Journal of clinical oncology}, -volume = {37}, -year = {2019}, -accession_number = {EMBASE 629301271}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer staging; *chemoradiotherapy; *monotherapy; *non small cell lung cancer; Adult; Brain; Comparative effectiveness; Conference abstract; Controlled study; Disease course; Double blind procedure; Drug combination; Drug safety; Drug therapy; Female; Gene expression; Human; Male; Pharmacokinetics; Phase 3 clinical trial; Protein expression; Quality control; Radiotherapy; Randomization; Randomized controlled trial}, -abstract = {Background: cCRT improves survival vs RT alone and is a global standard of care in patients (pts) with stage III NSCLC, but survival remains poor for these pts. Combining PD‐1/PD‐L1‐targeting immunotherapies and cCRT may lead to synergistic activity and improved outcomes. Tislelizumab (anti‐PD‐1) demonstrated clinical activity and tolerability in solid tumors, including NSCLC. This phase III, randomized, double‐blind, placebo‐controlled study (RATIONALE 001) will evaluate efficacy and safety of tislelizumab + cCRT Methods: Pts (N ≈ 840) will be randomized 1:1:1 in a 3‐arm study design to evaluate whether the timing of giving tislelizumab earlier upfront with cCRT in addition to as consolidation (Arm 1) or giving tislelizumab as consolidation only (Arm 2) will improve outcomes vs cCRT alone (Arm 3; Table). RT will be given in 2 Gy fractions to a target dose of 60 Gy (30 fractions). Chemotherapy will be investigator's choice of cisplatin + etoposide or carboplatin + paclitaxel. A safety analysis specific to the cisplatin + etoposide component of the cCRT + tislelizumab combination is planned. All sites must pass a radiation quality assurance review process. The primary endpoint is PFS. Secondary endpoints include ORR, OS, OS at 24 months, and safety. As an exploratory endpoint, blood and tumor biomarkers will be assessed for correlations with clinical benefit. With a one‐sided α of 1.25%, a total of 580 PFS events are required to allow ≈ 90% power to detect a HR for progression or death of 0.7 for either pairwise comparison (Arm 1 vs Arm 3 or Arm 2 vs Arm 3). Key eligibility criteria are locally advanced, unresectable, stage III NSCLC; FDG‐PET and brain imaging confirmation of stage III status; no prior treatment; and ECOG PS ≤ 1. PD‐L1 expression assessment is not required prior to randomization. EudraCT number 2018‐001132‐22.}, -DOI = {10.1200/JCO.2019.37.15_suppl.TPS8574}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01990776/full} -} - - -Record #198 of 538 -@article{Ratto96, -author = {Ratto, GB, Zino, P, Mirabelli, S, Minuti, P, Aquilina, R, Fantino, G, Spessa, E, Ponte, M, Bruzzi, P, and Melioli, G}, -title = {A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma}, -journal = {Cancer}, -volume = {78}, -number = {2}, -review groups = {Anaesthesia; SR-CANCER; Lung Cancer; Gynaecological, Neuro-oncology and Orphan Cancer}, -pages = {244‐251}, -year = {1996}, -accession_number = {PUBMED 8673999}, -publication type = {Journal article}, -keywords = {Antineoplastic Agents [therapeutic use]; Carcinoma, Non‐Small‐Cell Lung [radiotherapy, surgery, *therapy]; Combined Modality Therapy; Follow‐Up Studies; Humans; Immunotherapy, Adoptive; Infusions, Intravenous; Injections, Subcutaneous; Interleukin‐2 [administration & dosage, adverse effects, *therapeutic use]; Lung Neoplasms [radiotherapy, surgery, *therapy]; Lymphocytes, Tumor‐Infiltrating [*immunology]; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local [pathology, prevention & control]; Neoplasm Staging; Neoplasm, Residual; Pneumonectomy; Postoperative Care; Survival Rate; Treatment Outcome}, -abstract = {BACKGROUND: A previous pilot study from our group suggested that: (1) adoptive immunotherapy (A1) with tumor‐infiltrating lymphocytes (TIL) and recombinant interleukin‐2 (rIL‐2) may be applied with safety to more than 80% of the patients who had surgery for Stage III nonsmall cell lung carcinoma (NSCLC); and (2) AI could be useful in patients with locally advanced disease. The present randomized study was planned to assess the efficacy of AI in the postoperative treatment of Stage II, IIIa, or IIIb NSCLC: METHODS: TIL were expanded in vitro from tissue samples obtained from the surgically removed specimens of 131 patients. Eighteen cultures yielded no growth of TIL. The remaining 113 patients were stratified according to disease stage and randomized to receive AI or standard chemoradiotherapy. TIL were infused intravenously 6 to 8 weeks after surgery, rIL‐2 was administered subcutaneously at escalating doses for 2 weeks, and then at reduced doses for 2 weeks and then for 2 to 3 months. RESULTS: Three‐year survival was significantly better (P < 0.05) for patients who underwent AI than for controls. AI was of no benefit to patients with Stage II NSCLC, potentially useful to patients with Stage IIIa NSCLC (P = 0.06), and significantly advantageous to patients with Stage IIIb (T4) NSCLC (P < 0.01). For patients with Stage III NSCLC, local relapse (but not distant relapse) was significantly reduced following AI (P < 0.05). CONCLUSIONS: AI should be considered when designing future adjuvant therapy protocols for the treatment of NSCLC:}, -DOI = {10.1002/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00126722/full} -} - - -Record #199 of 538 -@article{NCT0492437421, -author = {NCT04924374,}, -title = {Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy}, -journal = {https://clinicaltrials.gov/show/NCT04924374}, -year = {2021}, -accession_number = {CTgov NCT04924374}, -publication type = {Trial registry record}, -keywords = {Antibodies, Monoclonal; Lung Neoplasms}, -abstract = {Lung cancer is a leading cause of mortality worldwide, and its treatment and prognosis are being revolutionized by immunotherapy. The gut microbiome has been shown able to modulate the antitumor efficacy of immunotherapeutic agents in pre‐clinical models, demonstrating that patients can be stratified into responders and nonresponders to immunotherapy on the basis of their microbiota composition. Fecal microbiota transplants have demonstrated to improve the efficacy of immunotherapy in animal models. In this study, investigators will include 20 stage III/V non‐small cell lung cancer naïve for PD/PD L‐1 inhibitors that require treatment in monotherapy or combined with chemotherapy as consolidation strategy after concurrent chemotherapy and radiotherapy (stage III), upfront treatment (stage IV patients with PDL1 status > 50%) or as second line strategy for those patients with advanced disease who progressed to chemotherapy alone. The participants will be randomized to receive either fecal microbiota capsules from 3 donors selected based on the fecal abundance of bacterial taxa shown to correlate with a greater response to immunotherapy or not, in combination with the PDL/PDL1 agent. The primary outcome will be safety. The secondary outcomes will be treatment response (iRECIST criteria). Investigators will also examine engraftment of donor's microbiota on host microbiota using Illumina DNA shotgun sequencing, changes in the bacterial metabolism using metaproteomics, and in the plasma metabolite fingerprint by untargeted mass spectrometry in bacterial and plasma samples, and changes in peripheral immune cells subpopulations and antitumoral immunity. MORELIA could improve the prognosis of a lung cancer in a subset of patients with limited therapeutic options and inform on how to exploit host‐microbiota interactions with tailored fecal microbiota transplantation to boost the clinical response to immunotherapy in advanced cancer.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02278406/full} -} - - -Record #200 of 538 -@article{Vokes17, -author = {Vokes, E}, -title = {New developments for systemic therapies in stage III NSCLC}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {1}, -pages = {S49‐S50}, -year = {2017}, -accession_number = {EMBASE 615339410}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *non small cell lung cancer; *radiosensitization; *systemic therapy; Antineoplastic activity; Bone marrow tumor; Clinical trial; Controlled clinical trial; Controlled study; Drug combination; Drug therapy; Exploratory research; Gene amplification; Gene mutation; Gene overexpression; Human; Human cell; Immunotherapy; Induction chemotherapy; Lung metastasis; Major clinical study; Median survival time; Molecularly targeted therapy; Oncology; Overall survival; Phase 2 clinical trial; Preclinical study; Radiotherapy; Randomized controlled trial; Toxicity; Vaccination}, -abstract = {Concomitant chemoradiotherapy is currently the most widely accepted standard of care for patients with locoregionally advanced NSCLC. Induction chemotherapy represents an evidence‐based alternative and is a particular attractive prior to surgery in patients with marginally resectable disease.1 Over the past two decades, the regimens of cisplatin and etoposide and carboplatin and paclitaxel with concurrent radiotherapy, respectively have been most widely used, with cisplatin and vinorelbine with radiotherapy as possible alternative. More recently interest in the cisplatin/pemetrexed/radiotherapy combination has gained interest based on the superior toxicity and efficacy profile of this regimen in the stage IV setting for patients with non‐squamous cell malignancies.2 In addition, it is possible to administer this combination of drugs at systemic doses together with radiotherapy.3 In the randomized phase III PROCLAIM study, this regimen was directly compared with etoposide and cisplatin. The goal of this trial was to establish superiority of this regimen. The trial was closed prior to full enrollment with approximately 300 patients per arm evaluated, due to futility for superiority. Median survival for both study groups was very similar at 26.8 and 25.0 months, respectively and better than statistically assumed.4 Additional chemoradiotherapy regiments of current interest include the addition of the PARP inhibitor veliparib to chemoradiotherapy as recently presented. 5 Over the last decade, systemic therapy for patients with metastatic lung cancer has been transformed through the use of tumor mutation analyses and targeted therapies as well as the emergence of immune‐oncology. However, application of these strategies to the stage III setting has been slow and no definitive data exist currently to support these strategies in the curative intent setting. The addition of cetuximab to chemoradiotherapy did not result in a survival benefit in RTOG 0612.6 There are, however several ongoing trials that will be described, including RTOG 1306‐Alliance 31101. In this trial patients with EGFR mutation or an alk translocation are randomized to either induction chemotherapy with the appropriate targeted agent (erlotinib and crizotinib, respectively) followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone. This trial is actively accruing patients. Regarding immune‐ oncology, a trial evaluating a liposome‐based MUC vaccine (tecemotide) has been completed. MUC1 is a mucinous glycoprotein that is overexpressed and aberrantly glycosylated in NSCLC and a vaccination strategy was supported by preclinical studies as well as clinical data in a stage III subgroup analysis of an earlier exploratory trial. Butts et al7 reported on a randomized trial in which patients completing locoregional sequential or concurrent therapy were randomized to placebo versus tecemotide vaccination therapy reporting a trend for improved overall survival that was statistically significant in the subset analysis of patients receiving concurrent radiotherapy as their primary therapy. Further investigations of this agent however were halted following emergence of additional negative data from a Japanese phase II trial that remains unpublished. Regarding PD‐1 or PDL1 inhibitors, trials have recently been activated investigating the addition of such agents in the consolidation setting following primary treatment of patients with unresectable SCLC. For example, in the 'Pacific' trial patients are randomized in a 2‐1 fashion to durvalumab for up to 12 months or placebo. In the Alliance, a trial looking at induction chemotherapy with atezolizumab is currently in the process of activation. Here patients will receive induction chemotherapy with atezolizumab for up to four cycles followed by concurrent chemoradiotherapy and additional adjuvant immune therapy. These strategies are well supported by preclinical data showing irradiation upregulating PD1 expression on myeloid and tumor cells and synergistic amplification of radiation antitumor effects by PD‐L1 blockade.8 Updated information on these trials and relevant preclinical data will be presented.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01734121/full} -} - - -Record #201 of 538 -@article{EUCTR2014-003084-37-CZ14, -author = {EUCTR2014-003084-37-CZ,}, -title = {Evaluation of safety and efficacy of DCVAC/LuCa (immunotherapy of lung cancer) in patients with metastatic lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2014-003084-37-CZ}, -year = {2014}, -accession_number = {ICTRP EUCTR2014‐003084‐37‐CZ}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: DCVAC/LuCa Product Code: DCVAC/LuCa Pharmaceutical Form: Suspension for injection INN or Proposed INN: DCVAC/LuCa Other descriptive name: CELL SUSPENSION CONTAINING DENDRITIC CELLS Concentration unit: Other Concentration type: equal Concentration number: 10000000‐ CONDITION: Stage IV Non‐Small Cell Lung Cancer ; MedDRA version: 20.1 Level: PT Classification code 10025070 Term: Lung carcinoma cell type unspecified stage IV System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Respiratory Tract Diseases [C08] PRIMARY OUTCOME: Main Objective: To compare efficacy of DCVAC/LuCa + chemotherapy without immune enhancers vs. chemotherapy alone in patients with stage IV NSCLC, as measured by overall survival (OS). Primary end point(s): OS defined as the time from the date of randomization to the date of death due to any cause. Secondary Objective: • Comparison of PFS in patients treated with DCVAC/LuCa + chemotherapy without immune enhancers vs. chemotherapy alone.; • Comparison of safety in patients treated with DCVAC/LuCa + chemotherapy without immune enhancers vs. chemotherapy alone.; • Further comparison of efficacy of DCVAC/LuCa + chemotherapy without immune enhancers vs. chemotherapy alone, as measured by objective response rate (ORR) and duration of response (per RECIST 1.1); Timepoint(s) of evaluation of this end point: The primary efficacy analysis will be performed approximately 12 months after the last patient randomization. SECONDARY OUTCOME: Secondary end point(s): PFS ; Safety parameters as AEs, SAEs, laboratory abnormalities, vital ; signs ; ORR and duration of response (per RECIST 1.1) ; Timepoint(s) of evaluation of this end point: The primary efficacy analysis will be performed approximately 12 months after the last patient randomization. INCLUSION CRITERIA: 1 Histologically or cytologically confirmed non‐small cell lung cancer (NSCLC) of either adenomatous, squamous or large cell carcinoma differentiation; mixed tumors will be categorized by the predominant cell type. 2 Advanced NSCLC (stage IV unresectable disease) 3 Patients must have measurable or non‐measurable disease 4 Patients (male and female) = 18 years 5 Eastern Cooperative Oncology Group (ECOG) Performance status 0‐1 6 Patients must have recovered from toxicity of any prior therapy (e.g. surgery, radiotherapy, or therapy for other diseases than NSCLC). Recovery is defined as less than or equal to grade 2 toxicity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (except alopecia 7 Laboratory criteria 7.1 Platelet count of at least 100,000/mm3 (100 x 109/L) 7.2 White blood cells (WBC) greater than 4,000/mm3 (4.0 x109/L) 7.3 Hemoglobin (Hb) at least 9g/dL (90 g/}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01852537/full} -} - - -Record #202 of 538 -@article{West18, -author = {West, HJ}, -title = {Debate #1: locally Ablative Therapies Should Be Standard Treatment for Patients with NSCLC Oligometastese (PRO)}, -journal = {Journal of thoracic oncology}, -volume = {13}, -number = {10}, -pages = {S248}, -year = {2018}, -accession_number = {EMBASE 2001208699}, -publication type = {Journal article; Conference proceeding}, -keywords = {*ablation therapy; *cancer patient; *non small cell lung cancer; Adult; Advanced cancer; Brain; Cancer prognosis; Cancer recurrence; Cancer surgery; Cancer survival; Case study; Clinical article; Complication; Conference abstract; Disease control; Distant metastasis; Driver; Drug safety; Drug therapy; Female; Horse; Human; Immunotherapy; Local therapy; Long term survival; Lung lesion; Maintenance therapy; Male; Metastasis resection; Minimal residual disease; Molecularly targeted therapy; Monotherapy; Multicenter study; Mutation; Nonhuman; Oncology; Open surgery; Overall survival; Phase 2 clinical trial; Physician; Practice guideline; Primary tumor; Progression free survival; Prospective study; Radiotherapy; Randomized controlled trial; Retrospective study; Selection bias; Surgery; Systemic disease; Systemic therapy; Theoretical study; Thoracotomy; Whole body radiation}, -abstract = {The longstanding dogma that local therapies do not apply for metastatic cancers like non‐small cell lung cancer (NSCLC) because “the horse is out of the barn” is predicated on two concepts that do not necessarily apply to a subset of patients with oligometastatic NSCLC. First, local ablative therapy (LAT) is assumed to be futile when the pace of the cancer is defined by a diffuse disease process. Second, LAT is presumed to incur challenging toxicities that limit its applicability. For patients with oligometastatic NSCLC, these limitations do not apply, making LATs a standard treatment strategy. Patients with a solitary brain or adrenal “precocious metastasis” have long been recognized as having a potential for prolonged survival after definitive treatment of both the primary tumor and the (usually) resected metastatic focus, with approximately 25% remaining alive and without evidence of recurrent cancer years later (1). This underscores that metastatic disease is not a binary variable that necessarily connotes a diffuse process and highlights that effective local therapy can render some patients in the spectrum of metastatic disease durably cancer‐free. Patients with advanced NSCLC who are now strong candidates to benefit from LAT include those with oligometastatic disease, whether as their “de novo” presentation, induced oligometastatic disease after highly effective systemic therapy, “oligorecurrent” disease following prior treatment, or “oligoprogressing” disease after a prolonged duration of good disease control (2). The population of appropriate candidates has increased in recent years due to the growing range of systemic therapies that may induce deep and prolonged responses that becomes an oligometastatic state, or sustained disease control prior to oligoprogression. Along with the minority of patients with driver mutations who benefit dramatically from targeted therapies, a majority of patients with NSCLC who receive immunotherapy alone or in combination with chemotherapy can now achieve a good response to their first line systemic therapy. Along with a greater anticipated pool of strong candidates with oligometastatic NSCLC, LATs can now be pursued with markedly lower risk for the same or greater efficacy. Surgery to resect sites of metastatic/residual disease is typically feasible as a minimally invasive approach with good outcomes but fewer complications and easier recovery than the historical open surgeries required in the past (3). At the same time, stereotactic ablative body radiation (SABR) for primary or metastatic sites has now become widely established as an effective and generally very well tolerated option for patients (4), with a steadily growing body of evidence leading to wider availability of SABR. But are the theoretical benefits from LAT realized in this setting? Retrospective case series have consistent demonstrated that a subset of patients with oligometatatic NSCLC can achieve very favorable outcomes, particularly in terms of progression‐free survival (PFS) as well as overall survival (OS) in some series (5). Of course, it is not possible to determine from a retrospective case series whether these patients do extremely well because of the intervention or the selection bias due to their candidacy for LAT. Prospective randomized trial results up to this point have been limited but highly supportive of significant benefits. An MD Anderson‐led trial for patients with <3 sites of residual disease after three months of initial systemic therapy, testing LAT vs. maintenance therapy or surveillance alone, demonstrated a benefit in PFS so profound for LAT (median 11.9 vs. 3.9 mo, HR 0.35; LR p = 0.0054) that the trial was closed early by the Data Safety Monitoring Committee, with 49 patients randomized (6). Though the data from this trial were too immature to demonstrate a significant difference in OS, there was a significant improvement in the time to development of new metastatic sites. A similar trial from UT‐Southwestern was also terminated after just 29 patients were enrolled, after demonstrating a similarly dramatic difference in PFS favoring the LAT arm (7). Notably, PFS interpretation in studies of LAT is limited by the fact that the most common site of progression is in the area(s) of known disease, but the fact that LAT extends the time to development of new and distant metastases illustrates that local therapy can change the trajectory of systemic disease. It is important to offer some caveats. First, LAT is an appropriate standard only for the subset of patients with very limited foci of disease that are amenable to eradication with LAT and without a more diffuse disease process. Whether the subset of patients for whom LAT is a standard should be 1‐2 or 3‐5 lesions has yet to be clarified, but it is critical to apply LAT selectively, just as a molecularly targeted therapy or pembrolizumab monotherapy confers benefits only selectively. Broadening the treated population excessively will dilute the value compared to that in a more narrowly defined subset. Second, LAT cannot be presumed or insinuated to be curative in the setting of oligometastatic NSCLC, but like immunotherapy or targeted therapy, it should be considered as a standard based on it conferring a significant improvement in PFS without attendant significant toxicities, and/or time to new metastases, and potentially OS. Despite the limited prospective data, the NCCN recommends consideration of LAT for patients with oligometastatic NSCLC in the various clinical settings outlined above (8). Clinical trials of LAT for oligometastatic NSCLC are ongoing, but with such substantial potential benefits alongside such limited anticipated risks, LAT for appropriate patients is rightly considered a standard for appropriately selected patients. References: 1) Congedo MT, Cesario A, Lococo F, et al. Surgery for oligometastatic non‐small cell lung cancer: 137 long term results from a single center experience. J Thorac Cardiovasc Surg 2012; 144 (2): 444‐ 138 452. 2) Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13 (1): 8‐10. 3) Mutsaerts ELAR, Zoetmulder FAN, Meijer S, et al. Long term survival of thoracoscopic metastasectomy vs metastasectomy by thoracotomy in patients with a solitary pulmonary lesion. Euro J Surg Onc 2002; 28 (8): 864‐868. 4) Shults DB, Filippi AR, Thariat J, et al. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. J Thorac Oncol 2014; 9 (10): 1426‐1433. 5) Griffloen GH, Toguri D, Dehele M, et al. Radical treatment of synchronous oligometastatic non‐small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer 2013; 82 (1): 95‐102. 6) Gomez DR, Blumenschein Jr. GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non‐small‐cell lung cancer without progression after first‐line systemic therapy: a multicentre, randomised, controlled phase 2 study. Lancet Oncol 2016; 17 (12): 1672‐1682. 7) Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non‐small‐cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 2018: 4(1): e173501. https://doi.org/10.1001/jamaoncol.2017.3501 8) NCCN clinical practice guidelines in oncology (NCCN guidelines): non‐small cell lung cancer. Version 5.2018. Website: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf, accessed 6/29/2018. Keywords: oligometastatic, LAT, SABR}, -DOI = {10.1016/j.jtho.2018.08.114}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01654254/full} -} - - -Record #203 of 538 -@article{ChiCTR200003678220, -author = {ChiCTR2000036782,}, -title = {Phase II randomized, open, controlled trial for PD-1 monoclonal antibody combined with platinum-containing chemotherapy versus PD-1 monoclonal antibody for first-line treatment of recurrent or advanced metastatic non-small cell lung cancer with positive PD-L1 expression}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2000036782}, -year = {2020}, -accession_number = {ICTRP ChiCTR2000036782}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: A:Non‐squamous cell carcinoma: Pembrolizumab + platinum + Pemetrexed. squamous cell carcinoma: Pembrolizumab+nab‐paclitaxel+platinum;B:Pembrolizumab; CONDITION: non‐small cell lung cancer PRIMARY OUTCOME: ORR;PFS;OS;TRAE; INCLUSION CRITERIA: 1. Aged 18 to 75 years; 2. Patients with advanced (stage IV) or recurrent NSCLC confirmed by histopathology or cytology according to AJCC TNM stage (8th edition); 3. There is at least one measurable lesion according to RECIST 1.1 standard, and the lesion has not received radiotherapy; 4. The patient has not received systematic treatment before; 5. Patients with positive EXPRESSION of PD‐L1 (TPS>=1%) who were provided with detectable tissue samples before enrollment and confirmed by the central laboratory; 6. Patients with negative EGFR‐sensitive mutation and ALK fusion gene test results by genetic testing; 7. ECOG score 0‐1, and the expected survival time is more than 3 months; 8. Patients may have a history of brain/meningeal metastasis, but must undergo local treatment (surgery/radiotherapy) prior to study initiation and be clinically stable for at least 1 month (corticosteroid administration prior to the first administration of the stu}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02185084/full} -} - - -Record #204 of 538 -@article{De Ruysscher19, -author = {De Ruysscher, D, and Nakaerts, K}, -title = {ES23.04 Optimal Supportive Care During and After Concurrent Chemoradiotherapy and I/O}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S71}, -year = {2019}, -accession_number = {EMBASE 2003406477}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; Adult; Advanced cancer; Adverse drug reaction; Breast cancer; Cancer patient; Cancer staging; Cancer survival; Clinical evaluation; Conference abstract; Correlation coefficient; Coughing; Disease free survival; Double blind procedure; Drug therapy; Dyspnea; Endoscopy; Esophagus candidiasis; Esophagus motility; Female; Gastritis; Honey; Hospital patient; Human; Lozenge; Major clinical study; Non small cell lung cancer; Odynophagia; Overall survival; Pain assessment; Patient care; Prevention; Prospective study; Radiation injury; Radiotherapy; Radiotherapy dosage; Randomized controlled trial; Side effect; Vomiting}, -abstract = {Concurrent chemotherapy and radiotherapy (CCRT) is the treatment of choice for most fit patients with locally advanced NSCLC. Recently, adjuvant durvalumab has improved the overall survival further. However, CCRT is a toxic treatment. Treatment‐related deaths occur in a few percent of patients and many suffer severe side effects that require medical interventions and even in‐patient care. In contrast to extensive research on infections and emesis, most data on other important side effects are scant. Two examples of this are acute esophagitis and cough and dyspnea. Correlation between dysphagia and endoscopic findings In a prospective trial with 38 patients receiving radiotherapy alone for lung cancer, an endoscopy was done during radiotherapy when patients had received a dose of 30‐40 Gy on the esophagus. Eighteen patients (47 %) had dysphagia of any grade, but only in 12 of them (67 %) endoscopy showed esophagitis. Of the remaining 20 patients without complaints, 5 (25 %) had endoscopic signs of esophagitis. Gastritis was found in 18 patients (47 %), with or without esophagitis. In another study, 82 NSCLC patients were evaluated by endoscopy. There was a good correlation between the RTOG clinical score for dysphagia and the endoscopic findings (Spearman rank correlation coefficient 0.428; p< 0.0001). All patients with clinical grade 3 dysphagia had endoscopic grade 2 or 3 esophagitis. Also in case of RTOG grade 2 dysphagia, all patients had endoscopic esophagitis, although 40 % had endoscopic grade 1 and 27 % had endoscopic grade 3 esophagitis. Of patients with or without only mild (grade 1) dysphagia, 11 % showed grade 3 endoscopic esophagitis. Sixteen percent of patients has esophageal candidiasis, but its relation with dysphagia or endoscopic grade of esophagitis was not reported. No data on the incidence of gastritis were given. Effect of radiotherapy on esophageal motility An impaired esophageal motility may also lead to dysphagia. The esophageal transit time (ETT) before and during (10 Gy and 30 Gy) radiotherapy alone was evaluated in 11 patients. An increase in the ETT was seen in 9 of 11 patients (82%) (p<0.05). The ETT was also investigated in 18 breast cancer patients receiving radiotherapy to the inner quadrants of the breast using a dose of 50 Gy/ 25 fractions. The cranial part of the esophagus received a mean dose of 6 Gy/ 25 fractions, and the distal two‐thirds a mean dose of 15.3 Gy/ 25 fractions. Comparing the ETT before and after radiotherapy, for the upper third and the distal two‐thirds of the esophagus, the ETT increased from 4.77 ± 1.08 sec. to 6.92 ± 2.15 sec., from 11.22 ± 2.85 sec to 23.30 ± 5.65 sec. and from 11.61 ± 2.97 sec. to 23.74 ± 5.70 sec., respectively (p<0.001). Because of the motility impairment even at very low radiotherapy doses, the use of proton pump inhibitors is logical. Prevention and treatment of acute esophagitis In a randomized study with advanced NSCLC patients, treated with radiotherapy alone or radiotherapy plus amifostine, amifostine reduced the incidence of esophagitis in week 4 during radiotherapy from 42 % (31/73) to 4 % (3/73) (p<0.001), without decreasing the tumor response 2 months after treatment. In a larger randomized series of the RTOG, 243 stage II‐III NSCLC patients were enrolled and randomized between carboplatin‐paclitaxel concurrent chemo‐radiotherapy with or without amifostine. No significant differences between the arms regarding overall survival, disease‐free survival or long‐term toxicity were observed. In another study, 60 stage III NSCLC patients were randomized between concurrent carboplatin‐paclitaxel and radiotherapy with or without amifostine. No significant difference in esophagitis was observed. Therefore, amifostine has no consistently proven effect of preventing acute radiation‐induced esophagitis. In a small double‐blind study, 14 stage III NSCLC patients were randomized between placebo or prophylactic indomethacin. Endoscopically‐assessed esophagitis seemed to be milder, but no firm conclusions could be drawn. Another small, placebo‐controlled randomized trial, investigated naproxen in 28 stage III NSCLC patients receiving radiotherapy alone. There were no differences in clinical or endoscopic esophagitis rates. Eight patients (29 %) developed esophageal candidiasis, with no difference between the groups. A placebo‐controlled randomized trial could not demonstrate a beneficial effect of sucralfate on dysphagia. In NRG/ RTOG 1012, patients were randomized between prophylactic Manuka honey, either in liquid or in lozenge form, and standard supportive care during concurrent chemo‐radiotherapy for NSCLC. Standard supportive care consisted of a compound containing viscous lidocaine, an antacid such as magnesium aluminum oxide, and liquid or solid oxycodone, 5–10 mg, every 3 hours as needed. The primary endpoint was patient‐reported pain on swallowing utilizing an eleven point (0–10) scale at 4 weeks (Numerical Rating Pain Scale, NRPS). Fifty‐three patients were randomized to supportive care, 54 randomized to liquid honey and 56 to lozenge honey. There was no significant difference in the primary endpoint of change in the NRPS at 4 weeks between arms. There were no differences in any of the secondary endpoints except for opioid use at 4 weeks during treatment between the supportive care and liquid honey arms (p=0.03), with 52 % vs. 67 % of patients experiencing no pain with liquid honey. No difference was observed with lozenge honey. with more patients on the supportive care arm taking opioids. However, the differences were only observed at 4 weeks and not at the end of radiotherapy. From this example, already, it is clear that more in‐depth knowledge of the physiopathology of radiation injury is needed. A joint task force between ESTRO and ESMO members will address a spectrum of supportive care interventions in patients receiving concurrent chemotherapy and radiotherapy for lung cancer. Keywords: Non‐Small Cell Lung Cancer, supportive care, esophagitis}, -DOI = {10.1016/j.jtho.2019.08.174}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01996308/full} -} - - -Record #205 of 538 -@article{UMIN00000744112, -author = {UMIN000007441,}, -title = {Pilot study of nutritional intervention by elemental diet for lung cancer during chemotherapy}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000007441}, -year = {2012}, -accession_number = {ICTRP UMIN000007441}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: We performed nutritional intervention by elemental diet (Elental) in patieints with non‐small cell lung cancer and small‐cell lung cancer for 16 weeks from first day of the initial chemotherapy. CONDITION: Lung cancer PRIMARY OUTCOME: Decrease ratio of body weight SECONDARY OUTCOME: Alb, Pre‐Alb, Transfferin, QOL, Side effects, Overall survival, Progression free survival, one year survival rate, chemotherapeutical drug, Chemotherapeutical drug compliance INCLUSION CRITERIA: "1)Histologically proven non‐squamous non‐small cell lung cancer 2)Patient who has measurable lesion by RECIST 3‐1)Non‐small cell lung cancer: Stage 3B/4 NSCLC 3‐2)Small cell lung cancer: extensive small‐cell lung cancer 4)ECOG performance status: 0‐1 5)Aged>=20 years 6)No chemotherapy, radiotherapy, immunotherapy as prior therapy as for NSCLC 7)Adequate organ functions WBC>= 4000/mm3 & <= 12000mm3 Neutro>=2000/mm3 Platelet >= 100000/mm3 Hemoglobin>= 9.5g/dL GOTand GPT< 2.5*the upper limit of normal Bilirubin<= 2.0mg/dL Serum creatinine<= 1.2mg/dL or 24hr creatinine clearance> 60mL/min PaO2>= 60Torr 8)Life expectancy >= 4months 9)Written informed consent"}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01831121/full} -} - - -Record #206 of 538 -@article{NCT0580638523, -author = {NCT05806385,}, -title = {Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers}, -journal = {https://clinicaltrials.gov/show/NCT05806385}, -year = {2023}, -accession_number = {CTgov NCT05806385}, -publication type = {Trial registry record}, -keywords = {Breast Neoplasms; Immune Checkpoint Inhibitors; Triple Negative Breast Neoplasms}, -abstract = {AIMS: The main goal of proposed study is to assess synergy of tumor cryoablation and immune checkpoint inhibitor in high‐risk breast cancer in humans. This will be achieved by comparing cryoablation alone and cryoablation in combination with pembrolizumab ‐ a [checkpoint inhibitor (anti PD‐1/PD‐L1 antibody) currently FDA approved as cancer therapy] with the current standard of care including surgical resection. The current standard of neoadjuvant/ adjuvant therapies will remain unchanged for ethical reasons of providing best‐known standard of care to all patients. OBJECTIVES: The investigators propose a prospective randomized exploratory trial where patients with clinical stage I/II, triple negative invasive breast cancer will be randomized to one of the three arms of the study: 1. Standard of care ‐ neoadjuvant therapy followed by surgical resection followed by appropriate adjuvant therapy as needed. 2. Cryoablation arm ‐ cryoablation followed by appropriate neoadjuvant therapy followed by surgical resection followed by appropriate adjuvant therapy as needed. 3. Cryoablation with Pembrolizumab ‐ Single dose of Pembrolizumab of 200 mg before (within 24‐48 hours) of cryoablation followed by appropriate neoadjuvant therapy followed by surgical resection followed by appropriate adjuvant therapy as needed. Outcome measures will include blood and tumor analysis of immune response with flow cytometry and cytokine analysis at baseline, after intervention, and before surgery. Tissue from core biopsy at baseline, repeat biopsy before chemotherapy and tumor resection will also be analyzed for tumor microenvironment. INTRODUCTION / BACKGROUND / SIGNIFICANCE: High Risk Breast Cancer and Need for Newer Treatment Approaches: Triple‐ negative breast cancer, which represent 15‐20% of all breast cancer diagnoses are considered high‐risk. While surgical resection remains the mainstay of treatment, therapeutic backbone includes neoadjuvant and adjuvant chemotherapy. For patients who continue to have significant residual disease even after surgical resection and completion of chemotherapy, further aggressive systemic therapies such as capecitabine are performed. Triple‐negative subtype is associated with the highest number of mutations across the genome and non‐metastatic disease is associated with 17‐20% local failure and 35‐ 40% distant failure at 5‐10 years of follow up. These data suggest that micrometastatic hematogenous spread happens in a substantial number of patients with operable high‐risk breast cancer and newer approaches are required that potentiate local control while simultaneously controlling the systemic spread of disease. Scope of Immune‐modulation: Cancer immunotherapy has experienced extraordinary success in recent decades. Antigens that can evoke anti‐tumor immune responses form a suitable immunotherapeutic target. The approach of T cell checkpoint blockade therapies has shown remarkable clinical responses in several types of solid cancers such as, melanoma, non‐small cell lung cancer, bladder cancer and mismatch repair‐ deficient cancers. An effective anti‐tumor immune response is thought to be initiated by the taking up of tumor antigens by antigen‐ presenting cells (APCs), which is turn present them, and provide co‐stimulatory signals to both CD4+ and CD8+ T cells. APCs, particularly dendritic cells, process antigens through an exogenous antigen processing pathway where tumor cell material is phagocytosed and converted into HLA class I and class II binding peptides that are presented to CD8+ (cross‐presentation) and CD4+ T cells, respectively. Utilizing this knowledge, recent phase 1 trials have reported enhanced response to immune checkpoint inhibitor therapy in combination with conventional chemotherapy in triple‐negative breast cancers. Certainly, percentage of tumor infiltrating lymphocytes (TILs) has been identified as an important immunologic parameter, particularly for high‐risk breast cancers, that correlates with response to systemic therapy, suggesting a strong role of host immune response in cancer control irrespective of therapeutic intervention. Limitation of Immune‐modulation ‐ T cells are key players in anti‐tumor immunity and therefore form the major target for immunotherapeutic research. The current breakthrough in cancer immunotherapy results from the identification and targeting of checkpoint mechanism involving CTLA‐4, PD‐1, and PD‐L1. CTLA‐4 and PD‐1 are co‐inhibitory receptors found on the surface of T cells. Upon binding to their corresponding ligands (CD 80/86 and PD‐L1/L2, respectively), T cells become anergic ‐ a physiologic mechanism of tolerance. In the context of tumor microenvironment, the aberrant expression along with chronic exposure to tumor antigens can lead to undesirable suppression of T cell immunity. Recently developed checkpoint blockers, such as PD‐1/ PD‐L1 inhibitor, pembrolizumab, has provide a new weapon against cancer with durable clinical responses and long‐term remissions. However, checkpoint blockade has been shown to be most effective in tumors with high mutation burden, in line with the notion that T cell recognition of neo‐antigens plays a major role in checkpoint blockade. Many studies show that when the tumor‐reactive T cell infiltrate is absent or low (low percentage of TILs), the substrate for checkpoint blockade is lacking. Additionally, majority of patients with so called hyper‐mutated tumors do not respond to checkpoint blockade due to immune‐editing, which compromises the T cells' ability to fulfill their cytotoxic activity of adequate tumor infiltration and recognition of tumor‐antigen‐loaded HLA class I molecules. Therefore enhancing antigen presentation within the tumor is essential for checkpoint blockade to be effective. Role of Ablative Therapies ‐ Particularly Cryoablation: Thermal ablation with cryotherapy, laser, radiofrequency, microwave, and focused ultrasound present a unique opportunity to address both, the primary tumor and the micrometastatic disease. The effects of tumor ablation are multifold: (1) the destruction of tumor mass, lowering tumor burden and (2) the release of tumor antigens, making them available for uptake by antigen presenting cells (APCs) and the treatment itself leads to (3) the release of damage associated molecular patterns (DAMPs) and (4) the induction of a physiological wound healing response. Ablation leads to creation of an in situ antigen depot containing all types of tumor protein, which leads to initiation of systemic anti‐tumor immune response that can potentially eliminate occult metastatic disease. Ablation of tumors at temperatures above 65 °C leads to denaturation of proteins. This can affect immune responses in opposing ways as high temperatures denature immune activating signals, such as danger signals like heat shock proteins (HSPs). Therefore cryoablation is the most promising ablative technique, as it offers minimal invasiveness, less damage to surrounding tissues, and better preservation of tumor antigens, and most robust data on immune stimulation. Immune Stimulation Effected by Cryoablation ‐ Deep freezing and thawing during cryoablation induces necrosis and the up‐regulation of DAMP molecules that render tumor cells more susceptible to APCs and tumor specific T‐cell‐mediated killing. Cryoablation upregulates DAMPs, such as HMG1, calreticulin, S100A8/A9 and HSP70, which stimulate the immune system through Receptor for Advanced Glycosylation End‐products (RAGE) and toll‐like receptors and enhance antigen presentation. Additionally, the central zone cytokine milieu resulting from cryoablation is typically a Th1 cytokine profile of IL‐2, INF‐γ, TNF‐α, and IL‐12. These cytokines and DAMPs presumably drive the cytotoxic CD8+ T‐cell response. Preclinical evidence supporting immune response of cryoablation: Several preclinical studies on cryoimmunology explored whether freezing the tumor and leaving it in situ would render the animal resistant to a re‐challenge. Animal models utilizing carcinoma and sarcoma cell lines in rabbits and mice demonstrated tumor‐ specific resistance to re‐challenge. Re‐challenge with same tumor cell lines showed resistance to growth in animals after cryoablation compared to surgical resection. Similar experience was reported by Blackwood and Cooper with models involving rats inoculated with myosarcoma and carcinosarcoma cell lines. Rats with cryoablated tumors were more likely to resist re‐challenge, and demonstrated regression of secondary tumors compared to surgically treated rats. Bagley compared cryoablation with surgery in using MCA‐10 fibrosarcoma in C57BL/6 mice, harvesting splenic lymphocytes at weekly intervals after treatment for cytotoxicity assays. Mice undergoing cryoablation had significantly higher cytotoxicity than surgically treated or untreated mice. Sabel studied MT‐901 mammary adenocarcinoma tumors in BALB/c mice treated with cryoablation or surgical resection. After re‐challenge, 86% of mice treated with surgery developed second tumors compared with 16% of mice treated with cryoablation. This was tumor‐ specific, as the cryoablation offered no protection against challenge with other cell lines. More recently, Kim utilizing renal cell carcinoma cell lines in BALB/c mice reported similar results. More recently, abscopal effect of tumor regression in untreated tumors in animal models where only one of the implanted tumors was cryoablated, has been reported as a result of systemic immune response. Clinical evidence supporting immune response of cryoablation: Although clinical use of cryoablation for cancer has recently expanded, there are relatively few studies examining the immunological impact in humans. Ravindranath measured the level of serum tumor gangliosides and their antibody titers in patients receiving cryoablation, radiofrequency ablation or resection of liver metastasis from colorectal cancer. Serum ganglioside levels were significantly higher in cryoablated patients compared to radiofrequency or surgery. Cryoablated patients also demonstrated higher titers of IgM against tumor gangliosides. Si studied 20 patients with prostate cancer undergoing cryoablation of primary tumor and reported an increase in in cytolytic activity against LNCaP, and an increase in number of IFN‐ɣ producing T cells. Thakur conducted a pilot study of cryoablation and GM‐SCF for patients with renal cell carcinoma metastatic to lung. GM‐CSF was infiltrated near a lung metastatic lesion selected for cryoablation. Additional GM‐CSF therapy was used post‐procedure. The combination of GM‐CSF and cryoablation produced an enhanced immune response in terms of cytotoxicity and serum antibodies. Limitation of Cryoablation: Despite the data reviewed above, immune response to cryoablation has not been uniform. Some preclinical studies on osteogenic sarcoma, and prostate cancer models, failed to show any increase in immune function after cryoablation. More importantly, several studies have reported immune suppression with cryosurgery. The majority of these studies involved fibrosarcoma cell lines in rats and showed decreased resistance to re‐challenge after cryoablation, as well increased growth of metastatic tumors and secondary tumors. From a breast cancer perspective, Sabel reported that a high freeze rate resulted in increased tumor‐specific T‐cells in the tumor draining lymph nodes, reduction in lung metastasis and improved survival compared to low freeze rates which also had more Tregs (CD3,CD4,CD127‐,CD25+). Therefore, the magnitude of systemic effect induced by cryotherapy alone has proven to be either insufficient or counter‐productive. Current understanding is that close to the ablative source, direct injury and cell death with necrosis releases tumor antigens and (DAMPs) which recruit and activate dendritic cells that in turn stimulate proliferation of T cells and immune components. Transition zone away from the ablative source causes indirect cellular injury and apoptotic cell death without release of DAMPs, which causes release of suppressive cytokines and T‐cell clonal deletion and anergy. Intuitively, cryoablation stimulates an immune response but the ultimate clinical impact is dictated by the ratio of CD4+ T‐effector cells to T‐regulatory cells. Higher T‐effector to T‐regulatory cell ratio promotes the more favorable CD8 cytotoxic T cell response. While CD8+ cytotoxic cells eliminate the primary tumor and systemic micrometastasis, it is important that anergy is kept in check and both effector (CD45RO+, CCR7‐) and central (CCR7+, CD45RO+) memory T‐cells are established for long‐term protective anti‐ tumor immunity. HYPOTHESIS: "Combination of cryoablation with Pembrolizumab for local control in high‐risk triple negative breast cancer is superior to surgical resection alone or cryoablation alone in generating antitumor immune response". METHODS: Site of Study: Proposed exploratory work is a randomized trial that will be conducted at Texas Tech University Health Sciences Center‐Breast Center of Excellence, UMC Cancer Center. Type of study: Prospective Randomized Trial ‐ hypothesis driven Experimental Design: The investigators propose a single blinded prospective randomized trial, where women with Stage I/II triple negative breast cancer will be enrolled in one of the three arms in 1:1:1 randomized fashion: (I) Control arm with neoadjuvant chemotherapy followed by lumpectomy/mastectomy with sentinel node biopsy +/‐ axillary dissection; (II) Intervention with cryoablation alone followed by neoadjuvant chemotherapy followed by lumpectomy/mastectomy with sentinel node biopsy +/‐ axillary dissection; (III) Intervention with cryoablation + Pembrolizumab followed by neoadjuvant chemotherapy followed by lumpectomy/mastectomy with sentinel node biopsy +/‐ axillary dissection. The treatment schedule is designed to optimize antigen exposure time. The trial will be registered at the National Clinical Trials Network once IRB approval is obtained. Subjects: All patients 18 and older with clinical stage I/II triple negative disease will be offered to participate. These patients will be screened during an oncology/surgery appointment by the study team. A computerized randomization list will be used for treatment arm assignment using the website: https://www.sealedenvelope.com/simple‐randomiser/v1/lists Inclusion Criteria: ‐ Females ‐ Stage I/II Cancer ‐ Age range 18 ‐ 90 years ‐ Diagnoses: Invasive carcinoma, ER ‐, PR‐, HER2‐ (triple negative) ‐ Radiology findings: Unifocal disease visible on ultrasound Exclusion Criteria: ‐ Additional primary cancer ‐ Inflammatory breast cancer ‐ History of autoimmune disease ‐ History of chronic immunosuppression ‐ Prior immunotherapy ‐ Recent vaccination (within 4 wks.) ‐ Prior radiation therapy ‐ Prior investigational agent therapy within last 1 year ‐ Pregnancy at the time of diagnosis and/ or treatment ‐ Breast feeding Study visits: Informed consent will be obtained then the patient will be randomized. All visit will coincide with standard of care visits. Next, the following will occur: Visit 1: Day 1: Baseline Blood draw; up to 20ml will be collected in EDTA tubes; the blood will be centrifuged at TTUHSC. Plasma will be used for cytokine analysis and phenotyping at TTU lab. One EDTA tube will be sent to University of Houston (throughout the study time‐points). Following outcomes will be measured: Cytokine analysis ‐ RNA seq PBMC analysis Baseline core biopsy tissue (already available from diagnostic workup) will be evaluated for: (2 unstained slides will be prepared for RNA seq from fixed tissue) ‐ TIL % ‐ RNA Seq tumor tissue Visit 2 (Group II & III Only) After Cryoablation: Day 3 (+/‐ 7 days): Post‐ablation blood draw (Group II & III)‐ up to 10ml of blood in EDTA tube(s): • Cytokine analysis Visit 3 (All groups) Pre Neoadjuvant Chemotherapy: Day 21 (+/‐ 14 days): Blood draw at the time of port insertion for chemotherapy‐ up to 20ml of blood in EDTA tubes: ‐ Immune phenotyping by flow cytometry ‐ Cytokine analysis ‐ RNA seq PBMC analysis ‐ Tumor biopsy will be repeated for TIL and RNA seq analysis Visit 4 (All groups): Post Chemotherapy Resection (approximately 6 months after original biopsy): Preoperative blood draw‐ up to 20ml blood in EDTA tubes (similar to baseline): ‐ Immune phenotyping by flow cytometry ‐ Cytokine analysis ‐ RNA seq PBMC analysis Surgical specimen tissue analysis (2 unstained slides from fixed tissues will be prepared for RNA seq) ‐ TIL% ‐ RNA seq tumor tissue Sample Size: Tumor‐infiltrating lymphocytes (TILs), particularly in the stroma of triple negative breast cancer are prognostic and predictive of response to therapy. Therefore, recommendations by the International TILs Working Group were used to calculate the sample size for this project. The percentage change of TILs is assumed to be 10% for the control arm and 50% for the treatment arm. A sample of 10 patients per group can achieve 80% power to detect a mean difference of 0.4 (0.5 vs. 0.1) with a standard deviation of 0.3, using a two‐sided two‐sample equal variance t‐test (alpha=0.05). Assuming 30% drop out rate, a total of 12 patients in each arm would suffice for a total of 36 patients; this would achieve a 90% power. This means that a minimum of 10 patients per arm and a maximum of 12 patients per arm will lead to a statistically meaningful study. Statistical Plan: Descriptive statistics will be used to compute the ranges, means, and variances for the independent variables standard care, cryo, cryo+pembro. This will suggest that the concentration of the observations around the mean, and variation of the observations from the means. The normality test will be considered to check whether or not data follow normal distribution. Normal quantile‐quantile plots (also called q‐q plots) will be utilized to determine if data sets come from a normal population. To detect the outliers (if there is any) several statistical measures will be taken into consideration. To check the homogeneity of variances for the independent variables standard care, cryo, cryo+pembro, Levene's test will be performed by setting up null and alternative hypotheses. To compare the significance difference among the means of the variables, a one‐way analysis of variance (ANOVA) will be performed. The null and alternative hypotheses for the means will be introduced. In ANOVA, statistical significance of the means will be tested (α = 0.05) by using the F‐test statistic. If the means are found statistical significant difference then the post‐hoc multiple comparisons tests will be performed. Post‐hoc multiple comparisons tests (LSD, Bonferroni, Scheffe, Tukey, etc.) will be utilized to detect the appropriate significant group means. If the samples do not meet the normality assumptions then several non‐parametric tests will be considered for the statistical analyses. Tumor Cryoablation: All registered patients will be randomized to one of the three arms of the study. Patients in arm II and III will receive cryoablation according to the following protocol (similar to the protocol used in ACOSOG Z1072 trial). Cryoablation Device: Cryoablation will be performed using the commercially available ProSense Cryosurgical System (IceCure Medical Ltd, Caesarea, Israel) consisting of a console, cryoprobe and associated liquid nitrogen (cryogen) Case Dewars. The console is a self‐contained unit that features an interface for controlling and monitoring the cryoablation procedure. It operates with standard 120 VAC (60Hz) power. Device Operation: The ProSense Cryosurgical System uses a closed system to circulate liquid nitrogen within the cryoprobe tip creating sub‐freezing temperatures that result in ablation of target tissue. The lesion is identified with ultrasound and the cryoprobe is placed in the center of the lesion under ultrasound guidance after adequate local anesthesia, and ablation is carried out according to predetermined freeze‐thaw‐freeze algorithm. The probe is then warmed by an internal electrical resistance heater and removed from the patient. Cryoablation Procedure: Tumor is identified using high‐resolution linear array ultrasound probe in two orthogonal views. Longest dimension of the tumor is identified for parallel insertion of the probe. This dimension is entered into the console; the console provides the length of cryoprobe tip to be past the lesion upon insertion. After insertion, the probe position is confirmed in two orthogonal views. Cryoablation is done using the freeze‐thaw‐freeze cycle according to the tumor size. Entire procedure is monitored under vision and saline is infiltrated to avoid skin frostbite by hydro‐ dissecting the skin away from the ice‐ball. Size of ice‐ball is recorded in orthogonal dimensions. In our protocol, if a patient has more than one lesions, only one lesion will be ablated; however biopsies from other lesions will be studied for abscopal affect. Infusion of Pembrolizumab and Dosing: As an initial step, the investigators confirmed the safety and tolerability of immune checkpoint inhibitors with tumor cryoablation in women with newly diagnosed breast cancer. One important consideration was selection of an immune modulating antibody. Pembrolizumab, an FDA‐approved antibody against PD‐1/PD‐L1, has a well‐established safety profile, and induces long‐term remissions lasting >10 years in 10‐20% of advanced melanoma patients. Furthermore, because T cells acutely upregulate expression of PD‐1/PD‐L1 after being exposed to antigens, which in turn may blunt the cytotoxic response, pembrolizumab is ideally suited for immune modulation in combination with cryoablation. Memorial Sloan Kettering Cancer Center (MSKCC) published a pilot study on this combination; no serious side effects attributable to ipilimumab were reported; no surgery was delayed. MSKCC used 10 mg/Kg as a single dose; however, since the studies report higher adverse events at that dose, the investigator propose the recommended 200 mg for IV over 90 minutes dose before cryoablation, which is the currently utilized dose in clinical setting for triple negative cancers. Methodology for Outcome Measures: The investigators will observe and monitor the immune response(s) following the cryoablation procedures with and without the pembrolizumab. Blood samples will be collected in EDTA‐blood collection tubes and then aliquoted for T‐cell phenotypic analysis, and plasma collection for cytokine/chemokine, and for RNA seq analysis, at the indicated time points. Pathology slides will be made for research from core biopsy samples at baseline and from lumpectomy and sentinel nodes at the time of surgery. Five slides will be made per specimen (after completion of routine pathology) for H&E and immunohistochemistry for immune cell infiltrates to calculate TILs percentage. All collaborators/Key personnel involved in performing the outcome measure analysis will be blinded to the randomization groups. Following are the details for outcome analysis: TIL Calculation: All tissue specimens that undergo routine pathology reporting will be evaluated for TIL reporting according to guidelines put forth by the International TILs Working Group. Change in TIL score between original core biopsy tissue and surgical tissue will be the focus of analysis to assess the impact of proposed interventions. Measurement of T‐cell Changes in Blood: T‐cell subtypes can be defined by differential expression of cell surface markers. The investigators will monitor T‐cells for activation, increased CD8+ effector T‐cells and development of effector and central memory. For T‐cell phenotyping, whole blood staining (100 µl/stain) will be performed with antibodies to CD3, CD4, CD8, CD25, CD27, CD45RO, CD127, CD137, ICOS, CCR7 and Ki67 with appropriate isotype controls. Following RBC lysis, the stained mononuclear cells will be run on an Attune NxT 14‐color flow cytometer (Thermofisher, Waltham, MA) and analyzed using FlowJo software (Becton, Dickinson and Company). T‐cells (CD3+, CD4+ or CD8+) will be analyzed for changes in naïve (CD27+, CCR7+, CD45RO‐), effector (CCR7‐, CD45RO‐), effector memory (CD27‐, CCR7‐,CD45RO+) and central memory (CD27+, CCR7+, CD45RO+) phenotypic markers as well as for activation (ICOS and CD137) and proliferation (Ki67). The investigators will further analyze for percentages of T‐regulatory cells (CD25+, CD127‐). The investigators will use this data to determine a T‐cell immune signature to correlate the effectiveness of the cryoabalation+/‐ Pembrolizumab to predict the long‐term anti‐tumor immunity. Plasma Cytokine/Chemokine Analysis: Our initial analysis will be to determine which cytokines/chemokines and what concentrations are detected in the blood following cryoablation +/‐ pembrolizumab and how their profiles are altered. The investigators will focus on the inflammatory and helper T‐cell cytokine profiles and how these cytokines influence and direct the T‐cell response. Additionally, the investigators will look at changes in chemokines. Their altered expression in malignancies have been shown to dictate leukocyte recruitment and activation, angiogenesis, cancer cell proliferation, and metastasis in all the stages of the disease. At baseline, 24‐48 hours post ablation, between pre chemotherapy, blood will be collected and plasma isolated by centrifuging 1‐2 mls of blood at 1‐2000 x g for 10 minutes and then aliquoting 120 µl into 0.65 mL microcentrifuge tubes. Standard of care group will only have 3 blood sample time points. Plasma samples will be analyzed with a Bio‐Plex 200 at Eve Technologies Corporation (Calgary, AB Canada) using the Human High Sensitivity T‐Cell Discovery Array 14‐plex (HDHSTC14): GM‐CSF, IFNy, IL‐1B, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8, IL‐10, IL‐12p70, IL‐13, IL‐17A, IL‐23, TNF‐a. DATA SHEET: See Excel spreadsheet. The RNA seq will be collected as heat maps for differentially expressed genes. RISKS: Blood draw risks: The risks of a blood draw include: pain, discomfort, bleeding, bruising, redness, infection where the needle enters the skin; feeling lightheaded, fainting. Cryoablation related risks: Cryoablation has been a very safe procedure; PI has been routinely offering this procedure to benign and cancer disease in the breast; so far, 18 cancer patients and 36 benign lesions have been subjected to the procedure. The following mild complications have been reported thus far: ‐ Bruising at the site of ablation ‐ self‐limited. ‐ Pain ‐ managed with OTC analgesics. ‐ Skin necrosis is a theoretical possibility however, following the procedure protocol; the investigators have never had this complication. Pembrolizumab related risks: There have been extensive studies on toxicities of immune checkpoint inhibitors. Standard recommended dose for Pemrolizumab is 200 mg IV per dose (approved by the FDA). Anticipated adverse effects include: ‐ Rash ‐ Diarrhea ‐ Constipation ‐ Nausea ‐ Weight loss ‐ Dry eyes ‐ Fatigue ‐ Headache ‐ Fever ‐ Joint pain ‐ Thyroid dysfunction Loss of Confidentiality: All data will be maintained in password‐protected files within the CRI and PI's office. All data will be de‐identified for compilation and analysis. All protocols for HIPAA compliance will be followed. However, minimal risk of breach in confidentiality is possible due to human error. BENEFITS: The patients in arm II and III may benefit by participation in the trial. If our intuition of immune modulation via combination of cryotherapy and checkpoint inhibitor drug actually affects the control of tumor, these two groups will directly benefit form participation. However, the control arm I is not going to benefit from the trial beyond providing a comparison arm for the study. The main goal of the proposed study is to identify a novel low‐risk treatment approach to these high‐risk cancers, which will ultimately benefit the future cancer patients. MONITORING: To ensure compliance with the study protocol, GCP guidelines, and TTUHSC Human Research Protection Program research policies and procedures during the conduct of the study, as well as quality data, a monitor in the Clinical Research Institute will conduct the monitoring of the study. The first monitoring visit will be conducted within two weeks after the first subject has been enrolled into the study. The succeeding monitoring visits will be scheduled periodically, but no less than every 2 months when there is an active study participant, at a mutually agreed timeframe by the PI and study monitor. All data collected will be 100% source document verified. The study monitor may inspect and audit all study documents, i.e. data collection forms, questionnaires, drug accountability, and medical records within the applicable confidentiality regulations. FUNDING: Applied for NIH grant R21}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02544185/full} -} - - -Record #207 of 538 -@article{ChiCTR230007639923, -author = {ChiCTR2300076399,}, -title = {Phase 3 multicenter randomized controlled study of consolidation immunotherapy for unresectable locally advanced non-small cell lung cancer receiving intensity modulated radiotherapy and Brachytherapy combined with platinum-containing chemotherapy}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2300076399}, -year = {2023}, -accession_number = {ICTRP ChiCTR2300076399}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Experimental group (group A):Insert plant radiation;The control group (group B):IMRT; CONDITION: Non‐small cell lung cancer PRIMARY OUTCOME: progression‐free survival PFS;security; SECONDARY OUTCOME: overall survival OS;ORR;DCR; INCLUSION CRITERIA: 1. Confirmed by pathological histology and cytology examination of non‐small cell lung cancer, clinical stage III (according to the international association for the study of lung cancer and lung cancer TNM staging the American joint committee on cancer classification system version 8), whether surgical resection should be decided by a multidisciplinary team, at least contains a thoracic surgery doctors to assess; 2. Ages 18 to 80 years; 3. No radiation therapy contraindications, expected survival more than 6 months after radiotherapy. (PACIFIC 5:1 days life expectancy for at least 12 weeks) 4. ZPS score 0 to 2 points; 5. Pulmonary function test: forced expiratory volume in one second. FEV1 acuity 1.2 liters per second, or 50 or more 9 ? ? ? meter value; 6. No other previous history of pulmonary malignant tumor, is not made for systemic chemotherapy or radiotherapy chest lung cancer; 7. Women of childbearing age must be within 14 days before}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02603310/full} -} - - -Record #208 of 538 -@article{CTIS2023-510089-28-0024, -author = {CTIS2023-510089-28-00,}, -title = {COMBINATORY IMMUNOTHERAPY-2 (COM-IT-2) A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy combined with extensive radiotherapyfor the treatment of stage IV non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTIS2023-510089-28-00}, -year = {2024}, -accession_number = {ICTRP CTIS2023‐510089‐28‐00}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Tecentriq 1 200 mg concentrate for solution for infusion,Product Code: PRD5434939,Pharmaceutical Form: SOLUTION FOR INFUSION,Other descriptive name: ,Strength: Atezolizumab 1200mg / 20mL,Product Name: OPDIVO 10 mg/mL concentrate for solution for infusion.,Product Code: PRD6183485,Pharmaceutical Form: SOLUTION FOR INFUSION,Other descriptive name: ,Strength: Nivolumab 10mg,Product Name: LIBTAYO 350 mg concentrate for solution for infusion.,Product Code: PRD7478447,Pharmaceutical Form: CONCENTRATE FOR SOLUTION FOR INFUSION,Other descriptive name: ,Strength: Cemiplimab 350mg / 7mL,Product Name: KEYTRUDA 25 mg/mL concentrate for solution for infusion,Product Code: PRD4323105,Pharmaceutical Form: SOLUTION FOR INFUSION,Other descriptive name: ,Strength: Pembrolizumab 25mg CONDITION: Non‐small cell lung cancer (Stage IV) Therapeutic area: Diseases [C] ‐ Pathological Conditions, Signs and Symptoms [C23] PRIMARY OUTCOME: Main Objective:The primary objective is to evaluate the acute toxicity (<3 months) and subacute toxicity (3‐6 months) of immunotherapy combined with extensive radiotherapy in patients with stage IV NSCLC. Primary end point(s):The primary objective is to evaluate the acute toxicity (<3 months) and subacute toxicity (3‐6 months) toxicity) of immunotherapy combined with extensive radiotherapy in patients with stage IV NSCLC compared with immunotherapy without radiotherapy. Secondary Objective:The secondary objectives are to evaluate measures of treatment effect (PFS, OS, DoR, ORR, TNT) and HRQoL between the treatment arms. SECONDARY OUTCOME: Secondary end point(s):Adverse events and laboratory values will be graded according to the NCI‐CTCAE version 5.0. and published Secondary end point(s):HRQoL will be evaluated at baseline, end of radiotherapy and at 3 and 6 months for both study arms and published. Secondary end point(s):Response will be evaluated by iRECIST 1.1 and RECIST 1.1. Survival data (PFS and OS) and response rates (RR and DOR) will be evaluated and published. INCLUSION CRITERIA: • Stage IV NSCLC with clinical indication of starting systemic treatment with immunotherapy alone or in combination with chemotherapy (first or later lines),Women of childbearing potential (WOCBP) should use a highly effective method during the treatment period and for at least 5 months after the last dose of immunotherapy to avoid pregnancy. Methods considered as highly effective birth control methods include combined (estrogen and progestogen containing) or progestogen‐only hormonal contraception associated with inhibition of ovulation (oral, intravaginal, injectable, implantable or transdermal), intrauterine device (including hormone‐releasing), male condom, bilateral tubal occlusion, vasectomised partner or sexual abstinence,Able to understand oral and written information and able to answer questionnaires,• Available core or excisional biopsy of a tumour lesion,• Measurable disease according to RECIST criteria (RECIST 1.1),• Eastern Cooperative Oncology Group (E}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02704126/full} -} - - -Record #209 of 538 -@article{ChiCTR210004491121, -author = {ChiCTR2100044911,}, -title = {Different modes of stereotactic radiotherapy combined with chemotherapy and immunotherapy for locally advanced / unresectable (stage III) non-small cell lung cancer: a prospective, randomized, controlled phase III study}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2100044911}, -year = {2021}, -accession_number = {ICTRP ChiCTR2100044911}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Group A:Stereotactic radiotherapy with tomo: GTV 60Gy / 20 times;Group B:Stereotactic radiotherapy with tomo: GTV 60Gy / 30 times; CONDITION: lung cancer PRIMARY OUTCOME: Progression Free Survival (PFS); INCLUSION CRITERIA: 1.They are willing to participate in the clinical study, fully understand and know the study and sign the master ICF (informed consent); 2.At the date of signing ICF, the age was over 18 years old; 3.Histologically or cytologically confirmed locally advanced unresectable stage III non‐small cell lung cancer (according to the 8th edition of the international society for the study of lung cancer (IASLC), Non squamous cell carcinoma: (1) Epidermal growth factor receptor (EGFR) mutation: subjects with known EGFR mutation need to be excluded (the detection method and results are approved by the research center and the sponsor, and the method conforming to NCCN or CSCO guidelines is recommended); subjects with unknown EGFR mutation status must be detected by the experimental method approved by our unit, if EGFR mutations were excluded. (2) For anaplastic lymphoma kinase (ALK) translocation and c‐ros sarcoma carcinogen 1‐receptor tyrosine kinase (ros1)}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02349201/full} -} - - -Record #210 of 538 -@article{Erraisse19, -author = {Erraisse, MA, Abboud, FZ, and Hassouni, K}, -title = {EP1.01-79 Chemoradiotherapy in Advanced Non Small Cell Lung Cancer}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S942}, -year = {2019}, -accession_number = {EMBASE 2003405726}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *chemoradiotherapy; *non small cell lung cancer; Adenocarcinoma; Adjuvant chemotherapy; Adult; Bone metastasis; Brain metastasis; Cancer adjuvant therapy; Cancer patient; Cancer prognosis; Cancer size; Cancer staging; Cancer survival; Clinical article; Conference abstract; Conformal radiotherapy; Controlled study; Counseling; Distant metastasis; Drug combination; Drug therapy; Dyspnea; Follow up; Hemoptysis; Histopathology; Human; Immunotherapy; Induction chemotherapy; Irradiation; Kidney function; Male; Micrometastasis; Middle aged; Neoadjuvant chemotherapy; Overall survival; Positron emission tomography‐computed tomography; Radiotherapy; Randomized controlled trial; Remission; Retrospective study; Simulation; Smoking; Squamous cell carcinoma; Thorax pain; University hospital}, -abstract = {Background: Advanced NSCLC is a frequent cancer among our patients. Delay in diagnosis and treatment leads to advanced stages that require complex treatment modalities and poor prognosis. We report our experience in term of epidemiological, diagnostic, therapeutic and prognostic aspects of this disease in our department. Method: This is a retrospective study of 38 cases of advanced NSCLC treated with concurrent chemoradiotherapy, collected in the radiotherapy department in the University Hospital Hassan II in Fez, between January 2012 and January 2017. All cancers were prooved histologically by biopsy. The standard treatment was concurrent chemoradiotherapy alone or after induction chemotherapy mostly due to a large tumor volume where radiotherapy is not feasible upfront. Chemotherapy drugs were mainly cisplatin‐based with vinorelbine or paclitaxel and in some cases carboplatin if renal function is not correct. Radiotherapy was delivered through 3D conformal technique after CT‐simulation and image fusion with CT or in rare cases PET‐CT. After completion of treatment, no patient received adjuvant chemotherapy. Immune therapy was not affordable due to the high price. Follow‐up was done clinically and with control CTscan. Tobacco control counseling was recommended to all our patients. Result: The average age was 59 years (38 to 81 years). The patients were all males and chronic smokers. Significant clinical symptoms were mainly chest pain, dyspnea and hemoptysis. There were 21 cases of adenocarcinoma, 17 cases of squamous cell carcinoma. 18 cases were classified as stage IIIA, 20 cases as stage IIIB. Neoadjuvant chemotherapy was received in 23 cases from 2 to 4 cycles. All patients received radiotherapy with doses to PTV between 60‐70Gy with concomitant chemotherapy including cisplatin or carboplatin. After an average follow‐up of 12 months, the evolution was marked by the occurrence of 2 deaths, distant metastasis in 14 patients (6 cases of cerebral metastasis and 8 cases of bone metastasis), 2 cases of progressive disease, 14 patients in complete clinical remission and are always followed, and 6 patients were lost to follow‐up, Conclusion: It is now proven that the survival of patients with locally advanced lung cancer is better if chemotherapy is combined with radiotherapy. The survival gain obtained is essentially related to better control of micro‐metastases even though the local control remains very poor. Some irradiation techniques seem to be able to improve this local control: conformal radiotherapy with intensity modulation, hypofractionation. Immue therapy concomitant to radiation might be the future but still needs randomized clinical trials to approve it. Keywords: Advanced NSCLC ‐ Chemotherapy ‐ Radiotherapy}, -DOI = {10.1016/j.jtho.2019.08.2052}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01996538/full} -} - - -Record #211 of 538 -@article{Wei20, -author = {Wei, X, Guo, Z, Zhang, W, Zhang, T, Chen, X, Dong, J, Han, D, Lei, T, Du, Q, Pang, Q, and Wang, P}, -title = {Safety and efficacy of programmed cell death-1 antibody SHR-1210 combined with concurrent chemoradiotherapy to treat locally advanced esophageal squamous cell carcinoma: a study protocol for an exploratory single-arm phase Ib trial}, -journal = {Precision radiation oncology}, -volume = {4}, -number = {4}, -pages = {113‐119}, -year = {2020}, -accession_number = {EMBASE 2007686037}, -publication type = {Journal article}, -keywords = {*chemoradiotherapy; *esophageal squamous cell carcinoma /diagnosis /drug therapy /radiotherapy; Adult; Aged; Alcohol consumption; Antineoplastic activity; Apoptosis; Article; Bleeding tendency /diagnosis; Cancer recurrence; Computer assisted tomography; Controlled study; Creatinine clearance; Drug efficacy; Drug safety; Echography; Female; Fever; Follow up; Human; Human tissue; Lung adenocarcinoma /diagnosis; Lung embolism /diagnosis; Lung volume; Lymphadenopathy /diagnosis; Major clinical study; Male; Merkel cell carcinoma /diagnosis; Metastatic colorectal cancer; Molecularly targeted therapy; Non small cell lung cancer; Overall survival; Phase 1 clinical trial; Phase 3 clinical trial; Platelet count; Positron emission tomography; Positron emission tomography‐computed tomography; Progression free survival; Quality of life; Questionnaire; Radiation dose; Randomized controlled trial; Thrombocytopenia /diagnosis; Total lung capacity; Tumor volume}, -abstract = {Objective: Esophageal squamous cell carcinoma (ESCC) is the most common pathological pattern in China, with poor prognosis due to its early and frequent metastasis. Definitive concurrent chemoradiotherapy is the standard treatment for inoperable locally advanced ESCC. Studies have shown promising efficacy of immune‐checkpoint inhibitors in ESCC. This study explores the safety and efficacy of immunotherapy combined with definitive concurrent chemoradiotherapy for locally advanced ESCC. Method: This study was an exploratory, open, single‐arm clinical trial involving 20 untreated patients with locally advanced ESCC. The patients were treated with eight cycles (4 weeks per cycle) of SHR‐1210 concurrently combined with 6 weeks of radiotherapy, and 4 weeks of chemotherapy and apatinib beginning from 4 weeks after the completion of radiotherapy to the end of treatment. Primary end‐points were treatment‐related adverse events, serious adverse events, and patients’ quality of life (European Organization for Research and Treatment of Cancer's Quality of Life Questionnaire (QLQ)‐C30 and QLQ‐OES18). Secondary end‐points were the objective response rate, progression‐free survival, and overall survival. Discussion: This phase Ib study evaluates the tolerability and efficacy of programmed cell death‐1 antibody along with definitive concurrent chemoradiotherapy in treating locally advanced ESCC. This novel combination is expected to yield fewer side‐effects and better survival.}, -DOI = {10.1002/pro6.1105}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02291454/full} -} - - -Record #212 of 538 -@article{Crombet Ramos21, -author = {Crombet Ramos, T, Santos Morales, O, Dy, GK, Leon Monzon, K, and Lage Davila, A}, -title = {The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer}, -journal = {Frontiers in oncology}, -volume = {11}, -year = {2021}, -accession_number = {EMBASE 635392336}, -publication type = {Journal article}, -keywords = {*non small cell lung cancer; Adenocarcinoma; CD4+ T lymphocyte; CD8+ T lymphocyte; Cancer immunotherapy; Cancer staging; Cell proliferation; Chemotherapy; Chronic disease; Disease exacerbation; EGFR signaling; Gene expression; Gene mutation; Histology; Human; Immune response; Immunosenescence; Inflammation; Innate immunity; Liver toxicity; Mutation; Neisseria meningitidis; Neutrophil lymphocyte ratio; Overall survival; Progression free survival; Protein expression; Quality of life; Review; Sensitivity analysis; Squamous cell carcinoma; Survival; Survival rate; Tumor associated leukocyte; Tumor growth; Tumor immunity; Tumor microenvironment; Tumor volume}, -abstract = {Advanced non‐small cell lung cancer (NSCLC) has faced a therapeutic revolution with the advent of tyrosine kinase inhibitors (TKIs) and immune checkpoints inhibitors (ICIs) approved for first and subsequent therapies. CIMAvax‐EGF is a chemical conjugate between human‐recombinant EGF and P64, a recombinant protein from Neisseria meningitides, which induces neutralizing antibodies against EGF. In the last 15 years, it has been extensively evaluated in advanced NSCLC patients. CIMAvax‐EGF is safe, even after extended use, and able to keep EGF serum concentration below detectable levels. In a randomized phase III study, CIMAvax‐EGF increased median overall survival of advanced NSCLC patients with at least stable disease after front‐line chemotherapy. Patients bearing squamous‐cell or adenocarcinomas and serum EGF concentration above 870 pg/ml had better survival compared to control patients treated with best supportive care as maintenance, confirming tumors’ sensitivity to the EGF depletion. This manuscript reviews the state‐of‐the‐art NSCLC therapy and proposes the most promising scenarios for evaluating CIMAvax‐EGF, particularly in combination with TKIs or ICIs. We hypothesize that the optimal combination of CIMAvax‐EGF with established therapies can further contribute to transform advanced cancer into a manageable chronic disease, compatible with years of good quality of life.}, -DOI = {10.3389/fonc.2021.639745}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02293322/full} -} - - -Record #213 of 538 -@article{Delmonte22, -author = {Delmonte, A, Bonanno, L, Landi, L, Andrikou, K, Dal Maso, A, Minuti, G, Papi, M, Metro, G, Attili, I, Piantedosi, F, Pilotto, S, Gori, S, Rossi, G, Buglioni, S, Giannarelli, D, and Cappuzzo, F}, -title = {EP08.01-030 Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: the Randomized SQUINT Trial}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S351}, -year = {2022}, -accession_number = {EMBASE 2020098518}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer combination chemotherapy; *squamous cell lung carcinoma; *strabismus; Adult; Adverse drug reaction; Blood toxicity; Bone metastasis; Brain metastasis; Cancer chemotherapy; Cancer patient; Cancer survival; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Drug combination; Drug therapy; Ex‐smoker; Follow up; Human; Human tissue; Immunotherapy; Liver metastasis; Lung metastasis; Major clinical study; Male; Overall survival; Phase 2 clinical trial; Preliminary data; Progression free survival; Randomized controlled trial; Side effect; Squamous cell carcinoma}, -abstract = {Introduction: Single‐agent immunotherapy or the combination of chemotherapy and immunotherapy are the standard of care for metastatic non‐small‐cell lung cancer (NSCLC), regardless of histology. The combination of the anti PD‐1 nivolumab and the anti CTLA‐4 ipilimumab (NI) activates anti‐tumor T‐cell response through distinct but complementary mechanisms. This combination showed efficacy in NSCLC, including lung squamous cell carcinoma (LSCC). Nevertheless, no trial has specifically investigated the efficacy of NI or chemotherapy + nivolumab (CT‐Nivo) in LSCC. Methods: The SQUINT trial was a randomized, phase II trial which assesses the efficacy of two different immunotherapy strategies in patients with advanced/metastatic LSCC. All eligible patients were randomly assigned to either NI or to investigator‐choice platinum‐based CT and nivolumab. Nivolumab was administered at the standard dose of 360 mg every 3 weeks, while ipilimumab was administered at the dose of 1 mg/kg every 6 weeks. In both arms, immunotherapy was continued up to disease progression, toxicity, or patient refusal, for a maximum of 24 months. Platinum‐based CT was given up to 6 cycles. The primary endpoint was overall survival (OS) at 12 months. Results: From September 2017 to February 2022, a total of 91 patients were included in the study; 45 were assigned to NI and 46 to CT‐Nivo. In both arms,the majority of patients were males (84.4% and 73.9%, respectively), with a performance status 0‐1 (97.8% and 100%), current or former smokers (95.6% and 95.7%). Bone, liver or brain metastases were present in 26.7%, 13.3% and 6.7% of patients in the NI arm and in 26.1%, 10.9% and 6.5% of patients on CT‐Nivo, respectively. Carboplatin or cisplatin in combination with gemcitabine was the most common CT regimen used in patients assigned to CT‐Nivo (98%, 28% CDDP, 70% Carbo). At the time of the present analysis, with a median follow‐up of 11 months, 62 patients are evaluable for response. At 1 year, OS rate was 59.1% with NI and 62.4% with CT‐Nivo. Median progression‐free survival was 3.8 months in the NI arm and 6.1 months in the CT‐Nivo arm. Response rate was 22.2% and 30.4%, respectively. Grade 3‐4 treatment‐related adverse events were more frequently reported with CT‐Nivo (34.8%) than with NI (15.5%), and mainly consisted in hematological toxicity. Conclusions: The preliminary results of the SQUINT trial suggest that NI or CT‐Nivo have similar activity in advanced LSCC. Additional analyses are ongoing and will be presented at the meeting. Keywords: Immunotherapy, Nivolumab, Squamous cell carcinoma}, -DOI = {10.1016/j.jtho.2022.07.602}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461484/full} -} - - -Record #214 of 538 -@article{Muro21, -author = {Muro, K, Yang Bruce, J, Baranda, J, Feinstein, T, Li, X, Gorla, S, Wu, C, and Braiteh, F}, -title = {P47.02 EV-202: phase 2 Study of Enfortumab Vedotin for Previously Treated Advanced Solid Tumors Including Non-Small Cell Lung Cancer}, -journal = {Journal of thoracic oncology}, -volume = {16}, -number = {10}, -pages = {S1096‐S1097}, -year = {2021}, -accession_number = {EMBASE 2015169469}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *drug tolerability; *non small cell lung cancer; Adult; Adverse drug reaction; Apoptosis; Bladder metastasis; Cancer adjuvant therapy; Cancer patient; Cancer recurrence; Cancer staging; Cancer survival; Cell cycle arrest; Central nervous system metastasis; Chemoradiotherapy; Clinical trial; Cohort analysis; Comparative effectiveness; Conference abstract; Controlled study; Diabetes mellitus; Disease control; Drug megadose; Drug safety; Drug therapy; ECOG Performance Status; Eligibility; Female; Food and Drug Administration; Gene expression; Histopathology; Human; Hypopituitarism; Hypothyroidism; Immunotherapy; Japan; Major clinical study; Male; Microtubule; Molecularly targeted therapy; Motor neuropathy; Neoadjuvant therapy; North America; Overall survival; Pharmacokinetics; Phase 2 clinical trial; Phase 3 clinical trial; Progression free survival; Protein expression; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Sensory neuropathy; Side effect; Transitional cell carcinoma}, -abstract = {Introduction: Despite therapeutic advances, lung cancer remains a leading cause of cancer death worldwide. Nectin‐4, a cell adhesion molecule, is highly expressed in several epithelial tumor types, including non‐small cell lung cancer (NSCLC). Targeting Nectin‐4 in NSCLC provides a novel treatment approach. Enfortumab vedotin (EV) is an antibody‐drug conjugate comprised of a fully human monoclonal antibody directed against Nectin‐4, and monomethyl auristatin E (MMAE), a microtubule‐disrupting agent, attached to the antibody via a protease‐cleavable linker. MMAE release within the cell disrupts the microtubule network, inducing cell cycle arrest and apoptosis. In 2019, EV received accelerated approval by the US FDA for the treatment of adults with locally advanced/metastatic urothelial carcinoma (la/mUC) who have previously received a PD‐1/L1 inhibitor and a platinum‐containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. In EV‐301, a phase 3, randomized clinical trial of patients with previously treated la/mUC, EV significantly prolonged overall survival compared with chemotherapy (docetaxel, paclitaxel, or vinflunine). This trial‐in‐progress describing general methodology for all cohorts was presented at the 2020 ASCO Annual Meeting. Methods: This multicohort, open‐label phase 2 study (NCT04225117) evaluates efficacy and safety/tolerability of EV in patients with previously treated locally advanced/metastatic solid tumors. Approximately 240 patients (∼40 patients/cohort) with histologically/cytologically confirmed disease and ECOG performance status of ≤1 are enrolling into six tumor‐specific cohorts (Figure). Within the NSCLC cohorts, patients must have previously received mutation‐targeted therapy (if eligible) and progressed, relapsed, or discontinued treatment due to toxicity after one platinum‐based therapy for locally advanced/metastatic disease, but received ≤2 lines of cytotoxic therapy, or have progressed or relapsed within 6 months of a platinum‐based neoadjuvant, adjuvant, concomitant chemoradiation regimen for early stage or locally advanced disease. Patients must have previously received therapy with a PD‐1/L1 inhibitor, unless therapy is contraindicated. Nectin‐4 expression is not required for eligibility and is being tested for exploratory outcomes. Patients with active CNS metastases, grade ≥2 sensory/motor neuropathy, ongoing grade ≥3 immunotherapy‐related hypothyroidism or panhypopituitarism, ongoing immunotherapy‐related adverse events requiring high‐dose steroids, or a history of uncontrolled diabetes mellitus are excluded. Patients will receive 1.25‐mg/kg EV intravenously on Days 1, 8, and 15 of each 28‐day cycle. The primary endpoint is investigator‐assessed confirmed objective response rate (RECIST v1.1); secondary endpoints include duration of response, disease control rate, progression‐free and overall survival, and safety/tolerability. An interim analysis is planned based upon prespecified response criteria. Recruitment is ongoing at ∼50 sites in North America and Japan. [Formula presented] Results: ▪▪▪ Conclusion: ▪▪▪ Keywords: Novel Therapeutics, Targeted Therapies}, -DOI = {10.1016/j.jtho.2021.08.495}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02336831/full} -} - - -Record #215 of 538 -@article{NCT0451330120, -author = {NCT04513301,}, -title = {Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: a Randomized,Open Labled, Phase II Clinical Study}, -journal = {https://clinicaltrials.gov/show/NCT04513301}, -year = {2020}, -accession_number = {CTgov NCT04513301}, -publication type = {Trial registry record}, -keywords = {Lung Neoplasms}, -abstract = {Lung cancer incidence and mortality have been increasing steeply in the past thirty years in the mainland of China. More than 80% of lung cancer is non‐small cell lung cancer (NSCLC). More than 40% of NSCLC patients are found to be in stage IIIb or IV, which is not resectable. The 5‐year survival rate for this group of patients is less than 5% in the SEER database. Currently, the NCCN guidelines recommend platinum‐containing double‐drug chemotherapy as the first‐ line standard of care for advanced NSCLC without driver gene mutations, and treatment options after failure of first‐line chemotherapy are limited. Immune Checkpoint Inhibitors, ICIs provide new treatment options, and in addition, radiotherapy can also be used in selected patients with advanced NSCLC, especially in patients with oligo progression, where irradiation of the thoracic primary lesions can improve the patient's respiratory‐related symptoms, reduce the tumor burden, improve the patient's quality of life, and prolong survival in some patients. Therefore, we propose that combination of immunotherapy and radiotherapy to the primary lesion for these patients, who are generally in good KPS status, may result in improved quality of life and prolonged survival. To date, there have been no clinical studies of immunotherapy combined with primary lesions radiation therapy in patients with advanced non‐small cell lung cancer (driver gene‐negative) after chemotherapy failure or recurrence, so we designed this prospective, randomized, controlled, investigator‐initiated, phase II clinical study with the primary objective of evaluating the efficacy of combined immunotherapy and primary lesions radiation therapy in this patient population. This trial aims at investigating the feasibility and efficacy of this treatment strategy.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02340813/full} -} - - -Record #216 of 538 -@article{Werner-Wasik18, -author = {Werner-Wasik, M}, -title = {Perspective}, -journal = {Journal of thoracic oncology}, -volume = {13}, -number = {10}, -pages = {S304‐S305}, -year = {2018}, -accession_number = {EMBASE 2001207705}, -publication type = {Journal article; Conference proceeding}, -keywords = {Adaptive radiation; Adult; Advanced cancer; Cancer immunotherapy; Cancer patient; Cancer size; Cancer staging; Cancer survival; Cardiotoxicity; Chemoradiotherapy; Comorbidity; Conference abstract; Controlled study; CyberKnife; Drug combination; Drug dose intensification; Drug therapy; Dyspnea; Evidence based practice center; Explosion; Female; Four dimensional computed tomography; Health insurance; Human; Image guided radiotherapy; Immunotherapy; Internal medicine; Learning curve; Lung metastasis; Lymphocytopenia; Male; Median survival time; Motion; Non small cell lung cancer; Nuclear magnetic resonance; Oncology; Overall survival; Particle radiation; Perception; Phase 2 clinical trial; Phase 3 clinical trial; Photon therapy; Positron emission tomography; Practice guideline; Prescription; Proton therapy; Quality of life; Radiation pneumonia; Radiotherapy; Randomized controlled trial; Simulation; Staging; Stratification}, -abstract = {Radiation therapy (RT) in locally advanced non‐small cell lung cancer (LA‐NSCLC) has not changed in its essence over many decades. The refinements in “standard‐of‐care” RT followed the general advancements applicable to many other malignancies, such as introduction of IMRT (including VMAT) and IGRT. Tumor motion appears more relevant in lung tumors than in other disease sites, and lung‐tumor interface allows for a measurable and intuitively observable movement, therefore enabling motion management in the lung to be more advanced, such as 4D CT for planning and tumor tracking (CyberKnife) or gating in daily practice. Nevertheless, the median survival time (MST) for good performance unresectable Stage II/III patients with NSCLC, treated with concurrent chemoradiotherapy (chemo‐RT) has improved significantly over last quarter century, from MST of 17.1 mo (RTOG 9410) to MST of 28.7 mo (RTOG 0617). Since the agents used in concurrent chemotherapy are not significantly different, other causes, mostly widespread use of PET scans for staging, as well as improved RT techniques, likely play a role. Use of CT simulation is associated with improved MST, even when adjusted for other variables, such as chemotherapy use, comorbidities or urban location. Volumetric (rather than 2D) dose prescription; use of lower energy photons and heterogeneity correction; accounting for tumor motion with a 4D CT simulation and IGRT; better understanding of normal tissue tolerance (lung V20) and of the need to limit RT course breaks, all add incremental benefits for a more favorable outcome. In addition, factors such as RT center's experience and volume of treated patients, as well as any protocol deviations in clinical trials, have been found to have a major impact in clinical practice, raising the possibility that strict adherence to RT planning guidelines might benefit all cancer patients treated with RT. Those factors have not yet been accounted for as eligibility/stratification factors in studies. Some much touted newer technologies, as particle RT (protons) have not so far demonstrated a verifiable superiority over photons. The Phase II randomized MDACC trial of photon vs. proton‐based chemoradiotherapy for patients with Stage III or oligometastatic NSCLC did not show a difference in radiation pneumonitis rates between the arms and no improvement in local control in the proton arm. However, a steep learning curve in using proton RT was discovered, with lower pneumonitis rates in those patients in the proton group who were treated in the latter half of the study vs. those treated in its early phase. The ongoing NRG Oncology/RTOG 1308 Phase III randomized trial of photon vs. proton chemo‐RT (70 Gy, but not lower than 60 Gy) has had a slow accrual, partially due to the paucity of participating centers, since proton technology is not widespread yet; also, a high percentage of patients not being able to enroll due to medical insurance coverage denial for protons, as well as possible perceptions of the superiority of protons. That study's design has been modified recently to allow for a faster study's completion. The original primary endpoint was overall survival, in contrast to the MDACC trial, where pneumonitis and local failure rate were co‐endpoints. In order to complete the RTOG 1308 trial sooner by lowering its target accrual, the current primary hypothesis is that the MST in the proton arm is non‐inferior to the photon arm (i.e. 28 mo), and major cardiac toxicity and grade 4 or higher lymphopenia is better in the proton vs. photon arm. Additionally, the Quality of Life hypothesis is that, compared with patients receiving photon therapy, patients on the proton arm will have less severe shortness of breath 6 months after the end of concurrent chemor‐RT (representing late adverse response to therapy), and that the differences in symptom ratings (based on MDASI shortness of breath item) between arms will be clinically meaningful. The recent availability of Magnetic Resonance (MR)‐Guided RT may open a new era in lung cancer RT, allowing for the real‐time intrafractional tumor tracking and “on the fly” adaptive RT, both likely to allow smaller tumor target volumes and a rigorous evaluation of doses delivered to the normal structures, therefore lowering toxicity and potentially opening the door to reassessment of RT dose intensification. Finally, with the explosion of evidence‐based applications of immunotherapy in metastatic lung cancer and the demonstration of an impressive survival prolongation in the Phase III randomized PACIFIC trial with the addition of maintenance durvalumab following chemo‐RT, the role of chemotherapy may be eventually challenged and reevaluated in Stage III NSCLC, to be possibly replaced by concurrent immunotherapy or a chemo‐immunotherapy combination. References: Curran WJ, Paulus R, Langer C et al, JNCI 2011 Bradley J, Paulus R, Komaki R et al, Lancet Oncology 2015 Chee KG, Nguyen DW, Brown M et al, Arch Internal Medicine 2008 Ohri N, Shen X, Dicker AP et al, JNCI 2013 Chen AB, Neville BA, Sher DJ et al, JCO 2011 Eaton BR, Pugh SL, Bradley JD et al, JNCI 2016 Liao Z, Lee JJ, Komaki R et al, JCO 2018 Antonia SJ, Villegas A, Daniel D et al, NEJM 2017 Keywords: radiation therapy, lung cancer, immunotherapy}, -DOI = {10.1016/j.jtho.2018.08.202}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01654334/full} -} - - -Record #217 of 538 -@article{NCT0641117124, -author = {NCT06411171,}, -title = {Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer}, -journal = {https://clinicaltrials.gov/ct2/show/NCT06411171}, -year = {2024}, -accession_number = {CTgov NCT06411171}, -publication type = {Trial registry record}, -keywords = {Docetaxel; Fluorouracil; Leucovorin; Oxaliplatin; Pembrolizumab}, -abstract = {Gastric cancer, including gastroesophageal junction cancer, is the fifth most common cancer and the third leading cause of death in the world. Among them, although the incidence of distal gastric adenocarcinoma is decreasing, the incidence of gastroesophageal junction cancer is increasing. At present, surgery is still the main treatment for gastroesophageal junction cancer. At the same time, multi‐mode comprehensive treatment such as chemotherapy and molecular targeted therapy can effectively alleviate pathological progression, facilitate R0 resection and improve the overall survival of patients. A large number of previous clinical trials on the combination of first‐line chemotherapy and molecular targeted drugs in the treatment of gastric and gastroesophageal junction cancer have shown that only trastuzumab can improve the overall survival rate of Her‐2 positive patients. In addition, despite various clinical chemotherapy regimens, the median survival time of gastric cancer and gastroesophageal junction cancer is not high. Therefore, the treatment mode of gastroesophageal junction cancer, especially for Her‐2 negative patients, needs to be explored and improved. In recent years, immune checkpoint inhibitors represented by programmed death receptor 1 (PD‐1)/programmed death receptor ligand 1 (PD‐L1) inhibitors have been applied to the treatment of a variety of solid tumors such as melanoma, non‐small cell lung cancer, renal cell carcinoma, head and neck cancer, and urothelial cancer. It has become another important treatment strategy after surgery, chemotherapy, radiotherapy and targeted therapy. Studies have shown that PD‐L1 is highly expressed in tumor cells and immune cells in gastric cancer and gastroesophageal junction cancer and plays a key role in tumor immune escape, therefore, the PD‐1/ PD‐L1 pathway will become an important target for effective intervention in gastroesophageal junction cancer. As a PD‐1 inhibitor, Pembrolizumab has been shown to have anti‐tumor activity and manageable safety in gastroesophageal junction cancer, and was approved by the US FDA in September 2017 for advanced PD‐L1‐positive gastric or gastroesophageal junction cancer . The phase Ⅱ KEYNOTE‐059 trial used Pembrolizumab as a single agent in the third‐line treatment of advanced gastric or gastroesophageal junction cancer, and the results showed that it had controllable safety in patients with PD‐L1 positive, with obvious advantages in objective response rate (ORR) and median duration of response (DOR) [12]. Chemotherapy enhances tumor immune responses by enhancing tumor cell immunogenicity and sensitivity to immune killing, and the combination of chemotherapy and immune checkpoint inhibitors has been shown to improve overall survival in several cancer types. Therefore, PD‐1/ PD‐L1 immunosuppressant combined with chemotherapy has become a hot spot in the research of advanced gastric cancer or gastroesophageal junction cancer . The phase 3 KEYNOTE‐062 trial compared Pembrolizumab plus chemotherapy (cisplatin plus 5‐FU or capecitabine) with chemotherapy alone or Pembrolizumab alone in the first‐line treatment of advanced gastric or gastroesophageal junction cancer. However, compared with chemotherapy alone, Pembrolizumab combined with chemotherapy could not significantly prolong the overall survival of patients, and the overall effect was not better than chemotherapy alone . In contrast, the phase III KEYNOTE‐590 study, designed to compare the efficacy and safety of Pembrolizumab plus chemotherapy (cisplatin plus fluorouracil) versus chemotherapy alone as first‐line treatment for advanced esophageal and Siwert type I gastroesophageal junction cancer, showed that Pembrolizumab combined with chemotherapy was significantly superior to chemotherapy alone . Neither the KEYNOTE‐062 trial nor the KEYNOTE‐590 trial analyzed a separate population of patients with gastroesophageal junction cancer, and there are some differences in response to drugs by tissue type. Therefore, The efficacy of Pembrolizumab plus chemotherapy in the only patient population with gastroesophageal junction cancer warrants further investigation.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02699900/full} -} - - -Record #218 of 538 -@article{ChiCTR200004107220, -author = {ChiCTR2000041072,}, -title = {A Phase II Open-Label Randomized Controlled Clinical Trial of Pembrolizumab Plus Chemotherapy Combined With Cox-2 Inhibitor (Celecoxib) Versus Pembrolizumab Plus Chemotherapy In Advanced Non-small Cell Lung Cancer (NSCLC)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2000041072}, -year = {2020}, -accession_number = {ICTRP ChiCTR2000041072}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trial group:Pembrolizumab + chemotherapy (squamous cell carcinoma: albumin paclitaxel + carboplatin / adenocarcinoma: pemetrexed + carboplatin) + celecoxib;Control group:Pembrolizumab + chemotherapy (squamous cell carcinoma: albumin paclitaxel + carboplatin / adenocarcinoma: pemetrexed + carboplatin); CONDITION: Lung Cancer PRIMARY OUTCOME: ORR;PFS;Side‐effect; INCLUSION CRITERIA: (1) Written informed consent, willing and able to comply with the trial protocol during the trial, including all treatment methods and planned laboratory tests. (2) Men or women over 18 years old and under 75 years old. (3) Locally advanced (IIIb) or metastatic (IV) non‐small cell lung cancer confirmed histologically as incurable surgery or radiotherapy, with at least one measurable lesion. (4) The patient must be able to provide fresh or archived tumor tissue and its pathology report. (5) The ECOG score is 0 or 1. (6) Have not received anti‐tumor therapy in the past, and the life expectancy is not less than 12 weeks. (7) The main organ functions are basically normal: a. Adequate liver function: AST and ALT <= 2.5 x ULN, if there is liver metastasis, this standard is <= 5 x ULN; total bilirubin <= 1.5x ULN. b. Adequate renal function: creatinine <= 1.5x the upper limit of normal value or creatinine clearance rate > 50ml/min. c. Sufficient bon}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02241474/full} -} - - -Record #219 of 538 -@article{ChiCTR220006175322, -author = {ChiCTR2200061753,}, -title = {Clinical trial of immune checkpoint inhibitor combined with anlotinib in the second-line treatment of refractory extensive-stage small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200061753}, -year = {2022}, -accession_number = {ICTRP ChiCTR2200061753}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Anlotinib + Nivolumab combination therapy group:Nivolumab (3 mg/kg intravenously every 2 weeks). Anlotinib 12mg orally, once a day, continuous medication for 2 weeks and 1 week off, that is, a 3‐week (21‐day) cycle program. ;Paclitaxel monotherapy group:Paclitaxel 175mg/m2 chemotherapy was given. Once every 3 weeks, follow up after 4‐6 consecutive times.; CONDITION: small cell lung cancer PRIMARY OUTCOME: safety;progression‐free survival; SECONDARY OUTCOME: overall survival;objective response rate;disease control rate; INCLUSION CRITERIA: 1. Pathologically confirmed small cell lung cancer with measurable lesions; 2. Using AJCC TNM 8th edition staging method combined with VALG staging method: AJCC stage IV (any T, any N, M1a/b/c), or T3‐4 due to multiple lung nodules or tumors/nodules The volume is too large to be included in a tolerable radiotherapy plan; 3. 18‐70 years old; ECOG PS score: 0‐1 points; expected survival period of more than 3 months; 4. Progression within 6 months after the end of first‐line etoposide + carboplatin/cisplatin therapy; 5. Major organ function within 7 days prior to initial treatment, meeting the following criteria: (1) Routine blood test standards (without blood transfusion within 14 days): 1) Hemoglobin (HB)>= 90g/L; 2) White blood cells (WBC) >= 3×10^9/L 3) Absolute neutrophil count (ANC)>= 1.5×10^9/L; 4) Platelet (PLT)>= 80×10^9/L (2) Biochemical tests are subject to the following criteria: 1) Albumin>= 30g/L; 2) Total b}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02556170/full} -} - - -Record #220 of 538 -@article{EUCTR2017-002842-60-FR17, -author = {EUCTR2017-002842-60-FR,}, -title = {Randomised phase III study testing nivolumab and ipilimumab versus a carboplatin based doublet in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2017-002842-60-FR}, -year = {2017}, -accession_number = {ICTRP EUCTR2017‐002842‐60‐FR}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trade Name: OPDIVO Product Name: nivolumab Pharmaceutical Form: Solution for infusion Trade Name: YERVOY Product Name: ipilimumab Pharmaceutical Form: Solution for infusion Product Name: carboplatin Pharmaceutical Form: Solution for injection Product Name: pemetrexed Pharmaceutical Form: Powder for concentrate for solution for infusion Product Name: paclitaxel Pharmaceutical Form: Solution for injection CONDITION: Advanced non small cell lung cancer ; MedDRA version: 20.0 Level: LLT Classification code 10007050 Term: Cancer System Organ Class: 100000020935 Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: To compare overall survival of patients in experimental arm versus; chemotherapy Primary end point(s): Overall survival Secondary Objective: To evaluate :; • survival at one year of patients treated with nivolumab + ipilimumab; versus patients treated with chemotherapy,; • the objective response rate,; • the progression free survival,; • the QOL ,; • the safety and the tolerability of nivolumab + ipilimumab versus; chemotherapy,; • the prognostic impact of PD‐L1 expression by immunochemistery; (IHC) on OS and PFS,; • the predictive impact of a geriatric mini data set on OS, PFS and; toxicity and its evolution under treatment, this analysis will be restricted; to patients =70 years old. Timepoint(s) of evaluation of this end point: 42 months SECONDARY OUTCOME: Secondary end point(s): • Percentage of patients alive one year after inclusion in the trial, ; • Objective response rate according to Recist 1.1, ; • Progression free survival time, ; • Safety tolerability according to CTCAE 4.0, ; • QOL evaluated by EQ5D and EORTC QLQ‐ELD14 every 6 weeks, ; • PD‐L1 testing by immunochemistery (IHC), ; • Geriatric mini data set (restricted to patients =70 years old). Timepoint(s) of evaluation of this end point: • Percentage of patients alive one year after inclusion in the trial, ; • Objective response rate according to Recist 1.1, ; • Progression free survival time, ; • Safety tolerability according to CTCAE 4.0, ; • QOL evaluated by EQ5D and EORTC QLQ‐ELD14 every 6 weeks, ; • PD‐L1 testing by immunochemistery (IHC), ; • Geriatric mini data set (restricted to patients =70 years old). INCLUSION CRITERIA: • Signed written informed consent • Cytologically or histologically proven NSCLC (adenocarcinoma, squamous cell carcinoma, large‐cell carcinoma) • Stage IV or non‐treatable by radiotherapy stage III (7th classification) • No previous systemic chemotherapy for lung cancer, except in case of relapse after adjuvant treatment for localized disease with 6 months or more between end of previous chemotherapy and relapse • Patients less than 70 years old and PS 2 or 70 years older PS 0 to 2 • Judged fit enough to receive chemotherapy according to ESMO guidelines • Presence of at least one measurable target lesion (RECIST 1.1 rules) in a non‐irradiated region and analysable by CT • Life expectancy >12 weeks • Prior radiation therapy is authorized if it involved less than 25% of the total bone marrow volume and finished 14 days before D1 of planned treatment • Screening laboratory values must meet the following crite}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01893505/full} -} - - -Record #221 of 538 -@article{EUCTR2019-003805-82-FR20, -author = {EUCTR2019-003805-82-FR,}, -title = {UCPVax plus Nivolumab versus standard chemotherapy as second line therapy in advanced non-small cell lung cancer : a randomized non-comparative phase II trial}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-003805-82-FR}, -year = {2020}, -accession_number = {ICTRP EUCTR2019‐003805‐82‐FR}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trade Name: OPVIDO Product Name: NIVOLUMAB Pharmaceutical Form: Solution for infusion INN or Proposed INN: NIVOLUMAB CAS Number: 946414‐94‐4 Current Sponsor code: BMS‐936558 Other descriptive name: NIVOLUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240‐ Product Name: UCPVax Pharmaceutical Form: Solution for injection CONDITION: lung cancer Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: Evaluer l’efficacité de la combinaison UCPVax plus Nivolumab comme seconde ligne de traitement des cancers du poumon non à petites cellules avancés. Primary end point(s): Progression‐free survival (PFS) rate at 6 months. PFS is defined by the duration from the date of initiation of the treatment to the disease progression (RECIST) or death from any cause whichever occurs first, censoring cases without progression at the date of last disease assessment.; ; Secondary Objective: 1. Evaluer le taux de réponses objectives à 6 mois selon les critères RECIST. ; 2. Evaluer la survie sans progression et le taux de réponses objectives selon les critères iRECIST dans le bras expérimental ; 3. Evaluer le taux de contrôle de la maladie (DCR) après 12 mois.; 4. Evaluer les toxicités selon les critères du NCI‐CTCAE version 5 à chaque visite; 5. Evaluer la survie globale (SG): intervalle de temps entre la date de l’initiation du traitement et la date de décès quelle que soit la cause.; 6. Evaluer l’immunogénicité de la combinaison évaluée par test ELISPOT‐interféron‐gamma dans le sang périphérique. ; 7. Evaluer la qualité de vie relative à la santé ; 8. Exploratoire: TMB, ctDNA, microbiote, angiogenèse tumorale, infiltrats immunitaires; Timepoint(s) of evaluation of this end point: 6 months SECONDARY OUTCOME: Secondary end point(s): 1. Objective Response Rate (ORR) at 6 months according to RECIST criteria. ORR is defined as the addition of complete response (CR) and partial response (PR) rates.; 2. PFS and ORR according to iRECIST criteria in the experimental arm; 3. Disease Control Rate (DCR) by 12 months defined as the percentage of patients who have achieved complete response, partial response and stable disease to the therapeutic intervention.; 4. Safety will be evaluated according to NCI CTCAE v 4.03 at each visit; 5. Overall survival (OS) is defined by the duration from the date of inclusion to death from any cause.; 6. Assessment of Telomerase‐specific T cell responses by IFN‐? ELISPOT in peripheral blood. ; 7. Health‐related quality of life (HRQoL) evaluated using EORTC QLQ‐C30 and LC‐13 modules specific to lung cancer; 8. Exploratory: TMB, ctDNA, microbiote, tumor angiogenesis, immune infiltrates Timepoint(s) of evaluation of this end point: 6 months / 12 months INCLUSION CRITERIA: 1‐ Signed informed consent 2‐ Male or female patients, age = 18 years 3‐ Histologically or cytologically confirmed NSCLC (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, undifferentiated carcinoma or other) 4‐ Advanced NSCLC cancer patient previously treated with a first line of combo chemotherapy plus anti‐PD‐1 or chemotherapy plus anti‐PDL‐1 combination 5‐ Measurable disease defined according to RECIST v1.1 guidelines (Note: Previously irradiated lesions can be considered as measurable disease only if disease progression has been unequivocally documented at that site since radiation.) 6‐ Patients must have a mandatory treatment‐free interval of at least 21 days following previous systemic anti‐cancer treatments 7‐ Patients who have received previous systemic anticancer treatment and/or radiotherapy should have recovered from any treatment related toxicity, to a level of = grade 1 (according to National Cancer Institute [NCI]}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02255356/full} -} - - -Record #222 of 538 -@article{EUCTR2016-001063-36-FR16, -author = {EUCTR2016-001063-36-FR,}, -title = {Randomised phase III study testing nivolumab versus chemotherapy in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2016-001063-36-FR}, -year = {2016}, -accession_number = {ICTRP EUCTR2016‐001063‐36‐FR}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trade Name: OPDIVO Product Name: nivolumab Pharmaceutical Form: Solution for infusion Product Name: carboplatin Pharmaceutical Form: Solution for injection Product Name: pemetrexed Pharmaceutical Form: Powder for concentrate for solution for infusion Product Name: paclitaxel Pharmaceutical Form: Solution for injection Product Name: gemcitabine Pharmaceutical Form: Powder for solution for infusion Product Name: vinorelbine Pharmaceutical Form: Capsule, soft CONDITION: Advanced non small cell lung cancer ; MedDRA version: 19.0 Level: LLT Classification code 10007050 Term: Cancer System Organ Class: 100000004864 Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: To compare overall survival of patients in experimental arm versus chemotherapy Primary end point(s): Overall survival Secondary Objective: To evaluate : ; • survival at one year of patients treated with nivolumab versus patients treated with chemotherapy,; • the objective response rate, ; • the progression free survival,; • the QOL (EQ5D) assessed every 6 weeks,; • the safety and the tolerability of nivolumab versus chemotherapy,; • the prognostic impact of PD‐L1 expression by immunochemistery (IHC) on OS and PFS. Timepoint(s) of evaluation of this end point: 42 months SECONDARY OUTCOME: Secondary end point(s): • Percentage of patients alive one year after inclusion in the trial, ; • Objective response rate according to Recist 1.1, ; • Progression free survival time, ; • Safety tolerability according to CTCAE 4.0, ; • QOL evaluated by EQ5D every 6 weeks, ; • PD‐L1 testing by immunochemistery (IHC). Timepoint(s) of evaluation of this end point: • Percentage of patients alive one year after inclusion in the trial, ; • Objective response rate according to Recist 1.1, ; • Progression free survival time, ; • Safety tolerability according to CTCAE 4.0, ; • QOL evaluated by EQ5D every 6 weeks, ; • PD‐L1 testing by immunochemistery (IHC). INCLUSION CRITERIA: • Signed written informed consent • Cytologically or histologically proven NSCLC (adenocarcinoma, squamous cell carcinoma, large‐cell carcinoma) • Stage IV or non‐treatable by radiotherapy stage III (7th classification) • No previous systemic chemotherapy for lung cancer, except in case of relapse after adjuvant treatment for localized disease with 6 months or more between end of previous chemotherapy and relapse • Patients less than 70 years old and PS 2 or 70 years older PS 0 to 2 • Judged fit enough to receive chemotherapy according to ESMO guidelines • Presence of at least one measurable target lesion (RECIST 1.1 rules) in a non‐irradiated region and analysable by CT • Life expectancy >12 weeks • Prior radiation therapy is authorized if it involved less than 25% of the total bone marrow volume and finished 14 days before D1 of planned treatment • Screening laboratory values must meet the following criteria and should be ob}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01852286/full} -} - - -Record #223 of 538 -@article{Thomas19, -author = {Thomas, R}, -title = {WS03.08 Panel - Emerging Therapies - Immunotherapy}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S1109‐S1110}, -year = {2019}, -accession_number = {EMBASE 2003406804}, -publication type = {Journal article; Conference proceeding}, -keywords = {*immunotherapy; Adult; Advanced cancer; Adverse drug reaction; Cancer patient; Cancer staging; Cancer survival; Care behavior; Case report; Chemoradiotherapy; Chest infection; Chronic obstructive lung disease; Clinical article; Clinical feature; Clinical nurse specialist; Clinical practice; Combination drug therapy; Comorbidity; Conference abstract; Distant metastasis; Drug combination; Drug therapy; Female; Flavor; Gene mutation; Gene rearrangement; Human; Immune‐related gene; Male; Mortality; Non small cell lung cancer; Organizing pneumonia; Overall survival; Progression free survival; Radiotherapy; Side effect}, -abstract = {IASLC Abstract for Presentation. By Rachel Thomas This panel session will focus on emerging immunotherapies, the aim is to bring the UK perspective to the panel particularly focusing on the role of the Lung Cancer Clinical Nurse Specialist (CNS) and how to support and counsel patients who are about to commence one of the new therapy combinations. The presentation from the UK will look at the current therapies in immunotherapy and then also look at two case studies which will bring the clinical trial data into real time perspective. In the UK there have been no new immunotherapies launched, however, what the landscape of immunotherapies is changing in the UK for non‐small cell lung cancer patients in the form of multi‐drug combinations. Most recently we have seen the introduction of Durvalumab as a treatment for locally advanced unresectable non‐small cell lung cancer post platinum based chemoradiation (1). This combination is still awaiting formal NICE approval but NHS patients can access this via a Cancer Drugs Fund. The PACIFIC Trial demonstrated that patients who received Durvalumab after platinum based chemoradiation had a significant improvement in their progression free survival when compared to chemoradiation plus a placebo. The median duration of progression free survival was 17.2 months in the Durvalumab arm compared to 5.6 months in the placebo arm. The median time to death or distant metastases was 28.3 months in the Durvalumab arm compared to 16.2 months in the placebo arm (2). In the advanced metastatic setting there has recently been the introduction of the KEYNOTE‐189 data which is looking at pembrolizamab + platinum/pemetrexed in patients who did not have any molecular mutations. This trial demonstrated an overall survival with a 51% reduction in the risk of death and superior progression free with a 48% reduction in the risk of progression or death. In March 2019 The IMpower150 trial showed significant improvements in progression‐free and overall survival with atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) versus the standard‐of‐care bevacizumab plus carboplatin plus paclitaxel (BCP) in chemotherapy‐naive patients with non‐squamous metastatic non‐small‐cell lung cancer who have an ALK rearrangement or who have an EGFR mutation. This combination has now been approved by NICE and will provide patients who progress on a tyrosine kinase inhibitor a multi‐drug treatment combination which has been demonstrated in the Impower 150 trial to deliver overall survival of around 19.2 months when compared to bevacizumab/carboplatin and paclitaxel. The UK has demonstrated the importance of the input of the Lung Cancer CNS in supporting patients who are about to commence treatment and also in proactively monitoring patients for potential adverse events (3). However, with the emergence of multidrug treatments how do we as Lung Cancer CNS’s assess which adverse events are related to the immunotherapy and which are related to the chemotherapy. Looking at the current clinical trial data from the studies above and then focusing on two real life patient case studies will provide some clear guidance on how to support patients whilst monitoring for any potential adverse events and dealing with these in a timely and accurate manner. The table below sets out just some of the main challenges faced in identifying immunotherapy related adverse events. [Figure presented] We as nurse specialists are now experienced at caring for patients on single agent immunotherapy treatments but one of the many challenges is that many lung cancer patients will have co‐morbidities which can cloud the identification of immunotherapy adverse events. For example 40‐70% of lung cancer patients will also have a diagnosis of COPD. Pneumonitis can present in a very similar pattern to organising pneumonia and chest infections meaning that accurate and detailed assessments are needed to ensure adverse events are identified and treated accordingly. However, when you also add into the treatment plan platinum doublet chemotherapy with or without radiotherapy the potential for adverse events increases, the panel will look at the PACIFIC data to assess the reporting of adverse events in this patient group. The panel will also then assess the trial data for platimum doublet chemotherapy and immunotherapy in the treatment of metastatic non‐small cell lung cancer and whether this patient group with a potentially higher symptom burden reported an increase in the number of adverse events when compared to either single agent immunotherapy or platinum doublet chemotherapy alone. One other important focus of the panel discussion will be to look at what the future treatment landscape for patients may be and how this will impact on progression free survival and living with lung cancer. This will mainly cover recent updates from ASCO and will aim to provide a flavour of what we may see coming into clinical practice in the coming months. References: Durvalumab for treating locally advanced unresectable non‐small‐cell lung cancer after platinum‐based chemoradiation. Technology appraisal guidance [TA578] Published date: 01 May 2019. Overall survival with Durvalumab after chemoradiotherapy in Stage III NSCLC. Scott. A; Augusto, V; Davey, D et al. The National Lung Cancer Audit (2018) Yoest JM (2017) Clinical features, predictive correlates and pathophysiology of immune related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. Immunotargets Therapeutics. 6. P 73‐82.}, -DOI = {10.1016/j.jtho.2019.08.2479}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02081649/full} -} - - -Record #224 of 538 -@article{Sun19, -author = {Sun, A}, -title = {IBS13.01 Radiation Related Toxicities in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S103}, -year = {2019}, -accession_number = {EMBASE 2003405500}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *non small cell lung cancer; Adult; Adverse drug reaction; Cancer adjuvant therapy; Cancer patient; Cancer staging; Cancer surgery; Cancer survival; Case report; Chemoradiotherapy; Clinical article; Clinical feature; Conference abstract; Drug therapy; Esophagitis; Female; Human; Male; Organs at risk; Overall survival; Patient history of radiotherapy; Phase 1 clinical trial; Phase 3 clinical trial; Quality of life; Radiation pneumonia; Radiotherapy; Randomized controlled trial; Secondary analysis; Side effect; Skull irradiation; Sun; Surgery}, -abstract = {Radical radiotherapy is used as definitive therapy in locally advanced non‐small cell lung cancer (LA‐NSCLC), either alone or in combination with chemotherapy and/or surgery. However, definitive doses of radiotherapy are associated with potential toxicity related to the organs at risk (OAR). The major OAR’s related to radical radiotherapy for LA‐NSCLC include the lung and esophagus. Therefore, we need to be able to identify and manage radiation pneumonitis and esophagitis during and after a course of definitive radiotherapy. For good performance status, unresectable stage III NSCLC, radical radiotherapy is delivered either concurrently or sequentially with chemotherapy to total doses of 60Gy or higher. Although the best outcomes have been obtained with concurrent chemoradiotherapy, higher rates of toxicity have also been observed. With the advent of the establishment of adjuvant durvalumab after definitive concurrent chemoradiotherapy, the management of pneumonitis in particular has become even more of a challenge given the potential overlapping toxicities. For poorer performance status patients, radical radiotherapy may be used alone. For resectable patients with LA‐NSCLC, radical radiotherapy can be given concurrently with chemotherapy prior to surgical resection as part of trimodality therapy. In other instances, radical radiotherapy can be given adjuvantly post‐operatively for positive margins and can be considered in pathological N2 disease. Prophylactic Cranial Irradiation (PCI) has also been delivered in LA‐NSCLC, although mostly in clinical trials as PCI has not been established as part of routine standard of care in stage III NSCLC. In this session, a discussion as well as case presentations will be used to illustrate how to identify and manage the above toxicities in stage III NSCLC. References (max 10) Baker S, Fairchild A. Radiation‐induced esophagitis in lung cancer. Lung Cancer: Targets and Therapy 2016:7 119–127. (Review Article). Mehmood Q, Sun A, Becker N, et al. Predicting Radiation Esophagitis Using 18F‐FDG PET During Chemoradiotherapy for Locally Advanced Non‐Small Cell Lung Cancer. J Thorac Oncol. 2016: 1;11(2):213‐21. Verma V, Simone CB, Werner‐Wasik M. Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally‐Advanced Non‐Small Cell Lung Cancer. Cancers. 2017; 9:120. (Review Article). Jain V and Berman AT. Radiation Pneumonitis: Old Problem, New Tricks. Cancers (Basel). 2018 Jul 3; 10(7). (Review Article). Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; 2018 Sep 25. Shaverdian, N, Lisberg AE, Bornazyan, K et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non‐small‐cell lung cancer: A secondary analysis of the KEYNOTE‐001 phase I trial. Lancet Oncol. 2017, 18(7), 895–903. Chuzi S, Tavora F, Cruz M, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor related pneumonitis. Cancer Manag Res. 2017;9:207‐213. (Review Article). Sun A, Bae K, Gore EM, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non‐small‐cell lung cancer: neurocognitive and quality‐of‐life analysis. J Clin Oncol 2011; 29: 279–86. Le Pechoux C, Sun A, Slotman BJ, et al. Prophylactic cranial irradiation for patients with lung cancer. Lancet Oncol 2016; 17(7): e277–293. (Review Article). Sun A, Hu C, Wong SJ, et al. Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non‐Small Cell Lung Cancer: A Long‐term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019 Mar 14. Keywords: Radiation Toxicity LA‐NSCLC}, -DOI = {10.1016/j.jtho.2019.08.226}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01999079/full} -} - - -Record #225 of 538 -@article{NCT0657692124, -author = {NCT06576921,}, -title = {Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction}, -journal = {https://clinicaltrials.gov/ct2/show/NCT06576921}, -year = {2024}, -accession_number = {CTgov NCT06576921}, -publication type = {Trial registry record}, -keywords = {Adenocarcinoma; Albumin‐Bound Paclitaxel; Esophageal Neoplasms; Oxaliplatin; Paclitaxel; Stomach Neoplasms}, -abstract = {Gastric Cancer (GC) is the fifth most common malignancy globally and the third leadingcause of cancer death. Half of the world's cases occur in eastern Asia [1], which has thehighest mortality rate. According to the latest data released by the National TumorRegistration Center, it is estimated that in 2015, there were 679,000 new cases ofgastric cancer in China, and 498,000 deaths, ranking second in both incidence andfatality rate among malignant tumors [2]. The overall prognosis is poor, posing a seriousthreat to human health.Environmental and genetic factors play an important role in the development of gastriccancer, with common risk factors including age, male gender, smoking, radiation andfamily history. Specific risk factors for gastric cancer include Helicobacter pyloriinfection and dietary factors [3]. Helicobacter pylori (H.pylori) infection often leadsto chronic gastritis, gastric atrophy, and then intestinal metaplasia, abnormalhyperplasia and gastric cancer [4‐6]. Dietary factors include low intake of fruits andvegetables, high salt, and intake of smoked foods.Radical surgical resection is still the main treatment for non‐metastatic gastric cancer,but the postoperative recurrence and metastasis rate is as high as 40‐80%, and the 5‐yearsurvival rate is 30‐60%[7‐8]. The treatment mode of neoadjuvant chemotherapy + surgery +adjuvant chemotherapy (perioperative treatment) is an important part of the comprehensivetreatment of gastric cancer at present. A number of studies have proved that comparedwith surgery alone, this treatment mode can reduce the tumor stage, increase the R0resection rate, and improve the overall survival, without increasing postoperativecomplications and mortality. The purpose of neoadjuvant chemotherapy is to reduce tumorload and increase the possibility of R0 resection [9], so as to improve the pathologicalcomplete response rate. Neoadjuvant chemotherapy can measure a patient's sensitivity tochemotherapy drugs and therefore predict a patient's response to subsequent chemotherapy.At present, it has been confirmed that pathological complete response rate is correlatedwith overall survival [10]. On September 28, 2019, at the ESMO Conference , Chinesescholars announced the results of the RESOLVE Phase III study on perioperative treatmentof locally advanced gastric cancer [11], adding new evidence‐based medical evidence forperioperative treatment of such patients. The RESOLVE study is A three‐arm, randomized,multicenter, open‐label Phase III trial comparing the efficacy and safety of using XELOX(Group A) or SOX (Group B) after radical D2 surgery versus perioperative use of SOX(group C). Finally, 1022 cases of ITT population were included in the analysis. In theperioperative group (group C), the R0 resection rate (92.88%) and the proportion of D2lymph node dissection (95.59%) showed an increasing trend. The R0 removal rates of groupA and group B were 86.47% and 87.83%, respectively. In patients with locally advancedgastric cancer, SOX chemotherapy during perioperative period improved 3‐year disease‐freesurvival (62.02% vs 54.78%, P=0.045, HR=0.79, 95%CI 0.62‐0.99) compared with XELOXadjuvant. Results of a multicenter Phase III clinical study in France [12] showed thatpreoperative neoadjuvant chemotherapy with PF regimen significantly increased R0resection rate compared with surgery alone (84% vs 73%, P=0.04). For initially treatedlocally advanced gastroesophageal cancer, XELOX regimen has been proven to be aseffective as cisplatin combined with fluorouracil regimen [13]. Results of a Chinesestudy showed that for patients with advanced gastric cancer, the ORR of neoadjuvantchemotherapy with FOLFOX regimen was 70%[14], and the R0 resection rate was significantlyimproved compared with surgery alone (86% vs 55%, P=0.011). A study from Japan showed[15] that neoadjuvant chemotherapy with SP protocol is safe and effective for stage IIand III gastric cancer with lymph node metastasis, with ORR of 75.5% and R0 removal rateof 87.8%. Chinese researchers have found [16] that SOX neoadjuvant application inadvanced gastric cancer has an ORR of 68.5%, and the R0 removal rate is alsosignificantly higher than that of operation alone (81.3%vs 73.5%, P=0.040). The resultsof the recent FLOT4 study [17] showed that the perioperative regimen of 5‐fluorouracil +docetaxel + oxaliplatin + calcium folinate (FLOT) was superior to the perioperativeregimen of epirubicin + cisplatin + 5‐fluorouracil or capecitabine (ECF/ECX) in terms ofR0 removal rate (85% vs 78%). P=0.0162).At present, the recommended preoperative chemotherapy for gastric cancer mainly includes:Epirubicin combined with Cisplatin and fluorouracil (ECF) and its modification, cisplatincombined with fluorouracil (PF), oxaliplatin combined with capecitabine (XELOX),oxaliplatin combined with fluorouracil (FOLFOX), Cisplatin combined with S‐1 (SP),oxaliplatin combined with S‐1 (SOX), FLOT (5‐fluorouracil + docetaxel + oxaliplatin +calcium folinate).As a highly heterogeneous malignant tumor, gastric cancer is an extremely complex processin which the immune microenvironment plays an important role, and the inhibitory immunemicroenvironment and immune escape have received more and more attention. programmeddeath receptor‐1 (PD‐1) and programmed death ligand‐1 (PD‐L1) belong to the B7/CD28superfamily and are very important negative co‐stimulatory molecules discovered in recentyears. It can negatively regulate the activity of immune cells [18]. PD‐1 is the mainimmunosuppressive molecule on the surface of T cells and B cells. PD‐1 has two ligands,PD‐L1 and PD‐L2. PD‐L1 is widely expressed in activated T cells, B cells, macrophages,dendritic cells, and tumor cells. PD‐L1 expressed by tumor cells and PD‐1 expressed bytumor Infiltrating Lymphocytes (TILs) (mainly CD8+T cells) bind to activate thePD‐1/PD‐L1 signaling pathway and inhibit the activation of tumor infiltratinglymphocytes. Reduced T cell reactivity leads to T cell incapacitated, induces T cellapoptosis, provides a suitable microenvironment for the development of tumor cells,mediates tumor immune escape, and promotes tumor growth [19]. Blocking the PD‐1/PD‐L1signaling pathway can reverse the tumor immune microenvironment and enhance theendogenous anti‐tumor immune effect. PD‐L1 is highly expressed in various solid malignanttumors [20‐21], including non‐small cell lung cancer, melanoma, renal cell carcinoma,prostate cancer, breast cancer, stomach cancer, etc., and its expression level variesaccording to different tumor types. At present, the relationship between PD‐L1 expressionand prognosis in gastric cancer is still controversial.In December 2018, the Phase II trial results of the Asian Attract‐04 study [22] werepublished. The study was designed to explore the safety and efficacy of Nivolumab incombination with SOX (Ticeo and oxaliplatin) or XELOX (capecitabine and oxaliplatin) infirst‐line treatment of advanced, unresectable, or recurrent gastric/gastroesophagealjunctional adenocarcinoma. The randomized ratio was 1:1, and the median OS follow‐up wasnot reached in the FAS population (NR (11.9, NR) and NR (11.2, NR), respectively). MedianPFS were 9.7 months (5.8‐NR) and 10.6 months (5.6‐12.5), respectively. The ORR ofNivolumab combined with SOX was 57.1%, and that of Nivolumab combined with XELOX was76.5%.In March 2019, the results of KEYNOTE‐059 study [23] Cohort 2 and cohort 3 Phase IIclinical trials were published. The study cohort 2 and cohort 3 were designed to explorethe safety and efficacy of Pembrolizumab± chemotherapy in first‐line treatment ofadvanced gastric or gastroesophageal junction adenocarcinoma. In cohort 2, 25 patientsreceived Pembrolizumab combined with chemotherapy. All patients had an ORR of 60.0%,including 73.3% ORR in the PD‐LI positive group and 37.5% ORR in the PD‐LI negativegroup, with a median OS of 13.8 months (8.6‐NR). The median PFS was 6.6 months(5.9‐10.6). In cohort 3, 31 PD‐L1 positive (CPS≥1) patients who received Pembrolizumabmonotherapy had an ORR of 25.8%, a median OS of 20.7 months (9.2‐20.7), and a median PFSof 3.3 months.At the American Society of Clinical Oncology Symposium (ASCO) in June 2019, Merckpresented the results of the KEYMAT‐062 Phase III study [24], which randomized untreatedPD‐L1‐positive advanced gastric or gastroesophageal junction adenocarcinoma into threegroups, group 1 being Pembrolizumab monotherapy (Group P). Pembrolizumab combined withchemotherapy in group 2 (P+C) and placebo combined with chemotherapy in group 3 (C) hadprimary endpoints of PFS in people with PD‐L1 CPS≥1 and OS in people with PD‐L1 CPS≥1 andCPS≥10. The results suggest that Pembrolizumab combined with chemotherapy is not superiorto chemotherapy for OS and PFS in any population. From the perspective of ORR alone, inpatients with CPS≥1, the ORR in group P vs group C vs group P+C was 14.8% vs 37.2% vs48.6%; In patients with CPS≥10, the ORR in group P vs C vs P+C was 25.0% vs 37.8%vs52.8%. In terms of safety, the P vs C group had better safety, with the incidence of anygrade of AE in the P+C vs C group being 94% vs 92%, and the incidence of grade 3‐4 TRAEbeing 71% vs 68%, with no unexpected adverse events.On November 5, 2022, at the CSCO Annual Meeting, Professor Huang Jing reported on theresearch related to the treatment of advanced esophageal cancer with Srulizumab ‐ASTRO‐007: In the whole population, the median PFS in the srulizumab and placebo groupswas 5.8 months vs5.3 months (HR=0.60, P < 0.0001), and the median OS was 15.3 months vs11.8 months (HR=0.68, P=0.0020). Among those with PD‐L1 CPS≥10, the median PFS for bothgroups was 7.1 months vs 5.3 months (HR=0.48, P < 0.0001), and the median OS was 18.6months vs 13.9 months (HR=0.59, P=0.0082). The study also confirmed the significance ofsrulizumab combined with chemotherapy in the first‐line treatment of advanced esophagealcancer, especially in those with CPS > 10.In other cancers, such as triple negative breast cancer and head and neck squamous cellcarcinoma, Pembrolizumab combined with neoadjuvant chemotherapy has shown promisingantitumor activity and clinical efficacy. At present, immunotherapy is also beingexplored in the perioperative period of gastric cancer, such as the phase III clinicalstudy of KEYKEYNOTE 585 perioperative chemotherapy for gastric cancer combined with orwithout PD‐1 inhibitor, and the clinical study of mFOLFOX combined with PD‐1 inhibitorfor the treatment of gastroesophageal conjoint adenocarcinoma or gastric adenocarcinomain perioperative period (NCT03488667), etc. In order to provide a new clinical thinkingfor the treatment of locally advanced gastric cancer.This is a multicenter, double‐blind, randomized, phase 2 trial to investigate theefficacy and safety of serlulimab combined with nab‐paclitaxel plus SOX versusnab‐paclitaxel plus SOX alone as neoadjuvant treatment for locally advanced GC or AEG.The goal of this clinical trial is to learn if serlulimab combined with nab‐paclitaxelplus SOX as neoadjuvant treatment for locally advanced AEG/GC.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02754849/full} -} - - -Record #226 of 538 -@article{jRCTs03121001321, -author = {jRCTs031210013,}, -title = {JCOG2007: a Multicenter Randomized Phase III Study comparing Pembrolizumab + Platinum Combination Chemotherapy with Nivolumab + Ipilimumab + Platinum Combination Chemotherapy for Treatment-naive Advanced Non-Small Cell Lung Cancer without Driver Gene alteration}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCTs031210013}, -year = {2021}, -accession_number = {ICTRP jRCTs031210013}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Group A (1) Non‐squamous NSCLC CBDCA AUC 5 (day 1) + Pemetrexed 500 mg/m2 (day 1) + Pembrolizumab 200 mg/body (day 1), every 3 weeks, up to 4 cycles Pemetrexed 500 mg/m2 (day 1) + Pembrolizumab 200 mg/body (day 1), every 3 weeks, up to 2 years (2) Squamous NSCLC CBDCA AUC 6 (day 1) + nab‐Paclitaxel 100 mg/m2 (day 1, 8, 15) + Pembrolizumab 200 mg/body (day 1), every 3 weeks, up to 4 cycles Pembrolizumab 200 mg/body (day 1), every 3 weeks, up to 2 years Group B (1) Non‐squamous NSCLC CBDCA AUC 5 (day 1) + Pemetrexed 500 mg/m2 (day 1) + Nivolumab 360 mg/body (day 1) + Ipilimumab 1 mg/kg (day 1), every 3 weeks, up to 2 cycles (Ipilimumab given every 6 weeks) Nivolumab 360 mg/body (day 1) + Ipilimumab 1 mg/kg (day 1), every 3 weeks, up to 2 years (Ipilimumab given every 6 weeks) (2) Squamous NSCLC CBDCA AUC 6 (day 1) + Paclitaxel 200 mg/m2 (day 1) + Nivolumab 360 mg/body (day 1) + Ipilimumab 1 mg/kg (day 1), every 3 weeks, up to 2 cycles (Ipilimumab given every 6 weeks) Nivolumab 360 mg/body (day 1) + Ipilimumab 1 mg/kg (day 1), every 3 weeks, up to 2 years (Ipilimumab given every 6 weeks) CONDITION: D002289 Treatment‐naive advanced non‐small cell lung cancer without driver gene alteration ; NSCLC, advanced, driver oncogene negative PRIMARY OUTCOME: Overall Survival SECONDARY OUTCOME: Overall survival of patients with PD‐L1 Tumor proportion score (TPS) <1%, Progression‐free survival, Duration of response, Response proportion, Area under the survival curve from registration until 3 years later(restricted mean survival time: RMST), Adverse events, Serious adverse events, Quality of Life (Patient Reported Outcome) INCLUSION CRITERIA: (1) Cytologically (including biopsy) or histologically confirmed non‐small cell lung cancer. (2) Clinical stage III without indication of definitive thoracic radiotherapy, stage IV, postoperative recurrent disease, or recurrence after radiation therapy. (3) No prior systemic chemotherapy. (4) No prior drug therapy that specifically target the T cell co‐stimulation or checkpoint pathway, such as anti‐PD‐1 antibody, anti‐PD‐L1 antibody, and anti‐CTLA‐4 antibody. (5) No EGFR gene mutations for non‐squamous cell carcinoma. (6) Negative or unknown ALK fusion gene, ROS1 fusion gene, BRAF (V600E) gene mutation, MET exon 14 skipping mutation, RET fusion gene, or NTRK fusion gene. (7) Over 20 years old. (8) Performance status 0 or 1. (9) Eligible regardless of PD‐L1 (22C3) expression. (10) Measureable or non‐measureable. (11) (i) No prior palliative radiation therapy for non‐central nervous system metastases within 7 days (ii) No prior ste}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02256596/full} -} - - -Record #227 of 538 -@article{EUCTR2021-004346-37-ES22, -author = {EUCTR2021-004346-37-ES,}, -title = {A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-004346-37-ES}, -year = {2022}, -accession_number = {ICTRP EUCTR2021‐004346‐37‐ES}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Durvalumab CAS Number: 1428935‐60‐7 Current Sponsor code: MEDI4736 Other descriptive name: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ Product Name: Monalizumab Product Code: IPH2201 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Monalizumab CAS Number: 1228763‐95‐8 Current Sponsor code: IPH2201 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: Oleclumab Product Code: MEDI9447 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Oleclumab CAS Number: 1803176‐05‐7 Current Sponsor code: MEDI9447 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100‐ Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use CONDITION: Patients With Locally Advanced (Stage III), Unresectable Non‐small Cell Lung Cancer (NSCLC) ; MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non‐small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Primary end point(s): Progression Free Survival (PFS) as assessed by BICR, per RECIST 1.1. Timepoint(s) of evaluation of this end point: Up to 5 years after first patient randomized. Main Objective: 1. To demonstrate superiority of durvalumab + oleclumab relative to durvalumab + placebo in participants with unresectable, Stage III NSCLC who have not progressed on prior platinum‐based cCRT; • Assessment by PFS as assessed by BICR; ; ; 2. To demonstrate superiority of durvalumab + monalizumab relative to durvalumab + placebo in participants with unresectable, Stage III NSCLC who have not progressed on prior platinum‐based cCRT; • Assessment by PFS as assessed by BICR Secondary Objective: To demonstrate superiority of durvalumab+oleclumab & durvalumab+monalizumab relative to durvalumab+placebo in patients with unresectable Stage III NSCLC who have not progressed on prior platinum‐based cCRT; assessment by OS, OS24, ORR, DoR, PFS6, PFS12, PFS18, PFS24, PFS2, TTDM, TFST, PFS as assessed by Investigator; ; To investigate relationship between patient’s PD‐L1 expression on tumor cells & efficacy outcomes with durvalumab+oleclumab, durvalumab+monalizumab & durvalumab+placebo; ; To assess PK of durvalumab when in combination with oleclumab & with monalizumab; ; To assess PK of oleclumab when in combination with durvalumab; ; To assess PK of monalizumab when in combination with durvalumab; ; To investigate immunogenicity of durvalumab,oleclumab & monalizumab; ; To assess time to deterioration in pulmonary symptoms SECONDARY OUTCOME: Secondary end point(s): 1. Overall survival (OS) ; 2. Overall survival (OS) at 24 months; 3. Objective response rate (ORR) per RECIST 1.1 as assessed by BICR; 4. Duration of response (DoR) per RECIST 1.1 as assessed by BICR; 5. Progression free survival (PFS) at 6, 12, 18, and 24 months respectively, per RECIST 1.1 as assessed by BICR; 6. Time from randomization to second progression (PFS2); 7. Time from randomization to first date of distant metastasis or death (TTDM); 8. Time from randomization to start date of first subsequent therapy (TFST); 9. Progression free survival (PFS) as assessed by Investigator; 10. IHC analysis of PD‐L1 TC expression relative to efficacy outcomes; 11. The pharmacokinetics (PK) of durvalumab, oleclumab, and monalizumab as determined by concentration; 12. The immunogenicity of durvalumab, oleclumab, and monalizumab as assessed by presence of anti‐drug antibodies (ADAs); 13. Time to deterioration in pulmonary symptoms (TTFCD) Timepoint(s) of evaluation of this end point: ORR, DoR, PFS6, PFS12, PFS18, PFS24, PFS2, TTDM, TFST, PFS: Up to 5 years after first patient randomized; ; OS, OS24: Up to 9 years after first patient randomized; ; ADA, PK: From date of randomization until 3 months after date of last IP dose; ; NSCLC‐SAQ: Up to 5 years after last patient randomized INCLUSION CRITERIA: ‐ Participant must be = 18 years at the time of screening. ‐Histologically‐ or cytologically‐documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease ‐ Provision of a tumour tissue sample obtained prior to CRT ‐ Documented tumour PD‐L1 status by central lab ‐ Documented EGFR and ALK wild‐type status (local or central). ‐ Patients must not have progressed following definitive, platinum‐based, concurrent chemoradiotherapy ‐ Participants must have received at least 2 cycles of platinum‐based chemotherapy concurrent with radiation therapy ‐ Participants must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy) as part of the chemoradiation therapy, to be randomised. Radiation therapy should be administered by intensity modulated RT (preferred) or 3D‐conforming technique. ‐ WHO performance status of 0 or 1 at randomization ‐ Adequate organ and marrow function 60 %). 6. Patients that have normal functioning of organs defined by the following parameters: Hemoglobin>? 90 g/L, Total leukocytes count> 3.0 x 109/L, Absolute neutrophils count>1.5 x 109/L, Platelet count>?100 x 109/L, Total Bilirubin: Within normal limits. TGP and TGO: ?2.5 times the normal highest institutional limit. Creatinine: Within normal limits for each institution. Blood glucose: Within normal limits for each institution. Total and fractioned proteins: Within normal limits for each insti}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01836718/full} -} - - -Record #231 of 538 -@article{Wang24, -author = {Wang, S, and Zhang, P}, -title = {Induction therapy with PD-1 antibody combined with platinum-based doublet chemotherapy for locally-advanced non-small cell lung cancer: a randomised controlled, open-label, phase 2 trial}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644913741}, -publication type = {Journal article; Conference proceeding}, -keywords = {*doublet chemotherapy; *non small cell lung cancer; Adult; Conference abstract; Controlled study; Drug combination; Drug dose; Drug therapy; Event free survival; Female; Human; Major clinical study; Major pathological response; Male; Multicenter study; Multiple cycle treatment; Overall survival; Pathological complete response; Phase 2 clinical trial; Pneumonia; Progression free survival; Quality of life; Radiotherapy; Randomized controlled trial; Surgery; Therapy}, -abstract = {Background: Chemoradiotherpay plus immunotherapy is recommended for unresectable locally‐advanced non‐small cell lung cancer (NSCLC) based on PACIFIC trial. However, it is unclear whether surgery can provide survival benefit for patients with tumors initially unresectable transformed into resectable ones after chemoimmunotherapy. This trial aims to investigate the efficacy and safety of the therapeutic regimen of chemoimmunotherapy plus surgery or radiotherapy. Methods: Patients with unresectable stage IIIB‐IIIC NSCLC were enrolled to receive 4 cycles (q21d) of PD‐1 antibody (Serplulimab, 4.5mg/kg) and platinumbased doublet chemotherapy. After the induction therapy, those with disease downstaged to IIIA or lower stage and resectable were randomized to receive radical surgery or radiotherapy with a ratio of 1:1, and those with stage IIIB or higher stage or unresectable disease after induction therapy were then treated by oncologists. Primary endpoint was event‐free survival (EFS). Secondary endpoints included objective response rate (ORR), major pathologic response (MPR), pathologic complete response (pCR), progression‐free survival (PFS), disease‐free survival (DFS), overall survival (OS), R0 rate of resection, severe adverse event (SAE) rate, and health related quality of life (HRQol). Preliminary short‐term results were collected. Results: One hundred patients will be enrolled as planned, and a total of 82 patients were enrolled by the data cutoff date (January 6, 2024). Fifty‐four and 28 patients were diagnosed with stage IIIB and IIIC disease, respectively. The percentage of squamous carcinomas, adenocarcinomas, and NSCLCs not otherwise specified were 68.3% (56/82), 15.9% (13/82), and 15.9% (13/82), respectively. ORR in 73 evaluable patients was 74.0% (54/73). Twenty‐six of them are still in induction therapy phase, and the other 47 and 9 patients received 4 cycles and 1‐3 cycles of induction therapy, respectively. Thirty‐one patients had downstaged and resectable disease after 4 cycles of induction therapy, and 26 of them were randomized to arm A (n = 13) and arm B (n = 13), and 5 refused randomization (3 received surgery). One patient received surgery after 2 cycles of induction therapy. In 56 patients finished 1‐4 cycles of induction therapy, the rate of conversion to resectability was 57.1% (32/56). In total, 17 patients received surgery, and the MPR and pCR rate in 16 evaluable patients were 62.5% (10/16) and 31.3% (5/16), respectively. The grade 3‐5 adverse event rate in 56 patients finished induction therapy was 50.0% (28/56). One patient died of immune‐related pneumonia. Conclusions: Induction therapy with PD‐1 antibody (Serplulimab) and chemotherapy could transform half of unresectable stage IIIB‐IIIC NSCLC into resectable, and the efficacy and safety were satisfactory.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02736441/full} -} - - -Record #232 of 538 -@article{Arcidiacono23, -author = {Arcidiacono, F, Trippa, F, Maranzano, E, Italiani, M, Casale, M, and Anselmo, P}, -title = {Stereotactic ablative radiotherapy and durvalumab: the backbone of unresectable locally advanced non-small cell lung cancer patients unfit to concurrent chemo-radiotherapy -Rib of START-NEW-ERA trial}, -journal = {Journal of thoracic oncology}, -volume = {18}, -number = {4}, -pages = {S112}, -year = {2023}, -accession_number = {EMBASE 2023625722}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *chemoradiotherapy; *histology; *non small cell lung cancer; *rib; *stereotactic body radiation therapy; Adenocarcinoma; Adult; Aged; Cancer recurrence; Cancer size; Cancer survival; Clinical outcome; Clinical trial; Conference abstract; Controlled study; Drug safety; Drug therapy; Feasibility study; Female; Follow up; Funding; Histopathology; Human; Human tissue; Immunotherapy; Local recurrence free survival; Major clinical study; Male; Neoadjuvant therapy; Outcome assessment; Overall survival; Phase 2 clinical trial; Primary tumor; Radiotherapy; Recurrent disease; Squamous cell carcinoma; Surgery}, -abstract = {Background Several real‐world experiences have been reported safety and effectiveness of Durvalumab after concurrent or sequential chemo‐radiotherapy (ChT‐RT) in lLA‐NSCLC patients. There is a lack of data after sequential ChT‐hypofractionated RT. In single arm phase II trial (NCT05291780) we assessed local control (LC) and safety of stereotactic ablative radiotherapy (SAbR) in unresectable LA‐NSCLC patients unfit for concurrent ChT‐RT (1). Here we report clinical outcomes of SAbR in LA‐NSCLC patients treated with radical‐intent based on PACIFIC trial. Methods Between December 31, 2015 and June 30, 2022 71 LA‐NSCLC patients were enrolled. 40 (56%) fit patients received neoadjuvant ChT and 15 (37%) received Durvalumab. The tumor volume included primary tumor (T) and any regionally positive node/s (N). The co‐primary study endpoints were LC and safety. Results The median age was 71 years (range, 52–78). Histology was adenocarcinoma (ADC) and squamous cell carcinoma (SCC) and in 9 (60%) and 6 (40%), respectively. The stage was IIIA, IIIB and IIIC in 7 (47%), 5 (33%) and 3 (20%) patients, respectively. Median prescribed dose was 45 Gy (range, 40–50) and 40 Gy (35–50) in 5 daily fractions to T and N, respectively. After a median follow‐up of 16 months (range, 6–62), 4 (27%) patients had experienced local recurrence (LR) at a median time of 13 months (range, 7–34). The median LR‐free survival (FS) was 34 months (95% CI, 14 to 34). The 1‐, 2‐ and 4‐year LR‐FS rates were 92 ± 8%, 72 ± 14% and 48 ± 22%, respectively. At last follow‐up, 23 (58%) patients were alive. Median overall survival (OS) was 50 months (95% CI, 31–55). The 1, 2, and 4‐year OS rates were 92 ± 5%, 70 ± 8% and 51 ± 9%, respectively. 7 patients had disease recurrence, 4 and 3 during and after completion of Durvalumab. 2(13%) discontinued Durvalumab due to G3 toxicity. Conclusions SABR and immunotherapy can be the backbone of patients unfit to concurrent ChT‐RT. Our early outcomes would suggest the feasibility of using this approach in LA‐NSCLC patients unfit for concurrent ChT‐RT. Int J Radiat Oncol Biol Phys. 2022 Oct 24;S0360–3016(22)03459–9. doi: 10.1016/j.ijrobp.2022.10.025. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.}, -DOI = {10.1016/S1556-0864(23)00382-9}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02571469/full} -} - - -Record #233 of 538 -@article{Peters15, -author = {Peters, S}, -title = {Immunotherapy for lung cancer}, -journal = {Annals of oncology}, -volume = {26}, -pages = {vii7}, -year = {2015}, -accession_number = {EMBASE 72209178}, -publication type = {Journal article; Conference proceeding}, -keywords = {*Japanese (people); *human; *immunotherapy; *lung cancer; *oncology; *society; Adaptive immunity; Algorithm; Antigen specificity; Chemoradiotherapy; Chemotherapy; Deregulation; Health care quality; Histology; Hope; Immune system; Immunological memory; Long term survival; Melanoma; Mesothelioma; Monotherapy; Neoplasm; Non small cell lung cancer; Overall survival; Patient; Population; Safety; Small cell lung cancer; Surgery; Survival; T lymphocyte; Therapy; Vaccination}, -abstract = {Despite advances in the treatment of non‐small cell lung cancer (NSCLC) over the past several decades, only small incremental overall survival benefits have been demonstrated. Although historically not considered immunogenic, lung cancer has emerged as an exciting new target for immune‐oncology, which uses the unique properties of the immune system to fight cancer. As more is learnt about the biology of lung cancer, the importance of T cells is becoming increasingly clear. The role of T cells is important as part of the adaptive immune response as they specifically target tumour antigens and induce immunological memory. These responses by T cells are regulated through a complex balance of inhibitory 'checkpoints' and activating signals. Deregulation of this process is one way that cancers evade the immune system. Vaccination strategies have failed to provide any clinical benefit in early disease after radical surgery (MAGEA3 antigen, MAGRIT trial), in consolidation after radiochemotherapy for stage III disease (Stimuvax®, START trial) or alternatively in the advanced disease setting (Lucanix™). Taking into account that well conducted large phase III randomized trials were negative despite the identification and the use of potent specific antigens in efficiently manufactured vaccines, such peptide/cellular based vaccines are not considered anymore as a promising potent tool against lung cancer when used as monotherapy. Proof‐of‐ concept for immunotherapy has been provided later by the approval of anti‐CTLA‐4 antibody, ipilimumab, for the treatment of patients with advanced melanoma. More recently, anti‐PD‐1/PD‐L1 agents have been shown to be a promising strategy in the management of various cancers, including lung cancer. Immunotherapy studies continue to improve our understanding of the immune system. A number of ongoing trials with immune checkpoint inhibitors, including anti‐PD‐1, anti‐PD‐L1 and anti‐CTLA‐4 agents have shown encouraging activity with the potential for long‐term survival and a manageable safety profile. These clinical benefits have been demonstrated in multiple lines of NSCLC therapy across a range of patient populations, regardless of tumour histology or mutational status. Importantly, the first large randomized trials in second line treatment of NSCLC have shown a very significant survival benefit of nivolumab as compared to docetaxel in squamous as well in non‐squamous unselected patients. The benefit of such approach is probably greater than the benefit of the introduction of second line chemotherapy versus placebo more than a decade ago. An important aspect of immunotherapy in lung cancer‐but also in other cancer types‐is the hope for long‐term benefit and “a plateau” effect regarding advanced disease patients survival, observed quite consistently accross all clinical trails. These two trials have thereafter defined a new standard of care and introduced immunotherapy in our guidelines and algorithms. Additionally, very encouraging early results are emerging in 2015 regarding the treatment of mesothelioma as well as small‐cell lung cancer. Lastly, the unique mechanism of action of immune‐oncology therapies also offers the opportunity for these agents to be combined with conventional treatments. These combinations have the potential to further improve clinical outcomes for patients with NSCLC and overcome resistance to targeted treatments.}, -DOI = {10.1093/annonc/mdv401.3}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01174407/full} -} - - -Record #234 of 538 -@article{Murakami22, -author = {Murakami, Y}, -title = {SY17-3 Current status and perspective of the combination of immunotherapy and chemoradiotherapy for locally advanced head and neck cancer}, -journal = {Annals of oncology}, -volume = {33}, -pages = {S441}, -year = {2022}, -accession_number = {EMBASE 2019358235}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer combination chemotherapy; *chemoradiotherapy; *head and neck cancer; *immunotherapy; Additive effect; Adjuvant chemotherapy; Adult; Cancer adjuvant therapy; Cancer surgery; Cancer survival; Clinical trial; Comparative effectiveness; Complication; Conference abstract; Controlled study; Drug combination; Drug megadose; Drug safety; Drug therapy; Female; Gastroesophageal junction; Head and neck squamous cell carcinoma; Human; Larynx; Local therapy; Male; Neoadjuvant therapy; Non small cell lung cancer; Postoperative complication; Progression free survival; Radiotherapy; Randomized controlled trial; Surgery}, -abstract = {The standard treatment for locally advanced squamous cell carcinoma of the head and neck (LA‐SCCHN) is surgery ± postoperative (chemo)radiation therapy [(C)RT] or definitive CRT. The standard concurrent chemotherapy regimen is tri‐weekly cisplatin. In the postoperative setting, weekly cisplatin is an alternative option. For laryngeal preservation, induction docetaxel, cisplatin, and 5‐FU followed by (C)RT is the treatment option. Recently, the efficacy of combined immunotherapy and CRT for curative intent has been reported. In the PACIFIC trial, definitive CRT followed by durvalumab significantly improved survival compared to placebo in non‐small cell lung cancer. In the CHECKMATE 577 study, nivolumab following neoadjuvant CRT plus surgery improved survival outcomes compared to placebo in esophageal or gastroesophageal junction cancer. On the other hand, in the JAVELIN head & neck 100 study, which examined the additive effect of avelumab to CRT for LA‐SCCHN, avelumab did not prolong progression‐free survival compared to the placebo. The GORETEC 2015‐01 trial compared the efficacy and safety of pembrolizumab + RT with cetuximab + RT in patients unfit for receiving high‐dose cisplatin. Compared to the cetuximab group, the pembrolizumab group did not improve locoregional control and survival outcomes. The KEYNOTE‐412 trial is currently underway to determine whether pembrolizumab should be added to standard CRT. The IMvoke010 study is also underway to evaluate the efficacy of atezolizumab as adjuvant therapy after definitive local therapy. The ongoing KEYNOTE‐689 trial evaluates the efficacy and safety of pembrolizumab as neoadjuvant and adjuvant therapy in combination with adjuvant RT ± cisplatin. Xevinapant is an antagonist of inhibitor of apoptosis proteins. In a randomized PII trial, xevinapant with the standard CRT improved locoregional control and survival outcomes compared to placebo. The confirmatory PIII Trilynx trial is ongoing.}, -DOI = {10.1016/j.annonc.2022.05.471}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02426482/full} -} - - -Record #235 of 538 -@article{Aggarwal19, -author = {Aggarwal, C}, -title = {ES02.03 Management of Other Non EGFR Oncogene Addicted Tumors}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S16‐S17}, -year = {2019}, -accession_number = {EMBASE 2003407112}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; *oncogene; Adjuvant chemotherapy; Adult; Advanced cancer; Cancer adjuvant therapy; Cancer patient; Cancer staging; Cancer surgery; Cancer survival; Chemoradiotherapy; Conference abstract; Controlled study; Drug therapy; Female; Gene mutation; Gene rearrangement; Genetic marker; Genetic screening; Human; Lobectomy; Lymph node; Male; Medline; Molecularly targeted therapy; Neoadjuvant therapy; Overall survival; Phase 3 clinical trial; Pneumonectomy; Preoperative chemotherapy; Preoperative evaluation; Progression free survival; Radiotherapy; Randomized controlled trial; Surgery; United States}, -abstract = {Stage III non‐small cell lung cancer accounts for heterogeneous group of diseases, due to differences in tumor size, location number of nodes involved, and lymph node station involved. Stage III non‐small cell lung cancer comprises 2 distinct stages, stage IIIA and IIIB disease that have different prognosis, and are usually treated differently. Approximately 15% of all patients with newly diagnosed non‐small cell lung cancer present with stage III disease. Options for stage III non‐small cell lung cancer include surgery, with lobectomy or pneumonectomy depending on the tumor stage, and lymph node involvement. Chemotherapy may be administered in the neoadjuvant, concurrent or adjuvant setting. Radiation therapy can be given in a concurrent, sequential approach, or may be administered in the postoperative fashion. Combination approaches are often used, and due to the significant need of multi‐modality therapy, treatment decisions are usually made in a multidisciplinary setting. The optimal therapeutic approach for patients with stage IIIA non‐small cell lung cancer remains controversial. For subset of patients with T3 to T4 N0‐1 disease, and superior sulcus location, surgery remains a viable and preferred option. However, the optimal treatment for patients with stage III A, with bulky lymph node involvement, or multi station lymph node involvement including N2 disease, remains an area of ongoing controversy. Tri‐modality approaches using preoperative chemotherapy, or upfront chemoradiation therapy followed by surgery have been evaluated (1). For patients with surgically unresectable, or medically inoperable disease, concurrent chemoradiation therapy has been established as the standard of care for patients spanning the spectrum of stage IIIA and IIIB disease. Recently, the PACIFIC trial demonstrated an improvement in progression free survival and overall survival with the administration of durvalumab as consolidation therapy (regardless of PDL‐1 status) for patients who had not progressed after 2 or more cycles of definitive concurrent platinum‐based chemoradiation therapy (2, 3). This approach represents a new paradigm in the management of unresectable NSCLC, and has now been adopted as standard of care. Management of Stage III patients with non EGFR oncogene addicted tumors is an area of active research. ALK or ROS directed oral tyrosine kinase inhibitors (TKIs) are not typically administered in the adjuvant setting outside of a clinical trial. There are several trials evaluating the use of targeted therapies. ALINA, is one such trial, that is a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase‐positive ALK positive NSCLC (4). Another study is comparing adjuvant alectinib versus adjuvant platinum‐based chemotherapy in patients with ALK positive NSCLC, here the alectinib is administered for 2 years (NCT 03456076). The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing (ALCHEMIST) trial is actively enrolling patients with operable NSCLC and will perform genetic screening of their tumors. Patients with EGFR mutation or ALK gene rearrangement in their tumor will be randomized to placebo versus erlotinib or crizotinib, respectively (NCT02194738). We await the results of these trials prior to routine incorporation of molecularly directed therapy in the management of locally advanced disease. References: 1. Albain KS, Swann RS, Rusch VW, Turrisi AT, 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non‐small‐cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379‐86. Epub 2009/07/28. ). PubMed PMID: 19632716; PubMed Central PMCID: PMC4407808. 2. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non‐Small‐Cell Lung Cancer. The New England journal of medicine. 2017;377(20):1919‐29. 3. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. 2018; 379:2342‐2350 4. Solomon BJ, Ahn JS, Barlesi F et al. ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase‐positive (ALK+) non‐small cell lung cancer (NSCLC). J Clin Oncol 37, 2019 (suppl; abstr TPS8569)}, -DOI = {10.1016/j.jtho.2019.08.075}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01995486/full} -} - - -Record #236 of 538 -@article{Jelinek17, -author = {Jelinek, MJ, Melotek, JM, Vokes, EE, Weichselbaum, RR, Chmura, SJ, and Patel, JD}, -title = {A phase I trial to evaluate concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in stage IV NSCLC}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {11}, -pages = {S1579‐S1580}, -year = {2017}, -accession_number = {EMBASE 619317613}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *non small cell lung cancer; *stereotactic body radiation therapy; Adaptive immunity; Adult; Cancer survival; Cell killing; Controlled study; Drug combination; Drug therapy; Female; Human; Human tissue; Hypofractionated radiotherapy; Immunogenicity; Immunotherapy; Liver; Major clinical study; Male; Mediastinum lymph node; Pharmacokinetics; Phase 1 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Sample size; Toxicity; Tumor cell; Tumor microenvironment}, -abstract = {Background: Combination checkpoint inhibition has clinical activity in various tumor types. A phase I trial of nivolumab and ipilimumab in advanced NSCLC demonstrated encouraging activity and manageable toxicity. Irradiation provides palliative and local responses in NSCLC. Increasing evidence suggests that apart from its direct effects, radiotherapy and particularly ablative hypofractionated radiotherapy can act as a trigger for the innate and adaptive immune system termed the abscopal effect. The balance of signals (pro‐immunogenic and immunosuppressive) may determine the effectiveness of both systemic antitumor immune responses and local tumor cell killing. Direct tumor debulking by radiation may also be particularly well suited as an adjunct to immunotherapy. In addition, immunotherapy after RT has demonstrated survival benefit. Methods: This is a phase I study to evaluate the safety and efficacy of combination nivolumab (3 mg/kg every 2 weeks), ipilimumab (1 mg/kg every 6 weeks), and sequential or concurrent SBRT in patients with stage IV NSCLC. Patients will be simultaneously accrued to sequential versus concurrent arms in a randomized 1:1 fashion as first‐line therapy. Eligibility criteria include EGFR/ALK negative stage IV disease with PS 0‐1. The primary outcome is the safest SBRT dose to various metastatic locations delivered prior to or concurrently with nivolumab and ipilimumab. Metastatic locations include 1)peripheral lung, 2)central lung or mediastinal lymph node, 3)liver, 4)osseous, and 5)abdominal/pelvic with doses ranging 30‐50 Gy in 3‐5 fractions. Secondary outcomes include toxicity, response rate, progression free survival, tumor microenvironment changes, and immunogenicity of combination therapy. Patients will undergo biopsies pre‐ and post‐SBRT to provide insight into the mechanism of the radiation‐induced pro‐inflammatory microenvironment. The total sample size will include 40‐80 patients depending on the number who contribute to multiple metastatic sites. Twenty patients per randomized arm will be needed to assess the initial starting dose. Results: Trial in progress.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01428348/full} -} - - -Record #237 of 538 -@article{EUCTR2014-004832-20-FR15, -author = {EUCTR2014-004832-20-FR,}, -title = {A trial comparing a drug named Abemaciclib and another drug named Docetaxel in patients with lung cancer who have already received chemotherapy treatements}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2014-004832-20-FR}, -year = {2015}, -accession_number = {ICTRP EUCTR2014‐004832‐20‐FR}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Abemaciclib Pharmaceutical Form: Capsule INN or Proposed INN: Not available CAS Number: 1231929‐97‐7 Other descriptive name: LY2835219 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50‐ INN or Proposed INN: Not available CAS Number: 1231929‐97‐7 Other descriptive name: LY2835219 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Product Name: Docetaxel Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: Docetaxel Other descriptive name: DOCETAXEL Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20‐ CONDITION: Stage IV squamous NSCLC patients who have progressed after platinum‐based chemotherapy ; MedDRA version: 18.0 Level: PT Classification code 10025125 Term: Lung squamous cell carcinoma stage IV System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: Compare treatment with abemaciclib versus docetaxel therapy with respect to investigator‐assessed progression‐free survival (PFS) in patients with Stage IV squamous cell carcinoma NSCLC who have relapsed after prior platinum‐based therapy for advanced disease. Primary end point(s): The primary efficacy measure is investigator‐assessed PFS as defined as the time from randomization until the first evidence of objective progression as defined by RECIST 1.1 (Eisenhauer et al. 2009) or death from any cause, whichever is earlier. Secondary Objective: •To evaluate the pharmacokinetic parameters including abemaciclib and its active metabolites; •To compare treatment of abemaciclib versus docetaxel with respect to the following:; • Overall survival; • Objective response rate ; • Disease control rate; • Time to worsening of Performance Status; • The safety and tolerability using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; • Change from baseline in patient‐reported outcomes including: 1) the MD Anderson Symptom Inventory Lung Cancer (MDASI‐LC) questionnaire pain and disease‐related symptoms scores; and 2) the EuroQol Group’s EQ‐5D‐5L questionnaire index score, derived from the 5‐item descriptive system, and visual analog scale (VAS) self‐rated health score.; Timepoint(s) of evaluation of this end point: Every 6 weeks SECONDARY OUTCOME: Secondary end point(s): Overall Survival ; PK ; Objective Response Rate ; Disease Control Rate ; Time to Worsening ECOG Performance Status ; Health Outcomes ; Timepoint(s) of evaluation of this end point: Every visit ; Cycle 1 and Cycle 4 ; Every visit ; Every visit ; Every visit ; Every visit ; INCLUSION CRITERIA: [1] Have confirmed diagnosis of stage IV NSCLC disease predominantly squamous histology according to the American Joint Committee on Cancer on Cancer Staging Handbook (Edge et al. 2009). Squamous NSCLC diagnosis must be confirmed by histology or cytology local pathology report. [2] Availability of adequate formalin‐fixed paraffin‐embedded (FFPE) tumor derived material (tumor blocks or 10 slides minimum) from a core needle biopsy or surgery for analysis of biomarkers. This sample should be the most recent available sample containing adequate material. Re‐biopsy after progression from prior therapy is not required. *The pa [3]Have failed first line platinum‐based therapy and who have had no more than two prior therapies one of which may be an immune checkpoint inhibitor.Patients with recurrent disease after adjuvant or neoadjuvant therapy or patients who have received combined chemotherapy and radiation for locally advanced disease are eligible, if:}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01858937/full} -} - - -Record #238 of 538 -@article{Lidija22, -author = {Lidija, B, Darijo, H, Marijo, B, Tihana, B-J, Jelena, V, and Eduard, V}, -title = {DURVALUMAB IN THE TREATMENT OF STAGE III NSCLC - SINGLE CENTER EXPERIENCE}, -journal = {Libri oncologici}, -volume = {50}, -number = {SUPPL 1}, -pages = {110‐111}, -year = {2022}, -accession_number = {EMBASE 638201328}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *immunotherapy; *non small cell lung cancer; Adenocarcinoma; Advanced cancer; Aged; Bone; Brain; Cancer patient; Cancer survival; Case report; Chemoradiotherapy; Clinical article; Clinical trial; Conference abstract; Diagnostic procedure; Drug therapy; Drug withdrawal; Female; Follow up; Gene expression; Health care quality; Hepatitis; Human; Hyperthyroidism; Hypothyroidism; Immune‐related gene; Kidney; Male; Overall survival; Phase 3 clinical trial; Pneumonia; Progression free survival; Protein expression; Radiotherapy; Rash; Retrospective study; Sample size; Side effect; Squamous cell carcinoma; Treatment duration; Treatment response; University hospital}, -abstract = {Background: In the phase 3, placebo‐controlled PACIFIC trial of patients with unresectable, stage III non‐small cell lung cancer (NSCLC) without disease progression after concurrent chemoradiotherapy, consolidative durvalumab was associated with significant improvements in the overall survival (OS) and progression‐free survival (PFS). Based on these results, durvalumab become the new standard of care for patients with locally advanced NSCLC who didn't progress on concomitant chemoradiotherapy. In this work we present the real world results of consolidation immunotherapy with durvalumab in patients with PD‐L1 expression positive stage III NSCLC in the Department of Oncology, University Hospital of Split. Methods: This retrospective analysis included 26 patients with PD‐L1 expression positive stage III NSCLC who were treated with concomitant chemoradiotherapy and there were no signs of disease progression on control lung CT, and who received at least one cycle of durvalumab in the period from 2018‐ 2021. First cycle of durvalumab had to be applied within 42 days from the last radiotherapy fraction. Durvalumab dose was 10 mg/kg every two weeks. Maximal treatment duration was one year. Results: Out of 26 included patients there were 19 men and 7 women. Median patient's age was 67,5 years. Squamous cell carcinoma was present in 17 patients (65%) and 9 patients (35%) had adenocarcinoma. PD‐L1 tumor‐membrane expression was as follows: 1‐49% in 18 patients (70%), 50% or more in 8 patients (30%). The median number of administered cycles of durvalumab was 14 (range 1‐25). The median PFS was 11 months. The median OS was not reached (at the time of analysis 16 patients (61,5%) were alive). The objective response rate on durvalumab was 34,6%. Stable disease was the best response to therapy in 12 patients (46%), disease progression was observed in 4 patients (15%), while 1 patient (3%) had not yet undergone control diagnostic procedure. Sites of disease progression on durvalumab were: intrathoracic in 4 patients and extrathoracal in 4 patients ‐ brain and bones in 3 patients and kidney in one patient. The immune‐related adverse events were observed in 13 patients (50%): hypothyroidism and hyperthyroidism grade 1‐2 in 8 patients (30%), pneumonitis grade 1‐2 in 2 patients, rash grade 1 in one patient and creatine kinase elevation grade 2 in one patient. In one patient there were hepatitis grade 2 and that was the reason for treatment discontinuation. Conclusion: Treatment with durvalumab in patients with unresectable stage III NSCLC without disease progression after concurrent chemoradiotherapy in our institution was effective and well tolerated. To draw firm conclusions and to compare it with results from registrational study longer follow up and larger sample size are needed.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02457785/full} -} - - -Record #239 of 538 -@article{Vrbanec21, -author = {Vrbanec, D, and Radosavljevic, D}, -title = {Top ten news (except COVID) in 2020 oncology}, -journal = {Libri oncologici}, -volume = {49}, -number = {SUPPL 2}, -pages = {33‐34}, -year = {2021}, -accession_number = {EMBASE 637428440}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer combination chemotherapy; *coronavirus disease 2019; Achievement; Adjuvant chemotherapy; Adult; Advanced cancer; Bladder cancer; Breast cancer; Cancer adjuvant therapy; Cancer mortality; Cancer patient; Cancer recurrence; Cancer staging; Cancer survival; Chemoradiotherapy; Clinical trial; Conference abstract; Conjugate; Controlled study; Disease free survival; Drug combination; Drug therapy; Electrocardiograph; Female; Follow up; Gene expression; Health care quality; Human; Immunotherapy; Liver cell carcinoma; Maintenance therapy; Major clinical study; Metastatic colorectal cancer; Non small cell lung cancer; Ovary cancer; Overall response rate; Phase 3 clinical trial; Progression free survival; Protein expression; Public health problem; Randomized controlled trial; Recurrent disease; Remission; Side effect; Transitional cell carcinoma; Treatment duration; Triple negative breast cancer}, -abstract = {Despite the many challenges faced in 2020, we have seen impressive progress in many areas of cancer research. Twenty‐one novel oncology drugs were approved by the U.S. Food and Drug Administration (FDA). Although cancer is one of the major public health problems worldwide, cancer mortality projections for 2021 confirm the persistent declines in cancer mortality in EU and US for many specific cancers. The breast cancer treatment landscape has evolved in the past year and several new drugs approved in 2020 as antibody drugs conjugates (ADC) sacituzumab in TNBC and fam‐trastuzumab deruxtecan‐nxki (T‐DXd) in metastatic HER2 positive BC, as well as tucatinib, a small kinase inhibitor. A few very important clinical trial /RxPONDER, ADAPT, PRIME II/ presented last year support de‐escalation of adjuvant chemotherapy and radiation, sparing patients from some of the side effects that can accompany treatments. In ovarian cancer five‐year follow‐up data from the SOLO‐1 trial continue to show progression‐free survival benefit of olaparib as maintenance therapy following platinum‐based chemotherapy in the frontline setting. In the final analysis of SOLO‐2 trial, maintenance olaparib provided an improvement of 12.9 months in median OS vs placebo in women with relapsed BRCA‐related ovarian cancer who had responded to their most recent platinum‐based chemotherapy after having received at least one more line of chemotherapy.In 2020 first new treatment for hepatocellular carcinoma approved in more than ten years according to the data from phase III IMbrave 150 trial. In that study, which includes 501 patients the combination of atezolizumab and bevacizumab provides the longest survival seen in a front‐line phase III study in advanced HCC, confirming atezo + bev as a standard of care for previously untreated, unresectable HCC.In the field of thoracic oncology there were some very important news in 2020, potentially practice changing. Osimertinib, next generation EGFR‐TKI, standard first line therapy in metastatic EGFR‐mutated advanced NSCLC was successfully used, in ADAURA study, in adjuvant setting vs placebo (planned treatment duration three years), in resected NSCLC patients, stage IB‐IIIA. Patients might had adjuvant chemotherapy also, and there was no outcome differences between these two groups. Overall, there was a 79% reduction in the risk of disease recurrence or death (DFS HR was 0.21, p<0.0001). Lorlatinib is the third generation of ALKinhibitors in the treatment of advanced NSCLC. The results of CROWN study where lorlatinib was given in the first line treatment were presented at ESMO 2020. In this randomized study, comparing lorlatinib with crizotinib, lorlatinib was superior in the term of PFS, HR was 0.28, p<0.001, this superiority was particularly pronounced in intracranial disease, where the percent of intracranial response was 82% in lorlatinib arm and only 23% in crizotinib arm, and percent of complete response per CT was 71% vs 7%. Lorlatinib has been recently approved for patients with advanced ALK‐positive NSCLC, irrespectively of treatment line. Also of interest were two studies that inovatively used immunologic drugs as a combination in advanced NSCLC: in Check Mate 9LA randomized study, cytotoxic chemotherapy was given in paralell with nivolumab + ipilimumab for first two cycles, and compared with four cycles of chemoherapy. Median OS was significantly better: 15.6 vs 10.9 months, HR 0.66 and a overall response rate was 38% vs 25%. CITYSCAPE study give us inovative combination of two immuno‐oncology drugs, tiragolumab as TIGIT inhibitor, and standard atezolizumab. Median PFS was particularly longer in the population of patients with high PD‐L1 expression (NE vs 4.11 months, HR 0.30). In gastrointestinal oncology, last year will be remembered by introducing immunotherapy in first line treatment of metastatic colorectal cancer for patients with MSI‐H tumors. In KN177, such patients were randomized to receive pembrolizumab or standard chemotherapy+/‐biologic therapy, and after second interim analysis, there was a very clear adventage for pembrolizumab in terms of mPFS (16.5 vs 8.2 months) and duraton of response (at 24 months, 83% vs 35%). The results are impressive, and it is for expected to be confirmed by OS adventage in future analyses. In urological oncology, JAVELIN Bladder 100 study demonstrated that the maintenance avelumab + best supportive care is superior over best supportive care alone after platinum‐based first‐line chemotherapy in advanced urothelial carcinoma. In overall population, OS was 21.4 vs 14.3 months, HR 0.69, p<0.001, and the results are even better in PD‐L1 positive population, with HR 0.56. These results are very probably practice changing, since cytotoxic chemotherapy have very modest achievements in the field of urothelial cancer.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02375405/full} -} - - -Record #240 of 538 -@article{Goldman24, -author = {Goldman, JW, Sands, J, Hallqvist, A, Kim, HR, Li, G, Wu, L, Su, W, Bayt, T, Yang, X-N, and Hochmair, M}, -title = {LIBRETTO-432: a phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET+) NSCLC}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644909505}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Adult; Aged; Conference abstract; Controlled study; Double blind procedure; Drug combination; Drug therapy; Event free survival; Female; High throughput sequencing; Histopathology; Human; Line of treatment; Male; Multicenter study; Neoplastic cell transformation; Phase 3 clinical trial; Radiotherapy; Response evaluation criteria in solid tumors; Surgery; Therapy; Treatment duration}, -abstract = {Background: Around 30% of NSCLC patients (pts) present with stage IB‐IIIA disease. Standard treatment options are definitive locoregional therapies w/wo chemotherapy (CT) and/or immunotherapy, followed by surveillance until disease recurrence. Targeted therapies are standard for metastatic NSCLC with driver alterations and recent Phase III trial data has emerged in support of their use in the adjuvant setting for stage IB‐IIIA (ADAURA and ALINA). RET is a key oncogenic driver in NSCLC and a promising target for adjuvant targeted therapy. Selpercatinib, a highly selective, potent and CNS active RET inhibitor, recently demonstrated longer PFS than platinum‐based CT as 1L treatment in pts with RET+ advanced NSCLC (Zhou et al. NEJM 2023). LIBRETTO‐432 is a Phase 3, global, multicenter, randomized, double‐blind, controlled trial evaluating efficacy and safety of adjuvant selpercatinib v Placebo in pts with RET+ Stage IB‐IIIA NSCLC following completion of definitive therapies with curative intent, and other adjuvant therapy if indicated (NCT04819100). Methods: Pts (n≈170) will be randomized (1:1) to selpercatinib BID [160mg≥50kg; 120mg< 50kg], or Placebo, in continuous 28‐day cycles for a maximum treatment duration of 3y. Stratification factors include disease stage (IB/ II/IIIA) and prior definitive therapy. Treatment will continue until disease recurrence/ progression, unacceptable toxicity, or another protocol‐defined reason. Crossover is allowed for Placebo pts who experience disease recurrence/progression. Key eligibility criteria include age ≥18 y; histologically confirmed Stage IB/II/IIIA NSCLC; RET+ tumor by PCR/NGS; prior definitive locoregional therapy with curative intent (surgery, radiotherapy) for Stage IB/II/IIIA NSCLC; and ECOG performance status 0‐1. Maximum time allowed from definitive therapy completion to randomization is 26 w. Key exclusion criteria are evidence of other known oncogenic drivers; SCLC; and disease recurrence/progression following definitive therapy. Primary endpoint is investigator‐assessed event‐free survival (IAEFS) in the primary analysis population (pts with Stage II‐IIIA). EFS is defined as time from randomization until locoregional disease recurrence with histopathological confirmation, distant disease recurrence per RECIST v1.1 or histopathological confirmation, or death. Gated secondary endpoints include IAEFS in the overall population (pts with Stage IB‐IIIA) and OS in both primary analysis and overall populations. Non‐gated secondary efficacy endpoints include BICR‐assessed EFS, BICR and investigator‐assessed time to distant disease recurrence in the CNS, and PFS on next line of treatment. Recruitment is ongoing, with enrollment across ∼170 sites and 30 countries. Results from this trial will further inform the value of RET inhibition and genomic testing for adjuvant NSCLC pts.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02748692/full} -} - - -Record #241 of 538 -@article{Patel19, -author = {Patel, J, Jelinek, M, Bestvina, C, Pitroda, S, Vokes, E, and Chmura, S}, -title = {P2.04-12 Ph I Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and SBRT to Multiple Sites in Patients with Stage IV NSCLC}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S712}, -year = {2019}, -accession_number = {EMBASE 2003406602}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *cancer staging; *non small cell lung cancer; *stereotactic body radiation therapy; Ablation therapy; Adult; Adverse drug reaction; Bone; Cancer survival; Cohort analysis; Comparative effectiveness; Conference abstract; Controlled study; DNA RNA hybridization; DNA sequence; Drug combination; Drug safety; Drug therapy; Female; Human; Immunotherapy; Liver; Major clinical study; Male; Pharmacokinetics; Phase 1 clinical trial; Preclinical study; Progression free survival; RNA sequence; Randomized controlled trial; Side effect; Tumor microenvironment}, -abstract = {Background: Despite the promise of immunotherapy for the treatment of advanced NSCLC, only a fraction of patients experience significant benefit from immunotherapy alone. Previous studies have shown that SBRT can stimulate innate and adaptive immunity to potentially augment immunotherapy. In addition, SBRT is used in patients with limited metastatic disease as consolidative approach, showing an improvement overall survival when compared to systemic treatment alone. Combining immunotherapy with ablative therapy is being studied by a number of investigators. While many of these pre‐clinical and clinical studies are promising, timing of immunotherapy with SBRT has not be formally studied. Further, few of these studies have addressed treatment of multiple sites of disease and little is known about what molecular changes occur in the tumor microenvironment immediately after ablative therapy. This trial is designed to evaluate the safety and efficacy of the combination of nivolumab (N) and ipilimumab (I) plus sequential(S) or concurrent(C) SBRT in patients with stage IV NSCLC. Method: This is a single‐center phase I, open‐label, two‐arm, randomized platform trial. Eligible patients include those with stage IV NSCLC with ≥2 metastatic lesions that meet criteria for SBRT (0.2 cc to 65 cc of viable tumor, larger tumors able to be partially treated up to 65 cc). Eligible patients are simultaneously accrued on arm I (S) and arm II (C) in a 1:1 ratio. Participants in arm I complete SBRT to 2‐4 sites followed by initiation of N/I 1‐7 days after completion of SBRT. Participants in arm II are treated with N/I within 24‐48 hours of SBRT with required SBRT completion to 2‐4 sites within two weeks (prior to the second dose of N). Protocol therapy consists of treatment with N 3mg/kg every 2 weeks and I 1mg/kg every 6 weeks for a maximum of 24 months. The primary endpoint is dose‐limiting toxicity defined as a >33% rate of grade ≥3 toxicity. DLT is defined as any grade ≥3 toxicity possibly, likely, or definitely related to SBRT plus N/I (the combination and not the individual components). Secondary endpoints include response rate and progression free survival at 6 months, control rate of treated lesions and non‐treated lesions, and comparison of efficacy and toxicity between the arms. Biopsies and blood draws performed pre‐ and post‐SBRT will facilitate molecular correlative studies including investigation of changes in the immune microenvironment induced by the two approaches. Result: Current enrollment includes 27 of the 40‐80 participants: 15 patients are enrolled on arm 1 (sequential) and 12 patients are enrolled on arm 2 (concurrent). SBRT safety cohorts, to which patients can contribute to more than one, include the following: central lung (n=20), peripheral lung (n=7), abdominal (n=5), osseous (n=9), and liver (n=5). All patients have paired pretreatment and posttreatment biopsies of at least one irradiated lesion. 79% of post‐ablative biopsies are suitable for DNA/RNA sequencing. Conclusion: Section not applicable Keywords: Immuno‐oncology, SBRT}, -DOI = {10.1016/j.jtho.2019.08.1517}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01998343/full} -} - - -Record #242 of 538 -@article{Persson19, -author = {Persson, G, Schytte, T, Appelt, AL, Borissova, S, Brink, C, Hansen, TS, Hoffmann, L, Josipovic, M, Khalil, AA, Knap, MM, Lund, MD, Lutz, CM, Moller, DS, Nielsen, TB, Nielsen, M, Ottosson, W, Pohl, M, Thomsen, JB, and Hansen, O}, -title = {Locally advanced NSCLC: performance status based eligibility for adjuvant check point inhibitor}, -journal = {Radiotherapy and oncology}, -volume = {133}, -pages = {S739‐S740}, -year = {2019}, -accession_number = {EMBASE 2003612992}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer adjuvant therapy; *non small cell lung cancer; Adult; Aspiration cytology; Cancer patient; Chemoradiotherapy; Combination chemotherapy; Conference abstract; Controlled study; Drug therapy; Endobronchial ultrasonography; Female; Follow up; Histology; Histopathology; Human; Human tissue; Major clinical study; Male; Mediastinum lymph node; Multicenter study; Phase 3 clinical trial; Positron emission tomography‐computed tomography; Practice guideline; Radiotherapy; Randomized controlled trial}, -abstract = {Purpose or Objective: The standard treatment of locally advanced non‐small cell lung cancer (LA‐NSCLC) has changed with the PACIFIC trial, stating that the addition of 1‐year adjuvant immune checkpoint inhibitor therapy after completed concomitant chemoradiotherapy increases the 2‐year survival rate compared to placebo. Inclusion criteria were a WHO performance status (PS) of 0‐1 and no sign of progression. Adjuvant therapy should start within 42 days of completed chemoradiotherapy. The aim of this analysis was to determine the fraction of patients with LA‐NSCLC that have PS 0‐1 within six weeks after completion of concomitant chemoradiotherapy and would hence be candidates for adjuvant immune checkpoint inhibitor therapy. Material and Methods: We are currently recruiting patients with LA‐NSCLC in a national multicenter randomized phase III isotoxic dose escalation trial. In the study the control arm receives 66 Gy in 33 fractions concomitantly with cis‐ or carboplatin every third week and fixed dose vinorelbine 50 mg three times weekly. The concomitant chemoradiotherapy is proceeded by a single series of induction platinum‐based combination chemotherapy. Radiotherapy is delivered with intensity modulated or volumetric arc modulated therapy. Daily image guidance with conebeam CT and treatment adaptation guidelines are used. The trial inclusion criteria are cytology or histology proven LA‐NSCLC and PS 0‐1. Diagnostic procedures include FDG‐PET/CT and endobronchial ultrasound (EBUS) with aspiration cytology from central mediastinal nodes. We are investigating the possibility of an amendment to allow for adjuvant immune checkpoint inhibitor therapy to enable continuous inclusion in the study. Thus, an unplanned interim analysis was performed within the trial, analyzing only baseline characteristics and PS at the first clinical follow‐up six weeks post radiotherapy. Results Patients were included from January 2015 and forward. Data lock for the interim analysis was September 1st, 2018. 124 patients had completed their treatment and attended their first clinical follow‐up. Clinical report form was filled out for 109 patients; PS data were missing for ten patients, leaving 99 for analysis. Patient characteristics are shown in Table 1. PS at start and six weeks after end of radiotherapy are shown in Figure 1. No patients were in PS3 or 4 after radiotherapy. Conclusion: The majority of patients (85%) with LA‐NSCLC, who were staged with EBUS and PET/CT and received state‐of‐the art concomitant chemoradiotherapy in a randomized dose escalation trial, remained in PS 0‐1 after finished radiotherapy and were thus candidates for adjuvant immune checkpoint inhibitor therapy. [Table Presented] [Figure Presented]}, -DOI = {10.1016/S0167-8140(19)31772-4}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02008299/full} -} - - -Record #243 of 538 -@article{Soo23, -author = {Soo, RA, Cho, BC, Kim, J-H, Ahn, M-J, Lee, KH, Zimina, A, Orlov, S, Bondarenko, I, Lee, Y-G, Yueh Ni, L, Lee, SS, Pang, YK, Fong, CH, Kang, JH, Lim, CS, Danchaivijitr, P, Lee, H, Park, S, and Cicin, I}, -title = {1324MO CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: a LASER301 subset analysis}, -journal = {Annals of oncology}, -volume = {34}, -pages = {S764‐S765}, -year = {2023}, -accession_number = {EMBASE 2027892299}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer combination chemotherapy; *central nervous system; *laser; *non small cell lung cancer; Adjuvant chemotherapy; Adult; Biomedicine; Biotechnology; Breast cancer; Cancer patient; Cancer radiotherapy; Cancer surgery; Cancer survival; Chemotherapy; Clinical trial; Comparative effectiveness; Conference abstract; Consultation; Controlled study; Double blind procedure; Drug combination; Drug safety; Drug therapy; Excision; Female; First‐line treatment; Follow up; Gene mutation; Hormonal therapy; Human; Liver cell carcinoma; Major clinical study; Metastatic breast cancer; Molecular fingerprinting; Monotherapy; Multicenter study; Nuclear magnetic resonance imaging; Open study; Parttime employment; Phase 2 clinical trial; Phase 3 clinical trial; Physician; Progression free survival; Prospective study; Protein fingerprinting; Randomization; Randomized controlled trial; Response evaluation criteria in solid tumors; Signal transduction; Surgery; Tumor volume}, -abstract = {Background: Up to 50% of patients (pts) with non‐small cell lung cancer (NSCLC) develop central nervous system (CNS) metastases (mets), which are a major source of mortality in NSCLC. Lazertinib (laz), a CNS‐active 3rd‐generation (gen) tyrosine kinase inhibitor (TKI) targeting mutant epidermal growth factor receptor (EGFR), improved progression‐free survival (PFS) vs the 1st‐gen TKI gefitinib (gef) in the LASER301 study. Here, we compared laz vs gef among LASER301 pts with CNS mets. Methods: In the phase 3 LASER301 study (NCT04248829), treatment (tx)‐naïve pts with EGFR‐mutated advanced or metastatic NSCLC were randomized 1:1 to laz (240 mg/day) or gef (250 mg/day). Pts with symptomatic/unstable CNS mets were excluded. If tx was required for pts with asymptomatic/stable CNS mets, radiation and/or surgery, and steroids were completed >2 weeks before randomization. Magnetic resonance imaging was performed at screening, every 6 weeks for 18 months (mo), then every 12 weeks relative to randomization, using the same modality at each follow‐up. Endpoints assessed by blinded independent central review and RECIST v1.1 included intracranial PFS (iPFS), intracranial objective response rate (iORR), intracranial duration of response (iDoR), and depth of intracranial response. Results: Of 393 pts in LASER301, 45 (23%) receiving laz and 41 (21%) receiving gef had measurable and/or non‐measurable baseline (BL) CNS mets. BL characteristics were balanced between groups, with most pts having 1–3 CNS lesions (laz: 91%, gef: 83%). Median BL target lesion size was 20.0 mm (laz) and 16.0 mm (gef). Median iPFS in the laz group was 28.2 mo (95% confidence interval [CI]: 14.8, 28.2) vs 8.4 mo (6.7, not reached [NR]) in the gef group (hazard ratio: 0.42; 95% CI: 0.20, 0.89; P=0.02). iORR was higher for the laz (n=17, 94%) vs gef (n=11, 73%) group. At data cutoff, median iDoR in the laz group was NR (8.3, NR) vs 6.3 mo (2.8, NR) in the gef group. The median best change from BL in CNS target lesion size was ‐57% and ‐47% for laz (n=17) and gef (n=14), respectively. No new safety signals were identified from LASER301. Conclusions: In pts with BL CNS mets, laz significantly improved iPFS vs gef with more durable responses. Laz has the potential to improve CNS outcomes in NSCLC. Clinical trial identification: NCT04248829. Editorial acknowledgement: Dylan Mori of Lumanity Communications Inc. Legal entity responsible for the study: Yuhan Corporation. Funding: Yuhan Corporation. Disclosure: R.A. Soo: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, BMS, Lily, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, Yuhan, Janssen, Merck Serono, Puma Biotech, Thermo Fisher; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Institutional, Research Grant: AstraZeneca, Boehringer Ingelheim. B.C. Cho: Financial Interests, Personal, Other, Consulting role: Abion, BeiGene, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus Therapeutics, Ono, Onegene Biotechnology, Yuhan, Pfizer, Eli Lilly, GI‐Cell, Guardant, HK Inno‐N, Imnewrun Biosciences Inc., Janssen, Takeda, MSD, Janssen; Financial Interests, Personal, Advisory Board: Kanaph Therapeutic Inc, BridgeBio Therapeutics, Cyrus Therapeutics, Guardant Health, Oscotec Inc; Financial Interests, Personal, Other, Advisory role: Medpacto, Blueprint Medicines, RandBio, Hanmi; Financial Interests, Personal, Member of Board of Directors: Interpark Bio Convergence Corp., J Ints Bio; Financial Interests, Personal, Stocks/Shares: TheraCanVac Inc, Gencurix Inc, BridgeBio Therapeutics, Kanaph Therapeutic Inc, Cyrus Therapeutics, Interpark Bio Convergence Corp., J Ints Bio; Financial Interests, Personal, Royalties: Champions Oncology, Crown Bioscience, Imagen; Financial Interests, Institutional, Research Grant: MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, GIInnovation, GI‐Cell, Abion, AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Champions Onoclogy, CJ Bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine, Janssen, Lilly, MSD, Novartis, Nuvalent, Oncternal, Ono, Regeneron, Dong‐A ST, BridgeBio therapeutics, Yuhan, ImmuneOncia, Illumina, Kanaph Therapeutics, Therapex, JINTSbio, Hanmi, CHA Bundang Medical Center; Other, Founder: Daan Biotherapeutics. M. Ahn: Financial Interests, Personal, Advisory Board: AstraZeneca, Takeda, MSD, Yuhan, Amgen, Alpha Pharmaceutical, Janssen, BMS, Roche, Daiichi Sankyo, Merck, Boronoi. K.H. Lee: Financial Interests, Personal, Other, Consultant: BMS, Eli Lilly, Pfizer, AstraZeneca, MSD, Yuhan; Financial Interests, Personal, Research Funding: MSD. A. Zimina: Non‐Financial Interests, Principal Investigator, Participation as PI in Yuhan LASER‐301 trial: Yuhan. Y. Lee: Financial Interests, Personal, Speaker’s Bureau: Pfizer, Boryung, Eli Lilly, Takeda; Financial Interests, Personal, Other, Consultant: Ono, Takeda, Yuhan, Guardant Health. L. Yueh Ni: Financial Interests, Personal, Other, Panel of Discussion for Hepatocellular Carcinoma: AstraZeneca; Financial Interests, Personal, Advisory Board, Advisory Board Meeting for early breast cancer management in our current practice.: Roche; Financial Interests, Personal and Institutional, Local PI, Research Title: A multicentre, open‐label, single‐arm, molecular profiling study of patient with EGFR mutation‐positive locally advanced or metastatic NSCLC treated with Osimertinib: AstraZeneca; Financial Interests, Personal and Institutional, Local PI, Research Title: A Phase 3 Double‐blinded, Two‐arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK‐3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE‐937): MSD; Financial Interests, Personal and Institutional, Local PI, Research Title: A Phase III, Randomized, Double‐blind Study to Assess the Efficacy and Safety of Lazertinib versus Gefitinib as the First‐line Treatment in Patients with Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non‐small Cell Lung Cancer: Yuhan; Financial Interests, Personal and Institutional, Local PI, Research Title: A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor‐positive/HER2‐negative inoperable locally advanced or metastatic breast cancer ‐ RIGHT Choice Study: Novartis; Financial Interests, Personal and Institutional, Local PI, Research Title: A Global, Randomized, Phase 3, Open‐Label Study of REGN2810 (Anti‐PD‐1 Antibody) versus Platinum‐Based Chemotherapy in First‐Line Treatment of Patients with Advanced or Metastatic PD‐L1+ Non‐Small Cell Lung Cancer: Regeneron; Financial Interests, Personal and Institutional, Local PI, Research Title: A Phase 3 study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB 154 in Front‐Line, PD‐L1 Positive, Locally Advanced or Metastatic Non‐Small Cell Lung Cancer: Arcus; Financial Interests, Personal and Institutional, Local PI, Research Title: A Prospective, Multicenter, Non‐Interventional Genomic Profiling Study in Subjects with Locally Advanced or Metastatic Non‐Small Cell Lung Cancer (NSCLC) using Foundation Medicine: Roche; Financial Interests, Personal and Institutional, Local PI, Research Title: A Phase 3, randomize, double‐blind trial of pembrolizumab (MK‐3475) with or without lenvatinib (E7080/MK‐7902) in participants with treatment naive, metastatic non‐small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP‐007): MSD. Y.K. Pang: Financial Interests, Personal, Research Funding: MSD, AstraZeneca, Sanofi.; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Personal, Advisory Board: Novartis, Specialised Therapeutics, MSD, Boehringer Ingelheim, Sanofi‐Aventis, Orient Europharma, Eurodrug Laboratories. C.H. Fong: Financial Interests, Personal, Local PI, Investigator fees: Yuhan Corporation, Janssen Research & Development, LLC, Arcus Biosciences, Inc., Novartis Pharmaceuticals, Hoffmann‐La Roche. J.H. Kang: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Merck, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Boeringer Ingelheim, Roche, MSD, Ono, Yuhan, Takeda; Financial Interests, Personal, Research Grant: ONO, Daiichi Sankyo, Boeringer Ingelheim; Financial Interests, Personal, Steering Committee Member: Yuhan. P. Danchaivijitr: Financial Interests, Personal, Speaker’s Bureau: MSD, Roche, AstraZeneca, BMS; Financial Interests, Personal, Advisory Board: MSD, Roche, AstraZeneca, BMS. H. Lee: Financial Interests, Personal, Full or part‐time Employment: Yuhan. S. Park: Financial Interests, Personal, Full or part‐time Employment: Yuhan Co. I. Cicin: Other, Principal investigator: Jounce Therapeutic. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2023.09.2357}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02613817/full} -} - - -Record #244 of 538 -@article{jRCTs03121039321, -author = {jRCTs031210393,}, -title = {JCOG2002: a randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCTs031210393}, -year = {2021}, -accession_number = {ICTRP jRCTs031210393}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Induction therapy ACE therapy Atezolizumab 1,200 mg/body (day 1)+CBCDA AUC 5 (day 1)+Etoposide 100 mg/m2 (day 1,2,3), every 3 weeks, up to 4 cycles DPE therapy ‐ Cisplatin Durvalumab 1,500 mg/body (day 1)+Cisplatin 80 mg/m2 (day 1)+Etoposide 100 mg/m2 (day 1,2,3), every 3 weeks, up to 4 cycles DPE therapy ‐ CBCDA Durvalumab 1,500 mg/body (day 1)+ CBCDA AUC 5 (day 1)+Etoposide 100 mg/m2 (day 1,2,3), every 3 weeks, up to 4 cycles Group A: maintenance therapy only Atezolizumab maintenance therapy Atezolizumab 1,200 mg/body (day 1), every 3 weeks Durvalumab maintenance therapy Durvalumab 1,500 mg/body (day 1), every 4 weeks Group B: maintenance therapy+chest radiation therapy Atezolizumab maintenance therapy+chest radiation therapy Atezolizumab 1,200 mg/body (day 1), every 3 weeks chest radiation therapy:30Gy/10fr. Durvalumab maintenance therapy+chest radiation therapy Durvalumab 1,500 mg/body (day 1), every 4 weeks chest radiation therapy:30Gy/10fr. CONDITION: Extensive stage small cell lung cancer PRIMARY OUTCOME: Overall survival SECONDARY OUTCOME: Progression‐free survival, Adverse event rate, Induction therapy response rate, Induction therapy complete response rate, Incidence rate of SVC syndrome / airway stenosis (>=Grade 2) INCLUSION CRITERIA: Primary registration criteria (1) Cytologically or histologically confirmed small cell lung cancer. class IV or class V was required for cytology. (2) Extensive stage was diagnosed by thoracoabdominal contrast‐enhanced CT, FDG‐PETand brain contrast‐enhanced MRI.Lymph node metastasis exists either the supraclavicular/mediastinal lymph node or the ipsilateral hilar lymph node. (3) Over 20 years old. (4) Performance status 0, 1 or 2. (5) Measureable or non‐measureable. (6) No history of radiation therapy or chemotherapy for small cell lung cancer. (7) No history of radiation therapy with supraclavicular, mediastinal, or hilar for other cancer types. (8) Major organ function is preserved. (i) Neutrophil count >= 1,500 /mm3 (ii) Hemoglobin >= 9.0 mg/dl (iii) Platelet count >= 100,000 /mm3 (iv) T‐bil <=1.5 mg/dL (v) AST =< 100 U/L (vi) ALT =< 100 U/L (vii) Serum creatinine <=1.5 mg/dL (viii) SpO2 >= 92% (9) No activ}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02429972/full} -} - - -Record #245 of 538 -@article{Aamdal16, -author = {Aamdal, E, Guren, TK, Inderberg Suso, EM, Kvalheim, G, Kyte, JA, Arnesen, OK, Aamdal, S, and Gaudernack, G}, -title = {Combining the telomerase peptide cancer vaccine UV1 with CTLA-4 blockade in patients with metastatic malignant melanoma: proof of principle and early clinical reports from a phase I/IIa trial}, -journal = {Cancer immunology research}, -volume = {4}, -number = {1}, -year = {2016}, -accession_number = {EMBASE 613321552}, -publication type = {Journal article; Conference proceeding}, -keywords = {*metastatic melanoma; Adverse drug reaction; Allogeneic stem cell transplantation; Antineoplastic activity; Autoimmune disease; Brain metastasis; Breast feeding; Cancer survivor; Cancer tissue; Cell immortalization; Clinical article; Clinical trial; Communicable disease; Controlled clinical trial; Controlled study; DNA sequence; Diagnosis; Disease duration; Drug combination; Drug therapy; Female; Gene expression; Human; Human cell; Human tissue; Hypersensitivity; Immune response; Immunoassay; Immunotherapy; Intervention study; Irradiation; Kidney function; Liver function; Long term survival; Male; Non small cell lung cancer; Pharmacokinetics; Phase 1 clinical trial; Phase 2 clinical trial; Pregnancy; Prostate cancer; Response evaluation criteria in solid tumors; Safety; Side effect; Spleen; Surgery; T lymphocyte; Telomere shortening; Toxicity; Tumor biopsy; Vaccination}, -abstract = {The purpose of this clinical phase I/IIa, open label, single arm, interventional study (EudraCT No 2013‐ 005582‐39) is to investigate the safety, clinical and immunological responses of a therapeutic telomerase peptide vaccine, UV1, combined with ipilimumab in patients with metastatic melanoma (MM). The CTLA‐4 antibody ipilimumab produces long term survival benefits in ca.20% of patients with MM. The mechanism of action of ipilimumab suggests that combinations with therapies inducing tumor‐specific immune responses, such as vaccines, may lead to additive and even synergistic anti‐tumor activity. We hypothesized that a telomerase peptide‐based vaccine in combination with ipilimumab would improve therapeutic efficacy in patients with MM. Telomerase promotes elongation of telomeres after each cell division, representing the key enzymatic process in preventing telomere shortening. It is responsible for human cell immortalization and cancer pathogenesis, and is present in 85‐90% of cancer tissues. Thus, telomerase‐based immunotherapy has been investigated in several tumor types. Available blood samples from long term cancer survivors previously treated with different types of human telomerase reverse transcriptase subunit (hTERT) vaccines identified a new set of peptide epitopes. T cell responses to these peptides form spontaneously after vaccination by epitope spreading and are found only in patients with remarkable clinical courses, suggesting a role in tumor eradication. This led to the development of UV1, a therapeutic cancer vaccine consisting of a mixture of 3 synthetic peptides representing naturally occurring fragments of human hTERT. Ongoing phase I/IIa trials with UV1 in non‐small‐cell lung cancer and prostate cancer (EudraCT No 2012‐001852‐20 and 2012‐002411‐26, respectively) have shown potent, durable T cell responses against UV1 peptides and low toxicity (unpublished data). In the present protocol, patients with a histologically or cytologically confirmed diagnosis of unresectable AJCC stage III/IV MM, ECOG 0‐1 and an adequate renal, hepatic and hematological function are eligible. Any previous treatment is allowed. Patients with active brain metastases, a history of autoimmune disease, splenic surgery or irradiation, allogenic stem cell transplantation, known hypersensitivity to the investigational products, uncontrolled infectious disease, pregnant or breastfeeding, will be excluded. Intradermal UV1 vaccines of 300 mcg and 75 mcg GM‐CSF are administered 7, 5, and 3 days before and 11 days after the first dose of ipilimumab, then 3 days before every dose of ipilimumab, and subsequently every 4th week until week 48 or treatment cessation. Ipilimumab 3 mg/kg is given IV every 3rd week for a total of 4 doses. Each patient will be followed up 5 weeks after the completion of the last study treatment. Adverse events are recorded in coherence with CTCAE vs. 4.0. Tumor response is evaluated according to RECIST vs.1.1. Immune responses against UV1 peptides are monitored by standard immunoassays. Potential predictive biomarkers will be explored in an extensive program involving sequential tumor biopsies, DNA sequencing and mRNA expression. The first patient was enrolled 16 January 2015, estimated completed recruitment by one year. 3 out of 20 patients have been recruited so far. Data from the first 3 patients until week 16 will be reported.}, -DOI = {10.1158/2326-6074.CRICIMTEATIAACR15-B141}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01250040/full} -} - - -Record #246 of 538 -@article{Mitchell21, -author = {Mitchell, P}, -title = {ES02.04 Systemic Therapy Influenced Trials in Oligometastatic Disease}, -journal = {Journal of thoracic oncology}, -volume = {16}, -number = {10}, -pages = {S829}, -year = {2021}, -accession_number = {EMBASE 2015167808}, -publication type = {Journal article; Conference proceeding}, -keywords = {*systemic therapy; Abscopal effect; Adrenal metastasis; Adult; Advanced cancer; Brain; Cancer control; Cancer growth; Cancer patient; Cancer radiotherapy; Cancer recurrence; Cancer resistance; Cancer staging; Cancer surgery; Cancer survival; Clinical trial; Conference abstract; Controlled study; Drug therapy; Female; Follow up; Fractionation; Human; Immunotherapy; Lung surgery; Maintenance chemotherapy; Male; Meta analysis; Multicenter study (topic); Non small cell lung cancer; Oncologist; Overall survival; Phase 1 clinical trial (topic); Phase 2 clinical trial (topic); Phase 3 clinical trial (topic); Progression free survival; Radiotherapy; Randomized controlled trial (topic); Stereotactic body radiation therapy}, -abstract = {A working definition of Oligometastatic Disease (OMD) in Non‐Small Cell Lung Cancer (NSCLC) is no more than 5 metastases involving 3 organs 1. This definition of OMD is largely for the purposes of offering local ablative therapy (LAT) ‐ which includes surgery, or more frequently radiotherapy and, in particular Stereotactic Ablative Body Radiotherapy (SABR). However, OMD is a heterogenous state – which encompasses many clinical scenarios: at diagnosis of NSCLC with synchronous metastases; at recurrence after effective therapy; at progression after systemic therapy; and persistent site (s) of disease on therapy. Cures in the setting of lung surgery and resection of a solitary brain and sometimes adrenal metastasis are well recognised, including in a synchronous setting although the longer the time to recurrence the greater the cure rate. However, the intent of aggressive management of OMD is to delay progression or NSCLC death. There may be other benefits including delaying onset of symptoms, and LAT of large metastases may delay the emergence of resistance clones. Generally, the data for combining systemic therapy and LAT in NSCLC come from the pre‐immunotherapy era. The SABR‐COMET trial recruited 99 solid tumour patients (18 NSCLC), with 1‐5 metastases, and randomised them to standard care or standard care plus SABR to all metastases. At median follow‐up of 51 months (mths), progression free survival (PFS) was increased, and most importantly overall survival (OS) was increased with estimated 42.3% of SABR‐treated patients alive at 5 years versus 17.7% (p=0.006) receiving standard care alone 2. Iyegar et al have reported on their trial of NSCLC patients stable for 3 mths and continuing on systemic maintenance therapy (mostly chemotherapy) with up to 6 tumour sites, randomised to receive SABR or no SABR. The trial recruited 29 patients and accrual was ceased early due to a positive result. PFS favoured the SABR plus systemic therapy arm at median 9.7 mths versus 3.5 mths with chemotherapy alone (HR 0.304; 95% CI 0.113‐0.815) 3. A similarly designed study including 49 NSCLC patients on maintenance chemotherapy (or EGFR or ALK tki, as appropriate) with up to 3 metastases, again closed to accrual early due to a positive result. Patients could receive LAT with surgery or radiotherapy. PFS for LAT‐treated patients was 14.2 mths vs 4.4 mths (p=0.02) and OS 41.2 mths vs 17 mths (p=0.017) 4. The recent SINDAS trial recruited 133 patients receiving first line first generation EGFR tki with up to 5 metastatic sites. Patients were randomised to SABR or no SABR. PFS favoured the SABR‐treated arm (HR 0.62, p< 0.001) as did OS 25.5 mths vs 17.4 mths, HR 0.69, p<0.001. It remains to be determined if similar results will be achieved for patients receiving Osimertinib or the new generations of EGFR therapies. Similarly, the role of LAT in metastatic ALK‐translocated NSCLC with newer‐generation tkis is unclear. Almost all stage III – IV NSCLC patients now receive immunotherapy as first line treatment, mostly combined with chemotherapy. As oncologists gained experience with checkpoint inhibitors, radiotherapy, often given as SABR, has become standard practice to control metastases which escape immune control. However, for patients with high tumour PD‐L1 score and treated with checkpoint inhibitors, it remains to be determined whether the already substantial proportion surviving 5 years can be augmented by LAT. There has recently been a focus on the role of radiotherapy in enhancing tumour control with checkpoint inhibitors via the abscopal effect – which is a recognised but infrequent out of field response in metastases distant from the radiotherapy‐treated tumour. In the PEMBR‐RT phase II trial 76 patients were randomised to receive ongoing pembrolizumab or pembrolizumab preceded by SBRT to a single tumour deposit. Outcomes favoured the SABR‐treated patients with response rate at 12 weeks 36% vs 18% (p=0.07), median PFS 6.6 mths vs 1.9 mths, and OS 15.9 mths vs 7.6 mths. The primary endpoint was not met but there were clear trends 6. In a similar phase II trial patients randomised to radiotherapy could be treated with SABR or conventional radiotherapy, and in addition patients randomised to pembrolizumab alone could receive radiotherapy after the second 3‐weekly pembrolizumab dose if the was progression 7. A combined analysis of these two trials indicated improved PFS, out of field (abscopal) response and OS in the experimental arm 8. The benefit of adding SABR to pembrolizumab were predominantly seen with tumours PD‐L1 < 1%. Important questions remain: these two trials were conducted with pembrolizumab alone whereas most patients now receive chemo‐immunotherapy, and this is certainly the case with PD‐L1 low tumours. In addition, the ideal dose and fractionation of radiotherapy to elicit an abscopal effect in the context of immunotherapy is unclear. Nevertheless, these encouraging results warrant a phase III study. 1 Dingemans A‐M, et al. Definition of synchronous oligometastatic non‐small cell lung cancer. J Thorac Oncol 2019; 14(12): 2109 2 Palma D, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long‐term results of the SABR‐COMET phase II randomized trial. J Clin Oncol 2020; 38(25): 2830 3 Iyegar P, et al. Consolidative radiotherapy for limited metastatic non‐small cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 2018; 4(1): e173501 4 Gomez D, et al. Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non‐small cell lung cancer: long‐term results of a multi‐institutional, phase II, randomized trial. J Clin Oncol 2019; 37(18): 1558 5 Wang X‐S, et al. Proc ASCO 2020. Abst. 9508 6 Theelen W, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumour response in patients with advanced non‐small cell lung cancer. Results of the PEMBRO‐RT Phase 2 randomized clinical trial. JAMA Oncol 2019; 5(9): 1276 7 Welsh J, et al. Pembrolizumab with or without radiation therapy for metastatic non‐small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer 2020; 8:e001001 8 Theelen W, et al. Pembrolizumab with or without radiotherapy for metastatic non‐small cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 2020; 9: 467 Keywords: Oligometastatic Disease, non‐small cell lung cancer, Systemic Therapy}, -DOI = {10.1016/j.jtho.2021.08.740}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02336818/full} -} - - -Record #247 of 538 -@article{NCT0603773323, -author = {NCT06037733,}, -title = {Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy}, -journal = {https://clinicaltrials.gov/ct2/show/NCT06037733}, -year = {2023}, -accession_number = {CTgov NCT06037733}, -publication type = {Trial registry record}, -keywords = {Lung Neoplasms}, -abstract = {Studies have confirmed that systemic therapy combined with primary tumor radiotherapy can improve symptoms and prolong survival of advanced NSCLC. Our previous sturdy indicated that patients who received immunotherapy and subsequent radiotherapy suffered higher proportion of pneumonitis. Patients suffered grade 2 or more pneumonitis have worse prognosis. It is urged to optimize the radiotherapy dose and target volume for patients treated with immunotherapy and radiotherapy. According to retrospective and prospective studies, omitting primary tumor CTV radiation therapy showed no reduction in local control and survival for locally advanced NSCLC. It is postulated that omitting CTV radiation for patients responded to therapy with immunotherapy and chemotherapy will have less pneumonitis without sacrificing the local control rate. Omitting CTV may also retain better immune function which will facilitate the immunotherapy.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02597759/full} -} - - -Record #248 of 538 -@article{Iwata19, -author = {Iwata, H, Akita, K, Ogino, H, Yamaba, Y, Mori, Y, Yoshihara, M, Nakajima, K, Hashimoto, S, Hattori, Y, Hayashi, K, Toshito, T, Baba, F, Nakamae, K, Mizoe, JE, and Shibamoto, Y}, -title = {Phase II Study of Concurrent Chemoproton Therapy Using Adaptive Planning for Stage III Locally Advanced Non-Small Cell Lung Cancer}, -journal = {International journal of radiation oncology biology physics}, -volume = {105}, -number = {1}, -pages = {E510}, -year = {2019}, -accession_number = {EMBASE 2002633911}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer staging; *non small cell lung cancer; Adult; Adverse event; Anemia; Cancer patient; Cancer survival; Case report; Chemoradiotherapy; Chi square test; Clinical article; Comparative effectiveness; Conference abstract; Drug safety; Drug therapy; Dyspnea; Enteritis; Esophagitis; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; Fatigue; Febrile neutropenia; Female; Follow up; Histology; Histopathology; Human; Human tissue; Immunotherapy; Incidence; Informed consent; Kaplan Meier method; Lymph node metastasis; Male; Organs at risk; Outpatient; Overall survival; Patient history of chemotherapy; Patient history of radiotherapy; Phase 2 clinical trial; Progression free survival; Quality of life; Radiation pneumonia; Randomized controlled trial; Respiratory gated imaging; Response evaluation criteria in solid tumors; Social interaction; Thrombocytopenia; X ray}, -abstract = {Purpose/Objective(s): The aim of this phase II study was to evaluate the efficacy and safety of concurrent chemoproton therapy (CCPT) using adaptive planning for stage III locally advanced non‐small cell lung cancer (NSCLC). Materials/Methods: Eligibility criteria were as follows: (1) histologically or cytologically‐confirmed unresectable stage III NSCLC; (2) chemo‐naïve status; (3) ECOG‐PS ≤ 1; (4) age ≥ 20 and < 75 years; (5) no previous radiotherapy around the lesion; (6) no previous chemotherapy; (7) dose constraints of the organs at risk achievable; (8) lesions evaluable with RECIST; and (9) written informed consent. Primary endpoint was the 2‐year overall survival (OS). Secondary endpoint was the local control rate (LCR), progression‐free survival (PFS), incidence of adverse events, and change of quality of life (QOL). Toxicities were evaluated with CTCAE ver. 4.0. QOL score were evaluated with EORTC QLQ‐C30 ver. 3.0 and QLQ‐LC13. We hypothesized that the 2‐year OS would be increased from a baseline of 40% to 60% and calculated that 41 patients would need to be enrolled to have a 80% chance of demonstrating improvement using a 1‐sided Chi‐square test with a significance level of.05 and 5% of drop‐out patients. Survival was analyzed by using the Kaplan‐Meier method. Patients received cisplatin (80 mg/m2) on day 1 and S‐1 (30‐40 mg/m2 twice daily) on days 1 to 14, q4w, up to 4 cycles, plus concurrent PT at a total dose of 70 GyE for primary lesion and 66 GyE for lymph node metastasis with 2 GyE per day. PT was performed using respiratory‐gated and image‐guided techniques, and adaptive plans were implemented. Results: From August 2013 to December 2017, 41 patients were enrolled. The patient characteristics were as follows: median age, 66 (31‐74) years; male/female, 30/11; PS 0, 34 pts; stage IIIA/IIIB, 22/19; non‐squamous histology, 24 (59%). Twenty‐three pts were out of indication for radical chemo‐radiation with X rays. All 4 cycles of S‐1 plus CDDP could be completed in 30 pts and the mean number of cycles was 3.5 (range: 1‐4). The median follow‐up period of surviving patients was 32 months (range: 14‐64). The mean number of replanning was 2.5 (range: 0‐4). Grade 3/4 toxicities were: neutropenia 32%, anemia 9.8%, thrombocytopenia 7.3%, fatigue 2.4%, esophagitis 2.4%, enteritis 9.8%, and radiation pneumonitis 0%. One case of febrile neutropenia was observed. The 2‐year OS, LCR and PFS were 74% (95% confidence interval: 60‐88%), 83% (70‐96%), and 43% (26‐59%), respectively. The median OS was not reached. There were no significant differences in the QOL score before treatment and after 24 months except for dyspnea. Conversely, emotional and social functioning significantly improved. Conclusion: CCPT with adaptive planning is considered to be effective and well tolerated for locally advanced NSCLC. Further evaluations in a large randomized controlled trial with immunotherapy are warranted.}, -DOI = {10.1016/j.ijrobp.2019.06.1339}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01977874/full} -} - - -Record #249 of 538 -@article{NL-OMON5393822, -author = {NL-OMON53938,}, -title = {Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab (MEDI4736) immunotherapy plus chemotherapy in extensive stage small-cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON53938}, -year = {2022}, -accession_number = {ICTRP NL‐OMON53938}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Reference therapy: Durvalumab plus carboplatin/etoposide Investigational therapy: Durvalumab plus carboplatin/etoposide and TRT CONDITION: ; cancer ; small‐cell lungcancer 10029107 PRIMARY OUTCOME: The primary endpoint of the study is to compare the 1‐year overall survival ; patients on reference therapy versus investigational therapy. ; SECONDARY OUTCOME: Secondary endpoints are the 2‐year, 3‐year, 4‐year and 5‐year overall survival, ; overall response rates, response rates in non‐irradiated lesions, PFS, PFS in ; non‐irradiated lesions, local control rates in the thorax, frequency and ; severity of adverse events, and health‐related quality of life. ; INCLUSION CRITERIA: 1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (e.g. Health Insurance Portability and Accountability Act in the US, European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol‐related procedures, including screening evaluations. 2. Age > 18 years at time of study entry. 3. ECOG performance status of 0 or 1. 4. Body weight >30 kg. 5. Adequate normal organ and marrow function as defined below: • Haemoglobin >=10.0 g/dL. • Absolute neutrophil count (ANC) >=1.5 × 109 /L • Platelet count >=100 × 109/L • Serum bilirubin <=1.5 Xinstitutional upper limit of normal (ULN). This does not apply to patients with confirmed Gilbert*s syndrome (persistent or <}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02715414/full} -} - - -Record #250 of 538 -@article{EUCTR2021-004327-32-HU22, -author = {EUCTR2021-004327-32-HU,}, -title = {A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC 8)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-004327-32-HU}, -year = {2022}, -accession_number = {ICTRP EUCTR2021‐004327‐32‐HU}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Durvalumab CAS Number: 1428935‐60‐7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ Product Name: Domvanalimab Product Code: AB154 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Domvanalimab CAS Number: 2368219‐35‐4 Current Sponsor code: AB154 Other descriptive name: Domvanalimab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60‐ Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use CONDITION: The target population of interest in this study is participants with locally advanced (Stage III), unresectable NSCLC, whose tumours express PD L1 TC = 1% as assessed by a central reference laboratory using the VENTANA PD‐L1 (SP263) IHC assay, and who did not progress after definitive platinum based cCRT. ; MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non‐small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Primary end point(s): Progression Free Survival (PFS) using Blinded Independent Central Review (BICR) assessment according to RECIST 1.1 with participants with PD‐L1 TC>=50%. Main Objective: To demonstrate superiority of durvalumab plus domvanalimab relative to durvalumab plus placebo in participants with locally advanced, unresectable NSCLC who have not progressed on prior platinum‐based cCRT, with PD‐L1 TC = 50%, progression free survival (PFS) assessed by blind independent committee review (BICR). Secondary Objective: To demonstrate superiority of durvalumab plus domvanalimab relative to durvalumab plus placebo in participants with TC = 1%, progression free survival (PFS) assessed by Blinded Independent Central Review (BICR).; ; To demonstrate superiority of durvalumab plus domvanalimab relative to durvalumab plus placebo in participants with TC = 1% or TC = 50% in the following outcomes:; • Overall response rate (ORR); • Duration of response (DoR); • Time to second progression (PFS2); • Time to death or distant metastatis (TTDM); • Time to First Subsequent Therapy (TFST); • PFS at 6, 12, 18 and 24 months ; • OS at 24 months; • PFS as assessed by investigator ; • Time to deterioration in pulmonary symptoms; Test the above objectives using an alternative PD‐L1 IHC assay, PD‐L1 IHC 22C3 pharmDx:PD‐L1 TPS = 50%, or PD‐L1 TPS = 1%. ; ; PK and immunogenicity of durvalumab and domvanalimab; To assess the safety and tolerability of durvalumab plus domvanalimab as compared to durvalumab plus placebo. Timepoint(s) of evaluation of this end point: Every 8 weeks (±7 days) from randomisation through 48 weeks, and q12w (± 7 days) thereafter until RECIST 1.1 defined radiological progression, plus 1 or more follow‐up scans. SECONDARY OUTCOME: Secondary end point(s): PFS measured by hazard ratio (HR), in participants with PD‐L1 TC = 1%. ; ; Comparison of durvalumab plus domvanalimab relative to durvalumab plus placebo in participants with TC = 1% or TC = 50% in the following outcomes ; ; 1. PFS using BICR assessment according to RECIST 1.1 ; 2. PFS6, PFS12, PFS18, PFS24 ; 3. Overall Survival (OS) ; 4. Objective response rate (ORR) using BICR assessment according to RECIST 1.1. ; 5. Duration of response (DoR) using BICR assessment according to RECIST 1.1 ; 6. Time from randomization to second progression (PFS2) ; 7. Time from randomization until the first date of distant metastasis or death in the absence o distant metastasis (TTDM). ; 8. Time to first subsequent therapy (TFST) ; 9. The pharmacokinetics (PK) of durvalumab and domvanalimab as determined by concentration. ; 10. The immunogenicity of Durvalumab and domvanalimab as assessed by presence of anti‐drug antibodies (ADAs) ; 11. Time to deterioration in pulmonary symptoms (TTFCD). Timepoint(s) of evaluation of this end point: ORR, DoR, PFS, PFS2, PFS6, PFS12, PFS18, PFS24, TTDM, TFST, TTFCD, up to approximately 8 years after first patient randomized ; ; OS and OS24, up to approximately 8 years after first patient randomized. ; ; ADA and PK: from date of randomization to approximately 12 weeks after last IP dose. INCLUSION CRITERIA: 1. Participant must be = 18 years at the time of screening. 2. Histologically‐ or cytologically‐documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease 3. Provision of a tumour tissue sample obtained prior to CRT 4. Documented tumour PD‐L1 status = 1% by central lab 5. Documented EGFR and ALK wild‐type status (local or central). 6. Patients must not have progressed following definitive, platinum‐based, concurrent chemoradiotherapy 7. Participants must have received at least 2 cycles of platinum‐based chemotherapy concurrent with radiation therapy 8. Participants must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy) as part of the chemoradiation therapy, to be randomised. Radiation therapy should be administered by intensity modulated RT (preferred) or 3D‐conforming technique. 9. WHO performance status of 0 or 1 at randomization 10. Adequate organ a}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02410446/full} -} - - -Record #251 of 538 -@article{Hoppe19, -author = {Hoppe, BS, Nichols, RC, Pham, DC, Mohindra, P, Hartsell, WF, Mohammed, N, Chon, BH, Morris, CG, Li, Z, Flampouri, S, and Simone, CB}, -title = {UF-Pcg Phase II Study of Hypofractionated Proton Therapy with Concurrent Chemotherapy for Stage II-III NSCLC}, -journal = {International journal of radiation oncology biology physics}, -volume = {105}, -number = {1}, -pages = {S144‐S145}, -year = {2019}, -accession_number = {EMBASE 2002634053}, -publication type = {Journal article; Conference proceeding}, -keywords = {*adjuvant chemotherapy; *cancer radiotherapy; *cancer staging; *non small cell lung cancer; *proton therapy; Adenocarcinoma; Adjuvant radiotherapy; Adult; Aged; Cancer patient; Cancer survival; Clinical article; Colitis; Conference abstract; Congestive heart failure; Controlled study; Disease exacerbation; Dosimetry; Drug combination; Drug therapy; Follow up; Human; Immunotherapy; Inappropriate vasopressin secretion; Infectious pneumonia; Lung hemorrhage; Male; Multicenter study; Overall survival; Phase 1 clinical trial; Phase 2 clinical trial; Progression free survival; Randomized controlled trial; Sample size; Side effect; Squamous cell carcinoma}, -abstract = {Purpose/Objective(s): While hypofractionated radiotherapy (HypoRT) has widely replaced standard fractionated RT in early‐stage non‐small cell lung cancer (NSCLC), major side effects have limited its use in advanced NSCLC. Based on improved dosimetry of proton therapy (PT), we investigated the HypoPT approach for stage II‐III NSCLC. Materials/Methods: Between March 2013 and November 2018, 28 patients from 4 centers were enrolled on an IRB‐approved clinical trial of HypoPT with concurrent chemotherapy followed by adjuvant chemotherapy or immunotherapy (after January 2018). Patients could be simultaneously enrolled in a phase 1 study and receive doses of 2.5 (n=14), 3 (n=6), 3.53(n=7), and 4 Gy/fraction (n=1) to a total dose of 60 GyRBE according to the open arm and organ‐at‐risk (OAR) dosimetric constraints. Weekly carboplatin and paclitaxel was the most common concurrent chemotherapy regimen (89%). The median patient age was 70 years (range, 50‐86); most patients were male (71%) and white (82%). Pathology included 50% adenocarcinoma, 46% squamous cell carcinoma, and 4% mixed. Patients had stage IIA (n=3), IIB (n=3), IIIA (n=15), and IIIB (n=7) NSCLC. N‐stage distribution included 5 patients with N0, 6 with N1, 15 with N2, and 2 with N3 disease. CTCAE, v4.0, was used for toxicity assessment. The primary endpoint of the study was 1‐year overall survival (OS). The study closed prematurely due to slow accrual and the need to increase the sample size based on the PACIFIC trial results. Results: The median follow‐up for surviving patients was 23 months (range, 1‐60). The 1‐ and 2‐year OS rates were 89% and 66%, and the 1‐ and 2‐year progression‐free survival rates were 70% and 60%, respectively. Three patients died within 3 months of HypoPT completion: 1 from a bronchial hemorrhage; 1 from congestive heart failure following infectious pneumonia and C. Diff colitis; and 1 from paraneoplastic SIADH after completing just 42 Gy at 3.53 Gy/fraction. Additionally, 6 patients died more than 1 year after HypoPT: 5 from disease progression and 1 from a cardiac event. Conclusion: In this phase II study, HypoPT at 2.5 to 3.53 Gy per fraction to 60 Gy (RBE) with concurrent chemotherapy was well tolerated with favorable PFS and OS. A large randomized clinical trial comparing HypoPT with standard fractionated RT or PT is warranted, especially in the setting of consolidation immunotherapy.}, -DOI = {10.1016/j.ijrobp.2019.06.143}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01980288/full} -} - - -Record #252 of 538 -@article{Brahmer19, -author = {Brahmer, J}, -title = {PC02.03 IO Should Be Given as a Single Agent}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S140‐S141}, -year = {2019}, -accession_number = {EMBASE 2003407103}, -publication type = {Journal article; Conference proceeding}, -keywords = {Adult; Advanced cancer; Adverse drug reaction; Allergy; Cancer patient; Cancer staging; Cancer survival; Case report; Cell activation; Cell differentiation; Chemoradiotherapy; Clinical article; Conference abstract; Dendritic cell; Drug combination; Drug therapy; Female; Human; Immunological memory; Immunology; Immunotherapy; Long term survival; Lymphocytopenia; Male; Natural killer cell mediated cytotoxicity; Nausea; Non small cell lung cancer; Overall survival; Phase 3 clinical trial; Prevention; Protein expression; Radiotherapy; Randomized controlled trial; Side effect; Signal transduction; Survival rate; T lymphocyte; United States}, -abstract = {Programmed cell death 1 (PD‐1) checkpoint pathway inhibitors have greatly changed the treatment paradigm for advanced stage non‐small cell lung cancer (NSCLC). Durvalumab is approved for use as a single agent after chemotherapy combined with radiation for stage 3 NSCLC.(1) Pembrolizumab is approved for use in the first line treatment setting for advanced NSCLC not amenable to radiation for patients whose tumor has a tumor proportion score (TPS) of 1% or greater in the United States.(2) For patients whose tumor has a TPS of ≥ 50%, it is approved for use in the first‐line treatment setting in multiple countries throughout the world.(3) However, PD‐1 checkpoint blockade combinations, either anti‐PD1 or anti‐PD‐L1 antibodies, with chemotherapy regardless of PD‐L1 status have shown benefit as well. (4,5,6) Single agent immunotherapy (IO) has several advantages. Cost of combination therapy is an issue. While these PD‐1 pathway blocking antibodies are expensive as single agents, combining them with chemotherapy adds to the cost, time in infusion, and adds chemotherapy related side effects. So, if patients can, single agent immunotherapy is still preferred, particularly in a population i.e. TPS ≥ 50% who is more likely to benefit compared to chemotherapy. Some would say the same is true for patients with TPS ≥ 1, but here the data for single agent IO compared to combinations with chemotherapy is mixed. While trials comparing this scenario, i.e. comparing single agent PD‐1 antibody compared to chemotherapy plus IO, head to head have not yet been done, it is hard not to do cross trial comparisons as seen in table 1. Clearly though, chemotherapy and IO combinations have increased objective response rates regardless of PD‐L1 TPS status where response rates range from 57.9%‐62.1%.(4,5,6,7,10) While combinations with chemotherapy show increased response rate regardless of PD‐L1 TPS, chemotherapy can have deleterious effects on the immune system. (8) Chemotherapy can alter immune function by causing lymphopenia. Steroids, added to chemotherapy regimens to prevent allergic reactions and control nausea, can suppress pro‐inflammatory cytokines and impair Natural Killer (NK) cell function and dendritic cell differentiation or activation. Taxanes specifically can cause inhibition of T‐cell and NK‐cell activation. Thus, these combinations may prevent immune activation and suppress immune memory. Duration of response in single agent IO in the first line treatment setting is 16.8‐20.2+ month.(9,2,3) The duration of response in the IO plus chemotherapy patient population is 7.7‐11.2 months.(4,5,6) The data from the chemotherapy IO combinations is too immature to know what the potential five‐year survival is compared to the impressive 23.2% 5 year survival rate of the initial trial of pembrolizumab in the treatment‐naïve setting(Keynote 001).(9) Immunotherapy, particularly PD‐1 pathway checkpoint antibodies, have drastically changed the treatment landscape for advanced stage lung cancer patients. Single agent pembrolizumab particularly in patients with TPS ≥ 50% lung cancer results in an impressive long term survival that is not seen with chemotherapy alone. Combining immunotherapy agents with chemotherapy increases disease response but long term survival outcome data and duration of response is immature. [Figure presented] 1‐Antonia SJ, Villegas A, Daniel D et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018 Dec 13;379(24):2342‐2350. 2‐Mok TSK, Wu YL, Kubaba I et al. Pembrolizumab versus Chemotherapy for Previously Untreated, PD‐L1‐expressing, locally advanced or metastatic non‐small‐cell lung cancer (KEYNOTE‐042): a randomized, open‐label, controlled, phase 3 trial. Lancet 2019 May 4:383(10183):1819‐1830. 3‐Reck M, Rodriquez‐Abreu D, Robinson AG et al. Pembrolizumab versus Chemotherapy for PD‐L1‐Positive Non‐Small‐cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823‐1833. 4‐Gandhi L, Rodriquez‐Abreu D, Gadgeel S et al. Pembrolizumab plus Chemotherapy in Metastatic Non‐Small‐Cell Lung Cancer. N Engl J Med. 2018 May 31;378(22):2078‐2092. 5‐Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for First‐Line treatment of Metastatic Nonsqumaous NSCLC. N Engl J Med 2018 Jun 14;378(24):2288‐2301. 6‐Paz‐Ares L, Alexander L, Vicente D et al. Pembrolizumab plus Chemotherapy for Squamous Non‐Small‐Cell Lung Cancer. N Engl J Med 2018;379:2040‐2051. 7‐Reck M, Rodriquez‐Abreu D, Robinson AG et al. Updated Analysis of KEYNOTE‐024: Pembrolizumab Versus Platinum‐Based Chemotherapy for Advanced Non‐Small‐Cell Lung Cancer with PD‐L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol 2019 Mar 1;37(7):537‐546. 8‐Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological Aspects of Cancer Chemotherapy, Nature Reviews Immunology 2008 (8), 59‐73. 9‐Garon, E, Hellmqann M, Carcereny Costa E et al. Five‐year long‐term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE‐001. J Clin Oncol 37, 2019(suppl; abstr LBA9015). 10‐Gadgeel S, Garassino M, Esteban E et al. KEYNOTE‐189: Updated Overall Survival and Progression After the Next Line of therapy with Pembrolizumab plus Chemotherapy with Pemetrexe3d and Platinum vs Placebo Plus Chemotherapy for Metastatic Nonsquamous NSCLC. J Clin Oncol 37, 2019 (Suppl; abstr LBA9013). Keywords: metastatic, Immunotherapy, Non‐Small Cell Lung Cancer}, -DOI = {10.1016/j.jtho.2019.08.290}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01995922/full} -} - - -Record #253 of 538 -@article{CTIS2023-507171-22-0024, -author = {CTIS2023-507171-22-00,}, -title = {A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination with Other Anti-Cancer Therapies in Patients with Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer with a KRAS G12C Mutation}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTIS2023-507171-22-00}, -year = {2024}, -accession_number = {ICTRP CTIS2023‐507171‐22‐00}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Product Code:PRD7936183, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: KEYTRUDA 25 mg/mL concentrate for solution for infusion, Product Code:PRD4323105, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: RO 743‐5846/F06, Product Code:PRD11081694, Pharmaceutical Form: FILM‐COATED TABLET, Other descriptive name: , Strength: , Product Name: CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, Product Code:PRD415259, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Product Code:PRD415296, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: RO 743‐5846/F07, Product Code:PRD11081695, Pharmaceutical Form: FILM‐COATED TABLET, Other descriptive name: , Strength: , Product Name: RO 743‐5846/F04, Product Code:PRD11081693, Pharmaceutical Form: FILM‐COATED TABLET, Other descriptive name: , Strength: , Product Name: Cisplatin NeoCorp 1 mg/ml ‐ Konzentrat zur Herstellung einer Infusionslösung, Product Code:PRD759858, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Product Code:PRD662245, Pharmaceutical Form: INJECTION, Other descriptive name: , Strength: , Product Name: CARBO‐cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, Product Code:PRD1969079, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Carboplatin‐GRY® 10 mg/ml Konzentrat zur Herstellu CONDITION: MedDRA version: 21.1Level: PTClassification code: 10059515Term: Non‐small cell lung cancer metastatic Class: 100000004864 MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non‐small cell lung cancer Class: 100000004864 Therapeutic area: Diseases [C] ‐ Neoplasms [C04] Untreated Advanced or Metastatic Non‐Small Cell Lung Cancer ; MedDRA version: 21.1Level: PTClassification code: 10059515Term: Non‐small cell lung cancer metastatic Class: 100000004864 ; MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non‐small cell lung cancer Class: 100000004864 PRIMARY OUTCOME: Main Objective: To evaluate the safety and tolerability of divarasib in combination with pembrolizumab (Cohort A) and divarasib in combination with pembrolizumab plus platinum‐based chemotherapy and pemetrexed (Cohort B) Primary end point(s): 1. Occurrence of adverse events, 2. Change from baseline at each visit in targeted safety parameters Secondary Objective: To evaluate the activity of divarasib in combination with pembrolizumab (Cohort A) and divarasib in combination with pembrolizumab plus platinum‐based chemotherapy and pemetrexed (Cohort B), To evaluate the tolerability of divarasib in combination with pembrolizumab (Cohort A) and divarasib in combination with pembrolizumab plus platinum‐based chemotherapy and pemetrexed (Cohort B), To characterize the divarasib PK profile, To identify a recommended dose of divarasib in combination regimens with pembrolizumab (Cohort A) and pembrolizumab plus platinum‐based chemotherapy and pemetrexed (Cohort B) SECONDARY OUTCOME: Secondary end point(s):1. Objective response rate Secondary end point(s):10. Recommended dose of divarasib in combination with pembrolizumab (Cohort A) or pembrolizumab plus platinum‐based chemotherapy and pemetrexed (Cohort B) based on the totality of safety, activity, and PK data Secondary end point(s):2. Duration of response Secondary end point(s):3. Progression free survival Secondary end point(s):4. Presence, frequency of occurrence, severity, and/or degree of interference with daily function of symptomatic side effects as assessed through use of the Patient‐Reported Outcomes Common Terminology Criteria for Adverse Events (PRO‐CTCAE) Secondary end point(s):5. Change from baseline in symptomatic side effects, as assessed through use of the PRO‐CTCAE Secondary end point(s):6. Proportion of participants reporting "frequent" or "almost constant" diarrhea during the first three cycles of treatment according to the PRO‐CTCAE criteria Secondary end point(s):7. Proportion of participants reporting "severe" or "very severe" nausea or vomiting during the first three cycles of treatment according to the PRO‐CTCAE Secondary end point(s):8. Frequency of participant's response of the degree they are troubled with treatment symptoms, as assessed through use of the single‐item European Organisation for Research and Treatment of Cancer (EORTC) Item List 46 (IL46) Secondary end point(s):9. Plasma concentration of divarasib at specified timepoints INCLUSION CRITERIA: Histologically or cytologically documented locally advanced unresectable or metastatic non‐squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy, No prior systemic treatment for advanced unresectable or metastatic NSCLC, Confirmation of Biomarker eligibility: – Valid results from either central testing of tissue or local testing of blood or tissue documenting the presence of the KRAS G12C mutation – Valid results from either central or local testing of tissue documenting expression of PD‐L1. For Cohort A, PD‐L1 tumor cell expression >= 1% is required to be eligible. Patients in Sweden are required to have documented history of PD‐L1 tumor cell expression =50%. For Cohort B, PD‐L1 tumor cell expression is not required to be eligible. Local testing of tumor tissue for PD‐L1 expression must be performed at an appropriately accredited/certified laboratory, Pretreatment tumor tissue along with an associated pathology report is requi}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02731332/full} -} - - -Record #254 of 538 -@article{EUCTR2016-005042-37-ES17, -author = {EUCTR2016-005042-37-ES,}, -title = {A phase II study that tests afatinib in combination with pembrolizumab in patients with squamous cell carcinoma of the lung}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2016-005042-37-ES}, -year = {2017}, -accession_number = {ICTRP EUCTR2016‐005042‐37‐ES}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trade Name: GIOTRIF 40 mg film‐coated tablets Product Name: Afatinib Product Code: BIBW 2992 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: Afatinib Current Sponsor code: BIBW 2992 Other descriptive name: AFATINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40‐ Trade Name: GIOTRIF 30 mg film‐coated tablets Product Name: Afatinib Product Code: BIBW 2992 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: Afatinib Current Sponsor code: BIBW 2992 Other descriptive name: AFATINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30‐ Trade Name: GIOTRIF 20 mg film‐coated tablets Product Name: Afatinib Product Code: BIBW 2992 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: Afatinib Current Sponsor code: BIBW 2992 Other descriptive name: AFATINIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20‐ Trade Name: KEYTRUDA® Product Name: KEYTRUDA® Pharmaceutical Form: Solution for infusion INN or Proposed INN: PEMBROLIZUMAB Other descriptive name: PEMBROLIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ CONDITION: locally advanced or metastatic squamous cell carcinoma of the lung ; MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non‐small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: The main objective is to assess the efficacy of afatinib in combination with pembrolizumab, as measured by objective response (OR) in patients with locally advanced or metastatic squamous NSCLC who progressed during or after first line platinum‐based treatment. Primary end point(s): 1) Objective Response (OR), defined as best overall response of complete response (CR) or partial response (PR) Secondary Objective: The secondary objectives are to confirm the RP2D, assess the safety profile, and the secondary measures of clinical efficacy including disease control (DC), duration of objective response (DoR), progression‐free survival (PFS), overall survival (OS), and tumour shrinkage. Timepoint(s) of evaluation of this end point: 1) Up to two years SECONDARY OUTCOME: Secondary end point(s): 1) Disease control (DC), defined as best overall response of CR, PR, or stable disease (SD); 2) Duration of objective response (DoR), defined as the time from first documented CR or PR until the earliest of disease progression or death among patients with OR.; 3) Progression‐free survival (PFS), defined as the time from first drug intake until disease progression or death from any cause, whichever occurs earlier.; 4) Overall survival (OS), defined as time from first drug intake until death from any cause.; 5) Tumour shrinkage (in millimeters), defined as the difference between the minimum post‐baseline sum of diameters of target lesions (longest for non‐nodal lesions, short axis for nodal lesions) and the baseline sum of diameters of the same set of target lesions. Timepoint(s) of evaluation of this end point: 1) up to two years after the last patient entered; 2) up to two years after the last patient entered; 3) up to two years after the last patient entered; 4) up to two years after the last patient entered; 5) up to two years after the last patient entered INCLUSION CRITERIA: ‐ Pathologically confirmed diagnosis of NSCLC considered to be of squamous histology, including mixed histology, in the opinion of the investigator. ‐ Locally advanced (stage IIIb) or metastatic (stage IV) NSCLC not considered eligible for curative therapy. ‐ Documented disease progression or relapse (based on investigator's assessment) during or after completion of at least 2 cycles of platinum‐based chemotherapy as first line treatment of Stage IIIB/IV SCC of the lung. This includes patients relapsing within 6 months of completing (neo)adjuvant/curative‐intent chemotherapy or definitive chemoradiotherapy. Patients should be eligible to receive 2nd line therapy in the opinion of the investigator. ‐ At least one target lesion (outside the brain) that can be accurately measured per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. In patients who only have one target lesion and a biopsy of the lesion}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01887012/full} -} - - -Record #255 of 538 -@article{Rizvi17, -author = {Rizvi, NA, and Peters, S}, -title = {Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer}, -journal = {New England journal of medicine}, -volume = {377}, -number = {20}, -pages = {1986‐1988}, -year = {2017}, -accession_number = {EMBASE 619258315, PUBMED 29141165}, -publication type = {Journal article}, -keywords = {*Carcinoma, Non‐Small‐Cell Lung; *Lung Neoplasms; *cancer staging; *immunotherapy; *non small cell lung cancer /drug therapy /drug therapy /radiotherapy; Adaptive immunity; Advanced cancer; Antineoplastic Combined Chemotherapy Protocols; Brain metastasis /complication; Cancer growth; Cancer mortality; Cancer recurrence; Cancer survival; Chemoradiotherapy; Combined Modality Therapy; Controlled study; Correlational study; Drug withdrawal; Editorial; Histology; Human; Humans; Immune response; Immunotherapy; Major clinical study; Neoadjuvant chemotherapy; Neoplasm Staging; Overall survival; Phase 3 clinical trial; Pneumonia /side effect; Priority journal; Progression free survival; Radiation dose; Randomized controlled trial; Sensitivity analysis; Squamous cell carcinoma; Treatment response}, -DOI = {10.1056/NEJMe1711430}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01428230/full} -} - - -Record #256 of 538 -@article{Lu21, -author = {Lu, S, Yu, X, Wang, J, Zhao, J, Yu, Y, Hu, C, Feng, G, Ying, K, Zhuang, W, Zhou, J, Wu, J, Leaw, SJ, Bai, F, and Lin, X}, -title = {P17.02 RATIONALE 307: a Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC}, -journal = {Journal of thoracic oncology}, -volume = {16}, -number = {10}, -pages = {S1019‐S1020}, -year = {2021}, -accession_number = {EMBASE 2015169381}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer staging; *non small cell lung cancer; Adult; Aged; Area under the curve; Cancer immunotherapy; Cancer patient; Cancer surgery; Cancer survival; Chemoradiotherapy; China; Clinical article; Clinical evaluation; Conference abstract; Controlled study; Drug combination; Drug safety; Drug therapy; Drug withdrawal; Female; Follow up; Gene expression; Histopathology; Human; Intravenous drug administration; Male; Middle aged; Multicenter study; Open study; Overall response rate; Pharmacokinetics; Phase 3 clinical trial; Progression free survival; Protein expression; Radiotherapy; Randomized controlled trial; Tumor cell}, -abstract = {Introduction: Tislelizumab ‐ a humanized, monoclonal antibody for programmed cell death protein 1 ‐ has demonstrated significantly improved progression‐free survival (PFS) and reduced risk of progression versus standard of care in advanced lung cancer (NCT03432598, NCT03594747). We conducted a Phase 3, multicenter, randomized, open‐label study to assess the safety and efficacy of tislelizumab plus chemotherapy in patients with advanced squamous non‐small cell lung cancer (NSCLC) (NCT03594747). Here, we report results from patients with stage IIIB disease. Methods: Adults in China with treatment‐naïve histologically confirmed locally advanced or metastatic (stage IIIB or IV) squamous NSCLC not amenable to surgery or not suitable for chemoradiation were randomized 1:1:1 to Arm A: tislelizumab (200 mg) plus paclitaxel 175 mg/m2 and carboplatin AUC 5 (every 3 weeks [Q3W] on day 1); Arm B: tislelizumab plus nab‐paclitaxel 100 mg/m2 (Q3W on days 1, 8 and 15) plus carboplatin (Q3W on day 1); or Arm C: paclitaxel plus carboplatin (Q3W on day 1). Paclitaxel, nab‐paclitaxel and carboplatin were administered for 4–6 cycles. All treatments were administered intravenously. Stratification factors were disease stage (IIIB vs IV), and programmed death‐ligand 1 expression (<1% vs 1–49% vs ≥50% tumor cells). Tislelizumab was administered until loss of benefit, withdrawal or start of new anticancer therapy. In this subgroup analysis, PFS, objective response rate (ORR) (assessed by independent review committee) and safety were evaluated in patients with stage IIIB disease. Results: Overall, 122/360 (33.9%) patients had stage IIIB NSCLC. Patients were randomized to Arm A (38 patients), B (40 patients) or C (44 patients). The median age was 61 years (range 34–74 years). At median follow‐up time of 8.6 months across all arms, PFS was numerically longer, and ORR higher, respectively, with tislelizumab (Arms A and B) versus chemotherapy alone (Arm C) (Table, PFS: HR=0.402 [Arm A] vs 0.372 [Arm B]). The PFS benefit observed was consistent with the ITT population (Table). TEAEs (≥1) and Grade ≥3 TEAEs were similar across all arms (Table). No new safety signals were observed. Laboratory abnormalities were the most commonly reported TEAEs across all arms. Conclusion: In this subgroup analysis, a clinically meaningful improvement in PFS and higher ORR was observed with tislelizumab plus chemotherapy versus standard of care in patients with stage IIIB advanced squamous NSCLC. The safety and efficacy profile of tislelizumab was consistent with the overall population. [Formula presented] Keywords: PD‐1, NSCLC, immunotherapy}, -DOI = {10.1016/j.jtho.2021.08.348}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02336825/full} -} - - -Record #257 of 538 -@article{Bauer16, -author = {Bauer, TM, Wang, JS, Lee, JK, Manji, GA, Kudchadkar, R, Kauh, JS, Tang, S, Laing, N, and Falchook, G}, -title = {Phase Ia/Ib trial investigating the CSF-1R inhibitor LY3022855 in combination with durvalumab (MEDI4736) or tremelimumab in patients with advanced solid malignancies}, -journal = {Journal for immunotherapy of cancer}, -volume = {4}, -number = {no pagination}, -year = {2016}, -accession_number = {EMBASE 613518652}, -publication type = {Journal article; Conference proceeding}, -keywords = {*controlled study; *mesothelioma; Antineoplastic activity; Biopsy; Chemotherapy; Clinical trial; Controlled clinical trial; Drug combination; Drug therapy; Female; Gene inactivation; Human; Human tissue; Immunogenicity; Major clinical study; Maximum tolerated dose; Melanoma; Murine; Non small cell lung cancer; Nonhuman; Ovary; Pharmacokinetics; Phase 1 clinical trial; Phase 2 clinical trial; Radiotherapy; Safety; Tumor model}, -abstract = {Background Checkpoint inhibitors of programmed cell death‐1 protein (PD‐1)/programmed cell death‐ligand 1 (PD‐L1) and cytotoxic T lymphocyte associated protein 4 (CTLA‐4) pathways have demonstrated clinically meaningful improvement in survival for patients with various tumor types. Preclinical data demonstrate significant interplay between innate and adaptive immune systems. Targeting colony‐stimulating factor 1 receptor (CSF‐1R) may lead to disruption of the immunosuppressive effects of innate immune cells expressing CSF‐1R. Treatment with an anti‐CSF‐1R monoclonal antibody (mAb) induces anti‐tumor responses in multiple murine tumor models when combined with CTLA‐4 blockade [1], suggesting that combining a checkpoint inhibitor with a CSF‐1 pathway inhibitor may potentiate the anti‐tumor response. Study I5F‐MC‐JSCC will evaluate the effects of CSF‐1R inhibition using LY3022855 (anti‐CSF‐1R mAb) in combination with durvalumab (MEDI4736; anti‐PD‐L1 mAb) or tremelimumab (anti‐CTLA‐4 mAb) in participants with advanced solid malignancies. Methods JSCC is a phase Ia/Ib open‐label, 3+3 dose‐escalation (Part A), followed by dose‐expansion (Part B) study of LY3022855 in combination with either durvalumab or tremelimumab. Eligible patients have confirmed solid malignancies (regardless of PD‐L1 status) and ECOG PS 0‐1. Patients must not have received small molecule therapy, chemotherapy, radiation therapy, monoclonal antibody treatment, or immunosuppressive medication within 14‐28 days of start of study treatment, but prior immune checkpoint therapy is permitted. Pretreatment and on‐treatment biopsies will be obtained (Part A all patients, Part B ovarian cohort). In the LY3022855+durvalumab regimen, LY3022855 (IV) will be administered at increasing dose levels as tolerated; durvalumab (IV) will be administered at a fixed dose. In the LY3022855 +tremelimumab regimen, both LY3022855 and tremelimumab (IV) will be administered at increasing dose levels as tolerated. Once a maximum tolerated dose has been identified for each combination, enrollment to Part B (5 disease‐specific expansion cohorts of 20 patients per cohort: LY3022855+durvalumab‐non‐small cell lung cancer, ovarian, melanoma; LY3022855+tremelimumab‐mesothelioma, melanoma) will begin. The primary objective is to characterize the safety and tolerability of each combination in treatment of patients with advanced solid malignancies, as well as define a recommended phase II dose. Secondary objectives include assessment of antitumor activity of each combination, immunogenicity, and pharmacokinetics. Exploratory objectives are to assess immunomodulatory effects of the combinations. Approximately 178 patients are planned.}, -DOI = {10.1186/s40425-016-0172-7}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01295366/full} -} - - -Record #258 of 538 -@article{ChiCTR240008160224, -author = {ChiCTR2400081602,}, -title = {Radiotherapy plus PD-1 inhibitor and anlotinib versus chemotherapy plus PD-1 inhibitor in locally advanced non-small cell lung cancer: a prospective, regional multi-center, Phase II clinical trial}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2400081602}, -year = {2024}, -accession_number = {ICTRP ChiCTR2400081602}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: intervention group:Radiotherapy combined with PD‐1 inhibitors and anlotinib;control group:Chemoradiotherapy combined with PD‐1 inhibition; CONDITION: Locally advanced non‐small cell lung cancer PRIMARY OUTCOME: One‐year progression‐free survival; SECONDARY OUTCOME: Objective remission rate, ORR;Progression‐free survival, PFS;Overall survival; INCLUSION CRITERIA: 1.Histologically or cytologically demonstrated patients with advanced NSCLC with definite stages, such as chest enhanced CT, liver and adrenal CT, skull magnetic resonance, or PET‐CT/ whole body bone imaging; 2. patients aged 18 to 75 years old were able to give informed consent and sign informed consent, and were able to comply with the study protocol and follow‐up procedure; 3. Life expectancy greater than 6 months; 4.American Eastern Cancer Cooperative Group ECOG score 0‐1; 5. Adequate pulmonary function, required: first second forced breathing volume (FEV1) =1.2 l/s or =50% of predicted value, postoperative expectation (FEV1) = 30%; 6.Have no previous history of other malignancies and have not received any systemic antitumor therapy for lung tumors; 7. patients who received hormone therapy more than 4 weeks ago and all adverse events from prior therapy have returned to = grade I (CTCAE 4.0); 8. The following laboratory tests performed within}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02682398/full} -} - - -Record #259 of 538 -@article{Kimura19, -author = {Kimura, H}, -title = {P1.04-08 Randomized Controlled Phase III Trial of Adjuvant Chemoimmunotherapy to Lung Cancer Patients: results of Malignant Effusions}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S441}, -year = {2019}, -accession_number = {EMBASE 2003407367}, -publication type = {Journal article; Conference proceeding}, -keywords = {*adjuvant chemotherapy; *cancer patient; *malignant pleura effusion; *non small cell lung cancer; Adoptive immunotherapy; Adult; Cancer chemotherapy; Cancer recurrence; Cancer surgery; Cancer survival; Catheter; Conference abstract; Cytotoxic T lymphocyte; Dendritic cell; Female; Human; Human cell; Human tissue; Intraperitoneal drug administration; Lymph node; Major clinical study; Male; Malignant ascites; Minimal residual disease; Overall survival; Peritoneum; Phase 3 clinical trial; Primary tumor; Randomization; Randomized controlled trial; Relapse; Thoracic cavity; Tumor cell}, -abstract = {Background: Elucidation of cancer immunoediting from immune surveillance to immune escape and approval of immune check point inhibitors by FDA prompted immunotherapy became a forth modality next to surgery, chemotherapy and radiotherapy. We have recruited advanced lung cancer patients with poor prognosis who had undergone surgery to improve prognosis by immunotherapy. Objective and methods: Post‐surgical lung cancer patients were randomly designated to receive either chemoimmunotherapy (4 courses of chemotherapy with 10‐14 courses of cellular immunotherapy: group A) or chemotherapy (4 courses of chemotherapy: group B). Immunotherapy comprised adoptive intravenous transfer of autologous activated killer T cells and dendritic cells (AKT‐DC) obtained from the regional lymph nodes of lung cancer patients. The study inclusion criteria were: <76 years; PS 0 or 1; non‐small cell lung cancer; pathological stage, IB‐IV. Patients whose surgery was palliative or in whom macroscopic residual tumors remained after surgery were excluded but those with microscopic residual tumors detected after a cytopathological examination were included in the study. Patients with pleural dissemination were excluded but those with malignant pleural effusion were included and received intra‐thoracic chemotherapy with 20mg CDDP 4 times (group B) or chemotherapy with 4 to 8 courses of AKT‐DC immunotherapy (group A) through a subcutaneous port with intrathoracic catheter installed in the thoracic cavity after resection of the primary tumors. A patient who had a recurrence of malignant ascites in group A received peritoneal infusion of AKT‐DC after cell‐free concentrated ascites reinfusion therapy (CART). Result: A hundred‐and three patients were selected for randomization. The 2‐, 5‐, and 7‐year overall survival rates were 96.0% 69.4%, and 55.1 in group A (n=51) and 64.7%, 45.1%, and 38.1% in group B (n=52), respectively. The Hazard ratio was 0.439 in favor of group A by multivariate analysis. There were 11 group A and 9 group B patients with malignant pleural effusion. One patient in group A and 6 patients in group B had recurrence and 3 died within 2 years in group B. The difference was also significant in favor of group A. A patient with malignant ascites received 5 times AKT‐DC therapy with 7 courses of CART in 2 months. Complete elimination of tumor cells accompanied with ascites eradication resulted in 9 months prolongation of survival after recurrence. Conclusion: Patients with lung cancer benefited from adoptive cellular immunotherapy as an adjuvant to surgery. Intrathoracic and peritoneal cellular immunotherapy with AKT‐DC are effective to patients with malignant effusions. Keywords: adoptive immunotherapy, malignant effusion, randomized controlled phase III study}, -DOI = {10.1016/j.jtho.2019.08.911}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01997407/full} -} - - -Record #260 of 538 -@article{Juloori21, -author = {Juloori, A, Bestvina, C, Pitroda, S, Pointer, K, Jelinek, M, Hoffman, P, Vokes, E, Patel, J, and Chmura, S}, -title = {RO01.01 Prospective Evaluation of Ipilimumab and Nivolumab in Patients with Non-Small Cell Lung Cancer Brain Metastasis}, -journal = {Journal of thoracic oncology}, -volume = {16}, -number = {1}, -pages = {S45}, -year = {2021}, -accession_number = {EMBASE 2010627900}, -publication type = {Journal article; Conference proceeding}, -keywords = {*brain metastasis; *cancer patient; *non small cell lung cancer; *prospective study; Adult; Advanced cancer; Cancer growth; Cancer radiotherapy; Cancer staging; Cancer survival; Clinical article; Clinical trial; Cohort analysis; Conference abstract; Controlled study; Developmental toxicity; Drug therapy; Female; Follow up; Human; Immunotherapy; Male; Nuclear magnetic resonance imaging; Phase 1 clinical trial; Progression free survival; Radiation necrosis; Radiotherapy; Randomized controlled trial; Remission; Stereotactic body radiation therapy; Systemic therapy; Whole brain radiotherapy}, -abstract = {Background: Nivolumab combined with Ipilimumab (Ipi/Nivo) has been shown to improve overall survival compared to chemotherapy in first‐line treatment of stage IV non‐small cell lung cancer (NSCLC). Brain metastasis patients have often been excluded from many clinical trials. We examined outcomes of brain metastasis patients included on a phase 1 trial of combined immune checkpoint blockade and multi‐site stereotactic body radiation therapy (SBRT) in newly diagnosed stage IV NSCLC. Methods: All patients underwent brain MRI as part of trial screening. Treatment naïve patients with advanced NSCLC were eligible for enrollment. Patients received SBRT to 1 to 4 extracranial metastases and were randomized to receive 1st cycle of Ipi/Nivo either during or after multi‐site SBRT. Ipi/Nivo continued until progression, development of toxicity, or up to two years. Brain metastases > 3 mm in size were treated with radiosurgery or WBRT prior to starting systemic therapy and multi‐site SBRT. Results: 35 patients were treated with multi‐site SBRT and received at least one cycle of Ipi/Nivo. 9 patients had brain metastasis at diagnosis. 8 patients received SRS while one received WBRT. With a median follow‐up time of 15 months for all patients, median OS for the brain metastasis cohort has not been reached. All 9 brain metastasis patients remain alive; 7 of these patients have remained alive for at least 15 months and continue on Ipi/Nivo. Two of 18 treated lesions (11%) developed radiation necrosis. Of 26 patients enrolled without brain metastases, 5 developed intracranial disease. Four of these 5 patients underwent salvage WBRT and remain alive, free of intracranial progression. The 1‐year intracranial progression‐free survival (PFS) was 81.7% and was 87.0% in those enrolled without brain metastasis. In the 9 patients with brain metastasis, only 3 went on to progress intracranially, notably within a short time frame (within 3 months). Median PFS did not differ between BM (13.1 months) and non‐BM(5.86 months) cohorts (p=NS). Two patients in the brain metastasis cohort had lesions at diagnosis that were not treated with SRS which had complete response with immunotherapy alone. Conclusions: Ipi/nivo/SBRT is a successful treatment strategy in patients with NSCLC brain metastasis. Outcomes do not appear to be inferior for these patients compared to non‐brain metastasis stage IV patients and they should be included in trials in the immunotherapy era. Intracranial control appears promising. Further intracranial efficacy of Ipi/Nivo and outcomes of brain metastasis patients will be explored in a phase II expansion.}, -DOI = {10.1016/j.jtho.2020.10.089}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02246488/full} -} - - -Record #261 of 538 -@article{Wang22, -author = {Wang, B-C, Kuang, B-H, and Lin, G-H}, -title = {Immunotherapy Alone or in Combination with Stereotactic Body Radiotherapy in Advanced Lung Cancer: a Pooled Analysis of Randomized Clinical Trials}, -journal = {Journal of oncology}, -volume = {2022}, -year = {2022}, -accession_number = {EMBASE 2020565407}, -publication type = {Journal article}, -keywords = {*advanced cancer /radiotherapy /surgery /therapy; *cancer immunotherapy; *monotherapy; *non small cell lung cancer /radiotherapy /surgery /therapy; *small cell lung cancer /radiotherapy /surgery /therapy; *stereotactic body radiation therapy; Article; Cancer patient; Cancer survival; Cochrane Library; Combination chemotherapy; Comparative study; Controlled study; Data base; Disease control; Embase; Female; Human; Major clinical study; Male; Medline; Multiple cycle treatment; Outcome assessment; Overall response rate; Overall survival; Phase 2 clinical trial; Preferred Reporting Items for Systematic Reviews and Meta‐Analyses; Progression free survival; Publication bias; Radiation dose; Randomized controlled trial; Systematic review; Systemic therapy; Web of Science}, -abstract = {Background. Immunotherapy has revolutionized the treatment of advanced lung cancer. Nevertheless, it remains unclear whether adding stereotactic body radiotherapy (SBRT) to immunotherapy (IT) further improves responses and survival outcomes. Therefore, in this pooled analysis, we comprehensively compared IT plus SBRT with IT alone in patients with advanced lung cancer. Methods. Online databases, including PubMed, Web of Science, Embase, and Cochrane CENTRAL, were systematically searched on April 24, 2022. Eligible studies were randomized clinical trials comparing IT plus SBRT to IT. The primary outcomes were the objective response rate (ORR) and disease control rate (DCR). Progression‐free survival (PFS) and overall survival (OS) were explored as secondary outcomes. Results. Overall, three phase 2 randomized clinical trials with a total of 146 previously treated lung cancer patients were enrolled. The median PFS and OS were 3.8 months and 9.5 months for IT plus SBRT versus 2.4 months and 6.1 months for IT. Comparing IT plus SBRT with IT alone, pooled risk ratios for ORR and DCR were 1.95 (95% confidence interval 1.07‐3.53, p = 0.03) and 1.28 (0.94‐1.73, p = 0.12). While pooled hazard ratios were 0.77 (0.25‐2.42, p = 0.66) for PFS and 0.71 (0.16‐3.21, p = 0.65) for OS, respectively. No publication bias was found across the trials. Conclusion. Compared to IT alone, the addition of SBRT improved the best response but failed to prolong the survival outcomes in treating advanced lung cancer patients. Future studies are necessary to explore new modalities of the combination of IT and SBRT.}, -DOI = {10.1155/2022/7506300}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02501129/full} -} - - -Record #262 of 538 -@article{EUCTR2014-001473-14-SE14, -author = {EUCTR2014-001473-14-SE,}, -title = {OS Study of Pembrolizumab (MK-3475) vs. SOC in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic NSCLC (Keynote 042)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2014-001473-14-SE}, -year = {2014}, -accession_number = {ICTRP EUCTR2014‐001473‐14‐SE}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: MK‐3475; SCH900475; pembrolizumab Product Code: MK‐3475; SCH900475 Pharmaceutical Form: Solution for infusion INN or Proposed INN: pembrolizumab CAS Number: 1374853‐91‐4 Current Sponsor code: MK‐3475 Other descriptive name: Anti‐PD‐1 monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ Trade Name: ALIMTA Product Name: pemetrexed Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: PEMETREXED CAS Number: 137281‐23‐3 Other descriptive name: Alimta Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500‐ Trade Name: Paclitaxel 6mg/ml Concentrate For Solution For Infusion Product Name: paclitaxel Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: PACLITAXEL CAS Number: 33069‐62‐4 Other descriptive name: Abraxane, Taxol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6‐ Trade Name: Carboplatin 10mg/mL concentrate for infusion for solution Product Name: carboplatin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: carboplatin CAS Number: 41575‐94‐4 Other descriptive name: cis‐Diammine(1,1‐cyclobutanedicarboxylato)platinum(II) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ Trade Name: Paclitaxel 6mg/ml Concentrate For Solution For Infusion Product Name: paclitaxel Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: PACLITAXEL CAS Number: 33069‐62‐4 Other descriptive name: Abraxane, Taxol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6‐ Trade Name: Carboplatin 10mg/mL concentrate for infusion for solution Product Name: carboplatin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: carboplatin CAS Number: 41575‐94‐4 Other descriptive name: CARBOPLATIN CONDITION: Non‐Small Cell Lung Carcinoma Therapeutic area: Diseases [C] ‐ Cancer [C04] SECONDARY OUTCOME: Secondary end point(s): Progression‐Free Survival Timepoint(s) of evaluation of this end point: Subjects will be evaluated for progression‐free survival which is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central radiologists’ assessment or death due to any cause, whichever occurs first. Disease assessments including tumor imaging will be performed every 9 – 12 weeks until the time of progression. INCLUSION CRITERIA: •Have measurable disease based on RECIST 1.1. as determined by the site •Be =18 years of age on the day of signing informed consent. •Have a life expectancy of at least 3 months •Have not received prior systemic chemotherapy treatment for their advanced/metastatic NSCLC. Treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of advanced or metastatic disease. •Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status •Have adequate organ function •Have provi PRIMARY OUTCOME: Main Objective: 1) To compare the overall survival (OS) in subjects with PD‐L1 strongly positive, 1L advanced/metastatic NSCLC treated with pembrolizumab compared to standard of care (SOC) chemotherapies. ; 2) To compare the OS in subjects with PD‐L1 positive (strong and weak), 1L advanced/metastatic NSCLC treated with pembrolizumab compared; to SOC chemotherapies. Primary end point(s): Overall Survival Secondary Objective: 1)To compare the progression‐free survival (PFS) by RECIST 1.1 as assessed by central independent radiologists’ review in subjects with PD‐L1 strongly positive, 1L advanced/metastatic NSCLC treated with pembrolizumab compared to SOC chemotherapy. ; 2)To compare the PFS as assessed by RECIST 1.1 by central independent radiologists’ review in subjects with PD‐L1 positive (strong and weak), 1L advanced/metastatic NSCLC treated with pembrolizumab compared to SOC chemotherapy. ; 3)To evaluate the safety and tolerability profile of pembrolizumab in subjects with 1L advanced/metastatic PD‐L1 positive NSCLC. Timepoint(s) of evaluation of this end point: Subjects will be evaluated for Overall Survival which is defined as the time from randomization to the time of death due to any cause. Initially subjects will be evaluated for disease status every 9 – 12 weeks until the time of progression at which time they will be followed for overall survival via follow up phone contact. •Have no history of prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cervical cancer, or have undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01815532/full} -} - - -Record #263 of 538 -@article{UMIN00002455116, -author = {UMIN000024551,}, -title = {PhaseII study of the efficacy of DOCETAXEL plus RAMUCIRUMAB for NSCLC with brain metastasis}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000024551}, -year = {2016}, -accession_number = {ICTRP UMIN000024551}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Docetaxel plus Ramucirumab CONDITION: Non‐small cell lung carcinoma PRIMARY OUTCOME: progression free survival SECONDARY OUTCOME: intracranial progression free survival; overall survival; disease control rate; overall response rate; safety INCLUSION CRITERIA: 1. Patients who are histology or cytology confirmed as advanced non‐small cell lung cancer. 2. Patients have asymptomatic brain metastasis, at least one measurable lesion in the brain (defined as lesion more than 5mm and a double or more of a slice thickness in longest dimension) confirmed by brain MRI. Stereotactic radiosurgery (SRS) (including Gamma Knife or Cyber Knife) before enrollment is allowed. At least 2 weeks has elapsed from the completion of SRS. 3. Patients who have disease progression during or after first‐line chemotherapy (including platinum‐based agents, non‐platinum‐based agents, EGFR‐TKI, ALK inhibitor or immune checkpoint inhibitor) with or without maintenance therapy. ‐ Patients with progressed disease during or after completion of prior therapy for advanced/metastatic disease. ‐ Prior bevacizumab as first‐line and/or maintenance therapy is allowed. 4. Performance Status (ECOG) is 0 or 1 at the time of acquisition of consent. % positive tumor cells. Immune based prognostic markers: The TME consists of stromal cells including endothelial cells and fibroblasts and a number of immune cell types. Tumors may escape immune recognition in large part by modulating the recruitment and function of various immune cells into the TME.4 A comprehensive review of the prognostic value of different immune cells in NSCLC has been reported.5 Two recent studies have separately assessed tumor lymphocytic infiltration (TLI)6 or stromal CD8+ T‐cell density7 as potential prognostic markers in early stage NSCLC. Using the large, relatively homogenous population of curative resected NSCLC patients from the LACE‐Bio collaboration, Brambilla et al examine the prognostic and predictive value of TLI. Patients were separated into discovery and validation sets. An intense TLI (>50% stromal lymphocytes in tumor bulk) was strongly prognostic of favorable overall survival and disease free survival. Based on previous work, Donner et al selected stromal CD8+ tumor infiltrating lymphocyte as the most promising immunobased prognostic marker. Using four separate cohorts of curatively resected stage I‐III patients, they established training and validation sets. Tissue microarrays were scored for stromal CD8 TLI's; stromal CD8 TIL density was found to be an independent prognostic factor and retained significant prognostic impact within each stage. The value of PD‐L1 as a biomarker in NSCLC has been investigated primarily in advanced disease and focused on prediction of response and/or survival. Studies investigating the value of PD‐L1 as a prognostic marker in early stage NSCLC have many limitations. These studies are small, include heterogenous populations, assess PD‐L1 using different antibodies and scoring systems and included PDL1 on tumor cells only or tumor cells and TLI's. It is not surprising that these studies show conflicting results. Based on the available evidence, the prognostic value of PD‐L1 expression in early stage NSCLC remains uncertain. The adjuvant trials of anti‐PD1/PD‐L1 therapy currently being conductedmay clarify the value of PD‐L1 as both prognostic and predictive biomarkers in this setting. Challenges One of the fundamental challenges to developing effective cancer immunotherapies is our limited understanding of the human immune system in steady state and its response to stress. Animal models do not necessarily translate to humans. The Human Vaccines Project8 is a global initiative that has as one of its primary objectives the decoding of the human immune system and providing a map of the human “immunome”. This private‐public partnership uses state‐of‐the‐art machine learning and technologies to elucidate the principles of immunogenicity to accelerate the development of new immunotherapies against infectious diseases and cancer. A second challenge is howbest to target micrometastases in the adjuvant and locally advanced setting. While the primary tumor and metastatic lesions have many mutations in common, metastatic tumors possess mutations that are distinct from the primary. Do adjuvant therapies need to target the metastatic cascade and if so, which steps are the most susceptible to intervention? 9 The complex of the TME would predict that focusing on TIL's or PD‐L1 is likely to result in only modest improvements in outcome. Blank et al10 argue that it will take a combination of biomarkers, the “cancer immunogram,” to determine the best approach in individual patients.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01718552/full} -} - - -Record #265 of 538 -@article{Ruhstaller17, -author = {Ruhstaller, T}, -title = {Immunotherapy in oesophageal cancer}, -journal = {Oncology research and treatment}, -volume = {40}, -pages = {270}, -year = {2017}, -accession_number = {EMBASE 618607247}, -publication type = {Journal article; Conference proceeding}, -keywords = {*esophagus cancer; *immunotherapy; Adenocarcinoma; Adult; Antineoplastic activity; Biology; Cancer prognosis; Cancer regression; Cancer survival; Cardia; Chemoradiotherapy; Controlled study; Gastroesophageal junction; Human; Human cell; Human tissue; Lymphocyte; Microenvironment; Minimal residual disease; Molecularly targeted therapy; Morbidity; Mutational load; Phase 3 clinical trial; Prognosis; Radiotherapy; Randomized controlled trial; Stomach tumor; Surgery; Survival; Treatment failure; Tumor cell; Upregulation}, -abstract = {Immunotherapeutic approaches have demonstrated clinical efficacy in several advanced cancer types like melanoma, non‐small cell lung cancer and renal cell carcinoma. In oesophago‐gastric tumours we can found PD‐L1 upregulation in about 40%, but the PD‐L1 is expressed, in contrast to other tumour types, mainly on infiltrating lymphocytes and less on tumour cells. Other potential biomarkers could be the extent of infiltrating lymphocytes or the mutational load, which is often very high in the oesophago‐gastric adenocacrcinoma. A lot of phase ‐l/ll trials have been performed with single agent checkpoint inhibitors in gastric and oesophago‐gastric tumours and showed response rates of 22‐27% for patients with PD‐L1+ tumours and 10‐17% for unselected patients. In addition, in patients with squamous oesophageal cancer durable anti‐tumor activity was observed with 15‐20% overall response rate. Most of the ongoing studies in the advanced setting are now investigating combinations of checkpoint inhibitors with targeted therapies or chemotherapies. The adjuvant approach to improve patient outcomes has failed using chemotherapy and radiotherapy due to the high postoperative morbidity. Here immunotherapy could be an alternative. Additionally, to block the PD‐1 pathway earlier in a disease course may be the better way to have an immune‐mediated cancer regression. The most important study in this setting is the CheckMate‐577 study, a randomized phase III study of adjuvant nivolumab/placebo for patients with resected oesophageal cancer and still residual tumor in the specimen. For the inclusion in this trial a poor prognosis group of patients is clinically selected by the response to the neoadjuvant chemoradiation. This group of patients has a 5y‐survival of only 30‐40% without further therapy. This important and large trial in the adjuvant setting is ongoing; other smaller trials are investigating checkpoint inhibitors in the neoadjuvant setting together with radiation therapy. However, we already know that the biology of adenocarcinoma of distal oesophagus, gastro‐oesophageal junction carcinoma and adenocarcinoma of cardia is distinctive; therefore we may In the future select patients for immunotherapy according to mutational changes and immune microenvironment.}, -DOI = {10.1159/000479566}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01422824/full} -} - - -Record #266 of 538 -@article{EUCTR2011-004792-36-ES12, -author = {EUCTR2011-004792-36-ES,}, -title = {Study of BMS-936558 compared to Docetaxel in previously treated advanced or metastatic Squamous cell NSCLC}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2011-004792-36-ES}, -year = {2012}, -accession_number = {ICTRP EUCTR2011‐004792‐36‐ES}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: BMS‐936558 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: BMS‐936558‐01 CAS Number: 946414‐94‐4 Current Sponsor code: BMS‐936558‐01 Other descriptive name: Anti‐PD‐1 Human Monoclonal Antibody; MDX‐1106 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ Trade Name: Taxotere 160 mg (20 mg/mL) Product Name: Docetaxel Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: DOCETAXEL CAS Number: 114977‐28‐5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20‐ CONDITION: Squamous cell Non‐small cell lung cancer ; MedDRA version: 14.1 Level: PT Classification code 10061873 Term: Non‐small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: The purpose of the study is to compare the change in tumor size, and overall survival of BMS‐936558 as compared with Docetaxel in subjects with squamous cell non‐small cell lung cancer (NSCLC), after failure of prior platinum‐based chemotherapy Primary end point(s): Objective Response Rate, Overall Survival Secondary Objective: 1.To compare the progression‐free survival (PFS) of BMS‐936558 versus docetaxel; 2.To evaluate clinical benefit in terms of ORR and OS of BMS‐936558 versus docetaxel, in PD‐L1 + versus PD‐L1‐ protein expression subgroups; 3.To evaluate durability of and time to objective response in BMS‐936558 and docetaxel groups; 4.To evaluate the proportion of subjects exhibiting disease‐related symptom progression, as measured by LCSS, in BMS‐936558 and docetaxel groups Timepoint(s) of evaluation of this end point: 24 months SECONDARY OUTCOME: Secondary end point(s): 1. To compare the progression‐free survival (PFS) of BMS‐936558 versus docetaxel; 2. To evaluate clinical benefit in terms of ORR and OS of BMS‐936558 versus docetaxel, in PD‐L1 + versus PD‐L1‐ protein expression subgroups; 3. To evaluate durability of and time to objective response in BMS‐936558 and docetaxel groups; 4. To evaluate the proportion of subjects exhibiting disease‐related symptom progression, as measured by LCSS, in BMS‐936558 and docetaxel groups Timepoint(s) of evaluation of this end point: 24 months INCLUSION CRITERIA: 1) men & women ? 18 years of age 2) Subjects with histologically or cytologically‐documented squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent disease following radiation therapy or surgical resection. 3) Disease recurrence or progression during/after one prior platinum‐containing chemotherapy regimen for advanced or metastatic disease 4) Measurable disease by CT/MRI per RECIST 1.1 criteria 5) ECOG performance status ? 1 6) An FFPE tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 160 F.1.3 Elderly (>=65 years) yes F.1.3.1}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01835472/full} -} - - -Record #267 of 538 -@article{Kassouf22, -author = {Kassouf, W, Crabb, SJ, Duran, I, Brundage, MD, Reaume, MN, Dragomir, A, Wyatt, AW, Badillo, FEV, Lukka, H, Niazi, T, Souhami, L, Sridhar, SS, Griffiths, GO, Howell, D, Richardson, H, Djurfeldt, M, Ding, K, and Parulekar, WR}, -title = {CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570)}, -journal = {Journal of clinical oncology}, -volume = {40}, -number = {16}, -year = {2022}, -accession_number = {EMBASE 638833926}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *clinical assessment; *muscle invasive bladder cancer; Adult; Advanced cancer; Antineoplastic activity; Bladder tumor; Cancer adjuvant therapy; Cancer recurrence; Cancer staging; Cancer surgery; Cancer survival; Chemoradiotherapy; Clinical trial; Conference abstract; Controlled study; Disease free survival; Drug safety; Drug therapy; ECOG Performance Status; Economics; Feasibility study; Female; Human; Immune system; Immunotherapy; Male; Metastasis free survival; Mobile health application; Neoadjuvant chemotherapy; Non muscle invasive bladder cancer; Non small cell lung cancer; Outcome assessment; Overall survival; Phase 2 clinical trial; Quality of life; Radiation field; Radical cystectomy; Radiotherapy; Randomization; Randomized controlled trial; Recurrent disease; Response evaluation criteria in solid tumors; Sample size; Statistical design; Surgery; Transitional cell carcinoma; Transurethral resection}, -abstract = {Background: Immunotherapy improves outcomes in the advanced (Bellmunt 2019; Powles 2020) as well as in the adjuvant setting post cystectomy (Bajorin 2021) for muscle invasive bladder cancer (MIBC) patients. Trimodality treatment (TMT) consisting of transurethral resection of bladder tumor (TURBT) followed by chemoradiotherapy (CRT) may be considered an alternative to radical cystectomy in MIBC. The role of radiotherapy and chemotherapy as immune system stimulants provides a rationale to evaluate the anticancer activity of checkpoint inhibitors in this patient population. Durvalumab, an anti PDL1 inhibitor, administered after CRT leads to improvement in PFS and OS in patients with locally advanced NSCLC, which further supports the rationale for this study (Antonia 2017, 2018). We hypothesized that durvalumab will improve outcomes in patients with MIBC when administered in the adjuvant setting after completion of trimodality therapy. Methods: CCTG BL13 is a Canadian Cancer Trials Group, randomized phase II trial in patients with stage T2‐T4a N0M0, urothelial carcinoma treated with TURBT followed by radiotherapy with concurrent chemotherapy. Treatment arms consist of durvalumab 1500 mg IV q 4 weeks for 12 months versus surveillance. The primary objective: to compare disease free survival (DFS) between arms (RECIST 1.1, investigator assessed). Secondary endpoints include a non muscle‐invasive bladder cancer recurrence rate (< T2); locoregional control rate; overall survival; bladder intact DFS, patterns of disease recurrence; metastasis free survival; safety; quality of life ; economics evaluation. A pilot sub study (BL13F) has been activated and will evaluate the feasibility of electronic real‐time patient self‐reporting of immunotherapy related symptomatic adverse events using the SYMPTOM‐IQ Tool on the uMotif Mobile Health Application (APP). Statistical Design: Randomization 1:1 balanced for stratification factors: ECOG PS; neoadjuvant chemotherapy; radiation field extent; T2 vs T3/T4; centre. Assuming a 2‐year DFS rate 65% for patients on the control arm and estimated 12% improvement in the 2‐year DFS rate (65% to 77% (HR 0.61)) with 80% power using a 1‐sided 10% level test requires a sample size of 190 including 5% drop out rate. Conduct to Date: Study activation Dec 2018. Enrollment as of January 31 2022: 49. The DSMC reviewed and recommended trial continuation in November 2021.}, -DOI = {10.1200/JCO.2022.40.16_suppl.TPS4619}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02454501/full} -} - - -Record #268 of 538 -@article{Novello17, -author = {Novello, S, and Mecca, C}, -title = {GR 01.05 First-Line Management of ALK Mutant NSCLC}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {11}, -pages = {S1656‐S1657}, -year = {2017}, -accession_number = {EMBASE 2007585259}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; *relapse; Adult; Advanced cancer; Adverse drug reaction; Brain disease; Cancer chemotherapy; Cancer growth; Cancer patient; Cancer radiotherapy; Cancer recurrence; Cancer resistance; Cancer survival; Clinical outcome; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Diagnosis; Drug combination; Drug therapy; Enzyme activity; Female; Follow up; Fusion gene; Gene amplification; Gene mutation; Gene rearrangement; Genetic susceptibility; Human; Human tissue; Immunotherapy; Japanese (people); Male; Overall response rate; Pharmacokinetics; Phase 1 clinical trial; Phase 3 clinical trial; Practice guideline; Progression free survival; Protein function; Radiotherapy; Randomized controlled trial; Side effect; Signal transduction}, -abstract = {The identification of anaplastic lymphoma kinase (ALK) gene rearrangements as an oncogenic driver in NSCLC has radically changed the treatment of a subset of patients harboring this molecular alteration.1 ALK mutations occur in 3‐7% of NSCLCs and are more frequently associated with never/light smoker, younger age and adenocarcinoma histology. Crizotinib, an oral small‐molecule multitargeted ALK/c‐MET /ROS1 tyrosine kinase inhibitors, was the first‐in‐class agent approved from FDA for advanced, ALK‐rearranged NSCLC. The accelerated approval in 2011 was granted on the basis of pronounced activity observed in early phase I and II clinical studies, coupled with a favorable toxicity‐profile and concurrent development of a diagnostic test for ALK rearrangement.2 More recently, the results from a front‐line phase III trial in ALK‐positive NSCLC, PROFILE 1014, revealed the superiority, in terms of progression free survival (PFS) and overall response rate (ORR), of crizotinib versus standard pemetrexed‐platinum chemotherapy.3 Based on these data, crizotinib represents standard fist‐ line therapy in patients with advanced ALK mutant NSCLC.4 Despite marked and durable initial responses to crizotinib, most patients develop progressive disease after a median of 11 months, with the brain as a common site of relapse. This can be explained by pharmacokinetic limitations rather than a biologic resistance. Several acquired resistance mechanisms have been characterized, including secondary mutations in the ALK kinase domain and/or ALK copy number alterations. ALK‐independent resistance mechanisms can also occur through activation of alternative bypass signaling pathways, such as EGFR activation, KIT amplification, KRAS mutation and IGF‐R1 activation.5 This evidence has prompted the development of increasingly potent, selective and brain‐penetrant ALK inhibitors, with differential spectrum of activity against the most common resistance mutations.6 Several next‐generation ALK inhibitors, such as ceritinib, alectinib, brigatinib have demonstrated clinical benefit in patients with crizotinib‐refractory NSCLC patients also at the central nervous system (CNS) level. This observation has supported the assessment of these drugs as frontline therapy in patients crizotinb‐naïve with advanced ALK+ NSCLC.7 Soria and colleagues have published the results of the ASCEND‐4 trial, randomizing ALK+ treatment naïve patients to ceritinib or chemotherapy. Ceritinib treatment significantly has improved median PFS compared to chemotherapy (16.6 vs 8.1 months; hazard ratio [HR] 0.55,P<0.00001). This molecule was also associated with a better control of the disease in the brain (PFS10.7 vs 6.7 months, HR 0.70, 95% CI: 0.44–1.12). Dose‐limiting gastrointestinal adverse events were common with ceritinib at the starting dose of 750 mg daily and 80% of cases required dose reduction or interruption. Although ceritinib has not been compared head‐to‐head with crizotinib, data confirm ALK inhibitor superior efficacy compared to standard chemotherapy in the ALK‐rearranged NSCLC and suggest ceritinib as another option for the front line management.8 First Line Head to Head trials are ongoing or recently completed. Findings from J‐ALEX trial, involving untreated Japanese patients with ALK‐rearranged advanced NSCLC, have shown that alectinib induces longer durations of response compared to crizotinib. Median PFS exceeded 2 years in the alectinib group, compared with just over 10 months in the crizotinib group.9 Recently, Peters et al. have presented the results of global ALEX study. Data are consistent with previous Japanese analysis: PFS was significantly improved with alectinib as compared to crizotinib (25,7 5% vs 10,4%, HR 0.5, p<0.0001). In addition, 12% of patients in alectinib arm vs 45% in crizotinib arm has experienced brain progression (cause specific HR 0.16; 95% CI, 0.10 to 0.28; P<0.001). Alectinib appeared to be better tolerated than crizotinib with grade 3 to 5 adverse events occurring in 41% vs 50% of patients, respectively.10 Other studies with next‐generation ALK inhibitors versus crizotinib—such as lorlatinib, brigatinib, are ongoing and they will help define optimal sequencing therapy for patients with ALK‐rearranged NSCLC. To improve outcomes in this patient population, some studies are also currently investigating several combination strategies, including immunotherapy, anti‐angiogenetic agents or radiotherapy approach in association with ALK inhibitors as shown in Table 1. Treatment paradigms continue to evolve for patients with advanced ALK‐positive NSCLC subsequently to rapid development of ALK inhibitors history. It is expected that one of the next generation of ALK inhibitors will be used as first‐line. In this landscape it is necessary to define the impact of first‐line choice on patterns of progression and mechanisms of resistance.11 It is uncertain if a specific sequence of therapeutic agents influences the biology of the cancer and therefore the clinical course of the patient. The spectrum of ALK resistance mutations varies according to ALK inhibitor and it is unclear if the mechanisms of resistance to these agents as the first ALK inhibitor will be similar to the mechanisms of resistance identified when they are used after crizotinib. Future efforts should be focused on determining the best treatment sequence to maximize clinical outcomes. Key factors to guide the selection of therapies could include: molecular characteristics of the patient's tumor, different toxicity profile of different ALK inhibitors, availability of combinations/ multimodal therapy. References: 1. Identification of the transforming EML4‐ALK fusion gene in non‐small‐cell lung cancer. Soda M et al. Nature 2007; 448:561–567 2. The continuum of care for ALK‐positive NSCLC: from diagnosis to new treatment options‐an overview Solomon & Soria, Ann Oncol Vol 27 Supp 3 2016 3. First‐line crizotinib versus chemotherapy in ALK‐positive lung cancer Solomon et al N Engl J Med 2014 Dec 4;371(23):2167‐77 4. Metastatic non‐small‐cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Novello S et al. Annals of Oncology 27 (Supplement 5): v1–v27, 2016 5. Crizotinib resistance: implications for therapeutic strategies. Dagogo‐Jack & Shaw Ann Oncol Supp 3 2016 6. Molecular Mechanisms of Resistance to First‐ and Second‐Generation ALK Inhibitors in ALK‐Rearranged LungCancer. Gainor et al Cancer Discov2016Oct;6(10): 1118‐1133. 7. Ascending role of next‐generation ALK inhibitors. Costa. Lancet Oncol.2017 Jul; 18(7):837‐839. 8. First‐line ceritinib versus platinum‐based chemotherapy in advanced ALK‐rearranged non‐small‐cell lung cancer (ASCEND‐4): a randomized, open‐label, phase 3 study. Soria et al Lancet 2017; 389: 917–29 9. Alectinib versus crizotinib in patients with ALK‐positive non‐small‐cell lung cancer (J‐ALEX): an open‐label, randomized phase 3 trial Hida et al. Lancet 2017; 390: 29–39 10. Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer Peters et al for for the ALEX Trial Investigators NEJM N Engl J Med. 2017 Jun 6. 11. First‐line treatment options for ALK‐rearranged lung cancer. Solomon. Lancet Oncology 2017 Mar 4; 389(10072): 884‐886. Keywords: NSCLC, Alk, First line [Formula presented]}, -DOI = {10.1016/j.jtho.2017.09.182}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02195804/full} -} - - -Record #269 of 538 -@article{Yu19, -author = {Yu, H}, -title = {ES02.01 Biomarker Testing in LA Disease}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S15}, -year = {2019}, -accession_number = {EMBASE 2003406809}, -publication type = {Journal article; Conference proceeding}, -keywords = {Adjuvant chemotherapy; Adult; Advanced cancer; Cancer adjuvant therapy; Cancer patient; Cancer recurrence; Cancer staging; Cancer surgery; Cancer survival; Case report; Chemoradiotherapy; Clinical article; Conference abstract; Disease free survival; Drug combination; Drug therapy; Female; Gene mutation; Genetic marker; Human; Human tissue; Immunotherapy; Jordan; Lung adenocarcinoma; Lung metastasis; Male; Mediastinum lymph node; Molecularly targeted therapy; Neoadjuvant therapy; Non small cell lung cancer; Oncogene; Ontario; Overall survival; Personalized medicine; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Recurrent disease; Relapse; United States}, -abstract = {Routine biomarker testing in metastatic lung cancer has led to enormous improvements in outcomes for our patients with metastatic lung cancers. Oncogene testing has allowed us to identify the 50% of patients with metastatic lung cancer that are eligible for targeted therapies1. Consistently, targeted therapy for EGFR, ALK, ROS1, RET, BRAF have demonstrated superior progression‐free survival compared to standard cytotoxic chemotherapy2. Identification of these genomic biomarkers has provided additional treatment options for our patients that are more effective and less toxic than standard treatments. In addition, serial biomarker testing allows us to also identify mechanisms of resistance to targeted therapy which can then inform subsequent treatment decisions. PDL1 testing is also routinely performed in the metastatic setting and assists us in identifying patients that may benefit from immunotherapy alone instead of first‐line combination immunotherapy and chemotherapy treatment3. PDL1 testing allows us to predict likelihood of response to immunotherapy and selects patients that we can de‐escalate treatment; patients with high PDL1 expression derive benefit from treatment with immunotherapy alone. Routine utilization of biomarker testing in metastatic lung cancer is easily the most importance advancement in this field to date. Current recommendations: Biomarker testing for patients with locally advanced lung cancers is currently not recommended in the NCCN guidelines or any expert guidelines. This is likely because the current management for locally advanced lung cancers do not incorporate the use of biomarkers. Patients currently receive adjuvant durvalumab after concurrent chemoradiation for stage 3 disease irrespective of PDL1 status. Currently, adjuvant targeted therapies after definitive resection or radiation are not recommended in the NCCN or other cancer care guidelines. Oncogene testing: The risk of recurrence for early stage lung cancers remain high. After surgical resection, adjuvant chemotherapy for high risk stage 1B, stage 3 and stage 4 and post‐operative radiation for patients with mediastinal lymph node involvement are both recommended are they improve survival. Despite this, there is a large subset of patients that will have recurrent disease. Because of their demonstrated superiority over chemotherapy in the metastatic setting, there is great interest in assessing whether adjuvant targeted therapies would improve outcomes in the locally advanced disease setting. EGFR mutant lung cancer is the largest oncogene subset in which the bulk of previous studies have been done. However, all studies to date have been subsets of larger unselected patients (RADIANT study) or single arm studies (SELECT study). These smaller studies have shown a disease‐free survival benefit but have been underpowered to demonstrate a survival benefit. There are several well‐designed large studies ongoing that will definitively demonstrate whether adjuvant EGFR inhibitors improve overall survival. The ALCHEMIST study is a phase 3 randomized cooperative group study assessing erlotinib versus observation for patients with stage IB‐IIIA resected lung cancers; accrual is ongoing. The ADAURA study is a randomized phase 3 study where patients with stage IB‐IIIA resected lung cancers are randomized to osimertinib versus placebo for 3 years with a primary objective of DFS and a secondary objective of overall survival. These studies will help answer the question as to whether adjuvant targeted therapy should be utilized. PDL1 testing: In stage 3 lung cancers, more than 60 percent of patients will ultimately die of their lung cancer4. Adjuvant durvalumab has improved outcomes with a clear improvement in overall survival but many patients still recur and ultimately die of their disease. An unplanned subset analysis of the PACIFIC study suggests that patients with PDL1 0% expression may not derive benefit from durvalumab. Further assessment will be needed to ascertain whether PDL1 expression can be used to select patients who would derive benefit from adjuvant durvalumab. Due to their efficacy in the metastatic setting, there are a significant number of studies looking at immunotherapy as both neoadjuvant and adjuvant treatment for locally advanced disease. Just as we utilize PDL1 as a biomarker that helps select appropriate therapies in the metastatic setting, I see similar use of PDL1 in the future in the locally advanced setting. Future directions: As personalized medicine infiltrates our care of patients with lung cancers, we will need biomarker results for patients with locally advanced lung cancer to better tailor and personalize their care. In particular, if the EGFR TKI studies demonstrate improved overall survival with adjuvant EGFR TKI, we will certainly need to incorporate biomarker testing as standard of care for locally advanced disease. In addition, because a significant portion of patients recur, already having molecular test results available which were done on their surgical sample, makes their care later more stream‐lined. We also need to assess whether PDL1 is a useful biomarker to select patients for immunotherapy in the adjuvant setting. Results from ongoing clinical trials will provide definitive answers. Works cited: 1. Jordan, E.J., et al. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer discovery 7, 596‐609 (2017). 2. Sequist, L.V., et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of clinical oncology: official journal of the American Society of Clinical Oncology (2013). 3. Reck, M., et al. Pembrolizumab versus Chemotherapy for PD‐L1‐Positive Non‐Small‐Cell Lung Cancer. The New England journal of medicine 375, 1823‐1833 (2016). 4. Pisters, K.M., et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I‐IIIA resectable non small‐cell lung cancer guideline. Journal of clinical oncology 25, 5506‐5518 (2007).}, -DOI = {10.1016/j.jtho.2019.08.073}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01999666/full} -} - - -Record #270 of 538 -@article{Gong22, -author = {Gong, J, Su, D, Shang, J, Xu, S, Tang, L, Sun, Z, and Liu, G}, -title = {Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China}, -journal = {Frontiers in pharmacology}, -volume = {13}, -year = {2022}, -accession_number = {EMBASE 2017089467}, -publication type = {Journal article}, -keywords = {*advanced cancer /drug therapy; *cost effectiveness analysis; *non small cell lung cancer /drug therapy; Article; Cancer localization; Cancer survival; China; Clinical outcome; Drug cost; Drug efficacy; Drug safety; Drug tolerability; Economic evaluation; Health care cost; Health care system; Human; Incremental cost effectiveness ratio; Neutropenia /side effect; Overall survival; Phase 3 clinical trial (topic); Prediction; Progression free survival; Quality adjusted life year; Sensitivity analysis}, -abstract = {Background: Tislelizumab, a new high‐affinity programmed cell death protein‐1 (PD‐1) inhibitor, significantly prolonged the overall survival in pretreated non‐small‐cell lung cancer (NSCLC). This study aimed to assess the cost‐effectiveness of tislelizumab versus docetaxel for this population in China. Methods: A three‐state partitioned survival model was developed to simulate advanced NSCLC. Efficacy and safety data were based on a global phase 3 clinical trial (RATIONALE 303). Utilities were mainly extracted from previously published resources. Costs were calculated from the Chinese healthcare system’s perspective, and only direct medical costs were covered. The main outcomes included total costs, life years (LYs), quality‐adjusted life years (QALYs), and incremental cost effectiveness ratio (ICER). One‐way and probabilistic sensitivity analyses were carried to test the uncertainty of the modeling results. In addition, several scenarios including tislelizumab price before negotiation, different docetaxel price calculation, 50‐year time horizon, and alternative utility values were assessed. Results: The model predicted an average gain of 0.62 LYs and 0.51 QALY for tislelizumab vs. docetaxel, at the additional cost of $9,219. The resulting ICER was $15,033.92/LY and $18,122.04/QALY, both below the cost‐effective threshold (CET) of three times gross domestic product (GDP) per capita in China. Sensitivity analyses showed that the results are robust over a plausible range for majority of inputs. Utility of progression‐free survival (PFS), followed by the price of tislelizumab, had the greatest impact on the ICER. The probability of being cost‐effective for tislelizumab was 96.79% at the CET we set. Conclusion: Tislelizumab improves survival, increases QALYs, and can be considered a cost‐effective option at current price compared with docetaxel for pretreated advanced NSCLC in China.}, -DOI = {10.3389/fphar.2022.830380}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02492429/full} -} - - -Record #271 of 538 -@article{EUCTR2022-003408-33-DE22, -author = {EUCTR2022-003408-33-DE,}, -title = {Treating patients with locally advanced, unresectable non-small-cell lung cancer with a small volume accelerated chemoradiotherapy followed by immunotherapy with durvalumab}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2022-003408-33-DE}, -year = {2022}, -accession_number = {ICTRP EUCTR2022‐003408‐33‐DE}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trade Name: IMFINZI® Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Durvalumab CAS Number: 1428935‐60‐7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1500‐ CONDITION: Locally advanced, unresectable non‐small‐cell lung cancer (NSCLC) (Stage III) with a PD‐L1‐expression of = 1% ; MedDRA version: 21.1 Level: PT Classification code 10029519 Term: Non‐small cell lung cancer stage III System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: To assess the feasibility of an FDG‐PET‐based small volume accelerated chemoradiotherapy followed by immunotherapy with durvalumab compared to standard FDG‐PET‐based chemoradiotherapy followed by immunotherapy with durvalumab Primary end point(s): Completion rate defined as rate of patients having received:; • the prescribed radiotherapy dose ± 2 fractions and ; • simultaneous platinum‐based chemotherapy and ; • immunotherapy consolidation with durvalumab starting within 42 days after the last dose of chemoradiotherapy and; • either at least 3 doses of durvalumab or less than 3 doses of durvalumab in case immunotherapy was permanently discontinued due to documented extrathoracic immune‐related toxicity.; ; Secondary Objective: ‐ To assess the safety and tolerability of an FDG‐PET‐based small volume accelerated chemoradiotherapy followed by immunotherapy with durvalumab; ‐ To assess the efficacy of an FDG‐PET‐based small volume accelerated chemoradiotherapy followed by immunotherapy with durvalumab compared to standard FDG‐PET‐based chemoradiotherapy followed by immunotherapy with durvalumab in terms of time to locoregional progression, time to locoregional in‐ and out‐of‐RT‐field progression, time to distant progression, progression‐free survival, overall survival, objective response rate, disease control rate; ‐ To assess symptoms and patient‐reported health‐related quality of life (QoL) in patients receiving an FDG‐PET‐based small volume accelerated chemoradiotherapy followed by immunotherapy with durvalumab compared to patients receiving standard FDG‐PET‐based chemo‐radiotherapy followed by immunotherapy with durvalumab; ; For more information please refer to the most current study protocol (chapter 2) Timepoint(s) of evaluation of this end point: approximately 22 weeks after start of radio‐chemotherapy SECONDARY OUTCOME: Secondary end point(s): Safety endpoints:; Adverse events grade = 3 (according to NCI CTCAE v5.0), SAEs, unexpected AEs ; ; Efficacy endpoints:; • Time to locoregional progression: time from randomization to progression in the primary tumor or any of mediastinal lymph nodes; • Time to locoregional in‐RT‐field progres‐sion: time from randomization to progres‐sion in primary tumor or mediastinal lymph nodes within the target volume; • Time to locoregional out‐of‐RT‐field progression: time from randomization to progression in mediastinal lymph nodes outside the target volume; • Time to distant progression: time from randomization to appearance of metasta‐ses elsewhere; • Progression‐free survival (PFS); • Overall survival (OS); • Objective response rate (ORR) defined as the proportion of randomized patients with best response of complete or partial response; • Disease control rate (DCR) defined as the proportion of randomized patients with best response of complete response, partial response, or stable disease; ; Quality of Life:; EORTC QLQ‐C30 and QLQ‐LC13: Change in symptoms, functioning, and global healthstatus/QoL; ; Radiotherapy quality:; Percentage of patients without major proto‐col deviations regarding radiotherapy quality; Timepoint(s) of evaluation of this end point: Safety Endpoints: during the whole study; PFS: time from randomization to disease progression or death by any cause; OS: time from randomization to death by any cause; ORR, DCR: end of study; Quality of Life: during whole study; Radiotherapy quality: during whole study INCLUSION CRITERIA: 1. Written informed consent 2. Patients irrespective of se Xand gender, aged 18 years or older at the time of signing the ICF 3. Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study as determined by the investigator 4. Patients with histologically or cytologically documented NSCLC who present with locally advanced, unresectable (Stage III) disease (according to version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology (IASLC Staging Manual in Thoracic Oncology 2016)) 5. Patients fit for simultaneous chemoradiotherapy and consolidation immunotherapy according to interdisciplinary consensus 6. Histologically proven PD‐L1‐expression of = 1% (tumor proportion score; TPS) in tumor sample as assessed in routine staging using a validated test such as Ventana SP236 assay 7. Eastern Cooperative Oncology Group (ECOG)}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02618624/full} -} - - -Record #272 of 538 -@article{JPRN-jRCT108022176312, -author = {JPRN-jRCT1080221763,}, -title = {A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCT1080221763}, -year = {2012}, -accession_number = {ICTRP JPRN‐jRCT1080221763}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: investigational material(s) Generic name etc : Gefitinib‐pemetrexed combination INN of investigational material : Gefitinib, Pemetrexed Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Concurrent treatment with gefitinib (250 mg/day) and pemetrexed (500 mg/m^2 on Day 1 of every 21 day cycle) control material(s) Generic name etc : Gefitinib INN of investigational material : Gefitinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Single agent gefitinib (250 mg/day) CONDITION: Carcinoma, Non Small Cell Lung INCLUSION CRITERIA: ‐Histologically or cytologically confirmed advanced (Stage IV) or recurrent non‐squamous NSCLC. ‐Eastern Cooperative Oncology Group (ECOG) Performance Status 0‐1. ‐The participant's primary NSCLC tumor has an activating Epidermal Growth Factor Receptor (EGFR) mutation, as determined by any validated method. ‐The participant has measurable disease at the time of study entry. ‐The participant has not had any prior systemic chemotherapy, immunotherapy, or biological therapy (for example, targeted therapy, such as erlotinib or gefitinib) for Stage IV or recurrent non‐squamous NSCLC. ‐The participant has adequate organ function(hematopoietic function, liver function, renal function). ‐The participant is able to take folic acid, vitamin B12, and dexamethasone, according to the protocol's requirements. ‐Prior radiation therapy is allowed to <25% of the bone marrow.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02593218/full} -} - - -Record #273 of 538 -@article{EUCTR2019-001979-36-CZ19, -author = {EUCTR2019-001979-36-CZ,}, -title = {A Trial Comparing Selpercatinib to Chemotherapy in Patients with Non-Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-001979-36-CZ}, -year = {2019}, -accession_number = {ICTRP EUCTR2019‐001979‐36‐CZ}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: SELPERCATINIB Product Code: LY3527723 Pharmaceutical Form: Capsule INN or Proposed INN: Selpercatinib Other descriptive name: LOXO‐292 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40‐ Product Name: SELPERCATINIB Product Code: LY3527723 Pharmaceutical Form: Capsule INN or Proposed INN: Selpercatinib Other descriptive name: LOXO‐292 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 80‐ Trade Name: Ribocarbo®‐L Product Name: Carboplatin Pharmaceutical Form: Solution for infusion INN or Proposed INN: Carboplatin CAS Number: 41575‐94‐4 Other descriptive name: CARBOPLATIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: up to Concentration number: 10‐ Trade Name: Cisplatin Accord Product Name: Cisplatin Pharmaceutical Form: Solution for infusion INN or Proposed INN: CISPLATIN CAS Number: 15663‐27‐1 Other descriptive name: Cisplatin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1‐ Trade Name: Keytruda Product Name: Pembrolizumab Pharmaceutical Form: Powder and solvent for concentrate for solution for infusion INN or Proposed INN: PEMBROLIZUMAB Other descriptive name: Pembrolizumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Trade Name: Alimta Product Name: Pemetrexed Pharmaceutical Form: Solution for infusion INN or Proposed INN: PEMETREXED CAS Number: 137281‐23‐3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500‐ Trade Name: Carbomedac Product Name: Carboplatin Pharmaceutical Form: Solution for infusion INN or Proposed INN: Carboplatin CAS Number: 41575‐94‐4 Other descriptive name: CARBOPLATIN Concentration unit: mg/ml milligram(s CONDITION: Male or female patients with advanced, treatment‐naïve RET Fusion‐Positive Non‐Squamous NSCLC ; MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non‐small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: ‐ To compare PFS of selpercatinib and platinum‐ based (carboplatin or cisplatin) and pemetrexed therapy with or without pembrolizumab in patients with advanced or metastatic RET fusion‐positive NSCLC; ‐ To compare PFS of selpercatinib with the combination of platinumbased (carboplatin or cisplatin) and pemetrexed therapy, with or without pembrolizumab, in patients with advanced or metastatic RET fusionpositive NSCLC Primary end point(s): PFS per RECIST 1.1 as assessed by BIRC in patients receiving pembrolizumab and in the intent‐to‐treat population (with or without pembrolizumab)[Coprimary endpoint] Secondary Objective: ‐ To compare the efficacy of selpercatinib and with the combination of platinum‐based (carboplatin or cisplatin) therapy, pemetrexed, and pembrolizumab in patients with advanced or metastatic RET fusionpositive; NSCLC; ‐ To compare the efficacy of selpercatinib with the combination of platinum‐based (carboplatin or cisplatin) and pemetrexed therapy, with or without pembrolizumab, in patients with advanced or metastatic RET fusion‐positive NSCLC; ‐ To assess safety and tolerability of selpercatinib compared to platinumbased and pemetrexed therapy with pembrolizumab; ‐ To assess safety and tolerability of selpercatinib compared to platinum‐based and pemetrexed therapy with or without pembrolizumab; To assess/evaluate performance of RET local laboratory tests compared to a single, central test Timepoint(s) of evaluation of this end point: Time Frame: Baseline through Disease Progression or Death (Estimated at up to 24 Months) INCLUSION CRITERIA: ‐ Histologically or cytologically confirmed Stage IIIB‐IIIC or Stage IV non‐squamous NSCLC that is not suitable for radical surgery or radiation therapy ‐ A RET gene fusion in tumor and/or blood from a qualified laboratory ‐ Measurable disease as determined by RECIST 1.1 by the investigator ‐ ECOG performance status of 0‐2 ‐ Adequate hematologic, hepatic and renal function ‐ Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 6 months after ‐ Written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 125 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 125 SECONDARY OUTCOME: Secondary end point(s): 1. PFS per RECIST 1.1 by investigator assessment (with pembrolizumab); 2. PFS per RECIST 1.1 by investigator assessment (with or without pembrolizumab); 3. ORR per RECIST 1.1 by BICR (with pembrolizumab); 4. ORR per RECIST 1.1 by BICR (with or without pembrolizumab); 5. DOR per RECIST 1.1 by BICR (with pembrolizumab); 6. DOR per RECIST 1.1 by BICR (with or without pembrolizumab); 7. DCR per RECIST 1.1 by BICR (with pembrolizumab); 8. DCR per RECIST 1.1 by BICR (with or without pembrolizumab); 9. ORR per RECIST 1.1 by investigator assessment (with pembrolizumab); 10. ORR per RECIST 1.1 by investigator assessment (with or without pembrolizumab); 11. DOR per RECIST 1.1 by investigator assessment (with pembrolizumab); 12. DOR per RECIST 1.1 by investigator assessment (with or without pembrolizumab); 13. DCR per RECIST 1.1 by investigator assessment (with pembrolizumab); 14. DCR per RECIST 1.1 by investigator assessment (with or without pembrolizumab); 15. Intracranial response per RECIST 1.1 by investigator assessment (with pembrolizumab); 16. Intracranial response per RECIST 1.1 by investigator assessment (with or without pembrolizumab); 17. PFS2 (with pembrolizumab); 18. PFS2 (with or without pembrolizumab); 19. OS (with pembrolizumab); 20. OS (with or without pembrolizumab); 21. Time to deterioration in pulmonary symptoms per NSCLC SAQ (with pembrolizumab); 22. Time to deterioration in pulmonary symptoms per NSCLC SAQ (with or without pembrolizumab); 23. Safety, including but not limited to SAEs, AEs, deaths, and clinical laboratory abnormalities per CTCAE v5.0 (with pembrolizumab); 24. Safety, including but not limited to SAEs, AEs, deaths, and clinical laboratory abnormalities per CTCAE v5.0 (with and without; pembrolizumab); 25. RET fusion status Timepoint(s) of evaluation of this end point: 1. + 2. Baseline to Progressive Disease or Death from Any Cause (up to 24 Months); 3. Baseline to Second Disease Progression or Death from Any Cause (up to 36 Months); 4. + 5. Baseline through Disease Progression or Death (up to 24 Months); 6. Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (up to 24 Months); 7. Baseline through Disease Progression or Death (up to 24 Months); 8. + 9. Baseline to Date of Death from Any Cause (up to 48 Months); 10. + 11. Baseline through Disease Progression or Death (up to 24 Months); 12. + 13. Baseline to Deterioration of Pulmonary Symptoms (up to 24 Months); 14. Baseline through Disease Progression or Death (up to 24 Months)}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169229/full} -} - - -Record #274 of 538 -@article{Garassino19, -author = {Garassino, M}, -title = {PC04.01 Pro: chemotherapy Is Necessary}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S143‐S144}, -year = {2019}, -accession_number = {EMBASE 2003407656}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer chemotherapy; Addiction; Adult; Advanced cancer; Brain metastasis; Cancer patient; Cancer prognosis; Cancer size; Cancer staging; Cancer survival; Case report; Clinical article; Clinical evaluation; Combination chemotherapy; Conference abstract; Drug combination; Drug safety; Drug therapy; Ex‐smoker; Female; Gender; Gene expression; Histology; Histopathology; Human; Human cell; Human tissue; Immunotherapy; Liver metastasis; Male; Myeloid‐derived suppressor cell; Never smoker; Non small cell lung cancer; Overall survival; Pharmacokinetics; Phase 3 clinical trial; Preclinical study; Prognosis; Progression free survival; Protein expression; Randomized controlled trial; Regulatory T lymphocyte; Retrospective study; Smoking habit; Tumor growth; Tumor microenvironment}, -abstract = {As first‐line therapy single agent pembrolizumab showed better outcomes than chemotherapy (CT) in patients with NSCLC and PD‐L1 expression ≥50% [1]. Recently has been published another phase 3 trial in which patients with aNSCLC with an expression of PD‐L1 ≥1%, treated with pembrolizumab as single agent, results in better overall survival (OS) than CT in first‐line, mainly in subgroup with PD‐L1 ≥50% [2]. After the approval and subsequent use of pembrolizumab as single agent in first‐line in NSCLC with PD‐L1 ≥50%, in 2018 several phase III trials explored the combination of immunotherapy agents (pembrolizumab and atezolizumab), with no regards of PD‐L1 status, in association with standard CT, gaining better outcomes than CT alone in first‐line NSCLC [3‐8]. A matter of debate is what we have to do in patients with PD‐L1 ≥50% due to the absent comparison between combination therapy and ICI as single agent and similar results in 1‐year OS among these treatments [1,3‐4]. So, why should we suggest the use of combination over ICIs as single agent in patients with PD‐L1 ≥50% in first‐line? First of all, we can see that trials of combination therapy report benefit with CT plus ICI across all PD‐L1 subgroups, with a greater magnitude of benefit in patients with PD‐L1 ≥50% with no regards of kind of drugs used (either CT and ICI) and histology (squamous or non‐squamous) [3‐8]. This magnitude of benefit is supported from an higher objective‐response rate (ORR) in patients treated with combination therapy over ICI as single agent in subgroups of patients with PD‐L1 ≥50% [1‐4], suggesting combination therapy as best choice even in patients with highly symptomatic disease with the purpose of obtaining a fast shrinkage of tumor. Analyzing Kaplan‐Meyer curves of single agent trials [1,2], you can observe that there is a violation of proportional hazard assumptions. We can see a crossing of the curves within first 3‐6 months suggesting us that there’s a subgroup of patients who have a worse prognosis when treated with single agent immunotherapy over CT. This worse prognosis could be possibly partially due to a phenomenon called hyperprogressive disease [9], a quicken tumor growth during treatment with ICIs in NSCLC irrespectively of the line of therapy. If we look at Kaplan‐Meyer curves of all combination studies, we can see that the combination of CT plus ICI abrogates the crossing curves [3,4,6,8], probably overcoming hyperprogessive disease with the addiction of CT by modulating tumor microenvironment. In subgroups of patients with liver and/or brain metastases, generally considered at worse prognosis, combination therapy demonstrates a benefit. In a retrospective analysis of KEYNOTE189 [10] were evaluated outcomes of patients with brain and/or liver metastases. In this analysis the addiction of pembrolizumab to CT grants a benefit over CT alone either in progression‐free survival, OS and ORR in patients with liver and/or brain metastases. Another evidence of benefit in patients with liver metastases in combination therapy was seen in IMpower150, in which the addiction of atezolizumab to bevacizumab plus CT seemed to add something even though there’s a bias due to the use of bevacizumab [5]. In advanced NSCLC treated with ICI as single agent [1,2] we see a lower benefit in non‐smoker than in current or former smoker patients, whilst in combination studies this difference isn’t seen regardless kind of drug and histology [3,6‐8]. Even gender may be a possible reason to choose combination instead of ICI as single agent. As we previously do for smoking habit, we indirectly compare trials with single agent and with combination. We can see that in KEYNOTE024 there’s a stronger benefit using pembrolizumab in males over females. This reported benefit for male patients is lost in combination treatment, with slight better outcomes in women instead, with no regards of drugs used and histology [3,4,6‐8]. Finally, basing on preclinical evidences, we know that the combination between CT and ICIs may enhance the immune system activity due to immunological effect of cytotoxic agents through the expression of PD‐L1 on the surface of tumor cells, the depletion of myeloid‐derived suppressor cells and T‐regulatory cells and the augmentation of the presentation of antigens by cancer cells [10]. At the state of the art the aim of our discussion remains an unanswered question but based on what we previously said, at least in patients with high tumor burden, in never smokers, we suggest CT plus ICI as first‐line in aNSCLC with PD‐L1 ≥50%. This could allow us not to lose patients in the first six months of treatment. [1] Reck M et al. Pembrolizumab versus chemotherapy for PD‐L1 positive non‐small cell lung cancer. NEJM 2016; 375: 1822‐1833 [2] Mok TSK et al. Pembrolizumab versus chemotherapy for previously untreated, PD‐L1 expressing, locally advanced or metastatic non‐small cell lung cancer (KEYNOTE‐042): a randomised, open‐label, controlled, phase 3 trial. Lancet 2019; 393: 1819‐1830 [3] Gandhi L et al. Pembrolizumab plus chemotherapy in metastatic non‐small cell lung cancer. NEJM 2018; 378: 2078‐2092 [4] Paz‐Ares L et al. Pembrolizumab plus chemotherapy for squamous non‐small‐cell lung cancer. NEJM 2018; 379: 2040‐2051 [5] Socinski MA et al. Atezolizumab for first‐line treatment of metastatic nonsquamous NSCLC. NEJM 2018; 378(24): 2288‐2301 [6] Cappuzzo F et al. IMpower130: efficacy and safety from a randomise phase 3 study of carboplatin and nab‐paclitaxel with or without atezolizumab in 1L advanced non‐squamous NSCLC. Presented at ESMO 2018 [7] Jotte R et al. IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab‐paclitaxel vs carboplatin + nab‐paclitaxel as 1L therapy in advanced squamous NSCLC. Presented at ASCO 2018 [8] Papadimitrakopoulou VA et al. IMpower132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage IV non‐squamous NSCLC. Presented at WCLC 2019 [9] Proto C et al. Choosing wisely first line immunotherapy in non‐small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev 2019; 75:39‐51 [10] Garassino MC et al. Outcomes among patients with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab plus pemetrexed‐platinum: results from the KEYNOTE‐189 study. Keywords: Chemotherapy, Immunotherapy, first line}, -DOI = {10.1016/j.jtho.2019.08.295}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01996706/full} -} - - -Record #275 of 538 -@article{McCall18, -author = {McCall, NS, Dicker, AP, and Lu, B}, -title = {Beyond concurrent chemoradiation: the emerging role of PD-1/PD-L1 inhibitors in stage III lung cancer}, -journal = {Clinical cancer research}, -volume = {24}, -number = {6}, -pages = {1271‐1276}, -year = {2018}, -accession_number = {EMBASE 622381548, PUBMED 29358503}, -publication type = {Journal article}, -keywords = {Antineoplastic Agents, Immunological [pharmacology, therapeutic use]; B7‐H1 Antigen [antagonists & inhibitors]; Biomarkers, Tumor; Chemoradiotherapy [adverse effects, methods]; Combined Modality Therapy; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neoplasms [diagnosis, etiology, mortality, *therapy]; Patient Selection; Programmed Cell Death 1 Receptor [antagonists & inhibitors]; Treatment Outcome}, -abstract = {Concurrent chemoradiation (cCRT) with platinum‐based chemotherapy is standard‐of‐care therapy for patients with stage III unresectable non‐small cell lung cancer (NSCLC). Although cCRT is potentially curative, 5‐year overall survival has hovered around 20%, despite extensive efforts to improve outcomes with increasing doses of conformal radiation and intensification of systemic therapy with either induction or consolidation chemotherapy. PD‐1/PD‐L1 immune checkpoint inhibitors have demonstrated unprecedented efficacy in patients with stage IV NSCLC. In addition, preclinical and early clinical evidence suggests that chemotherapy and radiation may work synergistically with anti‐PD‐1/PD‐L1 therapy to promote antitumor immunity, which has led to the initiation of clinical trials testing these drugs in patients with stage III NSCLC. A preliminary report of a randomized phase III trial, the PACIFIC trial, demonstrated an impressive increase in median progression‐free survival with consolidative durvalumab, a PD‐L1 inhibitor, compared with observation after cCRT. Here, we discuss the clinical and translational implications of integrating PD‐1/PD‐L1 inhibitors in the management of patients with unresectable stage III NSCLC. Clin Cancer Res; 24(6); 1271‐6. ©2018 AACR.}, -DOI = {10.1158/1078-0432.CCR-17-3269}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01628661/full} -} - - -Record #276 of 538 -@article{Heinzerling23, -author = {Heinzerling, JH, Mileham, K, Robinson, M, Symanowski, JT, Induru, R, Corso, CD, Brouse, G, Prabhu, RS, Haggstrom, D, Moeller, BJ, Bobo, WE, Fasola, C, Thakkar, VV, Gregory, J, Burri, SH, and Simone, CB}, -title = {Prospective Phase II Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy (SBRT) Followed By Concurrent Mediastinal Chemoradiation and Adjuvant Immunotherapy for Locally-Advanced Non-Small Cell Lung Cancer (LA NSCLC)}, -journal = {International journal of radiation oncology biology physics}, -volume = {117}, -number = {2}, -pages = {S27‐S28}, -year = {2023}, -accession_number = {EMBASE 2026579231}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer adjuvant therapy; *chemoradiotherapy; *immunotherapy; *non small cell lung cancer; *stereotactic body radiation therapy; Adult; Cancer patient; Cancer size; Cancer staging; Cancer survival; Clinical article; Clinical trial; Conference abstract; Controlled study; Doublet chemotherapy; Drug safety; Drug therapy; Esophagitis; Female; Follow up; Health care quality; Heart disease; Human; Kaplan Meier method; Lung infection; Lymph node; Male; Outcome assessment; Overall survival; Phase 2 clinical trial; Phase 3 clinical trial; Pneumonia; Primary tumor; Progression free survival; Prospective study; Radiotherapy; Randomized controlled trial; Surgery; Treatment failure}, -abstract = {Purpose/Objective(s): To report the efficacy and toxicity outcomes of a prospective phase II trial of primary tumor SBRT followed by conventional chemoradiation to the lymph nodes and adjuvant immunotherapy in patients (pts) with unresectable LA NSCLC. Materials/Methods: Eligible pts included stage II‐III LA NSCLC with peripheral primary tumors ≤ 7cm or centrally based tumors that had at least 2 cm separation from involved nodal disease. Pts received SBRT to the primary tumor (50‐54 Gy in 3‐5 fractions) followed by standard radiation to 60 Gy in 30 fractions to the involved lymph nodes with concurrent platinum doublet chemotherapy. The trial was amended to allow pts without disease progression after chemoradiation to receive adjuvant durvalumab per the PACIFIC trial. The primary endpoint was 1 year progression free survival (PFS), evaluated as a binary variable. Frequencies and proportions were used for reporting this primary endpoint, in addition to adverse events and patterns of failure. Median PFS and OS were estimated using Kaplan Meier methods. Results: Safety and efficacy is reported on the first 50 pts enrolled in the trial with a median follow‐up of 24 months (mos) (range, 1‐54 mos). Pts were primarily stage IIIA (60%) or stage IIIB (34%), with 6% of pts stage IIB. Overall grade 3 or higher toxicity related to SBRT and/or mediastinal radiation was 8% with two pts (4%) developing grade 3 pneumonitis and one pt having a grade 5 lung infection possibly related to radiation. Overall grade 2 pneumonitis related to SBRT or mediastinal radiation was 20%. Only one pt (2%) developed grade 3 esophagitis. No late cardiac events have been observed. The one‐year PFS for all pts was 62% with a median PFS of 26.3 mos and median overall survival of 40.8 mos. Of the 50 pts enrolled, 37 received at least one dose of adjuvant durvalumab. The one‐year PFS for pts who received at least one dose of durvalumab was 70.3% with a median PFS not yet reached in this group (median follow‐up 24 mos). Patterns of failure were mostly distant with 26% of pts experiencing distant failure, 6% regional, and 2% distant and regional. There was only one local failure (2%) after SBRT in all 50 pts. Conclusion: SBRT to the primary tumor followed by conventional chemoradiation to the involved lymph nodes and adjuvant immunotherapy was well tolerated and showed improved 1‐year PFS compared to prior conventional chemoradiation trials for locally advanced NSCLC. The results of this trial will be further evaluated in a randomized phase III study, NRG LU‐008. Pts will receive either conventional chemoradiation vs. SBRT to the primary tumor followed by chemoradiation to the involved lymph nodes followed by consolidative immunotherapy to evaluate the possibility of utilization of SBRT as a new standard of care for LA NSCLC.}, -DOI = {10.1016/j.ijrobp.2023.06.287}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02611671/full} -} - - -Record #277 of 538 -@article{EUCTR2014-000336-42-ES14, -author = {EUCTR2014-000336-42-ES,}, -title = {A Phase III Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced Non-Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2014-000336-42-ES}, -year = {2014}, -accession_number = {ICTRP EUCTR2014‐000336‐42‐ES}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: MEDI4736 Product Code: MEDI4736 Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: MEDI4736 CAS Number: 1428935‐60‐7 Current Sponsor code: MEDI4736 Other descriptive name: MEDI4736 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200‐ Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use CONDITION: Locally Advanced, Unresectable Non‐Small Cell Lung Cancer (Stage III) ; MedDRA version: 17.0 Level: LLT Classification code 10066490 Term: Progression of non‐small cell lung cancer System Organ Class: 100000004864 ; MedDRA version: 17.0 Level: LLT Classification code 10029514 Term: Non‐small cell lung cancer NOS System Organ Class: 100000004864 Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: To assess the efficacy of MEDI4736 treatment compared with placebo in terms of OS and PFS Primary end point(s): Both Progression free survival (PFS) and Overall survival (OS) are co‐primary endpoints. Secondary Objective: ‐ To further assess the efficacy of MEDI4736 compared with placebo in terms of: OS24, ORR, DoR, APF12, APF18, PFS2 and DSR; ‐ To assess the safety and tolerability profile of MEDI4736 compared with placebo; ‐ To assess symptoms and health‐related quality of life in patients treated with MEDI4736 compared with placebo Timepoint(s) of evaluation of this end point: OS ‐ Overall Survival is defined as the time from the date of randomization until death due to any cause. Estimated to be from baseline up to 5 years.; PFS ‐ Progression‐Free Survival is defined as the time from randomization until the date of objective disease progression or death. Estimated to be from baseline up to 5 years. SECONDARY OUTCOME: Secondary end point(s): ‐ Proportion of patients alive at 24 months from randomization (OS24); ‐ Objective response rate (ORR) Timepoint(s) of evaluation of this end point: ‐ OS24: The proportion of patients alive at 24 months. Estimated to be from baseline up to 5 years.; ‐ ORR: Defined as the number (%) of patients with at least 1 visit response of CR (Complete response) or PR (Partial response) and will be based on all randomised patients who have measurable disease. Study data collection expected to last for approximately 3 years. INCLUSION CRITERIA: 1. Provision of signed, written and dated informed consent prior to any study specific procedures 2. Male or female aged 18 years or older 3. Patients must have histologically‐ or cytologically‐documented NSCLC who present with locally advanced, unresectable (Stage III) disease 4. Patients must have received at least 2 cycles of platinum‐based chemotherapy concurrent with radiation therapy. 5. Patients must have not progressed following definitive, platinumbased, concurrent chemoradiation therapy. 6. Patients must provide an archival tumour sample. 7. Life expectancy ?12 weeks 8. World Health Organization (WHO) Performance Status of 0 or 1 9. Evidence of post‐menopausal status, or negative urinary or serum pregnancy test for female pre‐menopausal patients. 10. Adequate organ and marrow function Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjec}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01812124/full} -} - - -Record #278 of 538 -@article{EUCTR2018-003973-82-IT21, -author = {EUCTR2018-003973-82-IT,}, -title = {Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2018-003973-82-IT}, -year = {2021}, -accession_number = {ICTRP EUCTR2018‐003973‐82‐IT}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trade Name: TECENTRIQ ‐ 1200 MG ‐ CONCENTRATO PER SOLUZIONE PER INFUSIONE ‐ USO ENDOVENOSO ‐ FLACONCINO (VETRO) ‐ 20 ML (60 MG/ML) ‐ 1 FLACONCINO Product Name: Atezolizumab Product Code: [RO5541267/F03] Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Atezolizumab Current Sponsor code: Atezolizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60‐ Trade Name: Avastin Product Name: Bevacizumab Product Code: [RO4876646] Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: BEVACIZUMAB Current Sponsor code: Bevacizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ CONDITION: Advanced non‐small‐cell lung cancer ; MedDRA version: 20.0 Level: LLT Classification code 10025055 Term: Lung cancer non‐small cell stage IV System Organ Class: 100000004864 ; MedDRA version: 20.0 Level: LLT Classification code 10025055 Term: Lung cancer non‐small cell stage IV System Organ Class: 100000004864 Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: To assess whether the combination of atezolizumab and bevacizumab improves overall survival (OS) over atezolizumab as single agent in untreated PD‐L1 high metastatic NSCLC. Primary end point(s): Overall Survival (OS) rate at 18 months in patients treated with atezolizumab alone versus atezolizumab‐bevacizumab combination Secondary Objective: To evaluate response rate (RR), progression free survival (PFS) and safety profile of the combination versus the single agent. ; To evaluate whether the combination of atezolizumab and bevacizumab improves overall survival (OS) over single agent atezolizumab according to presence of bone and/or hepatic metastases, considering their potential predictive value. Timepoint(s) of evaluation of this end point: Overall survival (OS) will be calculated from the date of randomization to the date of death due to any cause. SECONDARY OUTCOME: Secondary end point(s): Response rate (complete + partial responses); Progression‐free survival; Overall survival according to presence of bone and/ or hepatic metastases Timepoint(s) of evaluation of this end point: Tumor assessment will be performed every 6 weeks during treatment and every 3 months after PD or until initiation of new systemic anti‐cancer therapy, whichever occurs first, and at end of treatment; Tumor assessment will be performed every 6 weeks during treatment and every 3 months after PD or until initiation of new systemic anti‐cancer therapy, whichever occurs first, and at end of treatment.; Overall survival (OS) will be calculated from the date of randomization to the date of death due to any cause. INCLUSION CRITERIA: 1) Histologically confirmed diagnosis of stage IV non‐squamous NSCLC with no evidence of EGFR sensitizing mutations or ALK or ROS1 rearrangements. 2) Availability of tumor tissue. 3) 3) Evidence of high levels of PD‐L1 expression evaluated with immunohistochemistry (=50% by 22C3 or SP263 or TC/IC 3 scoring by SP 142) . 4) No previous chemotherapy. Patients who have received prior neo‐adjuvant, adjuvant chemotherapy, radiotherapy or chemoradiotherapy with curative intent for non‐metastatic disease must have experienced a treatment‐free interval of at least 6 months from randomization since the last dose of chemotherapy and/or radiotherapy. 5) ECOG performance status 0‐1. 6) Life expectancy > 3 months 7) Age =18 years. 8) Measurable disease, as defined by RECIST v1.1. 9) Adequate hematologic and organ function, defined by the following laboratory results obtained within 28 days prior to randomization: o ANC = 1500 cells/µL without gra}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02328978/full} -} - - -Record #279 of 538 -@article{CTIS2022-502480-38-0024, -author = {CTIS2022-502480-38-00,}, -title = {A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTIS2022-502480-38-00}, -year = {2024}, -accession_number = {ICTRP CTIS2022‐502480‐38‐00}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Tecentriq 840 mg concentrate for solution for infusion, Product Code:PRD7537923, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: IMFINZI 50 mg/mL concentrate for solution for infusion., Product Code:PRD6651406, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: IMFINZI 50 mg/mL concentrate for solution for infusion., Product Code:PRD6651404, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Tiragolumab, Product Code:PRD7846761, Pharmaceutical Form: CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: CONDITION: MedDRA version: 21.1Level: PTClassification code: 10029519Term: Non‐small cell lung cancer stage III Class: 100000004864 Non‐small cell lung cancer (NSCLC) ; MedDRA version: 21.1Level: PTClassification code: 10029519Term: Non‐small cell lung cancer stage III Class: 100000004864 Therapeutic area: Diseases [C] ‐ Neoplasms [C04] PRIMARY OUTCOME: Main Objective: To evaluate the efficacy of tiragolumab plus atezolizumab compared with durvalumab in the programmed death ligand 1 positive analysis set (PPAS) and in the full analysis set (FAS) on the basis of progression‐free survival (PFS), as assessed by an independent review facility (IRF) Primary end point(s): 1. PFS, as assessed by an IRF, defined as the time from randomization to the first occurrence of disease progression, as determined by the IRF according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), or death from any cause, whichever occurs first (PPAS), 2. PFS, as assessed by an IRF (FAS) Secondary Objective: To evaluate the efficacy of tiragolumab plus atezolizumab compared with durvalumab in the PPAS and FAS on the basis of overall survival (OS), PFS as assessed by investigator, confirmed objective response rate (ORR) as assessed by an IRF and investigator, DOR as assessed by an IRF and investigator, To evaluate the quality of life of patients treated with tiragolumab plus atezolizumab compared with durvalumab in the PPAS and FAS on the basis of time to confirmed deterioration (TTCD), To evaluate the efficacy of tiragolumab plus atezolizumab compared with durvalumab in the PPAS and the FAS on the basis of PFS rate at 12, 18, and 24 months, OS rate at 12, 24, 36, and 48 months, and time to distant metastasis (TTDM), To evaluate the safety and tolerability of tiragolumab plus atezolizumab compared with durvalumab SECONDARY OUTCOME: Secondary end point(s):1. Overall survival (FAS and PPAS) Secondary end point(s):10. TTDM (FAS and PPAS) Secondary end point(s):11. Incidence and severity of adverse events with severity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) Secondary end point(s):2. PFS, as assessed by the investigator (FAS and PPAS) Secondary end point(s):3. Confirmed ORR, as assessed by an IRF (FAS and PPAS) Secondary end point(s):4. Confirmed ORR, as assessed by the investigator (FAS and PPAS) Secondary end point(s):5. DOR, as assessed by an IRF (FAS and PPAS) Secondary end point(s):6. DOR, as assessed by the investigator (FAS and PPAS) Secondary end point(s):7. Time to confirmed deterioration (TTCD) (FAS and PPAS) Secondary end point(s):8. PFS rate at 12, 18, and 24 months (FAS and PPAS) Secondary end point(s):9. OS rate at 12, 24, 36, and 48 months (FAS and PPAS) INCLUSION CRITERIA: Eastern Cooperative Oncology Group Performance Status of 0 or 1, Histologically or cytologically documented NSCLC with locally advanced unresectable Stage III NSCLC of either squamous or non‐squamous histology, Whole‐body positron emission tomography (PET)‐CT scan for the purposes of staging, performed prior and within 42 days of the first dose of concurrent chemoradiotherapy (cCRT), At least two prior cycles of platinum‐based chemotherapy administered concurrently with radiotherapy (RT), which must be completed within 1 to 42 days prior to randomization in the study (one cycle of cCRT is defined as 21 or 28 days), The RT component in the cCRT must have been at a total dose of radiation of 60 Gy ± 10% (54 Gy to 66 Gy) administered by intensity‐modulated radiotherapy (preferred) or 3D‐conforming technique, No progression during or following concurrent platinum‐based CRT}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02730841/full} -} - - -Record #280 of 538 -@article{Xu11, -author = {Xu, Y-M, Xu, D-Y, Zhang, N-Z, Chen, F-X, Zhang, G-L, Liu, J-Q, and Li, C-Y}, -title = {Effection of NP concurrent chemotherapy radiotherapy and sequential adoptive immunity cell for locally advanced non-small cell lung cancer}, -journal = {Chinese journal of cancer prevention and treatment}, -volume = {18}, -number = {13}, -pages = {1032‐1035}, -year = {2011}, -accession_number = {EMBASE 364034387}, -publication type = {Journal article}, -keywords = {*cancer immunotherapy; *cytokine induced killer cell; *dendritic cell; *non small cell lung cancer /radiotherapy /therapy; Advanced cancer /radiotherapy /therapy; Article; Cancer chemotherapy; Cancer radiotherapy; Cellular immunity; Clinical article; Comparative study; Controlled study; Human; Lung cancer /radiotherapy /therapy; Progression free survival; Randomized controlled trial; Survival rate; Survival time; Treatment outcome}, -abstract = {OBJECTIVE: To evaluate the effects of chemotherapy, radiotherapy and CIK cell and DC therapy for locally advanced non‐small cell lung cancer (LANSCLC). METHODS: Totally 85 patients with LANSCLC were randomized into study group (chemotherapy + radiotherapy + CIK+ DC, n = 45 and control group (chemotherapy + radiotherapy, n = 40. Study group adoptted NP scheme chemotherapy concurrent radiotherapy and sequential CIK cell and DC, and effect, toxicant, quality of living, immunological function and survival rate were observed. RESULTS: In the study group and the control group, the effective rate were 80.0% (36/45) and 57.5% (23/40), respectively (P<0.05). Quality of living and immunological function of study group were higher than control group. The 2‐year survival rates and the 1‐year progressive free survival rates were 64.4% (29/45) vs 32.5% (13/40, P<0.01), 75.6% (34/56) vs 45.0% (18/40, P<0.05). The mean survival time of study group (25.5 months) was significantly higher than that of control group (17.2 months, P<0.05). There was no significant difference of 1 and 3 year survival rates between two groups (P>0.05). CONCLUSION: Concurrent chemotherapy radiotherapy and sequential CIK cell can get better curative effect and improve immmunity function of the patients with LANSCLC.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00898283/full} -} - - -Record #281 of 538 -@article{EUCTR2020-002202-20-SE20, -author = {EUCTR2020-002202-20-SE,}, -title = {Niraparib Ph 3 – 1L Maintenance Non-Small Cell Lung Cancer with Niraparib in combination with pembrolizumab Simplified Title for public to understand}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-002202-20-SE}, -year = {2020}, -accession_number = {ICTRP EUCTR2020‐002202‐20‐SE}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Niraparib Product Code: GSK3985771 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: NIRAPARIB CAS Number: 1038915‐60‐4 Current Sponsor code: GSK3985771 Other descriptive name: niraparib tosylate monohydrate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Pharmaceutical form of the placebo: Film‐coated tablet Route of administration of the placebo: Oral use Trade Name: KEYTRUDA Product Name: Pembrolizumab Pharmaceutical Form: Solution for infusion INN or Proposed INN: Pembrolizumab CAS Number: 1374853‐91‐4 Current Sponsor code: MK‐3475 Concentration unit: mg/l milligram(s)/litre Concentration type: equal Concentration number: 25‐ CONDITION: Non‐small Cell Lung Cancer ; MedDRA version: 21.1 Level: PT Classification code 10029521 Term: Non‐small cell lung cancer stage IIIB System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) ; MedDRA version: 21.1 Level: PT Classification code 10029522 Term: Non‐small cell lung cancer stage IV System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: ‐To compare PFS as assessed by BICR using RECIST v1.1 of niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy; ; ‐To compare OS of niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy Primary end point(s): Compare progression‐free survival (PFS) as assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors Version 1.1 of niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy. Compare overall survival (OS) of niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy. To evaluate and compare the time to progression (TTP) in the central nervous system (CNS) as assessed by BICR using Response Assessment in Neuro‐Oncology Brain Metastases (RANO‐BM) criteria.; Secondary Objective: ‐To evaluate and compare the TTP in the CNS as assessed by BICR using RANO‐BM criteria; ; ‐To evaluate PFS as assessed by the Investigator using RECIST v1.1; ; ‐To evaluate PFS as assessed by BICR using RECIST v1.1 and OS by PD‐L1 status (PDL1 TCs <1% versus >1%); ; ‐To evaluate and compare TTD, defined as time from randomization to meaningful deterioration on a composite endpoint of; dyspnea, chest pain, and cough, from the EORTC QLQ‐LC13; ; ‐To evaluate changes from baseline in HRQoL and symptoms as assessed by the EORTC QLQ‐C30 and the EORTC QLQ‐LC13 total and domain scores; ; ‐To evaluate safety and tolerability in participants treated with niraparib plus pembrolizumab compared to placebo plus pembrolizumab; ; ‐To evaluate population PK of niraparib when given in combination with pembrolizumab Timepoint(s) of evaluation of this end point: Three interim analysis are planned. First being when approximately 241 OS events have occurred (22 months from FPFD) Second IA to occur when 321 events have occurred (29 months from FSFD), final analysis when 401 events have occurred (39 months from FSFD) SECONDARY OUTCOME: Secondary end point(s): To evaluate PFS as assessed by the Investigator using RECIST v1.1. Evaluate PFS as assessed by BICR using RECIST v1.1 and OS by programmed cell death ligand (PD‐L1) status (PD‐L1 tumor cells [TCs] <1% versus =1%). To evaluate and compare time to deterioration in lung symptoms (TTD), defined as time from randomization to meaningful deterioration on a composite endpoint of dyspnea, chest pain, and cough, from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 13‐item lung cancer‐specific module (EORTC QLQ‐LC13). To evaluate changes from baseline in health‐related quality of life (HRQoL) and symptoms as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30‐item Core module (EORTC QLQ‐C30) and the EORTC QLQ‐LC13 total and domain scores. To evaluate safety and tolerability in participants treated with niraparib plus pembrolizumab compared to placebo plus pembrolizumab. To evaluate population pharmacokinetics (PK) of niraparib when given in combination with pembrolizumab.; Timepoint(s) of evaluation of this end point: Ongoing throughout trial INCLUSION CRITERIA: Participants will be eligible for study entry if all of the following criteria are met: 1. Participants must be = 18 years of age. 2. Participants must have a histologically or cytologically confirmed diagnosis of NSCLC without known targetable driver alteration (either non‐squamous or squamous histology; mixed histology is allowed). 3. Participants must have advanced (Stage IIIB not amenable to definitive chemoradiotherapy) or metastatic (Stage IV) NSCLC as defined by the AJCC 8th Edition Staging Manual. 4. Participants must have completed at least 4 but no more than 6 cycles of platinum‐based first‐line induction chemotherapy with pembrolizumab (according to standard of care defined by NCCN and/or ESMO Clinical Practice Guidelines for NSCLC). Note: Participants may be randomized directly after completing the induction period or, under the Investigator’s discretion, they may be randomized within 6 weeks of the last dose of chemotherapy. If the 6}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187009/full} -} - - -Record #282 of 538 -@article{Kelly17, -author = {Kelly, K}, -title = {Contra chemotherapy}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {1}, -pages = {S187‐S189}, -year = {2017}, -accession_number = {EMBASE 615338329}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemotherapy; *immunotherapy; *molecularly targeted therapy; *non small cell lung cancer; Adenocarcinoma; Adverse drug reaction; Biology; Cancer epidemiology; Case report; Cell therapy; Clinical trial; Controlled clinical trial; Controlled study; Dream; Driver; Drug combination; Drug therapy; Gene expression; Gene frequency; Gene mutation; Gene rearrangement; Heel; Human; Immune evasion; Immune system; Immunohistochemistry; Low drug dose; Maintenance therapy; Optimism; Overall survival; Phase 3 clinical trial; Progression free survival; Radiation; Randomized controlled trial; Side effect; Smoking; Toxicity; Treatment outcome}, -abstract = {Cytotoxic chemotherapy has undeniably provided benefit for our patients with non‐small cell lung cancer (NSCLC). However its nondiscriminatory application based on general tumor biology principles and not on the underlying biology of lung cancer has hampered its ability to dramatically improve survival and cures for lung cancer. Over the last twenty years we have seen multiple examples of how molecular characterization of lung tumors coupled with advances in drug development, have led to astonishing improvements in cancer outcomes. Hence, it is time to set a course toward abandoning chemotherapy. In addition to their superior efficacy, targeted therapies and immunotherapy have milder toxicity profiles compared to chemotherapy that all patients appreciate. We have already made significant progress in this quest. Our journey began with the discovery of EGFR (epidermal growth factor receptor) mutations and their exquisite sensitivity to EGFR‐TKI (tyrosine kinase inhibitors). This observation was confirmed in the landmark IPASS trial that demonstrated the superiority of EGFR‐TKIs over platinum‐based chemotherapy for the first line treatment of patients whose tumors harbor these mutations.1 On the heels of this therapeutic advancement came the discovery of ALK (anaplastic lymphoma kinase) gene rearrangements and the replacement of doublet chemotherapy with an ALKTKI in patients with ALK positive tumors.2 To date actionable driver mutations are found in at least 50% of patients with adenocarcinoma3 and inhibitors to all of these mutations are in clinical development with the hope that they will have similar success as their predecessors. Of particular interest is developing inhibitors to KRAS (V‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog) because it is the most frequent driver mutation occurring in approximately 20‐25% of tumors. Today there is optimism that we will achieve this goal given it is the focus of the Stand Up To Cancer (SU2C) lung cancer dream team initiative and several novel agents are in development including direct KRAS therapy. Driver mutations are typically identified in patients who are never smokers, light former smokers or have a lengthy quit time. The remaining groups of patients' (i.e. current smoker or recent former smokers) have a different biology that has been successfully exploited with immunotherapy. Immune checkpoint inhibitors have replaced single agent docetaxel as the standard of care for second line treatment of lung cancer for all histological subtypes of NSCLC.4‐6 Most recently the KEYNOTE‐024 a randomized trial of pembrolizumab versus doublet chemotherapy for untreated patients with advanced NSCLC whose tumor have ≥ 50% PD‐L1 (programmed death‐ligand 1) IHC (immunohistochemistry) expression met its primary progression‐free survival (PFS) endpoint and also improved overall survival.7 This will represent a new standard of care for approximately 25% of patients and will serve as the backbone for immune combinations. We are anxiously awaiting the results of a randomized trial of a PD‐1 (programmed cell death protein 1) inhibitor plus a CTLA‐4 (cytotoxic T‐lymphocyte‐associated protein 4) inhibitor versus platinum‐based chemotherapy that is expected to report out in mid‐2017. A similar study is actively accruing patients. The preliminary results on this dual immune combination were very promising and if positive would increase the number of patients receiving upfront immune therapy over chemotherapy.8 Additionally, there are numerous immune combinations involving drugs that target immune evasion and even more drugs that stimulate the immune system including cellular therapies that are being evaluated. The success of targeted therapy and immunotherapy in the advanced setting has quickly led to their evaluation in earlier stages of disease. There is a lot of enthusiasm for combining immunotherapy with radiation for patients with locally advanced lung cancer given the well‐known immune modulatory effects of radiation. Moreover the bar for replacing weekly low dose concurrent chemotherapy with immunotherapy is low. In the adjuvant setting our Asian colleagues designed and conducted two randomized phase III trials in patients whose tumors have an EGFR sensitizing mutation to replace chemotherapy with an EGFR‐TKI. Accrual is completed and we are awaiting the results. In regard to immunotherapy, enrolling phase III trials are evaluating immune checkpoint inhibitors as maintenance therapy but the pursuit of immunotherapy as a replacement for chemotherapy will follow. Beyond treatment of lung cancer, on the horizon is the exploration of targeted agents and immunotherapy as preventive agents. It is important to emphasize that our current and future success is the consequence of many factors: 1) the exponential advances in technology that has driven the science and drug development 2) rapid trial accrual and 3) regulatory authorities' responsiveness to bringing efficacious treatments to patients as quickly as possible. This momentum is what will lead us to replacing chemotherapy for lung cancer. With 20%+ of patients with driver mutations and 25% of all NSCLC with high PD‐L1 already benefiting from non‐chemotherapy treatment, we are well on our way to ousting chemotherapy in NSCLC by 2030.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01781340/full} -} - - -Record #283 of 538 -@article{Haakensen21, -author = {Haakensen, VD, Nymoen, HM, Langberg, CW, Horndalsveen, H, Farooqi, S, Bjaanaes, M, and Helland, A}, -title = {P28.03 Durvalumab Adjuvant to Chemoradiation for Patients With Locally Advanced Non-Small Cell Lung Cancer: real World Experience}, -journal = {Journal of thoracic oncology}, -volume = {16}, -number = {10}, -pages = {S1045}, -year = {2021}, -accession_number = {EMBASE 2015169955}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer adjuvant therapy; *cancer patient; *chemoradiotherapy; *non small cell lung cancer; Adult; Cancer growth; Cancer recurrence; Cancer surgery; Cancer survival; Clinical article; Clinical trial; Conference abstract; Controlled study; Drug therapy; Drug withdrawal; Fatigue; Female; Human; Hypertransaminasemia; Immunotherapy; Male; Metastasis; Osteomyelitis; Pneumonia; Prevention; Progression free survival; Psoriasis; Radiotherapy; Side effect; Surgery}, -abstract = {Introduction: Approximately one third of patients with non‐small cell lung cancer (NSCLC) are diagnosed with locally advanced disease (LA‐NSCLC). The standard treatment for patients with unresectable disease has been concurrent chemoradiation. The prognosis has been poor with median progression‐free survival of approximately 8 months and 15% 5‐year overall survival. The PACIFIC trial evaluated the effect of one year adjuvant treatment with durvalumab for patients who did not progress after chemoradiation, and presented favourable progression‐free survival for patients receiving durvalumab compared with placebo in September 2017. Methods: Following the first presentation of the PACIFIC‐data, a named‐patient use (NPU) program was established. From December 2017 to November 2018 a total of 41 patients were included in the program. Of these, 35 patients started treatment with durvalumab. After November 2019, durvalumab as implemented in routine practice. Results: Six patients included did not start durvalumab treatment. The reasons were: Progression, osteomyelitis, pneumonitis, poor performance status, discovery of a metastasis that was erroneously not detected during the initial diagnostic work‐up and surgery of the lung tumour. Of the 35 patients starting treatment with durvalumab, the mean days from completion of chemoradiation to start of durvalumab was 68 days, only 2 patients started earlier than 21 days. 19 patients (54%) completed one year of treatment. Of the 16 patients that discontinued treatment, eight stopped due to progression and eight due to side effects. The side effects leading to discontinuation were infusion reaction (n=1), fatigue (n=2), elevated liver enzymes (n=1), pneumonitis (n=3), worsening of psoriatic rash (n=1). Conclusion: Real‐world data of durvalumab adjuvant to chemoradiation was generally well tolerated. Completion of treatment was (54%) and comparable to that seen in the PACIFIC trial (49%). Time from end of chemoradiation to start of durvalumab treatment was longer than seen in the PACIFIC trial and also longer than seen after introduction of durvalumab in the routine practice. This was in line with recommendations in the NPU program. At the time, there was no data on the importance of early start of durvalumab. The time to start of durvalumab decreased during the program period. After introduction of durvalumab in routine treatment, most patients start within 3 weeks if they don’t have side effects that prevent an early start. Patients are followed with regards to future relapses and updates will be presented. Keywords: immunotherapy, durvalumab, chemoradiation}, -DOI = {10.1016/j.jtho.2021.08.394}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02369594/full} -} - - -Record #284 of 538 -@article{EUCTR2013-000177-69-BE13, -author = {EUCTR2013-000177-69-BE,}, -title = {Clinical study to evaluate atezolizumab (MPDL3280A) in patients with PD-L1- positive locally or metastatic non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-000177-69-BE}, -year = {2013}, -accession_number = {ICTRP EUCTR2013‐000177‐69‐BE}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Atezolizumab Product Code: MPDL3280A‐RO5541267 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Atezolizumab Current Sponsor code: MPDL3280A Other descriptive name: RO5541267 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 125‐ CONDITION: PD‐L1‐POSITIVE LOCALLY ADVANCED OR METASTATIC NON‐SMALL CELL LUNG CANCER ; MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non‐small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: The primary efficacy objective for this study is to evaluate the efficacy of atezolizumab in patients with PD‐L1‐positive locally advanced or metastatic NSCLC, as measured by investigator‐assessed ORR according to modified RECIST Primary end point(s): investigator overall response rate (ORR) per modified RECIST Secondary Objective: ‐ To evaluate PFS and DOR according to modified RECIST; ‐ To evaluate the efficacy of Atezolizumab in patients with PD‐L1‐positive locally advanced or metastatic NSCLC, as measured by investigator‐assessed ORR, DOR, PFS, where all response endpoints are determined according to RECIST 1.1; ‐ To evaluate OS; ‐ To evaluate PFS in patients who experience a confirmed partial response (PR) or confirmed response CR per modified RECIST at any time on study treatment; ‐ To evaluate the safety and tolerability of Atezolizumab in patients with PD‐L1‐positive locally advanced or metastatic NSCLC; ‐ To characterize the pharmacokinetics of Atezolizumab; ‐ To evaluate the incidence and titers of ATAs against Atezolizumab and to explore the potential relationship of the immunogenicity response with pharmacokinetics, safety, and efficacy Timepoint(s) of evaluation of this end point: timepoint for evaluation will be 6 months after approximately 130 patients have been enrolled; SECONDARY OUTCOME: Secondary end point(s): ORR, duration of response (DOR), progression‐free survival (PFS), and overall survival (OS) per RECIST v1.1, Timepoint(s) of evaluation of this end point: timepoint for evaluation is same as for primary endpoint, with updated analysis approximately 12 months after the last patient is enrolled in the study INCLUSION CRITERIA: ‐ Histologically or cytologically documented Stage IIIB (not eligible for definitive chemoradiotherapy), Stage IV, or recurrent NSCLC ‐ PD‐L1‐positive status as determined by an IHC assay performed by a central laboratory ‐ ECOG performance status of 0 or 1 ‐ Measurable disease, as defined by RECIST v1.1 ‐ For female patients of childbearing potential, agreement (by patient) to remain abstinent (refrain from heterosexual intercourse) or to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) during the treatment period and to continue its use for 5 months after the last dose of atezolizumab Inclusion Criteria Unique to Cohort 1: ‐ No prior chemotherapy for locally advanced or metastatic (i.e., Stage IIIB not eligible for definitive chemoradiotherapy, Stage IV, or recurrent) NSCLC Inclusion Criteria Unique to Cohorts 2 and 3 ‐ Disease progress}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01820259/full} -} - - -Record #285 of 538 -@article{Belderbos19, -author = {Belderbos, J}, -title = {CS01.02 “Hunting a Ghost for 25 Years – Will We Ever Catch OMD?” - Yes}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S77‐S78}, -year = {2019}, -accession_number = {EMBASE 2003405739}, -publication type = {Journal article; Conference proceeding}, -keywords = {Ablation therapy; Adult; Advanced cancer; Cancer patient; Cancer radiotherapy; Cancer size; Cancer staging; Cancer surgery; Cancer survival; Conference abstract; Consensus; Controlled study; Cryoablation; Drug combination; Female; Follow up; Human; Human cell; Immune system; Immunotherapy; Induction chemotherapy; Local therapy; Lung development; Maintenance chemotherapy; Major clinical study; Male; Metastasis; Minimal residual disease; Molecularly targeted therapy; Multicenter study; Necrosis; Non small cell lung cancer; Observational study; Open study; Overall survival; Palliative therapy; Phase 2 clinical trial; Primary tumor; Progression free survival; Prospective study; Quality of life; Radiotherapy; Randomized controlled trial; Stereotactic radiosurgery; Surgery; Systemic therapy; Therapy delay}, -abstract = {The treatment options for NSCLC patients with a limited number of metastases at diagnosis (oligometastatic disease) have increased the past decade. The focus lies at combining systemic‐ and local radical treatments. With the introduction of oligometastatic disease (OMD) as a separate entity, a more radical treatment approach is increasingly applied. For OMD we distinguish synchronous OMD (in case of OMD at diagnosis) and metachronous OMD (in case of a limited amount of metastases as first event of an initially locally limited disease). There is also the term oligometastatic progression in which case during systemic treatment of a pluri‐metastatic disease only few metastases progress. Finally, there could be a situation called oligo persistence in case of remaining metastatic lesions. The existing literature is seriously flawed by the lack of consensus on the definition of oligometastatic disease. Often a maximum of 2‐3 metastases are referred to as oligometastatic disease, but ≤5 metastases are also selected and considered for radical treatment. Important developments of local consolidative therapies in OMD Since 2016 several retrospective and prospective trials reported favorable progression free survival (PFS) for OMD treated with systemic therapy followed by local consolidative therapy (LCT). The intrathoracic disease is generally locally treated with radical radiotherapy or resection. Treatment of the metastases consists of radical or stereotactic radiotherapy, surgical resection or local ablative therapies. In an observational study radical local treatment for a selected group of NSCLC patients (n=91) with good performance status presenting with synchronous oligometastatic disease resulted in 14 months PFS and 32 months overall survival (OS). These results are comparable to outcomes for stage III NSCLC disease. De Ruysscher et.al. [2] reported a prospective single arm phase II study for synchronous oligometastatic disease treated with radical local treatment (radiotherapy or surgery) after first line chemotherapy. The median PFS and OS in this study were 12.1 months and 13.5 months respectively. After 24 months 15% of the patients did not show disease progression. In a trial Iyengar et al [4] randomized 29 metastatic NSCLC patients with up to 6 sites of extracranial disease (including primary) and a good performance. After induction chemotherapy non‐progressive patients were randomized for maintenance chemotherapy or stereotactic radiotherapy. In an unplanned interim analysis, the median PFS was 9.7 months in the stereotactic radiotherapy arm versus 3.5 months in the maintenance chemotherapy arm. In a randomized phase II trial Gomez included 49 patients with stage IV NSCLC with three or fewer metastases, and no progression after first‐line systemic therapy. The trial investigated LCT with stereotactic or conventionally fractionated radiotherapy or surgery versus maintenance therapy or observation. Patients in the LCT arm experienced improved PFS as well as improved OS [5].The trial was closed early because of a significant PFS and OS benefit in the LCT arm. With a median follow‐up time of 38.8 months the PFS benefit with additional local therapy was 14.2 months versus 4.4 months in the maintenance therapy/observation arm (p=0.022). They also reported an impressive OS benefit in the LCT arm: 41.2 months versus 17.0 months (p=0.017). This OS benefit was achieved despite the fact that 41% of the patients in the maintenance therapy/observation arm crossed over to the local consolidative therapy arm at the time of progression. No additional grade 3 or greater toxicities were observed. It is important to know that these studies were performed in the pre‐immunotherapy era. In patients with metachronous OMD (controlled primary tumour and 1‐5 oligometastatic lesions) the effect of LCT on survival, toxicity, and quality of life in 99 patients was recently reported in the SABR‐COMET trial: a randomized, phase 2 trial [4]. Patients were randomly assigned (1:2) to receive either palliative standard of care treatments alone (control group), or standard of care plus stereotactic or conventional radiotherapy to all metastatic lesions (SABR group). Median overall survival was 28 months in the control group versus 41 months in the SABR group (p=0.090). Several reasons could explain the benefit by adding LCT for OMD in these trials: 1) LCT potentiates the effects of systemic therapy 2) By reducing the residual tumor burden, LCT delays the growth of distant micrometastatic disease 3) LCT reduced the amount of treatment‐resistant lung cancer cells 4) Necrosis caused by LCT allows the immune system to induce an immune‐specific reaction that affects distant cancer cells Conclusion: The synergy of local consolidative therapies combined with systemic treatments in oligometastatic patients is currently one of the most exciting developments in lung cancer treatment. Ref: 1. Kwint M et al. Outcome of radical local treatment of non‐small cell lung cancer patients with synchronous oligometastases. Lung Cancer. 2017 Oct;112:134‐139. 2. De Ruysscher D et al. Progression‐Free‐Survival and Overall Survival beyond 5 years of non‐small cell lung cancer patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450). JTO 2018. 3. Iyengar P et al. Consolidative Radiotherapy for Limited Metastatic Non‐Small‐Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018 Jan 11;4(1):e173501. Epub 2018 Jan 11. 4. Gomez D et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non‐Small‐Cell Lung Cancer: Long‐Term Results of a Multi‐Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 Jun 20;37(18):1558‐1565. Epub 2019 May 8. 5. Palma D et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR‐COMET): a randomised, phase 2, open‐label trial.Lancet. 2019 May 18;393(10185):2051‐2058. ). Epub 2019 Apr 11 6. Gu X et al. Cryoablation combined with molecular target therapy improves the curative effect in patients with advanced non‐small cell lung cancer J Int Med Res. 2011;39(5):1736‐43 Keywords: oligo metastatic disease, stereotactic radiotherapy, Local consolidative therapy}, -DOI = {10.1016/j.jtho.2019.08.185}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01995785/full} -} - - -Record #286 of 538 -@article{CTIS2023-505035-12-0024, -author = {CTIS2023-505035-12-00,}, -title = {A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTIS2023-505035-12-00}, -year = {2024}, -accession_number = {ICTRP CTIS2023‐505035‐12‐00}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: PEMETREXED, Product Code:SUB09655MIG, Pharmaceutical Form: POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Sindaxel 6 mg/ml concentrat pentru solutie perfuzabila, Product Code:PRD4356093, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: CISPLATIN, Product Code:SUB07483MIG, Pharmaceutical Form: CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Abraxane 5 mg/ml powder for dispersion for infusion., Product Code:PRD9254301, Pharmaceutical Form: DISPERSION FOR INFUSION, Other descriptive name: , Strength: , Product Name: KEYTRUDA 25 mg/mL concentrate for solution for infusion, Product Code:PRD4323105, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: RO 749‐9790/F02‐02, Product Code:PRD9235050, Pharmaceutical Form: CAPSULE, HARD, Other descriptive name: , Strength: , Product Name: CARBOPLATIN, Product Code:SUB06614MIG, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: GEMCITABINE, Product Code:SUB07892MIG, Pharmaceutical Form: POWDER FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: CONDITION: MedDRA version: 20.0Level: LLTClassification code: 10007096Term: Cancer of lung Class: 10029104 MedDRA version: 21.1Level: LLTClassification code: 10029514Term: Non‐small cell lung cancer NOS Class: 10029104 RET fusion‐positive, metastatic Non‐Small Cell Lung Cancer ; MedDRA version: 20.0Level: LLTClassification code: 10007096Term: Cancer of lung Class: 10029104 ; MedDRA version: 21.1Level: LLTClassification code: 10029514Term: Non‐small cell lung cancer NOS Class: 10029104 Therapeutic area: Diseases [C] ‐ Neoplasms [C04] PRIMARY OUTCOME: Main Objective: To assess whether pralsetinib improves progression‐free survival (PFS) as compared with Investigator's choice of platinum‐containing anticancer treatment regimens for patients with RET fusion‐positive metastatic NSCLC Primary end point(s): 1. PFS, defined as the time from randomization date to the first of documented progressive disease (PD), as assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or death due to any cause, whichever occurs first Secondary Objective: To evaluate the efficacy of pralsetinib compared with investigator’s choice of SOC platinum containing anticancer treatment regimens with Corresponding Endpoint ORR (objective response rate), To evaluate overall survival (OS), To evaluate the safety and tolerability profile of pralsetinib as compared to investigator’s choice of SOC platinum containing anticancer treatment regimens, To compare additional measures of anticancer activity, including duration of response, disease control rate, and clinical benefit rate, To evaluate the efficacy of pralsetinib versus SOC anticancer treatment through patient‐reported endpoints SECONDARY OUTCOME: Secondary end point(s):1. Objective response rate (ORR) defined as the proportion of participants with a CR or a PR on two consecutive occasions = 4 weeks apart, as assessed by BICR according to RECIST v1.1 Secondary end point(s):10. Change from baseline in PROs of health‐related quality‐of‐life, lung cancer‐related symptoms, and their impact on functioning Secondary end point(s):11. Time to confirmed deterioration of participant‐reported physical functioning and health Secondary end point(s):2. Overall survival (OS), defined as the time to randomization date to death due to any cause. Secondary end point(s):3. Incidence and severity of adverse events, with severity, as determined according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0 Secondary end point(s):4. Change from baseline in ECOG performance status Secondary end point(s):5. Change from baseline in targeted vital signs Secondary end point(s):6. Change from baseline in targeted clinical laboratory test results Secondary end point(s):7. Duration of response (DOR), defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as assessed by BICR according to RECIST v1.1 Secondary end point(s):8. Disease control rate (DCR), defined as the proportion of participants who experience a best response of CR, or PR, or SD, as assessed by BICR according to RECIST v1.1 Secondary end point(s):9. Clinical benefit rate (CBR), defined as the proportion of participants who experience a best response of SD with a minimum duration of 6 months, a CR, or a PR, as assessed by BICR according to RECIST v1.1 INCLUSION CRITERIA: 1. Participant has pathologically or cytologically confirmed, definitively diagnosed, advanced unresectable NSCLC (i.e., Stage IIIB not eligible for definitive chemoradiotherapy) or metastatic NSCLC (i.e., Stage IV), per the Union Internationale Contre le Cancer/American Joint Committee on Cancer staging system (Amin et al. 2017) of either squamous or non‐squamous histology based on the major histologic component that has not been treated with systemic anticancer therapy for metastatic disease, 2. Participant has documented RET fusion that must meet 1 of the following 2 criteria: a. Documented RET fusion using either tissue or plasma as performed by a Clinical Laboratory Improvement Amendments (CLIA)‐certified or equivalent accredited diagnostic laboratory. b. Documented RET fusion by a positive result from tumor tissue testing performed centrally by Foundation Medicine (FMI) clinical trial assay or an alternate, approved central laboratory for that region, 3. Parti}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02731127/full} -} - - -Record #287 of 538 -@article{UMIN00000356610, -author = {UMIN000003566,}, -title = {Bevacizumab (Avastin) therapy in combination with carboplatin and weekly paclitaxel for advanced non-squamous non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000003566}, -year = {2010}, -accession_number = {ICTRP UMIN000003566}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Patients receive paclitaxel on days 1, 8, and 15 and carboplatin [area under the curve (AUC) = 6] on day 1 and Bevacizumab(15mg/kg,i.v.) on day1, every four weeks, up to six cycles. Patients who still control disease without unacceptable toxicity, then continuously treated with Bevacizumab(15mg/kg,i.v.) on Day1, every three weeks, until disease progression. CONDITION: Non‐squamous Non‐small‐cell Lung Cancer PRIMARY OUTCOME: Response rate SECONDARY OUTCOME: Safety, Progression free survival, Time to response, Response duration, Overall survival INCLUSION CRITERIA: (1) Written informed consent (2) Age: 20‐74 years old (3)ECOG performance status of 0 or 1 (4) Life expectancy more than 3 months (5)histologically or cytologically confirmed non‐squamous non‐small cell lung cancer(NSCLC) (6)StageIV or postoperative recurrence non‐squamous non‐small cell lung cancer (7)cheno‐naive patient (8)Measurable by RECST(ver 1.1) criteria. (9) If the patient underwent therapy, there should be the following interval between the therapy and the registration 1)immunotherapy and endcrintherapy ‐>3 weeks 2)Radiotherapy other than thoracic radiation ‐>2 week 3)Surgery ‐>4 weeks 4)Thoracic drainarge ‐>2 weeks 5)Open biopsy, treatment of injury ‐>2 weeks 6) Transfusion and growth factor ‐>2 weeks 7)Aspiration biopsy, CV‐port reservation ‐>1 week (10) Adequate organ function}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01803314/full} -} - - -Record #288 of 538 -@article{EUCTR2009-012964-14-BE09, -author = {EUCTR2009-012964-14-BE,}, -title = {Study of XL184 in subjects with advanced solid tumors}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2009-012964-14-BE}, -year = {2009}, -accession_number = {ICTRP EUCTR2009‐012964‐14‐BE}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: XL184 Product Code: XL184 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Cabozantinib CAS Number: 1140909‐48‐3 Current Sponsor code: XL184 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 19.7‐ Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: XL184 Product Code: XL184 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Cabozantinib CAS Number: 1140909‐48‐3 Current Sponsor code: XL184 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50‐ Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: XL184 Product Code: XL184 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Cabozantinib CAS Number: 1140909‐48‐3 Current Sponsor code: XL184 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 60‐ Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use CONDITION: To evaluate the efficacy of XL184 in subjects with one of the following advanced solid tumors: a. Breast Cancer b. Gastric and Gastroesophageal Junction Cancer c. Hepatocellular Carcinoma (HCC) d. Melanoma e. Non‐small Cell Lung Cancer f. Ovarian, primary peritoneal or fallopian tube Carcinoma g. Pancreatic Cancer h. Castration‐Resistanct Prostate Cancer (CRPC) i. Small Cell Lung Cancer PRIMARY OUTCOME: Main Objective: The primary objective of this study is:; ‐ To evaluate the efficacy of XL184 in subjects with advanced solid tumors Primary end point(s): Primary Endpoints:; Randomized Discontinuation Trial (RDT) Cohorts:; Lead‐in Stage:; • Objective Response Rate (ORR) per Modified Response Evaluation Criteria in Solid Tumors mRECIST (version 1.0; Appendix F), per investigator; ; Randomized Stage:; • Progression‐free survival (PFS), per investigator; ; Non‐Randomized Expansion (NRE) Cohorts:; • Castration‐resistant Prostate Cancer (CRPC) subjects: Bone scan response per IRF (primary analysis; Section 5.5.11.4) and investigator (supportive analysis; Appendix H); • Non‐CRPC subjects: ORR per mRECIST (version 1.1; Appendix G), per Independent Radiology Facility (IRF) (primary analysis) and investigator (supportive analysis); Secondary Objective: The secondary objectives of this study are:; ‐ To evaluate the safety and tolerability of XL184 in subjects with advanced solid tumors; ‐ To correlate the pathway dysfunction of desease‐related genes or proteins such as MET and downstream signaling molecules with clinical outcome; ‐ To further characterize the pharmacokinetic (PK) and pharmacodynamic parameters of XL184; ; To evaluate the safety and efficacy of cabozantinib at two starting dose levels ( 100mg and 39.4 mg once daily (qd)); ; The exploratory objective of this study is:; ‐ To identify surrogate biomarkers associated with clinical activity SECONDARY OUTCOME: Secondary end point(s): All tumor type cohorts unless otherwise specified: ; • Bone scan response in RDT cohorts, per IRF ; ORR (per mRECIST 1.0) in the Randomized Stage, per investigator ; • Duration of response, per investigator (all cohorts) and IRF (NRE cohorts) ; • PFS (NRE cohorts), per investigator and IRF ; • Overall survival (NRE cohorts) ; • Changes in tumor markers ; CRPC NRE cohorts: ; • ORR (per mRECIST 1.1), per IRF and investigator, among subjects with ; baseline measurable disease ; • Changes in pain and in analgesic medication ; • Skeletal‐related events (SREs) ; • Biomarker and laboratory assessments, including circulating tumor cells ; (CTCs), hemoglobin and hematocrit measurements, and markers of bone ; metabolism including serum bone‐specific alkaline phosphatase (ALP), ; CTx (carboxy‐terminal collagen crosslinks), and NTx (N‐telopeptide ; crosslinks) ; Safety endpoints include adverse events (AEs) and clinical laboratory parameters. INCLUSION CRITERIA: 1. The subject has a cytologically or histologically and radiologically confirmed, advanced, recurrent, or metastatic solid tumor of the nine types listed below (a i) The following limitations on prior systemic anticancer treatments apply: • The maximum number of prior systemic treatment regimens apply to the advanced, recurrent, or metastatic disease state. • Unless otherwise specified in a‐i, determination of the number of prior treatments will be based on the following: • Prior systemic treatments include standard and investigational chemotherapy and targeted therapies (including targeted biologic therapies). • Neoadjuvant, adjuvant, hormonal, or locally administered therapy (including embolization, ablation), radiotherapy, and immunotherapy do not count towards these restrictions. • Retreatment with the same systemic regimen is counted as one regimen. Specific restrictions to tumor histology and prior systemic anticancer tre}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01883706/full} -} - - -Record #289 of 538 -@article{NCT0444761220, -author = {NCT04447612,}, -title = {Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma}, -journal = {https://clinicaltrials.gov/show/NCT04447612}, -review groups = {Oral Health; ENT}, -year = {2020}, -accession_number = {CTgov NCT04447612}, -publication type = {Trial registry record}, -keywords = {Carcinoma; Gemcitabine; Nasopharyngeal Carcinoma}, -abstract = {Nasopharyngeal carcinoma (NPC) of the undifferentiated histology is endemic in southern China and southeast Asia including Hong Kong, Taiwan, Singapore and Malaysia, with a peak annual incidence of up to 30 per 100,000 persons. According to global cancer registry, NPC ranked 11th most common among all malignancies in China in 2008 with an incidence of 2.8/100,000 person‐years in men and 1.9/100,000 person‐years in females. It is highly associated with prior infection with Epstein‐Barr virus and thus it is a highly immune‐related malignancy. Treatment strategy is mainly based on the disease stage according to the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system. In general, stage I‐II diseases are treated with radiation therapy alone while stage III‐IV diseases are treated with concurrent chemoradiation with or without adjunct chemotherapy (induction or adjuvant). Intensive pretreatment workup including blood hematology and biochemistry, dedicated head and neck imaging with computed tomography and magnetic resonance imaging and positron‐emission tomography with integrated computed tomography (PET‐CT) and plasma Epstein‐Barr virus (EBV) deoxyribonucleic acid (DNA) are essential in high‐risk locoregionally advanced diseases to confirm non‐metastatic diseases, since the treatment protocol and overall prognosis between locoregionally advanced (stage III‐IVA) disease differ significantly from metastatic disease. Despite intensive radical treatment in the contemporary radiotherapy era with concurrent chemoradiation with or without adjunct chemotherapy, between 15% and 30% of these patients with stage III‐IVA disease develop metastatic diseases at distant sites. Further systemic chemotherapy following radical concurrent chemoradiation may not bring survival benefits, attributed by the compromised physique following intensive radical concurrent chemoradiation and the prolonged treatment‐related toxicities brought by adjuvant chemotherapy. The recent Hong Kong NPC Study Group NPC‐0502 study failed to show survival benefit in patients with post‐treatment detectable plasma EBV DNA after a further 6 cycles of adjuvant chemotherapy compared to those who just observed after radical concurrent chemoradiation. On the other hand, induction chemotherapy followed by concurrent chemoradiation may be the more preferred regimen due to the perceived efficacy of eradication of tumor micro‐metastasis and early shrinkage of primary tumor and bulky neck nodes, which allow a more radical radiotherapy dose and better coverage of both the primary tumor and neck nodes. Very recently, a China multi‐centre phase III randomised‐controlled trial demonstrated an improvement in recurrence‐free survival and overall survival (OS) with induction chemotherapy gemcitabine plus cisplatin followed by concurrent chemoradiation versus concurrent chemoradiation alone. Nevertheless, new treatment strategies must be developed to improve treatment outcomes of these high‐risk patients with stage III‐IVA disease, which has become the major research focus in the past decade. A recent meta‐analysis demonstrated that induction chemotherapy followed by concurrent chemoradiation improved overall survival compared to concurrent chemoradiation in the era of modern radiotherapy with intensity‐modulated radiation therapy (IMRT). Immune checkpoint inhibitors are now comprehensively and extensively tested in combination with radiotherapy (RT) as well (NCT01935921, NCT01860430). It has been recently known that RT increases the expression of the major histocompatibility complex (MHC). In turn, the MHC class‐I restricted tumor antigen‐specific cells elicited by RT will upregulate interferons in the tumors. This radiation‐induced local inflammation and tumor‐specific effector T cells will provide an additional mechanism for tumor control by modification of the tumor vasculature. In addition, RT will increase dendritic cell surface antigen presentation to T cells and production of cytokines leading to recruitment and activation of leucocytes from peripheral blood and extravasation to tumor parenchyma. These are part of the mechanisms of abscopal effect, a phenomenon where the tumors at the sites far away from the irradiated sites also regress after localized radiotherapy. Having learnt from the pivotal PACIFIC trial on the use of consolidation therapy with durvalumab (anti‐PD‐L1 monoclonal antibody) which confirmed the efficacy and safety of combination of chemoradiation and immunotherapy for stage III non‐small‐cell lung cancer, it is prime time to consider incorporation of immune checkpoint inhibitors into concurrent chemoradiation for other solid tumors like head and neck squamous cell carcinoma and NPC. In concurrent +/‐ adjuvant setting for locoregionally advanced NPC, there are at least two clinical trials on immune checkpoint inhibitors for locoregionally advanced disease. The first one is a phase II single‐arm study using nivolumab in combination with concurrent chemoradiation with or without by adjuvant nivolumab for up to 3 months at different dose schedules (NCT03267498). A phase III multi‐center randomized‐controlled trial (RCT) in China on the use of a locally‐manufactured PD‐1 monoclonal antibody (SHR‐1210) every 4 weeks for 12 cycles starting at 4‐6 weeks after concurrent chemoradiation for stage III‐IVA NPC versus no adjuvant therapy is currently under way (NCT03427827). It is highly expected and eagerly awaited that immunotherapy with immune checkpoint inhibitors will bring a new insight on the adjuvant treatment for NPC. In view of the above with promising synergy between radiation therapy and immune checkpoint inhibitors, the investigators propose a phase II RCT on adding durvalumab in combination with induction chemotherapy followed by concurrent chemoradiation and adjuvant durvalumab for previously untreated locoregionally advanced NPC. In parallel, the investigators will also perform collateral tumor and serum biomarker studies which will be correlated with the treatment response. The investigators will collect fresh tumour biopsies at pretreatment, then serially after induction chemotherapy and after concurrent chemoradiation to investigate the change in microenvironment of the tumour and the surrounding inflammatory cells before and after durvalumab. In addition, the investigators will also measure the change in number and intensity of PD‐L1‐positive circulating tumour cells before and after durvalumab and evaluate their correlation with treatment response.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02133927/full} -} - - -Record #290 of 538 -@article{Haddad24, -author = {Haddad, RI, Ruscica, D, Visa, A, Li, X, and Licitra, LF}, -title = {eVOLVE-HNSCC: a global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT)}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644913283}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *head and neck squamous cell carcinoma; Adult; Adverse drug reaction; Conference abstract; Controlled study; Drug combination; Drug therapy; Human; Human tissue; Immunogenicity; Maintenance therapy; Melanoma; Monotherapy; Multicenter study; Non small cell lung cancer; Oropharynx cancer; Patient‐reported outcome; Pharmacokinetics; Phase 3 clinical trial; Radiotherapy; Randomized controlled trial; Renal cell carcinoma; Response evaluation criteria in solid tumors; Side effect; Solid tumor; Therapy}, -abstract = {Background: Currently there are no approved maintenance therapies for patients (pts) with unresected LA‐HNSCC following definitive cCRT. The PD‐1 inhibitors pembrolizumab and nivolumab are licensed for treatment of pts with recurrent or metastatic HNSCC who have progressed on or after a platinum‐based therapy. Dual inhibition of CTLA‐4 and PD‐L1 is approved in solid tumors including renal cell carcinoma (RCC), NSCLC, and melanoma, and has shown a numerical trend towards improved survival in first‐line pts with recurrent/metastatic HNSCC whose tumors express PD‐L1. Volrustomig (MEDI5752) is a monovalent, PD‐1/CTLA‐4 bispecific, humanized IgG1 monoclonal antibody engineered to specifically inhibit PD‐1, with increased CTLA‐4 blockade on PD‐1+ activated T cells compared to PD‐1‐ resting peripheral T cells. In a first‐in‐human phase 1/2 study (NCT03530397), volrustomig monotherapy showed promising efficacy with acceptable tolerability in advanced clear cell RCC and in combination with chemotherapy in advanced NSCLC. The phase 3, randomized, open‐label, multicenter, eVOLVE‐HNSCC study will evaluate the efficacy and safety of sequential therapy with volrustomig compared with observation in pts with unresected LA‐HNSCC who have not progressed after receiving definitive cCRT (NCT06129864). Methods: Key eligibility criteria include histologically or cytologically confirmed, unresected LA‐HNSCC with no evidence of metastatic disease, i.e. AJCC 8th edition(TNMstaging system) stage IVA/B cancers of the hypopharynx, oral cavity, larynx or HPV‐negative oropharynx, or stage III HPV‐positive oropharynx cancer; age ≥18 years; WHO/ECOG performance score of 0 or 1; and adequate organ and bone marrow function. Key exclusion criteria include requiring further treatment with curative intent after definitive cCRT, resected LA‐HNSCC, recurrent/metastatic disease, and >1 primary tumor. Following initial screening and definitive cCRT (cisplatin or carboplatin + paclitaxel or carboplatin + 5‐FU, plus concomitant radiotherapy), approximately 1145 pts whose disease has not progressed within 12 weeks of the last dose of cCRT will be randomized 1:1 to Arm A or B. Arm A will receive volrustomig intravenously every 3 weeks for a maximum of 12 months or 18 cycles, or until RECIST v1.1‐defined radiological progressive disease (PD) or unacceptable toxicity. Arm B will undergo observation for a maximum of 12 months or until PD. The primary endpoint is PFS in pts with PD‐L1‐expressing tumors. Secondary endpoints include PFS in all randomized pts, OS in pts with PD‐L1‐expressing tumors and in all randomized pts, PFS2, safety, patientreported outcomes, pharmacokinetics, and immunogenicity. Exploratory biomarker analyses will also be conducted. Enrollment began in December 2023.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02736416/full} -} - - -Record #291 of 538 -@article{Woolf19, -author = {Woolf, D, Lee, C, Shah, R, Ahmed, M, Fraser, I, Billingham, L, Phillips, I, Mcaleese, J, Hiley, C, Taylor, A, Calman, L, Rachael, B, and Hatton, M}, -title = {P2.01-25 TOURIST: thoracic Umbrella Radiotherapy Study in Stage IV NSCLC: a Phase III Randomized Trial in Development}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S648‐S649}, -year = {2019}, -accession_number = {EMBASE 2003406631}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *non small cell lung cancer; *tourism; Adult; Advanced cancer; Cancer chemotherapy; Cancer mortality; Cancer patient; Cancer radiotherapy; Cancer survival; Conference abstract; Controlled study; Drug megadose; Female; Follow up; Human; Immunotherapy; Incidence; Low drug dose; Major clinical study; Male; Overall survival; Palliative therapy; Phase 3 clinical trial; Progression free survival; Quality of life; Radiation dose fractionation; Radiotherapy; Randomized controlled trial; Relapse; Systemic therapy; Telephone; Thorax disease}, -abstract = {Background: Non Small Cell Lung Cancer (NSCLC) is the leading cause of cancer mortality throughout the world with an incidence exceeding 1.2 million. 70% of NSCLC patients present with incurable disease with treatment aimed at alleviating symptoms, maintaining / improving quality of life as well as prolonging survival. In the last decade there have been dramatic changes in systemic therapy (chemotherapy, immunotherapy, Tyrosine kinase Inhibitors (TKIs)). Despite these advances, many patients suffer from lororegional symptomatic relapse. This may benefit from local radiotherapy in addition to other standards of care such as symptom control. Radiotherapy remains widely used in the management of stage IV NSCLC but strategies vary hugely because the data originates from a series of dose fractionations trials in the 1990s when systemic therapy options were limited. There is therefore limited evidence regarding the use and place of palliative radiotherapy in conjunction with modern systemic treatments and there is a need to assess benefits of advanced radiotherapy techniques in this population. The TOURIST trial aims to establish the utility of palliative thoracic radiotherapy in the primary treatment of stage IV NSCLC. Method: This is a phase III platform that currently has 2 study arms, to cover the needs of differing patient populations, defined by the use of first line systemic therapy. Study 1 (PRINCE) Patients receiving first line systemic therapy as standard of care, who have not progressed after 2‐4 cycles are randomised 1:1 to either high dose palliative radiotherapy to the thorax, or to no radiotherapy while continuing on their standard systemic therapy. Co‐primary endpoints: overall survival, PROMs recorded QOL, with progression free survival and time to next line of therapy, as secondary endpoints. Study 2 (QUARTZ Lung) Asymptomatic patients unsuitable for standard systemic therapy randomised 1:1 to low dose palliative radiotherapy dose to the thorax or no radiotherapy. Telephone follow up will be used for PROMs data collection to measure QOL improvements. Stratification factors for both studies will include bulk of thoracic disease, use of advanced radiotherapy techniques and performance status. The TOURIST trial intends to recruit 750 patients and is anticipated to open in 2020. Result: Section not applicable Conclusion: Section not applicable Keywords: trials in progress, advanced non‐small cell lung cancer, radiotherapy}, -DOI = {10.1016/j.jtho.2019.08.1369}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01999558/full} -} - - -Record #292 of 538 -@article{EUCTR2014-003443-35-IT14, -author = {EUCTR2014-003443-35-IT,}, -title = {A study of ficlatuzumab in subjects with metastatic lung cancer who will receive erlotinib}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2014-003443-35-IT}, -year = {2014}, -accession_number = {ICTRP EUCTR2014‐003443‐35‐IT}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Ficlatuzumab Product Code: AV‐299 Pharmaceutical Form: Concentrate for solution for injection/infusion INN or Proposed INN: Ficlatuzumab CAS Number: 1174900‐84‐5 Current Sponsor code: AV‐299 Other descriptive name: formerly known as SCH 900105 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use CONDITION: EGFR‐mutated non‐small cell lung cancer (NSCLC) ; MedDRA version: 17.1 Level: PT Classification code 10061873 Term: Non‐small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: To evaluate the efficacy of ficlatuzumab plus erlotinib versus placebo plus erlotinib in terms of PFS in subjects who have previously untreated metastatic EGFR‐mutated NSCLC and a BDX004 Positive Label. Primary end point(s): The primary efficacy endpoint PFS is defined as the time from the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause. Secondary Objective: • To evaluate OS in the 2 treatment groups.; • To compare ORR in the 2 treatment groups.; • To evaluate disease control rate (DCR) in the 2 treatment groups.; • To evaluate safety and tolerability of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic EGFR‐mutated NSCLC and a BDX004 Positive Label.; • To evaluate the pharmacokinetics of ficlatuzumab and erlotinib. Timepoint(s) of evaluation of this end point: please refer to E.5 SECONDARY OUTCOME: Secondary end point(s): ‐ overall survival (OS), as measured from the date of randomization to the date of death by any cause; ; ‐ objective response rate (ORR) based on subjects that had complete response (CR) or partial response (PR); ; ‐disease control rate (DCR) based on subjects that had CR or PR or stable disease (SD) for at least 4 cycles (16 weeks) Timepoint(s) of evaluation of this end point: please refer to E.5.2 INCLUSION CRITERIA: 1. Male or female and =18 years of age. 2. Histologically and/or cytologically confirmed primary diagnosis of Stage IV NSCLC (according to American Joint Committee on Cancer [AJCC] 7th edition lung cancer staging criteria). 3. Measurable disease according to RECIST v.1.1. 4. An EGFR exon 19 deletion and/or an exon 21 (L858R) substitution mutation. 5. BDX004 Positive Label. 6. Have received no prior systemic chemotherapy, immunotherapy, targeted therapy, or biologic therapy for metastatic NSCLC. Subjects may have previously been treated with postoperative adjuvant chemotherapy for early stage lung cancer or chemo‐radiotherapy for locally advanced disease provided this was completed at least 6 months prior to enrollment. No prior EGFR TKI therapy is allowed for any stage of NSCLC. 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 8. Clinical laboratory values meeting the following criteria prior to randomization: •}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01896600/full} -} - - -Record #293 of 538 -@article{Liu21, -author = {Liu, H, Qiu, B, Wang, D, Zhang, X, Zhou, Y, Li, Q, Chu, C, Liu, F, Chen, N, Hu, N, Ai, X, Guo, J, and Fan, W}, -title = {Dynamic 18F-FDG Total Body PET Imaging as a Predictive Marker of Induction Chemo-Immunotherapy Followed by Concurrent Chemoradiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer}, -journal = {International journal of radiation oncology biology physics}, -volume = {111}, -number = {3}, -pages = {e445}, -year = {2021}, -accession_number = {EMBASE 2014605792}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *chemoradiotherapy; *immunotherapy; *non small cell lung cancer; *positron emission tomography‐computed tomography; Adult; Cancer patient; Cancer staging; Clinical article; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Drug therapy; Female; Foot; Glycolysis; Human; Influx rate constant; Lymph node metastasis; Male; Metabolic tumor volume; Nuclear medicine; Phase 2 clinical trial; Prospective study; Radiation oncologist; Radiotherapy; Randomized controlled trial; Standardized uptake value}, -abstract = {Purpose/Objective(s): The purpose of this study was to evaluate the efficacy of dynamic 18F‐FDG total body PET imaging as a predictive maker of induction chemo‐immunotherapy followed by concurrent chemoradiotherapy (CCRT) response in locally advanced non‐small cell lung cancer (LA‐NSCLC) by a prospective study. Materials/Methods: Stage IIIA‐IIIC NSCLC patients were prospectively enrolled in a prospective total body PETCT study (NCT04654234, GASTO‐1067) and a randomized phase II clinical trial (NCT04085250) between September 2020 and December 2020. Patients underwent a dynamic total‐body 18F‐FDG PET/CT scan before any treatment, after 2 cycles of induction chemo‐immunotherapy (docetaxel + cisplatin + nivolumab), then after CCRT. The primary lung tumor, metastatic regional lymph node and inflammatory lymph node before and after treatment were manually delineated by a nuclear medicine physician and a radiation oncologist. Total Body PET was acquired between 0 – 60 mins after the injection of FDG from the subject's feet. Patients was separated into high dynamic FDG metabolic (H‐DFM) group and low DFM(L‐DFM) group by the scatter plot of SUV‐mean and Ki‐mean of baseline scan for primary lung tumor. We compared lesion heterogeneity and different image‐derived PET metrics including the metabolic tumor volume (MTV), SUV total lesion glycolysis (SUV‐TLG), Patlak‐derived influx rate constant (Ki) TLG (Ki‐TLG). Results: Fifteen patients completed three scans (before treatment, after induction chemo‐immunotherapy, after CCRT). Eight patients were in H‐DFM group and 7 in L‐DFM group by baseline scan. Patients in H‐DFM group had significant decreased levels of MTV (P < 0.001), SUV‐TLG (P < 0.001) and Ki‐TLG (P < 0.001) both in primary lung tumor and metastatic lymph node by the induction chemo‐immunotherapy and CCRT. However, patients in L‐DFM group only had a significant reduction of MTV in primary lung tumor (P < 0.05). There was no significant difference in the MTV of metastatic lymph node (P > 0.5), the SUV‐TLG (P > 0.5) and Ki‐TLG (P > 0.5) of primary lung tumor and metastatic lymph node during the treatment course in L‐DFM group. Conclusion: Patients in H‐DFM group had the better treatment response of induction chemo‐immunotherapy and CCRT with significant decreased levels of MTV, SUV‐TLG and Ki‐TLG. Dynamic 18F‐FDG Total body PET Imaging could be regarded as a potential predictive marker of induction chemo‐immunotherapy and CCRT response in the setting of LA‐NSCLC.}, -DOI = {10.1016/j.ijrobp.2021.07.1257}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02321696/full} -} - - -Record #294 of 538 -@article{UMIN00000129508, -author = {UMIN000001295,}, -title = {Phase I trial of CHP-HER2-pulsed dendritic cell vaccine for advanced breast and non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000001295}, -year = {2008}, -accession_number = {ICTRP UMIN000001295}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: subcutaneous injection of CHP‐HER2‐pulsed dendritic cells each cell dose, 0.3x10E7, 1x10E7, 3x10E7 four doses every two weeks three subjects for each cell dose, dose‐escalating study CONDITION: breast cancer, non‐small cell lung cancer PRIMARY OUTCOME: adverse effect profiles, including events, frequency and grades. SECONDARY OUTCOME: HER2‐specific immune responses; anti‐tumor effects INCLUSION CRITERIA: Either of breast cancer or non‐small cell lung cancer patients, who have standard‐therapy‐refractory disease with unrescteable stage III, IV or metastatic lesions. Performanec status 0 to 2. Aged 20 to 75. Four weeks apart from the previous therapy, including surgery, chemotherapy, radiation therapy, heat therapy and other immuno‐therapy. Life expectancy of three month or longer. preserved bone marrow, liver, kidney functions. HER2‐expression of 2+ and 3+. Not having uncontrolled cardiac disease. Not having interstial pneumonia. Not having uncontrolled diabetes mellitus. Not having auto‐immune disease. Having informed consent.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01813501/full} -} - - -Record #295 of 538 -@article{Bondarenko21, -author = {Bondarenko, I, Sezer, A, Kilickap, S, Gumus, M, Ozguroglu, M, Gogishvili, M, Turk, HM, Cicin, I, Bentsion, D, Gladkov, O, Clingan, P, Sriuranpong, V, Rizvi, N, Mcginniss, J, Pouliot, J, Lee, S, Seebach, F, Lowy, I, Gullo, G, and Rietschel, P}, -title = {FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: subgroup Analysis from EMPOWER-Lung 1}, -journal = {Journal of thoracic oncology}, -volume = {16}, -number = {10}, -pages = {S951}, -year = {2021}, -accession_number = {EMBASE 2015170075}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *histology; *non small cell lung cancer; Adult; Cancer staging; Cancer survival; Chemoradiotherapy; Clinical trial; Conference abstract; Controlled study; Doublet chemotherapy; Drug therapy; Follow up; Gene expression; Histopathology; Human; Human tissue; Major clinical study; Male; Metastasis; Monotherapy; Overall response rate; Overall survival; Phase 2 clinical trial; Phase 3 clinical trial; Progression free survival; Protein expression; Radiotherapy; Randomized controlled trial; Regulated cell death; Statistical significance}, -abstract = {Introduction: Agents which inhibit the programmed death receptor‐1 (anti–PD‐1) have transformed treatment for patients with metastatic non‐small cell lung cancer (NSCLC), however there is paucity of prospective clinical data investigating the use of these agents in patients with locally advanced NSCLC (laNSCLC) who are not candidates for definitive concurrent chemoradiotherapy. In the Phase 3 EMPOWER‐Lung 1 Study (NCT03088540), cemiplimab, a PD‐1 inhibitor, demonstrated improved overall survival (OS) and progression‐free survival (PFS) in patients with advanced NSCLC and programmed cell death‐ligand 1 (PD‐L1) expression in ≥50% of tumor cells vs platinum‐doublet chemotherapy. This study allowed the enrollment of patients with laNSCLC, in addition to those with metastatic disease, providing the largest prospective randomized evidence of first‐line (1L) anti–PD‐1 monotherapy in this patient population. Here, we present a post‐hoc subgroup analysis of patients with laNSCLC from the PD‐L1 ≥50% population in EMPOWER‐Lung 1. Methods: In EMPOWER‐Lung 1, patients were randomized 1:1 to cemiplimab 350 mg intravenous every 3 weeks or investigator’s choice of platinum‐doublet chemotherapy. Patients with laNSCLC were those with stage 3B/3C disease who were not candidates for definitive concurrent chemoradiotherapy. Data cut‐off for this subgroup analysis was March 1, 2020. Results: In the PD‐L1 ≥50% population of EMPOWER‐Lung 1 (n=563), 87 (15.5%) patients had laNSCLC; cemiplimab (n=45) and chemotherapy (n=42). In the total laNSCLC population (n=87), median (range) age was 63.0 (31.0–81.0); male: 86.2%; non‐squamous histology: 36.8%; stage 3B cancer: 79.3%; and stage 3C cancer: 20.7%. At a median follow‐up of 11.6 months (interquartile range 7.2–18.2 months), cemiplimab provided significantly better PFS vs chemotherapy and numerically longer OS (not reaching statistical significance) (see Table). Objective response rates (ORR) and Kaplan–Meier estimated median duration of response (DOR) were also numerically improved with cemiplimab vs chemotherapy. Conclusion: In patients with laNSCLC and with PD‐L1 ≥50%, 1L cemiplimab monotherapy demonstrated a significant improvement in PFS, numerically longer OS, and numerically better ORR and DOR vs chemotherapy. These results support clinical benefit provided by cemiplimab 1L monotherapy for patients with laNSCLC with PD‐L1 ≥50%. [Formula presented] Keywords: Randomised Controlled Trials, Phase II and III Clinical Trials, Immune checkpoint inhibitors}, -DOI = {10.1016/j.jtho.2021.08.217}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02336844/full} -} - - -Record #296 of 538 -@article{NL-OMON5374723, -author = {NL-OMON53747,}, -title = {A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH A KRAS G12C MUTATION}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON53747}, -year = {2023}, -accession_number = {ICTRP NL‐OMON53747}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: • GDC‐6036: 200 mg or 400 mg orally, once a day, on Days 1‐21 of each 21‐day cycle. The dose of GDC‐6036 can be reduced up to two times for management of drug related toxicities. • Pembrolizumab: 200 mg IV, every 3 weeks, on Day 1 of each 21‐day cycle. Modification of the pembrolizumab dose, including dose reductions, is not permitted. CONDITION: NON‐SMALL CELL LUNG CANCER MET EEN KRAS G12C MUTATION ; NON‐SMALL CELL LUNG CANCER WITH A KRAS G12C MUTATION PRIMARY OUTCOME: 1. Occurrence of adverse events ; 2. Change from baseline at each visit in targeted safety parameters; SECONDARY OUTCOME: 1. Objective response rate ; 2. Duration of response ; 3. Progression free survival ; 4. Presence, frequency of occurrence, severity, and/or degree of interference ; with daily function of symptomatic side effects as assessed ; through use of the Patient‐Reported Outcomes Common Terminology Criteria for ; Adverse Events (PRO*CTCAE) ; 5. Change from baseline in symptomatic side effects, as assessed through use of ; the PRO‐CTCAE ; 6. Proportion of participants reporting "frequent" or "almost constant" ; diarrhea during the first three cycles of treatment according to the PRO ; CTCAE‐criteria ; 7. Proportion of participants reporting "severe" or "very severe" nausea or ; vomiting during the first three cycles of treatment according to the ; PRO‐CTCAE ; 8. Frequency of participant's response of the degree they are troubled with ; treatment symptoms, as assessed through use of the single‐item ; European Organisation for Research and Treatment of Cancer (EORTC) Item List 46 ; (IL46) ; 9. Plasma concentration of GDC‐6036 at specified timepoints ; 10. Identification of GDC‐6036 recommended dose in combination with ; pembrolizumab based on the totality of safety, activity, and PK data ; INCLUSION CRITERIA: ‐ Histologically or cytologically documented locally advanced unresectable or metastatic NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy ‐ No prior systemic treatment for advanced unresectable or metastatic NSCLC ‐ Confirmation of Biomarker eligibility: .. Documented history of the KRAS G12C mutation .. Documented history of PD‐L1 tumor cell expression >=1% ‐ Pre‐treatment tumor tissue along with an associated pathology report is required for all participants enrolled on study. Representative tumor specimens must be in formalin*fixed, paraffin embedded (FFPE) blocks (preferred) or 15 unstained, freshly cut, serial slides. Although 15 slides are required, if only 10 slides are available, the participant may be eligible for the study following consultation with the Sponsor ‐ Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 ‐ Measurable disease, as defi}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02715385/full} -} - - -Record #297 of 538 -@article{ChiCTR210005039721, -author = {ChiCTR2100050397,}, -title = {A randomized, open, positives parallel-controlled, multicenter phase III clinical trial to evaluate the efficacy and safety of FHND9041 versus afatinib in first-line treatment of EGFRm+ locally advanced or metastatic non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2100050397}, -year = {2021}, -accession_number = {ICTRP ChiCTR2100050397}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Control group:Afatinib 40mg, orally taken once daily;Experimental group:FHND9041 80mg, orally taken once daily; CONDITION: Non‐small cell lung cancer PRIMARY OUTCOME: Progression‐free survival; SECONDARY OUTCOME: Objective response rate;Overall survival;Duration of response;Disease control rate;Quality of life; INCLUSION CRITERIA: 1. Aged >= 18 years, gender is not limited; 2. Locally advanced or metastatic non‐small cell lung cancer diagnosed by histopathology or cytopathology (including recurrence after previous surgical treatment or newly diagnosed stage IIIb, IIIc or IV patients, lung cancer The staging standard is in accordance with the 8th edition of AJCC); 3. Have not received any systemic anti‐tumor therapy (such as standard chemotherapy, targeted therapy, biological therapy, immunotherapy, etc., except for local treatment for non‐target lesions); patients who have received adjuvant therapy or neoadjuvant therapy (chemotherapy, radiotherapy or other treatments) can be included in the group if their disease progresses 6 months after the end of treatment; 4. Has one of two common EGFR‐positive gene mutations that are sensitive to EGFR‐TKI treatment, including exon 19 deletion or L858R; 5. At least one tumor lesion at baseline can meet the following requirements: (1)}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02408641/full} -} - - -Record #298 of 538 -@article{ChiCTR210004916821, -author = {ChiCTR2100049168,}, -title = {A randomized and controlled clinical study of microwave ablation combined with camrelizumab / chemotherapy and compared with camrelizumab / chemotherapy in the first-line treatment of advanced non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2100049168}, -year = {2021}, -accession_number = {ICTRP ChiCTR2100049168}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Experimental group:microwave ablation combined with camrelizumab / chemotherapy;Control Group:Camrelizumab/chemotherapy; CONDITION: lung cancer PRIMARY OUTCOME: objective response rate; SECONDARY OUTCOME: overall survival;progression‐free survival;Relief maintenance time;disease control rate; INCLUSION CRITERIA: 1. Pathologically diagnosed non‐small cell lung cancer at the time of initial treatment; 2. Peripheral non‐small cell lung cancer with clinical stage IIIB/IIIC and IV (if distant metastasis occurs, it must be oligometastasis); 3. The subjects have not received systemic chemotherapy for advanced NSCLC before; 4. Sensitive mutations of EGFR, ALK, ROS‐1 and other driver genes are negative; 5. ECOG score is 0‐1; 6. Expected survival period >= 3 months; 7. In addition to ablation lesions, at least one measurable lesion (according to RECIST 1.1 criteria, the long diameter of CT scan of tumor lesions is >=10mm, and the short diameter of CT scan of lymph node lesions is >=15mm); 8. Subjects should have never received anti‐PD‐1 or PD‐L1 or CTLA‐4 or Car‐T immunotherapy; 9. Asymptomatic brain metastases or disease control after radiotherapy for brain metastases; 10. There is no significant abnormality in routine laboratory examinations (blo}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02424859/full} -} - - -Record #299 of 538 -@article{CTIS2023-506783-14-0024, -author = {CTIS2023-506783-14-00,}, -title = {A Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab (LIBRETTO-431)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTIS2023-506783-14-00}, -year = {2024}, -accession_number = {ICTRP CTIS2023‐506783‐14‐00}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: , Product Code:SCP134220, Pharmaceutical Form: , Other descriptive name: , Strength: , Product Name: , Product Code:SCP6094344, Pharmaceutical Form: , Other descriptive name: , Strength: , Product Name: SELPERCATINIB, Product Code:SUB193120, Pharmaceutical Form: CAPSULE, HARD, Other descriptive name: , Strength: , Product Name: SELPERCATINIB, Product Code:SUB193120, Pharmaceutical Form: CAPSULE, HARD, Other descriptive name: , Strength: , Product Name: , Product Code:SCP11423984, Pharmaceutical Form: , Other descriptive name: , Strength: , Product Name: , Product Code:SCP10337134, Pharmaceutical Form: , Other descriptive name: , Strength: CONDITION: Advanced or Metastatic RET Fusion‐Positive Non‐Small Cell Lung Cancer Therapeutic area: Diseases [C] ‐ Neoplasms [C04] INCLUSION CRITERIA: Participants must have advanced/metastatic non‐squamous non‐small cell lung cancer (NSCLC) that cannot be treated with surgery or radiation therapy, Participants must have a RET gene fusion and sufficient tumor tissue available for confirmatory testing, Participants must be in fair to good health and not Have another serious medical condition, Participants must not have had prior chemotherapy for metastatic lung cancer. chemotherapy in the adjuvant/neoadjuvant setting is permitted, Participants must not have disease that has spread to the brain and is causing symptoms, Participants must be able to swallow capsules, Participants must be willing to use highly effective contraception during the study}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02731299/full} -} - - -Record #300 of 538 -@article{CTIS2023-505211-21-0024, -author = {CTIS2023-505211-21-00,}, -title = {A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTIS2023-505211-21-00}, -year = {2024}, -accession_number = {ICTRP CTIS2023‐505211‐21‐00}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Carboplatin 10 mg/ml Intravenous Infusion, Product Code:PRD1161259, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Paclitaxel 6 mg/mL concentrate for solution for infusion, Product Code:PRD4300779, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: KEYTRUDA 25 mg/mL concentrate for solution for infusion, Product Code:PRD4323105, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: RO7247669, Product Code:PRD9859362, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Pemetrexed medac 1,000 mg powder for concentrate for solution for infusion, Product Code:PRD9941711, Pharmaceutical Form: CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: CONDITION: MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non‐small cell lung cancer Class: 100000004864 Previously untreated locally advanced or metastatic non‐small cell lung cancer (NSCLC) ; MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non‐small cell lung cancer Class: 100000004864 Therapeutic area: Diseases [C] ‐ Neoplasms [C04] PRIMARY OUTCOME: Main Objective: To evaluate the efficacy of tobemstomig in combination with platinum‐based chemotherapy (Arm A) compared with pembrolizumab plus platinum‐based chemotherapy (Arm B) on the basis of progression‐free survival (PFS) after randomization and objective response rate (ORR) Primary end point(s): 1. PFS after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1, 2. ORR, defined as the proportion of participants with a complete response or a partial response on two consecutive occasions = 4 weeks apart, as determined by the investigator according to RECIST v1.1 Secondary Objective: To evaluate the efficacy of Arm A compared with Arm B on the basis of overall survival (OS) after randomization, duration of response for participants with confirmed objective response, PFS and OS in participants by programmed death‐ligand 1 (PD‐L1) expression groups and the change from baseline to Week 12 in patient‐reported outcomes of lung cancer symptoms, physical functioning, role functioning, and global health status/quality of life, To evaluate the safety of tobemstomig plus platinum‐based chemotherapy (Arm A) compared with pembrolizumab plus platinum‐based chemotherapy (Arm B), To investigate the pharmacokinetics of tobemstomig, pemetrexed, carboplatin, and paclitaxel, To evaluate the immune response to tobemstomig on the basis of prevalence of anti‐drug antibodies (ADAs) to tobemstomig at baseline and incidence of ADAs to tobemstomig during the study INCLUSION CRITERIA: Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, Histologically or cytologically documented locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) NSCLC who are not eligible for curative surgery and/or definitive chemoradiotherapy, No prior systemic treatment for metastatic NSCLC, Known tumor PD‐L1 status, Confirmed availability of representative tumor specimens, Adequate hematologic and end‐organ function SECONDARY OUTCOME: Secondary end point(s):1. OS after randomization, defined as the time from randomization to death from any cause Secondary end point(s):10. Area under the concentration‐time curve tobemstomig Secondary end point(s):11. Half‐life of tobemstomig Secondary end point(s):12. Concentrations of tobemstomig in serum at specified timepoints Secondary end point(s):13.Concentrations of carboplatin (measured as total platin), pemetrexed, and paclitaxel in plasma at specified timepoints Secondary end point(s):14.Prevalence of ADAs to tobemstomig at baseline and incidence of ADAs to tobemstomig during the study Secondary end point(s):2. Duration of response for participants with confirmed objective response, defined as the time from the first occurrence of a confirmed objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1 Secondary end point(s):3. PFS and OS in participants with PD‐L1 expression, defined as tumor cells < 1%, 1%‐49%, and < 50%, as assessed by retrospective central PD‐L1 testing Secondary end point(s):4. Change from baseline to Week 12 in patient‐reported outcomes of lung cancer symptoms, physical functioning, role functioning, and global health status/quality of life, as assessed through the use of the European Organisation for Research and Treatment of Cancer Item Libraries Secondary end point(s):5. Incidence and severity of adverse events, with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 The severity of cytokine release syndrome will also be determined according to the American Society for Transplantation and Cellular Therapy Consensus Grading Scale. Secondary end point(s):6. Maximum concentration of tobemstomig Secondary end point(s):7. Time of maximum concentration of tobemstomig Secondary end point(s):8. Clearance of tobemstomig Secondary end point(s):9. Volume of distribution at steady state of tobemstomig}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02731144/full} -} - - -Record #301 of 538 -@article{EUCTR2018-001420-19-FR18, -author = {EUCTR2018-001420-19-FR,}, -title = {Study of safety and efficacy of INC280 in combination with PDR001, compared to chemotherapy, in advanced/ metastatic non-small cell lung cancer patients with no EGFR mutations or ALK rearrangements}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2018-001420-19-FR}, -year = {2018}, -accession_number = {ICTRP EUCTR2018‐001420‐19‐FR}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Code: INC280 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: Capmatinib CAS Number: 1197376‐85‐4 Current Sponsor code: INC280 Other descriptive name: INC280 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200‐ Product Code: INC280 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: Capmatinib CAS Number: 1197376‐85‐4 Current Sponsor code: INC280 Other descriptive name: INC280 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150‐ Product Code: PDR001 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Spartalizumab Current Sponsor code: PDR001 Other descriptive name: PDR001 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ Trade Name: Docétaxel EBEWE Product Name: Docetaxel Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: DOCETAXEL Other descriptive name: DOCETAXEL Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ CONDITION: Non‐small cell lung cancer ; MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non‐small cell lung cancer metastatic System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) ; MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non‐small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: Part 1: Run‐in ; • To assess the safety and tolerability of the capmatinib and spartalizumab combination.; Part 2: Randomized ; • To assess the overall survival of the combination of capmatinib and spartalizumab in comparison to docetaxel.; Primary end point(s): Run‐in Part: Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs and ECGs, dose interruptions, reductions, and dose intensity; Randomized Part: Overall Survival; Secondary Objective: • To assess the objective response rate (ORR), disease control rate (DCR), progression‐free survival (PFS), duration of response (DOR), and time to response (TTR) of the capmatinib and spartalizumab combination and that of docetaxel; • To assess the safety profile of capmatinib and spartalizumab combination therapy; • To characterize the pharmacokinetics of capmatinib and spartalizumab as a combination therapy in this patient population; • To evaluate the prevalence and incidence of immunogenicity; Timepoint(s) of evaluation of this end point: Run‐in Part: During the first 8 weeks (56 days) of treatment; Randomized Part: Time from date of randomization to date of death due to any cause.; SECONDARY OUTCOME: Secondary end point(s): Objective response rate (ORR), disease control rate (DCR), progression‐free survival (PFS), duration of response (DOR), and time to response (TTR) based on RECIST 1.1; Incidence and severity of AEs and SAEs; Pharmacokinetic parameters (e.g. Ctrough, Cmax, AUC); Antidrug antibodies (ADA) prevalence at baseline and ADA incidence on treatment Timepoint(s) of evaluation of this end point: At final data analysis INCLUSION CRITERIA: 1. Written informed consent must be obtained prior to any screening procedures 2. Adult = 18 years old at the time of informed consent 3. Histologically confirmed locally advanced/metastatic (stage IIIB or IV per AJCC/IASLC v. 8) NSCLC 4. Histologically or cytologically confirmed diagnosis of NSCLC that is both EGFR wt status and ALK‐ negative rearrangement status: • Patients with NSCLC of pure squamous cell histology can enter screening without EGFR mutation or ALK rearrangement testing or result; however, patients with pure squamous cell histology who are known to have EGFR mutations in exons 19 or 21 or ALK rearrangements will be excluded 5. Patients must have demonstrated progression of locally advanced/ metastatic NSCLC (stage IIIB, not amenable for definitive chemo‐irradiation, or stage IV) following one prior platinum doublet and one prior PD‐(L)1 checkpoint inhibitor (either alone or in combination) • Maintenance therapy given a}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01950856/full} -} - - -Record #302 of 538 -@article{Reck22, -author = {Reck, M, Kollmeier, J, Kern, J, Hoffknecht, P, Sebastian, M, Tufman, A, Kambartel, K, Keller, R, Maenz, M, and Sadjadian, P}, -title = {EP08.01-057 Pembrolizumab Maintenance in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sNSCLC) - AIO-TRK-0115/PRIMUS}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S366‐S367}, -year = {2022}, -accession_number = {EMBASE 2020097703}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *drug tolerability; *squamous cell lung carcinoma; Acute kidney failure; Adult; Bleeding; Cancer chemotherapy; Cancer staging; Cancer survival; Clinical trial; Conference abstract; Double blind procedure; Drug safety; Drug therapy; Female; Gene expression; Human; Human cell; Hyperthyroidism; Immunotherapy; Maintenance therapy; Major clinical study; Male; Myocarditis; Nephritis; Overall response rate; Overall survival; Phase 2 clinical trial; Progression free survival; Protein expression; Quality of life; Questionnaire; Randomization; Randomized controlled trial; Treatment duration}, -abstract = {Introduction: Platinum‐containing chemotherapy represents one treatment opportunity for patients with advanced squamous NSCLC. With respect to comorbidities and decreased performance status, frequently seen in patients with sNSCLC novel effective and well tolerable treatment opportunities are required to enhance efficacy of systemic treatment. The PRIMUS trial was conducted to explore the potential of pembrolizumab maintenance treatment after induction treatment with platinum‐based chemotherapy. Methods: In this phase II multi‐center, double‐blind trial, patients with stage IV squamous NSCLC and at least stable disease after at least 2 cycles of first‐line chemotherapy with cisplatin or carboplatin were randomized 1:1 between Q3W maintenance treatment with pembrolizumab 200 mg and placebo, respectively. Patients were included irrespective of tumor PD‐L1 expression. Maximum treatment duration was 2 years. The primary endpoint was progression‐free survival (PFS) measured from randomization, secondary endpoints included objective response rate (ORR), overall survival (OS) measured from randomization, PD‐L1 expression in tumor samples, safety and tolerability, and quality of life by FACT‐L and LCSS questionnaires. Results: Planned patient enrollment of 65 per arm was not met due to changes of clinical treatment standards for first‐line treatment. Pembrolizumab (P) maintenance was administered to 16 patients, while 18 patients received placebo (Pla). Survival results favor P maintenance over placebo: Median PFS with P was 9.5 mo [95% CI 1.5‐23.5] versus 4.8 mo [95% CI 1.8‐10.5] with Pla. PFS rate at 6, 12 and 18 months was 50.3% [95% CI 23.1‐72.4%], 35.9% [95% CI 13.1‐59.6%] and 35.9% [95% CI 13.1‐59.6%] with P and 36.1% [95% CI 15.0‐57.9%], 18.1% [95% CI 4.5‐39.0%] and 9.0% [95% CI 0.7‐30.9%] with Pla. Median OS was 24.0 mo [95% CI 9.5‐30.9] with P and 10.9 mo [95% CI 4.8‐39.2] with Pla. OS rates at 6 and 12 months were 86.7% [95% CI 56.4‐96.5%] and 79.4% [95% CI 48.8‐92.9%] with P versus 69.3% [95% CI 41.1‐ 85.9] and 44.1% [95% CI 20.0‐65.9%] with Pla. Response and SD from start of maintenance: 11.1% vs 14.4% and 42.3% vs 23.1% (P vs Pla). AEs ≥ grade 3 potentially related to P according to investigator assessment occurred in 4 patients: grade 3 hyperthyreosis, myocarditis, nephritis and acute renal failure, and grade 4 bronchopulmonary hemorrhage. Conclusions: Our results indicate a notable benefit of the pembrolizumab maintenance strategy compared to placebo maintenance treatment, both in terms of PFS and OS. This is a remarkable finding given that the number of treated patients was considerably lower than planned. Further exploration is warranted. Keywords: Immunotherapy, Maintenance, Squamous Cell NSCLC}, -DOI = {10.1016/j.jtho.2022.07.629}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461464/full} -} - - -Record #303 of 538 -@article{Haakensen21, -author = {Haakensen, VD, Horndalsveen, H, Nymoen, HM, Holgersson, G, Land, LH, Koivunen, J, Cicenas, S, Oselin, K, Madebo, T, Van Helvoirt, R, Helbekkmo, N, Gronberg, BH, Aanerud, M, Rogg, L, and Helland, A}, -title = {P17.02 Durvalumab After chemoRadioTherapy (DART) for NSCLC Patients – a Phase II Translational and Biomarker Study}, -journal = {Journal of thoracic oncology}, -volume = {16}, -number = {3}, -pages = {S351‐S352}, -year = {2021}, -accession_number = {EMBASE 2011421808}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *chemoradiotherapy; *non small cell lung cancer; *relapse; Adult; Advanced cancer; Cancer prognosis; Cancer recurrence; Cancer staging; Cancer survival; Cell infiltration; Clinical outcome; Clinical trial; Conference abstract; Controlled study; Drug therapy; Female; Follow up; Gene expression; Genetic marker; Human; Human tissue; Immunocompetent cell; Immunotherapy; Intestine flora; Male; Meta analysis; Nonhuman; Overall survival; Phase 2 clinical trial (topic); Positron emission tomography‐computed tomography; Prediction; Primary tumor; Progression free survival; Protein expression; Quality of life; Radiotherapy; Randomization; Randomized controlled trial (topic); Rectum hemorrhage; Tumor biopsy; Tumor microenvironment}, -abstract = {Introduction: Lung cancer is the most common cause of cancer‐related deaths world‐wide. Approximately one third of patients with non–small‐cell lung cancer (NSCLC) are diagnosed with locally advanced disease (stage III) at diagnosis1, for whom the standard of care is platinum‐based doublet chemotherapy concurrent with radiotherapy resulting in 5‐year survival of 15‐20%. In the PACIFIC study, a superior outcome was observed for patients receiving the checkpoint inhibitor durvalumab after chemoradiation2. The median progression‐free survival from randomization was 16.8 month with durvalumab versus 5.6 months with placebo (p<0.001). The benefit was found in the intention to treat‐population, and PD‐L1 expression was not a good predictive biomarker. Despite impressive results, many patients relapsed, and more knowledge of the biology underlying responses and resistance is needed. Durvalumab is approved by the FDA for patients regardless of PD‐L1 status, while EMA limited the indication to patients whose tumours harbour PD‐L1 expression of ≥1%. Methods: This is an investigator initiated, multi‐centre phase II translational study. A total of 100 stage III NSCLC patients not progressing after chemoradiotherapy will be included from the Nordic and Baltic countries, 50 PD‐L1 negative and 50 PD‐L1 positive patients. Astra Zeneca provides durvalumab for all patients. The DART trial aims to identify prognostic and predictive biomarkers which may be used to identify patients who would benefit from durvalumab after chemoradiation. Our hypothesis is that the immunological microenvironment in the tumour influences response. Tumour biopsies will be collected before treatment, after chemoradiation and at progression. Blood and stool samples will be collected and images will be performed before and during treatment as well as during follow‐up. The analyses planned are described below linked to the study objectives Primary objectives: To investigate the immunological response, tumour development (if present) and dynamics in the tumour micro‐environment and in circulation. This includes the following: ‐ Evaluation of immune cell infiltration in the primary tumour and in the relapse tumour (if present) ‐ Evaluation of circulating biomarkers related to tumour (ctDNA) and host response (immune cells) ‐ Evaluations of genomic characteristics of the primary tumour and the relapse (if present) To investigate tumour mutational burden in tumour tissue and blood samples, as predictors for clinical response To evaluate imaging protocols for response prediction. PET‐CT will be done for screening, after chemoradiation and after 12 months. To investigate potential changes in gut microbiota in serial samples from patients treated with durvalumab and investigate whether microbiota profile prior to, or dynamic changes during treatment can predict clinical outcome Secondary objectives: To evaluate toxicity and quality of life in lung cancer patients receiving PDL1‐inhibitor after chemoradiotherapy To evaluate progression‐free survival and overall survival References 1. Aupérin A, Le Péchoux C, Rolland E, et al. Meta‐analysis of concomitant versus sequential radiochemotherapy in locally advanced non‐small‐cell lung cancer. J Clin Oncol. 2010;28(13):2181‐2190. 2. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018 Keywords: biomarker, Immunotherapy, locally advanced NSCLC}, -DOI = {10.1016/j.jtho.2021.01.555}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02278827/full} -} - - -Record #304 of 538 -@article{EUCTR2021-005115-32-GR22, -author = {EUCTR2021-005115-32-GR,}, -title = {Phase 2 Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated Advanced/Metastatic NonSmallCell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-005115-32-GR}, -year = {2022}, -accession_number = {ICTRP EUCTR2021‐005115‐32‐GR}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Dostarlimab Product Code: TSR‐042, GSK4057190 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Dostarlimab CAS Number: 2022215‐59‐2 Current Sponsor code: GSK4057190 Other descriptive name: Dostarlimab (50 mg/mL) Solution for Intravenous Infusion Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ Product Name: GSK4428859A Product Code: GSK4428859A Pharmaceutical Form: Solution for infusion INN or Proposed INN: GSK4428859A CAS Number: 2574438‐65‐4 Current Sponsor code: GSK4428859A Other descriptive name: EOS884448 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20‐ Trade Name: KEYTRUDA Product Name: Pembrolizumab Pharmaceutical Form: Solution for infusion INN or Proposed INN: Pembrolizumab CAS Number: 1374853‐91‐4 Current Sponsor code: MK‐3475 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ CONDITION: Non‐small Cell Lung Cancer ; MedDRA version: 21.1 Level: PT Classification code 10059515 Term: Non‐small cell lung cancer metastatic System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: • To evaluate the antitumor activity of novel immunotherapy combinations compared with pembrolizumab in participants with PD‐L1 high (TC/TPS =50%) NSCLC Primary end point(s): • ORR per RECIST 1.1 by investigator assessment Secondary Objective: • To assess the dose response relationship of novel immunotherapy combinations across a range of the novel components' dose levels and fixed dostarlimab dose (may not apply to all novel combinations); • To further assess the clinical activity of novel immunotherapy combinations compared with pembrolizumab in participants with PD‐L1 high (TC/TPS =50%); • To evaluate the antitumor activity of novel immunotherapy combinations via treatment arm comparisons for assessment of contribution of components for the combination regimens; • To further characterize the safety of novel immunotherapy combinations; • To determine the immunogenicity of individual agents comprising novel immunotherapy combinations; • To characterize the PK properties of novel immunotherapy combinations Timepoint(s) of evaluation of this end point: • every 6 weeks after randomization until week 25, every 9 weeks until week 52, and every 12 weeks thereafter until RECIST 1.1 defined PD." SECONDARY OUTCOME: Secondary end point(s): • ORR per RECIST v1.1 by investigator assessment at different dose levels; • PFS per RECIST 1.1 by investigator assessment; • OS; • DOR per RECIST 1.1 by investigator assessment; • ORR, PFS, and DOR per RECIST 1.1 by investigator assessment, and OS for assessment of contribution of components for the combination regimens; • Incidence of TEAEs, SAEs and AESI; • Incidence of TEAEs/SAEs leading to dose modifications or study intervention discontinuation; • Incidence of ADA; • Plasma PK parameters; Timepoint(s) of evaluation of this end point: • ORR: Every 6 weeks after randomization until week 25, every 9 weeks until week 52, and every 12 weeks thereafter until RECIST 1.1 defined PD."; • PFS: The time from the date of randomization to the date of first documented PD per RECIST 1.1 by investigator assessment, or death by any cause, whichever occurs first; • OS: Following treatment discontinuation, survival status will be assessed every 12 weeks after the last dose of study intervention, until death or participant’s withdrawal; • DOR: Time from the date of first documented CR or PR until the date of first documented PD per RECIST 1.1; ; All SAEs and AESI, Plasma PK parameters, Incidence of ADA will be collected throughout the study as per protocol; ; Refer protocol for other timepoints INCLUSION CRITERIA: Key Inclusion Criteria 1. Is capable of giving signed informed consent 2. Is, at the time of signing the ICF, at least 18 years old or the legal age of consent in the jurisdiction in which the study is taking place. 3. Has a histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or nonsquamous). Mixed tumors will be categorized by the predominant cell type; if small cell or neuroendocrine elements are present, the participant is ineligible. 4. Has not received prior systemic therapy for their locally advanced or metastatic NSCLC. NOTE: Completion of treatment with cytotoxic chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed if therapy was completed at least 6 months prior to the diagnosis of locally advanced or metastatic disease. Prior treatment with neoadjuv}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02513025/full} -} - - -Record #305 of 538 -@article{Zhou20, -author = {Zhou, Q, Chen, M, Wu, G, Chang, J-H, Jiang, O, Cui, J-W, Han, G, Lin, Q, Fang, J, Chen, G-Y, and Wu, Y-L}, -title = {GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/ unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy}, -journal = {Translational lung cancer research}, -volume = {9}, -number = {5}, -pages = {2008‐2015}, -year = {2020}, -accession_number = {EMBASE 2008595977}, -publication type = {Journal article}, -keywords = {*advanced cancer /drug therapy /radiotherapy; *chemoradiotherapy; *consolidation chemotherapy; *non small cell lung cancer /drug therapy /radiotherapy; Adult; Article; Controlled study; Double blind procedure; Drug efficacy; Drug safety; Follow up; Human; Multicenter study; Phase 3 clinical trial; Progression free survival; Randomized controlled trial; Response evaluation criteria in solid tumors}, -abstract = {Background: In China, platinum‐based doublet chemotherapy is the standard treatment for patients who have unresectable stage III non‐small cell lung cancer (NSCLC), administered with radiotherapy on either a concurrent or sequential basis. However, NSCLC patients who undergo this treatment can expect poor median progression‐free survival (PFS) of around 8‐10 months and a dismal 5‐year overall survival (OS) rate of about 15%. In the recent PACIFIC trial, durvalumab was demonstrated to hold significant clinical benefit for patients with locally advanced/unresectable NSCLC who experienced no disease progression after definitive concurrent chemoradiotherapy (cCRT). CS1001 is the first full‐length, fully human immunoglobin G4 (IgG4) monoclonal antibody (mAb) that targets programmed death ligand‐1 (PD‐L1) created through the OMT transgenic rat platform. The phase Ia/Ib study indicated CS1001 was well tolerated and exhibited anti‐tumor potential with a range of tumors. GEMSTONE‐301 is a phase III randomized, double‐blind, study to explore the efficacy and safety of CS1001 compared with a placebo as consolidation therapy for stage III unresectable NSCLC patients. Methods: In this trial, eligible patients will be randomized to receive CS1001 1,200 mg or placebo, every 3 weeks (Q3W). The primary endpoint will be investigator‐assessed PFS, based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The secondary endpoints will include OS, PFS assessment based on Blinded Independent Center Review (BICR), objective response rate (ORR), other efficacy measurements, safety, and tolerability. Discussion: This phase III trial will determine the efficacy and safety of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) NSCLC who did not have disease progression after prior concurrent/sequential chemoradiotherapy (cCRT or sCRT), and is the first phase III trial on an anti‐PD‐L1 mAb initiated in China for this indication. Protocol version: Version 3.0/September 12, 2019.}, -DOI = {10.21037/tlcr-20-608}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02208353/full} -} - - -Record #306 of 538 -@article{EUCTR2019-004773-29-DE20, -author = {EUCTR2019-004773-29-DE,}, -title = {A Study of Atezolizumab and Tiragolumab compared with Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Concurrent Platinum-based Chemoradiation}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-004773-29-DE}, -year = {2020}, -accession_number = {ICTRP EUCTR2019‐004773‐29‐DE}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: tiragolumab Product Code: RO7092284/F03‐01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: TIRAGOLUMAB CAS Number: 1918185‐84‐8 Current Sponsor code: RO7092284 Other descriptive name: MTIG7192A, anti‐TIGIT, aTIGIT, PRO400402, 4.1D3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60‐ Trade Name: TECENTRIQ® Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ATEZOLIZUMAB Current Sponsor code: RO5541267 Other descriptive name: MPDL3280A Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60‐ Trade Name: IMFINZI Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: DURVALUMAB CAS Number: 1428935‐60‐7 Current Sponsor code: RO7444835 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ Trade Name: IMFINZI Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: DURVALUMAB CAS Number: 1428935‐60‐7 Current Sponsor code: RO7444835 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ CONDITION: Non‐small cell lung cancer (NSCLC) ; MedDRA version: 21.1 Level: PT Classification code 10029519 Term: Non‐small cell lung cancer stage III System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: • To evaluate the efficacy of atezolizumab in combination with tiragolumab compared with durvalumab in the intent to treat (ITT) and the programmed death‐ligand 1 (PD‐L1)‐positive populations based on an independent review facility‐assessed progression‐free survival. Primary end point(s): 1. Independent review facility‐assessed Progression Free Survival in ITT and PD‐L1 positive populations. Secondary Objective: • To evaluate the efficacy of atezolizumab plus tiragolumab compared with durvalumab in the ITT and the PD‐L1‐positive populations based on OS after randomization, Investigator ‐assessed progression‐free survival, , time to death or distant metastasis, confirmed objective response rate, duration of response in patients with confirmed objective response rate, progression‐free survival rate, OS rate, time to confirmed deterioration ; • To evaluate the safety and tolerability of tiragolumab plus atezolizumab compared with placebo plus durvalumab; • To characterize pharmacokinetics of tiragolumab and atezolizumab; • To evaluate the immune response to tiragolumab plus atezolizumab. Timepoint(s) of evaluation of this end point: 1. Up to 90 months. SECONDARY OUTCOME: Secondary end point(s): 1. Overall survival; 2. Investigator ‐assessed Progression Free Survival ; 3. Time to death or distant metastasis; 4. Confirmed Objective response rate ; 5. Duration of Response in patients with confirmed ORR; 6. Progression Free Survival rate at 12 months, 18 months, and 24 months; 7. Overall Survival rate at 12 months, 24 months, 36 months, and 48 months; 8. Time to confirmed deterioration ; 9. Incidence and severity of adverse events; 10. Serum concentrations of tiragolumab and atezolizumab at specified timepoints; 11. Prevalence and incidence of anti‐drug antibodies (ADAs) to tiragolumab and atezolizumab at baseline and during the study. Timepoint(s) of evaluation of this end point: 1‐5. Up to 90 months ; 6. At 12 months, 18 months, and 24 months; 7. At 12 months, 24 months, 36 months, and 48 months; 8‐9. Up to 90 months; 10 and 11. Day 1 of Cycle 1‐4,8,10,12 and at treatment discontinuation or completion visit; for tiragolumab: Day 1 of cycle 3. INCLUSION CRITERIA: Age>= 18 years ‐ Eastern Cooperative Oncology Group Performance Status of 0 or 1 ‐ Histologically or cytologically documented NSCLC with locally advanced unresectable Stage III NSCLC of either squamous or non‐squamous histology ‐ Whole‐body positron emission tomography (PET)‐CT scan for the purposes of staging, performed prior and within 42 days of the first dose of concurrent chemoradiotherapy (CRT) ‐ At least two prior cycles of platinum‐based chemotherapy concurrent with RT (CRT), which must be completed within 1 to 42 days prior to randomization in the study ‐ The RT component in the CRT must have been at a total dose of radiation of 60 Gy±10% (54 Gy to 66 Gy) administered by intensity‐modulated radiotherapy (preferred) or 3D‐conforming technique ‐ No progression during or following concurrent platinum‐based CRT ‐ Tumor PD‐L1 expression, as determined by the investigational Ventana PD‐L1 (SP263) CDx assay and documented by cent}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02186869/full} -} - - -Record #307 of 538 -@article{Horvath23, -author = {Horvath, L, and Pall, G}, -title = {ESMO 2022 personal non-small lung cancer (NSCLC) highlights}, -journal = {Memo - magazine of european medical oncology}, -volume = {16}, -number = {2}, -pages = {97‐99}, -year = {2023}, -accession_number = {EMBASE 2023092307}, -publication type = {Journal article}, -keywords = {*non small cell lung cancer /drug therapy /radiotherapy /surgery; Adjuvant therapy; Cancer adjuvant therapy; Cancer immunotherapy; Cancer radiotherapy; Cancer recurrence; Cancer staging; Diarrhea /side effect; Disease course; Disease free survival; Drug dose reduction; Drug efficacy; Drug safety; Drug withdrawal; ECOG Performance Status; Gene mutation; Health care organization; Human; Hypertransaminasemia /side effect; Hypothyroidism /side effect; Liver disease /side effect; Molecularly targeted therapy; Overall survival; Patient selection; Phase 3 clinical trial (topic); Pneumonectomy; Pneumonia /side effect; Progression free survival; Randomized controlled trial (topic); Review; Treatment outcome; Treatment response; Tumor regression}, -abstract = {In this article, we summarize our personal non‐small cell lung cancer (NSCLC) highlights from the ESMO 2022 meeting, covering developments in early‐ and advanced‐stage NSCLC. In early‐stage disease, many studies underlined possibilities of neoadjuvant and adjuvant treatment, including neoadjuvant immunotherapy combination strategies (INCREASE trial) or adjuvant targeted therapy with osimertinib in epidermal growth factor receptor (EGFR)‐mutated NSCLC (updated results of ADAURA), both promoting interesting concepts to further improve outcomes in early‐stage NSCLC. In late‐stage disease, results from CodeBreak200, the first randomized phase III trial investigating the selective KRAS‐G12C inhibitor sotorasib, define this agent as the new standard‐of‐care in a molecular‐defined patient population after progression on platinum‐doublet and immunotherapy. The IPSOS study supports atezolizumab as preferred first‐line therapy in unfit older patients.}, -DOI = {10.1007/s12254-023-00887-0}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02596724/full} -} - - -Record #308 of 538 -@article{Weller16, -author = {Weller, M, Vlahovic, G, Khasraw, M, Brandes, AA, Zwirtes, R, Tatsuoka, K, Carpentier, AF, Reardon, DA, and Van Den Bent, M}, -title = {A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)-CheckMate-548}, -journal = {Annals of oncology}, -volume = {27}, -year = {2016}, -accession_number = {EMBASE 613910990}, -publication type = {Journal article; Conference proceeding}, -keywords = {*glioblastoma; *non small cell lung cancer; *visually impaired person; Adult; Clinical trial; Comparative effectiveness; Controlled clinical trial; Controlled study; Diagnosis; Disease duration; Drug combination; Drug therapy; Exploratory research; Follow up; Human; Karnofsky Performance Status; Kidney carcinoma; Major clinical study; Metastatic melanoma; Methylation; Overall survival; Pharmacokinetics; Phase 2 clinical trial; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Safety; Single blind procedure; Study design; Toxicity; Tumor growth; Young adult}, -abstract = {Background: GBM, the most common adult primary brain tumor, has an aggressive clinical course and a poor prognosis. Approximately 40% of pts with GBM have tumors with a methylated MGMT gene promoter, which is associated with DNA repair. In these pts, TMZ may induce DNA damage and cell death due to silencing of the MGMT promoter, a mechanism potentially augmented by combination with checkpoint inhibitors. Nivolumab, a fully human IgG4 monoclonal antibody to the programmed death‐1 receptor, has demonstrated overall survival (OS) benefit in the treatment of metastatic melanoma, non‐small cell lung cancer, and advanced renal cell carcinoma. CheckMate‐548 (NCT02667587) is a phase 2, randomized, single‐blind study evaluating the efficacy and safety of TMZ/RT ‐> TMZ with nivolumab or PBO in pts with newly diagnosed MGMT‐methylated GBM. In a companion phase 3 trial (CheckMate‐498; NCT02617589), eligible pts with MGMT‐unmethylated tumors (N = 550) will be randomized to receive nivolumab + RT followed by nivolumab, or TMZ/RT ‐> TMZ, with OS as the primary endpoint. Trial design: Eligibility criteria include newly diagnosed, histologically confirmed supratentorial GBM in pts aged ≥18 years with Karnofsky performance status ≥70, and a tumor test result that shows a MGMT methylated, partially methylated, or indeterminate methylation type. Pts previously treated for GBM other than by resection and those with recurrent or secondary GBM are ineligible. Approximately 320 pts, stratified by partial or complete resection, will be randomized 1:1 to receive TMZ/RT ‐> TMZ in combination with nivolumab or PBO. Treatment will continue until disease progression or unacceptable toxicity. The primary objective is OS in pts treated with TMZ/RT ‐> TMZ and nivolumab versus TMZ/RT ‐> TMZ and PBO; the secondary objective is progression‐free survival. Select exploratory objectives include safety, biomarker analyses, and neurocognitive outcomes. In the follow‐up period, safety and tolerability, tumor progression, and survival will be evaluated.}, -DOI = {10.1093/annonc/mdw367.34}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01296292/full} -} - - -Record #309 of 538 -@article{Mallesara20, -author = {Mallesara, G, Kumar, M, Nordman, I, Mandaliya, H, Ludbrook, J, Day, F, Govindarajulu, G, Paterson, R, Gupta, S, Gedye, C, Nadiotis, L, and Clark-Pitrolo, S}, -title = {Supervised exercise program in lung cancer patients on curative intent chemoradiation}, -journal = {Asia-Pacific journal of clinical oncology}, -volume = {16}, -number = {SUPPL 6}, -pages = {42}, -year = {2020}, -accession_number = {EMBASE 634009286}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *chemoradiotherapy; *exercise; *lung cancer; Adult; Advanced cancer; Cancer prognosis; Cancer staging; Clinical article; Conference abstract; Controlled study; Demography; Drug therapy; Feasibility study; Female; Follow up; Human; Human cell; Immunotherapy; Long term survival; Male; Neutrophil; Physiotherapist; Prospective study; Radiotherapy; Randomized controlled trial; Sample size; Writing}, -abstract = {Background: There is emerging recognition of the positive impact of exercise in cancer management. Currently, there are several clinical trials underway in different types of cancers assessing the impact of exercise on cancer treatment outcomes, including overall survival. Exercise has also been proposed to help with cancer‐related fatigue. Stage IIIA/B locally advanced non‐small cell cancers are generally treated with definitive (curative) chemoradiation. Although the recent introduction of maintenance immunotherapy (durvalumab) has improved outcomes, overall long‐term survival remains unsatisfactory. We plan to study the role of exercise in a group of lung cancer patients. We propose to conduct a prospective feasibility study incorporating supervised exercise program in lung cancer patients receiving definitive chemoradiation. Successful feasibility as demonstrated by this study is expected to lead to a larger randomized trial exploring the said benefits of exercise. Aims: To establish the feasibility of supervised exercise program in patients who are receiving definitive chemoradiation for lung cancer. Methods: Twenty eligible patients will be identified through lung multidisciplinary meetings and recruited to the study. We aim to administer 45 min of tailored exercise program for three sessions in a week. The exercise sessions will be conducted at The Kaden Centre under the supervision of a qualified physiotherapist. The program will begin 2 weeks prior to commencement of treatment and continue throughout the chemoradiation and beyond to a total of 10 weeks. We will document modified Glasgow prognostic score and neutrophil leucocyte ratio at three timepoints on the study ‐ prior to entering the exercise program, prior to starting chemoradiation, and 4 weeks after completion of treatment. Demographic data would also be collected. Other than the exercise program, the clinical care of patients and their long‐term follow up will be as per existing practice. Statistics:Wewill use only descriptive statistics given the small sample size and nature of the study.We expect that at least 14 patients completing minimum of 15 sessions on the program would demonstrate feasibility and allow us to continue to a larger study.We will also document the proportion of the patients who were approached to participate in the study and declined. Current status of the study: Protocol writing.}, -DOI = {10.1111/ajco.13473}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02243960/full} -} - - -Record #310 of 538 -@article{CTIS2022-502031-20-0024, -author = {CTIS2022-502031-20-00,}, -title = {A Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients with Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTIS2022-502031-20-00}, -year = {2024}, -accession_number = {ICTRP CTIS2022‐502031‐20‐00}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: KEYTRUDA 25 mg/mL concentrate for solution for infusion, Product Code:PRD4323786, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Tiragolumab, Product Code:PRD7846761, Pharmaceutical Form: CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Tecentriq 1 200 mg concentrate for solution for infusion, Product Code:PRD5434943, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Tiragolumab placebo, Product Code:N/A, Pharmaceutical Form: N/A, Other descriptive name: N/A , Strength: , Pharmaceutical form of the placebo: N/A CONDITION: MedDRA version: 20.0Level: LLTClassification code: 10079440Term: Non‐squamous non‐small cell lung cancer Class: 10029104 Non‐squamous non‐small cell lung cancer (NSCLC) ; MedDRA version: 20.0Level: LLTClassification code: 10079440Term: Non‐squamous non‐small cell lung cancer Class: 10029104 Therapeutic area: Diseases [C] ‐ Neoplasms [C04] PRIMARY OUTCOME: Main Objective: To evaluate the efficacy of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with pembrolizumab plus pemetrexed and carboplatin/cisplatin (Arm B) on the basis of confirmed objective response rate (ORR) and progression‐free survival (PFS), as assessed by investigators according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) (Phase 2) and to evaluate the efficacy of Arm A compared with Arm B on the basis of PFS, as determined by the investigator according to RECIST v1.1, and overall survival (OS) (Phase 3) Primary end point(s): 1. Investigator‐Assessed Confirmed Objective Response Rate (ORR) (Phase 2), 2. Investigator‐Assessed Progression‐free survival (PFS) (Phase 2 and Phase 3), 3. Overall survival (Phase 3) Secondary Objective: 1. To evaluate the efficacy of Arm A compared with Arm B on the basis of OS, duration of response (DOR), and time to confirmed deterioration (TTCD) in patient‐reported physical functioning and global health status/quality of life (GHS/QoL) (Phase 2), 2. To evaluate the efficacy of Arm A compared with Arm B on the basis of PFS, as determined by an independent review facility according to RECIST v1.1, PFS and OS in patients with PD‐L1 expression at TC = 50% and TC = 1% cut‐off, PFS rate at 6 months and 12 months, OS rate at 12 months and 24 months, confirmed ORR, DOR, and TTCD in patient‐reported physical functioning and GHS/QoL (Phase 3), 3. To evaluate the safety of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin compared with placebo in combination with pembrolizumab plus pemetrexed and carboplatin/cisplatin, 4. To characterize the pharmacokinetics of tiragolumab and atezolizumab, 5. To evaluate the immune response to tiragolumab and atezolizumab INCLUSION CRITERIA: 1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, 2. Histologically or cytologically documented locally advanced unresectable or metastatic non‐squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy, 3. No prior systemic treatment for metastatic non‐squamous NSCLC, 4. Known tumor PD‐L1 status, 5. Measurable disease, as defined by RECIST v1.1, 6.Negative HIV test and Serology test negative for active hepatitis B virus and active hepatitis C virus at screening SECONDARY OUTCOME: Secondary end point(s):1. Overall survival (Phase 2) Secondary end point(s):10. Frequency of patients’ response of the degree they are troubled with treatment symptoms, as assessed through use of the single‐item EORTC IL46 (Phase 2 and Phase 3) Secondary end point(s):11. Serum concentrations of tiragolumab and atezolizumab (Phase 2 and Phase 3) Secondary end point(s):12. Percentage of participants with anti‐drug antibodies (ADAs) to tiragolumab (Phase 2 and Phase 3) Secondary end point(s):13. Percentage of participants with ADAs to atezolizumab (Phase 2 and Phase 3) Secondary end point(s):2. PFS as determined by an independent review facility (IRF) (Phase 3) Secondary end point(s):3. PFS and OS in patients with PD L1 expression at TC =50% and TC =1% cut‐off, as determined by central testing with Ventana PD‐L1 (SP263) assay (Phase 3) Secondary end point(s):4. PFS at 6 months and 12 months (Phase 3) Secondary end point(s):5. OS rate at 12 months and 24 months (Phase 3) Secondary end point(s):6. Confirmed ORR (Phase 3) Secondary end point(s):7. Duration of response for patients with a confirmed objective response, defined as the time from first occurrence of a confirmed objective response to disease progression or death from any cause (whichever occurs first) (Phase 2 and Phase 3) Secondary end point(s):8. Time to confirmed deterioration (TTCD) in patient‐reported physical functioning and global health status/quality of life (GHS/QoL), as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality‐of‐Life Questionnaire Core 30 (QLQ‐C30), and in patient‐reported lung cancer symptoms for cough, dyspnea (a multi‐item subscale), and chest pain, as measured through the use of the EORTC Quality‐of‐Life Questionnaire Lung Cancer Module (QLQ‐LC13) (Phase 2 and Phase 3) Secondary end point(s):9. Percentage of Participants with Adverse Events (AEs) (Phase 2 and Phase 3)}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02730790/full} -} - - -Record #311 of 538 -@article{NL-OMON5294620, -author = {NL-OMON52946,}, -title = {LIBRETTO-431: a Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Platinum-Pemetrexed Chemotherapy Plus Investigator*s Choice of Pembrolizumab in Patients with Advanced, Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON52946}, -year = {2020}, -accession_number = {ICTRP NL‐OMON52946}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: You will get selpercatinib or one of the medication combinations listed below. You will know which medicine you are taking. Whether you receive selpercatinib or the medications listed below will be decided by chance. The chance that you will receive selpercatinib is 2 in 3. If you are not assigned to selpercatinib, your doctor will decide which of the following combinations you will get: • Cisplatin plus pemetrexed with pembrolizumab • Cisplatin plus pemetrexed without pembrolizumab • Carboplatin plus pemetrexed with pembrolizumab • Carboplatin plus pemetrexed without pembrolizumab Selpercatinib‐ Arm A‐ Tablets only Comparator‐ Arm B‐ IV injection. CONDITION: Oncology‐ Lung ; Lung Cancer ; Non small cell Lung Cancer PRIMARY OUTCOME: Objectives ; ; To compare PFS of selpercatinib and platinum‐based (carboplatin or cisplatin) ; and pemetrexed therapy with or without pembrolizumab in patients with advanced ; or metastatic RET fusion‐positive NSCLC ; ; Endpoints ; ; PFS per RECIST 1.1 by BICR; INCLUSION CRITERIA: ‐ Histologically confirmed Stage IIIB‐IIIC or Stage IV non‐squamous NSCLC that is not suitable for radical surgery or radiation therapy ‐ A RET gene fusion in tumor and/or blood from a qualified laboratory ‐ Measurable disease as determined by RECIST 1.1 by the investigator ‐ ECOG performance status of 0‐2 ‐ Adequate hematologic, hepatic and renal function ‐ Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 6 months after ‐ Written informed consent SECONDARY OUTCOME: Objectives ; ; To compare efficacy of selpercatinib and platinum‐based and pemetrexed therapy ; with pembrolizumab ; ; ; Endpoints ; ; * PFS per RECIST 1.1 by BICR ; * PFS per RECIST 1.1 by investigator ; * ORR/DOR/DCR per RECIST 1.1 by BICR ; * ORR/DOR/DCR per RECIST 1.1 by investigator ; * Intracranial ORR/DOR per RECIST 1.1 by BICR ; * Time to CNS progression per RECIST 1.1. by BICR ; * Intracranial ORR/DOR per RANO‐BM by BICR ; * OS ; * PFS2 ; * Time to deterioration in pulmonary symptoms: cough, chest pain, and dyspnea ; as measured by the NSCLC‐SAQ ; ; ; Objectives ; ; To compare efficacy of selpercatinib and platinum‐based and pemetrexed therapy ; with or without pembrolizumab ; ; Endpoints ; ; * PFS per RECIST 1.1 by investigator ; * ORR/DOR/DCR per RECIST 1.1 by BICR ; * ORR/DOR/DCR per RECIST 1.1 by investigator ; * Intracranial ORR/DOR per RECIST 1.1 by BICR ; * Time to CNS progression per RECIST 1.1. by BICR ; * Intracranial ORR/DOR per RANO‐BM by BICR* ; * OS ; * PFS2 ; * Time to deterioration in pulmonary symptoms: cough, chest pain, and dyspnea ; as measured by the NSCLC‐SAQ ; ; Objectives ; ; To assess safety and tolerability of selpercatinib compared to platinum‐based ; and pemetrexed therapy with or without pembrolizumab ; ; Endpoints: ; ; Including but not limited to SAEs, AEs, deaths, and clinical laboratory ; abnormalities per CTCAE v5.0 ; ; Objectives: ; ; To assess/evaluate performance of RET local laboratory tests compared to a ; single central test: ; ; Endpoints: ; RET fusion status ; ; Tertiary/exploratory: ; Please refer to objectives and endpoints table/section of study protocol. ;}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02719720/full} -} - - -Record #312 of 538 -@article{Liu22, -author = {Liu, S-Y, Zhou, Q, Yan, H-H, Gan, B, Yang, M-Y, Deng, J-Y, Tu, H-Y, Zhang, X-C, Su, J, Yang, J-J, and Wu, Y-L}, -title = {EP08.01-085 Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S381‐S382}, -year = {2022}, -accession_number = {EMBASE 2020097259}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer chemotherapy; *cancer combination chemotherapy; *monotherapy; *non small cell lung cancer; Adult; Advanced cancer; Adverse drug reaction; Brain metastasis; Cancer patient; Cancer staging; Cancer survival; Clinical trial; Conference abstract; Controlled study; Disease control; Drug safety; Drug therapy; Female; Follow up; Histopathology; Human; Human tissue; Immunotherapy; Major clinical study; Male; Overall response rate; Phase 2 clinical trial; Randomized controlled trial; Sample size; Side effect}, -abstract = {Introduction: Immunotherapy has become standard therapy for advanced non‐small‐cell lung cancer (NSCLC). However, no direct comparison between different PD‐1 inhibitors were reported. Methods: This is an open label, randomized, phase II clinical trial to compare sintilimab versus pembrolizumab as monotherapy or in combination with chemotherapy for treatment naïve local advanced or metastatic NSCLC. Eligible patients were EGFR or ALK negative. Patients with asymptomatic brain metastasis were allowed. PD‐L1 tumor proportion score (TPS) ≥50% patients were randomly assigned to sintilimab (A) or pembrolizumab (B) monotherapy arms. TPS<50% patients were randomly assigned to sintilimab (C) or pembrolizumab (D) with platin‐based chemotherapy arms. The primary endpoint was objective response rate (ORR). Sample size were determined per Optimal Two‐Stage Design, 1st stage would recruit 20 patients. Recruitment of the 2nd stage would start if ≥4 patients achieve partial response (PR) in sintilimab arms, and sample size would be determined based on the ORR of the 1st. Results: The ORR of the 1st stage was 57.1% in sintilimab and 33.3% in pembrolizumab arms, thus the study successfully entered into the 2nd stage. From Mar. 2020 to Jan. 2022, a total of 68 patients were enrolled. Histologic subtypes and brain metastasis were well balanced between arms. Until Dec. 31st 2021, the median follow‐up was 5.6 months. ORR was 57.6% in sintilimab arms vs. 42.9% in pembrolizumab arms, and the confirmed ORR was 45.5% (15/33) vs. 28.6% (10/35), separately. (Figure 1). The disease control rate was 87.9% vs. 91.4% in sintilimab and pembrolizumab arms, respectively. The primary endpoint was reached, with 15 confirmed PRs achieved in sintilimab arms. Survival data was still immature. Treatment‐related adverse events were comparable between sintilimab and pembrolizumab arms (Table 1). Conclusions: This head‐to‐head study of PD‐1 inhibitors suggested comparable tumor response and similar safety profile between sintilimab and pembrolizumab. [Formula presented] [Formula presented] Keywords: non‐small cell lung cancer, PD‐1 inhibitor, immunotherapy}, -DOI = {10.1016/j.jtho.2022.07.657}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461443/full} -} - - -Record #313 of 538 -@article{Kalinka23, -author = {Kalinka, E, Bondarenko, I, Gogishvili, M, Melkadze, T, Baramidze, A, Sezer, A, Makharadze, T, Kilickap, S, Gumus, M, Penkov, KD, Giorgadze, D, Ozguroglu, M, He, X, Pouliot, J-F, Seebach, F, Lowy, I, Gullo, G, and Rietschel, P}, -title = {114M0 First-line cemiplimab for locally advanced non-small cell lung cancer: updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3}, -journal = {Journal of thoracic oncology}, -volume = {18}, -number = {4}, -pages = {S106}, -year = {2023}, -accession_number = {EMBASE 2023626787}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *non small cell lung cancer; *protein expression; Adult; Cancer patient; Cancer survival; Case report; Chemoradiotherapy; Clinical article; Clinical trial; Conference abstract; Data interpretation; Drug efficacy; Drug therapy; Follow up; Funding; Gene expression; Human; Male; Medical literature; Monotherapy; Overall response rate; Overall survival; Parttime employment; Phase 3 clinical trial; Post hoc analysis; Progression free survival; Radiotherapy; Randomized controlled trial; Regulated cell death; Responsibility; Travel}, -abstract = {Background Patients (pts) with unresectable locally advanced non‐small cell lung cancer (laNSCLC) who are not candidates for concurrent chemoradiation have often been excluded from immunotherapy trials, and their care represent an unmet medical need. We report post hoc analyses of pts with laNSCLC who received cemiplimab (anti–programmed cell death‐1) from two phase III clinical trials with long‐term data. Methods EMPOWER‐Lung 1 and EMPOWER‐Lung 3 included pts with squamous or non‐squamous NSCLC that was metastatic or locally advanced (not suitable for definitive concurrent chemoradiation) without EGFR, ALK or ROS1 genomic aberrations. In EMPOWER‐Lung 1 pts were randomised 1:1 to first‐line (1L) cemiplimab monotherapy or chemo for NSCLC with ≥50% programmed cell death‐ligand 1 (PD‐L1) expression. In EMPOWER‐Lung 3 pts were randomised 2:1 to 1L cemiplimab + chemo or placebo + chemo regardless of PD‐L1 expression level. Results In each trial, 15% of pts were treated for laNSCLC. In EMPOWER‐Lung 1, at 3‐year follow‐up of pts with laNSCLC, 1L cemiplimab monotherapy led to a median overall survival (OS) of 26.1 vs 13.9 mo with chemo (HR: 0.67; 0.38–1.17; p = 0.1532). Progression‐free survival (PFS) was 8.1 vs 6.2 mo (HR: 0.56; 0.34–0.95; p = 0.0286). Objective response rate (ORR) was 49% vs 31%. Median duration of response (DOR) was 18.8 vs 6.2 mo. In EMPOWER‐Lung 3, at 2‐year follow‐up of pts with laNSCLC, greater efficacy was observed with 1L cemiplimab + chemo vs placebo + chemo. Median OS was 24.1 vs 13.8 mo (HR: 0.50; 0.27–0.95; p = 0.0293) and median PFS was 12.5 vs 6.2 mo (HR: 0.34; 0.19–0.61; p = 0.0002). ORR was 58% vs 29%. Median DOR was 27.8 vs 4.2 mo. [Formula presented] Conclusions Long‐term follow‐up data from EMPOWER‐Lung studies continue to suggest clinical benefit of 1L cemiplimab as monotherapy or in combination with platinum‐based chemo in pts with unresectable laNSCLC who are not candidates for definitive concurrent chemoradiation. Clinical trial identification NCT03088540 and NCT03409614. Editorial acknowledgement Medical writing support was provided by Rachel McGrandle, MSc, of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc. and Sanofi. Responsibility for all opinions, conclusions, and data interpretation lies with the authors. Legal entity responsible for the study Regeneron Pharmaceuticals, Inc. Funding Regeneron Pharmaceuticals, Inc. and Sanofi. Disclosure E. Kalinka: Financial Interests, Personal, Other, Honoraria: Amgen, AstraZeneca, Bristol‐Meyers Squibb, Merck Sharp & Dohme, Nektar, Pfizer, Roche, Regeneron Pharmaceuticals, Inc. A. Sezer: Financial Interests, Institutional, Research Grant: Roche, Merck Sharp & Dohme, Merck Serono, AstraZeneca, Eli Lilly, Novartis, Johnson & Johnson, Regeneron Pharmaceuticals, Inc., Sanofi. M. Gumus: Financial Interests, Personal, Other, Honoraria: Roche, Merck Sharp & Dohme, Gen İlaç, Novartis. K.D. Penkov: Financial Interests, Personal, Other, Honoraria: AstraZeneca, Merck Sharp & Dohme, Nektar, Pfizer, Regeneron Pharmaceuticals, Inc., Roche; Financial Interests, Personal, Advisory Role: Nektar. M. Özgüroğlu: Financial Interests, Personal, Other, Honoraria: Novartis, Roche, Janssen, Sanofi, Astellas; Financial Interests, Personal, Advisory Board: Janssen, Sanofi, Astellas; Financial Interests, Personal, Other, Travel support: Bristol‐Myers Squibb, Janssen, AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca. X. He: Financial Interests, Personal, Full or part‐time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. J. Pouliot: Financial Interests, Personal, Full or part‐time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. F. Seebach: Financial Interests, Personal, Full or part‐time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. I. Lowy: Financial Interests, Personal, Full or part‐time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. G. Gullo: Financial Interests, Personal, Full or part‐time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. P. Rietschel: Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Full or part‐time Employment: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/S1556-0864(23)00369-6}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02543515/full} -} - - -Record #314 of 538 -@article{Orosz24, -author = {Orosz, Z, and Kovacs, A}, -title = {The role of chemoradiotherapy and immunotherapy in stage III NSCLC}, -journal = {Pathology and oncology research}, -volume = {30}, -year = {2024}, -accession_number = {EMBASE 2029700615}, -publication type = {Journal article}, -keywords = {*chemoradiotherapy; *immunotherapy; *non small cell lung cancer; Controlled study; Drug therapy; Female; Human; Lung cancer; Maintenance therapy; Male; Middle aged; Multidisciplinary team; Overall survival; Radiotherapy; Randomized controlled trial; Short survey; Side effect; Special situation for pharmacovigilance; Survival rate; Therapy}, -abstract = {Locally advanced non‐small lung cancer encompasses a diverse range of tumors. In the last few years, the treatment of stage III unresectable non‐small lung cancer has evolved significantly. The PACIFIC trial opened a new therapeutic era in the treatment of locally advanced NSCLC, establishing durvalumab consolidation therapy as the new standard of care worldwide. A careful evaluation of this type of lung cancer and a discussion of the management of these patients within a multidisciplinary team represents a crucial step in defining the best treatment strategy for each patient. For unresectable stage III NSCLC, definitive concurrent chemoradiotherapy (CCRT) was historically recommended as a treatment with a 5‐year survival rate ranging from 20% to 30%. The PACIFIC study conducted in 2017 compared the use of chemoradiotherapy and maintenance therapy with the anti‐PD‐L1 monoclonal antibody durvalumab to a placebo in patients with locally advanced NSCLC who had not experienced disease progression. The study was prospective, randomized, and phase III. The administration of this medication in patients with locally advanced non‐small cell lung cancer (NSCLC) has demonstrated a notable improvement in overall survival. Multiple clinical trials are currently exploring various immune checkpoint inhibition regimens to enhance the treatment efficacy in patients with stage III cancer. Our goal is to offer an up‐to‐date summary of the planned clinical trials for treatment options, focusing on the significant obstacles and prospects in the post‐PACIFIC era.}, -DOI = {10.3389/pore.2024.1611716}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02697965/full} -} - - -Record #315 of 538 -@article{UMIN00002085516, -author = {UMIN000020855,}, -title = {Phase II study of nivolumab for advanced non-small-cell lung cancer patients not indicative of cytotoxic chemotherapy}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000020855}, -year = {2016}, -accession_number = {ICTRP UMIN000020855}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Nivolumab 3mg/kg (day 1, q2 weeks) until clinical progression or unacceptable toxicities CONDITION: advanced non‐small‐cell lung cancer PRIMARY OUTCOME: Response rate SECONDARY OUTCOME: Progression‐free survival, Overall survival, and Toxicity. AND, we will explore serum or blood‐based biomarker analysis and immune state as the accompanying research with the informed consent INCLUSION CRITERIA: 1) Definitively diagnosed with having previously treated advanced non‐small cell lung cancer by the specimens histologically or cytologically who have no indication for standard treatment of chemotherapy including cytotoxic chemotherapy and molecular targeted agents for driver mutation. 2) Age of 20 years and older 3) With adequate organ function of bone marrow reserve, liver, and kidney. (1) PS 2‐4 (2) neutrophil count => 500/mm^3 (3) platelet => 50,000/mm^3 (4) hemoglobin => 8.0g/dL (5) AST/ALT < 5 times less than ULN (6) T.Bil <= 3.0mg/dL (7) serum creatinine <= 3.0mg/dL (8) ECG: without clinically problematic abnormalities (9) SpO2 more than 92% 4) With the status of below previous treatment at the time of beginning of chemotherapy. (1) Radiotherapy: irradiated extrathoracic lesion: more than two weeks from the date of last irradiation (2) Surgical procedure, including pleurodesis or pleural drainage50%) expression demonstrate superior response and survival with immune checkpoint inhibitors compared to chemotherapy. We hypothesize that it is safe and feasible to substitute durvalumab instead of chemotherapy concurrently with radiotherapy (RT) in patients with Locally Advanced‐NSCLC (LA‐NSCLC) and high PD‐L1. Methods: NRG‐LU004 (NCT03801902) is a Phase I study for patients with stage II‐III unresectable or inoperable, LA‐NSCLC with PD‐L1> 50% (Dako 22C3 or Ventana SP263) expression. There were safety and expansion phases with a primary endpoint of safety. Patients started with 1500 mg durvalumab Q4 weeks and thoracic RT within 2 weeks from 1st infusion. Durvalumab continued once a month up to 1 year. In the safety cohort, 6 patients in cohort 1 were treated with accelerated fractionated RT (ACRT) to 60 Gy in 15 fractions, followed by a required safety hold for 90 days. During cohort 1 safety hold, cohort 2 patients were treated with conventional RT 60 Gy in 30 fractions (CONV) followed by a 60‐day safety hold. A cohort advanced to the expansion phase to enroll 6 more patients if safety criteria (0‐1 patients with a dose limiting toxicity [DLT]) were met. If both cohorts were deemed safe, patients would be randomized 1:1 to ACRT or CONV with safety defined as < 4 of 12 evaluable patients per arm experiencing a DLT. Feasibility was defined as at least 80% of patients in each arm receiving at least 80% of the planned dose of durvalumab during the first 8 weeks. Results: 24 evaluable patients enrolled between January 2019 and June 2021. No DLTs were reported in cohort 1, and 1 (unrelated bronchopulmonary hemorrhage leading to discontinuation of durvalumab) in cohort 2. Both safety cohorts advanced to the expansion phase. All but one patient (CONV) received RT per protocol/with an acceptable variation. At the time of analysis, 24% had received all 13 cycles of durvalumab. For the ACRT cohort, there were 4 grade 3, 1 grade 4 (lymphopenia), and 1 grade 5 AE (lung infection, assessed as unrelated to therapy). For CONV, there were 8 grade 3, 0 grade 4, and 1 grade 5 AE (respiratory failure, unrelated to therapy). For feasibility, 10 of 12 (85%) patients in the ACRT cohort received the second dose of durvalumab (2 not received due to shingles and unrelated death), while 9 of 12 (75%) of the CONV cohort received the second dose (reasons for not receiving: viral hepatitis, bronchopulmonary hemorrhage, and respiratory failure, all assessed as unrelated to therapy). Conclusions: Chemotherapy‐free thoracic RT approaches (ACRT or CONV RT) are safe, when given with concurrent durvalumab in patients with PD‐L1 high LA‐NSCLC. A trial to compare immunoradiotherapy and consolidation durvalumab to standard chemoradiation and consolidation durvalumab is planned.}, -DOI = {10.1200/JCO.2022.40.16_suppl.8513}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02469297/full} -} - - -Record #318 of 538 -@article{Stuschke17, -author = {Stuschke, M, and Pottgen, C}, -title = {Radiotherapy techniques in lung cancer}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {1}, -pages = {S155‐S156}, -year = {2017}, -accession_number = {EMBASE 615339206}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; *painting; Acceleration; Brain; Breathing; Bronchus; Chemotherapy; Clinical study; Clinical trial; Conformal radiotherapy; Controlled clinical trial; Controlled study; Drug megadose; Drug therapy; Esophagus; Fractionation; Human; Immunotherapy; Intensity modulated radiation therapy; Long term survival; Mediastinum; Metastasis; Molecularly targeted therapy; Multicenter study; Nuclear magnetic resonance imaging; Organs at risk; Patient selection; Positron emission tomography‐computed tomography; Proton therapy; Radiation dose distribution; Radiation pneumonia; Radiotherapy; Randomized controlled trial; Treatment failure; Tumor volume; Volumetric modulated arc therapy}, -abstract = {Dose escalation with conventional fractionation and concurrent platin‐based chemotherapy within the RTOG 0617 trial has failed to show a survival benefit. Proton therapy has failed to show a reduction in radiation pneumonitis in comparison to intensity modulated photon radiotherapy at the same total dose according to the NCT 00915005 trial. Randomized trials for comparison of IMRT and 3D conformal radiotherapy are lacking. While randomized trials conducted so far failed to show an increment in survival by newer radiotherapy concepts on one hand, the old standard of giving 60 Gy with conventional fractionation and concurrent chemotherapy consolidated on the other. So where does the hope come from that technological advances in radiotherapy lead to an improved survival in locally advanced lung cancer, if not from randomized trials? It comes from many small precious components that can lead to an increase of loco‐regional control by radiotherapy in locally advanced NSCLC, the primary goal of radiotherapy. First of all, the determination of tumor spread has been substantially improved by the introduction of FDG‐PET/CT, by systematic mediastinal evaluation with EBUS‐TBNA, and by brain MRI. The determination of tumor position during irradiation has been improved by stereoscopic KV imaging during irradiation or real‐time magnetic resonance imaging and therefore tumor targeting can be optimized. Volumetric modulated arc therapy can deliver conformal dose distributions within a breath hold of 20 s. With hyperfractionated acceleration and concurrent chemotherapy, high biologically effective doses can be given for patients with locally advanced NSCLC resulting in similar survival and local control rates than with trimodality treatment. Integrated boost radiotherapy controlling dose gradients form gross tumor volume towards organs at risk as the contra‐lateral bronchial wall or the esophagus has become feasible and is tested within prospective trials. Immunotherapy and molecular targeted therapies are upcoming as combination partners with radiotherapy in selected tumors. Proper patient selection criteria resulted long term survival as high as 30‐45% in multicenter prospective trials in locally advanced NSCLC. These advantages have to be bundled into new radiotherapeutic concepts and tested against the standard of conventional fractionated radiotherapy up to 60 Gy and simultaneous chemotherapy in future well designed randomized trials.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01718479/full} -} - - -Record #319 of 538 -@article{Suh19, -author = {Suh, Y-G, and Cho, J}, -title = {Local ablative radiotherapy for oligometastatic non-small cell lung cancer}, -journal = {Radiation oncology journal}, -volume = {37}, -number = {3}, -pages = {149‐155}, -year = {2019}, -accession_number = {EMBASE 2002757042}, -publication type = {Journal article}, -keywords = {*cancer radiotherapy; *local therapy; *metastasis /complication; *non small cell lung cancer /drug therapy /radiotherapy; Advanced cancer /drug therapy /radiotherapy; Cancer survival; Clinical effectiveness; Human; Hypofractionated radiotherapy; Long term survival; Overall survival; Phase 2 clinical trial (topic); Phase 3 clinical trial (topic); Progression free survival; Randomized controlled trial (topic); Review; Stereotactic radiosurgery; Systematic review; Treatment response}, -abstract = {In metastatic non‐small cell lung cancer (NSCLC), the role of radiotherapy (RT) has been limited to palliation to alleviate the symptoms. However, with the development of advanced RT techniques, recent advances in immuno‐oncology therapy targeting programmed death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) and targeted agents for epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation allowed new roles of RT in these patients. Within this metastatic population, there is a subset of patients with a limited number of sites of metastatic disease, termed as oligometastasis that can achieve long‐term survival from aggressive local management. There is no consensus on the definition of oligometastasis; however, most clinical trials define oligometastasis as having 3 to 5 metastatic lesions. Recent phase II randomized clinical trials have shown that ablative RT, including stereotactic ablative body radiotherapy (SABR) and hypofractionated RT, to primary and metastatic sites improved progression‐free survival (PFS) and overall survival (OS) in patients with oligometastatic NSCLC. The PEMBRO‐RT study, a randomized phase II study comparing SABR prior to pembrolizumab therapy and pembrolizumab therapy alone, revealed that the addition of SABR improved the overall response, PFS, and OS in patients with advanced NSCLC. The efficacy of RT in oligometastatic lung cancer has only been studied in phase II studies; therefore, large‐scale phase III studies are needed to confirm the benefit of local ablative RT in patients with oligometastatic NSCLC. Local intensified RT to primary and metastatic lesions is expected to become an important treatment paradigm in the near future in patients with metastatic lung cancer.}, -DOI = {10.3857/roj.2019.00514}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01999061/full} -} - - -Record #320 of 538 -@article{EUCTR2021-002605-10-ES22, -author = {EUCTR2021-002605-10-ES,}, -title = {Study of efficacy and safety of JDQ443 in comparison with docetaxel in participants with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-002605-10-ES}, -year = {2022}, -accession_number = {ICTRP EUCTR2021‐002605‐10‐ES}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: JDQ443 Product Code: JDQ443 Pharmaceutical Form: Tablet INN or Proposed INN: Not established yet. Current Sponsor code: JDQ443 Other descriptive name: JDQ443 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Trade Name: Docetaxel ‐ Taxotere and other docetaxel containing medicinal products Product Name: docetaxel Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Docetaxel CAS Number: 114977‐28‐5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20‐ CONDITION: Advanced non‐small cell lung cancer harboring the KRAS G12C mutation ; MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non‐small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: ? To compare the progression‐free survival (PFS) of JDQ443 versus docetaxel Primary end point(s): ? Progression‐free survival (PFS) per Blinded Independent Review Committee (BIRC) according to RECIST 1.1. Secondary Objective: ? To compare overall survival (OS) in the two treatment arms (key secondary objective); ? To assess the anti‐tumor activity of JDQ443 compared to docetaxel; ? To assess PFS2 in the two treatment arms; ? To characterize the safety profile of JDQ443; ? To assess the effect of JDQ443 vs docetaxel on PROs (NSCLC‐SAQ, EORTC QLQ‐C30, lung‐specific module QLQ‐LC13, and EQ‐5D‐5L) including lung cancer symptoms, health‐related quality of life, and health status; ? To characterize the pharmacokinetics of JDQ443; ? To assess the effect of JDQ443 vs docetaxel on ECOG performance status; ? To assess the safety of JDQ443 in participants who crossover from docetaxel Timepoint(s) of evaluation of this end point: The primary PFS analysis for the randomized part of the study will be performed after observing approximately 269 centrally confirmed PFS events, in the full analysis set (FAS) or based on the PFS interim analysis data in case the study is futile at that analysis. If PFS is statistically significant, the final OS analysis will be performed after observing approximately 228 deaths in the FAS or earlier if OS meets statistical significance at the planned interim analysis INCLUSION CRITERIA: ? Participants are male and female, aged 18 or older ? Histologically confirmed locally advanced stage IIIB/IIIC (and not eligible for definitive chemo‐radiation curative therapy or complete surgical resection) or stage IV previously treated NSCLC. Presence of a KRAS G12C mutation by central laboratory testing using tissue samples. ? Participants have received one prior platinum‐based chemotherapy and one prior immune checkpoint inhibitor therapy either in combination or in sequence. ? Participants with ECOG performance status from 0 to 2 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 360 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range SECONDARY OUTCOME: Secondary end point(s): ? OS; ? ORR, DCR, TTR, and DOR per RECIST 1.1 (by BIRC and local Investigator's assessment); ? PFS2 based on local investigator's assessment; ? Type, frequency and severity of adverse events, changes in laboratory values, vital signs, ECGs; ? Time to definitive 10‐point deterioration symptom scores of chest pain, cough, and dyspnea per QLQ‐LC13 questionnaire are primary PRO variables of interest; ? Time to definitive deterioration in global health status/QoL, shortness of breath, and pain per QLQ‐C30 are secondary PRO variables of interest; ? Change from baseline in EORTC‐QLQ C30 LC13, EQ‐5D‐5L, and NSCLC‐SAQ; ? The concentration of JDQ443 in plasma and pharmacokinetic; parameters for a subgroup of participants in mainland China.; ? Time to definitive deterioration of the ECOG performance status.; ? Type, frequency and severity of adverse events, changes in laboratory values, vital signs, ECGs Timepoint(s) of evaluation of this end point: • Efficacy: pre specified time‐points as per protocol ; • Safety/tolerability: continuously during on‐treatment period; • PK: as defined per protocol and Statistical Analysis Plan}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02429491/full} -} - - -Record #321 of 538 -@article{Palmero21, -author = {Palmero, R, Vilarino, N, Navarro-Martin, A, and Nadal, E}, -title = {Induction treatment in patients with stage III non-small cell lung cancer}, -journal = {Translational lung cancer research}, -volume = {10}, -number = {1}, -pages = {539‐554}, -year = {2021}, -accession_number = {EMBASE 2011035603, PUBMED 33569335}, -publication type = {Journal article}, -keywords = {*cancer staging; *non small cell lung cancer /drug therapy /radiotherapy /surgery; Adult; Advanced cancer /drug therapy /radiotherapy /surgery; Air leak syndrome; Article; Bronchopleural fistula /side effect; CD8+ T lymphocyte; Cancer combination chemotherapy; Cancer immunotherapy; Cancer localization; Cancer recurrence; Cancer survival; Chemoradiotherapy; Cohort analysis; Controlled study; Diarrhea /side effect; Disease marker; Drug safety; Empyema; Female; Health care quality; Heart atrium arrhythmia; Heart infarction; Human; Hypermagnesemia /side effect; Hyponatremia /side effect; Hypoxia /side effect; Induction chemotherapy; Infusion related reaction /side effect; Lung embolism; Major clinical study; Male; Multiple cycle treatment; Neoadjuvant chemotherapy; Neutropenia /side effect; Phase 2 clinical trial; Phase 3 clinical trial; Pleura effusion /side effect; Pneumonectomy; Pneumonia /side effect; Practice guideline; Preoperative care; Primary tumor /drug therapy /radiotherapy /surgery; Progression free survival; Prospective study; Radiation dose; Randomized controlled trial; Rash /side effect; Recurrence free survival; Respiratory failure /side effect; Surgical mortality; Surgical risk; Systemic therapy; Treatment response; Tumor microenvironment; Urinary tract infection}, -abstract = {Stage III non‐small cell lung cancer (NSCLC) comprises a highly heterogeneous group of patients defined according to the extent and localization of disease. Patients with discrete N2 involvement identified preoperatively with resectable disease are candidates for multimodal therapy either with definitive chemoradiation therapy, induction chemotherapy, or chemoradiotherapy (CTRT) followed by surgery. Neoadjuvant chemotherapy has yielded comparable survival benefit to adjuvant chemotherapy in patients with stage II–III disease and may allow for downstaging the tumor or the lymph nodes, an earlier delivery of systemic treatment, and better compliance to systemic therapy. The use of immune checkpoint inhibitors (ICIs) as induction therapy shows encouraging activity and a favorable safety profile in patients with resectable early stage or locally advanced NSCLC. An unprecedented rate of pathological response and downstaging has been reported in single‐arm clinical trials, especially when immunotherapy is combined with neoadjuvant chemotherapy. Ongoing randomized phase II/III clinical trials assessing the efficacy and safety of induction with immunotherapy plus chemotherapy have the potential to establish this therapeutic approach as a novel standard of care. These trials aim to validate pathological response as a surrogate marker of survival benefit and to demonstrate that this therapeutic strategy can improve the cure rate in patients with stage II–III NSCLC.}, -DOI = {10.21037/tlcr-20-420}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02266174/full} -} - - -Record #322 of 538 -@article{CTRI/2010/091/00134810, -author = {CTRI/2010/091/001348,}, -title = {A CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF PT 107 (VACCINE) IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2010/091/001348}, -year = {2010}, -accession_number = {ICTRP CTRI/2010/091/001348}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Intervention1: Allogeneic B7.1/HLA‐A1 Transfected NSCLC Tumor Cell Vaccine: 0.5ml of Vaccine administered through intradermal injection. Will be given total 9 vaccinations once in every 14 days Control Intervention1: Placebo (composed of sterile saline containing 0.5% human serum albumin and 10% DMSO without cells): 0.5ml placebo administered through intradermal injection. Will be given total 9 vaccinations once in every 14 days CONDITION: Advanced non‐small cell lung cancer (Stages IIIB/IV) who have failed first line of chemotherapy PRIMARY OUTCOME: Determine whether patients with advanced or metastatic non‐small cell lung cancer (stages IIIB/IV) who have failed previous platinum‐based chemotherapy (with or without radiation) have an increase in overall survival as a result of vaccination with PT 107.‐‐‐‐‐‐Timepoint: From the date of randomization to the recorded date of death SECONDARY OUTCOME: 1. Safety profile of the PT 107. 2. Time to disease progression in patients immunized with PT 107 vaccine as compared to placebo.‐‐‐‐‐‐Timepoint: 1. Monitored for safety throughout the study. 2. 1st assessment at 13th week and follow‐up assessment on 18th week INCLUSION CRITERIA: 1. Patients with documented stage IIIB or IV advanced or metastatic NSCLC who have completed 4‐6 cycles of platinum based chemotherapy, with or without radiation, and have either stable disease or have experienced disease progression (additional prior adjuvant chemotherapy is permitted). 2. ECOG performance status 0‐2. 3. Presence of at least one measurable lesion according to RECIST criteria. 4. Renal Requirements: The calculated creatinine clearance must be at least 50 ml/min. 5. Pulmonary Function Requirements All patients will undergo evaluation of pulmonary function prior to enrollment. Patients should have a FeV1 more than 30% of the predicted value and/or DLCO more than 30% of the predicted value with a PCO2 < 45mm. Any patient enrolled in the protocol whose respiratory symptoms have experienced marked deterioration not related to a known cause (e.g. pneumonia, CHF or PE) will have request PFT evaluation and if the above para}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01848739/full} -} - - -Record #323 of 538 -@article{UMIN00003078218, -author = {UMIN000030782,}, -title = {Phase II study for efficacy and safety of pembrolizumab for the cytotoxic chemotherapy unfit previously treated PD-L1 positive advanced non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000030782}, -year = {2018}, -accession_number = {ICTRP UMIN000030782}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Pembrolizumab 200mg (day 1, q3 weeks) until clinical progression or unacceptable toxicities CONDITION: PD‐L1 positive previously treated advanced non‐small‐cell lung cancer PRIMARY OUTCOME: Response rate SECONDARY OUTCOME: Progression‐free survival, Overall survival, and Toxicity. INCLUSION CRITERIA: 1) Definitively diagnosed with having PD‐L1 positive previously treated advanced non‐small cell lung cancer by the specimens histologically or cytologically who have no indication for standard treatment of chemotherapy including cytotoxic chemotherapy and molecular targeted agents for driver mutation. 2) Age of 20 years and older 3) With adequate organ function of bone marrow reserve, liver, and kidney. (1) PS 2‐4 (2) neutrophil count => 500/mm^3 (3) platelet => 50,000/mm^3 (4) hemoglobin => 6.5g/dL (5) AST/ALT < 5 times less than ULN (6) T.Bil <= 3.0mg/dL (7) serum creatinine <= 3.0mg/dL (8) ECG: without clinically problematic abnormalities (9) SpO2 more than 92% (O2 < 2L/min) 4) With the status of below previous treatment at the time of beginning of chemotherapy. (1) Radiotherapy: irradiated extrathoracic lesion: more than two weeks from the date of last irradiation (2) Surgical procedure, including pl}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01901018/full} -} - - -Record #324 of 538 -@article{Theelen19, -author = {Theelen, WSME, Peulen, HMU, Lalezari, F, van der Noort, V, de Vries, JF, Aerts, JGJV, Dumoulin, DW, Bahce, I, Niemeijer, AN, de Langen, AJ, Monkhorst, K, and Baas, P}, -title = {Effect of Pembrolizumab after Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer: results of the PEMBRO-RT Phase 2 Randomized Clinical Trial}, -journal = {JAMA oncology}, -volume = {5}, -number = {9}, -pages = {1276‐1282}, -year = {2019}, -accession_number = {EMBASE 628529570, PUBMED 31294749}, -publication type = {Journal article}, -keywords = {*advanced cancer /drug therapy /radiotherapy; *clinical effectiveness; *drug effect; *non small cell lung cancer /drug therapy /radiotherapy; *stereotactic body radiation therapy; *treatment response; Adult; Aged; Article; Cancer growth; Cancer radiotherapy; Cancer survival; Controlled study; Coughing /complication /side effect; Decision making; Fatigue /complication /side effect; Female; Human; Influenza /complication /side effect; Major clinical study; Male; Multicenter study; Overall survival; Phase 2 clinical trial; Pneumonia /complication; Progression free survival; Pruritus /side effect; Radiation dose; Randomized controlled trial}, -abstract = {Importance: Many patients with advanced non‐small cell lung cancer (NSCLC) receiving immunotherapy show primary resistance. High‐dose radiotherapy can lead to increased tumor antigen release, improved antigen presentation, and T‐cell infiltration. This radiotherapy may enhance the effects of checkpoint inhibition. Objective: To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC. Design, Setting, and Participants: Multicenter, randomized phase 2 study (PEMBRO‐RT) of 92 patients with advanced NSCLC enrolled between July 1, 2015, and March 31, 2018, regardless of programmed death‐ligand 1 (PD‐L1) status. Data analysis was of the intention‐to‐treat population. Interventions: Pembrolizumab (200 mg/kg every 3 weeks) either alone (control arm) or after radiotherapy (3 doses of 8 Gy) (experimental arm) to a single tumor site until confirmed radiographic progression, unacceptable toxic effects, investigator decision, patient withdrawal of consent, or a maximum of 24 months. Main Outcomes and Measures: Improvement in overall response rate (ORR) at 12 weeks from 20% in the control arm to 50% in the experimental arm with P <.10. Results: Of the 92 patients enrolled, 76 were randomized to the control arm (n = 40) or the experimental arm (n = 36). Of those, the median age was 62 years (range, 35‐78 years), and 44 (58%) were men. The ORR at 12 weeks was 18% in the control arm vs 36% in the experimental arm (P =.07). Median progression‐free survival was 1.9 months (95% CI, 1.7‐6.9 months) vs 6.6 months (95% CI, 4.0‐14.6 months) (hazard ratio, 0.71; 95% CI, 0.42‐1.18; P =.19), and median overall survival was 7.6 months (95% CI, 6.0‐13.9 months) vs 15.9 months (95% CI, 7.1 months to not reached) (hazard ratio, 0.66; 95% CI, 0.37‐1.18; P =.16). Subgroup analyses showed the largest benefit from the addition of radiotherapy in patients with PD‐L1‐negative tumors. No increase in treatment‐related toxic effects was observed in the experimental arm. Conclusions and Relevance: Stereotactic body radiotherapy prior to pembrolizumab was well tolerated. Although a doubling of ORR was observed, the results did not meet the study's prespecified end point criteria for meaningful clinical benefit. Positive results were largely influenced by the PD‐L1‐negative subgroup, which had significantly improved progression‐free survival and overall survival. These results suggest that a larger trial is necessary to determine whether radiotherapy may activate noninflamed NSCLC toward a more inflamed tumor microenvironment. Trial Registration: ClinicalTrials.gov identifier: NCT02492568.}, -DOI = {10.1001/jamaoncol.2019.1478}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01960926/full} -} - - -Record #325 of 538 -@article{EUCTR2018-002220-16-ES18, -author = {EUCTR2018-002220-16-ES,}, -title = {This is a Phase II, open-label, multi-centre study to determine the safety of a fixed dose of durvalumab in patients with Non-Small Cell Lung Cancer who have not progressed after sequential chemoradiation therapy}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2018-002220-16-ES}, -year = {2018}, -accession_number = {ICTRP EUCTR2018‐002220‐16‐ES}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: DURVALUMAB CAS Number: 1428935‐60‐7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ CONDITION: Patients with unresectable Stage III non‐small cell lung cancer (NSCLC), who have not progressed following platinum‐based sequential chemoradiation therapy (sCRT) ; MedDRA version: 20.0 Level: PT Classification code 10029519 Term: Non‐small cell lung cancer stage III System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: ‐ To assess the safety and tolerability profile of durvalumab (MEDI4736) as defined by Grade 3 and Grade 4 TRAEs within 6 months from the initiation of durvalumab (MEDI4736) treatment. Primary end point(s): Grade 3 or Grade 4 TRAEs Secondary Objective: ‐ To assess the efficacy of durvalumab (MEDI4736) treatment in terms of PFS and OS.; ‐ To further assess the efficacy of durvalumab (MEDI4736) treatment in terms of ORR and DoR.; ‐ To assess the efficacy of durvalumab (MEDI4736) treatment in terms of lung cancer mortality.; ‐ To further assess the safety and tolerability profile of durvalumab (MEDI4736) treatment, including all AEs. Timepoint(s) of evaluation of this end point: Patients will receive IMP every 4 weeks (q4w) for a maximum of 24 months.; ; Efficacy for all patients will be assessed every 8 weeks (q8w) for the first 12 months and every 12 weeks (q12w) thereafter, until disease progression; plus an additional follow‐up scan is performed if clinically feasible. Additional scans can be completed per standard practice post disease progression.; ; Patients who have discontinued treatment will be followed up for 90 days after IP discontinuation, and thereafter followed up with tumour assessments until RECIST 1.1‐defined radiological PD plus an additional follow‐up scan or until death (whichever comes first). SECONDARY OUTCOME: Secondary end point(s): ‐ Median PFS according to RECIST 1.1 as assessed by the Investigator.; ‐ PFS12 and PFS24 according to RECIST 1.1 as assessed by the Investigator.; ‐ Median OS, OS12, OS24, and OS36.; ‐ ORR according to RECIST 1.1 as assessed by the Investigator.; ‐ DoR according to RECIST 1.1 as assessed by the Investigator.; ‐ Lung cancer mortality.; ‐ AEs, SAEs, AESIs, imAEs, physical examinations, vital signs including BP, pulse, ECGs, and laboratory findings including clinical chemistry, haematology and urinalysis. Timepoint(s) of evaluation of this end point: Patients will receive IMP every 4 weeks (q4w) for a maximum of 24 months.; ; Efficacy for all patients will be assessed every 8 weeks (q8w) for the first 12 months and every 12 weeks (q12w) thereafter, until disease progression; plus an additional follow‐up scan is performed if clinically feasible. Additional scans can be completed per standard practice post disease progression.; ; Patients who have discontinued treatment will be followed up for 90 days after IP discontinuation, and thereafter followed up with tumour assessments until RECIST 1.1‐defined radiological PD plus an additional follow‐up scan or until death (whichever comes first).; ; All patients in the study should be followed up for survival every 12 weeks until death, withdrawal of consent, or the end of the study. INCLUSION CRITERIA: ‐ Informed consent as detailed in the protocol. ‐ 18 years or older at the time of signing the ICF. ‐ Histologically‐or cytologically‐documented NSCLC with locally‐advanced, unresectable Stage III disease (according to the IASLC Staging Manual Version 8 [IASLC 2016]). Positron emission tomography (PET)/CT, MRI of the brain, and endobronchial ultrasound with biopsy are highly encouraged at diagnosis. ‐ Receipt of sCRT which must have been completed within 28 days prior to first IP dose administration in the study as defined in the protocol. ‐ Patients must not have progressed following platinum‐based sCRT, as per Investigator‐assessed RECIST 1.1 criteria as defined in the protocol. ‐ Must have a life expectancy of at least 12 weeks at enrolment. ‐ WHO/ECOG PS =2. ‐ Adequate organ and marrow function at enrolment as defined in the protocol. ‐ Body weight >30 kg at enrolment and first IP dose administration. ‐ Male or female. ‐ Evidenc}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01950227/full} -} - - -Record #326 of 538 -@article{Antonoff21, -author = {Antonoff, M}, -title = {ES03.05 Surgery as a Component of Local Consolidative Therapy}, -journal = {Journal of thoracic oncology}, -volume = {16}, -number = {3}, -pages = {S68‐S69}, -year = {2021}, -accession_number = {EMBASE 2011421606}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer surgery; *histology; Adult; Advanced cancer; Bone metastasis; Cancer growth; Cancer patient; Cancer radiotherapy; Cancer survival; Chemotherapy; Clinical evaluation; Clinical trial; Conference abstract; Controlled study; Disease burden; Disease free interval; Drug safety; Drug therapy; Feasibility study; Female; Fibrosis; Follow up; Gene rearrangement; Histopathology; Human; Human tissue; Immunotherapy; Local therapy; Long term survival; Lung lobectomy; Lymph node; Maintenance therapy; Major clinical study; Male; Median survival time; Minimal residual disease; Molecularly targeted therapy; Mortality; Multicenter study; Non small cell lung cancer; Overall survival; Patient selection; Pharmacokinetics; Phase 2 clinical trial; Phase 3 clinical trial; Primary tumor; Progression free survival; Pulmonary artery; Radiotherapy; Randomized controlled trial; Remission; Resource allocation; Surgery; Systemic therapy; Thoracotomy}, -abstract = {Historically, treatment for non‐small cell lung cancer (NSCLC) has been stage‐dependent, with surgery typically considered the standard of care for stage I disease and a potential component of multi‐modality care for stages II‐III. By contrast, for stage IV disease, therapy aimed at prolongation of life has included systemic treatments, including chemotherapy, and, in recent years, targeted agents and immunotherapy. For metastatic disease, surgery has previously had a fairly limited role. However, oligometastatic disease may offer a potential opportunity for more aggressive local options. The distinct tumor biology and limited disease burden may be associated with improved outcomes.1 The landmark oligometastatic trial published by Gomez in 20162 aimed to assess the effect of local consolidative therapy (LCT) on progression‐free survival (PFS) of patients with 3 or fewer metastases who received standard first‐line chemotherapy, and patients were randomized to LCT vs maintenance treatment. LCT improved PFS and time to development of new metastatic lesions. Moreover, comprehensive LCT (cLCT) was also shown to improve overall survival (OS).3 A subsequent review from our institution of 194 patients, including those both on and off the oligometastatic clinical trial, aimed to identify those patients who would derive greatest benefit from LCT.4 This study revealed that cLCT was associated with improved OS, with median survival of 29 months for cLCT compared to 23 months for those with subcomprehensive LCT or no LCT. Moreover, lower intrathoracic stage, non‐squamous histology, and absence of bone metastases were all associated with improved OS after cLCT, theoretically identifying those patients most likely to benefit from aggressive local therapy—which can consist of surgery or radiation. In terms of surgery itself, we next aimed to evaluate the outcomes of operative pulmonary resection as LCT in oligometastatic disease,5 using radiotherapy as a benchmark comparator. Evaluating patients with 3 or fewer synchronous metastases and received LCT to all sites, we analyzed survival and progression. Surgery to the primary tumor was performed in 28% after a median of 3.7 months. 90‐day post‐treatment mortality after surgery was 0%, and, after a median follow‐up of 57 months, median OS after surgery was greater than 55 months. Median OS for radiation in this group was 23 months. Thus, it was concluded that surgery should remain a component of LCT for operable oligometastatic NSCLC patients, and it should be considered in randomized trial for patients with metastatic disease. While surgery has demonstrated survival benefits in the oligometastatic population, the potential complexity of these procedures cannot be overstated. In our institutional experience, thoracotomies have been required in more than 4/5 of operations, and adhesions and hilar fibrosis have been common. Events such as need for proximal pulmonary arterial control and unplanned changes in extent of operation are not infrequent, and the majority of cases have been reported as more difficult than usual. Thus, proper patient selection for surgery is imperative, as is preparation for the types of resources potentially needed for these cases. Despite surgical complexity, ability to achieve negative margins and to safely manage the patients perioperatively has been reassuring. Given the success of surgery as a component of LCT, surgery has become an important part of ongoing clinical trials evaluating LCT after novel agents for metastatic NSCLC. The LONESTAR trial6 aims to evaluate the benefits of LCT after immunotherapy, in that patients receive 12 weeeks of ipilumimab and nivolumab, after which those individuals with non‐progressive disease are randomized to LCT + continued immunotherapy vs continued immunotherapy alone. While radiation is required to at least one disease site, surgery to the primary site of disease is emphasized whenever possible. Similar to the LONESTAR trial, the NORTHSTAR trial is investigating the role of LCT after tyrosine‐kinase inhibitor therapy for patients with EGFR‐mutant metastatic NSCLC. Patients who have non‐progressive disease after 6‐12 weeks of osimertinib are randomized to LCT vs continued targeted therapy, again, offering surgery whenever feasible to the primary site of disease.7 More recently, the BRIGHTSTAR trial was initiated, evaluating the role of LCT after 8 weeks of brigatinib for patients with metastatic ALK‐mutated NSCLC, with the primary endpoints of safety and feasibility and secondary endpoints of PFS, OS, and time to progression.8 A number of patients have already undergone surgery on each of these trials, with promising perioperative outcomes. Despite the potential for innovation and expanded surgical indications, consideration must be given to the safety and potential technical challenges in such cases. We must consider issues related to fibrosis, adhesions, and sclerotic lymph nodes, as well as our limitations in identifying those patients with residual disease vs complete response. Surgery as LCT for oligometastatic NSCLC represents an exciting frontier for thoracic surgery, as a potential opportunity to help patients with advanced disease. Implications for training and resource allocation remain ever pertinent, and surgery needs to be considered as a potential therapeutic component in novel clinical trials in even advanced disease. References: 1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995 Jan;13(1):8‐10. 2. Gomez DR et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non‐small‐cell lung cancer without progression after first‐line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec;17(12):1672‐1682. 3. Gomez DR et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non‐Small‐Cell Lung Cancer: Long‐Term Results of a Multi‐Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 Jun 20;37(18):1558‐1565. 4. Mitchell KG et al. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non‐Small‐Cell Lung Cancer. Clin Lung Cancer. 2020 Jan;21(1):37‐46.e7. 5. Mitchell KG et al. Pulmonary resection is associated with long‐term survival and should remain a therapeutic option in oligometastatic lung cancer. J Thorac Cardiovasc Surg. 2020 Mar 25:S0022‐5223(20)30633‐4. 6. Phase III Trial of (LCT) After Nivolumab and Ipilimumab, 7. Elamin YY et al. Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR‐mutant metastatic NSCLC (NORTHSTAR). Annals of Oncology (2018)29 (suppl_8):viii493‐viii547. 8. Elamin Y et al. BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)‐naïve ALK‐rearranged advanced NSCLC.Journal of Clinical Oncology 2020 38:15_suppl, 9624‐9624 Keywords: Surgery, OLIGOMETASTATIC, NSCLC}, -DOI = {10.1016/j.jtho.2021.01.018}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02267475/full} -} - - -Record #327 of 538 -@article{Liveringhouse22, -author = {Liveringhouse, C, Latifi, K, Asous, A, Cruz-Chamorro, R, Mills, M, Li, J, Schell, M, Rosenberg, S, Dilling, T, and Perez, B}, -title = {Early Post-treatment Imaging Changes May Predict Pulmonary Toxicity in Patients with Locally Advanced Nonsmall Cell Lung Cancer Receiving Definitive Chemoradiation and Immunotherapy}, -journal = {American journal of clinical oncology: cancer clinical trials}, -volume = {45}, -number = {9}, -pages = {S17‐S18}, -year = {2022}, -accession_number = {EMBASE 639173545}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *chemoradiotherapy; *immunotherapy; *lung toxicity; *non small cell lung cancer; Aged; Cancer size; Chronic obstructive lung disease; Clinical article; Clinical trial; Computer assisted tomography; Conference abstract; Controlled study; Disease exacerbation; Drug combination; Drug therapy; Female; Human; Log rank test; Lung complication; Lung fibrosis; Male; Mitigation; Phase 1 clinical trial; Planning target volume; Pneumonia; Primary tumor; Prospective study; Radiotherapy; Thorax}, -abstract = {Background: High grade pulmonary toxicity is a rare but possibly lifethreatening complication in patients with locally advanced non‐small cell lung cancer (NSCLC) treated with chemoradiation (chemoRT) and immunotherapy (IO). Prior studies suggest that the percent of lung receiving 20 Gy (V20) is associated with the development of pneumonitis [1]. Objectives: We aimed to assess whether density changes within the region of lung receiving 20 Gy (ROL 20 Gy) on restaging imaging following definitive chemoRT were associated with subsequent development of grade ≥ 2 pulmonary toxicity. Methods: We assessed the time to grade ≥2 pulmonary adverse events (PAE; including pneumonitis, pulmonary fibrosis, exacerbation of chronic obstructive pulmonary disease, or pneumonia) in 19 patients participating in a multi‐institution phase I clinical trial in which they received chemoRT to 60 Gy with concurrent ipilimumab followed by maintenance nivolumab. We calculated the relative change in mean Hounsfield Units (HU) within the ROL 20 Gy on the first restaging computed tomography (CT) scan of the thorax following chemoRT, compared to the baseline staging CT thorax, expressed as the percent change from baseline. Means were compared between groups with T‐tests. Time to event analyses were performed with Kaplan‐Meier models and log‐rank tests. Results: The median age was 66 years (range 39‐76). Six patients received cisplatin/etoposide, five received carboplatin/paclitaxel, and eight received cisplatin/pemetrexed. The median primary tumor diameter was 4.95cm (range 1.7‐9.1) and the median planning target volume (PTV) was 627.9cc (range 220.5‐1774.8). The median HU change in the ROL 20 Gy was 4.9% (range 18.4‐39.8). Highest grade PAE was grade 2 (n=3, 16%), grade 3 (n=5, 26%), and grade 5 (n=3, 16%). The median time to grade ≥ 2 PAE was 4.1 months (95% confidence interval 2.6‐not reached). Patients with grade ≥2 PAE had non‐significantly increased mean lung V20 (28% vs 21%, P=0.18), mean lung dose (16.5 Gy vs 13.0 Gy, P=0.35), and PTV volume (717 cc vs 539 cc, P =0.43) compared to those without grade ≥2 PAE. The mean relative HU change in the ROL 20 Gy was significantly higher for patients with grade ≥2 PAE compared to those without (13.9% vs ‐1.8%, P=0.048). Patients with ROL 20 Gy HU change ≥ 4.9% (≥cohort median value) had significantly shorter median time to grade ≥2 PAE compared to those with HU change <4.9% (3.3 months, 95% CI 1.7‐4.1 vs not reached, 95% CI 4.3‐not reached; P= 0.017) (Fig. 1). Conclusions: Patients with early increases in density within the region of lung receiving 20 Gy may be at increased risk for high grade pulmonary adverse events after definitive chemoRT and IO. We hypothesize such patients might be candidates for early mitigation strategies, such as early steroid intervention or delay of maintenance IO. Prospective study will be necessary to validate these findings.}, -DOI = {10.1097/COC.0000000000000933}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02489825/full} -} - - -Record #328 of 538 -@article{Liu21, -author = {Liu, H, Qiu, B, Wang, D-Q, Zhang, X, Zhou, Y, Li, Q-W, Chu, C, Liu, F-J, Chen, N-B, Hu, N, Ai, X-L, Guo, J-Y, and Fan, W}, -title = {Dynamic 18F-FDG Total body PET Imaging as a predictive marker of induction chemo-immunotherapy response in locally advanced nonsmall cell lung cancer}, -journal = {Journal of clinical oncology}, -volume = {39}, -number = {15 SUPPL}, -year = {2021}, -accession_number = {EMBASE 635590691}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *immunotherapy; *non small cell lung cancer; *positron emission tomography‐computed tomography; Adult; Cancer patient; Cancer staging; Chemoradiotherapy; Clinical article; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Drug therapy; Female; Foot; Glycolysis; Human; Influx rate constant; Lymph node metastasis; Male; Metabolic tumor volume; Nuclear medicine; Phase 2 clinical trial; Prospective study; Radiation oncologist; Radiotherapy; Randomized controlled trial; Standardized uptake value}, -abstract = {Background: The purpose of this study was to evaluate the efficacy of dynamic 18F‐FDG total body PET imaging as a predictive maker of induction chemo‐immunotherapy response in locally advanced non‐small cell lung cancer(NSCLC) by a prospective study. Methods: Stage IIIA‐IIIC NSCLC patients were prospectively enrolled in a prospective total body PETCT study ( NCT04654234, GASTO‐1067) and a randomized phase II clinical trial ( NCT04085250) between September 2020 and December 2020. All patients underwent a dynamic total‐body 18F‐FDG PET/CT scan before any treatment and after 2 cycles of induction chemo‐immunotherapy (docetaxel+cisplatin+nivolumab). The primary lung tumor, metastatic regional lymph node and inflammatory lymph node before and after treatment were manually delineated by a nuclear medicine physician and a radiation oncologist. Total Body PET was acquired between 0 ‐ 60 mins after the injection of FDG from the subject's feet. Patients was separated into high dynamic FDG metabolic (H‐DFM) group and low DFM(L‐DFM) group by the scatter plot of SUV‐mean and Ki‐mean of primary lung tumor. We compared lesion heterogeneity and different image‐derived PET metrics including the metabolic tumor volume(MTV), SUV total lesion glycolysis(SUVTLG), Patlak‐derived influx rate constant (Ki) TLG (Ki‐TLG). Results: Fifteen patients were analyzed, 8 patients was in H‐DFM group and 7 in L‐DFM group. Patients in H‐DFM group had significant decreased levels of MTV(p < 0.001), SUV‐TLG(p < 0.001) and Ki‐TLG(p < 0.001) both in primary lung tumor and metastatic lymph node by the induction chemo‐immuotherapy. However, patients in L‐DFM group only had a significant reduction of MTV in primary lung tumor(p < 0.05). There was no significant difference in the MTV of metastatic lymph node(p > 0.5), the SUV‐TLG(p > 0.5) and Ki‐TLG(p > 0.5) of primary lung tumor and metastatic lymph node, before and after induction chemoradiotherapy. Conclusions: Patients in H‐DFM group had the better treatment response of induction chemo‐immunotherapy with significant decreased levels of MTV, SUV‐TLG and Ki‐TLG. Dynamic 18F‐FDG Total body PET Imaging could be regard as a potential predictive marker of induction chemoimmunotherapy response in the setting of LANSCLC.}, -DOI = {10.1200/JCO.2021.39.15-suppl.e20551}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02305793/full} -} - - -Record #329 of 538 -@article{ISRCTN7177293510, -author = {ISRCTN71772935,}, -title = {Immunotherapy with racotumomab versus support treatment in advanced non-small cell lung cancer patients}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN71772935}, -year = {2010}, -accession_number = {ICTRP ISRCTN71772935}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Patients will be randomised to: 1. Best support treatment alone 2. Best support treatment plus racotumomab All patients will receive best support treatment. In case a second line treatment is indicated, the drug to be used is docetaxel. Patients randomised to racotumomab group will be vaccinated until any causes of permanent discontinuation are met: unacceptable toxicity, intercurrent disease or other reactions that might in the investigator's opinion constitute an exclusion criteria and/or permanently prevent administration for more than 8 weeks, deterioration of the performance status (PS) greater than 3, patient request and/or failure to comply with treatment during 8 or more weeks. The vaccine is administered intradermically in 4 subdoses at selected sites: deltoid region, anterior forearms, anterior thighs and posterior calf. The first 5 doses are administered at 14 day intervals and the remaining doses at 28 day intervals. If for any reason the vaccine is discontinued the patient will continue with follow up visits (every 2 months) for evaluation of survival just as the patients in the best support treatment arm do. Tumour evaluations will be performed every 8 weeks. For racotumomab arm only blood sampling for immunological tests will be obtained at baseline for both groups and at month 2, 4, 8 and 12 and every 4 months onwards. For both treatment arms sampling for determination of suppressor cells (T reg) will be performed at baseline, month 2, 4, 8, 12 and every 4 months onwards, at disease progression and upon completion of second line therapy. CONDITION: Non‐small cell lung cancer (advanced) ; Cancer ; Malignant neoplasm of the lung PRIMARY OUTCOME: 1. Safety: will be evaluated at each study visit according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and will include physical examination with vital signs, performance status (ECOG scale), laboratory tests and clinical history. Patients in racotumomab arm attend five biweekly visits (induction period of vaccination), then monthly visits until vaccine is discontinued. After vaccine discontinuation, patients on this arm continue with visits every 2 months. Patients in best supportive care arm: visits every 2 months until end of study.; 2. Immunological response to racotumomab: blood sampling for this test will be performed at baseline, month 2, 4, 8 and 12 and thereafter every 4 months until death or patient withdrawal from the study; 3. Determination of T reg cells for both arms: blood sampling for this test will be performed at baseline, month 2, 4, 8, 12 and thereafter every 4 months until end of second‐line onco‐specific therapy SECONDARY OUTCOME: 1. Survival: survival time will be monitored from the date of random assignment to the date of death or last censored observation; 2. Progression‐free survival: tumour evaluations will be performed from baseline visit and every 2 months and evaluated as per RECIST INCLUSION CRITERIA: 1. The patient (aged over 21 years, either sex) can comply with the protocol and scheduled appointments and voluntarily sign the informed consent form 2. Diagnosis of NSCLC stages IIIA (surgically unresectable), IIIB or IV, according to the TNM classification version 6a, confirmed by cytology or histology, if possible available for determination of ganglioside expression 3. Patients may enter the study if they have accomplished an objective response (complete response or partial response) or disease stabilisation (by Response Evaluation Criteria In Solid Tumours [RECIST]) after completion of standard onco‐specific treatment. In all cases, response should be documented. 3.1. For stage IIIA and IIIB without pleural effusion ('dry IIIB') standard treatment is considered as follows: 2 ‐ 4 cycles of platinum‐based chemotherapy and/or radiotherapy with curative intent in accordance with NCCN guidelines 3.2. For stage IIIB with pleural effusion ('wet IIIB') and}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01846490/full} -} - - -Record #330 of 538 -@article{Smit19, -author = {Smit, E}, -title = {IBS12.02 Questions to Be Addressed}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S103}, -year = {2019}, -accession_number = {EMBASE 2003405586}, -publication type = {Journal article; Conference proceeding}, -keywords = {Adult; Advanced cancer; Avoidance behavior; Brain metastasis; Cancer patient; Cancer prognosis; Cancer radiotherapy; Cancer recurrence; Cancer surgery; Cancer survival; Conference abstract; Controlled study; Decision making; Drug combination; Drug megadose; Female; Hippocampus; Histology; Histopathology; Human; Human tissue; Immunotherapy; Local metastasis; Local therapy; Male; Netherlands; Non small cell lung cancer; Patient preference; Prognosis; Quality of life; Radiation oncology; Radiotherapy; Randomized controlled trial; Relapse; Stereotactic radiosurgery; Survival; Systemic therapy; Whole brain radiotherapy}, -abstract = {Case‐Based Management of Brain Metastasis (Bm) in Advanced Lung Cancer Patients: Changing the Standards. Questions to Be Addressed M. Guckenberger, E.F. Smit Dept. of Radiation Oncology, USZ, Switserland, Dept. of Thoracic Oncology, NCI, The Netherlands. Brain metastases develop in relevant numbers of patients through their courses of metastatic non‐small cell lung cancer (NSCLC) and are associated with worsening of quality‐of‐live and survival. Traditionally, outcome was very poor due to the lack of effective treatment options, for the brain metastases but also for extracranial metastatic disease. Recent advances in imaging, local and systemic treatment options have changed the prognosis of patients with NSCLC brain metastases and have challenged traditional treatment strategies. Management of patients with brain metastases today needs a more individualized approach due to the multiple factors influencing the decision‐making process: patient performance status; number, location and size of brain metastases; presence of symptoms and neurological deficits; presence and extend of extracranial disease; histology and presence of activating driver mutations; available systematic treatment options and their CNS activity; patient preference. From a local treatment perspective, radiosurgery and neurosurgical resection are treatment options, which have shown to improve survival in patients with limited brain metastases. Whole brain radiotherapy is not recommended after radiosurgery and neurosurgical resection; however stereotactic radiotherapy should be added to the resection cavity to improve local metastasis control. The value of radiosurgery without whole brain irradiation for multiple brain metastases is currently under investigation. Whole brain irradiation is today still recommended for patients with multiple and in particular symptomatic brain metastases; whether hippocampal avoidance can reduce the risk of damage to the neurocognitive system is not finally answered. The landscape is currently changing rapidly and fundamentally due to identification of activating driver mutations and the existence of effective targeted drugs. Additionally, treatment with immune checkpoint inhibition has also shown intracranial activity. Consequently, there is in particular a need to identify optimal combined modality strategies of local radiotherapy and systemic targeted drugs and immunotherapy. From a systemic treatment perspective, it has become apparent that brain metastases may also be sensitive to tyrosine kinase inhibitors against a variety of targets and emerging data suggest that immune checkpoint inhibitors display activity as well. Therefore, in case of asymptomatic brain metastases at diagnosis when the primary lung cancer is characterized by an oncogenic driver, nowadays many would favour initial treatment with tyrosine kinase inhibitors in an effort to delay radiotherapy to the brain as long as possible. Whether symptomatic brain metastases at diagnosis may be managed in a similar manner, especially when refractory to high dose steroids, is less clear. The third generation EGFR TKI (osimertinib) and second/third generation Alk inhibitors (ceritinib, alectinib, brigatinib and lorlatinib) are associated with response rates in the brain in the relapse setting on treatment of first/second generation EGFR TKi’s or first generation Alk inhibitor that are not different from extracranial response rates. Thus, also in this clinical situation, systemic treatment plays an important role in delaying radiotherapy – in particular whole brain radiotherapy‐ as long as possible. It should be noted however, that there are no formal randomized comparisons available of these treatment modalities. Keywords: NSCLC, brain metastases}, -DOI = {10.1016/j.jtho.2019.08.225}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01998935/full} -} - - -Record #331 of 538 -@article{Gomez18, -author = {Gomez, DR}, -title = {Radiation therapy in lung cancer: recent trends and future directions}, -journal = {Clinical cancer research}, -volume = {24}, -number = {17}, -year = {2018}, -accession_number = {EMBASE 627851668}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Adult; Advanced cancer; Cancer staging; Chemoradiotherapy; Conference abstract; Controlled study; Drug combination; Female; Human; Immunotherapy; Male; Multicenter study; Phase 2 clinical trial; Prospective study; Proton therapy; Radiotherapy; Randomized controlled trial; Whole body radiation}, -abstract = {Radiation techniques for lung cancer have evolved substantially over the past decade. While previously many patients were treated with 3D conformal therapy, with large uniform margins placed to estimate respiratory motion in the 'average' tumor, patients are now simulated with sophisticated, real‐time monitoring of internal motion such that treatment volumes can be individualized to maximize normal tissue sparing through image‐guided radiation therapy (IGRT). In addition, many patients are now treated with intensity‐modulated radiation therapy (IMRT), which has served to drastically improve conformality in select cases and increase the proportion of patients in which high doses are achievable. Concurrent with these advances, proton beam therapy (PBT) has been implemented in a limited number of centers, with the hope of utilizing the dosimetric distribution advantage of the Bragg Peak to further reduce toxicity. The role of PBT in both early‐stage and locally advanced non‐small cell lung cancer continues to be defined, as results from a phase II multicenter randomized trial predominantly in patients with stage II‐III disease did not demonstrate superiority with PBT and concurrent chemotherapy when compared to similar regimens with IMRT. Finally, there have been much data produced with regard to dosing regimens. In early‐stage disease, there has been increased implementation of stereotactic ablative body radiation (SABR), with prospective data emerging for both peripheral and central lesions. In the locally advanced setting, results from RTOG 0617 demonstrated no difference when comparing 60 Gy vs. 74 Gy in the setting of chemoradiation. There has also been a trend towards hypofractionation for patients who are unable to tolerate concurrent chemoradiation or those with oligometastatic disease, yet the benefit of hypofractionated radiation sequentially vs. combined modality treatment will need to be further assessed in prospective randomized trials, particularly in the era of immunotherapy.}, -DOI = {10.1158/1557-3265.AACRIASLC18-IA31}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01934844/full} -} - - -Record #332 of 538 -@article{Simone24, -author = {Simone, CB, Hu, C, Heinzerling, JH, Mileham, K, Higgins, KA, Lin, L, Abazeed, M, Ohri, N, and Bradley, JD}, -title = {NRG LU008: phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy (SBRT) Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC)}, -journal = {International journal of radiation oncology biology physics}, -volume = {120}, -number = {2}, -pages = {e63}, -year = {2024}, -accession_number = {EMBASE 2034286422}, -publication type = {Conference proceeding}, -keywords = {*chemoradiotherapy; *lung tumor; *non small cell lung cancer; *stereotactic body radiation therapy; Adult; Cardiotoxicity; Clinical trial; Conference abstract; Drug therapy; Female; Human; Lung function; Lung ventilation; MRI scanner; Maintenance therapy; Nuclear magnetic resonance imaging; Overall survival; Phase 2 clinical trial; Phase 3 clinical trial; Primary tumor site; Progression free survival; Quality of life; Radiotherapy; Randomized controlled trial; Systemic therapy}, -abstract = {Purpose/Objective(s): Outcomes remain poor for unresectable LA‐NSCLC treated with concurrent chemoradiation followed by immunotherapy. The primary tumor is the most common site of non‐metastatic failure, and local failure (LF) is associated with overall survival (OS). While local control (LC) and OS have improved by increasing the biological effective dose with SBRT in early‐stage NSCLC, SBRT use in LA‐NSCLC has largely been limited to primary tumor boost after chemoradiation, which has high morbidity. A recent phase II trial of SBRT to the primary tumor and chemoradiation to involved lymph nodes demonstrated lower rates of pulmonary and cardiac toxicities relative to historical controls, while improving LC, progression‐free survival (PFS), and OS. We hypothesize that replacing conventionally fractionated radiotherapy with SBRT to the primary tumor followed by concurrent chemoradiation to the mediastinum will be associated with lower rates of toxicity and improved QOL, while also improving LC, PFS, and OS. Materials/Methods: LU008 is a phase III randomized trial in stage II‐III NSCLC conducted by NRG Oncology (NCT05624996). Inclusion criteria include node‐positive stage II‐III NSCLC, medically inoperable or surgery declined, identified primary tumor ≤7 cm, ECOG performance status (PS) 0‐2, and ≤4 cycles of systemic therapy prior to registration. Key exclusion includes central primary tumor location that is <2cm from involved nodal disease. Patients are randomized to chemoradiation to all disease (60/2 Gy) (control arm) or SBRT to the primary (BED ≥100 Gy in 3‐5 fractions) followed by chemoradiation to nodal disease (60/2 Gy) (experimental arm). Standard concurrent chemotherapy regimens are allowed in both arms. Maintenance therapy is pragmatic, with most patients expected to receive durvalumab for up to 12 months. The primary objectives are to compare OS and PFS. Secondary objectives are to compare response rate, LC, patterns of failure, pulmonary function changes, QOL, and toxicity. Exploratory objectives include biospecimen analyses, regional lung ventilation, and proton vs. photon differences. Real‐time pre‐treatment reviews are conducted. Results: LU008 was activated nationally on 5/10/23. As of 3/1/24, 30 patients have been accrued, and 266 sites have the trial open to accrual. Final target accrual is 474 subjects, with an expected 9.5 accruals per month after a 6‐month ramp up. Conclusion: LU008 is a thoracic NCI National Clinical Trial Network (NCTN) trial with highly pragmatic eligibility criteria, with no lab/PFT cutoffs, no CT chest/MRI brain/lab time windows, no exclusions for actionable mutations, and allowing ECOG PS 2. LU008 is the only phase III NCTN trial accruing for inoperable LA‐NSCLC and may change the standard of care in inoperable LA‐NSCLC by improving LC, PFS, and OS. Funding: Grants U10CA180868 (NRG Operations), U10CA180822 (NRG SDMC), UG1CA189867 (NCORP), U24CA196067 (NRG Specimen Bank), U24CA180803 (IROC) from the National Cancer Institute (NCI).}, -DOI = {10.1016/j.ijrobp.2024.07.1917}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02747338/full} -} - - -Record #333 of 538 -@article{N24, -author = {N, C, Jain, A, C, S, Shreevatsa, B, Rajendrasozhan, S, Dharmashekar, C, Suresh, KP, Patil, SS, Singh, P, Vishwanath, P, Srinivasa, C, Kollur, SP, and Shivamallu, C}, -title = {Progression-free survival estimation of docetaxel-based second-line treatment for advanced non-small cell lung cancer: a pooled analysis from 18 randomized control trials}, -journal = {Frontiers in oncology}, -volume = {14}, -pages = {1298786}, -year = {2024}, -accession_number = {PUBMED 38807763}, -publication type = {Journal article}, -abstract = {BACKGROUND: Lung cancer is the foremost cause of cancer‐related death globally, with non‐small cell lung cancer (NSCLC) accounting for 85‐90% of cases. Targeted therapy is the most essential therapeutic option for NSCLC, other common treatments include radiation therapy, surgery, chemotherapy, and immunotherapy. OBJECTIVE: Our study objective was to estimate whether progression‐free survival (PFS) is an outcome of NSCLC extracted from 18 randomized control trials (RCTs) with docetaxel as experimental group and antineoplastic agent, kinase inhibitor, and monoclonal antibodies as a control group. METHODS: We selected relevant studies published between 2011 and 2022 using Google Scholar, PubMed, Scopus, Science Direct, and Cochrane Library. Advanced NSCLC, chemotherapy, RCT, docetaxel, and second‐line treatment were the terms included in the search. A total of 9738 patients were evaluated from the 18 identified studies. We used the meta package of R Studio to perform the meta‐analysis. Graphical funnel plots were used to evaluate publication bias visually. RESULTS: Patients who underwent docetaxel‐based therapy had a considerably longer PFS than those who got antineoplastic agents, kinase inhibitors, or monoclonal antibodies‐based treatment. Patients in the standard treatment arm had a slightly longer PFS than those in the experimental therapy arm in the overall meta‐analysis. CONCLUSION: Docetaxel outperformed monoclonal antibodies, antineoplastic agents, and kinase inhibitors in the second‐line therapy of advanced NSCLC since PFS was extensively utilized.}, -DOI = {10.3389/fonc.2024.1298786}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02703866/full} -} - - -Record #334 of 538 -@article{ChiCTR220005545322, -author = {ChiCTR2200055453,}, -title = {A randomized, double-blind, placebo-controlled study of Fuzheng Kang'ai Decoction combined with PD-1 inhibitor in the treatment of phlegm-damp-type advanced non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200055453}, -year = {2022}, -accession_number = {ICTRP ChiCTR2200055453}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Experimental group:PD‐1 Inhibitor + Fuzheng Kang'ai Fang Granules;Control group:PD‐1 Inhibitor + Fuzheng Kang'ai Fang Placebo; CONDITION: non‐small cell lung cancer (NSCLC) PRIMARY OUTCOME: progression free survival; SECONDARY OUTCOME: objective response rate;overall survival;disease control rate;1‐year survival rate;quality of life;intestinal flora structure; INCLUSION CRITERIA: 1. According to the 8th edition of the TNM staging classification of lung cancer by the International Association for the Study of Lung Cancer and the American Joint Committee on Classification of Cancer, subjects with histologically or cytologically proven inoperable metastatic or recurrent (stage IV) NSCLC who have received first‐line therapy, or first‐line subjects who refuse chemotherapy; 2. PD‐L1<50%; 3. The TCM syndrome type is phlegm‐dampness syndrome; 4. Aged 18‐80 years; 5. Life expectancy is more than 3 months; 6. Investigator‐certified at least one measurable lesion according to RECIST 1.1 criteria. Measurable lesions located in the field of previous radiotherapy or after local treatment can be selected as target lesions if progression is confirmed; 7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; 8. Sufficient hematological function, defined as absolute neutrophil count >=1.5x10^9/L, platelet co}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02520433/full} -} - - -Record #335 of 538 -@article{ChiCTR200003141120, -author = {ChiCTR2000031411,}, -title = {A clinical trial of fecal bacteria transplantation combined with pembrolizumab, pemetrexed and carboplatin as a first-line treatment of EGFR and ALK wild-type metastatic non-squamous, non-small cell lung cancer}, -journal = {http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000031411}, -year = {2020}, -accession_number = {ICTRP ChiCTR2000031411}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Experience group:Fecal bacteria transplantation, Pembrolizumab, Pemetrexed and Carboplatin.;Control group:Placebo, Pembrolizumab, Pemetrexed and Carboplatin; CONDITION: Lung cancer PRIMARY OUTCOME: ???;Progression free survival;Fecal flora analysis; INCLUSION CRITERIA: 1. Voluntary written informed consent. The informed consent must be signed before proceeding with any program related procedures. Subjects must be willing and able to comply with scheduled visits, treatment regiments, laboratory tests, and other requirements of the study. 2. The age at the time of signing the informed consent is >= 18 years old and <= 75 years old, , both male and female. 3. The eastern oncology collaboration (ECOG) physical fitness score is 0 or 1. 4. Expected survival >= 3 months. 5. Metastatic (stage IV) non‐squamous, non‐small cell lung cancer (NSCLC) with histological or cytological confirmation that it is inoperable and cannot be treated with radical concurrent chemoradiotherapy, according to TNM staging in the 8th edition of the international association for lung cancer research and the American joint committee on the classification of cancer. 6. Subjects have not received systemic chemotherapy for advanced or}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02446986/full} -} - - -Record #336 of 538 -@article{EUCTR2012-002472-14-IT12, -author = {EUCTR2012-002472-14-IT,}, -title = {Study of BMS-936558 compared to Docetaxel in previously treated advanced or metastatic Non-squamous NSCLC}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2012-002472-14-IT}, -year = {2012}, -accession_number = {ICTRP EUCTR2012‐002472‐14‐IT}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: NA Product Code: BMS‐936558 Pharmaceutical Form: Solution for infusion CAS Number: 946414‐94‐4 Current Sponsor code: BMS‐936558‐01 Other descriptive name: Anti‐PD‐1 Human Monoclonal Antibody; MDX‐1106 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ Trade Name: Taxotere 160 mg (20 mg/mL) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: DOCETAXEL CAS Number: 114977‐28‐5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20‐ CONDITION: Non‐Squamous cell Non‐small cell lung cancer ; MedDRA version: 14.1 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: The purpose of the study is to compare the overall survival of BMS‐ 936558 as compared with Docetaxel in subjects with non‐ squamous cell non‐small cell lung cancer (NSCLC) after failure of prior platinumbased chemotherapy Primary end point(s): Overall Survival Secondary Objective: 1. To compare the objective response rate of BMS‐936558 versus docetaxel 2. To compare the progression‐free survival (PFS) of BMS‐936558 versus docetaxel 3. To evaluate clinical benefit of BMS‐936558 versus docetaxel, in PD‐L1 + versus PD‐L1‐ protein expression subgroups 4. To evaluate the proportion of subjects exhibiting disease‐related symptom progression, as measured by LCSS, in BMS‐936558 and docetaxel groups Timepoint(s) of evaluation of this end point: 24 months SECONDARY OUTCOME: Secondary end point(s): 1. To compare the objective response rate of BMS‐936558 versus docetaxel 2. To compare the progression‐free survival (PFS) of BMS‐936558 versus docetaxel 3. To evaluate clinical benefit of BMS‐936558 versus docetaxel, in PD‐L1 + versus PD‐L1‐ protein expression subgroups 4. To evaluate the proportion of subjects exhibiting disease‐related symptom progression, as measured by LCSS, in BMS‐936558 and docetaxel groups Timepoint(s) of evaluation of this end point: 24 months INCLUSION CRITERIA: 1) Men & women >= 18 years of age 2) Subjects with histologically or cytologically‐documented nonsquamous cell NSCLC who present with Stage IIIB/IV disease or recurrent disease following radiation therapy or surgical resection. 3)Disease recurrence or progression during/after one prior platinumcontaining chemotherapy regimen for advanced or metastatic disease 4) Measurable disease by CT/MRI per RECIST 1.1 criteria 5) ECOG performance status <= 1 6) An FFPE tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 120 F.1.3 Elderly (>=65 years) yes F.1.3.1 Num}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01881089/full} -} - - -Record #337 of 538 -@article{KCT000656321, -author = {KCT0006563,}, -title = {Pembrolizumab with standard cytotoxic chemotherapy in treatment naive non-small cell lung cancer patients with asymptomatic brain metastases}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=KCT0006563}, -year = {2021}, -accession_number = {ICTRP KCT0006563}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Drug : This is a Phase II single center, open‐label, single arm study in patients with advanced non‐small cell lung cancer (stage IV) with brain metastases. Patients will be treated with combination of Pembrolizumab 200mg plus platinum doublet based on histology subtypes. After the 4 cycles of combination phase with cytotoxic chemotherapy, maintenance phase will be followed for maximum of 35 cycles. CONDITION: Neoplasms PRIMARY OUTCOME: Intracranial overall response rate SECONDARY OUTCOME: Adverse events Intracranial duration of response Intracranial progression‐free survival Objective response rate Overall survival (OS) Progression free survival (PFS) INCLUSION CRITERIA: 1. Male/female participants who are at least 19 years of age on the day of signing informed consent with histologically confirmed diagnosis of stage IV non‐small cell lung cancer with asymptomatic brain metastases will be enrolled in this study. 2. Must have at least one intracranial target lesion. Intracranial lesion must be equal or greater than the 10mm in longest diameter. 3. Have confirmation that EGFR or ALK‐directed therapy is not indicated (documentation of absence of tumor activating EGFR mutations AND absence of ALK gene rearrangements OR presence of a K‐Ras mutation. However, patients with squamous histology are eligible without genomic data) 4. Have measurable disease based on RECIST 1.1 as determined by the local site investigator/radiology assessment. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. Otherwise, previously treated with radiation is not cons}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02438836/full} -} - - -Record #338 of 538 -@article{CTRI/2022/12/04792322, -author = {CTRI/2022/12/047923,}, -title = {A Phase III, Study to Investigate the Efficacy, Safety, and Pharmacokinetics of ZRC-3276 Versus Opdivo® (Nivolumab) in Subjects with locally advanced or Metastatic Non-Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2022/12/047923}, -year = {2022}, -accession_number = {ICTRP CTRI/2022/12/047923}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Intervention1: ZRC‐3276 (Cadila Healthcare Ltd.): Dose :‐ 3 mg/kg Route :‐ IV infusion Frequency :‐ every 14 day Duration :‐ 6 month Control Intervention1: Opdivo (Bristol‐Myers Squibb): Dose :‐ 3 mg/kg Route :‐ IV infusion Frequency :‐ every 14 day Duration :‐ 6 month CONDITION: Health Condition 1: C349‐ Malignant neoplasm of unspecifiedpart of bronchus or lung PRIMARY OUTCOME: Compare the efficacy of ; ZRC‐3276 IV infusion versus ; Opdivo IV infusion in subjects ; with locally advanced or ; metastatic non‐small cell lung ; cancer.Timepoint: Baseline and Cycle 12 SECONDARY OUTCOME: To assess the immunogenicity ; of ZRC‐3276 IV infusion ; compared to Opdivo IV ; infusionTimepoint: Baseline, end of Cycle 6 (pre‐dose ; of Cycle 7), and end of Cycle 12 (EOS) To assess the pharmacokinetics ; of ZRC‐3276 IV infusion ; compared to Opdivo IV ; infusionTimepoint: Cycle 1 for various PK parameters ; and trough concentration evaluation at ; pre‐dose of Cycle 4, 6, 8, 10, 12, and at ; EOS To compare the safety and ; tolerability in subjects exposed ; to the investigational medicinal ; productsTimepoint: Baseline to throughout the study INCLUSION CRITERIA: 1.Male or female withâ?¥ 18 years of age 2.Subjects with histologically or cytologically‐documented locally advanced or metastatic NSCLC who present with Stage IIIB/IIIC/Stage IV or recurrent or progressive disease following multi‐modality therapy (radiation therapy, surgical resection or definitive chemo radiation therapy for locally advanced disease). Note: Subjects eligible for study therapy after acceptable prior therapy are as specified below: o Subjects must have experienced disease recurrence or progression during or after one first line therapy for advanced or metastatic disease. o A switch of an agent within a regimen in order to manage toxicity does not define the start of a new line of therapy. Subjects must have received at least 2 cycles of platinum doublet based chemotherapy before discontinuation for toxicity. o Maintenance therapy following first line chemotherapy is not considered as a sepa}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02512485/full} -} - - -Record #339 of 538 -@article{Zhou16, -author = {Zhou, C, Altorki, N, Vallieres, E, Felip, E, Zuo, Y, Howland, M, Xia, F, Hoang, T, Sandler, A, and Wakelee, H}, -title = {IMpower010: a Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC}, -journal = {Annals of oncology}, -volume = {27}, -pages = {ix134‐ix135}, -year = {2016}, -accession_number = {EMBASE 619107641}, -publication type = {Journal article; Conference proceeding}, -keywords = {*adjuvant chemotherapy; *non small cell lung cancer; Adult; Autoimmune disease; Cancer recurrence; Cancer size; Cancer staging; Cancer surgery; Cancer survival; Comparative effectiveness; Controlled study; Disease free survival; Drug therapy; Female; Gene expression; Human; Human cell; Human tissue; Immunocompetent cell; Immunohistochemistry; Immunotherapy; Major clinical study; Male; Open study; Patient history of chemotherapy; Pharmacokinetics; Phase 3 clinical trial; Radiotherapy; Randomized controlled trial; Recurrent disease; Stratification; Study design; Surgery; Tumor cell; Tumor‐related gene}, -abstract = {Background: Atezo, an anti‐PD‐L1 mAb, prevents the binding of PD‐L1 to PD‐1 and B7.1 and restores antitumor immune response. Single‐agent atezo has promising efficacy and tolerability in pts with previously treated advanced NSCLC, with a survival benefit observed across PD‐L1 expression levels. Given the need to improve survival of pts with early‐stage NSCLC, IMpower010 (NCT02486718) has been initiated. This global Phase III, randomized, open‐label trial will evaluate the efficacy and safety of atezo vs BSC, following adjuvant cisplatin (cis)‐based chemo in pts with resected stage IB (tumors ≥ 4 cm)‐IIIA NSCLC. Trial design: Eligibility criteria include complete tumor resection 4‐12 weeks prior to enrollment for pathologic stage IB (tumors ≥ 4 cm)‐IIIA NSCLC. Pts must have adequately recovered from surgery, be eligible to receive cis‐based adjuvant chemo and have an ECOG PS 0‐1. Exclusion criteria include the presence of other malignancies, use of hormonal cancer or radiation therapy within 5 years, prior chemo, exposure to prior immunotherapy and autoimmune disease. Approximately 1127 pts will be enrolled regardless of PD‐L1 expression status. Suitable pts will receive up to four 21‐d cycles of cis‐based chemo (cis [75 mg/m2 IV, d 1]+ either vinorelbine [30 mg/m2 IV, d 1, 8], docetaxel [75 mg/m2 IV, d 1] or gemcitabine [1250 mg/m2 IV, d 1, 8], or pemetrexed [500 mg/m2 IV, d 1; nonsquamous NSCLC only]). Adjuvant radiation therapy is not permitted. After adjuvant treatment, eligible pts will be randomized 1:1 to receive atezo 1200 mg q3w, 16 cycles or BSC. Stratification factors include sex, histology (squamous vs nonsquamous), extent of disease (stage IB vs II vs IIIA) and PD‐L1 expression by IHC (tumor cell [TC]; tumor‐infiltrating immune cell [IC]; TC2/3 [≥ 5% expressing PD‐L1] and any IC vs TC0/1 [< 5%] and IC2/3 vs TC0/1 and IC0/1 [<5%]). The primary endpoint is disease‐free survival; secondary endpoints include OS and safety. Exploratory endpoints include PD‐L1 status, immune‐and tumor‐related biomarkers before, during and after treatment with atezo and at radiographic disease recurrence, or confirmation of new primary NSCLC.}, -DOI = {10.1093/annonc/mdw592.004}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01430609/full} -} - - -Record #340 of 538 -@article{EUCTR2021-001648-91-NO21, -author = {EUCTR2021-001648-91-NO,}, -title = {Does radiotherapy given in addition to immunotherapy and chemotherapy prolong survival in patients with extended stage small-cell lung cancer?}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-001648-91-NO}, -year = {2021}, -accession_number = {ICTRP EUCTR2021‐001648‐91‐NO}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: PF‐06863135 Product Code: PF‐06863135 Pharmaceutical Form: Solution for injection INN or Proposed INN: PF‐06863135 Current Sponsor code: PF‐06863135 Other descriptive name: Humanised IgG2k Fc‐modified bispecific monoclonal antibody against CD3 and BCMA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40‐ Trade Name: DARZALEX Product Name: Daratumumab Pharmaceutical Form: Solution for injection INN or Proposed INN: DARATUMUMAB CAS Number: 945721‐28‐8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120‐ Trade Name: Imnovid Product Name: Pomalidomide Pharmaceutical Form: Capsule INN or Proposed INN: Pomalidomide CAS Number: 19171‐19‐8 Other descriptive name: POMALIDOMIDE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 1‐4 Trade Name: Dexamethasone Product Name: Dexamethasone Pharmaceutical Form: Tablet INN or Proposed INN: DEXAMETHASONE Other descriptive name: DEXAMETHASONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4‐ CONDITION: MULTIPLE MYELOMA ; MedDRA version: 21.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: PART 1:; •To assess DLTs, safety and tolerability of elranatamab + daratumumab in order to select a RP3D for the combination to be used in Part 2 of this study; ; PART 2:; •To compare the efficacy of elranatamab (Arm A) vs daratumumab + pomalidomide + dexamethasone (Arm C) as measured by PFS; •To compare the efficacy of elranatamab + daratumumab (Arm B) vs. Arm C as measured by PFS Primary end point(s): PART 1:; •DLTs during the DLT observation period (14 days from first elranatamab dose + first 28 days following first dose of elranatamab + daratumumab).; ; PART 2:; •PFS by BICR per IMWG; •OS Secondary Objective: PART 1:; •To assess the rate of Grade =2 CRS when elranatamab is administered with 2 step‐up priming regimen along with premedications.; •To evaluate the overall safety profile of elranatamab using 2 step priming doses and in combination with daratumumab.; •To evaluate the efficacy of elranatamab + daratumumab as measured by PFS, ORR, DOR, CCRR, DOCCR, TTR, OS, and % MRD negative.; •To evaluate the PK of elranatamab ; •To evaluate the immunogenicity of elranatamab ; •To evaluate the PK of daratumumab ; ; PART 2:; •To compare the efficacy of Arm A vs Arm C as measured by OS; •To compare the efficacy of Arm B vs Arm C as measured by OS; •To compare the efficacy of Arm A vs Arm C as measured by PFS, ORR, DOR, CCRR, DOCCR, TTR, and % MRD negative; •To compare the efficacy of Arm B vs Arm C as measured by PFS, ORR, DOR, CCRR, DOCCR, TTR, and % MRD negative; •To determine the safety and tolerability of elranatamab; ; Please refer to section 3 of the protocol for full list. Timepoint(s) of evaluation of this end point: Assessments are to be conducted at the time points specified in the Schedule of Activity (SoA) in Section 1 of the protocol SECONDARY OUTCOME: Secondary end point(s): PART 1:; •Grade =2 CRS rate during the 28 days following the first dose of elranatamab.; •AEs as characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), timing, seriousness, and relationship to elranatamab in combination with daratumumab. Severity of CRS and ICANS will be assessed according to ASTCT criteria;; •Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), and timing.; •ORR and CCRR, per IMWG response criteria as determined by investigator;; •Time to event endpoints: TTR, DOR, DOCCR and PFS per IMWG response criteria as determined by investigator, and OS;; •MRD negativity rate (central lab) per IMWG sequencing criteria.; •Predose and postdose concentrations of elranatamab; •ADAs and NAbs against elranatamab; •Predose concentrations of daratumumab; ; PART 2:; •PFS by Investigator per IMWG; •ORR by BICR and investigator per IMWG; •DOR by BICR and investigator per IMWG; •CCRR by BICR and investigator per IMWG; •DOCCR by BICR and investigator per IMWG; •TTR by BICR and investigator per IMWG; •MRD negativity rate (central lab) per IMWG; •AEs as characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), timing, seriousness, and relationship to study treatment. The severity of CRS and ICANS will be assessed according to ASTCT criteria.; •Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), and timing.; •Predose and postdose concentrations of elranatamab; •ADAs and NAbs against elranatamab; •Predose concentrations of daratumumab; •EORTC QLQ‐C30 and MY20 Timepoint(s) of evaluation of this end point: Assessments are to be conducted at the time points specified in the Schedule of Activity (SoA) in Section 1 of the protocol INCLUSION CRITERIA: Age and Sex: 1. Participants age =18 years (or the minimum country specific age of consent if >18). a.Male participants and female participants of childbearing potential must agree to use methods of contraception as described in Section 5.3.1. •Refer to Appendi X4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants. Type of Participant and Disease Characteristics: 2.Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. 3.Prior diagnosis of MM as defined according to IMWG criteria. 4.Measurable disease based on IMWG criteria as defined by at least 1 of the following: a.Serum M‐protein =0.5 g/dL by SPEP; b.Urinary M‐protein excretion =200 mg/24 hours by UPEP; c.Serum immunoglobulin FLC =10 mg/dL (=100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02632281/full} -} - - -Record #341 of 538 -@article{CTIS2023-503999-24-0023, -author = {CTIS2023-503999-24-00,}, -title = {A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTIS2023-503999-24-00}, -year = {2023}, -accession_number = {ICTRP CTIS2023‐503999‐24‐00}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: INFLIXIMAB, Product Code:SUB02681MIG, Pharmaceutical Form: POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: SODIUM CHLORIDE, Product Code:SUB12581MIG, Pharmaceutical Form: SOLUTION FOR INJECTION, Other descriptive name: , Strength: , Pharmaceutical form of the placebo: SOLUTION FOR INJECTION , Product Name: MYCOPHENOLATE MOFETIL, Product Code:SUB03360MIG, Pharmaceutical Form: FILM‐COATED TABLET, Other descriptive name: , Strength: , Product Name: GLUCOSE, Product Code:SUB13981MIG, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Pharmaceutical form of the placebo: SOLUTION FOR INFUSION , Product Name: Monalizumab, Product Code:PRD10970031, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: MYCOPHENOLATE MOFETIL, Product Code:SUB03360MIG, Pharmaceutical Form: FILM‐COATED TABLET, Other descriptive name: , Strength: , Product Name: Oleclumab, Product Code:PRD10969991, Pharmaceutical Form: CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: IMFINZI 50 mg/mL concentrate for solution for infusion., Product Code:PRD6651663, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: IMFINZI 50 mg/mL concentrate for solution for infusion., Product Code:PRD6651398, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: CONDITION: Patients With Locally Advanced (Stage III), Unresectable Non‐small Cell Lung Cancer (NSCLC) Therapeutic area: Diseases [C] ‐ Neoplasms [C04] PRIMARY OUTCOME: Main Objective: "1. To demonstrate superiority of durvalumab + oleclumab relative to durvalumab + placebo in participants with unresectable, Stage III NSCLC who have not progressed on prior platinum‐based cCRT; •Assessment by PFS as assessed by BICR; 2. To demonstrate superiority of durvalumab + monalizumab relative to durvalumab + placebo in participants with unresectable, Stage III NSCLC who have not progressed on prior platinum‐based cCRT; •Assessment by PFS as assessed by BICR" Primary end point(s): Progression Free Survival (PFS) as assessed by BICR, per RECIST 1.1. Up to 5 years after first patient randomized. Secondary Objective: "To demonstrate superiority of durvalumab+oleclumab & durvalumab+monalizumab relative to durvalumab+placebo in patients with unresectable Stage III NSCLC who have not progressed on prior platinum‐based cCRT; assessment by OS, OS24, ORR, DoR, PFS6, PFS12, PFS18, PFS24, PFS2, TTDM, TFST, PFS as assessed by Investigator To investigate relationship between patient’s PD‐L1 expression on tumor cells & efficacy outcomes with durvalumab+oleclumab, durvalumab+monalizumab & durvalumab+placebo To assess PK of durvalumab when in combination with oleclumab & with monalizumab To assess PK of oleclumab when in combination with durvalumab To assess PK of monalizumab when in combination with durvalumab To investigate immunogenicity of durvalumab,oleclumab & monalizumab To assess time to deterioration in pulmonary symptoms" INCLUSION CRITERIA: "•Participant must be = 18 years at the time of screening. •Histologically‐ or cytologically‐documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease •Provision of a tumour tissue sample obtained prior to CRT •Documented tumour PD‐L1 status by central lab •Documented EGFR and ALK wild‐type status (local or central). •Patients must not have progressed following definitive, platinum‐based, concurrent chemoradiotherapy •Participants must have received at least 2 cycles of platinum‐based chemotherapy concurrent with radiation therapy •Participants must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy) as part of the chemoradiation therapy, to be randomised. Radiation therapy should be administered by intensity modulated RT (preferred) or 3D‐conforming technique. •WHO performance status of 0 or 1 at randomization •Adequate organ and marrow function"}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02731019/full} -} - - -Record #342 of 538 -@article{Reck22, -author = {Reck, M, Barlesi, F, Yang, JC-H, Westeel, V, Felip, E, Ozguroglu, M, Dols, MC, Sullivan, R, Kowalski, D, Andric, Z, Lee, DH, Sezer, A, Shamrai, V, Szalai, Z, Wang, X, Xiong, H, Jacob, N, Mehr, KT, and Park, K}, -title = {OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: primary Analysis from JAVELIN Lung 100}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S39}, -year = {2022}, -accession_number = {EMBASE 2020098448}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer chemotherapy; *histology; *non small cell lung cancer; *protein expression; Adult; Cancer patient; Cancer recurrence; Cancer staging; Cancer survival; Clinical trial; Conference abstract; Controlled study; Doublet chemotherapy; Drug dose regimen; Drug safety; Drug therapy; Female; Follow up; Gene expression; Histopathology; Human; Human tissue; Immunohistochemical test kit; Intravenous drug administration; Major clinical study; Male; Monotherapy; Multicenter study; Overall survival; Pharmacokinetics; Phase 3 clinical trial; Progression free survival; Randomized controlled trial; Tumor cell; Wild type}, -abstract = {Introduction: Avelumab is an anti‐PD‐L1 antibody that has shown antitumor activity and an acceptable safety profile in patients with non‐small cell lung cancer (NSCLC). We report results from the phase 3 JAVELIN Lung 100 trial, which compared first‐line (1L) avelumab monotherapy (2 dose schedules) vs platinum‐based doublet chemotherapy in patients with previously untreated PD‐L1+ advanced NSCLC. Methods: JAVELIN Lung 100 (NCT02576574) was an open‐label, multicenter, phase 3 trial that enrolled adult patients with previously untreated metastatic or recurrent stage IV PD‐L1+ (PD‐L1 expression on ≥1% of tumor cells determined by Dako PD‐L1 IHC 73‐10 pharmDx) and EGFR/ALK‐wild‐type NSCLC. Patients were initially randomized 1:1 to receive avelumab 10 mg/kg every 2 weeks (Q2W) or platinum‐based doublet chemotherapy every 3 weeks (Q3W) intravenously, stratified by histology. Following a protocol amendment based on pharmacokinetics/exposure analyses, patients were randomized 1:2:2 to receive avelumab 10 mg/kg Q2W, platinum‐based doublet chemotherapy Q3W, or avelumab 10 mg/kg weekly (QW) for 12 weeks and Q2W thereafter, stratified by histology and PD‐L1 expression cutoffs (high, ≥80%; moderate, ≥50%; and any, ≥1% of tumor cells). Primary endpoints were overall survival (OS) and progression‐free survival (PFS) per independent review committee (IRC) in patients with high‐expression PD‐L1+ tumors (≥80% of tumor cells). Results: 1,214 patients with PD‐L1+ tumors (≥1% of tumor cells) were randomized to the avelumab Q2W (n=366), chemotherapy (n=526), or avelumab QW (n=322) arms. At data cutoff (October 2021), median follow‐up was >41 months in all arms. No statistically significant difference in OS or PFS was observed between each of the avelumab arms and the chemotherapy arm (Table). Among patients with high‐expression PD‐L1+ tumors, 5.3% and 20.2 % of patients in the avelumab Q2W and QW arms vs 30.6% of patients in the chemotherapy arm received poststudy anti‐PD‐(L)1 treatment. Among all treated patients in the avelumab Q2W, avelumab QW, and chemotherapy arms, treatment‐emergent adverse events (TEAEs) occurred in 95.8%, 96.9%, and 96.8%, including grade ≥3 TEAEs in 60.1%, 56.9%, and 64.8%, respectively. Conclusions: JAVELIN Lung 100 did not meet its primary objective of demonstrating superior OS or PFS by IRC with 1L avelumab (Q2W or QW) vs platinum‐based doublet chemotherapy in patients with high‐expression PD‐L1+ tumors. The safety profile of avelumab was consistent with that observed in previous studies of avelumab monotherapy. [Formula presented] Keywords: avelumab, NSCLC, first–line}, -DOI = {10.1016/j.jtho.2022.07.072}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461482/full} -} - - -Record #343 of 538 -@article{EUCTR2022-003048-28-PL23, -author = {EUCTR2022-003048-28-PL,}, -title = {A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination with Other Anti-Cancer Therapies in Patients with Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer with a KRAS G12C Mutation}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2022-003048-28-PL}, -year = {2023}, -accession_number = {ICTRP EUCTR2022‐003048‐28‐PL}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: GDC‐6036 Product Code: RO7435846 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: GDC‐6036 Current Sponsor code: Ro 743‐5846/F07 Other descriptive name: 1‐((S)‐4‐((R)‐7‐(6‐amino‐4‐methyl‐3‐(trifluoromethyl)pyridin‐2‐yl)‐6‐chloro‐8‐fluoro‐2‐(((S)‐1‐methylpyrrolidin‐2‐yl)methoxy)quinazolin‐4‐yl)‐3‐methylpiperazin‐1‐yl)prop‐2‐en‐1‐one Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200‐ Product Name: GDC‐6036 Product Code: RO7435846 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: GDC‐6036 Current Sponsor code: Ro 743‐5846/F04 Other descriptive name: 1‐((S)‐4‐((R)‐7‐(6‐amino‐4‐methyl‐3‐(trifluoromethyl)pyridin‐2‐yl)‐6‐chloro‐8‐fluoro‐2‐(((S)‐1‐methylpyrrolidin‐2‐yl)methoxy)quinazolin‐4‐yl)‐3‐methylpiperazin‐1‐yl)prop‐2‐en‐1‐one Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Product Name: GDC‐6036 Product Code: RO7435846 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: GDC‐6036 Current Sponsor code: Ro 743‐5846/F06 Other descriptive name: 1‐((S)‐4‐((R)‐7‐(6‐amino‐4‐methyl‐3‐(trifluoromethyl)pyridin‐2‐yl)‐6‐chloro‐8‐fluoro‐2‐(((S)‐1‐methylpyrrolidin‐2‐yl)methoxy)quinazolin‐4‐yl)‐3‐methylpiperazin‐1‐yl)prop‐2‐en‐1‐one Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25‐ Trade Name: Keytruda Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Keytruda Other descriptive name: Pembrolizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ Trade Name: Carboplatin Product Name: Carboplatin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Carboplatin Current Sponsor code: N/A Concentration unit: mg/ml milli CONDITION: Therapeutic area: Diseases [C] ‐ Cancer [C04] Untreated Advanced or Metastatic Non‐Small Cell Lung Cancer ; MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non‐small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) ; MedDRA version: 21.1 Level: PT Classification code 10059515 Term: Non‐small cell lung cancer metastatic System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) PRIMARY OUTCOME: Main Objective: To evaluate the safety and tolerability of divarasib in combination with pembrolizumab (Cohort A) and divarasib in combination with pembrolizumab plus platinum‐based chemotherapy and pemetrexed (Cohort B) Primary end point(s): 1. Occurrence of adverse events; 2. Change from baseline at each visit in targeted safety parameters Secondary Objective: ‐ To evaluate the activity of divarasib in combination with pembrolizumab (Cohort A) and divarasib in combination with pembrolizumab plus platinum‐based chemotherapy and pemetrexed (Cohort B); ‐ To evaluate the tolerability of divarasib in combination with pembrolizumab (Cohort A) and divarasib in combination with pembrolizumab plus platinum‐based chemotherapy and pemetrexed (Cohort B); ‐ To characterize the divarasib PK profile; ‐ To identify a recommended dose of divarasib in combination regimens with pembrolizumab (Cohort A) and pembrolizumab plus platinum‐based; chemotherapy and pemetrexed (Cohort B) Timepoint(s) of evaluation of this end point: 1‐2. Until 60 days after the final dose of study treatment or until initiation of another anti‐cancer therapy, whichever occurs first SECONDARY OUTCOME: Secondary end point(s): 1. Objective response rate; 2. Duration of response; 3. Progression free survival; 4. Presence, frequency of occurrence, severity, and/or degree of interference with daily function of symptomatic side effects as assessed through use of the Patient‐Reported Outcomes Common Terminology Criteria for Adverse Events (PRO‐CTCAE); 5. Change from baseline in symptomatic side effects, as assessed through use of the PRO‐CTCAE; 6. Proportion of participants reporting "frequent" or "almost constant" diarrhea during the first three cycles of treatment according to the PRO‐CTCAE criteria; 7. Proportion of participants reporting "severe" or "very severe" nausea or vomiting during the first three cycles of treatment according to the PRO‐CTCAE; 8. Frequency of participant's response of the degree they are troubled with treatment symptoms, as assessed through use of the single‐item European Organisation for Research and Treatment of Cancer (EORTC) Item List 46 (IL46); 9. Plasma concentration of divarasib at specified timepoints; 10. Recommended dose of divarasib in combination with pembrolizumab (Cohort A) or pembrolizumab plus platinum‐based chemotherapy and pemetrexed (Cohort B) based on the totality of safety, activity, and PK data Timepoint(s) of evaluation of this end point: 1‐8. Up to 2 years; 9. At Days 1, 8 and 15 of Cycles 1 and 2; Days 1 and 15 of Cycles 3 and 4; Day 1 of every other Cycle after Cycle 5 ; 10. Up to 2 years; INCLUSION CRITERIA: ‐ Histologically or cytologically documented locally advanced unresectable or metastatic non‐squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy ‐ No prior systemic treatment for advanced unresectable or metastatic NSCLC ‐Confirmation of Biomarker eligibility: .. Documented history of the KRAS G12C mutation .. Documented history of PD‐L1 expression ‐ For Cohort A, PD‐L1 tumor cell expression >= 1% is required to be eligible ‐ For Cohort B, PD‐L1 tumor cell expression is not required to be eligible ‐ Pre‐treatment tumor tissue along with an associated pathology report is required for all participants enrolled on study. Representative tumor specimens must be in formalin‐fixed, paraffin embedded (FFPE) blocks (preferred) or 15 unstained, freshly cut, serial slides. Although 15 slides are required, if only 10 slides are available, the participant may be eligible for the study following consultation}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02725884/full} -} - - -Record #344 of 538 -@article{NL-OMON5443920, -author = {NL-OMON54439,}, -title = {A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON54439}, -year = {2020}, -accession_number = {ICTRP NL‐OMON54439}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: In the experimental arm, atezolizumab will be administered to patients by IV infusion at a fixed dose of 1680 mg, followed by tiragolumab at a fixed dose of 840 mg administered by IV infusion on Day 1 of each 28‐day cycle for a maximum of 13 cycles. The comparator arm gives 2 options: ‐ patients will receive the approved durvalumab dose, 10 mg/kg Q2W, administered by IV infusion on Days 1 and 15 of each 28‐day cycle for a maximum of 13 cycles (not to exceed 26 doses) . ‐ Patients receive a fixed dose of 1500 mg, Q4W, administered by IV infusion on Day 1 of each 28‐day cycle, for a maximum of 13 cycles (not to exceed 13 doses) CONDITION: ; lung cancer ; Non‐small cell lung cancer 10029107 10038666 PRIMARY OUTCOME: ‐ To evaluate the efficacy of tiragolumab plus atezolizumab compared with ; durvalumab with durvalumab in the programmed death ligand 1 positive analysis ; set (PPAS) on the basis of PFS, as assessed by an IRF as assessed by an ; independent review facility (IRF) ; ; ; ‐ To evaluate the efficacy of tiragolumab plus atezolizumab compared with ; durvalumab in the programmed death ligand 1 positive analysis set ; (PPAS) on the basis of PFS, as assessed by an IRF.; SECONDARY OUTCOME: The secondary efficacy objective for this study is to evaluate the efficacy of ; atezolizumab plus tiragolumab compared with durvalumab in the ITT and the ; PD‐L1‐positive populations on the basis of the following endpoints: ; ; ‐ To evaluate the efficacy of tiragolumab plus atezolizumab compared with ; durvalumab in the FAS and PPAS on the basis of overall survival ; (OS), PFS as assessed by investigator, Confirmed objective response rate (ORR), ; as assessed by an IRF and investigator, DOR, as assessed by ; an IRF and investigator ; ‐ To evaluate the quality of life of patients treated with tiragolumab plus ; atezolizumab compared with durvalumab in the FAS and PPAS ; ‐ To evaluate the efficacy of tiragolumab plus atezolizumab compared with ; durvalumab on the basis of PFS rate at 12, 18, and 24 months (FAS and PPAS), OS ; rate at 12, 24, 36, and 48 months (FAS and PPAS), and time to distant ; metastasis (TTDM) (FAS and PPAS) ; ‐ To evaluate the safety and tolerability of tiragolumab plus atezolizumab ; compared with durvalumab. ; ; See chapter 2 of protocol for all endpoints ; INCLUSION CRITERIA: Age>= 18 years ‐ Eastern Cooperative Oncology Group Performance Status of 0 or 1 ‐ Histologically or cytologically documented NSCLC with locally advanced unresectable Stage III NSCLC of either squamous or non‐squamous histology ‐ Whole‐body PET‐CT scan for the purposes of staging, performed prior and within 42 days of the first dose of concurrent chemoradiotherapy (CRT) ‐ At least two prior cycles of platinum‐based chemotherapy concurrent with radio therapy (cCRT), which must be completed within 1 to 42 days prior to randomization in the study (one cycle of cCRT is defined as 21 or 28 days) ‐ The RT component in the CRT must have been at a total dose of radiation of 60 Gy±10% (54 Gy to 66 Gy) administered by intensity‐modulated radiotherapy (preferred) or 3D‐conforming technique ‐ No progression during or following concurrent platinum‐based CRT ‐ Tumor PD‐L1 expression, as determined by the investigational Ventana P}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02716028/full} -} - - -Record #345 of 538 -@article{Varlotto21, -author = {Varlotto, JM, Sun, Z, Ramalingam, SS, Wakelee, HA, Lovly, CM, Oettel, KR, Masters, GA, and Pennell, N}, -title = {Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: a trial of the ECOG-ACRIN Cancer Research Group (EA5181)}, -journal = {Journal of clinical oncology}, -volume = {39}, -number = {15 SUPPL}, -year = {2021}, -accession_number = {EMBASE 635590381}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer research; *cancer staging; *non small cell lung cancer; Adult; Age; Autoimmune disease; Blood toxicity; Cancer patient; Cancer survival; Chemoradiotherapy; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Diffusing capacity for carbon monoxide; Drug combination; Drug efficacy; Drug therapy; ECOG Performance Status; Eligibility criteria; Female; Follow up; Forced expiratory volume; Human; Human tissue; Lung function; Major clinical study; Male; Median survival time; Overall survival; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Sample size}, -abstract = {Background: Platinum‐based concurrent chemoradiation(CRT) followed by one year of the human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody, durvalumab, which blocks the interaction of PD‐L1 with its receptors PD‐1 and CD80, is the standard of care for locally advanced, unresectable non‐small cell lung cancer (NSCLC). Early studies have noted the feasibility of concomitant administration of radiotherapy and immune checkpoint inhibition in NSCLC. EA5181 will evaluate the use of concomitant durvalumab with chemoradiotherapy for locally advanced NSCLC. Methods: EA5181 is a randomized, multi‐center, phase III study for patients with unresectable Stage III NSCLC comparing the efficacy of CRT with concomitant durvalumab to CRT, followed by one year of durvalumab. Eligibility criteria include: an ECOG PS of 0‐1, adequate pulmonary function (FEV1 and DLCO both > 40%), no history of auto‐immune disease and no past chemotherapy or RT for this lung cancer. Stratification factors include age, sex, stage, and planned concurrent chemotherapy type. Eligible patients with be randomized 1:1 to receive 60Gy RT (2Gy fractions) CRT and durvalumab (Arm A) or 60Gy CRT (Arm B). Investigators will be allowed to choose from three different chemotherapy options: cisplatin/etoposide q 28 days, Pemetrexed/cisplatin q 21 days, and weekly paclitaxel/Carboplatin. Arm A will use 750mg fixed of durvalumab (considered equivalent to 10mg/kg) on days 1, 11, and 21 of RT. Assuming no disease progression, patients in both arms will be followed by monthly (q28 days) fixed dose of 1500mg durvalumab for one year which will be given optimally within 14 days of radiation or when (non)hematologic toxicity is < Grade 2. The primary endpoint is overall survival. Secondary endpoints include progression‐free survival, incidence of local/distant progression and toxicity. The target sample size is 660 patients, anticipated to recruit over 55 months, with follow up for an additional 42 months. This provides approximately 82% power if the true hazard ratio for overall survival was 0.75 or less, with 2‐ sided alpha of 0.05, and assuming a median survival of 42.5 months in the control arm. The study was activated on 04/09/20 and has currently accrued 90 patients on 02/03/21.}, -DOI = {10.1200/JCO.2021.39.15-suppl.TPS8584}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02305758/full} -} - - -Record #346 of 538 -@article{NL-OMON5176622, -author = {NL-OMON51766,}, -title = {A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON51766}, -year = {2022}, -accession_number = {ICTRP NL‐OMON51766}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: The assigned study intervention will be administered per the applicable SoA. For participants enrolled in the pembrolizumab monotherapy arm, treatment duration will be until disease progression, unacceptable toxicity, death, or withdrawal for a maximum total duration of approximately 2 years. Treatment with pembrolizumab may extend beyond 2 years in countries where continued pembrolizumab use beyond 2 years is approved in accordance with standard of care per local prescribing information and upon sponsor approval. For participants enrolled in the dostarlimab monotherapy arm or the immunotherapy combination substudies, treatment duration will be until disease progression, unacceptable toxicity, death, or withdrawal. At the discretion of the investigator and with the approval of the sponsor/medical monitor, participants will be permitted to continue study intervention after RECIST 1.1 criteria for PD are met if they meet all of the criteria for clinical stability as presented in Section 7.1.1 and provide informed consent for continuation of study intervention past PD per RECIST 1.1. Regardless of clinical benefit, the maximum total duration of treatment is approximately 2 years for participants receiving pembrolizumab beyond initial PD, unless otherwise permitted by the applicable local prescribing information and the sponsor. CONDITION: ; lung cancer ; NSCLC 10029107 PRIMARY OUTCOME: To evaluate the antitumor activity of novel immunotherapy combinations compared ; with pembrolizumab in participants with PD‐L1‐high NSCLC.; SECONDARY OUTCOME: * To assess the dose‐response relationship of novel immunotherapy combinations ; across a range of the novel components' dose levels and fixed dostarlimab dose. ; * To further assess the clinical activity of novel immunotherapy combinations ; compared with pembrolizumab in participants with PD‐L1‐high NSCLC. ; * To evaluate the antitumor activity of novel immunotherapy combinations via ; treatment arm comparisons for assessment of contribution of components for the ; combination regimens. ; * To further characterize the safety of novel immunotherapy combinations. ; * To determine the immunogenicity of individual agents comprising novel ; immunotherapy combinations. ; * To characterize the PK properties of novel immunotherapy combinations ; INCLUSION CRITERIA: Participants are eligible to be included in the study only if all of the following criteria apply. 1. Is capable of giving signed informed consent as described in Section 11.6 of the protocol, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. 2. Is, at the time of signing the ICF, at least 18 years old or the legal age of consent in the jurisdiction in which the study is taking place. 3. Has a histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or nonsquamous). Mixed tumors will be categorized by the predominant cell type; if small‐cell or neuroendocrine elements are present, the participant is ineligible. 4. Has not received prior systemic therapy for their locally advanced or meta}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02719528/full} -} - - -Record #347 of 538 -@article{EUCTR2013-003331-30-PL14, -author = {EUCTR2013-003331-30-PL,}, -title = {A study comparing the clinical benefit and side effects of Atezolizumab to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-003331-30-PL}, -year = {2014}, -accession_number = {ICTRP EUCTR2013‐003331‐30‐PL}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Code: MPDL3280A‐RO5541267 Pharmaceutical Form: Solution for infusion Current Sponsor code: MPDL3280A Other descriptive name: RO5541267 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60‐ Trade Name: Docetaxel Pharmaceutical Form: Concentrate and solvent for concentrate for solution for infusion Current Sponsor code: RO‐0647746 Other descriptive name: DOCETAXEL Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20‐ CONDITION: NON‐SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE ; MedDRA version: 20.0 Level: LLT Classification code 10029514 Term: Non‐small cell lung cancer NOS System Organ Class: 100000004864 Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: The primary objective of this study is to determine if Atezolizumab treatment results in superior OS compared with docetaxel treatment in patients with locally advanced or metastatic NSCLC who have progressed during or following a platinum‐containing regimen; Primary end point(s): The primary efficacy endpoint for this trial is duration (in months) of OS; (overall survival). OS duration is defined as the difference in time from; the date of randomization to the date of death due to any cause. Data for; patients who are not reported as having died at the time of analysis will; be censored at the date they were last known to be alive. Patients who; do not have post‐baseline information will be censored at the date of; randomization plus 1 day.; The OS analyses will be performed for the PP (Primary Population) at the; PAT (Primary Analysis Time) and for the SP (Secondary Population) at; the SAT (Secondary Analysis Time). Secondary Objective: The secondary efficacy objectives of this study are:; ‐ To evaluate efficacy of atezolizumab compared with docetaxel with respect to anti‐tumor effects as measured by PFS per investigator using RECIST v1.1; ‐ To evaluate efficacy of atezolizumab compared with docetaxel with; respect to anti‐tumor effects as measured by DOR per RECIST v1.1 for; responding patients Timepoint(s) of evaluation of this end point: Time from the date of randomization to the date of death due to any cause SECONDARY OUTCOME: Secondary end point(s): PFS is defined as the time (in months) between the date of ; randomization and the date of first documented disease progression or ; death, whichever occurs first. Disease progression will be determined ; based on investigator assessment using RECIST v1.1. Timepoint(s) of evaluation of this end point: Time (in months) between the date of randomization and the date of first documented disease progression or death, whichever occurs first INCLUSION CRITERIA: •Histologically or cytologically documented locally advanced or metastatic (i.e., Stage IIIB not eligible for definitive chemoradiotherapy, Stage IV, or recurrent) NSCLC •Representative formalin‐fixed paraffin‐embedded (FFPE) tumor specimens in paraffin blocks (preferred) or at least 15 unstained slides, with an associated pathology report, for central testing and determined to be evaluable for tumor PD‐L1 expression prior to study enrollment •Measurable disease, as defined by RECIST v1.1 •ECOG performance status of 0 or 1 •Life expectancy > 12 weeks • For female patients of childbearing potential, agreement (by patient) to remain abstinent (refrain from heterosexual intercourse) o •Disease progression during or following treatment with a prior platinum‐containing regimen for locally advanced, unresectable/inoperable or metastatic NSCLC or disease recurrence within 6 months of treatment with a platinum‐based adjuvant/neoadjuvant regimen}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01862150/full} -} - - -Record #348 of 538 -@article{EUCTR2021-004149-19-NO22, -author = {EUCTR2021-004149-19-NO,}, -title = {A Study to Find Out How Effective and Safe Different Treatments are in Patients Who Have a Type of Lung Cancer (Known as Non-Small Cell Lung Cancer [Stage III])}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-004149-19-NO}, -year = {2022}, -accession_number = {ICTRP EUCTR2021‐004149‐19‐NO}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trade Name: Gavreto Product Name: PRALSETINIB Product Code: 2097132‐94‐8 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Pralsetinib CAS Number: 2097132‐94‐8 Current Sponsor code: RO7499790/F02‐02 Other descriptive name: BLU123244, BLU3244, X581238, C683, SEE, 72C683 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Trade Name: Rozlytrek Product Name: ENTRECTINIB Product Code: RO5424802‐F08 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Entrectinib CAS Number: 1108743‐60‐7 Current Sponsor code: RO7102122‐F08 Other descriptive name: NMS‐1191372 (Nerviano Medical Sciences),RXDX‐101 (Ignyta, Inc),M023284, C‐026222 (Carbogen Amcis) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Trade Name: Rozlytrek Product Name: ENTRECTINIB Product Code: RO5424802‐F09 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Entrectinib CAS Number: 1108743‐60‐7 Current Sponsor code: RO7102122‐F09 Other descriptive name: NMS‐1191372 (Nerviano Medical Sciences),RXDX‐101 (Ignyta, Inc),M023284, C‐026222 (Carbogen Amcis) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Trade Name: Rozlytrek Product Name: ENTRECTINIB Product Code: RO5424802‐F20 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Entrectinib CAS Number: 1108743‐60‐7 Current Sponsor code: RO7102122‐F20 Other descriptive name: NMS‐1191372 (Nerviano Medical Sciences),RXDX‐101 (Ignyta, Inc),M023284, C‐026222 (Carbogen Amcis) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Trade Name: Rozlytrek Product Name: ENTRECTINIB Product Code: RO5424802‐F11 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Entrectinib CAS Number: 1108743‐60‐7 Current Spons CONDITION: Therapeutic area: Diseases [C] ‐ Cancer [C04] Non‐Small Cell Lung Cancer (NSCLC) ; MedDRA version: 23.1 Level: LLT Classification code 10084713 Term: Tumor System Organ Class: 100000004864 PRIMARY OUTCOME: Timepoint(s) of evaluation of this end point: 1. Up to approximately 5 years Main Objective: To evaluate the efficacy of study treatment (alectinib or entrectinib or pralsetinib) compared with durvalumab in patients with biomarker‐selected, locally advanced, unresectable, Stage III NSCLC who have received concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT) and have not had radiographic disease progression Primary end point(s): 1.Progression‐free survival (PFS), as determined by Blinded independent central review (BICR) per RECIST v1.1 Secondary Objective: To evaluate the health‐related quality of life of patients with biomarker‐selected locally advanced, unresectable, Stage III NSCLC who have received cCRT or sCRT and have not had radiographic disease progression in the study treatment arm compared with in the durvalumab arm; To evaluate the safety and tolerability of study treatment compared with durvalumab in patients with biomarker selected, locally advanced, unresectable, Stage III NSCLC who have received cCRT or sCRT and have not had radiographic disease progression; SECONDARY OUTCOME: Secondary end point(s): 1. PFS, defined as the time from randomization to the first documented disease progression, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurs first; 2. Time to central nervous system (CNS) progression, as determined by BICR and investigator per RECIST v1.1; 3. Distant metastasis‐free survival (DMFS), s determined by BICR per RECIST v1.1; 4. Objective response rate (ORR), as determined by BICR and investigator per RECIST v1.1; 5. Duration of response (DOR), as determined by BICR and investigator per RECIST v1.1; 6. Overall survival (OS); 7. Time‐to‐confirmed deterioration (TTCD), in the following patient‐reported scales and lung cancer symptoms: Physical functioning, Role functioning, Cough, Chest pain, Dyspnea; 8. Change from baseline score as measured through the use of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30) at 5, 11, and 17 months in the following patient‐reported scales and lung cancer symptoms: Physical functioning, Role functioning, Cough, Chest pain, Dyspnea; 9. Incidence, type, and severity of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0); 10. Changes in vital signs, physical findings, and clinical laboratory results during and following administration of protocol‐specified investigational medicinal products (IMPs); Timepoint(s) of evaluation of this end point: 1‐7. Up to approximately 5 years; 8. Baseline to 5 years; 9. Up to approximately 5 years; 10. Baseline to 5 years; INCLUSION CRITERIA: Age >=18 years Body weight >=30 kg Whole‐body positron emission tomography/computed tomography scan (PET/CT) performed prior and within 42 days of the first dose of cCRT or sCRT Histologically or cytologically documented locally advanced, unresectable Stage III NSCLC of either squamous or non‐squamous histology (Version 8, American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system (Amin et al. 2017). Prior receipt of at least two prior cycles of platinum‐based chemotherapy given concurrently with radiotherapy (cCRT); or at least two prior cycles of platinum‐based chemotherapy given prior to radiotherapy (sCRT) The RT component in the cCRT or sCRT must have been at a total dose of radiation of 60 (± 10%) Gy (54 Gy to 66 Gy) administered by intensity‐modulated radiotherapy (preferred) or three dimension (3D)‐conforming technique No disease progression during or following platinum‐based cCRT or sCRT L}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02410440/full} -} - - -Record #349 of 538 -@article{Macias11, -author = {Macias, A, Alfonso, S, Santiesteban, E, Toledo, D, Viada, C, Mendoza, I, Guerra, PP, Ardigo, ML, Gomez, RE, Vazquez, AM, Crombet, T, Perez, R, and Lage, A}, -title = {Active specific immunotherapy with racotumomab in the treatment of advanced non small cell lung cancer (NSCLC)}, -journal = {Journal of thoracic oncology}, -volume = {6}, -number = {6}, -pages = {S468}, -year = {2011}, -accession_number = {EMBASE 71235402}, -publication type = {Journal article; Conference proceeding}, -keywords = {*immunotherapy; *lung cancer; *non small cell lung cancer; Arm; Breast; Chemotherapy; Control group; Data base; Double blind procedure; Electrocorticography; Erythema; Human; Human tissue; Immunization; Immunogenicity; Influenza; Injection site; Intention to treat analysis; Life expectancy; Log rank test; Melanoma; Neoplasm; Normal human; Oncology; Overall survival; Pain; Patient; Phase 1 clinical trial; Population; Radiotherapy; Safety; Solid malignant neoplasm; Staging; Surgery; Toxicity; Vaccination}, -abstract = {Background: Gangliosides are an attractive target for immunotherapy in cancer since they are not expressed in normal human tissue, are overexpressed in several solid tumors, including NSCLC, and have been implicated in tumor development and progression. Racotumomab is an antiidiotype murine monoclonal antibody specific to P3 Ab1 MAb, an antibody that reacts with NeuGc‐containing gangliosides, sulfatides and other antigens expressed in tumors. Phase I trials conducted in advanced melanoma, breast and lung cancer have demonstrated the low toxicity and high immunogenicity of Racotumomab. Methods: A phase II multicenter, controlled, randomized, double blind trial is ongoing to evaluate the effect of Racotumomab in Overall Survival (OS) in patients with advanced (IIIB and IV) NSCLC who have completed onco‐specific treatment as per the Oncology Therapeutic Guidelines (surgery, chemotherapy, radiotherapy according to initial staging) and have achieved partial, complete response or disease stabilization. ECOG status was < 2 and life expectancy ≥ 4 months. Vaccination began 4‐8 weeks after the end of the onco‐specific treatment. Prior chemotherapy in most cases was cisplatin/ vinblastin (4 ‐ 6 cycles). Patients were randomized (1:1) to control group (placebo) or vaccine (Racotumomab). Vaccination consisted in 5 doses, 1 every 14 days (induction period), followed by a maintenance period (1 dose every 28 days) until patient refusal or worsening of ECOG status. Results: Safety: The most common adverse events were mild and moderate reactions at the injection site (pain, erythema, induration) and “flu‐like” symptoms, none unexpected. No differences were observed between both groups. Overall Survival: Intent to Treat Analysis (ITT): Data presented corresponds to 132/176 patients (75% of the sample), who had been followed for ≥ 8 months. Median OS is 8.23 months in Arm B and 6.17 months in Arm A (log rank test, p= 0.036). Long‐ term OS rate (%) at 24 months: 19.4% in Arm B and 7.7% in Arm A. Per Protocol Population Analysis (PPP): Shown data only include patients who have received ≥ 5 doses of vaccine (92/132 patients, 70% of the patients in the database). Median OS was 10.97 months in Arm B and 6.27 months in Arm A (log rank test, p= 0.0115). Long‐ term OS rate (%) at 24 months: 24% in Arm B and 6.2 % Arm A. Conclusion: • Immunization with Racotumomab is safe. • There is an OS benefit for Arm B, both in ITT and PPP analyses. • Additional data about this trial will be presented at the IASLC meeting.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01024301/full} -} - - -Record #350 of 538 -@article{EUCTR2014-005118-49-NL15, -author = {EUCTR2014-005118-49-NL,}, -title = {Pembrolizumab after high dose radiation versus Pembrolizumab alone in patients with non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2014-005118-49-NL}, -year = {2015}, -accession_number = {ICTRP EUCTR2014‐005118‐49‐NL}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: MK3475 Product Code: 1374853‐91‐4 Pharmaceutical Form: Powder for injection INN or Proposed INN: PEMBROLIZUMAB CAS Number: 1374853‐91‐4 Current Sponsor code: M14PRT Other descriptive name: Anti‐PD‐1 monoclonal antibody Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50‐ CONDITION: Advanced non‐small cell lung cancer ; MedDRA version: 19.0 Level: LLT Classification code 10025048 Term: Lung cancer non‐small cell recurrent System Organ Class: 100000004864 Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: To observe an increase in Overall Response Rate (ORR) from 20% in the pembrolizumab alone arm to 50% in the pembrolizumab after SBRT arm at 12 weeks. ; ; Primary end point(s): Overall Respons Rate (ORR) Secondary Objective: ‐ Disease Control Rate, defined as the percentage of patients having a complete response, partial response or stable disease at 12 weeks ; ‐ PFS, defined as time from randomization to disease progression or death, ; ‐ OS, defined as time from randomization to death (of any cause). ; ‐ Toxicity; ; Timepoint(s) of evaluation of this end point: at 12 weeks; SECONDARY OUTCOME: Secondary end point(s): DCR, PFS, OS and toxicity ; ; Timepoint(s) of evaluation of this end point: DCR: 12 weeks ; PFS: every 6 weeks ; OS: every 12 weeks ; Toxicity: every 3 weeks INCLUSION CRITERIA: 1. Be willing and able to provide written informed consent/assent for the trial. 2. Be = 18 years of age on day of signing informed consent. 3. Have measurable disease based on RECIST 1.1. 4. Must provide newly obtained tissue from a core or excisional biopsy of a tumor lesion and are willing to have a second biopsy performed form any non‐irradiated lesion after the radiation and immune‐modulating treatment. 5. Have a performance status of 0 or 1 on the ECOG Performance Scale. 6. Stage IV NSCLC; treated with at least 1 regimen of chemotherapy. 7. Have at least 2 separate (metastatic) lesions of which one is amenable for irradiation with a size of < 5 cm. 8. Demonstrate adequate organ function: Absolute neutrophil count (ANC) =1,500 /mcL; Platelets =100,000 / mcL; Hemoglobin =9 g/dL or =5.6 mmol/L; Serum creatinine =1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (GFR can also be used in place of}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01872302/full} -} - - -Record #351 of 538 -@article{Yoon17, -author = {Yoon, S, Lee, DH, and Kim, S-W}, -title = {Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505)}, -journal = {Journal of thoracic disease}, -volume = {9}, -number = {10}, -pages = {3525‐3528}, -year = {2017}, -accession_number = {EMBASE 619471804}, -publication type = {Journal article}, -keywords = {*cancer combination chemotherapy; *cancer radiotherapy; *non small cell lung cancer /drug therapy /drug therapy; Advanced cancer; Cancer immunotherapy; Cancer survival; Chemoradiotherapy; Conformal radiotherapy; Consolidation chemotherapy; Editorial; Human; Inoperable cancer; Overall survival; Progression free survival; Radiation dose; Radiation pneumonia /complication; Survival rate; Survival time}, -DOI = {10.21037/jtd.2017.09.12}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01643727/full} -} - - -Record #352 of 538 -@article{jRCTs03120023020, -author = {jRCTs031200230,}, -title = {JCOG1914: a clinical trial for elderly patients with unresectable locally advanced non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCTs031200230}, -year = {2020}, -accession_number = {ICTRP jRCTs031200230}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Arm A: Radiotherapy (60 Gy/30 fr, 5 days/week) with intravenous administration of CBDCA (30mg/m2, on the first 20 days of radiotherapy). Arm B: Radiotherapy (60 Gy/30 fr, 5 days/week) with intravenous administration of CBDCA (AUC 2 (min*mg/mL), weekly, on the first day of radiotherapy) and nab‐PTX (30mg/m2, weekly, on the first day of radiotherapy). CONDITION: Unresectable locally advanced non‐small cell lung cancer. PRIMARY OUTCOME: Overall survival SECONDARY OUTCOME: Progression free survival, response rate, proportion of patients starting maintenance durvalumab therapy, proportion of patients with adverse events, proportion of patients with serious adverse events, location of progression, proportion of patients without FACT‐TOI deterioration, proportion of patients without IADL deterioration. INCLUSION CRITERIA: (1) Histologically or cytologically proven non‐small cell lung cancer. (2) Diagnosed as c‐stage III and also fulfills at least one of the following conditions on imaging studies. (i) N0‐1 and presence of direct invasion into the parietal pleura, chest wall, phrenic nerve, or pericardium. (ii) N0‐1 and presence of direct invasion into the diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina. (iii) N2‐3 with any T. (iv) Judged unresectable by both an oncologist and a thoracic surgeon. (3) Aged 75 years and older at the time of enrollment. (4) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. (5) IMRT or 3D‐CRT according to the protocol is considered possible by a radiation oncologist. (6) If prior history of radiotherapy is present, the patient fulfills both of the following requirements. (i) No past radiotherapy to the hilums of the lungs or the media}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02241772/full} -} - - -Record #353 of 538 -@article{Kim22, -author = {Kim, HR, Gridelli, C, Kapur, D, Tufman, A, Felip, E, Velcheti, V, Kim, YJ, Goetze, TO, Lopez, PG, Corre, R, Penkov, K, Anjum, R, Di Pace, B, Liu, W, Borgovan, T, Ledger, D, Carver, J, Waszak, A, Dhar, A, and Novello, S}, -title = {P1.11-01 Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S109‐S110}, -year = {2022}, -accession_number = {EMBASE 2020097608}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *drug tolerability; *non small cell lung cancer; Adult; Cancer recurrence; Cancer resistance; Cancer survival; Chemotherapy; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Drug combination; Drug safety; Drug therapy; Drug withdrawal; ECOG Performance Status; Female; Follow up; Health care quality; Human; Major clinical study; Male; Multicenter study; Overall response rate; Overall survival; Parallel design; Pharmacokinetics; Phase 1 clinical trial; Phase 2 clinical trial; Phase 3 clinical trial; Progression free survival; Quality of life assessment; Randomized controlled trial; Response evaluation criteria in solid tumors}, -abstract = {Introduction: TIM‐3 and PD‐1 are markers of T‐cell exhaustion co‐expressed on tumor‐infiltrating T cells (CD4+, CD8+) and antigen presenting cells in lung cancer. TIM‐3 expression has also been associated with poor overall survival (OS) outcomes in NSCLC. In the Phase 1 AMBER study (NCT02817633), cobolimab (GSK4069889, a TIM‐3 inhibitor) plus dostarlimab (a PD‐1 inhibitor) showed clinical responses with an acceptable safety profile in patients with heavily pretreated, PD‐1/PD‐L1 relapsed/refractory, advanced or metastatic NSCLC. COSTAR Lung (NCT04655976) aims to compare the efficacy and safety of cobolimab plus dostarlimab and standard of care chemotherapy (CT, docetaxel; Arm A) to dostarlimab plus docetaxel (Arm B) to docetaxel alone (Arm C) in patients with PD‐1/PD‐L1 relapsed/refractory NSCLC. Methods: This is an ongoing global, multicenter, parallel‐group treatment, randomized, Phase 2, open‐label, 3‐arm study, with the potential for a Phase 3 expansion. Eligible patients will be ≥18 years old, with pathologically confirmed advanced/metastatic NSCLC (squamous or non‐squamous) who have received ≤2 prior lines of therapy that include an anti‐PD‐1/PD‐L1 therapy plus platinum‐based CT only. Additional inclusion criteria are documented radiological disease progression on prior therapy, confirmed PD‐L1 status, absence of sensitizing EGFR, ALK, or ROS‐1 mutations, and ECOG PS 0‐1. Patients will be randomized 2:2:1 to Arm A, Arm B, or Arm C. Patients will receive cobolimab (300 mg IV), dostarlimab (500 mg IV), and/or docetaxel (75 mg/m2 IV) Q3W. Cobolimab and dostarlimab treatment will continue until disease progression, unacceptable toxicity, patient withdrawal, investigator’s decision, or death. Docetaxel treatment will continue for ≥4 cycles or until unacceptable toxicity or disease progression. The primary endpoint is OS for Arms A or B vs C. Secondary endpoints include OS for Arm A vs B and investigator‐assessed confirmed objective response rate (ORR); progression‐free survival (PFS) and duration of response (RECIST v1.1); quality of life assessments; safety; and tolerability. Exploratory endpoints include investigator‐assessed confirmed ORR and PFS (iRECIST), pharmacokinetics, biomarkers of response, and patient‐reported efficacy and tolerability. Approximately 250 patients will be randomized to the Phase 2 portion with an interim analysis planned after at least 18 weeks of follow‐up. An additional 500 patients (n=200 each in Arms A‐B and n=100 in Arm C) may be included in the Phase 3 portion. Funding: GSK (213410). Editorial support provided by Fishawack Indicia Ltd., UK, part of Fishawack Health, and funded by GSK.}, -DOI = {10.1016/j.jtho.2022.07.183}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461459/full} -} - - -Record #354 of 538 -@article{EUCTR2017-003684-35-PL18, -author = {EUCTR2017-003684-35-PL,}, -title = {A study of REGN2810 (Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in patients with lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2017-003684-35-PL}, -year = {2018}, -accession_number = {ICTRP EUCTR2017‐003684‐35‐PL}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: cemiplimab Product Code: REGN2810 Pharmaceutical Form: Solution for infusion INN or Proposed INN: cemiplimab Current Sponsor code: REGN2810 Other descriptive name: HUMAN IGG4 ISOTYPE MONOCLONAL (GDF8) ANTIBODY Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 350‐ Trade Name: Yervoy Product Name: ipilimumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: IPILIMUMAB CAS Number: 477202‐00‐9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ Product Name: cemiplimab Product Code: REGN2810 Pharmaceutical Form: Solution for infusion INN or Proposed INN: cemiplimab Current Sponsor code: REGN2810 Other descriptive name: HUMAN IGG4 ISOTYPE MONOCLONAL (GDF8) ANTIBODY Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1050‐ CONDITION: Non‐Small Cell Lung Cancer Therapeutic area: Diseases [C] ‐ Cancer [C04] SECONDARY OUTCOME: Secondary end point(s): ‐Objective response rate in all patients; ‐Overall survival in patients whose tumors express PD‐L1 in <50% of; tumor cells and in all patients.; Overall survival is defined as the time from randomization to the date of; death. A patient; who is lost to follow‐up will be censored at the last date that the patient; was known to be; alive.; ‐PFS in patients whose tumors express PD‐L1 in <50% of tumor cells; and in all patients.; Progression‐free survival is defined as the time from randomization to; the date of the first documented tumor progression, as determined by; the IRC (based on RECIST 1.1 assessments, or death. Patients will be; censored according to the rules listed below:; o Patients without a documented tumor progression or death will be; censored on the; date of their last evaluable tumor assessment.; o Patients without any evaluable tumor assessments after randomization; and did not die will be censored on the date of randomization.; ‐The incidences of TEAEs, serious adverse events (SAEs), deaths, and; laboratory; abnormalities. Timepoint(s) of evaluation of this end point: The secondary endpoint of OS will be analyzed 12 months after the analysis of ORR. The secondary endpoint of PFS will be analyzed at the same time as analysis of ORR. PRIMARY OUTCOME: Main Objective: The primary objective of the study is to compare the objective response rate (ORR) of high dosecemiplimab ("HDREGN2810") and standard dose cemiplimab plus ipilimumab combination therapy ("SDREGN2810/ipi") to the ORR of standard dose cemiplimab ("SDREGN2810") in the second line treatment of patients with advanced squamous or non‐squamous non‐small cell lung cancer (NSCLC), in patients whose tumors express programmed cell death ligand 1 (PD‐L1) in <50% of tumor cells. Primary end point(s): The primary endpoint is objective response rate (ORR) defined as the; proportion of patients achieving CR or PR as assessed by a blinded IRC; based on RECIST 1.1 assessments, in patients whose tumors express; PD‐L1 in <50% of tumor cells.; Objective response rate is defined as the number of patients with a best; overall response (BOR); of confirmed CR or PR divided by the number of patients in the efficacy; analysis set.; Best overall response will be defined as the best response recorded, as; determined by the IRC per; RECIST 1.1, between the date of randomization and the date of the first; objectively documented; progression or the date of subsequent anti‐cancer therapy, whichever; comes first. Secondary Objective: ‐To compare the ORR of HDREGN2810 and SDREGN2810/ipi to the ORR of SDREGN2810 in the second‐line treatment of patients with advanced squamous or non‐squamous NSCLC in all patients.; ‐To compare the OS of HDREGN2810, and SDREGN2810/ipi combination therapy compared to the OS of SDREGN2810 in the second‐line treatment of patients with advanced squamous or non‐squamous NSCLC in patients with PD‐L1 in <50% of tumor cells and in all patients.; ‐To compare the PFS of HDREGN2810 and SDREGN2810/ipi combination therapy to the PFS of SDREGN2810 in the second‐line treatment of patients with advanced squamous or non‐squamous NSCLC in patients with PD‐L1 in <50% of tumor cells and in all patients.; ‐To evaluate the safety and tolerability of HDREGN2810 and SDREGN2810/ipi compared to those of SDREGN2810 therapy; ; Timepoint(s) of evaluation of this end point: The primary endpoint of ORR will be analyzed when all enrolled patients have an opportunity to; complete 7 months of study treatment and have had at least two on‐treatment tumor assessments. INCLUSION CRITERIA: 1. Men and women =18 years of age 2. Patients with histologically or cytologically documented squamous or non‐squamous NSCLC with stage IIIb or stage IIIc disease who are not candidates for treatment with definitive concurrent chemo‐radiation or patients with stage IV disease. Patients must have PD after receiving one prior line of chemotherapy treatment for advanced NSCLC 3. Availability of an archival or on‐study obtained formalin‐fixed, paraffin‐embedded tumor tissue biopsy sample. Guidance on biopsy sites: a. Archival or fresh biopsies are acceptable; b. If an archival biopsy is used, it has to be less than 5 months old; c. The biopsy should be from a metastatic or recurrent site which has not previously been irradiated. Exception: the primary tumor is still in place and the other metastatic sites are either not accessible (brain) or cannot be used (bone) or the biopsy would put the patient at risk 4. Biopsy evaluable for expressio}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01904556/full} -} - - -Record #355 of 538 -@article{Theelen18, -author = {Theelen, W, Peulen, FH, Lalezari, F, De Vries, J, De Langen, J, Aerts, J, Monkhorst, K, and Baas, P}, -title = {Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: the PEMBRO-RT study}, -journal = {Journal of clinical oncology}, -volume = {36}, -number = {15}, -year = {2018}, -accession_number = {EMBASE 625968424}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *cancer radiotherapy; *non small cell lung cancer; *stereotactic body radiation therapy; Adult; Biopsy; Conference abstract; Controlled study; Drug therapy; Fatigue; Female; Fever; Gene expression; Human; Hypothyroidism; Immune response; Major clinical study; Male; Metastasis; Nausea; Phase 2 clinical trial; Protein expression; Randomized controlled trial; Response evaluation criteria in solid tumors; Writing}, -abstract = {Background: High dose radiation can lead to increased tumor antigen release, improved antigen presentation and T‐cell infiltration. It may therefore enhance the effects of checkpoint inhibition. We evaluated if stereotactic body radiation therapy (SBRT) on a single metastasis preceding pembrolizumab treatment in patients with NSCLC is well tolerated and leads to an increased tumor response. Methods: Patients (n = 74) with advanced NSCLC (≥2 line) regardless of PD‐L1 status were randomized (1:1) between pembrolizumab (200mg q3w) alone (control arm) or pembrolizumab preceded by SBRT (3x8Gy within 7 days prior to the first cycle) on a single metastasis (experimental arm). Sequential biopsies were obtained from the same, non‐irradiated tumor site at baseline and after two cycles of pembrolizumab. The primary endpoint was improvement in overall response rate (ORR) at 12 weeks from 20% in the control arm to 50% in the experimental arm according to RECIST 1.1. Results: From July 2015 until the time of writing, 72 patients had been randomized and 64 patients who received at least one cycle of pembrolizumab could be evaluated for the primary endpoint. ORR at 12 weeks was 19% in the control arm (n = 32) vs 41% in the experimental arm (n = 32); the number of patients with a CR, PR, SD and PD were 0/6/7/19 and 1/12/6/13, respectively. Median PFS was 1.8 months in the control arm vs 6.4 months in the experimental arm; HR 0.55 (CI 0.31 ‐ 0.98, p = 0.04). Grade ≥3 toxicity was experienced in 22% of patients in the control arm vs 17% in the experimental arm. The most common AEs were fatigue, nausea, fever and hypothyroidism. No increase in treatment related toxicity was observed in the experimental arm. Conclusions: With 86% of patients evaluable, we conclude that pembrolizumab preceded by SBRT resulted in a doubling of the ORR without increase in toxicity. The primary endpoint of 50% DCR was not (yet) met. This is a well‐tolerated and promising treatment strategy to augment the antitumor immune response with checkpoint blockade. Definitive results as well as correlations with PD‐L1 expression will be available and discussed at ASCO.}, -DOI = {10.1200/JCO.2018.36.15-suppl.9023}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01788262/full} -} - - -Record #356 of 538 -@article{Nymoen24, -author = {Nymoen, HM, Alver, TN, Horndalsveen, H, Eide, HA, Bjaanaes, MM, Brustugun, OT, Gronberg, BH, Haakensen, VD, and Helland, A}, -title = {Thoracic radiation in combination with erlotinib—results from a phase 2 randomized trial}, -journal = {Frontiers in oncology}, -volume = {14}, -year = {2024}, -accession_number = {EMBASE 2030975387}, -publication type = {Journal article}, -keywords = {*allergic rash; Abdominal pain; Adult; Adverse event; Aged; Anorexia; Article; Atrial fibrillation; Chemotherapy; Computer assisted tomography; Constipation; Controlled study; Coughing; Diarrhea; Dizziness; Dysphagia; Dyspnea; Electrocorticography; Fatigue; Female; Heart failure; Histology; Human; Immunotherapy; Major clinical study; Male; Multicenter study; Nausea; Non small cell lung cancer; Overall survival; Phase 2 clinical trial; Quality of life; Questionnaire; Radiosensitivity; Randomized controlled trial; Rash; Thorax pain; Thrombosis; Toxicity; Treatment response; Tumor volume; Very elderly; Vomiting}, -abstract = {Background: Radiotherapy (RT) can be used to reduce symptoms and maintain open airways for patients with non‐small cell lung cancer when systemic treatment is not sufficient. For some patients, tumor control is not achieved due to radioresistance. Concurrent inhibition of epidermal growth factor receptors has been proposed as a strategy to overcome radioresistance but may increase toxicity. We performed a randomized trial to assess the efficacy, tolerance, and quality of life of concurrent erlotinib and palliative thoracic RT for patients with advanced non‐small cell lung cancer. Methods: Patients were randomized 1:1 to RT alone (arm A) or in combination with erlotinib (arm B). A computed tomography (CT) scan at baseline and one at 4–12 weeks after inclusion was used to evaluate treatment response. Adverse events were registered during treatment and the subsequent 30 days. Health‐related quality‐of‐life questionnaires were completed by the patients at baseline, weeks 2, 6, and 20. Results: A total of 114 patients were included. Of the 74 patients with CT scans available for evaluation of treatment effect, there were no significant differences in tumor size reduction between the two groups: median 14.5% reduction in the control arm A and 17.0% in the erlotinib arm B (p = 0.68). Overall survival was not significantly different between the two treatment arms: 7.0 and 7.8 months in arm A and arm B, respectively (log‐rank p = 0.32). There was no significant increase in adverse events in the experimental arm, other than what is expected from erlotinib treatment alone. Overall, patients reported similar quality of life in both treatment arms. Conclusion: Concurrent erlotinib and palliative thoracic RT for patients with advanced non‐small cell lung cancer was well tolerated but did not improve the efficacy of the RT. Clinical trial registration: ClinicalTrials.gov, identifier NCT02714530.}, -DOI = {10.3389/fonc.2024.1412716}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02739852/full} -} - - -Record #357 of 538 -@article{UMIN00002798517, -author = {UMIN000027985,}, -title = {Nivolumab maintenance as monotherapy after carboplatine plus nab-paclitaxel for first-line treatment of advanced Non-small-cell lung cancer: feasibility study}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000027985}, -year = {2017}, -accession_number = {ICTRP UMIN000027985}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Level 1:carboplatin AUC 6+nab‐paclitaxel,4cycles Level 0:carboplatin AUC 5+nab‐paclitaxel,3cycles If 3 or more of the first 6 patients who had been originally allocated to the level 1 experienced nivolumab‐induced grade 3‐4 toxicity, additinal 6 patients were enrolled to the level 0. If 2 or less of the first 6 patients in level 1 who had experienced nivolumab‐induced grade 3‐4 toxicity,additinal 6 patients were enrolled to the level 1. CONDITION: Non‐Small Cell Lung Cancer PRIMARY OUTCOME: Feasibility of nivolumab maintenance therapy after carboplatine plus nab‐paclitaxel SECONDARY OUTCOME: Anti‐tumor efficacy INCLUSION CRITERIA: 1)Histology/cytology‐proven non‐small cell lung cancer 2)No prior treatment 3)Stage IIIB, IV and unsuitable for radiotherapy 4)EGFR(‐),ALK(‐) 5)PD‐L1 staining:1%‐49% 6)With one or more measurable disease based on RECIST 7)Performance status(ECOG): 0‐1 8)Age 20<80 9)Adequate organ function 10)Written informed consent}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01888534/full} -} - - -Record #358 of 538 -@article{ChiCTR210004365621, -author = {ChiCTR2100043656,}, -title = {A randomized, controlled, single-center clinical study of Xiaoyan Decoction in combination with Durvalumab in the treatment of unresectable advanced NSCLC after radiotherapy and chemotherapy}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2100043656}, -year = {2021}, -accession_number = {ICTRP ChiCTR2100043656}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: experimental group:Xiaoyan Decoction;control group:Durvalumab; CONDITION: lung cancer PRIMARY OUTCOME: ORR;DCR; INCLUSION CRITERIA: 1. Age: 18 75 years old, male or female; 2. Patients with advanced non‐small cell lung cancer diagnosed histomathologically and/or cytologically (Note: unresectable non‐small cell lung cancer: A, tumor involving the heart, large blood vessels, trachea, or adjacent organs.B. Patients with multi‐station or large lymph node metastases should be considered unresectable;It should be considered in conjunction with other factors, including age, PS score and response to treatment.C. Patients with supraclavicular lymph node involvement should be considered unresectable.D. Patients with distant metastasis (including non‐regional lymph nodes) are unresectable. 3. Patients who have received at least previous radiotherapy and chemotherapy, and whose driver gene epidermal growth factor‐receptor (EGFR) and anaplasticlymphoma kinase (ALK) related to lung cancer are wild‐type; 4. ECOG PS: 0‐2 points 5. Life expectancy, at least for 3 months and qi deficiency syndro}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02280529/full} -} - - -Record #359 of 538 -@article{Herbst19, -author = {Herbst, R, Barlesi, F, Paz-Ares, L, Raben, D, Aggarwal, C, Bothos, J, Samadani, R, He, P, Angra, N, and Martinez, P}, -title = {P1.04-28 COAST: durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S450‐S451}, -year = {2019}, -accession_number = {EMBASE 2003406174}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer staging; *non small cell lung cancer; *seashore; Adult; Cancer patient; Cancer survival; Chemoradiotherapy; Clinical evaluation; Conference abstract; Controlled study; Disease control; Drug combination; Drug efficacy; Drug safety; Drug therapy; Female; Human; Immunogenicity; Major clinical study; Male; Monotherapy; Overall survival; Pharmacokinetics; Phase 2 clinical trial; Preclinical study; Progression free survival; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors}, -abstract = {Background: The standard of care for patients with unresectable stage III non‐small cell lung cancer (NSCLC) is platinum‐based chemotherapy with concurrent radiotherapy, followed by durvalumab consolidation for 12 months. When administered after completion of concurrent chemoradiotherapy (cCRT) in patients with unresectable NSCLC in the PACIFIC study, durvalumab demonstrated superior clinical outcomes vs placebo in terms of progression‐free survival (PFS; hazard ratio [HR] 0.51; 95% CI: 0.41, 0.63) and overall survival (OS; HR 0.68; 99.73% CI 0.47, 0.997; p=0.0025).1 Comparing durvalumab with placebo, the 24‐month OS rate (95% CI) was 66.3% (61.7, 70.4) vs 55.6% (48.9, 61.8), median PFS was 17.2 months (13.1, 23.9) vs 5.6 months (4.6, 7.7) and objective response rate was 30.0% (25.8, 34.5) vs 17.8% (13.0, 23.6).1,2 However, despite cCRT followed by durvalumab, most patients with unresectable stage III NSCLC relapse and eventually die from NSCLC. The COAST study (NCT03822351) is a platform trial that aims to identify potential combinations of durvalumab with novel agents to improve response rates over monotherapy. Method: This multidrug, randomized, phase 2 trial is evaluating the clinical activity and safety of durvalumab alone or in combination with the novel agents oleclumab (MEDI9447) and monalizumab (IPH2201) in patients with unresectable, stage III NSCLC who have not progressed following definitive cCRT. New treatment arms evaluating other durvalumab combinations may be added based on emerging preclinical and clinical data. The primary endpoint is objective response per RECIST v1.1 with monotherapy and combination therapy. Secondary endpoints include safety, efficacy (duration of response, disease control, PFS, 12‐month PFS rate, OS), pharmacokinetics and immunogenicity. The COAST study is open for accrual with an estimated total target enrollment of up to 60 patients per treatment arm. References 1Antonia SJ, et al. N Engl J Med 2018;379:2342–50. 2Antonia SJ, et al. N Engl J Med 2017;377:1919–29. Result: Section not applicable Conclusion: Section not applicable Keywords: locally advanced NSCLC, consolidation treatment, checkpoint inhibition}, -DOI = {10.1016/j.jtho.2019.08.931}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01997018/full} -} - - -Record #360 of 538 -@article{EUCTR2018-002931-35-PT19, -author = {EUCTR2018-002931-35-PT,}, -title = {A study of durvalumab alone or in combination with other agents in subjects with non-small cell lung cancer that is not removable by surgery}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2018-002931-35-PT}, -year = {2019}, -accession_number = {ICTRP EUCTR2018‐002931‐35‐PT}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935‐60‐7 Current Sponsor code: MEDI4736 Other descriptive name: Immunoglobulin G1, anti‐human CD antigen Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ Product Name: oleclumab Product Code: MEDI9447 Pharmaceutical Form: Concentrate and solvent for solution for infusion INN or Proposed INN: oleclumab Current Sponsor code: MEDI9447 Other descriptive name: human IgG1? monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ Product Name: monalizumab Product Code: IPH2201 Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: monalizumab Current Sponsor code: IPH2201 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 375‐ CONDITION: Stage III non‐small cell lung cancer ; MedDRA version: 20.0 Level: PT Classification code 10029519 Term: Non‐small cell lung cancer stage III System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: ; Main Objective: Clinical activity; ‐ To compare the antitumor activity of durvalumab alone vs durvalumab in combination with novel agents.; ; Primary end point(s): Clinical activity; ‐ Objective response (OR) per Response Evaluation Criteria for Solid Tumors version 1.1 (RECIST v1.1); ; Secondary Objective: Safety; ‐ To evaluate the safety and tolerability of durvalumab alone and durvalumab in combination with novel agents.; ; Clinical activity; ‐ To further compare the efficacy of durvalumab alone vs durvalumab in combination with novel agents.; ; Pharmacokinetics; (a) To describe the pharmacokinetics (PK) of durvalumab alone and durvalumab in combination with novel agents.; (b) To describe the PK of novel agents in combination with durvalumab.; ; Immunogenicity; (a) To assess the immunogenicity of durvalumab alone or in combination with novel agents; (b) To assess the immunogenicity of novel biologic agents in combination with durvalumab; Timepoint(s) of evaluation of this end point: From randomization until documention of disease progression, or the last evaluable disease assessment in the absence of PD prior to the initiation of subsequent anticancer therapy or discontinuation from the study, whichever occurs first. SECONDARY OUTCOME: ; Secondary end point(s): Safety; ‐ Presence of adverse events (AEs), serious adverse events (SAEs), and abnormal laboratory parameters and vital signs.; ; Clinical activity; ‐ Duration of response (DoR), disease control (DC), progression‐free survival (PFS) at 12 months, and PFS per RECIST v1.1 and overall survival (OS).; ; Pharmacokinetics; ‐ Concentration of durvalumab or novel agents in serum.; ; Immunogenicity; ‐ Antidrug antibody (ADA) incidence of durvalumab or novel biologic agents; ; Timepoint(s) of evaluation of this end point: Safety ‐ From time of informed consent through treatment period (12 months) or up to 3 months post last dose of study treatment.; ; DoR ‐ From randomization until documention of disease progression.; ; DC ‐ From randomization until progression, or the last evaluable disease assessment in the absence of PD prior to the initiation of subsequent anticancer therapy or discontinuation from the study, whichever occurs first.; ; PFS and OS ‐ From start of treatment until study completion or death, whichever comes first.; ; Pharmacokinetics and immunogenicity ‐ During the treatment period and follow‐up.; INCLUSION CRITERIA: 1. Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol‐related procedures, including screening evaluation 2. Age 18 years or older 3. Body weight = 35 kg 4. Subjects must have histologically or cytologically documented NSCLC who present with locally advanced, unresectable, Stage III disease 5. Subjects must have completed, without progressing, definitive cCRT within 28 days prior to being randomized into the study. 6. Subjects must have at least one previously irradiated tumor lesion that can be measured by RECIST v1.1 7. Provision of tumor tissue sample, when available, from original diagnosis obtained before initiation of chemoradiotherapy 8. Life expectancy = 12 weeks 9. Eastern Cooperative Oncology Group (ECOG) Performance}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02068167/full} -} - - -Record #361 of 538 -@article{EUCTR2020-000035-50-HU20, -author = {EUCTR2020-000035-50-HU,}, -title = {SAR408701 in combination with pembrolizumab and pembrolizumab alone in patients with non-squamous non-small cell lung cancer (NSQ NSCLC)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-000035-50-HU}, -year = {2020}, -accession_number = {ICTRP EUCTR2020‐000035‐50‐HU}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Code: SAR408701 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Not assigned Current Sponsor code: SAR408701 Other descriptive name: SAR408701 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5‐ Trade Name: Keytruda Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Pembrolizumab CAS Number: 1374853‐91‐4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ CONDITION: Non‐squamous non–small‐cell lung cancer (NSQ NSCLC) ; MedDRA version: 20.0 Level: LLT Classification code 10079440 Term: Non‐squamous non‐small cell lung cancer System Organ Class: 100000004864 Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: • Part 1 (safety run‐in): To assess the tolerability and to confirm the recommended dose of SAR408701 in combination with pembrolizumab in the NSQ NSCLC population; • Part 2: To assess the antitumor activity of SAR408701 in combination with pembrolizumab and pembrolizumab single agent in the NSQ NSCLC population; Primary end point(s): Part 1: Number of partcipants with study drug‐related dose‐limiting toxicity (DLTs) at Cycle 1 (C1D1 to C1D21) ‐ Study drug‐related dose‐limiting toxicity (DLTs) at Cycle 1 (C1D1 to C1D21), including but not limited to corneal toxicity; ; Part 2: Objective response rate (ORR) of SAR408701 + pembrolizumab and pembrolizumab single agent ‐ ORR is defined as proportion of participants who have a confirmed complete response (CR) or partial response (PR) as per response evaluation criteria in solid tumors (RECIST v1.1) Secondary Objective: • To assess the safety and tolerability of SAR408701 in combination with pembrolizumab and pembrolizumab single agent; • To assess the durability of the response to treatment with SAR408701 in combination with pembrolizumab and pembrolizumab single agent; • To assess the efficacy on progression‐free survival (PFS) of SAR408701 in combination with pembrolizumab and pembrolizumab single agent ; • To assess the pharmacokinetics (PK) of SAR408701 and pembrolizumab when given in combination, and of pembrolizumab when given as a single agent; • To assess the immunogenicity of SAR408701 when given in combination with pembrolizumab; Timepoint(s) of evaluation of this end point: Part 1 and Part 2 : Baseline up to 10 months after last participant treated SECONDARY OUTCOME: Secondary end point(s): 1. Number of participants with treatment‐emergent adverse events (TEAEs), serious adverse events (SAEs) and laboratory abnormalities ‐ TEAEs, SAEs and laboratory abnormalities according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V5 ; ; 2. Duration of response ‐ Duration of response (DOR), defined as the time from first documented evidence of CR or PR until progressive disease determined per RECIST 1.1 or death from any cause, whichever occurs first ; ; 3. Progression‐free surviva ‐ Progression‐free survival, defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause, whichever comes first ; ; ; ; 6. Tmax of SAR408701 and pembrolizumab ‐ Time to reach Cmax (Tmax) of SAR408701 and pembrolizumab when given in combination and Ceoi of pembrolizumab when given alone ; ; ; INCLUSION CRITERIA: ‐ Histologically‐ or cytologically‐confirmed diagnosis of advanced or metastatic NSQ NSCLC with no EGFR sensitizing mutation or BRAF mutation or ALK/ROS alterations. ‐ PD‐L1 positive tumor (TPS =1%) as determined locally by an approved test ‐ Measurable disease based on RECIST 1.1. ; 4. Ceoi of SAR408701 and pembrolizumab ‐ Concentration observed at the end of IV infusion (Ceoi) of SAR408701 and pembrolizumab when given in combination and Ceoi of pembrolizumab when given alone ; 5. Cmax of SAR408701 and pembrolizumab ‐ Maximum concentration observed after infusion (Cmax) of SAR408701 and pembrolizumab when given in combination and Ceoi of pembrolizumab when given alone ; 7. Clast of SAR408701 and pembrolizumab ‐ Last concentration observed above the lower limit of quantification after infusion (Clast)of SAR408701 and pembrolizumab when given in combination and Ceoi of pembrolizumab when given alone ; 8. Tlast of SAR408701 and pembrolizumab ‐ Time of Clast (Tlast) of SAR408701 and pembrolizumab when given in combination and Ceoi of pembrolizumab when given alone Timepoint(s) of evaluation of this end point: 1. to 8. : Baseline up to 10 months after last participant treated ‐ No prior systemic chemotherapy for the treatment of the participant's advanced or metastatic disease (treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as completed at least 6 months prior to diagnosis of advanced or metastatic disease). ‐ Expression of CEACAM5 as demonstrated prospectively by a centrally assessed IHC assay of =2+ in intensity involving at least 50% of the tumor cell population in archival tumor sample (or if not available fresh biopsy sample). ‐ Eastern Cooperative Oncology Group (ECOG) performance status 0‐1 ‐ Contraceptive use by men or women should be consistent with local regulations}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169562/full} -} - - -Record #362 of 538 -@article{CTRI/2024/03/06350024, -author = {CTRI/2024/03/063500,}, -title = {Tislelizumab in Combination With Chemotherapy in First-line Treatment of Unresectable/Metastatic Non-small Cell Lung Cancer or Recurrent/Metastatic Squamous Cell Head and Neck Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2024/03/063500}, -year = {2024}, -accession_number = {ICTRP CTRI/2024/03/063500}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Intervention1: Tislelizumab: Tislelizumab is a humanized immunoglobulin G4 (IgG4) variant monoclonal antibody that binds to the T‐cell surface receptor programmed cell death protein 1 (PD‐1), prevents interaction of PD‐1 with its ligands PD‐L1 and PD‐L2, and blocks PD‐1‐mediated inhibitory signaling. As a result, tislelizumab can activate T‐cells to mount immune responses for eradication of cancer and viral infection in humans. The target modulation function may be quantitatively assessed by binding ELISA, binding analysis by fluorescence activated sorting, competitive binding analysis against PD‐L1 and PD‐L2 by fluorescence activated cell sorter (FACs), and P3Z assay by reverse signal transduction by interleukin‐2 secretion. Dose and frequency: Tislelizumab 200 mg will be administered on Day 1 of each 21 day cycle (once every 3 weeks). Route of administration: Tislelizumab will be administered by intravenous administration through an intravenous line. Control Intervention1: Carboplatin: Carboplatin is one of the platinum‐based anti‐cancer drugs and its parent compound is cisplatin. Carboplatin undergoes activation inside cells and forms reactive platinum complexes that cause the intra‐ and inter‐strand cross‐linkage of DNA molecules within the cell. This modifies the DNA structure and inhibits DNA synthesis. This may affect a cell in all the phases of its cycle. Dose, Frequency and Route of Administration: Carboplatin AUC 6 mg/ml/min will be administered intravenous administration on Day 1 of each cycle for 4 to 6 cycles in the induction phase of the treatment. Control Intervention2: Paclitaxel: Paclitaxel is a type of chemotherapy called a taxane. Taxanes interfere with structures in a cell called microtubules that help move chromosomes during mitosis (cell division CONDITION: Health Condition 1: C760‐ Malignant neoplasm of head, face and neck Health Condition 2: C349‐ Malignant neoplasm of unspecifiedpart of bronchus or lung PRIMARY OUTCOME: To assess the safety and tolerability profile of tislelizumab in combination with chemotherapy (comparator agents)Timepoint: The incidence and severity of AEs Will be assessed every 3 weeks during the entire course of the study. SECONDARY OUTCOME: To assess the efficacy of ; tislelizumab in combination with ; chemotherapy in terms of disease control rate ; (DCRTimepoint: Frequency: Every 9 weeks for the first 52 weeks then every 12 weeks thereafter. ; DCR (proportion of patients with confirmed Complete, response partial response, stable disease) To assess the efficacy of ; tislelizumab in combination with ; chemotherapy in terms of duration of ; response (DOR)Timepoint: Frequency: Every 9 weeks for the first 52 weeks then every 12 weeks thereafter. ; DOR as assessed by investigators (time from the first ; determination of an objective response per RECIST v1.1 ; until the first documentation of progression or death, ; whichever occurs first) To assess the efficacy of tislelizumab in ; combination with chemotherapy in terms of ; overall response rate (ORR)Timepoint: Frequency: Every 9 weeks for the first 52 weeks then every 12 weeks thereafter. ; ORR as assessed by investigators (proportion of patients ; with a documented, confirmed complete response [CR] ; or partial response [PR] per RECIST v1.1) To assess the Health‐Related Quality of ; Life (HRQoL) assessment using patientreported ; outcomes (PRO)Timepoint: Frequency: Before First dose then every 3 weeks & in End of treatment visit. ; HRQoL using PRO using 5‐level European Quality of ; Life 5 Dimensions (EQ‐5D‐5L) health questionnaire To evaluate potential biomarkers of safety ; or efficacy & longitudinal tumor ; dynamics using a multiomic approach of ; tissue specimens obtained at baseline, on ; treatment, & or at end of treatment (EOT)Timepoint: Frequency: Baseline, anytime during treatment & end of treatment visit. ; Potential biomarkers of safety or efficacy and ; longitudinal tumor dynamics using a multiomic ; approach including but not limited to imaging, ; histopathology, genomics, proteomics, and ; transcriptomic analysis of tissue specimens obtained at ; baseline, on treatment, & or at EOT To further assess the efficacy of ; tislelizumab in combination with ; chemotherapy in terms of clinical benefit rate (CBR)Timepoint: Frequency: Every 9 weeks for the first 52 weeks then every 12 weeks thereafter. ; CBR (proportion of patients with confirmed CR PR ; durable stable disease [stable disease for more than 24 weeks]) per RECIST v1.1 as assessed by investigators To further assess the efficacy of tislelizumab in combination with chemotherapy in terms of overall survival (OS)Timepoint: Frequency: Every 3 weeks. ; OS (time from the date of enrollment to the date of ; death due to any cause) To further assess the efficacy of tislelizumab in combination with chemotherapy in terms of progression free survival (PFS)Timepoint: Frequency: Every 9 weeks for the first 52 weeks then every 12 weeks thereafter. ; PFS as assessed by investigators (time from the date of enrollment to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first) INCLUSION CRITERIA: 1) Patient must sign a written ICF and understand and agree to comply with the requirements of the study and the schedule of assessments. 2) Age greater than or equals to 18 years on the day of signing the ICF (or the legal age of consent in the jurisdiction in which the study is taking place) 3) Cohort 1: NSCLC a) Locally advanced or recurrent NSCLC that is not eligible for curative surgery and or definitive radiotherapy with or without chemoradiotherapy, or metastatic nonsquamous or squamous NSCLC. b) No prior systemic treatment for metastatic NSCLC. Patients who have received prior neoadjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for nonmetastatic disease must have experienced a disease‐free interval of = 6 months from the last dose of chemotherapy and or radiotherapy prior to signing informed consent. c) No known mutations in: (a)EGFR‐sensitizing gene (e.g., ex}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02684000/full} -} - - -Record #363 of 538 -@article{Wu24, -author = {Wu, Y-L, Johnson, M, Soo, R, Baktash, N, Maier, D, Eigenbrod-Giese, S, and Yoshida, T}, -title = {A phase 3 randomized controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations: beamion LUNG-2}, -journal = {Cancer research}, -volume = {84}, -number = {7}, -year = {2024}, -accession_number = {EMBASE 644223214}, -publication type = {Journal article; Conference proceeding}, -keywords = {*health care quality; *metastasis; *non small cell lung cancer; Adult; Adverse drug reaction; Common Terminology Criteria for Adverse Events; Conference abstract; Controlled study; Drug combination; Drug therapy; Human; Intravenous drug administration; Major clinical study; Multiple cycle treatment; Open study; Overall survival; Patient‐reported outcome; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Side effect; Solid tumor; Systemic therapy}, -abstract = {Background: First‐line (1L) standard of care for patients with HER2 mutation‐positive (HER2m+) nonsmall cell lung cancer (NSCLC) is platinum‐based chemotherapy ± immunotherapy. To date, no targeted 1L treatments have been approved. Zongertinib is a HER2‐selective tyrosine kinase inhibitor that binds to wild‐type and mutated HER2, and spares EGFR. In Phase Ia of Beamion LUNG‐1 (NCT04886804), zongertinib conferred objective response/disease control rates of 49/91% in patients with pretreated HER2 aberration‐positive solid tumors, and 58/97% in those patients with HERm+ NSCLC, with manageable safety with few EGFR‐associated adverse events. Purpose: Here we describe Beamion LUNG‐2 (NCT06151574), a phase 3, randomized, controlled, open‐label trial that will compare the efficacy and safety of 1L zongertinib with standard of care in patients with HER2m+, locally advanced/metastatic nonsquamous NSCLC. Experimental design: Approximately 270 patients will be randomized 1:1 to receive either zongertinib or standard of care. Key inclusion criteria: histologically/cytologically diagnosed advanced/metastatic nonsquamous NSCLC; no prior systemic treatment for locally advanced/metastatic disease; HER2 mutation in the tyrosine kinase domain; ≥1 measurable lesion (RECIST 1.1). Key exclusion criteria: tumors that have alterations with available therapy, and radiotherapy/major surgery ≤4 weeks prior to randomization. In the experimental arm, oral zongertinib 120 mg once daily will be given in 21‐day cycles. In the comparator arm, intravenous pemetrexed 500 mg/m 2 chemotherapy plus either cisplatin 75 mg/m2 or carboplatin area under the curve 5, plus pembrolizumab 200 mg will be given on day 1 every 3 weeks for 4 cycles, followed by pemetrexed 500 mg/m2 plus pembrolizumab 200 mg every 3 weeks for ≤35 cycles. In both arms, treatment will continue until progressive disease (RECIST 1.1), undue toxicity, or other criteria are met. Primary endpoint: progression‐free survival (RECIST 1.1). Secondary endpoints: overall response (defined as best overall response of complete or partial response, RECIST 1.1), patient‐reported outcomes (changes from baseline to Week 25), overall survival, and adverse events during the on‐treatment period (CTCAE 5.0).}, -DOI = {10.1158/1538-7445.AM2024-CT284}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02699524/full} -} - - -Record #364 of 538 -@article{NL-OMON5293519, -author = {NL-OMON52935,}, -title = {A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON52935}, -year = {2019}, -accession_number = {ICTRP NL‐OMON52935}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: The study intervention consists of 60 Gy of radiation therapy concurrent with standard chemotherapy plus M7824 in Arm 1 or placebo in Arm 2, followed by up to 26 doses of M7824 (Arm 1) or durvalumab (Arm 2). CONDITION: ; lung cancer ; Non‐small cell lung cancer 10038666 PRIMARY OUTCOME: PFS according to RECIST 1.1 assessed by IRC; SECONDARY OUTCOME: * Occurrence of TEAEs and treatment‐related AEs ; * OS ; * Changes from Baseline in pulmonary function tests and images and association ; with study intervention: ; ‐ DLCO ; ‐ HRCT ; ‐ FEV1 and FVC ; ‐ 6‐min WT ; * PD‐L1 expression in tumors at Baseline assessed with IHC and association with ; efficacy ; * Objective response according to RECIST assessed by IRC ; * Duration of response assessed from CR or PR until PD, death, or last tumor ; assessment ; * PK profile of M7824 in terms of Ceoi and Ctrough during treatment and Safety ; followup visit. ; * Immunogenicity of M7824 as measured by ADA assays from Screening through last ; Safety Follow‐up visit. ; INCLUSION CRITERIA: Participants are eligible to be included in the study only if all the following criteria apply: Age 1. Are * 18 years of age at the time of signing the informed consent. In Japan, if a patient is < 20 years, the written informed consent from his/her parent or guardian will be required in addition to the patient*s written consent., Type of Participant and Disease Characteristics 2. Participants must have measurable or non‐measurable but evaluable disease assessed by the Investigator. Participants must have histologically documented NSCLC who present with Stage III locally advanced, unresectable disease (International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology [IASLC Staging Manual in Thoracic Oncology], v8). 3. Availability of tumor material (< 6 months old) adequate for biomarker analysis is Mandatory for all participants and central laboratory confirmation is required. For p}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02719723/full} -} - - -Record #365 of 538 -@article{Tanzawa22, -author = {Tanzawa, S, Makiguchi, T, Tasaka, S, Inaba, M, Ochiai, R, Nakamura, J, Inoue, K, Kishikawa, T, Nakashima, M, Fujiwara, K, Kohyama, T, Ishida, H, Kuyama, S, Miyazawa, N, Nakamura, T, Miyawaki, H, Oda, N, Ishikawa, N, Morinaga, R, Kusaka, K, Miyamoto, Y, Yokoyama, T, Matsumoto, C, Tsuda, T, Ushijima, S, Shibata, K, Shibayama, T, Bessho, A, Kaira, K, Misumi, T, Shiraishi, K, Matsutani, N, and Seki, N}, -title = {Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)}, -journal = {Therapeutic advances in medical oncology}, -volume = {14}, -year = {2022}, -accession_number = {EMBASE 2018373641}, -publication type = {Journal article}, -keywords = {*advanced cancer /drug therapy /radiotherapy /surgery; *non small cell lung cancer /drug therapy /radiotherapy /surgery; *prediction; *thorax; Aged; Anorexia /complication; Article; Cancer staging; Chemoradiotherapy; Computer assisted tomography; Continuous infusion; Controlled study; Creatinine blood level; Creatinine clearance; Cytology; Disease control; Drug efficacy; Drug safety; ECOG Performance Status; Electrocardiography; Esophagitis /epidemiology /side effect; Febrile neutropenia /epidemiology /side effect; Female; Forced expiratory volume; Gene mutation; Hemoglobin blood level; Histology; Human; Lung parenchyma; Male; Multicenter study; Multiple cycle treatment; Neutropenia /complication; Neutrophil count; Nuclear magnetic resonance imaging; Phase 2 clinical trial; Platelet count; Pneumonia /epidemiology /side effect; Progression free survival; Radiation dose; Response evaluation criteria in solid tumors; Smoking; Survival rate; Thorax radiography}, -abstract = {Background: The standard of care for unresectable, locally advanced non‐small cell lung cancer (LA‐NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC trial. Disease progression and pneumonitis were reported as the main reasons to preclude the initiation of durvalumab in multiple retrospective studies. However, the transition rate and the reasons for failure to proceed to consolidation therapy with durvalumab after CRT were not evaluated prospectively. Although phase II studies in Japan have shown high efficacy and tolerability of CRT with cisplatin + S‐1 (SP), no prospective study using durvalumab after SP‐based CRT has yet been reported. We therefore conducted a phase II study to verify the efficacy and safety of durvalumab following SP‐based CRT. In this interim analysis, we report the transition rate and the reasons for its failure. Methods: In treatment‐naïve LA‐NSCLC, cisplatin (60 mg/m2, day 1) and S‐1 (80–120 mg/body, days 1–14) were administered with two 4‐week cycles with concurrent thoracic radiotherapy (60 Gy) followed by durvalumab every 2 weeks for up to 12 months. The primary endpoint was 12 month progression‐free survival rate. Results: Fifty‐nine patients were enrolled, of whom 86.4% (51/59) proceeded to durvalumab. All of them initiated durvalumab within 42 days after CRT [median 18 days (range: 3–38)], including 27.5% (14/51) in <14 days. Common reasons for failure to proceed to durvalumab were disease progression (2/59, 3.4%) and adverse events (6/59, 10.2%). Among the latter cases, four resumed treatment and proceeded to durvalumab within 42 days on off‐protocol. The objective response rate and the disease control rate were 62.7% and 93.2%, respectively. The incidences of ⩾grade 3 pneumonitis, febrile neutropenia, and esophagitis were 0%, 8.5%, and 3.4%, respectively. Conclusion: Regarding durvalumab after CRT, this interim analysis of the SAMURAI study clarified the high transition rate, early introduction, and reasons for failure to proceed to consolidation therapy, which were not determined in the PACIFIC trial. Trial registration: Japan Registry of Clinical Trials, jRCTs031190127, registered 1 November, 2019, https://jrct.niph.go.jp/latest‐detail/jRCTs031190127.}, -DOI = {10.1177/17588359221116603}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02467342/full} -} - - -Record #366 of 538 -@article{Weinberg17, -author = {Weinberg, U, Farber, O, Giladi, M, Bomzon, Z, and Kirson, E}, -title = {LUNAR - A phase 3 trial of TTFields in combination with PD-1 inhibitors or docetaxel for second line treatment of non-small cell lung cancer (NSCLC)}, -journal = {Cancer research}, -volume = {77}, -number = {13}, -year = {2017}, -accession_number = {EMBASE 618664401}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Abdomen; Adult; Adverse event; Brain metastasis; Cancer surgery; Cancer survival; Controlled study; Daily life activity; Drug therapy; Female; Follow up; Hazard ratio; Histology; Human; Human tissue; Immune‐related gene; In vitro study; Liver; Major clinical study; Male; Medical device; Overall survival; Patient history of surgery; Phase 1 clinical trial; Phase 3 clinical trial; Pilot study; Progression free survival; Prospective study; Quality of life; Questionnaire; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Sample size; Thorax; Trunk; X‐ray computed tomography}, -abstract = {BACKGROUND: Tumor Treating Fields (TTFields) is a novel, non‐invasive, anti‐mitotic treatment modality, based on low intensity alternating electric fields. TTFields predominantly affect two phases of mitosis: metaphase ‐ by disrupting the formation of the mitotic spindle, and cytokinesis ‐ by dielectrophoretic dislocation of intracellular constituents. TTFields were shown to significantly extend the survival of newly diagnosed glioblastoma patients when combined with temozolomide. Efficacy of TTFields in non‐small cell lung cancer (NSCLC) of all histologies has been demonstrated in multiple in vitro and in vivo models as well as in a phase I/II pilot study in combination with pemetrexed, where overall survival was extended by more than five months compared to historical controls. LUNAR TRIAL DESIGN: The hypothesis of the study is that the addition of TTFields to standard of care second line therapies in advanced NSCLC will increase OS compared to treatment with standard second line alone. 512 patients with either squamous or non‐squamous NSCLC will be enrolled in this prospective, randomized study. Patients will be stratified based on: 1) second line therapy (either PD‐1 inhibitor or docetaxel), histology (squamous Vs. non‐squamous) and geographical region. The main eligibility criteria are first disease progression (per RECIST Criteria 1.1), ECOG score of 0‐1, no prior surgery or radiation therapy, no electronic medical devices in the upper torso and absence of brain metastasis. Docetaxel or PD‐1 inhibitors (either nivolumab or pembrolizumab) will be administered at the standard dose. TTFields will be applied to the upper torso using a small, portable medical device for at least 18 hours/day at home, allowing patients to maintain daily activities. TTFields will be continued until progression in the thorax and/or liver according to the immune‐related response criteria (irRC). Follow up will be performed once q6 weeks, including a CT scan of the chest and abdomen. Following progression in the upper torso, patients will be followed monthly for survival. The primary endpoint will be superiority in overall survival (OS) between patients treated with TTFields in combination with either docetaxel or PD‐1 inhibitors, compared to docetaxel or PD‐1 inhibitors alone. A co‐primary endpoint will compare the OS in patients treated with TTFields and docetaxel to those treated with PD‐1 inhibitors alone in a non‐inferiority analysis. Secondary endpoints include progression‐free survival, radiological response rate based on the irRC, quality of life based on the EORTC QLQ C30 questionnaire and severity and frequency of adverse events. The sample size is powered to detect a Hazard Ratio of 0.75 of TTFields‐treated patients compare to the control group.}, -DOI = {10.1158/1538-7445.AM2017-CT071}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01424055/full} -} - - -Record #367 of 538 -@article{EUCTR2015-004633-27-FR16, -author = {EUCTR2015-004633-27-FR,}, -title = {A Dose Frequency Optimization Study with Nivolumab Every 2 Weeks vsNivolumab Every 4 Weeks in advanced NSCLC patients Who Received 4 Months of Nivolumab Every 2 Weeks}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2015-004633-27-FR}, -year = {2016}, -accession_number = {ICTRP EUCTR2015‐004633‐27‐FR}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Nivolumab Product Code: BMS‐936558 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: NIVOLUMAB CAS Number: 946414‐94‐4 Current Sponsor code: BMS‐936558 Other descriptive name: BMS936558 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ CONDITION: Advanced or Metastatic Non‐small Cell Lung Cancer ; MedDRA version: 19.0 Level: PT Classification code 10059515 Term: Non‐small cell lung cancer metastatic System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: The coprimary objectives are to compare Progression Free Survival rate at 6 months after randomization and PFS rate at 1 year after randomization, as measured by investigator‐assessed response using Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria, of nivolumab 240 mg every 2 weeks (Arm 1) and nivolumab 480 mg every 4 weeks (Arm 2) in subjects with advanced/metastatic (Stage IIIb/IV) NSCLC (non‐Sq and Sq). Primary end point(s): The coprimary objectives of this trial will be assessed by PFS rate at 6 months after randomization and PFS rate at 1 year after randomization. PFS is defined as the time from the date of randomization to the date of first documented tumor progression determined by the investigator or death, whichever is earlier. Subjects who did not progress or die will be censored on the date of their last evaluable tumor assessment. The PFS rate at 6 months is the rate from KM estimate 6 months after randomization; PFS rate at 1 year is the rate from KM estimate at 1 year after randomization.; Secondary Objective: ‐ To compare PFS rate in Arms 1 and 2 at 1 year after randomization by tumor histology and by response criteria before randomization; ‐ To compare PFS rate at 2 years after randomization in Arms 1 and 2; ‐ To compare the overall survival rate at 1 year after randomization and up to 5 years after randomization in Arms 1 and 2, in all treated subjects, by tumor histology, and by response criteria before randomization; ‐ To assess safety and tolerability of nivolumab, as measured by the incidence and severity of AEs and specific laboratory abnormalities, in all treated subjects, in Arms 1 and 2, by tumor histology, and response criteria before randomization Timepoint(s) of evaluation of this end point: 6 months and 1 year after randomization SECONDARY OUTCOME: Secondary end point(s): Secondary objectives will be assessed by: ; ‐ PFS rate at 1 year after randomization by tumor histology and by response criteria ; ‐ PFS rate at 2 years after randomization ; ‐ OS rate at 1 year and OS up to 5 years by arm, histology, and response status at randomization.OS is defined as time from the date of randomization to the date of death. Subjects who did not die by the end of the study will be censored at the last known date alive. OS rate at 1 year is the rate from KM estimated at one year after randomization. ; ‐ Safety and tolerability of nivolumab, as measured by incidence and severity of AEs and specific laboratory abnormalities Timepoint(s) of evaluation of this end point: Tumor assessment ‐ every 8 weeks (±1 week) for the first year of the study, then every 3 months for the second year of the study, followed by the local standard of care afterwards ; ; ; ; Laboratory tests conducted at every cycle with the exception of thyroid and pregnancy tests (see protocol for details) ; INCLUSION CRITERIA: 1. Signed Written Informed Consent subject care. b) Subjects must be willing and able to comply with scheduled visits, treatment schedule,laboratory tests, and other requirements of the study. ; OS assessment ‐ once per cycle. For subjects receiving nivolumab 240 mg every 2 weeks, cycle= each 14‐day dosing period. For subjects receiving nivolumab 480 mg every 4 weeks, cycle=each 28‐day dosing period. ; The collection of non serious AE information should begin at initiation of study drug. Nonserious AE information should also be collected from the start of a placebo lead‐in period or other observational period intended to establish a baseline status for the subjects a) Subjects must have signed and dated an IRB/IEC‐approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol‐related procedures that are not part of normal 2. Target Population a) Subjects with histologically or cytologically documented Sq‐ or non‐SqNSCLC who present with Stage IIIB/Stage IV disease (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or with recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemoradiotherapy for locally advanced disease). b) Subjects must have received and tolerated nivolumab 3 mg/}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01819791/full} -} - - -Record #368 of 538 -@article{Wakelee17, -author = {Wakelee, H, Altorki, N, Vallieres, E, Zhou, C, Zuo, Y, Howland, M, Xia, F, Hoang, T, Sandler, A, and Felip, E}, -title = {IMpower010: phase III study of atezolizumab vs bsc after adjuvant chemotherapy in patients with completely resected NSCLC}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {1}, -pages = {S1305}, -year = {2017}, -accession_number = {EMBASE 615338614}, -publication type = {Journal article; Conference proceeding}, -keywords = {*adjuvant chemotherapy; *immunotherapy; *non small cell lung cancer; Autoimmune disease; Cancer size; Cancer surgery; Clinical trial; Comparative effectiveness; Controlled clinical trial; Controlled study; Disease free survival; Drug therapy; Exposure; Gene expression; Human; Human tissue; Immunocompetent cell; Immunohistochemistry; Major clinical study; Monotherapy; Open study; Overall survival; Patient history of chemotherapy; Pharmacokinetics; Phase 3 clinical trial; Radiotherapy; Randomized controlled trial; Safety; Stratification; Surgery; Tumor cell}, -abstract = {Background: Early‐stage non‐small cell lung cancer (NSCLC) is treated surgically, but 30%e70% of patients experience post‐resection recurrence and succumb to disease. Adjuvant chemotherapy is the standard of care for fully resected NSCLC (stages IB [tumors ≥4 cm]‐IIIA), and although cisplatin‐based chemotherapy provides some benefit, the 5‐year absolute survival benefit is≈5%, underscoring the unmet need. Atezolizumab is an anti‐PDL1 monoclonal antibody that inhibits PD‐L1 from binding to its receptors PD‐1 and B7.1, thereby restoring anti‐tumor immune response. Atezolizumab monotherapy has demonstrated promising efficacy and tolerable safety in patients with previously‐treated advanced NSCLC, with a survival benefit observed across all PD‐L1 expression levels. Given the need to improve survival for patients with early‐stage NSCLC, IMpower010 (NCT02486718), a global Phase III randomized, open‐label trial, has been initiated to compare the efficacy and safety of atezolizumab with best supportive care (BSC), following adjuvant cisplatin‐based chemotherapy in patients with resected stage IB (tumors ≥4 cm)‐IIIA NSCLC. Methods: Eligibility criteria include complete tumor resection 4‐12 weeks prior to enrollment for pathologic stage IB (tumors ≥4 cm)eIIIA NSCLC. Patients must have adequately recovered from surgery, be eligible to receive cisplatin‐based adjuvant chemotherapy and have an ECOG PS 0‐1. Exclusion criteria include the presence of other malignancies, use of hormonal cancer or radiation therapy within 5 years, prior chemotherapy, autoimmune disease or exposure to prior immunotherapy. Approximately 1127 patients, regardless of PD‐L1 expression status, will be enrolled. Eligible patients will receive up to four 21‐day cycles of cisplatin‐based chemotherapy (cisplatin [75 mg/ m2 IV, day 1] + either vinorelbine [30 mg/m2 IV days 1, 8], docetaxel [75 mg/m2 IV day 1] or gemcitabine [1250 mg/ m2 IV days 1, 8], or pemetrexed [500mg/m2 IV day 1; nonsquamous NSCLC only]). Adjuvant radiation therapy is not permitted. Following adjuvant treatment, eligible patients will be randomized 1:1 to receive atezolizumab (1200 mg q3w, 16 cycles) or BSC. Stratification factors will include sex, histology (squamous vs non‐squamous), extent of disease (stage IB vs II vs IIIA) and PD‐L1 expression by IHC (TC, tumor cell; IC, tumor‐infiltrating immune cell; TC2/3 [≥5% expressing PD‐L1] and any IC vs TC0/1 [<5%] and IC2/3 [≥5%] vs TC0/1and IC0/1 [<5%]). The primary endpoint is disease‐free survival, and secondary endpoints include overall survival and safety. Exploratory endpoints include PD‐L1 status, immune and tumor related biomarkers before, during and after treatment with atezolizumab and at radiographic disease occurrence or confirmation of new primary NSCLC. Results: Section not applicable. Conclusion: Section not applicable.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01765502/full} -} - - -Record #369 of 538 -@article{Goodman22, -author = {Goodman, KA, Xu, R-H, Chau, I, Chen, MH, Cho, BC, Shah, MA, Muro, K, Wang, Y, Ichimaru, M, Liu, Q, and Wang, L}, -title = {SKYSCRAPER-07: a phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy}, -journal = {Journal of clinical oncology}, -volume = {40}, -number = {4 SUPPL}, -year = {2022}, -accession_number = {EMBASE 637296545}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *chemoradiotherapy; *esophageal squamous cell carcinoma; Adult; Animal experiment; Animal model; Asia; Cancer immunotherapy; Cancer survival; Conference abstract; Controlled study; Double blind procedure; Drug combination; Drug efficacy; Drug therapy; ECOG Performance Status; Human; Immunogenicity; Male; Monotherapy; Mouse; Mouse model; Non small cell lung cancer; Nonhuman; Pharmacokinetics; Phase 2 clinical trial; Phase 3 clinical trial; Practice guideline; Preclinical study; Radiotherapy; Response evaluation criteria in solid tumors}, -abstract = {Background: The current standard of care for patients (pts) diagnosed with unresectable, locally advanced esophageal squamous‐cell carcinoma (ESCC) is definitive platinum‐based concurrent chemoradiotherapy (dCRT). However, ESCC has poor prognosis, with more than half of tumors reoccurring after dCRT (Smyth et al. Nat Rev Dis Primers 2017), highlighting the need for additional therapy options in this setting. Cancer immunotherapies have demonstrated activity in ESCC, and targeted inhibition of the PD‐L1/PD‐1 pathway may be further amplified using novel anti‐TIGIT agents such as tiragolumab. In preclinical mouse models, concomitant blockade of PDL1/PD‐1 and TIGIT pathways demonstrated prolonged survival over the respective singleagents. In the phase II CITYSCAPE study (NCT03563716), tiragolumab plus atezolizumab (anti‐PD‐L1) resulted in a clinically meaningful improvement in PFS and higher ORR vs atezolizumab alone (31.3 vs 16.2%) in first‐line pts with PD‐L1+ (TPS ≥1%) metastatic NSCLC. SKYSCRAPER‐07 (NCT04543617) will determine if tiragolumab plus atezolizumab combination therapy provides superior clinical benefit to atezolizumab monotherapy or placebo in pts with unresectable ESCC whose cancers have not progressed following dCRT. We hypothesize that combination therapy will prolong PFS and OS compared with placebo in this setting. Methods: Eligible pts (≥18 years) must have unresectable ESCC, without progressive disease (PD) after platinum‐based dCRT (according to regional oncology guidelines for ESCC); ECOG PS 0‐1; no prior treatment with any immune checkpoint inhibitor. Approximately 750 pts will be randomized 1:1:1 to either Arm A (tiragolumab 600mg + atezolizumab 1200mg IV Q3W), Arm B (atezolizumab 1200mg + placebo IV Q3W) or Arm C (double placebo IV Q3W). Treatment will continue for up to 17 cycles of 21 days, or until unacceptable toxicity or investigator‐assessed radiographic PD (per RECIST v1.1). Stratification factors include geographic region (Asia vs rest of world), PD‐L1 expression and staging prior to dCRT (II vs III vs IV). Co‐primary efficacy endpoints are investigator‐assessed PFS and OS; key secondary endpoints include independent review facility‐assessed PFS and DoR. Safety, pharmacokinetic, biomarker and immunogenicity analyses will be performed. Recruitment is ongoing.}, -DOI = {10.1200/JCO.2022.40.4_suppl.TPS374}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02385044/full} -} - - -Record #370 of 538 -@article{EUCTR2022-001440-18-FR23, -author = {EUCTR2022-001440-18-FR,}, -title = {A Study of RO7247669 plus Platinum-Based Chemotherapy vs. Pembrolizumab plus Platinum-Based Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2022-001440-18-FR}, -year = {2023}, -accession_number = {ICTRP EUCTR2022‐001440‐18‐FR}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: PD1‐LAG3 Product Code: RO7247669/F01‐01 Pharmaceutical Form: Solution for infusion INN or Proposed INN: n/a Other descriptive name: RO7247669 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ Trade Name: Keytruda Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Pembrolizumab CAS Number: 1374853‐91‐4 Current Sponsor code: RO7223188 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ Trade Name: Carboplatin Pharmaceutical Form: Solution for infusion INN or Proposed INN: Carboplatin CAS Number: 41575‐94‐4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ Trade Name: ALIMTA Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Pemetrexed CAS Number: 137281‐23‐3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500‐ Trade Name: Paclitaxel Pharmaceutical Form: Solution for infusion INN or Proposed INN: Paclitaxel CAS Number: 33069‐62‐4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150‐ CONDITION: Previously untreated locally advanced or metastatic non‐small cell lung cancer (NSCLC) ; MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non‐small cell lung cancer System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: • To evaluate the efficacy of RO7247669 in combination with platinum‐based chemotherapy (Arm A) compared with pembrolizumab plus platinum‐based chemotherapy (Arm B) on the basis of progression‐free survival (PFS) after randomization ; • To evaluate the efficacy of RO7247669 in combination with platinum‐based chemotherapy (Arm A) compared with pembrolizumab plus platinum‐based chemotherapy (Arm B) on the basis of objective response rate (ORR); Primary end point(s): 1. PFS after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1 ; 2. ORR, defined as the proportion of participants with a complete response or a partial response on two consecutive occasions = 4 weeks apart, as determined by the investigator according to RECIST v1.1 ; Secondary Objective: • To evaluate the efficacy of Arm A compared with Arm B on the basis of overall survival (OS) after randomization, duration of response for participants with confirmed objective response, PFS and OS in participants by programmed death‐ligand 1 (PD‐L1) expression groups and the change from baseline to Week 12 in patient‐reported outcomes of lung cancer symptoms, physical functioning, role functioning, and global health status/quality of life; • To evaluate the safety of Arm A compared with Arm B ; • To investigate the pharmacokinetics of RO7247669, pemetrexed, carboplatin, and paclitaxel ; • To evaluate the immune response to RO7247669 on the basis of prevalence of anti‐drug antibodies (ADAs) to RO7247669 at baseline and incidence of ADAs to RO7247669 during the study Timepoint(s) of evaluation of this end point: 1‐2. Up to approximately 58 months SECONDARY OUTCOME: Secondary end point(s): 1. OS after randomization, defined as the time from randomization to death from any cause; 2. Duration of response for participants with confirmed objective response, defined as the time from the first occurrence of a confirmed objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1 ; 3. PFS and OS in participants with PD‐L1 expression, defined as tumor cells < 1%, 1%‐49%, and = 50%, as assessed by retrospective central PD‐L1 testing ; 4. Change from baseline to Week 12 in patient‐reported outcomes of lung cancer symptoms, physical functioning, role functioning, and global health status/quality of life, as assessed through the use of the European Organisation for Research and Treatment of Cancer Item Libraries ; 5. Incidence and severity of adverse events, with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0; The severity of cytokine release syndrome will also be determined according to the American Society for Transplantation and Cellular Therapy Consensus Grading Scale.; 6. Maximum concentration of RO7247669; 7. Time of maximum concentration of RO7247669; 8. Clearance of RO7247669; 9. Volume of distribution at steady state of RO7247669; 10. Area under the concentration‐time curve RO7247669; 11. Half‐life of RO7247669; 12. Concentrations of RO7247669 in serum at specified timepoints ; 13. Concentrations of carboplatin (measured as total platin), pemetrexed, and paclitaxel in plasma at specified timepoints ; 14. Prevalence of ADAs to RO7247669 at baseline and incidence of ADAs to RO7247669 during the study Timepoint(s) of evaluation of this end point: 1‐3. Up to approximately 58 months; 4. From baseline to Week 12; 5. Up to approximately 58 months; 6‐12. On Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond (until disease progression); 13. On Day 1 of Cycles 1 and 5; 14. From baseline up to approximately 58 months INCLUSION CRITERIA: • Age = 18 years • Eastern Cooperative Oncology Group Performance Status of 0 or 1 • Histologically or cytologically documented locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) NSCLC who are not eligible for curative surgery and/or definitive chemoradiotherapy (8th edition of the UICC/AJCC‐ staging system) • No prior systemic treatment for metastatic NSCLC • Known tumor PD‐L1 status through a documented local assessment using a health authority‐approved PD L1 immunohistochemistry assay • Confirmed availability of representative tumor specimens in formalin‐fixed, paraffin‐embedded blocks or 15 unstained serial slides, along with an associated pathology report • Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) • Life expectancy = 12 weeks • Adequate hematologic and end‐organ function • Negative human immunodeficiency viruses (HIV) test at screening = 18 years of age on day of signing informed consent. 3. Have measurable disease based on RECIST 1.1. 4. Must provide newly obtained tissue from a core or excisional biopsy of a tumor lesion and are willing to have a second biopsy performed form any non‐irradiated lesion after the radiation and immune‐modulating treatment. 5. Have a performance status of 0 or 1 on the ECOG Performance Scale. 6. Stage IV NSCLC; treated with at least 1 regimen of chemotherapy. 7. Have at least 2 separate (metastatic) lesions of which one is amenable for irradiation with a size of < 5 cm. 8. Demonstrate adequate organ function: Absolute neutrophil count (ANC) >=1,500 /mcL; Platelets >=100,000 / mcL; Hemoglobin >=9 g/dL or >=5.6 mmol/L; Serum creatinine <=1.5 Xupper limit of normal (ULN) OR measured or calculated creatinine clearance (GFR can also be used in place o}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02717860/full} -} - - -Record #379 of 538 -@article{Reckamp19, -author = {Reckamp, KL, Akerley, W, Calvo, E, Clarke, J, Edelman, MJ, He, K, Moreno, V, Neal, JW, Owonikoko, TK, Patel, JD, Patel, SP, Riess, JW, Sacher, AG, Turcotte, S, Villaruz, LC, Zauderer, MG, Farsaci, B, Skoura, N, Chisamore, M, and Johnson, ML}, -title = {Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: a phase Ib/IIa randomised pilot study}, -journal = {Annals of oncology}, -volume = {30}, -pages = {v657}, -year = {2019}, -accession_number = {EMBASE 630602210}, -publication type = {Journal article; Conference proceeding}, -keywords = {*T lymphocyte; *advanced cancer; *drug safety; *non small cell lung cancer; *pilot study; Adult; Cancer patient; Cancer staging; Chemoradiotherapy; Clinical article; Conference abstract; Controlled study; Disease course; Drug combination; Drug therapy; Female; Health care quality; Human; Intravenous drug administration; Leukapheresis; Male; Metastatic melanoma; Molecularly targeted therapy; Multiple myeloma; Open study; Pharmacokinetics; Phase 1 clinical trial; Protein expression; Radiotherapy; Randomized controlled trial; Side effect; Synovial sarcoma}, -abstract = {Background: NY‐ESO‐1 and LAGE‐1a are antigens expressed in several tumours, including non‐small cell lung cancer (NSCLC). Previous clinical trials using autologous T cells directed against NY‐ESO‐1/LAGE‐1a have shown objective responses between 40% and 60% in synovial sarcoma, metastatic melanoma and multiple myeloma. Pembrolizumab (PEM) is a monoclonal antibody that blocks PD‐1/PD‐L1 interaction and increases anti‐tumour activity in anti‐tumour T cells. Here, PEM will be used in combination with NY‐ESO‐1/LAGE‐1a T‐cell receptor engineered patient T cells (GSK3377794) to potentially improve clinical benefit in this patient population. Trial design: This is a phase Ib/IIa, randomised, multi‐arm, open‐label study (NCT03709706) of GSK3377794 in HLA‐A∗02:01, HLA‐A∗02:05 and/or HLA‐A∗02:06 positive adults with NY‐ESO‐1 and/or LAGE‐1a‐expressing tumours. Eligible patients with unresectable Stage IIIb/IV NSCLC are either ineligible for standard‐of‐care chemoradiotherapy, have received PD‐1 therapy or appropriate targeted therapy, have terminated prior treatment due to intolerable side effects, or have refused standard approved treatment. At least 30 patients with NSCLC without EGFR or ALK/ROS1 aberrations will be randomised (1:1) to Arm A or B; at least 15 patients with EGFR or ALK/ROS1 aberration will be assigned to Arm C. Patients in Arm A will receive a single IV infusion of GSK3377794; those in Arms B and C will receive GSK3377794 IV on Day 1, then PEM 200 mg starting on Day 22 and continuing for up to 35 cycles or disease progression. Patients in Arm A who progress within 25 weeks post GSK3377794 infusion may receive PEM at the same dose/duration as Arms B and C. The study will have 3 parts: eligibility screening (Part 1); leukapheresis and manufacture of GSK3377794 (Part 2); lymphodepletion and infusion of GSK3377794 (interventional phase; Part 3). Primary objectives are to assess the safety and tolerability of GSK3377794 alone or in combination with PEM and to determine the clinical response. The first patient was screened on December 31, 2018.}, -DOI = {10.1093/annonc/mdz260.112}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02074592/full} -} - - -Record #380 of 538 -@article{Sands20, -author = {Sands, J, Mandrekar, SJ, Oxnard, GR, Kozono, DE, Hillman, SL, Dahlberg, SE, Sun, Z, Chaft, JE, Govindan, R, Gerber, DE, Gray, JE, Malik, SM, Mooney, MM, Janne, PA, Vokes, EE, Kelly, K, Ramalingam, SS, and Stinchcombe, T}, -title = {ALCHEMIST: adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC}, -journal = {Journal of clinical oncology}, -volume = {38}, -number = {15}, -year = {2020}, -accession_number = {EMBASE 636606330}, -publication type = {Journal article; Conference proceeding}, -keywords = {*adjuvant radiotherapy; *immunotherapy; *molecularly targeted therapy; *non small cell lung cancer; Adult; Autoimmune disease; Cancer patient; Cancer radiotherapy; Cancer staging; Cancer surgery; Conference abstract; Controlled study; Drug therapy; ECOG Performance Status; Female; Gene mutation; Genetic marker; Human; Human tissue; Immunohistochemistry; Nursing; Pregnancy; Radiotherapy; Randomization; Randomized controlled trial (topic); Second cancer; Signal transduction; Spring; Surgery; Systemic therapy}, -abstract = {Background: ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a clinical trial platform of the National Cancer Institute that offers biomarker analysis for high‐risk resected non‐small cell lung cancer (NSCLC) to support randomized trials of novel adjuvant therapies within the National Clinical Trials Network (NCTN). EA5142, a trial of adjuvant nivolumab for patients (pts) without EGFR / ALK alterations, has completed enrollment. Given the survival benefit seen with 1stline chemo‐immunotherapy (chemo‐IO) for advanced NSCLC without EGFR / ALK alterations, there was compelling rationale for the launch of a trial offering concurrent immunotherapy with adjuvant chemo. Here we report updated enrollment to ALCHEMIST as of Jan 14, 2020. Methods: ALCHEMIST includes a screening trial (A151216, 5362 registered) that enrolls pts with completely resected clinical stage IB (≥4 cm)‐IIIA (per AJCC 7) NSCLC. Tissue and blood are collected, biomarker testing includes EGFR sequencing, ALK FISH and PD‐L1 IHC. 733 active sites are enrolling across the NCTN. Pts with EGFR mutations may enroll to adjuvant erlotinib vs observation (A081105, 352 randomized); those with ALK fusions may enroll to adjuvant crizotinib vs observation (E4512, 99 randomized). A trial offering adjuvant nivolumab vs observation regardless of PDL1 status (EA5142, 935 randomized) recently completed enrollment. To support ongoing investigation of adjuvant immunotherapy, ALCHEMIST is adding A081801 (opens spring 2020). Pts will be randomized to one of 3 arms: chemo‐IO with pembrolizumab during and after chemo vs sequential chemo followed by pembrolizumab vs chemo alone. Pts with pathological N2 nodes are eligible and can undergo postoperative radiotherapy after completing chemo. Pts are eligible if enrolled to A151216, negative for EGFR and ALK alterations, and with PD‐L1 testing completed (required for stratification). Local testing for EGFR, ALK and PD‐L1 will be accepted for enrollment; central testing will not delay randomization. Pts may not have received any therapy except surgery for the lung cancer and must be age >18, Eastern Cooperative Oncology Group performance status 0‐1, have no active autoimmune disease requiring systemic treatment within 2 years, must not be pregnant or nursing, have no active second malignancy within 3 years and meet standard organ function values. By building off the ongoing ALCHEMIST platform, we hope to facilitate rapid enrollment to A081801 across participating NCTN sites.}, -DOI = {10.1200/JCO.2020.38.15-suppl.TPS9077}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02348872/full} -} - - -Record #381 of 538 -@article{UMIN00002625917, -author = {UMIN000026259,}, -title = {Phase II study for efficacy and safety of pembrolizumab for chemotherapy unfit previously untreated patients highly expressing PD-L1 positive advanced non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000026259}, -year = {2017}, -accession_number = {ICTRP UMIN000026259}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Pembroliaumab 200mg/body (day 1, q3 weeks) until clinical progression or unacceptable toxicities CONDITION: lung cancer PRIMARY OUTCOME: Response rate SECONDARY OUTCOME: Progression‐free survival, Overall survival, and Toxicity INCLUSION CRITERIA: 1) Definitively diagnosed with having previously untreated advanced non‐small cell lung cancer by the specimens histologically or cytologically who have no indication for standard treatment of chemotherapy including cytotoxic chemotherapy and molecular targeted agents for driver mutation. Also, PD‐L1 highly expressing NSCLC using PD‐L1 IHC 22C3 pharmDx. 2) Age of 20 years and older 3) With adequate organ function of bone marrow reserve, liver, and kidney. (1) PS 3‐4 (2) neutrophil count => 5,000/mm^3 (3) platelet => 50,000/mm^3 (4) hemoglobin => 8.0g/dL (5) AST/ALT < 5.0 times less than ULN (6) T.Bil <= 3.0mg/dL (7) serum creatinine <= 3.0mg/dL (8) ECG: without clinically problematic abnormalities (9) SpO2 more than 92% 4) With the status of below previous treatment at the time of beginning of chemotherapy. (1) Radiotherapy: irradiated extrathoracic lesion: more than two weeks from the date of}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01826573/full} -} - - -Record #382 of 538 -@article{Spieler20, -author = {Spieler, B, Azzam, G, Kwon, D, Saravia, D, Lopes, G, Dal Pra, A, Diwanji, T, Yechieli, R, Freedman, LM, and Mihaylov, IB}, -title = {Checkpoint Inhibitor Pneumonitis in Patients with Advanced NSCLC on Nivolumab Monotherapy is Underreported and Associated with Prior Radiotherapy History}, -journal = {International journal of radiation oncology biology physics}, -volume = {108}, -number = {3}, -pages = {e89‐e90}, -year = {2020}, -accession_number = {EMBASE 2007858320}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *monotherapy; *non small cell lung cancer; *patient history of radiotherapy; *pneumonia; Adult; Cancer radiotherapy; Cancer size; Conference abstract; Controlled study; Diagnosis; Drug therapy; Effect size; Female; Human; Immunotherapy; Incidence; Lung volume; Major clinical study; Male; Medical record review; Probability; Radiomics; Radiotherapy; Randomized controlled trial}, -abstract = {Purpose/Objective(s): For patients with advanced non‐small cell lung cancer (NSCLC) treated with Immunotherapy (ImT), checkpoint inhibitor pneumonitis (CIP) is an uncommon and sometimes life‐threatening adverse event that may be underreported. Recent studies suggest that radiomic analysis of pre‐ImT imaging can predict CIP. We hypothesized that for patients with advanced NSCLC treated with Nivolumab monotherapy, pre‐ImT radiotherapy (RT) is predictive of CIP and that radiomics features can identify CIP that has been clinically misclassified. Materials/Methods: From an IRB‐approved database (DB) of 159 patients with advanced NSCLC treated with Nivolumab, chart review identified 9 patients diagnosed with CIP of any grade (6%). 40 additional patients from the same DB without diagnosis of CIP were randomly selected for analysis. For all patients, baseline characteristics including pre‐ImT RT were collected for comparison between CIP and non‐CIP groups. Both lungs were contoured semi‐automatically through thresholding on the last pre‐ImT CT imaging studies, with intrathoracic lesions subtracted from the lung volumes prior to radiomics analysis. A logistic regression model incorporating radiomics assigned a CIP probability score to every patient. Results: Six radiomics features correlated with CIP (p‐values range from 0.02 to 0.03). Each feature had an AUC of ∼0.79 (range 0.789 to 0.794) showing large effect size, with odds ratios greater than 3.50 (4 features) or less than 0.3 (2 features). While pre‐ImT thoracic RT was not predictive of pneumonitis, pre‐ImT RT irrespective of treatment location was borderline predictive with high effect size (p = 0.09, OR 0.27). The radiomics‐based probability model assigned 7/42 patients (16.7%) without clinical diagnosis of CIP a greater than 50% probability of CIP. Chart and imaging review revealed that 6/7 “misclassified” patients exhibited symptoms or radiographic features highly suggestive of CIP. These findings originally were attributed to disease progression or clinically overshadowed by other symptoms. Conclusion: For patients with advanced NSCLC treated with Nivolumab, the incidence of checkpoint‐inhibitor pneumonitis (CIP) is underreported and radiomics features can help identify CIP that has been clinically misclassified. Preliminary findings suggest that pre‐ImT RT irrespective of treatment location may be predictive of CIP, and therefore that immunomodulatory effects of RT‐ImT synergy are not restricted to the local irradiated area. Future directions include expansion of this study across the full database, correlation of radiomics features with blood and tissue biomarkers, and the inclusion of tumor burden as an additional covariate in the analysis.}, -DOI = {10.1016/j.ijrobp.2020.07.1188}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02175329/full} -} - - -Record #383 of 538 -@article{Deslypere18, -author = {Deslypere, G, Gullentops, D, Wauters, E, and Vansteenkiste, J}, -title = {Immunotherapy in non-metastatic non-small cell lung cancer: can the benefits of stage IV therapy be translated into earlier stages?}, -journal = {Therapeutic advances in medical oncology}, -volume = {10}, -year = {2018}, -accession_number = {EMBASE 624260652}, -publication type = {Journal article}, -keywords = {*cancer immunotherapy; *cancer staging; *non small cell lung cancer /drug therapy /radiotherapy; Autoimmune disease; CD8+ T lymphocyte; Cancer immunization; Controlled study; Diarrhea /side effect; Drug efficacy; Fluorescence in situ hybridization; Gene mutation; Gene translocation; Human; Immune response; Immunohistochemistry; Karnofsky Performance Status; Multiple cycle treatment; Overall survival; Positron emission tomography; Priority journal; Progression free survival; Radiation dose; Randomized controlled trial; Rash /side effect; Review; Tumor cell}, -abstract = {Over the last decade, several steps forward in the treatment of patients with stage IV non‐small cell lung cancer (NCSLC) were made. Examples are the use of pemetrexed, pemetrexed maintenance therapy, or bevacizumab for patients with nonsquamous NSCLC. A big leap forward was the use of tyrosine kinase inhibitors in patients selected on the basis of an activating oncogene, such as epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) translocations. However, all of these achievements could not be translated into survival benefits when studied in randomized controlled trials in patients with nonmetastatic NSCLC. Aside from chemotherapy and targeted therapy, immunotherapy has become the third pillar in the treatment armamentarium of advanced NSCLC. Antigen‐specific immunotherapy (cancer vaccination) has been disappointing in large phase III clinical trials in stages I–III NSCLC. Based on the recent breakthroughs with immune checkpoint inhibitor immunotherapy in metastatic NSCLC, much hope currently rests on the use of this approach in patients with stage I–III NSCLC as well. Here we give a brief overview of how most new therapeutic approaches for advanced NSCLC failed in other stages, and then elaborate on the role of immunotherapy in patients with stage I–III NSCLC.}, -DOI = {10.1177/1758835918772810}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01715740/full} -} - - -Record #384 of 538 -@article{Ozawa24, -author = {Ozawa, Y, Yamamoto, K, Sugawara, S, Niho, S, Ohe, Y, Okamoto, H, Hotta, K, Ikeda, N, and Yamamoto, N}, -title = {Comprehensive analysis of predictive factors for efficacy in concurrent chemoradiotherapy for locally advanced non-small cell lung cancer, utilizing individual patient data from the Japan lung cancer society integrated clinical trial database: is there room for further improvement?}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644913640}, -publication type = {Journal article; Conference proceeding}, -keywords = {*Japan; *chemoradiotherapy; *data base; *lung cancer; *non small cell lung cancer; *patient coding; Adult; Adverse drug reaction; Aged; Body weight loss; Clinical trial; Conference abstract; Controlled study; Drug therapy; Esophagitis; Female; Human; Least absolute shrinkage and selection operator; Major clinical study; Male; Pneumonia; Side effect}, -abstract = {Background: The standard treatment for unresectable, locally advanced NSCLC is concurrent chemoradiotherapy followed by durvalumab. While the effectiveness of chemoradiotherapy is pivotal, the exploration into predictive factors of the efficacy is notably limited. Methods: The Japanese Lung Cancer Society (JLCS) integrated eight randomized Phase II/III trials (JCOG9812, JCOG0301, NJLCG0601, OLCSG0007, SPECTRA, TORG1018, WJOG5008L, WJTOG0105) concerning chemoradiotherapy for locally advanced NSCLC, constructing the JLCS Integrated Clinical Trial Database (JIDB), with individual data of 1288 patients. This study analyzed 1162 patients who underwent concurrent chemoradiotherapy, focusing on factors impacting PFS. A logistic regression with the least absolute shrinkage and selection operator (LASSO) analyses for 3‐yr PFS were performed, and the five most related factors were further evaluated using the Kaplan‐ Meier method and log‐rank tests. The impact of pneumonitis and esophagitis on PFS was also explored. Results: Age [median (Q1;Q3)]; 64 (57;71), male/female; 961/201, Ad/Sq/Oth; 580/ 446/134, PS 0/1/2; 562/578/5, stage IIIA/IIIB; 468/694, T factor 4/3/2/1/0; 436/158/341/156/3, N factor 3/2/1/0; 300/692/44/62, PS 0/1/2; 562/578/5, primary site; upper, middle/lower lobe; 599/161, BMI; 21.8 (19.7;24.0), weight loss (≥5% within 6m) yes/no; 135/644, LDH (IU/l); 203 (175;276), CRP (mg/dl); 0.70 (0.20;2.60), irradiated dose (Gy); 60 (60;60), combined regimen; platinum/taxane 303, CDDP/mitomycin/vindesine; 254, CDDP/5‐FU‐based; 196, CDDP/ vinorelbine 87, CDDP/pemetrexed 50, others 272. The median PFS in all patients was 9.72m (95% CI; 9.33 ‐ 10.38), with 3‐yr, 5‐yr, and 10‐yr PFS rates of 19.7, 14.3, 10.1%. LASSO logistic regression identified Sq, lower lobe primary, age, pack‐years, and weight loss as the top negative influencers. The PFS curve was significantly shorter in patients with lower lobe primary (median of 8.15 vs. 9.46m, p = 0.023) and weight loss (median of 7.29 vs. 9.72m, p < 0.0001). Pneumonitis occurred in 50.9% (grade≥3 in 6.7%) and esophagitis in 41.9% (grade≥3 in 3.9%). Grade≥2 pneumonitis shortened PFS (8.2 vs. 10.2m, p = 0.00015), while, unexpectedly, grade≥1 esophagitis was associated with longer PFS (12.9 vs. 8.6m, p < 0.0001). Conclusions: The efficacy of concurrent chemoradiotherapy varies significantly based on the primary site. Weight loss is a significant predictor of efficacy, as is in metastatic disease. The impact of pneumonitis and esophagitis suggest that modifying lung and esophageal irradiation might enhance treatment efficacy. Further research in this area is still certainly warranted.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02750528/full} -} - - -Record #385 of 538 -@article{ChiCTR210005440621, -author = {ChiCTR2100054406,}, -title = {A prospective randomized-controlled phase II clinical study of PD-1 inhibitors combined with statins in the treatment of newly diagnosed driver gene negative advanced or metastatic NSCLC and related mechanisms}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2100054406}, -year = {2021}, -accession_number = {ICTRP ChiCTR2100054406}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Control group:DP or AP chemotherapy+Tislelizumab;Experimental group:DP or AP chemotherapy+Tislelizumab+Atorvastatin; CONDITION: non‐small cell lung cancer PRIMARY OUTCOME: Progression Free Survival; SECONDARY OUTCOME: Overall Survival;Objective Response Rate;Disease Control Rate;Duration of Response;Adverse Effects Rate; INCLUSION CRITERIA: 1. Aged 18 to 75 years; 2. Histological and pathological diagnosis of non‐small cell lung cancer, and clinical stage IIIB or IV (AJCC, 8th edition, 2017) 3. EGFR wild‐type, and ALK and ROS1 fusion gene negative 4. Have not received tumor‐related treatment, and cannot receive radical surgery or radiation therapy; 5. Have measurable disease (RECIST, version 1.1) 6. Evaluate according to the activity status scale developed by the Eastern Cooperative Oncology Group (ECOG), and include patients with an ECOG score of 0‐1; 7. Adequate organ function: (1) Blood routine (no blood transfusion within 14 days before treatment, no use of granulocyte colony stimulating factor (G‐CSF), no correction with other drugs) 1) Neutrophil count (NE)>1500/µL; 2) Hemoglobin count (HGB) > 8.0 g/dL; 3) Platelet count (PLT) > 100 000/µL; (2) Blood biochemistry (liver and kidney function) 1) Serum creatinine (Cr) <= 1.5 Xupper limit of normal (ULN}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02498104/full} -} - - -Record #386 of 538 -@article{Durm21, -author = {Durm, GA, Furqan, M, Feldman, LE, Patel, M, Hall, RD, Jalal, SI, Birdas, TJ, Kesler, K, Rieger, KM, Ceppa, D-K, and Hanna, NH}, -title = {A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: big Ten Cancer Research Consortium BTCRC-LUN18-153}, -journal = {Journal of clinical oncology}, -volume = {39}, -number = {15 SUPPL}, -year = {2021}, -accession_number = {EMBASE 635590275}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer adjuvant therapy; *cancer research; *cancer staging; *cancer surgery; *non small cell lung cancer; *primary tumor; Adjuvant chemotherapy; Adult; Advanced cancer; Cancer recurrence; Cancer size; Cancer survival; Chemoradiotherapy; Clinical trial; Conference abstract; Controlled study; Disease free survival; Drug therapy; Female; Follow up; Human; Immunotherapy; Indiana; Major clinical study; Male; Multicenter study; Neoadjuvant therapy; Overall survival; Phase 2 clinical trial; Radiotherapy; Randomized controlled trial; Recurrence risk; X‐ray computed tomography}, -abstract = {Background: There are approximately 35,000 cases of stage I lung cancer in the United States each year. While these patients have better 5‐ year overall survival (OS) rates than their counterparts with locally advanced and metastatic disease, there is still considerable room for improvement. Based on a recent publication validating the 8 edition of the TNM classification, the 5‐year OS for node‐negative pathologically‐staged NSCLC between 1‐4cm ranges from 73‐86%, and recurrence rates for resected stage I NSCLC can range from 18‐38%. Previous studies looking at adjuvant chemotherapy in this setting have shown no benefit for stage IA tumors, and the current standard of care is observation alone. Checkpoint blockade with PD‐1/PD‐L1 inhibitors has shown considerable activity in NSCLC including in metastatic disease, as consolidation in stage III disease after chemoradiation, and in studies evaluating neoadjuvant immunotherapy. Given this activity and their favorable safety profile, we designed a study of adjuvant PD‐1 inhibition following resection in stage I NSCLC. Methods: This study is a randomized phase II multicenter trial of adjuvant Pembrolizumab versus observation alone following complete resection of stage I NSCLC with tumors between 1‐4cm. The trial will enroll 368 patients randomized 1:1 to either Pembrolizumab 400mg IV every 6 weeks for up to 9 cycles or observation alone with scheduled CT scans and routine clinical follow‐up. Stratification factors include PD‐L1 ≥50% vs. < 50% and tumor size of 1‐2cm vs. > 2‐4cm. Thelead site is Indiana University, and the trial will be conducted through the Big Ten Cancer Research Consortium. The primary endpoint is disease free survival (DFS), and secondary endpoints include OS, DFS at 1‐, 2‐, and 3‐year time points, and toxicity. The trial opened to accrual at the lead site in May 2020, and there are currently 6 patients enrolled.}, -DOI = {10.1200/JCO.2021.39.15-suppl.TPS8583}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02305741/full} -} - - -Record #387 of 538 -@article{Jabbour20, -author = {Jabbour, SK, Houghton, B, Robinson, AG, Quantin, X, Wehler, T, Kowalski, D, Ahn, M-J, Erman, M, Giaccone, G, Borghaei, H, McLean, J, Zhang, J, Souza, F, and Decker, R}, -title = {Phase 3, randomized, placebo-controlledstudy of stereotactic body radiotherapy (SBRT) with orwithout pembrolizumab in patients with inoperable stageI/IIA non-small-cell lung cancer (NSCLC): KEYNOTE-867}, -journal = {Cancer research}, -volume = {80}, -number = {16 SUPPL}, -year = {2020}, -accession_number = {EMBASE 633640022}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *cancer radiotherapy; *non small cell lung cancer; *stereotactic body radiation therapy; Adult; Asia; Cancer recurrence; Cancer staging; Clinical trial; Conference abstract; Controlled study; Disease specific survival; Distant metastasis; Drug safety; Drug therapy; Female; Histopathology; Human; Kaplan Meier method; Log rank test; Major clinical study; Male; Phase 3 clinical trial; Randomization; Randomized controlled trial; Recurrent disease}, -abstract = {Background : Anti‐PD‐(L)1‐directed therapy following radiotherapy or following concurrent chemoradiation isassociated with significantly longer PFS and OS in patients with advanced or metastatic NSCLC, including those with locally advanced inoperable tumors. KEYNOTE‐867 ( NCT03924869 ) evaluates the efficacy and safety of SBRT with or without pembrolizumab in patients with inoperable stage I/IIA NSCLC. Trial Design : In this phase 3,randomized, placebo‐controlled study, approximately 530 adult patients with previously untreated, medicallyinoperable, histologically/cytologically confirmed stage I/IIA NSCLC are randomized 1:1 to receive thoracic SBRT toprimary tumors for ≤2 wk ( Table ) and either pembrolizumab 200 mg or placebo every 3 wk for 17 cycles(approximately 1 year) or until disease recurrence, development of unacceptable AEs, SBRT not started for anyreason, or study with drawal. Randomization is stratified by disease stage (I/IIA), ECOG PS (0‐1/2), and geographicregion (East Asia/other). Imaging assessment by blinded independent central review (BICR) occurs at 12 wk (≥10wk after SBRT completion), followed by every 16 wk for 3 y, and then every 6 mo. Primary endpoints are event‐freesurvival (EFS) by BICR and OS. Secondary endpoints include time to death or distant metastases and safety;exploratory endpoints are time to subsequent treatment, disease‐specific survival, and time torecurrence/progression on subsequent line of therapy. AEs are monitored throughout the trial until 30 d after lastdose (90 for serious AEs) and graded according to NCI CTCAE version 4.0. EFS and OS are analyzed by thenonparametric Kaplan‐Meier method, treatment differences by stratified log‐rank test, and hazard ratios by stratifiedCox proportional hazard model with Efron's method of tie handling. Enrollment started on June 17, 2019, at 131sites.}, -DOI = {10.1158/1538-7445.AM2020-CT288}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02213001/full} -} - - -Record #388 of 538 -@article{Weinberg17, -author = {Weinberg, U, Farber, O, Giladi, M, Bomzon, Z, and Kirson, E}, -title = {LUNAR-A phase 3 trial of TTFields in Combination with PD-1 inhibitors or docetaxel for 2nd line treatment of non-small-cell lung cancer (NSCLC)}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {1}, -pages = {S1093‐S1094}, -year = {2017}, -accession_number = {EMBASE 615340009}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Adverse drug reaction; Brain metastasis; Clinical effectiveness; Clinical trial; Control group; Controlled clinical trial; Controlled study; Daily life activity; Disease model; Drug therapy; Follow up; Hazard ratio; Histology; Human; Human tissue; Liver; Major clinical study; Medical device; Overall survival; Patient history of surgery; Phase 1 clinical trial; Phase 2 clinical trial; Phase 3 clinical trial; Preclinical study; Progression free survival; Quality of life; Questionnaire; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Sample size; Side effect; Thorax; Trunk; X‐ray computed tomography}, -abstract = {Background: Tumor Treating Fields (TTFields) is a novel, non‐invasive, anti‐mitotic treatment modality, based on low intensity alternating electric fields. TTFields predominantly affect two phases of mitosis: metaphase ‐ by disrupting the mitotic spindle, and cytokinesis ‐ by dielectrophoretic dislocation of organelles. TTFields were shown to extend the survival of newly diagnosed glioblastoma patients when combined with temozolomide. Efficacy of TTFields in non‐small cell lung cancer (NSCLC) of all histologies has been demonstrated multiple preclinical models as well as in a phase I/II study in combination with pemetrexed, where overall survival was extended in more than five months compared to historical controls. Methods: The hypothesis of the study is that the addition of TTFields to standard of care second line therapies in advanced NSCLC will increase OS compared to treatment with standard second line alone. 512 patients with either squamous or non‐squamous NSCLC will be enrolled in this prospective, randomized study. Patients will be stratified based on: 1) second line therapy (either PD‐1 inhibitor or docetaxel), histology (squamous Vs. non‐squamous) and geographical region. The main eligibility criteria are first disease progression (per RECIST Criteria 1.1), ECOG score of 0‐1, no prior surgery or radiation therapy, no electronic medical devices in the upper torso and absence of brain metastasis. Docetaxel or PD‐1 inhibitors (nivolumab or pembrolizumab) will be administered at the standard dose. TTFields will be applied to the upper torso using a small, portable medical device for at least 18 hours/day at home, allowing patients to maintain daily activities. TTFields will be continued until progression in the thorax and/or liver according to the immune‐related response criteria (irRC). Follow up will be performed once q6 weeks, including a CT scan. Following progression in the upper torso, patients will be followed monthly for survival. The primary endpoint will be superiority in overall survival (OS) between patients treated with TTFields in combination with either docetaxel or PD‐1 inhibitors, compared to docetaxel or PD‐1 inhibitors alone. A coprimary endpoint will compare the OS in patients treated with TTFields and docetaxel to those treated with PD‐1 inhibitors alone in a non‐inferiority analysis. Secondary endpoints include progression‐free survival, radiological response rate based on the irRC, quality of life based on the EORTC QLQ C30 questionnaire and severity & frequency of adverse events. The sample size is powered to detect a Hazard Ratio of 0.75 of TTFieldstreated patients compare to the control group.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01727928/full} -} - - -Record #389 of 538 -@article{Wu19, -author = {Wu, Y-L, Wang, L, Sendur, MAN, Kim, Y-C, Zhu, Z, Cheng, Y, Li, P, Qin, Y, MacPherson, E, Dennis, PA, and Lu, S}, -title = {PACIFIC-5: phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC}, -journal = {Annals of oncology}, -volume = {30}, -pages = {ix113‐ix114}, -year = {2019}, -accession_number = {EMBASE 630551842}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *cancer staging; *chemoradiotherapy; *non small cell lung cancer; Adult; Advanced cancer; Cancer survival; China; Conference abstract; Controlled study; Distant metastasis; Double blind procedure; Drug safety; Drug therapy; Drug withdrawal; Female; Histopathology; Human; Immunogenicity; Major clinical study; Male; Multicenter study; Overall survival; Pharmacokinetics; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Remission; Risk assessment}, -abstract = {Background: Non‐small‐cell lung cancer (NSCLC) represents >80% of lung cancer cases worldwide and 30% of patients (pts) present with Stage III disease. Historically, platinum‐based CRT has been the standard of care (SoC) for such pts, yet outcomes are poor. Durvalumab (durva) is a selective, high‐affinity, human IgG1 monoclonal antibody that blocks PD‐L1 binding to PD‐1 and CD80. Results from the PACIFIC trial of durva in pts with locally advanced, unresectable, Stage III NSCLC, who did not progress on concurrent CRT (cCRT), showed significant improvements in progression‐free survival (PFS) and overall survival (OS) with durva vs placebo (PFS: HR 0.52; 95% CI 0.42‐0.65; P < 0.001; OS: HR 0.68; 99.73% CI 0.47‐0.997; P = 0.0025), and similar safety profiles (Antonia et al, NEJM 2017; 2018). Consequently, treatment with durva after CRT, the PACIFIC regimen, is quickly becoming the new SoC. However, the PACIFIC trial only assessed pts who had received cCRT, but due to the higher toxicity of this approach, some patients may be better suited to sequential CRT (sCRT). Therefore, the objective of the PACIFIC‐5 (NCT03706690) study is to assess durva post‐CRT in a broader population, including pts with NSCLC who did not progress following either platinum‐based cCRT or sCRT. Trial design: PACIFIC‐5 is a phase 3, randomized, double‐blind, placebo‐controlled, multicenter study. Approximately 360 pts with histologically or cytologically confirmed Stage III, locally advanced, unresectable NSCLC will be enrolled from China and the rest of the world. Eligible pts have not progressed following definitive, platinum‐based cCRT or sCRT, and are in complete response, partial response or have stable disease. Pts are being randomized 2:1 to receive either durva (1500 mg i.v.) every 4 weeks, or placebo, until disease progression, toxicity or withdrawal of consent. The primary endpoint is PFS per blinded independent central review; OS is the key secondary endpoint. Other secondary endpoints include OS24, overall response rate, duration of response, PFS2, PFS12, PFS18, time to distant metastases, pt‐reported outcomes, durva pharmacokinetics and immunogenicity, and safety assessments. Recruitment is ongoing.}, -DOI = {10.1093/annonc/mdz438.021}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02075867/full} -} - - -Record #390 of 538 -@article{ISRCTN1463405817, -author = {ISRCTN14634058,}, -title = {PARIS-Pembrolizumab in combination with radiotherapy in locally advanced non-small cell lung cancer (NSCLC)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN14634058}, -year = {2017}, -accession_number = {ICTRP ISRCTN14634058}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Participants receive the first dose of pembrolizumab two weeks before the start of radiotherapy. Pembrolizumab is subsequently delivered every three weeks, starting on the first day of radiotherapy and are continued after completion of radiotherapy for up to 12 months. Participants receive radiotherapy for up to six and a half weeks. As this combination of treatment has not been given before, participants are registered initially into a dose finding phase where dose limiting toxicities (DLTs) is monitored during and for 12 weeks after completion of combined pembrolizumab and thoracic radiotherapy at each dose level in order to confirm the recommended phase II dose. Participants are given a different dose of pembrolizumab treatment depending on the group or ‘cohort’ they are recruited into. The starting dose of pembrolizumab for the first patients are 200 mg (dose level 1). This dose may be reduced to a dose of 100 mg (dose level ‐1) if unacceptable numbers of dose limiting toxicities are experienced at dose level 1. A maximum of 12 participants are treated in the dose finding part of the study aiming to establish the recommended phase II dose (RP2D). Once the recommended phase II dose is found, an expanded cohort of 13 participants are treated at this dose of pembrolizumab to obtain further safety data. During radiotherapy treatment the patient are seen weekly for follow‐up. After completion of combination pembrolizumab and radiotherapy treatment, patient visits are scheduled at these time‐points: 1. Weekly visits until toxicity resolved to grade 0‐1 after radiotherapy. Patients in the dose finding cohort will also be seen weekly to week four regardless of toxicity. 2. Patients on maintenance Pembrolizumab: Three weekly visit up to 12 months 3. Patients not on maintenance Pembrolizumab: Monthly visits for up to four months post RT and then at months six, nine and 12. 4. CT scan assessment within a month of completing RT, three, six and 12 months (following RT) CONDITION: Specialty: Cancer, Primary sub‐specialty: Lung Cancer; UKCRC code/ Disease: Cancer/ Malignant neoplasms of respiratory and intrathoracic organs ; Cancer ; Cancer/ Malignant neoplasms of respiratory and intrathoracic organs PRIMARY OUTCOME: 1. Recommended phase II dose is measured using the amount of participants in the dose finding phase experiencing dose limiting toxicity (DLT) in the time period during and for 12 weeks after treatment with combined Pembrolizumab and thoracic radiotherapy; 2. Dose limiting toxicity is measured using toxicities experienced from the start of treatment to 12 weeks post combination therapy SECONDARY OUTCOME: 1. Safety profile of Pembrolizumab combined with thoracic RT (acute and late toxicity) is measured by assessing the occurrence of SAEs, SARs, and SUSARs until 90 days after the participant has stopped trial treatment. The toxicity profile is measured by assessing the occurrence of adverse events until 30 days after the participant has stopped trial treatment.; 2. Treatment compliance of Pembrolizumab combined with thoracic RT is measured by recording dose reductions, delays, omissions, and withdrawals throughout each participant’s treatment on the study; 3. Best overall response to Pembrolizumab combined with thoracic RT is measured using the RECIST criteria from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started); 4. Best overall response to Pembrolizumab combined with thoracic RT measured according to immune‐related response criteria (irRC) is measured as the best confirmed irRC overall response over the study as a whole, recorded between the date of first dose until the last tumour assessment before subsequent therapy (except for local palliative radiotherapy for painful bone lesions) for the individual participant; 5. Progression‐free survival is measured using date of registration to first documented evidence of disease progression or death; 6. Overall survival is measured from participant records from date of registration to death INCLUSION CRITERIA: 1. Histologically or cytologically confirmed NSCLC 2. Unresectable stage III NSCLC not suitable for concurrent chemoradiotherapy i.e; 2.1. Patient unsuitable for cisplatin (eg poor renal function); 2.2. Large volume of disease with predicted dose to thoracic organs at risk that are likely to exceed the constraints for concurrent chemoradiotherapy, in the opinion of a clinical oncologist specialised in lung cancer 3. Stage IV NSCLC with dominant chest symptoms and low burden of metastatic disease who may benefit from thoracic RT 4. Patient considered suitable for radical radiotherapy 5. If chemotherapy has been given previously, the maximum interval between the last day of chemotherapy and the start of radiotherapy must be 6 weeks. The minimum interval between the last day of chemotherapy and the start of Pembrolizumab must be one week 6. Age = 18 7. Life expectancy estimated to be greater than 6 months 8. Performance status (ECOG) 0 or 1 (}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01884478/full} -} - - -Record #391 of 538 -@article{Park19, -author = {Park, K}, -title = {ES02.02 Management of EGFR LA Disease}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S15‐S16}, -year = {2019}, -accession_number = {EMBASE 2003407123}, -publication type = {Journal article; Conference proceeding}, -keywords = {Adjuvant chemotherapy; Adult; Advanced cancer; Adverse drug reaction; Cancer adjuvant therapy; Cancer patient; Cancer prognosis; Cancer recurrence; Cancer staging; Cancer surgery; Cancer survival; Case report; Chemoradiotherapy; Clinical article; Comparative effectiveness; Conference abstract; Disease free survival; Double blind procedure; Drug combination; Drug safety; Drug therapy; Enzyme activity; Feasibility study; Female; Fluorescence in situ hybridization; Gene amplification; Gene deletion; Genetic marker; Histopathology; Human; Human tissue; Immunohistochemistry; Lung adenocarcinoma; Male; Molecular fingerprinting; Molecularly targeted therapy; Mortality; Multimodality cancer therapy; Neoadjuvant therapy; Overall survival; Pharmacokinetics; Phase 2 clinical trial; Phase 3 clinical trial; Predictive value; Progression free survival; Prospective study; Protein expression; Protein function; Radiotherapy; Randomized controlled trial; Relapse; Retrospective study; Side effect; Surgery; Treatment failure}, -abstract = {Management of EGFR mutation(+) Locally Advanced Non‐Small Cell Lung Cancer Keunchil Park, MD, PhD Division of Hematology‐Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea The standard of care for the locally advanced non‐small cell lung cancer (LA‐NSCLC) is concurrent chemoradiotherapy (CCRT). Recently, the addition of consolidation immune checkpoint inhibitor following CCRT demonstrated improved outcome and is now recommended as the new standard of care for this heterogeneous group of LA‐NSCLC patients. In advanced/metastatic setting EGFR mutation (+), NSCLC cancer patients define a unique subset with a dramatic response to the EGFR TKIs. Currently, molecular profiling of tumor tissue for EGFR mutations (as part of multiplex testing) is a routine procedure at the time of initial diagnosis of patients with recurrent or metastatic NSCLC. For advanced or metastatic EGFR mutant NSCLC patients EGFR TKI therapy is the treatment of choice and the median overall survival is >30 months. Despite the great success of EGFR TKI in metastatic NSCLC, the role of EGFR TKIs in LA‐NSCLC is less well defined and controversial. Early clinical trials in unselected NSCLC patients failed to demonstrate the benefits of EGFR‐TKIs as an adjuvant treatment. The first prospective randomized phase III trial to investigate the role of EGFR TKI in earlier stage NSCLC includes the SWOG 0023 study (J Clin Oncol 2008;26:2450‐6) which failed to support the role of maintenance gefitinib (versus placebo) following definitive chemoradiation in unresectable stage III NSCLC. The CALGB 30106 phase II study also failed to show the benefits of adding gefitinib to sequential or concurrent chemoradiotherapy in unresectable stage III NSCLC (J Thorac Oncol 2010;5:1382‐90). And the randomized prospective placebo‐controlled adjuvant gefitinib trial in unselected patients with stage IB–IIIA resected disease (BR.19) was prematurely closed (J Clin Oncol 2013;31:3320‐6). Another randomized double‐blind trial in adjuvant NSCLC with tarceva (RADIANT) in patients with completely resected state IB to IIIA NSCLC whose tumors expressed EGFR protein by immunohistochemistry or EGFR amplification by fluorescence in situ hybridization did not show prolonged DFS (J Clin Oncol 2015;33:4007‐14). The prognostic or predictive value of EGFR mutation in early stage NSCLC patients is not well defined. In a retrospective single institutional analysis (J Thorac Oncol. 2012;7: 1815–1822), patients with resected stage I–III lung cancers and EGFR mutation have a lower risk of death compared to patients without EGFR mutation. There was a trend toward improvement in DFS among individuals with resected stages I to III lung adenocarcinomas harboring mutations in EGFR exon 19 or 21 who received adjuvant EGFR TKI therapy (J Thorac Oncol 2011;6:569–575). There have been recently reported several prospective trials of adjuvant EGFR TKI in early stage NSCLC patients enriched with EGFR mutation. CTONG1104 study (ADJUVANT), a randomized, open‐label, phase III trial of adjuvant gefitinib for 24 months versus intravenous vinorelbine plus cisplatin for 4 cycles in patients with completely resected (R0), stage II–IIIA (N1–N2), EGFR‐mutant (exon 19 deletion or exon 21 Leu858Arg) NSCLC, demonstrated that adjuvant gefitinib compared to cisplatin‐based chemotherapy significantly increases disease‐free survival, diminishes toxic effects, and improves HRQoL in patients with completely resected stage II–IIIA EGFR‐mutant NSCLC (Lancet Oncol 2018; 19: 139–48). In the phase II SELECT trial, adjuvant erlotinib for 2 years in patients with resected stage IA to IIIA EGFR‐mutant NSCLC after standard adjuvant chemotherapy with or without radiotherapy (J Clin Oncol 2019;37:97‐104) showed an improved 2‐year DFS. Patients rechallenged with erlotinib after recurrence experienced durable benefits. There are also some neoadjuvant trials of EGFR TKI for locally advanced NSCLC. RTOG 1306, a randomized phase II study of individualized combined modality therapy for stage III NSCLC (12‐weeks of either erlotinib hydrochloride or crizotinib followed by chemoradiation therapy in stage III NSCLC with EGFR TK mutations or EML4‐ ALK fusion). The primary objective was to assess whether patients with unresectable LA‐NSCLC treated with EGFR or ALK TK targeted agents based on molecular characteristics have a longer progression‐free survival than those treated with standard care therapy alone. The study was, however, unfortunately prematurely terminated due to poor accrual (NCT01822496). CTONG 1103 is an open‐label, randomized trial that compared the efficacy and safety of erlotinib versus gemcitabine plus cisplatin neoadjuvant therapy in patients with exon 19 or 21 EGFR mutations and untreated resectable stage IIIA‐N2 NSCLC. The study did not meet the primary end point of ORR with 42 days of neoadjuvant erlotinib, but the secondary end point PFS was significantly improved (J Clin Oncol 37. © 2019; published at on June 13, 2019: DOI ) There are also several ongoing clinical trials of EGFR TKIs in resected stage IB ‐ IIIA NSCLC with activating EGFR mutations. The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) is a prospective randomized double‐blind placebo‐controlled trial to investigate the benefits of the addition of molecularly targeted agents after standard postoperative chemotherapy in patients with resected NSCLC (Clin Cancer Res:2015; 21(24); 5439–44). It is worth noting that the primary objective for the ALCHEMIST adjuvant trials is overall survival (OS). ADAURA, a randomized phase III trial (osimertinib vs. placebo in patients with stage IB‐IIIA NSCLC, following complete tumor resection with or without adjuvant chemotherapy; NCT02511106) has been designed to assess the efficacy and safety of adjuvant osimertinib versus placebo in patients with resected stage IB‐IIIA EGFR mutation‐positive (Ex19Del or L858R) NSCLC. The primary efficacy objective is DFS. In brief, many neoadjuvant/adjuvant EGFR TKI trials in earlier stage of NSCLC have demonstrated its safety and feasibility with an improved DFS esp. in EGFR mutation(+) LA‐NSCLC. However, the real question should be “Can we improve the ‘overall survival’ and thus ultimately the ‘cure rate’ of locally advanced NSCLC with EGFR mutation?” In order to address this issue, there remain several critical questions to be answered, e.g., who is most likely to benefit from adjuvant EGFR TKI, what is the optimal duration of adjuvant TKI, what is the best regimen, etc. Whether the earlier introduction of EGFR targeted therapy in less advanced NSCLC would lead to improved ‘Cure Rate’ remains to be seen in future prospective trials in a larger number of EGFR mutation(+) patients. Keywords: management, EGFR mutation, locally advanced}, -DOI = {10.1016/j.jtho.2019.08.074}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01998321/full} -} - - -Record #392 of 538 -@article{Shaverdian17, -author = {Shaverdian, N, Lisberg, AE, Bornazyan, K, Veruttipong, D, Goldman, J, Formenti, SC, Garon, E, and Lee, P}, -title = {Impact of prior radiation therapy on the efficacy and toxicity of pembrolizumab in the treatment of non-small cell lung cancer}, -journal = {International journal of radiation oncology biology physics}, -volume = {99}, -number = {2}, -pages = {S151}, -year = {2017}, -accession_number = {EMBASE 618560396}, -publication type = {Journal article; Conference proceeding}, -keywords = {*lung toxicity; *non small cell lung cancer; Adult; Adverse drug reaction; Cancer survival; Clinical trial; Controlled clinical trial; Controlled study; Disease control; Drug combination; Drug therapy; Female; Human; Immune‐related gene; Major clinical study; Male; Multivariate analysis; Overall survival; Pharmacokinetics; Phase 1 clinical trial; Pneumonia; Progression free survival; Radiation; Radiotherapy; Secondary analysis; Side effect; Thorax}, -abstract = {Purpose/Objective(s): Preclinical studies show radiation therapy to enhance antitumor immune responses; however, clinical data on the impact of radiation therapy on the efficacy and toxicity of checkpoint immunotherapy is limited. We therefore sought to determine if patients who previously received radiation therapy for their non‐small‐cell lung cancer (NSCLC) would have enhanced disease control with pembrolizumab treatment and if patients with prior thoracic radiation would have more pulmonary toxicity with pembrolizumab treatment. Purpose/Objective(s): We present a secondary analysis of the phase 1 KEYNOTE‐001 trial. Patients (n = 97) had metastatic NSCLC and were treated at a single institution with pembrolizumab at a dose of either 2 mg or 10 mg/kg q 3 weeks or 10 mg/kg q 2 weeks. Disease response and pulmonary toxicity were prospectively assessed by the investigator using the immune related response criteria (irRC) and CTCAE grading. Patients were divided into subgroups to compare patients who previously received radiation for the treatment of their NSCLC to patients without a history of prior radiation with regards to progression‐free (PFS) and overall survival (OS) and pulmonary toxicity. Results: Among all patients, 43% previously received any radiation therapy (RT), 39% received extracranial radiation therapy (ERT) and 25% specifically received thoracic radiation therapy (TRT) for the treatment of their NSCLC. All radiation was delivered prior to the first dose of pembrolizumab. Patients with prior RT had a significantly longer PFS with pembrolizumab treatment vs. patients without prior RT (6 month PFS: 44.3% vs. 22.9%, P = 0.04). Patients with ERT had a significantly longer PFS with pembrolizumab vs. patients without ERT (median PFS: 4.1 months vs. 2.0 months; 6 month PFS: 49.3% vs. 21.4%, P < 0.01). On multivariate analysis both prior RT and ERT independently predicted for improved PFS with pembrolizumab treatment (HR, 0.60, 95% CI 0.37‐0.94, P = 0.03, and HR, 0.53, 95% CI, 0.33‐0.86, P = 0.01, respectively). Patients with prior RT and ERT also had a significantly longer OS with pembrolizumab treatment than patients without prior RT or ERT (P = 0.05 and P = 0.03, respectively). Patients with prior TRT had more overall treatment‐related pulmonary toxicity (12.5% vs. 1.4%, P = 0.04), and pneumonitis (12.5% vs. 2.7%, P = 0.09) with pembrolizumab treatment. However, the rates of any ≥ grade 3 pulmonary toxicities were similar (12.5% vs. 9.6%. P = 0.7). Conclusion: Patients treated with pembrolizumab on the phase 1 KEYNOTE‐001 trial who previously received radiation therapy had a significantly longer progression‐free and overall survival with pembrolizumab treatment. Overall, these data suggest an acceptable safety profile and a promising efficacy with the combination of radiation therapy and pembrolizumab for the treatment of advanced NSCLC.}, -DOI = {10.1016/j.ijrobp.2017.06.350}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01622547/full} -} - - -Record #393 of 538 -@article{Park22, -author = {Park, H, Jung, JS, Kim, YM, Kang, Y, Ji, W, Lee, JC, and Choi, C-M}, -title = {EP08.02-128 Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: expanded Observation from a Phase I/II A Randomized Controlled Trial}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S463‐S464}, -year = {2022}, -accession_number = {EMBASE 2020097827}, -publication type = {Journal article; Conference proceeding}, -keywords = {*drug efficacy; *non small cell lung cancer; Adult; Advanced cancer; Adverse drug reaction; Arthralgia; Cancer patient; Cancer survival; Case report; Clinical article; Clinical trial; Conference abstract; Drug therapy; Female; Human; Kaplan Meier method; Log rank test; Male; Monotherapy; Natural killer cell; Overall survival; Phase 1 clinical trial; Pneumonia; Progression free survival; Randomized controlled trial; Side effect; Survival rate; Treatment failure}, -abstract = {Introduction: Previous NK cell role with pembrolizumab for advanced NSCLC showed better efficacy than pembrolizumab alone. However, the prolonged effect of NK cells with pembrolizumab was not evaluated yet. This study evaluates the role of NK cells with pembrolizumab for more than 2 years from a previous randomized controlled trial. Methods: This trial recruited 20 patients with advanced NSCLC with a PD‐L1 tumor proportion score of 1% or greater who failed prior frontline platinum‐based therapy were randomized to receive pembrolizumab with SNK01 (N=14) or pembrolizumab monotherapy(n=6). Among the group treated with Pembrolizumab plus NK cell, two different doses were administered with 2 x 109 cells/dose (N = 7) and 4 x 109 cells/dose (N = 7). Patients who showed more than grade 3 adverse event were excluded in the analysis. The primary study endpoint was overall survival (OS), the secondary endpoint was progression‐free survival. Kaplan‐Meier curve was used to compare the treatment and the p‐value was calculated by log‐rank test. Results: Among the 20 patients, 2 patients were excluded for serious adverse event (N=1, arthralgia might related to pembrolizumab, N=1; pneumonia not related to NK cell). 11 patients have died and 5 patients from the pembrolizumab + NK cell group (41.6%, n=5/12), and 6 patients from pembrolizumab monotherapy (100%, n=6/6). The estimated two‐year survival rate was 58.3% vs 16.7% (Pembrolizumab + NK cell vs Pembrolizumab monotherapy). The hazard ratio (HR) of survival was 0.32 [95% CI: 0.1, 1.08, p‐value: 0.066]. The Survival rate did not statistically differ between the two NK cell dose groups. The median PFS was 6.2 vs 1.7 months (Pembrolizumab + NK cells vs Pembrolizumab monotherapy), with significantly higher PFS by log‐rank test [HR 0.15 95% CI: 0.05ᅳ0.53, p‐value: 0.003]. The PFS did not statistically differ between the two NK cell dose groups. Conclusions: Although the number of participants was small, this study shows that NK cells with pembrolizumab could be better than pembrolizumab alone for NSCLC. Moreover, prolonged PFS of more than 2 years of NK cells with pembrolizumab might represent the prolonged effect of pembrolizumab and NK cells. [Formula presented] Keywords: Natural Killer cell, NSCLC, pembrolizumab}, -DOI = {10.1016/j.jtho.2022.07.811}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461472/full} -} - - -Record #394 of 538 -@article{jRCTs03120007820, -author = {jRCTs031200078,}, -title = {Phase III study of Pembrolizumab versus Pembrolizumab plus Carboplatin plus Pemetrexed for non-Sq NSCLC with PD-L1 50% or more}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCTs031200078}, -year = {2020}, -accession_number = {ICTRP jRCTs031200078}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Group A: 200 mg of Pembro is intravenously infused over 30 minutes and more on day 1. Repeat the administration every 3 weeks as one cycle until the treatment cessation criteria are met. Upper limit of the Pembro administration is 35 cycles. Group B: 200 mg of Pembro, AUC 5 of Carboplatin and 500mg/m2 of Pemetrexed are intravenously infused on day 1. Carboplatin will finished up to 4 cycles. Repeat the administration every 3 weeks as one cycle until the treatment cessation criteria are met for the other drugs. When CR, PR or SD will be achieved after 4 cycles, maintenance therapy with Pembrolizumab plus Pemetrexed will be continued. Pembrolizumab will finished up to 35 cycles. CONDITION: non‐squamous non‐small cell lung cancer ; non‐squamous non‐small cell lung cancer, pembrolizumab, PD‐L1, carboplatin, pemetrexed PRIMARY OUTCOME: progression free survival SECONDARY OUTCOME: overall response rate; overall survival; toxicity INCLUSION CRITERIA: 1) Non‐squamous non‐small cell lung cancer (NSCLC) confirmed by histology or cytology. 2) Not received prior systemic treatment with stage III not eligible for radical radiotherapy, stage IV, or recurrent NSCLC. 3) PD‐L1 TPS of less than 50% with 22C3 antibody. 4) With at least one measurable lesion based on RECIST 1.1. 5) Age of 20 years or older on the day of informed consent. 6) ECOG Performance Status 0‐1. 7) Without activating mutation in EGFR or ALK chromosomal translocation. 8) Absence of severe impairments of major organs. 9) Life expectancy of 12 weeks or more from the treatment start date. 10) Prior to the study registration, able to provide written informed consent after a thorough explanation of the study content.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02188558/full} -} - - -Record #395 of 538 -@article{Lu24, -author = {Lu, Z, Xu, S, Ye, M, Shen, T, Zhang, X, Rao, D, Chen, J, Lin, Z, Chang, M, Xiong, G, Li, R, and Wang, Z}, -title = {Comparison of pembrolizumab plus chemotherapy versus concurrent or sequential radiochemotherapy in patients with driver mutation-lacking lung adenocarcinoma presenting with recurrent laryngeal nerve invasion leading to hoarseness}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644911857}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *hoarseness; *lung adenocarcinoma; *recurrent laryngeal nerve; Adult; Cancer staging; Conference abstract; Controlled study; Coughing; Doublet chemotherapy; Drug combination; Dysphagia; Female; High throughput sequencing; Human; Major clinical study; Male; Non small cell lung cancer; Progression free survival; Quality of life; Radiotherapy; Survival rate}, -abstract = {Background: For patients with advanced non‐small cell lung cancer (NSCLC), particularly those with adenocarcinoma lacking a driver mutation, the encroachment upon the recurrent laryngeal nerve causing hoarseness presents a substantial challenge in treatment. Such patients, at TNM stage IIIB or higher, may undergo platinum‐based doublet chemotherapy combined with concurrent or sequential radiotherapy. Despite these treatments, survival rates remain modest, and quality of life is significantly impaired by symptoms such as hoarseness, dysphagia, and coughing. Recently, pembrolizumab combined with chemotherapy has emerged as a frontline treatment for adenocarcinoma patients, showing promising outcomes in unresectable, advanced stages of the disease. However, its efficacy in patients experiencing hoarseness due to recurrent laryngeal nerve involvement has not been previously investigated. Methods: Between September 2018 and October 2022, Jiangmen Central Hospital admitted 71 patients with advanced adenocarcinoma and hoarseness, who lacked a driver mutation as confirmed by NGS testing. After excluding patients who did not complete the treatment plan, the remaining subjects were randomly divided into two groups. The treatment group, consisting of 21 patients, received pembrolizumab, pemetrexed, and platinum‐based doublet chemotherapy. The control group, also comprising 21 patients, underwent concurrent or sequential radiotherapy alongside pemetrexed and platinum‐based chemotherapy. Results: Among the treatment group, hoarseness was reversed in 13 out of 21 patients, with a return to normal vocal function. In the control group, 5 out of 21 patients experienced a reversal of hoarseness. The treatment group showed superior outcomes in reversing hoarseness caused by recurrent laryngeal nerve involvement (p=0.013). The objective response rate (ORR) in the treatment group was 28.57%, with a disease control rate (DCR) of 66.67%. In contrast, the control group had an ORR of 9.52% and a DCR of 28.57% (p<0.05). The Progression‐Free Survival (PFS), as calculated by the Kaplan‐Meier survival curve method, was 11.77 months (95% CI: 11.19‐12.35) in the treatment group and 7.53 months (95% CI: 6.73‐8.33) in the control group, indicating a significantly higher survival rate in the treatment group (p<0.05). Conclusions: In patients with advanced lung adenocarcinoma, pembrolizumab combined with chemotherapy appears to effectively reverse hoarseness caused by recurrent laryngeal nerve involvement, higher objective response rates, and increased PFS. This suggests the necessity for multicentric, prospective, evidence‐based studies in the treatment of lung adenocarcinoma patients with hoarseness due to recurrent laryngeal nerve invasion.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02750490/full} -} - - -Record #396 of 538 -@article{Jabbour21, -author = {Jabbour, SK, Cho, BC, Bria, E, Kato, T, Bhosle, J, Gainor, JF, Reguart, N, Wang, L, Morgensztern, D, Gurary, EB, Ashraf, TB, Lara-Guerra, H, and Reck, M}, -title = {KEYLYNK-012: a Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Durvalumab in Unresectable, Locally Advanced, Stage III Non‒Small-Cell Lung Cancer}, -journal = {International journal of radiation oncology biology physics}, -volume = {111}, -number = {3}, -pages = {e440‐e441}, -year = {2021}, -accession_number = {EMBASE 2014606128}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer combination chemotherapy; *cancer staging; *chemoradiotherapy; *drug tolerability; *non small cell lung cancer; Adult; Asia; Cancer patient; Clinical trial; Conference abstract; Controlled study; Double blind procedure; Doublet chemotherapy; Drug combination; Drug safety; Drug therapy; Drug withdrawal; ECOG Performance Status; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; Female; Histology; Histopathology; Human; Human tissue; Male; National health organization; Nomenclature; North America; Overall response rate; Phase 3 clinical trial; Quality of life; Radiotherapy; Randomization; Randomized controlled trial; Response evaluation criteria in solid tumors; Western Europe}, -abstract = {Purpose/Objective(s): Pembrolizumab, an anti‒PD‐1 antibody is standard of care therapy for metastatic non‒small‐cell lung cancer (NSCLC) as monotherapy and in combination with chemotherapy. Durvalumab, an anti–PD‐L1 antibody, is approved for unresectable, stage III NSCLC without disease progression following CCRT. Early trials of pembrolizumab in combination with chemoradiotherapy, either concurrently or as consolidation, showed acceptable tolerability and promising PFS in patients with unresectable stage III NSCLC. Early data suggest the combination of poly(ADP‐ribose) polymerase (PARP) plus anti–PD‐(L)1 inhibition can enhance treatment effects. KEYLYNK‐012 (NCT04380636) is evaluating pembrolizumab plus CCRT followed by pembrolizumab with/without the PARP inhibitor olaparib vs CCRT followed by durvalumab in patients with unresectable, locally advanced, stage III NSCLC. Materials/Methods: This global phase 3, randomized, placebo‐ and active‐controlled, double‐blind study is enrolling patients aged ≥18 y with previously untreated, pathologically confirmed, stage IIIA–C NSCLC, an ECOG PS of 0 or 1, and a tumor sample available for PD‐L1 evaluation. Patients are randomized 1:1:1 to CCRT (platinum‐doublet chemotherapy [cisplatin plus pemetrexed or etoposide; or carboplatin plus paclitaxel] plus radiotherapy 60 Gy over 6 wks [cycles 2–3]) with pembrolizumab 200 mg Q3W (groups A and B) or CCRT alone (group C) for 3 cycles. This is followed by pembrolizumab 200 mg Q3W for 17 cycles plus placebo (group A) or olaparib 300 mg BID (group B); or durvalumab 10 mg/kg Q2W for 26 cycles (group C). Randomization is stratified by disease stage (IIIA vs IIIB/IIIC), tumor histology (squamous vs nonsquamous), PD‐L1 tumor proportion score (≥50% vs < 50%) and region (East Asia vs North America/Western Europe/UK vs other). PFS (RECIST v1.1 by blinded independent central review [BICR]) and OS are dual primary endpoints. Secondary endpoints include ORR, duration of response, safety and tolerability, and quality of life (QoL). Tumor response will be evaluated per RECIST v1.1 by BICR at baseline, week 12, Q9W until year 2, Q12W until year 3, Q26W until year 5, and Q52W thereafter until disease progression, new cancer therapy, study withdrawal, or death. AEs will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 and monitored during the study and for 30 days after the final dose (90 days for serious AEs). QoL outcomes will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30 (EORTC QLQ‐C30) and the Lung Cancer Module (EORTC QLQ‐LC13). Enrollment began July 6, 2020 and as of Feb 26, 2021, is ongoing at 204 sites in 24 countries. Results: forthcoming Conclusion: forthcoming}, -DOI = {10.1016/j.ijrobp.2021.07.1246}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02321717/full} -} - - -Record #397 of 538 -@article{Garrido19, -author = {Garrido, P}, -title = {ES23.05 The Future of Systemic Therapy in Stage III}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S71‐S72}, -year = {2019}, -accession_number = {EMBASE 2003406547}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *systemic therapy; Adult; Advanced cancer; Cancer patient; Cancer survival; Case report; Chemoradiotherapy; Clinical article; Comparative effectiveness; Conference abstract; Double blind procedure; Drug combination; Drug safety; Drug therapy; Esophagitis; Female; Follow up; Histology; Histopathology; Human; Human tissue; Intensity modulated radiation therapy; Long term survival; Male; Non small cell lung cancer; Overall survival; Particle therapy; Pharmacokinetics; Phase 3 clinical trial; Practice guideline; Progression free survival; Radiation dose escalation; Radiotherapy; Randomized controlled trial}, -abstract = {Stage III NSCLC comprises a very heterogeneous group of patients with regard to tumor extent, prognosis, and treatment options. It represents between 25‐30% of NSCLCs and the majority of them are unresectable. Potentially curative treatment of unresectable stage III necessitates adequate locoregional control as well as control of the micrometastatic disease that is likely to be present in most patients. Several randomized clinical trials dating back as far as 20 years and metanalysis have shown the superiority of cisplatin‐based chemotherapy and radiotherapy over radiotherapy alone. Sequential versus concomitant approach has been directly compared in several trials; almost all of them showed a trend in favor of concomitant treatment. These results clearly supported the use of concomitant chemoradiotherapy as standard of care for these patients1 fit enough to tolerate the risk of severe toxicity, particularly grade 3‐4 esophagitis that is the most common adverse effect of the concomitant approach. Attempts to improve outcomes have included studies of radiotherapy dose escalation and new chemotherapy combinations, as well as adding biological agents and cancer vaccines to existing regimens. Technical radiotherapy modifications, including intensity‐modulated radiotherapy and particle beam therapy, have also been investigated. In spite of it, the long‐term survival has remained largely unchanged for many years, with only 15% of patients are alive at 5 years. In the last years, immune‐checkpoints blockade revolutionized the standard of care of metastatic NSCLC. The PACIFIC study is an randomized, double‐blind, placebo‐controlled, multi‐centre, phase 3 study to evaluate the efficacy and safety of durvalumab compared with placebo, as sequential therapy in patients with locally advanced, unresectable stage III NSCLC who have not progressed following definitive, concurrent platinum‐based chemotherapy and thoracic RT. The study was positive for both primary endpoints progression‐ free survival (HR=0.51; 95%CI: 0.41‐0.63)) and overall survival (HR=0.68; 95%CI: 0.49‐0.99; p=0.00251)2. This benefit was observed in both non‐squamous and squamous histology as well as in both stages IIIA and IIIB NSCLC. Based on this study, there is a new standard of care for unresectable stage III NSCLC patients. Nevertheless, improving outcomes for patients with stage III disease remains a challenge and many questions have to address in well‐designed clinical trials. 1.‐ Postmus PE, Kerr KM, Oudkerk M et al. Early and locally advanced non‐small‐cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol 2017; 28 Suppl 4: iv1‐iv21. 2.‐Antonia SJ, Villegas A, Daniel D et al. Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379: 2342‐50 Keywords: durvalumab, stage III, chemoradiation}, -DOI = {10.1016/j.jtho.2019.08.175}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01996718/full} -} - - -Record #398 of 538 -@article{EUCTR2019-001222-98-BE19, -author = {EUCTR2019-001222-98-BE,}, -title = {A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-001222-98-BE}, -year = {2019}, -accession_number = {ICTRP EUCTR2019‐001222‐98‐BE}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trade Name: Opdivo (100 mg/10 ml) Product Name: NIVOLUMAB ‐ 10ml vial‐COMMERCIAL Product Code: BMS‐936558 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NIVOLUMAB CAS Number: 946414‐94‐4 Current Sponsor code: BMS‐936558 Other descriptive name: BMS936558 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ Trade Name: Yervoy Product Name: Ipilimumab (40ml Vial) Product Code: BMS‐734016 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: IPILIMUMAB CAS Number: 477202‐00‐9 Current Sponsor code: BMS‐734016 Other descriptive name: BMS734016 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5‐ Trade Name: Cisplatin NeoCorp 1 mg/ml ‐ Concentrate for solution for infusion Product Name: Cisplatin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: CISPLATIN CAS Number: 15663‐27‐1 Other descriptive name: Cisplatin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1‐ Trade Name: Cisplatin‐Ebewe, 1 mg/ml concentrate for solution for infusion Product Name: Cisplatin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: CISPLATIN CAS Number: 15663‐27‐1 Other descriptive name: Cisplatin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1‐ Trade Name: Cisplatin Teva® 1 mg/ml concentrate for solution for infusion Product Name: Cisplatin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: CISPLATIN CAS Number: 15663‐27‐1 Other descriptive name: Cisplatin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1‐ Trade Name: ETO‐Cell Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ETOPOSIDE CAS Number: 33419‐42‐0 Other descriptive name: ETOPOSIDE Concentration unit: mg/ml mill CONDITION: Previously Untreated Locally Advanced Non‐small Cell Lung Cancer (LA NSCLC) ; MedDRA version: 20.0 Level: PT Classification code 10029519 Term: Non‐small cell lung cancer stage III System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] SECONDARY OUTCOME: Secondary end point(s): 3. Overall Survival (OS) for Arm B and Arm C ; 4. Progression Free Survival (PFS) Assessed as per BICR for Arm B and Arm C ; 5. Objective Response Rate (ORR) and Complete Response Rate Assessed as per BICR ; 6. Duration of Response (DOR) Assessed as per BICR ; 7. Time to Response (TTR) Assessed as per BICR ; 8. Time to Death or Distant Metastases (TTDM) Assessed as per BICR ; 9. Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and selected AEs ; 10. Percentage of Participants Without Meaningful Symptom Deterioration Following 48 Weeks of Maintenance Therapy Based on Lung Cancer Subscale (LCS) of FACT‐L and NSCLC‐SAQ Timepoint(s) of evaluation of this end point: 3. Up to 5 Years ; 4. Up to 5 Years ; 5. Up to 5 Years ; 6. Up to 5 Years ; 7. Up to 5 Years ; 8. Up to 5 Years ; 9. Up to 5 Years ; 10. 48 weeks INCLUSION CRITERIA: ‐ Eastern Cooperative Oncology Group (ECOG) performance status =1 ‐ Locally advanced stage IIIA, IIIB, or IIIC (T1‐2 N2‐3 M0, T3 N1‐3 M0, or T4 N0‐3 M0) histologically‐confirmed NSCLC, according to 8th TNM classification ‐ Newly diagnosed and treatment‐naïve, with no prior local or systemic anticancer therapy given as primary therapy for locally advanced disease PRIMARY OUTCOME: Main Objective: ‐ To compare the efficacy of nivolumab + CCRT followed by nivolumab + ipilimumab (Arm A) vs CCRT followed by durvalumab (Arm C) in participants with untreated LA NSCLC Primary end point(s): 1. Progression Free Survival (PFS) Assessed by RECIST 1.1 per Blinded Independent Central Review (BICR) for Arm A and Arm C; 2. Overall Survival (OS) for Arm A and Arm C Secondary Objective: ‐ To compare the efficacy of nivolumab + CCRT followed by nivolumab ipilimumab (Arm A) or nivolumab + CCRT followed by nivolumab alone (Arm B) as maintenance vs CCRT followed by durvalumab (Arm C) in participants with untreated LA NSCLC; ‐ To assess safety and tolerability; ‐ To compare the efficacy of nivolumab + CCRT followed by nivolumab + ipilimumab (Arm A) or nivolumab + CCRT followed by nivolumab alone (Arm B) as maintenance vs CCRT followed by durvalumab (Arm C) in participants with untreated LA NSCLC Timepoint(s) of evaluation of this end point: 1. Up to 5 Years; 2. Up to 5 Years; Other protocol defined inclusion criteria could apply Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 770 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 630}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02068641/full} -} - - -Record #399 of 538 -@article{JapicCTI-19456619, -author = {JapicCTI-194566,}, -title = {M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-JapicCTI-194566}, -year = {2019}, -accession_number = {ICTRP JapicCTI‐194566}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Intervention name : M7824 INN of the intervention : ‐ Dosage And administration of the intervention : Participants will receive an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks starting from Day 1 up to disease progression. Control intervention name : Pembrolizumab INN of the control intervention : ‐ Dosage And administration of the control intervention : Participants will receive an intravenous infusion of 200 mg Pembrolizumab once every 3 weeks starting from Day 1 up to disease progression. CONDITION: Non‐Small Cell Lung Cancer PRIMARY OUTCOME: efficacy; ‐Best Overall Response (BOR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as Evaluated by Independent Review Committee [Time Frame: Time from randomization to planned final assessment for unconfirmed BOR, expected at 26 months]; ‐Progression‐free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as Evaluated by Independent Review Committee [Time Frame: Time from randomization to planned final assessment, expected at 37 months] SECONDARY OUTCOME: safety, efficacy, pharmacokinetics, pharmacodynamics; ‐Occurrences of Treatment‐emergent Adverse Events (TEAEs) and Treatment‐related AEs According to National Cancer Institute‐Common Terminology Criteria for Adverse Events (NCI‐CTCAE) version 5.0 [Time Frame: Randomization up to the last safety follow‐up visit, expected at approximately 47 months]; ‐Overall Survival (OS) Time [Time Frame: Randomization up to 49 months]; ‐Best Overall Response (BOR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as Evaluated by Investigator [Time Frame: Time from randomization to planned final assessment for unconfirmed BOR, expected at 26 months]; ‐Progression‐free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as Evaluated by Investigator [Time Frame: Time from randomization to planned final assessment, expected at 37 months]; ‐Duration of Response Assessed from Complete Response (CR) or Partial Response (PR) according to RECIST 1.1 Assessed by Independent Review Committee [Time Frame: Time from CR or PR to planned assessment, expected at 37 months]; ‐Concentration of M7284 at the end of Infusion (Ceoi) [Time Frame: Pre‐dose, 30 minutes post‐dose at Week 1, 3, 5, 7 and 6 weekly during treatment up to safety follow‐up visit (28 days after last dose, assessed up to 47 months)]; ‐Concentration of M7284 at the end of the Dosing Interval (C trough) [Time Frame: Pre‐dose, 30 minutes post‐dose at Week 1, 3, 5, 7 and 6 weekly during treatment up to safety follow‐up visit (28 days after last dose, assessed up to 47 months)]; ‐Immunogenicity as measured by Anti‐drug Antibodies Concentration [Time Frame: Randomization up to safety follow‐up visit (28 days post last‐dose of study drug administration, assessed up to 47 months)] INCLUSION CRITERIA: ‐Histologically confirmed diagnosis of advanced NSCLC ‐Have not received prior systemic therapy treatment for their advanced/Stage four NSCLC. Completion of treatment with cytotoxic chemotherapy, biological therapy, and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease. Confirmation of resolution of toxic effects of previous neoadjuvant/adjuvant chemotherapy therapy to Grade less than or equal to 1. For radiation toxicity or prior major surgeries, participants should have recovered from side effects and/or complications. ‐Have measurable disease based on RECIST 1.1 ‐Have a life expectancy of at least 3 months ‐Availability of either tumor archival material (less than 6 months old) or fresh biopsies collected within 28 days (excluding bone biopsies) before the first dose is mandatory to determine PD‐L1 expression level prior to enrollment ‐PD‐L}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01970408/full} -} - - -Record #400 of 538 -@article{Rittmeyer21, -author = {Rittmeyer, A, De Ruysscher, D, Ramalingam, S, Urbanic, J, Gerber, DE, Tan, DSW, Cai, J, Li, A, and Peters, S}, -title = {CheckMate 73 L: a phase 3 study comparing nivolumab plus concurrentchemoradiotherapy followed by nivolumab ± ipilimumab versus concurrentchemoradiotherapy followed by durvalumab for previously untreated, locally advancedstage III non-small cell lung cancer}, -journal = {Pneumologie (Stuttgart, Germany)}, -volume = {75}, -number = {SUPPL 1}, -pages = {S9‐S10}, -year = {2021}, -accession_number = {EMBASE 635345070}, -publication type = {Journal article; Conference proceeding}, -keywords = {*drug tolerability; *non small cell lung cancer; Adult; Advanced cancer; Cancer patient; Cancer staging; Cancer survival; Chemoradiotherapy; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Distant metastasis; Drug combination; Drug efficacy; Drug safety; Drug therapy; ECOG Performance Status; Exploratory research; Female; Gene expression; Human; Major clinical study; Male; Pharmacokinetics; Phase 2 clinical trial; Phase 3 clinical trial; Progression free survival; Protein expression; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Treatment response time}, -abstract = {Background: Historically, the standard‐of‐care for patients (pts) with unresectable stage III non‐small cell lung cancer(NSCLC) was concurrent chemoradiotherapy (CCRT); however, outcomes are poor with 5‐y survival rates of 15‐30%. WhileCCRT primes anti‐tumour immunity, it also upregulates PD‐L1 expression, potentially blunting any immune response. Thus,concurrent immunotherapy + CCRT may improve outcomes. The safety and tolerability of nivolumab (NIVO), an anti‐PD‐1antibody, given concomitantly with CCRT in pts with stage III NSCLC was demonstrated in the phase 2 NICOLAS study(NCT02434081). Furthermore, combining NIVO with ipilimumab (IPI), an anti‐CTLA‐4 antibody, resulted in a longer medianoverall survival (OS) versus chemotherapy in pts with advanced NSCLC who had a PD‐L1 expression level of ≥ 1% in thephase 3 CheckMate 227 study (NCT02477826). In a prespecified exploratory analysis, NIVO + IPI showed an efficacybenefit versus NIVO. Previously, durvalumab (DURV), an anti‐PD‐L1 antibody, demonstrated significant improvementsversus placebo in progression‐free survival (PFS) and OS with manageable safety in pts without disease progression afterCCRT in the phase 3 PACIFIC study (NCT02125461). Therefore, we will evaluate the efficacy of NIVO + CCRT followed byNIVO ± IPI versus CCRT followed by DURV for untreated, locally advanced stage III NSCLC in the phase 3 randomizedCheckMate 73 L study (NCT04026412). Trial Design: In all, 888 pts aged ≥ 18 y with previously untreated stage III NSCLC and an ECOG PS ≤ 1 will be stratifiedby age, PD‐L1 expression, and disease stage, then randomized (1 : 1 : 1) to receive NIVO (360 mg Q3W) + CCRT followed byNIVO (360 mg Q3W) + IPI (1 mg/kg Q6W; Arm A) or NIVO alone (480 mg Q4W; Arm B) for ≤ 1 y, or CCRT followed byDURV (10 mg/kg Q2W; Arm C) for ≤ 1 y. Pts with progressive disease during CCRT will discontinue treatment and enterfollow‐up. Primary endpoints are PFS by RECIST 1.1, assessed by BICR (Arm A vs. C) and OS (Arm A vs. C). Secondaryendpoints are PFS (Arm B vs. A or C), OS (Arm B vs. A or C), objective response rate, time to response, duration ofresponse, time to distant metastases, and safety. Start date: Aug 2019.}, -DOI = {10.1055/s-0041-1723279}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02286696/full} -} - - -Record #401 of 538 -@article{Jabbour21, -author = {Jabbour, SK, Cho, BC, Bria, E, Kato, T, Bhosle, J, Gainor, JF, Reguart, N, Wang, L, Morgensztern, D, Gurary, E, Ashraf, TB, Lara-Guerra, H, and Reck, M}, -title = {Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III nonsmall cell lung cancer: KEYLYNK012}, -journal = {Journal of clinical oncology}, -volume = {39}, -number = {15 SUPPL}, -year = {2021}, -accession_number = {EMBASE 635590134}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer staging; *chemoradiotherapy; *drug tolerability; *non small cell lung cancer; Adult; Asia; Cancer patient; Clinical trial; Conference abstract; Controlled study; Double blind procedure; Doublet chemotherapy; Drug combination; Drug safety; Drug therapy; Drug withdrawal; ECOG Performance Status; Female; Histology; Histopathology; Human; Human tissue; Male; National health organization; Nomenclature; North America; Overall response rate; Phase 3 clinical trial; Quality of life; Radiotherapy; Randomization; Randomized controlled trial; Response evaluation criteria in solid tumors; Western Europe}, -abstract = {Background: Pembrolizumab, an anti‐PD‐1 antibody is standard of care therapy for metastatic non‐small‐cell lung cancer (NSCLC) as monotherapy and in combination with chemotherapy. Durvalumab, an anti‐PD‐L1 antibody, is approved for unresectable, stage III NSCLC without disease progression following concurrent chemoradiation therapy (CCRT). Early trials of pembrolizumab in combination with chemoradiotherapy, either concurrently or as consolidation, showed acceptable tolerability and promising PFS in patients with unresectable stage III NSCLC. Early data suggest the combination of poly(ADP‐ribose) polymerase (PARP) plus anti‐PD‐(L)1 inhibition can enhance treatment effects. KEYLYNK‐012 (NCT04380636) is evaluating pembrolizumab plus CCRT followed by pembrolizumab with/without the PARP inhibitor olaparib vs CCRT followed by durvalumab in patients with unresectable, locally advanced, stage III NSCLC. Methods: This global phase 3, randomized, placebo‐ and active‐controlled, double‐blind study is enrolling patients aged ≥18 y with previously untreated, pathologically confirmed, stage IIIA‐C NSCLC, an ECOG PS of 0 or 1, and a tumor sample available for PD‐L1 evaluation. Patients are randomized 1:1:1 to CCRT (platinum‐doublet chemotherapy [cisplatin plus pemetrexed or etoposide; or carboplatin plus paclitaxel] plus radiotherapy 60 Gy over 6 wks [cycles 2‐3]) with pembrolizumab 200 mg Q3W (groups A and B) or CCRT alone (group C) for 3 cycles. This is followed by pembrolizumab 200 mg Q3W for 17 cycles plus placebo (group A) or olaparib 300 mg BID (group B); or durvalumab 10 mg/kg Q2W for 26 cycles (group C). Randomization is stratified by disease stage (IIIA vs IIIB/IIIC), tumor histology (squamous vs nonsquamous), PD‐L1 tumor proportion score (≥50% vs < 50%) and region (East Asia vs North America/Western Europe/UK vs other). PFS (RECIST v1.1 by blinded independent central review [BICR]) and OS are dual primary endpoints. Secondary endpoints include ORR, duration of response, safety and tolerability, and quality‐of‐life outcomes. Tumor response will be evaluated per RECIST v1.1 by BICR after CCRT and at regular intervals throughout the study until disease progression, new cancer therapy, study withdrawal, or death. AEs will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. Enrollment began July 6, 2020 and is ongoing at 204 sites in 24 countries.}, -DOI = {10.1200/JCO.2021.39.15-suppl.TPS8580}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02305728/full} -} - - -Record #402 of 538 -@article{NL-OMON5285719, -author = {NL-OMON52857,}, -title = {A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON52857}, -year = {2019}, -accession_number = {ICTRP NL‐OMON52857}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: The study doctor has the option to skip cycle 1 and start your anticancer treatment at the same time as radiotherapy at cycle 2. Arm A: * CCRT Period: Nivolumab (360 mg flat dose IV Q3W) for cycles 1‐3 + platinum doublet chemotherapy (IV Q3W) for cycles 1‐3 + radiotherapy (total dose of 60‐66 Gy) for cycles 2‐3 * Maintenance Period: Nivolumab (360 mg flat dose IV Q3W) + Ipilimumab (1 mg/kg IV Q6W) for up to 12 months Arm B: * CCRT Period: Nivolumab (360 mg flat dose IV Q3W) for cycles 1‐3 + platinum doublet chemotherapy (IV Q3W) for cycles 1‐3 + radiotherapy (total dose of 60‐66 Gy) for cycles 2‐3 * Maintenance Period: Nivolumab (480 mg flat dose IV Q4W) for up to 12 months Arm C: * CCRT Period: Platinum doublet chemotherapy (IV Q3W) for cycles 1‐3 + radiotherapy (total dose of 60‐66 Gy) for cycles 2‐3 * Maintenance Period: Durvalumab (10 mg/kg IV Q2W) for up to 12 months. CONDITION: ; Lung cancer; non small cell lung cancer 10038666 PRIMARY OUTCOME: The primary endpoints are: ; * PFS by RECIST 1.1 per Blinded Independent Central Review (BICR) ; SECONDARY OUTCOME: The secondary endpoints are: ; • OS for Arm A vs Arm C ; • PFS by RECIST 1.1 per BICR for Arm B vs Arm C ; • OS for Arm B vs Arm C ; • PFS by RECIST 1.1 per BICR for Arm A vs Arm B ; • OS for Arm A vs. Arm B ; • Objective Response Rate (ORR) by RECIST 1.1 per BICR ; • Duration of Response by RECIST 1.1 per BICR ; • Time to Response (TTR) by RECIST 1.1 per BICR ; • PFS by RECIST 1.1 per Investigator assessment ; • ORR by RECIST 1.1 per Investigator assessment ; • DoR by RECIST 1.1 per Investigator assessment ; • TTR by RECIST 1.1 per Investigator assessment ; • TTDM by RECIST 1.1 per Investigator assessment ; • Incidence of AEs, SAEs, and select AEs ; • Proportion of participants without meaningful symptom deterioration following ; 48 weeks of maintenance therapy based on LCS subscale of FACT‐L and NSCLC‐SAQ ; INCLUSION CRITERIA: 1) ECOG performance status <=1 2) Locally advanced stage IIIA, IIIB, or IIIC (T1‐2 N2‐3 M0, T3 N1‐3 M0, or T4 N0‐3 M0) pathologically‐confirmed (including Cytology) NSCLC, according to 8th TNM classification, that is amenable to definitive CCRT. Participants who are not planned for potential curative surgical resection are eligible, except for those foregoing surgery due to clinical contraindication for general anesthesia/surgery. Participants must be evaluated by the site*s multidisciplinary team (eg, medical oncologist, surgeon, radiologist) during screening to assess the suitability of the participant for the study. i) Overt cT4 disease. Vertebral invasive disease must not extend into the spinal canal. OR ii) Nodal status N2 or N3 must be proven (by biopsy in at least one N2 or N3 node, via EBUS, mediastinoscopy, or thoracoscopy) OR iii) Nodal status N1 must be proven by biopsy in at least one N1 node, via E}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02719746/full} -} - - -Record #403 of 538 -@article{Felip17, -author = {Felip, E, Wakelee, H, Vallieres, E, Zhou, C, Zuo, Y, Xia, F, Sandler, A, and Altorki, N}, -title = {IMpower010: a phase III study of atezolizumab vs best supportive care following adjuvant chemotherapy in completely resected NSCLC}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {11}, -pages = {S2398‐S2399}, -year = {2017}, -accession_number = {EMBASE 620147955}, -publication type = {Journal article; Conference proceeding}, -keywords = {*adjuvant chemotherapy; *non small cell lung cancer; Adult; Autoimmune disease; Cancer recurrence; Cancer size; Cancer staging; Cancer surgery; Cancer survival; Comparative effectiveness; Controlled study; Drug therapy; Female; Gene expression; Human; Human cell; Human tissue; Immunocompetent cell; Immunohistochemistry; Immunotherapy; Major clinical study; Male; Open study; Patient history of chemotherapy; Pharmacokinetics; Phase 3 clinical trial; Radiotherapy; Randomized controlled trial; Recurrent disease; Stratification; Surgery; Tumor cell; Tumor‐related gene}, -abstract = {Background: Atezolizumab is an antiePD‐L1 mAb that blocks PD‐L1 from interacting with its receptors PD‐1 and B7.1 and restores anticancer immunity. In patients with 2L/3L advanced NSCLC, the OAK trial showed improved mOS in the atezolizumab arm (13.8 mo) vs the docetaxel arm (9.6 mo), with survival benefit observed across all PD‐L1 expression levels on tumor cells (TC) or tumor‐infiltrating immune cells (IC). In patients with fully resected NSCLC (stages IB [tumors ≥ 4 cm]‐IIIA), adjuvant chemotherapy remains the standard of care, but survival benefit is limited. Therefore, more effective therapies are still needed for patients with early‐stage NSCLC. IMpower010 (NCT02486718) is a global Phase III, randomized, open‐label trial conducted to evaluate the efficacy and safety of atezolizumab vs best supportive care (BSC) following adjuvant cisplatinebased chemotherapy in patients with resected stage IB (tumors ≥ 4 cm)‐IIIA NSCLC. Method: Eligibility criteria include complete tumor resection 4‐12 weeks prior to enrollment for pathological stage IB (tumors ≥ 4 cm)‐IIIA NSCLC, adequate recovery from surgery, ability to receive cisplatinbased adjuvant chemotherapy and ECOG PS 0‐1. Patients with other malignancies, autoimmune disease, hormonal cancer or radiation therapy within 5 years and prior chemotherapy or immunotherapy will be excluded. Approximately 1127 patients will be enrolled regardless of PD‐L1 status. Patients will receive up to four 21‐day cycles of cisplatin‐based chemotherapy (cisplatin [75 mg/m2 IV, day 1] + vinorelbine [30 mg/m2 IV, days 1, 8], docetaxel [75 mg/m2 IV, day 1] or gemcitabine [1250 mg/m2 IV, days 1, 8], or pemetrexed [500 mg/m2 IV, day 1; only non‐squamous NSCLC]). Adjuvant radiation therapy is not permitted. Eligible patients will be randomized 1:1 to receive 16 cycles of atezolizumab 1200 mg q3w or BSC post‐adjuvant chemotherapy. Stratification factors include sex, histology (squamous vs nonsquamous), disease stage (IB vs II vs IIA) and PD‐L1 status by IHC (TC2/3 [≥ 5% expressing PD‐L1] and any IC vs TC0/1 [< 5%], and IC2/3 vs TC0/1 and IC0/1 [< 5%]). The primary endpoint is diseasefree survival, and secondary endpoints include OS and safety. Exploratory biomarkers will be evaluated, including PD‐L1 expression and immune‐ and tumor‐related biomarkers before, during and after treatment with atezolizumab and at radiographic disease recurrence or confirmation of new primary NSCLC. Result: Not applicable. Conclusion: Not applicable.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01451683/full} -} - - -Record #404 of 538 -@article{EUCTR2019-003237-41-FR20, -author = {EUCTR2019-003237-41-FR,}, -title = {Phase 3 Study of Pembrolizumab with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib compared to Concurrent Chemoradiation Therapy Followed by Durvalumab in Stage III NSCLC}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-003237-41-FR}, -year = {2020}, -accession_number = {ICTRP EUCTR2019‐003237‐41‐FR}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: PEMBROLIZUMAB Product Code: MK‐3475 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Pembrolizumab CAS Number: 1374853‐91‐4 Current Sponsor code: MK‐3475 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ Trade Name: KEYTRUDA (pembrolizumab, MK‐3475) Pharmaceutical Form: Solution for infusion INN or Proposed INN: Pembrolizumab CAS Number: 1374853‐91‐4 Current Sponsor code: MK‐3475 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ Product Name: Olaparib Product Code: MK‐7339 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: OLAPARIB CAS Number: 763113‐22‐0 Current Sponsor code: MK‐7339 Other descriptive name: OLAPARIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150‐ Pharmaceutical form of the placebo: Film‐coated tablet Route of administration of the placebo: Oral use Product Name: Olaparib Product Code: MK‐7339 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: OLAPARIB CAS Number: 763113‐22‐0 Current Sponsor code: MK‐7339 Other descriptive name: OLAPARIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Pharmaceutical form of the placebo: Film‐coated tablet Route of administration of the placebo: Oral use Trade Name: Imfinzi Product Name: Durvalumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: DURVALUMAB Other descriptive name: DURVALUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ CONDITION: Therapeutic area: Diseases [C] ‐ Cancer [C04] unresectable, locally advanced, Stage III Non‐Small Cell Lung Cancer (NSCLC) ; MedDRA version: 21.1 Level: PT Classification code 10029519 Term: Non‐small cell lung cancer stage III System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) SECONDARY OUTCOME: Secondary end point(s): 1. Number of Participants Who Experienced At Least One Adverse Event (AE) ; 2. Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) ; 3. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) ; 4. Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) ; 5. Change From Baseline in Health‐Related Quality‐of‐Life (HRQoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30) Items 29 and 30 Score ; 6. Change From Baseline in Cough Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module 13 (EORTC QLQ‐LC13) Item 1 Score ; 7. Change From Baseline in Chest Pain Using the EORTC QLQ‐LC13 Item 10 Score ; 8. Change From Baseline in Dyspnea Using the EORTC QLQ‐C30 Item 8 Score ; 9. Change From Baseline in Physical Functioning Using the EORTC QLQ‐C30 Items 1‐ 5 Score ; 10. Time to Deterioration (TTD) in HRQoL Using the EORTC QLQ‐C30 Items 29 and 30 Score ; 11. TTD in Cough Using the EORTC QLQ‐LC13 Item 1 Score ; 12. TTD in Chest Pain Using the EORTC QLQ‐LC13 Item 10 Score ; 13. TTD in Dyspnea Using the EORTC QLQ‐C30 Item 8 Score ; 14. TTD in Physical Functioning Using the EORTC QLQ‐C30 Items 1‐ 5 Score ; Timepoint(s) of evaluation of this end point: 1. Up to approximately 72 months ; 2. Up to approximately 72 months ; 3. Up to approximately 72 months ; 4. Up to approximately 72 months ; 5. Baseline (Day 1) and up to approximately 72 months ; 6. Baseline (Day 1) and up to approximately 72 months ; 7. Baseline (Day 1) and up to approximately 72 months PRIMARY OUTCOME: Main Objective: 1. To compare pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab plus olaparib to concurrent chemoradiation therapy followed by durvalumab with respect to progression‐free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR).; 2. To compare pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab to concurrent chemoradiation therapy followed by durvalumab with respect to PFS per RECIST 1.1 as assessed by BICR.; 3. To compare pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab plus olaparib to concurrent chemoradiation therapy followed by durvalumab with respect to Overall Survival (OS).; 4. To compare pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab to concurrent chemoradiation therapy followed by durvalumab with respect to OS.; Primary end point(s): 1. Progression‐Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); 2. Overall Survival (OS); Secondary Objective: 1. To evaluate the safety and tolerability of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab alone or with olaparib compared to concurrent chemoradiation therapy followed by durvalumab.; 2. To compare pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab alone or with olaparib to concurrent chemoradiation therapy followed by durvalumab with respect to Objective Response Rate (ORR) and Duration of Response (DOR) per RECIST 1.1 as assessed by BICR.; 3. To evaluate the change from baseline (at Cycle 1) and the time to deterioration (TTD) in global health status/quality of life (QoL), cough, chest pain, dyspnea and physical functioning following treatment with pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab alone or with olaparib compared to concurrent chemoradiation therapy followed by durvalumab.; Timepoint(s) of evaluation of this end point: 1. Up to approximately 48 months; 2. Up to approximately 72 months; ; 8. Baseline (Day 1) and up to approximately 72 months ; 9. Baseline (Day 1) and up to approximately 72 months ; 10. Baseline (Day 1) and up to approximately 72 months ; 11. Baseline (Day 1) and up to approximately 72 months ; 12. Baseline (Day 1) and up to approximately 72 months ; 13. Baseline (Day 1) and up to approximately 72 months ; 14. Baseline (Day 1) and up to approximately 72 months ; INCLUSION CRITERIA: 1. Has pathologically (histologically or cytologically) confirmed NSCLC. 2. Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8. 3. Is unable to undergo surgery with curative intent for Stage III NSCLC as documented by a multidisciplinary tumor board or by the treating physician in consultation with a thoracic surgeon. 4. Has no evidence of metastatic disease, indicating Stage IV NSCLC, in whole‐body fluorodeoxyglucose (FDG)‐PET or FDG‐PET/CT and CT or MRI scans of diagnostic quality of chest, abdomen, pelvis and brain. 5. Has measurable disease as defined by RECIST 1.1, with at least one lesion being appropriate for selection as a target lesion, as determined by local site investigator/radiology review. 6. Has not received prior treatment (chemotherapy, targeted therapy or radiotherapy) for their Stage III NSCLC. 7. Has provided tumor tissue sample (tissue biopsy [core, incisional, or excisional]). FFPE bl}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169386/full} -} - - -Record #405 of 538 -@article{EUCTR2016-000109-35-GB17, -author = {EUCTR2016-000109-35-GB,}, -title = {A Phase I-II Trial of Combination Nab-paclitaxel and Nintedanib or Nab-paclitaxel and Placebo in Relapsed Non-Small Cell Lung Cancer Adenocarcinoma - N3 Study}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2016-000109-35-GB}, -year = {2017}, -accession_number = {ICTRP EUCTR2016‐000109‐35‐GB}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Trade Name: VARGATEF Product Name: VARGATEF Pharmaceutical Form: Capsule, soft INN or Proposed INN: Nintedanib esylate CAS Number: 656247‐18‐6 Current Sponsor code: BIBF 1120 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use Trade Name: Abraxane Product Name: Abraxane Pharmaceutical Form: Powder for suspension for injection INN or Proposed INN: Paclitaxel CAS Number: 33069‐62‐4 Current Sponsor code: ABI‐007 Concentration unit: mg/m2 milligram(s)/square meter Concentration type: equal Concentration number: 100‐ CONDITION: Relpased advanced or metastatic non‐small cell lung cancer of adenocarcinoma histology ; MedDRA version: 19.1 Level: PT Classification code 10025033 Term: Lung adenocarcinoma recurrent System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) ; MedDRA version: 19.1 Level: PT Classification code 10064049 Term: Lung adenocarcinoma metastatic System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) ; MedDRA version: 19.1 Level: PT Classification code 10025038 Term: Lung adenocarcinoma stage IV System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) ; MedDRA version: 19.1 Level: PT Classification code 10025037 Term: Lung adenocarcinoma stage III System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] SECONDARY OUTCOME: ; Secondary end point(s): ‐ To evaluate the frequency of all adverse events graded by NCI‐CTCAE version 4.0; ‐ To define number of cycles of nintedanib and nab‐paclitaxel given; ‐ To evaluate the objective tumour response and overall response rates by RECIST version 1.1; ‐ To explore the overall survival rates by treatment arm in ITT and predefined subgroups by time to progression after start of 1st line treatment and by previous immunotherapy; Timepoint(s) of evaluation of this end point: End of trial PRIMARY OUTCOME: ; Main Objective: The study is divided into 2 parts: Part 1 is the Phase Ib portion of the trial and Part 2 is the Phase II portion of the trial. Once the Trial Steering Committee has completed the dose limiting toxicity (DLT) assessment for Part 1 and confirmed RP2D for Part 2, Part 2 enrolment will proceed.; ; The objective(s) for each part are as follows:; Part 1: The objective of Part 1 is to evaluate the safety and tolerability of combination nab‐paclitaxel and nintedanib in patients with stage IIIb and IV adenocarcinoma of the lung in second and third treatment line setting and to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of nintedanib when given with nab‐paclitaxel at 100mg/m2 d1, d8 q21.; Part 2: The primary objective of Part 2 is to explore the efficacy of combination nab‐paclitaxel and nintedanib versus nab‐paclitaxel and placebo in the same patient population, with nintedanib/placebo given at the recommended phase 2 dose (RP2D) as defined during part 1 of the stu; ; Primary end point(s): The study is divided into 2 parts. Part 1 is the Phase Ib portion of the trial and Part 2 is the Phase II portion of the trial.; The primary outcome measure of Part 1 is the recommended phase 2 dose (RP2D).; The primary outcome measure of Part 2 is the progression free survival rate at 12 weeks from first dose of nab‐paclitaxel and nintedanib or nab‐paclitaxel and placebo in relapsed advanced or metastatic adenocarcinoma non‐small cell lung cancer.; The progression free survival (PFS) time is measured from first dose of IMP to the date of radiographic documentation of progression (as defined by RECIST v. 1.1) based on investigator assessment, or the date of death due to any cause, whichever is earlier. Patients who have neither progressed nor died will be censored at the day of their last radiographic tumor assessment.; ; Secondary Objective: Secondary objectives for Part 1:; • To examine the frequency of all adverse events graded by NCI‐CTCAE version 4.0.; • To examine the objective tumour response according to RECIST 1.1 criteria (investigator reported), and the overall response rate; •To explore the number of cycles of nab‐paclitaxel with nintedanib given; ; Secondary objectives for Part 2:; • To examine the frequency of all adverse events graded by NCI‐CTCAE version 4.0.; • To examine the objective tumour response according to RECIST 1.1 criteria (investigator reported), and the overall response rate.; • To examine overall survival in the intention to treat population and in two predefined subgroups: according to progressive disease before or after 9 months from start of first line systemic therapy; and according to prior or no prior immunotherapy.; Timepoint(s) of evaluation of this end point: At 12 weeks after 1st dose of phase II study treatment INCLUSION CRITERIA: Patients must meet all of the following criteria to be enrolled in the study: 1. Male or female patients aged 18 or over. 2. Patients with a pathologically confirmed diagnosis of stage III or stage IV adenocarcinoma of the lung; patients with locally recurrent disease (stage IIIa) and no radical treatment options are also eligible. 3. Patients who have previously received no more than 2 lines of systemic therapy for NSCLC with palliative intent: i. Chemotherapy as first‐line or more with palliative intent ii. Relapsing within 6 months of adjuvant chemotherapy after surgery or as part of radical chemo‐radiotherapy, which count as one line of therapy. iii. Licenced or experimental maintenance therapy is allowed (eg.pemetrexed) iv. Immunotherapy at prior line of treatment (first or second line) is=50%) NSCLC SECONDARY OUTCOME: ‐To assess the dose‐response relationship of novel immunotherapy combinations across a range of the novel components' dose levels and fixed dostarlimab dose (may not apply to all novel combinations); ‐To further assess the clinical activity of novel immunotherapy combinations compared with pembrolizumab in participants with PD‐L1‐high (TC/TPS>=50%) NSCLC; ‐To evaluate the antitumor activity of novel immunotherapy combinations via treatment arm comparisons for assessment of contribution of components for the combination regimens; ‐To further characterize the safety of novel immunotherapy combinations; ‐To determine the immunogenicity of individual agents comprising novel immunotherapy combinations; ‐To characterize the PK properties of novel immunotherapy combinations INCLUSION CRITERIA: Participant must be more than or equal to (>=)18 years of age. Has a histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or nonsquamous). Has not received prior systemic therapy for their locally advanced or metastatic NSCLC. Provides a tumor tissue sample obtained at the time of or after the initial diagnosis of locally advanced or metastatic NSCLC. Has a PD‐L1‐high (TC/TPS‐50%) tumor as determined by the DAKO 22C3 or VENTANA SP263 assay performed by a local laboratory or by the VENTANA SP263 assay at a central laboratory. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0‐1. Adequate organ function per protocol specifications. Male or female participants. Female participants are eligible to participate if they are not breastfeeding or pregnant (or intend to brea}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02538688/full} -} - - -Record #411 of 538 -@article{Kareff24, -author = {Kareff, SA, Han, S, Haaland, B, Jani, CJ, Kohli, R, Aguiar, PN, Huang, Y, Soo, RA, Rodriguez-Perez, A, Garcia-Foncillas, J, Domine, M, and de Lima Lopes, G}, -title = {International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer}, -journal = {JAMA network open}, -volume = {7}, -number = {5}, -pages = {e2413938}, -year = {2024}, -accession_number = {EMBASE 644397311, PUBMED 38814640}, -publication type = {Journal article}, -keywords = {*cost benefit analysis; *lung tumor; *non small cell lung cancer; Aged; Brazil; Cancer staging; Cost effectiveness analysis; Drug therapy; Economics; Female; Human; Male; Markov chain; Middle aged; Quality adjusted life year; Singapore; Spain; United States}, -abstract = {Importance: Standard of care for unresectable locally advanced non‐small cell lung cancer (NSCLC) involves definitive chemoradiotherapy followed by maintenance therapy with durvalumab. However, the cost of durvalumab has been cited as a barrier to its use in various health systems. Objective: To evaluate the cost‐effectiveness of durvalumab vs placebo as maintenance therapy in patients with unresectable stage III NSCLC from 4 international payer perspectives (US, Brazil, Singapore, and Spain). Design, Setting, and Participants: In this economic evaluation, a Markov model was designed to compare the lifetime cost‐effectiveness of maintenance durvalumab for unresectable stage III NSCLC with that of placebo, using 5‐year outcomes data from the PACIFIC randomized placebo‐controlled trial. Individual patient data were extracted from the PACIFIC, KEYNOTE‐189, ADAURA, ALEX, and REVEL randomized clinical trials to develop a decision‐analytic model to determine the cost‐effectiveness of durvalumab compared with placebo maintenance therapy over a 10‐year time horizon. Direct costs, adverse events, and patient characteristics were based on country‐specific payer perspectives and demographic characteristics. The study was conducted from June 1, 2022, through December 27, 2023. Main Outcomes and Measures: Life‐years, quality‐adjusted life years (QALYs), lifetime costs, and incremental cost‐effectiveness ratios (ICERs) were estimated at country‐specific willingness‐to‐pay thresholds ([data reported in US$] US: $150 000 per QALY; Brazil: $22 251 per QALY; Singapore: $55 288 per QALY, and Spain: $107 069 per QALY). One‐way and probabilistic sensitivity analyses were performed to account for parameters of uncertainty. A cost‐threshold analysis was also performed. Results: The US base‐case model found that treatment with durvalumab was associated with an increased cost of $114 394 and improved effectiveness of 0.50 QALYs compared with placebo, leading to an ICER of $228 788 per QALY. Incremental cost‐effectiveness ratios, according to base‐case models, were $141 146 for Brazil, $153 461 for Singapore, and $125 193 for Spain. Durvalumab price adjustments to the PACIFIC data improved cost‐effectiveness in Singapore, with an ICER of $45 164. The model was most sensitive to the utility of durvalumab. Conclusions and Relevance: In this cost‐effectiveness analysis of durvalumab as maintenance therapy for unresectable stage III NSCLC, the therapy was found to be cost‐prohibitive from the perspective of various international payers according to country‐specific willingness‐to‐pay thresholds per QALY. The findings of the study suggest that discounted durvalumab acquisition costs, as possible in Singapore, might improve cost‐effectiveness globally.}, -DOI = {10.1001/jamanetworkopen.2024.13938}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02708073/full} -} - - -Record #412 of 538 -@article{Mitchell21, -author = {Mitchell, P, O'Byrne, KJ, Brown, C, Jurkovic, H, Karapetis, CS, Kok, PS, Lao, L, Le, HV, Pavlakis, N, Ab Rahman, AS, Subramaniam, S, Walker, M, Yip, S, Stockler, MR, and Siva, S}, -title = {A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD)}, -journal = {International journal of radiation oncology, biology, physics}, -volume = {111}, -number = {3}, -pages = {S10‐S11}, -year = {2021}, -accession_number = {EMBASE 636623692, PUBMED 34700388}, -publication type = {Journal article}, -keywords = {*advanced cancer; *cancer chemotherapy; *cancer radiotherapy; *non small cell lung cancer; *stereotactic body radiation therapy; Adult; Adverse drug reaction; Aged; Article; Cancer survival; Clinical trial; Controlled study; Current smoker; Drug safety; Drug therapy; ECOG Performance Status; Follow up; Human; Immunotherapy; Major clinical study; Male; Overall survival; Pharmacokinetics; Phase 2 clinical trial; Progression free survival; Randomized controlled trial; Sample size; Side effect}, -abstract = {PURPOSE/OBJECTIVE(S): Synergy and abscopal phenomena have been observed with radiation and immunotherapy in pre‐clinical and early clinical studies. Nivolumab, a PD‐1 receptor antibody, improved overall survival in advanced NSCLC progressing after chemotherapy. We hypothesized that the addition of SABR might increase the activity of nivolumab. The aim of NIVORAD was to determine the activity and safety of treating a site of disease with a single fraction of SABR during therapy with nivolumab in advanced NSCLC progressing after 1 or 2 lines of chemotherapy. MATERIALS/METHODS: Adults with metastatic NSCLC progressing after 1 or 2 lines of chemotherapy and a disease site suitable for SABR were randomly assigned (2:1) to either nivolumab 240mg 2‐weekly until disease progression or prohibitive toxicity given together with a single fraction of SABR (18‐20 Gy on day 8‐14 of cycle 1); or, the same regimen of nivolumab without SABR. The primary endpoint was progression‐free survival (PFS) at 6 months. Secondary endpoints included objective tumor response rate (OTRR), overall survival (OS), PFS at 1 year and 2 years, and adverse events (AEs). The planned sample size of 120 provided 80% power with a 1‐sided type 1 error rate of 5% to distinguish the observed proportions alive and progression free at 6 months from benchmarks of 50% (worthy of pursuit) versus 35%. The study was closed early because of slow accrual. RESULTS: Fifty of the planned 120 participants were recruited from MAR2017 to JUN2019 (median age 66 years; male 58%; ECOG PS 0 32%, PS 1 68%; current smoker 30%) and randomly assigned to either nivolumab plus SABR (n = 34) or nivolumab alone (n = 16). Median follow‐up was 25 months. PFS was similar among those assigned nivolumab plus SABR versus nivolumab alone (HR = 0.82, 95% CI 0.44 to 1.54, P = 0.6; PFS at 6mo 44% vs 43%, at 1y 27% vs 19%, and at 2y 16% vs 6%, respectively). OTRR (8/34 [24%] vs 4/16 [25%]) and OS (HR 0.94, P = 0.9) were also similar in the two treatment groups, as were the numbers of participants with grade 3‐4 AEs: 24/30 (80%) vs 12/16 (75%) respectively. There were no treatment‐related deaths in either arm. CONCLUSION: Nivolumab plus SABR demonstrated similar activity and safety to nivolumab alone in NSCLC progressing after 1 or 2 lines of chemotherapy, with a potential signal of long‐term efficacy, although the study was underpowered to detect this. Research should focus on identifying more active regimens of SABR and immunotherapy worthy of further evaluation.}, -DOI = {10.1016/j.ijrobp.2021.07.056}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02357062/full} -} - - -Record #413 of 538 -@article{Lu22, -author = {Lu, S, Wang, J, Yu, Y, Yu, X, Hu, Y, Ma, Z, Li, X, He, W, Bao, Y, and Wang, M}, -title = {Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC): RATIONALE-304 updated analysis}, -journal = {Immuno-oncology and technology}, -volume = {16}, -year = {2022}, -accession_number = {EMBASE 2021560381}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer chemotherapy; *drug tolerability; *non small cell lung cancer; Adult; Cancer staging; Cancer surgery; Cancer survival; Clinical trial; Conference abstract; Controlled study; Drug safety; Drug therapy; Financial management; Follow up; Human; Incidence; Male; Medical literature; Overall response rate; Overall survival; Parttime employment; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Vascular guide wire}, -abstract = {Background: Interim analysis of the open‐label phase 3 RATIONALE‐304 study (NCT03663205) demonstrated clinical benefit of tislelizumab (TIS) plus chemotherapy (chemo) as first‐line (1L) therapy in patients with advanced nsq‐NSCLC vs chemo alone, with significantly improved progression‐free survival (PFS) and a manageable safety profile. Here, we report the updated results. Methods: Adults with treatment‐naive, stage IIIB (not amenable to curative surgery/radiotherapy)/IV nsq‐NSCLC were randomized (2:1) to receive platinum (carboplatin or cisplatin) and pemetrexed (PEM) every 3 weeks either with TIS (Arm A) or without (Arm B), followed by maintenance TIS + PEM (Arm A) or PEM (Arm B). The primary endpoint was PFS in Arm A vs Arm B, per independent review committee (IRC). Secondary endpoints included overall survival, objective response rate (ORR), duration of response (DoR), and safety. Results: As of 15 July 2022, the median PFS per IRC was 9.8 (95% confidence interval [CI]: 8.9, 11.7) vs 7.6 (95% CI: 5.4, 8.0) months (mo) in Arm A vs Arm B, respectively (stratified hazard ratio 0.61 [95% CI: 0.46, 0.82]). ORR was greater in Arm A (51.6% [95% CI: 44.8, 58.3]) vs Arm B (27.9% [95% CI: 19.8, 37.2]) and median DoR was longer (14.5 [95% CI: 10.1, 24.4] vs 8.4 [95% CI: 6.0, 15.5] mo, respectively). TIS plus chemo was tolerable with no new safety signals identified after longer follow‐up. The incidences of ≥grade 3 treatment‐emergent adverse events (TEAEs) and of TEAEs leading to death (including disease progression‐related AEs) in Arm A and Arm B were 69.4% and 56.4%, and 4.1% and 1.8%, respectively. Conclusions: In RATIONALE‐304, the addition of TIS to platinum plus PEM continued to demonstrate favorable efficacy and was generally well tolerated as 1L treatment of advanced nsq‐NSCLC vs chemo alone, with no new safety signals identified. Clinical trial identification: NCT03663205. Editorial acknowledgement: This study was sponsored by BeiGene, Ltd. Medical writing support, under the direction of the authors, was provided by Arezou Hossein, MPharm, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd. Legal entity responsible for the study: BeiGene, Ltd. Funding: BeiGene, Ltd. Disclosure: S. Lu: Financial Interests, Personal, Other, Research support: AstraZeneca, Hutchison, BMS, Heng Rui Beigene and Roche, Hansoh; Financial Interests, Personal, Other, Speaker fees: AstraZeneca, Roche, Hansoh; Financial Interests, Personal, Advisory Role: AstraZeneca, Pfizer, Hutchison MediPharma, ZaiLab, GenomiCare, Novarti, Yuhan Corporation, Menarini, Mirati Therapeutics Inc, and Roche. W. He, Y. Bao: Financial Interests, Personal, Full or part‐time Employment: BeiGene, Ltd. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.iotech.2022.100250}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02517172/full} -} - - -Record #414 of 538 -@article{ACTRN1261600035240416, -author = {ACTRN12616000352404,}, -title = {NIVORAD - A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12616000352404}, -year = {2016}, -accession_number = {ICTRP ACTRN12616000352404}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Nivolumab 240mg every 2 weeks plus Stereotactic Ablative Body Radiotherapy (SABR). Nivolumab (240mg) will be administered as an intravenous infusion every 2 weeks until disease progression or prohibitive toxicity. SABR (18‐20 Gy) will be administered to a single lesion between days 8 ‐ 14 of cycle 1 of Nivolumab. The specific day of SABR will be at clinical discretion of the treating radiation oncologist. Participants will receive 1 or 2 fractions of SABR, dependent on tumour location, determined by clinical discretion of the treating radiologist. Each SABR treatment will take approximately 1 hour. CONDITION: Advanced non‐small cell lung cancer, progressing after first of second line chemotherapy PRIMARY OUTCOME: Progression free survival (PFS) at 6 months (RECIST 1.1) SECONDARY OUTCOME: Adverse events (CTCAE v4.03 and RTOG/EORTC RMSS) Objective tumour response rate (OTRR, RECIST 1.1) Overall survival (OS) at 1 year and 2 years ; Overall Survival will be measured as the interval from the date of randomisation to the date of death from any cause. ; ; Progression Free Survival (PFS) at 1 year and 2 years. ; Progression Free Survival will be measured at the interval between the date of randomisation until the date that disease progression is first observed, or the date of death from any cause, whichever occurs first. Disease progression will be determined by a comparing imaging (scans) of documented disease prior to treatment to the first positive scan following study treatment. Tertiary studies aim to identify predictive biomarkers that will allow us to select patients most likely to respond to, and derive benefit from this treatment as well as the presence of other biomarkers whose presence may be indicative of better or worse longer term outcomes such as survival. These may include biomarkers which are often studied amongst patients with non‐small cell lung cancer such as PD‐L1 expression, EGFR and KRAS mutational status but also novel biomarkers relating to effects of radiation on the immune response. INCLUSION CRITERIA: 1. Adult (18 years or over) with a histologically or cytologically confirmed diagnosis of NSCLC. 2. At least one site of metastasis which is suitable for stereotactic radiotherapy, but for which radiotherapy is not urgently required at the time of enrollment. This must be outside of BOTH the thorax, and the central nervous system, and must not have been previously irradiated. The lesion/s is not required to be measurable or evaluable and must be nominated before randomisation. This lesion will be irradiated in patients randomised to receive radiation. 3. At least one lesion (target or non‐target according to RECIST 1.1) that is separate and in addition to the lesion nominated for irradiation. This lesion cannot have been irradiated previously. 4. Must have relapsed after receiving 1 or 2 lines of chemotherapy for advanced disease including a platinum‐based doublet. Maintenance chemotherapy following first line chemotherapy is considered a second line of}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01857759/full} -} - - -Record #415 of 538 -@article{Mitchell17, -author = {Mitchell, P, Siva, S, Sei Kok, P, O'Byrne, K, Yeung, A, Livingstone, A, Donoghoe, M, Yip, S, and Stockler, MR}, -title = {NIVORAD: a randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy}, -journal = {Journal of clinical oncology}, -volume = {35}, -number = {15}, -year = {2017}, -accession_number = {EMBASE 617435981}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemotherapy; *controlled study; *non small cell lung cancer; Adverse drug reaction; Australia and New Zealand; Blood; Cancer epidemiology; Clinical trial; Controlled clinical trial; Drug therapy; Female; Gene expression; Histology; Human; Human tissue; Immunotherapy; Major clinical study; Male; Metastasis; Overall survival; Progression free survival; Radiation oncology; Radiotherapy; Randomized controlled trial; Register; Sample size; Side effect; Translational research; University}, -abstract = {Background: Recent data has demonstrated improvements in overall survival in patients with advanced non‐small cell lung cancer (NSCLC) treated with nivolumab. Radiation may augment the immune response through abscopal effects ‐ evidence of tumour control at sites other than those irradiated. We hypothesize that the addition of stereotactic ablative body radiotherapy (SABR) to immunotherapy with nivolumab will improve progression free survival (PFS) compared with nivolumab alone. Methods: DESIGN: Open label, randomised phase II trial with 25 sites across Australia and New Zealand. ELIGIBILITY: Metastatic NSCLC progressing after 1 or 2 lines of chemotherapy with an extrapulmonary metastasis suitable for SABR. STRATIFICATION: Age, lines of chemotherapy, histology and treating institution. TREATMENT: A single dose of SABR (18‐20Gy) plus nivolumab or nivolumab alone (240mg 2‐weekly) given until disease progression or prohibitive adverse events. ENDPOINTS: PFS at 6 months (PFS6; primary), objective tumour response rate, adverse events, overall survival, PFS at 1 and 2 years. Tertiary correlative objectives include associations between possible prognostic/ predictive biomarkers and outcomes (including PD‐L1 expression). STATISTICS : Total sample size of 120 participants allocated in a ratio of 2:1, 80 to nivolumab + SABR and 40 nivolumab alone to provide 80% power, one‐sided type I error rate of 5% for PFS6 of 50% (worthy of pursuit) vs 35% (not worthy of pursuit). BIOSPECIMENS: Tumour tissue and serial bloods (4 time points) will be collected for translational research. CURRENT ENROLLMENT (as of Feb 2017): 2 out of 20 sites are open. NIVORAD is an investigator‐initiated, cooperative‐group trial led by the ALTG in collaboration with the NHMRC Clinical Trials Centre, University of Sydney and the Trans Tasman Radiation Oncology Group (TROG). Australian New Zealand Clinical Trials Registry: ACTRN12616000352404.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01397242/full} -} - - -Record #416 of 538 -@article{EUCTR2019-002660-27-NL20, -author = {EUCTR2019-002660-27-NL,}, -title = {Study of capmatinib and pembrolizumab in lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-002660-27-NL}, -year = {2020}, -accession_number = {ICTRP EUCTR2019‐002660‐27‐NL}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: INC280 Product Code: INC280 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: capmatinib Current Sponsor code: INC280 Other descriptive name: INC280 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150‐ Product Name: INC280 Product Code: INC280 Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: capmatinib Current Sponsor code: INC280 Other descriptive name: INC280 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200‐ CONDITION: non‐small cell lung cancer Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: To evaluate the efficacy of capmatinib plus pembrolizumab in comparison to pembrolizumab alone Primary end point(s): Progression‐free survival (PFS) based on local investigator assessment as per RECIST 1.1 Secondary Objective: • To evaluate the anti‐tumor activity of capmatinib plus pembrolizumab in comparison to pembrolizumab alone; • To characterize the safety profile of capmatinib plus pembrolizumab and pembrolizumab alone; • To characterize the pharmacokinetics of capmatinib and pembrolizumab ; • To evaluate the prevalence and incidence of immunogenicity of pembrolizumab ; Timepoint(s) of evaluation of this end point: at primary analysis (once 50 subjects have experienced a PFS event) and at final analysis after completion of the study SECONDARY OUTCOME: Secondary end point(s): • Objective response rate (ORR), disease control rate (DCR), time‐to‐response (TTR) and duration of response (DOR) based on local investigator assessment as per RECIST 1.1 and overall survival (OS) ; • Incidence and severity of AEs and SAEs, AEs leading to dose interruption, dose reduction and dose discontinuation ; • Pharmacokinetic parameters and concentration ; • Antidrug antibodies (ADA) prevalence at baseline and ADA incidence on treatment of pembrolizumab ; Timepoint(s) of evaluation of this end point: at primary analysis (once 50 subjects have experienced a PFS event) and at final analysis after completion of the study INCLUSION CRITERIA: • Histologically confirmed and documented locally advanced stage III (not candidates for surgical resection or definitive chemo‐radiation) or stage IV (metastatic) NSCLC (per AJCC/IASLC v.8) for treatment in the first‐line setting ‐ Treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy (other than immunotherapies) is allowed as long as therapy was completed at least 6 months prior to the diagnosis of advanced or metastatic disease. • Histologically or cytologically confirmed diagnosis of NSCLC that is both EGFR wild type status and ALK‐ negative rearrangement status: ‐ Patients with NSCLC of pure squamous cell histology can enter screening without EGFR mutation or ALK rearrangement testing or result; however, patients with pure squamous cell histology who are known to have EGFR mutations in exons 19 or 21 or ALK rearrangements will be excluded. • Have an archival tumor sample or newly obtained tumor biopsy}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169309/full} -} - - -Record #417 of 538 -@article{Gomez13, -author = {Gomez, RE, Macias, A, Crombet, T, Vazquez, AM, Perez, R, Ardigo, ML, and Lage, A}, -title = {Trial proactive: a prospective, randomized, multicenter, open label phase III study of active specific immunotherapy with racotumomab plus best support treatment versus best support treatment in patients with advanced non-small cell lung cancer}, -journal = {Journal of clinical oncology}, -volume = {31}, -number = {15}, -year = {2013}, -accession_number = {EMBASE 71102249}, -publication type = {Journal article; Conference proceeding}, -keywords = {*human; *immunotherapy; *non small cell lung cancer; *oncology; *patient; *society; Breast cancer; Cancer immunotherapy; Chemotherapy; Death; Double blind procedure; Hazard ratio; Human cell; Humoral immunity; Immunogenicity; Log rank test; Melanoma; Neoplasm; Normal human; Open study; Overall survival; Professional standard; Progression free survival; Radiotherapy; Safety; Survival; Therapy; Toxicity; Tumor growth; Vaccination}, -abstract = {Background: Gangliosides, especially NeuGc‐GM3, are attractive targets for cancer immunotherapy. They are not expressed in normal human cells but are overexpressed and involved in tumor growth in several tumors (melanoma, neuroectodermal pediatric tumors and breast cancer). More than 70% of non‐small cell lung cancers (NSCLC) express NeuGc‐GM3. Racotumomab is an anti‐idiotypic monoclonal antibody that mimics NeuGc gangliosides. Administered as a therapeutic vaccine it acts as an antigen, inducing a cellular and humoral immune response against NeuGc‐GM3 and other gangliosides. Previous trials have shown its low toxicity and high immunogenicity. Recently, a multicenter, randomized, placebo controlled, double‐blind trial in 176 NSCLC (IIIB and IV) patients with at least stable disease after first line therapy and progression free at inclusion showed a statistical significant survival benefit in favor of racotumomab. Methods: This phase III, multinational, randomized (1:1), open label trial will evaluate efficacy and safety of racotumomab plus best supportive care (BSC) versus BSC. 1,082 patients with NSCLC (stages III or IV) showing response or stable disease after standard first‐line therapy (platinum‐based chemotherapy and radiotherapy) are eligible if they remain free of progression and have a PS 1. Vaccination consists of an induction period (5 doses, 1 every 14 days) followed by a maintenance period (1 dose every 28 days, until worsening of the PS or unacceptable toxicity occur). Upon progression other onco‐specific therapies may be used and vaccination can continue. Overall survival (OS) will be compared using a two‐sided log rank test at a significance level (alpha) of 0.05 with 90% power to detect a hazard ratio of 0.79. There will be 3 interim analyses and a final analysis when 758 deaths occur. So far 190 patients have been randomized. An Independent Data Monitoring Committee oversees the study and has so far (last meeting September 2012) concluded that the trial can continue.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01026395/full} -} - - -Record #418 of 538 -@article{Mitchell18, -author = {Mitchell, P, Siva, S, Mersiades, A, O'Byrne, K, Chinchen, S, Brown, C, Yip, S, and Stockler, MR}, -title = {NIVORAD: a randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy (SABR) in advanced non-small cell lung cancer (NSCLC), progressing after first- or second-line chemotherapy}, -journal = {Asia-Pacific journal of clinical oncology}, -volume = {14}, -number = {Supplement 7}, -pages = {201}, -year = {2018}, -accession_number = {EMBASE 625146314}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer chemotherapy; *cancer radiotherapy; *non small cell lung cancer; Adult; Adverse event; Cancer prognosis; Cancer survival; Conference abstract; Controlled study; Disease exacerbation; Drug therapy; Female; Gene expression; Histology; Histopathology; Human; Human tissue; Major clinical study; Male; Metastasis; Overall survival; Phase 2 clinical trial; Progression free survival; Protein expression; Radiotherapy; Randomized controlled trial; Translational research}, -abstract = {Background: Recent data has demonstrated improvements in overall survival in patientswithNSCLCtreated with nivolumab. Radiationmay augment the immune response through abscopal effects ‐ evidence of tumour control at sites other than those irradiated. We hypothesise that the addition of SABR to immunotherapy with nivolumab will improve progression free survival (PFS) compared with nivolumab alone. Methods: DESIGN: open label, randomised phase II trial. ELIGIBILITY: metastatic NSCLC progressing after 1 or 2 lines of chemotherapy with an asymptomatic site of metastasis suitable for SABR. STRATIFICATION: age, lines of chemotherapy, histology and treating institution. TREATMENT: A single dose of SABR (18‐20Gy) delivered during cycle 1 (Day 8‐14) of nivolumab or nivolumab alone (240mg 2‐weekly) given until disease progression or prohibitive adverse events. ENDPOINTS: PFS at 6 months (PFS6; primary), objective tumour response rate, adverse events, overall survival, PFS at 1 and 2 years, associations between possible prognostic/predictive biomarkers and outcomes (including PD‐L1 expression). STATISTICS: 120 participants allocated in a ratio of 2:1, 80 to nivolumab + SABR and 40 nivolumab alone to provide 80% power, one‐sided type I error rate of 5%for PFS6 of 50% (worthy of pursuit) vs 35% (not worthy of pursuit). BIOSPECIMENS: Tumour tissue and serial bloods will be collected for translational research. CURRENT ENROLMENT (as of 3 Aug 2018): 15 sites open across ANZ, 22 patients have been enrolled. NIVORAD is an investigator‐initiated, cooperative‐group trial led by theAustralasian Lung Cancer Trials Group (ALTG) in collaboration with the NHMRC Clinical Trials Centre, University of Sydney and the Trans Tasman RadiationOncology Group (TROG).}, -DOI = {10.1111/ajco.13089}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01669373/full} -} - - -Record #419 of 538 -@article{ChiCTR210005095221, -author = {ChiCTR2100050952,}, -title = {A randomized, double-blind, placebo-controlled clinical study evaluating probiotic Bifidobacterium lactis V9 (Kex02) combined with immune checkpoint inhibitors and platinum-containing doublet in the treatment of non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2100050952}, -review groups = {Complementary Medicine}, -year = {2021}, -accession_number = {ICTRP ChiCTR2100050952}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Control group:placebo;Experimental group:lactic acid beneficial metabolites; CONDITION: lung cancer PRIMARY OUTCOME: Observation of clinical efficacy indicators;Intestinal mucosal barrier;Inflammatory factors;Changes in the intestinal flora;Intestinal flora metabolomics; INCLUSION CRITERIA: 1. Subjects aged >=18 years at the start of the study, regardless of gender; 2. Histologically or cytologically confirmed NSCLC, and participants with stage III inoperable or IV tumors (as judged by the International Association for the Study of Lung Cancer (IASLC) Thoracic Tumor Staging Manual, 8th Edition); 3. Gene detection EGFR(‐), ALK(‐) subjects; 4. Subjects must have measurable lesions according to RECIST 1.1 criteria; 5. The ECOG score is at least 0 or 1; 6. Systemic subjects who have received any number of operations, interventional therapy, chemotherapy, radiotherapy, etc. must meet all the following entry criteria to be eligible to enter this study; 7. The subject has not received systemic chemotherapy and immunotherapy for advanced/metastatic NSCLC before; 8. The expected survival period is greater than 6 months; 9. The functions of vital organs meet the following requirements (any blood components, cell growth factors, wh}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02408728/full} -} - - -Record #420 of 538 -@article{Jabbour22, -author = {Jabbour, SK, Houghton, B, Robinson, AG, Quantin, X, Wehler, T, Kowalski, D, Ahn, M-J, Erman, M, Giaccone, G, Borghaei, H, McLean, J, Xu, Y, Souza, F, and Pall, G}, -title = {Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non-small cell lung cancer (NSCLC): KEYNOTE-867}, -journal = {Journal of clinical oncology}, -volume = {40}, -number = {16}, -year = {2022}, -accession_number = {EMBASE 638842196}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *cancer staging; *non small cell lung cancer; *stereotactic body radiation therapy; Adult; Asia; Cancer recurrence; Cancer surgery; Clinical trial; Conference abstract; Controlled study; Disease specific survival; Distant metastasis; Drug safety; Drug therapy; Drug withdrawal; ECOG Performance Status; Event free survival; Female; Histopathology; Human; Kaplan Meier method; Log rank test; Major clinical study; Male; Phase 3 clinical trial; Primary tumor; Randomization; Randomized controlled trial; Recurrent disease}, -abstract = {Background: Anti‐PD‐(L)1‐directed therapy following radiotherapy or following concurrent chemoradiation is associated with significantly longer PFS and OS in patients with advanced or metastatic NSCLC, including those with locally advanced inoperable tumors. KEYNOTE‐867 (NCT03924869) evaluates the efficacy and safety of SBRT with or without pembrolizumab in patients with unresected stage I or II NSCLC. Methods: In this phase 3, randomized, placebo‐controlled study, approximately 530 adult patients with previously untreated, unresected, histologically/cytologically confirmed stage I or II (T1 to limited T3, N0, M0) NSCLC are randomized 1:1 to receive thoracic SBRT to primary tumors for ≤2 wk (Table) and either pembrolizumab 200 mg or placebo every 3 wk for 17 cycles (approximately 1 year) or until disease recurrence, development of unacceptable AEs, SBRT not started for any reason, or study withdrawal. Randomization is stratified by disease stage (I vs II), ECOG PS (0 or 1 vs 2), geographic region (East Asia vs non‐East Asia), and reason for not receiving surgery (medically inoperable vs refused surgery). Imaging assessment by blinded independent central review (BICR) occurs at 12 wk (≥10 wk after SBRT completion), followed by every 16 wk for 3 y, and then every 6 mo. Primary endpoints are event‐free survival (EFS) by BICR and OS. Secondary endpoints include time to death or distant metastases and safety; exploratory endpoints are time to subsequent treatment, disease‐specific survival, and time to recurrence/progression on subsequent line of therapy. AEs are monitored throughout the trial until 30 d after last dose (90 for serious AEs) and graded according to NCI CTCAE version 4.0. EFS and OS are analyzed by the nonparametric Kaplan‐Meier method, treatment differences by stratified log‐rank test, and hazard ratios by stratified Cox proportional hazard model with Efron's method of tie handling. Enrollment started on June 17, 2019, and is ongoing at 168 sites around the world.}, -DOI = {10.1200/JCO.2022.40.16_suppl.TPS8597}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02459543/full} -} - - -Record #421 of 538 -@article{Lee22, -author = {Lee, SY, Lee, JE, Choi, C-M, Oh, I-J, Lee, K, Jang, T, Lee, SH, Kim, EY, Park, DW, and Park, SH}, -title = {968TiP A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial)}, -journal = {Annals of oncology}, -volume = {33}, -pages = {S990}, -year = {2022}, -accession_number = {EMBASE 2020168109}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *cancer staging; *chemoradiotherapy; *gene mutation; *non small cell lung cancer; Adult; Cancer adjuvant therapy; Cancer surgery; Cancer survival; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Distant metastasis; Drug safety; Drug therapy; Drug withdrawal; Female; Gene deletion; Human; Major clinical study; Male; Multicenter study; Overall survival; Phase 2 clinical trial; Preclinical study; Preliminary data; Progression free survival; Protein function; Radiotherapy}, -abstract = {Background: The PACIFIC trial has demonstrated that durable progression free survival (PFS) and sustained overall survival (OS) benefit with durvalumab as consolidation therapy after concurrent chemoradiation therapy (CCRT). In a subgroup analysis, the effect was not proven in patients with EGFR mutation positive. There is an unmet need for consolidative therapy after CCRT in patients with unresectable stage III EGFR mutation positive. A recent ADAURA trial showed that osimertinib had a significant prolongation of PFS in the postoperative adjuvant treatment in EGFR mutation positive patients. Lazertinib is also 3rd generation EGFR TKI as osimertinib and shows good anti‐cancer effect in EGFR sensitive mutations in preclinical data. And Lazertinib showed promising clinical activity in patients with NSCLC progressing after EGFR TKI therapy. Given these positive 3rd G EGFR TKI data in the adjuvant setting, and the preliminary data obtained in EGFR TKI therapies in the early disease setting, there is a strong rationale to suggest that Lazertinib may provide clinical benefit in the consolidative treatment after CCRT treatment. Trial design: This study is a phase II, multicenter study assessing the efficacy and safety of Lazertinib as consolidation therapy in patients with locally advanced, unresectable NSCLC (Stage III) who have not progressed following definitive, platinum based, CCRT. Approximately 77 patients will be enrolled. The patients who have sensitizing EGFR mutation (e.g., exon 19 deletion or exon 21 L858R mutation) will be enrolled. Administration of Lazertinib will commence 1 to 42 days after the patients had received chemoradiotherapy and will continue a q4w schedule until clinical progression, confirmed radiological progression, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur. The primary end point is PFS and 2ndary end points are OS, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. Legal entity responsible for the study: The authors. Funding: Yuhan Corporation. Disclosure: All authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2022.07.1094}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02489009/full} -} - - -Record #422 of 538 -@article{JapicCTI-19456519, -author = {JapicCTI-194565,}, -title = {A multicentre, open-label, randomized Phase III Study of Atezolizumab with Platinum-Pemetrexed with or without Bevacizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer (WJOG11218L Investigator-Initiated Clinical Trial)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-JapicCTI-194565}, -year = {2019}, -accession_number = {ICTRP JapicCTI‐194565}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Intervention name : atezolizumab INN of the intervention : atezolizumab Dosage And administration of the intervention : 1200 mg as an IV infusion once every 21 days Intervention name : bevacizumab INN of the intervention : bevacizumab Dosage And administration of the intervention : 15 mg/kg as an IV infusion once every 21 days Intervention name : carboplatin INN of the intervention : carboplatin Dosage And administration of the intervention : AUC 5 as an IV infusion once every 21 days Intervention name : pemetrexed INN of the intervention : pemetrexed Dosage And administration of the intervention : 500mg/m2 as an IV infusion once every 21 days Control intervention name : ‐ INN of the control intervention : ‐ Dosage And administration of the control intervention : ‐ CONDITION: non‐small‐cell lung cancer PRIMARY OUTCOME: efficacy; Progression free survival (PFS) by central assessment; PFS will be assessed according to RECIST version 1.1. SECONDARY OUTCOME: safety, efficacy; Investigator‐assessed PFS, overall survival (OS), investigator‐assessed overall response rate (ORR), investigator assessed duration of response (DOR) and safety; PFS, ORR and DOR will be assessed based on RECIST version 1.1 and CTCAE will be used for safety assessment and so on. INCLUSION CRITERIA: 1. Patients with a histologically or cytologically confirmed diagnosis of non‐squamous NSCLC 2. Patients who have the results of EGFR mutation test 3. Patients with stage III and stage IV NSCLC not treatable with radical radiotherapy or postoperative recurrent NSCLC 4. Patients with tumor lesion, regardless of with or without measurable lesion as defined by the RECIST version 1.1 5. Absence of symptomatic brain metastasis 6. Patients who were not previously treated with chemotherapy, in the patients confirmed to be positive‐mutation in any driver gene, need previously treatment by appropriate TKI 7. ECOG PS 0 or 1}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01970406/full} -} - - -Record #423 of 538 -@article{NL-OMON5097321, -author = {NL-OMON50973,}, -title = {A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03) (D967YC00001)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=NL-OMON50973}, -year = {2021}, -accession_number = {ICTRP NL‐OMON50973}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Part 1: Dose Escalation Combinations and T‐DXd Monotherapy Arm 1A: Cisplatin combination ‐ Cisplatin: ascending dose levels (60 mg/ml2 [starting dose], 75 mg/ml2): IV Q3W, plus ‐ T‐DXd: ascending dose levels (3,2 mg/kg, 4,4 mg/kg [starting dose], 5,4 mg/kg) IV Q3W, plus ‐ Durvalumab: fixed dose (1120 mg): IV Q3W Arm 1B: Carboplatin combination ‐ Carboplatin: ascending dose levels (AUC 4 [staring dose], AUC 5): IV Q3W, plus ‐ T‐DXd: ascending dose levels (3,2 mg/kg, 4,4 mg/kg [starting dose], 5,4 mg/kg) IV Q3W, plus ‐ Durvalumab: fixed dose (1120 mg): IV Q3W Arm 1C: Pemetrexed combination ‐ Pemetrexed: ascending dose levels (375 mg/m2 [staring dose], 500 mg/m2): IV Q3W, plus ‐ T‐DXd: ascending dose levels (3,2 mg/kg, 4,4 mg/kg [starting dose], 5,4 mg/kg) IV Q3W, plus ‐ Durvalumab: fixed dose (1120 mg): IV Q3W Arm 1D: T‐DXd monotherapy ‐ T‐DXd: fixed dose 5,4 mg/kg IV Q3W Part 2: Dose Expansion: Arm 2A, 2B and 2C: ‐ will initiate after RP2D is identified from Part 1 Arm 2D: ‐ T‐DXd: 5,4 mg/kg IV Q3W, plus ‐ Durvalumab: fixed dose (1120 mg): IV Q3W CONDITION: 10038666 ; lungcancer ; Metatstatic Non Small Cell Lung Cancer PRIMARY OUTCOME: ‐ To assess the safety and tolerability and to determine the RP2D of T‐DXd plus ; durvalumab in combination with cisplatin, carboplatin or pemetrexed; SECONDARY OUTCOME: ‐ To assess the preliminary antitumor activity of T‐DXd monotherapy (Part 1 ; only); T‐DXd with durvalumab (Part 2 only); and T‐DXd plus durvalumab in ; combination with cisplatin, carboplatin or pemetrexed ; ‐ To assess the safety and tolerability of T‐DXd montherapy (Part 1) and T‐DXd ; plus durvalumab (Part 2) ; ‐ To assess the PK of T‐DXd, total anti‐HER2 antibody and MAAA‐1181 in all arms ; ‐ To assess the PK of durvalumab ; ‐ To investigate the immunogenicity of T‐DXd and durvalumab ; INCLUSION CRITERIA: ‐ Histologically documented stage III locally advanced/metastatic and unresectable non‐squamous NSCLC not amenable to curative surgery or radiation and/or stage IV NSCLC ‐ Part 1 (dose‐escalation combinations and T‐DXd monotherapy): Patients with therapy‐targetable alterations are allowed. ‐ Part 2 (dose‐expansion): Tumors that lack activating EGFR mutations or EML4‐ALK fusion ‐ Part 1 (dose‐escalation combinations and T‐DXd monotherapy): Progression on or after either one or 2 lines of therapy which is required to have included prior appropriate targeted therapy for patients with therapy‐targetable alterations. ‐ Part 2 (dose‐expansion): treatment‐naïve for locally advanced or mNSCLC. Prior adjuvant, neo adjuvant therapies are permitted if progression has occurred > 12 months from the end of last therapy ‐ HER2+ (IHC 3+ or 2+) status as determined by central review of tumor tissue ‐ WHO / ECOG performance s}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02723190/full} -} - - -Record #424 of 538 -@article{NCT0521331221, -author = {NCT05213312,}, -title = {Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC}, -journal = {https://clinicaltrials.gov/show/NCT05213312}, -year = {2021}, -accession_number = {CTgov NCT05213312}, -publication type = {Trial registry record}, -keywords = {Carcinoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Fluorouracil; Nivolumab; Paclitaxel}, -abstract = {1. Background Esophageal cancer, the 7th most common cancer globally, accounts for more than half a million deaths each year. The incidence of ESCC, the most common histologic type, has been stable, whereas the incidences of esophageal and gastroesophageal junction adenocarcinomas continue to increase in Western countries. Neoadjuvant chemoradiotherapy followed by surgery has become a standard of care for patients with locally advanced resectable esophageal or junctional cancer, especially in western countries. In Asia (especially Japan), nCT is considered as the standard of care for Stage II/III ESCC based on JCOG9204 and JCOG9907 trials. The superiority of nCRT/nCT, in terms of long‐term survival, remains to be elucidated. For Stage II/III ESCC patients with multiple stations of lymph nodes involvement, nCT might be more appropriate for the inaccessibility of radiotherapy. There are only limited studies on preoperative immune checkpoint inhibitor in combination with chemotherapy followed by surgery for the locally advanced ESCC. Therefore, this study intends to use Nivolumab 360 mg Q3W combined with standard chemotherapy as the neoadjuvant therapy regimen. 2. Sample Size The planned sample size is approximately 81 subjects. The sample size calculations are based on the results of neoadjuvant therapy clinical research in our center (Department of Thoracic Surgery, Zhongshan Hospital Affiliated to Fudan University). In the past two years, about 85% of patients can undergo surgery and complete the entire treatment plan, combining with the results of neoadjuvant immunotherapy in lung cancer. As calculated based on an asymptotic method, 81 patients will be 2:1 randomized to Nivolumab/Chemo and Chemo group, with 80% power to detect a 21% difference in the proportion of patients achieving a pCR at a one‐sided α of 0.05, assuming a pCR rate of 25% in the Nivolumab/Chemo group and 4% in the Chemo group. Considering a 10% drop rate, 90 patients will be enrolled. 10‐20 more subjects may be added to each group after the evaluation of feasibility and safety as the justification. 3. Research Process 3.1 Screening period 1) Tumor evaluation, including CT/MRI, PET/CT, endoscopy and pathological evaluation should be performed within 14 days before enrollment. 2) The following assessments should be performed within 14 days before enrollment: demographic data, concomitant diseases/treatment, full physical examination (including vital signs, KPS score, height, weight, and physical examination of the nervous system ), laboratory tests (blood routine / biochemical, fecal routine + occult blood, urine routine, coagulation function, tumor markers, thyroid function, hepatitis B and C markers, myocardial enzyme spectrum, T‐SPOT, HIV antibodies), electrocardiogram (ECG), echocardiography, and pregnancy tests (for all women with menopause less than 12 months). 3) Pulmonary function tests will be performed on patients suspected or known to have severe respiratory disease or have significant respiratory symptoms unrelated to underlying cancer, including but not limited to spirometry tests and assessment of lung dispersion during the screening period to help determine if it is appropriate to participate in this study. 4) After the completion of all screening items, the researcher must review the results/data, and the subjects can only be enrolled after passing the review. 5) Subjects are required to obtain written informed consent to participate in any specific research steps. (See table below) 3.2 Treatment period Baseline assessment 1. The baseline check is performed within 7 days after signing the informed consent, and treatment must be performed within 7 days after enrollment. 2. Make the following assessments within 1 week before treatment: vital signs (temperature, blood pressure, heart rate), physical examination (including PS score, height, weight, physical examination of each system), blood routine / biochemical examination (including creatinine clearance Calculation), coagulation function, fecal routine and occult blood, urine routine and pregnancy test, tumor markers, thyroid function, hepatitis B and C markers, myocardial enzyme spectrum, T‐SPOT, HIV antibodies, ECG, cardiac ultrasound, lung function. 3. When performing routine blood / biochemical examination, take 10ml blood samples for ctDNA, TCR‐Seq and other analysis, and if necessary, take tissue samples for further experiments. 4. According to the above schedule, if there are already laboratory tests in the screening period, the auxiliary tests can be used as a baseline within 7 days before the start of neoadjuvant therapy, and there is no need to repeat the tests. 5. Take the chest CT, PET/CT and endoscopy as the baseline for tumor evaluation during the screening period. After completing all screening activities and baseline assessments, eligible patients identified by the sponsor will be treated with medications, and treatment options will not be allowed to change during the study. After the investigator's first evaluation of disease progression based on RECIST, treatment can be continued if there is evidence of "pseudoprogression" and the consent of the sponsor and the patient's signing of the consent form again. Safety will be assessed throughout the study by monitoring AE / SAE (toxicity grades are assigned according to the National Cancer Institute's Common Criteria for Adverse Events Terminology [NCI‐CTCAE] version 5.0) and laboratory results. Vital signs, physical examination, changes in ECOG score, ECG results, and other tests will also be used for safety assessment. 3.3 Follow‐up period after study treatment 1. Follow up at the prescribed time (recommended physical examination, tumor markers, chest CT and PET/CT). If the patient has signs of recurrence (such as related clinical manifestations), additional tumor evaluations are performed during the treatment; possible reoperations and/or further cancer treatments are also documented. 2. During the follow‐up period without tumor recurrence, other cytotoxic agents are not allowed. 3. Inspection can be performed within ± 4 weeks of the specified date. 4. Patient recurrence and survival will be followed up to the patient's death, the last date on which the patient is known to survive, or 1 year after the primary effectiveness analysis. 4.Adverse Effect 4.1SERIOUS ADVERSE EVENT COLLECTION AND REPORTING All Serious Adverse Events (SAEs) that occur following the subject's written consent to participate in the study through 100 days of discontinuation of dosing must be reported to BMS Worldwide Safety, whether related or not related to study drug. If applicable, SAEs must be collected that relate to any follow‐up protocol‐specified procedure (eg, a follow‐up skin biopsy). 4.2 NON‐SERIOUS ADVERSE EVENT COLLECTION AND REPORTING The collection of non‐serious AE information should begin following the subject's written consent to participate in the study. All non serious adverse events (not only those deemed to be treatment‐related) should be collected continuously during the treatment period and for a minimum of 100 days following the last dose of study treatment. Non‐serious AEs should be followed to resolution or stabilization, or reported as SAEs if they become serious. Follow‐up is also required for non‐serious AEs that cause interruption or discontinuation of study drug and for those present at the end of study treatment as appropriate. Non‐serious Adverse Events (AE) are to be provided to BMS in aggregate via interim or final study reports as specified in the agreement or, if a regulatory requirement [eg, IND US trial] as part of an annual reporting requirement. 4.3 LABORATORY TEST ABNORMALITIES All laboratory test results captured as part of the study should be recorded following institutional procedures. Test results that constitute SAEs should be documented and reported to BMS as such. The following laboratory abnormalities should be documented and reported appropriately: any laboratory test result that is clinically significant or meets the definition of an SAE any laboratory abnormality that required the participant to have study drug discontinued or interrupted any laboratory abnormality that required the subject to receive specific corrective therapy. 4.4 OTHER SAFETY CONSIDERATIONS Any significant worsening noted during interim or final physical examinations, electrocardiograms, X‐rays, and any other potential safety assessments, whether or not these procedures are required by the protocol, should also be recorded as a non‐serious or serious AE, as appropriate, and reported accordingly. 5. Statistical analysis of research data 5.1 Statistical software All statistical analysis will be calculated using SPSS 24.0 statistical analysis software programming. 5.2 Descriptive statistics Continuous data: number of cases (number of missing cases), mean, median, standard deviation, P25, P75, minimum and maximum; Categorical data: frequency and the corresponding percentages. For primary safety endpoint, calculate the 95% CI in addition to the percentage. 5.3 Statistic inference All statistical tests are two‐sided. P values less than 0.05 will be considered statistically significant. The confidence interval (CI) is 95%. Statistical analysis for primary endpoint: pCR rates will be calculated as the proportions of the subjects in the analysis population who have a complete response in postoperative pathology. Statistical analysis for baseline variables and secondary endpoints: the 3‐year OS rates in the two treatment arms will be calculated by the Kaplan‐Meier method and compared by the log rank test. The Cox proportional hazard model will be used to evaluate the survival‐independent factors. Continuous variables were examined by independent sample t‐test or Wilcoxon rank‐sum test, and categorical variables were compared by Pearson chi‐square test, Fisher's exact test or CMH chi‐square test as appropriate. 5.4 Analysis of withdraw patients The number of patients who are enrolled, withdrawn, removed, completed, and number of every analysis set will be listed. 6. Research‐Related Ethics 6.1 Local regulations / Helsinki Declaration Researchers should ensure that the implementation of this research is in full compliance with the principles of the Helsinki Declaration or the law of the country in the country, regardless of the country's provisions on the protection of human rights. The research must strictly follow the "ICH guideline for Good Clinical Practice" ICH Tripartite Guideline (January 1997), or local law, whichever is more stringent. 6.2 Review by Ethics Committee This protocol, written informed consent, and data directly related to the subject must be submitted to the ethics committee, and formal research can only be conducted after obtaining written approval from the ethics committee. The researcher must submit an annual research report to the Ethics Committee at least annually (if applicable). When the study is suspended and / or completed, the researcher must notify the ethics committee in writing; the researcher must promptly report all changes to the ethics committee (such as amendments to the protocol and / or informed consent) to the ethics committee, and These changes shall not be implemented until approved by the Commission, except for changes made to eliminate obvious and immediate risks to the subject. In such cases, the Ethics Committee will be notified. 6.3 Informed consent The investigator must provide the subject or his or her legal representative with an easy‐to‐understand, informed consent form approved by the ethics committee, and give the subject or his or her legal representative sufficient time to consider the study. Subjects shall not be enrolled until a signed written informed consent is obtained. During the participant's participation, the subject will be provided with all updated versions of informed consent and written information. The informed consent form should be kept as an important document of the clinical trial for future reference. 7. Drug and specimen management 7.1 Management of trial drugs 7.1.1 Storage Nivolumab injection is clear to opalescent, colorless to pale yellow liquid, and there may be small (rare) particles. Divided into 40mg / 4mL and 100mg / 10mL two specifications. Store and transport at 2 to 8℃ protected from light, do not freeze. 7.1.2 Inventory Nivolumab will be provided by the sponsor. The research center will confirm the receipt of nivolumab through interactive feedback technology (IRT), and confirm the transportation conditions and contents. Any medicines that are damaged or lost during transportation will be replaced. Nivolumab will be processed at the research center in accordance with the standard operating procedures of the research center or returned to the sponsor with appropriate records. The research center's method of destroying the drug must be approved by the sponsor. The research center must obtain written authorization from the sponsor before the drug is destroyed, and the drug destruction must be recorded on the appropriate form. Accurate records of all drugs received, distributed, returned, and disposed of should be recorded in the research center's drug inventory log. 7.2 Specimen management Baseline pathological specimens and blood samples of patients, surgical pathological specimens will be uniformly numbered and properly stored in the pathology laboratory of our hospital. 8. Confidentiality measures The results of research through this project may be published in medical journals, but we will keep patient information confidential as required by law, and patients 'personal information will not be leaked unless required by relevant laws. When necessary, government management departments and hospital ethics committees and their related personnel may consult patient data as required.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02367309/full} -} - - -Record #425 of 538 -@article{Jabbour20, -author = {Jabbour, SK, Houghton, B, Robinson, AG, Quantin, X, Wehler, T, Kowalski, D, Ahn, MJ, Erman, M, Giaccone, G, Borghaei, H, McLean, J, Zhang, J, Souza, F, and Decker, RH}, -title = {Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or Without Pembrolizumab in Patients with Inoperable Stage I/IIA Non–Small-Cell Lung Cancer (NSCLC): KEYNOTE-867}, -journal = {International journal of radiation oncology biology physics}, -volume = {108}, -number = {3}, -pages = {e135‐e136}, -year = {2020}, -accession_number = {EMBASE 2007859180}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *cancer staging; *non small cell lung cancer; *stereotactic body radiation therapy; Adult; Asia; Australia and New Zealand; Canada; Cancer recurrence; Clinical trial; Conference abstract; Controlled study; Disease specific survival; Distant metastasis; Drug efficacy; Drug safety; Drug therapy; Drug withdrawal; Event free survival; Female; Histopathology; Human; Kaplan Meier method; Log rank test; Major clinical study; Male; Pharmacokinetics; Phase 3 clinical trial; Primary tumor; Randomization; Randomized controlled trial; Recurrent disease; Russian Federation; South America; United States}, -abstract = {Purpose/Objective(s): Anti–PD‐(L)1‐directed therapy following radiotherapy or following concurrent chemoradiation is associated with significantly longer PFS and OS in patients with advanced or metastatic NSCLC, including those with locally advanced inoperable tumors. KEYNOTE‐867 (NCT03924869) evaluates the efficacy and safety of SBRT with or without pembrolizumab in patients with inoperable stage I/IIA NSCLC. Materials/Methods: In this phase 3, randomized, placebo‐controlled study, approximately 530 adult patients with previously untreated, medically inoperable, histologically/cytologically confirmed stage I/IIA NSCLC are randomized 1:1 to receive thoracic SBRT to primary tumors for ≤2 wk (Table) and either pembrolizumab 200 mg or placebo every 3 wk for 17 cycles (approximately 1 year) or until disease recurrence, development of unacceptable AEs, SBRT not started for any reason, or study withdrawal. Randomization is stratified by disease stage (I/IIA), ECOG PS (0–1/2), and geographic region (East Asia/other). Imaging assessment by blinded independent central review (BICR) occurs at 12 wk (≥10 wk after SBRT completion), followed by every 16 wk for 3 y, and then every 6 mo. Primary endpoints are event‐free survival (EFS) by BICR and OS. Secondary endpoints include time to death or distant metastases and safety; exploratory endpoints are time to subsequent treatment, disease‐specific survival, and time to recurrence/progression on subsequent line of therapy. AEs are monitored throughout the trial until 30 d after last dose (90 for serious AEs) and graded according to NCI CTCAE version 4.0. EFS and OS are analyzed by the nonparametric Kaplan‐Meier method, treatment differences by stratified log‐rank test, and hazard ratios by stratified Cox proportional hazard model with Efron's method of tie handling. Results: Enrollment started on June 17, 2019, at 131 sites, including sites within the United States, Canada, Europe, Asia, South America, Russia, Australia, and New Zealand. Conclusion: KEYNOTE‐867 will provide important information on the efficacy and safety of SRBT with or without pembrolizumab in patients with inoperable stage I/IIA NSCLC. [Formula presented]}, -DOI = {10.1016/j.ijrobp.2020.07.1289}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02175380/full} -} - - -Record #426 of 538 -@article{ChiCTR230007828523, -author = {ChiCTR2300078285,}, -title = {Efficacy and safety study of thermotherapy combined with immunotherapy and chemotherapy in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2300078285}, -year = {2023}, -accession_number = {ICTRP ChiCTR2300078285}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: combined heat therapy group:Deep Thermal Therapy for Tumours+chemotherapy+Immune checkpoint inhibitors ;control group:chemotherapy+Immune checkpoint inhibitors; CONDITION: Non‐small‐cell lung cancer PRIMARY OUTCOME: PFS; SECONDARY OUTCOME: OS;objective response rate;disease control rate;safety; INCLUSION CRITERIA: (1) Subjects volunteered to participate and signed an informed consent form (ICF) and were able to comply with the study procedures; (2) Age =18 years old at the time of enrolment, both male and female; (3) Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) NSCLC that cannot be completely resected surgically and cannot be treated with radical synchronous/sequential radiotherapy (American Cancer Consortium [AJCC] 8th edition); (4) No EGFR‐sensitive mutations or ALK gene translocation alterations. For non‐squamous NSCLC subjects, a report of prior histological biopsy‐based testing for EGFR and ALK must be available. For squamous NSCLC subjects, if prior EGFR and ALK status is unknown, appropriate testing prior to enrolment in this study is not required and is considered negative; (5) Tissue PD‐L1 expression level can be detected; (6) Expected survival time = 3 months; detectable tissue PD‐L1 expression}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02670235/full} -} - - -Record #427 of 538 -@article{Jasna22, -author = {Jasna, R, Jasmina, MB, and Ana, F}, -title = {NEW DEVELOPMENTS IN NEOADJUVANT AND ADJUVANT TREATMENT OF NON-SMALL CELL LUNG CANCER}, -journal = {Libri oncologici}, -volume = {50}, -number = {SUPPL 1}, -pages = {32‐34}, -year = {2022}, -accession_number = {EMBASE 638201334}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer combination chemotherapy; *neoadjuvant chemotherapy; *non small cell lung cancer; Adjuvant chemotherapy; Adjuvant radiotherapy; Adult; Advanced cancer; Cancer growth; Cancer patient; Cancer prognosis; Cancer radiotherapy; Cancer recurrence; Cancer staging; Cancer surgery; Cancer survival; Canopy; Case report; Central nervous system; Chemotherapy; Clinical article; Clinical trial; Cohort analysis; Complication; Conference abstract; Digital pathology; Disease free survival; Drug safety; Drug therapy; Event free survival; Female; Follow up; Gene expression; Gene rearrangement; Health care quality; Human; Immunity; Immunotherapy; Male; Median survival time; Multicenter study; Outcome assessment; Overall survival; Patient selection; Peroperative complication; Phase 2 clinical trial; Phase 3 clinical trial; Preliminary data; Protein expression; Radioimmunotherapy; Radiomics; Recurrent disease; Remission; Standardization; Stereotactic body radiation therapy; Systemic therapy}, -abstract = {Implementation of biomarker testing and enabling access to novel therapies have significantly prolonged overall survival (OS) in stage IV non‐ small cell lung cancer (NSCLC). However, the standard of care for the past two decades for patients with stage IB‐IIIA surgically resected tumors has remained four cycles of cisplatin‐based adjuvant chemotherapy, with a survival benefit of 5% at 5 years. Neoadjuvant chemotherapy confers OS benefit over surgery alone, although there has been no robust head‐to‐head comparison with adjuvant chemotherapy. Encouraged by the success of a biomarker‐driven approach in advanced NSCLC and recognising the need to improve survival outcomes in early‐stage NSCLC, the interest in revisiting perioperative strategies is rising. Adjuvant treatment There are pros and cons to adjuvant therapies. There is no delay of surgery, no risk of disease progression resulting in missing opportunities to use curative surgery, and therapeutic decisions are guided by biomarkers. However, patients require longer treatment, there are no intermediate end points, biomarkers are less predictive, and long‐term follow‐up is needed to detect disease‐free survival (DFS) and OS. Results from the multicenter IMpower010 trial established PD‐L1 inhibitor atezolizumab as a potential new standard of care in adjuvant treatment. Updated findings published in 2021 showed that, compared with best supportive care, atezolizumab given for 1 year reduced the risk for disease recurrence or death by 34% in patients with stage II/IIIA NSCLC with PD‐L1 expression ≥ 1% and by 21% in all patients in the stage II/IIIA following surgery and chemotherapy. Preliminary results from the phase 3 KEYNOTE‐091 trial show that adjuvant pembrolizumab given for 1 year led to a statistically significant and clinically meaningful improvement in DFS vs placebo in patients with stage IB/IIIA NSCLC following resection regardless of PD‐L1 expression. At the interim analysis, there was also an improvement in DFS for patients with PD‐L1≥50% in favor of pembrolizumab. KEYNOTE‐091 appears to provide a second trial supporting the use of adjuvant PD‐L1 inhibition in early‐stage disease. The ANVIL trial (adjuvant nivolumab) has been completed but the data are still not available. Many phase 3 trials investigating adjuvant immunotherapy (BR31, CANOPY‐A) and chemoimmunotherapy (ALCHEMIST, MERMAID‐1) are ongoing. In the field of targeted adjuvant treatment, updated data of the pivotal phase 3 ADAURA trial that established neoadjuvant osimertinib in patients with resected, EGFR‐ mutated, stage IB‐IIIA NSCLC showed that osimertinib reduced the risk for CNS death or progression by 82% in this patient population. ADAURA has many limitations, for example, in the adjuvant setting, it is not known whether the 2‐year DFS superiority with EGFR directed therapy will translate into an OS benefit with osimertinib, so the ALCHEMIST trial is currently testing adjuvant EGFR‐ and ALK‐directed therapy using OS as the primary endpoint. Neoadjuvant treatment Neoadjuvant systemic therapy can lead to early eradication of micrometastatic disease, guide the choice of or need for adjuvant therapy; early treatment is better tolerated and induces fewer toxicities. There's somewhat earlier trial endpoints, not in terms of OS or DFS but in terms of potential predictive and prognostic biomarkers. However, neoadjuvant therapy delays surgery, which could increase the risk for surgical complications. Further, there is an increased risk for disease progression, which could result in missing the opportunity for curative surgery. The immune checkpoint inhibitors (ICIs) are the interesting treatment option in neoadjuvant therapy of NSCLC due to the fact that early‐stage tumors have a greater host immunity fitness and lower clonal heterogeneity, which is the basis for achieving better major pathologic response (MPR) rates with ICIs than neoadjuvant chemotherapy alone. Most initial studies with neoadjuvant immunotherapy selected MPR, pathologic complete response (pCR) and event‐ free survival (EFS) as primary or secondary endpoints, leading to a significant reduction in the time and cost of research and development compared with the use of OS and median survival time as endpoints. Other benefits of neoadjuvant immunotherapy are chronic effects on survival and potential synergetic effects with chemotherapy. Early, but promising results from the phase 3 CheckMate 816 trial which investigated neoadjuvant nivolumab plus chemotherapy for 3 cycles compared to chemotherapy alone for patients with resectable stage IB to IIIA NSCLC were presented in 2021. Nivolumab plus chemotherapy yielded significant improvement in pCR in the intent‐to‐treat population (24.0% vs 2.2% with chemotherapy alone) and at all disease stages. Surgical outcomes and EFS favoured the chemoimmunotherapy combination as well. To confirm these benefits, many phase III clinical trials are being conducted, and there is a growing demand for research on related issues, including the patient selection, optimization of chemoimmunotherapy regimens, influence of treatment on the safety of surgery, standardization of radiological response and pathologic evaluation and ways to identify pseudoprogression and avoid resultant misjudgment in surgery and adjuvant therapy Since 2019, studies have introduced stereotactic body radiotherapy (SBRT) before surgery in earlystage disease as safe and feasible approach. Coupled with encouraging data from neoadjuvant immunotherapy and the success of radioimmunotherapy approaches, ongoing studies are combining SBRT and immunotherapy in early‐stage disease. Early results are promising, showing high rates of MPR, but highlighting the need for careful patient selection and further studies in larger cohorts. There have been a number of targeted agents explored so far in the neoadjuvant setting, and have demonstrated trends toward improvements in pathologic response rates, mostly in the EGFR‐mutated population. Updated findings from a phase 2 trial that evaluated osimertinib given for 1‐2 cycles prior to surgery showed an induced pCR rate of 69% in patients with resectable EGFRmt NSCLC. The phase 3 NeoADAURA study is currently evaluating 9 weeks of neoadjuvant osimertinib, chemotherapy and their combination in patients with EGFRmt NSCLC. There are ongoing studies in other molecular subsets (eg, the ALINA trial in ALK rearranged NSCLC, NAUTIKA1 in multiple genomic alterations). Conclusion: The most effective treatment strategy for early stages of NSCLC remains unclear. With further standardisation of trial endpoints across studies, coupled with the implementation of novel tech nologies including radiomics and digital pathology, individual risk‐stratified neoadjuvant and adjuvant treatment approaches are poised to make a striking impact on the outcomes of early‐stage NSCLC.}, -DOI = {10.20471/lo.2022.50.01.06}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02458919/full} -} - - -Record #428 of 538 -@article{JPRN-jRCT208022268214, -author = {JPRN-jRCT2080222682,}, -title = {PACIFIC}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCT2080222682}, -year = {2014}, -accession_number = {ICTRP JPRN‐jRCT2080222682}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: investigational material(s) Generic name etc : MEDI4736 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier. The 2:1 ratio (MEDI4736 to placebo). control material(s) Generic name etc : PLACEBO INN of investigational material : Therapeutic category code : ‐‐‐ Other Dosage and Administration for Investigational material : PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier. The 2:1 ratio (MEDI4736 to placebo). CONDITION: Non‐Small Cell Lung Cancer INCLUSION CRITERIA: ‐Documented evidence of NSCLC (locally advanced, unresectable, Stage 3III) ‐Patients must have received at least 2 cycles of platinum‐based chemotherapy concurrent with radiation therapy. ‐World Health Organisation (WHO) Performance Status of 0 to 1. ‐Estimated life expectancy of more than 12 weeks.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02593599/full} -} - - -Record #429 of 538 -@article{Xu21, -author = {Xu, J-K}, -title = {Effect of intensity modulated radiotherapy (Imrt) on the immunity, physical status and clinical effect of locally advanced nsclc patients}, -journal = {Pakistan journal of medical sciences}, -volume = {37}, -number = {5}, -pages = {1480‐1485}, -year = {2021}, -accession_number = {EMBASE 2007824661}, -publication type = {Journal article}, -keywords = {*advanced cancer /therapy; *immunity; *intensity modulated radiation therapy; *non small cell lung cancer /therapy; *physical activity; Adenocarcinoma; Adult; Adverse drug reaction; Aged; Anemia; Article; Biochemical analysis; CD3+ T lymphocyte; CD4+ T lymphocyte; CD8+ T lymphocyte; Cancer patient; Cancer radiotherapy; Cancer staging; Chemoradiotherapy; Clinical article; Clinical target volume; Clinical trial; Comparative study; Controlled study; Coughing; Diagnostic test accuracy study; Diagnostic value; Dosimetry; Drug efficacy; Drug safety; Female; Fever; Gross tumor volume; Human; Leukocyte count; Leukopenia; Loss of appetite; Male; Middle aged; Overall response rate; Radiation pneumonia; Randomized controlled trial; T lymphocyte subpopulation; Tumor volume}, -abstract = {Objectives: To evaluate the clinical value of radiotherapy combined with Camrelizumab in treating locally advanced non‐small cell lung cancer (NSCLC) patients. Methods: 80 locally advanced NSCLC patients were randomly divided into two groups (n=40). The control group was administered with intensity modulated radiation therapy (IMRT), whereas the experimental group with Camrelizumab in addition to IMRT. All the patients underwent clinical efficacy evaluation in terms of adverse drug reaction (ADR), physical status improvement after the treatment, and changes in T lymphocyte subpopulations (incl. CD3+, CD4+, CD8+, CD4+/CD8+). Results: The efficacy was found to be 70% and 47.5 in experimental group and control group, respectively, with the former being significantly better than the latter (p=0.03). The ADR rates were 50% and 37.5% in the experimental group and control group, respectively; but the difference remained insignificant (p=0.26). As for physical status improvement, experimental group evidently excelled the control group (p=0.04). The post‐treatment indicators such as CD3+, CD4+, CD8+, CD4+/CD8+ were significantly more improved in the experimental group than the control group (CD3+, p=0.02; CD4+, p=0.00; and CD4+/CD8+, p=0.01). However, the changes in CD8+ were not significant at all (p=0.46). Conclusions: The combined therapy of IMRT with Camrelizumab appeared effective in dealing with the locally advanced NSCLC patients, as such patients presented significantly better immune state and physical status improvement but not increased ADR. The therapy is both safe and effective.}, -DOI = {10.12669/pjms.37.5.4188}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02291838/full} -} - - -Record #430 of 538 -@article{Antonia14, -author = {Antonia, S, Iannotti, NO, Salamat, MA, Krebs, AD, Jayawardene, D, Ballas, M, and Stockman, PK}, -title = {A phase 3, randomised, double-blind, placebo-controlled, international study of medi4736 in patients with locally advanced, unresectable NSCLC (stage III) who have not progressed following platinum-based, concurrent chemoradiation therapy (PACIFIC)}, -journal = {Annals of oncology}, -volume = {25}, -pages = {vi6}, -year = {2014}, -accession_number = {EMBASE 71800082}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *human; *oncology; *patient; *therapy; Antibody dependent cellular cytotoxicity; Apoptosis; Asia; Australia; Chemotherapy; Europe; Immune response; Immunogenicity; Metastasis; Multiple cancer; Non small cell lung cancer; Overall survival; Pharmacokinetics; Phase 1 clinical trial; Professional standard; Progression free survival; Quality of life; Radiotherapy; Randomization; Safety; Soft contact lens; South Africa; South America; Study design; Tumor cell}, -abstract = {Background: Thirty percent of patients with non‐small cell lung cancer (NSCLC) present with Stage III disease. Concurrent chemoradiation therapy with curative intent is the treatment of choice for these patients. Despite treatment, progression‐free survival (PFS) is usually short (approximately 9 months) and most patients ultimately die of metastatic disease. Chemotherapy and radiotherapy have been shown to up‐regulate the expression of programmed cell‐death ligand 1 (PD‐L1), an important inhibitory checkpoint used by tumour cells to evade antitumour immune responses. MEDI4736 is a human IgG1 antibody that blocks PD‐L1 binding to programmed cell‐death 1 and CD80 and is engineered to prevent antibody dependent cell‐mediated cytotoxicity. In a Phase 1 study, MEDI4736 has shown an encouraging safety profile and clinical activity in multiple tumour types, including NSCLC. Here we describe the PACIFIC study, which evaluates the efficacy and safety ofMEDI4736 as sequential therapy in patients with locally advanced, unresectable NSCLC (Stage III) who have not progressed following definitive, platinum‐based, concurrent chemoradiation therapy. Trial design: In this phase 3, double‐blind, international study (NCT02125461) patients will be randomised (2:1) to MEDI4736 (10 mg/kg intravenously every 2 weeks) or matching placebo for up to 12 months. Patients must have received at least 2 cycles of platinum‐based chemotherapy concurrent with radiation therapy prior to randomisation. The primary objective is to assess the efficacy of MEDI4736 versus placebo in terms of overall survival and PFS (RECIST 1.1). Secondary outcome measures will assess efficacy (including proportion of patients alive at 24 months and objective response rate), safety and tolerability, pharmacokinetics, immunogenicity of MEDI4736 and its effect on symptoms and health‐related quality of life. An independent data monitoring committee is in place to monitor safety. Recruitment is ongoing at sites across Australia, Asia, Europe, North and South America and South Africa.}, -DOI = {10.1093/annonc/mdu467.12}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01073895/full} -} - - -Record #431 of 538 -@article{EUCTR2018-002927-40-HR19, -author = {EUCTR2018-002927-40-HR,}, -title = {Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in patients with Advanced Non-Small Cell Lung Cancer (NSCLC)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2018-002927-40-HR}, -year = {2019}, -accession_number = {ICTRP EUCTR2018‐002927‐40‐HR}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Anamorelin Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: ANAMORELIN CAS Number: 249921‐19‐5 Current Sponsor code: 05‐ANAM Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use CONDITION: Therapeutic area: Diseases [C] ‐ Nutritional and Metabolic Diseases [C18] Treatment of malignancy associated weight loss or anorexia in patients with NSCLC PRIMARY OUTCOME: Main Objective: To demonstrate superiority of anamorelin HCl vs placebo on the gain in body weight and improvement in anorexia symptoms Primary end point(s): The primary efficacy endpoint is the occurrence of Composite Clinical Response (CCR) at Week 9. CCR is a composite measure including both a = 5% body weight gain from baseline and increase = 2 points (meaning a clinically relevant improvement) in the 5‐item Anorexia Symptom Scale score from baseline) in patients who survive until Day 64. Secondary Objective: To evaluate the safety and tolerability of anamorelin HCl Timepoint(s) of evaluation of this end point: Week 0, week 9 SECONDARY OUTCOME: ; Secondary end point(s): Change in body weight from baseline to Week 9 ; Change in patient‐reported anorexia symptoms from baseline to Week 9 as measured by the 5‐item Anorexia Symptom Scale; Timepoint(s) of evaluation of this end point: Week 9 INCLUSION CRITERIA: 1. Signed written informed consent 2. Female or male =18 years of age 3. Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (AJCC) Stage III or IV NSCLC. Stage III patient must have unresectable disease 4. Body mass index < 20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening 5. Ongoing problems with appetite/eating associated with the underlying cancer, as determined by having score of = 17 points on the 5‐item Anorexia Symptom Scale and = 37 points on the 12‐item FAACT A/CS 6. Patient receiving or not receiving systemic anti‐cancer treatment at the time of screening are eligible to participate. Systemic anti‐cancer treatment includes first, second, third treatment line with chemotherapy/radiation therapy, immunotherapy or targeted therapy. Patient not receiving systemi}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02068164/full} -} - - -Record #432 of 538 -@article{EUCTR2018-002926-22-HU19, -author = {EUCTR2018-002926-22-HU,}, -title = {Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in patients with Advanced Non-Small Cell Lung Cancer (NSCLC)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2018-002926-22-HU}, -year = {2019}, -accession_number = {ICTRP EUCTR2018‐002926‐22‐HU}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Anamorelin Pharmaceutical Form: Film‐coated tablet INN or Proposed INN: ANAMORELIN CAS Number: 249921‐19‐5 Current Sponsor code: 05‐ANAM Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use CONDITION: Therapeutic area: Diseases [C] ‐ Nutritional and Metabolic Diseases [C18] Treatment of malignancy associated weight loss or anorexia in patients with NSCLC PRIMARY OUTCOME: Main Objective: To demonstrate superiority of anamorelin HCl vs placebo on the gain in body weight and improvement in anorexia symptoms Primary end point(s): The primary efficacy endpoint is the occurrence of Composite Clinical Response (CCR) at Week 9. CCR is a composite measure including both a = 5% body weight gain from baseline and increase = 2 points (meaning a clinically relevant improvement) in the 5‐item Anorexia Symptom Scale score from baseline) in patients who survive until Day 64. Secondary Objective: To evaluate the safety and tolerability of anamorelin HCl Timepoint(s) of evaluation of this end point: Week 0, week 9 SECONDARY OUTCOME: ; Secondary end point(s): Change in body weight from baseline to Week 9 ; Change in patient‐reported anorexia symptoms from baseline to Week 9 as measured by the 5‐item Anorexia Symptom Scale ; Change in FAACT total score from baseline to Week 9; Timepoint(s) of evaluation of this end point: Week 9 INCLUSION CRITERIA: 1. Signed written informed consent 2. Female or male =18 years of age 3. Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (AJCC) Stage III or IV NSCLC. Stage III patient must have unresectable disease 4. Body mass index < 20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening 5. Ongoing problems with appetite/eating associated with the underlying cancer, as determined by having score of = 17 points on the 5‐item Anorexia Symptom Scale and = 37 points on the 12‐item FAACT A/CS 6. Patient receiving or not receiving systemic anti‐cancer treatment at the time of screening are eligible to participate. Systemic anti‐cancer treatment includes first, second, third treatment line with chemotherapy/radiation therapy, immunotherapy or targeted therapy. Patient not receiving systemi}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02068163/full} -} - - -Record #433 of 538 -@article{EUCTR2018-001517-32-ES18, -author = {EUCTR2018-001517-32-ES,}, -title = {1L NSCLC Phase II RCT M7824 vs Pembrolizumab}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2018-001517-32-ES}, -year = {2018}, -accession_number = {ICTRP EUCTR2018‐001517‐32‐ES}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Code: M7824 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ‐ CAS Number: ‐ Current Sponsor code: MSB0011359C Other descriptive name: M7824 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ Trade Name: KEYTRUDA 25 mg/ml concentrate for solution for infusion Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: PEMBROLIZUMAB Current Sponsor code: ‐ Other descriptive name: ‐ Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ Trade Name: KEYTRUDA 50 mg Powder for concentrate for solution for infusion Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: PEMBROLIZUMAB CAS Number: ‐ Current Sponsor code: ‐ Other descriptive name: ‐ Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50‐ CONDITION: Non‐small Cell Lung Cancer ; MedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non‐small cell lung cancer stage IV System Organ Class: 10029104 ‐ Neoplasms benign, malignant and unspecified (incl cysts and polyps) Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: To evaluate whether M7824 improves ORR compared with pembrolizumab in; first‐line participants with advanced NSCLC with high PD‐L1 tumor expression; ; To evaluate whether M7824 improves PFS compared with pembrolizumab in; first‐line participants with advanced NSCLC with high PD‐L1 tumor expression Primary end point(s): 1) BOR according to RECIST 1.1; assessed by IRC; ; 2) PFS according to RECIST 1.1; assessed by IRC Secondary Objective: Safety; ‐To evaluate the safety and tolerability of M7824 compared with pembrolizumab; ; Efficacy; ‐To evaluate whether M7824 improves overall survival time compared with pembrolizumab; ‐ ORR assessed by Investigators; ‐ PFS assessed by Investigators; ‐ DOR; ; PK; ‐To characterize PK profile of M7824; ; Immunogenicity; ‐To characterize the immunogenicity; of M7824 Timepoint(s) of evaluation of this end point: 1) Time from randomization to planned final assessment for unconfirmed BOR, expected at; 26 months.; ; 2) Time from randomization to planned final assessment for PFS after 192 events expected; at 37 months. SECONDARY OUTCOME: Secondary end point(s): 1) Occurrence of TEAEs and treatment‐related AEs according; to NCI‐CTCAE v5.0; 2) OS; 3) BOR according to RECIST 1.1 assessed by Investigator; 4) PFS according to RECIST 1.1 assessed by Investigator; 5) DOR assessed from CR or PR according to RECIST 1.1 assessed by IRC until PD, death,; or last tumor assessment; 6) PK profile of M7824 in terms of Ceoi; 7) PK profile of M7824 in terms of; Ctrough; 8) Immunogenicity as measured by ADA assays at Baseline and ontreatment Timepoint(s) of evaluation of this end point: 1) Time from random. to the last 12‐week safety follow‐up visit, expected at 47 months.; 2) From random. to assessment when 200 OS events occur, OS PA exp. at 49 months from first participant in the study ; 3) Time from random. to planned final assessment for unconfirmed BOR, exp. 26 months.; 4) Time from random. to final assessm.PFS after 192 events at 37 months.; 5) Time from CR or PR to planned assessment after 192 PFS events, expected at 37 months.; 6,7) Predose samples at Weeks 1,3,5,7, then 6 weekly during treatment; postdose (within 30 min) samples at 6 weekly during treatment and up to study’s Safety Follow‐up Visit at 28 days after last study intervention administ.; 8) From random. up to study’s Safety Folup Visit, defined as 28 days after last study intervention administr. INCLUSION CRITERIA: 1. >= 18 years of age inclusive, at the time of signing the informed consent 2. histologically confirmed diagnosis of advanced NSCLC and: a. Have not received prior systemic therapy treatment for their advanced/Stage IV NSCLC. Completion of treatment with cytotoxic chemotherapy, biological therapy, and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease. Confirmation of resolution of toxic effects of previous neoadjuvant/adjuvant chemotherapy therapy to Grade = 1. For radiation toxicity or prior major surgeries, participants should have recovered from side effects and/or complications. b. Have measurable disease based on RECIST 1.1 c. Have a life expectancy of at least 3 months d. Availability of either tumor archival material (< 6 months old) or fresh biopsies collected within 28 days (excluding bone biopsies) befo}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01951110/full} -} - - -Record #434 of 538 -@article{CTRI/2019/02/01779819, -author = {CTRI/2019/02/017798,}, -title = {Study of treatment with Durvalumab or Placebo in patients with locally advanced and surgically non-removable Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed after platinum-based chemotherapy and radiation}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2019/02/017798}, -year = {2019}, -accession_number = {ICTRP CTRI/2019/02/017798}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Intervention1: Durvalumab: Patients will be randomized in a 2:1 ratio to either Durvalumab or Placebo Patients with complete response Partial response or stable disease at 8 weeks tumor evaluation will receive Durvalumab or placebo as consolidation therapy Control Intervention1: Placebo: Placebo as consolidation therapy CONDITION: Malignant neoplasm of unspecifiedpart of bronchus or lung PRIMARY OUTCOME: To assess the efficacy of Durvalumab treatment compared with placebo in terms of Progression Free SurvivalTimepoint: Progression Free Survival Time frame approximately 5 years SECONDARY OUTCOME: â?¢ To further assess the efficacy of durvalumab compared with placebo in terms of OS24, ORR, DoR, PFS12, PFS18, PFS2, and TTDM ; ; Timepoint: Time Frame Approximately 5 years To assess symptoms and health related quality of life in patients treated with Durvalumab compared with placebo using EORTC QLQ C30 v3 and QLQ LC13Timepoint: Overall Survival Time Frame approximately 5 years To assess the PK of DurvalumabTimepoint: Time Frame approximately 5 years To further access the efficacy of Durvalumab compared with Placebo in terms of OSTimepoint: OS analysis will occur when approximately 255 death events have occurred To investigate the immunogenicity of DurvalumabTimepoint: Time Frame Approximately 5 years To investigate the relationship between a patients baseline tumor PD L1 expresssion and efficacy outcome with durvalumab compared with placeboTimepoint: Time Frame approximately 5 years To investigate the relationship between a patients tissue TMB and efficacy outcomes with DurvalumabTimepoint: Time frame approximately 5 years INCLUSION CRITERIA: 1. Capability to give signed informed consent that includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol 2. Provision of signed and dated written ICF prior to any mandatory study‐specific procedures sampling and analyses Histologically or cytologically documented NSCLC and present with locally advanced unresectable (Stage III) disease (according to Version 8 of the (IASLC Staging Manual in Thoracic Oncology]). Positron emission tomography/CT, MRI of the brain, and endobronchial ultrasound with biopsy are highly encouraged at diagnosis. 4. Receipt of concurrent or sequential chemoradiation therapy, which must be completed within 1 to 28 days prior to first dose of IP in the study. ‐For cCRT, patients must have received at least 2 cycles of platinum‐based chemotherapy co}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01971840/full} -} - - -Record #435 of 538 -@article{CTRI/2024/04/06624824, -author = {CTRI/2024/04/066248,}, -title = {This is a clinical study to compare Dr Reddy’s developed nivolumab vs. nivolumab originator in patients with Advanced lung cancer who have failed with previous chemotherapy}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2024/04/066248}, -year = {2024}, -accession_number = {ICTRP CTRI/2024/04/066248}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Intervention1: DRL_NU (DRL_Nivolumab): Patients who qualify the selection criteria will be randomized to 2 treatment arms and administered either DRL_NU or RMP at a dose of 3 mg/kg solution by intravenous (IV) route every 2 weeks till Week 23 (last dose) or until disease progression, withdrawal due to intolerable toxicity, patient consent withdrawal or investigator decision on the best interest of the patient. Control Intervention1: EU Approved Reference Medicinal Product (OPDIVO®): Patients who qualify the selection criteria will be randomized to 2 treatment arms and administered either DRL_NU or RMP at a dose of 3 mg/kg solution by intravenous (IV) route every 2 weeks till Week 23 (last dose) or until disease progression, withdrawal due to intolerable toxicity, patient consent withdrawal or investigator decision on the best interest of the patient. Control Intervention2: EU Approved Reference Medicinal Product (OPDIVO®): Patients who qualify the selection criteria will be randomized to 2 treatment arms and administered either DRL_NU or RMP at a dose of 3 mg/kg solution by intravenous (IV) route every 2 weeks till Week 23 (last dose) or until disease progression, withdrawal due to intolerable toxicity, patient consent withdrawal or investigator decision on the best interest of the patient. CONDITION: Health Condition 1: C349‐ Malignant neoplasm of unspecifiedpart of bronchus or lung PRIMARY OUTCOME: Proportion of patients achieving best overall response rate (BORR) up to Week 25. BORR is defined as proportion of patients who have achieved complete responses and partial responses (CR + PR) across all the visits as per RECIST 1.1 criteria based on blinded independent imaging tumor assessment.Timepoint: Base‐line to Week 25 SECONDARY OUTCOME: Efficacy Endpoints: ; ORR at Week 9, 17 and 25 ; OS till Week 25 ; PFS till Week 25 ; Safety Endpoint: ; Comparison of the incidence of AEs, AESI and SAEs between patients randomized to DRL_NU and RMP. ; Immunogenicity Endpoint: ; Comparison of the incidence of ADAs, NAb and titre between patients randomized to DRL_NU and RMP. ; Pharmacokinetic Endpoint: ; Descriptive comparison of AUC0‐14 days between patients treated with DRL_NU and RMP. ; Descriptive comparison of Ctrough concentrations of nivolumab over time between patients treated with DRL_NU and RMP. ; Other PK parameters that will be compared include: Cma Xafter first dose, Tma Xafter first dose and t1/2.Timepoint: Base‐line to Week 25 INCLUSION CRITERIA: 1. Patients of either gender greater than or equal to 18 to less than or equal to 75 years of age. 2. Patients capable and willing to voluntarily provide informed consent for participation as per the locally applicable regulations. 3. Patients must be willing and able to comply with the study requirements. 4. Patients with ECOG performance status score of 0 or 1. 5. Patients with histologically‐ or cytologically‐documented squamous cell NSCLC who present with Stage IIIB or Stage IIIC or Stage IV disease, or with recurrence or progressive disease following multimodal therapy (radiation therapy, surgical resection or definitive chemoradiation therapy for locally advanced disease). The diagnosis of disease indication should be by a biopsy which was excisional, incisional or core needle. Fine needle aspiration is considered as insufficient for confirmation of the diagnosis. 6. Patients must have experienced disease recur}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02694779/full} -} - - -Record #436 of 538 -@article{EUCTR2017-001041-27-LT18, -author = {EUCTR2017-001041-27-LT,}, -title = {A study of REGN2810 (Cemiplimab, Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy versus pembrolizumab in patients with lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2017-001041-27-LT}, -year = {2018}, -accession_number = {ICTRP EUCTR2017‐001041‐27‐LT}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: cemiplimab Product Code: REGN2810 Pharmaceutical Form: Solution for infusion INN or Proposed INN: cemiplimab Other descriptive name: REGN2810 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 350‐ Trade Name: Carboplatin 10 mg/ml concentrate for solution for infusion Product Name: Carboplatin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: carboplatin Other descriptive name: CARBOPLATIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ Trade Name: Cisplatin 1 mg/ml Concentrate for Solution for Infusion Product Name: Cisplatin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: CISPLATIN Current Sponsor code: Cisplatin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1‐ Trade Name: Gemcitabine 2 g Powder for Solution for Infusion Product Name: GEMCITABINE Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: GEMCITABINE CAS Number: 95058‐81‐4 Other descriptive name: gemcitabine Concentration unit: g gram(s) Concentration type: equal Concentration number: 2‐ Trade Name: Paclitaxel Product Name: PACLITAXEL Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: PACLITAXEL CAS Number: 33069‐62‐4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6‐ Trade Name: Armisarte Product Name: Armisarte (Pemetrexed) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: PEMETREXED CAS Number: 137281‐23‐3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ Trade Name: Yervoy Product Name: ipilimumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: IPILIMUMAB Other descriptive name: ipilimumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concent CONDITION: Non‐Small Cell Lung Cancer Therapeutic area: Diseases [C] ‐ Cancer [C04] SECONDARY OUTCOME: Secondary end point(s): The key secondary endpoints in the study are OS and ORR.; ; Timepoint(s) of evaluation of this end point: Through 108 weeks of treatment plus a follow up period. PRIMARY OUTCOME: Main Objective: The primary objective of the study is to compare the progression‐free survival (PFS) of cemiplimab plus ipilimumab combination therapy (hereinafter referred to as cemiplimab/ipi) and REGN2810 plus 2 cycles only of platinum‐based doublet chemotherapy plus ipilimumab combination therapy (hereinafter referred to as “ cemiplimab/chemo/ipi”) with standard‐of‐care pembrolizumab monotherapy in the first line treatment of patients with advanced squamous or non‐squamous non‐small cell lung cancer (NSCLC) whose tumors express programmed death ligand 1 (PD L1) in =50% of tumor cells. Primary end point(s): The primary endpoint is PFS as assessed by a blinded Independent Review Committee (IRC) based on RECIST (Response assessment in solid tumours) 1.1 assessments. Secondary Objective: The key secondary objectives of the study are the following:; •To compare the overall survival (OS) of cemiplimab/ipi and cemiplimab/chemo/ipi with pembrolizumab monotherapy in the first line treatment of patients with advanced squamous or non squamous NSCLC whose tumors express PD L1 in =50% of tumor cells; •To compare the objective response rate (ORR) of cemiplimab/ipi and cemiplimab/chemo/ipi with pembrolizumab monotherapy in the first line treatment of patients with advanced squamous or non‐squamous NSCLC whose tumors express PD L1 in =50% of tumor cells; ; Timepoint(s) of evaluation of this end point: Through 108 weeks of treatment plus a follow up period. INCLUSION CRITERIA: 1. Men and women =18 years of age. 2. Patients with histologically or cytologically documented squamous or non‐squamous NSCLC with stage IIIB or IIIC disease who are not candidates for treatment with definitive concurrent chemo/radiation or patients with stage IV disease if they have not received prior systemic treatment for recurrent or metastatic NSCLC. The histologic diagnosis of NSCLC may be confirmed by the central laboratory. 3. Availability of an archival or on‐study obtained formalin‐fixed, paraffin embedded tumor tissue sample 4. Expression of PD L1 in =50% of tumor cells determined by a commercially available assay. 5. At least 1 radiographically measureable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site. 6. ECOG performance status of =1. 7. Anticipa}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01900405/full} -} - - -Record #437 of 538 -@article{Durm21, -author = {Durm, G, Birdas, T, Liu, H, Jalal, S, Kesler, K, Rieger, K, Ceppa, D, and Hanna, N}, -title = {P03.01 A Randomized Phase II Trial of Adjuvant Pembrolizumab vs Observation after Curative Resection for Stage I NSCLC with Primary Tumors Between 1-4 cm}, -journal = {Journal of thoracic oncology}, -volume = {16}, -number = {3}, -pages = {S257‐S258}, -year = {2021}, -accession_number = {EMBASE 2011422070}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer adjuvant therapy; *cancer staging; *cancer surgery; *non small cell lung cancer; *primary tumor; Adjuvant chemotherapy; Adult; Advanced cancer; Cancer patient; Cancer recurrence; Cancer research; Cancer size; Cancer survival; Chemoradiotherapy; Clinical trial; Conference abstract; Controlled study; Disease free survival; Drug therapy; Female; Follow up; Human; Immunotherapy; Indiana; Major clinical study; Male; Multicenter study; Neoadjuvant therapy; Overall survival; Phase 2 clinical trial; Radiotherapy; Randomized controlled trial; Recurrence risk; Sample size; X‐ray computed tomography}, -abstract = {Introduction: There are approximately 35,000 cases of stage I lung cancer in the United States each year. While these patients have better 5‐year overall survival (OS) rates than their counterparts with locally advanced and metastatic disease, there is still considerable room for improvement. Based on a recent publication validating the 8th edition of the TNM classification, the 5‐year OS for node‐negative pathologically‐staged NSCLC between 1‐4cm ranges from 73‐86%, and recurrence rates for resected stage I NSCLC can range from 18‐38%. Previous studies looking at adjuvant chemotherapy in this setting have shown no benefit for stage IA tumors, and the current standard of care is observation alone. Checkpoint blockade with PD‐1/PD‐L1 inhibitors has shown considerable activity in NSCLC including in metastatic disease, as consolidation in stage III disease after chemoradiation, and in studies evaluating neoadjuvant immunotherapy. Given this activity and their favorable safety profile, we designed a study of adjuvant PD‐1 inhibition following resection in stage I NSCLC. Methods: This study is a randomized phase II multicenter trial of adjuvant Pembrolizumab versus observation alone following complete resection of stage I NSCLC with tumors between 1‐4cm. The trial will enroll 368 patients randomized 1:1 to either Pembrolizumab 200mg IV every 3 weeks for up to 17 cycles or observation alone with scheduled CT scans and routine clinical follow‐up. Stratification factors include PD‐L1 TPS ≥50% vs. <50% and tumor size of 1‐2cm vs. >2‐4cm. The sample size is based on the hypothesis that adjuvant Pembrolizumab will increase 3‐year disease free survival (DFS) from 75% to 84.15% (HR=0.6) with a power of 80% and a type I error of 0.1. The lead site is Indiana University, and the trial will be conducted through the Big Ten Cancer Research Consortium. The primary endpoint is DFS, and secondary endpoints include OS, DFS at 1‐, 2‐, and 3‐year time points, and toxicity. The trial opened to accrual at the lead site in May 2020, and there are currently 2 patients enrolled. [Formula presented] Results: Conclusion Keywords: Adjuvant, Immunotherapy, NSCLC}, -DOI = {10.1016/j.jtho.2021.01.374}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02267492/full} -} - - -Record #438 of 538 -@article{Kawajiri22, -author = {Kawajiri, K, Shinno, Y, Shirasawa, M, Sato, D, Takeyasu, Y, Torasawa, M, Matsumoto, Y, Masuda, K, Okuma, Y, Yoshida, T, Goto, Y, Horinouchi, H, Yamamoto, N, and Ohe, Y}, -title = {MO11-1 Efficacy of durvalumab after chemoradiotherapy with daily low-dose carboplatin for unresectable locally advanced NSCLC}, -journal = {Annals of oncology}, -volume = {33}, -pages = {S488}, -year = {2022}, -accession_number = {EMBASE 2019357800}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *chemoradiotherapy; *drug efficacy; *non small cell lung cancer; Aged; Cancer center; Cancer patient; Cancer staging; Cancer survival; Clinical evaluation; Clinical outcome; Clinical trial; Conference abstract; Drug therapy; Drug withdrawal; Fatigue; Female; Follow up; Human; Low drug dose; Major clinical study; Male; Myositis; Outcome assessment; Pneumonia; Progression free survival; Radiotherapy}, -abstract = {Background: On the basis of the PACIFIC trial, the standard of care for unresectable stage III non‐small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by 1 year of durvalumab consolidation therapy. Although CRT with platinum doublet is standard, low‐dose carboplatin (CBDCA) is widely used in Japan for patients who are not eligible for platinum‐based doublet chemotherapy. However, because only five patients received low‐dose CBDCA in the PACIFIC study, the efficacy of durvalumab after CRT with low‐dose CBDCA remains unclear. Methods: We evaluated patients who received low‐dose CBDCA‐based chemoradiotherapy for unresectable stage III NSCLC at the National Cancer Center Hospital between December 2007 and January 2021. The patients were divided into the following two groups: patients who received durvalumab after CRT (Durvalumab group) and those who received CRT alone (CRT alone group). We compared clinical outcomes between the two groups. Results: Of the 481 patients treated with CRT for stage III NSCLC, 56 received chemoradiotherapy with low‐dose CBDCA. The median age was 77 years (range: 67‐86 years). Twenty‐one patients received durvalumab after CRT, and thirty‐five patients did not. The median follow‐up time was 19.1 months in the Durvalumab group and 27.8 months in the CRT alone group. Median progression‐free survival was significantly longer in the Durvalumab group than in the CRT alone group (not reached vs. 12.9 months; p = 0.009). In the Durvalumab group, only 29% of patients (6/21) completed 1 year of treatment with durvalumab, and 13 patients (62%) discontinued durvalumab within 1 year. The reasons for discontinuation were disease progression in six cases and adverse events in seven cases (non‐infectious pneumonia in five cases, fatigue and myositis in one case, each). Conclusion: Durvalumab consolidation therapy after CRT can have benefit in patients with stage III NSCLC who received low‐dose CBDCA‐based chemoradiotherapy.}, -DOI = {10.1016/j.annonc.2022.05.125}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02465538/full} -} - - -Record #439 of 538 -@article{EUCTR2019-002463-10-NO19, -author = {EUCTR2019-002463-10-NO,}, -title = {A study of BLU-667 in patients with lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-002463-10-NO}, -year = {2019}, -accession_number = {ICTRP EUCTR2019‐002463‐10‐NO}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: Pralsetinib Product Code: BLU‐667 Pharmaceutical Form: Capsule INN or Proposed INN: BLU‐667 CAS Number: 2097132‐94‐8 Current Sponsor code: BLU‐667 Other descriptive name: BLU123244, BLU3244, X581238, C683, SEE, 72C683 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100‐ Trade Name: Carboplatin Product Name: Carboplatin Product Code: N/A Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Carboplatin CAS Number: 41575‐94‐4 Current Sponsor code: N/A Other descriptive name: CARBOPLATIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ Trade Name: Cisplatin Product Name: Cisplatin Product Code: N/A Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: CISPLATIN CAS Number: 15663‐27‐1 Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1‐ Trade Name: Keytruda Product Name: Keytruda Product Code: N/A Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: PEMBROLIZUMAB CAS Number: 1374853‐91‐4 Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25‐ Trade Name: Gemcitabine Product Name: Gemcitabine Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: GEMCITABINE CAS Number: 95058‐81‐4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000‐ Trade Name: Alimta Product Name: Alimta Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: PEMETREXED CAS Number: 137281‐23‐3 Concentration unit: mg milligram(s) Concentration t CONDITION: RET fusion‐positive, Metastatic Non‐Small Cell Lung Cancer ; MedDRA version: 21.1 Level: LLT Classification code 10029514 Term: Non‐small cell lung cancer NOS System Organ Class: 100000004864 ; MedDRA version: 20.0 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 100000004864 Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: ‐ To assess whether pralsetinib improves progression‐free survival (PFS) as compared to Investigator’s choice platinum‐containing chemotherapy regimens for patients with RET fusion‐positive metastatic NSCLC Primary end point(s): ‐ PFS, defined as the number of weeks from randomization date to the earlier of documented progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 central imaging review or death due to any cause Secondary Objective: The key secondary objectives are:; •To evaluate objective response rate (ORR) determined by central radiology assessment according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1; •To evaluate overall survival (OS); To control study‐wide Type I error, the key secondary objectives will be tested in the order presented, as part of the sequential testing scheme for the study if the primary analysis is significant.; Timepoint(s) of evaluation of this end point: Imaging will be performed at the following timepoints, regardless of treatment delays: Screening, at 6 and 12 weeks, then every 9 weeks for the first 48 weeks, and every 12 weeks thereafter. SECONDARY OUTCOME: Secondary end point(s): ORR / DOR / Intracranial Progression or Response Rate ‐ "Imaging will be performed at the following timepoints, regardless of treatment delays: Screening, at 6 and 12 weeks, then every 9 weeks for the first 48 weeks, and every 12 weeks thereafter."; ; OS ‐ "Patients who have confirmed progressive disease at EOT or during follow‐up for PFS or those who initiate another antineoplastic therapy will be followed for overall survival by telephone contact that will include questions regarding subsequent antineoplastic therapy and survival status approximately every 3 months from the EOT visit until death, withdrawal of consent, or closure of the study by the Sponsor."; ; PROs: EORTC‐QLQ‐LC13, EORTC‐QLQ‐C30 symptom scores, and EQ‐5D‐5L assessments will be evaluated as mean change from baseline to Week 12. Timepoint(s) of evaluation of this end point: ORR / DOR / Intracranial Progression or Response Rate ‐ "Imaging will be performed at the following timepoints, regardless of treatment delays: Screening, at 6 and 12 weeks, then every 9 weeks for the first 48 weeks, and every 12 weeks thereafter."; ; OS ‐ "Patients who have confirmed progressive disease at EOT or during follow‐up for PFS or those who initiate another antineoplastic therapy will be followed for overall survival by telephone contact that will include questions regarding subsequent antineoplastic therapy and survival status approximately every 3 months from the EOT visit until death, withdrawal of consent, or closure of the study by the Sponsor."; ; Please refer to protocol for more details. INCLUSION CRITERIA: 1. Patient must be =18 years of age inclusive, at the time of signing the informed consent. 2. Patient has pathologically confirmed, definitively diagnosed, advanced (not able to be treated with surgery or radiotherapy) or metastatic NSCLC and has not been treated with systemic anticancer therapy for metastatic disease. 3. Patient must meet 1 of the following 2 criteria: a. Have a documented RET fusion using either tissue or plasma as determined by a local test. Refer to laboratory manual for details on acceptable local RET fusion testing methods and tissue requirements. Patient agrees to provide adequate tumor tissue (archived, if available, or a fresh biopsy) for central confirmation of RET fusion using a next generation sequencing (NGS) based assay. If no adequate tumor tissue is available and a new biopsy is not feasible, the patient will not be eligible for enrolment. b. Have documentation of a RET fusion by a positive result from tumor tiss}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169287/full} -} - - -Record #440 of 538 -@article{Johnson24, -author = {Johnson, ML, Soo, RA, Wu, Y-L, Baktash, N, Maier, D, Eigenbrod-Giese, S, and Yoshida, T}, -title = {Beamion LUNG-2: a phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/ metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644909665}, -publication type = {Journal article; Conference proceeding}, -keywords = {*metastasis; *non small cell lung cancer; Adult; Adverse drug reaction; Common Terminology Criteria for Adverse Events; Conference abstract; Controlled study; Drug combination; Drug therapy; First‐line treatment; Human; Intravenous drug administration; Major clinical study; Major surgery; Male; Multicenter study; Multiple cycle treatment; Open study; Overall survival; Patient‐reported outcome; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Side effect; Solid tumor; Systemic therapy}, -abstract = {Background: HER2mutations are present in 2‐4% of NSCLC tumors, and ∼50% occur in the TKD. First‐line SoC for patients with HER2mutation‐positive (m+) NSCLC is platinum‐based chemotherapy 6 immunotherapy; however, no targeted first‐line treatment has been approved. Zongertinib is a HER2‐selective tyrosine kinase inhibitor (TKI) that binds to both wildtype and mutated HER2 but spares EGFR. In a Phase Ia trial in 53 pre‐treated patients with HER2aberration‐positive solid tumors, zongertinib conferred an objective response (OR)/ disease control rate (DCR) of 49/91% and an OR/DCR of 58/97% in those patients with HER2m+ NSCLC (n=36), with manageable safety with few EGFR‐associated toxicities (Beamion LUNG‐1; NCT04886804). Here, we describe Beamion LUNG‐2 (NCT06151574), a Phase III, randomized, active‐controlled, open‐label trial designed to assess the efficacy of first‐line zongertinib versus SoC in patients with HER2m+, locally advanced or metastatic non‐squamous NSCLC. Methods: Approximately 270 patients from ∼160 sites across 30 countries will be randomized 1: 1 to receive either zongertinib or SoC and stratified by the presence of the A775‐G77insYVMA HER2 mutation. In the experimental treatment arm, patients will receive 120 mg oral zongertinib once‐daily in 21‐day cycles. In the comparator treatment arm, patients will receive 500 mg/m2 intravenous pemetrexed chemotherapy, plus either 75 mg/m2 cisplatin or Area Under the Curve 5 carboplatin, plus 200 mg pembrolizumab on Day 1 once every 3 weeks (q3w) for four 21‐day cycles, then maintenance with 500 mg/m2 pemetrexed plus 200 mg pembrolizumab q3w for up to 35 cycles. Treatment in both arms will continue until progressive disease (PD; RECIST 1.1), undue toxicity, or other criteria are met. The primary endpoint is progressionfree survival (RECIST 1.1), by blinded central independent review. Secondary endpoints include OR (defined as best overall response of complete or partial response, RECIST 1.1); patientreported outcomes analysed as changes from baseline to Week 25; overall survival and occurrence of adverse events (CTCAE version 5.0). Key inclusion criteria are histologically or cytologically diagnosed advanced and/or metastatic non‐squamous NSCLC; ≥1 measurable lesion (RECIST 1.1); no prior systemic treatment for locally advanced or metastatic disease; a documented HER2 TKD mutation; and eligibility to receive the selected SoC. Key exclusion criteria are tumors with targetable alterations with an available treatment; presence/history of uncontrolled/symptomatic leptomeningeal disease; and radiotherapy or major surgery ≤4 weeks prior to randomization.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02736227/full} -} - - -Record #441 of 538 -@article{Ohri24, -author = {Ohri, N, Jolly, S, Cooper, BT, Kabarriti, R, Bodner, WR, Klein, J, Guha, C, Viswanathan, S, Shum, E, Sabari, JK, Cheng, H, Gucalp, RA, Castellucci, E, Qin, A, Gadgeel, SM, and Halmos, B}, -title = {Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT)}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {5}, -pages = {562‐570}, -year = {2024}, -accession_number = {EMBASE 2030407262, PUBMED 37988638}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; *radioimmunotherapy; Adult; Adverse drug reaction; Aged; Chemoradiotherapy; Complication; Conference paper; Controlled study; Drug combination; Drug therapy; Esophagitis; Female; Human; Male; Multiple cycle treatment; Overall survival; Progression free survival; Radiotherapy; Response evaluation criteria in solid tumors; Side effect}, -abstract = {PURPOSEStandard therapy for locally advanced non‐small‐cell lung cancer (LA‐NSCLC) is concurrent chemoradiotherapy followed by adjuvant durvalumab. For biomarker‐selected patients with LA‐NSCLC, we hypothesized that sequential pembrolizumab and risk‐adapted radiotherapy, without chemotherapy, would be well‐tolerated and effective.METHODSPatients with stage III NSCLC or unresectable stage II NSCLC and an Eastern Cooperative Oncology Group performance status of 0‐1 were eligible for this trial. Patients with a PD‐L1 tumor proportion score (TPS) of ≥50% received three cycles of induction pembrolizumab (200 mg, once every 21 days), followed by a 20‐fraction course of risk‐adapted thoracic radiotherapy (55 Gy delivered to tumors or lymph nodes with metabolic volume exceeding 20 cc, 48 Gy delivered to smaller lesions), followed by consolidation pembrolizumab to complete a 1‐year treatment course. The primary study end point was 1‐year progression‐free survival (PFS). Secondary end points included response rates after induction pembrolizumab, overall survival (OS), and adverse events.RESULTSTwenty‐five patients with a PD‐L1 TPS of ≥50% were enrolled. The median age was 71, most patients (88%) had stage IIIA or IIIB disease, and the median PD‐L1 TPS was 75%. Two patients developed disease progression during induction pembrolizumab, and two patients discontinued pembrolizumab after one infusion because of immune‐related adverse events. Using RECIST criteria, 12 patients (48%) exhibited a partial or complete response after induction pembrolizumab. Twenty‐four patients (96%) received definitive thoracic radiotherapy. The 1‐year PFS rate is 76%, satisfying our efficacy objective. One‐ and 2‐year OS rates are 92% and 76%, respectively. The most common grade 3 adverse events were colitis (n = 2, 8%) and esophagitis (n = 2, 8%), and no higher‐grade treatment‐related adverse events have occurred.CONCLUSIONPembrolizumab and risk‐adapted radiotherapy, without chemotherapy, are a promising treatment approach for patients with LA‐NSCLC with a PD‐L1 TPS of ≥50%.}, -DOI = {10.1200/JCO.23.00627}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02668662/full} -} - - -Record #442 of 538 -@article{Dziadziuszko21, -author = {Dziadziuszko, R, Ahn, MJ, Kelly, K, Popat, S, Wakelee, HA, Baird, AM, Rooney, I, Afshari, M, Coleman, S, Zhang, Z, Kiruki, H, Patil, N, Wen, X, and Bradley, JD}, -title = {SKYSCRAPER-03: a Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation}, -journal = {International journal of radiation oncology biology physics}, -volume = {111}, -number = {3}, -pages = {e420‐e421}, -year = {2021}, -accession_number = {EMBASE 2014606113}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *cancer staging; *chemoradiotherapy; *non small cell lung cancer; Adult; Antineoplastic activity; Cancer immunotherapy; Clinical assessment; Clinical trial; Conference abstract; Controlled study; Deterioration; Drug combination; Drug therapy; ECOG Performance Status; Female; Gene mutation; Gene rearrangement; Histology; Histopathology; Human; Human tissue; Maintenance therapy; Major clinical study; Male; Pharmacokinetics; Phase 2 clinical trial; Phase 3 clinical trial; Practice guideline; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors}, -abstract = {Purpose/Objective(s): Until recently, the standard of care for patients (pts) with locally advanced, unresectable, stage III non‐small cell lung cancer (NSCLC) has been platinum‐based concurrent chemoradiation (cCRT); however, the 5‐year OS rates are poor (13–36%; Goldstraw et al. J Thorac Oncol 2015). Durvalumab (anti‐PD‐L1) monotherapy was recently approved for pts without progressive disease (PD) after cCRT. However, long‐term OS data are not yet available and further evaluation of novel cancer immunotherapy combinations should be explored. Targeted inhibition of a novel checkpoint TIGIT/PVR, by the anti‐TIGIT antibody tiragolumab, may amplify the anti‐cancer activity of anti‐PD‐L1/PD‐1 antibodies. In the phase II CITYSCAPE study (NCT03563716), tiragolumab plus atezolizumab (anti‐PD‐L1) was well tolerated and improved ORR compared with atezolizumab alone (31.3 vs 16.2%) in 1L pts with PD‐L1+ (TPS ≥1%) metastatic NSCLC; with greater benefit in the PD‐L1‐high (TPS ≥50%) subset. We hypothesize that tiragolumab plus atezolizumab may provide greater clinical benefit vs single‐agent anti‐PD‐L1 as maintenance therapy in pts with unresectable, stage III NSCLC who have not progressed after platinum‐based cCRT. SKYSCRAPER‐03 (NCT04513925) will determine if tiragolumab plus atezolizumab provides superior clinical benefit to durvalumab in this setting. Current data suggests that cCRT upregulates PD‐L1 expression, potentially enabling PD‐L1 low or negative tumors to derive benefit, so outcomes will be evaluated in all‐comer (ITT) and PD‐L1+ sub‐populations. Materials/Methods: Eligible pts (≥18 years) must have unresectable, stage III NSCLC without PD after ≥2 cycles of platinum‐based cCRT per NCCN/ESMO guidelines, and without an EGFR mutation or ALK rearrangement; known PD‐L1 status; ECOG PS 0–1. Approximately 800 pts will be randomized 1:1 to receive tiragolumab 840mg IV plus atezolizumab 1680mg IV Q4W or durvalumab 10mg/kg IV Q2W / 1500mg IV Q4W. Treatment will continue for up to 13 cycles of 28 days, or until unacceptable toxicity or symptomatic deterioration due to PD; in pts with radiographic PD (per RECIST v1.1) treatment may continue if evidence of ongoing clinical benefit. Stratification factors include PD‐L1 status, histology (squamous vs non‐squamous), staging (IIIA vs IIIB or IIIC) and ECOG PS (0 vs 1). Primary endpoint is independent review facility‐assessed PFS in the ITT and PD‐L1+ (TC ≥1%) populations. Secondary endpoints include investigator‐assessed PFS, OS, ORR and DoR. Safety and biomarker analyses will be performed. Recruitment is ongoing. Results: forthcoming Conclusion: forthcoming}, -DOI = {10.1016/j.ijrobp.2021.07.1203}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02321715/full} -} - - -Record #443 of 538 -@article{Zeidan19, -author = {Zeidan, AM, Cavenagh, J, Voso, MT, Taussig, D, Tormo, M, Boss, I, Copeland, WB, Gray, VE, Previtali, A, O'Connor, T, Rose, S, Beach, CL, and Silverman, LR}, -title = {Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): results from a Large, International, Randomized Phase 2 Study}, -journal = {Blood}, -volume = {134}, -pages = {829}, -year = {2019}, -accession_number = {EMBASE 2013287433}, -publication type = {Journal article; Conference proceeding}, -keywords = {*GATA2 deficiency; *cancer chemotherapy; *cancer patient; *drug safety; Adjuvant chemotherapy; Adult; Advanced cancer; Antineoplastic activity; Aspiration; Bladder metastasis; Bone marrow culture; Cancer radiotherapy; Cancer staging; Clinical outcome; Clinical trial; Cohort analysis; Comparative effectiveness; Conference abstract; Controlled study; DNA methylation; Demography; Drug combination; Drug therapy; ECOG Performance Status; Employment; Female; Flow cytometry; Funding; Gene locus; Genetic susceptibility; Granulocyte; Human; Human cell; Human tissue; Immunocompetent cell; International Prognostic Scoring System; Leukemia remission; Major clinical study; Male; Monocyte; Multicenter study; Neoadjuvant therapy; Non small cell lung cancer; Outcome assessment; Overall response rate; Pharmacokinetics; Phase 2 clinical trial; Protein expression; Protein function; Radiotherapy; Randomized controlled trial; Risk assessment; Seashore; Transitional cell carcinoma; Upregulation}, -abstract = {[Formula presented] Background: Loss of immune surveillance, mediated through immune checkpoint (ICP) interactions, is thought to be a key step in the development of cancers including AML and HR‐MDS. AZA is a standard therapy for pts with AML who are unfit for IC and for pts with HR‐MDS. AZA can promote immune recognition of tumor cells and potentially increase expression of ICP molecules, which can mediate resistance to AZA. As myeloid cell lines and samples from pts treated with hypomethylating agents demonstrated up‐regulation of PD‐L1 expression, blockade of the PD‐L1 ICP with durva in combination with AZA may enhance antitumor activity and improve clinical outcomes. Here, we report the final results from a large phase 2 study evaluating the efficacy and safety of AZA+durva vs. AZA alone in pts with HR‐MDS or AML (NCT02775903). Methods: This randomized, open‐label, international, multicenter study enrolled untreated pts in 2 cohorts: 1) MDS (aged ≥18 years; IPSS‐R intermediate, high, and very high) and 2) older AML pts (aged ≥65 years) who were ineligible for IC. All pts had ECOG performance status 0‐2 and were separately randomized (1:1) to receive SC AZA 75 mg/m2 Days 1‐7 and durva 1500 mg IV on Day 1 Q4W (Arm A) or AZA alone (Arm B) and stratified according to cytogenetic risk (MDS, very good/good/intermediate vs. poor/very poor; AML, intermediate vs. poor). Treatment was planned to continue until progression or unacceptable toxicity. Disease status was evaluated every third treatment cycle. Primary MDS endpoints included overall response rate (ORR, defined as complete remission [CR], marrow [m]CR, partial response [PR], or hematologic improvement [HI]) based on IWG 2006 response criteria, while for AML ORR was defined as CR or CR with incomplete blood recovery (CRi) based on modified IWG 2003 response criteria. Secondary endpoints included PFS, OS, and safety. Peripheral blood samples were collected to assess changes in DNA methylation using the EPIC methylation array (Illumina). Bone marrow (BM) aspirates were obtained for quantitation of PD‐L1 surface expression by flow cytometry and values are reported as molecules of equivalent soluble fluorochrome. Results: A total of 213 pts, 84 with MDS (each arm, n=42) and 129 with AML (Arm A, n=64; Arm B, n=65) were randomized. As of October 31, 2018, 32 pts (MDS, n=14; AML, n=18) continued to receive trial treatment while 181 (MDS, n=70; AML, n=111) had discontinued. Baseline demographics and disease characteristics were generally balanced across treatment groups in both cohorts. Median number of treatment cycles for AML Arm A vs. B, 6.5 vs. 6.7; for MDS Arm A vs. B, 7.9 vs. 7.0. No statistically significant differences in ORR between treatment arms were observed in either cohort (Tables 1 and 2). In MDS Arm A vs. B, median OS was 11.6 vs. 16.7 months (mo) and PFS was 8.7 vs. 8.6 mo. In the AML cohort, median OS was 13.0 vs. 14.4 mo and PFS was 8.1 vs. 7.2 mo. Caution should be used when interpreting results because >50% of patients were censored. The most frequent TEAEs (≥15%) were hematologic and GI toxicity. In the MDS and AML cohorts, 7 and 17, respectively, immune‐mediated AEs were observed; all were treated and resolved. AZA induced similar trends in global hypomethylation, along with focal hypomethylation of PD‐L1 and PD‐L2 gene loci, at the end of treatment cycle 1 in all treatment groups and cohorts. Mean PD‐L1 surface expression in BM immune cells at baseline was highest in monocytes (MDS=1,425; AML=1,536), followed by granulocytes (MDS=550; AML=758) and myeloid blasts (MDS=532; AML=735). Increased surface expression of PD‐L1, but not PD‐L2, was observed at the end of treatment cycle 3 on BM granulocytes and monocytes from MDS pts and on BM monocytes from AML pts, but no increase was detected on myeloid blasts. Conclusions: To our knowledge, this is the first large randomized trial of AZA with or without ICP blockade in older unfit AML and HR‐MDS pts reported to date. No clinically meaningful difference in efficacy was observed between treatments for either cohort. No new safety signals or potential overlapping risks were identified with the combination. While the hypomethylating activity of AZA on PD‐L1 gene was confirmed, no treatment‐mediated induction of PD‐L1 surface expression was observed on myeloid blasts. [Formula presented] Disclosures: Zeidan: Acceleron Pharma: Consultancy, Honoraria, Research Funding; Celgene Corporation: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Otsuka: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; Medimmune/AstraZeneca: Research Funding; Boehringer‐Ingelheim: Consultancy, Honoraria, Research Funding; Trovagene: Consultancy, Honoraria, Research Funding; Incyte: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; ADC Therapeutics: Research Funding; Jazz: Honoraria; Ariad: Honoraria; Agios: Honoraria; Novartis: Honoraria; Astellas: Honoraria; Daiichi Sankyo: Honoraria; Cardinal Health: Honoraria; Seattle Genetics: Honoraria; BeyondSpring: Honoraria. Voso: Novartis: Speakers Bureau; Celgene: Research Funding, Speakers Bureau. Taussig: Celgene: Research Funding. Boss: Celgene Corporation: Employment, Equity Ownership. Copeland: Celgene Corporation: Employment, Equity Ownership. Gray: Celgene Corporation: Employment, Equity Ownership. Previtali: Celgene Corporation: Employment, Equity Ownership. O'Connor: Celgene Corporation: Employment, Equity Ownership. Rose: Celgene Corporation: Employment, Equity Ownership. Beach: Celgene Corporation: Employment, Equity Ownership. OffLabel Disclosure: Durvalumab is a PD‐L1 blocking antibody indicated for the treatment of patients with 1) locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum‐containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum‐containing chemotherapy, or 2) unresectable, stage 3 NSCLC whose disease has not progressed following concurrent platinum‐based chemotherapy and radiation therapy.}, -DOI = {10.1182/blood-2019-122896}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02295875/full} -} - - -Record #444 of 538 -@article{Mitchell18, -author = {Mitchell, P}, -title = {Implications for Routine Practice}, -journal = {Journal of thoracic oncology}, -volume = {13}, -number = {10}, -pages = {S267‐S268}, -year = {2018}, -accession_number = {EMBASE 2001207526}, -publication type = {Journal article; Conference proceeding}, -keywords = {Adult; Advanced cancer; Adverse drug reaction; Brain metastasis; Cancer patient; Cancer staging; Cancer survival; Chemoradiotherapy; Conference abstract; Controlled study; Double blind procedure; Drug combination; Drug safety; Drug therapy; Female; Human; Immunogenicity; Immunotherapy; Irradiation; Low drug dose; Major clinical study; Male; Metastatic melanoma; Multicenter study; Non small cell lung cancer; Overall survival; Palliative therapy; Pharmacokinetics; Phase 1 clinical trial; Phase 2 clinical trial; Phase 3 clinical trial; Pneumonia; Prospective study; Protein expression; Radiotherapy; Randomized controlled trial; Side effect; Stereotactic body radiation therapy; Stereotactic radiosurgery}, -abstract = {Over the last 3 years checkpoint inhibitors (CPI) have become established as key components in the treatment of stage III and IV NSCLC. The established CPI are PD‐1 and PD‐L1 inhibitors and more recently CTLA4 inhibitors, with ongoing research into other modulators of T‐cell function. Used alone, these agents have their greatest efficacy in a subset of patients while combination with other treatment modalities may enhance efficacy. Already concurrent pembrolizumab and chemotherapy has been shown to be more effective than chemotherapy alone for first‐line metastatic NSCLC. 1 In the clinic there are two major issues to consider when combining immunotherapy and radiotherapy. The first is safety, particularly when irradiating lung or the brain. The second issue is, can we harness radiotherapy to improve the efficacy of immunotherapy? Pneumonitis is a major concern when combining radiotherapy to the lung. Lower dose palliative radiotherapy is less of a concern but when treating primary lung cancer with curative intent, especially concurrent with chemotherapy, toxicity may impact on patient survival. In the phase III PACIFIC trial, of the 476 stage III NSCLC patients who received concurrent chemoradiation to the lung followed by durvalumab consolidation, grade ≥3 pneumonitis was 4.5% and no different from chemoradiation alone. 2 In 93 stage III patients treated with concurrent chemoradiation followed by 12 months pembrolizumab consolidation grade ≥3 pneumonitis was 6.5%. 3 We now have safety data for stage III patients with nivolumab given concurrently with thoracic chemoradiotherapy, followed by consolidation nivolumab. For the 58 patients evaluable for toxicity in the NICOLAS trial, grade ≥3 pneumonitis was 10.3%. 4 We now also have safety data for SABR (Stereotactic Ablative Radiotherapy) combined with CPI. Seventy nine patients (53 NSCLC) received SABR to multiple metastases, followed within 7 days by pembrolizumab. The toxicity was as expected for pembrolizumab alone. 5 Similarly Campbell has reported on treatment with concurrent SABR and pembrolizumab with either melanoma or NSCLC, with no increased toxicity. 6 Treating brain melanoma metastases with radiosurgery concurrent with ipilimumab in 57 patients, Mortier found toxicity to be as expected for immunotherapy alone 7, while a similar study by the same group found toxicity was not increased beyond that for pembrolizumab alone. There have been multiple reports, mostly of single cases, whereby local radiotherapy to a tumour causes shrinkage of a distant non‐irradiated metastasis, termed an abscopal effect. 8 It is hoped that likewise radiotherapy will enhance the effectiveness of CPI. Prior to CPI entering the clinic, in the START trial stage III patients treated with consolidation tecemotide (liposomal MUC1) vaccine following concurrent chemoradiation showed a 10 month survival advantage not seen in those who had received sequential chemoradiotherapy. 9,10 Although overall the START trial was negative for the primary endpoint, this suggested that concurrent chemoradiotherapy might enhance immunogenicity. In the PACIFIC trial of stage III NSCLC, all patients received concurrent chemoradiation. Patients randomised to a year of consolidation durvalumab had markedly improved PFS (HR 0.52) irrespective of tumour PD‐L1 expression, and overall survival data are awaited. 2 There are also now data suggesting an outcome benefit for NSCLC patients treated with concurrent SABR and CPI. In the PEMBRO‐RT trial 74 NSCLC patients were randomised to receive SABR (3 x 8GY) to a single metastasis followed within 7 days by pembrolizumab, or pembrolizumab alone. 11 All endpoints trended in favour of the combination. The primary endpoint of response rate at 12 weeks was 39% vs 21% (p=0.28), for SABR + CPI vs CPI respectively, while PFS (HR 0.61 p=0.08) and OS (HR 0.58 p=0.1) favoured combined SABR and pembrolizumab. A similar trial, NIVORAD, is being conducted by the ALTG co‐operative group, where patients are randomised to receive nivolumab with or without SABR to a metastasis site during week 2. 12 There are now good data to indicate that combining CPI and radiotherapy is safe, including radiotherapy to the lung and to the brain. Sequential concurrent chemoradiation in stage III NSCLC followed by durvalumab is highly effective. Emerging data suggest that radiotherapy may enhance the effectiveness of immunotherapy in stage IV disease but further randomised data are required. References: 1 Gandhi L. Pembrolizumab plus chemotherapy in metastatic NSCLC. N Engl J Med 2018: 378; 2078‐2092 2 Antonia S. Durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2017; 377: 1919‐1929 3 Durm G. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III NSCLC. J Clin Oncol 2018; 36: suppl. abstract 8500 4 Peters S. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first‐line chemo‐RT regimen in unresectable locally advanced NSCLC – the ETOP NICOLAS phase II trial. J Clin Oncol 2018; 36: suppl. abstract 8510 5 Luke J. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumours. J Clin Oncol 2018; 36: 1611‐1618 6 Campbell AM. Final results of a phase 1 prospective trial evaluating the combination of stereotactic body radiotherapy with concurrent pembrolizumab in patients with metastatic NSCLC or melanoma. J Cin Oncol 2018; 36: suppl. abstract 9099 7 Mortier L. Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicentre, open label, phase 2 trial. J Clin Oncol 2018; 38: suppl. abstract 9250 8 Siva S. Asbcopal effects after conventional and stereotactic lung irradiation of NSCLC. J Thorac Oncol 2013. 9 Butts C. Tecemotide (L‐BLP‐25) versus placebo after chemoradiotherapy for stage III NSCLC (START): a randomized double‐blind phase 3 trial. Lancet Oncol 2014; 15(1): 59‐68 10 Mitchell PL. Tecemotide in unresectable stage III NSCLC in the phase III START study: updated overall survival, further endpoints and biomarker analysis. Ann Oncol 2015; 26; 1134‐1142 11 Theelen WSME. Randomized phase II study of pembrolizumab after stereotactic body radiotherapy versus pembrolizumab alone in patients with advanced NSCLC: The PEMBRO‐RT study. J Clin Oncol 2018; 36: suppl. abstract 9023 12 Mitchell PLR. NIVORAD: a randomised phase 2 trial of nivolumab and stereotactic ablative radiotherapy in advanced NSCLC progressing after first or second line chemotherapy. J Clin Oncol 2017; 35: suppl. TPS9097 Keywords: Checkpoint inhibitors, radiotherapy, NSCLC}, -DOI = {10.1016/j.jtho.2018.08.146}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01654346/full} -} - - -Record #445 of 538 -@article{Langer19, -author = {Langer, C}, -title = {IBS03.01 Managing Locally Advanced NSCLC in the Elderly in 2019}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S91}, -year = {2019}, -accession_number = {EMBASE 2003406773}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *non small cell lung cancer; Aged; Cancer patient; Cancer prognosis; Cancer staging; Cancer survival; Case report; Chemoradiotherapy; Clinical article; Conference abstract; Drug combination; Drug therapy; Female; Gene mutation; Human; Japan; Low drug dose; Male; Median survival time; Monotherapy; Overall survival; Prognosis; Protein expression; Radiotherapy; Randomized controlled trial; Retrospective study}, -abstract = {In the management of locally advanced (LA) non‐small cell lung cancer (NSCLC), at least 10 studies over the past 25 years have shown superiority for chemoradiation over radiation (XRT) alone; more recently, concurrent chemoradiation has proven superior to sequential or asynchronous chemotherapy followed by XRT. Retrospective analyses evaluating outcomes in the elderly receiving these regimens have generally demonstrated similar progression‐free (PFS) and overall survival (OS) compared to their younger counterparts on study, albeit with increased toxicity.1,2,3 Generally, those over 70 years of age were under‐represented on these trials compared to the NSCLC population at large ‐ while more than 40% of those diagnosed with LA‐NSCLC were 70 years of age or older, fewer than 20% of those enrolled on relevant clinical trials were elderly.4 Virtually all of the earlier efforts were cisplatin‐based, which made the routine use of this approach in elderly patients outside of clinical trials somewhat problematic, particularly in the face of age‐associated co‐morbidities that might preclude or limit the application of platinating agents. Since the beginning of the new millennia, non‐cisplatin regimens, generally using weekly carboplatin in combination with a taxane or other partner agents active in NSCLC have been shown to yield “equivalent” efficacy with less toxicity. For elderly patients treated outside of a clinical trial, I generally favor weekly carboplatin (AUC 2) coupled with weekly solvent‐based paclitaxel (45‐50 mg/m2) in conjunction with a minimum dose of 60 Gy administered over a 6‐7 week period. At least one trial from Japan conducted exclusively in the elderly with LA‐NSCLC showed superior OS for concurrent XRT and low dose daily carboplatin vs XRT alone with median survival of 22.4 mos compared to 16.5 mos in the control group (HR 0.64).5 However, monotherapy with carboplatin during XRT is not considered the standard approach in LA‐NSCLC. The only randomized trial to compare cisplatin‐ to carboplatin‐based combinations in LA‐NSCLC was a Japanese study which randomized patients to either MVP during thoracic XRT or to weekly carbo and either irinotecan or paclitaxel; this study showed virtually no difference in long term outcome (18 to 20% 5 year survival), with pacitaxel/carboplatin proving better tolerated.6 These results are dissatisfying, but clearly better than historic controls with XRT alone (5‐7% 5 year OS). To date, unfortunately, in North American, we have no prospective, randomized, head‐to‐head comparisons of cisplatin based treatment vs. paclitaxel/carboplatin or other carboplatin‐based regimens in stage IIIA/B NSCLC. Retrospective data from the VA and the SEER database, however, suggest little difference in long term OS.7 The results of RTOG 0617 would tend to validate paclitaxel/carboplaitn as a "viable” regimen in "good prognosis” LA‐NSCLC pts with median survival in the 23 to 29 month range for weekly paclitaxel/carboplatin during radical XRT, with no advantage for 74 Gy over 60 Gy or the addition of cetuximab.8 More recently, the PACIFIC trial showed that patients with LA‐NSCLC who received “consolidative” durvalumab, a PDL1 inhibitor, for up to a year, after responding to or stabilizing on concurrent chemoradiation, could enjoy a three‐fold increase in PFS (16.8 vs 5.6 mos) and a 10% absolute improvement in OS (66.3% vs 55.6%).9 These benefits were both statistically significant (HR 0.68) and clinically meaningful; and the PACIFIC regimen featuring concurrent chemo‐radiation followed by durvalumab has emerged as the “standard of comparison” if not the “standard of care” in fit individuals with LA‐NSCLC, regardless of age. Of note, the HR for OS benefit in PACIFIC in those 65 years of age and older was 0.76 (95% CI: 0.55 ‐ 1.05) vs 0.62 (95% CI: 0.44‐ 0.88) for patients under 65. Whether this approach should be applied to patients whose tumors do not harbor PDL1 expression or whose tumors have an oncogenic driver such as EGFR mutations remains controversial. References: 1. Rocha‐Lima, C et al, Cancer 2002 2. Langer, C et al, ASCO 2002 3. Schild, S et al, JCO 2002 4. Auperin et al, JCO 2010 5. Atagi et al, Lancet Oncology, 2012 6. Yamamoto et al, JCO 2010 7. Santana‐Davila, R et al, JCO 2015 8. Bradley, J et al, Lancet Oncology 2015 9. Antonia, S et al, NEJM 2018. Keywords: elderly, locally advanced NSCLC}, -DOI = {10.1016/j.jtho.2019.08.205}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01997548/full} -} - - -Record #446 of 538 -@article{KCT000582421, -author = {KCT0005824,}, -title = {Chemotherapy plus pembrolizumab after progression with previous PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: placebo-controlled randomized phase II study}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=KCT0005824}, -year = {2021}, -accession_number = {ICTRP KCT0005824}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Drug : Arm a : pembrolizumab plus chemotherapy (Gemcitabine or Pemetrexed or Docetaxel or Vinorelbine) Arm b: placebo plus chemotherapy (Gemcitabine or Pemetrexed or Docetaxel or Vinorelbine) Pembrolizumab 200 mg: Every 3 weeks, 30mins IV injection. Gemcitabine 1250mg / m2: Every 3 weeks (Day 1, 8), 30mins IV injection. Pemetrexed 500mg / m2: Every 3 weeks, 10mins IV injection. Docetaxel 60mg / m2: Every 3 weeks, 30mins IV injection. Vinorelbine 30mg / m2: Every 3 weeks, 6‐10mins IV injection. CONDITION: Neoplasms PRIMARY OUTCOME: The primary efficacy objective of this study is to evaluate the progression‐free survival of pembrolizumab plus chemotherapy. SECONDARY OUTCOME: Safety, Overall survival, Response rate INCLUSION CRITERIA: (1) Histologically confirmed diagnosis of advanced NSCLC, ineligible for surgery or definitive radiotherapy, will be enrolled in this study. (2) The participant (or legally acceptable representative if applicable) provides written informed consent for the trial. (3) Advanced stage which is difficult to topical treatment. (4) Male/female participants who are at least 20 years of age on the day of signing informed consent. (5) Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. (6) Received one or two cytotoxic chemotherapy for advanced NSCLC including at least one platinum‐doublet (example 1: patients with 1st line pemetrexed/cisplatin ? 2nd line docetaxel ? 3rd line pembrolizumab therapy can be enrolled, because they received two cytotoxic chemotherapy. Example 2: patients with 1st line weekly paclitaxel/carboplatin‐based definitive concurrent chemoradiotherapy for stage III NSCLC? 2nd line pembrolizumab can be enrolled}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02238279/full} -} - - -Record #447 of 538 -@article{Lin19, -author = {Lin, SH, Lin, Y, Mok, I, Young, JA, Phan, S, Sandler, A, Papadimitrakopoulou, V, Heymach, J, and Tsao, AS}, -title = {Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer}, -journal = {Journal of clinical oncology}, -volume = {37}, -year = {2019}, -accession_number = {EMBASE 629301180}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *chemoradiotherapy; *non small cell lung cancer; Adult; Adverse drug reaction; Arthralgia; Cancer patient; Cancer recurrence; Cancer survival; Case report; Clinical article; Conference abstract; Diarrhea; Drug combination; Drug safety; Drug therapy; Drug withdrawal; Dyspnea; Fatigue; Feasibility study; Female; Fistula; Follow up; Gene expression; Heart failure; Human; Immunotherapy; Low drug dose; Male; Nephritis; Overall survival; Phase 2 clinical trial; Progression free survival; Protein expression; Radiation pneumonia; Radiotherapy; Randomized controlled trial; Side effect; Survivor; Tumor biopsy}, -abstract = {Background: Consolidation durvalumab after chemoradiation (CRT) is the new standard of care in locally advanced NSCLC (LA‐NSCLC). We hypothesized that adding immunotherapy concurrently with CRT (cCRT) would increase efficacy without significant additive toxicity. To test this concept, we conducted a phase II trial called DETERRED combining atezolizumab (atezo) with cCRT followed by consolidation full dose carboplatin/paclitaxel (CP) with atezo (CP‐atezo) for 2 cycles and then maintenance atezo for 1 year. The primary endpoint was safety/toxicity and feasibility. Methods: This study enrolled patients (pts) between February 2016‐April 2018 and was done in two parts: In part 1 (N=10), conventionally fractionated CRT (60‐66 Gy in 30‐33 fractions combined with weekly low dose CP) was followed by CP‐atezo then maintenance atezo. Part 2 was cCRT (N=30) with atezo followed by CP‐atezo then maintenance atezo. Atezo was given at 1200 mg IV Q3 weeks. Severe adverse events (SAEs) ≥ grade 3 were defined by CTCAE v5.0. Evaluable pts received at least one dose of atezo. PD‐L1 staining utilizes the DAKO 22C3 platform. Kaplan Meier were analyzed for progression free survival (PFS) and overall survival (OS), and chi‐square test for PD‐L1 levels on any recurrence, with significance set at <0.05. Results: In Part 1, atezo related SAEs were seen in 4 pts (40%) (2 grade 3 arthralgia, 1 grade 3 dyspnea and 1 grade 5 TE fistula). Grade 2 radiation pneumonitis (RP) was seen in 1 pt. In Part 2, seven (23%) pts had atezo related SAEs (diarrhea, nephritis, dyspnea, fatigue and heart failure). RP was seen in 3 pts, 2 grade 2 and 1 grade 3, which led to atezo discontinuation. In Part 1, with an overall median follow up (f/u) time of 22.5 months and 27.4 months for survivors, the 1‐year PFS is 50%, and OS is 79%. In part 2, with a median f/u time of 11.8 months and 13.7 months for survivors, the 1‐year PFS was 57%, and OS is 79%. Baseline tumor biopsy PD‐L1 status was evaluable for 34 pts. There were no significant differences in cancer recurrence for PD‐L1 <1% (7/16=44%) vs ≥1% (6/18=33%), or for the PD‐L1 cutoff of <50% (11/26=42%) vs ≥50% (2/8=25%). Conclusions:Concurrent atezo with CRT followed by CP‐atezo and maintenance atezo is safe without increased toxicities compared to CRT alone followed by CP‐atezo and maintenance atezo. Updated efficacy results from DETERRED will be presented. Ultimately, the clinical benefit of immunotherapy with cCRT followed by consolidation chemo‐immunotherapy will need to be compared to the PACIFIC regimen in a larger randomized trial.}, -DOI = {10.1200/JCO.2019.37.15_suppl.8512}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01987389/full} -} - - -Record #448 of 538 -@article{PER-054-1414, -author = {PER-054-14,}, -title = {A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTRE, INTERNATIONAL STUDY OF MEDI4736 AS SEQUENTIAL THERAPY IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE NON-SMALL CELL LUNG CANCER (STAGE III) WHO HAVE NOT PROGRESSED FOLLOWING DEFINITIVE, PLATINUM-BASED, CONCURRENT CHEMORADIATION THERAPY (PACIFIC)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=PER-054-14}, -year = {2014}, -accession_number = {ICTRP PER‐054‐14}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: 2 treatment arms: • MEDI4736 (10 mg/kg every 2 weeks [Q2W] intravenous [iv] for up to 12 months) • Placebo (matching placebo for infusion Q2W iv for up to 12 months). ‐ MEDI4736 200mg/vial Lyophilized Powder for infusion requires reconstitution before the use. Patients enrolled in the study will receive either MEDI4736 10 mg/kg or placebo via IV infusion Q2W ±3 days. Administration of study drug will commence on Day 1 following randomisation to MEDI4736 or placebo after confirmation of eligibility and will continue on a Q2W schedule for a maximum duration of 12 months. Following preparation of MEDI4736 or matched placebo, the entire contents of the IV bag should be administered as an iv infusion over approximately 60 minutes (±5 minutes), using a 0.2‐μm in‐line filter. CONDITION: ‐C34 Malignant neoplasm of bronchus and lung ; Malignant neoplasm of bronchus and lung Malignant neoplasm of bronchus and lung SECONDARY OUTCOME: To further assess the efficacy of MEDI4736 compared with placebo in terms of: OS24, ORR, DoR, APF12, APF18, PFS2 and DSR ; NAME OF THE RESULT: To further assess the efficacy of MEDI4736 compared with placebo in terms of: OS24, ORR, DoR, APF12, APF18, PFS2 and DSR ; ; ORR Objective response rate ; DSR Deep sustained response ; DoR Duration of response ; OS24 = Proportion of patient alive at 24 months after randomization patients. ; APF12 = Proportion of patients alive and progression free at 12 months from randomization ; APF18 = Proportion of patients alive and progression free at 18 months from randomization ; PFS2 = Time from randomisation to second progression ; ; USED MEASURING METHOD :Tumour assessments using computed tomography (CT)/magnetic resonance imaging (MRI) will be performed in specified times. Response Evaluation Criteria In Solid Tumours 1.1 measurements (using site investigator tumour data) will be used to derive the co‐primary variable of PFS and secondary variables of ORR, DoR, APF12, APF18, and DSR. ; PERIOD OF TIME WHERE THE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE SECONDARY RESULT: OS24 = Proportion of patient alive at 24 months after randomization patients. ; APF12 = Proportion of patients alive and progression free at 12 months from randomization ; APF18 = Proportion of patients alive and progression free at 18 months from randomization ; PFS2 = Time from randomisation to second progression ; INCLUSION CRITERIA: For inclusion in the study patients should fulfil the following criteria: 1. Provision of signed, written and dated informed consent prior to any study specific procedures 2. Male or female aged 18 years or older 3. Patients must have histologically‐ or cytologically‐documented NSCLC who present with locally advanced, unresectable (Stage III) disease (according to Version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology [IASLC Staging Manual in Thoracic Oncology]), OR 4. Patients must have received at least 2 cycles of platinum‐based chemotherapy concurrent with radiation therapy, which must be completed within 5 to 10 days prior to randomisation in the study. For patients who are recovering from toxicities associated with prior treatment, randomisation may be delayed by up to 14 days from the end of the chemoradiation therapy. The platinum‐based chemotherapy regimen may contain one of the following PRIMARY OUTCOME: Efficacy of MEDI4736 treatment compared with placebo in terms of overall survival (OS) and progression free survival (PFS).; NAME OF THE RESULT: Efficacy of MEDI4736 treatment compared with placebo in terms of overall survival (OS) and progression free survival (PFS).; ; OS is defined as the time from the date of randomisation until death due to any cause. PFS will be defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti‐cancer therapy prior to progression. Thus, the two co‐primary endpoints of this study are OS and PFS.; ; USED MEASURING METHOD :RECIST 1.1 criteria will be used to assess patient response to treatment by determining PFS, ORR, DoR and DSR.; ; The methods of assessment of tumour burden used at baseline CT/MRI scans of the chest and abdomen (including liver and adrenal glands) must be used at each subsequent follow‐up assessment.; ; PERIOD OF TIME WHERE THE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: The baseline assessment should be performed within 28 days of randomisation and within 5 to 10 days post the end of chemoradiation therapy, and ideally as close as possible before the start of study drug. For patients who are recovering from toxicities associated with prior treatment, randomisation may be delayed by up to 14 days from the end of the chemoradiation therapy. Efficacy for all patients will be assessed by objective tumour assessments every 8 weeks for the first 12 months (relative to the date of randomisation; then every 12 weeks thereafter until confirmed objective disease progression as defined by RECIST 1.1 (irrespective of the reason for stopping study drug and/or subsequent therapy). If an unscheduled assessment is performed, and the patient has not progressed, every attempt should be made to perform the subsequent assessments at their scheduled visits.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01862270/full} -} - - -Record #449 of 538 -@article{Ohri22, -author = {Ohri, N, Jolly, S, Cooper, BT, Kabarriti, R, Bodner, WR, Klein, J, Viswanathan, S, Shum, E, Sabari, JK, Cheng, H, Gucalp, RA, Castellucci, E, Qin, A, Gadgeel, SM, and Halmos, B}, -title = {The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): initial results}, -journal = {Journal of clinical oncology}, -volume = {40}, -number = {16}, -year = {2022}, -accession_number = {EMBASE 638834490}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *immunotherapy; *non small cell lung cancer; Aged; Anemia; Arthritis; Cancer patient; Cancer radiotherapy; Cancer staging; Cancer survival; Chemotherapy; Clinical article; Clinical trial; Conference abstract; Contraindication; Controlled study; Diarrhea; Drug therapy; ECOG Performance Status; Esophagitis; Exploratory research; Female; Follow up; Human; Immune‐related gene; Lymphatic system tumor; Male; Metabolic tumor volume; Overall survival; Pneumonia; Positron emission tomography‐computed tomography; Progression free survival; Prospective study; Radiotherapy; Response evaluation criteria in solid tumors}, -abstract = {Background: Standard therapy for unresectable locally advanced non‐small cell lung cancer (LANSCLC) is concurrent chemoradiotherapy followed by adjuvant durvalumab. We performed a prospective trial testing sequential pembrolizumab and risk‐adapted radiotherapy without chemotherapy for biomarker‐selected LA‐NSCLC patients. Methods: Patients with stage III NSCLC or unresectable stage II NSCLC, ECOG performance status 0‐1, and no contraindications to protocol‐specified therapy were eligible for this trial. Subjects with PD‐L1 tumor proportion score (TPS) ≥ 50% underwent baseline FDG‐PET/CT, received three cycles of induction pembrolizumab (200 mg, every 21 days), underwent restaging FDG‐PET/CT, received risk‐adapted thoracic radiotherapy (55 Gy delivered to tumors or lymph nodes with metabolic tumor volume exceeding 20 cc and 48 Gy delivered to smaller lesions, all in 20 daily fractions), and then received up to 13 cycles of additional pembrolizumab. The primary study endpoint was one‐year progression‐free survival (PFS). Here we report response rates following induction pembrolizumab, PFS and overall survival (OS) rates, and adverse event rates (CTCAE v. 4.03). Results: Twenty‐five subjects with PD‐L1 TPS ≥ 50% from three institutions were enrolled between August 2018 and November 2021. Median age was 71 (interquartile range [IQR] 62 to 77). One subject had stage II disease, 13 had stage IIIA disease, nine had stage IIIB disease, and two had stage IIIC disease. Median PD‐L1 TPS was 75% (IQR 60 to 80%). Two subjects (8%) developed disease progression during induction pembrolizumab, and two subjects discontinued pembrolizumab after one infusion due to immune‐related adverse events. Using RECIST 1.1 criteria, 12 subjects (48%) exhibited a partial (n = 11) or complete (n = 1) response following induction pembrolizumab on CT. Using PERCIST criteria, 12 subjects (48%) exhibited a partial response following induction pembrolizumab on PET. Four subjects had responses on PET but not on CT, and four had responses on CT but not on PET. With a median follow‐up duration of 13 months, the actuarial 1‐year PFS rate is 74%, and the actuarial 1‐year OS rate is 95%. Grade 3 adverse events have been limited to single cases of anemia, arthritis, diarrhea, esophagitis, and pneumonitis, and no grade 4‐5 adverse events have occurred. Exploratory analyses suggest that response to induction pembrolizumab on PET predicts efficacy of this treatment approach, with a 1‐year PFS rate of 100% for responders, compared to 61% for nonresponders (logrank p = 0.007). Conclusions: Treatment with pembrolizumab and risk‐adapted radiotherapy is a promising treatment approach for LA‐NSCLC patients with PD‐L1 TPS ≥ 50%. Response on PET following induction pembrolizumab may be useful for identifying patients who can be treated successfully without chemotherapy.}, -DOI = {10.1200/JCO.2022.40.16_suppl.8510}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02469296/full} -} - - -Record #450 of 538 -@article{Mitchell13, -author = {Mitchell, PL, Butts, CA, Socinski, MA, Thatcher, N, Wickart-Johansson, G, Ellis, PM, Gladkov, O, Pereira, JR, Eberhardt, WEE, Horwood, K, Szczesna, A, Helwig, C, Schroder, A, and Shepherd, FA}, -title = {Tecemotide (L-BLP25) in unresectable stage iii non-small cell lung cancer in the phase iii start study: further endpoint and exploratory biomarker results}, -journal = {Journal of thoracic oncology}, -volume = {8}, -pages = {S135‐S136}, -year = {2013}, -accession_number = {EMBASE 71395923}, -publication type = {Journal article; Conference proceeding}, -keywords = {*immunotherapy; *lung cancer; *non small cell lung cancer; Blood; Cancer immunotherapy; Disease course; Experimental therapy; Human; Imaging; Institutional care; Lymphocyte; Lymphocyte count; Neutrophil; Overall survival; Patient; Population; Progression free survival; Proportional hazards model; Radiotherapy; Randomization; Safety; Sensitivity analysis; Serum; Single drug dose; Survival; Therapy; Time to treatment; Treatment failure}, -abstract = {Background: The phase III START study evaluated the mucin 1 (MUC1) antigen‐specific cancer immunotherapy tecemotide (L‐BLP25) vs. placebo in patients with stage III unresectable nonsmall cell lung cancer (NSCLC) who did not progress following initial chemo‐radiotherapy (chemo/RT). The primary objective of overall survival (OS) prolongation was not met, however, pre‐defined subgroup analyses revealed a clinically meaningful prolongation of survival with tecemotide in patients previously treated with concurrent chemo/RT (p=0.016). Sensitivity analyses suggested the observed treatment effect may have been under‐estimated due to a clinical hold, which resulted in a median suspension of recruitment and investigational treatment of about 4.4 months. Tecemotide was well tolerated and no safety concerns were identified. Methods: From January 2007 to November 2011, 1513 patients with unresectable stage III NSCLC and stable disease or objective response following initial chemo/RT were randomized (2:1, double‐blind) to subcutaneous tecemotide (806 μg lipopeptide) or placebo, weekly for 8 weeks and then 6‐weekly until disease progression or withdrawal. A single dose of cyclophosphamide (300 mg/m2) or saline was given 3 days prior to first tecemotide/ placebo dose. Primary endpoint, OS, and secondary endpoints progression‐free‐survival (PFS) and time‐to‐treatment‐failure (TTF) used a Cox proportional hazards regression model adjusting for randomization strata. While RECIST 1.0 had to be observed for determination of disease progression, there was no formal imaging schedule to determine disease progression; this was done according to institutional practice. Exploratory analyses were done for treatment interaction for HLA‐A02, ‐DRB4 and ‐B08. Baseline peripheral blood anti‐nuclear antibodies (ANA), serum MUC1 (sMUC1), lymphocyte count and neutrophil:lymphocyte ratio (NLR) currently are being explored. Results: The primary analysis population (N=1239) was defined prospectively to account for the clinical hold and prospectively excluded 274 patients randomized within 6 months prior to onset of the hold. Median PFS was 9.6 months with tecemotide vs. 7.7 months with placebo (HR 0.865, 95%CI 0.755‐0.990, p=0.036). In keeping with OS data, tecemotide treatment effects on PFS were more pronounced in patients treated with concurrent chemo/RT (N=806; HR 0.826, 95%CI 0.696‐0.980, p=0.029) vs. sequential chemo/RT (N=433; HR 0.947, 95%CI 0.756‐1.187, p=0.638). Median TTF was 8.9 months with tecemotide vs. 7.2 months with placebo (HR 0.887, 95%CI 0.777‐1.012, p=0.075). A prolongation of TTF with tecemotide was seen in patients with prior concurrent chemo/ RT (HR 0.844, 95%CI 0.715‐0.996, p=0.045), which was absent in the subgroup with prior sequential chemo/RT (HR 0.977, 95%CI 0.784‐1.217, p=0.835). Detailed biomarker results will be presented. Conclusion: While the primary endpoint of prolongation of OS was not met, secondary endpoints PFS and TTF support the previously‐ reported finding of a more favorable effect of tecemotide in patients treated with concurrent but not sequential chemo/RT. Any potential further clinical investigation of tecemotide in locally advanced NSCLC should focus on patients following concurrent chemo/RT therapy.}, -DOI = {10.1097/01.JTO.0000438438.14562.c8}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01059043/full} -} - - -Record #451 of 538 -@article{Balmanoukian14, -author = {Balmanoukian, AS, Rizvi, NA, Garon, EB, Patnaik, A, Gandhi, L, Leighl, NB, Goldman, JW, Eder, JP, Johnson, EA, Blumenschein, GR, Gubens, MA, Papadopoulos, KP, Lubiniecki, GM, Zhang, J, Niewood, M, Emancipator, K, Dolled-Filhart, M, Hanson, ME, and Hui, R}, -title = {Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC)}, -journal = {International journal of radiation oncology biology physics}, -volume = {90}, -number = {5}, -pages = {S1‐S2}, -year = {2014}, -accession_number = {EMBASE 71817176}, -publication type = {Journal article; Conference proceeding}, -keywords = {*United States; *human; *non small cell lung cancer; *oncology; *patient; *safety; *therapy; Adjuvant therapy; Antineoplastic activity; Assay; Death; Dermatitis; Diarrhea; Disease course; Dyspnea; Electrocorticography; Fatigue; Metastasis; Neoplasm; Pericardial effusion; Phase 1 clinical trial; Pruritus; Relapse; Systemic therapy; T lymphocyte activation; Tissues; Treatment duration; Tumor biopsy; Tumor cell}, -abstract = {Purpose/Objective(s): Programmed death‐1 (PD‐1) receptor‐ligand interaction inhibits T cell activation against tumor cells. MK‐3475 is a potent and highly selective humanized monoclonal antibody against PD‐1 designed to directly block its interaction with its ligands, PD‐L1 and PDL2, thus removing the inhibition of T cell activation against cancer. MK‐ 3475 led to prolonged antitumor activity in previously treated NSCLC patients. This phase 1 study evaluated the safety, tolerability, and clinical activity of MK‐3475 as initial therapy in patients with locally advanced or metastatic NSCLC. Materials/Methods: Patients with no prior systemic therapy for metastatic disease whose tumors expressed PD‐L1 by a preliminary immunohistochemical assay were randomized to MK‐3475 10 mg/kg every 2 or 3 weeks (Q3W). The first 11 patients were randomized to 2 mg/kg and 10 mg/kg Q3W. At least one measurable tumor lesion, ECOG performance status of 0 to 1, adequate organ function, and adequate tumor biopsy were required for enrollment. Prior adjuvant therapy was allowed if it preceded relapse by at least 1 year. Tumor response was assessed every 9 weeks until confirmed disease progression per immune‐related response criteria (irRC; investigator review); RECIST 1.1 by independent central review will also be performed. Results: Eighty‐four patients submitted tissue for PD‐L1 assessment, and 57 patients had tumors that expressed PD‐L1. Between Feb 2013 and Oct 2013, 45 patients started treatment (n=6 2Q3W, n=23 10Q3W, n=16 10Q2W). Preliminary data indicate an ORR (confirmed and unconfirmed) of 36% (67% 2 mg/kg Q3W, 27% 10 mg/kg Q3W, 35% 10 mg/kg Q2W) by irRC. Twenty‐five patients (55%), including all but 2 responders, remain on treatment (treatment duration from 12+ to 48+ weeks). Fiftytwo percent of patients experienced a drug‐related adverse event (AE), usually grade 1‐2 in severity, most commonly fatigue (14%), pruritus (8%), dermatitis acneiform (6%), diarrhea (6%), and dyspnea (6%). There was a single drug‐related grade 3‐5 AE, a grade 3 pericardial effusion. Conclusions: These data suggest that MK‐3475 is generally well tolerated and provides robust antitumor activity in a first‐line setting in patients with locally advanced or metastatic NSCLC that expresses PD‐L1.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01088085/full} -} - - -Record #452 of 538 -@article{Vansteenkiste15, -author = {Vansteenkiste, J}, -title = {Vaccines}, -journal = {Journal of thoracic oncology}, -volume = {10}, -number = {9}, -pages = {S95‐S96}, -year = {2015}, -accession_number = {EMBASE 72232649}, -publication type = {Journal article; Conference proceeding}, -keywords = {*human; *immunotherapy; *lung cancer; *randomized controlled trial; Adjuvant chemotherapy; Bayes theorem; Cancer immunization; Cancer immunotherapy; Chemoradiotherapy; Chemotherapy; Cytotoxic T lymphocyte; Death; Disease control; Disease free survival; Epithelium; Glycosylation; Hazard ratio; Histology; Hypothesis; Immune system; Immunogenicity; Japanese (people); Lymphocyte; Maintenance therapy; Modulation; Natural killer cell; Neoplasm; Non small cell lung cancer; Overall survival; Patient; Patient history of radiotherapy; Phase 2 clinical trial; Population; Predictive value; Radiotherapy; Side effect; Surgical patient; Tandem repeat; Therapy; Tissues; Toxicity; Tumor cell; Tumor immunity; Vaccinia virus}, -abstract = {Cancer immunotherapy in a broad sense is any interaction with the immune system to treat cancer. One approach is non‐antigen‐specific modulation of the immune system. Historical examples with e.g. BCG, interferon, interleukins, were disappointing in lung cancer. More recently, specific antibodies against the Programmed Death 1 (PD‐1) receptor or its ligands (PD‐L1) have delivered exciting results, with major patient benefits in randomised controlled trials (RCTs) in relapsing NSCLC {Brahmer, 2015 19949 / id}. Antigen‐specific immunotherapy aims at specific priming of immune system to recognize the tumour as foreign, thereby generating specific antibodies and/or cytotoxic T cells. This is “therapeutic cancer vaccination (TCV)”. Conditions for optimal TCV are: 1/ specificity (well‐defined target antigen(s) in the tumour, not in other tissues); 2/ selectivity (use in the population expressing the target); 3/ immunogenicity (interaction with antigen leads to effective humoral and/or cellular response); 4/ tumour sensitive to immune kill in order to obtain improvement in patients' outcome. Better knowledge of tumour immunity has led to encouraging data in phase II RCTs with several TCVs, which then have entered large phase III trials. Examples are the MAGE‐A3 vaccine studied in resected early stage NSCLC, the BLP‐25 vaccine in locally advanced NSCLC after chemoradiotherapy, and e.g. belagenpumatucel‐L and the TG4010 vaccine in advanced stage NSCLC. The MAGE‐A3 protein is totally tumour‐specific and present in about 35% of early stage NSCLC. In the hypothesis generating double‐blind, randomized, placebocontrolled phase II study, 182 patients with completely resected MAGE‐A3‐positive stage IB‐II NSCLC received recombinant MAGE‐A3 protein combined with an immunostimulant (13 doses over 27 months) or placebo (2). No significant toxicity was observed. There was a 24% ‐ non‐significant ‐ improvement in disease‐free survival (DFS, HR 0.76; 95% CI 0.48 to 1.21). The ensuing large phase III study MAGRIT (MAGE‐A3 as Adjuvant Non‐ Small Cell LunG cancer ImmunoTherapy) was reported at the ESMO 2014 meeting (3). MAGE‐A3 positive patients with completely resected stage IB‐II‐IIIA NSCLC and adjuvant chemotherapy as clinically indicated, were randomly 2:1 assigned to receive MAGE‐A3 vaccine or placebo. Almost 14,000 surgical patients were screened, 4210 patients were MAGE‐A3 positive (33%), and 2312 patients were randomised. The median DFS (primary endpoint) was slightly better with MAGE‐A3 (60.5 versus 57.9 months), but the difference was unfortunately not significant (Hazard Ratio, HR, 1.02, 95%CI: 0.89, 1.18, P=0.74). No subgroups with potential benefit could be identified. Based on this disappointing result, further development of the MAGE‐A3 vaccine in NSCLC has been abandoned. Mucins like the MUC1 protein are present in many epithelia, but MUC1 expression is altered (mainly by aberrant glycosylation) in many cancer types, including NSCLC. The tandem repeat MUC1‐peptide liposomal vaccine BLP‐25 has been studied in patients with stage IIIB‐IV NSCLC (4). While overall survival (OS) was not significantly different in the total group, a challenging effect was observed in stage IIIB patients (HR 0.524; 95%CI 0.261‐ 1.052). This led to START (Stimulating Targeted Antigenic Responses to NSCLC Trial), a phase III, double blind, RCT comparing maintenance therapy with Tecemotide (n=829) or placebo (n=410) in patients with unresectable stage III NSCLC who did not progress after sequential or concurrent chemo‐radiotherapy (5). The primary endpoint ‐ OS ‐ was not significantly different between the vaccine and placebo group (25.6 and 22.3 months). However, pre‐planned subgroup analysis showed that the patients treated with concurrent chemoradiotherapy (N=829) had a 10.2‐month improvement in OS (30.8 versus 20.6 months, adjusted HR 0.78, P=0.016). The consequential trial was START 2, a similar large RCT in patients who completed concurrent chemoradiotherapy for unresectable stage III NSCLC (NCT02049151). However, this RCT and further development of Tecemotide was abandoned after disappointing results of a smaller trial in Japanese patients with stage III NSCLC and concurrent chemoradiotherapy. Belagenpumatucel‐L is a vaccine based on a mixture of allogeneic tumour cells with TGF‐β2 antisense blockade as adjuvant. A phase III trial in patients with stage III‐IV NSCLC in disease control after first‐line therapy was reported at the 2013 ESMO meeting (STOP, NCT00676507) (6). Patients without progression after 1st line chemotherapy, were randomly assigned to intradermal belagenpumatucel‐L (N=270) versus placebo (N=262)for 24 months. Median OS was 20.3 months with belagenpumatucel‐L versus 17.8 months with placebo (HR 0.94, p=0.594). In subgroup analysis of patients randomized <12 weeks after the last chemotherapy, the HR of the median OS was 0.77 (P=0.092). For patients enrolled within 12 weeks and treated with previous radiotherapy, the HR was HR 0.45 (P=0.014). The vaccine was well tolerated with mainly mild local administration side‐effects. TG4010 is a vaccine based on a recombinant viral vector (attenuated strain of vaccinia virus) expressing both the tumour‐associated antigen MUC1 and interleukin‐2. This vaccine is explored in the phase IIB/III RCT TIME trial (NCT01383148). This double‐blind, placebocontrolled trial evaluates standard first‐line chemotherapy with or without TG4010 in MUC1‐positive stage IV NSCLC patients. In the phase IIB part, the predictive value of activated NKs (TrPAL: triple positive activated lymphocytes) was evaluated based on a PFS endpoint, and reported in an interim report at the 2014 ESMO meeting (7). Based on a Bayesian analysis, the predefined endpoint of a HR <1 in the patients with low level of NK cells was met. The PFS was not significantly different between vaccine and placebo (HR 0.78, 95%CI 0.55‐1.10]. In subgroup analyses, the effect was more pronounced in patients with non‐squamous NSCLC (HR 0.71, 95CI 0.51‐0.97) than in squamous histology. Therefore, a decision was made to continue the phase III part of the trial in non‐squamous NSCLC only, with OS a the primary endpoint.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01142708/full} -} - - -Record #453 of 538 -@article{Lin17, -author = {Lin, SH, Lin, Y, Price, J, Parker, M, Gomez, DR, Welsh, JW, Komaki, R, Kurie, JM, Simon, GR, Blumenschein, GR, Young, JA, Phan, S-C, Sandler, A, Papadimitrakopoulou, V, Heymach, J, and Tsao, AS}, -title = {DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab)}, -journal = {Journal of clinical oncology}, -volume = {35}, -number = {15}, -year = {2017}, -accession_number = {EMBASE 617435087}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *non small cell lung cancer; *radiation dose; *safety; Adverse drug reaction; Arthralgia; Chronic obstructive lung disease; Clinical article; Clinical trial; Controlled clinical trial; Controlled study; Disease duration; Disease exacerbation; Drug therapy; Dyspnea; Feasibility study; Female; Human; Low drug dose; Male; Monotherapy; Pharmacokinetics; Phase 2 clinical trial; Radiation pneumonia; Radiotherapy; Side effect; Toxicity}, -abstract = {Background: Immune checkpoint blockade in non‐small cell lung cancer (NSCLC) may be enhanced when combined with radiation therapy. Atezolizumab (atezo) is a humanized and Fc receptor modified monoclonal antibody that blocks programmed death‐ligand‐1 (PD‐L1) interacting with PD‐1 or B7.1 sparing PD‐L2, which may result in less pulmonary toxicity. We report the early safety data of combining atezo added sequentially after standard concomitant chemoradiation (CRT) for locally advanced NSCLC (LA‐NSCLC). Methods: This is a phase II study in LA‐NSCLC assessing the safety and feasibility of adding atezo to CRT in two parts: I) sequentially (N = 10) with CP after completing CRT, or II) concurrently (N = 30) with CRT followed by consolidation atezo with CP. We report on the early toxicity results from part I of the trial. Atezo was given at 1200 mg IV Q3 weeks with consolidation CP for 2 cycles after CRT followed by atezo monotherapy for up to one year. Radiation dose at 60‐66 Gy in 30‐33 fractions was combined with weekly low dose CP, followed by 2 cycles of full dose CP. Dose limiting toxicities were defined as any adverse events (AEs) ≥ grade 3 within 15 weeks of start of therapy or any immune‐related AEs during atezo treatment. Results: From January to December 2016, 10 evaluable patients were enrolled. Seven patients have received consolidation atezo ranging from 1 to 14 doses, with 3 yet to receive atezo after completing CRT. Three patients reported potential immune‐related AEs. One patient developed grade 3 arthralgia, and another developed grade 2 radiation‐induced pneumonitis, which resolved with steroids. A third patient who experienced grade 3 dyspnea due to COPD exacerbation after 1 dose of atezo discontinued additional therapy. Of the 7 patients who have received atezo, 2 patients developed progression of disease after 6 and 8 doses of atezo. Conclusions: Atezo consolidation with 2 cycles of CP after CRT appears to be feasible and well tolerated with manageable toxicities. Additional data from part I will be reported. Conditions for proceeding after part I are met and part II of the study which adds atezo to CRT followed by atezo‐CP consolidation is open for accrual.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01397692/full} -} - - -Record #454 of 538 -@article{Weinberg17, -author = {Weinberg, U, Farber, O, Giladi, M, Bomzon, Z, and Kirson, ED}, -title = {TTFields combined with PD-1 inhibitors or docetaxel for 2nd line treatment of non-small cell lung cancer (NSCLC): phase 3 LUNAR study}, -journal = {Annals of oncology}, -volume = {28}, -number = {Supplement 2}, -pages = {iii51}, -year = {2017}, -accession_number = {EMBASE 619249057}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Abdomen; Adult; Adverse event; Brain metastasis; Cancer surgery; Cancer survival; Clinical trial; Controlled clinical trial; Controlled study; Daily life activity; Drug therapy; Female; Follow up; Histology; Human; Human tissue; Immune‐related gene; Liver; Major clinical study; Male; Medical device; Overall survival; Patient history of surgery; Phase 1 clinical trial; Phase 3 clinical trial; Pilot study; Preclinical study; Progression free survival; Quality of life; Questionnaire; Radiotherapy; Response evaluation criteria in solid tumors; Sample size; Study design; Thorax; Trunk; X‐ray computed tomography}, -abstract = {Background: Tumor Treating Fields (TTFields) are a non‐invasive, anti‐mitotic treatment modality. TTFields disrupt the formation of the mitotic spindle, and dislocation of intracellular constituents. TTFields significantly extend the survival of newly diagnosed glioblastoma patients when combined with temozolomide. Efficacy of TTFields in NSCLC has been shown preclinically and in a phase I/II pilot study with pemetrexed where overall survival (OS) improved by>5 months vs historical controls. Trial design: We hypothesize that adding TTFields to 2nd line therapies in advanced NSCLC will increase OS. Patients (N=512) with squamous or non‐squamous NSCLC are enrolled in this Phase 3 study LUNAR [NCT02973789]. Patients are stratified by 2nd line therapy (PD‐1 inhibitor or docetaxel), histology (squamous vs. nonsquamous) and geographical region. Key inclusion criteria are 1st disease progression (RECIST 1.1), ECOG 0‐1, no prior surgery or radiation therapy, no electronic medical devices in the upper torso, and absence of brain metastasis. Docetaxel or PD‐1 inhibitors (either nivolumab or pembrolizumab) are given at standard doses. TTFields are applied to the upper torso for at least 18 hours/day, allowing patients to maintain daily activities. TTFields are continued until progression in the thorax and/or liver according to the immune‐related response criteria (irRC). Follow up is performed once q6 weeks including CT scans of the chest and abdomen. On progression in the upper torso patients are followed monthly for survival. The primary endpoint is superiority in OS between patients treated with TTFields in combination with either docetaxel or PD‐1 inhibitors, compared to docetaxel or PD‐1 inhibitors alone. A co‐primary endpoint compares the OS in patients treated with TTFields and docetaxel to those treated with PD‐1 inhibitors alone in a non‐inferiority analysis. Secondary endpoints include progression‐free survival, radiological response rate based on the irRC, quality of life based on the EORTC QLQ C30 questionnaire and severity & frequency of adverse events. The sample size is powered to detect a HR of 0.75 in TTFields‐treated patients versus control group.}, -DOI = {10.1093/annonc/mdx085}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01471319/full} -} - - -Record #455 of 538 -@article{Wang22, -author = {Wang, J, Lu, S, Yu, X, Hu, Y, Zhao, J, Sun, ML, Yu, Y, Hu, C, Yang, K, Song, Y, Lin, X, Liang, L, Leaw, S, and Zheng, W}, -title = {Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC): RATIONALE-307 updated analysis}, -journal = {Immuno-oncology and technology}, -volume = {16}, -year = {2022}, -accession_number = {EMBASE 2021560006}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer chemotherapy; *non small cell lung cancer; Adult; Cancer patient; Cancer radiotherapy; Cancer staging; Cancer surgery; Cancer survival; Clinical trial; Conference abstract; Controlled study; Drug combination; Drug safety; Drug therapy; Female; Financial management; Follow up; Human; Incidence; Intravenous drug administration; Major clinical study; Male; Medical literature; Overall response rate; Overall survival; Parttime employment; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial}, -abstract = {Background: Interim analysis of the open‐label phase 3 RATIONALE‐307 study (NCT03594747) demonstrated clinical benefit, including significantly improved progression‐free survival (PFS) with a manageable safety profile, of tislelizumab (TIS) plus chemotherapy (chemo) as first‐line (1L) therapy in patients (pts) with advanced sq‐NSCLC vs chemo alone. Here, we report updated results. Methods: Adults with previously untreated stage IIIB (not amenable to curative surgery/radiotherapy)/IV sq‐NSCLC were randomized (1:1:1) to intravenous TIS (200mg, 21‐day cycles) + paclitaxel + carboplatin (Arm A); TIS + nab‐paclitaxel + carboplatin (Arm B); or paclitaxel + carboplatin (Arm C). The primary endpoint was PFS in Arms A and B vs Arm C, per independent review committee (IRC). Secondary endpoints included overall survival, objective response rate (ORR), duration of response (DoR), and safety. Results: As of 30 September 2020 (median follow‐up 16.7 months), of 360 randomized pts, 355 received treatment. The updated median (95% confidence interval [CI]) PFS benefit was maintained for Arms A (7.7 [95%CI: 6.7, 10.4] months [mo], stratified hazard ratio [HR] 0.45 [95%CI: 0.33, 0.62]) and B (9.6 mo [95%CI: 7.4, 10.8], HR 0.43 [95%CI: 0.31, 0.60]) vs C (5.5 mo [95%CI: 4.2, 5.6]). Consistent improvements in ORR in Arms A (74.2% [95%CI: 65.4, 81.7]) and B (73.9% [95%CI: 65.1, 81.6]) vs C (47.9% [95%CI: 38.8, 57.2]) were observed. Median DoR in Arms A and B was 8.4 (95%CI: 5.0, 15.8) mo and 8.6 (95%CI: 7.1, 12.5) mo, respectively vs 4.3 (95%CI: 2.9, 5.4) mo in Arm C. The incidences of any grade (Arm A 100%; Arm B 99.2%; Arm C 100%) or ≥grade 3 (Arm A 89.2%; Arm B 87.3%; Arm C 84.6%) treatment‐emergent adverse events (TEAE) were similar between arms. The rate of treatment discontinuation due to TEAE was similar between Arms A (17.5%) and C (15.4%), and lower than in Arm B (32.2%). No new safety signal was identified. Conclusions: In RATIONALE‐307, the addition of TIS to chemo continued to demonstrate clinical benefit as 1L treatment of advanced sq‐NSCLC vs chemo alone after a longer follow‐up, with a manageable safety profile. Clinical trial identification: NCT03594747. Editorial acknowledgement: Medical writing support, under the direction of the authors, was provided by Arezou Hossein, MPharm, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd. Legal entity responsible for the study: BeiGene, Ltd. Funding: BeiGene, Ltd. Disclosure: S. Lu: Financial Interests, Personal, Other, Research support: AstraZeneca, Hutchison, BMS, Heng Rui Beigene and Roche, Hansoh; Financial Interests, Personal, Other, Speaker fees: AstraZeneca, Roche, Hansoh; Financial Interests, Personal, Advisory Role: AstraZeneca, Pfizer, Hutchison MediPharma, ZaiLab, GenomiCare, Novarti, Yuhan Corporation, Menarini., Mirati Therapeutics Inc, and Roche. C. Hu: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca. X. Lin, L. Liang, S. Leaw, W. Zheng: Financial Interests, Personal, Full or part‐time Employment: BeiGene, Ltd. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.iotech.2022.100244}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02517163/full} -} - - -Record #456 of 538 -@article{Liu24, -author = {Liu, H, Qiu, B, Zhao, Y, He, W-Z, Feng, W, Zeng, W, Jia, J, Meng, F, Wang, D, Liu, F-J, Guo, J-Y, Zou, Y-Y, Guo, S-P, Wu, Y-J, Luo, Q-T, Li, J-B, Yang, Y, Xia, L-P, and Zhang, L}, -title = {A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091)}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644914049}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *neoadjuvant chemotherapy; *non small cell lung cancer; Adult; Adverse drug reaction; Aged; Clinical outcome; Conference abstract; Controlled study; Drug therapy; Female; Follow up; Human; Hypofractionated radiotherapy; Major clinical study; Male; Multiple cycle treatment; Neoadjuvant therapy; Phase 2 clinical trial; Pneumonia; Progression free survival; Randomized controlled trial; Side effect; Smoking; Tracheobronchial tree}, -abstract = {Background: Enhancing clinical outcomes in resectable non‐small cell lung cancer (NSCLC) has been associated with neoadjuvant or perioperative administration of nivolumab. However, the efficacy and safety of consolidation nivolumab versus observation following neoadjuvant chemotherapy plus nivolumab, hypofractionated radiotherapy and concurrent chemotherapy (hypo‐CCRT) in patients with unresectable stage III NSCLC remain underexplored. Methods: Conducted as a randomized, multi‐center, phase 2 trial in patients with unresectable stage IIIA‐C NSCLC, this study enrolled individuals aged 18 to 75 with an ECOG performance status of 0 or 1. Neoadjuvant therapy consisted of docetaxel, cisplatin, and nivolumab (360mg every 3 weeks for 2 cycles), followed by hypo‐CCRT. Patients without disease progression or G2+ pneumonitis after hypo‐CCRT were randomly assigned to receive nivolumab (360 mg every 3 weeks for up to 12 months) or undergo observation. Randomization factors included age, sex, smoking history, and EGFR mutation status. The primary endpoint was progression‐free survival (PFS) from randomization, with preplanned analysis results reported herein. The trial is registered with ClinicalTrials.gov, NCT04085250. Results: Between Dec 3rd, 2019, and Aug 18th, 2023, 264 patients underwent neoadjuvant therapy, 242 received hypo‐CCRT, and 172 were randomly assigned to nivolumab consolidation (n = 86) or observation (n = 86) post hypo‐ CCRT. At the January 31, 2024, data cutoff, the median follow‐up for all randomized patients was 22.8 months. Nivolumab consolidation exhibited significantly longer PFS compared to observation (median not reached vs. 12.2 months [95% CI 6.2‐18.1]; hazard ratio 0.49 [95% CI 0.31‐0.79], p = 0.002). The 12‐month and 18‐month PFS rates were 72.6% and 64.8% in the consolidation group, contrasting with 52.5% and 42.3% in the observation group. Grade 3‐4 nonhematological adverse events occurred in 14.0% (37/264) during neoadjuvant therapy and hypo‐CCRT. Following randomization, grade 3‐5 adverse events occurred in 7.0% (6/86) with consolidation (G3 pneumonitis, 2.3%; G5 pneumonitis, 1.2%; G3 proximal bronchial tree toxicity, 3.5%) and 4.6% (4/86) with observation (G3 pneumonitis, 2.3%; G3 proximal bronchial tree toxicity, 2.3%). Conclusions: Consolidation with nivolumab after neoadjuvant chemotherapy plus nivolumab and hypo‐CCRT demonstrates effectiveness and tolerability for patients with unresectable stage III NSCLC. Extended follow‐up is essential for confirming these findings.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02736470/full} -} - - -Record #457 of 538 -@article{ChiCTR210004696921, -author = {ChiCTR2100046969,}, -title = {Efficacy and safety of first-line Albumin-Bound Paclitaxel + Anlotinib + Camrelizumab in subjects with locally advanced or metastatic squamous NSCLC: a Multicenter, Randomized, Phase III Clinical Study}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2100046969}, -year = {2021}, -accession_number = {ICTRP ChiCTR2100046969}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: experimental group:Albumin‐bound paclitaxel + Anlotinib + Camrelizumab;Control group:Albumin‐bound paclitaxel +Platinum; CONDITION: squamous NSCLC PRIMARY OUTCOME: Progression free survival time; SECONDARY OUTCOME: Efficient;Survival time;Disease control rate;Duration of relief; INCLUSION CRITERIA: 1. Aged 18 to 70 years; 2. ECOG PS 0‐1, life expectancy exceeds 3 months; 3. Histological or cytological pathology confirmed as squamous non‐small cell lung cancer; 4. Researchers confirm that there is at least one measurable lesion according to the RECIST 1.1 standard; 5. According to the 8th edition of the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer Classification, TNM staging is IIIB‐IV or recurrence. For locally advanced disease, it is necessary to prove that it cannot be operated and cannot receive radical concurrent radiotherapy and chemotherapy; 6. Genetic testing showed that EGFR and ALK driver genes were negative; 7. The main organs function well. Blood routine absolute neutrophil count>=1.5x10^9/L, platelet count>=100x10^9/L, erythropoietin>=90 g/L. Liver function total bilirubin level <= 1.5 times the upper limit of normal (ULN). Transaminase (AST) and alanine transaminase (ALT)}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02376613/full} -} - - -Record #458 of 538 -@article{Schulz18, -author = {Schulz, C, Laack, E, Wolff, T, Ruckert, A, Reck, M, Faehling, M, Fischer, JR, and De Wit, M}, -title = {PACIFIC: a double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC}, -journal = {Oncology research and treatment}, -volume = {41}, -pages = {270}, -year = {2018}, -accession_number = {EMBASE 627141104}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *chemoradiotherapy; *non small cell lung cancer; *visually impaired person; Adult; Adverse event; Cancer staging; Cancer survival; Conference abstract; Controlled study; Death; Distant metastasis; Double blind procedure; Drug safety; Drug therapy; Female; Follow up; Germany; Human; Major clinical study; Male; Overall survival; Phase 3 clinical trial; Pneumonia; Progression free survival; Radiotherapy; Randomization; Randomized controlled trial; Reaction time; Response evaluation criteria in solid tumors; Smoking}, -abstract = {Background: Most patients (pts) with locally advanced, unresectable non‐small cell lung cancer (NSCLC) progress despite concurrent chemoradiation therapy (cCRT). Here we report interim results from a global, Phase 3 study (NCT02125461) of the anti‐PD‐L1 durvalumab as consolidation therapy in Stage III pts without progression following platinumbased cCRT. Methods: Pts with a WHO performance status 0/1 (any PD‐L1 status) who received ≥2 cycles of platinum‐based cCRT without progression were randomized (2:1) 1‐42 days post‐cCRT to receive durvalumab 10 mg/kg IV Q2W or placebo for up to 12 months, stratified by age, sex, and smoking history. Coprimary endpoints were progression‐free survival (PFS; blinded independent central review, RECIST v1.1) and overall survival (OS). Secondary endpoints included 12‐ and 18‐month PFS rates, objective response rate (ORR), duration of response (DoR), time to death or distant metastasis (TTDM) and safety. Results: Between May 2014 and April 2016, Germany contributed 26 pts to the globally randomized 713 pts of whom 709 received consolidated treatment (durvalumab, n = 473; placebo, n = 236). Baseline characteristics were well balanced. As of Feb 13, 2017 (data cutoff), median followup was 14.5 months. Median PFS from randomization was significantly longer with durvalumab (16.8 months, 95% CI, 13.0‐18.1) versus placebo (5.6 months, 95% CI, 4.6‐7.8; stratified HR 0.52, 95% CI, 0.42‐0.65; P < 0.0001). 12‐ and 18‐month PFS rates were 55.9% versus 35.3% and 44.2% versus 27.0%, respectively. ORR was higher (28.4% vs 16.0%; P < 0.001) and median DoR was longer (not reached vs 13.8 months) with durvalumab consolidation therapy. Median TTDM was longer with durvalumab (23.2 vs 14.6 months; stratified HR 0.52, 95% CI, 0.39‐0.69; P < 0.0001). OS data were immature at the time of interim PFS analysis. Comparing durvalumab with placebo, grade 3/4 adverse events (AEs) occurred in 29.9% and 26.1%; most common was pneumonia (4.4% vs 3.8%). 15.4% and 9.8% discontinued due to AEs. Conclusions: Durvalumab demonstrated significant and clinically meaningful improvement in PFS, which was supported by secondary endpoints, and was well tolerated. Durvalumab is a promising therapeutic option in this setting.}, -DOI = {10.1159/000492737}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01935864/full} -} - - -Record #459 of 538 -@article{Vansteenkiste13, -author = {Vansteenkiste, J}, -title = {Lung cancer vaccines}, -journal = {Journal of thoracic oncology}, -volume = {8}, -pages = {S54‐S55}, -year = {2013}, -accession_number = {EMBASE 71395827}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer immunization; *immunotherapy; *lung cancer; Antigen presenting cell; Arm; Cancer immunotherapy; Chemoradiotherapy; Chemotherapy; Clinical trial (topic); Cytotoxic T lymphocyte; Disease control; Disease free survival; Epithelium; Gene; Glycosylation; Human; Hypothesis; Immune system; Immunization; Immunogenicity; Immunohistochemistry; Melanoma; Minimal residual disease; Modulation; Molecular pathology; Mutation; Neoplasm; Open study; Overall survival; Patient; Phase 1 clinical trial; Phase 2 clinical trial; Population; Progression free survival; Radiotherapy; Relapse; Surgery; Survival; T lymphocyte; Tandem repeat; Telecommunication; Therapy; Tissues; Toxicity; Tumor cell; Tumor immunity; Vaccinia virus}, -abstract = {Surgical resection is the standard therapy for early stage NSCLC, but about half of the patients still develop a relapse and die of their cancer. In case of unresectable locally advanced disease, the combination of chemo‐ and radiotherapy may cure some patients, but the majority will relapse. Targeted agents have brought progress for patients with advanced NSCLC selected based on molecular factors such as EGFR or ALK mutation, but other novel approaches are needed. One is therapeutic cancer vaccination (TCV), which may become an important part in our future treatment armamentarium, especially for patients with local or locally advanced NSCLC. Cancer immunotherapy in a broad sense is any interaction with the immune system to treat cancer. A first approach is non‐antigen‐specific modulation of the immune system. Historical experience (BCG, C. parvum, interferon, interleukins, thymosin, etc.) was disappointing. Promising response rates in heavily pre‐treated NSCLC patients were reported in recent phase I trials with agents acting on the interaction between antigen presenting cells, T‐lymphocytes and tumor cells. Examples are antibodies against Cytotoxic T‐lymphocyte Antigen 4 (CTLA‐4) or against Programmed Death 1 receptor or its ligands. Antigen‐specific immunotherapy aims at specific priming of immune system to recognize the tumor as foreign, thereby generating specific antibodies and/or cytotoxic T cells. This is “therapeutic cancer vaccination”. Conditions for optimal TCV are: 1/ specificity (well‐defined target antigen in the tumor, not in other tissues); 2/ selectivity (use in the population expressing the target); 3/ immunogenicity (interaction with antigen leads to effective humoral and/or cellular response); 4/ tumor sensitive to immune kill in order to obtain improvement in patients' outcome. Although the historical results of TCV for NSCLC were disappointing, knowledge from the last decades about the molecular pathology of tumors, of the immune system in general, and of tumor immunity in particular, has led to the introduction of several modern and more sophisticated TCVs. These vaccine formulations have shown encouraging data in phase II randomized clinical trials, and are now being studies in large phase III studies. Important examples are the MAGE‐A3 vaccine in resected early stage NSCLC, the BLP‐25 vaccine in locally advanced NSCLC after chemoradiotherapy, and e.g. belagenpumatucel‐L and the TG4010 vaccine in advanced stage NSCLC. The MAGE‐A3 protein is totally tumor‐specific and present in about 35% of early stage NSCLC. In the hypothesis generating double‐blind, randomized, placebo‐controlled phase II study, 182 patients with completely resected MAGE‐A3‐positive stage IB‐II NSCLC received recombinant MAGE‐A3 protein combined with an immunostimulant (13 doses over 27 months) or placebo 1. No significant toxicity was observed. There was a 24% ‐ non‐significant ‐ improvement in disease‐free survival (HR 0.76; 95% CI 0.48 to 1.21). Moreover, a predictive gene signature, initially described in advanced melanoma patients could be confirmed in early stage NSCLC 2.A large phase III study (n=2270) with MAGE‐A3 vaccine is recruited and awaiting results (MAGRIT, NCT00480025). Mucins like the MUC1 protein are present in many epithelia, but MUC1 expression is altered (mainly by aberrant glycosylation) in many cancer types, including NSCLC. The tandem repeat MUC1‐peptide liposomal vaccine BLP‐25 has been studied in patients with stage IIIB‐IV NSCLC 3. Patients in disease control after conventional treatment with chemo(‐radio)therapy were randomly assigned to BLP25 (8 weekly s.c. immunizations, followed by administration at 6‐week intervals) plus BSC or BSC alone. While overall survival (OS) was not significantly different in the total group, a challenging effect was observed in stage IIIB patients (HR 0.524; 95%CI 0.261‐ 1.052). No significant toxicity was observed. At the 2013 ASCO meeting, the double‐blind, randomized, placebo‐controlled phase III study was presented (START, NCT00409188) 4. Patients not progressing after primary chemoradiotherapy for unresectable stage III NSCLC were randomized to BLP25 or placebo. In the primary analysis population (n=1239), OS was better with the vaccine (HR 0.88, 95%CI 0.75‐1.03). In the predefined subgroup analysis in patients after concurrent chemoradiotherapy (n=806) there was a median OS difference of 10.2 months (HR 0.78, 95%CI 0.64‐0.95). While the most obvious role for TCV is for patients with small residual disease after treatment, several compound are in phase III testing in advanced NSCLC as well. Belagenpumatucel‐L is a vaccine based on a mixture of allogeneic tumor cells with TGF‐β2 antisense blockade as adjuvant. In a phase II open trial, survival was related to the dose administered 5. A phase III trial in patients with stage III‐IV NSCLC in disease control after firstline therapy is now fully recruited (STOP, NCT00676507). TG4010 is a vaccine based on a recombinant viral vector (attenuated strain of vaccinia virus) expressing both the tumor‐associated antigen MUC1 and interleukin‐2. In a phase II randomized study, 148 patients with advanced NSCLC expressing MUC1 by immunohistochemistry received either up to 6 cycles of cisplatingemcitabine plus TG4010, or the same chemotherapy alone 6. The primary endpoint, a 6‐month progression‐free survival more than 40% in the experimental arm was met.}, -DOI = {10.1097/01.JTO.0000438438.14562.c8}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01059046/full} -} - - -Record #460 of 538 -@article{EUCTR2021-005135-23-ES22, -author = {EUCTR2021-005135-23-ES,}, -title = {A study of MK7684A in Combination with radiation and chemotherapy versus radiation and chemotherapy followed by Durvalumab for patients with Stage III lung cancer that cannot be surgically treated}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-005135-23-ES}, -year = {2022}, -accession_number = {ICTRP EUCTR2021‐005135‐23‐ES}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Product Name: MK‐7684A Product Code: MK‐7684A Pharmaceutical Form: Solution for infusion INN or Proposed INN: Vibostolimab CAS Number: 2231305‐30‐7 Current Sponsor code: MK‐7684 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ INN or Proposed INN: Pembrolizumab CAS Number: 1374853‐91‐4 Current Sponsor code: MK‐3475 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10‐ Trade Name: Imfinxi Product Name: Durvalumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Durvalumab CAS Number: 1428935‐60‐7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50‐ CONDITION: Unresectable, locally advanced, Stage III non‐small cell lung cancer (NSCLC) ; MedDRA version: 21.1 Level: LLT Classification code 10029514 Term: Non‐small cell lung cancer NOS System Organ Class: 100000004864 Therapeutic area: Diseases [C] ‐ Cancer [C04] PRIMARY OUTCOME: Main Objective: 1. To compare PFS per RECIST 1.1 as assessed by BICR.; 2. To compare OS. Primary end point(s): 1. Progression Free Survival (PFS) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR); 2. Overall Survival (OS) Timepoint(s) of evaluation of this end point: 1. Up to 57 months; 2. Up to 6 years Secondary Objective: 1. To compare MK‐7684A with cCRT followed by MK‐7684A to cCRT followed by durvalumab with respect to ORR per RECIST 1.1 as assessed by BICR in participants with TPS =1% and PD‐LI.; 2. To evaluate the safety and tolerability of MK‐7684A with cCRT followed by MK‐7684A compared to cCRT followed by durvalumab.; 3. To compare MK‐7684A with cCRT followed by MK‐7684A to cCRT followed by durvalumab with respect to DOR per RECIST 1.1 as assessed by BICR in participants with TPS =1% and PD‐LI.; 4. To evaluate the change from baseline in GHS/QoL, cough, chest pain, dyspnea and physical functioning following treatment with MK‐7684A with cCRT followed by MK‐7684A compared to cCRT followed by durvalumab in participants with TPS =1% & PD‐L1.; 5. To evaluate the TTD in GHS/QoL, cough, chest pain, dyspnea and physical functioning following treatment with MK‐7684A with cCRT followed by MK‐7684A compared to cCRT followed by durvalumab in participants with TPS =1% & PD‐L1. 57 months; 2. Up to 18 months; 3. Up to 15 months; 4. Up to 57 months; 5. Baseline and up to 15 months; 6. Baseline and up to 15 months; 7. Baseline and up to 15 months; 8. Baseline and up to 15 months; 9. Baseline and up to 15 months; 10. Up to 15 months; 11. Up to 15 months; 12. Up to 15 months; 13. Up to 15 months; 14. Up to 15 months SECONDARY OUTCOME: Secondary end point(s): 1. Objective response rate (ORR) per RECIST 1.1 as assessed by BICR; 2. Number of participants with one or more adverse events (AEs); 3. Number of participants that discontinued study intervention due to AEs; 4. Duration of response (DOR) per RECIST 1.1 as assessed by BICR; 5. Change from baseline in European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) Core 30 (C30) items 29 and 30, Global Health Score/Quality of Life (GHS/QOL) ; 6. Change from baseline in EORTC QLQ‐Lung cancer 13 (LC13) item 1, cough; 7. Change from baseline in EORTC QLQ‐LC13 item 10, chest pain; 8. Change from baseline in EORTC QLQ C30 item 8, dyspnea; 9. Change from baseline in EORTC QLQ C30 items 1‐5, physical functioning; 10. Time‐to‐true deterioration (TTD) in EORTC QLQ C30 items 29 and 30, GHS/QOL; 11. TTD in EORTC QLQ‐LC13 item 1, cough; 12. TTD in EORTC QLQ‐LC13 item 10, chest pain; 13. TTD in EORTC QLQ C30 item 8, dyspnea; 14. TTD in EORTC QLQ C30 items 1‐5, physical functioning Timepoint(s) of evaluation of this end point: 1. Up to INCLUSION CRITERIA: 1. Has pathologically confirmed diagnosis of NSCLC 2. Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8 3. Is determined to have unresectable, Stage III NSCLC as documented by a multidisciplinary tumor board or by the treating physician in consultation with a thoracic surgeon 4. Has no evidence of metastatic disease, indicating Stage IV NSCLC, in whole‐body FDGPET or FDG‐PET/CT and CT or MRI scans of diagnostic quality of chest, abdomen, pelvis and brain 5. Has measurable disease as defined by RECIST 1.1, with at least 1 lesion being appropriate for selection as a target lesion, as determined by local site investigator/radiology review 6. Has not received prior treatment for their Stage III NSCLC 7. Has provided tumor tissue sample. FFPE blocks are preferred to slides 8. Has an ECOG Performance Status of 0 or 1 assessed within 7 days prior to the first administration of study intervention 9. Has a life ex}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02410469/full} -} - - -Record #461 of 538 -@article{Dziadziuszko21, -author = {Dziadziuszko, R, Ahn, M-J, Kelly, KA, Popat, S, Wakelee, H, Baird, A-M, Rooney, IA, Afshari, M, Yao, ES, Zhang, Z, Kuriki, H, Patil, NS, Wen, X, and Bradley, JD}, -title = {1190TiP SKYSCRAPER-03: phase III, open-label randomised study of atezolizumab + tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT)}, -journal = {Annals of oncology}, -volume = {32}, -pages = {S947‐S948}, -year = {2021}, -accession_number = {EMBASE 2014621458}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *cancer staging; *chemoradiotherapy; *non small cell lung cancer; Adult; Applied research; Cancer immunotherapy; Cancer survival; Clinical assessment; Clinical trial; Comparative effectiveness; Conference abstract; Consultation; Controlled study; Deterioration; Drug efficacy; Drug safety; Drug therapy; ECOG Performance Status; Female; Gene mutation; Histology; Histopathology; Human; Human tissue; Ireland; Leadership; Major clinical study; Male; Medical education; Medical literature; Mesothelioma; Organization; Overall response rate; Overall survival; Parttime employment; Pharmacokinetics; Phase 2 clinical trial; Phase 3 clinical trial; Practice guideline; Progression free survival; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Signal transduction}, -abstract = {Background: Previously the standard of care for patients (pts) with locally advanced, unresectable, stage III NSCLC has been cCRT; however, 5‐year overall survival (OS) rates are poor. Durvalumab (durva) is approved for pts without progressive disease (PD) after cCRT. However, long‐term OS data are not yet available. Further evaluation of novel cancer immunotherapy combinations should be explored. Targeted inhibition of the PD‐L1/PD‐1 pathway may be further amplified by combining with novel anti‐TIGIT agents such as tiragolumab (tira). In the phase II CITYSCAPE study (NCT03563716), atezo + tira was well tolerated and improved objective response rate (ORR) compared with atezo alone in 1L pts with metastatic PD‐L1+ NSCLC; with greater benefit in the PD‐L1‐high (TPS ≥50%) subset. Trial design: SKYSCRAPER‐03 (NCT04513925) aims to evaluate the efficacy of atezo + tira vs single‐agent anti‐PD‐L1 (durva) in pts with unresectable, stage III NSCLC who have not progressed after platinum‐based cCRT. Data suggests that cCRT upregulates PD‐L1 expression, potentially enabling PD‐L1 low or negative tumours to derive benefit, so outcomes will be evaluated in all‐comer (ITT) and PD‐L1+ sub‐populations. Approximately 800 pts with unresectable, stage III NSCLC without PD after ≥2 cycles of platinum‐based cCRT per NCCN/ESMO guidelines, without EGFR/ALK mutations; known PD‐L1 status; ECOG PS 0–1; will be randomised 1:1 to receive atezo 1680mg IV + tira 840mg IV Q4W or durva 10mg/kg IV Q2W/1500mg IV Q4W. Treatment will continue for up to 13 cycles of 28 days, or until unacceptable toxicity or symptomatic deterioration due to PD; in pts with radiographic PD (per RECIST v1.1) treatment may continue if evidence of ongoing clinical benefit. Stratification factors include PD‐L1 status, histology, staging and ECOG PS. Primary endpoint: independent review facility‐assessed progression‐free survival (PFS) in the ITT and PD‐L1+ (TC ≥1%) populations. Secondary endpoints: investigator‐assessed PFS, OS, ORR and duration of response, safety and biomarker analyses. Recruitment is ongoing. Clinical trial identification: NCT04513925. Editorial acknowledgement: Medical writing support for the development of this abstract, under the direction of the authors, was provided by Abigail Robertson, PhD, of Ashfield MedComms, an Ashfield Health company, and funded by F. Hoffmann‐La Roche Ltd. Legal entity responsible for the study: F. Hoffmann‐La Roche Ltd. Funding: F. Hoffmann‐La Roche Ltd. Disclosure: R. Dziadziuszko: Financial Interests, Advisory Board: F. Hoffmann‐La Roche Ltd., Pfizer, Boehringer Ingelheim, Bayer, Novartis, AstraZeneca, Merck Sharp & Dohme, Seattle Genetics, Foundation Medicine, Takeda; Financial Interests, Principal Investigator: F. Hoffmann‐La Roche Ltd., Merck Sharp & Dohme, Amgen, Janssen, Bristol Myers Squibb, AstraZeneca; Non‐Financial Interests, Product Samples: F. Hoffmann‐La Roche Ltd., Novartis, Pfizer. M. Ahn: Financial Interests, Invited Speaker: AstraZeneca, Takeda, MSD, Ono, BMS, Lilly, Amgen, Merck, Roche; Financial Interests, Advisory Board: AstraZeneca, Takeda, MSD, Ono, BMS, Lilly, Amgen, Merck, Roche, Alpha Pharmaceuticals; Financial Interests, Funding: AstraZeneca, Roche. K.A. Kelly: Financial Interests, Full or part‐time Employment: UC Davis Medical Center; Financial Interests, Advisory Board: Genentech, Inc., AstraZeneca; Financial Interests, Research Grant: Genentech, Inc., AstraZeneca. S. Popat: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, Beigene, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Guardant Health, Janssen, Lilly, Merck KGaA, Novartis, Roche, Takeda; Financial Interests, Institutional, Other, Sub‐investigator: Amgen; Financial Interests, Institutional, Other, Coordinating PI: Ariad, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Takeda, Turning Point Therapeutics; Financial Interests, Institutional, Other, Local PI: AstraZeneca, GSK, Roche, Trizel; Financial Interests, Institutional, Other, Sub‐Investigator: MSD; Non‐Financial Interests, Advisory Role, Honorary Clinical Advisor: ALK Positive UK; Non‐Financial Interests, Leadership Role, Chair of Steering Committee: British Thoracic Oncology Group; Non‐Financial Interests, Officer, Thoracic Faculty: European Society of Medical Oncology; Non‐Financial Interests, Leadership Role, Foundation Council Member: European Thoracic Oncology Platform; Non‐Financial Interests, Advisory Role, Communications Committee Member: International Association for the Study of Lung Cancer; Non‐Financial Interests, Advisory Role, Scientific Advisory Board Member: Lung Cancer Europe; Non‐Financial Interests, Member of the Board of Directors: Mesothelioma Applied Research Foundation; Non‐Financial Interests, Advisory Role, Research Advisory Group Member: Ruth Strauss Foundation. H. Wakelee: Financial Interests, Personal, Advisory Board: AstraZeneca, Janssen, Daiichi Sankyo, Blueprint, Mirati, Helsinn; Financial Interests, Personal, Invited Speaker: Fishawack Facilitate LTD, Medscape, Research to Practice, MJH Holdings, Axis Medical Education, Nexus Oncology; Financial Interests, Personal, Other: Curio Science; Financial Interests, Personal, Writing Engagements: UpToDate; Financial Interests, Institutional, Other, Local PI: ACEA Biosciences, Arrys Therapeutics, AstraZeneca/MedImmunne, BMS, Clovis Oncology, Novartis, Seagen, Xcovery; Financial Interests, Institutional, Other, Coordinating PI: Celgene; Financial Interests, Institutional, Member, Steering Committee Member: Genentech/Roche, Merck; Non‐Financial Interests, Officer, President‐Elect: International Association for the Study of Lung Cancer (IASLC); Non‐Financial Interests, Leadership Role, Executive Committee: ECOG‐ACRIN. A. Baird: Financial Interests, Invited Speaker, Honorarium: MSD Ireland, Roche Ireland; Financial Interests, Advisory Board, Honorarium: Roche Ireland; Non‐Financial Interests, Leadership Role: Chair, IASLC Communications Committee; Non‐Financial Interests, Other, I was a board member of LuCE (2018‐2020) and have been president since May 2020. This is a non‐remunerated position, however, LuCE has received support from the following organisations: Amgen, AstraZeneca, Bayer. Blueprint Medicines, BMS, Boehringer Ingelheim, Genzyme Corporation, Lilly, Merck, MSD, Novartis, Pfizer, Regeneron, Roche, Takeda; Janssen (honorarium). In this role, I also partake in patient Advisory Boards, Steering Committees and other patient related events: Lung Cancer Europe (LuCE). I.A. Rooney: Financial Interests, Full or part‐time Employment: Roche‐Genentech; Financial Interests, Stocks/Shares: Roche‐Genentech. M. Afshari: Financial Interests, Full or part‐time Employment: Genentech, Inc. E.S. Yao: Financial Interests, Full or part‐time Employment: Roche/Genentech; Financial Interests, Stocks/Shares: Roche/Genentech. Z. Zhang: Financial Interests, Full or part‐time Employment: Genentech, Inc. H. Kuriki: Financial Interests, Full or part‐time Employment: Genentech, Inc., Chugai Pharmaceutical Co., Ltd.; Financial Interests, Stocks/Shares: Chugai Pharmaceutical Co., Ltd. N.S. Patil: Financial Interests, Full or part‐time Employment: Genentech, Inc. X. Wen: Financial Interests, Full or part‐time Employment: Genentech, Inc. J.D. Bradley: Financial Interests, Advisory Board, Honorarium: Mevion Medical Systems; AstraZeneca; Financial Interests, Research Grant, PI of research grant: Varian, Inc.; Financial Interests, Principal Investigator, Consultant: AstraZeneca; Financial Interests, Advisory Role, for Skyscraper 3: Genentech, Inc.}, -DOI = {10.1016/j.annonc.2021.08.1794}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02322515/full} -} - - -Record #462 of 538 -@article{Mauti23, -author = {Mauti, LA, Finazzi, T, Holer, L, Bettini, A, Konig, D, Fruh, M, Haefliger, S, Addeo, A, Mark, MT, Buess, M, Froesch, P, Janthur, WD, Waibel, C, Ackermann, CJ, Dorn, P, Scheibe, B, Pless, M, Guckenberger, M, Prince, SS, and Rothschild, S}, -title = {SAKK 16/18: immune-modulatory radiotherapy to enhance the effects of neoadjuvant PDL1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)-A multicenter phase II trial}, -journal = {Journal of clinical oncology}, -volume = {41}, -number = {16}, -pages = {8547}, -year = {2023}, -accession_number = {EMBASE 642930381}, -publication type = {Journal article; Conference proceeding}, -keywords = {*neoadjuvant chemotherapy; *non small cell lung cancer; Adult; Cancer surgery; Clinical article; Conference abstract; Coronavirus disease 2019; Drug combination; Event free survival; Human; Human tissue; Induction chemotherapy; Major clinical study; Mediastinum lymph node; Multimodality cancer therapy; Multiple cycle treatment; Organs at risk; Phase 2 clinical trial; Pneumonia; Radiotherapy; Remission; Surgery; Surgical mortality}, -abstract = {Background: Neoadjuvant chemo‐immunotherapy has become a new standard of care in locally advanced, resectable NSCLC. The SAKK 16/14 trial demonstrated a major improvement in pathological response (pCR), major pathological remission (MPR) and event‐free survival (EFS) with the addition of perioperative durvalumab after standard induction chemotherapy (ChT) with cisplatin and docetaxel. Based on data suggesting a potential enhancement of immunotherapy efficacy, the ongoing SAKK 16/18 trial investigates the addition of immune‐modulatory radiotherapy (RT) given concurrently with neoadjuvant durvalumab. Methods: In this non‐comparative randomized phase II trial patients (pts) with resectable stage IIIA‐B(N2) (cT1‐3 or T4 due to size N2 M0) NSCLC receive 3 cycles of cisplatin 100mg/m2 and docetaxel 85mg/m2 followed by durvalumab (1500mg) and one of three randomized RT regimens before tumor resection and adjuvant durvalumab for 1 year. RT is delivered to the primary tumor only, using either 20x2 Gy, 5x5 Gy, or 3x8 Gy (deliverd inhomogenously). RT planning is optimized for strict organ at risk and mediastinal lymph node sparing. The primary endpoint is 1‐year EFS. We report a preplanned interim analysis of the secondary endpoints safety, surgical outcomes and pathological response after surgery in 25 pts. Results: At data cut‐off on Oct 8, 2022, 25 pts had reached post‐operative day 30 and a total of 31 pts were included in the safety analysis. Thirty pts (97%) had at least one treatment related adverse events (TRAE). Eighty‐eight % were attributed to neoadjuvant ChT (16% G3‐4), 4%each to neoadjuvant durvalumab (1% G3) and RT (1% G4), and 8% to surgery (35% G3‐4). One fatal TRAE occurred in a pt with COVID‐pneumonia during neoadjuvant ChT. No difference in safety was seen between the three RT arms. There was no treatment‐related cancellation or delay in surgery and 0% 30‐day postoperative mortality. Eighty‐one%of pts underwent tumor resection (96% R0). Non‐resection was due to death (n = 1), progressive disease (n = 3), or unresectable tumor (n = 2). The pCR‐rate was 28%, andMPR (≤10% viable tumor cells) was detected in 76% of all specimens. Details of pathological responses with regard to immune‐modulatory RT regimen will be presented at the meeting. Conclusions: The preplanned interim safety analysis of the SAKK 16/18 trial did not show a relevant increase in TRAE due to immune‐modulatory RT. Surgical feasibility and safety are confirmed and the trial continues enrolment to a planned total of 90 pts (30 per RT arm). Preliminary pathological responses are promising, and exploratory analyses will study potential differences between the RT regimens, in order to better understand the potential role of immune‐modulatory RT in the multimodal treatment of resectable stage III(N2) NSCLC.}, -DOI = {10.1200/jco.2023.41.16_suppl.8547}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02661742/full} -} - - -Record #463 of 538 -@article{Paz-Ares23, -author = {Paz-Ares, L, Gay, CM, Zhou, C, Kato, T, Corrales, L, Redhead, K, Rahman, A, Bradley, D, Theogaraj, E, Hutchinson, KE, Shagan, SM, and Solomon, BJ}, -title = {131TiP A phase I–III platform study evaluating the safety and efficacy of multiple therapies in patients (pts) with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC)}, -journal = {Journal of thoracic oncology}, -volume = {18}, -number = {4}, -pages = {S114}, -year = {2023}, -accession_number = {EMBASE 2023625628}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *cancer staging; *drug safety; *non small cell lung cancer; Adult; Cancer survival; Central nervous system; Chemoradiotherapy; China; Clinical trial; Cohort analysis; Conference abstract; Deterioration; Distant metastasis free survival; Drug combination; Drug therapy; Drug withdrawal; ECOG Performance Status; Eligibility; Experimental therapy; Funding; Hairdresser; Human; Major clinical study; Male; Medical literature; Molecularly targeted therapy; Nuclear magnetic resonance imaging; Outcome assessment; Overall survival; Parttime employment; Patent; Patient‐reported outcome; Phase 1 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Treatment duration; Tumor cell}, -abstract = {Background Durvalumab following chemoradiation (CRT) is a standard of care for stage III unresectable NSCLC, but there remains an unmet need for improved therapeutic options among pts with driver mutated tumours that are unresponsive to immunotherapy. As targeting of specific driver mutations (e.g., ALK, RET, ROS1) has proven effective in the metastatic setting, it is hypothesised that outcomes could also be improved for pts with driver‐mutated stage III NSCLC. Trial design BO42777 is a phase I–III platform study evaluating the safety and efficacy of multiple targeted therapies vs durvalumab following CRT in pts with locally advanced, unresectable, Stage III NSCLC. Biomarker eligibility is determined via local tissue testing or central testing within the BX43361 master screening study. Biomarker‐eligible pts are enrolled into the relevant cohort and randomised 1:1 to receive durvalumab or targeted therapy (alectinib [ALK+], entrectinib [ROS1+], or pralsetinib [RETfusion+]). New cohorts maybe added in the future. Key inclusion criteria: locally advanced, unresectable Stage III NSCLC, age ≥18 years, ≥2 prior cycles of concurrent or sequential CRT (cCRT or sCRT), ECOG PS 0–2. Pts are stratified based on staging (IIIA vs IIIB or IIIC), CRT type (cCRT vs sCRT), and PD‐L1 status (tumour cell score <1% vs ≥1% vs unknown) and will receive investigational treatment for 3 years or durvalumab for 1 year, until progression or maximum duration of treatment, unacceptable toxicity, consent withdrawal, or death. Primary endpoint: progression‐free survival (RECIST v1.1) by blinded independent central review. Key secondary endpoints: distant metastasis‐free survival, time to CNS progression, objective response rate, duration of response, overall survival, and safety (adverse events). Time to confirmed deterioration and patient‐reported outcomes will be assessed through questionnaires. Tumour response will be assessed by CT/MRI imaging at regular intervals. Enrolment is ongoing (target of 320 pts) across 200 sites in 11 countries. As of 6 Jan 2023, 2 pts have been randomised. Clinical trial identification NCT05419375 & NCT05170204. Editorial acknowledgement These trials are sponsored by F. Hoffmann‐La Roche Ltd. Medical writing support for the development of this abstract, under the direction of the authors, was provided by Olivia Barber, BSc and Laura Vergoz, PhD of Ashfield MedComms, an Inizio company, and funded by F. Hoffmann‐La Roche Ltd. Legal entity responsible for the study F. Hoffmann‐La Roche Ltd. Funding F. Hoffmann‐La Roche Ltd. Disclosure L. Paz‐Ares: Financial Interests, Personal, Other, Board member: Altum sequencing, Genomica, AECC; Financial Interests, Personal, Member: AECC, ASCO, ASEICA, ESMO, Small Lung Cancer Group; Financial Interests, Personal, Other, Speaker fees and/or advisory board: Amgen, AstraZeneca, Bayer, BeiGene, BMS, Daiichi Sankyo, GSK, Janssen, Eli Lilly, Medscape, Merck Serono, Mirati, MSD, Novartis, PER, Pfizer, PharmaMar, Roche, Sanofi, Takeda, AACR; Financial Interests, Personal, Other, Coordinating PI: Alkermes, Amgen, AstraZeneca, BMS, Daiichi Sankyo, Janssen‐Cilag, Eli Lilly, Merck Sharp & Dohme corp., Novartis, Pfizer, PharmaMar, Roche, Sanofi, Takeda, Tesaro; Financial Interests, Personal, Other, Foundation president: ONCOSUR. C.M. Gay: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, BeiGene; Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Myers Squibb, G1 Therapeutics, Jazz Pharmaceuticals, MonteRosa Therapeutics; Financial Interests, Personal, Research Grant: AstraZeneca. C. Zhou: Financial Interests, Personal, Other, Consulting fees: Innovent Biologics, Qilu, Hengrui, TopAlliance Biosciences Inc; Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Eli Lilly China, Sanofi, Boehringer Ingelheim, Roche, MSD, Qilu, Hengrui, Innovent Biologics, C‐Stone LUYE Pharma, TopAlliance Biosciences Inc, Amoy Diagnositics, AnHeart. T. Kato: Financial Interests, Institutional, Research Grant: AbbVie, Amgen, AstraZeneca, Blueprint, Chugai, Eli Lilly, Haihe, Merck Biopharma, MSD, Novartis, Pfizer, Regeneron, Takeda; Financial Interests, Personal, Other, Honoraria for lectures, presentations or educational events: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi‐Sankyo, Eli Lilly, Merck Biopharma, MSD, Novartis, Ono, Pfizer, Roche; Financial Interests, Personal, Other, Participation on a Data Safety Monitoring Board or Advisory Board: AbbVie, Amgen, AstraZeneca, BeiGene, Chugai, Daiichi‐Sankyo, Eli Lilly, Glaxo, Merck Biopharma, MSD, Nippon Kayaku, Novartis, Ono, Pfizer, Taiho, Takeda. K. Redhead: Financial Interests, Personal, Full or part‐time Employment: Roche Products Limited; Financial Interests, Personal, Stocks/Shares: Roche Products Limited. A. Rahman: Financial Interests, Personal, Full or part‐time Employment: Roche Products Limited; Financial Interests, Personal, Stocks/Shares: Roche Products Limited. D. Bradley: Financial Interests, Personal, Full or part‐time Employment: Roche Products Limited; Financial Interests, Personal, Stocks/Shares: Roche Products Limited; Financial Interests, Personal, Other, Named on Roche Products Limited patent: Roche Products Limited. E. Theogaraj: Financial Interests, Personal, Full or part‐time Employment: Roche Products Limited. K.E. Hutchinson: Financial Interests, Personal, Full or part‐time Employment: Roche/Genentech; Financial Interests, Personal, Stocks/Shares: Roche/Genentech. S.M. Shagan: Financial Interests, Personal, Full or part‐time Employment: Roche/Genentech; Financial Interests, Personal, Stocks/Shares: Roche/Genentech. B.J. Solomon: Financial Interests, Personal, Invited Speaker: Roche, Pfizer, Bristol Myers Squibb, Merck Sharp Dohme, AstraZeneca, Eli Lilly, Amgen, Takeda; Financial Interests, Personal, Advisory Board: Roche, Pfizer, Novartis, Bristol Myers Squibb, Merck Sharp Dohme, Merck Serono, AstraZeneca, Eli Lilly, Amgen, Takeda, BeiGene; Financial Interests, Personal, Research Grant: Sanofi, Pfizer. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/S1556-0864(23)00386-6}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02543501/full} -} - - -Record #464 of 538 -@article{Jabbour22, -author = {Jabbour, S, Lu, B, Fu, X, Goksel, T, Sugawara, S, Song, A, Quinn, S, Yang, P, and Reck, M}, -title = {969TiP Randomized, phase III study of MK-7684A plus concurrent chemoradiotherapy (cCRT) followed by MK-7684A vs cCRT followed by durvalumab for unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYVIBE-006}, -journal = {Annals of oncology}, -volume = {33}, -pages = {S990}, -year = {2022}, -accession_number = {EMBASE 2020167611}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer combination chemotherapy; *cancer staging; *chemoradiotherapy; *non small cell lung cancer; Adult; Area under the curve; Asia; Australia; Chemotherapy; China; Clinical trial; Conference abstract; Controlled study; Drug combination; Drug safety; Drug therapy; ECOG Performance Status; Employee; Europe; Female; Histology; Histopathology; Human; Human tissue; Intravenous drug administration; Major clinical study; Male; Medical literature; North America; Outcome assessment; Parttime employment; Patient‐reported outcome; Phase 3 clinical trial; Radiotherapy; Randomization; Randomized controlled trial; Response evaluation criteria in solid tumors; Western Europe}, -abstract = {Background: Pembrolizumab (pembro; anti‒PD‐1) + cCRT demonstrated robust antitumor activity and manageable safety in the KEYNOTE‐799 study in previously untreated, locally advanced, stage III NSCLC. The combination of vibostolimab (MK‐7684; monoclonal antibody that inhibits T‐cell immunoglobulin and ITIM domain [TIGIT] immunomodulatory receptor) + pembro with/without chemotherapy (chemo) has shown promising antitumor activity with manageable safety in patients (pts) with advanced NSCLC in the KEYVIBE‐001 study. The KEYVIBE‐006 study (NCT05298423) is evaluating MK‐7684A (co‐formulation of vibostolimab + pembro) + cCRT followed by MK‐7684A vs cCRT followed by durvalumab (anti‒PD‐L1) in unresectable, locally advanced, stage III NSCLC. Trial design: In this phase 3, open‐label, randomized study, ∼784 eligible adults with previously untreated, unresectable, pathologically confirmed stage IIIA‒C NSCLC; measurable disease by RECIST v1.1; and ECOG PS of 0/1 will be randomized 1:1. In arm A, pts receive intravenous (IV) MK‐7684A (vibostolimab 200 mg + pembro 200 mg) Q3W + 3 cycles of chemo (one of: cisplatin 75 mg/m2 + pemetrexed 500 mg/m2 [nonsquamous only]; cisplatin 50 mg/m2 + etoposide 50 mg/m2; or carboplatin AUC 6 mg/mL/min [cycle 1] and AUC 2 mg/mL/min [cycles 2/3] + paclitaxel 200 mg/m2 [cycle 1] and 45 mg/m2 [cycles 2/3]) + standard thoracic radiotherapy (TRT; 60 Gy in 2‐Gy fractions; cycles 2/3) followed by vibostolimab 200 mg + pembro 200 mg for up to 17 cycles. Pts in arm B receive 3 cycles of chemo + TRT (as above) followed by durvalumab 10 mg/kg IV Q2W for up to 26 cycles. Treatment continues until treatment completion, PD, unacceptable toxicity, or investigator decision. Randomization is stratified by histology (squamous vs nonsquamous), stage (IIIA vs IIIB/IIIC), PD‐L1 TPS (<1% vs ≥1%), and region (East Asia vs North America/Western Europe/Australia vs rest of world). Dual primary endpoints are PFS per RECIST v1.1 by blinded independent central review (BICR) and OS. Secondary endpoints include ORR and DOR per RECIST v1.1 by BICR, safety, and patient‐reported outcomes. Enrollment began in May 2022. Clinical trial identification: NCT05298423 Editorial acknowledgement: Medical writing support was provided by Christabel Wilson, MSc, of ICON plc (Blue Bell, PA, USA). Legal entity responsible for the study: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Funding: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Disclosure: S. Jabbour: Financial Interests, Personal, Advisory Role: Merck Sharp & Dohme Llc, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Syntactx Adjudication Committee; IMX Medical Reviewer; Financial Interests, Institutional, Research Grant: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and NCI. T. Goksel: Financial Interests, Personal, Research Grant: Eli Lilly, Merck Sharp & Dohme Corp, AstraZeneca, Sanofi, Jounce Therapeutics, BeiGene, Ltd. S. Sugawara: Financial Interests, Personal, Other, Honoraria: AstraZeneca, Bristol Myers Squibb, Chugai Pharma, Kyowa Kirin, Lilly, MSD K.K., Nippon, Boehringer Ingelheim, Novartis, Ono Pharmaceuticals, Pfizer, Taiho Pharmaceuticals, and Yakult Honsha. A. Song: Financial Interests, Personal, Full or part‐time Employment: Employee of Merck Sharp & Dohme Llc, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Rahway, NJ, USA. S. Quinn: Financial Interests, Personal, Full or part‐time Employment: Employee of Merck Sharp & Dohme Llc, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. P. Yang: Financial Interests, Personal, Full or part‐time Employment: MSD China; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Rahway, NJ, USA. M. Reck: Financial Interests, Personal, Advisory Role: Lilly, MSD Oncology, Merck Serono, Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, Roche/Genentech, AbbVie, Amgen, Mirati Therapeutics, Samsung Bioepis, Sanofi/Regeneron, and Daiichi Sankyo Europe; Financial Interests, Personal, Speaker’s Bureau: Roche/Genentech, Lilly, MSD Oncology, Merck Serono, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Pfizer, Novartis, Amgen, Mirati Therapeutics, and Sanofi/Aventis. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2022.07.1095}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02463800/full} -} - - -Record #465 of 538 -@article{Gerber17, -author = {Gerber, DE, Urbanic, JJ, Langer, CJ, Hu, C, Chang, I-F, Lu, B, Movsas, B, Jeraj, R, Curran, WJ, and Bradley, JD}, -title = {Randomized phase III trial of concurrent chemoradiation followed by nivolumab or placebo for locally advanced non-small cell lung cancer (NSCLC) (RTOG 3505)}, -journal = {Journal of clinical oncology}, -volume = {35}, -number = {15}, -year = {2017}, -accession_number = {EMBASE 617435915}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *non small cell lung cancer; Autoimmune disease; Clinical trial; Controlled clinical trial; Controlled study; Drug combination; Drug therapy; Female; Gene expression; Hazard ratio; Histology; Human; Human tissue; Immunotherapy; Lung toxicity; Major clinical study; Male; Organ; Overall survival; Patient‐reported outcome; Progression free survival; Quality of life; Radiology; Radiotherapy; Randomization; Randomized controlled trial; Stratification; Surgery; Thorax}, -abstract = {Background: Despite aggressive therapy with concurrent chemoradiation, fewer than 25% of patients with stage 3 NSCLC achieve 5‐year survival and are presumably cured. To date, treatment modifications‐including consolidation chemotherapy, maintenance therapy with molecularly targeted agents, concomitant administration of monoclonal antibodies, and escalation of radiation therapy (RT) dose‐have not improved these outcomes. Immune checkpoint inhibitors represent an effective treatment for advanced NSCLC and may enhance RT‐associated anti‐tumor immunity. RTOG 3505 will test whether the addition of the anti‐programmed death 1 (PD1) antibody nivolumab after chemoradiation improves overall survival (OS) and progression‐free survival (PFS) in this population. Methods: Key eligibility criteria include surgically unresectable stage 3 NSCLC, ECOG 0‐1, adequate organ function, available archival tissue, and absence of active autoimmune disease. Patients will receive thoracic RT to 60 Gy with concurrent cisplatin 50 mg/m2IV on Days 1, 8, 29, and 36, and etoposide 50 mg/m2IV on Days 1‐5 and 29‐33. This regimen was selected to (1) minimize risk of pulmonary toxicity and steroid requirements, and (2) optimize timing of immunotherapy. Between 4 and 12 weeks after completion of chemoradiation, eligible patients will be randomized to nivolumab 240 mg IV or placebo every 2 weeks for 1 year. Stratification factors include performance status, histology, and tumor PD‐L1 status. Co‐primary endpoints are OS and PFS, as determined by central radiology review. Secondary objectives include toxicity assessment, patient‐reported outcomes and quality of life, and OS and PFS according to PD‐L1 expression. Exploratory objectives include biomarkers to predict treatment efficacy and toxicity. A total of 660 patients will be enrolled to provide ≥90% power to detect (1) a hazard ratio (HR) of 0.7 for OS with two‐sided type I error of 0.04, and (2) HR of 0.667 for PFS twosided type I error of 0.01, allowing a 16.7% drop‐out rate before randomization.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01397271/full} -} - - -Record #466 of 538 -@article{Camerini19, -author = {Camerini, A, Morabito, A, Montanino, A, Bernabe Caro, R, Grossi, F, Ramlau, R, Ciuleanu, T-E, Ceresoli, GL, Pasello, G, De Marinis, F, Bosch-Barrera, J, Landreau, P, Gautier, S, Ta Thanh Minh, C, and Kowalski, D}, -title = {Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: an exploratory analysis of randomized Tempo-Lung trial}, -journal = {Annals of oncology}, -volume = {30}, -pages = {ix172}, -year = {2019}, -accession_number = {EMBASE 630553039}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *exploratory research; *non small cell lung cancer; Adult; Asthenia; Blood toxicity; Cancer chemotherapy; Cancer radiotherapy; Cancer survival; Case report; Clinical article; Conference abstract; Creatinine clearance; Drug safety; Drug therapy; Febrile neutropenia; Female; Hearing impairment; Heart failure; Human; Immunotherapy; Male; New York Heart Association class; Physician; Progression free survival; Quality of life; Radiotherapy; Randomized controlled trial; Treatment failure}, -abstract = {Background: Tempo‐Lung trial randomly assessed the role of metronomic oral vinorelbine (OV) vs standard weekly oral vinorelbine in advanced NSCLC patients (pts) unfit to platinum doublets. Little data are available on treatment options after first‐line in platinum‐unfit pts. Methods: Advanced NSCLC pts unfit to receive platinum doublets (Creatinine clearance <60 ml/min; heart failure NYHA class II‐III; hearing loss >G2; any medical condition impairing platinum treatment according to physician's opinion) were randomized to arm A (metronomic): OV 50mg x3/week (wk) or arm B (standard): OV 60 mg/m2/ wk cycle 1, then 80 mg/m2/wk. Primary endpoint was progression free‐survival without grade 4 toxicity (PFSG4) and secondary efficacy and safety end‐point, quality of life (QoL). Data on treatment after failure of first‐line vinorelbine were collected. Results: Intention‐to‐treat population included 165 (arm A 83 ‐ arm B 82) pts. Baseline characteristics were well balanced between both arms. Mean dose intensity by cycle: 73.56 mg/m2/week (arm A), 55.85 mgm2/week (arm B). Median PFSG4 significantly differ in favor of metronomic arm [95%CI]: 4.0 [2.6‐4.3] vs2.2 [1.5‐2.9] months (p = 0.0068), HR [95%CI] = 0.63 [0.45‐0.88]. Overall treatment related adverse events (61.4% vs84%): haematological toxicities (27.7% vs55.6%), G3/4 neutropenia (11% vs 42%), febrile neutropenia (3.6% vs 6.2%) and G3/4 asthenia (4.8% vs 8.6%) were reduced with metronomic OV. It was observed that 40% of patients (subset) had second line treatment: immunotherapy, chemotherapy, protein kinase inhibitor, radiotherapy. No difference was found for changes in EORTC QoL scores. Secondary endpoints will be presented. Conclusions: Metronomic OV could be a suitable option for advanced NSCLC pts unfit to receive platinum doublets. Less toxicity was observed in metronomic arm. QoL scores were similar in both arms. A subset of platinum unfit patients could receive second‐line treatment mainly consisting on immunotherapy, chemotherapy.}, -DOI = {10.1093/annonc/mdz437.035}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02074939/full} -} - - -Record #467 of 538 -@article{Paz-Ares23, -author = {Paz-Ares, LG, Gay, CM, Zhou, C, Kato, T, Corrales, L, Redhead, K, Rahman, A, Bradley, D, Theogaraj, E, Hutchinson, KE, Shagan, SM, and Solomon, BJ}, -title = {A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small-cell lung cancer (NSCLC)}, -journal = {Journal of clinical oncology}, -volume = {41}, -number = {16}, -pages = {TPS8605}, -year = {2023}, -accession_number = {EMBASE 642929217}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Adult; Chemoradiotherapy; Conference abstract; Distant metastasis free survival; Drug therapy; Female; Human; MRI scanner; Multicenter study; Nuclear magnetic resonance imaging; Overall survival; Patient‐reported outcome; Progression free survival; Questionnaire; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Therapy; Treatment duration}, -abstract = {Background: Durvalumab following chemoradiation (CRT) is a standard of care for unresectable stage III NSCLC, but there remains an unmet need for improved therapeutic options among patients with drivermutated tumors that are unresponsive to immunotherapy. As targeting of specific driver mutations (e.g. ALK, RET, ROS1) has proven effective in the metastatic setting, it is hypothesized that outcomes could also be improved for patients with driver‐mutated stage III NSCLC. Methods: BO42777 (NCT05170204) is a phase I‐III platform study evaluating the safety and efficacy of multiple targeted therapies versus durvalumab following CRT in patients with locally advanced, unresectable stage III NSCLC. Biomarker eligibility is determined via local tissue testing or central testing within the BX43361 master screening study (NCT05419375). Biomarker‐eligible patients are enrolled into the relevant cohort and randomized 1:1 to receive durvalumab or targeted therapy (alectinib [ALK+], entrectinib [ROS1+], or pralsetinib [RET fusion+]). New cohorts may be added in the future. Key inclusion criteria: locally advanced, unresectable stage III NSCLC, age ≥18 years, ≥2 prior cycles of concurrent or sequential CRT (cCRT or sCRT), and ECOG PS 0‐2. Patients are stratified based on staging (IIIA vs IIIB or IIIC), CRT type (cCRT vs sCRT), and PD‐L1 status (tumor cell score<1%vs≥1% vs unknown) and will receive investigational treatment for three years or durvalumab for one year, until progression or maximum duration of treatment, unacceptable toxicity, consent withdrawal, or death. Primary endpoint: progression‐free survival (RECIST v1.1) by blinded independent central review. Key secondary endpoints: distant metastasis‐free survival, time to CNS progression, objective response rate, duration of response, overall survival, and safety (adverse events). Time to confirmed deterioration and patient‐reported outcomes will be assessed through questionnaires. Tumor response will be assessed by CT/MRI imaging at regular intervals. Enrolment is ongoing (target of 320 patients) across 200 sites in 11 countries. As of 7 February 2023, five patients have been randomized. This trial in progress was previously presented at ELCC, Luis Paz‐Ares et al. (#744), and reused with permission.}, -DOI = {10.1200/jco.2023.41.16_suppl.tps8605}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02633115/full} -} - - -Record #468 of 538 -@article{Shim20, -author = {Shim, BY, Lee, S, de Castro Carpeno, J, Chiu, C-H, Cobo, M, Kim, HR, Ryu, JS, Tarruella, MM, Summers, Y, Thomas, CA, Xu, Y, Lowy, I, and Rietschel, P}, -title = {EMPOWER-lung 4: phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC)}, -journal = {Annals of oncology}, -volume = {31}, -pages = {S820}, -year = {2020}, -accession_number = {EMBASE 2007889949}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *histology; *non small cell lung cancer; Adult; Antineoplastic activity; Cancer patient; Case report; Clinical article; Clinical trial; Conference abstract; Constipation; Decreased appetite; Drug combination; Drug megadose; Drug therapy; Female; Funding; Gene expression; Histopathology; Human; Human tissue; Hypothyroidism; Immune‐related gene; Male; Medical literature; Monotherapy; Overall response rate; Parttime employment; Patient history of radiotherapy; Pneumonia; Protein expression; Randomized controlled trial; Summer; Travel; Treatment duration}, -abstract = {Background: Programmed cell death‐1/ligand 1 (PD‐1/PD‐L1) inhibitors have become key treatment options for advanced NSCLC without EGFR, ALK, or ROS1 mutations. Here, we report on the antitumour activity of cemiplimab, an anti–PD‐1, alone or plus ipilimumab (an anti‐cytotoxic T‐lymphocyte‐associated protein 4 agent) in second‐line (2L) advanced NSCLC. Methods: Patients with advanced NSCLC were randomised (1:1:1; stratified by histology and PD‐L1 status) to receive cemiplimab 350 mg once every 3 weeks (Q3W) (Arm A); or cemiplimab 350 mg Q3W plus ipilimumab 50 mg once every 6 weeks (Q6W) (up to 4 doses) (Arm B); or cemiplimab 1050 mg Q3W (Arm C), for up to 108 weeks or until disease progression. Primary endpoint was objective response rate (ORR) in patients with PD‐L1 expression <50%, per independent central review. Data cut‐off was 28 Aug 2019. Results: Of 28 patients enrolled, 27 received treatment (Arm A, n=8; Arm B, n=11; and Arm C, n=8). Median (range) age was 68 (46–80) years; 71.4% were male; 39.3% had prior radiotherapy; 67.9% had non‐squamous NSCLC; and 57.1% had a PD‐1 level <1%. Median duration of treatment exposure was 10.8 (Arm A), 17.9 (Arm B), and 10.8 (Arm C) weeks. ORR (95% confidence interval) was 0% (0.0–36.9%) in Arm A, 45.5% (16.7–76.6%) in Arm B and 11.1% (0.3–48.2%) in Arm C. For patients with PD‐L1 levels <1%, ORR was 36.4% (Arm B), and 11.1% (Arm C); for patients with PD‐L1 levels of 1–49%, ORR was 9.1% (Arm B), and 0% (Arm C). Median duration of response (DOR) has not been reached; observed DOR was 2+ to 6.9+ (Arm B) and 4.8+ months (Arm C). Most common treatment‐emergent adverse events of any grade were decreased appetite and constipation (each 37.5%) in Arm A; hypothyroidism and pneumonia (each 36.4%) in Arm B; and decreased appetite (37.5%) in Arm C. Across all arms, increased alanine aminotransferase was the only Grade ≥3 immune‐related adverse event reported in >1 patient (Arm B; 18.2%). Conclusions: In patients with advanced NSCLC and <50% PD‐L1 expression, 2L combination treatment with cemiplimab 350 mg + ipilimumab 50 mg exhibited numerically higher antitumour activity than cemiplimab monotherapy (350 or 1050 mg). Clinical trial identification: NCT03430063. Editorial acknowledgement: Medical writing support was provided by Atif Riaz, PhD of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc. and Sanofi. Legal entity responsible for the study: Regeneron Pharmaceuticals, Inc. and Sanofi. Funding: Regeneron Pharmaceuticals, Inc. and Sanofi. Disclosure: S. Lee: Shareholder/Stockholder/Stock options, Full/Part‐time employment: Regeneron Pharmaceuticals, Inc. J. de Castro Carpeño: Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Bristol‐Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: Hoffmann‐la Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Merck Sharp and Dohme; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Takeda. M.M. Tarruella: Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Bristol‐Myers Squibb; Advisory/Consultancy: Kyowa Kirin; Advisory/Consultancy, Travel/Accommodation/Expenses: Merck Sharp & Dohme; Advisory/Consultancy: Pierre Fabre; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche. Y. Summers: Advisory/Consultancy: Bristol‐Myers Squibb. Y. Xu, I. Lowy, P. Rietschel: Shareholder/Stockholder/Stock options, Full/Part‐time employment: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2020.08.1583}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02176806/full} -} - - -Record #469 of 538 -@article{Seto19, -author = {Seto, T, Niho, S, Yoshida, T, Akimoto, T, Sakamaki, K, Ono, A, Nishio, M, Yamamoto, N, Hida, T, Okamoto, H, Kurata, T, Hattori, Y, Goto, K, Yamanaka, T, and Ohe, Y}, -title = {OA12.02 Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined with Thoracic RT for Locally Advanced Non-Sq NSCLC: SPECTRA Study}, -journal = {Journal of thoracic oncology}, -volume = {14}, -number = {10}, -pages = {S237}, -year = {2019}, -accession_number = {EMBASE 2003407983}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *non small cell lung cancer; Adenocarcinoma; Adult; Cancer recurrence; Cancer staging; Cancer survival; Chemoradiotherapy; Conference abstract; Controlled study; Distant metastasis; Drug therapy; Enzyme activity; Febrile neutropenia; Female; Follow up; Gene mutation; Human; Human tissue; Japan; Major clinical study; Male; Multicenter study; Never smoker; Phase 2 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Relapse; Sample size; Treatment failure}, -abstract = {Background: SPECTRA, a multicenter, randomized phase II study of CDDP+S‐1 versus CDDP+pemetrexed (PEM) combined with thoracic radiotherapy (TRT) for locally advanced non‐squamous non‐small cell lung cancer (NSCLC), previously reported that toxicities were tolerable and manageable in both arms; however, febrile neutropenia was more frequently observed in the CDDP+S‐1 arm (9.6%/2%). Completion rate of TRT (60Gy) and chemotherapy (4 cycles) was 92%/98% and 73%/86%, respectively. Response rate was 60%/64% (WCLC 2017, MA17.06). Here, we present primary analysis of 2‐year survival data. Method: Patients were randomly assigned to receive CDDP+S‐1 (CDDP 60mg/m2, d1, and S‐1 80mg/m2, d1‐14, q4w, up to 4 cycles) or CDDP+PEM (CDDP 75mg/m2, d1, and PEM 500mg/m2, d1, q3w, up to 4 cycles) combined with TRT 60Gy in 30 fractions. The primary endpoint was 2‐year progression‐free survival (PFS) rate. The sample size was set at 100 patients. Result: Between Jan 2013 and Oct 2016, 102 patients were enrolled in this study from 9 institutions in Japan. All 102 patients were eligible and assessable, of whom 52 were assigned to CDDP+S‐1 and 50 to CDDP+PEM. Baseline characteristics were similar (CDDP+S‐1/CDDP+PEM): median age (range) 64.5 (39‐73)/63.5 (32‐74) years; women, n=17 (33%)/n=17 (34%); stage IIIB, n=21 (40%)/n=20 (40%); ECOG PS of 1, n=14 (27%)/n=14 (28%); never smoker, n=12 (23%)/n=12 (24%); and adenocarcinoma, n=47(90%)/n=45(90%); activating EGFR mutation, n=9 (17%)/n=4 (8%); ALK fusion, n=2 (4%)/n=3 (6%). A total of 72 PFS events were observed at the data cut‐off (28 November 2018). After a median follow‐up of 32.1 months, median PFS was 12.7/13.8 months (HR=1.16, 95% CI, 0.73‐1.84, p=0.538), and 2‐year PFS rate was 36.5% (95% CI, 23.5‐49.6)/32.1% (95%CI, 18.9‐45.4). Disease progression was observed in 33 and 36 patients. Distant metastases were the first site of failure in 24 and 31 patients. Local relapse as the first site of failure was observed in 14 and 13 patients. After a median follow‐up of 34.6 months, 44 OS events were observed. Median OS was 48.3/59.1 months (HR=1.05, 95%CI, 0.58‐1.90, p=0.883), and 2‐year OS rate was 69.2% (95%CI, 56.7‐81.8)/66.4% (95%CI, 53.0‐79.9). 27 patients in each arm received post‐study chemotherapy including EGFR‐TKIs (n=7/n=5), ALK‐TKIs (n=0/n=3), and immune checkpoint inhibitors (n=6/n=10). Conclusion: 2‐year PFS rate in the CDDP+S‐1 arm was better than that in the CDDP+PEM arm. We will select the CDDP+S‐1 arm as the investigational arm in a future phase III study. UMIN000009914 (release date: 31/Jan/2013) Keywords: chemoradiotherapy, NSCLC, non‐Sq}, -DOI = {10.1016/j.jtho.2019.08.472}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01998815/full} -} - - -Record #470 of 538 -@article{Hui17, -author = {Hui, R, Ozguroglu, M, Daniel, D, Baz, D, Murakami, S, Yokoi, T, Chiappori, A, Lee, KH, De Wit, M, Chul Cho, B, Gray, J, Ryden, A, Viviers, L, Poole, L, Dennis, P, and Antonia, S}, -title = {Patient-reported outcomes with durvalumab after chemoradiation in locally advanced, unresectable NSCLC: data from PACIFIC}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {11}, -pages = {S1604}, -year = {2017}, -accession_number = {EMBASE 620146574}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *non small cell lung cancer; *outcome assessment; *patient‐reported outcome; Adult; Alopecia; Clinical trial; Controlled study; Coughing; Deterioration; Double blind procedure; Drug therapy; Dysphagia; Dyspnea; Fatigue; Female; Global health; Hazard ratio; Human; Log rank test; Loss of appetite; Major clinical study; Male; Phase 3 clinical trial; Quality of life; Questionnaire; Radiation; Radiotherapy; Randomized controlled trial; Thorax pain; Toxicity; Visually impaired person}, -abstract = {Background: Durvalumab, an engineered human IgG1 anti‐PD‐L1 mAb, demonstrated an improvement in PFS vs placebo and favorable benefit/risk profile in the Phase 3 PACIFIC study in locally advanced, unresectable NSCLC. Here we summarize patient‐reported outcomes from PACIFIC. Method: In the randomized, double‐blind, Phase 3 PACIFIC study (NCT02125461), patients who had previously received ≥2 cycles of platinum‐based concurrent chemotherapy with definitive dose radiation without disease progression were randomized (2:1) to durvalumab 10 mg/kg i.v. q2w or placebo for up to 12 months. Secondary endpoints included evaluation of symptoms, function and global health status/QoL using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ‐C30 v3 questionnaire and its lung cancermodule, QLQ‐LC13. Patients completed the questionnaires at baseline, Week 4, Week 8, q8w until Week 48, then q12w until disease progression. Changes from baseline for key symptoms were analyzed using a mixed model for repeated measures (MMRM). Time to deterioration (TTD) and odds of improvement were analyzed. Deterioration or improvement was defined as a change in score from baseline ≥10. Hazard ratios (HR) were calculated using a stratified log‐rank test and odds ratios (OR) using logistic regression. Result: Compliance with completing the questionnaires was high in both durvalumab (n = 476) and placebo (n = 237) groups (>80% up to Week 48). There were no differences between groups at baseline in symptoms, function or global health status/QoL. MMRM analysis showed no statistically significant differences between treatment groups in adjusted mean changes from baseline (average over 12 months) in the prespecified symptoms of dyspnea, cough, chest pain, fatigue and appetite loss, and for global health status/QoL and physical functioning. Clinically relevant improvements from baseline were observed throughout the study in both durvalumab and placebo groups for dysphagia (mean [SD] change at Week 48, ‐14.2 [26.1] and ‐14.8 [25.3], respectively) and alopecia (‐22.1 [33.0] and ‐21.4 [29.5]). There were no differences in median TTD between groups except 'other pain' (9.2 months with durvalumab vs 5.6 months with placebo [HR 0.72; 95% CI 0.58, 0.89]). The only difference in improvement rates between groups was for appetite loss (26.1% improvement rate with durvalumab vs 24.9% with placebo [OR 1.72; 95%CI 1.04, 2.85]). Other symptoms, function and health‐related QoL remained stable throughout with no between‐group differences in TTD or improvement rates. Conclusion: Durvalumab treatment did not worsen symptoms, function or healthrelated QoL. Clinically relevant improvement in alopecia and dysphagia with durvalumab and placebo was likely due to resolution of toxicities related to prior chemoradiation.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01451815/full} -} - - -Record #471 of 538 -@article{Johnson19, -author = {Johnson, BE, Kim, TM, Hiltermann, TJN, Barlesi, F, Grohe, C, Goto, Y, Gunnarsson, O, Overbeck, T, Reguart, N, Wermke, M, Castro, G, Felip, E, Greystoke, A, Solomon, BJ, Nebot, N, Deudon, S, Louveau, A-L, Passos, VQ, and Tan, DSW}, -title = {Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)}, -journal = {Molecular cancer therapeutics}, -volume = {18}, -number = {12 SUPPL 1}, -year = {2019}, -accession_number = {EMBASE 638178103}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer combination chemotherapy; *cancer patient; *canopy; *doublet chemotherapy; *drug safety; *non small cell lung cancer; Adult; Adverse drug reaction; Cancer mortality; Cancer staging; Chemoradiotherapy; Clinical article; Clinical trial; Cohort analysis; Comparative effectiveness; Conference abstract; Constipation; Controlled study; Double blind procedure; Drug combination; Drug therapy; Drug withdrawal; Fatigue; Female; Follow up; Heart tamponade; Hepatitis; Human; Immunogenicity; Incidence; Male; Middle aged; Nausea; Neutrophil count; Peripheral neuropathy; Phase 3 clinical trial; Polyneuropathy; Randomized controlled trial; Side effect; Vomiting}, -abstract = {Cytokine interleukin‐1β (IL‐1β) has multiple pro‐tumorogenic effects on tumor microenvironment, thereby promoting carcinogenesis, tumor invasiveness, and immunosuppression. CAN is a selective IL‐1β inhibitor that aims to target tumor‐promoting inflammation to reduce immune suppression, thereby potentiating effects of immunotherapy with PD‐1 inhibitors such as PEM. Results of phase 3 CANTOS study have shown that IL‐1β inhibition with CAN was associated with reduced incidence of lung cancer and lung cancer mortality, thus providing a rationale to investigate therapeutic role of CAN in lung cancer. CANOPY‐1 (NCT03631199) is a placebo‐controlled, double‐blind, randomized, phase 3 trial designed to evaluate efficacy and safety of PEM + Ctx ± CAN in previously untreated pts with stage IIIB/IIIC (not eligible for definitive chemo‐radiation curative tx) or stage IV squamous and nonsquamous NSCLC. The study was divided into 2 parts: part 1 is non‐randomized, safety run‐in part where pts received CAN 200 mg s.c Q3W + PEM 200 mg i.v Q3W + platinum‐based Ctx [Cohort A (non‐squamous), carboplatin + pemetrexed; Cohort B (non‐squamous), cisplatin + pemetrexed; Cohort C (squamous or non‐squamous), carboplatin + paclitaxel]. Part 2 of the study randomizes pts to evaluate efficacy and safety of CAN combination regimen vs placebo combination regimen. Primary objective of safety run‐in part: RP3R for CAN in combination with PEM + Ctx. Secondary objectives: ORR, DCR, DOR, safety, PK, and immunogenicity. As of 14 May 2019 (follow‐up of ≥42 days from C1D1 unless pt discontinued earlier), 10 pts in cohort A (A), 11 pts in cohort B (B), and 9 pts in cohort C (C) were treated, of which 73% were male, median age was 63 yrs. In total, 24/30 (80%) pts enrolled were still receiving tx; primary reason for tx discontinuation was progressive disease (5 pts; 3 pts in A and 1 pt each in B and C) and 1 patient died due to study indication. Dose‐limiting toxicity (DLT) occurring during first 42 days of study tx was reported only in 1 pt (cohort C: grade 3 hepatitis, not related to CAN). Recommended phase 3 regimen (RP3R) of CAN in combination with standard dose of PEM + Ctx was confirmed as 200 mg SC Q3W based on Bayesian logistic regression model (BLRM). Serious AEs regardless of study drug relationship were reported in 8 (27%) pts (2 pts in A and 3 pts each in B and C), none of which considered to be related to CAN. Most common AEs (≥20%, any grade) across all cohorts (n=30) were nausea (37%), vomiting (30%), constipation and fatigue (each 23%), and neutrophil count decrease (20%). Overall, 14 pts (47%) experienced grade 3 AEs and 1 pt experienced grade 4 AE (cardiac tamponade unrelated to study drugs). No fatal serious AEs were reported. AEs leading to discontinuation of one of the study drugs were reported in 3 (10%) pts (hepatitis, peripheral neuropathy, and polyneuropathy) but none were CAN related. AEs leading to dose reduction and dose interruption of one of study drugs were reported in 3 (10%) pts and 5 (17%) pts, respectively. Only 1 DLT was reported with this triplet combination of CAN + PEM + Ctx. Based on BLRM and all relevant data, the RP3R of CAN as 200 mg SC Q3W combination was considered safe and well tolerated. Enrolment is ongoing in randomized phase 3 part of study to evaluate efficacy and safety.}, -DOI = {10.1158/1535-7163.TARG-19-C100}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02404037/full} -} - - -Record #472 of 538 -@article{Newman19, -author = {Newman, NB, Anderson, JL, Shinohara, ET, Michael, P, Attia, A, and Osmundson, EC}, -title = {Neoadjuvant Stereotactic Ablative and Hypofractionated Radiotherapy for Oligometastatic NSCLC}, -journal = {International journal of radiation oncology biology physics}, -volume = {104}, -number = {5}, -pages = {1196}, -year = {2019}, -accession_number = {EMBASE 2002296325}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer radiotherapy; *hypofractionated radiotherapy; *non small cell lung cancer; Adult; Advanced cancer; Analgesia; Cancer patient; Cancer size; Cancer staging; Cancer survival; Central nervous system metastasis; Conference abstract; Controlled study; Dosimetry; Drug combination; Drug megadose; Employee; Feasibility study; Female; Fractionation; Human; Immune response; Immunotherapy; Maintenance chemotherapy; Major clinical study; Male; Neoadjuvant therapy; Obstruction; Organs at risk; Overall survival; Palliative therapy; Progression free survival; Quality of life; Radiotherapy; Radiotherapy dosage; Randomized controlled trial; Secondary analysis; Stereotactic body radiation therapy; Stratification; Systemic therapy; T lymphocyte; Travel}, -abstract = {Approximately 40‐50% of all patients with NSCLC present with Stage IV or metastatic disease. Although advances in systemic therapy have led to significant improvements in response rates, OS remains poor. Data suggest that oligometastatic patients, defined here as having ≤ 5 metastases, may have improved outcomes in comparison to patients with more significant metastatic burden Immunotherapy containing regimens are now standard of care in Stage IV NSCLC and have led to improved outcomes. However, response rates to immunotherapy are variable, are often not sustained, and optimal predictors of response have yet to be determined. Recent data suggest that responses to immunotherapy may in part be determined by pretreatment tumor burden and that even robust induction of anti‐tumor T cell response by immune therapy may be clinically ineffective in the tumor burden is too high. Both human and animal data have demonstrated that radiotherapy can potentiate response to immunotherapy checkpoint inhibitors through multiple mechanisms. High dose per fraction radiotherapy, such as the type employed in stereotactic body radiotherapy, are particularly effective in enhancing anti‐tumor immune responses. While radiation therapy plays a central role in curative intent management of non‐metastatic (Stages I‐III) NSCLC, its role in metastatic disease has traditionally been confined to palliation of pain, relief of lumenal obstruction, or CNS metastases. Stereotactic Ablative Radiotherapy (SABR) is an advanced form of treatment which permits precise targeting of tumors with high doses of radiation using steep dosimetric gradients for protection of surrounding normal tissues. Randomized studies have demonstrated that oligometastatic patients who receive consolidative local radiotherapy (radiotherapy given after initial systemic therapy) to all metastatic sites experience improved outcomes in comparison to maintenance chemotherapy alone. It is notable that these studies were conceived and performed before immunotherapy regimens were first‐line standard of care. These and data described above imply that neoadjuvant delivery of SBRT may enhance response to immunotherapy and minimize pre‐immunotherapy tumor burden. We hypothesize that neoadjuvant SABR/Hypofractionated radiotherapy to oligometastatic NSCLC (≤5 metastases) can synergize with immunotherapy containing systemic agents leading to improved outcomes and response rates. We plan to evaluate this hypothesis with the following specific aims. Aim 1: Establish logistical feasibility and safety of neoadjuvant SBRT to oligometastatic sites of disease. Aim 2: Evaluate treatment responses and outcomes of patients randomized to be treated with neoadjuvant SBRT followed by standard of care systemic therapy vs standard of care therapy alone. In this Aim we compare OS, PFS, time to new metastases, and toxicity and quality of life in patients receive standard of care. Secondary analyses will evaluate responses based on PDL‐1 expression status, number and sites of metastases, and other clinical factors. Brief Methods and Eligibility: After stratification by PDL‐1 expression status and number of metastases, patients will be randomized between two arms as follows: Arm 1 ‐ standard of care systemic therapy; and Arm 2 – SABR/Hypofractionated RT to all radiographically identified disease followed by standard of care systemic therapy. Patients will be randomized 1:2 (Arm 1: Arm 2). Radiotherapy dose and fractionation for patients receiving SABR will depend on proximity to and/or dosimetry to organs at risk. This study aims to accrue a total of 90 patients within 4 years. The primary endpoint is overall survival, and secondary endpoints include toxicity, quality of life, progression‐free survival, local and regional control rates, and systemic therapy‐free survival. Author Disclosure: N.B. Newman: None. J.L. Anderson: None. E.T. Shinohara: None. P. Michael: None. A. Attia: Employee; Vanderbilt University. Independent Contractor; AstraZeneca, Novocure. Honoraria; Brainlab, qfix. Advisory Board; AstraZeneca. Travel Expenses; qfix. E.C. Osmundson: None.}, -DOI = {10.1016/j.ijrobp.2019.05.059}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01964645/full} -} - - -Record #473 of 538 -@article{Murakami17, -author = {Murakami, S, Ozguroglu, M, Villegas, A, Daniel, D, Baz, DV, Hui, R, Yokoi, T, Chiappori, A, Lee, KH, De Wit, M, Cho, BC, Bourhaba, M, Quantin, X, Tokito, T, Mekhail, T, Planchard, D, Jiang, H, Huang, Y, Antonia, SJ, and Dennis, PA}, -title = {PACIFIC: a double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC}, -journal = {Annals of oncology}, -volume = {28}, -pages = {x122}, -year = {2017}, -accession_number = {EMBASE 620035765}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *non small cell lung cancer; *visually impaired person; Adult; Adverse event; Cancer staging; Cancer survival; Clinical trial; Controlled study; Death; Distant metastasis; Double blind procedure; Drug therapy; Female; Follow up; Human; Major clinical study; Male; Overall survival; Phase 3 clinical trial; Pneumonia; Radiotherapy; Randomization; Randomized controlled trial; Reaction time; Response evaluation criteria in solid tumors; Smoking; Survival analysis; Survival rate}, -abstract = {Background: Most patients (pts) with locally advanced, unresectable non‐small cell lung cancer (NSCLC) progress despite concurrent chemoradiation therapy (cCRT). Here we report interimresults from a global, Phase 3 study of the anti‐PD‐L1 durvalumab as consolidation therapy in Stage III pts without progression following platinumbased cCRT. Methods: Pts with aWHOperformance status 0/1 (any PD‐L1 status) who received 2 cycles of platinum‐based cCRT without progression were randomized (2:1) 1‐42 days post‐cCRT to receive durvalumab 10 mg/kg IV Q2W or placebo for up to 12 months, stratified by age, sex, and smoking history. Co‐primary endpoints were progressionfree survival (PFS; blinded independent central review, RECIST v1.1) and overall survival (OS). Secondary endpoints included 12‐and 18‐month PFS rates, objective response rate (ORR), duration of response (DoR), time to death or distant metastasis (TTDM) and safety. Results: Between May 2014 and April 2016, 713 pts were randomized of whom 709 received consolidated treatment (durvalumab, n 473; placebo, n 236). Baseline characteristics were well balanced. As of Feb 13, 2017 (data cutoff), median follow‐up was 14.5 months. Median PFS from randomization was significantly longer with durvalumab (16.8 months, 95% CI, 13.0‐18.1) versus placebo (5.6 months, 95% CI, 4.6‐7.8; stratified HR 0.52, 95% CI, 0.42‐0.65; P<0.0001). 12‐and 18‐month PFS rates were 55.9% versus 35.3% and 44.2% versus 27.0%, respectively. ORR was higher (28.4% vs 16.0%; P<0.001) and median DoR was longer (not reached vs 13.8 months) with durvalumab consolidation therapy. Median TTDM was longer with durvalumab (23.2 vs 14.6 months; stratified HR 0.52, 95% CI, 0.39‐0.69; P<0.0001). OS data were immature at the time of interim PFS analysis. Comparing durvalumab with placebo, grade 3/4 adverse events (AEs) occurred in 29.9% and 26.1%; most common was pneumonia (4.4% vs 3.8%). 15.4% and 9.8%discontinued due to AEs. Conclusions: Durvalumab demonstrated significant and clinically meaningful improvement in PFS, which was supported by secondary endpoints, and was well tolerated. Durvalumab is a promising therapeutic option in this setting.}, -DOI = {10.1093/annonc/mdx670}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01452606/full} -} - - -Record #474 of 538 -@article{ChiCTR220006457222, -author = {ChiCTR2200064572,}, -title = {PD-1 inhibitors plus platinum-based chemotherapy with or without electroacupuncture in patients with previously untreated advanced NSCLC: a pilot study}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2200064572}, -year = {2022}, -accession_number = {ICTRP ChiCTR2200064572}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Group 1:PD‐1 inhibitors plus platinum‐based chemotherapy with electroacupuncture;Group 2:PD‐1 inhibitors plus platinum‐based chemotherapy; CONDITION: Lung cancer PRIMARY OUTCOME: Objective response rate (ORR); SECONDARY OUTCOME: Progression free survival (PFS);Disease control rate (DCR);Overall survival (OS);Generalized Anxiexy Disorde‐7 (GAD‐7);Patient health question‐9 (PHQ‐9);Adreno‐cortico‐tropic‐hormone (ACTH);Cortisol (CORT);lymphocyte subsets;Gut microbiome; INCLUSION CRITERIA: 1. Locally advanced or metastatic non‐small cell lung cancer diagnosed by tissue or cytopathology without bone metastasis; 2. Genetic testing shows that the driver genes (EGFR, ALK) are negative; 3. Have not received anti‐tumor therapy (chemotherapy, radiotherapy, targeted, immune and radiotherapy, etc.) in the past; 4. PS score (ECOG) <= 2 points; 5. Age 18‐75 years; 6. There is at least one measurable lesion; 7. Normal liver and kidney function. Normal renal function: serum creatinine <= 1.5 mg/dl (133 µmol/L) and or creatinine clearance >= 60 ml/min; normal liver function: total serum bilirubin level <= 1.5 times the upper limit of normal (ULN), serum aspartate Transaminase (AST) & alanine aminotransferase (ALT) 2.5 times ULN; 8. Sign the informed consent form, the patient voluntarily accepts the treatment of this program, and those with good compliance.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02552965/full} -} - - -Record #475 of 538 -@article{PER-042-1920, -author = {PER-042-19,}, -title = {A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1SELECTED NONSMALL CELL LUNG CANCER}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=PER-042-19}, -year = {2020}, -accession_number = {ICTRP PER‐042‐19}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Group name:hhhh Type of group;1 N° of participants:10 Intervention(s) description:hhhh CONDITION: ‐C349 Bronchus or lung, unspecified ; Bronchus or lung, unspecified Bronchus or lung, unspecified C349 PRIMARY OUTCOME: Outcome name:•OS (overall survival) after randomization, defined as the time from randomization to death from any cause.; Measure:•OS (overall survival); Timepoints:Throughout study. Outcome name:•PFS (progression‐free survival) after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1; Measure:•PFS (progression‐free survival); Timepoints:Throughout study. SECONDARY OUTCOME: Outcome name:•Confirmed ORR (objective response rate), defined as the proportion of patients with a complete response (CR) or partial response (PR) on two consecutive occasions 4 weeks apart, as determined by the investigator according to RECIST v1.1 ; Measure:• ORR (objective response rate) ; Timepoints:Throughout study. Outcome name:•DOR (duration of response) for patients with confirmed ORR, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to ; RECIST v1.1 ; ; Measure:• DOR (duration of response) ; Timepoints:Throughout study. Outcome name:•OS (overall survival) rate at 12 months and 24 months, defined as the proportion of patients who have not experienced death from any cause at 12 and 24 months, respectively ; Measure:•OS (overall survival) rate ; Timepoints:Throughout study. Outcome name:•PFS (progression‐free survival) rate at 6 months and 12 months, defined as the proportion of patients who have not experienced disease progression or death from any cause at 6 months and 12 months respectively, as determined by the investigator according to ; RECIST v1.1 ; ; Measure:•PFS (progression‐free survival) rate ; Timepoints:Throughout study. Outcome name:•Time to sustained deterioration (TTSD) in patient‐reported physical functioning and ; global health status, as measured by the European Organisation for Research and ; Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer (QLQ‐C30) ; ; Measure:•Time to sustained deterioration (TTSD), according to results reported by patient with questionnaires QLQ‐C30 y EORTC ; Timepoints:Throughout study. INCLUSION CRITERIA: •Signed Informed Consent Form •Age 18 years at time of signing Informed Consent Form •Ability to comply with the study protocol, in the investigator´s judgment •ECOG Performance Status of 0 or 1 •Histologically or cytologically documented locally advanced or recurrent NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy, or metastatic Stage IV NSCLC •No prior systemic treatment for metastatic NSCLC Patients who received prior neo‐adjuvant, adjuvant chemotherapy, and/or chemoradiotherapy with curative intent for non‐metastatic disease are eligible for the study if the therapy was completed at least 6 months prior to initiation of study treatment. •Tumor PD‐L1 expression with a TPS 50%, as determined by the PD‐L1 IHC 22C3 pharmDx assay and documented through central testing of a representa}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02173553/full} -} - - -Record #476 of 538 -@article{Viani21, -author = {Viani, GA, Gouveia, AG, and Moraes, FY}, -title = {Sequential or concomitant chemotherapy with hypofractionated radiotherapy for locally advanced non-small cell lung cancer: a meta-analysis of randomized trials}, -journal = {Journal of thoracic disease}, -volume = {13}, -number = {11}, -pages = {6272‐6282}, -year = {2021}, -accession_number = {PUBMED 34992807}, -publication type = {Journal article}, -abstract = {BACKGROUND: For patients with locally advanced non‐small cell lung cancer (NSCLC), the standard treatment is concurrent or sequential chemotherapy with radiotherapy. Most treatment schedules use radiotherapy with conventional fractionation; however, the application of hypofractionated radiotherapy (HYPO‐RT) regimens is rising. A meta‐analysis was performed to assess the efficacy and safety of chemotherapy combined with HYPO‐RT and indirectly compare with the outcomes from previous studies employing concomitant conventional radiotherapy (CONV‐RT). METHODS: Randomized controlled trials (RCTs) were identified on the electronic database sources through June 2020. Following the PRISMA guidelines, a meta‐analysis was performed to assess if there were significant differences in the overall mortality (OM), local failure (LF), and disease progression (DP), comparing HYPO‐RT‐C vs. sequential chemotherapy followed HYPO‐RT (HYPO‐RT‐S). To establish an indirect comparison with the current standard treatment, we calculate the risk ratio (RR) of the OM from RCTs using conventional chemoradiation, concurrent (CONV‐RT‐C), and sequential (CONV‐RT‐S), and compared with HYPO‐RT. A P value <0.05 was considered significant. RESULTS: Two RCTs with a total of 288 patients were included. The RR for the OM, DP and LF at 3 year comparing HYPO‐RT‐C vs. HYPO‐RT‐S were 1.09 (95% CI: 0.96‐1.28, P=0.17), 1.06 (95% CI: 0.82‐1.23, P=0.610), and 1.06 (95% CI: 0.86‐1.29, P=0.490), respectively. The late grade 3 pneumonitis and esophagitis had no significant difference between HYPO‐RT groups. In the indirect comparison of RCTs using CONV‐RT, the RR for the OM at 3 years was 1.03 (95% CI: 0.96‐1.10, P=0.36) with no significant difference for the HYPO‐RT arms 1.09 (95% CI: 0.96‐1.28, P=0.17). DISCUSSION: HYPO‐RT given with chemotherapy provides satisfactory OM, LF, and DP in locally advanced NSCLC with similar rates to the CONV‐RT. These findings support HYPO‐RT inclusion in future clinical trials as an experimental arm in addition to the incorporation of new strategies, such as immunotherapy.}, -DOI = {10.21037/jtd-21-573}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02638898/full} -} - - -Record #477 of 538 -@article{Wu22, -author = {Wu, L, Wu, Z, Xiao, Z, Ma, Z, Weng, J, Chen, Y, Cao, Y, Cao, P, Xiao, M, Zhang, H, Duan, H, Wang, Q, Li, J, Xu, Y, Pu, X, and Li, K}, -title = {EP08.02-158 Final Analyses of ALTER-L018: a Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S480}, -year = {2022}, -accession_number = {EMBASE 2020097509}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer combination chemotherapy; *non small cell lung cancer; Adult; Advanced cancer; Adverse drug reaction; Angiogenesis; Cancer patient; Cancer survival; Chemotherapy; China; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Demographics; Drug combination; Drug safety; Drug therapy; Female; Human; Leukopenia; Major clinical study; Male; Neutropenia; Overall response rate; Phase 2 clinical trial; Phase 3 clinical trial; Randomized controlled trial; Side effect; Survival; Wild type}, -abstract = {Introduction: Docetaxel is one of the standard 2nd‐line treatments for advanced non‐small cell lung cancer (NSCLC), but the effect is limited. The combination of docetaxel and ramucirumab/nintedanib has demonstrated antitumor activity as 2nd‐line therapy in advanced NSCLC. Anlotinib, an oral multi‐target angiogenesis, can prolong both PFS and OS of refractory advanced NSCLC patients in phase III trial (ALTER0303). We conducted ALTER‐L018 to evaluate improvement of the efficacy and safety of anlotinib plus docetaxel in EGFR‐negative advanced NSCLC. Methods: In this multi‐center, randomized, controlled comparative, phase II trial, patients from 10 sites in China, with EGFR wild‐type NSCLC progressing after 1st‐line platinum‐based therapy (combined with or without Immune checkpoint inhibitors), were randomly allocated (1:1) to receive anlotinib (12mg QD from day 1 to 14 of a 21‐day cycle) plus docetaxel (75mg/m2 Q3W) (group A+D) or docetaxel (75mg/m2 Q3W) only (group D). Primary end point was PFS, and secondary end points included OS, ORR, DCR and safety. [ Clinical Trials Registration: NCT03624309 ]. Results: Between Jan 14, 2019, and Jun 18, 2021, 96 patients (pts) were enrolled and 13 pts were excluded due to inclusion violations. At data cutoff (Feb 24, 2022), 83 pts. (demographics are shown in Table 1) were available for efficacy and safety analysis. The median PFS in group A+D was significantly improved compared with group D [4.36m (95%CI: 2.78‐5.94) vs 1.64m (95%CI: 1.48‐1.80); HR 0.38 (95%CI: 0.22‐0.65), p<0.001)]. The median OS was 11.97m (95%CI: 3.08‐20.86) in group A+D and 10.85m (95%CI: 5.44‐16.26) in group D [HR 0.82 (95%CI: 0.45‐1.47), p=0.501)]. For tumor response, ORR were 35.14% vs 9.52% (p=0.007) and DCR were 83.78% vs 54.76% (p=0.006) in group A+D and group D, respectively. We noted treatment‐related adverse events (TRAEs) of grade 3 or above occurred in in 12 (30.0%) of 40 pts in group A+D safety population and 8 (18.6%) of 43 pts in group D safety population. The most common grade 3 or worse TRAEs were Leucopenia (15.0% vs 7.0%), Neutropenia (10.0% vs 4.7%) in group A+D and group D, respectively. The toxicities in both groups were manageable with appropriate dose reductions and supportive care. Conclusions: The combination of anlotinib plus docetaxel improves survival as second‐line treatment of EGFR wild‐type NSCLC patients in terms of PFS, ORR, DCR, and has a manageable safety profile. It has been proved to be an effective regimen for EGFR wild‐type NSCLC patients progressing after first‐line platinum‐based chemotherapy combined with Immune checkpoint inhibitors. [Formula presented] Keywords: anlotinib, EGFR‐negative NSCLC, second‐line treatment}, -DOI = {10.1016/j.jtho.2022.07.841}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461455/full} -} - - -Record #478 of 538 -@article{Barlesi24, -author = {Barlesi, F, Felip, E, Popat, S, Solomon, BJ, Wolf, J, Li, BT, Wu, Y-L, Kerr, K, Akamatsu, H, Camidge, DR, Gupta, RG, Meloni, A, Dai, T, and Borghaei, H}, -title = {Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644909339}, -publication type = {Journal article; Conference proceeding}, -keywords = {*doublet chemotherapy; *first‐line treatment; *metastasis; *non small cell lung cancer; Adult; Antineoplastic activity; Brain metastasis; Cancer inhibition; Chemoradiotherapy; Clinical trial; Conference abstract; Controlled study; Drug combination; Drug therapy; Female; Histology; Human; Maintenance therapy; Major clinical study; Male; Multicenter study; Multiple cycle treatment; Overall survival; Progression free survival; Randomized controlled trial; Response evaluation criteria in solid tumors; Therapy}, -abstract = {Background: The 5‐year progression free survival (PFS) rate of patients with metastatic, PD‐L1 negative, non‐small cell lung cancer (NSCLC) remains poor, ranging from approximately2%to 10% with standard immunotherapy‐based treatment regimens. Based on promising antitumor activity in the phase 1 CodeBreaK 101 study, with partial responses observed in 62% (8/13) of PD‐L1 negative patients in the first‐line setting, we hypothesize that sotorasib plus platinum doublet chemotherapy will demonstrate durable clinical response and improved outcomes in this population. CodeBreaK 202 (NCT05920356) is a global phase 3 randomized study evaluating the efficacy of sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first‐line treatment for metastatic or locally advanced, PD‐L1 negative, KRAS G12C‐mutated NSCLC. Methods: Patients will be randomized 1:1 to either sotorasib 960 mg once daily or pembrolizumab administered in combination with carboplatin and pemetrexed for 4 cycles, followed by maintenance treatment with sotorasib or pembrolizumab administered in combination with pemetrexed. Key eligibility criteria include treatment‐ naïve metastatic or locally advanced stage IIIB/C disease that is not amenable to definitive chemoradiation, PD‐L1 ,1% expression, presence of KRAS G12C mutation, nonsquamous tumor histology, and absence of actionable genomic alterations such as EGFR mutations and ALK rearrangements. Patients with both treated and untreated brain metastases are eligible if clinically asymptomatic. The primary endpoint is PFS per RECIST v1.1 by blinded independent central review (BICR). Key secondary endpoints include overall survival and objective response rate. Exploratory endpoints include intra‐cranial PFS perRANO‐BMcriteria. Approximately 750 patients are planned to be enrolled and recruitment began on November 18, 2023. Contact Amgen Medical Information for more information: medinfo@amgen.com. Clinical trial information: NCT05920356.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02736197/full} -} - - -Record #479 of 538 -@article{Okamoto23, -author = {Okamoto, I, Kuyama, S, Girard, N, Lu, S, Franke, FA, Pan, E, Ren, N, Chen, A, Oputa, E, and Lisberg, AE}, -title = {1505TiP TROPION-Lung07: a phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression}, -journal = {Annals of oncology}, -volume = {34}, -pages = {S847‐S848}, -year = {2023}, -accession_number = {EMBASE 2027889135}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *area under the curve; *chemotherapy; *drug tolerability; *gene expression; *non small cell lung cancer; *protein expression; Adult; Advocacy group; Antineoplastic activity; Australia; Cancer cell; Cancer patient; Cancer staging; Cancer surgery; Cancer survival; Chemoradiotherapy; China; Clinical trial; Conference abstract; Consultation; Controlled study; Disease control; Drug combination; Drug industry; Drug safety; Drug therapy; ECOG Performance Status; Employee; Female; Human; Human cell; Japan; Leadership; Major clinical study; Male; Massachusetts; Medical literature; Overall response rate; Overall survival; Parttime employment; Pharmacokinetics; Phase 1 clinical trial; Phase 3 clinical trial; Practice guideline; Progression free survival; Radiotherapy; Randomized controlled trial; Reaction time; South Korea; Systemic therapy; Taiwan; Thailand; Thymus cancer; Travel; United States}, -abstract = {Background: Immunotherapy has improved survival in patients (pts) with adv/met NSCLC. However, outcomes remain poor in pts with PD‐L1 expression <50%, and more efficacious treatments are needed. Dato‐DXd is an antibody‐drug conjugate composed of a TROP2 directed monoclonal antibody covalently linked to a highly potent cytotoxic payload via a stable, tumor‐selective, tetrapeptide‐based cleavable linker. In the phase 1b TROPION‐Lung02 trial, Dato‐DXd + pembro ± Pt‐CT had tolerable safety and promising antitumor activity in pts with adv/met NSCLC, notably as 1L therapy and irrespective of PD‐L1 levels. Here, we describe the TROPION‐Lung07 trial of Dato‐DXd + pembro ± Pt‐CT in pts with adv/met NSCLC without actionable genomic alterations (AGA) and PD‐L1 expression <50%. Trial design: TROPION‐Lung07 (NCT05555732) is a global, randomized, open‐label, phase 3 trial of 1L Dato‐DXd + pembro ± Pt‐CT in pts with nonsquamous adv/met NSCLC without AGA with PD‐L1 expression <50%. Dato‐DXd + pembro ± Pt‐CT will be compared with pemetrexed + pembro + Pt‐CT. Approximately 975 pts will be randomized 1:1:1 to Dato‐DXd 6 mg/kg + pembro 200 mg (max, 35 cycles) ± Pt‐CT (cisplatin 75 mg/m2 or carboplatin area under the curve 5; max, 4 cycles) every 3 weeks (Q3W) or pemetrexed 500 mg/m2 + pembro 200 mg + Pt‐CT Q3W. Pts will be stratified by PD‐L1 levels, Eastern Cooperative Oncology Group performance status, geographic region, and investigator choice of Pt‐CT. Pts must have stage IIIB/C NSCLC ineligible for resection or definitive chemoradiation or stage IV disease and must not have received prior systemic therapy for adv/met NSCLC. The primary endpoints are progression‐free survival by blinded independent central review and overall survival. Secondary endpoints include objective response rate (ORR), duration of response, time to response, disease control rate, and safety. Pt‐reported outcomes, pharmacokinetics, and biomarkers will be explored. Enrollment is currently ongoing in the United States, Australia, China, Japan, Republic of Korea, Taiwan, and Thailand. Clinical trial identification: NCT05555732. Editorial acknowledgement: Medical writing support was provided by Martin Haschak, PhD, of SciMentum, Inc, a Nucleus Holdings Ltd company, and was funded by Daiichi Sankyo, Inc. Editorial support was provided in accordance with good publication practice guidelines (ismpp.org/gpp‐2022). Legal entity responsible for the study: Daiichi Sankyo, Inc. Funding: Daiichi Sankyo, Inc. Disclosure: I. Okamoto: Financial Interests, Personal, Speaker, Consultant, Advisor: Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd, AstraZeneca, Eli Lilly Japan K.K., Takeda Pharmaceutical Company Limited, Novartis Pharma K.K.; Financial Interests, Institutional, Research Funding: Daiichi Sankyo, Chugai Pharma, Lilly, Bristol Myers Squibb, MSD Oncology, AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical. S. Kuyama: Financial Interests, Other, Honoraria: AstraZeneca K.K., Bristol Myers Squibb Company, Hisamitsu Pharmaceutical Co.,Inc., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited., Kyowa Kirin Co., Ltd. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Non‐Financial Interests, Officer, International Thymic malignancy interest group, president: ITMIG; Other, Family member is an employee: AstraZeneca. S. Lu: Financial Interests, Other, Grants or contracts: AstraZeneca, Hutchison, BMS, Heng Rui, BeiGene, Roche, Hansoh; Financial Interests, Other, Consulting fees: AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison, MediPharma, Simcere, ZaiLab, GenomiCare, Yuhan Corporation, PrIME Oncology, Menarini, InventisBio Co. Ltd., Roche; Financial Interests, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AstraZeneca, Roche, Hansoh, Hengrui Therapeutics; Financial Interests, Other, Participation on a Data Safety Monitoring Board or Advisory Board: Roche, Regenron, AstraZeneca, Simcere Zaiming Pharmaceutical Co., Ltd; Financial Interests, Other, Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Chinese Lung Cancer Associate, CSCO. F.A. Franke: Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis, BMS, MSD, Daiichi Sankyo; Financial Interests, Institutional, Principal Investigator: Daiichi Sankyo, Lilly, Bristol Myers Squibb, MSD Oncology, AstraZeneca, Takeda, Roche, Amgen, Pfizer, Novartis, Gilead, Merck. N. Ren: Financial Interests, Personal, Full or part‐time Employment: Daiichi Sankyo; Financial Interests, Personal, Stocks or ownership: Daiichi Sankyo; Financial Interests, Personal, Other, Travel, accommodations, expenses: Daiichi Sankyo. E. Oputa: Financial Interests, Personal, Full or part‐time Employment: Daiichi Sankyo; Financial Interests, Personal, Stocks or ownership: PPD, Syneos Health. A.E. Lisberg: Financial Interests, Personal, Full or part‐time Employment, Immediate Family Member: Boston Scientific; Financial Interests, Personal, Stocks or ownership, Immediate Family Member: Boston Scientific; Financial Interests, Personal, Other, Consulting or advisory role: AstraZeneca, Bristol Myers Squibb, Leica Biosystems, Jazz Pharmaceuticals, Novocure, Pfizer, MorphoSys, Eli Lilly, Oncocyte, Novartis, Regeneron, Janssen Oncology, Sanofi group of companies; Financial Interests, Institutional, Research Funding: Daiichi Sankyo, Calithera Biosciences, AstraZeneca, Dracen Pharmaceuticals, WindMIL, eFFECTOR Therapeutics. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2023.09.2536}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02613720/full} -} - - -Record #480 of 538 -@article{Negrao24, -author = {Negrao, MV, Arbour, KC, Burns, TF, Cappuzzo, F, Dingemans, A-MC, Girard, N, Gronberg, BH, Hochmair, M, Leal, T, Lindsay, CR, Lu, S, Nishio, M, Paz-Ares, LG, Reck, M, Sabari, JK, Spira, AI, William, WN, Chen, A, Grul, CMV, and Peters, S}, -title = {SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12Cmutant advanced NSCLC}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644907637}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Brain metastasis; Conference abstract; Controlled study; Drug therapy; Female; Human; Interstitial lung disease; Major clinical study; Malabsorption; Male; Neoplastic cell transformation; Patient‐reported outcome; Phase 3 clinical trial; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Side effect; Surgery; Systemic therapy; Vascular guide wire}, -abstract = {Background: Mutations in KRAS are among the most frequent oncogenic drivers with the G12C variant found in ∼13% of NSCLC. Outcomes for KRAS G12C‐mutant NSCLC may be improved by combining KRAS G12C inhibitors with current 1L standard of care (SOC). Olomorasib is a potent and highly selective second‐generation inhibitor of KRAS G12C, which delivers.90%sustained target occupancy in preclinical models. In the LOXO‐RAS‐20001 phase 1/2 study, olomorasib in combination with pembrolizumab demonstrated preliminary efficacy and a favorable safety profile.1 Methods: SUNRAY‐01 (NCT06119581) is a pivotal, global, phase 3 study in 1L advanced KRAS G12C‐mutated NSCLC designed to seamlessly 1) optimize the dosing of olomorasib in combination with 1L SOC, and then 2) compare efficacy and safety of olomorasib plus SOC with placebo plus SOC. In the open‐label randomized dose optimization (pembrolizumab plus olomorasib 50 mg vs 100 mg BID) and single arm safety lead‐in (olomorasib plus pembrolizumab, pemetrexed, platinum), the optimal dose of olomorasib for combination therapy will be determined before the phase 3 study (parts A and B) is opened for enrollment. In part A, 384 participants with PD‐L1 expression ≥50% are randomized (1:1) to pembrolizumab plus olomorasib or placebo. In part B, 552 participants are randomized (1:1) to pembrolizumab, pemetrexed, platinum plus olomorasib or placebo regardless of PD‐L1 expression. Allocation of participants with PD‐L1 expression≥50% to either part A or part B will be at the discretion of the investigator. The primary objective is to compare efficacy based on PFS per RECIST v1.1 by blinded independent central review. Secondary endpoints include OS, ORR, DOR, DCR, TTR, PFS2, safety and tolerability, and patient‐reported outcomes. Eligible participants (≥18 years) must have a KRAS G12C mutation in tumor or blood and known PD‐L1 expression (0‐100%), stage IIIB, IIIC, or IV NSCLC not suitable for curative intent radical surgery or radiation therapy, measurable disease per RECIST v1.1, and an ECOG PS 0‐1. Participants can be enrolled based on local KRAS and PD‐L1 testing results. Participants should not have received prior systemic therapy for advanced or metastatic NSCLC, however 1 cycle of SOC treatment prior to enrollment is allowed if immediate treatment is clinically indicated. Participants with asymptomatic (lesions≤1.5 cm) or previously treated radiographically stable brain metastases are eligible. Key exclusion criteria include history of pneumonitis/interstitial lung disease and clinically significant active cardiovascular disease or malabsorption syndrome. The study opened for enrollment in December 2023. 1Murciano‐Goroff et al. 2023 Cancer Res 83 (8 Suppl): CT028.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02736087/full} -} - - -Record #481 of 538 -@article{PER-009-1818, -author = {PER-009-18,}, -title = {A PHASE III, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTI-CENTER, INTERNATIONAL STUDY OF DURVALUMAB GIVEN CONCURRENTLY WITH PLATINUM-BASED CHEMORADIATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE NON-SMALL CELL LUNG CANCER (STAGE III)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=PER-009-18}, -year = {2018}, -accession_number = {ICTRP PER‐009‐18}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: All patients will receive 1 of the following platinum‐based SoC chemotherapy options, based on Investigator discretion, in addition to radiation therapy: cisplatin/etoposide, carboplatin/paclitaxel, pemetrexed/cisplatin, or pemetrexed/carboplatin. Chemotherapy treatment regimens are outlined in Table 5. Patients will also receive durvalumab 1500 mg or placebo every 4 weeks via intravenous infusion concurrent with SoC CRT (ie, starting on Cycle 1 Day 1 [±3 days]). Patients with complete response (CR), partial response (PR), or SD following completion of SoC CRT will continue to receive durvalumab/placebo as consolidation treatment. Patients with RECIST 1.1 defined radiological progressive disease at the 16 week tumor evaluation following completion of SoC CRT will proceed to follow‐up. CONDITION: ‐C34 Malignant neoplasm of bronchus and lung ; Malignant neoplasm of bronchus and lung Malignant neoplasm of bronchus and lung SECONDARY OUTCOME: OS is defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive. ; Note: Survival calls will be made in the week following the date of DCO for the analysis. (These contacts should generally occur within 7 days of the DCO.) If patients are confirmed to be alive or if the death date is after the DCO date, these patients will be censored at the date of DCO. Death dates may be found by checking publicly available death registries. ; ; NAME OF THE RESULT: Rate of complete response ; USED MEASURING METHOD :The rate of CR (per RECIST 1.1 as assessed by BICR) is defined as the number (%) of patients with at least 1 visit response of CR. Data obtained up until progression, or the last evaluable assessment in the absence of progression, will be included in the assessment of rate of CR. Patients who go off treatment without progression, receive a subsequent therapy, and then respond will not be included as responders in the rate of CR. ; PERIOD OF TIME WHERE THE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE SECONDARY RESULT: DoR (per RECIST 1.1 as assessed by BICR) will be defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring – date of first response+1). The end of response should coincide with the date of progression or death from any cause used for the RECIST 1.1 PFS endpoint. ; The time of the initial response will be defined as the latest of the dates contributing toward the first visit response of CR or PR. If a patient does not progress following a response, then his or her DoR will be censored at the PFS censoring time. DoR will not be defined for those patients who do not have documented response. ; INCLUSION CRITERIA: 1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. 2. Provision of signed and dated, written ICF prior to any mandatory study‐specific procedures, sampling, and analyses. 3. 18 years or older at the time of signing the ICF. In Japan, patients must be 20 years or older at the time of signing the ICF. PRIMARY OUTCOME: Analyses will be performed by AstraZeneca or its representatives. A comprehensive SAP will be developed and finalized before database lock and will describe the patient populations to be included in the analyses and procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary and secondary endpoints. Any deviations from this plan will be reported in the CSR.; Descriptive statistics will be used for all variables, as appropriate, and will be presented by treatment arm. Continuous variables will be summarized by the number of observations, mean, standard deviation, median, minimum, and maximum. Categorical variables will be summarized by frequency counts and percentages for each category. Unless otherwise stated, percentages will be calculated out of the population total for the corresponding treatment arm.; ; NAME OF THE RESULT: Progression‐free survival; USED MEASURING METHOD :PFS (per RECIST 1.1 as assessed by the BICR) will be defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to progression (ie, date of event or censoring – date of randomization + 1). Patients who have not progressed or died at the time of analysis will be censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment. However, if the patient progresses or dies after 2 or more missed visits, the patient will be censored at the time of the latest evaluable RECIST 1.1 assessment prior to the 2 missed visits. If the patient has no evaluable visits or does not have baseline data, he or she will be censored at Day 1 unless he or she dies within 2 visits of baseline, then they will be treated as an event with date of death as the event date.; PERIOD OF TIME WHERE THE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: The PFS time will always be derived based on scan/assessment dates and not visit dates.; RECIST 1.1 assessments/scans contributing toward a particular visit may be performed on different dates. The following rules will be applied:; • For BICR assessments, the date of progression will be determined based on the earliest scan dates of the component that triggered the progression for the adjudicated reviewer selecting PD or of the reviewer who read baseline first if there is no adjudication.; • For Investigator assessments, the date of progression will be determined based on the earliest of the RECIST 1.1 assessment/scan dates of the component that indicates progression.; • When censoring a patient for PFS, the patient will be censored at the latest of the scan dates contributing to a particular overall visit assessment.; Note: For TLs, only the latest scan date within an imaging visit window is recorded in the RECIST 1.1 eCRF out of all scans performed at that assessment for the TLs, and similarly for NTLs, only the latest scan date is recorded out of all scans performed at that assessment for the NTLs.; A sensitivity analysis of PFS will be performed using Investigator assessments according to RECIST 1.1.; 4. Histologically or cytologically documented NSCLC who present with locally advanced, unresectable (Stage III) disease (according to Version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology [IASLC Staging Manual in Thoracic Oncology 2016]).  Except for overt cT4 disease, nodal status N2 or N3 should be proven by biopsy, via endobronchial ultrasound, mediastinoscopy, or thoracoscopy. Absent biopsy, nodal status should be confirmed with whole body 18F‐fluoro‐deoxyglucose pos}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01908778/full} -} - - -Record #482 of 538 -@article{Quoix14, -author = {Quoix, E, Losonczy, G, Forget, F, Chouaid, C, Papai, Z, Gervais, R, Ottensmeier, C, Szczesna, A, Kazarnowicz, A, Beck, JT, Westeel, V, Vanderheyde, K, Lacoste, G, Bastien, B, Halluard, C, Marchand, S, Limacher, JM, and Lena, H}, -title = {Time, a phase 2B/3 study evaluating TG4010 in combination with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase 2B results}, -journal = {International journal of radiation oncology biology physics}, -volume = {90}, -number = {5}, -pages = {S35}, -year = {2014}, -accession_number = {EMBASE 71817249}, -publication type = {Journal article; Conference proceeding}, -keywords = {*United States; *non small cell lung cancer; *oncology; *therapy; Arm; Chemotherapy; Fever; Hazard ratio; Histology; Human; Immunohistochemistry; Immunotherapy; Injection site reaction; Lymphocyte; Neoplasm; Overall survival; Patient; Poxviridae; Predictive value; Prescription; Procedures; Progression free survival; Randomization; Safety; Stratification; Survival}, -abstract = {Purpose/Objective(s): TG4010 immunotherapy product is a poxvirus (MVA) coding for MUC1 tumor‐associated antigen and interleukin‐2. A previous study showed that a normal baseline level of Triple Positive Activated Lymphocytes (TrPAL, CD16+CD56+CD69+) might be a predictive biomarker for TG4010 efficacy in NSCLC. TIME is a double‐blind phase 2b/3 study (NCT01383148) comparing the combination of first line therapy with TG4010 or placebo. The phase 2b part aims at prospectively validating the baseline TrPAL level as a predictive biomarker. Materials/Methods: Primary endpoint of the phase 2b part of the study was to compare progression‐free survival (PFS, according to RECIST 1.1) between TG4010 and placebo arms using a Bayesian design, in stage IV NSCLC patients with a MUC1 expressing tumor by immunohistochemistry. Secondary objectives were response rate, safety, survival and subgroup analyses according to stratification factors and level of TrPAL at baseline. A dynamic minimization procedure was applied at randomization for histology, prescription of bevacizumab, type of chemotherapy, performance status, and center. Results: Two hundred seventeen patients have been enrolled out of which 170 patients with a normal TrPAL level (predetermined threshold) and an analysis of PFS was conducted in this cohort after 137 events of progression were recorded. The hazard ratio (HR) for PFS is 0.76 (95%CI: 0.54‐1.06). This corresponds to a 97.5% Bayesian probability that the true HR is <1, passing the threshold of 95% needed to consider the endpoint met in patients with normal TrPAL. TG4010 related adverse events were limited to mild or moderate fever and injection site reaction. Analysis in the 75% of patients with the lowest baseline level of TrPAL (3 lowest quartiles, n=152) shows a HR for PFS of 0.72 (95%CI: 0.50‐1.03) consistent with the observation made in the previous study. Additional preplanned analyses by subgroup show that patients with nonsquamous tumors had a statistically significant improvement in PFS when treated with TG4010 (n=145, HR=0.67; CI: 0.46‐0.97; P=.016) and especially when belonging to the 3 lowest quartiles (n=131, HR=0.63; 95% CI: 0.42‐ 0.93, P=.009). Overall survival data of the phase 2b part will be presented at the time of the meeting. Conclusions: These data support the predictive value of the TrPAL biomarker. They also confirm TG4010 efficacy and safety profile in stage IV NSCLC patients and warrant the continuation of the TIME study phase 3 part with overall survival as a primary endpoint.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01088078/full} -} - - -Record #483 of 538 -@article{PER-082-1213, -author = {PER-082-12,}, -title = {AN OPEN-LABEL RANDOMIZED PHASE III TRIAL OF BMS-936558 VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC SQUAMOUS CELL NON-SMALL CELL LUNG CANCER (NSCLC)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=PER-082-12}, -year = {2013}, -accession_number = {ICTRP PER‐082‐12}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: SUBJECTS WILL UNDERGO SCREENING EVALUATIONS TO DETERMINE ELIGIBILITY WITHIN 28 DAYS PRIOR TO RANDOMIZATION. SUBJECTS WILL BE ASSIGNED TO ONE OF TWO TREATMENT ARMS IN A 1:1 RATIO (SEE STUDY DESIGN AND DURATION IN FIGURE 3.1 BELOW). RANDOMIZATION WILL BE STRATIFIED ACCORDING TO THE FOLLOWING FACTORS: PRIOR TREATMENT WITH PACLITAXEL‐BASED DOUBLET VS. OTHER DOUBLET, AND REGION (US VS. EUROPE VS. REST OF WORLD). TREATMENT SHOULD BE INITIATED WITHIN 3 DAYS OF RANDOMIZATION. BMS‐936558 OR DOCETAXEL (DEPENDING ON RANDOMIZED TREATMENT ARM) WILL BE ADMINISTERED AS AN IV INFUSION OVER 60 MINUTES ON TREATMENT DAY 1. A TREATMENT CYCLE IS DEFINED AS 2 WEEKS FOR BMS‐936558 AND 3 WEEKS FOR DOCETAXEL. THIS STUDY WILL CONSIST OF 3 PHASES: SCREENING, TREATMENT, AND FOLLOW‐UP. THIS STUDY END WHEN COMPLETE ANALYSIS OF SURVIVAL. BE THE DURATION OF THE STUDY OF APPROXIMATELY 2 ARIOS (24 MONTHS). WITH THE COMPLETION OF THE STUDY, PATIENTS WILL CONTINUE SHOWING CLINICAL BENEFIT ELIGIBLE TO RECEIVE THE STUDY DRUG. THE STUDY DRUG BE PROVIDED THROUGH EXTENSION STUDY, STUDY APPROVAL REQUIRED ROLLOVER OF HEALTH AUTHORITY RESPONSIBLE AND ETHICS COMMITTEE OR THROUGH ANOTHER SPONSOR´S DISCRETION MECHANISM. CONDITION: PRIMARY OUTCOME: Objective Response Rate.; NAME OF THE RESULT: Objective Response Rate.; USED MEASURING METHOD :Defined as the number of subjects with a Best objective Response of Complete response or Partial Response divided by the number of randomized subjects.; PERIOD OF TIME WHERE THE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: 24 months. SECONDARY OUTCOME: The progression‐free survival (PFS) of BMS‐936558 versus docetaxel. ; NAME OF THE RESULT: The progression‐free survival of BMS‐936558 versus docetaxel. ; USED MEASURING METHOD :Defined as the time from randomization to the date of the first documented tumor progression as determined by the IRC (per RECIST 1.1), or death due to any cause. ; PERIOD OF TIME WHERE THE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE SECONDARY RESULT: 24 months. INCLUSION CRITERIA: 1) SIGNED WRITTEN INFORMED CONSENT 1. SUBJECTS MUST HAVE SIGNED AND DATED AN IRB/IEC APPROVED WRITTEN INFORMED CONSENT FORM IN ACCORDANCE WITH REGULATORY AND INSTITUTIONAL GUIDELINES. THIS MUST BE OBTAINED BEFORE THE PERFORMANCE OF ANY PROTOCOL RELATED PROCEDURES THAT ARE NOT PART OF NORMAL SUBJECT CARE. 2. SUBJECTS MUST BE WILLING AND ABLE TO COMPLY WITH SCHEDULED VISITS, TREATMENT SCHEDULE, LABORATORY TESTS INCLUDING COMPLETION OF PATIENT REPORTED OUTCOMES QUESTIONNAIRES AND OTHER REQUIREMENTS OF THE STUDY. 2) TARGET POPULATION 1. MEN AND WOMEN 18 YEARS OF AGE 2. SUBJECTS WITH HISTOLOGICALLY‐ OR CYTOLOGICALLY‐DOCUMENTED SQUAMOUS CELL NSCLC WHO PRESENT WITH STAGE IIIB/ STAGE IV DISEASE (ACCORDING TO VERSION 7 OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER STAGING MANUAL IN THORACIC ONCOLOGY), OR RECURRENT DISEASE FOLLOWING RADIATION THERAPY OR SURGICAL RESECTION. 3. SUBJECTS MUST HAVE EXPERIENCED DISEASE RECURRENCE OR PROGRESS}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01836025/full} -} - - -Record #484 of 538 -@article{PER-071-1516, -author = {PER-071-15,}, -title = {A PHASE III RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF MEDI4736 IN COMBINATION WITH TREMELIMUMAB THERAPY VERSUS STANDARD OF CARE PLATINUM-BASED CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) (NEPTUNE)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=PER-071-15}, -year = {2016}, -accession_number = {ICTRP PER‐071‐15}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Target patient population Adult patients (age ≥18 years) with advanced or metastatic (Stage IV) histologically or cytologically documented EGFR and ALK wild‐type NSCLC who are treatment naive. Duration of treatment Until specific treatment discontinuation criteria are met, treatment will continue for a 12‐month period for the MEDI4736 + tremelimumab combination therapy group and with no maximum treatment duration for the SoC group. After completing 12 months of treatment, if patients in the MEDI4736 + tremelimumab combination therapy group develop progressive disease (PD), they may restart their assigned investigational product (IP) with the same treatment guidelines followed previously. Investigational product, dosage, and mode of administration MEDI4736 + tremelimumab combination therapy •MEDI4736 20 mg/kg via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 doses/cycles, and then continue MEDI4736 20 mg/kg via IV infusion q4w, starting on Week 16, for up to a total of 8 months (9 doses) •Tremelimumab 1 mg/kg via IV infusion q4w, starting on Week 0, for up to 4 doses/cycles Standard of Care therapy Patients randomized to SoC therapy will receive 1 of the following: •Paclitaxel + carboplatin •Gemcitabine + cisplatin (squamous patients only) •Gemcitabine + carboplatin (squamous patients only) •Pemetrexed + cisplatin (non‐squamous patients only) • Pemetrexed + carboplatin (non‐squamous patients only) CONDITION: ‐C34 Malignant neoplasm of bronchus and lung ; Malignant neoplasm of bronchus and lung Malignant neoplasm of bronchus and lung SECONDARY OUTCOME: To assess the efficacy of MEDI4736+tremelimumab combination therapy compared to SoC in terms of OS in patients with PD‐L1–negative NSCLC ; To further assess the efficacy of MEDI4736+tremelimumab combination therapy compared to SoC in terms of PFS, ORR, DoR, OS12, OS18, APF12, and PFS2 ; To assess the PK of MEDI4736+tremelimumab combination therapy ; To investigate the immunogenicity of ; MEDI4736 and tremelimumab ; ; NAME OF THE RESULT: Overal Suvirval in patients with PD‐L1–negative NSCLC ; USED MEASURING METHOD :The full analysis set (FAS) will include all randomized patients. The full analysis set will be used for all efficacy analyses. Treatment groups will be compared on the basis of randomized IP, regardless of the treatment actually received. Patients who were randomized but did not subsequently go on to receive IP are included in the analysis in the treatment group to which they were randomized. ; INCLUSION CRITERIA: 1. Age ≥18 years at the time of screening 2. Written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act in the US, European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol‐related procedures, including screening evaluations. (For patients aged <20 years and enrolling in Japan, a written informed consent should be obtained from the patient and his or her legally acceptable representative.) Staging Manual in Thoracic Oncology). 4. Patients must have tumors that lack activating EGFR mutation (eg, exon 19 deletion or exon 21 L858R, exon 21 L861, exon 18 G719, or exon 20 S7681 PRIMARY OUTCOME: This study will analyze the primary endpoint of OS. In addition, the analyses of the secondary endpoints of PFS, ORR, DoR, and APF12 will be based on Investigator tumor assessments according to RECIST 1.1. PFS2 will be defined by local clinical practice, and survival rate (OS12 and OS18) will also be analyzed. ; Primary endpoint ‐ overall survival OS is defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive. ; Note: Survival calls will be made following the date of data cut‐off for the analysis (these contacts should generally occur within 7 days of the data cut off). If patients are confirmed to; be alive or if the death date is post the data cut‐off date, hese patients will be censored at the date of data cut‐off. Death dates may be found by checking publicly available death registries.; The Kaplan‐Meier estimates of OS12 and OS18 (survival rate, that is, proportion of patients alive at 12 months and 18 months) will also be derived as secondary endpoints.; ; NAME OF THE RESULT: All outputs will be summarized by treatment arm for all randomized patients and where required, for all randomized patients within the PD‐L1‐negative subgroup.; Results of all statistical analysis will be presented using a 95% confidence interval (CI) and 2‐sided p‐value, unless otherwise stated.; USED MEASURING METHOD :The formal statistical analysis will be performed to test the main hypotheses:;  H0: No difference between MEDI4736 + tremelimumab combination therapy and; SoC;  H1: Difference between MEDI4736 + tremelimumab combination therapy and SoC; The primary endpoint is OS in all patients regardless of PD‐LI status. The study has been; sized to characterize the OS benefit of MEDI4736 + tremelimumab combination therapy; versus SoC. The analysis will be performed when:;  (approximately) 596 OS events have occurred across the MEDI4736 +; tremelimumab combination therapy and SoC treatment groups (75% maturity); AND;  (approximately) 380 OS events have occurred across the MEDI4736 +; tremelimumab combination therapy and SoC treatment groups in patients with; PD‐L1‐negative tumors (73% maturity); Descriptive statistics will be used for all variables, as appropriate, and will be presented by; treatment group. Continuous variables will be summarized by the number of observations,; mean, standard deviation, median, minimum, and maximum. Categorical variables will be; summarized by frequency counts and percentages for each category. Unless otherwise stated,; percentages will be calculated out of the population total for the corresponding treatment arm.; PERIOD OF TIME WHERE THE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: In order to analyze the DoR between MEDI4736 + tremelimumab combination therapy and; SoC, the expected DoR (EDoR) will be derived for each treatment arm (Ellis et al 2008) using; the Investigator tumor data. The EDoR is the product of the proportion of patients responding; to treatment and the mean DoR in responding patients and provides an estimate based on all; randomized patients. Treatments will be compared by calculating the ratio of EDoRs, using; an appropriate probability distribution (to be specified in the SAP) for DoR in responding; patients. Additionally, descriptive data will be provided for the DoR in responding patients,; including the associated Kaplan‐Meier curves (without any formal comparison of treatment; arms or p‐value attached). This analysis will be performed in the ITT population; ; PERIOD OF TIME WHERE THE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE SECONDARY RESULT: PFS2 will be defined as the time from the date of randomization to the earliest of the progression event subsequent to that used for the PFS endpoint or death. The date of second progression will be recorded by the Investigator in the eCRF and defined according to local standard clinical practice and may involve any of the following: objective radiological imaging, symptomatic progression, or death. Second progression status will be reviewed (q6w for the first 48 weeks relative to the date of randomization and then q8w thereafter) following the progression event used for the primary variable PFS (the first progression) and status recorded. Patients alive and for whom a second disease progression has not been observed should be censored at the last time known to be alive and without a second disease progression, that is, censored at the latest of the PFS or PFS2 assessment date if the patient has not had a second progression or death. 3. Histologically or cytologically documented Stage IV NSCLC not amendable to curative surgery or radiation (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology; IASLC}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01858761/full} -} - - -Record #485 of 538 -@article{Hu18, -author = {Hu, C, Machtay, M, Dignam, JJ, Paulus, R, and Bradley, JD}, -title = {Progression-free survival (PFS) and cardiac-toxicity-adjusted-PFS (CTA-PFS) as predictors of overall survival (OS) in locally advanced non-small cell lung cancers (LA-NSCLC) treated with concurrent chemoradiation (CCRT): a secondary analysis of NRG Oncology RTOG 0617}, -journal = {Journal of clinical oncology}, -volume = {36}, -number = {15}, -year = {2018}, -accession_number = {EMBASE 625971855}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer survival; *cardiotoxicity; *chemoradiotherapy; *non small cell lung cancer; *oncology; *overall survival; *progression free survival; *secondary analysis; Adult; Conference abstract; Controlled study; Death; Drug megadose; Female; Human; Immunotherapy; Major clinical study; Male; Median survival time; Radiotherapy; Randomized controlled trial; Validation process}, -abstract = {Background: OS is the gold standard for LA‐NSCLC with CCRT, with complex relationships among RT dosimetry, systemic therapies, cardiopulmonary toxicity, progression (PD) and OS of growing scientific and clinical interest. Methods: RTOG 0617 (NCT00533949) randomized standard (SD, 60 Gy) versus high‐dose (HD, 74 Gy) CCRT +/‐ cetuximab from 11/07‐06/11. This analysis includes 469 patients (pts) given ≥50 Gy. A PFS event was defined as the first occurrence of local, regional, distant PD or death w/o documented PD. A CTA‐PFS event was the first occurrence of grade 2+ treatment‐related cardiac toxicity event or a PFS event. Landmark analyses at 6mo and 12mo were used to minimize the immortal time bias. Cox model with PD or CT/PD as a time‐dependent covariate was used to evaluate their predictive roles. Median f/u time for surviving pts was 5.1 years. Results: As reported, pts treated with HD had significantly lower OS rates (HR = 1.28, 95%CI: 1.04‐1.58, p = 0.018) and CTA‐PFS rates (HR = 1.24, 95%CI: 1.02‐1.51, p = 0.035), and marginally lower PFS rates (HR = 1.21, 95%CI: 0.99‐1.47, p = 0.06) than pts treated with SD. Median survival time (MST) among pts having PD within 6mo versus not were 13.4mo (95%CI: 10.0‐19.0) and 30.7mo (95%CI: 28.0‐37.0) (p < 0.001). MST for pts having PD within 12mo versus not were 20.6mo (95%CI: 18.8‐25.0) and 60mo (95%CI: 47.6‐74.5)(p < 0.001). Results are similar when using CTA‐PFS with 6mo or 12mo cutoff (p < 0.001). RT dose was no longer significantly associated with OS (p = 0.08 or p = 0.15) when PD or CT/PD was included in multivariable analysis (p < 0.001), suggesting OS differences in HD/SD may be partially captured by PFS or CTA‐PFS. Conclusions: RTOG 0617 survival results suggest that PFS (or CTA‐PFS) status at 6mo or 12mo predicts long‐term OS, and may potentially be considered as a surrogate endpoint of OS in clinical trials. Pts who were progression‐free at 12mo had a MST of 5 years. Further validation on external datasets and in the modern era of immunotherapy are needed.}, -DOI = {10.1200/JCO.2018.36.15-suppl.8539}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01790597/full} -} - - -Record #486 of 538 -@article{Wakelee17, -author = {Wakelee, H}, -title = {Perspectives of targeted therapies and immunotherapy in completely resected NSCLC}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {1}, -pages = {S45‐S46}, -year = {2017}, -accession_number = {EMBASE 615339266}, -publication type = {Journal article; Conference proceeding}, -keywords = {*adjuvant chemotherapy; *immunotherapy; *molecularly targeted therapy; *non small cell lung cancer; Cancer epidemiology; China; Controlled clinical trial; Controlled study; Disease free survival; Driver; Drug combination; Drug therapy; Gene activation; Gene expression; Gene mutation; Human; Human tissue; Immunohistochemistry; Japan; Meta analysis; Overall survival; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Secondary analysis; Treatment duration; Treatment failure; United States; Validation study}, -abstract = {The use of four cycles of cisplatin‐based adjuvant chemotherapy is now the standard of care for patients with resected stage II and IIIA NSCLC and is commonly used for patients with larger (at least 4 cm in size) stage IB tumors. The survival benefit with adjuvant chemotherapy though is limited with meta‐analyses revealing a 4‐5% absolute survival benefit at 5 years for patients receiving adjuvant cisplatin‐based chemotherapy.1,2 Some recent attempts to improve outcomes with the addition of other agents to cisplatin doublets (or as longer term therapy) have been disappointing. The addition of bevacizumab to chemotherapy in the ECOGACRIN E1505 adjuvant trial failed to show a benefit in disease free survival (DFS) or overall survival (OS).3 The use of the MAGE‐A3 vaccine in the MAGRIT trial was similarly negative.4 With knowledge about molecular drivers of NSCLC and targeted treatment options in advanced disease, multiple studies are either completed or underway to study molecularly targeted agents in earlier stages of lung cancer, particularly with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). In metastatic NSCLC the EGFR TKIs produce superior response and progression free survival (PFS) compared with platinum doublet chemotherapy in treatment naïve patients with tumors with activating EGFR mutations (EGFRmut).5,6 Similar outcomes with significant response and PFS improvements with the anaplastic lymphoma kinase (ALK) inhibitor crizotinib compared to chemotherapy have been reported in patients with tumors harboring translocations of ALK Encouraging data from retrospective and non‐randomized trials looking at adjuvant EGFR TKI use led to randomized trials. Earlier trials that did not select based on EGFRmut status were negative, but more recent trials have been more encouraging. The phase III RADIANT trial selected patients with resected early stage NSCLC for EGFR expression by IHC/FISH, but not by EGFR mutation status, and randomized them to adjuvant erlotinib or placebo.8 The primary end point was DFS in the full data set, with secondary analyses focused on patients with tumors harboring del19 or L858R EGFR mutations. No differences were found in DFS or OS based on treatment arm for the nearly 1000 patients who were enrolled. In the EGFRmut subset (N=161) DFS did favor erlotinib (HR 0.61, 95% CI = 0.384‐0.981, p = 0.0391), but this was not considered statistically significant, as the primary endpoint of the trial was negative. The overall survival results, while still immature, were not in favor of the erlotinib arm, even in the EGFRmut subset. The conclusion from this study is that adjuvant EGFR TKI therapy requires further investigation and should not be considered a standard treatment option at this time. Multiple ongoing trials are exploring adjuvant EGFR TKI (and adjuvant ALK TKI) therapy for resected early stage NSCLC patients with tumors harboring the appropriate molecular marker. (Table 1) The ongoing trials are looking not only at whether or not an OS benefit can be obtained with adjuvant molecularly targeted therapy but also duration of therapy and the potential to use EGFR TKIs instead of chemotherapy in selected patients. The largest United States study is the NCI National Clinical Trials Network (NCTN) ALCHEMIST trial. The study is open to patients with resected early stage (IB‐IIIA) NSCLC who are screened for EGFR activating mutations and ALK translocations. Patients with tumors harboring EGFR mutations or ALK translocations enter the appropriate sub‐study and, after completion of all planned adjuvant chemotherapy or radiation therapy, are randomized to targeted TKI therapy or placebo for 2 years. Both sub‐studies will enroll approximately 400 patients (410 EGFR; 378 ALK) and are powered for an OS endpoint. Patients without actionable mutations can enroll on the ANVIL sub‐study looking at adjuvant nivolumab, a PD‐1 targeted agent. (Table 1) Globally most targeted therapy adjuvant trials are being conducted in Asia, particularly China and Japan. ADJUVANT (C‐TONG 1104) trial in China and IMPACT WJOG6410L in Japan are phase III trials for patients with resected stage II‐IIIA EGFRmut NSCLC comparing gefitinib to cisplatin/vinorelbine using DFS as the primary endpoint. (Table 1) Other trials outlined in the Table are exploring variations on this theme using gefitinib or icotinib and either after or instead of adjuvant chemotherapy. The PD‐1 inhibitors nivolumab and pembrolizumab are approved for the second line treatment of advanced stage NSCLC and will likely be utilized in first‐line in the near future.9‐11 Based on their promise in advanced stage NSCLC, multiple trials with PD‐1 and PD‐L1 agents are ongoing. Most studies are for patients who have completed adjuvant chemotherapy (though some allow chemotherapy naïve patients) and they predominantly randomize patients to approximately 1 year of PD‐1 or PD‐L1 inhibitor therapy. Most include testing for PD‐L1 expression, but do not exclude patients with low tumor levels of PD‐L1. Many are placebo controlled. (Table 1) Chemotherapy has helped improve outcomes but continued investigations with novel approaches will be necessary to continue to improve cure rates for patients with resected early stage NSCLC. The use of molecularly targeted agents for patients with tumors containing EGFRmut or ALK translocations are promising with validation studies ongoing and the hope of immunotherapy is being investigated as well in multiple global trials.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01718539/full} -} - - -Record #487 of 538 -@article{Hu18, -author = {Hu, C, Machtay, M, Dignam, J, Paulus, R, and Bradley, J}, -title = {PFS and Cardiac-Toxicity-Adjusted-PFS As Predictors of OS in Locally Advanced NSCLC Treated with Concurrent Chemoradiation}, -journal = {Journal of thoracic oncology}, -volume = {13}, -number = {10}, -pages = {S373}, -year = {2018}, -accession_number = {EMBASE 2001207246}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cardiotoxicity; *chemoradiotherapy; *non small cell lung cancer; Adult; Cancer surgery; Cancer survival; Conference abstract; Controlled study; Death; Drug megadose; Drug therapy; Female; Funding; Human; Immunotherapy; Long term survival; Major clinical study; Male; Median survival time; National health organization; Oncology; Overall survival; Phase 3 clinical trial; Progression free survival; Radiotherapy; Randomized controlled trial; Secondary analysis; Validation process}, -abstract = {Background: Overall survival (OS) is the gold standard for LA‐NSCLC with chemoradiation (CCRT), while the complex relationships among RT dosimetry, systemic therapies, cardiopulmonary toxicity, progression (PD) and OS are also of increasing scientific and clinical interest. Method: NRG Oncology RTOG 0617 (NCT00533949) was a randomized phase 3 trial comparing standard (SD, 60 Gy) versus high‐dose (HD, 74 Gy) CCRT +/‐ cetuximab from 11/07‐06/11. This secondary analysis includes 469 patients (pts) given ≥50 Gy. A PFS event was defined as the first occurrence of local, regional, distant PD or death w/o documented PD. A CTA‐PFS event was the first occurrence of grade 2+ treatment‐related cardiac toxicity event or a PFS event. Landmark analyses at 6mo and 12mo were used to minimize the immortal time bias. Cox model with PD or CT/PD as a time‐dependent covariate was used to evaluate their predictive roles. Median f/u time for surviving pts was 5.1 years. Result: As previously reported, pts treated with HD had significantly lower OS rates (HR=1.28, 95%CI: 1.04‐1.58, p=0.018) and CTA‐PFS rates (HR=1.24, 95%CI: 1.02‐1.51, p=0.035), and marginally lower PFS rates (HR=1.21, 95%CI: 0.99‐1.47, p=0.06) than pts treated with SD. Median survival time (MST) among pts having PD within 6mo versus not were 13.4mo (95%CI: 10.0‐19.0mo) and 30.7mo (95%CI: 28.0‐37.0mo) (p<0.001). MST for pts having PD within 12mo versus not were 20.6mo (95%CI: 18.8‐25.0mo) and 60mo (95%CI: 47.6‐74.5mo)(p<0.001). Results are similar when using CTA‐PFS with 6mo or 12mo cutoff (p<0.001). RT dose was no longer significantly associated with OS (p=0.08 or p=0.15) when PD or CT/PD was included in multivariable analysis (p<0.001), suggesting OS differences in HD/SD may be partially captured by PFS or CTA‐PFS. Conclusion: Long‐term survival results from RTOG 0617 suggest that PFS (or CTA‐PFS) status at 6mo or 12mo predicts long‐term OS, and may potentially be considered as a surrogate endpoint of OS in clinical trials. Pts who were progression‐free at 12mo had a MST of 5 years. Further validation on external datasets and in the modern era of immunotherapy are needed. Funding: This project was supported by grants NCORP (UG1CA189867), NRG Operations (U10CA180868), NRG SDMC (U10CA180822), IROC (U24CA180803), and CTEP from the National Cancer Institute (NCI). Keywords: Surrogate endpoint, Locally advanced NSCLC, Progression‐free survival}, -DOI = {10.1016/j.jtho.2018.08.355}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01670080/full} -} - - -Record #488 of 538 -@article{Hui18, -author = {Hui, R, Ozguroglu, M, Villegas, A, Daniel, D, Vicente, D, Murakami, S, Ryden, A, Zhang, Y, Dennis, P, and Antonia, S}, -title = {Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: post-hoc analysis of PACIFIC patient-reported outcomes}, -journal = {Journal of thoracic oncology}, -volume = {13}, -number = {4}, -pages = {S71}, -year = {2018}, -accession_number = {EMBASE 621998572}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer staging; *deterioration; *non small cell lung cancer; *patient‐reported outcome; *post hoc analysis; Adult; Arm pain; Cancer survival; Case report; Chemoradiotherapy; Clinical article; Conference abstract; Controlled study; Drug combination; Drug therapy; Female; Hazard ratio; Hemoptysis; Human; Insomnia; Male; Nausea and vomiting; Overall survival; Progression free survival; Proportional hazards model; Radiotherapy; Randomization; Randomized controlled trial; Shoulder pain; Thorax pain}, -abstract = {Background: Along with improving efficacy outcomes such as progression‐free survival (PFS) after concurrent chemoradiotherapy (cCRT) in locally advanced, unresectable NSCLC, it is critical that new therapies are well tolerated in the curative intent setting. We studied the impact of 12 mo of durvalumab on disease symptoms in this setting using patient‐reported outcomes (PROs). In a post‐hoc analysis of time to deterioration, we adjusted for transient symptom changes by requiring two consecutive deterioration recordings. Methods: Patients whose disease did not progress after ≥2 cycles of platinum‐based cCRT were randomised 2:1 1‐42 days post‐cCRT to durvalumab 10 mg/kg i.v. or placebo every 2 weeks for up to 12 mo/progression. Coprimary endpoints were PFS and overall survival. PROs were assessed using EORTC QLQ‐C30 v3 and QLQ‐LC13. Time to deterioration was defined as time from randomisation until the first clinically relevant deterioration (≥10 point change); in the post‐hoc analysis, deterioration confirmation was required at the next time point. Hazard ratios (HR) and 95% confidence intervals (CIs) were estimated using a stratified Cox proportional‐hazards model. Results: In the pre‐specified analysis, there was no difference between treatment arms in time to deterioration besides other pain, which favoured durvalumab vs placebo (HR 0.72; 95% CI 0.58‐0.89). Our post‐hoc analysis indicated notable delays in deterioration of overall pain (HR 0.75; 95% CI 0.60‐0.93), chest pain (HR 0.74; 95% CI 0.57‐0.97), arm/shoulder pain (HR 0.74; 95% CI 0.58‐0.95), nausea/vomiting (HR 0.72; 95% CI 0.54‐0.97), insomnia (HR 0.75; 95% CI 0.58‐0.97) and haemoptysis (HR 0.70; 95% CI 0.50‐0.99) in favour of durvalumab, with no between‐group differences for other items. Conclusions: PACIFIC primary analysis showed that durvalumab significantly improved PFS vs placebo (16.8 mo vs 5.6 mo, respectively) in the post‐cCRT setting, and waswell tolerated, largely without PRO deterioration. Our post‐hoc analysis indicates a delay in several PROs with durvalumab not observed in the pre‐specified analysis. Confirmation of worsening may provide a more precise picture of deterioration than one time point alone.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01607757/full} -} - - -Record #489 of 538 -@article{Rizvi14, -author = {Rizvi, NA, Antonia, SJ, Shepherd, FA, Chow, LQ, Goldman, J, Shen, Y, Chen, AC, and Gettinger, S}, -title = {Nivolumab (anti-PD-1; BMS-936558, ONO-4538) maintenance as monotherapy or in combination with bevacizumab (BEV) for non-small cell lung cancer (NSCLC) previously treated with chemotherapy}, -journal = {International journal of radiation oncology biology physics}, -volume = {90}, -number = {5}, -pages = {S32}, -year = {2014}, -accession_number = {EMBASE 71817244}, -publication type = {Journal article; Conference proceeding}, -keywords = {*United States; *chemotherapy; *monotherapy; *non small cell lung cancer; *oncology; Algorithm; Arm; Coughing; Death; Follow up; Human; Interstitial nephritis; Maintenance therapy; Melanoma; Overall survival; Patient; Phase 1 clinical trial; Pleura effusion; Pneumonia; Progression free survival; Safety; Toxicity}, -abstract = {Purpose/Objective(s): Nivolumab, a fully human IgG4 programmed death‐1 (PD‐1) immune checkpoint inhibitor antibody, has demonstrated durable responses and tolerability in chemotherapy‐naïve and heavily pretreated patients (pts) with NSCLC. BEV has shown tolerability and enhanced activity in combination with the CTLA‐4 immune checkpoint antibody ipilimumab in melanoma. We report preliminary results from a phase 1 study evaluating the safety and efficacy of switching to nivolumab maintenance therapy, as monotherapy or combined with BEV, in pts with advanced NSCLC who did not progress on first‐line platinum (PT) based chemotherapy. Materials/Methods: Pts with no progression within 42 days of completing ≥4 cycles first‐line PT‐based chemotherapy (± BEV) were assigned to either nivolumab (N) 5 mg/kg IV Q3W + BEV 15 mg/kg IV Q3W (nonsquamous [non‐sq] pts only; n=12) or N 3 mg/kg IV Q2W monotherapy (sq arm [n=8], non‐sq arm [n=13]) until progression or unacceptable toxicity (treatment beyond progression allowed based on protocol‐defined criteria). Objective response rate (ORR) was evaluated using RECIST 1.1. Results: Median follow‐up was 80.4, 25.6, and 35.1 wks for N + BEV, N monotherapy in sq pts, and N monotherapy in non‐sq pts. Any‐grade treatment‐related adverse events (AEs) occurred in 11/12 (92%) pts switching to N + BEV and in 13/21 (62%) pts switching to N monotherapy (managed with standard algorithms). No treatment‐related grade 4 AEs were reported; grade 3 AEs included pneumonitis (n=2) and cough and tubulointerstitial nephritis (n=1 each) with N + BEV; and pneumonitis (n=2) and pleural effusion (n=1) with N monotherapy. Four pts in each of the N + BEV and N monotherapy (non‐sq) arms discontinued due to treatment‐related AEs. Median progression‐free survival (PFS) was 37.1 wks with N + BEV, 16 wks with sq N monotherapy and 21.4 wks with non‐sq N monotherapy. ORR with N + BEV was 8% (1/12, ongoing). ORR with N monotherapy was 10% (2/21; both non‐sq, duration of responses 15.7 and 18.3 wks). Stable disease was best overall response in 50% with N + BEV and 48% with N monotherapy (50% sq, 46% non‐sq). Median overall survival (OS) was not reached with N + BEV (range 33.3, 86.7+ wks) or N monotherapy (range 2.1+, 56.3+ wks); 1‐yr OS rate was 75% with N + BEV (not calculated for N monotherapy [insufficient follow‐up]). Conclusions: Switching to nivolumab either as monotherapy or + BEV demonstrated PFS similar to that seen with other agents approved as maintenance therapy after PT‐based chemotherapy in advanced NSCLC. These preliminary data support further evaluation of the safety and efficacy of switching to nivolumab maintenance therapy in chemotherapy‐treated pts. Additional follow‐up will be presented.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01088079/full} -} - - -Record #490 of 538 -@article{PACTR20230183499844323, -author = {PACTR202301834998443,}, -title = {A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=PACTR202301834998443}, -year = {2023}, -accession_number = {ICTRP PACTR202301834998443}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Placebo plus Pembrolizumab plus Pemetrexed plus Carboplatin or Cisplatin Tiragolumab plus Atezolizumab plus Pemetrexed plus Carboplatin or Cisplatin CONDITION: ; Cancer Cancer PRIMARY OUTCOME: ‐Investigator‐Assessed Confirmed Objective Response Rate (ORR) (Phase 2) [ Time Frame: Up to approximately 5 years ]; ‐Investigator‐Assessed Progression‐Free Survival (PFS) (Phase 2 and Phase 3) [ Time Frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 5 years [Phase 2], up to approximately 7 years [Phase 3]) ]; ‐Overall Survival (Phase 3) [ Time Frame: From randomization to death from any cause (up to approximately 7 years) ] SECONDARY OUTCOME: ‐Investigator‐Assessed Confirmed ORR (Phase 3) [ Time Frame: Up to approximately 7 years ] ; ‐Investigator‐Assessed Duration of Response (DOR) (Phase 2 and Phase 3) [ Time Frame: From first occurrence of a documented confirmed objective response to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 5 years [Phase 2]; up to approximately 7 years [Phase 3]) ] ; ‐Time to Confirmed Deterioration (TTCD) in Participant‐Reported Physical Functioning and Global Health Status (GHS)/Quality of Life (QoL) as Measured by European Organisation for Research and Treatment of Cancer (EORTC) QLQ‐C30 (Phase 2 and Phase 3) [ Time Frame: Up to approximately 5 years (Phase 2); up to approximately 7 years (Phase 3) ] ; TTCD using EORTC Quality‐of‐Life Questionnaire Core 30 (QLQ‐C30) is an initial 10‐point decrease in GHS and physical functioning from baseline that must be held for at least two consecutive assessments or an initial clinically meaningful decrease above baseline followed by death. EORTC QLQ‐C30: a self‐reported measure, consisting of 30 questions that assess 5 aspects of participants functioning (physical, emotional, role, cognitive and social), 3 symptom scales (fatigue, nausea/vomiting and pain), GHS and QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) with a recall period of the previous week. Functioning items are scored on a 4‐point scale: 1=Not at all to 4=Very much, with higher score indicating worse outcome. Symptom items (GHS and QoL) are scored on a 7‐point scale: 1=Very poor to 7=Excellent. Scores will be linearly transformed with a minimum score of 0 and maximum score of 100. Higher score indicates better outcome. ‐Overall Survival (Phase 2) [ Time Frame: From randomization to death from any cause (up to approximately 5 years) ] ; ‐PFS as Determined by an Independent Review Facility (IRF) (Phase 3) [ Time Frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 7 years) ] ; ‐Investigator‐assessed PFS in Participants With PD‐L1 Expression at TC =50% and TC =1% Cut‐off, as Determined by Central Testing With Ventana PD‐L1 (SP263) Assay (Phase 3) [ Time Frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 7 years) ] ; ‐OS in Participants With PD‐L1 Expression at TC =50% and TC =1% Cut‐off, as Determined by Central Testing With Ventana PD‐L1 (SP263) Assay (Phase 3) [ Time Frame: From randomization to death from any cause (up to approximately 7 years) ] ; ‐Investigator‐Assessed PFS at 6 Months and 12 Months (Phase 3) [ Time Frame: 6 months, 12 months ] ; ‐OS Rate at 12 Months and 24 Months (Phase 3) [ Time Frame: 12 months, 24 months ] ‐Serum Concentration of Tiragolumab (Phase 2 and Phase 3) [ Time Frame: Cycle 1 (each cycle=21 days), Day 1: predose, 0.5 hour (h) postdose; Cycles 2, 3, 4, 8, 12, 16, Day 1: predose and at treatment discontinuation (TD) visit (up to approximately 5 years [Phase 2]; up to approximately 7 years [Phase 3]) ] ; ‐Serum Concentration of Atezolizumab (Phase 2 and Phase 3) [ Time Frame: Cycle 1 (each cycle=21 days), Day 1: predose, 0.5 hour (h) postdose; Cycles 2, 3, 4, 8, 12, 16, Day 1: predose and at TD visit (up to approximately 5 years [Phase 2]; up to approximately 7 years [Phase 3]) ] ; ‐Percentage of Participants With Anti‐Drug Antibodies (ADAs) to Tiragolumab (Phase 2 and Phase 3) [ Time Frame: Predose on Day 1 of Cycles (each cycle=21 days) 1, 2, 3, 4, 8, 12, 16 and at TD visit (up to approximately 5 years [Phase 2]; up to approximately 7 years [Phase 3]) ] ; ‐Percentage of Participants With ADAs to Atezolizumab (Phase 2 and Phase 3) [ Time Frame: Predose on Day 1 of Cycles (each cycle=21 days) 1, 2, 3, 4, 8, 12, 16 and at TD visit (up to approximately 5 years [Phase 2]; up to approximately 7 years [Phase 3]) ] ‐TTCD in Participant‐Reported Lung Cancer Symptoms for Cough, Dyspnea, and Chest Pain, as Measured by EORTC QLQ‐LC13 (Phase 2 and Phase 3) [ Time Frame: Up to approximately 5 years (Phase 2); up to approximately 7 years (Phase 3) ] ; TTCD using EORTC Quality‐of‐Life Questionnaire Lung Cancer Module (QLQ‐LC13) is an initial 10‐point increase in symptom score from baseline that must be held for at least two consecutive assessments or an initial clinically meaningful decrease above baseline followed by death. EORTC QLQ‐LC13 consists of 13 lung cancer specific items and includes 11 disease‐specific scales/items (dyspnea, coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, pain medication). Each item is scored on a 4‐point scale of 1=Not at all to 4=Very much. Scores will be linearly transformed to a score range of 0 to 100. Higher score indicates worsening of symptoms. ; ; ‐Percentage of Participants With Adverse Events (AEs) (Phase 2 and Phase 3) [ Time Frame: Up to approximately 5 years (Phase 2); up to approximately 7 years (Phase 3) ] ; ‐Participants' Response to Side Effects of Treatment as Assessed by EORTC IL46 (Phase 2 and Phase 3) [ Time Frame: Up to approximately 5 years (Phase 2); up to approximately 7 years (Phase 3) ] ; EORTC Item List 46 (IL46) is a validated single‐item question that assesses overall side effect impact. Each item is scored on a 4‐point scale of 1=Not at all to 4=Very much. Scores will be linearly transformed to a score range of 0 to 100. Higher score indicates a worse outcome. INCLUSION CRITERIA: ‐Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 ‐Histologically or cytologically documented locally advanced unresectable or metastatic non‐squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy ‐No prior systemic treatment for metastatic non‐squamous NSCLC ‐Known tumor programmed death‐ligand 1 (PD‐L1) status ‐Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) ‐Life expectancy >= 12 weeks ‐Adequate hematologic and end‐organ function ‐Negative human immunodeficiency virus (HIV) test at screening ‐Serology test negative for active hepatitis B virus or active hepatitis C virus at screening.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02521656/full} -} - - -Record #491 of 538 -@article{Dy23, -author = {Dy, G, Alexander, M, and Camidge, DR}, -title = {83TiP A phase II study of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, alone and in combination with nivolumab in adult patients with metastatic NSCLC who had prior disease progression on or are intolerant to a PD-1/L1, EGFR, or ALK inhibitor}, -journal = {Journal of thoracic oncology}, -volume = {18}, -number = {4}, -pages = {S88}, -year = {2023}, -accession_number = {EMBASE 2023625774}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer combination chemotherapy; *cancer patient; *non small cell lung cancer; Adult; Adverse drug reaction; Cancer radiotherapy; Cancer recurrence; Chemotherapy; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Drug combination; Drug safety; Drug therapy; Drug withdrawal; Female; Funding; Human; Male; Molecularly targeted therapy; Monotherapy; Phase 2 clinical trial; Protein expression; Radiotherapy; Response evaluation criteria in solid tumors; Side effect; Treatment failure; Upregulation}, -abstract = {Background Mecbotamab vedotin (BA3011) is a conditionally active biologic (CAB) anti‐AXL antibody‐drug conjugate being developed as an anticancer therapy for patients with advanced solid tumors. Conditional and reversible binding by CABs is designed to reduce off‐tumor toxicity and immunogenicity, avoid tissue‐mediated drug disposition, and improve pharmacokinetics. AXL is a cell‐surface transmembrane receptor protein tyrosine kinase highly expressed in several tumor types including sarcoma. Increased AXL expression has been associated with tumor resistance to chemotherapy, programmed death‐1 (PD‐1) inhibitors, molecular targeted therapy, and radiation therapy. The upregulation of AXL in PD‐1 resistant tumor strongly suggests its role in resistance and recurrence in this population. Additionally, as patients who have experienced failure of either an epidermal growth factor receptor (EGFR), or anaplastic lymphoma kinase (ALK) inhibitor have been shown to achieve minimal benefit with subsequent exposure to PD‐1 monotherapy, there is considerable additional rationale for use of BA3011‐based therapy. Trial design Study BA3011‐002 is an ongoing multi‐center, open‐label, phase II trial designed to evaluate the efficacy and safety of BA3011 alone or in combination with nivolumab in patients with AXL‐expressing (tumor membrane percent score ≥ 1%), metastatic NSCLC who have measurable disease by RECIST version 1.1 criteria. To enroll, patients must have experienced failure of an approved programmed death1/ ligand‐1(PD‐1/L1) treatment, epidermal growth factor receptor (EGFR), or anaplastic lymphoma kinase (ALK) inhibitor (either monotherapy or in combination with another therapy such as ipilimumab). Treatment failure is defined as disease progression on a PD‐1/L1, EGFR, or ALK inhibitor, or discontinuation of a PD‐1/L1, EGFR, or ALK inhibitor due to an adverse event. Enrollment completion is anticipated in 2023. Clinical trial identification NCT04681131, EudraCT 2022‐000135‐23. Legal entity responsible for the study BioAtla, Inc. Funding BioAtla, Inc. Disclosure G. Dy: Financial Interests, Personal, Other, Consulting/honoraria: Amgen, AstraZeneca, Eli Lilly, Mirati, Regeneron, Takeda; Financial Interests, Personal, Principal Investigator: BioAtla. M. Alexander: Financial Interests, Personal, Principal Investigator: BioAtla. D.R. Camidge: Financial Interests, Personal, Advisory Role, Scientific Review Committee: Appolomics; Financial Interests, Personal, Advisory Role, ILD Adjudication Committee: AstraZeneca/ Daiichi Sankyo, Mersana; Financial Interests, Personal, Advisory Role, DSMB: BeiGene; Financial Interests, Personal, Other, Consultancy: EMD Serono, Medtronic, Mirati, Onkure, Roche; Financial Interests, Personal, Principal Investigator: AbbVie, Pfizer, Dizal, Verastem, Karyopharm, Turning Point Therapeutics, Promontory Therapeutics, BioAtla.}, -DOI = {10.1016/S1556-0864(23)00337-4}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02571470/full} -} - - -Record #492 of 538 -@article{De Ruysscher20, -author = {De Ruysscher, D, Ramalingam, SS, Urbanic, J, Gerber, DE, Tan, DSW, Cai, J, Li, A, and Peters, S}, -title = {CheckMate 73L: a phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO ± ipilimumab (IPI) versus CCRT followed by durvalumab (DURV) for previously untreated, locally advanced (LA) stage III non-small cell lung cancer (NSCLC)}, -journal = {Annals of oncology}, -volume = {31}, -pages = {S810}, -year = {2020}, -accession_number = {EMBASE 2007890447}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *chemoradiotherapy; *non small cell lung cancer; Adult; Advanced cancer; Cancer patient; Cancer survival; Catalyst; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Distant metastasis; Drug combination; Drug efficacy; Drug safety; Drug therapy; Exploratory research; Female; Follow up; Funding; Gene expression; Human; Major clinical study; Male; Overall survival; Parttime employment; Pharmacokinetics; Phase 2 clinical trial; Phase 3 clinical trial; Plant stem; Progression free survival; Protein expression; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Travel; Treatment response time; Writing}, -abstract = {Background: Historically, the standard‐of‐care for patients (pts) with unresectable stage III NSCLC was CCRT; however, outcomes are poor with 5‐y survival rates of 15–30%. While CCRT primes anti‐tumour immunity, it also upregulates PD‐L1 expression, potentially blunting any immune response. Thus, concurrent immunotherapy + CCRT may improve outcomes. The safety and tolerability of NIVO, an anti–PD‐1 antibody, given concomitantly with CCRT in pts with stage III NSCLC was demonstrated in the phase 2 NICOLAS study (NCT02434081). Furthermore, combining NIVO with IPI, an anti–CTLA‐4 antibody, resulted in a longer median overall survival (OS) versus chemotherapy in pts with advanced NSCLC who had a PD‐L1 expression level of ≥1% in the phase 3 CheckMate 227 study (NCT02477826). In a prespecified exploratory analysis, NIVO + IPI showed an efficacy benefit versus NIVO. Previously, DURV, an anti–PD‐L1 antibody, demonstrated significant improvements versus placebo in progression‐free survival (PFS) and OS with manageable safety in pts without disease progression after CCRT in the phase 3 PACIFIC study (NCT02125461). Therefore, we will evaluate the efficacy of NIVO + CCRT followed by NIVO ± IPI versus CCRT followed by DURV for untreated, LA stage III NSCLC in the phase 3 randomized CheckMate 73L study (NCT04026412). Trial design: In all, 888 pts aged ≥18 y with previously untreated stage III NSCLC and an ECOG PS ≤1 will be stratified by age, PD‐L1 expression, and disease stage, then randomized (1:1:1) to receive NIVO (360 mg Q3W) + CCRT followed by NIVO (360 mg Q3W) + IPI (1 mg/kg Q6W; Arm A) or NIVO alone (480 mg Q4W; Arm B) for ≤1 y, or CCRT followed by DURV (10 mg/kg Q2W; Arm C) for ≤1 y. Pts with PD during CCRT will discontinue treatment and enter follow‐up. Primary endpoints are PFS by RECIST 1.1, assessed by BICR (Arm A vs C) and OS (Arm A vs C). Secondary endpoints are PFS (Arm B vs A or C), OS (Arm B vs A or C), objective response rate, time to response, duration of response, time to distant metastases, and safety. Start date: Aug 2019. Clinical trial identification: NCT04026412; July 19, 2019. Editorial acknowledgement: Writing and editorial assistance was provided by Simon Wigfield, PhD, of Caudex, funded by Bristol‐Myers Squibb Company. Legal entity responsible for the study: Bristol‐Myers Squibb Company. Funding: Bristol‐Myers Squibb Company. Disclosure: D. De Ruysscher: Honoraria (institution): Bristol‐Myers Squibb Company, Celgene, Merck/Pfizer, Roche/Genentech, AstraZeneca, MSD, Seattle Genetics; Advisory/Consultancy, To institution: Bristol‐Myers Squibb Company, Celgene, Merck/Pfizer, Roche/Genentech, AstraZeneca, MSD, Seattle Genetics; Research grant/Funding (institution): Boehringer Ingelheim, Bristol‐Myers Squibb Company. AstraZeneca, Philips, Olink. S.S. Ramalingam: Advisory/Consultancy: Amgen, AbbVie, Bristol‐Myers Squibb Company, Genentech/Roche, Merck, AstraZeneca, Takeda; Research grant/Funding (institution): Advaxis, Amgen, AstraZeneca, Bristol‐Myers Squibb Company, Merck, Takeda, Tesaro. D.E. Gerber: Advisory/Consultancy: Catalyst Pharmaceuticals; Research grant/Funding (institution): AstraZeneca, BerGenBio, Karyopharm, 3V Biosciences; Shareholder/Stockholder/Stock options: Gilead; Non‐remunerated activity/ies: Bristol‐Myers Squibb Company, Karyopharm. D.S.W. Tan: Honoraria (self): Boehringer Ingelheim, Merck, Roche, Pfizer, Novartis, Takeda; Advisory/Consultancy: Novartis, Bayer, Boehringer Ingelheim, Celgene, AstraZeneca, Eli Lilly, Loxo, Pfizer, Takeda, Merrimack; Research grant/Funding (self): Novartis, Bayer, AstraZeneca, GlaxoSmithKline, Pfizer; Travel/Accommodation/Expenses: Pfizer, Takeda, Boehringer Ingelheim, Novartis, Merck. J. Cai: Full/Part‐time employment: Bristol‐Myers Squibb Company. A. Li: Full/Part‐time employment: Bristol‐Myers Squibb Company. S. Peters: Honoraria (institution), Advisory/Consultancy: AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer Ingelheim, Bristol‐Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann‐La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp & Dohme Corp., M; Research grant/Funding (institution): Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol‐Myers Squibb, Clovis, F. Hoffmann‐La Roche, Illumina, Merck Sharp & Dohme Corp., Merck Serono, Novartis, Pfizer; Travel/Accommodation/Expenses, Travel for adboards/meetings: AstraZeneca, Bayer, Bristol‐Myers Squibb, F. Hoffmann‐La Roche, Foundation Medicine, Illumina, Merck Sharp & Dohme Corp., Pfizer, Seattle Genetics. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2020.08.128}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02176899/full} -} - - -Record #493 of 538 -@article{Barlesi24, -author = {Barlesi, F, Felip, E, Popat, S, Solomon, B, Wolf, J, Li, BT, Wu, Y-L, Kerr, KM, Akamatsu, H, Camidge, DR, Gupta, R, Meloni, A, Dai, T, and Borghaei, H}, -title = {103TiP Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)}, -journal = {ESMO open}, -volume = {9}, -year = {2024}, -accession_number = {EMBASE 2030948507}, -publication type = {Journal article; Conference proceeding}, -keywords = {*doublet chemotherapy; *first‐line treatment; *metastasis; *non small cell lung cancer; Adult; Advisory committee; Advocacy group; Aged; Antineoplastic activity; Aortic aneurysm endovascular graft; Australia and New Zealand; Brain metastasis; Cancer cell; Cancer center; Cancer inhibition; Chemoradiotherapy; Clinical trial; Conference abstract; Controlled study; Europe; Expert witness; Female; Histology; Human; Immunotherapy; Japan; Lobbying; Lung cancer; Maintenance therapy; Male; Medical oncologist; Mesothelioma; Middle aged; Multinational corporation; Overall survival; Parttime employment; Patient advocacy; Progression free survival; Response evaluation criteria in solid tumors; Travel; Wolf}, -abstract = {Background: The 5‐year progression free survival (PFS) rate of patients with metastatic, PD‐L1 negative, non‐small cell lung cancer (NSCLC) remains poor, ranging from approximately 2% to 10% with standard immunotherapy‐based treatment regimens. Based on promising anti‐tumor activity in the phase I CodeBreaK 101 study, with partial responses observed in 62% (8/13) of PD‐L1 negative patients in the first‐line setting, we hypothesize that sotorasib plus platinum doublet chemotherapy will demonstrate durable clinical response and improved outcomes in this population. CodeBreaK 202 (NCT05920356) is a global phase III randomized study evaluating the efficacy of sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first‐line treatment for metastatic or locally advanced, PD‐L1 negative, KRAS G12C‐mutated NSCLC. Trial design: Patients will be randomized 1:1 to either sotorasib 960 mg once daily or pembrolizumab administered in combination with carboplatin and pemetrexed for 4 cycles, followed by maintenance treatment with sotorasib or pembrolizumab administered in combination with pemetrexed. Key eligibility criteria include treatment‐naïve metastatic or locally advanced stage IIIB/C disease that is not amenable to definitive chemoradiation, PD‐L1 <1% expression, presence of KRAS G12C mutation, non‐squamous tumor histology, and absence of actionable genomic alterations such as EGFR mutations and ALK rearrangements. Patients with both treated and untreated brain metastases are eligible if clinically asymptomatic. The primary endpoint is PFS per RECIST v1.1 by blinded independent central review (BICR). Key secondary endpoints include overall survival and objective response rate. Exploratory endpoints include intra‐cranial PFS per RANO‐BM criteria. Approximately 750 patients are planned to be enrolled and recruitment began on November 18, 2023. Clinical trial identification: NCT05920356. Editorial acknowledgement: Medical writing support was provided by Tim Harrison, PharmD (Amgen Inc.). Legal entity responsible for the study: Amgen Inc. Funding: Amgen Inc. Disclosure: F. Barlesi: Financial Interests, Institutional, Advisory Board: AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, Mirati, MSD, Pierre Fabre, Pfizer, Sanofi Aventis, Seattle Genetics, Takeda, abbvie, ACEA, Amgen, Eisai, Ignyta; Non‐Financial Interests, Personal, Principal Investigator: AstraZeneca, BMS, Merck, Pierre Fabre, F. Hoffmann‐La Roche Ltd., Innate Pharma, Mirati. E. Felip: Financial Interests, Personal, Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F. Hoffmann‐La Roche, Gilead, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Peptomyc, Regeneron, Sanofi, Takeda, Turning Point, Pfizer; Financial Interests, Personal, Invited Speaker: Amgen, Daiichi Sankyo, Genentech, Janssen, Medical Trends, Medscape, Merck Serono, PeerVoice, Pfizer, Sanofi, Takeda, Touch Oncology, AstraZeneca, Bristol Myers Squibb, Eli Lilly, F. Hoffmann‐La Roche, Merck Sharp & Dohme; Financial Interests, Personal, Member of Board of Directors, Independent member: Grifols; Financial Interests, Institutional, Invited Speaker, Clinical Trial: AstraZeneca AB, AbbVie, Amgen, Bayer Consumer Care AG, BeiGene, Boehringer Ingelheim GmbH, Bristol Myers Squibb International Corporation, Daiichi Sankyo Inc., Exelixis Inc., F. Hoffmann‐La Roche Ltd., Genentech Inc., GSK Research and Development Limited, Janssen Cilag International NV, Merck Sharp & Dohme Corp, Merck KGAA, Mirati Therapeutics Inc, Novartis Pharmaceutica SA, Pfizer, Takeda Pharmaceuticals International; Non‐Financial Interests, Personal, Leadership Role, President (2021‐2023): SEOM (Sociedad Espanola de Oncologia Medica); Non‐Financial Interests, Personal, Member, Member of Scientific Committee: ETOP (European Thoracic Oncology Platform); Non‐Financial Interests, Personal, Member, Member of the Scientiffic Advisory Committee: CAC Hospital Universitari Parc Taulí. S. Popat: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, Novartis, Amgen, Janssen, Daiichi Sankyo, AstraZeneca, Bayer, BMS, Blueprint, Guardant Health, BeiGene, Takeda, Lilly, Turning Point Therapeutics, GSK, MSD, Pfizer, Sanofi, EQRx; Financial Interests, Personal, Expert Testimony: Merck Serono, Roche; Financial Interests, Personal, Invited Speaker: Medscape, VJ Oncology; Financial Interests, Personal, Other, Journal Deputy Editor, Lung Cancer: Elsevier; Financial Interests, Institutional, Other, Sub‐investigator: Amgen; Financial Interests, Institutional, Invited Speaker: Ariad, AstraZeneca, Roche, Boehringer Ingelheim, Celgene, Daiichi Sankyo, GSK, Takeda, Trizel, Turning Point Therapeutics, Roche, Janssen, BMS, Lilly; Financial Interests, Institutional, Other, Sub‐Investigator:MSD, Blueprint; Financial Interests, Institutional, Research Grant: Guardant Health; Non‐Financial Interests, Personal, Leadership Role, Chair of Steering Committee, Unpaid: British Thoracic Oncology Group; Non‐Financial Interests, Personal, Officer, Thoracic Faculty, Unpaid: European Society of Medical Oncology; Non‐Financial Interests, Personal, Leadership Role, Foundation Council Member, Unpaid: European Thoracic Oncology Platform; Non‐Financial Interests, Personal, Advisory Role, Mesothelioma Task‐force Member, Unpaid: International Association for the Study of Lung Cancer; Non‐Financial Interests, Personal, Member of Board of Directors, Unpaid: Mesothelioma Applied Research Foundation; Non‐Financial Interests, Personal, Advisory Role, Honorary Clinical Advisor, Unpaid: ALK Positive UK; Non‐Financial Interests, Personal, Advisory Role, Research Advisory Group Member, Unpaid: Ruth Strauss Foundation; Non‐Financial Interests, Personal, Advisory Role, Scientific Advisory Board Member, Unpaid: Lung Cancer Europe. B. Solomon: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Merck, Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche/Genentech; Financial Interests, Personal, Advisory Board: Amgen, Roche‐Genentech, Eli Lilly, Takeda, Janssen; Financial Interests, Personal, Full or part‐time Employment, Employed as a consultant Medical Oncologist at Peter MacCallum Cancer Centre: Peter MacCallum Cancer Centre; Financial Interests, Personal, Member of Board of Directors: Cancer Council of Victoria, Thoracic Oncology Group of Australasia; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Invited Speaker, Principal Investigator and Steering committee Chair: Roche/Genentech, Pfizer; Financial Interests, Institutional, Invited Speaker: Novartis. J. Wolf: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Lilly, Loxo, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda, Nuvalent, Pierre Fabre, Merck, Mirati; Financial Interests, Personal, Invited Speaker: Bayer, Chugai; Financial Interests, Institutional, Research Grant: BMS, Janssen, Novartis, Pfizer. B.T. Li: Financial Interests, Personal, Royalties, Intellectual property rights as a book author: Karger Publishers, Shanghai Jiao Tong University Press; Financial Interests, Institutional, Other, Inventor on institutional patents at MSK (US62/685,057, US62/514,661): Memorial Sloan Kettering Cancer Center; Financial Interests, Institutional, Invited Speaker, Institutional clinical trials funding to Memorial Sloan Kettering Cancer Center: Amgen, AstraZeneca, Bolt Biotherapeutics, Daiichi Sankyo, Genentech, Hengrui, Lilly; Non‐Financial Interests, Personal, Advisory Role, Uncompensated advisor and consultant: Amgen, AstraZeneca, Boehringer Ingelheim, Bolt Biotherapeutics, Daiichi Sankyo, Genentech, Lilly; Non‐Financial Interests, Personal, Other, Academic travel support, but without compensation: MORE Health, Jiangsu Hengrui Pharmaceuticals; Non‐Financial Interests, Personal, Member: American Society of Clinical Oncology, International Association for the Study of Lung Cancer. Y. Wu: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Hengrui, Merck, MSD, Pfizer, Roche, Sanofi, AstraZeneca, Boehringer Ingelheim, BMS, Hengrui, Merck, MSD, Pfizer, Roche, Sanofi, Yunhan, Eli Lilly; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Takeda; Non‐Financial Interests, Personal, Leadership Role: Chinese Thoracic Oncology Group (CTONG); Non‐Financial Interests, Personal, Other, WCLC 2020 Conference Chair: IASLC; Non‐Financial Interests, Personal, Leadership Role, Past President: Chinese Society of Clinical Oncology (CSCO). K.M. Kerr: Financial Interests, Personal, Advisory Board, Consultancy: AbbVie, Amgen, AstraZeneca, Bayer, Debiopharm, Diaceutics, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Roche Diagnostics/Ventana, Janssen; Financial Interests, Personal, Invited Speaker: AstraZeneca, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Roche Diagnostics/Ventana, Medscape, Prime Oncology; Financial Interests, Personal, Advisory Board: Sanofi; Non‐Financial Interests, Personal, Leadership Role, Past Pathology Committee Chair: IASLC; Non‐Financial Interests, Personal, Member, Lobbying and pressure group for UK ‐ generally writing reports to lobby government.: UK Lung Cancer Consortium. H. Akamatsu: Financial Interests, Personal, Research Grant: Amgen Inc., Chugai Pharmaceutial Co. Ltd, MSD K.K.; Financial Interests, Personal, Other, Lecture honoraria or fees: Amgen Inc., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol Myers Squibb, Eli Lilly Japan K.K., MSD K.K., Nippon Kayaku Co. Ltd, Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd, Pfizer Inc., Takeda Pharmaceutical Co. Ltd, Taiho Pharmaceutical Co. Ltd; Financial Interests, Personal, Advisory Board: Amgen Inc., Janssen Pharmaceutical K.K., Sandoz, Boehringer Ingelheim; Financial Interests, Personal, Leadership Role: IASLC patient advocacy committee. D.R. Camidge: Financial Interests, Personal, Advisory Role: AbbVie, Anheart, Apollomics, AstraZeneca, Aveo, BeiGene, Bristol Myers Squibb, Coherus, Eli Lilly, Gilead, Hengrui, Immunocore, Janssen, Lianbio, Merck KGa, Mirati, Nalo Therapeutics, Newsoara, Nextcure, Prelude, Roche, Sanofi, SeaGen, Sutro, Takeda, Valence, Xencor, Daiichi Sankyo, EMD Serono, Elevation, Medtronic, Mersana, Onkure, Regeneron, Turning Point, Theseus, Xcovery, Amgen, Bio‐Thera, Blueprint, Helsinn, Puma, Ribon, Genentech, Dizal; Financial Interests, Personal, Advisory Board: Imagene, Kestrel, Nuvalent; Financial Interests, Personal, Stocks/Shares: Kestrel; Financial Interests, Institutional, Principal Investigator: AbbVie, AstraZeneca, Blueprint, Dizal, Inhibrx, Karyopharm, Nuvalent, Pfizer, Phosplatin, Psioxus, Rain, Roche/Genentech, SeaGen, Takeda, Turning Point, Verastem. R. Gupta, A. Meloni, T. Dai: Financial Interests, Personal, Full or part‐time Employment: Amgen; Financial Interests, Personal, Stocks/Shares: Amgen. H. Borghaei: Financial Interests, Personal, Advisory Board: BMS, Genentech, Eli Lilly, Merck, EMD‐Serono, AstraZeneca, Novartis, Genmab, Regeneron, Amgen, Takeda, PharmaMar, Jazz Pharma, Mirati, Daiichi Sankyo, Guardant, Natera, Oncocyte, BeiGene, iTeo, Boehringer Ingelheim, Puma, BerGenbio, Janssen; Financial Interests, Personal, Other, Training discussion: Pfizer; Financial Interests, Personal, Other, DSMB: Novartis; Financial Interests, Institutional, Other, Clinical trial support: BMS, Amgen; Financial Interests, Personal, Stocks/Shares, Options for scientific advisory role: Sonnetbio; Financial Interests, Personal, Stocks/Shares, Options for scientific advisory board: Nucleai, Inspira (Rgenix); Financial Interests, Institutional, Invited Speaker, Investigator initiated trial support: BMS, Amgen, Lilly; Financial Interests, Personal and Institutional, Invited Speaker, Chair steering committee: Mirati; Financial Interests, Personal and Institutional, Invited Speaker: Amgen, AstraZeneca; Financial Interests, Personal, Invited Speaker, Also trial support: BMS; Other, Personal, Other, DSMB: Novartis, Takeda, Incyte, Springworks.}, -DOI = {10.1016/j.esmoop.2024.102682}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02682731/full} -} - - -Record #494 of 538 -@article{Wakelee17, -author = {Wakelee, HA, Altorki, NK, Vallieres, E, Zhou, C, Zuo, Y, Howland, M, Xia, F, Sandler, A, and Felip, E}, -title = {A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: iMpower010}, -journal = {Journal of clinical oncology}, -volume = {35}, -number = {15}, -year = {2017}, -accession_number = {EMBASE 617434674}, -publication type = {Journal article; Conference proceeding}, -keywords = {*adjuvant chemotherapy; *non small cell lung cancer; Autoimmune disease; Cancer size; Cancer surgery; Clinical trial; Comparative effectiveness; Controlled clinical trial; Controlled study; Disease free survival; Drug therapy; Female; Gene expression; Human; Human tissue; Immunocompetent cell; Immunohistochemistry; Immunotherapy; Major clinical study; Male; Open study; Patient history of chemotherapy; Pharmacokinetics; Phase 3 clinical trial; Radiotherapy; Randomized controlled trial; Recurrent disease; Safety; Stratification; Surgery; Tumor cell}, -abstract = {Background: The anti‐PD‐L1 mAb atezo blocks the interaction between PD‐L1 and its receptors PD‐1 and B7.1 and restores anti‐tumor immunity. In the OAK trial, pts with 2L/3L advanced NSCLC had improved mOS in the atezo arm (13.8 mo) vs the docetaxel (doc) arm (9.6 mo), with a survival benefit observed regardless of PD‐L1 expression levels on tumor cells (TC) or tumor‐infiltrating immune cells (IC). However, more effective treatment options are needed for pts with early‐stage NSCLC. A global Phase III, randomized, open‐label trial, IMpower010 (NCT02486718), is being conducted to evaluate the efficacy and safety of atezo vs BSC following adjuvant cisplatin (cis)‐based chemotherapy (chemo) in pts with resected stage IB (tumors ≥ 4 cm)‐IIIA NSCLC. Methods: Pts eligible for study must have complete tumor resection 4 to 12 weeks prior to enrollment for pathologic stage IB (tumors ≥ 4 cm)‐IIIA NSCLC, be adequately recovered from surgery, be able to receive cis‐based adjuvant chemo and have an ECOG PS 0‐1. Pts with other malignancies, autoimmune disease, hormonal cancer or radiation therapy within 5 years and prior chemo or immunotherapy are excluded from study. Approximately 1127 pts will be enrolled regardless of PD‐L1 status. Pts will receive up to four 21‐d cycles of cis‐based chemo (cis [75 mg/m2IV, d 1] + vinorelbine [30 mg/m2IV, d 1, 8], doc [75 mg/m IV, d 1] or gemcitabine [1250 mg/m2IV, d 1, 8], or pemetrexed [500 mg/m2IV, d 1; only non‐squamous NSCLC]). No adjuvant radiation therapy is permitted. After adjuvant chemo, eligible pts will be randomized 1:1 to receive 16 cycles of atezo 1200 mg q3w or BSC. Stratification factors include sex, histology (squamous vs non‐squamous), disease stage (IB vs II vs IIA) and PD‐L1 status by IHC (TC2/3 [≥ 5% expressing PD‐L1] and any IC vs TC0/1 [ < 5%] and IC2/3 vs TC0/1 and IC0/1 [ < 5%]). The primary endpoint is disease‐free survival; secondary endpoints include OS and safety. Exploratory biomarkers, including PD‐L1 expression, immune‐ and tumor‐related biomarkers before, during and after treatment with atezo and at radiographic disease recurrence, or confirmation of new primary NSCLC, will be evaluated.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01397879/full} -} - - -Record #495 of 538 -@article{Iyengar24, -author = {Iyengar, P, Hu, C, Gomez, DR, Timmerman, RD, Simone, CB, Robinson, CG, Gerber, DE, Waqar, SN, Donington, J, Swisher, S, Weldon, M, Wu, J, Faller, BA, Rashdan, S, Stephans, KL, Sampson, P, Higgins, KA, Nowak, RK, Lyness, J, and Bradley, JD}, -title = {NRG-LU002: randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644907650}, -publication type = {Journal article; Conference proceeding}, -keywords = {*metastasis; *non small cell lung cancer; *systemic therapy; Adult; Adverse drug reaction; Aged; Caucasian; Conference abstract; Controlled study; Drug therapy; Female; First‐line treatment; Follow up; Histology; Human; Major clinical study; Male; Metastasis site; Multiple cycle treatment; Overall survival; Phase 2 clinical trial; Phase 3 clinical trial; Pneumonia; Progression free survival; Quality of life; Randomized controlled trial; Side effect; Surgery; Therapy}, -abstract = {Background: First line therapy options for advanced NSCLC without actionable molecular alterations include immunotherapy (IO) ‐/+ chemotherapy or chemotherapy alone. NRGLU002 was a randomized phase II/III study assessing the benefits of local consolidative therapy (LCT) when added to systemic therapy as maintenance in management of oligometastatic NSCLC. Methods: Eligible patients had metastatic NSCLC with 3 or fewer extracranial metastatic sites (excluding primary) exhibiting at least stable disease after 4 cycles of 1st line systemic therapy. Patients were randomized 1:2 to maintenance systemic therapy or LCT (radiation and/or surgery) followed by maintenance systemic therapy until progression, death, or intolerable toxicity. Stratification factors included histology and IO use. In the randomized phase II (RPhII) portion of the study, the primary endpoint was progression‐free survival (PFS) with a planned decision analysis after 216 patients were enrolled and 138 PFS events observed. Secondary endpoints included overall survival (OS), quality of life, and toxicity. The RPhII portion was designed to provide at least 95% power to detect a PFS hazard ratio (HR) of 0.60 at 1‐sided significance level of 0.15, and the phase III portion warranted only if the estimated HR was less than 0.83. Results: NRG‐LU002 accrual was initiated in 4/2017 and suspended in 11/ 2021 when the RPhII portion sample size was met. Following the planned interim analysis, the study was closed in 12/2023. Overall, 215 patients (81 ‐LCT arm, 134 +LCT arm) were enrolled from 68 sites with a median age of 65 years (40‐86), 77% white, 95% PS 0/1, 78% nonsquamous histology, and 90% having received IO‐based systemic therapy. Median follow‐up among all/surviving patients were 21.9/29.4 months, respectively. With 138 PFS events from both arms, estimated 1‐yr and 2‐yr PFS rates were 48% (95% CI: 35.9, 59.0) and 36% (95% CI: 24.8, 47.2) in the maintenance systemic therapy arm and 52% (95% CI: 42.5, 59.8) and 40% (95% CI: 31.5, 48.6) in the LCT + maintenance systemic therapy arm, respectively (2‐sided logrank test p‐value = 0.66). Corresponding HR was 0.93 (95% CI: 0.66, 1.31). Of 185 patients treated with IO‐containing regimens, the PFS HR was 0.90 (95% CI: 0.61, 1.32). OS HR between two arms was 1.05 (0.70, 1.56) among all patients and 1.05 (0.68, 1.63) among IO‐treated patients. For adverse events reported as definitely, probably or possibly related to treatment, there were more LCT + maintenance systemic therapy patients with overall grade 2 or higher toxicities (73% vs 84%) and grade 3 or higher pneumonitis (1% vs 10%). Conclusions: LCT added to IO‐based 1st line systemic therapy was associated with a PFS HR of 0.90. Reducing toxicity and increasing biologically‐driven patient selection may optimize this therapeutic ratio.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02736088/full} -} - - -Record #496 of 538 -@article{JPRN-jRCT208022293815, -author = {JPRN-jRCT2080222938,}, -title = {CAURAL}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCT2080222938}, -year = {2015}, -accession_number = {ICTRP JPRN‐jRCT2080222938}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: investigational material(s) Generic name etc : AZD9291, MEDI4736 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : AZD9291: Once daily tablet 80mg, MEDI4736: 10mg/kg q2w (IV) infusion CONDITION: Locally Advanced or Metastatic EGFR T790M+ NSCLC INCLUSION CRITERIA: ‐ Locally advanced/metastatic NSCLC, not amenable to curative surgery or radiotherapy ‐ Confirmation from a previous archival sample that the tumour harbours an EGFR mutation known to be associated with EGFR TKI sensitivity ‐ Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI. Additional other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study ‐ Patients must have central lab confirmation of tumour T790M status from a biopsy taken after disease progression on the most recent treatment regimen. Only patients with T790M+ will be included in the study ‐ At least one lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline as 10mm or more in the longest diameter (except lymph nodes which must ha}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02593617/full} -} - - -Record #497 of 538 -@article{Nishio24, -author = {Nishio, M, Negrao, MV, Arbour, KC, Burns, TF, Cappuzzo, F, Dingemans, A-MC, Girard, N, Gronberg, BH, Hochmair, M, Leal, T, Lindsay, CR, Lu, S, Paz-Ares, LG, Reck, M, Sabari, JK, Spira, AI, William, WN, Chen, A, Grul, CMV, and Peters, S}, -title = {SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12Cmutant advanced NSCLC}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {23}, -year = {2024}, -accession_number = {EMBASE 645166391}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Adult; Brain metastasis; Conference abstract; Controlled study; Drug therapy; Female; Human; Interstitial lung disease; Major clinical study; Malabsorption; Neoplastic cell transformation; Patient‐reported outcome; Phase 3 clinical trial; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Side effect; Surgery; Systemic therapy; Vascular guide wire}, -abstract = {Background: Mutations in KRAS are among the most frequent oncogenic drivers with the G12C variant found in ∼13% of NSCLC. Outcomes for KRAS G12C‐mutant NSCLC may be improved by combining KRAS G12C inhibitors with current 1L standard of care (SOC). Olomorasib is a potent and highly selective second‐generation inhibitor of KRAS G12C, which delivers >90%sustained target occupancy in preclinical models. In the LOXO‐RAS‐20001 phase 1/2 study, olomorasib in combination with pembrolizumab demonstrated preliminary efficacy and a favorable safety profile >1 Methods: SUNRAY‐01 (NCT06119581) is a pivotal, global, phase 3 study in 1L advanced KRAS G12C‐mutated NSCLC designed to seamlessly 1) optimize the dosing of olomorasib in combination with 1L SOC, and then 2) compare efficacy and safety of olomorasib plus SOC with placebo plus SOC. In the open‐label randomized dose optimization (pembrolizumab plus olomorasib 50 mg vs 100 mg BID) and single arm safety lead‐in (olomorasib plus pembrolizumab, pemetrexed, platinum), the optimal dose of olomorasib for combination therapy will be determined before the phase 3 study (parts A and B) is opened for enrollment. In part A, 384 participants with PD‐L1 expression ≥50% are randomized (1:1) to pembrolizumab plus olomorasib or placebo. In part B, 552 participants are randomized (1:1) to pembrolizumab, pemetrexed, platinum plus olomorasib or placebo regardless of PD‐L1 expression. Allocation of participants with PD‐L1 expression≥50% to either part A or part B will be at the discretion of the investigator. The primary objective is to compare efficacy based on PFS per RECIST v1.1 by blinded independent central review. Secondary endpoints include OS, ORR, DOR, DCR, TTR, PFS2, safety and tolerability, and patient‐reported outcomes. Eligible participants (≥18 years) must have a KRAS G12C mutation in tumor or blood and known PD‐L1 expression (0‐100%), stage IIIB, IIIC, or IV NSCLC not suitable for curative intent radical surgery or radiation therapy, measurable disease per RECIST v1.1, and an ECOG PS 0‐1. Participants can be enrolled based on local KRAS and PD‐L1 testing results. Participants should not have received prior systemic therapy for advanced or metastatic NSCLC, however 1 cycle of SOC treatment prior to enrollment is allowed if immediate treatment is clinically indicated. Participants with asymptomatic (lesions≤1.5 cm) or previously treated radiographically stable brain metastases are eligible. Key exclusion criteria include history of pneumonitis/interstitial lung disease and clinically significant active cardiovascular disease or malabsorption syndrome.}, -DOI = {10.1200/JCO.2024.42.23_suppl.TPS218}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02749258/full} -} - - -Record #498 of 538 -@article{Paz-Ares19, -author = {Paz-Ares, L, Senan, S, Planchard, D, Wang, L, Cheong, A, Slepetis, R, Nguyen, MH, and Vokes, EE}, -title = {RATIONALE 001: tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)}, -journal = {Annals of oncology}, -volume = {30}, -pages = {ii67‐}, -year = {2019}, -accession_number = {EMBASE 2005032001, PUBMED 32131325}, -publication type = {Journal article}, -keywords = {*cancer staging; *chemoradiotherapy; *non small cell lung cancer /diagnosis /drug therapy /radiotherapy; Article; Consolidation chemotherapy; Controlled study; Double blind procedure; Drug efficacy; Drug safety; Human; Major clinical study; Monotherapy; Neuroimaging; Phase 3 clinical trial; Positron emission tomography‐computed tomography; Priority journal; Protein expression; Randomized controlled trial; Tumor volume}, -DOI = {10.1093/annonc/mdz063.083}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02095678/full} -} - - -Record #499 of 538 -@article{Spigel21, -author = {Spigel, DR, Peters, S, Ahn, M-J, Tsuboi, M, Chaft, J, Harpole, D, Barlesi, F, Abbosh, C, Mann, H, May, R, Dennis, PA, and Swanton, C}, -title = {93TiP MERMAID-2: phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy}, -journal = {Journal of thoracic oncology}, -volume = {16}, -number = {4}, -pages = {S745‐S746}, -year = {2021}, -accession_number = {EMBASE 2011485930}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *cancer staging; *non small cell lung cancer; Adjuvant chemotherapy; Adult; Advanced cancer; Aptitude; Awards and prizes; Bicycle; Biotechnology; Cancer adjuvant therapy; Cancer center; Cancer immunotherapy; Cancer recurrence; Cancer surgery; Cancer survival; Catalyst; Chemoradiotherapy; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Disease free survival; Double blind procedure; Dream; Drug safety; Drug therapy; Eligibility; England; Entertainment industry; European Union; Expert witness; Flame; Funding; Gene expression; Genetic susceptibility; Heterozygosity loss; Histopathology; Human; Human tissue; Indel mutation; Japan; Licence; Major clinical study; Male; Medical literature; Minimal residual disease; Multicenter study; Neoadjuvant therapy; New York; Nonhuman; Overall survival; Parttime employment; Patent; Patient‐reported outcome; Pharmacokinetics; Phase 3 clinical trial; Physician; Practice guideline; Progression free survival; Protein expression; Proteus; Radiotherapy; Randomized controlled trial; Signal transduction; Survival rate; Transgene; Translational research; Trust; Tumor cell; Tumor recurrence; Wild type}, -abstract = {Background: In patients with resected, stage II‐III NSCLC, the 5‐year disease‐free survival (DFS) rate with SoC adjuvant chemotherapy is 40%. Despite advances with immunotherapy (IO) in the metastatic setting, overall survival (OS) rates for patients with recurrence remain low. Detection of minimal residual disease (MRD), as indicated by circulating tumor DNA (ctDNA), may indicate the presence of clinically indiscernible residual tumor following curative‐intent therapy and enable earlier therapeutic intervention, thereby improving outcomes in patients at highest risk of recurrence. In the phase III PACIFIC trial, consolidation durvalumab improved survival outcomes in patients with unresectable, stage III NSCLC without detectable disease progression after curative‐intent chemoradiotherapy (Antonia, 2018), suggesting MRD is vulnerable to additional therapy, particularly IO, a concept supported by recent data in MRD+ patients (Moding, 2020). MERMAID‐2 will assess the efficacy and safety of durvalumab, versus placebo, in patients with resected, stage II‐III NSCLC who become MRD+ after curative‐intent therapy. Trial design: MERMAID‐2 (NCT04642469) is a global, phase III, double‐blind multicenter study that is currently recruiting patients. Patients with histologically confirmed EGFR/ALK wild‐type stage II‐III NSCLC who have completed curative‐intent therapy (complete resection + optional neoadjuvant and/or adjuvant therapy) will be enrolled in a 96‐week surveillance period. During this period, patients will be monitored regularly for MRD emergence via ctDNA analysis of plasma samples, based on personalized MRD panels. Patients who become MRD+ during the surveillance period will be further evaluated to confirm eligibility (no disease recurrence visible on imaging; known PD‐L1 status) and 284 MRD+ patients will be randomized 1:1 to receive durvalumab 1500 mg IV or placebo q4w, up to 24 months or until investigator‐assessed disease recurrence. The primary endpoint is DFS in patients with PD–L1 tumor cell expression ≥1%. Secondary endpoints include DFS in the full analysis set, progression‐free survival, OS, time to subsequent therapy, patient‐reported outcomes, and safety. Clinical trial identification: NCT04642469. Editorial acknowledgement: Medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Andrew Gannon and Connor Keating of Cirrus Communications (New York, NY), an Ashfield company, and was funded by AstraZeneca. Legal entity responsible for the study: AstraZeneca. Funding: AstraZeneca. Disclosure: D.R. Spigel: Research grant/Funding (institution), Conduct of clinical trials and consultancy: AstraZeneca/BMS/Celgene/EMD Serono/Roche/Genetech/GSK/Ipsen/Novartis/Takeda; Research grant/Funding (institution), Conduct of clinical trials: Aeglea Biotherapeutics/Agios/Astellas Pharma/ BIND Therapeutics/Celldex Therapeutics/Clovis/ Daiichi Sankyo/Eisai/Eli Lilly/ G1 Therapeutics/GRAIL; Research grant/Funding (institution), Conduct of clinical trials: ImClone Systems/Janssen/MedImmune/Merck/ Nektar Therapeutics/ Neon Therapeutics/Tesaro/ Transgene/UT Southwestern/Cyteir Therapeutics/ Apollomics/Elevation Oncology; Research grant/Funding (institution), Payment to institution for consulting services: Aptitude Health/Bayer/Dracen Pharmaceuticals/Exelixis/Iksuda Therapeutics/ Intellisphere/ Jazz Pharmaceuticals/ Mirati Therapeutics/ Molecular Templates /Puma Biotechnology. S. Peters: Advisory/Consultancy, Personal fees (advisory board and honorarium): AbbVie/Amgen/AstraZeneca/Bayer/Biocartis/Boehringer Ingelheim/Bristol‐Myers Squibb/Clovis/Daiichi Sankyo/ Debiopharm/Eli Lilly/F, Hoffman‐La Roche/Foundation Medicine/Illumina/Janssen/MSD/Merck Serono/ Merrimack/Novartis; Advisory/Consultancy, Personal fees (advisory board and honorarium): Pharma Mar/ Pfizer/Regeneron/Bioinvent/Sanofi/Seattle Genetics and Takeda; Speaker Bureau/Expert testimony, Personal fees (talks and honorarium): AstraZeneca/Boehringer Ingelheim/ Bristol‐Myers Squibb/Eli Lilly/F. Hoffmann la Roche/MSD/Novartis/Pfizer/Takeda/Sanofi; Research grant/Funding (self), Non‐financial support for clinical trial investigation: Amgen/AstraZeneca/Boehringer Ingelheim/ Bristol‐Myers Squibb/Clovis/F. Hoffmann‐La Roche/Illumina/MSD/Merck Serono/Novartis /Pfizer. M. Tsuboi: Advisory/Consultancy, Personal fees for advisory boards and lectures: AstraZeneca KK/Chugai Pharmaceutical/MSD; Advisory/Consultancy, Personal fees for advisory boards: Novartis; Research grant/Funding (self), Personal fees for lectures: Medtronic Japan/ONO Pharmaceutical/Johnson & Johnson Japan/Eli Lilly Japan/Bristol‐Myers Squibb KK/Teijin Pharma/Taiho Pharma; Research grant/Funding (institution), Research funding: Boehringer Ingelheim Japan; Research grant/Funding (institution), Commissioned research for clinical trials: MSD/AstraZeneca KK/ONO Pharmaceutical/ Bristol‐Myers Squibb KK/Eli Lilly Japan. J. Chaft: Advisory/Consultancy: AstraZeneca/Bristol‐Myers Squibb/Genentech/Flame Biosciences/Merck. D. Harpole: Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy: AstraZeneca/Medtronic. F. Barlesi: Research grant/Funding (self), Personal fees: AstraZeneca/Bayer/Bristol‐Myers Squibb/Boehringer Ingelheim/Eli Lilly Oncology; Research grant/Funding (self), Personal fees: F. Hoffmann–La Roche Ltd/Novartis/Merc/MSD/Pierre Fabre/Pfizer/Takeda. C. Abbosh: Advisory/Consultancy: AstraZeneca; Speaker Bureau/Expert testimony: Bristol‐Myers Squibb; Research grant/Funding (self), Contracted/support research grant: AstraZeneca; Research grant/Funding (institution), Current AstraZeneca Physician Fellow (grant to University College London): AstraZeneca; Licensing/Royalties, Royalty/intellectual property/patent holder ‐ author on two pending patents: AstraZeneca. H. Mann: Full/Part‐time employment: AstraZeneca. R. May: Full/Part‐time employment: AstraZeneca. P.A. Dennis: Full/Part‐time employment: AstraZeneca; Shareholder/Stockholder/Stock options: AstraZeneca. C. Swanton: Honoraria (self), Research grant/Funding (self), Chief Investigator for the MeRmaiD1 clinical trial: AstraZeneca; Advisory/Consultancy, Chief Investigator for the MeRmaiD1 clinical trial: AstraZeneca; Honoraria (self), Research grant/Funding (self): Bristol‐Myers Squibb; Honoraria (self), Research grant/Funding (self): Pfizer; Honoraria (self), Research grant/Funding (self): Roche‐Ventana; Honoraria (self), Research grant/Funding (self): Ono Pharmaceutical; Research grant/Funding (self), collaboration in minimal residual disease sequencing technologies: Archer Dx Inc; Research grant/Funding (self): Boehringer Ingelheim; Honoraria (self): Novartis; Honoraria (self): GSK; Honoraria (self): Celgene; Honoraria (self): MSD; Honoraria (self): Illumina; Honoraria (self): Genentech; Honoraria (self): Sarah Cannon Research Institute; Honoraria (self): Medixci; Honoraria (self): Bicycle Therapeutics; Shareholder/Stockholder/Stock options: GRAIL; Shareholder/Stockholder/Stock options: Apogen Biotechnologies; Shareholder/Stockholder/Stock options: Epic Biosciences; Honoraria (self), Shareholder/Stockholder/Stock options: Achilles Therapeutics; Intellectual property [patents issued]: Assay technology to detect tumour recurrence (PCT/GB2017/053289), Targeting neoantigens (PCT/EP2016/059401), Identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), Determining HLA LOH (PCT/GB2018/052004), Predicting survival rates of patients with cancer (PCT/GB2020/050221), Identifying patients who respond to cancer treatment (PCT/GB2018/051912), Detecting tumour mutations (PCT/US2017/28013), Insertion/deletion mutation targets (PCT/GB2018/051892); Other: Charles Swanton is Royal Society Napier Research Professor (RP150154). His work is supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001169), the UK Medical Research Council (FC001169) and the Wellcome Trust (FC001169). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Charles Swanton is funded by Cancer Research UK (TRACERx, PEACE and CRUK Cancer Immunotherapy Catalyst Network), Cancer Research UK Lung Cancer Centre of Excellence, the Rosetrees Trust, Butterfield and Stoneygate Trusts, NovoNordisk Foundation (ID16584), Royal Society Research Professorship Enhancement Award (RP/EA/180007), the NIHR BRC at University College London Hospitals, the CRUK‐UCL Centre, Experimental Cancer Medicine Centre and the Breast Cancer Research Foundation, USA (BCRF). His research is supported by a Stand Up To Cancer‐LUNGevity‐American Lung Association Lung Cancer Interception Dream Team Translational Research Grant (SU2C‐AACR‐DT23–17). Stand Up To Cancer is a programme of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C. Charles Swanton also receives funding from the European Research Council (ERC) under the European Union's Seventh Framework Programme (FP7/2007–2013) Consolidator Grant (FP7‐THESEUS‐617844), European Commission ITN (FP7‐PloidyNet 607722), an ERC Advanced Grant (PROTEUS) from the European Research Council under the European Union's Horizon 2020 research and innovation programme (835297) and Chromavision from the European Union's Horizon 2020 research and innovation programme (665233). All other authors have declared no conflicts of interest.}, -DOI = {10.1016/S1556-0864(21)01935-3}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02303998/full} -} - - -Record #500 of 538 -@article{Kelly16, -author = {Kelly, K, Patel, M, Infante, JR, Iannotti, N, Nikolinakos, P, Leach, J, Wang, D, Chandler, J, Jerusalem, G, Gurtler, J, Arkenau, H-T, Bajars, M, Von Heydebreck, A, Speit, I, Heery, CR, and Gulley, JL}, -title = {Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase Ib JAVELIN Solid Tumor trial}, -journal = {Cancer research}, -volume = {76}, -number = {14}, -year = {2016}, -accession_number = {EMBASE 613609459}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; *safety; Acute liver failure; Adult; Adverse drug reaction; Aged; Anemia; Autoimmune hepatitis; Breast; Cancer epidemiology; Cancer therapy; Cause of death; Clinical trial; Colitis; Controlled clinical trial; Controlled study; Disease course; Drug therapy; Drug withdrawal; Fatigue; Female; Gene expression; Human; Hypothyroidism; Infusion; Major clinical study; Ovary; Pharmacokinetics; Phase 1 clinical trial; Phase 3 clinical trial; Radiation pneumonia; Respiratory distress; Side effect; Stomach; Toxicity; Treatment duration}, -abstract = {Background: The programmed death‐1 receptor (PD‐1) and its ligand (PD‐L1) are key therapeutic targets in the reactivation of the immune response against multiple cancers. Avelumab∗ (MSB0010718C) is a fully human antiPD‐L1 IgG1 antibody currently being investigated in clinical trials. The primary objective of this phase Ib, open‐label expansion study (NCT01772004) was to assess the safety and tolerability of avelumab in patients (pts) with locally advanced or metastatic (LA/M) solid tumors. Methods: Pts from 16 different expansion cohorts (including NSCLC, gastric, ovarian, urothelial, and breast; ECOG performance status [PS] of 01 at trial entry) and unselected for PD‐L1 expression were treated with avelumab at 10 mg/kg IV, Q2W until confirmed progression, unacceptable toxicity, or any criteria for withdrawal occurred. Adverse events (AEs) were graded by NCI‐CTCAE v4.0. Results: As of Aug 4, 2015, 900 pts were treated with avelumab and followed for ?4 wks. Median age was 62 years (range, 23‐91), ECOG PS was 0 (39.1%), 1 (60.6%), or 23 (0.2%), and median number of prior lines of anticancer therapy was 2 (range, 113). Median duration of treatment with avelumab and number of administrations were 10.0 wks (range, 292) and 5 infusions (range, 143), respectively. Treatment‐related (TR) AEs of any grade occurred in 585 pts (65.0%). Grade ?3 TRAEs occurred in 91 pts (10.1%). The most frequent (?0.5%) grade ?3 TRAEs were IRRs (n = 8, 0.9%), GGT elevation (n = 7, 0.8%), lipase elevation (n = 7, 0.8%), anemia (n = 7, 0.8%), and fatigue (n = 6, 0.7%). Seventyfive pts (8.3%) experienced potential immune‐related (ir) TRAEs, with hypothyroidism (n = 34, 3.8%) and pneumonitis (n = 8, 0.9%) occurring most frequently (?0.5%). Grade ?3 potential irTRAEs were reported for 17 pts (1.9%); the most frequent (?0.3%) were autoimmune hepatitis (n = 4; 0.4%), colitis (n = 3; 0.3%), and pneumonitis (n = 3; 0.3%). TRAEs resulted in permanent treatment discontinuation for 64 pts (7.1%); 2.6% (n = 23) discontinued due to an IRR and 1.3% (n = 12) discontinued due to a potential irTRAE. TRAEs were considered the primary cause of death by the investigator for 4 pts (0.4%): radiation pneumonitis (1), autoimmune hepatitis (1), acute liver failure (1), and respiratory distress (1). Conclusion: Singleagent avelumab shows an acceptable safety profile in a heavily pretreated population of pts with LA/M malignancies. To date, >1,500 pts have been enrolled in the JAVELIN Solid Tumor clinical trial. Additional safety and efficacy analyses from this study are ongoing, and recruitment to several phase III trials is underway.}, -DOI = {10.1158/1538-7445.AM2016-CT132}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01294364/full} -} - - -Record #501 of 538 -@article{Lu20, -author = {Lu, S, Casarini, I, Kato, T, Dols, MC, Ozguroglu, M, Zeng, L, van der Gronde, T, Saggese, M, and Ramalingam, S}, -title = {374TiP LAURA: osimertinib maintenance following definitive chemoradiation therapy (CRT) in patients (pts) with unresectable stage III epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC)}, -journal = {Annals of oncology}, -volume = {31}, -pages = {S1385}, -year = {2020}, -accession_number = {EMBASE 2008603838}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer patient; *cancer staging; *chemoradiotherapy; *gene mutation; *non small cell lung cancer; Adult; Advanced cancer; Cancer survival; Central nervous system; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Creatinine clearance; Double blind procedure; Drug safety; Drug therapy; Expert witness; Female; Follow up; Funding; Human; Japan; Licensing; Maintenance therapy; Male; Parttime employment; Pharmacokinetics; Progression free survival; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors}, -abstract = {Background: Platinum‐based CRT followed by durvalumab consolidation (PACIFIC study regimen) is standard of care for pts with unresectable Stage III NSCLC, without progression after platinum‐based CRT. In PACIFIC, only 6% of pts had EGFRm NSCLC. Osimertinib is a 3rd‐generation, CNS‐active, oral, irreversible EGFR tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR‐TKI sensitizing and EGFR T790M resistance mutations. FLAURA data (median OS: HR 0.80; 95.05% CI 0.64, 1.00; P=0.046) indicate osimertinib could provide benefit to pts with unresectable Stage III NSCLC. LAURA (NCT03521154) will assess the efficacy and safety of osimertinib as maintenance therapy in pts with locally advanced, unresectable, EGFRm, Stage III NSCLC without disease progression during/following definitive platinum‐based CRT. Previously presented: WCLC, Shun L et al. 2018 J Thorac Oncol;13(10 suppl):S497; we report protocol updates (Feb 2020). Trial design: In this Ph III, double blind, placebo‐controlled trial, pts will be randomized (2:1) to osimertinib 80 mg/day or placebo, until objective radiological disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, confirmed by blinded independent central review (BICR). Key inclusion criteria: ≥18 years (≥20 Japan); locally advanced unresectable Stage III NSCLC; central/local confirmation of Ex19del/L858R; WHO PS 0–1; ≥2 cycles of concurrent/sequential platinum‐based CRT; no investigator‐assessed (IA) progression; creatinine <1.5x ULN and creatinine clearance ≥30 mL/min. Primary objective: to assess the efficacy of osimertinib by BICR progression‐free survival (PFS). Secondary objectives: PFS by mutation status, CNS PFS, OS and safety. Pts with BICR‐confirmed disease progression (IA‐confirmed if after PFS analysis) may be un‐blinded to receive open‐label osimertinib; all will have post‐progression follow‐up. Serious adverse events (SAEs) and AEs of special interest will be collected throughout the study and survival follow‐up. First pt enrolled July 2018; results expected late 2022. Clinical trial identification: NCT03521154. Legal entity responsible for the study: AstraZeneca. Funding: AstraZeneca. Disclosure: S. Lu: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Hutchison MediPharma; Advisory/Consultancy: Simcere; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): Roche; Advisory/Consultancy: GenomiCare; Research grant/Funding (self): Hutchison; Research grant/Funding (self): Bristol Myers Squibb; Research grant/Funding (self): Heng Rui; Speaker Bureau/Expert testimony: Hansoh. T. Kato: Advisory/Consultancy, Speaker Bureau/Expert testimony: Amgen; Advisory/Consultancy, Speaker Bureau/Expert testimony: AbbVie; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eli Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck Biopharma; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony: Ono; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy: Nippon Kayaku; Advisory/Consultancy: Nitto Denko; Advisory/Consultancy: Takeda; Speaker Bureau/Expert testimony: Boehringer Ingelheim; Speaker Bureau/Expert testimony: Bristol‐Myers Squibb; Speaker Bureau/Expert testimony: Chugai; Speaker Bureau/Expert testimony: Taiho, Daiichi‐Sankyo, F. Hoffmann‐La Roche, Shionogi, Sumitomo Dainippon; Licensing/Royalties: Astellas, Kyorin, Kyowa‐Kirin, Regeneron; Research grant/Funding (self), Personal fees: AstraZeneca. M. Özgüroğlu: Honoraria (self), Honoraria (institution), Advisory/Consultancy: Janssen; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Sanofi; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Astellas; Honoraria (self), Honoraria (institution): Novartis; Honoraria (self), Honoraria (institution): Roche. L. Zeng: Shareholder/Stockholder/Stock options, Full/Part‐time employment: AstraZeneca. T. van der Gronde, M. Saggese: Full/Part‐time employment: AstraZeneca. S. Ramalingam: Advisory/Consultancy, Research grant/Funding (self): Amgen; Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy, Research grant/Funding (self): BMS; Advisory/Consultancy, Research grant/Funding (self): Genentech; Advisory/Consultancy, Research grant/Funding (self): Merck; Advisory/Consultancy, Research grant/Funding (self): Tesaro; Advisory/Consultancy, Research grant/Funding (self): Takeda; Research grant/Funding (self): Advaxis; Research grant/Funding (self): Genmab. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2020.10.367}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02202179/full} -} - - -Record #502 of 538 -@article{Wu22, -author = {Wu, L, and Fang, Y}, -title = {EP08.02-160 A Pooled Efficacy and Safety Analysis of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Immunotherapy}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S482‐S483}, -year = {2022}, -accession_number = {EMBASE 2020097354}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *drug safety; *immunotherapy; *non small cell lung cancer; Adult; Cancer patient; Chemotherapy; Clinical laboratory; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Demographics; Drug combination; Drug therapy; Female; Human; Leukopenia; Major clinical study; Male; Multicenter study; Neutropenia; Oral mucositis; Overall response rate; Phase 2 clinical trial; Physical examination; Pneumonia; Randomized controlled trial; Risk assessment}, -abstract = {Introduction: Immune checkpoint inhibitors (ICIs) are widely used in 1st ‐line or 2nd ‐line treatment of advanced NSCLC, but effective treatment after resistance to ICIs is still controversial. We previously reported that anlotinib plus docetaxel as 2nd‐line treatment in advanced NSCLC showed better clinical efficacy than docetaxel alone in two phase II trials (ALTER‐L016, ALTER‐L018). Therefore, to further assess the efficacy and safety of anlotinib plus docetaxel in advanced NSCLC patients (pts) who had been pre‐treated with ICIs by pooling raw data from the two phase II trials. Methods: Efficacy and safety data from 2 multi‐institutional, randomized, controlled comparative, phase II trials of 73 advanced NSCLC pts who had progressed after 1st‐line platinum‐based chemotherapy were pooled for this analysis. The studies shared similar dosing intervals and doses, pts were randomly allocated to receive anlotinib (10/12 mg QD from day 1 to 14 of a 21‐day cycle) plus docetaxel (60/75 mg/m2 Q3W) (group A+D) or docetaxel (60/75 mg/m2 Q3W) only (group D). Safety assessments included adverse events (AEs), physical examination and clinical laboratory tests. [Clinical Trials Registration. NCT03726736 and NCT03624309.]. Results: At data cut‐off (Mar 1, 2022), 73 pts. were available for efficacy and safety analysis (demographics are shown in Table 1). The median PFS was 7.60 months (95%Cl: 4.44‐10.76) vs 2.50 months (95%Cl: 1.34‐3.66) in group A+D and group D, respectively (HR: 0.28; 95%Cl: 0.15‐0.53, p<0.0001). The median OS has not been reached. For tumor response, the ORR was 34.88% vs 12.50% (p=0.048) and the DCR was 93.02% vs 62.50% (p=0.002) in group A+D and group D, respectively. The adverse events that possibly or definitely related to therapy occurred in 38 (88%) of pts. experienced total of 43 grade 1‐2 adverse events in group A+D, and in 21 (70%) of pts. experienced total of 30 grade 1‐2 adverse events in group D. The most common grade ≥3 TRAEs were neutropenia (5, 12%), leukopenia (2, 7%), and oral mucositis (1, 2%) in group A+D, and leukopenia (1, 3%), pneumonia (1, 3%) in group D. Conclusions: Anlotinib plus docetaxel exhibited clinically meaningful efficacy and a manageable safety profile in advanced NSCLC pts who had been pre‐treated with ICIs, which might be an especially effective option in this setting. [Formula presented] Keywords: anlotinib, NSCLC, pre‐treated with immunotherapy}, -DOI = {10.1016/j.jtho.2022.07.843}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461449/full} -} - - -Record #503 of 538 -@article{Hui17, -author = {Hui, R, and Antonia, SJ}, -title = {Clinical activity, patient-reported outcomes, and safetywith durvalumab after chemoradiation in locally advanced, unresectable NSCLC: pacific study}, -journal = {Asia-Pacific journal of clinical oncology}, -volume = {13}, -pages = {145}, -year = {2017}, -accession_number = {EMBASE 619351256}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *non small cell lung cancer; *patient‐reported outcome; *response evaluation criteria in solid tumors; Adult; Cancer staging; Cancer survival; Clinical trial; Controlled study; Death; Distant metastasis; Double blind procedure; Drug therapy; Female; Follow up; Human; Major clinical study; Male; Overall survival; Pharmacokinetics; Phase 3 clinical trial; Pneumonia; Progression free survival; Radiotherapy; Randomized controlled trial; Reaction time; Smoking; Visually impaired person}, -abstract = {Background: Most patients with locally advanced, unresectable nonsmall cell lung cancer (NSCLC) progress despite standard platinumbased, concurrent chemoradiation therapy (cCRT).We report interim results for clinical activity, patient‐reported outcomes (PROs), and safety from a global, Phase 3 study (NCT02125461) of durvalumab as consolidation therapy in Stage III patients. Methods: In this double‐blind study, patients with WHO PS 0/1 (any PD‐L1 status) who received ≥2 platinum‐based cCRT cycles without progression were randomized (2:1) 142 days post‐cCRT to durvalumab 10 mg/kg IV Q2W or placebo up to 12 months, stratified by age, sex, and smoking history. Co‐primary endpointswere progression‐free survival (PFS; blinded independent central review, RECIST v1.1) and overall survival (OS). Secondary endpoints included 12‐and 18‐month PFS rates, objective response rate (ORR), duration of response (DoR), time to death or distant metastasis (TTDM), PROs (EORTC QLQ‐C30 and QLQ‐LC13) and safety. Results: Of 713 randomized patients, 709 received treatment (durvalumab, n=473; placebo, n=236). Baseline characteristics were well balanced. At cutoff, median follow‐up was 14.5 months. Median PFS from randomizationwas significantly longer with durvalumab (16.8 months, 95% CI, 13.0‐18.1) versus placebo (5.6 months, 95% CI, 4.6‐7.8; stratified HR 0.52, 95% CI, 0.42‐0.65; P<0.0001). 12‐and 18‐month PFS rates were 55.9% versus 35.3% and 44.2% versus 27.0%, respectively. ORR was higher (28.4% vs 16.0%; P<0.001) and median DoR longer (not reached vs 13.8 months) with durvalumab. Median TTDM was longer with durvalumab (23.2 vs 14.6 months; stratified HR 0.52, 95% CI, 0.390.69; P<0.0001). OS data were immature. Comparing durvalumab with placebo, grade 3/4 AEs occurred in 29.9% and 26.1%; most common was pneumonia (4.4% vs 3.8%). 15.4% and 9.8% discontinued due to AEs. PROs will be presented. Conclusions: Durvalumab demonstrated a statistically significant, robust improvement in PFS, supported by secondary endpoints. No new safety signals were identified.}, -DOI = {10.1111/ajco.12799}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01428063/full} -} - - -Record #504 of 538 -@article{Cooke21, -author = {Cooke, S, de Ruysscher, D, Reymen, B, Lambrecht, M, Persson, GF, Faivre-Finn, C, Dieleman, EM, van Diessen, J, Sikorska, K, Lalezari, F, Sonke, JJ, and Belderbos, J}, -title = {Sites of First Progression in the Randomized PET-Boost Trial for Patients With Locally Advanced NSCLC}, -journal = {International journal of radiation oncology biology physics}, -volume = {111}, -number = {3}, -pages = {S91}, -year = {2021}, -accession_number = {EMBASE 2014606572}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *non small cell lung cancer; Adjuvant chemotherapy; Adult; Atelectasis; Cancer chemotherapy; Cancer recurrence; Cancer staging; Cancer surgery; Cancer survival; Clinical trial; Cohort analysis; Conference abstract; Controlled study; Cumulative incidence; Distant metastasis; Female; Fibrosis; Follow up; Gross tumor volume; Human; Immunotherapy; Inflammation; Kaplan Meier method; Major clinical study; Male; Maximum standardized uptake value; Multicenter study; Overall survival; Phase 2 clinical trial; Positron emission tomography‐computed tomography; Primary tumor; Randomized controlled trial; Risk assessment; Thorax; X‐ray computed tomography}, -abstract = {Purpose/Objective(s): Curative intent conventional chemoradiotherapy for patients with locally advanced NSCLC is typically associated with high progression rates. In the PET‐Boost trial, individualized dose escalation utilizing hypofractionation and functional imaging was tested as a strategy to improve local control. Here we report on sites of first recurrence. Materials/Methods: We conducted a multi‐institutional phase II study (NCT01024829). Patients with stage II‐III NSCLC were randomized to receive either a boosted dose to the primary tumor (PT) as a whole (arm A) or to a region inside the PT with high FDG‐uptake (> 50%SUVmax) (arm B). Boosted dose was delivered in 24 fractions of 3.0 Gy up to 5.4 Gy, limited by predefined OAR limits. Individualized isotoxic treatment plans were produced by equalizing the mean lung dose. Concurrent/sequential/no chemotherapy was allowed. This trial was conducted before immunotherapy became standard adjuvant treatment. Follow‐up (PET/)CT‐scans were scheduled at 3, 6, 12 and 18‐months. The trial had a phase II, “pick the winner”, non‐comparative design with freedom from local failure rate at 1‐year as primary endpoint. Overall survival was estimated using the Kaplan‐Meier method. Local and regional failures (LF, RF) were assessed by central review of chest‐CT scans. Distant metastases (DM) were reported by local investigators. LF, RF and DM are reported as site of first recurrence. Cumulative incidence rates of first recurrence site were, in competing risk with death, estimated by Aalen‐Johansen method. Results: Between April 2010 and Sept 2017, 54 patients were randomized to arm A and 53 to arm B. Majority of patients had a good performance status (WHO 0‐1, 93%), stage III disease (82%) and were treated with concurrent‐chemotherapy (72%). In arms A and B respectively, median PT GTV was 99 cc (IQR 67‐175) and 115 cc (IQR 64‐179). Median fraction dose was 3.25 Gy to PTVwhole PT and 3.5 Gy to PTV50%SUVmax, resulting in median total planned physical dose 78 Gy and 84 Gy respectively. Central review identified 9 patients with missing scans, and 8 not‐evaluable scans at 1 year (n = 4 due to surgery, n = 4 due to atelectasis, inflammation or fibrosis). Median FU for LF and RF was 12.6 months. At time of analysis, 36 and 39 patients had experienced a recurrence or died. In arms A and B respectively, the 1‐year cumulative incidence rates (reported with 95% CI) for LF as site of first recurrence were 1.9% (0‐6%) and 1.9% (0‐6%), for RF 1.9% (0‐6%) and 5.7% (0‐12%), for DM 37.4% (24‐50%) and 35.8% (23‐49%), and for simultaneous multiple sites 3.7% (0‐8%) and 1.9% (0‐6%). Median FU for OS was 70.4 months. In arms A and B respectively, estimated 1‐year survival was 77% and 62%. Conclusion: While high local control rates were achieved in this phase II trial of hypofractionated dose escalation in patients with stage II‐III NSCLC, distant metastases were frequently seen in this patient cohort with large primary tumors.}, -DOI = {10.1016/j.ijrobp.2021.07.215}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02321741/full} -} - - -Record #505 of 538 -@article{Wakelee17, -author = {Wakelee, HA, Altorki, NK, Vallieres, E, Zhou, C, Zuo, Y, Howland, M, Xia, F, Sandler, A, and Felip, E}, -title = {A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: iMpower010}, -journal = {Journal of clinical oncology}, -volume = {35}, -number = {15}, -year = {2017}, -accession_number = {EMBASE 644257599}, -publication type = {Journal article; Conference proceeding}, -keywords = {*adjuvant chemotherapy; *non small cell lung cancer; Adult; Antineoplastic activity; Cancer inhibition; Cancer surgery; Conference abstract; Controlled study; Drug combination; Drug therapy; Female; Human; Immunocompetent cell; Intravenous drug administration; Open study; Patient history of chemotherapy; Phase 3 clinical trial; Phase 4 clinical trial; Radiotherapy; Surgery; Tumor immunity}, -abstract = {Background: The anti‐PD‐L1 mAb atezo blocks the interaction between PD‐L1 and its receptors PD‐1 and B7.1 and restores anti‐tumor immunity. In the OAK trial, pts with 2L/3L advanced NSCLC had improved mOS in the atezo arm (13.8 mo) vs the docetaxel (doc) arm (9.6 mo), with a survival benefit observed regardless of PD‐L1 expression levels on tumor cells (TC) or tumor‐infiltrating immune cells (IC). However, more effective treatment options are needed for pts with early‐stage NSCLC. A global Phase III, randomized, open‐label trial, IMpower010 (NCT02486718), is being conducted to evaluate the efficacy and safety of atezo vs BSC following adjuvant cisplatin (cis)‐based chemotherapy (chemo) in pts with resected stage IB (tumors ≥ 4 cm)‐IIIA NSCLC. Methods: Pts eligible for study must have complete tumor resection 4 to 12 weeks prior to enrollment for pathologic stage IB (tumors ≥ 4 cm)‐IIIA NSCLC, be adequately recovered from surgery, be able to receive cis‐based adjuvant chemo and have an ECOG PS 0‐1. Pts with other malignancies, autoimmune disease, hormonal cancer or radiation therapy within 5 years and prior chemo or immunotherapy are excluded from study. Approximately 1127 pts will be enrolled regardless of PD‐L1 status. Pts will receive up to four 21‐d cycles of cis‐based chemo (cis [75 mg/m2 IV, d 1] + vinorelbine [30 mg/m2 IV, d 1, 8], doc [75 mg/m2 IV, d 1] or gemcitabine [1250 mg/m2 IV, d 1, 8], or pemetrexed [500 mg/m2 IV, d 1; only non‐squamous NSCLC]). No adjuvant radiation therapy is permitted. After adjuvant chemo, eligible pts will be randomized 1:1 to receive 16 cycles of atezo 1200 mg q3w or BSC. Stratification factors include sex, histology (squamous vs non‐squamous), disease stage (IB vs II vs IIA) and PD‐L1 status by IHC (TC2/3 [≥ 5% expressing PD‐L1] and any IC vs TC0/1 [ < 5%] and IC2/3 vs TC0/1 and IC0/1 [ < 5%]). The primary endpoint is disease‐free survival; secondary endpoints include OS and safety. Exploratory biomarkers, including PD‐L1 expression, immune‐ and tumor‐related biomarkers before, during and after treatment with atezo and at radiographic disease recurrence, or confirmation of new primary NSCLC, will be evaluated.}, -DOI = {10.1200/JCO.2017.35.15-suppl.TPS8576}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02702859/full} -} - - -Record #506 of 538 -@article{Fidias17, -author = {Fidias, P}, -title = {Maintenance therapy versus early second-line therapy in advanced NSCLC}, -journal = {Journal of thoracic oncology}, -volume = {12}, -number = {1}, -pages = {S167‐S169}, -year = {2017}, -accession_number = {EMBASE 615339583}, -publication type = {Journal article; Conference proceeding}, -keywords = {*chemoradiotherapy; *injection; *maintenance chemotherapy; *median survival time; *non small cell lung cancer; *overall survival; Asian; Cell line; Clinical trial; Controlled clinical trial; Controlled study; Disease model; Drug combination; Drug resistance; Drug therapy; Gene mutation; Gene silencing; Histology; Human; Human cell; Human tissue; Major clinical study; Phase 3 clinical trial; Randomized controlled trial; Squamous cell; Symptom}, -abstract = {Several trials have evaluated the appropriate initial duration of platinum based chemotherapy: 3 versus 6 cycles, 4 versus continuous cycles, or 2 versus 4 cycles after non‐progression to the initial 2 treatments. In all situations there was no benefit to longer duration of chemotherapy and both ASCO and NCCN recommend no more than 6 cycles of initial treatment. Continuation of lower intensity therapy (typically with a single agent from the initial doublet) was also tested. Studies of weekly paclitaxel after carboplatin‐paclitaxel (Belani et al) or gemcitabine after cisplatin‐gemcitabine (Brodowicz et al) showed no OS difference, but a possible benefit in PFS. Studies evaluated the introduction of a non‐cross resistant agent (early second line) in patients without progression after initial chemotherapy. Westeel et al. randomized patients after MIC x 3 to either observation versus vinorelbine; Fidias et al. evaluated immediate versus delayed docetaxel after carboplatingemcitabine x 4 and JMEN study looked into pemetrexed versus placebo after four cycles of platinum doublet. For the latter two studies, about 50% of patients completed 6 maintenance cycles and 50‐60% of patients in the observation arm received second line therapy; this is consistent with rates of second line therapy in multiple studies of NSCLC. Results showed a 2‐3 month difference in PFS favoring immediate therapy. In terms of overall survival, there was no difference with vinorelbine, and a 2.6‐2.8 month difference with either docetaxel or pemetrexed (significant only with pemetrexed). QoL was not affected by continuous chemotherapy and tumor related symptoms improved with pemetrexed. Erlotinib has been evaluated in 3 randomized trials against placebo (SATURN), observation (IFCT‐GFPC 0502) or in combination with bevacizumab against placebo‐bevacizumab (ATLAS). In all studies there was a PFS benefit (HR 0.71‐0.82), but OS was only significant in the SATURN trial (HR 0.81). PFS benefit was limited to non‐squamous histology for pemetrexed, as opposed to the docetaxel and erlotinib trials. Despite the initial negative trials, continuation pemetrexed following platinum‐pemetrexed doublet has emerged as a standard option for non‐squamous NSCLC. PARAMOUNT randomized between pemetrexed and placebo following four cycles of cisplatin pemetrexed. It showed a PFS benefit (HR 0.64) and also an OS benefit (2.9 month difference, HR 0.78) in favor of continuation maintenance. AVAPERL used a similar design, however with the addition of bevacizumab throughout therapy, i.e. initial cisplatin‐pemetrexedbevacizumab followed by pemetrexed‐bevacizumab versus bevacizumab. PFS significantly favored pemetrexed (10.2 versus 6.6 months), and although OS was also superior (19.8 versus 15.9 months) it was not statistically significant. The IFCT‐GFPC 0502 trial also evaluated continuation gemcitabine and demonstrated a PFS advantage, but no OS benefit in an underpowered study. Bevacizumab continuation is an accepted approach based on the design of E4599, although its contribution has never been established in a randomized trial. However, a direct comparison between E4599 (carboplatin‐paclitaxel‐bevacizumab followed by bevacizumab) and carboplatin‐pemetrexed‐bevacizumab followed by pemetrexed‐bevacizumab was undertaken in the POINTBREAK study. It showed no OS differences (numerically favored E4599: 13.4 versus 12.6 months), although in pre‐specified analysis of patients going through maintenance (as opposed to ITT) there was a 2‐month difference favoring the combination of pemetrexed‐bevacizumab. E5508 [Clinical‐ Trials.gov identifier:NCT01107626] is attempting to answer this question by directly randomizing patients to either bevacizumab, pemetrexed or the combination after carboplatin‐paclitaxel‐bevacizumab. Subset data from the SATURN trial strongly supports switch maintenance with erlotinib for EGFR mutant patients, who had an impressive three fold higher median PFS (44 vs 14 weeks; HR: 0.10; 95% CI: 0.04‐0.25). INFORM included 296 Asian patients, who were randomized between gefitinib and placebo. PFS favored gefitinib maintenance (4.8 vs 2.6 months, HR=0.42; 95% CI: 0.33‐0.55; p <0.0001). No overall survival benefit has been found for squamous cell patients. However, a PFS benefit was seen in IFCT‐GFPC 0502 for continuation maintenance with gemcitabine and in SATURN for sequential erlotinib. The ABOUND study with carboplatin/ nab‐paclitaxel is exploring the nab‐paclitaxel maintenance in squamous‐cell and results are awaited. The SQUIRE trial evaluated the anti‐EGFR monoclonal antibody necitumumab in combination with cisplatingemcitabine followed by maintenance necitumumab. It modestly improved overall survival and PFS over chemotherapy alone (median OS 11.5 vs 9.9 months, HR 0.84, p=0.012; PFS HR 0.85, p=0.02). The contribution of bevacizumab maintenance phase was not prospectively been established. However, a retrospective landmark analysis of E4599 evaluated the patients who were alive without progression for at least 3 weeks after completion of 6 cycles of chemotherapy. The PFS favored bevacizumab maintenance (4.4 vs 2.8 months; HR 0.64). OS was also longer (median 12.8 vs 11.4 months). ECOG 5508 is an important ongoing study, as mentioned previously. Another ongoing study (MO 22097) is evaluating the role of continuing bevacizumab in combination with a second line chemotherapy, beyond progression to maintenance bevacizumab. In a phase III placebo‐controlled study, carboplatin and paclitaxel were given with or without concurrent and maintenance sorafenib, but no improvement in overall survival was shown and the results were detrimental in patients with squamous cell histology. CALGB 30607 of maintenance sunitinib versus placebo met its primary endpoint of improving PFS (4.3 versus 2.8 mos), including squamous histology. There was no effect on OS. EORTC 08092 evaluated pazopanib given as maintenance treatment following standard first line platinum‐based chemotherapy in patients with advanced NSCLC. This study was stopped due to lack of efficacy by stringent criteria for PFS at a futility interim analysis. A phase III trial of carboplatin, paclitaxel with or without concomitant and maintenance ipilimumab (an anti‐CTLA4 agent) is ongoing, and was initiated taking into account the positive results obtained adding maintenance ipilimumab to the platinum doublet in a previous phase II study. Vaccine therapy has also been studied as maintenance treatment in NSCLC. Belagenpumatucel‐ L (Lucanix) is an allogeneic cancer vaccine, obtained from TGF‐beta2 antisense gene modified whole NSCLC cell lines. There was no difference in overall survival between arms (median survival 20.3 versus 17.8 months with belagenpumatucel‐L versus placebo, respectively. Tecemotide (L‐BLP‐25) is a vaccine against MUC1 antigen. START trial randomized patients with stage III NSCLC who completed chemoradiotherapy between tecemotide injections or placebo. No significant difference in overall survival with the administration of tecemotide after chemoradiotherapy was found ‐ median OS was 25.6 months with tecemotide versus 22,3 months with placebo.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01781268/full} -} - - -Record #507 of 538 -@article{jRCTs07118004919, -author = {jRCTs071180049,}, -title = {Japanese Intergroup Study of Nintedanib for NSCLC with IPF}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCTs071180049}, -year = {2019}, -accession_number = {ICTRP jRCTs071180049}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: carboplatin + nab‐paclitaxel carboplatin + nab‐paclitaxel + nintedanib CONDITION: Advanced Non‐small cell lung cancer with idiopathic pulmonary fibrosis PRIMARY OUTCOME: Time to acute exacerbation of IPF (Initiation of 2nd line chemotherapy for non‐small cell lung cancer is not treated as censored) SECONDARY OUTCOME: Time to acute exacerbation of IPF (Initiation of 2nd line chemotherapy for non‐small cell lung cancer is treated as censored), Exacerbation‐free survival of IPF, Frequency of patients with acute exacerbation of IPF, Rate of decline in FVC (expressed in mL over 12 weeks), Quality of life (QOL), Overall response rate (ORR), Progression‐free survival (PFS) of non‐small cell lung cancer, Time to treatment failure (TTF), Overall survival (OS), toxicity INCLUSION CRITERIA: 1) Written informed consent 2) 20 years of age or older 3) Histologically or cytologically proven non‐small cell lung carcinoma 4) Clinical stage III, IV or recurrent disease after surgery 5) With or without measurable lesions 6) Without symptomatic central nervous system metastases 7) Without uncontrollable cardiac effusion, pleural effusion, ascites, superior vena cava syndrome or spinal cord compression 8) No prior chemotherapy 9) No history of treatment with nintedanib, nab‐paclitaxel or immune checkpoint inhibitor 10) No prior operation under general anesthesia within 14 days before registration 11) No prior palliative radiotherapy within 14 days before registration 12) No prior biopsy under incision, thoracoscopic biopsy, or treatment for wound occurred within 7 days before registration 13) No prior blood transfusion or hematopoietic factor administration within 7 days before registration 14) No history of tr}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01975630/full} -} - - -Record #508 of 538 -@article{Antonia18, -author = {Antonia, SJ, Hellmann, MD, Dennis, PA, Melillo, G, Abdullah, SE, Lloyd, A, and Rizvi, NA}, -title = {A comparative safety analysis for durvalumab in patients with locally advanced, unresectable NSCLC: PACIFIC versus pooled durvalumab monotherapy studies}, -journal = {Journal of clinical oncology}, -volume = {36}, -number = {15}, -year = {2018}, -accession_number = {EMBASE 625969544}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *drug safety; *monotherapy; *non small cell lung cancer; Adult; Conference abstract; Controlled study; Drug therapy; Female; Human; Major clinical study; Male; Pharmacokinetics; Phase 2 clinical trial}, -abstract = {Background: In PACIFIC, durvalumab significantly extended PFS compared with placebo (HR 0.52; P<0.0001) for pts with locally advanced, unresectable NSCLC who had previously received concurrent chemoradiotherapy (cCRT). The safety profile of durvalumab in this study was similar to placebo. Here we report a safety analysis of a descriptive comparison of PACIFIC with a pooled dataset of durvalumab monotherapy studies. Methods: Data were pooled for pts treated with durvalumab monotherapy (10 mg/kg IV Q2W) from three trials (N=1,889), the Phase III PACIFIC (n=475), Phase II ATLANTIC (n=444 advanced NSCLC pts), and Phase I/II 1108 (n=970 solid tumor pts, including 304 NSCLC pts) studies. The incidences of all‐causality AEs (as of Feb 13, 2017, data cutoff for the PACIFIC analysis) were graded using CTCAE v4.03 and summarized descriptively for comparison between PACIFIC and the pooled dataset. Results: Compared with the pooled dataset (Table), PACIFIC had lower incidences of grade 3/4 AEs and SAEs, but a higher rate of AEs leading to discontinuation (15.4% [durvalumab] vs. 9.8% [placebo] compared with 9.4% [pooled dataset]). In a separate comparison excluding PACIFIC from the pooled dataset (N=1,414), any‐grade (grade 3/4) pneumonitis/radiation pneumonitis occurred in 33.9% (3.4%) of pts on durvalumab and 24.8% (3.0%) on placebo in PACIFIC (with similar grade 3/4 incidences for both) and 2.3% (0.5%) of pts in the reduced pooled dataset. Conclusions: Durvalumab monotherapy has a well‐defined and acceptable safety profile. Differences observed in the rates of AEs with durvalumab on the PACIFIC regimen may be attributable to the pt population or prior cCRT. (Table Presented) .}, -DOI = {10.1200/JCO.2018.36.15-suppl.8556}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01932337/full} -} - - -Record #509 of 538 -@article{Wu24, -author = {Wu, L, Zhang, Z, Sun, X, Yan, Y, Jiang, C, Zhu, Y, and Yaping, X}, -title = {Integration of circulating tumor DNA and metabolic parameters for outcome prediction in unresectable locally advanced non-small cell lung cancer}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644913362}, -publication type = {Journal article; Conference proceeding}, -keywords = {*metabolic parameters; *non small cell lung cancer; *prediction; Adult; Aged; Chemoradiotherapy; Clinical article; Conference abstract; Controlled study; Drug therapy; Female; Gene frequency; Human; Human tissue; Male; Minimal residual disease; Positron emission tomography‐computed tomography; Radiotherapy; Treatment response}, -abstract = {Background: An effective biomarker to direct precise consolidation treatment after CRT is still lacking. Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curativeintent treatment strongly predicts recurrence in multiple tumor types, but whether further treatment can improve outcomes in patients with MRD remains unclear. Hereby, we applied CAPP‐Seq ctDNA analysis to plasma samples collected before and after definitive chemoradiotherapy (CRT) or radiotherapy (RT) in unresectable LA‐NSCLC. Methods: A total of 62 unresectable LA‐NSCLC patients were prospectively enrolled, providing 62 baseline and 49 post‐definitive CRT/RT plasma samples. All patients underwent a PET/CT scan at baseline and 33 patients received a mid‐treatment PET/CT scan upon reaching a RT dose of 40Gy/20f during therapy. These 33 patients were randomly assigned to either receive or not receive adaptive dose‐escalated RT. A group of patients who received immune checkpoint inhibitor (ICI) consolidation after CRT/RT was compared with patients who were ctDNA‐/high 4TMTV post‐treatment. Results: ctDNA was detected at baseline in 44 (71.0%) patients. Pretreatment ctDNA concentration was significantly correlated with TMTV (p = 0.004) and TLG (p = 0.010). Baseline ctDNA detection and concentration were not able to differentiate patients with varying treatment responses or predict survival. However, patients with undetectable ctDNA and lowTMTVexhibited significantly better PFS (p = 0.024). One month after completing CRT or RT, ctDNA was detected in 25 (47.2%) patients. While the concentration of circulating free DNA (cfDNA) remained relatively stable (p = 0.652), both the mean ctDNA Variant Allele Frequency (VAF) (p = 0.002) and ctDNA concentration (p = 0.043) showed a significant decrease. Patients with undetectable ctDNA post‐treatment exhibited significantly longer PFS and OS. A lower ΔTMTV was significantly associated with longer PFS and OS. Compared to the nonresponse group, the response group exhibited significantly lower change in 4SUVmax (p = 0.024), with a trend towards lower change in TMTV, although not significant (p = 0.064). Compared with the matched 30 patient receiving ICI consolidation, those with negative ctDNA and high 4TMTV after CRT demonstrated significantly better PFS (p = 0.042) and OS (p = 0.039). Conclusions: Baseline ctDNA combined with TMTV can enhance the predictive ability for survival. Post‐CRT ctDNA and 4TMTV possess strong prognostic capabilities. Patients who are ctDNA‐ and with high 4TMTV may be exempt from ICI consolidation therapy.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02750511/full} -} - - -Record #510 of 538 -@article{Reinmuth22, -author = {Reinmuth, N, Reznick, D, Liu, SY, Garassino, MC, Girard, N, De Marinis, F, Mekan, SF, Patel, R, Ding, M, and Paz-Ares, L}, -title = {P1.16-04 Phase 3 EVOKE-01 Study of Sacituzumab Govitecan vs Docetaxel in NSCLC After Prior Platinum and Checkpoint Inhibitors}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S128}, -year = {2022}, -accession_number = {EMBASE 2020097497}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer combination chemotherapy; *implanted spinal cord stimulator; *non small cell lung cancer; Adult; Advanced cancer; Adverse drug reaction; Cancer patient; Cancer staging; Cancer survival; Chemotherapy; Clinical evaluation; Clinical trial; Comparative effectiveness; Conference abstract; Controlled study; Disease control; Drug combination; Drug safety; Drug therapy; Dyspnea; ECOG Performance Status; Eligibility criteria; Female; Histology; Histopathology; Human; Human tissue; Immunotherapy; Intravenous drug administration; Kidney function; Liver; Major clinical study; Male; Multicenter study; Overall response rate; Phase 1 clinical trial; Phase 3 clinical trial; Progression free survival; Randomized controlled trial; Response evaluation criteria in solid tumors}, -abstract = {Introduction: Single‐agent chemotherapy, such as docetaxel, is the standard of care in patients with metastatic NSCLC who progressed on platinum‐based therapy and checkpoint inhibitors. However, docetaxel is associated with poor survival (median overall survival [OS] of <1 year); thus, novel agents are needed to further improve outcomes in this setting. Sacituzumab govitecan (SG) is an antibody‐drug conjugate composed of an anti‐Trop‐2 antibody coupled to the cytotoxic SN‐38 payload via a proprietary, hydrolyzable linker. In a single‐arm expansion of the phase 1/2 IMMU‐132‐01 basket study of advanced epithelial cancers (NCT01631552), SG demonstrated an objective response rate (ORR) of 17% and median OS of 9.5 months, with a manageable safety profile in 54 patients with metastatic NSCLC who had multiple prior therapies (Heist RS, et al. J Clin Oncol. 2017). EVOKE‐01 randomized phase 3 study was designed to further evaluate SG in patients with metastatic NSCLC. Methods: EVOKE‐01 (NCT05089734) is an open‐label, global, multicenter, randomized, phase 3 study comparing the efficacy and safety of SG vs docetaxel in patients with metastatic NSCLC. Key eligibility criteria include age ≥18 years, pathologically documented stage IV NSCLC at time of study entry, and progression after platinum‐based chemotherapy and anti‐PD(L)1 therapy given either in combination or sequentially. Patients with EGFR, ALK, or other known actionable genomic alterations must have also received treatment with ≥1 approved appropriate TKI. Other inclusion criteria are ECOG performance status 0‐1 and adequate hematologic, hepatic, and renal function. Patients with prior treatment with topoisomerase inhibitors are excluded. Patients are randomized 1:1 to receive intravenous SG (10 mg/kg on day 1 and 8) or docetaxel (75 mg/m2 on day 1) in 21‐day cycles until progressive disease or unacceptable toxicity. Stratification is based on predominant histology (squamous vs nonsquamous), best response to prior immune therapy (PD/SD vs CR/PR), and prior therapy for actionable genomic alteration (yes vs no). The primary endpoint is OS. Key secondary endpoints include progression‐free survival, ORR, duration of response, and disease control rate, as assessed by investigator RECIST v1.1, mean change from baseline in NSCLC‐SAQ total score and shortness of breath, and safety. This study plans to enroll ∼520 patients globally and is open for recruitment. Keywords: antibody‐drug conjugate, immune checkpoint inhibitors, phase III clinical trial}, -DOI = {10.1016/j.jtho.2022.07.213}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461454/full} -} - - -Record #511 of 538 -@article{Wu24, -author = {Wu, Y-L, Johnson, ML, Soo, RA, Baktash, N, Maier, D, Eigenbrod-Giese, S, and Yoshida, T}, -title = {102TiP A phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care (SoC) in patients (pts) with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain (TKD) mutations: beamion LUNG-2}, -journal = {ESMO open}, -volume = {9}, -year = {2024}, -accession_number = {EMBASE 2030949559}, -publication type = {Journal article; Conference proceeding}, -keywords = {*health care quality; *metastasis; *non small cell lung cancer; Adult; Adverse drug reaction; Area under the curve; China; Clinical trial; Common Terminology Criteria for Adverse Events; Conference abstract; Controlled study; Disease control; Female; Human; Immunotherapy; Intravenous drug administration; Major surgery; Male; Middle aged; Open study; Oral drug administration; Overall survival; Parttime employment; Pharmaceutics; Progression free survival; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Side effect; Solid tumor; Wild type}, -abstract = {Background: First‐line (1L) SoC for pts with HER2‐mutation positive (HER2m+) NSCLC is platinum‐based chemotherapy ± immunotherapy. To date, no targeted 1L treatments (txs) have been approved. Zongertinib is a HER2‐selective tyrosine kinase inhibitor that binds to wild‐type and mutated HER2, sparing EGFR. In Phase Ia of Beamion LUNG‐1 (NCT04886804), zongertinib conferred objective response (OR)/disease control rates of 49/91% in pts with pretreated HER2 aberration‐positive solid tumours, and 58/97% in those pts with HER2m+ NSCLC, with manageable safety with few EGFR‐associated adverse events. Here, we describe Beamion LUNG‐2 (NCT06151574), a phase III, randomised, controlled, open‐label trial which will compare the efficacy and safety of 1L zongertinib with SoC in pts with HER2m+, locally advanced/metastatic non‐squamous NSCLC. Trial design: ∼270 pts will be randomised 1:1 to receive either zongertinib or SoC. Key inclusion criteria: histologically/cytologically diagnosed advanced/metastatic non‐squamous NSCLC; no prior systemic tx for locally advanced/metastatic disease; HER2 mutation in the TKD; ≥1 measurable lesion (RECIST 1.1). Key exclusion criteria: tumours that have alterations with available therapy, and radiotherapy/major surgery ≤4 weeks prior to randomisation. In the experimental arm, 120 mg oral zongertinib QD will be given in 21‐day cycles. In the comparator arm, 500 mg/m2 intravenous pemetrexed chemotherapy plus either 75 mg/m2 cisplatin or Area Under the Curve 5 carboplatin, plus 200 mg pembrolizumab will be given on Day 1 q3w for four cycles, followed by 500 mg/m2 pemetrexed plus 200 mg pembrolizumab q3w for ≤35 cycles. In both arms, tx will continue until progressive disease (RECIST 1.1), undue toxicity, or other criteria are met. Primary endpoint: progression‐free survival (RECIST 1.1). Secondary endpoints: OR (defined as best overall response of complete or partial response, RECIST 1.1); pt‐reported outcomes (changes from baseline to Week 25); overall survival; and adverse events during the on‐treatment period (CTCAE 5.0). Clinical trial identification: NCT06151574. Editorial acknowledgement: Medical writing support for the development of this abstract, under direction of the authors, was provided by Ellie Sherwood MPhil, of Ashfield MedComms, an Inizio Company, and funded by Boehringer Ingelheim. Legal entity responsible for the study: Boehringer Ingelheim. Funding: Boehringer Ingelheim. Disclosure: Y. Wu: Financial Interests, Personal, Advisory Role: AstraZeneca, Roche, Boehringer Ingelheim, Takeda; Financial Interests, Personal, Other, Honoraria: AstraZeneca, Lilly, Roche, Pfizer, Boehringer Ingelheim, MSD Oncology, Bristol Myers Squibb, Hengrui Pharmaceutical, BeiGene Beijing; Financial Interests, Institutional, Research Grant: Boehringer Ingelheim, Roche, Pfizer, Bristol Myers Squibb. M.L. Johnson: Financial Interests, Institutional, Research Grant: AbbVie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma, ArriVent BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Calithera Biosciences, Carisma Therapeutics, Checkpoint Therapeutics, City of Hope National Medical Center, Corvus Pharmaceuticals, Curis, Daiichi Sankyo, CytomX, Dracen Pharmaceuticals, Dynavax, Lilly, Eikon Therapeutics, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchinson MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunitas Therapeutics, Immunocore, Incyte, Janssen, Jounce Therapeutics, Kadmon Pharmaceuticals, Kartos Therapeutics, LockBody Therapeutics, Loxo Oncology, Lycera, Memorial Sloan‐Kettering, Merck, Merus, Mirati Therapeutics, Mythic Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, Nuvalent, OncoMed Pharmaceuticals, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Stem CentRx, Syndax Pharmaceuticals, Taiho Oncology, Takeda Pharmaceuticals, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, TMUNITY Therapeutics, Turning Point Therapeutics, University of Michigan, Vyriad, WindMIL Therapeutics, Y‐mAbs Therapeutics; Financial Interests, Institutional, Other, Consulting: AbbVie, Alentis Therapeutics, Amgen, Arcus Biosciences, Arrivent, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, D3 Bio Limited, Daiichi Sankyo, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, Gilead Sciences, GSK, Gritstone Oncology, Hookipa Biotech, Immunocore, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Mirati Therapeutics, Molecular Axiom, Normunity, Novartis, Novocure, Pfizer, Pyramid Biosciences, Revolution Medicines, Sanofi‐Aventis, SeaGen, Synthekine, Takeda Pharmaceuticals, VBL Therapeutics. R.A. Soo: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, J INTS BIO, Janssen, Lily, Merck, Merck Serono, Novartis, Pfizer, Puma, Roche, Taiho, Takeda, Thermo Fisher, Yuhan; Financial Interests, Personal, Research Grant: AstraZeneca, Boehringer Ingelheim, Pfizer. N. Baktash: Financial Interests, Personal, Full or part‐time Employment: Boehringer Ingelheim. D. Maier: Financial Interests, Personal, Full or part‐time Employment: Boehringer Ingelheim. S. Eigenbrod‐Giese: Financial Interests, Personal, Full or part‐time Employment: Boehringer Ingelheim. T. Yoshida: Financial Interests, Personal, Speaker’s Bureau: Novartis, AbbVie, Amgen, Daiichi Sankyo, AstraZeneca, MSD, Chugai, Astellas, Medpace, Boehringer Ingelheim, BMS, Ono, Merck; Financial Interests, Personal, Advisory Board: Pfizer, Novartis, MSD, Amgen, Boehringer Ingelheim; Financial Interests, Institutional, Research Grant: Novartis, AbbVie, Amgen, Daiichi Sankyo, AstraZeneca, MSD, Chugai, Astellas, Medpace, Boehringer Ingelheim, BMS, Ono, Merck; Financial Interests, Institutional, Principal Investigator: Novartis, AbbVie, Amgen, Daiichi Sankyo, AstraZeneca, MSD, Chugai, Astellas, Medpace, Boehringer Ingelheim, BMS, Ono, Merck.}, -DOI = {10.1016/j.esmoop.2024.102681}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02671589/full} -} - - -Record #512 of 538 -@article{Johnson20, -author = {Johnson, BE, Kim, TM, Hiltermann, TJN, Barlesi, F, Grohe, C, Goto, Y, Gunnarsson, O, Overbeck, T, Reguart, N, Wermke, M, Castro, GC, Felip, E, Greystoke, A, Solomon, BJ, Deudon, S, Louveau, A-L, Passos, V, and Tan, DSW}, -title = {CANOPY-1: safety run-in results fromphase (ph) 3 study of canakinumab (CAN) or placebo(PBO) in combination (comb) with pembrolizumab (PEM)plus platinum-based doublet chemotherapy (Ctx) as 1 line therapy in patients (pts) with advanced or metastaticNSCLC}, -journal = {Cancer research}, -volume = {80}, -number = {16 SUPPL}, -year = {2020}, -accession_number = {EMBASE 633640183}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *canopy; *doublet chemotherapy; *drug safety; Adult; Cancer patient; Cancer staging; Chemoradiotherapy; Clinical article; Clinical trial; Cohort analysis; Comparative effectiveness; Conference abstract; Constipation; Controlled study; Double blind procedure; Drug combination; Drug therapy; Drug withdrawal; Fatigue; Female; Follow up; Heart tamponade; Hepatitis; Human; Immunogenicity; Male; Middle aged; Nausea; Neutrophil count; Non small cell lung cancer; Peripheral neuropathy; Pharmacokinetics; Polyneuropathy; Randomized controlled trial; Vomiting}, -abstract = {Cytokine interleukin‐1β (IL‐1β) has multiple pro‐tumorogenic effects on tumor microenvironment, thereby promotingcarcinogenesis, tumor invasiveness, and immunosuppression. CAN is a selective IL‐1β inhibitor that aims to targettumor‐promoting inflammation to reduce immune suppression, thereby potentiating effects of immunotherapy with PD‐1 inhibitors such as PEM. Ph 3 CANTOS study has shown IL‐1β inhibition with CAN was associated with reduced incidence of lung cancer (LC) and LC mortality in pts with atherosclerosis, providing a rationale toinvestigate therapeutic role of CAN in LC. CANOPY‐1 ( NCT03631199 ) is a PBO‐controlled, double‐blind,randomized, ph 3 trial designed to evaluate efficacy and safety of PEM + Ctx ± CAN in tx naive pts with stageIIIB/IIIC (not eligible for definitive chemo‐radiation curative tx) or stage IV squamous and nonsquamous NSCLC.The study was divided into 2 parts: part 1 is open labelled, safety run‐in part where pts received CAN 200 mg s.cQ3W + PEM 200 mg i.v Q3W + platinum‐based Ctx (as induction during first 4 cycles only); Cohort A (A, non‐squamous), carboplatin + pemetrexed; Cohort B (B, non‐squamous), cisplatin + pemetrexed; Cohort C (C,squamous or non‐squamous), carboplatin + paclitaxel. Part 2 is randomized and evaluates efficacy and safety of CAN comb regimen vs PBO comb regimen. Primary objective of safety run‐in part: recommended ph 3 doseregimen (RP3R) of CAN comb. Secondary objectives: ORR, DCR, DOR, safety, PK, and immunogenicity. As of 14May 2019 (follow‐up of ≥42 days from C1D1 unless pt discontinued earlier), 10 pts in A, 11 pts in B, and 9 pts in C were treated, of which 73% were male, median age was 63 yrs. In total, 24/30 (80%) pts enrolled were still receivingtx; primary reason for tx discontinuation was progressive disease (3 pts in A and 1 pt each in B and C) and 1 pt dieddue to study indication. 1 pt reported DLT during first 42 days of study tx (C: grade 3 hepatitis, not related to CAN).RP3R of CAN in comb with standard dose PEM + Ctx was 200 mg SC Q3W based on Bayesian logistic regressionmodel (BLRM). Serious AEs regardless of causality were reported in 8 (27%) pts (2 pts in A and 3 pts each in B and C), none of which were considered to be related to CAN. Most common AEs (≥20%, any grade) across all cohorts(n=30) were nausea (37%), vomiting (30%), constipation and fatigue (each 23%), and neutrophil count decrease(20%). 14 pts (47%) experienced grade 3 AEs and 1 pt experienced grade 4 AE (cardiac tamponade [unrelated]).No fatal serious AEs were reported. AEs leading to discontinuation of one of the study drugs were reported in 3(10%) pts (hepatitis, peripheral neuropathy, and polyneuropathy) but none were CAN related. AEs leading to dosereduction and dose interruption of one of study drugs were reported in 3 (10%) pts and 5 (17%) pts, respectively.Only 1 DLT was reported with CAN + PEM + Ctx. Based on BLRM and all relevant clinical data, the RP3R of CANas 200 mg SC Q3W comb was considered safe and well tolerated. Enrollment for the randomized part is completed.}, -DOI = {10.1158/1538-7445.AM2020-CT214}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02213013/full} -} - - -Record #513 of 538 -@article{Grohe20, -author = {Grohe, C, Johnson, BE, Kim, TM, Hiltermann, TJN, Barlesi, F, Goto, Y, Gunnarsson, O, Overbeck, T, Reguart, N, Wermke, M, De Castro, G, Felip, E, Greystoke, A, Solomon, BJ, Deudon, S, Louveau, A-L, Passos, V, and Tan, DSW}, -title = {CANOPY-1: safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC}, -journal = {Oncology research and treatment}, -volume = {43}, -pages = {152}, -year = {2020}, -accession_number = {EMBASE 640123592}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer combination chemotherapy; *cancer patient; *canopy; *doublet chemotherapy; *drug safety; *non small cell lung cancer; Adult; Cancer staging; Chemoradiotherapy; Clinical article; Clinical trial; Cohort analysis; Comparative effectiveness; Conference abstract; Constipation; Controlled study; Double blind procedure; Drug combination; Drug dose regimen; Drug therapy; Drug withdrawal; Fatigue; Female; Follow up; Heart tamponade; Hepatitis; Human; Male; Middle aged; Nausea; Neutrophil count; Peripheral neuropathy; Phase 3 clinical trial; Polyneuropathy; Randomized controlled trial; Vomiting}, -abstract = {CANOPY‐1 (NCT03631199) is a PBO‐controlled, double‐blind, randomized, ph 3 trial designed to evaluate efficacy and safety of PEM + Ctx ± CAN in tx naive pts with stage IIIB/IIIC (not eligible for defnitive chemo‐radiation curative tx) or stage IV squamous and nonsquamous NSCLC. The study was divided into 2 parts: part 1 is open labelled, safety run‐in part where pts received CAN 200 mg s.c Q3W + PEM 200 mg i.v Q3W + platinum‐based Ctx (as induction during first 4 cycles only); Cohort A (A, non‐squamous), carboplatin + pemetrexed; Cohort B (B, non‐squamous), cisplatin + pemetrexed; Cohort C (C, squamous or non‐squamous), car‐boplatin + paclitaxel. Part 2 is randomized and evaluates efficacy and safety of CAN comb regimen vs PBO comb regimen. Primary objective of safety run‐in part: recommended ph 3 dose regimen (RP3R) of CAN comb. Secondary objectives: ORR, DCR, DOR, safety, PK, and immuno‐genicity. As of 14 May 2019 (follow‐up of ≥42 days from C1D1 unless pt discontinued earlier), 10 pts in A, 11 pts in B, and 9 pts in C were treated, of which 73% were male, median age was 63 yrs. In total, 24/30 (80%) pts enrolled were still receiving tx; primary reason for tx discontinuation was progressive disease (3 pts in A and 1 pt each in B and C) and 1 pt died due to study indication. 1 pt reported DLT during first 42 days of study tx (C: grade 3 hepatitis, not related to CAN). RP3R of CAN in comb with standard dose PEM + Ctx was 200 mg SC Q3W based on Bayesian logistic regression model (BLRM). Serious AEs regardless of causality were reported in 8 (27%) pts (2 pts in A and 3 pts each in B and C), none of which were considered to be related to CAN. Most common AEs (≥20%, any grade) across all cohorts (n=30) were nausea (37%), vomiting (30%), constipation and fatigue (each 23%), and neutrophil count decrease (20%). 14 pts (47%) experienced grade 3 AEs and 1 pt experienced grade 4 AE (cardiac tamponade [unrelated]). No fatal serious AEs were reported. AEs leading to discontinuation of one of the study drugs were reported in 3 (10%) pts (hepatitis, peripheral neuropathy, and polyneuropathy) but none were CAN related. AEs leading to dose reduction and dose interruption of one of study drugs were reported in 3 (10%) pts and 5 (17%) pts, respectively. Only 1 DLT was reported with CAN + PEM + Ctx. Based on BLRM and all relevant clinical data, the RP3R of CAN as 200 mg SC Q3W comb was considered safe and well tolerated. Enrollment for the randomized part is completed.}, -DOI = {10.1159/000510995}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02519180/full} -} - - -Record #514 of 538 -@article{Sequist18, -author = {Sequist, LV, Willers, H, Lanuti, M, Muzikansky, A, Chen, AB, Janne, PA, Choi, NC, Mino-Kenudson, M, Swanson, S, Wright, CD, Marcoux, JP, Piotrowska, Z, Oxnard, GR, and Mak, RH}, -title = {The ASCENT trial: a phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC}, -journal = {Journal of clinical oncology}, -volume = {36}, -number = {15}, -year = {2018}, -accession_number = {EMBASE 625972221}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *cancer surgery; *chemoradiotherapy; *gene mutation; *neoadjuvant therapy; *non small cell lung cancer; Adult; Cancer adjuvant therapy; Cancer recurrence; Cancer size; Central nervous system; Clinical article; Conference abstract; Controlled study; Death; Diarrhea; Drug therapy; Esophagitis; Feasibility study; Febrile neutropenia; Female; Follow up; Genotype; Human; Immunotherapy; Landscape; Male; Nausea; Outcome assessment; Phase 2 clinical trial; Pneumonia; Radiotherapy; Randomized controlled trial; Rash; Relapse}, -abstract = {Background: The stage III NSCLC paradigm now includes immunotherapy (IO), but advanced EGFR‐mutant (EGFR+) pts typically don't respond to IO. In 2011 we began a phase II trial of neoadjuvant afatinib (NeoAfat) and standard of care (SOC) curative intent treatment for EGFR+ stage III NSCLC, NCT01553942. We present an interim analysis given the evolving SOC landscape. Methods: EGFR+ stage III pts amenable to curative‐intent chemoradiation (CRT) ± surgery were treated with NeoAfat 40mg po QD x2mo, then concurrent CRT: cisplatin 75mg/m2 + pemetrexed 500mg/m2 IV q3wk up to 4 cycles and 3D conformal RT or IMRT personalized to tumor size, site, operability. Surgery and adjuvant afatinib (AdjAfat) x2yr were optional. Primary outcome was objective response rate (ORR) to NeoAfat. Results: 13 pts were treated (10F/3M); med age 56 (range 34‐75). EGFR mutations: del19 (n = 9); L858R (n = 4). Stage: operable IIIA (n = 7); inoperable IIIA/B (n = 6). NeoAfat ORR = 69% (95% CI 39‐91); 5 (38%) pts dose reduced NeoAfat. All pts proceeded to CRT with pre‐op med RT dose of 54 Gy (range 45‐66; n = 7), definitive med dose of 65 Gy (range 63‐72; n = 6). 5 (71%) of the 7 surgical pts had major (4) or complete (1) pathologic response. 7 (54%) pts started AdjAfat at med dose of 30mg QD; 4 completed 2yr, 2 aborted early, 1 ongoing . Key grade 3/4 toxicities: rash 5), diarrhea (5), esophagitis (3), nausea (3), pneumonitis (2 gr 3) and febrile neutropenia (1); no treatment‐related deaths. With med follow‐up of 24.1 mo (range 5.0‐64.2), 6 (46%) pts have recurred; including 4/6 inoperable pts, 2/7 who had surgery, 1/5 with major path response (CNS‐only recurrence). Med PFS is 34.6 mo (95% CI 12.6‐ NR). 2‐yr OS is 85% (95% CI 33‐98). Conclusions: Neo‐adjuvant afatinib achieves high ORR and major surgical path responses, and doesn't impair receipt of SOC, curative CRT ± surgery in EGFR+ stage III NSCLC. Feasibility of NeoAfat exceeds AdjAfat in stage III setting. The prolonged PFS compares favorably to PACIFIC IO arm; more data is needed about optimal strategy for stage III EGFR+ pts. ASCENT is still ongoing, but it and similar randomized RTOG 1306 have accrued slowly, highlighting the challenge of studying curative approaches in genotype‐defined subgroups.}, -DOI = {10.1200/JCO.2018.36.15-suppl.8544}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01792207/full} -} - - -Record #515 of 538 -@article{Dercle22, -author = {Dercle, L, Gomez, D, Zhao, B, Kelly, K, Herbst, RS, Redman, MW, Gandara, DR, and Schwartz, LH}, -title = {P2.12-03 External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients with Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S152}, -year = {2022}, -accession_number = {EMBASE 2020099098}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer combination chemotherapy; *cancer patient; *cancer prognosis; *non small cell lung cancer; Adult; Advanced cancer; Artificial intelligence; Axillary lymph node; Cancer chemotherapy; Cancer size; Cancer survival; Clinical trial; Cohort analysis; Conference abstract; Controlled study; Drug combination; Drug therapy; Female; High risk population; Human; Immunotherapy; Liver tumor; Log rank test; Low risk patient; Major clinical study; Male; Median survival time; Mediastinum lymph node; Metadata; Mortality; Overall survival; Phase 3 clinical trial; Phenotype; Radiomics; Randomized controlled trial; Retrospective study; Risk assessment; Systemic therapy; Tumor volume}, -abstract = {Introduction: There is an unmet need in elucidating effective correlative biomarkers for individualized selection of therapeutic regimens in patients with a diagnosis of advanced NSCLC. Recent innovations in artificial intelligence (AI) can enhance the role of CT imaging by taking advantage of previously unutilized information through the ability to identify imaging biomarkers through quantitative analysis that is objective, reproducible, and rapidly obtainable. Our group has previously leveraged this approach by applying AI in patients with NSCLC treated with nivolumab in CheckMate017, CheckMate026, and CheckMate063. In this cohort, we identified a radiomics signature (NivoSig) that was correlated with overall survival (OS). In the current analysis, we sought to validate NivoSig in a separate cohort of patients with distinct systemic therapy regimens who were enrolled in a large randomized trial. Methods: We retrospectively analyzed CT images and associated clinical metadata for patients enrolled on SWOG S0819 [NCT00946712]. Participants (n=1,229) had a diagnosis of advanced NSCLC and were randomized to treatment with chemotherapy (carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab) alone (n=607) or the same chemotherapy regimen in combination with cetuximab (n=622). All participants were included as an external validation set for NivoSig. From CT images, the volume of measurable tumor lesions was semi‐automatically segmented and seven radiomic variables depicting tumor phenotype were extracted. The radiomic signature used a predefined and locked combination of these imaging variables to output a continuous value, ranging from 0 to 1 (from most to least favorable estimated OS); patients were categorized as low‐ vs. high‐risk groups as previously determined. Cox regression and the log‐rank test was used to validate the NivoSig risk‐groupings with OS. Survival distributions were estimated via Kaplan‐Meier. Radiomic features between risk groups were compared using a t‐test. Results: The primary publication reported no difference in OS (Hazard ratio (HR)=0.93[95CI: 0.83‐1.04], P=0.22) and data in this analysis were consistent (HR=0.94[95CI: 0.84‐1.06], P=0.315). Patients with high‐risk prognostic NivoSig had a 50% increased risk of death compared to low‐risk NivoSig (HR=1.50 [95CI: 1.33‐1.69], P<0.0001), and shorter median survival (n=697, 12.3 months [95CI: 11.1‐13.3]) vs. high‐risk NivoSig (n=532, 8.4 months [95CI: 7.48‐8.98]).In addition, comparison of NivoSig’s individual radiomic features stratified high‐risk (n=532) vs. low‐risk (n=697) patients as follows (mean(SD), P‐value): A) distinct tumor texture in two radiomics components, laws boundary and spatial correlation (P<0.001 for both); B) higher overall tumor volume (157.3(202.2) vs. 53(51.5) cm3, P<0.001); C) higher liver tumor volume (20.4(88.3) vs. 0(0.4) cm3, P<0.001); D) higher mediastinal lymph node tumor volume (25.2(40.2) vs. 10.9(15) cm3, P<0.001); E) higher axillary lymph node tumor volume (2.2(32.6) vs. 0(0) cm3, P=0.078); and F) higher number of target lesions (6.18(3.71) vs. 3.97(2.29) cm3, P<0.001). Conclusions: NivoSig is a novel AI‐guided radiomics signature previously derived in patients treated with immunotherapy. In this analysis we found that it was generalizable to patients in a large, randomized trial receiving a distinct treatment approach without immunotherapy. In addition, individual AI‐generated radiomic features stratified high‐ vs. low‐risk patients with respect to OS. Future directions will incorporate these features to better elucidate mechanisms of resistance. Keywords: NSCLC, Artificial Intelligence, Radiomics}, -DOI = {10.1016/j.jtho.2022.07.251}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461491/full} -} - - -Record #516 of 538 -@article{Reck22, -author = {Reck, M, Liu, SV, Owen, SP, Garon, EB, Neal, JW, Vicente, D, Mekan, SF, Safavi, F, Fernando, N, and Mok, TSK}, -title = {EP08.02-098 Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab±Platinum in First-Line Metastatic NSCLC}, -journal = {Journal of thoracic oncology}, -volume = {17}, -number = {9}, -pages = {S448}, -year = {2022}, -accession_number = {EMBASE 2020097581}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer combination chemotherapy; *implanted spinal cord stimulator; *non small cell lung cancer; Adult; Advanced cancer; Adverse drug reaction; Area under the curve; Cancer patient; Cancer staging; Cancer survival; Chemotherapy; Clinical trial; Cohort analysis; Conference abstract; Controlled study; Disease control; Drug combination; Drug safety; Drug therapy; ECOG Performance Status; Eligibility criteria; Female; Gene expression; Human; Hydrolysis; Incidence; Intravenous drug administration; Major clinical study; Male; Multicenter study; Outcome assessment; Overall response rate; Overall survival; Phase 1 clinical trial; Phase 2 clinical trial; Progression free survival; Protein expression; Randomized controlled trial; Response evaluation criteria in solid tumors; Side effect; Systemic therapy}, -abstract = {Introduction: Most patients with advanced NSCLC do not harbor genomic alterations associated with approved first‐line targeted therapies. The standard of care for these patients is a programmed death (ligand)‐1 (PD‐[L]1) inhibitor alone, if the tumor highly expresses PD‐L1, or in combination with platinum doublet chemotherapy, independent of PD‐L1 expression. However, most patients do not respond to these therapies or achieve only a transient response, highlighting an unmet need. Sacituzumab govitecan (SG) is an antibody‐drug conjugate composed of an anti‐Trop‐2 antibody coupled to the cytotoxic SN‐38 payload via a proprietary, hydrolyzable linker. In the phase 1/2 IMMU‐132‐01 basket study (NCT01631552), SG demonstrated an objective response rate (ORR) of 17% and median overall survival (OS) of 9.5 months, with a manageable safety profile in 54 patients with metastatic NSCLC after multiple prior therapies (Heist RS, et al. J Clin Oncol. 2017). We hypothesize that combining SG with pembrolizumab or with pembrolizumab + platinum chemotherapy will improve outcomes for patients with advanced NSCLC. Methods: EVOKE‐02 (NCT05186974) is an open‐label, multicenter, multicohort, global phase 2 study evaluating SG plus pembrolizumab with or without carboplatin (carbo) or cisplatin (cis) in advanced NSCLC. Key eligibility criteria include age ≥18 years, stage IV NSCLC at enrollment, measurable disease by RECIST v1.1, ECOG performance status of 0 or 1, and adequate organ function. Patients must not have actionable genomic alterations and must not have received prior systemic therapy for metastatic NSCLC. Up to 164 patients will be enrolled. SG plus pembrolizumab will be assessed in squamous/nonsquamous NSCLC with Tumor Proportion Score (TPS) ≥50% (cohort A, ∼30 patients) and TPS <50% (cohort B, ∼30 patients) and SG plus pembrolizumab with carbo/cis in nonsquamous (cohort C, ∼40 patients) and squamous (cohort D, ∼40 patients) NSCLC regardless of PD‐L1 expression. Patients are randomly assigned if cohorts enrolling concurrently have overlapping eligibility. SG will be administered intravenously (IV) at 10 mg/kg on day 1 and 8 until disease progression or unacceptable toxicity, pembrolizumab 200 mg IV on day 1 for up to 35 cycles, carbo AUC 5 or cis 75 mg/m2 on day 1 for up to 4 cycles in 21‐d cycles. A safety run‐in will be conducted for cohorts C and D (up to 24 patients each) to determine the optimal SG dose by dose de‐escalation. Choice of platinum will be based on preliminary efficacy in safety run‐in. The primary endpoints are ORR assessed by independent review per RECIST v1.1 and the incidence of dose‐limiting toxicities per dose for the first 21 days of the safety run‐in to determine the recommended phase 2 dose of SG in combination with pembrolizumab and a platinum. Key secondary endpoints include progression‐free survival by independent review, OS, duration of response, disease control rate, and safety. This study is open for recruitment and is enrolling globally. Keywords: antibody‐drug conjugate, immune checkpoint inhibitors, phase II clinical trial}, -DOI = {10.1016/j.jtho.2022.07.781}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02461457/full} -} - - -Record #517 of 538 -@article{Naidoo22, -author = {Naidoo, J, Antonia, SJ, Wu, Y-L, Cho, BC, Thiyagarajah, P, Mann, H, Newton, MD, and Faivre-Finn, C}, -title = {Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: a post hoc subgroup analysis from PACIFIC}, -journal = {Journal of clinical oncology}, -volume = {40}, -number = {16}, -year = {2022}, -accession_number = {EMBASE 638834797}, -publication type = {Journal article; Conference proceeding}, -keywords = {*cancer staging; *chemoradiotherapy; *gene mutation; *non small cell lung cancer; Adult; Advanced cancer; Cancer patient; Cancer survival; Clinical trial; Conference abstract; Controlled study; Drug safety; Drug therapy; ECOG Performance Status; Exploratory research; Female; Follow up; Gene expression; Health care quality; Human; Immunotherapy; Induction chemotherapy; Kaplan Meier method; Major clinical study; Male; Outcome assessment; Overall response rate; Overall survival; Phase 3 clinical trial; Pneumonia; Progression free survival; Protein expression; Radiation pneumonia; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Smoking; Tumor cell}, -abstract = {Background: Standard of care for patients (pts) with unresectable (UR) stage III NSCLC is the 'PACIFIC regimen', based on data from the phase 3 placebo (pbo)‐controlled trial where consolidation durva following CRT improved overall survival (OS; hazard ratio [HR], 0.68 [95% CI, 0.53, 0.87]) and progression‐ free survival (PFS; HR, 0.52 [95% CI 0.42, 0.65]), in an all‐comer population. However, the benefit of immunotherapy (IO) in pts with EGFRm stage III NSCLC is unclear. We report a post hoc exploratory efficacy and safety analysis from 35 pts with EGFRm NSCLC from the PACIFIC trial (NCT02125461). Methods: Pts with stage III UR‐NSCLC, WHO performance status (PS) 0/1 and no progression after ≥2 cycles platinum‐based concurrent CRT were randomized 2:1 (1‐42 days post CRT) to receive durva (10mg/kg IV q2w for up to 1 year) or pbo, stratified by age, sex, and smoking history; enrollment was not restricted by oncogenic driver gene mutation status or PD‐L1 expression. Primary endpoints: PFS (BICR; RECIST v1.1) and OS; key secondary endpoints: objective response rate (ORR) and safety. Treatment effects for the EGFRm subgroup were estimated using an unstratified Cox proportional hazard model; medians were estimated using the Kaplan‐Meier method. Statistical analyses were exploratory. Data cut‐off (DCO) for the EGFRm subgroup efficacy analysis was 11 January 2021. Results: Of 713 pts randomized, 35 had EGFRm NSCLC based on local testing (durva n = 24, pbo n = 11). In the EGFRm subgroup, more pts in the pbo vs durva arm were male (73% vs 54%), had stage IIIA disease (64% vs 46%), PS 0 (64% vs 54%) and received pre‐CRT induction chemotherapy (36% vs 8%). More pts in the durva arm were Asian (63% vs 55%) and had PD‐L1 on < 25% tumor cells (67% vs 36%); median age was consistent across arms. At DCO, median duration of follow‐up for survival was 42.7 months (range, 3.7‐74.3 months) for all randomized pts in the subgroup. Median PFS was 11.2 months (95% CI 7.3, 20.7) with durva vs 10.9 months (95% CI 1.9, not evaluable [NE]) with pbo; HR 0.91 (95% CI 0.39, 2.13). Median OS was 46.8 months (95% CI 29.9, NE) with durva vs 43.0 months (95% CI 14.9, NE) with pbo; HR 1.02 (95% CI 0.39, 2.63). ORR was 26.1% (95% CI, 10.2, 48.4) and 18.2% (95% CI 2.3, 51.8) with durva and pbo, respectively. The safety profile for durva was consistent with the overall population. In the durva and pbo subgroup arms, radiation pneumonitis was reported in 42% vs 36% of pts, and pneumonitis was reported in 17% vs 18% of pts (1 grade 3, pbo arm), respectively. Conclusions: In this post hoc exploratory analysis of 35 pts, PFS and OS outcomes with durva were similar to pbo in the EGFRm population, with wide CIs. The benefit of IO in this population remains unclear. The ongoing LAURA study (NCT03521154) is investigating the efficacy and safety of maintenance osimertinib in pts with locally advanced EGFRm stage III URNSCLC with no progression after CRT.}, -DOI = {10.1200/JCO.2022.40.16_suppl.8541}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02454637/full} -} - - -Record #518 of 538 -@article{De Wit18, -author = {De Wit, M, Laack, E, Schulz, C, Wolff, T, Rueckert, A, Reck, M, Faehling, M, and Fischer, J}, -title = {PACIFIC: a double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC}, -journal = {Strahlentherapie und Onkologie}, -volume = {194}, -number = {1}, -pages = {24}, -year = {2018}, -accession_number = {EMBASE 622759268}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer patient; *cancer staging; *chemoradiotherapy; *non small cell lung cancer; *visually impaired person; Adult; Conference abstract; Controlled study; Death; Disease course; Distant metastasis; Double blind procedure; Drug safety; Drug therapy; Female; Follow up; Global health; Human; Major clinical study; Male; Phase 3 clinical trial; Physical performance; Pneumonia; Radiotherapy; Randomized controlled trial}, -abstract = {Introduction: Most patients (pts) with locally advanced NSCLC progress despite concurrent CRT. Here we report interim results from a global, Phase 3 study of the anti‐PD‐L1 durvalumab (D) as consolidation therapy in Stage III pts without progression following pt‐based cCRT. Methods: Pts with a WHO PS 0/1 who received ≥2 cycles of Pt‐based cCRT without progression were randomized (2:1) 1‐42 days postcCRT to receive D 10 mg/kg IV Q2 W or placebo for up to 12 months (mo.). Co‐primary endpoints were PFS and OS. Secondary endpoints were 12‐ and 18‐month PFS rates, ORR, DoR, time to death or distant metastasis (TTDM) and safety. Physical performance and global health status were also assessed. Results: Between 05/2014 and 04/2016, 709 (26 from Deutschland) received consolidation treatment (D, n = 473; placebo, n = 236). Median follow‐up was 14.5 mo. Median PFS was significantly longer with D (16.8 mo., 95% CI, 13.0‐18.1) vs placebo (5.6 mo., 95% CI, 4.6‐7.8; stratified HR 0.52, 95% CI, 0.42‐0.65; P < 0.0001). 12‐ and 18‐month PFS rates were 55.9% versus 35.3% and 44.2% vs 27.0%. ORR was higher (28.4% vs 16.0%; P < 0.001) and median DoR was longer (n. r. vs 13.8 mo.) with D consolidation therapy. Median TTDM was longer with D (23.2 vs 14.6 mo.; stratified HR 0.52, 95% CI, 0.39‐ 0.69; P < 0.0001). OS data were immature at the time of interim PFS analysis. Comparing D with placebo, grade 3/4 AEs occurred in 29.9% and 26.1%; most common was pneumonia (4.4% vs 3.8%). 15.4% and 9.8% discontinued due to AEs. Conclusions: D demonstrated significant and clinically meaningful improvement in PFS and was well tolerated.}, -DOI = {10.1007/s00066-018-1301-7}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01729240/full} -} - - -Record #519 of 538 -@article{Jabbour20, -author = {Jabbour, S, Cho, BC, Bria, E, Kato, T, Bhosle, J, Gainor, JF, Reguart, N, Wang, L, Morgensztern, D, Gurary, EB, Ashraf, TB, Lara-Guerra, H, and Reck, M}, -title = {Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT followed by durvalumab (Durva) in unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYLYNK-012}, -journal = {Annals of oncology}, -volume = {31}, -pages = {S810‐S811}, -year = {2020}, -accession_number = {EMBASE 2007889416}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer staging; *chemoradiotherapy; *non small cell lung cancer; Adult; Biotechnology; Cancer patient; Clinical trial; Conference abstract; Controlled study; Double blind procedure; Doublet chemotherapy; Drug combination; Drug safety; Drug therapy; Drug withdrawal; Employee; Female; Funding; Histology; Histopathology; Human; Human tissue; Japan; Licensing; Male; North America; Parttime employment; Phase 3 clinical trial; Quality of life; Radiotherapy; Randomization; Randomized controlled trial; Response evaluation criteria in solid tumors; Travel; Wales; Writing}, -abstract = {Background: Pembro, an anti‒PD‐1 antibody is standard of care therapy for metastatic NSCLC as monotherapy and in combination with chemotherapy. Durva, an anti–PD‐L1 antibody, is approved for unresectable, stage III NSCLC without disease progression (PD) following CCRT. Early trials of pembro in combination with CRT, either concurrent or as consolidation, showed acceptable tolerability and promising PFS in patients (pts) with unresectable stage III NSCLC. Early data suggest the combination of poly(ADP‐ribose) polymerase (PARP) + anti–PD‐(L)1 inhibition can enhance treatment effects. KEYLYNK‐012 (NCT04380636) evaluates pembro + CCRT followed by pembro with/without the PARP inhibitor ola vs CCRT followed by durva in pts with unresectable, locally advanced, stage III NSCLC. Trial design: This global phase 3, randomized, placebo‐ and active‐controlled, double‐blind study will enroll pts aged ≥18 y with previously untreated, pathologically confirmed, stage IIIA–C NSCLC, ECOG PS 0/1, and tumor sample available for PD‐L1 evaluation. Pts will be randomized 1:1:1 to CCRT (platinum‐doublet chemotherapy [cisplatin + pemetrexed or etoposide; or carboplatin + paclitaxel] + radiotherapy 60 Gy over 6 wk [cycles 2–3]) with pembro 200 mg Q3W (groups A and B) or CCRT alone (group C) for 3 cycles. This will be followed by pembro 200 mg Q3W for 17 cycles + placebo (group A) or ola 300 mg BID (group B); or durva 10 mg/kg Q2W for 26 cycles (group C). Randomization is stratified by disease stage (IIIA vs IIIB/IIIC), tumor histology (squamous vs nonsquamous), PD‐L1 tumor proportion score (≥50% vs <50%) and region (East Asia vs North America/Western Europe/UK vs other). PFS (RECIST v1.1 by blinded independent central review [BICR]) and OS are dual primary endpoints. Secondary endpoints include ORR, DOR, safety and tolerability, and QOL outcomes. After CCRT, tumor response will be evaluated per RECIST v1.1 by BICR and at regular intervals throughout the study until PD, new cancer therapy, study withdrawal, or death. AEs will be graded by NCI CTCAE v5.0. Enrollment will begin Jun 8, 2020 at 220 sites. Clinical trial identification: NCT04380636; EudraCT, 2019‐003237‐41. Editorial acknowledgement: Writing support was provided by Christabel Wilson, MSc, of ICON plc (North Wales, PA, USA). Legal entity responsible for the study: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Disclosure: S. Jabbour: Research grant/Funding (institution): Merck, Nestle; Advisory/Consultancy: Merck. B.C. Cho: Research grant/Funding (institution): Novartis, Bayer, AstraZeneca, Mogam Biotechnology Institute, Dong‐A ST, Champions Oncology, Janssen, Yuhan, Ono Pharmaceutical, Dizal Pharma, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, AbbVie, Medpacto, and GI Innov; Advisory/Consultancy: Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Bristol‐Myers Squibb, Ono Pharmaceutical, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Shareholder/Stockholder/Stock options: TheraCanVac Inc, Gencurix Inc., and BridgeBio Inc.; Licensing/Royalties: Champions Oncology. E. Bria: Honoraria (self), Travel/Accommodation/Expenses: MSD, AstraZeneca, Celgene, Pfizer, Helsinn, Eli Lilly, Bristol‐Myers Squibb, Novartis and Roche; Advisory/Consultancy: Roche, Pfizer; Research grant/Funding (institution): AstraZeneca, Roche. T. Kato: Full/Part‐time employment: Eli Lilly; Honoraria (self): Chugai Pharma; Roche; Boehringer Ingelheim; Ono Pharmaceutical; Eli Lilly; AstraZeneca; Taiho Pharmaceutical; Pfizer; Bristol‐Myers Squibb Japan; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Novartis; Sumitomo Dainipp; Advisory/Consultancy: AstraZeneca; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Eli Lilly; Chugai Pharma; Nitto Denko; AbbVie; Merck Serono; Pfizer; Research grant/Funding (institution): Chugai Pharma; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Kyowa Hakko Kirin; Pfizer; Taiho Pharmaceutical; AstraZeneca; Eli Lilly; AbbVie; Astellas Pharma; Ono Pharmaceutical; Merck Serono; Research grant/Funding (self): Kyorin; Regeneron. J.F. Gainor: Honoraria (self), Advisory/Consultancy: Bristol‐Myers Squibb, Genentech/Roche, Ariad/Takeda, Loxo, Lilly, Blueprint, Oncorus, Regeneron, Gilead, Pfizer, Incyte, Novartis, Merck, Agios, Amgen, Array, Clovis Oncology; Research grant/Funding (self): Novartis, Genentech/Roche, and Ariad/Takeda; Research grant/Funding (institution): Bristol‐Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck, Adaptimmune, Novartis, and Alexo; Full/Part‐time employment, Immediate family member is an employee: Ironwood Pharmaceuticals. N. Reguart: Honoraria (self), Advisory/Consultancy: MSD, Bristol‐Myers Squibb, Roche, Boehringer Ingelheim, Guardant Health, Pfizer, AbbVie, Ipsen, Novartis, AstraZeneca, Lilly, Takeda, Amgen, Agilent Technologies. Research grants: Novartis, Pfizer. D. Morgensztern: Advisory/Consultancy: Gilead, Bristol‐Myers Squibb, AbbVie, Takeda, PharmaMar. E.B. Gurary: Full/Part‐time employment: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. T.B. Ashraf: Full/Part‐time employment: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. H. Lara‐Guerra: Full/Part‐time employment: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Shareholder/Stockholder/Stock options: Merck & Co., Inc., Kenilworth, NJ, USA; Aeglea BioTherapeutics, Inc. M. Reck: Honoraria (self), Advisory/Consultancy: Amgen; AstraZeneca; Bristol‐Myers Squibb; Boehringer Ingelheim; Celgene; Merck; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Eli Lilly; Pfizer; AbbVie; Roche; Novartis. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2020.08.151}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02176726/full} -} - - -Record #520 of 538 -@article{Perol24, -author = {Perol, M, Goto, K, Solomon, BJ, Park, K, Nadal, E, Bria, E, Martin, C, Bar, J, Williams, J, Puri, T, Li, J, Uh, M, Lin, BK, and Zhou, C}, -title = {Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {16}, -year = {2024}, -accession_number = {EMBASE 644911944}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Adult; Brain metastasis; Conference abstract; Controlled study; Drug therapy; Human; Major clinical study; Male; Phase 3 clinical trial; Prevention; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Special situation for pharmacovigilance; Therapy}, -abstract = {Background: Selpercatinib is a highly selective and potent CNS active RET inhibitor approved for treatment of advanced RET fusion‐positive (RET+) NSCLC. Treatment or prevention of CNS disease is critical in RET+ NSCLC patients (pts), who have nearly a 50% lifetime prevalence of brain metastases (mets) (Drilon et al. JTO 2018). LIBRETTO‐431 is the first study to compare intracranial (IC) efficacy of a targeted therapy to chemo/IO in pts with oncogene driven NSCLC. Methods: LIBRETTO‐431 (NCT04194944) is a randomized, open‐label, phase 3 trial comparing 1L selpercatinib vs chemotherapy (cisplatin/carboplatin + pemetrexed) +/‐ pembrolizumab. As previously reported, the study met its primary endpoint of PFS by blinded independent central review (BICR) at the pre‐planned interim analysis. IC analyses included CNS and non‐CNS PD, IC PFS and IC responses by BICR per RECIST 1.1 in all pts who had a baseline and one or more post‐baseline CNS scans (CNS‐evaluable) and were designated to receive pembrolizumab if randomized to the control arm (CNS‐pembro population). Adverse events were evaluated in the CNS safety population. Results: A total of 192 of 261 pts enrolled were CNS‐evaluable (selpercatinib: 120, control: 72). Baseline characteristics were generally balanced with the selpercatinib arm having a slightly lower proportion of pts with BICR‐assessed baseline brain mets (21% vs 25%) and prior CNS radiotherapy (RT; 6% vs 10%) compared to the control arm. Selpercatinib delayed CNS PD as evidenced by a lower 12 mo cumulative incidence rate (CIR) for CNS PD, as well as delaying non‐CNS PD compared to control in pts with and without brain mets (Table). In pts with measurable brain mets at baseline (n=29), median time to IC response per RECIST 1.1 was similar between selpercatinib and control (1.4 mo [range: 1.2‐2.9] vs 1.6 mo [range: 1.2‐ 2.9]); however, as previously reported the IC response rates were higher (82% vs 58%) and more durable (12 mo DOR rate 76% vs 63%) with selpercatinib vs control (Zhou et al. NEJM 2023). IC responses to selpercatinib were more common in pts without prior CNS RT (14/15, 93%) than with prior CNS RT (3/6, 50%). Conclusions: Selpercatinib delayed IC progression in advanced RET+ NSCLC pts with or without baseline brain mets and achieved higher IC response rates compared to chemotherapy + pembrolizumab. LIBRETTO‐431 is the first study to demonstrate IC efficacy improvement of a targeted therapy vs chemo/IO in a biomarker selected NSCLC population. These data further support selpercatinib as the preferred 1L regimen in pts with advanced RET+ NSCLC.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02736365/full} -} - - -Record #521 of 538 -@article{Uh24, -author = {Uh, M, Perol, M, Goto, K, Solomon, BJ, Park, K, Nadal, E, Bria, E, Martin, C, Bar, J, Williams, J, Puri, T, Li, J, Lin, BK, and Zhou, C}, -title = {Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study}, -journal = {Journal of clinical oncology}, -volume = {42}, -number = {23}, -year = {2024}, -accession_number = {EMBASE 645166759}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Adult; Brain metastasis; Conference abstract; Controlled study; Drug therapy; Human; Major clinical study; Phase 3 clinical trial; Phase 4 clinical trial; Prevention; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Special situation for pharmacovigilance; Therapy}, -abstract = {Background: Selpercatinib is a highly selective and potent CNS active RET inhibitor approved for treatment of advanced RET fusion‐positive (RET+) NSCLC. Treatment or prevention of CNS disease is critical in RET+ NSCLC patients (pts), who have nearly a 50% lifetime prevalence of brain metastases (mets) (Drilon et al. JTO 2018). LIBRETTO‐431 is the first study to compare intracranial (IC) efficacy of a targeted therapy to chemo/IO in pts with oncogene driven NSCLC. Methods: LIBRETTO‐431 (NCT04194944) is a randomized, open‐label, phase 3 trial comparing 1L selpercatinib vs chemotherapy (cisplatin/carboplatin + pemetrexed) +/‐ pembrolizumab. As previously reported, the study met its primary endpoint of PFS by blinded independent central review (BICR) at the pre‐planned interim analysis. IC analyses included CNS and non‐CNS PD, IC PFS and IC responses by BICR per RECIST 1.1 in all pts who had a baseline and one or more post‐baseline CNS scans (CNS‐evaluable) and were designated to receive pembrolizumab if randomized to the control arm (CNS‐pembro population). Adverse events were evaluated in the CNS safety population. Results: A total of 192 of 261 pts enrolled were CNS‐evaluable (selpercatinib: 120, control: 72). Baseline characteristics were generally balanced with the selpercatinib arm having a slightly lower proportion of pts with BICR‐assessed baseline brain mets (21% vs 25%) and prior CNS radiotherapy (RT; 6% vs 10%) compared to the control arm. Selpercatinib delayed CNS PD as evidenced by a lower 12 mo cumulative incidence rate (CIR) for CNS PD, as well as delaying non‐CNS PD compared to control in pts with and without brain mets (Table). In pts with measurable brain mets at baseline (n=29), median time to IC response per RECIST 1.1 was similar between selpercatinib and control (1.4 mo [range: 1.2‐2.9] vs 1.6 mo [range: 1.2‐ 2.9]); however, as previously reported the IC response rates were higher (82% vs 58%) and more durable (12 mo DOR rate 76% vs 63%) with selpercatinib vs control (Zhou et al. NEJM 2023). IC responses to selpercatinib were more common in pts without prior CNS RT (14/15, 93%) than with prior CNS RT (3/6, 50%). Conclusions: Selpercatinib delayed IC progression in advanced RET+ NSCLC pts with or without baseline brain mets and achieved higher IC response rates compared to chemotherapy + pembrolizumab. LIBRETTO‐431 is the first study to demonstrate IC efficacy improvement of a targeted therapy vs chemo/IO in a biomarker selected NSCLC population. These data further support selpercatinib as the preferred 1L regimen in pts with advanced RET+ NSCLC. (Table Presented).}, -DOI = {10.1200/JCO.2024.42.23_suppl.199}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02749267/full} -} - - -Record #522 of 538 -@article{Laack18, -author = {Laack, H-E, Schulz, C, Wolff, T, Ruckert, A, Reck, M, Faehling, M, Fischer, JR, and De Wit, M}, -title = {PACIFIC: a double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC}, -journal = {Oncology research and treatment}, -volume = {41}, -pages = {186‐187}, -year = {2018}, -accession_number = {EMBASE 621265795}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer staging; *chemoradiotherapy; *non small cell lung cancer; *visually impaired person; Adult; Conference abstract; Controlled study; Death; Disease course; Distant metastasis; Double blind procedure; Drug therapy; Female; Follow up; Germany; Global health; Human; Major clinical study; Male; Phase 3 clinical trial; Physical performance; Pneumonia; Radiotherapy; Randomized controlled trial}, -abstract = {Purpose: Most patients (pts) with locally advanced NSCLC progress despite concurrent CRT.Here we report interim results from a global, Phase 3 study of the anti‐PD‐L1 durvalumab (D) as consolidation therapy in Stage III pts without progression following pt‐based cCRT. Methods: Pts with a WHO PS 0/1 who received ��2 cycles of Pt‐based cCRT without progression were randomized (2:1) 1‐42 days post‐cCRT to receive D 10 mg/kg IV Q2W or placebo for up to 12 months (mo.). Co‐primary endpoints were PFS and OS. Secondary endpoints were 12‐ and 18‐month PFS rates, ORR, DoR, time to death or distant metastasis (TTDM) and safety. Physical performance and global health status were also assessed. Results: Between 05/2014 and 04/2016, 709 (26 from Germany) received consolidation treatment (D, n = 473; placebo, n = 236). Median follow‐ up was 14.5 mo. Median PFS was significantly longer with D (16.8 mo., 95% CI, 13.0‐18.1) vs placebo (5.6 mo., 95% CI, 4.6‐7.8; stratified HR 0.52, 95% CI, 0.42‐0.65; P < 0.0001). 12‐ and 18‐month PFS rates were 55.9% versus 35.3% and 44.2% vs 27.0%. ORR was higher (28.4% vs 16.0%; P < 0.001) and median DoR was longer (n.r. vs 13.8 mo.) with D consolidation therapy. Median TTDM was longer with D (23.2 vs 14.6 mo.; stratified HR 0.52, 95% CI, 0.39‐0.69; P < 0.0001). OS data were immature at the time of interim PFS analysis. Comparing D with placebo, grade 3/4 AEs occurred in 29.9% and 26.1%; most common was pneumonia (4.4% vs 3.8%). 15.4% and 9.8% discontinued due to AEs. Conclusions: D demonstrated significant and clinically meaningful improvement in PFS and was well tolerated.}, -DOI = {10.1159/000487109}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01467348/full} -} - - -Record #523 of 538 -@article{Faivre-Finn18, -author = {Faivre-Finn, C, Spigel, DR, Senan, S, Langer, CJ, Raben, D, Perez, B, Ozgu roglu, M, Daniel, D, Villegas, A, Vicente, D, Hui, R, Murakami, S, Paz-Ares, L, Poole, L, Wadsworth, C, Dennis, PA, and Antonia, SJ}, -title = {Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC}, -journal = {Annals of oncology}, -volume = {29}, -pages = {viii488}, -year = {2018}, -accession_number = {EMBASE 628559449}, -publication type = {Journal article; Conference proceeding}, -keywords = {*drug safety; *randomization; Adult; Advanced cancer; Chemoradiotherapy; Conference abstract; Controlled study; Death; Distant metastasis; Double blind procedure; Drug efficacy; Drug therapy; Female; Human; Incidence; Major clinical study; Male; Non small cell lung cancer; Pharmacokinetics; Radiation pneumonia; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Smoking}, -abstract = {Background: In the Ph 3 PACIFIC study of durvalumab (durva) versus placebo (pbo) in pts with stage III, locally advanced (LA), unresectable NSCLC after concurrent chemoradiotherapy (cCRT), PFS was significantly longer with durva (stratified HR 0.52; 95% CI 0.42‐0.65; P<0.0001). This exploratory analysis characterizes outcomes based on time from completing RT to Tx. Methods: PACIFIC (NCT02125461) was a randomized, double‐blind, all‐comers study of LA NSCLC pts withWHOPS 0/1 who did not progress after ≥2 cycles of platinumbased cCRT. Pts were stratified by age, sex and smoking history and randomized (2:1) to durva 10 mg/kg IV Q2W or pbo up to 12 months. Co‐primary endpoints were PFS (BICR, RECIST v1.1) and OS (not available). Secondary endpoints included ORR, time to death/distant metastases (TTDM) and safety. We investigated potential associations between time to randomized Tx (<14 or≥14 days) with efficacy and safety. Results: As of Feb 13, 2017, 713 pts were randomized, 26% within 14 days of RT. Baseline characteristics between the durva and pbo arm were well balanced in both the <14 and≥14 days groups. PFS benefit with durva compared to pbo was observed regardless of timing from RT to randomization (<14 days: median NR vs 4.8 months, HR=0.39, 95% CI: 0.26‐0.58;≥14 days: median 14.0 vs 5.6 months, HR=0.63, 95% CI: 0.49‐0.80). In addition, TTDM (<14 days: HR=0.33, 95% CI: 0.20‐0.55;≥14 days: HR=0.70, 95% CI: 0.51‐0.95) and ORR (<14 days: 34.2% vs 16.4%; ≥14 days: 26.5% vs 15.8%) favored durva, regardless of time to randomization. There were no reported differences in safety with durva based on time to randomization, with incidences of any‐cause grade 3/4 AEs (34.2% vs 31.3%) and SAEs (30.0% vs 28.2%) comparable across subgroups. In contrast, earlier randomization in the pbo arm was associated with increased rates of grade 3/4 AEs (33.3% vs 25.9%) and SAEs (33.3% vs 19.0%). Early randomization had minimal impact on grade ≥3 pneumonitis/radiation pneumonitis with durva (4.2% vs 4.5%). Conclusions: Durva provided clinical benefit compared to pbo, regardless of time from RT to randomization. There was no meaningful difference in safety, including high grade AEs, in durva‐treated patients randomized within 2 weeks from RT versus later.}, -DOI = {10.1093/annonc/mdy291}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01961366/full} -} - - -Record #524 of 538 -@article{Cao17, -author = {Cao, Y, Qiu, X, Xiao, G, and Hao, H}, -title = {Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: an observational real-world study}, -journal = {Annals of oncology}, -volume = {28}, -pages = {x129}, -year = {2017}, -accession_number = {EMBASE 620035349}, -publication type = {Journal article; Conference proceeding}, -keywords = {*non small cell lung cancer; Adenocarcinoma; Adult; Adverse event; Aged; Brain metastasis; Cancer staging; Cancer survival; Chemotherapy; Clinical article; Clinical practice; Comparative effectiveness; Controlled study; Cytology; Drug therapy; Fatigue; Female; Human; Human tissue; Immunotherapy; Macao; Male; Middle aged; Molecularly targeted therapy; Mutation; Nausea; Observational study; Pharmacokinetics; Plasma; Pneumonia; Progression free survival; Radiation; Randomized controlled trial; Rash; Remission}, -abstract = {Background: Osimertinib is an irreversible EGFR tyrosine kinase inhibitor (TKI) selective for both EGFR activating and T790M resistance mutations. In randomized controlled trials (RCTs), osimertinib showed encouraging efficacy in patients with advanced EGFR T790M mutation‐positive NSCLC; however, further investigation is needed in the real‐world where the patient population is more diverse. This study aimed to assess the effectiveness and safety of osimertinib in a real‐world setting. Methods: This observational study enrolled 47 patients with metastatic EGFR T790M‐positive NSCLC who progressed on prior EGFR TKI therapy and commenced osimertinib treatment between May and Oct 2016 in Macau. All patients received osimertinib 80 mg once daily until physician‐assessed disease progression. Primary endpoint was response rate (RR). Secondary endpoints included progression free survival (PFS), adverse events (AEs), T790M testing characteristics, and treatment patterns. Results: All patients had stage IV adenocarcinoma and 23.4% had brain metastases; median age was 59.0 years (range 37‐83 years) and 68.1% were female. Prior treatments included EGFR TKI targeted therapy (100%), chemotherapy (46.8%), radiation (19.1%), and immunotherapy (2.1%). 57.5% of patients received osimertinib as a second line therapy. T790M mutation was detected in either plasma (46.8%) or tissue/cytology (42.6%) samples; sample type was unknown in 5 (10.6%) patients. At data cut‐off (15 Jun 2017), 22 patients were still on osimertinib therapy. Physician‐assessed RR was 53.2% (95% CI 38.1‐67.9%; 6.4% complete response; 46.8% partial response) and 38.3% had stable disease. Median PFS was 9.6 months (95% CI 5.6‐10.9 months). Frequency of all AEs and AEs grade >3 were 38.3% and 4.3%, respectively. Most common AEs were rash (14.9%), fatigue (12.8%), and nausea (10.6%). Pneumonitis was reported in 1 patient (2.1%). Conclusions: Real‐world physician‐assessed RR and PFS with osimertinib appear comparable to that reported in RCTs; no new safety signals were observed. Our data corroborate the findings of RCTs and suggest that osimertinib provides encouraging effectiveness and similar safety when used in real‐world clinical practice.}, -DOI = {10.1093/annonc/mdx671.014}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01452627/full} -} - - -Record #525 of 538 -@article{Xing21, -author = {Xing, L, Yu, J, Peters, S, Besse, B, Spira, A, Wang, J, Yang, Y, and Wang, H}, -title = {167TiP AdvanTIG-301: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) + tislelizumab (TIS) + concurrent chemoradiotherapy (cCRT) followed by OCI + TIS or TIS + cCRT followed by TIS vs cCRT followed by durvalumab (DUR) in previously untreated, locally advanced, unresectable NSCLC}, -journal = {Annals of oncology}, -volume = {32}, -pages = {S1455}, -year = {2021}, -accession_number = {EMBASE 2015743773}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *chemoradiotherapy; *drug tolerability; *non small cell lung cancer; Adult; Antineoplastic activity; Aptitude; Cancer patient; Cancer staging; Cancer survival; Clinical trial; Conference abstract; Consultation; Controlled study; Drug safety; Drug therapy; ECOG Performance Status; Eligibility criteria; Female; Financial management; Gene mutation; Histopathology; Human; Human cell; Leukocyte activation; Macrophage; Major clinical study; Male; Medical literature; Multicenter study; Oncologist; Open study; Overall response rate; Overall survival; Parttime employment; Phagocytosis; Phase 3 clinical trial; Preclinical study; Progression free survival; Radiotherapy; Randomized controlled trial; Remission; Response evaluation criteria in solid tumors; Tumor cell}, -abstract = {Background: Around one third of patients (pts) with NSCLC present with Stage III, locally advanced disease at initial diagnosis. Programmed death‐ligand 1 (PD‐L1) inhibitor, DUR, is the current standard of care for pts whose disease had not progressed following cCRT. Anti‐T cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif domain (TIGIT) is a co‐inhibitory immune checkpoint receptor upregulated on T cells and natural killer cells in multiple solid tumors. OCI is a humanized mAb that binds TIGIT with high specificity and affinity, blocking interaction with its ligands on tumor cells. TIS is an anti‐PD‐1 antibody engineered to minimize binding to FcγR on macrophages to abrogate antibody‐dependent phagocytosis. Dual targeting with OCI and TIS produced synergistic immune cell activation and enhanced antitumor activity in preclinical models. Trial Design: AdvanTIG‐301 is a Phase 3, multicenter, international, randomized, open‐label study (NCT04866017) in adult pts with newly diagnosed, histologically confirmed, locally advanced, Stage III unresectable NSCLC. Approximately 900 pts will be randomized 1:1:1 to receive: two cycles of OCI 900 mg IV + TIS 200 mg IV Q3W + cCRT followed by OCI 900 mg IV + TIS 200 mg IV Q3W up to 1 year after cCRT (Arm A), two cycles of TIS 200 mg IV Q3W + cCRT followed by TIS 200 mg IV Q3W up to 1 year after cCRT (Arm B), two cycles of cCRT followed by DUR 10 mg/kg IV Q2W (or 1500 mg IV Q4W) up to 1 year after cCRT (Arm C). Key eligibility criteria include ECOG PS ≤1 and no EGFR and ALK mutation. Primary endpoints, all by Independent Review Committee (IRC; RECIST v1.1), are progression‐free survival (PFS) between Arm A and C, complete response rate between Arm A and C, and PFS between Arm B and C. Secondary endpoints include overall survival, IRC‐assessed PFS between Arm A and C in the PD‐L1‐positive population, and investigator‐assessed PFS, IRC‐ and investigator‐assessed overall response rate and duration of response (all between Arm A and B, Arm A and C and Arm B and C), and safety and tolerability. Clinical trial identification: NCT04866017. Editorial acknowledgement: This study is sponsored by BeiGene, Ltd. Medical writing support, under the direction of the authors, was provided by Tamsin Grewal, MSc, and Jessica Jones, PhD, of Ashfield Medcomms, an Ashfield Health company, and funded by BeiGene, Ltd. Legal entity responsible for the study: BeiGene Ltd. Funding: BeiGene Ltd. Disclosure: S. Peters: Consultation / Advisory role: AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Bio Invent, Blueprint Medicines, Boehringer Ingelheim, Bristol‐Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, Elsevier, F. Hoffmann‐La Roche/Genentech, Foundation Medicine, Illumina, Incyte, IQVIA, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Novartis, Pharma Mar, Phosplatin Therapeutics, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, Vaccibody; Talk in a company’s organized public event: AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, e‐cancer, Eli Lilly, F. Hoffmann‐La Roche/Genentech, Illumina, Medscape, Merck Sharp and Dohme, Novartis, PER, Pfizer, Prime, RTP, Sanofi, Takeda; Receipt of grants/research supports: (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol‐Myers Squibb, Clovis, F. Hoffmann‐La Roche/Genentech, GSK, Illumina, Lilly, Merck Sharp and Dohme, Merck Serono, Mirati, Novartis, and Pfizer, Phosplatin Therapeutics. B. Besse: Financial Interests, Institutional, Research Grant: 4D Pharma; Financial Interests, Institutional, Research Grant: AbbVie; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Research Grant: Aptitude Health; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: BeiGene; Financial Interests, Institutional, Research Grant: Blueprint Medicines; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Financial Interests, Institutional, Research Grant: Boehringer‐Ingelheim; Financial Interests, Institutional, Research Grant: Celgene; Financial Interests, Institutional, Research Grant: Cergentis; Financial Interests, Institutional, Research Grant: Cristal Therapeutics; Financial Interests, Institutional, Research Grant: Daiichi‐Sankyo; Financial Interests, Institutional, Research Grant: Eli Lilly; Financial Interests, Institutional, Research Grant: GSK; Financial Interests, Institutional, Research Grant: Inivata; Financial Interests, Institutional, Research Grant: Janssen; Financial Interests, Institutional, Research Grant: Onexo; Financial Interests, Institutional, Research Grant: OSE Immunotherapeutics; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Roche‐Genentech; Financial Interests, Institutional, Research Grant: Sanofi; Financial Interests, Institutional, Research Grant: Takeda; Financial Interests, Institutional, Research Grant: Tolero Pharmaceuticals. A. Spira: Financial Interests, Personal and Institutional, Advisory Board: Incyte; Financial Interests, Personal and Institutional, Advisory Board: Amgen; Financial Interests, Personal and Institutional, Advisory Board: Novartis; Financial Interests, Personal and Institutional, Advisory Board: Mirati Therapeutics; Financial Interests, Personal and Institutional, Advisory Board: Gritstone Oncology; Financial Interests, Personal and Institutional, Advisory Board: Jazz Pharmaceuticals; Financial Interests, Personal and Institutional, Advisory Board: Takeda; Financial Interests, Personal and Institutional, Advisory Board: Janssen Research and Development; Financial Interests, Personal and Institutional, Advisory Board: Array BioPharma; Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca; Financial Interests, Personal and Institutional, Advisory Board: Merck; Financial Interests, Personal and Institutional, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Full or part‐time Employment: Virginia Cancer Specialists; Financial Interests, Personal, Stocks/Shares: Eli Lilly; Financial Interests, Personal and Institutional, Funding: LAM Therapeutics; Financial Interests, Personal and Institutional, Funding: Roche; Financial Interests, Personal and Institutional, Funding: AstraZeneca; Financial Interests, Personal and Institutional, Funding: Boehringer‐Ingelheim; Financial Interests, Personal and Institutional, Funding: Astellas Pharma; Financial Interests, Personal and Institutional, Funding: MedImmune; Financial Interests, Personal and Institutional, Funding: Novartis; Financial Interests, Personal and Institutional, Funding: Newlink Genetics; Financial Interests, Personal and Institutional, Funding: Incyte; Financial Interests, Personal and Institutional, Funding: AbbVie; Financial Interests, Personal and Institutional, Funding: Ignyta; Financial Interests, Personal and Institutional, Funding: Trovagene; Financial Interests, Personal and Institutional, Funding: Takeda; Financial Interests, Personal and Institutional, Funding: Macrogenics; Financial Interests, Personal and Institutional, Funding: CytomX Therapeutics; Financial Interests, Personal and Institutional, Funding: Astex Pharmaceuticals; Financial Interests, Personal and Institutional, Funding: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Funding: Loxo; Financial Interests, Personal and Institutional, Funding: Arch Therapeutics; Financial Interests, Personal and Institutional, Funding: Gritstone; Financial Interests, Personal and Institutional, Funding: Plexxikon; Financial Interests, Personal and Institutional, Funding: Amgen; Financial Interests, Personal and Institutional, Funding: Daiichi‐Sankyo; Financial Interests, Personal and Institutional, Funding: ADCT; Financial Interests, Personal and Institutional, Funding: Janssen Oncology; Financial Interests, Personal and Institutional, Funding: Mirati Therapeutics; Financial Interests, Personal and Institutional, Funding: Rubius; Financial Interests, Personal and Institutional, Funding: BeiGene; Financial Interests, Personal and Institutional, Principal Investigator: LAM Therapeutics; Financial Interests, Personal and Institutional, Principal Investigator: Roche; Financial Interests, Personal and Institutional, Principal Investigator: AstraZeneca; Financial Interests, Personal and Institutional, Principal Investigator: Boehringer; Financial Interests, Personal and Institutional, Principal Investigator: Astellas Pharma; Financial Interests, Personal and Institutional, Principal Investigator: MedImmune; Financial Interests, Personal and Institutional, Principal Investigator: Novartis; Financial Interests, Personal and Institutional, Principal Investigator: Newlink Genetics; Financial Interests, Personal and Institutional, Principal Investigator: Incyte; Financial Interests, Personal and Institutional, Principal Investigator: Trovagene; Financial Interests, Personal and Institutional, Principal Investigator: Takeda; Financial Interests, Personal and Institutional, Principal Investigator: Macrogenics; Financial Interests, Personal and Institutional, Principal Investigator: CytomX Therapeutics; Financial Interests, Personal and Institutional, Principal Investigator: Astex Pharmaceuticals; Financial Interests, Personal and Institutional, Principal Investigator: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Principal Investigator: Loxo; Financial Interests, Personal and Institutional, Principal Investigator: Arch Therapeutics; Financial Interests, Personal and Institutional, Principal Investigator: Gritstone; Financial Interests, Personal and Institutional, Principal Investigator: Plexxikon; Financial Interests, Personal and Institutional, Principal Investigator: Amgen; Financial Interests, Personal and Institutional, Principal Investigator: Daiichi‐Sankyo; Financial Interests, Personal and Institutional, Principal Investigator: ADCT; Financial Interests, Personal and Institutional, Principal Investigator: Janssen Oncology; Financial Interests, Personal and Institutional, Principal Investigator: Mirati Therapeutics; Financial Interests, Personal and Institutional, Principal Investigator: Rubius; Financial Interests, Personal and Institutional, Principal Investigator: BeiGene; Financial Interests, Personal and Institutional, Principal Investigator: AbbVie; Financial Interests, Personal and Institutional, Principal Investigator: Ignyta; Financial Interests, Personal and Institutional, Advisory Role: Incyte; Financial Interests, Personal and Institutional, Advisory Role: Amgen; Financial Interests, Personal and Institutional, Advisory Role: Novartis; Financial Interests, Personal and Institutional, Advisory Role: Mirati Therapeutics; Financial Interests, Personal and Institutional, Advisory Role: Gritstone Oncology; Financial Interests, Personal and Institutional, Advisory Role: Jazz Pharmaceuticals; Financial Interests, Personal and Institutional, Advisory Role: Takeda; Financial Interests, Personal and Institutional, Advisory Role: Janssen Research and Development; Financial Interests, Personal and Institutional, Advisory Role: Array BioPharma; Financial Interests, Personal and Institutional, Advisory Role: AstraZeneca; Financial Interests, Personal and Institutional, Advisory Role: Merck; Financial Interests, Personal and Institutional, Advisory Role: Bristol Myers Squibb. Y. Yang: Financial Interests, Personal, Full or part‐time Employment: BeiGene. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2021.10.186}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02387532/full} -} - - -Record #526 of 538 -@article{Loong20, -author = {Loong, HHF, Goto, K, Elamin, YY, Solomon, B, Santini, FC, Soldatenkova, V, Sashegyi, A, Lin, AB, Lin, BK, Wolf, J, Oxnard, GR, Zhou, C, Drilon, A, and Park, K}, -title = {LIBRETTO-431: selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC)}, -journal = {Annals of oncology}, -volume = {31}, -pages = {S893}, -year = {2020}, -accession_number = {EMBASE 2007890862}, -publication type = {Journal article; Conference proceeding}, -keywords = {*area under the curve; *cancer patient; *non small cell lung cancer; Adult; Advanced cancer; Antineoplastic activity; Brain metastasis; Cancer growth; Cancer radiotherapy; Cancer staging; Cancer survival; China; Clinical trial; Conference abstract; Controlled study; Deterioration; Drug efficacy; Drug safety; Drug therapy; Drug withdrawal; Education; Employee; Expert witness; Female; Funding; Geography; Human; Japan; Licensing; Male; Medical literature; Overall response rate; Overall survival; Parttime employment; Patent; Pharmacokinetics; Phase 1 clinical trial; Phase 3 clinical trial; Physician; Polymerase chain reaction; Progression free survival; Radiotherapy; Randomized controlled trial; Response evaluation criteria in solid tumors; Travel}, -abstract = {Background: Platinum‐based chemotherapy +/‐ an immune checkpoint inhibitor, the current standard of care in patients (pts) with RET+ NSCLC, does not account for underlying oncogenic drivers. In the LIBRETTO‐001 phase 1/2 trial, selpercatinib (Loxo‐292), a selective and potent RET inhibitor, demonstrated antitumor activity [objective response rate (ORR) 85%] with a tolerable profile in pts with Tx‐naïve, RET+ NSCLC. This global, open‐label, randomized, controlled, phase 3 trial will evaluate selpercatinib vs platinum‐based and pemetrexed (pem) Tx with or without pembrolizumab (+/‐pembro) in Tx‐naïve pts with advanced or metastatic RET+ non‐squamous NSCLC. Trial design: Pts will be randomized to Arm A: selpercatinib 160 mg BID in continuous 3 week (wk) cycles or Arm B: pem (500 mg/m2 IV) in 3 wk cycles plus investigator’s choice of carboplatin (carbo) (AUC 5) or cisplatin (cis) (75 mg/m2 IV) for 4 cycles. For Arm B, at the investigator’s discretion, pembro (200 mg IV) may also be given for up to 35 cycles and pts may receive maintenance pem +/‐pembro. Crossover is allowed for Arm B pts who progress. Tx will continue until PD, unacceptable toxicity, decision to withdraw or death. Stratification factors are geography: East vs non‐East Asian, brain metastases: yes vs no and intended Tx for Arm B: +/‐pembro. Eligibility criteria are age ≥18 years; Tx‐naïve; non‐squamous Stage IIIB‐IIIC not suitable for surgery/radiation therapy or Stage IV NSCLC; RET+ identification by PCR or NGS (tumor) or NGS (blood); measurable disease by RECIST 1.1; ECOG performance status 0‐2. Key exclusion criteria are presence of other oncogenic drivers or symptomatic CNS metastases. Efficacy assessments will be performed until PD, the start of a new anticancer Tx, death or study completion. The primary endpoint is progression free survival (PFS) per RECIST 1.1 by independent review. Investigator assessed PFS, ORR/duration of response (DOR), intracranial ORR/DOR, overall survival (OS), time to deterioration in pulmonary symptoms, PFS2, RET fusion status: local vs central, safety and pharmacokinetics are secondary endpoints. Clinical trial identification: NCT04194944. Editorial acknowledgement: Hannah Davis, PhD, an Eli Lilly and Company employee, provided medical writing support. Legal entity responsible for the study: Eli Lilly and Company. Funding: Eli Lilly and Company. Disclosure: H.H.F. Loong: Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Celgene; Advisory/Consultancy: Eli Lilly and Company; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis; Advisory/Consultancy: Bayer; Speaker Bureau/Expert testimony: Guardant Health; Speaker Bureau/Expert testimony: Eisai; Research grant/Funding (institution), Travel/Accommodation/Expenses: Merck, Sharp & Dohme; Research grant/Funding (institution): Mundipharma; Travel/Accommodation/Expenses: Pfizer. K. Goto: Honoraria (self), Research grant/Funding (self): Astellas Pharma Inc; Honoraria (self), Research grant/Funding (self): AstraZeneca; Honoraria (self), Research grant/Funding (self): Boehringer Ingelheim; Honoraria (self), Research grant/Funding (self): Bristol‐Myers Squibb; Honoraria (self), Research grant/Funding (self): Chugai Pharma; Honoraria (self), Research grant/Funding (self): Daiichi Sankyo; Honoraria (self): Guardant Health Inc; Honoraria (self): IQVIA Services Japan K.K.; Honoraria (self), Research grant/Funding (self): Janssen Pharmaceutical K.K.; Honoraria (self), Research grant/Funding (self): Kyowa Hakko Kirin Co.,Ltd; Honoraria (self), Research grant/Funding (self): Life Technologies; Honoraria (self), Research grant/Funding (self): Lilly; Honoraria (self), Research grant/Funding (self): MSD; Honoraria (self), Research grant/Funding (self): Nippon Kayaku; Honoraria (self), Research grant/Funding (self): Novartis; Honoraria (self), Research grant/Funding (self): Ono Pharmaceutical; Honoraria (self): Otsuka Pharmaceutica; Honoraria (self), Research grant/Funding (self): Pfizer; Honoraria (self), Research grant/Funding (self): Taiho Pharmaceutical; Honoraria (self), Research grant/Funding (self): Takeda; Advisory/Consultancy: Otsuka; Research grant/Funding (self): Amgen Inc; Research grant/Funding (self): Loxo; Research grant/Funding (self): Medical & Biological Laboratories Co., Ldt.; Research grant/Funding (self): Merck Serono; Research grant/Funding (self): Riken Genesis; Research grant/Funding (self): Sumitomo Dainippon; Research grant/Funding (self): Sysmex Corporation; Research grant/Funding (self): Xcoo. B. Solomon: Advisory/Consultancy: Roche/Genentech; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Bristol‐Myers Squibb; Advisory/Consultancy: Merck; Advisory/Consultancy: Amgen. F.C. Santini: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck Sharp Dohme; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Bayer; Advisory/Consultancy: Lilly; Honoraria (self): Roche; Honoraria (self): Bristol‐Myers Squibb; Honoraria (self): Novartis. V. Soldatenkova: Shareholder/Stockholder/Stock options, Full/Part‐time employment: Eli Lilly & Company. A. Sashegyi: Shareholder/Stockholder/Stock options, Full/Part‐time employment: Eli Lilly & Company. A. Bence Lin: Shareholder/Stockholder/Stock options, Full/Part‐time employment: Eli Lilly & Company. B.K. Lin: Shareholder/Stockholder/Stock options, Full/Part‐time employment: Eli Lilly and Company. J. Wolf: Advisory/Consultancy: AbbVie; Advisory/Consultancy: AstraZeneca; Honoraria (self): Bristol‐Myers Squibb; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Chugai; Advisory/Consultancy: Lilly; Advisory/Consultancy: MSD; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Janssen; Advisory/Consultancy: Loxo/Lilly; Advisory/Consultancy: Amgen; Advisory/Consultancy: Takeda; Speaker Bureau/Expert testimony: Blueprint Medicines. G.R. Oxnard: Honoraria (self): Foundation Medicine; Honoraria (self): Guardant Health; Honoraria (self): Sysmex; Advisory/Consultancy: AbbVie; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: DropWorks; Advisory/Consultancy: GRAIL; Advisory/Consultancy: Illumina; Advisory/Consultancy: Inivata; Advisory/Consultancy: Janssen; Advisory/Consultancy: Loxo; Advisory/Consultancy: Merck; Advisory/Consultancy: Sysmex; Advisory/Consultancy: Takeda; Licensing/Royalties: Patent by DFCI, "Non‐invasive blood‐based monitoring of genomic alterations in cancer", on which I am a co‐author. C. Zhou: Speaker Bureau/Expert testimony: Lilly China; Speaker Bureau/Expert testimony: Sanofi; Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony: Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony: Hengrui; Advisory/Consultancy, Speaker Bureau/Expert testimony: Qilu; Advisory/Consultancy, Speaker Bureau/Expert testimony: Innovent Biologics; Speaker Bureau/Expert testimony: LUYE Phiosciences Inc; Speaker Bureau/Expert testimony: Amoy Diagnostics; Advisory/Consultancy: Topalliance Biosciences Inc. A. Drilon: Honoraria (self), Research grant/Funding (self): Foundation Medicine; Honoraria (self): Medscape; Honoraria (self), Advisory/Consultancy: MORE Health; Honoraria (self): OncLive; Honoraria (self): Peerview; Honoraria (self): PeerVoice; Honoraria (self): Physicians Education Resources;; Honoraria (self): Research to Practice; Honoraria (self): Targeted Oncology; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Bayer; Advisory/Consultancy: BeiGene; Advisory/Consultancy: BerGenBio; Advisory/Consultancy: Blueprint Medicines; Advisory/Consultancy: Exelixis; Advisory/Consultancy: Genentech/Roche; Advisory/Consultancy: Helsinn Therapeutics; Advisory/Consultancy: Hengrui Therapeutics; Advisory/Consultancy: Ignyta; Advisory/Consultancy: Lilly; Advisory/Consultancy: Loxo; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Takeda/Ariad/Millenium; Advisory/Consultancy: TP Therapeutics; Advisory/Consultancy: Tyra Biosciences; Advisory/Consultancy: Verastem. K. Park: Advisory/Consultancy: AbbVie; Advisory/Consultancy: Amgen; Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy: Blueprint Medicines; Advisory/Consultancy, Speaker Bureau/Expert testimony: Boehringer Ingelheim; Advisory/Consultancy: Bristol‐Myers Squibb; Advisory/Consultancy: Daiichi Sankyo; Advisory/Consultancy: Hanmi; Advisory/Consultancy: Lilly; Advisory/Consultancy: Loxo: Advisory/Consultancy: Merck KGaA; Advisory/Consultancy: MSD; Advisory/Consultancy: Novartis; Advisory/Consultancy: Ono Pharmaceutical; Advisory/Consultancy: Roche; Speaker Bureau/Expert testimony: AZ; Research grant/Funding (self): MSD Oncology. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2020.08.1727}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02176967/full} -} - - -Record #527 of 538 -@article{UMIN00002679917, -author = {UMIN000026799,}, -title = {A randomized phse II study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000026799}, -year = {2017}, -accession_number = {ICTRP UMIN000026799}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: A: 4 cycles of Carboplatin (AUC 6, day 1) plus nab‐Paclitaxel (100 mg/m2, day 1, 8, 15) repeated every 3 weeks B: 4 cycles of Carboplatin (AUC 6, day 1) plus nab‐Paclitaxel (100 mg/m2, day 1, 8, 15) in combination with nintedanib (150 mg B.I.D, daily) repeated every 3 weeks followed by single‐agent administration of nintedanib (150 mg B.I.D, daily) CONDITION: Non‐small‐cell lung cancer with idiopathic pulmonary fibrosis PRIMARY OUTCOME: Time to acute exacerbation of IPF (Initiation of 2nd line chemotherapy for non‐small cell lung cancer is not treated as censored) SECONDARY OUTCOME: Time to acute exacerbation of IPF (Initiation of 2nd line chemotherapy for non‐small cell lung cancer is treated as censored), Exacerbation‐free survival of IPF, Frequency of patients with acute exacerbation of IPF, Rate of decline in FVC (expressed in mL over 12 weeks), Quality of life (QOL), Overall response rate (ORR), Progression‐free survival (PFS) of non‐small cell lung cancer, Time to treatment failure (TTF), Overall survival (OS), toxicity INCLUSION CRITERIA: 1) Written informed consent 2) 20 years of age or older 3) Histologically or cytologically proven non‐small cell lung carcinoma 4) Clinical stage III, IV or recurrent disease after surgery 5) With or without measurable lesions 6) Without symptomatic central nervous system metastases 7) Without uncontrollable cardiac effusion, pleural effusion, ascites, superior vena cava syndrome or spinal cord compression 8) No prior chemotherapy 9) No history of treatment with nintedanib, nab‐paclitaxel or immune checkpoint inhibitor 10) No prior operation under general anesthesia within 14 days before registration 11) No prior palliative radiotherapy within 14 days before registration 12) No prior biopsy under incision, thoracoscopic biopsy, or treatment for wound occurred within 7 days before registration 13) No prior blood transfusion or hematopoietic factor administration within 7 days before registration 14) No history of treatment wi}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01827235/full} -} - - -Record #528 of 538 -@article{Martinez-Marti21, -author = {Martinez-Marti, A, Majem, M, Barlesi, F, Carcereny Costa, E, Chu, Q, Monnet, I, Sanchez, A, Dahkil, S, Camidge, DR, He, P, Soo-Hoo, Y, Cooper, Z, Kumar, R, Bothos, J, Aggarwal, C, and Herbst, RS}, -title = {LBA42 COAST: an open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC}, -journal = {Annals of oncology}, -volume = {32}, -pages = {S1320}, -year = {2021}, -accession_number = {EMBASE 2014622998}, -publication type = {Journal article; Conference proceeding}, -keywords = {*advanced cancer; *cancer combination chemotherapy; *cancer patient; *cancer staging; *histology; *non small cell lung cancer; *seashore; Adult; Antineoplastic activity; Canada; Clinical trial; Conference abstract; Controlled study; Drug safety; Drug therapy; ECOG Performance Status; Follow up; Heat; Histopathology; Human; Human tissue; Identifiable information; Incidence; Leadership; Lymphocyte count; Lymphocytopenia; Major clinical study; Male; Medical literature; Mesothelioma; New York; Parttime employment; Patent; Phase 2 clinical trial; Preclinical study; Protein function; Radiation pneumonia; Randomized controlled trial; Response evaluation criteria in solid tumors; Travel}, -abstract = {Background: PACIFIC established consolidation durvalumab (D) as SoC for unresectable Stage III NSCLC with no progression after cCRT. Combination therapy may improve outcomes. CD73 is involved in RT resistance. RT induces NKG2A ligand and shows additive antitumour effects with PD‐1 blockade preclinically. COAST (NCT03822351) is a global phase 2 study of D alone or combined with the anti‐CD73 mAb oleclumab (O) or anti‐NKG2A mAb monalizumab (M) as consolidation therapy. Methods: Pts with histologically/cytologically documented unresectable Stage III NSCLC, ECOG PS 0/1 and no progression after cCRT were randomised 1:1:1 ≤42 days post cCRT to receive D 1500 mg IV Q4W alone or combined with O 3000 mg IV Q2W (first 2 cycles, then Q4W) or M 750 mg IV Q2W for up to 12 months, stratified by histology. The primary endpoint was investigator‐assessed post cCRT ORR per RECIST v1.1. Key secondary endpoints included PFS and safety. Results: Between Jan 2019 and Jul 2020, 189 pts were randomised, of whom 186 received D (n=66), D+O (n=59) or D+M (n=61). As of 17 May 2021, median follow‐up was 11.5 months (range, 0.4–23.4; all pts). D+O and D+M numerically increased ORR (odds ratio [95% CI] 1.83 [0.80, 4.20] and 1.77 [0.77, 4.11] respectively) and significantly improved PFS versus D alone. Grade ≥3 treatment‐emergent AE (TEAE, all‐cause) incidence was 39.4%, 40.7% and 27.9% with D, D+O and D+M respectively. Overall, the most common grade 3/4 TEAEs were pneumonia (5.9%) and decreased lymphocyte count (3.2%); both were more common with D and D+O than with D+M. Combined rates of pneumonitis and radiation pneumonitis of any grade were 21.2% with D, 28.8% with D+O and 21.3% with D+M, with grade ≥3 events in 3.0%, 3.4% and 1.6%. Biomarker data will be presented. Conclusions: Addition of both novel agents improved ORR, PFS and 10‐month PFS rate over D alone. Safety was similar across arms with no new safety signals identified. [Formula presented] Clinical trial identification: NCT03822351 (release date: January 30, 2019). Editorial acknowledgement: Medical writing support, under the direction of the authors, was provided by Connor Keating, BSc, and Andrew Gannon, MS, MA, of Ashfield MedComms (New York, NY), an Ashfield Health company, and was funded by AstraZeneca. Legal entity responsible for the study: AstraZeneca. Funding: AstraZeneca. Disclosure: A. Martinez‐Marti: Financial Interests, Personal, Other, Honoraria/Advisory Board, Personal Fees and Travel Expenses: Bristol Myers Squibb; Financial Interests, Personal, Other, Honoraria/Advisory Board, Personal Fees and Travel Expenses: F Hoffmann‐La Roche; Financial Interests, Personal, Other, Honoraria/Advisory Board, Personal Fees and Travel Expenses: Merck Sharp and Dohme; Financial Interests, Personal, Other, Honoraria/Advisory Board, Personal Fees and Travel Expenses: Pfizer; Financial Interests, Personal, Other, Honoraria/Advisory Board, Personal Fees and Travel Expenses: AstraZeneca; Financial Interests, Personal, Other, Honoraria/Advisory Board, Personal Fees and Travel Expenses: MSD Oncology; Financial Interests, Personal, Other, Honoraria/Advisory Board, Personal Fees and Travel Expenses: Boehringer Ingelheim. M. Majem: Financial Interests, Personal, Other, Honorarium received from promotional activities: Bristol Myers Squibb; Financial Interests, Personal, Other, Honorarium received from promotional activities: MSD; Financial Interests, Personal, Other, Honorarium received from promotional activities: Boehringer Ingelheim; Financial Interests, Personal, Other, Honorarium received from promotional activities: AstraZeneca; Financial Interests, Personal, Other, Honorarium received from promotional activities: Roche; Financial Interests, Personal, Other, Honorarium received from promotional activities: Kyowa Kirin; Financial Interests, Personal, Other, Honorarium received from promotional activities: Pierre Fabre; Financial Interests, Personal, Other, Honorarium received from promotional activities: Takeda; Financial Interests, Personal, Other, Honorarium received from promotional activities: Bayer; Financial Interests, Personal and Institutional, Research Grant, Contracted support/research grant: Bristol Myers Squibb. F. Barlesi: Financial Interests, Personal, Other, Personal Fees: AstraZeneca; Financial Interests, Personal, Other, Personal Fees: Bayer; Financial Interests, Personal, Other, Personal Fees: Bristol Myers Squibb; Financial Interests, Personal, Other, Personal Fees: Boehringer Ingelheim; Financial Interests, Personal, Other, Personal Fees: Eli Lilly; Financial Interests, Personal, Other, Personal Fees: F Hoffmann‐La Roche; Financial Interests, Personal, Other, Personal Fees: Novartis; Financial Interests, Personal, Other, Personal Fees: Merck; Financial Interests, Personal, Other, Personal Fees: MSD; Financial Interests, Personal, Other, Personal Fees: Pierre Fabre; Financial Interests, Personal, Other, Personal Fees: Pfizer; Financial Interests, Personal, Other, Personal Fees: Takeda. Q. Chu: Financial Interests, Personal, Research Grant: AstraZeneca; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: AbbVie; Financial Interests, Personal, Advisory Role: Astellas; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal and Institutional, Research Grant: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Boehringer Ingelheim; Financial Interests, Personal, Advisory Role: Eli Lilly; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Takeda; Other, Personal, Member, Data Safety and Monitoring Board: Merck KgAa; Financial Interests, Personal, Writing Engagements: Kaleidoscope Strategic Inc.; Non‐Financial Interests, Personal, Leadership Role: Lung Cancer Canada; Non‐Financial Interests, Personal, Leadership Role: Canadian Mesothelioma Foundation; Financial Interests, Personal, Research Grant: Exactis. I. Monnet: Non‐Financial Interests, Personal, Other, ESMO 2019 Congress Invitation: Pfizer; Non‐Financial Interests, Personal, Other, ESMO 2018 Congress Invitation: Roche. A. Sanchez: Financial Interests, Personal, Other, Honoraria, Personal Fees and Travel Expenses: AstraZeneca; Financial Interests, Personal, Other, Honoraria, Personal Fees and Travel Expenses: Janssen; Financial Interests, Personal, Other, Honoraria, Personal Fees and Travel Expenses: Eli Lilly; Financial Interests, Personal, Other, Honoraria, Personal Fees and Travel Expenses: Amgen; Financial Interests, Personal, Other, Honoraria, Personal Fees and Travel Expenses: Roche; Financial Interests, Personal, Other, Honoraria, Personal Fees and Travel Expenses: MSD; Financial Interests, Personal, Other, Honoraria, Personal Fees and Travel Expenses: Bristol Myers Squibb; Financial Interests, Personal, Other, Honoraria, Personal Fees and Travel Expenses: Novartis; Financial Interests, Personal, Other, Honoraria, Personal Fees and Travel Expenses: Sanofi; Financial Interests, Personal, Other, Honoraria, Personal Fees and Travel Expenses: Pfizer. D.R. Camidge: Financial Interests, Personal, Other, Personal Fees: AstraZeneca. P. He: Financial Interests, Personal, Full or part‐time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. Y. Soo‐Hoo: Financial Interests, Personal, Full or part‐time Employment: AstraZeneca. Z. Cooper: Financial Interests, Personal, Full or part‐time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. R. Kumar: Financial Interests, Personal, Full or part‐time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca; Other, Personal, Other, Patent planned/pending: AstraZeneca. J. Bothos: Financial Interests, Personal, Full or part‐time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. C. Aggarwal: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: Blueprint; Financial Interests, Personal, Advisory Role: Daiichi Sankyo; Financial Interests, Personal, Advisory Role: Eli Lilly; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Advisory Role: Roche. R.S. Herbst: Financial Interests, Personal, Other, Personal Fees: AbbVie; Financial Interests, Personal, Other, Personal Fees: ARMO Biosciences; Financial Interests, Personal and Institutional, Research Grant: AstraZeneca; Financial Interests, Personal, Other, Personal fees: Biodesix; Financial Interests, Personal, Other, Personal fees: Bolt Biotherapy; Financial Interests, Personal, Other, Personal fees: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Research Grant: Eli Lilly and Company; Financial Interests, Personal, Other, Personal fees: EMD Serono; Financial Interests, Personal and Institutional, Research Grant: Genentech/Roche; Financial Interests, Personal, Other, Personal fees: Genmab; Financial Interests, Personal, Other, Personal fees: Halozyme; Financial Interests, Personal, Other, Personal fees: Heat Biologics; Financial Interests, Personal, Other, Personal fees: IMAB Biopharma; Financial Interests, Personal, Other, Personal fees: Immunocore; Financial Interests, Personal, Other, Personal fees: Infinity Pharmaceuticals; Other, Personal, Member, Board Member (non‐executive/ independent): Junshi Pharmaceuticals; Financial Interests, Personal, Other, Personal fees: Loxo Oncology; Financial Interests, Personal and Institutional, Research Grant: Merck and Company; Financial Interests, Personal, Other, Personal fees: Mirati Therapeutics; Financial Interests, Personal, Other, Personal fees: Nektar; Financial Interests, Personal, Other, Personal fees: Neon Therapeutics; Financial Interests, Personal, Other, Personal fees: NextCure; Financial Interests, Personal, Other, Personal fees: Novartis; Financial Interests, Personal, Other, Personal fees: Seattle Genetics; Financial Interests, Personal, Other, Personal fees: Shire PLC; Financial Interests, Personal, Other, Personal fees: Spectrum Pharmaceuticals; Financial Interests, Personal, Other, Personal fees: Symphogen; Financial Interests, Personal, Other, Personal fees: Takeda; Financial Interests, Personal, Other, Personal fees: Tesaro; Financial Interests, Personal, Other, Personal fees: Tocagen; Financial Interests, Personal, Other, Personal fees: Cybrexa; Financial Interests, Personal, Other, Personal fees: Oncternal Therapeutics; Financial Interests, Personal, Other, Personal Fees: Pfizer; Financial Interests, Personal, Other, Personal Fees: Sanofi. All other authors have declared no conflicts of interest.}, -DOI = {10.1016/j.annonc.2021.08.2121}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02322700/full} -} - - -Record #529 of 538 -@article{ChiCTR-ONRC-1300366913, -author = {ChiCTR-ONRC-13003669,}, -title = {T cell-based immunotherapy for advanced non-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR-ONRC-13003669}, -year = {2013}, -accession_number = {ICTRP ChiCTR‐ONRC‐13003669}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: treatment group:Radiotherapy; chemotherapy; immunotherapy;control group:Radiotherapy; chemotherapy; CONDITION: Non‐small cell lung cancer PRIMARY OUTCOME: tumour; SECONDARY OUTCOME: tumor markers;Flow cytometry;TCR;Progression‐free survival; INCLUSION CRITERIA: Non‐small Lung cancer was diagnosed based on imaging studies and pathology; TNM stage of tumor is ?B or IV; no chance to operat. No acute and serious complications, including bleeding,organ failure, older than 18 years.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01841068/full} -} - - -Record #530 of 538 -@article{UMIN00003237618, -author = {UMIN000032376,}, -title = {A Feasibility Study of Carboplatin/Paclitaxel/Nivolumab with Concurrent Thoracic Radiotherapy in Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000032376}, -year = {2018}, -accession_number = {ICTRP UMIN000032376}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Concurrent phase carboplatin, paclitaxel, nivolumab, thoracic radiotherapy Chemoeherapy (consolidation) carboplatin, paclitaxel, nivolumab Maintenance therapy nivolumab CONDITION: Unresectable locally advanced non‐small‐cell lung cancer PRIMARY OUTCOME: Dose limiting toxicity (DLT): for 90 days from start of therapy SECONDARY OUTCOME: 1) Safety: adverse events; 2) Efficacy: response rate, progression free survival, overall survival, 2‐year survival rate; 3) Completion rate of therapy (concurrent phase) INCLUSION CRITERIA: 1) Cytologically or Histologically confirmed unresectable locally advanced non‐small‐cell lung cancer 2) Clinical stage III, possible radical irradiation 3) Untreated by systemic anticancer therapy or thoracic radiotherapy 4) ECOG PS 0‐1}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01903803/full} -} - - -Record #531 of 538 -@article{NCT0610205723, -author = {NCT06102057,}, -title = {PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC}, -journal = {https://clinicaltrials.gov/ct2/show/NCT06102057}, -year = {2023}, -accession_number = {CTgov NCT06102057}, -publication type = {Trial registry record}, -keywords = {Carcinoma, Non‐Small‐Cell Lung; Immunomodulating Agents}, -abstract = {Multinational, randomized, controlled, open‐label, multicenter phase II trial. Eligiblepatients will be randomized in a ratio of 1:1 to Experimental Arm (FDG‐PET‐based smallvolume accelerated radiotherapy with concurrent standard of care chemotherapy) orConventional Arm (standard FDG‐PET‐based radiotherapy with concurrent standard of carechemotherapy). Patients showing complete response, partial response, or stable diseasefollowing chemoradiotherapy will receive standard of care consolidation therapy withdurvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression ofdisease, unacceptable toxicity, patient┬┤s wish, or investigator┬┤s decision, whichevercomes first.After end of durvalumab therapy, patients will undergo safety follow up for 90 (+7) daysfollowed by survival follow up until overall end of study. Overall end of study will bereached 24 months after the last patient has started durvalumab therapy. Patients showingPD following chemoradiotherapy will be treated according to investigator┬┤s decision butwill be followed up until overall end of study.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02608103/full} -} - - -Record #532 of 538 -@article{ChiCTR-IIR-1600882316, -author = {ChiCTR-IIR-16008823,}, -title = {A prospective, multicenter study: assessment of efficacy and safety of SBRT combined withindividualized specific activated T cells immunotherapy (TAA-sT/IMPACT) in advanced stage none-small cell lung cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR-IIR-16008823}, -year = {2016}, -accession_number = {ICTRP ChiCTR‐IIR‐16008823}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Therapy group 1:SBRT+TAA‐sT immunotherapy;Therapy group 2:SBRT+IMPACT immunotherapy;Control group:Best supportive care; CONDITION: lung cancer PRIMARY OUTCOME: Efficacy; SECONDARY OUTCOME: Overal survival;Progression‐free survival;Time to progress;abscopal effect;Circulating tumor cell in peripheral blood;Quality of life; INCLUSION CRITERIA: 1. Histologically or cytologically confirmed diagnosis of none‐small cell lung cancer; 2. Clinical stage IV accodring to AJCC Cancer Staging (Version 7); 3. Failure of second‐line chemotherapy or targeted therapy; 4. Long diameter of >=2 measurement of disease >1.5 cm; 5. Aged more than 18 years; 6. ECOG performance status <=2; 7. Normal bone marrow function: Leukocytes > 3.5×10^9/L, hemoglobin > 90g/L and platelets > 100×10^9/L; 8. Normal renal function: Creatinine clearance > 60 ml/min; 9. Pulmonary function: (1) FEV1>30%; (2) DLCO>30%; 10. Signed written informed consent.}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01812804/full} -} - - -Record #533 of 538 -@article{UMIN00000613911, -author = {UMIN000006139,}, -title = {Phase II Study of Pemetrexed in Combination with Carboplatin Followed by Pemetrexed Maintenance Therapy for Elderly Advanced Non-squamous and Non-small Cell Lung Cancer}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000006139}, -year = {2011}, -accession_number = {ICTRP UMIN000006139}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: PEM/CBDCA CONDITION: Non‐squamous non‐small‐cell lung cancer PRIMARY OUTCOME: progression free survival SECONDARY OUTCOME: response rate, safety, overall survival, 1 year survival INCLUSION CRITERIA: (1)Histologically proven non‐squamous non‐small cell lung cancer (2)Patient who has measurable lesion by RECIST (3)Stage 3B/4 NSCLC (4)ECOG performance status: 0‐1 (5)Aged>=70 years (6)No chemotherapy, radiotherapy, immunotherapy as prior therapy as for NSCLC (7)Adequate organ functions (8)Life expectancy >= 3 months (9)Written informed consent}, -URL = {https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01836094/full} -} - - -Record #534 of 538 -@article{UMIN00001147213, -author = {UMIN000011472,}, -title = {Phase II study of erlotinib monotherapy for elderly patients with untreated advanced non-small cell lung cancer, 75 years-old or older, and positive EGFR mutation status (OSAKA-LCSG1303)}, -journal = {https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000011472}, -year = {2013}, -accession_number = {ICTRP UMIN000011472}, -publication type = {Trial registry record}, -abstract = {INTERVENTION: Erlotinib CONDITION: non‐small cell lung cancer PRIMARY OUTCOME: Progression Free Survival : PFS SECONDARY OUTCOME: Response Rate(RR), 1 year survival rate, Frequency and grade of adverse event, QOL assessment(EORTC QLQ‐C30, EORTC QLQ‐LC13) INCLUSION CRITERIA: (1)75 years‐old or older (2) Histologically or cytologically confirmed non‐small cell lung cancer (3) Stage III/IV non‐small cell lung cancer without any indications for radiotherapy or surgery, or recurrence 6 months after postoperative adjuvant chemotherapy (4) With positive EGFR mutation status (deletion of exon 19 or L858R point mutation in exon 21), and without T790M point mutation status in exon 20 (5) ECOG performance status of 0 to 2 (6) Evaluable disease (RECIST ver1.1) (7) No history of EGFR‐TKI (8) Adequate organ function, evaluated within 14 days before enrollment as; ALT 18 years) with advanced non‐small cell lung cancer (NSCLC), whatever the line of treatment. Data collection and analysis We used standard methodological procedures expected by Cochrane. Our primary outcomes were overall survival, progression‐free survival, and serious adverse events; secondary outcomes were three‐ and five‐year survival rates and health‐related quality of life. Main results We included 10 studies with 2177 participants. The outcome analyses included only 2045 participants (1401 men and 644 women). The certainty of the evidence varied by vaccine and outcome, and ranged from moderate to very low. We report only the results for primary outcomes here. TG4010 The addition of the vector‐based vaccine, TG4010, to chemotherapy, compared with chemotherapy alone in first‐line treatment, may result in little to no difference in overall survival (hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.65 to 1.05; 2 studies, 370 participants; low‐certainty evidence). It may increase progression‐free survival slightly (HR 0.74, 95% CI 0.55 to 0.99; 1 study, 222 participants; low‐certainty evidence). It may result in little to no difference in the proportion of participants with at least one serious treatment‐related adverse event, but the evidence is very uncertain (risk ratio (RR) 0.70, 95% CI 0.23 to 2.19; 2 studies, 362 participants; very low‐certainty evidence). Epidermal growth factor vaccine Epidermal growth factor vaccine, compared to best supportive care as switch maintenance treatment after first‐line chemotherapy, may result in little to no difference in overall survival (HR 0.82, 95% CI 0.66 to 1.02; 1 study, 378 participants; low‐certainty evidence), and in the proportion of participants with at least one serious treatment‐related adverse event (RR 1.32, 95% CI 0.88 to 1.98; 2 studies, 458 participants; low‐certainty evidence). hTERT (vx‐001) The hTERT (vx‐001) vaccine compared to placebo as maintenance treatment after first‐line chemotherapy may result in little to no difference in overall survival (HR 0.97, 95% CI 0.70 to 1.34; 1 study, 190 participants). Racotumomab Racotumomab compared to placebo as a switch maintenance treatment post‐chemotherapy was assessed in one study with 176 participants. It may increase overall survival (HR 0.63, 95% CI 0.46 to 0.87). It may make little to no difference in progression‐free survival (HR 0.73, 95% CI 0.53 to 1.00) and in the proportion of people with at least one serious treatment‐related adverse event (RR 1.03, 95% CI 0.15 to 7.18). Racotumomab versus docetaxel as switch maintenance therapy post‐chemotherapy was assessed in one study with 145 participants. The study did not report hazard rates on overall survival or progression‐free survival time, but the difference in median survival times was very small – less than one month. Racotumomab may result in little to no difference in the proportion of people with at least one serious treatment‐related adverse event compared with docetaxel (RR 0.89, 95% CI 0.44 to 1.83). Personalised peptide vaccine Personalised peptide vaccine plus docetaxel compared to docetaxel plus placebo post‐chemotherapy treatment may result in little to no difference in overall survival (HR 0.80, 95% CI 0.42 to 1.52) and progression‐free survival (HR 0.78, 95% CI 0.43 to 1.42). OSE2101 The OSE2101 vaccine compared with chemotherapy, after chemotherapy or immunotherapy, was assessed in one study with 219 participants. It may result in little to no difference in overall survival (HR 0.86, 95% CI 0.62 to 1.19). It may result in a small difference in the proportion of people with at least one serious treatment‐related adverse event (RR 0.95, 95% CI 0.91 to 0.99). SRL172 The SRL172 vaccine of killed Mycobacterium vaccae , added to chemotherapy, compared to chemotherapy alone, may result in no difference in overall survival, and may increase the proportion of people with at least one serious treatment‐related adverse event (RR 2.07, 95% CI 1.76 to 2.43; 351 participants). Authors' conclusions Adding a vaccine resulted in no differences in overall survival, except for racotumomab, which showed some improvement compared to placebo, but the difference in median survival time was very small (1.4 months) and the study only included 176 participants. Regarding progression‐free survival, we observed no differences between the compared treatments, except for TG4010, which may increase progression‐free survival slightly. There were no differences between the compared treatments in serious treatment‐related adverse events, except for SRL172 (killed Mycobacterium vaccae ) added to chemotherapy, which was associated with an increase in the proportion of participants with at least one serious treatment‐related adverse event, and OSE2101, which may decrease slightly the proportion of people having at least one serious treatment‐related adverse event. These conclusions should be interpreted cautiously, as the very low‐ to moderate‐certainty evidence prevents drawing solid conclusions: many vaccines were evaluated in a single study with small numbers of participants and events. Plain language summary Do cancer vaccines help people with advanced non‐small cell lung cancer? Key messages ‐ The vaccines evaluated in this review do not improve peoples' survival, or progression‐free survival, or do so to a negligible extent. ‐ Unwanted effects of the vaccines are not frequent. What is lung cancer? Lung cancer is one of the most common cancers worldwide. Non‐small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for around 87% of lung cancers. Non‐small cell lung cancer is often diagnosed when it is at an advanced stage, which is associated with high death rates and a short life expectancy. How is non‐small cell lung cancer treated? Most of these cancers are treated first with chemotherapy – that is, medicine consisting of powerful chemicals to kill fast‐growing cancer cells. New therapies to improve survival rates for people with NSCLC are focused on treatment with immunotherapy after chemotherapy. Cancer vaccines are a type of immunotherapy. Unlike vaccines to protect us from disease, cancer vaccines are for people who already have cancer. Therapeutic cancer vaccines aim to stimulate the immune system to recognise and destroy cancer cells. What did we want to find out? We wanted to find out whether vaccines lengthen people's survival time and time without disease progression, and whether they are associated with any unwanted effects. What did we do? We searched for studies that looked at therapeutic cancer vaccines alone or in combination with chemotherapy compared with supportive care, no treatment, or placebo (inactive or 'dummy' medicine) in people with advanced NSCLC. We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. What did we find? We found 10 studies that involved 2177 participants with advanced NSCLC. The biggest study involved 419 people and the smallest study 50. Seven different types of vaccines were evaluated. Three vaccines were evaluated in 2 studies each: TG4010 vector‐based vaccine; epidermal growth factor vaccine; and racotumomab. The remaining 4 vaccines were each evaluated in a single study. Main results ‐ None of the vaccines increased participants' survival time, except racotumomab, which may improve it slightly compared to placebo. The median survival time for those in the racotumomab vaccine group was 8.2 months, compared to 6.8 months in the group that did not receive the vaccine. (The median is the middle value of a set of numbers.) ‐ None of the vaccines improved progression‐free survival time, except TG4010, which may increase it slightly. The median progression‐free survival time for people in the TG4010 vaccine group was 5.9 months, compared to 5.1 months in the non‐vaccine group. ‐ The 7 different vaccines tested largely appear to be safe: there were no differences between the people given vaccines and those not given vaccines in terms of serious adverse (unwanted) events. However, 1 vaccine (SLR172) added to chemotherapy increased the proportion of people having at least 1 serious adverse event. A different vaccine (OSE2101) may result in a slight decrease in the proportion of people having at least 1 serious adverse event. What are the limitations of the evidence? Our confidence in the evidence varied from moderate to very low for the different vaccines and outcomes assessed, mainly because the studies were small and there were not enough studies to be sure of the results. How up to date is this evidence? The evidence is current to August 2023.}, -DOI = {10.1002/14651858.CD013377.pub2}, -keywords = {*Carcinoma, Non-Small-Cell Lung [therapy]; *Lung Neoplasms [therapy]; *Mycobacteriaceae; *Vaccines; Adult; Docetaxel; EGF Family of Proteins; Female; Humans; Male; Quality of Life; Randomized Controlled Trials as Topic}, -URL = {http://dx.doi.org/10.1002/14651858.CD013377.pub2} -} - - -Record #5 of 54 -@article{Zhu17, -author = {Zhu, J, Yuan, Y, Wan, X, Yin, D, Li, R, Chen, W, Suo, C, and Song, H}, -title = {Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent}, -journal = {Cochrane Database of Systematic Reviews}, -number = {12}, -year = {2021}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Non‐small cell lung cancer (NSCLC) is the most common lung cancer, accounting for approximately 80% to 85% of all cases. For people with localised NSCLC (stages I to III), it has been speculated that immunotherapy may be helpful for reducing postoperative recurrence rates, or improving the clinical outcomes of current treatment for unresectable tumours. This is an update of a Cochrane Review first published in 2017 and it includes two new randomised controlled trials (RCTs). Objectives To assess the effectiveness and safety of immunotherapy (excluding checkpoint inhibitors) among people with localised NSCLC of stages I to III who received curative intent of radiotherapy or surgery. Search methods We searched the following databases (from inception to 19 May 2021): CENTRAL, MEDLINE, Embase, CINAHL, and five trial registers. We also searched conference proceedings and reference lists of included trials. Selection criteria We included RCTs conducted in adults (≥ 18 years) diagnosed with NSCLC stage I to III after surgical resection, and those with unresectable locally advanced stage III NSCLC receiving radiotherapy with curative intent. We included participants who underwent primary surgical treatment, postoperative radiotherapy or chemoradiotherapy if the same strategy was provided for both intervention and control groups. Data collection and analysis Two review authors independently selected eligible trials, assessed risk of bias, and extracted data. We used survival analysis to pool time‐to‐event data, using hazard ratios (HRs). We used risk ratios (RRs) for dichotomous data, and mean differences (MDs) for continuous data, with 95% confidence intervals (CIs). Due to clinical heterogeneity (immunotherapeutic agents with different underlying mechanisms), we combined data by applying random‐effects models. Main results We included 11 RCTs involving 5128 participants (this included 2 new trials with 188 participants since the last search dated 20 January 2017). Participants who underwent surgical resection or received curative radiotherapy were randomised to either an immunotherapy group or a control group. The immunological interventions were active immunotherapy Bacillus Calmette‐Guérin (BCG) adoptive cell transfer (i.e. transfer factor (TF), tumour‐infiltrating lymphocytes (TIL), dendritic cell/cytokine‐induced killer (DC/CIK), antigen‐specific cancer vaccines (melanoma‐associated antigen 3 (MAGE‐A3) and L‐BLP25), and targeted natural killer (NK) cells. Seven trials were at high risk of bias for at least one of the risk of bias domains. Three trials were at low risk of bias across all domains and one small trial was at unclear risk of bias as it provided insufficient information. We included data from nine of the 11 trials in the meta‐analyses involving 4863 participants. There was no evidence of a difference between the immunotherapy agents and the controls on any of the following outcomes: overall survival (HR 0.94, 95% CI 0.84 to 1.05; P = 0.27; 4 trials, 3848 participants; high‐quality evidence), progression‐free survival (HR 0.94, 95% CI 0.86 to 1.03; P = 0.19; moderate‐quality evidence), adverse events (RR 1.12, 95% CI 0.97 to 1.28; P = 0.11; 4 trials, 4126 evaluated participants; low‐quality evidence), and severe adverse events (RR 1.14, 95% CI 0.92 to 1.40; 6 trials, 4546 evaluated participants; low‐quality evidence). Survival rates at different time points showed no evidence of a difference between immunotherapy agents and the controls. Survival rate at 1‐year follow‐up (RR 1.02, 95% CI 0.96 to 1.08; I 2 = 57%; 7 trials, 4420 participants; low‐quality evidence), 2‐year follow‐up (RR 1.02, 95% CI 0.93 to 1.12; 7 trials, 4420 participants; moderate‐quality evidence), 3‐year follow‐up (RR 0.99, 95% CI 0.90 to 1.09; 7 trials, 4420 participants; I 2 = 22%; moderate‐quality evidence) and at 5‐year follow‐up (RR 0.98, 95% CI 0.86 to 1.12; I 2 = 0%; 7 trials, 4389 participants; moderate‐quality evidence). Only one trial reported overall response rates. Two trials provided health‐related quality of life results with contradicting results. Authors' conclusions Based on this updated review, the current literature does not provide evidence that suggests a survival benefit from adding immunotherapy (excluding checkpoint inhibitors) to conventional curative surgery or radiotherapy, for people with localised NSCLC (stages I to III). Several ongoing trials with immune checkpoints inhibitors (PD‐1/PD‐L1) might bring new insights into the role of immunotherapy for people with stages I to III NSCLC. Plain language summary Effect of immunotherapy on the prognosis for stages I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent Review question Do treatments that help the body's immune system fight cancer cells (immunotherapy) make people with non‐small cell lung cancer (NSCLC) who have had surgery or radiotherapy aimed at a cure, live longer? Background Many people with NSCLC, who have had surgery or radiotherapy to cure their cancer, eventually die because the cancer comes back, either in the chest, or somewhere else in the body. There have been a number of trials over the years that have looked at whether immunotherapy helps people live longer. Some seemed to show a benefit, others did not. Study characteristics We searched four computerised databases and five trial registers to 19 May 2021. We looked for all trials that randomly allocated participants to one treatment or another (randomised controlled trials, RCTs), and included adults (aged 18 years or older) with early NSCLC (stages I to III), confirmed by laboratory testing of a sample of the tumour. We found 11 RCTs, which included over 5000 participants who had received surgery or curative radiotherapy, and were randomly allocated to receive either immunotherapy or no further treatment. Key results We found that giving immunotherapy, mainly vaccine‐based (aiming to activate the host immune system to induce human immune response to tumour‐specific antigens), after surgery or radiotherapy did not make people live longer. People who were given vaccine‐based immunotherapy did not seem to experience more side effects than the others. We did not find results that could tell us whether the addition of immunotherapy improved quality of life. At the moment, there is no evidence to support or refute giving immunotherapy (mainly vaccine‐based) to people with localised NSCLC (stages I to III). RCTs in progress are testing new, more promising immunotherapy drugs (e.g. checkpoint inhibitors). Quality of the evidence The evidence we found about overall survival and progression‐free survival was of high and moderate quality, respectively. When we looked for evidence about how many participants lived to one, two, three, or five years, it was only moderate or low quality, because the RCTs were not very well done, and their results did not agree with each other. The evidence for both any and severe adverse events was of low quality.}, -DOI = {10.1002/14651858.CD011300.pub3}, -keywords = {*Carcinoma, Non-Small-Cell Lung [drug therapy]; *Lung Neoplasms [drug therapy]; Chemoradiotherapy; Humans; Immunotherapy; Progression-Free Survival; Randomized Controlled Trials as Topic}, -URL = {http://dx.doi.org/10.1002/14651858.CD011300.pub3} -} - - -Record #6 of 54 -@article{Orillard24, -author = {Orillard, E, Adhikari, A, Malouf, RS, Calais, F, Marchal, C, and Westeel, V}, -title = {Immune checkpoint inhibitors plus platinum‐based chemotherapy compared to platinum‐based chemotherapy with or without bevacizumab for first‐line treatment of older people with advanced non‐small cell lung cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {8}, -year = {2024}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Lung cancer is a cancer of the elderly, with a median age at diagnosis of 71. More than one‐third of people diagnosed with lung cancer are over 75 years old. Immune checkpoint inhibitors (ICIs) are special antibodies that target a pathway in the immune system called the programmed cell death 1/programmed cell death‐ligand 1 (PD‐1/PD‐L1) pathway. These antibodies help the immune system fight cancer cells by blocking signals that cancer cells use to avoid being attacked by the immune system. ICIs have changed the treatment of people with lung cancer. In particular, for people with previously‐untreated advanced non‐small cell lung cancer (NSCLC), current first‐line treatment now comprises ICIs plus platinum‐based chemotherapy, rather than platinum‐based chemotherapy alone, regardless of their PD‐L1 expression status. However, as people age, their immune system changes, becoming less effective in its T cell responses. This raises questions about how well ICIs work in older adults. Objectives To assess the effects of immune checkpoint inhibitors (ICIs) in combination with platinum‐based chemotherapy compared to platinum‐based chemotherapy (with or without bevacizumab) in treatment‐naïve adults aged 65 years and older with advanced NSCLC. Search methods We searched the Cochrane Lung Cancer Group Trial Register, CENTRAL, MEDLINE, Embase, two other trial registers, and the websites of drug regulators. The latest search date was 23 August 2023. We also checked references and searched abstracts from the meetings of seven cancer organisations from 2019 to August 2023. Selection criteria We included randomised controlled trials (RCTs) that reported on the efficacy and safety of adding ICIs to platinum‐based chemotherapy compared to platinum‐based chemotherapy alone for people 65 years and older who had not previously been treated. All data emanated from international multicentre studies involving adults with histologically‐confirmed advanced NSCLC who had not received any previous systemic anticancer therapy for their advanced disease. Data collection and analysis We used standard methodological procedures expected by Cochrane. Our primary outcomes were overall survival and treatment‐related adverse events (grade 3 or higher). Our secondary outcomes were progression‐free survival, objective response rate, time to response, duration of response, and health‐related quality of life (HRQoL). Main results We included 17 primary studies, with a total of 4276 participants, in the review synthesis. We identified nine ongoing studies, and listed one study as 'awaiting classification'. Twelve of the 17 studies included people older than 75 years, accounting for 9% to 13% of their participants. We rated some studies as having 'some concerns' for risk of bias arising from the randomisation process, deviations from the intended interventions, or measurement of the outcome. The overall GRADE rating for the certainty of the evidence ranged from moderate to low because of the risk of bias, imprecision, or inconsistency. People aged 65 years and older The addition of ICIs to platinum‐based chemotherapy probably increased overall survival compared to platinum‐based chemotherapy alone (hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.70 to 0.88; 8 studies, 2093 participants; moderate‐certainty evidence). Only one study reported data for treatment‐related adverse events (grade 3 or higher). The frequency of treatment‐related adverse events may not differ between the two treatment groups (risk ratio (RR) 1.09, 95% CI 0.89 to 1.32; 1 study, 127 participants; low‐certainty evidence). The addition of ICIs to platinum‐based chemotherapy probably improves progression‐free survival (HR 0.61, 95% CI 0.54 to 0.68; 7 studies, 1885 participants; moderate‐certainty evidence). People aged 65 to 75 years, inclusive The addition of ICIs to platinum‐based chemotherapy probably improved overall survival compared to platinum‐based chemotherapy alone (HR 0.75, 95% CI 0.65 to 0.87; 6 studies, 1406 participants; moderate‐certainty evidence). Only one study reported data for treatment‐related adverse events (grade 3 or higher). The frequency of treatment‐related adverse events probably increased in people treated with ICIs plus platinum‐based chemotherapy compared to those treated with platinum‐based chemotherapy alone (RR 1.47, 95% CI 1.02 to 2.13; 1 study, 97 participants; moderate‐certainty evidence). The addition of ICIs to platinum‐based chemotherapy probably improved progression‐free survival (HR 0.64, 95% CI 0.57 to 0.73; 8 studies, 1466 participants; moderate‐certainty evidence). People aged 75 years and older There may be no difference in overall survival in people treated with ICIs combined with platinum‐based chemotherapy compared to platinum‐based chemotherapy alone (HR 0.90, 95% CI 0.70 to 1.16; 4 studies, 297 participants; low‐certainty evidence). No data on treatment‐related adverse events were available in this age group. The effect of combination ICI and platinum‐based chemotherapy on progression‐free survival is uncertain (HR 0.83, 95% CI 0.51 to 1.36; 3 studies, 226 participants; very low‐certainty evidence). Only three studies assessed the objective response rate. For time to response, duration of response, and health‐related quality of life, we do not have any evidence yet. Authors' conclusions Compared to platinum‐based chemotherapy alone, adding ICIs to platinum‐based chemotherapy probably leads to higher overall survival and progression‐free survival, without an increase in treatment‐related adverse events (grade 3 or higher), in people 65 years and older with advanced NSCLC. These data are based on results from studies dominated by participants between 65 and 75 years old. However, the analysis also suggests that the improvements reported in overall survival and progression‐free survival may not be seen in people older than 75 years. Plain language summary Is immunotherapy plus chemotherapy better than chemotherapy alone for older people with non‐small cell lung cancer? Key messages • For people 65 years and older with advanced non‐small cell lung cancer (NSCLC) who have not previously been treated for cancer, adding immunotherapy to chemotherapy prolongs life and extends the time before their cancer progresses. This finding comes from studies that mainly included people between 65 and 75 years old.
• We did not find these same beneficial effects of adding immunotherapy to chemotherapy in people over 75 years old. What is advanced non‐small cell lung cancer (NSCLC)? NSCLC is one of two main types of lung cancer. About 80% to 85% of lung cancer cases are NSCLC. It mainly affects older people: diagnosis occurs at an average age of 71. NSCLC is usually detected when it is at the metastatic, or advanced, stage, which means cancer has spread beyond the original affected lung. At this stage, it can't be cured, but treatment can help to control it, and improve symptoms and quality of life. How is NSCLC treated? Treatment options vary, depending on the cancer stage, tumour characteristics, and other factors. Chemotherapy – powerful chemicals that kill cancer cells – has been the mainstay of lung cancer treatment. Immunotherapies are newer treatments that can help the immune system fight cancer. They have had positive results when combined with chemotherapy for people with advanced lung cancer. However, as people age, their immune system changes, becoming less effective at fighting cancer. This is called immunosenescence. What did we want to find out? We wanted to find out if, in this context of immunosenescence, immunotherapies are effective for people 65 years and older with advanced NSCLC, and what are the effects of intensifying chemotherapy‐based treatment with the addition of immunotherapy. What did we do? We searched for studies that investigated the effect of giving chemotherapy plus immunotherapy versus chemotherapy alone to people 65 years and older with advanced NSCLC who had not previously had cancer treatment. We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. What did we find? We found 17 studies with a total of 4276 people eligible for inclusion in this review. The studies compared immunotherapy plus chemotherapy to chemotherapy alone for people 65 years and older with previously untreated advanced NSCLC. Twelve of 17 studies included people older than 75 years, but this age group represented only 9% to 13% of all participants in the studies. • For people 65 years and older, adding immunotherapy to chemotherapy prolonged life and extended the time before cancer progression, compared to chemotherapy alone. Both treatments had the same rate of toxic effects. Most of the people included in these studies were between 65 and 75 years old.
• For people 75 years and older, adding immunotherapy to chemotherapy may not prolong life or extend the time before cancer progression compared to chemotherapy alone. What are the limitations of the evidence? Our confidence in the evidence varied from moderate to very low, and was reduced because of concerns about how some of the studies were conducted. Only one study assessed some of the outcomes we were interested in. None of the studies assessed people's health‐related quality of life. How up to date is this evidence? The evidence is current to 23 August 2023.}, -DOI = {10.1002/14651858.CD015495}, -keywords = {*Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; *Bevacizumab [therapeutic use]; *Carcinoma, Non-Small-Cell Lung [drug therapy, mortality, pathology]; *Immune Checkpoint Inhibitors [adverse effects, therapeutic use]; *Lung Neoplasms [drug therapy, mortality, pathology]; *Randomized Controlled Trials as Topic; Aged; Humans; Platinum Compounds [therapeutic use]; Progression-Free Survival; Quality of Life}, -URL = {http://dx.doi.org/10.1002/14651858.CD015495} -} - - -Record #7 of 54 -@article{Akl07, -author = {Akl, EA, Kahale, LA, Hakoum, MB, Matar, CF, Sperati, F, Barba, M, Yosuico, VED, Terrenato, I, Synnot, A, and Schünemann, H}, -title = {Parenteral anticoagulation in ambulatory patients with cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {9}, -year = {2017}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Anticoagulation may improve survival in patients with cancer through a speculated anti‐tumour effect, in addition to the antithrombotic effect, although may increase the risk of bleeding. Objectives To evaluate the efficacy and safety of parenteral anticoagulants in ambulatory patients with cancer who, typically, are undergoing chemotherapy, hormonal therapy, immunotherapy or radiotherapy, but otherwise have no standard therapeutic or prophylactic indication for anticoagulation. Search methods A comprehensive search included (1) a major electronic search (February 2016) of the following databases: Cochrane Central Register of Controlled Trials (CENTRAL) (2016, Issue 1), MEDLINE (1946 to February 2016; accessed via OVID) and Embase (1980 to February 2016; accessed via OVID); (2) handsearching of conference proceedings; (3) checking of references of included studies; (4) use of the 'related citation' feature in PubMed and (5) a search for ongoing studies in trial registries. As part of the living systematic review approach, we are running searches continually and we will incorporate new evidence rapidly after it is identified. This update of the systematic review is based on the findings of a literature search conducted on 14 August 2017. Selection criteria Randomized controlled trials (RCTs) assessing the benefits and harms of parenteral anticoagulation in ambulatory patients with cancer. Typically, these patients are undergoing chemotherapy, hormonal therapy, immunotherapy or radiotherapy, but otherwise have no standard therapeutic or prophylactic indication for anticoagulation. Data collection and analysis Using a standardized form we extracted data in duplicate on study design, participants, interventions outcomes of interest, and risk of bias. Outcomes of interested included all‐cause mortality, symptomatic venous thromboembolism (VTE), symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), major bleeding, minor bleeding, and quality of life. We assessed the certainty of evidence for each outcome using the GRADE approach (GRADE handbook [GRADE handbook]). Main results Of 6947 identified citations, 19 RCTs fulfilled the eligibility criteria. These trials enrolled 9650 participants. Trial registries' searches identified nine registered but unpublished trials, two of which were labeled as 'ongoing trials'. In all included RCTs, the intervention consisted of heparin (either unfractionated heparin or low molecular weight heparin). Overall, heparin appears to have no effect on mortality at 12 months (risk ratio (RR) 0.98; 95% confidence interval (CI) 0.93 to 1.03; risk difference (RD) 10 fewer per 1000; 95% CI 35 fewer to 15 more; moderate certainty of evidence) and mortality at 24 months (RR 0.99; 95% CI 0.96 to 1.01; RD 8 fewer per 1000; 95% CI 31 fewer to 8 more; moderate certainty of evidence). Heparin therapy reduces the risk of symptomatic VTE (RR 0.56; 95% CI 0.47 to 0.68; RD 30 fewer per 1000; 95% CI 36 fewer to 22 fewer; high certainty of evidence), while it increases in the risks of major bleeding (RR 1.30; 95% 0.94 to 1.79; RD 4 more per 1000; 95% CI 1 fewer to 11 more; moderate certainty of evidence) and minor bleeding (RR 1.70; 95% 1.13 to 2.55; RD 17 more per 1000; 95% CI 3 more to 37 more; high certainty of evidence). Results failed to confirm or to exclude a beneficial or detrimental effect of heparin on thrombocytopenia (RR 0.69; 95% CI 0.37 to 1.27; RD 33 fewer per 1000; 95% CI 66 fewer to 28 more; moderate certainty of evidence); quality of life (moderate certainty of evidence). Authors' conclusions Heparin appears to have no effect on mortality at 12 months and 24 months. It reduces symptomatic VTE and likely increases major and minor bleeding. Future research should further investigate the survival benefit of different types of anticoagulants in patients with different types and stages of cancer. The decision for a patient with cancer to start heparin therapy should balance the benefits and downsides, and should integrate the patient's values and preferences. Editorial note:This is a living systematic review. Living systematic reviews offer a new approach to review updating in which the review is continually updated, incorporating relevant new evidence, as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review. Plain language summary Injectable blood thinners (anticoagulants) in patients with cancer Background 
Research evidence suggests that blood thinners may improve the survival of patients with cancer, by preventing life‐threatening blood clots and might also have a direct anticancer effect. However, blood thinners can also increase the risk of bleeding, which can be serious and reduce survival. It is therefore important to understand the pros and cons of treatment to allow patients and their doctors to be aware of the balance of risks and benefits. Study characteristics 
We searched the scientific literature for studies of anticoagulants in people with cancer. The evidence is current to 14 August 2017. We included 19 eligible trials. Key results 
We selected 19 trials including 9650 participants with cancer. Most trials included participants with various types of cancer, especially small cell lung cancer, non‐small cell lung cancer, and pancreatic cancer. All studies were conducted in the outpatient setting. The results suggest that the effect of injectable blood thinners on survival is uncertain, but if anything of small size. Also the results suggest that injectable blood thinners reduce the risk of blood clots by about half and possibly increase the risk of major bleeding and minor bleeding by 4 more per 1000 and 17 more per 1000, respectively. The effect on quality of life is uncertain. Certainty of evidence 
We judged the certainty of evidence to be high for symptomatic VTE and minor bleeding, and moderate for mortality, major bleeding and quality of life. Editorial note: This is a living systematic review. Living systematic reviews offer a new approach to review updating in which the review is continually updated, incorporating relevant new evidence, as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.}, -DOI = {10.1002/14651858.CD006652.pub5}, -keywords = {Anticoagulants [*administration & dosage, adverse effects]; Cause of Death; Hemorrhage [chemically induced, epidemiology]; Heparin [*administration & dosage, adverse effects]; Heparin, Low-Molecular-Weight [administration & dosage]; Humans; Neoplasms [*mortality]; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors; Venous Thromboembolism [epidemiology, *prevention & control]; Warfarin [administration & dosage]}, -URL = {http://dx.doi.org/10.1002/14651858.CD006652.pub5} -} - - -Record #8 of 54 -@article{Kahale07, -author = {Kahale, LA, Matar, CF, Tsolakian, IG, Hakoum, MB, Barba, M, Yosuico, VED, Terrenato, I, Sperati, F, Schünemann, H, and Akl, EA}, -title = {Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation}, -journal = {Cochrane Database of Systematic Reviews}, -number = {10}, -year = {2021}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Oral anticoagulants may improve the survival of people with cancer through an antithrombotic effect, yet increase the risk of bleeding. Objectives To evaluate the efficacy and safety of oral anticoagulants in ambulatory people with cancer undergoing chemotherapy, targeted therapy, immunotherapy, or radiotherapy (either alone or in combination), with no standard therapeutic or prophylactic indication for anticoagulation. Search methods We conducted comprehensive searches on 14 June 2021, following the original electronic searches performed in February 2016 (last major search). We electronically searched the following databases: CENTRAL, MEDLINE, Embase. In addition, we handsearched conference proceedings, checked references of included studies, and searched for ongoing studies. As part of the living systematic review approach, we are running continual searches and will incorporate new evidence rapidly after it is identified. Selection criteria We included randomised controlled trials (RCTs) assessing the benefits and harms of vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) in ambulatory people with cancer (i.e., not hospital inpatients during the time of their participation in trials) These people are typically undergoing systemic anticancer therapy, possibly including chemotherapy, targeted therapy, immunotherapy, or radiotherapy, but otherwise have no standard therapeutic or prophylactic indication for anticoagulation. Data collection and analysis Using a standardised form, two review authors independently extracted data on study design, participants, intervention outcomes of interest, and risk of bias. Outcomes of interest included all‐cause mortality, pulmonary embolism, symptomatic deep vein thrombosis (DVT), major bleeding, minor bleeding and health‐related quality of life. We assessed the certainty of evidence for each outcome using the GRADE approach. Main results Of 12,620 identified citations, 10 RCTs fulfilled the inclusion criteria. The oral anticoagulant was a vitamin K antagonist (VKA) in six of these RCTs, and a direct oral anticoagulant (DOAC) in the remaining four RCTs (three studies used apixaban; one used rivaroxaban). The comparator was either placebo or no prophylaxis. Compared to no prophylaxis, vitamin K antagonists (VKAs) probably reduce mortality at six months slightly (risk ratio (RR) 0.93, 95% confidence interval (CI) 0.77 to 1.13; risk difference (RD) 22 fewer per 1000, 95% CI 72 fewer to 41 more; moderate‐certainty evidence), and probably reduce mortality at 12 months slightly (RR 0.95, 95% CI 0.87 to 1.03; RD 29 fewer per 1000, 95% CI 75 fewer to 17 more; moderate‐certainty evidence). One study assessed the effect of a VKA compared to no prophylaxis on thrombosis; the evidence was very uncertain about the effect of VKA compared to no VKA on pulmonary embolism and symptomatic DVT (RR 1.05, 95% CI 0.07 to 16.58; RD 0 fewer per 1000, 95% CI 6 fewer to 98 more; very low‐certainty evidence; RR 0.08, 95% CI 0.01 to 1.42; RD 35 fewer per 1000, 95% CI 37 fewer to 16 more; very low‐certainty evidence, respectively). Also, VKAs probably increase major and minor bleeding at 12 months (RR 2.93, 95% CI 1.86 to 4.62; RD 107 more per 1000, 95% CI 48 more to 201 more; moderate‐certainty evidence for major bleeding, and RR 3.14, 95% CI 1.85 to 5.32; RD 167 more per 1000, 95% CI 66 more to 337 more; moderate‐certainty evidence for minor bleeding). Compared to no prophylaxis, at three to six months, direct oral anticoagulants (DOACs) probably reduce mortality slightly (RR 0.94, 95% CI 0.64 to 1.38, RD 11 fewer per 1000, 95% CI 67 fewer to 70 more; moderate‐certainty evidence), probably reduce the risk of pulmonary embolism slightly compared to no prophylaxis (RR 0.48, 95% CI 0.24 to 0.98; RD 24 fewer per 1000, 95% CI 35 fewer to 1 fewer; moderate‐certainty evidence), probably reduce symptomatic DVT slightly (RR 0.58, 95% CI 0.30 to 1.15; RD 21 fewer per 1000, 95% CI 35 fewer to 8 more; moderate‐certainty evidence), probably do not increase major bleeding (RR 1.65, 95% CI 0.72 to 3.80; RD 9 more per 1000, 95% CI 4 fewer to 40 more; moderate‐certainty evidence), and may increase minor bleeding (RR 3.58, 95% CI 0.55 to 23.44; RD 55 more per 1000, 95% CI 10 fewer to 482 more; low‐certainty evidence). Authors' conclusions In ambulatory people with cancer undergoing chemotherapy, targeted therapy, immunotherapy, or radiotherapy (either alone or in combination), the current evidence on VKA thromboprophylaxis suggests that the harm of major bleeding might outweigh the benefit of reduction in venous thromboembolism. With DOACs, the benefit of reduction in venous thromboembolic events outweighs the risk of major bleeding. Editorial note: this is a living systematic review. Living systematic reviews offer a new approach to review updating in which the review is continually updated, incorporating relevant new evidence, as it becomes available. Please refer to the 'What's new' section in the Cochrane Database of Systematic Reviews for the current status of this review. Plain language summary Are oral blood thinners safe and effective for people being treated for cancer? Key messages ‐ It is reasonable to give direct oral anticoagulants (a type of blood thinning medicine) to people being treated for cancer, especially if they have an increased risk of blood clots, because the benefit of reduction in blood clots appears to outweigh the risk of major bleeding. ‐ For a different type of blood thinner, vitamin K antagonists (warfarin), the risk of major bleeding might outweigh the benefit of a reduction in formation of blood clots in the legs and lungs. ‐ More research is needed on the effects of blood thinners in people with different types and stages of cancers. What are blood thinners Blood thinners are medicines that help prevent blood from clotting. People at a high risk of getting blood clots can take blood thinners to reduce their chances of developing serious conditions such as heart attacks and strokes. Why might blood‐thinning treatment be helpful for people with cancer? People with cancer undergoing systemic treatment (any medication that travels through your body in the bloodstream to find, damage or destroy cancer cells, including chemotherapy, radiotherapy, immunotherapy and target therapy) are at increased risk of blood clots. While blood thinners can decrease the risk of getting blood clots, they can also increase the risk of serious and fatal bleeding. Therefore, it is important to understand the benefits and harms of using blood thinners in these people to allow them and their doctors to make informed decisions. What did we want to find out? We wanted to find out if giving preventative, oral (by mouth) blood thinners was better than no preventative treatment for people being treated for cancer. We focused on people with cancer who were not admitted to hospital for their cancer treatment. We were interested in the effects of blood thinners on: ‐ death; ‐ formation of blood clots in veins (venous thromboembolism). Venous thromboembolism includes deep vein thrombosis (DVT) where a clot lodges in the lower leg, thigh or pelvis, and pulmonary embolism where a clot lodges in the lungs; ‐ major and minor bleeding. What did we do? We searched for studies that examined the benefits and harms of blood thinners for people being treated for cancer who otherwise had no signs, symptoms or conditions that suggested blood thinning was definitely needed. We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. What did we find? We found 10 studies that involved 2934 people with cancer. The biggest study had 841 people and the smallest had 24 people. The studies used two types of blood thinner: ‐ the vitamin K antagonist, warfarin; or ‐ direct [ER1] oral anticoagulants (specifically, apixaban and rivaroxaban). Main results Compared to no preventative treatment, warfarin, the vitamin K antagonist medicine: ‐ probably reduces death at 6 months and at 12 months slightly (22 and 29 fewer deaths, respectively, per 1000 people); ‐ may have little to no effect on formation of blood clots, but we are very uncertain about the results; ‐ probably increases major bleeding and minor bleeding at 12 months (107 more major bleeds and 167 more minor bleeds per 1000 people). Compared to no preventative treatment, direct oral anticoagulant medicines: ‐ probably reduce death at 3 to 6 months slightly (11 fewer deaths per 1000 people); ‐ probably reduce blood clots in the lungs and legs slightly (24 fewer in the lungs and 19 fewer in the legs per 1000 people); ‐ probably do not increase major bleeding (9 more major bleeds per 1000 people); ‐ may increase minor bleeding (55 more minor bleeds per 1000 people). This suggests that : with a vitamin K antagonist, the risk of major bleeding might outweigh the benefit of any reduction in the risk of blood clots in the legs and lungs; with direct oral anticoagulants, the benefit of reduction in the risk of blood clots in the legs and lungs outweighs the risk of major bleeding. What are the limitations of the evidence? We are moderately confident in the evidence for death, major bleeding and minor bleeding. In eight of the studies, the methods used may have affected the results. We are not confident in the evidence for blood clots in people who were given vitamin K antagonist medicine because the evidence came from one study only. This study gave the medicine in a fixed rather than variable dose, which is not current best practice. How up to date is this evidence? This review updates our previous review. The evidence is up to date to June 2021. Editorial note: this is a living systematic review. Living systematic reviews offer a new approach to review updating in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the 'What's new' section on the Cochrane Database of Systematic Reviews for the current status of this review.}, -DOI = {10.1002/14651858.CD006466.pub7}, -keywords = {*Neoplasms [complications, drug therapy]; *Venous Thromboembolism [prevention & control]; Anticoagulants [adverse effects]; Heparin; Heparin, Low-Molecular-Weight; Humans; Systematic Reviews as Topic}, -URL = {http://dx.doi.org/10.1002/14651858.CD006466.pub7} -} - - -Record #9 of 54 -@article{Granger17, -author = {Granger, C, and Cavalheri, V}, -title = {Preoperative exercise training for people with non‐small cell lung cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {9}, -year = {2022}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Surgical resection for early‐stage non‐small cell lung cancer (NSCLC) offers the best chance of cure, but it is associated with a risk of postoperative pulmonary complications. It is unclear if preoperative exercise training, and the potential resultant improvement in exercise capacity, may improve postoperative outcomes. This review updates our initial 2017 systematic review. Objectives 1. To evaluate the benefits and harm of preoperative exercise training on postoperative outcomes, such as the risk of developing a postoperative pulmonary complication and the postoperative duration of intercostal catheter, in adults scheduled to undergo lung resection for NSCLC. 2. To determine the effect on length of hospital stay (and costs associated with postoperative hospital stay), fatigue, dyspnoea, exercise capacity, lung function and postoperative mortality. Search methods We used standard, extensive Cochrane search methods. The latest search date was from 28 November 2016 to 23 November 2021. Selection criteria We included randomised controlled trials (RCTs) in which study participants who were scheduled to undergo lung resection for NSCLC were allocated to receive either preoperative exercise training or no exercise training. Data collection and analysis We used standard Cochrane methods. Our primary outcomes were 1. risk of developing a postoperative pulmonary complication; 2. postoperative duration of intercostal catheter and 3. safety. Our secondary outcomes were 1. postoperative length of hospital stay; 2. postintervention fatigue; 3. postintervention dyspnoea; 4. postintervention and postoperative exercise capacity; 5. postintervention lung function and 6. postoperative mortality. We used GRADE to assess the certainty of evidence for each outcome. Main results Along with the five RCTs included in the original version, we identified an additional five RCTs, resulting in 10 RCTs involving 636 participants. Preoperative exercise training results in a large reduction in the risk of developing a postoperative pulmonary complication compared to no preoperative exercise training (risk ratio (RR) 0.45, 95% CI 0.33 to 0.61; I 2 = 0%; 9 studies, 573 participants; high‐certainty evidence). The evidence is very uncertain about its effect on postoperative intercostal catheter duration (MD −2.07 days, 95% CI −4.64 to 0.49; I 2 = 77%, 3 studies, 111 participants; very low‐certainty evidence). Preoperative exercise training is likely safe as studies reported no adverse events. Preoperative exercise training likely results in a reduction in postoperative length of hospital stay (MD −2.24 days, 95% CI −3.64 to −0.85; I 2 = 85%; 9 studies, 573 participants; moderate‐certainty evidence). Preoperative exercise training likely increases postintervention exercise capacity measured by peak oxygen consumption (MD 3.36 mL/kg/minute, 95% CI 2.70 to 4.02; I 2 = 0%; 2 studies, 191 participants; moderate‐certainty evidence); but the evidence is very uncertain about its effect on postintervention exercise capacity measured by the 6‐minute walk distance (MD 29.55 m, 95% CI 12.05 to 47.04; I 2 = 90%; 6 studies, 474 participants; very low‐certainty evidence). Preoperative exercise training may result in little to no effect on postintervention lung function (forced expiratory volume in one second: MD 5.87% predicted, 95% CI 4.46 to 7.28; I 2 = 0%; 4 studies, 197 participants; low‐certainty evidence). Authors' conclusions Preoperative exercise training results in a large reduction in the risk of developing a postoperative pulmonary complication compared to no preoperative exercise training for people with NSCLC. It may also reduce postoperative length of hospital stay, and improve exercise capacity and lung function in people undergoing lung resection for NSCLC. The findings of this review should be interpreted with caution due to risk of bias. Research investigating the cost‐effectiveness and long‐term outcomes associated with preoperative exercise training in NSCLC is warranted. Plain language summary Exercise training before lung surgery in people with non‐small cell lung cancer Review questions What is the benefit of exercise undertaken before surgery for lung cancer and how safe is exercise at this time? Background Lung surgery for non‐small cell lung cancer offers people a chance of cure; however, lung surgery is associated with a risk of complications. Exercise training before surgery, through its improvement in fitness, may reduce the risk of lung complications and improve other outcomes, such as number of days people need a chest drain (a plastic tube inserted into the chest to drain off fluid or air that might be collecting after the operation), and length of hospital stay. In the 2017 version of this review, we found that exercise training was associated with a reduced risk of developing lung complications after surgery, shorter time people needed a chest drain, shorter hospital stay, and improved fitness and lung function before surgery. However, the quality of evidence was low. Study characteristics The evidence is current to November 2021. This review included data from 636 people in 10 studies. Key results Exercise training for people with lung cancer before surgery results in a large reduction (55%) in their risk of developing a lung complication after surgery compared to people who do no exercise before surgery. There were no side effects reported during exercise. Exercise before surgery is likely safe. Preoperative exercise likely reduces length of hospital stay after surgery (by about two days) and increases fitness levels upon completion of the exercise programme. The evidence is very uncertain for its effects on chest drain time. Quality of the evidence The overall quality of evidence ranged from very low to high, mainly because of limitations in the studies' methods, the small number of participants in the included studies and variability in the results.}, -DOI = {10.1002/14651858.CD012020.pub3}, -keywords = {*Carcinoma, Non-Small-Cell Lung [surgery]; *Lung Neoplasms [surgery]; Adult; Dyspnea; Fatigue; Forced Expiratory Volume; Humans; Postoperative Complications [epidemiology]}, -URL = {http://dx.doi.org/10.1002/14651858.CD012020.pub3} -} - - -Record #10 of 54 -@article{Gijtenbeek23, -author = {Gijtenbeek, RGP, de Jong, K, Venmans, BJW, van Vollenhoven, FHM, Ten Brinke, A, Van der Wekken, AJ, and van Geffen, WH}, -title = {Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status}, -journal = {Cochrane Database of Systematic Reviews}, -number = {7}, -year = {2023}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Most people who are newly diagnosed with non‐small cell lung cancer (NSCLC) have advanced disease. For these people, survival is determined by various patient‐ and tumor‐related factors, of which the performance status (PS) is the most important prognostic factor. People with PS 0 or 1 are usually treated with systemic therapies, whereas people with PS 3 or 4 most often receive supportive care. However, treatment for people with PS 2 without a targetable mutation remains unclear. Historically, people with a PS 2 cancer are frequently excluded from (important) clinical trials because of poorer outcomes and increased toxicity. We aim to address this knowledge gap, as this group of people represents a significant proportion (20% to 30%) of the total population with newly diagnosed lung cancer. Objectives To identify the best first‐line therapy for advanced lung cancer in people with performance status 2 without a targetable mutation or with an unknown mutation status. Search methods We used standard, extensive Cochrane search methods. The latest search date was 17 June 2022. Selection criteria We included randomized controlled trials (RCTs) that compared different chemotherapy (with or without angiogenesis inhibitor) or immunotherapy regimens, specifically designed for people with PS 2 only or studies including a subgroup of these people. Data collection and analysis We used standard Cochrane methods. Our primary outcomes were 1. overall survival (OS), 2. health‐related quality of life (HRQoL), and 3. toxicity/adverse events. Our secondary outcomes were 4. tumor response rate, 5. progression‐free survival, and 6. survival rates at six and 12 months' treatment. We used GRADE to assess certainty of evidence for each outcome. Main results We included 22 trials in this review and identified one ongoing trial. Twenty studies compared chemotherapy with different regimens, of which 11 compared non‐platinum therapy (monotherapy or doublet) versus platinum doublet. We found no studies comparing best supportive care with chemotherapy and only two abstracts analyzing chemotherapy versus immunotherapy. We found that platinum doublet therapy showed superior OS compared to non‐platinum therapy (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.57 to 0.78; 7 trials, 697 participants; moderate‐certainty evidence). There were no differences in six‐month survival rates (risk ratio [RR] 1.00, 95% CI 0.72 to 1.41; 6 trials, 632 participants; moderate‐certainty evidence), whereas 12‐month survival rates were improved for treatment with platinum doublet therapy (RR 0.92, 95% CI 0.87 to 0.97; 11 trials, 1567 participants; moderate‐certainty evidence). PFS and tumor response rate were also better for people treated with platinum doublet therapy, with moderate‐certainty evidence (PFS: HR 0.57, 95% CI 0.42 to 0.77; 5 trials, 487 participants; tumor response rate: RR 2.25, 95% CI 1.67 to 3.05; 9 trials, 964 participants). When analyzing toxicity rates, we found that platinum doublet therapy increased grade 3 to 5 hematologic toxicities, all with low‐certainty evidence (anemia: RR 1.98, 95% CI 1.00 to 3.92; neutropenia: RR 2.75, 95% CI 1.30 to 5.82; thrombocytopenia: RR 3.96, 95% CI 1.73 to 9.06; all 8 trials, 935 participants). Only four trials reported HRQoL data; however, the methodology was different per trial and we were unable to perform a meta‐analysis. Although evidence is limited, there were no differences in 12‐month survival rates or tumor response rates between carboplatin and cisplatin regimens. With an indirect comparison, carboplatin seemed to have better 12‐month survival rates than cisplatin compared to non‐platinum therapy. The assessment of the efficacy of immunotherapy in people with PS 2 was limited. There might be a place for single‐agent immunotherapy, but the data provided by the included studies did not encourage the use of double‐agent immunotherapy. Authors' conclusions This review showed that as a first‐line treatment for people with PS 2 with advanced NSCLC, platinum doublet therapy seems to be preferred over non‐platinum therapy, with a higher response rate, PFS, and OS. Although the risk for grade 3 to 5 hematologic toxicity is higher, these events are often relatively mild and easy to treat. Since trials using checkpoint inhibitors in people with PS 2 are scarce, we identified an important knowledge gap regarding their role in people with advanced NSCLC and PS 2. Plain language summary Best therapy for people with advanced non‐small cell lung cancer who have not been treated without a targetable mutation and moderately impaired performance status Key messages – The preferred chemotherapy for people with moderately impaired performance status (PS) with advanced non‐small cell lung cancer (NSCLC) and that have never received any treatment before should contain two medicines, one of which is a platinum‐based medicine. – Although the risk for bone marrow damage is higher with a platinum‐based medicine, these events are often relatively mild and easy to treat. – We were unable to assess the effects of immunotherapy on moderately impaired people. What is non‐small cell lung cancer? Lung cancer is the most frequent cause of cancer‐related death worldwide and NSCLC is the most common subtype. At the time of diagnosis, the disease has already spread in more than half of all cases. In the tumors of a minority of people diagnosed with NSCLC that has spread to other parts of the body specific mutations can be found, which are treated distinct from the majority of people without such mutations. How can non‐small cell lung cancer be treated? NSCLC can only be treated with life‐prolonging medicines such as chemotherapy (a medicine used to destroy cancer cells) or immunotherapy (a medicine that boosts the person's immune system and helps the body find and destroy cancer cells). Selecting the best treatment depends on the health condition of the person. That condition is determined using a scale from 0 (no symptoms) to 5 (dead). There is no discussion on the treatment of relatively fit people (scoring 0 or 1), as they often tolerate these treatments relatively well. People with a low health condition (scoring 3 or 4) receive only supportive care in most cases. However, although representing 20% to 30% of all people, the best treatment for moderately impaired people (PS 2) is not clear, as they often do not participate in trials. What did we want to find out? Our objective was to investigate the best therapy for people with advanced NSCLC without a specific mutation with PS 2. What did we do? We searched medical databases for clinical trials comparing treatments for advanced NSCLC with best supportive care or other treatments. What did we find? We found 22 trials; 20 compared different types of chemotherapy and two compared chemotherapy versus immunotherapy. Main results People treated with chemotherapy regimens using two medicines, including a platinum‐based medicine, had longer survival than people treated with chemotherapies without a platinum‐based medicine. However, these people did have more side effects, especially with a negative influence on the bone marrow (matter found in the center of bones), resulting in a temporary lack of red and white blood cells, and platelets. The few studies that analyzed health‐related quality of life all used different methods of measurement. We found no difference in quality of life when we looked at those studies individually. We found two partly published trials studying immunotherapy, which found no survival benefit compared to chemotherapy. What are the limitations of the evidence? We are moderately confident in our results that chemotherapies with a platinum‐based medicine increases survival. We are also moderately confident in the evidence evaluating the time to progression of disease because in all included studies, both investigators and trial participants were fully aware of which treatment the participants received. This might lead to substantial bias. In addition, we have little confidence in the evidence regarding toxicities because the evidence is based on a small number of studies with conflicting outcomes. How up to date is this evidence? The evidence is up to date to 17 June 2022.}, -DOI = {10.1002/14651858.CD013382.pub2}, -keywords = {*Carcinoma, Non-Small-Cell Lung [drug therapy, genetics]; *Lung Neoplasms [drug therapy, genetics]; Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; Carboplatin [therapeutic use]; Cisplatin; Humans; Mutation}, -URL = {http://dx.doi.org/10.1002/14651858.CD013382.pub2} -} - - -Record #11 of 54 -@article{Ferrara20, -author = {Ferrara, R, Imbimbo, M, Malouf, R, Paget-Bailly, S, Calais, F, Marchal, C, and Westeel, V}, -title = {Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {4}, -year = {2021}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis have changed the first‐line treatment of people with advanced non‐small cell lung cancer (NSCLC). Single‐agent pembrolizumab (a PD‐1 inhibitor) is currently the standard of care as monotherapy in patients with PD‐L1 expression ≥ 50%, either alone or in combination with chemotherapy when PD‐L1 expression is less than 50%. Atezolizumab (PD‐L1 inhibitor) has also been approved in combination with chemotherapy and bevacizumab (an anti‐angiogenic antibody) in first‐line NSCLC regardless of PD‐L1 expression. The combination of first‐line PD‐1/PD‐L1 inhibitors with anti‐CTLA‐4 antibodies has also been shown to improve survival compared to platinum‐based chemotherapy in advanced NSCLC, particularly in people with high tumour mutational burden (TMB). The association of ipilimumab (an anti CTLA4) and nivolumab (PD‐1 inhibitor) has been approved by the US Food and Drug Administration (FDA) in all patients with PD‐L1 expression ≥1%. Although these antibodies are currently used in clinical practice, some questions remain unanswered, such as the best‐treatment strategy, the role of different biomarkers for treatment selection and the effectiveness of immunotherapy according to specific clinical characteristics. Objectives To determine the effectiveness and safety of first‐line immune checkpoint inhibitors (ICIs), as monotherapy or in combination, compared to platinum‐based chemotherapy, with or without bevacizumab for people with advanced NSCLC, according to the level of PD‐L1 expression. Search methods We performed an electronic search of the main databases (Cochrane Central Register of Controlled Trials, MEDLINE, Embase) from inception until 31 December 2020 and conferences meetings from 2015 onwards. Selection criteria We included randomised controlled trials (RCTs) reporting on the efficacy or safety of first‐line ICI treatment for adults with advanced NSCLC who had not previously received any anticancer treatment. We included trials comparing single‐ or double‐ICI treatment to standard first‐line therapy (platinum‐based chemotherapy +/‐ bevacizumab). All data come from ‘international multicentre studies involving adults, age 18 or over, with histologically‐confirmed stage IV NSCLC. Data collection and analysis Three review authors independently assessed the search results and a fourth review author resolved any disagreements. Primary outcomes were overall survival (OS) and progression‐free survival (PFS); secondary outcomes were overall objective response rate (ORR) by RECIST v 1.1, grade 3 to 5 treatment‐related adverse events (AEs) (CTCAE v 5.0) and health‐related quality of life (HRQoL). We performed meta‐analyses where appropriate using the random‐effects model for hazard ratios (HRs) or risk ratios (RRs), with 95% confidence intervals (95% CIs), and used the I² statistic to investigate heterogeneity. Main results Main results We identified 15 trials for inclusion, seven completed and eight ongoing trials. We obtained data for 5893 participants from seven trials comparing first‐line single‐ (six trials) or double‐ (two trials) agent ICI with platinum‐based chemotherapy, one trial comparing both first‐line single‐ and double‐agent ICsI with platinum‐based chemotherapy. All trials were at low risk of selection and detection bias, some were classified at high risk of performance, attrition or other source of bias. The overall certainty of evidence according to GRADE ranged from moderate‐to‐low because of risk of bias, inconsistency, or imprecision. The majority of the included trials reported their outcomes by PD‐L1 expressions, with PD‐L1 ≥ 50 being considered the most clinically useful cut‐off level for decision makers. Also, iIn order to avoid overlaps between various PDL‐1 expressions we prioritised the review outcomes according to PD‐L1 ≥ 50. Single‐agent ICI 
In the PD‐L1 expression ≥ 50% group single‐agent ICI probably improved OS compared to platinum‐based chemotherapy (hazard ratio (HR) 0.68, 95% confidence interval (CI) 0.60 to 0.76, 6 RCTs, 2111 participants, moderate‐certainty evidence). In this group, single‐agent ICI also may improve PFS (HR: 0.68, 95% CI 0.52 to 0.88, 5 RCTs, 1886 participants, low‐certainty evidence) and ORR (risk ratio (RR):1.40, 95% CI 1.12 to 1.75, 4 RCTs, 1672 participants, low‐certainty evidence). HRQoL data were available for only one study including only people with PD‐L1 expression ≥ 50%, which suggested that single‐agent ICI may improve HRQoL at 15 weeks compared to platinum‐based chemotherapy (RR: 1.51, 95% CI 1.08 to 2.10, 1 RCT, 297 participants, low‐certainty evidence).
In the included studies, treatment‐related AEs were not reported according to PD‐L1 expression levels. Grade 3‐4 AEs may be less frequent with single‐agent ICI compared to platinum‐based chemotherapy (RR: 0.41, 95% CI 0.33 to 0.50, I² = 62%, 5 RCTs, 3346 participants, low‐certainty evidence). More information about efficacy of single‐agent ICI compared to platinum‐based chemotherapy according to the level of PD‐L1 expression and to TMB status or specific clinical characteristics is available in the full text. Double‐agent ICI 
Double‐ICI treatment probably prolonged OS compared to platinum‐based chemotherapy in people with PD‐L1 expression ≥50% (HR: 0.72, 95% CI 0.59 to 0.89 2 RCTs, 612 participants, moderate‐certainty evidence).
Trials did not report data on HRQoL, PFS and ORR according to PD‐L1 groups.
Treatment related AEs were not reported according to PD‐L1 expression levels. The frequency of grade 3‐4 AEs may not differ between double‐ICI treatment and platinum‐based chemotherapy (RR: 0.78, 95% CI 0.55 to 1.09, I² = 81%, 2 RCTs, 1869 participants, low‐certainty evidence). More information about efficacy of double‐agent ICI according to the level of PD‐L1 expression and to TMB status is available in the full text. Authors' conclusions Authors' conclusions The evidence in this review suggests that single‐agent ICI in people with NSCLC and PD‐L1 ≥50% probably leads to a higher overall survival rate and may lead to a higher progression‐free survival and overall response rate when compared to platinum‐based chemotherapy and may also lead to a lower rate of adverse events and higher HRQoL. Combined ICI in people with NSCLC and PD‐L1 ≥50% also probably leads to a higher overall survival rate when compared to platinum‐based chemotherapy, but its effect on progression‐free survival, overall response rate and HRQoL is unknown due to a lack of data. The rate of adverse events may not differ between groups. This review used to be a living review. It is transitioned out of living mode because current research is exploring ICI in association with chemotherapy or other immunotherapeutic drugs versus ICI as single agent rather than platinum based chemotherapy. Plain language summary Immunotherapy versus chemotherapy for people with advanced non‐small cell lung cancer who have not been not previously been treated Review question Is immunotherapy more effective and less toxic than chemotherapy for people diagnosed with non‐small cell lung cancer (a subtype of lung cancer) who have not previously been treated and who are not suitable for curative treatment? Background Lung cancer is the leading cause of cancer deaths and non‐small cell lung cancer represent more than 85% of all lung cancer cases. Curative surgery and radiotherapy are not treatment options when the disease is at an advanced stage and until recently these people were offered chemotherapy. Since 2016, immunotherapies (antibodies able to stimulate the immune system against cancer cells) have been shown to improve survival for these patients. Side effects of immunotherapies are mainly inflammation of the tissues caused by the activation of the immune system against different organs, while chemotherapy usually causes a reduction in the white blood cells and red blood cells, hair loss, nausea and vomiting.
In this Cochrane Review, we tried to find out how effective and safe immunotherapies (given alone or as combinations) are compared to standard chemotherapy for people with non‐small cell lung cancer who are not suitable for possibly curative treatment. Study characteristics We searched the main databases and records of conference meetings up to 31st December 2020. We included seven studies (5893 participants) comparing immunotherapies (antibodies that interact with specific proteins called immune checkpoints) with chemotherapy for people with non‐small cell lung cancer not previously treated. Key results We reported the results by PD‐L1 levels (a protein produced by the tumour or immune cells and bound by immune checkpoint inhibitors) In people with more than 50% of tumour/immune cells expressing PD‐L1 protein, single immunotherapy might improve survival with fewer side effects. In addition, treatment with combined immunotherapies may improve survival in both people with high expression of PD‐L1 protein.The rate of toxic effects may be the same for people treated with combined immunotherapies or chemotherapy. Certainty of evidence Overall, the certainty of the evidence ranged from moderate to low. Conclusions For people with advanced non‐small cell lung cancer with a high expression of PD‐L1 protein, immunotherapies alone or combinations of immunotherapies prolonged life compared to chemotherapy. The frequency of side effects may be lower with the use of immunotherapies alone compared to chemotherapy. The frequency of side effects may not differ between combinations of immunotherapies and chemotherapy. }, -DOI = {10.1002/14651858.CD013257.pub3}, -keywords = {Aged; Antibodies, Monoclonal [therapeutic use]; Antibodies, Monoclonal, Humanized [therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; B7-H1 Antigen [metabolism]; Bevacizumab [adverse effects, *therapeutic use]; Bias; Carcinoma, Non-Small-Cell Lung [*drug therapy, metabolism, mortality, pathology]; Female; Humans; Immune Checkpoint Inhibitors [adverse effects, *therapeutic use]; Lung Neoplasms [*drug therapy, mortality, pathology]; Male; Middle Aged; Nivolumab [adverse effects, therapeutic use]; Platinum Compounds [adverse effects, therapeutic use]; Progression-Free Survival; Randomized Controlled Trials as Topic}, -URL = {http://dx.doi.org/10.1002/14651858.CD013257.pub3} -} - - -Record #12 of 54 -@article{Abdel‐Rahman18, -author = {Abdel‐Rahman, O, Elsayed, Z, Mohamed, H, and Eltobgy, M}, -title = {Radical multimodality therapy for malignant pleural mesothelioma}, -journal = {Cochrane Database of Systematic Reviews}, -number = {1}, -year = {2018}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Malignant pleural mesothelioma is an almost always fatal tumour, for which palliative platinum‐based chemotherapy is currently the standard treatment. Multimodal therapeutic strategies incorporating surgery, radiation therapy or photodynamic therapy and chemotherapy have been recommended for selected patients but there is no consensus about their effectiveness. Objectives To assess the benefits and harms of radical multimodal treatment options (including radical surgery ± radical radiotherapy ± photodynamic therapy ± systemic therapy) compared to each other or to palliative treatments, for people with malignant pleural mesothelioma. Search methods We reviewed data from the Cochrane Lung Cancer group's Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase. We also checked reference lists of primary original studies, review articles and relevant conference proceedings manually for further related articles up to 21 March 2017. Selection criteria We included parallel‐group randomised controlled trials of multimodal therapy for people with malignant pleural mesothelioma (stages I, II or III) that measured at least one of the following endpoints: overall survival, health‐related health‐related quality of life, adverse events or progression‐free survival. We considered studies regardless of language or publication status. Data collection and analysis Two review authors independently extracted relevant information on participant characteristics, interventions, study outcomes, and data on the outcomes for this review, as well as information on the design and methodology of the studies. Two review authors assessed the risk of bias in the included trials using pre‐defined 'Risk of bias' domains. We assessed the methodological quality using GRADE. Main results We conducted this review in accordance with the published Cochrane protocol. Two randomised clinical trials with 104 participants fulfilled our inclusion criteria. Both trials were at high risk of bias (for outcomes other than overall survival), and we rated the evidence as moderate quality for overall survival and low quality for all other outcomes. One trial compared combined extrapleural pneumonectomy (EPP) plus neoadjuvant platinum‐based chemotherapy plus postoperative high‐dose hemithoracic radiotherapy with combined EPP plus platinum‐based chemotherapy. The other trial compared EPP plus postoperative hemithoracic radiotherapy with standard (non‐radical) therapy alone following platinum‐based chemotherapy (patients in the standard therapy arm received continued oncological management according to local policy, which could include further chemotherapy or palliative radiotherapy). For the first trial, median overall survival calculated from registration was 20.8 months (95% confidence interval (CI) 14.4 to 27.8) in the no‐radiotherapy group and 19.3 months (95% CI 11.5 to 21.8) in the radiotherapy group. For the second trial, median overall survival was 14.4 months (95% CI 5.3 to 18.7) for patients allocated to EPP and 19.5 months (95% CI 13.4 to time not yet reached) for patients randomised to standard non‐radical therapy. In the second trial, 12 serious adverse events were reported during the study period: ten in the EPP group and two in the non‐radical therapy group. Overall health‐related quality of life scores were not different between the two arms in either study. We could not perform a meta‐analysis of the two included trials due to clinical heterogeneity. We also identified three ongoing trials evaluating the topic of our review. Authors' conclusions The overall strength of the evidence gathered in this review is low and there is a lack of available evidence to support the use of radical multimodality therapy in routine clinical practice (particularly as one trial suggests greater harm). Given the added cost of multimodality treatment and the possible increase in risk of adverse effects, the lack of evidence of their effectiveness probably means that these interventions should currently be limited to clinical trials alone. Plain language summary Multimodality treatment for malignant pleural mesothelioma (primary pleural cancer) Review question Does radical surgery with or without radiotherapy improve the length and health‐related quality of life in people with localised malignant mesothelioma, compared with chemotherapy and supportive care only? Background Malignant pleural mesothelioma (that is, primary pleural cancer) is a difficult tumour to treat. Chemotherapy is usually given first to people who are fit enough to have it. It is not clear whether radical surgery and radiotherapy help people to live longer or improve their overall health‐related quality of life. Study characteristics We searched published medical articles to find research papers that looked at combined treatment strategies with surgery for treating people with primary pleural cancer. We looked for randomised clinical trials (where people were allocated at random to one of two or more treatments groups) and used information from those we found to form our conclusions. We found evidence up to 21 March 2017. Key results The review authors found two small randomised clinical trials, in which a total of 104 people with pleural mesothelioma were randomised. One trial compared the addition of surgery and radiotherapy to chemotherapy with chemotherapy alone. The other trial compared the addition of radiotherapy to chemotherapy and surgery with chemotherapy and surgery alone. These two small trials suggested that there is no added value for either radiotherapy or combined radiotherapy and surgery. We could not combine the data from the trials as we had intended, because the two trials were too different. We rated the quality of evidence as moderate for survival and low quality for all the other outcomes studied. The review authors identified three ongoing randomised clinical trials, the results of which have not been published yet. Quality of evidence and conclusions We only found two relevant trials. Both were small, which made the results uncertain. It is not clear whether giving a combination of surgery and radical radiotherapy after chemotherapy is better than giving chemotherapy alone. Radical radiotherapy does not seem to improve the results of surgery alone.}, -DOI = {10.1002/14651858.CD012605.pub2}, -keywords = {Antineoplastic Agents [*therapeutic use]; Combined Modality Therapy [*methods]; Humans; Lung Neoplasms [mortality, *therapy]; Mesothelioma [mortality, *therapy]; Mesothelioma, Malignant; Platinum Compounds [therapeutic use]; Pneumonectomy [*methods]; Radiotherapy Dosage; Randomized Controlled Trials as Topic}, -URL = {http://dx.doi.org/10.1002/14651858.CD012605.pub2} -} - - -Record #13 of 54 -@article{Trommer23, -author = {Trommer, M, Marnitz, S, Skoetz, N, Rupp, R, Niels, T, Morgenthaler, J, Theurich, S, von Bergwelt-Baildon, M, Baues, C, and Baumann, FT}, -title = {Exercise interventions for adults with cancer receiving radiation therapy alone}, -journal = {Cochrane Database of Systematic Reviews}, -number = {3}, -year = {2023}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Radiation therapy (RT) is given to about half of all people with cancer. RT alone is used to treat various cancers at different stages. Although it is a local treatment, systemic symptoms may occur. Cancer‐ or treatment‐related side effects can lead to a reduction in physical activity, physical performance, and quality of life (QoL). The literature suggests that physical exercise can reduce the risk of various side effects of cancer and cancer treatments, cancer‐specific mortality, recurrence of cancer, and all‐cause mortality. Objectives To evaluate the benefits and harms of exercise plus standard care compared with standard care alone in adults with cancer receiving RT alone. Search methods We searched CENTRAL, MEDLINE (Ovid), Embase (Ovid), CINAHL, conference proceedings and trial registries up to 26 October 2022. Selection criteria We included randomised controlled trials (RCTs) that enrolled people who were receiving RT without adjuvant systemic treatment for any type or stage of cancer. We considered any type of exercise intervention, defined as a planned, structured, repetitive, objective‐oriented physical activity programme in addition to standard care. We excluded exercise interventions that involved physiotherapy alone, relaxation programmes, and multimodal approaches that combined exercise with other non‐standard interventions such as nutritional restriction. Data collection and analysis We used standard Cochrane methodology and the GRADE approach for assessing the certainty of the evidence. Our primary outcome was fatigue and the secondary outcomes were QoL, physical performance, psychosocial effects, overall survival, return to work, anthropometric measurements, and adverse events. Main results Database searching identified 5875 records, of which 430 were duplicates. We excluded 5324 records and the remaining 121 references were assessed for eligibility. We included three two‐arm RCTs with 130 participants. Cancer types were breast and prostate cancer. Both treatment groups received the same standard care, but the exercise groups also participated in supervised exercise programmes several times per week while undergoing RT. Exercise interventions included warm‐up, treadmill walking (in addition to cycling and stretching and strengthening exercises in one study), and cool‐down. In some analysed endpoints (fatigue, physical performance, QoL), there were baseline differences between exercise and control groups. We were unable to pool the results of the different studies owing to substantial clinical heterogeneity. All three studies measured fatigue. Our analyses, presented below, showed that exercise may reduce fatigue (positive SMD values signify less fatigue; low certainty). • Standardised mean difference (SMD) 0.96, 95% confidence interval (CI) 0.27 to 1.64; 37 participants (fatigue measured with Brief Fatigue Inventory (BFI))
• SMD 2.42, 95% CI 1.71 to 3.13; 54 participants (fatigue measured with BFI)
• SMD 1.44, 95% CI 0.46 to 2.42; 21 participants (fatigue measured with revised Piper Fatigue Scale) All three studies measured QoL, although one provided insufficient data for analysis. Our analyses, presented below, showed that exercise may have little or no effect on QoL (positive SMD values signify better QoL; low certainty). • SMD 0.40, 95% CI −0.26 to 1.05; 37 participants (QoL measured with Functional Assessment of Cancer Therapy‐Prostate)
• SMD 0.47, 95% CI −0.40 to 1.34; 21 participants (QoL measured with World Health Organization QoL questionnaire (WHOQOL‐BREF)) All three studies measured physical performance. Our analyses of two studies, presented below, showed that exercise may improve physical performance, but we are very unsure about the results (positive SMD values signify better physical performance; very low certainty) • SMD 1.25, 95% CI 0.54 to 1.97; 37 participants (shoulder mobility and pain measured on a visual analogue scale)
• SMD⁠⁠⁠⁠⁠⁠ 3.13 (95% CI 2.32 to 3.95; 54 participants (physical performance measured with the six‐minute walk test) Our analyses of data from the third study showed that exercise may have little or no effect on physical performance measured with the stand‐and‐sit test, but we are very unsure about the results (SMD 0.00, 95% CI −0.86 to 0.86, positive SMD values signify better physical performance; 21 participants; very low certainty). Two studies measured psychosocial effects. Our analyses (presented below) showed that exercise may have little or no effect on psychosocial effects, but we are very unsure about the results (positive SMD values signify better psychosocial well‐being; very low certainty). • SMD 0.48, 95% CI −0.18 to 1.13; 37 participants (psychosocial effects measured on the WHOQOL‐BREF social subscale)
• SMD 0.29, 95% CI −0.57 to 1.15; 21 participants (psychosocial effects measured with the Beck Depression Inventory) Two studies recorded adverse events related to the exercise programmes and reported no events. We estimated the certainty of the evidence as very low. No studies reported adverse events unrelated to exercise. No studies reported the other outcomes we intended to analyse (overall survival, anthropometric measurements, return to work). Authors' conclusions There is little evidence on the effects of exercise interventions in people with cancer who are receiving RT alone. While all included studies reported benefits for the exercise intervention groups in all assessed outcomes, our analyses did not consistently support this evidence. There was low‐certainty evidence that exercise improved fatigue in all three studies. Regarding physical performance, our analysis showed very low‐certainty evidence of a difference favouring exercise in two studies, and very low‐certainty evidence of no difference in one study. We found very low‐certainty evidence of little or no difference between the effects of exercise and no exercise on quality of life or psychosocial effects. We downgraded the certainty of the evidence for possible outcome reporting bias, imprecision due to small sample sizes in a small number of studies, and indirectness of outcomes. In summary, exercise may have some beneficial outcomes in people with cancer who are receiving RT alone, but the evidence supporting this statement is of low certainty. There is a need for high‐quality research on this topic. Plain language summary Exercise interventions for adults with cancer who are receiving radiation therapy without additional cancer therapy What is radiation therapy? Radiation therapy (also called radiotherapy) is a treatment that delivers high doses of radiation to a specific part of the body to kill cancer cells. One in two people with cancer will undergo radiation therapy. Some people receive radiation therapy alone, while others receive radiation therapy combined with other cancer treatments that affect the whole body (chemotherapy, immunotherapy, or hormone therapy). The unwanted effects of radiation therapy usually affect the part of the body where the radiation is delivered, but there may also be symptoms that affect the whole body. These unwanted effects can lead to reduced physical activity, physical performance, and quality of life. There is evidence that people with cancer who perform exercise may be less likely to die from cancer or from other causes, may be less likely to have their cancer return, and may have fewer unwanted effects of cancer treatment. What did we want to find out? We wanted to find out if exercise could help to improve the following outcomes in people with cancer receiving radiation therapy alone. • Fatigue
• Quality of life
• Physical performance
• Psychosocial effects (such as depression)
• Overall survival
• Return to work
• Anthropometric measurements (such as weight)
• Unwanted effects What did we do? We searched electronic medical literature databases for randomised controlled trials (RCTs) that enrolled people with all types and stages of cancer who were receiving RT alone. Eligible RCTs randomly assigned some participants to receive any type of exercise intervention plus standard care and others to standard care alone. We excluded exercise interventions that involved physiotherapy alone, relaxation programmes, or combination programmes with exercise and, for example, dietary restrictions. We compared the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. What did we find? We included three studies that enrolled 130 people with breast or prostate cancer. The exercise groups participated in a supervised exercise programme three to five times per week for five to eight weeks. The exercise interventions included warm‐up, aerobic exercise, and cool‐down. We analysed the differences between the exercise groups and control groups in the outcome values after radiation therapy. We could not compare the differences between the groups in the change in outcome values from before to after radiotherapy because the studies did not provide enough information for this comparison. In some outcomes (fatigue, physical performance, quality of life), there were already differences between the exercise and control groups at the beginning of the studies. Exercise may improve fatigue and may have little or no effect on quality of life. Exercise may improve physical performance, but we are very uncertain about the results. Exercise may have little or no effect on psychosocial effects, but we are very uncertain about the results. Two studies reported no unwanted effects of exercise. No studies measured our other outcomes of interest. Exercise programmes in people with cancer receiving RT alone may provide some benefits, but the evidence to support this is poor. Due to the lack of evidence, we could not detect and also not rule out clear differences in outcomes. What are the limitations of the evidence? We have little or very little confidence in the evidence because the results are based on a small number of studies that enrolled very few people, because the people in two studies knew which group they were in, and because the evidence focused on a specific population whereas the question we wanted to answer was broader. Further research is likely to change our results. How up to date is the evidence? The evidence is up to date to 26 October 2022. }, -DOI = {10.1002/14651858.CD013448.pub2}, -keywords = {*Exercise; *Neoplasms [complications, radiotherapy]; Adult; Exercise Therapy [adverse effects]; Fatigue [etiology, therapy]; Humans; Male; Quality of Life; Walk Test; Walking}, -URL = {http://dx.doi.org/10.1002/14651858.CD013448.pub2} -} - - -Record #14 of 54 -@article{Cameron22, -author = {Cameron, LB, Hitchen, N, Chandran, E, Morris, T, Manser, R, Solomon, BJ, and Jordan, V}, -title = {Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {1}, -year = {2022}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Targeted therapies directed at specific driver oncogenes have improved outcomes for individuals with advanced non‐small cell lung cancer (NSCLC). Approximately 5% of lung adenocarcinomas, the most common histologic subtype of NSCLC, harbour rearrangements in the anaplastic lymphoma kinase ( ALK ) gene leading to constitutive activity of the ALK kinase. Crizotinib was the first tyrosine kinase inhibitor (TKI) demonstrated to be effective in advanced NSCLC. Next‐generation ALK TKIs have since been developed including ceritinib, alectinib, brigatinib, ensartinib, and lorlatinib, and have been compared with crizotinib or chemotherapy in randomised controlled trials (RCTs). These ALK ‐targeted therapies are currently used in clinical practice and are endorsed in multiple clinical oncology guidelines. Objectives To evaluate the safety and efficacy of ALK inhibitors given as monotherapy to treat advanced ALK ‐rearranged NSCLC. Search methods We conducted electronic searches in the Cochrane Lung Cancer Group Specialised Register, Cochrane Central Register of Controlled Trials, MEDLINE, and Embase. We also searched conference proceedings from the American Society for Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), and International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, as well as the reference lists of retrieved articles. All searches were conducted from 2007 until 7 January 2021. Selection criteria We included RCTs comparing ALK inhibitors with cytotoxic chemotherapy or another ALK inhibitor in individuals with incurable locally advanced or metastatic pathologically confirmed ALK ‐rearranged NSCLC. Data collection and analysis Two review authors independently assessed studies for eligibility, extracted study characteristics and outcome data, and assessed risk of bias using the Cochrane risk of bias tool for each included study. We assessed the certainty of evidence using GRADE. Primary outcomes were progression‐free survival (PFS) and adverse events (AE); secondary outcomes were overall survival (OS), OS at one year, overall response rate (ORR) by RECIST (Response Evaluation Criteria in Solid Tumours) criteria, and health‐related quality of life (HRQoL). We performed a meta‐analysis for all outcomes, where appropriate, using the fixed‐effect model. We reported hazard ratios (HR) for PFS, OS, and a composite HRQoL of life outcome (time to deterioration), and risk ratios (RR) for AE, ORR, and one‐year OS. We presented 95% confidence intervals (95% CIs) and used the I² statistic to investigate heterogeneity. We planned comparisons of 'ALK inhibitor versus chemotherapy' and 'next‐generation ALK inhibitor versus crizotinib’ with subgroup analysis by type of ALK inhibitor, line of treatment, and baseline central nervous system involvement. Main results Eleven studies (2874 participants) met our inclusion criteria: six studies compared an ALK inhibitor (crizotinib, ceritinib, and alectinib) to chemotherapy, and five studies compared a next‐generation ALK inhibitor (alectinib, brigatinib, and lorlatinib) to crizotinib. We assessed the evidence for most outcomes as of moderate to high certainty. Most studies were at low risk for selection, attrition, and reporting bias; however, no RCTs were blinded, resulting in a high risk of performance and detection bias for outcomes reliant on subjective measurement. ALK inhibitor versus chemotherapy Treatment with ALK inhibitors resulted in a large increase in PFS compared to chemotherapy (HR 0.45, 95% CI 0.40 to 0.52, 6 RCTs, 1611 participants, high‐certainty evidence). This was found regardless of line of treatment. ALK inhibitors may result in no difference in overall AE rate when compared to chemotherapy (RR 1.01, 95% CI 1.00 to 1.03, 5 RCTs, 1404 participants, low‐certainty evidence). ALK inhibitors slightly improved OS (HR 0.84, 95% CI 0.72 to 0.97, 6 RCTs, 1611 participants, high‐certainty evidence), despite most included studies having a significant number of participants crossing over from chemotherapy to receive an ALK inhibitor after the study period. ALK inhibitors likely increase ORR (RR 2.43, 95% CI 2.16 to 2.75, 6 RCTs, 1611 participants, moderate‐certainty evidence) including in measurable baseline brain metastases (RR 4.88, 95% CI 2.18 to 10.95, 3 RCTs, 108 participants) when compared to chemotherapy. ALK inhibitors result in a large increase in the HRQoL measure, time to deterioration (HR 0.52, 95% CI 0.44 to 0.60, 5 RCTs, 1504 participants, high‐certainty evidence) when compared to chemotherapy. Next‐generation ALK inhibitor versus crizotinib Next‐generation ALK inhibitors resulted in a large increase in PFS (HR 0.39, 95% CI 0.33 to 0.46, 5 RCTs, 1263 participants, high‐certainty evidence), particularly in participants with baseline brain metastases. Next‐generation ALK inhibitors likely result in no difference in overall AE (RR 1.00, 95% CI 0.98 to 1.01, 5 RCTs, 1263 participants, moderate‐certainty evidence) when compared to crizotinib. Next‐generation ALK inhibitors likely increase OS (HR 0.71, 95% CI 0.56 to 0.90, 5 RCTs, 1263 participants, moderate‐certainty evidence) and slightly increase ORR (RR 1.18, 95% CI 1.10 to 1.25, 5 RCTs, 1229 participants, moderate‐certainty evidence) including a response in measurable brain metastases (RR 2.45, 95% CI 1.7 to 3.54, 4 RCTs, 138 participants) when compared to crizotinib. Studies comparing ALK inhibitors were conducted exclusively or partly in the first‐line setting. Authors' conclusions Next‐generation ALK inhibitors including alectinib, brigatinib, and lorlatinib are the preferred first systemic treatment for individuals with advanced ALK ‐rearranged NSCLC. Further trials are ongoing including investigation of first‐line ensartinib. Next‐generation inhibitors have not been compared to each other, and it is unknown which should be used first and what subsequent treatment sequence is optimal. Plain language summary Targeted treatment of non‐small cell lung cancer with an anaplastic lymphoma kinase ( ALK ) gene mutation Background The most common type of lung cancer is non‐small cell lung cancer (NSCLC). About 5% of NSCLC will be driven by a gene mutation known as anaplastic lymphoma kinase ( ALK ). Targeted treatments for those with advanced (not curable) ALK‐ mutated NSCLC cancer have been developed and found to be more effective than chemotherapy. The first ALK inhibitor to be developed was crizotinib. Newer ALK ‐targeted drugs have also been developed and include ceritinib, alectinib, brigatinib, ensartinib, and lorlatinib. In this review we looked at treatments that target ALK‐ mutated NSCLC to find out how well they work. Objectives The primary objective of this review was to find out whether people with ALK‐ mutated NSCLC given treatments targeted towards ALK live longer without recurrence and have fewer side effects than those treated with chemotherapy. We also planned to evaluate whether newer ALK ‐targeted drugs achieve this better than crizotinib. Study characteristics We searched the main medical databases and records of conferences up to 7 January 2021. We found 11 studies (2874 participants): six studies compared an ALK ‐targeted drug to chemotherapy, and five studies compared a newer ALK ‐targeted drug to crizotinib. The studies were conducted in people with advanced ALK‐ mutated NSCLC using these drugs as their first or later treatment. A total of five different ALK inhibitors were used across studies: alectinib, brigatinib, ceritinib, crizotinib, and lorlatinib. Results People treated with ALK ‐targeted drugs lived longer without their cancer growing than those on chemotherapy. These improvements were also seen in people with cancer that had spread to the brain. People receiving ALK ‐targeted drugs lived longer overall, even when some had received chemotherapy first. ALK ‐targeted drugs cause a similar number of side effects as chemotherapy. ALK ‐targeted drugs caused more tumours to reduce in size and resulted in a longer time until worsening of symptoms when compared to chemotherapy. People treated with newer ALK ‐targeted drugs lived longer without their cancer growing than those receiving crizotinib, including in people with cancer involving the brain. People treated with newer ALK ‐targeted drugs as first treatment were likely to live longer overall with a similar number of overall side effects. Newer ALK ‐targeted drugs caused more tumours to reduce in size when compared to crizotinib. The evidence for most reported measures was of moderate or high certainty. Conclusions The best first treatment for people with incurable ALK‐ mutated lung cancer is a newer ALK inhibitor such as alectinib, brigatinib, ceritinib, or lorlatinib. More studies are needed to determine which of these options is best and what treatment should be used when the cancer grows after these medicines have been given.}, -DOI = {10.1002/14651858.CD013453.pub2}, -keywords = {*Carcinoma, Non-Small-Cell Lung [drug therapy, genetics]; *Lung Neoplasms [drug therapy, genetics]; Anaplastic Lymphoma Kinase [genetics]; Humans; Progression-Free Survival; Protein Kinase Inhibitors [adverse effects]}, -URL = {http://dx.doi.org/10.1002/14651858.CD013453.pub2} -} - - -Record #15 of 54 -@article{Schlaak12, -author = {Schlaak, M, Pickenhain, J, Theurich, S, Skoetz, N, von Bergwelt‐Baildon, M, and Kurschat, P}, -title = {Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T‐cell lymphoma}, -journal = {Cochrane Database of Systematic Reviews}, -number = {8}, -year = {2013}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Primary cutaneous T‐cell lymphomas (CTCL) belong to the group of non‐Hodgkin lymphomas and usually run an indolent course. However, some patients progress to advanced tumour or leukaemic stages. To date, there is no cure for those cases. In the last few years, several publications reported durable responses in some patients following allogeneic stem cell transplantation (alloSCT). This is an update of a Cochrane review first published in 2011 and updated in 2013. Objectives To compare the efficacy and safety of conventional therapies with allogeneic stem cell transplantation in patients with advanced primary cutaneous T‐cell lymphomas. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 1), MEDLINE (1950 to January 2013), Internet‐databases of ongoing trials, conference proceedings of the American Society of Clinical Oncology (ASCO, 2009 to July 2013) and the American Society of Hematology (ASH, 2009 to July 2013). We also contacted members of the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force to check for ongoing study activities. We handsearched citations from identified trials and relevant review articles. In addition, we handsearched randomised controlled trials from the European Group for Blood and Marrow Transplantation (EBMT) and International Conference on Cutaneous T‐cell Lymphoma, ASCO and ASH up to July 2013. Selection criteria Trials eligible for inclusion were genetically randomised controlled trials (RCTs) comparing alloSCT plus conditioning therapy (regardless of agents) with conventional therapy as treatment for advanced CTCL. Data collection and analysis Two review authors would have extracted data from eligible studies and assessed their quality. The primary outcome measure was overall survival; secondary outcomes were time to progression, response rate, treatment‐related mortality, adverse events and quality of life. Main results We did not identify any randomised controlled trials from the updated search in January 2013. In 2011, we found 2077 citations but none were relevant genetically or non‐genetically randomised controlled trials. All 41 studies that were thought to be potentially suitable were excluded after full text screening for being non‐randomised, not including CTCL or being review articles. Authors' conclusions We planned to report evidence from genetically or non‐genetically randomised controlled trials comparing conventional therapy and allogeneic stem cell transplantation. However, we did not identify any randomised controlled trials addressing this question. Nevertheless, prospective genetically randomised controlled trials need to be initiated to evaluate the precise role of alloSCT in advanced CTCL. Plain language summary The role of allogeneic stem cell transplantation for patients with advanced stage primary cutaneous T‐cell lymphoma Primary cutaneous T‐cell lymphomas (CTCLs) are a subgroup of blood cancers called non‐Hodgkin lymphomas. CTCL is usually seen first in the skin. It is characterised by an uncontrolled increase in T‐lymphocytes, which are a special kind of white blood cell. Most people who get the disease are older than 60 years of age. Compared to other T‐lymphocyte diseases, this type usually progresses slowly. The likely course and outcome of the disease is also better for this type of cancer. However, there is still no cure yet. The most common subtype of CTCL is Mycosis fungoides (MF) which typically grows slowly in the early stages. However, approximately 20% of people in early‐stage of the disease will get worse and progress to tumour stage or develop a type of leukaemia called Sézary syndrome. Most of these people are then subjected to chemotherapies to kill off the cancer cells. The chemotherapy may involve one or more drugs (known as monochemotherapy or polychemotherapies). Although some patients respond well at the beginning of treatment, the disease often returns and life expectancy is uncertain. Furthermore, many patients can experience severe side effects from the treatment. In the last few years, several publications have reported durable responses following a procedure called allogeneic stem cell transplantation (alloSCT). This is when the patient receives a transplant of stem cells from another donor. Before the transplant begins, the patient undergoes treatment to reduce the size of the tumour. This is called full‐intensity or reduced‐intensity conditioning (RIC). Reduced‐intensity conditioning allows the patient to avoid the standard regimes of high‐dose therapy. It appears to be equally effective but with significantly less toxicity. The use of reduced‐intensity conditioning means that older people, who are the majority of patients with this disease, can be treated with stem cells. We planned to carry out a review of the effect of allogeneic stem cell transplantation compared to standard therapy in patients with cutaneous T‐cell lymphomas. However, after thorough searches, we did not find any relevant studies. Instead we have only been able to give a summary of some case series and clinical evaluations. These do not allow us to clearly assess the possibilities and limitations of this treatment. Nevertheless, they do show that allogeneic stem cell transplantation may be of some benefit, with acceptable side effects. Therefore, it can be considered as a promising treatment option for patients with advanced CTCL but more research is needed.}, -DOI = {10.1002/14651858.CD008908.pub3}, -keywords = {*Stem Cell Transplantation; Humans; Lymphoma, T‐Cell, Cutaneous [*therapy]; Skin Neoplasms [*therapy]; Transplantation, Homologous}, -URL = {http://dx.doi.org/10.1002/14651858.CD008908.pub3} -} - - -Record #16 of 54 -@article{Wolf11, -author = {Wolf, E, Milazzo, S, Boehm, K, Zwahlen, M, and Horneber, M}, -title = {Thymic peptides for treatment of cancer patients}, -journal = {Cochrane Database of Systematic Reviews}, -number = {2}, -year = {2011}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Purified thymus extracts (pTE) and synthetic thymic peptides (sTP) are thought to enhance the immune system of cancer patients in order to fight the growth of tumour cells and to resist infections due to immunosuppression induced by the disease and antineoplastic therapy. Objectives To evaluate the effectiveness of pTE and sTP for the management of cancer. Search methods We searched CENTRAL ( The Cochrane Library 2010, Issue 3), MEDLINE, EMBASE, AMED, BIOETHICSLINE, BIOSIS, CATLINE, CISCOM, HEALTHSTAR, HTA, SOMED and LILACS (to February 2010). Selection criteria Randomised trials of pTE or sTP in addition to chemotherapy or radiotherapy, or both, compared to the same regimen with placebo or no additional treatment in adult cancer patients. Data collection and analysis Two authors independently extracted data from published trials. We derived odds ratios (OR) from overall survival (OS) and disease‐free survival (DFS) rates, tumour response (TR) rates, and rates of adverse effects (AE) related to antineoplastic treatments. We used a random‐effects model for meta‐analysis. Main results We identified 26 trials (2736 patients). Twenty trials investigated pTE (thymostimulin or thymosin fraction 5) and six trials investigated sTP (thymopentin or thymosin α 1 ). Twenty‐one trials reported results for OS, six for DFS, 14 for TR, nine for AE and 10 for safety of pTE and sTP. Addition of pTE conferred no benefit on OS (RR 1.00, 95% CI 0.79 to 1.25); DFS (RR 0.97, 95% CI 0.82 to 1.16); or TR (RR 1.07, 95% CI 0.92 to 1.25). Heterogeneity was moderate to high for all these outcomes. For thymosin α 1 the pooled RR for OS was 1.21 (95% CI 0.94 to 1.56, P = 0.14), with low heterogeneity; and 3.37 (95% CI 0.66 to 17.30, P = 0.15) for DFS, with moderate heterogeneity. The pTE reduced the risk of severe infectious complications (RR 0.54, 95% CI 0.38 to 0.78, P = 0.0008; I² = 0%). The RR for severe neutropenia in patients treated with thymostimulin was 0.55 (95% CI 0.25 to 1.23, P = 0.15). Tolerability of pTE and sTP was good. Most of the trials had at least a moderate risk of bias. Authors' conclusions Overall, we found neither evidence that the addition of pTE to antineoplastic treatment reduced the risk of death or disease progression nor that it improved the rate of tumour responses to antineoplastic treatment. For thymosin α 1 , there was a trend for a reduced risk of dying and of improved DFS. There was preliminary evidence that pTE lowered the risk of severe infectious complications in patients undergoing chemotherapy or radiotherapy. Plain language summary Thymic peptides for treatment of cancer patients in addition to chemotherapy or radiotherapy, or both The immune system plays a key role in the body’s own defences against cancer cells. The thymus gland plays a central part in this and modifies T‐cells, a subset of lymphocytes. Studies with thymic peptides have shown a variety of effects on the immune system. There are two groups of thymic peptides available for use in treatment: purified extracts from animal (mostly calf) thymus glands and synthetically produced thymus gland peptides.
 This review aims to answer the question whether having thymic peptides can improve the response to and tolerability of standard chemotherapy or radiotherapy, or combined treatment. Further questions are whether the peptides inhibit or reduce the progression and recurrence of disease, whether they prolong the life of cancer patients and whether quality of life is improved. This review looked at the evidence from 26 clinical trials with a total of 2736 adult cancer patients. Many of the trials were small and of moderate quality. Only three studies were less than 10 years old. Thymosin α 1 is a synthetic peptide that shows some promise as a treatment option for patients with metastatic melanoma when used in addition to chemotherapy. Severe problems occur during chemotherapy and radiotherapy due to low white blood cell counts and infections. These were reduced by using purified thymus extracts. However, the use of purified thymus extracts should be investigated more thoroughly before the extracts are used routinely in patients. The findings were not conclusive and caution is advised. Overall, thymic peptides seem to be well tolerated.}, -DOI = {10.1002/14651858.CD003993.pub3}, -keywords = {Adjuvants, Immunologic [adverse effects, *therapeutic use]; Adult; Disease‐Free Survival; Female; Humans; Immune System [*drug effects]; Immunocompromised Host; Male; Neoplasms [drug therapy, *immunology]; Peptides [adverse effects, *therapeutic use]; Thymalfasin; Thymopentin [therapeutic use]; Thymosin [analogs & derivatives, therapeutic use]; Thymus Extracts [adverse effects, *therapeutic use]; Thymus Gland [*chemistry]}, -URL = {http://dx.doi.org/10.1002/14651858.CD003993.pub3} -} - - -Record #17 of 54 -@article{Wei13, -author = {Wei, M-L, Kang, D, Gu, L, Qiu, M, Zhengyin, L, and Mu, Y}, -title = {Chemotherapy for thymic carcinoma and advanced thymoma in adults}, -journal = {Cochrane Database of Systematic Reviews}, -number = {8}, -year = {2013}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Thymic carcinoma or advanced thymoma is a rare cancer of the thymus gland that tends to be aggressive and infiltrate neighbouring organs, making total resection very difficult. Induction or adjuvant chemotherapy, or both, are often used in a multimodality approach to treat people affected by this condition, but the effectiveness of chemotherapy for thymic carcinoma or advanced thymoma remains uncertain. Objectives To assess the role of chemotherapy in adults with thymic carcinoma or advanced thymoma. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2012, Issue 7 ) , MEDLINE (accessed via Ovid from 1966 to July 2012), EMBASE (accessed via Ovid, from 1980 to July 2012), Latin American and Caribbean Literature on Health Sciences (LILACS), the Chinese Biological Medicine Database (CBM, 1978 to July 2012), China National Knowledge Infrastructure (CNKI, 1980 to July 2012) and the Chinese scientific periodical database VIP Information (VIP, 1989 to July 2012). There was no language restriction in searching for studies. Selection criteria We planned to include randomised controlled trials (RCTs) of trials using chemotherapy (either single‐agent or combination chemotherapy plus surgery, radiotherapy or not) for thymic carcinoma and/or advanced thymoma. We planned to include all adults (aged 18 years and over) diagnosed with thymic carcinoma and/or with Masaoka stage III or IV thymic tumours. The intended primary outcomes were overall survival (OS) and progression‐free survival (PFS). Data collection and analysis Two review authors independently evaluated the search results according to the inclusion and exclusion criteria. There were no studies identified for inclusion and therefore no data extraction was completed. Main results No RCTs were eligible for inclusion in this review. We report details of excluded prospective studies in an additional table and try to provide some useful evidence regarding current practice. Authors' conclusions There were no RCTs eligible for inclusion in this review. In current practice the most common regimen for adult patients with thymic carcinoma or advanced thymoma is cisplatin‐based chemotherapy. Considering the condition is rare, it is suggested that an international group is set up to organise and evaluate prospective collection of data from cohorts of patients to inform current clinical practice. Plain language summary Chemotherapy (drug treatment) for inoperable thymic cancer in adults Question : Which type and when should chemotherapy (drug treatment) be given to people with thymic carcinoma or advanced thymoma? Background : Thymic cancers are rare tumours arising in the thymus gland behind the breastbone in the chest cavity. For people with advanced‐stage thymic tumours complete surgical resection is normally not possible and the only treatment option is combined chemotherapy. This review aimed to assess the role of chemotherapy in people with advanced thymic tumours. Main findings : We did not identify any suitable clinical trials for inclusion in this review from our search (up to July 2012). We have reported details of prospective studies that are not suitable for inclusion in the review, which provide some useful evidence about current clinical practice. Quality of the evidence : While various treatment options are used, cisplatin‐based chemotherapy is currently the usual regimen of choice, however this is not supported by good‐quality trials.}, -DOI = {10.1002/14651858.CD008588.pub2}, -keywords = {Adult; Antineoplastic Agents [*therapeutic use]; Humans; Prospective Studies; Thymoma [*drug therapy, pathology]; Thymus Neoplasms [*drug therapy, pathology]}, -URL = {http://dx.doi.org/10.1002/14651858.CD008588.pub2} -} - - -Record #18 of 54 -@article{Storman13, -author = {Storman, D, Swierz, MJ, Mitus, JW, Pedziwiatr, M, Liang, N, Wolff, R, and Bala, MM}, -title = {Microwave coagulation for liver metastases}, -journal = {Cochrane Database of Systematic Reviews}, -number = {3}, -year = {2024}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Liver metastases (i.e. secondary hepatic malignancies) are significantly more common than primary liver cancer. Long‐term survival after radical surgical treatment is approximately 50%. For people in whom resection for cure is not feasible, other treatments must be considered. One treatment option is microwave coagulation utilising electromagnetic waves. It involves placing an electrode into a lesion under ultrasound or computed tomography guidance. Objectives To evaluate the beneficial and harmful effects of microwave coagulation versus no intervention, other ablation methods, or systemic treatments in people with liver metastases regardless of the location of the primary tumour. Search methods We used standard, extensive Cochrane search methods. The latest date of search was 14 April 2023. Selection criteria Randomised clinical trials assessing beneficial or harmful effects of microwave coagulation and its comparators in people with liver metastases, irrespective of the location of the primary tumour. We included trials no matter the outcomes reported. Data collection and analysis We followed standard Cochrane methodological procedures. Our primary outcomes were: all‐cause mortality at the last follow‐up and time to mortality; health‐related quality of life (HRQoL); and any adverse events or complications. Our secondary outcomes were: cancer mortality; disease‐free survival; failure to clear liver metastases; recurrence of liver metastases; time to progression of liver metastases; and tumour response measures. We used risk ratios (RR) and hazard ratios (HR) with 95% confidence intervals (CI) to present the results. Two review authors independently extracted data and assessed the risk of bias using the Cochrane RoB 1 tool. We used GRADE methodology to assess the certainty of the evidence. Main results Three randomised clinical trials fulfilled the inclusion criteria. The control interventions differed in the three trials; therefore, meta‐analyses were not possible. The trials were at high risk of bias. The certainty of evidence of the assessed outcomes in the three comparisons was very low. Data on our prespecified outcomes were either missing or not reported. Microwave coagulation plus conventional transarterial chemoembolisation (TACE) versus conventional TACE alone One trial, conducted in China, randomised 50 participants (mean age 60 years, 76% males) with liver metastases from various primary sites. Authors reported that the follow‐up period was at least one month. The trial reported adverse events or complications in the experimental group only and for tumour response measures. There were no dropouts in the trial. The trial did not report on any other outcomes. Microwave ablation versus conventional surgery One trial, conducted in Japan, randomised 40 participants (mean age 61 years, 53% males) with multiple liver metastases of colorectal cancer. Ten participants were excluded after randomisation (six from the experimental and four from the control group); thus, the trial analyses included 30 participants. Follow‐up was three years. The reported number of deaths from all causes was 9/14 included participants in the microwave group versus 12/16 included participants in the conventional surgery group. The mean overall survival was 27 months in the microwave ablation and 25 months in the conventional surgery group. The three‐year overall survival was 14% with microwave ablation and 23% with conventional surgery, resulting in an HR of 0.91 (95% CI 0.39 to 2.15). The reported frequency of adverse events or complications was comparable between the two groups, except for the required blood transfusion, which was more common in the conventional surgery group. There was no intervention‐related mortality. Disease‐free survival was 11.3 months in the microwave ablationgroup and 13.3 months in the conventional surgery group. The trial did not report on HRQoL. Microwave ablation versus radiofrequency ablation One trial, conducted in Germany, randomised 50 participants (mean age 62.8 years, 46% males) who were followed for 24 months. Two‐year mortality showed an RR of 0.62 (95% CI 0.26 to 1.47). The trial reported that, by two years, 76.9% of participants in the microwave ablationgroup and 62.5% of participants in the radiofrequency ablation group survived (HR 0.63, 95% CI 0.23 to 1.73). The trial reported no deaths or major complications during the procedures in either group. There were two minor complications only in the radiofrequency ablation group (RR 0.19, 95% CI 0.01 to 3.67). The trial reported technical efficacy in 100% of procedures in both groups. Distant recurrence was reported for 10 participants in the microwave ablation group and nine participants in the radiofrequency ablation group (RR 1.03, 95% CI 0.50 to 2.08). No participant in the microwave ablation group demonstrated local progression at 12 months, while that occurred in two participants in the radiofrequency ablation group (RR 0.19, 95% CI 0.01 to 3.67). The trial did not report on HRQoL. One trial reported partial support by Medicor (MMS Medicor Medical Supplies GmbH, Kerpen, Germany) for statistical analysis. The remaining two trials did not provide information on funding. We identified four ongoing trials. Authors' conclusions The evidence is very uncertain about the effect of microwave ablation in addition to conventional TACE compared with conventional TACE alone on adverse events or complications. We do not know if microwave ablation compared with conventional surgery may have little to no effect on all‐cause mortality. We do not know the effect of microwave ablation compared with radiofrequency ablation on all‐cause mortality and adverse events or complications either. Data on all‐cause mortality and time to mortality, HRQoL, adverse events or complications, cancer mortality, disease‐free survival, failure to clear liver metastases, recurrence of liver metastases, time to progression of liver metastases, and tumour response measures were either insufficient or were lacking. In light of the current inconclusive evidence and the substantial gaps in data, the pursuit of additional good‐quality, large randomised clinical trials is not only justified but also essential to elucidate the efficacy and comparative benefits of microwave ablation in relation to various interventions for liver metastases. The current version of the review, in comparison to the previous one, incorporates two new trials in two additional microwave ablation comparisons: 1. in addition to conventional TACE versus conventional TACE alone and 2. versus radiofrequency ablation. Plain language summary Microwave coagulation for liver metastases Key messages – We do not know whether microwave coagulation, added to another method of destroying cancer cells given directly to the liver (conventional transarterial chemoembolisation (TACE)), as compared with TACE alone, has benefit in terms of side effects or complications. – We do not know whether microwave coagulation compared with conventional surgery or another method of destroying cancer cells (radiofrequency ablation) has benefit in terms of death, longer life, and side effects or complications. What are liver metastases and microwave coagulation? Liver metastases are new cancer sites that spread to other parts of the body. They commonly originate from cancers of the lung, stomach, colon (large intestine), rectum, and endometrium (lining of the womb). There are different ways to treat liver metastases in people in whom resection (surgical removal of the cancer) for cure is not feasible. One method, microwave ablation, requires placing a special electrode near the cancer site, which destroys surrounding cancer cells using electromagnetic waves. What did we want to find out? We wanted to find out if microwave ablation provides benefit over no intervention, other methods of destroying cancer cells given directly to the liver, or other types of treatments working throughout the whole body, when applied to people with liver metastases, regardless of the location of the primary cancer. We looked at the likelihood of death, how long people lived, whether it was possible to eliminate metastases, how often tumours returned, whether disease worsened, the quality of life in terms of health changes, and whether any side effects occurred. What did we do? We searched medical databases for randomised trials comparing microwave ablation with no intervention or other types of treatment of liver metastases. In a randomised trial, participants are allocated at random to the study treatments. What did we find? We found three trials, all conducted in upper‐middle and high‐income countries. One study in China allocated 50 people to microwave ablation plus conventional TACE versus conventional TACE alone. In conventional TACE, a mixture of a drug toxic for cancer cells and a substance blocking blood vessels is injected directly to the artery feeding the tumour to destroy and close it. The study was very uncertain about the effect of microwave ablation plus conventional TACE on decreasing the size of the tumour. It reported side effects in the microwave ablation group only, such as fever, mild stomach pain, signs of mild liver inflammation or damaged, and mild fluid accumulation in the abdomen. Authors did not report how many people died, whether quality of life improved after treatment, whether people lived longer, whether metastases were eliminated, and whether cancer returned. One study in Japan allocated 40 people to microwave ablation versus conventional surgery. The trial reported that the proportion of people surviving three years later was similar in both groups. People lived for similar periods of time (about 27 months with microwave ablation and 25 months with conventional surgery). The frequency of side effects or complications was similar between treatments, but people in the conventional surgery group more frequently required blood transfusion. The trial did not provide data on quality of life, whether metastases were eliminated, and whether cancer returned. One study in Germany allocated 50 people to microwave ablation versus another method of destroying cancer cells (using radiofrequency waves called radiofrequency ablation). The study reported that the proportion of people dying was similar in both groups. Comparable numbers of people in both groups lived for one, two, and three years. There were two minor complications in the radiofrequency ablation group. In the microwave ablation group, cancer did not return to the same area after 12 months in any participants. However, in the radiofrequency ablation group, cancer returned to the same area in two people. Cancer appeared in a different area of the body in 10 people in the microwave ablation group and nine people in the radiofrequency ablation group. The trial did not report on quality of life, time to death, and whether metastases were eliminated. Further randomised clinical trials are needed to strengthen the evidence on the effect of microwave ablation compared with treatments described above. We found no evidence for the comparison of microwave ablation with other methods of destroying cancer cells and treatments working throughout the whole body. What are the limitations of the evidence? Our confidence in the results is limited because none of the trials clearly reported their methods, or whether trial participants knew the treatment received. We still lack evidence on the effect of microwave ablation in addition to conventional TACE as compared with conventional TACE alone on death, quality of life, living longer, eliminating metastases, cancer returning, as well as on the effect of microwave ablation compared to conventional surgery and radiofrequency ablation on quality of life, eliminating metastases, and cancer returning. How up to date is this evidence? The evidence is up to date to 14 April 2023.}, -DOI = {10.1002/14651858.CD010163.pub3}, -keywords = {*Liver Neoplasms [mortality, secondary]; *Microwaves [therapeutic use]; *Randomized Controlled Trials as Topic; Bias; Cause of Death; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life}, -URL = {http://dx.doi.org/10.1002/14651858.CD010163.pub3} -} - - -Record #19 of 54 -@article{Goldkuhle18, -author = {Goldkuhle, M, Dimaki, M, Gartlehner, G, Monsef, I, Dahm, P, Glossmann, JP, Engert, A, von Tresckow, B, and Skoetz, N}, -title = {Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)}, -journal = {Cochrane Database of Systematic Reviews}, -number = {7}, -year = {2018}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Hodgkin's lymphoma (HL) is a cancer of the lymphatic system, and involves the lymph nodes, spleen and other organs such as the liver, lung, bone or bone marrow, depending on the tumour stage. With cure rates of up to 90%, HL is one of the most curable cancers worldwide. Approximately 10% of people with HL will be refractory to initial treatment or will relapse; this is more common in people with advanced stage or bulky disease. Standard of care for these people is high‐dose chemotherapy and autologous stem cell transplantation (ASCT), but only 55% of participants treated with high‐dose chemotherapy and ASCT are free from treatment failure at three years, with an overall survival (OS) of about 80% at three years. Checkpoint inhibitors that target the interaction of the programmed death (PD)‐1 immune checkpoint receptor, and its ligands PD‐L1 and PD‐L2, have shown remarkable activity in a wide range of malignancies. Nivolumab is an anti‐(PD)‐1 monoclonal antibody and currently approved by the US Food and Drug Administration (FDA) for the treatment of melanoma, non‐small cell lung cancer, renal cell carcinoma and, since 2016, for classical Hodgkin's lymphoma (cHL) after treatment with ASCT and brentuximab vedotin. Objectives To assess the benefits and harms of nivolumab in adults with HL (irrespective of stage of disease). Search methods We searched CENTRAL, MEDLINE, Embase, International Pharmaceutical Abstracts, conference proceedings and six study registries from January 2000 to May 2018 for prospectively planned trials evaluating nivolumab. Selection criteria We included prospectively planned trials evaluating nivolumab in adults with HL. We excluded trials in which less than 80% of participants had HL, unless the trial authors provided the subgroup data for these participants in the publication or after we contacted the trial authors. Data collection and analysis Two review authors independently extracted data and assessed potential risk of bias. We used the software RobotReviewer to extract data and compared results with our findings. As we did not identify any randomised controlled trials (RCTs) or non‐RCTs, we did not meta‐analyse data. Main results Our search found 782 potentially relevant references. From these, we included three trials without a control group, with 283 participants. In addition, we identified 14 ongoing trials evaluating nivolumab, of which two are randomised. Risk of bias of the three included studies was moderate to high. All of the participants were in relapsed stage, most of them were heavily pretreated and had received at least two previous treatments, most of them had also undergone ASCT. As we did not identify any RCTs, we could not use the software RobotReviewer to assess risk of bias. The software identified correctly that one study was not an RCT and did not extract any trial data, but extracted characteristics of the other two studies (although also not RCTs) in a sufficient way. Two studies with 260 participants evaluated OS. After six months, OS was 100% in one study and median OS (the timepoint when only 50% of participants were alive) was not reached in the other trial after a median follow‐up of 18 months (interquartile range (IQR) 15 to 22 months) (very low certainty evidence, due to observational trial design, heterogenous patient population in terms of pretreatments and various follow‐up times (downgrading by 1 point)). In one study, one out of three cohorts reported quality of life. It was unclear whether there was an effect on quality of life as only a subset of participants filled out the follow‐up questionnaire (very low certainty evidence). Three trials (283 participants) evaluated progression‐free survival (PFS) (very low certainty evidence). Six‐month PFS ranged between 60% and 86%, and median PFS ranged between 12 and 18 months. All three trials (283 participants) reported complete response rates, ranging from 12% to 29%, depending on inclusion criteria and participants' previous treatments (very low certainty evidence). One trial (243 participants) reported drug‐related grade 3 or 4 adverse events (AEs) only after a median follow‐up of 18 months (IQR 15 to 22 months); these were fatigue (23%), diarrhoea (15%), infusion reactions (14%) and rash (12%). The other two trials (40 participants) reported 23% to 52% grade 3 or 4 AEs after six months' follow‐up (very low certainty evidence). Only one trial (243 participants) reported drug‐related serious AEs; 2% of participants developed infusion reactions and 1% pneumonitis (very low certainty evidence). None of the studies reported treatment‐related mortality. Authors' conclusions To date, data on OS, quality of life, PFS, response rate, or short‐ and long‐term AEs are available from small uncontrolled trials only. The three trials included heavily pretreated participants, which had previously undergone regimens of BV or ASCT. For these participants, median OS was not reached after follow‐up times of at least 16 months (more than 50% of participants with a limited life expectancy were alive at this timepoint). Only one cohort out of three only reported quality of life, with limited follow‐up data so that meaningful conclusions were not possible. Serious adverse events occurred rarely. Currently, data are too sparse to make a clear statement on nivolumab for people with relapsed or refractory HL except for heavily pretreated people, which had previously undergone regimens of BV or ASCT. When interpreting these results, it is important to consider that proper RCTs should confirm these findings. As there are 14 ongoing trials evaluating nivolumab, of which two are RCTs, it is possible that an update of this review will be published in the near future and that this update will show different results to those reported here. Plain language summary Nivolumab for adults with Hodgkin's lymphoma Background Hodgkin's lymphoma (HL) is a cancer of the lymphatic system. As part of the immune system, the lymphatic system comprises a network of lymphatic vessels, which transport lymph throughout the body. Lymph is a fluid which contains white blood cells, that tackle infection. HL occurs in children and adults, but it is more common in the third decade of life. It is one of the most curable forms of cancer and up to 90% of people will be cured; however, approximately 10% of people with HL will relapse (the cancer will return). Treatment options are chemotherapy, radiotherapy, or both, or newly developed agents, called checkpoint inhibitors that target the cancer cell directly. Nivolumab is one checkpoint inhibitor and currently approved by the US Food and Drug Administration for the treatment of various cancers and relapsed HL after treatment with stem cell transplantation and brentuximab vedotin, which is a medicine used to treat cancer. In stem cell transplantation patients receive blood building cells, so called stem cells, which replace their own when they have been destroyed along the disease or previous therapy regimens. Review question This systematic review evaluated the benefits and harms of nivolumab for adults with Hodgkin's lymphoma. Study characteristics We searched important medical databases for clinical trials assessing the benefits and harms of nivolumab in adults with HL. Two review authors independently screened, summarised and analysed the results. In addition, we tested the computer software RobotReviewer to extract data. Our search led to the inclusion of three studies involving 283 participants and 14 ongoing trials. The evidence provided is current to May 2018. Key results Two studies with 260 participants evaluated survival. After six months, all participants were alive in one trial (17 participants). One trial reported quality of life for a subgroup of participants using a questionnaire but not all follow‐up data were available. Although it seemed that the participants answering the questionnaire might have had a benefit, it was unclear whether this applied to all the participants. The studies also reported tumour control and tumour response, but with different results, depending on the treatment and how many previous treatments participants had received before nivolumab was given. As nivolumab is given until the disease progresses (gets worse) or until unacceptable side effects occur, people receive the drug for a long time. Therefore, reporting of side effects is related to the time the person received the medicine, with potentially more side effects with longer usage. The most commonly reported side effects were fatigue (tiredness), diarrhoea (loose stools), infusion reactions (during or shortly after giving the medicine by a vein) and rash. Only one study reported medicine‐related serious side effects. They occurred rarely (infusion reactions and lung disease). Deaths related to the medicine were not reported. Reliability of the evidence Due to the study design and varied type of participants with different numbers of previous treatments and various treatment options, the reliability of the evidence was low to very low. Conclusion This systematic review evaluated the benefits and harms of nivolumab in adults with HL. Data on survival, quality of life, tumour response and side effects were available from small trials only. The three trials included only people different previous treatment options, very often also with a previous stem cell transplantation. In one trial, all participants were alive after six months. Quality of life data were not reported for all the included participants; moreover, data after a long period of treatment were not available for all evaluated participants, therefore meaningful conclusions were not possible. Serious side effects occurred rarely. Currently, data are too sparse to make a clear statement on nivolumab for people with relapsed or refractory HL except for those who had received several treatments before. As there are currently 14 ongoing trials evaluating nivolumab, of which two are well designed, it is possible that an update of this review will be published in the near future and that this update will show different results to those reported here.}, -DOI = {10.1002/14651858.CD012556.pub2}, -keywords = {Adult; Antibodies, Monoclonal [*therapeutic use]; Antineoplastic Agents [*therapeutic use]; Hodgkin Disease [*drug therapy, pathology]; Humans; Nivolumab; Software}, -URL = {http://dx.doi.org/10.1002/14651858.CD012556.pub2} -} - - -Record #20 of 54 -@article{Haveman21, -author = {Haveman, LM, van Ewijk, R, van Dalen, EC, Breunis, WB, Kremer, LCM, van den Berg, H, Dirksen, U, and Merks, JHM}, -title = {High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with first recurrence of Ewing sarcoma}, -journal = {Cochrane Database of Systematic Reviews}, -number = {9}, -year = {2021}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Ewing sarcoma is a solid tumour, which is the second most common primary bone malignancy in children, often occurring in the long bones and pelvis. An incidence rate of 4.5 per million a year is reported, with a peak incidence of 11 per million at the age of 12 years. Despite more intensive chemotherapy, 30% to 40% of young people with Ewing sarcoma will have recurrence of the disease. Less than 30% of young people with a recurrence of Ewing sarcoma are alive at 24 months, and less than 10% are alive at 48 months. High‐dose chemotherapy (HDC), followed by autologous haematopoietic cell transplantation (AHCT), is used in a variety of paediatric groups with diverse solid tumours. The hypothesis is that HDC regimens may overcome resistance to standard polychemotherapy, and this way may eradicate minimal residual disease, leading to improved survival after a first recurrence of disease. Objectives To assess the efficacy of HDC with AHCT versus conventional chemotherapy in improving event‐free survival, overall survival, quality‐adjusted survival, and progression‐free survival in children, adolescents, and young adults with first recurrence of Ewing sarcoma, and to determine the toxicity of the treatment. Search methods We searched CENTRAL, MEDLINE, Embase, conference proceedings from the SIOP, ASPHO, CTOS, ASBMT, EBMT, and EMSOS, and two trial registries in January 2020. We also searched reference lists of relevant articles and review articles. Selection criteria We planned to include randomised controlled trials (RCTs) or (historical) controlled clinical trials (CCTs) comparing the effectiveness of HDC plus AHCT with conventional chemotherapy for children, adolescents, and young adults (up to 30 years old at the date of diagnostic biopsy) with a first recurrence of Ewing sarcoma. Data collection and analysis We used standard methodological procedures expected by Cochrane. Main results We did not identify any eligible studies. Authors' conclusions Since we did not identify any eligible studies, we are unable to draw any conclusions about the efficacy and toxicity of HDC with AHCT versus conventional chemotherapy in children, adolescents, and young adults with a first recurrence of Ewing sarcoma. Further high‐quality research is urgently needed. Plain language summary High‐dose chemotherapy (HDC) and autologous haematopoietic cell transplantation (AHCT) for children, adolescents, and young adults with a first recurrence of Ewing sarcoma Review question We were looking for evidence on whether HDC plus AHCT improved event‐free survival, overall survival, quality‐adjusted survival, and progression‐free survival better than conventional chemotherapy in children, adolescents, and young adults with their first recurrence of Ewing sarcoma. We were also looking for adverse effects that occurred because of these treatments. Background Ewing sarcoma is a tumour that occurs in the bone and soft tissue, especially in the long bones and pelvis, and mainly in children, adolescents and young adults. Since the introduction of chemotherapy following surgery, with or without radiation, the outcome of people with Ewing sarcoma has improved. However, even with improved chemotherapy, there are still too many people who eventually die of the disease, because it has progressed or come back. People with a first recurrence of Ewing sarcoma do not have a great prognosis: fewer than 3 out of 10 young people are still alive at 24 months, and fewer than 1 out of 10 are alive at 48 months. Improved therapy is essential for these people. High‐dose chemotherapy (HDC), followed by autologous haematopoietic cell transplantation (AHCT; intravenous infusion of earlier collected stem cells to re‐establish bone marrow ), is successfully used for young people with a variety of tumours. Theoretically, this seems to be a good option to treat the small number of remaining cancer cells, and to improve the survival rate after the first recurrence of Ewing sarcoma. Key results We conducted an extensive search of the medical literature, including related conference proceedings, and registers for ongoing trials, but we did not find any relevant studies. Therefore, we are unable to draw any conclusions as to whether HDC with AHCT improves event‐free survival, overall survival, quality‐adjusted survival, or progression‐free survival better than conventional chemotherapy, or if it causes any side effects, in children, adolescents, and young adults with their first recurrence of Ewing sarcoma. Our results show that further research is needed. How current is the evidence The evidence is current to January 2020.}, -DOI = {10.1002/14651858.CD011406.pub2}, -keywords = {*Bone Neoplasms [drug therapy]; *Hematopoietic Stem Cell Transplantation; *Sarcoma, Ewing [drug therapy]; Adolescent; Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; Child; Humans; Transplantation, Autologous; Young Adult}, -URL = {http://dx.doi.org/10.1002/14651858.CD011406.pub2} -} - - -Record #21 of 54 -@article{Gorry23, -author = {Gorry, C, McCullagh, L, O'Donnell, H, Barrett, S, Schmitz, S, Barry, M, Curtin, K, Beausang, E, Barry, R, and Coyne, I}, -title = {Neoadjuvant treatment for stage III and IV cutaneous melanoma}, -journal = {Cochrane Database of Systematic Reviews}, -number = {1}, -year = {2023}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Cutaneous melanoma is amongst the most aggressive of all skin cancers. Neoadjuvant treatment is a form of induction therapy, given to shrink a cancerous tumour prior to the main treatment (usually surgery). The purpose is to improve survival and surgical outcomes. This review systematically appraises the literature investigating the use of neoadjuvant treatment for stage III and IV cutaneous melanoma. Objectives To assess the effects of neoadjuvant treatment in adults with stage III or stage IV melanoma according to the seventh edition American Joint Committee on Cancer (AJCC) staging system. Search methods We searched the following databases up to 10 August 2021 inclusive: Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, LILACS and four trials registers, together with reference checking and contact with study authors to identify additional studies. We also handsearched proceedings from specific conferences from 2016 to 2020 inclusive. Selection criteria Randomised controlled trials (RCTs) of people with stage III and IV melanoma, comparing neoadjuvant treatment strategies (using targeted treatments, immunotherapies, radiotherapy, topical treatments or chemotherapy) with any of these agents or current standard of care (SOC), were eligible for inclusion. Data collection and analysis We used standard Cochrane methods. Primary outcomes were overall survival (OS) and adverse effects (AEs). Secondary outcomes included time to recurrence (TTR), quality of life (QOL), and overall response rate (ORR). We used GRADE to evaluate the certainty of the evidence. Main results We included eight RCTs involving 402 participants. Studies enrolled adults, mostly with stage III melanoma, investigated immunotherapies, chemotherapy, or targeted treatments, and compared these with surgical excision with or without adjuvant treatment. Duration of follow‐up and therapeutic regimens varied, which, combined with heterogeneity in the population and definitions of the endpoints, precluded meta‐analysis of all identified studies. We performed a meta‐analysis including three studies. We are very uncertain if neoadjuvant treatment increases OS when compared to no neoadjuvant treatment (hazard ratio (HR) 0.43, 95% confidence interval (CI) 0.15 to 1.21; 2 studies, 171 participants; very low‐certainty evidence). Neoadjuvant treatment may increase the rate of AEs, but the evidence is very uncertain (26% versus 16%, risk ratio (RR) 1.58, 95% CI 0.97 to 2.55; 2 studies, 162 participants; very low‐certainty evidence). We are very uncertain if neoadjuvant treatment increases TTR (HR 0.51, 95% CI 0.22 to 1.17; 2 studies, 171 participants; very low‐certainty evidence). Studies did not report ORR as a comparative outcome or measure QOL data. We are very uncertain whether neoadjuvant targeted treatment with dabrafenib and trametinib increases OS (HR 0.28, 95% CI 0.03 to 2.25; 1 study, 21 participants; very low‐certainty evidence) or TTR (HR 0.02, 95% CI 0.00 to 0.22; 1 study, 21 participants; very low‐certainty evidence) when compared to surgery. The study did not report comparative rates of AEs and overall response, and did not measure QOL. We are very uncertain if neoadjuvant immunotherapy with talimogene laherparepvec increases OS when compared to no neoadjuvant treatment (HR 0.49, 95% CI 0.15 to 1.64; 1 study, 150 participants, very low‐certainty evidence). It may have a higher rate of AEs, but the evidence is very uncertain (16.5% versus 5.8%, RR 2.84, 95% CI 0.96 to 8.37; 1 study, 142 participants; very low‐certainty evidence). We are very uncertain if it increases TTR (HR 0.75, 95% CI 0.31 to 1.79; 1 study, 150 participants; very low‐certainty evidence). The study did not report comparative ORRs or measure QOL. OS was not reported for neoadjuvant immunotherapy (combined ipilimumab and nivolumab) when compared to the combination of ipilimumab and nivolumab as adjuvant treatment. There may be little or no difference in the rate of AEs between these treatments (9%, RR 1.0, 95% CI 0.75 to 1.34; 1 study, 20 participants; low‐certainty evidence). The study did not report comparative ORRs or measure TTR and QOL. Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) likely results in little to no difference in OS when compared to neoadjuvant nivolumab monotherapy (P = 0.18; 1 study, 23 participants; moderate‐certainty evidence). It may increase the rate of AEs, but the certainty of this evidence is very low (72.8% versus 8.3%, RR 8.73, 95% CI 1.29 to 59; 1 study, 23 participants); this trial was halted early due to observation of disease progression preventing surgical resection in the monotherapy arm and the high rate of treatment‐related AEs in the combination arm. Neoadjuvant combination treatment may lead to higher ORR, but the evidence is very uncertain (72.8% versus 25%, RR 2.91, 95% CI 1.02 to 8.27; 1 study, 23 participants; very low‐certainty evidence). It likely results in little to no difference in TTR (P = 0.19; 1 study, 23 participants; low‐certainty evidence). The study did not measure QOL. OS was not reported for neoadjuvant immunotherapy (combined ipilimumab and nivolumab) when compared to neoadjuvant sequential immunotherapy (ipilimumab then nivolumab). Only Grade 3 to 4 immune‐related AEs were reported; fewer were reported with combination treatment, and the sequential treatment arm closed early due to a high incidence of severe AEs. The neoadjuvant combination likely results in a higher ORR compared to sequential neoadjuvant treatment (60.1% versus 42.3%, RR 1.42, 95% CI 0.87 to 2.32; 1 study, 86 participants; low‐certainty evidence). The study did not measure TTR and QOL. No data were reported on OS, AEs, TTR, or QOL for the comparison of neoadjuvant interferon (HDI) plus chemotherapy versus neoadjuvant chemotherapy. Neoadjuvant HDI plus chemotherapy may have little to no effect on ORR, but the evidence is very uncertain (33% versus 22%, RR 1.75, 95% CI 0.62 to 4.95; 1 study, 36 participants; very low‐certainty evidence). Authors' conclusions We are uncertain if neoadjuvant treatment increases OS or TTR compared with no neoadjuvant treatment, and it may be associated with a slightly higher rate of AEs. There is insufficient evidence to support the use of neoadjuvant treatment in clinical practice. Priorities for research include the development of a core outcome set for neoadjuvant trials that are adequately powered, with validation of pathological and radiological responses as intermediate endpoints, to investigate the relative benefits of neoadjuvant treatment compared with adjuvant treatment with immunotherapies or targeted therapies. Plain language summary What are the benefits and risks of neoadjuvant treatment (drug treatment prior to surgery to remove a tumour) for melanoma, a type of skin cancer? What did we want to find out? Cutaneous melanoma is a very aggressive form of skin cancer. It is generally fatal if detected at an advanced stage. Earlier treatment may allow for surgical removal of the tumour and an improved chance of long‐term survival. Neoadjuvant treatment is drug treatment administered before surgery, to reduce the tumour size so that it is easier to remove, to reduce complications of surgery, and to reduce the risk of spread of the disease. New drug types, immunotherapies and targeted treatments, have been developed which may be effective for neoadjuvant use. We wanted to find out if neoadjuvant treatment of stage III or IV melanoma helps people live longer, and to compare adverse (unwanted) effects with neoadjuvant treatment and routine care. What did we do? We searched the medical literature for randomised controlled trials that compared certain types of treatments for melanoma skin cancer. The types of treatment included are: ‐ targeted treatments ‐ such as dabrafenib and trametinib; ‐ immunotherapies ‐ such as ipilimumab and nivolumab; ‐ chemotherapy ‐ such as dacarbazine and temozolomide; ‐ topical treatments ‐ such as imiquimod; ‐ radiotherapy. We considered both single‐drug and combination‐drug treatments. We described and compared the results from these studies, taking into account the differences between the studies. What did we find? We identified eight randomised controlled trials that included 402 adults. The majority of people had stage III melanoma and were treated in hospital. Most studies used immunotherapies or targeted treatments, and compared these with surgery, with or without adjuvant treatment (treatment given after surgery to remove the tumour, to reduce the risk of the tumour coming back). No studies considered the impact of treatment on quality of life, and most studies did not compare tumour response rates after different treatments. We are uncertain whether neoadjuvant treatment helps people live longer when compared with no neoadjuvant treatment. It may lead to more adverse events, and we are uncertain if it increases the time until the tumour comes back. We are uncertain whether neoadjuvant targeted treatment with dabrafenib and trametinib helps people live longer, compared with no neoadjuvant treatment, or if it can increase the time until the tumour comes back. The study did not compare safety outcomes with each treatment. We are uncertain if neoadjuvant immunotherapy with talimogene laherparepvec (T‐VEC) helps people live longer when compared with no neoadjuvant treatment. It may lead to more adverse events. We are uncertain if it increases the time until the tumour comes back. No data were reported on whether neoadjuvant immunotherapy with combined ipilimumab and nivolumab helps people live longer, when compared with adjuvant (treatment given only after surgery) combined ipilimumab and nivolumab. There may be little or no difference in the rate of adverse events. No data were reported on whether neoadjuvant immunotherapy with combined ipilimumab and nivolumab increases the time until the tumour comes back. Neoadjuvant combination of ipilimumab and nivolumab likely results in little or no difference in how long people live, when compared with neoadjuvant nivolumab. It may increase the rate of adverse events, but our confidence in the evidence is very low. It is worth noting that this trial was stopped early as patients in the neoadjuvant nivolumab arm may not be able to receive surgery due to disease progression and also because of a high rate of treatment‐related adverse events in the combination treatment arm. Combination treatment may lead to higher tumour response rates, but our confidence in the evidence is very low. The time until the tumour comes back may not be different. No data were available on whether neoadjuvant immunotherapy with combined ipilimumab and nivolumab helps people live longer, when compared with neoadjuvant sequential treatment with ipilimumab and nivolumab. It likely results in fewer adverse events compared to sequential treatment, and may result in higher tumour response rates. The sequential treatment arm of the trial stopped recruiting patients due to a high incidence of severe AEs. Data on the time taken for the tumour to return were not collected. No data were reported on whether neoadjuvant high‐dose interferon plus chemotherapy, when compared to neoadjuvant chemotherapy, can help people live longer, increase the time taken for the tumour to reoccur, reduce adverse events, or impact quality of life. It may have little to no effect on tumour response rates. What does this mean? We are uncertain if neoadjuvant treatment of stage III or IV melanoma will help people to live longer, or to have more time before the disease recurs. We are also uncertain if the benefits of neoadjuvant treatment outweigh the risks of adverse events. How up to date is this evidence? The evidence is up to date to August 2021.}, -DOI = {10.1002/14651858.CD012974.pub2}, -keywords = {*Antineoplastic Agents [adverse effects]; *Melanoma [drug therapy, pathology]; *Skin Neoplasms [drug therapy, pathology]; Adult; Humans; Ipilimumab; Melanoma, Cutaneous Malignant; Neoplasm Staging; Nivolumab; Randomized Controlled Trials as Topic}, -URL = {http://dx.doi.org/10.1002/14651858.CD012974.pub2} -} - - -Record #22 of 54 -@article{Aldin23, -author = {Aldin, A, Besiroglu, B, Adams, A, Monsef, I, Piechotta, V, Tomlinson, E, Hornbach, C, Dressen, N, Goldkuhle, M, Maisch, P, Dahm, P, Heidenreich, A, and Skoetz, N}, -title = {First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis}, -journal = {Cochrane Database of Systematic Reviews}, -number = {5}, -year = {2023}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Since the approval of tyrosine kinase inhibitors, angiogenesis inhibitors and immune checkpoint inhibitors, the treatment landscape for advanced renal cell carcinoma (RCC) has changed fundamentally. Today, combined therapies from different drug categories have a firm place in a complex first‐line therapy. Due to the large number of drugs available, it is necessary to identify the most effective therapies, whilst considering their side effects and impact on quality of life (QoL). Objectives To evaluate and compare the benefits and harms of first‐line therapies for adults with advanced RCC, and to produce a clinically relevant ranking of therapies. Secondary objectives were to maintain the currency of the evidence by conducting continuous update searches, using a living systematic review approach, and to incorporate data from clinical study reports (CSRs). Search methods We searched CENTRAL, MEDLINE, Embase, conference proceedings and relevant trial registries up until 9 February 2022. We searched several data platforms to identify CSRs. Selection criteria We included randomised controlled trials (RCTs) evaluating at least one targeted therapy or immunotherapy for first‐line treatment of adults with advanced RCC. We excluded trials evaluating only interleukin‐2 versus interferon‐alpha as well as trials with an adjuvant treatment setting. We also excluded trials with adults who received prior systemic anticancer therapy if more than 10% of participants were previously treated, or if data for untreated participants were not separately extractable. Data collection and analysis All necessary review steps (i.e. screening and study selection, data extraction, risk of bias and certainty assessments) were conducted independently by at least two review authors. Our outcomes were overall survival (OS), QoL, serious adverse events (SAEs), progression‐free survival (PFS), adverse events (AEs), the number of participants who discontinued study treatment due to an AE, and the time to initiation of first subsequent therapy. Where possible, analyses were conducted for the different risk groups (favourable, intermediate, poor) according to the International Metastatic Renal‐Cell Carcinoma Database Consortium Score (IMDC) or the Memorial Sloan Kettering Cancer Center (MSKCC) criteria. Our main comparator was sunitinib (SUN). A hazard ratio (HR) or risk ratio (RR) lower than 1.0 is in favour of the experimental arm. Main results We included 36 RCTs and 15,177 participants (11,061 males and 4116 females). Risk of bias was predominantly judged as being 'high' or 'some concerns' across most trials and outcomes. This was mainly due to a lack of information about the randomisation process, the blinding of outcome assessors, and methods for outcome measurements and analyses. Additionally, study protocols and statistical analysis plans were rarely available. Here we present the results for our primary outcomes OS, QoL, and SAEs, and for all risk groups combined for contemporary treatments: pembrolizumab + axitinib (PEM+AXI), avelumab + axitinib (AVE+AXI), nivolumab + cabozantinib (NIV+CAB), lenvatinib + pembrolizumab (LEN+PEM), nivolumab + ipilimumab (NIV+IPI), CAB, and pazopanib (PAZ). Results per risk group and results for our secondary outcomes are reported in the summary of findings tables and in the full text of this review. The evidence on other treatments and comparisons can also be found in the full text. Overall survival (OS) Across risk groups, PEM+AXI (HR 0.73, 95% confidence interval (CI) 0.50 to 1.07, moderate certainty) and NIV+IPI (HR 0.69, 95% CI 0.69 to 1.00, moderate certainty) probably improve OS, compared to SUN, respectively. LEN+PEM may improve OS (HR 0.66, 95% CI 0.42 to 1.03, low certainty), compared to SUN. There is probably little or no difference in OS between PAZ and SUN (HR 0.91, 95% CI 0.64 to 1.32, moderate certainty), and we are uncertain whether CAB improves OS when compared to SUN (HR 0.84, 95% CI 0.43 to 1.64, very low certainty). The median survival is 28 months when treated with SUN. Survival may improve to 43 months with LEN+PEM, and probably improves to: 41 months with NIV+IPI, 39 months with PEM+AXI, and 31 months with PAZ. We are uncertain whether survival improves to 34 months with CAB. Comparison data were not available for AVE+AXI and NIV+CAB. Quality of life (QoL) One RCT measured QoL using FACIT‐F (score range 0 to 52; higher scores mean better QoL) and reported that the mean post‐score was 9.00 points higher (9.86 lower to 27.86 higher, very low certainty) with PAZ than with SUN. Comparison data were not available for PEM+AXI, AVE+AXI, NIV+CAB, LEN+PEM, NIV+IPI, and CAB. Serious adverse events (SAEs) Across risk groups, PEM+AXI probably increases slightly the risk for SAEs (RR 1.29, 95% CI 0.90 to 1.85, moderate certainty) compared to SUN. LEN+PEM (RR 1.52, 95% CI 1.06 to 2.19, moderate certainty) and NIV+IPI (RR 1.40, 95% CI 1.00 to 1.97, moderate certainty) probably increase the risk for SAEs, compared to SUN, respectively. There is probably little or no difference in the risk for SAEs between PAZ and SUN (RR 0.99, 95% CI 0.75 to 1.31, moderate certainty). We are uncertain whether CAB reduces or increases the risk for SAEs (RR 0.92, 95% CI 0.60 to 1.43, very low certainty) when compared to SUN. People have a mean risk of 40% for experiencing SAEs when treated with SUN. The risk increases probably to: 61% with LEN+PEM, 57% with NIV+IPI, and 52% with PEM+AXI. It probably remains at 40% with PAZ. We are uncertain whether the risk reduces to 37% with CAB. Comparison data were not available for AVE+AXI and NIV+CAB. Authors' conclusions Findings concerning the main treatments of interest comes from direct evidence of one trial only, thus results should be interpreted with caution. More trials are needed where these interventions and combinations are compared head‐to‐head, rather than just to SUN. Moreover, assessing the effect of immunotherapies and targeted therapies on different subgroups is essential and studies should focus on assessing and reporting relevant subgroup data. The evidence in this review mostly applies to advanced clear cell RCC. Plain language summary Initial treatment for adults with advanced kidney cancer (renal cell carcinoma) Abbreviations • renal cell carcinoma (RCC) • avelumab (AVE) • axitinib (AXI) • cabozantinib (CAB) • ipilimumab (IPI) • lenvatinib (LEN)) • nivolumab (NIV) • pazopanib (PAZ) • pembrolizumab (PEM) • sunitinib (SUN) Key messages • When making treatment decisions, it is important to think about whether drugs lengthen life, and whether they decrease or increase harmful side effects. • The findings in this review apply mostly to advanced renal cell carcinoma (RCC) with a clear cell component. What is advanced RCC, and how is it treated? RCC is a type of kidney cancer. It is more common in older people and in men than in women. This is because age (≥60 years) and male sex put people at higher risk of getting it. Other risk factors include body weight, smoking, a history of kidney stones and high blood pressure. More than half of people with RCC discover they have it from routine health check‐ups, because many do not have symptoms in the early stages. When symptoms appear, they can impact people's quality of life and day‐to‐day activities. Before 2005, drugs for treatment of advanced RCC were few and treatments caused many side effects. Now, there are new types of drugs: immunotherapy (use people’s own immune system to find and destroy cancer cells), or targeted therapy (interferes with molecules that are responsible for helping cancer cells to grow, divide, and spread). Combinations of these drugs are used for therapy. With these drugs, people may live longer, with a good quality of life and fewer or milder side effects. These drugs are evaluated in clinical studies with people with RCC. What did we want to find out? We wanted to use the most up‐to‐date information from clinical studies to measure the benefits and harms of different treatments for people with advanced RCC. We also wanted to learn if the drugs worked better for some people than others. What did we do? We searched for studies that explored different drugs that are immunotherapies or targeted therapies. We examined these in adults (≥18 years) with advanced RCC who receive their first therapy. We compared these drugs to the drug SUN, which is a widely used targeted drug and a commonly used comparator drug in studies. We used a standardised process to assess the quality of the findings and our certainty in them. We rated our certainty in the findings based on factors such as study methods, the number of participants in them, and the precision of study results. What did we find? We found 36 studies with 4116 women and 11,061 men, around 60 years of age, with advanced RCC. Most people had ≥2 metastatic sites. We found 22 drugs and 17 combinations of drugs that were measured in the studies. We also performed analyses for different risk groups of advanced RCC. We present and discuss our results for the different risk groups, drugs and combinations in the main text of this review, plus further outcomes. Below we present our main results for our primary outcomes, when all risk groups are combined. We focus on selected drugs (and combinations) (PEM+AXI, AVE+AXI, NIV+CAB, LEN+PEM, NIV+IPI, CAB alone, PAZ alone) that are currently recommended in international guidelines for the treatment of advanced RCC. We report their impact on survival, quality of life and serious side effects. How long do people live? People live an average of 28 months when treated with SUN. In comparison, people may live an average of 43 months with LEN+PEM, probably 41 months with NIV+IPI, probably 39 months with PEM+AXI, and probably 31 months with PAZ alone. We are uncertain whether people live an average of 34 months with CAB alone. We do not have information for AVE+AXI and NIV+CAB. How do people rate their quality of life? People who receive PAZ alone reported a higher level of quality of life than people who receive SUN, but we are uncertain about the findings. We do not have information for PEM+AXI, AVE+AXI, NIV+CAB, LEN+PEM, NIV+IPI or CAB alone. What is people's risk for serious side effects? People who receive SUN have an average risk of 40% for experiencing serious side effects. In comparison, the average risk is probably: 61% with LEN+PEM, 57% with NIV+IPI, 52% with PEM+AXI, and 40% with PAZ. We are uncertain whether the risk is on average 37% with CAB alone. We do not have information for AVE+AXI and NIV+CAB. What are the limitations of the evidence? More studies are needed where these new drugs (and combinations) are not only compared to SUN alone, but also to each other. We lack information on the comparative benefits and harms of these drugs in different people, e.g. when comparing men with women, or different histology types of RCC (e.g. clear cell type, papillary type, sarcomatoid type). How up to date is this evidence? We conducted our last search for studies in February 2022 and incorporated the most recent study results into this review. }, -DOI = {10.1002/14651858.CD013798.pub2}, -keywords = {*Carcinoma, Renal Cell [drug therapy]; Adult; Axitinib; Female; Humans; Male; Network Meta-Analysis; Nivolumab; Sunitinib}, -URL = {http://dx.doi.org/10.1002/14651858.CD013798.pub2} -} - - -Record #23 of 54 -@article{Figueredo08, -author = {Figueredo, A, Coombes, ME, and Mukherjee, S}, -title = {Adjuvant Therapy for completely resected Stage II Colon Cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {3}, -year = {2008}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background : Colon cancer is potentially curable by surgery. Although adjuvant chemotherapy benefits patients with stage III disease, there is uncertainty of such benefit in stage II colon cancer. A systematic review of the literature was performed to better define the potential benefits of adjuvant therapy for patients with stage II colon cancer. Objectives : To determine the effects of adjuvant therapy on overall survival and disease‐free survival in patients with stage II colon cancer. Search methods : Ovid MEDLINE(R) (1986‐2007), EMBASE (1980‐2007), and EBM Reviews ‐ Cochrane Central Register of Controlled Trials ( to 2007) were searched using the medical headings "colonic neoplasms", "colorectal neoplasms", "adjuvant chemotherapy", "adjuvant radiotherapy" and "immunotherapy", and the text words "colon cancer" and "colonic neoplasms". In addition, proceedings from the annual meetings of the American Society of Clinical Oncology and the European Society of Medical Oncology (1996 to 2004) as well as personal files were searched for additional information. Selection criteria : Randomized trials or meta‐analyses containing data on stage II colon cancer patients undergoing adjuvant therapy versus surgery alone. Data collection and analysis : Three reviewers summarized the results of selected studies. The main outcomes of interest were overall and disease‐free survival, however, data on toxicity and treatment delivery were also recorded. Main results : With regards to the effect of adjuvant therapy on stage II colon cancer, the pooled relative risk ratio for overall survival was 0.96 (95% confidence interval 0.88, 1.05). With regards to disease‐free survival, the pooled relative risk ratio was 0.83 (95% confidence interval 0.75, 0.92). Authors' conclusions : Although there was no improvement in overall survival in the pooled analysis, we did find that disease‐free survival in patients with stage II colon cancer was signficantly better with the use of adjuvant therapy. It seems reasonable to discuss the benefits of adjuvant systemic chemotherapy with those stage II patients who have high risk features, including obstruction, perforation, inadequate lymph node sampling or T4 disease. The co‐morbidities and likelihood of tolerating adjuvant systemic chemotherapy should be considered as well. There exists a need to further define which high‐risk features in stage II colon cancer patients should be used to select patients for adjuvant therapy. Also, researchers must continue to search for other therapies which might be more effective, shorter in duration and less toxic than those available today. Plain language summary Adjuvant therapy for completely resected stage II colon cancer Colon cancer is the second most common cause of cancer deaths in the Western world. A large proportion of colon cancer patients can be cured by surgical resection alone. For those patients with lymph node positive (stage III) disease, the recurrence rate can exceed 50% and adjuvant chemotherapy has been shown to significantly reduce the risk of recurrence. In patients without lymph node involvement (stage I and II), the prognosis is quite good with surgery alone, with survival rates of 75% to 95% at 5 years. However, some patients with high risk stage II disease have a relapse rate approaching that of stage III colon cancer patients. Due to the effectiveness of systemic chemotherapy in stage III disease, a similar approach has been considered for patients with stage II disease. We performed a systematic review looking at all randomized clinical trials evaluating stage II colon cancer patients and adjuvant therapy versus surgery alone. Our review found that adjuvant therapy ‐either systemic or regional chemotherapy or immunotherapy‐ can improve the outcomes of stage II patients. In counselling individual patients, the advice given should be conditioned by the patient's age and comorbidities. In addition, the high risk features of the tumour should also be considered when contemplating the benefits of systemic therapy in patients with stage II colon cancer. Further investigation is needed to elucidate which patient and tumour factors can be used to select stage II colon cancer patients for adjuvant therapy. There also exists a need to continue to search for other adjuvant therapies which might be more effective, shorter in duration and less toxic than those available today.}, -DOI = {10.1002/14651858.CD005390.pub2}, -keywords = {Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Chemotherapy, Adjuvant; Colonic Neoplasms [pathology, *therapy]; Humans; Immunotherapy; Neoplasm Staging; Randomized Controlled Trials as Topic}, -URL = {http://dx.doi.org/10.1002/14651858.CD005390.pub2} -} - - -Record #24 of 54 -@article{Haveman21, -author = {Haveman, LM, van Ewijk, R, van Dalen, EC, Breunis, WB, Kremer, LCM, van den Berg, H, Dirksen, U, and Merks, JHM}, -title = {High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma}, -journal = {Cochrane Database of Systematic Reviews}, -number = {9}, -year = {2021}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Ewing sarcomas are solid tumours of the bone and soft tissue, that usually affect children, adolescents, and young adults. The incidence is about three cases per million a year, with a peak incidence at 12 years of age. Metastatic disease is detected in about 20 % to 30% of people, and is typically found in the lungs, bone, bone marrow, or a combination of these. Presence of metastatic disease at diagnosis (primary metastatic disease) is the most important adverse prognostic factor, and is associated with a five‐year survival lower than 30%. High‐dose chemotherapy (HDC) followed by autologous haematopoietic cell transplantation (AHCT) is used in various solid tumours with unfavourable prognoses in children, adolescents, and young adults. It has also been used as rescue after multifocal radiation of metastases. The hypothesis is that HDC regimens may overcome the resistance to standard multidrug chemotherapy and improve survival rates. Objectives To assess the effects of high‐dose chemotherapy with autologous haematopoietic cell transplantation compared with conventional chemotherapy in improving event‐free survival, overall survival, quality‐adjusted survival, and progression‐free survival in children, adolescents, and young adults with primary metastatic Ewing sarcoma, and to determine the toxicity of the treatment. Search methods We searched CENTRAL, MEDLINE, Embase, conference proceedings from major international cancer‐related conferences, and ongoing trial registers until January 2020. We also searched reference lists of included articles and review articles. Selection criteria We included randomised controlled trials (RCTs) or (historical) controlled clinical trials (CCTs) comparing the effectiveness of HDC and AHCT with conventional chemotherapy for children, adolescents, and young adults (younger than 30 years at the date of diagnostic biopsy) with primary metastatic Ewing sarcoma. Data collection and analysis We used standard methodological procedures expected by Cochrane. Main results We identified one RCT, which investigated the effects of HDC with AHCT versus conventional chemotherapy with whole lung irradiation (WLI) in people with Ewing sarcoma metastasised to the lungs only at diagnosis. Only a selection of the participants were eligible for our review (N = 267: HDC with AHCT group N = 134; control group N = 133). There may be no difference in event‐free survival between the two treatment groups (hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.59 to 1.17; low‐certainty evidence). We downgraded one level each because of study limitations and imprecision. Overall survival and toxicity were not reported separately for the participants eligible for this review, while quality‐adjusted survival and progression‐free survival were not reported at all. We did not identify any studies that addressed children, adolescents, and young adults with Ewing sarcoma with metastases to other locations. Authors' conclusions In people with Ewing sarcoma with primary metastases to locations other than the lungs, there is currently no evidence from RCTs or CCTs to determine the efficacy of HDC with AHCT compared to conventional chemotherapy. Based on low‐certainty evidence from one study (267 participants), there may be no difference in event‐free survival between children, adolescents, and young adults with primary pulmonary metastatic Ewing sarcoma who receive HDC with AHCT and those who receive conventional chemotherapy with WLI. Further high‐quality research is needed. Results are anticipated for the EuroEwing 2008R3 study, in which the effects of HDC with treosulfan and melphalan followed by AHCT on survival, in people with Ewing sarcoma with metastatic disease to bone, other sites, or both were explored. Achieving high‐quality studies in a selection of people with rare sarcoma requires long‐term, multi‐centre, international participant inclusion. Plain language summary High‐dose chemotherapy and haematopoietic cell transplantation for children, adolescents, and young adults with metastatic Ewing sarcoma at diagnosis Review question We were looking for evidence on whether high‐dose chemotherapy plus autologous haematopoietic cell transplantation (intravenous infusion of stem cells collected previously from the patient to re‐establish bone marrow) improved event‐free survival, overall survival, quality‐adjusted survival, and progression‐free survival better than conventional chemotherapy in children, adolescents, and young adults with primary metastatic Ewing sarcoma (cancer that has spread to other parts of the body at time of diagnosis). We were also looking for adverse effects that occurred because of these treatments. Background Ewing sarcoma is a tumour that usually occurs in the bone and soft tissue of children and young adults. People with metastatic Ewing sarcoma at diagnosis have a poor chance of survival. Less than 30% of affected people survive after five years. People with solitary lung metastases have a better chance of survival (50% survival after five years). Current treatment consists of multidrug chemotherapy combined with surgery, radiotherapy, or both. Improved therapy is essential for these people. We conducted this review to find out whether high‐dose chemotherapy, combined with autologous haematopoietic cell transplantation can help to improve survival in children, adolescents, and young adults with metastatic Ewing sarcoma at diagnosis, compared to conventional chemotherapy. Study characteristics We identified one study (267 participants, who were included over a 15‐year period, from 144 international centres) that compared high dose chemotherapy plus autologous haematopoietic cell transplantation with conventional chemotherapy and whole lung irradiation in children, adolescents, and young adults with Ewing sarcoma with pulmonary metastases at diagnosis. Key results In young people with pulmonary metastatic Ewing sarcoma at diagnosis, low‐certainty evidence from one study found no clear difference between treatment groups in event‐free survival. There were no data available for overall survival, quality‐adjusted survival, adverse effects, or progression‐free survival. We did not find any studies that addressed children, adolescents, and young adults with Ewing sarcoma that had metastasised to locations besides the lungs at diagnosis. We need high‐quality research before definite conclusions can be made. Certainty of the evidence The certainty of the evidence was low. How current is the evidence The evidence is current to January 2020.}, -DOI = {10.1002/14651858.CD011405.pub2}, -keywords = {*Hematopoietic Stem Cell Transplantation; *Sarcoma, Ewing [drug therapy]; Adolescent; Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; Child; Humans; Progression-Free Survival; Transplantation, Autologous; Young Adult}, -URL = {http://dx.doi.org/10.1002/14651858.CD011405.pub2} -} - - -Record #25 of 54 -@article{Chan15, -author = {Chan, KKW, Glenny, AM, Weldon, JC, Furness, S, Worthington, HV, and Wakeford, H}, -title = {Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy}, -journal = {Cochrane Database of Systematic Reviews}, -number = {12}, -year = {2015}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Oral cancers are the sixth most common cancer worldwide, yet the prognosis following a diagnosis of oral cavity or oropharyngeal cancers remains poor, with approximately 50% survival at five years. Despite a sharp increase in research into molecularly targeted therapies and a rapid expansion in the number of clinical trials assessing new targeted therapies, their value for treating oral cancers is unclear. Therefore, it is important to summarise the evidence to determine the efficacy and toxicity of targeted therapies and immunotherapies for the treatment of these cancers. Objectives To assess the effects of molecularly targeted therapies and immunotherapies, in addition to standard therapies, for the treatment of oral cavity or oropharyngeal cancers. Search methods We searched the following electronic databases: Cochrane Oral Health Group Trials Register (to 3 February 2015), Cochrane Central Register of Controlled Trials (CENTRAL) ( The Cochrane Library , 2015, Issue 1), MEDLINE via Ovid (1946 to 3 February 2015) and EMBASE via Ovid (1980 to 3 February 2015). We searched the US National Institutes of Health Trials Register ( clinicaltrials.gov ), the World Health Organization Clinical Trials Registry Platform, the American Society of Clinical Oncology conference abstracts and the Radiation Therapy Oncology Group clinical trials protocols for ongoing trials. We placed no restrictions on the language or date of publication. Selection criteria We included randomised controlled trials where more than 50% of participants had primary tumours of the oral cavity or oropharynx, and which compared targeted therapy or immunotherapy, plus standard therapy, with standard therapy alone. Data collection and analysis Two review authors independently screened the results of the electronic searches, extracted data and assessed the risk of bias of the included studies. We attempted to contact study authors for missing data or clarification where necessary. We combined sufficiently similar studies in meta‐analyses using random‐effects models when there were at least four studies and fixed‐effect models when fewer than four studies. We obtained or calculated a hazard ratio (HR) and 95% confidence interval (CI) for the primary outcomes where possible. For dichotomous outcomes, we reported risk ratios (RR) and 95% CIs. Main results Twelve trials (2488 participants) satisfied the inclusion criteria. In the included trials, 12% of participants (298 participants) had tumours of the oral cavity and 59% (1468 participants) had oropharyngeal tumours. The remaining 29% had tumours of the larynx or hypopharynx and less than 1% had tumours at other sites. No included trial was at low risk of bias; seven had an unclear risk of bias, and five had a high risk of bias. We grouped trials by intervention type into three main comparisons: standard therapy plus epidermal growth factor receptor monoclonal antibody (EGFR mAb) therapy (follow‐up period 24 to 70 months); standard therapy plus tyrosine kinase inhibitors (TKIs) (follow‐up period 40 to 60 months) and standard therapy plus immunotherapy (follow‐up period 24 to 70 months), all versus standard therapy alone. Moderate quality evidence showed that EGFR mAb therapy may result in 18% fewer deaths when added to standard therapy (HR of mortality 0.82; 95% CI 0.69 to 0.97; 1421 participants, three studies, 67% oropharyngeal tumours, 2% oral cavity tumours). There was also moderate quality evidence that EGFR mAb may result in 32% fewer locoregional failures when added to radiotherapy (RT) (HR 0.68; 95% CI 0.52 to 0.89; 424 participants, one study, 60% oropharyngeal tumours). A subgroup analysis separating studies by type of standard therapy (radiotherapy (RT) or chemoradiotherapy (CRT)) showed some evidence that adding EGFR mAb therapy to RT may result in a 30% reduction in the number of people whose disease progresses (HR 0.70; 95% CI 0.54 to 0.91; 424 participants, one study, 60% oropharyngeal tumours, unclear risk of bias). For the subgroup comparing EGFR mAb plus CRT with CRT alone there was insufficient evidence to determine whether adding EGFR mAb therapy to CRT impacts on progression‐free survival (HR 1.08; 95% CI 0.89 to 1.32; 891 participants, one study, 70% oropharyngeal tumours, high risk of bias). The high subgroup heterogeneity meant that we were unable to pool these subgroups. There was evidence that adding cetuximab to standard therapy may result in increased skin toxicity and rash (RR 6.56; 95% CI 5.35 to 8.03; 1311 participants, two studies), but insufficient evidence to determine any difference in skin toxicity and rash in the case of nimotuzumab (RR 1.06; 95% CI 0.85 to 1.31; 92 participants, one study). There was insufficient evidence to determine whether TKIs added to standard therapy impacts on overall survival (HR 0.99; 95% CI 0.62 to 1.57; 271 participants, two studies; very low quality evidence), locoregional control (HR 0.89; 95% CI 0.53 to 1.49; 271 participants, two studies; very low quality evidence), disease‐free survival (HR 1.51; 95% CI 0.61 to 3.71; 60 participants, one study; very low quality evidence) or progression‐free survival (HR 0.80; 95% CI 0.51 to 1.28; 271 participants, two studies; very low quality evidence). We did find evidence of an increase in skin rash (erlotinib: RR 6.57; 95% CI 3.60 to 12.00; 191 participants, one study; lapatinib: RR 2.02; 95% CI 1.23 to 3.32; 67 participants, one study) and gastrointestinal complaints (lapatinib: RR 15.53; 95% CI 2.18 to 110.55; 67 participants, one study). We found very low quality evidence from one small trial that adding recombinant interleukin (rIL‐2) to surgery may increase overall survival (HR 0.52; 95% CI 0.31 to 0.87; 201 participants, 62% oral cavity tumours, 38% oropharyngeal tumours) and there was insufficient evidence to determine whether rIL‐2 impacts on adverse effects. Authors' conclusions We found some evidence that adding EGFR mAb to standard therapy may increase overall survival, progression‐free survival and locoregional control, while resulting in an increase in skin toxicity for some mAb (cetuximab). There is insufficient evidence to determine whether adding TKIs to standard therapies changes any of our primary outcomes. Very low quality evidence from a single study suggests that rIL‐2 combined with surgery may increase overall survival compared with surgery alone. Plain language summary Treatments for cancers of the mouth and throat: therapies targeted at cancer cells and therapies to boost the body’s immune system Review question This review looks at the evidence for the benefits of new kinds of therapies for treating cancer of the mouth (oral cavity cancer) and cancer of the throat (oropharyngeal cancer) used together with standard treatments. One is the targeting of cancer cells directly whilst the other aims to boost the body’s own immune system to combat the cancer more effectively. Do these treatments result in differences in overall survival, cancer‐free survival, keeping the cancer limited to that area of the body, recurrence of the cancer, quality of life and harmful or unwanted effects? Background Oral cancers (cancer of the mouth and cancer of the throat) are the sixth most common cancer worldwide, accounting for an estimated 4% of all cancers. There is a higher frequency of these cancers in men. Smoking, alcohol consumption and betel quid chewing are the main risk factors. Cancer of the throat is associated with infection from the human papilloma virus (HPV), which can be transmitted through sexual contact. Low socioeconomic status (a measure of a person's income, education and occupation in relation to other people's) is associated with a higher frequency of oral cancers and poorer survival rates. Survival following a diagnosis of mouth or throat cancer remains poor, with around 50% of people still alive at five years (five‐year survival rate). New therapies targeted at the cells that give rise to oral cancers are being developed. The advantage these may have over conventional chemotherapy is that rather than affecting both healthy and cancerous cells they just target cancer cells. Immunotherapy (also known as biological therapy, biotherapy or biological response modifier therapy) may improve the functioning of the immune system so it is more effective at destroying cancer cells. Local immunotherapy delivers treatment directly into the tumour and systemic immunotherapy targets the whole body, and may be useful for stopping the cancer spreading or the return of primary tumours in more advanced cancer. Study characteristics The evidence in this review is up‐to‐date as of February 2015 . We found 12 studies suitable for inclusion with a total of 2488 participants. Twelve per cent of participants (298) had tumours in the mouth and 59% (1468) had tumours in the throat. The remaining 29% of participants had tumours of the voice box or lower part of throat and less than 1% had tumours at other sites. We grouped trials by treatment into three main comparisons: standard therapy with or without epidermal growth factor receptor monoclonal antibody (EGFR mAb) therapy (which is a targeted therapy), standard therapy with or without tyrosine kinase inhibitors (TKIs) (which is a targeted therapy) and standard therapy with or without immunotherapy (which is an immune‐boosting therapy). Key results We found that adding EGFR mAb, a targeted therapy, to standard therapy may increase overall survival, cancer‐free survival, keeping the cancer limited to that area of the body and may decrease recurrence of the cancer. However, it may result in an increase in skin problems for some. There is not enough evidence to know whether TKIs added to standard therapies results in a change in overall survival, cancer‐free survival, keeping the cancer limited to that area of the body or recurrence of the cancer. One study suggested that a type of immunotherapy, rIL‐2, combined with surgery, may increase overall survival. Quality of the evidence Overall, the evidence available ranges from moderate quality (for EGFR mAb) to very low quality (for TKIs and rIL‐2), which limits our confidence in the reliability of our findings.}, -DOI = {10.1002/14651858.CD010341.pub2}, -keywords = {Antibodies, Monoclonal, Humanized [therapeutic use]; Antineoplastic Agents [*therapeutic use]; Carcinoma, Squamous Cell [mortality, *therapy]; Cetuximab [therapeutic use]; Cisplatin [therapeutic use]; Docetaxel; ErbB Receptors; Gefitinib; Humans; Immunotherapy [adverse effects, *methods]; Lapatinib; Molecular Targeted Therapy [adverse effects, *methods]; Mouth Neoplasms [mortality, *therapy]; Oropharyngeal Neoplasms [mortality, *therapy]; Protein Kinase Inhibitors [therapeutic use]; Protein‐Tyrosine Kinases [antagonists & inhibitors]; Quinazolines [therapeutic use]; Randomized Controlled Trials as Topic; Taxoids [therapeutic use]}, -URL = {http://dx.doi.org/10.1002/14651858.CD010341.pub2} -} - - -Record #26 of 54 -@article{Swierz13, -author = {Swierz, MJ, Storman, D, Riemsma, RP, Wolff, R, Mitus, JW, Pedziwiatr, M, Kleijnen, J, and Bala, MM}, -title = {Percutaneous ethanol injection for liver metastases}, -journal = {Cochrane Database of Systematic Reviews}, -number = {2}, -year = {2020}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background The liver is affected by two of the most common groups of malignant tumours: primary liver tumours and liver metastases from colorectal carcinoma or other extrahepatic primary cancers. Liver metastases are significantly more common than primary liver cancer, and the reported long‐term survival rate after radical surgical treatment is approximately 50%. However, R0 resection (resection for cure) is not feasible in the majority of patients; therefore, other treatments have to be considered. One of these is percutaneous ethanol injection (PEI), which causes dehydration and necrosis of tumour cells, accompanied by small‐vessel thrombosis, leading to tumour ischaemia and destruction of the tumour. Objectives To assess the beneficial and harmful effects of percutaneous ethanol injection (PEI) compared with no intervention, other ablation methods, or systemic treatments in people with liver metastases. Search methods We searched the following databases up to 10 September 2019: the Cochrane Hepato‐Biliary Group Controlled Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library; MEDLINE Ovid; Embase Ovid; Science Citation Index Expanded; Conference Proceedings Citation Index – Science; Latin American Caribbean Health Sciences Literature (LILACS); and the Cumulative Index to Nursing and Allied Health Literature (CINAHL). We also searched clinical trials registers such as ClinicalTrials.gov, the International Clinical Trials Registry Platform (ICTRP), and the US Food and Drug Administration (FDA) (17 September 2019) . Selection criteria Randomised clinical trials assessing beneficial and harmful effects of percutaneous ethanol injection and its comparators (no intervention, other ablation methods, systemic treatments) for liver metastases. Data collection and analysis We followed standard methodological procedures as outlined by Cochrane. We extracted information on participant characteristics, interventions, study outcomes, study design, and trial methods. Two review authors performed data extraction and assessed risk of bias independently. We assessed the certainty of evidence by using GRADE. We resolved disagreements by discussion. Main results We identified only one randomised clinical trial comparing percutaneous intratumour ethanol injection (PEI) in addition to transcatheter arterial chemoembolisation (TACE) versus TACE alone. The trial was conducted in China and included 48 trial participants with liver metastases: 25 received PEI plus TACE, and 23 received TACE alone. The trial included 37 male and 11 female participants. Mean participant age was 49.3 years. Sites of primary tumours included colon (27 cases), stomach (12 cases), pancreas (3 cases), lung (3 cases), breast (2 cases), and ovary (1 case). Seven participants had a single tumour, 15 had two tumours, and 26 had three or more tumours in the liver. The bulk diameter of the tumour on average was 3.9 cm, ranging from 1.2 cm to 7.6 cm. Participants were followed for 10 months to 43 months. The trial reported survival data after one, two, and three years. In the PEI + TACE group, 92%, 80%, and 64% of participants survived after one year, two years, and three years; in the TACE alone group, these percentages were 78.3%, 65.2%, and 47.8%, respectively. Upon conversion of these data to mortality rates, the calculated risk ratio (RR) for mortality at last follow‐up when PEI plus TACE was compared with TACE alone was 0.69 (95% confidence interval (CI) 0.36 to 1.33; very low‐certainty evidence) after three years of follow‐up. Local recurrence was 16% in the PEI plus TACE group and 39.1% in the TACE group, resulting in an RR of 0.41 (95% CI 0.15 to 1.15; very low‐certainty evidence). Forty‐five out of a total of 68 tumours (66.2%) shrunk by at least 25% in the PEI plus TACE group versus 31 out of a total of 64 tumours (48.4%) in the TACE group. Trial authors reported some adverse events but provided very few details. We did not find data on time to mortality, failure to clear liver metastases, recurrence of liver metastases, health‐related quality of life, or time to progression of liver metastases. The single included trial did not provide information on funding nor on conflict of interest. Authors' conclusions Evidence for the effectiveness of PEI plus TACE versus TACE in people with liver metastases is of very low certainty and is based on one small randomised clinical trial at high risk of bias. Currently, it cannot be determined whether adding PEI to TACE makes a difference in comparison to using TACE alone. Evidence for benefits or harms of PEI compared with no intervention, other ablation methods, or systemic treatments is lacking. Plain language summary Percutaneous ethanol injection for liver metastases Is local destruction of the cancer that spread to the liver with percutaneous ethanol injection beneficial? Review question What is the effect of using percutaneous ethanol injection (PEI) to destroy any cancer metastases in the liver? Metastases are new cancer sites that are found in parts of the body other than the site of the original cancer. We were looking for any randomised trial (a study in which patients are allocated to groups by a play of chance) assessing effects of PEI in people with metastases in the liver from cancer of any location compared with no PEI with or without co‐interventions. We looked at effects of PEI on risk of death, progression of disease, health‐related quality of life, and adverse events (unwanted effects caused by the intervention). Background When cancer spreads in the body (metastasis), one of the most common sites of metastasis is the liver. Besides cancers of the liver (primary liver cancer), liver metastases from colorectal cancer are the most common cancers affecting the liver. More than half of people who have cancer spread to the liver die of complications. Metastases in the liver can be destroyed by several different methods, one of them being PEI. This procedure is performed under ultrasound or computed tomography guidance; a special needle is placed at the cancer site and is subsequently used to inject alcohol with the goal of killing cancer tissues. Ultrasound and computed tomography are imaging procedures. Alcohol induces tumour destruction by drawing water out of tumour cells (dehydrating them), thereby altering (denaturing) the structure of the cellular proteins. Search results and study characteristics We last searched for evidence on 10 September 2019. We included only one randomised trial comparing percutaneous intratumour ethanol injection in combination with transcatheter arterial chemoembolisation (TACE; a liver‐directed treatment whereby chemotherapy is administered through the catheter directly to blood vessels supplying the tumour) to TACE alone. Forty‐eight people with liver metastases were included; 25 received PEI with TACE, and 23 received TACE alone. Primary tumours were colon, stomach, pancreas, lung, breast, and ovary cancers. The included study did not provide information on funding nor on conflict of interest. Key results Results of one small randomised clinical trial do not show beneficial or harmful effects of adding percutaneous intratumour ethanol injection to TACE in people with liver metastases with respect to mortality or local recurrence in comparison with TACE alone. Participants were followed for between 10 and 43 months. The tumour necrosis was larger in the combined treatment group. Trial authors reported some adverse events but gave very few details. We found no data on time to mortality, failure to clear liver metastases, recurrence of liver metastases, health‐related quality of life, or time to progression of liver metastases. Quality of evidence We judged the evidence to be of very low certainty because the identified study was at high risk of bias, had a relatively small sample size, described few events overall, and reported inconclusive results.}, -DOI = {10.1002/14651858.CD008717.pub3}, -keywords = {Administration, Cutaneous; Chemoembolization, Therapeutic [methods]; Colorectal Neoplasms [pathology]; Ethanol [administration & dosage, *therapeutic use]; Humans; Liver Neoplasms [*drug therapy, secondary]; Randomized Controlled Trials as Topic}, -URL = {http://dx.doi.org/10.1002/14651858.CD008717.pub3} -} - - -Record #27 of 54 -@article{Van Deuren20, -author = {van Deuren, S, Boonstra, A, van Dulmen‐den Broeder, E, Blijlevens, N, Knoop, H, and Loonen, J}, -title = {Severe fatigue after treatment for childhood cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {3}, -year = {2020}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Treatment strategies for childhood cancer are improving, resulting in higher survival rates. However, the consequences of childhood cancer do not end with the successful completion of cancer treatment. Most patients will develop late effects after cessation of treatment. Severe fatigue is seen as a common and debilitating late effect in cancer survivors. Although most research on fatigue has been performed in patients after adult‐onset cancer, our review focuses on fatigue after childhood cancer. Objectives To estimate the prevalence of severe fatigue after treatment for childhood cancer. Secondary objectives are to describe the course of severe fatigue following cancer treatment and to examine risk factors for fatigue, or factors associated with it. Search methods We searched the Cochrane Central Register of Controlled Trials (the Cochrane Library 2019 ; issue 8 March 2019), MEDLINE/PubMed (from 1945 to 8 March 2019), Embase/Ovid (from 1947 to 8 March 2019), reference lists of included articles and several conference proceedings from 2011 to 2018. Selection criteria Observational studies, randomised controlled trials and controlled clinical trials reporting on fatigue in participants after treatment for childhood cancer. Case series and case reports were not eligible for inclusion. Data collection and analysis Two review authors independently extracted data and assessed risks of bias. If the publication did not present the prevalence of severe fatigue, we contacted study authors for additional information. Main results We included 30 studies (18,682 participants in total). Eighteen studies contributed to the main objective and 22 studies contributed to the secondary objectives. We found substantial differences between studies in cancer diagnosis, cancer treatment, age of participants, questionnaires used to assess fatigue, and sample size. All included studies scored at least one 'Risk of bias' item as unclear or high risk. We identified both clinical and statistical heterogeneity and therefore could not pool results, so we present them descriptively. Eighteen studies (describing 14,573 survivors) reported the prevalence of severe fatigue, which ranged from 0% to 61.7%. In a subgroup of three studies including children aged up to 18 years at fatigue assessment (268 survivors), prevalence rates ranged from 6.7% to 12.5%. In comparison, in a subgroup of 12 studies including participants aged 16 and over (13,952 survivors), prevalence rates ranged from 4.4% to 61.7%. The prevalence of severe fatigue in a subgroup of survivors of haematological cancer was presented in seven studies and ranged from 1.8% to 35.9% (1907 survivors). Prevalence of severe fatigue in brain cancer survivors was presented in two studies (252 survivors) and was 14.6% and 21.1% respectively. One study presented a prevalence for bone cancer survivors of 0.0% (17 survivors). Four studies provided prevalence rates of severe fatigue in control groups of siblings or population‐based controls, which ranged from 3.1% to 10.3%. In these four studies, survivors were more often fatigued than controls, but this difference was statistically significant in only two studies. Studies assessing risk and associated factors for fatigue were heterogeneous, and definitions of the factors under study were often inconsistent, with results therefore presented descriptively. They found that depression might be associated with fatigue. In contrast, age at diagnosis and education level did not seem to be associated with fatigue. We were unable to calculate any overall risk estimate for any of the reported risks and associated factors, because we could not conduct meta‐analysis. One study provided information about the course of fatigue over time, and found that over the course of 2.7 years, 32 of the 102 participants (31.4%) reported persistent severe fatigue. Authors' conclusions It is unclear how many childhood cancer survivors suffer from severe fatigue. This review encountered several difficulties. We found statistical and clinical heterogeneity and great variation in the reporting of possible risk and associated factors. The evidence in this review is therefore weak, and the exact prevalence of severe fatigue after treatment for childhood cancer remains to be determined. This is also the case for the course of severe fatigue following treatment and the strength of the relationship between fatigue and associated and risk factors. Despite these limitations, our review does provide a comprehensive overview of the existing literature about severe fatigue after treatment for childhood cancer. Plain language summary Severe fatigue after treatment for childhood cancer Review question We reviewed the literature to determine how common (prevalence) severe fatigue is in patients after treatment for childhood cancer. We also wanted to describe the course of severe fatigue after completion of cancer treatment, and to identify possible risk factors for the development of fatigue in this population. Background Treatments for childhood cancer are improving and becoming more effective in curing cancer. The impact of having had cancer at a young age, together with often intensive cancer therapy, can affect physical and mental well‐being later in life. Most survivors will develop one or more of these so‐called late effects. Severe fatigue is a common late effect in people with adult‐onset cancer and can affect a person's daily life in many ways. We do not currently know how often severe fatigue occurs after treatment for childhood cancer, nor which risk factors might be responsible for developing fatigue. Study characteristics The evidence is up to date to March 2019. We include 30 studies, describing 18,682 participants after treatment for childhood cancer. We found a lot of variation between studies in cancer diagnosis, cancer treatment, age of participants, the questionnaires used to assess fatigue, and the size of the study. Key results Eighteen studies reported a prevalence of severe fatigue, which ranged from 0% to 61.7%. Four studies reported a prevalence of severe fatigue in the patient's brothers and sisters or in population‐based controls. Prevalence rates in these control groups ranged from 3.1% to 10.3%. In these four studies, survivors were more often fatigued than controls. This difference was only significant in two studies. When we looked at the prevalence of severe fatigue in survivors of lymphoma and leukaemia (types of blood cancers), we found that they ranged from 1.8% to 35.9%. Two studies reported on severe fatigue in brain cancer survivors, with rates of 21.13% and 14.6%. One study in bone cancer survivors reported no cases of severe fatigue. For survivors aged 18 and younger, prevalence rates ranged from 6.7% to 12.5%. By contrast, in studies including participants aged 16 years and over (but mostly over 18), prevalence rates ranged from 4.4% to 61.7%. Twenty‐two studies assessed one or more possible risk factors for fatigue. Our review shows that depression might increase fatigue. The age at cancer diagnosis and the education level of the survivor did not seem to influence fatigue. Only one study provided information about the course of fatigue over time, and found that over the course of 2.7 years 32 of the 102 participants (31.4%) reported persistent severe fatigue. Quality of the evidence All included studies had problems with the quality of the evidence, and we found many differences between studies for several characteristics. The evidence to address our review question is therefore weak. The occurrence of severe fatigue after treatment for childhood cancer remains uncertain. This is also the case for the course of severe fatigue after completion of cancer treatment and the risk factors that might be responsible for developing fatigue.}, -DOI = {10.1002/14651858.CD012681.pub2}, -keywords = {*Cancer Survivors; Adolescent; Adult; Antineoplastic Agents [*adverse effects, therapeutic use]; Child; Fatigue [*etiology]; Humans; Neoplasms [drug therapy]; Randomized Controlled Trials as Topic; Risk Factors; Young Adult}, -URL = {http://dx.doi.org/10.1002/14651858.CD012681.pub2} -} - - -Record #28 of 54 -@article{Bala13, -author = {Bala, MM, Riemsma, RP, Wolff, R, Pedziwiatr, M, Mitus, JW, Storman, D, Swierz, MJ, and Kleijnen, J}, -title = {Cryotherapy for liver metastases}, -journal = {Cochrane Database of Systematic Reviews}, -number = {7}, -year = {2019}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background The liver is affected by two of the most common groups of malignant tumours: primary liver tumours and liver metastases from colorectal carcinoma. Liver metastases are significantly more common than primary liver cancer and long‐term survival rates reported for patients after radical surgical treatment is approximately 50%. However, R0 resection (resection for cure) is not feasible in the majority of patients. Cryotherapy is performed with the use of an image‐guided cryoprobe which delivers liquid nitrogen or argon gas to the tumour tissue. The subsequent process of freezing is associated with formation of ice crystals, which directly damage exposed tissue, including cancer cells. Objectives To assess the beneficial and harmful effects of cryotherapy compared with no intervention, other ablation methods, or systemic treatments in people with liver metastases. Search methods We searched The Cochrane Hepato‐Biliary Group Controlled Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE Ovid, Embase Ovid, and six other databases up to June 2018. Selection criteria Randomised clinical trials assessing beneficial and harmful effects of cryotherapy and its comparators for liver metastases, irrespective of the location of the primary tumour. Data collection and analysis We used standard methodological procedures expected by Cochrane. We extracted information on participant characteristics, interventions, study outcomes, and data on the outcomes important for our review, as well as information on the design and methodology of the trials. Two review authors independently assessed risk of bias in each study. One review author performed data extraction and a second review author checked entries. Main results We found no randomised clinical trials comparing cryotherapy versus no intervention or versus systemic treatments; however, we identified one randomised clinical trial comparing cryotherapy with conventional surgery. The trial was conducted in Ukraine. The trial included 123 participants with solitary, or multiple unilobar or bilobar liver metastases; 63 participants received cryotherapy and 60 received conventional surgery. There were 36 women and 87 men. The primary sites for the metastases were colon and rectum (66.6%), stomach (7.3%), breast (6.5%), skin (4.9%), ovaries (4.1%), uterus (3.3%), kidney (3.3%), intestines (1.6%), pancreas (1.6%), and unknown (0.8%). The trial was not reported sufficiently enough to assess the risk of bias of the randomisation process, allocation concealment, or presence of blinding. It was also not possible to assess incomplete outcome data and selective outcome reporting bias. The certainty of evidence was low because of risk of bias and imprecision. The participants were followed for up to 10 years (minimum five months). The trial reported that the mortality at 10 years was 81% (51/63) in the cryotherapy group and 92% (55/60) in the conventional surgery group. The calculated by us relative risk (RR) with 95% Confidence Interval (CI) was: RR 0.88, 95% CI 0.77 to 1.02. We judged the evidence as low‐certainty evidence. Regarding adverse events and complications, separately and in total, our calculation showed no evidence of a difference in recurrence of the malignancy in the liver: 86% (54/63) of the participants in the cryotherapy group and 95% (57/60) of the participants in the conventional surgery group developed a new malignancy (RR 0.90, 95% CI 0.80 to 1.01; low‐certainty evidence). The frequency of reported complications was similar between the cryotherapy group and the conventional surgery group, except for postoperative pain. Both insignificant and pronounced pain were reported to be more common in the cryotherapy group while intense pain was reported to be more common in the conventional surgery group. However, the authors did not report whether there was any evidence of a difference. There were no intervention‐related mortality or bile leakages. We identified no evidence for health‐related quality of life, cancer mortality, or time to progression of liver metastases. The study reported tumour response in terms of the carcinoembryonic antigen level in 69% of participants, and reported results in the form of a graph for 30% of participants. The carcinoembryonic antigen level was lower in the cryotherapy group, and decreased to normal values faster in comparison with the control group (P < 0.05). Funding: the trial did not provide information on funding. Authors' conclusions The evidence for the effectiveness of cryotherapy versus conventional surgery in people with liver metastases is of low certainty. We are uncertain about our estimate and cannot determine whether cryotherapy compared with conventional surgery is beneficial or harmful. We found no evidence for the benefits or harms of cryotherapy compared with no intervention, or versus systemic treatments. Plain language summary Cryotherapy for liver metastases Review question Is cryotherapy (cooling) beneficial or harmful for local destruction of cancer (tumours) spread to the liver? Background When cancer spreads in the body (metastasis), one of the most common sites is the liver. Besides cancers of the liver (primary liver cancer), liver metastases from colorectal cancer are the most common cancer affecting the liver. More than half of people who have cancer spread to the liver die from complications. Cryotherapy is one of methods, used to destroy metastases in the liver. This method requires placing a special probe near the cancer site. The probe is used to deliver extreme cold to the site, which is produced by liquid nitrogen or argon gas. Placement of the probe can be guided using ultrasound or computed tomography (a special x‐ray). The rapid freezing process kills the cancer cells, and the size of the cancer is reduced. However, it is not clear if this treatment prolongs life or increases quality of life of affected people. We reviewed the evidence about the effect of cryotherapy in destroying cancer metastases in the liver. We searched for studies assessing the effect of cryotherapy in comparison with no treatment or any other treatment in people with liver metastases from cancer of any location. We aimed to assess the effect of cryotherapy on the risk of death, quality of life, and adverse events (side effects caused by the treatment). Study characteristics We last searched for evidence in June 2018. We included only one trial conducted in Ukraine, and participants' primary cancer was colorectal (bowel) cancer in 66% of instances, but there were also people with stomach, breast, skin, and other tumours. All of them had cancer spread to the liver. In this trial, 123 participants were allocated at random to receive either cryotherapy (63 people) or conventional surgery (affected parts of the liver were removed; 60 people). Funding The trial did not provide information on funding. Key results The trial was at high risk of bias. The participants were followed for up to 10 years (minimum five months). The trial reported that the mortality at 10 years was 81% (51/63) in the cryotherapy group and 92% (55/60) in the conventional surgery group. We judged the evidence as low‐certainty evidence. We found no evidence of a difference in proportion of participants with recurrence of the malignancy in the liver: 86% (54/63) of the participants in the cryotherapy group and 95% (57/60) of the participants in the conventional surgery group developed a new malignancy (low‐certainty evidence). The frequency of reported complications was similar between the cryotherapy group and the conventional surgery group, except for postoperative pain. Both insignificant and pronounced pain were reported to be more common in the cryotherapy group while intense pain was reported to be more common in the conventional surgery group. However, it was not reported whether there was any evidence of a difference. The frequency of unwanted effects (adverse events or complications) was mostly similar in both groups, but pain intensity and frequency seemed to differ between the groups. There were no intervention‐related mortality or bile leakages. The trial did not provide data on quality of life; cancer mortality, and time to progression of liver metastases. Reliability of the evidence The evidence for the effectiveness of cryotherapy versus conventional surgery in people with liver metastases is of low certainty. We are uncertain about our estimate and cannot determine whether cryotherapy compared with conventional surgery is beneficial or harmful. We found no evidence for the benefits or harms of cryotherapy compared with no intervention, or versus systemic treatments.}, -DOI = {10.1002/14651858.CD009058.pub3}, -keywords = {*Cryotherapy [methods]; Colorectal Neoplasms [pathology]; Humans; Liver Neoplasms [*secondary, *therapy]; Quality of Life; Randomized Controlled Trials as Topic}, -URL = {http://dx.doi.org/10.1002/14651858.CD009058.pub3} -} - - -Record #29 of 54 -@article{Goedendorp09, -author = {Goedendorp, MM, Gielissen, MFM, Verhagen, CAHHVM, and Bleijenberg, G}, -title = {Psychosocial interventions for reducing fatigue during cancer treatment in adults}, -journal = {Cochrane Database of Systematic Reviews}, -number = {1}, -year = {2009}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Fatigue is a common symptom in cancer patients receiving active treatment. There are a limited number of reviews evaluating interventions for fatigue during active treatment, and they are restricted to patients with advanced cancer, or to patients during radiotherapy. To date there is no systematic review on psychosocial interventions for fatigue during cancer treatment. Objectives To evaluate if psychosocial interventions are effective in reducing fatigue in cancer patients receiving active treatment for cancer, and which types of psychosocial interventions are the most effective. Search methods In September 2008 we searched the Cochrane Central Register of Controlled Trials (CENTRAL) ( The Cochrane Library ), PUBMED, MEDLINE, EMBASE, CINAHL and PsycINFO, and checked the reference lists. Selection criteria Randomised controlled trials (RCTs) were included which evaluated psychosocial interventions in adult cancer patients during treatment, with fatigue as an outcome measure. Data collection and analysis Three review authors independently extracted data from the selected studies, and assessed the methodological quality using several quality rating scales and additional criteria. Main results Twenty‐seven studies met the inclusion criteria with a total of 3324 participants, and seven studies reported significant effects of the psychosocial intervention on fatigue. In three studies the effect was maintained at follow‐up. The quality of the studies was generally moderate. Effect sizes varied between 0.17 to 1.07. The effectiveness of interventions specific for fatigue was significantly higher (80%) compared to interventions not specific for fatigue (14%). In five studies the interventions were specifically focused on fatigue, with four being effective. The five interventions were brief, consisting of three individual sessions, provided by (oncology) nurses. In general, during these interventions participants were educated about fatigue, were taught in self‐care or coping techniques, and learned activity management. Of the remaining 22 studies only three were effective in reducing fatigue, and these interventions had a more general approach. These interventions were aimed at psychological distress, mood and physical symptoms, and varied strongly in duration and content. Authors' conclusions There is limited evidence that psychosocial interventions during cancer treatment are effective in reducing fatigue. At present, psychosocial interventions specifically for fatigue are a promising type of intervention. However, there is no solid evidence for the effectiveness of interventions not specific for fatigue. Most aspects of the included studies were heterogeneous, and therefore it could not be established which other types of interventions, or elements were essential in reducing fatigue. Plain language summary The effect of psychosocial interventions on fatigue during cancer treatment in adults There is limited evidence that psychosocial interventions are effective in reducing fatigue during active treatment in cancer patients. Most promising are psychosocial interventions specifically designed to treat fatigue. In general, during these interventions patients were educated about fatigue, were taught in self‐care or coping techniques, and learned to manage their activity. Interventions that did not focus on fatigue were rarely effective in reducing fatigue.}, -DOI = {10.1002/14651858.CD006953.pub2}, -keywords = {Fatigue [etiology, *therapy]; Female; Humans; Male; Mind‐Body Therapies [*methods]; Neoplasms [complications, *therapy]; Psychotherapy [*methods]; Randomized Controlled Trials as Topic}, -URL = {http://dx.doi.org/10.1002/14651858.CD006953.pub2} -} - - -Record #30 of 54 -@article{Schmidt20, -author = {Schmidt, S, Kunath, F, Coles, B, Draeger, DL, Krabbe, LM, Dersch, R, Kilian, S, Jensen, K, Dahm, P, and Meerpohl, JJ}, -title = {Intravesical Bacillus Calmette‐Guérin versus mitomycin C for Ta and T1 bladder cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {1}, -year = {2020}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background People with urothelial carcinoma of the bladder are at risk for recurrence and progression following transurethral resection of a bladder tumour (TURBT). Mitomycin C (MMC) and Bacillus Calmette‐Guérin (BCG) are commonly used, competing forms of intravesical therapy for intermediate‐ or high‐risk non‐muscle invasive (Ta and T1) urothelial bladder cancer but their relative merits are somewhat uncertain. Objectives To assess the effects of BCG intravesical therapy compared to MMC intravesical therapy for treating intermediate‐ and high‐risk Ta and T1 bladder cancer in adults. Search methods We performed a systematic literature search in multiple databases (CENTRAL, MEDLINE, Embase, Web of Science, Scopus, LILACS), as well as in two clinical trial registries. We searched reference lists of relevant publications and abstract proceedings. We applied no language restrictions. The latest search was conducted in September 2019. Selection criteria We included randomised controlled trials (RCTs) that compared intravesical BCG with intravesical MMC therapy for non‐muscle invasive urothelial bladder cancer. Data collection and analysis Two review authors independently screened the literature, extracted data, assessed risk of bias and rated the quality of evidence according to GRADE per outcome. In the meta‐analyses, we used the random‐effects model. Main results We identified 12 RCTs comparing BCG versus MMC in participants with intermediate‐ and high‐risk non‐muscle invasive bladder tumours (published from 1995 to 2013). In total, 2932 participants were randomised. Time to death from any cause: BCG may make little or no difference on time to death from any cause compared to MMC (hazard ratio (HR) 0.97, 95% confidence interval (CI) 0.79 to 1.20; participants = 1132, studies = 5; 567 participants in the BCG arm and 565 in the MMC arm; low‐certainty evidence). This corresponds to 6 fewer deaths (40 fewer to 36 more) per 1000 participants treated with BCG at five years. We downgraded the certainty of the evidence two levels due to study limitations and imprecision. Serious adverse effects: 12/577 participants treated with BCG experienced serious non‐fatal adverse effects compared to 4/447 participants in the MMC group. The pooled risk ratio (RR) is 2.31 (95% CI 0.82 to 6.52; participants = 1024, studies = 5; low‐certainty evidence). Therefore, BCG may increase the risk for serious adverse effects compared to MMC. This corresponds to nine more serious adverse effects (one fewer to 37 more) with BCG. We downgraded the certainty of the evidence two levels due to study limitations and imprecision. Time to recurrence: BCG may reduce the time to recurrence compared to MMC (HR 0.88, 95% CI 0.71 to 1.09; participants = 2616, studies = 11, 1273 participants in the BCG arm and 1343 in the MMC arm; low‐certainty evidence). This corresponds to 41 fewer recurrences (104 fewer to 29 more) with BCG at five years. We downgraded the certainty of the evidence two levels due to study limitations, imprecision and inconsistency. Time to progression: BCG may make little or no difference on time to progression compared to MMC (HR 0.96, 95% CI 0.73 to 1.26; participants = 1622, studies = 6; 804 participants in the BCG arm and 818 in the MMC arm; low‐certainty evidence). This corresponds to four fewer progressions (29 fewer to 27 more) with BCG at five years. We downgraded the certainty of the evidence two levels due to study limitations and imprecision. Quality of life: we found very limited data for this outcomes and were unable to estimate an effect size. Authors' conclusions Based on our findings, BCG may reduce the risk of recurrence over time although the Confidence Intervals include the possibility of no difference. It may have no effect on either the risk of progression or risk of death from any cause over time. BCG may cause more serious adverse events although the Confidence Intervals once again include the possibility of no difference. We were unable to determine the impact on quality of life. The certainty of the evidence was consistently low, due to concerns that include possible selection bias, performance bias, given the lack of blinding in these studies, and imprecision. Plain language summary Bacillus Calmette‐Guérin or mitomycin C for treatment of non‐muscle‐invasive bladder cancer Review question In people with cancer of the inner lining of the bladder, how do two different medicines, that are called Bacillus Calmette‐Guérin (BCG) and mitomycin (MMC), that are put into the bladder, after the tumour is taken out, compare? Background Tumours of the superficial layers of the bladder, so‐called non‐muscle‐invasive bladder cancer, are treated by putting small instruments into the bladder and shaving them out. This works well but these tumours often come back. When they do come back they can be more aggressive and advanced than before. Different types of medicines put into the bladder afterwards can make that happen less often, with BCG and MMC being those used most often. We are not sure how the two treatments compare when it comes to wanted and unwanted effects. Study characteristics The content of this review is current to September 2019. We included only studies where chance determined what treatment people in the study would get. Key results We found 12 studies including 2932 people who matched our question. We found that BCG may lead to similar risk of dying from any cause over time (low‐quality evidence), but may increase the risk of serious unwanted effects (low‐quality evidence), although it is possible that it does not make a difference. BCG may reduce the risk that the tumour comes back over time (low‐quality evidence), although it is possible that it does not make a difference. BCG may have little or no effect on the risk that the tumour gets worse over time (low‐quality evidence). We found no data on quality of life. Quality of the evidence The quality of the evidence was consistently rated as low, meaning that our confidence is limited, and future research may change these findings.}, -DOI = {10.1002/14651858.CD011935.pub2}, -keywords = {Administration, Intravesical; Antibiotics, Antineoplastic [administration & dosage, *therapeutic use]; BCG Vaccine; Carcinoma, Transitional Cell [*drug therapy]; Humans; Mitomycin [administration & dosage, *therapeutic use]; Randomized Controlled Trials as Topic; Treatment Outcome; Urinary Bladder Neoplasms [*drug therapy]}, -URL = {http://dx.doi.org/10.1002/14651858.CD011935.pub2} -} - - -Record #31 of 54 -@article{Yalçin10, -author = {Yalçin, B, Kremer, LCM, and van Dalen, EC}, -title = {High‐dose chemotherapy and autologous haematopoietic stem cell rescue for children with high‐risk neuroblastoma}, -journal = {Cochrane Database of Systematic Reviews}, -number = {10}, -year = {2015}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Despite the development of new treatment options, the prognosis of high‐risk neuroblastoma patients is still poor; more than half of patients experience disease recurrence. High‐dose chemotherapy and haematopoietic stem cell rescue (i.e. myeloablative therapy) might improve survival. This review is the second update of a previously published Cochrane review. Objectives Primary objective To compare the efficacy, that is event‐free and overall survival, of high‐dose chemotherapy and autologous bone marrow or stem cell rescue with conventional therapy in children with high‐risk neuroblastoma. Secondary objectives To determine adverse effects (e.g. veno‐occlusive disease of the liver) and late effects (e.g. endocrine disorders or secondary malignancies) related to the procedure and possible effects of these procedures on quality of life. Search methods We searched the electronic databases The Cochrane Central Register of Controlled Trials (CENTRAL) ( The Cochrane Library 2014, issue 11), MEDLINE/PubMed (1966 to December 2014) and EMBASE/Ovid (1980 to December 2014). In addition, we searched reference lists of relevant articles and the conference proceedings of the International Society for Paediatric Oncology (SIOP) (from 2002 to 2014), American Society for Pediatric Hematology and Oncology (ASPHO) (from 2002 to 2014), Advances in Neuroblastoma Research (ANR) (from 2002 to 2014) and American Society for Clinical Oncology (ASCO) (from 2008 to 2014). We searched for ongoing trials by scanning the ISRCTN register (www.isrct.com) and the National Institute of Health Register (www.clinicaltrials.gov). Both registers were screened in April 2015. Selection criteria Randomised controlled trials (RCTs) comparing the efficacy of myeloablative therapy with conventional therapy in high‐risk neuroblastoma patients. Data collection and analysis Two authors independently performed study selection, data extraction and risk of bias assessment. If appropriate, we pooled studies. The risk ratio (RR) and 95% confidence interval (CI) was calculated for dichotomous outcomes. For the assessment of survival data, we calculated the hazard ratio (HR) and 95% CI. We used Parmar's method if hazard ratios were not reported in the study. We used a random‐effects model. Main results We identified three RCTs including 739 children. They all used an age of one year as the cut‐off point for pre‐treatment risk stratification. The first updated search identified a manuscript reporting additional follow‐up data for one of these RCTs, while the second update identified an erratum of this study. There was a significant statistical difference in event‐free survival in favour of myeloablative therapy over conventional chemotherapy or no further treatment (three studies, 739 patients; HR 0.78, 95% CI 0.67 to 0.90). There was a significant statistical difference in overall survival in favour of myeloablative therapy over conventional chemotherapy or no further treatment (two studies, 360 patients; HR 0.74, 95% CI 0.57 to 0.98). However, when additional follow‐up data were included in the analyses the difference in event‐free survival remained statistically significant (three studies, 739 patients; HR 0.79, 95% CI 0.70 to 0.90), but the difference in overall survival was no longer statistically significant (two studies, 360 patients; HR 0.86, 95% CI 0.73 to 1.01). The meta‐analysis of secondary malignant disease and treatment‐related death did not show any significant statistical differences between the treatment groups. Data from one study (379 patients) showed a significantly higher incidence of renal effects, interstitial pneumonitis and veno‐occlusive disease in the myeloablative group compared to conventional chemotherapy, whereas for serious infections and sepsis no significant difference between the treatment groups was identified. No information on quality of life was reported. In the individual studies we evaluated different subgroups, but the results were not univocal in all studies. All studies had some methodological limitations. Authors' conclusions Based on the currently available evidence, myeloablative therapy seems to work in terms of event‐free survival. For overall survival there is currently no evidence of effect when additional follow‐up data are included. No definitive conclusions can be made regarding adverse effects and quality of life, although possible higher levels of adverse effects should be kept in mind. A definitive conclusion regarding the effect of myeloablative therapy in different subgroups is not possible. This systematic review only allows a conclusion on the concept of myeloablative therapy; no conclusions can be made regarding the best treatment strategy. Future trials on the use of myeloablative therapy for high‐risk neuroblastoma should focus on identifying the most optimal induction and/or myeloablative regimen. The best study design to answer these questions is a RCT. These RCTs should be performed in homogeneous study populations (e.g. stage of disease and patient age) and have a long‐term follow‐up. Different risk groups, using the most recent definitions, should be taken into account. It should be kept in mind that recently the age cut‐off for high risk disease was changed from one year to 18 months. As a result it is possible that patients with what is now classified as intermediate‐risk disease have been included in the high‐risk groups. Consequently the relevance of the results of these studies to the current practice can be questioned. Survival rates may be overestimated due to the inclusion of patients with intermediate‐risk disease. Plain language summary High‐dose chemotherapy and stem cell transplant compared to conventional therapy for children with high‐risk neuroblastoma Despite the development of new treatment options, the prognosis of high‐risk neuroblastoma patients still remains poor; in more than half of patients the disease returns. Stem cell rescue replaces blood‐forming stem cells that were destroyed by high‐dose chemotherapy in order to recover the bone marrow. It is also known as myeloablative therapy and might improve the survival of these patients. A well‐informed decision on the use of myeloablative therapy in the treatment of children with high‐risk neuroblastoma should be based on high quality evidence of effectiveness for treating tumours and side effects. This systematic review focused on randomised studies comparing the effectiveness of myeloablative therapy with conventional therapy in children with high‐risk neuroblastoma. The authors found three studies including 739 patients. These studies provide evidence that myeloablative therapy improves event‐free survival (that is, the time until a certain event, for example tumour progression, the development of a second tumour, or death from any cause occurs). For overall survival (that is, the time until a patient dies from any cause, so not only from the tumour or its treatment, but for example, also from a car accident) there is no evidence of a better outcome in patients treated with myeloablative therapy. Side effects such as renal (kidney) effects, interstitial pneumonitis (a type of lung disease) and veno‐occlusive disease (a condition in which some of the small veins in the liver are obstructed) were more common in patients treated with myeloablative therapy than conventional chemotherapy. It should be noted that this systematic review only allows a conclusion on the concept of myeloablative therapy; no conclusions regarding the best treatment strategy with regard to, for example, types of chemotherapeutic agents and the use of radiation therapy, could be made. More high quality research is needed. It should be noted that recently the age cut‐off for high‐risk disease was changed from one year to 18 months. As a result it is possible that patients with what is now classified as intermediate‐risk disease were included in the high‐risk groups. Consequently the relevance of the results of these studies to the current practice can be questioned. Survival rates may be overestimated due to the inclusion of patients with intermediate‐risk disease.}, -DOI = {10.1002/14651858.CD006301.pub4}, -keywords = {Age Factors; Antineoplastic Combined Chemotherapy Protocols [*administration & dosage, adverse effects]; Bone Marrow [drug effects]; Child; Child, Preschool; Disease‐Free Survival; Hematopoietic Stem Cell Transplantation [*methods, mortality]; Humans; Infant; Neoplasm Recurrence, Local; Neuroblastoma [mortality, *therapy]; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy [methods]}, -URL = {http://dx.doi.org/10.1002/14651858.CD006301.pub4} -} - - -Record #32 of 54 -@article{Dinnes19, -author = {Dinnes, J, Ferrante di Ruffano, L, Takwoingi, Y, Cheung, ST, Nathan, P, Matin, RN, Chuchu, N, Chan, SA, Durack, A, Bayliss, SE, Gulati, A, Patel, L, Davenport, C, Godfrey, K, Subesinghe, M, Traill, Z, Deeks, JJ, and Williams, HC}, -title = {Ultrasound, CT, MRI, or PET‐CT for staging and re‐staging of adults with cutaneous melanoma}, -journal = {Cochrane Database of Systematic Reviews}, -number = {7}, -year = {2019}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Melanoma is one of the most aggressive forms of skin cancer, with the potential to metastasise to other parts of the body via the lymphatic system and the bloodstream. Melanoma accounts for a small percentage of skin cancer cases but is responsible for the majority of skin cancer deaths. Various imaging tests can be used with the aim of detecting metastatic spread of disease following a primary diagnosis of melanoma (primary staging) or on clinical suspicion of disease recurrence (re‐staging). Accurate staging is crucial to ensuring that patients are directed to the most appropriate and effective treatment at different points on the clinical pathway. Establishing the comparative accuracy of ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET)‐CT imaging for detection of nodal or distant metastases, or both, is critical to understanding if, how, and where on the pathway these tests might be used. Objectives Primary objectives We estimated accuracy separately according to the point in the clinical pathway at which imaging tests were used. Our objectives were: • to determine the diagnostic accuracy of ultrasound or PET‐CT for detection of nodal metastases before sentinel lymph node biopsy in adults with confirmed cutaneous invasive melanoma; and • to determine the diagnostic accuracy of ultrasound, CT, MRI, or PET‐CT for whole body imaging in adults with cutaneous invasive melanoma: ○ for detection of any metastasis in adults with a primary diagnosis of melanoma (i.e. primary staging at presentation); and ○ for detection of any metastasis in adults undergoing staging of recurrence of melanoma (i.e. re‐staging prompted by findings on routine follow‐up). We undertook separate analyses according to whether accuracy data were reported per patient or per lesion. Secondary objectives We sought to determine the diagnostic accuracy of ultrasound, CT, MRI, or PET‐CT for whole body imaging (detection of any metastasis) in mixed or not clearly described populations of adults with cutaneous invasive melanoma. For study participants undergoing primary staging or re‐staging (for possible recurrence), and for mixed or unclear populations, our objectives were: • to determine the diagnostic accuracy of ultrasound, CT, MRI, or PET‐CT for detection of nodal metastases; • to determine the diagnostic accuracy of ultrasound, CT, MRI, or PET‐CT for detection of distant metastases; and • to determine the diagnostic accuracy of ultrasound, CT, MRI, or PET‐CT for detection of distant metastases according to metastatic site. Search methods We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central Register of Controlled Trials; MEDLINE; Embase; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of Health Ongoing Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization International Clinical Trials Registry Platform. We studied reference lists as well as published systematic review articles. Selection criteria We included studies of any design that evaluated ultrasound (with or without the use of fine needle aspiration cytology (FNAC)), CT, MRI, or PET‐CT for staging of cutaneous melanoma in adults, compared with a reference standard of histological confirmation or imaging with clinical follow‐up of at least three months' duration. We excluded studies reporting multiple applications of the same test in more than 10% of study participants. Data collection and analysis Two review authors independently extracted all data using a standardised data extraction and quality assessment form (based on the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS‐2)). We estimated accuracy using the bivariate hierarchical method to produce summary sensitivities and specificities with 95% confidence and prediction regions. We undertook analysis of studies allowing direct and indirect comparison between tests. We examined heterogeneity between studies by visually inspecting the forest plots of sensitivity and specificity and summary receiver operating characteristic (ROC) plots. Numbers of identified studies were insufficient to allow formal investigation of potential sources of heterogeneity. Main results We included a total of 39 publications reporting on 5204 study participants; 34 studies reporting data per patient included 4980 study participants with 1265 cases of metastatic disease, and seven studies reporting data per lesion included 417 study participants with 1846 potentially metastatic lesions, 1061 of which were confirmed metastases. The risk of bias was low or unclear for all domains apart from participant flow. Concerns regarding applicability of the evidence were high or unclear for almost all domains. Participant selection from mixed or not clearly defined populations and poorly described application and interpretation of index tests were particularly problematic. The accuracy of imaging for detection of regional nodal metastases before sentinel lymph node biopsy (SLNB) was evaluated in 18 studies. In 11 studies (2614 participants; 542 cases), the summary sensitivity of ultrasound alone was 35.4% (95% confidence interval (CI) 17.0% to 59.4%) and specificity was 93.9% (95% CI 86.1% to 97.5%). Combining pre‐SLNB ultrasound with FNAC revealed summary sensitivity of 18.0% (95% CI 3.58% to 56.5%) and specificity of 99.8% (95% CI 99.1% to 99.9%) (1164 participants; 259 cases). Four studies demonstrated lower sensitivity (10.2%, 95% CI 4.31% to 22.3%) and specificity (96.5%,95% CI 87.1% to 99.1%) for PET‐CT before SLNB (170 participants, 49 cases). When these data are translated to a hypothetical cohort of 1000 people eligible for SLNB, 237 of whom have nodal metastases (median prevalence), the combination of ultrasound with FNAC potentially allows 43 people with nodal metastases to be triaged directly to adjuvant therapy rather than having SLNB first, at a cost of two people with false positive results (who are incorrectly managed). Those with a false negative ultrasound will be identified on subsequent SLNB. Limited test accuracy data were available for whole body imaging via PET‐CT for primary staging or re‐staging for disease recurrence, and none evaluated MRI. Twenty‐four studies evaluated whole body imaging. Six of these studies explored primary staging following a confirmed diagnosis of melanoma (492 participants), three evaluated re‐staging of disease following some clinical indication of recurrence (589 participants), and 15 included mixed or not clearly described population groups comprising participants at a number of different points on the clinical pathway and at varying stages of disease (1265 participants). Results for whole body imaging could not be translated to a hypothetical cohort of people due to paucity of data. Most of the studies (6/9) of primary disease or re‐staging of disease considered PET‐CT, two in comparison to CT alone, and three studies examined the use of ultrasound. No eligible evaluations of MRI in these groups were identified. All studies used histological reference standards combined with follow‐up, and two included FNAC for some participants. Observed accuracy for detection of any metastases for PET‐CT was higher for re‐staging of disease (summary sensitivity from two studies: 92.6%, 95% CI 85.3% to 96.4%; specificity: 89.7%, 95% CI 78.8% to 95.3%; 153 participants; 95 cases) compared to primary staging (sensitivities from individual studies ranged from 30% to 47% and specificities from 73% to 88%), and was more sensitive than CT alone in both population groups, but participant numbers were very small. No conclusions can be drawn regarding routine imaging of the brain via MRI or CT. Authors' conclusions Review authors found a disappointing lack of evidence on the accuracy of imaging in people with a diagnosis of melanoma at different points on the clinical pathway. Studies were small and often reported data according to the number of lesions rather than the number of study participants. Imaging with ultrasound combined with FNAC before SLNB may identify around one‐fifth of those with nodal disease, but confidence intervals are wide and further work is needed to establish cost‐effectiveness. Much of the evidence for whole body imaging for primary staging or re‐staging of disease is focused on PET‐CT, and comparative data with CT or MRI are lacking. Future studies should go beyond diagnostic accuracy and consider the effects of different imaging tests on disease management. The increasing availability of adjuvant therapies for people with melanoma at high risk of disease spread at presentation will have a considerable impact on imaging services, yet evidence for the relative diagnostic accuracy of available tests is limited. Plain language summary How good are ultrasound, CT, MRI, and PET‐CT for identifying spread of disease in the body among people with melanoma? What is the aim of the review? We wanted to find out which imaging tests are better for identifying spread of disease among people with a first diagnosis of melanoma (primary staging) and among people with possible recurrence of melanoma (re‐staging). We looked at the evidence for ultrasound, CT, MRI, and PET‐CT and included 39 studies to answer these questions. Why are imaging tests for melanoma important? Melanoma is one of the most aggressive forms of skin cancer, with potential for metastases (cancer cells) to spread to the lymph nodes and other organs of the body. To make sure that people with melanoma receive the most appropriate and effective treatment, it is important to identify whether the disease has spread and to which parts of the body it has spread. This is called 'staging of disease'. Staging is done to find out if a melanoma has spread to regional lymph nodes or to lymph nodes close to the original melanoma, and to determine if the melanoma has spread to lymph nodes in other parts of the body or to organs of the body such as the liver or the brain (distant metastases). Imaging tests are tools that can be used to help find out how much the disease has spread. Several new treatments are now available for reducing the risk of spread of melanoma and for treating melanoma when it has spread. What was studied in the review? The review includes four imaging tests that create images of the body in different ways. Ultrasound uses high‐frequency sound waves to create images, CT scans use ionising radiation in the form of X‐rays (a very low dose of radiation), and MRI uses large magnets and non‐ionising radiation in the form of radio waves (which are not harmful) to generate images of the body. PET‐CT requires injection of a weakly radioactive substance (FDG). The PET part of the scan identifies areas of the body that take up a lot of FDG (indicating possibly cancerous cells), and the CT part of the scan helps to improve image quality and to more accurately pinpoint areas using more FDG. Ultrasound can also be performed along with a fairly simple procedure called 'fine needle aspiration cytology' (FNAC), by which a very fine needle is used to take a small sample of cells from a lymph node that looks suspicious on ultrasound. A microscope is then used to identify whether or not the cells are malignant. Imaging can be used at different time points after diagnosis of melanoma. Healthcare providers can use imaging to look at the regional lymph nodes closest to the melanoma before a type of surgery called sentinel lymph node biopsy is performed. Sentinel lymph node biopsy takes out the lymph nodes that are most likely to have metastases inside them so they can be tested in a laboratory. Imaging can also be used after sentinel lymph node biopsy or in people with higher‐risk melanoma to look for any spread of disease. Imaging can be used in people who were treated for melanoma at an earlier point and who might be having a recurrence of their disease. What are the main results of the review? Ultrasound of regional lymph nodes before sentinel lymph node biopsy We found 11 relevant studies including 2614 people. Three of these studies compared ultrasound on its own to ultrasound combined with FNAC. Results suggest that the combined procedure correctly identifies around one‐fifth of people with metastases in the lymph nodes with very few false positive results (people with incorrect diagnosis of metastasis). These results can be illustrated by imagining a group of 1000 people with melanoma who are going to have sentinel lymph node biopsy, of whom 237 (24%) have metastases in the lymph nodes. The combination of ultrasound with FNAC potentially allows 43 people with lymph node metastases to be identified and avoid a sentinel lymph node biopsy, at a cost of two people with false positive results who might go on to have the wrong treatment. Those with metastases in the lymph nodes that are missed on ultrasound (false negatives) will be identified on subsequent SLNB. Whole body imaging (detection of any metastases) We found 24 studies, but only nine were clear about the point in the time course of disease that imaging was carried out. Six studies including 492 people looked at imaging for primary staging following a confirmed diagnosis of melanoma, and three studies in 589 people evaluated re‐staging of disease in people with possible recurrence of disease. Most of the studies (6/9) considered PET‐CT, two in comparison to CT alone, and three studies examined the use of ultrasound. We did not find any suitable studies of MRI in these groups. Overall results suggest that PET‐CT is better for correctly identifying people with metastatic spread of disease who might be having a recurrence of disease (re‐staging) than people who have a new diagnosis of melanoma (primary staging). PET‐CT also seems to be better than CT for identifying spread of disease in both groups of people, but studies were very small and results might not be reliable. How reliable are the results of the studies included in this review? In most of our studies, a reliable diagnosis of spread of disease (or reference standard) was made by performing biopsy and by following up with people over time using clinical assessment and imaging. There was often a lack of detail on how patients were followed up and which tests were used. Lots of studies did not include people at clearly defined time points in the disease process, making it difficult to assess the relevance of their results. Reporting of application and interpretation of tests was poor. To whom do the results of this review apply? Thirty‐three studies were done in Europe (85%), and the rest in North America (n = 4), Asia (n = 1), or Oceania (n = 1). The average age of people in the studies was between 50 and 67 years, and around half were men. Studies mostly included people with melanoma on any part of the body, but two included only people with melanoma on the head or neck. Studies often included people at different stages of disease, and we were not able to look at the accuracy of tests for people at any particular disease stage. Studies were small, and their results might not match what happens in real life. What are the implications of this review? Reviewers found some evidence to support the use of imaging with ultrasound combined with FNAC before sentinel lymph node biopsy, but further work is needed to establish cost‐effectiveness. Limited evidence is available for whole body imaging for primary staging or re‐staging of disease. Available evidence is focused on PET‐CT; there are few comparisons with CT and no comparisons with MRI. Future research needs to look at more than test accuracy and must consider the effects of different imaging tests on treatment decisions for patients. How up‐to‐date is this review? The reviewers searched for and included studies published up to August 2016.* *In these studies, biopsy and clinical or imaging follow‐up were the reference standards (methods of establishing the final diagnosis).}, -DOI = {10.1002/14651858.CD012806.pub2}, -keywords = {*Neoplasm Metastasis; *Neoplasm Staging; Adult; Diagnosis, Computer-Assisted [methods]; Humans; Magnetic Resonance Imaging; Melanoma [*diagnostic imaging]; Melanoma, Cutaneous Malignant; Neoplasm Recurrence, Local [diagnostic imaging]; Positron Emission Tomography Computed Tomography; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Skin Neoplasms [*diagnostic imaging]; Tomography, X-Ray Computed; Ultrasonography}, -URL = {http://dx.doi.org/10.1002/14651858.CD012806.pub2} -} - - -Record #33 of 54 -@article{Narayan18, -author = {Narayan, V, Kahlmeyer, A, Dahm, P, Skoetz, N, Risk, MC, Bongiorno, C, Patel, N, Hwang, EC, Jung, JH, Gartlehner, G, and Kunath, F}, -title = {Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review}, -journal = {Cochrane Database of Systematic Reviews}, -number = {7}, -year = {2018}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background The use of systemic immunotherapy targets is emerging as an important treatment option for metastatic urothelial carcinoma, particularly for patients who cannot tolerate or who fail cisplatin‐based chemotherapy. One such target is the inhibition of the checkpoint protein programmed cell death‐1 (PD‐1) receptor and its ligand (PD‐L1) by monoclonal antibodies. Objectives To assess the effects of pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. Search methods We performed a Cochrane Rapid Review, limiting our search to published studies in the English language. We searched databases of the medical literature, including the Cochrane Central Register of Controlled Trials and MEDLINE, as well as trial registries including ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP). Our search extended from January 2000 to June 2018. Selection criteria We included randomised controlled trials except cross‐over trials and cluster randomised trials. We excluded all other study designs. Participants included had locally advanced or metastatic urothelial carcinoma of the bladder, with disease progression during or following platinum‐containing chemotherapy (synonymous with second‐/third‐/fourth‐line therapy). This review focused on pembrolizumab (synonyms: MK‐3475, lambrolizumab, Keytruda). Data collection and analysis Two review authors independently classified and abstracted data from the included study. The certainty of evidence was rated according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Main results We identified one randomised controlled trial that included 542 participants, which compared the use of pembrolizumab monotherapy versus chemotherapy for the treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. Results were reported after a median follow‐up of 14.1 months (range 9.9 to 22.1 months). Primary outcomes Pembrolizumab probably reduces the risk of death from any cause (hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.59 to 0.90; moderate certainty evidence). This corresponds to 115 fewer deaths (191 fewer to 38 fewer) per 1000 participants with pembrolizumab at 12 months. We downgraded the certainty of evidence one level for imprecision. Pembrolizumab may slightly improve quality of life (change from baseline to week 15 assessed with the Core Quality of Life Questionnaire; higher value reflects better quality of life; scale 0 to 100) with a mean difference (MD) of 9.05, 95% CI 4.61 to 13.50; low certainty evidence). We downgraded the certainty of evidence two levels for study limitations and imprecision. Secondary outcomes Pembrolizumab may have little or no effect on disease progression (HR 0.98, 95% CI 0.81 to 1.19; low certainty evidence). This corresponds to three fewer patients (42 fewer to 24 more) whose disease progressed per 1000 participants at 12 months. We downgraded the certainty of evidence two levels for study limitations and imprecision. Pembrolizumab probably improves treatment response (based on complete or partial radiologic response) with a risk ratio (RR) of 1.85, 95% CI 1.24 to 2.77; moderate certainty evidence). This corresponds to 97 more respondents (27 more to 202 more) per 1000 participants with pembrolizumab. We downgraded the certainty of evidence one level for imprecision. Pembrolizumab may have little or no effect on treatment‐related mortality (RR 0.96, 95% CI 0.24 to 3.79; low certainty evidence). This corresponds to one fewer (12 fewer to 44 more) treatment‐related deaths per 1000 participants with pembrolizumab. We downgraded the certainty of evidence two levels for study limitations and imprecision. Pembrolizumab may have little or no effect on discontinuations due to adverse events (RR 0.66, 95% CI 0.39 to 1.10). This corresponds to 54 fewer discontinuations per 1000 participants (95% CI 79 fewer to 7 more). We downgraded the certainty of evidence for study limitations and imprecision. Pembrolizumab may reduce serious adverse events (RR 0.83, 95 CI 0.72 to 0.97; low certainty evidence). This corresponds to 107 fewer serious averse events per 1000 participants (95% CI 19 fewer to 176 fewer). We downgraded two levels for study limitations and imprecision. Authors' conclusions The use of pembrolizumab in men with advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy probably improves overall survival when compared with chemotherapy alone. At 12 months follow‐up about 70% of those in the chemotherapy group had died, compared with 59% of those treated with pembrolizumab. We are very uncertain about the effects of pembolizumab on quality of life. Pembolizumab may also improve treatment response rates, and reduce the risk of serious adverse events, but may make little or no difference to discontinuations of treatment due to adverse events. These conclusions are based on a single trial that was sponsored by the producer of pembrolizumab. Plain language summary Pembrolizumab versus chemotherapy for treating advanced bladder cancer after recurrence/progression following platinum‐based chemotherapy Review question How does pembrolizumab (a newer medicine that works through the body's immune system) compare to chemotherapy in patients with cancer of the inner lining of the urinary system, called urothelial cancer, that has either come back or worsened after treatment? Background Medications that target the body's immune system have been used for a long time to treat urothelial cancer. When the cancer has spread to other organs outside the urinary tract, patients are often treated with chemotherapy using medicines called cisplatin or carboplatin (platinum‐containing chemotherapy). However, often the cancer comes back or becomes worse despite treatment. This review considers the evidence for pembrolizumab, which is a member of a new class of medications that work through the immune sytem, and compares it to chemotherapy. Study characteristics We considered only randomised controlled trials in this Cochrane Rapid Review, as they offer the most reliable results. This review is current to 20 June 2018. Key results We found only one randomised study for our question. Participants included in this trial had metastatic (cancer that has spread to other parts of the body) or advanced cancer that could not be removed by surgery, that had come back or worsened with other chemotherapy. We found that pembrolizumab probably improves overall survival a little (evidence of moderate certainty). It may improve quality of life slightly (low certainty evidence). Pembrolizumab may have little or not effect on the time for the cancer to worsen or advance (low certainty evidence). It probably improves treatment response as seen on X‐ray scans such as computer tomography (moderate certainty of evidence). Pembrolizumab may have little or no effect on deaths resulting from the treatment itself (low certainty evidence) but may result in fewer patients stopping treatment due to unwanted side effects (low certainty evidence). It may also cause less serious side effects. These conclusions are based on a single trial paid for by the company that makes pembrolizumab. Certainty of evidence The certainty of evidence ranged from moderate to very low.}, -DOI = {10.1002/14651858.CD012838.pub2}, -keywords = {Antibodies, Monoclonal, Humanized [adverse effects, *therapeutic use]; Antineoplastic Agents, Immunological [adverse effects, *therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; Carcinoma [*drug therapy, pathology]; Disease Progression; Docetaxel; Humans; Paclitaxel [administration & dosage]; Quality of Life; Taxoids [administration & dosage]; Urinary Bladder Neoplasms [*drug therapy, pathology]; Vinblastine [administration & dosage, analogs & derivatives]}, -URL = {http://dx.doi.org/10.1002/14651858.CD012838.pub2} -} - - -Record #34 of 54 -@article{Valipour12, -author = {Valipour, A, Jäger, M, Wu, P, Schmitt, J, Bunch, C, and Weberschock, T}, -title = {Interventions for mycosis fungoides}, -journal = {Cochrane Database of Systematic Reviews}, -number = {7}, -year = {2020}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Mycosis fungoides (MF) is the most common type of cutaneous T‐cell lymphoma, a malignant, chronic disease initially affecting the skin. Several therapies are available, which may induce clinical remission for a time. This is an update of a Cochrane Review first published in 2012: we wanted to assess new trials, some of which investigated new interventions. Objectives To assess the effects of interventions for MF in all stages of the disease. Search methods We updated our searches of the following databases to May 2019: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We searched 2 trials registries for additional references. For adverse event outcomes, we undertook separate searches in MEDLINE in April, July and November 2017. Selection criteria Randomised controlled trials (RCTs) of local or systemic interventions for MF in adults with any stage of the disease compared with either another local or systemic intervention or with placebo. Data collection and analysis We used standard methodological procedures expected by Cochrane. The primary outcomes were improvement in health‐related quality of life as defined by participants, and common adverse effects of the treatments. Key secondary outcomes were complete response (CR), defined as complete disappearance of all clinical evidence of disease, and objective response rate (ORR), defined as proportion of patients with a partial or complete response. We used GRADE to assess the certainty of evidence and considered comparisons of psoralen plus ultraviolet A (PUVA) light treatment as most important because this is first‐line treatment for MF in most guidelines. Main results This review includes 20 RCTs (1369 participants) covering a wide range of interventions. The following were assessed as either treatments or comparators: imiquimod, peldesine, hypericin, mechlorethamine, nitrogen mustard and intralesional injections of interferon‐α (IFN‐α) (topical applications); PUVA, extracorporeal photopheresis (ECP: photochemotherapy), and visible light (light applications); acitretin, bexarotene, lenalidomide, methotrexate and vorinostat (oral agents); brentuximab vedotin; denileukin diftitox; mogamulizumab; chemotherapy with cyclophosphamide, doxorubicin, etoposide, and vincristine; a combination of chemotherapy with electron beam radiation; subcutaneous injection of IFN‐α; and intramuscular injections of active transfer factor (parenteral systemics). Thirteen trials used an active comparator, five were placebo‐controlled, and two compared an active operator to observation only. In 14 trials, participants had MF in clinical stages IA to IIB. All participants were treated in secondary and tertiary care settings, mainly in Europe, North America or Australia. Trials recruited both men and women, with more male participants overall. Trial duration varied from four weeks to 12 months, with one longer‐term study lasting more than six years. We judged 16 trials as at high risk of bias in at least one domain, most commonly performance bias (blinding of participants and investigators), attrition bias and reporting bias. None of our key comparisons measured quality of life, and the two studies that did presented no usable data. Eighteen studies reported common adverse effects of the treatments. Adverse effects ranged from mild symptoms to lethal complications depending upon the treatment type. More aggressive treatments like systemic chemotherapy generally resulted in more severe adverse effects. In the included studies, CR rates ranged from 0% to 83% (median 31%), and ORR ranged from 0% to 88% (median 47%). Five trials assessed PUVA treatment, alone or combined, summarised below. There may be little to no difference between intralesional IFN‐α and PUVA compared with PUVA alone for 24 to 52 weeks in CR (risk ratio (RR) 1.07, 95% confidence interval (CI) 0.87 to 1.31; 2 trials; 122 participants; low‐certainty evidence). Common adverse events and ORR were not measured. One small cross‐over trial found once‐monthly ECP for six months may be less effective than twice‐weekly PUVA for three months, reporting CR in two of eight participants and ORR in six of eight participants after PUVA, compared with no CR or ORR after ECP (very low‐certainty evidence). Some participants reported mild nausea after PUVA but no numerical data were given. One participant in the ECP group withdrew due to hypotension. However, we are unsure of the results due to very low‐certainty evidence. One trial comparing bexarotene plus PUVA versus PUVA alone for up to 16 weeks reported one case of photosensitivity in the bexarotene plus PUVA group compared to none in the PUVA‐alone group (87 participants; low‐certainty evidence). There may be little to no difference between bexarotene plus PUVA and PUVA alone in CR (RR 1.41, 95% CI 0.71 to 2.80) and ORR (RR 0.94, 95% CI 0.61 to 1.44) (93 participants; low‐certainty evidence). One trial comparing subcutaneous IFN‐α injections combined with either acitretin or PUVA for up to 48 weeks or until CR indicated there may be little to no difference in the common IFN‐α adverse effect of flu‐like symptoms (RR 1.32, 95% CI 0.92 to 1.88; 82 participants). There may be lower CR with IFN‐α and acitretin compared with IFN‐α and PUVA (RR 0.54, 95% CI 0.35 to 0.84; 82 participants) (both outcomes: low‐certainty evidence). This trial did not measure ORR. One trial comparing PUVA maintenance treatment to no maintenance treatment, in participants who had already had CR, did report common adverse effects. However, the distribution was not evaluable. CR and OR were not assessable. The range of treatment options meant that rare adverse effects consequently occurred in a variety of organs. Authors' conclusions ​ ​There is a lack of high‐certainty evidence to support decision making in the treatment of MF. Because of substantial heterogeneity in design, missing data, small sample sizes, and low methodological quality, the comparative safety and efficacy of these interventions cannot be reliably established on the basis of the included RCTs. PUVA is commonly recommended as first‐line treatment for MF, and we did not find evidence to challenge this recommendation. There was an absence of evidence to support the use of intralesional IFN‐α or bexarotene in people receiving PUVA and an absence of evidence to support the use of acitretin or ECP for treating MF. Future trials should compare the safety and efficacy of treatments to PUVA, as the current standard of care, and should measure quality of life and common adverse effects. Plain language summary Treatments for mycosis fungoides (a malignant cancerous condition of immune cells in the blood that affects the skin) What was the aim of this review? This Cochrane Review compared treatments for mycosis fungoides (also called cutaneous T‐cell lymphoma, Alibert‐Bazin syndrome or granuloma fungoides). What was studied in the review? Mycosis fungoides (MF) typically starts as flat and scaly pink or red areas (patches) on the torso, upper thighs or buttocks. At this stage, life expectancy is unaffected. As the disease develops, life expectancy reduces. Patches can turn into raised, itchy plaques. Plaques can become thicker, deeper, and develop into tumours. In rare cases, the disease spreads to other organs. Many treatments exist for MF; these target specific body areas (local therapy) or the entire body (systemic therapy). Treatments include creams, ointments, oral or injected medicines, light therapy, radiotherapy (radiation that kills cancer cells) and chemotherapy (medicines that kill cancer cells). We compared the benefits and harms of different treatments in adults, at different disease stages. We identified 20 studies published up to May 2019. The studies included 1369, mainly male, adults. Most ran from 4 weeks to 12 months. Only five studies investigated the later stages of disease. All were set in specialised healthcare centres in Europe (12 studies), North America (11 studies), Australia (three studies), Brazil and Japan (one study each; satellite centres for studies already listed). Treatments were compared with another treatment (13 studies); an inactive treatment (placebo) (five studies); or no treatment (two studies). Five studies did not report their funding. Eleven studies were funded by pharmaceutical companies and four by academic institutions or hospitals. Key results We do not know how different treatments for MF affect quality of life. Very few studies assessed this outcome and they presented no usable data. Unwanted (adverse) effects ranged from mild symptoms to severe life‐threatening complications. More aggressive treatments (such as chemotherapy) generally caused more severe adverse effects. PUVA (a light treatment) is the first treatment used for MF. Results from five studies provided low‐certainty evidence: There may be little to no difference between giving PUVA alone and PUVA plus injected interferon‐α (IFN‐ α) (a messenger substance of the immune system) for 24 to 52 weeks for making the disease disappear completely. No studies investigated adverse events in these treatments or disappearance of at least 50% of the disease. There may be little to no difference between an oral vitamin A derivative (bexarotene) plus PUVA, and PUVA alone, for complete or at least 50% disease disappearance (treatment duration: up to 16 weeks). Extreme sensitivity to ultraviolet (UV) rays occurred in some people who received bexarotene and PUVA, but not PUVA alone. There may be little to no difference between IFN‐ α plus PUVA and IFN‐α plus acitretin (another oral vitamin A derivative) on flu‐like symptoms, when treatment is given for up to 48 weeks or until complete disease disappearance. However, there may be a lower rate of complete disease disappearance with IFN‐α plus acitretin. No studies investigated the effect on partial disappearance. It is not clear how PUVA maintenance treatment (to prevent the disease from reappearing after it has disappeared) compares with no maintenance treatment, since the only study on this reported very limited information. One small trial (eight people) compared extracorporeal photopheresis (ECP, a light therapy) once monthly for six months with twice‐weekly PUVA for three months. It reported complete or at least 50% disappearance of MF in some participants treated with PUVA and none who received ECP. Common side effects were reported with each treatment (PUVA may be associated with mild nausea, and ECP with hypotension). However, the very‐low certainty evidence means we are not sure of these results. How confident are we in the results of this review? Our confidence in the results of this review is mainly low, but very low for one set of key results. The review is based on small and poorly designed studies. Further research is likely to change its message. Conclusion We found no evidence to challenge or support the standard treatment (PUVA). In the absence of a cure, treatment of MF should be based on disease stage, with a focus on limiting severe adverse effects.}, -DOI = {10.1002/14651858.CD008946.pub3}, -keywords = {Acitretin [adverse effects, therapeutic use]; Antineoplastic Agents [administration & dosage, adverse effects]; Bexarotene [therapeutic use]; Combined Modality Therapy [methods]; Humans; Immunologic Factors [therapeutic use]; Interferon-alpha [therapeutic use]; Mycosis Fungoides [pathology, *therapy]; Neoplasm Staging [methods]; PUVA Therapy [methods]; Photochemotherapy [methods]; Photopheresis [methods]; Randomized Controlled Trials as Topic; Skin Neoplasms [pathology, *therapy]}, -URL = {http://dx.doi.org/10.1002/14651858.CD008946.pub3} -} - - -Record #35 of 54 -@article{Aldin19, -author = {Aldin, A, Umlauff, L, Estcourt, LJ, Collins, G, Moons, KG, Engert, A, Kobe, C, von Tresckow, B, Haque, M, Foroutan, F, Kreuzberger, N, Trivella, M, and Skoetz, N}, -title = {Interim PET‐results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta‐analysis of prognostic factor studies}, -journal = {Cochrane Database of Systematic Reviews}, -number = {1}, -year = {2020}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Hodgkin lymphoma (HL) is one of the most common haematological malignancies in young adults and, with cure rates of 90%, has become curable for the majority of individuals. Positron emission tomography (PET) is an imaging tool used to monitor a tumour’s metabolic activity, stage and progression. Interim PET during chemotherapy has been posited as a prognostic factor in individuals with HL to distinguish between those with a poor prognosis and those with a better prognosis. This distinction is important to inform decision‐making on the clinical pathway of individuals with HL. Objectives To determine whether in previously untreated adults with HL receiving first‐line therapy, interim PET scan results can distinguish between those with a poor prognosis and those with a better prognosis, and thereby predict survival outcomes in each group. Search methods We searched MEDLINE, Embase, CENTRAL and conference proceedings up until April 2019. We also searched one trial registry ( ClinicalTrials.gov ). Selection criteria We included retrospective and prospective studies evaluating interim PET scans in a minimum of 10 individuals with HL (all stages) undergoing first‐line therapy. Interim PET was defined as conducted during therapy (after one, two, three or four treatment cycles). The minimum follow‐up period was at least 12 months. We excluded studies if the trial design allowed treatment modification based on the interim PET scan results. Data collection and analysis We developed a data extraction form according to the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS). Two teams of two review authors independently screened the studies, extracted data on overall survival (OS), progression‐free survival (PFS) and PET‐associated adverse events (AEs), assessed risk of bias (per outcome) according to the Quality in Prognosis Studies (QUIPS) tool, and assessed the certainty of the evidence (GRADE). We contacted investigators to obtain missing information and data. Main results Our literature search yielded 11,277 results. In total, we included 23 studies (99 references) with 7335 newly‐diagnosed individuals with classic HL (all stages). Participants in 16 studies underwent (interim) PET combined with computed tomography (PET‐CT), compared to PET only in the remaining seven studies. The standard chemotherapy regimen included ABVD (16) studies, compared to BEACOPP or other regimens (seven studies). Most studies (N = 21) conducted interim PET scans after two cycles (PET2) of chemotherapy, although PET1, PET3 and PET4 were also reported in some studies. In the meta‐analyses, we used PET2 data if available as we wanted to ensure homogeneity between studies. In most studies interim PET scan results were evaluated according to the Deauville 5‐point scale (N = 12). Eight studies were not included in meta‐analyses due to missing information and/or data; results were reported narratively. For the remaining studies, we pooled the unadjusted hazard ratio (HR). The timing of the outcome measurement was after two or three years (the median follow‐up time ranged from 22 to 65 months) in the pooled studies. Eight studies explored the independent prognostic ability of interim PET by adjusting for other established prognostic factors (e.g. disease stage, B symptoms). We did not pool the results because the multivariable analyses adjusted for a different set of factors in each study. Overall survival Twelve (out of 23) studies reported OS. Six of these were assessed as low risk of bias in all of the first four domains of QUIPS (study participation, study attrition, prognostic factor measurement and outcome measurement). The other six studies were assessed as unclear, moderate or high risk of bias in at least one of these four domains. Four studies were assessed as low risk, and eight studies as high risk of bias for the domain other prognostic factors (covariates). Nine studies were assessed as low risk, and three studies as high risk of bias for the domain 'statistical analysis and reporting'. We pooled nine studies with 1802 participants. Participants with HL who have a negative interim PET scan result probably have a large advantage in OS compared to those with a positive interim PET scan result (unadjusted HR 5.09, 95% confidence interval (CI) 2.64 to 9.81, I² = 44%, moderate‐certainty evidence). In absolute values, this means that 900 out of 1000 participants with a negative interim PET scan result will probably survive longer than three years compared to 585 (95% CI 356 to 757) out of 1000 participants with a positive result. Adjusted results from two studies also indicate an independent prognostic value of interim PET scan results (moderate‐certainty evidence). Progression‐free survival Twenty‐one studies reported PFS. Eleven out of 21 were assessed as low risk of bias in the first four domains. The remaining were assessed as unclear, moderate or high risk of bias in at least one of the four domains. Eleven studies were assessed as low risk, and ten studies as high risk of bias for the domain other prognostic factors (covariates). Eight studies were assessed as high risk, thirteen as low risk of bias for statistical analysis and reporting. We pooled 14 studies with 2079 participants. Participants who have a negative interim PET scan result may have an advantage in PFS compared to those with a positive interim PET scan result, but the evidence is very uncertain (unadjusted HR 4.90, 95% CI 3.47 to 6.90, I² = 45%, very low‐certainty evidence). This means that 850 out of 1000 participants with a negative interim PET scan result may be progression‐free longer than three years compared to 451 (95% CI 326 to 569) out of 1000 participants with a positive result. Adjusted results (not pooled) from eight studies also indicate that there may be an independent prognostic value of interim PET scan results (low‐certainty evidence). PET‐associated adverse events No study measured PET‐associated AEs. Authors' conclusions This review provides moderate‐certainty evidence that interim PET scan results predict OS, and very low‐certainty evidence that interim PET scan results predict progression‐free survival in treated individuals with HL. This evidence is primarily based on unadjusted data. More studies are needed to test the adjusted prognostic ability of interim PET against established prognostic factors. Plain language summary Imaging with positron emission tomography (PET) during chemotherapy to predict outcome in adults with Hodgkin lymphoma Review question This Cochrane Review aimed to find out whether the results of a positron emission tomography (PET) during therapy in people with Hodgkin lymphoma (HL) can help to distinguish between those with a poor prognosis and those with a better prognosis, and predict survival outcomes in each group. Background Hodgkin lymphoma is a cancer which affects the lymphoid system of the body. It is considered a relatively rare disease (two to three cases per 100,000 people every year in Western countries), that is most common in young adults in their twenties, but it can also occur in children and elderly people. As treatment options have improved, most people with HL can now be cured. It is important that individuals receive the treatment with the greatest efficacy and least toxicity possible. PET is an imaging tool for assessing the disease stage of an individual, and monitoring tumour activity. It has been suggested that PET performed during therapy (so‐called interim PET, e.g. after two cycles of chemotherapy) can distinguish between people who respond well to therapy and those who do not respond well. The aim of this review was to demonstrate the prognostic ability to distinguish between these groups, and predict survival outcomes in each group, to help clinicians make an informed decision on the treatment pathway to improve long‐term outcomes and safety for people with HL. Study characteristics We included 23 studies to explore the association between interim PET scan results after one to four cycles of chemotherapy and survival outcomes in adults with HL (all stages). We contacted 10 authors, and six provided us with relevant information and/or data. Key results In 16 included studies, participants received either ABVD chemotherapy or BEACOPP chemotherapy (four studies) only, with or without radiotherapy. In 16 studies, participants underwent an interim PET scan in combination with a computed tomography (CT) (PET‐CT), which have higher accuracy in detecting primary and secondary cancers than a PET scan alone. In the remaining seven studies, PET‐only was conducted. Twenty‐one studies conducted interim PET scans after two cycles (PET2) of chemotherapy. Eight studies did not report enough data on our outcomes or population of interest, so we reported the results from these studies narratively. We combined individual study results in meta‐analyses to provide robust evidence for our outcomes of interest overall survival and progression‐free survival. No study measured PET‐associated adverse events (harms). For overall survival, combined results from nine studies (1802 participants) show that there is probably a large advantage in overall survival for people with a negative interim PET scan compared to people with a positive interim PET scan. For progression‐free survival, combined results from 14 studies (2079 participants) show that interim PET‐negative people may have an advantage for progression‐free survival, compared to interim PET‐positive people, but we are uncertain about this result. These are unadjusted results, where interim PET was tested as the only prognostic factor. Eight studies reported adjusted results, where the independent prognostic ability of interim PET was assessed against other established prognostic factors (e.g. disease stage, B symptoms). We could not combine individual study results because the studies did not include identical sets of covariates. Nevertheless, their results indicate a probable independent prognostic ability of interim PET to predict both outcomes. Certainty of the evidence Regarding the unadjusted results, we rated our certainty of the evidence as 'moderate' for overall survival. This means that the true effect is likely to be close to the estimated effect, but there is a possibility that it is substantially different. For progression‐free survival, we rated our certainty of the evidence as 'very low', meaning that we have little confidence in the effect estimate, and that the true effect is likely to be substantially different from the estimated effect. Regarding the adjusted results, we rated our certainty of the evidence as 'moderate' for overall survival, and 'low' for progression‐free survival. How up‐to‐date is this review? We searched data bases up until 2 April 2019, and one trial registry on 25 January 2019.}, -DOI = {10.1002/14651858.CD012643.pub3}, -keywords = {Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Chemoradiotherapy; Decision Making; Disease Progression; Disease-Free Survival; Hodgkin Disease [*drug therapy]; Humans; Positron Emission Tomography Computed Tomography [*methods]; Prognosis; Young Adult}, -URL = {http://dx.doi.org/10.1002/14651858.CD012643.pub3} -} - - -Record #36 of 54 -@article{Chin18, -author = {Chin, V, Nagrial, A, Sjoquist, K, O'Connor, CA, Chantrill, L, Biankin, AV, Scholten, RJPM, and Yip, D}, -title = {Chemotherapy and radiotherapy for advanced pancreatic cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {3}, -year = {2018}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Pancreatic cancer (PC) is a highly lethal disease with few effective treatment options. Over the past few decades, many anti‐cancer therapies have been tested in the locally advanced and metastatic setting, with mixed results. This review attempts to synthesise all the randomised data available to help better inform patient and clinician decision‐making when dealing with this difficult disease. Objectives To assess the effect of chemotherapy, radiotherapy or both for first‐line treatment of advanced pancreatic cancer. Our primary outcome was overall survival, while secondary outcomes include progression‐free survival, grade 3/4 adverse events, therapy response and quality of life. Search methods We searched for published and unpublished studies in CENTRAL (searched 14 June 2017), Embase (1980 to 14 June 2017), MEDLINE (1946 to 14 June 2017) and CANCERLIT (1999 to 2002) databases. We also handsearched all relevant conference abstracts published up until 14 June 2017. Selection criteria All randomised studies assessing overall survival outcomes in patients with advanced pancreatic ductal adenocarcinoma. Chemotherapy and radiotherapy, alone or in combination, were the eligible treatments. Data collection and analysis Two review authors independently analysed studies, and a third settled any disputes. We extracted data on overall survival (OS), progression‐free survival (PFS), response rates, adverse events (AEs) and quality of life (QoL), and we assessed risk of bias for each study. Main results We included 42 studies addressing chemotherapy in 9463 patients with advanced pancreatic cancer. We did not identify any eligible studies on radiotherapy. We did not find any benefit for chemotherapy over best supportive care. However, two identified studies did not have sufficient data to be included in the analysis, and many of the chemotherapy regimens studied were outdated. Compared to gemcitabine alone, participants receiving 5FU had worse OS (HR 1.69, 95% CI 1.26 to 2.27, moderate‐quality evidence), PFS (HR 1.47, 95% CI 1.12 to 1.92) and QoL. On the other hand, two studies showed FOLFIRINOX was better than gemcitabine for OS (HR 0.51 95% CI 0.43 to 0.60, moderate‐quality evidence), PFS (HR 0.46, 95% CI 0.38 to 0.57) and response rates (RR 3.38, 95% CI 2.01 to 5.65), but it increased the rate of side effects. The studies evaluating CO‐101, ZD9331 and exatecan did not show benefit or harm when compared with gemcitabine alone. Giving gemcitabine at a fixed dose rate improved OS (HR 0.79, 95% CI 0.66 to 0.94, high‐quality evidence) but increased the rate of side effects when compared with bolus dosing. When comparing gemcitabine combinations to gemcitabine alone, gemcitabine plus platinum improved PFS (HR 0.80, 95% CI 0.68 to 0.95) and response rates (RR 1.48, 95% CI 1.11 to 1.98) but not OS (HR 0.94, 95% CI 0.81 to 1.08, low‐quality evidence). The rate of side effects increased. Gemcitabine plus fluoropyrimidine improved OS (HR 0.88, 95% CI 0.81 to 0.95), PFS (HR 0.79, 95% CI 0.72 to 0.87) and response rates (RR 1.78, 95% CI 1.29 to 2.47, high‐quality evidence), but it also increased side effects. Gemcitabine plus topoisomerase inhibitor did not improve survival outcomes but did increase toxicity. One study demonstrated that gemcitabine plus nab‐paclitaxel improved OS (HR 0.72, 95% CI 0.62 to 0.84, high‐quality evidence), PFS (HR 0.69, 95% CI 0.58 to 0.82) and response rates (RR 3.29, 95% CI 2.24 to 4.84) but increased side effects. Gemcitabine‐containing multi‐drug combinations (GEMOXEL or cisplatin/epirubicin/5FU/gemcitabine) improved OS (HR 0.55, 95% CI 0.39 to 0.79, low‐quality evidence), PFS (HR 0.43, 95% CI 0.30 to 0.62) and QOL. We did not find any survival advantages when comparing 5FU combinations to 5FU alone. Authors' conclusions Combination chemotherapy has recently overtaken the long‐standing gemcitabine as the standard of care. FOLFIRINOX and gemcitabine plus nab‐paclitaxel are highly efficacious, but our analysis shows that other combination regimens also offer a benefit. Selection of the most appropriate chemotherapy for individual patients still remains difficult, with clinicopathological stratification remaining elusive. Biomarker development is essential to help rationalise treatment selection for patients. Plain language summary The effects of anti‐cancer therapies on advanced pancreatic cancer Review question This review aimed to answer the question, which therapies are the most effective for advanced pancreatic cancer? Background Pancreatic cancer (PC) is a serious, often fatal disease, and many people are not diagnosed until they have advanced tumours that cannot be removed with surgery. Symptoms include abdominal pain, weight loss, and yellowing of the skin and eyes. Up until recently, gemcitabine was the standard drug for treating advanced pancreatic cancer, but this gave people only a modest benefit. Study characteristics We looked for all studies in people with pancreatic cancer that could not be operated on (locally advanced) or that had already spread beyond the pancreas (metastatic). We found 42 clinical studies involving 9463 participants who were receiving their first therapy for PC. Our search is current to June 2017. The studies compared one therapy against either best supportive care (symptom management only) or another type of therapy. Studies had to evaluate overall survival (or time to death). The study could be testing either chemotherapy (drugs that kill or slow the growth of cancer cells) or radiotherapy (X‐ray treatment). We collected data on survival, tumour response rate, side effects and quality of life. The results of clinical studies addressing targeted/biological therapies, immunotherapies, second‐line therapies and local treatments for locally advanced disease will be reported in a separate Cochrane Review. Key results This review has shown that in advanced disease, combination chemotherapy with FOLFIRINOX (5‐fluorouracil, irinotecan, oxaliplatin combination); GEMOXEL (gemcitabine, oxaliplatin and capecitabine); cisplatin/epirubicin/5FU/gemcitabine; gemcitabine plus nab‐paclitaxel; and gemcitabine plus a fluoropyrimidine agent, provide a survival advantage over gemcitabine alone. These combinations do increase side effects. Gemcitabine given slowly using a fixed rate of infusion may be more effective than giving it in the standard way, which is quickly over 30 minutes. Quality of the evidence The quality of the evidence varied greatly amongst comparisons. The highest quality evidence was for gemcitabine versus fixed dose rate gemcitabine and some of the gemcitabine combinations (fluoropyrimidine, topoisomerase, and taxane). We judged the studies for quality using factors like how well they were conducted, how well they reported results and whether they used a placebo.}, -DOI = {10.1002/14651858.CD011044.pub2}, -keywords = {Albumins [administration & dosage]; Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Cisplatin [administration & dosage]; Deoxycytidine [administration & dosage, adverse effects, analogs & derivatives]; Epirubicin [administration & dosage]; Fluorouracil [administration & dosage]; Humans; Paclitaxel [administration & dosage]; Pancreatic Neoplasms [*drug therapy, mortality, pathology, radiotherapy]; Pyrimidines [administration & dosage]; Randomized Controlled Trials as Topic; Treatment Outcome}, -URL = {http://dx.doi.org/10.1002/14651858.CD011044.pub2} -} - - -Record #37 of 54 -@article{Ngoi22, -author = {Ngoi, NYL, Syn, NLX, Goh, RM, Goh, BC, Huang, RYun-Ju, Soon, YY, James, E, Cook, A, Clamp, A, and Tan, DSP}, -title = {Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {2}, -year = {2022}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Epithelial ovarian cancer is the sixth most common cancer worldwide: 295,414 new cases were diagnosed in 2018, with 184,799 deaths. The lack of an effective screening strategy has led to the majority of women being diagnosed at an advanced stage. For these women, intravenous carboplatin combined with paclitaxel for six cycles is widely accepted as the standard first‐line treatment for epithelial ovarian cancer, in combination with debulking surgery. However, there is conflicting evidence regarding the optimal dosing schedule of paclitaxel when combined with carboplatin in this setting. Objectives To compare the efficacy and tolerability of intravenous weekly paclitaxel with that of tri‐weekly paclitaxel, in combination with intravenous carboplatin, as first‐line treatment for epithelial ovarian cancer (defined as epithelial ovarian, primary peritoneal and fallopian tube cancer). Search methods We searched CENTRAL, MEDLINE, and Embase databases for relevant studies up to 15 November 2021, using keywords and MeSH terms. We additionally handsearched conference libraries, online clinical trial databases and screened through lists of retrieved references. Selection criteria We Included randomised controlled trials (RCTs) comparing weekly paclitaxel in combination with carboplatin versus tri‐weekly paclitaxel in combination with carboplatin, for treatment of newly‐diagnosed epithelial ovarian cancer. Data collection and analysis We used the hazard ratio (HR) to estimate the primary efficacy outcomes progression‐free (PFS) and overall survival (OS). We used the risk ratio (RR) to estimate the primary toxicity outcome of severe neutropenia and secondary outcomes of quality of life (QoL) and treatment‐related adverse events. Two review authors independently selected studies, extracted data, and assessed risk of bias, using standard Cochrane methodological procedures. We included individual participant data (IPD) from one of the included studies, ICON‐8, provided by the study team. We analysed data using a random‐effects model in Review Manager 5.4 software. Additionally, we reconstructed IPD for PFS and OS data from published Kaplan‐Meier curves from all studies and subsequently pooled these to analyse the two primary efficacy outcomes. Main results From 2469 records, we identified four eligible RCTs with data for 3699 participants. All eligible studies were included in the main meta‐analysis and reported on PFS and OS. There was likely a slight improvement in PFS when paclitaxel was dosed weekly compared to tri‐weekly (HR 0.89, 95% confidence interval (CI) 0.81 to 0.98; 4 studies, 3699 participants; moderate‐certainty evidence). We found little to no improvement in OS when paclitaxel was dosed weekly compared to tri‐weekly (HR 0.92, 95% CI 0.79 to 1.06; 4 studies, 3699 participants; high‐certainty evidence). There was likely little to no difference in high‐grade (grade 3 or 4) neutropenia when paclitaxel was dosed weekly compared to tri‐weekly (RR 1.11, 95% CI 0.86 to 1.43; 4 studies, 3639 participants; moderate‐certainty evidence). However, weekly paclitaxel increased high‐grade (grade 3 or 4) anaemia when compared to tri‐weekly dosing (RR 1.57, 95% CI 1.12 to 2.20; 4 studies, 3639 participants; high‐certainty evidence). There may be little to no difference in high‐grade neuropathy when paclitaxel was dosed weekly compared to tri‐weekly (RR 1.12, 95% CI 0.64 to 1.94; 4 studies, 3639 participants; low‐certainty evidence). The overall risk of detection bias and performance bias was low for OS, but was unclear for other outcomes, as treatments were not blinded. The risk of bias in other domains was low or unclear. We note that OS data were immature for three of the included studies (GOG‐0262, ICON‐8 and MITO‐7). Authors' conclusions Weekly paclitaxel combined with carboplatin for first‐line treatment of epithelial ovarian cancer likely improves PFS slightly (moderate‐certainty evidence) but not OS (high‐certainty evidence), compared to tri‐weekly paclitaxel combined with carboplatin. However, this was associated with increased risk for high‐grade anaemia, treatment discontinuation, dose delays and dose omissions (high‐ to low‐certainty evidence). Our findings may not apply to women receiving bevacizumab in first‐line therapy, those receiving treatment in the neo‐adjuvant setting, or those with rare subtypes of clear cell or mucinous ovarian cancer. Plain language summary Does weekly dosing of paclitaxel improve survival, compared with tri‐weekly dosing of paclitaxel in the initial treatment of ovarian cancer? Background 
Ovarian cancer is the sixth most common cancer worldwide. Treatment consists of a combination of surgery and chemotherapy (most commonly including paclitaxel and carboplatin), with the aim to reduce or delay the return of the cancer (known as progression‐free survival (PFS)), and improve chances for cancer survival (known as overall survival (OS)). Several clinical trials (studies) have investigated whether the dosing schedule (timing) of paclitaxel affects these outcomes. However, the results from reported studies are conflicting. The aim of the review 
We reviewed the evidence about the effect of different schedules of paclitaxel on survival in women with newly‐diagnosed ovarian cancer. Study characteristics 
The evidence is current up to 15 November 2021. We included four studies with a total of 3699 participants. All studies included were randomised controlled trials (clinical trials where people are randomly put into one of two or more treatment groups) of women aged 18 years or older with newly diagnosed ovarian cancer. The studies compared weekly versus tri‐weekly dosing of paclitaxel, plus carboplatin. Main findings 
We found that, compared with tri‐weekly paclitaxel dosing, weekly paclitaxel plus carboplatin likely slightly improves progression‐free survival, although results in little to no difference in overall survival (high‐certainty evidence). For adverse effects, we found that weekly paclitaxel plus carboplatin likely results in little to no difference in severe low neutrophil count (a type of white blood cell that helps to fight infections) (moderate‐certainty evidence); increases severe anaemia (haemoglobin level ‐ an important component of red blood cells) (high‐certainty evidence) and may result in little to no difference in severe damage to nerves (low‐certainty evidence). Conclusions 
Weekly dosing of paclitaxel likely prolongs progression‐free survival compared to tri‐weekly dosing of paclitaxel, when combined with carboplatin in the initial treatment of ovarian cancer. However, this does not improve overall survival.}, -DOI = {10.1002/14651858.CD012007.pub2}, -keywords = {*Ovarian Neoplasms [surgery]; *Paclitaxel [adverse effects]; Bevacizumab [therapeutic use]; Carboplatin [adverse effects]; Carcinoma, Ovarian Epithelial [drug therapy, surgery]; Female; Humans}, -URL = {http://dx.doi.org/10.1002/14651858.CD012007.pub2} -} - - -Record #38 of 54 -@article{Wagner05, -author = {Wagner, AD, Syn, NLX, Moehler, M, Grothe, W, Yong, WP, Tai, BC, Ho, J, and Unverzagt, S}, -title = {Chemotherapy for advanced gastric cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {8}, -year = {2017}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Gastric cancer is the fifth most common cancer worldwide. In "Western" countries, most people are either diagnosed at an advanced stage, or develop a relapse after surgery with curative intent. In people with advanced disease, significant benefits from targeted therapies are currently limited to HER‐2 positive disease treated with trastuzumab, in combination with chemotherapy, in first‐line. In second‐line, ramucirumab, alone or in combination with paclitaxel, demonstrated significant survival benefits. Thus, systemic chemotherapy remains the mainstay of treatment for advanced gastric cancer. Uncertainty remains regarding the choice of the regimen. Objectives To assess the efficacy of chemotherapy versus best supportive care (BSC), combination versus single‐agent chemotherapy and different chemotherapy combinations in advanced gastric cancer. Search methods We searched the Cochrane Central Register of Controlled Trials, MEDLINE and Embase up to June 2016, reference lists of studies, and contacted pharmaceutical companies and experts to identify randomised controlled trials (RCTs). Selection criteria We considered only RCTs on systemic, intravenous or oral chemotherapy versus BSC, combination versus single‐agent chemotherapy and different chemotherapy regimens in advanced gastric cancer. Data collection and analysis Two review authors independently identified studies and extracted data. A third investigator was consulted in case of disagreements. We contacted study authors to obtain missing information. Main results We included 64 RCTs, of which 60 RCTs (11,698 participants) provided data for the meta‐analysis of overall survival. We found chemotherapy extends overall survival (OS) by approximately 6.7 months more than BSC (hazard ratio (HR) 0.3, 95% confidence intervals (CI) 0.24 to 0.55, 184 participants, three studies, moderate‐quality evidence). Combination chemotherapy extends OS slightly (by an additional month) versus single‐agent chemotherapy (HR 0.84, 95% CI 0.79 to 0.89, 4447 participants, 23 studies, moderate‐quality evidence), which is partly counterbalanced by increased toxicity. The benefit of epirubicin in three‐drug combinations, in which cisplatin is replaced by oxaliplatin and 5‐FU is replaced by capecitabine is unknown. Irinotecan extends OS slightly (by an additional 1.6 months) versus non‐irinotecan‐containing regimens (HR 0.87, 95% CI 0.80 to 0.95, 2135 participants, 10 studies, high‐quality evidence). Docetaxel extends OS slightly (just over one month) compared to non‐docetaxel‐containing regimens (HR 0.86, 95% CI 0.78 to 0.95, 2001 participants, eight studies, high‐quality evidence). However, due to subgroup analyses, we are uncertain whether docetaxel‐containing combinations (docetaxel added to a single‐agent or two‐drug combination) extends OS due to moderate‐quality evidence (HR 0.80, 95% CI 0.71 to 0.91, 1466 participants, four studies, moderate‐quality evidence). When another chemotherapy was replaced by docetaxel, there is probably little or no difference in OS (HR 1.05; 0.87 to 1.27, 479 participants, three studies, moderate‐quality evidence). We found there is probably little or no difference in OS when comparing capecitabine versus 5‐FU‐containing regimens (HR 0.94, 95% CI 0.79 to 1.11, 732 participants, five studies, moderate‐quality evidence) . Oxaliplatin may extend (by less than one month) OS versus cisplatin‐containing regimens (HR 0.81, 95% CI 0.67 to 0.98, 1105 participants, five studies, low‐quality evidence). We are uncertain whether taxane‐platinum combinations with (versus without) fluoropyrimidines extend OS due to very low‐quality evidence (HR 0.86, 95% CI 0.71 to 1.06, 482 participants, three studies, very low‐quality evidence). S‐1 regimens improve OS slightly (by less than an additional month) versus 5‐FU‐containing regimens (HR 0.91, 95% CI 0.83 to 1.00, 1793 participants, four studies, high‐quality evidence), however since S‐1 is used in different doses and schedules between Asian and non‐Asian population, the applicability of this finding to individual populations is uncertain. Authors' conclusions Chemotherapy improves survival (by an additional 6.7 months) in comparison to BSC, and combination chemotherapy improves survival (by an additional month) compared to single‐agent 5‐FU. Testing all patients for HER‐2 status may help to identify patients with HER‐2‐positive tumours, for whom, in the absence of contraindications, trastuzumab in combination with capecitabine or 5‐FU in combination with cisplatin has been shown to be beneficial. For HER‐2 negative people, all different two‐and three‐drug combinations including irinotecan, docetaxel, oxaliplatin or oral 5‐FU prodrugs are valid treatment options for advanced gastric cancer, and consideration of the side effects of each regimen is essential in the treatment decision. Irinotecan‐containing combinations and docetaxel‐containing combinations (in which docetaxel was added to a single‐agent or two‐drug (platinum/5‐FUcombination) show significant survival benefits in the comparisons studied above. Furthermore, docetaxel‐containing three‐drug regimens have increased response rates, but the advantages of the docetaxel‐containing three‐drug combinations (DCF, FLO‐T) are counterbalanced by increased toxicity. Additionally, oxaliplatin‐containing regimens demonstrated a benefit in OS as compared to the same regimen containing cisplatin, and there is a modest survival improvement of S‐1 compared to 5‐FU‐containing regimens. Whether the survival benefit for three‐drug combinations including cisplatin, 5‐FU, and epirubicin as compared to the same regimen without epirubicin is still valid when second‐line therapy is routinely administered and when cisplatin is replaced by oxaliplatin and 5‐FU by capecitabine is questionable. Furthermore, the magnitude of the observed survival benefits for the three‐drug regimens is not large enough to be clinically meaningful as defined recently by the American Society for Clinical Oncology ( Ellis 2014 ). In contrast to the comparisons in which a survival benefit was observed by adding a third drug to a two‐drug regimen at the cost of increased toxicity, the comparison of regimens in which another chemotherapy was replaced by irinotecan was associated with a survival benefit (of borderline statistical significance), but without increased toxicity. For this reason irinotecan/5‐FU‐containing combinations are an attractive option for first‐line treatment. Although they need to be interpreted with caution, subgroup analyses of one study suggest that elderly people have a greater benefit form oxaliplatin, as compared to cisplatin‐based regimens, and that people with locally advanced disease or younger than 65 years might benefit more from a three‐drug regimen including 5���FU, docetaxel, and oxaliplatin as compared to a two‐drug combination of 5‐FU and oxaliplatin, a hypothesis that needs further confirmation. For people with good performance status, the benefit of second‐line chemotherapy has been established in several RCTs. Plain language summary Chemotherapy for advanced gastric cancer Background Of all people with gastric cancer, in countries where screening is not routinely performed, 80% to 90% are either diagnosed at an advanced stage when the tumour is inoperable, or develop a recurrence within five years after surgery. Before starting any systemic chemotherapy in advanced disease, testing for over expression of the H uman E pidermal growth factor R eceptor‐2 (abbreviated HER‐2) testing is mandatory, and people with HER‐2 over expression need, in the absence of contraindications, to be treated by a combination of a cisplatin/fluoropyrimidine‐based chemotherapy and trastuzumab (i.e. a monoclonal antibody directed against the human epidermal growth factor receptor II). Study Characteristics We searched biomedical databases (MEDLINE, Embase, Cochrane Central Register of Clinical Trials) until June 2016. We included 64 RCTs, of which 60 studies with 11,698 participants contained data on overall survival, in this review. We excluded 195 studies with reasons. Quality of the evidence The quality of evidence ranged from very low to high, depending on the comparison and outcome being assessed. Reasons for down grading the quality were due to risk of bias due to lack of blinded or independent radiological review, imprecision or heterogeneity. Key results Chemotherapy improves survival (by approximately 6.7 months) and quality of life in comparison to best supportive care alone, and first‐line combination chemotherapy improves survival (by one month) compared to single‐agent 5‐FU. The addition of docetaxel to platinum‐fluoropyrimidine‐based chemotherapy regimens appears to extend survival (by just over one additional month) at the cost of increased toxicity. Whether the benefit from adding a third drug (docetaxel or epirubicin) to a two‐drug platinum‐fluoropyrimidine chemotherapy combination outweighs its toxicity is unclear. Consideration of the profile of side effects and the impact of these side effects on the individual person's quality of life, as well as the tumour burden and necessity to obtain a response rapidly is therefore essential in the choice of the regimen. Additionally, irinotecan‐containing regimens prolonged overall survival (by an additional 1.6 months) compared to non‐irinotecan‐containing regimens.}, -DOI = {10.1002/14651858.CD004064.pub4}, -keywords = {Anthracyclines [administration & dosage]; Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Camptothecin [administration & dosage, analogs & derivatives]; Cisplatin [administration & dosage]; Docetaxel; Fluorouracil [administration & dosage]; Humans; Irinotecan; Randomized Controlled Trials as Topic; Stomach Neoplasms [*drug therapy, mortality]; Taxoids [administration & dosage]}, -URL = {http://dx.doi.org/10.1002/14651858.CD004064.pub4} -} - - -Record #39 of 54 -@article{Tomita20, -author = {Tomita, Y, Moldovan, M, Chang Lee, R, Hsieh, AHC, Townsend, A, and Price, T}, -title = {Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma}, -journal = {Cochrane Database of Systematic Reviews}, -number = {11}, -year = {2020}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Salvage systemic therapy has become the new standard of care in patients with advanced gastric and oesophago‐gastric junction (OGJ) adenocarcinoma, following disease progression on first‐line fluoropyrimidine and platinum‐containing chemotherapy. Pharmacological agents proven to be effective in this setting include both chemotherapy and biological therapy, however, the consensus on the best salvage systemic therapy has not been reached. Objectives To assess the effects of systemic chemotherapy and biological therapy, either alone or in combination, on overall survival (OS) and progression‐free survival (PFS) in patients with advanced gastric and OGJ adenocarcinoma, whose disease has progressed on, or relapsed after first‐line fluoropyrimidine and platinum‐containing chemotherapy. Adverse events (AEs), tumour response rate (TRR) and quality of life (QoL) associated with systemic chemotherapy and/or biological therapy were additionally assessed. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, trial registries and proceedings of the major oncology conferences up to October 2020. We additionally handsearched the reference lists of studies. No language restriction was applied. Selection criteria We included randomised controlled trials (RCTs) comparing salvage systemic therapy (chemotherapy and/or biological therapy) and either another type of salvage systemic therapy, placebo, best supportive care (BSC) or no treatment in patients with gastric and OGJ adenocarcinoma refractory to first‐line fluoropyrimidine and platinum‐containing chemotherapy. Data collection and analysis Two review authors independently performed selection of eligible studies and the primary author extracted study characteristics and outcome data from included studies. We assessed the quality and risk of bias of eligible studies according to the Cochrane Handbook for Systematic Reviews of Interventions . We expressed pooled estimates of effect using hazard ratio (HR) calculated using an inverse variance random‐effects model for time‐to‐event data, and risk ratio (RR) calculated using Mantel‐Haenszel random‐effects model for binary data. The certainty of evidence was graded using GRADEpro. Main results We identified 17 RCTs with 5110 participants for inclusion in this review. Tweenty‐nine studies are ongoing and twenty studies are awaiting classification. No studies examined the following comparisons: chemotherapy combined with biological therapy versus placebo, BSC or no treatment, chemotherapy combined with biological therapy versus biological therapy, biological therapy versus biological therapy and chemotherapy combined with biological therapy versus chemotherapy combined with biological therapy. Chemotherapy versus placebo, best supportive care or no treatment Chemotherapy probably improves OS (HR = 0.66, 95% CI 0.52 to 0.83, moderate‐certainty evidence) based on two studies involving 547 participants and improves PFS (HR = 0.57, 95% CI 0.47 to 0.69, high‐certainty evidence) based on one study involving 507 participants over placebo and BSC. Chemotherapy probably increases serious AEs (SAEs) (RR = 1.38, 95% CI 1.20 to 1.59, moderate‐certainty evidence) based on one study involving 503 participants. Biological therapy versus placebo, best supportive care or no treatment Biological therapy improves OS (HR = 0.55, 95% CI 0.41 to 0.73, high‐certainty evidence) and probably improves PFS (HR = 0.33, 95% CI 0.19 to 0.57, moderate‐certainty evidence) over placebo based on three studies involving 781 participants. There is currently insufficient evidence for increased SAEs from biological therapy (RR = 1.14, 95% CI 0.95 to 1.37, low‐certainty evidence) based on two studies involving 638 participants. Chemotherapy versus biological therapy This comparison only considered immunotherapy. There is probably no evidence of a difference for OS (HR = 0.82, 95% CI 0.66 to 1.02, moderate‐certainty evidence) between chemotherapy and immunotherapy, and immunotherapy probably reduces PFS (HR = 1.27, 95% CI 1.03 to 1.57, moderate‐certainty evidence) based on one study involving 395 participants. SAEs may be less frequent with immunotherapy compared to chemotherapy (RR = 0.41, 95% CI 0.30 to 0.57, low‐certainty evidence). Chemotherapy combined with biological therapy versus chemotherapy Addition of biological therapy to chemotherapy probably does not improve OS (HR = 0.93, 95% CI 0.83 to 1.04, moderate‐certainty evidence) and we are uncertain whether it improves PFS (HR = 0.87, 95% CI 0.74 to 1.02, very low‐certainty evidence) based on seven studies involving 2743 participants. We are similarly uncertain whether combined chemotherapy and biological therapy increases SAEs (RR = 1.17, 95% CI 0.95 to 1.44, very low‐certainty evidence) based on four studies involving 1618 participants. Chemotherapy versus chemotherapy There is no evidence of a difference for OS and PFS between irinotecan and paclitaxel (HR = 1.13, 95% CI 0.86 to 1.48, low‐certainty evidence for OS; HR = 1.14, 95% CI 0.88 to 1.48, low‐certainty evidence for PFS) based on one study involving 219 participants. Similarly, there is no evidence to indicate improved OS and PFS from addition of another chemotherapy to docetaxel (HR = 1.05, 95% CI 0.72 to 1.54, low‐certainty evidence for OS; HR = 0.75, 95% CI 0.52 to 1.09, low‐certainty evidence for PFS) based on two studies involving 121 participants. Grade ≥ 3 neutropenia occurred commonly with both mono‐ and poly‐chemotherapy except for docetaxel‐S1 and EOX chemotherapy. Authors' conclusions Survival outcome of patients with advanced gastric and OGJ adenocarcinoma whose disease progressed on first‐line fluoropyrimidine and platinum‐containing chemotherapy can be improved by chemotherapy and biological therapy. Biological therapy, in particular, achieves this without clear increase in SAEs or QoL impairment. Whether biological therapy is preferred over chemotherapy is still unclear and there is no evidence of a difference for OS outcome, although immunotherapy may be associated with less SAEs. Addition of biological therapy to chemotherapy and poly‐chemotherapy are associated with frequent treatment‐related toxicity without clear survival benefit. Plain language summary Which treatments work best for advanced stomach cancer that has not responded to standard chemotherapy? What is advanced stomach cancer? Gastric (stomach) cancer usually begins in the mucous‐producing cells lining the stomach. Oesophago‐gastric junction (OGJ) cancer starts where the food pipe (oesophagus) joins the stomach. Advanced cancer is cancer that has spread to nearby tissues, or to another part of the body, despite treatment. Treatments for gastric and OGJ cancer include: • operation to remove the cancer; • chemotherapy (medicines that kill cancer cells); • radiotherapy (radiation to kill cancer cells); and • biological therapy (medicines made from proteins and other substances that occur naturally in the body). Biological therapies include immunotherapy (medicines that help the immune system to recognise and kill cancer cells) and therapies that target something in, or surrounding, the cancer, such as the cancer's blood supply. Standard chemotherapy usually combines two medicines containing fluoropyrimidine and platinum. When standard chemotherapy for advanced cancer has not worked, further treatment aims to slow the growth of the cancer to help people live longer. Further treatments include: other chemotherapy medicines, biological therapies, and best supportive care (care that helps a person cope with life‐limiting illness and its treatment). Why we did this Cochrane Review Stomach and OGJ cancer are difficult to treat. We wanted to find out which treatments work best to control these cancers and help people live longer, when standard chemotherapy has not worked. What did we do? We searched for studies that looked at chemotherapy and/or biological therapies for advanced stomach or OGJ cancer that had not responded to standard chemotherapy. We looked for studies in which the treatment each person received was decided at random. These studies usually give the most reliable evidence about the effects of treatments. Search date We included evidence published up to October 2020. What we found We found 17 studies in 5110 people with advanced stomach or OGJ cancer. Studies compared further chemotherapy and/or biological therapies, given by mouth or through the bloodstream (systemic), with: • another systemic chemotherapy and/or biological therapy; • a placebo ('dummy' treatment); • best supportive care; and • no treatment. The studies looked at: • how long people lived; • any adverse (unwanted) effects; and • their quality of life (well‐being). What are the results of our review? People probably live longer after further chemotherapy (irinotecan or trifluridine plus tipiracil) than with placebo treatment or best supportive care. But chemotherapy probably increases serious unwanted effects, including diarrhoea, fever, and lower numbers of red and white blood cells. People may live as long after irinotecan chemotherapy as after paclitaxel chemotherapy. Adding another chemotherapy (oxaliplatin or cisplatin) to docetaxel may not affect how long people live. People live longer after biological therapy (nivolumab, apatinib or regorafenib) than with placebo treatment. We did not find enough evidence about whether biological therapy increases unwanted effects. People given immunotherapy (pembrolizumab) probably live as long as people given chemotherapy (paclitaxel), but may not have as many unwanted effects as with chemotherapy. Combining chemotherapy with biological therapy probably does not help people live longer than chemotherapy alone, and we are uncertain whether it increases unwanted effects. How reliable are these results? We are moderately confident that chemotherapy probably helps people to live longer than placebo treatment or best supportive care. We are confident that people live longer on biological therapy than placebo treatment. We think more evidence is unlikely to change this result. We are less confident about the results for unwanted effects. Some studies had missing data or did not report these; and in some studies people and their doctors knew which treatment was given, which could have affected the study results. These results are likely to change when more evidence becomes available. Conclusions If advanced stomach or OGJ cancer has not responded to standard chemotherapy, further chemotherapy or biological therapy help people to live longer than placebo treatment, best supportive care, or no treatment. However, chemotherapy is more clearly associated with unwanted effects than biological therapy. We are unsure if biological therapies work better than chemotherapy, but they may cause fewer unwanted effects. Combining chemotherapy and biological therapies may cause more unwanted effects without giving any extra benefit.}, -DOI = {10.1002/14651858.CD012078.pub2}, -keywords = {*Esophagogastric Junction; Adenocarcinoma [mortality, pathology, *therapy]; Antineoplastic Agents [adverse effects, *therapeutic use]; Combined Modality Therapy [methods]; Docetaxel [therapeutic use]; Esophageal Neoplasms [mortality, pathology, *therapy]; Humans; Immunotherapy [adverse effects, *methods]; Irinotecan [therapeutic use]; Neoplasm Recurrence, Local [therapy]; Paclitaxel [therapeutic use]; Placebos [therapeutic use]; Progression-Free Survival; Quality of Life; Randomized Controlled Trials as Topic; Salvage Therapy [*methods]; Stomach Neoplasms [mortality, pathology, *therapy]}, -URL = {http://dx.doi.org/10.1002/14651858.CD012078.pub2} -} - - -Record #40 of 54 -@article{Sickinger15, -author = {Sickinger, MT, von Tresckow, B, Kobe, C, Engert, A, Borchmann, P, and Skoetz, N}, -title = {Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma}, -journal = {Cochrane Database of Systematic Reviews}, -number = {1}, -year = {2015}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Hodgkin lymphoma (HL) is a B‐cell lymphoma accounting for 10% to 15% of all lymphoma in industrialised countries. It has a bimodal age distribution with one peak around the age of 30 years and another after the age of 60 years. Although HL accounts for fewer than 1% of all neoplasms worldwide, it is considered to be one of the most common malignancies in young adults and, with cure rates of 90%, one of the most curable cancers worldwide. Current treatment options for HL comprise more‐ or less‐intensified regimens of chemotherapy plus radiotherapy, depending on disease stage. [18F]‐fluorodeoxy‐D‐glucose (FDG)‐positron emission tomography (PET, also called PET scanning) is an imaging tool that can be used to illustrate a tumour's metabolic activity, stage and progression. Therefore, it could be used as a standard interim procedure during HL treatment, to help distinguish between individuals who are good or poor early responders to therapy. Subsequent therapy could then be de‐escalated in PET‐negative individuals (good responders) or escalated in those who are PET‐positive (poor responders). It is currently unknown whether such response‐adapted therapeutic strategies are of benefit to individuals in terms of overall and progression‐free survival, and the incidence of long‐term adverse events (AEs). Objectives To assess the effects of interim [18F]‐FDG‐PET imaging treatment modification in individuals with HL. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL; latest issue) and MEDLINE (from 1990 to September 2014) as well as conference proceedings (American Society of Hematology; American Society of Clinical Oncology; European Hematology Association; and International Symposium on Hodgkin Lymphoma) for studies. Two review authors independently screened search results. Selection criteria We included randomised controlled trials (RCTs) comparing FDG‐PET‐adapted therapy with non‐adapted treatment in individuals with previously untreated HL of all stages and ages. Data collection and analysis Two review authors independently extracted data and assessed the quality of trials. As none of the included studies provided HRs for OS, we described risk ratios (RRs) for this outcome and did not pool the data. As an effect measure we used hazard ratios (HRs) for progression‐free survival (PFS). We described RRs for the dichotomous data on AEs. We also calculated 95% confidence intervals (CIs). Main results Our search strategies led to 308 potentially relevant references. From these, we included three studies involving 1999 participants. We judged the overall potential risk of bias as moderate. The studies were reported as RCTs; blinding was not reported, but given the study design it is likely that there was no blinding. One study was published in abstract form only; hence, detailed assessment of the risk of bias was not possible. Two trials compared standard treatment (chemotherapy plus radiotherapy) with PET‐adapted therapy (chemotherapy only) in individuals with early‐stage HL and negative PET scans. The study design of the third trial was more complex. Participants with early‐stage HL were divided into those with a favourable or unfavourable prognosis. They were then randomised to receive PET‐adapted or standard treatment. Following a PET scan, participants were further divided into PET‐positive and PET‐negative groups. To date, data have been published for the PET‐negative arms only, making it possible to perform a meta‐analysis including all three trials. Of the 1999 participants included in the three trials only 1480 were analysed. The 519 excluded participants were either PET‐positive, or were excluded because they did not match the inclusion criteria. One study reported no deaths. The other two studies reported two deaths in participants receiving PET‐adapted therapy and two in participants receiving standard therapy (very‐low‐quality evidence). Progression‐free survival was shorter in participants with PET‐adapted therapy (without radiotherapy) than in those receiving standard treatment with radiotherapy (HR 2.38; 95% CI 1.62 to 3.50; P value < 0.0001). This difference was also apparent in comparisons of participants receiving no additional radiotherapy (PET‐adapted therapy) versus radiotherapy (standard therapy) (HR 1.86; 95% CI 1.07 to 3.23; P value = 0.03) and in those receiving chemotherapy but no radiotherapy (PET‐adapted therapy) versus standard radiotherapy (HR 3.00; 95% CI 1.75 to 5.14; P value < 0.0001) (moderate‐quality evidence). Short‐term AEs only were assessed in one trial, which showed no evidence of a difference between the treatment arms (RR 0.91; 95% CI 0.54 to 1.53; P value = 0.72) (very‐low‐quality evidence). No data on long‐term AEs were reported in any of the trials. Authors' conclusions To date, no robust data on OS, response rate, TRM, QoL, or short‐ and long‐term AEs are available. However, this systematic review found moderate‐quality evidence that PFS was shorter in individuals with early‐stage HL and a negative PET scan receiving chemotherapy only (PET‐adapted therapy) than in those receiving additional radiotherapy (standard therapy). More RCTs with longer follow ups may lead to more precise results for AEs, TRM and QoL, and could evaluate whether this PFS advantage will translate into an overall survival benefit. It is still uncertain whether PET‐positive individuals benefit from PET‐based treatment adaptation and the effect of such an approach in those with advanced HL. Plain language summary Imaging‐adapted therapy for individuals with Hodgkin lymphoma Background Hodgkin lymphoma (HL) is a malignant disease of the lymphatic system of the body. It accounts for 10% to 15% of all lymphoma in industrialised countries and tends to show two peaks in incidence at around 30 and 60 years of age. While it is considered a relatively rare disease, it is one of the most common malignancies in young adults. With cure rates of up to 90% over 5 years, it is one of the most curable cancers worldwide. The imaging of tumour tissue using a technique termed positron emission tomography (PET) has been shown to provide a good way of estimating the activity of a tumour. The question therefore arises of whether this technique could be used as an tool during therapy to identify individuals who are, or are not, responding to chemotherapy. This would enable further treatment to be modified, resulting in individualised therapy. Treatment could be reduced or stopped in individuals who show a good response to chemotherapy, thus reducing the risk of long‐term adverse events, or increased in those showing a poor response to chemotherapy. Review question In this systematic review we address the issue of whether PET‐adapted therapy in individuals with HL results in beneficial outcomes such as longer overall survival (OS) and survival without disease progression (termed progression‐free survival or PFS), higher responses to therapy and participant quality of life (QoL), or reductions in adverse events (such as second malignancies) or treatment‐related mortality. Study characteristics We searched important medical databases such as the Cochrane Central Register of Controlled Trials and MEDLINE. Two review authors independently screened, summarised and analysed the results. This lead to the inclusion of three randomised controlled trials (RCTs) with 1999 participants. Currently, only data for 1480 of these participants have been published and were included in this systematic review. Participants were randomised to receive either standard therapy (chemotherapy followed by radiotherapy) or PET‐adapted therapy (chemotherapy only). The median age of participants was 32 years and 52% were male. The evidence provided is current to September 2014. Key results We are unable to draw conclusions about the effect of PET‐adapted therapy on OS as there was insufficient data available (4 deaths in 1480 participants). However, PFS was shorter following PET‐adapted therapy than with standard treatment. Based on our data, we can assume that of 1000 individuals receiving PET‐adapted treatment over 4 years, 222 individuals would experience disease progression or death compared with 100 of 1000 individuals receiving standard treatment. Only one trial reported on short‐term adverse events and the findings were uncertain and do not provide reliable evidence. The studies did not provide any information on the outcomes of QoL, response to therapy or treatment‐related mortality. Quality of evidence We judged the quality of evidence for the outcomes of OS and adverse events as very low. We considered the quality of evidence for PFS to be moderate. Conclusion To date, no robust data on OS are available. This systematic review shows that individuals with early‐stage HL have a shorter PFS after PET‐adapted therapy compared with those who receive standard therapy. More RCTs with longer follow ups may lead to more information on adverse events, treatment‐related mortality and QoL, and could evaluate whether the PFS advantage seen with standard therapy will translate into a benefit in terms of OS.}, -DOI = {10.1002/14651858.CD010533.pub2}, -keywords = {*Positron‐Emission Tomography [methods]; Antineoplastic Agents [therapeutic use]; Chemoradiotherapy [methods]; Disease‐Free Survival; Female; Fluorodeoxyglucose F18; Hodgkin Disease [*diagnostic imaging, mortality, pathology, *therapy]; Humans; Male; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Selection Bias}, -URL = {http://dx.doi.org/10.1002/14651858.CD010533.pub2} -} - - -Record #41 of 54 -@article{Hannon21, -author = {Hannon, CW, McCourt, C, Lima, HC, Chen, S, and Bennett, C}, -title = {Interventions for cutaneous disease in systemic lupus erythematosus}, -journal = {Cochrane Database of Systematic Reviews}, -number = {3}, -year = {2021}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Lupus erythematosus is an autoimmune disease with significant morbidity and mortality. Cutaneous disease in systemic lupus erythematosus (SLE) is common. Many interventions are used to treat SLE with varying efficacy, risks, and benefits. Objectives To assess the effects of interventions for cutaneous disease in SLE. Search methods We searched the following databases up to June 2019: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, Wiley Interscience Online Library, and Biblioteca Virtual em Saude (Virtual Health Library). We updated our search in September 2020, but these results have not yet been fully incorporated. Selection criteria We included randomised controlled trials (RCTs) of interventions for cutaneous disease in SLE compared with placebo, another intervention, no treatment, or different doses of the same intervention. We did not evaluate trials of cutaneous lupus in people without a diagnosis of SLE. Data collection and analysis We used standard methodological procedures expected by Cochrane. Primary outcomes were complete and partial clinical response. Secondary outcomes included reduction (or change) in number of clinical flares; and severe and minor adverse events. We used GRADE to assess the quality of evidence. Main results Sixty‐one RCTs, involving 11,232 participants, reported 43 different interventions. Trials predominantly included women from outpatient clinics; the mean age range of participants was 20 to 40 years. Twenty‐five studies reported baseline severity, and 22 studies included participants with moderate to severe cutaneous lupus erythematosus (CLE); duration of CLE was not well reported. Studies were conducted mainly in multi‐centre settings. Most often treatment duration was 12 months. Risk of bias was highest for the domain of reporting bias, followed by performance/detection bias. We identified too few studies for meta‐analysis for most comparisons. We limited this abstract to main comparisons (all administered orally) and outcomes. We did not identify clinical trials of other commonly used treatments, such as topical corticosteroids, that reported complete or partial clinical response or numbers of clinical flares. Complete clinical response Studies comparing oral hydroxychloroquine against placebo did not report complete clinical response. Chloroquine may increase complete clinical response at 12 months' follow‐up compared with placebo (absence of skin lesions) (risk ratio (RR) 1.57, 95% confidence interval (CI) 0.95 to 2.61; 1 study, 24 participants; low‐quality evidence). There may be little to no difference between methotrexate and chloroquine in complete clinical response (skin rash resolution) at 6 months' follow‐up (RR 1.13, 95% CI 0.84 to 1.50; 1 study, 25 participants; low‐quality evidence). Methotrexate may be superior to placebo with regard to complete clinical response (absence of malar/discoid rash) at 6 months' follow‐up (RR 3.57, 95% CI 1.63 to 7.84; 1 study, 41 participants; low‐quality evidence). At 12 months' follow‐up, there may be little to no difference between azathioprine and ciclosporin in complete clinical response (malar rash resolution) (RR 0.83, 95% CI 0.46 to 1.52; 1 study, 89 participants; low‐quality evidence). Partial clinical response Partial clinical response was reported for only one key comparison: hydroxychloroquine may increase partial clinical response at 12 months compared to placebo, but the 95% CI indicates that hydroxychloroquine may make no difference or may decrease response (RR 7.00, 95% CI 0.41 to 120.16; 20 pregnant participants, 1 trial; low‐quality evidence). Clinical flares Clinical flares were reported for only two key comparisons: hydroxychloroquine is probably superior to placebo at 6 months' follow‐up for reducing clinical flares (RR 0.49, 95% CI 0.28 to 0.89; 1 study, 47 participants; moderate‐quality evidence). At 12 months' follow‐up, there may be no difference between methotrexate and placebo, but the 95% CI indicates there may be more or fewer flares with methotrexate (RR 0.77, 95% CI 0.32 to 1.83; 1 study, 86 participants; moderate‐quality evidence). Adverse events Data for adverse events were limited and were inconsistently reported, but hydroxychloroquine, chloroquine, and methotrexate have well‐documented adverse effects including gastrointestinal symptoms, liver problems, and retinopathy for hydroxychloroquine and chloroquine and teratogenicity during pregnancy for methotrexate. Authors' conclusions Evidence supports the commonly‐used treatment hydroxychloroquine, and there is also evidence supporting chloroquine and methotrexate for treating cutaneous disease in SLE. Evidence is limited due to the small number of studies reporting key outcomes. Evidence for most key outcomes was low or moderate quality, meaning findings should be interpreted with caution. Head‐to‐head intervention trials designed to detect differences in efficacy between treatments for specific CLE subtypes are needed. Thirteen further trials are awaiting classification and have not yet been incorporated in this review; they may alter the review conclusions. Plain language summary What are the benefits and risks of different treatments for skin disease in people with systemic lupus erythematosus (an autoimmune disease that affects the whole body) Why is this question important? Systemic lupus erythematosus (SLE; also known as ‘lupus’) is a disease in which the body's immune (defence) system mistakenly attacks healthy tissue in many parts of the body. It affects 7.5 million people worldwide. Around 70% of affected people develop skin problems such as rash on the nose or cheeks. Often, SLE also causes pain in joints and muscles and extreme tiredness. Symptoms can improve temporarily, or they can worsen suddenly (flares). In severe cases, SLE can cause life‐threatening damage to the heart, lungs, brain, or kidneys. There is no cure for SLE. However, there are treatments designed to improve symptoms. In particular, there are a range of options for treating skin problems. • Medicines that can be taken by mouth (orally), applied as creams, or given as injections. • Therapies to help people cope with their skin problems, such as talking therapies. • Other approaches, including herbal medicine, light therapy, or make‐up. To find out which treatments work best for people with SLE, and to compare adverse (unwanted) effects, we reviewed the evidence from research studies. How did we identify and evaluate the evidence? We searched the medical literature for studies that compared any treatment for skin disease in SLE against: • a placebo (dummy) treatment; • no treatment; • another treatment; or • a different dose of the same treatment. We compared the results and summarised the evidence from all the studies. Finally, we rated our confidence in the evidence based on factors such as study methods and sizes and the consistency of findings across studies. What did we find? We found 61 studies that included 11,232 people (mostly women) and investigated 43 different treatments. Most treatments lasted one year, and people were followed for up to 48 months. Here we report the main findings of our review on the effects of five different oral medicines: hydroxychloroquine, chloroquine, methotrexate, ciclosporin, and azathioprine. Disappearance of skin problems We do not know if hydroxychloroquine is better or worse than placebo at making skin problems disappear because no studies reported information about this. The evidence suggests that: • chloroquine may be better at making skin problems disappear after 12 months than placebo (1 study, 24 people); • when we compare methotrexate and choloroquine, there may be little to no difference in how often they make skin rashes disappear after six months (1 study, 25 people); • methotrexate may be better for making skin rashes disappear after six months than placebo (1 study, 41 people); and • there may be little to no difference in how often skin problems disappear after 12 months between ciclosporin and aziathropine (1 study, 25 people). Partial disappearance of skin problems (at least 50% improvement in the skin condition) It is unclear if hydroxycholoroquine is better or worse than placebo at making skin problems disappear at least partially after 12 months. This is because the evidence is too imprecise (1 study, 20 pregnant women). No other studies have examined how treatments affect the partial disappearance of skin problems. Flares The evidence suggests that after six months, fewer flares probably occur with hydroxychloroquine than with placebo (1 study, 47 people). It is unclear if flares are more, or less, likely to occur after 12 months with methotrexate compared to placebo (1 study, 86 people). No other studies have reported information on how treatments affect flares. Adverse events Evidence is often imprecise, and whether treatments lead to more or fewer adverse events than placebo or other treatments is not clear. We found limited data for adverse events, and reports were discrepant, but hydroxychloroquine, chloroquine, and methotrexate have well‐known adverse effects including stomach and liver problems. Hydroxychloroquine and chloroquine can cause eye problems, and methotrexate can cause serious harm to a developing baby if taken during pregnancy. Other outcomes We do not know how treatments affect other aspects of disease severity or quality of life. This is because studies did not report information on this. What does this mean? When compared against a placebo, studies in people with SLE show that: • fewer flares probably occur with hydroxychloroquine; and • methotrexate and chloroquine may be better at making skin problems disappear. Information about adverse effects is limited. How up‐to‐date is this review? The evidence in this Cochrane Review is current to June 2019.}, -DOI = {10.1002/14651858.CD007478.pub2}, -keywords = {Age of Onset; Azathioprine [therapeutic use]; Bias; Biological Factors [therapeutic use]; Chloroquine [adverse effects, therapeutic use]; Cosmetic Techniques; Cyclosporine [therapeutic use]; Dermatologic Agents [adverse effects, *therapeutic use]; Exanthema; Female; Humans; Hydroxychloroquine [adverse effects, therapeutic use]; Immunosuppressive Agents [*therapeutic use]; Lupus Erythematosus, Cutaneous [classification, diagnosis, therapy]; Lupus Erythematosus, Systemic [classification, complications, *therapy]; Male; Medicine, Chinese Traditional; Methotrexate [adverse effects, therapeutic use]; Placebos [therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Skin Diseases [etiology, *therapy]; Symptom Flare Up}, -URL = {http://dx.doi.org/10.1002/14651858.CD007478.pub2} -} - - -Record #42 of 54 -@article{Pasquali18, -author = {Pasquali, S, Hadjinicolaou, AV, Chiarion Sileni, V, Rossi, CR, and Mocellin, S}, -title = {Systemic treatments for metastatic cutaneous melanoma}, -journal = {Cochrane Database of Systematic Reviews}, -number = {2}, -year = {2018}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is generally poor. Recently, new classes of drugs (e.g. immune checkpoint inhibitors and small‐molecule targeted drugs) have significantly improved patient prognosis, which has drastically changed the landscape of melanoma therapeutic management. This is an update of a Cochrane Review published in 2000. Objectives To assess the beneficial and harmful effects of systemic treatments for metastatic cutaneous melanoma. Search methods We searched the following databases up to October 2017: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase and LILACS. We also searched five trials registers and the ASCO database in February 2017, and checked the reference lists of included studies for further references to relevant randomised controlled trials (RCTs). Selection criteria We considered RCTs of systemic therapies for people with unresectable lymph node metastasis and distant metastatic cutaneous melanoma compared to any other treatment. We checked the reference lists of selected articles to identify further references to relevant trials. Data collection and analysis Two review authors extracted data, and a third review author independently verified extracted data. We implemented a network meta‐analysis approach to make indirect comparisons and rank treatments according to their effectiveness (as measured by the impact on survival) and harm (as measured by occurrence of high‐grade toxicity). The same two review authors independently assessed the risk of bias of eligible studies according to Cochrane standards and assessed evidence quality based on the GRADE criteria. Main results We included 122 RCTs (28,561 participants). Of these, 83 RCTs, encompassing 21 different comparisons, were included in meta‐analyses. Included participants were men and women with a mean age of 57.5 years who were recruited from hospital settings. Twenty‐nine studies included people whose cancer had spread to their brains. Interventions were categorised into five groups: conventional chemotherapy (including single agent and polychemotherapy), biochemotherapy (combining chemotherapy with cytokines such as interleukin‐2 and interferon‐alpha), immune checkpoint inhibitors (such as anti‐CTLA4 and anti‐PD1 monoclonal antibodies), small‐molecule targeted drugs used for melanomas with specific gene changes (such as BRAF inhibitors and MEK inhibitors), and other agents (such as anti‐angiogenic drugs). Most interventions were compared with chemotherapy. In many cases, trials were sponsored by pharmaceutical companies producing the tested drug: this was especially true for new classes of drugs, such as immune checkpoint inhibitors and small‐molecule targeted drugs. When compared to single agent chemotherapy, the combination of multiple chemotherapeutic agents (polychemotherapy) did not translate into significantly better survival (overall survival: HR 0.99, 95% CI 0.85 to 1.16, 6 studies, 594 participants; high‐quality evidence; progression‐free survival: HR 1.07, 95% CI 0.91 to 1.25, 5 studies, 398 participants; high‐quality evidence. Those who received combined treatment are probably burdened by higher toxicity rates (RR 1.97, 95% CI 1.44 to 2.71, 3 studies, 390 participants; moderate‐quality evidence). (We defined toxicity as the occurrence of grade 3 (G3) or higher adverse events according to the World Health Organization scale.) Compared to chemotherapy, biochemotherapy (chemotherapy combined with both interferon‐alpha and interleukin‐2) improved progression‐free survival (HR 0.90, 95% CI 0.83 to 0.99, 6 studies, 964 participants; high‐quality evidence), but did not significantly improve overall survival (HR 0.94, 95% CI 0.84 to 1.06, 7 studies, 1317 participants; high‐quality evidence). Biochemotherapy had higher toxicity rates (RR 1.35, 95% CI 1.14 to 1.61, 2 studies, 631 participants; high‐quality evidence). With regard to immune checkpoint inhibitors, anti‐CTLA4 monoclonal antibodies plus chemotherapy probably increased the chance of progression‐free survival compared to chemotherapy alone (HR 0.76, 95% CI 0.63 to 0.92, 1 study, 502 participants; moderate‐quality evidence), but may not significantly improve overall survival (HR 0.81, 95% CI 0.65 to 1.01, 2 studies, 1157 participants; low‐quality evidence). Compared to chemotherapy alone, anti‐CTLA4 monoclonal antibodies is likely to be associated with higher toxicity rates (RR 1.69, 95% CI 1.19 to 2.42, 2 studies, 1142 participants; moderate‐quality evidence). Compared to chemotherapy, anti‐PD1 monoclonal antibodies (immune checkpoint inhibitors) improved overall survival (HR 0.42, 95% CI 0.37 to 0.48, 1 study, 418 participants; high‐quality evidence) and probably improved progression‐free survival (HR 0.49, 95% CI 0.39 to 0.61, 2 studies, 957 participants; moderate‐quality evidence). Anti‐PD1 monoclonal antibodies may also result in less toxicity than chemotherapy (RR 0.55, 95% CI 0.31 to 0.97, 3 studies, 1360 participants; low‐quality evidence). Anti‐PD1 monoclonal antibodies performed better than anti‐CTLA4 monoclonal antibodies in terms of overall survival (HR 0.63, 95% CI 0.60 to 0.66, 1 study, 764 participants; high‐quality evidence) and progression‐free survival (HR 0.54, 95% CI 0.50 to 0.60, 2 studies, 1465 participants; high‐quality evidence). Anti‐PD1 monoclonal antibodies may result in better toxicity outcomes than anti‐CTLA4 monoclonal antibodies (RR 0.70, 95% CI 0.54 to 0.91, 2 studies, 1465 participants; low‐quality evidence). Compared to anti‐CTLA4 monoclonal antibodies alone, the combination of anti‐CTLA4 plus anti‐PD1 monoclonal antibodies was associated with better progression‐free survival (HR 0.40, 95% CI 0.35 to 0.46, 2 studies, 738 participants; high‐quality evidence). There may be no significant difference in toxicity outcomes (RR 1.57, 95% CI 0.85 to 2.92, 2 studies, 764 participants; low‐quality evidence) (no data for overall survival were available). The class of small‐molecule targeted drugs, BRAF inhibitors (which are active exclusively against BRAF‐mutated melanoma), performed better than chemotherapy in terms of overall survival (HR 0.40, 95% CI 0.28 to 0.57, 2 studies, 925 participants; high‐quality evidence) and progression‐free survival (HR 0.27, 95% CI 0.21 to 0.34, 2 studies, 925 participants; high‐quality evidence), and there may be no significant difference in toxicity (RR 1.27, 95% CI 0.48 to 3.33, 2 studies, 408 participants; low‐quality evidence). Compared to chemotherapy, MEK inhibitors (which are active exclusively against BRAF‐mutated melanoma) may not significantly improve overall survival (HR 0.85, 95% CI 0.58 to 1.25, 3 studies, 496 participants; low‐quality evidence), but they probably lead to better progression‐free survival (HR 0.58, 95% CI 0.42 to 0.80, 3 studies, 496 participants; moderate‐quality evidence). However, MEK inhibitors probably have higher toxicity rates (RR 1.61, 95% CI 1.08 to 2.41, 1 study, 91 participants; moderate‐quality evidence). Compared to BRAF inhibitors, the combination of BRAF plus MEK inhibitors was associated with better overall survival (HR 0.70, 95% CI 0.59 to 0.82, 4 studies, 1784 participants; high‐quality evidence). BRAF plus MEK inhibitors was also probably better in terms of progression‐free survival (HR 0.56, 95% CI 0.44 to 0.71, 4 studies, 1784 participants; moderate‐quality evidence), and there appears likely to be no significant difference in toxicity (RR 1.01, 95% CI 0.85 to 1.20, 4 studies, 1774 participants; moderate‐quality evidence). Compared to chemotherapy, the combination of chemotherapy plus anti‐angiogenic drugs was probably associated with better overall survival (HR 0.60, 95% CI 0.45 to 0.81; moderate‐quality evidence) and progression‐free survival (HR 0.69, 95% CI 0.52 to 0.92; moderate‐quality evidence). There may be no difference in terms of toxicity (RR 0.68, 95% CI 0.09 to 5.32; low‐quality evidence). All results for this comparison were based on 324 participants from 2 studies. Network meta‐analysis focused on chemotherapy as the common comparator and currently approved treatments for which high‐ to moderate‐quality evidence of efficacy (as represented by treatment effect on progression‐free survival) was available (based on the above results) for: biochemotherapy (with both interferon‐alpha and interleukin‐2); anti‐CTLA4 monoclonal antibodies; anti‐PD1 monoclonal antibodies; anti‐CTLA4 plus anti‐PD1 monoclonal antibodies; BRAF inhibitors; MEK inhibitors, and BRAF plus MEK inhibitors. Analysis (which included 19 RCTs and 7632 participants) generated 21 indirect comparisons. The best evidence (moderate‐quality evidence) for progression‐free survival was found for the following indirect comparisons:
• both combinations of immune checkpoint inhibitors (HR 0.30, 95% CI 0.17 to 0.51) and small‐molecule targeted drugs (HR 0.17, 95% CI 0.11 to 0.26) probably improved progression‐free survival compared to chemotherapy;
• both BRAF inhibitors (HR 0.40, 95% CI 0.23 to 0.68) and combinations of small‐molecule targeted drugs (HR 0.22, 95% CI 0.12 to 0.39) were probably associated with better progression‐free survival compared to anti‐CTLA4 monoclonal antibodies;
• biochemotherapy (HR 2.81, 95% CI 1.76 to 4.51) probably lead to worse progression‐free survival compared to BRAF inhibitors;
• the combination of small‐molecule targeted drugs probably improved progression‐free survival (HR 0.38, 95% CI 0.21 to 0.68) compared to anti‐PD1 monoclonal antibodies;
• both biochemotherapy (HR 5.05, 95% CI 3.01 to 8.45) and MEK inhibitors (HR 3.16, 95% CI 1.77 to 5.65) were probably associated with worse progression‐free survival compared to the combination of small‐molecule targeted drugs; and
• biochemotherapy was probably associated with worse progression‐free survival (HR 2.81, 95% CI 1.54 to 5.11) compared to the combination of immune checkpoint inhibitors. The best evidence (moderate‐quality evidence) for toxicity was found for the following indirect comparisons:
• combination of immune checkpoint inhibitors (RR 3.49, 95% CI 2.12 to 5.77) probably increased toxicity compared to chemotherapy;
• combination of immune checkpoint inhibitors probably increased toxicity (RR 2.50, 95% CI 1.20 to 5.20) compared to BRAF inhibitors;
• the combination of immune checkpoint inhibitors probably increased toxicity (RR 3.83, 95% CI 2.59 to 5.68) compared to anti‐PD1 monoclonal antibodies; and
• biochemotherapy was probably associated with lower toxicity (RR 0.41, 95% CI 0.24 to 0.71) compared to the combination of immune checkpoint inhibitors. Network meta‐analysis‐based ranking suggested that the combination of BRAF plus MEK inhibitors is the most effective strategy in terms of progression‐free survival, whereas anti‐PD1 monoclonal antibodies are associated with the lowest toxicity. Overall, the risk of bias of the included trials can be considered as limited. When considering the 122 trials included in this review and the seven types of bias we assessed, we performed 854 evaluations only seven of which (< 1%) assigned high risk to six trials. Authors' conclusions We found high‐quality evidence that many treatments offer better efficacy than chemotherapy, especially recently implemented treatments, such as small‐molecule targeted drugs, which are used to treat melanoma with specific gene mutations. Compared with chemotherapy, biochemotherapy (in this case, chemotherapy combined with both interferon‐alpha and interleukin‐2) and BRAF inhibitors improved progression‐free survival; BRAF inhibitors (for BRAF‐mutated melanoma) and anti‐PD1 monoclonal antibodies improved overall survival. However, there was no difference between polychemotherapy and monochemotherapy in terms of achieving progression‐free survival and overall survival. Biochemotherapy did not significantly improve overall survival and has higher toxicity rates compared with chemotherapy. There was some evidence that combined treatments worked better than single treatments: anti‐PD1 monoclonal antibodies, alone or with anti‐CTLA4, improved progression‐free survival compared with anti‐CTLA4 monoclonal antibodies alone. Anti‐PD1 monoclonal antibodies performed better than anti‐CTLA4 monoclonal antibodies in terms of overall survival, and a combination of BRAF plus MEK inhibitors was associated with better overall survival for BRAF‐mutated melanoma, compared to BRAF inhibitors alone. The combination of BRAF plus MEK inhibitors (which can only be administered to people with BRAF‐mutated melanoma) appeared to be the most effective treatment (based on results for progression‐free survival), whereas anti‐PD1 monoclonal antibodies appeared to be the least toxic, and most acceptable, treatment. Evidence quality was reduced due to imprecision, between‐study heterogeneity, and substandard reporting of trials. Future research should ensure that those diminishing influences are addressed. Clinical areas of future investigation should include the longer‐term effect of new therapeutic agents (i.e. immune checkpoint inhibitors and targeted therapies) on overall survival, as well as the combination of drugs used in melanoma treatment; research should also investigate the potential influence of biomarkers. Plain language summary Systemic treatments (tablets or injections) taken for metastatic melanoma (expanded from its starting point to other parts of the body) Background Melanoma is the most dangerous common skin cancer. Early diagnosis offers the best chance of cure. People affected by early stage melanoma represent about 70% to 80% of all those with melanoma and can be treated by surgical removal of the original tumour (known as the primary tumour). However, when a primary melanoma is detected at a later stage, there is a risk of disease spreading to the nearest lymph nodes (glands that are part of the body's immune system) and distant sites, such as the lungs, liver, bone and brain. In this case, systemic chemotherapy (giving drugs that kill cells throughout the body) and biochemotherapy (chemotherapy combined with substances that can improve the immune response, known as immunostimulating cytokines, such as interleukin‐2 and interferon‐alpha) have been the main treatments for over three decades. However, only few people experience spontaneous (i.e. not resulting from therapy) regression of the primary tumour. Over the past few years, new classes of drugs have been used with promising results. We aimed to look at how new systemic treatments compare with older therapies, as well as with each other, in terms of survival, acceptability, tumour response, and quality of life. We assessed these outcomes in people with metastatic melanoma (AJCC TNM stage IV). Review question We aimed to assess the effects of systemic treatments for people with metastatic cutaneous melanoma (melanoma of skin tissue). We searched for relevant trials up to October 2017 and included 122 studies. We summarised the results of melanoma treatments (delivered systemically), such as conventional chemotherapy, biochemotherapy, as well as newer drug classes, such as immune checkpoint inhibitors (anti‐CTLA4 and anti‐PD1 monoclonal antibodies, which increase the anti‐tumour activity of the immune system), small‐molecule targeted drugs (BRAF inhibitors, which are used only for melanomas containing specific BRAF gene mutations that promote tumour progression, and MEK inhibitors, which work on the same molecular pathway), and anti‐angiogenic drugs (which reduce blood supply to cancer cells). We compared these treatments with conventional chemotherapy. Study characteristics All 122 studies were randomised controlled trials that enrolled participants with metastatic cutaneous melanoma and compared different systemic treatments (28,561 participants). Study participants were adults of either sex, with a mean age of 57.5 years. There were 29 studies that included people whose cancer had spread to the brain, which is important because the detection and treatment of brain metastases often present unique challenges. Most treatments were compared with chemotherapy, and all studies were set in hospitals. Frequently, the pharmaceutical company who produced a tested drug also sponsored the study in which it was assessed, especially in the case of new classes of drugs, such as immune checkpoint inhibitors and small‐molecule targeted drugs. Key results Compared to conventional chemotherapy, several treatments can improve the progression‐free survival of people with metastatic melanoma. These include biochemotherapy (high‐quality evidence), anti‐CTLA4 monoclonal antibodies plus chemotherapy (moderate‐quality evidence), anti‐PD1 monoclonal antibodies (moderate‐quality evidence), BRAF inhibitors (high‐quality evidence), MEK inhibitors (moderate‐quality evidence), and anti‐angiogenic drugs (moderate‐quality evidence). However, no difference was found for use of a combination of several chemotherapy agents (polychemotherapy) (high‐quality evidence). Moreover, the combination of immune checkpoint inhibitors (anti‐PD1 plus anti‐CTLA4 monoclonal antibodies) performed better than anti‐CTLA4 monoclonal antibodies alone (high‐quality evidence), but anti‐PD1 monoclonal antibodies performed better than anti‐CTLA4 monoclonal antibodies (high‐quality evidence). The combination of small‐molecule inhibitors (BRAF plus MEK inhibitors) lead to better results than BRAF inhibitors alone (moderate‐quality evidence), for people with melanoma that has a BRAF gene change . Anti‐PD1 monoclonal antibodies improved patients' overall survival compared with either standard chemotherapy (high‐quality evidence) or anti‐CTLA4 monoclonal antibodies (high‐quality evidence). Compared to chemotherapy alone, both BRAF inhibitors (high‐quality evidence), and anti‐angiogenic agents combined with chemotherapy (moderate‐quality evidence) also prolong overall survival, but anti‐CTLA4 monoclonal antibodies plus chemotherapy (low‐quality evidence), MEK inhibitors (low‐quality evidence), combined multiple chemotherapeutic agents (polychemotherapy) (high‐quality evidence), or biochemotherapy (high‐quality evidence) did not lead to significantly improved overall survival. WE also found that the combination of small‐molecule inhibitors performed better than BRAF inhibitors alone (high‐quality evidence). No data on overall survival were available for anti‐CTLA4 monoclonal antibodies alone compared with the combination of anti‐CTLA4 plus anti‐PD1 monoclonal antibodies. In terms of toxicity (defined as occurrence of high‐grade side effects), biochemotherapy (high‐quality evidence), anti‐CTLA4 monoclonal antibodies (moderate‐quality evidence), polychemotherapy (moderate‐quality evidence), and MEK inhibitors (moderate‐quality evidence) were associated with worse toxicity compared to chemotherapy. In contrast, anti‐PD1 monoclonal antibodies appear to be better tolerated than chemotherapy alone. Anti‐PD1 monoclonal antibodies also appeared to be better tolerated than anti‐CTLA4 monoclonal antibodies. However, evidence quality supporting these findings was assessed as low. Furthermore, the frequency of side effects did not differ significantly between anti‐PD1 plus anti‐CTLA4 monoclonal antibodies versus anti‐CTLA4 monoclonal antibodies alone (low‐quality evidence), anti‐angiogenic drugs combined with chemotherapy versus chemotherapy (low‐quality evidence), BRAF inhibitors versus chemotherapy (low‐quality evidence), and BRAF plus MEK inhibitors versus BRAF inhibitors alone (moderate‐quality evidence). We also conducted an analysis that compared treatments that had not been directly compared in a study. This is known as a network meta‐analysis. For the outcome of progression��free survival, looking at only the best evidence available, we found the following results (please note that because the highest quality level was moderate, the following results can only be deemed probable):
• both combination of immune checkpoint inhibitors and combination of small‐molecule targeted drugs were favoured compared to chemotherapy;
• both BRAF inhibitors and combination of small‐molecule targeted drugs were favoured compared to anti‐CTLA4 monoclonal antibodies;
• biochemotherapy led to less favourable results than BRAF inhibitors;
• the combination of small‐molecule targeted drugs was favoured compared to anti‐PD1 monoclonal antibodies;
• both biochemotherapy and MEK inhibitors led to less favourable results than the combination of small‐molecule targeted drugs; and
• biochemotherapy led to less favourable results than the combination of immune checkpoint inhibitors For the outcome of toxicity, looking at only the best evidence available, we found the following results (again, evidence quality was no higher than moderate):
• combination of immune checkpoint inhibitors led to less favourable results than chemotherapy;
• combination of immune checkpoint inhibitors led to less favourable results than BRAF inhibitors;
• the combination of immune checkpoint inhibitors led to less favourable results than anti‐PD1 monoclonal antibodies; and
• biochemotherapy was favoured compared to the combination of immune checkpoint inhibitors. Our results suggest that the combination of small‐molecule targeted drugs (BRAF plus MEK inhibitors) is the most effective treatment strategy, for people with melanoma that has a BRAF gene change, at least in terms of progression‐free survival; however, this combination therapy is burdened by a higher rate of severe toxicity compared to effects observed among people treated with anti‐PD1 monoclonal antibodies, which can be used in all melanoma types, and rank highest in terms of tolerability. These results need long‐term analysis from randomised trials to be confirmed, with special attention to effects on patients' overall survival. Quality of the evidence GRADE findings showed that most evidence was high‐ to moderate‐quality for three (overall survival, progression‐free survival and tumour response) out of four outcomes (toxicity). Evidence quality was reduced due to small numbers of participants in some comparisons, differences between the studies, and poor reporting of trials.}, -DOI = {10.1002/14651858.CD011123.pub2}, -keywords = {Angiogenesis Inhibitors [adverse effects, therapeutic use]; Antibodies, Monoclonal [adverse effects, therapeutic use]; Antineoplastic Agents [adverse effects, therapeutic use]; Brain Neoplasms [secondary]; CTLA-4 Antigen [antagonists & inhibitors]; Disease-Free Survival; Drug Therapy, Combination [adverse effects]; Female; Humans; Immunotherapy [methods]; Interferon-alpha [therapeutic use]; Interleukin-2 [therapeutic use]; Male; Melanoma [mortality, secondary, *therapy]; Middle Aged; Programmed Cell Death 1 Receptor [antagonists & inhibitors]; Proto-Oncogene Proteins B-raf [antagonists & inhibitors]; Randomized Controlled Trials as Topic; Skin Neoplasms [mortality, *therapy]}, -URL = {http://dx.doi.org/10.1002/14651858.CD011123.pub2} -} - - -Record #43 of 54 -@article{Kreuzberger22, -author = {Kreuzberger, N, Hirsch, C, Andreas, M, Böhm, L, Bröckelmann, PJ, Di Cristanziano, V, Golinski, M, Hausinger, RIlona, Mellinghoff, S, Lange, B, Lischetzki, T, Kappler, V, Mikolajewska, A, Monsef, I, Park, YS, Piechotta, V, Schmaderer, C, Stegemann, M, Vanshylla, K, Weber, F, Weibel, S, Stephani, C, and Skoetz, N}, -title = {Immunity after COVID‐19 vaccination in people with higher risk of compromised immune status: a scoping review}, -journal = {Cochrane Database of Systematic Reviews}, -number = {8}, -year = {2022}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background High efficacy in terms of protection from severe COVID‐19 has been demonstrated for several SARS‐CoV‐2 vaccines. However, patients with compromised immune status develop a weaker and less stable immune response to vaccination. Strong immune response may not always translate into clinical benefit, therefore it is important to synthesise evidence on modified schemes and types of vaccination in these population subgroups for guiding health decisions. As the literature on COVID‐19 vaccines continues to expand, we aimed to scope the literature on multiple subgroups to subsequently decide on the most relevant research questions to be answered by systematic reviews. Objectives To provide an overview of the availability of existing literature on immune response and long‐term clinical outcomes after COVID‐19 vaccination, and to map this evidence according to the examined populations, specific vaccines, immunity parameters, and their way of determining relevant long‐term outcomes and the availability of mapping between immune reactivity and relevant outcomes. Search methods We searched the Cochrane COVID‐19 Study Register, the Web of Science Core Collection, and the World Health Organization COVID‐19 Global literature on coronavirus disease on 6 December 2021. Selection criteria We included studies that published results on immunity outcomes after vaccination with BNT162b2, mRNA‐1273, AZD1222, Ad26.COV2.S, Sputnik V or Sputnik Light, BBIBP‐CorV, or CoronaVac on predefined vulnerable subgroups such as people with malignancies, transplant recipients, people undergoing renal replacement therapy, and people with immune disorders, as well as pregnant and breastfeeding women, and children. We included studies if they had at least 100 participants (not considering healthy control groups); we excluded case studies and case series. Data collection and analysis We extracted data independently and in duplicate onto an online data extraction form. Data were represented as tables and as online maps to show the frequency of studies for each item. We mapped the data according to study design, country of participant origin, patient comorbidity subgroup, intervention, outcome domains (clinical, safety, immunogenicity), and outcomes. Main results Out of 25,452 identified records, 318 studies with a total of more than 5 million participants met our eligibility criteria and were included in the review. Participants were recruited mainly from high‐income countries between January 2020 and 31 October 2021 (282/318); the majority of studies included adult participants (297/318). Haematological malignancies were the most commonly examined comorbidity group (N = 54), followed by solid tumours (N = 47), dialysis (N = 48), kidney transplant (N = 43), and rheumatic diseases (N = 28, 17, and 15 for mixed diseases, multiple sclerosis, and inflammatory bowel disease, respectively). Thirty‐one studies included pregnant or breastfeeding women. The most commonly administered vaccine was BNT162b2 (N = 283), followed by mRNA‐1273 (N = 153), AZD1222 (N = 66), Ad26.COV2.S (N = 42), BBIBP‐CorV (N = 15), CoronaVac (N = 14), and Sputnik V (N = 5; no studies were identified for Sputnik Light). Most studies reported outcomes after regular vaccination scheme. The majority of studies focused on immunogenicity outcomes, especially seroconversion based on binding antibody measurements and immunoglobulin G (IgG) titres (N = 179 and 175, respectively). Adverse events and serious adverse events were reported in 126 and 54 studies, whilst SARS‐CoV‐2 infection irrespective of severity was reported in 80 studies. Mortality due to SARS‐CoV‐2 infection was reported in 36 studies. Please refer to our evidence gap maps for more detailed information. Authors' conclusions Up to 6 December 2021, the majority of studies examined data on mRNA vaccines administered as standard vaccination schemes (two doses approximately four to eight weeks apart) that report on immunogenicity parameters or adverse events. Clinical outcomes were less commonly reported, and if so, were often reported as a secondary outcome observed in seroconversion or immunoglobulin titre studies. As informed by this scoping review, two effectiveness reviews (on haematological malignancies and kidney transplant recipients) are currently being conducted. Plain language summary Immunity in vulnerable groups after COVID‐19 vaccination What did we want to find out? We wanted to find out which studies on the most commonly used COVID‐19 vaccines in vulnerable subgroups have been published, and which outcomes were reported (e.g. effectiveness outcomes, safety, or immune response), to decide on the most relevant questions and answer these in further effectiveness systematic reviews (syntheses of the medical literature). What did we do? We searched medical databases and trial registries for studies on COVID‐19 vaccines that were authorised for use in the European Union (European Medicines Agency (EMA)‐approved) and those approved in at least 10 countries worldwide at the time of our search. We included studies on additional conditions (comorbidities) that can reduce the immune reaction to vaccination, if they had more than 100 participants; they could include any age, sex, ethnicity, or country of recruitment. We excluded studies looking at the general population and other than preselected COVID‐19 vaccines and subgroups. Once we found the studies, we categorised the vaccines into the following groups: EMA‐approved COVID‐19 vaccines, other COVID‐19 vaccines, and schemes with different COVID‐19 vaccines. We summarised the results in an interactive online map. We mapped the study outcomes, the country in which the study was conducted, the study design, and the vulnerable population. What did we find? We included 318 studies. Most studies came from high‐income countries and included adults. We found that haematological malignancies (cancers that affect the blood, bone marrow, and lymph nodes) and solid tumours were examined in many studies, followed by people receiving dialysis and kidney transplants, rheumatic diseases, and others. Thirty‐one studies included pregnant or breastfeeding women. The majority of studies explored mRNA vaccines (N = 283 and N = 153 for BNT162b2 and mRNA‐1273) at two doses, and EMA‐approved vaccines were more commonly administered than other vaccines and schemes with different COVID‐19 vaccines. Outcomes related to immunogenicity (how well a vaccine works, or the ability to stimulate the development of antibodies), especially the presence or absence of antibodies in the blood of patients or an estimate for the amount of these antibodies, were the most frequently reported outcome in more than 170 studies each. In addition, adverse events were assessed often (N = 126 studies), whilst SARS‐CoV‐2 infection was reported in only 80 studies. What are the limitations of the evidence? Due to the quick development of the pandemic, the research landscape may have changed. The newer Omicron variant has become the dominant variant, and a new vaccine has been approved by the EMA, which is not covered by our search. How up‐to‐date is this evidence? The evidence is up‐to‐date to December 2021. What are the next steps? Based on the overview from this review, we have decided to conduct two detailed systematic reviews on haematological malignancies and kidney transplant recipients.}, -DOI = {10.1002/14651858.CD015021}, -keywords = {*COVID-19 [epidemiology, prevention & control]; *Hematologic Neoplasms; *Vaccines; Ad26COVS1; Adult; BNT162 Vaccine; COVID-19 Vaccines; ChAdOx1 nCoV-19; Child; Female; Humans; Pregnancy; SARS-CoV-2; Vaccination}, -URL = {http://dx.doi.org/10.1002/14651858.CD015021} -} - - -Record #44 of 54 -@article{Posadzki16, -author = {Posadzki, P, Mastellos, N, Ryan, R, Gunn, LH, Felix, LM, Pappas, Y, Gagnon, MP, Julious, SA, Xiang, L, Oldenburg, B, and Car, J}, -title = {Automated telephone communication systems for preventive healthcare and management of long‐term conditions}, -journal = {Cochrane Database of Systematic Reviews}, -number = {12}, -year = {2016}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Automated telephone communication systems (ATCS) can deliver voice messages and collect health‐related information from patients using either their telephone's touch‐tone keypad or voice recognition software. ATCS can supplement or replace telephone contact between health professionals and patients. There are four different types of ATCS: unidirectional (one‐way, non‐interactive voice communication), interactive voice response (IVR) systems, ATCS with additional functions such as access to an expert to request advice (ATCS Plus) and multimodal ATCS, where the calls are delivered as part of a multicomponent intervention. Objectives To assess the effects of ATCS for preventing disease and managing long‐term conditions on behavioural change, clinical, process, cognitive, patient‐centred and adverse outcomes. Search methods We searched 10 electronic databases (the Cochrane Central Register of Controlled Trials; MEDLINE; Embase; PsycINFO; CINAHL; Global Health; WHOLIS; LILACS; Web of Science; and ASSIA); three grey literature sources (Dissertation Abstracts, Index to Theses, Australasian Digital Theses); and two trial registries (www.controlled‐trials.com; www.clinicaltrials.gov) for papers published between 1980 and June 2015. Selection criteria Randomised, cluster‐ and quasi‐randomised trials, interrupted time series and controlled before‐and‐after studies comparing ATCS interventions, with any control or another ATCS type were eligible for inclusion. Studies in all settings, for all consumers/carers, in any preventive healthcare or long term condition management role were eligible. Data collection and analysis We used standard Cochrane methods to select and extract data and to appraise eligible studies. Main results We included 132 trials (N = 4,669,689). Studies spanned across several clinical areas, assessing many comparisons based on evaluation of different ATCS types and variable comparison groups. Forty‐one studies evaluated ATCS for delivering preventive healthcare, 84 for managing long‐term conditions, and seven studies for appointment reminders. We downgraded our certainty in the evidence primarily because of the risk of bias for many outcomes. We judged the risk of bias arising from allocation processes to be low for just over half the studies and unclear for the remainder. We considered most studies to be at unclear risk of performance or detection bias due to blinding, while only 16% of studies were at low risk. We generally judged the risk of bias due to missing data and selective outcome reporting to be unclear. For preventive healthcare, ATCS (ATCS Plus, IVR, unidirectional) probably increase immunisation uptake in children (risk ratio (RR) 1.25, 95% confidence interval (CI) 1.18 to 1.32; 5 studies, N = 10,454; moderate certainty) and to a lesser extent in adolescents (RR 1.06, 95% CI 1.02 to 1.11; 2 studies, N = 5725; moderate certainty). The effects of ATCS in adults are unclear (RR 2.18, 95% CI 0.53 to 9.02; 2 studies, N = 1743; very low certainty). For screening, multimodal ATCS increase uptake of screening for breast cancer (RR 2.17, 95% CI 1.55 to 3.04; 2 studies, N = 462; high certainty) and colorectal cancer (CRC) (RR 2.19, 95% CI 1.88 to 2.55; 3 studies, N = 1013; high certainty) versus usual care. It may also increase osteoporosis screening. ATCS Plus interventions probably slightly increase cervical cancer screening (moderate certainty), but effects on osteoporosis screening are uncertain. IVR systems probably increase CRC screening at 6 months (RR 1.36, 95% CI 1.25 to 1.48; 2 studies, N = 16,915; moderate certainty) but not at 9 to 12 months, with probably little or no effect of IVR (RR 1.05, 95% CI 0.99, 1.11; 2 studies, 2599 participants; moderate certainty) or unidirectional ATCS on breast cancer screening. Appointment reminders delivered through IVR or unidirectional ATCS may improve attendance rates compared with no calls (low certainty). For long‐term management, medication or laboratory test adherence provided the most general evidence across conditions (25 studies, data not combined). Multimodal ATCS versus usual care showed conflicting effects (positive and uncertain) on medication adherence. ATCS Plus probably slightly (versus control; moderate certainty) or probably (versus usual care; moderate certainty) improves medication adherence but may have little effect on adherence to tests (versus control). IVR probably slightly improves medication adherence versus control (moderate certainty). Compared with usual care, IVR probably improves test adherence and slightly increases medication adherence up to six months but has little or no effect at longer time points (moderate certainty). Unidirectional ATCS, compared with control, may have little effect or slightly improve medication adherence (low certainty). The evidence suggested little or no consistent effect of any ATCS type on clinical outcomes (blood pressure control, blood lipids, asthma control, therapeutic coverage) related to adherence, but only a small number of studies contributed clinical outcome data. The above results focus on areas with the most general findings across conditions. In condition‐specific areas, the effects of ATCS varied, including by the type of ATCS intervention in use. Multimodal ATCS probably decrease both cancer pain and chronic pain as well as depression (moderate certainty), but other ATCS types were less effective. Depending on the type of intervention, ATCS may have small effects on outcomes for physical activity, weight management, alcohol consumption, and diabetes mellitus. ATCS have little or no effect on outcomes related to heart failure, hypertension, mental health or smoking cessation, and there is insufficient evidence to determine their effects for preventing alcohol/substance misuse or managing illicit drug addiction, asthma, chronic obstructive pulmonary disease, HIV/AIDS, hypercholesterolaemia, obstructive sleep apnoea, spinal cord dysfunction or psychological stress in carers. Only four trials (3%) reported adverse events, and it was unclear whether these were related to the interventions. Authors' conclusions ATCS interventions can change patients' health behaviours, improve clinical outcomes and increase healthcare uptake with positive effects in several important areas including immunisation, screening, appointment attendance, and adherence to medications or tests. The decision to integrate ATCS interventions in routine healthcare delivery should reflect variations in the certainty of the evidence available and the size of effects across different conditions, together with the varied nature of ATCS interventions assessed. Future research should investigate both the content of ATCS interventions and the mode of delivery; users' experiences, particularly with regard to acceptability; and clarify which ATCS types are most effective and cost‐effective. Plain language summary Automated telephone communication systems for preventing disease and managing long‐term conditions Background Automated telephone communication systems (ATCS) send voice messages and collect health information from people using their telephone's touch‐tone keypad or voice recognition software. This could replace or supplement telephone contact between health professionals and patients. There are several types of ATCS: one‐way voice messages to patients (unidirectional), interactive voice response (IVR) systems, those with added functions like referral to advice (ATCS Plus), or those where ATCS are part of a complex intervention (multimodal). Review question This review assessed the effectiveness of ATCS for preventing disease and managing long‐term conditions. Results We found 132 trials with over 4 million participants across preventive healthcare areas and for the management of long‐term conditions. Studies compared ATCS types in many ways. Some studies reported findings across diseases. For prevention, ATCS probably increase immunisation uptake in children, and slightly in adolescents, but in adults effects are uncertain. Also for prevention, multimodal ATCS increase numbers of people screened for breast or colorectal cancers, and may increase osteoporosis screening. ATCS Plus probably slightly increases attendance for cervical cancer screening, with uncertain effects on osteoporosis screening. IVR probably increases the numbers screened for colorectal cancer up to six months, with little effect on breast cancer screening. ATCS (unidirectional or IVR) may improve appointment attendance, key to both preventing and managing disease. For long‐term management, multimodal ATCS had inconsistent effects on medication adherence. ATCS Plus probably improves medication adherence versus usual care. Compared with control, ATCS Plus and IVR probably slightly improve adherence, while unidirectional ATCS may have little, or slightly positive, effects. No intervention consistently improved clinical outcomes. IVR probably improves test adherence, but ATCS Plus may have little effect. ATCS were also used in specific conditions. Effects varied by condition and ATCS type. Multimodal ATCS, but not other ATCS types, probably decrease cancer pain and chronic pain. Outcomes may improve to a small degree when ATCS are applied to physical activity, weight management, alcohol use and diabetes.However, there is little or no effect in heart failure, hypertension, mental health or quitting smoking. In several areas (alcohol/substance misuse, addiction, asthma, chronic obstructive pulmonary disease, HIV/AIDS, high cholesterol, obstructive sleep apnoea, spinal cord dysfunction, carers' psychological stress), there is not enough evidence to tell what effects ATCS have. Only four trials reported adverse events. Our certainty in the evidence varied (high to very low), and was often lowered because of study limitations, meaning that further research may change some findings. Conclusion ATCS may be promising for changing certain health behaviours, improving health outcomes and increasing healthcare uptake.}, -DOI = {10.1002/14651858.CD009921.pub2}, -keywords = {*Preventive Health Services; *Primary Prevention; *Speech Recognition Software; *Telephone; Adolescent; Adult; Child; Chronic Disease [*therapy]; Exercise; Health Behavior; Health Communication [*methods]; Humans; Immunization [statistics & numerical data]; Patient Compliance; Randomized Controlled Trials as Topic; Reminder Systems}, -URL = {http://dx.doi.org/10.1002/14651858.CD009921.pub2} -} - - -Record #45 of 54 -@article{Fisher19, -author = {Fisher, SA, Cutler, A, Doree, C, Brunskill, SJ, Stanworth, SJ, Navarrete, C, and Girdlestone, J}, -title = {Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition}, -journal = {Cochrane Database of Systematic Reviews}, -number = {1}, -year = {2019}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Recipients of allogeneic haematopoietic stem cell transplants (HSCT) can develop acute or chronic, or both forms of graft‐versus‐host disease (a/cGvHD), whereby immune cells of the donor attack host tissues. Steroids are the primary treatment, but patients with severe, refractory disease have limited options and a poor prognosis. Mesenchymal stromal cells (MSCs) exhibit immunosuppressive properties and are being tested in clinical trials for their safety and efficacy in treating many immune‐mediated disorders. GvHD is one of the first areas in which MSCs were clinically applied, and it is important that the accumulating evidence is systematically reviewed to assess whether their use is favoured. Objectives To determine the evidence for the safety and efficacy of MSCs for treating immune‐mediated inflammation post‐transplantation of haematopoietic stem cells. Search methods We searched for randomised controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library 2018, Issue 12), MEDLINE (from 1946), Embase (from 1974), CINAHL (from 1937), Web of Science: Conference Proceedings Citation Index‐Science (CPCI‐S) (from 1990) and ongoing trial databases to 6 December 2018. No constraints were placed on language or publication status. Selection criteria We included RCTs of participants with a haematological condition who have undergone an HSCT as treatment for their condition and were randomised to MSCs (intervention arm) or no MSCs (comparator arm), to prevent or treat GvHD. We also included RCTs which compared different doses of MSCs or MSCs of different sources (e.g. bone marrow versus cord). We included MSCs co‐transplanted with haematopoietic stem cells as well as MSCs administered post‐transplantation of haematopoietic stem cells. Data collection and analysis We used standard methodological procedures expected by Cochrane. We employed a random‐effects model for all analyses due to expected clinical heterogeneity arising from differences in participant characteristics and interventions. Main results We identified 12 completed RCTs (879 participants), and 13 ongoing trials (1532 enrolled participants planned). Of 12 completed trials, 10 compared MSCs versus no MSCs and two compared different doses of MSCs. One trial was in people with thalassaemia major, the remaining trials were for haematological malignancies. Seven trials administered MSCs to prevent GvHD, whereas five trials gave MSCs to treat GvHD. In the comparison of MSCs with no MSCs, cells were administered at a dose of between 10 5 and 10 7 cells/kg in either a single dose (six trials) or in multiple doses (four trials) over a period of three days to four months. The dose‐comparison trials compared 2 x 10 6 cells/kg with 8 x 10 6 cells/kg in two infusions, or 1 x 10 6 cells/kg with 3 x 10 6 cells/kg in a single infusion. The median duration of follow‐up in seven trials which administered MSCs prophylactically ranged from 10 to 60 months. In three trials of MSCs as treatment for aGvHD, participants were followed up for 90 or 100 days. In two trials of MSCs as treatment for cGvHD, the mean duration of follow‐up was 13.4 months (MSC group) and 23.6 months (control group) in one trial, and 56 weeks in the second trial. Five trials included adults only, six trials included adults and children, and one trial included children only. In eight trials which reported the gender distribution, the percentage of females ranged from 20% to 59% (median 35.8%). The overall quality of the included studies was low: randomisation methods were poorly reported and several of the included studies were subject to a high risk of performance bias and reporting bias. One trial which started in 2008 has not been published and the progress of this trial in unknown, leading to potential publication bias. The quality of evidence was therefore low or very low for all outcomes due to a high risk of bias as well as imprecision due to the low number of overall participants, and in some cases evidence based on a single study. We found that MSCs may make little or no difference in the risk of all‐cause mortality in either prophylactic trials (HR 0.85, 95% CI 0.50 to 1.42; participants = 301; studies = 5; I 2 = 34% ; low‐quality evidence) or therapeutic trials (HR 1.12, 95% CI 0.80 to 1.56; participants = 244; studies = 1; very low‐quality evidence), and no difference in the risk of relapse of malignant disease (prophylactic trials: RR 1.08, 95% CI 0.73 to 1.59; participants = 323; studies = 6; I 2 = 0%; low‐quality evidence) compared with no MSCs. MSCs were well‐tolerated, no infusion‐related toxicity or ectopic tissue formation was reported. No study reported health‐related quality of life. In prophylactic trials, MSCs may reduce the risk of chronic GvHD (RR 0.66, 95% CI 0.49 to 0.89; participants = 283; studies = 6; I 2 = 0%; low‐quality evidence). This means that only 310 (95% CI 230 to 418) in every 1000 patients in the MSC arm are expected to develop chronic GvHD compared to 469 in the control arm. However, MSCs may make little or no difference to the risk of aGvHD (RR 0.86, 95% CI 0.63 to 1.17; participants = 247; studies = 6; I 2 = 0%; low‐quality evidence). In GvHD therapeutic trials, we are very uncertain whether MSCs improve complete response of either aGvHD (RR 1.16, 95% CI 0.79 to 1.70, participants = 260, studies = 1; very low‐quality evidence) or cGvHD (RR 5.00, 95%CI 0.75 to 33.21, participants = 40, studies = 1; very low‐quality evidence). In two trials which compared different doses of MSCs, we found no evidence of any differences in outcomes. Authors' conclusions MSCs are an area of intense research activity, and an increasing number of trials have been undertaken or are planned. Despite a number of reports of positive outcomes from the use of MSCs for treating acute GvHD, the evidence to date from RCTs has not supported the conclusion that they are an effective therapy. There is low‐quality evidence that MSCs may reduce the risk of cGvHD. New trial evidence will be incorporated into future updates of this review, which may better establish a role for MSCs in the prevention or treatment of GvHD. Plain language summary Mesenchymal stromal cells to treat or prevent graft‐versus‐host disease in stem cell transplant recipients Review question In people who receive a stem cell transplant for a haematological condition, can an additional infusion of mesenchymal stromal cells (MSCs) prevent the development of graft‐versus‐host disease (GvHD)? In people who have already developed GvHD as a result of their stem cell transplant, can MSCs improve their clinical outcome? Background Patients with leukaemia or other blood disorders may be treated with blood stem cells from another person, but the immune cells in the graft can attack their tissues in a serious complication referred to as graft‐versus‐host disease (GvHD). Steroids are the standard treatment for GvHD, but if they are unable stop the damage then treatment options are limited. In order to look for potential new treatments, a number of hospitals around the world have investigated the use of MSCs for inhibiting GvHD. MSCs are a type of cell that can develop into connective tissue (e.g. bone or cartilage), but they have also been found to have anti‐inflammatory properties. For clinical trials, MSCs have been isolated from different tissue sources (e.g. bone marrow, fat, or umbilical cords) and then grown in large numbers in the laboratory. The MSC preparations are then injected intravenously into the patient at the time they have their stem cell transplant or afterward, either to prevent GvHD (prophylaxis) or to treat ongoing disease. For patients being treated for GvHD, is treatment with MSCs safe and effective against complications of inflammation associated with GvHD? Study characteristics The evidence is current to 6 December 2018. We identified 12 studies and 13 ongoing trials. Ten studies compared MSCs with a control group, and two studies compared different doses of MSCs. Five trials included only adults, whereas six trials include both adults and children and one trial was exclusively performed in children. Of the 12 completed trials, one trial was in people with inherited blood disorders (thalassaemia major), and 11 trials were in people with blood cancers. In seven trials, MSCs were given to prevent GvHD, whereas in five trials, MSCs were given to people who had already developed GvHD. MSCs were derived from umbilical cord in two trials, bone marrow in seven trials and adipose tissue in one trial; in two trials the origin of MSCs was unknown. In the comparison of MSCs with no MSCs, cells were administered at a dose of between 10 5 and 10 7 cells/kg. Seven trials gave MSCs in a single dose, whereas five trials gave multiple doses of MSCs. Trial participants were followed up for between 10 and 60 months, or in those who had already developed GvHD, up to two years. Three trials were funded and carried out by a commercial manufacturer, using their cultured mesenchymal stromal cells known as Prochymal. All trials included both men and women. Key results MSCs may have little or no difference in the risk of death or relapse of malignant disease, in either GvHD prevention or treatment trials, as the quality of evidence was low. MSCs were well‐tolerated, no infusion‐related toxicity or ectopic tissue formation was reported. No study reported health‐related quality‐of‐life. In trials where MSCs were administered to prevent GvHD, MSCs may reduce the risk of developing chronic GvHD, but may make little or no difference to the risk of developing acute GvHD. In GvHD treatment trials, we are very uncertain whether MSCs improve complete response of either acute or chronic GvHD as the quality of evidence is very low. We found no differences in outcomes between participants who received a higher dose of MSCs when compared with those who received a lower dose of MSCs. Quality of the evidence The quality of evidence is low or very low for all outcome measures, due to the small number of trials and low number of study participants included in this review. One trial started in 2008, but its results are unknown as it is not yet published. It is therefore difficult to draw conclusions or provide recommendations on the use of MSCs, either to prevent or treat GvHD. More trials with large numbers of study participants are needed to improve the quality of evidence.}, -DOI = {10.1002/14651858.CD009768.pub2}, -keywords = {*Mesenchymal Stem Cell Transplantation [mortality]; Acute Disease; Chronic Disease; Graft vs Host Disease [epidemiology, *therapy]; Hematologic Neoplasms [mortality, *therapy]; Hematopoietic Stem Cell Transplantation [*adverse effects]; Humans; Incidence; Randomized Controlled Trials as Topic; Recurrence; beta-Thalassemia [*therapy]}, -URL = {http://dx.doi.org/10.1002/14651858.CD009768.pub2} -} - - -Record #46 of 54 -@article{Patel17, -author = {Patel, SV, Paskar, DD, Nelson, RL, Vedula, SS, and Steele, SR}, -title = {Closure methods for laparotomy incisions for preventing incisional hernias and other wound complications}, -journal = {Cochrane Database of Systematic Reviews}, -number = {11}, -year = {2017}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Surgeons who perform laparotomy have a number of decisions to make regarding abdominal closure. Material and size of potential suture types varies widely. In addition, surgeons can choose to close the incision in anatomic layers or mass ('en masse'), as well as using either a continuous or interrupted suturing technique, of which there are different styles of each. There is ongoing debate as to which suturing techniques and suture materials are best for achieving definitive wound closure while minimising the risk of short‐ and long‐term complications. Objectives The objectives of this review were to identify the best available suture techniques and suture materials for closure of the fascia following laparotomy incisions, by assessing the following comparisons: absorbable versus non‐absorbable sutures; mass versus layered closure; continuous versus interrupted closure techniques; monofilament versus multifilament sutures; and slow absorbable versus fast absorbable sutures. Our objective was not to determine the single best combination of suture material and techniques, but to compare the individual components of abdominal closure. Search methods On 8 February 2017 we searched CENTRAL, MEDLINE, Embase, two trials registries, and Science Citation Index. There were no limitations based on language or date of publication. We searched the reference lists of all included studies to identify trials that our searches may have missed. Selection criteria We included randomised controlled trials (RCTs) that compared suture materials or closure techniques, or both, for fascial closure of laparotomy incisions. We excluded trials that compared only types of skin closures, peritoneal closures or use of retention sutures. Data collection and analysis We abstracted data and assessed the risk of bias for each trial. We calculated a summary risk ratio (RR) for the outcomes assessed in the review, all of which were dichotomous. We used random‐effects modelling, based on the heterogeneity seen throughout the studies and analyses. We completed subgroup analysis planned a priori for each outcome, excluding studies where interventions being compared differed by more than one component, making it impossible to determine which variable impacted on the outcome, or the possibility of a synergistic effect. We completed sensitivity analysis, excluding trials with at least one trait with high risk of bias. We assessed the quality of evidence using the GRADEpro guidelines. Main results Fifty‐five RCTs with a total of 19,174 participants met the inclusion criteria and were included in the meta‐analysis. Included studies were heterogeneous in the type of sutures used, methods of closure and patient population. Many of the included studies reported multiple comparisons. For our primary outcome, the proportion of participants who developed incisional hernia at one year or more of follow‐up, we did not find evidence that suture absorption (absorbable versus non‐absorbable sutures, RR 1.07, 95% CI 0.86 to 1.32, moderate‐quality evidence; or slow versus fast absorbable sutures, RR 0.81, 95% CI 0.63 to 1.06, moderate‐quality evidence), closure method (mass versus layered, RR 1.92, 95% CI 0.58 to 6.35, very low‐quality evidence) or closure technique (continuous versus interrupted, RR 1.01, 95% CI 0.76 to 1.35, moderate‐quality evidence) resulted in a difference in the risk of incisional hernia. We did, however, find evidence to suggest that monofilament sutures reduced the risk of incisional hernia when compared with multifilament sutures (RR 0.76, 95% CI 0.59 to 0.98, I 2 = 30%, moderate‐quality evidence). For our secondary outcomes, we found that none of the interventions reduced the risk of wound infection, whether based on suture absorption (absorbable versus non‐absorbable sutures, RR 0.99, 95% CI 0.84 to 1.17, moderate‐quality evidence; or slow versus fast absorbable sutures, RR 1.16, 95% CI 0.85 to 1.57, moderate‐quality evidence), closure method (mass versus layered, RR 0.93, 95% CI 0.67 to 1.30, low‐quality evidence) or closure technique (continuous versus interrupted, RR 1.13, 95% CI 0.96 to 1.34, moderate‐quality evidence). Similarily, none of the interventions reduced the risk of wound dehiscence whether based on suture absorption (absorbable versus non‐absorbable sutures, RR 0.78, 95% CI 0.55 to 1.10, moderate‐quality evidence; or slow versus fast absorbable sutures, RR 1.55, 95% CI 0.92 to 2.61, moderate‐quality evidence), closure method (mass versus layered, RR 0.69, 95% CI 0.31 to 1.52, moderate‐quality evidence) or closure technique (continuous versus interrupted, RR 1.21, 95% CI 0.90 to 1.64, moderate‐quality evidence). Absorbable sutures, compared with non‐absorbable sutures (RR 0.49, 95% CI 0.26 to 0.94, low‐quality evidence) reduced the risk of sinus or fistula tract formation. None of the other comparisons showed a difference (slow versus fast absorbable sutures, RR 0.88, 95% CI 0.05 to 16.05, very low‐quality evidence; mass versus layered, RR 0.49, 95% CI 0.15 to 1.62, low‐quality evidence; continuous versus interrupted, RR 1.51, 95% CI 0.64 to 3.61, very low‐quality evidence). Authors' conclusions Based on this moderate‐quality body of evidence, monofilament sutures may reduce the risk of incisional hernia. Absorbable sutures may also reduce the risk of sinus or fistula tract formation, but this finding is based on low‐quality evidence. We had serious concerns about the design or reporting of several of the 55 included trials. The comparator arms in many trials differed by more than one component, making it impossible to attribute differences between groups to any one component. In addition, the patient population included in many of the studies was very heterogeneous. Trials included both emergency and elective cases, different types of disease pathology (e.g. colon surgery, hepatobiliary surgery, etc.) or different types of incisions (e.g. midline, paramedian, subcostal). Consequently, larger, high‐quality trials to further address this clinical challenge are warranted. Future studies should ensure that proper randomisation and allocation techniques are performed, wound assessors are blinded, and that the duration of follow‐up is adequate. It is important that only one type of intervention is compared between groups. In addition, a homogeneous patient population would allow for a more accurate assessment of the interventions. Plain language summary What is the best way to close abdominal incisions following surgery? What is the Issue? Laparotomy, an incision through the abdominal wall to access the abdominal cavity, is performed for a variety of surgical procedures. Incisional hernia, infection, dehiscence (an opening of the wound or muscle layers) and chronic drainage from the wound, are potential complications of this procedure. Why is it Important? Incisional hernias affect up to 20% of people undergoing a laparotomy. Incisional hernias, as they enlarge over time, cause patient discomfort, which in turn, result in patients restricting their work and other physical activities. Cosmetic concerns may also arise. We asked: Does the type of suture material, or type of closure prevent these complications? We compared absorbable sutures (sutures that lose their tensile strength as they are dissolved by the patient's body) versus non‐absorbable (permanent) sutures; mass closure (closure of all anatomical layers of abdominal wall at once) versus layered closure (closing the anatomic layers individually); continuous closure (running suture) versus interrupted closure; monofilament sutures versus multifilament (braided) sutures; and slow absorbable sutures (those that maintain their tensile strength for more than 30 days) versus fast absorbable sutures (those that lose their tensile strength within 30 days). We found: A search of all relevant publications (up to date as of 8 February 2017) found a total of 55 studies with 19,174 participants to include in the review. The included studies differed greatly in the type of suture materials used, the closure technique and the type of underlying surgical procedures performed. We found that using monofilament sutures reduced the occurrence of incisional hernia. Absorbable sutures reduced the risk of chronic drainage from the wound (sinus or fistula formation). This review included a notably large number of trials; however, we had concerns regarding their collective methodological design and scientific reporting. This means: Monofilament sutures can be considered for abdominal closure to reduce the risk of incisional hernia. Absorbable sutures can be considered to reduce the risk of chronic drainage from the wound.}, -DOI = {10.1002/14651858.CD005661.pub2}, -keywords = {*Abdominal Wound Closure Techniques; *Laparotomy; *Suture Techniques; *Sutures; Fistula [epidemiology]; Humans; Incisional Hernia [epidemiology, *prevention & control]; Randomized Controlled Trials as Topic; Surgical Wound Dehiscence [epidemiology]; Surgical Wound Infection [epidemiology]}, -URL = {http://dx.doi.org/10.1002/14651858.CD005661.pub2} -} - - -Record #47 of 54 -@article{Archambault17, -author = {Archambault, PM, van de Belt, TH, Kuziemsky, C, Plaisance, A, Dupuis, A, McGinn, CA, Francois, R, Gagnon, MP, Turgeon, AF, Horsley, T, Witteman, W, Poitras, J, Lapointe, J, Brand, K, Lachaine, J, and Légaré, F}, -title = {Collaborative writing applications in healthcare: effects on professional practice and healthcare outcomes}, -journal = {Cochrane Database of Systematic Reviews}, -number = {5}, -year = {2017}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Collaborative writing applications (CWAs), such as wikis and Google Documents, hold the potential to improve the use of evidence in both public health and healthcare. Although a growing body of literature indicates that CWAs could have positive effects on healthcare, such as improved collaboration, behavioural change, learning, knowledge management, and adaptation of knowledge to local context, this has never been assessed systematically. Moreover, several questions regarding safety, reliability, and legal aspects exist. Objectives The objectives of this review were to (1) assess the effects of the use of CWAs on process (including the behaviour of healthcare professionals) and patient outcomes, (2) critically appraise and summarise current evidence on the use of resources, costs, and cost‐effectiveness associated with CWAs to improve professional practices and patient outcomes, and (3) explore the effects of different CWA features (e.g. open versus closed) and different implementation factors (e.g. the presence of a moderator) on process and patient outcomes. Search methods We searched CENTRAL, MEDLINE, Embase, and 11 other electronic databases. We searched the grey literature, two trial registries, CWA websites, individual journals, and conference proceedings. We also contacted authors and experts in the field. We did not apply date or language limits. We searched for published literature to August 2016, and grey literature to September 2015. Selection criteria We included randomised controlled trials (RCTs), non‐randomised controlled trials (NRCTs), controlled before‐and‐after (CBA) studies, interrupted time series (ITS) studies, and repeated measures studies (RMS), in which CWAs were used as an intervention to improve the process of care, patient outcomes, or healthcare costs. Data collection and analysis Teams of two review authors independently assessed the eligibility of studies. Disagreements were resolved by discussion, and when consensus was not reached, a third review author was consulted. Main results We screened 11,993 studies identified from the electronic database searches and 346 studies from grey literature sources. We analysed the full text of 99 studies. None of the studies met the eligibility criteria; two potentially relevant studies are ongoing. Authors' conclusions While there is a high number of published studies about CWAs, indicating that this is an active field of research, additional studies using rigorous experimental designs are needed to assess their impact and cost‐effectiveness on process and patient outcomes. Plain language summary Collaborative writing applications to support the implementation of best practices in healthcare. What is the aim of this review? The aim of this Cochrane review was to find out whether collaborative writing applications (CWAs), also known as collaborative writing tools, could improve the way health professionals work, and improve patients’ health. Another goal of our study was to examine the costs and resources needed to use CWAs. Finally, we wanted to know if certain CWA features (for example, being open, like Wikipedia, versus being closed, like the Canadian CPOE toolkit), and different clinical practice change factors (for example, the presence of a moderator) increased the CWAs' impact on healthcare. We searched for studies to answer these questions. Key messages We did not identify any studies that measured the effect of CWAs on how healthcare professionals care for their patients. What was studied in this review? When people receive healthcare, it is important that they are treated according to best practices. However, decision makers, health professionals, researchers, and patients need tools to support best practices. Collaborative writing applications are a new category of information and communication technologies that allow multiple individuals to share, create, and revise online documents at the same time. They could help implement best practices in healthcare. Collaborative writing applications could also help adapt online documents to local contexts. This could help reduce duplication and waste of resources. The most widely known example of a CWA is Wikipedia, the online encyclopaedia. However, there are many other examples of CWAs (e.g. WikEM, WikiDoc, Canadian CPOE toolkit, WikiTrauma). Despite the fact that CWAs are promising tools, it is not yet known if they improve how healthcare professionals care for their patients. What are the main results of the review? We searched 14 scientific bibliographic databases, two trial registries, and grey literature sources. We also contacted 106 authors and experts in the field to ask for relevant papers. No studies met our eligibility criteria; two potentially relevant studies are ongoing. How up to date is this review? We searched for evidence to August 2016.}, -DOI = {10.1002/14651858.CD011388.pub2}, -keywords = {*Cooperative Behavior; *Database Management Systems; *Outcome and Process Assessment, Health Care; *Professional Practice; Data Mining [*methods, standards]; Humans; Social Media [*standards]; Writing [*standards]}, -URL = {http://dx.doi.org/10.1002/14651858.CD011388.pub2} -} - - -Record #48 of 54 -@article{Hanna20, -author = {Hanna, C, Lawrie, TA, Rogozińska, E, Kernohan, A, Jefferies, S, Bulbeck, H, Ali, UM, Robinson, T, and Grant, R}, -title = {Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis}, -journal = {Cochrane Database of Systematic Reviews}, -number = {3}, -year = {2020}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background A glioblastoma is a fatal type of brain tumour for which the standard of care is maximum surgical resection followed by chemoradiotherapy, when possible. Age is an important consideration in this disease, as older age is associated with shorter survival and a higher risk of treatment‐related toxicity. Objectives To determine the most effective and best‐tolerated approaches for the treatment of elderly people with newly diagnosed glioblastoma. To summarise current evidence for the incremental resource use, utilities, costs and cost‐effectiveness associated with these approaches. Search methods We searched electronic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase to 3 April 2019, and the NHS Economic Evaluation Database (EED) up to database closure. We handsearched clinical trial registries and selected neuro‐oncology society conference proceedings from the past five years. Selection criteria Randomised trials (RCTs) of treatments for glioblastoma in elderly people. We defined ‘elderly' as 70+ years but included studies defining ‘elderly' as over 65+ years if so reported. Data collection and analysis We used standard Cochrane methods for study selection and data extraction. Where sufficient data were available, treatment options were compared in a network meta‐analysis (NMA) using Stata software (version 15.1). For outcomes with insufficient data for NMA, pairwise meta‐analysis were conducted in RevMan. The GRADE approach was used to grade the evidence. Main results We included 12 RCTs involving approximately 1818 participants. Six were conducted exclusively among elderly people (either defined as 65 years or older or 70 years or older) with newly diagnosed glioblastoma, the other six reported data for an elderly subgroup among a broader age range of participants. Most participants were capable of self‐care. Study quality was commonly undermined by lack of outcome assessor blinding and attrition. NMA was only possible for overall survival; other analyses were pair‐wise meta‐analyses or narrative syntheses. Seven trials contributed to the NMA for overall survival, with interventions including supportive care only (one trial arm); hypofractionated radiotherapy (RT40; four trial arms); standard radiotherapy (RT60; five trial arms); temozolomide (TMZ; three trial arms); chemoradiotherapy (CRT; three trial arms); bevacizumab with chemoradiotherapy (BEV_CRT; one trial arm); and bevacizumab with radiotherapy (BEV_RT). Compared with supportive care only, NMA evidence suggested that all treatments apart from BEV_RT prolonged survival to some extent. Overall survival High‐certainty evidence shows that CRT prolongs overall survival (OS) compared with RT40 (hazard ratio (HR) 0.67, 95% confidence interval (CI) 0.56 to 0.80) and low‐certainty evidence suggests that CRT may prolong overall survival compared with TMZ (TMZ versus CRT: HR 1.42, 95% CI 1.01 to 1.98). Low‐certainty evidence also suggests that adding BEV to CRT may make little or no difference (BEV_CRT versus CRT: HR 0.83, 95% CrI 0.48 to 1.44). We could not compare the survival effects of CRT with different radiotherapy fractionation schedules (60 Gy/30 fractions and 40 Gy/15 fractions) due to a lack of data. When treatments were ranked according to their effects on OS, CRT ranked higher than TMZ, RT and supportive care only, with the latter ranked last. BEV plus RT was the only treatment for which there was no clear benefit in OS over supportive care only. One trial comparing tumour treating fields (TTF) plus adjuvant chemotherapy (TTF_AC) with adjuvant chemotherapy alone could not be included in the NMA as participants were randomised after receiving concomitant chemoradiotherapy, not before. Findings from the trial suggest that the intervention probably improves overall survival in this selected patient population. We were unable to perform NMA for other outcomes due to insufficient data. Pairwise analyses were conducted for the following. Quality of life Moderate‐certainty narrative evidence suggests that overall, there may be little difference in QoL between TMZ and RT, except for discomfort from communication deficits, which are probably more common with RT (1 study, 306 participants, P = 0.002). Data on QoL for other comparisons were sparse, partly due to high dropout rates, and the certainty of the evidence tended to be low or very low. Progression‐free survival High‐certainty evidence shows that CRT increases time to disease progression compared with RT40 (HR 0.50, 95% CI 0.41 to 0.61); moderate‐certainty evidence suggests that RT60 probably increases time to disease progression compared with supportive care only (HR 0.28, 95% CI 0.17 to 0.46), and that BEV_RT probably increases time to disease progression compared with RT40 alone (HR 0.46, 95% CI 0.27 to 0.78). Evidence for other treatment comparisons was of low‐ or very low‐certainty. Severe adverse events Moderate‐certainty evidence suggests that TMZ probably increases the risk of grade 3+ thromboembolic events compared with RT60 (risk ratio (RR) 2.74, 95% CI 1.26 to 5.94; participants = 373; studies = 1) and also the risk of grade 3+ neutropenia, lymphopenia, and thrombocytopenia. Moderate‐certainty evidence also suggests that CRT probably increases the risk of grade 3+ neutropenia, leucopenia and thrombocytopenia compared with hypofractionated RT alone. Adding BEV to CRT probably increases the risk of thromboembolism (RR 16.63, 95% CI 1.00 to 275.42; moderate‐certainty evidence). Economic evidence There is a paucity of economic evidence regarding the management of newly diagnosed glioblastoma in the elderly. Only one economic evaluation on two short course radiotherapy regimen (25 Gy versus 40 Gy) was identified and its findings were considered unreliable. Authors' conclusions For elderly people with glioblastoma who are self‐caring, evidence suggests that CRT prolongs survival compared with RT and may prolong overall survival compared with TMZ alone. For those undergoing RT or TMZ therapy, there is probably little difference in QoL overall. Systemic anti‐cancer treatments TMZ and BEV carry a higher risk of severe haematological and thromboembolic events and CRT is probably associated with a higher risk of these events. Current evidence provides little justification for using BEV in elderly patients outside a clinical trial setting. Whilst the novel TTF device appears promising, evidence on QoL and tolerability is needed in an elderly population. QoL and economic assessments of CRT versus TMZ and RT are needed. More high‐quality economic evaluations are needed, in which a broader scope of costs (both direct and indirect) and outcomes should be included. Plain language summary Treatment options for newly diagnosed glioblastoma in older people What is the issue? 
 Glioblastoma is a fatal type of brain tumour. The standard treatment of newly diagnosed glioblastoma is to remove as much of the tumour as possible by operation, and then to give chemotherapy (an anti‐cancer medicine called temozolomide (TMZ)) and radiotherapy. TMZ is usually given at the same time as radiotherapy (concomitant chemotherapy), and also for about six months after radiotherapy (adjuvant chemotherapy). Together, these treatments can be called chemoradiotherapy (CRT). However, not all people, particularly the elderly, are fit enough to receive CRT, which can have serious side‐effects. In this review we evaluated evidence on different treatments that have been looked at in older people with newly diagnosed glioblastoma, to find out which treatments may help. How we conducted the review 
 We searched for trials that compared different treatments in elderly people with newly diagnosed glioblastoma and also for studies on cost‐effectiveness. We defined 'the elderly' as 70+ years, but also included data from patients 65+ years old if studies did not give results for the 70+ age group. We used standard Cochrane methods to assess studies and collect data. We compared treatments in a network meta‐analysis (NMA), which allowed us to rank different treatments options. What we found 
 We found 12 studies evaluating different options including radiotherapy, chemotherapy, supportive (palliative) care, combinations of treatments, and a medical device that is worn on the head and emits an electric field (known as tumour treating fields). Most people enrolled in these studies did not have serious disabilities. In the NMA, we compared the effects of seven treatments on patients overall survival. All treatments tested in the NMA apart from one, in which an agent called bevacizumab (BEV) was combined with radiotherapy, clearly prolonged survival compared with supportive care only. The strongest evidence we found showed that CRT leads to a longer survival time than short‐course radiotherapy only; but weaker evidence suggested that CRT also prolongs survival compared with TMZ only. When we ranked all treatments according to their effectiveness in prolonging survival time, CRT ranked higher than TMZ, RT and supportive care only, with the latter ranked last. A study of tumour treating fields could not be included in the NMA because it was conducted among fitter elderly patients who had already received part of their CRT. Evidence from this study suggested that adding tumour treating fields after radiotherapy probably improves survival in this fitter group of patients. With regard to quality of life, evidence suggested that the impact of TMZ and radiotherapy‐only treatments is probably not very different, except for greater discomfort from communication deficits with radiotherapy. Quality of life evidence was hard to interpret for other treatment options because it tended to be limited by high dropout rates, as people with glioblastoma do not live very long and may not feel like filling out questionnaires when they feel unwell. With regard to other outcomes, high‐certainty evidence showed that CRT delays disease progression compared with radiotherapy only. Evidence also suggested that adding BEV to short‐course radiotherapy probably delays disease progression, but may not improve overall survival. TMZ and BEV are more toxic to blood cells than radiotherapy and are associated with an increased risk of blood clots and blood vessel blockages (thromboembolism). Our conclusions 
 For reasonably fit elderly people with glioblastoma, evidence suggests that CRT prolongs survival compared with radiotherapy or TMZ alone, and that any of these three treatment options may prolong survival compared with supportive care only. Serious adverse events affecting blood components are more common with anti‐cancer medicines TMZ and BEV. There is not enough evidence on BEV to support its use in elderly people with glioblastoma outside of a research setting. More evidence is needed on how different treatments impact quality of life and health costs. Age alone is unlikely to be the best determinant of optimal treatment of older people with glioblastoma.}, -DOI = {10.1002/14651858.CD013261.pub2}, -keywords = {Aged; Aged, 80 and over; Brain Neoplasms [surgery, *therapy]; Chemoradiotherapy; Chemotherapy, Adjuvant; Craniotomy; Female; Glioblastoma [surgery, *therapy]; Humans; Male; Network Meta‐Analysis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome}, -URL = {http://dx.doi.org/10.1002/14651858.CD013261.pub2} -} - - -Record #49 of 54 -@article{Buder14, -author = {Buder, K, Zirngibl, M, Bapistella, S, Meerpohl, JJ, Strahm, B, Bassler, D, and Weitz, M}, -title = {Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents}, -journal = {Cochrane Database of Systematic Reviews}, -number = {6}, -year = {2022}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Chronic graft‐versus‐host disease (cGvHD) is a major cause of morbidity and mortality after haematopoietic stem cell transplantation, occurring in 6% to 65% of the paediatric recipients. Currently, the therapeutic mainstay for cGvHD is treatment with corticosteroids, frequently combined with other immunosuppressive agents in people with steroid‐refractory manifestations. There is no established standard treatment for steroid‐refractory cGvHD. The therapeutic options for these patients include extracorporeal photopheresis (ECP), an immunomodulatory treatment that involves ex vivo collection of mononuclear cells from peripheral blood, exposure to the photoactive agent 8‐methoxypsoralen, ultraviolet radiation and re‐infusion of the processed cell product. The mechanisms of action of ECP are not completely understood. This is the second update of a Cochrane Review first published in 2014 and first updated in 2015. Objectives To evaluate the effectiveness and safety of ECP for the management of cGvHD in children and adolescents after haematopoietic stem cell transplantation. Search methods We searched the Cochrane Register of Controlled Trials (CENTRAL) (2021), MEDLINE (PubMed) and Embase databases from their inception to 25 January 2021. We searched the reference lists of potentially relevant studies without any language restrictions. We searched five conference proceedings and nine clinical trial registries on 9 November 2020 and 12 November 2020, respectively. Selection criteria We aimed to include randomised controlled trials (RCTs) comparing ECP with or without alternative treatment versus alternative treatment alone in children and adolescents with cGvHD after haematopoietic stem cell transplantation. Data collection and analysis Two review authors independently performed the study selection. We resolved disagreements in the selection of trials by consultation with a third review author. Main results We found no studies meeting the criteria for inclusion in this 2021 review update. Authors' conclusions We could not evaluate the efficacy of ECP in the treatment of cGvHD in children and adolescents after haematopoietic stem cell transplantation since the second review update again found no RCTs. Current recommendations are based on retrospective or observational studies only. Thus, ideally, ECP should be applied in the context of controlled trials only. However, performing RCTs in this population will be challenging due to the limited number of eligible participants, variable disease presentation and the lack of well‐defined response criteria. International collaboration, multicentre trials and appropriate funding for such trials will be needed. If treatment decisions based on clinical data are made in favour of ECP, recipients should be carefully monitored for beneficial and harmful effects. In addition, efforts should be made to share this information with other clinicians, for example by setting up registries for children and adolescents treated with ECP. Plain language summary Extracorporeal photopheresis treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents Background Chronic graft‐versus‐host disease (cGvHD) is a common complication after haematopoietic stem cell transplantation (HSCT; transplant of blood‐forming stem cells). Immune cells (white blood cells) from the donor recognise the recipient's cells as foreign ('non‐self'). Therefore, the transplanted immune cells attack the cells of the recipient. The main affected organs are skin, liver and gut, among others. These immune reactions may cause acute inflammation (sudden swelling) followed by chronic (long‐term) changes to organs (e.g. fibrosis; scarring of the lungs). First‐line therapy usually consists of immunosuppressive drugs (which reduce the strength of the body's immune system) in the form of corticosteroids in combination with other immunosuppressive agents in refractory cases (where the disease is resistant to treatment). These drugs are supposed to suppress the immune‐mediated attack of the patient's cells. Limited effectiveness and severe side effects of these drugs have led to several alternative approaches. Extracorporeal photopheresis (ECP) is an immunomodulatory therapy (a treatment that makes changes to immune function) that involves collection of immune cells from peripheral blood outside the patient's body. These immune cells are exposed to a photoactive agent (a chemical that responds to exposure to light; e.g. 8‐methoxypsoralen) with subsequent ultraviolet‐A radiation and then re‐infused. We are not sure how this affects immune function. Several current clinical practice recommendations suggest consideration of ECP in children and adolescents with cGvHD. Study characteristics We searched scientific databases for randomised controlled trials (RCTs) (clinical studies where people are randomly put into one of two or more treatment groups) that were designed to evaluate the effectiveness and safety of ECP for the management of chronic graft‐versus‐host disease in children and adolescents (less than 18 years of age) after HSCT. Results We did not find any RCTs that analysed the efficacy of ECP for children and adolescents with cGvHD after HSCT. Current recommendations are only based on retrospective studies (where outcomes occurred to the participants before the study began) or observational studies (where investigators did not intervene, and simply observed the course of events). Ideally, ECP should only be given to children and adolescents in the context of RCTs. ECP may be considered in people with steroid‐refractory cGvHD, keeping in mind that such a treatment is not supported by high‐level evidence. If children and adolescents are given ECP, doctors should collect information about beneficial and harmful effects and set up registries for people treated with ECP.}, -DOI = {10.1002/14651858.CD009898.pub4}, -keywords = {*Graft vs Host Disease [therapy]; *Hematopoietic Stem Cell Transplantation [adverse effects]; *Photopheresis [adverse effects]; Adolescent; Child; Chronic Disease; Humans; Methoxsalen; Steroids}, -URL = {http://dx.doi.org/10.1002/14651858.CD009898.pub4} -} - - -Record #50 of 54 -@article{Jaaback06, -author = {Jaaback, K, Johnson, N, and Lawrie, TA}, -title = {Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {1}, -year = {2016}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Ovarian cancer tends to be chemosensitive and confine itself to the surface of the peritoneal cavity for much of its natural history. These features have made it an obvious target for intraperitoneal (IP) chemotherapy. Chemotherapy for ovarian cancer is usually given as an intravenous (IV) infusion repeatedly over five to eight cycles. Intraperitoneal chemotherapy is given by infusion of the chemotherapeutic agent directly into the peritoneal cavity. There are biological reasons why this might increase the anticancer effect and reduce some systemic adverse effects in comparison to IV therapy. Objectives To determine if adding a component of the chemotherapy regime into the peritoneal cavity affects overall survival, progression‐free survival, quality of life (QOL) and toxicity in the primary treatment of epithelial ovarian cancer. Search methods We searched the Gynaecological Cancer Review Group's Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 2, 2011, MEDLINE (1951 to May 2011) and EMBASE (1974 to May 2011). We updated these searches in February 2007, August 2010, May 2011 and September 2015. In addition, we handsearched and cascade searched the major gynaecological oncology journals up to May 2011. Selection criteria The analysis was restricted to randomised controlled trials (RCTs) assessing women with a new diagnosis of primary epithelial ovarian cancer, of any FIGO stage, following primary cytoreductive surgery. Standard IV chemotherapy was compared with chemotherapy that included a component of IP administration. Data collection and analysis We extracted data on overall survival, disease‐free survival, adverse events and QOL and performed meta‐analyses of hazard ratios (HR) for time‐to‐event variables and relative risks (RR) for dichotomous outcomes using RevMan software. Main results Nine randomised trials studied 2119 women receiving primary treatment for ovarian cancer. We considered six trials to be of high quality. Women were less likely to die if they received an IP component to chemotherapy (eight studies, 2026 women; HR = 0.81; 95% confidence interval (CI): 0.72 to 0.90). Intraperitoneal component chemotherapy prolonged the disease‐free interval (five studies, 1311 women; HR = 0.78; 95% CI: 0.70 to 0.86). There was greater serious toxicity with regard to gastrointestinal effects, pain, fever and infection but less ototoxicity with the IP than the IV route. Authors' conclusions Intraperitoneal chemotherapy increases overall survival and progression‐free survival from advanced ovarian cancer. The results of this meta‐analysis provide the most reliable estimates of the relative survival benefits of IP over IV therapy and should be used as part of the decision making process. However, the potential for catheter related complications and toxicity needs to be considered when deciding on the most appropriate treatment for each individual woman. The optimal dose, timing and mechanism of administration cannot be addressed from this meta‐analysis. This needs to be addressed in the next phase of clinical trials. Plain language summary Intraperitoneal chemotherapy (administered into the peritoneal cavity) for advanced ovarian cancer improves both overall and disease‐free survival Ovarian cancer commonly spreads through the peritoneal cavity and usually responds to intravenous (IV) chemotherapy. This review compared the effectiveness of IV chemotherapy to chemotherapy administered directly into the peritoneal cavity (intraperitoneal, or IP). The evidence suggests an improvement in survival if some of the chemotherapy is administered via the intraperitoneal route. The disadvantage is an increase in adverse effects principally relating to the presence of a peritoneal catheter, including pain, catheter blockage, gastrointestinal effects and infection.}, -DOI = {10.1002/14651858.CD005340.pub4}, -keywords = {Antineoplastic Agents [*administration & dosage, adverse effects]; Disease-Free Survival; Female; Humans; Induction Chemotherapy [adverse effects, *methods]; Infusions, Intravenous; Infusions, Parenteral [adverse effects, *methods]; Ovarian Neoplasms [*drug therapy, mortality]; Randomized Controlled Trials as Topic}, -URL = {http://dx.doi.org/10.1002/14651858.CD005340.pub4} -} - - -Record #51 of 54 -@article{Itchaki13, -author = {Itchaki, G, Gafter‐Gvili, A, Lahav, M, Vidal, L, Raanani, P, Shpilberg, O, and Paul, M}, -title = {Anthracycline‐containing regimens for treatment of follicular lymphoma in adults}, -journal = {Cochrane Database of Systematic Reviews}, -number = {7}, -year = {2013}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Anthracycline‐containing regimens (ACR) are the most prevalent regimens in the management of patients with advanced follicular lymphoma (FL). However, there is no proof that they are superior to non‐anthracycline‐containing regimens (non‐ACR). Objectives To compare the efficacy of ACRs to other chemotherapy regimens, in the treatment of FL. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) ( The Cochrane Library 2013, Issue 3), MEDLINE (January 1966 to April 2013), smaller databases, relevant conference proceedings (2004 to 2012) and the National Medical Library (April 2013). Selection criteria We included randomized controlled trials (RCTs) comparing ACR with non‐ACR for adult patients with FL. We excluded trials in which immunotherapy, radiotherapy alone or stem‐cell transplantation were used in one arm alone. Our primary outcome was overall survival (OS). Secondary outcomes included disease control, as measured by progression‐free survival (PFS) or remission duration (RD). Data collection and analysis Two review authors assessed the quality of trials and extracted data. We contacted study authors for additional information. We analyzed trials separately according to resemblance of the chemotherapeutic regimens in study arms, other than the addition of anthracyclines ('same' versus 'different' chemotherapy). Hazard ratios (HR) and risk ratios (RR) with 95% confidence intervals (CI) were estimated and pooled using the fixed‐effect model. Main results Eight RCTs, conducted between 1974 and 2011, and involving 2636 patients were included in this meta‐analysis. All trials included therapy‐naive patients. Rituximab was used in one trial only. Follow‐up was between three and five years in most trials (range three to 18 years). All trials were published in peer‐reviewed journals. Five trials compared similar chemotherapeutic regimens, except for the anthracycline. In three studies reporting overall survival specifically in FL patients, there was no statistically significant difference between ACR and non‐ACR arms (HR 0.99; 95% CI 0.77 to 1.29; I 2 = 0%). ACR significantly improved disease control (HR 0.65; 95% CI 0.52 to 0.81; four trials). Progression or relapse at three years were reduced (RR 0.73; 95% CI 0.63 to 0.85). Anthracyclines did not significantly increase rates of complete response (RR 1.05; 95% CI 0.94 to 1.18) or overall response (RR 1.06; 95% CI 1.00 to 1.12), but heterogeneity was substantial. Overall, ACR were more often associated with cytopenias, but not with serious infections or death related to chemotherapy. Cardiotoxicity, albeit rare, was associated with anthracycline use (RR 4.55; 95% CI 0.92 to 22.49; four trials). Three trials added anthracycline to one arm of two different regimens. None showed benefit to ACR regarding OS, yet there was a trend in favor of anthracyclines for disease control. Results were heterogeneous. We judged the overall quality of these trials as moderate as all are unblinded, some are outdated and are not uniform in outcome definitions. Authors' conclusions The use of anthracyclines in patients with FL has no demonstrable benefit on overall survival, although it may have been mitigated by the more intense regimens given in the control arms of three of five trials. ACR improved disease control, as measured by PFS and RD with an increased risk for side effects, notably cardiotoxicity. The current evidence on the added value of ACR in the management of FL is limited. Further studies involving immunotherapy during induction and maintenance may change conclusion. Plain language summary Anthracyclines in the treatment of follicular lymphoma (FL) in adults FL is the most common indolent non‐Hodgkin's lymphoma (NHL). It is a slowly progressive disease, with a risk of transformation to a more aggressive lymphoma. Advanced disease (stage III and IV) has been considered incurable. However, in recent years, the use of combination therapy and treatment with the monoclonal anti‐CD20 antibody rituximab, have prolonged survival and decreased transformation rate, and is now considered standard of care in FL patients. One of the most common chemotherapies used in the treatment of FL is the combination of rituximab with cyclophosphamide, vincristine, adriamycin, prednisone (R‐CHOP), which contains an anthracycline (adriamycin). Other anthracycline‐containing regimens (ACR) have also been used to treat FL patients. However, there is no proof that ACRs are better than non‐anthracycline‐containing regimens (non‐ACRs), and there are no standard guidelines for the initial treatment of advanced FL. Importantly, anthracyclines have serious side effects, notably a decrease in blood counts and potential damage to the heart, depending on the dose. The aim of this systematic review and meta‐analysis was to examine if there is a benefit in the use of anthracyclines for patients with FL. We looked at overall survival (OS); measures of disease control; response rates; and side effects. We found eight randomized controlled trials, of which five compared similar chemotherapy regimens in both trial arms, except for the anthracycline. Even among these five trials, three included more intense chemotherapy in the control arm. Most trials were conducted in the 1980s and 1990s. Only one of them included rituximab as part of the chemotherapy regimen. Almost all patients were treatment‐naive with advanced disease. Follow‐up ranged between three and five years in most trials. The main results from this set of trials are. 1. There is no evidence that OS is prolonged with the use of anthracyclines, although it may have been hampered by the more intense regimens given in the control arms of three of five trials. 2. Anthracyclines improved disease control. Concordantly, less patients progressed or relapsed within three years of treatment with ACR. 3. There is no statistically significant difference in complete or overall response rates. 4. Qualitatively, more side effects were reported with ACR, myelotoxicity and cardiotoxicity included. This evidence is limited, mainly due to disparities in regimens between control and study arms, but also since most included trials were conducted over one to two decades ago, and only one employed rituximab. Importantly, results from this study were in agreement with pooled‐outcomes from trials of the pre‐rituximab era. It is essential to find the optimal chemotherapeutic regimen in conjunction with rituximab and other novel agents, and understand the role of anthracyclines in this combination, especially with current methods that are able to reduce their toxicity. With longer follow‐up periods we may better understand whether improved disease control will eventually translate to an increase in survival.}, -DOI = {10.1002/14651858.CD008909.pub2}, -keywords = {Adult; Anthracyclines [*therapeutic use]; Antibiotics, Antineoplastic [*therapeutic use]; Antibodies, Monoclonal, Murine‐Derived [therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; Humans; Induction Chemotherapy [methods]; Lymphoma, Follicular [*drug therapy, mortality, pathology]; Maintenance Chemotherapy [methods]; Randomized Controlled Trials as Topic; Rituximab}, -URL = {http://dx.doi.org/10.1002/14651858.CD008909.pub2} -} - - -Record #52 of 54 -@article{Swierz24, -author = {Swierz, MJ, Storman, D, Mitus, JW, Hetnal, M, Kukielka, A, Szlauer-Stefanska, A, Pedziwiatr, M, Wolff, R, Kleijnen, J, and Bala, MM}, -title = {Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases}, -journal = {Cochrane Database of Systematic Reviews}, -number = {8}, -year = {2024}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background The liver is affected by two groups of malignant tumours: primary liver cancers and liver metastases. Liver metastases are significantly more common than primary liver cancer, and five‐year survival after radical surgical treatment of liver metastases ranges from 28% to 50%, depending on primary cancer site. However, R0 resection (resection for cure) is not feasible in most people; therefore, other treatments have to be considered in the case of non‐resectability. One possible option is based on the concept that the blood supply to hepatic tumours originates predominantly from the hepatic artery. Transarterial chemoembolisation (TACE) of the peripheral branches of the hepatic artery can be achieved by administering a chemotherapeutic drug followed by vascular occlusive agents and can lead to selective necrosis of the cancer tissue while leaving normal liver parenchyma virtually unaffected. The entire procedure can be performed without infusion of chemotherapy and is then called bland transarterial embolisation (TAE). These procedures are usually applied over a few sessions. Another possible treatment option is systemic chemotherapy which, in the case of colorectal cancer metastases, is most commonly performed using FOLFOX (folinic acid, 5‐fluorouracil, and oxaliplatin) and FOLFIRI (folinic acid, 5‐fluorouracil, and irinotecan) regimens applied in multiple sessions over a long period of time. These therapies disrupt the cell cycle, leading to death of rapidly dividing malignant cells. Current guidelines determine the role of TAE and TACE as non‐curative treatment options applicable in people with liver‐only or liver‐dominant metastatic disease that is unresectable or non‐ablatable, and in people who have failed systemic chemotherapy. Regarding the treatment modalities in people with colorectal cancer liver metastases, we found no systematic reviews comparing the efficacy of TAE or TACE versus systemic chemotherapy. Objectives To evaluate the beneficial and harmful effects of transarterial embolisation (TAE) or transarterial chemoembolisation (TACE) compared with systemic chemotherapy in people with liver‐dominant unresectable colorectal cancer liver metastases. Search methods We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, and three additional databases up to 4 April 2024. We also searched two trials registers and the European Medicines Agency database and checked reference lists of retrieved publications. Selection criteria We included randomised clinical trials assessing beneficial and harmful effects of TAE or TACE versus systemic chemotherapy in adults (aged 18 years or older) with colorectal cancer liver metastases. Data collection and analysis We used standard Cochrane methods. Our primary outcomes were all‐cause mortality; overall survival (time to mortality); and any adverse events or complications. Our secondary outcomes were cancer mortality; health‐related quality of life; progression‐free survival; proportion of participants dying or surviving with progression of the disease; time to progression of liver metastases; recurrence of liver metastases; and tumour response measures (complete response, partial response, stable disease, and progressive disease). For the purpose of the review and to perform necessary analyses, whenever possible, we converted survival rates to mortality rates, as this was our primary outcome. For the analysis of dichotomous outcomes, we used the risk ratio (RR); for continuous outcomes, we used the mean difference; and for time to event outcomes, we calculated hazard ratios (HRs), all with 95% confidence intervals (CI). We used the standardised mean difference with 95% CIs when the trials used different instruments. We used GRADE to assess the certainty of evidence for each outcome. We based our conclusions on outcomes analysed at the longest follow‐up. Main results We included three trials with 118 participants randomised to TACE versus 120 participants to systemic chemotherapy. Four participants were excluded; one due to disease progression prior to treatment and three due to decline in health. The trials reported data on one or more outcomes. Two trials were performed in China and one in Italy. The trials differed in terms of embolisation techniques and chemotherapeutic agents. Follow‐up ranged from 12 months to 50 months. TACE may reduce mortality at longest follow‐up (RR 0.86, 95% CI 0.79 to 0.94; 3 trials, 234 participants; very low‐certainty evidence), but the evidence is very uncertain. TACE may have little to no effect on overall survival (time to mortality) (HR 0.61, 95% CI 0.37 to 1.01; 1 trial, 70 participants; very low‐certainty evidence), any adverse events or complications (3 trials, 234 participants; very low‐certainty evidence), health‐related quality of life (2 trials, 154 participants; very low‐certainty evidence), progression‐free survival (1 trial, 70 participants; very low‐certainty evidence), and tumour response measures (presented as the overall response rate) (RR 1.81, 95% CI 1.11 to 2.96; 3 trials, 234 participants; very low‐certainty evidence), but the evidence is very uncertain. No trials reported cancer mortality, proportion of participants dying or surviving with progression of the disease, and recurrence of liver metastases. We found no trials comparing the effects of TAE versus systemic chemotherapy in people with colorectal cancer liver metastases. Authors' conclusions The evidence regarding effectiveness of TACE versus systemic chemotherapy in people with colorectal cancer liver metastases is of very low certainty and is based on three trials. Our confidence in the results is limited due to the risk of bias, inconsistency, indirectness, and imprecision. It is very uncertain whether TACE confers benefits with regard to reduction in mortality, overall survival (time to mortality), reduction in adverse events or complications, improvement in health‐related quality of life, improvement in progression‐free survival, and tumour response measures (presented as the overall response rate). Data on cancer mortality, proportion of participants dying or surviving with progression of the disease, and recurrence of liver metastases are lacking. We found no trials assessing TAE versus systemic chemotherapy. More randomised clinical trials are needed to strengthen the body of evidence and provide insight into the benefits and harms of TACE or TAE in comparison with systemic chemotherapy in people with liver metastases from colorectal cancer. Plain language summary Is transarterial (chemo)embolisation better than systemic chemotherapy for treating bowel cancer that has spread to the liver? Key messages – Transarterial chemoembolisation (abbreviated as TACE) is a method of destroying cancer cells by giving anticancer medicines and tiny beads that block the blood supply to the tumour directly or giving beads that are coated with anticancer medication. TACE may reduce deaths compared with an anticancer medicine that is given by injection into a blood vessel travelling to cells all over the body (called systemic chemotherapy), but the evidence is very uncertain. TACE may have little to no effect on time to death, unwanted effects, quality of life, the length of time people survived without the cancer getting worse, and changes in the size of tumours, but the evidence is very uncertain. – We found no studies assessing another method of destroying cancer cells called transarterial embolisation (which is similar to TACE in that tiny beads are injected but differs in that no anticancer medicines are given; abbreviated as TAE) versus systemic chemotherapy. – Further research is needed as we found only three small studies and confidence in these results is limited. New studies might bring additional evidence and change the results and our confidence in them. What are metastases? Metastases are new cancer growths that spread to different parts of the body from the original cancer site (sometimes called secondaries). One of the most common sites for colorectal (bowel) cancer metastases is the liver. How are metastases treated? There are several different ways to treat liver metastases. We were interested in comparing three methods; transarterial chemoembolisation (abbreviated as TACE), transarterial embolisation (abbreviated as TAE), and systemic chemotherapy. TACE involves injection of an anticancer medicine and an injection of tiny beads directly into the blood vessel (the hepatic artery) that feeds the tumour or the use of beads that are coated in anticancer medication. The anticancer medicine is toxic and the beads block the blood supply to the tumour, so some of the tumour cells die. Other parts of the liver are kept alive as they receive their blood supply mainly from a different blood vessel (the portal vein). TAE is similar to TACE in that an injection of tiny beads is given to block the blood vessel but differs in that no anticancer medicines are given. Systemic chemotherapy is where anticancer medicines are given through a blood vessel on the back of the hand or forearm (usually) so they travel to, and affect, all cells in the body. What did we want to find out? We wanted to find out if TACE or TAE was better than systemic chemotherapy by looking at deaths, how long people survived, how often cancer returned and progressed (got worse), how the treatments affected how well the people felt, and if there were any unwanted effects. What did we do? We searched for studies comparing TACE or TAE versus systemic chemotherapy in people with bowel cancer that had spread to the liver. What did we find? We found three small studies with 238 people with metastases only or mainly in the liver that compared TACE versus systemic chemotherapy. It was not possible to remove the cancers with surgery. The studies reported no details on funding. We found no studies comparing TAE versus systemic chemotherapy in people with colorectal cancer liver metastases. TACE compared with systemic chemotherapy may reduce death, but the evidence is very uncertain (3 studies, 234 people). About 79 out of 100 people died with TACE compared with 92 out of 100 people with systemic chemotherapy. One small study (70 people) reported time to death, but we were very uncertain about the results. People who received TACE survived about 22 months, while those who received systemic chemotherapy survived about 15 months. In one small study (70 people), people who had TACE had a longer time before their cancer got worse in the liver (seven months) compared with those who received systemic chemotherapy (four months), but we were very uncertain about the results. We were very uncertain about the effects of TACE compared with systemic chemotherapy when looking at how metastases changed in size and unwanted effects. There was no information on the likelihood of death specifically due to cancer, the proportion of people dying or surviving with worsening of the disease, and recurrence (return) of liver metastases. What are the limitations of the evidence? Our confidence in the results is limited because none of the studies clearly reported their methods. It was unclear whether investigators, healthcare staff, and people taking part in the studies knew what treatment they had received. Not all the studies provided data about everything that we were interested in. All of this could have influenced the results. Further research is needed, which may change the results. How up to date is this evidence? The evidence is up to date to 4 April 2024.}, -DOI = {10.1002/14651858.CD012757.pub2}, -keywords = {*Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; *Chemoembolization, Therapeutic [methods]; *Colorectal Neoplasms [pathology, therapy]; *Fluorouracil [administration & dosage, therapeutic use]; *Leucovorin [administration & dosage, therapeutic use]; *Liver Neoplasms [secondary, therapy]; *Randomized Controlled Trials as Topic; Antineoplastic Agents [administration & dosage, therapeutic use]; Camptothecin [administration & dosage, analogs & derivatives, therapeutic use]; Hepatic Artery; Humans; Organoplatinum Compounds [administration & dosage]}, -URL = {http://dx.doi.org/10.1002/14651858.CD012757.pub2} -} - - -Record #53 of 54 -@article{De Zwart16, -author = {de Zwart, V, Gouw, SC, and Meyer‐Wentrup, FAG}, -title = {Antibody therapies for lymphoma in children}, -journal = {Cochrane Database of Systematic Reviews}, -number = {1}, -year = {2016}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Lymphomas are the third most common malignancy in childhood. Cure rates are high but have reached a plateau. Therefore new treatment modalities should be developed. Antibody therapy is a successful new treatment option in adult lymphoma. However, none of the therapeutic antibodies available for adults with cancer have been approved for treatment of paediatric lymphoma. Objectives To assess the efficacy of antibody therapy for childhood lymphoma in terms of survival, response and relapse rates, compared with therapy not including antibody treatment. To assess quality of life and the occurrence of adverse effects caused by antibody therapy treatment in children compared with therapy not including antibody treatment. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL, 2014, Issue 10), MEDLINE in PubMed (from 1945 to October 2014), EMBASE in EMBASE.com (from 1980 to October 2014) and reference lists of relevant articles. Furthermore, we searched conference proceedings abstracts of SIOP, ASCO and ASH for studies from 2009 to 2013), and the World Health Organization (WHO) ICTRP portal and ClinicalTrials.gov for ongoing trials. Selection criteria Randomised controlled trials and controlled clinical trials comparing conventional therapy with antibody therapy in children with lymphoma. Data collection and analysis Two authors independently performed the study selection. Main results We found no studies meeting the inclusion criteria of the review. Authors' conclusions At this moment, it is not possible to draw evidence‐based conclusions regarding clinical practice. Phase I and II studies show a positive effect of using antibody therapy in childhood lymphoma. Further research is needed to evaluate and implement antibody therapy for paediatric lymphoma. Plain language summary Antibody therapies for lymphoma in children Review question The objective of this review was to assess the efficacy of the treatment of lymphoma in children with antibody therapy in terms of survival, relapse rates and response to treatment, compared with therapy not including antibody treatment. Furthermore, it aimed to evaluate the effects of antibody therapy on quality of life and side effects. Background Lymphomas are the third most common cancer of childhood. They are cancer of the lymphatic system, which is part of the immune system and protects the body from infection. They often present as painless masses, accompanied by signs and symptoms resulting from local compression, as well as other signs and symptoms, such as fever and weight loss. Cure rates are high, exceeding 80%, but over the past years a plateau has been reached. Furthermore, cure rates for recurrent disease are dramatically lower. The long term effects of chemotherapy (chemicals used to treat cancer) are of great concern. Therefore, new treatments must be developed. Antibodies are produced by our bodies to help fight infection. Treatment with antibodies (antibody therapy) is a successful new treatment option in adults with lymphoma. However, none of the therapeutic antibodies available for adults with cancer have been approved for treatment of paediatric lymphomas. Monoclonal antibodies are proteins that recognise specific proteins on the surface of our body's cells. This binding could be used as a therapy for cancer. Binding of the antibody could result in direct cell death, or could mark the cells that need to be cleared by our body using the immune system. Search date 8 October 2014. Study characteristics We included only studies comparing the use of antibody therapy to the standard care in identical groups of children. Study funding sources We included no studies in our analysis. Key results We found no studies. The authors analysed 27 publications investigating the safety and tolerability of two antibody therapies, rituximab and brentuximab vedotin, in children with various types of lymphoma. These trials indicated that antibody therapy is safe to use in children and is well tolerated. Furthermore, there seems to be a positive effect on survival rates. To further evaluate the effects randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) must be performed. Use of statistics We performed no analyses. Quality of the evidence We found no studies.}, -DOI = {10.1002/14651858.CD011181.pub2}, -keywords = {Antibodies, Monoclonal [*therapeutic use]; Child; Humans; Lymphoma [*drug therapy]}, -URL = {http://dx.doi.org/10.1002/14651858.CD011181.pub2} -} - - -Record #54 of 54 -@article{Wiysonge02, -author = {Wiysonge, CS, Ntsekhe, M, Thabane, L, Volmink, J, Majombozi, D, Gumedze, F, Pandie, S, and Mayosi, BM}, -title = {Interventions for treating tuberculous pericarditis}, -journal = {Cochrane Database of Systematic Reviews}, -number = {9}, -year = {2017}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Background Tuberculous pericarditis can impair the heart's function and cause death; long term, it can cause the membrane to fibrose and constrict causing heart failure. In addition to antituberculous chemotherapy, treatments include corticosteroids, drainage, and surgery. Objectives To assess the effects of treatments for tuberculous pericarditis. Search methods We searched the Cochrane Infectious Diseases Group Specialized Register (27 March 2017); the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (2017, Issue 2); MEDLINE (1966 to 27 March 2017); Embase (1974 to 27 March 2017); and LILACS (1982 to 27 March 2017). In addition we searched the metaRegister of Controlled Trials (mRCT) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal using 'tuberculosis' and 'pericard*' as search terms on 27 March 2017. We searched ClinicalTrials.gov and contacted researchers in the field of tuberculous pericarditis. This is a new version of the original 2002 review. Selection criteria We included randomized controlled trials (RCTs) and quasi‐RCTs. Data collection and analysis Two review authors independently screened search outputs, evaluated study eligibility, assessed risk of bias, and extracted data; and we resolved any discrepancies by discussion and consensus. One trial assessed the effects of both corticosteroid and Mycobacterium indicus pranii treatment in a two‐by‐two factorial design ; we excluded data from the group that received both interventions. We conducted fixed‐effect meta‐analysis and assessed the certainty of the evidence using the GRADE approach. Main results Seven trials met the inclusion criteria; all were from sub‐Saharan Africa and included 1959 participants, with 1051/1959 (54%) HIV‐positive. All trials evaluated corticosteroids and one each evaluated colchicine, M. indicus pranii immunotherapy, and open surgical drainage. Four trials (1841 participants) were at low risk of bias, and three trials (118 participants) were at high risk of bias. In people who are not infected with HIV, corticosteroids may reduce deaths from all causes (risk ratio (RR) 0.80, 95% confidence interval (CI) 0.59 to 1.09; 660 participants, 4 trials, low certainty evidence ) and the need for repeat pericardiocentesis (RR 0.85, 95% CI 0.70 to 1.04; 492 participants, 2 trials, low certainty evidence ). Corticosteroids probably reduce deaths from pericarditis (RR 0.39, 95% CI 0.19 to 0.80; 660 participants, 4 trials, moderate certainty evidence ). However, we do not know whether or not corticosteroids have an effect on constriction or cancer among HIV‐negative people ( very low certainty evidence ). In people living with HIV, only 19.9% (203/1959) were on antiretroviral drugs. Corticosteroids may reduce constriction (RR 0.55, 0.26 to 1.16; 575 participants, 3 trials, low certainty evidence ). It is uncertain whether corticosteroids have an effect on all‐cause death or cancer ( very low certainty evidence ); and may have little or no effect on repeat pericardiocentesis (RR 1.02, 0.89 to 1.18; 517 participants, 2 trials, low certainty evidence ). For colchicine among people living with HIV, we found one small trial (33 participants) which had insufficient data to make any conclusions about any effects on death or constrictive pericarditis. Irrespective of HIV status, due to very low certainty evidence from one trial, it is uncertain whether adding M. indicus pranii immunotherapy to antituberculous drugs has an effect on any outcome. Open surgical drainage for effusion may reduce repeat pericardiocentesis In HIV‐negative people (RR 0.23, 95% CI 0.07 to 0.76; 122 participants, 1 trial, low certainty evidence ) but may make little or no difference to other outcomes. We did not find an eligible trial that assessed the effects of open surgical drainage in people living with HIV. The review authors found no eligible trials that examined the length of antituberculous treatment needed nor the effects of other adjunctive treatments for tuberculous pericarditis. Authors' conclusions For HIV‐negative patients, corticosteroids may reduce death. For HIV‐positive patients not on antiretroviral drugs, corticosteroids may reduce constriction. For HIV‐positive patients with good antiretroviral drug viral suppression, clinicians may consider the results from HIV‐negative patients more relevant. Further research may help evaluate percutaneous drainage of the pericardium under local anaesthesia, the timing of pericardiectomy in tuberculous constrictive pericarditis, and new antibiotic regimens. 2 April 2019 Up to date All studies incorporated from most recent search All eligible published studies found in the last search (27 Mar, 2017) were included and one ongoing study was identified (see 'Characteristics of ongoing studies' section) Plain language summary Treatment for tuberculosis infection of the membrane around the heart What is the issue? Tuberculosis infection of the pericardium surrounding the heart is uncommon but life‐threatening. What is the aim of this review? The aim of this Cochrane Review was to assess the effects of treatments for people with tuberculous pericarditis. What is this important? Doctors prescribe antituberculous drugs for six months, drain fluid from the pericardium if the patient has heart failure, and sometimes remove the pericardium if it is thick and making the patient ill and sometimes give corticosteroids to reduce the effects of the inflammation. What are the main results of the review? Cochrane researchers collected and examined all potentially relevant studies and found seven trials, all conducted in sub‐Saharan Africa. Six trials evaluated corticosteroids. Other treatments evaluated included Mycobacterium indicus pranii immunotherapy, colchicine, and surgical removal of fluid under general anaesthesia. This review is a new edition of the 2002 review. In people not infected with HIV, six trials found that additional steroids may reduce deaths overall ( low certainty evidence ) and probably reduce deaths caused by pericarditis ( moderate certainty evidence ). Steroids may prevent reaccumulation of fluid in the pericardial space ( low certainty evidence ). However, we do not know whether or not corticosteroids have an effect on constriction or cancer among HIV‐negative people ( very low certainty evidence ). In people living with HIV, most people evaluated in the included trials were not on antiretroviral drugs. For these patients, corticosteroids may reduce constrictive pericarditis ( low certainty evidence ), but we do not know if this translates into a reduction in the number of deaths or cancer ( very low certainty evidence ). Corticosteroids may have little or no effect on reaccumulation of fluid in the pericardial space ( low certainty evidence ). Colchicine was evaluated in one trial of 33 people, with insufficient data to make any conclusions about an effect. Based on one trial, it is uncertain whether adding M. indicus pranii immunotherapy to antituberculous drugs has an effect on any outcome in people with tuberculous pericarditis regardless of their HIV status ( very low certainty evidence ). Open surgical drainage of the fluid accumulating between the heart and the membrane using general anaesthesia may be associated with less life‐threatening reaccumulation of fluid in people who are not infected with HIV, but conclusions are not possible as the number of participants studied was too small. We did not find an eligible trial that assessed the effects of open surgical drainage in people living with HIV. The review authors found no eligible trials that examined the length of antituberculous treatment needed nor the effects of other adjunctive treatments for tuberculous pericarditis. How up‐to‐date is this review? The review authors searched for trials published up to 27 March 2017.}, -DOI = {10.1002/14651858.CD000526.pub2}, -keywords = {Adrenal Cortex Hormones [therapeutic use]; Antitubercular Agents [therapeutic use]; Cause of Death; Colchicine [therapeutic use]; Drainage; HIV Seronegativity; HIV Seropositivity [drug therapy]; Humans; Immunotherapy; Pericardiectomy; Pericarditis, Tuberculous [complications, *drug therapy, mortality, *surgery]; Pericardium [surgery]; Randomized Controlled Trials as Topic}, -URL = {http://dx.doi.org/10.1002/14651858.CD000526.pub2} -} - - diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/citation-export Cochrane protocols 20.bib" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/citation-export Cochrane protocols 20.bib" deleted file mode 100644 index ac41d35..0000000 --- "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/citation-export Cochrane protocols 20.bib" +++ /dev/null @@ -1,300 +0,0 @@ -Record #1 of 20 -@article{Gao21, -author = {Gao, Y, Shi, S, Liu, M, Wu, F, Zhang, J, Song, F, and Tian, J}, -title = {Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {10}, -year = {2021}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the efficacy and safety of immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide compared with platinum‐etoposide alone for the first‐line treatment of extensive‐stage small cell lung cancer (ES‐SCLC).}, -DOI = {10.1002/14651858.CD014809}, -URL = {http://dx.doi.org/10.1002/14651858.CD014809} -} - - -Record #2 of 20 -@article{Gao22, -author = {Gao, Y, Liu, M, Li, L, Zhang, J, Song, F, and Tian, J}, -title = {Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple‐negative breast cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {9}, -year = {2022}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the efficacy and safety of PD‐1 inhibitors or PD‐L1 inhibitors plus chemotherapy compared with chemotherapy for people with early triple‐negative breast cancer.}, -DOI = {10.1002/14651858.CD015072}, -URL = {http://dx.doi.org/10.1002/14651858.CD015072} -} - - -Record #3 of 20 -@article{Kim23, -author = {Kim, S, Kang, TW, Cha, H, Kim, MH, Jung, JH, and You, SH}, -title = {Consolidative thoracic radiotherapy for extensive disease small cell lung cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {8}, -year = {2023}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effectiveness and safety of consolidative thoracic radiotherapy after chemotherapy in comparison with chemotherapy alone for ED SCLC.}, -DOI = {10.1002/14651858.CD015567}, -URL = {http://dx.doi.org/10.1002/14651858.CD015567} -} - - -Record #4 of 20 -@article{Nishie21, -author = {Nishie, K, Yamamoto, S, Yamaga, T, Horita, N, Mori, R, Gouda, MA, and Hanaoka, M}, -title = {Prophylactic cranial irradiation for extensive‐stage small cell lung cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {3}, -year = {2021}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effectiveness and safety of PCI plus standard treatment compared to standard treatment alone in people with ED‐SCLC who have responded to first‐line chemotherapy.}, -DOI = {10.1002/14651858.CD014559}, -URL = {http://dx.doi.org/10.1002/14651858.CD014559} -} - - -Record #5 of 20 -@article{Zhu19, -author = {Zhu, Z, Zhang, K, Cai, N, Charbek, E, Miller, AC, Zhu, S, Suo, C, Chen, X, and Song, H}, -title = {Checkpoint inhibitors for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol}, -journal = {Cochrane Database of Systematic Reviews}, -number = {6}, -year = {2019}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors in people with stage I to III NSCLC who receive surgery or radiotherapy with curative intent.}, -DOI = {10.1002/14651858.CD013364}, -URL = {http://dx.doi.org/10.1002/14651858.CD013364} -} - - -Record #6 of 20 -@article{Marchal24, -author = {Marchal, C, Orillard, E, Calais, F, and Westeel, V}, -title = {Immunotherapy for non‐small cell lung cancer in the elderly population: a generic protocol}, -journal = {Cochrane Database of Systematic Reviews}, -number = {7}, -year = {2024}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors (ICI) as monotherapy or in combination compared to standard of care for elderly people (≥ 65 years) with non‐small cell lung cancer (NSCLC).}, -DOI = {10.1002/14651858.CD014907.pub2}, -URL = {http://dx.doi.org/10.1002/14651858.CD014907.pub2} -} - - -Record #7 of 20 -@article{Syn18, -author = {Syn, NLX, Roudi, R, Wang, LZ, Wang, L, Loh, M, Huang, Y, Ou, SHI, Soong, R, Drilon, A, and Wee, I}, -title = {Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first‐line treatment of advanced non‐small cell lung cancer: a generic protocol}, -journal = {Cochrane Database of Systematic Reviews}, -number = {4}, -year = {2018}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine the effectiveness and toxicity of immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy alone as first‐line treatment of advanced non‐small cell lung cancer (NSCLC).}, -DOI = {10.1002/14651858.CD013009}, -URL = {http://dx.doi.org/10.1002/14651858.CD013009} -} - - -Record #8 of 20 -@article{Haugaard24, -author = {Haugaard, AK, Saude Conde, R, J Maria, AR, Vithal Yergolkar, A, Jørgensen, KJ, and Heleno, B}, -title = {Immunotherapy for advanced and recurrent malignant pleural mesothelioma}, -journal = {Cochrane Database of Systematic Reviews}, -number = {9}, -year = {2024}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of immune checkpoint inhibitors (single‐agent or combination therapy) in people with advanced malignant pleural mesothelioma in a first‐line or salvage setting.}, -DOI = {10.1002/14651858.CD014720}, -URL = {http://dx.doi.org/10.1002/14651858.CD014720} -} - - -Record #9 of 20 -@article{Van der Veen17, -author = {van der Veen, J, Laenen, A, and Nuyts, S}, -title = {Modern radiotherapy techniques versus three‐dimensional conformal radiotherapy for head and neck cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {12}, -year = {2017}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of modern radiotherapy techniques (IMRT, VMAT, proton beam therapy and adaptive radiotherapy) compared to 3DCRT on disease control and toxicity in head and neck cancer patients.}, -DOI = {10.1002/14651858.CD012904}, -URL = {http://dx.doi.org/10.1002/14651858.CD012904} -} - - -Record #10 of 20 -@article{Chan23, -author = {Chan, WY, Sim, H-W, Abdi Haryono, M, Yip, D, and Chin, V}, -title = {Immune checkpoint inhibitors for advanced pancreatic cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {2}, -year = {2023}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of immune checkpoint inhibitors (ICIs), as monotherapy or in combination (with chemotherapy or targeted therapy), for people with advanced pancreatic cancer compared with chemotherapy, targeted therapy, or placebo.}, -DOI = {10.1002/14651858.CD014523}, -URL = {http://dx.doi.org/10.1002/14651858.CD014523} -} - - -Record #11 of 20 -@article{Soon18, -author = {Soon, YY, Zheng, Q, Shi, L, Chan, ESY, Leong, CN, Koh, WY, and Tham, IWK}, -title = {Chemo‐radiotherapy versus surgery‐based treatment for Stage IIIA non‐small cell lung cancer: a systematic review and network meta‐analysis}, -journal = {Cochrane Database of Systematic Reviews}, -number = {4}, -year = {2018}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effectiveness and safety of chemo‐radiotherapy with surgery for people with Stage IIIA non‐small cell lung cancer (NSCLC).}, -DOI = {10.1002/14651858.CD012999}, -URL = {http://dx.doi.org/10.1002/14651858.CD012999} -} - - -Record #12 of 20 -@article{Moraes17, -author = {Moraes, FY, Perry, LA, Penny‐Dimri, JC, Ramson, D, de Castria, TB, Bowman, RV, Santos, FN, Fong, KM, and Riera, R}, -title = {Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) versus chemotherapy for second‐ or third‐line treatment of metastatic non‐small cell lung cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {4}, -year = {2017}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) compared with standard chemotherapy for second‐ or third‐line treatment of metastatic non‐small cell lung cancer (NSCLC).}, -DOI = {10.1002/14651858.CD012644}, -URL = {http://dx.doi.org/10.1002/14651858.CD012644} -} - - -Record #13 of 20 -@article{Madrid18, -author = {Madrid, E, Barros Monge, MJ, Urrútia, G, Roqué i Figuls, M, Pérez Bracchiglione, J, Vargas Peirano, M, Loézar Hernández, CN, and Bonfill Cosp, X}, -title = {Taxanes for advanced non‐small cell lung cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {7}, -year = {2018}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of taxanes as part of a combined or single‐agent therapy versus other agents or best supportive care as first‐ or second‐line treatment for advanced non‐small cell lung cancer (NSCLC). A secondary objective is to assess different modes or schemes of administration of taxanes in patients with this disease.}, -DOI = {10.1002/14651858.CD013075}, -URL = {http://dx.doi.org/10.1002/14651858.CD013075} -} - - -Record #14 of 20 -@article{Zhao22, -author = {Zhao, Y, Feng, H-m, Tian, J, Li, B, Wang, C, Ge, L, Feng, S-f, and Yu, Q}, -title = {Stereotactic body radiation therapy versus more fractionated radical radiotherapy for adults with stage I/II non‐small cell lung cancer: a systematic review and network meta‐analysis}, -journal = {Cochrane Database of Systematic Reviews}, -number = {4}, -year = {2022}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effectiveness and toxicity of different SBRT schedules (± additional treatments) in comparison with various more fractionated radical radiotherapy schedules (± additional treatments) in controlling primary tumor and prolonging survival in people with early stage NSCLC, and to rank all the schedules based on their efficacy and tolerability. }, -DOI = {10.1002/14651858.CD014744}, -URL = {http://dx.doi.org/10.1002/14651858.CD014744} -} - - -Record #15 of 20 -@article{Liu23, -author = {Liu, L, Wang, T, Chen, Y, and Cao, Y}, -title = {Electronic symptom monitoring for patients with advanced cancer}, -journal = {Cochrane Database of Systematic Reviews}, -number = {7}, -year = {2023}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of electronic symptom monitoring (ESM) on patient survival, hospital admission, emergency visit, changes in treatment protocol, adverse events, patient‐reported outcomes (PROs), and cost‐effectiveness for patients with advanced cancer.}, -DOI = {10.1002/14651858.CD015732}, -URL = {http://dx.doi.org/10.1002/14651858.CD015732} -} - - -Record #16 of 20 -@article{Galvão20, -author = {Galvão, TF, Livinalli, A, Lopes, LC, Zimmermann, IR, and Silva, MT}, -title = {Biosimilar monoclonal antibodies for cancer treatment}, -journal = {Cochrane Database of Systematic Reviews}, -number = {2}, -year = {2020}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the efficacy, effectiveness, and safety of biosimilar monoclonal antibodies for treating cancer, when compared to their originator biologic.}, -DOI = {10.1002/14651858.CD013539}, -URL = {http://dx.doi.org/10.1002/14651858.CD013539} -} - - -Record #17 of 20 -@article{Ma24, -author = {Ma, M, Yao, L, Li, M, Qin, Y, Yang, M, Guo, K, Duan, Y, Liu, B, and Yang, K}, -title = {Granulopoiesis‐stimulating factors to prevent adverse effects in the treatment of solid tumors}, -journal = {Cochrane Database of Systematic Reviews}, -number = {1}, -year = {2024}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the efficacy of prophylactic granulopoiesis‐stimulating factors compared with placebo or no prophylaxis for improving survival and preventing adverse effects of cancer treatment in people with solid tumors.}, -DOI = {10.1002/14651858.CD015656}, -URL = {http://dx.doi.org/10.1002/14651858.CD015656} -} - - -Record #18 of 20 -@article{Williams18, -author = {Williams, M, Chen, J, Hart, MG, Hunter, A, Hawkins, N, Si, S, and Toni, F}, -title = {First‐line treatments for people with single or multiple brain metastases}, -journal = {Cochrane Database of Systematic Reviews}, -number = {12}, -year = {2018}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To compare the safety and efficacy of surgery, radiotherapy, and chemotherapy as first‐line treatment for people with single or multiple brain metastases, either alone or in combination.}, -DOI = {10.1002/14651858.CD013223}, -URL = {http://dx.doi.org/10.1002/14651858.CD013223} -} - - -Record #19 of 20 -@article{Abdel‐Rahman19, -author = {Abdel‐Rahman, O, and Elsayed, Z}, -title = {Immune checkpoint inhibitors for unresectable hepatocellular carcinoma}, -journal = {Cochrane Database of Systematic Reviews}, -number = {9}, -year = {2019}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits and harms of immune checkpoint inhibitors versus placebo, no treatment, or other systemic or locoregional therapies for people with unresectable hepatocellular carcinoma.}, -DOI = {10.1002/14651858.CD013431}, -URL = {http://dx.doi.org/10.1002/14651858.CD013431} -} - - -Record #20 of 20 -@article{Thielecke21, -author = {Thielecke, L, Stocker, LD, Florou, V, Monsef, I, Skoetz, N, and Herling, M}, -title = {The role of high‐dose chemotherapy with autologous stem cell transplantation in adults with mature T‐cell lymphomas}, -journal = {Cochrane Database of Systematic Reviews}, -number = {9}, -year = {2021}, -publisher = {John Wiley & Sons, Ltd}, -ISSN = {1465-1858}, -abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To define the role of HDT followed by autoSCT in the treatment of MTCL in adults (≥18 years of age), particularly with respect to its efficacy and safety as a first‐line therapy, and secondarily for its efficacy and safety as a salvage option.}, -DOI = {10.1002/14651858.CD014671}, -URL = {http://dx.doi.org/10.1002/14651858.CD014671} -} - - diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/citation-export clinical answers 2.bib" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/citation-export clinical answers 2.bib" deleted file mode 100644 index 372e7e6..0000000 --- "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/citation-export clinical answers 2.bib" +++ /dev/null @@ -1,22 +0,0 @@ -Record #1 of 2 -@article{Tort22, -author = {Tort, Sera, and Fong, Kwun M}, -title = {What are the benefits and harms of non‐checkpoint‐based immunotherapy in people with stage I to III non‐small cell lung cancer (NSCLC) treated with surgery or chemoradiotherapy with curative intent?}, -journal = {Cochrane Clinical Answers}, -year = {2022}, -DOI = {10.1002/cca.3934}, -URL = {http://dx.doi.org/10.1002/cca.3934} -} - - -Record #2 of 2 -@article{Mocellin21, -author = {Mocellin, Simone}, -title = {How do immune checkpoint inhibitors (ICIs) compare with platinum‐based chemotherapy for people with advanced non‐small cell lung cancer (NSCLC)?}, -journal = {Cochrane Clinical Answers}, -year = {2021}, -DOI = {10.1002/cca.3535}, -URL = {http://dx.doi.org/10.1002/cca.3535} -} - - diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/pubmed-29AND32-set 851.txt" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/pubmed-29AND32-set 851.txt" deleted file mode 100644 index 4aa49f4..0000000 --- "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/pubmed-29AND32-set 851.txt" +++ /dev/null @@ -1,114784 +0,0 @@ -PMID- 31378236 -OWN - NLM -STAT- MEDLINE -DCOM- 20200109 -LR - 20200109 -IS - 1942-5546 (Electronic) -IS - 0025-6196 (Linking) -VI - 94 -IP - 8 -DP - 2019 Aug -TI - Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. -PG - 1623-1640 -LID - S0025-6196(19)30070-9 [pii] -LID - 10.1016/j.mayocp.2019.01.013 [doi] -AB - Lung cancer remains the leading cause of cancer deaths in the United States. In - the past decade, significant advances have been made in the science of non-small - cell lung cancer (NSCLC). Screening has been introduced with the goal of early - detection. The National Lung Screening Trial found a lung cancer mortality - benefit of 20% and a 6.7% decrease in all-cause mortality with the use of - low-dose chest computed tomography in high-risk individuals. The treatment of - lung cancer has also evolved with the introduction of several lines of tyrosine - kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. - Similarly, immune checkpoint inhibitors (ICIs) have dramatically changed the - landscape of NSCLC treatment. Furthermore, the results of new trials continue to - help us understand the role of these novel agents and which patients are more - likely to benefit; ICIs are now part of the first-line NSCLC treatment - armamentarium as monotherapy, combined with chemotherapy, or after definite - chemoradiotherapy in patients with stage III unresectable NSCLC. Expression of - programmed cell death protein-ligand 1 in malignant cells has been studied as a - potential biomarker for response to ICIs. However, important drawbacks exist that - limit its discriminatory potential. Identification of accurate predictive - biomarkers beyond programmed cell death protein-ligand 1 expression remains - essential to select the most appropriate candidates for ICI therapy. Many - questions remain unanswered regarding the proper sequence and combinations of - these new agents; however, the field is moving rapidly, and the overall direction - is optimistic. -CI - Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by - Elsevier Inc. All rights reserved. -FAU - Duma, Narjust -AU - Duma N -AD - Division of Medical Oncology, Mayo Clinic, Rochester, MN. -FAU - Santana-Davila, Rafael -AU - Santana-Davila R -AD - Division of Medical Oncology, Department of Medicine, University of Washington, - Seattle. -FAU - Molina, Julian R -AU - Molina JR -AD - Division of Medical Oncology, Mayo Clinic, Rochester, MN. -LA - eng -PT - Journal Article -PT - Review -PL - England -TA - Mayo Clin Proc -JT - Mayo Clinic proceedings -JID - 0405543 -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/*diagnosis/epidemiology/prevention & - control/*therapy -MH - Chemoradiotherapy/*methods -MH - Chemotherapy, Adjuvant -MH - Disease-Free Survival -MH - Early Detection of Cancer/*methods -MH - Education, Medical, Continuing -MH - Female -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/*diagnosis/epidemiology/prevention & control/*therapy -MH - Male -MH - Molecular Targeted Therapy/methods -MH - Pneumonectomy/methods -MH - Prognosis -MH - Risk Assessment -MH - Survival Analysis -MH - United States -EDAT- 2019/08/06 06:00 -MHDA- 2020/01/10 06:00 -CRDT- 2019/08/06 06:00 -PHST- 2018/04/27 00:00 [received] -PHST- 2019/01/04 00:00 [revised] -PHST- 2019/01/21 00:00 [accepted] -PHST- 2019/08/06 06:00 [entrez] -PHST- 2019/08/06 06:00 [pubmed] -PHST- 2020/01/10 06:00 [medline] -AID - S0025-6196(19)30070-9 [pii] -AID - 10.1016/j.mayocp.2019.01.013 [doi] -PST - ppublish -SO - Mayo Clin Proc. 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. - -PMID- 37979378 -OWN - NLM -STAT- MEDLINE -DCOM- 20231207 -LR - 20231207 -IS - 1950-6007 (Electronic) -IS - 0753-3322 (Linking) -VI - 169 -DP - 2023 Dec 31 -TI - Advances and challenges in the treatment of lung cancer. -PG - 115891 -LID - S0753-3322(23)01689-X [pii] -LID - 10.1016/j.biopha.2023.115891 [doi] -AB - Lung cancer accounts for a relatively high proportion of malignant tumors. As the - most prevalent type of lung cancer, non-small cell lung cancer (NSCLC) is - characterized by high morbidity and mortality. Presently, the arsenal of - treatment strategies encompasses surgical resection, chemotherapy, targeted - therapy and radiotherapy. However, despite these options, the prognosis remains - distressingly poor with a low 5-year survival rate. Therefore, it is urgent to - pursue a paradigm shift in treatment methodologies. In recent years, the advent - of sophisticated biotechnologies and interdisciplinary integration has provided - innovative approaches for the treatment of lung cancer. This article reviews the - cutting-edge developments in the nano drug delivery system, molecular targeted - treatment system, photothermal treatment strategy, and immunotherapy for lung - cancer. Overall, by systematically summarizing and critically analyzing the - latest progress and current challenges in these treatment strategies of lung - cancer, we aim to provide a theoretical basis for the development of novel drugs - for lung cancer treatment, and thus improve the therapeutic outcomes for lung - cancer patients. -CI - Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights - reserved. -FAU - Li, Yuting -AU - Li Y -AD - School of Integrated Chinese and Western Medicine, Anhui University of Chinese - Medicine, Hefei, People's Republic of China. -FAU - Yan, Bingshuo -AU - Yan B -AD - School of Integrated Chinese and Western Medicine, Anhui University of Chinese - Medicine, Hefei, People's Republic of China. -FAU - He, Shiming -AU - He S -AD - School of Integrated Chinese and Western Medicine, Anhui University of Chinese - Medicine, Hefei, People's Republic of China. Electronic address: - hesm@ahtcm.edu.cn. -LA - eng -PT - Journal Article -PT - Review -DEP - 20231116 -PL - France -TA - Biomed Pharmacother -JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie -JID - 8213295 -SB - IM -MH - Humans -MH - *Lung Neoplasms/therapy/drug therapy -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - Immunotherapy/methods -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -OTO - NOTNLM -OT - Immunotherapy -OT - Lung cancer -OT - Molecular targeted treatment system -OT - Nano drug delivery system -OT - Photothermal treatment strategy -COIS- Declaration of Competing Interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2023/11/19 09:42 -MHDA- 2023/12/07 12:43 -CRDT- 2023/11/18 18:08 -PHST- 2023/09/13 00:00 [received] -PHST- 2023/11/04 00:00 [revised] -PHST- 2023/11/13 00:00 [accepted] -PHST- 2023/12/07 12:43 [medline] -PHST- 2023/11/19 09:42 [pubmed] -PHST- 2023/11/18 18:08 [entrez] -AID - S0753-3322(23)01689-X [pii] -AID - 10.1016/j.biopha.2023.115891 [doi] -PST - ppublish -SO - Biomed Pharmacother. 2023 Dec 31;169:115891. doi: 10.1016/j.biopha.2023.115891. - Epub 2023 Nov 16. - -PMID- 37879444 -OWN - NLM -STAT- MEDLINE -DCOM- 20240127 -LR - 20240127 -IS - 1569-8041 (Electronic) -IS - 0923-7534 (Linking) -VI - 35 -IP - 1 -DP - 2024 Jan -TI - Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced - NSCLC after disease progression on osimertinib: primary results from the phase - III MARIPOSA-2 study. -PG - 77-90 -LID - S0923-7534(23)04281-3 [pii] -LID - 10.1016/j.annonc.2023.10.117 [doi] -AB - BACKGROUND: Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and - without lazertinib demonstrated antitumor activity in patients with refractory - epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung - cancer (NSCLC) in phase I studies. These combinations were evaluated in a global - phase III trial. PATIENTS AND METHODS: A total of 657 patients with EGFR-mutated - (exon 19 deletions or L858R) locally advanced or metastatic NSCLC after disease - progression on osimertinib were randomized 2 : 2 : 1 to receive - amivantamab-lazertinib-chemotherapy, chemotherapy, or amivantamab-chemotherapy. - The dual primary endpoints were progression-free survival (PFS) of - amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus - chemotherapy. During the study, hematologic toxicities observed in the - amivantamab-lazertinib-chemotherapy arm necessitated a regimen change to start - lazertinib after carboplatin completion. RESULTS: All baseline characteristics - were well balanced across the three arms, including by history of brain - metastases and prior brain radiation. PFS was significantly longer for - amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus - chemotherapy [hazard ratio (HR) for disease progression or death 0.48 and 0.44, - respectively; P < 0.001 for both; median of 6.3 and 8.3 versus 4.2 months, - respectively]. Consistent PFS results were seen by investigator assessment (HR - for disease progression or death 0.41 and 0.38 for amivantamab-chemotherapy and - amivantamab-lazertinib-chemotherapy, respectively; P < 0.001 for both; median of - 8.2 and 8.3 versus 4.2 months, respectively). Objective response rate was - significantly higher for amivantamab-chemotherapy and - amivantamab-lazertinib-chemotherapy versus chemotherapy (64% and 63% versus 36%, - respectively; P < 0.001 for both). Median intracranial PFS was 12.5 and 12.8 - versus 8.3 months for amivantamab-chemotherapy and - amivantamab-lazertinib-chemotherapy versus chemotherapy (HR for intracranial - disease progression or death 0.55 and 0.58, respectively). Predominant adverse - events (AEs) in the amivantamab-containing regimens were hematologic, EGFR-, and - MET-related toxicities. Amivantamab-chemotherapy had lower rates of hematologic - AEs than amivantamab-lazertinib-chemotherapy. CONCLUSIONS: - Amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy improved PFS and - intracranial PFS versus chemotherapy in a population with limited options after - disease progression on osimertinib. Longer follow-up is needed for the modified - amivantamab-lazertinib-chemotherapy regimen. -CI - Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. -FAU - Passaro, A -AU - Passaro A -AD - Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, - Italy. Electronic address: antonio.passaro@ieo.it. -FAU - Wang, J -AU - Wang J -AD - Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, - China. -FAU - Wang, Y -AU - Wang Y -AD - Department of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Lee, S-H -AU - Lee SH -AD - Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, - Republic of Korea. -FAU - Melosky, B -AU - Melosky B -AD - British Columbia Cancer Agency, Vancouver, Canada. -FAU - Shih, J-Y -AU - Shih JY -AD - Department of Internal Medicine, National Taiwan University Hospital, Taipei - City, Taiwan. -FAU - Wang, J -AU - Wang J -AD - Fudan University Shanghai Cancer Center, Shanghai, China. -FAU - Azuma, K -AU - Azuma K -AD - Kurume University School of Medicine, Kurume, Japan. -FAU - Juan-Vidal, O -AU - Juan-Vidal O -AD - Hospital Universitari i Politécnic La Fe, Valencia, Spain. -FAU - Cobo, M -AU - Cobo M -AD - Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University - Hospitals, IBIMA, Málaga, Spain. -FAU - Felip, E -AU - Felip E -AD - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, - Barcelona, Spain. -FAU - Girard, N -AU - Girard N -AD - Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; Paris Saclay - University, UVSQ, Versailles, France. -FAU - Cortot, A B -AU - Cortot AB -AD - University of Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, - UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to - Therapies, F-59000 Lille, France. -FAU - Califano, R -AU - Califano R -AD - Department of Medical Oncology, Christie NHS Foundation Trust and Division of - Cancer Sciences, The University of Manchester, Manchester, UK. -FAU - Cappuzzo, F -AU - Cappuzzo F -AD - IRCCS Regina Elena National Cancer Institute, Rome, Italy. -FAU - Owen, S -AU - Owen S -AD - Department of Medical Oncology, McGill University Health Centre, Montreal, - Quebec, Canada. -FAU - Popat, S -AU - Popat S -AD - Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, - London, UK. -FAU - Tan, J-L -AU - Tan JL -AD - Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia. -FAU - Salinas, J -AU - Salinas J -AD - Centro de Especialidades Medicas Ambulatorias e Investigación Clínica, Córdoba, - Argentina. -FAU - Tomasini, P -AU - Tomasini P -AD - Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance - Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France. -FAU - Gentzler, R D -AU - Gentzler RD -AD - Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA, - USA. -FAU - William, W N Jr -AU - William WN Jr -AD - Centro Oncológico BP, Beneficência Portuguesa de São Paulo, and Grupo - Oncoclínicas, São Paulo, Brazil. -FAU - Reckamp, K L -AU - Reckamp KL -AD - Cedars-Sinai Medical Center, Los Angeles, USA. -FAU - Takahashi, T -AU - Takahashi T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan. -FAU - Ganguly, S -AU - Ganguly S -AD - Tata Medical Center, Kolkata, India. -FAU - Kowalski, D M -AU - Kowalski DM -AD - Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National - Research Institute of Oncology, Warsaw, Poland. -FAU - Bearz, A -AU - Bearz A -AD - Medical Oncology, Centro di Riferimento Oncologico-CRO, Aviano, Italy. -FAU - MacKean, M -AU - MacKean M -AD - Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK. -FAU - Barala, P -AU - Barala P -AD - Janssen Research & Development, Spring House, PA, USA. -FAU - Bourla, A B -AU - Bourla AB -AD - Janssen Research & Development, Raritan, NJ, USA. -FAU - Girvin, A -AU - Girvin A -AD - Janssen Research & Development, Spring House, PA, USA. -FAU - Greger, J -AU - Greger J -AD - Janssen Research & Development, Spring House, PA, USA. -FAU - Millington, D -AU - Millington D -AD - Janssen Research & Development, San Diego, CA, USA. -FAU - Withelder, M -AU - Withelder M -AD - Janssen Research & Development, Spring House, PA, USA. -FAU - Xie, J -AU - Xie J -AD - Janssen Research & Development, Raritan, NJ, USA. -FAU - Sun, T -AU - Sun T -AD - Janssen Research & Development, Raritan, NJ, USA. -FAU - Shah, S -AU - Shah S -AD - Janssen Research & Development, Spring House, PA, USA. -FAU - Diorio, B -AU - Diorio B -AD - Janssen Research & Development, Raritan, NJ, USA. -FAU - Knoblauch, R E -AU - Knoblauch RE -AD - Janssen Research & Development, Spring House, PA, USA. -FAU - Bauml, J M -AU - Bauml JM -AD - Janssen Research & Development, Spring House, PA, USA. -FAU - Campelo, R G -AU - Campelo RG -AD - University Hospital A Coruña, A Coruña, Spain. -FAU - Cho, B C -AU - Cho BC -AD - Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of - Medicine, Seoul, Republic of Korea. -CN - MARIPOSA-2 Investigators -LA - eng -PT - Clinical Trial, Phase III -PT - Journal Article -DEP - 20231023 -PL - England -TA - Ann Oncol -JT - Annals of oncology : official journal of the European Society for Medical - Oncology -JID - 9007735 -RN - 0 (Acrylamides) -RN - 0 (amivantamab-vmjw) -RN - 0 (Aniline Compounds) -RN - 0 (Antibodies, Bispecific) -RN - BG3F62OND5 (Carboplatin) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - 0 (Indoles) -RN - 4A2Y23XK11 (lazertinib) -RN - 0 (Morpholines) -RN - 3C06JJ0Z2O (osimertinib) -RN - 0 (Protein Kinase Inhibitors) -RN - 0 (Pyrazoles) -RN - 0 (Pyrimidines) -SB - IM -MH - Humans -MH - *Acrylamides -MH - *Aniline Compounds -MH - *Antibodies, Bispecific -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - Carboplatin/adverse effects -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Disease Progression -MH - ErbB Receptors/genetics -MH - *Indoles -MH - *Lung Neoplasms/drug therapy/genetics -MH - *Morpholines -MH - Mutation -MH - Protein Kinase Inhibitors/therapeutic use -MH - *Pyrazoles -MH - *Pyrimidines -OTO - NOTNLM -OT - EGFR-mutated -OT - NSCLC -OT - amivantamab -OT - lazertinib -OT - post-osimertinib -COIS- Disclosure AP: consulting or advisory role for AstraZeneca, Bayer, Bristol Myers - Squibb, Daiichi Sankyo, Lilly, GSK, Janssen, Merck Sharp & Dohme, Mundipharma, - Novartis, and Roche; speakers bureaus for AstraZeneca, Boehringer Ingelheim, - Daiichi Sankyo, eCancer, Janssen, Merck Sharp & Dohme, Medscape, PeerVoice, and - touchONCOLOGY; steering committee member for Janssen and ArriVent Biopharma. SHL: - received honoraria from AstraZeneca/MedImmune, Roche, Merck, Lilly, and Amgen; - consulting or advisory role for AstraZeneca, Roche, Merck, Pfizer, and Lilly; - received research funding from Merck. BM: received speaking honoraria from - AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Janssen, - Jazz Pharmaceuticals, Merck, Novartis, Pfizer, Roche, Sanofi, and Takeda; - received support for attending meetings from Janssen, Pfizer, and Sanofi. JYS: - participated in advisory boards for AstraZeneca, Roche, Boehringer Ingelheim, - Lilly, Pfizer, Novartis, Merck Sharp & Dohme, Chugai Pharmaceutical Co, Ono - Pharmaceutical, Takeda, CStone Pharmaceuticals, Janssen, and Bristol Myers - Squibb; received speaking honoraria from AstraZeneca, Roche, Boehringer - Ingelheim, Lilly, Pfizer, Novartis, Merck Sharp & Dohme, Chugai Pharmaceutical - Co, Ono Pharmaceutical, and Bristol Myers Squibb; received grant from Roche. KA: - received lecture fees for AstraZeneca K.K., MSD K.K., Ono Pharmaceutical Co. - Ltd., Bristol Myers Squibb, and Chugai Pharmaceutical Co. OJV: honoraria or - advisory role for Bristol Myers Squibb, Merck Sharp & Dohme, Roche/Genentech, - AstraZeneca, Pfizer, Lilly, Takeda, and Janssen; received travel, accommodations, - and expenses from Takeda, AstraZeneca, Merck Sharp & Dohme, Pfizer, and - Roche/Genentech. EF: consulting or advisory role for Amgen, AstraZeneca, Bayer, - Bristol Myers Squibb, Lilly, GSK, Janssen, Merck Serono, Novartis, Pfizer, - Sanofi, Takeda, Peptomyc, Daiichi Sankyo Europe GmbH, F. Hoffman La-Roche, Merck - Sharp & Dohme, BerGenBio, and Turning Point Therapeutics; speakers bureaus for - AstraZeneca, Bristol Myers Squibb, Lilly, Medscape, Merck Sharp & Dohme, - PeerVoice, Pfizer, Takeda, Amgen, F. Hoffman La-Roche, Janssen, Medical Trends, - Merck Serono, Sanofi, and touchONCOLOGY; other relationships with GRIFOLS; - received research funding from Merck and Merck KgaA. NG: invited speaker for - Amgen, AstraZeneca, Bristol Myers Squibb, Mirati Therapeutics, MSD, Novartis, - Pfizer, Roche, and Sanofi; advisory roles for AbbVie, Amgen, AstraZeneca, Bristol - Myers Squibb, Boehringer Ingelheim, Grünenthal, Janssen, Lilly, MSD, Novartis, - Owkin, Pfizer, Roche, Sanofi, and Takeda; received research funding for - institution from Bristol Myers Squibb, Janssen, Roche, and Sivan; leadership role - at ITMIG; family employment at AstraZeneca. ABC: invited speaker for Pfizer, - Amgen, Takeda, Novartis, Roche, AstraZeneca, MSD, Janssen, Bristol Myers Squibb, - and Sanofi; advisory roles for Novartis, AbbVie, Roche, Exeliom Biosciences, - Pfizer, Janssen, Amgen, Takeda, AstraZeneca, and MSD; research funding of - institution from Exeliom Biosciences; support for attending meetings from Roche, - MSD, Novartis, Pfizer, AstraZeneca, Amgen, and Bristol Myers Squibb; - participation on data monitoring safety board for InhaTarget Therapeutics and - Merck. RC: invited speaker for Amgen, AstraZeneca, Lilly, GSK, Janssen, MSD, - Pfizer, Roche, and Takeda; participated in advisory boards for Amgen, - AstraZeneca, Bayer, Lilly, GSK, Janssen, MSD, Novartis, Pfizer, PharmaMar, Roche, - Sanofi, and Takeda; speaker in educational activities for Medscape, PeerVoice, - and TouchIME; holds stocks or shares in Supportive Care UK; has ownership - interest in Christie Private Care; principal investigator for AbbVie, - AstraZeneca, Bristol Myers Squibb, Clovis, Lilly, GSK, Janssen, MSD, Novartis, - Pfizer, PharmaMar, Roche, and Takeda. FC: received consulting fees from Roche, - AstraZeneca, Bristol Myers Squibb, Pfizer, Takeda, Lilly, Bayer, Amgen, Sanofi, - PharmaMar, Novocure, Mirati Therapeutics, Galecto, OSE Immunotherapeutics, and - MSD; received honoraria for advisory role from Roche, AstraZeneca, Bristol Myers - Squibb, Pfizer, Takeda, Lilly, Bayer, Amgen, Sanofi, PharmaMar, Novocure, Mirati - Therapeutics, Galecto, OSE Immunotherapeutics, and MSD; received support for - attending meetings from OSE Immunotherapeutics; participated in advisory boards - for Roche, AstraZeneca, Bristol Myers Squibb, Pfizer, Takeda, Lilly, Bayer, - Amgen, Sanofi, PharmaMar, Novocure, Mirati Therapeutics, Galecto, OSE - Immunotherapeutics, and MSD. SO: received advisory board consulting fees from - Janssen, Bristol Myers Squibb, Novocure, and Roche. SP: participated in advisory - boards for Amgen, AstraZeneca, Bayer, BeiGene, Blueprint Medicines, Bristol Myers - Squibb, Boehringer Ingelheim, Daiichi Sankyo, EQRx, GSK, Guardant Health, - Janssen, Lilly, Medscape, MSD, Novartis, Pfizer, Sanofi, and Takeda; consulting - fees from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, - Boehringer Ingelheim, Daiichi Sankyo, GSK, Guardant Health, Incyte, Janssen, - Lilly, Merck Serono, MSD, Novartis, Roche, Takeda, Pfizer, Seattle Genetics, - Turning Point Therapeutics, and EQRx; expert testimony for Merck Serono and - Roche; invited speaker for VJOncology; received payment or honoraria from - AstraZeneca, Bayer, Guardant Health, Janssen, Merck Serono, Roche, and Takeda; - principal investigator for ARIAD Pharmaceuticals, AstraZeneca, Bristol Myers - Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Janssen, Lilly, Roche, - Takeda, Trizel, and Turning Point Therapeutics; received support for attending - meetings from Janssen and Roche; research grant from Guardant Health; other - financial relationships with Amgen, Blueprint Medicines, Elsevier, and MSD. JLT: - invited speaker for AstraZeneca, Lilly, MSD, Boehringer Ingelheim, Pfizer, and - Takeda; participated in advisory boards for Amgen and AstraZeneca; received - support for attending meetings from MSD. PT: received grants and nonfinancial - support from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, - Roche, and Takeda. RDG: received grants from Alliance Foundation, Amgen, - AstraZeneca, Big Ten Cancer Research Consortium, Bristol Myers Squibb, Chugai - Pharmaceutical Co, Daiichi Sankyo, ECOG-ACRIN, Helsinn, Hoosier Cancer Research - Network, Janssen, Jounce Therapeutics, Merck, National Cancer Institute, Pfizer, - and Takeda; received payment or honoraria from Clinical Care Options, OncLive, - Society for Immunotherapy of Cancer, and Targeted Oncology; received support for - attending meetings from the International Association for the Study of Lung - Cancer; participated in advisory boards for AstraZeneca, Blueprint Medicines, - Daiichi Sankyo, Gilead, Janssen, Jazz Pharmaceuticals, Mirati Therapeutics, - Oncocyte, Sanofi, and Takeda; leadership or other role in ASCO Scientific Review - Committee and Meeting Abstracts, Hoosier Cancer Research Network, Journal of - Clinical Oncology, National Cancer Institute Investigational Drug Steering - Committee, and the Thoracic Clinical Trial Working Group. WNWJr: participated in - advisory boards for AstraZeneca, Bayer, Merck, Novartis, Sanofi, and Takeda; - invited speaker for Amgen, Bristol Myers Squibb, Lilly, Genentech/Roche, Janssen, - Pfizer, and United Medical; expert testimony for Boehringer Ingelheim. KR: - consultant for Amgen, AstraZeneca, Blueprint Medicines, Daiichi Sankyo, EMD - Serono, Genentech, GSK, Janssen, Lilly, Merck KGA, Mirati Therapeutics, Seattle - Genetics, and Takeda; writing assistance from Blueprint Medicines, Genentech, - Janssen, Merck, Mirati Therapeutics, Seattle Genetics, and Takeda; research - funding of institution from Genentech, Blueprint Medicines, Calithera, Daiichi - Sankyo, Elevation Oncology, and Janssen. TT: received honoraria from AstraZeneca - K.K., Pfizer Japan Inc, Eli Lilly Japan, Chugai Pharmaceutical Co, MSD K.K., - Pfizer Japan Inc, Takeda, Bristol Myers Squibb Japan, Amgen K.K., and Novartis; - research funding of institution from Janssen Pharmaceutical K.K., AstraZeneca - K.K., Pfizer Japan Inc, Eli Lilly Japan, Chugai Pharmaceutical Co, MSD K.K., - Amgen K.K., Merck Biopharma Co., Ltd., and AnHeart Therapeutics Inc. SG: - principal investigator for AstraZeneca, Novartis, and Janssen (fees to - institution). DMK: participated in advisory boards for MSD, Merck, Roche, Bristol - Myers Squibb, Takeda, Boehringer Ingelheim, Pfizer, Johnson & Johnson, Amgen, - Sanofi-Aventis, and Novartis. AB: received consulting fees from Pfizer and Roche; - honoraria from Novartis and Eli Lilly; participated in advisory boards for - Pfizer, Roche, and Regeneron. MM: received consulting fees from Boehringer - Ingelheim, Roche, Takeda, and AstraZeneca. PB, ABB, AG, JG, DM, MW, JX, TS, SS, - BD, REK, JMB: employee of Janssen and may hold stock in Johnson & Johnson. RGC: - invited speaker for AstraZeneca, Bristol Myers Squibb, Janssen, Lilly, Novartis, - Pfizer, Roche, and Takeda; advisory roles for AstraZeneca, Bristol Myers Squibb, - Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, and Takeda; steering - committee member for AstraZeneca and Janssen. BCC: consulting or advisory role - for AstraZeneca, Boehringer Ingelheim, Roche, Bristol Myers Squibb, Pfizer, Yuhan - Corporation, Janssen, Takeda, Merck Sharp & Dohme, Ono Pharmaceutical, Lilly, - MedPacto, Blueprint Medicines, Cyrus Therapeutics, Guardant Health, Novartis, CJ, - ABION, BeiGene, CureLogen, Onegene Biotechnology, GI-Cell, HK inno.N, IMNEWRUN, - Hanmi Pharmaceutical, Kanaph Therapeutics, BridgeBio, and Oscotec; leadership - roles for Interpark Bio and J INTS BIO; patents, royalties, or other intellectual - property for Champions Oncology, Crown Bioscience, and Imagen; other - relationships with DAAN Biotherapeutics; owns stock or has other ownership - interests with Theravance Biopharma, Gencurix, BridgeBio, Kanaph Therapeutics, - Cyrus Therapeutics, Interpark Bio, and J INTS BIO; received research funding from - Novartis, Bayer, AstraZeneca, MOGAM Biotechnology Research Institute, Dong-A ST, - Champions Oncology, Janssen, Yuhan Corporation, Ono Pharmaceutical, Dizal Pharma, - Merck Sharp & Dohme, AbbVie, GI Innovation, Lilly, Blueprint Medicines, Interpark - Bio, LG Chem, Oscotec, GI-Cell, ABION, Boehringer Ingelheim, CJ Bioscience, CJ - Blossom Park, Cyrus Therapeutics, Genexine, Nuvalent Inc, Oncternal Therapeutics, - Regeneron, BridgeBio, ImmuneOncia, Illumina, Kanaph Therapeutics, Therapex, J - INTS Bio, Hanmi Pharmaceutical, and CHA Bundang Medical Center. All other authors - have declared no conflicts of interest. -EDAT- 2023/10/26 00:42 -MHDA- 2024/01/15 12:42 -CRDT- 2023/10/25 19:20 -PHST- 2023/09/22 00:00 [received] -PHST- 2023/10/11 00:00 [revised] -PHST- 2023/10/12 00:00 [accepted] -PHST- 2024/01/15 12:42 [medline] -PHST- 2023/10/26 00:42 [pubmed] -PHST- 2023/10/25 19:20 [entrez] -AID - S0923-7534(23)04281-3 [pii] -AID - 10.1016/j.annonc.2023.10.117 [doi] -PST - ppublish -SO - Ann Oncol. 2024 Jan;35(1):77-90. doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct - 23. - -PMID- 28885881 -OWN - NLM -STAT- MEDLINE -DCOM- 20171201 -LR - 20240210 -IS - 1533-4406 (Electronic) -IS - 0028-4793 (Linking) -VI - 377 -IP - 20 -DP - 2017 Nov 16 -TI - Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. -PG - 1919-1929 -LID - 10.1056/NEJMoa1709937 [doi] -AB - BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell - lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy - (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the - anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with - placebo in patients with stage III NSCLC who did not have disease progression - after two or more cycles of platinum-based chemoradiotherapy. METHODS: We - randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of - 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up - to 12 months. The study drug was administered 1 to 42 days after the patients had - received chemoradiotherapy. The coprimary end points were progression-free - survival (as assessed by means of blinded independent central review) and overall - survival (unplanned for the interim analysis). Secondary end points included - 12-month and 18-month progression-free survival rates, the objective response - rate, the duration of response, the time to death or distant metastasis, and - safety. RESULTS: Of 713 patients who underwent randomization, 709 received - consolidation therapy (473 received durvalumab and 236 received placebo). The - median progression-free survival from randomization was 16.8 months (95% - confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% - CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or - death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free - survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival - rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than - with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was - longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). - The median time to death or distant metastasis was longer with durvalumab than - with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events - occurred in 29.9% of the patients who received durvalumab and 26.1% of those who - received placebo; the most common adverse event of grade 3 or 4 was pneumonia - (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab - group and 9.8% of those in the placebo group discontinued the study drug because - of adverse events. CONCLUSIONS: Progression-free survival was significantly - longer with durvalumab than with placebo. The secondary end points also favored - durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; - PACIFIC ClinicalTrials.gov number, NCT02125461 .). -FAU - Antonia, Scott J -AU - Antonia SJ -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Villegas, Augusto -AU - Villegas A -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Daniel, Davey -AU - Daniel D -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Vicente, David -AU - Vicente D -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Murakami, Shuji -AU - Murakami S -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Hui, Rina -AU - Hui R -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Yokoi, Takashi -AU - Yokoi T -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Chiappori, Alberto -AU - Chiappori A -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Lee, Ki H -AU - Lee KH -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - de Wit, Maike -AU - de Wit M -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Cho, Byoung C -AU - Cho BC -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Bourhaba, Maryam -AU - Bourhaba M -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Quantin, Xavier -AU - Quantin X -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Tokito, Takaaki -AU - Tokito T -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Mekhail, Tarek -AU - Mekhail T -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Planchard, David -AU - Planchard D -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Kim, Young-Chul -AU - Kim YC -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Karapetis, Christos S -AU - Karapetis CS -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Hiret, Sandrine -AU - Hiret S -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Ostoros, Gyula -AU - Ostoros G -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Kubota, Kaoru -AU - Kubota K -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Gray, Jhanelle E -AU - Gray JE -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Paz-Ares, Luis -AU - Paz-Ares L -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - de Castro Carpeño, Javier -AU - de Castro Carpeño J -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Wadsworth, Catherine -AU - Wadsworth C -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Melillo, Giovanni -AU - Melillo G -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Jiang, Haiyi -AU - Jiang H -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Huang, Yifan -AU - Huang Y -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Dennis, Phillip A -AU - Dennis PA -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -FAU - Özgüroğlu, Mustafa -AU - Özgüroğlu M -AD - From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., - A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and - Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee - Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in - Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and - Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de - Cáncer, Universidad Complutense and the Spanish National Cancer Research Center - (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; - Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, - Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical - School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the - University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical - Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National - University Hospital, Chungbuk National University College of Medicine, Cheongju - (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul - (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National - University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes - Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, - Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer - Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave - Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René - Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of - Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom - (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul - University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.). -CN - PACIFIC Investigators -LA - eng -SI - ClinicalTrials.gov/NCT02125461 -SI - ClinicalTrials.gov/NCT02125461 -GR - 20465/CRUK_/Cancer Research UK/United Kingdom -PT - Clinical Trial, Phase III -PT - Comparative Study -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20170908 -PL - United States -TA - N Engl J Med -JT - The New England journal of medicine -JID - 0255562 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (durvalumab) -SB - IM -CIN - Nat Rev Clin Oncol. 2017 Nov;14(11):647. doi: 10.1038/nrclinonc.2017.159. PMID: - 28948976 -CIN - N Engl J Med. 2017 Nov 16;377(20):1986-1988. doi: 10.1056/NEJMe1711430. PMID: - 29141165 -CIN - Strahlenther Onkol. 2018 Mar;194(3):269-271. doi: 10.1007/s00066-017-1253-3. - PMID: 29374302 -CIN - N Engl J Med. 2018 Mar 01;378(9):868. doi: 10.1056/NEJMc1716426. PMID: 29504720 -CIN - N Engl J Med. 2018 Mar 01;378(9):869. doi: 10.1056/NEJMc1716426. PMID: 29504721 -CIN - Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S19-S24. doi: - 10.21037/tlcr.2017.12.12. PMID: 29531898 -CIN - J Thorac Dis. 2018 Jan;10(1):60-63. doi: 10.21037/jtd.2017.12.14. PMID: 29600022 -CIN - J Thorac Dis. 2018 Feb;10(2):657-660. doi: 10.21037/jtd.2018.01.22. PMID: - 29607130 -CIN - J Thorac Dis. 2018 Mar;10(3):1198-1200. doi: 10.21037/jtd.2018.01.160. PMID: - 29707266 -CIN - J Thorac Dis. 2018 Mar;10(3):1205-1206. doi: 10.21037/jtd.2018.03.55. PMID: - 29707267 -CIN - J Thorac Dis. 2018 Mar;10(3):1225-1226. doi: 10.21037/jtd.2018.02.39. PMID: - 29707271 -CIN - Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S153-S157. doi: - 10.21037/tlcr.2018.03.18. PMID: 29780708 -CIN - J Thorac Dis. 2018 Apr;10(Suppl 9):S991-S994. doi: 10.21037/jtd.2018.04.29. PMID: - 29850180 -CIN - J Thorac Dis. 2018 Apr;10(Suppl 9):S1032-S1036. doi: 10.21037/jtd.2018.04.61. - PMID: 29850182 -CIN - J Thorac Dis. 2018 Apr;10(Suppl 9):S1108-S1112. doi: 10.21037/jtd.2018.03.180. - PMID: 29850190 -CIN - J Thorac Cardiovasc Surg. 2018 Sep;156(3):1249-1254. doi: - 10.1016/j.jtcvs.2018.05.059. PMID: 30017445 -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal/adverse effects/*therapeutic use -MH - Antineoplastic Agents/adverse effects/*therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/mortality/secondary/*therapy -MH - Chemoradiotherapy -MH - Disease-Free Survival -MH - Female -MH - Humans -MH - Intention to Treat Analysis -MH - Kaplan-Meier Estimate -MH - Lung Neoplasms/mortality/pathology/*therapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -FIR - Jasas, Kevin -IR - Jasas K -FIR - Obyrne, Kenneth -IR - Obyrne K -FIR - Houghton, Baerin -IR - Houghton B -FIR - Hughes, Brett -IR - Hughes B -FIR - Lewis, Craig -IR - Lewis C -FIR - Links, Matthew -IR - Links M -FIR - Ng, Say -IR - Ng S -FIR - Parente, Phillip -IR - Parente P -FIR - Gauden, Stanislaw -IR - Gauden S -FIR - Forget, Frederic -IR - Forget F -FIR - Vercauter, Piet -IR - Vercauter P -FIR - Vansteenkiste, Johan -IR - Vansteenkiste J -FIR - Canon, Jean-Luc -IR - Canon JL -FIR - Cheema, Parnet -IR - Cheema P -FIR - Vincent, Mark -IR - Vincent M -FIR - Murray, Nevin -IR - Murray N -FIR - Rothenstein, Jeffrey -IR - Rothenstein J -FIR - Zibdawi, Labib -IR - Zibdawi L -FIR - Bradbury, Penelope -IR - Bradbury P -FIR - Butts, Charles -IR - Butts C -FIR - El-Maraghi, Robert -IR - El-Maraghi R -FIR - Bebb, Dafydd -IR - Bebb D -FIR - Acevedo Gaete, Alejandro -IR - Acevedo Gaete A -FIR - Orellana Ulunque, Eric Armando -IR - Orellana Ulunque EA -FIR - Aren Frontera, Osvaldo Rudy -IR - Aren Frontera OR -FIR - Mazières, Julien -IR - Mazières J -FIR - Renault, Patrick Aldo -IR - Renault PA -FIR - Robinet, Gilles -IR - Robinet G -FIR - Cortot, Alexis -IR - Cortot A -FIR - Hilgers, Werner -IR - Hilgers W -FIR - Poudenx, Michel -IR - Poudenx M -FIR - Barlesi, Fabrice -IR - Barlesi F -FIR - El Kouri, Claude -IR - El Kouri C -FIR - Perol, Maurice -IR - Perol M -FIR - Lena, Hervé -IR - Lena H -FIR - Sabatini, Marielle -IR - Sabatini M -FIR - Pujol, Jean-Louis -IR - Pujol JL -FIR - Laack, Eckart -IR - Laack E -FIR - Schulz, Christian -IR - Schulz C -FIR - Brugger, Wolfram -IR - Brugger W -FIR - Faehling, Martin -IR - Faehling M -FIR - Reck, Martin -IR - Reck M -FIR - Wolff, Thomas -IR - Wolff T -FIR - Fischer, Juergen -IR - Fischer J -FIR - Emde, Till-Oliver -IR - Emde TO -FIR - Scholz, Christian -IR - Scholz C -FIR - Rueckert, Anja -IR - Rueckert A -FIR - Kalofonos, Haralabos -IR - Kalofonos H -FIR - Kotsakis, Athanasios -IR - Kotsakis A -FIR - Syrigos, Konstantinos -IR - Syrigos K -FIR - Papazisis, Konstantinos -IR - Papazisis K -FIR - Zarogoulidis, Kostantinos -IR - Zarogoulidis K -FIR - Sztancsik, Zsuzsanna -IR - Sztancsik Z -FIR - Losonczy, Gyorgy -IR - Losonczy G -FIR - Csanky, Eszter -IR - Csanky E -FIR - Nechushtan, Hovav -IR - Nechushtan H -FIR - Wollner, Mirjana -IR - Wollner M -FIR - Chella, Antonio -IR - Chella A -FIR - Bearz, Alessandra -IR - Bearz A -FIR - Chiuri, Vincenzo Emanuele -IR - Chiuri VE -FIR - Garassino, Marina -IR - Garassino M -FIR - Gianni, Luca -IR - Gianni L -FIR - Brighenti, Matteo -IR - Brighenti M -FIR - Ciardiello, Fortunato -IR - Ciardiello F -FIR - Milella, Michele -IR - Milella M -FIR - Soto Parra, Hector -IR - Soto Parra H -FIR - Sugawara, Shunichi -IR - Sugawara S -FIR - Atagi, Shinji -IR - Atagi S -FIR - Hirashima, Tomonori -IR - Hirashima T -FIR - Imamura, Fumio -IR - Imamura F -FIR - Iwamoto, Yasuo -IR - Iwamoto Y -FIR - Kanda, Shintaro -IR - Kanda S -FIR - Masuda, Noriyuki -IR - Masuda N -FIR - Minato, Koichi -IR - Minato K -FIR - Nakagawa, Kazuhiko -IR - Nakagawa K -FIR - Niho, Seiji -IR - Niho S -FIR - Saka, Hideo -IR - Saka H -FIR - Takahashi, Toshiaki -IR - Takahashi T -FIR - Fujisaka, Yasuhito -IR - Fujisaka Y -FIR - Sakai, Hiroshi -IR - Sakai H -FIR - Takahashi, Kazuhisa -IR - Takahashi K -FIR - Baba, Tomohisa -IR - Baba T -FIR - Harada, Masao -IR - Harada M -FIR - Kasahara, Kazuo -IR - Kasahara K -FIR - Maeda, Tadashi -IR - Maeda T -FIR - Maemondo, Makoto -IR - Maemondo M -FIR - Okamoto, Isamu -IR - Okamoto I -FIR - Takeda, Yuichiro -IR - Takeda Y -FIR - Kobayashi, Kunihiko -IR - Kobayashi K -FIR - Nogami, Naoyuki -IR - Nogami N -FIR - Kiura, Katsuyuki -IR - Kiura K -FIR - Kato, Terufumi -IR - Kato T -FIR - Hotta, Katsuyuki -IR - Hotta K -FIR - Park, Keunchil -IR - Park K -FIR - Cho, Eun Kyung -IR - Cho EK -FIR - Kim, Hoon Kyo -IR - Kim HK -FIR - Lee, Jong-Seok -IR - Lee JS -FIR - Son, Choonhee -IR - Son C -FIR - Kim, Sang-We -IR - Kim SW -FIR - Shin, Sang-Won -IR - Shin SW -FIR - Kim, Joo-Hang -IR - Kim JH -FIR - De Langen, Joop -IR - De Langen J -FIR - van den Borne, Ben -IR - van den Borne B -FIR - Kloover, Jeroen Steven -IR - Kloover JS -FIR - van den Heuvel, Michael -IR - van den Heuvel M -FIR - van der Leest, Kornelis Harm -IR - van der Leest KH -FIR - Aerts, Joachim G J V -IR - Aerts JGJV -FIR - Hashemi, Sayed -IR - Hashemi S -FIR - Rodriguez Pantigoso, Wuilbert -IR - Rodriguez Pantigoso W -FIR - Bermudez Alfaro, Vanessa -IR - Bermudez Alfaro V -FIR - Jassem, Jacek -IR - Jassem J -FIR - Mandziuk, Slawomir -IR - Mandziuk S -FIR - Kowalski, Dariusz -IR - Kowalski D -FIR - Chopra, Akhil -IR - Chopra A -FIR - Tan, Eng Huat -IR - Tan EH -FIR - Chin, Tan Min -IR - Chin TM -FIR - Soo, Ross Andrew -IR - Soo RA -FIR - Stresko, Marian -IR - Stresko M -FIR - Demo, Pavol -IR - Demo P -FIR - Packan, Tibor -IR - Packan T -FIR - Chovanec, Jozef -IR - Chovanec J -FIR - Cohen, Graham -IR - Cohen G -FIR - Jacobs, Conrad -IR - Jacobs C -FIR - Rens, Daniel -IR - Rens D -FIR - Corral Jaime, Jesus -IR - Corral Jaime J -FIR - Vidal, Oscar Juan -IR - Vidal OJ -FIR - Taus Garcia, Alvaro -IR - Taus Garcia A -FIR - Cardenal Alemany, Felipe -IR - Cardenal Alemany F -FIR - Garcia Gomez, Ramon -IR - Garcia Gomez R -FIR - Holgado Martin, Esther -IR - Holgado Martin E -FIR - Ponce Aix, Santiago -IR - Ponce Aix S -FIR - Porta Balanya, Rut -IR - Porta Balanya R -FIR - Isla Casado, Dolores -IR - Isla Casado D -FIR - Majem Tarruella, Margarita -IR - Majem Tarruella M -FIR - Marquez Medina, Diego -IR - Marquez Medina D -FIR - Alfaro Lizaso, Jesus -IR - Alfaro Lizaso J -FIR - Blasco Cordellat, Ana -IR - Blasco Cordellat A -FIR - Sanchez Torres, Jose Miguel -IR - Sanchez Torres JM -FIR - Massuti Sureda, Bartomeu -IR - Massuti Sureda B -FIR - Sanchez, Amparo -IR - Sanchez A -FIR - Belda Iniesta, Cristobal -IR - Belda Iniesta C -FIR - Alvarez, Rosa -IR - Alvarez R -FIR - Hsia, Te-Chun -IR - Hsia TC -FIR - Chen, Yuh-Min -IR - Chen YM -FIR - Lee, Kang-Yun -IR - Lee KY -FIR - Lien, Yung-Chang -IR - Lien YC -FIR - Yang, Chih-Hsin -IR - Yang CH -FIR - Chung, Chi-Li -IR - Chung CL -FIR - Reungwetwattana, Thanyanan -IR - Reungwetwattana T -FIR - Chewaskulyong, Busayamas -IR - Chewaskulyong B -FIR - Geater, Sarayut Lucien -IR - Geater SL -FIR - Goksel, Tuncay -IR - Goksel T -FIR - Harputluoglu, Hakan -IR - Harputluoglu H -FIR - Artac, Mehmet -IR - Artac M -FIR - Paydas, Semra -IR - Paydas S -FIR - Altundag, Ozden -IR - Altundag O -FIR - Sencan, Orhan -IR - Sencan O -FIR - Hicks, Jonathan -IR - Hicks J -FIR - Faivre-Finn, Corinne -IR - Faivre-Finn C -FIR - Talbot, Toby -IR - Talbot T -FIR - Telivala, Bijoy -IR - Telivala B -FIR - Hussein, Maen -IR - Hussein M -FIR - McCLeod, Michael -IR - McCLeod M -FIR - Slater, Dennis -IR - Slater D -FIR - Uyeki, James V H -IR - Uyeki JVH -FIR - Waterhouse, David -IR - Waterhouse D -FIR - Chen, Franklin L -IR - Chen FL -FIR - Hao, Zhonglin -IR - Hao Z -FIR - Kelly, Ronan -IR - Kelly R -FIR - Morgensztern, Daniel -IR - Morgensztern D -FIR - Page, Ray -IR - Page R -FIR - Spira, Alexander I -IR - Spira AI -FIR - Awad, Mark -IR - Awad M -FIR - Beck, Joseph Thaddeus -IR - Beck JT -FIR - Berg, Alan Richard -IR - Berg AR -FIR - Choksi, Janak -IR - Choksi J -FIR - Dorroh, Scott -IR - Dorroh S -FIR - Goldman, Jonathan -IR - Goldman J -FIR - Iannotti, Nicholas -IR - Iannotti N -FIR - Kubiak, Kendra -IR - Kubiak K -FIR - Rao, Suman -IR - Rao S -FIR - Chaudhry, Arvind -IR - Chaudhry A -FIR - Dalsania, Chirag J -IR - Dalsania CJ -FIR - Farrell, Nicholas J -IR - Farrell NJ -FIR - Hermann, Robert -IR - Hermann R -FIR - Kuzma, Charles S -IR - Kuzma CS -FIR - McIntyre, Kristi J -IR - McIntyre KJ -FIR - Mitchell, William -IR - Mitchell W -FIR - Rodriguez, Estelamari -IR - Rodriguez E -FIR - Sangal, Ashish -IR - Sangal A -FIR - Smith, David A -IR - Smith DA -FIR - Zu, Kai -IR - Zu K -FIR - Anderson, Ian C -IR - Anderson IC -FIR - Behl, Deepti -IR - Behl D -FIR - Edenfield, William J -IR - Edenfield WJ -FIR - Ghazal, Hassan -IR - Ghazal H -FIR - Giaccone, Giuseppe -IR - Giaccone G -FIR - Hagenstad, Christopher Thomas -IR - Hagenstad CT -FIR - Haigentz, Missak Jr -IR - Haigentz M Jr -FIR - Harper, Harry -IR - Harper H -FIR - Henderson, Charles -IR - Henderson C -FIR - Hrinczenko, Borys -IR - Hrinczenko B -FIR - Konduri, Kartik -IR - Konduri K -FIR - Levine, Marshall -IR - Levine M -FIR - Martincic, Danko -IR - Martincic D -FIR - Pillai, Rathi Narayana -IR - Pillai RN -FIR - Salamat, Muhammad -IR - Salamat M -FIR - Shtivelband, Mikhail -IR - Shtivelband M -FIR - Singh, Joginder -IR - Singh J -FIR - Socoteanu, Matei P -IR - Socoteanu MP -FIR - Spigel, David -IR - Spigel D -FIR - Zorsky, Paul -IR - Zorsky P -FIR - Ferrarotto, Renata -IR - Ferrarotto R -FIR - Gomez, Jorge -IR - Gomez J -FIR - Horn, Leora -IR - Horn L -FIR - Kendall, Stephan -IR - Kendall S -FIR - Lawler, William E -IR - Lawler WE -FIR - Gandhi, Leena -IR - Gandhi L -FIR - Zylla, Dylan -IR - Zylla D -FIR - Assikis, Vasileios -IR - Assikis V -FIR - McCune, Steven -IR - McCune S -FIR - Bailey, Samuel -IR - Bailey S -FIR - Le, Anh Tuan -IR - Le AT -FIR - Mai, Khoa -IR - Mai K -FIR - Nguyen, Luu -IR - Nguyen L -EDAT- 2017/09/09 06:00 -MHDA- 2017/12/02 06:00 -CRDT- 2017/09/09 06:00 -PHST- 2017/09/09 06:00 [pubmed] -PHST- 2017/12/02 06:00 [medline] -PHST- 2017/09/09 06:00 [entrez] -AID - 10.1056/NEJMoa1709937 [doi] -PST - ppublish -SO - N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub - 2017 Sep 8. - -PMID- 31590988 -OWN - NLM -STAT- MEDLINE -DCOM- 20191206 -LR - 20200126 -IS - 1474-547X (Electronic) -IS - 0140-6736 (Linking) -VI - 394 -IP - 10212 -DP - 2019 Nov 23 -TI - Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line - treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, - controlled, open-label, phase 3 trial. -PG - 1929-1939 -LID - S0140-6736(19)32222-6 [pii] -LID - 10.1016/S0140-6736(19)32222-6 [doi] -AB - BACKGROUND: Most patients with small-cell lung cancer (SCLC) have extensive-stage - disease at presentation, and prognosis remains poor. Recently, immunotherapy has - demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN - trial assessed durvalumab, with or without tremelimumab, in combination with - etoposide plus either cisplatin or carboplatin (platinum-etoposide) in - treatment-naive patients with ES-SCLC. METHODS: This randomised, open-label, - phase 3 trial was done at 209 sites across 23 countries. Eligible patients were - adults with untreated ES-SCLC, with WHO performance status 0 or 1 and measurable - disease as per Response Evaluation Criteria in Solid Tumors, version 1.1. - Patients were randomly assigned (in a 1:1:1 ratio) to durvalumab plus - platinum-etoposide; durvalumab plus tremelimumab plus platinum-etoposide; or - platinum-etoposide alone. All drugs were administered intravenously. - Platinum-etoposide consisted of etoposide 80-100 mg/m(2) on days 1-3 of each - cycle with investigator's choice of either carboplatin area under the curve 5-6 - mg/mL per min or cisplatin 75-80 mg/m(2) (administered on day 1 of each cycle). - Patients received up to four cycles of platinum-etoposide plus durvalumab 1500 mg - with or without tremelimumab 75 mg every 3 weeks followed by maintenance - durvalumab 1500 mg every 4 weeks in the immunotherapy groups and up to six cycles - of platinum-etoposide every 3 weeks plus prophylactic cranial irradiation - (investigator's discretion) in the platinum-etoposide group. The primary endpoint - was overall survival in the intention-to-treat population. We report results for - the durvalumab plus platinum-etoposide group versus the platinum-etoposide group - from a planned interim analysis. Safety was assessed in all patients who received - at least one dose of their assigned study treatment. This study is registered at - ClinicalTrials.gov, NCT03043872, and is ongoing. FINDINGS: Patients were enrolled - between March 27, 2017, and May 29, 2018. 268 patients were allocated to the - durvalumab plus platinum-etoposide group and 269 to the platinum-etoposide group. - Durvalumab plus platinum-etoposide was associated with a significant improvement - in overall survival, with a hazard ratio of 0·73 (95% CI 0·59-0·91; p=0·0047]); - median overall survival was 13·0 months (95% CI 11·5-14·8) in the durvalumab plus - platinum-etoposide group versus 10·3 months (9·3-11·2) in the platinum-etoposide - group, with 34% (26·9-41·0) versus 25% (18·4-31·6) of patients alive at 18 - months. Any-cause adverse events of grade 3 or 4 occurred in 163 (62%) of 265 - treated patients in the durvalumab plus platinum-etoposide group and 166 (62%) of - 266 in the platinum-etoposide group; adverse events leading to death occurred in - 13 (5%) and 15 (6%) patients. INTERPRETATION: First-line durvalumab plus - platinum-etoposide significantly improved overall survival in patients with - ES-SCLC versus a clinically relevant control group. Safety findings were - consistent with the known safety profiles of all drugs received. FUNDING: - AstraZeneca. -CI - Copyright © 2019 Elsevier Ltd. All rights reserved. -FAU - Paz-Ares, Luis -AU - Paz-Ares L -AD - Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO - Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain. Electronic - address: lpazaresr@seom.org. -FAU - Dvorkin, Mikhail -AU - Dvorkin M -AD - BHI of Omsk Region Clinical Oncology Dispensary, Omsk, Russia. -FAU - Chen, Yuanbin -AU - Chen Y -AD - Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, USA. -FAU - Reinmuth, Niels -AU - Reinmuth N -AD - Asklepios Lung Clinic, Munich-Gauting, Germany. -FAU - Hotta, Katsuyuki -AU - Hotta K -AD - Okayama University Hospital, Okayama, Japan. -FAU - Trukhin, Dmytro -AU - Trukhin D -AD - Odessa National Medical University, Odessa, Ukraine. -FAU - Statsenko, Galina -AU - Statsenko G -AD - Omsk Regional Cancer Center, Omsk, Russia. -FAU - Hochmair, Maximilian J -AU - Hochmair MJ -AD - Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Krankenhaus - Nord, Vienna, Austria. -FAU - Özgüroğlu, Mustafa -AU - Özgüroğlu M -AD - Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey. -FAU - Ji, Jun Ho -AU - Ji JH -AD - Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, - South Korea. -FAU - Voitko, Oleksandr -AU - Voitko O -AD - Kyiv City Clinical Oncological Centre, Kiev, Ukraine. -FAU - Poltoratskiy, Artem -AU - Poltoratskiy A -AD - Petrov Research Institute of Oncology, St Petersburg, Russia. -FAU - Ponce, Santiago -AU - Ponce S -AD - Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO - Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain. -FAU - Verderame, Francesco -AU - Verderame F -AD - AO Ospedali Riuniti PO Vincenzo Cervello, Palermo, Italy. -FAU - Havel, Libor -AU - Havel L -AD - Thomayer Hospital, First Faculty of Medicine, Charles University, Prague, - Czechia. -FAU - Bondarenko, Igor -AU - Bondarenko I -AD - Dnipropetrovsk Medical Academy, Dnipro, Ukraine. -FAU - Kazarnowicz, Andrzej -AU - Kazarnowicz A -AD - Tuberculosis and Lung Disease Hospital, Olsztyn, Poland. -FAU - Losonczy, György -AU - Losonczy G -AD - Semmelweis University, Budapest, Hungary. -FAU - Conev, Nikolay V -AU - Conev NV -AD - Clinic of Medical Oncology, UMHAT St Marina, Varna, Bulgaria. -FAU - Armstrong, Jon -AU - Armstrong J -AD - AstraZeneca, Cambridge, UK. -FAU - Byrne, Natalie -AU - Byrne N -AD - AstraZeneca, Cambridge, UK. -FAU - Shire, Norah -AU - Shire N -AD - AstraZeneca, Gaithersburg, MD, USA. -FAU - Jiang, Haiyi -AU - Jiang H -AD - AstraZeneca, Gaithersburg, MD, USA. -FAU - Goldman, Jonathan W -AU - Goldman JW -AD - David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. -CN - CASPIAN investigators -LA - eng -SI - ClinicalTrials.gov/NCT03043872 -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20191004 -PL - England -TA - Lancet -JT - Lancet (London, England) -JID - 2985213R -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Antineoplastic Agents, Phytogenic) -RN - 28X28X9OKV (durvalumab) -RN - 6PLQ3CP4P3 (Etoposide) -RN - BG3F62OND5 (Carboplatin) -RN - Q20Q21Q62J (Cisplatin) -RN - QEN1X95CIX (tremelimumab) -SB - IM -CIN - Lancet. 2019 Nov 23;394(10212):1884-1885. doi: 10.1016/S0140-6736(19)32235-4. - PMID: 31590987 -MH - Aged -MH - Antibodies, Monoclonal/*administration & dosage/adverse effects -MH - Antibodies, Monoclonal, Humanized/administration & dosage -MH - Antineoplastic Agents, Immunological/*administration & dosage/adverse effects -MH - Antineoplastic Agents, Phytogenic/*administration & dosage -MH - Antineoplastic Combined Chemotherapy Protocols -MH - Carboplatin/administration & dosage/adverse effects -MH - Cisplatin/administration & dosage/adverse effects -MH - Drug Administration Schedule -MH - Etoposide/*administration & dosage/adverse effects -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/mortality -MH - Male -MH - Middle Aged -MH - Progression-Free Survival -MH - Small Cell Lung Carcinoma/*drug therapy/mortality -FIR - Batagelj, Emilio -IR - Batagelj E -FIR - Casarini, Ignacio -IR - Casarini I -FIR - Pastor, Anea Viviana -IR - Pastor AV -FIR - Sena, Susana Noemi -IR - Sena SN -FIR - Zarba, Juan Jose -IR - Zarba JJ -FIR - Burghuber, Otto -IR - Burghuber O -FIR - Hartl, Sylvia -IR - Hartl S -FIR - Hochmair, Maximilian J -IR - Hochmair MJ -FIR - Lamprecht, Bernd -IR - Lamprecht B -FIR - Studnicka, Michael -IR - Studnicka M -FIR - Alberto Schlittler, Luis -IR - Alberto Schlittler L -FIR - Augusto Martinelli de Oliveira, Fabricio -IR - Augusto Martinelli de Oliveira F -FIR - Calabrich, Aknar -IR - Calabrich A -FIR - Colagiovanni Girotto, Gustavo -IR - Colagiovanni Girotto G -FIR - Dos Reis, Peo -IR - Dos Reis P -FIR - Fausto Nino Gorini, Carlos -IR - Fausto Nino Gorini C -FIR - Rafael Martins De Marchi, Peo -IR - Rafael Martins De Marchi P -FIR - Serodio da Rocha Baldotto, Clarissa -IR - Serodio da Rocha Baldotto C -FIR - Sette, Claudia -IR - Sette C -FIR - Zukin, Mauro -IR - Zukin M -FIR - Conev, Nikolay V -IR - Conev NV -FIR - Dudov, Assen -IR - Dudov A -FIR - Ilieva, Rumyana -IR - Ilieva R -FIR - Koynov, Krassimir -IR - Koynov K -FIR - Krasteva, Rositsa -IR - Krasteva R -FIR - Tonev, Ivan -IR - Tonev I -FIR - Valev, Spartak -IR - Valev S -FIR - Venkova, Violetka -IR - Venkova V -FIR - Bi, Minghong -IR - Bi M -FIR - Chen, Chengshui -IR - Chen C -FIR - Chen, Yuan -IR - Chen Y -FIR - Chen, Zhendong -IR - Chen Z -FIR - Fang, Jian -IR - Fang J -FIR - Feng, Jifeng -IR - Feng J -FIR - Han, Zhigang -IR - Han Z -FIR - Hu, Jie -IR - Hu J -FIR - Hu, Yi -IR - Hu Y -FIR - Li, Wei -IR - Li W -FIR - Liang, Zongan -IR - Liang Z -FIR - Lin, Zhong -IR - Lin Z -FIR - Ma, Rui -IR - Ma R -FIR - Ma, Shenglin -IR - Ma S -FIR - Nan, Kejun -IR - Nan K -FIR - Shu, Yongqian -IR - Shu Y -FIR - Wang, Kai -IR - Wang K -FIR - Wang, Mengzhao -IR - Wang M -FIR - Wu, Gang -IR - Wu G -FIR - Yang, Nong -IR - Yang N -FIR - Yang, Zhixiong -IR - Yang Z -FIR - Zhang, Helong -IR - Zhang H -FIR - Zhang, Wei -IR - Zhang W -FIR - Zhao, Jun -IR - Zhao J -FIR - Zhao, Yanqiu -IR - Zhao Y -FIR - Zhou, Caicun -IR - Zhou C -FIR - Zhou, Jianying -IR - Zhou J -FIR - Zhou, Xiangdong -IR - Zhou X -FIR - Havel, Libor -IR - Havel L -FIR - Kolek, Vitezslav -IR - Kolek V -FIR - Koubkova, Leona -IR - Koubkova L -FIR - Roubec, Jaromir -IR - Roubec J -FIR - Skrickova, Jana -IR - Skrickova J -FIR - Zemanova, Milada -IR - Zemanova M -FIR - Chouaid, Christos -IR - Chouaid C -FIR - Hilgers, Werner -IR - Hilgers W -FIR - Lena, Hervé -IR - Lena H -FIR - Moro-Sibilot, Denis -IR - Moro-Sibilot D -FIR - Robinet, Gilles -IR - Robinet G -FIR - Souquet, Pierre-Jean -IR - Souquet PJ -FIR - Alt, Jürgen -IR - Alt J -FIR - Bischoff, Helge -IR - Bischoff H -FIR - Grohe, Christian -IR - Grohe C -FIR - Laack, Eckart -IR - Laack E -FIR - Lang, Susanne -IR - Lang S -FIR - Panse, Jens -IR - Panse J -FIR - Reinmuth, Niels -IR - Reinmuth N -FIR - Schulz, Christian -IR - Schulz C -FIR - Bogos, Krisztina -IR - Bogos K -FIR - Csánky, Eszter -IR - Csánky E -FIR - Fülöp, Anea -IR - Fülöp A -FIR - Horváth, Zsolt -IR - Horváth Z -FIR - Kósa, Judit -IR - Kósa J -FIR - Laczó, Ibolya -IR - Laczó I -FIR - Losonczy, György -IR - Losonczy G -FIR - Pajkos, Gábor -IR - Pajkos G -FIR - Pápai, Zsuzsanna -IR - Pápai Z -FIR - Pápai Székely, Zsolt -IR - Pápai Székely Z -FIR - Sárosi, Veronika -IR - Sárosi V -FIR - Somfay, Attila -IR - Somfay A -FIR - Somogyiné Ezer, Éva -IR - Somogyiné Ezer É -FIR - Telekes, Anás -IR - Telekes A -FIR - Bar, Jair -IR - Bar J -FIR - Gottfried, Maya -IR - Gottfried M -FIR - Heching, Norman Isaac -IR - Heching NI -FIR - Zer Kuch, Alona -IR - Zer Kuch A -FIR - Bartolucci, Roberta -IR - Bartolucci R -FIR - Bettini, Anna Cecilia -IR - Bettini AC -FIR - Delmonte, Angelo -IR - Delmonte A -FIR - Garassino, Marina Chiara -IR - Garassino MC -FIR - Minelli, Mauro -IR - Minelli M -FIR - Roila, Fausto -IR - Roila F -FIR - Verderame, Francesco -IR - Verderame F -FIR - Atagi, Shinji -IR - Atagi S -FIR - Azuma, Koichi -IR - Azuma K -FIR - Goto, Hisatsugu -IR - Goto H -FIR - Goto, Koichi -IR - Goto K -FIR - Hara, Yu -IR - Hara Y -FIR - Hayashi, Hidetoshi -IR - Hayashi H -FIR - Hida, Toyoaki -IR - Hida T -FIR - Hotta, Katsuyuki -IR - Hotta K -FIR - Kanazawa, Kenya -IR - Kanazawa K -FIR - Kanda, Shintaro -IR - Kanda S -FIR - Kim, Young Hak -IR - Kim YH -FIR - Kuyama, Shoichi -IR - Kuyama S -FIR - Maeda, Tadashi -IR - Maeda T -FIR - Morise, Masahiro -IR - Morise M -FIR - Nakahara, Yasuharu -IR - Nakahara Y -FIR - Nishio, Makoto -IR - Nishio M -FIR - Nogami, Naoyuki -IR - Nogami N -FIR - Okamoto, Isamu -IR - Okamoto I -FIR - Saito, Haruhiro -IR - Saito H -FIR - Shinoda, Masahiro -IR - Shinoda M -FIR - Umemura, Shigeki -IR - Umemura S -FIR - Yoshida, Tatsuya -IR - Yoshida T -FIR - Claessens, Niels -IR - Claessens N -FIR - Cornelissen, Robin -IR - Cornelissen R -FIR - Heniks, Lizza -IR - Heniks L -FIR - Hiltermann, Jeroen -IR - Hiltermann J -FIR - Smit, Egbert -IR - Smit E -FIR - Staal van den Brekel, Agnes -IR - Staal van den Brekel A -FIR - Kazarnowicz, Andrzej -IR - Kazarnowicz A -FIR - Kowalski, Dariusz -IR - Kowalski D -FIR - Mańdziuk, Slawomir -IR - Mańdziuk S -FIR - Mróz, Robert -IR - Mróz R -FIR - Wojtukiewicz, Marek -IR - Wojtukiewicz M -FIR - Ciuleanu, Tudor -IR - Ciuleanu T -FIR - Ganea, Doina -IR - Ganea D -FIR - Ungureanu, Anei -IR - Ungureanu A -FIR - Dvorkin, Mikhail -IR - Dvorkin M -FIR - Luft, Alexander -IR - Luft A -FIR - Moiseenko, Vladimir -IR - Moiseenko V -FIR - Poltoratskiy, Artem -IR - Poltoratskiy A -FIR - Sakaeva, Dina -IR - Sakaeva D -FIR - Smolin, Alexey -IR - Smolin A -FIR - Statsenko, Galina -IR - Statsenko G -FIR - Vasilyev, Alexander -IR - Vasilyev A -FIR - Vladimirova, Lyubov -IR - Vladimirova L -FIR - Anasina, Igor -IR - Anasina I -FIR - Chovanec, Jozef -IR - Chovanec J -FIR - Demo, Pavol -IR - Demo P -FIR - Godal, Robert -IR - Godal R -FIR - Kasan, Peter -IR - Kasan P -FIR - Stresko, Marian -IR - Stresko M -FIR - Urda, Michal -IR - Urda M -FIR - Cho, Eun Kyung -IR - Cho EK -FIR - Ji, Jun Ho -IR - Ji JH -FIR - Kim, Joo-Hang -IR - Kim JH -FIR - Kim, Sang-We -IR - Kim SW -FIR - Lee, Gyeong-Won -IR - Lee GW -FIR - Lee, Jong-Seok -IR - Lee JS -FIR - Lee, Ki Hyeong -IR - Lee KH -FIR - Lee, Kyung Hee -IR - Lee KH -FIR - Lee, Yun Gyoo -IR - Lee YG -FIR - Amelia Insa Molla, Maria -IR - Amelia Insa Molla M -FIR - Domine Gomez, Manuel -IR - Domine Gomez M -FIR - Ignacio Delgado Mingorance, Juan -IR - Ignacio Delgado Mingorance J -FIR - Isla Casado, Dolores -IR - Isla Casado D -FIR - Lopez Brea, Marta -IR - Lopez Brea M -FIR - Majem Tarruella, Margarita -IR - Majem Tarruella M -FIR - Morán Bueno, Teresa -IR - Morán Bueno T -FIR - Navarro Mendivil, Alejano -IR - Navarro Mendivil A -FIR - Paz-Ares Rodríguez, Luis -IR - Paz-Ares Rodríguez L -FIR - Ponce Aix, Santiago -IR - Ponce Aix S -FIR - Rosario Garcia Campelo, Maria -IR - Rosario Garcia Campelo M -FIR - Chang, Gee-Chen -IR - Chang GC -FIR - Chen, Yen-Hsun -IR - Chen YH -FIR - Chiu, Chao-Hua -IR - Chiu CH -FIR - Hsia, Te-Chun -IR - Hsia TC -FIR - Lee, Kang-Yun -IR - Lee KY -FIR - Li, Chien-Te -IR - Li CT -FIR - Wang, Chin-Chou -IR - Wang CC -FIR - Wei, Yu-Feng -IR - Wei YF -FIR - Wu, Shang-Yin -IR - Wu SY -FIR - Alacacıoğlu, Ahmet -IR - Alacacıoğlu A -FIR - Çiçin, Irfan -IR - Çiçin I -FIR - Demirkazik, Ahmet -IR - Demirkazik A -FIR - Erman, Mustafa -IR - Erman M -FIR - Göksel, Tuncay -IR - Göksel T -FIR - Özgüroğlu, Mustafa -IR - Özgüroğlu M -FIR - Adamchuk, Hryhoriy -IR - Adamchuk H -FIR - Bondarenko, Igor -IR - Bondarenko I -FIR - Kolesnik, Oleksii -IR - Kolesnik O -FIR - Kryzhanivska, Anna -IR - Kryzhanivska A -FIR - Ostapenko, Yuriv -IR - Ostapenko Y -FIR - Shevnia, Serhii -IR - Shevnia S -FIR - Shparyk, Yaroslav -IR - Shparyk Y -FIR - Trukhin, Dmytro -IR - Trukhin D -FIR - Ursol, Grygorii -IR - Ursol G -FIR - Voitko, Nataliia -IR - Voitko N -FIR - Voitko, Oleksandr -IR - Voitko O -FIR - Vynnychenko, Ihor -IR - Vynnychenko I -FIR - Babu, Sunil -IR - Babu S -FIR - Chen, Yuanbin -IR - Chen Y -FIR - Chiang, Anne -IR - Chiang A -FIR - Chua, Winston -IR - Chua W -FIR - Dakhil, Shaker -IR - Dakhil S -FIR - Dowlati, Afshin -IR - Dowlati A -FIR - Goldman, Jonathan W -IR - Goldman JW -FIR - Haque, Basir -IR - Haque B -FIR - Jamil, Rodney -IR - Jamil R -FIR - Knoble, Jeanna -IR - Knoble J -FIR - Lakhanpal, Shailena -IR - Lakhanpal S -FIR - Mi, Kailhong -IR - Mi K -FIR - Nikolinakos, Petros -IR - Nikolinakos P -FIR - Powell, Steven -IR - Powell S -FIR - Ross, Helen -IR - Ross H -FIR - Schaefer, Eric -IR - Schaefer E -FIR - Schneider, Jeffrey -IR - Schneider J -FIR - Spahr, Joseph -IR - Spahr J -FIR - Spigel, David -IR - Spigel D -FIR - Stilwill, Joseph -IR - Stilwill J -FIR - Sumey, Christopher -IR - Sumey C -FIR - Williamson, Michael -IR - Williamson M -EDAT- 2019/10/09 06:00 -MHDA- 2019/12/18 06:00 -CRDT- 2019/10/09 06:00 -PHST- 2019/08/21 00:00 [received] -PHST- 2019/09/16 00:00 [revised] -PHST- 2019/09/16 00:00 [accepted] -PHST- 2019/10/09 06:00 [pubmed] -PHST- 2019/12/18 06:00 [medline] -PHST- 2019/10/09 06:00 [entrez] -AID - S0140-6736(19)32222-6 [pii] -AID - 10.1016/S0140-6736(19)32222-6 [doi] -PST - ppublish -SO - Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. - Epub 2019 Oct 4. - -PMID- 37236329 -OWN - NLM -STAT- MEDLINE -DCOM- 20230612 -LR - 20240102 -IS - 1096-3650 (Electronic) -IS - 1044-579X (Linking) -VI - 93 -DP - 2023 Aug -TI - Advancements in small cell lung cancer. -PG - 123-128 -LID - S1044-579X(23)00082-2 [pii] -LID - 10.1016/j.semcancer.2023.05.008 [doi] -AB - Small cell lung cancer (SCLC) is a recalcitrant cancer with an urgent need for - novel therapeutics, preclinical models, and elucidation of the molecular pathways - responsible for its rapid resistance. Recently, there have been many significant - advancements in our knowledge of SCLC that led to the development of novel - treatments. This review will go over the recent attempts to provide new molecular - subcategorization of SCLC, recent breakthroughs in various systemic treatments - including immunotherapy, targeted therapy, cellular therapy, as well as - advancements in radiation therapy. -CI - Copyright © 2023 Elsevier Ltd. All rights reserved. -FAU - Lee, Jung-Hoon -AU - Lee JH -AD - Department of Hematology and Medical Oncology, Weill Cornell Medical College, New - York, NY, United States. Electronic address: jul9112@nyp.org. -FAU - Saxena, Ashish -AU - Saxena A -AD - Department of Hematology and Medical Oncology, Weill Cornell Medical College, New - York, NY, United States. -FAU - Giaccone, Giuseppe -AU - Giaccone G -AD - Department of Hematology and Medical Oncology, Weill Cornell Medical College, New - York, NY, United States. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230524 -PL - England -TA - Semin Cancer Biol -JT - Seminars in cancer biology -JID - 9010218 -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/therapy/drug therapy -MH - *Lung Neoplasms/therapy/drug therapy -MH - Immunotherapy -OTO - NOTNLM -OT - Cell cycle regulator inhibitors -OT - Immunotherapy -OT - Lung cancer -OT - Small cell lung cancer -OT - Targeted therapy -COIS- Declaration of Competing Interest A conflicting interest exists when professional - judgement concerning a primary interest (such as patient’s welfare or the - validity of research) may be influenced by a secondary interest (such as - financial gain or personal rivalry). It may arise for the authors when they have - financial interest that may influence their interpretation of their results or - those of others. Examples of potential conflicts of interest include employment, - consultancies, stock ownership, honoraria, paid expert testimony, patent - applications/registrations, and grants or other funding. -EDAT- 2023/05/27 09:41 -MHDA- 2023/06/12 06:42 -CRDT- 2023/05/26 19:24 -PHST- 2022/02/04 00:00 [received] -PHST- 2023/05/02 00:00 [revised] -PHST- 2023/05/23 00:00 [accepted] -PHST- 2023/06/12 06:42 [medline] -PHST- 2023/05/27 09:41 [pubmed] -PHST- 2023/05/26 19:24 [entrez] -AID - S1044-579X(23)00082-2 [pii] -AID - 10.1016/j.semcancer.2023.05.008 [doi] -PST - ppublish -SO - Semin Cancer Biol. 2023 Aug;93:123-128. doi: 10.1016/j.semcancer.2023.05.008. - Epub 2023 May 24. - -PMID- 37030062 -OWN - NLM -STAT- MEDLINE -DCOM- 20230501 -LR - 20230501 -IS - 1532-1967 (Electronic) -IS - 0305-7372 (Linking) -VI - 116 -DP - 2023 May -TI - Immunotherapy-based combinations in metastatic NSCLC. -PG - 102545 -LID - S0305-7372(23)00036-1 [pii] -LID - 10.1016/j.ctrv.2023.102545 [doi] -AB - Immuno-oncology has revolutionized the treatment of metastatic non-small cell - lung cancer (mNSCLC) since the approval of immunotherapy by the U.S. FDA in 2015. - Despite the advancements, outcomes for patients have room for further - improvement. Combination therapies have shown promise in overcoming resistance - and improving outcomes. This review focuses on current immunotherapy-based - combination approaches, reported and ongoing trials, as well as novel combination - strategies, challenges, and future directions for mNSCLC treatment. We summarize - approaches in combination with chemotherapy, novel immune checkpoints, tyrosine - kinase inhibitors and other strategies including vaccines, and radiation therapy. - The promise of biomarker-driven studies to understand resistance and design - multi-arm platform trials that evaluate novel therapies is becoming of increasing - relevance with the ultimate goal of administering precision immunotherapy by - identifying the right dose of the right combination for the right patient at the - right time. -CI - Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. -FAU - Desai, Aakash -AU - Desai A -AD - Division of Medical Oncology, MayoClinic, Rochester, MN, USA. -FAU - Peters, Solange -AU - Peters S -AD - Department of Oncology, Lausanne University, Switzerland. Electronic address: - solange.peters@chuv.ch. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230327 -PL - Netherlands -TA - Cancer Treat Rev -JT - Cancer treatment reviews -JID - 7502030 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - *Lung Neoplasms/drug therapy/pathology -MH - Immunotherapy -MH - Combined Modality Therapy -OTO - NOTNLM -OT - Immune checkpoints -OT - Immunotherapy -OT - Metastatic -OT - NSCLC -OT - Non-small cell lung cancer -COIS- Declaration of Competing Interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2023/04/09 06:00 -MHDA- 2023/05/01 06:42 -CRDT- 2023/04/08 18:03 -PHST- 2023/01/23 00:00 [received] -PHST- 2023/03/12 00:00 [revised] -PHST- 2023/03/16 00:00 [accepted] -PHST- 2023/05/01 06:42 [medline] -PHST- 2023/04/09 06:00 [pubmed] -PHST- 2023/04/08 18:03 [entrez] -AID - S0305-7372(23)00036-1 [pii] -AID - 10.1016/j.ctrv.2023.102545 [doi] -PST - ppublish -SO - Cancer Treat Rev. 2023 May;116:102545. doi: 10.1016/j.ctrv.2023.102545. Epub 2023 - Mar 27. - -PMID- 34735819 -OWN - NLM -STAT- MEDLINE -DCOM- 20211117 -LR - 20211117 -IS - 1474-5488 (Electronic) -IS - 1470-2045 (Linking) -VI - 22 -IP - 11 -DP - 2021 Nov -TI - Revisiting neoadjuvant therapy in non-small-cell lung cancer. -PG - e501-e516 -LID - S1470-2045(21)00383-1 [pii] -LID - 10.1016/S1470-2045(21)00383-1 [doi] -AB - Despite the rapidly evolving treatment landscape in advanced non-small-cell lung - cancer (NSCLC), developments in neoadjuvant and adjuvant treatments have been - nascent by comparison. Establishing overall survival benefit in the early-stage - setting has been challenging because of the need for large trials and long-term - survival data. Encouraged by improved treatment outcomes with a biomarker-driven - approach in advanced NSCLC, and recognising the need to improve survival outcomes - in early-stage NSCLC, there has been renewed interest in revisiting neoadjuvant - strategies. Multiple neoadjuvant trials with targeted therapy and immunotherapy, - either alone or in combination with chemotherapy, have yielded unique insights - into traditional response parameters, such as the discordance between RECIST - response and pathological response, and expanded opportunities for biomarker - discovery. With further standardisation of trial endpoints across studies, - coupled with the implementation of novel technologies including radiomics and - digital pathology, individual risk-stratified neoadjuvant treatment approaches - are poised to make a striking impact on the outcomes of early-stage NSCLC. -CI - Copyright © 2021 Elsevier Ltd. All rights reserved. -FAU - Saw, Stephanie P L -AU - Saw SPL -AD - Division of Medical Oncology, National Cancer Centre Singapore, SingHealth - Duke-NUS Oncology Academic Clinical Programme, Singapore. -FAU - Ong, Boon-Hean -AU - Ong BH -AD - Department of Cardiothoracic Surgery, National Heart Centre Singapore, Singapore. -FAU - Chua, Kevin L M -AU - Chua KLM -AD - Division of Radiation Oncology, National Cancer Centre Singapore, SingHealth - Duke-NUS Oncology Academic Clinical Programme, Singapore. -FAU - Takano, Angela -AU - Takano A -AD - Department of Anatomical Pathology, Singapore General Hospital, Singapore. -FAU - Tan, Daniel S W -AU - Tan DSW -AD - Division of Medical Oncology, National Cancer Centre Singapore, SingHealth - Duke-NUS Oncology Academic Clinical Programme, Singapore; Genome Institue of - Singapore A*Star, Singapore. Electronic address: - daniel.tan.s.w@singhealth.com.sg. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - England -TA - Lancet Oncol -JT - The Lancet. Oncology -JID - 100957246 -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Biomarkers, Tumor -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Endpoint Determination -MH - Humans -MH - Immunotherapy -MH - Lung Neoplasms/*drug therapy/pathology -MH - *Neoadjuvant Therapy -MH - Treatment Outcome -COIS- Declaration of interests B-HO reports personal fees from AstraZeneca, personal - fees and non-financial support from Johnson and Johnson and Stryker, and - non-financial support from Medtronic and Broncus, outside the submitted work. - KLMC reports personal fees from AstraZeneca and PeerVoice, outside the submitted - work. DSWT reports grants and personal fees from Novartis, Bayer, AstraZeneca, - and Pfizer; personal fees from Boehringer Ingelheim, Eli lilly, LOXO, Merck, - Roche, Takeda, and Merrimack; and grants from GlaxoSmithKline, outside the - submitted work. SPLS and AT declare no competing interests. -EDAT- 2021/11/05 06:00 -MHDA- 2021/11/18 06:00 -CRDT- 2021/11/04 20:08 -PHST- 2021/02/28 00:00 [received] -PHST- 2021/05/12 00:00 [revised] -PHST- 2021/06/21 00:00 [accepted] -PHST- 2021/11/04 20:08 [entrez] -PHST- 2021/11/05 06:00 [pubmed] -PHST- 2021/11/18 06:00 [medline] -AID - S1470-2045(21)00383-1 [pii] -AID - 10.1016/S1470-2045(21)00383-1 [doi] -PST - ppublish -SO - Lancet Oncol. 2021 Nov;22(11):e501-e516. doi: 10.1016/S1470-2045(21)00383-1. - -PMID- 34558640 -OWN - NLM -STAT- MEDLINE -DCOM- 20220128 -LR - 20220128 -IS - 1791-2423 (Electronic) -IS - 1019-6439 (Print) -IS - 1019-6439 (Linking) -VI - 59 -IP - 5 -DP - 2021 Nov -TI - Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced - non‑small cell lung cancer (Review). -LID - 90 [pii] -LID - 10.3892/ijo.2021.5270 [doi] -AB - Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase - inhibitors (TKIs) is a standard modality of the 1st‑line treatments for patients - with advanced EGFR‑mutated non‑small cell lung cancer (NSCLC), and substantially - improves their prognosis. However, EGFR T790M mutation is the primary mechanism - of 1st‑ and 2nd‑generation EGFR‑TKI resistance. Osimertinib is a representative - of the 3rd‑generation EGFR‑TKIs that target T790M mutation, and has satisfactory - efficacy in the treatment of T790M‑positive NSCLC with disease progression - following use of 1st‑ or 2nd‑generation EGFR‑TKIs. Other 3rd‑generation - EGFR‑TKIs, such as abivertinib, rociletinib, nazartinib, olmutinib and - alflutinib, are also at various stages of development. However, the occurrence of - acquired resistance is inevitable, and the mechanisms of 3rd‑generation EGFR‑TKI - resistance are complex and incompletely understood. Genomic studies in tissue and - liquid biopsies of resistant patients reveal multiple candidate pathways. The - present review summarizes the recent findings in mechanisms of resistance to - 3rd‑generation EGFR‑TKIs in advanced NSCLC, and provides possible strategies to - overcome this resistance. The mechanisms of acquired resistance mainly include an - altered EGFR signaling pathway (EGFR tertiary mutations and amplification), - activation of aberrant bypassing pathways (hepatocyte growth factor receptor - amplification, human epidermal growth factor receptor 2 amplification and - aberrant insulin‑like growth factor 1 receptor activation), downstream pathway - activation (RAS/RAF/MEK/ERK and PI3K/AKT/mTOR) and histological/phenotypic - transformations (SCLC transformation and epithelial‑mesenchymal transition). The - combination of targeted therapies is a promising strategy to treat - osimertinib‑resistant patients, and multiple clinical studies on novel combined - therapies are ongoing. -FAU - He, Jingyi -AU - He J -AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan - University, Wuhan, Hubei 430071, P.R. China. -FAU - Huang, Zhengrong -AU - Huang Z -AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan - University, Wuhan, Hubei 430071, P.R. China. -FAU - Han, Linzhi -AU - Han L -AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan - University, Wuhan, Hubei 430071, P.R. China. -FAU - Gong, Yan -AU - Gong Y -AD - Department of Biological Repositories, Zhongnan Hospital of Wuhan University, - Wuhan, Hubei 430071, P.R. China. -FAU - Xie, Conghua -AU - Xie C -AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan - University, Wuhan, Hubei 430071, P.R. China. -LA - eng -PT - Journal Article -PT - Review -DEP - 20210924 -PL - Greece -TA - Int J Oncol -JT - International journal of oncology -JID - 9306042 -RN - 0 (Bcl-2-Like Protein 11) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Bcl-2-Like Protein 11/genetics -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/pathology -MH - Drug Resistance, Neoplasm -MH - ErbB Receptors/*antagonists & inhibitors/genetics/physiology -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology -MH - Lung Neoplasms/*drug therapy/genetics/pathology -MH - Mutation -MH - Protein Kinase Inhibitors/*pharmacology/therapeutic use -MH - Signal Transduction/drug effects/physiology -PMC - PMC8562388 -OTO - NOTNLM -OT - epidermal growth factor receptor‑tyrosine kinase inhibitor -OT - non‑small cell lung cancer -OT - osimertinib -OT - resistance mechanism -OT - targeted therapy -COIS- The authors declare that they have no competing interests. -EDAT- 2021/09/25 06:00 -MHDA- 2022/01/29 06:00 -PMCR- 2021/09/24 -CRDT- 2021/09/24 08:49 -PHST- 2021/06/25 00:00 [received] -PHST- 2021/09/09 00:00 [accepted] -PHST- 2021/09/24 08:49 [entrez] -PHST- 2021/09/25 06:00 [pubmed] -PHST- 2022/01/29 06:00 [medline] -PHST- 2021/09/24 00:00 [pmc-release] -AID - 90 [pii] -AID - ijo-59-05-05270 [pii] -AID - 10.3892/ijo.2021.5270 [doi] -PST - ppublish -SO - Int J Oncol. 2021 Nov;59(5):90. doi: 10.3892/ijo.2021.5270. Epub 2021 Sep 24. - -PMID- 33911215 -OWN - NLM -STAT- MEDLINE -DCOM- 20210917 -LR - 20240903 -IS - 1759-4782 (Electronic) -IS - 1759-4774 (Print) -IS - 1759-4774 (Linking) -VI - 18 -IP - 9 -DP - 2021 Sep -TI - Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung - cancer. -PG - 547-557 -LID - 10.1038/s41571-021-00501-4 [doi] -AB - The treatment goal for patients with early-stage lung cancer is cure. - Multidisciplinary discussions of surgical resectability and medical operability - determine the modality of definitive local treatment (surgery or radiotherapy) - and the associated systemic therapies to further improve the likelihood of cure. - Trial evidence supports cisplatin-based adjuvant therapy either after surgical - resection or concurrently with radiotherapy. Consensus guidelines support - neoadjuvant chemotherapy in lieu of adjuvant chemotherapy and carboplatin-based - regimens for patients who are ineligible for cisplatin. The incorporation of - newer agents, now standard for patients with stage IV lung cancer, into the - curative therapy paradigm has lagged owing to inefficient trial designs, the - lengthy follow-up needed to assess survival end points and a developmental focus - on the advanced-stage disease setting. Surrogate end points, such as pathological - response, are being studied and might shorten trial durations. In 2018, the - anti-PD-L1 antibody durvalumab was approved for patients with stage III lung - cancer after concurrent chemoradiotherapy. Since then, the study of targeted - therapies and immunotherapies in patients with early-stage lung cancer has - rapidly expanded. In this Review, we present the current considerations in the - treatment of patients with early-stage lung cancer and explore the current and - future state of clinical research to develop systemic therapies for - non-metastatic lung cancer. -CI - © 2021. Springer Nature Limited. -FAU - Chaft, Jamie E -AU - Chaft JE -AD - Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering - Cancer Center, New York, NY and Weill Cornell Medical College, New York, NY, USA. - chaftj@mskcc.org. -FAU - Rimner, Andreas -AU - Rimner A -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, NY, USA. -FAU - Weder, Walter -AU - Weder W -AD - Thoracic Surgery, Klinik Bethanien Zurich, Zurich, Switzerland. -FAU - Azzoli, Christopher G -AU - Azzoli CG -AD - Division of Hematology/Oncology, Lifespan Cancer Institute, Brown University, - Providence, RI, USA. -FAU - Kris, Mark G -AU - Kris MG -AD - Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering - Cancer Center, New York, NY and Weill Cornell Medical College, New York, NY, USA. -FAU - Cascone, Tina -AU - Cascone T -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -LA - eng -GR - P30 CA008748/CA/NCI NIH HHS/United States -GR - P30 CA016672/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Review -DEP - 20210428 -PL - England -TA - Nat Rev Clin Oncol -JT - Nature reviews. Clinical oncology -JID - 101500077 -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Chemotherapy, Adjuvant -MH - Combined Modality Therapy -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology -MH - Neoadjuvant Therapy -MH - Neoplasm Staging -MH - Therapies, Investigational/methods/*trends -PMC - PMC9447511 -MID - NIHMS1831789 -EDAT- 2021/04/30 06:00 -MHDA- 2021/09/18 06:00 -PMCR- 2022/09/06 -CRDT- 2021/04/29 06:16 -PHST- 2021/03/10 00:00 [accepted] -PHST- 2021/04/30 06:00 [pubmed] -PHST- 2021/09/18 06:00 [medline] -PHST- 2021/04/29 06:16 [entrez] -PHST- 2022/09/06 00:00 [pmc-release] -AID - 10.1038/s41571-021-00501-4 [pii] -AID - 10.1038/s41571-021-00501-4 [doi] -PST - ppublish -SO - Nat Rev Clin Oncol. 2021 Sep;18(9):547-557. doi: 10.1038/s41571-021-00501-4. Epub - 2021 Apr 28. - -PMID- 28534531 -OWN - NLM -STAT- MEDLINE -DCOM- 20170911 -LR - 20231112 -IS - 1759-4782 (Electronic) -IS - 1759-4774 (Print) -IS - 1759-4774 (Linking) -VI - 14 -IP - 9 -DP - 2017 Sep -TI - Unravelling the biology of SCLC: implications for therapy. -PG - 549-561 -LID - 10.1038/nrclinonc.2017.71 [doi] -AB - Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor - prognosis. First-line treatment has remained unchanged for decades, and a paucity - of effective treatment options exists for recurrent disease. Nonetheless, - advances in our understanding of SCLC biology have led to the development of - novel experimental therapies. Poly [ADP-ribose] polymerase (PARP) inhibitors have - shown promise in preclinical models, and are under clinical investigation in - combination with cytotoxic therapies and inhibitors of cell-cycle - checkpoints.Preclinical data indicate that targeting of histone-lysine - N-methyltransferase EZH2, a regulator of chromatin remodelling implicated in - acquired therapeutic resistance, might augment and prolong chemotherapy - responses. High expression of the inhibitory Notch ligand Delta-like protein 3 - (DLL3) in most SCLCs has been linked to expression of Achaete-scute homologue 1 - (ASCL1; also known as ASH-1), a key transcription factor driving SCLC - oncogenesis; encouraging preclinical and clinical activity has been demonstrated - for an anti-DLL3-antibody-drug conjugate. The immune microenvironment of SCLC - seems to be distinct from that of other solid tumours, with few - tumour-infiltrating lymphocytes and low levels of the immune-checkpoint protein - programmed cell death 1 ligand 1 (PD-L1). Nonetheless, immunotherapy with - immune-checkpoint inhibitors holds promise for patients with this disease, - independent of PD-L1 status. Herein, we review the progress made in uncovering - aspects of the biology of SCLC and its microenvironment that are defining new - therapeutic strategies and offering renewed hope for patients. -FAU - Sabari, Joshua K -AU - Sabari JK -AD - Department of Medicine, Memorial Sloan Kettering Cancer Center. -FAU - Lok, Benjamin H -AU - Lok BH -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 300 - East 66th Street, New York, New York 10065, USA. -FAU - Laird, James H -AU - Laird JH -AD - New York University School of Medicine, 550 1st Avenue, New York, New York 10016, - USA. -FAU - Poirier, John T -AU - Poirier JT -AD - Department of Medicine, Memorial Sloan Kettering Cancer Center. -AD - Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center. -FAU - Rudin, Charles M -AU - Rudin CM -AD - Department of Medicine, Memorial Sloan Kettering Cancer Center. -AD - Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center. -AD - Weill Cornell Medical College, 1300 York Avenue, New York, New York 10065, USA. -LA - eng -GR - R25 CA020449/CA/NCI NIH HHS/United States -GR - R01 CA197936/CA/NCI NIH HHS/United States -GR - U24 CA213274/CA/NCI NIH HHS/United States -GR - T32 CA009207/CA/NCI NIH HHS/United States -GR - P30 CA008748/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Review -DEP - 20170523 -PL - England -TA - Nat Rev Clin Oncol -JT - Nature reviews. Clinical oncology -JID - 101500077 -RN - 0 (Antineoplastic Agents) -SB - IM -MH - Antineoplastic Agents/pharmacology/therapeutic use -MH - Genome -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/*drug therapy/genetics/metabolism/pathology -MH - Molecular Targeted Therapy/*methods -MH - Mutation -MH - Proteomics -MH - Small Cell Lung Carcinoma/*drug therapy/genetics/metabolism/pathology -PMC - PMC5843484 -MID - NIHMS946711 -COIS- Competing interests statement C.M.R. has been a paid consultant regarding - oncology drug development for Bristol Myers Squibb, Celgene, G1 Therapeutics, - Harpoon Therapeutics, Medivation, and Novartis. The other authors declare no - competing interests. -EDAT- 2017/05/24 06:00 -MHDA- 2017/09/12 06:00 -PMCR- 2018/09/01 -CRDT- 2017/05/24 06:00 -PHST- 2017/05/24 06:00 [pubmed] -PHST- 2017/09/12 06:00 [medline] -PHST- 2017/05/24 06:00 [entrez] -PHST- 2018/09/01 00:00 [pmc-release] -AID - nrclinonc.2017.71 [pii] -AID - 10.1038/nrclinonc.2017.71 [doi] -PST - ppublish -SO - Nat Rev Clin Oncol. 2017 Sep;14(9):549-561. doi: 10.1038/nrclinonc.2017.71. Epub - 2017 May 23. - -PMID- 30526458 -OWN - NLM -STAT- MEDLINE -DCOM- 20200921 -LR - 20200921 -IS - 1873-5576 (Electronic) -IS - 1568-0096 (Linking) -VI - 19 -IP - 8 -DP - 2019 -TI - Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small - Cell Lung Cancer. -PG - 595-630 -LID - 10.2174/1568009619666181210114559 [doi] -AB - Lung cancer is the leading cause of cancer death worldwide. Molecular targeted - therapy has greatly advanced the field of treatment for non-small cell lung - cancer (NSCLC), which accounts for the majority of lung cancers. Indeed, - gefitinib, which was the first molecular targeted therapeutic agent, has actually - doubled the survival time of NSCLC patients. Vigorous efforts of clinicians and - researchers have revealed that lung cancer develops through the activating - mutations of many driver genes including the epidermal growth factor receptor - (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), v-Raf murine - sarcoma viral oncogene homolog B (BRAF), and rearranged during transfection (RET) - genes. Although ALK, ROS1, and RET are rare genetic abnormalities, corresponding - tyrosine kinase inhibitors (TKIs) can exert dramatic therapeutic effects. In - addition to anticancer drugs targeting driver genes, bevacizumab specifically - binds to human vascular endothelial growth factor (VEGF) and blocks the VEGF - signaling pathway. The VEGF signal blockade suppresses angiogenesis in tumor - tissues and inhibits tumor growth. In this review, we also explore immunotherapy, - which is a promising new NSCLC treatment approach. In general, antitumor immune - responses are suppressed in cancer patients, and cancer cells escape from the - immune surveillance mechanism. Immune checkpoint inhibitors (ICIs) are antibodies - that target the primary escape mechanisms, immune checkpoints. Patients who - respond to ICIs are reported to experience longlasting therapeutic effects. A - wide range of clinical approaches, including combination therapy involving - chemotherapy or radiation plus adjuvant therapy, are being developed. -CI - Copyright© Bentham Science Publishers; For any queries, please email at - epub@benthamscience.net. -FAU - Nagano, Tatsuya -AU - Nagano T -AD - Division of Respiratory Medicine, Department of Internal Medicine, Kobe - University Graduate School of Medicine, Kobe, Japan. -FAU - Tachihara, Motoko -AU - Tachihara M -AD - Division of Respiratory Medicine, Department of Internal Medicine, Kobe - University Graduate School of Medicine, Kobe, Japan. -FAU - Nishimura, Yoshihiro -AU - Nishimura Y -AD - Division of Respiratory Medicine, Department of Internal Medicine, Kobe - University Graduate School of Medicine, Kobe, Japan. -LA - eng -PT - Journal Article -PT - Review -PL - Netherlands -TA - Curr Cancer Drug Targets -JT - Current cancer drug targets -JID - 101094211 -RN - 0 (Antineoplastic Agents) -SB - IM -MH - Animals -MH - Antineoplastic Agents/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/*immunology/metabolism/pathology -MH - Humans -MH - *Immunotherapy -MH - Lung Neoplasms/*drug therapy/*immunology/metabolism/pathology -MH - *Molecular Targeted Therapy -OTO - NOTNLM -OT - ALK -OT - BRAF -OT - EGFR -OT - Immune checkpoint inhibitor -OT - Non-small cell lung cancer -OT - RET -OT - ROS-1 -OT - VEGF. -EDAT- 2018/12/12 06:00 -MHDA- 2020/09/22 06:00 -CRDT- 2018/12/12 06:00 -PHST- 2018/09/25 00:00 [received] -PHST- 2018/11/21 00:00 [revised] -PHST- 2018/11/28 00:00 [accepted] -PHST- 2018/12/12 06:00 [pubmed] -PHST- 2020/09/22 06:00 [medline] -PHST- 2018/12/12 06:00 [entrez] -AID - CCDT-EPUB-95116 [pii] -AID - 10.2174/1568009619666181210114559 [doi] -PST - ppublish -SO - Curr Cancer Drug Targets. 2019;19(8):595-630. doi: - 10.2174/1568009619666181210114559. - -PMID- 37602492 -OWN - NLM -STAT- MEDLINE -DCOM- 20231030 -LR - 20231102 -IS - 1097-0142 (Electronic) -IS - 0008-543X (Linking) -VI - 129 -IP - 22 -DP - 2023 Nov 15 -TI - Advancing immunotherapy in small cell lung cancer. -PG - 3525-3534 -LID - 10.1002/cncr.34977 [doi] -AB - Small cell lung cancer (SCLC) is a rapidly progressive neuroendocrine carcinoma - that, until recently, had a very small armamentarium of effective treatments. - Advances in DNA sequencing and whole transcriptomics have delineated key - subtypes; therefore, SCLC is no longer viewed as a homogeneous cancer. - Chemoimmunotherapy with PD1 blockade is now the standard of care for advanced - disease, and ongoing research efforts are moving this strategy into the limited - stage setting. Combination strategies of immunotherapy with radiation are also - under active clinical trial in both limited and extensive stage disease. PLAIN - LANGUAGE SUMMARY: Small cell lung cancer (SCLC) is a rapidly progressive - neuroendocrine carcinoma that, until recently, had a very small armamentarium of - effective treatments. Chemoimmunotherapy with immune check point inhibitors is - now the standard of care for advanced disease. This comprehensive review provides - an overview of current treatment strategies for SCLC, unmet needs in this patient - population, and emerging treatment strategies incorporating immunotherapy that - will hopefully further improve outcomes for patients. -CI - © 2023 American Cancer Society. -FAU - Carlisle, Jennifer W -AU - Carlisle JW -AUID- ORCID: 0000-0001-7085-4640 -AD - Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory - University School of Medicine, Atlanta, Georgia, USA. -FAU - Leal, Ticiana -AU - Leal T -AUID- ORCID: 0000-0002-3735-9063 -AD - Department of Hematology and Medical Oncology, Thoracic Medical Oncology Program, - Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, - USA. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230821 -PL - United States -TA - Cancer -JT - Cancer -JID - 0374236 -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Immunotherapy -MH - Treatment Outcome -MH - *Carcinoma, Neuroendocrine -OTO - NOTNLM -OT - EGFR transformation -OT - biomarker -OT - checkpoint blockade -OT - immunotherapy -OT - small cell lung carcinoma -EDAT- 2023/08/21 12:42 -MHDA- 2023/10/30 06:46 -CRDT- 2023/08/21 07:28 -PHST- 2023/06/26 00:00 [revised] -PHST- 2023/01/17 00:00 [received] -PHST- 2023/06/28 00:00 [accepted] -PHST- 2023/10/30 06:46 [medline] -PHST- 2023/08/21 12:42 [pubmed] -PHST- 2023/08/21 07:28 [entrez] -AID - 10.1002/cncr.34977 [doi] -PST - ppublish -SO - Cancer. 2023 Nov 15;129(22):3525-3534. doi: 10.1002/cncr.34977. Epub 2023 Aug 21. - -PMID- 34580079 -OWN - NLM -STAT- MEDLINE -DCOM- 20220531 -LR - 20240927 -IS - 2157-1422 (Electronic) -IS - 2157-1422 (Linking) -VI - 12 -IP - 5 -DP - 2022 May 27 -TI - Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. -LID - 10.1101/cshperspect.a037895 [doi] -LID - a037895 -AB - Historically, non-small-cell lung cancer (NSCLC) has been regarded as a - nonimmunogenic tumor; however, recent studies have shown that NSCLCs are among - the most responsive cancers to monoclonal antibody immune checkpoint inhibitors - (ICIs). ICIs have dramatically improved clinical outcomes for a subset of - patients (∼20%) with locally advanced and metastatic NSCLC, and they have also - demonstrated promise as neoadjuvant therapy for early-stage resectable disease. - Nevertheless, the majority of patients with NSCLC are refractory to ICIs for - reasons that are poorly understood. Thus, major questions are: how do we - initially identify the patients most likely to derive significant clinical - benefit from these therapies; how can we increase the number of patients - benefiting; what are the mechanisms of primary and acquired resistance to - immune-based therapies; are there additional immune checkpoints besides - PD-1/PD-L1 and CTLA-4 that can be targeted to provide greater clinical benefit to - patients; and how do we best combine ICI therapy with surgery, radiotherapy, - chemotherapy, and targeted therapy? To answer these questions, we need to deploy - the latest technologies to study tumors and their microenvironment and how they - interact with components of the innate and adaptive immune systems. There is also - a need for new preclinical model systems to investigate the molecular mechanisms - of resistance to treatment and identify novel therapeutic targets. Recent - advances in technology are beginning to shed new light on the immune landscape of - NSCLC that may uncover biomarkers of response and maximize the clinical benefit - of immune-based therapies. Identification of the mechanisms of resistance should - lead to the identification of novel targets and the generation of new therapeutic - strategies that improve outcomes for a greater number of patients. In the - sections below, we discuss the results of studies examining the immune - microenvironment in NSCLC, summarize the clinical experience with immunotherapy - for NSCLC, and review candidate biomarkers of response to these agents in NSCLC. -CI - Copyright © 2022 Cold Spring Harbor Laboratory Press; all rights reserved. -FAU - Cascone, Tina -AU - Cascone T -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, Texas 77030, USA. -FAU - Fradette, Jared -AU - Fradette J -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, Texas 77030, USA. -FAU - Pradhan, Monika -AU - Pradhan M -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, Texas 77030, USA. -FAU - Gibbons, Don L -AU - Gibbons DL -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, Texas 77030, USA. -AD - Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas 77030, USA. -LA - eng -GR - P30 CA016672/CA/NCI NIH HHS/United States -GR - P50 CA070907/CA/NCI NIH HHS/United States -GR - R37 CA214609/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20220527 -PL - United States -TA - Cold Spring Harb Perspect Med -JT - Cold Spring Harbor perspectives in medicine -JID - 101571139 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Biomarkers, Tumor) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - Biomarkers, Tumor -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Immunotherapy -MH - *Lung Neoplasms/therapy -MH - Tumor Microenvironment -PMC - PMC8957639 -MID - NIHMS1756042 -EDAT- 2021/09/29 06:00 -MHDA- 2022/06/01 06:00 -PMCR- 2024/05/01 -CRDT- 2021/09/28 05:49 -PHST- 2021/09/29 06:00 [pubmed] -PHST- 2022/06/01 06:00 [medline] -PHST- 2021/09/28 05:49 [entrez] -PHST- 2024/05/01 00:00 [pmc-release] -AID - cshperspect.a037895 [pii] -AID - a037895 [pii] -AID - 10.1101/cshperspect.a037895 [doi] -PST - epublish -SO - Cold Spring Harb Perspect Med. 2022 May 27;12(5):a037895. doi: - 10.1101/cshperspect.a037895. - -PMID- 33581821 -OWN - NLM -STAT- MEDLINE -DCOM- 20210528 -LR - 20221207 -IS - 1474-547X (Electronic) -IS - 0140-6736 (Linking) -VI - 397 -IP - 10274 -DP - 2021 Feb 13 -TI - Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung - cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, - randomised, controlled trial. -PG - 592-604 -LID - S0140-6736(21)00228-2 [pii] -LID - 10.1016/S0140-6736(21)00228-2 [doi] -AB - BACKGROUND: We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, - in the first-line treatment of advanced non-small-cell lung cancer with - programmed cell death ligand 1 (PD-L1) of at least 50%. METHODS: In EMPOWER-Lung - 1, a multicentre, open-label, global, phase 3 study, eligible patients recruited - in 138 clinics from 24 countries (aged ≥18 years with histologically or - cytologically confirmed advanced non-small-cell lung cancer, an Eastern - Cooperative Oncology Group performance status of 0-1; never-smokers were - ineligible) were randomly assigned (1:1) to cemiplimab 350 mg every 3 weeks or - platinum-doublet chemotherapy. Crossover from chemotherapy to cemiplimab was - allowed following disease progression. Primary endpoints were overall survival - and progression-free survival per masked independent review committee. Primary - endpoints were assessed in the intention-to-treat population and in a - prespecified PD-L1 of at least 50% population (per US Food and Drug - Administration request to the sponsor), which consisted of patients with PD-L1 of - at least 50% per 22C3 assay done according to instructions for use. Adverse - events were assessed in all patients who received at least one dose of the - assigned treatment. This study is registered with ClinicalTrials.gov, NCT03088540 - and is ongoing. FINDINGS: Between June 27, 2017 and Feb 27, 2020, 710 patients - were randomly assigned (intention-to-treat population). In the PD-L1 of at least - 50% population, which consisted of 563 patients, median overall survival was not - reached (95% CI 17·9-not evaluable) with cemiplimab (n=283) versus 14·2 months - (11·2-17·5) with chemotherapy (n=280; hazard ratio [HR] 0·57 [0·42-0·77]; - p=0·0002). Median progression-free survival was 8·2 months (6·1-8·8) with - cemiplimab versus 5·7 months (4·5-6·2) with chemotherapy (HR 0·54 [0·43-0·68]; - p<0·0001). Significant improvements in overall survival and progression-free - survival were also observed with cemiplimab in the intention-to-treat population - despite a high crossover rate (74%). Grade 3-4 treatment-emergent adverse events - occurred in 98 (28%) of 355 patients treated with cemiplimab and 135 (39%) of 342 - patients treated with chemotherapy. INTERPRETATION: Cemiplimab monotherapy - significantly improved overall survival and progression-free survival compared - with chemotherapy in patients with advanced non-small-cell lung cancer with PD-L1 - of at least 50%, providing a potential new treatment option for this patient - population. FUNDING: Regeneron Pharmaceuticals and Sanofi. -CI - Copyright © 2021 Elsevier Ltd. All rights reserved. -FAU - Sezer, Ahmet -AU - Sezer A -AD - Department of Medical Oncology, Başkent University, Adana, Turkey. Electronic - address: drasezer@hotmail.com.tr. -FAU - Kilickap, Saadettin -AU - Kilickap S -AD - Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, - Turkey. -FAU - Gümüş, Mahmut -AU - Gümüş M -AD - Department of Medical Oncology, School of Medicine, Istanbul Medeniyet - University, Istanbul, Turkey. -FAU - Bondarenko, Igor -AU - Bondarenko I -AD - Department of Oncology and Medical Radiology; Dnipropetrovsk Medical Academy, - Dnipro, Ukraine. -FAU - Özgüroğlu, Mustafa -AU - Özgüroğlu M -AD - Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey. -FAU - Gogishvili, Miranda -AU - Gogishvili M -AD - High Technology Medical Centre, University Clinic, Tbilisi, Georgia. -FAU - Turk, Haci M -AU - Turk HM -AD - Department of Medical Oncology, Bezmialem Vakif University, Medical Faculty, - Istanbul, Turkey. -FAU - Cicin, Irfan -AU - Cicin I -AD - Department of Medical Oncology, Trakya University, Edirne, Turkey. -FAU - Bentsion, Dmitry -AU - Bentsion D -AD - Radiotherapy Department, Sverdlovsk Regional Oncology Centre, Sverdlovsk, Russia. -FAU - Gladkov, Oleg -AU - Gladkov O -AD - LLC, "EVIMED", Chelyabinsk, Russia. -FAU - Clingan, Philip -AU - Clingan P -AD - Southern Medical Day Care Centre and Illawarra Health and Medical Research - Institute, University of Wollongong-Illawarra Cancer Centre, Wollongong Hospital, - Wollongong, NSW, Australia. -FAU - Sriuranpong, Virote -AU - Sriuranpong V -AD - Division of Medical Oncology, Department of Medicine, Faculty of Medicine, - Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, - Thailand. -FAU - Rizvi, Naiyer -AU - Rizvi N -AD - Division of Hematology-Oncology, Columbia University Medical Center, New York, - New York, NY, USA. -FAU - Gao, Bo -AU - Gao B -AD - Regeneron Pharmaceuticals, Basking Ridge, New Jersey, USA. -FAU - Li, Siyu -AU - Li S -AD - Regeneron Pharmaceuticals, Basking Ridge, New Jersey, USA. -FAU - Lee, Sue -AU - Lee S -AD - Regeneron Pharmaceuticals, Basking Ridge, New Jersey, USA. -FAU - McGuire, Kristina -AU - McGuire K -AD - Regeneron Pharmaceuticals, Tarrytown, New York, NY, USA. -FAU - Chen, Chieh-I -AU - Chen CI -AD - Regeneron Pharmaceuticals, Basking Ridge, New Jersey, USA. -FAU - Makharadze, Tamta -AU - Makharadze T -AD - High Technology Hospital Medcenter, Batumi, Georgia. -FAU - Paydas, Semra -AU - Paydas S -AD - Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, - Turkey. -FAU - Nechaeva, Marina -AU - Nechaeva M -AD - Arkhangelsk Clinical Oncology Center, Arkhangelsk, Russia. -FAU - Seebach, Frank -AU - Seebach F -AD - Regeneron Pharmaceuticals, Tarrytown, New York, NY, USA. -FAU - Weinreich, David M -AU - Weinreich DM -AD - Regeneron Pharmaceuticals, Tarrytown, New York, NY, USA. -FAU - Yancopoulos, George D -AU - Yancopoulos GD -AD - Regeneron Pharmaceuticals, Tarrytown, New York, NY, USA. -FAU - Gullo, Giuseppe -AU - Gullo G -AD - Regeneron Pharmaceuticals, Tarrytown, New York, NY, USA. -FAU - Lowy, Israel -AU - Lowy I -AD - Regeneron Pharmaceuticals, Tarrytown, New York, NY, USA. -FAU - Rietschel, Petra -AU - Rietschel P -AD - Regeneron Pharmaceuticals, Tarrytown, New York, NY, USA. -LA - eng -SI - ClinicalTrials.gov/NCT03088540 -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -PL - England -TA - Lancet -JT - Lancet (London, England) -JID - 2985213R -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 04Q9AIZ7NO (Pemetrexed) -RN - 0W860991D6 (Deoxycytidine) -RN - 6QVL057INT (cemiplimab) -RN - BG3F62OND5 (Carboplatin) -RN - P88XT4IS4D (Paclitaxel) -RN - Q20Q21Q62J (Cisplatin) -RN - 0 (Gemcitabine) -SB - IM -CIN - Lancet. 2021 Feb 13;397(10274):557-559. doi: 10.1016/S0140-6736(21)00196-3. PMID: - 33581807 -MH - Aged -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - Antineoplastic Agents, Immunological/therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors/*metabolism -MH - Carboplatin/administration & dosage -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/pathology -MH - Cisplatin/administration & dosage -MH - Deoxycytidine/administration & dosage/analogs & derivatives -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Lung Neoplasms/*drug therapy/metabolism -MH - Male -MH - Middle Aged -MH - Paclitaxel/administration & dosage -MH - Pemetrexed/administration & dosage -MH - Progression-Free Survival -MH - Survival Rate -MH - Gemcitabine -EDAT- 2021/02/15 06:00 -MHDA- 2021/05/29 06:00 -CRDT- 2021/02/14 20:22 -PHST- 2020/09/21 00:00 [received] -PHST- 2020/12/04 00:00 [revised] -PHST- 2021/01/04 00:00 [accepted] -PHST- 2021/02/14 20:22 [entrez] -PHST- 2021/02/15 06:00 [pubmed] -PHST- 2021/05/29 06:00 [medline] -AID - S0140-6736(21)00228-2 [pii] -AID - 10.1016/S0140-6736(21)00228-2 [doi] -PST - ppublish -SO - Lancet. 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2. - -PMID- 35597478 -OWN - NLM -STAT- MEDLINE -DCOM- 20220608 -LR - 20220817 -IS - 1872-7980 (Electronic) -IS - 0304-3835 (Linking) -VI - 541 -DP - 2022 Aug 10 -TI - Radiation therapy for extensive-stage small-cell lung cancer in the era of - immunotherapy. -PG - 215719 -LID - S0304-3835(22)00203-8 [pii] -LID - 10.1016/j.canlet.2022.215719 [doi] -AB - Unlike non-small-cell lung cancer (NSCLC), the progression of small-cell lung - cancer (SCLC) is slow. Extensive-stage SCLC (ES-SCLC) is a serious threat to - human health, with a 5-year survival rate of <7%. Chemotherapy has been the - first-line treatment for the past 30 years. The anti-PD-L1 checkpoint blockades - durvalumab and atezolizumab have greatly prolonged overall survival and have - become the standard first-line therapy for ES-SCLC since the CASPIAN and - IMpower133 trials. In the era of chemotherapy, radiation therapy (RT), including - thoracic radiation therapy (TRT) and brain radiation therapy (BRT), has shown - clinical effects in randomized and retrospective studies on ES-SCLC. - RT-immunotherapy has shown exciting synergistic effects in NSCLC. For ES-SCLC, - the clinical effects of combining TRT/BRT with immunotherapy have not yet been - systematically explored. In this review, we found that studies on - RT-immunotherapy in ES-SCLC are relatively few and limited to early phase studies - focusing on toxicity. The efficacy and safety profiles of early phase studies - encourage prospective clinical trials. In this review, we discuss the best - population, optimum TRT dose, proper TRT time, and strategies for reducing - radiation-induced neurotoxicity. Furthermore, we suggest that biomarkers and - patient performance status should be fully assessed before RT-immunotherapy - treatment. Prospective trials are needed to provide more evidence for - RT-immunotherapy applications in ES-SCLC. -CI - Copyright © 2022 Elsevier B.V. All rights reserved. -FAU - Tian, Yaru -AU - Tian Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan, - Shandong, China. -FAU - Ma, Ji -AU - Ma J -AD - Department of Oncology, The People's Hospital of Leling, Leling, Shandong, China. -FAU - Jing, Xuquan -AU - Jing X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan, - Shandong, China. -FAU - Zhai, Xiaoyang -AU - Zhai X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan, - Shandong, China. -FAU - Li, Yuying -AU - Li Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan, - Shandong, China. -FAU - Guo, Zhijun -AU - Guo Z -AD - Department of Intensive Care Unit, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of - Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, - China; Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Zhu, Hui -AU - Zhu H -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan, - Shandong, China. Electronic address: drzhuh@126.com. -LA - eng -PT - Journal Article -PT - Review -DEP - 20220518 -PL - Ireland -TA - Cancer Lett -JT - Cancer letters -JID - 7600053 -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Prospective Studies -MH - Retrospective Studies -MH - *Small Cell Lung Carcinoma/drug therapy/radiotherapy -OTO - NOTNLM -OT - ES-SCLC -OT - Immunotherapy -OT - Radiation therapy -EDAT- 2022/05/22 06:00 -MHDA- 2022/06/09 06:00 -CRDT- 2022/05/21 19:27 -PHST- 2022/03/07 00:00 [received] -PHST- 2022/04/30 00:00 [revised] -PHST- 2022/05/03 00:00 [accepted] -PHST- 2022/05/22 06:00 [pubmed] -PHST- 2022/06/09 06:00 [medline] -PHST- 2022/05/21 19:27 [entrez] -AID - S0304-3835(22)00203-8 [pii] -AID - 10.1016/j.canlet.2022.215719 [doi] -PST - ppublish -SO - Cancer Lett. 2022 Aug 10;541:215719. doi: 10.1016/j.canlet.2022.215719. Epub 2022 - May 18. - -PMID- 35705538 -OWN - NLM -STAT- MEDLINE -DCOM- 20220617 -LR - 20220729 -IS - 2059-3635 (Electronic) -IS - 2095-9907 (Print) -IS - 2059-3635 (Linking) -VI - 7 -IP - 1 -DP - 2022 Jun 15 -TI - Signal pathways and precision therapy of small-cell lung cancer. -PG - 187 -LID - 10.1038/s41392-022-01013-y [doi] -LID - 187 -AB - Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is - characterized by a high rate of proliferation, a tendency for early metastasis - and generally poor prognosis. Most of the patients present with distant - metastatic disease at the time of clinical diagnosis, and only one-third are - eligible for potentially curative treatment. Recently, investigations into the - genomic make-up of SCLC show extensive chromosomal rearrangements, high - mutational burden and loss-of-function mutations of several tumor suppressor - genes. Although the clinical development of new treatments for SCLC has been - limited in recent years, a better understanding of oncogenic driver alterations - has found potential novel targets that might be suitable for therapeutic - approaches. Currently, there are six types of potential treatable signaling - pathways in SCLC, including signaling pathways targeting the cell cycle and DNA - repair, tumor development, cell metabolism, epigenetic regulation, tumor immunity - and angiogenesis. At this point, however, there is still a lack of understanding - of their role in SCLC tumor biology and the promotion of cancer growth. - Importantly optimizing drug targets, improving drug pharmacology, and identifying - potential biomarkers are the main focus and further efforts are required to - recognize patients who benefit most from novel therapies in development. This - review will focus on the current learning on the signaling pathways, the status - of immunotherapy, and targeted therapy in SCLC. -CI - © 2022. The Author(s). -FAU - Yuan, Min -AU - Yuan M -AD - Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, - 200072, Shanghai, China. -FAU - Zhao, Yu -AU - Zhao Y -AD - Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, - 200072, Shanghai, China. -FAU - Arkenau, Hendrik-Tobias -AU - Arkenau HT -AD - Drug Development Unit, Sarah Cannon Research Institute, London, UK. -FAU - Lao, Tongnei -AU - Lao T -AD - Department of Oncology, Centro Medico BO CHI, Macao, SAR, China. -FAU - Chu, Li -AU - Chu L -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - 200032, Shanghai, China. luckylily6@163.com. -AD - Department of Oncology, Shanghai Medical College, Fudan University, 200032, - Shanghai, China. luckylily6@163.com. -FAU - Xu, Qing -AU - Xu Q -AD - Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, - 200072, Shanghai, China. xuqingmd@tongji.edu.cn. -LA - eng -PT - Journal Article -PT - Review -DEP - 20220615 -PL - England -TA - Signal Transduct Target Ther -JT - Signal transduction and targeted therapy -JID - 101676423 -SB - IM -MH - Epigenesis, Genetic/genetics -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy/genetics -MH - Signal Transduction/genetics -MH - *Small Cell Lung Carcinoma/drug therapy/therapy -PMC - PMC9200817 -COIS- The authors declare no competing interests. -EDAT- 2022/06/16 06:00 -MHDA- 2022/06/18 06:00 -PMCR- 2022/06/15 -CRDT- 2022/06/15 23:14 -PHST- 2021/09/29 00:00 [received] -PHST- 2022/04/29 00:00 [accepted] -PHST- 2022/03/05 00:00 [revised] -PHST- 2022/06/15 23:14 [entrez] -PHST- 2022/06/16 06:00 [pubmed] -PHST- 2022/06/18 06:00 [medline] -PHST- 2022/06/15 00:00 [pmc-release] -AID - 10.1038/s41392-022-01013-y [pii] -AID - 1013 [pii] -AID - 10.1038/s41392-022-01013-y [doi] -PST - epublish -SO - Signal Transduct Target Ther. 2022 Jun 15;7(1):187. doi: - 10.1038/s41392-022-01013-y. - -PMID- 33435596 -OWN - NLM -STAT- MEDLINE -DCOM- 20210329 -LR - 20220603 -IS - 1422-0067 (Electronic) -IS - 1422-0067 (Linking) -VI - 22 -IP - 2 -DP - 2021 Jan 8 -TI - Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. -LID - 10.3390/ijms22020593 [doi] -LID - 593 -AB - Lung cancer is one of the most common malignant neoplasms. As a result of the - disease's progression, patients may develop metastases to the central nervous - system. The prognosis in this location is unfavorable; untreated metastatic - lesions may lead to death within one to two months. Existing - therapies-neurosurgery and radiation therapy-do not improve the prognosis for - every patient. The discovery of Epidermal Growth Factor Receptor - (EGFR)-activating mutations and Anaplastic Lymphoma Kinase (ALK) rearrangements - in patients with non-small cell lung adenocarcinoma has allowed for the - introduction of small-molecule tyrosine kinase inhibitors to the treatment of - advanced-stage patients. The Epidermal Growth Factor Receptor (EGFR) is a - transmembrane protein with tyrosine kinase-dependent activity. EGFR is present in - membranes of all epithelial cells. In physiological conditions, it plays an - important role in the process of cell growth and proliferation. Binding the - ligand to the EGFR causes its dimerization and the activation of the - intracellular signaling cascade. Signal transduction involves the activation of - MAPK, AKT, and JNK, resulting in DNA synthesis and cell proliferation. In cancer - cells, binding the ligand to the EGFR also leads to its dimerization and - transduction of the signal to the cell interior. It has been demonstrated that - activating mutations in the gene for EGFR-exon19 (deletion), L858R point mutation - in exon 21, and mutation in exon 20 results in cancer cell proliferation. - Continuous stimulation of the receptor inhibits apoptosis, stimulates invasion, - intensifies angiogenesis, and facilitates the formation of distant metastases. As - a consequence, the cancer progresses. These activating gene mutations for the - EGFR are present in 10-20% of lung adenocarcinomas. Approximately 3-7% of - patients with lung adenocarcinoma have the echinoderm microtubule-associated - protein-like 4 (EML4)/ALK fusion gene. The fusion of the two genes EML4 and ALK - results in a fusion gene that activates the intracellular signaling pathway, - stimulates the proliferation of tumor cells, and inhibits apoptosis. A new group - of drugs-small-molecule tyrosine kinase inhibitors-has been developed; the first - generation includes gefitinib and erlotinib and the ALK inhibitor crizotinib. - These drugs reversibly block the EGFR by stopping the signal transmission to the - cell. The second-generation tyrosine kinase inhibitor (TKI) afatinib or ALK - inhibitor alectinib block the receptor irreversibly. Clinical trials with TKI in - patients with non-small cell lung adenocarcinoma with central nervous system - (CNS) metastases have shown prolonged, progression-free survival, a high - percentage of objective responses, and improved quality of life. Resistance to - treatment with this group of drugs emerging during TKI therapy is the basis for - the detection of resistance mutations. The T790M mutation, present in exon 20 of - the EGFR gene, is detected in patients treated with first- and second-generation - TKI and is overcome by Osimertinib, a third-generation TKI. The I117N resistance - mutation in patients with the ALK mutation treated with alectinib is overcome by - ceritinib. In this way, sequential therapy ensures the continuity of treatment. - In patients with CNS metastases, attempts are made to simultaneously administer - radiation therapy and tyrosine kinase inhibitors. Patients with lung - adenocarcinoma with CNS metastases, without activating EGFR mutation and without - ALK rearrangement, benefit from immunotherapy. This therapeutic option blocks the - PD-1 receptor on the surface of T or B lymphocytes or PD-L1 located on cancer - cells with an applicable antibody. Based on clinical trials, pembrolizumab and - all antibodies are included in the treatment of non-small cell lung carcinoma - with CNS metastases. -FAU - Rybarczyk-Kasiuchnicz, Agnieszka -AU - Rybarczyk-Kasiuchnicz A -AD - Department of Chemotherapy, Poznan University of Medical Sciences, Clinical - Hospital of Lord Transfiguration, 61-848 Poznan, Poland. -FAU - Ramlau, Rodryg -AU - Ramlau R -AD - Department of Chemotherapy, Poznan University of Medical Sciences, Clinical - Hospital of Lord Transfiguration, 61-848 Poznan, Poland. -FAU - Stencel, Katarzyna -AU - Stencel K -AUID- ORCID: 0000-0003-0857-2030 -AD - Department of Chemotherapy, Poznan University of Medical Sciences, Clinical - Hospital of Lord Transfiguration, 61-848 Poznan, Poland. -LA - eng -PT - Journal Article -PT - Review -DEP - 20210108 -PL - Switzerland -TA - Int J Mol Sci -JT - International journal of molecular sciences -JID - 101092791 -RN - 0 (Acrylamides) -RN - 0 (Aniline Compounds) -RN - 0 (Protein Kinase Inhibitors) -RN - 0 (Pyrimidines) -RN - 0 (Sulfones) -RN - 3C06JJ0Z2O (osimertinib) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - K418KG2GET (ceritinib) -SB - IM -MH - Acrylamides/therapeutic use -MH - Aniline Compounds/therapeutic use -MH - Brain Neoplasms/*drug therapy/genetics/secondary -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/pathology -MH - Drug Resistance, Neoplasm/*drug effects/genetics -MH - ErbB Receptors/antagonists & inhibitors/genetics/metabolism -MH - Humans -MH - Lung Neoplasms/*drug therapy/genetics/pathology -MH - Mutation -MH - Protein Kinase Inhibitors/*therapeutic use -MH - Pyrimidines/therapeutic use -MH - Sulfones/therapeutic use -PMC - PMC7826874 -OTO - NOTNLM -OT - ALK -OT - EGFR -OT - brain metastases -OT - immunotherapy -OT - non-small cell lung carcinoma -OT - treatment -COIS- The authors declare no conflict of interest. -EDAT- 2021/01/14 06:00 -MHDA- 2021/03/30 06:00 -PMCR- 2021/01/08 -CRDT- 2021/01/13 01:02 -PHST- 2020/12/03 00:00 [received] -PHST- 2020/12/28 00:00 [revised] -PHST- 2020/12/30 00:00 [accepted] -PHST- 2021/01/13 01:02 [entrez] -PHST- 2021/01/14 06:00 [pubmed] -PHST- 2021/03/30 06:00 [medline] -PHST- 2021/01/08 00:00 [pmc-release] -AID - ijms22020593 [pii] -AID - ijms-22-00593 [pii] -AID - 10.3390/ijms22020593 [doi] -PST - epublish -SO - Int J Mol Sci. 2021 Jan 8;22(2):593. doi: 10.3390/ijms22020593. - -PMID- 33285097 -OWN - NLM -STAT- MEDLINE -DCOM- 20210126 -LR - 20210308 -IS - 1474-5488 (Electronic) -IS - 1470-2045 (Linking) -VI - 22 -IP - 1 -DP - 2021 Jan -TI - Durvalumab, with or without tremelimumab, plus platinum-etoposide versus - platinum-etoposide alone in first-line treatment of extensive-stage small-cell - lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, - phase 3 trial. -PG - 51-65 -LID - S1470-2045(20)30539-8 [pii] -LID - 10.1016/S1470-2045(20)30539-8 [doi] -AB - BACKGROUND: First-line durvalumab plus etoposide with either cisplatin or - carboplatin (platinum-etoposide) showed a significant improvement in overall - survival versus platinum-etoposide alone in patients with extensive-stage - small-cell lung cancer (ES-SCLC) in the CASPIAN study. Here we report updated - results, including the primary analysis for overall survival with durvalumab plus - tremelimumab plus platinum-etoposide versus platinum-etoposide alone. METHODS: - CASPIAN is an ongoing, open-label, sponsor-blind, randomised, controlled phase 3 - trial at 209 cancer treatment centres in 23 countries worldwide. Eligible - patients were aged 18 years or older (20 years in Japan) and had treatment-naive, - histologically or cytologically documented ES-SCLC, with a WHO performance status - of 0 or 1. Patients were randomly assigned (1:1:1) in blocks of six, stratified - by planned platinum, using an interactive voice-response or web-response system - to receive intravenous durvalumab plus tremelimumab plus platinum-etoposide, - durvalumab plus platinum-etoposide, or platinum-etoposide alone. In all groups, - patients received etoposide 80-100 mg/m(2) on days 1-3 of each cycle with - investigator's choice of either carboplatin area under the curve 5-6 mg/mL/min or - cisplatin 75-80 mg/m(2) on day 1 of each cycle. Patients in the - platinum-etoposide group received up to six cycles of platinum-etoposide every 3 - weeks and optional prophylactic cranial irradiation (investigator's discretion). - Patients in the immunotherapy groups received four cycles of platinum-etoposide - plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed - by maintenance durvalumab 1500 mg every 4 weeks. The two primary endpoints were - overall survival for durvalumab plus platinum-etoposide versus platinum-etoposide - and for durvalumab plus tremelimumab plus platinum-etoposide versus - platinum-etoposide in the intention-to-treat population. Safety was assessed in - all patients who received at least one dose of study treatment. This study is - registered at ClinicalTrials.gov, NCT03043872. FINDINGS: Between March 27, 2017, - and May 29, 2018, 972 patients were screened and 805 were randomly assigned (268 - to durvalumab plus tremelimumab plus platinum-etoposide, 268 to durvalumab plus - platinum-etoposide, and 269 to platinum-etoposide). As of Jan 27, 2020, the - median follow-up was 25·1 months (IQR 22·3-27·9). Durvalumab plus tremelimumab - plus platinum-etoposide was not associated with a significant improvement in - overall survival versus platinum-etoposide (hazard ratio [HR] 0·82 [95% CI - 0·68-1·00]; p=0·045); median overall survival was 10·4 months (95% CI 9·6-12·0) - versus 10·5 months (9·3-11·2). Durvalumab plus platinum-etoposide showed - sustained improvement in overall survival versus platinum-etoposide (HR 0·75 [95% - CI 0·62-0·91]; nominal p=0·0032); median overall survival was 12·9 months (95% CI - 11·3-14·7) versus 10·5 months (9·3-11·2). The most common any-cause grade 3 or - worse adverse events were neutropenia (85 [32%] of 266 patients in the durvalumab - plus tremelimumab plus platinum-etoposide group, 64 [24%] of 265 patients in the - durvalumab plus platinum-etoposide group, and 88 [33%] of 266 patients in the - platinum-etoposide group) and anaemia (34 [13%], 24 [9%], and 48 [18%]). - Any-cause serious adverse events were reported in 121 (45%) patients in the - durvalumab plus tremelimumab plus platinum-etoposide group, 85 (32%) in the - durvalumab plus platinum-etoposide group, and 97 (36%) in the platinum-etoposide - group. Treatment-related deaths occurred in 12 (5%) patients in the durvalumab - plus tremelimumab plus platinum-etoposide group (death, febrile neutropenia, and - pulmonary embolism [n=2 each]; enterocolitis, general physical health - deterioration and multiple organ dysfunction syndrome, pneumonia, pneumonitis and - hepatitis, respiratory failure, and sudden death [n=1 each]), six (2%) patients - in the durvalumab plus platinum-etoposide group (cardiac arrest, dehydration, - hepatotoxicity, interstitial lung disease, pancytopenia, and sepsis [n=1 each]), - and two (1%) in the platinum-etoposide group (pancytopenia and thrombocytopenia - [n=1 each]). INTERPRETATION: First-line durvalumab plus platinum-etoposide showed - sustained overall survival improvement versus platinum-etoposide but the addition - of tremelimumab to durvalumab plus platinum-etoposide did not significantly - improve outcomes versus platinum-etoposide. These results support the use of - durvalumab plus platinum-etoposide as a new standard of care for the first-line - treatment of ES-SCLC. FUNDING: AstraZeneca. -CI - Copyright © 2021 Elsevier Ltd. All rights reserved. -FAU - Goldman, Jonathan W -AU - Goldman JW -AD - David Geffen School of Medicine at University of California Los Angeles, Los - Angeles, CA, USA. -FAU - Dvorkin, Mikhail -AU - Dvorkin M -AD - BHI of Omsk Region Clinical Oncology Dispensary, Omsk, Russia. -FAU - Chen, Yuanbin -AU - Chen Y -AD - Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, USA. -FAU - Reinmuth, Niels -AU - Reinmuth N -AD - Asklepios Lung Clinic, Munich-Gauting, Germany. -FAU - Hotta, Katsuyuki -AU - Hotta K -AD - Okayama University Hospital, Okayama, Japan. -FAU - Trukhin, Dmytro -AU - Trukhin D -AD - Odessa Regional Oncological Dispensary, Odessa, Ukraine. -FAU - Statsenko, Galina -AU - Statsenko G -AD - Omsk Regional Cancer Centre, Omsk, Russia. -FAU - Hochmair, Maximilian J -AU - Hochmair MJ -AD - Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik - Floridsdorf, Vienna, Austria. -FAU - Özgüroğlu, Mustafa -AU - Özgüroğlu M -AD - Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey. -FAU - Ji, Jun Ho -AU - Ji JH -AD - Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, - South Korea. -FAU - Garassino, Marina Chiara -AU - Garassino MC -AD - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. -FAU - Voitko, Oleksandr -AU - Voitko O -AD - Kyiv City Clinical Oncological Centre, Kiev, Ukraine. -FAU - Poltoratskiy, Artem -AU - Poltoratskiy A -AD - Petrov Research Institute of Oncology, St Petersburg, Russia. -FAU - Ponce, Santiago -AU - Ponce S -AD - Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO - Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain. -FAU - Verderame, Francesco -AU - Verderame F -AD - Azienda Ospedaliera Ospedali Riuniti PO Vincenzo Cervello, Palermo, Italy. -FAU - Havel, Libor -AU - Havel L -AD - Thomayer Hospital, First Faculty of Medicine, Charles University, Prague, Czech - Republic. -FAU - Bondarenko, Igor -AU - Bondarenko I -AD - Dnipropetrovsk Medical Academy, Dnipro, Ukraine. -FAU - Każarnowicz, Andrzej -AU - Każarnowicz A -AD - Tuberculosis and Lung Disease Hospital, Olsztyn, Poland. -FAU - Losonczy, György -AU - Losonczy G -AD - Department of Pulmonology, Semmelweis University, Budapest, Hungary. -FAU - Conev, Nikolay V -AU - Conev NV -AD - Clinic of Medical Oncology, University Multiprofile Hospital for Active Treatment - St Marina, Varna, Bulgaria. -FAU - Armstrong, Jon -AU - Armstrong J -AD - AstraZeneca, Cambridge, UK. -FAU - Byrne, Natalie -AU - Byrne N -AD - AstraZeneca, Cambridge, UK. -FAU - Thiyagarajah, Piruntha -AU - Thiyagarajah P -AD - AstraZeneca, Cambridge, UK. -FAU - Jiang, Haiyi -AU - Jiang H -AD - AstraZeneca, Gaithersburg, MD, USA. -FAU - Paz-Ares, Luis -AU - Paz-Ares L -AD - Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO - Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain. Electronic - address: lpazaresr@seom.org. -CN - CASPIAN investigators -LA - eng -SI - ClinicalTrials.gov/NCT03043872 -PT - Clinical Trial, Phase III -PT - Comparative Study -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20201204 -PL - England -TA - Lancet Oncol -JT - The Lancet. Oncology -JID - 100957246 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 28X28X9OKV (durvalumab) -RN - 6PLQ3CP4P3 (Etoposide) -RN - BG3F62OND5 (Carboplatin) -RN - Q20Q21Q62J (Cisplatin) -RN - QEN1X95CIX (tremelimumab) -SB - IM -CIN - Lancet Oncol. 2021 Mar;22(3):e83. doi: 10.1016/S1470-2045(21)00008-5. PMID: - 33662291 -CIN - Lancet Oncol. 2021 Mar;22(3):e84. doi: 10.1016/S1470-2045(21)00083-8. PMID: - 33662292 -MH - Aged -MH - Antibodies, Monoclonal/*administration & dosage/adverse effects -MH - Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use -MH - Carboplatin/*administration & dosage/adverse effects -MH - Cisplatin/*administration & dosage/adverse effects -MH - Disease Progression -MH - Etoposide/*administration & dosage/adverse effects -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/mortality/pathology -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Progression-Free Survival -MH - Small Cell Lung Carcinoma/*drug therapy/mortality/pathology -MH - Time Factors -FIR - Dvorkin, Mikhail -IR - Dvorkin M -FIR - Trukhin, Dmytro -IR - Trukhin D -FIR - Statsenko, Galina -IR - Statsenko G -FIR - Voitko, Nataliia -IR - Voitko N -FIR - Poltoratskiy, Artem -IR - Poltoratskiy A -FIR - Bondarenko, Igor -IR - Bondarenko I -FIR - Chen, Yuanbin -IR - Chen Y -FIR - Kazarnowicz, Andrzej -IR - Kazarnowicz A -FIR - Paz-Ares, Luis -IR - Paz-Ares L -FIR - Özgüroglu, Mustafa -IR - Özgüroglu M -FIR - Conev, Nikolay -IR - Conev N -FIR - Hochmair, Maximilian -IR - Hochmair M -FIR - Burghuber, Otto -IR - Burghuber O -FIR - Havel, Libor -IR - Havel L -FIR - Çiçin, Irfan -IR - Çiçin I -FIR - Losonczy, György -IR - Losonczy G -FIR - Moiseenko, Vladimir -IR - Moiseenko V -FIR - Erman, Mustafa -IR - Erman M -FIR - Kowalski, Dariusz -IR - Kowalski D -FIR - Wojtukiewicz, Marek -IR - Wojtukiewicz M -FIR - Adamchuk, Hryhoriy -IR - Adamchuk H -FIR - Vasilyev, Alexander -IR - Vasilyev A -FIR - Shevnia, Serhii -IR - Shevnia S -FIR - Valev, Spartak -IR - Valev S -FIR - Reinmuth, Niels -IR - Reinmuth N -FIR - Ji, Jun Ho -IR - Ji JH -FIR - Insa Molla, Maria Amelia -IR - Insa Molla MA -FIR - Ursol, Grygorii -IR - Ursol G -FIR - Chiang, Anne -IR - Chiang A -FIR - Hartl, Sylvia -IR - Hartl S -FIR - Horváth, Zsolt -IR - Horváth Z -FIR - Pajkos, Gábor -IR - Pajkos G -FIR - Verderame, Francesco -IR - Verderame F -FIR - Hotta, Katsuyuki -IR - Hotta K -FIR - Kim, Sang-We -IR - Kim SW -FIR - Smolin, Alexey -IR - Smolin A -FIR - Göksel, Tuncay -IR - Göksel T -FIR - Dakhil, Shaker -IR - Dakhil S -FIR - Roubec, Jaromir -IR - Roubec J -FIR - Bogos, Krisztina -IR - Bogos K -FIR - Garassino, Marina Chiara -IR - Garassino MC -FIR - Cornelissen, Robin -IR - Cornelissen R -FIR - Lee, Jong-Seok -IR - Lee JS -FIR - Garcia Campelo, Maria Rosario -IR - Garcia Campelo MR -FIR - Lopez Brea, Marta -IR - Lopez Brea M -FIR - Alacacioglu, Ahmet -IR - Alacacioglu A -FIR - Casarini, Ignacio -IR - Casarini I -FIR - Ilieva, Rumyana -IR - Ilieva R -FIR - Tonev, Ivan -IR - Tonev I -FIR - Somfay, Attila -IR - Somfay A -FIR - Bar, Jair -IR - Bar J -FIR - Zer Kuch, Alona -IR - Zer Kuch A -FIR - Minelli, Mauro -IR - Minelli M -FIR - Bartolucci, Roberta -IR - Bartolucci R -FIR - Roila, Fausto -IR - Roila F -FIR - Saito, Haruhiro -IR - Saito H -FIR - Azuma, Koichi -IR - Azuma K -FIR - Lee, Gyeong-Won -IR - Lee GW -FIR - Luft, Alexander -IR - Luft A -FIR - Urda, Michal -IR - Urda M -FIR - Delgado Mingorance, Juan Ignacio -IR - Delgado Mingorance JI -FIR - Majem Tarruella, Margarita -IR - Majem Tarruella M -FIR - Spigel, David -IR - Spigel D -FIR - Koynov, Krassimir -IR - Koynov K -FIR - Zemanova, Milada -IR - Zemanova M -FIR - Panse, Jens -IR - Panse J -FIR - Schulz, Christian -IR - Schulz C -FIR - Pápai Székely, Zsolt -IR - Pápai Székely Z -FIR - Sárosi, Veronika -IR - Sárosi V -FIR - Delmonte, Angelo -IR - Delmonte A -FIR - Bettini, Anna Cecilia -IR - Bettini AC -FIR - Nishio, Makoto -IR - Nishio M -FIR - Okamoto, Isamu -IR - Okamoto I -FIR - Hendriks, Lizza -IR - Hendriks L -FIR - Mandziuk, Slawomir -IR - Mandziuk S -FIR - Lee, Yun Gyoo -IR - Lee YG -FIR - Vladimirova, Lyubov -IR - Vladimirova L -FIR - Isla Casado, Dolores -IR - Isla Casado D -FIR - Domine Gomez, Manuel -IR - Domine Gomez M -FIR - Navarro Mendivil, Alejandro -IR - Navarro Mendivil A -FIR - Morán Bueno, Teresa -IR - Morán Bueno T -FIR - Wu, Shang-Yin -IR - Wu SY -FIR - Knoble, Jeanna -IR - Knoble J -FIR - Skrickova, Jana -IR - Skrickova J -FIR - Venkova, Violetka -IR - Venkova V -FIR - Hilgers, Werner -IR - Hilgers W -FIR - Laack, Eckart -IR - Laack E -FIR - Bischoff, Helge -IR - Bischoff H -FIR - Fülöp, Andrea -IR - Fülöp A -FIR - Laczó, Ibolya -IR - Laczó I -FIR - Kósa, Judit -IR - Kósa J -FIR - Telekes, András -IR - Telekes A -FIR - Yoshida, Tatsuya -IR - Yoshida T -FIR - Kanda, Shintaro -IR - Kanda S -FIR - Hida, Toyoaki -IR - Hida T -FIR - Hayashi, Hidetoshi -IR - Hayashi H -FIR - Maeda, Tadashi -IR - Maeda T -FIR - Kawamura, Tetsuji -IR - Kawamura T -FIR - Nakahara, Yasuharu -IR - Nakahara Y -FIR - Claessens, Niels -IR - Claessens N -FIR - Lee, Ki Hyeong -IR - Lee KH -FIR - Chiu, Chao-Hua -IR - Chiu CH -FIR - Lin, Sheng-Hao -IR - Lin SH -FIR - Li, Chien-Te -IR - Li CT -FIR - Demirkazik, Ahmet -IR - Demirkazik A -FIR - Schaefer, Eric -IR - Schaefer E -FIR - Nikolinakos, Petros -IR - Nikolinakos P -FIR - Schneider, Jeffrey -IR - Schneider J -FIR - Babu, Sunil -IR - Babu S -FIR - Lamprecht, Bernd -IR - Lamprecht B -FIR - Studnicka, Michael -IR - Studnicka M -FIR - Fausto Nino Gorini, Carlos -IR - Fausto Nino Gorini C -FIR - Kultan, Juraj -IR - Kultan J -FIR - Kolek, Vitezslav -IR - Kolek V -FIR - Souquet, Pierre-Jean -IR - Souquet PJ -FIR - Moro-Sibilot, Denis -IR - Moro-Sibilot D -FIR - Gottfried, Maya -IR - Gottfried M -FIR - Smit, Egbert -IR - Smit E -FIR - Lee, Kyung Hee -IR - Lee KH -FIR - Kasan, Peter -IR - Kasan P -FIR - Chovanec, Jozef -IR - Chovanec J -FIR - Goloborodko, Olexandr -IR - Goloborodko O -FIR - Kolesnik, Oleksii -IR - Kolesnik O -FIR - Ostapenko, Yuriy -IR - Ostapenko Y -FIR - Lakhanpal, Shailendra -IR - Lakhanpal S -FIR - Haque, Basir -IR - Haque B -FIR - Chua, Winston -IR - Chua W -FIR - Stilwill, Joseph -IR - Stilwill J -FIR - Sena, Susana Noemi -IR - Sena SN -FIR - Girotto, Gustavo Colagiovanni -IR - Girotto GC -FIR - De Marchi, Pedro Rafael Martins -IR - De Marchi PRM -FIR - Martinelli de Oliveira, Fabricio Augusto -IR - Martinelli de Oliveira FA -FIR - Dos Reis, Pedro -IR - Dos Reis P -FIR - Krasteva, Rositsa -IR - Krasteva R -FIR - Zhao, Yanqiu -IR - Zhao Y -FIR - Chen, Chengshui -IR - Chen C -FIR - Koubkova, Leona -IR - Koubkova L -FIR - Robinet, Gilles -IR - Robinet G -FIR - Chouaid, Christos -IR - Chouaid C -FIR - Grohe, Christian -IR - Grohe C -FIR - Alt, Jürgen -IR - Alt J -FIR - Csánky, Eszter -IR - Csánky E -FIR - Somogyiné Ezer, Éva -IR - Somogyiné Ezer É -FIR - Heching, Norman Isaac -IR - Heching NI -FIR - Kim, Young Hak -IR - Kim YH -FIR - Aatagi, Shinji -IR - Aatagi S -FIR - Kuyama, Shoichi -IR - Kuyama S -FIR - Harada, Daijiro -IR - Harada D -FIR - Nogami, Naoyuki -IR - Nogami N -FIR - Nokihara, Hiroshi -IR - Nokihara H -FIR - Goto, Hisatsugu -IR - Goto H -FIR - Staal van den Brekel, Agnes -IR - Staal van den Brekel A -FIR - Cho, Eun Kyung -IR - Cho EK -FIR - Kim, Joo-Hang -IR - Kim JH -FIR - Ganea, Doina -IR - Ganea D -FIR - Ciuleanu, Tudor -IR - Ciuleanu T -FIR - Popova, Ekaterina -IR - Popova E -FIR - Sakaeva, Dina -IR - Sakaeva D -FIR - Stresko, Marian -IR - Stresko M -FIR - Demo, Pavol -IR - Demo P -FIR - Godal, Robert -IR - Godal R -FIR - Wei, Yu-Feng -IR - Wei YF -FIR - Chen, Yen-Hsun -IR - Chen YH -FIR - Hsia, Te-Chun -IR - Hsia TC -FIR - Lee, Kang-Yun -IR - Lee KY -FIR - Chang, Huang-Chih -IR - Chang HC -FIR - Wang, Chin-Chou -IR - Wang CC -FIR - Dowlati, Afshin -IR - Dowlati A -FIR - Sumey, Christopher -IR - Sumey C -FIR - Powell, Steven -IR - Powell S -FIR - Goldman, Jonathan -IR - Goldman J -FIR - Zarba, Juan Jose -IR - Zarba JJ -FIR - Batagelj, Emilio -IR - Batagelj E -FIR - Pastor, Andrea Viviana -IR - Pastor AV -FIR - Zukin, Mauro -IR - Zukin M -FIR - Baldotto, Clarissa Serodio da Rocha -IR - Baldotto CSDR -FIR - Schlittler, Luis Alberto -IR - Schlittler LA -FIR - Calabrich, Aknar -IR - Calabrich A -FIR - Sette, Claudia -IR - Sette C -FIR - Dudov, Asen -IR - Dudov A -FIR - Zhou, Caicun -IR - Zhou C -FIR - Lena, Hervé -IR - Lena H -FIR - Lang, Susanne -IR - Lang S -FIR - Pápai, Zsuzsanna -IR - Pápai Z -FIR - Goto, Koichi -IR - Goto K -FIR - Umemura, Shigeki -IR - Umemura S -FIR - Kanazawa, Kenya -IR - Kanazawa K -FIR - Hara, Yu -IR - Hara Y -FIR - Shinoda, Masahiro -IR - Shinoda M -FIR - Morise, Masahiro -IR - Morise M -FIR - Hiltermann, Jeroen -IR - Hiltermann J -FIR - Mróz, Robert -IR - Mróz R -FIR - Ungureanu, Andrei -IR - Ungureanu A -FIR - Andrasina, Igor -IR - Andrasina I -FIR - Chang, Gee-Chen -IR - Chang GC -FIR - Vynnychenko, Ihor -IR - Vynnychenko I -FIR - Shparyk, Yaroslav -IR - Shparyk Y -FIR - Kryzhanivska, Anna -IR - Kryzhanivska A -FIR - Ross, Helen -IR - Ross H -FIR - Mi, Kailhong -IR - Mi K -FIR - Jamil, Rodney -IR - Jamil R -FIR - Williamson, Michael -IR - Williamson M -FIR - Spahr, Joseph -IR - Spahr J -FIR - Han, Zhigang -IR - Han Z -FIR - Wang, Mengzhao -IR - Wang M -FIR - Yang, Zhixiong -IR - Yang Z -FIR - Hu, Jie -IR - Hu J -FIR - Li, Wei -IR - Li W -FIR - Zhao, Jun -IR - Zhao J -FIR - Feng, Jifeng -IR - Feng J -FIR - Ma, Shenglin -IR - Ma S -FIR - Zhou, Xiangdong -IR - Zhou X -FIR - Liang, Zongan -IR - Liang Z -FIR - Hu, Yi -IR - Hu Y -FIR - Chen, Yuan -IR - Chen Y -FIR - Bi, Minghong -IR - Bi M -FIR - Shu, Yongqian -IR - Shu Y -FIR - Nan, Kejun -IR - Nan K -FIR - Zhou, Jianying -IR - Zhou J -FIR - Zhang, Wei -IR - Zhang W -FIR - Ma, Rui -IR - Ma R -FIR - Yang, Nong -IR - Yang N -FIR - Lin, Zhong -IR - Lin Z -FIR - Wu, Gang -IR - Wu G -FIR - Fang, Jian -IR - Fang J -FIR - Zhang, Helong -IR - Zhang H -FIR - Wang, Kai -IR - Wang K -FIR - Chen, Zhendong -IR - Chen Z -EDAT- 2020/12/08 06:00 -MHDA- 2021/01/27 06:00 -CRDT- 2020/12/07 20:07 -PHST- 2020/06/29 00:00 [received] -PHST- 2020/08/14 00:00 [revised] -PHST- 2020/09/02 00:00 [accepted] -PHST- 2020/12/08 06:00 [pubmed] -PHST- 2021/01/27 06:00 [medline] -PHST- 2020/12/07 20:07 [entrez] -AID - S1470-2045(20)30539-8 [pii] -AID - 10.1016/S1470-2045(20)30539-8 [doi] -PST - ppublish -SO - Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 - Dec 4. - -PMID- 36206679 -OWN - NLM -STAT- MEDLINE -DCOM- 20221216 -LR - 20221222 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 174 -DP - 2022 Dec -TI - Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment. -PG - 1-13 -LID - S0169-5002(22)00642-0 [pii] -LID - 10.1016/j.lungcan.2022.09.013 [doi] -AB - Leptomeningeal metastasis (LM) is a rare complication of non-small cell lung - cancer (NSCLC) with highly mortality. LM will occur once tumor cells spread to - the cerebrospinal fluid (CSF) space. Patients may suffer blindness, paralysis, - and mental disorders that seriously affect their quality of life. There is a - clear unmet need to improve the efficacy of diagnosis and treatment of LM. To - better solve this problem, it is helpful to clarify the potential mechanisms of - LM. Clinical manifestations, magnetic resonance imaging, and CSF biopsy are the - key components in the diagnosis of NSCLC with LM. CSF cytology is insufficient - and should be combined with liquid biology. The application of radiotherapy, - intrathecal treatment, targeted therapy and immunotherapy provides more options - for LM patients. Each treatment has a particular level of efficacy and can be - used alone or in combination for individual patients. New technologies in - radiotherapy, drug repositioning in intrathecal treatment, and the higher CSF - permeability in TKIs have brought new breakthroughs in the treatment of LM. This - review focused on clarifying the potential mechanisms, discussing the major - clinical challenges, and summarizing recent advances in the diagnosis and - treatment of LM from NSCLC. Future research is essential to improve the - efficiency of diagnosis, to optimize therapy and to enhance patient prognosis. -CI - Copyright © 2022 Elsevier B.V. All rights reserved. -FAU - Wang, Yan -AU - Wang Y -AD - Thoracic Oncology Ward, Cancer Center and State Key Laboratory of Biotherapy, - West China Hospital, Sichuan University, Chengdu, Sichuan, China. -FAU - Yang, Xue -AU - Yang X -AD - Thoracic Oncology Ward, Cancer Center and State Key Laboratory of Biotherapy, - West China Hospital, Sichuan University, Chengdu, Sichuan, China. -FAU - Li, Nan-Jing -AU - Li NJ -AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan - University, Chengdu, China. -FAU - Xue, Jian-Xin -AU - Xue JX -AD - Thoracic Oncology Ward, Cancer Center and State Key Laboratory of Biotherapy, - West China Hospital, Sichuan University, Chengdu, Sichuan, China; Laboratory of - Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu 610041, - China. Electronic address: radjianxin@163.com. -LA - eng -PT - Journal Article -PT - Review -DEP - 20221001 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy -MH - *Lung Neoplasms/therapy/drug therapy -MH - Quality of Life -MH - *Meningeal Carcinomatosis/therapy/drug therapy -MH - Prognosis -OTO - NOTNLM -OT - Diagnosis -OT - Leptomeningeal metastases -OT - Non-small cell lung cancer -OT - Treatment -COIS- Declaration of Competing Interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2022/10/08 06:00 -MHDA- 2022/12/15 06:00 -CRDT- 2022/10/07 18:23 -PHST- 2022/07/06 00:00 [received] -PHST- 2022/09/08 00:00 [revised] -PHST- 2022/09/27 00:00 [accepted] -PHST- 2022/10/08 06:00 [pubmed] -PHST- 2022/12/15 06:00 [medline] -PHST- 2022/10/07 18:23 [entrez] -AID - S0169-5002(22)00642-0 [pii] -AID - 10.1016/j.lungcan.2022.09.013 [doi] -PST - ppublish -SO - Lung Cancer. 2022 Dec;174:1-13. doi: 10.1016/j.lungcan.2022.09.013. Epub 2022 Oct - 1. - -PMID- 33689225 -OWN - NLM -STAT- MEDLINE -DCOM- 20211018 -LR - 20240331 -IS - 2523-3548 (Electronic) -IS - 2523-3548 (Linking) -VI - 41 -IP - 4 -DP - 2021 Apr -TI - Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. -PG - 287-302 -LID - 10.1002/cac2.12153 [doi] -AB - Lung cancer mortality has decreased over the past decade and can be partly - attributed to advances in targeted therapy and immunotherapy. Immune checkpoint - inhibitors (ICIs) have rapidly evolved from investigational drugs to standard of - care for the treatment of metastatic non-small cell lung cancer (NSCLC). In - particular, antibodies that block inhibitory immune checkpoints, such as - programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 - (PD-L1), have revolutionized the treatment of advanced NSCLC, when administered - alone or in combination with chemotherapy. Immunotherapy is associated with - higher response rates, improved overall survival (OS), and increased tolerability - compared with conventional cytotoxic chemotherapy. These benefits may increase - the utility of immunotherapy and its combinational use with chemotherapy in the - neoadjuvant treatment of patients with NSCLC. Early findings from various ongoing - clinical trials suggest that neoadjuvant ICIs alone or combined with chemotherapy - may significantly reduce systemic recurrence and improve long-term OS or cure - rates in resectable NSCLC. Here we further summarize the safety and efficacy of - various neoadjuvant treatment regimens including immunotherapy from ongoing - clinical trials and elaborate the role of neoadjuvant immunotherapy in patients - with resectable NSCLC. In addition, we discuss several unresolved challenges, - including the evaluations to assess neoadjuvant immunotherapy response, the role - of adjuvant treatment after neoadjuvant immunotherapy, the efficacy of treatment - for oncogenic-addicted tumors, and predictive biomarkers. We also provide our - perspective on ways to overcome current obstacles and establish neoadjuvant - immunotherapy as a standard of care. -CI - © 2021 The Authors. Cancer Communications published by John Wiley & Sons - Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center. -FAU - Kang, Jin -AU - Kang J -AUID- ORCID: 0000-0002-3160-5403 -AD - Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of - Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, - Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, Guangdong, - 510080, P. R. China. -FAU - Zhang, Chao -AU - Zhang C -AD - Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of - Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, - Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, Guangdong, - 510080, P. R. China. -FAU - Zhong, Wen-Zhao -AU - Zhong WZ -AD - Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of - Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, - Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, Guangdong, - 510080, P. R. China. -AD - Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20210310 -PL - United States -TA - Cancer Commun (Lond) -JT - Cancer communications (London, England) -JID - 101723675 -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -MH - Neoadjuvant Therapy -MH - Neoplasm Recurrence, Local -PMC - PMC8045926 -OTO - NOTNLM -OT - chemoimmunotherapy -OT - clinical trials -OT - imaging -OT - immunotherapy -OT - neoadjuvant -OT - non-small cell lung cancer -OT - perioperative -OT - radiotherapy -OT - surgery -COIS- The authors declare that they have no competing interests. -EDAT- 2021/03/11 06:00 -MHDA- 2021/10/21 06:00 -PMCR- 2021/03/10 -CRDT- 2021/03/10 12:38 -PHST- 2021/03/02 00:00 [revised] -PHST- 2020/12/09 00:00 [received] -PHST- 2021/03/03 00:00 [accepted] -PHST- 2021/03/11 06:00 [pubmed] -PHST- 2021/10/21 06:00 [medline] -PHST- 2021/03/10 12:38 [entrez] -PHST- 2021/03/10 00:00 [pmc-release] -AID - CAC212153 [pii] -AID - 10.1002/cac2.12153 [doi] -PST - ppublish -SO - Cancer Commun (Lond). 2021 Apr;41(4):287-302. doi: 10.1002/cac2.12153. Epub 2021 - Mar 10. - -PMID- 35500460 -OWN - NLM -STAT- MEDLINE -DCOM- 20220613 -LR - 20220702 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 169 -DP - 2022 Jul -TI - Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. -PG - 42-53 -LID - S0959-8049(22)00182-4 [pii] -LID - 10.1016/j.ejca.2022.03.034 [doi] -AB - BACKGROUND: The current standard treatment for limited-stage small-cell lung - cancer (LS-SCLC) is chemotherapy with concurrent chemoradiotherapy (CCRT). - METHODS: In this single-arm phase II study, patients with LS-SCLC received four - cycles of etoposide, cisplatin, and durvalumab every 3 weeks. Thoracic - radiotherapy of 52.5 Gy in 25 once-daily fractions was started with the third - cycle of chemoimmunotherapy. After CCRT plus durvalumab, patients received - durvalumab consolidation therapy every 4 weeks for a maximum of 2 years after - study enrolment. Prophylactic cranial irradiation (PCI) was recommended. RESULTS: - Fifty-one patients were enrolled, and 50 were included in the full analysis set. - With the median follow-up duration of 26.6 months, the median PFS was 14.4 months - (95% confidence interval: 10.3-NA), and the 24-month PFS rate was 42.0%. The - median overall survival was not reached with a 24-month overall survival rate of - 67.8%. The positive PD-L1 group (n = 22) was not associated with longer PFS - (hazard ratio, 0.70; 0.31-1.58) and overall survival (0.64; 0.22-1.84) compared - with the negative PD-L1 group (n = 20). Among the 43 patients who were candidates - for PCI treatment, the PCI group (n = 22) had significantly fewer events of brain - metastasis as the first failure sites compared to the no PCI group (n = 21) - (13.6% vs. 42.9%, P = 0.033). There were several grade 3 or 4 adverse events - which were well managed with appropriate supportive care. CONCLUSIONS: Durvalumab - with CCRT for LS-SCLC exhibited promising clinical efficacy with a tolerable - safety profile, prompting its validation in a randomized study. TRIAL - REGISTRATION: NCT03585998. -CI - Copyright © 2022 Elsevier Ltd. All rights reserved. -FAU - Park, Sehhoon -AU - Park S -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. -FAU - Noh, Jae Myoung -AU - Noh JM -AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University - School of Medicine, Seoul, Republic of Korea. -FAU - Choi, Yoon-La -AU - Choi YL -AD - Department of Pathology and Translational Genomics, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. -FAU - Chi, Sang Ah -AU - Chi SA -AD - Department of Health Sciences and Technology, Samsung Advanced Institute for - Health Sciences & Technology, Sungkyunkwan University, Seoul, Republic of Korea. -FAU - Kim, Kyunga -AU - Kim K -AD - Biomedical Statistics Center, Research Institute for Future Medicine, Samsung - Medical Center, Seoul, Republic of Korea. -FAU - Jung, Hyun Ae -AU - Jung HA -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. -FAU - Lee, Se-Hoon -AU - Lee SH -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. -FAU - Ahn, Jin Seok -AU - Ahn JS -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. -FAU - Ahn, Myung-Ju -AU - Ahn MJ -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. -FAU - Sun, Jong-Mu -AU - Sun JM -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic - address: jongmu.sun@skku.edu. -LA - eng -SI - ClinicalTrials.gov/NCT03585998 -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20220429 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (B7-H1 Antigen) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - B7-H1 Antigen -MH - Chemoradiotherapy/adverse effects -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Neoplasm Staging -MH - *Small Cell Lung Carcinoma/drug therapy -OTO - NOTNLM -OT - Durvalumab -OT - Limited-stage -OT - PD-L1 -OT - Prophylactic cranial irradiation -OT - Small-cell lung cancer -EDAT- 2022/05/03 06:00 -MHDA- 2022/06/14 06:00 -CRDT- 2022/05/02 18:24 -PHST- 2021/12/08 00:00 [received] -PHST- 2022/02/18 00:00 [revised] -PHST- 2022/03/24 00:00 [accepted] -PHST- 2022/05/03 06:00 [pubmed] -PHST- 2022/06/14 06:00 [medline] -PHST- 2022/05/02 18:24 [entrez] -AID - S0959-8049(22)00182-4 [pii] -AID - 10.1016/j.ejca.2022.03.034 [doi] -PST - ppublish -SO - Eur J Cancer. 2022 Jul;169:42-53. doi: 10.1016/j.ejca.2022.03.034. Epub 2022 Apr - 29. - -PMID- 31948903 -OWN - NLM -STAT- MEDLINE -DCOM- 20210402 -LR - 20210402 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 21 -IP - 2 -DP - 2020 Mar -TI - Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of - Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for - Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. -PG - e84-e88 -LID - S1525-7304(19)30374-2 [pii] -LID - 10.1016/j.cllc.2019.12.006 [doi] -AB - Limited-stage (LS) small-cell lung cancer (SCLC) remains an area of high unmet - medical need. The standard-of-care therapy comprises curative-intent - platinum-based chemotherapy with concurrent radiotherapy (cCRT), which can be - followed by prophylactic brain irradiation and then observation. However, most - patients will relapse. Durvalumab (antiprogrammed cell death ligand-1) has - enhanced the efficacy outcomes after cCRT for patients with unresectable, stage - III non-small-cell lung cancer. Recently, durvalumab combined with - platinum-etoposide demonstrated a significant survival benefit compared with - platinum-etoposide as first-line treatment of patients with extensive-stage SCLC - and has also shown antitumor activity as monotherapy and combined with - tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4) in pretreated - patients with extensive-stage SCLC. ADRIATIC, a phase III, randomized, - double-blind, placebo-controlled, multicenter, global study (ClinicalTrials.gov - identifier, NCT03703297), is designed to investigate the efficacy of durvalumab, - with or without tremelimumab, as consolidation therapy for patients with LS-SCLC - without disease progression after cCRT. Approximately 600 patients with - documented histologic or cytologic LS-SCLC, World Health Organization/Eastern - Cooperative Oncology Group performance status 0 or 1, and no progression after 4 - cycles of cCRT will be randomized (1:1:1) to treatment (durvalumab 1500 mg plus - placebo every 4 weeks [q4w] for 4 cycles, followed by durvalumab 1500 mg q4w; - durvalumab 1500 mg plus tremelimumab 75 mg q4w for 4 cycles, followed by - durvalumab 1500 mg q4w; or dual placebo q4w for 4 cycles, followed by single - placebo q4w) within 1 to 42 days of completing cCRT, stratified by stage and - receipt of prophylactic brain irradiation. The primary endpoints are - progression-free survival and overall survival. The secondary endpoints are - overall survival and progression-free survival rates, objective response rate, - and safety and tolerability. Recruitment began in September 2018. -CI - Copyright © 2020. Published by Elsevier Inc. -FAU - Senan, Suresh -AU - Senan S -AD - Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije - Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands. - Electronic address: s.senan@amsterdamumc.nl. -FAU - Okamoto, Isamu -AU - Okamoto I -AD - Research Institute for Diseases of the Chest, Graduate School of Medical - Sciences, Kyushu University, Fukuoka, Japan. -FAU - Lee, Gyeong-Won -AU - Lee GW -AD - Department of Internal Medicine, Gyeongsang National University Hospital, - Gyeongsang National University College of Medicine, Jinju, Gyeongsang, Republic - of Korea. -FAU - Chen, Yuanbin -AU - Chen Y -AD - Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI. -FAU - Niho, Seiji -AU - Niho S -AD - Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, - Japan. -FAU - Mak, Gabriel -AU - Mak G -AD - AstraZeneca, Gaithersburg, MD. -FAU - Yao, Wenliang -AU - Yao W -AD - AstraZeneca, Gaithersburg, MD. -FAU - Shire, Norah -AU - Shire N -AD - AstraZeneca, Gaithersburg, MD. -FAU - Jiang, Haiyi -AU - Jiang H -AD - AstraZeneca, Gaithersburg, MD. -FAU - Cho, Byoung Chul -AU - Cho BC -AD - Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea. -LA - eng -SI - ClinicalTrials.gov/NCT03703297 -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -DEP - 20191228 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 28X28X9OKV (durvalumab) -RN - QEN1X95CIX (tremelimumab) -SB - IM -MH - Adolescent -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal/administration & dosage -MH - Antibodies, Monoclonal, Humanized/administration & dosage -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Chemoradiotherapy -MH - Double-Blind Method -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology/therapy -MH - Male -MH - Middle Aged -MH - Prognosis -MH - *Research Design -MH - Small Cell Lung Carcinoma/*drug therapy/pathology/therapy -MH - Young Adult -OTO - NOTNLM -OT - Clinical study -OT - Cytotoxic T-lymphocyte–associated antigen-4 -OT - Immunotherapy -OT - Programmed cell death ligand-1 -OT - SCLC -EDAT- 2020/01/18 06:00 -MHDA- 2021/04/07 06:00 -CRDT- 2020/01/18 06:00 -PHST- 2019/11/21 00:00 [received] -PHST- 2019/12/23 00:00 [accepted] -PHST- 2020/01/18 06:00 [pubmed] -PHST- 2021/04/07 06:00 [medline] -PHST- 2020/01/18 06:00 [entrez] -AID - S1525-7304(19)30374-2 [pii] -AID - 10.1016/j.cllc.2019.12.006 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2020 Mar;21(2):e84-e88. doi: 10.1016/j.cllc.2019.12.006. Epub - 2019 Dec 28. - -PMID- 36307040 -OWN - NLM -STAT- MEDLINE -DCOM- 20230126 -LR - 20231227 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 18 -IP - 2 -DP - 2023 Feb -TI - Treatment Characteristics and Real-World Progression-Free Survival in Patients - With Unresectable Stage III NSCLC Who Received Durvalumab After - Chemoradiotherapy: Findings From the PACIFIC-R Study. -PG - 181-193 -LID - S1556-0864(22)01853-6 [pii] -LID - 10.1016/j.jtho.2022.10.003 [doi] -AB - INTRODUCTION: The phase 3 PACIFIC trial established consolidation therapy with - durvalumab as standard of care for patients with unresectable, stage III NSCLC - and no disease progression after definitive chemoradiotherapy (CRT). The - observational PACIFIC-R study assesses the real-world effectiveness of durvalumab - in patients from an early access program. Here, we report treatment - characteristics and a preplanned analysis of real-world progression-free survival - (rwPFS). METHODS: PACIFIC-R (NCT03798535) is an ongoing, international, - retrospective study of patients who started durvalumab (intravenously; 10 mg/kg - every 2 wk) within an early access program between September 2017 and December - 2018. The primary end points are investigator-assessed rwPFS and overall survival - (analyzed by Kaplan-Meier method). RESULTS: As of November 30, 2020, the full - analysis set comprised 1399 patients from 11 countries (median follow-up - duration, 23.5 mo). Patients received durvalumab for a median of 11.0 months. - Median rwPFS was 21.7 months (95% confidence interval: 19.1-24.5). RwPFS was - numerically longer among patients who received concurrent versus sequential CRT - (median, 23.7 versus 19.3 mo) and among patients with programmed cell - death-ligand 1 expression greater than or equal to 1% versus less than 1% (22.4 - versus 15.6 mo). Overall, 16.5% of the patients had adverse events leading to - treatment discontinuation; 9.5% of all patients discontinued because of - pneumonitis or interstitial lung disease. CONCLUSIONS: Consolidation durvalumab - after definitive CRT was well tolerated and effective in this large, real-world - cohort study of patients with unresectable, stage III NSCLC. As expected, rwPFS - was longer among patients who received concurrent versus sequential CRT and - patients with higher programmed cell death-ligand 1 expression. Nevertheless, - favorable rwPFS outcomes were observed regardless of these factors. -CI - Copyright © 2022 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Girard, Nicolas -AU - Girard N -AD - Institut du Thorax Curie Montsouris, Institut Curie, Paris, France and UVSQ, - Paris Saclay, Versailles, France. Electronic address: nicolas.girard2@curie.fr. -FAU - Bar, Jair -AU - Bar J -AD - Institute of Oncology, Sheba Medical Centre, Ramat Gan, Israel; Faculty of - Medicine, Tel Aviv University, Tel Aviv, Israel. -FAU - Garrido, Pilar -AU - Garrido P -AD - Medical Oncology Department, Hospital Ramón y Cajal, Universidad de Alcalá, - Madrid, Spain. -FAU - Garassino, Marina C -AU - Garassino MC -AD - Department of Hematology/Oncology, The University of Chicago, Chicago, Illinois. -FAU - McDonald, Fiona -AU - McDonald F -AD - Lung Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom. -FAU - Mornex, Françoise -AU - Mornex F -AD - Department of Radiation Oncology, Centre Hospitalier Universitaire de Lyon, Lyon, - France. -FAU - Filippi, Andrea R -AU - Filippi AR -AD - Radiation Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere - Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy. -FAU - Smit, Hans J M -AU - Smit HJM -AD - Department of Pulmonary Diseases, Rijnstate Hospital, Arnhem, The Netherlands. -FAU - Peters, Solange -AU - Peters S -AD - Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, - Switzerland. -FAU - Field, John K -AU - Field JK -AD - Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical - Cancer Medicine, University of Liverpool, Liverpool, United Kingdom. -FAU - Christoph, Daniel C -AU - Christoph DC -AD - Department of Medical Oncology/Hematology, Evang. Kliniken Essen-Mitte, Evang. - Huyssens-Stiftung Essen-Huttrop, Essen, Germany. -FAU - Sibille, Anne -AU - Sibille A -AD - Department of Pneumology and Allergology, Centre Hospitalier Universitaire de - Liège, Liège, Belgium. -FAU - Fietkau, Rainer -AU - Fietkau R -AD - Department of Radiation Oncology, Universitätsklinikums Erlangen, Erlangen, - Germany. -FAU - Haakensen, Vilde D -AU - Haakensen VD -AD - Department of Oncology and Institute for Cancer Research, Oslo University - Hospital, Oslo, Norway. -FAU - Chouaid, Christos -AU - Chouaid C -AD - Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, Créteil, - France. -FAU - Markman, Ben -AU - Markman B -AD - Cabrini Hospital and Monash University, Melbourne, Victoria, Australia. -FAU - Hiltermann, T Jeroen N -AU - Hiltermann TJN -AD - University of Groningen, Department of Pulmonary Diseases, University Medical - Center Groningen, Groningen, The Netherlands. -FAU - Taus, Alvaro -AU - Taus A -AD - Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain. -FAU - Sawyer, William -AU - Sawyer W -AD - AstraZeneca, Cambridge, United Kingdom. -FAU - Allen, Allison -AU - Allen A -AD - AstraZeneca, Gaithersburg, Maryland. -FAU - Chander, Pratibha -AU - Chander P -AD - AstraZeneca, Gaithersburg, Maryland. -FAU - Licour, Muriel -AU - Licour M -AD - AstraZeneca, Courbevoie, France. -FAU - Solomon, Benjamin -AU - Solomon B -AD - Department of Medical Oncology, Peter MacCallum Cancer Centre and University of - Melbourne, Victoria, Australia. -LA - eng -SI - ClinicalTrials.gov/NCT03798535 -PT - Journal Article -PT - Observational Study -PT - Research Support, Non-U.S. Gov't -DEP - 20221025 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 28X28X9OKV (durvalumab) -RN - 0 (Ligands) -SB - IM -CIN - J Thorac Oncol. 2023 Feb;18(2):133-135. doi: 10.1016/j.jtho.2022.11.015. PMID: - 36682838 -CIN - J Thorac Oncol. 2023 Apr;18(4):e38-e39. doi: 10.1016/j.jtho.2022.11.002. PMID: - 36990576 -MH - Humans -MH - *Antineoplastic Agents, Immunological/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Cohort Studies -MH - Ligands -MH - *Lung Neoplasms/drug therapy -MH - Progression-Free Survival -MH - Retrospective Studies -OTO - NOTNLM -OT - Consolidation therapy -OT - Immunotherapy -OT - Locally advanced NSCLC -OT - PD-L1 inhibition -OT - Real-world data -EDAT- 2022/10/29 06:00 -MHDA- 2023/01/25 06:00 -CRDT- 2022/10/28 19:27 -PHST- 2022/05/10 00:00 [received] -PHST- 2022/09/16 00:00 [revised] -PHST- 2022/10/02 00:00 [accepted] -PHST- 2022/10/29 06:00 [pubmed] -PHST- 2023/01/25 06:00 [medline] -PHST- 2022/10/28 19:27 [entrez] -AID - S1556-0864(22)01853-6 [pii] -AID - 10.1016/j.jtho.2022.10.003 [doi] -PST - ppublish -SO - J Thorac Oncol. 2023 Feb;18(2):181-193. doi: 10.1016/j.jtho.2022.10.003. Epub - 2022 Oct 25. - -PMID- 35961520 -OWN - NLM -STAT- MEDLINE -DCOM- 20221123 -LR - 20240226 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 17 -IP - 12 -DP - 2022 Dec -TI - Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: - The Phase 2 PACIFIC-6 Trial. -PG - 1415-1427 -LID - S1556-0864(22)01500-3 [pii] -LID - 10.1016/j.jtho.2022.07.1148 [doi] -AB - INTRODUCTION: On the basis of the findings of the phase 3 PACIFIC trial - (NCT02125461), durvalumab is standard of care for patients with stage III, - unresectable NSCLC and no disease progression after concurrent chemoradiotherapy - (cCRT). Many patients are considered unsuitable for cCRT owing to concerns with - tolerability. The phase 2 PACIFIC-6 trial (NCT03693300) evaluates the safety and - tolerability of durvalumab after sequential CRT (sCRT). METHODS: Patients with - stage III, unresectable NSCLC and no progression after platinum-based sCRT were - enrolled to receive durvalumab (1500 mg intravenously) every 4 weeks for up to 24 - months. The primary end point was the incidence of grade 3 or 4 adverse events - possibly related to treatment occurring within 6 months. Secondary end points - included investigator-assessed progression-free survival (PFS; Response - Evaluation Criteria in Solid Tumors version 1.1) and overall survival. RESULTS: - Overall, 117 patients were enrolled (59.8% with performance status >0, 65.8% aged - ≥65 y, and 37.6% with stage IIIA disease). Median treatment duration was 32.0 - weeks; 37.6% of patients remained on treatment at data cutoff (July 15, 2021). - Grade 3 or 4 AEs occurred in 18.8% of patients. Five patients had grade 3 or 4 - possibly related adverse events within 6 months (incidence: 4.3%; 95% confidence - interval: 1.4-9.7), including two pneumonitis cases. Two patients (1.7%) had - grade 5 AEs of any cause. Survival data maturity was limited. Median PFS was 10.9 - months (95% confidence interval: 7.3-15.6), and 12-month PFS and overall survival - rates were 49.6% and 84.1%, respectively. CONCLUSIONS: Durvalumab after sCRT had - a comparable safety profile with that observed with durvalumab after cCRT in - PACIFIC and had encouraging preliminary efficacy in a frailer population. -CI - Copyright © 2022 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Garassino, Marina C -AU - Garassino MC -AD - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of - Hematology/Oncology, The University of Chicago, Chicago, Illinois. Electronic - address: mgarassino@medicine.bsd.uchicago.edu. -FAU - Mazieres, Julien -AU - Mazieres J -AD - Centre Hospitalier Universitaire, Université Paul Sabatier, Toulouse, France. -FAU - Reck, Martin -AU - Reck M -AD - Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung - Research, Grosshansdorf, Germany. -FAU - Chouaid, Christos -AU - Chouaid C -AD - Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, Créteil, - France. -FAU - Bischoff, Helge -AU - Bischoff H -AD - Thoraxklinik Heidelberg, Heidelberg, Germany. -FAU - Reinmuth, Niels -AU - Reinmuth N -AD - Asklepios Fachkliniken München-Gauting, German Center for Lung Research, Gauting, - Germany. -FAU - Cove-Smith, Laura -AU - Cove-Smith L -AD - The Christie NHS Foundation Trust and Manchester University Hospitals Foundation - Trust, Manchester, United Kingdom. -FAU - Mansy, Talal -AU - Mansy T -AD - South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom. -FAU - Cortinovis, Diego -AU - Cortinovis D -AD - Oncology Unit, ASST-Monza, San Gerardo Hospital, Monza, Italy. -FAU - Migliorino, Maria R -AU - Migliorino MR -AD - San Camillo-Forlanini Hospital, Rome, Italy. -FAU - Delmonte, Angelo -AU - Delmonte A -AD - IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, - Italy. -FAU - Sánchez, José Garcia -AU - Sánchez JG -AD - Medical Oncology Department, Hospital Arnau de Vilanova, Fundación para el - Fomento de la Investigación Sanitaria i Biomédica de la Comunidad Valenciana - (FISABIO), Valencia, Spain. -FAU - Chara Velarde, Luis Enrique -AU - Chara Velarde LE -AD - Hospital Universitario de Guadalajara, Guadalajara, Spain. -FAU - Bernabe, Reyes -AU - Bernabe R -AD - Hospital Universitario Virgen del Rocio, Seville, Spain. -FAU - Paz-Ares, Luis -AU - Paz-Ares L -AD - Universidad Complutense, CiberOnc, CNIO and Hospital Universitario 12 de Octubre, - Madrid, Spain. -FAU - Perez, Ignacio Diaz -AU - Perez ID -AD - AstraZeneca, Gaithersburg, Maryland. -FAU - Trunova, Nataliya -AU - Trunova N -AD - AstraZeneca, Gaithersburg, Maryland. -FAU - Foroutanpour, Kayhan -AU - Foroutanpour K -AD - AstraZeneca, Gaithersburg, Maryland. -FAU - Faivre-Finn, Corinne -AU - Faivre-Finn C -AD - The University of Manchester and The Christie NHS Foundation Trust, Manchester, - United Kingdom. -LA - eng -SI - ClinicalTrials.gov/NCT03693300 -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20220809 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 28X28X9OKV (durvalumab) -SB - IM -CIN - J Thorac Oncol. 2022 Dec;17(12):1330-1332. doi: 10.1016/j.jtho.2022.08.019. PMID: - 36410966 -CIN - J Thorac Oncol. 2023 Jan;18(1):e1-e2. doi: 10.1016/j.jtho.2022.09.002. PMID: - 36543435 -CIN - J Thorac Oncol. 2024 Jan;19(1):173-174. doi: 10.1016/j.jtho.2023.08.013. PMID: - 38185511 -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Neoplasm Staging -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -OTO - NOTNLM -OT - Durvalumab -OT - Immunotherapy -OT - Locally advanced -OT - Non–small-cell lung cancer -OT - Sequential chemoradiotherapy -EDAT- 2022/08/13 06:00 -MHDA- 2022/11/24 06:00 -CRDT- 2022/08/12 19:26 -PHST- 2022/05/26 00:00 [received] -PHST- 2022/07/15 00:00 [revised] -PHST- 2022/07/20 00:00 [accepted] -PHST- 2022/08/13 06:00 [pubmed] -PHST- 2022/11/24 06:00 [medline] -PHST- 2022/08/12 19:26 [entrez] -AID - S1556-0864(22)01500-3 [pii] -AID - 10.1016/j.jtho.2022.07.1148 [doi] -PST - ppublish -SO - J Thorac Oncol. 2022 Dec;17(12):1415-1427. doi: 10.1016/j.jtho.2022.07.1148. Epub - 2022 Aug 9. - -PMID- 38740994 -OWN - NLM -STAT- MEDLINE -DCOM- 20240619 -LR - 20240808 -IS - 1546-170X (Electronic) -IS - 1078-8956 (Print) -IS - 1078-8956 (Linking) -VI - 30 -IP - 6 -DP - 2024 Jun -TI - Association between pretreatment emotional distress and immune checkpoint - inhibitor response in non-small-cell lung cancer. -PG - 1680-1688 -LID - 10.1038/s41591-024-02929-4 [doi] -AB - Emotional distress (ED), commonly characterized by symptoms of depression and/or - anxiety, is prevalent in patients with cancer. Preclinical studies suggest that - ED can impair antitumor immune responses, but few clinical studies have explored - its relationship with response to immune checkpoint inhibitors (ICIs). Here we - report results from cohort 1 of the prospective observational STRESS-LUNG study, - which investigated the association between ED and clinical efficacy of first-line - treatment of ICIs in patients with advanced non-small-cell lung cancer. ED was - assessed by Patient Health Questionnaire-9 and Generalized Anxiety Disorder - 7-item scale. The study included 227 patients with 111 (48.9%) exhibiting ED who - presented depression (Patient Health Questionnaire-9 score ≥5) and/or anxiety - (Generalized Anxiety Disorder 7-item score ≥5) symptoms at baseline. On the - primary endpoint analysis, patients with baseline ED exhibited a significantly - shorter median progression-free survival compared with those without ED - (7.9 months versus 15.5 months, hazard ratio 1.73, 95% confidence interval 1.23 - to 2.43, P = 0.002). On the secondary endpoint analysis, ED was associated with - lower objective response rate (46.8% versus 62.1%, odds ratio 0.54, P = 0.022), - reduced 2-year overall survival rate of 46.5% versus 64.9% (hazard ratio for - death 1.82, 95% confidence interval 1.12 to 2.97, P = 0.016) and detriments in - quality of life. The exploratory analysis indicated that the ED group showed - elevated blood cortisol levels, which was associated with adverse survival - outcomes. This study suggests that there is an association between ED and worse - clinical outcomes in patients with advanced non-small-cell lung cancer treated - with ICIs, highlighting the potential significance of addressing ED in cancer - management. ClinicalTrials.gov registration: NCT05477979 . -CI - © 2024. The Author(s). -FAU - Zeng, Yue -AU - Zeng Y -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -AD - National Clinical Research Center for Mental Disorders, and National Center for - Mental Disorders, The Second Xiangya Hospital of Central South University, - Changsha, China. -FAU - Hu, Chun-Hong -AU - Hu CH -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -AD - Hunan Cancer Mega-Data Intelligent Application and Engineering Research Centre, - Changsha, China. -FAU - Li, Yi-Zheng -AU - Li YZ -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -AD - Key Laboratory of Molecular Radiation Oncology Hunan Province, Xiangya Hospital, - Central South University, Changsha, China. -FAU - Zhou, Jian-Song -AU - Zhou JS -AD - National Clinical Research Center for Mental Disorders, and National Center for - Mental Disorders, The Second Xiangya Hospital of Central South University, - Changsha, China. -FAU - Wang, Shu-Xing -AU - Wang SX -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -AD - Xiangya School of Medicine, Central South University, Changsha, China. -FAU - Liu, Meng-Dong -AU - Liu MD -AD - Department of Psychology, University of Washington, Seattle, WA, USA. -FAU - Qiu, Zhen-Hua -AU - Qiu ZH -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Deng, Chao -AU - Deng C -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Ma, Fang -AU - Ma F -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Xia, Chun-Fang -AU - Xia CF -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Liang, Fei -AU - Liang F -AUID- ORCID: 0000-0002-4184-7844 -AD - Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, - China. -FAU - Peng, Yu-Rong -AU - Peng YR -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Liang, Ao-Xi -AU - Liang AX -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Shi, Sheng-Hao -AU - Shi SH -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Yao, Shi-Jiao -AU - Yao SJ -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Liu, Jun-Qi -AU - Liu JQ -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Xiao, Wen-Jie -AU - Xiao WJ -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -AD - Xiangya School of Medicine, Central South University, Changsha, China. -FAU - Lin, Xiao-Qiao -AU - Lin XQ -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -AD - Xiangya School of Medicine, Central South University, Changsha, China. -FAU - Tian, Xin-Yu -AU - Tian XY -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -AD - Xiangya School of Medicine, Central South University, Changsha, China. -FAU - Zhang, Ying-Zhe -AU - Zhang YZ -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Tian, Zhuo-Ying -AU - Tian ZY -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Zou, Ji-An -AU - Zou JA -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -AD - Xiangya School of Medicine, Central South University, Changsha, China. -FAU - Li, Yun-Shu -AU - Li YS -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -AD - Xiangya School of Medicine, Central South University, Changsha, China. -FAU - Xiao, Chao-Yue -AU - Xiao CY -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Xu, Tian -AU - Xu T -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Zhang, Xiao-Jie -AU - Zhang XJ -AD - National Clinical Research Center for Mental Disorders, and National Center for - Mental Disorders, The Second Xiangya Hospital of Central South University, - Changsha, China. -FAU - Wang, Xiao-Ping -AU - Wang XP -AD - National Clinical Research Center for Mental Disorders, and National Center for - Mental Disorders, The Second Xiangya Hospital of Central South University, - Changsha, China. -FAU - Liu, Xian-Ling -AU - Liu XL -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Wu, Fang -AU - Wu F -AUID- ORCID: 0000-0002-6627-3437 -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. wufang4461@csu.edu.cn. -AD - National Clinical Research Center for Mental Disorders, and National Center for - Mental Disorders, The Second Xiangya Hospital of Central South University, - Changsha, China. wufang4461@csu.edu.cn. -AD - Hunan Cancer Mega-Data Intelligent Application and Engineering Research Centre, - Changsha, China. wufang4461@csu.edu.cn. -AD - Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second - Xiangya Hospital, Central South University, Changsha, China. - wufang4461@csu.edu.cn. -AD - Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, The - Second Xiangya Hospital, Central South University, Changsha, China. - wufang4461@csu.edu.cn. -AD - FuRong Laboratory, Changsha, China. wufang4461@csu.edu.cn. -LA - eng -SI - ClinicalTrials.gov/NCT05477979 -GR - kq1907077/Science and Technology Bureau, Changsha (Changsha Municipal Science and - Technology Bureau)/ -GR - 295228/Education Department of Hunan Province (Hunan Province Education - Department)/ -GR - Y-HS202102-0130/Chinese Society of Clinical Oncology (Chinese Society of Clinical - Oncology, Beijing Xisike Clinical Oncology Research Foundation)/ -GR - 82272806/National Natural Science Foundation of China (National Science - Foundation of China)/ -GR - 2021JJ20088/Natural Science Foundation of Hunan Province (Hunan Provincial - Natural Science Foundation)/ -PT - Journal Article -PT - Observational Study -DEP - 20240513 -PL - United States -TA - Nat Med -JT - Nature medicine -JID - 9502015 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/immunology/pathology -MH - *Immune Checkpoint Inhibitors/therapeutic use/adverse effects -MH - Female -MH - Male -MH - *Lung Neoplasms/drug therapy/immunology -MH - Middle Aged -MH - Aged -MH - *Psychological Distress -MH - Prospective Studies -MH - Depression/drug therapy -MH - Anxiety/drug therapy -MH - Treatment Outcome -MH - Progression-Free Survival -MH - Adult -MH - Aged, 80 and over -PMC - PMC11186781 -COIS- The authors declare no competing interests. -EDAT- 2024/05/14 00:43 -MHDA- 2024/06/20 00:42 -PMCR- 2024/05/13 -CRDT- 2024/05/13 23:44 -PHST- 2023/10/17 00:00 [received] -PHST- 2024/03/18 00:00 [accepted] -PHST- 2024/06/20 00:42 [medline] -PHST- 2024/05/14 00:43 [pubmed] -PHST- 2024/05/13 23:44 [entrez] -PHST- 2024/05/13 00:00 [pmc-release] -AID - 10.1038/s41591-024-02929-4 [pii] -AID - 2929 [pii] -AID - 10.1038/s41591-024-02929-4 [doi] -PST - ppublish -SO - Nat Med. 2024 Jun;30(6):1680-1688. doi: 10.1038/s41591-024-02929-4. Epub 2024 May - 13. - -PMID- 35576956 -OWN - NLM -STAT- MEDLINE -DCOM- 20220606 -LR - 20220622 -IS - 1474-5488 (Electronic) -IS - 1470-2045 (Linking) -VI - 23 -IP - 6 -DP - 2022 Jun -TI - Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for - extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, - double-blind, placebo-controlled, phase 3 trial. -PG - 739-747 -LID - S1470-2045(22)00224-8 [pii] -LID - 10.1016/S1470-2045(22)00224-8 [doi] -AB - BACKGROUND: Extensive-stage small-cell lung cancer (ES-SCLC) is associated with - poor prognosis and treatment options are scarce. Immunotherapy has shown robust - clinical activity in ES-SCLC in previous phase 3 trials. We aimed to assess the - efficacy and safety of adebrelimab (SHR-1316), a novel anti-PD-L1 antibody, with - standard chemotherapy as a first-line treatment for ES-SCLC. METHODS: The - CAPSTONE-1 study was a randomised, double-blind, placebo-controlled, phase 3 - trial, done in 47 tertiary hospitals in China. Key inclusion criteria were - patients aged 18-75 years, with previously untreated histologically or - cytologically confirmed ES-SCLC and an Eastern Cooperative Oncology Group (ECOG) - performance status of 0-1. Eligible patients were randomly assigned (1:1) to - receive four to six cycles of carboplatin (area under the curve of 5 mg/mL per - min, day 1 of each cycle) and etoposide (100 mg/m(2) of body-surface area, on - days 1-3 of each cycle) with either adebrelimab (20 mg/kg, day 1 of each cycle) - or matching placebo, followed by maintenance therapy with adebrelimab or placebo. - All treatments were given intravenously in 21-day cycles. Randomisation was done - using a centralised interactive web response system with a block size of four, - stratified by liver metastases, brain metastases, and lactate dehydrogenase - concentration. The primary endpoint was overall survival in patients who received - at least one dose of study medication. Safety was analysed in the as-treated - population. This study is complete and registered with ClinicalTrials.gov, - NCT03711305. FINDINGS: Between Dec 26, 2018, and Sept 4, 2020, 462 eligible - patients were enrolled and randomly assigned: 230 (50%) patients received - adebrelimab plus chemotherapy (adebrelimab group) and 232 (50%) patients received - placebo plus chemotherapy (placebo group). At data cutoff (Oct 8, 2021), median - follow-up was 13·5 months (IQR 8·9-20·1). Median overall survival was - significantly improved in the adebrelimab group (median 15·3 months [95% CI - 13·2-17·5]) compared with the placebo group (12·8 months [11·3-13·7]; hazard - ratio 0·72 [95% CI 0·58-0·90]; one-sided p=0·0017). The most common - treatment-related grade 3 or 4 adverse events were decreased neutrophil count - (174 [76%] patients in the adebrelimab group and 175 [75%] patients in the - placebo group), decreased white blood cell count (106 [46%] and 88 [38%]), - decreased platelet count (88 [38%] and 78 [34%]), and anaemia (64 [28%] and 66 - [28%]). Treatment-related serious adverse events occurred in 89 (39%) patients in - the adebrelimab group and 66 (28%) patients in the placebo group. Four - treatment-related deaths were reported: two each in the adebrelimab group - (respiratory failure and interstitial lung disease and pneumonia) and placebo - group (multiple organ dysfunction and unknown cause of death). INTERPRETATION: - Adding adebrelimab to chemotherapy significantly improved overall survival with - an acceptable safety profile in patients with ES-SCLC, supporting this - combination as a new first-line treatment option for this population. FUNDING: - Jiangsu Hengrui Pharmaceuticals. -CI - Copyright © 2022 Elsevier Ltd. All rights reserved. -FAU - Wang, Jie -AU - Wang J -AD - Department of Medical Oncology, National Cancer Center, National Clinical - Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences - & Peking Union Medical College, Beijing, China. -FAU - Zhou, Caicun -AU - Zhou C -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai, China. -FAU - Yao, Wenxiu -AU - Yao W -AD - Department of Thoracic Oncology, Sichuan Cancer Hospital & Institute, Chengdu, - China. -FAU - Wang, Qiming -AU - Wang Q -AD - Department of Internal Medicine, Henan Cancer Hospital, Affiliated Cancer - Hospital of Zhengzhou University, Zhengzhou, China. -FAU - Min, Xuhong -AU - Min X -AD - Department of Tumor Radiotherapy, Anhui Chest Hospital, Hefei, China. -FAU - Chen, Gongyan -AU - Chen G -AD - Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, - Harbin, China. -FAU - Xu, Xingxiang -AU - Xu X -AD - Department of Respiratory Medicine, Northern Jiangsu People's Hospital, Yangzhou, - China. -FAU - Li, Xingya -AU - Li X -AD - Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou - University, Zhengzhou, China. -FAU - Xu, Fei -AU - Xu F -AD - Department of Respiratory Medicine, The First Affiliated Hospital of Nanchang - University, Nanchang, China. -FAU - Fang, Yong -AU - Fang Y -AD - Department of Medical Oncology, Sir Run Run Shaw Hospital Zhejiang University - School of Medicine, Hangzhou, China. -FAU - Yang, Runxiang -AU - Yang R -AD - Department of Internal Medicine, Yunnan Cancer Hospital, Kunming, China. -FAU - Yu, Guohua -AU - Yu G -AD - Department of Medical Oncology, Weifang People's Hospital, Weifang, China. -FAU - Gong, Youling -AU - Gong Y -AD - Department of Thoracic Oncology, West China Hospital, Sichuan University, - Chengdu, China. -FAU - Zhao, Jun -AU - Zhao J -AD - Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, China. -FAU - Fan, Yun -AU - Fan Y -AD - Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China. -FAU - Liu, Quan -AU - Liu Q -AD - Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China. -FAU - Cao, Lejie -AU - Cao L -AD - Department of Respiratory Medicine, Affiliated Hospital of University of Science - and Technology of China, Anhui Provincial Hospital, Hefei, China. -FAU - Yao, Yu -AU - Yao Y -AD - Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, China. -FAU - Liu, Yunpeng -AU - Liu Y -AD - Department of Oncology, The First Hospital of China Medical University, Shenyang, - China. -FAU - Li, Xiaoling -AU - Li X -AD - Department of Thoracic Surgery, Liaoning Cancer Hospital & Institute, Shenyang, - China. -FAU - Wu, Jingxun -AU - Wu J -AD - Department of Oncology, The First Affiliated Hospital of Xiamen University, - Xiamen, China. -FAU - He, Zhiyong -AU - He Z -AD - Department of Thoracic Medical Oncology, Fujian Medical University Cancer - Hospital/Fujian Cancer Hospital, Fuzhou, China. -FAU - Lu, Kaihua -AU - Lu K -AD - Department of Oncology, Jiangsu Province Hospital, Nanjing, China. -FAU - Jiang, Liyan -AU - Jiang L -AD - Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai, China. -FAU - Hu, Chengping -AU - Hu C -AD - Department of Respiratory Medicine, Xiangya Hospital of Central South University, - Changsha, China. -FAU - Zhao, Wenhua -AU - Zhao W -AD - Department of Respiratory Oncology, Guangxi Medical University Affiliated Tumour - Hospital, Nanning, China. -FAU - Zhang, Ben -AU - Zhang B -AD - Jiangsu Hengrui Pharmaceuticals, Shanghai, China. -FAU - Shi, Wei -AU - Shi W -AD - Jiangsu Hengrui Pharmaceuticals, Shanghai, China. -FAU - Zhang, Xiaojing -AU - Zhang X -AD - Jiangsu Hengrui Pharmaceuticals, Shanghai, China. -FAU - Cheng, Ying -AU - Cheng Y -AD - Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China. - Electronic address: jl.cheng@163.com. -CN - CAPSTONE-1 Study Group -LA - eng -SI - ClinicalTrials.gov/NCT03711305 -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20220513 -PL - England -TA - Lancet Oncol -JT - The Lancet. Oncology -JID - 100957246 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 6PLQ3CP4P3 (Etoposide) -RN - BG3F62OND5 (Carboplatin) -SB - IM -CIN - Lancet Oncol. 2022 Jun;23(6):692-693. doi: 10.1016/S1470-2045(22)00288-1. PMID: - 35576958 -MH - Antibodies, Monoclonal/adverse effects -MH - Antibodies, Monoclonal, Humanized -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - Carboplatin -MH - Double-Blind Method -MH - Etoposide -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - *Lung Neoplasms/pathology -MH - *Small Cell Lung Carcinoma/drug therapy -COIS- Declaration of interests CZ reports honoraria as a speaker from Roche, Lily - China, Boehringer Ingelheim, Merck, Hengrui, Qilu, Sanofi, Merck Sharp & Dohme, - Innovent Biologics, C-Stone, Luye Pharma, TopAlliance Biosciences, and Amoy - Diagnositics; and advisor fees from Innovent Biologics, Hengrui, Qilu, and - TopAlliance Biosciences. BZ, WS, and XZ are employees of Hengrui Pharmaceuticals. - All other authors declare no competing interests. -FIR - Cheng, Ying -IR - Cheng Y -FIR - Wang, Jie -IR - Wang J -FIR - Zhou, Caicun -IR - Zhou C -FIR - Yao, Wenxiu -IR - Yao W -FIR - Wang, Qiming -IR - Wang Q -FIR - Min, Xuhong -IR - Min X -FIR - Chen, Gongyan -IR - Chen G -FIR - Xu, Xingxiang -IR - Xu X -FIR - Li, Xingya -IR - Li X -FIR - Xu, Fei -IR - Xu F -FIR - Fang, Yong -IR - Fang Y -FIR - Yang, Runxiang -IR - Yang R -FIR - Yu, Guohua -IR - Yu G -FIR - Gong, Youling -IR - Gong Y -FIR - Zhao, Jun -IR - Zhao J -FIR - Fan, Yun -IR - Fan Y -FIR - Liu, Quan -IR - Liu Q -FIR - Cao, Lejie -IR - Cao L -FIR - Yao, Yu -IR - Yao Y -FIR - Liu, Yunpeng -IR - Liu Y -FIR - Li, Xiaoling -IR - Li X -FIR - Wu, Jingxun -IR - Wu J -FIR - He, Zhiyong -IR - He Z -FIR - Lu, Kaihua -IR - Lu K -FIR - Jiang, Liyan -IR - Jiang L -FIR - Hu, Chengping -IR - Hu C -FIR - Zhao, Wenhua -IR - Zhao W -FIR - Yu, Huiqing -IR - Yu H -FIR - Zhao, Jian -IR - Zhao J -FIR - Wu, Gang -IR - Wu G -FIR - Huang, Dingzhi -IR - Huang D -FIR - Chen, Chengshui -IR - Chen C -FIR - Ding, Cuimin -IR - Ding C -FIR - Zhang, Baihong -IR - Zhang B -FIR - Wang, Xiuwen -IR - Wang X -FIR - Luo, Hui -IR - Luo H -FIR - Li, Baolan -IR - Li B -FIR - Zhang, Shucai -IR - Zhang S -FIR - Lu, Hong -IR - Lu H -FIR - Shi, Meiqi -IR - Shi M -FIR - Chen, Xi -IR - Chen X -FIR - Guo, Yubiao -IR - Guo Y -FIR - Liu, Hailong -IR - Liu H -FIR - Liu, Jiwei -IR - Liu J -FIR - Gao, Hongjun -IR - Gao H -FIR - Hu, Sheng -IR - Hu S -FIR - Hong, Qunying -IR - Hong Q -FIR - Li, Qi -IR - Li Q -FIR - Zhang, Ben -IR - Zhang B -FIR - Shi, Wei -IR - Shi W -FIR - Zhang, Xiaojing -IR - Zhang X -EDAT- 2022/05/17 06:00 -MHDA- 2022/06/07 06:00 -CRDT- 2022/05/16 19:02 -PHST- 2022/03/02 00:00 [received] -PHST- 2022/04/07 00:00 [revised] -PHST- 2022/04/08 00:00 [accepted] -PHST- 2022/05/17 06:00 [pubmed] -PHST- 2022/06/07 06:00 [medline] -PHST- 2022/05/16 19:02 [entrez] -AID - S1470-2045(22)00224-8 [pii] -AID - 10.1016/S1470-2045(22)00224-8 [doi] -PST - ppublish -SO - Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub - 2022 May 13. - -PMID- 34923163 -OWN - NLM -STAT- MEDLINE -DCOM- 20220429 -LR - 20220429 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 17 -IP - 4 -DP - 2022 Apr -TI - Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced - Squamous NSCLC (CameL-Sq): A Phase 3 Trial. -PG - 544-557 -LID - S1556-0864(21)03392-X [pii] -LID - 10.1016/j.jtho.2021.11.018 [doi] -AB - INTRODUCTION: Camrelizumab, a humanized immunoglobulin G4-κ monoclonal antibody - against programmed cell death protein 1, has exhibited antitumor activity and - tolerability across various tumors, including lung cancers. We conducted this - double-blind, randomized phase 3 trial to investigate the efficacy and safety of - camrelizumab or placebo plus chemotherapy as first-line treatment for patients - with advanced squamous NSCLC. The predictive value of circulating tumor DNA - (ctDNA) dynamics was also analyzed. METHODS: CameL-sq, a double-blind, randomized - phase 3 trial (NCT03668496), was conducted in 53 centers in the People's Republic - of China. A total of 389 patients with stage IIIB-IV squamous NSCLC were - randomized (1:1) to receive 4 to 6 cycles of carboplatin plus paclitaxel with - camrelizumab or placebo (every 3 wk), followed by maintenance therapy with - camrelizumab or placebo. Peripheral blood ctDNA samples were collected at - baseline and the time after two cycles of treatment. RESULTS: Of 389 eligible - patients, 193 patients allocated camrelizumab plus chemotherapy and 196 patients - allocated placebo plus chemotherapy were included in the efficacy and safety - analysis. The results revealed significantly prolonged progression-free survival - (median, 8.5 vs. 4.9 mo; p <0.0001) and overall survival (median, not reached vs. - 14.5 mo; p <0.0001) with camrelizumab-chemotherapy versus placebo-chemotherapy. - No unexpected treatment immune-related adverse events were observed in both - groups. Biomarker analysis revealed that ctDNA clearance after two cycles of - treatment was independently associated with dramatically longer progression-free - survival (p <0.0001) and overall survival (p <0.0001) in camrelizumab plus - chemotherapy group. CONCLUSIONS: Our findings support camrelizumab plus - chemotherapy as a first-line treatment option in advanced squamous NSCLC. - On-treatment ctDNA dynamics exhibited the potency to predict the efficacy of - camrelizumab plus chemotherapy. -CI - Copyright © 2021 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Ren, Shengxiang -AU - Ren S -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University - School of Medicine, Shanghai, People's Republic of China. -FAU - Chen, Jianhua -AU - Chen J -AD - Department of Medical Oncology-Chest (1), Hunan Cancer Hospital, Changsha, - People's Republic of China. -FAU - Xu, Xingxiang -AU - Xu X -AD - Respiratory Department, Northern Jiangsu People's Hospital, Yangzhou, People's - Republic of China. -FAU - Jiang, Tao -AU - Jiang T -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University - School of Medicine, Shanghai, People's Republic of China. -FAU - Cheng, Ying -AU - Cheng Y -AD - Department of Medical Oncology, Jilin Cancer Hospital, Changchun, People's - Republic of China. -FAU - Chen, Gongyan -AU - Chen G -AD - First Ward of Respiratory Medicine, Harbin Medical University Cancer Hospital, - Harbin, People's Republic of China. -FAU - Pan, Yueyin -AU - Pan Y -AD - Department of Chemotherapy Oncology, Anhui Provincial Hospital, Hefei, People's - Republic of China. -FAU - Fang, Yong -AU - Fang Y -AD - Department of Medical Oncology, Sir Run Run Shaw Hospital Zhejiang University - School of Medicine, Hangzhou, People's Republic of China. -FAU - Wang, Qiming -AU - Wang Q -AD - Department of Oncology, Henan Cancer Hospital, Zhengzhou, People's Republic of - China. -FAU - Huang, Yunchao -AU - Huang Y -AD - Department of Thoracic Surgery, Yunnan Cancer Hospital and the Third Affiliated - Hospital of Kunming Medical University and Yunnan Cancer Centre, Kunming, - People's Republic of China. -FAU - Yao, Wenxiu -AU - Yao W -AD - Department of Thoracic Oncology, Sichuan Provincial Cancer Hospital, Chengdu, - People's Republic of China. -FAU - Wang, Rui -AU - Wang R -AD - Department of Medical Oncology, Anhui Chest Hospital, Hefei, People's Republic of - China. -FAU - Li, Xingya -AU - Li X -AD - Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou - University, Zhengzhou, People's Republic of China. -FAU - Zhang, Wei -AU - Zhang W -AD - Department of Respiratory Medicine, The First Affiliated Hospital of Nanchang - University, Nanchang, People's Republic of China. -FAU - Zhang, Yanjun -AU - Zhang Y -AD - The 3rd departement of Medical Oncology, Shaanxi Provincial Cancer Hospital, - Xi'an, People's Republic of China. -FAU - Hu, Sheng -AU - Hu S -AD - Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, People's Republic - of China. -FAU - Guo, Renhua -AU - Guo R -AD - Department of Oncology, Jiangsu Province Hospital, Nanjing, People's Republic of - China. -FAU - Shi, Jianhua -AU - Shi J -AD - Internal Medicine Ward 2, LinYi Cancer Hospital, Linyi, People's Republic of - China. -FAU - Wang, Zhiwu -AU - Wang Z -AD - Second Department of Radiotherapy and Chemotherapy, Tangshan People's Hospital, - Tangshan, People's Republic of China. -FAU - Cao, Peiguo -AU - Cao P -AD - Oncology Department, The Third Xiangya Hospital of Central South University, - Changsha, People's Republic of China. -FAU - Wang, Donglin -AU - Wang D -AD - Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, - People's Republic of China. -FAU - Fang, Jian -AU - Fang J -AD - The Second Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, - People's Republic of China. -FAU - Luo, Hui -AU - Luo H -AD - The Second Department of Thoracic Oncology, Jiangxi Cancer Hospital, Nanchang, - People's Republic of China. -FAU - Geng, Yi -AU - Geng Y -AD - Oncology Department, Baoji Central Hospital, Baoji, People's Republic of China. -FAU - Xing, Chunyan -AU - Xing C -AD - Department of Respiratory Medicine, Jinan Central Hospital, Jinan, People's - Republic of China. -FAU - Lv, Dongqing -AU - Lv D -AD - Department of Breath Internal Medicine, Taizhou Hospital of Zhejiang Province, - Taizhou, People's Republic of China. -FAU - Zhang, Yiping -AU - Zhang Y -AD - Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, People's - Republic of China. -FAU - Yu, Junyan -AU - Yu J -AD - Department of Internal Medicine-Oncology, Heping Hospital Affiliated to Changzhi - Medical College, Changzhi, People's Republic of China. -FAU - Cang, Shundong -AU - Cang S -AD - Department of Medical Oncology, Henan Provincial People's Hospital, Zhengzhou, - People's Republic of China. -FAU - Yang, Zeyu -AU - Yang Z -AD - Department of Medicine, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, - People's Republic of China. -FAU - Shi, Wei -AU - Shi W -AD - Department of Medicine, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, - People's Republic of China. -FAU - Zou, Jianjun -AU - Zou J -AD - Department of Medicine, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, - People's Republic of China. -FAU - Zhou, Caicun -AU - Zhou C -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University - School of Medicine, Shanghai, People's Republic of China. Electronic address: - caicunzhou_dr@163.com. -CN - CameL-sq Study Group -LA - eng -SI - ClinicalTrials.gov/NCT03668496 -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20211216 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 73096E137E (camrelizumab) -RN - BG3F62OND5 (Carboplatin) -RN - P88XT4IS4D (Paclitaxel) -SB - IM -CIN - J Thorac Oncol. 2022 Apr;17(4):477-480. doi: 10.1016/j.jtho.2022.01.001. PMID: - 35307102 -MH - Animals -MH - Antibodies, Monoclonal, Humanized -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Camelus -MH - Carboplatin -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Carcinoma, Squamous Cell/drug therapy -MH - Humans -MH - *Lung Neoplasms/pathology -MH - Paclitaxel -OTO - NOTNLM -OT - Biomarker -OT - Chemotherapy -OT - Immunotherapy -OT - Lung squamous cell carcinoma -OT - PD-1 -EDAT- 2021/12/20 06:00 -MHDA- 2022/04/30 06:00 -CRDT- 2021/12/19 20:47 -PHST- 2021/10/09 00:00 [received] -PHST- 2021/11/14 00:00 [revised] -PHST- 2021/11/19 00:00 [accepted] -PHST- 2021/12/20 06:00 [pubmed] -PHST- 2022/04/30 06:00 [medline] -PHST- 2021/12/19 20:47 [entrez] -AID - S1556-0864(21)03392-X [pii] -AID - 10.1016/j.jtho.2021.11.018 [doi] -PST - ppublish -SO - J Thorac Oncol. 2022 Apr;17(4):544-557. doi: 10.1016/j.jtho.2021.11.018. Epub - 2021 Dec 16. - -PMID- 35777706 -OWN - NLM -STAT- MEDLINE -DCOM- 20220913 -LR - 20220915 -IS - 1569-8041 (Electronic) -IS - 0923-7534 (Linking) -VI - 33 -IP - 9 -DP - 2022 Sep -TI - Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the - art and novel therapeutic approaches. -PG - 893-908 -LID - S0923-7534(22)01742-2 [pii] -LID - 10.1016/j.annonc.2022.06.013 [doi] -AB - The standard of care for patients with stage III non-small-cell lung cancer - (NSCLC) is concurrent chemoradiotherapy (CCRT) followed by 1 year of adjuvant - durvalumab. Despite the survival benefit granted by immunotherapy in this - setting, only 1/3 of patients are alive and disease free at 5 years. Novel - treatment strategies are under development to improve patient outcomes in this - setting: different anti-programmed cell death protein 1/programmed death-ligand 1 - [anti-PD-(L)1] antibodies after CCRT, consolidation immunotherapy after - sequential chemoradiotherapy, induction immunotherapy before CCRT and - immunotherapy concurrent with CCRT and/or sequential chemoradiotherapy. - Cross-trial comparison is particularly challenging in this setting due to the - different timing of immunotherapy delivery and different patients' inclusion and - exclusion criteria. In this review, we present the results of clinical trials - investigating immune therapy in unresectable stage III NSCLC and discuss in-depth - their biological rationale, their pitfalls and potential benefits. Particular - emphasis is placed on the potential mechanisms of synergism between chemotherapy, - radiation therapy and different monoclonal antibodies, and how this affects the - tumor immune microenvironment. The designs and questions tackled by ongoing - clinical trials are also discussed. Last, we address open questions and unmet - clinical needs, such as the necessity for predictive biomarkers (e.g. radiomics - and circulating tumor DNA). Identifying distinct subsets of patients to tailor - anticancer treatment is a priority, especially in a heterogeneous disease such as - stage III NSCLC. -CI - Copyright © 2022 European Society for Medical Oncology. Published by Elsevier - Ltd. All rights reserved. -FAU - Cortiula, F -AU - Cortiula F -AD - Department of Radiation Oncology (Maastro), Maastricht University Medical - Centre(+), GROW School for Oncology and Reproduction, Maastricht, the - Netherlands; Department of Medical Oncology, Udine University Hospital, Udine, - Italy. -FAU - Reymen, B -AU - Reymen B -AD - Department of Radiation Oncology (Maastro), Maastricht University Medical - Centre(+), GROW School for Oncology and Reproduction, Maastricht, the - Netherlands. -FAU - Peters, S -AU - Peters S -AD - Oncology Department, Lausanne University Hospital, Lausanne, Switzerland. -FAU - Van Mol, P -AU - Van Mol P -AD - Department of Respiratory Diseases KU Leuven, Respiratory Oncology Unit, - University Hospitals KU Leuven, Leuven, Belgium. -FAU - Wauters, E -AU - Wauters E -AD - Department of Respiratory Diseases KU Leuven, Respiratory Oncology Unit, - University Hospitals KU Leuven, Leuven, Belgium. -FAU - Vansteenkiste, J -AU - Vansteenkiste J -AD - Department of Respiratory Diseases KU Leuven, Respiratory Oncology Unit, - University Hospitals KU Leuven, Leuven, Belgium. Electronic address: - yanah.vandiest@uzleuven.be. -FAU - De Ruysscher, D -AU - De Ruysscher D -AD - Department of Radiation Oncology (Maastro), Maastricht University Medical - Centre(+), GROW School for Oncology and Reproduction, Maastricht, the - Netherlands. -FAU - Hendriks, L E L -AU - Hendriks LEL -AD - Department of Pulmonary Diseases, Maastricht University Medical Centre(+), GROW - School for Oncology and Reproduction, Maastricht, the Netherlands. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20220628 -PL - England -TA - Ann Oncol -JT - Annals of oncology : official journal of the European Society for Medical - Oncology -JID - 9007735 -RN - 0 (Immunologic Factors) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - Chemoradiotherapy/methods -MH - Humans -MH - Immunologic Factors -MH - Immunotherapy/methods -MH - *Lung Neoplasms/pathology -MH - Neoplasm Staging -MH - Tumor Microenvironment -OTO - NOTNLM -OT - biomarkers -OT - circulating tumor DNA -OT - immunotherapy -OT - locally advanced NSCLC -OT - radiomics -OT - stage III NSCLC -COIS- Disclosure FC support for attending meeting: Eli-Lilly (institutional fees). SP - AbbVie, advisory board, institutional. Amgen, advisory board, institutional. - Arcus, advisory board, institutional. AstraZeneca, advisory board, institutional. - AstraZeneca, invited speaker, institutional. Bayer, advisory board, - institutional. BeiGene, advisory board, institutional. BioInvent, advisory board, - institutional. Biocartis, advisory board, institutional. Blueprint Medicines, - advisory board, institutional. Bristol Myers Squibb (BMS), advisory board, - Institutional. BMS, invited speaker, institutional. Boehringer Ingelheim, invited - speaker, institutional. Boehringer Ingelheim, advisory board, institutional. - Daiichi Sankyo, advisory board, institutional. Debiopharm, advisory board, - institutional. ecancer, invited speaker, institutional. Eli Lilly, invited - speaker, institutional. Eli Lilly, advisory board, institutional. Elsevier, - other, personal, associate Editor Annals of Oncology. F-Star, advisory board, - institutional. Fishawack, invited speaker, institutional. Foundation Medicine, - advisory board, institutional. Genzyme, advisory board, institutional. Gilead, - advisory board, institutional. GlaxoSmithKline (GSK), advisory board, - institutional. Illumina, advisory board, institutional. Illumina, invited - speaker, institutional. Imedex, invited speaker, institutional. Incyte, advisory - board, institutional. IQVIA, advisory board, institutional. iTheo, advisory - board, institutional. Janssen, advisory board, institutional. Medscape, invited - speaker, institutional. Merck Serono, advisory board, institutional. Mirati, - advisory board, institutional. Mirati, invited speaker, institutional. Merck - Sharp & Dohme (MSD), advisory board, institutional. MSD, invited speaker, - institutional. Novartis, advisory board, institutional. Novartis, invited - speaker, institutional. Novocure, advisory board, institutional. Oncology - Education, invited speaker, institutional. PER, invited speaker, institutional. - Pfizer, invited speaker, institutional. Pfizer, advisory board, institutional. - PharmaMar, advisory board, institutional. Phosplatin Therapeutics, advisory - board, institutional. PRIME, invited speaker, institutional. Regeneron, advisory - board, institutional. RMEI, invited speaker, institutional. Roche/Genentech, - advisory board, institutional. Roche/Genentech, invited speaker, institutional. - RTP, invited speaker, institutional. Sanofi, invited speaker, institutional. - Sanofi, advisory board, institutional. Seattle Genetics, advisory board, - institutional. Takeda, invited speaker, institutional. Takeda, advisory board, - institutional. Vaccibody, advisory board, institutional. No financial interest, - Coordinating PI: MERMAID-1, Steering Committee Member, MERMAID-2, POSEIDON, - MYSTIC, BGB-A317-A1217-301/AdvanTIG-301, CheckMate 743, CheckMate 73L, CheckMate - 331 and 451 RELATIVITY 095, Clinical Trial Chair ZEAL-1, Phase 2 Inupadenant with - chemo, SAPPHIRE, PEARLS, MK-7684A, LAGOON, phase I/II trials, Skyscraper-01; - ALEX; BFAST; BEAT-Meso; ImPower-030, IMforte. EW research grant: AstraZeneca; - invited speaker: AstraZeneca; support for attending meeting: AstraZeneca, - Boehringer Ingelheim, MSD, BMS, Daiichi Sankyo; advisory board: Boehringer - Ingelheim; consulting fee: MSD. Payment for manuscript writing: BMS (all - institutional fees). JV AstraZeneca, advisory board, institutional. AstraZeneca, - invited speaker, institutional BMS, advisory board, institutional. BMS, invited - speaker, institutional. Daiichi Sankyo, advisory board, institutional. Eli Lilly, - invited speaker, institutional. Janssen, invited speaker, institutional. Janssen, - advisory board, institutional. Merck, advisory board, institutional. MSD, - advisory board, institutional. Novartis, advisory board, institutional. Novartis, - invited speaker, institutional. PDC∗line, advisory board, institutional. Pfizer, - advisory board, institutional. Roche, advisory board, institutional. Roche, - invited speaker, institutional. Sanofi, advisory board, institutional. MSD, - research grant, institutional. DDR investigator initiated study: AstraZeneca, - BMS, BeiGene; research support: AstraZeneca, Philips, advisory board. - AstraZeneca, BMS, Philips (all institutional fees). LELH Outside of current - manuscript: research funding Roche Genentech, AstraZeneca, Boehringer Ingelheim, - Takeda (all institution, BeiGene under negotiation); advisory board: BMS, Eli - Lilly, Roche Genentech, Pfizer, Takeda, MSD, Merck, Novartis, Boehringer - Ingelheim, Amgen, Janssen (all institution, Roche one time self); speaker: MSD, - Lilly, AstraZeneca (institution); travel/conference reimbursement: Roche - Genentech (self); mentorship program with key opinion leaders: funded by - AstraZeneca; fees for educational webinars/podcast: Benecke, Medtalks, VJOncology - (self), high5oncology, Takeda (institution); interview sessions funded by Roche - Genentech, Bayer, Lilly (institution); local PI of clinical trials: AstraZeneca, - Novartis, BMS, MSD/Merck, GSK, Takeda, Blueprint Medicines, Roche Genentech, - Mirati, AbbVie. All other authors have declared no conflicts of interest. -EDAT- 2022/07/02 06:00 -MHDA- 2022/09/14 06:00 -CRDT- 2022/07/01 19:28 -PHST- 2022/05/06 00:00 [received] -PHST- 2022/06/21 00:00 [revised] -PHST- 2022/06/21 00:00 [accepted] -PHST- 2022/07/02 06:00 [pubmed] -PHST- 2022/09/14 06:00 [medline] -PHST- 2022/07/01 19:28 [entrez] -AID - S0923-7534(22)01742-2 [pii] -AID - 10.1016/j.annonc.2022.06.013 [doi] -PST - ppublish -SO - Ann Oncol. 2022 Sep;33(9):893-908. doi: 10.1016/j.annonc.2022.06.013. Epub 2022 - Jun 28. - -PMID- 32723363 -OWN - NLM -STAT- MEDLINE -DCOM- 20210405 -LR - 20210405 -IS - 1756-8722 (Electronic) -IS - 1756-8722 (Linking) -VI - 13 -IP - 1 -DP - 2020 Jul 28 -TI - SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the - mechanisms, advances, and future challenges. -PG - 105 -LID - 10.1186/s13045-020-00940-z [doi] -LID - 105 -AB - Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed - cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and - have revolutionized the treatment protocols of a broad spectrum of tumor types, - especially non-small-cell lung cancer (NSCLC). Despite the substantial optimism - of treatment with PD-1/PD-L1 inhibitors, there is still a large proportion of - patients with advanced NSCLC who are resistant to the inhibitors. Preclinical and - clinical trials have demonstrated that radiotherapy can induce a systemic - antitumor immune response and have a great potential to sensitize refractory - "cold" tumors to immunotherapy. Stereotactic body radiation therapy (SBRT), as a - novel radiotherapy modality that delivers higher doses to smaller target lesions, - has shown favorable antitumor effects with significantly improved local and - distant control as well as better survival benefits in various solid tumors. - Notably, research has revealed that SBRT is superior to conventional - radiotherapy, possibly because of its more powerful immune activation effects. - Thus, PD-1/PD-L1 inhibitors combined with SBRT instead of conventional - radiotherapy might be more promising to fight against NSCLC, further achieving - more favorable survival outcomes. In this review, we focus on the underlying - mechanisms and recent advances of SBRT combined with PD-1/PD-L1 inhibitors with - an emphasis on some future challenges and directions that warrant further - investigation. -FAU - Chen, Yu -AU - Chen Y -AD - Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Gao, Min -AU - Gao M -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Huang, Zhaoqin -AU - Huang Z -AD - Department of Radiology, Shandong Provincial Hospital, Shandong First Medical - University, Jinan, Shandong, China. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. sdyujinming@126.com. -FAU - Meng, Xiangjiao -AU - Meng X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. mengxiangjiao@126.com. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20200728 -PL - England -TA - J Hematol Oncol -JT - Journal of hematology & oncology -JID - 101468937 -RN - 0 (Antigens, Neoplasm) -RN - 0 (Antineoplastic Agents) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Neoplasm Proteins) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antigens, Neoplasm/immunology -MH - Antineoplastic Agents/adverse effects/*therapeutic use -MH - Antineoplastic Agents, Immunological/adverse effects/therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors/physiology -MH - Biomarkers -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/immunology/*radiotherapy -MH - Chemotaxis, Leukocyte/radiation effects -MH - Clinical Trials as Topic -MH - Combined Modality Therapy -MH - Drug Resistance, Neoplasm -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects/*therapeutic use -MH - Immunity/*radiation effects -MH - Lung Neoplasms/drug therapy/immunology/*radiotherapy -MH - Lymphocytes, Tumor-Infiltrating/immunology/radiation effects -MH - Multicenter Studies as Topic -MH - Neoplasm Proteins/antagonists & inhibitors -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors/physiology -MH - Progression-Free Survival -MH - Radiation Dose Hypofractionation -MH - *Radiosurgery/adverse effects/methods -MH - Radiotherapy Planning, Computer-Assisted -MH - T-Lymphocytes, Regulatory/immunology/radiation effects -MH - Treatment Outcome -MH - Tumor Escape -PMC - PMC7390199 -OTO - NOTNLM -OT - Advances -OT - Challenges -OT - Combination treatment -OT - Non-small-cell lung cancer (NSCLC) -OT - PD-1/PD-L1 inhibitors -OT - Stereotactic body radiation therapy (SBRT) -COIS- The authors declare that they have no competing interests. -EDAT- 2020/07/30 06:00 -MHDA- 2021/04/07 06:00 -PMCR- 2020/07/28 -CRDT- 2020/07/30 06:00 -PHST- 2020/06/01 00:00 [received] -PHST- 2020/07/20 00:00 [accepted] -PHST- 2020/07/30 06:00 [entrez] -PHST- 2020/07/30 06:00 [pubmed] -PHST- 2021/04/07 06:00 [medline] -PHST- 2020/07/28 00:00 [pmc-release] -AID - 10.1186/s13045-020-00940-z [pii] -AID - 940 [pii] -AID - 10.1186/s13045-020-00940-z [doi] -PST - epublish -SO - J Hematol Oncol. 2020 Jul 28;13(1):105. doi: 10.1186/s13045-020-00940-z. - -PMID- 35038429 -OWN - NLM -STAT- MEDLINE -DCOM- 20220223 -LR - 20240229 -IS - 1474-5488 (Electronic) -IS - 1470-2045 (Linking) -VI - 23 -IP - 2 -DP - 2022 Feb -TI - Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in - patients with locally advanced, unresectable, stage III non-small-cell lung - cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, - multicentre, phase 3 trial. -PG - 209-219 -LID - S1470-2045(21)00630-6 [pii] -LID - 10.1016/S1470-2045(21)00630-6 [doi] -AB - BACKGROUND: A substantial proportion of patients with unresectable stage III - non-small-cell lung cancer (NSCLC) cannot either tolerate or access concurrent - chemoradiotherapy, so sequential chemoradiotherapy is commonly used. We assessed - the efficacy and safety of sugemalimab, an anti-PD-L1 antibody, in patients with - stage III NSCLC whose disease had not progressed after concurrent or sequential - chemoradiotherapy. METHODS: GEMSTONE-301 is a randomised, double-blind, - placebo-controlled, phase 3 trial in patients with locally advanced, - unresectable, stage III NSCLC, done at 50 hospitals or academic research centres - in China. Eligible patients were aged 18 years or older with an Eastern - Cooperative Oncology Group (ECOG) performance status of 0 or 1 who had not - progressed after concurrent or sequential chemoradiotherapy. We randomly assigned - patients (2:1, using an interactive voice-web response system) to receive - sugemalimab 1200 mg or matching placebo, intravenously every 3 weeks for up to 24 - months. Stratification factors were ECOG performance status, previous - chemoradiotherapy, and total radiotherapy dose. The investigators, trial - coordination staff, patients, and study sponsor were masked to treatment - allocation. The primary endpoint was progression-free survival as assessed by - blinded independent central review (BICR) in the intention-to-treat population. - Safety was assessed in all participants who received at least one dose of - assigned study treatment. The study has completed enrolment and the results of a - preplanned analysis of the primary endpoint are reported here. The trial is - registered with ClinicalTrials.gov, NCT03728556. FINDINGS: Between Aug 30, 2018 - and Dec 30, 2020, we screened 564 patients of whom 381 were eligible. Study - treatment was received by all patients randomly assigned to sugemalimab (n=255) - and to placebo (n=126). At data cutoff (March 8, 2021), median follow-up was 14·3 - months (IQR 6·4-19·4) for patients in the sugemalimab group and 13·7 months - (7·1-18·4) for patients in the placebo group. Progression-free survival assessed - by BICR was significantly longer with sugemalimab than with placebo (median 9·0 - months [95% CI 8·1-14·1] vs 5·8 months [95% CI 4·2-6·6]; stratified hazard ratio - 0·64 [95% CI 0·48-0·85], p=0·0026). Grade 3 or 4 treatment-related adverse events - occurred in 22 (9%) of 255 patients in the sugemalimab group versus seven (6%) of - 126 patients in the placebo group, the most common being pneumonitis or - immune-mediated pneumonitis (seven [3%] of 255 patients in the sugemalimab group - vs one [<1%] of 126 in the placebo group). Treatment-related serious adverse - events occurred in 38 (15%) patients in the sugemalimab group and 12 (10%) in the - placebo group. Treatment-related deaths were reported in four (2%) of 255 - patients (pneumonia in two patients, pneumonia with immune-mediated pneumonitis - in one patient, and acute hepatic failure in one patient) in the sugemalimab - group and none in the placebo group. INTERPRETATION: Sugemalimab after definitive - concurrent or sequential chemoradiotherapy could be an effective consolidation - therapy for patients with stage III NSCLC whose disease has not progressed after - sequential or concurrent chemoradiotherapy. Longer follow-up is needed to confirm - this conclusion. FUNDING: CStone Pharmaceuticals and the National Key Research - and Development Program of China. TRANSLATION: For the Chinese translation of the - abstract see Supplementary Materials section. -CI - Copyright © 2022 Elsevier Ltd. All rights reserved. -FAU - Zhou, Qing -AU - Zhou Q -AD - Guangdong Lung Cancer Insitute, Guangdong Provincial People's Hospital, Guangdong - Academy of Medical Sciences, Guangzhou, China. -FAU - Chen, Ming -AU - Chen M -AD - The Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, - China; Sun Yat-sen University Cancer Centre, Guangzhou, China. -FAU - Jiang, Ou -AU - Jiang O -AD - The Second People's Hospital of Neijiang, Neijiang, China. -FAU - Pan, Yi -AU - Pan Y -AD - Guangdong Lung Cancer Insitute, Guangdong Provincial People's Hospital, Guangdong - Academy of Medical Sciences, Guangzhou, China. -FAU - Hu, Desheng -AU - Hu D -AD - Hubei Cancer Hospital, Wuhan, China. -FAU - Lin, Qin -AU - Lin Q -AD - The First Affiliated Hospital of Xiamen University, Xiamen, China. -FAU - Wu, Gang -AU - Wu G -AD - Cancer Centre, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, China. -FAU - Cui, Jiuwei -AU - Cui J -AD - The First Hospital of Jilin University, Changchun, China. -FAU - Chang, Jianhua -AU - Chang J -AD - Fudan University Cancer Centre, Shanghai, China; Cancer Hospital, Chinese Academy - of Medical Sciences, Shenzhen Centre, Shenzhen, China. -FAU - Cheng, Yufeng -AU - Cheng Y -AD - Qilu Hospital of Shandong University, Jinan, China. -FAU - Huang, Cheng -AU - Huang C -AD - Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou, China. -FAU - Liu, Anwen -AU - Liu A -AD - The Second Affiliated Hospital of Nanchang University, Nanchang, China. -FAU - Yang, Nong -AU - Yang N -AD - Hunan Cancer Hospital, Changsha, China. -FAU - Gong, Youling -AU - Gong Y -AD - West China Hospital of Sichuan University, Chengdu, China. -FAU - Zhu, Chuan -AU - Zhu C -AD - Chongqing University Three Gorges Hospital, Chongqing, China. -FAU - Ma, Zhiyong -AU - Ma Z -AD - The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, - Zhengzhou, China. -FAU - Fang, Jian -AU - Fang J -AD - Beijing Cancer Hospital, Beijing, China. -FAU - Chen, Gongyan -AU - Chen G -AD - Harbin Medical University Cancer Hospital, Harbin, China. -FAU - Zhao, Jun -AU - Zhao J -AD - Beijing Cancer Hospital, Beijing, China. -FAU - Shi, Anhui -AU - Shi A -AD - Beijing Cancer Hospital, Beijing, China. -FAU - Lin, Yingcheng -AU - Lin Y -AD - Cancer Hospital of Shantou University Medical College, Shantou, China. -FAU - Li, Guanghui -AU - Li G -AD - Xinqiao Hospital of Army Medical University, Chongqing, China. -FAU - Liu, Yunpeng -AU - Liu Y -AD - The First Hospital of China Medical University, Shenyang, China. -FAU - Wang, Dong -AU - Wang D -AD - Army Medical Centre of PLA, Chongqing, China. -FAU - Wu, Rong -AU - Wu R -AD - Shengjing Hospital of China Medical University, Shenyang, China. -FAU - Xu, Xinhua -AU - Xu X -AD - The First College of Clinical Medical Science, China Three Gorges University, - Yichang Central People's Hospital, Yichang, China. -FAU - Shi, Jianhua -AU - Shi J -AD - Linyi Cancer Hospital, Linyi, China. -FAU - Liu, Zhihua -AU - Liu Z -AD - Jiangxi Cancer Hospital, Nanchang, China. -FAU - Cui, Na -AU - Cui N -AD - CStone Pharmaceuticals Suzhou, Shanghai, China. -FAU - Wang, Jingru -AU - Wang J -AD - CStone Pharmaceuticals Suzhou, Shanghai, China. -FAU - Wang, Qiang -AU - Wang Q -AD - CStone Pharmaceuticals Suzhou, Shanghai, China. -FAU - Zhang, Ran -AU - Zhang R -AD - CStone Pharmaceuticals Suzhou, Shanghai, China. -FAU - Yang, Jason -AU - Yang J -AD - CStone Pharmaceuticals Suzhou, Shanghai, China. -FAU - Wu, Yi-Long -AU - Wu YL -AD - Guangdong Lung Cancer Insitute, Guangdong Provincial People's Hospital, Guangdong - Academy of Medical Sciences, Guangzhou, China. Electronic address: - syylwu@live.cn. -LA - eng -SI - ClinicalTrials.gov/NCT03728556 -PT - Clinical Trial, Phase III -PT - Comparative Study -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -DEP - 20220114 -PL - England -TA - Lancet Oncol -JT - The Lancet. Oncology -JID - 100957246 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (sugemalimab) -SB - IM -CIN - Lancet Oncol. 2022 Feb;23(2):186-188. doi: 10.1016/S1470-2045(21)00698-7. PMID: - 35038431 -CIN - Lancet Oncol. 2022 Apr;23(4):e158. doi: 10.1016/S1470-2045(22)00133-4. PMID: - 35358458 -CIN - Lancet Oncol. 2022 Apr;23(4):e159. doi: 10.1016/S1470-2045(22)00144-9. PMID: - 35358459 -MH - Aged -MH - Female -MH - Humans -MH - Male -MH - Middle Aged -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/mortality/pathology -MH - *Chemoradiotherapy -MH - Double-Blind Method -MH - *Immune Checkpoint Inhibitors/therapeutic use -MH - *Lung Neoplasms/drug therapy/mortality/pathology -MH - Neoplasm Staging -COIS- Declaration of interests Y-LW reports advisory services for AstraZeneca, - Boehringer Ingelheim, Novartis, and Takeda; personal fees from AstraZeneca, - Beigene, Boehringer Ingelheim, Bristol Meyer Squibb, Eli Lilly, MSD, Pfizer, - Roche, and Sanofi; grants from AstraZeneca, Boehringer Ingelheim, BMS, Hengrui, - and Roche, outside of the submitted work. QZ reports honoraria from AstraZeneca, - Boehringer Ingelheim, Bristol Meyer Squibb, Eli Lilly, MSD, Pfizer, Roche, and - Sanofi, outside the submitted work. NC, JW, QW, RZ, and JY are employed by CStone - Pharmaceuticals and NC, JW, QW, and JY declare stock ownership in the company. - All other authors declare no competing interests. -EDAT- 2022/01/18 06:00 -MHDA- 2022/02/23 06:00 -CRDT- 2022/01/17 20:10 -PHST- 2021/09/16 00:00 [received] -PHST- 2021/10/20 00:00 [revised] -PHST- 2021/10/20 00:00 [accepted] -PHST- 2022/01/18 06:00 [pubmed] -PHST- 2022/02/23 06:00 [medline] -PHST- 2022/01/17 20:10 [entrez] -AID - S1470-2045(21)00630-6 [pii] -AID - 10.1016/S1470-2045(21)00630-6 [doi] -PST - ppublish -SO - Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub - 2022 Jan 14. - -PMID- 38316378 -OWN - NLM -STAT- MEDLINE -DCOM- 20240623 -LR - 20240802 -IS - 1552-6259 (Electronic) -IS - 0003-4975 (Print) -IS - 0003-4975 (Linking) -VI - 118 -IP - 1 -DP - 2024 Jul -TI - The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer. -PG - 119-129 -LID - S0003-4975(24)00080-8 [pii] -LID - 10.1016/j.athoracsur.2024.01.024 [doi] -AB - BACKGROUND: Despite surgical resection, long-term survival of patients with - resectable non-small cell lung cancer (NSCLC) remains poor. Adjuvant - chemotherapy, the standard of care for locally advanced NSCLC, provides a - marginal 5.4% benefit in survival. Immune checkpoint inhibitors (ICIs) have shown - a significant survival benefit in some patients with advanced NSCLC and are being - evaluated for perioperative use in resectable NSCLC. METHODS: We conducted a - literature search using the PubMed online database to identify clinical trials of - immunotherapy in resectable NSCLC and studies analyzing biomarkers and immune - priming strategies. RESULTS: Building on previous phase I and II trials, - randomized phase III trials have shown efficacy of neoadjuvant nivolumab, - perioperative pembrolizumab, adjuvant atezolizumab, and adjuvant pembrolizumab in - the treatment of NSCLC with improvement of event-free/disease-free survival of - 24% to 42%, leading to United States Food and Drug Administration approval of - these drugs in the treatment of resectable NSCLC. Three additional phase III - trials have also recently reported the use of immunotherapy both before and after - surgery, with pathologic complete response rates of 17% to 25%, significantly - better than chemotherapy alone. Perioperative ICI therapy has comparable - perioperative morbidity to chemotherapy alone and does not impair surgical - outcomes. CONCLUSIONS: Perioperative immunotherapy, in combination with - chemotherapy, is safe and improves outcomes in patients with resectable NSCLC. - Questions regarding patient selection, the need for adjuvant ICI therapy after - neoadjuvant chemoimmunotherapy, and the duration of perioperative immunotherapy - remain to be answered by future trials. -CI - Copyright © 2024 The Society of Thoracic Surgeons. Published by Elsevier Inc. All - rights reserved. -FAU - Dunne, Elizabeth G -AU - Dunne EG -AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, - New York, New York. -FAU - Fick, Cameron N -AU - Fick CN -AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, - New York, New York. -FAU - Isbell, James M -AU - Isbell JM -AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, - New York, New York; Druckenmiller Center for Lung Cancer Research, Memorial Sloan - Kettering Cancer Center, New York, New York. -FAU - Chaft, Jamie E -AU - Chaft JE -AD - Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer - Center, New York, New York; Department of Medicine, Memorial Sloan Kettering - Cancer Center, New York, New York. -FAU - Altorki, Nasser -AU - Altorki N -AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York. -FAU - Park, Bernard J -AU - Park BJ -AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, - New York, New York; Druckenmiller Center for Lung Cancer Research, Memorial Sloan - Kettering Cancer Center, New York, New York. -FAU - Spicer, Jonathan -AU - Spicer J -AD - Department of Thoracic Surgery, McGill University Health Centre, Montreal, - Quebec, Canada. -FAU - Forde, Patrick M -AU - Forde PM -AD - Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins - University, Baltimore, Maryland. -FAU - Gomez, Daniel -AU - Gomez D -AD - Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer - Center, New York, New York; Department of Radiation Oncology, Memorial Sloan - Kettering Cancer Center, New York, New York. -FAU - Iyengar, Puneeth -AU - Iyengar P -AD - Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer - Center, New York, New York; Department of Radiation Oncology, Memorial Sloan - Kettering Cancer Center, New York, New York. -FAU - Harpole, David H Jr -AU - Harpole DH Jr -AD - Division of Cardiovascular and Thoracic Surgery, Duke University Medical Center, - Durham, North Carolina. -FAU - Stinchcombe, Thomas E -AU - Stinchcombe TE -AD - Division of Medical Oncology, Duke Cancer Institute, Duke University Medical - Center, Durham, North Carolina. -FAU - Liberman, Moishe -AU - Liberman M -AD - Division of Thoracic Surgery, University of Montreal, Montreal, Quebec, Canada. -FAU - Bott, Matthew J -AU - Bott MJ -AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, - New York, New York; Druckenmiller Center for Lung Cancer Research, Memorial Sloan - Kettering Cancer Center, New York, New York. -FAU - Adusumilli, Prasad S -AU - Adusumilli PS -AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, - New York, New York; Druckenmiller Center for Lung Cancer Research, Memorial Sloan - Kettering Cancer Center, New York, New York. -FAU - Huang, James -AU - Huang J -AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, - New York, New York; Druckenmiller Center for Lung Cancer Research, Memorial Sloan - Kettering Cancer Center, New York, New York. -FAU - Rocco, Gaetano -AU - Rocco G -AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, - New York, New York; Druckenmiller Center for Lung Cancer Research, Memorial Sloan - Kettering Cancer Center, New York, New York. -FAU - Jones, David R -AU - Jones DR -AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, - New York, New York; Druckenmiller Center for Lung Cancer Research, Memorial Sloan - Kettering Cancer Center, New York, New York. Electronic address: - jonesd2@mskcc.org. -LA - eng -GR - P30 CA008748/CA/NCI NIH HHS/United States -GR - R01 CA217169/CA/NCI NIH HHS/United States -GR - R01 CA240472/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Review -DEP - 20240203 -PL - Netherlands -TA - Ann Thorac Surg -JT - The Annals of thoracic surgery -JID - 15030100R -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/therapy/immunology/drug therapy -MH - Humans -MH - *Lung Neoplasms/therapy/drug therapy/immunology -MH - *Immunotherapy/methods -MH - Pneumonectomy -MH - Neoadjuvant Therapy -PMC - PMC11194155 -MID - NIHMS1964655 -COIS- James M. Isbell has stock ownership in LumaCyte, consultant/advisory board member - for AstraZeneca and Merck and receives institutional research support from - Foresight, Guardant Health, Intuitive Surgical and Invitae. Jaime Chaft serves as - a consultant for AstraZeneca, Bristol-Myers Squibb, Flame Biosciences, - Regeneron-Sanofi, Guardant Health and Arcus Biosciences and receives - institutional research funding from AztraZeneca, Bristol-Myers Squibb, Merck and - Novartis. Nasser Altorki reports grant support from AstraZeneca and Janssen as - well as a leadership role in Roche IMpower010 Steering Committee. Bernard J. Park - serves as a consultant for Intuitive Surgical, AstraZeneca, CEEVRA, and - Medtronic. Jonathan Spicer serves as a consultant for AstraZeneca, Merck, Roche, - Bristol Myers Squibb, Novartis, Chemocentryx, Amgen, Protalix Biotherapeutics, - Xenetic Biosciences, Regeneron, Eisai, as clinical trial leadership for Bristol - Myers Squibb, Novartis, Roche, Merck, AstraZeneca and institutional grant support - from AstraZeneca, Merck, Roche, CLS Therapeutics and Protalix Biotherapeutics. - Patrick M. Forde reports research grants to his institution from AstraZeneca, - BMS, Novartis, Regeneron, BioNTech, consulting fees from Ascendis, AstraZeneca, - BMS, Curevac, Novartis, Regeneron, G1, Genelux, Genentech, Gritstone, Merck, - Janssen, F Star, Sanofi, Amgen, Fosun, Teva, Synthekine, Flame, Iteos, Tavotek, - Teva and DSMB membership for Polaris. Daniel Gomez reports research funding from - Merck, AstraZeneca, Varian, and Bristol Myers Squibb and serves on the advisory - boards of MedLearning Group, Medtronic, GRAIL, Johnson & Johnson, AstraZeneca, - and Varian. Puneeth Iyengar serves on the advisory board of AstraZeneca and - institutional grant support from Incyte. David Harpole serves as a speaker for - and on the advisory board of AstraZeneca and is on the AEGEAN and MERMAID - Executive Committees. Tom Stinchombe is a consultant/advisory board member for - Janssen Oncology, Genentech/Roche, Daiichi Sankyo/AstraZeneca, Takeda, Eisai/H3 - Biomedicine, G1 Therapeutics, Spectrum Pharmaceuticals, Gilead Sciences, - AstraZeneca, Coherus Biosciences, Abbvie, a DSMB membership for GlaxoSmithKline, - Genetech/Roche, travel support from Pfizer, and institutional research support - from AstraZeneca, SEagen, Mirati Therapeutics and Genentech/Roche Moishe Liberman - reports advisory relationship with Endocision, AssistIQ, Ditch Labs, Johnson - &Johnson Lung Cancer Initiative, Noah Medical, Sparrow and research and - educational grants from Boston Scientific, Olympus, Johnson & Johnson, Intuitive, - Broncus, BMS, Merck, AstraZeneca, Pfizer, Roche, Novartis, POINT Biopharma, - Galavanize Therapeutics, Caprion and ODS Medical. Matthew J. Bott is a consultant - for AstraZeneca. Prasad S. Adusumilli declares research funding from ATARA - Biotherapeutics; Scientific Advisory Board Member and Consultant for ATARA - Biotherapeutics, Bayer, Bio4T2, Carisma Therapeutics, Imugene, ImmPactBio, - Johnston & Johnston, Orion pharma, Outpace Bio; Patents, royalties and - intellectual property on mesothelin-targeted CAR and other T-cell therapies, - which have been licensed to ATARA Biotherapeutics, issued patent method for - detection of cancer cells using virus, and pending patent applications on PD-1 - dominant negative receptor, wireless pulse-oximetry device, and on an ex vivo - malignant pleural effusion culture system. Gaetano Rocco has a financial - relationship with Scanlan, AstraZeneca, and Medtronic. David R. Jones serves as a - consultant or speaker for or has received grant support from Merck, AstraZeneca, - Genentech, More Health, and DAVA Oncology. The other authors have no disclosures. -EDAT- 2024/02/06 00:42 -MHDA- 2024/06/24 05:41 -PMCR- 2025/07/01 -CRDT- 2024/02/05 19:27 -PHST- 2023/10/25 00:00 [received] -PHST- 2024/01/09 00:00 [revised] -PHST- 2024/01/22 00:00 [accepted] -PHST- 2025/07/01 00:00 [pmc-release] -PHST- 2024/06/24 05:41 [medline] -PHST- 2024/02/06 00:42 [pubmed] -PHST- 2024/02/05 19:27 [entrez] -AID - S0003-4975(24)00080-8 [pii] -AID - 10.1016/j.athoracsur.2024.01.024 [doi] -PST - ppublish -SO - Ann Thorac Surg. 2024 Jul;118(1):119-129. doi: 10.1016/j.athoracsur.2024.01.024. - Epub 2024 Feb 3. - -PMID- 37676681 -OWN - NLM -STAT- MEDLINE -DCOM- 20231128 -LR - 20240908 -IS - 2374-2445 (Electronic) -IS - 2374-2437 (Print) -IS - 2374-2437 (Linking) -VI - 9 -IP - 11 -DP - 2023 Nov 1 -TI - Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced - Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial. -PG - 1505-1513 -LID - 10.1001/jamaoncol.2023.3309 [doi] -AB - IMPORTANCE: Administration of durvalumab after concurrent chemoradiotherapy is - the standard treatment of unresectable, locally advanced non-small cell lung - cancer (NSCLC); however, 20% to 30% of patients do not receive durvalumab because - of adverse events (AEs) during concurrent chemoradiotherapy. In addition, - radiotherapy and immunotherapy have a synergistic effect. OBJECTIVE: To - investigate the efficacy and safety of durvalumab immunotherapy plus concurrent - radiotherapy followed by maintenance with durvalumab therapy for treatment of - locally advanced NSCLC without chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: - The multicenter, single-arm DOLPHIN (Phase II Study of Durvalumab [MEDI4736] Plus - Concurrent Radiation Therapy in Advanced Localized NSCLC Patients) nonrandomized - controlled trial was performed by 12 institutions in Japan from September 13, - 2019, to May 31, 2022. Participants in the primary registration phase included 74 - patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, - locally advanced NSCLC. The current analyses were conducted from June 1, 2022, to - October 31, 2022. INTERVENTIONS: Patients received radiotherapy (60 Gy) in - combination with concurrent and maintenance durvalumab immunotherapy, 10 mg/kg - every 2 weeks, for up to 1 year. MAIN OUTCOMES AND MEASURES: The primary end - point of the rate of 12-month progression-free survival (PFS), as assessed by an - independent central review, was estimated using the Kaplan-Meier method and - evaluated with 90% CIs calculated using the Greenwood formula. The key secondary - end points were PFS, objective response rate, treatment completion rate, and AEs. - RESULTS: Data from 35 patients (median [range] age, 72 [44-83] years; 31 [88.6%] - men) were included in the full analysis set of the evaluable population. The - 12-month PFS rate was 72.1% (90% CI, 59.1%-85.1%), and the median PFS was 25.6 - months (95% CI, 13.1 months to not estimable) at a median follow-up of 22.8 - months (range, 4.3-31.8 months). Scheduled radiation therapy was completed in - 97.1% of patients. The confirmed objective response rate was 90.9% (95% CI, - 75.7%-98.1%), and the treatment completion rate was 57.6% (95% CI, 39.2%-74.5%). - Among 34 patients evaluated in the safety analysis set, AEs of grade 3 or 4 - occurred in 18 patients (52.9%), and of grade 5 in 2 patients (5.9%). Pneumonitis - or radiation pneumonitis of any grade occurred in 23 patients (67.6%), and of - grades 3 or 4 in 4 patients (11.8%). CONCLUSIONS AND RELEVANCE: Findings from - this phase 2 nonrandomized controlled trial indicate that durvalumab - immunotherapy combined with curative radiotherapy for patients with - PD-L1-positive, unresectable, locally advanced NSCLC is a promising treatment - with tolerable AEs and is appropriate as a study treatment for phase 3 clinical - trials. TRIAL REGISTRATION: Japan Registry of Clinical Trials ID: jRCT2080224763. -FAU - Tachihara, Motoko -AU - Tachihara M -AD - Division of Respiratory Medicine, Department of Internal Medicine, Kobe - University Graduate School of Medicine, Kobe, Japan. -FAU - Tsujino, Kayoko -AU - Tsujino K -AD - Department of Radiation Oncology, Hyogo Cancer Center, Akashi, Japan. -FAU - Ishihara, Takeaki -AU - Ishihara T -AD - Division of Radiation Oncology, Kobe University Graduate School of Medicine, - Kobe, Japan. -FAU - Hayashi, Hidetoshi -AU - Hayashi H -AD - Department of Medical Oncology, Kindai University, Osakasayama, Japan. -FAU - Sato, Yuki -AU - Sato Y -AD - Department of Respiratory Medicine, Kobe City Medical Center General Hospital, - Kobe, Japan. -FAU - Kurata, Takayasu -AU - Kurata T -AD - Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, - Japan. -FAU - Sugawara, Shunichi -AU - Sugawara S -AD - Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan. -FAU - Shiraishi, Yoshimasa -AU - Shiraishi Y -AD - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu - University, Fukuoka, Japan. -FAU - Teraoka, Shunsuke -AU - Teraoka S -AD - Internal Medicine III, Wakayama Medical University, Wakayama, Japan. -FAU - Azuma, Koichi -AU - Azuma K -AD - Division of Respirology, Neurology, and Rheumatology, Department of Internal - Medicine, Kurume University School of Medicine, Fukuoka, Japan. -FAU - Daga, Haruko -AU - Daga H -AD - Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan. -FAU - Yamaguchi, Masafumi -AU - Yamaguchi M -AD - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer - Center, Fukuoka, Japan. -FAU - Kodaira, Takeshi -AU - Kodaira T -AD - Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, - Japan. -FAU - Satouchi, Miyako -AU - Satouchi M -AD - Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan. -FAU - Shimokawa, Mototsugu -AU - Shimokawa M -AD - Department of Biostatistics, Yamaguchi University Graduate School of Medicine, - Ube, Japan. -FAU - Yamamoto, Nobuyuki -AU - Yamamoto N -AD - Internal Medicine III, Wakayama Medical University, Wakayama, Japan. -FAU - Nakagawa, Kazuhiko -AU - Nakagawa K -AD - Department of Medical Oncology, Kindai University, Osakasayama, Japan. -CN - West Japan Oncology Group (WJOG) -LA - eng -SI - JPRN/jRCT2080224763 -PT - Clinical Trial, Phase II -PT - Controlled Clinical Trial -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -PL - United States -TA - JAMA Oncol -JT - JAMA oncology -JID - 101652861 -RN - 0 (B7-H1 Antigen) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Aged -MH - Female -MH - Humans -MH - Male -MH - B7-H1 Antigen -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - Chemoradiotherapy/adverse effects/methods -MH - Disease-Free Survival -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Neoplasm Staging -MH - Adult -MH - Middle Aged -MH - Aged, 80 and over -PMC - PMC10485744 -COIS- Conflict of Interest Disclosures: Dr Tachihara reported receiving grants from - AstraZeneca and personal fees from AstraZeneca during the conduct of the study; - receiving grants from Eli Lilly Japan and Chugai Pharmaceutical outside the - submitted work; and receiving personal fees from Chugai Pharmaceutical, Eli Lilly - Japan, Ono Pharmaceutical, Taiho Pharmaceutical, MSD, Nippon Boehringer - Ingelheim, Bristol Myers Squibb, and Novartis Pharmaceuticals outside the - submitted work. Dr Tsujino reported receiving personal fees from AstraZeneca - outside the submitted work. Dr Hayashi reported receiving grants from - AstraZeneca, Astellas Pharma, Ono Pharmaceutical, Nippon Boehringer Ingelheim, - Novartis Pharma, Pfizer Japan, Bristol Myers Squibb, Eli Lilly Japan, Chugai - Pharmaceutical, Daiichi Sankyo, Merck Serono, Merck Biopharma, Takeda - Pharmaceutical, Taiho Pharmaceutical, SymBio Pharmaceuticals, AbbVie, inVentiv - Health Japan, ICON Japan, Gritstone Oncology, Parexel International Corp, Kissei - Pharmaceutical, EPS Corp, Syneos Health, Pfizer R&D Japan, A2 Healthcare Corp, - Quintiles Inc, IQVIA Services Japan, EP-CRSU, Linical, Eisai, CMIC Shift Zero, - Kyowa Hakko Kirin, Bayer Yakuhin, EPS International, and Otsuka Pharmaceutical - outside the submitted work; receiving personal fees from Amgen, AstraZeneca, - Boehringer Ingelheim Japan, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi - Sankyo, Eli Lilly Japan, Janssen Pharmaceutical, Merck Biopharma, MSD, Novartis - Pharmaceuticals, Ono Pharmaceutical, and Takeda Pharmaceutical outside the - submitted work; receiving consulting fees from AstraZeneca, Boehringer Ingelheim - Japan, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, Guardant - Health, Pfizer Japan, Takeda Pharmaceutical, and Merck Biopharma outside the - submitted work; and holding a patent for Sysmex. Dr Sato reported receiving - personal fees from AstraZeneca during the conduct of the study; and receiving - personal fees from Chugai Pharmaceutical, MSD, Ono Pharmaceutical, Novartis, - Pfizer, Taiho Pharmaceutical, Nippon Kayaku Bristol Myers Squibb, Eli Lilly & Co, - Takeda, and Kyowa Kirin outside the submitted work. Dr Kurata reported receiving - grants, personal fees, and honoraria from AstraZeneca during the conduct of the - study; receiving grants from MSD, Bristol Myers Squibb, Amgen, Daiichi Sankyo, - and Takeda outside the submitted work; and receiving personal fees from MSD, - Chugai Honoraria, Bristol Myers Squibb, Pfizer Honoraria, Ono, Nippon Kayaku, - Boehringer Ingelheim, and Takeda outside the submitted work. Dr Sugawara reported - receiving personal fees from AstraZeneca during the conduct of the study; and - receiving personal fees from Chugai Pharma, MSD, Ono Pharmaceutical, Bristol - Myers Squibb, Takeda, Nippon Boehringer Ingelheim, Taiho Pharmaceutical, Pfizer, - Eli Lilly Japan, Novartis, Kyowa Kirin, Nippon Kayaku, Merck, Amgen, AbbVie, - Otsuka, Thermo Fisher Scientific, and Towa Pharmaceutical outside the submitted - work. Dr Shiraishi reported receiving grants from Chugai Pharma outside the - submitted work; and receiving personal fees from Chugai Pharma, Ono - Pharmaceutical, AstraZeneca, Bristol Myers Squibb, and Taiho Pharmaceutical - outside the submitted work. Dr Teraoka reported receiving personal fees from - AstraZeneca, Chugai Pharmaceutical, Eli Lilly Japan, Novartis Pharma, Ono - Pharmaceutical, Pfizer R&D Japan, Taiho Pharmaceutical, and Thermo Fisher - Scientific outside the submitted work. Dr Azuma reported receiving personal fees - from AstraZeneca, MSD, Ono Pharmaceutical, Bristol Myers Squibb, and Chugai - Pharmaceutical outside the submitted work. Dr Daga reported receiving personal - fees from Chugai, AstraZeneca, and Eli Lilly Japan outside the submitted work. Dr - Yamaguchi reported receiving personal fees from AstraZeneca, Novartis Pharma, - Bristol Myers Squibb, and Chugai Pharma during the conduct of the study. Dr - Kodaira reported receiving personal fees from AstraZeneca, Ono Pharmaceutical, - Takeda, Otsuka, and Merck Biopharma outside the submitted work. Dr Satouchi - reported receiving grants and personal fees from AstraZeneca during the conduct - of the study; grants from MSD, Taiho Pharmaceutical, Pfizer, Bristol Myers - Squibb, GlaxoSmithKline, Novartis, Amgen, AbbVie, Takeda, Daiichi Sankyo, and - Janssen outside the submitted work; and receiving personal fees from Chugai - Pharmaceutical, Eli Lilly Japan, Taiho Pharmaceutical, Pfizer, Boehringer - Ingelheim, Bristol Myers Squibb, Ono Pharmaceutical, Novartis, MSD, Eisai Merck, - Amgen, and Bayer outside the submitted work. Dr Yamamoto receiving reported - grants from AstraZeneca during the conduct of the study; receiving grants from - Eli Lilly Japan, MSD, Boehringer Ingelheim Japan, Chugai Pharmaceutical, and - AstraZeneca outside the submitted work; and receiving personal fees from - AstraZeneca, Boehringer Ingelheim Japan, Chugai Pharmaceutical, MSD, Taiho - Pharmaceutical, Daiichi-Sankyo, Merck Biopharma, Ono Pharmaceutical, Takeda - Pharmaceutical, and Eli Lilly Japan outside the submitted work. Dr Nakagawa - reported receiving grants from AstraZeneca, MSD, Chugai Pharmaceutical Co, and - Ono Pharmaceutical during the conduct of the study; receiving personal fees from - Ono Pharmaceutical, AstraZeneca, Chugai Pharmaceutical, and MSD during the - conduct of the study; receiving grants from Labcorp Development Japan, Japan - Clinical Research Operations, Takeda Pharmaceutical, GlaxoSmithKline, Sanofi, - Ascent Development Services, Nippon Boehringer Ingelheim, Amgen, Novartis Pharma, - Otsuka Pharmaceutical, SRL Pharma, Pfizer R&D Japan, Bayer Yakuhin, Sysmex - Corporation, Eisai, Mochida Pharmaceutical, Eli Lilly Japan, Medical Research - Support, Parexel International Corp, PRA Health Sciences, EPS Corporation, Kissei - Pharmaceutical, EPS International, Daiichi Sankyo, PPD-SNBL, SymBio - Pharmaceuticals, IQVIA Services Japan, Syneos Health, Nippon Kayaku, EP-CRSU, - Mebix, Bristol Myers Squibb, Janssen Pharmaceutical, CMIC Group, Shionogi & Co, - Astellas Pharma, and Kobayashi Pharmaceutical outside the submitted work; - receiving personal fees from Amgen, Nippon Kayaku, Eli Lilly Japan, Pfizer Japan, - Nippon Boehringer Ingelheim, Taiho Pharmaceutical, Bayer Yakuhin, CMIC ShiftZero, - Life Technologies Japan, Neo Communication, Daiichi Sankyo, Incyte Biosciences - Japan, Merck Biopharma, Kyowa Kirin, Takeda Pharmaceutical, 3H Clinical Trial, - Care Net, Medical Review, Medical Mobile Communications, Yodosha, Nikkei Business - Publications, Japan Clinical Research Operations, CMIC Group, Novartis Pharma, - TAIYO Pharma, Bristol Myers Squibb, and Janssen Pharmaceutical outside the - submitted work; and holding a patent for Daiichi Sankyo. No other disclosures - were reported. -EDAT- 2023/09/07 12:42 -MHDA- 2023/11/17 15:28 -PMCR- 2024/09/07 -CRDT- 2023/09/07 11:33 -PHST- 2023/11/17 15:28 [medline] -PHST- 2023/09/07 12:42 [pubmed] -PHST- 2023/09/07 11:33 [entrez] -PHST- 2024/09/07 00:00 [pmc-release] -AID - 2809271 [pii] -AID - coi230043 [pii] -AID - 10.1001/jamaoncol.2023.3309 [doi] -PST - ppublish -SO - JAMA Oncol. 2023 Nov 1;9(11):1505-1513. doi: 10.1001/jamaoncol.2023.3309. - -PMID- 30595194 -OWN - NLM -STAT- MEDLINE -DCOM- 20190111 -LR - 20201218 -IS - 1769-6917 (Electronic) -IS - 0007-4551 (Linking) -VI - 105 Suppl 1 -DP - 2018 Dec -TI - [Not Available]. -PG - S16-S23 -LID - S0007-4551(18)30386-2 [pii] -LID - 10.1016/S0007-4551(18)30386-2 [doi] -AB - STATE OF THE ART AND PERSPECTIVES: Immune checkpoint inhibitors (ICI) are - monoclonal antibodies that inhibit molecular interaction between an immune - checkpoint and its ligand, which leads to increased anti-tumoral immune response, - Programmed Death 1 (PD-1) and Cytotoxic T-Lymphocyte Associated-4 (CTLA-4) are - the most commonly known immune checkpoints. ICIs are currently placed early in - the course of the treatment of patients with non-small cell lung cancer (NSCLC). - In France, approvals have been pronounced for nivolumab and pembrolizumab - (anti-PD-1 antibodies) as second-line treatments after chemotherapy in patients - with advanced NSCLC, and pembrolizumab has been approved as a first-line - treatment in patients with advanced NSCLC, without EGFR mutation or ALK - rearrangement, with strong (≥50%) PD-L1 (Programmed Death Ligand 1) expression. - Atezolizumab is currently soon to be approved as a second-line treatment. - Numerous studies are currently evaluating ICIs in thoracic oncology. In this - article, we will develop perspectives regarding ICIs for early stage or locally - advanced NSCLCs, ICIs used in other thoracic cancers (small cell lung cancer, - malignant pleural mesothelioma, thymic epithelial tumors), and trials with - combinations involving ICIs: two ICIs combined, or ICIs combined with - chemotherapy, radiotherapy or other anti-cancer treatments. -CI - © 2018 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits - réservés. -FAU - Mignard, Xavier -AU - Mignard X -AD - Sorbonne Université, GRC N° 04, Theranoscan, AP-HP, Hôpital Tenon, F-75020, - Paris, France. -FAU - Chaabane, Nouha -AU - Chaabane N -AD - Service de pneumologie, AP-HP, Hôpital Tenon, F-75020, Paris, France. -FAU - Fallet, Vincent -AU - Fallet V -AD - Service de pneumologie, AP-HP, Hôpital Tenon, F-75020, Paris, France. -FAU - Wislez, Marie -AU - Wislez M -AD - Sorbonne Université, GRC N° 04, Theranoscan, AP-HP, Hôpital Tenon, F-75020, - Paris, France; Service de pneumologie, AP-HP, Hôpital Tenon, F-75020, Paris, - France. Electronic address: marie.wislez@aphp.fr. -LA - fre -PT - Journal Article -PT - Review -TT - Actualités et perspectives concernant l’immunothérapie en oncologie thoracique. -PL - France -TA - Bull Cancer -JT - Bulletin du cancer -JID - 0072416 -RN - 0 (Angiogenesis Inhibitors) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (CTLA-4 Antigen) -RN - 0 (CTLA4 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 31YO63LBSN (Nivolumab) -RN - 52CMI0WC3Y (atezolizumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Angiogenesis Inhibitors/therapeutic use -MH - Antibodies, Monoclonal/therapeutic use -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors -MH - CTLA-4 Antigen/antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/*therapy -MH - Chemoradiotherapy/methods -MH - Combined Modality Therapy -MH - Humans -MH - *Immunotherapy -MH - Lung Neoplasms/drug therapy/*therapy -MH - Mesothelioma/*therapy -MH - Mesothelioma, Malignant -MH - Nivolumab/therapeutic use -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - Thymus Neoplasms/*therapy -OTO - NOTNLM -OT - CBNPC -OT - Combinaisons -OT - Combinations -OT - Immune checkpoint -OT - Inhibiteurs -OT - NSCLC -OT - Oncologie thoracique -OT - Perspectives -OT - Thoracic oncology -OT - du checkpoint -OT - immunitaire -OT - inhibitors -EDAT- 2019/01/01 06:00 -MHDA- 2019/01/12 06:00 -CRDT- 2019/01/01 06:00 -PHST- 2019/01/01 06:00 [entrez] -PHST- 2019/01/01 06:00 [pubmed] -PHST- 2019/01/12 06:00 [medline] -AID - S0007-4551(18)30386-2 [pii] -AID - 10.1016/S0007-4551(18)30386-2 [doi] -PST - ppublish -SO - Bull Cancer. 2018 Dec;105 Suppl 1:S16-S23. doi: 10.1016/S0007-4551(18)30386-2. - -PMID- 33476803 -OWN - NLM -STAT- MEDLINE -DCOM- 20210524 -LR - 20220531 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 16 -IP - 5 -DP - 2021 May -TI - Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an - Update From the PACIFIC Trial. -PG - 860-867 -LID - S1556-0864(21)00022-8 [pii] -LID - 10.1016/j.jtho.2020.12.015 [doi] -AB - INTRODUCTION: In the Phase 3, placebo-controlled PACIFIC trial of patients with - unresectable, stage III NSCLC without disease progression after concurrent - chemoradiotherapy, consolidative durvalumab was associated with significant - improvements in the primary end points of overall survival (OS) (hazard ratio - [HR] = 0.68; 95% confidence interval [CI]: 0.53-0.87; p = 0.00251; data cutoff, - March 22, 2018) and progression-free survival (PFS) (blinded independent central - review; Response Evaluation Criteria in Solid Tumors version 1.1) (HR = 0.52; 95% - CI: 0.42-65; p < 0.0001; February 13, 2017) with manageable safety. Here, we - report updated analyses of OS and PFS, approximately 4 years after the last - patient was randomized. METHODS: Patients with WHO performance status of 0 or 1 - (and any tumor programmed death-ligand 1 status) were randomized (2:1) to - intravenous durvalumab (10 mg/kg) or placebo, administered every 2 weeks (≤12 - months), stratified by age, sex, and smoking history. OS and PFS were analyzed - using a stratified log-rank test in the intent-to-treat population. Medians and - 4-year OS and PFS rates were estimated by the Kaplan-Meier method. RESULTS: - Overall, 709 of 713 randomized patients received durvalumab (n/N=473/476) or - placebo (n/N=236/237). As of March 20, 2020 (median follow-up = 34.2 months; - range: 0.2-64.9), updated OS (HR = 0.71; 95% CI: 0.57-0.88) and PFS (HR = 0.55; - 95% CI: 0.44-0.67) remained consistent with the primary analyses. The median OS - for durvalumab was reached (47.5 mo; placebo, 29.1 months). Estimated 4-year OS - rates were 49.6% versus 36.3% for durvalumab versus placebo, and 4-year PFS rates - were 35.3% versus 19.5% respectively. CONCLUSION: These updated exploratory - analyses demonstrate durable PFS and sustained OS benefit with durvalumab after - chemoradiotherapy. An estimated 49.6% of patients randomized to durvalumab remain - alive at 4 years (placebo, 36.3%), and 35.3% remain alive and progression-free - (placebo, 19.5%). -CI - Copyright © 2021 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Faivre-Finn, Corinne -AU - Faivre-Finn C -AD - The University of Manchester, Manchester, United Kingdom; The Christie NHS - Foundation Trust, Manchester, United Kingdom. Electronic address: - corinne.finn@nhs.net. -FAU - Vicente, David -AU - Vicente D -AD - Department of Medical Oncology, Hospital Universitario Virgen Macarena, Seville, - Spain. -FAU - Kurata, Takayasu -AU - Kurata T -AD - Department of Internal Medicine, Kansai Medical University Hospital, Hirakata, - Japan. -FAU - Planchard, David -AU - Planchard D -AD - Department of Medical Oncology, Thoracic Unit, Gustave Roussy, Villejuif, France. -FAU - Paz-Ares, Luis -AU - Paz-Ares L -AD - CiberOnc, Universidad Complutense, Madrid, Spain; Centro Nacional De - Investigaciones Oncologicas (CNIO), Hospital Universitario 12 de Octubre, Madrid, - Spain. -FAU - Vansteenkiste, Johan F -AU - Vansteenkiste JF -AD - Department of Chronic Disease and Metabolism, University Hospitals KU Leuven, - Leuven, Belgium. -FAU - Spigel, David R -AU - Spigel DR -AD - Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee. -FAU - Garassino, Marina C -AU - Garassino MC -AD - Division of Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere - Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy. -FAU - Reck, Martin -AU - Reck M -AD - Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung - Research, Grosshansdorf, Germany. -FAU - Senan, Suresh -AU - Senan S -AD - Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije - Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands. -FAU - Naidoo, Jarushka -AU - Naidoo J -AD - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at John Hopkins - University, Baltimore, Maryland. -FAU - Rimner, Andreas -AU - Rimner A -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, New York. -FAU - Wu, Yi-Long -AU - Wu YL -AD - Department of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, - People's Republic of China. -FAU - Gray, Jhanelle E -AU - Gray JE -AD - Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, Florida. -FAU - Özgüroğlu, Mustafa -AU - Özgüroğlu M -AD - Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa School - of Medicine, Istanbul University - Cerrahpaşa, Istanbul, Turkey. -FAU - Lee, Ki H -AU - Lee KH -AD - Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk - National University College of Medicine, Cheongju, Korea. -FAU - Cho, Byoung C -AU - Cho BC -AD - Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College - of Medicine, Seoul, Korea. -FAU - Kato, Terufumi -AU - Kato T -AD - Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan. -FAU - de Wit, Maike -AU - de Wit M -AD - Department of Hematology, Oncology, and Palliative Medicine, Vivantes Klinikum - Neukölln, Berlin, Germany. -FAU - Newton, Michael -AU - Newton M -AD - Department of Clinical Oncology, AstraZeneca, Gaithersburg, Maryland. -FAU - Wang, Lu -AU - Wang L -AD - Department of Clinical Oncology, AstraZeneca, Gaithersburg, Maryland. -FAU - Thiyagarajah, Piruntha -AU - Thiyagarajah P -AD - Department of Clinical Oncology, AstraZeneca, Cambridge, United Kingdom. -FAU - Antonia, Scott J -AU - Antonia SJ -AD - Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, Florida. -LA - eng -SI - ClinicalTrials.gov/NCT02125461 -GR - P30 CA008748/CA/NCI NIH HHS/United States -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Randomized Controlled Trial -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20210119 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -CIN - J Thorac Oncol. 2021 May;16(5):715-718. doi: 10.1016/j.jtho.2021.02.006. PMID: - 33896569 -MH - Antibodies, Monoclonal/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy -OTO - NOTNLM -OT - Durvalumab -OT - Locally advanced NSCLC -OT - Overall survival -OT - PACIFIC -OT - Progression-free survival -EDAT- 2021/01/22 06:00 -MHDA- 2021/05/25 06:00 -CRDT- 2021/01/21 20:11 -PHST- 2020/10/09 00:00 [received] -PHST- 2020/12/02 00:00 [revised] -PHST- 2020/12/23 00:00 [accepted] -PHST- 2021/01/22 06:00 [pubmed] -PHST- 2021/05/25 06:00 [medline] -PHST- 2021/01/21 20:11 [entrez] -AID - S1556-0864(21)00022-8 [pii] -AID - 10.1016/j.jtho.2020.12.015 [doi] -PST - ppublish -SO - J Thorac Oncol. 2021 May;16(5):860-867. doi: 10.1016/j.jtho.2020.12.015. Epub - 2021 Jan 19. - -PMID- 37988638 -OWN - NLM -STAT- MEDLINE -DCOM- 20240209 -LR - 20240209 -IS - 1527-7755 (Electronic) -IS - 0732-183X (Linking) -VI - 42 -IP - 5 -DP - 2024 Feb 10 -TI - Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell - Lung Cancer Trial (SPRINT). -PG - 562-570 -LID - 10.1200/JCO.23.00627 [doi] -AB - PURPOSE: Standard therapy for locally advanced non-small-cell lung cancer - (LA-NSCLC) is concurrent chemoradiotherapy followed by adjuvant durvalumab. For - biomarker-selected patients with LA-NSCLC, we hypothesized that sequential - pembrolizumab and risk-adapted radiotherapy, without chemotherapy, would be - well-tolerated and effective. METHODS: Patients with stage III NSCLC or - unresectable stage II NSCLC and an Eastern Cooperative Oncology Group performance - status of 0-1 were eligible for this trial. Patients with a PD-L1 tumor - proportion score (TPS) of ≥50% received three cycles of induction pembrolizumab - (200 mg, once every 21 days), followed by a 20-fraction course of risk-adapted - thoracic radiotherapy (55 Gy delivered to tumors or lymph nodes with metabolic - volume exceeding 20 cc, 48 Gy delivered to smaller lesions), followed by - consolidation pembrolizumab to complete a 1-year treatment course. The primary - study end point was 1-year progression-free survival (PFS). Secondary end points - included response rates after induction pembrolizumab, overall survival (OS), and - adverse events. RESULTS: Twenty-five patients with a PD-L1 TPS of ≥50% were - enrolled. The median age was 71, most patients (88%) had stage IIIA or IIIB - disease, and the median PD-L1 TPS was 75%. Two patients developed disease - progression during induction pembrolizumab, and two patients discontinued - pembrolizumab after one infusion because of immune-related adverse events. Using - RECIST criteria, 12 patients (48%) exhibited a partial or complete response after - induction pembrolizumab. Twenty-four patients (96%) received definitive thoracic - radiotherapy. The 1-year PFS rate is 76%, satisfying our efficacy objective. One- - and 2-year OS rates are 92% and 76%, respectively. The most common grade 3 - adverse events were colitis (n = 2, 8%) and esophagitis (n = 2, 8%), and no - higher-grade treatment-related adverse events have occurred. CONCLUSION: - Pembrolizumab and risk-adapted radiotherapy, without chemotherapy, are a - promising treatment approach for patients with LA-NSCLC with a PD-L1 TPS of ≥50%. -FAU - Ohri, Nitin -AU - Ohri N -AUID- ORCID: 0000-0001-9593-513X -AD - Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer - Center, Bronx, NY. -FAU - Jolly, Shruti -AU - Jolly S -AUID- ORCID: 0000-0002-8174-5199 -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, MI. -FAU - Cooper, Benjamin T -AU - Cooper BT -AD - Department of Radiation Oncology, Perlmutter Cancer Center, New York University - Grossman School of Medicine, New York, NY. -FAU - Kabarriti, Rafi -AU - Kabarriti R -AUID- ORCID: 0000-0001-7835-718X -AD - Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer - Center, Bronx, NY. -FAU - Bodner, William R -AU - Bodner WR -AD - Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer - Center, Bronx, NY. -FAU - Klein, Jonathan -AU - Klein J -AUID- ORCID: 0000-0002-6996-3572 -AD - Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer - Center, Bronx, NY. -FAU - Guha, Chandan -AU - Guha C -AD - Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer - Center, Bronx, NY. -FAU - Viswanathan, Shankar -AU - Viswanathan S -AUID- ORCID: 0000-0003-3349-9090 -AD - Department of Epidemiology and Population Health, Montefiore Einstein - Comprehensive Cancer Center, Bronx, NY. -FAU - Shum, Elaine -AU - Shum E -AUID- ORCID: 0000-0002-0390-5716 -AD - Division of Medical Oncology, Department of Medicine, Perlmutter Cancer Center, - New York University Grossman School of Medicine, New York, NY. -FAU - Sabari, Joshua K -AU - Sabari JK -AUID- ORCID: 0000-0002-1556-1543 -AD - Division of Medical Oncology, Department of Medicine, Perlmutter Cancer Center, - New York University Grossman School of Medicine, New York, NY. -FAU - Cheng, Haiying -AU - Cheng H -AUID- ORCID: 0000-0002-6051-2732 -AD - Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, - NY. -FAU - Gucalp, Rasim A -AU - Gucalp RA -AD - Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, - NY. -FAU - Castellucci, Enrico -AU - Castellucci E -AD - Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, - NY. -FAU - Qin, Angel -AU - Qin A -AUID- ORCID: 0000-0002-0339-3087 -AD - Department of Internal Medicine, Division of Hematology-Oncology, University of - Michigan, Ann Arbor, MI. -FAU - Gadgeel, Shirish M -AU - Gadgeel SM -AUID- ORCID: 0000-0001-5240-3811 -AD - Department of Internal Medicine, Henry Ford Cancer Institute, Henry Ford Health - System, Detroit, MI. -FAU - Halmos, Balazs -AU - Halmos B -AUID- ORCID: 0000-0001-7548-8360 -AD - Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, - NY. -LA - eng -SI - ClinicalTrials.gov/NCT03523702 -PT - Journal Article -DEP - 20231121 -PL - United States -TA - J Clin Oncol -JT - Journal of clinical oncology : official journal of the American Society of - Clinical Oncology -JID - 8309333 -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - Aged -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Radioimmunotherapy/adverse effects -MH - B7-H1 Antigen/metabolism -MH - Progression-Free Survival -EDAT- 2023/11/21 18:43 -MHDA- 2024/02/09 06:42 -CRDT- 2023/11/21 16:02 -PHST- 2024/02/09 06:42 [medline] -PHST- 2023/11/21 18:43 [pubmed] -PHST- 2023/11/21 16:02 [entrez] -AID - 10.1200/JCO.23.00627 [doi] -PST - ppublish -SO - J Clin Oncol. 2024 Feb 10;42(5):562-570. doi: 10.1200/JCO.23.00627. Epub 2023 Nov - 21. - -PMID- 29140105 -OWN - NLM -STAT- MEDLINE -DCOM- 20180814 -LR - 20180814 -IS - 1744-8301 (Electronic) -IS - 1479-6694 (Linking) -VI - 14 -IP - 3 -DP - 2018 Feb -TI - Durvalumab in non-small-cell lung cancer patients: current developments. -PG - 205-222 -LID - 10.2217/fon-2017-0373 [doi] -AB - Immune checkpoint inhibitors (ICIs) are a key component of treating advanced - cancer patients, principally antibodies against CTLA-4 and PD-1 or PD-L1. - Durvalumab (MEDI4736) is a selective, high-affinity, human IgG1 monoclonal - antibody that blocks PD-L1, which binds to PD-1 and CD80, but not to PD-L2. - Single-agent durvalumab showed clinical efficacy and a manageable safety profile - in advanced non-small-cell lung cancer, particularly the ≥25% PD-L1+ population. - Durvalumab is under evaluation in early, locally advanced and advanced disease as - monotherapy and combined with ICIs, targeted therapies, chemotherapy and - radiotherapy. Impressive activity has been recently reported after chemoradiation - in locally advanced patients; promising activity was observed with other ICI - combinations, and potentially with other drugs including platinum-based - chemotherapy. In contrast, early data reveal lower response rates in EGFR and - ALK-positive patients. -FAU - Mezquita, Laura -AU - Mezquita L -AD - Medical Oncology Department, Gustave Roussy, Villejuif, France. -FAU - Planchard, David -AU - Planchard D -AD - Medical Oncology Department, Gustave Roussy, Villejuif, France. -LA - eng -PT - Journal Article -PT - Review -DEP - 20171115 -PL - England -TA - Future Oncol -JT - Future oncology (London, England) -JID - 101256629 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -RN - 0 (CD274 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal/pharmacology/*therapeutic use -MH - Antineoplastic Agents, Immunological/pharmacology/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors/metabolism -MH - Biomarkers, Tumor -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/mortality/pathology -MH - Clinical Trials as Topic -MH - Combined Modality Therapy -MH - Humans -MH - Lung Neoplasms/*drug therapy/metabolism/mortality/pathology -MH - *Molecular Targeted Therapy -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors/metabolism -MH - Signal Transduction/drug effects -MH - Treatment Outcome -OTO - NOTNLM -OT - MEDI4736 -OT - NSCLC -OT - PD-L1 -OT - durvalumab -OT - immune checkpoint inhibitors -EDAT- 2017/11/16 06:00 -MHDA- 2018/08/15 06:00 -CRDT- 2017/11/16 06:00 -PHST- 2017/11/16 06:00 [pubmed] -PHST- 2018/08/15 06:00 [medline] -PHST- 2017/11/16 06:00 [entrez] -AID - 10.2217/fon-2017-0373 [doi] -PST - ppublish -SO - Future Oncol. 2018 Feb;14(3):205-222. doi: 10.2217/fon-2017-0373. Epub 2017 Nov - 15. - -PMID- 38897205 -OWN - NLM -STAT- MEDLINE -DCOM- 20240717 -LR - 20240831 -IS - 2666-3791 (Electronic) -IS - 2666-3791 (Linking) -VI - 5 -IP - 7 -DP - 2024 Jul 16 -TI - Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial - interim results (NEOTIDE/CTONG2104). -PG - 101615 -LID - S2666-3791(24)00319-7 [pii] -LID - 10.1016/j.xcrm.2024.101615 [doi] -LID - 101615 -AB - The clinical efficacy of neoadjuvant immunotherapy plus chemotherapy remains - elusive in localized epidermal growth factor receptor (EGFR)-mutant non-small - cell lung cancer (NSCLC). Here, we report interim results of a Simon's two-stage - design, phase 2 trial using neoadjuvant sintilimab with carboplatin and - nab-paclitaxel in resectable EGFR-mutant NSCLC. All 18 patients undergo radical - surgery, with one patient experiencing surgery delay. Fourteen patients exhibit - confirmed radiological response, with 44% achieving major pathological response - (MPR) and no pathological complete response (pCR). Similar genomic alterations - are observed before and after treatment without influencing the efficacy of - subsequent EGFR-tyrosine kinase inhibitors (TKIs) in vitro. Infiltration and - T cell receptor (TCR) clonal expansion of CCR8(+) regulatory T - (Treg)(hi)/CXCL13(+) exhausted T (Tex)(lo) cells define a subtype of EGFR-mutant - NSCLC highly resistant to immunotherapy, with the phenotype potentially serving - as a promising signature to predict immunotherapy efficacy. Informed circulating - tumor DNA (ctDNA) detection in EGFR-mutant NSCLC could help identify patients - nonresponsive to neoadjuvant immunochemotherapy. These findings provide - supportive data for the utilization of neoadjuvant immunochemotherapy and insight - into immune resistance in EGFR-mutant NSCLC. -CI - Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved. -FAU - Zhang, Chao -AU - Zhang C -AD - Department of Pulmonary Surgery, Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China; School of Medicine, South China University - of Technology, Guangzhou, China. -FAU - Sun, Yu-Xuan -AU - Sun YX -AD - School of Life Sciences, Peking University, Beijing, China. -FAU - Yi, Ding-Cheng -AU - Yi DC -AD - School of Life Sciences, Peking University, Beijing, China. -FAU - Jiang, Ben-Yuan -AU - Jiang BY -AD - Department of Pulmonary Surgery, Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China. -FAU - Yan, Li-Xu -AU - Yan LX -AD - Department of Pathology, Guangdong Provincial People's Hospital (Guangdong - Academy of Medical Sciences), Southern Medical University, Guangzhou, China. -FAU - Liu, Ze-Dao -AU - Liu ZD -AD - School of Life Sciences, Peking University, Beijing, China. -FAU - Peng, Li-Shan -AU - Peng LS -AD - Department of Pulmonary Surgery, Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China. -FAU - Zhang, Wen-Jie -AU - Zhang WJ -AD - School of Life Sciences, Peking University, Beijing, China. -FAU - Sun, Hao -AU - Sun H -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital - (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, - China. -FAU - Chen, Zhi-Yong -AU - Chen ZY -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital - (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, - China; Department of Radiation Therapy, Guangdong Provincial People's Hospital - (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, - China. -FAU - Wang, Dan-Hua -AU - Wang DH -AD - Burning Rock Biotech, Guangzhou, China. -FAU - Peng, Di -AU - Peng D -AD - Burning Rock Biotech, Guangzhou, China. -FAU - Chen, Song-An -AU - Chen SA -AD - Burning Rock Biotech, Guangzhou, China. -FAU - Li, Si-Qi -AU - Li SQ -AD - Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, - Guangzhou, China. -FAU - Zhang, Ze -AU - Zhang Z -AD - Institute of Biomedical Research, Yunnan University, Kunming, China. -FAU - Tan, Xiao-Yue -AU - Tan XY -AD - PET Center, Department of Nuclear Medicine, Guangdong Provincial People's - Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, - Guangzhou, China. -FAU - Yang, Jie -AU - Yang J -AD - Department of Pulmonary Surgery, Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China. -FAU - Zhao, Zhang-Yi -AU - Zhao ZY -AD - School of Life Sciences, Peking University, Beijing, China. -FAU - Zhang, Wan-Ting -AU - Zhang WT -AD - School of Life Sciences, Peking University, Beijing, China. -FAU - Su, Jian -AU - Su J -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital - (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, - China. -FAU - Li, Yang-Si -AU - Li YS -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital - (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, - China. -FAU - Liao, Ri-Qiang -AU - Liao RQ -AD - Department of Pulmonary Surgery, Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China. -FAU - Dong, Song -AU - Dong S -AD - Department of Pulmonary Surgery, Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China. -FAU - Xu, Chong-Rui -AU - Xu CR -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital - (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, - China. -FAU - Zhou, Qing -AU - Zhou Q -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital - (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, - China. -FAU - Yang, Xue-Ning -AU - Yang XN -AD - Department of Pulmonary Surgery, Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China. -FAU - Wu, Yi-Long -AU - Wu YL -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital - (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, - China. -FAU - Zhang, Ze-Min -AU - Zhang ZM -AD - School of Life Sciences, Peking University, Beijing, China; BIOPIC, Beijing - Advanced Innovation Center for Genomics, Peking University, Beijing, China. -FAU - Zhong, Wen-Zhao -AU - Zhong WZ -AD - Department of Pulmonary Surgery, Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong - Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern - Medical University, Guangzhou, China. Electronic address: - syzhongwenzhao@scut.edu.cn. -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20240618 -PL - United States -TA - Cell Rep Med -JT - Cell reports. Medicine -JID - 101766894 -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 8FU7FQ8UPK (sintilimab) -RN - P88XT4IS4D (Paclitaxel) -RN - BG3F62OND5 (Carboplatin) -RN - 0 (130-nm albumin-bound paclitaxel) -RN - 0 (Circulating Tumor DNA) -RN - 0 (Albumins) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology -MH - *ErbB Receptors/genetics -MH - *Neoadjuvant Therapy/methods -MH - *Lung Neoplasms/drug therapy/genetics/pathology -MH - Female -MH - Male -MH - Middle Aged -MH - Aged -MH - *Mutation/genetics -MH - *Antibodies, Monoclonal, Humanized/therapeutic use -MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Paclitaxel/therapeutic use -MH - Carboplatin/therapeutic use -MH - Adult -MH - Treatment Outcome -MH - Circulating Tumor DNA/genetics -MH - Albumins -PMC - PMC11293361 -COIS- Declaration of interests W.-Z.Z.. received speech honoraria from AstraZeneca, - Roche, Eli Lilly, and Pfizer outside the submitted work. Z.-M.Z. is a founder of - Analytical BioSciences. Y.-L.W. received research funding from Roche and speech - honoraria from AstraZeneca, Roche, Eli Lilly, Pfizer, and Sanofi, and he was a - research consultant for AstraZeneca. Q.Z. reports honoraria from AstraZeneca, - Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, and Sanofi outside the - submitted work. -EDAT- 2024/06/20 00:42 -MHDA- 2024/07/18 00:42 -PMCR- 2024/06/18 -CRDT- 2024/06/19 18:42 -PHST- 2023/11/02 00:00 [received] -PHST- 2024/01/31 00:00 [revised] -PHST- 2024/05/23 00:00 [accepted] -PHST- 2024/07/18 00:42 [medline] -PHST- 2024/06/20 00:42 [pubmed] -PHST- 2024/06/19 18:42 [entrez] -PHST- 2024/06/18 00:00 [pmc-release] -AID - S2666-3791(24)00319-7 [pii] -AID - 101615 [pii] -AID - 10.1016/j.xcrm.2024.101615 [doi] -PST - ppublish -SO - Cell Rep Med. 2024 Jul 16;5(7):101615. doi: 10.1016/j.xcrm.2024.101615. Epub 2024 - Jun 18. - -PMID- 34489161 -OWN - NLM -STAT- MEDLINE -DCOM- 20220517 -LR - 20220520 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 23 -IP - 3 -DP - 2022 May -TI - CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent - Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus - Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, - Locally Advanced Stage III Non-Small-Cell Lung Cancer. -PG - e264-e268 -LID - S1525-7304(21)00186-8 [pii] -LID - 10.1016/j.cllc.2021.07.005 [doi] -AB - INTRODUCTION: The 5 year survival rate for patients with locally advanced - non-small-cell lung cancer (NSCLC) not amenable for definitive resection with - historical standard-of-care concurrent chemoradiotherapy (cCRT) ranges from 15% - to 32%. cCRT primes anti-tumor immunity and also upregulates programmed death - ligand-1 (PD-L1), providing a rationale for combining an immune checkpoint - inhibitor with cCRT to improve outcomes. In the PACIFIC trial, consolidation - therapy with the PD-L1 inhibitor durvalumab improved progression-free survival - (PFS) and overall survival (OS) vs. placebo in patients with stage III NSCLC who - did not have disease progression after cCRT. CheckMate73L (NCT04026412), a - randomized phase 3 study, evaluates the efficacy of nivolumab plus cCRT followed - by nivolumab with or without ipilimumab vs. cCRT followed by durvalumab for - untreated, stage III NSCLC. PATIENTS AND METHODS: Patients with untreated, stage - III NSCLC will be randomized 1:1:1 to nivolumab plus cCRT followed by nivolumab - in combination with ipilimumab (Arm A) or nivolumab alone (Arm B); or cCRT - followed by durvalumab (Arm C). Primary endpoints are PFS and OS (Arm A vs. Arm - C). Secondary endpoints include additional analyses of PFS and OS (Arm A vs. Arm - B; Arm B vs. Arm C), as well as objective response rate, complete response rate, - time to response, duration of response, time to death or distant metastases, and - safety and tolerability. Recruitment began on August 20, 2019, and the estimated - primary completion date is October 17, 2022. -CI - Copyright © 2021. Published by Elsevier Inc. -FAU - De Ruysscher, Dirk -AU - De Ruysscher D -AD - Department of Radiation Oncology (Maastro), Maastricht University Medical Center, - GROW School for Oncology and Developmental Biology, The Netherlands. Electronic - address: dirk.deruysscher@maastro.nl. -FAU - Ramalingam, Suresh -AU - Ramalingam S -AD - Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory - University, Atlanta, GA. -FAU - Urbanic, James -AU - Urbanic J -AD - Department of Radiation Medicine and Applied Sciences, University of California - San Diego, La Jolla, CA. -FAU - Gerber, David E -AU - Gerber DE -AD - Division of Hematology Oncology, Harold C. Simmons Comprehensive Cancer Center, - University of Texas Southwestern Medical Center, Dallas, TX. -FAU - Tan, Daniel S W -AU - Tan DSW -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore. -FAU - Cai, Junliang -AU - Cai J -AD - Oncology Clinical Development, Biometrics and Data Sciences, Bristol Myers - Squibb, Lawrenceville, NJ. -FAU - Li, Ang -AU - Li A -AD - Oncology Clinical Development, Biometrics and Data Sciences, Bristol Myers - Squibb, Lawrenceville, NJ. -FAU - Peters, Solange -AU - Peters S -AD - Oncology Department, Centre hospitalier universitaire vaudois (CHUV), Lausanne - University, Switzerland. -LA - eng -SI - ClinicalTrials.gov/NCT04026412 -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20210719 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Ipilimumab) -RN - 28X28X9OKV (durvalumab) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Antibodies, Monoclonal -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - Ipilimumab/therapeutic use -MH - *Lung Neoplasms/pathology -MH - Nivolumab/therapeutic use -OTO - NOTNLM -OT - Chemoradiation -OT - Cytotoxic T-lymphocyte antigen-4 -OT - Immune checkpoint inhibitor -OT - PD-1/PD-L1 -OT - Progression-free survival -EDAT- 2021/09/08 06:00 -MHDA- 2022/05/18 06:00 -CRDT- 2021/09/07 06:13 -PHST- 2021/05/14 00:00 [received] -PHST- 2021/06/28 00:00 [revised] -PHST- 2021/07/04 00:00 [accepted] -PHST- 2021/09/08 06:00 [pubmed] -PHST- 2022/05/18 06:00 [medline] -PHST- 2021/09/07 06:13 [entrez] -AID - S1525-7304(21)00186-8 [pii] -AID - 10.1016/j.cllc.2021.07.005 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2022 May;23(3):e264-e268. doi: 10.1016/j.cllc.2021.07.005. Epub - 2021 Jul 19. - -PMID- 33847617 -OWN - NLM -STAT- MEDLINE -DCOM- 20210428 -LR - 20230103 -IS - 1536-5964 (Electronic) -IS - 0025-7974 (Print) -IS - 0025-7974 (Linking) -VI - 100 -IP - 15 -DP - 2021 Apr 16 -TI - Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as - first-line treatment in patients with extensive-stage small cell lung cancer: A - systematic review and network meta-analysis. -PG - e25180 -LID - 10.1097/MD.0000000000025180 [doi] -LID - e25180 -AB - BACKGROUND: In recent years, immune checkpoint inhibitors (ICIs) including - atezolizumab, durvalumab, pembrolizumab, and nivolumab have reported their - efficacy and safety profile in patients with extensive-stage small cell lung - cancer (ES-SCLC). However, given the diverse efficacy and inconsistent safety - among the ICIs, with the absence of head-to-head researches designed to evaluate - the efficacy among them, it might bring with confusion on selection in clinical - practice. OBJECTIVES: The present systematic review and network meta-analysis was - performed to conduct indirect comparisons on efficacy and safety profile among - ICIs, including atezolizumab, durvalumab, pembrolizumab, and nivolumab as - first-line treatment in patients with ES-SCLC. DESIGN: Several databases were - retrieved with established criteria until June 20, 2020, with the main MeSH Terms - and their similarities. Hazard ratios of overall survival (OS) and - progression-free survival (PFS), odds ratios (ORs) of disease control rate (DCR), - objective response rate (ORR), and adverse events (AEs) were compared indirectly - with network meta-analysis. DATA SOURCES: Medline, Cochrane library, and Embase. - ELIGIBILITY CRITERIA: Prospective, randomized, controlled clinical studies, which - reported PFS, OS, and AEs. DATA EXTRACTION AND SYNTHESIS: Clinical - characteristics were extracted by the 2 authors independently. Comparisons of HRs - were calculated for PFS and OS by random effect model. ORR, DCR, and AEs were - presented with ORs. Based on surface under the cumulative ranking curve, and - forest plots, efficacy and safety of the treatments were ranked, with predicted - histogram described. RESULTS: In total, there were 4 studies including 1547 - patients who met the eligibility criteria and enrolled. For indirect comparisons, - no significant difference on PFS was observed between atezolizumab and durvalumab - (HR 0.96, 95% CI, 0.72-1.29), or between atezolizumab and pembrolizumab (HR 1.05, - 95% CI, 0.78-1.43), or between atezolizumab and nivolumab (HR 1.18, 95% CI, - 0.79-1.79), or between durvalumab and pembrolizumab (HR 1.10, 95% CI, 0.84-1.43). - or between durvalumab and nivolumab (HR 1.23, 95% CI, 0.83-1.82), or between - pembrolizumab and nivolumab (HR 1.12, 95% CI, 0.76-1.66), nor significant - difference on OS observed between atezolizumab and durvalumab (HR 0.93, 95% CI, - 0.67-1.30), or between atezolizumab and pembrolizumab (HR 0.88, 95% CI, - 0.62-1.24), or between atezolizumab and nivolumab (HR 1.04, 95% CI, 0.66-1.66), - or between durvalumab and pembrolizumab (HR 0.94, 95% CI, 0.70-1.25), or between - durvalumab and nivolumab (HR 1.12, 95% CI, 0.73-1.71), or between pembrolizumab - and nivolumab (HR 1.19, 95% CI, 0.77-1.84). However, durvalumab was shown - statistical superiority on ORR when compared with atezolizumab (HR 0.79, 95% CI, - 0.64-0.98), also with significantly higher risk on immune-related AEs when - compared with atezolizumab (OR 0.22, 95% CI, 0.10-0.50), and pembrolizumab (OR - 3.12, 95% CI, 1.27-7.64). CONCLUSIONS: Results of the study revealed that there - was no statistical difference on PFS or OS among agents of atezolizumab, - durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with - ES-SCLC. However, durvalumab was shown superiority on ORR when compared with - atezolizumab, also with significantly higher risk on immune-related AEs. -CI - Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. -FAU - Chen, Jianxin -AU - Chen J -AD - Department of Medical Oncology. -FAU - Wang, Junhui -AU - Wang J -AD - Department of Radiation Oncology. -FAU - Xu, Hui -AU - Xu H -AD - Medical Department, Quzhou People's Hospital, Quzhou, Zhejiang, China. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Systematic Review -PL - United States -TA - Medicine (Baltimore) -JT - Medicine -JID - 2985248R -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 28X28X9OKV (durvalumab) -RN - 31YO63LBSN (Nivolumab) -RN - 52CMI0WC3Y (atezolizumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - Antineoplastic Agents, Immunological/administration & dosage/adverse - effects/*therapeutic use -MH - Humans -MH - Lung Neoplasms/*drug therapy -MH - Neoplasm Staging -MH - Network Meta-Analysis -MH - Nivolumab/therapeutic use -MH - Progression-Free Survival -MH - Randomized Controlled Trials as Topic -MH - Small Cell Lung Carcinoma/*drug therapy -PMC - PMC8051984 -COIS- The authors have no conflicts of interest to disclose. -EDAT- 2021/04/14 06:00 -MHDA- 2021/04/29 06:00 -PMCR- 2021/04/16 -CRDT- 2021/04/13 12:12 -PHST- 2020/12/02 00:00 [received] -PHST- 2021/02/25 00:00 [accepted] -PHST- 2021/04/13 12:12 [entrez] -PHST- 2021/04/14 06:00 [pubmed] -PHST- 2021/04/29 06:00 [medline] -PHST- 2021/04/16 00:00 [pmc-release] -AID - 00005792-202104160-00013 [pii] -AID - MD-D-20-11985 [pii] -AID - 10.1097/MD.0000000000025180 [doi] -PST - ppublish -SO - Medicine (Baltimore). 2021 Apr 16;100(15):e25180. doi: - 10.1097/MD.0000000000025180. - -PMID- 33881745 -OWN - NLM -STAT- MEDLINE -DCOM- 20210622 -LR - 20240415 -IS - 1865-8652 (Electronic) -IS - 0741-238X (Print) -IS - 0741-238X (Linking) -VI - 38 -IP - 6 -DP - 2021 Jun -TI - Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. -PG - 2759-2778 -LID - 10.1007/s12325-021-01675-0 [doi] -AB - The introduction of immunotherapy has fundamentally transformed the treatment - landscape in cancer, providing long-term survival benefit for patients with - advanced disease across multiple tumor types, including non-small cell lung - cancer (NSCLC). In the placebo-controlled phase 3 PACIFIC trial, the PD-L1 - inhibitor durvalumab demonstrated significant improvements in progression-free - survival and overall survival in patients with unresectable, stage III NSCLC who - had not progressed after platinum-based chemoradiotherapy (CRT). These findings - have led to the widespread acceptance of the 'PACIFIC regimen' (durvalumab after - CRT) as the standard of care in this setting. Moreover, the PACIFIC trial is the - first study to demonstrate a proven survival advantage with an immunotherapy in a - curative-intent setting, thereby providing a strong rationale for further - investigation of durvalumab in early-stage cancers. Herein, we describe the - extensive clinical development program for durvalumab across multiple tumor types - in curative-intent settings, outlining the scientific rationale(s) for its use - and highlighting the innovative research (e.g., personalized cancer monitoring) - advanced by these trials. -FAU - Melillo, Giovanni -AU - Melillo G -AD - AstraZeneca, Gaithersburg, MD, USA. -FAU - Chand, Vikram -AU - Chand V -AD - AstraZeneca, Gaithersburg, MD, USA. -FAU - Yovine, Alejandro -AU - Yovine A -AD - AstraZeneca, Cambridge, UK. -FAU - Gupta, Ashok -AU - Gupta A -AD - AstraZeneca, Gaithersburg, MD, USA. -FAU - Massacesi, Cristian -AU - Massacesi C -AD - AstraZeneca, Gaithersburg, MD, USA. cristian.massacesi@astrazeneca.com. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20210421 -PL - United States -TA - Adv Ther -JT - Advances in therapy -JID - 8611864 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -MH - Antibodies, Monoclonal/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy -PMC - PMC8190020 -OTO - NOTNLM -OT - Bladder cancer -OT - Cervical cancer -OT - Curative intent -OT - Durvalumab -OT - Early-stage cancer -OT - Esophageal cancer -OT - Gastric cancer -OT - Hepatocellular carcinoma -OT - Lung cancer -OT - PACIFIC -EDAT- 2021/04/22 06:00 -MHDA- 2021/06/23 06:00 -PMCR- 2021/04/21 -CRDT- 2021/04/21 12:25 -PHST- 2021/01/22 00:00 [received] -PHST- 2021/02/16 00:00 [accepted] -PHST- 2021/04/22 06:00 [pubmed] -PHST- 2021/06/23 06:00 [medline] -PHST- 2021/04/21 12:25 [entrez] -PHST- 2021/04/21 00:00 [pmc-release] -AID - 10.1007/s12325-021-01675-0 [pii] -AID - 1675 [pii] -AID - 10.1007/s12325-021-01675-0 [doi] -PST - ppublish -SO - Adv Ther. 2021 Jun;38(6):2759-2778. doi: 10.1007/s12325-021-01675-0. Epub 2021 - Apr 21. - -PMID- 37430270 -OWN - NLM -STAT- MEDLINE -DCOM- 20230712 -LR - 20230718 -IS - 1478-811X (Electronic) -IS - 1478-811X (Linking) -VI - 21 -IP - 1 -DP - 2023 Jul 10 -TI - Single-cell RNA sequencing reveals enhanced antitumor immunity after combined - application of PD-1 inhibitor and Shenmai injection in non-small cell lung - cancer. -PG - 169 -LID - 10.1186/s12964-023-01184-3 [doi] -LID - 169 -AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) have altered the clinical - management of non-small cell lung cancer (NSCLC). However, the low response rate, - severe immune-related adverse events (irAEs), and hyperprogressive disease - following ICIs monotherapy require attention. Combination therapy may overcome - these limitations and traditional Chinese medicine with immunomodulatory effects - provides a promising approach. Shenmai injection (SMI) is a clinically effective - adjuvant treatment for cancer with chemotherapy and radiotherapy. Therefore, the - combined effects and mechanisms of SMI and programmed death-1 (PD-1) inhibitor - against NSCLC was focused on this study. METHODS: A Lewis lung carcinoma mouse - model and a lung squamous cell carcinoma humanized mouse model were used to - investigate the combined efficacy and safety of SMI and PD-1 inhibitor. The - synergistic mechanisms of the combination therapy against NSCLC were explored - using single-cell RNA sequencing. Validation experiments were performed using - immunofluorescence analysis, in vitro experiment, and bulk transcriptomic - datasets. RESULTS: In both models, combination therapy alleviated tumor growth - and prolonged survival without increasing irAEs. The GZMA(high) and XCL1(high) - natural killer (NK) cell subclusters with cytotoxic and chemokine signatures - increased in the combination therapy, while malignant cells from combination - therapy were mainly in the apoptotic state, suggesting that mediating tumor cell - apoptosis through NK cells is the main synergistic mechanisms of combination - therapy. In vitro experiment confirmed that combination therapy increased - secretion of Granzyme A by NK cells. Moreover, we discovered that PD-1 inhibitor - and SMI combination blocked inhibitory receptors on NK and T cells and restores - their antitumoral activity in NSCLC better than PD-1 inhibitor monotherapy, and - immune and stromal cells exhibited a decrease of angiogenic features and - attenuated cancer metabolism reprogramming in microenvironment of combination - therapy. CONCLUSIONS: This study demonstrated that SMI reprograms tumor immune - microenvironment mainly by inducing NK cells infiltration and synergizes with - PD-1 inhibitor against NSCLC, suggested that targeting NK cells may be an - important strategy for combining with ICIs. Video Abstract. -CI - © 2023. The Author(s). -FAU - Yu, Dingyi -AU - Yu D -AD - Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, - Zhejiang University, Hangzhou, China. -FAU - Yang, Penghui -AU - Yang P -AD - Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, - Zhejiang University, Hangzhou, China. -FAU - Lu, Xiaoyan -AU - Lu X -AD - Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, - Zhejiang University, Hangzhou, China. luxy@zju.edu.cn. -AD - National Key Laboratory of Chinese Medicine Modernization, Innovation Center of - Yangtze River Delta, Zhejiang University, Jiaxing, China. luxy@zju.edu.cn. -AD - Innovation Center in Zhejiang University, State Key Laboratory of Component-Based - Chinese Medicine, Hangzhou, China. luxy@zju.edu.cn. -AD - Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China. - luxy@zju.edu.cn. -AD - Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang - University School of Medicine, Hangzhou, China. luxy@zju.edu.cn. -FAU - Huang, Shaoze -AU - Huang S -AD - Zhejiang Engineering Research Center for Advanced Manufacturing of Traditional - Chinese Medicine, Huzhou, China. -FAU - Liu, Li -AU - Liu L -AD - Zhejiang Engineering Research Center for Advanced Manufacturing of Traditional - Chinese Medicine, Huzhou, China. boltliu@163.com. -FAU - Fan, Xiaohui -AU - Fan X -AD - Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, - Zhejiang University, Hangzhou, China. fanxh@zju.edu.cn. -AD - National Key Laboratory of Chinese Medicine Modernization, Innovation Center of - Yangtze River Delta, Zhejiang University, Jiaxing, China. fanxh@zju.edu.cn. -AD - Innovation Center in Zhejiang University, State Key Laboratory of Component-Based - Chinese Medicine, Hangzhou, China. fanxh@zju.edu.cn. -AD - Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China. - fanxh@zju.edu.cn. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Video-Audio Media -DEP - 20230710 -PL - England -TA - Cell Commun Signal -JT - Cell communication and signaling : CCS -JID - 101170464 -RN - 0 (fructus schizandrae, radix ginseng, radix ophiopogonis drug combination) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Animals -MH - Mice -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use -MH - *Lung Neoplasms/drug therapy -MH - Sequence Analysis, RNA -MH - Tumor Microenvironment -PMC - PMC10332015 -OTO - NOTNLM -OT - Natural killer cells -OT - Non-small cell lung cancer -OT - Programmed death-1 inhibitor -OT - Shenmai injection -OT - Single-cell RNA sequencing -COIS- The authors declare no competing interests. -EDAT- 2023/07/11 01:08 -MHDA- 2023/07/12 06:42 -PMCR- 2023/07/10 -CRDT- 2023/07/10 23:39 -PHST- 2023/03/17 00:00 [received] -PHST- 2023/06/04 00:00 [accepted] -PHST- 2023/07/12 06:42 [medline] -PHST- 2023/07/11 01:08 [pubmed] -PHST- 2023/07/10 23:39 [entrez] -PHST- 2023/07/10 00:00 [pmc-release] -AID - 10.1186/s12964-023-01184-3 [pii] -AID - 1184 [pii] -AID - 10.1186/s12964-023-01184-3 [doi] -PST - epublish -SO - Cell Commun Signal. 2023 Jul 10;21(1):169. doi: 10.1186/s12964-023-01184-3. - -PMID- 37410476 -OWN - NLM -STAT- MEDLINE -DCOM- 20230925 -LR - 20240707 -IS - 2374-2445 (Electronic) -IS - 2374-2437 (Print) -IS - 2374-2437 (Linking) -VI - 9 -IP - 9 -DP - 2023 Sep 1 -TI - Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in - Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical - Trial. -PG - 1205-1213 -LID - 10.1001/jamaoncol.2023.2132 [doi] -AB - IMPORTANCE: Although immune checkpoint inhibitors (ICIs) targeting programmed - cell death 1 (PD-1) and PD-1 ligand 1 have improved the outcome for many cancer - types, the majority of patients fails to respond to ICI monotherapy. - Hypofractionated radiotherapy has the potential to improve the therapeutic ratio - of ICIs. OBJECTIVE: To assess the addition of radiotherapy to ICIs compared with - ICI monotherapy in patients with advanced solid tumors. DESIGN, SETTING, AND - PARTICIPANTS: This open-label, multicenter, randomized phase 2 trial was - conducted in 5 Belgian hospitals and enrolled participants between March 2018 and - October 2020. Patients 18 years or older with locally advanced or metastatic - melanoma, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell - carcinoma, or non-small cell lung carcinoma were eligible. A total of 99 patients - were randomly assigned to either the control arm (n = 52) or the experimental arm - (n = 47). Of those, 3 patients (1 in the control arm vs 2 in the experimental - arm) withdrew consent and thus were not included in the analysis. Data analyses - were performed between April 2022 and March 2023. INTERVENTIONS: Patients were - randomized (1:1) to receive anti-PD-1/PD-1 ligand 1 ICIs alone as per standard of - care (control arm) or combined with stereotactic body radiotherapy 3 × 8 gray to - a maximum of 3 lesions prior to the second or third ICI cycle, depending on the - frequency of administration (experimental arm). Randomization was stratified - according to tumor histologic findings and disease burden (3 and fewer or more - than 3 cancer lesions). MAIN OUTCOMES AND MEASURES: The primary end point was - progression-free survival (PFS) as per immune Response Evaluation Criteria in - Solid Tumors. Key secondary end points included overall survival (OS), objective - response rate, local control rate, and toxic effects. Efficacy was assessed in - the intention-to-treat population, while safety was evaluated in the as-treated - population. RESULTS: Among 96 patients included in the analysis (mean age, 66 - years; 76 [79%] female), 72 (75%) had more than 3 tumor lesions and 65 (68%) had - received at least 1 previous line of systemic treatment at time of inclusion. - Seven patients allocated to the experimental arm did not complete the - study-prescribed radiotherapy course due to early disease progression (n = 5) or - intercurrent illness (n = 2). With a median (range) follow-up of 12.5 (0.7-46.2) - months, median PFS was 2.8 months in the control arm compared with 4.4 months in - the experimental arm (hazard ratio, 0.95; 95% CI, 0.58-1.53; P = .82). Between - the control and experimental arms, no improvement in median OS was observed (11.0 - vs 14.3 months; hazard ratio, 0.82; 95% CI, 0.48-1.41; P = .47), and objective - response rate was not statistically significantly different (22% vs 27%; - P = .56), despite a local control rate of 75% in irradiated patients. Acute - treatment-related toxic effects of any grade and grade 3 or higher occurred in - 79% and 18% of patients in the control arm vs 78% and 18% in the experimental - arm, respectively. No grade 5 adverse events occurred. CONCLUSIONS AND RELEVANCE: - This phase 2 randomized clinical trial demonstrated that while safe, adding - subablative stereotactic radiotherapy of a limited number of metastatic lesions - to ICI monotherapy failed to show improvement in PFS or OS. TRIAL REGISTRATION: - ClinicalTrials.gov Identifier: NCT03511391. -FAU - Spaas, Mathieu -AU - Spaas M -AD - Department of Radiation Oncology, Ghent University Hospital, Ghent University, - Ghent, Belgium. -FAU - Sundahl, Nora -AU - Sundahl N -AD - Department of Radiation Oncology, AZ Groeninge, Kortrijk, Belgium. -FAU - Kruse, Vibeke -AU - Kruse V -AD - Department of Medical Oncology, AZ Nikolaas, Sint-Niklaas, Belgium. -FAU - Rottey, Sylvie -AU - Rottey S -AD - Department of Medical Oncology, Ghent University Hospital, Ghent University, - Ghent, Belgium. -FAU - De Maeseneer, Daan -AU - De Maeseneer D -AD - Department of Medical Oncology, Ghent University Hospital, Ghent University, - Ghent, Belgium. -AD - Department of Medical Oncology, AZ Sint-Lucas, Bruges, Belgium. -FAU - Duprez, Fréderic -AU - Duprez F -AD - Department of Radiation Oncology, Ghent University Hospital, Ghent University, - Ghent, Belgium. -FAU - Lievens, Yolande -AU - Lievens Y -AD - Department of Radiation Oncology, Ghent University Hospital, Ghent University, - Ghent, Belgium. -FAU - Surmont, Veerle -AU - Surmont V -AD - Department of Pulmonary Medicine, Ghent University Hospital, Ghent University, - Ghent, Belgium. -FAU - Brochez, Lieve -AU - Brochez L -AD - Department of Dermatology, Ghent University Hospital, Ghent University, Ghent, - Belgium. -FAU - Reynders, Dries -AU - Reynders D -AD - Department of Applied Mathematics, Computer Science and Statistics and Stat-Gent - CRESCENDO Consortium, Ghent University, Ghent, Belgium. -FAU - Danckaert, Willeke -AU - Danckaert W -AD - Department of Radiation Oncology, Ghent University Hospital, Ghent University, - Ghent, Belgium. -FAU - Goetghebeur, Els -AU - Goetghebeur E -AD - Department of Applied Mathematics, Computer Science and Statistics and Stat-Gent - CRESCENDO Consortium, Ghent University, Ghent, Belgium. -FAU - Van den Begin, Robbe -AU - Van den Begin R -AD - Department of Radiation Oncology, Jules Bordet Institute, Université Libre de - Bruxelles, Brussels, Belgium. -FAU - Van Gestel, Dirk -AU - Van Gestel D -AD - Department of Radiation Oncology, Jules Bordet Institute, Université Libre de - Bruxelles, Brussels, Belgium. -FAU - Renard, Vincent -AU - Renard V -AD - Department of Medical Oncology, AZ Sint-Lucas, Ghent, Belgium. -FAU - Dirix, Piet -AU - Dirix P -AD - Department of Radiation Oncology, Iridium Network, Wilrijk, Belgium. -FAU - Ost, Piet -AU - Ost P -AD - Department of Radiation Oncology, Ghent University Hospital, Ghent University, - Ghent, Belgium. -AD - Department of Radiation Oncology, Iridium Network, Wilrijk, Belgium. -LA - eng -SI - ClinicalTrials.gov/NCT03511391 -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -PL - United States -TA - JAMA Oncol -JT - JAMA oncology -JID - 101652861 -RN - 0 (Ligands) -SB - IM -MH - Humans -MH - Female -MH - Aged -MH - Male -MH - Treatment Outcome -MH - *Carcinoma, Transitional Cell/drug therapy -MH - *Radiosurgery/adverse effects -MH - Ligands -MH - *Urinary Bladder Neoplasms/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Antineoplastic Combined Chemotherapy Protocols -PMC - PMC10326732 -COIS- Conflict of Interest Disclosures: Dr Spaas reported grants from Astellas outside - the submitted work. Prof Kruse reported personal fees from Bristol Myers Squibb, - MSD, and Novartis outside the submitted work. Prof Lievens reported fees paid to - institution from ImmunoSABR and AstraZeneca and grants paid to institution as - Chair of ESTRO Value-Based Radiation Oncology outside the submitted work, as well - as unpaid work for the European Organisation for Research and Treatment of Cancer - as an investigator. Dr Van den Begin reported grants from the Association Jules - Bordet outside the submitted work. Prof Van Gestel reported personal fees from - Sanofi, Takeda, Novartis, and Merck outside the submitted work. Dr Renard - reported travel and accommodation expenses from Pfizer and MSD outside the - submitted work. Dr Ost reported personal fees from Janssen, Bayer, Novartis, and - MSD during the conduct of the study. No other disclosures were reported. -EDAT- 2023/07/06 13:14 -MHDA- 2023/09/25 06:41 -PMCR- 2024/07/06 -CRDT- 2023/07/06 11:33 -PHST- 2023/09/25 06:41 [medline] -PHST- 2023/07/06 13:14 [pubmed] -PHST- 2023/07/06 11:33 [entrez] -PHST- 2024/07/06 00:00 [pmc-release] -AID - 2806787 [pii] -AID - coi230027 [pii] -AID - 10.1001/jamaoncol.2023.2132 [doi] -PST - ppublish -SO - JAMA Oncol. 2023 Sep 1;9(9):1205-1213. doi: 10.1001/jamaoncol.2023.2132. - -PMID- 31782989 -OWN - NLM -STAT- MEDLINE -DCOM- 20200320 -LR - 20200320 -IS - 1744-8328 (Electronic) -IS - 1473-7140 (Linking) -VI - 19 -IP - 12 -DP - 2019 Dec -TI - Durvalumab for the treatment of non-small cell lung cancer. -PG - 1009-1016 -LID - 10.1080/14737140.2019.1699407 [doi] -AB - Introduction: The prognosis of patients with advanced non-small cell lung cancer - (NSCLC) remains poor, with a 5-year overall survival rate of around 15%. Immune - checkpoint inhibitors, such as programmed cell death protein 1 and programmed - death-ligand 1 (PD-L1) inhibitors, have opened a new era in the management of - NSCLC. Three checkpoint inhibitors (nivolumab, pembrolizumab, and atezolizumab) - are currently approved by the US Food and Drug Administration (FDA) for advanced - NSCLC. Durvalumab, an anti-PD-L1 antibody, is under investigation in several - trials.Areas covered: This article reviews the pharmacological properties, - clinical efficacy, and safety of durvalumab as monotherapy and in combination - with other drugs for the treatment of locally advanced and advanced NSCLC.Expert - opinion: Durvalumab as monotherapy or in combination with tremelimumab was - effective with well-tolerated safety profiles for advanced NSCLC in several phase - I or II studies. The PACIFIC study assessed the effectiveness of durvalumab as - maintenance therapy following definitive chemoradiotherapy for unresectable stage - III NSCLC, and met its primary endpoints of progression-free survival and overall - survival. These results led to FDA approval for this NSCLC population. It will be - exciting to follow ongoing phase III studies assessing how durvalumab fits into - the rapidly evolving therapeutic landscape for advanced NSCLC. -FAU - Murakami, Shuji -AU - Murakami S -AUID- ORCID: 0000-0001-5104-5493 -AD - Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan. -LA - eng -PT - Journal Article -PT - Review -DEP - 20191203 -PL - England -TA - Expert Rev Anticancer Ther -JT - Expert review of anticancer therapy -JID - 101123358 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 28X28X9OKV (durvalumab) -RN - QEN1X95CIX (tremelimumab) -SB - IM -MH - Antibodies, Monoclonal/*administration & dosage/adverse effects/pharmacology -MH - Antibodies, Monoclonal, Humanized/administration & dosage -MH - Antineoplastic Agents, Immunological/administration & dosage/adverse - effects/pharmacology -MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse - effects/pharmacology -MH - B7-H1 Antigen/antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology -MH - Prognosis -MH - Survival Rate -OTO - NOTNLM -OT - Durvalumab -OT - NSCLC -OT - PD-1 -OT - PD-L1 -OT - immune checkpoint inhibitors -EDAT- 2019/11/30 06:00 -MHDA- 2020/03/21 06:00 -CRDT- 2019/11/30 06:00 -PHST- 2019/11/30 06:00 [pubmed] -PHST- 2020/03/21 06:00 [medline] -PHST- 2019/11/30 06:00 [entrez] -AID - 10.1080/14737140.2019.1699407 [doi] -PST - ppublish -SO - Expert Rev Anticancer Ther. 2019 Dec;19(12):1009-1016. doi: - 10.1080/14737140.2019.1699407. Epub 2019 Dec 3. - -PMID- 28551359 -OWN - NLM -STAT- MEDLINE -DCOM- 20170911 -LR - 20220410 -IS - 1474-5488 (Electronic) -IS - 1470-2045 (Print) -IS - 1470-2045 (Linking) -VI - 18 -IP - 7 -DP - 2017 Jul -TI - Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in - the treatment of non-small-cell lung cancer: a secondary analysis of the - KEYNOTE-001 phase 1 trial. -PG - 895-903 -LID - S1470-2045(17)30380-7 [pii] -LID - 10.1016/S1470-2045(17)30380-7 [doi] -AB - BACKGROUND: Preclinical studies have found radiotherapy enhances antitumour - immune responses. We aimed to assess disease control and pulmonary toxicity in - patients who previously received radiotherapy for non-small-cell lung cancer - (NSCLC) before receiving pembrolizumab. METHODS: We assessed patients with - advanced NSCLC treated on the phase 1 KEYNOTE-001 trial at a single institution - (University of California, Los Angeles, CA, USA). Patients were aged 18 years or - older, had an Eastern Cooperative Oncology Group performance status of 1 or less, - had adequate organ function, and no history of pneumonitis. Patients received - pembrolizumab at a dose of either 2 mg/kg of bodyweight or 10 mg/kg every 3 - weeks, or 10 mg/kg every 2 weeks, until disease progression, unacceptable - toxicity, or other protocol-defined reasons for discontinuation. Disease response - and pulmonary toxicity were prospectively assessed by Immune-related Response - Criteria and Common Terminology Criteria for Adverse Events version 4.0. The - primary objective of the KEYNOTE-001 trial was to assess the safety, side-effect - profile, and antitumour activity of pembrolizumab. For our secondary analysis, - patients were divided into subgroups to compare patients who previously received - radiotherapy with patients who had not. Our primary objective was to determine - whether previous radiotherapy affected progression-free survival, overall - survival, and pulmonary toxicity in the intention-to-treat population. The - KEYNOTE-001 trial was registered with ClinicalTrials.gov, number NCT01295827. - FINDINGS: Between May 22, 2012, and July 11, 2014, 98 patients were enrolled and - received their first cycle of pembrolizumab. One patient was lost to follow-up. - 42 (43%) of 97 patients had previously received any radiotherapy for the - treatment of NSCLC before the first cycle of pembrolizumab. 38 (39%) of 97 - patients received extracranial radiotherapy and 24 (25%) of 97 patients received - thoracic radiotherapy. Median follow-up for surviving patients was 32·5 months - (IQR 29·8-34·1). Progression-free survival with pembrolizumab was significantly - longer in patients who previously received any radiotherapy than in patients - without previous radiotherapy (hazard ratio [HR] 0·56 [95% CI 0·34-0·91], - p=0·019; median progression-free survival 4·4 months [95% CI 2·1-8·6] vs 2·1 - months [1·6-2·3]) and for patients who previously received extracranial - radiotherapy compared with those without previous extracranial radiotherapy (HR - 0·50 [0·30-0·84], p=0·0084; median progression-free survival 6·3 months [95% CI - 2·1-10·4] vs 2·0 months [1·8-2·1]). Overall survival with pembrolizumab was - significantly longer in patients who previously received any radiotherapy than in - patients without previous radiotherapy (HR 0·58 [95% CI 0·36-0·94], p=0·026; - median overall survival 10·7 months [95% CI 6·5-18·9] vs 5·3 months [2·7-7·7]) - and for patients who previously received extracranial radiotherapy compared with - those without previous extracranial radiotherapy (0·59 [95% CI 0·36-0·96], - p=0·034; median overall survival 11·6 months [95% CI 6·5-20·5] vs 5·3 months - [3·0-8·5]). 15 (63%) of 24 patients who had previously received thoracic - radiotherapy had any recorded pulmonary toxicity versus 29 (40%) of 73 patients - with no previous thoracic radiotherapy. Three (13%) patients with previous - thoracic radiotherapy had treatment-related pulmonary toxicity compared with one - (1%) of those without; frequency of grade 3 or worse treatment-related pulmonary - toxicities was similar (one patient in each group). INTERPRETATION: Our data - suggest that previous treatment with radiotherapy in patients with advanced NSCLC - results in longer progression-free survival and overall survival with - pembrolizumab treatment than that seen in patients who did not have previous - radiotherapy, with an acceptable safety profile. Further clinical trials - investigating this combination are needed to determine the optimal treatment - strategy for patients with advanced NSCLC. FUNDING: US National Institutes of - Health. -CI - Copyright © 2017 Elsevier Ltd. All rights reserved. -FAU - Shaverdian, Narek -AU - Shaverdian N -AD - Department of Radiation Oncology, University of California Los Angeles, Los - Angeles, CA, USA. -FAU - Lisberg, Aaron E -AU - Lisberg AE -AD - Department of Hematology and Oncology, University of California Los Angeles, Los - Angeles, CA, USA. -FAU - Bornazyan, Krikor -AU - Bornazyan K -AD - Department of Hematology and Oncology, University of California Los Angeles, Los - Angeles, CA, USA. -FAU - Veruttipong, Darlene -AU - Veruttipong D -AD - Department of Radiation Oncology, University of California Los Angeles, Los - Angeles, CA, USA. -FAU - Goldman, Jonathan W -AU - Goldman JW -AD - Department of Hematology and Oncology, University of California Los Angeles, Los - Angeles, CA, USA. -FAU - Formenti, Silvia C -AU - Formenti SC -AD - Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA. -FAU - Garon, Edward B -AU - Garon EB -AD - Department of Hematology and Oncology, University of California Los Angeles, Los - Angeles, CA, USA. -FAU - Lee, Percy -AU - Lee P -AD - Department of Radiation Oncology, University of California Los Angeles, Los - Angeles, CA, USA. Electronic address: percylee@mednet.ucla.edu. -LA - eng -SI - ClinicalTrials.gov/NCT01295827 -GR - R01 CA208403/CA/NCI NIH HHS/United States -PT - Clinical Trial, Phase I -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20170524 -PL - England -TA - Lancet Oncol -JT - The Lancet. Oncology -JID - 100957246 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -CIN - Lancet Oncol. 2017 Jul;18(7):840-842. doi: 10.1016/S1470-2045(17)30354-6. PMID: - 28551358 -EIN - Lancet Oncol. 2017 Jul;18(7):e371. doi: 10.1016/S1470-2045(17)30409-6. PMID: - 28552211 -CIN - Nat Rev Clin Oncol. 2017 Jul;14(7):392-393. doi: 10.1038/nrclinonc.2017.85. PMID: - 28607520 -CIN - Strahlenther Onkol. 2017 Sep;193(9):763-764. doi: 10.1007/s00066-017-1179-9. - PMID: 28698902 -CIN - Lancet Oncol. 2017 Sep;18(9):e504. doi: 10.1016/S1470-2045(17)30472-2. PMID: - 28884692 -CIN - Lancet Oncol. 2017 Sep;18(9):e505. doi: 10.1016/S1470-2045(17)30588-0. PMID: - 28884693 -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use -MH - Antineoplastic Agents/adverse effects/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/radiotherapy/secondary -MH - Combined Modality Therapy -MH - Disease-Free Survival -MH - Female -MH - Humans -MH - Lung Diseases/*etiology -MH - Lung Neoplasms/*drug therapy/pathology/radiotherapy -MH - Male -MH - Middle Aged -MH - Radiotherapy/adverse effects -MH - Retreatment -MH - Survival Rate -PMC - PMC5538772 -MID - NIHMS880399 -COIS- Declaration of interests EBG reports grants from Merck during the conduct of the - KEYNOTE-001 study; grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers - Squibb, Eli Lilly, Genentech, Mirati, Pfizer, and Novartis outside the submitted - work. All other authors declare no competing interests. -EDAT- 2017/05/30 06:00 -MHDA- 2017/09/12 06:00 -PMCR- 2018/07/01 -CRDT- 2017/05/29 06:00 -PHST- 2017/02/28 00:00 [received] -PHST- 2017/04/03 00:00 [revised] -PHST- 2017/04/13 00:00 [accepted] -PHST- 2017/05/30 06:00 [pubmed] -PHST- 2017/09/12 06:00 [medline] -PHST- 2017/05/29 06:00 [entrez] -PHST- 2018/07/01 00:00 [pmc-release] -AID - S1470-2045(17)30380-7 [pii] -AID - 10.1016/S1470-2045(17)30380-7 [doi] -PST - ppublish -SO - Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub - 2017 May 24. - -PMID- 33465302 -OWN - NLM -STAT- MEDLINE -DCOM- 20210805 -LR - 20210805 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 10 -IP - 4 -DP - 2021 Feb -TI - Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in - patients with non-small-cell lung cancer: a systematic review and meta-analysis. -PG - 1222-1239 -LID - 10.1002/cam4.3718 [doi] -AB - BACKGROUND: A combination of programmed cell death protein-1 (PD-1)/programmed - cell death ligand-1 (PD-L1) inhibitors and radiotherapy (RT) is increasingly - being used to treat non-small-cell lung cancer (NSCLC). However, the safety and - efficacy of this approach remains controversial. We performed a systematic review - and meta-analysis to summarize the related research. METHODS: We searched the - China Biology Medicine, EMBASE, Cochrane Library, and PubMed databases for all - the relevant studies. The Stata software, version 12.0 was used for the - meta-analysis. RESULTS: The study included 20 clinical trials that enrolled 2027 - patients with NSCLC. Compared with non-combination therapy, combination therapy - using PD-1/PD-L1 inhibitors and RT was associated with prolonged overall survival - (OS) (1-year OS: odds ratio [OR] 1.77, 95% confidence interval [CI] 1.35-2.33, - p = 0.000; 2-year OS: OR 1.77, 95% CI 1.35-2.33, p = 0.000) and progression-free - survival (PFS) (0.5-year PFS: OR 1.83, 95% CI 1.13-2.98, p = 0.014; 1-year PFS: - OR 2.09, 95% CI 1.29-3.38, p = 0.003; 2-year PFS: OR 2.47, 95% CI 1.13-5.37, - p = 0.023). Combination therapy also improved the objective response rate (OR - 2.76, 95% CI 1.06-7.19, p = 0.038) and disease control rate (OR 1.80, 95% CI - 1.21-2.68, p = 0.004). This meta-analysis showed that compared with - non-combination therapy, combination therapy using PD-1/PD-L1 inhibitors and RT - did not increase the serious adverse event rates (≥grade 3); however, this - approach increased the rate of grade 1-2 immune-related or radiation pneumonitis. - Subgroup analyses revealed that the sequence of PD-1/PD-L1 inhibitors followed RT - outperformed in which concurrent PD-1/PD-L1 inhibitor and RT followed PD-1/PD-L1 - inhibitor. Combination of stereotactic body RT or stereotactic radiosurgery with - PD-1/PD-L1 inhibitors may be more effective than a combination of conventional RT - with PD-1/PD-L1 inhibitors in patients with advanced NSCLC. CONCLUSION: - Combination therapy using PD-1/PD-L1 inhibitors and RT may improve OS, PFS, and - tumor response rates without an increase in serious adverse events in patients - with advanced NSCLC. However, combination therapy was shown to increase the - incidence of mild pneumonitis. -CI - © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Geng, Yichao -AU - Geng Y -AUID- ORCID: 0000-0001-5157-4571 -AD - The First School of Clinical Medicine, Lanzhou University, Lanzhou, China. -FAU - Zhang, Qiuning -AU - Zhang Q -AD - Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China. -AD - Lanzhou Heavy Ion Hospital, Lanzhou, China. -FAU - Feng, Shuangwu -AU - Feng S -AUID- ORCID: 0000-0001-5272-7840 -AD - The First School of Clinical Medicine, Lanzhou University, Lanzhou, China. -FAU - Li, Chengcheng -AU - Li C -AUID- ORCID: 0000-0001-7511-9311 -AD - The First School of Clinical Medicine, Lanzhou University, Lanzhou, China. -FAU - Wang, Lina -AU - Wang L -AD - The First School of Clinical Medicine, Lanzhou University, Lanzhou, China. -FAU - Zhao, Xueshan -AU - Zhao X -AD - The First School of Clinical Medicine, Lanzhou University, Lanzhou, China. -FAU - Yang, Zhen -AU - Yang Z -AD - Basic Medical College, Lanzhou University, Lanzhou, China. -FAU - Li, Zheng -AU - Li Z -AD - Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China. -AD - Lanzhou Heavy Ion Hospital, Lanzhou, China. -FAU - Luo, Hongtao -AU - Luo H -AD - Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China. -AD - Lanzhou Heavy Ion Hospital, Lanzhou, China. -FAU - Liu, Ruifeng -AU - Liu R -AD - Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China. -AD - Lanzhou Heavy Ion Hospital, Lanzhou, China. -FAU - Lu, Bing -AU - Lu B -AD - Department of Oncology, The Affiliated Hospital of Guizhou Medical University, - Guiyang, China. -AD - Department of Oncology, Guizhou Cancer Hospital, Guiyang, China. -FAU - Wang, Xiaohu -AU - Wang X -AUID- ORCID: 0000-0002-0018-1847 -AD - The First School of Clinical Medicine, Lanzhou University, Lanzhou, China. -AD - Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China. -AD - Lanzhou Heavy Ion Hospital, Lanzhou, China. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Research Support, Non-U.S. Gov't -PT - Systematic Review -DEP - 20210119 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - B7-H1 Antigen/*antagonists & inhibitors/immunology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/pathology/*radiotherapy -MH - Chemoradiotherapy/methods -MH - Combined Modality Therapy -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Immunotherapy/*methods -MH - Lung Neoplasms/*drug therapy/immunology/pathology/*radiotherapy -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors/immunology -MH - Radiosurgery/methods -MH - Randomized Controlled Trials as Topic -MH - Survival Rate -PMC - PMC7926021 -OTO - NOTNLM -OT - combined radio-immunotherapy -OT - meta-analysis -OT - non-small-cell lung cancer -OT - programmed cell death protein-1/programmed cell death ligand-1 inhibitors -OT - radiotherapy -OT - systematic review -COIS- The authors have no conflict of interest. -EDAT- 2021/01/20 06:00 -MHDA- 2021/08/06 06:00 -PMCR- 2021/01/19 -CRDT- 2021/01/19 17:13 -PHST- 2020/10/15 00:00 [received] -PHST- 2020/11/30 00:00 [revised] -PHST- 2020/12/26 00:00 [accepted] -PHST- 2021/01/20 06:00 [pubmed] -PHST- 2021/08/06 06:00 [medline] -PHST- 2021/01/19 17:13 [entrez] -PHST- 2021/01/19 00:00 [pmc-release] -AID - CAM43718 [pii] -AID - 10.1002/cam4.3718 [doi] -PST - ppublish -SO - Cancer Med. 2021 Feb;10(4):1222-1239. doi: 10.1002/cam4.3718. Epub 2021 Jan 19. - -PMID- 34015311 -OWN - NLM -STAT- MEDLINE -DCOM- 20210617 -LR - 20210910 -IS - 1474-5488 (Electronic) -IS - 1470-2045 (Linking) -VI - 22 -IP - 6 -DP - 2021 Jun -TI - Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients - with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 - trial. -PG - 824-835 -LID - S1470-2045(21)00149-2 [pii] -LID - 10.1016/S1470-2045(21)00149-2 [doi] -AB - BACKGROUND: Previous phase 2 trials of neoadjuvant anti-PD-1 or anti-PD-L1 - monotherapy in patients with early-stage non-small-cell lung cancer have reported - major pathological response rates in the range of 15-45%. Evidence suggests that - stereotactic body radiotherapy might be a potent immunomodulator in advanced - non-small-cell lung cancer (NSCLC). In this trial, we aimed to evaluate the use - of stereotactic body radiotherapy in patients with early-stage NSCLC as an - immunomodulator to enhance the anti-tumour immune response associated with the - anti-PD-L1 antibody durvalumab. METHODS: We did a single-centre, open-label, - randomised, controlled, phase 2 trial, comparing neoadjuvant durvalumab alone - with neoadjuvant durvalumab plus stereotactic radiotherapy in patients with - early-stage NSCLC, at NewYork-Presbyterian and Weill Cornell Medical Center (New - York, NY, USA). We enrolled patients with potentially resectable early-stage - NSCLC (clinical stages I-IIIA as per the 7th edition of the American Joint - Committee on Cancer) who were aged 18 years or older with an Eastern Cooperative - Oncology Group performance status of 0 or 1. Eligible patients were randomly - assigned (1:1) to either neoadjuvant durvalumab monotherapy or neoadjuvant - durvalumab plus stereotactic body radiotherapy (8 Gy × 3 fractions), using - permuted blocks with varied sizes and no stratification for clinical or molecular - variables. Patients, treating physicians, and all study personnel were unmasked - to treatment assignment after all patients were randomly assigned. All patients - received two cycles of durvalumab 3 weeks apart at a dose of 1·12 g by - intravenous infusion over 60 min. Those in the durvalumab plus radiotherapy group - also received three consecutive daily fractions of 8 Gy stereotactic body - radiotherapy delivered to the primary tumour immediately before the first cycle - of durvalumab. Patients without systemic disease progression proceeded to - surgical resection. The primary endpoint was major pathological response in the - primary tumour. All analyses were done on an intention-to-treat basis. This trial - is registered with ClinicalTrial.gov, NCT02904954, and is ongoing but closed to - accrual. FINDINGS: Between Jan 25, 2017, and Sept 15, 2020, 96 patients were - screened and 60 were enrolled and randomly assigned to either the durvalumab - monotherapy group (n=30) or the durvalumab plus radiotherapy group (n=30). 26 - (87%) of 30 patients in each group had their tumours surgically resected. Major - pathological response was observed in two (6·7% [95% CI 0·8-22·1]) of 30 patients - in the durvalumab monotherapy group and 16 (53·3% [34·3-71·7]) of 30 patients in - the durvalumab plus radiotherapy group. The difference in the major pathological - response rates between both groups was significant (crude odds ratio 16·0 [95% CI - 3·2-79·6]; p<0·0001). In the 16 patients in the dual therapy group with a major - pathological response, eight (50%) had a complete pathological response. The - second cycle of durvalumab was withheld in three (10%) of 30 patients in the dual - therapy group due to immune-related adverse events (grade 3 hepatitis, grade 2 - pancreatitis, and grade 3 fatigue and thrombocytopaenia). Grade 3-4 adverse - events occurred in five (17%) of 30 patients in the durvalumab monotherapy group - and six (20%) of 30 patients in the durvalumab plus radiotherapy group. The most - frequent grade 3-4 events were hyponatraemia (three [10%] patients in the - durvalumab monotherapy group) and hyperlipasaemia (three [10%] patients in the - durvalumab plus radiotherapy group). Two patients in each group had serious - adverse events (pulmonary embolism [n=1] and stroke [n=1] in the durvalumab - monotherapy group, and pancreatitis [n=1] and fatigue [n=1] in the durvalumab - plus radiotherapy group). No treatment-related deaths or deaths within 30 days of - surgery were reported. INTERPRETATION: Neoadjuvant durvalumab combined with - stereotactic body radiotherapy is well tolerated, safe, and associated with a - high major pathological response rate. This neoadjuvant strategy should be - validated in a larger trial. FUNDING: AstraZeneca. -CI - Copyright © 2021 Elsevier Ltd. All rights reserved. -FAU - Altorki, Nasser K -AU - Altorki NK -AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine-New York - Presbyterian Hospital, New York, NY, USA. Electronic address: - nkaltork@med.cornell.edu. -FAU - McGraw, Timothy E -AU - McGraw TE -AD - Department of Biochemistry, Weill Cornell Medicine-New York Presbyterian - Hospital, New York, NY, USA. -FAU - Borczuk, Alain C -AU - Borczuk AC -AD - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine-New York - Presbyterian Hospital, New York, NY, USA. -FAU - Saxena, Ashish -AU - Saxena A -AD - Division of Hematology Oncology, Weill Cornell Medicine-New York Presbyterian - Hospital, New York, NY, USA. -FAU - Port, Jeffrey L -AU - Port JL -AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine-New York - Presbyterian Hospital, New York, NY, USA. -FAU - Stiles, Brendon M -AU - Stiles BM -AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine-New York - Presbyterian Hospital, New York, NY, USA. -FAU - Lee, Benjamin E -AU - Lee BE -AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine-New York - Presbyterian Hospital, New York, NY, USA. -FAU - Sanfilippo, Nicholas J -AU - Sanfilippo NJ -AD - Department of Radiation Oncology, Weill Cornell Medicine-New York Presbyterian - Hospital, New York, NY, USA. -FAU - Scheff, Ronald J -AU - Scheff RJ -AD - Division of Hematology Oncology, Weill Cornell Medicine-New York Presbyterian - Hospital, New York, NY, USA. -FAU - Pua, Bradley B -AU - Pua BB -AD - Department of Radiology, Weill Cornell Medicine-New York Presbyterian Hospital, - New York, NY, USA. -FAU - Gruden, James F -AU - Gruden JF -AD - Department of Radiology, Weill Cornell Medicine-New York Presbyterian Hospital, - New York, NY, USA. -FAU - Christos, Paul J -AU - Christos PJ -AD - Department of Population Health Sciences, Weill Cornell Medicine-New York - Presbyterian Hospital, New York, NY, USA. -FAU - Spinelli, Cathy -AU - Spinelli C -AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine-New York - Presbyterian Hospital, New York, NY, USA. -FAU - Gakuria, Joyce -AU - Gakuria J -AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine-New York - Presbyterian Hospital, New York, NY, USA. -FAU - Uppal, Manik -AU - Uppal M -AD - Department of Physiology and Biophysics, Weill Cornell Medicine-New York - Presbyterian Hospital, New York, NY, USA. -FAU - Binder, Bhavneet -AU - Binder B -AD - Department of Physiology and Biophysics, Weill Cornell Medicine-New York - Presbyterian Hospital, New York, NY, USA. -FAU - Elemento, Olivier -AU - Elemento O -AD - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine-New York - Presbyterian Hospital, New York, NY, USA. -FAU - Ballman, Karla V -AU - Ballman KV -AD - Department of Population Health Sciences, Weill Cornell Medicine-New York - Presbyterian Hospital, New York, NY, USA. -FAU - Formenti, Silvia C -AU - Formenti SC -AD - Department of Radiation Oncology, Weill Cornell Medicine-New York Presbyterian - Hospital, New York, NY, USA. -LA - eng -SI - ClinicalTrials.gov/NCT02904954 -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20210518 -PL - England -TA - Lancet Oncol -JT - The Lancet. Oncology -JID - 100957246 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 28X28X9OKV (durvalumab) -SB - IM -CIN - Lancet Oncol. 2021 Jun;22(6):744-746. doi: 10.1016/S1470-2045(21)00261-8. PMID: - 34015310 -CIN - Nat Rev Clin Oncol. 2021 Sep;18(9):545-546. doi: 10.1038/s41571-021-00540-x. - PMID: 34226694 -MH - Adolescent -MH - Adult -MH - Aged -MH - Antibodies, Monoclonal/*administration & dosage/adverse effects -MH - B7-H1 Antigen/antagonists & inhibitors/*genetics/immunology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/pathology/*radiotherapy -MH - Combined Modality Therapy -MH - Female -MH - Humans -MH - Male -MH - Middle Aged -MH - Neoadjuvant Therapy/adverse effects -MH - Neoplasm Staging -MH - Radiosurgery/methods -MH - Young Adult -COIS- Declaration of interests NKA reports stock options from TMRW, Angiocrine - Bioscience, and View Point Medical; and is on the research advisory committee for - AstraZeneca. AS reports personal fees from AstraZeneca, Blueprint Medicines, - Genentech, Medtronic, and Takeda. JLP reports leadership and stock options from - TMRW, Angiocrine Bioscience, and View Point Medical. BMS reports personal fees - from AstraZeneca, Pfizer, Flame Biosciences, Gala Therapeutics, Bristol Myers - Squibb, and Ribon Therapeutics; and is on the board of directors for the Lung - Cancer Research Foundation. BEL reports personal fees from AstraZeneca. KVB - reports personal fees from Janssen, Eli Lilly, Takeda, Johnson and Johnson, - Sanfoi, and Ariad. SCF has received grants from Bristol Myers Squibb, Varian, - Merck, Eisai, Eli Lilly, Janssen, and Regeneron; and personal fees from Accuray, - AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Elekta, EMD Serono/Merck, - GlaxoSmithKline, Janssen, MedImmune, Merck US, Regeneron, Varian, and ViewRay. - PJC was partially supported by a grant from the Clinical and Translational - Science Center at Weill Cornell Medical College (grant number 1-UL1-TR002384-01). - All other authors declare no competing interests. -EDAT- 2021/05/21 06:00 -MHDA- 2021/06/22 06:00 -CRDT- 2021/05/20 20:12 -PHST- 2021/01/17 00:00 [received] -PHST- 2021/03/08 00:00 [revised] -PHST- 2021/03/11 00:00 [accepted] -PHST- 2021/05/21 06:00 [pubmed] -PHST- 2021/06/22 06:00 [medline] -PHST- 2021/05/20 20:12 [entrez] -AID - S1470-2045(21)00149-2 [pii] -AID - 10.1016/S1470-2045(21)00149-2 [doi] -PST - ppublish -SO - Lancet Oncol. 2021 Jun;22(6):824-835. doi: 10.1016/S1470-2045(21)00149-2. Epub - 2021 May 18. - -PMID- 38706775 -OWN - NLM -STAT- MEDLINE -DCOM- 20240506 -LR - 20240628 -IS - 1532-2807 (Electronic) -IS - 1219-4956 (Print) -IS - 1219-4956 (Linking) -VI - 30 -DP - 2024 -TI - The role of chemoradiotherapy and immunotherapy in stage III NSCLC. -PG - 1611716 -LID - 10.3389/pore.2024.1611716 [doi] -LID - 1611716 -AB - Locally advanced non-small lung cancer encompasses a diverse range of tumors. In - the last few years, the treatment of stage III unresectable non-small lung cancer - has evolved significantly. The PACIFIC trial opened a new therapeutic era in the - treatment of locally advanced NSCLC, establishing durvalumab consolidation - therapy as the new standard of care worldwide. A careful evaluation of this type - of lung cancer and a discussion of the management of these patients within a - multidisciplinary team represents a crucial step in defining the best treatment - strategy for each patient. For unresectable stage III NSCLC, definitive - concurrent chemoradiotherapy (CCRT) was historically recommended as a treatment - with a 5-year survival rate ranging from 20% to 30%. The PACIFIC study conducted - in 2017 compared the use of chemoradiotherapy and maintenance therapy with the - anti-PD-L1 monoclonal antibody durvalumab to a placebo in patients with locally - advanced NSCLC who had not experienced disease progression. The study was - prospective, randomized, and phase III. The administration of this medication in - patients with locally advanced non-small cell lung cancer (NSCLC) has - demonstrated a notable improvement in overall survival. Multiple clinical trials - are currently exploring various immune checkpoint inhibition regimens to enhance - the treatment efficacy in patients with stage III cancer. Our goal is to offer an - up-to-date summary of the planned clinical trials for treatment options, focusing - on the significant obstacles and prospects in the post-PACIFIC era. -CI - Copyright © 2024 Orosz and Kovács. -FAU - Orosz, Zsuzsanna -AU - Orosz Z -AD - Department of Pulmonology, Faculty of Medicine, University of Debrecen, Debrecen, - Hungary. -FAU - Kovács, Árpád -AU - Kovács Á -AD - Department of Oncoradiology, Faculty of Medicine, University of Debrecen, - Debrecen, Hungary. -LA - eng -PT - Journal Article -PT - Review -DEP - 20240419 -PL - Switzerland -TA - Pathol Oncol Res -JT - Pathology oncology research : POR -JID - 9706087 -RN - 28X28X9OKV (durvalumab) -RN - 0 (Antibodies, Monoclonal) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/pathology/drug therapy -MH - *Chemoradiotherapy/methods -MH - *Lung Neoplasms/therapy/pathology/drug therapy -MH - *Immunotherapy/methods -MH - Neoplasm Staging -MH - *Antibodies, Monoclonal -PMC - PMC11066192 -OTO - NOTNLM -OT - NSCLC -OT - chemoradiotherapy -OT - durvalumab -OT - immunotherapy -OT - locally advanced -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2024/05/06 06:43 -MHDA- 2024/05/06 06:44 -PMCR- 2024/04/19 -CRDT- 2024/05/06 04:01 -PHST- 2024/01/31 00:00 [received] -PHST- 2024/04/08 00:00 [accepted] -PHST- 2024/05/06 06:44 [medline] -PHST- 2024/05/06 06:43 [pubmed] -PHST- 2024/05/06 04:01 [entrez] -PHST- 2024/04/19 00:00 [pmc-release] -AID - 1611716 [pii] -AID - 10.3389/pore.2024.1611716 [doi] -PST - epublish -SO - Pathol Oncol Res. 2024 Apr 19;30:1611716. doi: 10.3389/pore.2024.1611716. - eCollection 2024. - -PMID- 37249335 -OWN - NLM -STAT- MEDLINE -DCOM- 20230706 -LR - 20230710 -IS - 1745-7270 (Electronic) -IS - 1672-9145 (Print) -IS - 1672-9145 (Linking) -VI - 55 -IP - 6 -DP - 2023 May 30 -TI - Understanding SCLC heterogeneity and plasticity in cancer metastasis and - chemotherapy resistance. -PG - 948-955 -LID - 10.3724/abbs.2023080 [doi] -AB - Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer - cases and features a strong predilection for early metastasis and extremely poor - prognosis. Despite being highly sensitive to chemotherapy and/or radiotherapy - initially, most SCLC patients develop therapeutic resistance within one year and - die of distant metastases. Multiple studies have revealed the high heterogeneity - and strong plasticity of SCLC associated with frequent metastases and early - development of therapeutic resistance as well as poor clinical outcome. - Importantly, different SCLC subtypes are associated with different therapeutic - vulnerabilities, and the inflamed subtype tends to have the best response to - immunotherapy, which highlights the importance of precision medicine in the - clinic. Here, we review recent advances in SCLC heterogeneity and plasticity and - their link to distant metastases and chemotherapy resistance. We hope that a - better understanding of the molecular mechanisms underlying SCLC malignant - progression will help to develop better intervention strategies for this deadly - disease. -FAU - Jin, Yujuan -AU - Jin Y -AD - State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell - Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of - Sciences, Shanghai 200031, China. -FAU - Chen, Yanxu -AU - Chen Y -AD - University of Chinese Academy of Sciences, Beijing 100190, China. -FAU - Qin, Zhen -AU - Qin Z -AD - State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell - Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of - Sciences, Shanghai 200031, China. -FAU - Hu, Liang -AU - Hu L -AD - State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell - Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of - Sciences, Shanghai 200031, China. -FAU - Guo, Chenchen -AU - Guo C -AD - State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell - Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of - Sciences, Shanghai 200031, China. -FAU - Ji, Hongbin -AU - Ji H -AD - State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell - Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of - Sciences, Shanghai 200031, China. -AD - School of Life Science and Technology, Shanghai Tech University, Shanghai 201210, - China. -AD - School of Life Science, Hangzhou Institute for Advanced Study, University of - Chinese Academy of Sciences, Hangzhou 310024, China. -LA - eng -PT - Journal Article -PT - Review -PL - China -TA - Acta Biochim Biophys Sin (Shanghai) -JT - Acta biochimica et biophysica Sinica -JID - 101206716 -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/drug therapy/pathology -MH - *Lung Neoplasms/pathology -PMC - PMC10326415 -OTO - NOTNLM -OT - chemotherapy resistance -OT - heterogeneity -OT - metastases -OT - plasticity -OT - small cell lung cancer -COIS- The authors declare that they have no conflict of interest. -EDAT- 2023/05/30 13:07 -MHDA- 2023/07/06 06:42 -PMCR- 2023/05/30 -CRDT- 2023/05/30 09:12 -PHST- 2023/07/06 06:42 [medline] -PHST- 2023/05/30 13:07 [pubmed] -PHST- 2023/05/30 09:12 [entrez] -PHST- 2023/05/30 00:00 [pmc-release] -AID - 10.3724/abbs.2023080 [doi] -PST - ppublish -SO - Acta Biochim Biophys Sin (Shanghai). 2023 May 30;55(6):948-955. doi: - 10.3724/abbs.2023080. - -PMID- 38964333 -OWN - NLM -STAT- MEDLINE -DCOM- 20241012 -LR - 20241012 -IS - 2666-6340 (Electronic) -IS - 2666-6340 (Linking) -VI - 5 -IP - 10 -DP - 2024 Oct 11 -TI - Preclinical study and phase II trial of adapting low-dose radiotherapy to - immunotherapy in small cell lung cancer. -PG - 1237-1254.e9 -LID - S2666-6340(24)00248-4 [pii] -LID - 10.1016/j.medj.2024.06.002 [doi] -AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) provide modest but unsatisfactory - benefits for extensive-stage small cell lung cancer (ES-SCLC). Developing - strategies for treating ES-SCLC is critical. METHODS: We preliminarily explored - the outcomes of salvage low-dose radiotherapy (LDRT) plus ICI on refractory SCLC - patients. Next, we evaluated the combinational efficacy in murine SCLC. The tumor - immune microenvironment (TIME) was analyzed for mechanistic study. Subsequently, - we conducted a multicenter, prospective phase II trial that administered - concurrent thoracic LDRT plus chemoimmunotherapy to treatment-naive ES-SCLC - patients (MATCH trial, NCT04622228). The primary endpoint was confirmed objective - response rate (ORR), and the key secondary endpoints included progression-free - survival (PFS) and safety. FINDINGS: Fifteen refractory SCLC patients treated - with LDRT plus ICI were retrospectively reviewed. The ORR was 73.3% (95% - confidence interval [CI], 44.9-92.2). We identified a specific dose of LDRT (15 - Gy/5 fractions) that exhibited growth retardation and improved survival in murine - SCLC when combined with ICIs. This combination recruited a special T cell - population, TCF1(+) PD-1(+) CD8(+) stem-like T cells, from tumor-draining lymph - nodes into the TIME. The MATCH trial showed a confirmed ORR of 87.5% (95% CI, - 75.9-94.8). The median PFS was 6.9 months (95% CI, 5.4-9.3). CONCLUSIONS: These - findings verified that LDRT plus chemoimmunotherapy was safe, feasible, and - effective for ES-SCLC, warranting further investigation. FUNDING: This research - was funded by West China Hospital (no. ZYJC21003), the National Natural Science - Foundation of China (no. 82073336), and the MATCH trial was fully funded by Roche - (China) Holding Ltd. (RCHL) and Shanghai Roche Pharmaceuticals Ltd. (SRPL). -CI - Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved. -FAU - Wang, Hui -AU - Wang H -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Yao, Zhuoran -AU - Yao Z -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Kang, Kai -AU - Kang K -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Zhou, Lin -AU - Zhou L -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Xiu, Weigang -AU - Xiu W -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Sun, Jianguo -AU - Sun J -AD - Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China. -FAU - Xie, Conghua -AU - Xie C -AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan - University, Wuhan, China. -FAU - Yu, Min -AU - Yu M -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Li, Yanying -AU - Li Y -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Zhang, Yan -AU - Zhang Y -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Center of Lung Cancer, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Zheng, Yue -AU - Zheng Y -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Lin, Guo -AU - Lin G -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Pan, Xiangyu -AU - Pan X -AD - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, - Sichuan University, Chengdu, China. -FAU - Wu, Yijun -AU - Wu Y -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Luo, Ren -AU - Luo R -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Wang, Laduona -AU - Wang L -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Tang, Min -AU - Tang M -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Liao, Shuangsi -AU - Liao S -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Zhu, Jiang -AU - Zhu J -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Zhou, Xiaojuan -AU - Zhou X -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Zhang, Xuanwei -AU - Zhang X -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Xu, Yong -AU - Xu Y -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Liu, Yongmei -AU - Liu Y -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Peng, Feng -AU - Peng F -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Wang, Jin -AU - Wang J -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Xiang, Lisha -AU - Xiang L -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Yin, Limei -AU - Yin L -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Health Management & - Institute of Health Management, Sichuan Provincial People's Hospital, University - of Electronic Science and Technology of China, Chengdu, China. -FAU - Deng, Lei -AU - Deng L -AD - University of Washington School of Medicine/Fred Hutchinson Cancer Center, - Seattle, WA, USA. -FAU - Huang, Meijuan -AU - Huang M -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Gong, Youling -AU - Gong Y -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Zou, Bingwen -AU - Zou B -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Wang, Hui -AU - Wang H -AD - Department of Radiation Oncology, Hunan Cancer Hospital, Changsha, China. -FAU - Wu, Lin -AU - Wu L -AD - Department of Thoracic Medicine, Hunan Cancer Hospital, Changsha, China. -FAU - Yuan, Zhiyong -AU - Yuan Z -AD - Department of Radiation Oncology, Tianjin Medical University Cancer Institute and - Hospital, Tianjin, China. -FAU - Bi, Nan -AU - Bi N -AD - Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical - Sciences and Peking Union Medical College, Beijing, China. -FAU - Fan, Min -AU - Fan M -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -FAU - Xu, Yaping -AU - Xu Y -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University - School of Medicine, Shanghai, China. -FAU - Tong, Ruizhan -AU - Tong R -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Yi, Linglu -AU - Yi L -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. -FAU - Gan, Lu -AU - Gan L -AD - Research Laboratory of Emergency Medicine, Department of Emergency Medicine, - National Clinical Research Center for Geriatrics, West China Hospital, Sichuan - University, Chengdu, China. -FAU - Xue, Jianxin -AU - Xue J -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Mo, Xianming -AU - Mo X -AD - Laboratory of Stem Cell Biology, West China Hospital, Sichuan University, - Chengdu, China. -FAU - Chen, Chong -AU - Chen C -AD - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, - Sichuan University, Chengdu, China. -FAU - Na, Feifei -AU - Na F -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China. Electronic address: - nafeifei@scu.edu.cn. -FAU - Lu, You -AU - Lu Y -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China - Hospital, Sichuan University, Chengdu, China; Department of Radiation Oncology, - Cancer Center, West China Hospital, Sichuan University, Chengdu, China. - Electronic address: radyoulu@hotmail.com. -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Multicenter Study -DEP - 20240703 -PL - United States -TA - Med -JT - Med (New York, N.Y.) -JID - 101769215 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - *Small Cell Lung Carcinoma/radiotherapy/immunology/pathology/therapy/mortality -MH - *Lung Neoplasms/radiotherapy/pathology/immunology/mortality/therapy -MH - Animals -MH - Humans -MH - Mice -MH - Female -MH - Male -MH - Middle Aged -MH - *Immune Checkpoint Inhibitors/therapeutic use/pharmacology -MH - Aged -MH - *Immunotherapy/methods -MH - Tumor Microenvironment/immunology/drug effects -MH - Prospective Studies -MH - Combined Modality Therapy -MH - Radiotherapy Dosage -MH - Progression-Free Survival -OTO - NOTNLM -OT - Translation to patients -OT - extensive-stage small cell lung cancer -OT - immune checkpoint inhibitor -OT - low-dose radiotherapy -OT - stem-like T cell -OT - tumor-draining lymph node -COIS- Declaration of interests Y. Lu has an invited speaker/project lead/principal - investigator role with Roche, AstraZeneca, and BeiGene and an invited speaker - role with Pfizer, Merck Sharp & Dohme, and Bristol-Myers Squibb. L.Z., Y. Zhang, - M.H., Y.G., Y. Liu, J.Z., and B.Z. have an invited investigator role with Roche. - J.S., C.X., H.W.,(9) L. Wu, Z. Yuan, N.B., M.F., and Yaping Xu have an invited - principal investigator role with Roche. -EDAT- 2024/07/05 00:42 -MHDA- 2024/10/13 04:18 -CRDT- 2024/07/04 18:42 -PHST- 2023/10/19 00:00 [received] -PHST- 2024/03/11 00:00 [revised] -PHST- 2024/06/12 00:00 [accepted] -PHST- 2024/10/13 04:18 [medline] -PHST- 2024/07/05 00:42 [pubmed] -PHST- 2024/07/04 18:42 [entrez] -AID - S2666-6340(24)00248-4 [pii] -AID - 10.1016/j.medj.2024.06.002 [doi] -PST - ppublish -SO - Med. 2024 Oct 11;5(10):1237-1254.e9. doi: 10.1016/j.medj.2024.06.002. Epub 2024 - Jul 3. - -PMID- 37931445 -OWN - NLM -STAT- MEDLINE -DCOM- 20231216 -LR - 20240125 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 186 -DP - 2023 Dec -TI - Clinical and molecular characterization of long-term survivors with - extensive-stage small cell lung cancer treated with first-line atezolizumab plus - carboplatin and etoposide. -PG - 107418 -LID - S0169-5002(23)00956-X [pii] -LID - 10.1016/j.lungcan.2023.107418 [doi] -AB - OBJECTIVES: In the Phase I/III IMpower133 study, first-line atezolizumab plus - carboplatin and etoposide (CP/ET) treatment for extensive-stage small cell lung - cancer (ES-SCLC) significantly improved overall survival (OS) and - progression-free survival versus placebo plus CP/ET. We explored patient and - disease characteristics associated with long-term survival in IMpower133, and - associations of differential gene expression and SCLC-A (ASCL1-driven), SCLC-N - (NEUROD1-driven), SCLC-P (POU2F3-driven), and SCLC-inflamed (SCLC-I) - transcriptional subtypes with long-term survival. MATERIALS AND METHODS: Patients - with previously untreated ES-SCLC were randomized 1:1 to four 21-day cycles of - CP/ET with atezolizumab or placebo. Long-term survivors (LTS) were defined as - patients who lived ≥ 18 months post randomization. A generalized linear model was - used to evaluate the odds of living ≥ 18 months. Differential gene expression was - analyzed using RNA-sequencing data in LTS and non-LTS. OS was assessed by - T-effector and B-cell gene signature expression. Distribution of SCLC - transcriptional subtypes was assessed in LTS and non-LTS. RESULTS: More LTS were - in the atezolizumab arm (34%) than in the placebo arm (20%). The odds ratio for - living ≥ 18 months in the atezolizumab arm versus the placebo arm was 2.1 - (P < 0.03). Enhanced immune-related signaling was seen in LTS in both arms. - Exploratory OS analyses showed atezolizumab treatment benefit versus placebo - across T-effector and B-cell gene signature expression subgroups. A higher - proportion of LTS than non-LTS in both arms had the SCLC-I subtype; this - difference was particularly pronounced in the atezolizumab arm. CONCLUSION: These - exploratory analyses suggest that long-term survival is more likely with - atezolizumab than placebo in ES-SCLC, confirming the treatment benefit of the - IMpower133 regimen. CLINICALTRIAL: gov Identifier: NCT02763579. -CI - Copyright © 2023. Published by Elsevier B.V. -FAU - Liu, Stephen V -AU - Liu SV -AD - Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. - Electronic address: stephen.v.liu@gunet.georgetown.edu. -FAU - Mok, Tony S K -AU - Mok TSK -AD - State Key Laboratory of Translational Oncology, The Chinese University of Hong - Kong, Hong Kong, China. -FAU - Nabet, Barzin Y -AU - Nabet BY -AD - Genentech Inc., South San Francisco, CA, USA. -FAU - Mansfield, Aaron S -AU - Mansfield AS -AD - Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. -FAU - De Boer, Richard -AU - De Boer R -AD - Peter MacCallum Cancer Centre, Melbourne, Australia. -FAU - Losonczy, György -AU - Losonczy G -AD - Department of Pulmonology, Semmelweis University, Budapest, Hungary. -FAU - Sugawara, Shunichi -AU - Sugawara S -AD - Sendai Kousei Hospital, Sendai, Japan. -FAU - Dziadziuszko, Rafal -AU - Dziadziuszko R -AD - Department of Oncology and Radiotherapy and Early Phase Clinical Trials Center, - Medical University of Gdańsk, Gdańsk, Poland. -FAU - Krzakowski, Maciej -AU - Krzakowski M -AD - Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland. -FAU - Smolin, Alexey -AU - Smolin A -AD - Burdenko Main Military Clinical Hospital, Moscow, Russia. -FAU - Hochmair, Maximilian J -AU - Hochmair MJ -AD - Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna North - Hospital Klinik Floridsdorf, Vienna, Austria. -FAU - Garassino, Marina C -AU - Garassino MC -AD - The University of Chicago Department of Hematology/Oncology, Chicago, IL, USA. -FAU - Gay, Carl M -AU - Gay CM -AD - Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Heymach, John V -AU - Heymach JV -AD - Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Byers, Lauren A -AU - Byers LA -AD - Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Lam, Sivuonthanh -AU - Lam S -AD - Genentech Inc., South San Francisco, CA, USA. -FAU - Cardona, Andrés -AU - Cardona A -AD - F. Hoffmann-La Roche Ltd., Basel, Switzerland. -FAU - Morris, Stefanie -AU - Morris S -AD - F. Hoffmann-La Roche Ltd., Basel, Switzerland. -FAU - Adler, Leah -AU - Adler L -AD - F. Hoffmann-La Roche Ltd., Basel, Switzerland. -FAU - Shames, David S -AU - Shames DS -AD - Genentech Inc., South San Francisco, CA, USA. -FAU - Reck, Martin -AU - Reck M -AD - Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung - Research, Grosshansdorf, Germany. -LA - eng -SI - ClinicalTrials.gov/NCT02763579 -PT - Journal Article -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20231031 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - BG3F62OND5 (Carboplatin) -RN - 6PLQ3CP4P3 (Etoposide) -RN - 52CMI0WC3Y (atezolizumab) -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/drug therapy/genetics -MH - Carboplatin -MH - Etoposide -MH - *Lung Neoplasms/drug therapy/genetics -MH - Survivors -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -OTO - NOTNLM -OT - (maximum 6): Small cell lung carcinoma -OT - Atezolizumab -OT - Carboplatin -OT - Clinical trial IMpower133 -OT - Etoposide -OT - Gene expression profiling -OT - Immune checkpoint inhibitors -OT - RNA Sequence analysis -COIS- Declaration of Competing Interest The authors declare the following financial - interests/personal relationships which may be considered as potential competing - interests: S.V.L. declares grants or contracts from Alkermes, Bayer, Blueprint, - Bristol Myers Squibb, Elevation Oncology, Genentech, Lilly, Merck, Merus, Pfizer, - Rain Therapeutics, RAPT, Turning Point Therapeutics; consulting fees from Amgen, - AstraZeneca, Bayer, BeiGene, Blueprint, Bristol Myers Squibb, Daiichi Sankyo, - Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, - Jazz Pharmaceuticals, Lilly, Merck/Merck Sharpe & Dohme, Novartis, Regeneron, - Sanofi, Takeda, Turning Point Therapeutics; and participation on a Data Safety - Monitoring or Advisory Board for Candel Therapeutics. T.S.K.M. declares - consulting and advisory personal fees from AbbVie, Inc., ACEA Pharma, Alpha - Biopharma Co. Ltd., Amgen, Amoy Diagnostics Co. Ltd., AstraZeneca, BeiGene, - Boehringer-Ingelheim, Bristol Myers Squibb, Blueprint Medicines Corporation, - CStone Pharmaceuticals, Daiichi Sankyo, Eisai, Fishawack Facilitate Ltd., - geneDecode (uncompensated), Gritstone Oncology Inc., Guardant Health, Hengrui - Therapeutics, Ignyta Inc., IQVIA, Incyte Corporation, Janssen, Lilly, - Loxo-Oncology, Lunit USA, Inc., Merck Serono, Merck Sharp & Dohme, Mirati - Therapeutics Inc., Novartis, OrigiMed, Pfizer, Inc., Puma Biotechnology Inc., - Roche, Sanofi-Aventis R&D, Takeda, Yuhan Corporation, SFJ Pharmaceuticals, Curio - Science, Inivata, Berry Oncology, Qiming Development (HK) Ltd., Gilead Sciences, - Inc., Vertex Pharmaceuticals, and Covidien LP; lecture personal fees from ACEA - Pharmaceuticals, Alpha Biopharma Co. Ltd., Amgen, Amoy Diagnostics Co. Ltd., - AstraZeneca, BeiGene, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, - Fishawack Facilitate Ltd., geneDecode, (uncompensated), InMed Medical - Communication, Janssen, Lilly, Lunit USA, Inc., MD Health (Brazil), - Medscape/WebMD, Merck Serono, Merck Sharpe & Dohme, Novartis, OrigiMed, - PeerVoice, Physicians’ Education Resource, P. Permanyer SL, Pfizer, Inc., PrIME - Oncology, Research to Practice, Roche, Sanofi-Aventis R&D, Takeda, Touch Medical - Media, Daz Group, Lucence Health Inc., Merck Pharmaceuticals HK Ltd., Shanghai - BeBirds Translation & Consulting Co. Ltd., Liangyihui Network Technology Co. - Ltd., and Taiho; grants from AstraZeneca, Bristol Myers Squibb, Merck Serono, - Merck Sharpe & Dohme, Novartis, Pfizer, Inc., Roche, Takeda, Clovis Oncology, SFJ - Pharmaceuticals, XCovery, and G1 Therapeutics Inc.; personal fees for supporting - an advisory board for Inivata, Berry Therapeutics Inc., and G1 Therapeutics Inc.; - shareholding for Aurora, Sanomics Ltd., Hutchison ChiMed; and a role on the Board - of Directors for Lunit USA, Inc., AstraZeneca PLC, Hutchison ChiMed, Sanomics - Ltd., Aurora. B.Y.N declares employment by Genentech and stockholding in Roche. - A.S.M declares grants or contracts from NIH/NCI, Verily, Novartis, Department of - Defense, and Mark Foundation; payment or honoraria to institution for lecture, - presentations, speakers bureaus, manuscript writing or education events from - AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech; support for - attending meetings and/or travel from Shanghai Roche Pharmaceuticals; patents - planned, issues, or pending for patents submitted unrelated to this work; and - other financial or non-financial interests from non-remunerated director of the - Mesothelioma Applied Research Foundation. R. De Boer declares payment of - honoraria from Novartis, AstraZeneca, and Gilead; and support for attending - meetings and/or travel from Amgen, Novartis, and Roche. S.S. declares payment or - honoraria for lectures, presentation, speakers bureaus, manuscript writing, or - educations events from Chugai Pharma, AstraZeneca, Ono Pharmaceutical, Bristol - Myers Squibb, Merck Sharpe & Dohme, Nippon Boehringer-Ingelheim, Pfizer, Taiho - Pharmaceutical, Eli Lilly, and Company, Novartis, Kyowa Kirin, Yakult Honsha, and - Towa Pharmaceutical. R. Dziadziuszko declares consulting fees from Roche, - Boehringer-Ingelheim, AstraZeneca, Takeda, Pfizer, Foundation Medicine, Novartis, - and Karyopharm; and payment or honoraria from Roche, Novartis, AstraZeneca, and - Pfizer. A.S. declares payment or honoraria from AstraZeneca, Bristol Myers - Squibb, Roche, Merck Sharpe & Dohme, Novartis, and Pfizer; support for attending - meetings and/or travel from Bristol Myers Squibb, Roche, Boehringer-Ingelheim, - and AstraZeneca; and participation on data safety monitoring or advisory boards - for Bristol Myers Squibb, Roche, Takeda, AstraZeneca, BIOCAD, and - Boehringer-Ingelheim. M.J.H declares payment or honoraria from - Boehringer-Ingelheim, AstraZeneca, Takeda, Pfizer, Merck Sharpe & Dohme, and - Roche; and participation on data safety monitoring or advisory boards for - Boehringer-Ingelheim, AstraZeneca, Takeda, Pfizer, Merck Sharpe & Dohme, and - Roche. M.C.G. declares grants from AstraZeneca, Bayer, Bristol Myers Squibb, - Janssen, Merck Serono, Merck Sharpe & Dohme, Novartis, Pfizer, Roche, Amgen, GSK, - Sanofi; consulting fees from AstraZeneca, Bayer, Bristol Myers Squibb, - Boehringer-Ingelheim, Janssen, Lilly, Yuhan, Merck Serono, Merck Sharpe & Dohme, - Novartis, Pfizer, Roche, Amgen, Libbs, and Sanofi; payment of honoraria from - Boehringer-Ingelheim, Pfizer, Bayer, Roche, Merck Sharpe & Dohme, Bristol Myers - Squibb, AstraZeneca, Novartis, Merck Serono, Janssen, and Amgen; support for - attending meetings and/or travel from Boehringer-Ingelheim, Pfizer, Bayer, Roche, - Merck Sharpe & Dohme, Bristol Myers Squibb, AstraZeneca, Novartis, and Merck - Serono; participation on data safety monitoring or advisory boards for TEVA, - Boehringer-Ingelheim, Bayer, Pfizer, Roche, Merck Sharpe & Dohme, Bristol Myers - Squibb, AstraZeneca, Yuhan, Janssen, Merck Serono, Novartis, Amgen; and payment - of honoraria for promotional activities from Boehringer-Ingelheim, Pfizer, Roche, - Merck Sharpe & Dohme, Bristol Myers Squibb, AstraZeneca, Novartis, TEVA, Amgen, - and Janssen. C.M.G. declares research grants/funding to self from AstraZeneca; - advisory/consultancy to AstraZeneca, Kisoji Biotechnology, Jazz Pharmaceuticals, - and Bristol Myers Squibb; and speaker bureau/expert testimony for AstraZeneca and - BeiGene. J.V.H declares advisory/consultancy for Bristol Myers Squibb, BrightPath - Biotherapeutics, Janssen Global Services, Nexus Health Systems Pneuma - Respiratory, Kairos Venture Investments, Roche, Leads Biolabs, AstraZeneca, - Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, - Foundation Medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, EMD - Serono, Sanofi, Takeda, and Mirati Therapeutics; research support to AstraZeneca, - GlaxoSmithKline, and Spectrum; and royalties/licensing fees from Spectrum. L.A.B. - declares an advisory role/consultancy for AstraZeneca, AbbVie, Bristol Myers - Squibb, and Merck; and research funding from AstraZeneca and AbbVie. S.L. - declares employment by Genentech and stockholding in Roche. A.C. declares - employment by Roche and stockholding in Roche. S.M. declares employment by Roche - and stockholding in Roche. L.A. declares employment by Roche and stockholding in - Roche. D.S.S. declares employment by Genentech and stockholding in Roche. M.R. - declares consulting fees from Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol - Myers Squibb, Lilly, Merck, Merck Sharpe & Dohme, Mirati, Novartis, Pfizer, - Sanofi, and Roche; payment of honoraria from Amgen, AstraZeneca, - Boehringer-Ingelheim, Bristol Myers Squibb, Lilly, Merck, Merck Sharpe & Dohme, - Mirati, Novartis, Pfizer, Sanofi, and Roche; support for attending meetings - and/or travel from Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol Myers - Squibb, Lilly, Merck, Merck Sharpe & Dohme, Mirati, Novartis, Pfizer, Sanofi, and - Roche; and participation on data safety monitoring or advisory boards for DSMB - Sanofi. G.L. and M.K. declare no conflicts of interest. -EDAT- 2023/11/07 00:42 -MHDA- 2023/12/17 13:19 -CRDT- 2023/11/06 18:07 -PHST- 2023/06/27 00:00 [received] -PHST- 2023/10/06 00:00 [revised] -PHST- 2023/10/29 00:00 [accepted] -PHST- 2023/12/17 13:19 [medline] -PHST- 2023/11/07 00:42 [pubmed] -PHST- 2023/11/06 18:07 [entrez] -AID - S0169-5002(23)00956-X [pii] -AID - 10.1016/j.lungcan.2023.107418 [doi] -PST - ppublish -SO - Lung Cancer. 2023 Dec;186:107418. doi: 10.1016/j.lungcan.2023.107418. Epub 2023 - Oct 31. - -PMID- 38896941 -OWN - NLM -STAT- MEDLINE -DCOM- 20240706 -LR - 20240706 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 193 -DP - 2024 Jul -TI - Immune checkpoint inhibition in early-stage non-small cell lung cancer. -PG - 107855 -LID - S0169-5002(24)00389-1 [pii] -LID - 10.1016/j.lungcan.2024.107855 [doi] -AB - The introduction of immune checkpoint inhibitors significantly advanced outcomes - in both metastatic and locally advanced non-small cell lung cancer. Despite these - advancements, the 5-year survival rate remains suboptimal. Even in early-stage - disease a significant portion of patients relapse and die from metastatic - progression. The integration of immunotherapy in the management of early-stage - NSCLC demonstrated promising results, supported by a plethora of positive - clinical trials conducted in recent years. Nonetheless, numerous questions - persist. In this manuscript we comprehensively review the currently available - data on adjuvant, neoadjuvant, and perioperative treatment strategies. We also - address the challenges inherent to these approaches from different stakeholders' - perspective. -CI - Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved. -FAU - Cuppens, Kristof -AU - Cuppens K -AD - Department of Pulmonology and Thoracic Oncology and Jessa & Science, Jessa - Hospital Hasselt, Belgium; Faculty of Medicine and Life Sciences, LCRC, UHasselt, - Diepenbeek, Belgium; Department of Thoracic Oncology, The Netherlands Cancer - Institute and Leiden University Medical Center, Amsterdam, the Netherlands. - Electronic address: kristof.cuppens@jessazh.be. -FAU - Du Pont, Bert -AU - Du Pont B -AD - Department of Thoracic and Vascular Surgery, Jessa Hospital Hasselt, Belgium. -FAU - Knegjens, Joost -AU - Knegjens J -AD - Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, - Netherlands. -FAU - Maes, Brigitte -AU - Maes B -AD - Faculty of Medicine and Life Sciences, LCRC, UHasselt, Diepenbeek, Belgium; - Laboratory for Molecular Diagnostics, Department of Laboratory Medicine, Jessa - Hospital Hasselt, Belgium. -FAU - Baas, Paul -AU - Baas P -AD - Department of Thoracic Oncology, The Netherlands Cancer Institute and Leiden - University Medical Center, Amsterdam, the Netherlands. -LA - eng -PT - Journal Article -PT - Review -DEP - 20240614 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology/immunology/mortality -MH - *Lung Neoplasms/drug therapy/pathology/immunology -MH - *Immune Checkpoint Inhibitors/therapeutic use -MH - *Neoplasm Staging -MH - Immunotherapy/methods -MH - Neoadjuvant Therapy/methods -OTO - NOTNLM -OT - Early stage -OT - Immune checkpoint inhibition -OT - Neoadjuvant -OT - Non-small cell lung cancer -OT - Perioperative -COIS- Declaration of competing interest The authors declare the following financial - interests/personal relationships which may be considered as potential competing - interests: Kristof Cuppens: Consultancy for BMS, MSD and AstraZeneca. Bert Du - Pont: none. Joost Knegjens: none. Brigitte Maes: none. Paul Baas: Research - funding and consultancy for BMS, Consultancy for MSD. -EDAT- 2024/06/20 00:42 -MHDA- 2024/07/07 00:42 -CRDT- 2024/06/19 18:03 -PHST- 2024/04/29 00:00 [received] -PHST- 2024/06/06 00:00 [revised] -PHST- 2024/06/09 00:00 [accepted] -PHST- 2024/07/07 00:42 [medline] -PHST- 2024/06/20 00:42 [pubmed] -PHST- 2024/06/19 18:03 [entrez] -AID - S0169-5002(24)00389-1 [pii] -AID - 10.1016/j.lungcan.2024.107855 [doi] -PST - ppublish -SO - Lung Cancer. 2024 Jul;193:107855. doi: 10.1016/j.lungcan.2024.107855. Epub 2024 - Jun 14. - -PMID- 37870696 -OWN - NLM -STAT- MEDLINE -DCOM- 20231113 -LR - 20231124 -IS - 1534-6269 (Electronic) -IS - 1523-3790 (Print) -IS - 1523-3790 (Linking) -VI - 25 -IP - 11 -DP - 2023 Nov -TI - Novel Therapeutic Options for Small Cell Lung Cancer. -PG - 1277-1294 -LID - 10.1007/s11912-023-01465-7 [doi] -AB - PURPOSE OF REVIEW: The aim of this review is to focus on the recent advances in - the molecular knowledge of small cell lung cancer (SCLC) and potential promising - new treatment strategies, like targeting the DNA damage pathway, epigenetics, - angiogenesis, and oncogenic drivers. RECENT FINDINGS: In the last few years, the - addition of immunotherapy to chemotherapy has led to significant improvements in - clinical outcomes in this complex neoplasia. Nevertheless, the prognosis remains - dismal. Recently, numerous genomic alterations have been identified, and they may - be useful to classify SCLC into different molecular subtypes (SCLC-A, SCLC-I, - SCLC-Y, SCLC-P). SCLC accounts for 10-20% of all lung cancers, most patients have - an extensive disease at the diagnosis, and it is characterized by poor prognosis. - Despite the progresses in the knowledge of the disease, efficacious targeted - treatments are still lacking. In the near future, the molecular characterisation - of SCLC will be fundamental to find more effective treatment strategies. -CI - © 2023. The Author(s). -FAU - Canova, Stefania -AU - Canova S -AD - SC Medical Oncology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. -FAU - Trevisan, Benedetta -AU - Trevisan B -AD - SC Medical Oncology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. -AD - Department of Medical-Surgical Specialties, University of Brescia, Radiological - Sciences and Public Health, Brescia, Italy. -FAU - Abbate, Maria Ida -AU - Abbate MI -AD - SC Medical Oncology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. -FAU - Colonese, Francesca -AU - Colonese F -AD - SC Medical Oncology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. -FAU - Sala, Luca -AU - Sala L -AD - SC Medical Oncology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. -FAU - Baggi, Alice -AU - Baggi A -AD - SC Medical Oncology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. -AD - Department of Medical-Surgical Specialties, University of Brescia, Radiological - Sciences and Public Health, Brescia, Italy. -FAU - Bianchi, Sofia Paola -AU - Bianchi SP -AD - Radiation Oncology Department, Fondazione IRCCS San Gerardo Dei Tintori, Monza, - Italy. -AD - School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy. -FAU - D'Agostino, Anna -AU - D'Agostino A -AD - SC Medical Oncology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. -FAU - Cortinovis, Diego Luigi -AU - Cortinovis DL -AUID- ORCID: 0000-0001-7611-7369 -AD - SC Medical Oncology, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. - diegoluigi.cortinovis@irccs-sangerardo.it. -AD - Medicine and Surgery Department, University of Milano Bicocca, Milan, Italy. - diegoluigi.cortinovis@irccs-sangerardo.it. -LA - eng -PT - Journal Article -PT - Review -DEP - 20231023 -PL - United States -TA - Curr Oncol Rep -JT - Current oncology reports -JID - 100888967 -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/drug therapy/genetics -MH - *Lung Neoplasms/drug therapy/genetics -MH - Immunotherapy -MH - Prognosis -MH - Molecular Targeted Therapy -PMC - PMC10640463 -OTO - NOTNLM -OT - Immunotherapy -OT - PARP inhibitors -OT - SCLC classification -OT - Target therapy -COIS- The authors declare no competing interests. -EDAT- 2023/10/23 12:44 -MHDA- 2023/11/13 06:42 -PMCR- 2023/10/23 -CRDT- 2023/10/23 11:10 -PHST- 2023/09/19 00:00 [accepted] -PHST- 2023/11/13 06:42 [medline] -PHST- 2023/10/23 12:44 [pubmed] -PHST- 2023/10/23 11:10 [entrez] -PHST- 2023/10/23 00:00 [pmc-release] -AID - 10.1007/s11912-023-01465-7 [pii] -AID - 1465 [pii] -AID - 10.1007/s11912-023-01465-7 [doi] -PST - ppublish -SO - Curr Oncol Rep. 2023 Nov;25(11):1277-1294. doi: 10.1007/s11912-023-01465-7. Epub - 2023 Oct 23. - -PMID- 37698765 -OWN - NLM -STAT- MEDLINE -DCOM- 20231110 -LR - 20231111 -IS - 2190-3883 (Electronic) -IS - 1234-1983 (Print) -IS - 1234-1983 (Linking) -VI - 64 -IP - 4 -DP - 2023 Dec -TI - Modern therapies of nonsmall cell lung cancer. -PG - 695-711 -LID - 10.1007/s13353-023-00786-4 [doi] -AB - Lung cancer (LC), particularly nonsmall cell lung cancer (NSCLC), is one of the - most prevalent types of neoplasia worldwide, regardless of gender, with the - highest mortality rates in oncology. Over the years, treatment for NSCLC has - evolved from conventional surgery, chemotherapy, and radiotherapy to more - tailored and minimally invasive approaches. The use of personalised therapies has - increased the expected efficacy of treatment while simultaneously reducing the - frequency of severe adverse effects (AEs). In this review, we discuss established - modern approaches, including immunotherapy and targeted therapy, as well as - experimental molecular methods like clustered regularly interspaced short - palindromic repeat (CRISPR) and nanoparticles. These emerging methods offer - promising outcomes and shorten the recovery time for various patients. Recent - advances in the diagnostic field, including imaging and genetic profiling, have - enabled the implementation of these methods. The versatility of these modern - therapies allows for multiple treatment options, such as single-agent use, - combination with existing conventional treatments, or incorporation into new - regimens. As a result, patients can survive even in the advanced stages of NSCLC, - leading to increased survival indicators such as overall survival (OS) and - progression-free survival (PFS). -CI - © 2023. The Author(s). -FAU - Jachowski, Andrzej -AU - Jachowski A -AD - Department of Biochemistry and Molecular Biology, Poznań University of Medical - Sciences, Święcickiego 6 Street, 60-781, Poznań, Poland. -FAU - Marcinkowski, Mikołaj -AU - Marcinkowski M -AD - Department of Biochemistry and Molecular Biology, Poznań University of Medical - Sciences, Święcickiego 6 Street, 60-781, Poznań, Poland. -FAU - Szydłowski, Jakub -AU - Szydłowski J -AD - Department of Biochemistry and Molecular Biology, Poznań University of Medical - Sciences, Święcickiego 6 Street, 60-781, Poznań, Poland. -FAU - Grabarczyk, Oskar -AU - Grabarczyk O -AD - Department of Biochemistry and Molecular Biology, Poznań University of Medical - Sciences, Święcickiego 6 Street, 60-781, Poznań, Poland. -FAU - Nogaj, Zuzanna -AU - Nogaj Z -AD - Department of Biochemistry and Molecular Biology, Poznań University of Medical - Sciences, Święcickiego 6 Street, 60-781, Poznań, Poland. -FAU - Marcin, Łaz -AU - Marcin Ł -AD - Department of Biochemistry and Molecular Biology, Poznań University of Medical - Sciences, Święcickiego 6 Street, 60-781, Poznań, Poland. -FAU - Pławski, Andrzej -AU - Pławski A -AD - Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32 Street, - 60-479, Poznań, Poland. -FAU - Jagodziński, Paweł Piotr -AU - Jagodziński PP -AD - Department of Biochemistry and Molecular Biology, Poznań University of Medical - Sciences, Święcickiego 6 Street, 60-781, Poznań, Poland. -FAU - Słowikowski, Bartosz Kazimierz -AU - Słowikowski BK -AUID- ORCID: 0000-0002-6547-486X -AD - Department of Biochemistry and Molecular Biology, Poznań University of Medical - Sciences, Święcickiego 6 Street, 60-781, Poznań, Poland. - slowikowski.bartek@gmail.com. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230912 -PL - England -TA - J Appl Genet -JT - Journal of applied genetics -JID - 9514582 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy -MH - *Lung Neoplasms/genetics/therapy -MH - Immunotherapy/methods -PMC - PMC10632224 -OTO - NOTNLM -OT - CRISPR -OT - Immunotherapy -OT - Lung cancer -OT - NSCLC -OT - Nanoparticles -OT - Targeted therapy -COIS- The authors declare no competing interests. -EDAT- 2023/09/12 12:41 -MHDA- 2023/11/10 06:45 -PMCR- 2023/09/12 -CRDT- 2023/09/12 11:22 -PHST- 2023/06/21 00:00 [received] -PHST- 2023/09/01 00:00 [accepted] -PHST- 2023/09/01 00:00 [revised] -PHST- 2023/11/10 06:45 [medline] -PHST- 2023/09/12 12:41 [pubmed] -PHST- 2023/09/12 11:22 [entrez] -PHST- 2023/09/12 00:00 [pmc-release] -AID - 10.1007/s13353-023-00786-4 [pii] -AID - 786 [pii] -AID - 10.1007/s13353-023-00786-4 [doi] -PST - ppublish -SO - J Appl Genet. 2023 Dec;64(4):695-711. doi: 10.1007/s13353-023-00786-4. Epub 2023 - Sep 12. - -PMID- 38309287 -OWN - NLM -STAT- MEDLINE -DCOM- 20240502 -LR - 20240514 -IS - 2213-2619 (Electronic) -IS - 2213-2600 (Linking) -VI - 12 -IP - 5 -DP - 2024 May -TI - First-line penpulimab combined with paclitaxel and carboplatin for metastatic - squamous non-small-cell lung cancer in China (AK105-302): a multicentre, - randomised, double-blind, placebo-controlled phase 3 clinical trial. -PG - 355-365 -LID - S2213-2600(23)00431-9 [pii] -LID - 10.1016/S2213-2600(23)00431-9 [doi] -AB - BACKGROUND: Penpulimab is a novel programmed death (PD)-1 inhibitor. This study - aimed to establish the efficacy and safety of first line penpulimab plus - chemotherapy for advanced squamous non-small-cell lung cancer. METHODS: This - multicentre, randomised, double-blind, placebo-controlled, phase 3 clinical trial - enrolled patients with locally advanced or metastatic squamous non-small-cell - lung cancer from 74 hospitals in China. Eligible participants were aged 18-75 - years, had histologically or cytologically confirmed locally advanced (stage IIIb - or IIIc) or metastatic (stage IV) squamous non-small-cell lung cancer, were - ineligible to complete surgical resection and concurrent or sequential - chemoradiotherapy, had an Eastern Cooperative Oncology Group (ECOG) performance - status of 0-1, did not have previous systemic chemotherapy for locally advanced - or metastatic non-small-cell lung cancer, and had one or more measurable lesions - according to RECIST (version 1.1). Participants were randomly assigned (1:1) to - receive intravenous penpulimab 200 mg or placebo (excipient of penpulimab - injection), plus paclitaxel 175 mg/m(2) and carboplatin AUC of 5 intravenously on - day 1 every 3 weeks for four cycles, followed by penpulimab or placebo as - maintenance therapy. Stratification was done according to the PD-L1 tumour - proportion score (<1% vs 1-49% vs ≥50%) and sex (male vs female). The - participants, investigators, and other research staff were masked to group - assignment. The primary outcome was progression-free survival assessed by the - masked Independent Radiology Review Committee in the intention-to-treat - population and patients with a PD-L1 tumour proportion score of 1% or more - (PD-L1-positive subgroup). The primary analysis was based on the - intention-to-treat analysis set (ie, all randomly assigned participants) and the - PD-L1-positive subgroup. The safety analysis included all participants who - received at least one dose of study drug after enrolment. This trial was - registered with ClinicalTrials.gov (NCT03866993). FINDINGS: Between Dec 20, 2018, - and Oct 10, 2020, 485 patients were screened, and 350 participants were randomly - assigned (175 in the penpulimab group and 175 in the placebo group). Of 350 - participants, 324 (93%) were male and 26 (7%) were female, and 347 (99%) were of - Han ethnicity. In the final analysis (June 1, 2022; median follow-up, 24·7 months - [IQR 0-41·4]), the penpulimab group showed an improved progression-free survival - compared with the placebo group, both in the intention-to-treat population - (median 7·6 months, 95% CI 6·8--9·6 vs 4·2 months, 95% CI 4·2-4·3; HR 0·43, 95% - CI 0·33-0·56; p<0·0001) and in the PD-L1-positive subgroup (8·1 months, 5·7-9·7 - vs 4·2 months, 4·1-4·3; HR 0·37, 0·27-0·52, p<0·0001). Grade 3 or worse - treatment-emergent adverse events occurred in 120 (69%) 173 patients in the - penpulimab group and 119 (68%) of 175 in the placebo group. INTERPRETATION: - Penpulimab plus chemotherapy significantly improved progression-free survival in - patients with advanced squamous non-small-cell lung cancer compared with - chemotherapy alone. The treatment was safe and tolerable. Penpulimab combined - with paclitaxel and carboplatin is a new option for first-line treatment in - patients with this advanced disease. FUNDING: The National Natural Science - Foundation of China, Shanghai Municipal Health Commission, Chia Tai Tianqing - Pharmaceutical, Akeso. -CI - Copyright © 2024 Elsevier Ltd. All rights reserved. -FAU - Zhong, Hua -AU - Zhong H -AD - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, - Shanghai Jiao Tong University School of Medicine, Shanghai, China. -FAU - Sun, Shengjie -AU - Sun S -AD - Department of Oncology, The Fifth Medical Center of PLA General Hospital, - Beijing, China. -FAU - Chen, Jianhua -AU - Chen J -AD - Department of Thoracic Oncology, Hunan Cancer Hospital, Changsha, China. -FAU - Wang, Ziping -AU - Wang Z -AD - Department of Thoracic Oncology, Peking University Cancer Hospital and Institute, - Beijing, China. -FAU - Zhao, Yanqiu -AU - Zhao Y -AD - Department of Oncology, Henan Cancer Hospital, Zhengzhou, China. -FAU - Zhang, Guojun -AU - Zhang G -AD - Department of Respiratory, The First Affiliated Hospital of Zhengzhou University, - Zhengzhou, China. -FAU - Chen, Gongyan -AU - Chen G -AD - First Ward of Respiratory Medicine, Harbin Medical University Cancer Hospital, - Harbin, China. -FAU - Zhou, Ming -AU - Zhou M -AD - Department of Thoracic Surgery, Affiliated Cancer Hospital and Institute of - Guangzhou Medical University, Guangzhou, China. -FAU - Zhou, Jianying -AU - Zhou J -AD - Department of Respiratory, The First Affiliated Hospital, Zhejiang University - School of Medicine, Hangzhou, China. -FAU - Du, Yingying -AU - Du Y -AD - Department of Oncology, The First Affiliated Hospital of Anhui Medical - University, Hefei, China. -FAU - Wu, Lin -AU - Wu L -AD - Department of Thoracic Oncology, Hunan Cancer Hospital, Changsha, China. -FAU - Xu, Zhi -AU - Xu Z -AD - Department of Respiratory, Xinqiao Hospital of Army Medical University, - Chongqing, China. -FAU - Mei, Xiaodong -AU - Mei X -AD - Department of Respiratory and Critical Care Medicine, Anhui Provincial Hospital, - Heifei, China. -FAU - Zhang, Weidong -AU - Zhang W -AD - Department of Respiratory, Hunan Provincial People's Hospital, Changsha, China. -FAU - He, Jingdong -AU - He J -AD - Department of Oncology, Huai'an First People's Hospital, Huai'an, China. -FAU - Cui, Jiuwei -AU - Cui J -AD - Department of Oncology, The First Hospital of Jilin University, Changchun, China. -FAU - Zhang, Zhihong -AU - Zhang Z -AD - Department of Respiratory, Anhui Cancer Hospital, Hefei, China. -FAU - Luo, Hui -AU - Luo H -AD - Department of Thoracic Oncology Radiotherapy, Jiangxi Cancer Hospital, Nanchang, - China. -FAU - Liu, Weiyou -AU - Liu W -AD - Department of Respiratory and Critical Care Medicine, The First Affiliated - Hospital of Gannan Medical University, Ganzhou, China. -FAU - Sun, Meili -AU - Sun M -AD - Department of Oncology, Jinan Central Hospital, Jinan, China. -FAU - Wu, Jingxun -AU - Wu J -AD - Department of Oncology, The First Affiliated Hospital of Xiamen University, - Xiamen, China. -FAU - Shen, Yongchun -AU - Shen Y -AD - Department of Respiratory and Critical Care Medicine, West China Hospital of - Sichuan University, Chengdu, China. -FAU - Zhang, Shucai -AU - Zhang S -AD - Department of Oncology, Beijing Chest Hospital, Capital Medical University, - Beijing, China. -FAU - Yang, Nong -AU - Yang N -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital, Changsha, China. -FAU - Wang, Mengzhao -AU - Wang M -AD - Department of Respiratory and Critical Care Medicine, Peking Union Medical - College Hospital, Beijing, China. -FAU - Lu, Junguo -AU - Lu J -AD - Department of Respiratory, Nantong Tumor Hospital, Nantong, China. -FAU - Li, Kai -AU - Li K -AD - Department of Thoracic Oncology, Tianjin Medical University Cancer Hospital, - Tianjin, China. -FAU - Yao, Weirong -AU - Yao W -AD - Department of Oncology, Jiangxi Provincial People's Hospital, Nanchang, China. -FAU - Sun, Qian -AU - Sun Q -AD - Department of Oncology, Henan Provincial Chest Hospital, Zhengzhou, China. -FAU - Yue, Hongmei -AU - Yue H -AD - Department of Respiratory and Critical Care Medicine, The First Hospital of - Lanzhou University, Lanzhou, China. -FAU - Wang, Lin -AU - Wang L -AD - Department of Oncology, Hainan General Hospital, Haikou, China. -FAU - Ye, Sheng -AU - Ye S -AD - Department of Oncology, The First Affiliated Hospital of Sun Yat sen University, - Guangzhou, China. -FAU - Li, Bin -AU - Li B -AD - Department of Oncology, Xiangya Hospital of Central South University, Changsha, - China. -FAU - Zhuang, Xibin -AU - Zhuang X -AD - Department of Respiratory and Critical Care Medicine, Quanzhou First Hospital, - Quanzhou, China. -FAU - Pan, Yueyin -AU - Pan Y -AD - Department of Chemotherapy Oncology, Anhui Provincial Hospital, Hefei, China. -FAU - Zhang, Min -AU - Zhang M -AD - Department of Respiratory and Critical Care Medicine, Ganzhou People's Hospital, - Ganzhou, China. -FAU - Shu, Yongqian -AU - Shu Y -AD - Department of Oncology, Jiangsu Province Hospital, Nanjing, China. -FAU - He, Zhiyong -AU - He Z -AD - Department of Thoracic Oncology, Fujian Cancer Hospital, Fuzhou, China. -FAU - Pan, Lei -AU - Pan L -AD - Department of Respiratory and Critical Care Medicine, Beijing Shijitan Hospital, - CMU, Beijing, China. -FAU - Ling, Yang -AU - Ling Y -AD - Department of Oncology, Changzhou Cancer Hospital, Changzhou, China. -FAU - Liu, Shengming -AU - Liu S -AD - Department of Respiratory and Critical Care Medicine, The First Affiliated - Hospital of Jinan University, Guangzhou, China. -FAU - Zhang, Qi -AU - Zhang Q -AD - Department of Respiratory, The First Hospital of Jiaxing, Jiaxing, China. -FAU - Jiao, Shunchang -AU - Jiao S -AD - Department of Oncology, The Fifth Medical Center of PLA General Hospital, - Beijing, China. Electronic address: jiaosc@vip.sina.com. -FAU - Han, Baohui -AU - Han B -AD - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, - Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic - address: hanbaohui@csco.org.cn. -LA - eng -SI - ClinicalTrials.gov/NCT03866993 -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20240131 -PL - England -TA - Lancet Respir Med -JT - The Lancet. Respiratory medicine -JID - 101605555 -RN - P88XT4IS4D (Paclitaxel) -RN - BG3F62OND5 (Carboplatin) -RN - 0 (Antibodies, Monoclonal, Humanized) -SB - IM -MH - Humans -MH - *Paclitaxel/administration & dosage/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - Male -MH - Middle Aged -MH - Female -MH - Double-Blind Method -MH - *Lung Neoplasms/drug therapy/pathology -MH - *Carboplatin/administration & dosage/therapeutic use -MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Aged -MH - China -MH - Adult -MH - Antibodies, Monoclonal, Humanized/therapeutic use/administration & dosage -MH - Treatment Outcome -MH - Progression-Free Survival -COIS- Declaration of interests We declare no competing interests. -EDAT- 2024/02/04 00:42 -MHDA- 2024/05/03 00:50 -CRDT- 2024/02/03 18:53 -PHST- 2023/05/15 00:00 [received] -PHST- 2023/10/19 00:00 [revised] -PHST- 2023/11/09 00:00 [accepted] -PHST- 2024/05/03 00:50 [medline] -PHST- 2024/02/04 00:42 [pubmed] -PHST- 2024/02/03 18:53 [entrez] -AID - S2213-2600(23)00431-9 [pii] -AID - 10.1016/S2213-2600(23)00431-9 [doi] -PST - ppublish -SO - Lancet Respir Med. 2024 May;12(5):355-365. doi: 10.1016/S2213-2600(23)00431-9. - Epub 2024 Jan 31. - -PMID- 34698669 -OWN - NLM -STAT- MEDLINE -DCOM- 20220502 -LR - 20230901 -IS - 1531-703X (Electronic) -IS - 1040-8746 (Linking) -VI - 34 -IP - 1 -DP - 2022 Jan 1 -TI - Treatment of small cell lung cancer: recent advances. -PG - 83-88 -LID - 10.1097/CCO.0000000000000804 [doi] -AB - PURPOSE OF REVIEW: In this article, we aimed to summarize the recent progress - being made in treatment of small cell lung cancer (SCLC). RECENT FINDINGS: SCLC - is characterized by strong invasiveness, easy recurrence and early metastasis. In - recent years, the emergence of immune checkpoint inhibitors (ICIs) therapy has - broken the deadlock in the treatment field of SCLC. Combination strategies, such - as the addition of ICIs to chemotherapy and radiotherapy, are actively underway. - Some of these strategies have yielded significant survival benefits and tolerable - adverse events, whereas several of them have failed with no significant - improvement. In addition, the new classification of SCLC based on genomic - analysis has deepened the understanding of SCLC and suggested new therapeutic - directions. Similarly, the discovery of some new therapeutic targets, such as - DDL3, CDK7 and PARP, also brings new hope for improving the survival of patients - with SCLC. SUMMARY: In this article, we will review the recent advances of - therapeutic regimen for patients with SCLC. Following the revolutionary success - of adding ICIs to chemotherapy, more varieties of combination strategies have - been explored in recent trials. In addition, therapeutic drug research and - efficacy evaluation against for new targets are under investigation. Altogether, - progress on genomic analysis, investigation of biological pathways and treatment - regimen combination are providing renewed hope for patients with SCLC. -CI - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. -FAU - Chu, Xiangling -AU - Chu X -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer - Institute, School of Medicine, Tongji University, Shanghai, People's Republic of - China. -FAU - Han, Chaonan -AU - Han C -FAU - Su, Chunxia -AU - Su C -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - Curr Opin Oncol -JT - Current opinion in oncology -JID - 9007265 -SB - IM -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy/genetics -MH - *Small Cell Lung Carcinoma/drug therapy/genetics -EDAT- 2021/10/27 06:00 -MHDA- 2022/05/03 06:00 -CRDT- 2021/10/26 12:22 -PHST- 2021/10/27 06:00 [pubmed] -PHST- 2022/05/03 06:00 [medline] -PHST- 2021/10/26 12:22 [entrez] -AID - 00001622-202201000-00012 [pii] -AID - 10.1097/CCO.0000000000000804 [doi] -PST - ppublish -SO - Curr Opin Oncol. 2022 Jan 1;34(1):83-88. doi: 10.1097/CCO.0000000000000804. - -PMID- 31460972 -OWN - NLM -STAT- MEDLINE -DCOM- 20200330 -LR - 20200330 -IS - 1547-1896 (Print) -IS - 0893-7400 (Linking) -VI - 32 -IP - 9 -DP - 2019 Sep -TI - Immunotherapy for non-small cell lung cancer. -PG - 37-42 -LID - 10.1097/01.JAA.0000569792.99069.e6 [doi] -AB - Immunotherapy is a new genre of treatment for patients with advanced cancer. - Initially approved for use in metastatic melanoma, immunotherapy has found a - significant place in treating non-small cell lung cancer (NSCLC). Clinical trials - using several combinations of immunotherapy are underway to help to determine the - best treatment for specific patient groups. This article reviews approved uses of - immunotherapy for NSCLC, immune-related toxicities, and explores the future - direction of this treatment. -FAU - Vafadar, Sam -AU - Vafadar S -AD - Sam Vafadar practices thoracic oncology at Moffitt Cancer Center in Tampa, Fla. - The author has disclosed no potential conflicts of interest, financial or - otherwise. -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - JAAPA -JT - JAAPA : official journal of the American Academy of Physician Assistants -JID - 9513102 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 28X28X9OKV (durvalumab) -RN - 31YO63LBSN (Nivolumab) -RN - 52CMI0WC3Y (atezolizumab) -RN - DPT0O3T46P (pembrolizumab) -MH - Adenocarcinoma of Lung/*drug therapy -MH - Antibodies, Monoclonal/therapeutic use -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Carcinoma, Squamous Cell/*drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - Immunotherapy, Adoptive -MH - Lung Neoplasms/*drug therapy -MH - Nivolumab/therapeutic use -EDAT- 2019/08/29 06:00 -MHDA- 2020/03/31 06:00 -CRDT- 2019/08/29 06:00 -PHST- 2019/08/29 06:00 [entrez] -PHST- 2019/08/29 06:00 [pubmed] -PHST- 2020/03/31 06:00 [medline] -AID - 01720610-201909000-00008 [pii] -AID - 10.1097/01.JAA.0000569792.99069.e6 [doi] -PST - ppublish -SO - JAAPA. 2019 Sep;32(9):37-42. doi: 10.1097/01.JAA.0000569792.99069.e6. - -PMID- 39151281 -OWN - NLM -STAT- MEDLINE -DCOM- 20241017 -LR - 20241017 -IS - 1532-1967 (Electronic) -IS - 0305-7372 (Linking) -VI - 130 -DP - 2024 Nov -TI - Central nervous system metastases in advanced non-small cell lung cancer: A - review of the therapeutic landscape. -PG - 102807 -LID - S0305-7372(24)00135-X [pii] -LID - 10.1016/j.ctrv.2024.102807 [doi] -AB - Up to 40% of patients with non-small cell lung cancer (NSCLC) develop central - nervous system (CNS) metastases. Current treatments for this subgroup of patients - with advanced NSCLC include local therapies (surgery, stereotactic radiosurgery, - and, less frequently, whole-brain radiotherapy), targeted therapies for - oncogene-addicted NSCLC (small molecules, such as tyrosine kinase inhibitors, and - antibody-drug conjugates), and immune checkpoint inhibitors (as monotherapy or - combination therapy), with multiple new drugs in development. However, confirming - the intracranial activity of these treatments has proven to be challenging, given - that most lung cancer clinical trials exclude patients with untreated and/or - progressing CNS metastases, or do not include prespecified CNS-related endpoints. - Here we review progress in the treatment of patients with CNS metastases - originating from NSCLC, examining local treatment options, systemic therapies, - and multimodal therapeutic strategies. We also consider challenges regarding - assessment of treatment response and provide thoughts around future directions - for managing CNS disease in patients with advanced NSCLC. -CI - Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. -FAU - Weller, Michael -AU - Weller M -AD - Department of Neurology, University Hospital and University of Zurich, Zurich, - Switzerland. Electronic address: michael.weller@usz.ch. -FAU - Remon, Jordi -AU - Remon J -AD - Paris-Saclay University, Department of Cancer Medicine, Gustave Roussy, - Villejuif, France. Electronic address: JORDI.REMON-MASIP@gustaveroussy.fr. -FAU - Rieken, Stefan -AU - Rieken S -AD - Department of Radiation Oncology, University Hospital Göttingen (UMG), Göttingen, - Germany; Comprehensive Cancer Center Lower Saxony (CCC-N), University Hospital - Göttingen (UMG), Göttingen, Germany. Electronic address: - stefan.rieken@med.uni-goettingen.de. -FAU - Vollmuth, Philipp -AU - Vollmuth P -AD - Division for Computational Radiology & Clinical AI, Clinic for Neuroradiology, - University Hospital Bonn, Bonn, Germany; Division for Medical Image Computing, - German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: - p.vollmuth@dkfz-heidelberg.de. -FAU - Ahn, Myung-Ju -AU - Ahn MJ -AD - Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University - School of Medicine, Seoul, South Korea. Electronic address: silkahn@skku.edu. -FAU - Minniti, Giuseppe -AU - Minniti G -AD - Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza - University of Rome, Rome, Italy; IRCCS Neuromed, Pozzilli, Italy. Electronic - address: giuseppe.minniti@unisi.it. -FAU - Le Rhun, Emilie -AU - Le Rhun E -AD - Departments of Neurosurgery and Neurology, University Hospital and University of - Zurich, Zurich, Switzerland. Electronic address: emilie.lerhun@usz.ch. -FAU - Westphal, Manfred -AU - Westphal M -AD - Department of Neurosurgery and Institute for Tumor Biology, University Hospital - Hamburg-Eppendorf, Hamburg, Germany. Electronic address: westphal@uke.de. -FAU - Brastianos, Priscilla K -AU - Brastianos PK -AD - Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, - USA. Electronic address: pbrastianos@mgh.harvard.edu. -FAU - Soo, Ross A -AU - Soo RA -AD - Department of Hematology-Oncology, National University Hospital, Singapore, - Singapore. Electronic address: ross_soo@nuhs.edu.sg. -FAU - Kirkpatrick, John P -AU - Kirkpatrick JP -AD - Departments of Radiation Oncology and Neurosurgery, Duke University, Durham, NC, - USA. Electronic address: john.kirkpatrick@duke.edu. -FAU - Goldberg, Sarah B -AU - Goldberg SB -AD - Department of Medicine (Medical Oncology), Yale School of Medicine, Yale Cancer - Center, New Haven, CT, USA. Electronic address: sarah.goldberg@yale.edu. -FAU - Öhrling, Katarina -AU - Öhrling K -AD - Amgen (Europe) GmbH, Rotkreuz, Switzerland. Electronic address: - katarina.ohrling@gmail.com. -FAU - Hegi-Johnson, Fiona -AU - Hegi-Johnson F -AD - Department of Radiation Oncology, Peter MacCallum Cancer Centre, University of - Melbourne, Melbourne, Australia; Sir Peter MacCallum Department of Clinical - Oncology, University of Melbourne, Melbourne, Australia. Electronic address: - Fiona.Hegi-Johnson@petermac.org. -FAU - Hendriks, Lizza E L -AU - Hendriks LEL -AD - Department of Respiratory Medicine, Maastricht University Medical Centre, GROW - School for Oncology and Reproduction, Maastricht, Netherlands. Electronic - address: lizza.hendriks@mumc.nl. -LA - eng -PT - Journal Article -PT - Review -DEP - 20240802 -PL - Netherlands -TA - Cancer Treat Rev -JT - Cancer treatment reviews -JID - 7502030 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/pathology/drug therapy -MH - *Lung Neoplasms/pathology/therapy -MH - *Central Nervous System Neoplasms/secondary/therapy -MH - Combined Modality Therapy -OTO - NOTNLM -OT - CNS metastases -OT - Immune checkpoint inhibitors -OT - Non-small cell lung cancer -OT - Small molecules -OT - Stereotactic radiosurgery -OT - Tyrosine kinase inhibitors -COIS- Declaration of competing interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2024/08/17 15:43 -MHDA- 2024/10/18 00:30 -CRDT- 2024/08/16 18:04 -PHST- 2023/12/22 00:00 [received] -PHST- 2024/07/19 00:00 [revised] -PHST- 2024/07/29 00:00 [accepted] -PHST- 2024/08/17 15:43 [pubmed] -PHST- 2024/10/18 00:30 [medline] -PHST- 2024/08/16 18:04 [entrez] -AID - S0305-7372(24)00135-X [pii] -AID - 10.1016/j.ctrv.2024.102807 [doi] -PST - ppublish -SO - Cancer Treat Rev. 2024 Nov;130:102807. doi: 10.1016/j.ctrv.2024.102807. Epub 2024 - Aug 2. - -PMID- 34879738 -OWN - NLM -STAT- MEDLINE -DCOM- 20220328 -LR - 20220328 -IS - 1744-8301 (Electronic) -IS - 1479-6694 (Linking) -VI - 18 -IP - 6 -DP - 2022 Feb -TI - The treatment of advanced pulmonary sarcomatoid carcinoma. -PG - 727-738 -LID - 10.2217/fon-2021-1071 [doi] -AB - Pulmonary sarcomatoid carcinoma (PSC) is a pathological subtype of non-small-cell - lung cancer. Although the incidence of PSC in lung cancer is very low, it is an - aggressive cancer, leading to a poor prognosis. Currently, there is no standard - treatment for advanced PSC. Targeted therapy can be used for patients with - METex14 mutations and patients with other driver gene mutations may also benefit - from treatment. The emergence of immune checkpoint inhibitors also provides - potential options for advanced PSC treatment, but more clinical data is needed. - Additionally, more research may be warranted to explore the effects of - chemotherapy, radiotherapy and antiangiogenic therapy. In this review, the - authors summarize the research regarding the treatment of advanced PSC. -FAU - Zheng, Yue -AU - Zheng Y -AUID- ORCID: 0000-0003-0455-5102 -AD - Department of Biotherapy, Cancer Center, West China Hospital, West China Medical - School, Sichuan University, Chengdu 610041, China. -FAU - Fu, Yang -AU - Fu Y -AD - Department of Biotherapy, Cancer Center, West China Hospital, West China Medical - School, Sichuan University, Chengdu 610041, China. -FAU - Zhong, Qin -AU - Zhong Q -AD - Department of Oncology, The People's Hospital of Guizhou Province, - Guiyang 550001, China. -FAU - Deng, Rong -AU - Deng R -AD - Department of Oncology, The People's Hospital of Guizhou Province, - Guiyang 550001, China. -FAU - Zhang, Yu -AU - Zhang Y -AUID- ORCID: 0000-0002-4594-3868 -AD - Department of Oncology, The People's Hospital of Guizhou Province, - Guiyang 550001, China. -LA - eng -GR - GZSYQCC [2016] 003/Guizhou Province High-level and Innovative Talents Program/ -GR - NSFC81760557/National Natural Science Foundation of China/ -GR - 2018YFC1311400/National Key R&D Program of China/ -PT - Journal Article -PT - Review -DEP - 20211209 -PL - England -TA - Future Oncol -JT - Future oncology (London, England) -JID - 101256629 -RN - 0 (Angiogenesis Inhibitors) -RN - 0 (Antineoplastic Agents) -RN - 0 (Biomarkers, Tumor) -RN - 0 (Immune Checkpoint Inhibitors) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) -RN - Q20Q21Q62J (Cisplatin) -SB - IM -MH - Angiogenesis Inhibitors/therapeutic use -MH - Antineoplastic Agents/therapeutic use -MH - Biomarkers, Tumor/genetics -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/radiotherapy -MH - Cisplatin/therapeutic use -MH - ErbB Receptors/antagonists & inhibitors -MH - Humans -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Lung Neoplasms/*drug therapy/genetics/radiotherapy -MH - Molecular Targeted Therapy -MH - Protein-Tyrosine Kinases/antagonists & inhibitors -OAB - Lay abstract Pulmonary sarcomatoid carcinoma (PSC) is a special type of - non-small-cell lung cancer. PSC is an uncommon form of cancer that is associated - with poor outcomes. Currently, there is no standard treatment for advanced PSC. - Targeted therapies for patients with specific mutations may be effective. - Additionally, immunotherapy may provide new options for PSC treatment, however, - more research is needed. Moreover, the effects of traditional chemotherapies and - radiotherapy are not fully understood for PSC. In this review, the authors - summarize what is known regarding the treatment of advanced PSC. -OABL- eng -OTO - NOTNLM -OT - MET exon 14 -OT - immune checkpoint inhibitors -OT - pulmonary sarcomatoid carcinoma -OT - treatment -OT - tyrosine kinase inhibitors -EDAT- 2021/12/10 06:00 -MHDA- 2022/03/29 06:00 -CRDT- 2021/12/09 05:26 -PHST- 2021/12/10 06:00 [pubmed] -PHST- 2022/03/29 06:00 [medline] -PHST- 2021/12/09 05:26 [entrez] -AID - 10.2217/fon-2021-1071 [doi] -PST - ppublish -SO - Future Oncol. 2022 Feb;18(6):727-738. doi: 10.2217/fon-2021-1071. Epub 2021 Dec - 9. - -PMID- 33293672 -OWN - NLM -STAT- MEDLINE -DCOM- 20210218 -LR - 20231110 -IS - 1532-1827 (Electronic) -IS - 0007-0920 (Print) -IS - 0007-0920 (Linking) -VI - 123 -IP - Suppl 1 -DP - 2020 Dec -TI - Beyond chemoradiotherapy: improving treatment outcomes for patients with stage - III unresectable non-small-cell lung cancer through immuno-oncology and - durvalumab (Imfinzi®▼, AstraZeneca UK Limited). -PG - 18-27 -LID - 10.1038/s41416-020-01071-5 [doi] -AB - The treatment paradigm of non-small-cell lung cancer (NSCLC) has rapidly changed - in recent years following the introduction of immune-checkpoint inhibition (ICI). - Pre-clinically, both chemotherapy and radiotherapy modulate the tumour - microenvironment, providing the rationale for clinical trials evaluating their - role in combination with immunotherapy. Standard-of-care treatment for patients - with unresectable stage III disease is concurrent chemoradiotherapy (cCRT); - however, only recently, the combination with ICI has been explored. The Phase 3 - PACIFIC study randomised 713 patients with confirmed locally advanced, - unresectable, stage III NSCLC, whose disease has not progressed following cCRT, - to either the anti-programmed death-ligand 1 (PD-L1) agent durvalumab - (Imfinzi(®)▼, AstraZeneca UK Limited) or placebo. Patients with a PD-L1 status - ≥1% treated with durvalumab had a significantly longer median progression-free - survival compared with placebo (17.2 vs. 5.6 months, respectively; HR: 0.51; 95% - CI: 0.41-0.63), prolonged median overall survival (OS) (NR vs. 28.7 months, - respectively; HR: 0.68; 99.73% CI: 0.47-0.997; P = 0.0025) and long-term clinical - benefit (3-year OS HR: 0.69; 95% CI: 0.55-0.86). Grade 3 or 4 toxicity was - marginally greater in the durvalumab cohort versus placebo (30.5% vs. 26.1%). - Based on these results, durvalumab has been licensed in this setting, and further - clinical trials are exploring the use of ICI in unresectable stage III NSCLC. -FAU - Patel, Priyanka -AU - Patel P -AD - Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK. -FAU - Alrifai, Doraid -AU - Alrifai D -AD - Lungs for Living Research Centre, UCL Respiratory, Rayne Institute, University - College London, London, UK. -AD - University College Hospital, London, UK. -FAU - McDonald, Fiona -AU - McDonald F -AD - Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK. - Fiona.McDonald@rmh.nhs.uk. -FAU - Forster, Martin -AU - Forster M -AD - University College Hospital, London, UK. -AD - UCL Cancer Institute, University College London, London, UK. -CN - AstraZeneca UK Limited -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - England -TA - Br J Cancer -JT - British journal of cancer -JID - 0370635 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal/adverse effects/*therapeutic use -MH - Antineoplastic Agents, Immunological -MH - B7-H1 Antigen/adverse effects/genetics -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/epidemiology/immunology/radiotherapy -MH - Chemoradiotherapy/*adverse effects -MH - Humans -MH - Immunotherapy -MH - Progression-Free Survival -MH - Treatment Outcome -MH - Tumor Microenvironment/*drug effects -PMC - PMC7735213 -COIS- D.A. has received speaker fees from Teva UK and travel grants from Merck Serono. - F.M. has received speaker fees for Elekta and AstraZeneca, travel grants from - AstraZeneca, grant support from Varian and MSD (and has grant support under - negotiation with Elekta) and has consulted or attended advisory boards for - AstraZeneca. M.F. has received speaker fees from AstraZeneca and has consulted or - attended advisory boards for AstraZeneca. P.P. received grant support from - Prostate Cancer UK. The authors do not report any conflict of interest with - regard to the contents of this study other than those stated. -EDAT- 2020/12/10 06:00 -MHDA- 2021/02/20 06:00 -PMCR- 2020/12/08 -CRDT- 2020/12/09 06:10 -PHST- 2020/12/09 06:10 [entrez] -PHST- 2020/12/10 06:00 [pubmed] -PHST- 2021/02/20 06:00 [medline] -PHST- 2020/12/08 00:00 [pmc-release] -AID - 10.1038/s41416-020-01071-5 [pii] -AID - 1071 [pii] -AID - 10.1038/s41416-020-01071-5 [doi] -PST - ppublish -SO - Br J Cancer. 2020 Dec;123(Suppl 1):18-27. doi: 10.1038/s41416-020-01071-5. - -PMID- 34757446 -OWN - NLM -STAT- MEDLINE -DCOM- 20220126 -LR - 20220126 -IS - 1432-1750 (Electronic) -IS - 0341-2040 (Linking) -VI - 199 -IP - 6 -DP - 2021 Dec -TI - Update 2021: Management of Small Cell Lung Cancer. -PG - 579-587 -LID - 10.1007/s00408-021-00486-y [doi] -AB - BACKGROUND: Accounting for 14% of lung cancer, small cell lung cancer (SCLC) is a - highly aggressive neuroendocrine malignancy with rapid proliferation, early - spread, and poor survival. AIM AND METHODS: We provide an overview of recent - advances regarding SCLC pathogenesis, subtypes, and treatment development through - literature review of key trials. RESULTS: There are no validated biomarkers or - approved targeted treatments for this overly heterogeneous disease, but recent - analyses have identified some promising targets and four major subtypes which may - carry unique therapeutic vulnerabilities in SCLC. Treatment wise, only a third of - patients present with limited stage SCLC, which can be managed with a combined - modality approach with curative intent (usually chemo-radiotherapy, but in some - eligible patients, surgery followed by systemic treatment). For advanced or - extensive stage SCLC, combined chemotherapy (platinum-etoposide) and - immunotherapy (atezolizumab or durvalumab during and after chemotherapy) has - become the new standard front-line treatment, with modest improvement in overall - survival. In the second-line setting, for disease relapse ≤ 6 months, topotecan, - lurbinectedin, and clinical trials are reasonable treatment options; for disease - relapse > 6 months, original regimen, topotecan or lurbinectedin can be - considered. Moreover, Trilaciclib, a CD4/CD6 inhibitor, was recently FDA-approved - to decrease the incidence of chemotherapy-related myelosuppression in SCLC - patients. CONCLUSIONS: While modest improvements in survival have been made - especially in the metastatic setting with chemo-immunotherapy, further research - in understanding the biology of SCLC is warranted to develop biomarker-driven - therapeutic strategies and combinational approaches for this aggressive disease. -CI - © 2021. The Author(s), under exclusive licence to Springer Science+Business - Media, LLC, part of Springer Nature. -FAU - Tariq, Sara -AU - Tariq S -AD - Department of Medical Oncology, Montefiore Medical Center/Albert Einstein College - of Medicine, Bronx, NY, 10461, USA. -FAU - Kim, So Yeon -AU - Kim SY -AD - Department of Medical Oncology, Montefiore Medical Center/Albert Einstein College - of Medicine, Bronx, NY, 10461, USA. -FAU - Monteiro de Oliveira Novaes, Jose -AU - Monteiro de Oliveira Novaes J -AD - Montefiore Medical Center, Bronx, NY, 10461, USA. -FAU - Cheng, Haiying -AU - Cheng H -AUID- ORCID: 0000-0002-6051-2732 -AD - Department of Medical Oncology, Montefiore Medical Center/Albert Einstein College - of Medicine, Bronx, NY, 10461, USA. hcheng@montefiore.org. -LA - eng -PT - Journal Article -PT - Review -DEP - 20211110 -PL - United States -TA - Lung -JT - Lung -JID - 7701875 -RN - 6PLQ3CP4P3 (Etoposide) -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Etoposide -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -MH - *Small Cell Lung Carcinoma/drug therapy -OTO - NOTNLM -OT - Chemotherapy -OT - Extensive stage -OT - Immunotherapy -OT - Limited stage -OT - Small cell lung cancer -EDAT- 2021/11/11 06:00 -MHDA- 2022/01/27 06:00 -CRDT- 2021/11/10 16:35 -PHST- 2021/07/12 00:00 [received] -PHST- 2021/10/16 00:00 [accepted] -PHST- 2021/11/11 06:00 [pubmed] -PHST- 2022/01/27 06:00 [medline] -PHST- 2021/11/10 16:35 [entrez] -AID - 10.1007/s00408-021-00486-y [pii] -AID - 10.1007/s00408-021-00486-y [doi] -PST - ppublish -SO - Lung. 2021 Dec;199(6):579-587. doi: 10.1007/s00408-021-00486-y. Epub 2021 Nov 10. - -PMID- 38972134 -OWN - NLM -STAT- MEDLINE -DCOM- 20240816 -LR - 20240816 -IS - 1532-1967 (Electronic) -IS - 0305-7372 (Linking) -VI - 129 -DP - 2024 Sep -TI - Treatment of unresectable stage III non-small cell lung cancer for patients who - are under-represented in clinical trials. -PG - 102797 -LID - S0305-7372(24)00125-7 [pii] -LID - 10.1016/j.ctrv.2024.102797 [doi] -AB - Concurrent chemoradiotherapy (cCRT) followed by one year of consolidation - durvalumab is the current standard-of-care for patients with unresectable stage - III non-small cell lung cancer (NSCLC), of good functional status. However, cCRT - and consolidation durvalumab may be challenging to administer for selected - patient populations underrepresented or even excluded in clinical trials: older - and/or frail patients; those with cardiovascular or respiratory comorbidities in - which treatment-related adverse events may be higher, and patients with - pre-existing autoimmune disorders for whom immunotherapy use is controversial. In - this narrative review, we discuss the current evidence, challenges, ongoing - clinical trials and potential future treatment scenarios in relevant subgroups of - patients with locally advanced NSCLC, who are underrepresented in clinical - trials. -CI - Copyright © 2024. Published by Elsevier Ltd. -FAU - Bortolot, Martina -AU - Bortolot M -AD - University of Udine, Department of Medicine (DAME), Udine, Italy; University - Hospital of Udine, Department of Oncology, Udine, Italy. -FAU - Cortiula, Francesco -AU - Cortiula F -AD - University Hospital of Udine, Department of Oncology, Udine, Italy; Department of - Radiation Oncology (Maastro), Maastricht University Medical Centre (+), GROW - School for Oncology and Reproduction, Maastricht, the Netherlands. Electronic - address: francesco.cortiula@maastro.nl. -FAU - Fasola, Gianpiero -AU - Fasola G -AD - University Hospital of Udine, Department of Oncology, Udine, Italy. -FAU - De Ruysscher, Dirk -AU - De Ruysscher D -AD - Department of Radiation Oncology (Maastro), Maastricht University Medical Centre - (+), GROW School for Oncology and Reproduction, Maastricht, the Netherlands. -FAU - Naidoo, Jarushka -AU - Naidoo J -AD - Beaumont Hospital and RCSI University of Health Sciences, Dublin, Ireland; Sidney - Kimmel Comprehensive Cancer Centre at Johns Hopkins University, Baltimore, USA. -FAU - Hendriks, Lizza E L -AU - Hendriks LEL -AD - Department of Pulmonary Diseases, Maastricht University Medical Centre (+), GROW - School for Oncology and Reproduction, Maastricht, the Netherlands. -LA - eng -PT - Journal Article -PT - Review -DEP - 20240703 -PL - Netherlands -TA - Cancer Treat Rev -JT - Cancer treatment reviews -JID - 7502030 -RN - 28X28X9OKV (durvalumab) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy/pathology -MH - *Lung Neoplasms/pathology/therapy/drug therapy -MH - Neoplasm Staging -MH - Chemoradiotherapy/methods -MH - Clinical Trials as Topic -MH - Antibodies, Monoclonal/therapeutic use -MH - Antineoplastic Agents, Immunological/therapeutic use -OTO - NOTNLM -OT - Comorbidities -OT - Elderly -OT - Frail -OT - NSCLC -OT - Special populations -OT - Unresectable stage III -COIS- Declaration of competing interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2024/07/08 00:43 -MHDA- 2024/08/17 15:44 -CRDT- 2024/07/07 18:02 -PHST- 2024/04/26 00:00 [received] -PHST- 2024/06/27 00:00 [revised] -PHST- 2024/07/02 00:00 [accepted] -PHST- 2024/08/17 15:44 [medline] -PHST- 2024/07/08 00:43 [pubmed] -PHST- 2024/07/07 18:02 [entrez] -AID - S0305-7372(24)00125-7 [pii] -AID - 10.1016/j.ctrv.2024.102797 [doi] -PST - ppublish -SO - Cancer Treat Rev. 2024 Sep;129:102797. doi: 10.1016/j.ctrv.2024.102797. Epub 2024 - Jul 3. - -PMID- 29925736 -OWN - NLM -STAT- MEDLINE -DCOM- 20190327 -LR - 20190327 -IS - 0387-821X (Print) -IS - 0387-821X (Linking) -VI - 40 -IP - 2 -DP - 2018 -TI - Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). -PG - 173-189 -LID - 10.7888/juoeh.40.173 [doi] -AB - Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has become a "game - changer" in the treatment of advanced non-small cell lung cancer (NSCLC). Its - most clinically important advantage over traditional chemotherapy using cytotoxic - agents are its long-term survival benefits, and some advanced NSCLC patients - treated with an antibody against programmed cell death 1 (PD-1) have survived for - 5 years or longer. Immune checkpoint inhibitors (ICIs) are also potentially - useful for earlier-stage NSCLC when used in combination with surgery or - radiotherapy. A recent clinical trial has shown that consolidation treatment with - an antibody against a ligand of PD-1 (PD-L1) following chemo-radiotherapy - significantly improves progression-free survival for patients with locally - advanced NSCLC. However, current single-agent treatment with an anti-PD-1/PD-L1 - antibody may provide significant survival benefits only in a small subset of - patients. PD-L1 expression status on tumor cells is an approved biomarker to - predict response to ICIs, but is not enough for optimal patient selection. To - improve the therapeutic outcomes, development of novel biomarkers other than - PD-L1 expression status is essential. Combination treatment strategies based on - blockade of PD-1/PD-L1 may also be promising, and a variety of combinations, such - as ICIs plus chemotherapy, are being examined in ongoing clinical trials. Here we - review and discuss the current status and future perspectives of immunotherapy - with ICIs. -FAU - Yoneda, Kazue -AU - Yoneda K -AD - Second Department of Surgery (Chest Surgery), School of Medicine, University of - Occupational and Environmental Health, Japan. -FAU - Imanishi, Naoko -AU - Imanishi N -AD - Second Department of Surgery (Chest Surgery), School of Medicine, University of - Occupational and Environmental Health, Japan. -FAU - Ichiki, Yoshinobu -AU - Ichiki Y -AD - Second Department of Surgery (Chest Surgery), School of Medicine, University of - Occupational and Environmental Health, Japan. -FAU - Tanaka, Fumihiro -AU - Tanaka F -AD - Second Department of Surgery (Chest Surgery), School of Medicine, University of - Occupational and Environmental Health, Japan. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - Japan -TA - J UOEH -JT - Journal of UOEH -JID - 7909645 -RN - 0 (B7-H1 Antigen) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - B7-H1 Antigen/immunology -MH - Carcinoma, Non-Small-Cell Lung/immunology/*therapy -MH - Humans -MH - *Immunotherapy -MH - Lung Neoplasms/immunology/*therapy -MH - Molecular Targeted Therapy -MH - Programmed Cell Death 1 Receptor/immunology -OTO - NOTNLM -OT - PD-1 -OT - PD-L1 -OT - cancer immunity -OT - immune checkpoint -OT - lung cancer -EDAT- 2018/06/22 06:00 -MHDA- 2019/03/28 06:00 -CRDT- 2018/06/22 06:00 -PHST- 2018/06/22 06:00 [entrez] -PHST- 2018/06/22 06:00 [pubmed] -PHST- 2019/03/28 06:00 [medline] -AID - 10.7888/juoeh.40.173 [doi] -PST - ppublish -SO - J UOEH. 2018;40(2):173-189. doi: 10.7888/juoeh.40.173. - -PMID- 32140986 -OWN - NLM -STAT- MEDLINE -DCOM- 20210712 -LR - 20210712 -IS - 1534-6269 (Electronic) -IS - 1523-3790 (Linking) -VI - 22 -IP - 4 -DP - 2020 Mar 5 -TI - Locally Advanced, Unresectable Non-Small Cell Lung Cancer. -PG - 31 -LID - 10.1007/s11912-020-0882-3 [doi] -AB - PURPOSE OF REVIEW: Treatment of locally advanced, unresectable non-small cell - lung cancer (NSCLC) has recently been revolutionized by the incorporation of - immunotherapy to standard platinum-based concurrent chemoradiation. This review - examines the current standard practices and ongoing studies on the management of - locally advanced, unresectable NSCLC. RECENT FINDINGS: Concurrent chemoradiation - is the cornerstone of treatment of unresectable, locally advanced NSCLC. However, - chemoradiation can be associated with high therapy-related toxicities, and risk - of disease relapse remains significantly elevated despite treatment with curative - intent. Durvalumab, a PD-L1 inhibitor, was recently approved as consolidation - therapy following concurrent chemoradiation; this agent represents a major - advancement in treatment of unresectable stage III NSCLC. Several clinical trials - are currently underway to evaluate the benefit of different immunotherapy - sequencing and other biomarker-driven strategies in this disease setting. - Multiple trials are presently ongoing to assess novel immunotherapy and targeted - therapy strategies to improve outcomes and decrease treatment-associated - toxicities in patients with locally advanced NSCLC. -FAU - Puri, Sonam -AU - Puri S -AUID- ORCID: 0000-0001-8068-5051 -AD - Division of Medical Oncology, The University of Utah Huntsman Cancer Institute, - Salt Lake City, UT, USA. -FAU - Saltos, Andreas -AU - Saltos A -AD - Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, FL, USA. -FAU - Perez, Bradford -AU - Perez B -AD - Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, FL, USA. -FAU - Le, Xiuning -AU - Le X -AD - Department of Thoracic and Head and Neck Medical Oncology, The University of - Texas MD Anderson Cancer Center, Houston, TX, USA. -FAU - Gray, Jhanelle E -AU - Gray JE -AD - Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, FL, USA. jhanelle.gray@moffitt.org. -LA - eng -PT - Journal Article -PT - Review -DEP - 20200305 -PL - United States -TA - Curr Oncol Rep -JT - Current oncology reports -JID - 100888967 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antineoplastic Agents, Immunological/therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/therapy -MH - Chemoradiotherapy/methods -MH - Humans -MH - Immunotherapy/*methods -MH - Lung Neoplasms/*drug therapy/pathology/therapy -MH - Neoplasm Staging -MH - Survival Analysis -OTO - NOTNLM -OT - Chemotherapy -OT - Immunotherapy -OT - Locally advanced -OT - Non-small cell lung cancer -OT - Radiation -OT - Unresectable -EDAT- 2020/03/07 06:00 -MHDA- 2021/07/13 06:00 -CRDT- 2020/03/07 06:00 -PHST- 2020/03/07 06:00 [entrez] -PHST- 2020/03/07 06:00 [pubmed] -PHST- 2021/07/13 06:00 [medline] -AID - 10.1007/s11912-020-0882-3 [pii] -AID - 10.1007/s11912-020-0882-3 [doi] -PST - epublish -SO - Curr Oncol Rep. 2020 Mar 5;22(4):31. doi: 10.1007/s11912-020-0882-3. - -PMID- 36963241 -OWN - NLM -STAT- MEDLINE -DCOM- 20230417 -LR - 20230417 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 184 -DP - 2023 May -TI - Biomarkers of response to immunotherapy in early stage non-small cell lung - cancer. -PG - 179-196 -LID - S0959-8049(23)00078-3 [pii] -LID - 10.1016/j.ejca.2023.01.029 [doi] -AB - Immunotherapy with immune-checkpoint inhibitors (ICIs) targeting programmed cell - death 1 or programmed death-ligand 1 has revolutionised the treatment of advanced - non-small cell lung cancer (NSCLC) and has been investigated in early NSCLC, - alone or in combination with chemotherapy, anti-CTLA-4 antibodies and - radiotherapy. Although more mature data are needed before setting a change of - paradigm in early stages, reports of pathological response rates and disease-free - survival are promising, especially with neoadjuvant multimodality approaches. - Nevertheless, major pathological response rates for neoadjuvant anti-PD-(L)1 - monotherapy rarely exceed 40%, and biomarkers for characterising patients who may - benefit the most from ICIs are lacking. These biomarkers have a distinct value - from the metastatic setting, with highly different tumour biologies. Among the - most investigated so far in this context, programmed death-ligand 1 expression - and, to a lesser extent, tumour mutational burden seem to correlate better with - higher pathological response rates and survival. Epidermal growth factor - receptor, Serine/Threonine Kinase 11and Kelch-like ECH-associated protein 1 - mutations rise as essential determinations for the treatment selection in - early-stage NSCLC. Emerging and promising approaches comprise evaluation of - blood-based ratios, microbiota, and baseline intratumoural TCR clonality. - Circulating tumour DNA will be of great help in the near future when selecting - best candidates for adjuvant ICIs, monitoring the tumour response to the - neoadjuvant treatment in order to improve the rates of complete resections in the - early stage. -CI - Copyright © 2023 Elsevier Ltd. All rights reserved. -FAU - Roulleaux Dugage, Matthieu -AU - Roulleaux Dugage M -AD - Department of Oncology, Hôpital Européen Georges Pompidou, AP-HP, Université - Paris Cité, Paris, France; Laboratoire D'Immunomonitoring en Oncologie, INSERM - US23, CNRS UMS 3655, Gustave Roussy, Villejuif, Île-de-France, France. -FAU - Albarrán-Artahona, Víctor -AU - Albarrán-Artahona V -AD - Medical Oncology Department, Hospital Clinic de Barcelona, Spain; Laboratory of - Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, - Barcelona, Spain. -FAU - Laguna, Juan Carlos -AU - Laguna JC -AD - Medical Oncology Department, Hospital Clinic de Barcelona, Spain. -FAU - Chaput, Nathalie -AU - Chaput N -AD - Laboratoire D'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave - Roussy, Villejuif, Île-de-France, France. -FAU - Vignot, Stéphane -AU - Vignot S -AD - Department of Oncology, Institut Godinot, Reims, France. -FAU - Besse, Benjamin -AU - Besse B -AD - Department of Oncology, Gustave Roussy, Villejuif, Île-de-France, France. -FAU - Mezquita, Laura -AU - Mezquita L -AD - Medical Oncology Department, Hospital Clinic de Barcelona, Spain; Laboratory of - Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, - Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, - Spain. -FAU - Auclin, Edouard -AU - Auclin E -AD - Department of Oncology, Hôpital Européen Georges Pompidou, AP-HP, Université - Paris Cité, Paris, France. Electronic address: edouard.auclin@aphp.fr. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230217 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -RN - 0 (Biomarkers, Tumor) -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - *Small Cell Lung Carcinoma -MH - Biomarkers, Tumor/genetics -MH - Immunotherapy -MH - B7-H1 Antigen -OTO - NOTNLM -OT - Adjuvant -OT - Anti-PD-1 -OT - Biomarkers -OT - Chemoimmunotherapy -OT - Immunotherapy -OT - NSCLC -OT - Neoadjuvant -OT - TLS -COIS- Conflict of interest statement The authors declare the following financial - interests/personal relationships which may be considered as potential competing - interests: NC: Financial Interests, Personal, Advisory Board, Strong-Iopredi - Scientific Advisory Board: AstraZeneca; Financial Interests, Institutional, - Invited Speaker, Educational Session On Immune Cell Death: Servier; Financial - Interests, Institutional, Expert Testimony, Expertise On Immune Cell Death - Biomarkers: Servier; Financial Interests, Personal, Invited Speaker: Cytune - Pharma; Financial Interests, Institutional, Research Grant, Research grant to - identify immune biomarkers associated to clinical response in patients treated - with agonistic mAbs: GSK; Financial Interests, Institutional, Research Grant, - Preclinical studies in mice: GSK; Financial Interests, Institutional, Research - Grant, Immune profiling of Head & Neck tumors: Sanofi. BB: Financial Interests, - Institutional, Funding: 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, - BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celgene, Cergentis, Cristal - Therapeutics, Daiichi Sankyo, Eli Lilly, GSK, Janssen, Onxeo, Ose - Immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero - Pharmaceuticals; Financial Interests, Institutional, Research Grant: Chugai - Pharmaceutical, EISAI, Genzyme Corporation, Inivata, Ipsen, Turning Point - Therapeutics. LM: Financial Interests, Personal, Advisory Board: Takeda, - AstraZeneca, Roche; Financial Interests, Personal, Invited Speaker: Roche, BMS, - AstraZeneca, Takeda; Financial Interests, Personal, Research Grant, SEOM Beca - Retorno 2019: BI; Financial Interests, Personal, Research Grant, ESMO TR Research - Fellowship 2019: BMS; Financial Interests, Institutional, Research Grant, COVID - research Grant: Amgen; Financial Interests, Institutional, Invited Speaker: - Inivata, Stilla. EA: Financial Interests, Personal, Advisory Board: Sanofi, - Amgen. The other authors have nothing to declare. -EDAT- 2023/03/25 06:00 -MHDA- 2023/04/17 06:41 -CRDT- 2023/03/24 19:05 -PHST- 2022/12/09 00:00 [received] -PHST- 2023/01/30 00:00 [accepted] -PHST- 2023/04/17 06:41 [medline] -PHST- 2023/03/25 06:00 [pubmed] -PHST- 2023/03/24 19:05 [entrez] -AID - S0959-8049(23)00078-3 [pii] -AID - 10.1016/j.ejca.2023.01.029 [doi] -PST - ppublish -SO - Eur J Cancer. 2023 May;184:179-196. doi: 10.1016/j.ejca.2023.01.029. Epub 2023 - Feb 17. - -PMID- 27528240 -OWN - NLM -STAT- MEDLINE -DCOM- 20180619 -LR - 20210103 -IS - 0890-9091 (Print) -IS - 0890-9091 (Linking) -VI - 30 -IP - 8 -DP - 2016 Aug -TI - Using Immune Checkpoint Inhibitors in Lung Cancer. -PG - 713-21 -LID - 218403 [pii] -AB - Immune checkpoint inhibition using targeted monoclonal antibodies is changing the - treatment paradigm for lung cancer. Approval by the US Food and Drug - Administration of two anti-programmed death 1 immune checkpoint inhibitors for - second-line treatment of advanced or metastatic non-small-cell lung cancer - (NSCLC) has led to increased use of these agents in the clinic. Ongoing clinical - trials are evaluating the administration of immune checkpoint inhibitors alone or - in combination with each other, and in combination with targeted therapy, - radiation therapy, and chemotherapy regimens. Other trials are evaluating these - monoclonal antibodies in small-cell lung cancer and across a variety of treatment - regimens and disease stages in NSCLC. Ongoing translational work to identify - relevant biomarkers will deepen our understanding of when and how to use immune - checkpoint agents in our patients with lung cancer. We must continue to improve - the cost-benefit ratios for efficacy, safety, and outcomes associated with the - use of these medications. This is an exciting time in the field of lung cancer - research as we work to understand how best to use this novel class of agents. -FAU - Marrone, Kristen A -AU - Marrone KA -FAU - Brahmer, Julie R -AU - Brahmer JR -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - United States -TA - Oncology (Williston Park) -JT - Oncology (Williston Park, N.Y.) -JID - 8712059 -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -CIN - Oncology (Williston Park). 2016 Aug;30(8):722-3. PMID: 27528241 -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Humans -MH - Lung Neoplasms/*drug therapy -EDAT- 2016/08/17 06:00 -MHDA- 2018/06/21 06:00 -CRDT- 2016/08/17 06:00 -PHST- 2016/08/17 06:00 [entrez] -PHST- 2016/08/17 06:00 [pubmed] -PHST- 2018/06/21 06:00 [medline] -AID - 218403 [pii] -PST - ppublish -SO - Oncology (Williston Park). 2016 Aug;30(8):713-21. - -PMID- 35716328 -OWN - NLM -STAT- MEDLINE -DCOM- 20220804 -LR - 20240923 -IS - 1534-6277 (Electronic) -IS - 1527-2729 (Print) -IS - 1534-6277 (Linking) -VI - 23 -IP - 8 -DP - 2022 Aug -TI - Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung - Cancer. -PG - 1104-1120 -LID - 10.1007/s11864-022-00989-7 [doi] -AB - Limited-stage small cell lung cancer (LS-SCLC) is a potentially curable disease. - However, most patients develop disease relapse shortly after definitive - treatment. The landmark trials IMpower133 and CASPIAN demonstrated a survival - benefit with the addition of immunotherapy to first-line platinum/etoposide for - extensive-stage small cell lung cancer. Therefore, it is critical to determine - whether advancements in overall survival with immunotherapy can be translated - earlier into the treatment paradigm for LS-SCLC. Decades of robust preclinical - research into the synergism of radiation therapy and immunotherapy set the stage - for the combination of these treatment modalities. Recently published data - suggests tolerability of single agent immunotherapy concurrent with - chemoradiation in LS-SCLC, along with promising efficacy. However, combination - immunotherapy in the consolidation setting appears too toxic, although this may - be reflective of the dosing schedule rather than inherent to any combination - immune checkpoint blockade. Here, we review underlying mechanisms of synergy with - the combination of radiation and immunotherapy, the safety and efficacy of - respective treatment modalities, and the ongoing trials that are exploring novel - therapeutic approaches for LS-SCLC. Pivotal trials in LS-SCLC are ongoing and - anticipated to aid in understanding efficacy and safety of immunotherapy with - concurrent platinum-based chemoradiotherapy. -CI - © 2022. The Author(s). -FAU - Schlick, Brian -AU - Schlick B -AD - Department of Oncologic Sciences, Morsani College of Medicine, University of - South Florida, 12902 Magnolia Dr, GME Office, Tampa, FL, 33612, USA. -FAU - Shields, Misty Dawn -AU - Shields MD -AD - Department of Oncologic Sciences, Morsani College of Medicine, University of - South Florida, 12902 Magnolia Dr, GME Office, Tampa, FL, 33612, USA. -FAU - Marin-Acevedo, Julian A -AU - Marin-Acevedo JA -AD - Department of Oncologic Sciences, Morsani College of Medicine, University of - South Florida, 12902 Magnolia Dr, GME Office, Tampa, FL, 33612, USA. -FAU - Patel, Ishika -AU - Patel I -AD - Department of Public Health, University of South Florida, 4202 E Fowler Ave, - Tampa, FL, 33620, USA. -FAU - Pellini, Bruna -AU - Pellini B -AUID- ORCID: 0000-0003-0898-0202 -AD - Department of Oncologic Sciences, Morsani College of Medicine, University of - South Florida, 12902 Magnolia Dr, GME Office, Tampa, FL, 33612, USA. - Bruna.Pellini@moffitt.org. -AD - Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute, - 12902 Magnolia Dr, CSB 6-THOR PROG, Tampa, FL, 33612, USA. - Bruna.Pellini@moffitt.org. -LA - eng -GR - P30 CA076292/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Review -DEP - 20220618 -PL - United States -TA - Curr Treat Options Oncol -JT - Current treatment options in oncology -JID - 100900946 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Immunologic Factors) -SB - IM -MH - Chemoradiotherapy -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use -MH - Immunologic Factors/therapeutic use -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -MH - Neoplasm Recurrence, Local/drug therapy -MH - *Small Cell Lung Carcinoma/drug therapy -PMC - PMC9345799 -OTO - NOTNLM -OT - Concurrent immunotherapy chemoradiation -OT - Immune checkpoint inhibitors -OT - Immunotherapy -OT - LS-SCLC -OT - Limited-stage small cell lung cancer -COIS- The author Bruna Pellini receives research support to the institution from - Bristol Myers Squibb, has received speaker honoraria from BioAscend, OncLive/MJH - Life Science, and has done consulting work/advisory board with Guidepoint, - Guardant Health, and AstraZeneca. The other authors Brian Schlick, Misty Dawn - Shields, Julian A. Marin-Acevedo, and Ishika Patel have nothing to disclose. -EDAT- 2022/06/19 06:00 -MHDA- 2022/08/05 06:00 -PMCR- 2022/06/18 -CRDT- 2022/06/18 11:19 -PHST- 2022/05/15 00:00 [accepted] -PHST- 2022/06/19 06:00 [pubmed] -PHST- 2022/08/05 06:00 [medline] -PHST- 2022/06/18 11:19 [entrez] -PHST- 2022/06/18 00:00 [pmc-release] -AID - 10.1007/s11864-022-00989-7 [pii] -AID - 989 [pii] -AID - 10.1007/s11864-022-00989-7 [doi] -PST - ppublish -SO - Curr Treat Options Oncol. 2022 Aug;23(8):1104-1120. doi: - 10.1007/s11864-022-00989-7. Epub 2022 Jun 18. - -PMID- 30483900 -OWN - NLM -STAT- MEDLINE -DCOM- 20191024 -LR - 20191024 -IS - 1534-6277 (Electronic) -IS - 1534-6277 (Linking) -VI - 19 -IP - 12 -DP - 2018 Nov 27 -TI - Proton Therapy in Non-small Cell Lung Cancer. -PG - 76 -LID - 10.1007/s11864-018-0588-z [doi] -AB - Non-small cell lung cancer (NSCLC) accounts for 85% of new lung cancer cases and - has 5-year survival rates ranging from 92% in early-stage disease to as low as - 13% in locally advanced cases. Radiation therapy is a key component in the - treatment repertoire for NSCLC, where it is currently used alone or in - combinations with chemotherapy and surgery. Despite the broad use of modern - photon radiation techniques, as many as 25% of patients experience isolated - locoregional recurrences, and toxicity has been proven to be a limiting factor in - many cases. Proton beam therapy (PBT) has emerged as a potential solution to - improve upon clinical outcomes in both early-stage and locally advanced disease. - The proton beam allows for a sharp dose build-up and drop-off, which is - particularly important in lung cancer where nearby structures include the heart, - spinal cord, esophagus, and uninvolved lung. There are now numerous studies - showing dosimetric advantages of PBT in early and locally advanced NSCLC, - particularly in the heart and lung doses. Randomized data comparing clinical - outcomes between proton and photon radiation are limited to a small number of - studies. Despite early results suggesting improvements or at least comparable - outcomes with PBT, the most recent randomized comparisons have failed to show - significant differences in toxicity and local control between photon and proton - therapy. As newer PBT techniques (e.g., intensity-modulated proton therapy) are - increasingly utilized, more dramatic improvements in tumor control and toxicity - may be demonstrated. It is also important to recognize that there may be certain - subpopulations in which the benefits of proton therapy are greater, such as - central early-stage tumors, previously irradiated tumors, and locally advanced - tumors, while others may best be treated with traditional photon techniques. As - immunotherapy becomes more prevalent in the treatment of NSCLC, improving local - control and limiting the toxicity contributed by radiation will be increasingly - important. The unique dosimetric advantages of PBT may allow for tumor dose - escalation while maintaining normal tissue doses to improve local control, or - treating the tumor to the standard dose while decreasing normal tissue doses to - improve toxicity. Finally, given the high costs of proton therapy, where low - insurance approval rates have limited trial enrollment, it will be important to - determine the overall cost-benefit ratio. -FAU - Mesko, Shane -AU - Mesko S -AD - Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, - 1515 Holcombe Blvd, Houston, TX, 77030, USA. -FAU - Gomez, Daniel -AU - Gomez D -AD - Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, - 1515 Holcombe Blvd, Houston, TX, 77030, USA. dgomez@mdanderson.org. -LA - eng -PT - Journal Article -PT - Review -DEP - 20181127 -PL - United States -TA - Curr Treat Options Oncol -JT - Current treatment options in oncology -JID - 100900946 -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/pathology/*radiotherapy -MH - Humans -MH - Lung Neoplasms/pathology/*radiotherapy -MH - Neoplasm Recurrence, Local/epidemiology -MH - Proton Therapy/*adverse effects/*methods -MH - Radiation Injuries/prevention & control -MH - Radiotherapy Dosage -MH - Treatment Outcome -OTO - NOTNLM -OT - IMPT -OT - Lung cancer -OT - NSCLC -OT - Passive scatter -OT - Proton therapy -EDAT- 2018/11/30 06:00 -MHDA- 2019/10/28 06:00 -CRDT- 2018/11/29 06:00 -PHST- 2018/11/29 06:00 [entrez] -PHST- 2018/11/30 06:00 [pubmed] -PHST- 2019/10/28 06:00 [medline] -AID - 10.1007/s11864-018-0588-z [pii] -AID - 10.1007/s11864-018-0588-z [doi] -PST - epublish -SO - Curr Treat Options Oncol. 2018 Nov 27;19(12):76. doi: 10.1007/s11864-018-0588-z. - -PMID- 38287788 -OWN - NLM -STAT- MEDLINE -DCOM- 20240412 -LR - 20240425 -IS - 1349-7006 (Electronic) -IS - 1347-9032 (Print) -IS - 1347-9032 (Linking) -VI - 115 -IP - 4 -DP - 2024 Apr -TI - Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR - mutation: A real-world study (HOT2101). -PG - 1273-1282 -LID - 10.1111/cas.16094 [doi] -AB - Durvalumab has been administered to patients with unresectable stage III - non-small cell lung cancer (NSCLC). However, it remains unclear whether - durvalumab benefits these patients with epidermal growth factor receptor (EGFR) - mutation. We conducted a retrospective, multicenter study of patients with EGFR - mutation who received chemoradiotherapy (CRT) between June 2018 and March 2021. - We assessed patient characteristics, efficacy of durvalumab, and durvalumab - safety before and after targeted therapy. We collected data on a total of 673 - patients, of whom 401 (59.6%) underwent EGFR mutation testing. Fifty-one patients - were EGFR positive and 311 were EGFR negative. In the EGFR-positive group, there - were higher proportions of females, never-smokers, and patients with - adenocarcinoma histology. Of the 51 patients in the positive group and 311 in the - negative group who received CRT, 45 (88.2%) and 247 (79.4%) received durvalumab, - with median progression-free survival of 23.0 and 24.2 months in the positive and - negative groups, respectively (hazard ratio 1.03; 95% confidence interval: - 0.64-1.67). The main adverse event was pneumonitis (positive group: 62.2%; 4.4% - grade 3; negative group: 62.3%; 6.9% grade 3). No treatment-related deaths were - observed. Of the 45 patients in the positive group who received durvalumab, 14 - (31.1%) received targeted therapy after durvalumab at the data cutoff. One - patient discontinued targeted therapy after developing pneumonitis. In patients - with unresectable stage III NSCLC with EGFR mutation, durvalumab after CRT is - potentially safe and effective. This may be a suitable treatment sequence for - these patients. -CI - © 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd - on behalf of Japanese Cancer Association. -FAU - Tsuji, Kosuke -AU - Tsuji K -AD - Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, - Sapporo, Japan. -FAU - Mizugaki, Hidenori -AU - Mizugaki H -AUID- ORCID: 0000-0003-1167-2497 -AD - Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, - Sapporo, Japan. -AD - Department of Advanced Medical Development, The Cancer Institute Hospital of - Japanese Foundation for Cancer Research, Tokyo, Japan. -AD - Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan. -FAU - Yokoo, Keiki -AU - Yokoo K -AD - Department of Respiratory Medicine, Teine Keijinkai Hospital, Sapporo, Japan. -FAU - Kobayashi, Maki -AU - Kobayashi M -AD - Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan. -FAU - Kawashima, Yosuke -AU - Kawashima Y -AD - Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan. -FAU - Kimura, Nozomu -AU - Kimura N -AUID- ORCID: 0009-0002-4596-0964 -AD - Department of Respiratory Medicine, Tohoku University Graduate School of - Medicine, Sendai, Japan. -FAU - Yokouchi, Hiroshi -AU - Yokouchi H -AD - Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan. -FAU - Kikuchi, Hajime -AU - Kikuchi H -AD - Department of Respiratory Medicine, Obihiro-Kousei General Hospital, Obihiro, - Japan. -FAU - Sumi, Toshiyuki -AU - Sumi T -AUID- ORCID: 0000-0002-2540-5878 -AD - Department of Respiratory Medicine, Hakodate Goryoukaku Hospital, Hakodate, - Japan. -FAU - Kawai, Yasutaka -AU - Kawai Y -AD - Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Japan. -FAU - Kobashi, Kenta -AU - Kobashi K -AD - Department of Pulmonary Medicine, Steel Memorial Muroran Hospital, Muroran, - Japan. -FAU - Morita, Ryo -AU - Morita R -AD - Department of Respiratory Medicine, Akita Kousei Medical Center, Akita, Japan. -FAU - Ito, Kenichiro -AU - Ito K -AD - Department of Respiratory Medicine, KKR Sapporo Medical Center, Sapporo, Japan. -FAU - Kitamura, Yasuo -AU - Kitamura Y -AD - Department of Respiratory Medicine, Kushiro City General Hospital, Kushiro, - Japan. -FAU - Minemura, Hiroyuki -AU - Minemura H -AD - Department of Pulmonary Medicine, Fukushima Medical University School of - Medicine, Fukushima, Japan. -FAU - Nakamura, Keiichi -AU - Nakamura K -AD - Department of Respiratory Medicine, National Hospital Organization Asahikawa - Medical Center, Asahikawa, Japan. -FAU - Aso, Mari -AU - Aso M -AD - Department of Respiratory Medicine, Yamagata Prefectural Central Hospital, - Yamagata, Japan. -FAU - Honjo, Osamu -AU - Honjo O -AD - Department of Respiratory Medicine, Sapporo Minami-Sanjo Hospital, Sapporo, - Japan. -FAU - Tanaka, Hisashi -AU - Tanaka H -AD - Department of Respiratory Medicine, Graduate School of Medicine, Hirosaki - University, Hirosaki, Japan. -FAU - Takashina, Taichi -AU - Takashina T -AD - Department of Respiratory Medicine, Iwamizawa Municipal General Hospital, - Iwamizawa, Japan. -FAU - Tsurumi, Kyoji -AU - Tsurumi K -AD - Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan. -FAU - Sugisaka, Jun -AU - Sugisaka J -AD - Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan. -FAU - Tsukita, Yoko -AU - Tsukita Y -AD - Department of Respiratory Medicine, Tohoku University Graduate School of - Medicine, Sendai, Japan. -FAU - Konno, Satoshi -AU - Konno S -AD - Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, - Sapporo, Japan. -FAU - Oizumi, Satoshi -AU - Oizumi S -AD - Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan. -LA - eng -PT - Journal Article -PT - Multicenter Study -DEP - 20240129 -PL - England -TA - Cancer Sci -JT - Cancer science -JID - 101168776 -RN - 28X28X9OKV (durvalumab) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - 0 (Antibodies, Monoclonal) -SB - IM -MH - Female -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Retrospective Studies -MH - *Lung Neoplasms/drug therapy/genetics -MH - Chemoradiotherapy -MH - *Pneumonia -MH - Mutation -MH - ErbB Receptors/genetics -MH - *Antibodies, Monoclonal -PMC - PMC11006989 -OTO - NOTNLM -OT - PACIFIC -OT - chemoradiotherapy -OT - durvalumab -OT - epidermal growth factor receptor -OT - non‐small cell lung cancer -COIS- During this study, HY, YT, and SK received grants from AstraZeneca. SO received - honoraria and grants from AstraZeneca. The other authors declare no conflict of - interest. -EDAT- 2024/01/30 06:42 -MHDA- 2024/04/12 06:45 -PMCR- 2024/01/29 -CRDT- 2024/01/30 02:43 -PHST- 2024/01/01 00:00 [revised] -PHST- 2023/11/02 00:00 [received] -PHST- 2024/01/14 00:00 [accepted] -PHST- 2024/04/12 06:45 [medline] -PHST- 2024/01/30 06:42 [pubmed] -PHST- 2024/01/30 02:43 [entrez] -PHST- 2024/01/29 00:00 [pmc-release] -AID - CAS16094 [pii] -AID - 10.1111/cas.16094 [doi] -PST - ppublish -SO - Cancer Sci. 2024 Apr;115(4):1273-1282. doi: 10.1111/cas.16094. Epub 2024 Jan 29. - -PMID- 32663833 -OWN - NLM -STAT- MEDLINE -DCOM- 20201119 -LR - 20201119 -IS - 1423-0232 (Electronic) -IS - 0030-2414 (Linking) -VI - 98 -IP - 11 -DP - 2020 -TI - Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer. -PG - 749-754 -LID - 10.1159/000508516 [doi] -AB - Lung cancer is a leading cause of cancer death in the United States and around - the world. Approximately 13% of lung cancers are small cell lung cancer (SCLC). - SCLC is generally classified as a limited-stage and extensive-stage disease - depending on the extent of involvement. For patients with the extensive-stage - disease, until recently, chemotherapy alone has been the recommended treatment, - although radiotherapy could be used in select patients for palliation of - symptoms. The standard of care for extensive-stage SCLC is platinum doublet - chemotherapy with either cisplatin or carboplatin in combination with etoposide. - Even though first-line therapy has an initial response rate of 60-80%, the - prognosis is poor, with overall survival of 10-12 months. The only FDA-approved - second line of therapy is topotecan, approved both as an intravenous formulation - as well as an oral formulation, with response rates of 6-12% in chemorefractory - disease and 15-37% in chemosensitive disease. Immunotherapy has recently been - approved as a first-line agent in metastatic SCLC in combination with - chemotherapy. It is also approved as a third-line agent in metastatic SCLC after - the failure of two chemotherapy regimens. The FDA approved four drugs, two of - them being PD-1 inhibitors (pembrolizumab, nivolumab), and two of them being - PD-L1 inhibitors (atezolizumab and durvalumab) in SCLC. This review article - summarizes the significance of immunotherapy in the treatment of extensive-stage - SCLC, its side effects, and limitations. -CI - © 2020 S. Karger AG, Basel. -FAU - Konala, Venu Madhav -AU - Konala VM -AD - Ashland Bellefonte Cancer Center, Ashland, Kentucky, USA, drvenumadhav@gmail.com. -FAU - Madhira, Bhaskar Reddy -AU - Madhira BR -AD - SUNY Upstate Medical University, Syracuse, New York, USA. -FAU - Ashraf, Sara -AU - Ashraf S -AD - Marshall University, Joan C Edwards School of Medicine, Huntington, West - Virginia, USA. -FAU - Graziano, Stephen -AU - Graziano S -AD - SUNY Upstate Medical University, Syracuse, New York, USA. -LA - eng -PT - Journal Article -PT - Review -DEP - 20200714 -PL - Switzerland -TA - Oncology -JT - Oncology -JID - 0135054 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antineoplastic Agents, Immunological/administration & dosage/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors/immunology -MH - Clinical Trials as Topic -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/*drug therapy/immunology/pathology -MH - Neoplasm Staging -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology -MH - Randomized Controlled Trials as Topic -MH - Small Cell Lung Carcinoma/*drug therapy/immunology/pathology -OTO - NOTNLM -OT - Checkpoint inhibitors -OT - Extensive-stage small cell lung cancer -OT - Immunotherapy -OT - PD-1 inhibitors -OT - PD-L1 inhibitors -OT - Small cell lung cancer -EDAT- 2020/07/15 06:00 -MHDA- 2020/11/20 06:00 -CRDT- 2020/07/15 06:00 -PHST- 2020/04/23 00:00 [received] -PHST- 2020/05/05 00:00 [accepted] -PHST- 2020/07/15 06:00 [pubmed] -PHST- 2020/11/20 06:00 [medline] -PHST- 2020/07/15 06:00 [entrez] -AID - 000508516 [pii] -AID - 10.1159/000508516 [doi] -PST - ppublish -SO - Oncology. 2020;98(11):749-754. doi: 10.1159/000508516. Epub 2020 Jul 14. - -PMID- 31534086 -OWN - NLM -STAT- MEDLINE -DCOM- 20200608 -LR - 20200608 -IS - 1349-7235 (Electronic) -IS - 0918-2918 (Print) -IS - 0918-2918 (Linking) -VI - 59 -IP - 2 -DP - 2020 Jan 15 -TI - Managing Lung Cancer with Comorbid Interstitial Pneumonia. -PG - 163-167 -LID - 10.2169/internalmedicine.3481-19 [doi] -AB - Systemic therapy for advanced non-small cell lung cancer (NSCLC) has dramatically - changed in the latest 15 years. Molecular-targeted therapy has brought about an - era of precision medicine, and immune checkpoint inhibitors have brought hope for - a cure for advanced NSCLC. In the wake of this remarkable advancement, lung - cancer with comorbid interstitial pneumonia (IP) has been completely left behind, - as most clinical trials exclude patients with comorbid IP. IP, especially - idiopathic pulmonary fibrosis (IPF), is often accompanied by lung cancer, and - acute exacerbation can develop during various cancer therapies, including - surgery, radiotherapy and pharmacotherapy. In this review, we focus on the - clinical questions concerning pharmacotherapy in cases of advanced lung cancer - with comorbid IP and discuss what we can do with the currently available data. -FAU - Ichihara, Eiki -AU - Ichihara E -AD - Department of Allergy and Respiratory Medicine, Okayama University Hospital, - Japan. -FAU - Miyahara, Nobuaki -AU - Miyahara N -AD - Department of Medical Technology, Okayama University Graduate School of Health - Sciences, Japan. -FAU - Maeda, Yoshinobu -AU - Maeda Y -AD - Department of Hematology, Oncology and Respiratory Medicine, Okayama University - Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan. -FAU - Kiura, Katsuyuki -AU - Kiura K -AD - Department of Allergy and Respiratory Medicine, Okayama University Hospital, - Japan. -LA - eng -PT - Journal Article -PT - Review -DEP - 20190918 -PL - Japan -TA - Intern Med -JT - Internal medicine (Tokyo, Japan) -JID - 9204241 -SB - IM -MH - Acute Disease -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/*epidemiology -MH - Humans -MH - Idiopathic Pulmonary Fibrosis/epidemiology -MH - Lung Diseases, Interstitial/*epidemiology -MH - Lung Neoplasms/*drug therapy/*epidemiology -PMC - PMC7008037 -OTO - NOTNLM -OT - interstitial pneumonia -OT - lung cancer -COIS- The authors state that they have no Conflict of Interest (COI). -EDAT- 2019/09/20 06:00 -MHDA- 2020/06/09 06:00 -PMCR- 2020/01/15 -CRDT- 2019/09/20 06:00 -PHST- 2019/09/20 06:00 [pubmed] -PHST- 2020/06/09 06:00 [medline] -PHST- 2019/09/20 06:00 [entrez] -PHST- 2020/01/15 00:00 [pmc-release] -AID - 10.2169/internalmedicine.3481-19 [doi] -PST - ppublish -SO - Intern Med. 2020 Jan 15;59(2):163-167. doi: 10.2169/internalmedicine.3481-19. - Epub 2019 Sep 18. - -PMID- 28214087 -OWN - NLM -STAT- MEDLINE -DCOM- 20180226 -LR - 20180226 -IS - 1535-6345 (Electronic) -IS - 0147-0272 (Linking) -VI - 41 -IP - 2 -DP - 2017 Mar-Apr -TI - Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. -PG - 111-124 -LID - S0147-0272(16)30188-X [pii] -LID - 10.1016/j.currproblcancer.2016.12.002 [doi] -AB - The last decade has witnessed rapid advances in the discovery and development of - immune checkpoint inhibitors in cancer medicine, particularly drugs targeting - programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in - non-small cell lung cancer (NSCLC). The proven antitumor efficacy coupled with - low rates of drug-related toxicities observed, albeit idiosyncratic, with these - novel immunotherapeutics have led to the registration of multiple PD-1 and PD-L1 - inhibitors, such as nivolumab, pembrolizumab, and atezolizumab, in second-line - advanced NSCLC, whereas durvalumab and avelumab are in late-phase clinical - testing. Moreover, pembrolizumab has shown a survival advantage in the first-line - setting; however, nivolumab failed to show a survival benefit possibly relating - to patient selection based on PD-L1 expression. Current patient selection is - based on PD-L1 expression, using the relevant companion diagnostic test, where - patients with strong PD-L1 expression being more likely to respond to these novel - agents. Ongoing clinical research focuses on the development of PD-1 and PD-L1 - inhibitor monotherapy in neoadjuvant and adjuvant NSCLC. There is also much - interest in using these drugs as a therapeutic backbone for rational combinations - with other treatment modalities including cytotoxic chemotherapies in the - first-line NSCLC, other immunotherapies such as cytotoxic T-lymphocyte-associated - protein 4 antagonists, molecularly targeted agents including EGFR and ALK - inhibitors, and radiotherapy. Concurrent treatment with radiotherapy is of - particular interest owing to the potential for the abscopal effect, using - radiotherapy to facilitate systemic treatment. -CI - Copyright © 2017 Elsevier Inc. All rights reserved. -FAU - Kumar, Rajiv -AU - Kumar R -AD - Lung Cancer Unit, Department of Medicine, Royal Marsden NHS Foundation Trust, - London, UK. -FAU - Collins, Dearbhaile -AU - Collins D -AD - Royal Marsden NHS Foundation Trust, London, UK. -FAU - Dolly, Saoirse -AU - Dolly S -AD - Royal Marsden NHS Foundation Trust, London, UK. -FAU - McDonald, Fiona -AU - McDonald F -AD - Lung Cancer Unit, Department of Medicine, Royal Marsden NHS Foundation Trust, - London, UK. -FAU - O'Brien, Mary E R -AU - O'Brien MER -AD - Lung Cancer Unit, Department of Medicine, Royal Marsden NHS Foundation Trust, - London, UK. -FAU - Yap, Timothy A -AU - Yap TA -AD - Lung Cancer Unit, Department of Medicine, Royal Marsden NHS Foundation Trust, - London, UK; Royal Marsden NHS Foundation Trust, London, UK; Cancer Biomarkers, - The Institute of Cancer Research, London, UK. Electronic address: - TYap@mdanderson.org. -LA - eng -PT - Journal Article -PT - Review -DEP - 20161223 -PL - United States -TA - Curr Probl Cancer -JT - Current problems in cancer -JID - 7702986 -RN - 0 (Antineoplastic Agents) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Animals -MH - Antineoplastic Agents/*therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Humans -MH - Lung Neoplasms/*drug therapy -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -OTO - NOTNLM -OT - CTLA-4 antagonists -OT - Chemotherapy -OT - Immune checkpoint inhibitors -OT - Non–small cell lung cancer -OT - PD-1 -OT - PD-L1 -OT - Radiotherapy -OT - Small molecule inhibitors -EDAT- 2017/02/19 06:00 -MHDA- 2018/02/27 06:00 -CRDT- 2017/02/19 06:00 -PHST- 2016/11/14 00:00 [received] -PHST- 2016/12/10 00:00 [accepted] -PHST- 2017/02/19 06:00 [pubmed] -PHST- 2018/02/27 06:00 [medline] -PHST- 2017/02/19 06:00 [entrez] -AID - S0147-0272(16)30188-X [pii] -AID - 10.1016/j.currproblcancer.2016.12.002 [doi] -PST - ppublish -SO - Curr Probl Cancer. 2017 Mar-Apr;41(2):111-124. doi: - 10.1016/j.currproblcancer.2016.12.002. Epub 2016 Dec 23. - -PMID- 33651512 -OWN - NLM -STAT- MEDLINE -DCOM- 20210604 -LR - 20210604 -IS - 1876-8784 (Electronic) -IS - 0028-2162 (Linking) -VI - 165 -DP - 2021 Feb 4 -TI - [Treatment of non-small cell lung cancer]. -LID - D5486 [pii] -AB - In this review article we discuss the diagnostic workup and current treatment - strategies for non-small cell lung cancer (NSCLC). Anatomical resection and - systematic lymph node dissection is the recommended treatment for early-stage - NSCLC. Stereotactic body radiotherapy (SBRT) is an alternative for non-operable - patients. Locally advanced NSCLC could be treated with a combination of - chemotherapy, radiotherapy and immunotherapy, and in select cases followed by - surgical resection. Treatment for patients with metastasized NSCLC depends on - molecular tumor characteristics, PD-L1 expression and could consist of - chemotherapy, immunotherapy, targeted therapy or a combination of these - modalities. In all stages, best supportive care is an option to consider. Because - of the success of immunotherapy and targeted therapy for stage IV NSCLC, numerous - trials have started to investigate the efficacy of these modalities in - early-stage NSCLC as well, further optimizing treatment strategies for this - patient group. -FAU - Hopstaken, J S -AU - Hopstaken JS -AD - Nederlands Kankerinstituut-Antoni van Leeuwenhoek, afd. Chirurgie, Amsterdam - (thans: Radboudumc, afd. Chirurgie, Nijmegen). -FAU - de Ruiter, J C -AU - de Ruiter JC -AD - Nederlands Kankerinstituut-Antoni van Leeuwenhoek, afd. Chirurgie, Amsterdam. -FAU - van Diessen, J N A -AU - van Diessen JNA -AD - Nederlands Kankerinstituut-Antoni van Leeuwenhoek, afd. Radiotherapie, Amsterdam. -FAU - Theelen, W S M E -AU - Theelen WSME -AD - Nederlands Kankerinstituut-Antoni van Leeuwenhoek, afd. Thoracale Oncologie, - Amsterdam. -FAU - Monkhorst, K -AU - Monkhorst K -AD - Nederlands Kankerinstituut-Antoni van Leeuwenhoek, afd. Pathologie, Amsterdam. -FAU - Hartemink, K J -AU - Hartemink KJ -AD - Nederlands Kankerinstituut-Antoni van Leeuwenhoek, afd. Chirurgie, Amsterdam. -AD - Contact: K.J. Hartemink (k.hartemink@nki.nl). -LA - dut -PT - Journal Article -PT - Review -TT - Niet-kleincellig longcarcinoom. -DEP - 20210204 -PL - Netherlands -TA - Ned Tijdschr Geneeskd -JT - Nederlands tijdschrift voor geneeskunde -JID - 0400770 -RN - 0 (Antineoplastic Agents) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -SB - IM -MH - Antineoplastic Agents/*therapeutic use -MH - B7-H1 Antigen/metabolism -MH - Carcinoma, Non-Small-Cell Lung/metabolism/pathology/*therapy -MH - Combined Modality Therapy -MH - Humans -MH - *Immunotherapy -MH - Lung/pathology/surgery -MH - Lung Neoplasms/metabolism/pathology/therapy -MH - *Lymph Node Excision -MH - Lymph Nodes/pathology/surgery -MH - *Pneumonectomy -MH - *Radiosurgery -EDAT- 2021/03/03 06:00 -MHDA- 2021/06/05 06:00 -CRDT- 2021/03/02 12:17 -PHST- 2021/03/02 12:17 [entrez] -PHST- 2021/03/03 06:00 [pubmed] -PHST- 2021/06/05 06:00 [medline] -AID - D5486 [pii] -PST - epublish -SO - Ned Tijdschr Geneeskd. 2021 Feb 4;165:D5486. - -PMID- 37504325 -OWN - NLM -STAT- MEDLINE -DCOM- 20230731 -LR - 20231102 -IS - 1718-7729 (Electronic) -IS - 1198-0052 (Print) -IS - 1198-0052 (Linking) -VI - 30 -IP - 7 -DP - 2023 Jun 30 -TI - Canadian Consensus Recommendations on the Management of Extensive-Stage - Small-Cell Lung Cancer. -PG - 6289-6315 -LID - 10.3390/curroncol30070465 [doi] -AB - Small-cell lung cancer (SCLC) is an aggressive, neuroendocrine tumour with high - relapse rates, and significant morbidity and mortality. Apart from advances in - radiation therapy, progress in the systemic treatment of SCLC had been stagnant - for over three decades despite multiple attempts to develop alternative - therapeutic options that could improve responses and survival. Recent promising - developments in first-line and subsequent therapeutic approaches prompted a - Canadian Expert Panel to convene to review evidence, discuss practice patterns, - and reach a consensus on the treatment of extensive-stage SCLC (ES-SCLC). The - literature search included guidelines, systematic reviews, and randomized - controlled trials. Regular meetings were held from September 2022 to March 2023 - to discuss the available evidence to propose and agree upon specific - recommendations. The panel addressed biomarkers and histological features that - distinguish SCLC from non-SCLC and other neuroendocrine tumours. Evidence for - initial and subsequent systemic therapies was reviewed with consideration for - patient performance status, comorbidities, and the involvement and function of - other organs. The resulting consensus recommendations herein will help clarify - evidence-based management of ES-SCLC in routine practice, help clinician - decision-making, and facilitate the best patient outcomes. -FAU - Melosky, Barbara L -AU - Melosky BL -AUID- ORCID: 0000-0003-2865-659X -AD - Department of Medical Oncology, BC Cancer-Vancouver Centre, Vancouver, BC V5Z - 4E6, Canada. -FAU - Leighl, Natasha B -AU - Leighl NB -AD - Department of Medicine, Princess Margaret Cancer Centre, University Health - Network, University of Toronto, Toronto, ON M5S 1A8, Canada. -FAU - Dawe, David -AU - Dawe D -AUID- ORCID: 0000-0001-9762-3156 -AD - CancerCare Manitoba Research Institute, CancerCare Manitoba, Department of - Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, - Winnipeg, MB R3E 0V9, Canada. -FAU - Blais, Normand -AU - Blais N -AUID- ORCID: 0000-0003-2698-4362 -AD - Department of Medicine, Centre Hospitalier de l'Université de Montréal, - University of Montreal, Montreal, QC H2X 3E4, Canada. -FAU - Wheatley-Price, Paul F -AU - Wheatley-Price PF -AD - Department of Medicine, The Ottawa Hospital Research Institute, The Ottawa - Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada. -FAU - Chu, Quincy S-C -AU - Chu QS -AD - Division of Medical Oncology, Department of Oncology, Cross Cancer Institute, - University of Alberta, Edmonton, AB T6G 1Z2, Canada. -FAU - Juergens, Rosalyn A -AU - Juergens RA -AD - Department of Medical Oncology, Juravinski Cancer Centre, McMaster University, - Hamilton, ON L8V 5C2, Canada. -FAU - Ellis, Peter M -AU - Ellis PM -AD - Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, - ON L8V 5C2, Canada. -FAU - Sun, Alexander -AU - Sun A -AD - Princess Margaret Cancer Centre, Radiation Medicine Program, University Health - Network, Toronto, ON M5G 2M9, Canada. -AD - Department of Radiation Oncology, University of Toronto, Toronto, ON M5G 2M9, - Canada. -FAU - Schellenberg, Devin -AU - Schellenberg D -AD - Department of Radiation Oncology, BC Cancer-Surrey Centre, 13750 96 Avenue, - Surrey, BC V3V 1Z2, Canada. -FAU - Ionescu, Diana N -AU - Ionescu DN -AD - Department of Pathology, BC Cancer, Vancouver, BC V5Z 4E6, Canada. -AD - Department of Pathology and Laboratory Medicine, University of British Columbia, - Vancouver, BC V6T 1Z7, Canada. -FAU - Cheema, Parneet K -AU - Cheema PK -AD - Division of Medical Oncology, William Osler Health System, University of Toronto, - Brampton, ON L6R 3J7, Canada. -AD - Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada. -LA - eng -PT - Guideline -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20230630 -PL - Switzerland -TA - Curr Oncol -JT - Current oncology (Toronto, Ont.) -JID - 9502503 -SB - IM -MH - Humans -MH - Canada -MH - Combined Modality Therapy -MH - Consensus -MH - *Lung Neoplasms/drug therapy -MH - *Small Cell Lung Carcinoma/drug therapy -PMC - PMC10378571 -OTO - NOTNLM -OT - PD-1 -OT - PD-L1 -OT - etoposide -OT - extensive stage small-cell lung cancer -OT - immune checkpoint inhibitors -OT - platinum -OT - radiation therapy -COIS- B.L.M. has received honoraria and/or has participated in advisory board meetings - with AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Pfizer, and Roche. - N.B.L. has received honoraria and has participated in advisory board meetings - with Xcovery; has received honoraria or travel expenses (or both) for independent - continuing medical education lectures from AstraZeneca, Bristol Myers Squibb, - Merck Sharp & Dohme, Roche, and Pfizer; and reports institutional research - funding from AstraZeneca, Array, Guardant, Merck Sharp & Dohme, and Roche. D.D. - has received honoraria and/or has participated in advisory board meetings with - Merck Canada, Novartis, Jazz Pharmaceuticals, Pfizer, and AstraZeneca, honoraria - for educational content from Boehringer-Ingelheim, Roche, and Bristol Myers - Squibb and a research grant from AstraZeneca. N.B. has participated in consult - meetings with Amgen, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Eli - Lilly, EMD Serono, Ipsen, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, - Servier, and Takeda; has received research grant support from AstraZeneca for - project CLEAR. P.F.W.-P. reports receiving consulting fees and/or honoraria from - Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, EMD Serono, Guardant, Janssen, - Jazz Pharmaceuticals, Merck, Pfizer, Roche, Sanofi, and Takeda. P.W.-P. served as - a data safety monitoring board member or chair for the POISE and REaCT-HER TIME - trials, respectively, and is a previous President of Lung Cancer Canada - (2016–2021). Q.S.-C.C. has received honoraria and/or has participated in advisory - board meetings with AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, - Bristol Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, and Takeda; has - received educational grant support from AnHeart, Bristol Myers Squibb, Janssen, - and Jazz; has received research funding from AstraZeneca and Exactis; has - received clinical trial research funding from Alkermes, Amgen, Apollomics, - Astellas, AstraZeneca, Boehringer Ingelheim, Bicycle, Bristol Myers Squibb, - Debiopharm, Eli Lilly, Epizyme, GlaxoSmithKline, Ocellaris, Pfizer, Spectrum, - Turning Point Therapeutics, Treadwell, and VelosBio. R.A.J. has participated on - advisory boards for AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, EMD - Serono, Fusion Pharmaceuticals, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme, - Novartis, Pfizer, Roche Canada, Sanofi/Regeneron, and Takeda; has received - honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, - Novartis Pharmaceuticals Canada, and Roche Canada; and has received research - funding from AstraZeneca/MedImmune, Bristol Myers Squibb, Debiopharm Group, Merck - Sharp & Dohme, Novartis and Turnstone Bio. P.M.E. has received honoraria and/or - has participated in advisory board meetings with AstraZeneca, Bristol Myers - Squibb, Janssen, Roche, Lilly, Merck, Sanofi, Jazz, Novartis, Takeda, Pfizer. - A.S. has received honoraria and/or has participated in advisory board meetings - with Astra Zeneca. D.S. has received honoraria and/or has participated in - advisory board meetings with AstraZeneca, Merck and Bristol Myers Squibb. D.N.I. - reports an institutional grant from Roche, honoraria from AstraZeneca, Pfizer, - Bristol Myers Squibb, Roche, Merck, Amgen, Eli Lilly, and Bayer, support for - attending meetings from Pfizer, participation in a stat safety monitoring board - or advisory board from AstraZeneca, Pfizer, Bristol Myers Squibb, Roche, Merck, - Amgen, Eli Lilly, and Bayer, and a leadership/fiduciary role with Lung Cancer - Canada. P.K.C. has received honoraria and/or has participated in advisory board - meetings with Amgen, AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck, - Janssen, Bayer, Novartis, Pfizer, Roche, and Takeda. -EDAT- 2023/07/28 13:11 -MHDA- 2023/07/31 11:42 -PMCR- 2023/06/30 -CRDT- 2023/07/28 08:35 -PHST- 2023/06/09 00:00 [received] -PHST- 2023/06/27 00:00 [revised] -PHST- 2023/06/29 00:00 [accepted] -PHST- 2023/07/31 11:42 [medline] -PHST- 2023/07/28 13:11 [pubmed] -PHST- 2023/07/28 08:35 [entrez] -PHST- 2023/06/30 00:00 [pmc-release] -AID - curroncol30070465 [pii] -AID - curroncol-30-00465 [pii] -AID - 10.3390/curroncol30070465 [doi] -PST - epublish -SO - Curr Oncol. 2023 Jun 30;30(7):6289-6315. doi: 10.3390/curroncol30070465. - -PMID- 28482670 -OWN - NLM -STAT- MEDLINE -DCOM- 20180316 -LR - 20181202 -IS - 2304-3873 (Electronic) -IS - 2304-3865 (Linking) -VI - 6 -IP - 2 -DP - 2017 Apr -TI - Immune checkpoint inhibitors in lung cancer: current status and future - directions. -PG - 17 -LID - 10.21037/cco.2017.02.05 [doi] -AB - Recently, the immune checkpoint inhibitors that target programmed death 1 - (PD-1)/programmed death ligand 1 (PD-L1) have made a breakthrough in treating - advanced non-small cell lung cancer (NSCLC) with the efficacy of approximately - 20%; among which, nivolumab has acquired treatment indications in lung squamous - cell carcinoma. The inhibitors targeting cytotoxic T lymphocyte associated - antigen 4 (CTLA-4) are also undergoing clinical trials. Researches on immune - checkpoint inhibitors have been rapidly implemented in a variety of different - types of lung cancer, such as small cell lung cancer (SCLC) and locally advanced - NSCLC, and these inhibitors began to be applied in combination with some - established treatments, including chemotherapy, targeting therapy and - radiotherapy. Undoubtedly, the immune checkpoint inhibitors have become a hot - spot in the research and treatment of lung cancer. However, many problems wait to - be solved, such as searching for ideal biomarkers, constituting the best criteria - for curative effect evaluation, exploring different combination treatment models, - and clearly understanding the mechanisms of primary or secondary drug resistance. - Along with these problems to be successfully solved, the immune checkpoint - inhibitors will have more broad applications in lung cancer therapy. -FAU - Fan, Yun -AU - Fan Y -AD - Department of Cancer Medicine (Thoracic), Zhejiang Cancer Hospital, Key - Laboratory Diagnosis and Treatment Technology on Thoracic Oncology (Esophagus, - Lung), Hangzhou 310022, China. fanyun@zjcc.org.cn. -FAU - Mao, Weimin -AU - Mao W -AD - Department of Cancer Medicine (Thoracic), Zhejiang Cancer Hospital, Key - Laboratory Diagnosis and Treatment Technology on Thoracic Oncology (Esophagus, - Lung), Hangzhou 310022, China. -LA - eng -PT - Journal Article -PT - Review -PL - China -TA - Chin Clin Oncol -JT - Chinese clinical oncology -JID - 101608375 -RN - 0 (Antineoplastic Agents) -RN - 0 (Programmed Cell Death 1 Ligand 2 Protein) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antineoplastic Agents/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Carcinoma, Squamous Cell/*drug therapy -MH - Humans -MH - Immunotherapy/*methods -MH - Lung Neoplasms/*drug therapy -MH - Programmed Cell Death 1 Ligand 2 Protein -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -MH - Small Cell Lung Carcinoma/*drug therapy -OTO - NOTNLM -OT - Immune checkpoint inhibitors -OT - efficacy -OT - lung cancer -OT - toxicity -EDAT- 2017/05/10 06:00 -MHDA- 2018/03/17 06:00 -CRDT- 2017/05/10 06:00 -PHST- 2016/06/20 00:00 [received] -PHST- 2016/12/28 00:00 [accepted] -PHST- 2017/05/10 06:00 [entrez] -PHST- 2017/05/10 06:00 [pubmed] -PHST- 2018/03/17 06:00 [medline] -AID - 10.21037/cco.2017.02.05 [doi] -PST - ppublish -SO - Chin Clin Oncol. 2017 Apr;6(2):17. doi: 10.21037/cco.2017.02.05. - -PMID- 36421007 -OWN - NLM -STAT- MEDLINE -DCOM- 20221215 -LR - 20230901 -IS - 1531-703X (Electronic) -IS - 1040-8746 (Linking) -VI - 35 -IP - 1 -DP - 2023 Jan 1 -TI - Prophylactic cranial irradiation in small cell lung cancer: an update. -PG - 61-67 -LID - 10.1097/CCO.0000000000000910 [doi] -AB - PURPOSE OF REVIEW: The current review presents recent updates in the seminal - literature of research on prophylactic cranial irradiation (PCI) in small cell - lung cancer (SCLC). RECENT FINDINGS: Brain MRI restaging before the - administration of PCI reveals a substantial proportion of brain metastasis in - baseline brain metastasis free extensive-stage SCLC (ES-SCLC) and limited-stage - SCLC (LS-SCLC). Posthoc analyses from the CASPIAN and IMpower133 trials revealed - decreases in brain metastasis rates in ES-SCLC treated with chemoimmunotherapy - relative to the brain metastasis rates in ES-SCLC treated with chemotherapy - alone. A recent meta-analysis of literature published after the landmark 1999 - Auperin meta-analysis confirmed the survival benefit of PCI in LS-SCLC patients. - A recent study employing PET before and after PCI demonstrated that hippocampal - avoidance -PCI (HA-PCI) preserved the metabolic activity of the hippocampi - compared with regular PCI. Two phase III trials evaluating neurocognitive - functions after HA-PCI versus PCI have yielded conflicting results. Ongoing - clinical trials (MAVERICK, PRIMALung, NRG CC003, NCT04535739, NCT04829708 and - NCT03514849) regarding PCI versus MRI surveillance and HA-PCI versus PCI were - also discussed. SUMMARY: Currently, the indications for PCI in SCLC are under - question in the modern MRI era. Result from prospective phase III, MRI staged and - MRI monitored RCTs are expected to elucidate the role of PCI in LS-SCLC and - ES-SCLC. Preliminary results indicated that adding immunotherapy to chemotherapy - may reduce brain metastasis rate in SCLC. Further data to this aspect are - warranted to determine the role of PCI in the immuno-chemotherapy era. The future - direction for PCI should be the comprehensive integration of personalized patient - selection, HA-PCI utilization and potential employment of other neurocognitive - preservation strategies. -CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. -FAU - Chu, Xiao -AU - Chu X -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center. -AD - Department of Oncology, Shanghai Medical College, Fudan University. -AD - Shanghai Clinical Research Center for Radiation Oncology. -AD - Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. -FAU - Zhu, Zhengfei -AU - Zhu Z -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center. -AD - Department of Oncology, Shanghai Medical College, Fudan University. -AD - Shanghai Clinical Research Center for Radiation Oncology. -AD - Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20221124 -PL - United States -TA - Curr Opin Oncol -JT - Current opinion in oncology -JID - 9007265 -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/drug therapy/radiotherapy -MH - Prospective Studies -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Cranial Irradiation -EDAT- 2022/11/25 06:00 -MHDA- 2022/12/15 06:00 -CRDT- 2022/11/24 08:32 -PHST- 2022/11/25 06:00 [pubmed] -PHST- 2022/12/15 06:00 [medline] -PHST- 2022/11/24 08:32 [entrez] -AID - 00001622-202301000-00010 [pii] -AID - 10.1097/CCO.0000000000000910 [doi] -PST - ppublish -SO - Curr Opin Oncol. 2023 Jan 1;35(1):61-67. doi: 10.1097/CCO.0000000000000910. Epub - 2022 Nov 24. - -PMID- 37690180 -OWN - NLM -STAT- MEDLINE -DCOM- 20231023 -LR - 20231023 -IS - 1532-1967 (Electronic) -IS - 0305-7372 (Linking) -VI - 120 -DP - 2023 Nov -TI - Local control strategies for management of NSCLC with oligoprogressive disease. -PG - 102621 -LID - S0305-7372(23)00114-7 [pii] -LID - 10.1016/j.ctrv.2023.102621 [doi] -AB - Progresses of systemic treatments in advanced non-small cell lung cancer (NSCLC), - such as immune checkpoint blockers (ICB) and targeted therapies, led to the - increased incidence of oligoprogressive disease (OPD). The OPD is a subtype of - oligometastatic disease (OMD) defined as a progression of a limited number of - lesions during systemic treatment exposure. The hypothesis was formulated that - local radical treatments (LRT) could eradicate progressive lesions resulting from - resistant clones, ultimately leading to systemic treatment sensitivity - restoration. Recently published international consensuses and guidelines aim to - obtain a uniform definition of OMD NSCLC, to standardize the inclusion of these - patients in future clinical trials, as well as their management in daily - practice. Although there is no specific definition of OPD, LRT strategies in OPD - are supported after reporting promising results. Both retrospective and - preliminary prospective randomized data of LRT for patients with OPD NSCLC are - encouraging. More clinical and translational data are needed for selecting best - scenarios where LRT should be delivered. In this review, we analyze the current - available literature on LRT for patients with OPD in advanced NSCLC and discuss - about future trial design and challenges. -CI - Copyright © 2023 Elsevier Ltd. All rights reserved. -FAU - Mavrikios, Antoine -AU - Mavrikios A -AD - Department of Radiation Oncology, International Center for Thoracic Cancers - (CICT), Gustave Roussy, F-94805 Villejuif, France. -FAU - Remon, Jordi -AU - Remon J -AD - Department of Cancer Medicine, International Center for Thoracic Cancers (CICT), - Gustave Roussy, F-94805 Villejuif, France. -FAU - Quevrin, Clément -AU - Quevrin C -AD - Université Paris-Saclay, INSERM U1030, Molecular Radiotherapy and Therapeutic - Innovations, F-94805 Villejuif, France. -FAU - Mercier, Olaf -AU - Mercier O -AD - Université Paris-Saclay, Faculté de Médecine, 94270 Le Kremlin-Bicêtre, France; - Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, - International Center for Thoracic Cancers (CICT), Marie-Lannelongue Hospital, Le - Plessis Robinson, France. -FAU - Tselikas, Lambros -AU - Tselikas L -AD - Université Paris-Saclay, Faculté de Médecine, 94270 Le Kremlin-Bicêtre, France; - Department of Anesthesia, Surgery and Interventional Radiology (DACI), - International Center for Thoracic Cancers (CICT), Gustave Roussy, F-94805 - Villejuif, France. -FAU - Botticella, Angela -AU - Botticella A -AD - Department of Radiation Oncology, International Center for Thoracic Cancers - (CICT), Gustave Roussy, F-94805 Villejuif, France. -FAU - Nicolas, Eliot -AU - Nicolas E -AD - Department of Radiation Oncology, International Center for Thoracic Cancers - (CICT), Gustave Roussy, F-94805 Villejuif, France. -FAU - Deutsch, Eric -AU - Deutsch E -AD - Department of Radiation Oncology, International Center for Thoracic Cancers - (CICT), Gustave Roussy, F-94805 Villejuif, France; Université Paris-Saclay, - INSERM U1030, Molecular Radiotherapy and Therapeutic Innovations, F-94805 - Villejuif, France; Université Paris-Saclay, Faculté de Médecine, 94270 Le - Kremlin-Bicêtre, France. -FAU - Besse, Benjamin -AU - Besse B -AD - Department of Cancer Medicine, International Center for Thoracic Cancers (CICT), - Gustave Roussy, F-94805 Villejuif, France; Université Paris-Saclay, Faculté de - Médecine, 94270 Le Kremlin-Bicêtre, France. -FAU - Planchard, David -AU - Planchard D -AD - Department of Cancer Medicine, International Center for Thoracic Cancers (CICT), - Gustave Roussy, F-94805 Villejuif, France; Université Paris-Saclay, Faculté de - Médecine, 94270 Le Kremlin-Bicêtre, France. -FAU - Barlesi, Fabrice -AU - Barlesi F -AD - Department of Cancer Medicine, International Center for Thoracic Cancers (CICT), - Gustave Roussy, F-94805 Villejuif, France; Université Paris-Saclay, Faculté de - Médecine, 94270 Le Kremlin-Bicêtre, France. -FAU - Le Péchoux, Cécile -AU - Le Péchoux C -AD - Department of Radiation Oncology, International Center for Thoracic Cancers - (CICT), Gustave Roussy, F-94805 Villejuif, France. -FAU - Levy, Antonin -AU - Levy A -AD - Department of Radiation Oncology, International Center for Thoracic Cancers - (CICT), Gustave Roussy, F-94805 Villejuif, France; Université Paris-Saclay, - INSERM U1030, Molecular Radiotherapy and Therapeutic Innovations, F-94805 - Villejuif, France; Université Paris-Saclay, Faculté de Médecine, 94270 Le - Kremlin-Bicêtre, France. Electronic address: antonin.levy@gustaveroussy.fr. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230902 -PL - Netherlands -TA - Cancer Treat Rev -JT - Cancer treatment reviews -JID - 7502030 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - *Lung Neoplasms/drug therapy/pathology -MH - Prospective Studies -MH - Retrospective Studies -MH - Disease Progression -MH - *Radiosurgery/methods -OTO - NOTNLM -OT - Ablative treatment -OT - Dissociated response -OT - Lung cancer -OT - Stereotactic radiotherapy -COIS- Declaration of Competing Interest The authors declare the following financial - interests/personal relationships which may be considered as potential competing - interests: E.D. reports grants and personal fees from Roche-Genentech, grants and - personal fees from AstraZeneca, grants and personal fees from Merck Serono, - grants and personal fees from Boehringer, grants and personal fees from BMS, and - grants and personal fees from MSD. B.B. reports sponsored research at Gustave - Roussy Cancer Center by Abbvie, Amgen, AstraZeneca, Chugai Pharmaceutical, - Daiichi-Sankyo, Ellipse Pharma, EISAI, Genmab, Genzyme Corporation, Hedera Dx, - Inivata, IPSEN, Janssen, MSD, Pharmamar, Roche-Genentech, Sanofi, Socar Research, - Tahio Oncology, Turning Point Therapeutics. A.L. reports sponsored research at - Gustave Roussy Cancer Center by Amgen, AstraZeneca, Beigene, Roche. The other - authors declare that they have no conflicts of interest. -EDAT- 2023/09/11 00:42 -MHDA- 2023/10/23 12:43 -CRDT- 2023/09/10 18:01 -PHST- 2023/06/25 00:00 [received] -PHST- 2023/08/28 00:00 [revised] -PHST- 2023/09/01 00:00 [accepted] -PHST- 2023/10/23 12:43 [medline] -PHST- 2023/09/11 00:42 [pubmed] -PHST- 2023/09/10 18:01 [entrez] -AID - S0305-7372(23)00114-7 [pii] -AID - 10.1016/j.ctrv.2023.102621 [doi] -PST - ppublish -SO - Cancer Treat Rev. 2023 Nov;120:102621. doi: 10.1016/j.ctrv.2023.102621. Epub 2023 - Sep 2. - -PMID- 34693454 -OWN - NLM -STAT- MEDLINE -DCOM- 20220316 -LR - 20220316 -IS - 1534-6277 (Electronic) -IS - 1534-6277 (Linking) -VI - 22 -IP - 12 -DP - 2021 Oct 25 -TI - Systemic Therapy for Lung Cancer Brain Metastases. -PG - 110 -LID - 10.1007/s11864-021-00911-7 [doi] -AB - Systemic therapy for brain metastases (BM) is quickly moving from conventional - cytotoxic chemotherapy toward targeted therapies, that allow a disruption of - driver molecular pathways. The discovery of actionable driver mutations has led - to the development of an impressive number of tyrosine kinase inhibitors (TKIs), - that target the epidermal growth factor receptor (EGFR) mutations, - anaplastic-lymphoma-kinase (ALK) rearrangements, and other rare molecular - alterations in patients bearing metastatic non-small cell lung cancer (NSCLC) in - the brain, with remarkable results in terms of intracranial disease control and - overall survival. Moreover, these drugs may delay the use of local therapies, - such as stereotactic radiosurgery (SRS) or whole-brain radiotherapy (WBRT). New - drugs with higher molecular specificity and ability to cross the CNS barriers - (BBB, BTB and blood-CSF) are being developed. Two major issues are related to - targeted therapies. First, the emergence of a resistance is a common event, and a - deeper understanding of molecular pathways that are involved is critical for the - successful development of effective new targeted agents. Second, an early - detection of tumor progression is of utmost importance to avoid the prolongation - of an ineffective therapy while changing to another drug. In order to monitor - over time the treatment to targeted therapies, liquid biopsy, that allows the - detection in biofluids of either circulating tumor cells (CTCs) or circulating - tumor DNA (ctDNA) or exosomes, is increasingly employed in clinical trials: with - respect to BM the monitoring of both blood and CSF is necessary. Also, radiomics - is being developed to predict the mutational status of the BM on MRI.For patients - without druggable mutations or who do not respond to targeted agents, - immunotherapy with checkpoint inhibitors is increasingly employed, alone or in - combination with radiotherapy. Pseudoprogression after immunotherapy alone maybe - a challenge for several months after the start of treatment, and the same is true - for radionecrosis after the combination of immunotherapy and SRS. In this regard, - the value of advanced MRI techniques and PET imaging for a better distinction of - pseudoprogression/radionecrosis and true tumor progression is promising, but - needs validation in large prospective datasets. Last, a new frontier in the near - future will be chemoprevention (primary and secondary), but we need to identify - among solid tumors those subgroups of patients with a higher risk of relapsing - into the brain and novel drugs, active on either neoplastic or normal cells of - the microenvironment, that are cooperating in the invasion of brain tissue. -CI - © 2021. The Author(s), under exclusive licence to Springer Science+Business - Media, LLC, part of Springer Nature. -FAU - Pellerino, Alessia -AU - Pellerino A -AUID- ORCID: 0000-0003-3243-0059 -AD - Department of Neuro-Oncology, University and City of Health and Science Hospital, - via Cherasco 15, 10126, Turin, Italy. alessia.pellerino85@gmail.com. -FAU - Bruno, Francesco -AU - Bruno F -AD - Department of Neuro-Oncology, University and City of Health and Science Hospital, - via Cherasco 15, 10126, Turin, Italy. -FAU - Rudà, Roberta -AU - Rudà R -AD - Department of Neuro-Oncology, University and City of Health and Science Hospital, - via Cherasco 15, 10126, Turin, Italy. -AD - Department of Neurology, Castelfranco Veneto and Treviso Hospital, via Sant' - Ambrogio di Fiera 37, 31100, Treviso, Italy. -FAU - Soffietti, Riccardo -AU - Soffietti R -AD - Department of Neuro-Oncology, University and City of Health and Science Hospital, - via Cherasco 15, 10126, Turin, Italy. -LA - eng -PT - Journal Article -PT - Review -DEP - 20211025 -PL - United States -TA - Curr Treat Options Oncol -JT - Current treatment options in oncology -JID - 100900946 -RN - 0 (Circulating Tumor DNA) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (Anaplastic Lymphoma Kinase) -SB - IM -MH - Anaplastic Lymphoma Kinase/genetics -MH - Blood-Brain Barrier/metabolism -MH - Brain Neoplasms/*drug therapy/genetics/secondary -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/secondary -MH - Chemoradiotherapy -MH - Circulating Tumor DNA/blood/cerebrospinal fluid -MH - Computational Biology -MH - Gene Rearrangement -MH - Genes, erbB-1/genetics -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Lung Neoplasms/*genetics/pathology -MH - Magnetic Resonance Imaging -MH - Molecular Targeted Therapy -MH - Neoplastic Cells, Circulating/metabolism -MH - Protein Kinase Inhibitors/*therapeutic use -OTO - NOTNLM -OT - ALK inhibitors -OT - Brain metastases -OT - EGFR tyrosine kinase inhibitors -OT - Immunotherapy -OT - Radiotherapy -OT - Rare druggable mutations -EDAT- 2021/10/26 06:00 -MHDA- 2022/03/17 06:00 -CRDT- 2021/10/25 06:51 -PHST- 2021/06/07 00:00 [accepted] -PHST- 2021/10/25 06:51 [entrez] -PHST- 2021/10/26 06:00 [pubmed] -PHST- 2022/03/17 06:00 [medline] -AID - 10.1007/s11864-021-00911-7 [pii] -AID - 10.1007/s11864-021-00911-7 [doi] -PST - epublish -SO - Curr Treat Options Oncol. 2021 Oct 25;22(12):110. doi: - 10.1007/s11864-021-00911-7. - -PMID- 27693088 -OWN - NLM -STAT- MEDLINE -DCOM- 20170919 -LR - 20190117 -IS - 1728-7731 (Electronic) -IS - 1726-4901 (Linking) -VI - 80 -IP - 1 -DP - 2017 Jan -TI - Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. -PG - 7-14 -LID - S1726-4901(16)30162-9 [pii] -LID - 10.1016/j.jcma.2016.08.005 [doi] -AB - Immune checkpoint inhibition with blocking antibodies that target cytotoxic - T-lymphocyte antigen-4 (CTLA-4) and the programmed cell death protein 1 (PD-1) - pathway [PD-1/programmed death-ligand 1 (PD-L1)] have demonstrated promise in a - variety of malignancies. While ipilimumab has been approved as a CTLA-4 blocking - antibody by the US Food and Drug Administration for the treatment of advanced - melanoma, it is still not approved for lung cancer treatment. In contrast, - nivolumab and pembrolizumab, both PD-1 blocking antibodies, have been approved - for second-line treatment of nonsmall cell lung cancer in 2015 because of their - high potency and long-lasting effects in some patient subgroups. Other PD-1 and - PD-L1 monoclonal antibodies are also in active development phase. Treatment with - such immune checkpoint inhibitors is associated with a unique pattern of - immune-related adverse events or side effects. Combination approaches involving - CTLA-4 and PD-1/PD-L1 blockade or checkpoint inhibitors with chemotherapy or - radiotherapy are being investigated to determine whether they may enhance the - efficacy of treatment. Despite many challenges ahead, immunotherapy with - checkpoint inhibitors has already become a new and important treatment modality - for lung cancer in the last decade following the discovery of targeted therapy. -CI - Copyright © 2016. Published by Elsevier Taiwan LLC. -FAU - Chen, Yuh-Min -AU - Chen YM -AD - Division of General Chest Medicine, Department of Chest Medicine, Taipei Veterans - General Hospital, Taipei, Taiwan, ROC; School of Medicine, National Yang-Ming - Medical University, Taipei, Taiwan, ROC; School of Medicine, Taipei Medical - University, Taipei, Taiwan, ROC. Electronic address: ymchen@vghtpe.gov.tw. -LA - eng -PT - Journal Article -PT - Review -DEP - 20160929 -PL - Netherlands -TA - J Chin Med Assoc -JT - Journal of the Chinese Medical Association : JCMA -JID - 101174817 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (CTLA-4 Antigen) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 28X28X9OKV (durvalumab) -RN - 31YO63LBSN (Nivolumab) -RN - 52CMI0WC3Y (atezolizumab) -RN - DPT0O3T46P (pembrolizumab) -RN - KXG2PJ551I (avelumab) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - CTLA-4 Antigen/*antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Humans -MH - Lung Neoplasms/*drug therapy -MH - Nivolumab -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -OTO - NOTNLM -OT - adenocarcinoma -OT - checkpoint inhibitor -OT - immunotherapy -OT - lung cancer -OT - lymphocytes -EDAT- 2016/10/04 06:00 -MHDA- 2017/09/20 06:00 -CRDT- 2016/10/04 06:00 -PHST- 2016/02/21 00:00 [received] -PHST- 2016/07/18 00:00 [accepted] -PHST- 2016/10/04 06:00 [pubmed] -PHST- 2017/09/20 06:00 [medline] -PHST- 2016/10/04 06:00 [entrez] -AID - S1726-4901(16)30162-9 [pii] -AID - 10.1016/j.jcma.2016.08.005 [doi] -PST - ppublish -SO - J Chin Med Assoc. 2017 Jan;80(1):7-14. doi: 10.1016/j.jcma.2016.08.005. Epub 2016 - Sep 29. - -PMID- 26703804 -OWN - NLM -STAT- MEDLINE -DCOM- 20160505 -LR - 20220419 -IS - 0065-2598 (Print) -IS - 0065-2598 (Linking) -VI - 890 -DP - 2016 -TI - Personalized Therapy of Small Cell Lung Cancer. -PG - 149-74 -LID - 10.1007/978-3-319-24932-2_9 [doi] -AB - Small cell lung cancer (SCLC) is an aggressive, poorly differentiated - neuroendocrine carcinoma with distinct clinical, pathological and molecular - characteristics. Despite robust responses to initial chemotherapy and radiation, - the prognosis of patients with SCLC remains poor with an overall 5-year survival - rate of less than 10 %. Despite the fact that numerous molecularly targeted - approaches have thus far failed to demonstrate clinical utility in SCLC, further - advances will rely on better definition of the biological pathways that drive - survival, proliferation and metastasis. Recent next-generation, molecular - profiling studies have identified many new therapeutic targets in SCLC, as well - as extreme genomic instability which explains the high degree of resistance. A - wide variety of anti-angiogenic agents, growth factor inhibitors, pro-apoptotic - agents, and epigenetic modulators have been evaluated in SCLC and many studies of - these strategies are on-going. Perhaps the most promising approaches involve - agents targeting cancer stem cell pathways and immunomodulatory drugs that - interfere with the PD1 and CTLA-4 pathways. SCLC offers many barriers to the - development of successful therapy, including limited tumor samples, inadequate - preclinical models, high mutational burden, and aggressive tumor growth which - impairs functional status and hampers enrollment on clinical trials. -FAU - Schneider, Bryan J -AU - Schneider BJ -AD - Division of Hematology/Oncology, University of Michigan, C411 Med Inn-SPC 5848, - 1500 E. Medical Center Dr., Ann Arbor, MI, 48109-5848, USA. bryansch@umich.edu. -FAU - Kalemkerian, Gregory P -AU - Kalemkerian GP -AD - Division of Hematology/Oncology, University of Michigan, C350 Med Inn-SPC 5848, - 1500 E. Medical Center Dr., Ann Arbor, MI, 48109-5848, USA. kalemker@umich.edu. -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - Adv Exp Med Biol -JT - Advances in experimental medicine and biology -JID - 0121103 -RN - 0 (Antineoplastic Agents) -RN - 0 (CTLA-4 Antigen) -RN - 0 (Immunologic Factors) -RN - 0 (Neoplasm Proteins) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antineoplastic Agents/*therapeutic use -MH - CTLA-4 Antigen/antagonists & inhibitors/genetics/immunology -MH - Cell Proliferation/drug effects -MH - Cell Survival/drug effects -MH - Drug Resistance, Neoplasm/genetics -MH - *Gene Expression Regulation, Neoplastic -MH - Genomic Instability -MH - Humans -MH - Immunologic Factors/*therapeutic use -MH - Lung Neoplasms/*drug therapy/genetics/mortality/pathology -MH - Neoplasm Proteins/antagonists & inhibitors/*genetics/immunology -MH - Neoplastic Stem Cells/drug effects/metabolism/pathology -MH - Precision Medicine -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors/genetics/immunology -MH - Small Cell Lung Carcinoma/*drug therapy/genetics/mortality/pathology -MH - Survival Analysis -OTO - NOTNLM -OT - Genetic profiling -OT - Immunotherapy -OT - Lung cancer -OT - Small cell -OT - Targeted therapy -EDAT- 2015/12/26 06:00 -MHDA- 2016/05/06 06:00 -CRDT- 2015/12/26 06:00 -PHST- 2015/12/26 06:00 [entrez] -PHST- 2015/12/26 06:00 [pubmed] -PHST- 2016/05/06 06:00 [medline] -AID - 10.1007/978-3-319-24932-2_9 [doi] -PST - ppublish -SO - Adv Exp Med Biol. 2016;890:149-74. doi: 10.1007/978-3-319-24932-2_9. - -PMID- 38052684 -OWN - NLM -STAT- MEDLINE -DCOM- 20240301 -LR - 20240410 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 25 -IP - 2 -DP - 2024 Mar -TI - Sterotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic - SCLC: The SAMOS Cohort. -PG - 151-158 -LID - S1525-7304(23)00240-1 [pii] -LID - 10.1016/j.cllc.2023.11.005 [doi] -AB - AIMS: SCLC is the most aggressive lung cancer histology with a 5-year OS <10%. At - the diagnosis, almost two-thirds of the SCLC an Extended Disease presentation. - Two randomized studies (CASPIAN and ImPower133) demonstrated an OS improvement, - when immunotherapy was prescribed as maintenance therapy after standard - chemotherapy. To date, SABR has had a limited indication in managing metastatic - SCLC, although recent reports proposed it as a valid treatment option in selected - patients. We propose a retrospective multicentric analysis of patients treated - with SABR for oligometastatic SCLC. METHOD: Data of patients affected by - oligometastatic-SCLC treated with SABR between 2017 and 2022 in 11 Italian - centers were collected. Clinical and therapeutic variables together with OS and - time to next treatment were analyzed. Univariate analysis with Kaplan-Meier curve - were calculated, and log-rank test were applied. Cox proportional hazard model - was used for multivariate analysis. RESULTS: Data from 93 patients and 132 - metastatic lesions were analyzed. The median age was 64 years (36-86) and all but - 1 had Performance Status 0 or 1. Fifty-two patients presented ED at diagnosis. - The first line treatment was radiochemotherapy in 42%, CHT alone in 24% and - CHT-IO in 28%, others treatment accounts for 4% and only 2% of patients underwent - best supportive care. Of the 132 lesions treated with SBRT 55 were in brain, 27 - in lung, 11 in liver, 10 in lymph nodes, 8 in bones and 20 in adrenal gland. - Median OS was 14 months, 1 year-OS and 2 years OS were 53% and 27%, respectively. - The median TtNT was 14 months for the entire population. Of all the analyzed - variables only, the anatomical site of the metastases and their number showed - statistical significance in the univariate analysist, confirmed in the subsequent - multivariate. CONCLUSION: SABR seems to play a role in delaying further systemic - lines in oligometastatic disease and to extend the use of ongoing treatment in - oligoprogressive state. Prospective studies are needed to confirm these findings. -CI - Copyright © 2023 Elsevier Inc. All rights reserved. -FAU - Borghetti, Paolo -AU - Borghetti P -AD - Radiation Oncology Department, ASST Spedali Civili and University of Brescia, - Brescia, Italy. -FAU - Facheris, Giorgio -AU - Facheris G -AD - Radiation Oncology Department, ASST Spedali Civili and University of Brescia, - Brescia, Italy. -FAU - Ciammella, Patrizia -AU - Ciammella P -AD - Radiation Oncology Unit, Azienda-USL IRCCS di Reggio Emilia, Reggio Emilia, - Italy. -FAU - Galaverni, Marco -AU - Galaverni M -AD - Radiation Oncology, University Hospital of Parma, Parma, Italy. -FAU - Granello, Lorenzo -AU - Granello L -AD - Radiation Oncology Department, ASST Spedali Civili and University of Brescia, - Brescia, Italy. Electronic address: l.granello@unibs.it. -FAU - Scotti, Vieri -AU - Scotti V -AD - Radiation Oncology Department, Azienda Ospedaliero-Universitaria Careggi, - Florence, Italy. -FAU - Franceschini, Davide -AU - Franceschini D -AD - Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, - Rozzano, Milan, Italy. -FAU - Romei, Andrea -AU - Romei A -AD - Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", - University of Florence, Florence, Italy. -FAU - Giaj Levra, Niccolò -AU - Giaj Levra N -AD - Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, - Negrar di Valpolicella, Italy. -FAU - Federico, Manuela -AU - Federico M -AD - U.O. Radioterapia Oncologica, Casa di Cura Macchiarella, Palermo, Italy. -FAU - La Vecchia, Maria -AU - La Vecchia M -AD - U.O. Radioterapia Oncologica, Casa di Cura Macchiarella, Palermo, Italy. -FAU - Merlotti, Anna -AU - Merlotti A -AD - Department of Radiation Oncology, S. Croce and Carle Teaching Hospital, Cuneo, - Italy. -FAU - Sepulcri, Matteo -AU - Sepulcri M -AD - Radiotherapy, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. -FAU - Piperno, Gaia -AU - Piperno G -AD - Division of Radiation Oncology, IEO-European Institute of Oncology, IRCCS, Milan, - Italy. -FAU - Marvaso, Giulia -AU - Marvaso G -AD - Division of Radiation Oncology, IEO-European Institute of Oncology, IRCCS, Milan, - Italy. -FAU - Simoni, Nicola -AU - Simoni N -AD - Radiation Oncology, University Hospital of Parma, Parma, Italy. -FAU - Alì, Emanuele -AU - Alì E -AD - Radiation Oncology Unit, Azienda-USL IRCCS di Reggio Emilia, Reggio Emilia, - Italy. -FAU - Pontoriero, Antonio -AU - Pontoriero A -AD - Department of Biomedical, Radiation Oncology Unit, Dental Science and - Morphological and Functional Images, University of Messina, Messina, Italy. -FAU - Cappelli, Anna -AU - Cappelli A -AD - Radiotherapy Unit, University of Modena and Reggio Emilia, Modena, Reggio Emilia, - Italy. -FAU - Dionisi, Valeria -AU - Dionisi V -AD - Department of Radiation Oncology, University of Verona Hospital Trust, Verona, - Italy. -FAU - Menis, Jessica -AU - Menis J -AD - Medical Oncology Department, University and Hospital Trust of Verona, Verona, - Italy. -FAU - Martino, Antonella -AU - Martino A -AD - Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, - Italy. -FAU - Vagge, Stefano -AU - Vagge S -AD - Radiotherapy Department, E.O. Galliera, Genoa, Italy. -FAU - Canova, Stefania -AU - Canova S -AD - Medical Oncology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. -FAU - Montesi, Giampaolo -AU - Montesi G -AD - Radiation Oncology Unit, Santa Maria della Misericordia Hospital, Rovigo, Italy. -FAU - Cuccia, Francesco -AU - Cuccia F -AD - Radiation Oncology - ARNAS Civico Hospital, Palermo, Italy. -FAU - Boldrini, Luca -AU - Boldrini L -AD - Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, - Italy. -FAU - Franzese, Ciro -AU - Franzese C -AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. -FAU - Grisanti, Salvatore -AU - Grisanti S -AD - Department of Medical and Surgical Specialties, Radiological Sciences, and Public - Health, University of Brescia, ASST Spedali Civili, Medical Oncology Unit, - Brescia, Italy. -FAU - Bruni, Alessio -AU - Bruni A -AD - Department of Oncology and Ematology, Radiotherapy Unit, University Hospital of - Modena, Modena, Italy. -FAU - Scorsetti, Marta -AU - Scorsetti M -AD - Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, - Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, - Milan, Italy. -LA - eng -PT - Journal Article -DEP - 20231117 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -SB - IM -MH - Humans -MH - Middle Aged -MH - *Lung Neoplasms/radiotherapy/drug therapy -MH - Retrospective Studies -MH - *Radiosurgery/adverse effects -MH - Kaplan-Meier Estimate -MH - Proportional Hazards Models -OTO - NOTNLM -OT - Oligoprogressive -OT - SABR -OT - Small cell lung cancer -EDAT- 2023/12/06 03:43 -MHDA- 2024/03/01 06:44 -CRDT- 2023/12/05 21:59 -PHST- 2023/09/01 00:00 [received] -PHST- 2023/11/09 00:00 [revised] -PHST- 2023/11/09 00:00 [accepted] -PHST- 2024/03/01 06:44 [medline] -PHST- 2023/12/06 03:43 [pubmed] -PHST- 2023/12/05 21:59 [entrez] -AID - S1525-7304(23)00240-1 [pii] -AID - 10.1016/j.cllc.2023.11.005 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2024 Mar;25(2):151-158. doi: 10.1016/j.cllc.2023.11.005. Epub - 2023 Nov 17. - -PMID- 38175464 -OWN - NLM -STAT- MEDLINE -DCOM- 20240214 -LR - 20240529 -IS - 1534-6269 (Electronic) -IS - 1523-3790 (Linking) -VI - 26 -IP - 1 -DP - 2024 Jan -TI - Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted - and Immunotherapies. -PG - 80-89 -LID - 10.1007/s11912-023-01490-6 [doi] -AB - PURPOSE OF REVIEW: This review discusses the definitions, treatment modalities, - management, future directions, and ongoing clinical trials of oligoprogressive - disease in oncogene-driven and non-oncogene-driven NSCLC. RECENT FINDINGS: During - the last decades, diagnostic and treatment modalities for oligometastatic NSCLC - have advanced significantly, leading to improved survival. Additionally, our - understanding of the tumor biology of oligoprogressive disease has expanded. - However, despite the efforts of organizations, such as EORTC, ESTRO, and ASTRO - proposing definitions for oligometastatic and oligoprogressive disease, - heterogeneity in definitions persists in (ongoing) trials. Recognizing the - significance of subclassification within oligoprogressive disease in NSCLC and - the varying risks associated with subsequent metastatic spread, there is a call - for tailored management strategies. A consensus on standardized criteria for the - definition of oligoprogressive disease is urgently needed and will not only - facilitate meaningful comparisons between studies but also pave the way for the - development of personalized treatment plans that take into account the - heterogeneous nature of oligoprogressive disease. -CI - © 2024. The Author(s), under exclusive licence to Springer Science+Business - Media, LLC, part of Springer Nature. -FAU - Jongbloed, Mandy -AU - Jongbloed M -AD - Department of Pulmonary Diseases, GROW School for Oncology and Reproduction, - Maastricht University Medical Center, Maastricht, the Netherlands. -FAU - Khosla, Atulya A -AU - Khosla AA -AUID- ORCID: 0000-0002-8373-4290 -AD - Division of Internal Medicine, William Beaumont University Hospital, Royal Oak, - MI, USA. -FAU - Bartolomeo, Valentina -AU - Bartolomeo V -AD - Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. -AD - Department of Clinical Surgical, Diagnostic and Pediatric Sciences, Pavia - University, Pavia, Italy. -AD - Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical - Center, GROW School for Oncology and Reproduction (GROW), Maastricht, - Netherlands. -FAU - Jatwani, Karan -AU - Jatwani K -AD - Division of Hematology-Oncology, Roswell Park Cancer Center, Buffalo, NY, USA. -FAU - Singh, Rohit -AU - Singh R -AD - Division of Hematology-Oncology, University of Vermont, Burlington, VT, USA. -FAU - De Ruysscher, Dirk K M -AU - De Ruysscher DKM -AD - Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical - Center, GROW School for Oncology and Reproduction (GROW), Maastricht, - Netherlands. -FAU - Hendriks, Lizza E L -AU - Hendriks LEL -AD - Department of Pulmonary Diseases, GROW School for Oncology and Reproduction, - Maastricht University Medical Center, Maastricht, the Netherlands. -FAU - Desai, Aakash -AU - Desai A -AUID- ORCID: 0000-0002-2943-3817 -AD - Division of Hematology and Oncology, Department of Medicine, University of - Alabama at Birmingham, 1824 6th Ave S, Birmingham, AL, 35233, USA. - aakashdesai@uabmc.edu. -LA - eng -PT - Journal Article -PT - Review -DEP - 20240102 -PL - United States -TA - Curr Oncol Rep -JT - Current oncology reports -JID - 100888967 -SB - IM -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Disease Progression -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Radiosurgery -MH - Immunotherapy -OTO - NOTNLM -OT - Definition -OT - Local radical therapy -OT - NSCLC -OT - Oligometastatic disease -OT - Oligoprogressive disease -OT - Treatment strategies -EDAT- 2024/01/04 12:42 -MHDA- 2024/02/10 22:55 -CRDT- 2024/01/04 11:24 -PHST- 2023/12/11 00:00 [accepted] -PHST- 2024/02/10 22:55 [medline] -PHST- 2024/01/04 12:42 [pubmed] -PHST- 2024/01/04 11:24 [entrez] -AID - 10.1007/s11912-023-01490-6 [pii] -AID - 10.1007/s11912-023-01490-6 [doi] -PST - ppublish -SO - Curr Oncol Rep. 2024 Jan;26(1):80-89. doi: 10.1007/s11912-023-01490-6. Epub 2024 - Jan 2. - -PMID- 36289059 -OWN - NLM -STAT- MEDLINE -DCOM- 20230126 -LR - 20230304 -IS - 2573-8348 (Electronic) -IS - 2573-8348 (Linking) -VI - 6 -IP - 1 -DP - 2023 Jan -TI - Effectiveness of immunological agents in non-small cell lung cancer. -PG - e1739 -LID - 10.1002/cnr2.1739 [doi] -LID - e1739 -AB - BACKGROUND AND AIM: Non-small cell lung cancer (NSCLC) continues to claim - millions of lives worldwide. Although its poor prognosis is largely attributed to - the lack of adequate and precise detection technologies, cancer cells' - suppression of the immune system adds on to the difficulty of identifying - abnormal NSCLC tumors in their early stages. Therefore, cancer immunotherapy, - which activates the immune system and helps it fight tumors, has recently become - the most sought-after technique, especially in the advanced stages of NSCLC, - where surgery or chemotherapy may or may not bring about the desired survival - benefits in patients. METHODS: This review focuses on the various - immunotherapeutic interventions and their efficacy in advanced NSCLC clinical - trials. Monoclonal antibodies like anti-PD-1/PD-L1 agents and anti-CTLA-4 - antibodies, cancer vaccines, oncolytic viruses and adoptive T cell therapy have - been discussed in brief. Furthermore, the effects of gender, age, and race on the - efficacy of immune checkpoint inhibitors and suggest plausible future approaches - in the realm of immuno-oncology. RESULTS: Immunotherapy is used alone or in - combination either with other immunological agents or with chemotherapy. However, - the efficacy of these strategies depends extensively on various demographic - variables, as some patients respond perfectly well to immunotherapy, while others - do not benefit at all or experience disease progression. By targeting a - "hallmark" of cancer (immune evasion), immunotherapy has transformed NSCLC - management, though several barriers prevent its complete effectiveness. - CONCLUSIONS: All these immunological strategies should be interpreted in the - current setting of synergistic treatment, in which these agents can be combined - with chemotherapy, radiotherapy, and, or surgery following patient and tumor - characteristics to proportionate the best-individualized treatment and achieve - superior results. To better pursue this goal, further investigations on - cost-effectiveness and sex-gender, race, and age differences in immunotherapy are - needed. -CI - © 2022 The Authors. Cancer Reports published by Wiley Periodicals LLC. -FAU - Rekulapelli, Akhil -AU - Rekulapelli A -AD - Department of Public Health Sciences, University of Virginia School of Medicine, - Charlottesville, Virginia, USA. -FAU - E Flausino, Lucas -AU - E Flausino L -AD - Department of Public Health Sciences, University of Virginia School of Medicine, - Charlottesville, Virginia, USA. -AD - Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. -FAU - Iyer, Gayatri -AU - Iyer G -AD - Department of Pharmaceutical Sciences and Technology, Institute of Chemical - Technology, Mumbai, India. -FAU - Balkrishnan, Rajesh -AU - Balkrishnan R -AUID- ORCID: 0000-0001-9363-9257 -AD - Department of Public Health Sciences, University of Virginia School of Medicine, - Charlottesville, Virginia, USA. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20221026 -PL - United States -TA - Cancer Rep (Hoboken) -JT - Cancer reports (Hoboken, N.J.) -JID - 101747728 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Immunologic Factors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Antibodies, Monoclonal/therapeutic use -MH - Immunotherapy/methods -MH - Immunologic Factors -PMC - PMC9981233 -OTO - NOTNLM -OT - NSCLC -OT - adoptive T cell therapy -OT - cancer -OT - cancer vaccines -OT - immunotherapy -OT - monoclonal antibodies -OT - oncolytic viruses -COIS- No funding has been obtained for this review. Dr. Balkrishnan is currently a - consultant for Ostuka Pharmaceuticals Inc. None of the other authors have any - pertinent conflict of interests. -EDAT- 2022/10/27 06:00 -MHDA- 2023/01/27 06:00 -PMCR- 2022/10/26 -CRDT- 2022/10/26 22:54 -PHST- 2022/08/28 00:00 [revised] -PHST- 2021/11/01 00:00 [received] -PHST- 2022/10/08 00:00 [accepted] -PHST- 2022/10/27 06:00 [pubmed] -PHST- 2023/01/27 06:00 [medline] -PHST- 2022/10/26 22:54 [entrez] -PHST- 2022/10/26 00:00 [pmc-release] -AID - CNR21739 [pii] -AID - 10.1002/cnr2.1739 [doi] -PST - ppublish -SO - Cancer Rep (Hoboken). 2023 Jan;6(1):e1739. doi: 10.1002/cnr2.1739. Epub 2022 Oct - 26. - -PMID- 32986224 -OWN - NLM -STAT- MEDLINE -DCOM- 20210726 -LR - 20210726 -IS - 1179-1950 (Electronic) -IS - 0012-6667 (Linking) -VI - 80 -IP - 17 -DP - 2020 Nov -TI - First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: - State of the Art and Future Directions. -PG - 1783-1797 -LID - 10.1007/s40265-020-01409-6 [doi] -AB - The advent of PD-(L)1 and CTLA-4 immune check point inhibitors (CPIs) has - dramatically changed the treatment landscape of advanced non-small-cell lung - cancer (NSCLC). For up to a quarter of patients with advanced NSCLC, CPIs have - the potential to induce durable responses with long-term survival outcomes. Since - the approval of first-line pembrolizumab for patients whose tumors express a - PD-L1 ≥ 50%, several pivotal first-line CPI-based phase 3 studies have been - conducted investigating combination treatments combining CPIs with chemotherapy - (ChT) or combining different CPIs with or without ChT. As a result, there has - been an increase in front-line treatment options for advanced NSCLC, and - treatment algorithms are changing very quickly. In fit patients with advanced - NSCLC, combination treatments including CPI and ChT are considered the new - standard of care with improved clinical outcomes. CPI combination treatments are - well tolerated and quality of life also seems to be better when CPIs are - implemented in the first-line setting. The aim of this review is to provide a - summary of the recently published first-line phase 3 studies investigating CPIs - as monotherapy or in combination with other CPIs or ChT in advanced NSCLC, and to - suggest possible treatment algorithms. -FAU - Ackermann, Christoph Jakob -AU - Ackermann CJ -AD - Department of Medical Oncology, Spital STS AG, Thun, Switzerland. -FAU - Adderley, Helen -AU - Adderley H -AD - Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, - Manchester, UK. -FAU - Ortega-Franco, Ana -AU - Ortega-Franco A -AD - Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, - Manchester, UK. -FAU - Khan, Adeel -AU - Khan A -AD - Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, - Manchester, UK. -FAU - Reck, Martin -AU - Reck M -AD - Department of Thoracic Oncology, Airway Research Center North (ARCN), German - Center for Lung Research, LungenClinic Grosshansdorf, Grosshansdorf, Germany. -FAU - Califano, Raffaele -AU - Califano R -AD - Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, - Manchester, UK. raffaele.califano@christie.nhs.uk. -AD - Department of Medical Oncology, Manchester University NHS Foundation Trust, - Manchester, UK. raffaele.califano@christie.nhs.uk. -AD - Division of Cancer Sciences, University of Manchester, Manchester, UK. - raffaele.califano@christie.nhs.uk. -LA - eng -PT - Journal Article -PT - Review -PL - New Zealand -TA - Drugs -JT - Drugs -JID - 7600076 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (CTLA-4 Antigen) -RN - 0 (CTLA4 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Ipilimumab) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 04Q9AIZ7NO (Pemetrexed) -RN - 31YO63LBSN (Nivolumab) -RN - 52CMI0WC3Y (atezolizumab) -RN - BG3F62OND5 (Carboplatin) -RN - DPT0O3T46P (pembrolizumab) -RN - P88XT4IS4D (Paclitaxel) -RN - QEN1X95CIX (tremelimumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors/metabolism -MH - CTLA-4 Antigen/antagonists & inhibitors/metabolism -MH - Carboplatin/pharmacology/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/mortality -MH - Clinical Trials, Phase III as Topic -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology/*therapeutic use -MH - Ipilimumab/pharmacology/therapeutic use -MH - Lung/immunology/pathology -MH - Lung Neoplasms/*drug therapy/immunology/mortality -MH - Neoplasm Recurrence, Local/*drug therapy/immunology/mortality -MH - Nivolumab/pharmacology/therapeutic use -MH - Paclitaxel/pharmacology/therapeutic use -MH - Pemetrexed/pharmacology/therapeutic use -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors/metabolism -MH - Progression-Free Survival -MH - Quality of Life -MH - Review Literature as Topic -EDAT- 2020/09/29 06:00 -MHDA- 2021/07/27 06:00 -CRDT- 2020/09/28 12:58 -PHST- 2020/09/29 06:00 [pubmed] -PHST- 2021/07/27 06:00 [medline] -PHST- 2020/09/28 12:58 [entrez] -AID - 10.1007/s40265-020-01409-6 [pii] -AID - 10.1007/s40265-020-01409-6 [doi] -PST - ppublish -SO - Drugs. 2020 Nov;80(17):1783-1797. doi: 10.1007/s40265-020-01409-6. - -PMID- 37221584 -OWN - NLM -STAT- MEDLINE -DCOM- 20230525 -LR - 20240918 -IS - 1478-811X (Electronic) -IS - 1478-811X (Linking) -VI - 21 -IP - 1 -DP - 2023 May 23 -TI - Radiation combined with immune checkpoint inhibitors for unresectable locally - advanced non-small cell lung cancer: synergistic mechanisms, current state, - challenges, and orientations. -PG - 119 -LID - 10.1186/s12964-023-01139-8 [doi] -LID - 119 -AB - Until the advent of immune checkpoint inhibitors (ICIs), definitive radiotherapy - (RT) concurrently with chemotherapy was recommended for unresectable, locally - advanced non-small cell lung cancer (LA-NSCLC). The trimodality paradigm with - consolidation ICIs following definitive concurrent chemoradiotherapy has been the - standard of care since the PACIFIC trial. Preclinical evidence has demonstrated - the role of RT in the cancer-immune cycle and the synergistic effect of RT - combined with ICIs (iRT). However, RT exerts a double-edged effect on immunity - and the combination strategy still could be optimized in many areas. In the - context of LA-NSCLC, optimized RT modality, choice, timing, and duration of ICIs, - care for oncogenic addicted tumors, patient selection, and novel combination - strategies require further investigation. Targeting these blind spots, novel - approaches are being investigated to cross the borders of PACIFIC. We discussed - the development history of iRT and summarized the updated rationale for the - synergistic effect. We then summarized the available research data on the - efficacy and toxicity of iRT in LA-NSCLC for cross-trial comparisons to eliminate - barriers. Progression during and after ICIs consolidation therapy has been - regarded as a distinct resistance scenario from primary or secondary resistance - to ICIs, the subsequent management of which has also been discussed. Finally, - based on unmet needs, we probed into the challenges, strategies, and auspicious - orientations to optimize iRT in LA-NSCLC. In this review, we focus on the - underlying mechanisms and recent advances of iRT with an emphasis on future - challenges and directions that warrant further investigation. Taken together, iRT - is a proven and potential strategy in LA-NSCLC, with multiple promising - approaches to further improve the efficacy. Video Abstract. -CI - © 2023. The Author(s). -FAU - Wu, Leilei -AU - Wu L -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University - School of Medicine, Shanghai, China. -AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of - Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, - China. -FAU - Zhang, Zhenshan -AU - Zhang Z -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan - University Cancer Hospital, Shanghai, China. -FAU - Bai, Menglin -AU - Bai M -AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of - Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, - China. -FAU - Yan, Yujie -AU - Yan Y -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University - School of Medicine, Shanghai, China. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of - Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, - China. sdyujinming@163.com. -FAU - Xu, Yaping -AU - Xu Y -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University - School of Medicine, Shanghai, China. xuyaping1207@126.com. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PT - Video-Audio Media -DEP - 20230523 -PL - England -TA - Cell Commun Signal -JT - Cell communication and signaling : CCS -JID - 101170464 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung -MH - Immune Checkpoint Inhibitors -MH - *Lung Neoplasms -PMC - PMC10207766 -OTO - NOTNLM -OT - Advances -OT - Biomarkers -OT - Challenges -OT - Immune checkpoint inhibitors (ICIs) -OT - Locally advanced non-small cell lung cancer (LA-NSCLC) -OT - RT combined with ICIs (iRT) -OT - Radiotherapy -COIS- All authors have no conflicts of interest to declare. The figures were created - with the help of BioRender.com. -EDAT- 2023/05/24 01:06 -MHDA- 2023/05/25 06:42 -PMCR- 2023/05/23 -CRDT- 2023/05/24 00:00 -PHST- 2023/01/21 00:00 [received] -PHST- 2023/04/22 00:00 [accepted] -PHST- 2023/05/25 06:42 [medline] -PHST- 2023/05/24 01:06 [pubmed] -PHST- 2023/05/24 00:00 [entrez] -PHST- 2023/05/23 00:00 [pmc-release] -AID - 10.1186/s12964-023-01139-8 [pii] -AID - 1139 [pii] -AID - 10.1186/s12964-023-01139-8 [doi] -PST - epublish -SO - Cell Commun Signal. 2023 May 23;21(1):119. doi: 10.1186/s12964-023-01139-8. - -PMID- 35226309 -OWN - NLM -STAT- MEDLINE -DCOM- 20220429 -LR - 20220629 -IS - 1534-6277 (Electronic) -IS - 1534-6277 (Linking) -VI - 23 -IP - 2 -DP - 2022 Feb -TI - Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future - Perspective. -PG - 268-294 -LID - 10.1007/s11864-022-00949-1 [doi] -AB - Despite advancements in clinical research, both prognosis and treatment for SCLC - patients are still in the nascent stage. SCLC is a fatal disease with high tumor - mutational burden and is strongly associated with exposure to tobacco. This leads - to the development of potential neo-antigens, inhibition of immune responses, and - development of paraneoplastic disorders. Surgery, radiation, and chemotherapy are - widely accepted treatments for cancer globally, and most recently, immunotherapy - has now become the "fourth pillar" of SCLC treatment. Various immune checkpoint - pathways regulate the activation of T cells at multiple stages during an immune - response. T cell checkpoint inhibitors such as anti-PD1 (pembrolizumab, - nivolumab), anti-PDL1, and anti-CTLA-4 (tremelimumab, ipilimumab) have potential - to show anti-cancer activity along with the promise to prolong survival in - patients with SCLC. Treatment with the CTLA-4-specific antibodies can restore the - immune response by increasing the accumulation and survival of T-cells whereas - monoclonal antibodies block either PD-1 or its ligands that prevent - downregulation of effector T-cell, which enables the T-cells to mediate the death - of tumor cells. Furthermore, monoclonal antibody in combination with chemotherapy - has attained quite a focus to enhance the survival of SCLC patients. Apart from - this, various immunotherapeutic approaches have been evaluated in the clinical - trials for SCLC patients such as TLR9 agonist, anti-CD47, anti-ganglioside - therapy, and anti-Notch signaling. The current review focuses on the rationale as - well as on the clinical studies of immunotherapy in SCLC along with the clinical - end results of certain immunotherapeutic agents and novel therapeutic - combinations in SCLC patients. -CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business - Media, LLC, part of Springer Nature. -FAU - Walia, Harleen Kaur -AU - Walia HK -AD - Department of Biotechnology, Thapar Institute of Engineering & Technology, - Patiala, Punjab, 147004, India. -FAU - Sharma, Parul -AU - Sharma P -AD - Department of Biotechnology, Thapar Institute of Engineering & Technology, - Patiala, Punjab, 147004, India. -FAU - Singh, Navneet -AU - Singh N -AD - Department of Pulmonary Medicine, Post-Graduate Institute of Medical Education & - Research, Chandigarh, 160012, India. -FAU - Sharma, Siddharth -AU - Sharma S -AUID- ORCID: 0000-0001-9414-3771 -AD - Department of Biotechnology, Thapar Institute of Engineering & Technology, - Patiala, Punjab, 147004, India. siddharthsharma.phd@thapar.edu. -LA - eng -PT - Journal Article -PT - Review -DEP - 20220228 -PL - United States -TA - Curr Treat Options Oncol -JT - Current treatment options in oncology -JID - 100900946 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (CTLA-4 Antigen) -RN - 0 (Immunologic Factors) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - CTLA-4 Antigen -MH - Humans -MH - Immunologic Factors/therapeutic use -MH - Immunotherapy/methods -MH - *Lung Neoplasms/drug therapy/therapy -MH - Nivolumab/therapeutic use -MH - *Small Cell Lung Carcinoma/drug therapy/therapy -OTO - NOTNLM -OT - CTLA-4 -OT - Check-point Inhibitors -OT - Immunotherapy -OT - Lung cancer -OT - PD-1 -OT - SCLC -EDAT- 2022/03/01 06:00 -MHDA- 2022/04/30 06:00 -CRDT- 2022/02/28 12:17 -PHST- 2022/01/03 00:00 [accepted] -PHST- 2022/03/01 06:00 [pubmed] -PHST- 2022/04/30 06:00 [medline] -PHST- 2022/02/28 12:17 [entrez] -AID - 10.1007/s11864-022-00949-1 [pii] -AID - 10.1007/s11864-022-00949-1 [doi] -PST - ppublish -SO - Curr Treat Options Oncol. 2022 Feb;23(2):268-294. doi: - 10.1007/s11864-022-00949-1. Epub 2022 Feb 28. - -PMID- 36880420 -OWN - NLM -STAT- MEDLINE -DCOM- 20230607 -LR - 20240919 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 12 -IP - 10 -DP - 2023 May -TI - Advances in immune checkpoint inhibitors therapy for small cell lung cancer. -PG - 11097-11106 -LID - 10.1002/cam4.5659 [doi] -AB - BACKGROUND: As one of the most aggressive neuroendocrine tumors, small cell lung - cancer (SCLC) has the most disappointing prognosis of all lung cancers. Although - SCLC responds well to initial chemotherapy, the majority of patients experience - disease recurrence within one year, and patient survival is poor. It is still - necessary to explore the application of ICIs in SCLC since the beginning of the - road to immunotherapy, which broke the 30-year treatment deadlock of SCLC. - METHODS: We searched PubMed, Web of Science, and Embase with search terms such as - "SCLC", "ES-SCLC", "ICIs", and "ICBs", and categorized and summarized the - relevant literature obtained, and we compiled the latest progress about the - application of ICIs in SCLC. RESULTS: We listed 14 clinical trials on ICIs, - including 8 clinical trials on first-line SCLC treatment, 2 clinical trials on - second-line SCLC treatment, 3 clinical trials on third-line SCLC treatment, and 1 - clinical trial on SCLC maintenance treatment. CONCLUSION: ICIs in combination - with chemotherapy can improve OS in SCLC patients, but the extent to which SCLC - patients can benefit from ICIs is limited, and ICIs' combination treatment - strategies still need to be continuously explored. -CI - © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Li, Longhui -AU - Li L -AUID- ORCID: 0000-0001-8403-8484 -AD - Department of Oncology, First Teaching Hospital of Tianjin University of - Traditional Chinese Medicine, Tianjin, China. -AD - National Clinical Research Center for Chinese Medicine Acupuncture and - Moxibustion, Tianjin, China. -FAU - Liang, Yangyueying -AU - Liang Y -AD - Department of Oncology, First Teaching Hospital of Tianjin University of - Traditional Chinese Medicine, Tianjin, China. -AD - National Clinical Research Center for Chinese Medicine Acupuncture and - Moxibustion, Tianjin, China. -FAU - Yu, Minghui -AU - Yu M -AD - Department of Oncology, First Teaching Hospital of Tianjin University of - Traditional Chinese Medicine, Tianjin, China. -AD - National Clinical Research Center for Chinese Medicine Acupuncture and - Moxibustion, Tianjin, China. -FAU - Zhao, Lu -AU - Zhao L -AD - Department of Oncology, First Teaching Hospital of Tianjin University of - Traditional Chinese Medicine, Tianjin, China. -AD - National Clinical Research Center for Chinese Medicine Acupuncture and - Moxibustion, Tianjin, China. -FAU - Mei, Qingyun -AU - Mei Q -AD - Department of Oncology, First Teaching Hospital of Tianjin University of - Traditional Chinese Medicine, Tianjin, China. -AD - National Clinical Research Center for Chinese Medicine Acupuncture and - Moxibustion, Tianjin, China. -FAU - Yu, Yongchao -AU - Yu Y -AD - Department of Oncology, First Teaching Hospital of Tianjin University of - Traditional Chinese Medicine, Tianjin, China. -AD - National Clinical Research Center for Chinese Medicine Acupuncture and - Moxibustion, Tianjin, China. -FAU - Wang, Na -AU - Wang N -AUID- ORCID: 0000-0001-6230-0234 -AD - Department of Oncology, First Teaching Hospital of Tianjin University of - Traditional Chinese Medicine, Tianjin, China. -AD - National Clinical Research Center for Chinese Medicine Acupuncture and - Moxibustion, Tianjin, China. -FAU - Zhang, Dou -AU - Zhang D -AD - Department of Oncology, First Teaching Hospital of Tianjin University of - Traditional Chinese Medicine, Tianjin, China. -AD - National Clinical Research Center for Chinese Medicine Acupuncture and - Moxibustion, Tianjin, China. -FAU - Wang, Ziwei -AU - Wang Z -AD - Department of Oncology, First Teaching Hospital of Tianjin University of - Traditional Chinese Medicine, Tianjin, China. -AD - National Clinical Research Center for Chinese Medicine Acupuncture and - Moxibustion, Tianjin, China. -FAU - Jia, Yingjie -AU - Jia Y -AD - Department of Oncology, First Teaching Hospital of Tianjin University of - Traditional Chinese Medicine, Tianjin, China. -AD - National Clinical Research Center for Chinese Medicine Acupuncture and - Moxibustion, Tianjin, China. -FAU - Kong, Fanming -AU - Kong F -AD - Department of Oncology, First Teaching Hospital of Tianjin University of - Traditional Chinese Medicine, Tianjin, China. -AD - National Clinical Research Center for Chinese Medicine Acupuncture and - Moxibustion, Tianjin, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20230307 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/pathology -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Neoplasm Recurrence, Local/drug therapy -MH - *Lung Neoplasms/pathology -MH - Radioimmunotherapy -MH - Immunotherapy -PMC - PMC10242320 -OTO - NOTNLM -OT - SCLC -OT - clinical trials -OT - immune checkpoint inhibitors -OT - tumor microenvironment -COIS- This article contains no conflicts of interest. -EDAT- 2023/03/08 06:00 -MHDA- 2023/06/07 06:42 -PMCR- 2023/03/07 -CRDT- 2023/03/07 05:23 -PHST- 2023/01/09 00:00 [revised] -PHST- 2022/10/07 00:00 [received] -PHST- 2023/01/17 00:00 [accepted] -PHST- 2023/06/07 06:42 [medline] -PHST- 2023/03/08 06:00 [pubmed] -PHST- 2023/03/07 05:23 [entrez] -PHST- 2023/03/07 00:00 [pmc-release] -AID - CAM45659 [pii] -AID - 10.1002/cam4.5659 [doi] -PST - ppublish -SO - Cancer Med. 2023 May;12(10):11097-11106. doi: 10.1002/cam4.5659. Epub 2023 Mar 7. - -PMID- 35790251 -OWN - NLM -STAT- MEDLINE -DCOM- 20220706 -LR - 20220706 -IS - 1791-7530 (Electronic) -IS - 0250-7005 (Linking) -VI - 42 -IP - 7 -DP - 2022 Jul -TI - Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential - Molecular Targets. -PG - 3275-3284 -LID - 10.21873/anticanres.15816 [doi] -AB - From radiation therapy and surgery to chemotherapy and targeted therapy, the - treatment of non-small cell lung cancer (NSCLC) has remarkably evolved over the - past few decades. In recent years, immunotherapy has become an increasingly - attractive area of interest in the treatment of NSCLC, especially those in - advanced stages. Cytokine and immune checkpoint inhibitors are among the most - studied immunotherapies for many cancer types. Herein, we provide an overview of - current popular cytokine and checkpoint inhibitor treatment regimens available - for patients with NSCLC. Ongoing clinic trials and novel molecular targets that - are discussed here could lead to promising new treatment options for NSCLC. The - evidence summarized in this review might be helpful for clinicians to better - manage patients with NSCLC. -CI - Copyright © 2022 International Institute of Anticancer Research (Dr. George J. - Delinasios), All rights reserved. -FAU - Sham, Nelson Ow -AU - Sham NO -AD - Department of Microbiology, Immunology & Pathology, Des Moines University, Des - Moines, IA, U.S.A. -FAU - Zhao, Lei -AU - Zhao L -AD - Department of Respiratory Medicine, the 2 People's Hospital of Hefei and Hefei - Hospital Affiliated to Anhui Medical University, Hefei, PR. China. -FAU - Zhu, Ziwen -AU - Zhu Z -AD - Department of Surgery, University of Missouri School of Medicine, Columbia, MO, - U.S.A. -FAU - Roy, Tanner M -AU - Roy TM -AD - Department of Surgery, University of Missouri School of Medicine, Columbia, MO, - U.S.A. -FAU - Xiao, Huaping -AU - Xiao H -AD - Department of Surgery, University of Missouri School of Medicine, Columbia, MO, - U.S.A. -FAU - Bai, Qian -AU - Bai Q -AD - Department of Surgery, University of Missouri School of Medicine, Columbia, MO, - U.S.A. -FAU - Wakefield, Mark R -AU - Wakefield MR -AD - Department of Surgery, University of Missouri School of Medicine, Columbia, MO, - U.S.A. -FAU - Fang, Yujiang -AU - Fang Y -AD - Department of Surgery, University of Missouri School of Medicine, Columbia, MO, - U.S.A. yujiang.fang@dmu.edu. -AD - Department of Microbiology, Immunology & Pathology, Des Moines University, Des - Moines, IA, U.S.A. -LA - eng -PT - Journal Article -PT - Review -PL - Greece -TA - Anticancer Res -JT - Anticancer research -JID - 8102988 -RN - 0 (Cytokines) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Cytokines/therapeutic use -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -OTO - NOTNLM -OT - Immune checkpoint inhibitor combined therapies -OT - Immunotherapy -OT - checkpoint inhibitors -OT - cytokine immunotherapy -OT - non-small cell lung cancer -OT - review -EDAT- 2022/07/06 06:00 -MHDA- 2022/07/07 06:00 -CRDT- 2022/07/05 20:41 -PHST- 2022/05/25 00:00 [received] -PHST- 2022/06/17 00:00 [revised] -PHST- 2022/06/18 00:00 [accepted] -PHST- 2022/07/05 20:41 [entrez] -PHST- 2022/07/06 06:00 [pubmed] -PHST- 2022/07/07 06:00 [medline] -AID - 42/7/3275 [pii] -AID - 10.21873/anticanres.15816 [doi] -PST - ppublish -SO - Anticancer Res. 2022 Jul;42(7):3275-3284. doi: 10.21873/anticanres.15816. - -PMID- 32667262 -OWN - NLM -STAT- MEDLINE -DCOM- 20210414 -LR - 20210414 -IS - 1744-8328 (Electronic) -IS - 1473-7140 (Linking) -VI - 20 -IP - 8 -DP - 2020 Aug -TI - The changing landscape of stage III lung cancer: a literature review. -PG - 675-686 -LID - 10.1080/14737140.2020.1796645 [doi] -AB - INTRODUCTION: The treatment of stage III non-small cell lung cancer (NSCLC) - remains challenging and associated with overall poor outcomes. Since seminal - studies in the early 90s introduced concurrent chemo-radiotherapy as standard of - care for treatment of this disease, no major advances have been introduced in - this landscape. Both radiation dose escalation and neoadjuvant/adjuvant - chemotherapy strategies were unsuccessful to improve the survival over standard - of care radiation dose and chemotherapy schedule: five-year overall survival (OS) - ranging from 15-20%. However, in 2017 the PACIFIC Trial demonstrated that the - addition of consolidative immune checkpoint inhibitor durvalumab for 1 year led - to superior progression-free survival (PFS) and 3-year overall survival with no - significant increase in toxicity compared to placebo in patients who achieved - disease control with concurrent chemo-RT. AREAS COVERED: This article reviews the - treatment evolution of stage III NSCLC over the past decades, discusses current - standard of care strategies, and highlights potential future directions for the - management of this condition. EXPERT OPINION: Ongoing trials incorporating - upfront checkpoint inhibitors with radiotherapy will answer whether adding - checkpoint inhibitors to chemotherapy or substituting them for chemotherapy - altogether will improve long-term outcome. -FAU - Patel, Monaliben -AU - Patel M -AD - University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, - Case Western Reserve University , Cleveland, OH, USA. -FAU - Bruno, Debora -AU - Bruno D -AD - University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, - Case Western Reserve University , Cleveland, OH, USA. -FAU - Grubb, William -AU - Grubb W -AD - University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, - Case Western Reserve University , Cleveland, OH, USA. -FAU - Biswas, Tithi -AU - Biswas T -AD - University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, - Case Western Reserve University , Cleveland, OH, USA. -LA - eng -PT - Journal Article -PT - Review -DEP - 20200801 -PL - England -TA - Expert Rev Anticancer Ther -JT - Expert review of anticancer therapy -JID - 101123358 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Animals -MH - Antibodies, Monoclonal/administration & dosage/pharmacology -MH - Carcinoma, Non-Small-Cell Lung/pathology/*therapy -MH - Combined Modality Therapy -MH - Humans -MH - Immune Checkpoint Inhibitors/*administration & dosage/pharmacology -MH - Lung Neoplasms/pathology/*therapy -MH - Neoplasm Staging -MH - Progression-Free Survival -MH - Survival Rate -OTO - NOTNLM -OT - Lung cancer -OT - durvalumab -OT - lung cancer review -OT - non-small cell lung cancer -OT - stage III lung cancer -EDAT- 2020/07/16 06:00 -MHDA- 2021/04/15 06:00 -CRDT- 2020/07/16 06:00 -PHST- 2020/07/16 06:00 [pubmed] -PHST- 2021/04/15 06:00 [medline] -PHST- 2020/07/16 06:00 [entrez] -AID - 10.1080/14737140.2020.1796645 [doi] -PST - ppublish -SO - Expert Rev Anticancer Ther. 2020 Aug;20(8):675-686. doi: - 10.1080/14737140.2020.1796645. Epub 2020 Aug 1. - -PMID- 38900703 -OWN - NLM -STAT- MEDLINE -DCOM- 20240917 -LR - 20241007 -IS - 1557-9034 (Electronic) -IS - 1092-6429 (Linking) -VI - 34 -IP - 9 -DP - 2024 Sep -TI - Molecular Markers, Immune Therapy, and Non-Small Cell Lung - Cancer-State-of-the-Art Review for Surgeons. -PG - 786-797 -LID - 10.1089/lap.2024.0164 [doi] -AB - Background: Lung cancer is a leading cause of cancer deaths in the United States. - An increasing understanding of relevant non-small cell lung cancer (NSCLC) - biomarkers has led to the recent development of molecular-targeted therapies and - immune checkpoint inhibitors that have revolutionized treatment for patients with - advanced and metastatic disease. The purpose of this review is to provide - surgeons with a state-of-the-art understanding of the current medical and - surgical treatment trends and their implications in the future of management of - NSCLC. Materials and Methods: A systematic search of PubMed was conducted to - identify English language articles published between January 2010 and March 2024 - focusing on molecular markers, tumor targeting, and immunotherapy in the - diagnosis and treatment of NSCLC. Case series, observational studies, randomized - trials, guidelines, narrative reviews, systematic reviews, and meta-analyses were - included. Results: There is now increasing data to suggest that - molecular-targeted therapies and immune therapies have a role in the neoadjuvant - setting. Advances in intraoperative imaging allow surgeons to perform - increasingly parenchymal-sparing lung resections without compromising tumor - margins. Liquid biopsies can noninvasively detect targetable mutations in cancer - cells and DNA from a blood draw, potentially allowing for earlier diagnosis, - personalized therapy, and long-term monitoring for disease recurrence. - Conclusions: The management of NSCLC has advanced dramatically in recent years - fueled by a growing understanding of the cancer biology of NSCLC. Advances in - medical therapies, surgical techniques, and diagnostic and surveillance - modalities continue to evolve but have already impacted current treatment - strategies for NSCLC, which are encompassed in this review. -FAU - Young, Robert W C -AU - Young RWC -AUID- ORCID: 0000-0001-7190-8292 -AD - Department of Surgery, George Washington University Hospital, Washington, - District of Columbia, USA. -FAU - Rodriguez, Gustavo R -AU - Rodriguez GR -AUID- ORCID: 0009-0003-9452-439X -AD - Department of Surgery, George Washington University Hospital, Washington, - District of Columbia, USA. -FAU - Kucera, John -AU - Kucera J -AD - Department of Surgery, Walter Reed National Military Medical Center, Bethesda, - Maryland, USA. -FAU - Carrera, Daniel -AU - Carrera D -AD - Department of Surgery, George Washington University Hospital, Washington, - District of Columbia, USA. -FAU - Antevil, Jared L -AU - Antevil JL -AD - Department of Surgery, George Washington University Hospital, Washington, - District of Columbia, USA. -AD - Division of Cardiothoracic Surgery and Heart Center, Washington DC Veterans - Affairs Medical Center, Washington, District of Columbia, USA. -FAU - Trachiotis, Gregory D -AU - Trachiotis GD -AD - Department of Surgery, George Washington University Hospital, Washington, - District of Columbia, USA. -AD - Division of Cardiothoracic Surgery and Heart Center, Washington DC Veterans - Affairs Medical Center, Washington, District of Columbia, USA. -LA - eng -PT - Journal Article -PT - Review -DEP - 20240620 -PL - United States -TA - J Laparoendosc Adv Surg Tech A -JT - Journal of laparoendoscopic & advanced surgical techniques. Part A -JID - 9706293 -RN - 0 (Biomarkers, Tumor) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Biomarkers, Tumor/blood -MH - *Carcinoma, Non-Small-Cell Lung/blood/drug therapy/immunology/surgery -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - *Immunotherapy/methods -MH - *Lung Neoplasms/blood/drug therapy/immunology/surgery -MH - Molecular Targeted Therapy/methods -MH - Neoadjuvant Therapy/methods -OTO - NOTNLM -OT - biomarkers -OT - immunotherapy -OT - liquid biopsy -OT - molecular markers -OT - non-small cell lung cancer (NSCLC) -OT - tumor targeting -EDAT- 2024/06/20 18:43 -MHDA- 2024/09/17 23:44 -CRDT- 2024/06/20 13:13 -PHST- 2024/09/17 23:44 [medline] -PHST- 2024/06/20 18:43 [pubmed] -PHST- 2024/06/20 13:13 [entrez] -AID - 10.1089/lap.2024.0164 [doi] -PST - ppublish -SO - J Laparoendosc Adv Surg Tech A. 2024 Sep;34(9):786-797. doi: - 10.1089/lap.2024.0164. Epub 2024 Jun 20. - -PMID- 30869543 -OWN - NLM -STAT- MEDLINE -DCOM- 20200625 -LR - 20200625 -IS - 1747-6356 (Electronic) -IS - 1747-6348 (Linking) -VI - 13 -IP - 5 -DP - 2019 May -TI - The role of immune checkpoint inhibitors in advanced non-small cell lung cancer. -PG - 435-447 -LID - 10.1080/17476348.2019.1593828 [doi] -AB - Cancer immunotherapy represents a major therapeutic breakthrough. Immune - checkpoint inhibitors alone or in the context of a combination are considered the - new standard of care in advanced non-small cell lung cancer (NSCLC). Areas - covered: This review explains the biologic rationale behind the implementation of - immune checkpoint inhibitors for the therapy of advanced NSCLC. It provides a - detailed description of the clinical trials that have studied the various agents - now in use and the results that lead to the currently approved indications. It - also explores the area of established and developing biomarkers, and the trends - of combining immunotherapy with other treatment modalities (chemotherapy, - antiangiogenic agents, radiotherapy), or with other immune modulators. Expert - opinion: Immune checkpoint inhibitors have been established as the new standard - of care for patients with advanced NSCLC. They can be administered according to - PD-L1 expression upfront as monotherapy or in combination with chemotherapy- - regardless of PD-L1 status - or in the later lines of therapy. They also - represent a less toxic and more effective treatment choice than chemotherapy - alone. The development of reliable biomarkers for patient selection and the - subsequent use of the appropriate immune-based approach for each patient will - define the role of immunotherapy in the years to come. -FAU - Pistamaltzian, Nikolaos F -AU - Pistamaltzian NF -AD - a Department of Medical Oncology , MITERA Hospital , Athens , Greece. -FAU - Georgoulias, Vassilis -AU - Georgoulias V -AD - b School of Medicine , University of Crete , Heraklion, Crete , Greece. -FAU - Kotsakis, Athanasios -AU - Kotsakis A -AD - c Department of Medical Oncology , University Hospital of Larissa , Larissa , - Greece. -LA - eng -PT - Journal Article -PT - Review -DEP - 20190322 -PL - England -TA - Expert Rev Respir Med -JT - Expert review of respiratory medicine -JID - 101278196 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -RN - 0 (CD274 protein, human) -RN - 31YO63LBSN (Nivolumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - B7-H1 Antigen/analysis/genetics -MH - Biomarkers, Tumor/analysis -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/metabolism/*therapy -MH - Clinical Trials as Topic -MH - Gene Expression Regulation, Neoplastic -MH - Humans -MH - *Immunotherapy -MH - Lung Neoplasms/drug therapy/metabolism -MH - Nivolumab/therapeutic use -MH - Treatment Outcome -OTO - NOTNLM -OT - Immune checkpoint inhibitors -OT - advanced NSCLC -OT - nivolumab -OT - pembrolizumab -EDAT- 2019/03/15 06:00 -MHDA- 2020/06/26 06:00 -CRDT- 2019/03/15 06:00 -PHST- 2019/03/15 06:00 [pubmed] -PHST- 2020/06/26 06:00 [medline] -PHST- 2019/03/15 06:00 [entrez] -AID - 10.1080/17476348.2019.1593828 [doi] -PST - ppublish -SO - Expert Rev Respir Med. 2019 May;13(5):435-447. doi: - 10.1080/17476348.2019.1593828. Epub 2019 Mar 22. - -PMID- 32916308 -OWN - NLM -STAT- MEDLINE -DCOM- 20210201 -LR - 20231027 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Print) -IS - 1556-0864 (Linking) -VI - 15 -IP - 12 -DP - 2020 Dec -TI - Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for - Limited-Stage SCLC. -PG - 1919-1927 -LID - S1556-0864(20)30713-9 [pii] -LID - 10.1016/j.jtho.2020.08.022 [doi] -AB - INTRODUCTION: Few advancements in treating limited-stage SCLC (LS-SCLC) have been - made in decades. We report here a phase 1/2 trial of concurrent chemoradiotherapy - (CRT) and pembrolizumab. METHODS: This single-center, open-label phase 1/2 study - recruited adults with LS-SCLC or other neuroendocrine tumors and good performance - status (Eastern Cooperative Oncology Group ≤ 2). The primary end point was - safety, as assessed by dose-limiting toxicities. Concurrent CRT consisted of - etoposide and a platin with 45 Gy radiotherapy (30 twice daily). Prophylactic - cranial irradiation (25 Gy, 10 fractions) was given at the physician's - discretion. Pembrolizumab was started concurrently with CRT and continued for up - to 16 cycles. The phase 1 portion consisted of a 3 + 3 design. Toxicity was - assessed with Common Terminology Criteria for Adverse Events version 4.0. - Secondary outcomes were progression-free survival, overall survival, and tumor - response as measured by the immune-related response criteria. RESULTS: A total of - 45 patients were screened, and 40 were enrolled. All completed radiation therapy - and received greater than or equal to one cycle of pembrolizumab. A total of 27 - (61%) received percutaneous coronary intervention. One dose-limiting toxicity was - observed in the phase 1 portion. There were no grade 5 toxicities, but there were - three grade 4 events (two neutropenia, one respiratory failure). Pneumonitis rate - was 15% (three grade 2 and three grade 3). All 17 esophagitis events (42.5%) were - grades 1 to 2. At median follow-up time of 23.1 months, the median - progression-free survival time was 19.7 months (95% confidence interval: - 8.8‒30.5) and the median overall survival time was 39.5 months (95% confidence - interval: 8.0‒71.0). CONCLUSION: Concurrent CRT and pembrolizumab for LS-SCLC was - well tolerated and yielded favorable outcomes, providing a basis for randomized - studies. -CI - Copyright © 2020 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Welsh, James W -AU - Welsh JW -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. Electronic address: jwelsh@mdanderson.org. -FAU - Heymach, John V -AU - Heymach JV -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Guo, Chunxiao -AU - Guo C -AD - Department of Interventional Radiology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Menon, Hari -AU - Menon H -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Klein, Katherine -AU - Klein K -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Cushman, Taylor R -AU - Cushman TR -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Verma, Vivek -AU - Verma V -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Hess, Kenneth R -AU - Hess KR -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, Texas. -FAU - Shroff, Girish -AU - Shroff G -AD - Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Tang, Chad -AU - Tang C -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Skoulidis, Ferdinandos -AU - Skoulidis F -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Jeter, Melenda -AU - Jeter M -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Comeaux, Nathan -AU - Comeaux N -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Patel, Roshal R -AU - Patel RR -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Chen, Dawei -AU - Chen D -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Ozgen, Tugce -AU - Ozgen T -AD - Department of Radiation Oncology, Ankara University School of Medicine, Ankara, - Turkey. -FAU - Nguyen, Quynh-Nhu -AU - Nguyen QN -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Chang, Joe Y -AU - Chang JY -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Altan, Mehmet -AU - Altan M -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Zhang, Jianjun -AU - Zhang J -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Papadimitrakopoulou, Vassiliki A -AU - Papadimitrakopoulou VA -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Simon, George R -AU - Simon GR -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Byers, Lauren A -AU - Byers LA -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Glisson, Bonnie -AU - Glisson B -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -LA - eng -GR - P30 CA016672/CA/NCI NIH HHS/United States -PT - Clinical Trial, Phase I -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20200908 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - DPT0O3T46P (pembrolizumab) -RN - Q20Q21Q62J (Cisplatin) -SB - IM -CIN - J Thorac Oncol. 2020 Dec;15(12):1806-1808. doi: 10.1016/j.jtho.2020.09.021. PMID: - 33246593 -MH - Adult -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Chemoradiotherapy -MH - Cisplatin/therapeutic use -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - *Small Cell Lung Carcinoma/drug therapy -PMC - PMC10600713 -MID - NIHMS1932491 -OTO - NOTNLM -OT - Immunotherapy -OT - PD-1 -OT - PD-L1 -OT - Radiation therapy -OT - SCLC -COIS- Disclosure: Dr. Welsh contributed as a founder, one of the board of directors, - and a holder of patents, royalties of other IP, and stock or ownership of - MolecularMatch; has stock or ownership with Alpine Immune Sciences, Checkmate - Pharmaceuticals, Mavu Pharma, Legion Healthcare Partners, Nanorobotix, - OncoResponse, Inc., and Reflexion; received travel cost from Nanobiotix S.A., - Reflexion, Aileron Therapeutics, Inc., Ventana, and Varian; contributed as a - consultant or advisory role with Merck, Alpine Immune Sciences, AstraZeneca - Pharmaceuticals, Checkmate Pharmaceuticals, Mavu Pharma, Legion Healthcare - Partners, Nanorobotix, OncoResponse, Inc., GI Innovation, MolecularMatch, - Reflexion, Aileron Therapeutics, Inc., and Ventana; received research funding - from Nanobiotix S.A., Checkmate Pharmaceuticals, and Mavu Pharma; and has a - clinical trial-sponsored research from Bristol-Myers Squibb, Varian, and Merck. - Drs. Heymach, Klein, and Cushman report receiving grants and other fees from - AstraZeneca, GlaxoSmithKline, and Spectrum; and other fees from Boehringer - Ingelheim, Bristol-Myers Squibb, Merck, Catalyst, EMD Serono, Foundation - Medicine, Hengrui Therapeutics, Genentech/Roche, Guardant Health, Eli Lilly, - Novartis, Pfizer, Sanofi, Seattle Genetics, and Takeda outside the submitted - work. Dr. Skoulidis reports receiving personal fees from Bristol-Myers Squibb - outside the submitted work. Dr. Chang reports receiving grants from Bristol-Myers - Squibb-MDACC; personal fees from AstraZeneca, Legion, and Varian; and other fees - from Global Oncology One outside the submitted work. Dr. Altan reports receiving - grants from Genentech, Nektar Therapeutics, Merck, Novartis, Jounce Therapeutics, - Bristol-Myers Squibb, Eli Lilly, Adaptimmune, and GlaxoSmithKline; and personal - fees from GlaxoSmithKline and Shattuck Laboratory outside the submitted work. Dr. - Zhang reports receiving grants from Merck and Johnson and Johnson; and personal - fees from Bristol-Myers Squibb, AstraZeneca, GenePlus, and Innovent outside the - submitted work. Dr. Papadimitrakopoulou reports receiving honoraria from F. - Hoffman-La Roche; receiving research funding and contributed as a scientific - advisor for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novartis, Merck, F. - Hoffman-La Roche, Nektar Therapeutics, and Janssen; contributed as a scientific - advisor for AbbVie, Araxes, Arrys Therapeutics, Bolt Therapeutics, Clovis - Oncology, Exelixis, G2 Innovation, Gritstone, Ideaya, Leeds Biolabs, Loxo - Oncology, Takeda, Tesaro, and TRM Oncology; has a research funding from Checkmate - and Incyte; and has employment in Pfizer, Inc. Dr. Byers contributed as an - advisor/consultant for PharmaMar, AbbVie, Bristol-Myers Squibb, Alethia, Merck, - Pfizer, and Jazz Pharmaceuticals; and has received a research funding in oncology - from AstraZeneca (GenMab), Sierra Oncology, and Tolero Pharmaceuticals. Dr. - Glisson reports receiving research funding to her institution for clinical - research from Pfizer, Inc., Medimmune, ISA Pharmaceuticals, and CUE-BIO. The - remaining authors declare no conflict of interest. -EDAT- 2020/09/12 06:00 -MHDA- 2021/02/02 06:00 -PMCR- 2023/10/26 -CRDT- 2020/09/11 20:12 -PHST- 2020/06/18 00:00 [received] -PHST- 2020/08/18 00:00 [revised] -PHST- 2020/08/23 00:00 [accepted] -PHST- 2020/09/12 06:00 [pubmed] -PHST- 2021/02/02 06:00 [medline] -PHST- 2020/09/11 20:12 [entrez] -PHST- 2023/10/26 00:00 [pmc-release] -AID - S1556-0864(20)30713-9 [pii] -AID - 10.1016/j.jtho.2020.08.022 [doi] -PST - ppublish -SO - J Thorac Oncol. 2020 Dec;15(12):1919-1927. doi: 10.1016/j.jtho.2020.08.022. Epub - 2020 Sep 8. - -PMID- 38318930 -OWN - NLM -STAT- MEDLINE -DCOM- 20240207 -LR - 20240311 -IS - 2095-3941 (Print) -IS - 2095-3941 (Linking) -VI - 20 -IP - 12 -DP - 2024 Feb 5 -TI - Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new - regimen for locally advanced non-small cell lung cancer? -PG - 1035-46 -LID - j.issn.2095-3941.2023.0402 [pii] -LID - 10.20892/j.issn.2095-3941.2023.0402 [doi] -AB - Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard - therapeutic approach in patients with unresectable locally advanced non-small - cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy - in stage IV NSCLC has incited interest in similar approaches for LA-NSCLC. - Several recent investigations involving the synergistic potential of - immunotherapy combined with radiotherapy (iRT) have generated encouraging - results. This review discusses the existing studies and prospective directions of - chemotherapy-free iRT strategies in unresectable LA-NSCLC. Although the initial - findings of chemotherapy-free iRT strategies have shown promising efficacy, we - must consider the methodologic limitations of current studies and the myriad of - challenges that accompany the implementation of chemotherapy-free iRT. These - challenges include determining the optimal dose and fractionation, precise target - volume delineation, and identification of additional suitable patient cohorts. - Furthermore, the feasibility of chemotherapy-free iRT as a novel treatment - modality for select patients with LA-NSCLC is contingent upon validation through - randomized phase III trials. -CI - Copyright © 2023 Cancer Biology & Medicine. -FAU - Ma, Lin -AU - Ma L -AD - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430000, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan - 250117, China. -FAU - Deng, Liufu -AU - Deng L -AD - School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China. -FAU - Peng, Jianfeng -AU - Peng J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan - 250117, China. -FAU - Yu, Jinming -AU - Yu J -AUID- ORCID: 0000-0001-5933-9912 -AD - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430000, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan - 250117, China. -FAU - Meng, Xiangjiao -AU - Meng X -AUID- ORCID: 0000-0001-7380-5510 -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan - 250117, China. -LA - eng -GR - 81972796/National Natural Science Foundation of China/ -GR - 82272845/National Natural Science Foundation of China/ -GR - 81972863/National Natural Science Foundation of China/ -GR - 82030082/National Natural Science Foundation of China/ -GR - 2021SFGC0501/Key Research and Development Program of Shandong (Major Science - & Technology Innovation Project/ -GR - Y-HS202102-0089/CSCO-Haosen Foundation/ -GR - Y-XD202001-0008/CSCO-Xinda Foundation/ -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - China -TA - Cancer Biol Med -JT - Cancer biology & medicine -JID - 101588850 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use -MH - Prospective Studies -MH - Chemoradiotherapy/methods -PMC - PMC10845940 -OTO - NOTNLM -OT - Locally advanced non-small cell lung cancer (LA-NSCLC) -OT - challenges -OT - immunotherapy -OT - new regimen -OT - radiotherapy -COIS- No potential conflicts of interest are disclosed. -EDAT- 2024/02/06 13:19 -MHDA- 2024/02/07 06:41 -PMCR- 2023/12/15 -CRDT- 2024/02/06 08:21 -PHST- 2024/02/07 06:41 [medline] -PHST- 2024/02/06 13:19 [pubmed] -PHST- 2024/02/06 08:21 [entrez] -PHST- 2023/12/15 00:00 [pmc-release] -AID - j.issn.2095-3941.2023.0402 [pii] -AID - 10.20892/j.issn.2095-3941.2023.0402 [doi] -PST - ppublish -SO - Cancer Biol Med. 2024 Feb 5;20(12):1035-46. doi: - 10.20892/j.issn.2095-3941.2023.0402. - -PMID- 31099642 -OWN - NLM -STAT- MEDLINE -DCOM- 20191113 -LR - 20191113 -IS - 1548-8756 (Electronic) -IS - 1548-8748 (Linking) -VI - 39 -DP - 2019 Jan -TI - Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the - EGFR-Mutated/ALK-Rearranged Populations. -PG - e187-e197 -LID - 10.1200/EDBK_237821 [doi] -AB - Personalized therapy based on actionable molecular markers has completely - transformed the therapeutic landscape in advanced non-small cell lung cancer - (NSCLC). In less than 15 years, multiple molecular targets, led by EGFR and - anaplastic lymphoma kinase (ALK), have been identified, and myriad oral tyrosine - kinase inhibitors (TKIs) are now available to target these oncogenic drivers, - with the expectation that the majority of patients will respond to treatment and - that progression-free survival (PFS) will exceed 10 to 30 months, far better than - we observed historically with chemotherapy alone. As a result, prognosis has - improved dramatically in this subset of patients. Osimertinib has largely - displaced first- and second-generation EGFR TKIs, including gefitinib, erlotinib, - and afatinib, in the management of EGFR-mutated NSCLC. PFS now exceeds 18 months, - and central nervous system penetrance is enhanced. Dacomitinib has the - distinction of being the first EGFR TKI to demonstrate a survival advantage - compared with older TKIs. Recent data suggest therapeutic additivity, if not - synergy, for the concurrent use of chemotherapy, as well as monoclonal antibodies - targeting angiogenesis, with EGFR TKIs. Alectinib and brigatinib, very specific - ALK inhibitors, have proven superior to the erstwhile standard crizotinib in - treatment-naive ALK+ NSCLC; PFS now routinely exceeds 2 to 3 years. In addition, - these newer agents have far superior central nervous system penetration. As a - result, many patients with ALK+ advanced NSCLC with brain metastases, even some - who are symptomatic, can defer or indefinitely avoid brain irradiation. - Mechanisms of resistance in ALK are complicated, with multiple new agents being - developed in this arena. Although many patients with molecular targets can - reasonably expect to live 5 years or more, the emergence of molecular resistance - is virtually inevitable. In this regard, systemic platinum-based chemotherapy is - the final common therapeutic pathway for virtually all patients with oncogenic - drivers. Standard regimens include pemetrexed and carboplatin, as well as the - E4599 regimen, combination solvent-based paclitaxel, carboplatin, and - bevacizumab. Checkpoint inhibitors, as single agents, have not yielded much - benefit, even in those with high levels of PD-L1 expression. However, in a - subanalysis of patients with ALK and EGFR mutations enrolled in IMpower150, the - addition of atezolizumab to the E4599 regimen led to a major overall survival - benefit (hazard ratio < 0.40). In the absence of systemic chemotherapy, combining - checkpoint inhibitors with TKIs in this setting remains investigational; several - studies have demonstrated untoward pulmonary and hepatic toxicity. -FAU - Singhi, Eric K -AU - Singhi EK -AD - 1 Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, - Nashville, TN. -FAU - Horn, Leora -AU - Horn L -AD - 1 Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, - Nashville, TN. -FAU - Sequist, Lecia V -AU - Sequist LV -AD - 2 Massachusetts General Hospital, Boston, MA. -FAU - Heymach, John -AU - Heymach J -AD - 3 MD Anderson Cancer Center, Houston, TX. -FAU - Langer, Corey J -AU - Langer CJ -AD - 4 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. -LA - eng -PT - Journal Article -PT - Review -DEP - 20190517 -PL - United States -TA - Am Soc Clin Oncol Educ Book -JT - American Society of Clinical Oncology educational book. American Society of - Clinical Oncology. Annual Meeting -JID - 101233985 -RN - 0 (Antineoplastic Agents) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (ALK protein, human) -RN - EC 2.7.10.1 (Anaplastic Lymphoma Kinase) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Anaplastic Lymphoma Kinase/*genetics -MH - Antineoplastic Agents/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/*genetics/mortality/*pathology -MH - ErbB Receptors/genetics -MH - *Gene Rearrangement -MH - Genetic Association Studies -MH - Genetic Predisposition to Disease -MH - Humans -MH - Lung Neoplasms/drug therapy/*genetics/mortality/*pathology -MH - Molecular Targeted Therapy -MH - *Mutation -MH - Protein Kinase Inhibitors/therapeutic use -MH - Retreatment -EDAT- 2019/05/18 06:00 -MHDA- 2019/11/14 06:00 -CRDT- 2019/05/18 06:00 -PHST- 2019/05/18 06:00 [entrez] -PHST- 2019/05/18 06:00 [pubmed] -PHST- 2019/11/14 06:00 [medline] -AID - 10.1200/EDBK_237821 [doi] -PST - ppublish -SO - Am Soc Clin Oncol Educ Book. 2019 Jan;39:e187-e197. doi: 10.1200/EDBK_237821. - Epub 2019 May 17. - -PMID- 33608812 -OWN - NLM -STAT- MEDLINE -DCOM- 20210921 -LR - 20210921 -IS - 1976-3786 (Electronic) -IS - 0253-6269 (Linking) -VI - 44 -IP - 2 -DP - 2021 Feb -TI - Mechanisms of resistance to chemotherapy in non-small cell lung cancer. -PG - 146-164 -LID - 10.1007/s12272-021-01312-y [doi] -AB - Non-small cell lung cancer (NSCLC), which represents 80-85% of lung cancer cases, - is one of the leading causes of human death worldwide. The majority of patients - undergo an intensive and invasive treatment regimen, which may include - radiotherapy, chemotherapy, targeted therapy, immunotherapy, or a combination of - these, depending on disease stage and performance status. Despite advances in - therapeutic regimens, the 5-year survival of NSCLC is approximately 20-30%, - largely due to diagnosis at advanced stages. Conventional chemotherapy is still - the standard treatment option for patients with NSCLC, especially those with - advanced disease. However, the emergence of resistance to chemotherapeutic agents - (chemoresistance) poses a significant obstacle to the management of patients with - NSCLC. Therefore, to develop efficacious chemotherapeutic approaches for NSCLC, - it is necessary to understand the mechanisms underlying chemoresistance. Several - mechanisms are known to mediate chemoresistance. These include altered cellular - targets for chemotherapy, decreased cellular drug concentrations, blockade of - chemotherapy-induced cell cycle arrest and apoptosis, acquisition of - epithelial-mesenchymal transition and cancer stem cell-like phenotypes, - deregulated expression of microRNAs, epigenetic modulation, and the interaction - with tumor microenvironments. In this review, we summarize the mechanisms - underlying chemoresistance and tumor recurrence in NSCLC and discuss potential - strategies to avoid or overcome chemoresistance. -FAU - Min, Hye-Young -AU - Min HY -AD - Creative Research Initiative Center for Concurrent Control of Emphysema and Lung - Cancer, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, - Seoul, 08826, Republic of Korea. -AD - College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul - National University, Seoul, 08826, Republic of Korea. -FAU - Lee, Ho-Young -AU - Lee HY -AD - Creative Research Initiative Center for Concurrent Control of Emphysema and Lung - Cancer, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, - Seoul, 08826, Republic of Korea. hylee135@snu.ac.kr. -AD - College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul - National University, Seoul, 08826, Republic of Korea. hylee135@snu.ac.kr. -LA - eng -GR - NRF-2016R1A3B1908631/National Research Foundation of Korea/ -PT - Journal Article -PT - Review -DEP - 20210219 -PL - Korea (South) -TA - Arch Pharm Res -JT - Archives of pharmacal research -JID - 8000036 -RN - 0 (Antineoplastic Agents) -SB - IM -MH - Animals -MH - Antineoplastic Agents/chemistry/pharmacology/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/metabolism -MH - DNA Repair/drug effects/physiology -MH - Drug Resistance, Neoplasm/*drug effects/physiology -MH - Epithelial-Mesenchymal Transition/drug effects/physiology -MH - Humans -MH - Lung Neoplasms/*drug therapy/genetics/metabolism -MH - Neoplasm Recurrence, Local/drug therapy/genetics/metabolism -MH - Tumor Microenvironment/drug effects/physiology -OTO - NOTNLM -OT - Cancer -OT - Chemoresistance -OT - Chemotherapy -OT - Non-small cell lung cancer -OT - Resistance -EDAT- 2021/02/21 06:00 -MHDA- 2021/09/22 06:00 -CRDT- 2021/02/20 05:37 -PHST- 2020/10/15 00:00 [received] -PHST- 2021/01/16 00:00 [accepted] -PHST- 2021/02/21 06:00 [pubmed] -PHST- 2021/09/22 06:00 [medline] -PHST- 2021/02/20 05:37 [entrez] -AID - 10.1007/s12272-021-01312-y [pii] -AID - 10.1007/s12272-021-01312-y [doi] -PST - ppublish -SO - Arch Pharm Res. 2021 Feb;44(2):146-164. doi: 10.1007/s12272-021-01312-y. Epub - 2021 Feb 19. - -PMID- 38360117 -OWN - NLM -STAT- MEDLINE -DCOM- 20240626 -LR - 20240627 -IS - 1879-355X (Electronic) -IS - 0360-3016 (Linking) -VI - 119 -IP - 4 -DP - 2024 Jul 15 -TI - Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in - Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review - and Meta-Analysis. -PG - 1179-1207 -LID - S0360-3016(24)00298-0 [pii] -LID - 10.1016/j.ijrobp.2024.01.217 [doi] -AB - PURPOSE: Chemoradiotherapy (CRT) combined with immune checkpoint inhibitors - (ICIs) is the standard of care for patients with unresectable and locally - advanced non-small cell lung cancer. This study aimed to determine whether the - addition of ICIs to CRT is associated with an increased risk of pneumonitis. - METHODS AND MATERIALS: The PubMed, Embase, Cochrane Library, and Web of Science - databases were searched for eligible studies published between January 1, 2015, - and July 31, 2023. The outcome of interest was the incidence rate of pneumonitis. - A random-effects model was used for statistical analysis. RESULTS: A total of 185 - studies with 24,527 patients were included. The pooled rate of grade ≥2 - pneumonitis for CRT plus ICIs was significantly higher than that for CRT alone - (29.6%; 95% CI, 25.7%-33.6% vs 20.2%; 95% CI, 17.7%-22.8%; P < .0001) but not - that of grade ≥3 (5.7%; 95% CI, 4.8%-6.6% vs 5.6%; 95% CI, 4.7%-6.5%; P = .64) or - grade 5 (0.1%; 95% CI, 0.0%-0.2% vs 0.3%; 95% CI, 0.1%-0.4%; P = .68). The - results from the subgroup analyses of prospective studies, retrospective studies, - Asian and non-Asian studies, concurrent CRT (cCRT), and durvalumab consolidation - were comparable to the overall results. However, CRT or cCRT plus PD-1 inhibitors - not only significantly increased the incidence of grade ≥2 but also that of grade - ≥3 pneumonitis compared to CRT alone or cCRT plus PD-L1 inhibitors. CONCLUSIONS: - Compared with CRT alone, durvalumab consolidation after CRT appears to be - associated with a higher incidence of moderate pneumonitis and CRT plus PD-1 - inhibitors with an increased risk of severe pneumonitis. Nevertheless, these - findings are based on observational studies and need to be validated in future - large head-to-head studies. -CI - Copyright © 2024 Elsevier Inc. All rights reserved. -FAU - Han, Chong -AU - Han C -AD - Department of Radiation Oncology, First Hospital of China Medical University, - Shenyang, China. -FAU - Qiu, Jingping -AU - Qiu J -AD - Department of Radiation Oncology, First Hospital of China Medical University, - Shenyang, China. -FAU - Bai, Lu -AU - Bai L -AD - Department of Radiation Oncology, First Hospital of China Medical University, - Shenyang, China. -FAU - Liu, Tingting -AU - Liu T -AD - Department of Radiation Oncology, Anshan Cancer Hospital, Anshan, China. -FAU - Chen, Jun -AU - Chen J -AD - Department of Radiation Oncology, Shenyang Tenth People's Hospital, Shenyang, - China. -FAU - Wang, He -AU - Wang H -AD - Department of Radiation Oncology, First Hospital of China Medical University, - Shenyang, China. -FAU - Dang, Jun -AU - Dang J -AD - Department of Radiation Oncology, First Hospital of China Medical University, - Shenyang, China. Electronic address: dangjunsy@163.com. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Review -PT - Systematic Review -DEP - 20240213 -PL - United States -TA - Int J Radiat Oncol Biol Phys -JT - International journal of radiation oncology, biology, physics -JID - 7603616 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy/pathology/radiotherapy -MH - *Lung Neoplasms/drug therapy/therapy/pathology -MH - *Chemoradiotherapy/adverse effects -MH - *Pneumonia/etiology -MH - *Immune Checkpoint Inhibitors/adverse effects/therapeutic use -MH - *Immunotherapy/adverse effects -MH - Incidence -MH - Risk -EDAT- 2024/02/16 00:42 -MHDA- 2024/06/27 00:42 -CRDT- 2024/02/15 21:41 -PHST- 2023/09/09 00:00 [received] -PHST- 2023/12/28 00:00 [revised] -PHST- 2024/01/28 00:00 [accepted] -PHST- 2024/06/27 00:42 [medline] -PHST- 2024/02/16 00:42 [pubmed] -PHST- 2024/02/15 21:41 [entrez] -AID - S0360-3016(24)00298-0 [pii] -AID - 10.1016/j.ijrobp.2024.01.217 [doi] -PST - ppublish -SO - Int J Radiat Oncol Biol Phys. 2024 Jul 15;119(4):1179-1207. doi: - 10.1016/j.ijrobp.2024.01.217. Epub 2024 Feb 13. - -PMID- 37734560 -OWN - NLM -STAT- MEDLINE -DCOM- 20231216 -LR - 20231229 -IS - 1879-2561 (Electronic) -IS - 0304-419X (Linking) -VI - 1878 -IP - 6 -DP - 2023 Nov -TI - Long non-coding RNAs in non-small cell lung cancer: implications for preventing - therapeutic resistance. -PG - 188982 -LID - S0304-419X(23)00131-2 [pii] -LID - 10.1016/j.bbcan.2023.188982 [doi] -AB - Lung cancer has the highest mortality and morbidity rates among all cancers - worldwide. Despite many complex treatment options, including radiotherapy, - chemotherapy, targeted drugs, immunotherapy, and combinations of these - treatments, efficacy is low in cases of resistance to therapy, metastasis, and - advanced disease, contributing to low overall survival. There is a pressing need - for the discovery of novel biomarkers and therapeutic targets for the early - diagnosis of lung cancer and to determine the efficacy and outcomes of drug - treatments. There is now substantial evidence for the diagnostic and prognostic - value of long noncoding RNAs (lncRNAs). This review briefly discusses recent - findings on the roles and mechanisms of action of lncRNAs in the responses to - therapy in non-small cell lung cancer. -CI - Copyright © 2023. Published by Elsevier B.V. -FAU - Liu, Wenjuan -AU - Liu W -AD - Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, - Shandong Cancer Hospital and Institute, Shandong First Medical University and - Shandong Academy of Medical Sciences, Jinan, Shandong Province 250117, China. -FAU - Zuo, Bingli -AU - Zuo B -AD - Human Resources Department, Shandong Cancer Hospital and Institute, Shandong - First Medical University and Shandong Academy of Medical Sciences, Jinan, - Shandong Province 250117, China. -FAU - Liu, Wenting -AU - Liu W -AD - Department of Neurology, Weifang People's Hospital, Weifang, Shandong Province - 261041, China. -FAU - Huo, Yanfei -AU - Huo Y -AD - Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, - Shandong Cancer Hospital and Institute, Shandong First Medical University and - Shandong Academy of Medical Sciences, Jinan, Shandong Province 250117, China. -FAU - Zhang, Nasha -AU - Zhang N -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong Province 250117, China; Jiangsu Key Lab of Cancer Biomarkers, - Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized - Medicine, Nanjing Medical University, Nanjing, Jiangsu Province 211166, China. - Electronic address: wownseva@126.com. -FAU - Yang, Ming -AU - Yang M -AD - Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, - Shandong Cancer Hospital and Institute, Shandong First Medical University and - Shandong Academy of Medical Sciences, Jinan, Shandong Province 250117, China; - Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative - Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, - Nanjing, Jiangsu Province 211166, China. Electronic address: aaryoung@yeah.net. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20230919 -PL - Netherlands -TA - Biochim Biophys Acta Rev Cancer -JT - Biochimica et biophysica acta. Reviews on cancer -JID - 9806362 -RN - 0 (RNA, Long Noncoding) -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - *Lung Neoplasms/drug therapy/genetics -MH - *RNA, Long Noncoding/genetics -MH - Drug Resistance, Neoplasm/genetics -MH - Biomarkers, Tumor/genetics/therapeutic use -OTO - NOTNLM -OT - Angiogenesis -OT - Drug resistance -OT - Immunotherapy resistance -OT - Long noncoding RNA -OT - Non-small cell lung cancer -OT - Radioresistance -COIS- Declaration of Competing Interest The authors declare that there are no conflicts - of interest. -EDAT- 2023/09/22 00:42 -MHDA- 2023/12/17 09:43 -CRDT- 2023/09/21 19:16 -PHST- 2023/06/21 00:00 [received] -PHST- 2023/08/14 00:00 [revised] -PHST- 2023/08/15 00:00 [accepted] -PHST- 2023/12/17 09:43 [medline] -PHST- 2023/09/22 00:42 [pubmed] -PHST- 2023/09/21 19:16 [entrez] -AID - S0304-419X(23)00131-2 [pii] -AID - 10.1016/j.bbcan.2023.188982 [doi] -PST - ppublish -SO - Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):188982. doi: - 10.1016/j.bbcan.2023.188982. Epub 2023 Sep 19. - -PMID- 38307393 -OWN - NLM -STAT- MEDLINE -DCOM- 20240614 -LR - 20240621 -IS - 1879-0461 (Electronic) -IS - 1040-8428 (Linking) -VI - 199 -DP - 2024 Jul -TI - Management of patients with extensive small-cell lung cancer in the immunotherapy - era: An Italian consensus through a Delphi approach. -PG - 104247 -LID - S1040-8428(23)00335-9 [pii] -LID - 10.1016/j.critrevonc.2023.104247 [doi] -AB - BACKGROUND: Immunotherapy represented a turning point for treating extensive - small-cell lung cancer (ES-SCLC). Although, many issues remain debated. METHODS: - A group of Italian medical and radiation oncologists with expertise in managing - patients with ES-SCLC developed a list of statements divided in six areas of - interest. The Delphi method was used to assess the consensus on the defined list - of statements. RESULTS: 32 statements were included in the final list to be voted - by the Delphi panel, and 26 reached a consensus on the agreement. A prompt - involvement of a multidisciplinary team is a priority to provide an integrated - treatment strategy. First-line recommended treatment is immunotherapy in - combination with platinum-based chemotherapy and etoposide for four cycles - followed by maintenance immunotherapy. CONCLUSIONS: While awaiting new data from - clinical trials and real-world studies, these recommendations can represent a - useful tool to guide the management of ES-SCLC patients in daily practice. -CI - Copyright © 2024. Published by Elsevier B.V. -FAU - Ceresoli, Giovanni Luca -AU - Ceresoli GL -AD - Department of Medical Oncology, Humanitas Gavazzeni Hospital, Bergamo, Italy. - Electronic address: giovanni.ceresoli@asst-valleolona.it. -FAU - Rossi, Giulio -AU - Rossi G -AD - Pathology Unit, Hospital Institute Fondazione Poliambulanza, Via Bissolati 57, - 25124 Brescia, Italy. -FAU - Agustoni, Francesco -AU - Agustoni F -AD - Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, - Italy; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, - Italy. -FAU - Bonomi, Lucia -AU - Bonomi L -AD - Unit of Oncology, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy. -FAU - Borghetti, Paolo -AU - Borghetti P -AD - Radiation Oncology Department, ASST Spedali Civili and University of Brescia, - Brescia, Italy. -FAU - Bulotta, Alessandra -AU - Bulotta A -AD - Department of Oncology, IRCCS San Raffaele, via Olgettina 60, Milan, Italy. -FAU - Casartelli, Clelia -AU - Casartelli C -AD - Unit of Oncology, Valduce Hospital, Como, Italy. -FAU - Cerea, Giulio -AU - Cerea G -AD - Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, - Italy. -FAU - Colonese, Francesca -AU - Colonese F -AD - ASST San Gerardo Monza, Medical Oncology Unit, Monza, Italy. -FAU - Del Signore, Ester -AU - Del Signore E -AD - Division of Thoracic Oncology, European Institute of Oncology, IEO, Milan, Italy. -FAU - Finocchiaro, Giovanna -AU - Finocchiaro G -AD - Medical Oncology and Hematologic Unit, Humanitas Cancer Center, Istituto Clinico - Humanitas-IRCCS, Rozzano, Italy. -FAU - Gianoncelli, Letizia -AU - Gianoncelli L -AD - Medical Oncology Unit, San Paolo Hospital, ASST Santi Paolo e Carlo, Milan, - Italy. -FAU - Grisanti, Salvatore -AU - Grisanti S -AD - Medical Oncology Unit, Department of Medical and Surgical Specialties, - Radiological Sciences, and Public Health, University of Brescia, ASST Spedali - Civili di Brescia, Brescia, Italy. -FAU - Maiolani, Martina -AU - Maiolani M -AD - U.O.C Oncologia Medica ASST Valtellina e Alto Lario, Sondrio, Italy. -FAU - Pagni, Fabio -AU - Pagni F -AD - Pathology, Department of Medicine and Surgery, University Milan Bicocca, Via - Cadore 48, 20900 Monza, Italy. -FAU - Proto, Claudia -AU - Proto C -AD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, - Milan, Italy. -FAU - Rijavec, Erika -AU - Rijavec E -AD - Unit of Medical Oncology, Ospedale di Circolo e Fondazione Macchi, ASST Sette - Laghi, Varese, Italy. -FAU - Vittimberga, Isabella -AU - Vittimberga I -AD - Oncology Department, Ospedale A. Manzoni, Lecco, Italy. -FAU - Arcangeli, Stefano -AU - Arcangeli S -AD - Department of Radiation Oncology, University of Milan Bicocca, Milan, Italy. -FAU - Filippi, Andrea Riccardo -AU - Filippi AR -AD - Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University - of Pavia, Pavia, Italy; Radiation Oncology, Fondazione IRCCS Policlinico San - Matteo, Pavia, Italy. -LA - eng -PT - Journal Article -PT - Review -DEP - 20240201 -PL - Netherlands -TA - Crit Rev Oncol Hematol -JT - Critical reviews in oncology/hematology -JID - 8916049 -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/therapy/pathology -MH - *Lung Neoplasms/therapy/pathology -MH - *Immunotherapy/methods -MH - *Delphi Technique -MH - Italy/epidemiology -MH - *Consensus -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Disease Management -OTO - NOTNLM -OT - Immunotherapy -OT - Patient management -OT - SCLC -OT - Small-cell lung cancer -COIS- Declaration of Competing Interest Francesco Agustoni received a grant for an - advisory role from Roche. Lucia Bonomi received honoraria from Bristol-Myers - Squibb/Celgene, MSD Oncology, AstraZeneca, Astellas Pharma, Janssen Oncology; fee - for consulting or advisory roles from Janssen Oncology, Ipsen, Roche. Paolo - Borghetti received honoraria from AstraZeneca, Roche. Giovanni Luca Ceresoli - received fees for speaker engagements from Bristol Myers Squibb, Merck Sharp & - Dohme, Novocure, AstraZeneca, Bayer, and Astellas; and fees for advisory roles - from Bristol Myers Squibb, Novocure, and AstraZeneca. Andrea Riccardo Filippi - received fees as speakers’ bureau from Astra Zeneca, MSD, Roche, Ipsen; fees for - advisory role from Astra Zeneca, Roche; and research funding from Astra Zeneca. - He also participated (no financial interest) in sponsored research from Astra - Zeneca, Roche, MSD. Giovanna Finocchiaro received personal fees for speaker - engagements from AstraZeneca and for advisory roles from MSD, and AMGEN. Letizia - Gianoncelli received personal fees for speaker engagements from AstraZeneca, - Bristol Myers Squibb, MSD, and Roche. Salvatore Grisanti received a fee for an - advisory board from Roche. Fabio Pagni received consulting or advisory fees from - Lilly, Amgen, Roche, MSD, Novartis, and Janssen. Prof Pagni participated in the - paper during his involvement as PI of the Italian MUR Dipartimenti di Eccellenza - 2023–2027 (l. 232/2016, art. 1, comma 314 - 337). Claudia Proto received - consulting or advisory fees from AstraZeneca, Roche, MSD, BMS, and Janssen; - research funding from Roche, AstraZeneca, Pfizer, Celgene, MSD, BMS, Daichii; - fees for travel, accommodation, and expenses from AstraZeneca, Roche, and MSD. - Erika Rijavec received honoraria from Bristol-Myers Squibb, AstraZeneca MSD, and - Roche; advisory board fees from Sanofi; and travel grants from Daichii Sankyo. - All other authors have no conflicts of interest to declare. -EDAT- 2024/02/03 00:41 -MHDA- 2024/06/15 10:44 -CRDT- 2024/02/02 19:33 -PHST- 2023/01/30 00:00 [received] -PHST- 2023/12/06 00:00 [revised] -PHST- 2023/12/19 00:00 [accepted] -PHST- 2024/06/15 10:44 [medline] -PHST- 2024/02/03 00:41 [pubmed] -PHST- 2024/02/02 19:33 [entrez] -AID - S1040-8428(23)00335-9 [pii] -AID - 10.1016/j.critrevonc.2023.104247 [doi] -PST - ppublish -SO - Crit Rev Oncol Hematol. 2024 Jul;199:104247. doi: - 10.1016/j.critrevonc.2023.104247. Epub 2024 Feb 1. - -PMID- 29931587 -OWN - NLM -STAT- MEDLINE -DCOM- 20191011 -LR - 20191011 -IS - 1534-6277 (Electronic) -IS - 1534-6277 (Linking) -VI - 19 -IP - 8 -DP - 2018 Jun 21 -TI - Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell - Lung Cancer. -PG - 39 -LID - 10.1007/s11864-018-0556-7 [doi] -AB - Surgical resection ± chemotherapy ± radiation or stereotactic body radiation - therapy (SBRT) are established treatment modalities for resectable stage - non-small cell lung cancer (NSCLC), and concurrent chemotherapy with radiation is - the therapy of choice for unresectable locally advanced disease. Despite - treatment with curative intent, most patients subsequently relapse and develop - distant disease. Treatment with checkpoint inhibitors represents a major - advancement in the treatment of metastatic NSCLC. Therapy against programed cell - death-1/programmed cell death ligand 1 (PD-1/PD-L1) is associated with a - significant improvement in overall survival in stage IV disease, and these - results have led to a great interest in evaluating these agents in earlier-stage - NSCLC. The preliminary data from ongoing trials suggest that the integration of - checkpoint blockage into the treatment of early-stage and locally advanced NSCLC - is safe, tolerable, and has the potential to improve outcomes without adding - substantial toxicity. In the current review, we provide an overview of the - emerging data on the role of PD-1/PD-L1 and cytotoxic T lymphocyte-associated - protein 4 (CTLA-4) inhibitors in the treatment of early-stage and locally - advanced NSCLC, with a focus on ongoing clinical trials and combination - strategies. -FAU - Puri, Sonam -AU - Puri S -AD - Department of Internal Medicine, Division of Hematology and Oncology, H. Lee - Moffitt Cancer Center and Research Institute/University of South Florida, 12902 - Magnolia Drive, GME 4th Floor, Tampa, FL, 33612, USA. -FAU - Shafique, Michael -AU - Shafique M -AD - Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research - Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA. -FAU - Gray, Jhanelle E -AU - Gray JE -AD - Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research - Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA. - jhanelle.gray@moffitt.org. -LA - eng -PT - Journal Article -PT - Review -DEP - 20180621 -PL - United States -TA - Curr Treat Options Oncol -JT - Current treatment options in oncology -JID - 100900946 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Animals -MH - Antineoplastic Agents, Immunological/pharmacology/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use -MH - *Biomarkers, Tumor -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/etiology/mortality/*pathology -MH - Chemotherapy, Adjuvant -MH - Clinical Trials as Topic -MH - Combined Modality Therapy -MH - Disease Management -MH - Humans -MH - Immunomodulation/*drug effects -MH - Lung Neoplasms/*drug therapy/etiology/mortality/*pathology -MH - *Molecular Targeted Therapy -MH - Neoadjuvant Therapy -MH - Neoplasm Metastasis -MH - Neoplasm Staging -MH - Treatment Outcome -OTO - NOTNLM -OT - Adjuvant -OT - Checkpoint inhibitors -OT - Neoadjuvant -OT - Non-small cell lung cancer -EDAT- 2018/06/23 06:00 -MHDA- 2019/10/12 06:00 -CRDT- 2018/06/23 06:00 -PHST- 2018/06/23 06:00 [entrez] -PHST- 2018/06/23 06:00 [pubmed] -PHST- 2019/10/12 06:00 [medline] -AID - 10.1007/s11864-018-0556-7 [pii] -AID - 10.1007/s11864-018-0556-7 [doi] -PST - epublish -SO - Curr Treat Options Oncol. 2018 Jun 21;19(8):39. doi: 10.1007/s11864-018-0556-7. - -PMID- 37350968 -OWN - NLM -STAT- MEDLINE -DCOM- 20230626 -LR - 20240315 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 14 -DP - 2023 -TI - Hypofractionated radiotherapy with immunochemotherapy for extensive-stage - small-cell lung cancer. -PG - 1175960 -LID - 10.3389/fimmu.2023.1175960 [doi] -LID - 1175960 -AB - INTRODUCTION: The combination of a PD-L1 inhibitor plus carboplatin/cisplatin and - etoposide (EC/EP) has become a new standard first-line treatment for - extensive-stage small-cell lung cancer (ES-SCLC). Combining concurrent palliative - hypofractionated radiotherapy of the thorax (HFRT) and immunochemotherapy may - have a synergistic effect. In this study, we explored an optimal model of - combination radiotherapy with immunochemotherapy as first-line treatment of - ES-SCLC. PATIENTS AND METHODS: In this multicenter single-arm phase 2 trial, - patients with ES-SCLC received atezolizumab with EC/EP for two cycles (induction - phase), then, those who did not progress received concurrent palliative HFRT and - two cycles of atezolizumab with EC/EP (combination phase). Afterward they - received atezolizumab every 3 weeks for a maximum of 2 years after study - enrolment (maintenance phase). Prophylactic cranial irradiation (PCI) was - recommended. The primary endpoints were safety and tolerance; the second - endpoints were progression-free survival (PFS). RESULTS: Forty patients were - enrolled, and all had completed palliative HFRT and four cycles of - immunochemotherapy. There were seven grade 3 adverse events (3 decreased - neutrophil count, 1 anemia, 2 pneumonitis, 1 esoenteritis), two grade 4 adverse - events (2 decreased white cell count) and no grade 5 toxicities. The pneumonitis - rate was 12.5% (three grade 2 and two grade 3 events). At the median follow-up of - 14.2 months (range, 6.8-28.7), the median PFS was 8.6 months (95%CI, 6.1-11.1). - CONCLUSION: The addition of concurrent hypofractionated thoracic radiotherapy to - first-line immunochemotherapy for ES-SCLC was well tolerated and showed promising - clinical efficacy. Additional randomized trials are needed to validate benefits. - CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/ (NCT04636762). -CI - Copyright © 2023 Liu, Zeng, Deng, Jiang, Wang, Zhou, Liu, Wang, Zhou, Qiu, Zeng, - Wu, Weng, Liu, Yang and Ma. -FAU - Liu, Chaoyuan -AU - Liu C -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, Hunan, China. -FAU - Zeng, Liang -AU - Zeng L -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Deng, Chao -AU - Deng C -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, Hunan, China. -FAU - Jiang, Wenjuan -AU - Jiang W -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Wang, Yapeng -AU - Wang Y -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, Hunan, China. -FAU - Zhou, Yiguang -AU - Zhou Y -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, Hunan, China. -FAU - Liu, Li -AU - Liu L -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Wang, Sisi -AU - Wang S -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, Hunan, China. -FAU - Zhou, Chunhua -AU - Zhou C -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Qiu, Zhenhua -AU - Qiu Z -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, Hunan, China. -FAU - Zeng, Fanxu -AU - Zeng F -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Wu, Fang -AU - Wu F -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, Hunan, China. -FAU - Weng, Jie -AU - Weng J -AD - Department of Oncology, Yueyang Center Hospital, Yueyang, China. -FAU - Liu, Xianling -AU - Liu X -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, Hunan, China. -AD - Department of Oncology, Guilin Hospital of the Second Xiangya Hospital, Central - South University, Guilin, China. -FAU - Yang, Nong -AU - Yang N -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Ma, Fang -AU - Ma F -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, Hunan, China. -LA - eng -SI - ClinicalTrials.gov/NCT04636762 -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -DEP - 20230607 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - Q20Q21Q62J (Cisplatin) -RN - BG3F62OND5 (Carboplatin) -SB - IM -MH - Humans -MH - *Lung Neoplasms/radiotherapy/drug therapy -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - *Small Cell Lung Carcinoma/radiotherapy/drug therapy -MH - Cisplatin/therapeutic use -MH - Carboplatin/therapeutic use -PMC - PMC10282832 -OTO - NOTNLM -OT - extensive-stage small-cell lung cancer -OT - immunochemotherapy -OT - progression free survival -OT - safety -OT - thoracic radiation -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2023/06/23 13:07 -MHDA- 2023/06/26 06:41 -PMCR- 2023/01/01 -CRDT- 2023/06/23 10:27 -PHST- 2023/02/28 00:00 [received] -PHST- 2023/05/18 00:00 [accepted] -PHST- 2023/06/26 06:41 [medline] -PHST- 2023/06/23 13:07 [pubmed] -PHST- 2023/06/23 10:27 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2023.1175960 [doi] -PST - epublish -SO - Front Immunol. 2023 Jun 7;14:1175960. doi: 10.3389/fimmu.2023.1175960. - eCollection 2023. - -PMID- 28705024 -OWN - NLM -STAT- MEDLINE -DCOM- 20171226 -LR - 20210503 -IS - 1744-7682 (Electronic) -IS - 1471-2598 (Linking) -VI - 17 -IP - 10 -DP - 2017 Oct -TI - MEDI 4736 (durvalumab) in non-small cell lung cancer. -PG - 1317-1323 -LID - 10.1080/14712598.2017.1351939 [doi] -AB - Immune checkpoint inhibitors (ICI) are now a therapeutic option for advanced - non-small cell lung cancer (NSCLC) patients. ICI, such as the PD-1 inhibitors - nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab, have already - been marketed for the treatment of pretreated patients with advanced NSCLC. Other - notable PD-L1 inhibitors under development include avelumab and durvalumab. Areas - covered: This article reviews literature on durvalumab development, from the - preclinical data to the results of phase III clinical trials, whether published - or presented at international scientific conferences. Ongoing clinical trials - were also reviewed. Expert opinion: Early phase trials of durvalumab monotherapy - (and in combination) have demonstrated activity in advanced NSCLC patients and it - has demonstrated a good safety profile. The authors believe that durvalumab will - likely play an important role in future treatment strategies for NSCLC. The - PACIFIC trial assessing durvalumab after standard chemoradiotherapy for locally - advanced NSCLC has already met its primary endpoint and the potential of - durvalumab will be reinforced if phase III randomized studies of first-line - (MYSTIC trial) and second or subsequent (ARCTIC trial) lines of therapy - demonstrate superiority over the current standard of care. -FAU - Jeanson, Arnaud -AU - Jeanson A -AD - a Aix Marseille University, Assistance Publique Hôpitaux de Marseille , Early - Phase Cancer Center CLIP2 , Marseille , France. -FAU - Barlesi, Fabrice -AU - Barlesi F -AD - a Aix Marseille University, Assistance Publique Hôpitaux de Marseille , Early - Phase Cancer Center CLIP2 , Marseille , France. -LA - eng -PT - Journal Article -DEP - 20170713 -PL - England -TA - Expert Opin Biol Ther -JT - Expert opinion on biological therapy -JID - 101125414 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal/immunology/pharmacokinetics/*therapeutic use -MH - Antineoplastic Agents/metabolism/pharmacokinetics/*therapeutic use -MH - B7-H1 Antigen/immunology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Clinical Trials as Topic -MH - Half-Life -MH - Humans -MH - Lung Neoplasms/*drug therapy -OTO - NOTNLM -OT - PD-1 -OT - PD-L1 -OT - durvalumab -OT - immune checkpoint inhibitors -OT - non-small cell lung cancer -EDAT- 2017/07/15 06:00 -MHDA- 2017/12/27 06:00 -CRDT- 2017/07/15 06:00 -PHST- 2017/07/15 06:00 [pubmed] -PHST- 2017/12/27 06:00 [medline] -PHST- 2017/07/15 06:00 [entrez] -AID - 10.1080/14712598.2017.1351939 [doi] -PST - ppublish -SO - Expert Opin Biol Ther. 2017 Oct;17(10):1317-1323. doi: - 10.1080/14712598.2017.1351939. Epub 2017 Jul 13. - -PMID- 36982933 -OWN - NLM -STAT- MEDLINE -DCOM- 20230330 -LR - 20230331 -IS - 1422-0067 (Electronic) -IS - 1422-0067 (Linking) -VI - 24 -IP - 6 -DP - 2023 Mar 20 -TI - Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and - Concurrent Radiotherapy-A Review. -LID - 10.3390/ijms24065858 [doi] -LID - 5858 -AB - Lung cancer is the leading cause of death worldwide for both men and women. - Surgery can be offered as a radical treatment at stages I and II and selected - cases of stage III (III A). Whereas at more advanced stages, combined modalities - of treatment are applied: radiochemotherapy (IIIB) and molecularly targeted - treatment (small molecule tyrosine kinase inhibitors, VEGF receptor inhibitors, - monoclonal antibodies, and immunological treatment with monoclonal antibodies). - Combination treatment, composed of radiotherapy and molecular therapy, is - increasingly employed in locally advanced and metastatic lung cancer management. - Recent studies have indicated a synergistic effect of such treatment and - modification of immune response. The combination of immunotherapy and - radiotherapy may result in the enhancement of the abscopal effect. - Anti-angiogenic therapy, in combination with RT, is associated with high toxicity - and should be not recommended. In this paper, the authors discuss the role of - molecular treatment and the possibility of its concurrent use with radiotherapy - in non-small cell lung cancer (NSCLC). -FAU - Król, Katarzyna -AU - Król K -AD - Department of Radiotherapy, St. John's Cancer Centre, Regional Oncology Centre of - Lublin, Jaczewskiego 7, 20-090 Lublin, Poland. -FAU - Mazur, Anna -AU - Mazur A -AD - Department of Radiotherapy, St. John's Cancer Centre, Regional Oncology Centre of - Lublin, Jaczewskiego 7, 20-090 Lublin, Poland. -FAU - Stachyra-Strawa, Paulina -AU - Stachyra-Strawa P -AD - Department of Radiotherapy, Medical University in Lublin, Chodźki 7, 20-093 - Lublin, Poland. -FAU - Grzybowska-Szatkowska, Ludmiła -AU - Grzybowska-Szatkowska L -AD - Department of Radiotherapy, Medical University in Lublin, Chodźki 7, 20-093 - Lublin, Poland. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230320 -PL - Switzerland -TA - Int J Mol Sci -JT - International journal of molecular sciences -JID - 101092791 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Male -MH - Female -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Molecular Targeted Therapy -MH - Antibodies, Monoclonal/therapeutic use -MH - Immunotherapy -MH - B7-H1 Antigen -PMC - PMC10052930 -OTO - NOTNLM -OT - EGFR -OT - NSCLC -OT - PD-1 -OT - PD-L1 -OT - VEGFR -COIS- The authors declare no conflict of interest. -EDAT- 2023/03/30 06:00 -MHDA- 2023/03/30 06:11 -PMCR- 2023/03/20 -CRDT- 2023/03/29 01:40 -PHST- 2023/02/01 00:00 [received] -PHST- 2023/03/13 00:00 [revised] -PHST- 2023/03/13 00:00 [accepted] -PHST- 2023/03/30 06:11 [medline] -PHST- 2023/03/29 01:40 [entrez] -PHST- 2023/03/30 06:00 [pubmed] -PHST- 2023/03/20 00:00 [pmc-release] -AID - ijms24065858 [pii] -AID - ijms-24-05858 [pii] -AID - 10.3390/ijms24065858 [doi] -PST - epublish -SO - Int J Mol Sci. 2023 Mar 20;24(6):5858. doi: 10.3390/ijms24065858. - -PMID- 28688973 -OWN - NLM -STAT- MEDLINE -DCOM- 20170920 -LR - 20210103 -IS - 1872-7980 (Electronic) -IS - 0304-3835 (Linking) -VI - 405 -DP - 2017 Oct 1 -TI - PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development - and challenges. -PG - 29-37 -LID - S0304-3835(17)30415-9 [pii] -LID - 10.1016/j.canlet.2017.06.033 [doi] -AB - PD-1/PD-L1 checkpoint blockades have dramatically changed the landscape for - second-line treatment of non-small cell lung cancer (NSCLC). Based on the - promising results of Keynote-024 presented so far, pembrolizumab has been - approved as first-line treatment for advanced PD-L1 positive NSCLC patients. - However, overall response rate (ORR) is limited to PD-1/PD-L1 checkpoint - blockades when used as single agent. Combining with chemotherapy, anti-CTLA-4 - antibodies, targeted therapy, radiotherapy or other treatment options is - perceived as an appealing method aimed at achieving higher efficacy. There are - many clinical trials on going or finished assessing the efficacy and safety of - the PD-1/PD-L1 blockades alone or combining with other approaches in first-line - or second-line treatments. A lot of challenges need to be overcome before - PD-1/PD-L1 checkpoint blockades are widely used in the patients with NSCLC - including the identification of optimal combination, treatment-related adverse - effects, the high cost and lack of effective predictive markers. In this review, - we focus on outlining current clinical trials and challenges for future research - of PD-1/PD-L1 pathway checkpoint blockades in NSCLC. -CI - Copyright © 2017 Elsevier B.V. All rights reserved. -FAU - Meng, Xiangjiao -AU - Meng X -AD - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong - University, Shandong Academic of Medical Science, Jinan, 250117, China. -FAU - Liu, Yanli -AU - Liu Y -AD - Provincial Key Laboratory of Radio-oncology, Shandong Cancer Hospital Affiliated - to Shandong University, Shandong Academic of Medical Science, Jinan, 250117, - China. -FAU - Zhang, Jianjun -AU - Zhang J -AD - Department of Chemotherapy, Shandong Cancer Hospital Affiliated to Shandong - University, Shandong Academic of Medical Science, Jinan, 250117, China. -FAU - Teng, Feifei -AU - Teng F -AD - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong - University, Shandong Academic of Medical Science, Jinan, 250117, China. -FAU - Xing, Ligang -AU - Xing L -AD - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong - University, Shandong Academic of Medical Science, Jinan, 250117, China. - Electronic address: xinglg@medmail.com.cn. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong - University, Shandong Academic of Medical Science, Jinan, 250117, China. - Electronic address: sdyujinming@126.com. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20170706 -PL - Ireland -TA - Cancer Lett -JT - Cancer letters -JID - 7600053 -RN - 0 (Antineoplastic Agents) -RN - 0 (CTLA-4 Antigen) -RN - 0 (CTLA4 protein, human) -RN - 0 (Immunologic Factors) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antineoplastic Agents/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - CTLA-4 Antigen/metabolism -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism -MH - Cell Cycle Checkpoints/drug effects -MH - Clinical Trials as Topic -MH - Combined Modality Therapy -MH - Humans -MH - Immunologic Factors/*therapeutic use -MH - Immunotherapy/*methods -MH - Lung Neoplasms/*drug therapy/metabolism -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -OTO - NOTNLM -OT - Challenges -OT - Efficacy -OT - NSCLC -OT - PD-L1 -OT - PD1 -EDAT- 2017/07/10 06:00 -MHDA- 2017/09/21 06:00 -CRDT- 2017/07/10 06:00 -PHST- 2017/03/30 00:00 [received] -PHST- 2017/06/21 00:00 [revised] -PHST- 2017/06/28 00:00 [accepted] -PHST- 2017/07/10 06:00 [pubmed] -PHST- 2017/09/21 06:00 [medline] -PHST- 2017/07/10 06:00 [entrez] -AID - S0304-3835(17)30415-9 [pii] -AID - 10.1016/j.canlet.2017.06.033 [doi] -PST - ppublish -SO - Cancer Lett. 2017 Oct 1;405:29-37. doi: 10.1016/j.canlet.2017.06.033. Epub 2017 - Jul 6. - -PMID- 37548029 -OWN - NLM -STAT- MEDLINE -DCOM- 20231030 -LR - 20231102 -IS - 1097-0142 (Electronic) -IS - 0008-543X (Linking) -VI - 129 -IP - 22 -DP - 2023 Nov 15 -TI - Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a - poor performance status. -PG - 3546-3553 -LID - 10.1002/cncr.34966 [doi] -AB - BACKGROUND: Immune checkpoint inhibitor combined with platinum-etoposide is the - standard first-line therapy for patients with extensive-stage small cell lung - cancer (ES-SCLC). The phase 3 clinical trials that led to the approval of - chemoimmunotherapy in ES-SCLC excluded patients who had an Eastern Cooperative - Group (ECOG) performance status (PS) of 2-3. Therefore, data on the efficacy of - chemoimmunotherapy in patients with an ECOG PS of 2-3 are limited. METHODS: A - retrospective analysis was performed on patients diagnosed with ES-SCLC who - received chemoimmunotherapy (atezolizumab or durvalumab) within the Mayo Clinic - Health System between January 2016 and January 2021. The objective of this study - was to compare the overall survival (OS), progression-free survival (PFS), and - best clinical response to therapy in patients with an ECOG PS of 0-1 vs. patients - with an ECOG PS of 2-3 who received chemoimmunotherapy for newly diagnosed - ES-SCLC. RESULTS: In total, 82 patients were included in the study. The - mean ± standard deviation age was 68.1 ± 8.3 years. Of these, 56 patients were - identified with an ECOG PS of 0-1, and 26 patients were identified with an ECOG - PS of 2-3. The median PFS was similar regardless of ECOG PS (5.8 months [95% CI, - 4.3-6.0 months] in the ECOG PS 0-1 group vs. 4.1 months [95% CI, 3.8-6.9 months] - in the ECOG PS 2-3; p = .2994). The median OS was also similar regardless of ECOG - PS (10.6 months [95% CI, 8.4-13.4 months] in the ECOG PS 0-1 group vs. 9.3 months - [95% CI, 4.9-12.8 months]; p = .2718) in the ECOG PS 2-3 group. CONCLUSIONS: The - study results demonstrated no significant difference in PFS or OS among the ECOG - PS 2-3 and ECOG PS 0-1 groups. Therefore, chemoimmunotherapy should be considered - for patients who have ES-SCLC with an ECOG PS of 2-3. -CI - © 2023 American Cancer Society. -FAU - Agarwal, Muskan -AU - Agarwal M -AUID- ORCID: 0000-0003-0052-4982 -AD - Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona, USA. -FAU - Liu, Alex -AU - Liu A -AD - Division of Hematology-Oncology, Mayo Clinic Cancer Center, Phoenix, Arizona, - USA. -FAU - Almquist, Daniel -AU - Almquist D -AD - Division of Hematology-Oncology, Sanford Roger Maris Cancer Center, Fargo, North - Dakota, USA. -FAU - Langlais, Blake T -AU - Langlais BT -AD - Department of Quantitative Health Sciences, Mayo Clinic, Phoenix, Arizona, USA. -FAU - Leventakos, Konstantinos -AU - Leventakos K -AD - Division of Hematology-Oncology, Mayo Clinic Cancer Center, Rochester, Minnesota, - USA. -FAU - Yu, Nathan Y -AU - Yu NY -AUID- ORCID: 0000-0003-4059-650X -AD - Department of Radiation Oncology, Mayo Clinic Cancer Center, Phoenix, Arizona, - USA. -FAU - Manochakian, Rami -AU - Manochakian R -AD - Division of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, - Florida, USA. -FAU - Ernani, Vinicius -AU - Ernani V -AUID- ORCID: 0000-0002-1865-5801 -AD - Division of Hematology-Oncology, Mayo Clinic Cancer Center, Phoenix, Arizona, - USA. -LA - eng -PT - Journal Article -DEP - 20230807 -PL - United States -TA - Cancer -JT - Cancer -JID - 0374236 -RN - 6PLQ3CP4P3 (Etoposide) -SB - IM -MH - Humans -MH - Middle Aged -MH - Aged -MH - *Small Cell Lung Carcinoma/drug therapy -MH - *Lung Neoplasms/drug therapy/chemically induced -MH - Retrospective Studies -MH - Etoposide/adverse effects -MH - Progression-Free Survival -OTO - NOTNLM -OT - chemoimmunotherapy -OT - chemotherapy -OT - eastern cooperative oncology group performance status -OT - extensive-stage small cell lung cancer -OT - overall survival -OT - progression-free survival -EDAT- 2023/08/07 06:42 -MHDA- 2023/10/30 06:46 -CRDT- 2023/08/07 05:27 -PHST- 2023/04/02 00:00 [revised] -PHST- 2022/09/16 00:00 [received] -PHST- 2023/06/01 00:00 [accepted] -PHST- 2023/10/30 06:46 [medline] -PHST- 2023/08/07 06:42 [pubmed] -PHST- 2023/08/07 05:27 [entrez] -AID - 10.1002/cncr.34966 [doi] -PST - ppublish -SO - Cancer. 2023 Nov 15;129(22):3546-3553. doi: 10.1002/cncr.34966. Epub 2023 Aug 7. - -PMID- 37551698 -OWN - NLM -STAT- MEDLINE -DCOM- 20231102 -LR - 20231103 -IS - 1744-8328 (Electronic) -IS - 1473-7140 (Linking) -VI - 23 -IP - 9 -DP - 2023 Jul-Dec -TI - Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung - Cancer. -PG - 913-926 -LID - 10.1080/14737140.2023.2245140 [doi] -AB - INTRODUCTION: The current standard of care of locally advanced non-small cell - lung cancer (LA-NSCLC) is concurrent chemoradiation, followed by consolidation - durvalumab. However, there is evidence that the efficacy of chemoradiation and - also immunotherapy in many oncogene-positive LA-NSCLC are attenuated, and - dependent on the subgroup. AREAS COVERED: We will firstly review the outcomes of - standard-of-care therapy in oncogene-driven LA-NSCLC. We looked at various - oncogene driven subgroups and the tumor microenvironment that may explain - differential response. Finally, we review the role of targeted therapy in the - treatment of LA-NSCLC. EXPERT OPINION: Each oncogene-positive subgroup should be - treated as its own entity, and continued efforts should be undertaken to - incorporate targeted therapy, which is likely to yield superior survival outcomes - if trial design can be optimized and toxicities can be managed. -FAU - Loh, Jerold -AU - Loh J -AD - Department of Haematology-Oncology, National University Cancer Institute, - Singapore (NCIS), National University Health System, Singapore, Singapore. -FAU - Low, Jia Li -AU - Low JL -AD - Department of Haematology-Oncology, National University Cancer Institute, - Singapore (NCIS), National University Health System, Singapore, Singapore. -FAU - Sachdeva, Manavi -AU - Sachdeva M -AD - Department of Haematology-Oncology, National University Cancer Institute, - Singapore (NCIS), National University Health System, Singapore, Singapore. -FAU - Low, Peter Qj -AU - Low PQ -AD - Department of Haematology-Oncology, National University Cancer Institute, - Singapore (NCIS), National University Health System, Singapore, Singapore. -FAU - Wong, Rachel Su Jen -AU - Wong RSJ -AD - Department of Haematology-Oncology, National University Cancer Institute, - Singapore (NCIS), National University Health System, Singapore, Singapore. -FAU - Huang, Yiqing -AU - Huang Y -AD - Department of Haematology-Oncology, National University Cancer Institute, - Singapore (NCIS), National University Health System, Singapore, Singapore. -FAU - Chia, Puey Ling -AU - Chia PL -AD - Department of Medical Oncology, Tan Tock Seng Hospital, Singapore, Singapore. -FAU - Soo, Ross A -AU - Soo RA -AD - Department of Haematology-Oncology, National University Cancer Institute, - Singapore (NCIS), National University Health System, Singapore, Singapore. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230813 -PL - England -TA - Expert Rev Anticancer Ther -JT - Expert review of anticancer therapy -JID - 101123358 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - *Lung Neoplasms/drug therapy/genetics -MH - Chemoradiotherapy -MH - Oncogenes -MH - Tumor Microenvironment -OTO - NOTNLM -OT - ALK -OT - EGFR -OT - chemoradiation -OT - immunotherapy -OT - non-small cell lung cancer -OT - targeted therapy -EDAT- 2023/08/08 12:42 -MHDA- 2023/08/08 12:43 -CRDT- 2023/08/08 06:42 -PHST- 2023/08/08 12:43 [medline] -PHST- 2023/08/08 12:42 [pubmed] -PHST- 2023/08/08 06:42 [entrez] -AID - 10.1080/14737140.2023.2245140 [doi] -PST - ppublish -SO - Expert Rev Anticancer Ther. 2023 Jul-Dec;23(9):913-926. doi: - 10.1080/14737140.2023.2245140. Epub 2023 Aug 13. - -PMID- 37999109 -OWN - NLM -STAT- MEDLINE -DCOM- 20231127 -LR - 20240524 -IS - 1718-7729 (Electronic) -IS - 1198-0052 (Print) -IS - 1198-0052 (Linking) -VI - 30 -IP - 11 -DP - 2023 Oct 29 -TI - Update on the Management of Stage III NSCLC: Navigating a Complex and - Heterogeneous Stage of Disease. -PG - 9514-9529 -LID - 10.3390/curroncol30110689 [doi] -AB - BACKGROUND: Stage III nonsmall cell lung cancer (NSCLC) represents a - heterogeneous group of patients. Many patients are treated with curative intent - multimodality therapy, either surgical resection plus systemic therapy or - chemoradiation plus immunotherapy. However, many patients are not suitable for - curative intent therapy and are treated with palliative systemic therapy or best - supportive care. METHODS: This paper is a review of recent advances in the - management of patients with curative intent disease. RESULTS: There have been - significant advances in curative intent therapy for patients with stage III NSCLC - in recent years. These include both adjuvant and neoadjuvant systemic therapies. - For patients with resectable NSCLC, two trials have demonstrated that adjuvant - atezolizumab or pembrolizumab, following chemotherapy, significantly improved - disease-free survival (DFS). In patients with tumours harbouring a common - mutation of the EGFR gene, adjuvant osimertinib therapy was associated with a - large improvement in both DFS and overall survival (OS). Five randomized trials - have evaluated chemotherapy plus nivolumab, pembrolizumab, durvalumab, or - toripalimab, either as neoadjuvant or perioperative (neoadjuvant plus adjuvant) - therapy. All five trials show significant improvements in the rate of pathologic - complete response (pCR) and event-free survival (EFS). OS data are currently - immature. This would now be considered the standard of care for resectable stage - III NSCLC. The addition of durvalumab to chemoradiation has also become the - standard of care in unresectable stage III NSCLC. One year of consolidation - durvalumab following concurrent chemoradiation has demonstrated significant - improvements in both progression-free and overall survival. CONCLUSIONS: Immune - checkpoint inhibitor (ICI) therapy has become a standard recommendation in - curative intent therapy for stage III NSCLC. -FAU - Sathiyapalan, Arani -AU - Sathiyapalan A -AD - Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON L8V 5C2, - Canada. -AD - Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada. -FAU - Baloush, Ziad -AU - Baloush Z -AD - Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON L8V 5C2, - Canada. -AD - Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada. -FAU - Ellis, Peter M -AU - Ellis PM -AD - Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON L8V 5C2, - Canada. -AD - Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada. -LA - eng -PT - Journal Article -PT - Review -DEP - 20231029 -PL - Switzerland -TA - Curr Oncol -JT - Current oncology (Toronto, Ont.) -JID - 9502503 -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Combined Modality Therapy -MH - Nivolumab/therapeutic use -MH - Disease-Free Survival -PMC - PMC10670056 -OTO - NOTNLM -OT - NSCLC -OT - adjuvant therapy -OT - chemotherapy -OT - immunotherapy -OT - neoadjuvant therapy -OT - radiation -COIS- A.S. has received honoraria for speaking and advisory board meetings from - AstraZeneca; Z.B. has no conflict of interest to declare; P.E. has received - honoraria for speaking or advisory board meetings from AstraZeneca, BMS, Eli - Lilly, Jannsen, Jazz, Merck, Novartis, Roche, Sanofi, and Pfizer. -EDAT- 2023/11/24 12:41 -MHDA- 2023/11/27 12:43 -PMCR- 2023/10/29 -CRDT- 2023/11/24 09:40 -PHST- 2023/09/19 00:00 [received] -PHST- 2023/10/22 00:00 [revised] -PHST- 2023/10/25 00:00 [accepted] -PHST- 2023/11/27 12:43 [medline] -PHST- 2023/11/24 12:41 [pubmed] -PHST- 2023/11/24 09:40 [entrez] -PHST- 2023/10/29 00:00 [pmc-release] -AID - curroncol30110689 [pii] -AID - curroncol-30-00689 [pii] -AID - 10.3390/curroncol30110689 [doi] -PST - epublish -SO - Curr Oncol. 2023 Oct 29;30(11):9514-9529. doi: 10.3390/curroncol30110689. - -PMID- 32402357 -OWN - NLM -STAT- MEDLINE -DCOM- 20201110 -LR - 20201110 -IS - 1557-8216 (Electronic) -IS - 0272-5231 (Linking) -VI - 41 -IP - 2 -DP - 2020 Jun -TI - Advances in the Treatment of Stage III Non-Small Cell Lung Cancer. -PG - 211-222 -LID - S0272-5231(20)30010-1 [pii] -LID - 10.1016/j.ccm.2020.02.008 [doi] -AB - Treatment of stage III non-small cell lung cancer (NSCLC) traditionally has - involved combinations of chemotherapy, radiation, and surgical resection. - Although the multimodality approach remains standard, only a fraction of patients - with stage III lung cancer can undergo complete resection, and long-term - prognosis remains poor. The PACIFIC trial generated significant enthusiasm when - it demonstrated that the programmed death ligand-1 inhibitor, durvalumab, - improved survival in patients with unresectable stage III NSCLC after completion - of definitive concurrent chemoradiation. This article reviews the indications for - traditional therapies in stage III NSCLC and highlights ongoing advances that - have led to the incorporation of novel therapeutic agents. -CI - Published by Elsevier Inc. -FAU - Myall, Nathaniel J -AU - Myall NJ -AD - Department of Medicine, Division of Medical Oncology, Stanford Cancer Institute, - Stanford, CA 94305, USA. -FAU - Das, Millie -AU - Das M -AD - Department of Medicine, Division of Medical Oncology, Stanford Cancer Institute, - Stanford, CA 94305, USA; Department of Medicine, VA Palo Alto Health Care System, - 3801 Miranda Avenue (111ONC), Palo Alto, CA 94304, USA. Electronic address: - mdas@stanford.edu. -LA - eng -GR - U01 CA231851/CA/NCI NIH HHS/United States -GR - R01 CA206540/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Review -PL - United States -TA - Clin Chest Med -JT - Clinics in chest medicine -JID - 7907612 -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/pathology/*therapy -MH - Humans -MH - Lung Neoplasms/pathology/*therapy -MH - Neoplasm Staging -OTO - NOTNLM -OT - Chemoradiation -OT - Durvalumab -OT - LACE -OT - Non–small cell lung cancer -OT - PACIFIC -OT - Stage III -OT - Targeted therapy -COIS- Disclosure Dr. Myall has no funding groups to acknowledge. Dr. Das has the - following disclosures at the time of publication: Research funding: Celgene, - United Therapeutics, Abbvie, Verily, Varian, Genzyme, Novartis - Consulting/Honoraria: Bristol Myer Squibb, Astra Zeneca. Dr. Das also has - received research funding from the following NIH grants: U01 CA231851-01 (PI: - Krasnow) and RO1 CA206540-01 (PI: Sage). -EDAT- 2020/05/14 06:00 -MHDA- 2020/11/11 06:00 -CRDT- 2020/05/14 06:00 -PHST- 2020/05/14 06:00 [entrez] -PHST- 2020/05/14 06:00 [pubmed] -PHST- 2020/11/11 06:00 [medline] -AID - S0272-5231(20)30010-1 [pii] -AID - 10.1016/j.ccm.2020.02.008 [doi] -PST - ppublish -SO - Clin Chest Med. 2020 Jun;41(2):211-222. doi: 10.1016/j.ccm.2020.02.008. - -PMID- 37418123 -OWN - NLM -STAT- MEDLINE -DCOM- 20230817 -LR - 20231030 -IS - 1699-3055 (Electronic) -IS - 1699-048X (Print) -IS - 1699-048X (Linking) -VI - 25 -IP - 9 -DP - 2023 Sep -TI - SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of - small-cell lung cancer (SCLC) (2022). -PG - 2679-2691 -LID - 10.1007/s12094-023-03216-3 [doi] -AB - Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising - approximately 15% of lung cancers. Only one-third of patients are diagnosed at - limited-stage (LS). Surgical resection can be curative in early stages, followed - by platinum-etoposide adjuvant therapy, although only a minority of patients with - SCLC qualify for surgery. Concurrent chemo-radiotherapy is the standard of care - for LS-SCLC that is not surgically resectable, followed by prophylactic cranial - irradiation (PCI) for patients without progression. For extensive-stage - (ES)-SCLC, a combination of platinum and etoposide has historically been a - mainstay of treatment. Recently, the efficacy of programmed death-ligand 1 - inhibitors combined with chemotherapy has become the new front-line standard of - care for ES-SCLC. Emerging knowledge regarding SCLC biology, including genomic - characterization and molecular subtyping, and new treatment approaches will - potentially lead to advances in SCLC patient care. -CI - © 2023. The Author(s). -FAU - García-Campelo, Rosario -AU - García-Campelo R -AUID- ORCID: 0000-0003-2113-1504 -AD - Department of Medical Oncology, Hospital Universitario A Coruña, Health Research - Institute, INIBIC, A Coruña, Spain. ma.rosario.garcia.campelo@sergas.es. -FAU - Sullivan, Ivana -AU - Sullivan I -AUID- ORCID: 0000-0002-0434-3436 -AD - Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, IIB Sant - Pau, Barcelona, Spain. -AD - Universitat Autònoma de Barcelona, Barcelona, Spain. -FAU - Arriola, Edurne -AU - Arriola E -AD - Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain. -FAU - Insa, Amelia -AU - Insa A -AD - Departmert of Medical Oncology, Hospital Clínico de Valencia, Valencia, Spain. -FAU - Juan Vidal, Oscar -AU - Juan Vidal O -AD - Department of Medical Oncology, Hospital Universitari i Politécnic La Fe de - Valencia, Valencia, Spain. -FAU - Cruz-Castellanos, Patricia -AU - Cruz-Castellanos P -AD - Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain. -FAU - Morán, Teresa -AU - Morán T -AD - Department of Medical Oncology, Badalona Applied Research Group in Oncology, - Catalan Institute of Oncology Badalona, Hospital Universitario Germans Trias i - Pujol, Institut Germans Trias i Pujol, Barcelona, Spain. -AD - Universitat Autònoma de Barcelona, Barcelona, Spain. -FAU - Reguart, Noemí -AU - Reguart N -AD - Department of Medical Oncology, Hospital Clinic, Barcelona, Spain. -FAU - Zugazagoitia, Jon -AU - Zugazagoitia J -AD - Department of Medical Oncology, Tumor Microenvironment and Immunotherapy Research - Group, Hospital Universitario 12 de Octubre, Madrid, Health Research Institute - Hospital Universitario 12 de Octubre (i+12), H12O-CNIO Lung Cancer Clinical - Research Unit, Health Research Institute, CIBERONC, Madrid, Spain. -FAU - Dómine, Manuel -AU - Dómine M -AD - Department of Medical Oncology. Hospital, Universitario Fundación Jiménez Díaz, - IIS-FJD, Oncohealth Institute, Universidad Autónoma de Madrid, Madrid, Spain. -LA - eng -PT - Journal Article -DEP - 20230707 -PL - Italy -TA - Clin Transl Oncol -JT - Clinical & translational oncology : official publication of the Federation of - Spanish Oncology Societies and of the National Cancer Institute of Mexico -JID - 101247119 -RN - 6PLQ3CP4P3 (Etoposide) -RN - 49DFR088MY (Platinum) -SB - IM -EIN - Clin Transl Oncol. 2023 Sep;25(9):2760-2762. doi: 10.1007/s12094-023-03290-7. - PMID: 37556098 -MH - Humans -MH - Etoposide/therapeutic use -MH - Platinum/therapeutic use -MH - Follow-Up Studies -MH - *Small Cell Lung Carcinoma/therapy/drug therapy -MH - *Lung Neoplasms/therapy/drug therapy -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -PMC - PMC10425483 -OTO - NOTNLM -OT - Clinical practice guidelines -OT - Diagnosis -OT - Follow-up -OT - Small-cell lung cancer -OT - Treatment -COIS- RGC reports Advisory boards, Consultancy and Speaker honoraria from MSD, BMS, - Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takea and - Amgen. IS reports Advisory Board from Roche, Novartis, Boehringer Ingelheim, - Takeda and Sanofi; Speaker from Roche, MSD, Pfizer, BMS and AstraZeneca; Grant - from Roche, Takeda, Pfizer, BMS and AstraZeneca; Non-financial Support from - Member of GECP. EA reports Advisory Board, Speakerand Grant from Roche; Advisory - Board and Speaker from Astra Zeneca and BMS; Advisory Board, Speaker and - Non-financial Support from Takeda; Advisory Board from Lilly and - Boehringer-Ingelheim; Speaker from MSD, Merck, Thermo Fisher Scientific and - Guardant Health; Speaker and- Non-financial Support from Pfizer. AI reports - Advisory Board and Speaker from Roche, AstraZeneca and Sanofi; Speaker from - Takeda and BMS. OJJV reports Advisory Board and Speaker from BMS and Janssen; - Speker from Roche; Advisory Board, Speaker and Other from AstraZeneca, Takeda and - Janssen; Advisory Board from Lilly. NR reports Advisory Board, Speaker and- Other - from MSD; Advisory Board and Speaker from AstraZeneca, Takeda, Amgen, Lilly, - Sanofi, Roche and Janssen. JZ reports Speaker, Grant and Personal Feels from BMS - and AstraZencea; Advisory Board and Personal Feels from Sanofi; Speaker from MSD; - Grant and Personal Feels from Roche; Speaker and Personal Feels from Pfizer; - Advisory Board from Novartis and Speaker from NanoString. MD reports Advisory - Board and Speaker from AatraZeneca, Pfizer and Takeda; Speaker from BMS, MSD and - Roche; Advisory Board from Janssen and Sanofi. TM and PCC have nothing to - disclose. -EDAT- 2023/07/07 13:05 -MHDA- 2023/08/17 06:43 -PMCR- 2023/07/07 -CRDT- 2023/07/07 11:14 -PHST- 2023/05/08 00:00 [received] -PHST- 2023/05/09 00:00 [accepted] -PHST- 2023/08/17 06:43 [medline] -PHST- 2023/07/07 13:05 [pubmed] -PHST- 2023/07/07 11:14 [entrez] -PHST- 2023/07/07 00:00 [pmc-release] -AID - 10.1007/s12094-023-03216-3 [pii] -AID - 3216 [pii] -AID - 10.1007/s12094-023-03216-3 [doi] -PST - ppublish -SO - Clin Transl Oncol. 2023 Sep;25(9):2679-2691. doi: 10.1007/s12094-023-03216-3. - Epub 2023 Jul 7. - -PMID- 35838638 -OWN - NLM -STAT- MEDLINE -DCOM- 20220913 -LR - 20221015 -IS - 1744-8328 (Electronic) -IS - 1473-7140 (Linking) -VI - 22 -IP - 9 -DP - 2022 Sep -TI - Clinically-meaningful improvements in therapy for unresectable NSCLC. -PG - 927-937 -LID - 10.1080/14737140.2022.2102483 [doi] -AB - INTRODUCTION: The ideal management of patients with unresectable non-small-cell - lung cancer (NSCLC) is still developing. Unresectable NSCLC has a high mortality - rate and poor prognosis. The development of immune checkpoint inhibitors (ICIs) - and molecular-targeted therapies has been a breakthrough in the treatment. The - correct treatment of this patient population is crucial to maximize the clinical - benefits without compromising quality of life (QOL). AREAS COVERED: We review the - chemoradiotherapies, cytotoxic chemotherapies, immunotherapies, and - molecular-targeted therapies available for unresectable NSCLC, focusing on their - effects on overall survival, progression-free survival, and QOL. EXPERT OPINION: - Although cure is the ultimate goal of cancer treatment, it is often difficult to - achieve in advanced NSCLC. Biomarker surveillance techniques, such as - next-generation sequencing, have made it possible to provide the most appropriate - treatment for each patient. This has led to clinically-meaningful improvements in - therapies for unresectable NSCLC. The development of new molecular-targeted - therapies and the establishment of treatment for patients who acquired drug - resistance after initial treatment have a positive impact on patients' long-term - survival. ICIs lead the long-term survival that can be considered a cure of some - patients with advanced NSCLC, but such curative survival is difficult to achieve - with cytotoxic chemotherapies and molecular-targeted therapies. -FAU - Katakura, Seigo -AU - Katakura S -AD - Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan. -FAU - Murakami, Shuji -AU - Murakami S -AUID- ORCID: 0000-0001-5104-5493 -AD - Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan. -LA - eng -PT - Journal Article -PT - Review -DEP - 20220722 -PL - England -TA - Expert Rev Anticancer Ther -JT - Expert review of anticancer therapy -JID - 101123358 -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immunotherapy/methods -MH - *Lung Neoplasms/drug therapy -MH - Molecular Targeted Therapy -MH - Quality of Life -OTO - NOTNLM -OT - Chemoradiotherapy -OT - Molecular-targeted therapy -OT - Non-small-cell lung cancer -OT - cytotoxic chemotherapy -OT - immunotherapy -OT - quality of life -EDAT- 2022/07/16 06:00 -MHDA- 2022/09/14 06:00 -CRDT- 2022/07/15 11:03 -PHST- 2022/07/16 06:00 [pubmed] -PHST- 2022/09/14 06:00 [medline] -PHST- 2022/07/15 11:03 [entrez] -AID - 10.1080/14737140.2022.2102483 [doi] -PST - ppublish -SO - Expert Rev Anticancer Ther. 2022 Sep;22(9):927-937. doi: - 10.1080/14737140.2022.2102483. Epub 2022 Jul 22. - -PMID- 34154332 -OWN - NLM -STAT- MEDLINE -DCOM- 20211206 -LR - 20211214 -IS - 1802-5307 (Electronic) -IS - 0862-495X (Linking) -VI - 34 -IP - Supplementum 1 -DP - 2021 Spring -TI - Advances in the therapy of small cell lung cancer. -PG - 66-70 -LID - 10.48095/ccko2021S66 [doi] -AB - Small cell lung cancer represents a disease with poor prognosis. Despite rapid - progress in the fields of medical or radiation oncology, the treatment strategy - of the small cell lung cancer has remained almost unchanged for over the last 30 - years. Prophylactic cranial irradiation and irradiation of the primary lung tumor - according to CREST clinical trial improved the median overall survival in months. - Until the launch on immunotherapy, the systemic treatment didnt make significant - progress, unfortunately including targeted therapy. Immunotherapy significantly - changed the treatment outcomes of the several tumor types and finally even the - prognosis of small cell lung cancer. Clinical trials with atezolizumab and - durvalumab have further moved forward the median overall survival by more than 2 - months without significant increase in the treatment toxicity and worsening of - the patients quality of life. In the combination with chemotherapy, atezolizumab - and durvalumab represents a new gold standard in the treatment of small cell lung - cancer. -FAU - Vrána, D -AU - Vrána D -LA - eng -PT - Journal Article -PT - Review -TT - Pokroky v léčbě malobuněčného karcinomu plic. -PL - Czech Republic -TA - Klin Onkol -JT - Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti -JID - 9425213 -SB - IM -MH - Combined Modality Therapy -MH - Humans -MH - Lung Neoplasms/pathology/*therapy -MH - Small Cell Lung Carcinoma/pathology/*therapy -OTO - NOTNLM -OT - Chemotherapy -OT - chemother­apy -OT - immunotherapy -OT - immunother­apy -OT - lung cancer -EDAT- 2021/06/23 06:00 -MHDA- 2021/12/15 06:00 -CRDT- 2021/06/22 05:28 -PHST- 2021/06/22 05:28 [entrez] -PHST- 2021/06/23 06:00 [pubmed] -PHST- 2021/12/15 06:00 [medline] -AID - 127168 [pii] -AID - 10.48095/ccko2021S66 [doi] -PST - ppublish -SO - Klin Onkol. 2021 Spring;34(Supplementum 1):66-70. doi: 10.48095/ccko2021S66. - -PMID- 30100047 -OWN - NLM -STAT- MEDLINE -DCOM- 20181029 -LR - 20211204 -IS - 1769-6917 (Electronic) -IS - 0007-4551 (Linking) -VI - 105 -IP - 10 -DP - 2018 Oct -TI - [Medical treatment of small cell lung cancer: Can we leave the area of - cisplatin-etoposide?]. -PG - 955-966 -LID - S0007-4551(18)30187-5 [pii] -LID - 10.1016/j.bulcan.2018.05.014 [doi] -AB - Small cell lung cancer accounts for 14% of all lung cancers. It remains a major - challenge for oncology as the progresses made in the past three decades are - modest. After a rapid overview of current knowledge regarding somatic genomic - alterations, this state-of-art addresses pathways to improve small-cell lung - cancer outcome such as the targeting of DNA damage repair mechanisms firstly - anti-PARPs, inhibitory molecules of EZH2, derepression of the NOTCH pathway, - rovalbituzumab-tesirine, inhibition of serine/threonine Aurora A kinase, - temozolomide and its dependence on methylation of the MGMT promoter. This first - chapter suggests the beginning of precision medicine in small cell lung cancer. - The last section focuses on the development of immuno-oncological agents and the - information collected from phase 1 and 2 studies: the low intensity of PD-L1 - tissue expression and the possible relationship of the activity of these agents - as a function of tumor mutational burden are pointed out. -CI - Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. - All rights reserved. -FAU - Pujol, Jean-Louis -AU - Pujol JL -AD - Hôpital Arnaud-de-Villeneuve, service des maladies respiratoires, unité - d'oncologie thoracique, avenue du Doyen-Giraud, 34295 Montpellier cedex, France. - Electronic address: jl-pujol@chu-montpellier.fr. -FAU - Roch, Benoît -AU - Roch B -AD - Hôpital Arnaud-de-Villeneuve, service des maladies respiratoires, unité - d'oncologie thoracique, avenue du Doyen-Giraud, 34295 Montpellier cedex, France. -FAU - Pujol, Camille N -AU - Pujol CN -AD - Institut de génomique fonctionnelle, Inserm U-661, CNRS UMR-5203, 34094 - Montpellier, France. -FAU - Goze, Catherine -AU - Goze C -AD - Laboratoire de biologie cellulaire, hôpital Arnaud-de-Villeneuve, unité - d'oncologie thoracique, avenue du Doyen-Giraud, 34295 Montpellier cedex, France. -LA - fre -PT - Journal Article -PT - Review -TT - Traitement médical du cancer bronchique à petites cellules : peut-on sortir de - l’aire du cisplatine–étoposide ? -DEP - 20180809 -PL - France -TA - Bull Cancer -JT - Bulletin du cancer -JID - 0072416 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents) -RN - 0 (Benzodiazepinones) -RN - 0 (Immunoconjugates) -RN - 0 (Poly(ADP-ribose) Polymerase Inhibitors) -RN - 0 (Receptors, Notch) -RN - 0 (Tumor Suppressor Proteins) -RN - 0 (rovalpituzumab tesirine) -RN - 7GR28W0FJI (Dacarbazine) -RN - EC 2.1.1.- (DNA Modification Methylases) -RN - EC 2.1.1.43 (EZH2 protein, human) -RN - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein) -RN - EC 2.1.1.63 (MGMT protein, human) -RN - EC 2.7.11.1 (Aurora Kinase A) -RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) -RN - EC 6.5.1.- (DNA Repair Enzymes) -RN - YF1K15M17Y (Temozolomide) -SB - IM -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - Antineoplastic Agents/*therapeutic use -MH - Aurora Kinase A/antagonists & inhibitors -MH - Benzodiazepinones/therapeutic use -MH - DNA Damage -MH - DNA Modification Methylases/metabolism -MH - DNA Repair -MH - DNA Repair Enzymes/metabolism -MH - Dacarbazine/analogs & derivatives/therapeutic use -MH - Enhancer of Zeste Homolog 2 Protein/antagonists & inhibitors -MH - Humans -MH - Immunoconjugates/therapeutic use -MH - Lung Neoplasms/*drug therapy/genetics/pathology -MH - Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use -MH - Protein Serine-Threonine Kinases/antagonists & inhibitors -MH - Receptors, Notch/metabolism -MH - Small Cell Lung Carcinoma/*drug therapy/genetics/pathology -MH - Temozolomide -MH - Tumor Suppressor Proteins/metabolism -OTO - NOTNLM -OT - Alisertib -OT - Anti-PARP -OT - Atezolizumab -OT - Atézolizumab -OT - Aurora A -OT - C-myc -OT - Cancer du poumon à petites cellules -OT - EZH2 -OT - Extensive-disease -OT - Maladie étendue -OT - NOTCH -OT - Nivolumab -OT - P53 -OT - Pembrolizumab -OT - RB1 -OT - Rovalpituzumab–teserine -OT - Rovalpituzumab–tésirine -OT - SLNF-11 -OT - Small cell lung cancer -OT - Veliparib -OT - Véliparib -EDAT- 2018/08/14 06:00 -MHDA- 2018/10/30 06:00 -CRDT- 2018/08/14 06:00 -PHST- 2018/04/03 00:00 [received] -PHST- 2018/05/04 00:00 [revised] -PHST- 2018/05/16 00:00 [accepted] -PHST- 2018/08/14 06:00 [pubmed] -PHST- 2018/10/30 06:00 [medline] -PHST- 2018/08/14 06:00 [entrez] -AID - S0007-4551(18)30187-5 [pii] -AID - 10.1016/j.bulcan.2018.05.014 [doi] -PST - ppublish -SO - Bull Cancer. 2018 Oct;105(10):955-966. doi: 10.1016/j.bulcan.2018.05.014. Epub - 2018 Aug 9. - -PMID- 35902427 -OWN - NLM -STAT- MEDLINE -DCOM- 20220923 -LR - 20230202 -IS - 1437-2320 (Electronic) -IS - 0344-5607 (Print) -IS - 0344-5607 (Linking) -VI - 45 -IP - 5 -DP - 2022 Oct -TI - State of affairs regarding targeted pharmacological therapy of cancers - metastasized to the brain. -PG - 3119-3138 -LID - 10.1007/s10143-022-01839-8 [doi] -AB - In 1999 a visionary short article by The Wall Street Journal writers Robert - Langreth and Michael Waldholz popularized the new term "personalized medicine," - that is to say, the targeting of drugs to each unique genetic profile. From - today's perspective, targeted approaches have clearly found the widest use in the - antineoplastic domain. The current review was initiated to review the progress - that has been made regarding the treatment of patients with advanced cancer and - brain metastases. PubMed was searched for the terms brain metastasis, brain - metastases, or metastatic brain in the Title/Abstract. Selection was limited to - randomized controlled trial (RCT) and publication date January 2010 to February - 2022. Following visual review, 51 papers on metastatic lung cancer, 12 on - metastatic breast cancer, and 9 on malignant melanoma were retained and underwent - full analysis. Information was extracted from the papers giving specific numbers - for intracranial response rate and/or overall survival. Since most - pharmacological trials on advanced cancers excluded patients with brain - metastases and since hardly any information on adjuvant radiotherapy and - radiosurgery is available from the pharmacological trials, precise assessment of - the effect of targeted medication for the subgroups with brain metastases is - difficult. Some quantitative information regarding the success of targeted - pharmacological therapy is only available for patients with breast and lung - cancer and melanoma. Overall, targeted approaches approximately doubled the - lifespan in the subgroups of brain metastases from tumors with targetable surface - receptors such as anaplastic lymphoma kinase (ALK) fusion receptor in non-small - cell lung cancer or human epidermal growth factor receptor 2 (HER2)-positive - breast cancer. For these types, overall survival in the situation of brain - metastases is now more than a year. For receptor-negative lung cancer and - melanoma, introduction of immune checkpoint blockers brought a substantial - advance, although overall survival for melanoma metastasized to the brain appears - to remain in the range of 6 to 9 months. The outlook for small cell lung cancer - metastasized to the brain apparently remains poor. The introduction of targeted - therapy roughly doubled survival times of advanced cancers including those - metastasized to the brain, but so far, targeted therapy does not differ - essentially from chemotherapy, therefore also facing tumors developing escape - mechanisms. With the improved perspective of patients suffering from brain - metastases, it becomes important to further optimize treatment of this specific - patient group within the framework of randomized trials. -CI - © 2022. The Author(s). -FAU - Steiger, Hans-Jakob -AU - Steiger HJ -AD - Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland. - steiger@uni-duesseldorf.de. -AD - Klinik Für Neurochirurgie, Neurozentrum, Kantonsspital Aarau, Tellstr. 25, - CH-5001, Aarau, Switzerland. steiger@uni-duesseldorf.de. -AD - Department of Neurosurgery, University Hospital Düsseldorf, Düsseldorf, Germany. - steiger@uni-duesseldorf.de. -FAU - Vollmer, Kathrin -AU - Vollmer K -AD - Division of Oncology, Hematology and Transfusion Medicine, Kantonsspital Aarau, - Aarau, Switzerland. -FAU - Rogers, Susanne -AU - Rogers S -AD - Radio-Oncology-Centre KSA-KSB, Kantonsspital Aarau, Aarau, Switzerland. -FAU - Schwyzer, Lucia -AU - Schwyzer L -AD - Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland. -LA - eng -PT - Journal Article -PT - Review -DEP - 20220729 -PL - Germany -TA - Neurosurg Rev -JT - Neurosurgical review -JID - 7908181 -RN - 0 (Antineoplastic Agents) -RN - 0 (Immune Checkpoint Inhibitors) -RN - EC 2.7.10.1 (Anaplastic Lymphoma Kinase) -SB - IM -MH - Anaplastic Lymphoma Kinase/metabolism -MH - *Antineoplastic Agents/therapeutic use -MH - Brain/pathology -MH - *Brain Neoplasms/drug therapy/genetics -MH - *Breast Neoplasms/drug therapy/pathology -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - *Lung Neoplasms/chemically induced/drug therapy/pathology -MH - *Melanoma/drug therapy -PMC - PMC9492578 -OTO - NOTNLM -OT - Advanced cancer -OT - Brain metastasis -OT - Personalized therapy -OT - Targeted therapy -COIS- None of the authors declares any competing interests in context with the current - study. -EDAT- 2022/07/29 06:00 -MHDA- 2022/09/24 06:00 -PMCR- 2022/07/29 -CRDT- 2022/07/28 23:14 -PHST- 2022/05/19 00:00 [received] -PHST- 2022/07/20 00:00 [accepted] -PHST- 2022/07/19 00:00 [revised] -PHST- 2022/07/29 06:00 [pubmed] -PHST- 2022/09/24 06:00 [medline] -PHST- 2022/07/28 23:14 [entrez] -PHST- 2022/07/29 00:00 [pmc-release] -AID - 10.1007/s10143-022-01839-8 [pii] -AID - 1839 [pii] -AID - 10.1007/s10143-022-01839-8 [doi] -PST - ppublish -SO - Neurosurg Rev. 2022 Oct;45(5):3119-3138. doi: 10.1007/s10143-022-01839-8. Epub - 2022 Jul 29. - -PMID- 27729297 -OWN - NLM -STAT- MEDLINE -DCOM- 20171121 -LR - 20220331 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 12 -IP - 2 -DP - 2017 Feb -TI - The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic - Treatment of Advanced NSCLC. -PG - 194-207 -LID - S1556-0864(16)31142-X [pii] -LID - 10.1016/j.jtho.2016.10.003 [doi] -AB - Over the past few years, there have been considerable advances in the treatments - available to patients with metastatic or locally advanced NSCLC, particularly - those who have progressed during first-line treatment. Some of the treatment - options available to patients are discussed here, with a focus on checkpoint - inhibitor immunotherapies (nivolumab and pembrolizumab) and antiangiogenic agents - (bevacizumab, ramucirumab, and nintedanib). It is hypothesized that combining - immunotherapy with antiangiogenic treatment may have a synergistic effect and - enhance the efficacy of both treatments. In this review, we explore the theory - and potential of this novel treatment option for patients with advanced NSCLC. We - discuss the growing body of evidence that proangiogenic factors can modulate the - immune response (both by reducing T-cell infiltration into the tumor - microenvironment and through systemic effects on immune-regulatory cell - function), and we examine the preclinical evidence for combining these - treatments. Potential challenges are also considered, and we review the - preliminary evidence of clinical efficacy and safety with this novel combination - in a variety of solid tumor types. -CI - Copyright © 2016 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Manegold, Christian -AU - Manegold C -AD - Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. - Electronic address: prof.manegold@t-online.de. -FAU - Dingemans, Anne-Marie C -AU - Dingemans AC -AD - Department of Pulmonary Diseases, GROW-School for Oncology and Developmental - Biology, Maastricht University Medical Centre, Maastricht, The Netherlands. -FAU - Gray, Jhanelle E -AU - Gray JE -AD - Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, Florida. -FAU - Nakagawa, Kazuhiko -AU - Nakagawa K -AD - Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, - Japan. -FAU - Nicolson, Marianne -AU - Nicolson M -AD - Oncology Department, Aberdeen Royal Infirmary, Aberdeen, United Kingdom. -FAU - Peters, Solange -AU - Peters S -AD - Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), - Lausanne, Switzerland. -FAU - Reck, Martin -AU - Reck M -AD - Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research - Center North, Grosshansdorf, Germany. -FAU - Wu, Yi-Long -AU - Wu YL -AD - Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy - of Medical Sciences, Guangzhou, People's Republic of China. -FAU - Brustugun, Odd Terje -AU - Brustugun OT -AD - Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, - Oslo, Norway. -FAU - Crinò, Lucio -AU - Crinò L -AD - Medical Oncology Department, Perugia University Medical School, Perugia, Italy. -FAU - Felip, Enriqueta -AU - Felip E -AD - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, - Barcelona, Spain. -FAU - Fennell, Dean -AU - Fennell D -AD - Department of Oncology, University of Leicester and Leicester University - Hospitals, Leicester, United Kingdom. -FAU - Garrido, Pilar -AU - Garrido P -AD - Servicio de Oncología Médica, IRYCIS Hospital Universitario Ramón y Cajal, - Madrid, Spain. -FAU - Huber, Rudolf M -AU - Huber RM -AD - Ludwig-Maximilians-Universität München, University Hospital, Division of - Respiratory Medicine and Thoracic Oncology, Münich, Germany. -FAU - Marabelle, Aurélien -AU - Marabelle A -AD - Gustave Roussy, Université Paris-Saclay, Département d'Innovation Thérapeutique - et d'Essais Précoces, INSERM U1015, Villejuif, France. -FAU - Moniuszko, Marcin -AU - Moniuszko M -AD - Department of Regenerative Medicine and Immune Regulation, Medical University of - Bialystok, Bialystok, Poland. -FAU - Mornex, Françoise -AU - Mornex F -AD - Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Université Claude - Bernard, Lyon, France. -FAU - Novello, Silvia -AU - Novello S -AD - Department of Oncology, University of Turin, Turin, Italy. -FAU - Papotti, Mauro -AU - Papotti M -AD - Department of Oncology, University of Turin, Turin, Italy. -FAU - Pérol, Maurice -AU - Pérol M -AD - Département de Cancérologie, Médicale Centre Léon Bérard, Lyon, France. -FAU - Smit, Egbert F -AU - Smit EF -AD - Department of Pulmonary Diseases and Department of Thoracic Oncology, VU - University Medical Centre, Netherlands Cancer Institute, Amsterdam, The - Netherlands. -FAU - Syrigos, Kostas -AU - Syrigos K -AD - Oncology Unit GPP, Sotiria General Hospital, Athens University School of - Medicine, Athens, Greece. -FAU - van Meerbeeck, Jan P -AU - van Meerbeeck JP -AD - Thoracic Oncology, Antwerp University Hospital and Ghent University, Edegem, - Belgium. -FAU - van Zandwijk, Nico -AU - van Zandwijk N -AD - Asbestos Diseases Research Institute, University of Sydney, New South Wales, - Australia. -FAU - Yang, James Chih-Hsin -AU - Yang JC -AD - Department of Oncology, National Taiwan University Hospital and National Taiwan - University Cancer Center, Taipei, Taiwan. -FAU - Zhou, Caicun -AU - Zhou C -AD - Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, People's Republic - of China. -FAU - Vokes, Everett -AU - Vokes E -AD - Department of Medicine, University of Chicago Medical Center, Chicago, Illinois. -LA - eng -PT - Journal Article -PT - Review -DEP - 20161008 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Angiogenesis Inhibitors) -SB - IM -MH - Angiogenesis Inhibitors/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/blood supply/*drug therapy/immunology/pathology -MH - Humans -MH - *Immunotherapy -MH - Lung Neoplasms/blood supply/*drug therapy/immunology/pathology -OTO - NOTNLM -OT - Antiangiogenesis -OT - Combination therapy -OT - Immunotherapy -OT - NSCLC -EDAT- 2016/10/13 06:00 -MHDA- 2017/11/29 06:00 -CRDT- 2016/10/13 06:00 -PHST- 2016/08/04 00:00 [received] -PHST- 2016/09/30 00:00 [revised] -PHST- 2016/10/02 00:00 [accepted] -PHST- 2016/10/13 06:00 [pubmed] -PHST- 2017/11/29 06:00 [medline] -PHST- 2016/10/13 06:00 [entrez] -AID - S1556-0864(16)31142-X [pii] -AID - 10.1016/j.jtho.2016.10.003 [doi] -PST - ppublish -SO - J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub - 2016 Oct 8. - -PMID- 26233240 -OWN - NLM -STAT- MEDLINE -DCOM- 20160722 -LR - 20181113 -IS - 1534-6277 (Electronic) -IS - 1534-6277 (Linking) -VI - 16 -IP - 10 -DP - 2015 Oct -TI - Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and - Duration. -PG - 47 -LID - 10.1007/s11864-015-0364-2 [doi] -AB - Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related - mortality in the USA. The treatment of locally advanced NSCLC (LA-NSCLC) is - challenging and must be individualized. For patients with completely resected - stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4 cycles is - recommended. For patients with inoperable or unresectable stage III NSCLC, - chemoradiation is the preferred treatment. Patients with a good performance - status, minimal or no weight loss, and adequate pulmonary function should be - offered concurrent chemoradiation. The optimal chemotherapeutic agents to be used - concurrently with radiation remain undefined. In the USA, cisplatin plus - etoposide or carboplatin plus paclitaxel are the most commonly used regimens. In - addition, the optimal duration of therapy remains undefined, including the role - of consolidation chemotherapy. Thus far, randomized phase III trials have failed - to identify a survival advantage for administering chemotherapy beyond that - delivered during radiation therapy. Molecularly targeted agents, angiogenesis - inhibitors, and immunotherapy have a defined role for patients with metastatic - disease. The role, if any, of these new classes of agents is undergoing - investigation for patients with earlier stage disease, including stage III - disease. -FAU - Mamdani, Hirva -AU - Mamdani H -AD - Hematology/Oncology, Indiana University Melvin and Bren Simon Cancer Center, 535, - Barnhill Dr, Ste 418, Indianapolis, IN, 46202, USA, hmamdani@iu.edu. -FAU - Jalal, Shadia I -AU - Jalal SI -FAU - Hanna, Nasser -AU - Hanna N -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - United States -TA - Curr Treat Options Oncol -JT - Current treatment options in oncology -JID - 100900946 -RN - 0 (Antineoplastic Agents) -RN - 6PLQ3CP4P3 (Etoposide) -RN - BG3F62OND5 (Carboplatin) -RN - P88XT4IS4D (Paclitaxel) -RN - Q20Q21Q62J (Cisplatin) -RN - VP-P protocol -SB - IM -MH - Antineoplastic Agents/*administration & dosage -MH - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage -MH - Carboplatin/*administration & dosage -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Chemotherapy, Adjuvant -MH - Cisplatin/administration & dosage -MH - Etoposide/administration & dosage -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology -MH - Paclitaxel/*administration & dosage -MH - Patient Selection -MH - Precision Medicine -MH - Radiotherapy, Adjuvant -MH - Risk Factors -EDAT- 2015/08/04 06:00 -MHDA- 2016/07/23 06:00 -CRDT- 2015/08/03 06:00 -PHST- 2015/08/03 06:00 [entrez] -PHST- 2015/08/04 06:00 [pubmed] -PHST- 2016/07/23 06:00 [medline] -AID - 10.1007/s11864-015-0364-2 [doi] -PST - ppublish -SO - Curr Treat Options Oncol. 2015 Oct;16(10):47. doi: 10.1007/s11864-015-0364-2. - -PMID- 30121715 -OWN - NLM -STAT- MEDLINE -DCOM- 20190916 -LR - 20220408 -IS - 1534-6293 (Electronic) -IS - 1528-4042 (Linking) -VI - 18 -IP - 10 -DP - 2018 Aug 18 -TI - Management of Brain Metastases in the New Era of Checkpoint Inhibition. -PG - 70 -LID - 10.1007/s11910-018-0877-8 [doi] -AB - PURPOSE OF THE REVIEW: Brain metastasis is a common complication of advanced - malignancies, especially, lung cancer, breast cancer, renal cell carcinoma, and - melanoma. Traditionally surgery, when indicated, and radiation therapy, either as - whole-brain radiation therapy or stereotactic radiosurgery, constituted the major - treatment options for brain metastases. Until recently, most of the systemic - chemotherapy agents had limited activity for brain metastases. However, with the - advent of small molecule tyrosine kinase inhibitors and immunotherapy agents, - there has been renewed interest in using these agents in the management of brain - metastases. RECENT FINDINGS: Immune checkpoint inhibitors have revolutionized the - treatment of metastatic melanoma, lung cancer, kidney cancer, and bladder cancer - among others. They modulate the immune system to recognize tumor antigens as - "non-self" antigens and mount an immune response against them. Initial studies of - using immune checkpoint inhibitors in brain metastases have shown promising - activity, and several clinical trials are currently underway. Studies are also - assessing the combination of radiation therapy and immunotherapy in brain - metastases. The results of these ongoing clinical trials have the potential to - change the therapeutic paradigm in patients with brain metastases. -FAU - Lauko, Adam -AU - Lauko A -AD - Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, - Cleveland Clinic, 9500 Euclid Ave, S73, Cleveland, OH, 44195, USA. -FAU - Thapa, Bicky -AU - Thapa B -AD - Fairview Hospital-Cleveland Clinic, Cleveland, OH, USA. -FAU - Venur, Vyshak Alva -AU - Venur VA -AD - University of Iowa Hospitals and Clinics, Iowa City, IA, USA. -FAU - Ahluwalia, Manmeet S -AU - Ahluwalia MS -AD - Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, - Cleveland Clinic, 9500 Euclid Ave, S73, Cleveland, OH, 44195, USA. - ahluwam@ccf.org. -LA - eng -PT - Journal Article -PT - Review -DEP - 20180818 -PL - United States -TA - Curr Neurol Neurosci Rep -JT - Current neurology and neuroscience reports -JID - 100931790 -SB - IM -MH - Brain Neoplasms/*drug therapy -MH - Cranial Irradiation -MH - Humans -MH - Immunotherapy/*methods -MH - Melanoma -MH - Radiosurgery/methods -OTO - NOTNLM -OT - Brain metastases -OT - Checkpoint inhibitors -OT - Immunotherapy -OT - Ipilimumab -OT - Nivolumab -OT - Pembrolizumab -EDAT- 2018/08/20 06:00 -MHDA- 2019/09/17 06:00 -CRDT- 2018/08/20 06:00 -PHST- 2018/08/20 06:00 [entrez] -PHST- 2018/08/20 06:00 [pubmed] -PHST- 2019/09/17 06:00 [medline] -AID - 10.1007/s11910-018-0877-8 [pii] -AID - 10.1007/s11910-018-0877-8 [doi] -PST - epublish -SO - Curr Neurol Neurosci Rep. 2018 Aug 18;18(10):70. doi: 10.1007/s11910-018-0877-8. - -PMID- 30725206 -OWN - NLM -STAT- MEDLINE -DCOM- 20190328 -LR - 20240426 -IS - 1432-0851 (Electronic) -IS - 0340-7004 (Print) -IS - 0340-7004 (Linking) -VI - 68 -IP - 3 -DP - 2019 Mar -TI - Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights - from long-term survivors. -PG - 341-352 -LID - 10.1007/s00262-019-02310-2 [doi] -AB - Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 - (PD-1)-programmed cell death ligand-1 (PD-L1) axis have shown promising results - in non-small cell lung cancer (NSCLC) patients, some of them with persistent - responses to these agents that form a population of long-term survivors. Despite - the variable definition of PD-L1 positivity in tumors, an association between - expression and response has been reasonably consistent in advanced NSCLC. In - addition, the clinical efficacy of ICIs seems to be related to the genomic - landscape of the tumor in terms of mutational burden and clonal neoantigens. - Furthermore, increasing evidence shows that excessive activation of the immune - response elicited by ICIs, leading to immune-related toxicities, might be - associated with an improved response to immunotherapy. There are still many - unanswered questions about the proper use of these agents to maximize their - efficacy, which may be improved through combination with radiation, chemotherapy, - targeted therapies, or other immune mediators, including dual checkpoint - blockade. To search for clues for addressing these challenges, this review - focused on the characteristics and clinical features of long-term NSCLC survivors - and the potential biomarkers of response to ICIs. -FAU - Nadal, Ernest -AU - Nadal E -AUID- ORCID: 0000-0002-9674-5554 -AD - Department of Medical Oncology, Catalan Institute of Oncology (ICO), Avda Gran - via, 199-203. L'Hospitalet, 08908, Barcelona, Spain. esnadal@iconcologia.net. -AD - Clinical Research in Solid Tumors (CReST) Group, OncoBell Program, IDIBELL, - L'Hospitalet, Barcelona, Spain. esnadal@iconcologia.net. -FAU - Massuti, Bartomeu -AU - Massuti B -AD - Department of Medical Oncology, Hospital Universitario de Alicante, ISABIAL, - Alicante, Spain. -FAU - Dómine, Manuel -AU - Dómine M -AD - Department of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, - Oncohealth Institute, Universidad Autónoma de Madrid, Madrid, Spain. -FAU - García-Campelo, Rosario -AU - García-Campelo R -AD - Department of Medical Oncology, A Coruña University Hospital, A Coruña, Spain. -FAU - Cobo, Manuel -AU - Cobo M -AD - Medical Oncology Department, Hospital Universitario Málaga Regional y Virgen de - la Victoria, IBIMA, Málaga, Spain. -FAU - Felip, Enriqueta -AU - Felip E -AD - Lung Cancer Unit, Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute - of Oncology (VHIO), Barcelona, Spain. -LA - eng -PT - Journal Article -PT - Review -DEP - 20190206 -PL - Germany -TA - Cancer Immunol Immunother -JT - Cancer immunology, immunotherapy : CII -JID - 8605732 -RN - 0 (B7-H1 Antigen) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - B7-H1 Antigen/analysis/*antagonists & inhibitors -MH - Cancer Survivors -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/mortality -MH - Humans -MH - Immunohistochemistry -MH - Immunotherapy -MH - Lung Neoplasms/*drug therapy/immunology/mortality -MH - Nivolumab/adverse effects/therapeutic use -PMC - PMC11028247 -OTO - NOTNLM -OT - Biomarker -OT - Immune checkpoint inhibitors -OT - Immunotherapy -OT - Long-term survival -OT - Non-small cell lung cancer -OT - PD-L1 -COIS- Ernest Nadal has received honoraria for participating in advisory boards and - speaking honorarium from Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, - Pfizer, Takeda, Boehringer Ingelheim and AstraZeneca. Bartomeu Massuti has - received honoraria for participation in advisory boards and speaking from Amgen, - AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Serono, Merck - Sharp & Dohme, Pfizer, and Roche. Manuel Dómine declares that he has no conflict - of interest. Rosario García-Campelo has received honoraria for participation in - advisory boards and speaking from AstraZeneca, Bristol-Myers Squibb, Boehringer - Ingelheim, Merck Sharp & Dohme, Novartis, Pfizer, Roche/Genentech, and Takeda. - Manuel Cobo has received speaker honorarium from AstraZeneca, Bristol-Myers - Squibb, Merck Sharp & Dohme, and Roche. Enriqueta Felip has received honoraria - for participation in advisory boards and speaking from AstraZeneca, Boehringer - Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, GuardantHealth, Merck Sharp - & Dohme, Novartis, Pfizer, Roche, and Takeda. -EDAT- 2019/02/07 06:00 -MHDA- 2019/03/29 06:00 -PMCR- 2019/02/06 -CRDT- 2019/02/07 06:00 -PHST- 2018/05/03 00:00 [received] -PHST- 2019/01/25 00:00 [accepted] -PHST- 2019/02/07 06:00 [pubmed] -PHST- 2019/03/29 06:00 [medline] -PHST- 2019/02/07 06:00 [entrez] -PHST- 2019/02/06 00:00 [pmc-release] -AID - 10.1007/s00262-019-02310-2 [pii] -AID - 2310 [pii] -AID - 10.1007/s00262-019-02310-2 [doi] -PST - ppublish -SO - Cancer Immunol Immunother. 2019 Mar;68(3):341-352. doi: - 10.1007/s00262-019-02310-2. Epub 2019 Feb 6. - -PMID- 33506253 -OWN - NLM -STAT- MEDLINE -DCOM- 20210325 -LR - 20210325 -IS - 1465-3621 (Electronic) -IS - 0368-2811 (Linking) -VI - 51 -IP - 3 -DP - 2021 Mar 3 -TI - Surgical challenges in multimodal treatment of N2-stage IIIA non-small cell lung - cancer. -PG - 333-344 -LID - 10.1093/jjco/hyaa249 [doi] -AB - Locally advanced non-small cell lung cancer, especially mediastinal lymph node - metastasis-positive stage IIIA-N2 cancer, is a heterogeneous disease state - characterized by anatomically locally advanced disease with latent - micrometastases. Thus, surgical resection or radiotherapy alone has historically - failed to cure this disease. During the last three decades, persistent efforts - have been made to develop a suitable treatment modality to overcome these - problems using chemotherapy and/or radiotherapy with surgical resection. However, - the role of surgical resection remains unclear, and the standard treatment for - stage IIIA-N2 disease is concurrent chemoradiotherapy. In general, adjuvant - chemotherapy is indicated for completely resected pathological stage IB disease - or lymph node metastasis-positive pathological stage II or IIIA disease. - Platinum-based doublet cytotoxic chemotherapy is currently the standard regimen. - Additionally, post-operative radiotherapy might be indicated for post-operatively - proven mediastinal lymph node metastasis; i.e. clinical N0-1 and pathological N2 - disease. With the remarkable progression that has recently been made in the field - of chemotherapy, such as advances in molecular targeting agents and immune - checkpoint inhibitors, the basic policy of chemotherapy has been shifting to - personalized treatment based on the individual patient's oncogene driver mutation - status, immune status and other parameters. The same trend is being seen in the - treatment of stage IIIA-N2 disease. We should consider the past and upcoming - results of several clinical trials to optimize the coming era of personalized - treatment. -CI - © The Author(s) 2021. Published by Oxford University Press. All rights reserved. - For permissions, please e-mail: journals.permission@oup.com. -FAU - Yamaguchi, Masafumi -AU - Yamaguchi M -AD - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer - Center, Fukuoka, Japan. -FAU - Nakagawa, Kazuo -AU - Nakagawa K -AD - Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan. -FAU - Suzuki, Kenji -AU - Suzuki K -AD - Department of General Thoracic Surgery, Juntendo University Hospital, Tokyo, - Japan. -FAU - Takamochi, Kazuya -AU - Takamochi K -AD - Department of General Thoracic Surgery, Juntendo University Hospital, Tokyo, - Japan. -FAU - Ito, Hiroyuki -AU - Ito H -AD - Department of Thoracic Surgery, Kanagawa Cancer Center, Kanagawa, Japan. -FAU - Okami, Jiro -AU - Okami J -AD - Department of General Thoracic Surgery, Osaka International Cancer Institute, - Osaka, Japan. -FAU - Aokage, Keiju -AU - Aokage K -AD - Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, - Japan. -FAU - Shiono, Satoshi -AU - Shiono S -AD - Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, Yamagata, - Japan. -FAU - Yoshioka, Hiroshige -AU - Yoshioka H -AD - Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, - Japan. -FAU - Aoki, Tadashi -AU - Aoki T -AD - Department of Thoracic Surgery, Niigata Cancer Center Hospital, Niigata, Japan. -FAU - Tsutani, Yasuhiro -AU - Tsutani Y -AD - Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan. -FAU - Okada, Morihito -AU - Okada M -AD - Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan. -FAU - Watanabe, Shun-Ichi -AU - Watanabe SI -AD - Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan. -CN - Lung Cancer Surgical Study Group (LCSSG) of the Japan Clinical Oncology Group - (JCOG) -LA - eng -PT - Journal Article -PT - Review -PL - England -TA - Jpn J Clin Oncol -JT - Japanese journal of clinical oncology -JID - 0313225 -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/*pathology/*surgery -MH - Clinical Trials, Phase III as Topic -MH - Combined Modality Therapy -MH - Humans -MH - Induction Chemotherapy -MH - Lung Neoplasms/drug therapy/*pathology/*surgery -MH - Neoplasm Staging -OTO - NOTNLM -OT - adjuvant treatment -OT - clinical stage IIIA -OT - induction treatment -OT - non-small cell lung cancer -EDAT- 2021/01/29 06:00 -MHDA- 2021/03/26 06:00 -CRDT- 2021/01/28 05:45 -PHST- 2020/08/27 00:00 [received] -PHST- 2020/11/24 00:00 [accepted] -PHST- 2021/01/29 06:00 [pubmed] -PHST- 2021/03/26 06:00 [medline] -PHST- 2021/01/28 05:45 [entrez] -AID - 6121627 [pii] -AID - 10.1093/jjco/hyaa249 [doi] -PST - ppublish -SO - Jpn J Clin Oncol. 2021 Mar 3;51(3):333-344. doi: 10.1093/jjco/hyaa249. - -PMID- 36534236 -OWN - NLM -STAT- MEDLINE -DCOM- 20230315 -LR - 20230315 -IS - 1573-4978 (Electronic) -IS - 0301-4851 (Linking) -VI - 50 -IP - 3 -DP - 2023 Mar -TI - Immunotherapeutics in lung cancers: from mechanistic insight to clinical - implications and synergistic perspectives. -PG - 2685-2700 -LID - 10.1007/s11033-022-08180-9 [doi] -AB - BACKGROUND: Lung cancer is one of the highly lethal forms of cancer whose - incidence has worldwide rapidly increased over the past few decades. About 80-85% - of all lung cancer cases constitute non-small cell lung cancer (NSCLC), with - adenocarcinoma, squamous cell carcinoma and large cell carcinoma as the main - subtypes. Immune checkpoint inhibitors have led to significant advances in the - treatment of a variety of solid tumors, significantly improving cancer patient - survival rates. METHODS AND RESULTS: The cytotoxic drugs in combination with - anti-PD-(L)1 antibodies is a new method that aims to reduce the activation of - immunosuppressive and cancer cell prosurvival responses while also improving - direct cancer cell death. The most commonly utilized immune checkpoint inhibitors - for patients with non-small cell lung cancer are monoclonal antibodies - (Atezolizumab, Cemiplimab, Ipilimumab, Pembrolizumab etc.) against PD-1, PD-L1, - and CTLA-4. Among them, Atezolizumab (TECENTRIQ) and Cemiplimab (Libtayo) are - engineered monoclonal anti programmed death ligand 1 (PD-L1) antibodies that - inhibit binding of PD-L1 to PD-1 and B7.1. As a result, T-cell proliferation and - cytokine synthesis are inhibited leading to restoring the immune homeostasis to - fight cancer cells. CONCLUSIONS: In this review article, the path leading to the - introduction of immunotherapeutic options in lung cancer treatment is described, - with analyzing the benefits and shortages of the current immunotherapeutic drugs. - In addition, possibilities to co-administer immunotherapeutic agents with - standard cancer treatment modalities are also considered. -CI - © 2022. The Author(s), under exclusive licence to Springer Nature B.V. -FAU - Tuli, Hardeep Singh -AU - Tuli HS -AUID- ORCID: 0000-0003-1155-0094 -AD - Department of Biotechnology, Maharishi Markandeshwar Engineering College, - Maharishi Markandeshwar (Deemed to Be University), Mullana- Ambala, Haryana, 133 - 207, India. hardeep.biotech@gmail.com. -FAU - Garg, Vivek K -AU - Garg VK -AD - Department of Medical Lab Technology, University Institute of Applied Health - Sciences, Chandigarh University, Gharuan, Mohali, Punjab, 140413, India. -FAU - Choudhary, Renuka -AU - Choudhary R -AD - Department of Biotechnology, Maharishi Markandeshwar Engineering College, - Maharishi Markandeshwar (Deemed to Be University), Mullana- Ambala, Haryana, 133 - 207, India. -FAU - Iqubal, Ashif -AU - Iqubal A -AD - Department of Pharmacology, School of Pharmaceutical Education and Research - (Formerly, Faculty of Pharmacy), Jamia Hamdard (Deemed to Be University), Delhi, - India. -FAU - Sak, Katrin -AU - Sak K -AD - NGO Praeventio, 50407, Tartu, Estonia. -FAU - Saini, Adesh K -AU - Saini AK -AD - Department of Biotechnology, Maharishi Markandeshwar Engineering College, - Maharishi Markandeshwar (Deemed to Be University), Mullana- Ambala, Haryana, 133 - 207, India. -FAU - Saini, Reena V -AU - Saini RV -AD - Department of Biotechnology, Maharishi Markandeshwar Engineering College, - Maharishi Markandeshwar (Deemed to Be University), Mullana- Ambala, Haryana, 133 - 207, India. -FAU - Vashishth, Kanupriya -AU - Vashishth K -AD - Advance Cardiac Centre Department of Cardiology, Post Graduate Institute of - Medical Education and Research (PGIMER), Chandigarh, 160012, India. -FAU - Dhama, Kuldeep -AU - Dhama K -AD - Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar - Pradesh, 243122, India. -FAU - Mohapatra, Ranjan K -AU - Mohapatra RK -AD - Department of Chemistry, Government College of Engineering, Keonjhar, Odisha, - 758002, India. -FAU - Gupta, Dhruv Sanjay -AU - Gupta DS -AD - Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's - NMIMS, Mumbai, Maharashtra, 40056, India. -FAU - Kaur, Ginpreet -AU - Kaur G -AD - Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's - NMIMS, Mumbai, Maharashtra, 40056, India. -LA - eng -PT - Journal Article -PT - Review -DEP - 20221219 -PL - Netherlands -TA - Mol Biol Rep -JT - Molecular biology reports -JID - 0403234 -RN - 0 (B7-H1 Antigen) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Humans -MH - *Lung Neoplasms/pathology -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - B7-H1 Antigen -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Programmed Cell Death 1 Receptor -MH - Immunotherapy/methods -OTO - NOTNLM -OT - Chemotherapeutics -OT - Clinical trials -OT - Immunotherapeutic -OT - Lung cancer -OT - Radiotherapy -EDAT- 2022/12/20 06:00 -MHDA- 2023/03/16 06:00 -CRDT- 2022/12/19 11:18 -PHST- 2022/10/04 00:00 [received] -PHST- 2022/12/06 00:00 [accepted] -PHST- 2022/12/20 06:00 [pubmed] -PHST- 2023/03/16 06:00 [medline] -PHST- 2022/12/19 11:18 [entrez] -AID - 10.1007/s11033-022-08180-9 [pii] -AID - 10.1007/s11033-022-08180-9 [doi] -PST - ppublish -SO - Mol Biol Rep. 2023 Mar;50(3):2685-2700. doi: 10.1007/s11033-022-08180-9. Epub - 2022 Dec 19. - -PMID- 37095669 -OWN - NLM -STAT- MEDLINE -DCOM- 20230925 -LR - 20240613 -IS - 1546-3141 (Electronic) -IS - 0361-803X (Print) -IS - 0361-803X (Linking) -VI - 221 -IP - 4 -DP - 2023 Oct -TI - Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer: AJR Expert Panel - Narrative Review. -PG - 409-424 -LID - 10.2214/AJR.23.29104 [doi] -AB - Lung cancer continues to be the most common cause of cancer-related death - worldwide. In the past decade, with the implementation of lung cancer screening - programs and advances in surgical and nonsurgical therapies, the survival of - patients with lung cancer has increased, as has the number of imaging studies - that these patients undergo. However, most patients with lung cancer do not - undergo surgical re-section, because they have comorbid disease or lung cancer in - an advanced stage at diagnosis. Nonsurgical therapies have continued to evolve - with a growing range of systemic and targeted therapies, and there has been an - associated evolution in the imaging findings encountered at follow-up - examinations after such therapies (e.g., with respect to posttreatment changes, - treatment complications, and recurrent tumor). This AJR Expert Panel Narrative - Review describes the current status of nonsurgical therapies for lung cancer and - their expected and unexpected imaging manifestations. The goal is to provide - guidance to radiologists regarding imaging assessment after such therapies, - focusing mainly on non-small cell lung cancer. Covered therapies include systemic - therapy (conventional chemotherapy, targeted therapy, and immunotherapy), - radiotherapy, and thermal ablation. -FAU - Murphy, David J -AU - Murphy DJ -AD - Department of Radiology, St Vincent's University Hospital and University College - Dublin, Dublin, Ireland. -FAU - Mayoral, Maria -AU - Mayoral M -AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. -AD - Medical Imaging Department, Hospital Clinic Barcelona, Barcelona, Spain. -FAU - Larici, Anna R -AU - Larici AR -AD - Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, - Fondazione Policlinico Universitario A. Gemelli, Rome, Italy. -AD - Department of Radiological and Hematological Sciences, Section of Radiology, - Università Cattolica del Sacro Cuore, Rome, Italy. -FAU - Ginsberg, Michelle S -AU - Ginsberg MS -AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. -FAU - Cicchetti, Giuseppe -AU - Cicchetti G -AD - Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, - Fondazione Policlinico Universitario A. Gemelli, Rome, Italy. -AD - Department of Radiological and Hematological Sciences, Section of Radiology, - Università Cattolica del Sacro Cuore, Rome, Italy. -FAU - Fintelmann, Florian J -AU - Fintelmann FJ -AD - Department of Radiology, Massachusetts General Hospital and Harvard Medical - School, Boston, MA. -FAU - Marom, Edith M -AU - Marom EM -AD - Chaim Sheba Medical Center, Ramat Gan, and Tel Aviv University, Tel Aviv, Israel. -FAU - Truong, Mylene T -AU - Truong MT -AD - Department of Thoracic Imaging, The University of Texas MD Anderson Cancer - Center, Houston, TX. -FAU - Gill, Ritu R -AU - Gill RR -AD - Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical - School, 330 Brookline Ave, Boston, MA 02115. -LA - eng -GR - P30 CA008748/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Review -DEP - 20230405 -PL - United States -TA - AJR Am J Roentgenol -JT - AJR. American journal of roentgenology -JID - 7708173 -SB - IM -MH - Humans -MH - *Lung Neoplasms/therapy/drug therapy -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy -MH - Follow-Up Studies -MH - Early Detection of Cancer -MH - Neoplasm Recurrence, Local -PMC - PMC11037936 -MID - NIHMS1980297 -OTO - NOTNLM -OT - RECIST -OT - ablation -OT - imaging follow-up -OT - lung cancer -OT - radiation therapy -OT - response assessment -OT - targeted therapy -EDAT- 2023/04/25 06:42 -MHDA- 2023/09/25 06:42 -PMCR- 2024/04/23 -CRDT- 2023/04/25 01:01 -PHST- 2023/09/25 06:42 [medline] -PHST- 2023/04/25 06:42 [pubmed] -PHST- 2023/04/25 01:01 [entrez] -PHST- 2024/04/23 00:00 [pmc-release] -AID - 10.2214/AJR.23.29104 [doi] -PST - ppublish -SO - AJR Am J Roentgenol. 2023 Oct;221(4):409-424. doi: 10.2214/AJR.23.29104. Epub - 2023 Apr 5. - -PMID- 36371941 -OWN - NLM -STAT- MEDLINE -DCOM- 20221216 -LR - 20221221 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 174 -DP - 2022 Dec -TI - Final efficacy outcomes of atezolizumab with chemoradiation for unresectable - NSCLC: The phase II DETERRED trial. -PG - 112-117 -LID - S0169-5002(22)00666-3 [pii] -LID - 10.1016/j.lungcan.2022.10.006 [doi] -AB - INTRODUCTION: The phase II DETERRED trial assessed the safety and efficacy of - consolidation and concurrent immunotherapy with chemoradiation in unresectable - locally advanced non-small cell lung cancer. We present updated efficacy analysis - of this trial. METHODS: The trial was conducted in 2 parts with patients in part - 1 (n = 10) receiving chemoradiation with consolidation atezolizumab, while - patients in part 2 (n = 30) received concurrent and consolidation atezolizumab. - Progression-free survival (PFS), time to second progression (PFS2), and overall - survival (OS) were assessed using Kaplan-Meier analysis. Subset analyses were - performed by programmed cell death ligand-1 (PD-L1) status and targetable driver - oncogene mutation status. RESULTS: At a median follow-up of 39.2 months, the - median PFS for part 1 was 18.9 months and 15.1 months for part 2. Median OS for - part 1 was 26.5 months and was not reached for part 2. For the cohort, 3-year OS - was 53.8%, while 4-year OS was 47.4%. Patients with targetable driver oncogene - mutations had a median PFS of 9.4 months and OS of not reached compared to - 16.6 months (HR: 3.49, p = 0.02) and 26.9 months (HR: 0.40, p = 0.12) - respectively compared to those without targetable driver oncogene mutations. - Patients with PD-L1 < 1% had median PFS of 11.0 months and OS of 26.5 months - compared to 27.4 months (HR: 2.01, p = 0.10) and not reached (HR: 1.49, p = 0.41) - respectively for those with PD-L1 ≥ 1%. CONCLUSIONS: In the DETERRED trial, - chemoradiation with concurrent and/or consolidative atezolizumab led to - comparable efficacy as consolidative durvalumab in the PACIFIC trial. The - presence of targetable driver oncogene mutations led to worse PFS, while - PD-L1 < 1% trended to worse PFS. -CI - Copyright © 2022 Elsevier B.V. All rights reserved. -FAU - Liu, Yufei -AU - Liu Y -AD - Departments of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, United States. -FAU - Yao, Luyang -AU - Yao L -AD - Departments of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, United States. -FAU - Kalhor, Neda -AU - Kalhor N -AD - Departments of Pathology, The University of Texas MD Anderson Cancer Center, - Houston, TX, United States. -FAU - Carter, Brett W -AU - Carter BW -AD - Departments of Diagnostic Radiology, The University of Texas MD Anderson Cancer - Center, Houston, TX, United States. -FAU - Altan, Mehmet -AU - Altan M -AD - Departments of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, United States. -FAU - Blumenschein, George -AU - Blumenschein G -AD - Departments of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, United States. -FAU - Byers, Lauren A -AU - Byers LA -AD - Departments of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, United States. -FAU - Fossella, Frank -AU - Fossella F -AD - Departments of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, United States. -FAU - Gibbons, Don L -AU - Gibbons DL -AD - Departments of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, United States. -FAU - Kurie, Jonathan M -AU - Kurie JM -AD - Departments of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, United States. -FAU - Lu, Charles -AU - Lu C -AD - Departments of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, United States. -FAU - Skoulidis, Ferdinandos -AU - Skoulidis F -AD - Departments of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, United States. -FAU - Chang, Joe Y -AU - Chang JY -AD - Departments of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, United States. -FAU - Liao, Zhongxing -AU - Liao Z -AD - Departments of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, United States. -FAU - Gomez, Daniel R -AU - Gomez DR -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, NY, United States. -FAU - O'Reilly, Michael -AU - O'Reilly M -AD - Departments of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, United States. -FAU - Heymach, John V -AU - Heymach JV -AD - Departments of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, United States. -FAU - Tsao, Anne S -AU - Tsao AS -AD - Departments of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, United States. -FAU - Lin, Steven H -AU - Lin SH -AD - Departments of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, United States. Electronic address: shlin@mdanderson.org. -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20221029 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy -MH - B7-H1 Antigen/genetics/metabolism -MH - *Lung Neoplasms/drug therapy/genetics -MH - Immunotherapy -MH - Chemoradiotherapy -OTO - NOTNLM -OT - Atezolizumab -OT - Driver mutations -OT - Immunotherapy -OT - Non-small cell lung cancer -OT - Radiation -OT - Targeted therapy -COIS- Declaration of Competing Interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2022/11/14 06:00 -MHDA- 2022/12/15 06:00 -CRDT- 2022/11/13 18:25 -PHST- 2022/08/22 00:00 [received] -PHST- 2022/10/13 00:00 [revised] -PHST- 2022/10/21 00:00 [accepted] -PHST- 2022/11/14 06:00 [pubmed] -PHST- 2022/12/15 06:00 [medline] -PHST- 2022/11/13 18:25 [entrez] -AID - S0169-5002(22)00666-3 [pii] -AID - 10.1016/j.lungcan.2022.10.006 [doi] -PST - ppublish -SO - Lung Cancer. 2022 Dec;174:112-117. doi: 10.1016/j.lungcan.2022.10.006. Epub 2022 - Oct 29. - -PMID- 38462413 -OWN - NLM -STAT- MEDLINE -DCOM- 20240516 -LR - 20240516 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 25 -IP - 3 -DP - 2024 May -TI - Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application - of Emerging Data and New Challenges. -PG - 197-214 -LID - S1525-7304(24)00015-9 [pii] -LID - 10.1016/j.cllc.2024.02.004 [doi] -AB - Immune checkpoint inhibition, with or without chemotherapy, is an established - standard of care for metastatic non-small cell lung cancer (NSCLC). For locally - advanced NSCLC treated with chemoradiotherapy, consolidation immunotherapy has - dramatically improved outcomes. Recently, immunotherapy has also been established - as a valuable component of treatment for resectable NSCLC with pembrolizumab, - atezolizumab, and nivolumab all approved for use in this setting. As more results - read out from ongoing perioperative clinical trials, navigating treatment options - will likely become increasingly complex for the practicing oncologist. In this - paper, we distill key outcomes from major perioperative trials and highlight - current knowledge gaps. In addition, we provide practical considerations for - incorporating perioperative immunotherapy into the clinical management of - operable NSCLC. -CI - Copyright © 2024 Elsevier Inc. All rights reserved. -FAU - D'Aiello, Angelica -AU - D'Aiello A -AD - Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert - Einstein College of Medicine, Bronx, NY. Electronic address: - adaiell@montefiore.org. -FAU - Stiles, Brendon -AU - Stiles B -AD - Division of Thoracic Surgery and Surgical Oncology, Montefiore Einstein - Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY. -FAU - Ohri, Nitin -AU - Ohri N -AD - Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer - Center, Albert Einstein College of Medicine, Bronx, NY. -FAU - Levy, Benjamin -AU - Levy B -AD - The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of - Medicine, Baltimore, MD. -FAU - Cohen, Perry -AU - Cohen P -AD - Division of Anatomic and Clinical Pathology, Department of Pathology, Montefiore - Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, - NY. -FAU - Halmos, Balazs -AU - Halmos B -AD - Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert - Einstein College of Medicine, Bronx, NY. Electronic address: - bahalmos@montefiore.org. -LA - eng -PT - Journal Article -PT - Review -DEP - 20240213 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/pathology -MH - *Lung Neoplasms/therapy/pathology/drug therapy -MH - *Immunotherapy/methods -MH - Perioperative Care/methods -MH - Immune Checkpoint Inhibitors/therapeutic use -OTO - NOTNLM -OT - Adjuvant -OT - Immunotherapy -OT - Lung cancer -OT - NSCLC -OT - Neoadjuvant -EDAT- 2024/03/11 00:42 -MHDA- 2024/05/17 00:43 -CRDT- 2024/03/10 22:54 -PHST- 2023/10/02 00:00 [received] -PHST- 2024/01/30 00:00 [revised] -PHST- 2024/02/07 00:00 [accepted] -PHST- 2024/05/17 00:43 [medline] -PHST- 2024/03/11 00:42 [pubmed] -PHST- 2024/03/10 22:54 [entrez] -AID - S1525-7304(24)00015-9 [pii] -AID - 10.1016/j.cllc.2024.02.004 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2024 May;25(3):197-214. doi: 10.1016/j.cllc.2024.02.004. Epub - 2024 Feb 13. - -PMID- 37024843 -OWN - NLM -STAT- MEDLINE -DCOM- 20230410 -LR - 20230412 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 23 -IP - 1 -DP - 2023 Apr 6 -TI - First-line atezolizumab/durvalumab plus platinum-etoposide combined with - radiotherapy in extensive-stage small-cell lung cancer. -PG - 318 -LID - 10.1186/s12885-023-10784-8 [doi] -LID - 318 -AB - BACKGROUND: Immunotherapy has made significant advances in the treatment of - extensive-stage small-cell lung cancer (ES-SCLC), but data in combination with - radiotherapy are scarce. This study aims to assess the safety and efficacy of - chemoimmunotherapy combined with thoracic radiotherapy in patients with ES-SCLC. - METHODS: This single-center retrospective study analyzed patients with ES-SCLC - who received standard platinum-etoposide chemotherapy combined with atezolizumab - or durvalumab immunotherapy as induction treatment, followed by consolidative - thoracic radiotherapy (CTRT) before disease progression in the first-line - setting. Adverse events during radiotherapy with or without maintenance - immunotherapy and survival outcomes were assessed. RESULTS: Between December 2019 - and November 2021, 36 patients with ES-SCLC were identified to have received such - treatment modality at one hospital. The number of metastatic sites at diagnosis - was 1-4. The biological effective dose of CTRT ranged from 52 to 113 Gy. Only two - patients (6%) developed grade 3 toxic effect of thrombocytopenia, but none - experienced grade 4 or 5 toxicity. Four patients developed immune-related - pneumonitis during the induction treatment period but successfully completed - later CTRT. The rate of radiation-related pneumonitis was 8% with grades 1-2 and - well tolerated. The median progression-free survival (PFS) was 12.8 months, but - the median overall survival (OS) was not determined. The estimated 1-year OS was - 80.2% and 1-year PFS was 53.4%. CONCLUSIONS: Immunotherapy combined with CTRT for - ES-SCLC is safe and has ample survival benefit. -CI - © 2023. The Author(s). -FAU - Li, Lijuan -AU - Li L -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department of Radiation Oncology, Peking University Cancer - Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, - China. -FAU - Yang, Dan -AU - Yang D -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department of Radiation Oncology, Peking University Cancer - Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, - China. -FAU - Min, Yanmei -AU - Min Y -AD - Department of Oncology, The Third Hospital of Mianyang (Sichuan Mental Health - center), Mianyang, China. -FAU - Liao, Anyan -AU - Liao A -AD - Department of Radiation Oncology, Beijing United Family Medical Center (New - Hope), Beijing, China. -FAU - Zhao, Jing -AU - Zhao J -AD - Department of Radiation Oncology, Beijing United Family Medical Center (New - Hope), Beijing, China. -FAU - Jiang, Leilei -AU - Jiang L -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department of Radiation Oncology, Peking University Cancer - Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, - China. -FAU - Dong, Xin -AU - Dong X -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department of Radiation Oncology, Peking University Cancer - Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, - China. -FAU - Deng, Wei -AU - Deng W -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department of Radiation Oncology, Peking University Cancer - Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, - China. -FAU - Yu, Huiming -AU - Yu H -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department of Radiation Oncology, Peking University Cancer - Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, - China. -FAU - Yu, Rong -AU - Yu R -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department of Radiation Oncology, Peking University Cancer - Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, - China. -FAU - Zhao, Jun -AU - Zhao J -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer - Hospital and Institute, Beijing, China. ohjerry@163.com. -FAU - Shi, Anhui -AU - Shi A -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department of Radiation Oncology, Peking University Cancer - Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, - China. anhuidoctor@163.com. -LA - eng -GR - Y-2019AZMS-0519/CSCO-Linghang cancer research foundation/ -GR - Y-2019AZMS-0519/CSCO-Linghang cancer research foundation/ -GR - Y-2019AZMS-0519/CSCO-Linghang cancer research foundation/ -GR - Y-2019AZMS-0519/CSCO-Linghang cancer research foundation/ -GR - Y-2019AZMS-0519/CSCO-Linghang cancer research foundation/ -GR - Y-2019AZMS-0519/CSCO-Linghang cancer research foundation/ -GR - Y-2019AZMS-0519/CSCO-Linghang cancer research foundation/ -GR - Y-2019AZMS-0519/CSCO-Linghang cancer research foundation/ -GR - Y-2019AZMS-0519/CSCO-Linghang cancer research foundation/ -GR - Y-2019AZMS-0519/CSCO-Linghang cancer research foundation/ -GR - Y-2019AZMS-0519/CSCO-Linghang cancer research foundation/ -GR - Y-2019AZMS-0519/CSCO-Linghang cancer research foundation/ -PT - Journal Article -DEP - 20230406 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 52CMI0WC3Y (atezolizumab) -RN - Q20Q21Q62J (Cisplatin) -RN - 28X28X9OKV (durvalumab) -RN - 6PLQ3CP4P3 (Etoposide) -RN - 49DFR088MY (Platinum) -SB - IM -MH - Humans -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Cisplatin -MH - Etoposide -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Platinum/therapeutic use -MH - Retrospective Studies -MH - *Small Cell Lung Carcinoma/drug therapy/radiotherapy -MH - *Immunotherapy -PMC - PMC10080806 -OTO - NOTNLM -OT - Extensive-stage small-cell lung cancer -OT - Immunotherapy -OT - Radiotherapy -COIS- The authors declare that they have no competing interests. -EDAT- 2023/04/07 06:00 -MHDA- 2023/04/10 10:16 -PMCR- 2023/04/06 -CRDT- 2023/04/06 23:46 -PHST- 2022/11/14 00:00 [received] -PHST- 2023/03/28 00:00 [accepted] -PHST- 2023/04/10 10:16 [medline] -PHST- 2023/04/06 23:46 [entrez] -PHST- 2023/04/07 06:00 [pubmed] -PHST- 2023/04/06 00:00 [pmc-release] -AID - 10.1186/s12885-023-10784-8 [pii] -AID - 10784 [pii] -AID - 10.1186/s12885-023-10784-8 [doi] -PST - epublish -SO - BMC Cancer. 2023 Apr 6;23(1):318. doi: 10.1186/s12885-023-10784-8. - -PMID- 27138756 -OWN - NLM -STAT- MEDLINE -DCOM- 20170913 -LR - 20180924 -IS - 1873-5592 (Electronic) -IS - 1389-4501 (Linking) -VI - 18 -IP - 3 -DP - 2017 -TI - Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for - an Old Problem. -PG - 341-362 -LID - 10.2174/1389450117666160502152331 [doi] -AB - Small cell lung cancer is a highly aggressive, difficult to treat neoplasm. Among - all lung tumors, small cell lung cancers account for about 20%. Patients - typically include heavy smokers in 70s age group, presenting with symptoms such - as intrathoracic tumors growth, distant spread or paraneoplastic syndromes at the - time of diagnosis. A useful and functional classification divides small cell lung - cancers into limited disease and extensive disease. Concurrent chemo-radiotherapy - is the standard treatment for limited disease, with improved survival when - combined with prophylactic cranial irradiation. Platinum compounds - (cisplatin/carboplatin) plus etoposide remain the cornerstone for extensive - disease. Nevertheless, despite high chemo- and radio-sensitivity of this cancer, - nearly all patients relapse within the first two years and the prognosis is - extremely poor. A deeper understanding about small cell lung cancer - carcinogenesis led to develop and test a considerable number of new and targeted - agents but the results are currently weak or insufficient. To date, small cell - lung cancer is still a challenge for researchers. In this review, key aspects of - small cell lung cancer management and controversial points of standard and new - treatments will be discussed. -CI - Copyright© Bentham Science Publishers; For any queries, please email at - epub@benthamscience.org. -FAU - Lo Russo, Giuseppe -AU - Lo Russo G -AD - Fondazione IRCCS, Istituto Nazionale dei Tumori, Department of Medical Oncology, - Thoracic Unit, Via Giacomo Venezian, 1 Milano, Italy. -FAU - Macerelli, Marianna -AU - Macerelli M -FAU - Platania, Marco -AU - Platania M -FAU - Zilembo, Nicoletta -AU - Zilembo N -FAU - Vitali, Milena -AU - Vitali M -FAU - Signorelli, Diego -AU - Signorelli D -FAU - Proto, Claudia -AU - Proto C -FAU - Ganzinelli, Monica -AU - Ganzinelli M -FAU - Gallucci, Rosaria -AU - Gallucci R -FAU - Agustoni, Francesco -AU - Agustoni F -FAU - Fasola, Gianpiero -AU - Fasola G -FAU - de Braud, Filippo -AU - de Braud F -FAU - Garassino, Marina Chiara -AU - Garassino MC -LA - eng -PT - Journal Article -PT - Review -PL - United Arab Emirates -TA - Curr Drug Targets -JT - Current drug targets -JID - 100960531 -SB - IM -MH - Aged -MH - Aged, 80 and over -MH - Chemoradiotherapy -MH - Disease Management -MH - Humans -MH - Lung Neoplasms/pathology/*therapy -MH - Recurrence -MH - Small Cell Lung Carcinoma/pathology/*therapy -MH - Survival Analysis -MH - Treatment Outcome -OTO - NOTNLM -OT - Chemotherapy -OT - immunotherapy -OT - management -OT - radiotherapy -OT - small cell lung cancer -OT - target therapies. -EDAT- 2016/05/04 06:00 -MHDA- 2017/09/14 06:00 -CRDT- 2016/05/04 06:00 -PHST- 2015/03/31 00:00 [received] -PHST- 2016/01/05 00:00 [revised] -PHST- 2016/03/01 00:00 [accepted] -PHST- 2016/05/04 06:00 [pubmed] -PHST- 2017/09/14 06:00 [medline] -PHST- 2016/05/04 06:00 [entrez] -AID - CDT-EPUB-75335 [pii] -AID - 10.2174/1389450117666160502152331 [doi] -PST - ppublish -SO - Curr Drug Targets. 2017;18(3):341-362. doi: 10.2174/1389450117666160502152331. - -PMID- 37283751 -OWN - NLM -STAT- MEDLINE -DCOM- 20230609 -LR - 20230611 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 14 -DP - 2023 -TI - Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer - treated by immune checkpoints inhibitors. -PG - 1171649 -LID - 10.3389/fimmu.2023.1171649 [doi] -LID - 1171649 -AB - Lung cancer remains the first cause of cancer-related death despite many - therapeutic innovations, including immune checkpoint inhibitors (ICI). ICI are - now well used in daily practice at late metastatic stages and locally advanced - stages after a chemo-radiation. ICI are also emerging in the peri-operative - context. However, all patients do not benefit from ICI and even suffer from - additional immune side effects. A current challenge remains to identify patients - eligible for ICI and benefiting from these drugs. Currently, the prediction of - ICI response is only supported by Programmed death-ligand 1 (PD-L1) tumor - expression with perfectible results and limitations inherent to tumor-biopsy - specimen analysis. Here, we reviewed alternative markers based on liquid biopsy - and focused on the most promising biomarkers to modify clinical practice, - including non-tumoral blood cell count such as absolute neutrophil counts, - platelet to lymphocyte ratio, neutrophil to lymphocyte ratio, and derived - neutrophil to lymphocyte ratio. We also discussed soluble-derived immune - checkpoint-related products such as sPD-L1, circulating tumor cells (detection, - count, and marker expression), and circulating tumor DNA-related products. - Finally, we explored perspectives for liquid biopsies in the immune landscape and - discussed how they could be implemented into lung cancer management with a - potential biological-driven decision. -CI - Copyright © 2023 Ancel, Dormoy, Raby, Dalstein, Durlach, Dewolf, Gilles, Polette - and Deslée. -FAU - Ancel, Julien -AU - Ancel J -AD - Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, - Reims, France. -AD - Department of Respiratory Diseases, Centre Hospitalier Universitaire de Reims, - Hôpital Maison Blanche, Reims, France. -FAU - Dormoy, Valérian -AU - Dormoy V -AD - Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, - Reims, France. -FAU - Raby, Béatrice Nawrocki -AU - Raby BN -AD - Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, - Reims, France. -FAU - Dalstein, Véronique -AU - Dalstein V -AD - Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, - Reims, France. -AD - Department of Biopathology, Centre Hospitalier Universitaire de Reims, Hôpital - Maison Blanche, Reims, France. -FAU - Durlach, Anne -AU - Durlach A -AD - Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, - Reims, France. -AD - Department of Biopathology, Centre Hospitalier Universitaire de Reims, Hôpital - Maison Blanche, Reims, France. -FAU - Dewolf, Maxime -AU - Dewolf M -AD - Department of Respiratory Diseases, Centre Hospitalier Universitaire de Reims, - Hôpital Maison Blanche, Reims, France. -FAU - Gilles, Christine -AU - Gilles C -AD - Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège, - Liège, Belgium. -FAU - Polette, Myriam -AU - Polette M -AD - Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, - Reims, France. -AD - Department of Biopathology, Centre Hospitalier Universitaire de Reims, Hôpital - Maison Blanche, Reims, France. -FAU - Deslée, Gaëtan -AU - Deslée G -AD - Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, - Reims, France. -AD - Department of Respiratory Diseases, Centre Hospitalier Universitaire de Reims, - Hôpital Maison Blanche, Reims, France. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20230522 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/metabolism -MH - *Lung Neoplasms/pathology -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Biomarkers, Tumor -MH - Lymphocytes/metabolism -PMC - PMC10239865 -OTO - NOTNLM -OT - circulating tumor (ctDNA) -OT - circulating tumor cell (CTC) -OT - immunotherapy -OT - liquid biopsy -OT - neutrophil lymphocyte ratio (NLR) -OT - non-small cell lung cancer (NSCLC) -OT - soluble biomarkers -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2023/06/07 13:10 -MHDA- 2023/06/09 06:42 -PMCR- 2023/01/01 -CRDT- 2023/06/07 09:37 -PHST- 2023/02/22 00:00 [received] -PHST- 2023/05/11 00:00 [accepted] -PHST- 2023/06/09 06:42 [medline] -PHST- 2023/06/07 13:10 [pubmed] -PHST- 2023/06/07 09:37 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2023.1171649 [doi] -PST - epublish -SO - Front Immunol. 2023 May 22;14:1171649. doi: 10.3389/fimmu.2023.1171649. - eCollection 2023. - -PMID- 26484629 -OWN - NLM -STAT- MEDLINE -DCOM- 20161102 -LR - 20161230 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 10 -IP - 12 -DP - 2015 Dec -TI - Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung - Cancer. -PG - 1685-93 -LID - 10.1097/JTO.0000000000000686 [doi] -AB - Methods of harnessing the immune system to treat cancer have been investigated - for decades, but yielded little clinical progress. However, in recent years, - novel drugs that allow immune recognition and destruction of tumor cells are - emerging as potent cancer therapies. Building upon previous immunotherapy - strategies that included therapeutic vaccines, recombinant cytokines, and other - immunostimulatory agents, newer immunotherapy agents targeting immune checkpoints - including programmed cell death 1, programmed cell death ligand-1, and cytotoxic - T-lymphocyte-associated protein 4, among others, have garnered substantial - enthusiasm after demonstrating clinical activity in a broad spectrum of tumor - types. Trials evaluating immune checkpoint inhibitors in metastatic - non-small-cell lung cancer (NSCLC) demonstrate robust and durable responses in a - subset of patients. However, with overall response rates less than 20%, - combinatorial strategies that extend the benefit of these agents to more patients - are desirable. The integration of radiotherapy with immunotherapy is a - conceptually promising strategy, as radiotherapy has potent immunomodulatory - effects and may contribute not only to local control but may also augment - systemic antitumor immune response. Preclinical data and case reports suggest the - potential for robust clinical responses in metastatic NSCLC patients using this - strategy, but prospective clinical trials evaluating the integration of radiation - and immunotherapy are limited. The use of immunotherapy in nonmetastatic settings - is also intriguing but understudied. We review the potential clinical settings of - interest for the partnering of immunotherapy and radiation in NSCLC, including - early stage, locally advanced, and metastatic disease, and review completed, - accruing, and developing clinical trials. -FAU - Daly, Megan E -AU - Daly ME -AD - *Department of Radiation Oncology, and †Division of Medical Oncology, Department - of Medicine, University of California Davis Comprehensive Cancer Center, - Sacramento, California. -FAU - Monjazeb, Arta M -AU - Monjazeb AM -FAU - Kelly, Karen -AU - Kelly K -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/immunology/radiotherapy/*therapy -MH - Clinical Trials as Topic -MH - Humans -MH - Immunotherapy/*methods -MH - Lung Neoplasms/drug therapy/immunology/radiotherapy/*therapy -EDAT- 2015/10/21 06:00 -MHDA- 2016/11/03 06:00 -CRDT- 2015/10/21 06:00 -PHST- 2015/10/21 06:00 [entrez] -PHST- 2015/10/21 06:00 [pubmed] -PHST- 2016/11/03 06:00 [medline] -AID - S1556-0864(15)35089-9 [pii] -AID - 10.1097/JTO.0000000000000686 [doi] -PST - ppublish -SO - J Thorac Oncol. 2015 Dec;10(12):1685-93. doi: 10.1097/JTO.0000000000000686. - -PMID- 33293671 -OWN - NLM -STAT- MEDLINE -DCOM- 20210218 -LR - 20241003 -IS - 1532-1827 (Electronic) -IS - 0007-0920 (Print) -IS - 0007-0920 (Linking) -VI - 123 -IP - Suppl 1 -DP - 2020 Dec -TI - Rationale for concurrent chemoradiotherapy for patients with stage III - non-small-cell lung cancer. -PG - 10-17 -LID - 10.1038/s41416-020-01070-6 [doi] -AB - When treating patients with unresectable stage III non-small-cell lung cancer - (NSCLC), those with a good performance status and disease measured within a - radical treatment volume should be considered for definitive concurrent - chemoradiotherapy (cCRT). This guidance is based on key scientific rationale from - two large Phase 3 randomised studies and meta-analyses demonstrating the - superiority of cCRT over sequential (sCRT). However, the efficacy of cCRT comes - at the cost of increased acute toxicity versus sequential treatment. Currently, - there are several documented approaches that are addressing this drawback, which - this paper outlines. At the point of diagnosis, a multidisciplinary team (MDT) - approach can enable accurate assessment of patients, to determine the optimal - treatment strategy to minimise risks. In addition, reviewing the Advisory - Committee on Radiation Oncology Practice (ACROP) guidelines can provide clinical - oncologists with additional recommendations for outlining target volume and - organ-at-risk delineation for standard clinical scenarios in definitive cCRT (and - adjuvant radiotherapy). Furthermore, modern advances in radiotherapy treatment - planning software and treatment delivery mean that radiation oncologists can - safely treat substantially larger lung tumours with higher radiotherapy doses, - with greater accuracy, whilst minimising the radiotherapy dose to the surrounding - healthy tissues. The combination of these advances in cCRT may assist in creating - comprehensive strategies to allow patients to receive potentially curative - benefits from treatments such as immunotherapy, as well as minimising - treatment-related risks. -FAU - Conibear, John -AU - Conibear J -AD - Department of Clinical Oncology, St. Bartholomew's Hospital, London, UK. - John.Conibear@NHS.net. -CN - AstraZeneca UK Limited -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - England -TA - Br J Cancer -JT - British journal of cancer -JID - 0370635 -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/*radiotherapy -MH - Chemoradiotherapy/adverse effects/standards -MH - Combined Modality Therapy -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology/*radiotherapy -MH - Neoplasm Staging -PMC - PMC7735212 -COIS- J. Conibear has attended advisory boards for, and received speaker fees from, - AstraZeneca. The author does not report any competing interests with regard to - the contents of this study other than those stated. -EDAT- 2020/12/10 06:00 -MHDA- 2021/02/20 06:00 -PMCR- 2020/12/08 -CRDT- 2020/12/09 06:10 -PHST- 2020/12/09 06:10 [entrez] -PHST- 2020/12/10 06:00 [pubmed] -PHST- 2021/02/20 06:00 [medline] -PHST- 2020/12/08 00:00 [pmc-release] -AID - 10.1038/s41416-020-01070-6 [pii] -AID - 1070 [pii] -AID - 10.1038/s41416-020-01070-6 [doi] -PST - ppublish -SO - Br J Cancer. 2020 Dec;123(Suppl 1):10-17. doi: 10.1038/s41416-020-01070-6. - -PMID- 27520630 -OWN - NLM -STAT- MEDLINE -DCOM- 20170926 -LR - 20220419 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 18 -IP - 2 -DP - 2017 Mar -TI - Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in - Small-Cell Lung Cancer. -PG - 132-140 -LID - S1525-7304(16)30183-8 [pii] -LID - 10.1016/j.cllc.2016.07.004 [doi] -AB - Small-cell lung cancer (SCLC) is distinguished from non-small-cell lung cancer by - its rapid growth and more frequent metastases. Although patients with SCLC are - highly responsive to chemotherapy and radiation therapy, long-term prognosis - remains poor, with relapse and disease recurrence occurring in almost all cases. - Whereas combination chemotherapies continue to be the standard of care in - extensive-stage SCLC, there is value in exploring whether immune-checkpoint - inhibition is an effective treatment strategy, given the durable responses in - non-small-cell lung cancer. Data from SCLC trials have shown clinical activity - and response to cytotoxic T-lymphocyte antigen-4 protein and programmed cell - death-1 blockade, suggesting that antibodies targeting these pathways may be - effective in improving survival outcome. However, data on clinical activity by - programmed cell death-1 ligand expression in SCLC are not widely available. - Limited data indicate that programmed cell death-1 ligand expression may not be - an ideal biomarker for patient selection. Continued research is necessary to - better optimize patient selection and response to therapy. -CI - Copyright © 2016 Elsevier Inc. All rights reserved. -FAU - Chae, Young Kwang -AU - Chae YK -AD - Developmental Therapeutics Program of the Division of Hematology Oncology, - Feinberg School of Medicine, Northwestern University, Chicago, IL; Division of - Hematology Oncology, Department of Medicine, Feinberg School of Medicine, - Northwestern University, Chicago, IL; The Robert H. Lurie Comprehensive Cancer - Center of Northwestern University, Chicago, IL. Electronic address: - young.chae@northwestern.edu. -FAU - Pan, Alan -AU - Pan A -AD - Division of Hematology Oncology, Department of Medicine, Feinberg School of - Medicine, Northwestern University, Chicago, IL. -FAU - Davis, Andrew A -AU - Davis AA -AD - Division of Hematology Oncology, Department of Medicine, Feinberg School of - Medicine, Northwestern University, Chicago, IL. -FAU - Mohindra, Nisha -AU - Mohindra N -AD - Developmental Therapeutics Program of the Division of Hematology Oncology, - Feinberg School of Medicine, Northwestern University, Chicago, IL; Division of - Hematology Oncology, Department of Medicine, Feinberg School of Medicine, - Northwestern University, Chicago, IL; The Robert H. Lurie Comprehensive Cancer - Center of Northwestern University, Chicago, IL. -FAU - Matsangou, Maria -AU - Matsangou M -AD - Developmental Therapeutics Program of the Division of Hematology Oncology, - Feinberg School of Medicine, Northwestern University, Chicago, IL; Division of - Hematology Oncology, Department of Medicine, Feinberg School of Medicine, - Northwestern University, Chicago, IL; The Robert H. Lurie Comprehensive Cancer - Center of Northwestern University, Chicago, IL. -FAU - Villaflor, Victoria -AU - Villaflor V -AD - Developmental Therapeutics Program of the Division of Hematology Oncology, - Feinberg School of Medicine, Northwestern University, Chicago, IL; Division of - Hematology Oncology, Department of Medicine, Feinberg School of Medicine, - Northwestern University, Chicago, IL; The Robert H. Lurie Comprehensive Cancer - Center of Northwestern University, Chicago, IL. -FAU - Giles, Francis -AU - Giles F -AD - Developmental Therapeutics Program of the Division of Hematology Oncology, - Feinberg School of Medicine, Northwestern University, Chicago, IL; Division of - Hematology Oncology, Department of Medicine, Feinberg School of Medicine, - Northwestern University, Chicago, IL; The Robert H. Lurie Comprehensive Cancer - Center of Northwestern University, Chicago, IL. -LA - eng -PT - Journal Article -PT - Review -DEP - 20160709 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -SB - IM -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antineoplastic Agents/*therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - Humans -MH - *Immunotherapy -MH - Lung Neoplasms/*drug therapy/immunology -MH - Prognosis -MH - Small Cell Lung Carcinoma/immunology/*therapy -OTO - NOTNLM -OT - CTLA-4 -OT - Immunotherapy -OT - PD-1 -OT - PD-L1 -OT - Small-cell lung cancer -EDAT- 2016/08/16 06:00 -MHDA- 2017/09/28 06:00 -CRDT- 2016/08/14 06:00 -PHST- 2016/05/29 00:00 [received] -PHST- 2016/07/05 00:00 [accepted] -PHST- 2016/08/16 06:00 [pubmed] -PHST- 2017/09/28 06:00 [medline] -PHST- 2016/08/14 06:00 [entrez] -AID - S1525-7304(16)30183-8 [pii] -AID - 10.1016/j.cllc.2016.07.004 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2017 Mar;18(2):132-140. doi: 10.1016/j.cllc.2016.07.004. Epub - 2016 Jul 9. - -PMID- 36755027 -OWN - NLM -STAT- MEDLINE -DCOM- 20230210 -LR - 20240912 -IS - 2041-1723 (Electronic) -IS - 2041-1723 (Linking) -VI - 14 -IP - 1 -DP - 2023 Feb 8 -TI - Efficacy and clinicogenomic correlates of response to immune checkpoint - inhibitors alone or with chemotherapy in non-small cell lung cancer. -PG - 695 -LID - 10.1038/s41467-023-36328-z [doi] -LID - 695 -AB - The role of combination chemotherapy with immune checkpoint inhibitors (ICI) - (ICI-chemo) over ICI monotherapy (ICI-mono) in non-small cell lung cancer (NSCLC) - remains underexplored. In this retrospective study of 1133 NSCLC patients, - treatment with ICI-mono vs ICI-chemo associate with higher rates of early - progression, but similar long-term progression-free and overall survival. - Sequential vs concurrent ICI and chemotherapy have similar long-term survival, - suggesting no synergism from combination therapy. Integrative modeling identified - PD-L1, disease burden (Stage IVb; liver metastases), and STK11 and JAK2 - alterations as features associate with a higher likelihood of early progression - on ICI-mono. CDKN2A alterations associate with worse long-term outcomes in - ICI-chemo patients. These results are validated in independent external (n = 89) - and internal (n = 393) cohorts. This real-world study suggests that ICI-chemo may - protect against early progression but does not influence overall survival, and - nominates features that identify those patients at risk for early progression who - may maximally benefit from ICI-chemo. -CI - © 2023. The Author(s). -FAU - Hong, Lingzhi -AU - Hong L -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Aminu, Muhammad -AU - Aminu M -AUID- ORCID: 0000-0002-9903-8812 -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Li, Shenduo -AU - Li S -AD - Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA. -FAU - Lu, Xuetao -AU - Lu X -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Petranovic, Milena -AU - Petranovic M -AD - Department of Radiology, Massachusetts General Hospital, Boston, MA, USA. -FAU - Saad, Maliazurina B -AU - Saad MB -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Chen, Pingjun -AU - Chen P -AUID- ORCID: 0000-0003-0528-1713 -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Qin, Kang -AU - Qin K -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Varghese, Susan -AU - Varghese S -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Rinsurongkawong, Waree -AU - Rinsurongkawong W -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Rinsurongkawong, Vadeerat -AU - Rinsurongkawong V -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Spelman, Amy -AU - Spelman A -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Elamin, Yasir Y -AU - Elamin YY -AUID- ORCID: 0000-0002-5312-909X -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Negrao, Marcelo V -AU - Negrao MV -AUID- ORCID: 0000-0001-8938-6699 -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Skoulidis, Ferdinandos -AU - Skoulidis F -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Gay, Carl M -AU - Gay CM -AUID- ORCID: 0000-0002-4907-0718 -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Cascone, Tina -AU - Cascone T -AUID- ORCID: 0000-0003-3008-5407 -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Gandhi, Saumil J -AU - Gandhi SJ -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Lin, Steven H -AU - Lin SH -AUID- ORCID: 0000-0003-4411-0634 -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Lee, Percy P -AU - Lee PP -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Carter, Brett W -AU - Carter BW -AD - Department of Thoracic Imaging, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Wu, Carol C -AU - Wu CC -AUID- ORCID: 0000-0003-1005-0995 -AD - Department of Thoracic Imaging, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Antonoff, Mara B -AU - Antonoff MB -AUID- ORCID: 0000-0001-6247-9537 -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Sepesi, Boris -AU - Sepesi B -AUID- ORCID: 0000-0003-1442-611X -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Lewis, Jeff -AU - Lewis J -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Gibbons, Don L -AU - Gibbons DL -AUID- ORCID: 0000-0003-2362-3094 -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Vaporciyan, Ara A -AU - Vaporciyan AA -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Le, Xiuning -AU - Le X -AUID- ORCID: 0000-0002-8554-1185 -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Jack Lee, J -AU - Jack Lee J -AUID- ORCID: 0000-0001-5469-9214 -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Roy-Chowdhuri, Sinchita -AU - Roy-Chowdhuri S -AUID- ORCID: 0000-0002-9447-7701 -AD - Department of Pathology, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Routbort, Mark J -AU - Routbort MJ -AD - Department of Pathology, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Gainor, Justin F -AU - Gainor JF -AUID- ORCID: 0000-0001-8697-4081 -AD - Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. -FAU - Heymach, John V -AU - Heymach JV -AUID- ORCID: 0000-0001-9068-8942 -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Lou, Yanyan -AU - Lou Y -AD - Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA. -FAU - Wu, Jia -AU - Wu J -AUID- ORCID: 0000-0001-8392-8338 -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Zhang, Jianjun -AU - Zhang J -AUID- ORCID: 0000-0001-7872-3477 -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. jzhang20@mdanderson.org. -AD - Department of Genomic Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. jzhang20@mdanderson.org. -FAU - Vokes, Natalie I -AU - Vokes NI -AUID- ORCID: 0000-0002-3766-5335 -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. nvokes@mdanderson.org. -AD - Department of Genomic Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. nvokes@mdanderson.org. -LA - eng -GR - P30 CA016672/CA/NCI NIH HHS/United States -GR - P50 CA070907/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20230208 -PL - England -TA - Nat Commun -JT - Nature communications -JID - 101528555 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Retrospective Studies -MH - *Lung Neoplasms/drug therapy/genetics -MH - Drug Therapy, Combination -PMC - PMC9908867 -COIS- M.V.N. reports Research funding to institution from Mirati, Novartis, - Alaunos, Checkmate, AstraZeneca, Pfizer, Genentech; and Consultant/Advisory Board - from Mirati, Novartis, Genentech, and Merck/MSD, outside the submitted work. - Y.Y.E. reports research support from Spectrum, AstraZeneca, Takeda, Eli Lilly, - Xcovery, and Tuning Point Therapeutics; and advisory role for AstraZeneca, Eli - Lilly, Sanofi, BMS, Spectrum and Turning Point; and accommodation expenses from - Eli Lilly. F.S. reports consulting fees and advisory roles from Amgen Inc., - AstraZeneca Pharmaceuticals, Novartis, BeiGene, Tango Therapeutics, Calithera - Biosciences, Navire Pharma, Medscape LLC, Intellisphere LLC, Guardant Health, and - BergenBio; speaker fees from BMS, RV MaisPromocao Eventos LTDS, the Visiting - Speakers Program in Oncology at McGill University and the Universite´ de - Montre´al, AIM Group International, and ESMO; fees for travel, food, and beverage - from Tango Therapeutics, AstraZeneca Pharmaceuticals, Amgen Inc., Guardant - Health, and Dava Oncology; stock or stock options in BioNTech SE and Moderna - Inc.; research grants (to institution) from Amgen Inc., Mirati Therapeutics, - Boehringer Ingelheim, Merck & Co, and Novartis; Study Chair funds (to - institution) from Pfizer; and research grants (spouse, to institution) from - Almmune. C.M.G. reports fees for advisory committees from AstraZeneca, Bristol - Myers Squibb, Jazz Pharmaceuticals, G1 therapeutics, and Monte Rosa Therapeutics, - research support from AstraZeneca, and speaker’s fees from AstraZeneca and - Beigene. T.C. reports speaker fees/honoraria from the Society for Immunotherapy - of Cancer (SITC), Bristol Myers Squibb, Roche, Medscape, IDEOlogy Health, - Physicians’ Education Resource®, LLC (PER®), OncLive and PeerView; travel, food - and beverage expenses from Physicians' Education Resource®, LLC (PER®), Dava - Oncology, SITC, International Association for the Study of Lung Cancer, IDEOlogy - Health and Bristol Myers Squibb; advisory role/consulting fees from - MedImmune/AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck, Genentech, - Arrowhead Pharmaceuticals and Regeneron; and institutional research funding from - MedImmune/AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim and EMD Serono, - all outside of the submitted work. S.J.G. reports research support from - AstraZeneca, BMS, and Millenium Pharmaceuticals, all outside of the submitted - work. P.P.L. reports personal fees from Viewray, Inc., AstraZeneca, Inc., - personal fees and non-financial support from Varian, Inc., personal fees from - Genentech, Inc., outside the submitted work. D.L.G. reports honoraria for - scientific advisory boards from AstraZeneca, Sanofi, Alethia Biotherapeutics, - Menarini, Eli Lilly, 4D Pharma and Onconova, and research support from Janssen, - Takeda, Astellas, Ribon Therapeutics, NGM Biopharmaceuticals, Boehringer - Ingelheim, Mirati Therapeutics and AstraZeneca, all outside of the submitted - work. X.L. reports receiving consultant and advisory fee from Eli Lilly, - AstraZeneca, EMD Serono, Daiishi Sanko, Spectrum Therapeutics, Boehringer - Ingelheim, Hengrui Therapeutics, Novartis, and research funding from Eli Lilly, - Boehringer Ingelheim, all outside of the submitted work. J.F.G. has served as a - compensated consultant or received honoraria from Bristol-Myers Squibb, - Genentech/Roche, Takeda, Loxo/Lilly, Blueprint, AstraZeneca, Gilead, Moderna, - AstraZeneca, Curie Therapeutics, Mirati, Nuvalent, Pfizer, Novartis, Merck, - iTeos, Karyopharm, Silverback Therapeutics, and GlydeBio; research support from - Novartis, Genentech/Roche, and Takeda; institutional research support from - Bristol-Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck, - Adaptimmune, Novartis, and Alexo; and has an immediate family member who is an - employee with equity at Ironwood Pharmaceuticals. J.V.H. reports receiving - advisory/consulting fees from AstraZeneca, Boehringer-Ingeheim, Catalyst, - Genentech, GlaxoSmithKline, Guardant Health, Foundation Medicine, Hengrui - Therapeutics, Eli Lilly, Novartis, Spectrum, Sanofi, Takeda Pharmaceuticals, - Mirati Therapeutics, Bristiol-Myers Squibb, BrightPath Biotherapeutics, Janssen - Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos - Venture Investments, Leads Biolabs, RefleXion, and research funding from - GlaxoSmithKline, AstraZeneca, Spectrum, all outside of the submitted work. Y.L. - reports research funding from Merck, MacroGenics, Tolero Pharmaceuticals, - AstraZeneca, Vaccinex, Blueprint Medicines, Harpoon Therapeutics, Sun Pharma - Advanced Research, Bristol-Myers Squibb, Kyowa Pharmaceuticals, Tesaro, Bayer - HealthCare, Mirati Therapeutics, Daiichi Sankyo. Scientific Advisory boards for - AstraZeneca Pharmaceuticals, Janssen Pharmaceutical, Lilly Oncology, Turning - point therapeutics. Consultation fee from AstraZeneca. Honorarium from Clarion - Health Care. J.Z. reports grants from Merck, Novartis, Johnson and Johnson, - personal fees from BMS, AZ, Novartis, Johnson and Johnson, GenePlus, Hengrui, - Innovent, outside the submitted work. N.I.V. receives consulting fees from - Sanofi, Regeneron, Oncocyte, and Eli Lilly, and research funding from Mirati, - outside the submitted work. The other authors declare no competing interests in - the submitted work. -EDAT- 2023/02/09 06:00 -MHDA- 2023/02/11 06:00 -PMCR- 2023/02/08 -CRDT- 2023/02/08 23:49 -PHST- 2022/04/08 00:00 [received] -PHST- 2023/01/24 00:00 [accepted] -PHST- 2023/02/08 23:49 [entrez] -PHST- 2023/02/09 06:00 [pubmed] -PHST- 2023/02/11 06:00 [medline] -PHST- 2023/02/08 00:00 [pmc-release] -AID - 10.1038/s41467-023-36328-z [pii] -AID - 36328 [pii] -AID - 10.1038/s41467-023-36328-z [doi] -PST - epublish -SO - Nat Commun. 2023 Feb 8;14(1):695. doi: 10.1038/s41467-023-36328-z. - -PMID- 31815565 -OWN - NLM -STAT- MEDLINE -DCOM- 20210112 -LR - 20210112 -IS - 1747-6356 (Electronic) -IS - 1747-6348 (Linking) -VI - 14 -IP - 2 -DP - 2020 Feb -TI - The evolving use of pembrolizumab in combination treatment approaches for - non-small cell lung cancer. -PG - 137-147 -LID - 10.1080/17476348.2020.1702526 [doi] -AB - Introduction: The immune checkpoint inhibitor, pembrolizumab, has revolutionized - the treatment of non-small cell lung cancer (NSCLC). It is currently approved and - widely used in patients with advanced NSCLC whose tumors have no EGFR or ALK - genomic aberrations that express PD-L1 as single-agent treatment and irrespective - of PD-L1 expression in combination with platinum-based doublet chemotherapy in - the first-line setting.Areas covered: The authors have reviewed articles - discussing pembrolizumab and NSCLC in MEDLINE between July 2013 to August 2019 - and focus on recent advances in combining pembrolizumab with chemotherapy, - radiotherapy and other novel agents in various stages of NSCLC.Expert opinion: - Although pembrolizumab has revolutionized the treatment of advanced NSCLC, only a - subset of patients benefit from single-agent therapy. Numerous trials combining - pembrolizumab with chemotherapy and radiation have shown benefit and a large - spectrum of novel combination strategies are being explored for improved - synergies. In addition to PD-L1 tumor proportion score, validation of other - biomarkers would be beneficial in stratifying patients and improving the - predictive value of combining immune check point inhibitors and chemotherapy. -FAU - Alexander, Mariam -AU - Alexander M -AD - Department of Oncology, Montefiore Medical Center, Albert Einstein College of - Medicine, Bronx, NY, USA. -FAU - Ko, Brian -AU - Ko B -AD - Department of Oncology, Montefiore Medical Center, Albert Einstein College of - Medicine, Bronx, NY, USA. -FAU - Lambert, Remy -AU - Lambert R -AD - Department of Oncology, Montefiore Medical Center, Albert Einstein College of - Medicine, Bronx, NY, USA. -FAU - Gadgeel, Shirish -AU - Gadgeel S -AD - Division of Oncology, Department of Medicine, University of Michigan Medical - School, Ann Arbor, MI, USA. -FAU - Halmos, Balazs -AU - Halmos B -AD - Department of Oncology, Montefiore Medical Center, Albert Einstein College of - Medicine, Bronx, NY, USA. -LA - eng -PT - Journal Article -PT - Review -DEP - 20191217 -PL - England -TA - Expert Rev Respir Med -JT - Expert review of respiratory medicine -JID - 101278196 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/therapy -MH - Clinical Trials as Topic -MH - Combined Modality Therapy -MH - Humans -MH - Lung Neoplasms/*drug therapy/therapy -OTO - NOTNLM -OT - Pembrolizumab -OT - biomarkers; NSCLC -OT - chemotherapy -EDAT- 2019/12/10 06:00 -MHDA- 2021/01/13 06:00 -CRDT- 2019/12/10 06:00 -PHST- 2019/12/10 06:00 [pubmed] -PHST- 2021/01/13 06:00 [medline] -PHST- 2019/12/10 06:00 [entrez] -AID - 10.1080/17476348.2020.1702526 [doi] -PST - ppublish -SO - Expert Rev Respir Med. 2020 Feb;14(2):137-147. doi: - 10.1080/17476348.2020.1702526. Epub 2019 Dec 17. - -PMID- 33147608 -OWN - NLM -STAT- MEDLINE -DCOM- 20210111 -LR - 20210111 -IS - 1465-3621 (Electronic) -IS - 0368-2811 (Linking) -VI - 51 -IP - 1 -DP - 2021 Jan 1 -TI - Recent advances and future perspectives in adjuvant and neoadjuvant - immunotherapies for lung cancer. -PG - 28-36 -LID - 10.1093/jjco/hyaa187 [doi] -AB - The superior efficacy of immune checkpoint inhibitors for the treatment of - advanced non-small cell lung cancer has inspired many clinical trials to use - immune checkpoint inhibitors in earlier stages of lung cancer worldwide. Based on - the theoretical feasibility that neoantigens derived from a tumor tissue are - present in vivo, some clinical trials have recently evaluated the neoadjuvant, - rather than the adjuvant, use of immune checkpoint inhibitors. Some of these - trials have already produced evidence on the safety and efficacy of immune - checkpoint inhibitors in a neoadjuvant setting, with a favorable major pathologic - response and few adverse events. In the most impactful report from Johns Hopkins - University and the Memorial Sloan Kettering Cancer Center, the programed death-1 - inhibitor nivolumab was administered to 21 patients in a neoadjuvant setting. The - authors reported a major pathologic response rate of 45%, with no unexpected - delay of surgery related to the adverse effects of nivolumab. The adjuvant as - well as the neoadjuvant administration of immune checkpoint inhibitors has also - been considered in various clinical trials, with or without the combined use of - chemotherapy or radiotherapy. The development of appropriate biomarkers to - predict the efficacy of immune checkpoint inhibitors is also underway. The - expression of programed death ligand-1 and the tumor mutation burden are - promising biomarkers that have been evaluated in many settings. To establish an - appropriate method for using immune checkpoint inhibitors in combination with - surgery, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology - Group will manage clinical trials using a multimodality treatment, including - immune checkpoint inhibitors and surgery. -CI - © The Author(s) 2020. Published by Oxford University Press. All rights reserved. - For permissions, please e-mail: journals.permission@oup.com. -FAU - Yotsukura, Masaya -AU - Yotsukura M -AD - Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan. -FAU - Nakagawa, Kazuo -AU - Nakagawa K -AD - Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan. -FAU - Suzuki, Kenji -AU - Suzuki K -AD - Division of General Thoracic Surgery, Juntendo University Hospital, Tokyo, Japan. -FAU - Takamochi, Kazuya -AU - Takamochi K -AD - Division of General Thoracic Surgery, Juntendo University Hospital, Tokyo, Japan. -FAU - Ito, Hiroyuki -AU - Ito H -AD - Department of Thoracic Surgery, Kanagawa Cancer Center, Kanagawa, Japan. -FAU - Okami, Jiro -AU - Okami J -AD - Department of Thoracic Surgery, Osaka International Cancer Institute, Osaka, - Japan. -FAU - Aokage, Keiju -AU - Aokage K -AD - Division of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan. -FAU - Shiono, Satoshi -AU - Shiono S -AD - Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, Yamagata, - Japan. -FAU - Yoshioka, Hiroshige -AU - Yoshioka H -AD - Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, - Japan. -FAU - Aoki, Tadashi -AU - Aoki T -AD - Department of Thoracic Surgery, Niigata Cancer Center Hospital, Niigata, Japan. -FAU - Tsutani, Yasuhiro -AU - Tsutani Y -AD - Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan. -FAU - Okada, Morihito -AU - Okada M -AD - Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan. -FAU - Watanabe, Shun-Ichi -AU - Watanabe SI -AD - Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan. -CN - Lung Cancer Surgical Study Group (LCSSG) of the Japan Clinical Oncology Group - (JCOG) -LA - eng -PT - Journal Article -PT - Review -PL - England -TA - Jpn J Clin Oncol -JT - Japanese journal of clinical oncology -JID - 0313225 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics -MH - Clinical Trials as Topic -MH - Combined Modality Therapy -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Immunotherapy/methods -MH - Lung Neoplasms/*drug therapy/genetics -MH - Neoadjuvant Therapy -MH - Nivolumab/therapeutic use -OTO - NOTNLM -OT - clinical trials -OT - immunotherapy -OT - lung cancer -OT - lung surgery -EDAT- 2020/11/05 06:00 -MHDA- 2021/01/12 06:00 -CRDT- 2020/11/04 20:10 -PHST- 2020/06/30 00:00 [received] -PHST- 2020/09/01 00:00 [accepted] -PHST- 2020/11/05 06:00 [pubmed] -PHST- 2021/01/12 06:00 [medline] -PHST- 2020/11/04 20:10 [entrez] -AID - 5956163 [pii] -AID - 10.1093/jjco/hyaa187 [doi] -PST - ppublish -SO - Jpn J Clin Oncol. 2021 Jan 1;51(1):28-36. doi: 10.1093/jjco/hyaa187. - -PMID- 38394494 -OWN - NLM -STAT- MEDLINE -DCOM- 20240226 -LR - 20240810 -IS - 1536-5964 (Electronic) -IS - 0025-7974 (Print) -IS - 0025-7974 (Linking) -VI - 103 -IP - 8 -DP - 2024 Feb 23 -TI - Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant - undifferentiated lung cancer. -PG - e36959 -LID - 10.1097/MD.0000000000036959 [doi] -LID - e36959 -AB - The present study was conducted to characterize the clinicopathologic - characteristics, immunohistochemical staining results, and immune checkpoint - inhibitors (ICIs) efficacy in patients with SMARCA4-deficient/TP53 mutant lung - cancer. Patients diagnosed with advanced or metastatic undifferentiated lung - cancer harboring SMARCA4-deficient and TP53 mutations, however, without - targetable sensitive mutations were retrieved from the electronic medical record - system. Descriptive statistics were used to describe the baseline characteristics - and clinical features including age, gender, eastern cooperative oncology group - performance status, disease stage, smoking status, chief complaint, site of the - primary mass, tumor size, gross type, symptoms, local invasion, and metastatic - sizes. Immunological markers and potential drive genes were detected by - immunohistochemical staining and next generation sequencing. Efficacy and safety - profile of ICIs in included patients was evaluated with progression-free survival - and overall survival. Between January 2019 and September 2022, there were 4 - patients included within the inclusion criteria in the present study. Biomarkers - including CK, CK7, and integrase interactor 1 were detected positive, however, - other immunological markers including CK20, CD56, P63, P40, NapsinA, TTF-1, CgA, - Syn, BRG1, or PD-L1 were detected negative among them. Results of next generation - sequencing panel were failed to discover any targetable sensitive mutations. A - total of 4 mutation types of TP53, including p.C141Y, p.S240G, p.E339X - (terminator acquired), and p.L130F detected for the patients, respectively. - Microsatellite stability status, as well as low tumor mutation burden was - identified among all the patients. Median progression-free survival for ICIs as - first line treatment and median overall survival were 3.25 months (range from 1.3 - to 6.8 months), and 6.0 months (range from 2.7 to 9.6 months), respectively. Our - results indicated that advanced lung cancer patients harboring co-occurring - SMARCA4-deficient/TP53 mutations might respond to ICIs treatment, though within - negative programmed cell death-ligand 1 expression or low tumor mutation burden. - However, hyperprogressive disease by ICIs may also happen for such patients. The - mutation types of TP53 might play a role during the exposure of ICIs, however, - need further identification in basic experiments. -CI - Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc. -FAU - Chen, Jianxin -AU - Chen J -AD - Department of Medical Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical - University, Quzhou People's Hospital, Quzhou, Zhejiang, China. -FAU - Zheng, Qinhong -AU - Zheng Q -AD - Department of Medical Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical - University, Quzhou People's Hospital, Quzhou, Zhejiang, China. -FAU - Wang, Junhui -AU - Wang J -AD - Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou - Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China. -FAU - Zhang, Xueli -AU - Zhang X -AD - Department of General Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical - University, Quzhou People's Hospital, Quzhou, Zhejiang, China. -FAU - Lv, Yingguo -AU - Lv Y -AD - Department of Imaging, The Quzhou Affiliated Hospital of Wenzhou Medical - University, Quzhou People's Hospital, Quzhou, Zhejiang, China. -LA - eng -PT - Journal Article -PL - United States -TA - Medicine (Baltimore) -JT - Medicine -JID - 2985248R -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Biomarkers, Tumor) -RN - 0 (B7-H1 Antigen) -RN - 0 (TP53 protein, human) -RN - 0 (Tumor Suppressor Protein p53) -RN - EC 3.6.1.- (SMARCA4 protein, human) -RN - EC 3.6.4.- (DNA Helicases) -RN - 0 (Nuclear Proteins) -RN - 0 (Transcription Factors) -SB - IM -MH - Humans -MH - *Lung Neoplasms/drug therapy/genetics/pathology -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - *Antineoplastic Agents, Immunological/therapeutic use -MH - Immunotherapy/methods -MH - Biomarkers, Tumor/genetics -MH - Mutation -MH - B7-H1 Antigen -MH - Tumor Suppressor Protein p53/genetics -MH - DNA Helicases/genetics -MH - Nuclear Proteins/genetics -MH - Transcription Factors/genetics -PMC - PMC11309689 -COIS- The authors have no conflicts of interest to disclose. -EDAT- 2024/02/23 18:42 -MHDA- 2024/02/26 06:44 -PMCR- 2024/02/23 -CRDT- 2024/02/23 16:03 -PHST- 2024/02/26 06:44 [medline] -PHST- 2024/02/23 18:42 [pubmed] -PHST- 2024/02/23 16:03 [entrez] -PHST- 2024/02/23 00:00 [pmc-release] -AID - 00005792-202402230-00013 [pii] -AID - 10.1097/MD.0000000000036959 [doi] -PST - ppublish -SO - Medicine (Baltimore). 2024 Feb 23;103(8):e36959. doi: - 10.1097/MD.0000000000036959. - -PMID- 36944282 -OWN - NLM -STAT- MEDLINE -DCOM- 20230503 -LR - 20230509 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 179 -DP - 2023 May -TI - Use of radiation therapy among patients with Extensive-stage Small-cell lung - cancer receiving Immunotherapy: Canadian consensus recommendations. -PG - 107166 -LID - S0169-5002(23)00087-9 [pii] -LID - 10.1016/j.lungcan.2023.03.002 [doi] -AB - OBJECTIVES: Thoracic radiation therapy (TRT) and prophylactic cranial irradiation - (PCI) are commonly used in the management of extensive-stage small-cell lung - cancer (ES-SCLC); however, Phase III trials of first-line immunotherapy often - excluded these options. Guidance is needed regarding appropriate use of TRT, PCI, - and magnetic resonance imaging (MRI) surveillance while new data are awaited. - MATERIALS AND METHODS: In two web-based meetings, a pan-Canadian expert working - group of five radiation oncologists and four medical oncologists addressed eight - clinical questions regarding use of radiation therapy (RT) and MRI surveillance - among patients with ES-SCLC receiving immunotherapy. A targeted literature review - was conducted using PubMed and conference proceedings to identify recent (January - 2019-April 2022) publications in this setting. Fifteen recommendations were - developed; online voting was conducted to gauge agreement with each - recommendation. RESULTS: After considering recently available evidence across - lung cancer populations and clinical experience, the experts recommended that all - patients with a response to chemo-immunotherapy, good performance status (PS), - and limited metastases be considered for consolidation TRT (e.g., 30 Gy in 10 - fractions). When considered appropriate after multidisciplinary team discussion, - TRT can be initiated during maintenance immunotherapy. All patients who respond - to concurrent chemo-immunotherapy should undergo restaging with brain MRI to - guide decision-making regarding PCI versus MRI surveillance alone. MRI - surveillance should be conducted for two years after response to initial therapy. - PCI (e.g., 25 Gy in 10 fractions or 20 Gy in 5 fractions) can be considered for - patients without central nervous system involvement who have a response to - chemo-immunotherapy and good PS. Concurrent treatment with PCI and immunotherapy - or with TRT, PCI, and immunotherapy is appropriate after completion of initial - therapy. All recommendations were agreed upon unanimously. CONCLUSIONS: These - consensus recommendations provide practical guidance regarding appropriate use of - RT and immunotherapy in ES-SCLC while awaiting new clinical trial data. -CI - Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. -FAU - Sun, Alexander -AU - Sun A -AD - Princess Margaret Cancer Centre, 700 University Avenue, Toronto, ON M5G 1Z5, - Canada. Electronic address: alex.sun@rmp.uhn.ca. -FAU - Abdulkarim, Bassam -AU - Abdulkarim B -AD - McGill University Health Centre, McGill University, 1001 Decarie Boulevard, - Montréal, QC H4A 3J1, Canada. Electronic address: bassam.abdulkarim@mcgill.ca. -FAU - Blais, Normand -AU - Blais N -AD - Centre Hospitalier de l'Université de Montréal, University of Montréal, 1051 Rue - Sanguinet, Montréal, QC H2X 3E4, Canada. Electronic address: - normand.blais.med@ssss.gouv.qc.ca. -FAU - Greenland, Jonathan -AU - Greenland J -AD - Eastern Health, 300 Prince Philip Drive, St. John's, NL A1B 3V6, Canada. - Electronic address: jonathan.greenland@easternhealth.ca. -FAU - Louie, Alexander V -AU - Louie AV -AD - Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON M4N 3M5, - Canada. Electronic address: alexander.louie@sunnybrook.ca. -FAU - Melosky, Barbara -AU - Melosky B -AD - BC Cancer-Vancouver Centre, 600 W 10th Avenue, Vancouver, BC V5Z 4E6, Canada. - Electronic address: bmelosky@bccancer.bc.ca. -FAU - Schellenberg, Devin -AU - Schellenberg D -AD - BC Cancer-Surrey Centre, 13750 96 Avenue Surrey, BC V3V 1Z2, Canada. Electronic - address: dschellenberg@bccancer.bc.ca. -FAU - Snow, Stephanie -AU - Snow S -AD - QEII Health Sciences Centre, Dalhousie University, 5788 University Avenue, - Halifax, NS B3H 1V8, Canada. Electronic address: stephanie.snow@nshealth.ca. -FAU - Liu, Geoffrey -AU - Liu G -AD - Princess Margaret Cancer Centre, University Health Network, 610 University - Avenue, Toronto, ON M5G 2M9, Canada. Electronic address: geoffrey.liu@uhn.ca. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20230309 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -SB - IM -MH - Humans -MH - *Lung Neoplasms/pathology -MH - Consensus -MH - Canada -MH - *Small Cell Lung Carcinoma/drug therapy -MH - Cranial Irradiation/adverse effects/methods -MH - *Brain Neoplasms/secondary -MH - Immunotherapy -OTO - NOTNLM -OT - Consensus recommendations -OT - Extensive-stage small-cell lung cancer -OT - Guidelines -OT - Immunotherapy -OT - Prophylactic cranial irradiation -OT - Thoracic radiation therapy -COIS- Declaration of Competing Interest The authors declare the following financial - interests/personal relationships which may be considered as potential competing - interests: A. Sun has received honoraria from and participated in advisory boards - with AstraZeneca. B. Abdulkarim has no conflicts to disclose. N. Blais reports - receiving consulting fees from AstraZeneca. J. Greenland has received honoraria - from AstraZeneca for attendance at advisory boards. A.V. Louie reports receiving - honoraria from AstraZeneca for a speakers bureau and an advisory board. B. - Melosky has received honoraria from AstraZeneca, BMS, Merck, and Roche. D. - Schellenberg reports receiving institutional grants from Varian Medical Systems - and payments from AstraZeneca, Merck, and Pfizer for presentations/educational - events and advisory board participation. He also reports participation in Linear - Accelerator selection for BC Cancer and receipt of a class action lawsuit payment - from Medtronic. S. Snow reports research/trial funding paid to her institution by - AstraZeneca, BMS, Merck, Novartis, Sanofi, and Takeda and receiving consulting - fees from Novartis and Roche. She has also received honoraria for lectures and - presentations at educational events from Amgen, AstraZeneca, Bayer, BMS, Elvium - Life Sciences, Jazz Pharmaceuticals, Pfizer, and Taiho. S. Snow has also - participated in advisory boards for Amgen, Astellas, AstraZeneca, Bayer, BeiGene, - BMS, EMD Serono, Janssen, Jazz Pharmaceuticals, Merck, MSD, Novartis, Pfizer, - Roche, Sanofi, Takeda, and Taiho, and was the President of Lung Cancer Canada and - on its Board of Directors at the time of publication. G. Liu has received - institutional research grants from NCI (US), CIHR (Canada), CCSRI (Canada), - Amgen, AstraZeneca, Boehringer Ingelheim, and Takeda. He has received payment or - honoraria from AstraZeneca, EMD Serono, Jazz Pharmaceuticals, Novartis, Pfizer, - and Takeda, and has participated in data safety monitoring boards or advisory - boards with AbbVie, AstraZeneca, BMS, EMD Serono, Jazz Pharmaceuticals, Eli - Lilly, Merck, Novartis, Pfizer, Roche, and Takeda. -EDAT- 2023/03/22 06:00 -MHDA- 2023/05/03 06:42 -CRDT- 2023/03/21 19:00 -PHST- 2022/12/21 00:00 [received] -PHST- 2023/02/23 00:00 [revised] -PHST- 2023/03/06 00:00 [accepted] -PHST- 2023/05/03 06:42 [medline] -PHST- 2023/03/22 06:00 [pubmed] -PHST- 2023/03/21 19:00 [entrez] -AID - S0169-5002(23)00087-9 [pii] -AID - 10.1016/j.lungcan.2023.03.002 [doi] -PST - ppublish -SO - Lung Cancer. 2023 May;179:107166. doi: 10.1016/j.lungcan.2023.03.002. Epub 2023 - Mar 9. - -PMID- 33331739 -OWN - NLM -STAT- MEDLINE -DCOM- 20230105 -LR - 20230111 -IS - 2724-6116 (Electronic) -IS - 2724-6116 (Linking) -VI - 47 -IP - 4 -DP - 2022 Dec -TI - Recent advances in small cell lung cancer: the future is now? -PG - 460-474 -LID - 10.23736/S2724-6507.20.03213-7 [doi] -AB - Small cell lung cancer is a relevant clinical issue as it is a highly malignant - cancer, often diagnosed in advanced stage. Similarly to non-small cell lung - cancer, tobacco smoking is currently the main risk factor. Its incidence, at - least in males, has declined over the past decades, due to the worldwide - decreased percentage of active smokers. The typical small cells of this tumor - type are characterized by a high Proliferation Index, chromosomal deletions such - as 3p(14-23) involving the tumor-suppressor gene FHIT, alterations of the MYC or - Notch family proteins and the frequent expression of neuroendocrine markers. The - combination of thoracic radiotherapy and chemotherapy is the standard treatment - for limited stage disease, while platinum-based chemotherapy is the most - effective choice for extensive stage disease. Unfortunately, whatever - chemotherapy is used, the results are disappointing. No regimen has proved to be - effective in the long run, indeed small cell lung cancer rapidly progresses after - a frequent initial strong response, and the mortality rate remains still high. - The advent of immunotherapy is actually changing the landscape in oncology. As - well as in other cancers, recent trials have demonstrated the efficacy of the - combination of immune checkpoint inhibitors and chemotherapy, opening new - perspectives for the future of our patients. -FAU - Luciani, Andrea -AU - Luciani A -AD - Unit of Medical Oncology, San Paolo Hospital, Milan, Italy - - andrea.luciani@asst-santipaolocarlo.it. -FAU - Blasi, Miriam -AU - Blasi M -AD - Unit of Medical Oncology, San Paolo Hospital, Milan, Italy. -FAU - Provenzano, Leonardo -AU - Provenzano L -AD - Unit of Medical Oncology, San Paolo Hospital, Milan, Italy. -FAU - Zonato, Sabrina -AU - Zonato S -AD - Unit of Medical Oncology, San Paolo Hospital, Milan, Italy. -FAU - Ferrari, Daris -AU - Ferrari D -AD - Unit of Medical Oncology, San Paolo Hospital, Milan, Italy. -LA - eng -PT - Journal Article -DEP - 20201217 -PL - Italy -TA - Minerva Endocrinol (Torino) -JT - Minerva endocrinology -JID - 101777342 -RN - 0 (Proteins) -SB - IM -MH - Male -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/epidemiology/genetics/therapy -MH - *Lung Neoplasms/drug therapy -MH - *Small Cell Lung Carcinoma/therapy/drug therapy -MH - Proteins/therapeutic use -EDAT- 2020/12/18 06:00 -MHDA- 2023/01/06 06:00 -CRDT- 2020/12/17 09:03 -PHST- 2020/12/18 06:00 [pubmed] -PHST- 2023/01/06 06:00 [medline] -PHST- 2020/12/17 09:03 [entrez] -AID - S0391-1977.20.03213-7 [pii] -AID - 10.23736/S2724-6507.20.03213-7 [doi] -PST - ppublish -SO - Minerva Endocrinol (Torino). 2022 Dec;47(4):460-474. doi: - 10.23736/S2724-6507.20.03213-7. Epub 2020 Dec 17. - -PMID- 28416123 -OWN - NLM -STAT- MEDLINE -DCOM- 20180213 -LR - 20181202 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 18 -IP - 5 -DP - 2017 Sep -TI - Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung - Cancer: A Systematic Review. -PG - 444-459.e1 -LID - S1525-7304(17)30043-8 [pii] -LID - 10.1016/j.cllc.2017.02.001 [doi] -AB - Second-line treatment options are limited for patients with advanced - non-small-cell lung cancer (NSCLC). Standard therapy includes the cytotoxic - agents docetaxel and pemetrexed, and the epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors erlotinib and gefitinib. Immune checkpoint inhibitors - are a new class of treatment that have shown durable overall radiologic response - rates and have been well tolerated. The objective of this systematic review was - to investigate the efficacy of immune checkpoint inhibitors compared with other - chemotherapies in patients with advanced NSCLC. Medline, Embase, and PubMed were - searched for randomized controlled trials comparing treatment with immune - checkpoint inhibitors against treatment with chemotherapy in patients with stage - IIIB or IV NSCLC. Nine randomized controlled trials with 15 publications were - included. A significant overall survival benefit of second-line nivolumab - (nonsquamous: hazard ratio [HR] = 0.72, 95% confidence interval [CI], 0.60-0.77; - P < .001; squamous: HR = 0.59, 95% CI, 0.44-0.79; P < .001) or second-line - atezolizumab (HR = 0.73, 95% CI, 0.62-0.87; P = .0003) or second-line - pembrolizumab (in patients with programmed cell death ligand 1 [PD-L1]-positive - tumors) (pembrolizumab 2 mg/kg HR = 0.71, 95% CI, 0.58-0.88; P = .0008; - pembrolizumab 10 mg/kg HR = 0.61, 95% CI, 0.49-0.75; P < .0001) or first-line - pembrolizumab (HR = 0.60, 95% CI, 0.41-0.89; P = .005) compared with chemotherapy - was found. The adverse effects were mainly higher in the chemotherapy arms. For - patients with advanced stage IIIB/IV NSCLC, the improvement in overall survival - outweighed the harms and supported the use of first-line pembrolizumab (in - patients with ≥ 50% PD-L1-positive tumors) or second-line nivolumab, - atezolizumab, or pembrolizumab (in patients with PD-L1-positive tumors). -CI - Copyright © 2017 Elsevier Inc. All rights reserved. -FAU - Ellis, Peter M -AU - Ellis PM -AD - Medical Oncology, Juravinski Cancer Centre, and Department of Oncology, McMaster - University, Hamilton, Ontario, Canada. -FAU - Vella, Emily T -AU - Vella ET -AD - Program in Evidence-Based Care, McMaster University, Hamilton, Ontario, Canada. - Electronic address: ccopgi@mcmaster.ca. -FAU - Ung, Yee C -AU - Ung YC -AD - Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada. -LA - eng -PT - Comparative Study -PT - Journal Article -PT - Review -PT - Systematic Review -DEP - 20170216 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 31YO63LBSN (Nivolumab) -RN - 52CMI0WC3Y (atezolizumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/secondary -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology -MH - Neoplasm Staging -MH - Nivolumab -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -MH - Randomized Controlled Trials as Topic -MH - Survival Rate -OTO - NOTNLM -OT - Atezolizumab -OT - Chemotherapy -OT - Docetaxel -OT - Nivolumab -OT - Pembrolizumab -EDAT- 2017/04/19 06:00 -MHDA- 2018/02/14 06:00 -CRDT- 2017/04/19 06:00 -PHST- 2016/08/17 00:00 [received] -PHST- 2017/02/01 00:00 [revised] -PHST- 2017/02/07 00:00 [accepted] -PHST- 2017/04/19 06:00 [pubmed] -PHST- 2018/02/14 06:00 [medline] -PHST- 2017/04/19 06:00 [entrez] -AID - S1525-7304(17)30043-8 [pii] -AID - 10.1016/j.cllc.2017.02.001 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2017 Sep;18(5):444-459.e1. doi: 10.1016/j.cllc.2017.02.001. - Epub 2017 Feb 16. - -PMID- 39240166 -OWN - NLM -STAT- MEDLINE -DCOM- 20240906 -LR - 20240910 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 13 -IP - 17 -DP - 2024 Sep -TI - Impact of thoracic radiotherapy on first-line treatment outcomes in ES-SCLC - patients. -PG - e70175 -LID - 10.1002/cam4.70175 [doi] -LID - e70175 -AB - BACKGROUND: The therapeutic advantage of thoracic radiotherapy (tRT) as an - adjunct to first-line immunotherapy and chemotherapy in patients with - extensive-stage small cell lung cancer (ES-SCLC) remains unclear. We sought to - elucidate this in a retrospective cohort study comparing the effectiveness and - safety of tRT in combination with first-line immunotherapy and chemotherapy. - METHODS: Our retrospective study included patients with ES-SCLC, treated at the - West China Hospital between January 2019 and December 2022. They received - first-line immunotherapy and chemotherapy and were categorized into two cohorts - based on the administration of tRT. The primary outcomes were overall survival - (OS) and progression-free survival (PFS). Cox regression analysis was utilized to - identify potential independent predictors of prognosis and to compare the - treatment outcomes across various patient subgroups. Treatment-related toxicities - across both cohorts were compared using the Chi-squared test. RESULTS: A total of - 99patients were eligible for the study, out of which 55 received tRT. The - medianduration of follow-up was 39 months. Remarkably, patients who received - tRTdemonstrated superior OS and PFS in comparison to those who did not - (P < 0.05). Subgroup analysis further confirmed these findings. Multivariate - analysisidentified treatment group and liver metastasis as independent - prognosticfactors (P < 0.05). The incidence of grade 3-4 adverse events showed - nostatistically significant difference between the two cohorts. CONCLUSIONS: - Thus, weconfirmed that the addition of tRT to the conventional regimen of - first-linechemotherapy and immunotherapy yields better survival outcomes without - asignificant increase in toxicity. -CI - © 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Mu, Xiaoli -AU - Mu X -AD - The Department of Biotherapy, Cancer Center, West China Hospital, Sichuan - University, Chengdu, Sichuan, China. -FAU - Zhou, Yixin -AU - Zhou Y -AUID- ORCID: 0000-0001-5443-4582 -AD - The Department of Biotherapy, Cancer Center, West China Hospital, Sichuan - University, Chengdu, Sichuan, China. -FAU - Liu, Qing -AU - Liu Q -AUID- ORCID: 0000-0002-9430-8238 -AD - Lung cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan, - China. -FAU - Wang, Jiantao -AU - Wang J -AD - Lung cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan, - China. -FAU - Xu, Feng -AU - Xu F -AD - Lung cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan, - China. -FAU - Luo, Feng -AU - Luo F -AD - Lung cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan, - China. -FAU - Wang, Ke -AU - Wang K -AD - Lung cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan, - China. -FAU - Li, Lu -AU - Li L -AD - Lung cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan, - China. -FAU - Tian, Panwen -AU - Tian P -AUID- ORCID: 0000-0002-6313-3228 -AD - Lung cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan, - China. -FAU - Li, Yalun -AU - Li Y -AD - Lung cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan, - China. -FAU - Liu, Jiewei -AU - Liu J -AD - Lung cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan, - China. -FAU - Zhang, Yan -AU - Zhang Y -AUID- ORCID: 0000-0001-8738-2053 -AD - Lung cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan, - China. -FAU - Liu, Jiyan -AU - Liu J -AUID- ORCID: 0000-0003-4885-5481 -AD - The Department of Biotherapy, Cancer Center, West China Hospital, Sichuan - University, Chengdu, Sichuan, China. -FAU - Li, Yan -AU - Li Y -AUID- ORCID: 0000-0001-8105-3072 -AD - Lung cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan, - China. -LA - eng -GR - 2023HXFH020/West China Hospital of Sichuan University 2023 Clinical Research - Incubation Project/ -GR - HX-H2212352/2022 Wu Jieping Medical Foundation/ -GR - 2024YFHZ0012/Sichuan Provincial Science and Technology Support Program/ -GR - 2022-I2M-C&T-B-106/Clinical and Translational Medicine Research Special - Programme, Chinese Academy of Medical Sciences/ -PT - Journal Article -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -SB - IM -MH - Humans -MH - Male -MH - Female -MH - Middle Aged -MH - Retrospective Studies -MH - *Lung Neoplasms/therapy/radiotherapy/mortality/pathology -MH - *Small Cell Lung Carcinoma/radiotherapy/mortality/therapy/pathology/drug therapy -MH - Aged -MH - Treatment Outcome -MH - Adult -MH - Progression-Free Survival -MH - Immunotherapy/methods -MH - Prognosis -MH - Combined Modality Therapy -PMC - PMC11378358 -OTO - NOTNLM -OT - Chemotherapy -OT - Extensive‐stage small cell lung cancer -OT - Immunotherapy -OT - Survival outcomes -OT - Thoracic radiotherapy -COIS- The authors have no conflict of interest. -EDAT- 2024/09/06 12:43 -MHDA- 2024/09/06 12:44 -PMCR- 2024/09/06 -CRDT- 2024/09/06 09:33 -PHST- 2024/07/17 00:00 [revised] -PHST- 2023/11/27 00:00 [received] -PHST- 2024/08/20 00:00 [accepted] -PHST- 2024/09/06 12:44 [medline] -PHST- 2024/09/06 12:43 [pubmed] -PHST- 2024/09/06 09:33 [entrez] -PHST- 2024/09/06 00:00 [pmc-release] -AID - CAM470175 [pii] -AID - 10.1002/cam4.70175 [doi] -PST - ppublish -SO - Cancer Med. 2024 Sep;13(17):e70175. doi: 10.1002/cam4.70175. - -PMID- 33952600 -OWN - NLM -STAT- MEDLINE -DCOM- 20211124 -LR - 20221115 -IS - 1600-0617 (Electronic) -IS - 0905-9180 (Print) -IS - 0905-9180 (Linking) -VI - 30 -IP - 160 -DP - 2021 Jun 30 -TI - New developments in locally advanced nonsmall cell lung cancer. -LID - 10.1183/16000617.0227-2020 [doi] -LID - 200227 -AB - Locally advanced nonsmall cell lung cancer, due to its varying prognosis, is - grouped according to TNM stage IIIA, IIIB and IIIC. Developments over the last - 3 years have been focused on the integration of immunotherapy into the - combination treatment of a locally definitive therapy (surgery or radiotherapy) - and chemotherapy. For concurrent chemoradiotherapy, consolidation therapy with - durvalumab was established. Adjuvant targeted therapy has again gained increasing - interest. In order to adapt treatment to the specific stage subgroup and its - prognosis, fluorodeoxyglucose positron emission tomography/computed tomography - and pathological evaluation of the mediastinum are important. Tumours should be - investigated for immunological features and driver mutations. Regarding toxicity, - evaluation of pulmonary and cardiac function, as well as symptoms and quality of - life, is of increasing importance. To improve the management and prognosis of - this heterogeneous entity, clinical trials and registries should take these - factors into account. -CI - Copyright ©ERS 2021. -FAU - Huber, Rudolf M -AU - Huber RM -AUID- ORCID: 0000-0001-7041-6368 -AD - Division of Respiratory Medicine and Thoracic Oncology, Dept of Medicine, - University of Munich - Campus Innenstadt, Comprehensive Pneumology Center Munich - (CPC-M) and Thoracic Oncology Centre Munich, Munich, Germany - huber@med.uni-muenchen.de. -AD - Member of the German Centre of Lung Research. -FAU - Kauffmann-Guerrero, Diego -AU - Kauffmann-Guerrero D -AD - Division of Respiratory Medicine and Thoracic Oncology, Dept of Medicine, - University of Munich - Campus Innenstadt, Comprehensive Pneumology Center Munich - (CPC-M) and Thoracic Oncology Centre Munich, Munich, Germany. -AD - Member of the German Centre of Lung Research. -FAU - Hoffmann, Hans -AU - Hoffmann H -AD - Division of Thoracic Surgery, Technical University of Munich, Munich, Germany. -FAU - Flentje, Michael -AU - Flentje M -AD - Dept of Radiation Oncology and Palliative Medicine, University of Würzburg, - Würzburg, Germany. -LA - eng -PT - Journal Article -DEP - 20210505 -PL - England -TA - Eur Respir Rev -JT - European respiratory review : an official journal of the European Respiratory - Society -JID - 9111391 -SB - IM -CIN - doi: 10.1183/16000617.0226-2020 -CIN - doi: 10.1183/16000617.0234-2020 -CIN - doi: 10.1183/16000617.0224-2020 -MH - Antineoplastic Combined Chemotherapy Protocols -MH - *Carcinoma, Non-Small-Cell Lung/diagnostic imaging/drug therapy/genetics -MH - Chemoradiotherapy -MH - Combined Modality Therapy -MH - Humans -MH - *Lung Neoplasms/diagnostic imaging/drug therapy/genetics -MH - Neoplasm Staging -MH - Quality of Life -PMC - PMC9488500 -COIS- Conflict of interest: R.M. Huber reports grants from German Ministry of Education - and Research and AstraZeneca, and personal fees from AstraZeneca, BMS, Bayer, - Boehringer Ingelheim, Lilly, MSD, Takeda, Pfizer, Novartis, Roche, Celgene, - Abbvie and Tesaro, outside the submitted work. Conflict of interest: D. - Kauffmann-Guerrero reports personal fees from AstraZeneca, BMS, Roche, MSD, - Pfizer and Boehringer Ingelheim, outside the submitted work. Conflict of - interest: H. Hoffmann has nothing to disclose. Conflict of interest: M. Flentje - has nothing to disclose. -EDAT- 2021/05/07 06:00 -MHDA- 2021/11/25 06:00 -PMCR- 2021/05/05 -CRDT- 2021/05/06 05:55 -PHST- 2020/07/10 00:00 [received] -PHST- 2020/11/17 00:00 [accepted] -PHST- 2021/05/06 05:55 [entrez] -PHST- 2021/05/07 06:00 [pubmed] -PHST- 2021/11/25 06:00 [medline] -PHST- 2021/05/05 00:00 [pmc-release] -AID - 30/160/200227 [pii] -AID - ERR-0227-2020 [pii] -AID - 10.1183/16000617.0227-2020 [doi] -PST - epublish -SO - Eur Respir Rev. 2021 May 5;30(160):200227. doi: 10.1183/16000617.0227-2020. Print - 2021 Jun 30. - -PMID- 36358986 -OWN - NLM -STAT- MEDLINE -DCOM- 20221114 -LR - 20221201 -IS - 2218-273X (Electronic) -IS - 2218-273X (Linking) -VI - 12 -IP - 11 -DP - 2022 Nov 4 -TI - Curcumin and Its Analogs in Non-Small Cell Lung Cancer Treatment: Challenges and - Expectations. -LID - 10.3390/biom12111636 [doi] -LID - 1636 -AB - Researchers have made crucial advances in understanding the pathogenesis and - therapeutics of non-small cell lung cancer (NSCLC), improving our understanding - of lung tumor biology and progression. Although the survival of NSCLC patients - has improved due to chemoradiotherapy, targeted therapy, and immunotherapy, - overall NSCLC recovery and survival rates remain low. Thus, there is an urgent - need for the continued development of novel NSCLC drugs or combination therapies - with less toxicity. Although the anticancer effectiveness of curcumin (Cur) and - some Cur analogs has been reported in many studies, the results of clinical - trials have been inconsistent. Therefore, in this review, we collected the latest - related reports about the anti-NSCLC mechanisms of Cur, its analogs, and Cur in - combination with other chemotherapeutic agents via the Pubmed database (accessed - on 18 June 2022). Furthermore, we speculated on the interplay of Cur and various - molecular targets relevant to NSCLC with discovery studio and collected clinical - trials of Cur against NSCLC to clarify the role of Cur and its analogs in NSCLC - treatment. Despite their challenges, Cur/Cur analogs may serve as promising - therapeutic agents or adjuvants for lung carcinoma treatment. -FAU - Tang, Chunyin -AU - Tang C -AD - Evidence-Based Pharmacy Center, Key Laboratory of Birth Defects and Related - Diseases of Women and Children, Department of Pharmacy, West China Second - University Hospital, Sichuan University, Chengdu 610000, China. -FAU - Liu, Jieting -AU - Liu J -AD - Heilongjiang Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical - University, Mudanjiang 157000, China. -FAU - Yang, Chunsong -AU - Yang C -AD - Evidence-Based Pharmacy Center, Key Laboratory of Birth Defects and Related - Diseases of Women and Children, Department of Pharmacy, West China Second - University Hospital, Sichuan University, Chengdu 610000, China. -FAU - Ma, Jun -AU - Ma J -AD - Department of Pharmacy, Banan Second People's Hospital, Banan District, Chongqing - 401320, China. -FAU - Chen, Xuejiao -AU - Chen X -AD - Evidence-Based Pharmacy Center, Key Laboratory of Birth Defects and Related - Diseases of Women and Children, Department of Pharmacy, West China Second - University Hospital, Sichuan University, Chengdu 610000, China. -FAU - Liu, Dongwen -AU - Liu D -AD - Evidence-Based Pharmacy Center, Key Laboratory of Birth Defects and Related - Diseases of Women and Children, Department of Pharmacy, West China Second - University Hospital, Sichuan University, Chengdu 610000, China. -FAU - Zhou, Yao -AU - Zhou Y -AD - Evidence-Based Pharmacy Center, Key Laboratory of Birth Defects and Related - Diseases of Women and Children, Department of Pharmacy, West China Second - University Hospital, Sichuan University, Chengdu 610000, China. -FAU - Zhou, Wei -AU - Zhou W -AD - Evidence-Based Pharmacy Center, Key Laboratory of Birth Defects and Related - Diseases of Women and Children, Department of Pharmacy, West China Second - University Hospital, Sichuan University, Chengdu 610000, China. -FAU - Lin, Yunzhu -AU - Lin Y -AD - Evidence-Based Pharmacy Center, Key Laboratory of Birth Defects and Related - Diseases of Women and Children, Department of Pharmacy, West China Second - University Hospital, Sichuan University, Chengdu 610000, China. -FAU - Yuan, Xiaohuan -AU - Yuan X -AD - Heilongjiang Key Laboratory of Anti-Fibrosis Biotherapy, Mudanjiang Medical - University, Mudanjiang 157000, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20221104 -PL - Switzerland -TA - Biomolecules -JT - Biomolecules -JID - 101596414 -RN - IT942ZTH98 (Curcumin) -RN - 0 (Antineoplastic Agents) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - *Curcumin/pharmacology/therapeutic use -MH - *Lung Neoplasms/drug therapy/pathology -MH - Motivation -MH - *Antineoplastic Agents/pharmacology/therapeutic use -MH - Cell Line, Tumor -PMC - PMC9688036 -OTO - NOTNLM -OT - combined treatment -OT - curcumin -OT - curcumin analogs -OT - non-small cell lung cancer -OT - signaling pathways -COIS- The authors declare no conflict of interest regarding this manuscript. -EDAT- 2022/11/12 06:00 -MHDA- 2022/11/15 06:00 -PMCR- 2022/11/04 -CRDT- 2022/11/11 01:08 -PHST- 2022/09/28 00:00 [received] -PHST- 2022/10/23 00:00 [revised] -PHST- 2022/10/29 00:00 [accepted] -PHST- 2022/11/11 01:08 [entrez] -PHST- 2022/11/12 06:00 [pubmed] -PHST- 2022/11/15 06:00 [medline] -PHST- 2022/11/04 00:00 [pmc-release] -AID - biom12111636 [pii] -AID - biomolecules-12-01636 [pii] -AID - 10.3390/biom12111636 [doi] -PST - epublish -SO - Biomolecules. 2022 Nov 4;12(11):1636. doi: 10.3390/biom12111636. - -PMID- 38885371 -OWN - NLM -STAT- MEDLINE -DCOM- 20241009 -LR - 20241009 -IS - 1460-2105 (Electronic) -IS - 0027-8874 (Linking) -VI - 116 -IP - 10 -DP - 2024 Oct 1 -TI - Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced - NSCLC: a network meta-analysis. -PG - 1571-1586 -LID - 10.1093/jnci/djae137 [doi] -AB - INTRODUCTION: Programmed death 1 (PD-1)/programmed death 1 ligand 1 - (PD-L1)-directed immunotherapy has revolutionized the treatments for advanced - non-small cell lung cancer (NSCLC), whereas the optimal therapeutic combinations - remain uncertain. METHODS: Our study encompassed phase II/III randomized - controlled trials (RCTs) that involved anti-PD-(L)1-based therapies for stage-IV - NSCLC. The primary outcomes included overall survival (OS), progression-free - survival (PFS), objective response rate (ORR), and incidences of adverse events. - Subgroup analyses were conducted by treatment lines, PD-L1 expression levels, - histological types, and metastatic sites. RESULTS: Our analysis incorporated 38 - publications, covering 14 therapeutic combinations and involving 18 048 - participants. PD-(L)1+chemotherapy (CT), PD-(L)1+ cytotoxic T - lymphocyte-associated antigen-4 (CTLA4) +CT, and PD-(L)1+ T-cell immunoglobulin - and ITIM domain were notably effective in prolonging OS. Overall, PD-(L)1+CT and - PD-(L)1+CT+ vascular endothelial growth factor (VEGF) were significantly - beneficial for PFS and ORR. As for the subsequent-line treatments, incorporating - radiotherapy can enhance PFS and ORR (ranked fourth among enrolled treatments). - For patients with PD-L1 <1%, PD-(L)1+CT+VEGF and PD-(L)1+CTLA4+CT were favorable - approaches. Conversely, in patients with PD-L1 ≥50%, PD-(L)1+CT represented an - effective treatment. Patients with nonsquamous cell carcinoma or liver metastases - might benefit from the addition of VEGF. In cases of squamous cell carcinoma or - brain metastases, the combination of PD-(L)1+CTLA4+CT yielded superior benefits. - CONCLUSIONS: This study underscores the enhanced efficacy of combination - immunotherapies over monotherapy. It highlights the necessity for personalized - treatment, considering individual factors. These insights are vital for clinical - decision making in the management of advanced NSCLC. -CI - © The Author(s) 2024. Published by Oxford University Press. All rights reserved. - For permissions, please email: journals.permissions@oup.com. -FAU - Chu, Xianjing -AU - Chu X -AD - Department of Oncology, Xiangya Hospital, Central South University, Changsha, - China. -FAU - Tian, Wentao -AU - Tian W -AD - Department of Oncology, Xiangya Hospital, Central South University, Changsha, - China. -FAU - Ning, Jiaoyang -AU - Ning J -AD - Department of Oncology, Xiangya Hospital, Central South University, Changsha, - China. -FAU - Zhou, Rongrong -AU - Zhou R -AUID- ORCID: 0000-0003-4483-0615 -AD - Department of Oncology, Xiangya Hospital, Central South University, Changsha, - China. -AD - Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, - China. -AD - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, - Central South University, Changsha, China. -LA - eng -GR - 320.6750.2023-5-109/Clinical Research Special Fund of Wu Jieping Medical - Foundation/ -GR - 2022LNJJ10/Xiangya Hospital, Central South University/ -GR - Chen Xiao-Ping Foundation/ -GR - CXPJJH121005-01/Development of Science and Technology of Hubei Province/ -GR - CTONG-YC20210303/Advanced Lung Cancer Targeted Therapy Research Foundation of - China/ -GR - z027002/National Multidisciplinary Cooperative Diagnosis and Treatment Capacity/ -PT - Journal Article -PT - Meta-Analysis -PL - United States -TA - J Natl Cancer Inst -JT - Journal of the National Cancer Institute -JID - 7503089 -RN - 0 (B7-H1 Antigen) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (CD274 protein, human) -RN - 0 (CTLA-4 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology/therapy/immunology -MH - *Lung Neoplasms/drug therapy/pathology/immunology/therapy -MH - *B7-H1 Antigen/antagonists & inhibitors/metabolism -MH - *Immune Checkpoint Inhibitors/therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Network Meta-Analysis -MH - Precision Medicine -MH - Randomized Controlled Trials as Topic -MH - Immunotherapy/methods -MH - Clinical Trials, Phase II as Topic -MH - Progression-Free Survival -MH - Clinical Trials, Phase III as Topic -MH - CTLA-4 Antigen/antagonists & inhibitors -EDAT- 2024/06/17 18:43 -MHDA- 2024/10/09 10:18 -CRDT- 2024/06/17 15:13 -PHST- 2024/01/24 00:00 [received] -PHST- 2024/05/20 00:00 [revised] -PHST- 2024/06/10 00:00 [accepted] -PHST- 2024/10/09 10:18 [medline] -PHST- 2024/06/17 18:43 [pubmed] -PHST- 2024/06/17 15:13 [entrez] -AID - 7695242 [pii] -AID - 10.1093/jnci/djae137 [doi] -PST - ppublish -SO - J Natl Cancer Inst. 2024 Oct 1;116(10):1571-1586. doi: 10.1093/jnci/djae137. - -PMID- 38734764 -OWN - NLM -STAT- MEDLINE -DCOM- 20240718 -LR - 20240819 -IS - 1476-5500 (Electronic) -IS - 0929-1903 (Print) -IS - 0929-1903 (Linking) -VI - 31 -IP - 7 -DP - 2024 Jul -TI - Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms - and therapeutic potential. -PG - 961-969 -LID - 10.1038/s41417-024-00778-4 [doi] -AB - Lung malignant tumors are a type of cancer with high incidence and mortality - rates worldwide. Non-small cell lung cancer (NSCLC) accounts for over 80% of all - lung malignant tumors, and most patients are diagnosed at advanced stages, - leading to poor prognosis. Over the past decades, various oncogenic driver - alterations associated with lung cancer have been identified, each of which can - potentially serve as a therapeutic target. Rat sarcoma (RAS) genes are the most - commonly mutated oncogenes in human cancers, with Kirsten rat sarcoma (KRAS) - being the most common subtype. The role of KRAS oncogene in NSCLC is still not - fully understood, and its impact on prognosis remains controversial. Despite the - significant advancements in targeted therapy and immune checkpoint inhibitors - (ICI) that have transformed the treatment landscape of advanced NSCLC in recent - years, targeting KRAS (both directly and indirectly) remains challenging and is - still under intensive research. In recent years, significant progress has been - made in the development of targeted drugs targeting the NSCLC KRASG12C mutant - subtype. However, research progress on target drugs for the more common KRASG12D - subtype has been slow, and currently, no specific drugs have been approved for - clinical use, and many questions remain to be answered, such as the mechanisms of - resistance in this subtype of NSCLC, how to better utilize combination strategies - with multiple treatment modalities, and whether KRASG12D inhibitors offer - substantial efficacy in the treatment of advanced NSCLC patients. -CI - © 2024. The Author(s). -FAU - Tang, Yining -AU - Tang Y -AUID- ORCID: 0009-0006-5142-9538 -AD - Department of Radiation Oncology, Cancer Institute of Jiangsu University, - Affiliated Hospital of Jiangsu University, Zhenjiang, 212000, Jiangsu, China. -FAU - Pu, Xi -AU - Pu X -AD - Department of Radiation Oncology, Cancer Institute of Jiangsu University, - Affiliated Hospital of Jiangsu University, Zhenjiang, 212000, Jiangsu, China. -FAU - Yuan, Xiao -AU - Yuan X -AD - Department of Radiation Oncology, Cancer Institute of Jiangsu University, - Affiliated Hospital of Jiangsu University, Zhenjiang, 212000, Jiangsu, China. -FAU - Pang, Zhonghao -AU - Pang Z -AD - Department of Thoracic Surgery, Affiliated Hospital of Jiangsu University, - Zhenjiang, 212000, Jiangsu, China. -FAU - Li, Feng -AU - Li F -AUID- ORCID: 0009-0001-2819-7779 -AD - Department of Thoracic Surgery, Affiliated Hospital of Jiangsu University, - Zhenjiang, 212000, Jiangsu, China. 1000011360@ujs.edu.cn. -FAU - Wang, Xu -AU - Wang X -AD - Department of Radiation Oncology, Cancer Institute of Jiangsu University, - Affiliated Hospital of Jiangsu University, Zhenjiang, 212000, Jiangsu, China. - wangxu@ujs.edu.cn. -LA - eng -PT - Journal Article -PT - Review -DEP - 20240511 -PL - England -TA - Cancer Gene Ther -JT - Cancer gene therapy -JID - 9432230 -RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) -RN - 0 (KRAS protein, human) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/genetics/drug therapy/pathology -MH - *Lung Neoplasms/genetics/drug therapy/pathology -MH - *Proto-Oncogene Proteins p21(ras)/genetics/antagonists & inhibitors -MH - *Mutation -MH - Molecular Targeted Therapy/methods -MH - Animals -PMC - PMC11257988 -COIS- The authors declare no competing interests. -EDAT- 2024/05/12 00:44 -MHDA- 2024/07/19 00:42 -PMCR- 2024/05/11 -CRDT- 2024/05/11 23:26 -PHST- 2023/11/14 00:00 [received] -PHST- 2024/04/22 00:00 [accepted] -PHST- 2024/03/22 00:00 [revised] -PHST- 2024/07/19 00:42 [medline] -PHST- 2024/05/12 00:44 [pubmed] -PHST- 2024/05/11 23:26 [entrez] -PHST- 2024/05/11 00:00 [pmc-release] -AID - 10.1038/s41417-024-00778-4 [pii] -AID - 778 [pii] -AID - 10.1038/s41417-024-00778-4 [doi] -PST - ppublish -SO - Cancer Gene Ther. 2024 Jul;31(7):961-969. doi: 10.1038/s41417-024-00778-4. Epub - 2024 May 11. - -PMID- 32810975 -OWN - NLM -STAT- MEDLINE -DCOM- 20210726 -LR - 20210726 -IS - 1999-6187 (Electronic) -IS - 1009-3419 (Print) -IS - 1009-3419 (Linking) -VI - 23 -IP - 10 -DP - 2020 Oct 20 -TI - [CAR-T Immunotherapy and Non-small Cell Lung Cancer: Bottleneck and Dawn]. -PG - 916-920 -LID - 10.3779/j.issn.1009-3419.2020.103.10 [doi] -AB - With the deeper understanding of the pathophysiology and pathogenesis of - non-small cell lung cancer (NSCLC) which threatens human health, NSCLC treatment - has entered a new era. Transition from traditional treatment based on surgery, - radiotherapy and chemotherapy to individualized and precise targeted therapy and - safer and more effective immunotherapy. Immune checkpoint inhibitor therapy has - been approved as a first-line or second-line treatment for advanced NSCLC, and - has achieved extraordinary clinical results. Meanwhile, other types of - immunotherapy are rarely explored in NSCLC. Chimeric antigen receptor modified T - cells (CAR-T cells) perform well in treating several hematological malignancies. - However, it is not ideal for treating patients with solid tumors including NSCLC. - This review aims to systematically explain the latest progress of CAR-T in the - treatment of NSCLC, mainly including: CAR molecular target selection, CAR-T - function enhancement and related toxicity management, as well as the difficulties - and prospects of CAR-T treatment of NSCLC. It aims to open up new perspectives - and unique ideas for the immunotherapy of NSCLC, and contribute to the building - of tumor immunotherapy.
. -FAU - Zhang, Li -AU - Zhang L -AD - Department of Thoracic Surgery, Yunnan Cancer Hospital, Kunming 650118, China. -FAU - Li, Heng -AU - Li H -AD - Department of Thoracic Surgery, Yunnan Cancer Hospital, Kunming 650118, China. -FAU - Zhang, Feiyue -AU - Zhang F -AD - Department of Thoracic Surgery, Yunnan Cancer Hospital, Kunming 650118, China. -FAU - Wang, Shuting -AU - Wang S -AD - Department of Thoracic Surgery, Yunnan Cancer Hospital, Kunming 650118, China. -FAU - Li, Gaofeng -AU - Li G -AD - Department of Thoracic Surgery, Yunnan Cancer Hospital, Kunming 650118, China. -LA - chi -PT - Journal Article -PT - Review -DEP - 20200819 -PL - China -TA - Zhongguo Fei Ai Za Zhi -JT - Zhongguo fei ai za zhi = Chinese journal of lung cancer -JID - 101126433 -RN - 0 (Receptors, Chimeric Antigen) -SB - IM -MH - Animals -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/immunology -MH - Humans -MH - *Immunotherapy -MH - Lung Neoplasms/*drug therapy/genetics/immunology -MH - Receptors, Chimeric Antigen/genetics/*immunology -MH - T-Lymphocytes/*immunology -PMC - PMC7583876 -OTO - NOTNLM -OT - Chimeric antigen receptor modified T cells -OT - Lung neoplasms -OT - Target -OT - Toxicity -EDAT- 2020/08/20 06:00 -MHDA- 2021/07/27 06:00 -PMCR- 2020/10/20 -CRDT- 2020/08/19 06:00 -PHST- 2020/08/20 06:00 [pubmed] -PHST- 2021/07/27 06:00 [medline] -PHST- 2020/08/19 06:00 [entrez] -PHST- 2020/10/20 00:00 [pmc-release] -AID - zgfazz-23-10-916 [pii] -AID - 10.3779/j.issn.1009-3419.2020.103.10 [doi] -PST - ppublish -SO - Zhongguo Fei Ai Za Zhi. 2020 Oct 20;23(10):916-920. doi: - 10.3779/j.issn.1009-3419.2020.103.10. Epub 2020 Aug 19. - -PMID- 37852738 -OWN - NLM -STAT- MEDLINE -DCOM- 20231030 -LR - 20240210 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 11 -IP - 10 -DP - 2023 Oct -TI - Increased interleukin-6/C-reactive protein levels are associated with the - upregulation of the adenosine pathway and serve as potential markers of - therapeutic resistance to immune checkpoint inhibitor-based therapies in - non-small cell lung cancer. -LID - 10.1136/jitc-2023-007310 [doi] -LID - e007310 -AB - BACKGROUND: Systemic immune activation, hallmarked by C-reactive protein (CRP) - and interleukin-6 (IL-6), can modulate antitumor immune responses. In this study, - we evaluated the role of IL-6 and CRP in the stratification of patients with - non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors - (ICIs). We also interrogated the underlying immunosuppressive mechanisms driven - by the IL-6/CRP axis. METHODS: In cohort A (n=308), we estimated the association - of baseline CRP with objective response rate (ORR), progression-free survival - (PFS), and overall survival (OS) in patients with NSCLC treated with ICIs alone - or with chemo-immunotherapy (Chemo-ICI). Baseline tumor bulk RNA sequencing - (RNA-seq) of lung adenocarcinomas (LUADs) treated with pembrolizumab (cohort B, - n=59) was used to evaluate differential expression of purine metabolism, as well - as correlate IL-6 expression with PFS. CODEFACS approach was applied to - deconvolve cohort B to characterize the tumor microenvironment by reconstructing - the cell-type-specific transcriptome from bulk expression. Using the LUAD cohort - from The Cancer Genome Atlas (TCGA) we explored the correlation between IL-6 - expression and adenosine gene signatures. In a third cohort (cohort C, n=18), - plasma concentrations of CRP, adenosine 2a receptor (A2aR), and IL-6 were - measured using ELISA. RESULTS: In cohort A, 67.2% of patients had a baseline - CRP≥10 mg/L (CRP-H). Patients with CRP-H achieved shorter OS (8.6 vs 14.8 months; - p=0.006), shorter PFS (3.3 vs 6.6 months; p=0.013), and lower ORR (24.7% vs - 46.3%; p=0.015). After adjusting for relevant clinical variables, CRP-H was - confirmed as an independent predictor of increased risk of death (HR 1.51, 95% - CI: 1.09 to 2.11) and lower probability of achieving disease response (OR 0.34, - 95% CI: 0.13 to 0.89). In cohort B, RNA-seq analysis demonstrated higher IL-6 - expression on tumor cells of non-responders, along with a shorter PFS (p<0.05) - and enrichment of the purinergic pathway. Within the TCGA LUAD cohort, tumor IL-6 - expression strongly correlated with the adenosine signature (R=0.65; p<2.2e-16). - Plasma analysis in cohort C demonstrated that CRP-H patients had a greater median - baseline level of A2aR (6.0 ng/mL vs 1.3 ng/mL; p=0.01). CONCLUSIONS: This study - demonstrates CRP as a readily available blood-based prognostic biomarker in - ICI-treated NSCLC. Additionally, we elucidate a potential link of the CRP/IL-6 - axis with the immunosuppressive adenosine signature pathway that could drive - inferior outcomes to ICIs in NSCLC and also offer novel therapeutic avenues. -CI - © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published - by BMJ. -FAU - Naqash, Abdul Rafeh -AU - Naqash AR -AD - Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, - Oklahoma City, Oklahoma, USA alessiocortellini@gmail.com - abdulrafeh-naqash@ouhsc.edu. -AD - Hematology / Oncology Division, East Carolina University, Greenville, South - Carolina, USA. -FAU - McCallen, Justin D -AU - McCallen JD -AD - Department of Internal Medicine, University of North Carolina at Chapel Hill, - Chapel Hill, North Carolina, USA. -AD - Brody School of Medicine, East Carolina University, Greenville, NC, USA. -FAU - Mi, Emma -AU - Mi E -AD - Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College - London, London, UK. -FAU - Iivanainen, Sanna -AU - Iivanainen S -AUID- ORCID: 0000-0003-1075-1134 -AD - Oncology and Radiation Department, Oulu University Hospital, University of Oulu, - MRC Oulu, Oulu, Finland. -FAU - Marie, Mona A -AU - Marie MA -AD - Hematology / Oncology Division, East Carolina University, Greenville, South - Carolina, USA. -FAU - Gramenitskaya, Daria -AU - Gramenitskaya D -AD - Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College - London, London, UK. -FAU - Clark, James -AU - Clark J -AD - Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College - London, London, UK. -FAU - Koivunen, Jussi Pekka -AU - Koivunen JP -AD - Oncology and Radiation Department, Oulu University Hospital, University of Oulu, - MRC Oulu, Oulu, Finland. -FAU - Macherla, Shravanti -AU - Macherla S -AD - Hematology / Oncology Division, East Carolina University, Greenville, South - Carolina, USA. -FAU - Jonnalagadda, Sweta -AU - Jonnalagadda S -AD - Hematology / Oncology Division, East Carolina University, Greenville, South - Carolina, USA. -FAU - Polsani, Shanker -AU - Polsani S -AD - Hematology / Oncology Division, East Carolina University, Greenville, South - Carolina, USA. -FAU - Jiwani, Rahim Ali -AU - Jiwani RA -AD - Department of Internal Medicine, East Carolina University, Greenville, NC, USA. -FAU - Hafiz, Maida -AU - Hafiz M -AD - Division of Pulmonary Critical Care, University of Oklahoma Health Sciences - Center, Oklahoma City, Oklahoma, USA. -AD - Division of Pulmonary and Critical Care, East Carolina University, Greenville, - NC, USA. -FAU - Muzaffar, Mahvish -AU - Muzaffar M -AD - Hematology / Oncology Division, East Carolina University, Greenville, South - Carolina, USA. -FAU - Brunetti, Leonardo -AU - Brunetti L -AD - Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario - Campus Bio-Medico, Via Alvaro del Portillo 200, Roma, Italy, Italy. -FAU - Stroud, Chipman R G -AU - Stroud CRG -AD - Genentech, South San Francisco, California, USA. -FAU - Walker, Paul R -AU - Walker PR -AD - Hematology / Oncology Division, East Carolina University, Greenville, South - Carolina, USA. -AD - Circulogene, Birmingham, Alabama, USA. -FAU - Wang, Kun -AU - Wang K -AD - Cancer Data Science Lab, National Cancer Institute, National Institute of Health, - Bethesda, Maryland, USA. -FAU - Chung, Youngmin -AU - Chung Y -AD - Department of Artificial Intelligence, Sungkyunkwan University, Suwon, Reuplic of - Korea. -FAU - Ruppin, Eytan -AU - Ruppin E -AD - Cancer Data Science Lab, National Cancer Institute, National Institute of Health, - Bethesda, Maryland, USA. -FAU - Lee, Se-Hoon -AU - Lee SH -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center - School of Medicine, Sungkyunkwan University, Seoul, Republic of Korea. -AD - Department of Health Sciences and Technology, Samsung Advanced Institute of - Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of - Korea. -FAU - Yang, Li V -AU - Yang LV -AD - Hematology / Oncology Division, East Carolina University, Greenville, South - Carolina, USA. -FAU - Pinato, David J -AU - Pinato DJ -AUID- ORCID: 0000-0002-3529-0103 -AD - Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College - London, London, UK. -AD - Division of Oncology, Department of Translational Medicine, University of - Piemonte Orientale, Novara, Italy. -FAU - Lee, Joo Sang -AU - Lee JS -AD - Department of Artificial Intelligence, Sungkyunkwan University, Suwon, Reuplic of - Korea. -AD - Department of Precision Medicine, School of Medicine, Sungkyunkwan University, - Suwon, Republic of Korea. -AD - Department of Digital Health, Samsung Advanced Institute of Health Sciences and - Technology, Sungkyunkwan University, Seoul, Republic of Korea. -FAU - Cortellini, Alessio -AU - Cortellini A -AUID- ORCID: 0000-0002-1209-5735 -AD - Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College - London, London, UK alessiocortellini@gmail.com abdulrafeh-naqash@ouhsc.edu. -AD - Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario - Campus Bio-Medico, Via Alvaro del Portillo 200, Roma, Italy, Italy. -LA - eng -GR - WT_/Wellcome Trust/United Kingdom -GR - PS3416/WT_/Wellcome Trust/United Kingdom -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - K72T3FS567 (Adenosine) -RN - 9007-41-4 (C-Reactive Protein) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Interleukin-6) -RN - 0 (CRP protein, human) -RN - 0 (IL6 protein, human) -SB - IM -MH - Humans -MH - Adenosine -MH - C-Reactive Protein -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Drug Resistance, Neoplasm -MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use -MH - Interleukin-6 -MH - *Lung Neoplasms/drug therapy/genetics -MH - Tumor Microenvironment -MH - Up-Regulation -PMC - PMC10603340 -OTO - NOTNLM -OT - Adenosine -OT - Immune Checkpoint Inhibitors -OT - Inflammation -OT - Lung Neoplasms -OT - Tumor Microenvironment -COIS- Competing interests: The authors disclose no conflicts of interest in relation to - the published work. AC received grants for consultancies/advisory boards: BMS, - MSD, OncoC4, IQVIA, Roche, GSK, AstraZeneca, Access Infinity, Ardelis Health. He - also received speaker fees from AstraZeneca, EISAI, MSD and Pierre-Fabre. DJP - received lecture fees from ViiV Healthcare, Bayer Healthcare, AstraZeneca, Roche, - IPSEN and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina - Therapeutics, EISAI, Roche, AstraZeneca, DaVolterra, Exact Sciences, MURSLA, - Avamune, BMS; received research funding (to institution) from MSD, BMS, GSK. -EDAT- 2023/10/19 00:45 -MHDA- 2023/10/23 01:18 -PMCR- 2023/10/18 -CRDT- 2023/10/18 21:03 -PHST- 2023/09/13 00:00 [accepted] -PHST- 2023/10/23 01:18 [medline] -PHST- 2023/10/19 00:45 [pubmed] -PHST- 2023/10/18 21:03 [entrez] -PHST- 2023/10/18 00:00 [pmc-release] -AID - jitc-2023-007310 [pii] -AID - 10.1136/jitc-2023-007310 [doi] -PST - ppublish -SO - J Immunother Cancer. 2023 Oct;11(10):e007310. doi: 10.1136/jitc-2023-007310. - -PMID- 28778960 -OWN - NLM -STAT- MEDLINE -DCOM- 20180723 -LR - 20240606 -IS - 1549-490X (Electronic) -IS - 1083-7159 (Print) -IS - 1083-7159 (Linking) -VI - 22 -IP - 12 -DP - 2017 Dec -TI - Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage - Small Cell Lung Cancer. -PG - 1510-1517 -LID - 10.1634/theoncologist.2017-0204 [doi] -AB - The prevalence of small cell lung cancer (SCLC) has declined in the U.S. as the - prevalence of tobacco use has declined. However, a significant number of people - in the U.S. are current or former smokers and are at risk of developing SCLC. - Routine histological or cytological evaluation can reliably make the diagnosis of - SCLC, and immunohistochemistry stains (thyroid transcription factor-1, - chromogranin, synaptophysin, and CD56) can be used if there is uncertainty about - the diagnosis. Rarely do patients present with SCLC amendable to surgical - resection, and evaluation requires a meticulous workup for extra-thoracic - metastases and invasive staging of the mediastinum. Resected patients require - adjuvant chemotherapy and/or thoracic radiation therapy (TRT), and prophylactic - cranial radiation (PCI) should be considered depending on the stage. For - limited-stage disease, concurrent platinum-etoposide and TRT followed by PCI is - the standard. Thoracic radiation therapy should be started early in treatment, - and can be given twice daily to 45 Gy or once daily to 60-70 Gy. For - extensive-stage disease, platinum-etoposide remains the standard first-line - therapy, and the standard second-line therapy is topotecan. Preliminary studies - have demonstrated the activity of immunotherapy, and the response rate is - approximately 10-30% with some durable responses observed. Rovalpituzumab - tesirine, an antibody drug conjugate, has shown promising activity in patients - with high delta-like protein 3 tumor expression (approximately 70% of patients - with SCLC). The emergence of these and other promising agents has rekindled - interest in drug development in SCLC. Several ongoing trials are investigating - novel agents in the first-line, maintenance, and second-line settings. - IMPLICATIONS FOR PRACTICE: This review will provide an update on the standard - therapies for surgically resected limited-stage small cell lung cancer and - extensive-stage small cell lung cancer that have been investigated in recent - clinical trials. -CI - © AlphaMed Press 2017. -FAU - Stinchcombe, Thomas E -AU - Stinchcombe TE -AD - Duke Cancer Institute, Durham, North Carolina, USA Thomas.stinchcombe@duke.edu. -LA - eng -PT - Journal Article -PT - Review -DEP - 20170804 -PL - England -TA - Oncologist -JT - The oncologist -JID - 9607837 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Benzodiazepinones) -RN - 0 (CD56 Antigen) -RN - 0 (Immunoconjugates) -RN - 0 (rovalpituzumab tesirine) -SB - IM -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - Benzodiazepinones/therapeutic use -MH - CD56 Antigen/genetics -MH - *Chemotherapy, Adjuvant -MH - Combined Modality Therapy -MH - Humans -MH - Immunoconjugates/therapeutic use -MH - Mediastinum/*pathology -MH - Neoplasm Invasiveness/*pathology -MH - Neoplasm Staging -MH - Percutaneous Coronary Intervention -MH - Small Cell Lung Carcinoma/*drug therapy/pathology/radiotherapy/surgery -PMC - PMC5728020 -OTO - NOTNLM -OT - Antibody drug conjugated -OT - Chemoradiotherapy -OT - Clinical trials -OT - Immunotherapy -OT - Prophylactic cranial radiation -OT - Rovalpituzumab tesirine -COIS- Disclosures of potential conflicts of interest may be found at the end of this - article. -EDAT- 2017/08/06 06:00 -MHDA- 2018/07/24 06:00 -PMCR- 2018/12/01 -CRDT- 2017/08/06 06:00 -PHST- 2017/05/07 00:00 [received] -PHST- 2017/07/06 00:00 [accepted] -PHST- 2017/08/06 06:00 [pubmed] -PHST- 2018/07/24 06:00 [medline] -PHST- 2017/08/06 06:00 [entrez] -PHST- 2018/12/01 00:00 [pmc-release] -AID - theoncologist.2017-0204 [pii] -AID - ONCO12223 [pii] -AID - 10.1634/theoncologist.2017-0204 [doi] -PST - ppublish -SO - Oncologist. 2017 Dec;22(12):1510-1517. doi: 10.1634/theoncologist.2017-0204. Epub - 2017 Aug 4. - -PMID- 35986515 -OWN - NLM -STAT- MEDLINE -DCOM- 20230131 -LR - 20230226 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 12 -IP - 2 -DP - 2023 Jan -TI - Radiotherapy combined with PD-1/PD-L1 inhibitors in NSCLC brain metastases - treatment: The mechanisms, advances, opportunities, and challenges. -PG - 995-1006 -LID - 10.1002/cam4.5016 [doi] -AB - At present, whole-brain radiation therapy/stereotactic radiosurgery is one of the - main local treatments for brain metastasis of non-small-cell lung cancer (NSCLC). - Currently, it has been proved that radiotherapy (RT) can regulate the immune - response, and small-sample studies have shown that patients with NSCLC brain - metastases (BMs) can benefit from RT combined with immunotherapy (IO). However, - the efficacy and safety of the combination treatment have not been deeply - elaborated. Notably, as a challenge that is still being explored, the timing of - RT combined with IO is likely to be an important factor affecting efficacy and - prognosis. This article reviews the current application and challenges of RT - combined with IO from the perspectives of molecular mechanism, combination - timing, safety, and efficacy. The purpose is to provide information on clinical - evidence-based medicine of combination between RT with IO. For further - investigation, we also discuss the major challenges and prospects of RT combined - with IO in NSCLC BMs. -CI - © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Chen, Zi-Ying -AU - Chen ZY -AD - Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, - Guangzhou, China. -FAU - Duan, Xiao-Tong -AU - Duan XT -AD - Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, - Guangzhou, China. -FAU - Qiao, Si-Miao -AU - Qiao SM -AD - Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, - Guangzhou, China. -FAU - Zhu, Xiao-Xia -AU - Zhu XX -AUID- ORCID: 0000-0003-3030-0306 -AD - Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, - Guangzhou, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20220819 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Lung Neoplasms/pathology -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Programmed Cell Death 1 Receptor -MH - *Brain Neoplasms/drug therapy -MH - Cranial Irradiation -PMC - PMC9883424 -OTO - NOTNLM -OT - brain metastases -OT - immunotherapy -OT - mechanism -OT - non-small-cell lung cancer -OT - radiotherapy -OT - safety -OT - timing -COIS- The authors declare that they have no conflict of interest. -EDAT- 2022/08/21 06:00 -MHDA- 2023/02/01 06:00 -PMCR- 2022/08/19 -CRDT- 2022/08/20 01:42 -PHST- 2022/06/10 00:00 [revised] -PHST- 2022/03/04 00:00 [received] -PHST- 2022/06/29 00:00 [accepted] -PHST- 2022/08/21 06:00 [pubmed] -PHST- 2023/02/01 06:00 [medline] -PHST- 2022/08/20 01:42 [entrez] -PHST- 2022/08/19 00:00 [pmc-release] -AID - CAM45016 [pii] -AID - 10.1002/cam4.5016 [doi] -PST - ppublish -SO - Cancer Med. 2023 Jan;12(2):995-1006. doi: 10.1002/cam4.5016. Epub 2022 Aug 19. - -PMID- 37584783 -OWN - NLM -STAT- MEDLINE -DCOM- 20230912 -LR - 20230922 -IS - 1573-7276 (Electronic) -IS - 0262-0898 (Linking) -VI - 40 -IP - 5 -DP - 2023 Oct -TI - Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung - cancer after immunotherapy in real world. -PG - 423-429 -LID - 10.1007/s10585-023-10227-5 [doi] -AB - The immunotherapy combined chemotherapy has been the standard treatment strategy - for extensive-stage small lung cancer (ES-SCLC). The CREST trial reported - consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for - ES-SCLC with intrathoracic residual after chemotherapy. In this study, patients - with ES-SCLC who received immunotherapy were assigned to receive either TRT or no - TRT. TRT significantly improved progression-free survival (PFS), local - recurrence-free survival (LRFS) and OS with well tolerated toxicity. Further - sub-cohort analysis, TRT significantly improved LRFS in patients with - oligo-metastasis and without liver metastasis. -CI - © 2023. The Author(s), under exclusive licence to Springer Nature B.V. -FAU - Fang, Min -AU - Fang M -AD - Department of Thoracic Radiotherapy, Key Laboratory of Radiation Oncology of - Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, 310022, China. - fangmin@zjcc.org.cn. -AD - Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, - 310018, China. fangmin@zjcc.org.cn. -AD - Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, 310022, - China. fangmin@zjcc.org.cn. -FAU - Wang, Le -AU - Wang L -AD - Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, - 310018, China. -AD - Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, 310022, - China. -FAU - Gu, Qing -AU - Gu Q -AD - Department of Thoracic Radiotherapy, Key Laboratory of Radiation Oncology of - Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, 310022, China. -AD - Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, - 310018, China. -FAU - Wu, Huiwen -AU - Wu H -AD - Department of Thoracic Radiotherapy, Key Laboratory of Radiation Oncology of - Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, 310022, China. -FAU - Du, Xianghui -AU - Du X -AD - Department of Thoracic Radiotherapy, Key Laboratory of Radiation Oncology of - Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, 310022, China. -AD - Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, - 310018, China. -FAU - Lai, Xiaojing -AU - Lai X -AD - Department of Thoracic Radiotherapy, Key Laboratory of Radiation Oncology of - Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, 310022, China. - laixj@zjcc.org.cn. -AD - Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, - 310018, China. laixj@zjcc.org.cn. -LA - eng -PT - Clinical Trial -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20230816 -PL - Netherlands -TA - Clin Exp Metastasis -JT - Clinical & experimental metastasis -JID - 8409970 -SB - IM -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Neoplasm Staging -MH - *Small Cell Lung Carcinoma/drug therapy/radiotherapy -MH - Treatment Outcome -OTO - NOTNLM -OT - Chemoimmunotherapy -OT - ES-SCLC -OT - Thoracic Radiotherapy -OT - Toxicity -EDAT- 2023/08/16 12:41 -MHDA- 2023/09/12 06:41 -CRDT- 2023/08/16 11:08 -PHST- 2023/05/04 00:00 [received] -PHST- 2023/07/24 00:00 [accepted] -PHST- 2023/09/12 06:41 [medline] -PHST- 2023/08/16 12:41 [pubmed] -PHST- 2023/08/16 11:08 [entrez] -AID - 10.1007/s10585-023-10227-5 [pii] -AID - 10.1007/s10585-023-10227-5 [doi] -PST - ppublish -SO - Clin Exp Metastasis. 2023 Oct;40(5):423-429. doi: 10.1007/s10585-023-10227-5. - Epub 2023 Aug 16. - -PMID- 36480416 -OWN - NLM -STAT- MEDLINE -DCOM- 20230721 -LR - 20230721 -IS - 1743-7563 (Electronic) -IS - 1743-7555 (Linking) -VI - 19 -IP - 4 -DP - 2023 Aug -TI - Image-guided thermal ablation for patients with epidermal growth factor - receptor-mutant nonsmall cell lung cancer. -PG - 427-433 -LID - 10.1111/ajco.13875 [doi] -AB - Nonsmall cell lung cancer (NSCLC) is treated by various therapies such as - surgical intervention, radiotherapy, chemotherapy, molecular targeted therapy, - and immunotherapy. Currently, molecular targeted therapy, including epidermal - growth factor receptor (EGFR) inhibitors and Anaplastic Lymphoma Kinase (ALK) and - Kirsten Rat Sarcoma viral Oncogene (KRAS) inhibitors, has received much attention - and improved the prognosis of NSCLC. Nevertheless, the terminal point of - molecular targeted drugs is resistance. Drug resistance has been classified into - oligoprogression and extensive progression based on the tumor lesion progression - after drug resistance. There is extensive research demonstrating that local - therapy (surgical resection, radiotherapy, and thermal ablation) can prolong the - survival of patients with drug resistance. This review is intended to determine - the efficacy of image-guided thermal ablation in patients with NSCLC with EGFR - mutation. -CI - © 2022 John Wiley & Sons Australia, Ltd. -FAU - Huang, Yahan -AU - Huang Y -AD - Department of Oncology, The First Affiliated Hospital of Shandong, First Medical - University and Shandong Provincial Qianfoshan Hospital, Shandong Key, Laboratory - of Rheumatic Disease and Translational medicine, Shandong Lung Cancer, Jinan, - China. -AD - Shandong First Medical University, Jinan, China. -FAU - Kong, Yongmei -AU - Kong Y -AD - Department of Oncology, The First Affiliated Hospital of Shandong, First Medical - University and Shandong Provincial Qianfoshan Hospital, Shandong Key, Laboratory - of Rheumatic Disease and Translational medicine, Shandong Lung Cancer, Jinan, - China. -AD - Shandong First Medical University, Jinan, China. -FAU - Wei, Zhigang -AU - Wei Z -AD - Department of Oncology, The First Affiliated Hospital of Shandong, First Medical - University and Shandong Provincial Qianfoshan Hospital, Shandong Key, Laboratory - of Rheumatic Disease and Translational medicine, Shandong Lung Cancer, Jinan, - China. -FAU - Ye, Xin -AU - Ye X -AUID- ORCID: 0000-0002-4906-7746 -AD - Department of Oncology, The First Affiliated Hospital of Shandong, First Medical - University and Shandong Provincial Qianfoshan Hospital, Shandong Key, Laboratory - of Rheumatic Disease and Translational medicine, Shandong Lung Cancer, Jinan, - China. -LA - eng -GR - ZR2020MH294/The Shandong Provincial Natural Science Foundation/ -PT - Journal Article -PT - Review -DEP - 20221208 -PL - Australia -TA - Asia Pac J Clin Oncol -JT - Asia-Pacific journal of clinical oncology -JID - 101241430 -RN - EC 2.7.10.1 (ErbB Receptors) -RN - 0 (Protein Kinase Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy -MH - *Lung Neoplasms/therapy/drug therapy -MH - Mutation -MH - ErbB Receptors/genetics -MH - Prognosis -MH - Protein Kinase Inhibitors/therapeutic use -OTO - NOTNLM -OT - EGFR-mutation -OT - nonsmall cell lung cancer -OT - oligoprogression -OT - thermal ablation -EDAT- 2022/12/09 06:00 -MHDA- 2023/07/21 06:43 -CRDT- 2022/12/08 15:08 -PHST- 2022/06/08 00:00 [received] -PHST- 2022/09/24 00:00 [accepted] -PHST- 2023/07/21 06:43 [medline] -PHST- 2022/12/09 06:00 [pubmed] -PHST- 2022/12/08 15:08 [entrez] -AID - 10.1111/ajco.13875 [doi] -PST - ppublish -SO - Asia Pac J Clin Oncol. 2023 Aug;19(4):427-433. doi: 10.1111/ajco.13875. Epub 2022 - Dec 8. - -PMID- 32991781 -OWN - NLM -STAT- MEDLINE -DCOM- 20210719 -LR - 20210719 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 9 -IP - 22 -DP - 2020 Nov -TI - Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell - lung cancer. -PG - 8406-8411 -LID - 10.1002/cam4.3456 [doi] -AB - Multiple randomized studies have shown that combination of chemotherapy and - immune checkpoint inhibitors (ICIs) leads to better response rates and survival - as compared to chemotherapy alone in the advanced stage of NSCLC. Data suggesting - a benefit to using ICIs in the neoadjuvant therapy of patients with early stage - NSCLC are emerging. Eligible subjects were treatment naïve patients with stage - IB, II, and resectable IIIA NSCLC. Patients received three cycles of neoadjuvant - chemotherapy with four doses of avelumab every 2 weeks. Patients with squamous - cell cancer received cisplatin or carboplatin on day 1 and gemcitabine on days 1 - and 8 of each cycle of chemotherapy. Patients with nonsquamous histology received - cisplatin or carboplatin with pemetrexed on day 1 of each cycle. Patients then - proceeded to their planned surgery. Out of 15 patients accrued as part of stage 1 - of the study, four had a radiologic response (1 complete response), lower than - the minimum of six responses needed to continue to phase 2 of the study. The - study was therefore terminated. Majority had adenocarcinoma histology and stage - IIIA disease. The treatment was well tolerated with no unexpected side effects. - Four patients (26.7%) had grade III/IV CTCAE toxicity. This study confirms that - the preoperative administration of chemotherapy and avelumab is safe. There was - no indication of increased surgical complications. The benefit of adding - immunotherapy to chemotherapy did not appear to enhance the overall response rate - of patients in the neoadjuvant setting in patients with resectable NSCLC because - this study failed to meet its primary endpoint. -CI - © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Tfayli, Arafat -AU - Tfayli A -AUID- ORCID: 0000-0002-0633-2538 -AD - Division of Hematology-Oncology, American University of Beirut Medical Center, - Beirut, Lebanon. -FAU - Al Assaad, Majd -AU - Al Assaad M -AD - Division of Hematology-Oncology, American University of Beirut Medical Center, - Beirut, Lebanon. -FAU - Fakhri, Ghina -AU - Fakhri G -AD - Division of Hematology-Oncology, American University of Beirut Medical Center, - Beirut, Lebanon. -FAU - Akel, Reem -AU - Akel R -AD - Division of Hematology-Oncology, American University of Beirut Medical Center, - Beirut, Lebanon. -FAU - Atwi, Hanine -AU - Atwi H -AD - Division of Hematology-Oncology, American University of Beirut Medical Center, - Beirut, Lebanon. -FAU - Ghanem, Hady -AU - Ghanem H -AD - Department of Internal Medicine, Lebanese American University Medical Center-Rizk - Hospital, Beirut, Lebanon. -FAU - El Karak, Fadi -AU - El Karak F -AD - Department of Internal Medicine, Saint Joseph University, Beirut, Lebanon. -FAU - Farhat, Fadi -AU - Farhat F -AD - Division of Hematology-Oncology, Hammoud Hospital University Medical Center, - Saida, Lebanon. -FAU - Al Rabi, Kamal -AU - Al Rabi K -AD - Department of Internal Medicine, King Hussien Cancer Center, Amman, Jordan. -FAU - Sfeir, Pierre -AU - Sfeir P -AD - Division of Cardiothoracic Surgery, American University of Beirut Medical Center, - Beirut, Lebanon. -FAU - Youssef, Pierre -AU - Youssef P -AD - Division of Cardiothoracic Surgery, Hammoud Hospital University Medical Center, - Saida, Lebanon. -FAU - Mansour, Ziad -AU - Mansour Z -AD - Division of Cardiothoracic Surgery, Geitaoui Medical Center, Beirut, Lebanon. -FAU - Assi, Hazem -AU - Assi H -AUID- ORCID: 0000-0002-8483-0938 -AD - Division of Hematology-Oncology, American University of Beirut Medical Center, - Beirut, Lebanon. -FAU - Haidar, Mohamad -AU - Haidar M -AD - Department of Radiology, American University of Beirut Medical Center, Beirut, - Lebanon. -FAU - Abi Ghanem, Alain -AU - Abi Ghanem A -AD - Department of Radiology, American University of Beirut Medical Center, Beirut, - Lebanon. -FAU - Khalifeh, Ibrahim -AU - Khalifeh I -AD - Department of Pathology, American University of Beirut Medical Center, Beirut, - Lebanon. -FAU - Boulos, Fouad -AU - Boulos F -AD - Department of Pathology, American University of Beirut Medical Center, Beirut, - Lebanon. -FAU - Mahfouz, Ramy -AU - Mahfouz R -AD - Department of Pathology, American University of Beirut Medical Center, Beirut, - Lebanon. -FAU - Youssef, Bassem -AU - Youssef B -AD - Department of Radiation Oncology, American University of Beirut Medical Center, - Beirut, Lebanon. -FAU - Zeidan, Youssef -AU - Zeidan Y -AD - Department of Radiation Oncology, American University of Beirut Medical Center, - Beirut, Lebanon. -FAU - Bejjany, Rachelle -AU - Bejjany R -AD - Division of Hematology-Oncology, American University of Beirut Medical Center, - Beirut, Lebanon. -FAU - Khuri, Fadlo -AU - Khuri F -AD - Division of Hematology-Oncology, American University of Beirut Medical Center, - Beirut, Lebanon. -LA - eng -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -DEP - 20200929 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Immune Checkpoint Inhibitors) -RN - KXG2PJ551I (avelumab) -SB - IM -MH - Adenocarcinoma of Lung/*drug therapy/mortality/pathology -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects/*therapeutic use -MH - Lung Neoplasms/*drug therapy/mortality/pathology -MH - Male -MH - Middle Aged -MH - *Neoadjuvant Therapy/adverse effects/mortality -MH - Neoplasm Staging -MH - *Pneumonectomy/adverse effects/mortality -MH - Progression-Free Survival -MH - Time Factors -PMC - PMC7666740 -OTO - NOTNLM -OT - immune checkpoint inhibitors -OT - neoadjuvant therapy -OT - nonsmall cell lung cancer -OT - oncogenic drivers -COIS- The authors declare no conflict of interest. -EDAT- 2020/09/30 06:00 -MHDA- 2021/07/20 06:00 -PMCR- 2020/09/29 -CRDT- 2020/09/29 17:15 -PHST- 2020/05/13 00:00 [received] -PHST- 2020/08/17 00:00 [revised] -PHST- 2020/08/19 00:00 [accepted] -PHST- 2020/09/30 06:00 [pubmed] -PHST- 2021/07/20 06:00 [medline] -PHST- 2020/09/29 17:15 [entrez] -PHST- 2020/09/29 00:00 [pmc-release] -AID - CAM43456 [pii] -AID - 10.1002/cam4.3456 [doi] -PST - ppublish -SO - Cancer Med. 2020 Nov;9(22):8406-8411. doi: 10.1002/cam4.3456. Epub 2020 Sep 29. - -PMID- 31383534 -OWN - NLM -STAT- MEDLINE -DCOM- 20200520 -LR - 20200520 -IS - 1433-2981 (Electronic) -IS - 0936-6555 (Linking) -VI - 31 -IP - 12 -DP - 2019 Dec -TI - When Should we Irradiate the Primary in Metastatic Lung Cancer? -PG - 815-823 -LID - S0936-6555(19)30292-4 [pii] -LID - 10.1016/j.clon.2019.07.012 [doi] -AB - Metastatic lung cancer encompasses a heterogenous group of patients in terms of - burdens of disease, ranging from patients with extensive metastases to those with - a limited number of metastatic lesions (oligometastatic disease). - Histopathological heterogeneity also exists within two broad categories, - non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), portraying - different patterns and evolution of disease. Local consolidative therapy to the - primary tumour and metastatic sites, including surgery and/or radical dose - radiotherapy, is increasingly being used to improve survival outcomes, - particularly in the context of oligometastatic disease, with or without the use - of molecular targeted therapy and immunotherapy. Recently, randomised studies in - oligometastatic NSCLC have shown that local consolidative therapy may confer a - survival advantage. This review explores whether treating just the primary tumour - with radiotherapy may similarly produce improved clinical outcomes. Such a - treatment strategy may carry less potential toxicity than treating multiple sites - upfront. The biological rationale behind the potential benefits of treating just - the primary in metastatic malignancy is discussed. The clinical evidence of such - an approach across tumour sites, such as breast and prostate cancer, is also - explored. Then the review focuses on treating the primary in NSCLC and SCLC with - radiotherapy, by first exploring patterns of failure in metastatic NSCLC and - second exploring evidence on survival outcomes from studies in metastatic NSCLC - and SCLC. It is challenging to draw conclusions on the clinical benefit of - treating the primary cancer in isolation from the evidence available. This - highlights the need to collect data within the ongoing clinical trials on the - clinical outcome and toxicity of radiotherapy delivery to primary thoracic - disease specifically. This challenge also identifies the need to design future - clinical trials to produce randomised evidence for such an approach. -CI - Copyright © 2019 The Royal College of Radiologists. All rights reserved. -FAU - Shiarli, A-M -AU - Shiarli AM -AD - Radiotherapy Department, The Royal Marsden Hospital, Sutton, UK. Electronic - address: anna.shiarli@icr.ac.uk. -FAU - McDonald, F -AU - McDonald F -AD - Radiotherapy Department, The Royal Marsden Hospital, Sutton, UK. -FAU - Gomez, D R -AU - Gomez DR -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, New York, USA. -LA - eng -GR - CRUK_/Cancer Research UK/United Kingdom -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20190802 -PL - England -TA - Clin Oncol (R Coll Radiol) -JT - Clinical oncology (Royal College of Radiologists (Great Britain)) -JID - 9002902 -SB - IM -CIN - Clin Oncol (R Coll Radiol). 2019 Dec;31(12):813-814. doi: - 10.1016/j.clon.2019.07.002. PMID: 31326144 -MH - Adolescent -MH - Adult -MH - Carcinoma, Non-Small-Cell Lung/pathology/*secondary -MH - Humans -MH - Lung Neoplasms/pathology/*secondary -MH - Male -MH - Neoplasms, Unknown Primary/*radiotherapy -MH - Small Cell Lung Carcinoma/drug therapy/secondary -MH - Young Adult -OTO - NOTNLM -OT - Lung cancer -OT - non-small cell lung cancer -OT - oligometastatic disease -OT - primary tumour -OT - radiotherapy -OT - small cell lung cancer -EDAT- 2019/08/07 06:00 -MHDA- 2020/05/21 06:00 -CRDT- 2019/08/07 06:00 -PHST- 2019/06/24 00:00 [received] -PHST- 2019/06/28 00:00 [revised] -PHST- 2019/07/02 00:00 [accepted] -PHST- 2019/08/07 06:00 [pubmed] -PHST- 2020/05/21 06:00 [medline] -PHST- 2019/08/07 06:00 [entrez] -AID - S0936-6555(19)30292-4 [pii] -AID - 10.1016/j.clon.2019.07.012 [doi] -PST - ppublish -SO - Clin Oncol (R Coll Radiol). 2019 Dec;31(12):815-823. doi: - 10.1016/j.clon.2019.07.012. Epub 2019 Aug 2. - -PMID- 37313918 -OWN - NLM -STAT- MEDLINE -DCOM- 20231005 -LR - 20231005 -IS - 1998-4138 (Electronic) -IS - 1998-4138 (Linking) -VI - 19 -IP - 2 -DP - 2023 Jan-Mar -TI - Successful treatment with durvalumab: A case report and review. -PG - 470-473 -LID - 10.4103/jcrt.jcrt_1430_21 [doi] -AB - Stage III non-small-cell lung cancer (NSCLC) represents a heterogeneous group of - disease entities with multimodality treatments. For most patients, platinum-based - doublet with concurrent chemoradiotherapy (CRT) has become the first-choice - treatment over the past decade. Immune checkpoint inhibition has revolutionized - the management of metastatic NSCLC; however, no major advances in systemic - therapy for Stage III NSCLC have been made. The following report is the case of a - patient with unresectable Stage IIIA NSCLC successfully treated with durvalumab. - The patient completed 1 year of treatment without interruptions, and disease - control has been maintained for more than 20 months since the start of - durvalumab. -FAU - Bejarano, Ana Peláez -AU - Bejarano AP -AD - Hospital Pharmacy, Unidad de Gestión Clínica Farmacia, Hospital Juan Ramón - Jiménez, Huelva, Spain. -FAU - Pérez, Olalla Montero -AU - Pérez OM -AD - Hospital Pharmacy, Unidad de Gestión Clínica Farmacia, Hospital Juan Ramón - Jiménez, Huelva, Spain. -LA - eng -PT - Case Reports -PT - Review -PL - India -TA - J Cancer Res Ther -JT - Journal of cancer research and therapeutics -JID - 101249598 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Humans -MH - Antibodies, Monoclonal/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -OTO - NOTNLM -OT - Antiprogrammed cell death ligand 1 -OT - consolidation -OT - durvalumab -OT - immunotherapy -OT - non-small-cell lung cancer -COIS- None -EDAT- 2023/06/14 13:07 -MHDA- 2023/06/15 06:42 -CRDT- 2023/06/14 06:14 -PHST- 2023/06/15 06:42 [medline] -PHST- 2023/06/14 13:07 [pubmed] -PHST- 2023/06/14 06:14 [entrez] -AID - JCanResTher_2023_19_2_470_331104 [pii] -AID - 10.4103/jcrt.jcrt_1430_21 [doi] -PST - ppublish -SO - J Cancer Res Ther. 2023 Jan-Mar;19(2):470-473. doi: 10.4103/jcrt.jcrt_1430_21. - -PMID- 37993218 -OWN - NLM -STAT- MEDLINE -DCOM- 20231124 -LR - 20240410 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 24 -IP - 8 -DP - 2023 Dec -TI - The Impact of Prophylactic Cranial Irradiation and Consolidative Thoracic - Radiation Therapy for Extensive Stage Small-Cell Lung Cancer in the Transition to - the Chemo-Immunotherapy Era: A Single Institution Series. -PG - 696-705 -LID - S1525-7304(23)00154-7 [pii] -LID - 10.1016/j.cllc.2023.08.009 [doi] -AB - INTRODUCTION: Extensive-stage small-cell lung cancer (ES-SCLC) continues to have - poor survival due to its aggressive behavior, despite improvements with - incorporation of immunotherapy with standard chemotherapy. Controversy exists - regarding the role of consolidative thoracic radiation therapy (TRT) and - prophylactic cranial irradiation (PCI) in ES-SCLC due to high recurrence rates. - We report our institutional result of the benefit of PCI and TRT in ES-SCLC. - METHODS: Patients with ES-SCLC without intracranial metastasis at diagnosis - (N = 163) were included. All patients completed systemic therapy with or without - immunotherapy based on time of standard of care. Cohorts were divided by systemic - therapy use and further subdivided by treatment with PCI and TRT. Overall - survival (OS) and progression-free survival (PFS) were estimated by the - Kaplan-Meier method with log-rank test for comparison. The effects of TRT and PCI - were estimated by multivariable (MVA) Cox regression. RESULTS: Seventy-four - patients (45.4%) received TRT, and 33.1% (n = 54) received PCI. The median - follow-up was 11 months (3-85 months). PCI improved median OS to 15 months from - 10 months, P = .02) and median PFS to 8.5 months from 5 months (P = .02) which - remained significant on MVA, P = .02 and P = .02, respectively. TRT improved OS - on UVA (P = 0.002) but was not significant on MVA. TRT did not improve PFS. - CONCLUSION: This study including chemotherapy and chemo-immunotherapy suggests - improved outcomes with addition of PCI in patients with ES-SCLC while TRT did not - show benefit to either OS or PFS. A future trial is needed to evaluate the role - of TRT and PCI in the era of chemo-immunotherapy. -CI - Copyright © 2023 Elsevier Inc. All rights reserved. -FAU - Gross, Andrew J -AU - Gross AJ -AD - Department of Radiation Oncology, University Hospitals Cleveland Medical Center, - Seidman Cancer Center, Cleveland, OH. -FAU - Sheikh, Saad -AU - Sheikh S -AD - Department of Radiation Oncology, University Hospitals Cleveland Medical Center, - Seidman Cancer Center, Cleveland, OH. -FAU - Kharouta, Michael -AU - Kharouta M -AD - Department of Radiation Oncology, Advocate Illinois Masonic Hospital, Chicago, - IL. -FAU - Chaung, Kevin -AU - Chaung K -AD - Department of Radiation Oncology, University Hospitals Cleveland Medical Center, - Seidman Cancer Center, Cleveland, OH. -FAU - Choi, Serah -AU - Choi S -AD - Department of Radiation Oncology, University Hospitals Cleveland Medical Center, - Seidman Cancer Center, Cleveland, OH. -FAU - Margevicius, Seunghee -AU - Margevicius S -AD - Department of Population and Quantitative Health Sciences, Case Western Reserve - University, Cleveland, OH. -FAU - Fu, Pingfu -AU - Fu P -AD - Department of Population and Quantitative Health Sciences, Case Western Reserve - University, Cleveland, OH. -FAU - Machtay, Mitchell -AU - Machtay M -AD - Department of Radiation Oncology, Penn State College of Medicine, Hershey, PA. -FAU - Bruno, Debora S -AU - Bruno DS -AD - Department of Medicine, University Hospitals Cleveland Medical Center, Seidman - Cancer Center, Cleveland, OH; Case Western School of Medicine, Cleveland, OH. -FAU - Dowlati, Afshin -AU - Dowlati A -AD - Department of Medicine, University Hospitals Cleveland Medical Center, Seidman - Cancer Center, Cleveland, OH; Case Western School of Medicine, Cleveland, OH. -FAU - Biswas, Tithi -AU - Biswas T -AD - Department of Radiation Oncology, University Hospitals Cleveland Medical Center, - Seidman Cancer Center, Cleveland, OH; Case Western School of Medicine, Cleveland, - OH. Electronic address: tithipodder@gmail.com. -LA - eng -PT - Journal Article -DEP - 20230809 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -SB - IM -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - *Small Cell Lung Carcinoma/drug therapy -MH - Cranial Irradiation/methods -MH - Immunotherapy -OTO - NOTNLM -OT - Chemo-ICI -OT - ES-SCLC -OT - Intracranial failure -OT - PCI -OT - TRT -COIS- Disclosure All authors have completed the ICMJE uniform disclosure form. The - authors have no conflicts of interest to declare for the manuscript publication. -EDAT- 2023/11/23 00:42 -MHDA- 2023/11/24 06:42 -CRDT- 2023/11/22 21:00 -PHST- 2023/05/17 00:00 [received] -PHST- 2023/07/28 00:00 [revised] -PHST- 2023/08/07 00:00 [accepted] -PHST- 2023/11/24 06:42 [medline] -PHST- 2023/11/23 00:42 [pubmed] -PHST- 2023/11/22 21:00 [entrez] -AID - S1525-7304(23)00154-7 [pii] -AID - 10.1016/j.cllc.2023.08.009 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2023 Dec;24(8):696-705. doi: 10.1016/j.cllc.2023.08.009. Epub - 2023 Aug 9. - -PMID- 30853796 -OWN - NLM -STAT- MEDLINE -DCOM- 20200220 -LR - 20240714 -IS - 1718-7729 (Electronic) -IS - 1198-0052 (Print) -IS - 1198-0052 (Linking) -VI - 26 -IP - 1 -DP - 2019 Feb -TI - Perspectives on treatment advances for stage III locally advanced unresectable - non-small-cell lung cancer. -PG - 37-42 -LID - 10.3747/co.25.4096 [doi] -AB - For more than a decade, there has been no improvement in outcomes for patients - with unresectable locally advanced (la) non-small-cell lung cancer (nsclc). The - standard treatment in that setting is definitive concurrent chemotherapy and - radiation (ccrt). Although the intent of treatment is curative, most patients - rapidly progress, and their prognosis is poor, with a 5-year overall survival - (os) rate in the 15%-25% range. Those patients therefore represent a critical - unmet need, warranting expedited approval of, and access to, new treatments that - can improve outcomes. The pacific trial, which evaluated durvalumab consolidation - therapy after ccrt in unresectable la nsclc, demonstrated a statistically - significant and clinically meaningful improvement in progression-free survival - (pfs) and a significant improvement in os. Durvalumab thus fills a critical unmet - need in the setting of unresectable la nsclc and provides a new option for - patients treated with curative intent. Here, we review the treatment of - unresectable la nsclc, with a focus on the effect of the clinical data for - durvalumab. -FAU - Cheema, P K -AU - Cheema PK -AD - William Osler Health System, Brampton/Toronto, and University of Toronto, - Toronto, ON. -FAU - Rothenstein, J -AU - Rothenstein J -AD - R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, and Queen's University, - Kingston, ON. -FAU - Melosky, B -AU - Melosky B -AD - BC Cancer-Vancouver and University of British Columbia, Vancouver, BC. -FAU - Brade, A -AU - Brade A -AD - Peel Regional Cancer Centre, Mississauga, and University of Toronto, Toronto, ON. -FAU - Hirsh, V -AU - Hirsh V -AD - Royal Victoria Hospital and McGill University, Montreal, QC. -LA - eng -PT - Journal Article -PT - Review -DEP - 20190201 -PL - Switzerland -TA - Curr Oncol -JT - Current oncology (Toronto, Ont.) -JID - 9502503 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/pathology/*therapy -MH - *Chemoradiotherapy -MH - Humans -MH - Lung Neoplasms/pathology/*therapy -MH - Neoplasm Staging -PMC - PMC6380636 -OTO - NOTNLM -OT - Lung cancer -OT - immunotherapy -OT - stage III disease -COIS- CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s - policy on disclosing conflicts of interest, and we declare the following - interests: PKC reports attending advisory boards and receiving honoraria from - AstraZeneca, Boehringer Ingelheim, Bristol–Myers Squibb, Merck, Novartis, Pfizer, - Roche, and Takeda, all of which were outside of the submitted work; JR reports - attending advisory boards and receiving honoraria from AstraZeneca, Bristol–Myers - Squibb, Merck, Pfizer, and Hoffmann–La Roche, all of which were outside the - submitted work; PKC and JR were also investigators in the pacific clinical trial; - BM reports attending advisory boards and receiving honoraria from AstraZeneca, - Merck, Bristol–Myers Squibb, Boehringer Ingelheim, Novartis, and Pfizer, all of - which were outside the submitted work; AB reports travel support to a conference - from Eli Lilly and attending an advisory board for AstraZeneca, both of which - were outside the submitted work; VH reports attending advisory boards and - receiving honoraria from AstraZeneca, Boehringer Ingelheim, Bristol–Myers Squibb, - Merck, Pfizer, Hoffmann–La Roche, and AbbVie, all which were outside the - submitted work. -EDAT- 2019/03/12 06:00 -MHDA- 2020/02/23 06:00 -PMCR- 2019/02/01 -CRDT- 2019/03/12 06:00 -PHST- 2019/03/12 06:00 [entrez] -PHST- 2019/03/12 06:00 [pubmed] -PHST- 2020/02/23 06:00 [medline] -PHST- 2019/02/01 00:00 [pmc-release] -AID - 17_conc_cheemafeb_37-42 [pii] -AID - 10.3747/co.25.4096 [doi] -PST - ppublish -SO - Curr Oncol. 2019 Feb;26(1):37-42. doi: 10.3747/co.25.4096. Epub 2019 Feb 1. - -PMID- 31196369 -OWN - NLM -STAT- MEDLINE -DCOM- 20191126 -LR - 20200904 -IS - 1999-6187 (Electronic) -IS - 1009-3419 (Print) -IS - 1009-3419 (Linking) -VI - 22 -IP - 6 -DP - 2019 Jun 20 -TI - [New Advances in the Treatment for Small Cell Lung Cancer]. -PG - 355-362 -LID - 10.3779/j.issn.1009-3419.2019.06.05 [doi] -AB - Small cell lung cancer (SCLC) is a refractory cancer with high degree of - malignancy, rapid disease progression, poor prognosis and easy recurrence. In the - past 30 years, the traditional treatment of SCLC, mainly chemotherapy and - radiotherapy, has not changed significantly, and the effective treatment method - for clinical needs is extremely urgent. The rapid development of precision - medicine has revealed the molecular biological characteristics of SCLC, so its - diagnosis and treatment will into a new era. At present, some studies have shown - that anti-angiogenic drugs, immunotherapy and so on have improved the efficacy of - SCLC treatment to some extent, and there are more studies on the diagnosis and - treatment of SCLC, so a new field of SCLC treatment are coming and bringing more - survival benefits to patients. New studies on targeted therapy, anti-angiogenesis - drugs and immunotherapy of molecular pathology of SCLC are emerging. This paper - reviews the new diagnosis and treatment methods of SCLC to provide new guidance - for its clinical treatment.
. -FAU - Cui, Xiaoxia -AU - Cui X -AD - Department of Pulmonary and Critical Care Medicine, Peking Union Medical College - Hospital, Chinese Academy of Medical Science & Peking Union Medical College, - Beijing 100730, China. -FAU - Song, Peng -AU - Song P -AD - Department of Pulmonary and Critical Care Medicine, Peking Union Medical College - Hospital, Chinese Academy of Medical Science & Peking Union Medical College, - Beijing 100730, China. -FAU - Zhang, Li -AU - Zhang L -AD - Department of Pulmonary and Critical Care Medicine, Peking Union Medical College - Hospital, Chinese Academy of Medical Science & Peking Union Medical College, - Beijing 100730, China. -LA - chi -PT - Journal Article -PT - Review -PL - China -TA - Zhongguo Fei Ai Za Zhi -JT - Zhongguo fei ai za zhi = Chinese journal of lung cancer -JID - 101126433 -RN - 0 (Angiogenesis Inhibitors) -RN - 0 (Immunologic Factors) -SB - IM -MH - Angiogenesis Inhibitors/*administration & dosage -MH - Animals -MH - Humans -MH - Immunologic Factors/*administration & dosage -MH - *Immunotherapy -MH - Lung Neoplasms/diagnosis/*drug therapy -MH - Small Cell Lung Carcinoma/diagnosis/*drug therapy -PMC - PMC6580078 -OTO - NOTNLM -OT - Antiangiogenic agents -OT - Biology -OT - Immune checkpoint inhibitors -OT - Lung neoplasms -OT - Molecular-target therapy -EDAT- 2019/06/15 06:00 -MHDA- 2019/11/27 06:00 -PMCR- 2019/06/20 -CRDT- 2019/06/15 06:00 -PHST- 2019/06/15 06:00 [entrez] -PHST- 2019/06/15 06:00 [pubmed] -PHST- 2019/11/27 06:00 [medline] -PHST- 2019/06/20 00:00 [pmc-release] -AID - zgfazz-22-6-355 [pii] -AID - 10.3779/j.issn.1009-3419.2019.06.05 [doi] -PST - ppublish -SO - Zhongguo Fei Ai Za Zhi. 2019 Jun 20;22(6):355-362. doi: - 10.3779/j.issn.1009-3419.2019.06.05. - -PMID- 17927281 -OWN - NLM -STAT- MEDLINE -DCOM- 20080116 -LR - 20211020 -IS - 0012-6667 (Print) -IS - 0012-6667 (Linking) -VI - 67 -IP - 15 -DP - 2007 -TI - Modern management of small-cell lung cancer. -PG - 2135-52 -AB - In this article, we review best standard practice for the management of - small-cell lung cancer (SCLC) and indicate the likely areas of development over - the next 5-10 years. A number of prognostic scores have been developed and these - allow more rational decisions on treatment. Treatment with cisplatin plus - etoposide with early, concurrent radiotherapy is the standard of care for - patients with limited-stage disease (LD) suitable for this approach. A 5-year - survival rate of 25% has been reported for concurrent hyperfractionated - radiotherapy; however, the applicability of this in most busy hospitals is - uncertain and this treatment is currently being compared with a high-dose, - once-daily regimen. Patients unsuitable for concurrent chemo-radiotherapy are - treated with a sequential approach. Patients with LD responding to treatment - should be offered prophylactic cranial irradiation (PCI). A variety of strategies - for improving survival have been investigated. Intensification of chemotherapy - has not shown any clear survival advantage, but maintenance of dose intensity in - patients with good prognosis is important. The evidence around maintenance - therapy is conflicting and this is not routinely used. Patients with - extensive-stage disease but few other adverse prognostic factors should be - treated with a platinum compound plus etoposide, and carboplatin is a reasonable - choice. Responding patients should be offered PCI as this is associated with a - survival benefit. The initial positive results for irinotecan have not been - repeated in a larger study. Age is not a prognostic factor, but caution needs to - be exercised as prognostic scores do not reflect co-morbidity. Patients with - relapsed disease have a poor prognosis, but there is evidence of a survival - benefit for salvage chemotherapy in those fit for treatment. The choice of - treatment will depend on a number of factors, including the disease-free - interval. Topotecan is the only drug licensed in this indication, but - myelosuppression is considerable. A number of new drugs are under evaluation and - showing promise in SCLC. One of the most promising of these is amrubicin. A large - randomised study has failed to show any benefit from the addition of thalidomide - to chemotherapy with carboplatin and etoposide in extensive-stage disease - patients responding to chemotherapy. Studies of a number of targeted treatments - are also ongoing. The challenge for the future is to identify new targets, - overcome drug-resistance mechanisms and redundancy in biological systems, and - incorporate these new treatments into concurrent chemo-radiotherapy schedules. -FAU - Ferraldeschi, Roberta -AU - Ferraldeschi R -AD - Christie Hospital NHS Foundation Trust, Manchester, UK. -FAU - Baka, Sofia -AU - Baka S -FAU - Jyoti, Babita -AU - Jyoti B -FAU - Faivre-Finn, Corinne -AU - Faivre-Finn C -FAU - Thatcher, Nick -AU - Thatcher N -FAU - Lorigan, Paul -AU - Lorigan P -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - New Zealand -TA - Drugs -JT - Drugs -JID - 7600076 -RN - 0 (Antineoplastic Agents) -SB - IM -MH - Aged -MH - Animals -MH - Antineoplastic Agents/therapeutic use -MH - Carcinoma, Small Cell/drug therapy/pathology/radiotherapy/surgery/*therapy -MH - Combined Modality Therapy -MH - Drug Resistance, Neoplasm -MH - Humans -MH - Immunotherapy -MH - Karnofsky Performance Status -MH - Lung Neoplasms/drug therapy/pathology/radiotherapy/surgery/*therapy -MH - Neoplasm Recurrence, Local/drug therapy -MH - Prognosis -RF - 158 -EDAT- 2007/10/12 09:00 -MHDA- 2008/01/17 09:00 -CRDT- 2007/10/12 09:00 -PHST- 2007/10/12 09:00 [pubmed] -PHST- 2008/01/17 09:00 [medline] -PHST- 2007/10/12 09:00 [entrez] -AID - 67153 [pii] -AID - 10.2165/00003495-200767150-00003 [doi] -PST - ppublish -SO - Drugs. 2007;67(15):2135-52. doi: 10.2165/00003495-200767150-00003. - -PMID- 37563966 -OWN - NLM -STAT- MEDLINE -DCOM- 20231011 -LR - 20231011 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 12 -IP - 17 -DP - 2023 Sep -TI - Meta-analysis of PD-(L)1 inhibitor plus chemotherapy versus chemotherapy as - first-line treatment in extensive-stage small-cell lung cancer. -PG - 17924-17933 -LID - 10.1002/cam4.6433 [doi] -AB - BACKGROUND: Immunotherapy targeting programmed death 1(PD-1) and its ligand - (PD-L1) has been successful in extensive-stage small cell lung cancer (ES-SCLC). - However, first-line PD-(L)1 inhibitor combined with chemotherapy - (immunochemotherapy) versus chemotherapy has not been well studied. METHODS: - Randomized controlled trials had been searched from PubMed, Embase, and the - Cochrane Library until December 29, 2022. Randomized effect consistency models - were applied for estimating the pooled hazard ratios (HRs) and odds ratios (ORs). - Study outcomes included overall response rate (ORR), progression-free survival - (PFS), overall survival (OS), 6-month and 1-year disease progression rate, 1-year - and 2-year mortality rate, and Grade ≥3 adverse events (AEs). RESULTS: Six - eligible trials with 2600 ES-SCLC patients were included. Compared with - chemotherapy, immunochemotherapy significantly improved ORR (OR 1.32, 95% CI - 1.07-1.63; p = 0.01), PFS (HR 0.68, 95% CI 0.58-0.78; p < 0.001), and OS (HR - 0.72, 96% CI 0.66-0.78, p < 0.001) without increasing Grade ≥3 AEs (p = 0.07). - Compared with patients with chemotherapy, the 6-month disease progression rate - was reduced by 0.39 (p = 0.01) and the 1-year disease progression rate was - reduced by 0.75 (p < 0.001), the 1-year mortality rate was reduced by 0.33 - (p < 0.001) and the 2-year mortality rate was reduced by 0.50 (p < 0.001) - respectively in patients with immunochemotherapy. However, patients with brain - metastases failed to prolong PFS and OS from immunochemotherapy (p > 0.05). - CONCLUSION: Compared with chemotherapy, PD-(L)1 inhibitor plus chemotherapy as - first-line treatment could improve the efficacy and prognosis of ES-SCLC patients - without more serious side effects. However, more research is needed to validate - these results. -CI - © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Lu, Jiangyue -AU - Lu J -AD - Department of Radiation Oncology, The Fifth Medical Center of Chinese PLA General - Hospital, Beijing, China. -AD - Medical School of Chinese PLA, Beijing, China. -FAU - Lei, Xiao -AU - Lei X -AUID- ORCID: 0000-0002-0428-1749 -AD - Department of Radiation Oncology, The Fifth Medical Center of Chinese PLA General - Hospital, Beijing, China. -FAU - Zhang, Pei -AU - Zhang P -AD - Department of Radiation Oncology, The Fifth Medical Center of Chinese PLA General - Hospital, Beijing, China. -FAU - Du, Lehui -AU - Du L -AD - Department of Radiation Oncology, The Fifth Medical Center of Chinese PLA General - Hospital, Beijing, China. -FAU - Zhang, Zhibo -AU - Zhang Z -AUID- ORCID: 0000-0001-8534-7190 -AD - The 78th Group Army Hospital of Chinese PLA, Mudanjiang, China. -FAU - Qu, Baolin -AU - Qu B -AD - Department of Radiation Oncology, The Fifth Medical Center of Chinese PLA General - Hospital, Beijing, China. -LA - eng -PT - Journal Article -PT - Meta-Analysis -DEP - 20230811 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - Disease Progression -MH - Immunotherapy/methods -MH - *Lung Neoplasms/drug therapy/pathology -MH - *Small Cell Lung Carcinoma/drug therapy/pathology -MH - *Immune Checkpoint Inhibitors/therapeutic use -MH - Neoplasm Staging -PMC - PMC10524002 -OTO - NOTNLM -OT - chemotherapy -OT - extensive-stage -OT - immunotherapy -OT - meta-analysis -OT - small-cell lung cancer -COIS- All authors declare no conflict of interest. -EDAT- 2023/08/11 06:43 -MHDA- 2023/10/04 06:43 -PMCR- 2023/08/11 -CRDT- 2023/08/11 03:10 -PHST- 2023/05/29 00:00 [revised] -PHST- 2023/03/23 00:00 [received] -PHST- 2023/07/31 00:00 [accepted] -PHST- 2023/10/04 06:43 [medline] -PHST- 2023/08/11 06:43 [pubmed] -PHST- 2023/08/11 03:10 [entrez] -PHST- 2023/08/11 00:00 [pmc-release] -AID - CAM46433 [pii] -AID - 10.1002/cam4.6433 [doi] -PST - ppublish -SO - Cancer Med. 2023 Sep;12(17):17924-17933. doi: 10.1002/cam4.6433. Epub 2023 Aug - 11. - -PMID- 38833971 -OWN - NLM -STAT- MEDLINE -DCOM- 20240624 -LR - 20240827 -IS - 2059-7029 (Electronic) -IS - 2059-7029 (Linking) -VI - 9 -IP - 6 -DP - 2024 Jun -TI - Real-world outcomes with durvalumab after chemoradiotherapy in patients with - unresectable stage III NSCLC: interim analysis of overall survival from - PACIFIC-R. -PG - 103464 -LID - S2059-7029(24)01233-X [pii] -LID - 10.1016/j.esmoop.2024.103464 [doi] -LID - 103464 -AB - BACKGROUND: Based on the findings of the PACIFIC trial, consolidation durvalumab - following platinum-based chemoradiotherapy (CRT) is a global standard of care for - patients with unresectable, stage III non-small-cell lung cancer (NSCLC). An - earlier analysis from the ongoing PACIFIC-R study (NCT03798535) demonstrated the - effectiveness of this regimen in terms of progression-free survival (PFS). Here, - we report the first planned overall survival (OS) analysis. PATIENTS AND METHODS: - PACIFIC-R is an observational/non-interventional, retrospective study of patients - with unresectable, stage III NSCLC who started durvalumab (10 mg/kg intravenously - every 2 weeks) within an AstraZeneca-initiated early access program between - September 2017 and December 2018. Primary endpoints are OS and - investigator-assessed PFS, estimated using the Kaplan-Meier method. RESULTS: By - 30 November 2021, the full analysis set included 1154 participants from 10 - countries (median follow-up in censored patients: 38.7 months). Median OS was not - reached, and the 3-year OS rate was 63.2% (95% confidence interval 60.3% to - 65.9%). Three-year OS rates were numerically higher among patients with - programmed death-ligand 1 (PD-L1) expression on ≥1% versus <1% of tumor cells - (TCs; 67.0% versus 54.4%) and patients who received concurrent CRT (cCRT) versus - sequential CRT (sCRT) (64.8% versus 57.9%). CONCLUSIONS: PACIFIC-R data continue - to provide evidence for the effectiveness of consolidation durvalumab after CRT - in a large, diverse, real-world population. Better outcomes were observed among - patients with PD-L1 TCs ≥1% and patients who received cCRT. Nevertheless, - encouraging outcomes were still observed among patients with TCs <1% and patients - who received sCRT, supporting use of consolidation durvalumab in a broad - population of patients with unresectable, stage III NSCLC. -CI - Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. -FAU - Filippi, A R -AU - Filippi AR -AD - Radiation Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere - Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy. - Electronic address: andreariccardo.filippi@istitutotumori.mi.it. -FAU - Bar, J -AU - Bar J -AD - Institute of Oncology, Sheba Medical Centre, Ramat Gan; Faculty of Medicine, Tel - Aviv University, Tel Aviv, Israel. -FAU - Chouaid, C -AU - Chouaid C -AD - Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, Créteil, - France. -FAU - Christoph, D C -AU - Christoph DC -AD - Department of Medical Oncology, Evang. Kliniken Essen-Mitte, Evang. - Huyssens-Stiftung Essen-Huttrop, Essen, Germany. -FAU - Field, J K -AU - Field JK -AD - Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical - Cancer Medicine, University of Liverpool, Liverpool, UK. -FAU - Fietkau, R -AU - Fietkau R -AD - Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, - Germany. -FAU - Garassino, M C -AU - Garassino MC -AD - Department of Hematology/Oncology, The University of Chicago, Chicago, USA. -FAU - Garrido, P -AU - Garrido P -AD - Medical Oncology Department, Hospital Ramón y Cajal, Universidad de Alcalá, - Madrid, Spain. -FAU - Haakensen, V D -AU - Haakensen VD -AD - Department of Oncology and Institute for Cancer Research, Oslo University - Hospital, Oslo, Norway. -FAU - Kao, S -AU - Kao S -AD - Chris O'Brien Lifehouse, Sydney. -FAU - Markman, B -AU - Markman B -AD - Cabrini Hospital and Monash University, Melbourne, Australia. -FAU - McDonald, F -AU - McDonald F -AD - Lung Unit, The Royal Marsden NHS Foundation Trust, London, UK. -FAU - Mornex, F -AU - Mornex F -AD - Department of Radiation Oncology, Centre Hospitalier Universitaire de Lyon, Lyon, - France. -FAU - Moskovitz, M -AU - Moskovitz M -AD - Rambam Health Care Campus, Haifa, Israel. -FAU - Peters, S -AU - Peters S -AD - Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, - Switzerland. -FAU - Sibille, A -AU - Sibille A -AD - Department of Pneumology, Centre Hospitalier Universitaire de Liège, Liège, - Belgium. -FAU - Siva, S -AU - Siva S -AD - Peter MacCallum Cancer Centre and The University of Melbourne, Melbourne, - Australia. -FAU - van den Heuvel, M -AU - van den Heuvel M -AD - Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, - The Netherlands. -FAU - Vercauter, P -AU - Vercauter P -AD - Department of Pneumology, OLV Hospital Aalst, Aalst, Belgium. -FAU - Anand, S -AU - Anand S -AD - AstraZeneca, Gaithersburg, USA. -FAU - Chander, P -AU - Chander P -AD - AstraZeneca, Gaithersburg, USA. -FAU - Licour, M -AU - Licour M -AD - AstraZeneca, Courbevoie, France. -FAU - de Lima, A R -AU - de Lima AR -AD - AstraZeneca, Gaithersburg, USA. -FAU - Qiao, Y -AU - Qiao Y -AD - AstraZeneca, Gaithersburg, USA. -FAU - Girard, N -AU - Girard N -AD - Institut du Thorax Curie Montsouris, Institut Curie, Paris; UVSQ, Paris Saclay, - Versailles, France. -LA - eng -PT - Journal Article -PT - Multicenter Study -PT - Observational Study -DEP - 20240603 -PL - England -TA - ESMO Open -JT - ESMO open -JID - 101690685 -RN - 28X28X9OKV (durvalumab) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/mortality/pathology/therapy/drug therapy -MH - Female -MH - Male -MH - *Lung Neoplasms/mortality/therapy/pathology/drug therapy -MH - Middle Aged -MH - Retrospective Studies -MH - Aged -MH - *Chemoradiotherapy/methods -MH - *Antibodies, Monoclonal/therapeutic use -MH - *Antineoplastic Agents, Immunological/therapeutic use/pharmacology -MH - Adult -MH - Neoplasm Staging -MH - Aged, 80 and over -PMC - PMC11179087 -OTO - NOTNLM -OT - PD-L1 -OT - durvalumab -OT - immunotherapy -OT - locally advanced NSCLC -OT - real-world evidence -EDAT- 2024/06/05 01:46 -MHDA- 2024/06/25 00:43 -PMCR- 2024/06/03 -CRDT- 2024/06/04 18:08 -PHST- 2023/11/23 00:00 [received] -PHST- 2024/04/10 00:00 [revised] -PHST- 2024/04/12 00:00 [accepted] -PHST- 2024/06/25 00:43 [medline] -PHST- 2024/06/05 01:46 [pubmed] -PHST- 2024/06/04 18:08 [entrez] -PHST- 2024/06/03 00:00 [pmc-release] -AID - S2059-7029(24)01233-X [pii] -AID - 103464 [pii] -AID - 10.1016/j.esmoop.2024.103464 [doi] -PST - ppublish -SO - ESMO Open. 2024 Jun;9(6):103464. doi: 10.1016/j.esmoop.2024.103464. Epub 2024 Jun - 3. - -PMID- 34625620 -OWN - NLM -STAT- MEDLINE -DCOM- 20220125 -LR - 20230921 -IS - 2045-2322 (Electronic) -IS - 2045-2322 (Linking) -VI - 11 -IP - 1 -DP - 2021 Oct 8 -TI - CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung - cancer. -PG - 20059 -LID - 10.1038/s41598-021-99524-1 [doi] -LID - 20059 -AB - Immune checkpoint blockade (ICB) improves outcomes in non-small cell lung cancer - (NSCLC) though most patients progress. There are limited data regarding molecular - predictors of progression. In particular, there is controversy regarding the role - of CDKN2A loss-of-function (LOF) in ICB resistance. We analyzed 139 consecutive - patients with advanced NSCLC who underwent NGS prior to ICB initiation to explore - the association of CDKN2A LOF with clinical outcomes. 73% were PD-L1 positive - (≥ 1%). 48% exhibited high TMB (≥ 10 mutations/megabase). CDKN2A LOF was present - in 26% of patients and was associated with inferior PFS (multivariate hazard - ratio [MVA-HR] 1.66, 95% CI 1.02-2.63, p = 0.041) and OS (MVA-HR 2.08, 95% CI - 1.21-3.49, p = 0.0087) when compared to wild-type (WT) patients. These findings - held in patients with high TMB (median OS, LOF vs. WT 10.5 vs. 22.3 months; - p = 0.069) and PD-L1 ≥ 50% (median OS, LOF vs. WT 11.1 vs. 24.2 months; - p = 0.020), as well as in an independent dataset. CDKN2A LOF vs. WT tumors were - twice as likely to experience disease progression following ICB (46% vs. 21%; - p = 0.021). CDKN2A LOF negatively impacts clinical outcomes in advanced NSCLC - treated with ICB, even in high PD-L1 and high TMB tumors. This novel finding - should be prospectively validated and presents a potential therapeutic target. -CI - © 2021. The Author(s). -FAU - Gutiontov, Stanley I -AU - Gutiontov SI -AD - Department of Radiation and Cellular Oncology, The University of Chicago, 5758 S - Maryland Ave, MC 9006, Chicago, IL, 60637, USA. -FAU - Turchan, William Tyler -AU - Turchan WT -AD - Department of Radiation and Cellular Oncology, The University of Chicago, 5758 S - Maryland Ave, MC 9006, Chicago, IL, 60637, USA. -FAU - Spurr, Liam F -AU - Spurr LF -AD - Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA. -FAU - Rouhani, Sherin J -AU - Rouhani SJ -AD - Section of Hematology/Oncology, Department of Medicine, The University of - Chicago, Chicago, IL, USA. -FAU - Chervin, Carolina Soto -AU - Chervin CS -AD - Section of Hematology/Oncology, Department of Medicine, The University of - Chicago, Chicago, IL, USA. -FAU - Steinhardt, George -AU - Steinhardt G -AD - Department of Pathology, The University of Chicago, Chicago, IL, USA. -FAU - Lager, Angela M -AU - Lager AM -AD - Section of Hematology/Oncology, Department of Medicine, The University of - Chicago, Chicago, IL, USA. -FAU - Wanjari, Pankhuri -AU - Wanjari P -AD - Department of Pathology, The University of Chicago, Chicago, IL, USA. -FAU - Malik, Renuka -AU - Malik R -AD - Department of Radiation and Cellular Oncology, The University of Chicago, 5758 S - Maryland Ave, MC 9006, Chicago, IL, 60637, USA. -FAU - Connell, Philip P -AU - Connell PP -AD - Department of Radiation and Cellular Oncology, The University of Chicago, 5758 S - Maryland Ave, MC 9006, Chicago, IL, 60637, USA. -FAU - Chmura, Steven J -AU - Chmura SJ -AD - Department of Radiation and Cellular Oncology, The University of Chicago, 5758 S - Maryland Ave, MC 9006, Chicago, IL, 60637, USA. -FAU - Juloori, Aditya -AU - Juloori A -AD - Department of Radiation and Cellular Oncology, The University of Chicago, 5758 S - Maryland Ave, MC 9006, Chicago, IL, 60637, USA. -FAU - Hoffman, Philip C -AU - Hoffman PC -AD - Section of Hematology/Oncology, Department of Medicine, The University of - Chicago, Chicago, IL, USA. -FAU - Ferguson, Mark K -AU - Ferguson MK -AD - Section of Thoracic Surgery, Department of Surgery, The University of Chicago, - Chicago, IL, USA. -FAU - Donington, Jessica S -AU - Donington JS -AD - Section of Thoracic Surgery, Department of Surgery, The University of Chicago, - Chicago, IL, USA. -FAU - Patel, Jyoti D -AU - Patel JD -AD - Section of Hematology/Oncology, Department of Medicine, Northwestern University, - Evanston, IL, USA. -FAU - Vokes, Everett E -AU - Vokes EE -AD - Section of Hematology/Oncology, Department of Medicine, The University of - Chicago, Chicago, IL, USA. -FAU - Weichselbaum, Ralph R -AU - Weichselbaum RR -AD - Department of Radiation and Cellular Oncology, The University of Chicago, 5758 S - Maryland Ave, MC 9006, Chicago, IL, 60637, USA. -AD - Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL, - USA. -FAU - Bestvina, Christine M -AU - Bestvina CM -AD - Section of Hematology/Oncology, Department of Medicine, The University of - Chicago, Chicago, IL, USA. -FAU - Segal, Jeremy P -AU - Segal JP -AD - Department of Pathology, The University of Chicago, Chicago, IL, USA. -FAU - Pitroda, Sean P -AU - Pitroda SP -AD - Department of Radiation and Cellular Oncology, The University of Chicago, 5758 S - Maryland Ave, MC 9006, Chicago, IL, 60637, USA. spitroda@radonc.uchicago.edu. -AD - Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL, - USA. spitroda@radonc.uchicago.edu. -LA - eng -GR - T32 CA009566/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20211008 -PL - England -TA - Sci Rep -JT - Scientific reports -JID - 101563288 -RN - 0 (Biomarkers, Tumor) -RN - 0 (CDKN2A protein, human) -RN - 0 (Cyclin-Dependent Kinase Inhibitor p16) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Biomarkers, Tumor/*genetics -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/*pathology -MH - Cyclin-Dependent Kinase Inhibitor p16/*genetics -MH - Drug Resistance, Neoplasm/*genetics -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Immunotherapy/*methods -MH - *Loss of Function Mutation -MH - Lung Neoplasms/drug therapy/genetics/*pathology -MH - Male -MH - Middle Aged -MH - Prognosis -MH - Retrospective Studies -MH - Survival Rate -PMC - PMC8501138 -COIS- The authors declare no competing interests. -EDAT- 2021/10/10 06:00 -MHDA- 2022/01/27 06:00 -PMCR- 2021/10/08 -CRDT- 2021/10/09 06:08 -PHST- 2021/07/16 00:00 [received] -PHST- 2021/09/28 00:00 [accepted] -PHST- 2021/10/09 06:08 [entrez] -PHST- 2021/10/10 06:00 [pubmed] -PHST- 2022/01/27 06:00 [medline] -PHST- 2021/10/08 00:00 [pmc-release] -AID - 10.1038/s41598-021-99524-1 [pii] -AID - 99524 [pii] -AID - 10.1038/s41598-021-99524-1 [doi] -PST - epublish -SO - Sci Rep. 2021 Oct 8;11(1):20059. doi: 10.1038/s41598-021-99524-1. - -PMID- 37543472 -OWN - NLM -STAT- MEDLINE -DCOM- 20231124 -LR - 20240410 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 24 -IP - 8 -DP - 2023 Dec -TI - Effect of Surgical Treatment for N2-Positive c-stage III Non-Small Cell Lung - Carcinoma in the "PACIFIC" Era. -PG - 733-742 -LID - S1525-7304(23)00144-4 [pii] -LID - 10.1016/j.cllc.2023.07.004 [doi] -AB - BACKGROUND: The PACIFIC trial findings drastically changed the c-stage III - non-small cell lung cancer (NSCLC) treatment strategy. However, it remains - uncertain whether surgery is no longer needed for treatment. We aimed to evaluate - the efficacy of surgery and explore the prognostic factors of better outcomes in - surgery-treated patients than in PACIFIC regimen-treated patients. PATIENTS AND - METHODS: From 2010 to 2020, 107 patients with clinical N2-stage III NSCLC - underwent lung resection in our institute. We analyzed and compared the yearly - postoperative overall survival (OS) benchmarks of these patients to those of - patients treated in the PACIFIC trial. RESULTS: The 1-, 2-, 3-, 4-, and 5-year OS - rates of patients were 87.7%, 73.9%, 64.9%, 58.2%, and 55.4%, respectively, all - of which were superior to those of PACIFIC regimen-treated patients. However, - patients with cT3/T4 tumors and skip, multistation, distant, and bulky N2 - metastases, as well as those who underwent bronchoplasty, showed inferior results - in several yearly benchmarks than in PACIFIC regimen-treated patients. - Multivariate analyses conducted among factors mentioned above showed that cT3/T4 - tumor was a worse prognostic factor for surgery-treated patients than for PACIFIC - regimen-treated patients (hazard ratio [HR] 1.89, P = .036). Distant N2 - metastasis was also a worse prognostic factor, although its effect was not - statistically significant (HR 1.81, P = .082). CONCLUSION: Surgery remains the - mainstay of N2-positive c-stage III NSCLC treatment, and the PACIFIC regimen may - be suitable only for patients with unresectable disease. However, surgery should - be cautiously considered for patients with cT3/4 disease. -CI - Copyright © 2023 Elsevier Inc. All rights reserved. -FAU - Adachi, Hiroyuki -AU - Adachi H -AD - Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan. - Electronic address: adachi-fam@white.plala.or.jp. -FAU - Ito, Hiroyuki -AU - Ito H -AD - Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan. -FAU - Isaka, Tetsuya -AU - Isaka T -AD - Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan. -FAU - Murakami, Kotaro -AU - Murakami K -AD - Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan. -FAU - Miura, Jun -AU - Miura J -AD - Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan. -FAU - Kikunishi, Noritake -AU - Kikunishi N -AD - Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan. -FAU - Shigeta, Naoko -AU - Shigeta N -AD - Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan. -FAU - Saito, Haruhiro -AU - Saito H -AD - Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan. -FAU - Yoshida, Daisaku -AU - Yoshida D -AD - Department of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Japan. -FAU - Yokose, Tomoyuki -AU - Yokose T -AD - Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan. -FAU - Saito, Aya -AU - Saito A -AD - Department of Surgery, Yokohama City University, Yokohama, Japan. -LA - eng -PT - Journal Article -DEP - 20230725 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -SB - IM -CIN - Clin Lung Cancer. 2024 Mar;25(2):e75-e76. doi: 10.1016/j.cllc.2023.11.002. PMID: - 38057187 -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Lung Neoplasms/pathology -MH - Treatment Outcome -MH - Neoplasm Staging -MH - Proportional Hazards Models -MH - Chemoradiotherapy -OTO - NOTNLM -OT - Chemoradiotherapy -OT - Durvalumab -OT - Locally advanced -OT - Lymph node metastasis -OT - Surgical resection -EDAT- 2023/08/06 05:42 -MHDA- 2023/11/24 06:42 -CRDT- 2023/08/05 21:55 -PHST- 2023/04/14 00:00 [received] -PHST- 2023/07/21 00:00 [accepted] -PHST- 2023/11/24 06:42 [medline] -PHST- 2023/08/06 05:42 [pubmed] -PHST- 2023/08/05 21:55 [entrez] -AID - S1525-7304(23)00144-4 [pii] -AID - 10.1016/j.cllc.2023.07.004 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2023 Dec;24(8):733-742. doi: 10.1016/j.cllc.2023.07.004. Epub - 2023 Jul 25. - -PMID- 34080379 -OWN - NLM -STAT- MEDLINE -DCOM- 20210604 -LR - 20210604 -IS - 0370-629X (Print) -IS - 0370-629X (Linking) -VI - 76 -IP - 5-6 -DP - 2021 May -TI - [Small cell lung cancer : update of therapy]. -PG - 452-457 -AB - Small cell lung cancer is a malignant tumour with a poor prognosis. Standard - treatment of metastatic stages has been a platinum doublet since 1980, but the - addition of immunotherapy has improved prognosis. For locally advanced stages, - the combination of radio-chemotherapy remains the treatment of choice, with no - evidence at present of the value of immunotherapy in consolidation, and for - localized stages, surgery is the first-line therapy. Unfortunately, in the second - line, we have no other molecule than the topotecan despite several studies. - Prophylactic brain irradiation remains debated even if it has been validated in - localized forms. Finally, there is hope with targeted therapy following the - development of subtypes of small cell lung cancer but studies remain difficult to - conduct. -FAU - Paulus, A -AU - Paulus A -AD - Service de Pneumologie, CHU Liège, Belgique. -FAU - Lousberg, L -AU - Lousberg L -AD - Service d'Oncologie médicale, CHU Liège, Belgique. -FAU - Duysinx, B -AU - Duysinx B -AD - Service de Pneumologie, CHU Liège, Belgique. -FAU - Sibille, A -AU - Sibille A -AD - Service de Pneumologie, CHU Liège, Belgique. -FAU - Duquenne, J B -AU - Duquenne JB -AD - Service de Pneumologie, CHU Liège, Belgique. -FAU - Corhay, J L -AU - Corhay JL -AD - Service de Pneumologie, CHU Liège, Belgique. -FAU - Louis, R -AU - Louis R -AD - Service de Pneumologie, CHU Liège, Belgique. -FAU - Vaillant, F -AU - Vaillant F -AD - Service de Pneumologie, CHU Liège, Belgique. -LA - fre -PT - Journal Article -TT - Le cancer pulmonaire à petites cellules : mise au point thérapeutique. -PL - Belgium -TA - Rev Med Liege -JT - Revue medicale de Liege -JID - 0404317 -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/therapy -MH - Prognosis -MH - *Small Cell Lung Carcinoma/drug therapy -OTO - NOTNLM -OT - Chemotherapy -OT - Immunotherapy -OT - Small cells -OT - SCLC -EDAT- 2021/06/04 06:00 -MHDA- 2021/06/05 06:00 -CRDT- 2021/06/03 07:05 -PHST- 2021/06/03 07:05 [entrez] -PHST- 2021/06/04 06:00 [pubmed] -PHST- 2021/06/05 06:00 [medline] -PST - ppublish -SO - Rev Med Liege. 2021 May;76(5-6):452-457. - -PMID- 38471416 -OWN - NLM -STAT- MEDLINE -DCOM- 20240408 -LR - 20240826 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 190 -DP - 2024 Apr -TI - Durvalumab in combination with chemoradiotherapy for patients with unresectable - stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study. -PG - 107530 -LID - S0169-5002(24)00063-1 [pii] -LID - 10.1016/j.lungcan.2024.107530 [doi] -AB - INTRODUCTION: For patients with unresectable, stage III non-small-cell lung - cancer (NSCLC), current standard of care is concurrent chemoradiotherapy (cCRT) - followed by consolidation durvalumab. However, earlier initiation of durvalumab - simultaneously with cCRT may increase antitumor activity relative to initiation - after cCRT. The phase 1 CLOVER study (NCT03509012) evaluated durvalumab combined - with cCRT in patients with advanced solid tumors; we report findings from the - NSCLC cohort. METHODS: CLOVER comprised a dose-limiting toxicity (DLT) assessment - part, followed by an expansion part. In the NSCLC cohort, patients with - previously untreated, unresectable, stage III NSCLC were enrolled in three - treatment arms: durvalumab every 4 weeks - (Q4W) + cisplatin + etoposide + radiotherapy (Arm 1); durvalumab - Q4W + carboplatin + paclitaxel + radiotherapy (Arm 2); or durvalumab - Q4W + carboplatin or cisplatin + pemetrexed + radiotherapy (non-squamous - histology only; Arm 3). Patients received durvalumab until disease progression or - unacceptable toxicity. The primary endpoint was safety and tolerability. RESULTS: - Sixty-four patients were enrolled: 21, 22, and 21 in Arms 1, 2, and 3, - respectively. One patient in Arm 1 had DLT (grade 3 aspartate aminotransferase - increase and grade 4 alanine aminotransferase increase); no DLTs were observed in - Arms 2 or 3. Grade 3/4 adverse events occurred in 76.6 % of patients overall; the - most common were neutropenia (51.6 %), leukopenia (20.3 %), and anemia (17.2 %). - In a post-hoc analysis, 7.8 % of patients had grade 3 pneumonitis/radiation - pneumonitis (grouped term) events. Overall, the objective response rate was - 60.9 % (95 % confidence interval [CI], 47.9-72.9); median duration of response - was 15.8 months (95 % CI, 9.0-not estimable [NE]). Median progression-free - survival was 13.4 months (95 % CI, 8.8-20.1) and median overall survival was not - reached (95 % CI, 21.9-NE). CONCLUSION: Durvalumab in combination with cCRT was - well tolerated, with a manageable safety profile and showed encouraging antitumor - activity in patients with unresectable, stage III NSCLC. -CI - Copyright © 2024. Published by Elsevier B.V. -FAU - Kim, Dong-Wan -AU - Kim DW -AD - Seoul National University College of Medicine and Seoul National University - Hospital, Seoul, Republic of Korea. Electronic address: kimdw@snu.ac.kr. -FAU - Chul Cho, Byoung -AU - Chul Cho B -AD - Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of - Korea. -FAU - Pachipala, Krishna -AU - Pachipala K -AD - Millenium Oncology, Houston, TX, USA. -FAU - Kim, Sang-We -AU - Kim SW -AD - Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of - Korea. -FAU - Wang, Chih-Liang -AU - Wang CL -AD - Chang-Gung Medical Foundation Linkou, Taoyuan City, Taiwan. -FAU - Chang, Gee-Chen -AU - Chang GC -AD - School of Medicine and Institute of Medicine, Chung Shan Medical University, - Taichung, Taiwan; Division of Pulmonary Medicine, Department of Internal - Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; Institute of - Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan; Division - of Chest Medicine, Department of Internal Medicine, Taichung Veterans General - Hospital, Taichung, Taiwan. -FAU - Ahn, Myung-Ju -AU - Ahn MJ -AD - Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, - Republic of Korea. -FAU - Alvarez, Rosa -AU - Alvarez R -AD - Hospital General Universitario Gregorio Marañón, Instituto de Investigacion - Sanitaria Gregorio Marañón, Madrid, Spain. -FAU - Chiu, Chao-Hua -AU - Chiu CH -AD - Taipei Veterans General Hospital, Taipei, Taiwan. -FAU - Trigo, José -AU - Trigo J -AD - UGC Intercentros Oncología Hospital Regional y Virgen de la Victoria, Málaga, - Spain. -FAU - Estival, Anna -AU - Estival A -AD - Hospital Germans Trias i Pujol, Barcelona, Spain. -FAU - Karam, Sana D -AU - Karam SD -AD - University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. -FAU - O'Brien, Cathy -AU - O'Brien C -AD - AstraZeneca, Cambridge, UK. -FAU - Gowda, Hema -AU - Gowda H -AD - AstraZeneca, Gaithersburg, MD, USA. -FAU - Jiang, Haiyi -AU - Jiang H -AD - AstraZeneca, Gaithersburg, MD, USA. -FAU - Bauman, Julie E -AU - Bauman JE -AD - University of Arizona Cancer Center, Tucson, AZ, USA. -LA - eng -PT - Clinical Trial, Phase I -PT - Journal Article -DEP - 20240307 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 28X28X9OKV (durvalumab) -RN - Q20Q21Q62J (Cisplatin) -RN - BG3F62OND5 (Carboplatin) -RN - P88XT4IS4D (Paclitaxel) -RN - 0 (Antibodies, Monoclonal) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Cisplatin/therapeutic use -MH - Carboplatin -MH - Paclitaxel -MH - Chemoradiotherapy/methods -MH - Neoplasm Staging -MH - *Antibodies, Monoclonal -OTO - NOTNLM -OT - Concurrent chemoradiotherapy -OT - Durvalumab -OT - Phase 1 study -OT - Stage III NSCLC -OT - Unresectable -COIS- Declaration of competing interest Dong-Wan Kim reports research funding (to - institution) from Alpha Biopharma, Amgen, AstraZeneca/Medimmune, - Boehringer-Ingelheim, Bridge BioTherapeutics, Chong Keun Dang, Daiichi-Sankyo, - GSK, Hanmi, InnoN Janssen, Merck, Merus, Mirati Therapeutics, MSD, Novartis, ONO - Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, and - Yuhan, reports uncompensated consultation or advisory roles for Amgen, - AstraZeneca, BMS/ONO Pharmaceuticals, Daiichi-Sankyo, GSK, Janssen, Meck, MSD, - NoveltyNobility, Oncobix, Pfizer, SK Biopharm, and Takeda, and has received - medical writing assistance from Amgen, AstraZeneca, Boehringer-Ingelheim, Bridge - BioTherapeutics, Chong Keun Dang, Daiichi-Sankyo, GSK, Janssen, Merus, Mirati - Therapeutics, MSD, Meck, Novartis, Pfizer, Roche, Takeda, and Yuhan. Byoung Chul - Cho is an employee of Yonsei University Health System, reports stock/share - ownership in TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, KANAPH - Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp., and J INTS - BIO, reports advisory council or committee membership for KANAPH Therapeutic Inc, - Bridgebio Therapeutics, Cyrus Therapeutics, Guardant Health, and Oscotec Inc, is - a member of the board of directors for Interpark Bio Convergence Corp., and J - INTS BIO, is an invited speaker for ASCO, AstraZeneca, Guardant, Roche, ESMO, - IASLC, Korean Cancer Association, Korean Society of Medical Oncology, Korean - Society of Thyroid-Head and Neck Surgery, Korean Cancer Study Group, Novartis, - MSD, The Chinese Thoracic Oncology Society, and Pfizer, is a consultant for - Abion, BeiGene, Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, CJ, - CureLogen, Cyrus Therapeutics, Ono, Onegene Biotechnology, Yuhan, Pfizer, Eli - Lilly, GI-Cell, Guardant, HK Inno-N, Imnewrun Biosciences Inc., Takeda, MSD, - Janssen, Medpacto, Blueprint Medicines, RandBio, and Hanmi, reports grants or - funds from MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, - GIInnovation, GI-Cell, Abion, Abbvie, AstraZeneca, Bayer, Blueprint Medicines, - Boehringer Ingelheim, Champions Oncology, CJ bioscience, CJ Blossom Park, Cyrus, - Dizal Pharma, Genexine, Janssen, Lilly, MSD, Novartis, Nuvalent, Oncternal, Ono, - Regeneron, Dong-A ST, Bridgebio therapeutics, Yuhan, ImmuneOncia, Illumina, - Kanaph therapeutics, Therapex, JINTSbio, Hanmi, and CHA Bundang Medical Center, - reports royalties from Champions Oncology, Crown Bioscience, and Imagen, and is a - founder of DAAN Biotherapeutics. Sang-We Kim reports advisory meeting - participation for AstraZeneca, Amgen, Boehringer Ingelheim, Janssen, Novartis, - Takeda, Therapex, and Yuhan, lecture fees from Boehringer Ingelheim, and research - funding from Yuhan. Gee-Chen Chang reports honoraria from F. Hoffmann–La Roche, - Ltd, Eli Lilly and Company Oncology, AstraZeneca, Novartis, Pfizer, - Boehringer-Ingelheim, Bristol-Myers Squibb, and Merck Sharp & Dohme. Myung-Ju Ahn - reports advisory council or committee membership for AstraZeneca, YUHAN, Roche, - Pfizer, Amgen, Merck, Takeda, Alpha Pharmaceutical, and VORONOI. Rosa Alvarez - reports advisory council or committee membership for Astra Zeneca, Pharmamar, - Boehringer Ingelheim, Novartis, Sanofi, and GSK, reports research funding (to - institution) from PharmaMar, Astra Zeneca, Rain Therapeutics, GSK, Boehringer - Ingelheim, Cebiotex, Roche, Philogen, MSD, Janssen, Pfizer, Daichii Sankyo, - Gilead, and Seagen, speaker fees from Pharmamar, and travel support from Roche - and Pharmamar. Chao-Hua Chiu reports honoraria from Amgen, AstraZeneca, - Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, - Janssen, Merck KGaA, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, - Roche, Shionogi, and Takeda. José Trigo reports consulting fees from AstraZeneca, - MSD, Eisai, and BMS. Ana Estiva reports advisory council or committee membership - for Takeda, Roche, and MSD, and honoraria from Pfizer, MSD, Roche, Takeda, - Pharmamar, and GSK. Sana D. Karam reports grants or funds from AstraZeneca - (clinical trial), Genentech (clinical trial), and Roche (preclinical). Cathy - O’Brien is a contractor for AstraZeneca. Hema Gowda is an employee of - AstraZeneca, and reports stock/share ownership in AstraZeneca and Incyte. Haiyi - Jiang reports employment and stock/share ownership with AstraZeneca. Julie E. - Bauman reports consulting fees from BluedotBio and Exelixis. Krishna Pachipala - and Chih-Liang Wang do not have any competing interests to disclose. -EDAT- 2024/03/13 00:44 -MHDA- 2024/04/08 06:43 -CRDT- 2024/03/12 19:10 -PHST- 2023/12/22 00:00 [received] -PHST- 2024/03/04 00:00 [revised] -PHST- 2024/03/06 00:00 [accepted] -PHST- 2024/04/08 06:43 [medline] -PHST- 2024/03/13 00:44 [pubmed] -PHST- 2024/03/12 19:10 [entrez] -AID - S0169-5002(24)00063-1 [pii] -AID - 10.1016/j.lungcan.2024.107530 [doi] -PST - ppublish -SO - Lung Cancer. 2024 Apr;190:107530. doi: 10.1016/j.lungcan.2024.107530. Epub 2024 - Mar 7. - -PMID- 39001619 -OWN - NLM -STAT- MEDLINE -DCOM- 20241004 -LR - 20241004 -IS - 1532-6535 (Electronic) -IS - 0009-9236 (Linking) -VI - 116 -IP - 4 -DP - 2024 Oct -TI - Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab - Using Pre- and on-Treatment Prognostic Biomarkers. -PG - 1110-1120 -LID - 10.1002/cpt.3371 [doi] -AB - Existing survival prediction models rely only on baseline or tumor kinetics data - and lack machine learning integration. We introduce a novel kinetics-machine - learning (kML) model that integrates baseline markers, tumor kinetics, and four - on-treatment simple blood markers (albumin, C-reactive protein, lactate - dehydrogenase, and neutrophils). Developed for immune-checkpoint inhibition (ICI) - in non-small cell lung cancer on three phase II trials (533 patients), kML was - validated on the two arms of a phase III trial (ICI and chemotherapy, 377 and 354 - patients). It outperformed the current state-of-the-art for individual - predictions with a test set C-index of 0.790, 12-months survival accuracy of - 78.7% and hazard ratio of 25.2 (95% CI: 10.4-61.3, P < 0.0001) to identify - long-term survivors. Critically, kML predicted the success of the phase III trial - using only 25 weeks of on-study data (predicted HR = 0.814 (0.64-0.994) vs. final - study HR = 0.778 (0.65-0.931)). Modeling on-treatment blood markers combined with - predictive machine learning constitutes a valuable approach to support - personalized medicine and drug development. The code is publicly available at - https://gitlab.inria.fr/benzekry/nlml_onco. -CI - © 2024 The Author(s). Clinical Pharmacology & Therapeutics published by Wiley - Periodicals LLC on behalf of American Society for Clinical Pharmacology and - Therapeutics. -FAU - Benzekry, Sébastien -AU - Benzekry S -AUID- ORCID: 0000-0002-3749-8637 -AD - COMPutational Pharmacology and Clinical Oncology Department, Centre Inria de - l'Université Côte d'Azur, Cancer Research Center of Marseille, Inserm UMR1068, - CNRS UMR7258, Aix Marseille University UM105, Marseille, France. -FAU - Karlsen, Mélanie -AU - Karlsen M -AD - COMPutational Pharmacology and Clinical Oncology Department, Centre Inria de - l'Université Côte d'Azur, Cancer Research Center of Marseille, Inserm UMR1068, - CNRS UMR7258, Aix Marseille University UM105, Marseille, France. -FAU - Bigarré, Célestin -AU - Bigarré C -AD - COMPutational Pharmacology and Clinical Oncology Department, Centre Inria de - l'Université Côte d'Azur, Cancer Research Center of Marseille, Inserm UMR1068, - CNRS UMR7258, Aix Marseille University UM105, Marseille, France. -FAU - Kaoutari, Abdessamad El -AU - Kaoutari AE -AD - COMPutational Pharmacology and Clinical Oncology Department, Centre Inria de - l'Université Côte d'Azur, Cancer Research Center of Marseille, Inserm UMR1068, - CNRS UMR7258, Aix Marseille University UM105, Marseille, France. -FAU - Gomes, Bruno -AU - Gomes B -AD - Pharma Research and Early Development, Early Development Oncology, Roche - Innovation Center Basel, Basel, Switzerland. -FAU - Stern, Martin -AU - Stern M -AD - Pharma Research and Early Development, Early Development Oncology, Roche - Innovation Center Zurich, Zurich, Switzerland. -FAU - Neubert, Ales -AU - Neubert A -AD - Pharma Research and Early Development, Data & Analytics, Roche Innovation Center - Basel, Basel, Switzerland. -FAU - Bruno, Rene -AU - Bruno R -AUID- ORCID: 0000-0003-0200-039X -AD - Modeling and Simulation, Clinical Pharmacology, Genentech Research and Early - Development, Marseille, France. -FAU - Mercier, François -AU - Mercier F -AUID- ORCID: 0000-0002-5685-1408 -AD - Modeling and Simulation, Clinical Pharmacology, Genentech Research and Early - Development, Roche Innovation Center Basel, Basel, Switzerland. -FAU - Vatakuti, Suresh -AU - Vatakuti S -AD - Pharma Research and Early Development, Predictive Modeling and Data Analytics, - Roche Innovation Center Basel, Basel, Switzerland. -FAU - Curle, Peter -AU - Curle P -AD - Inovigate, Basel, Switzerland. -FAU - Jamois, Candice -AU - Jamois C -AUID- ORCID: 0000-0001-7018-9687 -AD - Pharma Research and Early Development, Translational PKPD and Clinical - Pharmacology, Roche Innovation Center Basel, Basel, Switzerland. -LA - eng -PT - Journal Article -DEP - 20240712 -PL - United States -TA - Clin Pharmacol Ther -JT - Clinical pharmacology and therapeutics -JID - 0372741 -RN - 52CMI0WC3Y (atezolizumab) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Biomarkers, Tumor) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/mortality/blood -MH - *Antibodies, Monoclonal, Humanized/therapeutic use -MH - *Lung Neoplasms/drug therapy/mortality/blood -MH - *Machine Learning -MH - *Biomarkers, Tumor/blood -MH - Prognosis -MH - Female -MH - Male -MH - Middle Aged -MH - Aged -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Clinical Trials, Phase II as Topic -MH - Clinical Trials, Phase III as Topic -EDAT- 2024/07/13 07:47 -MHDA- 2024/10/04 08:43 -CRDT- 2024/07/13 02:33 -PHST- 2024/03/14 00:00 [received] -PHST- 2024/06/19 00:00 [accepted] -PHST- 2024/10/04 08:43 [medline] -PHST- 2024/07/13 07:47 [pubmed] -PHST- 2024/07/13 02:33 [entrez] -AID - 10.1002/cpt.3371 [doi] -PST - ppublish -SO - Clin Pharmacol Ther. 2024 Oct;116(4):1110-1120. doi: 10.1002/cpt.3371. Epub 2024 - Jul 12. - -PMID- 38105153 -OWN - NLM -STAT- MEDLINE -DCOM- 20240516 -LR - 20240614 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 25 -IP - 3 -DP - 2024 May -TI - Association Between Lung Immune Prognostic Index and Durvalumab Consolidation - Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer. -PG - 233-243.e8 -LID - S1525-7304(23)00242-5 [pii] -LID - 10.1016/j.cllc.2023.11.007 [doi] -AB - INTRODUCTION: The LIPI, based on pretreatment derived - neutrophils/[leukocytes-neutrophils] ratio (dNLR) and LDH, is associated with - immune checkpoint inhibitors (ICI) outcomes in advanced non-small-cell lung - cancer (NSCLC). We aimed to assess baseline LIPI correlation with durvalumab - consolidation outcomes in the locally advanced setting. MATERIAL AND METHODS: - Multicentre retrospective study (330 patients) with stage III unresectable NSCLC - treated with durvalumab after chemo-radiotherapy between April 2015 and December - 2020; 65 patients treated with chemo-radiotherapy only. Baseline LIPI - characterized 3 groups: good (dNLR≤3+LDH≤ULN), intermediate (dNLR>3/LDH>ULN) and - poor (dNLR>3+LDH>ULN). Primary endpoint was overall survival (OS). RESULTS: In - the durvalumab cohort, median age was 67 years, 95% smokers, 98% with a - performance status of 0-1; 60% had nonsquamous histology and 16% a PD-L1 - expression <1%. Radiotherapy was delivered concurrently in 81%. LIPI was - evaluable in 216 patients: 66% good, 31% intermediate, 3% poor. LIPI - significantly correlated with median OS (median follow-up: 19 months): 18.1 - months vs. 47.0 months vs. not reached in poor, intermediate and good LIPI - groups, respectively (P = .03). A trend between objective response rate and LIPI - groups was observed: 0% vs. 41% vs. 45%, respectively (P = .05). The pooled - intermediate/poor LIPI group was associated with shorter OS (HR 1.97; P = .03) - and higher risk of progressive disease (OR 2.68; P = .047). Survivals and - response were not influenced in the control cohort. CONCLUSION: Baseline LIPI - correlated with outcomes in patients with locally advanced NSCLC treated with - durvalumab consolidation, but not in those who only received chemo-radiotherapy, - providing further evidence of its prognostic and potential predictive role of ICI - benefit in NSCLC. -CI - Copyright © 2023 Elsevier Inc. All rights reserved. -FAU - Riudavets, Mariona -AU - Riudavets M -AD - Medical Oncology Department, Gustave Roussy cancer campus, Villejuif, France. -FAU - Auclin, Edouard -AU - Auclin E -AD - Medical Oncology Department, Hôpital Européen Georges Pompidou, AP-HP Centre, - Université Paris Cité, Paris, France. -FAU - Mosteiro, Miguel -AU - Mosteiro M -AD - Medical Oncology Department, Institut Català d'Oncologia - ICO Hospitalet, - Barcelona, Spain. -FAU - Dempsey, Naomi -AU - Dempsey N -AD - Medical Oncology Department, Jackson Memorial Hospital, Miami, FL. -FAU - Majem, Margarita -AU - Majem M -AD - Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, - Spain. -FAU - Prelaj, Arsela -AU - Prelaj A -AD - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di - Milan, Milano, Italy. -FAU - López-Castro, Rafael -AU - López-Castro R -AD - Medical Oncology Department, Hospital Clínico Universitario de Valladolid, - Valladolid, Spain. -FAU - Bosch-Barrera, Joaquim -AU - Bosch-Barrera J -AD - Medical Oncology Department, Catalan Institute of Oncology, Hospital Universitari - Josep Trueta, Girona, Spain. -FAU - Pilotto, Sara -AU - Pilotto S -AD - Medical Oncology Department, University and Hospital Trust of Verona, Verona, - Italy. -FAU - Escalera, Elena -AU - Escalera E -AD - Medical Oncology Department, Hospital Clínico de Salamanca, Salamanca, Spain. -FAU - Tagliamento, Marco -AU - Tagliamento M -AD - Medical Oncology Department, Gustave Roussy cancer campus, Villejuif, France; - Internal Medicine and Medical Specialties Department, University of Genova, - Genova, Italy. -FAU - Mosquera, Joaquin -AU - Mosquera J -AD - Medical Oncology Department, Hospital Universitario A Coruña, A Coruña, Spain. -FAU - Zalcman, Gérard -AU - Zalcman G -AD - Université Paris Cité, Thoracic Oncology Department, CIC Inserm 1425, Hôpital - Bichat-Claude Bernard, Paris, France. -FAU - Aboubakar Nana, Frank -AU - Aboubakar Nana F -AD - Division of Pneumology, Cliniques universitaires Saint-Luc, Bruxelles, Belgium. -FAU - Ponce, Santiago -AU - Ponce S -AD - Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain. -FAU - Albarrán-Artahona, Víctor -AU - Albarrán-Artahona V -AD - Medical Oncology Department, Department of Medicine, Hospital Clinic, Laboratory - of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, - University of Barcelona, Barcelona, Spain. -FAU - Dal Maso, Alessandro -AU - Dal Maso A -AD - Medical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy. -FAU - Spotti, Martina -AU - Spotti M -AD - Medical Oncology Department, Hospital Alemán, Buenos Aires, Argentina. -FAU - Mielgo, Xabier -AU - Mielgo X -AD - Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Madrid, - Spain. -FAU - Mussat, Elodie -AU - Mussat E -AD - Medical Oncology Department, Hôpital Européen Georges Pompidou, AP-HP Centre, - Université Paris Cité, Paris, France. -FAU - Reyes, Roxana -AU - Reyes R -AD - Medical Oncology Department, Department of Medicine, Hospital Clinic, Laboratory - of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, - University of Barcelona, Barcelona, Spain. -FAU - Benítez, Jose-Carlos -AU - Benítez JC -AD - Medical Oncology Department, Gustave Roussy cancer campus, Villejuif, France; - Medical Oncology Department, Hospital Universitari Mutua Terrassa, Terrassa, - Barcelona, Spain. -FAU - Lupinacci, Lorena -AU - Lupinacci L -AD - Medical Oncology Department, Hospital Italiano, Buenos Aires, Argentina. -FAU - Duchemann, Boris -AU - Duchemann B -AD - Medical Oncology Department, Hôpital Avicenne, Bobigny, France. -FAU - De Giglio, Andrea -AU - De Giglio A -AD - Medical Oncology Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, - Bologna, Italy. -FAU - Blaquier, Juan Bautista -AU - Blaquier JB -AD - Medical Oncology Department, Centro de Educación Médica e Investigaciones - Clínicas (CEMIC), Buenos Aires, Argentina. -FAU - Audigier-Valette, Clarisse -AU - Audigier-Valette C -AD - Medical Oncology Department, Centre Hospitalier Toulon Sainte-Mousse, Toulon, - France. -FAU - Scheffler, Matthias -AU - Scheffler M -AD - Internal Medicine I Department, Faculty of Medicine and University Hospital - Cologne, University of Cologne, Cologne, Germany. -FAU - Nadal, Ernest -AU - Nadal E -AD - Medical Oncology Department, Institut Català d'Oncologia - ICO Hospitalet, - Barcelona, Spain. -FAU - Lopes, Gilberto -AU - Lopes G -AD - Medical Oncology Department, Jackson Memorial Hospital, Miami, FL. -FAU - Signorelli, Diego -AU - Signorelli D -AD - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di - Milan, Milano, Italy; Niguarda Cancer Center, Grande Ospedale Metropolitano - Niguarda, Milan, Italy. -FAU - Garcia-Campelo, Rosario -AU - Garcia-Campelo R -AD - Medical Oncology Department, Hospital Universitario A Coruña, A Coruña, Spain. -FAU - Menis, Jessica -AU - Menis J -AD - Medical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy. -FAU - Bluthgen, Virginia -AU - Bluthgen V -AD - Medical Oncology Department, Hospital Alemán, Buenos Aires, Argentina. -FAU - Campayo, Marc -AU - Campayo M -AD - Medical Oncology Department, Hospital Universitari Mutua Terrassa, Terrassa, - Barcelona, Spain. -FAU - Recondo, Gonzalo -AU - Recondo G -AD - Medical Oncology Department, Centro de Educación Médica e Investigaciones - Clínicas (CEMIC), Buenos Aires, Argentina. -FAU - Besse, Benjamin -AU - Besse B -AD - Medical Oncology Department, Gustave Roussy cancer campus, Villejuif, France. -FAU - Mezquita, Laura -AU - Mezquita L -AD - Medical Oncology Department, Department of Medicine, Hospital Clinic, Laboratory - of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, - University of Barcelona, Barcelona, Spain. Electronic address: - lmezquita@clinic.cat. -FAU - Planchard, David -AU - Planchard D -AD - Medical Oncology Department, Gustave Roussy cancer campus, Villejuif, France. -LA - eng -PT - Journal Article -PT - Multicenter Study -DEP - 20231122 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (durvalumab) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology/mortality/therapy -MH - *Lung Neoplasms/pathology/drug therapy/mortality/therapy -MH - Female -MH - Male -MH - Retrospective Studies -MH - Aged -MH - Prognosis -MH - Middle Aged -MH - *Antibodies, Monoclonal/therapeutic use/administration & dosage -MH - Aged, 80 and over -MH - Adult -MH - Antineoplastic Agents, Immunological/therapeutic use -MH - Survival Rate -MH - Neutrophils/pathology -MH - Chemoradiotherapy/methods -OTO - NOTNLM -OT - Consolidation -OT - Durvalumab -OT - Host-related biomarkers -OT - LIPI -OT - Stage III -COIS- Disclosure VAA: Lectures and educational activities: Bristol-Myers Squibb, - AstraZeneca, MSD; Travel, Accommodations, Expenses: Takeda, Sanofi, Janssen; RL: - Personal fees: AstraZeneca, Bristol-Myers Squibb. Travel, Accommodations: Roche, - Italfarmaco; RLC: Consulting, advisory role or lectures: Amgen, Bristol-Myers - Squibb, Pierre-Fabre, Boehringer Ingelheim, Novartis, Roche. Honoraria: - AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Pierre-Fabre, MSD, - Novartis, Pfizer, Roche, Takeda. Clinical trials research: AstraZeneca, Roche. - Travel, Accommodations, Expenses: Roche, Novartis, Takeda, Boehringer Ingelheim; - JBB: Reports grants and personal fees from Roche and Pfizer, and personal fees - from MSD, BMS, AstraZeneca, Boehringer-Ingelheim, Sanofi, and Novartis, outside - the submitted work; SP: Consulting, advisory role or lectures: AstraZeneca, - Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Roche, - Amgen, Takeda (outside the submitted manuscript); MT: Travel, accommodation, - expenses: Roche, Bristol-Myers Squibb, AstraZeneca, Takeda, Eli Lilly. Honoraria - as medical writer: Novartis, Amgen, MSD. None related to the current manuscript; - MS: Speaker, Advisory Role: Amgen, AstraZeneca, BMS, Boehringer Ingelheim, - Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi Avemtis, Siemens Healthineers, - Takeda; Research support (institutional): Amgen, BMS, Dracen Pharmaceuticals, - Janssen, Novartis, Pfizer, Siemens Healthiness; EN: has participated in lectures - and advisory boards from Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Merck - Serono, Pfizer, Lilly, Amgen, Boehringer Ingelheim, AstraZeneca, Takeda, Sanofi - and Bayer. E. N. has received research funding support from Pfizer, Roche, Merck - Serono, Bristol Myers Squibb and Nanostring; GL: Honorary from Boehringer - Ingelheim, Blueprint Medicines, AstraZeneca, Merck, Janssen; Consulting and - advisory role from Pfizer and AstraZeneca; Research funding from AstraZeneca, - Lucence, Xilis, Merck Sharp and Dohme, EMD Serono, Blueprint Medicines, Tesaro, - Vavarian Nordic, Novartis, G1 Therapeutics. AdaptImmune, BMS, GSK, Abbvie, - Rgenix, Pfizer, Roche, Genentech, Lilly, Janssen; travel, accommodations and - expenses from Boehringer Ingelheim, Pfizer, Squibb Sons, Janssen, Seattle - Genetics, Celgene, Ibsen, Pharmacyclocs, Merck, AstraZeneca, Seagen; DS: - Consulting, advisory role: AstraZeneca, Bristol-Myers Squibb, Boehringer - Ingelheim, Merck Sharp & Dohme, Sanofi. Honoraria: AstraZeneca, Bristol-Myers - Squibb, Boehringer Ingelheim, Eli Lilly, Roche, Merck Sharp & Dohme. Principal - Investigator in clinical trial sponsored by Bristol-Myers Squibb, Merck Sharp & - Dohme, Eli Lilly. Travel, Accommodations: AstraZeneca, Roche, Bristol-Myers - Squibb, Merck Sharp & Dohme, Pfizer; RGC: Consulting, advisory role or lectures - from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Takeda, Janseen, - MSD, Roche, Pfizer, Eli Lilly, Amgen, Sanofi; honoraria (self) from AstraZeneca, - Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Roche, MSD, Takeda, Eli - Lilly, Novartis; clinical trials research from AstraZeneca, Bristol-Myers Squibb, - Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, - Sanofi-Aventis; VB: Consulting, advisory role: AstraZeneca, Bristol-Myers Squibb, - MSD, Merck, Novartis, Pfizer, Roche. Clinical trials research: AstraZeneca, MSD, - Roche; MC: Advisory or Consultancy role: AstraZeneca, Boehringer Ingelheim, - Bristol-Myers Squibb, EUSA Pharma, Lilly, Roche. Honoraria, lectures: Abbot, - AstraZeneca, Bristol-Myers Squibb, EUSA Pharma, Ipsen, Merck, Sharp & Dohme, - Novartis, Pfizer, Pierre Fabre, Roche, Takeda. Travel expenses: Ipsen, Lilly, - Merck, Pfizer, Pierre Fabre. Institutional financial interests: Astra Zeneca, - Merck, Pfizer, Roche; BB: Sponsored Research at Gustave Roussy Cancer Center, - Abbvie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, - GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, - Spectrum Pharmaceuticals, Takeda, Tiziana Pharma; DP: Consulting, advisory role - or lectures: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, - Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, - Roche. Honoraria: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, - Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche. - Clinical trials research: AstraZeneca, Bristol-Myers Squibb, Boehringer - Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, - Taiho Pharma, Novocure, Daiichi Sankyo. Travel, Accommodations, Expenses: - AstraZeneca, Roche, Novartis, prIME Oncology, Pfizer; LM: Research grant/Funding - (self): Bristol Myers Squibb, Boehringer Ingelheim, Amgen, Stilla, Inivata; - Advisory/Consultancy: Roche Diagnostics, Takeda; Honoraria (self): Bristol Myers - Squibb, Tecnofarma, Roche; Travel/Accommodation/Expenses: Roche, Boehringer - Ingelheim, Takeda, AstraZeneca. The remaining authors declare no conflict of - interest. -EDAT- 2023/12/18 00:41 -MHDA- 2024/05/17 00:43 -CRDT- 2023/12/17 21:56 -PHST- 2023/08/22 00:00 [received] -PHST- 2023/11/07 00:00 [revised] -PHST- 2023/11/13 00:00 [accepted] -PHST- 2024/05/17 00:43 [medline] -PHST- 2023/12/18 00:41 [pubmed] -PHST- 2023/12/17 21:56 [entrez] -AID - S1525-7304(23)00242-5 [pii] -AID - 10.1016/j.cllc.2023.11.007 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2024 May;25(3):233-243.e8. doi: 10.1016/j.cllc.2023.11.007. - Epub 2023 Nov 22. - -PMID- 37080641 -OWN - NLM -STAT- MEDLINE -DCOM- 20230424 -LR - 20230424 -IS - 1879-8519 (Electronic) -IS - 1879-8500 (Linking) -VI - 13 -IP - 3 -DP - 2023 May-Jun -TI - ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III - Non-Small Cell Lung Cancer. -PG - 195-202 -LID - S1879-8500(23)00005-X [pii] -LID - 10.1016/j.prro.2023.01.005 [doi] -AB - PURPOSE: To develop a radiation therapy summary of recommendations on the - management of locally advanced non-small cell lung cancer (NSCLC) based on the - Management of Stage III Non-Small Cell Lung Cancer: American Society of Clinical - Oncology Guideline, which was endorsed by the American Society for Radiation - Oncology (ASTRO). METHODS: The American Society of Clinical Oncology, ASTRO, and - the American College of Chest Physicians convened a multidisciplinary panel to - develop a guideline based on a systematic review of the literature and a formal - consensus process, that has been separately published. A new panel consisting of - radiation oncologists from the original guideline as well as additional ASTRO - members was formed to provide further guidance to the radiation oncology - community. A total of 127 articles met the eligibility criteria to answer 5 - clinical questions. This summary focuses on the 3 radiation therapy questions - (neoadjuvant, adjuvant, and unresectable settings). RESULTS: Radiation-specific - recommendations are summarized with additional relevant commentary on specific - questions regarding the management of preoperative radiation, postoperative - radiation, and combined chemoradiation. CONCLUSIONS: Patients with stage III - NSCLC who are planned for surgical resection, should receive either neoadjuvant - chemotherapy or chemoradiation. The addition of neoadjuvant treatment is - particularly important in patients planned for surgery in the N2 or superior - sulcus settings. Postoperatively, patients who did not receive neoadjuvant - chemotherapy should be offered adjuvant chemotherapy. The use of postoperative - radiation for completely resected N2 disease is not routinely recommended. - Unresectable patients with stage III NSCLC should ideally be managed with - combined concurrent chemoradiation using a platinum-based doublet with a standard - radiation dose of 60 Gy followed by consolidation durvalumab in patients without - progression after initial therapy. Patients who cannot tolerate a concurrent - chemoradiation approach can be managed either by sequential chemotherapy followed - by radiation or by dose-escalated or hypofractionated radiation alone. -CI - Copyright © 2023 American Society for Radiation Oncology. Published by Elsevier - Inc. All rights reserved. -FAU - Simone, Charles B 2nd -AU - Simone CB 2nd -AD - Department of Radiation Oncology, New York Proton Center, New York, New York. -FAU - Bradley, Jeffrey -AU - Bradley J -AD - Department of Radiation Oncology, Emory University School of Medicine, Atlanta, - Georgia. -FAU - Chen, Aileen B -AU - Chen AB -AD - Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, - Houston, Texas. -FAU - Daly, Megan E -AU - Daly ME -AD - Department of Radiation Oncology, University of California Davis Comprehensive - Cancer Center, Sacramento, California. -FAU - Louie, Alexander V -AU - Louie AV -AD - Department of Radiation Oncology, Sunnybrook Health Sciences Center, Toronto, - Ontario, Canada. -FAU - Robinson, Clifford G -AU - Robinson CG -AD - Department of Radiation Oncology, Washington University School of Medicine, St. - Louis, Missouri. -FAU - Videtic, Gregory M M -AU - Videtic GMM -AD - Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Institute, - Cleveland, Ohio. -FAU - Rodrigues, George -AU - Rodrigues G -AD - Department of Radiation Oncology, London Health Sciences Cancer, London, Ontario, - Canada. Electronic address: George.Rodrigues@lhsc.on.ca. -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - Pract Radiat Oncol -JT - Practical radiation oncology -JID - 101558279 -SB - IM -MH - Humans -MH - United States -MH - *Carcinoma, Non-Small-Cell Lung/radiotherapy/drug therapy -MH - *Radiation Oncology -MH - *Lung Neoplasms/radiotherapy/drug therapy -MH - Medical Oncology -MH - Chemoradiotherapy -MH - Neoplasm Staging -EDAT- 2023/04/21 00:41 -MHDA- 2023/04/24 06:42 -CRDT- 2023/04/20 20:57 -PHST- 2022/12/29 00:00 [received] -PHST- 2023/01/10 00:00 [revised] -PHST- 2023/01/12 00:00 [accepted] -PHST- 2023/04/24 06:42 [medline] -PHST- 2023/04/21 00:41 [pubmed] -PHST- 2023/04/20 20:57 [entrez] -AID - S1879-8500(23)00005-X [pii] -AID - 10.1016/j.prro.2023.01.005 [doi] -PST - ppublish -SO - Pract Radiat Oncol. 2023 May-Jun;13(3):195-202. doi: 10.1016/j.prro.2023.01.005. - -PMID- 37334528 -OWN - NLM -STAT- MEDLINE -DCOM- 20230908 -LR - 20230912 -IS - 1097-0215 (Electronic) -IS - 0020-7136 (Linking) -VI - 153 -IP - 9 -DP - 2023 Nov 1 -TI - Safety and efficacy of immune checkpoint blockade in patients with advanced - nonsmall cell lung cancer and brain metastasis. -PG - 1556-1567 -LID - 10.1002/ijc.34628 [doi] -AB - The presence of brain metastases (BM) is a negative prognostic factor for - patients with advanced nonsmall cell lung cancer (NSCLC). Their incidence seems - to be higher in patients with oncogene-driven tumours, especially those with - EGFR-mutated or ALK-rearranged tumours. Although targeted treatments demonstrate - significant efficacy regarding BM, they only apply to a minority of NSCLC - patients. On the other hand, systemic therapies for nononcogenic-driven NSCLC - with BM have shown limited clinical benefit. In recent years, immunotherapy alone - or combined with chemotherapy has been adopted as a new standard of care in - first-line therapy. This approach seems to be beneficial to patients with BM in - terms of efficacy and toxicity. Combined immune checkpoint inhibition as well as - the combination of immunotherapy and radiation therapy show promising results - with significant, but overall acceptable toxicity. A pragmatic approach of - allowing enrolment of patients with untreated or symptomatic BM in randomised - trials evaluating immune checkpoint inhibitors strategies, possibly coupled with - central nervous system-related endpoints may be needed to generate data to refine - treatment for this patient population. -CI - © 2023 The Authors. International Journal of Cancer published by John Wiley & - Sons Ltd on behalf of UICC. -FAU - Tsakonas, Georgios -AU - Tsakonas G -AUID- ORCID: 0000-0003-4397-7391 -AD - Department of Oncology-Pathology, Karolinska Institutet/Thoracic Oncology Center, - Karolinska University Hospital, Stockholm, Sweden. -FAU - Ekman, Simon -AU - Ekman S -AD - Department of Oncology-Pathology, Karolinska Institutet/Thoracic Oncology Center, - Karolinska University Hospital, Stockholm, Sweden. -FAU - Koulouris, Andreas -AU - Koulouris A -AUID- ORCID: 0000-0003-2334-444X -AD - Department of Oncology-Pathology, Karolinska Institutet/Thoracic Oncology Center, - Karolinska University Hospital, Stockholm, Sweden. -AD - Faculty of Medicine, University of Crete, Heraklion, Greece. -FAU - Adderley, Helen -AU - Adderley H -AD - Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, - UK. -FAU - Ackermann, Christoph Jakob -AU - Ackermann CJ -AD - Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, - UK. -FAU - Califano, Raffaele -AU - Califano R -AD - Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, - UK. -AD - Department of Medical Oncology, Manchester University NHS Foundation Trust, - Manchester, UK. -AD - Division of Cancer Sciences, University of Manchester, Manchester, UK. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20230619 -PL - United States -TA - Int J Cancer -JT - International journal of cancer -JID - 0042124 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - *Lung Neoplasms/pathology -MH - *Brain Neoplasms/drug therapy -MH - Immunotherapy/adverse effects/methods -OTO - NOTNLM -OT - NSCLC -OT - PDL1 -OT - brain metastasis -OT - immunotherapy -OT - nonsmall cell lung cancer -EDAT- 2023/06/19 06:41 -MHDA- 2023/09/08 06:43 -CRDT- 2023/06/19 03:53 -PHST- 2023/05/12 00:00 [revised] -PHST- 2023/02/07 00:00 [received] -PHST- 2023/06/02 00:00 [accepted] -PHST- 2023/09/08 06:43 [medline] -PHST- 2023/06/19 06:41 [pubmed] -PHST- 2023/06/19 03:53 [entrez] -AID - 10.1002/ijc.34628 [doi] -PST - ppublish -SO - Int J Cancer. 2023 Nov 1;153(9):1556-1567. doi: 10.1002/ijc.34628. Epub 2023 Jun - 19. - -PMID- 24582269 -OWN - NLM -STAT- MEDLINE -DCOM- 20141210 -LR - 20201222 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 84 -IP - 2 -DP - 2014 May -TI - Molecular targeted therapy for early-stage non-small-cell lung cancer: will it - increase the cure rate? -PG - 97-100 -LID - S0169-5002(14)00054-3 [pii] -LID - 10.1016/j.lungcan.2014.01.018 [doi] -AB - Non-small-cell lung cancer (NSCLC) represents approximately 85% of all lung - cancer cases, with a world-wide annual incidence of around 1.3 million. Surgery - remains the corner stone of treatment in early-stage NSCLC when feasible, and the - addition of adjuvant cisplatin-based chemotherapy has improved these results in - resected NSCLC patients. For those patients with non-metastatic NSCLC not - suitable for complete surgical resection, chemotherapy plus radiotherapy remains - the best treatment option. For patients with metastatic NSCLC, molecular targeted - agents have become part of the therapeutic arsenal in recent years. However, to - date no targeted agent has been approved for patients with early or - locally-advanced stages of NSCLC. Here, we review the rationale, literature and - studies addressing the role of targeted agents used in the adjuvant setting or as - part of chemoradiotherapy regimens. -CI - Copyright © 2014 Elsevier Ireland Ltd. All rights reserved. -FAU - Martinez, Pablo -AU - Martinez P -AD - Vall d́Hebron University Hospital, Department of Medical Oncology, Barcelona, - Spain. -FAU - Martinez-Marti, Alex -AU - Martinez-Marti A -AD - Vall d́Hebron University Hospital, Department of Medical Oncology, Barcelona, - Spain. -FAU - Navarro, Alejandro -AU - Navarro A -AD - Vall d́Hebron University Hospital, Department of Medical Oncology, Barcelona, - Spain. -FAU - Cedrés, Susana -AU - Cedrés S -AD - Vall d́Hebron University Hospital, Department of Medical Oncology, Barcelona, - Spain. -FAU - Felip, Enriqueta -AU - Felip E -AD - Vall d́Hebron University Hospital, Department of Medical Oncology, Barcelona, - Spain. Electronic address: efelip@vhebron.net. -LA - eng -PT - Editorial -PT - Review -DEP - 20140130 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Angiogenesis Inhibitors) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Angiogenesis Inhibitors/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology -MH - ErbB Receptors/antagonists & inhibitors -MH - Humans -MH - Immunotherapy -MH - Lung Neoplasms/*drug therapy/enzymology -MH - *Molecular Targeted Therapy -MH - Protein Kinase Inhibitors/therapeutic use -OTO - NOTNLM -OT - Early-stage -OT - Locally-advanced stage -OT - Non-small cell lung cancer -OT - Targeted therapies -EDAT- 2014/03/04 06:00 -MHDA- 2014/12/15 06:00 -CRDT- 2014/03/04 06:00 -PHST- 2014/01/06 00:00 [received] -PHST- 2014/01/21 00:00 [accepted] -PHST- 2014/03/04 06:00 [entrez] -PHST- 2014/03/04 06:00 [pubmed] -PHST- 2014/12/15 06:00 [medline] -AID - S0169-5002(14)00054-3 [pii] -AID - 10.1016/j.lungcan.2014.01.018 [doi] -PST - ppublish -SO - Lung Cancer. 2014 May;84(2):97-100. doi: 10.1016/j.lungcan.2014.01.018. Epub 2014 - Jan 30. - -PMID- 26878692 -OWN - NLM -STAT- MEDLINE -DCOM- 20160912 -LR - 20181202 -IS - 1744-7666 (Electronic) -IS - 1465-6566 (Linking) -VI - 17 -IP - 7 -DP - 2016 -TI - Optimal drugs for second-line treatment of patients with small-cell lung cancer. -PG - 969-76 -LID - 10.1517/14656566.2016.1154539 [doi] -AB - INTRODUCTION: Despite the high response rate to chemotherapy, there have been few - advances in the treatment of small-cell lung cancer (SCLC) in the last decades. - The state-of-the-art second-line therapy and future research developments in - relapsed SCLC are reviewed. AREAS COVERED: There are no optimal drugs for - second-line treatment of recurrent SCLC but only agents registered for this use. - Topotecan remains the standard-of-care for the treatment of second-line - platinum-sensitive SCLC patients worldwide, while amrubicin is another option, - but registered only in Japan. To date, no targeted agents reporting interesting - results in second-line SCLC treatment are available. The next-generation DNA - sequencing should discover somatic gene alterations and their roles in SCLC to - help in selecting patients who could benefit from a targeted agent. Two - immunotherapeutics, ipilimumab and nivolumab, have shown promising preliminary - results and are being investigated in ongoing trials. EXPERT OPINION: Second-line - treatment is not an option for most SCLC patients. Given the evidence up to now, - the potentials for immuno-oncology in SCLC are high. The hope is that these - expectations are met, and that all drugs being developed will offer new and - improved treatment options for SCLC patients. -FAU - Rossi, Antonio -AU - Rossi A -AD - a Division of Medical Oncology , 'S.G. Moscati' Hospital , Avellino , Italy. -FAU - Sacco, Paola Claudia -AU - Sacco PC -AD - a Division of Medical Oncology , 'S.G. Moscati' Hospital , Avellino , Italy. -FAU - Sgambato, Assunta -AU - Sgambato A -AD - b Department of Clinical and Experimental Medicine , Second University of Naples - , Naples , Italy. -FAU - Casaluce, Francesca -AU - Casaluce F -AD - b Department of Clinical and Experimental Medicine , Second University of Naples - , Naples , Italy. -FAU - Santabarbara, Giuseppe -AU - Santabarbara G -AD - a Division of Medical Oncology , 'S.G. Moscati' Hospital , Avellino , Italy. -FAU - Palazzolo, Giovanni -AU - Palazzolo G -AD - c Division of Medical Oncology , USLL5 , Cittadella (Pd) , Italy. -FAU - Maione, Paolo -AU - Maione P -AD - a Division of Medical Oncology , 'S.G. Moscati' Hospital , Avellino , Italy. -FAU - Gridelli, Cesare -AU - Gridelli C -AD - a Division of Medical Oncology , 'S.G. Moscati' Hospital , Avellino , Italy. -LA - eng -PT - Journal Article -PT - Review -DEP - 20160229 -PL - England -TA - Expert Opin Pharmacother -JT - Expert opinion on pharmacotherapy -JID - 100897346 -RN - 0 (Anthracyclines) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents) -RN - 0 (Ipilimumab) -RN - 31YO63LBSN (Nivolumab) -RN - 7M7YKX2N15 (Topotecan) -RN - 93N13LB4Z2 (amrubicin) -SB - IM -MH - Anthracyclines/therapeutic use -MH - Antibodies, Monoclonal/therapeutic use -MH - Antineoplastic Agents/*therapeutic use -MH - Humans -MH - Immunotherapy -MH - Ipilimumab -MH - Lung Neoplasms/*drug therapy/immunology -MH - Neoplasm Recurrence, Local/drug therapy/immunology -MH - Nivolumab -MH - Randomized Controlled Trials as Topic -MH - Small Cell Lung Carcinoma/*drug therapy/immunology -MH - Topotecan/therapeutic use -OTO - NOTNLM -OT - Amrubicin -OT - SCLC -OT - chemotherapy -OT - immunotherapy -OT - ipilimumab -OT - nivolumab -OT - targeted therapy -OT - topotecan -EDAT- 2016/02/16 06:00 -MHDA- 2016/09/13 06:00 -CRDT- 2016/02/16 06:00 -PHST- 2016/02/16 06:00 [entrez] -PHST- 2016/02/16 06:00 [pubmed] -PHST- 2016/09/13 06:00 [medline] -AID - 10.1517/14656566.2016.1154539 [doi] -PST - ppublish -SO - Expert Opin Pharmacother. 2016;17(7):969-76. doi: 10.1517/14656566.2016.1154539. - Epub 2016 Feb 29. - -PMID- 31813004 -OWN - NLM -STAT- MEDLINE -DCOM- 20200129 -LR - 20200129 -IS - 1432-1335 (Electronic) -IS - 0171-5216 (Linking) -VI - 146 -IP - 1 -DP - 2020 Jan -TI - Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in - the treatment of NSCLC brain metastases. -PG - 137-152 -LID - 10.1007/s00432-019-03094-9 [doi] -AB - With the advancement of imaging technology, systemic disease control rate and - survival rate, the morbidity of brain metastases (BMs) from non-small cell lung - cancer (NSCLC) has been riding on a steady upward trend (40%), but management of - BMs from NSCLC remains obscure. Systemic therapy is anticipated to offer novel - therapeutic avenues in the management of NSCLC BMs, and radiotherapy (RT) and - immunotherapy have their own advantages. Recently, it was confirmed that immune - checkpoint inhibitors (ICIs) and RT could mutually promote the efficacy in the - treatment of BMs from NSCLC. In this paper, we provide a review on current - understandings and practices of separating or combining ICIs and RT, which could - provide a reference for the coming laboratory and clinical studies and contribute - to the development of new approaches in NSCLC BMs. -FAU - Li, Wang -AU - Li W -AD - Dalian Medical University, Dalian, 116044, Liaoning, People's Republic of China. -FAU - Yu, Hong -AU - Yu H -AD - Radiation Oncology Department of Thoracic cancer, Cancer Hospital of China - Medical University, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, - Dadong District, Shenyang, 110042, Liaoning Province, People's Republic of China. - 2328901858@qq.com. -LA - eng -GR - 2015020263/Natural Science Foundation of Liaoning Province/ -PT - Journal Article -PT - Review -DEP - 20191207 -PL - Germany -TA - J Cancer Res Clin Oncol -JT - Journal of cancer research and clinical oncology -JID - 7902060 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (CTLA-4 Antigen) -RN - 0 (CTLA4 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antineoplastic Agents, Immunological/*administration & dosage -MH - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage -MH - B7-H1 Antigen/antagonists & inhibitors/immunology -MH - Brain Neoplasms/drug therapy/radiotherapy/*secondary/*therapy -MH - CTLA-4 Antigen/antagonists & inhibitors/immunology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/pathology/*radiotherapy -MH - Chemoradiotherapy -MH - Humans -MH - Lung Neoplasms/*drug therapy/immunology/pathology/*radiotherapy -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology -MH - Randomized Controlled Trials as Topic -MH - Retrospective Studies -OTO - NOTNLM -OT - Brain metastases -OT - CTLA-4 -OT - Immune checkpoint inhibitors -OT - NSCLC -OT - PD-1/PD-L1 -OT - Radiotherapy -EDAT- 2019/12/10 06:00 -MHDA- 2020/01/30 06:00 -CRDT- 2019/12/09 06:00 -PHST- 2019/03/04 00:00 [received] -PHST- 2019/11/21 00:00 [accepted] -PHST- 2019/12/10 06:00 [pubmed] -PHST- 2020/01/30 06:00 [medline] -PHST- 2019/12/09 06:00 [entrez] -AID - 10.1007/s00432-019-03094-9 [pii] -AID - 10.1007/s00432-019-03094-9 [doi] -PST - ppublish -SO - J Cancer Res Clin Oncol. 2020 Jan;146(1):137-152. doi: - 10.1007/s00432-019-03094-9. Epub 2019 Dec 7. - -PMID- 36130865 -OWN - NLM -STAT- MEDLINE -DCOM- 20221123 -LR - 20230126 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 23 -IP - 8 -DP - 2022 Dec -TI - Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic - Alternatives After Progression and Future Treatment Options. -PG - 643-658 -LID - S1525-7304(22)00190-5 [pii] -LID - 10.1016/j.cllc.2022.08.009 [doi] -AB - The treatment paradigm of non-small-cell lung cancer without oncogenic drivers - has varied dramatically in recent years and is constantly evolving. Immune- - checkpoint inhibitors have demonstrated unprecedented durable efficacy in a - subset of these patients, so these drugs have become the standard of care in most - cases. There are different ways to deliver these agents, such as monotherapy and - combinations of immunotherapy or chemotherapy plus immunotherapy. Treatment - selection is complicated by an absence of head-to-head comparisons in randomized - trials because these agents have gained approval by demonstrating superiority to - platinum-doublet chemotherapy alone. Unfortunately, most patients will progress - and die from their disease despite advances. Furthermore, after progression on - these agents, there is a lack of randomized controlled data to support further - management, constituting an unmet need. This review discusses the therapeutic - alternatives after progression, summarizes mechanisms of resistance and - progression patterns, and describes the main approaches under clinical - investigation in the field. -CI - Copyright © 2022. Published by Elsevier Inc. -FAU - Leal, Jose Luis -AU - Leal JL -AD - Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, - Victoria, Australia. -FAU - John, Thomas -AU - John T -AD - Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, - Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of - Melbourne, Parkville, Victoria, Australia.. Electronic address: - tom.john@petermac.org. -LA - eng -PT - Journal Article -PT - Review -DEP - 20220820 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - *Lung Neoplasms/drug therapy/genetics -MH - Immunotherapy -MH - Mutation/genetics -OTO - NOTNLM -OT - Angiogenesis inhibitors -OT - Antimetabolites -OT - Antineoplastic -OT - Immune checkpoint inhibitors -OT - Non-small cell lung cancer -OT - Radiation therapy -OT - Stereotactic -COIS- Declaration of Competing Interest Dr Leal has received investigation grants from - MSD, Roche, Boehringer Ingelheim, Pfizer, Astra Zeneca and BMS; and has received - personal fees from MSD, Roche, Boehringer Ingelheim, Pfizer, Astra Zeneca, BMS, - Sanofi, Elly-Lilly and Tecnofarma. All this is outside of the submitted work. Dr. - John has received personal fees from Ignyta, Roche, Astra Zeneca, Novartis, - Pfizer, BMS, and Merck, all outside of the submitted work. -EDAT- 2022/09/22 06:00 -MHDA- 2022/11/24 06:00 -CRDT- 2022/09/21 22:04 -PHST- 2022/06/01 00:00 [received] -PHST- 2022/08/04 00:00 [revised] -PHST- 2022/08/13 00:00 [accepted] -PHST- 2022/09/22 06:00 [pubmed] -PHST- 2022/11/24 06:00 [medline] -PHST- 2022/09/21 22:04 [entrez] -AID - S1525-7304(22)00190-5 [pii] -AID - 10.1016/j.cllc.2022.08.009 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2022 Dec;23(8):643-658. doi: 10.1016/j.cllc.2022.08.009. Epub - 2022 Aug 20. - -PMID- 31432705 -OWN - NLM -STAT- MEDLINE -DCOM- 20200413 -LR - 20200413 -IS - 1744-8301 (Electronic) -IS - 1479-6694 (Linking) -VI - 15 -IP - 29 -DP - 2019 Oct -TI - Pembrolizumab in lung cancer: current evidence and future perspectives. -PG - 3327-3336 -LID - 10.2217/fon-2019-0073 [doi] -AB - Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of - enhancing antitumor immune activity. The KEYNOTE-001 study showed that - pembrolizumab has activity in advanced non-small-cell lung cancer patients and - identified programmed death ligand 1 (PD-L1) as a companion test to select - patients most likely to benefit from pembrolizumab. Five randomized clinical - trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in - second-line setting PD-L1 ≥1% (KEYNOTE-010), in first-line setting PD-L1 ≥50% - (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with - platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future - challenges are the identification of the role of pembrolizumab in adjuvant, - neoadjuvant, locally advanced disease or oncogene-addicted patients, in - combination with radiotherapy or other biological agents. -FAU - Palumbo, Giuliano -AU - Palumbo G -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G Pascale', - IRCCS, Napoli, Italy. -FAU - Carillio, Guido -AU - Carillio G -AD - Department of Oncology & Hematology, Azienda Ospedaliera Pugliese-Ciaccio, - Catanzaro, Italy. -FAU - Manzo, Anna -AU - Manzo A -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G Pascale', - IRCCS, Napoli, Italy. -FAU - Montanino, Agnese -AU - Montanino A -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G Pascale', - IRCCS, Napoli, Italy. -FAU - Sforza, Vincenzo -AU - Sforza V -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G Pascale', - IRCCS, Napoli, Italy. -FAU - Costanzo, Raffaele -AU - Costanzo R -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G Pascale', - IRCCS, Napoli, Italy. -FAU - Sandomenico, Claudia -AU - Sandomenico C -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G Pascale', - IRCCS, Napoli, Italy. -FAU - Manna, Carmine La -AU - Manna C -AD - Thoracic Surgery, Istituto Nazionale Tumori, 'Fondazione G Pascale', IRCCS, - Napoli, Italy. -FAU - Luca, Giuseppe De -AU - Luca G -AD - Thoracic Surgery, Istituto Nazionale Tumori, 'Fondazione G Pascale', IRCCS, - Napoli, Italy. -FAU - Piccirillo, Maria Carmela -AU - Piccirillo MC -AD - Clinical Trials Unit, Istituto Nazionale Tumori, 'Fondazione G Pascale', IRCCS, - Napoli, Italy. -FAU - Daniele, Gennaro -AU - Daniele G -AD - Clinical Trials Unit, Istituto Nazionale Tumori, 'Fondazione G Pascale', IRCCS, - Napoli, Italy. -FAU - Cecio, Rossella De -AU - Cecio R -AD - Pathology, Istituto Nazionale Tumori, 'Fondazione G Pascale', IRCCS, Napoli, - Italy. -FAU - Botti, Gerardo -AU - Botti G -AD - Scientific Directorate, Istituto Nazionale Tumori, 'Fondazione G Pascale', IRCCS, - Napoli, Italy. -FAU - Totaro, Giuseppe -AU - Totaro G -AD - Radiotherapy, Istituto Nazionale Tumori, 'Fondazione G Pascale', IRCCS, Napoli, - Italy. -FAU - Muto, Paolo -AU - Muto P -AD - Radiotherapy, Istituto Nazionale Tumori, 'Fondazione G Pascale', IRCCS, Napoli, - Italy. -FAU - Picone, Carmine -AU - Picone C -AD - Radiology, Istituto Nazionale Tumori, 'Fondazione G Pascale', IRCCS, Napoli, - Italy. -FAU - Esposito, Giovanna -AU - Esposito G -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G Pascale', - IRCCS, Napoli, Italy. -FAU - Normanno, Nicola -AU - Normanno N -AD - Cellular Biology & Biotherapy, Istituto Nazionale Tumori, 'Fondazione G Pascale', - IRCCS, Napoli, Italy. -FAU - Morabito, Alessandro -AU - Morabito A -AUID- ORCID: 0000-0002-1319-9608 -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G Pascale', - IRCCS, Napoli, Italy. -LA - eng -PT - Clinical Trial, Phase I -PT - Clinical Trial, Phase II -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Randomized Controlled Trial -DEP - 20190821 -PL - England -TA - Future Oncol -JT - Future oncology (London, England) -JID - 101256629 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Receptors, Estrogen) -RN - 15H5577CQD (Docetaxel) -RN - 31YO63LBSN (Nivolumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Animals -MH - Antibodies, Monoclonal, Humanized/administration & dosage -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Docetaxel/administration & dosage -MH - Drug Evaluation -MH - Follow-Up Studies -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology -MH - Mice -MH - Nivolumab/administration & dosage -MH - Prognosis -MH - Receptors, Estrogen/*metabolism -MH - Small Cell Lung Carcinoma/*drug therapy/pathology -MH - Survival Rate -MH - Tumor Cells, Cultured -MH - Xenograft Model Antitumor Assays -OTO - NOTNLM -OT - NSCLC -OT - PD-1 -OT - PD-L1 -OT - SCLC -OT - pembrolizumab -EDAT- 2019/08/23 06:00 -MHDA- 2020/04/14 06:00 -CRDT- 2019/08/22 06:00 -PHST- 2019/08/23 06:00 [pubmed] -PHST- 2020/04/14 06:00 [medline] -PHST- 2019/08/22 06:00 [entrez] -AID - 10.2217/fon-2019-0073 [doi] -PST - ppublish -SO - Future Oncol. 2019 Oct;15(29):3327-3336. doi: 10.2217/fon-2019-0073. Epub 2019 - Aug 21. - -PMID- 33293673 -OWN - NLM -STAT- MEDLINE -DCOM- 20210218 -LR - 20240404 -IS - 1532-1827 (Electronic) -IS - 0007-0920 (Print) -IS - 0007-0920 (Linking) -VI - 123 -IP - Suppl 1 -DP - 2020 Dec -TI - Practical implications to contemplate when considering radical therapy for stage - III non-small-cell lung cancer. -PG - 28-35 -LID - 10.1038/s41416-020-01072-4 [doi] -AB - The type of patients with stage III non-small-cell lung cancer (NSCLC) selected - for concurrent chemoradiotherapy (cCRT) varies between and within countries, with - higher-volume centres treating patients with more co-morbidities and higher-stage - disease. However, in spite of these disease characteristics, these patients have - improved overall survival, suggesting that there are additional approaches that - should be optimised and potentially standardised. This paper aims to review the - current knowledge and best practices surrounding treatment for patients eligible - for cCRT. Initially, this includes timely acquisition of the full diagnostic - workup for the multidisciplinary team to comprehensively assess a patient for - treatment, as well as imaging scans, patient history, lung function and genetic - tests. Such information can provide prognostic information on how a patient will - tolerate their cCRT regimen, and to perhaps limit the use of additional - supportive care, such as steroids, which could impact on further treatments, such - as immunotherapy. Furthermore, knowledge of the safety profile of individual - double-platinum chemotherapy regimens and the technological advances in - radiotherapy could aid in optimising patients for cCRT treatment, improving its - efficacy whilst minimising its toxicities. Finally, providing patients with - preparatory and ongoing support with input from dieticians, palliative care - professionals, respiratory and care-of-the-elderly physicians during treatment - may also help in more effective treatment delivery, allowing patients to achieve - the maximum potential from their treatments. -FAU - Storey, Claire L -AU - Storey CL -AD - Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. -FAU - Hanna, Gerard G -AU - Hanna GG -AD - Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, - Belfast, UK. -AD - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, - Australia. -FAU - Greystoke, Alastair -AU - Greystoke A -AD - Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. - alastair.greystoke@newcastle.ac.uk. -AD - Newcastle University Centre for Cancer, Newcastle University, Newcastle upon - Tyne, UK. alastair.greystoke@newcastle.ac.uk. -CN - AstraZeneca UK Limited -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - England -TA - Br J Cancer -JT - British journal of cancer -JID - 0370635 -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/radiotherapy/surgery -MH - Chemoradiotherapy/*adverse effects -MH - Combined Modality Therapy -MH - Humans -MH - Neoplasm Staging -MH - *Prognosis -MH - Treatment Outcome -PMC - PMC7735214 -COIS- G.G.H. has received speaker fees from AstraZeneca UKMC, Roche Holding AG, - Novartis International AG, consulting fees from Pfizer Inc. and has grant support - under negotiation with the CTC committee of Cancer Research UK. A.G. has received - speaker fees from AstraZeneca, Pfizer, MSD, Boehringer Ingelheim, Novartis and - BMS, has received grant support from the Cancer Research UK Centre at the - Northern Institute for Cancer Research and has attended advisory boards for - AstraZeneca UKMC. C.L.S. has no conflicts of interest. The authors do not report - any conflict of interest with regard to the contents of this study other than - those stated. -EDAT- 2020/12/10 06:00 -MHDA- 2021/02/20 06:00 -PMCR- 2020/12/08 -CRDT- 2020/12/09 06:10 -PHST- 2020/12/09 06:10 [entrez] -PHST- 2020/12/10 06:00 [pubmed] -PHST- 2021/02/20 06:00 [medline] -PHST- 2020/12/08 00:00 [pmc-release] -AID - 10.1038/s41416-020-01072-4 [pii] -AID - 1072 [pii] -AID - 10.1038/s41416-020-01072-4 [doi] -PST - ppublish -SO - Br J Cancer. 2020 Dec;123(Suppl 1):28-35. doi: 10.1038/s41416-020-01072-4. - -PMID- 33166719 -OWN - NLM -STAT- MEDLINE -DCOM- 20210421 -LR - 20210421 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 16 -IP - 2 -DP - 2021 Feb -TI - Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, - Two-Stage, Phase 2 Trial. -PG - 299-309 -LID - S1556-0864(20)30806-6 [pii] -LID - 10.1016/j.jtho.2020.10.002 [doi] -AB - INTRODUCTION: Treatment options in the second-line extensive-stage SCLC (ED-SCLC) - setting are limited. The PASSION study (ClinicalTrials.gov identifier: - NCT03417895) was a phase 2 study of camrelizumab plus apatinib in ED-SCLC after - platinum-based chemotherapy. METHODS: In stage I of the study, patients were - randomized (1:1:1) to receive camrelizumab 200 mg every 2 weeks plus apatinib 375 - mg once daily (QD), 5 days on and 2 days off, or 7 days on and 7 days off (six - patients each cohort). On the basis of tolerability during the first 28-day cycle - and efficacy data at stage I, one cohort was chosen to expand to 45 patients at - stage II. The primary end point was objective response rate (ORR). RESULTS: From - April 20, 2018 to March 12, 2019, a total of 59 patients were enrolled, with 47 - patients in the QD cohort. In the QD cohort, confirmed ORR reached 34.0% (95% - confidence interval: 20.9‒49.3), the median progression-free survival was 3.6 - months, and the median overall survival was 8.4 months. Chemotherapy-sensitive - and chemotherapy-resistant patients (defined as patients with disease relapse at - ≥90 and <90 d after platinum-based chemotherapy, respectively) had comparable - confirmed ORR (37.5% versus 32.3%), median progression-free survival (3.6 versus - 2.7 mo), and median overall survival (9.6 versus 8.0 mo). Treatment-related - adverse events of grade 3 or higher were reported in 43 of 59 patients (72.9%). - Five patients (8.5%) discontinued because of treatment-related adverse events. - CONCLUSIONS: Camrelizumab plus apatinib exhibited potential antitumor activity in - patients with both chemotherapy-sensitive and chemotherapy-resistant ED-SCLC who - had failed platinum-based chemotherapy with an acceptable toxicity profile. This - phase 2 data warrant further clinical studies of camrelizumab plus apatinib in - SCLC. -CI - Copyright © 2020. Published by Elsevier Inc. -FAU - Fan, Yun -AU - Fan Y -AD - Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, - People's Republic of China. -FAU - Zhao, Jun -AU - Zhao J -AD - Department of Thoracic Medical Oncology, Beijing Cancer Hospital, Beijing, - People's Republic of China. -FAU - Wang, Qiming -AU - Wang Q -AD - Department of Internal Medicine, Henan Cancer Hospital, Zhengzhou, People's - Republic of China. -FAU - Huang, Dingzhi -AU - Huang D -AD - Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and - Hospital, Tianjin, People's Republic of China. -FAU - Li, Xingya -AU - Li X -AD - Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou - University, Zhengzhou, People's Republic of China. -FAU - Chen, Jianhua -AU - Chen J -AD - Department of Medical Oncology, Hunan Cancer Hospital, Changsha, People's - Republic of China. -FAU - Fang, Yong -AU - Fang Y -AD - Department of Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of - Medicine, Hangzhou, People's Republic of China. -FAU - Duan, Jianchun -AU - Duan J -AD - Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical - Sciences, Beijing, People's Republic of China. -FAU - Zhou, Caicun -AU - Zhou C -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University - School of Medicine, Shanghai, People's Republic of China. -FAU - Hu, Yanping -AU - Hu Y -AD - Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, People's Republic - of China. -FAU - Yang, Haihua -AU - Yang H -AD - Department of Radiotherapy Section, Taizhou Hospital of Zhejiang Province, - Taizhou, People's Republic of China. -FAU - Hu, Yi -AU - Hu Y -AD - Department of Medical Oncology, Chinese PLA General Hospital, Beijing, People's - Republic of China. -FAU - Zhou, Jianying -AU - Zhou J -AD - Department of Respiratory Medicine, The First Affiliated Hospital of Zhejiang - University, Hangzhou, People's Republic of China. -FAU - Lin, Xiaoyan -AU - Lin X -AD - Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, - People's Republic of China. -FAU - Wang, Lifeng -AU - Wang L -AD - Department of Medical Oncology, Drum Tower Hospital Affiliated to Medical School - of Nanjing University, Nanjing, People's Republic of China. -FAU - Wang, Zhijie -AU - Wang Z -AD - Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical - Sciences, Beijing, People's Republic of China. -FAU - Xu, Yanjun -AU - Xu Y -AD - Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, - People's Republic of China. -FAU - Zhang, Tao -AU - Zhang T -AD - Hengrui Medicine, Shanghai, People's Republic of China. -FAU - Shi, Wei -AU - Shi W -AD - Hengrui Medicine, Shanghai, People's Republic of China. -FAU - Zou, Jianjun -AU - Zou J -AD - Hengrui Medicine, Shanghai, People's Republic of China. -FAU - Wang, Jie -AU - Wang J -AD - Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical - Sciences, Beijing, People's Republic of China. Electronic address: - zlhuxi@163.com. -LA - eng -SI - ClinicalTrials.gov/NCT03417895 -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20201106 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Pyridines) -RN - 5S371K6132 (apatinib) -RN - 73096E137E (camrelizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Pyridines/therapeutic use -MH - *Small Cell Lung Carcinoma/drug therapy -OTO - NOTNLM -OT - Apatinib -OT - Camrelizumab -OT - PD-1 inhibitor -OT - SCLC -OT - VEGFR -EDAT- 2020/11/10 06:00 -MHDA- 2021/04/22 06:00 -CRDT- 2020/11/09 20:13 -PHST- 2020/08/12 00:00 [received] -PHST- 2020/09/29 00:00 [revised] -PHST- 2020/10/02 00:00 [accepted] -PHST- 2020/11/10 06:00 [pubmed] -PHST- 2021/04/22 06:00 [medline] -PHST- 2020/11/09 20:13 [entrez] -AID - S1556-0864(20)30806-6 [pii] -AID - 10.1016/j.jtho.2020.10.002 [doi] -PST - ppublish -SO - J Thorac Oncol. 2021 Feb;16(2):299-309. doi: 10.1016/j.jtho.2020.10.002. Epub - 2020 Nov 6. - -PMID- 37307617 -OWN - NLM -STAT- MEDLINE -DCOM- 20231216 -LR - 20231216 -IS - 2590-0412 (Electronic) -IS - 2590-0412 (Linking) -VI - 84 -DP - 2023 Nov -TI - Treatment patterns and clinical outcomes of extensive stage small cell lung - cancer (SCLC) in the real-world evidence ESME cohort before the era of - immunotherapy. -PG - 101012 -LID - S2590-0412(23)00024-7 [pii] -LID - 10.1016/j.resmer.2023.101012 [doi] -AB - BACKGROUND: Small cell lung cancer (SCLC) is a highly aggressive entity of lung - cancer with tendency toward early recurrence after first-line treatment. As per - recently updated European Society for Medical Oncology recommendations, - first-line treatment with up to 4 cycles of platinum-etoposide combined with - immune checkpoint inhibitor (ICIs)-targeting PD-L1, is now the standard of care. - The purpose of the current analysis is to identify current patient profiles and - treatment strategies in real life clinical practice, and report outcomes in - Extensive Stage (ES)-SCLC. METHODS: Non-interventional, retrospective, - multicentre, comparative study was carried out to describe the outcome of ES-SCLC - patients included in the Epidémiologie Stratégie Médico-Economique (ESME) data - platform for advanced and metastatic lung cancer. Patients were selected from 34 - health care facilities between January 2015 and December 2017, before the era of - immunotherapy. RESULTS: 1315 patients were identified, including 64% male and 78% - under 70 year-old; 24% had at least 3 metastatic sites, mainly liver metastases - (43%), bone metastases (36%), brain metastases (32%). 49% received only one line - of systemic treatment; 30% and 21% received 2 and 3 lines or more, respectively. - Carboplatin was more frequently used than cisplatin (71% and 29%, respectively). - Prophylactic cranial irradiation was infrequent (4% of patients), but 16% of - patients received thoracic radiation therapy, mainly after the completion of - first-line chemotherapy (72% of patients); such strategies were more frequently - applied in cisplatin/etoposide than carboplatin/etoposide patients (p = 0.006 and - p = 0.015, respectively). After a median follow-up time of 21.8 (95% CI: - 20.9-23.3) months, median real-world Progression-Free Survival (rw-PFS) was 6.2 - (95% CI: 5.7; 6.9) and 6.1 (95% CI: 5.8; 6.3) months for cisplatin/etoposide and - carboplatin/etoposide doublet regimens, respectively; 24-month rwPFS and Overall - Survival were 3.2% (95% CI: 2.3; 4;2) and 22.2% (95% CI: 19.4; 25.1) in the whole - population, respectively. CONCLUSION: Our data provide with landmark reference - findings on ES-SCLC before the immunotherapy era, and cover many aspects of the - treatment strategy, while highlighting on the role of radiotherapy, subsequent - lines of therapy, and the outcomes of patients. Generation of real-world data - focusing on patients who received platinum-based chemotherapy combined with - immune checkpoint inhibitors is under way. -CI - Copyright © 2023 SPLF and Elsevier Masson SAS. All rights reserved. -FAU - Valette, Clarisse Audigier -AU - Valette CA -AD - Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Toulon, France. -FAU - Filleron, Thomas -AU - Filleron T -AD - Institut Claudius Regaud IUCT, Toulouse, France. -FAU - Debieuvre, Didier -AU - Debieuvre D -AD - Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France. -FAU - Lena, Hervé -AU - Lena H -AD - Centre Hospitalier Universitaire de Rennes, Rennes, France. -FAU - Pérol, Maurice -AU - Pérol M -AD - Centre Léon Bérard, Lyon, France. -FAU - Chouaid, Christos -AU - Chouaid C -AD - Centre Hospitalier Intercommunal de Créteil, Créteil, France. -FAU - Simon, Gaëtane -AU - Simon G -AD - Unicancer, Paris, France. -FAU - Quantin, Xavier -AU - Quantin X -AD - Institut régional du Cancer de Montpellier, Montpellier, France. -FAU - Girard, Nicolas -AU - Girard N -AD - Institut du Thorax Curie Montsouris, Institut Curie, Paris, France et Université - Versailles Saint Quentin, Paris Saclay Campus, Versailles, France. Electronic - address: nicolas.girard2@curie.fr. -LA - eng -PT - Journal Article -DEP - 20230327 -PL - France -TA - Respir Med Res -JT - Respiratory medicine and research -JID - 101746324 -RN - Q20Q21Q62J (Cisplatin) -RN - BG3F62OND5 (Carboplatin) -RN - 6PLQ3CP4P3 (Etoposide) -SB - IM -MH - Humans -MH - Male -MH - Aged -MH - Female -MH - *Small Cell Lung Carcinoma/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Cisplatin/adverse effects -MH - Carboplatin/therapeutic use -MH - Etoposide/adverse effects -MH - Retrospective Studies -MH - Immunotherapy -OTO - NOTNLM -OT - Chemotherapy -OT - Immunotherapy -OT - Small cell lung cancer -OT - Targeted therapy -COIS- Declaration of Competing Interest Dr. Girard reports receiving research - grants/support from AstraZeneca, Amgen, Boehringer Ingelheim, Eli Lilly, - Hoffmann-La Roche, Janssen, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Sivan, - and Trizell; having consultative services for Bristol Myers Squibb, AstraZeneca, - AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann- La Roche, Janssen, - Merck, Merck Sharp & Dohme, Mirati, Novartis, Pfizer, Roche, Sanofi, and Sivan; - receiving payment for expert testimony from AstraZeneca; having participation on - a data safety monitoring board for Roche; having leadership role in the - International Thymic Malignancy Interest Group; and having employment of a family - member with AstraZeneca. Other authors declare no conflicts of interest. -EDAT- 2023/06/12 19:12 -MHDA- 2023/12/17 09:42 -CRDT- 2023/06/12 18:00 -PHST- 2022/06/08 00:00 [received] -PHST- 2023/03/13 00:00 [revised] -PHST- 2023/03/18 00:00 [accepted] -PHST- 2023/12/17 09:42 [medline] -PHST- 2023/06/12 19:12 [pubmed] -PHST- 2023/06/12 18:00 [entrez] -AID - S2590-0412(23)00024-7 [pii] -AID - 10.1016/j.resmer.2023.101012 [doi] -PST - ppublish -SO - Respir Med Res. 2023 Nov;84:101012. doi: 10.1016/j.resmer.2023.101012. Epub 2023 - Mar 27. - -PMID- 26712904 -OWN - NLM -STAT- MEDLINE -DCOM- 20161213 -LR - 20200206 -IS - 1569-8041 (Electronic) -IS - 0923-7534 (Linking) -VI - 27 -IP - 4 -DP - 2016 Apr -TI - Pathways to improving combined modality therapy for stage III nonsmall-cell lung - cancer. -PG - 590-9 -LID - 10.1093/annonc/mdv621 [doi] -AB - BACKGROUND: Lung cancer is the leading cause of cancer deaths, having caused an - estimated 1.6 million deaths worldwide in 2012 [Ferlay J, Soerjomataram I, - Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and - major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386]. MATERIALS - AND METHODS: Although the majority of patients are not cured with currently - available therapies, there have been significant improvements in stage-specific - outcomes over time [Videtic G, Vokes E, Turrisi A et al. The survival of patients - treated for stage III non-small cell lung cancer in North America has increased - during the past 25 years. In The 39th Annual Meeting of the American Society of - Clinical Oncology, ASCO 2003, Chicago, IL. Abstract 2557. p. 291]. This review - focuses on past progress and ongoing research in the treatment of locally - advanced, inoperable nonsmall-cell lung cancer (NSCLC). RESULTS: In the past, - randomized trials revealed advantages to the use of thoracic radiotherapy (TRT) - and then, the addition of induction chemotherapy. This was followed by studies - that determined concurrent chemoradiotherapy to be superior to sequential - therapy. A recent large phase III trial found that the administration of 74 Gy of - conventionally fractionated photon-based TRT provided poorer survival than did - the standard 60 Gy. However, further research on other methods of applying - radiotherapy (hypofractionation, adaptive TRT, proton therapy, and stereotactic - TRT boosting) is proceeding and may improve outcomes. The molecular - characterization of tumors has provided more effective and less toxic targeted - treatments in the stage IV setting and these agents are currently under - investigation for earlier stage disease. Similarly, immune-enhancing therapies - have shown promise in stage IV disease and are also being tested in the locally - advanced setting. CONCLUSION: For locally advanced, inoperable NSCLC, standard - therapy has evolved from TRT alone to combined modality therapy. We summarize the - recent clinical trial experience and outline promising areas of investigation in - an era of greater molecular and immunologic understanding of cancer care. -CI - © The Author 2015. Published by Oxford University Press on behalf of the European - Society for Medical Oncology. All rights reserved. For permissions, please email: - journals.permissions@oup.com. -FAU - Schild, S E -AU - Schild SE -AD - Department of Radiation Oncology, Mayo Clinic, Scottsdale sschild@mayo.edu. -FAU - Vokes, E E -AU - Vokes EE -AD - Department of Medicine and Comprehensive Cancer Center, University of Chicago - Medicine and Biologic Sciences, Chicago, USA. -LA - eng -PT - Journal Article -PT - Review -DEP - 20151227 -PL - England -TA - Ann Oncol -JT - Annals of oncology : official journal of the European Society for Medical - Oncology -JID - 9007735 -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/*radiotherapy -MH - Chemoradiotherapy/adverse effects -MH - Combined Modality Therapy -MH - Drug-Related Side Effects and Adverse Reactions/pathology -MH - Humans -MH - Neoplasm Recurrence, Local/*drug therapy/pathology/*radiotherapy -MH - Neoplasm Staging -MH - North America -MH - Radiography, Thoracic/adverse effects -OTO - NOTNLM -OT - chemotherapy -OT - immunotherapy -OT - nonsmall-cell lung cancer -OT - radiation therapy -OT - review -OT - targeted therapy -EDAT- 2015/12/30 06:00 -MHDA- 2016/12/15 06:00 -CRDT- 2015/12/30 06:00 -PHST- 2015/09/22 00:00 [received] -PHST- 2015/12/14 00:00 [accepted] -PHST- 2015/12/30 06:00 [entrez] -PHST- 2015/12/30 06:00 [pubmed] -PHST- 2016/12/15 06:00 [medline] -AID - S0923-7534(19)35749-7 [pii] -AID - 10.1093/annonc/mdv621 [doi] -PST - ppublish -SO - Ann Oncol. 2016 Apr;27(4):590-9. doi: 10.1093/annonc/mdv621. Epub 2015 Dec 27. - -PMID- 29153898 -OWN - NLM -STAT- MEDLINE -DCOM- 20190408 -LR - 20190408 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 19 -IP - 2 -DP - 2018 Mar -TI - The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant - Double Swords as Predictive and Prognostic Markers. -PG - 120-129 -LID - S1525-7304(17)30308-X [pii] -LID - 10.1016/j.cllc.2017.10.014 [doi] -AB - Lung cancer is the leading cause of death due to cancer worldwide. Surgery, - chemotherapy, and radiotherapy have been the standard treatment for lung cancer, - and targeted molecular therapy has greatly improved the clinical course of - patients with non-small-cell lung cancer (NSCLC) harboring driver mutations, such - as in epidermal growth factor receptor and anaplastic lymphoma kinase genes. - Despite advances in such therapies, the prognosis of patients with NSCLC without - driver oncogene mutations remains poor. Immunotherapy targeting programmed cell - death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) has recently been shown - to improve the survival in advanced NSCLC. The PD-L1 expression on the surface of - tumor cells has emerged as a potential biomarker for predicting responses to - immunotherapy and prognosis after surgery in NSCLC. However, the utility of PD-L1 - expression as a predictive and prognostic biomarker remains controversial because - of the existence of various PD-L1 antibodies, scoring systems, and positivity - cutoffs. In this review, we summarize the data from representative clinical - trials of PD-1/PD-L1 immune checkpoint inhibitors in NSCLC and previous reports - on the association between PD-L1 expression and clinical outcomes in patients - with NSCLC. Furthermore, we discuss the future perspectives of immunotherapy and - immune checkpoint factors. -CI - Copyright © 2017 Elsevier Inc. All rights reserved. -FAU - Takada, Kazuki -AU - Takada K -AD - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu - University, Fukuoka, Japan. Electronic address: - k_takada@surg2.med.kyushu-u.ac.jp. -FAU - Toyokawa, Gouji -AU - Toyokawa G -AD - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu - University, Fukuoka, Japan. -FAU - Shoji, Fumihiro -AU - Shoji F -AD - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu - University, Fukuoka, Japan. -FAU - Okamoto, Tatsuro -AU - Okamoto T -AD - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu - University, Fukuoka, Japan. -FAU - Maehara, Yoshihiko -AU - Maehara Y -AD - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu - University, Fukuoka, Japan. -LA - eng -PT - Journal Article -PT - Review -DEP - 20171028 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Pharmacological) -RN - 0 (Biomarkers, Tumor) -RN - 0 (CD274 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - B7-H1 Antigen/*metabolism -MH - Biomarkers, Pharmacological/*metabolism -MH - Biomarkers, Tumor/*metabolism -MH - Carcinoma, Non-Small-Cell Lung/diagnosis/drug therapy/*metabolism -MH - Humans -MH - Immunotherapy/*methods -MH - Lung Neoplasms/diagnosis/drug therapy/*metabolism -MH - Molecular Targeted Therapy -MH - Predictive Value of Tests -MH - Prognosis -MH - Programmed Cell Death 1 Receptor/*metabolism -OTO - NOTNLM -OT - Biomarker -OT - Immunotherapy -OT - Non–small-cell lung cancer -OT - Programmed cell death-1 -OT - Programmed cell death-ligand 1 -EDAT- 2017/11/21 06:00 -MHDA- 2019/04/09 06:00 -CRDT- 2017/11/21 06:00 -PHST- 2017/05/30 00:00 [received] -PHST- 2017/10/12 00:00 [revised] -PHST- 2017/10/18 00:00 [accepted] -PHST- 2017/11/21 06:00 [pubmed] -PHST- 2019/04/09 06:00 [medline] -PHST- 2017/11/21 06:00 [entrez] -AID - S1525-7304(17)30308-X [pii] -AID - 10.1016/j.cllc.2017.10.014 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub - 2017 Oct 28. - -PMID- 37871898 -OWN - NLM -STAT- MEDLINE -DCOM- 20240415 -LR - 20240426 -IS - 2005-9256 (Electronic) -IS - 1598-2998 (Print) -IS - 1598-2998 (Linking) -VI - 56 -IP - 2 -DP - 2024 Apr -TI - The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell - Lung Cancer: A Multicenter Prospective Cohort Study. -PG - 422-429 -LID - 10.4143/crt.2023.913 [doi] -AB - PURPOSE: The addition of immune checkpoint inhibitors to chemotherapy has - improved survival outcomes in patients with extensive-stage small cell lung - cancer (ES-SCLC). However, their real-world effectiveness remains unknown. - Therefore, we investigated the effectiveness of atezolizumab plus chemotherapy in - ES-SCLC in actual clinical settings. MATERIALS AND METHODS: In this multicenter - prospective cohort study, patients with ES-SCLC receiving or scheduled to receive - atezolizumab in combination with etoposide and carboplatin were enrolled between - June 2021 and August 2022. The primary outcomes were progression-free survival - (PFS) and the 1-year overall survival (OS) rate. RESULTS: A total of 100 patients - with ES-SCLC were enrolled from seven centers. Median age was 69 years, and 6% - had an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2. The - median PFS was 6.0 months, the 1-year OS rate was 62.2%, and the median OS was - 13.5 months. An ECOG PS of 2-3 and progressive disease as the best response were - poor prognostic factors for PFS, while an ECOG PS of 2-3 and brain metastasis - were associated with poor prognosis for OS. In addition, consolidative thoracic - radiotherapy was found to be an independent favorable prognostic factor for OS - (hazard ratio, 0.336; p=0.021). Grade ≥ 3 treatment-related adverse events were - observed in 7% of patients, with treatment-related deaths occurring in 2% of - patients. CONCLUSION: We provided evidence of the favorable real-world - effectiveness and safety of atezolizumab plus chemotherapy in ES-SCLC patients, - including in the elderly and those with poor ECOG PS. Additional consolidative - thoracic radiotherapy may also benefit ES-SCLC patients. -FAU - Choi, Myeong Geun -AU - Choi MG -AD - Department of Pulmonary and Critical Care Medicine, Asan Medical Center, - University of Ulsan College of Medicine, Seoul, Korea. -AD - Division of Pulmonary and Critical Care Medicine, Department of Internal - Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University College - of Medicine, Seoul, Korea. -FAU - Kim, Yeon Joo -AU - Kim YJ -AD - Department of pulmonology, Nowon Eulji Medical Center, Eulji University School of - Medicine, Seoul, Korea. -FAU - Lee, Jae Cheol -AU - Lee JC -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, Seoul, Korea. -FAU - Ji, Wonjun -AU - Ji W -AD - Department of Pulmonary and Critical Care Medicine, Asan Medical Center, - University of Ulsan College of Medicine, Seoul, Korea. -FAU - Oh, In-Jae -AU - Oh IJ -AD - Department of Internal Medicine, Chonnam National University Hwasun Hospital, - Chonnam National University Medical School, Hwasun, Korea. -FAU - Lee, Sung Yong -AU - Lee SY -AD - Division of Pulmonary, Allergy, and Critical Care Medicine, Department of - Internal Medicine, Korea University Guro Hospital, Korea University College of - Medicine, Seoul, Korea. -FAU - Yoon, Seong Hoon -AU - Yoon SH -AD - Division of Pulmonology, Allergy, and Critical Care Medicine, Department of - Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea. -FAU - Lee, Shin Yup -AU - Lee SY -AD - Department of Internal Medicine, Kyungpook National University, School of - Medicine, Daegu, Korea. -FAU - Lee, Jeong Eun -AU - Lee JE -AD - Division of Pulmonology, Department of Internal Medicine, Chungnam National - University College of Medicine, Daejeon, Korea. -FAU - Kim, Eun Young -AU - Kim EY -AD - Division of Pulmonary and Critical Care Medicine, Department of Internal - Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, - Korea. -FAU - Choi, Chang-Min -AU - Choi CM -AD - Department of Pulmonary and Critical Care Medicine, Asan Medical Center, - University of Ulsan College of Medicine, Seoul, Korea. -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, Seoul, Korea. -LA - eng -PT - Journal Article -PT - Multicenter Study -DEP - 20231023 -PL - Korea (South) -TA - Cancer Res Treat -JT - Cancer research and treatment -JID - 101155137 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 52CMI0WC3Y (atezolizumab) -SB - IM -MH - Aged -MH - Humans -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - *Lung Neoplasms/drug therapy -MH - Prospective Studies -MH - *Small Cell Lung Carcinoma/drug therapy -PMC - PMC11016637 -OTO - NOTNLM -OT - Atezolizumab -OT - Real-world -OT - Small cell lung carcinoma -COIS- Conflicts of Interest I-JO received grant from Roche. I-JO received personal fee - from Gencurix, Janssen, Merck Sharp & Dohme, Ono Pharma, Panagene, Pfizer, Roche, - and Yuhan. I-JO received honoraria from Amgen, AstraZeneca, Eli Lilly, Janssen, - Menarini, Merck Sharp & Dohme, Novartis, Pfizer, and Yuhan. All other authors - have no competing interests. -EDAT- 2023/10/24 00:41 -MHDA- 2024/04/15 06:42 -PMCR- 2024/04/01 -CRDT- 2023/10/23 19:40 -PHST- 2023/08/05 00:00 [received] -PHST- 2023/10/21 00:00 [accepted] -PHST- 2024/04/15 06:42 [medline] -PHST- 2023/10/24 00:41 [pubmed] -PHST- 2023/10/23 19:40 [entrez] -PHST- 2024/04/01 00:00 [pmc-release] -AID - crt.2023.913 [pii] -AID - crt-2023-913 [pii] -AID - 10.4143/crt.2023.913 [doi] -PST - ppublish -SO - Cancer Res Treat. 2024 Apr;56(2):422-429. doi: 10.4143/crt.2023.913. Epub 2023 - Oct 23. - -PMID- 37211066 -OWN - NLM -STAT- MEDLINE -DCOM- 20230605 -LR - 20230605 -IS - 1872-7980 (Electronic) -IS - 0304-3835 (Linking) -VI - 565 -DP - 2023 Jul 1 -TI - Tackling the current dilemma of immunotherapy in extensive-stage small cell lung - cancer: A promising strategy of combining with radiotherapy. -PG - 216239 -LID - S0304-3835(23)00190-8 [pii] -LID - 10.1016/j.canlet.2023.216239 [doi] -AB - Progress in the treatment of small cell lung cancer (SCLC) has been modest over - the past decades until the advent of immune checkpoint inhibitors, which have - redefined the standard first-line treatment for extensive-stage SCLC (ES-SCLC). - However, despite the positive results of several clinical trials, the limited - survival benefit achieved suggests that the priming and sustaining of - immunotherapeutic efficacy are poor and further investigation is urgently needed. - In this review, we aim to summarize the potential mechanisms underlying the - limited efficacy of immunotherapy and intrinsic resistance in ES-SCLC, including - impaired antigen presentation and limited T cell infiltration. Moreover, to - tackle the current dilemma, given the synergistic effects of radiotherapy on - immunotherapy, especially the unique advantages of low-dose radiotherapy (LDRT), - such as less immunosuppression and lower radiation toxicity, we propose - radiotherapy as a booster to enhance the immunotherapeutic efficacy by overcoming - the poor priming effect. Recent clinical trials, including ours, have also - focused on adding radiotherapy, including LDRT, to first-line treatment of - ES-SCLC. Additionally, we also suggest combination strategies to sustain the - immunostimulatory effect of radiotherapy, as well as the cancer-immunity cycle, - and further improve survival outcomes. -CI - Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. -FAU - Kang, Kai -AU - Kang K -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, and Laboratory - of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, - Sichuan, China. -FAU - Wu, Yijun -AU - Wu Y -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, and Laboratory - of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, - Sichuan, China. -FAU - Yao, Zhuoran -AU - Yao Z -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, and Laboratory - of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, - Sichuan, China. -FAU - Lu, You -AU - Lu Y -AD - Division of Thoracic Tumor Multimodality Treatment, Cancer Center, and Laboratory - of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, - Sichuan, China; Department of Radiation Oncology, Cancer Center, West China - Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: - radyoulu@hotmail.com. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20230519 -PL - Ireland -TA - Cancer Lett -JT - Cancer letters -JID - 7600053 -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/radiotherapy/drug therapy -MH - *Lung Neoplasms/radiotherapy/drug therapy -MH - Immunotherapy/methods -MH - Combined Modality Therapy -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -OTO - NOTNLM -OT - Immune checkpoint inhibitor -OT - Immunotherapy -OT - Low-dose radiotherapy -OT - Small cell lung cancer -COIS- Declaration of competing interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2023/05/22 00:41 -MHDA- 2023/06/05 06:42 -CRDT- 2023/05/21 19:22 -PHST- 2023/03/20 00:00 [received] -PHST- 2023/05/05 00:00 [revised] -PHST- 2023/05/17 00:00 [accepted] -PHST- 2023/06/05 06:42 [medline] -PHST- 2023/05/22 00:41 [pubmed] -PHST- 2023/05/21 19:22 [entrez] -AID - S0304-3835(23)00190-8 [pii] -AID - 10.1016/j.canlet.2023.216239 [doi] -PST - ppublish -SO - Cancer Lett. 2023 Jul 1;565:216239. doi: 10.1016/j.canlet.2023.216239. Epub 2023 - May 19. - -PMID- 38288117 -OWN - NLM -STAT- MEDLINE -DCOM- 20240131 -LR - 20240410 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 14 -DP - 2023 -TI - Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent - chemoradiotherapy and consolidation toripalimab for bulky locally advanced - non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist - study). -PG - 1341584 -LID - 10.3389/fimmu.2023.1341584 [doi] -LID - 1341584 -AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment - landscape for locally advanced non-small-cell lung cancer (LA-NSCLC), whereas - responses to anti-programmed cell death-1 (PD-1) or anti-programmed death-ligand - 1 (PD-L1) are heterogeneous. Though consolidation ICI following concurrent - chemoradiotherapy (cCRT) improves survival of NSCLC, this regimen is challenging - for patients with bulky tumors due to excessive target volumes and - radiation-resistant hypoxia during upfront cCRT, leading to higher risk of - pneumonitis and inferior local-regional control. Recent trials have demonstrated - neoadjuvant ICI brought greater benefit to stage III than stage I-II NSCLC. Our - previous study also supported the therapeutic advantage of 2-cycle induction ICI - for patients with bulky unresectable stage III NSCLC. In the context of induction - immunotherapy, radiotherapy is more likely to exert immune synergistic effects, - reverse anti-PD-1 resistance, and activate abscopal immune responses. Prospective - trials to determine the efficacy and safety of induction ICI for bulky LA-NSCLC - are necessary. METHODS: This randomized, open-label, two-arm phase II study aims - to explore whether 2 cycles of induction anti-PD-1 toripalimab plus chemotherapy - can improve progression-free survival (PFS) in bulky LA-NSCLC. Bulky tumors are - defined as primary lesion ≥5 cm in greatest dimension or metastatic lymph nodes - ≥2 cm in shortest diameter. A total of 50 patients with bulky unresectable stage - III NSCLC will be recruited and 1:1 randomized into the experimental arm: 2-cycle - induction PD-1 inhibitor toripalimab plus chemotherapy followed by cCRT and - consolidation toripalimab; or control arm: 2-cycle induction chemotherapy - followed by cCRT and consolidation toripalimab. Patients are stratified by - pathology (squamous versus non-squamous). The primary endpoint is PFS. Secondary - endpoints are overall survival, overall response rate, disease control rate, - duration of response, and incidence of adverse events. Exploratory analyses - include PD-L1 expression and liquid biopsy-based biomarker testing, tumor - microenvironment profiling at single-cell levels, and quality-of-life - assessments. DISCUSSION: The InTRist study is the first randomized phase II trial - to investigate the feasibility of induction anti-PD-1 toripalimab plus - chemotherapy followed by cCRT and consolidation toripalimab in bulky LA-NSCLC, - providing novel evidence for the synergistic strategy combining anti-PD-1 - blockade with radiotherapy to prolong immunotherapy benefits, overcome - resistance, and enhance abscopal immune response. CLINICAL TRIAL REGISTRATION: - ClinicalTrials.gov, identifier NCT05888402. -CI - Copyright © 2024 Wang, Deng, Wang, Zhang, Wang, Wang, Liu, Wu, Lv, Feng, Zhou, - Wang, Wang, Wang and Bi. -FAU - Wang, Yu -AU - Wang Y -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Deng, Lei -AU - Deng L -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Wang, Jianyang -AU - Wang J -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Zhang, Tao -AU - Zhang T -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Wang, Wenqing -AU - Wang W -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Wang, Xin -AU - Wang X -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Liu, Wenyang -AU - Liu W -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Wu, Yuqi -AU - Wu Y -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Lv, Jima -AU - Lv J -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Feng, Qinfu -AU - Feng Q -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Zhou, Zongmei -AU - Zhou Z -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Wang, Jie -AU - Wang J -AD - State Key Laboratory of Molecular Oncology, Department of Medical Oncology, - National Cancer Center/National Clinical Research Center for Cancer/Cancer - Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, - Beijing, China. -FAU - Wang, Luhua -AU - Wang L -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy - of Medical Sciences and Peking Union Medical College, Shenzhen, China. -FAU - Wang, Zhijie -AU - Wang Z -AD - State Key Laboratory of Molecular Oncology, Department of Medical Oncology, - National Cancer Center/National Clinical Research Center for Cancer/Cancer - Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, - Beijing, China. -FAU - Bi, Nan -AU - Bi N -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -AD - State Key Laboratory of Molecular Oncology, National Cancer Center/National - Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical - Sciences and Peking Union Medical College, Beijing, China. -LA - eng -SI - ClinicalTrials.gov/NCT05888402 -PT - Clinical Trial Protocol -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20240115 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 8JXN261VVA (toripalimab) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (B7-H1 Antigen) -RN - 0 (Antibodies, Monoclonal, Humanized) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - B7-H1 Antigen -MH - Prospective Studies -MH - Chemoradiotherapy/methods -MH - Tumor Microenvironment -MH - Clinical Trials, Phase II as Topic -MH - Randomized Controlled Trials as Topic -MH - *Antibodies, Monoclonal, Humanized -PMC - PMC10822928 -OTO - NOTNLM -OT - chemoradiotherapy -OT - immune checkpoint inhibitor -OT - induction therapy -OT - non-small-cell lung cancer -OT - programmed cell death-1 -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2024/01/30 06:42 -MHDA- 2024/01/31 06:42 -PMCR- 2023/01/01 -CRDT- 2024/01/30 03:38 -PHST- 2023/11/20 00:00 [received] -PHST- 2023/12/28 00:00 [accepted] -PHST- 2024/01/31 06:42 [medline] -PHST- 2024/01/30 06:42 [pubmed] -PHST- 2024/01/30 03:38 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2023.1341584 [doi] -PST - epublish -SO - Front Immunol. 2024 Jan 15;14:1341584. doi: 10.3389/fimmu.2023.1341584. - eCollection 2023. - -PMID- 34433717 -OWN - NLM -STAT- MEDLINE -DCOM- 20220218 -LR - 20220326 -IS - 1349-7235 (Electronic) -IS - 0918-2918 (Print) -IS - 0918-2918 (Linking) -VI - 61 -IP - 4 -DP - 2022 Feb 15 -TI - Durvalumab-associated Late-onset Myocarditis Successfully Treated with - Corticosteroid Therapy. -PG - 527-531 -LID - 10.2169/internalmedicine.7644-21 [doi] -AB - We herein report a 66-year-old man with locally advanced non-small-cell lung - cancer (NSCLC) who developed durvalumab-associated myocarditis. The patient - underwent durvalumab administration every two weeks following concurrent - chemoradiotherapy, without any adverse events or apparent disease progression. He - presented with fatigue and dyspnea on exertion seven months after the first - administration. Myocarditis was suspected based on laboratory data, an - electrocardiogram, echocardiography, and magnetic resonance imaging findings. The - definitive diagnosis was confirmed by a myocardial biopsy. Myocarditis was - alleviated by cessation of durvalumab and corticosteroid therapy. This is a - noteworthy case to describe late-onset myocarditis following the administration - of durvalumab for NSCLC. -FAU - Maetani, Tomoki -AU - Maetani T -AD - Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano - Hospital, Japan. -FAU - Hamaguchi, Toka -AU - Hamaguchi T -AD - Cardiovascular Center, Tazuke Kofukai Medical Research Institute, Kitano - Hospital, Japan. -FAU - Nishimura, Takafumi -AU - Nishimura T -AD - Department of Medical Oncology, Tazuke Kofukai Medical Research Institute, Kitano - Hospital, Japan. -FAU - Marumo, Satoshi -AU - Marumo S -AD - Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano - Hospital, Japan. -FAU - Fukui, Motonari -AU - Fukui M -AD - Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano - Hospital, Japan. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20210824 -PL - Japan -TA - Intern Med -JT - Internal medicine (Tokyo, Japan) -JID - 9204241 -RN - 0 (Adrenal Cortex Hormones) -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Adrenal Cortex Hormones/therapeutic use -MH - Aged -MH - Antibodies, Monoclonal -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - Chemoradiotherapy/methods -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Male -MH - *Myocarditis/chemically induced/diagnosis/drug therapy -PMC - PMC8907760 -OTO - NOTNLM -OT - durvalumab -OT - irAE -OT - lung cancer -OT - myocarditis -COIS- The authors state that they have no Conflict of Interest (COI). -EDAT- 2021/08/27 06:00 -MHDA- 2022/02/19 06:00 -PMCR- 2022/02/15 -CRDT- 2021/08/26 05:38 -PHST- 2021/08/27 06:00 [pubmed] -PHST- 2022/02/19 06:00 [medline] -PHST- 2021/08/26 05:38 [entrez] -PHST- 2022/02/15 00:00 [pmc-release] -AID - 10.2169/internalmedicine.7644-21 [doi] -PST - ppublish -SO - Intern Med. 2022 Feb 15;61(4):527-531. doi: 10.2169/internalmedicine.7644-21. - Epub 2021 Aug 24. - -PMID- 8380131 -OWN - NLM -STAT- MEDLINE -DCOM- 19930128 -LR - 20190514 -IS - 0012-3692 (Print) -IS - 0012-3692 (Linking) -VI - 103 -IP - 1 Suppl -DP - 1993 Jan -TI - Postoperative chemotherapy for non-small-cell lung cancer. -PG - 30S-34S -AB - The Lung Cancer Study Group has performed a number of postoperative adjuvant - trials in patients with resectable non-small-cell lung cancer (NSCLC). Adjuvant - cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy was compared with - immunotherapy in the treatment of 130 patients with stage II or III - adenocarcinoma or large cell undifferentiated carcinoma. Careful intraoperative - staging was performed in all patients. Disease-free interval was significantly - prolonged in the chemotherapy group (p = 0.032). After 7.5 years of follow-up, - the difference in time to recurrence and cancer deaths remains statistically - significant. Another study compared CAP chemotherapy plus radiotherapy with - radiotherapy alone in advanced stages II and III resected NSCLC. Again, the - chemotherapy arm had significantly increased disease-free survival. In a third - study, patients with high-risk stage I NSCLC were randomized after surgery to CAP - chemotherapy or observation. In this study there was no difference in - recurrence-free survival or overall survival. -FAU - Holmes, E C -AU - Holmes EC -AD - Department of Surgery, UCLA Medical Center. -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - Chest -JT - Chest -JID - 0231335 -RN - 80168379AG (Doxorubicin) -RN - 8N3DW7272P (Cyclophosphamide) -RN - Q20Q21Q62J (Cisplatin) -RN - CISCA protocol -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/surgery -MH - Chemotherapy, Adjuvant -MH - Cisplatin/administration & dosage -MH - Cyclophosphamide/administration & dosage -MH - Doxorubicin/administration & dosage -MH - Humans -MH - Immunotherapy -MH - Lung Neoplasms/*drug therapy/surgery -MH - Radiotherapy -MH - Randomized Controlled Trials as Topic -RF - 16 -EDAT- 1993/01/01 00:00 -MHDA- 1993/01/01 00:01 -CRDT- 1993/01/01 00:00 -PHST- 1993/01/01 00:00 [pubmed] -PHST- 1993/01/01 00:01 [medline] -PHST- 1993/01/01 00:00 [entrez] -AID - S0012-3692(15)38845-0 [pii] -AID - 10.1378/chest.103.1_supplement.30s [doi] -PST - ppublish -SO - Chest. 1993 Jan;103(1 Suppl):30S-34S. doi: 10.1378/chest.103.1_supplement.30s. - -PMID- 34633575 -OWN - NLM -STAT- MEDLINE -DCOM- 20220412 -LR - 20220711 -IS - 1573-0646 (Electronic) -IS - 0167-6997 (Print) -IS - 0167-6997 (Linking) -VI - 40 -IP - 2 -DP - 2022 Apr -TI - Prognostic impact of pneumonitis after durvalumab therapy in patients with - locally advanced non-small cell lung cancer. -PG - 403-410 -LID - 10.1007/s10637-021-01191-6 [doi] -AB - BACKGROUND: Prognostic data on Japanese patients receiving durvalumab after - chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer - (LA-NSCLC) are insufficient. Whether pneumonitis has prognostic implications in - patients with LA-NSCLC who have received durvalumab also remains unclear. - METHODS: We retrospectively assessed the data of 82 consecutive patients who had - received durvalumab after CRT at our institution between May 2018 and August - 2020. A multi-state model was used to establish the associations between - co-variables and progression-free survival (PFS). RESULTS: The median observation - period for all the censored cases was 14.5 months (5.7-28.9 months), the median - PFS was 22.7 months, and the 12-month PFS rate was 62.3% (95% CI: 50.2%-72.3%). - The median percentage of the lung volume receiving a radiation dose in excess of - 20 Gray (V20) was 22% (4%-35%). Thirteen patients (16%) had Grade 1 pneumonitis - before receiving durvalumab, and 62 patients developed pneumonitis after - durvalumab (Grades 1, 2, and 3 in 25 [30%], 32 [39%], and 4 [5%], respectively). - Twenty-four patients (29%) completed the 1-year durvalumab treatment period, 16 - patients (20%) were continuing to receive treatment, and 42 (51%) had - discontinued treatment. In a multi-state analysis, patients with pneumonitis - before durvalumab therapy had a poorer PFS than those without pneumonitis (HR: - 4.29, p = 0.002). The development of Grade 2 or higher pneumonitis after - durvalumab was not a significant prognostic factor for PFS (HR: 0.71, p = 0.852). - CONCLUSION: Grade 2 or higher pneumonitis after durvalumab was not a prognostic - factor of PFS in LA-NSCLC patients received durvalumab. -CI - © 2021. The Author(s). -FAU - Nishimura, Ari -AU - Nishimura A -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Ono, Akira -AU - Ono A -AUID- ORCID: 0000-0001-5705-9423 -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. - a.ono@scchr.jp. -FAU - Wakuda, Kazushige -AU - Wakuda K -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Kawabata, Takanori -AU - Kawabata T -AD - Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Yabe, Michitoshi -AU - Yabe M -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Miyawaki, Taichi -AU - Miyawaki T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Miyawaki, Eriko -AU - Miyawaki E -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Kodama, Hiroaki -AU - Kodama H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Nishioka, Naoya -AU - Nishioka N -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Mamesaya, Nobuaki -AU - Mamesaya N -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Kobayashi, Haruki -AU - Kobayashi H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Omori, Shota -AU - Omori S -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Kenmotsu, Hirotsugu -AU - Kenmotsu H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Naito, Tateaki -AU - Naito T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Murakami, Haruyasu -AU - Murakami H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Harada, Hideyuki -AU - Harada H -AD - Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Takahashi, Toshiaki -AU - Takahashi T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -LA - eng -PT - Journal Article -DEP - 20211011 -PL - United States -TA - Invest New Drugs -JT - Investigational new drugs -JID - 8309330 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -EIN - Invest New Drugs. 2022 Apr;40(2):464. doi: 10.1007/s10637-021-01198-z. PMID: - 34748131 -MH - Antibodies, Monoclonal -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy/adverse effects -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - *Pneumonia/chemically induced -MH - Prognosis -MH - Retrospective Studies -PMC - PMC8993741 -OTO - NOTNLM -OT - Chemoradiotherapy -OT - Durvalumab -OT - Locally advanced non-small cell lung cancer -OT - Pneumonitis -COIS- Ari Nishimura reports personal fees from Ono Pharmaceutical. Akira Ono reports - personal fees from AstraZeneca KK, Chugai Pharmaceutical, Ono Pharmaceutical, and - MSD. Kazushige Wakuda reports grants and personal fees from Chugai - Pharmaceutical, Ltd., personal fees from Taiho Pharmaceutical, personal fees from - Boehringer Ingelheim, personal fees from Eli Lilly K.K., personal fees from Ono - Pharmaceutical, personal fees from MSD, grants and personal fees from - AstraZeneca, grants from Novartis Pharma, grants from Abbvie. Nobuaki Mamesaya - reports personal fees from AstraZeneca KK, Pfizer Japan, Inc., personal fees from - Chugai Pharmaceutical Co., Ltd., grants and personal fees from Boehringer - Ingelheim, personal fees from MSD K.K., personal fees from Taiho Pharmaceutical, - personal fees from Ono Pharmaceutical. Shota Omori reports personal fees from - Chugai Pharmaceutical, personal fees from Ono Pharmaceutical, personal fees from - Taiho Pharmaceutical, personal fees from Daiichi Sankyo pharmaceutical, personal - fees from Amgen, personal fees from AstraZeneca, personal fees from Novartis - Pharma, outside the submitted work. HIrotsugu Kenmotsu reports grants and - personal fees from Chugai Pharmaceutical, personal fees from Ono Pharmaceutical, - personal fees from Boehringer Ingelheim, personal fees from Eli Lilly, personal - fees from Kyowa Hakko Kirin Co., Ltd., personal fees from Bristol-Myers Squibb, - personal fees from MSD, grants and personal fees from Novartis Pharma, grants and - personal fees from Daiichi-Sankyo pharmaceutical, grants and personal fees from - AstraZeneca, personal fees from Pfizer, personal fees from Taiho Pharma. Dr. - Naito reports grants from Ono Pharmaceutical, grants from Pfizer US, grants from - Mochida Pharmaceutical. Haruyasu Murakami reports grants and personal fees from - AstraZeneca, grants and personal fees from Chugai pharma, grants and personal - fees from Takeda, grants and personal fees from Daiichi Sankyo, grants from - Abbvie, grants from IQvia, personal fees from Ono Pharmaceutical, personal fees - from Bristol-Myers Squibb Japan, personal fees from MSD, personal fees from - Pfizer, personal fees from Novartis, personal fees from Lilly Japan, personal - fees from Taiho Pharmaceutical. Hideyuki Harada reports personal fees from - Daiichi Sankyo pharmaceutical, personal fees from AstraZeneca pharmaceutical, - personal fees from Brain lab, personal fees from Chugai pharmaceutical, grants - from Japan Agency for Medical Research and Development, grants from The National - Cancer Center Research and Development fund, personal fees from Novartis - pharmaceutical co., grants from Health, Labor and Welfare Science Research Grant, - personal fees from Eli Lilly Japan K.K., personal fees from Pfizer Japan. - Toshiaki Takahashi reports grants and personal fees from AstraZeneca KK, Pfizer - Japan, grants and personal fees from Eli Lilly Japan K.K., grants and personal - fees from Chugai Pharmaceutical, grants and personal fees from Ono - Pharmaceutical, grants and personal fees from MSD, grants and personal fees from - Boehringer Ingelheim Japan, Inc., grants and personal fees from Pfizer Japan, - personal fees from Roche Diagnostics K.K. For the remaining authors no conflict - interested are declared. -EDAT- 2021/10/12 06:00 -MHDA- 2022/04/13 06:00 -PMCR- 2021/10/11 -CRDT- 2021/10/11 12:31 -PHST- 2021/08/25 00:00 [received] -PHST- 2021/10/03 00:00 [accepted] -PHST- 2021/10/12 06:00 [pubmed] -PHST- 2022/04/13 06:00 [medline] -PHST- 2021/10/11 12:31 [entrez] -PHST- 2021/10/11 00:00 [pmc-release] -AID - 10.1007/s10637-021-01191-6 [pii] -AID - 1191 [pii] -AID - 10.1007/s10637-021-01191-6 [doi] -PST - ppublish -SO - Invest New Drugs. 2022 Apr;40(2):403-410. doi: 10.1007/s10637-021-01191-6. Epub - 2021 Oct 11. - -PMID- 36045016 -OWN - NLM -STAT- MEDLINE -DCOM- 20221026 -LR - 20230126 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 23 -IP - 7 -DP - 2022 Nov -TI - Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, - Unresectable KRAS-mutated Non-Small Cell Lung Cancer. -PG - 620-629 -LID - S1525-7304(22)00173-5 [pii] -LID - 10.1016/j.cllc.2022.08.002 [doi] -AB - BACKGROUND: Consolidation durvalumab immunotherapy following definitive - chemoradiation (CRT) for unresectable stage III non-small cell lung cancer - (NSCLC) improves overall survival. As therapeutic options for patients with - KRAS-driven disease evolve, more understanding regarding genomic determinants of - response and patterns of progression for durvalumab consolidation is needed to - optimize outcomes. METHODS: We conducted a single-institutional retrospective - analysis of real-world patients with locally advanced, unresectable NSCLC who - completed CRT and received durvalumab consolidation. Kaplan-Meier analyses - compared progression-free survival (PFS) and overall survival (OS) from start of - durvalumab consolidation between patients with KRAS-mutated and non-mutated - tumors. Fisher's exact test was used to compare rates of intrathoracic or - extrathoracic progression. RESULTS: Of 74 response-evaluable patients, 39 had - clinical genomic profiling performed. 18 patients had tumors with KRAS mutations, - 7 patients had tumors with non-KRAS actionable alterations (EGFR, ALK, ERBB2, - BRAF, MET, RET, or ROS1), and 14 patients had tumors without actionable - alterations. Median PFS for the overall cohort was 16.1 months. PFS for patients - with KRAS-mutated NSCLC was 12.6 months versus 12.7 months for patients with - non-actionable tumors (P= 0.77, log-rank). Fisher's exact test revealed a - statistically significantly higher rate of extrathoracic progression versus - intrathoracic-only progression for patients with KRAS-driven disease compared to - patients with non-actionable tumors (P= 0.015). CONCLUSION: Patients with - KRAS-mutated NSCLC derived similar benefit from durvalumab as patients with - non-actionable tumors. A higher rate of extrathoracic progression was also - observed among the patients with KRAS-mutated NSCLC compared to patients with - non-actionable tumors. This highlights the potential unmet needs for novel - systemic therapies and surveillance methods for KRAS-mutated stage III NSCLC. -CI - Copyright © 2022. Published by Elsevier Inc. -FAU - Guo, Matthew Z -AU - Guo MZ -AD - Department of Oncology, Johns Hopkins School of Medicine, Sidney Kimmel - Comprehensive Cancer Center, Baltimore, MD. -FAU - Murray, Joseph C -AU - Murray JC -AD - Department of Oncology, Johns Hopkins School of Medicine, Sidney Kimmel - Comprehensive Cancer Center, Baltimore, MD. -FAU - Ghanem, Paola -AU - Ghanem P -AD - Department of Oncology, Johns Hopkins School of Medicine, Sidney Kimmel - Comprehensive Cancer Center, Baltimore, MD. -FAU - Voong, K Ranh -AU - Voong KR -AD - Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins - School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. -FAU - Hales, Russell K -AU - Hales RK -AD - Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins - School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. -FAU - Ettinger, David -AU - Ettinger D -AD - Department of Oncology, Johns Hopkins School of Medicine, Sidney Kimmel - Comprehensive Cancer Center, Baltimore, MD. -FAU - Lam, Vincent K -AU - Lam VK -AD - Department of Oncology, Johns Hopkins School of Medicine, Sidney Kimmel - Comprehensive Cancer Center, Baltimore, MD. -FAU - Hann, Christine L -AU - Hann CL -AD - Department of Oncology, Johns Hopkins School of Medicine, Sidney Kimmel - Comprehensive Cancer Center, Baltimore, MD. -FAU - Forde, Patrick M -AU - Forde PM -AD - Department of Oncology, Johns Hopkins School of Medicine, Sidney Kimmel - Comprehensive Cancer Center, Baltimore, MD. -FAU - Brahmer, Julie R -AU - Brahmer JR -AD - Department of Oncology, Johns Hopkins School of Medicine, Sidney Kimmel - Comprehensive Cancer Center, Baltimore, MD. -FAU - Levy, Benjamin P -AU - Levy BP -AD - Department of Oncology, Johns Hopkins School of Medicine, Sidney Kimmel - Comprehensive Cancer Center, Baltimore, MD. -FAU - Feliciano, Josephine L -AU - Feliciano JL -AD - Department of Oncology, Johns Hopkins School of Medicine, Sidney Kimmel - Comprehensive Cancer Center, Baltimore, MD. -FAU - Marrone, Kristen A -AU - Marrone KA -AD - Department of Oncology, Johns Hopkins School of Medicine, Sidney Kimmel - Comprehensive Cancer Center, Baltimore, MD. Electronic address: - kmarron1@jhmi.edu. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20220808 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 28X28X9OKV (durvalumab) -RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) -RN - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) -RN - 0 (Proto-Oncogene Proteins) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) -RN - 0 (KRAS protein, human) -RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy -MH - *Lung Neoplasms/drug therapy/genetics -MH - Retrospective Studies -MH - Protein-Tyrosine Kinases -MH - Proto-Oncogene Proteins B-raf -MH - Proto-Oncogene Proteins -MH - Chemoradiotherapy/methods -MH - ErbB Receptors/genetics -MH - Receptor Protein-Tyrosine Kinases -MH - Proto-Oncogene Proteins p21(ras)/genetics -OTO - NOTNLM -OT - Immunotherapy -OT - KRAS -OT - NSCLC -EDAT- 2022/09/01 06:00 -MHDA- 2022/10/27 06:00 -CRDT- 2022/08/31 22:03 -PHST- 2022/04/01 00:00 [received] -PHST- 2022/07/22 00:00 [revised] -PHST- 2022/08/03 00:00 [accepted] -PHST- 2022/09/01 06:00 [pubmed] -PHST- 2022/10/27 06:00 [medline] -PHST- 2022/08/31 22:03 [entrez] -AID - S1525-7304(22)00173-5 [pii] -AID - 10.1016/j.cllc.2022.08.002 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2022 Nov;23(7):620-629. doi: 10.1016/j.cllc.2022.08.002. Epub - 2022 Aug 8. - -PMID- 29454155 -OWN - NLM -STAT- MEDLINE -DCOM- 20180316 -LR - 20220408 -IS - 1532-1967 (Electronic) -IS - 0305-7372 (Linking) -VI - 64 -DP - 2018 Mar -TI - Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on - special subgroups and unresolved burning questions. -PG - 21-29 -LID - S0305-7372(18)30012-4 [pii] -LID - 10.1016/j.ctrv.2018.02.002 [doi] -AB - Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment - strategy of advanced non-small cell lung cancer (NSCLC). Beyond the already - approved indications in first- and second-line setting of advanced NSCLC, new - data has recently emerged demonstrating its efficacy in locally advanced disease - as maintenance after chemo-radiotherapy and currently several trials are also - exploring its efficacy in earlier stages of the disease to evaluate whether these - results could be extrapolated to the adjuvant setting. With the advent of all - these new therapies, their potential in other thoracic malignancies such as - mesothelioma and small-cell lung cancer are also being evaluated with encouraging - preliminary data that endorses their short-term incorporation as new therapeutic - options in these thoracic malignancies. However, despite all these new evidence, - there are still several open questions that remain to be solved like the use of - immune agents in special subpopulations such as elderly or fragile patients or - the case of patients with brain metastases or autoimmune disorders. In addition - some other open questions remain with regards ICIs activity in patients receiving - corticosteroid or antibiotics, the potential use in oncogenic addicted tumours, - as well as the safety of retreatment after the onset of immune-related adverse - events (ir-AE) or the optimal dose schedule or time on treatment for ICIs - administration. Herein, we propose to address all these questions, reviewing most - recent evidence available in order to give readers some practical advises and - guidance on how to deal with these challenges when treating NSCLC patients with - immunotherapy. -CI - Copyright © 2018 Elsevier Ltd. All rights reserved. -FAU - Remon, J -AU - Remon J -AD - Hospital Vall d'Hebron, Medical Oncology Department, Barcelona, Spain. Electronic - address: jremon@vhio.net. -FAU - Vilariño, N -AU - Vilariño N -AD - Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. Electronic address: - VILARINO@clinic.cat. -FAU - Reguart, N -AU - Reguart N -AD - Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. Electronic address: - nreguart@clinic.cat. -LA - eng -PT - Journal Article -PT - Review -DEP - 20180208 -PL - Netherlands -TA - Cancer Treat Rev -JT - Cancer treatment reviews -JID - 7502030 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -SB - IM -MH - Animals -MH - Antibodies, Monoclonal/*pharmacology -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/*immunology/metabolism -MH - Humans -MH - *Immunotherapy -MH - Lung Neoplasms/drug therapy/immunology/metabolism -MH - *Molecular Targeted Therapy -OTO - NOTNLM -OT - Brain metastases -OT - Immune-checkpoint inhibitors -OT - Immune-related adverse events -OT - Non-small cell lung cancer -OT - Steroids -EDAT- 2018/02/18 06:00 -MHDA- 2018/03/17 06:00 -CRDT- 2018/02/18 06:00 -PHST- 2017/12/18 00:00 [received] -PHST- 2018/01/29 00:00 [revised] -PHST- 2018/02/04 00:00 [accepted] -PHST- 2018/02/18 06:00 [pubmed] -PHST- 2018/03/17 06:00 [medline] -PHST- 2018/02/18 06:00 [entrez] -AID - S0305-7372(18)30012-4 [pii] -AID - 10.1016/j.ctrv.2018.02.002 [doi] -PST - ppublish -SO - Cancer Treat Rev. 2018 Mar;64:21-29. doi: 10.1016/j.ctrv.2018.02.002. Epub 2018 - Feb 8. - -PMID- 38971369 -OWN - NLM -STAT- MEDLINE -DCOM- 20241006 -LR - 20241006 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 19 -IP - 10 -DP - 2024 Oct -TI - Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation - Immunotherapy in Unresectable Stage III NSCLC. -PG - 1427-1437 -LID - S1556-0864(24)00664-6 [pii] -LID - 10.1016/j.jtho.2024.06.024 [doi] -AB - INTRODUCTION: The current standard of care for patients with inoperable stage III - non-small cell lung cancer includes chemoradiotherapy (CRT) followed by 1 year of - checkpoint inhibitor (CPI) therapy. Nevertheless, the optimal duration of - consolidation CPI remains unknown. Here, we characterized the relationship - between circulating tumor DNA (ctDNA) minimal residual disease (MRD) and clinical - outcomes of patients with unresectable locally advanced non-small cell lung - cancer treated on a phase 2 trial of short-course consolidation immunotherapy - after CRT, with the goal of testing whether ctDNA may be able to identify - patients who do not require a full year of treatment. METHODS: Plasma samples for - ctDNA analysis were collected from patients on the Big Ten Cancer Research - Consortium LUN 16-081 trial after completion of CRT, before day 1 of cycle 2 - (C2D1) of CPI (i.e., 1 mo after treatment start), and at the end of up to 6 - months of treatment. Tumor-informed ctDNA MRD analysis was performed using cancer - personalized profiling by deep sequencing. Levels of ctDNA at each time point - were correlated with clinical outcomes. RESULTS: Detection of ctDNA predicted - significantly inferior progression-free survival after completion of CRT (24-mo - 29% versus 65%, p = 0.0048), before C2D1 of CPI (24-mo 0% versus 72%, p < 0.0001) - and at the end of CPI (24-mo 15% versus 67%, p = 0.0011). In addition, patients - with decreasing or undetectable ctDNA levels after 1 cycle of CPI had improved - outcomes compared with patients with increasing ctDNA levels (24-mo - progression-free survival 72% versus 0%, p < 0.0001). Progression of disease - occurred within less than 12 months of starting CPI in all patients with - increasing ctDNA levels at C2D1. CONCLUSIONS: Detection of ctDNA before, during, - or after 6 months of consolidation CPI is strongly associated with inferior - outcomes. Our findings suggest that analysis of ctDNA MRD may enable - personalizing the duration of consolidation immunotherapy treatment. -CI - Copyright © 2024 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Jun, Soyeong -AU - Jun S -AD - Department of Radiation Oncology, Stanford University, Stanford, California; - Stanford Cancer Institute, Stanford University, Stanford, California. -FAU - Shukla, Nikhil A -AU - Shukla NA -AD - Community Hospital Oncology Physicians, Community Health Network MD Anderson - Comprehensive Cancer Center, Indianapolis, Indiana. -FAU - Durm, Greg -AU - Durm G -AD - Division of Hematology/Oncology, IU Simon Comprehensive Cancer Center, - Indianapolis, Indiana. -FAU - Hui, Angela B -AU - Hui AB -AD - Department of Radiation Oncology, Stanford University, Stanford, California; - Stanford Cancer Institute, Stanford University, Stanford, California. -FAU - Cao, Sha -AU - Cao S -AD - Division of Hematology/Oncology, IU Simon Comprehensive Cancer Center, - Indianapolis, Indiana. -FAU - Ganti, Apar Kishor -AU - Ganti AK -AD - Division of Oncology-Hematology, Department of Internal Medicine, VA Nebraska - Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, - Nebraska. -FAU - Jabbour, Salma K -AU - Jabbour SK -AD - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers - University, New Brunswick, New Jersey. -FAU - Kunder, Christian -AU - Kunder C -AD - Department of Pathology, Stanford University, Stanford, California. -FAU - Alizadeh, Ash A -AU - Alizadeh AA -AD - Stanford Cancer Institute, Stanford University, Stanford, California; Division of - Oncology, Department of Medicine, Stanford University, Stanford, California; - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, - Stanford, California. -FAU - Hanna, Nasser H -AU - Hanna NH -AD - Division of Hematology/Oncology, IU Simon Comprehensive Cancer Center, - Indianapolis, Indiana. -FAU - Diehn, Maximilian -AU - Diehn M -AD - Department of Radiation Oncology, Stanford University, Stanford, California; - Stanford Cancer Institute, Stanford University, Stanford, California; Institute - for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, - California. Electronic address: diehn@stanford.edu. -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20240705 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Circulating Tumor DNA) -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Humans -MH - *Circulating Tumor DNA/blood/genetics -MH - *Carcinoma, Non-Small-Cell Lung/pathology/drug therapy/therapy/genetics/blood -MH - *Lung Neoplasms/pathology/drug therapy/therapy/blood/genetics -MH - *Immunotherapy/methods -MH - Male -MH - Female -MH - Middle Aged -MH - Aged -MH - Neoplasm Staging -MH - Neoplasm, Residual -MH - Biomarkers, Tumor/genetics/blood -OTO - NOTNLM -OT - Immunotherapy -OT - Minimal residual disease -OT - Non–small cell lung cancer -OT - ctDNA -COIS- Disclosure Dr. Durm receives support from Bristol-Myers Squibb; grants or - contracts from AstraZeneca, Merck, and Mirati; consulting fees from Cook Biotech; - payments or honoraria from Curio Science, DAVA Oncology, and AstraZeneca; and - participates on an advisory board for Curio Science, DAVA oncology, and - AstraZeneca. Dr. Ganti receives research grants or contracts from VA Office of - Research and Development, Merck, TAB Biosciences, NEKTAR Therapeutics, Mirati - Therapeutics, IOVANCE Therapeutics, and Apexigen; royalties or licenses from - Oxford University Press; consulting fees from AstraZeneca, Flagship Biosciences, - G1 Therapeutics, Jazz Pharmaceuticals, Cardinal Health, Mirati Therapeutics, - Beigene Ltd., Sanofi Genzyme, Blueprint Medicines, and Regeneron Pharmaceuticals; - payments or honoraria from MedLearning Group and Plexus Communications; - participates on a data safety monitoring board for YmAbs Therapeutics; holds - leadership or fiduciary roles at Academic and Community Cancer Research United - and A Breath of Hope for Lung Cancer; and has received equipment or materials - from Takeda Pharmaceuticals and Chimerx. Dr. Alizadeh receives research grants or - contracts from the National Cancer Institute, National Heart, Lung and Blood - Institute, National Institutes of Health, Celgene, Bristol-Myers Squibb, and - Pfizer; consulting fees from ADCT, Celgene, Chugai, Genentech, Gilead, Janssen, - Pharmacyclics, and Roche; has patents planned, issued, or pending with FortySeven - Inc., Foresight Diagnostics, CiberMed Inc., and Roche; participates on a data - safety monitoring board for Lymphoma Research Foundation; holds leadership or - fiduciary roles at the American Society of Hematology, American Society of - Clinical Oncology, American Society of Clinical Investigation, and Leukemia & - Lymphoma Society; and has equity ownership interests in CiberMed Inc., Foresight - Diagnostics, FortySeven Inc., and CARGO Therapeutics. Dr. Hanna receives grants - or contracts from Merck, Genentech, Bristol-Myers Squibb, and Natera. Dr. Diehn - receives grants or contracts from AstraZeneca and Varian Medical Systems; - royalties or licenses from Roche and Foresight Diagnostics; consulting fees from - AstraZeneca, Boehringer Ingelheim, Genentech, Illumina, Gritstone Bio, and - Regeneron; payments or honoraria from Bristol-Myers Squibb, Japan, and Novartis; - support for attending meetings or travel from Foresight Diagnostics and - Regeneron; has patents planned, issued, or pending with Stanford University; - holds leadership or fiduciary roles at Foresight Diagnostics; and holds stock or - stock options in CiberMed Inc., Foresight Diagnostics, and Gritstone Bio. The - remaining authors declare no conflict of interest. -EDAT- 2024/07/07 00:42 -MHDA- 2024/10/07 04:17 -CRDT- 2024/07/06 19:27 -PHST- 2024/02/29 00:00 [received] -PHST- 2024/06/13 00:00 [revised] -PHST- 2024/06/30 00:00 [accepted] -PHST- 2024/10/07 04:17 [medline] -PHST- 2024/07/07 00:42 [pubmed] -PHST- 2024/07/06 19:27 [entrez] -AID - S1556-0864(24)00664-6 [pii] -AID - 10.1016/j.jtho.2024.06.024 [doi] -PST - ppublish -SO - J Thorac Oncol. 2024 Oct;19(10):1427-1437. doi: 10.1016/j.jtho.2024.06.024. Epub - 2024 Jul 5. - -PMID- 36418442 -OWN - NLM -STAT- MEDLINE -DCOM- 20230622 -LR - 20230707 -IS - 1439-099X (Electronic) -IS - 0179-7158 (Print) -IS - 0179-7158 (Linking) -VI - 199 -IP - 7 -DP - 2023 Jul -TI - Survey of treatment and care practices in small-cell lung cancer among German - radiation oncologists. -PG - 631-644 -LID - 10.1007/s00066-022-02019-9 [doi] -AB - BACKGROUND: The management of small-cell lung cancer shows differences, - particularly with regard to the use of radio- (RT), chemo-, and immunotherapy. We - performed a survey among German radiation oncologists to assess the management of - small-cell lung cancer (SCLC). METHODS: A 34-question online survey was created - and sent out by e‑mail to radiation oncologists throughout Germany. The survey - period extended from August 2020 to January 2021. The questions addressed - indications for RT, planning techniques, dosing/fractionation, target volume - definition for consolidative thoracic irradiation, and the use of prophylactic - cranial irradiation (PCI). At the same time, we surveyed the use of atezolizumab. - The survey addressed the treatment practice for limited-stage SCLC (LS-SCLC) and - extensive-stage SCLC (ES-SCLC). RESULTS: We received 74 responses. In LS-SCLC, - treatment is planned predominantly based on diagnostic information from computed - tomography (CT) of the thorax/abdomen/pelvis (88%), PET-CT (86%), and pulmonary - function testing (88%). In LS-SCLC, 99% of respondents perform radiation - concurrently with chemotherapy, preferably starting with cycle one or two (71%) - of chemotherapy. The most common dose and fractionation schedule was 60-66 Gy in - 30-33 fractions (once daily: 62% of all respondents). In ES-SCLC, 30 Gy in - 10 fractions (once daily: 33% of all respondents) was the most commonly used - regimen in consolidative thoracic irradiation. Only 25% use chemosensitization - with RT. The inclusion criteria for PCI were similar for limited and extensive - disease, with Karnofsky index (78% and 75%) being the most important decision - factor. Respondents use a schedule of 30 Gy in 15 fractions most frequently in - both stages (68% limited stage [LS], 60% extensive stage [ES]). Immunotherapy was - used regularly or occasionally in LS-SCLC by 45% of respondents, with reduced - lung function (37%), cardiac comorbidities (30%), and hepatic insufficiency (30%) - being the most commonly mentioned exclusion criteria for this form of therapy. In - ES-SCLC, atezolizumab use was reported in 78% of all questionnaires. Half of the - respondents (49%) administer it simultaneously with cranial irradiation. - CONCLUSION: Our survey showed variability in the management of SCLC. Results from - future studies might help to clarify open questions regarding the optimal - treatment paradigms. In addition, new treatment modalities, such as - immunotherapy, might change practices in the near future. -CI - © 2022. The Author(s). -FAU - Gnüchtel, J -AU - Gnüchtel J -AD - Universitätsklinik und Poliklinik für Strahlentherapie, Martin-Luther-Universität - Halle-Wittenberg, Halle, Germany. jessica.gnuechtel@student.uni-halle.de. -FAU - Vordermark, D -AU - Vordermark D -AD - Universitätsklinik und Poliklinik für Strahlentherapie, Martin-Luther-Universität - Halle-Wittenberg, Halle, Germany. -FAU - Medenwald, D -AU - Medenwald D -AD - Universitätsklinik und Poliklinik für Strahlentherapie, Martin-Luther-Universität - Halle-Wittenberg, Halle, Germany. -LA - eng -PT - Journal Article -DEP - 20221123 -PL - Germany -TA - Strahlenther Onkol -JT - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et - al] -JID - 8603469 -SB - IM -MH - Humans -MH - *Lung Neoplasms/radiotherapy/drug therapy -MH - Radiation Oncologists -MH - Positron Emission Tomography Computed Tomography -MH - *Small Cell Lung Carcinoma/radiotherapy -MH - Surveys and Questionnaires -MH - Cranial Irradiation -PMC - PMC10281900 -OTO - NOTNLM -OT - Atezolizumab -OT - Chemotherapy -OT - Immunotherapy -OT - Prophylactic cranial irradiation -OT - Radiotherapy -COIS- J. Gnüchtel, D. Vordermark, and D. Medenwald declare that they have no competing - interests. -EDAT- 2022/11/24 06:00 -MHDA- 2023/06/22 06:42 -PMCR- 2022/11/23 -CRDT- 2022/11/23 23:31 -PHST- 2022/02/20 00:00 [received] -PHST- 2022/10/09 00:00 [accepted] -PHST- 2023/06/22 06:42 [medline] -PHST- 2022/11/24 06:00 [pubmed] -PHST- 2022/11/23 23:31 [entrez] -PHST- 2022/11/23 00:00 [pmc-release] -AID - 10.1007/s00066-022-02019-9 [pii] -AID - 2019 [pii] -AID - 10.1007/s00066-022-02019-9 [doi] -PST - ppublish -SO - Strahlenther Onkol. 2023 Jul;199(7):631-644. doi: 10.1007/s00066-022-02019-9. - Epub 2022 Nov 23. - -PMID- 38294959 -OWN - NLM -STAT- MEDLINE -DCOM- 20240517 -LR - 20240517 -IS - 1097-0142 (Electronic) -IS - 0008-543X (Linking) -VI - 130 -IP - 11 -DP - 2024 Jun 1 -TI - Acute hospitalizations after proton therapy versus intensity-modulated - radiotherapy for locally advanced non-small cell lung cancer in the durvalumab - era. -PG - 2031-2041 -LID - 10.1002/cncr.35230 [doi] -AB - INTRODUCTION: It was hypothesized that use of proton beam therapy (PBT) in - patients with locally advanced non-small cell lung cancer treated with concurrent - chemoradiation and consolidative immune checkpoint inhibition is associated with - fewer unplanned hospitalizations compared with intensity-modulated radiotherapy - (IMRT). METHODS: Patients with locally advanced non-small cell lung cancer - treated between October 2017 and December 2021 with concurrent chemoradiation - with either IMRT or PBT ± consolidative immune checkpoint inhibition were - retrospectively identified. Logistic regression was used to assess the - association of radiation therapy technique with 90-day hospitalization and grade - 3 (G3+) lymphopenia. Competing risk regression was used to compare G3+ - pneumonitis, G3+ esophagitis, and G3+ cardiac events. Kaplan-Meier method was - used for progression-free survival and overall survival. Inverse probability - treatment weighting was applied to adjust for differences in PBT and IMRT groups. - RESULTS: Of 316 patients, 117 (37%) received PBT and 199 (63%) received IMRT. The - PBT group was older (p < .001) and had higher Charlson Comorbidity Index scores - (p = .02). The PBT group received a lower mean heart dose (p < .0001), left - anterior descending artery V15 Gy (p = .001), mean lung dose (p = .008), and - effective dose to immune circulating cells (p < .001). On inverse probability - treatment weighting analysis, PBT was associated with fewer unplanned - hospitalizations (adjusted odds ratio, 0.55; 95% CI, 0.38-0.81; p = .002) and - less G3+ lymphopenia (adjusted odds ratio, 0.55; 95% CI, 0.37-0.81; p = .003). - There was no difference in other G3+ toxicities, progression-free survival, or - overall survival. CONCLUSIONS: PBT is associated with fewer unplanned - hospitalizations, lower effective dose to immune circulating cells and less G3+ - lymphopenia compared with IMRT. Minimizing dose to lymphocytes may be warranted, - but prospective data are needed. -CI - © 2024 American Cancer Society. -FAU - Iocolano, Michelle -AU - Iocolano M -AUID- ORCID: 0000-0002-6125-0754 -AD - Department of Radiation Oncology, University of Pennsylvania Perelman School of - Medicine, Philadelphia, Pennsylvania, USA. -FAU - Yegya-Raman, Nikhil -AU - Yegya-Raman N -AD - Department of Radiation Oncology, University of Pennsylvania Perelman School of - Medicine, Philadelphia, Pennsylvania, USA. -FAU - Friedes, Cole -AU - Friedes C -AD - Department of Radiation Oncology, University of Pennsylvania Perelman School of - Medicine, Philadelphia, Pennsylvania, USA. -FAU - Wang, Xingmei -AU - Wang X -AD - Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman - School of Medicine, Philadelphia, Pennsylvania, USA. -FAU - Kegelman, Timothy -AU - Kegelman T -AD - Department of Radiation Oncology, Delaware Radiation Oncology Associates, - Christiana Care Health Systems, Newark, Delaware, USA. -FAU - Lee, Sang Ho -AU - Lee SH -AD - Department of Radiation Oncology, Division of Physics, University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, USA. -FAU - Duan, Lian -AU - Duan L -AD - Department of Radiation Oncology, Division of Physics, University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, USA. -AD - Department of Radiation Physics, The University of Texas MD Anderson Cancer - Center, Houston, Texas, USA. -FAU - Li, Bolin -AU - Li B -AD - Department of Radiation Oncology, Division of Physics, University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, USA. -FAU - Levin, William P -AU - Levin WP -AD - Department of Radiation Oncology, University of Pennsylvania Perelman School of - Medicine, Philadelphia, Pennsylvania, USA. -FAU - Cengel, Keith A -AU - Cengel KA -AD - Department of Radiation Oncology, University of Pennsylvania Perelman School of - Medicine, Philadelphia, Pennsylvania, USA. -FAU - Konski, Andre -AU - Konski A -AD - Department of Radiation Oncology, University of Pennsylvania Perelman School of - Medicine, Philadelphia, Pennsylvania, USA. -AD - Leonard Davis Institute of Health Economics, University of Pennsylvania, - Philadelphia, Pennsylvania, USA. -FAU - Langer, Corey J -AU - Langer CJ -AD - Division of Hematology/Oncology University of Pennsylvania Perelman School of - Medicine, Philadelphia, Pennsylvania, USA. -FAU - Cohen, Roger B -AU - Cohen RB -AD - Division of Hematology/Oncology University of Pennsylvania Perelman School of - Medicine, Philadelphia, Pennsylvania, USA. -FAU - Sun, Lova -AU - Sun L -AD - Division of Hematology/Oncology University of Pennsylvania Perelman School of - Medicine, Philadelphia, Pennsylvania, USA. -FAU - Aggarwal, Charu -AU - Aggarwal C -AD - Division of Hematology/Oncology University of Pennsylvania Perelman School of - Medicine, Philadelphia, Pennsylvania, USA. -FAU - Doucette, Abigail -AU - Doucette A -AD - Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, - USA. -FAU - Xiao, Ying -AU - Xiao Y -AD - Department of Radiation Oncology, Division of Physics, University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, USA. -FAU - Kevin Teo, Boon-Keng -AU - Kevin Teo BK -AD - Department of Radiation Oncology, Division of Physics, University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, USA. -FAU - O'Reilly, Shannon -AU - O'Reilly S -AD - Department of Radiation Oncology, Division of Physics, University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, USA. -FAU - Zou, Wei -AU - Zou W -AD - Department of Radiation Oncology, Division of Physics, University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, USA. -FAU - Bradley, Jeffrey D -AU - Bradley JD -AD - Department of Radiation Oncology, University of Pennsylvania Perelman School of - Medicine, Philadelphia, Pennsylvania, USA. -FAU - Simone, Charles B 2nd -AU - Simone CB 2nd -AUID- ORCID: 0000-0002-0867-3694 -AD - New York Proton Center, New York, New York, USA. -FAU - Feigenberg, Steven J -AU - Feigenberg SJ -AD - Department of Radiation Oncology, University of Pennsylvania Perelman School of - Medicine, Philadelphia, Pennsylvania, USA. -LA - eng -PT - Comparative Study -PT - Journal Article -DEP - 20240131 -PL - United States -TA - Cancer -JT - Cancer -JID - 0374236 -RN - 0 (durvalumab) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/radiotherapy/therapy/pathology/drug therapy -MH - *Radiotherapy, Intensity-Modulated/methods/adverse effects -MH - Female -MH - Male -MH - *Lung Neoplasms/pathology/therapy/radiotherapy/drug therapy/mortality -MH - Aged -MH - Middle Aged -MH - *Hospitalization/statistics & numerical data -MH - *Proton Therapy/methods/adverse effects -MH - *Chemoradiotherapy/methods/adverse effects -MH - Retrospective Studies -MH - Immune Checkpoint Inhibitors/therapeutic use/adverse effects -MH - Lymphopenia/etiology -MH - Antibodies, Monoclonal -OTO - NOTNLM -OT - carcinoma -OT - hospitalization -OT - intensity‐modulated -OT - lung neoplasms -OT - lymphopenia -OT - non‐small cell lung -OT - proton therapy -OT - radiotherapy -EDAT- 2024/01/31 18:42 -MHDA- 2024/05/17 12:44 -CRDT- 2024/01/31 13:03 -PHST- 2023/11/25 00:00 [revised] -PHST- 2023/10/24 00:00 [received] -PHST- 2023/12/05 00:00 [accepted] -PHST- 2024/05/17 12:44 [medline] -PHST- 2024/01/31 18:42 [pubmed] -PHST- 2024/01/31 13:03 [entrez] -AID - 10.1002/cncr.35230 [doi] -PST - ppublish -SO - Cancer. 2024 Jun 1;130(11):2031-2041. doi: 10.1002/cncr.35230. Epub 2024 Jan 31. - -PMID- 33938936 -OWN - NLM -STAT- MEDLINE -DCOM- 20211231 -LR - 20211231 -IS - 2574-3805 (Electronic) -IS - 2574-3805 (Linking) -VI - 4 -IP - 5 -DP - 2021 May 3 -TI - Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment - of Advanced Non-Small Cell Lung Cancer. -PG - e218787 -LID - 10.1001/jamanetworkopen.2021.8787 [doi] -LID - e218787 -AB - IMPORTANCE: Treatment with nivolumab-ipilimumab combination therapy was found to - improve overall survival compared with chemotherapy among patients with advanced - non-small cell lung cancer (NSCLC) in the CheckMate 227 clinical trial. However, - these drugs are substantially more expensive than chemotherapy and, given the - high incidence of advanced NSCLC, the incorporation of dual immune checkpoint - inhibitors into the standard of care could have substantial economic - consequences. OBJECTIVE: To assess whether nivolumab-ipilimumab combination - therapy is a cost-effective first-line treatment for patients with advanced - NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation designed a - Markov model to compare the cost-effectiveness of nivolumab-ipilimumab - combination therapy with platinum-doublet chemotherapy as first-line treatment - for patients with advanced NSCLC. The Markov model was created to simulate - patients with advanced NSCLC who were receiving either nivolumab-ipilimumab - combination therapy or platinum-doublet chemotherapy. Transition probabilities, - including disease progression, survival, and treatment toxic effects, were - derived using data from the CheckMate 227 clinical trial. Costs and health - utilities were obtained from published literature. Data analyses were conducted - from November 2019 to September 2020. EXPOSURES: Nivolumab-ipilimumab combination - therapy. MAIN OUTCOMES AND MEASURES: The primary study outcomes were - quality-adjusted life-years (QALYs) and cost in 2020 US dollars. - Cost-effectiveness was measured using an incremental cost-effectiveness ratio - (ICER), with an ICER less than $100 000 per QALY considered cost-effective. Model - uncertainty was assessed with 1-way and probabilistic sensitivity analyses. - RESULTS: Treatment with nivolumab-ipilimumab combination therapy was associated - with an increase in overall cost of $201 900 and improved effectiveness of 0.50 - QALYs compared with chemotherapy, yielding an ICER of $401 700 per QALY. The - study model was sensitive to the cost and duration of immunotherapy. Treatment - with nivolumab-ipilimumab combination therapy became cost-effective when monthly - treatment costs were reduced from $26 425 to $5058 (80.9% reduction) or when the - maximum duration of immunotherapy was reduced from 24.0 months to 1.4 months. The - model was not sensitive to assumptions about survival or programmed cell death 1 - ligand 1 status. A probabilistic sensitivity analysis indicated that, at a - willingness-to-pay threshold of $100 000 per QALY, nivolumab-ipilimumab - combination therapy was less cost-effective than chemotherapy 99.9% of the time. - CONCLUSIONS AND RELEVANCE: In this study, first-line treatment with - nivolumab-ipilimumab combination therapy was not found to be cost-effective at - current prices despite clinical trial data indicating that this regimen increases - overall survival among patients with advanced NSCLC. -FAU - Courtney, P Travis -AU - Courtney PT -AD - University of California, San Diego School of Medicine, La Jolla. -AD - Department of Radiation Medicine and Applied Sciences, University of California, - San Diego, La Jolla. -FAU - Yip, Anthony T -AU - Yip AT -AD - University of California, San Diego School of Medicine, La Jolla. -AD - Department of Radiation Medicine and Applied Sciences, University of California, - San Diego, La Jolla. -FAU - Cherry, Daniel R -AU - Cherry DR -AD - University of California, San Diego School of Medicine, La Jolla. -AD - Department of Radiation Medicine and Applied Sciences, University of California, - San Diego, La Jolla. -FAU - Salans, Mia A -AU - Salans MA -AD - University of California, San Diego School of Medicine, La Jolla. -AD - Department of Radiation Medicine and Applied Sciences, University of California, - San Diego, La Jolla. -FAU - Kumar, Abhishek -AU - Kumar A -AD - University of California, San Diego School of Medicine, La Jolla. -AD - Department of Radiation Medicine and Applied Sciences, University of California, - San Diego, La Jolla. -FAU - Murphy, James D -AU - Murphy JD -AD - University of California, San Diego School of Medicine, La Jolla. -AD - Department of Radiation Medicine and Applied Sciences, University of California, - San Diego, La Jolla. -LA - eng -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20210503 -PL - United States -TA - JAMA Netw Open -JT - JAMA network open -JID - 101729235 -RN - 0 (Antineoplastic Agents) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Ipilimumab) -RN - 31YO63LBSN (Nivolumab) -RN - 49DFR088MY (Platinum) -SB - IM -EIN - JAMA Netw Open. 2021 Jun 1;4(6):e2118586. doi: - 10.1001/jamanetworkopen.2021.18586. PMID: 34132799 -MH - Antineoplastic Agents/administration & dosage/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Cost-Benefit Analysis -MH - Drug Therapy, Combination -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/administration & dosage/economics/*therapeutic use -MH - Ipilimumab/administration & dosage/economics/*therapeutic use -MH - Lung Neoplasms/*drug therapy -MH - Male -MH - Nivolumab/administration & dosage/economics/*therapeutic use -MH - Platinum/administration & dosage/therapeutic use -MH - Quality-Adjusted Life Years -MH - Treatment Outcome -MH - United States -PMC - PMC8094011 -COIS- Conflict of Interest Disclosures: Dr Kumar reported having equity in Sympto - Health outside the submitted work. Dr Murphy reported receiving personal fees - from Boston Consulting Group and having equity in Sympto Health outside the - submitted work. No other disclosures were reported. -EDAT- 2021/05/04 06:00 -MHDA- 2022/01/01 06:00 -PMCR- 2021/05/03 -CRDT- 2021/05/03 12:37 -PHST- 2021/05/03 12:37 [entrez] -PHST- 2021/05/04 06:00 [pubmed] -PHST- 2022/01/01 06:00 [medline] -PHST- 2021/05/03 00:00 [pmc-release] -AID - 2779418 [pii] -AID - zoi210280 [pii] -AID - 10.1001/jamanetworkopen.2021.8787 [doi] -PST - epublish -SO - JAMA Netw Open. 2021 May 3;4(5):e218787. doi: 10.1001/jamanetworkopen.2021.8787. - -PMID- 37783291 -OWN - NLM -STAT- MEDLINE -DCOM- 20231128 -LR - 20231204 -IS - 1879-0887 (Electronic) -IS - 0167-8140 (Linking) -VI - 189 -DP - 2023 Dec -TI - Risk of on-treatment lymphopenia is associated with treatment outcome and - efficacy of consolidation immunotherapy in patients with non-small cell lung - cancer treated with concurrent chemoradiotherapy. -PG - 109934 -LID - S0167-8140(23)89828-0 [pii] -LID - 10.1016/j.radonc.2023.109934 [doi] -AB - BACKGROUND AND PURPOSE: The ability of the effective dose to immune cells (EDIC) - and the pre-radiotherapy (RT) absolute lymphocyte count (ALC) to predict - lymphopenia during RT, treatment outcomes, and efficacy of consolidation - immunotherapy in patients with locally advanced non-small cell lung cancer was - investigated. METHODS AND MATERIALS: Among 517 patients treated with concurrent - chemoradiotherapy, EDIC was calculated using the mean doses to the lungs, heart, - and total body. The patients were grouped according to high and low EDIC and - pre-RT ALC, and the correlations with radiation-induced lymphopenia and survival - outcomes were determined. RESULTS: Altogether, 195 patients (37.7%) received - consolidation immunotherapy. The cutoff values of EDIC and pre-RT ALC for - predicting severe lymphopenia were 2.89 Gy and 2.03 × 10(9) cells/L, - respectively. The high-risk group was defined as EDIC ≥ 2.89 Gy and pre-RT - ALC < 2.03 × 10(9) cells/L, while the low-risk group as EDIC < 2.89 Gy and pre-RT - ALC ≥ 2.03 × 10(9) cells/L, and the rest of the patients as the intermediate-risk - group. The incidences of severe lymphopenia during RT in the high-, - intermediate-, and low-risk groups were 90.1%, 77.1%, and 52.3%, respectively - (P < 0.001). The risk groups could independently predict both progression-free - (P < 0.001) and overall survival (P < 0.001). The high-risk group showed a higher - incidence of locoregional and distant recurrence (P < 0.001). Consolidation - immunotherapy showed significant survival benefit in the low- and - intermediate-risk groups but not in the high-risk group. CONCLUSIONS: The - combination of EDIC and pre-RT ALC predicted severe lymphopenia, recurrence, and - survival. It may potentially serve as a biomarker for consolidation - immunotherapy. -CI - Copyright © 2023 Elsevier B.V. All rights reserved. -FAU - Yang, Gowoon -AU - Yang G -AD - Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy - Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-ro, - Seodaemun-gu, Seoul 03722, Republic of Korea. -FAU - Yoon, Hong In -AU - Yoon HI -AD - Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy - Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-ro, - Seodaemun-gu, Seoul 03722, Republic of Korea. -FAU - Lee, Joongyo -AU - Lee J -AD - Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy - Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-ro, - Seodaemun-gu, Seoul 03722, Republic of Korea. -FAU - Kim, Jihun -AU - Kim J -AD - Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University - College of Medicine, 211 Eon-ju-ro, Gangnam-gu, Seoul 06273, Republic of Korea. -FAU - Kim, Hojin -AU - Kim H -AD - Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy - Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-ro, - Seodaemun-gu, Seoul 03722, Republic of Korea. -FAU - Cho, Jaeho -AU - Cho J -AD - Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy - Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-ro, - Seodaemun-gu, Seoul 03722, Republic of Korea. -FAU - Lee, Chang Geol -AU - Lee CG -AD - Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy - Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-ro, - Seodaemun-gu, Seoul 03722, Republic of Korea. -FAU - Chang, Jee Suk -AU - Chang JS -AD - Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy - Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-ro, - Seodaemun-gu, Seoul 03722, Republic of Korea. -FAU - Cho, Yeona -AU - Cho Y -AD - Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University - College of Medicine, 211 Eon-ju-ro, Gangnam-gu, Seoul 06273, Republic of Korea. -FAU - Kim, Jin Sung -AU - Kim JS -AD - Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy - Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-ro, - Seodaemun-gu, Seoul 03722, Republic of Korea. -FAU - Kim, Kyung Hwan -AU - Kim KH -AD - Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy - Research Institute, Yonsei University College of Medicine, 50-1, Yonsei-ro, - Seodaemun-gu, Seoul 03722, Republic of Korea. Electronic address: - KYUNGHKIM@yuhs.ac. -LA - eng -PT - Journal Article -DEP - 20230930 -PL - Ireland -TA - Radiother Oncol -JT - Radiotherapy and oncology : journal of the European Society for Therapeutic - Radiology and Oncology -JID - 8407192 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/radiotherapy -MH - *Lung Neoplasms/radiotherapy -MH - *Lymphopenia/etiology -MH - Treatment Outcome -MH - Chemoradiotherapy/adverse effects -MH - Immunotherapy/adverse effects -MH - Retrospective Studies -OTO - NOTNLM -OT - Carcinoma -OT - Chemoradiotherapy -OT - Immunotherapy -OT - Lymphopenia -OT - Non-Small-Cell Lung -OT - Progression-free survival -OT - Survival -COIS- Declaration of competing interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2023/10/03 00:42 -MHDA- 2023/11/28 06:42 -CRDT- 2023/10/02 19:21 -PHST- 2023/03/30 00:00 [received] -PHST- 2023/09/22 00:00 [revised] -PHST- 2023/09/23 00:00 [accepted] -PHST- 2023/11/28 06:42 [medline] -PHST- 2023/10/03 00:42 [pubmed] -PHST- 2023/10/02 19:21 [entrez] -AID - S0167-8140(23)89828-0 [pii] -AID - 10.1016/j.radonc.2023.109934 [doi] -PST - ppublish -SO - Radiother Oncol. 2023 Dec;189:109934. doi: 10.1016/j.radonc.2023.109934. Epub - 2023 Sep 30. - -PMID- 37507279 -OWN - NLM -STAT- MEDLINE -DCOM- 20230911 -LR - 20230921 -IS - 1433-2981 (Electronic) -IS - 0936-6555 (Linking) -VI - 35 -IP - 10 -DP - 2023 Oct -TI - Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in - Patients with Locally Advanced Non-small Cell Lung Cancer. -PG - 630-639 -LID - S0936-6555(23)00242-X [pii] -LID - 10.1016/j.clon.2023.07.003 [doi] -AB - AIMS: Pneumonitis is a common and potentially deadly complication of combined - chemoradiation and immune checkpoint inhibition (CRT-ICI) in patients with - locally advanced non-small cell lung cancer (LA-NSCLC). In this study we sought - to identify the risk factors for pneumonitis with CRT-ICI therapy in LA-NSCLC - cases and determine its impact on survival. MATERIALS AND METHODS: We conducted a - retrospective chart review of 140 patients with LA-NSCLC who underwent - curative-intent CRT-ICI with durvalumab between 2018 and 2021. Pneumonitis was - diagnosed by a multidisciplinary team of clinical experts. We used multivariable - cause-specific hazard models to identify risk factors associated with grade ≥2 - pneumonitis. We constructed multivariable Cox proportional hazard models to - investigate the impact of pneumonitis on all-cause mortality. RESULTS: The median - age of the cohort was 67 years; most patients were current or former smokers - (86%). The cumulative incidence of grade ≥2 pneumonitis was 23%. Among survivors, - 25/28 patients had persistent parenchymal scarring. In multivariable analyses, - the mean lung dose (hazard ratio 1.14 per Gy, 95% confidence interval 1.03-1.25) - and interstitial lung disease (hazard ratio 3.8, 95% confidence interval - 1.3-11.0) increased the risk for pneumonitis. In adjusted models, grade ≥2 - pneumonitis (hazard ratio 2.5, 95% confidence interval 1.0-6.2, P = 0.049) and - high-grade (≥3) pneumonitis (hazard ratio 8.3, 95% confidence interval 3.0-23.0, - P < 0.001) were associated with higher all-cause mortality. CONCLUSIONS: Risk - factors for pneumonitis in LA-NSCLC patients undergoing CRT-ICI include the mean - radiation dose to the lung and pre-treatment interstitial lung disease. Although - most cases are not fatal, pneumonitis in this setting is associated with markedly - increased mortality. -CI - Copyright © 2023. Published by Elsevier Ltd. -FAU - Altan, M -AU - Altan M -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Soto, F -AU - Soto F -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Xu, T -AU - Xu T -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Wilson, N -AU - Wilson N -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Franco-Vega, M C -AU - Franco-Vega MC -AD - Department of General Internal Medicine, The University of Texas MD Anderson - Cancer Center, Houston, TX, USA. -FAU - Simbaqueba Clavijo, C A -AU - Simbaqueba Clavijo CA -AD - Department of General Internal Medicine, The University of Texas MD Anderson - Cancer Center, Houston, TX, USA. -FAU - Shannon, V R -AU - Shannon VR -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Faiz, S A -AU - Faiz SA -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Gandhi, S -AU - Gandhi S -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Lin, S H -AU - Lin SH -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Lopez, P -AU - Lopez P -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Zhong, L -AU - Zhong L -AD - Department of Investigational Cancer Therapeutics, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Akhmedzhanov, F -AU - Akhmedzhanov F -AD - Department of Investigational Cancer Therapeutics, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Godoy, M C B -AU - Godoy MCB -AD - Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Shroff, G S -AU - Shroff GS -AD - Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Wu, J -AU - Wu J -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Khawaja, F -AU - Khawaja F -AD - Department of Infectious Diseases, Infection Control and Employee Health, The - University of Texas MD Anderson Cancer Center, Houston, TX, USA. -FAU - Kim, S T -AU - Kim ST -AD - Department of Rheumatology, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Naing, A -AU - Naing A -AD - Department of Investigational Cancer Therapeutics, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Heymach, J V -AU - Heymach JV -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Daniel-Macdougall, C -AU - Daniel-Macdougall C -AD - Department of Epidemiology, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Liao, Z -AU - Liao Z -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Sheshadri, A -AU - Sheshadri A -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. Electronic address: asheshadri@mdanderson.org. -LA - eng -GR - K23 AI117024/AI/NIAID NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20230714 -PL - England -TA - Clin Oncol (R Coll Radiol) -JT - Clinical oncology (Royal College of Radiologists (Great Britain)) -JID - 9002902 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - Aged -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Retrospective Studies -MH - Chemoradiotherapy/adverse effects -MH - *Pneumonia/etiology/complications -MH - *Radiation Pneumonitis/epidemiology/etiology/drug therapy -OTO - NOTNLM -OT - Concurrent chemoradiation -OT - immune checkpoint inhibitor -OT - locally advanced non-small cell lung cancer -OT - mortality -OT - pneumonitis -EDAT- 2023/07/29 06:42 -MHDA- 2023/09/11 06:42 -CRDT- 2023/07/28 21:55 -PHST- 2023/02/03 00:00 [received] -PHST- 2023/06/20 00:00 [revised] -PHST- 2023/07/11 00:00 [accepted] -PHST- 2023/09/11 06:42 [medline] -PHST- 2023/07/29 06:42 [pubmed] -PHST- 2023/07/28 21:55 [entrez] -AID - S0936-6555(23)00242-X [pii] -AID - 10.1016/j.clon.2023.07.003 [doi] -PST - ppublish -SO - Clin Oncol (R Coll Radiol). 2023 Oct;35(10):630-639. doi: - 10.1016/j.clon.2023.07.003. Epub 2023 Jul 14. - -PMID- 37403111 -OWN - NLM -STAT- MEDLINE -DCOM- 20230706 -LR - 20240328 -IS - 1748-717X (Electronic) -IS - 1748-717X (Linking) -VI - 18 -IP - 1 -DP - 2023 Jul 4 -TI - Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in - the first-line treatment of extensive stage small cell lung cancer. -PG - 111 -LID - 10.1186/s13014-023-02308-2 [doi] -LID - 111 -AB - BACKGROUND: The CREST study showed that the addition of thoracic radiotherapy - (TRT) could improve the survival rate in patients with extensive stage small cell - lung cancer (ES-SCLC), but whether TRT can bring survival benefit in the era of - immunotherapy remains controversial. This study aimed to explore the efficacy and - safety of adding TRT to the combination of PD-L1 inhibitors and chemotherapy. - METHODS: The patients who received durvalumab or atezolizumab combined with - chemotherapy as the first-line treatment of ES-SCLC from January 2019 to December - 2021 were enrolled. They were divided into two groups, based on whether they - received TRT or not. Propensity score matching (PSM) with a 1:1 ratio was - performed. The primary endpoints were progression-free survival (PFS), overall - survival (OS) and safety. RESULTS: A total of 211 patients with ES-SCLC were - enrolled, of whom 70 (33.2%) patients received standard therapy plus TRT as - first-line treatment, and 141 (66.8%) patients in the control group received - PD-L1 inhibitors plus chemotherapy. After PSM, a total of 57 pairs of patients - were enrolled in the analysis. In all patients, the median PFS (mPFS) in the TRT - and non-TRT group was 9.5 and 7.2 months, respectively, with HR = 0.59 (95%CI - 0.39-0.88, p = 0.009). The median OS (mOS) in the TRT group was also - significantly longer than that in the non-TRT group (24.1 months vs. 18.5 months, - HR = 0.53, 95%CI 0.31-0.89, p = 0.016). Multivariable analysis showed that - baseline liver metastasis and the number of metastases ≥ 3 were independent - prognostic factors for OS. Addition of TRT increased the incidence of - treatment-related pneumonia (p = 0.018), most of which were grade 1-2. - CONCLUSIONS: Addition of TRT to durvalumab or atezolizumab plus chemotherapy - significantly improves survival in ES-SCLC. Although it may leads to increased - incidence of treatment-related pneumonia, a majority of the cases can be relieved - after symptomatic treatment. -CI - © 2023. The Author(s). -FAU - Peng, Jianfeng -AU - Peng J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, Jiyan - Road 440, Jinan, 250117, Shandong, China. -FAU - Zhang, Lemeng -AU - Zhang L -AD - Department of Thoracic Department, Hunan Cancer Hospital, Changsha, China. -FAU - Wang, Liping -AU - Wang L -AD - Department of Medical Oncology, Baotou Cancer Hospital, Baotou, China. -FAU - Feng, Hui -AU - Feng H -AD - Department of Clinical Oncolygy, The Affiliated Hospital of Qingdao University, - Qingdao, China. -FAU - Yao, Dongmei -AU - Yao D -AD - Department of Medical Oncology, Chaoyang Second Hospital, Chaoyang, China. -FAU - Meng, Rui -AU - Meng R -AD - Department of Cancer Center, Union Hospital, Tongji Medical College, Huazhong - University of Science and Technology, Wuhan, China. -FAU - Liu, Xiaomei -AU - Liu X -AD - Department of Oncology Department, Jinzhou Medical University, Jinzhou, China. -FAU - Li, Xiaohua -AU - Li X -AD - Department of Respiratory and Critical Care, Chifeng Municipal Hospital, Chifeng, - Inner Mongolia, China. -FAU - Liu, Ningbo -AU - Liu N -AD - Department of Radiation Oncology, Tianjin Medical University Cancer Institute & - Hospital, Tianjin, China. -FAU - Tan, Bingxu -AU - Tan B -AD - Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, - China. -FAU - Huang, Zhaoqin -AU - Huang Z -AD - Department of Radiology, Shandong Provincial Hospital, Jinan, China. -FAU - Li, Shanshan -AU - Li S -AD - Department of Oncology, Zibo Municipal Hospital, Zibo, China. -FAU - Meng, Xiangjiao -AU - Meng X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, Jiyan - Road 440, Jinan, 250117, Shandong, China. mengxiangjiao@sina.com. -LA - eng -GR - flzh202107/Bethune·Cancer Radiotherapy Translational Medicine Research Fund/ -GR - 81972796 and 82272845/National Natural Science Foundation of China/ -GR - 2021SFGC0501/Key Research and Development Program of Shandong (Major - Science&Technology Innovation Project)/ -PT - Journal Article -DEP - 20230704 -PL - England -TA - Radiat Oncol -JT - Radiation oncology (London, England) -JID - 101265111 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -CIN - Front Immunol. 2024 Jan 18;14:1289434. doi: 10.3389/fimmu.2023.1289434. PMID: - 38304255 -MH - Humans -MH - *Small Cell Lung Carcinoma/drug therapy/radiotherapy -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Immune Checkpoint Inhibitors/therapeutic use -PMC - PMC10320989 -OTO - NOTNLM -OT - Extensive stage small cell lung cancer -OT - PD-L1 inhibitors -OT - Survival -OT - Thoracic radiotherapy -OT - Toxicity -COIS- The authors declare that they have no competing interests. -EDAT- 2023/07/05 01:06 -MHDA- 2023/07/06 06:42 -PMCR- 2023/07/04 -CRDT- 2023/07/04 23:41 -PHST- 2023/04/15 00:00 [received] -PHST- 2023/06/22 00:00 [accepted] -PHST- 2023/07/06 06:42 [medline] -PHST- 2023/07/05 01:06 [pubmed] -PHST- 2023/07/04 23:41 [entrez] -PHST- 2023/07/04 00:00 [pmc-release] -AID - 10.1186/s13014-023-02308-2 [pii] -AID - 2308 [pii] -AID - 10.1186/s13014-023-02308-2 [doi] -PST - epublish -SO - Radiat Oncol. 2023 Jul 4;18(1):111. doi: 10.1186/s13014-023-02308-2. - -PMID- 37406774 -OWN - NLM -STAT- MEDLINE -DCOM- 20231106 -LR - 20231106 -IS - 1879-8519 (Electronic) -IS - 1879-8500 (Linking) -VI - 13 -IP - 6 -DP - 2023 Nov-Dec -TI - Full Dose SBRT in Combination With Mediastinal Chemoradiation for Locally - Advanced, Non-Small Cell Lung Cancer: A Practical Guide for Planning, Dosimetric - Results From a Phase 2 Study, and a Treatment Planning Guide for the Phase 3 NRG - Oncology LU-008 Trial. -PG - 531-539 -LID - S1879-8500(23)00173-X [pii] -LID - 10.1016/j.prro.2023.04.014 [doi] -AB - PURPOSE: Stereotactic body radiation therapy (SBRT) has been used with high - effectiveness in early-stage non-small cell lung cancer (NSCLC) but has not been - studied extensively in locally advanced NSCLC. We conducted a phase 2 study - delivering SBRT to the primary tumor followed by conventionally fractionated - chemoradiation to the involved lymph nodes for patients with node-positive - locally advanced NSCLC. This manuscript serves as both a guide to planning - techniques used on this trial and the subsequent phase 3 study, NRG Oncology - LU-008, and to report patient dosimetry and toxicity results. METHODS AND - MATERIALS: We initiated a phase 2 multicenter single arm study evaluating SBRT to - the primary tumor (50-54 Gy in 3-5 fractions) followed by conventionally - fractionated chemoradiation to 60 Gy in 2 Gy fractions with doublet chemotherapy - to the involved lymph nodes for patients with stage III or unresectable stage II - NSCLC. Patients eligible for adjuvant immunotherapy received up to 12 months of - durvalumab. We report a detailed guide for the entire treatment process from - computed tomography simulation through treatment planning and delivery. The - dosimetric outcomes from the 60 patients who completed therapy on study are - reported both for target coverage and normal structure doses. We also report - correlation between radiation-related toxicities and dosimetric parameters. - RESULTS: Sixty patients were enrolled between 2017 and 2022. Planning techniques - used were primarily volumetric modulated arc therapy for SBRT to the primary - tumor and conventionally fractionated radiation to the involved nodes, with a - minority of cases using dynamic conformal arc technique or static dynamic - multileaf collimator intensity modulated radiation therapy. Grade 2 or higher - pneumonitis was associated with lung dose V5 Gy > 70% and grade 2 or higher - pulmonary toxicity was associated with lung dose V10 Gy > 50%. Only 3 patients - (5%) experienced grade 3 or higher pneumonitis. Grade 2 or higher esophagitis was - associated with esophageal doses, including mean dose > 20 Gy, V60 Gy > 7%, and - D1cc > 55 Gy. Only 1 patient (1.7%) experienced grade 3 esophagitis. CONCLUSIONS: - SBRT to the primary tumor followed by conventionally fractionated chemoradiation - to the involved lymph nodes is feasible with planning techniques as described. - Radiation-related toxicity on this phase 2 study was low. This manuscript serves - as a guideline for the recently activated NRG Oncology LU-008 phase 3 trial - evaluating this experimental regimen. -CI - Copyright © 2023 American Society for Radiation Oncology. Published by Elsevier - Inc. All rights reserved. -FAU - Heinzerling, John H -AU - Heinzerling JH -AD - Levine Cancer Institute, Atrium Health, Southeast Radiation Oncology, Charlotte, - North Carolina. Electronic address: john.heinzerling@atriumhealth.org. -FAU - Pen, Olga V -AU - Pen OV -AD - Levine Cancer Institute, Atrium Health, Charlotte, North Carolina. -FAU - Robinson, Myra -AU - Robinson M -AD - Levine Cancer Institute, Atrium Health, Charlotte, North Carolina. -FAU - Foster, Ryan -AU - Foster R -AD - Levine Cancer Institute, Atrium Health, Charlotte, North Carolina. -FAU - Kelly, Brian -AU - Kelly B -AD - Levine Cancer Institute, Atrium Health, Charlotte, North Carolina. -FAU - Mileham, Kathryn F -AU - Mileham KF -AD - Levine Cancer Institute, Atrium Health, Charlotte, North Carolina. -FAU - Moeller, Benjamin -AU - Moeller B -AD - Levine Cancer Institute, Atrium Health, Southeast Radiation Oncology, Charlotte, - North Carolina. -FAU - Prabhu, Roshan S -AU - Prabhu RS -AD - Levine Cancer Institute, Atrium Health, Southeast Radiation Oncology, Charlotte, - North Carolina. -FAU - Corso, Christopher -AU - Corso C -AD - Levine Cancer Institute, Atrium Health, Southeast Radiation Oncology, Charlotte, - North Carolina. -FAU - Ward, Matt W -AU - Ward MW -AD - Levine Cancer Institute, Atrium Health, Southeast Radiation Oncology, Charlotte, - North Carolina. -FAU - Sullivan, Cara M -AU - Sullivan CM -AD - Levine Cancer Institute, Atrium Health, Charlotte, North Carolina. -FAU - Burri, Stuart -AU - Burri S -AD - Levine Cancer Institute, Atrium Health, Southeast Radiation Oncology, Charlotte, - North Carolina. -FAU - Simone, Charles B 2nd -AU - Simone CB 2nd -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, New York; New York Proton Center, New York, New York. -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Multicenter Study -DEP - 20230703 -PL - United States -TA - Pract Radiat Oncol -JT - Practical radiation oncology -JID - 101558279 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Lung Neoplasms/pathology -MH - *Radiosurgery/adverse effects/methods -MH - Radiotherapy Dosage -MH - *Radiation Injuries/etiology -MH - *Pneumonia/etiology -MH - *Esophagitis/etiology -EDAT- 2023/07/06 01:08 -MHDA- 2023/11/06 06:42 -CRDT- 2023/07/05 19:26 -PHST- 2023/03/28 00:00 [received] -PHST- 2023/04/21 00:00 [revised] -PHST- 2023/04/25 00:00 [accepted] -PHST- 2023/11/06 06:42 [medline] -PHST- 2023/07/06 01:08 [pubmed] -PHST- 2023/07/05 19:26 [entrez] -AID - S1879-8500(23)00173-X [pii] -AID - 10.1016/j.prro.2023.04.014 [doi] -PST - ppublish -SO - Pract Radiat Oncol. 2023 Nov-Dec;13(6):531-539. doi: 10.1016/j.prro.2023.04.014. - Epub 2023 Jul 3. - -PMID- 37100160 -OWN - NLM -STAT- MEDLINE -DCOM- 20230904 -LR - 20230906 -IS - 1879-355X (Electronic) -IS - 0360-3016 (Linking) -VI - 117 -IP - 2 -DP - 2023 Oct 1 -TI - Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly - concurrent chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: - Results of A Prospective Phase II Study (GASTO-1049). -PG - 387-399 -LID - S0360-3016(23)00384-X [pii] -LID - 10.1016/j.ijrobp.2023.04.021 [doi] -AB - PURPOSE: We launched a prospective phase 2 clinical trial to explore the safety - and efficacy of hypofractionated radiation therapy (hypo-RT) followed by - hypofractionated boost (hypo-boost) combined with concurrent weekly chemotherapy - in patients with unresectable locally advanced non-small cell lung cancer - (LA-NSCLC). METHODS AND MATERIALS: Patients with newly diagnosed LA-NSCLC with - unresectable stage III disease were recruited between June 2018 and June 2020. - Patients were treated with hypo-RT (40 Gy in 10 fractions) followed by hypo-boost - (24-28 Gy in 6-7 fractions) combined with concurrent weekly chemotherapy - (docetaxel 25 mg/m(2) and nedaplatin 25 mg/m(2)). The primary endpoint of the - study was progression-free survival (PFS), and the secondary endpoints included - overall survival (OS), locoregional failure-free survival (LRFS), distant - metastasis-free survival (DMFS), objective response rate (ORR), and toxicities. - RESULTS: From June 2018 to June 2020, 75 patients were enrolled with a median - follow-up duration of 28.0 months. The ORR of the whole cohort was 94.7%. Disease - progression or death was recorded in 44 (58.7%) patients, with a median PFS of - 21.6 months (95% confidence interval [CI], 15.6-27.6 months). The 1- and 2-year - PFS rates were 81.3% (95% CI, 72.5%-90.1%) and 43.3% (95% CI, 31.5%-55.1%), - respectively. The median OS, DMFS, and LRFS had not been reached at the time of - the last follow-up. The 1- and 2-year OS rates were 94.7% (95% CI, 89.6%-99.8%) - and 72.4% (95% CI, 62.0%-82.8%), respectively. The most frequent acute - nonhematologic toxicity was radiation esophagitis. Grade (G) 2 and G3 acute - radiation esophagitis were observed in 20 (26.7%) and 4 (5.3%) patients, - respectively. Thirteen patients (13/75, 17.3%) had G2 pneumonitis and no G3-G5 - acute pneumonitis occurred during follow-up. CONCLUSIONS: Hypo-RT followed by - hypo-boost combined with concurrent weekly chemotherapy could yield satisfactory - local control and survival outcomes with moderate radiation-induced toxicity in - patients with LA-NSCLC. The new potent hypo-CCRT regimen significantly shortened - treatment time and provided the potential opportunity for the combination of - consolidative immunotherapy. -CI - Copyright © 2023 Elsevier Inc. All rights reserved. -FAU - Zhou, Rui -AU - Zhou R -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, - China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, Guangzhou, China; Lung Cancer Institute of Sun Yat-sen - University, Guangzhou, China; Guangdong Association Study of Thoracic Oncology, - Guangzhou, China. -FAU - Qiu, Bo -AU - Qiu B -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, - China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, Guangzhou, China; Lung Cancer Institute of Sun Yat-sen - University, Guangzhou, China; Guangdong Association Study of Thoracic Oncology, - Guangzhou, China. -FAU - Xiong, Mai -AU - Xiong M -AD - Department of Cardiac Surgery, First Affiliated Hospital, Sun Yat-sen University, - Guangzhou, China. -FAU - Liu, YiMei -AU - Liu Y -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, - China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, Guangzhou, China; Lung Cancer Institute of Sun Yat-sen - University, Guangzhou, China; Guangdong Association Study of Thoracic Oncology, - Guangzhou, China. -FAU - Peng, KangQiang -AU - Peng K -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, - China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, Guangzhou, China; Department of Medical Imaging, Sun - Yat-sen University Cancer Center, Guangzhou, China. -FAU - Luo, YiFeng -AU - Luo Y -AD - Pulmonary and Critical Care Medicine, First Affiliated Hospital, Sun Yat-sen - University, Guangzhou, China. -FAU - Wang, DaQuan -AU - Wang D -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, - China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, Guangzhou, China; Lung Cancer Institute of Sun Yat-sen - University, Guangzhou, China; Guangdong Association Study of Thoracic Oncology, - Guangzhou, China. -FAU - Liu, FangJie -AU - Liu F -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, - China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, Guangzhou, China; Lung Cancer Institute of Sun Yat-sen - University, Guangzhou, China; Guangdong Association Study of Thoracic Oncology, - Guangzhou, China. -FAU - Chen, NaiBin -AU - Chen N -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, - China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, Guangzhou, China; Lung Cancer Institute of Sun Yat-sen - University, Guangzhou, China; Guangdong Association Study of Thoracic Oncology, - Guangzhou, China. -FAU - Guo, JinYu -AU - Guo J -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, - China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, Guangzhou, China; Lung Cancer Institute of Sun Yat-sen - University, Guangzhou, China; Guangdong Association Study of Thoracic Oncology, - Guangzhou, China. -FAU - Zhang, Jun -AU - Zhang J -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, - China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, Guangzhou, China; Lung Cancer Institute of Sun Yat-sen - University, Guangzhou, China; Guangdong Association Study of Thoracic Oncology, - Guangzhou, China. -FAU - Huang, XiaoYan -AU - Huang X -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, - China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, Guangzhou, China; Lung Cancer Institute of Sun Yat-sen - University, Guangzhou, China; Guangdong Association Study of Thoracic Oncology, - Guangzhou, China. -FAU - Rong, YuMing -AU - Rong Y -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, - China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, Guangzhou, China; Department of VIP Region, Sun Yat-sen - University Cancer Center, Guangzhou, China. -FAU - Liu, Hui -AU - Liu H -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, - China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, Guangzhou, China; Lung Cancer Institute of Sun Yat-sen - University, Guangzhou, China; Guangdong Association Study of Thoracic Oncology, - Guangzhou, China. Electronic address: liuhuisysucc@126.com. -LA - eng -SI - ClinicalTrials.gov/NCT03900117 -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20230425 -PL - United States -TA - Int J Radiat Oncol Biol Phys -JT - International journal of radiation oncology, biology, physics -JID - 7603616 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung -MH - *Lung Neoplasms -MH - Prospective Studies -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - Chemoradiotherapy/adverse effects/methods -MH - *Radiation Injuries/drug therapy -MH - *Esophagitis/etiology -EDAT- 2023/04/27 00:42 -MHDA- 2023/09/04 06:42 -CRDT- 2023/04/26 19:25 -PHST- 2022/10/30 00:00 [received] -PHST- 2023/03/31 00:00 [revised] -PHST- 2023/04/18 00:00 [accepted] -PHST- 2023/09/04 06:42 [medline] -PHST- 2023/04/27 00:42 [pubmed] -PHST- 2023/04/26 19:25 [entrez] -AID - S0360-3016(23)00384-X [pii] -AID - 10.1016/j.ijrobp.2023.04.021 [doi] -PST - ppublish -SO - Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):387-399. doi: - 10.1016/j.ijrobp.2023.04.021. Epub 2023 Apr 25. - -PMID- 37614219 -OWN - NLM -STAT- MEDLINE -DCOM- 20231023 -LR - 20240926 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 14 -IP - 29 -DP - 2023 Oct -TI - Exploratory analysis to predict pneumonitis during durvalumab consolidation - therapy for patients with locally advanced non-small cell lung cancer from - proteomic profiling of circulating extracellular vesicles. -PG - 2909-2923 -LID - 10.1111/1759-7714.15077 [doi] -AB - BACKGROUND: Risk factors for predicting pneumonitis during durvalumab - consolidation after chemoradiotherapy (CRT) in locally advanced non-small cell - lung cancer (LA-NSCLC) are still lacking. Extracellular vesicles (EVs) play a - crucial role in intercellular communication and are potential diagnostic tools - for various diseases. METHODS: We retrospectively collected predurvalumab - treatment serum samples from patients treated with durvalumab for LA-NSCLC, - isolated EVs using anti-CD9 and anti-CD63 antibodies, and performed proteomic - analyses. We examined EV proteins that could predict the development of - symptomatic pneumonitis (SP) during durvalumab treatment. Potential EV-protein - biomarkers were validated in an independent cohort. RESULTS: In the discovery - cohort, 73 patients were included, 49 with asymptomatic pneumonitis (AP) and 24 - with SP. Of the 5797 proteins detected in circulating EVs, 33 were significantly - elevated (fold change [FC] > 1.5, p < 0.05) in the SP group, indicating - enrichment of the nuclear factor kappa B (NF-κB) pathway. Patients with high - levels of EV-RELA, an NF-κB subunit, had a higher incidence of SP than those with - low levels of EV-RELA (53.8% vs. 13.4%, p = 0.0017). In the receiver operating - characteristic analysis, EV-RELA demonstrated a higher area under the curve (AUC) - than lung V20 (0.76 vs. 0.62) and was identified as an independent risk factor in - the multivariate logistic regression analysis (p = 0.008, odds ratio 7.72). - Moreover, high EV-RELA was also a predictor of SP in the validation cohort - comprising 43 patients (AUC of 0.80). CONCLUSIONS: Circulating EV-RELA may be a - predictive marker for symptomatic pneumonitis in patients with LA-NSCLC treated - with durvalumab. -CI - © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Torasawa, Masahiro -AU - Torasawa M -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -AD - Department of Respiratory Medicine, Juntendo University Graduate School of - Medicine, Tokyo, Japan. -FAU - Horinouchi, Hidehito -AU - Horinouchi H -AUID- ORCID: 0000-0001-9090-801X -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -FAU - Yagishita, Shigehiro -AU - Yagishita S -AD - Division of Molecular Pharmacology, National Cancer Center Research Institute, - Tokyo, Japan. -FAU - Utsumi, Hirofumi -AU - Utsumi H -AD - Division of Respiratory Diseases, Department of Internal Medicine, The Jikei - University School of Medicine, Tokyo, Japan. -FAU - Okuda, Keitaro -AU - Okuda K -AD - Division of Respiratory Diseases, Department of Internal Medicine, The Jikei - University School of Medicine, Tokyo, Japan. -FAU - Takekoshi, Daisuke -AU - Takekoshi D -AD - Division of Respiratory Diseases, Department of Internal Medicine, The Jikei - University School of Medicine, Tokyo, Japan. -FAU - Ito, Saburo -AU - Ito S -AD - Division of Respiratory Diseases, Department of Internal Medicine, The Jikei - University School of Medicine, Tokyo, Japan. -FAU - Wakui, Hiroshi -AU - Wakui H -AD - Division of Respiratory Diseases, Department of Internal Medicine, The Jikei - University School of Medicine, Tokyo, Japan. -FAU - Murata, Saori -AU - Murata S -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -FAU - Kaku, Sawako -AU - Kaku S -AD - Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, - Japan. -FAU - Okuma, Kae -AU - Okuma K -AD - Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan. -FAU - Matsumoto, Yuji -AU - Matsumoto Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -FAU - Shinno, Yuki -AU - Shinno Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -FAU - Okuma, Yusuke -AU - Okuma Y -AUID- ORCID: 0000-0001-5743-0149 -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -FAU - Yoshida, Tatsuya -AU - Yoshida T -AUID- ORCID: 0000-0003-4896-5824 -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -AD - Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, - Japan. -FAU - Goto, Yasushi -AU - Goto Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -FAU - Yamamoto, Noboru -AU - Yamamoto N -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -AD - Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, - Japan. -FAU - Araya, Jun -AU - Araya J -AD - Division of Respiratory Diseases, Department of Internal Medicine, The Jikei - University School of Medicine, Tokyo, Japan. -FAU - Ohe, Yuichiro -AU - Ohe Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -FAU - Fujita, Yu -AU - Fujita Y -AUID- ORCID: 0000-0002-8916-7303 -AD - Division of Respiratory Diseases, Department of Internal Medicine, The Jikei - University School of Medicine, Tokyo, Japan. -AD - Division of Next-Generation Drug Development Research, Research Center for - Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20230824 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 28X28X9OKV (durvalumab) -RN - 0 (NF-kappa B) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy -MH - *Lung Neoplasms/therapy -MH - Consolidation Chemotherapy -MH - Retrospective Studies -MH - NF-kappa B -MH - Proteomics -MH - *Pneumonia/chemically induced -MH - Chemoradiotherapy/adverse effects -PMC - PMC10569905 -OTO - NOTNLM -OT - chemoradiotherapy -OT - durvalumab -OT - extracellular vesicles -OT - pneumonitis -COIS- Dr Torasawa has nothing to disclose. Dr. Horinouchi reports receiving personal - fees from AstraZeneca.K.K during the conduct of the study; grants and personal - fees from Chugai, Merck Sharp & Dohme, Novartis, Ono, and Roche; grants from - AbbVie, Bristol‐Myers Squibb, Daiichi Sankyo, Genomic Health, Janssen, Merck - Biopharma; and personal fees from Eli Lilly and Kyowa‐Kirin, outside of the - submitted work. Dr Yagishita reports receiving grants from Nippon Boehringer - Ingelheim, outside of the submitted work. Dr Utsumi has nothing to disclose. Dr - Okuda has nothing to disclose. Dr Takekoshi has nothing to disclose. Dr Ito has - nothing to disclose. Dr Wakui reports receiving personal fees from - AstraZeneca.K.K during the conduct of the study. Dr Murata has nothing to - disclose. Dr Kaku has nothing to disclose. Dr Okuma has nothing to disclose. Dr - Sinnno reports receiving personal fees from AstraZeneca.K.K during the conduct of - the study; personal fees from Bristol‐Myers Squibb, Chugai, and Eli Lilly; grants - and personal fees from Ono; and grants from Janssen and Japan Clinical Research - Operations K.K. outside of the submitted work. Dr Matsumoto reports receiving - personal fees from AstraZeneca.K.K during the conduct of the study; grants from - Grant‐in‐Aid for Scientific Research on Innovative Areas, Hitachi, Ltd., and the - National Cancer Center Research and Development Fund; grants and personal fees - from Olympus; and personal fees from AMCO Inc., Chugai, COOK, Eli Lilly, Erbe - Elektromedizin GmbH, Fujifilm, Novartis, and Thermo Fisher Scientific outside of - the submitted work. Dr Okuma reports receiving personal fees from AstraZeneca.K.K - during the conduct of the study; grants from AbbVie K.K. and Roche; and personal - fees from Nippon Boehringer Ingelheim, Bristol‐Myers Squibb, Chugai Pharma Co. - Ltd., Ely Lilly K.K., Ono Pharma Co. Ltd., Pfizer Taiho Pharma Co. Ltd., and - Taiho Pharma Co. Ltd. outside of the submitted work. Dr Yoshida reports receiving - personal fees from AstraZeneca.K.K during the conduct of the study; grants and - personal fees from Amgen, Bristol‐Myers Squibb, Chugai, Merck Sharp & Dohme, - Novartis, and Ono; grants from AbbVie, Daiichi Sankyo, and Takeda; and personal - fees from ArcherDX, Eli Lilly, Roche, and Taiho outside of the submitted work. Dr - Goto reports receiving personal fees from AstraZeneca.K.K during the conduct of - the study; grants from AbbVie, AZK, Kyorin, and Preferred Network; grants and - personal fees from Bristol‐Myers Squibb, Daiichi Sankyo, Eli Lilly, Novartis, - Ono, and Pfizer; and personal fees from Boehringer Ingelheim, Chugai, Guardant - Health Inc., Illumina, Merck Sharp & Dohme, Taiho, and Thermo Fisher outside of - the submitted work. Dr. Yamamoto reports receiving personal fees from - AstraZeneca.K.K during the conduct of the study; grants from Astellas, Bayer, - Boehringer Ingelheim, Bristol‐Myers Squibb, Carna Biosciences, Chugai, Chiome - Bioscience Inc., Daiichi Sankyo, Eisai, Eli Lilly, Genmab, GlaxoSmithKline, - Janssen Pharma, Kyowa‐Hakko Kirin, Merck Sharp & Dohme, Novartis, Ono - Pharmaceutical Co., Ltd., Otsuka, Pfizer, Quintiles, Shionogi, Sumitomo - Dainippon, Takeda, and Taiho; and personal fees from Boehringer Ingelheim, - Bristol‐Myers Squibb, Chugai, Cimic, Eisai, Lilly, Ono Pharmaceutical Co., Ltd., - Otsuka, Pfizer, Sysmex, and Takeda, outside of the submitted work. Dr Araya - receiving grants from Japanese Respiratory Foundation and Kowa company, LTD - (campany x) outside of the submitted work. Dr Ohe reports receiving grants, - personal fees, and nonfinancial support from AstraZeneca.K.K during the conduct - of the study; personal fees from Amgen, AnHeeart Therapeutics Inc., Bayer, - Boehringer Ingelheim, Bristol‐Myers Squibb, Celltrion, Chugai, Kyowa‐Hakko Kirin, - Merck Sharp & Dohme, Nippon Kayaku, Ono Pharmaceutical Co., Ltd., Pfizer, and - Taiho; grants and personal fees from Eli Lilly; grants and nonfinancial support - from Kyorin; grants from Daiichi Sankyo, Dainippon‐Sumitomo, Janssen, Kissei, - LOXO, Novartis, Takeda, and Taiho, outside of the submitted work. Dr Fujita - reports receiving grants from AstraZeneca.K.K during the conduct of the study; - grants from Preferred networks, Showa Denko Materials Co. Ltd., SHIBUYA - Cooperation, H.U. Group Holdings, Inc., Merck Sharp & Dohme outside of the - submitted work. -EDAT- 2023/08/24 06:42 -MHDA- 2023/10/23 00:41 -PMCR- 2023/08/24 -CRDT- 2023/08/24 03:54 -PHST- 2023/08/01 00:00 [revised] -PHST- 2023/05/12 00:00 [received] -PHST- 2023/08/03 00:00 [accepted] -PHST- 2023/10/23 00:41 [medline] -PHST- 2023/08/24 06:42 [pubmed] -PHST- 2023/08/24 03:54 [entrez] -PHST- 2023/08/24 00:00 [pmc-release] -AID - TCA15077 [pii] -AID - 10.1111/1759-7714.15077 [doi] -PST - ppublish -SO - Thorac Cancer. 2023 Oct;14(29):2909-2923. doi: 10.1111/1759-7714.15077. Epub 2023 - Aug 24. - -PMID- 34087343 -OWN - NLM -STAT- MEDLINE -DCOM- 20210713 -LR - 20210713 -IS - 1879-0461 (Electronic) -IS - 1040-8428 (Linking) -VI - 163 -DP - 2021 Jul -TI - Treatment strategies for locally advanced non-small cell lung cancer in elderly - patients: Translating scientific evidence into clinical practice. -PG - 103378 -LID - S1040-8428(21)00166-9 [pii] -LID - 10.1016/j.critrevonc.2021.103378 [doi] -AB - Treatment of locally advanced NSCLC (LA-NSCLC) is focused on multimodal strategy, - including chemotherapy and radiotherapy (in combination or as alternative - treatments), followed by surgery in selected cases. Recently, durvalumab - consolidation after definitive chemo-radiation has shown a meaningful overall - survival benefit. However, it is important to note that elderly patients - represent a high proportion of NSCLC population and frailty and comorbidities can - significantly limit treatment options. Indeed, elderly patients are - under-represented in clinical trials and data to drive treatment selection in - this category of patients are scanty. Available data, main issues and - controversies on multimodal treatment in elderly LA-NSCLC patients will be - reviewed in this paper. -CI - Copyright © 2021 Elsevier B.V. All rights reserved. -FAU - Bonanno, Laura -AU - Bonanno L -AD - Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. Electronic - address: laura.bonanno@iov.veneto.it. -FAU - Attili, Ilaria -AU - Attili I -AD - Division of Thoracic Oncology, European Institute of Oncology IRCSS, Milan, - Italy. -FAU - Pavan, Alberto -AU - Pavan A -AD - Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. -FAU - Sepulcri, Matteo -AU - Sepulcri M -AD - Radiotherapy, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy. -FAU - Pasello, Giulia -AU - Pasello G -AD - Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy; Department - of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. -FAU - Rea, Federico -AU - Rea F -AD - Thoracic Surgery, Department of Cardiothoracic Surgery and Vascular Sciences, - University of Padova, Padova, Italy. -FAU - Guarneri, Valentina -AU - Guarneri V -AD - Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy; Department - of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. -FAU - Conte, PierFranco -AU - Conte P -AD - Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy; Department - of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. -LA - eng -PT - Journal Article -PT - Review -DEP - 20210601 -PL - Netherlands -TA - Crit Rev Oncol Hematol -JT - Critical reviews in oncology/hematology -JID - 8916049 -SB - IM -MH - Aged -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/therapy -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy/therapy -OTO - NOTNLM -OT - Chemotherapy -OT - Comorbidities -OT - Concurrent treatment -OT - Elderly -OT - Immunotherapy -OT - Radiotherapy -OT - Sequential treatment -OT - Stage III lung cancer -EDAT- 2021/06/05 06:00 -MHDA- 2021/07/14 06:00 -CRDT- 2021/06/04 20:14 -PHST- 2020/05/31 00:00 [received] -PHST- 2021/02/19 00:00 [revised] -PHST- 2021/05/29 00:00 [accepted] -PHST- 2021/06/05 06:00 [pubmed] -PHST- 2021/07/14 06:00 [medline] -PHST- 2021/06/04 20:14 [entrez] -AID - S1040-8428(21)00166-9 [pii] -AID - 10.1016/j.critrevonc.2021.103378 [doi] -PST - ppublish -SO - Crit Rev Oncol Hematol. 2021 Jul;163:103378. doi: - 10.1016/j.critrevonc.2021.103378. Epub 2021 Jun 1. - -PMID- 37027467 -OWN - NLM -STAT- MEDLINE -DCOM- 20230411 -LR - 20230421 -IS - 2375-2548 (Electronic) -IS - 2375-2548 (Linking) -VI - 9 -IP - 14 -DP - 2023 Apr 7 -TI - Small-molecule PIK-93 modulates the tumor microenvironment to improve immune - checkpoint blockade response. -PG - eade9944 -LID - 10.1126/sciadv.ade9944 [doi] -LID - eade9944 -AB - Immune checkpoint inhibitors (ICIs) targeting PD-L1 immunotherapy are - state-of-the-art treatments for advanced non-small cell lung cancer (NSCLC). - However, the treatment response of certain patients with NSCLC is unsatisfactory - because of an unfavorable tumor microenvironment (TME) and poor permeability of - antibody-based ICIs. In this study, we aimed to discover small-molecule drugs - that can modulate the TME to enhance ICI treatment efficacy in NSCLC in vitro and - in vivo. We identified a PD-L1 protein-modulating small molecule, PIK-93, using a - cell-based global protein stability (GPS) screening system. PIK-93 mediated PD-L1 - ubiquitination by enhancing the PD-L1-Cullin-4A interaction. PIK-93 reduced PD-L1 - levels on M1 macrophages and enhanced M1 antitumor cytotoxicity. Combined PIK-93 - and anti-PD-L1 antibody treatment enhanced T cell activation, inhibited tumor - growth, and increased tumor-infiltrating lymphocyte (TIL) recruitment in - syngeneic and human peripheral blood mononuclear cell (PBMC) line-derived - xenograft mouse models. PIK-93 facilitates a treatment-favorable TME when - combined with anti-PD-L1 antibodies, thereby enhancing PD-1/PD-L1 blockade cancer - immunotherapy. -FAU - Lin, Chia-Yi -AU - Lin CY -AUID- ORCID: 0000-0002-1027-1264 -AD - Department of Internal Medicine, College of Medicine, National Taiwan University, - Taipei 100, Taiwan. -AD - Institute of Biomedical Sciences, Academia Sinica, Nankang, Taipei 115, Taiwan. -FAU - Huang, Kuo-Yen -AU - Huang KY -AUID- ORCID: 0000-0002-5542-3567 -AD - Department of Clinical Laboratory Sciences and Medical Biotechnology, College of - Medicine, National Taiwan University, Taipei, Taiwan. -FAU - Kao, Shih-Han -AU - Kao SH -AD - Resuscitation Science Center of Emphasis, Department of Anesthesiology and - Critical Care Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA - 19104, USA. -FAU - Lin, Ming-Shiu -AU - Lin MS -AD - Department of Internal Medicine, College of Medicine, National Taiwan University, - Taipei 100, Taiwan. -AD - Institute of Biomedical Sciences, Academia Sinica, Nankang, Taipei 115, Taiwan. -FAU - Lin, Chih-Chien -AU - Lin CC -AD - Department of Internal Medicine, College of Medicine, National Taiwan University, - Taipei 100, Taiwan. -AD - Institute of Biomedical Sciences, Academia Sinica, Nankang, Taipei 115, Taiwan. -FAU - Yang, Shuenn-Chen -AU - Yang SC -AD - Institute of Biomedical Sciences, Academia Sinica, Nankang, Taipei 115, Taiwan. -FAU - Chung, Wei-Chia -AU - Chung WC -AD - Department of Internal Medicine, College of Medicine, National Taiwan University, - Taipei 100, Taiwan. -AD - Institute of Biomedical Sciences, Academia Sinica, Nankang, Taipei 115, Taiwan. -FAU - Chang, Ya-Hsuan -AU - Chang YH -AD - Institute of Statistical Science, Academia Sinica, Taipei, Taiwan. -FAU - Chein, Rong-Jie -AU - Chein RJ -AUID- ORCID: 0000-0002-0119-8288 -AD - Institute of Chemistry, Academia Sinica, Nankang, Taipei 115, Taiwan. -FAU - Yang, Pan-Chyr -AU - Yang PC -AUID- ORCID: 0000-0001-6330-6048 -AD - Department of Internal Medicine, College of Medicine, National Taiwan University, - Taipei 100, Taiwan. -AD - Institute of Biomedical Sciences, Academia Sinica, Nankang, Taipei 115, Taiwan. -AD - Genomics Research Center, Academia Sinica, Nankang, Taipei 115, Taiwan. -LA - eng -PT - Journal Article -DEP - 20230407 -PL - United States -TA - Sci Adv -JT - Science advances -JID - 101653440 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - Animals -MH - Mice -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - *Lung Neoplasms/drug therapy/pathology -MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use -MH - Tumor Microenvironment -MH - Lymphocytes, Tumor-Infiltrating -PMC - PMC10081850 -EDAT- 2023/04/08 06:00 -MHDA- 2023/04/11 06:42 -PMCR- 2023/04/07 -CRDT- 2023/04/07 14:02 -PHST- 2023/04/11 06:42 [medline] -PHST- 2023/04/07 14:02 [entrez] -PHST- 2023/04/08 06:00 [pubmed] -PHST- 2023/04/07 00:00 [pmc-release] -AID - ade9944 [pii] -AID - 10.1126/sciadv.ade9944 [doi] -PST - ppublish -SO - Sci Adv. 2023 Apr 7;9(14):eade9944. doi: 10.1126/sciadv.ade9944. Epub 2023 Apr 7. - -PMID- 32954834 -OWN - NLM -STAT- MEDLINE -DCOM- 20210603 -LR - 20210603 -IS - 1744-7593 (Electronic) -IS - 1742-5247 (Linking) -VI - 18 -IP - 1 -DP - 2021 Jan -TI - Targeted drug therapy in non-small cell lung cancer: Clinical significance and - possible solutions-Part I. -PG - 73-102 -LID - 10.1080/17425247.2021.1825377 [doi] -AB - INTRODUCTION: Non-small cell lung cancer (NSCLC) comprises of 84% of all lung - cancer cases. The treatment options for NSCLC at advanced stages are chemotherapy - and radiotherapy. Chemotherapy involves conventional nonspecific - chemotherapeutics, and targeted-protein/receptor-specific small molecule - inhibitors. Biologically targeted therapies such as an antibody-based - immunotherapy have been approved in combination with conventional therapeutics. - Approved targeted chemotherapy is directed against the kinase domains of mutated - cellular receptors such as epidermal growth factor receptor (EGFR), anaplastic - lymphoma kinases (ALK), neurotrophic receptor kinases (NTRK) and against - downstream signaling molecules such as BRAF (v-raf murine sarcoma viral oncogene - homolog B1). Approved biologically targeted therapy involves the use of - anti-angiogenesis antibodies and antibodies against immune checkpoints. AREAS - COVERED: The rationale for the employment of targeted therapeutics and the - resistance that may develop to therapy are discussed. Novel targeted therapeutics - in clinical trials are also included. EXPERT OPINION: Molecular and histological - profiling of a given tumor specimen to determine the aberrant onco-driver is a - must before deciding a targeted therapeutic regimen for the patient. Periodic - monitoring of the patients response to a given therapeutic regimen is also - mandatory so that any semblance of resistance to therapy can be deciphered and - the regimen may be accordingly altered. -FAU - Upadhya, Archana -AU - Upadhya A -AD - Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S - NMIMS , Mumbai, Maharashtra, India. -FAU - Yadav, Khushwant S -AU - Yadav KS -AD - Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S - NMIMS , Mumbai, Maharashtra, India. -FAU - Misra, Ambikanandan -AU - Misra A -AD - Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S - NMIMS , Mumbai, Maharashtra, India. -LA - eng -PT - Journal Article -DEP - 20200929 -PL - England -TA - Expert Opin Drug Deliv -JT - Expert opinion on drug delivery -JID - 101228421 -SB - IM -MH - Animals -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -MH - Mice -MH - Molecular Targeted Therapy -OTO - NOTNLM -OT - Non-small cell lung cancer -OT - immunotherapy -OT - resistance -OT - targeted therapy -OT - therapeutics in clinics -EDAT- 2020/09/22 06:00 -MHDA- 2021/06/04 06:00 -CRDT- 2020/09/21 08:40 -PHST- 2020/09/22 06:00 [pubmed] -PHST- 2021/06/04 06:00 [medline] -PHST- 2020/09/21 08:40 [entrez] -AID - 10.1080/17425247.2021.1825377 [doi] -PST - ppublish -SO - Expert Opin Drug Deliv. 2021 Jan;18(1):73-102. doi: - 10.1080/17425247.2021.1825377. Epub 2020 Sep 29. - -PMID- 30977778 -OWN - NLM -STAT- MEDLINE -DCOM- 20200623 -LR - 20240229 -IS - 1569-8041 (Electronic) -IS - 0923-7534 (Linking) -VI - 30 -IP - 7 -DP - 2019 Jul 1 -TI - Hyperprogressive disease during PD-1/PD-L1 blockade in patients with - non-small-cell lung cancer. -PG - 1104-1113 -LID - S0923-7534(19)31231-1 [pii] -LID - 10.1093/annonc/mdz123 [doi] -AB - BACKGROUND: Immune checkpoint blockade with Programmed cell death 1 (PD-1)/PD-L1 - inhibitors has been effective in various malignancies and is considered as a - standard treatment modality for patients with non-small-cell lung cancer (NSCLC). - However, emerging evidence show that PD-1/PD-L1 blockade can lead to - hyperprogressive disease (HPD), a flair-up of tumor growth linked to dismal - prognosis. This study aimed to evaluate the incidence of HPD and identify the - determinants associated with HPD in patients with NSCLC treated with PD-1/PD-L1 - blockade. PATIENTS AND METHODS: We enrolled patients with recurrent and/or - metastatic NSCLC treated with PD-1/PD-L1 inhibitors between April 2014 and - November 2018. Clinicopathologic variables, dynamics of tumor growth, and - treatment outcomes were analyzed in patients with NSCLC who received PD-1/PD-L1 - blockade. HPD was defined according to tumor growth kinetics (TGK), tumor growth - rate (TGR), and time to treatment failure (TTF). Immunophenotyping of peripheral - blood CD8+ T lymphocytes was conducted to explore the potential predictive - biomarkers of HPD. RESULTS: A total of 263 patients were analyzed. HPD was - observed in 55 (20.9%), 54 (20.5%), and 98 (37.3%) patients according to the TGK, - TGR, and TTF. HPD meeting both TGK and TGR criteria was associated with worse - progression-free survival [hazard ratio (HR) 4.619; 95% confidence interval (CI) - 2.868-7.440] and overall survival (HR, 5.079; 95% CI, 3.136-8.226) than - progressive disease without HPD. There were no clinicopathologic variables - specific for HPD. In the exploratory biomarker analysis with peripheral blood - CD8+ T lymphocytes, a lower frequency of effector/memory subsets (CCR7-CD45RA- T - cells among the total CD8+ T cells) and a higher frequency of severely exhausted - populations (TIGIT+ T cells among PD-1+CD8+ T cells) were associated with HPD and - inferior survival rate. CONCLUSION: HPD is common in NSCLC patients treated with - PD-1/PD-L1 inhibitors. Biomarkers derived from rationally designed analysis may - successfully predict HPD and worse outcomes, meriting further investigation of - HPD. -CI - © The Author(s) 2019. Published by Oxford University Press on behalf of the - European Society for Medical Oncology. All rights reserved. For permissions, - please email: journals.permissions@oup.com. -FAU - Kim, C G -AU - Kim CG -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon; Division of Medical Oncology, Department of - Internal Medicine. -FAU - Kim, K H -AU - Kim KH -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon; Department of Radiation Oncology, Yonsei Cancer - Center, Yonsei University College of Medicine, Seoul. -FAU - Pyo, K-H -AU - Pyo KH -AD - Division of Medical Oncology, Department of Internal Medicine; JE-UK Institute - for Cancer Research, JEUK Co. Ltd, Gumi. -FAU - Xin, C-F -AU - Xin CF -AD - JE-UK Institute for Cancer Research, JEUK Co. Ltd, Gumi. -FAU - Hong, M H -AU - Hong MH -AD - Division of Medical Oncology, Department of Internal Medicine. -FAU - Ahn, B-C -AU - Ahn BC -AD - Division of Medical Oncology, Department of Internal Medicine. -FAU - Kim, Y -AU - Kim Y -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon. -FAU - Choi, S J -AU - Choi SJ -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon. -FAU - Yoon, H I -AU - Yoon HI -AD - Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College - of Medicine, Seoul. -FAU - Lee, J G -AU - Lee JG -AD - Department of Thoracic and Cardiovascular Surgery. -FAU - Lee, C Y -AU - Lee CY -AD - Department of Thoracic and Cardiovascular Surgery. -FAU - Park, S Y -AU - Park SY -AD - Department of Thoracic and Cardiovascular Surgery. -FAU - Park, S-H -AU - Park SH -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon. -FAU - Cho, B C -AU - Cho BC -AD - Division of Medical Oncology, Department of Internal Medicine. -FAU - Shim, H S -AU - Shim HS -AD - Department of Pathology, Severance Hospital, Yonsei University College of - Medicine, Seoul, Republic of Korea. Electronic address: shimhs@yuhs.ac. -FAU - Shin, E-C -AU - Shin EC -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon. Electronic address: ecshin@kaist.ac.kr. -FAU - Kim, H R -AU - Kim HR -AD - Division of Medical Oncology, Department of Internal Medicine. Electronic - address: nobelg@yuhs.ac. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - England -TA - Ann Oncol -JT - Annals of oncology : official journal of the European Society for Medical - Oncology -JID - 9007735 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -CIN - Ann Oncol. 2019 Jul 1;30(7):1028-1031. doi: 10.1093/annonc/mdz184. PMID: 31173063 -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - CD8-Positive T-Lymphocytes/immunology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/*pathology -MH - Disease Progression -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Lung Neoplasms/*drug therapy/immunology/*pathology -MH - Lymphatic Metastasis -MH - Lymphocytes, Tumor-Infiltrating/immunology -MH - Male -MH - Middle Aged -MH - Neoplasm Metastasis -MH - Neoplasm Recurrence, Local/drug therapy/immunology/pathology -MH - Prognosis -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -MH - Survival Rate -MH - Tumor Burden -OTO - NOTNLM -OT - NSCLC -OT - PD-1/PD-L1 blockade -OT - biomarkers -OT - hyperprogressive disease -OT - tumor growth dynamics -EDAT- 2019/04/13 06:00 -MHDA- 2020/06/24 06:00 -CRDT- 2019/04/13 06:00 -PHST- 2019/04/13 06:00 [pubmed] -PHST- 2020/06/24 06:00 [medline] -PHST- 2019/04/13 06:00 [entrez] -AID - S0923-7534(19)31231-1 [pii] -AID - 10.1093/annonc/mdz123 [doi] -PST - ppublish -SO - Ann Oncol. 2019 Jul 1;30(7):1104-1113. doi: 10.1093/annonc/mdz123. - -PMID- 34421093 -OWN - NLM -STAT- MEDLINE -DCOM- 20220112 -LR - 20220112 -IS - 1881-2090 (Electronic) -IS - 0023-5679 (Linking) -VI - 66 -IP - 3 -DP - 2021 Oct 6 -TI - Phase I Study of Carboplatin Plus Pemetrexed with Concurrent Radiotherapy for - Locally Advanced Non-Squamous NSCLC (CJLSG0912). -PG - 139-143 -LID - 10.2739/kurumemedj.MS663002 [doi] -AB - Although concurrent chemoradiotherapy is the standard therapy for unresectable - stage III non-small cell lung cancer (NSCLC), no optimal concurrent - chemoradiotherapy regimen has been identified in non-squamous NSCLC. We conducted - an open-label, multicenter phase I trial to assess the safety of carboplatin - (CBDCA) plus pemetrexed (PEM) with concurrent thoracic radiotherapy (TRT) of 60 - Gy. The primary endpoint was determination of the maximum tolerated dose. In - total, 6 patients were registered during the period from February 2012 through - January 2014. Dose-limiting toxicities (DLTs) were observed in 2 patients (one - case each of prolonged neutropenia and pneumonitis). The overall response rate - was 83.3%, and median progression-free survival was 20.1 months. Since only two - DLTs were observed in the phase I cohort, we concluded that CBDCA plus PEM with - concurrent TRT was feasible in Japanese patients with unresectable stage III - non-squamous NSCLCs. We will recommend the dose of CBDCA area under the curve 5 - plus PEM 500 mg/m(2) for the next phase II trial. -FAU - Murata, Naohiko -AU - Murata N -AD - Department of Respiratory Medicine, National Hospital Organization Nagoya Medical - Center. -AD - Department of Respiratory Medicine, Japanese Red Cross Aichi Medical Center - Nagoya Daini Hospital. -FAU - Kogure, Yoshihito -AU - Kogure Y -AD - Department of Respiratory Medicine, National Hospital Organization Nagoya Medical - Center. -AD - Department of Medical Oncology, National Hospital Organization Nagoya Medical - Center. -FAU - Kondo, Masashi -AU - Kondo M -AD - Department of Respiratory Medicine, Fujita Medical University. -FAU - Kitagawa, Chiyoe -AU - Kitagawa C -AD - Department of Respiratory Medicine, National Hospital Organization Nagoya Medical - Center. -AD - Department of Medical Oncology, National Hospital Organization Nagoya Medical - Center. -FAU - Saka, Hideo -AU - Saka H -AD - Department of Respiratory Medicine, National Hospital Organization Nagoya Medical - Center. -AD - Department of Respiratory Medicine, Matsunami General Hospital. -LA - eng -PT - Clinical Trial, Phase I -PT - Journal Article -PT - Multicenter Study -DEP - 20210820 -PL - Japan -TA - Kurume Med J -JT - The Kurume medical journal -JID - 2985210R -RN - 0 (Antineoplastic Agents) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 04Q9AIZ7NO (Pemetrexed) -RN - BG3F62OND5 (Carboplatin) -SB - IM -MH - Adult -MH - Aged -MH - Antineoplastic Agents -MH - Carboplatin/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/epidemiology/*radiotherapy -MH - Chemoradiotherapy/*methods -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Japan/epidemiology -MH - Lung Neoplasms/drug therapy -MH - Male -MH - Middle Aged -MH - Pemetrexed/*therapeutic use -OTO - NOTNLM -OT - carboplatin -OT - concurrent radiation -OT - non-squamous NSCLC -OT - pemetrexed -OT - thoracic radiotherapy -EDAT- 2021/08/24 06:00 -MHDA- 2022/01/13 06:00 -CRDT- 2021/08/23 06:17 -PHST- 2021/08/24 06:00 [pubmed] -PHST- 2022/01/13 06:00 [medline] -PHST- 2021/08/23 06:17 [entrez] -AID - 10.2739/kurumemedj.MS663002 [doi] -PST - ppublish -SO - Kurume Med J. 2021 Oct 6;66(3):139-143. doi: 10.2739/kurumemedj.MS663002. Epub - 2021 Aug 20. - -PMID- 32944393 -OWN - NLM -STAT- MEDLINE -DCOM- 20211129 -LR - 20240322 -IS - 2095-3941 (Print) -IS - 2095-3941 (Linking) -VI - 17 -IP - 3 -DP - 2020 Aug 15 -TI - The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in - non-small cell lung cancer patients. -PG - 599-611 -LID - 10.20892/j.issn.2095-3941.2020.0102 [doi] -AB - Immune checkpoint inhibitors (ICIs) are new and promising therapeutic agents for - non-small cell lung cancer (NSCLC). However, along with demonstrating remarkable - efficacy, ICIs can also trigger immune-related adverse events. Checkpoint - inhibitor pneumonitis (CIP) has been reported to have a morbidity rate of 3% to - 5% and a mortality rate of 10% to 17%. Moreover, the incidence of CIP in NSCLC is - higher than that in other tumor types, reaching 7% to 13%. With the increased use - of ICIs in NSCLC, CIP has drawn extensive attention from oncologists and cancer - researchers. Identifying high risk factors for CIP and the potential mechanism of - CIP are key points in preventing and monitoring serious adverse events. In this - review, the results of our analysis and summary of previous studies suggested - that the risk factors for CIP may include previous lung disease, prior thoracic - irradiation, and combinations with other drugs. Our review also explored - potential mechanisms closely related to CIP, including increased T cell activity - against associated antigens in tumor and normal tissues, preexisting - autoantibodies, and inflammatory cytokines. -CI - Copyright: © 2020, Cancer Biology & Medicine. -FAU - Zhai, Xiaoyang -AU - Zhai X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan - 250117, China. -FAU - Zhang, Jian -AU - Zhang J -AD - Department of Thoracic Surgery, Shandong Cancer Hospital and Institute, Shandong - First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, - China. -FAU - Tian, Yaru -AU - Tian Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan - 250117, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute - affiliated with Shandong University, Jinan 250012, China. -FAU - Li, Ji -AU - Li J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan - 250117, China. -FAU - Jing, Wang -AU - Jing W -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan - 250117, China. -FAU - Guo, Hongbo -AU - Guo H -AD - Department of Thoracic Surgery, Shandong Cancer Hospital and Institute, Shandong - First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, - China. -FAU - Zhu, Hui -AU - Zhu H -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan - 250117, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - China -TA - Cancer Biol Med -JT - Cancer biology & medicine -JID - 101588850 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Immune Checkpoint Inhibitors) -CIN - Front Immunol. 2024 Feb 15;15:1266850. doi: 10.3389/fimmu.2024.1266850. PMID: - 38426102 -MH - Antineoplastic Agents, Immunological/*adverse effects -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/pathology -MH - Humans -MH - Immune Checkpoint Inhibitors/*adverse effects -MH - Lung Neoplasms/*drug therapy/immunology/pathology -MH - Pneumonia/chemically induced/*epidemiology -MH - Risk Factors -PMC - PMC7476083 -OTO - NOTNLM -OT - Immune checkpoint inhibitor -OT - non-small-cell lung cancer -OT - pneumonitis -OT - risk factors -COIS- *These authors contributed equally to this work. -EDAT- 2020/09/19 06:00 -MHDA- 2020/09/19 06:01 -PMCR- 2020/08/15 -CRDT- 2020/09/18 05:51 -PHST- 2020/03/30 00:00 [received] -PHST- 2020/05/27 00:00 [accepted] -PHST- 2020/09/18 05:51 [entrez] -PHST- 2020/09/19 06:00 [pubmed] -PHST- 2020/09/19 06:01 [medline] -PHST- 2020/08/15 00:00 [pmc-release] -AID - j.issn.2095-3941.2020.0102 [pii] -AID - 10.20892/j.issn.2095-3941.2020.0102 [doi] -PST - ppublish -SO - Cancer Biol Med. 2020 Aug 15;17(3):599-611. doi: - 10.20892/j.issn.2095-3941.2020.0102. - -PMID- 34729945 -OWN - NLM -STAT- MEDLINE -DCOM- 20220317 -LR - 20220317 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 10 -IP - 24 -DP - 2021 Dec -TI - HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell - lung cancer. -PG - 8808-8819 -LID - 10.1002/cam4.4381 [doi] -AB - BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is tyrosine kinase - receptor that belongs to the ErbB family and is overexpressed on the membrane - surface of various cancer cells, including small cell lung cancer (SCLC); - however, no HER2 targeted therapy for SCLC have yet been established. - Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy based on - photo-absorber, IRDye-700DX (IR700), -antibody conjugates, and near-infrared - (NIR) light. METHODS: We used HER2-positive SCLC parental cell lines (SBC-3) and - its chemoresistant cell lines, and examined therapeutic efficacy of HER2 - targeting NIR-PIT using anti HER2 antibody trastuzumab. RESULTS: We found that - HER2 expression was upregulated on chemoresistant cell lines, especially - cisplatin-resistance (SBC-3/CDDP). In vitro, the rate of cell death increased - with the amount of NIR-light irradiation, and it was significantly higher in - SBC-3/CDDP than in SBC-3. In vivo, tumor growth was more suppressed in SBC-3/CDDP - group than in SBC-3 group, and survival period tended to be prolonged. - CONCLUSION: In this study, we demonstrated that HER2 targeting NIR-PIT using - trastuzumab is promising therapy for HER2-positive SCLC, and is more effective - when HER2 expression is upregulated due to CDDP resistance, suggesting that the - HER2 expression level positively corelated with the efficacy of NIR-PIT. -CI - © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Takahashi, Kazuomi -AU - Takahashi K -AD - Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, - Japan. -FAU - Taki, Shunichi -AU - Taki S -AD - Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, - Japan. -FAU - Yasui, Hirotoshi -AU - Yasui H -AD - Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, - Japan. -FAU - Nishinaga, Yuko -AU - Nishinaga Y -AD - Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, - Japan. -FAU - Isobe, Yoshitaka -AU - Isobe Y -AD - Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, - Japan. -FAU - Matsui, Toshinori -AU - Matsui T -AD - Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, - Japan. -FAU - Shimizu, Misae -AU - Shimizu M -AD - B3 Unit, Advanced Analytical and Diagnostic Imaging Center (AADIC)/Medical - Engineering Unit (MEU), Nagoya University Institute for Advanced Research, - Nagoya, Japan. -FAU - Koike, Chiaki -AU - Koike C -AD - B3 Unit, Advanced Analytical and Diagnostic Imaging Center (AADIC)/Medical - Engineering Unit (MEU), Nagoya University Institute for Advanced Research, - Nagoya, Japan. -FAU - Sato, Kazuhide -AU - Sato K -AUID- ORCID: 0000-0003-3025-088X -AD - Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, - Japan. -AD - B3 Unit, Advanced Analytical and Diagnostic Imaging Center (AADIC)/Medical - Engineering Unit (MEU), Nagoya University Institute for Advanced Research, - Nagoya, Japan. -AD - JST, CREST, FOREST-Souhatsu, Tokyo, Japan. -AD - S-YLC, Nagoya University Institute for Advanced Research, Nagoya, Japan. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20211102 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - EC 2.7.10.1 (Erbb2 protein, mouse) -RN - EC 2.7.10.1 (Receptor, ErbB-2) -SB - IM -MH - Animals -MH - Cell Line, Tumor -MH - Female -MH - Humans -MH - Immunotherapy/*methods -MH - Lung Neoplasms/*drug therapy -MH - Mice -MH - Mice, Nude -MH - Phototherapy/*methods -MH - Receptor, ErbB-2/*metabolism -MH - Small Cell Lung Carcinoma/*drug therapy -MH - Xenograft Model Antitumor Assays -PMC - PMC8683547 -OTO - NOTNLM -OT - HER2 -OT - chemotherapy-resistant -OT - cisplatin -OT - near-infrared photoimmunotherapy -OT - small-cell lung cancer -COIS- The authors declare that they have no conflict of interest. -EDAT- 2021/11/04 06:00 -MHDA- 2022/03/18 06:00 -PMCR- 2021/11/02 -CRDT- 2021/11/03 07:24 -PHST- 2021/07/22 00:00 [revised] -PHST- 2021/05/26 00:00 [received] -PHST- 2021/07/23 00:00 [accepted] -PHST- 2021/11/04 06:00 [pubmed] -PHST- 2022/03/18 06:00 [medline] -PHST- 2021/11/03 07:24 [entrez] -PHST- 2021/11/02 00:00 [pmc-release] -AID - CAM44381 [pii] -AID - 10.1002/cam4.4381 [doi] -PST - ppublish -SO - Cancer Med. 2021 Dec;10(24):8808-8819. doi: 10.1002/cam4.4381. Epub 2021 Nov 2. - -PMID- 34337973 -OWN - NLM -STAT- MEDLINE -DCOM- 20220207 -LR - 20220207 -IS - 1744-8301 (Electronic) -IS - 1479-6694 (Linking) -VI - 17 -IP - 30 -DP - 2021 Oct -TI - Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging - evidence, controversies and future challenges. -PG - 4011-4025 -LID - 10.2217/fon-2020-1255 [doi] -AB - Lung cancer continues to be the leading cause of cancer mortality and a serious - health problem despite the numerous advances made in the last decade and the - rapid advance of research in this field. In recent years, there has been a - decrease in mortality from lung cancer coinciding with the approval times of - targeted therapy. To date, targeted therapy has been used in the context of - advanced disease in clinical practice, with great benefits in survival and - quality of life. The next step will be to incorporate targeted therapy into the - treatment of earlier stages of non-small-cell lung cancer, and there is already a - randomized trial showing a disease-free survival benefit. However, there are many - questions that need to be resolved first. In the present review, the authors - discuss the findings of published reports and ongoing clinical trials assessing - the role of targeted therapies in nonmetastatic disease. -FAU - Mielgo-Rubio, Xabier -AU - Mielgo-Rubio X -AUID- ORCID: 0000-0002-0985-6150 -AD - Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, - Budapest 1 Alcorcón, Madrid, 28922, Spain. -FAU - Martín, Margarita -AU - Martín M -AD - Department of Radiation Oncology, Ramón y Cajal University Hospital, M-607, km. - 9, 100, Madrid, 28034, Spain. -FAU - Remon, Jordi -AU - Remon J -AUID- ORCID: 0000-0002-9462-875X -AD - Department of Medical Oncology, Centro Integral Oncológico Clara Campal, Hospital - HM Delfos, HM Hospitales, Barcelona, Spain. -FAU - Higuera, Oliver -AU - Higuera O -AUID- ORCID: 0000-0002-6807-4511 -AD - Department of Medical Oncology, Hospital Universitario La Paz, Paseo de la - Castellana 261, Madrid, 28046, Spain. -FAU - Calvo, Virginia -AU - Calvo V -AUID- ORCID: 0000-0002-3503-4847 -AD - Department of Medical Oncology, Puerta de Hierro Hospital, Joaquín Rodrigo 1, - Majadahonda, Madrid, 28222, Spain. -FAU - Jarabo, José Ramón -AU - Jarabo JR -AUID- ORCID: 0000-0003-2125-0757 -AD - Department of Thoracic Surgery, Hospital Clínico San Carlos, Calle del Profesor - Martín Lagos, s/n, Madrid, 28040, Spain. -FAU - Conde, Esther -AU - Conde E -AUID- ORCID: 0000-0002-0914-0988 -AD - Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, 28041, - Spain. -FAU - Luna, Javier -AU - Luna J -AD - Department of Radiation Oncology, Fundación Jiménez Díaz, Oncohealth Institute, - Avda. Reyes Católicos 2, Madrid, 28040, Spain. -FAU - Provencio, Mariano -AU - Provencio M -AUID- ORCID: 0000-0001-6315-7919 -AD - Department of Medical Oncology, Puerta de Hierro Hospital, Joaquín Rodrigo 1, - Majadahonda, Madrid, 28222, Spain. -FAU - De Castro, Javier -AU - De Castro J -AUID- ORCID: 0000-0002-3622-6306 -AD - Department of Medical Oncology, Hospital Universitario La Paz, Paseo de la - Castellana 261, Madrid, 28046, Spain. -FAU - López-Ríos, Fernando -AU - López-Ríos F -AD - Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, 28041, - Spain. -FAU - Hernando-Trancho, Florentino -AU - Hernando-Trancho F -AUID- ORCID: 0000-0002-2296-0593 -AD - Department of Thoracic Surgery, Hospital Clínico San Carlos, Calle del Profesor - Martín Lagos, s/n, Madrid, 28040, Spain. -FAU - Couñago, Felipe -AU - Couñago F -AUID- ORCID: 0000-0001-7233-0234 -AD - Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, - Madrid, 28223, Spain. -AD - Department of Radiation Oncology, Hospital La Luz, Madrid, 28003, Spain. -AD - Medicine Department, School of Biomedical Sciences, Universidad Europea de - Madrid, Villaviciosa de Odón, 28670, Spain. -LA - eng -PT - Journal Article -PT - Review -DEP - 20210802 -PL - England -TA - Future Oncol -JT - Future oncology (London, England) -JID - 101256629 -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology -MH - Combined Modality Therapy -MH - ErbB Receptors/antagonists & inhibitors/genetics -MH - Humans -MH - Lung Neoplasms/*drug therapy/mortality/pathology -MH - *Molecular Targeted Therapy -MH - Mutation -MH - Neoplasm Staging -OAB - Lay abstract Despite major therapeutic advances over the last decade, lung cancer - continues to present the highest mortality rate of all cancers. Precision and - personalized therapy directed at specific alterations in the genetic material of - the tumor as well as immunotherapy has significantly improved survival in - metastatic non-small-cell lung cancer. The next step will be to incorporate - precision medicine into the treatment of earlier stages of non-small-cell lung - cancer. The recent publication of the results of the ADAURA phase III trial - showing a significant improvement in disease-free survival in patients with - resected EGFR-mutated non-small-cell lung cancer who received an adjuvant - EGFR-directed tyrosine kinase inhibitor called osimertinib has opened the doors - to the incorporation of this novel agent into routine clinical practice. However, - there are many questions that need to be resolved first. In the present review, - the authors discuss the findings of published reports and ongoing clinical trials - assessing the role of precision medicine in nonmetastatic disease. -OABL- eng -OTO - NOTNLM -OT - ALK -OT - EGFR -OT - NSCLC -OT - ROS1 -OT - adjuvant -OT - afatinib -OT - alectinib -OT - crizotinib -OT - early-stage -OT - erlotinib -OT - gefitinib -OT - localized NSCLC -OT - neoadjuvant -OT - non-small-cell lung cancer -OT - oncogenic driver -OT - osimertinib -OT - targeted therapy -EDAT- 2021/08/03 06:00 -MHDA- 2022/02/08 06:00 -CRDT- 2021/08/02 08:42 -PHST- 2021/08/03 06:00 [pubmed] -PHST- 2022/02/08 06:00 [medline] -PHST- 2021/08/02 08:42 [entrez] -AID - 10.2217/fon-2020-1255 [doi] -PST - ppublish -SO - Future Oncol. 2021 Oct;17(30):4011-4025. doi: 10.2217/fon-2020-1255. Epub 2021 - Aug 2. - -PMID- 38686383 -OWN - NLM -STAT- MEDLINE -DCOM- 20240430 -LR - 20240501 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 15 -DP - 2024 -TI - Development and validation of an MRI-Based nomogram to predict the effectiveness - of immunotherapy for brain metastasis in patients with non-small cell lung - cancer. -PG - 1373330 -LID - 10.3389/fimmu.2024.1373330 [doi] -LID - 1373330 -AB - INTRODUCTION: The variability and unpredictability of immune checkpoint - inhibitors (ICIs) in treating brain metastases (BMs) in patients with advanced - non-small cell lung cancer (NSCLC) is the main concern. We assessed the utility - of novel imaging biomarkers (radiomics) for discerning patients with NSCLC and - BMs who would derive advantages from ICIs treatment. METHODS: Data clinical - outcomes and pretreatment magnetic resonance images (MRI) were collected on - patients with NSCLC with BMs treated with ICIs between June 2019 and June 2022 - and divided into training and test sets. Metastatic brain lesions were contoured - using ITK-SNAP software, and 3748 radiomic features capturing both intra- and - peritumoral texture patterns were extracted. A clinical radiomic nomogram (CRN) - was built to evaluate intracranial progression-free survival, progression-free - survival, and overall survival. The prognostic value of the CRN was assessed by - Kaplan-Meier survival analysis and log-rank tests. RESULTS: In the study, a total - of 174 patients were included, and 122 and 52 were allocated to the training and - validation sets correspondingly. The intratumoral radiomic signature, peritumoral - radiomic signature, clinical signature, and CRN predicted intracranial objective - response rate. Kaplan-Meier analyses showed a significantly longer intracranial - progression-free survival in the low-CRN group than in the high-CRN group (p < - 0.001). The CRN was also significantly associated with progression-free survival - (p < 0.001) but not overall survival. DISCUSSION: Radiomics biomarkers from - pretreatment MRI images were predictive of intracranial response. Pretreatment - radiomics may allow the early prediction of benefits. -CI - Copyright © 2024 Xu, Wang, Li, Shi, Yin, Yu and Teng. -FAU - Xu, Junhao -AU - Xu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Wang, Peiliang -AU - Wang P -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Cheeloo - College of Medicine, Shandong University, Jinan, China. -FAU - Li, Yikun -AU - Li Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Shi, Xiaonan -AU - Shi X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Yin, Tianwen -AU - Yin T -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, China. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Teng, Feifei -AU - Teng F -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Validation Study -DEP - 20240415 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/diagnostic imaging/therapy/pathology -MH - *Brain Neoplasms/secondary/diagnostic imaging/therapy -MH - *Magnetic Resonance Imaging/methods -MH - Male -MH - *Lung Neoplasms/diagnostic imaging/pathology/therapy/mortality -MH - Female -MH - *Nomograms -MH - Middle Aged -MH - Aged -MH - *Immunotherapy/methods -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Prognosis -MH - Treatment Outcome -MH - Adult -PMC - PMC11057328 -OTO - NOTNLM -OT - MRI -OT - brain metastasis -OT - immunotherapy -OT - non-small cell lung cancer -OT - radiomics -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2024/04/30 06:45 -MHDA- 2024/04/30 06:46 -PMCR- 2024/01/01 -CRDT- 2024/04/30 03:42 -PHST- 2024/01/19 00:00 [received] -PHST- 2024/04/03 00:00 [accepted] -PHST- 2024/04/30 06:46 [medline] -PHST- 2024/04/30 06:45 [pubmed] -PHST- 2024/04/30 03:42 [entrez] -PHST- 2024/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2024.1373330 [doi] -PST - epublish -SO - Front Immunol. 2024 Apr 15;15:1373330. doi: 10.3389/fimmu.2024.1373330. - eCollection 2024. - -PMID- 38329610 -OWN - NLM -STAT- MEDLINE -DCOM- 20240614 -LR - 20240627 -IS - 1699-3055 (Electronic) -IS - 1699-048X (Linking) -VI - 26 -IP - 7 -DP - 2024 Jul -TI - Real-world evaluation of first-line treatment of extensive-stage small-cell lung - cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain - metastasis. -PG - 1664-1673 -LID - 10.1007/s12094-024-03387-7 [doi] -AB - PURPOSE: A previous real-world study conducted in China confirmed that first-line - atezolizumab, in combination with etoposide/platinum (EP), leads to significantly - longer progression-free survival (PFS) compared to EP alone in patients with - extensive-stage small-cell lung cancer (ES-SCLC). The present study aimed to - provide updated survival outcome data and evaluate the clinical efficacy of - atezolizumab plus chemotherapy in ES-SCLC patients with brain metastasis (BM). - METHODS: This retrospective study included 225 patients with ES-SCLC who were - treated with EP alone (EP group) or a combination of EP + atezolizumab - (atezolizumab group). Survival outcomes for the total study sample and patients - in the BM subgroup were estimated using the Kaplan-Meier method. RESULTS: The - atezolizumab group continued to demonstrate significantly longer PFS than the EP - group (hazard ratio [HR], 0.68). The median overall survival (OS) was 26.2 months - in the atezolizumab group vs. 14.8 months in the EP group (HR, 0.63). - Additionally, among the BM patients in our study, the median PFS was found to be - longer in the atezolizumab group (7.0 months) than in the EP group (4.1 months) - (HR, 0.46). The OS of the BM patients did not differ significantly between the - two treatment groups. CONCLUSIONS: The addition of atezolizumab to EP as a - first-line treatment for ES-SCLC was found to improve survival outcomes. This - treatment combination may also prolong PFS in patients with BM, regardless of the - administration of cranial irradiation. However, among the BM patients in our - study, there was no significant difference in OS between the two treatment - groups. -CI - © 2024. The Author(s), under exclusive licence to Federación de Sociedades - Españolas de Oncología (FESEO). -FAU - Chen, Hanxiao -AU - Chen H -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer - Hospital & Institute, Beijing, China. -FAU - Ma, Xiangjuan -AU - Ma X -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department II of Thoracic Oncology, Peking University Cancer - Hospital & Institute, Beijing, China. -FAU - Liu, Jie -AU - Liu J -AD - Cancer Center, Shandong Public Health Clinical Center, Public Health Clinical - Center Affiliated to Shandong University, Shandong University, Jinan, China. -FAU - Yang, Yu -AU - Yang Y -AD - Department of Oncology, The 2nd Affiliated Hospital of Harbin Medical University, - Harbin, China. -FAU - He, Yanhui -AU - He Y -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer - Hospital & Institute, Beijing, China. -FAU - Fang, Yong -AU - Fang Y -AD - Department of Oncology, Sir Run Run Shaw Hospital Zhejiang University School of - Medicine, Hangzhou, China. -FAU - Wang, Liping -AU - Wang L -AD - Department of Oncology, Baotou Cancer Hospital, Baotou, China. -FAU - Fang, Jian -AU - Fang J -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department II of Thoracic Oncology, Peking University Cancer - Hospital & Institute, Beijing, China. fangjian5555@163.com. -FAU - Zhao, Jun -AU - Zhao J -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer - Hospital & Institute, Beijing, China. ohjerry@163.com. -FAU - Zhuo, Minglei -AU - Zhuo M -AUID- ORCID: 0000-0003-2489-7791 -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer - Hospital & Institute, Beijing, China. zhuominglei@bjmu.edu.cn. -LA - eng -GR - 82141117/National Natural Science Foundation of China/ -GR - 2022-2-1023/The Capital's Funds for Health Improvement and Research/ -GR - PX2020045/The Beijing Municipal Administration of Hospitals Incubating Program/ -GR - 320.6750.2021-16-19/Wu Jieping Medical Foundation/ -GR - QNJJ2022012/Clinical Research Fund for Distinguished Young Scholars of Beijing - Cancer Hospital/ -GR - 1-35/Guangzhou Life oasis public service center Research and exchange program in - the field of health/ -PT - Journal Article -DEP - 20240208 -PL - Italy -TA - Clin Transl Oncol -JT - Clinical & translational oncology : official publication of the Federation of - Spanish Oncology Societies and of the National Cancer Institute of Mexico -JID - 101247119 -RN - 52CMI0WC3Y (atezolizumab) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 6PLQ3CP4P3 (Etoposide) -RN - Q20Q21Q62J (Cisplatin) -SB - IM -MH - Humans -MH - *Antibodies, Monoclonal, Humanized/therapeutic use/administration & dosage -MH - Male -MH - *Etoposide/administration & dosage/therapeutic use -MH - Retrospective Studies -MH - *Small Cell Lung Carcinoma/drug therapy/pathology/mortality -MH - *Brain Neoplasms/secondary/drug therapy/mortality -MH - Female -MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Middle Aged -MH - *Lung Neoplasms/drug therapy/pathology/mortality -MH - Aged -MH - Adult -MH - Progression-Free Survival -MH - Kaplan-Meier Estimate -MH - Cisplatin/administration & dosage/therapeutic use -MH - Survival Rate -MH - Aged, 80 and over -OTO - NOTNLM -OT - Brain metastases -OT - Extensive-stage SCLC -OT - Immunotherapy -OT - Real-world study -EDAT- 2024/02/08 12:42 -MHDA- 2024/06/14 12:43 -CRDT- 2024/02/08 11:13 -PHST- 2023/11/07 00:00 [received] -PHST- 2024/01/06 00:00 [accepted] -PHST- 2024/06/14 12:43 [medline] -PHST- 2024/02/08 12:42 [pubmed] -PHST- 2024/02/08 11:13 [entrez] -AID - 10.1007/s12094-024-03387-7 [pii] -AID - 10.1007/s12094-024-03387-7 [doi] -PST - ppublish -SO - Clin Transl Oncol. 2024 Jul;26(7):1664-1673. doi: 10.1007/s12094-024-03387-7. - Epub 2024 Feb 8. - -PMID- 36218023 -OWN - NLM -STAT- MEDLINE -DCOM- 20221205 -LR - 20230106 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 13 -IP - 23 -DP - 2022 Dec -TI - Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell - lung cancer based on real-world practice. -PG - 3295-3303 -LID - 10.1111/1759-7714.14684 [doi] -AB - BACKGROUND: The application of immune checkpoint inhibitors (ICIs) represents a - breakthrough in the current landscape for the treatment of extensive-stage - small-cell lung cancer (ES-SCLC), but the real-world outcome is limited. This - study aimed to investigate the treatment options and efficacy evaluation of - first-line, second-line, and subsequent-line immunotherapy in routine practice. - METHODS: A retrospective analysis of ES-SCLC patients treated with ICIs was - conducted between May 2016 and September 2021. Objective response rate, disease - control rate, progression-free survival (PFS) and overall survival were assessed - between groups to explore the value of ICIs at different treatment time periods. - PFS1 and PFS2 were defined as the duration from initial therapy to disease - progression or death in first-line or second-line treatment. RESULTS: Ninety-six - patients with ES-SCLC were included. PFS1 was prolonged in patients treated with - first-line ICIs-combined therapy (median PFS1 7.20 months vs. 5.30 months, hazard - ratio [HR] 0.55, 95% confidence interval [CI] 0.36-087, p = 0.0085). For patients - who progressed after first-line ICIs treatment (N = 22), PFS1 + PFS2 was longer - in the second-line ICIs continuation group with no significant difference (median - PFS1 + PFS2 11.27 months vs. 7.20 months, HR 0.45, 95% CI 0.14-1.51, p = 0.19). - For patients who experienced a progression event after first-line chemotherapy - (N = 50), PFS2 and PFS1 + PFS2 were prolonged in patients who accepted - second-line ICIs-combined therapy without significant difference (median PFS2 - 4.00 months vs. 2.43 months, HR 0.59, 95% CI 0.33-1.05, p = 0.070; median - PFS1 + PFS2 11.30 months vs. 8.70 months, HR 0.53, 95% CI 0.29-0.98, p = 0.056). - CONCLUSION: First-line ICIs plus chemotherapy should be applied in the clinical - practice of ES-SCLC. If patients did not receive ICIs plus chemotherapy in - first-line treatment, therapies that include ICIs in second-line treatment should - be considered. -CI - © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Yang, Yaning -AU - Yang Y -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, China. -FAU - Ai, Xin -AU - Ai X -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, China. -FAU - Xu, Haiyan -AU - Xu H -AUID- ORCID: 0000-0002-0048-3191 -AD - Department of Comprehensive Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Yang, Guangjian -AU - Yang G -AD - Department of Respiratory Medicine, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Yang, Lu -AU - Yang L -AUID- ORCID: 0000-0002-4286-9586 -AD - Department of Medical Oncology and Radiation Sickness, Peking University Third - Hospital, Beijing, China. -FAU - Hao, Xuezhi -AU - Hao X -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, China. -FAU - Yang, Ke -AU - Yang K -AD - Department of Medical Oncology, Cancer Hospital of Huanxing, Beijing, China. -FAU - Mi, Yuling -AU - Mi Y -AD - Department of Medical Oncology, Chaoyang Sanhuan Cancer Hospital, Beijing, China. -FAU - Wang, Guizhen -AU - Wang G -AD - State Key Laboratory of Molecular Oncology, National Cancer Center/National - Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical - Sciences and Peking Union Medical College, Beijing, China. -FAU - Zhang, Shuyang -AU - Zhang S -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, China. -FAU - Lei, Siyu -AU - Lei S -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, China. -FAU - Wang, Yan -AU - Wang Y -AUID- ORCID: 0000-0002-1743-6383 -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, China. -LA - eng -PT - Journal Article -DEP - 20221011 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Retrospective Studies -MH - *Small Cell Lung Carcinoma/drug therapy -MH - Immunotherapy -PMC - PMC9715773 -OTO - NOTNLM -OT - immunotherapy -OT - prognostication -OT - small-cell lung carcinoma -OT - survival -COIS- The authors declare that they have no conflict of interest. -EDAT- 2022/10/12 06:00 -MHDA- 2022/12/06 06:00 -PMCR- 2022/12/01 -CRDT- 2022/10/11 05:56 -PHST- 2022/09/22 00:00 [revised] -PHST- 2022/08/23 00:00 [received] -PHST- 2022/09/23 00:00 [accepted] -PHST- 2022/10/12 06:00 [pubmed] -PHST- 2022/12/06 06:00 [medline] -PHST- 2022/10/11 05:56 [entrez] -PHST- 2022/12/01 00:00 [pmc-release] -AID - TCA14684 [pii] -AID - 10.1111/1759-7714.14684 [doi] -PST - ppublish -SO - Thorac Cancer. 2022 Dec;13(23):3295-3303. doi: 10.1111/1759-7714.14684. Epub 2022 - Oct 11. - -PMID- 38072729 -OWN - NLM -STAT- MEDLINE -DCOM- 20240301 -LR - 20240410 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 25 -IP - 2 -DP - 2024 Mar -TI - A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line - Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) - Patients. -PG - e101-e111.e2 -LID - S1525-7304(23)00252-8 [pii] -LID - 10.1016/j.cllc.2023.11.009 [doi] -AB - BACKGROUND: First-line chemotherapy plus immunotherapy (CT-IO) has recently - demonstrated survival benefits over CT alone in extensive-stage small-cell lung - cancer (ES-SCLC), based on randomized phase III studies. This retrospective - multicenter study assessed the real-world use and effectiveness of CT-IO in - ES-SCLC patients. PATIENTS AND METHODS: All newly diagnosed ES-SCLC patients from - 4 French hospitals treated with CT alone or CT-IO between May 2020 and December - 2021 were included. Overall survival (OS) and real-world progression-free - survival (rwPFS) were estimated using the Kaplan-Meier method. Cox proportional - hazard models were performed to estimate hazard ratios (HRs) with 95 % confidence - intervals (CIs) in univariate and multivariate models. The aim was not to compare - efficacy between groups. RESULTS: Among 104 patients, 75 (72.1%) received CT-IO. - Brain metastases were diagnosed in 28.3% of patients, and 29.8% were performance - status (PS) ≥ 2. At a median follow-up of 16.8 months (95%CI, 14.9-23.4), the - median OS was 11.4 months (95%CI, 7.7-14.7) in the CT-IO group, and the 12-month - OS rate was 43.6% (95%CI, 33.3-57.2). In the CT group, the median OS was 7.8 - months (95%CI, 5.4-11.8) and the 12-month OS rate was 15.3% (95%CI, 5.7-41.0). In - multivariate analyses, baseline brain and liver metastases were associated with a - shorter OS for patients treated in the CT-IO group (HR, 3.80 [95%CI, 1.90-7.60] - and 3.12 [95%CI, 1.60-6.08] respectively; P < 0.001 for both). CONCLUSION: We - showed that clinicians have chosen to use IO beyond the specific criteria defined - in guidelines. Survival data appeared promising with a median OS comparable to - the one previously demonstrated in clinical trials. -CI - Copyright © 2023 Elsevier Inc. All rights reserved. -FAU - Porte, Marie -AU - Porte M -AD - Department of Medical Oncology, Centre Hospitalier Universitaire Nantes, Nantes - University, Nantes, France. -FAU - Vaudron, Adrien -AU - Vaudron A -AD - Nantes Université, CHU Nantes, Pôle Hospitalo-Universitaire 11: Santé Publique, - Clinique des données, INSERM, Nantes, France. -FAU - Crequit, Perrine -AU - Crequit P -AD - Department of Medical Oncology, Hospital Foch, Suresnes, France. -FAU - Vaugier, Loig -AU - Vaugier L -AD - Department of Radiotherapy, Comprehensive Cancer Center, Institut de Cancérologie - de l'Ouest, Saint-Herblain, France. -FAU - Chatellier, Thierry -AU - Chatellier T -AD - Medical Oncology Unit, Clinique Mutualiste de l'Estuaire, Saint-Nazaire, France. -FAU - Fronteau, Clémentine -AU - Fronteau C -AD - Clinical Pharmacy Unit, Nantes University Hospital, Nantes, France. -FAU - Raimbourg, Judith -AU - Raimbourg J -AD - Department of Medical Oncology, Comprehensive Cancer Center, Institut de - Cancérologie de l'Ouest, Saint-Herblain, France; Nantes Université, Inserm UMR - 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France. -FAU - Goronflot, Thomas -AU - Goronflot T -AD - Nantes Université, CHU Nantes, Pôle Hospitalo-Universitaire 11: Santé Publique, - Clinique des données, INSERM, Nantes, France. -FAU - Bennouna, Jaafar -AU - Bennouna J -AD - Department of Medical Oncology, Hospital Foch, Suresnes, France. -FAU - Pons-Tostivint, Elvire -AU - Pons-Tostivint E -AD - Department of Medical Oncology, Centre Hospitalier Universitaire Nantes, Nantes - University, Nantes, France; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, - Université d'Angers, CRCI2NA, Nantes, France. Electronic address: - elvire.pons@chu-nantes.fr. -LA - eng -PT - Journal Article -PT - Multicenter Study -DEP - 20231123 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -SB - IM -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - *Small Cell Lung Carcinoma/drug therapy -MH - Brain -MH - *Brain Neoplasms -MH - Immunotherapy -OTO - NOTNLM -OT - Brain metastases -OT - Extensive stage small-cell lung cancer -OT - Immune checkpoint inhibitors -OT - Platinum-doublet chemotherapy -OT - Real-world study -EDAT- 2023/12/11 00:42 -MHDA- 2024/03/01 06:44 -CRDT- 2023/12/10 21:57 -PHST- 2023/08/04 00:00 [received] -PHST- 2023/10/31 00:00 [revised] -PHST- 2023/11/16 00:00 [accepted] -PHST- 2024/03/01 06:44 [medline] -PHST- 2023/12/11 00:42 [pubmed] -PHST- 2023/12/10 21:57 [entrez] -AID - S1525-7304(23)00252-8 [pii] -AID - 10.1016/j.cllc.2023.11.009 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2024 Mar;25(2):e101-e111.e2. doi: 10.1016/j.cllc.2023.11.009. - Epub 2023 Nov 23. - -PMID- 34161003 -OWN - NLM -STAT- MEDLINE -DCOM- 20210625 -LR - 20210625 -IS - 2101-017X (Electronic) -IS - 0035-2640 (Linking) -VI - 71 -IP - 4 -DP - 2021 Apr -TI - ["Treatment of lung cancer with immune checkpoints inhibitors"]. -PG - 385-390 -AB - "Treatment of lung cancer with immune checkpoints inhibitors .Immunotherapy has - considerably changed the treatment of lung cancer. Anti-PD-1 or anti-PD-L1, - either as monotherapy or in combination with chemotherapy, are now the - cornerstone of the treatment of metastatic non-small cell lung cancer and enable - some patients to achieve prolonged survival, sometimes without evidence of - residual disease. Durvalumab has improved the survival of patients after - treatment with chemo-radiotherapy for locally advanced NSCLC. The contribution of - anti-PD(L)-1 in combination with chemotherapy is more modest in small cell - cancers, although for the first time it has improved survival in extensive stage - of the disease. The next step will be to integrate checkpoint inhibitors into the - treatment of earlier forms of the disease." -FAU - Lamkhioued, Mehdi -AU - Lamkhioued M -AD - Département de cancérologie médicale, centre Léon-Bérard, Lyon, France. -FAU - Dupont, Margaux -AU - Dupont M -AD - Département de cancérologie médicale, centre Léon-Bérard, Lyon, France. -FAU - Leriche, Pauline -AU - Leriche P -AD - Département de cancérologie médicale, centre Léon-Bérard, Lyon, France. -FAU - Pérol, Maurice -AU - Pérol M -AD - Département de cancérologie médicale, centre Léon-Bérard, Lyon, France. -LA - fre -PT - Journal Article -TT - Traitement des cancers du poumon par les inhibiteurs du contrôle immunitaire. -PL - France -TA - Rev Prat -JT - La Revue du praticien -JID - 0404334 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -OTO - NOTNLM -OT - Immunotherapy -OT - Lung Neoplasms -COIS- "M. Dupont, M. Lamkhioued et P. Leriche déclarent n’avoir aucun lien - d’intérêts.M. Perol déclare des liens ponctuels avec Roche, Eli Lilly, Pfizer, - Boehringer Ingelheim, MSD, BMS, Novartis, AstraZeneca, Takeda, Gritstone, Sanofi, - Amgen, Chugai, Illumina." -EDAT- 2021/06/24 06:00 -MHDA- 2021/06/29 06:00 -CRDT- 2021/06/23 12:44 -PHST- 2021/06/23 12:44 [entrez] -PHST- 2021/06/24 06:00 [pubmed] -PHST- 2021/06/29 06:00 [medline] -PST - ppublish -SO - Rev Prat. 2021 Apr;71(4):385-390. - -PMID- 37682730 -OWN - NLM -STAT- MEDLINE -DCOM- 20240108 -LR - 20240311 -IS - 1097-0142 (Electronic) -IS - 0008-543X (Linking) -VI - 130 -IP - 1 -DP - 2024 Jan 1 -TI - Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing - brain metastases in patients with extensive-stage small cell lung cancer: A - retrospective analysis. -PG - 18-30 -LID - 10.1002/cncr.35003 [doi] -AB - BACKGROUND: Immunotherapy (IO) has demonstrated promising results in treating - extensive-stage small cell lung cancer (ES-SCLC), and the management of ES-SCLC - brain metastases (BMs) is now receiving significant clinical attention. The - objective of this study was to evaluate the role of IO in the clinical management - of BMs. METHODS: Between January 2020 and December 2021, the study included the - records of 250 patients who were diagnosed with ES-SCLC. Overall survival (OS), - progression-free survival, intracranial progression-free survival, and the - cumulative incidence of BMs were calculated using the Kaplan-Meier method and - were compared using the log-rank test. In addition, the Cox regression model was - used to analyze prognostic factors. RESULTS: In the entire group, 85 patients had - baseline BMs (IO plus chemotherapy [IO + ChT], n = 38; ChT alone, n = 47), and - 165 patients (IO + ChT, n = 86; ChT alone, n = 79) did not have BMs at the time - of initial diagnosis. The median follow-up was 22.4 months. The OS benefit with - first-line antiprogrammed death ligand 1 therapy was maintained regardless of - whether patients had BMs (with BMs, 17.97 vs. 13.14 months [p = .03]; without - BMs, 18.46 vs. 15.05 months [p = .047]). However, in patients without BMs, IO did - not delay the median time to developing brain progression (10.84 vs. - 10.74 months; p = .84), and it did not significantly reduce the risk of - developing intracranial metastases (the 2-year actuarial risk of developing BMs - was 57.0% vs. 50.6%, respectively). CONCLUSIONS: Antiprogrammed death ligand 1 - therapy improved OS regardless of the presence of BMs. However, IO did not delay - the median time to brain progression or reduce the risk of intracranial - metastasis in patients without baseline BMs. The findings of this study have - important clinical implications for the future management of BMs from ES-SCLC. -CI - © 2023 American Cancer Society. -FAU - Lu, Shuangqing -AU - Lu S -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong Province, China. -FAU - Guo, Xiaokang -AU - Guo X -AD - Department of Surgical Oncology, Shandong Cancer Hospital and Institute, Shandong - First Medical University and Shandong Academy of Medical Sciences, Jinan, - Shandong Province, China. -FAU - Li, Yuying -AU - Li Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong Province, China. -FAU - Liu, Haoyu -AU - Liu H -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong Province, China. -FAU - Zhang, Yan -AU - Zhang Y -AD - Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong - First Medical University and Shandong Academy of Medical Sciences, Jinan, - Shandong Province, China. -FAU - Zhu, Hui -AU - Zhu H -AUID- ORCID: 0000-0001-9422-3886 -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong Province, China. -LA - eng -GR - 81972861/National Natural Science Foundation of China/ -GR - Y-2019AZZD-0352/Chinese Society for Clinical Oncology Pilot Cancer Research Fund/ -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20230908 -PL - United States -TA - Cancer -JT - Cancer -JID - 0374236 -RN - 0 (Ligands) -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/drug therapy -MH - *Lung Neoplasms/pathology -MH - Retrospective Studies -MH - Ligands -MH - *Brain Neoplasms/secondary -OTO - NOTNLM -OT - brain metastases (BMs) -OT - chemotherapy (ChT) -OT - disease progression pattern -OT - extensive-stage small cell lung cancer (ES-SCLC) -OT - immunotherapy (IO) -OT - programmed death ligand 1 (PD-L1) checkpoint inhibitors -EDAT- 2023/09/08 18:42 -MHDA- 2024/01/08 06:43 -CRDT- 2023/09/08 12:53 -PHST- 2023/07/21 00:00 [revised] -PHST- 2023/04/06 00:00 [received] -PHST- 2023/08/03 00:00 [accepted] -PHST- 2024/01/08 06:43 [medline] -PHST- 2023/09/08 18:42 [pubmed] -PHST- 2023/09/08 12:53 [entrez] -AID - 10.1002/cncr.35003 [doi] -PST - ppublish -SO - Cancer. 2024 Jan 1;130(1):18-30. doi: 10.1002/cncr.35003. Epub 2023 Sep 8. - -PMID- 30693419 -OWN - NLM -STAT- MEDLINE -DCOM- 20200318 -LR - 20200318 -IS - 1865-8652 (Electronic) -IS - 0741-238X (Linking) -VI - 36 -IP - 3 -DP - 2019 Mar -TI - Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung - Cancer: Treatment Strategies to Improve Patient Outcomes. -PG - 563-578 -LID - 10.1007/s12325-019-0876-4 [doi] -AB - Stage III locally advanced non-small cell lung cancer (LA NSCLC) comprises the - most heterogeneous group of patients, accounts for one-third of patients with - lung cancer, and is unresectable at presentation. Multiple treatment approaches - have evolved over the past few decades focusing on timing of chemoradiation - (concurrent vs. sequential) and sequencing of therapy (induction vs. - consolidation). Concurrent chemoradiation (CCRT) emerged as the standard of care - for the majority of the patients worldwide. Despite improvements in median and - overall survival (OS) using the concurrent approach, the rate of distant failure - remains high. Consolidation with chemotherapy or targeted agents, adding more - radiation dose, or induction chemotherapy did not improve OS. With continued - research on defining optimal radiation doses and schedules and integrating novel - systemic agents, immunotherapy consolidation has renewed optimism. Synergistic - use of radiation and immunotherapy can prevent micrometastatic disease and reduce - local failure and may have an abscopal effect in addition to survival benefits. - The PACIFIC study reported an absolute progression-free survival benefit of - 11.2 months with durvalumab consolidation after standard CCRT compared with - placebo. The OS data with durvalumab consolidation are encouraging. Durvalumab is - the only approved immunotherapy for unresectable stage III LA NSCLC. Improved - survival confirms the definitive role of durvalumab as an effective adjuvant - therapy after CCRT with no new safety signals. However, the potential mechanisms - driving interaction between immunotherapy and chemoradiotherapy require - definitive investigation. These mechanisms may help define the timing of - immunotherapy initiation as neoadjuvant, adjuvant, or consolidation and - maintenance therapy after progression. FUNDING: AstraZeneca Pharma India Limited. -FAU - Rajappa, Senthil -AU - Rajappa S -AD - Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, - India. senthiljrajappa@gmail.com. -FAU - Sharma, Sanjiv -AU - Sharma S -AD - Manipal Hospitals, Bengaluru, India. -FAU - Prasad, Krishna -AU - Prasad K -AD - Mangalore Institute of Oncology, Mangalore, India. -LA - eng -SI - figshare/10.6084/m9.figshare.7577633 -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20190129 -PL - United States -TA - Adv Ther -JT - Advances in therapy -JID - 8611864 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/pathology/*therapy -MH - Chemoradiotherapy/*methods -MH - Female -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/pathology/*therapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Radiation Dosage -MH - Survival Analysis -OTO - NOTNLM -OT - Durvalumab -OT - Immunotherapy -OT - Stage III LA NSCLC -OT - Survival benefit -OT - Unresectable -EDAT- 2019/01/30 06:00 -MHDA- 2020/03/19 06:00 -CRDT- 2019/01/30 06:00 -PHST- 2018/11/22 00:00 [received] -PHST- 2019/01/30 06:00 [pubmed] -PHST- 2020/03/19 06:00 [medline] -PHST- 2019/01/30 06:00 [entrez] -AID - 10.1007/s12325-019-0876-4 [pii] -AID - 10.1007/s12325-019-0876-4 [doi] -PST - ppublish -SO - Adv Ther. 2019 Mar;36(3):563-578. doi: 10.1007/s12325-019-0876-4. Epub 2019 Jan - 29. - -PMID- 33818208 -OWN - NLM -STAT- MEDLINE -DCOM- 20220602 -LR - 20220602 -IS - 2038-2529 (Electronic) -IS - 0300-8916 (Linking) -VI - 108 -IP - 3 -DP - 2022 Jun -TI - Systemic effect of radiotherapy before or after nivolumab in lung cancer: an - observational, retrospective, multicenter study. -PG - 250-257 -LID - 10.1177/03008916211004733 [doi] -AB - BACKGROUND: The combination of radiotherapy (RT) and programmed death 1 - inhibitors seems to increase antitumor immune responses. OBJECTIVE: To assess the - outcome and the role of the best combination sequence, i.e. immunotherapy given - before, during, and/or after RT, in patients with non-small cell lung cancer - (NSCLC). METHODS: We conducted an observational, retrospective analysis of 95 - consecutive patients with advanced NSCLC who received any radiotherapy treatment - and nivolumab, as clinically indicated. Median overall survival (OS) and the 95% - confidence interval (CI) were estimated with the Kaplan-Meier method. Cox model - was used to obtain hazard ratio (HR) and associated 95% CI with statistical - inference by log-rank statistic. RESULTS: Median OS was 11.9 months (95% CI, - 6.6-17.2). Patients who received radiotherapy during an immune checkpoint - inhibitor treatment started more than 60 days before showed a better outcome than - patients who started immunotherapy over 60 days after RT ending (HR, 2.90 - [1.37-6.12], p = 0.005; median OS, 22.4 months vs 8.6 months, p = 0.005). Median - progression-free survival was 6.3 months (95% CI, 4.6-8.0). CONCLUSIONS: This - study shows that combining irradiation with nivolumab for the treatment of - advanced NSCLC leads to improved OS. The optimal time window for the combination - of RT and immunotherapy seems to play a critical role for therapeutic antitumor - response derived by abscopal effect. -FAU - Bassanelli, Maria -AU - Bassanelli M -AUID- ORCID: 0000-0003-0111-7588 -AD - Department of Oncology, San Camillo de Lellis Hospital, Rieti, Italy. -FAU - Ricciuti, Biagio -AU - Ricciuti B -AD - Department of Oncology, Santa Maria della Misericordia Hospital, Azienda - Ospedaliera di Perugia, Perugia, Italy. -FAU - Giannarelli, Diana -AU - Giannarelli D -AD - Biostatistic Unit, IRCSS Regina Elena National Cancer Institute, Rome, Italy. -FAU - Cecere, Fabiana Letizia -AU - Cecere FL -AD - Division of Medical Oncology 1, IRCSS Regina Elena National Cancer Institute, - Rome, Italy. -FAU - Roberto, Michela -AU - Roberto M -AD - Department of Oncology, University of Rome "Sapienza," Rome, Italy. -FAU - Giacinti, Silvana -AU - Giacinti S -AD - Department of Oncology, Belcolle Hospital-Viterbo, Viterbo, Italy. -FAU - Barucca, Viola -AU - Barucca V -AD - Department of Oncology, Misericordia Hospital, Grosseto, Italy. -FAU - Santarelli, Mario -AU - Santarelli M -AD - Department of Radiotherapy, San Camillo de Lellis Hospital, Rieti, Lazio, Italy. -FAU - Ruggeri, Enzo Maria -AU - Ruggeri EM -AD - Department of Oncology, Belcolle Hospital-AUSL-Viterbo, Viterbo, Italy. -FAU - Marchetti, Paolo -AU - Marchetti P -AD - Department of Oncology, University of Rome "Sapienza," Rome, Italy. -FAU - Cognetti, Francesco -AU - Cognetti F -AD - Division of Medical Oncology 1, Regina Elena National Cancer Institute, Rome, - Italy. -AD - Department of Clinical and Molecular Medicine, La Sapienza University, Rome, - Italy. -FAU - Gelibter, Alain -AU - Gelibter A -AD - Medical Oncology Unit, Policlinico Umberto I, Rome, Italy. -FAU - Cortesi, Enrico -AU - Cortesi E -AD - Medical Oncology Unit, Policlinico Umberto I, Rome, Italy. -FAU - Chiari, Rita -AU - Chiari R -AD - Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda - Ospedaliera di Perugia, Perugia, Italy. -FAU - Milella, Michele -AU - Milella M -AD - Division of Oncology, Integrated University Hospital of Verona, Verona, Italy. -FAU - Ceribelli, Anna -AU - Ceribelli A -AD - Department of Oncology, San Camillo de Lellis Hospital, Rieti, Italy. -LA - eng -PT - Journal Article -PT - Multicenter Study -PT - Observational Study -DEP - 20210404 -PL - United States -TA - Tumori -JT - Tumori -JID - 0111356 -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - Humans -MH - Immunotherapy/methods -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Nivolumab/adverse effects -MH - Retrospective Studies -OTO - NOTNLM -OT - Combined modality therapy -OT - immunotherapy -OT - lung cancer -OT - radioimmunotherapy -OT - radiotherapy -EDAT- 2021/04/06 06:00 -MHDA- 2022/06/03 06:00 -CRDT- 2021/04/05 12:20 -PHST- 2021/04/06 06:00 [pubmed] -PHST- 2022/06/03 06:00 [medline] -PHST- 2021/04/05 12:20 [entrez] -AID - 10.1177/03008916211004733 [doi] -PST - ppublish -SO - Tumori. 2022 Jun;108(3):250-257. doi: 10.1177/03008916211004733. Epub 2021 Apr 4. - -PMID- 38880924 -OWN - NLM -STAT- MEDLINE -DCOM- 20240616 -LR - 20240620 -IS - 1999-6187 (Electronic) -IS - 1009-3419 (Print) -IS - 1009-3419 (Linking) -VI - 27 -IP - 5 -DP - 2024 May 20 -TI - [Current Status and Prospect of PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy - 
in Elderly Patients with Advanced NSCLC]. -PG - 367-375 -LID - 10.3779/j.issn.1009-3419.2024.106.10 [doi] -AB - The incidence of cancer is closely correlated with age, as 75% of non-small cell - lung cancer (NSCLC) patients are aged at least 65 years. The availability of - immune checkpoint inhibitors (ICIs) has altered the available NSCLC therapeutic - pattern. Limited studies on elderly patients have demonstrated that ICIs as - monotherapy provide substantial benefits for patients aged 65-75 years, showing - no significant difference compared to younger patients. This benefit is also - observed in combination with immune-combined chemotherapy or radiotherapy. For - individuals older than 75 years, the survival effect was not evident, though. - Immune-related adverse events (irAEs) with ICIs alone were similar in incidence - across age categories. Immune-combination chemotherapy resulted in a higher - incidence of irAEs than chemotherapy alone, and patients ≥75 years of age were - more likely to experience higher-grade irAEs. Besides the fact that - immunosenescence in older patients influences the immune milieu in a multifaceted - manner, which in turn impacts the effectiveness of immunotherapy, the prognosis - is also influenced by the Eastern Cooperative Oncology Group performance status - (ECOG PS) score, among other factors. For certain individuals aged ≥75 years or - in poor physical health, immunotherapy combined with low-intensity chemotherapy - has emerged as a viable treatment option. However, there are fewer related - studies, so there should be a conscious effort to increase the number of elderly - patients enrolled in the trial and a comprehensive assessment to explore - individualized treatment options. To provide additional references and guidance - for immunotherapy in elderly NSCLC patients and to propose new therapeutic - perspectives in combination with their characteristics, this review aims to - summarize and analyze the pertinent studies on the application of programmed cell - death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors in these - patients.
. -FAU - Mao, Yunye -AU - Mao Y -AD - Department of Oncology, Senior Department of Oncology, the Fifth Medical Center - of PLA General Hospital, Beijing 100071, China. -AD - Chinese PLA Medical School, Beijing 100853, China. -FAU - Sheng, Shu -AU - Sheng S -AD - Department of Oncology, Senior Department of Oncology, the Fifth Medical Center - of PLA General Hospital, Beijing 100071, China. -AD - Chinese PLA Medical School, Beijing 100853, China. -FAU - Wang, An -AU - Wang A -AD - Department of Oncology, Senior Department of Oncology, the Fifth Medical Center - of PLA General Hospital, Beijing 100071, China. -AD - Chinese PLA Medical School, Beijing 100853, China. -FAU - Zhai, Jinzhao -AU - Zhai J -AD - Department of Oncology, Senior Department of Oncology, the Fifth Medical Center - of PLA General Hospital, Beijing 100071, China. -AD - Chinese PLA Medical School, Beijing 100853, China. -FAU - Ge, Xiangwei -AU - Ge X -AD - Department of Oncology, Senior Department of Oncology, the Fifth Medical Center - of PLA General Hospital, Beijing 100071, China. -AD - Chinese PLA Medical School, Beijing 100853, China. -FAU - Lu, Di -AU - Lu D -AD - Department of Oncology, Senior Department of Oncology, the Fifth Medical Center - of PLA General Hospital, Beijing 100071, China. -AD - Chinese PLA Medical School, Beijing 100853, China. -FAU - Wang, Jinliang -AU - Wang J -AD - Department of Oncology, Senior Department of Oncology, the Fifth Medical Center - of PLA General Hospital, Beijing 100071, China. -LA - chi -PT - English Abstract -PT - Journal Article -PT - Review -PL - China -TA - Zhongguo Fei Ai Za Zhi -JT - Zhongguo fei ai za zhi = Chinese journal of lung cancer -JID - 101126433 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/immunology -MH - *Lung Neoplasms/drug therapy/immunology -MH - *Immune Checkpoint Inhibitors/therapeutic use/adverse effects -MH - Aged -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - B7-H1 Antigen/antagonists & inhibitors -MH - Immunotherapy -MH - Aged, 80 and over -PMC - PMC11183317 -OTO - NOTNLM -OT - Elderly non-small cell lung cancer -OT - Immunosenescence -OT - Immunotherapy -OT - Immunotherapy combined with low-intensity chemotherapy -OT - Lung neoplasms -COIS- Competing interests: The authors declare that they have no competing interests. -EDAT- 2024/06/17 00:42 -MHDA- 2024/06/17 00:43 -PMCR- 2024/05/20 -CRDT- 2024/06/16 23:15 -PHST- 2024/06/17 00:43 [medline] -PHST- 2024/06/17 00:42 [pubmed] -PHST- 2024/06/16 23:15 [entrez] -PHST- 2024/05/20 00:00 [pmc-release] -AID - 10.3779/j.issn.1009-3419.2024.106.10 [doi] -PST - ppublish -SO - Zhongguo Fei Ai Za Zhi. 2024 May 20;27(5):367-375. doi: - 10.3779/j.issn.1009-3419.2024.106.10. - -PMID- 38206614 -OWN - NLM -STAT- MEDLINE -DCOM- 20240322 -LR - 20240322 -IS - 2374-2445 (Electronic) -IS - 2374-2437 (Print) -IS - 2374-2437 (Linking) -VI - 10 -IP - 3 -DP - 2024 Mar 1 -TI - Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative - Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: - A Nonrandomized Controlled Trial. -PG - 352-359 -LID - 10.1001/jamaoncol.2023.6033 [doi] -LID - e236033 -AB - IMPORTANCE: Intrathoracic progression remains the predominant pattern of failure - in patients treated with concurrent chemoradiation followed by a consolidation - immune checkpoint inhibitor for locally advanced, unresectable non-small cell - lung cancer (NSCLC). OBJECTIVE: To determine the maximum tolerated dose (MTD) and - use of hypofractionated concurrent chemoradiation with an adaptive stereotactic - ablative radiotherapy (SABR) boost. DESIGN, SETTING, AND PARTICIPANTS: This was - an early-phase, single-institution, radiation dose-escalation nonrandomized - controlled trial with concurrent chemotherapy among patients with clinical stage - II (inoperable/patient refusal of surgery) or III NSCLC (American Joint Committee - on Cancer Staging Manual, seventh edition). Patients were enrolled and treated - from May 2011 to May 2018, with a median patient follow-up of 18.2 months. - Patients advanced to a higher SABR boost dose if dose-limiting toxic effects (any - grade 3 or higher pulmonary, gastrointestinal, or cardiac toxic effects, or any - nonhematologic grade 4 or higher toxic effects) occurred in fewer than 33% of the - boost cohort within 90 days of follow-up. The current analyses were conducted - from January to September 2023. INTERVENTION: All patients first received 4 - Gy × 10 fractions followed by an adaptive SABR boost to residual metabolically - active disease, consisting of an additional 25 Gy (low, 5 Gy × 5 fractions), 30 - Gy (intermediate, 6 Gy × 5 fractions), or 35 Gy (high, 7 Gy × 5 fractions) with - concurrent weekly carboplatin/paclitaxel. MAIN OUTCOME AND MEASURE: The primary - outcome was to determine the MTD. RESULTS: Data from 28 patients (median [range] - age, 70 [51-88] years; 16 [57%] male; 24 [86%] with stage III disease) enrolled - across the low- (n = 10), intermediate- (n = 9), and high- (n = 9) dose cohorts - were evaluated. The protocol-specified MTD was not exceeded. The incidences of - nonhematologic acute and late (>90 days) grade 3 or higher toxic effects were 11% - and 7%, respectively. No grade 3 toxic effects were observed in the - intermediate-dose boost cohort. Two deaths occurred in the high-dose cohort. - Two-year local control was 74.1%, 85.7%, and 100.0% for the low-, intermediate-, - and high-dose cohorts, respectively. Two-year overall survival was 30.0%, 76.2%, - and 55.6% for the low-, intermediate-, and high-dose cohorts, respectively. - CONCLUSIONS AND RELEVANCE: This early-phase, dose-escalation nonrandomized - controlled trial showed that concurrent chemoradiation with an adaptive SABR - boost to 70 Gy in 15 fractions with concurrent chemotherapy is a safe and - effective regimen for patients with locally advanced, unresectable NSCLC. TRIAL - REGISTRATION: ClinicalTrials.gov Identifier: NCT01345851. -FAU - Wu, Trudy C -AU - Wu TC -AD - Department of Radiation Oncology, University of California, Los Angeles. -FAU - Luterstein, Elaine -AU - Luterstein E -AD - University of California San Diego School of Medicine, San Diego. -FAU - Neilsen, Beth K -AU - Neilsen BK -AD - Department of Radiation Oncology, University of California, Los Angeles. -FAU - Goldman, Jonathan W -AU - Goldman JW -AD - Department of Medicine, University of California, Los Angeles. -FAU - Garon, Edward B -AU - Garon EB -AD - Department of Medicine, University of California, Los Angeles. -FAU - Lee, Jay M -AU - Lee JM -AD - Division of Thoracic Surgery, Department of Surgery, University of California, - Los Angeles. -FAU - Felix, Carol -AU - Felix C -AD - Department of Radiation Oncology, University of California, Los Angeles. -FAU - Cao, Minsong -AU - Cao M -AD - Department of Radiation Oncology, University of California, Los Angeles. -FAU - Tenn, Stephen E -AU - Tenn SE -AD - Department of Radiation Oncology, University of California, Los Angeles. -FAU - Low, Daniel A -AU - Low DA -AD - Department of Radiation Oncology, University of California, Los Angeles. -FAU - Kupelian, Patrick A -AU - Kupelian PA -AD - Varian Medical Systems, Palo Alto, California. -FAU - Steinberg, Michael L -AU - Steinberg ML -AD - Department of Radiation Oncology, University of California, Los Angeles. -FAU - Lee, Percy -AU - Lee P -AD - Department of Radiation Oncology, University of California, Los Angeles. -AD - Now with Department of Radiation Oncology, City of Hope Orange County, Lennar - Foundation Cancer Center, Irvine, California. -LA - eng -SI - ClinicalTrials.gov/NCT01345851 -GR - R01 CA276917/CA/NCI NIH HHS/United States -PT - Comment -PT - Journal Article -PL - United States -TA - JAMA Oncol -JT - JAMA oncology -JID - 101652861 -SB - IM -CON - JAMA Oncol. 2024 Mar 1;10(3):360-361. doi: 10.1001/jamaoncol.2023.5856. PMID: - 38206616 -MH - Humans -MH - Male -MH - Aged -MH - Female -MH - *Carcinoma, Non-Small-Cell Lung/radiotherapy/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - *Radiosurgery/adverse effects -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Dose Fractionation, Radiation -PMC - PMC10784998 -COIS- Conflict of Interest Disclosures: Dr Goldman reported grants from AstraZeneca and - Merck and personal fees from AstraZeneca outside the submitted work. Dr Garon - reported personal fees from AbbVie, ABL Bio, Arcus, AstraZeneca, Atreca, - Boehringer Ingelheim, BridgeBio, Bristol Myers Squibb, EMD Serono, Eisai, Eli - Lilly, Gilead, GlaxoSmithKline, Merck, Natera, Novartis, Personalis, Regeneron, - Sanofi, Seagen, Sensei, Summit, Synthekine, Xilio, and Zymeworks; grants from ABL - Bio, ArriVent, AstraZeneca, Bristol Myers Squibb, Daiichi Sanyko, Dynavax - Technologies, Eli Lilly, EMD Serono, Genentech, Gilead, Iovance Biotherapeutics, - Merck, Mirati Therapeutics, Neon, Novartis, Regeneron, and Synthekine; sponsored - independent medical education from Daiichi Sankyo and Ipsen; and travel fees from - A2 Bio and Novartis outside the submitted work. Dr J. Lee reported serving on the - advisory board for or as consultant with AstraZeneca, Bristol Myers Squibb, - Foundation Medicine Institute, Genentech, IDEOlogy Health, Merck, Novartis, - Regeneron Pharmaceuticals, and Roche; research support from Bristol Myers Squibb, - Genentech, Novartis, and Roche; serving on the steering committees for Genentech - and Novartis; serving in the speaker’s bureau for AstraZeneca, Bristol Myers - Squibb, DAVA Oncology, ecancer, Genentech, Medscape, Roche, and Targeted - Oncology; stock in Moderna; and patents through the University of California, Los - Angeles. Dr Cao reported grants from Varian Medical System and personal fees from - Varian Medical System and ViewRay outside the submitted work. Dr Low reported - grants from Varian, personal fees from ViewRay and TAE Life Sciences, serving as - a founder of Pulmonum LLC, and stock in Triplet State outside the submitted work. - Dr Kupelian reported employment with Varian during the conduct of the study. Dr - Steinberg reported personal fees from Viewray outside the submitted work. Dr P. - Lee reported personal fees from AstraZeneca, Genentech, and Roche, as well as - nonfinancial support from Varian and Viewray outside the submitted work. No other - disclosures were reported. -EDAT- 2024/01/11 12:43 -MHDA- 2024/03/22 06:44 -PMCR- 2025/01/11 -CRDT- 2024/01/11 11:34 -PHST- 2025/01/11 00:00 [pmc-release] -PHST- 2024/03/22 06:44 [medline] -PHST- 2024/01/11 12:43 [pubmed] -PHST- 2024/01/11 11:34 [entrez] -AID - 2813829 [pii] -AID - coi230080 [pii] -AID - 10.1001/jamaoncol.2023.6033 [doi] -PST - ppublish -SO - JAMA Oncol. 2024 Mar 1;10(3):352-359. doi: 10.1001/jamaoncol.2023.6033. - -PMID- 37768117 -OWN - NLM -STAT- MEDLINE -DCOM- 20230929 -LR - 20230929 -IS - 2060-0399 (Electronic) -IS - 0025-0244 (Linking) -VI - 67 -IP - 3 -DP - 2023 Sep 28 -TI - [Small cell lung cancer heterogeneity and molecular subtypes: biological and - clinical relevance]. -PG - 181-192 -AB - Small-cell lung cancer (SCLC) is a highly aggressive malignancy characterised by - genomic instability and early metastatic spread. Patients are typically diagnosed - at advanced disease stage, when platinum-based chemotherapy with immunotherapy - represents the standard therapeutic approach. The role of radiotherapy with - concomitant systemic therapy is also well established in the management of SCLC - patients. Although these therapeutic approaches are initially effective, most - patients rapidly develop resistance. This clearly highlights the need to improve - therapeutic efficacy and broaden the scope of current therapeutic strategies. - Recent advances in the study of this disease, once considered homogeneous, have - led to a new model of the SCLC classification scheme based on the relative - expression of certain transcriptional regulators and inflammatory - characteristics. New biological insights into the molecular subtypes of SCLC - could lead to the implementation of subtype-specific therapeutic approaches. - Here, we summarise our key findings concerning the biological and clinical - relevance of SCLC molecular subtypes. -FAU - Berta, Judit -AU - Berta J -AD - Országos Korányi Pulmonológiai Intézet, Budapest, Hungary. - berta.judit@koranyi.hu. -FAU - Ferencz, Bence -AU - Ferencz B -AD - Országos Korányi Pulmonológiai Intézet, Budapest, Hungary. - berta.judit@koranyi.hu. -FAU - Horváth, Lilla -AU - Horváth L -AD - Országos Korányi Pulmonológiai Intézet, Budapest, Hungary. - berta.judit@koranyi.hu. -FAU - Fillinger, János -AU - Fillinger J -AD - Országos Korányi Pulmonológiai Intézet, Budapest, Hungary. - berta.judit@koranyi.hu. -FAU - Lantos, András -AU - Lantos A -AD - Országos Korányi Pulmonológiai Intézet, Budapest, Hungary. - berta.judit@koranyi.hu. -FAU - Bogos, Krisztina -AU - Bogos K -AD - Országos Korányi Pulmonológiai Intézet, Budapest, Hungary. - berta.judit@koranyi.hu. -FAU - Rényi-Vámos, Ferenc -AU - Rényi-Vámos F -AD - Országos Korányi Pulmonológiai Intézet, Budapest, Hungary. - berta.judit@koranyi.hu. -FAU - Megyesfalvi, Zsolt -AU - Megyesfalvi Z -AD - Országos Korányi Pulmonológiai Intézet, Budapest, Hungary. - berta.judit@koranyi.hu. -FAU - Döme, Balázs -AU - Döme B -AD - Országos Korányi Pulmonológiai Intézet, Budapest, Hungary. - berta.judit@koranyi.hu. -LA - hun -PT - English Abstract -PT - Journal Article -TT - A molekuláris altípusok szerinti heterogenitás biológiai és klinikai jelentősége - kissejtes tüdőrákban. -DEP - 20230825 -PL - Hungary -TA - Magy Onkol -JT - Magyar onkologia -JID - 9313833 -RN - 49DFR088MY (Platinum) -SB - IM -MH - Humans -MH - Clinical Relevance -MH - *Small Cell Lung Carcinoma/genetics/therapy -MH - Immunotherapy -MH - Platinum -MH - *Lung Neoplasms/drug therapy/genetics -EDAT- 2023/09/28 12:43 -MHDA- 2023/09/29 06:44 -CRDT- 2023/09/28 09:23 -PHST- 2023/07/05 00:00 [received] -PHST- 2023/08/25 00:00 [accepted] -PHST- 2023/09/29 06:44 [medline] -PHST- 2023/09/28 12:43 [pubmed] -PHST- 2023/09/28 09:23 [entrez] -AID - MagyOnkol.2023.67.3.181 [pii] -PST - ppublish -SO - Magy Onkol. 2023 Sep 28;67(3):181-192. Epub 2023 Aug 25. - -PMID- 35271524 -OWN - NLM -STAT- MEDLINE -DCOM- 20220502 -LR - 20230903 -IS - 1537-453X (Electronic) -IS - 0277-3732 (Linking) -VI - 45 -IP - 4 -DP - 2022 Apr 1 -TI - Uptake of Adjuvant Durvalumab After Definitive Concurrent Chemoradiotherapy for - Stage III Nonsmall-cell Lung Cancer. -PG - 142-145 -LID - 10.1097/COC.0000000000000899 [doi] -AB - OBJECTIVES: The addition of adjuvant durvalumab improves overall survival in - locally advanced nonsmall-cell lung cancer (NSCLC) patients treated with - definitive chemoradiation, but the real-world uptake of adjuvant durvalumab is - unknown. MATERIALS AND METHODS: We identified patients with stage III NSCLC - treated with definitive concurrent chemoradiation from January 2018 to October - 2020 from a statewide radiation oncology quality consortium, representing a mix - of community (n=22 centers) and academic (n=5) across the state of Michigan. Use - of adjuvant durvalumab was ascertained at the time of routine 3-month or 6-month - follow-up after completion of chemoradiation. RESULTS: Of 421 patients with stage - III NSCLC who completed chemoradiation, 322 (76.5%) initiated adjuvant - durvalumab. The percentage of patients initiating adjuvant durvalumab increased - over time from 66% early in the study period to 92% at the end of the study - period. There was substantial heterogeneity by treatment center, ranging from 53% - to 90%. In multivariable logistic regression, independent predictors of - durvalumab initiation included more recent month (odds ratio [OR]: 1.05 per - month, 95% confidence interval [CI]: 1.02-1.08, P=0.003), lower Eastern - Cooperative Oncology Group score (OR: 4.02 for ECOG 0 vs. 2+, 95% CI: 1.67-9.64, - P=0.002), and a trend toward significance for female sex (OR: 1.66, 95% CI: - 0.98-2.82, P=0.06). CONCLUSION: Adjuvant durvalumab for stage III NSCLC treated - with definitive chemoradiation was rapidly and successfully incorporated into - clinical care across a range of community and academic settings in the state of - Michigan, with over 90% of potentially eligible patients starting durvalumab in - more recent months. -CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. -FAU - Bryant, Alex K -AU - Bryant AK -AD - Department of Radiation Oncology, Rogel Comprehensive Cancer Center at the - University of Michigan. -FAU - Yin, Huiying -AU - Yin H -AD - Department of Biostatistics, University of Michigan, Ann Arbor. -FAU - Schipper, Matthew J -AU - Schipper MJ -AD - Department of Radiation Oncology, Rogel Comprehensive Cancer Center at the - University of Michigan. -AD - Department of Biostatistics, University of Michigan, Ann Arbor. -FAU - Paximadis, Peter A -AU - Paximadis PA -AD - Spectrum Health Lakeland, St. Joseph. -FAU - Boike, Thomas P -AU - Boike TP -AD - 21st Century Oncology, Clarkston. -FAU - Bergsma, Derek P -AU - Bergsma DP -AD - Department of Radiation Oncology, Mercy Health Saint Mary's, Grand Rapids. -FAU - Movsas, Benjamin -AU - Movsas B -AD - Department of Radiation Oncology, Henry Ford Hospital, Detroit. -FAU - Dess, Robert T -AU - Dess RT -AD - Department of Radiation Oncology, Rogel Comprehensive Cancer Center at the - University of Michigan. -FAU - Mietzel, Melissa A -AU - Mietzel MA -AD - Department of Radiation Oncology, Rogel Comprehensive Cancer Center at the - University of Michigan. -FAU - Kendrick, Randi -AU - Kendrick R -AD - Department of Radiation Oncology, Rogel Comprehensive Cancer Center at the - University of Michigan. -FAU - Seferi, Merita -AU - Seferi M -AD - Department of Radiation Oncology, Rogel Comprehensive Cancer Center at the - University of Michigan. -FAU - Dominello, Michael M -AU - Dominello MM -AD - Department of Radiation Oncology, Barbara Ann Karmanos Cancer Institute, Wayne - State University School of Medicine, Detroit, MI. -FAU - Matuszak, Martha M -AU - Matuszak MM -AD - Department of Radiation Oncology, Rogel Comprehensive Cancer Center at the - University of Michigan. -FAU - Jagsi, Reshma -AU - Jagsi R -AD - Department of Radiation Oncology, Rogel Comprehensive Cancer Center at the - University of Michigan. -FAU - Hayman, James A -AU - Hayman JA -AD - Department of Radiation Oncology, Rogel Comprehensive Cancer Center at the - University of Michigan. -FAU - Pierce, Lori J -AU - Pierce LJ -AD - Department of Radiation Oncology, Rogel Comprehensive Cancer Center at the - University of Michigan. -FAU - Jolly, Shruti -AU - Jolly S -AD - Department of Radiation Oncology, Rogel Comprehensive Cancer Center at the - University of Michigan. -CN - Michigan Radiation Oncology Quality Consortium -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - United States -TA - Am J Clin Oncol -JT - American journal of clinical oncology -JID - 8207754 -RN - 0 (Adjuvants, Immunologic) -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Adjuvants, Immunologic/therapeutic use -MH - Antibodies, Monoclonal/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung -MH - Chemoradiotherapy -MH - Female -MH - Humans -MH - *Lung Neoplasms -COIS- The authors declare no conflicts of interest. -EDAT- 2022/03/11 06:00 -MHDA- 2022/05/03 06:00 -CRDT- 2022/03/10 17:14 -PHST- 2022/03/11 06:00 [pubmed] -PHST- 2022/05/03 06:00 [medline] -PHST- 2022/03/10 17:14 [entrez] -AID - 00000421-202204000-00002 [pii] -AID - 10.1097/COC.0000000000000899 [doi] -PST - ppublish -SO - Am J Clin Oncol. 2022 Apr 1;45(4):142-145. doi: 10.1097/COC.0000000000000899. - -PMID- 38233798 -OWN - NLM -STAT- MEDLINE -DCOM- 20240119 -LR - 20240201 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 24 -IP - 1 -DP - 2024 Jan 17 -TI - Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in - first-line treatment of extensive-stage small cell lung cancer: a multicenter - retrospective study. -PG - 100 -LID - 10.1186/s12885-024-11833-6 [doi] -LID - 100 -AB - BACKGROUND: Immunotherapy targeting PD-1/PD-L1 has revolutionized the treatment - of extensive-stage small cell lung cancer (ES-SCLC). However, clinical trials - suggest differential efficacy of anti-PD-1 agents and anti-PD-L1 agents in - first-line treatment of ES-SCLC. This retrospective multicenter study aimed to - compare the efficacy and safety of anti-PD-1 agents versus anti-PD-L1 agents in - first-line treatment of ES-SCLC in real-world practice. METHODS: Patients with - pathologically or cytologically confirmed ES-SCLC treated with platinum plus - etoposide combined with anti-PD-1 or PD-L1 agents as first-line treatment in - different centers of PLA General Hospital between January 2017 and October 2021 - were included for this study. Survival outcomes and safety were compared between - patients receiving anti-PD-1 and PD-L1 agents. RESULTS: Of the total 154 included - patients, 68 received anti-PD-1 agents plus chemotherapy (PD-1 group), and 86 - received anti-PD-L1 agents plus chemotherapy (PD-L1 group). Progression-free - survival (PFS) and overall survival (OS) in the entire cohort were 7.6 months - (95% confidence interval [CI]: 6.5-8.2 months) and 17.4 months (95% CI: 15.3-19.3 - months), respectively. Median PFS and OS were comparable between the PD-1 group - and PD-L1 group (PFS: 7.6 months vs. 8.3 months, HR = 1.13, 95% CI: 0.79-1.62, - p = 0.415; OS: 26.9 months vs. 25.6 months, HR = 0.96, 95% CI: 0.63-1.47, - p = 0.859. The objective response rate and disease control rate were comparable - between the two groups: 79.4% vs. 79.1% and 92.6% vs. 94.2%, respectively. The - 6-month, 12-month, and 18-month PFS and OS rates were slightly higher in the - PD-L1 group than in the PD-1 group, while the 24-month PFS rate was slightly - higher in the PD-1 group than in the PD-L1 group. Stratified analysis showed that - locoregional thoracic radiotherapy and normal lactate dehydrogenase level were - independent predictors of better OS in ES-SCLC patients treated with first-line - chemotherapy plus ICI. Adverse events were not significantly different between - the two groups. CONCLUSIONS: Anti-PD-1 agents and anti-PD-L1 agents combined with - chemotherapy as first-line treatment for ES-SCLC are comparably effective and - well tolerated. -CI - © 2024. The Author(s). -FAU - Qin, Boyu -AU - Qin B -AD - Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, - 4th West Ring Road 100, Fengtai district, 100039, Beijing, China. -FAU - Xin, Lingli -AU - Xin L -AD - Department of Gynaecology and Obstetrics, PLA Rocket Force Characteristic Medical - Center, Xinjiekou outer Street 16, Xicheng district, 100088, Beijing, China. -AD - Department of Graduate Administration, PLA General Hospital, Fuxing Road 28, - Haidian district, 100853, Beijing, China. -FAU - Liang, Chen -AU - Liang C -AD - Medical Service Department, PLA General Hospital, Fuxing Road 28, Haidian - district, 100853, Beijing, China. -FAU - Li, Lingling -AU - Li L -AD - Department of Graduate Administration, PLA General Hospital, Fuxing Road 28, - Haidian district, 100853, Beijing, China. -FAU - Song, Qi -AU - Song Q -AD - Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, - 4th West Ring Road 100, Fengtai district, 100039, Beijing, China. -FAU - Long, Yaping -AU - Long Y -AD - Department of Graduate Administration, PLA General Hospital, Fuxing Road 28, - Haidian district, 100853, Beijing, China. -FAU - Zhang, Xiaoling -AU - Zhang X -AD - Department of Oncology, The First Medical Center of PLA General Hospital, Fuxing - Road 28, Haidian district, 100853, Beijing, China. -FAU - Wang, Dan -AU - Wang D -AD - Department of Oncology, The First Medical Center of PLA General Hospital, Fuxing - Road 28, Haidian district, 100853, Beijing, China. -FAU - Shi, Weiwei -AU - Shi W -AD - Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, - 4th West Ring Road 100, Fengtai district, 100039, Beijing, China. -FAU - Zhang, Jing -AU - Zhang J -AD - Department of Oncology, The First Medical Center of PLA General Hospital, Fuxing - Road 28, Haidian district, 100853, Beijing, China. -FAU - Hu, Yi -AU - Hu Y -AD - Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, - 4th West Ring Road 100, Fengtai district, 100039, Beijing, China. - huyi301zlxb@sina.com. -FAU - Yang, Bo -AU - Yang B -AD - Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, - 4th West Ring Road 100, Fengtai district, 100039, Beijing, China. - yangbo@301hospital.com.cn. -FAU - Xiong, Qi -AU - Xiong Q -AD - Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, - 4th West Ring Road 100, Fengtai district, 100039, Beijing, China. - xiongq301@163.com. -LA - eng -GR - 82203116/National Natural Science Foundation of China/ -GR - 82203116/National Natural Science Foundation of China/ -GR - 82203116/National Natural Science Foundation of China/ -GR - 82203116/National Natural Science Foundation of China/ -PT - Journal Article -PT - Multicenter Study -DEP - 20240117 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (B7-H1 Antigen) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Humans -MH - B7-H1 Antigen -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Lung Neoplasms/drug therapy -MH - Programmed Cell Death 1 Receptor -MH - Retrospective Studies -MH - *Small Cell Lung Carcinoma/drug therapy -PMC - PMC10795417 -OTO - NOTNLM -OT - Anti-PD-1/PD-L1 -OT - Immunotherapy -OT - Lactate dehydrogenase -OT - Locoregional thoracic radiotherapy -OT - Small cell lung cancer -COIS- The authors declare no competing interests. -EDAT- 2024/01/18 00:42 -MHDA- 2024/01/19 06:42 -PMCR- 2024/01/17 -CRDT- 2024/01/17 23:35 -PHST- 2023/09/05 00:00 [received] -PHST- 2024/01/03 00:00 [accepted] -PHST- 2024/01/19 06:42 [medline] -PHST- 2024/01/18 00:42 [pubmed] -PHST- 2024/01/17 23:35 [entrez] -PHST- 2024/01/17 00:00 [pmc-release] -AID - 10.1186/s12885-024-11833-6 [pii] -AID - 11833 [pii] -AID - 10.1186/s12885-024-11833-6 [doi] -PST - epublish -SO - BMC Cancer. 2024 Jan 17;24(1):100. doi: 10.1186/s12885-024-11833-6. - -PMID- 35422812 -OWN - NLM -STAT- MEDLINE -DCOM- 20220418 -LR - 20231105 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 13 -DP - 2022 -TI - Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in - Non-Small Cell Lung Cancer Patients With Brain Metastases. -PG - 852811 -LID - 10.3389/fimmu.2022.852811 [doi] -LID - 852811 -AB - Brain metastases (BMs) in non-small-cell lung cancer (NSCLC) patients are - associated with significant morbidity and poor prognosis. Immune checkpoint - inhibitors (ICIs) have resulted in a paradigm shift in the management of advanced - NSCLC. However, the value of ICIs in NSCLC patients with BMs remains unclear - because patients with BMs are routinely excluded in numerous prospective trials - on ICIs. Here, starting from the mechanisms of ICIs for BMs, we will reveal the - value of ICIs by reviewing the efficacy and adverse effects of ICIs monotherapy - as well as promising combination strategies, such as combinations with - chemotherapy, radiotherapy, and anti-angiogenic drugs, etc. In addition, the - methods of patient selection and response assessment will be summarized to assist - clinical practice and further studies. -CI - Copyright © 2022 Yang, Xing and Sun. -FAU - Yang, Guanqun -AU - Yang G -AD - Cheeloo College of Medicine, Shandong University, Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Xing, Ligang -AU - Xing L -AD - Cheeloo College of Medicine, Shandong University, Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Sun, Xiaorong -AU - Sun X -AD - Cheeloo College of Medicine, Shandong University, Jinan, China. -AD - Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong - First Medical University and Shandong Academy of Medical Sciences, Jinan, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20220329 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Immunologic Factors) -SB - IM -MH - *Brain Neoplasms/drug therapy/secondary -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects -MH - Immunologic Factors/therapeutic use -MH - Immunotherapy/methods -MH - *Lung Neoplasms/drug therapy -MH - Prospective Studies -PMC - PMC9001915 -OTO - NOTNLM -OT - brain metastases (BMs) -OT - combination strategies -OT - immune checkpoint inhibitors (ICI) -OT - non-small cell lung cancer (NSCLC) -OT - patient selection -OT - response assessment -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/04/16 06:00 -MHDA- 2022/04/19 06:00 -PMCR- 2022/01/01 -CRDT- 2022/04/15 05:24 -PHST- 2022/01/11 00:00 [received] -PHST- 2022/02/28 00:00 [accepted] -PHST- 2022/04/15 05:24 [entrez] -PHST- 2022/04/16 06:00 [pubmed] -PHST- 2022/04/19 06:00 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2022.852811 [doi] -PST - epublish -SO - Front Immunol. 2022 Mar 29;13:852811. doi: 10.3389/fimmu.2022.852811. eCollection - 2022. - -PMID- 36806897 -OWN - NLM -STAT- MEDLINE -DCOM- 20230331 -LR - 20230412 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 178 -DP - 2023 Apr -TI - Systemic treatment and radiotherapy for patients with non-small cell lung cancer - (NSCLC) and HIV infection - A systematic review. -PG - 75-86 -LID - S0169-5002(23)00039-9 [pii] -LID - 10.1016/j.lungcan.2023.01.010 [doi] -AB - Lung cancer is the most common non-AIDS defining cancer among people living with - HIV (PLWH), but there is a paucity of data regarding the efficacy and toxicity of - radiotherapy and systemic regimens, including immunotherapy, in the treatment of - these patients. In order to answer this question, we have performed a systematic - search of the literature in Ovid Medline until March 17, 2022. We included 21 - publications, enrolling 513 PLWH with non-small cell lung cancer (NSCLC), mostly - male (75-100%), (ex-)smokers (75-100%) and with stage III-IV at diagnosis - (65-100%). The overall response rate (ORR) to chemotherapy (n = 186 patients, - mostly receiving platinum-based regimens) was highly variable (17 %-83 %), with a - substantial hematological toxicity. ORR varied between 13 % and 50 % with - single-agent immunotherapy (n = 68), with median overall survival between 9 and - 11 months and a very acceptable toxicity profile, in line with studies in the HIV - non-infected population. All five patients receiving tyrosine kinase inhibitors - (TKIs; gefitinib or erlotinib) showed a partial response and long overall - survival. Yet, combination of TKIs with antiretroviral therapy using - pharmacological boosters, such as ritonavir, should be avoided. Radiotherapy was - evaluated among 42 patients, showing high ORR (55 %-100 %), but 18 % of patients - had a pneumonitis. This systematic review shows that radiotherapy and systemic - therapy are effective and safe among PLWH with controlled infection diagnosed - with NSCLC. Nonetheless, most reports were small and heterogeneous and larger - studies are needed to confirm these encouraging findings. Moreover, clinical - trials should not restrict the inclusion of PLWH, as more data is needed - regarding the long-term efficacy and safety of treatments among this underserved - population, especially of immunotherapy. -CI - Copyright © 2023. Published by Elsevier B.V. -FAU - Brandão, Mariana -AU - Brandão M -AD - Medical Oncology Department, Institut Jules Bordet and l'Université Libre de - Bruxelles (U.L.B.), Rue Meylemeersch 90, 1070 Brussels, Belgium. Electronic - address: mariana.brandao@bordet.be. -FAU - Durieux, Valérie -AU - Durieux V -AD - Bibliothèque des Sciences de la Santé, Université Libre de Bruxelles (U.L.B.), - Route de lennik 808, 1070 Brussels, Belgium. Electronic address: - Valerie.Durieux@ulb.be. -FAU - Auprih, Maša -AU - Auprih M -AD - Medical Oncology Department, Institut Jules Bordet and l'Université Libre de - Bruxelles (U.L.B.), Rue Meylemeersch 90, 1070 Brussels, Belgium. -FAU - Fozza, Alessandra -AU - Fozza A -AD - Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino, Largo - Rosanna Benzi 10, 16132 Genova, Italy. Electronic address: - alessandra.fozza@hsanmartino.it. -FAU - Dauby, Nicolas -AU - Dauby N -AD - Department of Infectious Diseases, CHU Saint-Pierre, Rue haute 322, 1000 - Brussels, Belgium; School of Public Health, Université Libre de Bruxelles - (U.L.B.), Route de lennik 808, 1070 Brussels, Belgium. Electronic address: - nicolas.dauby@stpierre-bru.be. -FAU - Cuccia, Francesco -AU - Cuccia F -AD - Radiotherapy Unit, ARNAS Civico Hospital - Piazza Nicola Leotta 4, 90100 Palermo, - Italy. Electronic address: francesco.cuccia@arnascivico.it. -FAU - Aspeslagh, Sandrine -AU - Aspeslagh S -AD - Vrije Universiteit Brussel (V.U.B.), Universitair Ziekenhuis Brussel (UZ - Brussel), Department of Medical Oncology, Laarbeeklaan 101, 1090 Brussels, - Belgium. Electronic address: Sandrine.Aspeslagh@uzbrussel.be. -FAU - Verhaert, Marthe -AU - Verhaert M -AD - Vrije Universiteit Brussel (V.U.B.), Universitair Ziekenhuis Brussel (UZ - Brussel), Department of Medical Oncology, Laarbeeklaan 101, 1090 Brussels, - Belgium. Electronic address: Marthe.Verhaert@uzbrussel.be. -FAU - Giaj-Levra, Niccolò -AU - Giaj-Levra N -AD - Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, - Via Don A.Sempreboni, 37124 Negrar di Valpolicella, Italy. Electronic address: - niccolo.giajlevra@sacrocuore.it. -LA - eng -PT - Journal Article -PT - Review -PT - Systematic Review -DEP - 20230121 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Antineoplastic Agents) -RN - DA87705X9K (Erlotinib Hydrochloride) -SB - IM -MH - Humans -MH - Male -MH - Female -MH - *Carcinoma, Non-Small-Cell Lung/radiotherapy/drug therapy -MH - *Lung Neoplasms/radiotherapy/drug therapy -MH - *Antineoplastic Agents/therapeutic use -MH - *HIV Infections/complications/drug therapy -MH - Erlotinib Hydrochloride/therapeutic use -OTO - NOTNLM -OT - Chemotherapy -OT - HIV -OT - Immunotherapy -OT - Lung cancer -OT - Radiotherapy -OT - Survival -OT - Toxicity -COIS- Declaration of Competing Interest MB: travel grant from Roche and Takeda; speaker - honoraria from Roche and Janssen; advisory board participation for Sanofi. ND: - speaker honoraria from Boerhinger-Ingelheim; advisory board participation for - Roche therapeutics; travel grant from MSD. SA: membership on an advisory board or - board of directors:MSD, Sanofi, Roche, BMS, Pfizer. NGL: travel grant from - Philips; speaker honoraria from AstraZeneca, IPSEN, FERRING. The remaining - authors declare that they have no known competing financial interests or personal - relationships that could have appeared to influence the work reported in this - paper. -EDAT- 2023/02/23 06:00 -MHDA- 2023/03/31 06:42 -CRDT- 2023/02/22 11:05 -PHST- 2022/10/27 00:00 [received] -PHST- 2023/01/18 00:00 [revised] -PHST- 2023/01/19 00:00 [accepted] -PHST- 2023/03/31 06:42 [medline] -PHST- 2023/02/23 06:00 [pubmed] -PHST- 2023/02/22 11:05 [entrez] -AID - S0169-5002(23)00039-9 [pii] -AID - 10.1016/j.lungcan.2023.01.010 [doi] -PST - ppublish -SO - Lung Cancer. 2023 Apr;178:75-86. doi: 10.1016/j.lungcan.2023.01.010. Epub 2023 - Jan 21. - -PMID- 34558362 -OWN - NLM -STAT- MEDLINE -DCOM- 20220228 -LR - 20220228 -IS - 1477-092X (Electronic) -IS - 1078-1552 (Linking) -VI - 27 -IP - 8 -DP - 2021 Dec -TI - Cost-effectiveness of immune checkpoint inhibitors and radiotherapy in advanced - non-small cell lung cancer. -PG - 2004-2006 -LID - 10.1177/10781552211038925 [doi] -FAU - Giuliani, Jacopo -AU - Giuliani J -AUID- ORCID: 0000-0003-4096-2514 -AD - Department of Oncology, Mater Salutis Hospital, Italy. -FAU - Fiorica, Francesco -AU - Fiorica F -AD - 18586Department of Radiation Oncology, Mater Salutis Hospital, Italy. -LA - eng -PT - Journal Article -DEP - 20210924 -PL - England -TA - J Oncol Pharm Pract -JT - Journal of oncology pharmacy practice : official publication of the International - Society of Oncology Pharmacy Practitioners -JID - 9511372 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - Cost-Benefit Analysis -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -EDAT- 2021/09/25 06:00 -MHDA- 2022/03/01 06:00 -CRDT- 2021/09/24 08:42 -PHST- 2021/09/25 06:00 [pubmed] -PHST- 2022/03/01 06:00 [medline] -PHST- 2021/09/24 08:42 [entrez] -AID - 10.1177/10781552211038925 [doi] -PST - ppublish -SO - J Oncol Pharm Pract. 2021 Dec;27(8):2004-2006. doi: 10.1177/10781552211038925. - Epub 2021 Sep 24. - -PMID- 36447193 -OWN - NLM -STAT- MEDLINE -DCOM- 20221201 -LR - 20221213 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 22 -IP - 1 -DP - 2022 Nov 29 -TI - Prognostic ability of lung immune prognostic index in limited-stage small cell - lung cancer. -PG - 1233 -LID - 10.1186/s12885-022-10351-7 [doi] -LID - 1233 -AB - BACKGROUND: Lung immune prognostic index (LIPI) is a prognostic marker of - extensive-stage small cell lung cancer (ES-SCLC) patients received immunotherapy - or chemotherapy. However, its ability in limited-stage SCLC (LS-SCLC) should be - evaluated extensively. METHODS: We retrospectively enrolled 497 patients - diagnosed as LS-SCLC between 2015 and 2018, and clinical data included - pretreatment lactate dehydrogenase (LDH), white blood cell count, and absolute - neutrophil count levels were collected. According to the LIPI scores, the - patients were stratified into low-risk (0 points) and high-risk (1-2 points). The - correlations between LIPI and overall survival (OS) or progression-free survival - (PFS) were analyzed by the Cox regression. Additionally, the propensity score - matching (PSM) and inverse probability of treatment weight (IPTW) methods were - used to reduce the selection and confounding bias. A nomogram was constructed - using on multivariable Cox model. RESULTS: Two hundred fifty and 247 patients - were in the LIPI high-risk group and low-risk group, and their median OS was - 14.67 months (95% CI: 12.30-16.85) and 20.53 months (95% CI: 17.67-23.39), - respectively. In the statistical analysis, High-risk LIPI was significantly - against worse OS (HR = 1.377, 95%CI:1.114-1.702) and poor PFS (HR = 1.338, - 95%CI:1.1-1.626), and the result was similar after matching and compensating with - the PSM or IPTW method. A novel nomogram based on LIPI has a decent level of - predictive power. CONCLUSION: LIPI stratification was a significant factor - against OS or PFS of LS-SCLC patients. -CI - © 2022. The Author(s). -FAU - Sun, Bochen -AU - Sun B -AD - Department of Radiation Oncology, The Shanxi Province Cancer Hospital/Shanxi - Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical - Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No.3, - Zhigongxin Street, Taiyuan, 030010, Shanxi, China. -FAU - Hou, Qing -AU - Hou Q -AD - Department of Radiation Oncology, The Shanxi Province Cancer Hospital/Shanxi - Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical - Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No.3, - Zhigongxin Street, Taiyuan, 030010, Shanxi, China. -FAU - Liang, Yu -AU - Liang Y -AD - Department of Radiation Oncology, The Shanxi Province Cancer Hospital/Shanxi - Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical - Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No.3, - Zhigongxin Street, Taiyuan, 030010, Shanxi, China. -FAU - Xue, Shuqin -AU - Xue S -AD - Department of Nuclear Medicine, the First Affiliated Hospital of Anhui Medical - University, Hefei, 230022, Anhui Province, China. -FAU - Yao, Ningning -AU - Yao N -AD - Department of Radiation Oncology, The Shanxi Province Cancer Hospital/Shanxi - Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical - Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No.3, - Zhigongxin Street, Taiyuan, 030010, Shanxi, China. -FAU - Wei, Lijuan -AU - Wei L -AD - Department of Radiation Oncology, The Shanxi Province Cancer Hospital/Shanxi - Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical - Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No.3, - Zhigongxin Street, Taiyuan, 030010, Shanxi, China. -FAU - Cao, Xin -AU - Cao X -AD - Department of Radiation Oncology, The Shanxi Province Cancer Hospital/Shanxi - Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical - Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No.3, - Zhigongxin Street, Taiyuan, 030010, Shanxi, China. -FAU - Li, Hongwei -AU - Li H -AD - Department of Radiation Oncology, The Shanxi Province Cancer Hospital/Shanxi - Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical - Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No.3, - Zhigongxin Street, Taiyuan, 030010, Shanxi, China. -FAU - Si, Hongwei -AU - Si H -AD - Department of Nuclear Medicine, the First Affiliated Hospital of Anhui Medical - University, Hefei, 230022, Anhui Province, China. sihw@163.com. -FAU - Cao, Jianzhong -AU - Cao J -AD - Department of Radiation Oncology, The Shanxi Province Cancer Hospital/Shanxi - Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical - Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No.3, - Zhigongxin Street, Taiyuan, 030010, Shanxi, China. caolv2000@163.com. -LA - eng -PT - Journal Article -DEP - 20221129 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/therapy -MH - Prognosis -MH - Retrospective Studies -MH - Propensity Score -MH - *Lung Neoplasms/therapy -MH - Lung -PMC - PMC9706962 -OTO - NOTNLM -OT - Immunity -OT - Inflammation -OT - Limited-stage small-cell lung cancer (LS-SCLC) -OT - Lung immune prognostic index (LIPI) -OT - Prognostic biomarker -COIS- Not applicable. -EDAT- 2022/11/30 06:00 -MHDA- 2022/12/02 06:00 -PMCR- 2022/11/29 -CRDT- 2022/11/29 23:53 -PHST- 2022/05/24 00:00 [received] -PHST- 2022/11/22 00:00 [accepted] -PHST- 2022/11/29 23:53 [entrez] -PHST- 2022/11/30 06:00 [pubmed] -PHST- 2022/12/02 06:00 [medline] -PHST- 2022/11/29 00:00 [pmc-release] -AID - 10.1186/s12885-022-10351-7 [pii] -AID - 10351 [pii] -AID - 10.1186/s12885-022-10351-7 [doi] -PST - epublish -SO - BMC Cancer. 2022 Nov 29;22(1):1233. doi: 10.1186/s12885-022-10351-7. - -PMID- 34590937 -OWN - NLM -STAT- MEDLINE -DCOM- 20211111 -LR - 20211111 -IS - 1747-6356 (Electronic) -IS - 1747-6348 (Linking) -VI - 15 -IP - 11 -DP - 2021 Nov -TI - Current state of the art and future perspectives with immunotherapy in the - management of small cell lung cancer. -PG - 1427-1435 -LID - 10.1080/17476348.2021.1987887 [doi] -AB - INTRODUCTION: Small cell lung cancer (SCLC) is an aggressive tumor with a severe - prognosis. At the time of diagnosis, most patients present with extensive-stage - (ES) disease. For decades, platinum-based chemotherapy has been the only pillar - of SCLC treatment, but now, the clinical management of this disease is rapidly - evolving thanks to the introduction of immune checkpoint inhibitors (ICIs). AREAS - COVERED: In this review, we describe the most recent advances in the treatment of - SCLC and discuss the emerging challenges associated with ICI treatments. - Meaningful data were collected from the currently available literature on PubMed - and in international oncology meetings. EXPERT OPINION: Recently, meaningful - improvements in outcomes of SCLC patients have been achieved with anti-PD-L1 - atezolizumab or durvalumab combined with chemotherapy in first line. Results of - studies evaluating the role of ICIs in limited-stage (LS) SCLC patients are - awaited. Further efforts are required to better understand the role of - immunotherapy in the treatment of SCLC and to identify patients most likely to - benefit from this treatment strategy. -FAU - Rijavec, Erika -AU - Rijavec E -AD - Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, - Milano, Italy. -FAU - Genova, Carlo -AU - Genova C -AUID- ORCID: 0000-0003-3690-8582 -AD - Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy. -FAU - Biello, Federica -AU - Biello F -AD - Division of Oncology, Department of Translational Medicine, University of - Piemonte Orientale, Novara, Italy. -FAU - Rossi, Giovanni -AU - Rossi G -AD - Department of Medical, Surgical and Experimental Sciences, University of Sassari, - Sassari, Italy. -AD - Medical Oncology Unit, Ospedale Padre Antero Micone, Genova, Italy. -FAU - Indini, Alice -AU - Indini A -AD - Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, - Milano, Italy. -FAU - Grossi, Francesco -AU - Grossi F -AD - Division of Medical Oncology, University of Insubria, Asst Dei Sette Laghi, - Varese, Italy. -LA - eng -PT - Journal Article -PT - Review -DEP - 20211015 -PL - England -TA - Expert Rev Respir Med -JT - Expert review of respiratory medicine -JID - 101278196 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Immunologic Factors) -SB - IM -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Immunologic Factors/therapeutic use -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -MH - *Small Cell Lung Carcinoma/drug therapy -OTO - NOTNLM -OT - Small cell lung cancer -OT - atezolizumab -OT - durvalumab -OT - ipilimumab -OT - nivolumab -OT - pembrolizumab -OT - tremelimumab -EDAT- 2021/10/01 06:00 -MHDA- 2021/11/12 06:00 -CRDT- 2021/09/30 12:17 -PHST- 2021/10/01 06:00 [pubmed] -PHST- 2021/11/12 06:00 [medline] -PHST- 2021/09/30 12:17 [entrez] -AID - 10.1080/17476348.2021.1987887 [doi] -PST - ppublish -SO - Expert Rev Respir Med. 2021 Nov;15(11):1427-1435. doi: - 10.1080/17476348.2021.1987887. Epub 2021 Oct 15. - -PMID- 36191986 -OWN - NLM -STAT- MEDLINE -DCOM- 20221005 -LR - 20221005 -IS - 1791-7530 (Electronic) -IS - 0250-7005 (Linking) -VI - 42 -IP - 10 -DP - 2022 Oct -TI - Efficacy of Chemoimmunotherapy in NSCLC Patients With Brain Metastasis With or - Without Prior Brain Radiotherapy. -PG - 4805-4812 -LID - 10.21873/anticanres.15985 [doi] -AB - BACKGROUND/AIM: Many patients with advanced lung cancer develop brain metastasis - (BM); however, few reports confirming the efficacy of immune checkpoint - inhibitors (ICIs) plus chemotherapy in non-small cell lung cancer (NSCLC) - patients with symptomatic BM have been published. Therefore, we retrospectively - evaluated the effects of chemoimmunotherapy in NSCLC patients who did or did not - receive prior brain radiotherapy. PATIENTS AND METHODS: A total of 103 patients - with advanced NSCLC who received ICIs plus chemotherapy at our hospital from - January 2019 to July 2021 were retrospectively enrolled. RESULTS: Patients with - BM tended to have shorter progression-free survival (PFS) and overall survival - (OS) compared with patients without BM. The maximum size of BM and the proportion - of patients with symptomatic BM were greater among patients who received brain - radiotherapy before chemoimmunotherapy. However, patients who received prior - brain radiotherapy had better PFS and OS compared with patients who did not - receive prior brain radiotherapy. CONCLUSION: Patients who received prior brain - radiotherapy experienced a superior therapeutic benefit of ICIs plus - chemotherapy, including those with larger and more symptomatic BM. -CI - Copyright © 2022 International Institute of Anticancer Research (Dr. George J. - Delinasios), All rights reserved. -FAU - Takayama, Yusuke -AU - Takayama Y -AD - Department of Respiratory Medicine, Hiroshima Citizens Hospital, Hiroshima, Japan - highmt@city-hosp.naka.hiroshima.jp. -FAU - Yano, Jun -AU - Yano J -AD - Department of Respiratory Medicine, Hiroshima Citizens Hospital, Hiroshima, - Japan. -FAU - Seike, Ren -AU - Seike R -AD - Department of Respiratory Medicine, Hiroshima Citizens Hospital, Hiroshima, - Japan. -FAU - Mishima, Shohei -AU - Mishima S -AD - Department of Respiratory Medicine, Hiroshima Citizens Hospital, Hiroshima, - Japan. -FAU - Shoda, Hiroyasu -AU - Shoda H -AD - Department of Respiratory Medicine, Hiroshima Citizens Hospital, Hiroshima, - Japan. -LA - eng -PT - Journal Article -PL - Greece -TA - Anticancer Res -JT - Anticancer research -JID - 8102988 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Brain/pathology -MH - *Brain Neoplasms/drug therapy/radiotherapy -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - ErbB Receptors/therapeutic use -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Protein Kinase Inhibitors/therapeutic use -MH - Retrospective Studies -OTO - NOTNLM -OT - Chemoimmunotherapy -OT - abscopal effect -OT - brain metastasis -OT - non-small cell lung cancer -OT - radiotherapy -EDAT- 2022/10/04 06:00 -MHDA- 2022/10/06 06:00 -CRDT- 2022/10/03 20:53 -PHST- 2022/07/20 00:00 [received] -PHST- 2022/08/08 00:00 [revised] -PHST- 2022/08/09 00:00 [accepted] -PHST- 2022/10/03 20:53 [entrez] -PHST- 2022/10/04 06:00 [pubmed] -PHST- 2022/10/06 06:00 [medline] -AID - 42/10/4805 [pii] -AID - 10.21873/anticanres.15985 [doi] -PST - ppublish -SO - Anticancer Res. 2022 Oct;42(10):4805-4812. doi: 10.21873/anticanres.15985. - -PMID- 35698259 -OWN - NLM -STAT- MEDLINE -DCOM- 20220718 -LR - 20220816 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 13 -IP - 14 -DP - 2022 Jul -TI - Predicting the efficacy of first-line immunotherapy by combining cancer cachexia - and tumor burden in advanced non-small cell lung cancer. -PG - 2064-2074 -LID - 10.1111/1759-7714.14529 [doi] -AB - BACKGROUND: Cancer cachexia and tumor burden predict efficacies of programmed - cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors and chemotherapy - or pembrolizumab in non-small cell lung cancer (NSCLC). There are no predictive - models that simultaneously assess cancer cachexia and tumor burden. METHODS: In - the present retrospective study, we reviewed the medical records of patients with - advanced NSCLC who received cancer immunotherapy as first-line systemic therapy. - Clinical immune predictive scores were defined according to multivariate analysis - of progression-free survival (PFS) and overall survival (OS). RESULTS: A total of - 157 patients were included in the present study (75 treated with PD-1/PD-L1 - inhibitors + chemotherapy; 82, pembrolizumab monotherapy). Multivariate analysis - for PFS revealed that PD-L1 tumor proportion scores <50%, a total target lesion - diameter ≥76 mm, and cancer cachexia were independently associated with poor PFS. - Multivariate analysis for OS revealed that ≥4 metastases and cancer cachexia were - significantly associated with poor OS. In the immune predictive model, the median - PFS was 21.7 months in the low-risk group (N = 41); 7.6 in the medium-risk group - (N = 64); and 3.0 in the high-risk group (N = 47). The median OS were not - reached, 22.4 and 9.1 months respectively. Our immune predictive model was - significantly associated with PFS (p < 0.001) and OS (p < 0.001). CONCLUSION: We - proposed the immune predictive model, including tumor burden and cancer cachexia, - which may predict the efficacy and survival outcome of first-line immunotherapy - in advanced NSCLC. -CI - © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Miyawaki, Taichi -AU - Miyawaki T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -AD - Department of Respiratory Medicine, Juntendo University Graduate School of - Medicine, Tokyo, Japan. -FAU - Naito, Tateaki -AU - Naito T -AUID- ORCID: 0000-0003-4047-2929 -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Doshita, Kosei -AU - Doshita K -AUID- ORCID: 0000-0002-0475-573X -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Kodama, Hiroaki -AU - Kodama H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Mori, Mikiko -AU - Mori M -AD - Department of Respiratory Medicine, Juntendo University Graduate School of - Medicine, Tokyo, Japan. -FAU - Nishioka, Naoya -AU - Nishioka N -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Iida, Yuko -AU - Iida Y -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Miyawaki, Eriko -AU - Miyawaki E -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Mamesaya, Nobuaki -AU - Mamesaya N -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Kobayashi, Haruki -AU - Kobayashi H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Omori, Shota -AU - Omori S -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Ko, Ryo -AU - Ko R -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Wakuda, Kazushige -AU - Wakuda K -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Ono, Akira -AU - Ono A -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Kenmotsu, Hirotsugu -AU - Kenmotsu H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Murakami, Haruyasu -AU - Murakami H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Mori, Keita -AU - Mori K -AD - Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Harada, Hideyuki -AU - Harada H -AD - Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Endo, Masahiro -AU - Endo M -AD - Division of Diagnostic Radiology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Takahashi, Kazuhisa -AU - Takahashi K -AD - Department of Respiratory Medicine, Juntendo University Graduate School of - Medicine, Tokyo, Japan. -FAU - Takahashi, Toshiaki -AU - Takahashi T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -LA - eng -PT - Journal Article -PT - Review -DEP - 20220613 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - *Antineoplastic Agents, Immunological/therapeutic use -MH - B7-H1 Antigen/therapeutic use -MH - Cachexia/etiology/therapy -MH - *Carcinoma, Non-Small-Cell Lung/complications/drug therapy -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/complications/drug therapy -MH - Programmed Cell Death 1 Receptor/therapeutic use -MH - Retrospective Studies -MH - Tumor Burden -PMC - PMC9284192 -OTO - NOTNLM -OT - cancer cachexia -OT - immune checkpoint inhbitor -OT - non-small cell lung cancer -OT - predictive model -OT - tumor burden -COIS- Dr Kobayashi reports personal fees from Eli Lilly K.K., Taiho Pharmaceutical, and - AstraZeneca, outside the submitted work. Dr. Omori reports personal fees from - Chugai Pharma‐ceutical Co., Ltd., Ono Pharmaceutical, AstraZeneca K.K., - Boehringer Ingelheim, Taiho Pharmaceutical, and MSD, which are unrelated to the - submitted study. Dr Ko reports grants and personal fees from Boehringer Ingelheim - and AstraZeneca; personal fees from Taiho Pharmaceutical, Chugai Pharmaceutical, - Ono Pharmaceutical, Pfizer, and Eli Lilly K.K. outside the submitted work. Dr - Wakuda reports grants and personal fees from Chugai Pharmaceutical Co., Ltd.; - personal fees from Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly K.K., - Ono Pharmaceutical, and MSD; grants and personal fees from AstraZeneca; grants - from Novartis and AbbVie, outside the submitted study. Dr Ono reports grants from - Taiho Pharmaceutical, Ono Pharmaceutical, Chugai Pharmaceutical Co., Ltd., and - Novartis Pharma K.K., outside the submitted work. Dr Kenmotsu reports grants and - personal fees from Chugai Pharmaceutical Co., Ltd.; personal fees from Ono - Pharmaceutical Co., Ltd., Boehringer Ingelheim, Eli Lilly K.K., Kyowa Hakko Kirin - Co., Ltd., Bristol‐Myers Squibb, MSD; grants and personal fees from Novartis - Pharma K.K., Daiichi‐Sankyo Co., Ltd., AstraZeneca K.K.; personal fees from - Pfizer and Taiho Pharma, outside the submitted study. Dr Mamesaya reports - personal fees from AstraZeneca K.K., Pfizer Japan, Inc., and Chugai - Pharmaceutical Co., Ltd.; grants and personal fees from Boehringer Ingelheim - (Ingelheim, Germany); personal fees from MSD K.K., Taiho Phar‐Maceutical Co., - Ltd., and Ono Pharmaceutical Co., Ltd., outside the submitted study. Dr Murakami - reports personal fees from AstraZeneca K.K., Ono Pharmaceutical, Bris‐tol‐Myers - Squibb Japan, Chugai Pharmaceutical Co., Ltd., Pfizer Inc. (New York, United - States of America), Novartis Pharma K.K., Boehringer Ingelheim, Taiho - Pharmaceutical, Eli Lilly K.K., and MSD, which are unrelated to the submitted - work. Dr Harada reports personal fees from Daiichi‐Sankyo Pharmaceutical Co. - while this study was performed as well as personal fees from Daiichi‐Sankyo - Pharmaceutical Co., AstraZeneca K.K., Brain Labo Co., and Chugai Pharmaceutical - Co. and grants from the Japan Agency for Medical Research and Development and the - Na‐tional Cancer Center Research and Development Fund, which are unrelated to the - submitted work. Dr Endo reports personal fees from Ono Pharmaceutical, - AstraZeneca, Takeda Pharmaceutical Co., Ltd., and Daiichi‐Sankyo Co., Ltd., - outside the submitted work. Dr Kazuhisa Takahashi reports grants and personal - fees from AstraZeneca K.K., Pfizer Japan, Inc., Eli Lilly K.K., MSD, and - Boehringer Ingelheim as well as grants from Takeda Pharmaceutical Co., Ltd., - Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Kyorin - Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., GlaxoSmithKline Consumer - Healthcare Japan K.K., Shionogi & Co., Ltd., and Novartis Pharma K.K., which are - not related to the submitted work. Dr Toshiaki Takahashi reports grants and - personal fees from AstraZeneca K.K., Pfizer Japan, Inc., Eli Lilly Japan K.K., - Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., - Boehringer Ingelheim Japan, Inc., and Pfizer Japan, Inc.; and personal fees from - Roche Diagnostics (Pleasanton, CA, United States of America) K.K., outside the - submitted work. The remaining authors declare no conflict of interest. -EDAT- 2022/06/14 06:00 -MHDA- 2022/07/19 06:00 -PMCR- 2022/07/01 -CRDT- 2022/06/13 23:52 -PHST- 2022/05/17 00:00 [revised] -PHST- 2022/04/15 00:00 [received] -PHST- 2022/05/19 00:00 [accepted] -PHST- 2022/06/14 06:00 [pubmed] -PHST- 2022/07/19 06:00 [medline] -PHST- 2022/06/13 23:52 [entrez] -PHST- 2022/07/01 00:00 [pmc-release] -AID - TCA14529 [pii] -AID - 10.1111/1759-7714.14529 [doi] -PST - ppublish -SO - Thorac Cancer. 2022 Jul;13(14):2064-2074. doi: 10.1111/1759-7714.14529. Epub 2022 - Jun 13. - -PMID- 38032455 -OWN - NLM -STAT- MEDLINE -DCOM- 20240126 -LR - 20240206 -IS - 1437-7772 (Electronic) -IS - 1341-9625 (Linking) -VI - 29 -IP - 2 -DP - 2024 Feb -TI - Prognostic significance of initial tumor shrinkage in patients with stage III - non-small cell lung cancer treated with durvalumab following chemoradiotherapy. -PG - 115-123 -LID - 10.1007/s10147-023-02436-5 [doi] -AB - BACKGROUND: Baseline tumor size (BTS) is one of the prognostic factors of - advanced non-small cell lung cancer (NSCLC) treated with immunotherapy. However, - its prognostic value in patients with locally advanced NSCLC receiving durvalumab - maintenance therapy remains unclear. METHODS: The present study retrospectively - reviewed 136 patients with unresectable stage III NSCLC who underwent CRT and - durvalumab at two institutions in Japan. The maximum diameter of the target - lesion (max BTS) before CRT was measured, the best response to CRT before - durvalumab was evaluated, and the impact of the response on durvalumab was - explored. Progression-free survival (PFS) and overall survival (OS) were defined - as the time from the day of starting durvalumab. RESULTS: Of the total cohort, - 133 (97.8%) patients had at least one measurable lesion. The best response to CRT - resulting in CR, PR, and SD was seen in 0 (0%), 69 (51.9%), and 64 (48.1%) - patients, respectively. PFS was significantly longer in the patients with PR than - in those with SD after CRT (median not reached vs. 20.0 months; HR: 0.51; - P = 0.023). Moreover, the absence of a massive lesion (max BTS < 50 mm) was - associated with a superior CRT response (P < 0.001). CONCLUSION: The best - response to induction CRT was associated with better PFS in patients with stage - III NSCLC receiving durvalumab following chemoradiotherapy. Although the absence - of a massive lesion was associated with a better response to induction CRT in - this cohort, this was not translated into PFS and OS benefit. -CI - © 2023. The Author(s) under exclusive licence to Japan Society of Clinical - Oncology. -FAU - Terashima, Yuto -AU - Terashima Y -AUID- ORCID: 0000-0002-1797-9708 -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, - Bunkyo-Ku, Tokyo, 113-0021, Japan. -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, Tokyo, Japan. -FAU - Hakozaki, Taiki -AU - Hakozaki T -AUID- ORCID: 0000-0002-9980-4417 -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, - Bunkyo-Ku, Tokyo, 113-0021, Japan. t-hakozaki@akane.waseda.jp. -AD - Graduate School of Advanced Science and Engineering, Faculty of Science and - Engineering, Waseda University, Tokyo, Japan. t-hakozaki@akane.waseda.jp. -FAU - Uehara, Yuji -AU - Uehara Y -AUID- ORCID: 0000-0001-8047-8730 -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, - Bunkyo-Ku, Tokyo, 113-0021, Japan. -FAU - Miyanaga, Akihiko -AU - Miyanaga A -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, Tokyo, Japan. -FAU - Kasahara, Kazuo -AU - Kasahara K -AUID- ORCID: 0000-0001-5551-1543 -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, Tokyo, Japan. -FAU - Seike, Masahiro -AU - Seike M -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, Tokyo, Japan. -FAU - Hosomi, Yukio -AU - Hosomi Y -AUID- ORCID: 0000-0002-3849-5905 -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, - Bunkyo-Ku, Tokyo, 113-0021, Japan. -LA - eng -PT - Journal Article -DEP - 20231130 -PL - Japan -TA - Int J Clin Oncol -JT - International journal of clinical oncology -JID - 9616295 -RN - 28X28X9OKV (durvalumab) -RN - 0 (Antibodies, Monoclonal) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Prognosis -MH - Retrospective Studies -MH - *Lung Neoplasms/drug therapy -MH - Chemoradiotherapy -MH - *Antibodies, Monoclonal -OTO - NOTNLM -OT - Chemoradiation -OT - Durvalumab -OT - Non–small cell lung cancer -OT - Tumor size -EDAT- 2023/11/30 12:42 -MHDA- 2024/01/26 06:43 -CRDT- 2023/11/30 11:08 -PHST- 2023/06/14 00:00 [received] -PHST- 2023/11/05 00:00 [accepted] -PHST- 2024/01/26 06:43 [medline] -PHST- 2023/11/30 12:42 [pubmed] -PHST- 2023/11/30 11:08 [entrez] -AID - 10.1007/s10147-023-02436-5 [pii] -AID - 10.1007/s10147-023-02436-5 [doi] -PST - ppublish -SO - Int J Clin Oncol. 2024 Feb;29(2):115-123. doi: 10.1007/s10147-023-02436-5. Epub - 2023 Nov 30. - -PMID- 34786889 -OWN - NLM -STAT- MEDLINE -DCOM- 20220321 -LR - 20220321 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 11 -IP - 1 -DP - 2022 Jan -TI - Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung - cancer outcomes in the real world. -PG - 86-93 -LID - 10.1002/cam4.4427 [doi] -AB - The evolution of diagnosis and treatment of advanced nonsmall-cell lung cancer - (NSCLC) has led to increasing the use of targeted therapy and immune checkpoint - inhibitors. The study goal was to assess the effect of molecular testing and the - introduction of new therapies on overall survival (OS). All patients with stage - IV NSCLC referred to BC Cancer were included in the study. Four 1-year time - cohorts were created based on molecular testing implementation and funded drug - availability: C1 baseline (2009), C2 EGFR TKI access (2011), C3 ALK inhibitor - access (2015), C4 immunotherapy availability (2017). Baseline demographics, - disease characteristics, and systemic therapy details were collected - retrospectively. OS was calculated using the Kaplan-Meier method and compared - using the log-rank test. There were 3421 patients identified with stage IV NSCLC - and 1319 (39%) received systemic therapy. In the four 1-year time cohorts - C1/C2/C3/C4: driver mutation-targeted treatment increased 1/17/27/34% (of total - systemic therapy), as did treatment with any line immunotherapy <1/1/9/38%. - Median OS with best supportive care (BSC) was 3.4/3.1/3.2/2.9 m (p = 0.16) and - with systemic treatment 9.9/10.9/13.9/15.0 m (p < 0.001). Median OS by treatment - exposure was BSC 3.1 m, chemotherapy only 7.3 m, targeted therapy 17.5 m, and - immunotherapy 20.7 m. In our real-world study, following the introduction of - targeted therapy and immune checkpoint inhibitors, there was a significant - improvement in OS in each successive time cohort concordant with advancements in - therapeutic options. -CI - © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Shokoohi, Aria -AU - Shokoohi A -AUID- ORCID: 0000-0002-2093-7381 -AD - Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada. -FAU - Al-Hashami, Zamzam -AU - Al-Hashami Z -AD - Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada. -AD - Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, - Canada. -FAU - Moore, Sara -AU - Moore S -AD - Division of Medical Oncology, The Ottawa Hospital, Ottawa, Ontario, Canada. -FAU - Pender, Alexandra -AU - Pender A -AD - Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada. -AD - Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, - Canada. -FAU - Wong, Selina K -AU - Wong SK -AD - Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada. -AD - Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, - Canada. -FAU - Wang, Ying -AU - Wang Y -AD - Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada. -AD - Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, - Canada. -FAU - Leung, Bonnie -AU - Leung B -AD - Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada. -FAU - Wu, Jonn -AU - Wu J -AD - Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, - Canada. -AD - Department of Radiation Oncology, BC Cancer, Vancouver, British Columbia, Canada. -FAU - Ho, Cheryl -AU - Ho C -AD - Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada. -AD - Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, - Canada. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20211116 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 31YO63LBSN (Nivolumab) -RN - 53AH36668S (Crizotinib) -RN - DPT0O3T46P (pembrolizumab) -RN - S65743JHBS (Gefitinib) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - Antineoplastic Agents/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/mortality -MH - Crizotinib/therapeutic use -MH - DNA Mutational Analysis -MH - Female -MH - Gefitinib/therapeutic use -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Lung Neoplasms/*drug therapy/genetics/mortality -MH - Male -MH - Middle Aged -MH - *Molecular Targeted Therapy -MH - Nivolumab/therapeutic use -MH - Retrospective Studies -MH - Survival Analysis -PMC - PMC8704182 -OTO - NOTNLM -OT - chemotherapy -OT - immunotherapy -OT - medical oncology -OT - nonsmall-cell lung cancer -OT - targeted therapy -COIS- Dr. Pender reports receiving personal fees from Guardant Health and Bristol Myers - Squibb, outside the submitted work; Ms. Leung reports receiving personal fees - from Takeda Canada, outside the submitted work; and Dr. Ho reports receiving - grants and personal fees from AstraZeneca, EMD Serono, and Roche, and personal - fees from Bayer, Bristol Myers Squibb, Eisai, Merck, Novartis, and Takeda Canada, - all outside of the submitted work. The remaining authors declare no conflict of - interest. -EDAT- 2021/11/18 06:00 -MHDA- 2022/03/22 06:00 -PMCR- 2021/11/16 -CRDT- 2021/11/17 07:21 -PHST- 2021/09/19 00:00 [revised] -PHST- 2021/08/09 00:00 [received] -PHST- 2021/09/21 00:00 [accepted] -PHST- 2021/11/18 06:00 [pubmed] -PHST- 2022/03/22 06:00 [medline] -PHST- 2021/11/17 07:21 [entrez] -PHST- 2021/11/16 00:00 [pmc-release] -AID - CAM44427 [pii] -AID - 10.1002/cam4.4427 [doi] -PST - ppublish -SO - Cancer Med. 2022 Jan;11(1):86-93. doi: 10.1002/cam4.4427. Epub 2021 Nov 16. - -PMID- 38195320 -OWN - NLM -STAT- MEDLINE -DCOM- 20240516 -LR - 20240614 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 25 -IP - 3 -DP - 2024 May -TI - Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated - Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab - Consolidation. -PG - e161-e171 -LID - S1525-7304(23)00266-8 [pii] -LID - 10.1016/j.cllc.2023.12.009 [doi] -AB - BACKGROUND: Immune checkpoint inhibitor (ICI) consolidation following concurrent - chemoradiotherapy (CRT) substantially improved progression free survival (PFS) - and overall survival (OS) in the PACIFIC trial becoming the standard of care in - locally-advanced, unresectable NSCLC. KRAS mutation may influence response to - ICI. METHODS: In this single-institution, retrospective analysis, we compared - treatment outcomes for patients with unresectable KRAS mutated (KRAS-mt) and - wild-type (KRAS-wt) NSCLC treated with CRT between October 2017 and December - 2021. Kaplan-Meier analysis was conducted comparing median progression free - survival and median overall survival from completion of radiotherapy in all - KRAS-mt patients and KRAS-G12C-mutated patients. Outcomes were also compared with - and without ICI consolidation. RESULTS: Of 156 patients, 42 (26.9%) were KRAS-mt - and 114 (73.1%) were KRAS-wt. Baseline characteristics differed only in - histology; KRAS-mt NSCLC more likely to be adenocarcinoma. KRAS-mt patients had - worse PFS (median 6.3 vs. 10.7 months, P = .041) but similar OS (median 23.1 vs. - 27.3 months, P = .237). KRAS-mt patients were more likely to not receive ICI due - to rapid disease progression post-CRT (23.8% vs. 4.4%, P = .007). Among patients - who received ICI (n = 114), KRAS-mt was not associated with inferior PFS (8.1 vs. - 11.9 months, P = .355) or OS (30.5 vs. 31.7 months, P = .692). KRAS-G12C patients - (n = 22) had similar PFS and OS to other KRAS-mt. CONCLUSION: In one of the - largest post-CRT KRAS-mt cohort published, KRAS-mt was associated with inferior - PFS, largely due to rapid progression prior to ICI consolidation, but did not - affect OS. Among those who received ICI consolidation, outcomes were comparable - regardless of KRAS-mt status. -CI - Copyright © 2023 Elsevier Inc. All rights reserved. -FAU - Barsouk, Adam -AU - Barsouk A -AD - Division of Hematology and Oncology, Department of Medicine, Perelman School of - Medicine, University of Pennsylvania, Philadelphia, PA. Electronic address: - Adam.barsouk@pennmedicine.upenn.edu. -FAU - Friedes, Cole -AU - Friedes C -AD - Department of Radiation Oncology, Perelman School of Medicine, University of - Pennsylvania, Philadelphia, PA. -FAU - Iocolano, Michelle -AU - Iocolano M -AD - Department of Radiation Oncology, Perelman School of Medicine, University of - Pennsylvania, Philadelphia, PA. -FAU - Doucette, Abigail -AU - Doucette A -AD - Department of Radiation Oncology, Perelman School of Medicine, University of - Pennsylvania, Philadelphia, PA. -FAU - Cohen, Roger B -AU - Cohen RB -AD - Division of Hematology and Oncology, Department of Medicine, Perelman School of - Medicine, University of Pennsylvania, Philadelphia, PA. -FAU - Robinson, Kyle W -AU - Robinson KW -AD - Division of Hematology and Oncology, Department of Medicine, Perelman School of - Medicine, University of Pennsylvania, Philadelphia, PA. -FAU - D'Avella, Christopher A -AU - D'Avella CA -AD - Division of Hematology and Oncology, Department of Medicine, Perelman School of - Medicine, University of Pennsylvania, Philadelphia, PA. -FAU - Marmarelis, Melina E -AU - Marmarelis ME -AD - Division of Hematology and Oncology, Department of Medicine, Perelman School of - Medicine, University of Pennsylvania, Philadelphia, PA. -FAU - Kosteva, John A -AU - Kosteva JA -AD - Division of Hematology and Oncology, Department of Medicine, Perelman School of - Medicine, University of Pennsylvania, Philadelphia, PA. -FAU - Singh, Aditi P -AU - Singh AP -AD - Division of Hematology and Oncology, Department of Medicine, Perelman School of - Medicine, University of Pennsylvania, Philadelphia, PA. -FAU - Ciunci, Christine A -AU - Ciunci CA -AD - Division of Hematology and Oncology, Department of Medicine, Perelman School of - Medicine, University of Pennsylvania, Philadelphia, PA. -FAU - Levin, William P -AU - Levin WP -AD - Department of Radiation Oncology, Perelman School of Medicine, University of - Pennsylvania, Philadelphia, PA. -FAU - Cengel, Keith A -AU - Cengel KA -AD - Department of Radiation Oncology, Perelman School of Medicine, University of - Pennsylvania, Philadelphia, PA. -FAU - Bradley, Jeffrey D -AU - Bradley JD -AD - Department of Radiation Oncology, Perelman School of Medicine, University of - Pennsylvania, Philadelphia, PA. -FAU - Feigenberg, Steven J -AU - Feigenberg SJ -AD - Department of Radiation Oncology, Perelman School of Medicine, University of - Pennsylvania, Philadelphia, PA. -FAU - Sun, Lova -AU - Sun L -AD - Division of Hematology and Oncology, Department of Medicine, Perelman School of - Medicine, University of Pennsylvania, Philadelphia, PA. -FAU - Aggarwal, Charu -AU - Aggarwal C -AD - Division of Hematology and Oncology, Department of Medicine, Perelman School of - Medicine, University of Pennsylvania, Philadelphia, PA. -FAU - Langer, Corey J -AU - Langer CJ -AD - Division of Hematology and Oncology, Department of Medicine, Perelman School of - Medicine, University of Pennsylvania, Philadelphia, PA. -FAU - Yegya-Raman, Nikhil -AU - Yegya-Raman N -AD - Department of Radiation Oncology, Perelman School of Medicine, University of - Pennsylvania, Philadelphia, PA. Electronic address: - Nikhil.Yegya-Raman@pennmedicine.upenn.edu. -LA - eng -PT - Journal Article -DEP - 20231222 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (KRAS protein, human) -RN - 0 (durvalumab) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/genetics/drug therapy/therapy/pathology/mortality -MH - Female -MH - Male -MH - *Lung Neoplasms/drug therapy/genetics/pathology/therapy/mortality -MH - *Proto-Oncogene Proteins p21(ras)/genetics -MH - Middle Aged -MH - Retrospective Studies -MH - Aged -MH - *Chemoradiotherapy/methods -MH - *Mutation -MH - Adult -MH - Antibodies, Monoclonal/therapeutic use -MH - Aged, 80 and over -MH - Survival Rate -MH - Consolidation Chemotherapy -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Antineoplastic Agents, Immunological/therapeutic use -MH - Treatment Outcome -OTO - NOTNLM -OT - immunotherapy -OT - locally advanced NSCLC -EDAT- 2024/01/10 00:42 -MHDA- 2024/05/17 00:44 -CRDT- 2024/01/09 22:12 -PHST- 2023/09/03 00:00 [received] -PHST- 2023/12/11 00:00 [revised] -PHST- 2023/12/17 00:00 [accepted] -PHST- 2024/05/17 00:44 [medline] -PHST- 2024/01/10 00:42 [pubmed] -PHST- 2024/01/09 22:12 [entrez] -AID - S1525-7304(23)00266-8 [pii] -AID - 10.1016/j.cllc.2023.12.009 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2024 May;25(3):e161-e171. doi: 10.1016/j.cllc.2023.12.009. Epub - 2023 Dec 22. - -PMID- 33298727 -OWN - NLM -STAT- MEDLINE -DCOM- 20210927 -LR - 20210927 -IS - 1540-336X (Electronic) -IS - 1528-9117 (Linking) -VI - 26 -IP - 6 -DP - 2020 Nov/Dec -TI - Immunotherapy for Lung Cancer-Improving Outcomes in Patients With Locally - Advanced Non-Small Cell Lung Cancer With Immunotherapy. -PG - 548-554 -LID - 10.1097/PPO.0000000000000485 [doi] -AB - Patients with locally advanced non-small cell lung cancer (NSCLC), a heterogenous - group encompassing stage IIIA-IIIC disease, often have surgically unresectable - cancer and are managed with concurrent chemoradiation. Since the establishment of - platinum-based chemoradiation as standard of care for unresectable locally - advanced NSCLC, various strategies including escalating radiation dose, targeted - therapies, antiangiogenic agents, and induction or consolidation chemotherapy - have failed to show improvement in outcomes. However, recently, use of - consolidation immunotherapy with durvalumab following concurrent chemoradiation - therapy has been associated with improvement in survival and has led to a - paradigm shift. In this review, we will summarize results from trials of - immunotherapy in locally advanced NSCLC and comment on ongoing trials and - potential future investigations. -FAU - Sun, Lova -AU - Sun L -AD - From the Division of Hematology/Oncology, Department of Medicine, University of - Pennsylvania, Philadelphia, PA. -FAU - Aggarwal, Charu -AU - Aggarwal C -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - Cancer J -JT - Cancer journal (Sudbury, Mass.) -JID - 100931981 -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Combined Modality Therapy -MH - Humans -MH - *Immunotherapy -MH - *Lung Neoplasms/drug therapy -EDAT- 2020/12/11 06:00 -MHDA- 2021/09/28 06:00 -CRDT- 2020/12/10 05:43 -PHST- 2020/12/10 05:43 [entrez] -PHST- 2020/12/11 06:00 [pubmed] -PHST- 2021/09/28 06:00 [medline] -AID - 00130404-202011000-00011 [pii] -AID - 10.1097/PPO.0000000000000485 [doi] -PST - ppublish -SO - Cancer J. 2020 Nov/Dec;26(6):548-554. doi: 10.1097/PPO.0000000000000485. - -PMID- 37243795 -OWN - NLM -STAT- MEDLINE -DCOM- 20230614 -LR - 20231127 -IS - 1432-0843 (Electronic) -IS - 0344-5704 (Linking) -VI - 92 -IP - 1 -DP - 2023 Jul -TI - Subsequent treatment for locally advanced non-small-cell lung cancer that - progressed after definitive chemoradiotherapy and consolidation therapy with - durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02). -PG - 29-37 -LID - 10.1007/s00280-023-04547-2 [doi] -AB - PURPOSE: For patients with locally advanced non-small-cell lung cancer (LA-NSCLC) - that progressed after definitive chemoradiotherapy (CRT) and durvalumab - consolidation therapy, no subsequent standard treatment exists. The type of - treatment selected for each timing of disease progression and its efficacy have - not been investigated. METHODS: We retrospectively enrolled patients with - LA-NSCLC or inoperable NSCLC that progressed after definitive CRT and durvalumab - consolidation therapy at 15 Japanese institutions. Patients were classified into - the following: Early Discontinuation group (disease progression within 6 months - after durvalumab initiation), Late Discontinuation group (disease progression - from 7 to 12 months after durvalumab initiation), and Accomplishment group - (disease progression from 12 months after durvalumab initiation). RESULTS: - Altogether, 127 patients were analyzed, including 50 (39.4%), 42 (33.1%) and 35 - (27.5%) patients from the Early Discontinuation, Late Discontinuation, and - Accomplishment groups, respectively. Subsequent treatments were Platinum plus - immune checkpoint inhibitors (ICI) in 18 (14.2%), ICI in 7 (5.5%), Platinum in 59 - (46.4%), Non-Platinum in 35 (27.6%), and tyrosine kinase inhibitor in 8 (6.3%) - patients. In the Early Discontinuation, Late Discontinuation, and Accomplishment - groups, 4 (8.0%), 7 (16.7%), and 7 (20.0%) patients were receiving Platinum plus - ICI; 21 (42.0%), 22 (52.4%), and 16 (45.7%) were receiving Platinum, and 20 - (40.0%), 8 (19.0%), and 7 (20.0%) were receiving Non-Platinum, respectively. No - significant difference in progression-free survival was observed in the timing of - disease progression. CONCLUSION: In patients with LA-NSCLC hat progressed after - definitive CRT and durvalumab consolidation therapy, subsequent treatment may - change depending on the timing of disease progression. -CI - © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, - part of Springer Nature. -FAU - Hasegawa, Tsukasa -AU - Hasegawa T -AD - Division of Respiratory Disease, Department of Internal Medicine, The Jikei - University Daisan Hospital, Tokyo, Japan. -FAU - Ariyasu, Ryo -AU - Ariyasu R -AUID- ORCID: 0000-0003-4393-9176 -AD - Department of Thoracic Medical Oncology, The Cancer Institute Hospital of - Japanese Foundation for Cancer Research, Tokyo, Japan. ryo.ariyasu@jfcr.or.jp. -FAU - Tanaka, Hisashi -AU - Tanaka H -AD - Department of Respiratory Medicine, Hirosaki University Graduate School of - Medicine, Hirosaki, Japan. -FAU - Saito, Ryota -AU - Saito R -AD - Department of Respiratory Medicine, Tohoku University Hospital, Sendai, Japan. -FAU - Kawashima, Yosuke -AU - Kawashima Y -AD - Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan. -FAU - Horiike, Atsushi -AU - Horiike A -AD - Division of Medical Oncology, Department of Medicine, Showa University School of - Medicine, Tokyo, Japan. -FAU - Sakatani, Toshio -AU - Sakatani T -AD - Division of Respiratory, NTT Medical Center, Tokyo, Japan. -FAU - Tozuka, Takehiro -AU - Tozuka T -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, Tokyo, Japan. -FAU - Shiihara, Jun -AU - Shiihara J -AD - Department of Pulmonary Medicine, Saitama Medical Center, Jichi Medical - University, Saitama, Japan. -FAU - Saiki, Masafumi -AU - Saiki M -AD - Department of Respiratory Medicine, Graduate School of Medicine, University of - Yamanashi, Yamanashi, Japan. -FAU - Tambo, Yuichi -AU - Tambo Y -AD - Department of Respiratory Medicine, Kanazawa University, Kanazawa, Japan. -FAU - Sonoda, Tomoaki -AU - Sonoda T -AD - Third Department of Internal Medicine, Faculty of Medical Sciences, University of - Fukui, Fukui, Japan. -FAU - Miyazaki, Akito -AU - Miyazaki A -AD - Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama - Medical Center, Osaka, Japan. -FAU - Uematsu, Shinya -AU - Uematsu S -AD - Department of Respiratory Medicine, Osaka Red Cross Hospital, Osaka, Japan. -FAU - Tsuchiya-Kawano, Yuko -AU - Tsuchiya-Kawano Y -AD - Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, - Kitakyushu, Japan. -FAU - Yanagitani, Noriko -AU - Yanagitani N -AD - Department of Thoracic Medical Oncology, The Cancer Institute Hospital of - Japanese Foundation for Cancer Research, Tokyo, Japan. -FAU - Nishino, Makoto -AU - Nishino M -AD - Department of Thoracic Medical Oncology, The Cancer Institute Hospital of - Japanese Foundation for Cancer Research, Tokyo, Japan. -LA - eng -PT - Journal Article -PT - Multicenter Study -DEP - 20230527 -PL - Germany -TA - Cancer Chemother Pharmacol -JT - Cancer chemotherapy and pharmacology -JID - 7806519 -RN - 28X28X9OKV (durvalumab) -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Consolidation Chemotherapy -MH - Retrospective Studies -MH - *Antineoplastic Agents, Immunological -MH - Neoplasm Staging -MH - Chemoradiotherapy -MH - Disease Progression -OTO - NOTNLM -OT - Chemoradiotherapy -OT - Durvalumab -OT - Stage III non-small-cell lung cancer -OT - Subsequent treatment -EDAT- 2023/05/27 19:14 -MHDA- 2023/06/14 06:42 -CRDT- 2023/05/27 15:02 -PHST- 2023/03/08 00:00 [received] -PHST- 2023/05/19 00:00 [accepted] -PHST- 2023/06/14 06:42 [medline] -PHST- 2023/05/27 19:14 [pubmed] -PHST- 2023/05/27 15:02 [entrez] -AID - 10.1007/s00280-023-04547-2 [pii] -AID - 10.1007/s00280-023-04547-2 [doi] -PST - ppublish -SO - Cancer Chemother Pharmacol. 2023 Jul;92(1):29-37. doi: - 10.1007/s00280-023-04547-2. Epub 2023 May 27. - -PMID- 32462835 -OWN - NLM -STAT- MEDLINE -DCOM- 20200603 -LR - 20200603 -IS - 1660-9379 (Print) -IS - 1660-9379 (Linking) -VI - 16 -IP - 695 -DP - 2020 May 27 -TI - [Small-cell lung cancer: management and novelties]. -PG - 1079-1085 -AB - Small cell lung cancer is a recalcitrant malignancy with 5-year survival rates of - less than 20%. In the majority of cases, patients have metastatic disease at - diagnosis despite the new screening method by low-dose CT-scan. The high - throughput sequencing has deepened our understanding of its biology. While the - treatment of localized disease has changed little, the arrival of immune - checkpoint inhibitors have revolutionized the management of extensive disease. At - the same time, new strategies involving certain potential genetic targets are - being analyzed on a large scale that could become valuable therapeutic - alternatives in the future. Radiation therapy remains a very useful therapeutic - modality in all stages of the disease. This article aims to review the - epidemiology, molecular pathology, management and innovative therapies in - small-cell lung cancer. -FAU - Abdelhamid, Karim -AU - Abdelhamid K -AD - Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne. -FAU - Kakourou, Artemisia -AU - Kakourou A -AD - Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne. -FAU - Degrauwe, Nils -AU - Degrauwe N -AD - Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne. -FAU - Nikolopoulou, Asteria -AU - Nikolopoulou A -AD - Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne. -FAU - Bouchaab, Hasna -AU - Bouchaab H -AD - Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne. -FAU - Peters, Solange -AU - Peters S -AD - Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne. -FAU - Nguyen-Ngoc, Tu -AU - Nguyen-Ngoc T -AD - Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne. -FAU - Mederos, Nuria -AU - Mederos N -AD - Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne. -LA - fre -PT - Journal Article -PT - Review -TT - Cancer du poumon à petites cellules : prise en charge et nouveautés. -PL - Switzerland -TA - Rev Med Suisse -JT - Revue medicale suisse -JID - 101219148 -SB - IM -MH - Humans -MH - Lung Neoplasms/drug therapy/radiotherapy/*therapy -MH - Small Cell Lung Carcinoma/drug therapy/radiotherapy/*therapy -MH - Survival Rate -COIS- Dr Hasna Bouchaab a participé à des comités consultatifs de Takeda. Pr Solange - Peters : a reçu des fonds éducationnels, travaillé comme consultante - indépendante, et/ou a participé à des comités consultatifs et donné des - conférences pour : Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, - Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi - Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, - Illumina, Incyte, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, - Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics and Takeda, de - qui elle a reçu des honoraires. Dr Tu Nguyen-Ngoc a travaillé comme consultant - indépendant et/ou a participé à des comités consultatifs et donné des conférences - pour : AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche et Merck, Sharp - and Dohme, de qui il a reçu des honoraires. Les autres auteurs n’ont déclaré - aucun conflit d’intérêts en relation avec cet article. -EDAT- 2020/05/29 06:00 -MHDA- 2020/06/04 06:00 -CRDT- 2020/05/29 06:00 -PHST- 2020/05/29 06:00 [entrez] -PHST- 2020/05/29 06:00 [pubmed] -PHST- 2020/06/04 06:00 [medline] -AID - RMS0695-003 [pii] -PST - ppublish -SO - Rev Med Suisse. 2020 May 27;16(695):1079-1085. - -PMID- 37951887 -OWN - NLM -STAT- MEDLINE -DCOM- 20231113 -LR - 20231114 -IS - 1471-2466 (Electronic) -IS - 1471-2466 (Linking) -VI - 23 -IP - 1 -DP - 2023 Nov 11 -TI - PPIs therapy has a negative impact on the clinical outcomes of advanced SCLC - patients treated with PD-L1 inhibitors. -PG - 438 -LID - 10.1186/s12890-023-02754-4 [doi] -LID - 438 -AB - BACKGROUND: Programmed death-ligand 1 (PD-L1) inhibitors has emerged as a - first-line therapeutic strategy for advanced small cell lung cancer (SCLC), which - can stimulate T-cell activation, thereby preventing tumor avoidance of - immunologic surveillance, whereas, proton pump inhibitors (PPIs) can play an - important role in regulating immune function. This study assessed whether the - concomitantly use of PPIs affected outcomes of immunotherapy in advanced SCLC. - METHODS: Data from advanced SCLC patients who firstly treated with PD-L1 - inhibitors between July 2018 and February 2021 was retrospectively analyzed. The - impact of concomitant medications (especially PPIs) on objective response rate, - progression-free survival (PFS) and overall survival (OS) were evaluated. - RESULTS: Of 208 patients, 101 received immunotherapy concomitant PPIs. The median - PFS of patients receiving PPIs (6.6 months) were significantly shorter than those - without PPIs (10.6 months), and so was OS. There was associated with a 74.9% - increased risk of progression and 58.3% increased risk of death. Both first-line - and post-first-line immunotherapy, patients treated PPIs had poorer PFS. - CONCLUSION: PPIs therapy has a negative impact on the clinical outcomes of - advanced SCLC patients treated with PD-L1 inhibitors. -CI - © 2023. The Author(s). -FAU - Zhang, Sisi -AU - Zhang S -AD - Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, - Shandong, 250062, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Academy of Medical Sciences, Jinan, Shandong, - 250117, China. -FAU - Tian, Jing -AU - Tian J -AD - Department of Radiation Oncology, Jinan Zhangqiu District People's Hospital, - Jinan, Shandong, 250200, China. -FAU - Wang, Xinwei -AU - Wang X -AD - Department of Intensive Care Medical Center, Shandong Public Health Clinical - Center, Shandong University, Jinan, Shandong, 250013, China. -FAU - Liu, Chengxin -AU - Liu C -AUID- ORCID: 0000-0003-2962-0820 -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Academy of Medical Sciences, Jinan, Shandong, - 250117, China. 853486659@qq.com. -LA - eng -GR - 2020-4-181/the second batch of science and technology plan projects of Jinan - Municipal Health and Health Commission in 2020/ -GR - flzh202111/Beijing Bethune Public Welfare Foundation, Translational Medicine - Research Fund of Tumor radiotherapy/ -GR - 320.6750.2021-01-35/Wu Jieping Medical Foundation, Special fund for clinical - research/ -PT - Journal Article -DEP - 20231111 -PL - England -TA - BMC Pulm Med -JT - BMC pulmonary medicine -JID - 100968563 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Proton Pump Inhibitors) -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/drug therapy -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Retrospective Studies -MH - Immunotherapy -MH - Proton Pump Inhibitors/therapeutic use -MH - *Lung Neoplasms/drug therapy -PMC - PMC10638834 -OTO - NOTNLM -OT - Immune checkpoint inhibitors -OT - Immunotherapy -OT - Overall survival -OT - PD-L1 inhibitors -OT - Progression free survival -OT - Proton pump inhibitors -COIS- The authors declare no competing interests. -EDAT- 2023/11/12 00:42 -MHDA- 2023/11/13 06:42 -PMCR- 2023/11/11 -CRDT- 2023/11/11 23:15 -PHST- 2023/05/07 00:00 [received] -PHST- 2023/11/07 00:00 [accepted] -PHST- 2023/11/13 06:42 [medline] -PHST- 2023/11/12 00:42 [pubmed] -PHST- 2023/11/11 23:15 [entrez] -PHST- 2023/11/11 00:00 [pmc-release] -AID - 10.1186/s12890-023-02754-4 [pii] -AID - 2754 [pii] -AID - 10.1186/s12890-023-02754-4 [doi] -PST - epublish -SO - BMC Pulm Med. 2023 Nov 11;23(1):438. doi: 10.1186/s12890-023-02754-4. - -PMID- 32757454 -OWN - NLM -STAT- MEDLINE -DCOM- 20210105 -LR - 20210105 -IS - 1743-7563 (Electronic) -IS - 1743-7555 (Print) -IS - 1743-7555 (Linking) -VI - 16 -IP - 6 -DP - 2020 Dec -TI - Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis - in patients with advanced non-small cell lung cancer. -PG - 299-304 -LID - 10.1111/ajco.13380 [doi] -AB - Immune-related pneumonitis is an uncommon but potentially fatal immune-related - adverse event in advanced non-small cell lung cancer (NSCLC) patients during - treatment with anti-programmed cell death 1 (PD-1) and programmed cell - death-ligand 1 (PD-L1). Underlying emphysema, interstitial lung disease (ILD), - and previous radiation therapy for lung cancer might be factors precipitating - immune-related pneumonitis. The incidence of immune-related pneumonitis is - reported to be higher in those treated with PD-1 inhibitors than in those treated - with anti-PD-L1 inhibitors. Early detection and diagnosis and appropriate - management according to the severity are critical to improving the prognosis. The - first-line physicians, including the primary responsible oncologists, family - doctors, emergency physicians and NSCLC patients should be trained to identify - and report symptoms of immune-related pneumonitis as early as possible. - Multidisciplinary treatment teams involving clinicians (including ILD specialists - and lung cancer specialists), radiologists and pathologists are recommended for - the treatment of immune-related pneumonitis. -CI - © 2020 The Authors. Asia-Pacific Journal of Clinical Oncology published by John - Wiley & Sons Australia, Ltd. -FAU - Sun, Yuxin -AU - Sun Y -AD - Department of Pulmonary and Critical Care Medicine, Peking Union Medical College - Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, - Beijing, China. -FAU - Shao, Chi -AU - Shao C -AD - Department of Pulmonary and Critical Care Medicine, Peking Union Medical College - Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, - Beijing, China. -FAU - Li, Shan -AU - Li S -AD - Department of Pulmonary and Critical Care Medicine, Peking Union Medical College - Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, - Beijing, China. -FAU - Xu, Yan -AU - Xu Y -AD - Department of Pulmonary and Critical Care Medicine, Peking Union Medical College - Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, - Beijing, China. -FAU - Xu, Kai -AU - Xu K -AD - Radiological Department, Peking Union Medical College Hospital, Chinese Academy - of Medical Sciences & Peking Union Medical College, Beijing, China. -FAU - Zhang, Ying -AU - Zhang Y -AD - International Medical Service Department, Peking Union Medical College Hospital, - Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, - China. -FAU - Huang, Hui -AU - Huang H -AUID- ORCID: 0000-0001-7184-0005 -AD - Department of Pulmonary and Critical Care Medicine, Peking Union Medical College - Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, - Beijing, China. -FAU - Wang, Mengzhao -AU - Wang M -AD - Department of Pulmonary and Critical Care Medicine, Peking Union Medical College - Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, - Beijing, China. -FAU - Xu, Zuojun -AU - Xu Z -AD - Department of Pulmonary and Critical Care Medicine, Peking Union Medical College - Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, - Beijing, China. -LA - eng -GR - 2018-I2M-1-003/CAMS Innovation Fund for Medical Sciences/ -GR - 81600050/Chinese National Natural Science Fund Youth Fund project/ -GR - 2019ZX09734001-002/"13th Five-Year" National Science and Technology Major Project - for New Drugs/ -PT - Journal Article -PT - Review -DEP - 20200805 -PL - Australia -TA - Asia Pac J Clin Oncol -JT - Asia-Pacific journal of clinical oncology -JID - 101241430 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/*complications/drug therapy -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/*adverse effects -MH - Lung Neoplasms/*complications/drug therapy -MH - Male -MH - Pneumonia/*chemically induced -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -MH - Risk Factors -PMC - PMC7754394 -OTO - NOTNLM -OT - immune checkpoint inhibitor -OT - immune-related pneumonitis -OT - non-small cell lung cancer -COIS- No authors report any conflicts of interest. -EDAT- 2020/08/07 06:00 -MHDA- 2021/01/06 06:00 -PMCR- 2020/12/22 -CRDT- 2020/08/07 06:00 -PHST- 2019/09/08 00:00 [received] -PHST- 2020/05/07 00:00 [accepted] -PHST- 2020/08/07 06:00 [pubmed] -PHST- 2021/01/06 06:00 [medline] -PHST- 2020/08/07 06:00 [entrez] -PHST- 2020/12/22 00:00 [pmc-release] -AID - AJCO13380 [pii] -AID - 10.1111/ajco.13380 [doi] -PST - ppublish -SO - Asia Pac J Clin Oncol. 2020 Dec;16(6):299-304. doi: 10.1111/ajco.13380. Epub 2020 - Aug 5. - -PMID- 31686616 -OWN - NLM -STAT- MEDLINE -DCOM- 20200626 -LR - 20240721 -IS - 1753-4666 (Electronic) -IS - 1753-4658 (Print) -IS - 1753-4658 (Linking) -VI - 13 -DP - 2019 Jan-Dec -TI - Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence - and real-world experience. -PG - 1753466619885530 -LID - 10.1177/1753466619885530 [doi] -LID - 1753466619885530 -AB - Stage III non-small cell lung cancer (NSCLC) has a dismal prognosis, with only - 15-20% of patients alive at 5 years after concomitant chemo-radiotherapy, which - represents the standard treatment. Targeting immune-checkpoint inhibitors - represents a standard option for advanced NSCLC. Improvements in understanding of - the immune profile of NSCLC has led to the development of immunotherapeutic - strategies, including inhibitory molecules responsible for abrogating an - anticancer immune response such as programmed cell-death 1 and programmed - cell-death ligand 1. A recently published phase III trial (PACIFIC) showed for - the first time an improved overall survival in stage III NSCLC patients with - consolidative durvalumab. The aim of this review is to summarize and discuss the - clinical evidence for the use of durvalumab in stage III NSCLC, with a brief - overview on future perspectives in this setting. -FAU - Botticella, Angela -AU - Botticella A -AUID- ORCID: 0000-0002-9652-8744 -AD - Department of Radiation Oncology, Gustave Roussy, Villejuif, France. -FAU - Mezquita, Laura -AU - Mezquita L -AD - Medical Oncology Department, Gustave Roussy, Villejuif, France. -FAU - Le Pechoux, Cecile -AU - Le Pechoux C -AD - Department of Radiation Oncology, Gustave Roussy, Villejuif, France. -FAU - Planchard, David -AU - Planchard D -AD - Head of Thoracic Oncology Group, Medical Oncology Department, Gustave Roussy, 114 - Rue Edouard Vaillant, Villejuif 94805, France. -LA - eng -PT - Journal Article -PL - England -TA - Ther Adv Respir Dis -JT - Therapeutic advances in respiratory disease -JID - 101316317 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal/*administration & dosage/pharmacology -MH - Antineoplastic Agents, Immunological/administration & dosage/pharmacology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology -MH - Neoplasm Staging -MH - Prognosis -MH - Survival Rate -PMC - PMC6831969 -OTO - NOTNLM -OT - NSCLC -OT - chemo–radiation -OT - consolidation -OT - durvalumab -OT - stage III -COIS- Conflict of interest statement: AB: nothing to declare. LM: Consulting, advisory - role: Roche Diagnostics. Lectures and educational activities: Bristol-Myers - Squibb, Tecnofarma, Roche, AstraZeneca. Travel, accommodations, expenses: Chugai. - DP: Consulting, advisory role or lectures: AstraZeneca, Bristol-Myers Squibb, - Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, - Pfizer, prIME Oncology, Peer CME, Roche. Honoraria: AstraZeneca, Bristol-Myers - Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME - Oncology, Peer CME, Roche. Clinical trials research: AstraZeneca, Bristol-Myers - Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, - Medimmun, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo. Travel, - accommodations, expenses: AstraZeneca, Roche, Novartis, prIME Oncology, Pfizer. -EDAT- 2019/11/07 06:00 -MHDA- 2020/06/27 06:00 -PMCR- 2019/11/05 -CRDT- 2019/11/06 06:00 -PHST- 2019/11/06 06:00 [entrez] -PHST- 2019/11/07 06:00 [pubmed] -PHST- 2020/06/27 06:00 [medline] -PHST- 2019/11/05 00:00 [pmc-release] -AID - 10.1177_1753466619885530 [pii] -AID - 10.1177/1753466619885530 [doi] -PST - ppublish -SO - Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619885530. doi: - 10.1177/1753466619885530. - -PMID- 38302416 -OWN - NLM -STAT- MEDLINE -DCOM- 20240205 -LR - 20240206 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 12 -IP - 2 -DP - 2024 Feb 1 -TI - First exploration of the on-treatment changes in tumor and organ uptake of a - radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with - non-small cell lung cancer using whole body PET. -LID - 10.1136/jitc-2023-007659 [doi] -LID - e007659 -AB - BACKGROUND: In patients with locally advanced unresectable non-small cell lung - cancer (NSCLC), durvalumab, an anti-programmed cell death ligand-1 (PD-L1) - antibody, has shown improved overall survival when used as consolidation therapy - following concurrent chemoradiotherapy (CRT). However, it is unclear whether CRT - itself upregulates PD-L1 expression. Therefore, this study aimed to explore the - changes in the uptake of the anti PD-L1 antibody [(89)Zr]Zr-durvalumab in tumors - and healthy organs during CRT in patients with NSCLC. METHODS: Patients with - NSCLC scheduled to undergo CRT were scanned 7±1 days after administration of - 37±1 MBq [(89)Zr]Zr-durvalumab at baseline, 1-week on-treatment and 1 week after - finishing 6 weeks of CRT. First, [(89)Zr]Zr-durvalumab uptake was visually - assessed in a low dose cohort with a mass dose of 2 mg durvalumab (0.13% of - therapeutic dose) and subsequently, quantification was done in a high dose cohort - with a mass dose of 22.5 mg durvalumab (1.5% of therapeutic dose). Tracer - pharmacokinetics between injections were compared using venous blood samples - drawn in the 22.5 mg cohort. Visual assessment included suspected lesion - detectability. Positron emission tomography (PET) uptake in tumoral and healthy - tissues was quantified using tumor to plasma ratio (TPR) and organ to plasma - ratio, respectively. RESULTS: In the 2 mg dose cohort, 88% of the 17 identified - tumor lesions were positive at baseline, compared with 69% (9/13) for the 22.5 mg - cohort. Although the absolute plasma concentrations between patients varied, the - intrapatient variability was low. The ten quantitatively assessed lesions in the - 22.5 mg cohort had a median TPR at baseline of 1.3 (IQR 0.7-1.5), on-treatment of - 1.0 (IQR 0.7-1.4) and at the end of treatment of 0.7 (IQR 0.6-0.7). On-treatment, - an increased uptake in bone marrow was seen in three out of five patients - together with a decreased uptake in the spleen in four out of five patients. - CONCLUSIONS: This study successfully imaged patients with NSCLC with - [(89)Zr]Zr-durvalumab PET before and during CRT. Our data did not show any - increase in [(89)Zr]Zr-durvalumab uptake in the tumor 1-week on-treatment and at - the end of treatment. The changes observed in bone marrow and spleen may be due - to an CRT-induced effect on immune cells. TRIAL REGISTRATION NUMBER: EudraCT - number: 2019-004284-51. -CI - © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Pouw, Johanna E E -AU - Pouw JEE -AUID- ORCID: 0000-0003-1358-1804 -AD - Department of Medical Oncology, Amsterdam UMC Locatie VUmc, Amsterdam, - Netherlands. -AD - Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Netherlands. -FAU - Hashemi, Sayed M S -AU - Hashemi SMS -AD - Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Netherlands. -AD - Department of Pulmonary Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, - Netherlands. -FAU - Huisman, Marc C -AU - Huisman MC -AD - Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Netherlands. -AD - Department of Radiology and Nuclear Medicine, Amsterdam UMC Locatie VUmc, - Amsterdam, Netherlands. -FAU - Wijngaarden, Jessica E -AU - Wijngaarden JE -AD - Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Netherlands. -AD - Department of Radiology and Nuclear Medicine, Amsterdam UMC Locatie VUmc, - Amsterdam, Netherlands. -FAU - Slebe, Maarten -AU - Slebe M -AD - Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Netherlands. -AD - Department of Pulmonary Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, - Netherlands. -FAU - Oprea-Lager, Daniela E -AU - Oprea-Lager DE -AD - Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Netherlands. -AD - Department of Radiology and Nuclear Medicine, Amsterdam UMC Locatie VUmc, - Amsterdam, Netherlands. -FAU - Zwezerijnen, Gerben J C -AU - Zwezerijnen GJC -AD - Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Netherlands. -AD - Department of Radiology and Nuclear Medicine, Amsterdam UMC Locatie VUmc, - Amsterdam, Netherlands. -FAU - Vugts, Danielle -AU - Vugts D -AD - Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Netherlands. -AD - Department of Radiology and Nuclear Medicine, Amsterdam UMC Locatie VUmc, - Amsterdam, Netherlands. -FAU - Ulas, Ezgi B -AU - Ulas EB -AUID- ORCID: 0000-0003-1551-738X -AD - Department of Pulmonary Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, - Netherlands. -AD - Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, - Netherlands. -FAU - de Gruijl, Tanja D -AU - de Gruijl TD -AD - Department of Medical Oncology, Amsterdam UMC Locatie VUmc, Amsterdam, - Netherlands. -AD - Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Netherlands. -FAU - Radonic, Teodora -AU - Radonic T -AD - Department of Pathology, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands. -FAU - Senan, Suresh -AU - Senan S -AD - Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Netherlands. -AD - Department of Radiation Oncology, Amsterdam UMC Locatie VUmc, Amsterdam, - Netherlands. -FAU - Menke-van der Houven van Oordt, C Willemien -AU - Menke-van der Houven van Oordt CW -AD - Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Netherlands. -AD - Medical Oncology, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands. -FAU - Bahce, Idris -AU - Bahce I -AD - Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, Netherlands - i.bahce@amsterdamumc.nl. -AD - Department of Pulmonary Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, - Netherlands. -LA - eng -PT - Journal Article -DEP - 20240201 -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/diagnostic imaging/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - B7-H1 Antigen/metabolism -MH - Positron-Emission Tomography/methods -MH - Chemoradiotherapy -PMC - PMC10836378 -OTO - NOTNLM -OT - Immune Checkpoint Inhibitors -OT - Non-Small Cell Lung Cancer -OT - Programmed Cell Death 1 Receptor -OT - Radiotherapy -OT - Tumor Microenvironment -COIS- Competing interests: SMSH is on the advisory board and/or received institutional - research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, - Eli Lilly, Janssen, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche and - Takeda. DV received institutional research support from Bristol-Myers Squibb, - Daiichi Sankyo, GlaxoSmithKline, Boehringer Ingelheim, Roche and Aplagon. SS is - on the advisory board of AstraZeneca, receives institutional research support and - a speakers fee from AstraZeneca. SS is on the advisory board of Bristol-Myers - Squibb and receives institutional research support from Bristol-Myers Squibb. - CWM-vdHvO is advisor for GEHealthcare and Eli Lilly and received institutional - research support from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, G1 - Therapeutics and Bristol-Myers Squibb. -EDAT- 2024/02/02 00:42 -MHDA- 2024/02/05 06:43 -PMCR- 2024/02/01 -CRDT- 2024/02/01 23:31 -PHST- 2024/01/03 00:00 [accepted] -PHST- 2024/02/05 06:43 [medline] -PHST- 2024/02/02 00:42 [pubmed] -PHST- 2024/02/01 23:31 [entrez] -PHST- 2024/02/01 00:00 [pmc-release] -AID - jitc-2023-007659 [pii] -AID - 10.1136/jitc-2023-007659 [doi] -PST - epublish -SO - J Immunother Cancer. 2024 Feb 1;12(2):e007659. doi: 10.1136/jitc-2023-007659. - -PMID- 11890866 -OWN - NLM -STAT- MEDLINE -DCOM- 20030115 -LR - 20191025 -IS - 1471-2598 (Print) -IS - 1471-2598 (Linking) -VI - 2 -IP - 3 -DP - 2002 Mar -TI - The development of immunotherapies for non-small cell lung cancer. -PG - 265-78 -AB - Standard of care for non-small cell lung cancer (NSCLC) (surgery, chemotherapy - and radiation) may enhance patient survival but the enhancement is typically - transient and quite uncommon with advanced disease. Researchers and medical - professionals are using new approaches to improve patient mortality and - morbidity. One of these approaches, immunotherapy, seeks to stimulate antitumour - immunity above a threshold level needed for tumour regression or to induce - stability in the face of progression. Among the most established approaches are - vaccines involving monoclonal antibodies (mAbs) or immune effector cells. These - approaches stimulate the humoral and cell-mediated arms of the immune system, - respectively. As the development of humanised or fully human antibodies has - spurred exploration of radioimmunoconjugates and immunotoxins, mAbs have enjoyed - a revival of sorts. Cell-based therapies using the tumour cell itself as a - vaccine component has resulted in disease stabilisation or regression. In - addition, immune cells (e.g., T-lymphocytes and dendritic cells [DCs]) are the - focal point of numerous patient trials in which meaningful clinical impact was - achieved. In general, there are many tactics under development for the treatment - of NSCLC. This review primarily concerns immunotherapeutic cancer treatments that - are either already in clinical trial or well progressed into preclinical studies. -FAU - Salgaller, Michael L -AU - Salgaller ML -AD - Northwest Biotherapeutics, Inc., Suite 100, 21720 23rd Drive SE, Bothell, WA - 98021, USA. mls@nwbio.com -LA - eng -PT - Journal Article -PT - Review -PL - England -TA - Expert Opin Biol Ther -JT - Expert opinion on biological therapy -JID - 101125414 -RN - 0 (Cytokines) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Animals -MH - Carcinoma, Non-Small-Cell Lung/*therapy -MH - Combined Modality Therapy -MH - Cytokines/pharmacology -MH - ErbB Receptors/immunology -MH - Humans -MH - Immunotherapy/*methods -MH - Immunotherapy, Adoptive -MH - Lung Neoplasms/*therapy -MH - Radioimmunotherapy -RF - 167 -EDAT- 2002/03/14 10:00 -MHDA- 2003/01/16 04:00 -CRDT- 2002/03/14 10:00 -PHST- 2002/03/14 10:00 [pubmed] -PHST- 2003/01/16 04:00 [medline] -PHST- 2002/03/14 10:00 [entrez] -AID - 10.1517/14712598.2.3.265 [doi] -PST - ppublish -SO - Expert Opin Biol Ther. 2002 Mar;2(3):265-78. doi: 10.1517/14712598.2.3.265. - -PMID- 38902698 -OWN - NLM -STAT- MEDLINE -DCOM- 20240621 -LR - 20240925 -IS - 1465-993X (Electronic) -IS - 1465-9921 (Print) -IS - 1465-9921 (Linking) -VI - 25 -IP - 1 -DP - 2024 Jun 21 -TI - Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a - potential biomarker for atezolizumab-treated patients with extensive stage small - cell lung cancer. -PG - 253 -LID - 10.1186/s12931-024-02885-0 [doi] -LID - 253 -AB - BACKGROUND: There is a desperate for the identification of more accurate and - efficient biomarkers for ICI responses in patients with SCLC. METHODS: The data - of our study was obtained from IMpower133 study. A total of 202 patients with - SCLC received the treatment of placebo plus carboplatin plus etoposide (EC) while - a total of 201 patients with SCLC received the treatment of atezolizumab plus EC. - Overall survival (OS) was compared using Kaplan Meier analyses. Univariate and - multivariate Cox regression analysis were used to determine independent - prognostic variables affecting OS in patients with SCLC. RESULTS: We have - demonstrated that a higher TMB adjusted by a lower neutrophil-to-lymphocyte ratio - (NLR) is significantly correlated with improved OS, in patients with SCLC subject - to either atezolizumab or placebo (P = 0.001 for atezolizumab and P = 0.034 for - placebo). Moreover, Cox model showed that TMB < 10 mut/Mb adjusted by - NLR ≥ median was an independent factor of OS for atezolizumab-treated SCLC - patients (hazard ratio [HR], 2.82; 95% confidence interval; 1.52-5.24; - P = 0.001). Both univariate and multivariate cox regression analysis showed that - for patients with SCLC harboring low NLR and high TMB, survival is significantly - longer in those treated with atezolizumab than those treated with placebo. - Survival benefit is significantly higher in atezolizumab-treated patients with - SCLC than those treated with placebo (P = 0.018 for TMB cutoff = 10 mut/Mb, - P = 0.034 for TMB cutoff = 16 mut/Mb). CONCLUSION: Our findings provide a - promising insight into the utility of NLR-adjusted TMB in the prognosis and - immune responses in patients with SCLC. -CI - © 2024. The Author(s). -FAU - Zhang, Chenyue -AU - Zhang C -AD - Department of Integrated Therapy, Fudan University Shanghai Cancer Center, - Shanghai Medical College, Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - 200032, China. -FAU - Huo, Yanfei -AU - Huo Y -AD - Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, - Shandong Cancer Hospital and Institute, Shandong First Medical University, - Shandong Academy of Medical Sciences, Jinan, Shandong Province, 250117, China. -FAU - Shang, Xiaoling -AU - Shang X -AD - Shandong Cancer Hospital and Institute, Shandong University, Jinan, 250117, - China. -FAU - Zhang, Tongming -AU - Zhang T -AD - Department of Internal Medicine-Oncology, Shandong Rizhao Port Hospital, Rizhao, - 276800, China. -FAU - Tang, Ning -AU - Tang N -AD - Department of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, 250117, China. otammyo@foxmail.com. -FAU - Wang, Haiyong -AU - Wang H -AD - Department of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, 250117, China. wanghaiyong6688@126.com. -LA - eng -PT - Journal Article -PT - Randomized Controlled Trial -DEP - 20240621 -PL - England -TA - Respir Res -JT - Respiratory research -JID - 101090633 -RN - 52CMI0WC3Y (atezolizumab) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/drug therapy/blood -MH - *Neutrophils -MH - *Antibodies, Monoclonal, Humanized/therapeutic use -MH - Male -MH - *Lung Neoplasms/drug therapy/blood/pathology/mortality -MH - Female -MH - *Lymphocytes/drug effects -MH - Middle Aged -MH - Aged -MH - *Biomarkers, Tumor/genetics/blood -MH - Mutation -MH - Neoplasm Staging -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Lymphocyte Count -MH - Double-Blind Method -PMC - PMC11191253 -OTO - NOTNLM -OT - Neutrophil-to-lymphocyte ratio -OT - Overall survival -OT - SCLC -OT - TMB -COIS- The authors declare no competing interests. -EDAT- 2024/06/21 00:42 -MHDA- 2024/06/21 06:41 -PMCR- 2024/06/21 -CRDT- 2024/06/20 23:37 -PHST- 2023/12/17 00:00 [received] -PHST- 2024/06/14 00:00 [accepted] -PHST- 2024/06/21 06:41 [medline] -PHST- 2024/06/21 00:42 [pubmed] -PHST- 2024/06/20 23:37 [entrez] -PHST- 2024/06/21 00:00 [pmc-release] -AID - 10.1186/s12931-024-02885-0 [pii] -AID - 2885 [pii] -AID - 10.1186/s12931-024-02885-0 [doi] -PST - epublish -SO - Respir Res. 2024 Jun 21;25(1):253. doi: 10.1186/s12931-024-02885-0. - -PMID- 38512450 -OWN - NLM -STAT- MEDLINE -DCOM- 20240614 -LR - 20240726 -IS - 1699-3055 (Electronic) -IS - 1699-048X (Linking) -VI - 26 -IP - 7 -DP - 2024 Jul -TI - The S-REAL study: Spanish real-world data on unresectable stage III NSCLC - patients treated with durvalumab after chemoradiotherapy. -PG - 1779-1789 -LID - 10.1007/s12094-024-03404-9 [doi] -AB - OBJECTIVES: The S-REAL study aimed to assess the effectiveness of durvalumab as - consolidation therapy after definitive chemoradiotherapy (CRT) in a real-world - cohort of patients with locally advanced, unresectable stage III non-small cell - lung cancer (LA-NSCLC) included in a Spanish early access program (EAP). METHODS: - In this multicentre, observational, retrospective study we analysed data from - patients treated in 39 Spanish hospitals, who started intravenous durvalumab - (10 mg/kg every 2 weeks) between September 2017 and December 2018. The primary - endpoint was progression-free survival (PFS). Secondary endpoints included - patient characterization and adverse events of special interest (AESI). RESULTS: - A total of 244 patients were followed up for a median of 21.9 months [range - 1.2-34.7]. Median duration of durvalumab was 45.5 weeks (11.4 months) [0-145]. - Median PFS was 16.7 months (95% CI 12.2-25). No remarkable differences in PFS - were observed between patients with programmed cell death-ligand 1 (PD-L1) - expression ≥ 1% or < 1% (16.7 versus 15.6 months, respectively). However, PFS was - higher in patients who had received prior concurrent CRT (cCRT) versus sequential - CRT (sCRT) (20.6 versus 9.4 months). AESIs leading to durvalumab discontinuation - were registered in 11.1% of patients. CONCLUSIONS: These results are in line with - prior published evidence and confirm the benefits of durvalumab in the treatment - of LA-NSCLC patients in a real-world setting. We also observed a lower incidence - of important treatment-associated toxicities, such as pneumonitis, compared with - the pivotal phase III PACIFIC clinical study. -CI - © 2024. The Author(s), under exclusive licence to Federación de Sociedades - Españolas de Oncología (FESEO). -FAU - Gómez Rueda, Ana -AU - Gómez Rueda A -AD - Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, - Carretera Colmenar ViejoKM 9100, 28034, Madrid, Spain. -FAU - Taus, Álvaro -AU - Taus Á -AD - Medical Oncology Department, Hospital del Mar, Barcelona, Spain. -FAU - Álvarez Álvarez, Rosa -AU - Álvarez Álvarez R -AD - Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, - Spain. -FAU - Bernabé-Caro, Reyes -AU - Bernabé-Caro R -AD - Medical Oncology Department, Hospital Virgen del Rocío, Seville, Spain. -FAU - Chara, Luis -AU - Chara L -AD - Medical Oncology Department, Hospital Universitario de Guadalajara, Guadalajara, - Spain. -FAU - López-Brea, Marta -AU - López-Brea M -AD - Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, - Santander, Spain. -FAU - Vilà, Laia -AU - Vilà L -AD - Medical Oncology Department, Hospital Universitario Parc Taulí, Institut - d'Investigació I Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de - Barcelona, Sabadell, Spain. -FAU - Sala González, Maria Ángeles -AU - Sala González MÁ -AD - OSI Bilbao Basurto, Bibao, Spain. -FAU - Del Barrio Díaz Aldagalán, Anabel -AU - Del Barrio Díaz Aldagalán A -AD - HM Sanchinarro, Madrid, Spain. -FAU - Esteban Herrera, Beatriz -AU - Esteban Herrera B -AD - Hospital General de Segovia, Segovia, Spain. -FAU - López Castro, Rafael -AU - López Castro R -AD - Hospital Clínico Universitario de Valladolid, Valladolid, Spain. -FAU - Álvarez Cabellos, Ruth -AU - Álvarez Cabellos R -AD - Medical Oncology Service, Hospital Universitario de Toledo, Toledo, Spain. -FAU - Doménech, Marta -AU - Doménech M -AD - Medical Oncology Department, Instituto Catalán de Oncología, Badalona, Spain. -AD - Hospital Germans Trias i Pujol, Barcelona, Spain. -FAU - Falagan, Sandra -AU - Falagan S -AD - Hospital Universitario Infanta Sofía, Madrid, Spain. -FAU - Moreno Vega, Alberto -AU - Moreno Vega A -AD - Hospital Universitario Reina Sofía, Córdoba, Spain. -FAU - Aguado, Carlos -AU - Aguado C -AD - Medical Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, - Spain. -FAU - Barba, Andrés -AU - Barba A -AD - Medical Oncology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, - Spain. -FAU - Delgado Ureña, Maria Teresa -AU - Delgado Ureña MT -AD - Medical Oncology Department, Hospital Clínico San Cecilio, Granada, Spain. -FAU - Isla, Dolores -AU - Isla D -AD - Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. -FAU - Bellido Hernández, Lorena -AU - Bellido Hernández L -AD - Medical Oncology Department, Hospital Universitario de Salamanca, Salamanca, - Spain. -FAU - Fírvida Pérez, José Luis -AU - Fírvida Pérez JL -AD - Complejo Hospitalario Universitario de Ourense, Ourense, Spain. -FAU - Juan-Vidal, Óscar -AU - Juan-Vidal Ó -AD - Medical Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, - Spain. -FAU - Massutí, Bartomeu -AU - Massutí B -AD - Medical Oncology Department, Hospital Universitario de Alicante-ISABIAL, - Alicante, Spain. -FAU - Mielgo-Rubio, Xabier -AU - Mielgo-Rubio X -AD - Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Madrid, - Spain. -FAU - Ortega, Ana Laura -AU - Ortega AL -AD - UGC de Oncología Médica, Hospital Universitario de Jaén, Jaén, Spain. -FAU - Catot, Silvia -AU - Catot S -AD - Medical Oncology Department Althaia, Xarxa Assistencial Universitària Manresa, - Barcelona, Spain. -FAU - Dómine, Manuel -AU - Dómine M -AD - Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain. -FAU - Escoín-Pérez, Corina -AU - Escoín-Pérez C -AD - Medical Oncology Department, Hospital Universitario de La Ribera, Valencia, - Spain. -FAU - García Navalón, Francisco -AU - García Navalón F -AD - Medical Oncology Department, Hospital Universitario Son Llatzer, Mallorca, Spain. -FAU - Gil-Bazo, Ignacio -AU - Gil-Bazo I -AD - Medical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain. -AD - Fundación Instituto Valenciano de Oncología, Valencia, CIBERONC, Madrid, Spain. -FAU - Muñoz, Silvia -AU - Muñoz S -AD - Medical Oncology Department, Hospital General de Granollers, Barcelona, Spain. -FAU - Rodríguez-Abreu, Delvys -AU - Rodríguez-Abreu D -AD - Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, - Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain. -FAU - Villatoro Roldán, Rosa María -AU - Villatoro Roldán RM -AD - Medical Oncology Department, Hospital Costa del Sol, Málaga, Spain. -FAU - Alonso-Jáudenes Curbera, Guillermo -AU - Alonso-Jáudenes Curbera G -AD - Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, - Coruña, Spain. -FAU - León-Mateos, Luis -AU - León-Mateos L -AD - Medical Oncology Department, Complexo Hospitalario Universitario de Santiago de - Compostela (SERGAS), Instituto de Investigación Sanitaria (IDIS), Santiago de - Compostela, Spain. -FAU - Padilla, Airam -AU - Padilla A -AD - Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, - Spain. -FAU - Paredes Lario, Alfredo -AU - Paredes Lario A -AD - Department of Medical Oncology, Hospital Universitario de Donostia, San - Sebastián, Spain. -FAU - Sánchez-Torres, José Miguel -AU - Sánchez-Torres JM -AD - Department of Medical Oncology, Hospital Universitario la Princesa, Madrid, - Spain. -FAU - Garrido, Pilar -AU - Garrido P -AUID- ORCID: 0000-0002-5899-6125 -AD - Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, - Carretera Colmenar ViejoKM 9100, 28034, Madrid, Spain. pilargarridol@gmail.com. -CN - Spanish Lung Cancer Group -LA - eng -PT - Journal Article -PT - Multicenter Study -PT - Observational Study -DEP - 20240321 -PL - Italy -TA - Clin Transl Oncol -JT - Clinical & translational oncology : official publication of the Federation of - Spanish Oncology Societies and of the National Cancer Institute of Mexico -JID - 101247119 -RN - 28X28X9OKV (durvalumab) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/pathology/drug therapy/mortality -MH - Male -MH - Female -MH - *Lung Neoplasms/therapy/pathology/drug therapy/mortality -MH - Retrospective Studies -MH - Aged -MH - Middle Aged -MH - *Chemoradiotherapy -MH - Spain -MH - *Antibodies, Monoclonal/therapeutic use -MH - Adult -MH - Aged, 80 and over -MH - Antineoplastic Agents, Immunological/therapeutic use -MH - Neoplasm Staging -MH - Progression-Free Survival -MH - Consolidation Chemotherapy -MH - B7-H1 Antigen/antagonists & inhibitors -OTO - NOTNLM -OT - Chemoradiotherapy -OT - Durvalumab -OT - NSCLC -OT - PD-L1 -OT - PFS -OT - Real-world -EDAT- 2024/03/21 18:45 -MHDA- 2024/06/14 12:44 -CRDT- 2024/03/21 12:07 -PHST- 2023/11/08 00:00 [received] -PHST- 2024/02/01 00:00 [accepted] -PHST- 2024/06/14 12:44 [medline] -PHST- 2024/03/21 18:45 [pubmed] -PHST- 2024/03/21 12:07 [entrez] -AID - 10.1007/s12094-024-03404-9 [pii] -AID - 10.1007/s12094-024-03404-9 [doi] -PST - ppublish -SO - Clin Transl Oncol. 2024 Jul;26(7):1779-1789. doi: 10.1007/s12094-024-03404-9. - Epub 2024 Mar 21. - -PMID- 36208384 -OWN - NLM -STAT- MEDLINE -DCOM- 20221215 -LR - 20221221 -IS - 1826-6983 (Electronic) -IS - 0033-8362 (Linking) -VI - 127 -IP - 12 -DP - 2022 Dec -TI - Early GLS changes detection after chemoradiation in locally advanced non-small - cell lung cancer (NSCLC). -PG - 1355-1363 -LID - 10.1007/s11547-022-01557-7 [doi] -AB - PURPOSE: Chemoradiation is the standard treatment in patients with locally - advanced non-small-cell lung cancer (LA-NSCLC), and thanks to the recent - combination with immunotherapy, median survival has unexpectedly improved. This - study aims to evaluate early changes in cardiac function after chemoradiotherapy - (CRT) in LA-NSCLC by multimodal use of advanced imaging techniques. MATERIALS AND - METHODS: This is a prospective, observational cohort study. At the beginning of - combined treatment, screening tests including blood samples, electrocardiogram - (ECG), echocardiographic examination (TTE), and cardiac magnetic resonance were - performed in all patients with LA-NSCLC. ECG and cardiac marker assays were - performed weekly during treatment. ECG and TTE were performed at month 1 (M1) and - month 3 (M3) after the end of CRT. RESULTS: This preliminary analysis included - thirty-four patients with a mean age of 69.5 years. The median follow-up was - 27.8 months. 62% of patients were in stage IIIA. Radiation therapy was delivered - with a median total dose of 60 Gy with conventional fractionation. All patients - were treated with concurrent CRT, and 65% of cases were platinum-based therapy. - Global longitudinal strain (GLS) and ejection fraction (EF) progressively - decreased from baseline to M1 and M3. There was a strong correlation between GLS - and EF reduction (at M1: p = 0.034; at M3: p = 0.018). Cardiac arrhythmias - occurred in eight patients (23.5%) at a mean follow-up of 15.8 months after CRT. - CONCLUSIONS: Reduction in GLS is an early sign occurring after the end of CRT for - LA-NSCLC. Future studies are needed to identify variables that can increase the - risk of cardiac events in this patient population to implement adequate damage - prevention strategies. -CI - © 2022. Italian Society of Medical Radiology. -FAU - Mega, Simona -AU - Mega S -AD - Unit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of - Rome, Rome, Italy. -FAU - Fiore, Michele -AU - Fiore M -AD - Department of Radiation Oncology, Campus Bio-Medico University of Rome, Rome, - Italy. -FAU - Carpenito, Myriam -AU - Carpenito M -AD - Unit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of - Rome, Rome, Italy. m.carpenito@policlinicocampus.it. -FAU - Novembre, Maria Laura -AU - Novembre ML -AD - Unit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of - Rome, Rome, Italy. -FAU - Miele, Marianna -AU - Miele M -AD - Department of Radiation Oncology, Campus Bio-Medico University of Rome, Rome, - Italy. -FAU - Trodella, Luca Eolo -AU - Trodella LE -AD - Department of Radiation Oncology, Campus Bio-Medico University of Rome, Rome, - Italy. -FAU - Grigioni, Francesco -AU - Grigioni F -AD - Unit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of - Rome, Rome, Italy. -FAU - Ippolito, Edy -AU - Ippolito E -AD - Department of Radiation Oncology, Campus Bio-Medico University of Rome, Rome, - Italy. -FAU - Ramella, Sara -AU - Ramella S -AD - Department of Radiation Oncology, Campus Bio-Medico University of Rome, Rome, - Italy. -LA - eng -PT - Journal Article -PT - Observational Study -DEP - 20221008 -PL - Italy -TA - Radiol Med -JT - La Radiologia medica -JID - 0177625 -SB - IM -MH - Humans -MH - Aged -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy -MH - *Lung Neoplasms/therapy/drug therapy -MH - Cohort Studies -MH - Chemoradiotherapy -MH - Combined Modality Therapy -OTO - NOTNLM -OT - Chemoradiation -OT - Global longitudinal strain -OT - NSCLC -OT - Radiation therapy -EDAT- 2022/10/09 06:00 -MHDA- 2022/12/16 06:00 -CRDT- 2022/10/08 11:18 -PHST- 2022/03/04 00:00 [received] -PHST- 2022/09/05 00:00 [accepted] -PHST- 2022/10/09 06:00 [pubmed] -PHST- 2022/12/16 06:00 [medline] -PHST- 2022/10/08 11:18 [entrez] -AID - 10.1007/s11547-022-01557-7 [pii] -AID - 10.1007/s11547-022-01557-7 [doi] -PST - ppublish -SO - Radiol Med. 2022 Dec;127(12):1355-1363. doi: 10.1007/s11547-022-01557-7. Epub - 2022 Oct 8. - -PMID- 35882620 -OWN - NLM -STAT- MEDLINE -DCOM- 20221026 -LR - 20230126 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 23 -IP - 7 -DP - 2022 Nov -TI - A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and - Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the - Development of ECOG-ACRIN EA5181. -PG - 547-560 -LID - S1525-7304(22)00149-8 [pii] -LID - 10.1016/j.cllc.2022.06.005 [doi] -AB - ECOG-ACRIN EA5181 is a current prospective, randomized trial that is - investigating whether the addition of concomitant durvalumab to standard - chemo/radiation followed by 1 year of consolidative durvalumab results in an - overall survival benefit over standard chemo/radiation alone followed by 1 year - of consolidative durvalumab in patients with locally advanced, unresectable - non-small cell lung cancer (NSCLC). Because multiple phase I/II trials have shown - the relative safety of adding immunotherapy to chemo/radiation and due to the - known synergism between chemotherapy and immunotherapy, it is hoped that - concomitant durvalumab can reduce the relatively high incidence of local failure - (38%-46%) as seen in recent prospective, randomized trials of standard - chemo/radiation in this patient population. We will review the history of - radiation for LA-NSCLC and discuss the role of induction, concurrent and - consolidative chemotherapy as well as the concerns for late cardiac and pulmonary - toxicities associated with treatment. Furthermore, we will review the potential - role of next generation sequencing, PD-L1, ctDNA and tumor mutation burden and - their possible impact on this trial. -CI - Copyright © 2022 Elsevier Inc. All rights reserved. -FAU - Varlotto, John Michael -AU - Varlotto JM -AD - Department of Oncology, Edwards Comprehensive Cancer Center/Marshall University, - Huntington, WV. Electronic address: jmlotto@comcast.net. -FAU - Sun, Zhuoxin -AU - Sun Z -AD - Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA. -FAU - Ky, Bonnie -AU - Ky B -AD - Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, - PA. -FAU - Upshaw, Jenica -AU - Upshaw J -AD - Department of Medicine, Tufts University, Boston, MA. -FAU - Fitzgerald, Thomas J -AU - Fitzgerald TJ -AD - Imaging and Radiation Oncology Core (IROC), Lincoln, RI. -FAU - Diehn, Max -AU - Diehn M -AD - Department of Radiation Oncology, Stanford University, Stanford, CA. -FAU - Lovly, Christine -AU - Lovly C -AD - Division of Hematology Oncology, Vanderbilt University, Nashville, TN. -FAU - Belani, Chandra -AU - Belani C -AD - Department of Medical Oncology, Penn State Cancer Institute, Hershey, PA. -FAU - Oettel, Kurt -AU - Oettel K -AD - Department of Medical Oncology, Gundersen Lutheran Medical Center, La Crosse, WI. -FAU - Masters, Gregory -AU - Masters G -AD - Delaware/Christiana Care NCORP, Newark, DE. -FAU - Harkenrider, Matthew -AU - Harkenrider M -AD - Department of Radiation Oncology, Stritch School of Medicine Loyola University - Chicago, Maywood, IL. -FAU - Ross, Helen -AU - Ross H -AD - Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ. -FAU - Ramalingam, Suresh -AU - Ramalingam S -AD - Division of Medical Oncology, Emory University, Atlanta, GA. -FAU - Pennell, Nathan A -AU - Pennell NA -AD - Department of Hematology Oncology, Cleveland Clinic, Cleveland, OH. -LA - eng -PT - Journal Article -PT - Review -DEP - 20220630 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - B7-H1 Antigen -MH - *Lung Neoplasms/drug therapy -MH - Immunotherapy/methods -MH - Biomarkers, Tumor/genetics -MH - Randomized Controlled Trials as Topic -OTO - NOTNLM -OT - Immunotherapy -OT - Radiation therapy -OT - Stage 3 non-small cell lung cancdr -OT - Therapy-related cardiac morbidity -OT - Tumor mutation burden -COIS- Disclosure None. -EDAT- 2022/07/27 06:00 -MHDA- 2022/10/27 06:00 -CRDT- 2022/07/26 22:03 -PHST- 2021/10/31 00:00 [received] -PHST- 2022/06/20 00:00 [revised] -PHST- 2022/06/20 00:00 [accepted] -PHST- 2022/07/27 06:00 [pubmed] -PHST- 2022/10/27 06:00 [medline] -PHST- 2022/07/26 22:03 [entrez] -AID - S1525-7304(22)00149-8 [pii] -AID - 10.1016/j.cllc.2022.06.005 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2022 Nov;23(7):547-560. doi: 10.1016/j.cllc.2022.06.005. Epub - 2022 Jun 30. - -PMID- 36674491 -OWN - NLM -STAT- MEDLINE -DCOM- 20230124 -LR - 20240911 -IS - 1422-0067 (Electronic) -IS - 1422-0067 (Linking) -VI - 24 -IP - 2 -DP - 2023 Jan 4 -TI - Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do - Gynecologists Need to Know before Using Immune Checkpoint Inhibitors? -LID - 10.3390/ijms24020974 [doi] -LID - 974 -AB - Standard treatments for gynecological cancers include surgery, chemotherapy, and - radiation therapy. However, there are limitations associated with the - chemotherapeutic drugs used to treat advanced and recurrent gynecological - cancers, and it is difficult to identify additional treatments. Therefore, immune - checkpoint inhibitor (ICI) therapy products, including PD-1/PD-L1 inhibitors and - CTLA-4 inhibitors, are in the spotlight as alternatives for the treatment of - advanced gynecological cancers. Although the ICI monotherapy response rate in - gynecological cancers is lower than that in melanoma or non-small cell lung - cancer, the response rates are approximately 13-52%, 7-22%, and 4-17% for - endometrial, ovarian, and cervical cancers, respectively. Several studies are - being conducted to compare the outcomes of combining ICI therapy with - chemotherapy, radiation therapy, and antiangiogenesis agents. Therefore, it is - critical to determine the mechanism underlying ICI therapy-mediated anti-tumor - activity and its application in gynecological cancers. Additionally, - understanding the possible immune-related adverse events induced - post-immunotherapy, as well as the appropriate management of diagnosis and - treatment, are necessary to create a quality environment for immunotherapy in - patients with gynecological cancers. Therefore, in this review, we summarize the - ICI mechanisms, ICIs applied to gynecological cancers, and appropriate diagnosis - and treatment of immune-related side effects to help gynecologists treat - gynecological cancers using immunotherapy. -FAU - Lee, Seon-Mi -AU - Lee SM -AUID- ORCID: 0000-0003-2388-0111 -AD - Department of Obstetrics and Gynecology, Korea University College of Medicine, 73 - Koreadae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. -FAU - Lee, Sanghoon -AU - Lee S -AUID- ORCID: 0000-0002-5546-0763 -AD - Department of Obstetrics and Gynecology, Korea University College of Medicine, 73 - Koreadae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. -FAU - Cho, Hyun-Woong -AU - Cho HW -AD - Department of Obstetrics and Gynecology, Korea University College of Medicine, - 148, Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea. -FAU - Min, Kyung-Jin -AU - Min KJ -AUID- ORCID: 0000-0002-5783-4968 -AD - Department of Obstetrics and Gynecology, Korea University College of Medicine, - 123, Jeokgeum-ro, Danwon-gu, Ansan-si 15355, Gyeonggi-do, Republic of Korea. -FAU - Hong, Jin-Hwa -AU - Hong JH -AD - Department of Obstetrics and Gynecology, Korea University College of Medicine, - 148, Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea. -FAU - Song, Jae-Yun -AU - Song JY -AD - Department of Obstetrics and Gynecology, Korea University College of Medicine, 73 - Koreadae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. -FAU - Lee, Jae-Kwan -AU - Lee JK -AUID- ORCID: 0000-0003-3101-6403 -AD - Department of Obstetrics and Gynecology, Korea University College of Medicine, - 148, Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea. -FAU - Lee, Nak-Woo -AU - Lee NW -AD - Department of Obstetrics and Gynecology, Korea University College of Medicine, - 123, Jeokgeum-ro, Danwon-gu, Ansan-si 15355, Gyeonggi-do, Republic of Korea. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230104 -PL - Switzerland -TA - Int J Mol Sci -JT - International journal of molecular sciences -JID - 101092791 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Gynecologists -MH - *Lung Neoplasms/drug therapy -MH - Neoplasm Recurrence, Local/drug therapy -MH - Immunotherapy/adverse effects -PMC - PMC9865129 -OTO - NOTNLM -OT - gynecological cancer -OT - immune checkpoint inhibitor therapy -OT - immune-related adverse events -COIS- The authors declare no conflict of interest. -EDAT- 2023/01/22 06:00 -MHDA- 2023/01/25 06:00 -PMCR- 2023/01/04 -CRDT- 2023/01/21 01:24 -PHST- 2022/11/10 00:00 [received] -PHST- 2022/12/30 00:00 [revised] -PHST- 2022/12/30 00:00 [accepted] -PHST- 2023/01/21 01:24 [entrez] -PHST- 2023/01/22 06:00 [pubmed] -PHST- 2023/01/25 06:00 [medline] -PHST- 2023/01/04 00:00 [pmc-release] -AID - ijms24020974 [pii] -AID - ijms-24-00974 [pii] -AID - 10.3390/ijms24020974 [doi] -PST - epublish -SO - Int J Mol Sci. 2023 Jan 4;24(2):974. doi: 10.3390/ijms24020974. - -PMID- 38413988 -OWN - NLM -STAT- MEDLINE -DCOM- 20240229 -LR - 20240301 -IS - 1748-717X (Electronic) -IS - 1748-717X (Linking) -VI - 19 -IP - 1 -DP - 2024 Feb 27 -TI - Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung - cancer patients receiving first-line immunotherapy plus chemotherapy: a - propensity score matched multicentre retrospective analysis. -PG - 25 -LID - 10.1186/s13014-024-02420-x [doi] -LID - 25 -AB - BACKGROUND: Platinum-etoposide chemotherapy combined with immune checkpoint - inhibitors (ICIs) has been recommended as the first-line standard treatment for - extensive-stage small-cell lung cancer (ES-SCLC). However, the effect of thoracic - radiotherapy (TRT) on these patients is still unknown. This study aimed to - evaluate the efficacy and safety of TRT for ES-SCLC patients who responded to - first-line ICIs and chemotherapy (CHT). METHODS: Patients who received 4 to 6 - cycles of ICIs and CHT as first-line therapy at three hospitals between 2018 and - 2022 were included in the analysis. All patients were divided into two groups - based on whether they received TRT as first-line treatment, and propensity score - matching (PSM) was performed to ensure that the characteristics of two groups - were well-balanced. The primary endpoints were overall survival (OS) and - progression-free survival (PFS), and the secondary endpoint was toxic effects. - RESULTS: A total of 276 patients were included, and the median follow-up time was - 22.3 (range, 4.0-53.73) months. After PSM, 197 patients were further analysed, - and 99 of whom received TRT. The baseline characteristics were well-balanced - between patients in the TRT and non-TRT groups. There were significant - differences in PFS between the TRT and non-TRT groups, with the median PFS of - 10.76 and 7.63 months, respectively (P = 0.014). Significantly improved OS was - observed in the TRT group (21.67 vs. 16.6 months, P = 0.009). In addition, the - use of TRT was an independent prognostic factor for PFS and OS of ES-SCLC - patients receiving ICIs plus CHT. In terms of safety, no significant increase of - any grades adverse event (AE) (P = 0.874) and G3-4 AE (P = 0.909) was observed - for patients receiving TRT. Radiation esophagitis, gastrointestinal and - hematologic toxicities were the most common AEs in TRT group, which were - tolerable. And high-dose radiotherapy was associated with higher incidence of - pneumonitis. CONCLUSION: Addition of TRT showed significant survival benefits and - well tolerability in ES-SCLC patients receiving platinum-etoposide CHT and ICIs, - which could be a feasible first-line treatment strategy for ES-SCLC patients. -CI - © 2024. The Author(s). -FAU - Yao, Yueyuan -AU - Yao Y -AD - Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, - Shandong, 271016, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, Jiyan - Road 440, Jinan, 250117, China. -FAU - Li, Butuo -AU - Li B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, Jiyan - Road 440, Jinan, 250117, China. -FAU - Song, Ruiting -AU - Song R -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, Jiyan - Road 440, Jinan, 250117, China. -FAU - Yang, Linlin -AU - Yang L -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, Jiyan - Road 440, Jinan, 250117, China. -FAU - Zou, Bing -AU - Zou B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, Jiyan - Road 440, Jinan, 250117, China. -FAU - Wang, Linlin -AU - Wang L -AD - Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, - Shandong, 271016, China. wanglinlinatjn@163.com. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, Jiyan - Road 440, Jinan, 250117, China. wanglinlinatjn@163.com. -LA - eng -GR - 82172865/National Natural Science Foundation of China/ -GR - 2020-B14/Start-up fund of Shandong Cancer Hospital/ -GR - 320.6750.2021-02-51 and 320.6750.2021-17-13/Clinical Research Special Fund of Wu - Jieping Medical Foundation/ -GR - ZR2022QH023/Natural Science Foundation of Shandong Province/ -PT - Journal Article -PT - Multicenter Study -DEP - 20240227 -PL - England -TA - Radiat Oncol -JT - Radiation oncology (London, England) -JID - 101265111 -RN - 6PLQ3CP4P3 (Etoposide) -RN - 49DFR088MY (Platinum) -SB - IM -MH - Humans -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Etoposide/therapeutic use -MH - Retrospective Studies -MH - Propensity Score -MH - Platinum/therapeutic use -MH - *Small Cell Lung Carcinoma/drug therapy/radiotherapy -MH - Immunotherapy -PMC - PMC10900720 -OTO - NOTNLM -OT - Chemotherapy -OT - Extensive-stage small-cell lung cancer -OT - Immune checkpoint inhibitors -OT - Immunotherapy -OT - Real-world data -OT - Thoracic radiotherapy -COIS- The authors declare that they have no known competing financial interests or - personal relationships that could have appeared to influence the work reported in - this paper. -EDAT- 2024/02/28 00:43 -MHDA- 2024/02/29 06:43 -PMCR- 2024/02/27 -CRDT- 2024/02/27 23:56 -PHST- 2023/10/03 00:00 [received] -PHST- 2024/02/09 00:00 [accepted] -PHST- 2024/02/29 06:43 [medline] -PHST- 2024/02/28 00:43 [pubmed] -PHST- 2024/02/27 23:56 [entrez] -PHST- 2024/02/27 00:00 [pmc-release] -AID - 10.1186/s13014-024-02420-x [pii] -AID - 2420 [pii] -AID - 10.1186/s13014-024-02420-x [doi] -PST - epublish -SO - Radiat Oncol. 2024 Feb 27;19(1):25. doi: 10.1186/s13014-024-02420-x. - -PMID- 38865375 -OWN - NLM -STAT- MEDLINE -DCOM- 20240612 -LR - 20240614 -IS - 1932-6203 (Electronic) -IS - 1932-6203 (Linking) -VI - 19 -IP - 6 -DP - 2024 -TI - Efficacy and safety of concurrent immune checkpoint inhibitors combined with - radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A - systematic review and single-arm meta-analysis. -PG - e0304941 -LID - 10.1371/journal.pone.0304941 [doi] -LID - e0304941 -AB - BACKGROUND: The recent usage of immunotherapy combined with chemoradiotherapy has - improved survival in advanced non-small cell lung cancer (NSCLC) patients. - However, determining the most effective therapy combination remains a topic of - debate. Research suggests immune checkpoint inhibitors (ICIs) - post-chemoradiotherapy enhance survival, but the impact of concurrent ICIs during - chemoradiotherapy on rapid disease progression is unclear. This meta-analysis - aims to assess the effectiveness and safety of concurrent ICIs with radiotherapy - or chemoradiotherapy in advanced non-small cell lung cancer. METHODS: We searched - PubMed, Embase, the Cochrane Library, and Web of Science for relevant studies, - extracting data on overall response rate (ORR), progression-free survival (PFS), - overall survival (OS), and adverse events (AEs). RESULTS: The analysis included - ten studies with 490 participants. Stage III NSCLC ORR was 81.8%, while Stage IV - ORR was 39.9%. One-year PFS and OS for Stage III were 68.2% and 82.6%, compared - to 27.9% and 72.2% for Stage IV. Common adverse events included anemia (46.6%), - nausea (47.6%), rash (36.4%), and radiation pneumonitis (36.3%). CONCLUSIONS: Our - meta-analysis shows concurrent ICIs with chemoradiotherapy are effective and safe - in advanced NSCLC, particularly in stage III patients at risk of progression - before starting ICIs after chemoradiotherapy. The findings support further phase - III trials. The review protocol was registered on PROSPERO (CRD42023493685) and - is detailed on the NIHR HTA programme website. -CI - Copyright: © 2024 Cui et al. This is an open access article distributed under the - terms of the Creative Commons Attribution License, which permits unrestricted - use, distribution, and reproduction in any medium, provided the original author - and source are credited. -FAU - Cui, Ran -AU - Cui R -AD - Department of Oncology, The First People's Hospital of Neijiang, Neijiang, - Sichuan, China. -FAU - Li, Yun -AU - Li Y -AD - Department of Oncology, The First People's Hospital of Neijiang, Neijiang, - Sichuan, China. -FAU - Yu, Xinlin -AU - Yu X -AD - Department of Oncology, The Second People's Hospital of Neijiang, Neijiang, - Sichuan, China. -FAU - Wei, Chun -AU - Wei C -AD - Department of Oncology, The Second People's Hospital of Neijiang, Neijiang, - Sichuan, China. -FAU - Jiang, Ou -AU - Jiang O -AUID- ORCID: 0000-0002-8391-4961 -AD - Department of Oncology, The First People's Hospital of Neijiang, Neijiang, - Sichuan, China. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Systematic Review -DEP - 20240612 -PL - United States -TA - PLoS One -JT - PloS one -JID - 101285081 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/pathology/drug therapy -MH - *Immune Checkpoint Inhibitors/therapeutic use/adverse effects -MH - *Lung Neoplasms/therapy/pathology/drug therapy -MH - *Chemoradiotherapy/adverse effects/methods -MH - Progression-Free Survival -MH - Treatment Outcome -PMC - PMC11168700 -COIS- The authors have declared that no competing interests exist. -EDAT- 2024/06/12 18:42 -MHDA- 2024/06/12 18:43 -PMCR- 2024/06/12 -CRDT- 2024/06/12 13:43 -PHST- 2024/03/02 00:00 [received] -PHST- 2024/05/21 00:00 [accepted] -PHST- 2024/06/12 18:43 [medline] -PHST- 2024/06/12 18:42 [pubmed] -PHST- 2024/06/12 13:43 [entrez] -PHST- 2024/06/12 00:00 [pmc-release] -AID - PONE-D-24-08504 [pii] -AID - 10.1371/journal.pone.0304941 [doi] -PST - epublish -SO - PLoS One. 2024 Jun 12;19(6):e0304941. doi: 10.1371/journal.pone.0304941. - eCollection 2024. - -PMID- 38613182 -OWN - NLM -STAT- MEDLINE -DCOM- 20240415 -LR - 20240520 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 13 -IP - 7 -DP - 2024 Apr -TI - PD-L1 inhibitors combined with whole brain radiotherapy in patients with small - cell lung cancer brain metastases: Real-world evidence. -PG - e7125 -LID - 10.1002/cam4.7125 [doi] -LID - e7125 -AB - BACKGROUND: Numerous studies have demonstrated that brain metastases patients may - benefit from intracranial radiotherapy combined with immune checkpoint inhibitors - (ICIs). However, it is unclear whether this treatment is effective for patients - with small cell lung cancer brain metastases (SCLC-BMs). METHODS: We conducted a - retrospective study by analyzing medical records of patients with SCLC-BMs from - January 1, 2017 to June 1, 2022. Data related to median overall survival (mOS), - median progression-free survival (mPFS), and intracranial progression-free - survival (iPFS) were analyzed. RESULTS: A total of 109 patients were enrolled, of - which 60 received WBRT and 49 received WBRT-ICI. Compared to the WBRT alone - cohort, the WBRT-ICI cohort showed longer mOS (20.4 months vs. 29.3 months, - p = 0.021), mPFS (7.9 months vs. 15.1 months, p < 0.001), and iPFS (8.3 months - vs. 16.5 months, p < 0.001). Furthermore, WBRT-ICI cohort had a better response - rate for both BMs. (p = 0.035) and extracranial diseases (p < 0.001) compared to - those receiving WBRT alone. Notably, the use of WBRT before ICI was associated - with longer mOS compared to the use of WBRT after ICI (23.3 months for the - ICI-WBRT group vs. 34.8 months for the WBRT-ICI group, p = 0.020). CONCLUSION: - Our results indicated that WBRT combined with immunotherapy improved survival in - SCLC-BMs patients compared to WBRT monotherapy. Administering WBRT prior to ICI - treatment is associated with improved survival outcomes compared to WBRT - following ICI treatment, for patients with SCLC-BMs. These findings highlight the - significance of conducting further prospective researches on combination - strategies of intracranial radiotherapy and ICI in SCLC-BMs patients. -CI - © 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Huang, Litang -AU - Huang L -AUID- ORCID: 0000-0001-7334-6430 -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of - Medicine, Tongji University, Shanghai, China. -FAU - Chen, Shen -AU - Chen S -AD - Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, School of - Medicine, Shanghai, China. -FAU - Liu, Hui -AU - Liu H -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of - Medicine, Tongji University, Shanghai, China. -FAU - Meng, Lu -AU - Meng L -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of - Medicine, Tongji University, Shanghai, China. -FAU - Liu, Chengxing -AU - Liu C -AD - Department of Cardiology, Tongji Hospital, Tongji University, School of Medicine, - Shanghai, China. -FAU - Wu, Xiaoting -AU - Wu X -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of - Medicine, Tongji University, Shanghai, China. -FAU - Wang, Yingying -AU - Wang Y -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of - Medicine, Tongji University, Shanghai, China. -FAU - Luo, Shilan -AU - Luo S -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of - Medicine, Tongji University, Shanghai, China. -FAU - Tu, Hongbin -AU - Tu H -AD - Department of Integrated TCM and Western Medicine, Shanghai Pulmonary Hospital, - Tongji University, School of Medicine, Shanghai, China. -FAU - Wang, Chunlei -AU - Wang C -AD - Department of Endocrinology, The Fourth Affiliated Hospital of Nantong - University, Jiangsu, China. -FAU - Zhang, Ming -AU - Zhang M -AD - Department of Integrated Traditional Chinese and Western Medicine, Shanghai Jiao - Tong University School of Medicine, Shanghai Chest Hospital, Shanghai, China. -FAU - Gong, Xiaomei -AU - Gong X -AUID- ORCID: 0000-0002-3043-9562 -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of - Medicine, Tongji University, Shanghai, China. -LA - eng -GR - fkgg1808/Shanghai Pulmonary Hospital Backbone Program/ -GR - 202140256/Shanghai Municipal Health Commission/ -GR - 21ZR1453300/Natural Science Foundation of Shanghai Municipality/ -GR - 20Y11913600/Shanghai Science and Technology Innovation Action Plan/ -GR - 2021071/Shanghai Talents Development Fund Project/ -GR - SKPY2021006/Clinical Research foundation of Shanghai Pulmonary Hospital/ -PT - Journal Article -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Lung Neoplasms/therapy -MH - Retrospective Studies -MH - *Small Cell Lung Carcinoma/drug therapy/radiotherapy -MH - *Brain Neoplasms/radiotherapy -MH - Brain -PMC - PMC11015079 -OTO - NOTNLM -OT - extensive small cell lung cancer -OT - immunotherapy -OT - intracranial metastasis -OT - radiotherapy -COIS- The authors have no relevant financial or non‐financial interests to disclose. -EDAT- 2024/04/13 10:43 -MHDA- 2024/04/15 06:42 -PMCR- 2024/04/12 -CRDT- 2024/04/13 02:33 -PHST- 2024/02/28 00:00 [revised] -PHST- 2023/08/01 00:00 [received] -PHST- 2024/03/08 00:00 [accepted] -PHST- 2024/04/15 06:42 [medline] -PHST- 2024/04/13 10:43 [pubmed] -PHST- 2024/04/13 02:33 [entrez] -PHST- 2024/04/12 00:00 [pmc-release] -AID - CAM47125 [pii] -AID - 10.1002/cam4.7125 [doi] -PST - ppublish -SO - Cancer Med. 2024 Apr;13(7):e7125. doi: 10.1002/cam4.7125. - -PMID- 35525024 -OWN - NLM -STAT- MEDLINE -DCOM- 20220608 -LR - 20230701 -IS - 2213-2317 (Electronic) -IS - 2213-2317 (Linking) -VI - 53 -DP - 2022 Jul -TI - Pharmacological ascorbate improves the response to platinum-based chemotherapy in - advanced stage non-small cell lung cancer. -PG - 102318 -LID - S2213-2317(22)00090-8 [pii] -LID - 10.1016/j.redox.2022.102318 [doi] -LID - 102318 -AB - PURPOSE: Platinum-based chemotherapy with or without immunotherapy is the - mainstay of treatment for advanced stage non-small cell lung cancer (NSCLC) - lacking a molecular driver alteration. Pre-clinical studies have reported that - pharmacological ascorbate (P-AscH-) enhances NSCLC response to platinum-based - therapy. We conducted a phase II clinical trial combining P-AscH- with - carboplatin-paclitaxel chemotherapy. EXPERIMENTAL DESIGN: Chemotherapy naïve - advanced stage NSCLC patients received 75 g ascorbate twice per week - intravenously with carboplatin and paclitaxel every three weeks for four cycles. - The primary endpoint was to improve tumor response per Response Evaluation - Criteria in Solid Tumors (RECIST) v1.1 compared to the historical control of 20%. - The trial was conducted as an optimal Simon's two-stage design. Blood samples - were collected for exploratory analyses. RESULTS: The study enrolled 38 patients - and met its primary endpoint with an objective response rate of 34.2% (p = 0.03). - All were confirmed partial responses (cPR). The disease control rate was 84.2% - (stable disease + cPR). Median progression-free and overall survival were 5.7 - months and 12.8 months, respectively. Treatment-related adverse events (TRAE) - included one grade 5 (neutropenic fever) and five grade 4 events (cytopenias). - Cytokine and chemokine data suggest that the combination elicits an immune - response. Immunophenotyping of peripheral blood mononuclear cells demonstrated an - increase in effector CD8 T-cells in patients with a progression-free survival - (PFS) ≥ 6 months. CONCLUSIONS: The addition of P-AscH- to platinum-based - chemotherapy improved tumor response in advanced stage NSCLC. P-AscH- appears to - alter the host immune response and needs further investigation as a potential - adjuvant to immunotherapy. -CI - Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved. -FAU - Furqan, Muhammad -AU - Furqan M -AD - Department of Internal Medicine, University of Iowa, 200 Hawkins Dr, Iowa City, - IA, 52242, USA; Holden Comprehensive Cancer Center, University of Iowa, 200 - Hawkins Dr, Iowa City, IA, 52242, USA. Electronic address: - muhammad-furqan@uiowa.edu. -FAU - Abu-Hejleh, Taher -AU - Abu-Hejleh T -AD - Department of Internal Medicine, University of Iowa, 200 Hawkins Dr, Iowa City, - IA, 52242, USA; Holden Comprehensive Cancer Center, University of Iowa, 200 - Hawkins Dr, Iowa City, IA, 52242, USA. -FAU - Stephens, Laura M -AU - Stephens LM -AD - Interdisciplinary Graduate Program in Immunology, University of Iowa, 200 Hawkins - Dr, Iowa City, IA, 52242, USA. -FAU - Hartwig, Stacey M -AU - Hartwig SM -AD - Department of Microbiology and Immunology, University of Iowa, 51 Newton Rd., - Iowa City, IA, 52242, USA. -FAU - Mott, Sarah L -AU - Mott SL -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA. -FAU - Pulliam, Casey F -AU - Pulliam CF -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Radiation Oncology, Free Radical and - Radiation Biology Program, University of Iowa, 200 Hawkins Dr, Iowa City, IA, - 52242, USA. -FAU - Petronek, Michael -AU - Petronek M -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Radiation Oncology, Free Radical and - Radiation Biology Program, University of Iowa, 200 Hawkins Dr, Iowa City, IA, - 52242, USA. -FAU - Henrich, John B -AU - Henrich JB -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Radiation Oncology, Free Radical and - Radiation Biology Program, University of Iowa, 200 Hawkins Dr, Iowa City, IA, - 52242, USA. -FAU - Fath, Melissa A -AU - Fath MA -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Radiation Oncology, Free Radical and - Radiation Biology Program, University of Iowa, 200 Hawkins Dr, Iowa City, IA, - 52242, USA. -FAU - Houtman, Jon C -AU - Houtman JC -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Interdisciplinary Graduate Program in Immunology, - University of Iowa, 200 Hawkins Dr, Iowa City, IA, 52242, USA; Department of - Microbiology and Immunology, University of Iowa, 51 Newton Rd., Iowa City, IA, - 52242, USA. -FAU - Varga, Steven M -AU - Varga SM -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Interdisciplinary Graduate Program in Immunology, - University of Iowa, 200 Hawkins Dr, Iowa City, IA, 52242, USA; Department of - Microbiology and Immunology, University of Iowa, 51 Newton Rd., Iowa City, IA, - 52242, USA; Department of Pathology, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA. -FAU - Bodeker, Kellie L -AU - Bodeker KL -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Radiation Oncology, Free Radical and - Radiation Biology Program, University of Iowa, 200 Hawkins Dr, Iowa City, IA, - 52242, USA. -FAU - Bossler, Aaron D -AU - Bossler AD -AD - Department of Pathology, University of Iowa, 200 Hawkins Dr, Iowa City, IA, - 52242, USA. -FAU - Bellizzi, Andrew M -AU - Bellizzi AM -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Pathology, University of Iowa, 200 Hawkins - Dr, Iowa City, IA, 52242, USA. -FAU - Zhang, Jun -AU - Zhang J -AD - Department of Internal Medicine, University of Iowa, 200 Hawkins Dr, Iowa City, - IA, 52242, USA; Holden Comprehensive Cancer Center, University of Iowa, 200 - Hawkins Dr, Iowa City, IA, 52242, USA. -FAU - Monga, Varun -AU - Monga V -AD - Department of Internal Medicine, University of Iowa, 200 Hawkins Dr, Iowa City, - IA, 52242, USA; Holden Comprehensive Cancer Center, University of Iowa, 200 - Hawkins Dr, Iowa City, IA, 52242, USA. -FAU - Mani, Hariharasudan -AU - Mani H -AD - Department of Internal Medicine, University of Iowa, 200 Hawkins Dr, Iowa City, - IA, 52242, USA. -FAU - Ivanovic, Marina -AU - Ivanovic M -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Pathology, University of Iowa, 200 Hawkins - Dr, Iowa City, IA, 52242, USA. -FAU - Smith, Brian J -AU - Smith BJ -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Biostatistics, College of Public Health, - University of Iowa, 145 N. Riverside Dr, Iowa City, IA, 52242, USA. -FAU - Byrne, Margaret M -AU - Byrne MM -AD - Department of Internal Medicine, University of Iowa, 200 Hawkins Dr, Iowa City, - IA, 52242, USA; Holden Comprehensive Cancer Center, University of Iowa, 200 - Hawkins Dr, Iowa City, IA, 52242, USA. -FAU - Zeitler, William -AU - Zeitler W -AD - Department of Internal Medicine, University of Iowa, 200 Hawkins Dr, Iowa City, - IA, 52242, USA; Holden Comprehensive Cancer Center, University of Iowa, 200 - Hawkins Dr, Iowa City, IA, 52242, USA. -FAU - Wagner, Brett A -AU - Wagner BA -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Radiation Oncology, Free Radical and - Radiation Biology Program, University of Iowa, 200 Hawkins Dr, Iowa City, IA, - 52242, USA. -FAU - Buettner, Garry R -AU - Buettner GR -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Radiation Oncology, Free Radical and - Radiation Biology Program, University of Iowa, 200 Hawkins Dr, Iowa City, IA, - 52242, USA. -FAU - Cullen, Joseph J -AU - Cullen JJ -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Radiation Oncology, Free Radical and - Radiation Biology Program, University of Iowa, 200 Hawkins Dr, Iowa City, IA, - 52242, USA. -FAU - Buatti, John M -AU - Buatti JM -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Radiation Oncology, Free Radical and - Radiation Biology Program, University of Iowa, 200 Hawkins Dr, Iowa City, IA, - 52242, USA. -FAU - Spitz, Douglas R -AU - Spitz DR -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Radiation Oncology, Free Radical and - Radiation Biology Program, University of Iowa, 200 Hawkins Dr, Iowa City, IA, - 52242, USA. -FAU - Allen, Bryan G -AU - Allen BG -AD - Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Dr, Iowa - City, IA, 52242, USA; Department of Radiation Oncology, Free Radical and - Radiation Biology Program, University of Iowa, 200 Hawkins Dr, Iowa City, IA, - 52242, USA. -LA - eng -GR - P30 CA086862/CA/NCI NIH HHS/United States -GR - T32 CA078586/CA/NCI NIH HHS/United States -GR - R50 CA243693/CA/NCI NIH HHS/United States -GR - P01 CA217797/CA/NCI NIH HHS/United States -GR - P30 ES005605/ES/NIEHS NIH HHS/United States -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20220420 -PL - Netherlands -TA - Redox Biol -JT - Redox biology -JID - 101605639 -RN - 49DFR088MY (Platinum) -RN - BG3F62OND5 (Carboplatin) -RN - P88XT4IS4D (Paclitaxel) -SB - IM -MH - *Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - Carboplatin/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - Humans -MH - Leukocytes, Mononuclear/pathology -MH - *Lung Neoplasms/drug therapy/pathology -MH - Paclitaxel/therapeutic use -MH - Platinum/therapeutic use -PMC - PMC9079696 -OTO - NOTNLM -OT - Ascorbate -OT - Non-small cell -OT - Platinum -OT - Vitamin C -COIS- M Furqan acts as a institutional principal investigator/sub-investigator at - AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, - Genmab, Elicio Therapeutics, Mirati, Amgen, Replimmune, Checkmate - Pharmaceuticals, Gilead, GSK, Tesaro and Abbvie. On advisory board for Abbvie, - Jazz Pharma, Mirati, Astra Zeneca. DR Spitz and BG Allen received research - support from Galera and serve as consultant for Galera Therapeutics. All authors - report no conflicts of interest. -EDAT- 2022/05/08 06:00 -MHDA- 2022/06/09 06:00 -PMCR- 2022/04/20 -CRDT- 2022/05/07 18:14 -PHST- 2022/02/15 00:00 [received] -PHST- 2022/04/05 00:00 [revised] -PHST- 2022/04/17 00:00 [accepted] -PHST- 2022/05/08 06:00 [pubmed] -PHST- 2022/06/09 06:00 [medline] -PHST- 2022/05/07 18:14 [entrez] -PHST- 2022/04/20 00:00 [pmc-release] -AID - S2213-2317(22)00090-8 [pii] -AID - 102318 [pii] -AID - 10.1016/j.redox.2022.102318 [doi] -PST - ppublish -SO - Redox Biol. 2022 Jul;53:102318. doi: 10.1016/j.redox.2022.102318. Epub 2022 Apr - 20. - -PMID- 39202506 -OWN - NLM -STAT- MEDLINE -DCOM- 20240829 -LR - 20240901 -IS - 1648-9144 (Electronic) -IS - 1010-660X (Print) -IS - 1010-660X (Linking) -VI - 60 -IP - 8 -DP - 2024 Jul 28 -TI - Reinitiating Chemotherapy beyond Progression after Maintenance Immunotherapy in - Extensive-Stage Small-Cell Lung Cancer. -LID - 10.3390/medicina60081225 [doi] -LID - 1225 -AB - Introduction: Small-cell lung cancer (SCLC) is an aggressive form of cancer with - a poor prognosis. The two-year survival rate is 8% of all cases. Case - presentation: We present the case of a male patient who was 50 years old at the - time of diagnosis in May 2022. He was diagnosed with extensive-stage small-cell - lung cancer, treated with immunotherapy in combination with chemotherapy - (Durvalumab in combination with Etoposide plus Carboplatin) as a first-line - treatment, followed by maintenance immunotherapy. In December 2023, a PET-CT scan - revealed progressive disease with multiple metastases. Chemotherapy was - reinitiated with Etoposide plus Cisplatin in January 2024. After two cycles of - chemotherapy, the patient developed post-chemotherapy anemia, for which treatment - with Epoetinum alpha was initiated. Chemotherapy was continued for another five - cycles, until May 2024, with the maintenance of hemoglobin at a level within 9.9 - mg/dL-11 mg/dL. Upon assessment at the end of May 2024, the patient presented an - ECOG = 2 performance status, with a moderate general state, moderate-intensity - fatigue, no pain, no anxiety or depression and no dyspnea. Discussions, - Literature Review and Conclusions: Reinitiating chemotherapy after the failure of - maintenance immunotherapy may be an option in patients with SCLC. Epoetinum - allows oncological treatment by preventing chemotherapy-induced anemia. -FAU - Rahnea-Nita, Roxana-Andreea -AU - Rahnea-Nita RA -AD - 8th Clinical Department-Radiology, Oncology and Hematology, Faculty of Medicine, - "Carol Davila" University of Medicine and Phamacy, 020021 Bucharest, Romania. -AD - Department of Oncology-Palliative Care, "Sf. Luca" Chronic Diseases Hospital, - 041915 Bucharest, Romania. -FAU - Toma, Radu-Valeriu -AU - Toma RV -AD - 8th Clinical Department-Radiology, Oncology and Hematology, Faculty of Medicine, - "Carol Davila" University of Medicine and Phamacy, 020021 Bucharest, Romania. -AD - Department of Radiotherapy, "Prof. Dr. Alexandru Trestioreanu" Oncological - Institute, 022328 Bucharest, Romania. -FAU - Grigorean, Valentin Titus -AU - Grigorean VT -AD - 10th Clinical Department-General Surgery, Faculty of Medicine, "Carol Davila" - University of Medicine and Pharmacy, 020021 Bucharest, Romania. -AD - Department of General Surgery, "Bagdasar-Arseni" Clinical Emergency Hospital, - 041915 Bucharest, Romania. -FAU - Coman, Ionuţ Simion -AU - Coman IS -AUID- ORCID: 0000-0002-0535-7100 -AD - 10th Clinical Department-General Surgery, Faculty of Medicine, "Carol Davila" - University of Medicine and Pharmacy, 020021 Bucharest, Romania. -AD - Department of General Surgery, "Bagdasar-Arseni" Clinical Emergency Hospital, - 041915 Bucharest, Romania. -FAU - Coman, Violeta Elena -AU - Coman VE -AD - 10th Clinical Department-General Surgery, Faculty of Medicine, "Carol Davila" - University of Medicine and Pharmacy, 020021 Bucharest, Romania. -AD - Department of General Surgery, "Bagdasar-Arseni" Clinical Emergency Hospital, - 041915 Bucharest, Romania. -FAU - Pleşea, Iancu Emil -AU - Pleşea IE -AD - Department of Histopathology, "Bagdasar-Arseni Clinical Emergency Hospital", - 041915 Bucharest, Romania. -FAU - Erchid, Anwar -AU - Erchid A -AD - Department of General Surgery, "Bagdasar-Arseni" Clinical Emergency Hospital, - 041915 Bucharest, Romania. -FAU - Gorecki, Gabriel-Petre -AU - Gorecki GP -AUID- ORCID: 0000-0002-5340-8929 -AD - Department of Anesthesia and Intensive Care, Faculty of Medicine, "Titu - Maiorescu" University, 031593 Bucharest, Romania. -AD - Department of Anesthesia and Intensive Care, CF2 Clinical Hospital, 011464 - Bucharest, Romania. -FAU - Rahnea-Nita, Gabriela -AU - Rahnea-Nita G -AD - Department of Oncology-Palliative Care, "Sf. Luca" Chronic Diseases Hospital, - 041915 Bucharest, Romania. -AD - Specific Disciplines Department, Faculty of Nursing and Midwifery, "Carol Davila" - University of Medicine and Pharmacy, 020021 Bucharest, Romania. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20240728 -PL - Switzerland -TA - Medicina (Kaunas) -JT - Medicina (Kaunas, Lithuania) -JID - 9425208 -RN - 6PLQ3CP4P3 (Etoposide) -RN - 64FS3BFH5W (Epoetin Alfa) -SB - IM -MH - Humans -MH - Male -MH - *Small Cell Lung Carcinoma/drug therapy/complications -MH - Middle Aged -MH - *Lung Neoplasms/drug therapy -MH - *Immunotherapy/methods -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Disease Progression -MH - Etoposide/therapeutic use/administration & dosage -MH - Epoetin Alfa/therapeutic use -PMC - PMC11356350 -OTO - NOTNLM -OT - Epoetinum alpha -OT - first-line immunotherapy -OT - reinitiating chemotherapy -OT - small-cell lung cancer -COIS- The authors declare no conflicts of interest. -EDAT- 2024/08/31 09:51 -MHDA- 2024/09/01 16:15 -PMCR- 2024/07/28 -CRDT- 2024/08/29 01:19 -PHST- 2024/07/10 00:00 [received] -PHST- 2024/07/25 00:00 [revised] -PHST- 2024/07/26 00:00 [accepted] -PHST- 2024/09/01 16:15 [medline] -PHST- 2024/08/31 09:51 [pubmed] -PHST- 2024/08/29 01:19 [entrez] -PHST- 2024/07/28 00:00 [pmc-release] -AID - medicina60081225 [pii] -AID - medicina-60-01225 [pii] -AID - 10.3390/medicina60081225 [doi] -PST - epublish -SO - Medicina (Kaunas). 2024 Jul 28;60(8):1225. doi: 10.3390/medicina60081225. - -PMID- 33960209 -OWN - NLM -STAT- MEDLINE -DCOM- 20211206 -LR - 20211214 -IS - 1744-8301 (Electronic) -IS - 1479-6694 (Linking) -VI - 17 -IP - 21 -DP - 2021 Jul -TI - Role of radiation in extensive stage small cell lung cancer: a National Cancer - Database registry analysis. -PG - 2713-2724 -LID - 10.2217/fon-2020-1095 [doi] -AB - The role of prophylactic cranial irradiation (PCI) and thoracic radiation therapy - (TRT) in extensive-stage small cell lung cancer remains controversial. The - authors examined the National Cancer Database and identified patients with - extensive-stage small cell lung cancer with no brain metastasis. Patients were - excluded if they died 30 days from diagnosis, did not receive polychemotherapy, - had other palliative radiation or had missing information. A propensity - score-matched analysis was also performed. A total of 21,019 patients were - identified. The majority of patients did not receive radiation (69%), whereas 10% - received PCI and 21% received TRT. The addition of PCI and TRT improved median - survival and survival at 1 and 2 years (p ≤ 0.05). The propensity score-matched - analysis confirmed the same overall survival benefit with both PCI and TRT. This - registry-based analysis of >1500 accredited cancer programs shows that PCI and - TRT are not commonly utilized for extensive-stage small cell lung cancer patients - who are treated with multiagent chemotherapy. The addition of PCI and TRT - significantly improves overall survival in this otherwise poor prognostic group. - Further research is needed to confirm the role of PCI and TRT, especially in the - era of improved systemic therapy. -FAU - Sheikh, Saad -AU - Sheikh S -AUID- ORCID: 0000-0002-6886-6199 -AD - Department of Radiation Oncology, University Hospitals Seidman Cancer Center, - Case Western Reserve University, Cleveland, OH 44106, USA. -FAU - Dey, Asoke -AU - Dey A -AD - Department of Management, University of Akron, Akron, OH 44325, USA. -FAU - Datta, Sujay -AU - Datta S -AD - Department of Statistics, University of Akron, Akron, OH 44325, USA. -FAU - Podder, Tarun K -AU - Podder TK -AD - Department of Radiation Oncology, University Hospitals Seidman Cancer Center, - Case Western Reserve University, Cleveland, OH 44106, USA. -FAU - Jindal, Charulata -AU - Jindal C -AD - Priority Research Centre for Generational Health & Ageing, School of Medicine & - Public Health, University of Newcastle, Newcastle, 2308, Australia. -AD - Centre for Clinical Epidemiology & Biostatistics, School of Medicine & Public - Health, University of Newcastle, Newcastle, 2308, Australia. -FAU - Dowlati, Afshin -AU - Dowlati A -AD - Department of Medicine, University Hospitals Seidman Cancer Center, Case Western - Reserve University, Cleveland, OH 44106, USA. -FAU - Efird, Jimmy T -AU - Efird JT -AD - Cooperative Studies Program Epidemiology Center-Durham, Durham VA Health Care - System, Asheboro, NC 27203, USA. -FAU - Machtay, Mitchell -AU - Machtay M -AD - Department of Radiation Oncology, University Hospitals Seidman Cancer Center, - Case Western Reserve University, Cleveland, OH 44106, USA. -FAU - Biswas, Tithi -AU - Biswas T -AD - Department of Radiation Oncology, University Hospitals Seidman Cancer Center, - Case Western Reserve University, Cleveland, OH 44106, USA. -LA - eng -PT - Journal Article -PT - Multicenter Study -DEP - 20210507 -PL - England -TA - Future Oncol -JT - Future oncology (London, England) -JID - 101256629 -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Brain Neoplasms/mortality/*prevention & control/secondary -MH - Chemoradiotherapy/methods/*statistics & numerical data -MH - Cranial Irradiation/*statistics & numerical data -MH - Databases, Factual/statistics & numerical data -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Lung Neoplasms/diagnosis/mortality/pathology/*therapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Practice Patterns, Physicians'/statistics & numerical data -MH - Prognosis -MH - Registries/statistics & numerical data -MH - Retrospective Studies -MH - Small Cell Lung Carcinoma/diagnosis/mortality/*prevention & control/secondary -MH - Survival Analysis -MH - United States/epidemiology -MH - Young Adult -OAB - Lay abstract The role of radiation therapy in patients with metastatic small cell - lung cancer remains controversial. The authors examined the National Cancer - Database and identified patients with metastatic small cell lung cancer without - brain metastasis. Patients were excluded if they died 30 days from diagnosis, did - not receive multiagent chemotherapy, had other palliative radiation or had - missing information regarding treatment. A total of 21,019 patients were - identified. The majority of patients did not receive radiation (69%), whereas 10% - received radiation to the brain and 21% received radiation to their lungs. The - addition of brain and lung radiation therapy improved median survival and - survival at 1 and 2 years. The addition of prophylactic cranial irradiation and - thoracic radiation therapy improves survival in extensive-stage small cell lung - cancer. Future research is needed to evaluate the role of radiation in the era of - chemoimmunotherapy. -OABL- eng -OTO - NOTNLM -OT - chemoradiation -OT - chemotherapy -OT - extensive-stage small cell lung cancer -OT - immunotherapy -OT - radiation therapy -EDAT- 2021/05/08 06:00 -MHDA- 2021/12/15 06:00 -CRDT- 2021/05/07 08:46 -PHST- 2021/05/08 06:00 [pubmed] -PHST- 2021/12/15 06:00 [medline] -PHST- 2021/05/07 08:46 [entrez] -AID - 10.2217/fon-2020-1095 [doi] -PST - ppublish -SO - Future Oncol. 2021 Jul;17(21):2713-2724. doi: 10.2217/fon-2020-1095. Epub 2021 - May 7. - -PMID- 37293787 -OWN - NLM -STAT- MEDLINE -DCOM- 20230705 -LR - 20230705 -IS - 1744-8301 (Electronic) -IS - 1479-6694 (Linking) -VI - 19 -IP - 16 -DP - 2023 May -TI - Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in - locally advanced non-small-cell lung cancer: a systematic review and - meta-analysis. -PG - 1151-1160 -LID - 10.2217/fon-2022-1274 [doi] -AB - Aims: This study systematically evaluated cases of pneumonitis following combined - immune checkpoint inhibitors (ICI) and chemoradiotherapy (CRT) for locally - advanced non-small-cell lung cancer (LA-NSCLC). Methods: Studies from Embase, - PubMed and the Cochrane Library on patients with LA-NSCLC who received CRT and - ICIs were reviewed. The primary outcomes were rates of all-grade, grade 3-5 and - grade 5 pneumonitis. Results: Overall, 35 studies involving 5000 patients were - enrolled. The pooled rates of all-grade, grade 3-5 and grade 5 pneumonitis were - 33.0% (95% CI: 23.5-42.6), 6.1% (95% CI: 4.7-7.4) and 0.8% (95% CI: 0.3-1.2), - respectively, with 7.6% of patients discontinuing ICIs because of pneumonitis. - Conclusion: The incidence rates of pneumonitis following combined CRT and ICIs - for LA-NSCLC were acceptable. However, the pulmonary toxicity of concurrent CRT - and nivolumab plus ipilimumab should be noted. -FAU - Yang, Linlin -AU - Yang L -AD - Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong - First Medical University & Shandong Academy of Medical Science, Jinan, 250117, - China. -FAU - Li, Butuo -AU - Li B -AD - Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong - First Medical University & Shandong Academy of Medical Science, Jinan, 250117, - China. -FAU - Xu, Yiyue -AU - Xu Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong - First Medical University & Shandong Academy of Medical Science, Jinan, 250117, - China. -FAU - Zou, Bing -AU - Zou B -AD - Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong - First Medical University & Shandong Academy of Medical Science, Jinan, 250117, - China. -FAU - Fan, Bingjie -AU - Fan B -AD - Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong - First Medical University & Shandong Academy of Medical Science, Jinan, 250117, - China. -FAU - Wang, Chunni -AU - Wang C -AD - Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong - First Medical University & Shandong Academy of Medical Science, Jinan, 250117, - China. -FAU - Wang, Linlin -AU - Wang L -AUID- ORCID: 0000-0002-2231-6642 -AD - Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong - First Medical University & Shandong Academy of Medical Science, Jinan, 250117, - China. -LA - eng -GR - 82172865/National Natural Science Foundation of China/ -GR - 2020-B14/Start-up fund of Shandong Cancer Hospital/ -GR - 320.6750.2021-02-51 and 320.6750.2021-17-13/Clinical Research Special Fund of Wu - Jieping Medical Foundation/ -PT - Journal Article -PT - Meta-Analysis -PT - Review -PT - Systematic Review -DEP - 20230609 -PL - England -TA - Future Oncol -JT - Future oncology (London, England) -JID - 101256629 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Lung Neoplasms/drug therapy -MH - *Pneumonia/chemically induced/epidemiology -MH - Chemoradiotherapy/adverse effects -OAB - Combined immune checkpoint inhibitors (ICI) and chemoradiotherapy (CRT) may cause - severe pneumonitis due to overlapped pulmonary toxicity. However, the safety data - on pneumonitis are limited to a small number of prospective clinical trials and - retrospective studies with limited evidence. Thus we conducted a systematic - review of pneumonitis in relation to the combination treatment. A total of 35 - studies, involving 5000 patients, were included for the final analysis. The - pooled rates of all-grade, grade 3–5 and grade 5 pneumonitis were 33.0, 6.1 and - 0.8%, respectively, and 7.6% of patients stopped taking ICIs because of - pneumonitis. The pneumonitis rates following combined CRT and ICIs for LA-NSCLC - were acceptable, but the pulmonary toxicity of concurrent CRT and nivolumab plus - ipilimumab should be noted. -OABL- eng -OTO - NOTNLM -OT - chemoradiation -OT - immune checkpoint inhibitors -OT - locally advanced non-small-cell lung cancer -OT - pneumonitis -EDAT- 2023/06/09 06:41 -MHDA- 2023/07/05 06:42 -CRDT- 2023/06/09 05:27 -PHST- 2023/07/05 06:42 [medline] -PHST- 2023/06/09 06:41 [pubmed] -PHST- 2023/06/09 05:27 [entrez] -AID - 10.2217/fon-2022-1274 [doi] -PST - ppublish -SO - Future Oncol. 2023 May;19(16):1151-1160. doi: 10.2217/fon-2022-1274. Epub 2023 - Jun 9. - -PMID- 34697180 -OWN - NLM -STAT- MEDLINE -DCOM- 20211027 -LR - 20211214 -IS - 1791-7549 (Electronic) -IS - 0258-851X (Print) -IS - 0258-851X (Linking) -VI - 35 -IP - 6 -DP - 2021 Nov-Dec -TI - Relationship Between Radiation Pneumonitis Following Definitive Radiotherapy for - Non-small Cell Lung Cancer and Isodose Line. -PG - 3441-3448 -LID - 10.21873/invivo.12644 [doi] -AB - BACKGROUND/AIM: It is important to identify radiation pneumonitis above Common - Terminology Criteria for Adverse Events Grade 2 (G2) in order to safely continue - durvalumab maintenance after chemoradiotherapy for advanced lung cancer. The aim - of this study was to discover factors that predict pneumonitis above G2. PATIENTS - AND METHODS: A follow-up computed tomography (CT) image was superimposed on the - planning CT image using deformable image registration (DIR). The pneumonitis area - was contoured on follow-up CT after DIR and the dose-volume histogram parameters - of the contoured pneumonitis area were calculated. RESULTS: V5 (Percentage of - total volume receiving ≥5 Gy) to V50 of pneumonitis were significantly lower in - patients with G2 pneumonitis than in those with G1 pneumonitis. The pneumonitis - V15 was the most significant. The group with pneumonitis V15 <87.10% had - significantly more G2 pneumonitis than the group with pneumonitis V15 ≥87.10%. - CONCLUSION: Pneumonitis V15 <87.10% was a risk factor for G2 pneumonitis. -CI - Copyright © 2021 International Institute of Anticancer Research (Dr. George J. - Delinasios), All rights reserved. -FAU - Watanabe, Shigenobu -AU - Watanabe S -AD - Department of Radiation Oncology, Yokohama City University Medical Center, - Yokohama, Japan; wata_s@yokohama-cu.ac.jp. -FAU - Ogino, Ichiro -AU - Ogino I -AD - Department of Radiation Oncology, Yokohama City University Medical Center, - Yokohama, Japan. -FAU - Shigenaga, Daisuke -AU - Shigenaga D -AD - Department of Radiation Oncology, Yokohama City University Medical Center, - Yokohama, Japan. -FAU - Hata, Masaharu -AU - Hata M -AD - Department of Radiation Oncology, Graduate School of Medicine, Yokohama City - University, Yokohama, Japan. -LA - eng -PT - Journal Article -PL - Greece -TA - In Vivo -JT - In vivo (Athens, Greece) -JID - 8806809 -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/radiotherapy -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/radiotherapy -MH - *Pneumonia/diagnostic imaging/etiology -MH - *Radiation Pneumonitis/diagnostic imaging/etiology -MH - Radiotherapy Dosage -PMC - PMC8627737 -OTO - NOTNLM -OT - Radiation pneumonitis -OT - deformable image registration -OT - isodose line -OT - lung cancer -COIS- The Authors report no conflicts of interest related to this study. -EDAT- 2021/10/27 06:00 -MHDA- 2021/10/28 06:00 -PMCR- 2021/11/03 -CRDT- 2021/10/26 05:46 -PHST- 2021/08/04 00:00 [received] -PHST- 2021/09/26 00:00 [revised] -PHST- 2021/09/29 00:00 [accepted] -PHST- 2021/10/26 05:46 [entrez] -PHST- 2021/10/27 06:00 [pubmed] -PHST- 2021/10/28 06:00 [medline] -PHST- 2021/11/03 00:00 [pmc-release] -AID - 35/6/3441 [pii] -AID - 10.21873/invivo.12644 [doi] -PST - ppublish -SO - In Vivo. 2021 Nov-Dec;35(6):3441-3448. doi: 10.21873/invivo.12644. - -PMID- 34408921 -OWN - NLM -STAT- MEDLINE -DCOM- 20211015 -LR - 20211015 -IS - 2162-402X (Electronic) -IS - 2162-4011 (Print) -IS - 2162-4011 (Linking) -VI - 10 -IP - 1 -DP - 2021 -TI - Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally - advanced non-small cell lung cancer. -PG - 1959979 -LID - 10.1080/2162402X.2021.1959979 [doi] -LID - 1959979 -AB - The standard of care for stage III non-small cell lung cancer (NSCLC) is - chemoradiotherapy (CRT) followed by durvalumab. Although doses higher than 66 Gy - are standard in our center, they were used in only 6.9% of patients in the - PACIFIC trial. We report our experience with durvalumab after high-dose - radiotherapy. The database of a tertiary hospital for patients with stage III - NSCLC who were treated with CRT and adjuvant durvalumab was evaluated. - Progression-free survival (PFS), overall survival (OS), and local-regional - failure (LRF) were measured from the administration of durvalumab. Thirty-nine - patients were included. All were treated with intensity-modulated radiation (mean - dose 69.9 Gy); Median follow-up time was 20.4 months (range 1-35.4). At - 12 months, PFS was 49%, OS 79%, and LRF 14%. Intrathoracic failure at first - progression was demonstrated in 8 (21%) patients. Adverse events requiring - corticosteroids occurred in 10(25.6%) patients: pneumonitis - 6 (15.4%), - hepatitis - 2 (5.1%), and arthralgia and pericarditis - 1 (2.6%). One patient - (2.6%) died of pneumonitis. The occurrence of pneumonitis was significantly - associated with lung V5 (55% vs. 42%, p = .04) and V20 (28% vs. 19%, p = .01) and - mean lung dose (14.8 Gy vs.11.6 Gy, p = .05). The similar 12-month PFS and OS - rates of our cohort and the PACIFIC trial support the use of high-dose - radiotherapy in patients with stage III NSCLC. Treatment-related mortality was - similar to the PACIFIC results. The intrathoracic failure rate in our cohort was - lower than that reported from the PACIFIC trial, suggesting that radiation dose - escalation may improve local control. -CI - © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. -FAU - Landman, Yosef -AU - Landman Y -AD - Thoracic Oncology Service, Davidoff Cancer Center, Rabin Medical Center - - Beilinson Hospital, Petach Tikva, Israel. -FAU - Jacobi, Oded -AU - Jacobi O -AD - Thoracic Oncology Service, Davidoff Cancer Center, Rabin Medical Center - - Beilinson Hospital, Petach Tikva, Israel. -FAU - Kurman, Noga -AU - Kurman N -AD - Thoracic Oncology Service, Davidoff Cancer Center, Rabin Medical Center - - Beilinson Hospital, Petach Tikva, Israel. -FAU - Yariv, Orly -AU - Yariv O -AD - Thoracic Oncology Service, Davidoff Cancer Center, Rabin Medical Center - - Beilinson Hospital, Petach Tikva, Israel. -AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv; Israel. -FAU - Peretz, Idit -AU - Peretz I -AD - Thoracic Oncology Service, Davidoff Cancer Center, Rabin Medical Center - - Beilinson Hospital, Petach Tikva, Israel. -FAU - Rotem, Ofer -AU - Rotem O -AD - Thoracic Oncology Service, Davidoff Cancer Center, Rabin Medical Center - - Beilinson Hospital, Petach Tikva, Israel. -FAU - Dudnik, Elizabeth -AU - Dudnik E -AD - Thoracic Oncology Service, Davidoff Cancer Center, Rabin Medical Center - - Beilinson Hospital, Petach Tikva, Israel. -AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv; Israel. -FAU - Zer, Alona -AU - Zer A -AD - Thoracic Oncology Service, Davidoff Cancer Center, Rabin Medical Center - - Beilinson Hospital, Petach Tikva, Israel. -AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv; Israel. -FAU - Allen, Aaron M -AU - Allen AM -AUID- ORCID: 0000-0002-9367-2417 -AD - Thoracic Oncology Service, Davidoff Cancer Center, Rabin Medical Center - - Beilinson Hospital, Petach Tikva, Israel. -AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv; Israel. -LA - eng -PT - Journal Article -DEP - 20210810 -PL - United States -TA - Oncoimmunology -JT - Oncoimmunology -JID - 101570526 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy/adverse effects -MH - Humans -MH - *Lung Neoplasms/drug therapy -PMC - PMC8366536 -OTO - NOTNLM -OT - Chemoradiation -OT - dose escalation -OT - durvalumab -OT - immunotherapy -OT - non-small cell lung cancer -COIS- The authors report no conflict of interest. -EDAT- 2021/08/20 06:00 -MHDA- 2021/10/16 06:00 -PMCR- 2021/08/10 -CRDT- 2021/08/19 06:42 -PHST- 2021/08/19 06:42 [entrez] -PHST- 2021/08/20 06:00 [pubmed] -PHST- 2021/10/16 06:00 [medline] -PHST- 2021/08/10 00:00 [pmc-release] -AID - 1959979 [pii] -AID - 10.1080/2162402X.2021.1959979 [doi] -PST - epublish -SO - Oncoimmunology. 2021 Aug 10;10(1):1959979. doi: 10.1080/2162402X.2021.1959979. - eCollection 2021. - -PMID- 27764686 -OWN - NLM -STAT- MEDLINE -DCOM- 20170808 -LR - 20220408 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 68 -DP - 2016 Nov -TI - Concurrent irradiation with the anti-programmed cell death ligand-1 immune - checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 - trial. -PG - 156-162 -LID - S0959-8049(16)32434-0 [pii] -LID - 10.1016/j.ejca.2016.09.013 [doi] -AB - PURPOSE: To assess preliminary safety and efficacy results of the anti-programmed - cell death ligand-1 (anti-PD-L1) durvalumab in combination with radiotherapy (RT) - in an expansion cohort of patients included in a phase 1/2 trial at our - institution. PATIENTS AND METHODS: Data from patients who received concurrent - palliative RT with durvalumab (10 mg/kg every 2 weeks via intravenous infusion) - were analysed in terms of safety (CTCAE v4.0) and efficacy (RECIST v1.1 and - tumour growth rate [TGR]). RESULTS: Between 02/2014 and 04/2016, 10 patients - received palliative local irradiation of 15 isolated lesions. Most patients (90%) - had received one or more prior lines of systemic therapy for advanced disease. - The median duration of exposure to durvalumab was 5.2 months with a median - delivery of 11 cycles (range, 4-38 cycles). RT (conformal 3D RT, 79% and - intracranial stereotactic RT, 21%) was delivered at a median - biologically-effective dose of 28 Gy (range, 6-92), in a median number of five - fractions (range, 1-10) and over a median duration of 6 d (range, 1-14). Five - patients (50%) reported an irradiation-related adverse event (AE) grade (G) 1 or - 2 and one patient had two G2 AEs. The most frequently reported AE (3/6) was G2 - mucositis. There was no G3 or more RT-related AEs. All AEs were transient, lasted - less than one week, and were manageable by standard guidelines. There was no - unexpected AE. On 10/15 in-field (IF) evaluable lesions, the objective response - (OR) rate was 60% (complete response, 2/10 and partial response, 4/10) and 4/10 - stable disease (SD). All evaluated IF lesions had a TGR decrease resulting in a - significant decrease in the TGR between the two periods (before versus after RT; - p < 0.01). Outfields disease evaluation retrieved 10/14 SD and 4/14 progressive - disease (PD). There was no out-field OR, no abscopal effect and no out-field - difference between the two periods according to TGR (p = 0.09). CONCLUSION: In - this small data set of patients, concurrent palliative RT with the anti-PD-L1 - durvalumab was well tolerated. ClinicalTrials.gov number: NCT01693562; EudraCT - number: 2012-002206-52. -CI - Copyright © 2016 Elsevier Ltd. All rights reserved. -FAU - Levy, Antonin -AU - Levy A -AD - Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, - F-94805, Villejuif, France; DITEP, Gustave Roussy, Université Paris-Saclay, - F-94805, Villejuif, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy, - Université Paris-Saclay, F-94805, Villejuif, France; University Paris Sud, - Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France. Electronic address: - Antonin.LEVY@gustaveroussy.fr. -FAU - Massard, Christophe -AU - Massard C -AD - DITEP, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France. -FAU - Soria, Jean-Charles -AU - Soria JC -AD - DITEP, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France. -FAU - Deutsch, Eric -AU - Deutsch E -AD - Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, - F-94805, Villejuif, France; DITEP, Gustave Roussy, Université Paris-Saclay, - F-94805, Villejuif, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy, - Université Paris-Saclay, F-94805, Villejuif, France; University Paris Sud, - Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France. -LA - eng -SI - ClinicalTrials.gov/NCT01693562 -SI - EudraCT/2012-002206-52 -PT - Clinical Trial, Phase I -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20161017 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Adenocarcinoma/secondary/therapy -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antineoplastic Agents/*therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors -MH - Bone Neoplasms/secondary/therapy -MH - Brain Neoplasms/secondary/therapy -MH - Breast Neoplasms/pathology/therapy -MH - Carcinoma, Squamous Cell/pathology/therapy -MH - Carcinoma, Transitional Cell/secondary/therapy -MH - *Chemoradiotherapy -MH - Colonic Neoplasms/pathology/therapy -MH - Disease-Free Survival -MH - Eye Neoplasms/pathology/therapy -MH - Female -MH - Head and Neck Neoplasms/pathology/therapy -MH - Humans -MH - Kaplan-Meier Estimate -MH - Liver Neoplasms/secondary/therapy -MH - Lung Neoplasms/pathology/therapy -MH - Lymphatic Metastasis/radiotherapy -MH - Male -MH - Melanoma/secondary/therapy -MH - Middle Aged -MH - Neoplasms/*therapy -MH - Radiosurgery -MH - Radiotherapy, Conformal -MH - Small Cell Lung Carcinoma/secondary/therapy -MH - Squamous Cell Carcinoma of Head and Neck -MH - Survival Rate -MH - Urinary Bladder Neoplasms/pathology/therapy -OTO - NOTNLM -OT - Anti-PD-L1 -OT - Immunoradiotherapy -OT - Phase 1 -OT - Phase 2 -OT - Radiotherapy -EDAT- 2016/10/21 06:00 -MHDA- 2017/08/09 06:00 -CRDT- 2016/10/21 06:00 -PHST- 2016/08/09 00:00 [received] -PHST- 2016/09/04 00:00 [accepted] -PHST- 2016/10/21 06:00 [pubmed] -PHST- 2017/08/09 06:00 [medline] -PHST- 2016/10/21 06:00 [entrez] -AID - S0959-8049(16)32434-0 [pii] -AID - 10.1016/j.ejca.2016.09.013 [doi] -PST - ppublish -SO - Eur J Cancer. 2016 Nov;68:156-162. doi: 10.1016/j.ejca.2016.09.013. Epub 2016 Oct - 17. - -PMID- 36800677 -OWN - NLM -STAT- MEDLINE -DCOM- 20230306 -LR - 20230324 -IS - 2005-6648 (Electronic) -IS - 1226-3303 (Print) -IS - 1226-3303 (Linking) -VI - 38 -IP - 2 -DP - 2023 Mar -TI - Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line - treatment for extensive-stage small cell lung cancer. -PG - 218-225 -LID - 10.3904/kjim.2022.361 [doi] -AB - BACKGROUND/AIMS: Despite the obvious benefits of adding immune checkpoint - inhibitors to platinum-etoposide chemotherapy in patients with extensive-stage - small-cell lung cancer (ES-SCLC), real-world data remain scarce. METHODS: This - retrospective study included 89 patients with ES-SCLC treated with - platinum-etoposide chemotherapy alone (chemo-only group; n = 48) or in - combination with atezolizumab (atezolizumab group; n = 41) and compared the - survival outcomes between these two groups. RESULTS: Overall survival (OS) was - significantly longer in the atezolizumab group than in the chemo-only group (15.2 - months vs. 8.5 months; p = 0.047), whereas the median progression-free survival - was almost the same (5.1 months vs. 5.0 months) in both groups (p = 0.754). - Subsequent multivariate analysis revealed that thoracic radiation (hazard ratio - [HR], 0.223; 95% confidence interval [CI], 0.092-0.537; p = 0.001) and - atezolizumab administration (HR, 0.350; 95% CI, 0.184-0.668; p = 0.001) were - favorable prognostic factors for OS. In the thoracic radiation subgroup, patients - who received atezolizumab demonstrated favorable survival outcomes and no grade - 3-4 adverse events (AEs). CONCLUSION: The addition of atezolizumab to - platinum-etoposide resulted in favorable outcomes in this real-world study. - Thoracic radiation was associated with improved OS and acceptable AE risk in - combination with immunotherapy in patients with ES-SCLC. -FAU - Kim, Soo Han -AU - Kim SH -AD - Department of Internal Medicine, Pusan National University School of Medicine, - Busan, Korea. -AD - Biomedical Research Institute, Pusan National University Hospital, Busan, Korea. -FAU - Jo, Eun Jung -AU - Jo EJ -AD - Department of Internal Medicine, Pusan National University School of Medicine, - Busan, Korea. -FAU - Mok, Jeongha -AU - Mok J -AD - Department of Internal Medicine, Pusan National University School of Medicine, - Busan, Korea. -FAU - Lee, Kwangha -AU - Lee K -AD - Department of Internal Medicine, Pusan National University School of Medicine, - Busan, Korea. -FAU - Kim, Ki Uk -AU - Kim KU -AD - Department of Internal Medicine, Pusan National University School of Medicine, - Busan, Korea. -FAU - Park, Hye-Kyung -AU - Park HK -AD - Department of Internal Medicine, Pusan National University School of Medicine, - Busan, Korea. -FAU - Lee, Min Ki -AU - Lee MK -AD - Department of Internal Medicine, Pusan National University School of Medicine, - Busan, Korea. -FAU - Eom, Jung Seop -AU - Eom JS -AD - Department of Internal Medicine, Pusan National University School of Medicine, - Busan, Korea. -FAU - Kim, Mi-Hyun -AU - Kim MH -AD - Department of Internal Medicine, Pusan National University School of Medicine, - Busan, Korea. -AD - Biomedical Research Institute, Pusan National University Hospital, Busan, Korea. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20230221 -PL - Korea (South) -TA - Korean J Intern Med -JT - The Korean journal of internal medicine -JID - 8712418 -RN - BG3F62OND5 (Carboplatin) -RN - 6PLQ3CP4P3 (Etoposide) -RN - 52CMI0WC3Y (atezolizumab) -RN - 49DFR088MY (Platinum) -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/drug therapy -MH - Carboplatin/adverse effects -MH - Etoposide/adverse effects -MH - *Lung Neoplasms/drug therapy -MH - Platinum/therapeutic use -MH - Retrospective Studies -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -PMC - PMC9993105 -OTO - NOTNLM -OT - Immunotherapy -OT - Radiotherapy -OT - Real-world evidence -OT - Small cell lung carcinoma -COIS- No potential conflict of interest relevant to this article was reported. -EDAT- 2023/02/21 06:00 -MHDA- 2023/03/07 06:00 -PMCR- 2023/03/01 -CRDT- 2023/02/20 02:33 -PHST- 2022/11/16 00:00 [received] -PHST- 2022/12/21 00:00 [accepted] -PHST- 2023/02/21 06:00 [pubmed] -PHST- 2023/03/07 06:00 [medline] -PHST- 2023/02/20 02:33 [entrez] -PHST- 2023/03/01 00:00 [pmc-release] -AID - kjim.2022.361 [pii] -AID - kjim-2022-361 [pii] -AID - 10.3904/kjim.2022.361 [doi] -PST - ppublish -SO - Korean J Intern Med. 2023 Mar;38(2):218-225. doi: 10.3904/kjim.2022.361. Epub - 2023 Feb 21. - -PMID- 32037126 -OWN - NLM -STAT- MEDLINE -DCOM- 20200316 -LR - 20200316 -IS - 1769-6658 (Electronic) -IS - 1278-3218 (Linking) -VI - 24 -IP - 1 -DP - 2020 Feb -TI - [Role of immunotherapy in locally advanced non-small cell lung cancer]. -PG - 67-72 -LID - S1278-3218(20)30009-3 [pii] -LID - 10.1016/j.canrad.2019.09.007 [doi] -AB - Concomitant radiochemotherapy has been the standard of care for unresectable - stage III non-small cell lung cancer (NSCLC), irrespective of histological - sub-type or molecular characteristics. Currently, only 15-30 % of patients are - alive five years after radiochemotherapy, and this figure remains largely - unchanged despite multiple phase III randomised trials. In recent years, - immune-checkpoint blockades with anti-PD-(L)1 have revolutionised the care of - metastatic NSCLC, becoming the standard front- and second-line strategy. Several - preclinical studies reported an increased tumour antigen release, improved - antigen presentation, and T-cell infiltration in irradiated tumours. - Immunotherapy has therefore recently been evaluated for patients with locally - advanced stage III NSCLC. Following the PACIFIC trial, the anti-PD-L1 durvalumab - antibody has emerged as a new standard consolidative treatment for patients with - unresectable stage III NSCLC whose disease has not progressed following - concomitant platinum-based chemoradiotherapy. Immunoradiotherapy therefore - appears to be a promising association in patients with localised NSCLC. Many - trials are currently evaluating the value of concomitant immunotherapy and - chemoradiotherapy and/or consolidative chemotherapy with immunotherapy in - patients with locally advanced unresectable NSCLC. -CI - Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published - by Elsevier Masson SAS. All rights reserved. -FAU - Levy, A -AU - Levy A -AD - Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie - thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France; Université - Paris Sud, université Paris-Saclay, 94270, Le Kremlin-Bicêtre, France. Electronic - address: antonin.levy@gustaveroussy.fr. -FAU - Doyen, J -AU - Doyen J -AD - Département d'oncologie radiothérapie, centre Antoine-Lacassagne, 33, avenue de - Valombrose, 06189, Nice cedex 2, France; Université Côte d'Azur, fédération - Claude-Lalanne, Nice cedex 2, France. -FAU - Botticella, A -AU - Botticella A -AD - Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie - thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France. -FAU - Bourdais, R -AU - Bourdais R -AD - Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie - thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France. -FAU - Achkar, S -AU - Achkar S -AD - Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie - thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France. -FAU - Giraud, P -AU - Giraud P -AD - Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie - thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France. -FAU - Du, C -AU - Du C -AD - Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie - thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France. -FAU - Naltet, C -AU - Naltet C -AD - Département de médecine oncologique, Gustave-Roussy, institut d'oncologie - thoracique (IOT), université Paris-Saclay, 94805, Villejuif, France. -FAU - Lavaud, P -AU - Lavaud P -AD - Département de médecine oncologique, Gustave-Roussy, institut d'oncologie - thoracique (IOT), université Paris-Saclay, 94805, Villejuif, France. -FAU - Besse, B -AU - Besse B -AD - Département de médecine oncologique, Gustave-Roussy, institut d'oncologie - thoracique (IOT), université Paris-Saclay, 94805, Villejuif, France; Université - Paris Sud, université Paris-Saclay, 94270, Le Kremlin-Bicêtre, France. -FAU - Pradère, P -AU - Pradère P -AD - Département de chirurgie vasculaire et thoracique, hôpital Marie-Lannelongue, - université Paris-Saclay, Le Plessis Robinson, France. -FAU - Mercier, O -AU - Mercier O -AD - Département de chirurgie vasculaire et thoracique, hôpital Marie-Lannelongue, - université Paris-Saclay, Le Plessis Robinson, France. -FAU - Caramella, C -AU - Caramella C -AD - Département d'imagerie, Gustave-Roussy, institut d'oncologie thoracique (IOT), - université Paris-Saclay, 94805 Villejuif, France. -FAU - Planchard, D -AU - Planchard D -AD - Département de médecine oncologique, Gustave-Roussy, institut d'oncologie - thoracique (IOT), université Paris-Saclay, 94805, Villejuif, France. -FAU - Deutsch, E -AU - Deutsch E -AD - Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie - thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France; Université - Paris Sud, université Paris-Saclay, 94270, Le Kremlin-Bicêtre, France. -FAU - Le Péchoux, C -AU - Le Péchoux C -AD - Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie - thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France. -LA - fre -PT - Journal Article -TT - Place de l’immunothérapie dans le cancer bronchique non à petites cellules - localement avancé. -DEP - 20200206 -PL - France -TA - Cancer Radiother -JT - Cancer radiotherapie : journal de la Societe francaise de radiotherapie - oncologique -JID - 9711272 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/immunology/*therapy -MH - Chemotherapy, Adjuvant -MH - Clinical Trials as Topic -MH - Humans -MH - Lung Neoplasms/immunology/*therapy -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - Radiotherapy, Adjuvant -OTO - NOTNLM -OT - Cancer du poumon -OT - Immuno-oncologie -OT - Immuno-oncology -OT - Irradiation thoracique -OT - Lung cancer -OT - Radiotherapy -OT - Radiothérapie -OT - Thoracic irradiation -EDAT- 2020/02/11 06:00 -MHDA- 2020/03/17 06:00 -CRDT- 2020/02/11 06:00 -PHST- 2019/08/26 00:00 [received] -PHST- 2019/09/02 00:00 [revised] -PHST- 2019/09/11 00:00 [accepted] -PHST- 2020/02/11 06:00 [pubmed] -PHST- 2020/03/17 06:00 [medline] -PHST- 2020/02/11 06:00 [entrez] -AID - S1278-3218(20)30009-3 [pii] -AID - 10.1016/j.canrad.2019.09.007 [doi] -PST - ppublish -SO - Cancer Radiother. 2020 Feb;24(1):67-72. doi: 10.1016/j.canrad.2019.09.007. Epub - 2020 Feb 6. - -PMID- 38304255 -OWN - NLM -STAT- MEDLINE -DCOM- 20240205 -LR - 20240328 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 14 -DP - 2023 -TI - Consolidative thoracic radiation therapy for extensive-stage small cell lung - cancer in the era of first-line chemoimmunotherapy: preclinical data and a - retrospective study in Southern Italy. -PG - 1289434 -LID - 10.3389/fimmu.2023.1289434 [doi] -LID - 1289434 -AB - BACKGROUND: Consolidative thoracic radiotherapy (TRT) has been commonly used in - the management of extensive-stage small cell lung cancer (ES-SCLC). Nevertheless, - phase III trials exploring first-line chemoimmunotherapy have excluded this - treatment approach. However, there is a strong biological rationale to support - the use of radiotherapy (RT) as a boost to sustain anti-tumor immune responses. - Currently, the benefit of TRT after chemoimmunotherapy remains unclear. The - present report describes the real-world experiences of 120 patients with ES-SCLC - treated with different chemoimmunotherapy combinations. Preclinical data - supporting the hypothesis of anti-tumor immune responses induced by RT are also - presented. METHODS: A total of 120 ES-SCLC patients treated with - chemoimmunotherapy since 2019 in the South of Italy were retrospectively - analyzed. None of the patients included in the analysis experienced disease - progression after undergoing first-line chemoimmunotherapy. Of these, 59 patients - underwent TRT after a multidisciplinary decision by the treatment team. Patient - characteristics, chemoimmunotherapy schedule, and timing of TRT onset were - assessed. Safety served as the primary endpoint, while efficacy measured in terms - of overall survival (OS) and progression-free survival (PFS) was used as the - secondary endpoint. Immune pathway activation induced by RT in SCLC cells was - explored to investigate the biological rationale for combining RT and - immunotherapy. RESULTS: Preclinical data supported the activation of innate - immune pathways, including the STimulator of INterferon pathway (STING), - gamma-interferon-inducible protein (IFI-16), and mitochondrial - antiviral-signaling protein (MAVS) related to DNA and RNA release. Clinical data - showed that TRT was associated with a good safety profile. Of the 59 patients - treated with TRT, only 10% experienced radiation toxicity, while no ≥ G3 - radiation-induced adverse events occurred. The median time for TRT onset after - cycles of chemoimmunotherapy was 62 days. Total radiation dose and fraction dose - of TRT include from 30 Gy in 10 fractions, up to definitive dose in selected - patients. Consolidative TRT was associated with a significantly longer PFS than - systemic therapy alone (one-year PFS of 61% vs. 31%, p<0.001), with a trend - toward improved OS (one-year OS of 80% vs. 61%, p=0.027). CONCLUSION: - Multi-center data from establishments in the South of Italy provide a general - confidence in using TRT as a consolidative strategy after chemoimmunotherapy. - Considering the limits of a restrospective analysis, these preliminary results - support the feasibility of the approach and encourage a prospective evaluation. -CI - Copyright © 2024 Longo, Della Corte, Russo, Spinnato, Ambrosio, Ronga, Marchese, - Del Giudice, Sergi, Casaluce, Gilli, Montrone, Gristina, Sforza, Reale, Di - Liello, Servetto, Lipari, Longhitano, Vizzini, Manzo, Cristofano, Paolelli, - Nardone, De Summa, Perrone, Bisceglia, Derosa, Nardone, Viscardi, Galetta and - Vitiello. -FAU - Longo, Vito -AU - Longo V -AD - Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, - Italy. -FAU - Della Corte, Carminia Maria -AU - Della Corte CM -AD - Department of Precision Medicine, University of Campania Luigi Vanvitelli, - Naples, Italy. -FAU - Russo, Alessandro -AU - Russo A -AD - Department of Hematology-Oncology, Papardo Hospital, Messina, Italy. -FAU - Spinnato, Francesca -AU - Spinnato F -AD - UOC Oncologia Medica Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy. -FAU - Ambrosio, Francesca -AU - Ambrosio F -AD - UOC Oncologia AORN Cardarelli, Hospital Antonio Cardarelli, Naples, Italy. -FAU - Ronga, Riccardo -AU - Ronga R -AD - UOC Oncologia AORN Cardarelli, Hospital Antonio Cardarelli, Naples, Italy. -FAU - Marchese, Antonella -AU - Marchese A -AD - Ospedale La Maddalena, Palermo, Italy. -FAU - Del Giudice, Teresa -AU - Del Giudice T -AD - Medical Oncology Unit, AOU Renato Dubecco De Lellis Hospital, Catanzaro, Italy. -FAU - Sergi, Concetta -AU - Sergi C -AD - UOC Oncologia ARNAS Garibaldi Catania, Azienda Sanitaria Provinciale di Catania, - Catania, Italy. -FAU - Casaluce, Francesca -AU - Casaluce F -AD - Divison of Medical Oncology, AORN S.G. Moscati Hospital (San Giuseppe Moscati - Hospital of National Importance and High Specialty), Avellino, Italy. -FAU - Gilli, Marina -AU - Gilli M -AD - Department of Pulmonary Oncology, AORN Azienda Ospedaliera dei Colli Monaldi, - Naples, Italy. -FAU - Montrone, Michele -AU - Montrone M -AD - Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, - Italy. -FAU - Gristina, Valerio -AU - Gristina V -AD - Department of Surgical, Oncological and Oral Sciences, University of Palermo, - University of Palermo, Palermo, Italy. -FAU - Sforza, Vincenzo -AU - Sforza V -AD - Oncologia Clinica Sperimentale Toraco-Polmonare, G. Pascale National Cancer - Institute Foundation (IRCCS), Naples, Italy. -FAU - Reale, Maria Lucia -AU - Reale ML -AD - Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy. -FAU - Di Liello, Raimondo -AU - Di Liello R -AD - Oncology Unit Ospedale del Mare, ASL Napoli 1, Napoli, Italy. -FAU - Servetto, Alberto -AU - Servetto A -AD - Department of Clinical Medicine and Surgery, School of Medicine and Surgery, - University of Naples Federico II, Naples, Italy. -FAU - Lipari, Helga -AU - Lipari H -AD - Oncologia Ospedale Cannizzaro Catania, Medical Oncology Unit, Cannizzaro - Hospital, Catania, Italy. -FAU - Longhitano, Claudio -AU - Longhitano C -AD - UOC Oncologia Ospedale Maria Paterno Arezzo (OMPA), Ragusa, Italy. -FAU - Vizzini, Laura -AU - Vizzini L -AD - UOC Oncology Agrigento Health Authority, Agrigento, Italy. -FAU - Manzo, Anna -AU - Manzo A -AD - Oncologia Clinica Sperimentale Toraco-Polmonare, G. Pascale National Cancer - Institute Foundation (IRCCS), Naples, Italy. -FAU - Cristofano, Antonella -AU - Cristofano A -AD - Dipartimento di Oncologia e Oncoematologia, Ospedale Generale Regionale F. - Miulli, Acquaviva, Italy. -FAU - Paolelli, Loretta -AU - Paolelli L -AD - Oncology Unit Ospedale del Mare, ASL Napoli 1, Napoli, Italy. -FAU - Nardone, Annalisa -AU - Nardone A -AD - Unitá Opertiva Complessa di Radioterapia, I.R.C.C.S. Istituto Tumori "Giovanni - Paolo II", Bari, Italy. -FAU - De Summa, Simona -AU - De Summa S -AD - Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni - Paolo II", Bari, Italy. -FAU - Perrone, Antonella -AU - Perrone A -AD - Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, - Italy. -FAU - Bisceglia, Carmela -AU - Bisceglia C -AD - Department of Pulmonary Oncology, AORN Azienda Ospedaliera dei Colli Monaldi, - Naples, Italy. -FAU - Derosa, Caterina -AU - Derosa C -AD - Department of Precision Medicine, University of Campania Luigi Vanvitelli, - Naples, Italy. -FAU - Nardone, Valerio -AU - Nardone V -AD - Department of Precision Medicine, University of Campania Luigi Vanvitelli, - Naples, Italy. -FAU - Viscardi, Giuseppe -AU - Viscardi G -AD - Department of Pulmonary Oncology, AORN Azienda Ospedaliera dei Colli Monaldi, - Naples, Italy. -FAU - Galetta, Domenico -AU - Galetta D -AD - Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, - Italy. -FAU - Vitiello, Fabiana -AU - Vitiello F -AD - Department of Pulmonary Oncology, AORN Azienda Ospedaliera dei Colli Monaldi, - Naples, Italy. -LA - eng -PT - Comment -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20240118 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -SB - IM -CON - Radiat Oncol. 2023 Jul 4;18(1):111. doi: 10.1186/s13014-023-02308-2. PMID: - 37403111 -MH - Humans -MH - *Small Cell Lung Carcinoma/drug therapy/radiotherapy -MH - *Lung Neoplasms/drug therapy -MH - Retrospective Studies -MH - Progression-Free Survival -MH - Immunotherapy -PMC - PMC10830694 -OTO - NOTNLM -OT - SCLC - small cell lung cancer -OT - chemoimmunotherapy -OT - consolidative radiotherapy -OT - innate immunity -OT - safety -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. The author(s) declared that they were an editorial board - member of Frontiers, at the time of submission. This had no impact on the peer - review process and the final decision. -EDAT- 2024/02/02 06:43 -MHDA- 2024/02/05 06:43 -PMCR- 2023/01/01 -CRDT- 2024/02/02 04:03 -PHST- 2023/09/05 00:00 [received] -PHST- 2023/12/18 00:00 [accepted] -PHST- 2024/02/05 06:43 [medline] -PHST- 2024/02/02 06:43 [pubmed] -PHST- 2024/02/02 04:03 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2023.1289434 [doi] -PST - epublish -SO - Front Immunol. 2024 Jan 18;14:1289434. doi: 10.3389/fimmu.2023.1289434. - eCollection 2023. - -PMID- 32860288 -OWN - NLM -STAT- MEDLINE -DCOM- 20210618 -LR - 20231112 -IS - 1549-490X (Electronic) -IS - 1083-7159 (Print) -IS - 1083-7159 (Linking) -VI - 25 -IP - 11 -DP - 2020 Nov -TI - Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of - Extensive-Stage Small Cell Lung Cancer. -PG - 981-992 -LID - 10.1634/theoncologist.2020-0193 [doi] -AB - BACKGROUND: Small cell lung cancer (SCLC) represents approximately 15% of lung - cancers, and approximately 70% are diagnosed as extensive-stage SCLC (ES-SCLC). - Although ES-SCLC is highly responsive to chemotherapy, patients typically - progress rapidly, and there is an urgent need for new therapies. Immune - checkpoint inhibitors (ICIs) have recently been investigated in SCLC, and this - review provides guidance on the use of these agents in ES-SCLC based on phase III - evidence. METHODS: Published and presented literature on phase III data - addressing use of ICIs in ES-SCLC was identified using the key search terms - "small cell lung cancer" AND "checkpoint inhibitors" (OR respective aliases). - Directed searches of eligible studies were periodically performed to ensure - capture of the most recent data. RESULTS: Six phase III trials were identified, - with four assessing the benefits of ICIs plus chemotherapy first-line, one - evaluating ICIs as first-line therapy maintenance, and one assessing ICI - monotherapy after progression on platinum-based chemotherapy. The addition of - ipilimumab or tremelimumab to first-line treatment or as first-line maintenance - did not improve survival. Two out of three studies combining PD-1/PD-L1 - inhibitors with first-line platinum-based chemotherapy demonstrated significant - long-lasting survival benefits and improved quality of life with no unexpected - safety concerns. PD-1/PD-L1 inhibitors as first-line maintenance or in later - lines of therapy did not improve survival. Biomarker research is ongoing as well - as research into the role of ICIs in combination with radiation therapy in - limited-stage SCLC. CONCLUSION: The addition of atezolizumab or durvalumab to - first-line platinum-based chemotherapy for ES-SCLC prolongs survival and improves - quality of life. IMPLICATIONS FOR PRACTICE: Platinum-based chemotherapy has been - standard of care for extensive-stage small cell lung cancer (ES-SCLC) for more - than a decade. Six recent phase III trials investigating immune checkpoint - inhibitors (ICIs) have clarified the role of these agents in this setting. - Although ICIs were assessed first-line, as first-line maintenance, and in later - lines of therapy, the additions of atezolizumab or durvalumab to first-line - platinum-based chemotherapy were the only interventions that significantly - improved overall survival and increased quality of life. These combinations - should therefore be considered standard therapy for first-line ES-SCLC. Biomarker - research and investigations into the role of ICIs for limited-stage disease are - ongoing. -CI - © AlphaMed Press 2020. -FAU - Melosky, Barbara -AU - Melosky B -AUID- ORCID: 0000-0003-2865-659X -AD - BC Cancer, Vancouver Centre, University of British Columbia, Vancouver, British - Columbia, Canada. -FAU - Cheema, Parneet K -AU - Cheema PK -AD - William Osler Health System, University of Toronto, Brampton and Toronto, - Ontario, Canada. -FAU - Brade, Anthony -AU - Brade A -AD - Trillium Health Partners, University of Toronto, Mississauga, Ontario, Canada. -FAU - McLeod, Deanna -AU - McLeod D -AD - Kaleidoscope Strategic Inc., Toronto, Ontario, Canada. -FAU - Liu, Geoffrey -AU - Liu G -AD - Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. -FAU - Price, Paul Wheatley -AU - Price PW -AD - The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada. -FAU - Jao, Kevin -AU - Jao K -AD - Hôpital Sacré-Cœur, Université de Montréal, Montreal, Quebec, Canada. -FAU - Schellenberg, Devin D -AU - Schellenberg DD -AD - BC Cancer, Surrey Centre, University of British Columbia, Surrey, British - Columbia, Canada. -FAU - Juergens, Rosalyn -AU - Juergens R -AD - Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada. -FAU - Leighl, Natasha -AU - Leighl N -AD - Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. -FAU - Chu, Quincy -AU - Chu Q -AD - Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20200923 -PL - England -TA - Oncologist -JT - The oncologist -JID - 9607837 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -MH - Quality of Life -MH - *Small Cell Lung Carcinoma/drug therapy -PMC - PMC7648366 -OTO - NOTNLM -OT - Atezolizumab -OT - Durvalumab -OT - First-line -OT - Immune checkpoint inhibitors -OT - Small cell lung cancer -COIS- Disclosures of potential conflicts of interest may be found at the end of this - article. -EDAT- 2020/08/30 06:00 -MHDA- 2021/06/22 06:00 -PMCR- 2020/11/01 -CRDT- 2020/08/30 06:00 -PHST- 2020/03/08 00:00 [received] -PHST- 2020/07/02 00:00 [accepted] -PHST- 2020/08/30 06:00 [pubmed] -PHST- 2021/06/22 06:00 [medline] -PHST- 2020/08/30 06:00 [entrez] -PHST- 2020/11/01 00:00 [pmc-release] -AID - ONCO13496 [pii] -AID - 10.1634/theoncologist.2020-0193 [doi] -PST - ppublish -SO - Oncologist. 2020 Nov;25(11):981-992. doi: 10.1634/theoncologist.2020-0193. Epub - 2020 Sep 23. - -PMID- 24857075 -OWN - NLM -STAT- MEDLINE -DCOM- 20151103 -LR - 20240603 -IS - 1548-8756 (Electronic) -IS - 1548-8748 (Print) -IS - 1548-8748 (Linking) -DP - 2014 -TI - 50 Years of progress in the systemic therapy of non-small cell lung cancer. -PG - 177-89 -LID - 10.14694/EdBook_AM.2014.34.177 [doi] -AB - Non-small cell lung cancer constitutes 85% to 90% of lung cancer and is the most - common cause of cancer death. Over the past 50 years, substantial progress has - been made in all aspects of lung cancer including screening, diagnostic - evaluation, surgery, radiation therapy, and chemotherapy. This review focuses on - the advances in systemic therapy during this half century. -FAU - Wakelee, Heather -AU - Wakelee H -AD - From the Stanford Cancer Institute, Stanford University, Stanford, CA; University - of California, Davis Cancer Center, Sacramento, CA; University of New Mexico - Cancer Center, Albuquerque, NM. -FAU - Kelly, Karen -AU - Kelly K -AD - From the Stanford Cancer Institute, Stanford University, Stanford, CA; University - of California, Davis Cancer Center, Sacramento, CA; University of New Mexico - Cancer Center, Albuquerque, NM. -FAU - Edelman, Martin J -AU - Edelman MJ -AD - From the Stanford Cancer Institute, Stanford University, Stanford, CA; University - of California, Davis Cancer Center, Sacramento, CA; University of New Mexico - Cancer Center, Albuquerque, NM. -LA - eng -GR - P30 CA134274/CA/NCI NIH HHS/United States -GR - R21 CA130349/CA/NCI NIH HHS/United States -PT - Historical Article -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PT - Video-Audio Media -PL - United States -TA - Am Soc Clin Oncol Educ Book -JT - American Society of Clinical Oncology educational book. American Society of - Clinical Oncology. Annual Meeting -JID - 101233985 -RN - 0 (Antineoplastic Agents) -SB - IM -MH - Animals -MH - Antineoplastic Agents/adverse effects/history/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug - therapy/history/immunology/mortality/pathology -MH - Chemotherapy, Adjuvant -MH - History, 20th Century -MH - History, 21st Century -MH - Humans -MH - Immunotherapy -MH - Lung Neoplasms/*drug therapy/history/immunology/mortality/pathology -MH - Medical Oncology/history/*trends -MH - Molecular Targeted Therapy -MH - Pneumonectomy -MH - Radiotherapy, Adjuvant -MH - Treatment Outcome -PMC - PMC5600272 -MID - NIHMS899026 -EDAT- 2014/05/27 06:00 -MHDA- 2015/11/04 06:00 -PMCR- 2017/09/15 -CRDT- 2014/05/27 06:00 -PHST- 2014/05/27 06:00 [entrez] -PHST- 2014/05/27 06:00 [pubmed] -PHST- 2015/11/04 06:00 [medline] -PHST- 2017/09/15 00:00 [pmc-release] -AID - 00114000177 [pii] -AID - 10.14694/EdBook_AM.2014.34.177 [doi] -PST - ppublish -SO - Am Soc Clin Oncol Educ Book. 2014:177-89. doi: 10.14694/EdBook_AM.2014.34.177. - -PMID- 34187157 -OWN - NLM -STAT- MEDLINE -DCOM- 20220124 -LR - 20220124 -IS - 1999-6187 (Electronic) -IS - 1009-3419 (Print) -IS - 1009-3419 (Linking) -VI - 24 -IP - 7 -DP - 2021 Jul 20 -TI - [Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in - 
Non-small Cell Lung Cancer]. -PG - 503-512 -LID - 10.3779/j.issn.1009-3419.2021.102.24 [doi] -AB - Immune checkpoint inhibitors (ICI) have transformed the treatment landscape of - advanced non-small cell lung cancer (NSCLC). Biomarkers are essential for guiding - precision immunotherapy. Tissue-based programmed death ligand 1 (PD-L1) - expression and tumor mutational burden (TMB) are currently widely used biomarkers - for selecting patients for immunotherapy. However, tissue specimens are often - difficult to reach and couldn't overcome spatial and temporal heterogeneity. - Blood biomarkers offer an alternative non-invasive solution that could provide a - complete insight on patient's immune status and tumor as well, and show their - potential in predicting the outcome as well as in monitoring response to - immunotherapy. In this article, we summarize current knowledge on blood - biomarkers in NSCLC patients treated with ICI, and we hope to provide more - references for development of novel biomarkers.
. -FAU - Wang, Peng -AU - Wang P -AD - Department of Radiation Oncology, Peking University International Hospital, - Beijing 102206, China. -FAU - Tang, Chuanhao -AU - Tang C -AD - Department of Oncology, Peking University International Hospital, Beijing 102206, - China. -FAU - Liang, Jun -AU - Liang J -AD - Department of Radiation Oncology, Peking University International Hospital, - Beijing 102206, China. -LA - chi -PT - Journal Article -PT - Review -DEP - 20210630 -PL - China -TA - Zhongguo Fei Ai Za Zhi -JT - Zhongguo fei ai za zhi = Chinese journal of lung cancer -JID - 101126433 -RN - 0 (Biomarkers, Tumor) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - *Biomarkers, Tumor/biosynthesis/blood -MH - *Carcinoma, Non-Small-Cell Lung/blood/drug therapy/metabolism -MH - Humans -MH - *Immune Checkpoint Inhibitors/blood/therapeutic use -MH - Immunotherapy/methods -MH - *Lung Neoplasms/blood/drug therapy/metabolism -PMC - PMC8317092 -OTO - NOTNLM -OT - Blood biomarkers -OT - Immmune Checkpoint Inhibitors -OT - Immunotherapy -OT - Lung neoplasms -EDAT- 2021/07/01 06:00 -MHDA- 2022/01/27 06:00 -PMCR- 2021/07/20 -CRDT- 2021/06/30 03:04 -PHST- 2021/07/01 06:00 [pubmed] -PHST- 2022/01/27 06:00 [medline] -PHST- 2021/06/30 03:04 [entrez] -PHST- 2021/07/20 00:00 [pmc-release] -AID - zgfazz-24-7-503 [pii] -AID - 10.3779/j.issn.1009-3419.2021.102.24 [doi] -PST - ppublish -SO - Zhongguo Fei Ai Za Zhi. 2021 Jul 20;24(7):503-512. doi: - 10.3779/j.issn.1009-3419.2021.102.24. Epub 2021 Jun 30. - -PMID- 35976547 -OWN - NLM -STAT- MEDLINE -DCOM- 20220919 -LR - 20220919 -IS - 1573-7373 (Electronic) -IS - 0167-594X (Linking) -VI - 159 -IP - 3 -DP - 2022 Sep -TI - Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for - extensive-stage small-cell lung cancer with brain metastasis. -PG - 685-693 -LID - 10.1007/s11060-022-04111-7 [doi] -AB - INTRODUCTION: Anti-programmed cell death-ligand 1 (Anti-PD-L1) blockades have - become the first-line treatment of extensive-stage small-cell lung cancer - (ES-SCLC) from CASPIAN and IMpower133 trials. SCLC has a high incidence of brain - metastasis (BM) and brain radiotherapy (BRT) is the main local treatment method, - but there is limited data on the BRT-immunotherapy scheme. The aim of the - retrospective study is to investigate the clinical efficacy and safety of the - first-line anti-PD-L1 blockades combined with BRT in ES-SCLC with BM. METHODS: - Patients with newly diagnosed ES-SCLC with baseline BMs at Shandong Cancer - Hospital and Research Institute between 2017 and 2021 were selected. Patients - were divided into the anti-PD-L1+BRT group and BRT group. We also assessed the - leukoencephalopathy in both groups. RESULTS: A total of 46 patients were - selected. Fifteen were divided into anti-PD-L1+BRT group and 31 to BRT group. The - median overall survival (OS) was not reached (NR) vs 15.9 m (P = 0.172). - Progression-free survival (PFS) was numerically prolonged with anti-PD-L1 - blockades, but the significance was not reached (median: 9.4 m vs 7.4 m, - P = 0.362). The median intracranial PFS was not improved, neither (median: 8.2 m - vs 8.9 m, P = 0.620). Objective response rate (ORR) in the two groups was 73.33% - vs 77.42% (P = 0.949) and disease control rate (DCR) was both 100%. Intracranial - ORR and DCR were 53.33% vs 70.97% (P = 0.239) and 73.33% vs 80.65% (P = 0.855), - respectively. There was no significant difference in leukoencephalopathy - incidence between the two groups. CONCLUSION: The combination of first-line - anti-PD-L1 blockades with BRT did not confer a significant survival benefit in - ES-SCLC with BM, without enhancing cranial neurotoxicity. -CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business - Media, LLC, part of Springer Nature. -FAU - Ma, Ji -AU - Ma J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, 440 - Jiyan Road, Jinan, 250117, Shandong Province, China. -AD - Department of Oncology, The People's Hospital of Leling, Leling, China. -FAU - Tian, Yaru -AU - Tian Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, 440 - Jiyan Road, Jinan, 250117, Shandong Province, China. -FAU - Hao, Shaoyu -AU - Hao S -AD - Department of Thoracic Surgery, Shandong Cancer Hospital and Institute, Shandong - First Medical University and Shandong Academy of Medical Science, Jinan, China. -FAU - Zheng, Liangjie -AU - Zheng L -AD - Department of Oncology, The People's Hospital of Leling, Leling, China. -FAU - Hu, Weibo -AU - Hu W -AD - Department of Oncology, The People's Hospital of Leling, Leling, China. -FAU - Zhai, Xiaoyang -AU - Zhai X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, 440 - Jiyan Road, Jinan, 250117, Shandong Province, China. -FAU - Meng, Dongfang -AU - Meng D -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, 440 - Jiyan Road, Jinan, 250117, Shandong Province, China. -FAU - Zhu, Hui -AU - Zhu H -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, 440 - Jiyan Road, Jinan, 250117, Shandong Province, China. drzhuh@126.com. -LA - eng -GR - 82103632/National Natural Science Foundation of China/ -GR - ZR2021QH245/Natural Science Foundation of Shandong Province/ -GR - ZR2021QH208/Natural Science Foundation of Shandong Province/ -PT - Journal Article -DEP - 20220817 -PL - United States -TA - J Neurooncol -JT - Journal of neuro-oncology -JID - 8309335 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -SB - IM -MH - B7-H1 Antigen/metabolism -MH - Brain/pathology -MH - *Brain Neoplasms/radiotherapy/secondary -MH - Humans -MH - *Leukoencephalopathies -MH - *Lung Neoplasms -MH - Retrospective Studies -MH - *Small Cell Lung Carcinoma/drug therapy/radiotherapy -OTO - NOTNLM -OT - Anti-programmed cell death-ligand 1 -OT - Brain metastasis -OT - Brain radiotherapy -OT - Extensive-stage small-cell lung cancer -OT - Overall survival -EDAT- 2022/08/18 06:00 -MHDA- 2022/09/20 06:00 -CRDT- 2022/08/17 11:25 -PHST- 2022/07/03 00:00 [received] -PHST- 2022/08/02 00:00 [accepted] -PHST- 2022/08/18 06:00 [pubmed] -PHST- 2022/09/20 06:00 [medline] -PHST- 2022/08/17 11:25 [entrez] -AID - 10.1007/s11060-022-04111-7 [pii] -AID - 10.1007/s11060-022-04111-7 [doi] -PST - ppublish -SO - J Neurooncol. 2022 Sep;159(3):685-693. doi: 10.1007/s11060-022-04111-7. Epub 2022 - Aug 17. - -PMID- 39348997 -OWN - NLM -STAT- MEDLINE -DCOM- 20240930 -LR - 20240930 -IS - 1791-7530 (Electronic) -IS - 0250-7005 (Linking) -VI - 44 -IP - 10 -DP - 2024 Oct -TI - Safety and Efficacy of Durvalumab After Chemoradiotherapy in Antinuclear - Antibody-positive Patients With Non-small Cell Lung Cancer. -PG - 4517-4524 -LID - 10.21873/anticanres.17280 [doi] -AB - BACKGROUND/AIM: Pneumonitis during durvalumab consolidation therapy after - chemoradiotherapy (CRT) is a major cause of treatment discontinuation. Although - previous studies have revealed an association between antinuclear antibody (ANA) - positivity and the safety and efficacy of immune checkpoint inhibitors in - advanced non-small cell lung cancer (NSCLC), there are no reports on durvalumab - consolidation therapy. This study investigated the safety and efficacy of - durvalumab after CRT in ANA-positive patients. PATIENTS AND METHODS: We - retrospectively reviewed patients with unresectable NSCLC treated with durvalumab - after CRT between August 2018 and July 2022 at our institution. We evaluated the - association among ANA positivity, treatment-related adverse events (AEs), and - survival outcomes. RESULTS: Overall, 80 patients were enrolled, 39 of whom were - ANA-positive. Although there were no significant differences in the incidence of - each AE of any grade, ANA-positive patients tended to have a higher frequency of - pneumonitis of grade 3 to 5 than ANA-negative patients (12.8% vs. 2.4%, p=0.104). - ANA-positive patients had a significantly shorter median progression-free - survival (PFS) and overall survival (OS) than ANA-negative patients [14.9 months - vs. not reached (NR), p=0.005; NR vs. NR, p=0.013]. Multivariate analysis - revealed that ANA positivity was an independent predictor of shorter PFS - (HR=2.23; 95% CI=1.16-4.29; p=0.016) and OS (HR=2.28; 95% CI=1.01-5.12; p=0.046). - CONCLUSION: ANA-positive patients receiving durvalumab after CRT tended to have a - higher frequency of severe pneumonitis and significantly worse PFS and OS - compared with ANA-negative patients. -CI - Copyright © 2024 International Institute of Anticancer Research (Dr. George J. - Delinasios), All rights reserved. -FAU - Tsukaguchi, Akihiro -AU - Tsukaguchi A -AD - Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, - Japan; tsukaguchi.akihiro.mf@mail.hosp.go.jp. -FAU - Tamiya, Akihiro -AU - Tamiya A -AD - Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, - Japan. -FAU - Fukuda, Shoichi -AU - Fukuda S -AD - Department of Radiology, NHO Kinki Chuo Chest Medical Center, Osaka, Japan. -FAU - Iwahashi, Yuki -AU - Iwahashi Y -AD - Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, - Japan. -FAU - Kanaoka, Kensuke -AU - Kanaoka K -AD - Department of Respiratory Medicine and Clinical Immunology, Osaka University - Graduate School of Medicine, Osaka, Japan. -FAU - Tanaka, Yuya -AU - Tanaka Y -AD - Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, - Japan. -FAU - Inagaki, Yuji -AU - Inagaki Y -AD - Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, - Japan. -FAU - Taniguchi, Yoshihiko -AU - Taniguchi Y -AD - Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, - Japan. -FAU - Nakao, Keiko -AU - Nakao K -AD - Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, - Japan. -FAU - Kagawa, Tomoko -AU - Kagawa T -AD - Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, - Japan. -FAU - Matsuda, Yoshinobu -AU - Matsuda Y -AD - Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, - Japan. -FAU - Okishio, Kyoichi -AU - Okishio K -AD - Department of Clinical Research Center, NHO Kinki Chuo Chest Medical Center, - Osaka, Japan. -LA - eng -PT - Journal Article -PL - Greece -TA - Anticancer Res -JT - Anticancer research -JID - 8102988 -RN - 28X28X9OKV (durvalumab) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Antinuclear) -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Humans -MH - Female -MH - Male -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/therapy/pathology -MH - Aged -MH - *Chemoradiotherapy/adverse effects -MH - Middle Aged -MH - *Lung Neoplasms/drug therapy/pathology/therapy -MH - *Antibodies, Monoclonal/therapeutic use/adverse effects -MH - Retrospective Studies -MH - *Antibodies, Antinuclear/blood -MH - Aged, 80 and over -MH - Adult -MH - Antineoplastic Agents, Immunological/therapeutic use/adverse effects -MH - Treatment Outcome -OTO - NOTNLM -OT - Antinuclear antibodies -OT - chemoradiotherapy -OT - durvalumab -OT - non-small-cell lung cancer -OT - pneumonitis -EDAT- 2024/10/01 04:18 -MHDA- 2024/10/01 04:19 -CRDT- 2024/09/30 20:33 -PHST- 2024/07/22 00:00 [received] -PHST- 2024/08/19 00:00 [revised] -PHST- 2024/08/29 00:00 [accepted] -PHST- 2024/10/01 04:19 [medline] -PHST- 2024/10/01 04:18 [pubmed] -PHST- 2024/09/30 20:33 [entrez] -AID - 44/10/4517 [pii] -AID - 10.21873/anticanres.17280 [doi] -PST - ppublish -SO - Anticancer Res. 2024 Oct;44(10):4517-4524. doi: 10.21873/anticanres.17280. - -PMID- 38378398 -OWN - NLM -STAT- MEDLINE -DCOM- 20240516 -LR - 20240516 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 25 -IP - 3 -DP - 2024 May -TI - Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: - Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network. -PG - e133-e144.e4 -LID - S1525-7304(23)00264-4 [pii] -LID - 10.1016/j.cllc.2023.12.005 [doi] -AB - BACKGROUND: Several regulatory agencies have approved the use of the neoadjuvant - chemo-immunotherapy for resectable stage II and III of non-small cell lung cancer - (NSCLC) and numerous trials investigating novel agents are underway. However, - significant concerns exist around the feasibility and safety of offering curative - surgery to patients treated within such pathways. The goal in this study was to - evaluate the impact of a transition towards a large-scale neoadjuvant therapy - program for NSCLC. METHODS: Medical charts of patients with clinical stage II and - III NSCLC who underwent resection from January 2015 to December 2020 were - reviewed. The primary outcome was perioperative complication rate between - neoadjuvant-treated versus upfront surgery patients. Multivariable logistic - regression estimated occurrence of postoperative complications and overall - survival was assessed as an exploratory secondary outcome by Kaplan-Meier and - Cox-regression analyses. RESULTS: Of the 428 patients included, 106 (24.8%) - received neoadjuvant therapy and 322 (75.2%) upfront surgery. Frequency of minor - and major postoperative complications was similar between groups (P = .22). - Occurrence in postoperative complication was similar in both cohort (aOR = 1.31, - 95% CI 0.73-2.34). Neoadjuvant therapy administration increased from 10% to 45% - with a rise in targeted and immuno-therapies over time, accompanied by a reduced - rate of preoperative radiation therapy use. 1-, 2-, and 5-year overall survival - was higher in neoadjuvant therapy compared to upfront surgery patients (Log-Rank - P = .017). CONCLUSIONS: No significant differences in perioperative outcomes and - survival were observed in resectable NSCLC patients treated by neoadjuvant - therapy versus upfront surgery. Transition to neoadjuvant therapy among - resectable NSCLC patients is safe and feasible from a surgical perspective. -CI - Copyright © 2023. Published by Elsevier Inc. -FAU - Pilon, Yohann -AU - Pilon Y -AD - Division of Thoracic Surgery, Department of Surgery, McGill University Health - Centre, Montreal, QC, Canada. -FAU - Rokah, Merav -AU - Rokah M -AD - Division of Thoracic Surgery, Department of Surgery, McGill University Health - Centre, Montreal, QC, Canada. -FAU - Seitlinger, Joseph -AU - Seitlinger J -AD - Division of Thoracic Surgery, Department of Surgery, McGill University Health - Centre, Montreal, QC, Canada. -FAU - Sepesi, Boris -AU - Sepesi B -AD - No current official affiliation. -FAU - Rayes, Roni F -AU - Rayes RF -AD - Division of Thoracic Surgery, Department of Surgery, McGill University Health - Centre, Montreal, QC, Canada; Goodman Cancer Institute, McGill University, - Montreal, QC, Canada. -FAU - Cools-Lartigue, Jonathan -AU - Cools-Lartigue J -AD - Division of Thoracic Surgery, Department of Surgery, McGill University Health - Centre, Montreal, QC, Canada. -FAU - Najmeh, Sara -AU - Najmeh S -AD - Division of Thoracic Surgery, Department of Surgery, McGill University Health - Centre, Montreal, QC, Canada. -FAU - Sirois, Christian -AU - Sirois C -AD - Division of Thoracic Surgery, Department of Surgery, McGill University Health - Centre, Montreal, QC, Canada. -FAU - Mulder, David -AU - Mulder D -AD - Division of Thoracic Surgery, Department of Surgery, McGill University Health - Centre, Montreal, QC, Canada. -FAU - Ferri, Lorenzo -AU - Ferri L -AD - Division of Thoracic Surgery, Department of Surgery, McGill University Health - Centre, Montreal, QC, Canada. -FAU - Abdulkarim, Bassam -AU - Abdulkarim B -AD - Department of Oncology, McGill University, Montreal, QC, Canada. -FAU - Ezer, Nicole -AU - Ezer N -AD - Department of Epidemiology, Biostatistics and Occupational Health, McGill - University, QC, Canada. -FAU - Fraser, Richard -AU - Fraser R -AD - Department of Pathology, McGill University, Montreal, QC, Canada. -FAU - Camilleri-Broët, Sophie -AU - Camilleri-Broët S -AD - Department of Pathology, McGill University, Montreal, QC, Canada. -FAU - Fiset, Pierre-Olivier -AU - Fiset PO -AD - Department of Pathology, McGill University, Montreal, QC, Canada. -FAU - Wong, Annick -AU - Wong A -AD - Department of Oncology, McGill University, Montreal, QC, Canada; Hôpital du - Suroît, Salaberry-de-Valleyfield, QC, Canada. -FAU - Sud, Shelly -AU - Sud S -AD - Department of Oncology, Gatineau Hospital, Gatineau, QC, Canada. -FAU - Langleben, Adrian -AU - Langleben A -AD - Department of Oncology, McGill University, Montreal, QC, Canada. -FAU - Agulnik, Jason -AU - Agulnik J -AD - Department of Oncology, McGill University, Montreal, QC, Canada; Division of - Pulmonary Diseases, Jewish General Hospital, Montreal, Canada. -FAU - Pepe, Carmela -AU - Pepe C -AD - Department of Oncology, McGill University, Montreal, QC, Canada; Division of - Pulmonary Diseases, Jewish General Hospital, Montreal, Canada. -FAU - Shieh, Benjamin -AU - Shieh B -AD - Department of Oncology, McGill University, Montreal, QC, Canada. -FAU - Hirsh, Vera -AU - Hirsh V -AD - Department of Oncology, McGill University, Montreal, QC, Canada. -FAU - Ofiara, Linda -AU - Ofiara L -AD - Department of Oncology, McGill University, Montreal, QC, Canada. -FAU - Owen, Scott -AU - Owen S -AD - Department of Oncology, McGill University, Montreal, QC, Canada. -FAU - Spicer, Jonathan D -AU - Spicer JD -AD - Division of Thoracic Surgery, Department of Surgery, McGill University Health - Centre, Montreal, QC, Canada; Goodman Cancer Institute, McGill University, - Montreal, QC, Canada. Electronic address: jonathan.spicer@mcgill.ca. -LA - eng -PT - Journal Article -DEP - 20231219 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/pathology/therapy/mortality/drug therapy -MH - *Neoadjuvant Therapy/methods -MH - *Lung Neoplasms/pathology/therapy/drug therapy/mortality -MH - Male -MH - Female -MH - Aged -MH - Middle Aged -MH - Pneumonectomy -MH - Retrospective Studies -MH - Survival Rate -MH - Postoperative Complications/epidemiology -MH - Treatment Outcome -MH - Neoplasm Staging -MH - Follow-Up Studies -OTO - NOTNLM -OT - Locally advanced non-small cell lung cancer -OT - Perioperative outcomes -OT - Personalized medicine -OT - Preoperative therapies -OT - Thoracic oncology -COIS- Disclosure JDS has received honoraria and consulting fees from Roche, Merck, BMS, - AstraZeneca, Regeneron, Novartis, Protalix Biotherapeutics, Xenetic Biosciences - and Protalix Biotherapeutics. JS also received grants to his institution from - Roche, AstraZeneca, Protalix Biotherapeutics, CLS Therapeutics, BMS and Merck. BS - received speakers’ fees from AstraZeneca, Medscape, and PEER VIEW, and consulting - fees from AstraZeneca. SO received honoraria from Astra Zeneca, Bayer, BMS, and - Novocure. -EDAT- 2024/02/21 11:14 -MHDA- 2024/05/17 00:43 -CRDT- 2024/02/20 21:56 -PHST- 2023/08/01 00:00 [received] -PHST- 2023/11/24 00:00 [revised] -PHST- 2023/12/13 00:00 [accepted] -PHST- 2024/05/17 00:43 [medline] -PHST- 2024/02/21 11:14 [pubmed] -PHST- 2024/02/20 21:56 [entrez] -AID - S1525-7304(23)00264-4 [pii] -AID - 10.1016/j.cllc.2023.12.005 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2024 May;25(3):e133-e144.e4. doi: 10.1016/j.cllc.2023.12.005. - Epub 2023 Dec 19. - -PMID- 28447257 -OWN - NLM -STAT- MEDLINE -DCOM- 20180731 -LR - 20181202 -IS - 1699-3055 (Electronic) -IS - 1699-048X (Linking) -VI - 19 -IP - 10 -DP - 2017 Oct -TI - Recent developments in radiotherapy for small-cell lung cancer: a review by the - Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology - Society). -PG - 1183-1192 -LID - 10.1007/s12094-017-1667-5 [doi] -AB - Small-cell lung cancer (SCLC) accounts for 13% of all lung tumours. The standard - treatment in patients with limited-stage disease is radiotherapy combined with - chemotherapy. In extensive SCLC, the importance of consolidation thoracic - radiotherapy in patients with a good treatment response has become increasingly - recognized. In both limited and extensive disease, prophylactic cranial - irradiation is recommended in patients who respond to treatment. New therapeutic - approaches such as immunotherapy are being increasingly incorporated into the - treatment of SCLC, although more slowly than in non-small cell lung cancer - (NSCLC). Diverse radiation dose and fractionation schemes, administered in - varying combinations with these new drugs, are being investigated. In the present - study we review and update the role of radiotherapy in the treatment of SCLC. We - also discuss the main clinical trials currently underway in order to identify - future trends. -FAU - Rodriguez de Dios, N -AU - Rodriguez de Dios N -AD - Departament of Radiation Oncology, Hospital del Mar, Parc de Salut MAR, Passeig - Marítim, 25-29, 08003, Barcelona, Spain. nrodriguez@parcdesalutmar.cat. -AD - Hospital del Mar Medical Research Institute (IMIM), Doctor Aiguader 88, 08003, - Barcelona, Spain. nrodriguez@parcdesalutmar.cat. -AD - Pompeu Fabra University, Barcelona, Doctor Aiguader, 80, 08003, Barcelona, Spain. - nrodriguez@parcdesalutmar.cat. -FAU - Calvo, P -AU - Calvo P -AD - Department of Radiation Oncology, Hospital Universitario Santiago de Compostela, - Tr Choupana s/n, 15706, Santiago De Compostela, Spain. -FAU - Rico, M -AU - Rico M -AD - Department of Radiation Oncology, Complejo Hospitalario de Navarra, Calle de - Irunlarrea, 3, 31008, Pamplona, Navarra, Spain. -FAU - Martín, M -AU - Martín M -AD - Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, - Carretera de Colmenar KM 9,1, 28034, Madrid, Spain. -FAU - Couñago, F -AU - Couñago F -AD - Department of Radiation Oncology, Hospital Universitario Quirón Madrid, Diego de - Velázquez, 1, Pozuelo de Alarcón, 28223, Madrid, Spain. -FAU - Sotoca, A -AU - Sotoca A -AD - Department of Radiation Oncology, Hospital Ruber Internacional, Calle de la Masó, - 38, 28034, Madrid, Spain. -FAU - Taboada, B -AU - Taboada B -AD - Department of Radiation Oncology, Hospital Universitario Santiago de Compostela, - Tr Choupana s/n, 15706, Santiago De Compostela, Spain. -FAU - Rodríguez, A -AU - Rodríguez A -AD - Department of Radiation Oncology, Hospital Ruber Internacional, Calle de la Masó, - 38, 28034, Madrid, Spain. -LA - eng -PT - Journal Article -PT - Review -DEP - 20170426 -PL - Italy -TA - Clin Transl Oncol -JT - Clinical & translational oncology : official publication of the Federation of - Spanish Oncology Societies and of the National Cancer Institute of Mexico -JID - 101247119 -SB - IM -MH - *Dose Fractionation, Radiation -MH - Humans -MH - *Radiation Oncology -MH - Small Cell Lung Carcinoma/*radiotherapy -MH - Societies, Medical -OTO - NOTNLM -OT - Immunotherapy -OT - Prophylactic cranial irradiation -OT - Small-cell lung cancer -OT - Thoracic radiotherapy -EDAT- 2017/04/28 06:00 -MHDA- 2018/08/01 06:00 -CRDT- 2017/04/28 06:00 -PHST- 2017/04/12 00:00 [received] -PHST- 2017/04/19 00:00 [accepted] -PHST- 2017/04/28 06:00 [pubmed] -PHST- 2018/08/01 06:00 [medline] -PHST- 2017/04/28 06:00 [entrez] -AID - 10.1007/s12094-017-1667-5 [pii] -AID - 10.1007/s12094-017-1667-5 [doi] -PST - ppublish -SO - Clin Transl Oncol. 2017 Oct;19(10):1183-1192. doi: 10.1007/s12094-017-1667-5. - Epub 2017 Apr 26. - -PMID- 34678907 -OWN - NLM -STAT- MEDLINE -DCOM- 20211104 -LR - 20230103 -IS - 1536-5964 (Electronic) -IS - 0025-7974 (Print) -IS - 0025-7974 (Linking) -VI - 100 -IP - 42 -DP - 2021 Oct 22 -TI - Response to toripalimab combined with radiotherapy in advanced non-small cell - lung cancer-not otherwise specified: A case report. -PG - e27581 -LID - 10.1097/MD.0000000000027581 [doi] -LID - e27581 -AB - RATIONALE: The targeting of signal transduction through programmed cell death - receptor-1 (PD-1) and its ligand programmed cell death-ligand 1 (PD-L1) in - patients with non-small cell lung cancer (NSCLC) has been widely applied in - clinical research. However, the subtypes and treatment patterns that predict - responses to PD-1/PD-L1 inhibitors are not fully understood. Biomarkers, such as - PD-L1 expression, tumor mutation load, and DNA mismatch repair defects, have been - used to screen patients who respond to PD-1/PD-L1 inhibitors, but the appropriate - treatment mode requires further investigation. Immune checkpoint inhibitors - combined with radiotherapy provide benefits from remote effects, especially in - NSCLC patients with increased PD-L1 expression. PATIENT CONCERNS: We report a - 64-year-old man who presented with left back pain for 40 days. A computed - tomography scan showed a mass in the right upper lobe of the lung, with - metastases in the right hilar and mediastinal lymph nodes. DIAGNOSIS: NSCLC-not - otherwise specified was diagnosed by computed tomography-guided lung biopsy. - INTERVENTIONS: After the failure of first-line chemotherapy, next-generation - sequencing was performed for comprehensive gene analysis, and PD-L1 expression - levels were evaluated by immunohistochemistry. The patient was treated with - toripalimab (a PD-1 inhibitor) concurrently with radiotherapy for bone - metastases. OUTCOMES: The detection results showed a high tumor mutation burden - and increased PD-L1 expression. On the basis of these findings, the patient - received toripalimab (PD-1 inhibitor) combined with radiotherapy for bone - metastases. Partial response was achieved after 3 cycles, and the patient showed - stable disease at the end of the sixth and ninth cycles of toripalimab. The - patient was followed up for 26 months. At present, the patient is receiving - toripalimab maintenance treatment, which has been well-tolerated without adverse - events. LESSON: Toripalimab combined with radiotherapy may exert a synergistic - anti-tumor effect through remote effects in advanced or metastatic NSCLC with - high PD-L1 expression. However, the specific treatment mode requires further - confirmation by the investigation of additional cases. -CI - Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. -FAU - Jin, Yonglong -AU - Jin Y -AD - Department of Radiotherapy, Affiliated Hospital of Qingdao University, Qingdao, - China. -FAU - Xiao, Wenjing -AU - Xiao W -AD - Department of Radiotherapy, Affiliated Hospital of Qingdao University, Qingdao, - China. -FAU - Wang, Xintong -AU - Wang X -AD - Department of Radiotherapy, Affiliated Hospital of Qingdao University, Qingdao, - China. -FAU - Cui, Yinshi -AU - Cui Y -AD - Department of Cardiology, Qingdao Fuwai Cardiovascular Hospital, Qingdao, China. -FAU - Li, Bo -AU - Li B -AD - Department of Radiotherapy, Affiliated Hospital of Qingdao University, Qingdao, - China. -FAU - Liu, Xiguang -AU - Liu X -AUID- ORCID: 0000-0002-0629-288 -AD - Department of Radiotherapy, Affiliated Hospital of Qingdao University, Qingdao, - China. -LA - eng -GR - ZR2019BH083/natural science foundation of shandong province/ -PT - Case Reports -PT - Journal Article -PL - United States -TA - Medicine (Baltimore) -JT - Medicine -JID - 2985248R -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 8JXN261VVA (toripalimab) -SB - IM -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - B7-H1 Antigen/*biosynthesis -MH - Biomarkers, Tumor -MH - Bone Neoplasms/radiotherapy/secondary -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology -MH - Lymphatic Metastasis -MH - Male -MH - Middle Aged -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -PMC - PMC8542166 -COIS- The authors have no conflicts of interest to disclose. -EDAT- 2021/10/23 06:00 -MHDA- 2021/11/05 06:00 -PMCR- 2021/10/22 -CRDT- 2021/10/22 20:55 -PHST- 2021/07/30 00:00 [received] -PHST- 2021/10/07 00:00 [accepted] -PHST- 2021/10/22 20:55 [entrez] -PHST- 2021/10/23 06:00 [pubmed] -PHST- 2021/11/05 06:00 [medline] -PHST- 2021/10/22 00:00 [pmc-release] -AID - 00005792-202110220-00049 [pii] -AID - MD-D-21-05278 [pii] -AID - 10.1097/MD.0000000000027581 [doi] -PST - ppublish -SO - Medicine (Baltimore). 2021 Oct 22;100(42):e27581. doi: - 10.1097/MD.0000000000027581. - -PMID- 32505077 -OWN - NLM -STAT- MEDLINE -DCOM- 20210621 -LR - 20210621 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 146 -DP - 2020 Aug -TI - Real world data of durvalumab consolidation after chemoradiotherapy in stage III - non-small-cell lung cancer. -PG - 23-29 -LID - S0169-5002(20)30469-4 [pii] -LID - 10.1016/j.lungcan.2020.05.035 [doi] -AB - OBJECTIVES: The PACIFIC study demonstrated the benefits of durvalumab - consolidation on progression-free survival (PFS) and overall survival (OS) among - patients with unresectable locally advanced non-small-cell lung cancer - (LA-NSCLC). However, in real-world practice, patients with unresectable LA-NSCLC - are heterogeneous with diverse tumor burdens and clinical factors; thus, it is - important to examine the effectiveness and side effects of durvalumab when used - in real clinical practice. MATERIALS AND METHODS: We investigated the efficacy of - durvalumab consolidation and the incidence of radiation pneumonitis in patients - who received concurrent chemo-radiotherapy (CCRT) for unresectable LA-NSCLC in a - single institute. RESULTS: Overall, 55.3 % of patients did not meet the criteria - of the PACIFIC study; however, they still received consolidation durvalumab in - real-world practice. Durvalumab consolidation was associated with favorable PFS - in the total population as well as in the subgroup of patients who did not meet - the criteria of the PACIFIC study. However, radiation pneumonitis occurred more - frequently in the durvalumab group, especially within 3-6 months after CCRT. The - incidence of grade 3 radiation pneumonitis was 14.3 % in the durvalumab group - versus 2.5 % in the observation group. CONCLUSIONS: Durvalumab consolidation was - associated with favorable PFS in patients with LA-NSCLC in clinical practice. - However, careful selection of candidates for durvalumab treatment and active - surveillance and appropriate management for radiation pneumonitis are needed. -CI - Copyright © 2020. Published by Elsevier B.V. -FAU - Jung, Hyun Ae -AU - Jung HA -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. -FAU - Noh, Jae Myoung -AU - Noh JM -AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University - School of Medicine, Seoul, Republic of Korea. -FAU - Sun, Jong-Mu -AU - Sun JM -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. -FAU - Lee, Se-Hoon -AU - Lee SH -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. -FAU - Ahn, Jin Seok -AU - Ahn JS -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. -FAU - Ahn, Myung-Ju -AU - Ahn MJ -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. -FAU - Pyo, Hongryull -AU - Pyo H -AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University - School of Medicine, Seoul, Republic of Korea. -FAU - Ahn, Yong Chan -AU - Ahn YC -AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University - School of Medicine, Seoul, Republic of Korea. -FAU - Park, Keunchil -AU - Park K -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic - address: kpark@skku.edu. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20200531 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -CIN - Lung Cancer. 2020 Dec;150:249-251. doi: 10.1016/j.lungcan.2020.08.022. PMID: - 32958455 -MH - Antibodies, Monoclonal/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy -OTO - NOTNLM -OT - Concurrent chemo-radiotherapy -OT - Consolidation -OT - Durvalumab -OT - Non-small-cell lung cancer -COIS- Declaration of Competing Interest Keunchil Park has an advisor role in this study - and received research funding from Astra Zeneca outside of this study. -EDAT- 2020/06/07 06:00 -MHDA- 2021/06/22 06:00 -CRDT- 2020/06/07 06:00 -PHST- 2020/02/24 00:00 [received] -PHST- 2020/05/23 00:00 [revised] -PHST- 2020/05/26 00:00 [accepted] -PHST- 2020/06/07 06:00 [pubmed] -PHST- 2021/06/22 06:00 [medline] -PHST- 2020/06/07 06:00 [entrez] -AID - S0169-5002(20)30469-4 [pii] -AID - 10.1016/j.lungcan.2020.05.035 [doi] -PST - ppublish -SO - Lung Cancer. 2020 Aug;146:23-29. doi: 10.1016/j.lungcan.2020.05.035. Epub 2020 - May 31. - -PMID- 38101608 -OWN - NLM -STAT- MEDLINE -DCOM- 20240116 -LR - 20240123 -IS - 1872-7980 (Electronic) -IS - 0304-3835 (Linking) -VI - 582 -DP - 2024 Feb 1 -TI - Unrevealing the therapeutic benefits of radiotherapy and consolidation - immunotherapy using ctDNA-defined tumor clonality in unresectable locally - advanced non-small cell lung cancer. -PG - 216569 -LID - S0304-3835(23)00520-7 [pii] -LID - 10.1016/j.canlet.2023.216569 [doi] -AB - Progression occurs in approximately two-thirds of patients with locally advanced - non-small cell lung cancer (LA-NSCLC) receiving chemoradiation and consolidation - immunotherapy. Molecular indicators for outcome prediction are under development. - A novel metric, the ratio of mean to max variant allele frequency (mmVAF), was - derived from 431 pre-treatment tissue biopsies from The Cancer Genome Atlas and - evaluated in serial circulating tumor DNA (ctDNA) from 70 LA-NSCLC patients - receiving definitive radiotherapy/chemoradiotherapy (RT/CRT) with/without - immunotherapy. High mmVAFs in pre-treatment tissue biopsies, indicating clonal - predominant tumors (P < 0.01), were associated with inferior overall survival - [OS, hazard ratio (HR): 1.48, 95 % confidence interval (CI): 1.11-1.98]. Similar - associations of mmVAF with clonality (P < 0.01) and OS (HR: 2.24, 95 % CI: - 0.71-7.08) were observed in pre-treatment ctDNA. At 1-month post-RT, ctDNA - mmVAF-high patients receiving consolidation immunotherapy exhibited improved - progression-free survival (PFS) compared to those who did not (HR: 0.14, 95 % CI: - 0.03-0.67). From the baseline to week 4 of RT and/or 1-month post-RT, survival - benefits from consolidation immunotherapy were exclusively observed in ctDNA - mmVAF-increased patients (PFS, HR: 0.39, 95 % CI: 0.14-1.15), especially in terms - of distant metastasis (HR: 0.11, 95 % CI: 0.01-0.95). In summary, our - longitudinal data demonstrated the applicability of ctDNA-defined clonality for - prognostic stratification and immunotherapy benefit prediction in LA-NSCLC. -CI - Copyright © 2023 Elsevier B.V. All rights reserved. -FAU - Yang, Yufan -AU - Yang Y -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China; Department of Radiation - Oncology, Beijing Hospital, National Center of Gerontology, Institute of - Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. -FAU - Wang, Jianyang -AU - Wang J -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Wang, Jingbo -AU - Wang J -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Zhao, Xiaotian -AU - Zhao X -AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China. -FAU - Zhang, Tao -AU - Zhang T -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Yang, Yin -AU - Yang Y -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Pang, Jiaohui -AU - Pang J -AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China. -FAU - Ou, Qiuxiang -AU - Ou Q -AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China. -FAU - Wu, Linfang -AU - Wu L -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Xu, Xin -AU - Xu X -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Xu, Kunpeng -AU - Xu K -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy - of Medical Sciences and Peking Union Medical College, Shenzhen, China. -FAU - Zhao, Jingjing -AU - Zhao J -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Bai, Na -AU - Bai N -AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China. -FAU - Yang, Peng -AU - Yang P -AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China. -FAU - Wang, Sha -AU - Wang S -AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China. -FAU - Wang, Luhua -AU - Wang L -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China; Department of Radiation - Oncology, National Cancer Center/National Clinical Research Center for - Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Shenzhen, China. Electronic address: - wlhwq@yahoo.com. -FAU - Bi, Nan -AU - Bi N -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China; State Key Laboratory of - Molecular Oncology, National Cancer Center/National Clinical Research Center for - Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, China. Electronic address: binan_email@163.com. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20231213 -PL - Ireland -TA - Cancer Lett -JT - Cancer letters -JID - 7600053 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy -MH - *Lung Neoplasms/therapy/drug therapy -MH - Prognosis -MH - Chemoradiotherapy -MH - Immunotherapy -OTO - NOTNLM -OT - Circulating tumor DNA -OT - Immunotherapy -OT - Locally advanced non-small cell lung cancer -OT - Prognosis -OT - Radiotherapy -COIS- Declaration of competing interest The authors declare the following financial - interests/personal relationships which may be considered as potential competing - interests: X Zhao, J Pang, Q Ou, N Bai, P Yang, and S Wang are employees of - Nanjing Geneseeq Technology Inc., China. The remaining authors have nothing to - disclose. -EDAT- 2023/12/16 11:43 -MHDA- 2024/01/16 06:41 -CRDT- 2023/12/15 19:29 -PHST- 2023/09/07 00:00 [received] -PHST- 2023/10/30 00:00 [revised] -PHST- 2023/11/28 00:00 [accepted] -PHST- 2024/01/16 06:41 [medline] -PHST- 2023/12/16 11:43 [pubmed] -PHST- 2023/12/15 19:29 [entrez] -AID - S0304-3835(23)00520-7 [pii] -AID - 10.1016/j.canlet.2023.216569 [doi] -PST - ppublish -SO - Cancer Lett. 2024 Feb 1;582:216569. doi: 10.1016/j.canlet.2023.216569. Epub 2023 - Dec 13. - -PMID- 37648808 -OWN - NLM -STAT- MEDLINE -DCOM- 20231102 -LR - 20240723 -IS - 1432-1335 (Electronic) -IS - 0171-5216 (Print) -IS - 0171-5216 (Linking) -VI - 149 -IP - 17 -DP - 2023 Nov -TI - Treatment patterns in stage III non‑small‑cell lung cancer patients: a - population‑based study using German cancer registry data. -PG - 15489-15497 -LID - 10.1007/s00432-023-05289-7 [doi] -AB - PURPOSE: Lung cancer remains the leading cause of cancer-related mortality - worldwide, mostly due to delayed diagnosis. The objective of this study is to - examine the treatment patterns and overall survival (OS) outcomes in a cohort of - patients diagnosed with stage III non-small cell lung cancer (NSCLC) over a - period of 12 years in Germany. METHODS: This retrospective study is based on - German cancer registry data and included 14,606 stage III NSCLC patients - diagnosed during 2007-2018. Three time-periods were defined according to the - availability of advanced diagnostic and treatment strategies (2007-2010 low - availability era (LAE), 2011-2014 transition era (TE), 2015-2018 modern era - (ME)). Patients were categorized according to the treatment they received during - those eras. Kaplan-Meier curves and multivariate Cox proportional hazards models - were used to investigate the association between being diagnosed during a certain - era and survival. The hazard ratio (HR) estimates were reported along with the - 95% confidence interval (CI). RESULTS: The median OS rose from 16 months in the - LAE to 22 months in the ME. The HR for patients diagnosed and treated in the ME - was estimated to be [0.78; 95% CI (0.74-0.83)] compared to those diagnosed and - treated in LAE. The benefit was most evident for patients treated by radiotherapy - and chemotherapy [HR 0.73 95% CI (0.66-0.82)]. CONCLUSION: This study highlights - the importance of diagnostic and treatment advances in improving outcomes for - lung cancer patients. Further studies are needed to assess progress in survival - rates with current immunotherapy integration. -CI - © 2023. The Author(s). -FAU - Bedir, Ahmed -AU - Bedir A -AD - Department of Radiation Oncology, Health Services Research Group, University - Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany. -FAU - Mehrotra, Sneha -AU - Mehrotra S -AD - Faculty of Life Sciences and Medicine, King's College London, Guy's Campus, - London, SE1 1UL, UK. -FAU - Gnüchtel, Jessica -AU - Gnüchtel J -AD - Department of Radiation Oncology, University Hospital Halle (Saale), - Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany. -AD - Department of Traumatology, Elisabeth-Hospital Leipzig, Biedermannstraße 84, - 04277, Leipzig, Germany. -FAU - Vordermark, Dirk -AU - Vordermark D -AD - Department of Radiation Oncology, Health Services Research Group, University - Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany. -AD - Department of Radiation Oncology, University Hospital Halle (Saale), - Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany. -FAU - Medenwald, Daniel -AU - Medenwald D -AD - Department of Radiation Oncology, Health Services Research Group, University - Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany. - Daniel.Medenwald@uk-halle.de. -AD - Department of Radiation Oncology, University Hospital Halle (Saale), - Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany. Daniel.Medenwald@uk-halle.de. -LA - eng -PT - Journal Article -DEP - 20230830 -PL - Germany -TA - J Cancer Res Clin Oncol -JT - Journal of cancer research and clinical oncology -JID - 7902060 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy -MH - *Lung Neoplasms/therapy/drug therapy -MH - Retrospective Studies -MH - Routinely Collected Health Data -MH - Immunotherapy -MH - Neoplasm Staging -PMC - PMC10620268 -OTO - NOTNLM -OT - Cancer registries -OT - Germany -OT - Lung cancer -OT - Survival analysis -OT - Treatment patterns -COIS- The authors declare that they have no conflict of interest. -EDAT- 2023/08/31 00:41 -MHDA- 2023/11/02 12:46 -PMCR- 2023/08/30 -CRDT- 2023/08/30 23:27 -PHST- 2023/06/15 00:00 [received] -PHST- 2023/08/14 00:00 [accepted] -PHST- 2023/11/02 12:46 [medline] -PHST- 2023/08/31 00:41 [pubmed] -PHST- 2023/08/30 23:27 [entrez] -PHST- 2023/08/30 00:00 [pmc-release] -AID - 10.1007/s00432-023-05289-7 [pii] -AID - 5289 [pii] -AID - 10.1007/s00432-023-05289-7 [doi] -PST - ppublish -SO - J Cancer Res Clin Oncol. 2023 Nov;149(17):15489-15497. doi: - 10.1007/s00432-023-05289-7. Epub 2023 Aug 30. - -PMID- 37989364 -OWN - NLM -STAT- MEDLINE -DCOM- 20231123 -LR - 20231126 -IS - 2044-6055 (Electronic) -IS - 2044-6055 (Linking) -VI - 13 -IP - 11 -DP - 2023 Nov 21 -TI - Pembrolizumab monotherapy for non-small cell lung cancer (NSCLC): can patient - stratification be improved in the UK Tayside population? A retrospective cohort - study. -PG - e076715 -LID - 10.1136/bmjopen-2023-076715 [doi] -LID - e076715 -AB - OBJECTIVE: Pembrolizumab is a programmed cell death protein-1 (PD-1) inhibitor - used to treat advanced patients with non-small cell lung cancer (NSCLC) with a - programmed cell death ligand-1 (PD-L1) tumour proportion score (TPS) ≥50. Further - sub-division of TPS-based stratification has not been evaluated in the UK, - although smoking-induced tumour mutational burden and the immunogenic effects of - prior radiotherapy are suggested to improve response. AIMS: To investigate if - PD-L1 TPS ≥80%, smoking status or radiotherapy before or within 2 months of - treatment influenced progression-free survival (PFS) in patients with NSCLC - treated with pembrolizumab monotherapy. METHODS: PD-L1 TPS, smoking status and - radiotherapy exposure were compared in patients with NSCLC in National Health - Service (NHS) Tayside (n=100) treated with pembrolizumab monotherapy between 1 - November 2017 and 18 February 2022. Survival estimates were compared using - log-rank analysis, and Cox proportional hazards analysis was used to investigate - the influence of potential confounding factors, including tumour stage and - performance status. RESULTS: PFS was not significantly different (log-rank - HR=0.330, p=0.566) comparing patients with PD-L1 TPS 50-79% and PD-L1 TPS ≥80%. - Smokers had significantly improved PFS (log-rank HR=4.867, p=0.027), while - patients receiving radiotherapy had significantly decreased PFS (log-rank - HR=6.649, p=0.012). A Cox regression model confirmed that both radiotherapy - (p=0.022) and performance status (p=0.009) were independent negative predictors - of PFS. CONCLUSIONS: More rigorous PD-L1 TPS stratification did not influence - survival outcomes. Smoking history improved PFS, although it was not an - independent response predictor, while radiotherapy and performance status - independently influenced clinical response. We suggest that further - stratification of PD-L1 TPS is not warranted, while performance status and - radiotherapy treatment may be additional clinically useful biomarkers of response - to pembrolizumab in patients with NSCLC. -CI - © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Mander, Emily Susannah -AU - Mander ES -AUID- ORCID: 0009-0009-3307-9855 -AD - School of Medicine, University of Dundee, Dundee, UK. -FAU - Merrick, Christopher Brian -AU - Merrick CB -AD - Tayside Cancer Centre, NHS Tayside, Dundee, UK. -FAU - Nicholson, Hugh Adam -AU - Nicholson HA -AD - School of Medicine, University of Dundee, Dundee, UK. -FAU - Lord, Hannah Kate -AU - Lord HK -AD - Tayside Cancer Centre, NHS Tayside, Dundee, UK. -FAU - Ferguson, Michelle Jane -AU - Ferguson MJ -AD - Tayside Cancer Centre, NHS Tayside, Dundee, UK. -FAU - Smith, Gillian -AU - Smith G -AUID- ORCID: 0000-0001-9288-7566 -AD - School of Medicine, University of Dundee, Dundee, UK g.smith@dundee.ac.uk. -LA - eng -PT - Journal Article -DEP - 20231121 -PL - England -TA - BMJ Open -JT - BMJ open -JID - 101552874 -RN - DPT0O3T46P (pembrolizumab) -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - *Lung Neoplasms/drug therapy/pathology -MH - B7-H1 Antigen -MH - Retrospective Studies -MH - State Medicine -MH - United Kingdom -PMC - PMC10668179 -OTO - NOTNLM -OT - CHEMOTHERAPY -OT - Clinical Decision-Making -OT - ONCOLOGY -OT - RADIOTHERAPY -OT - Respiratory tract tumours -COIS- Competing interests: None declared. -EDAT- 2023/11/22 00:42 -MHDA- 2023/11/23 06:42 -PMCR- 2023/11/21 -CRDT- 2023/11/21 20:43 -PHST- 2023/11/23 06:42 [medline] -PHST- 2023/11/22 00:42 [pubmed] -PHST- 2023/11/21 20:43 [entrez] -PHST- 2023/11/21 00:00 [pmc-release] -AID - bmjopen-2023-076715 [pii] -AID - 10.1136/bmjopen-2023-076715 [doi] -PST - epublish -SO - BMJ Open. 2023 Nov 21;13(11):e076715. doi: 10.1136/bmjopen-2023-076715. - -PMID- 38907273 -OWN - NLM -STAT- MEDLINE -DCOM- 20240621 -LR - 20240624 -IS - 1465-993X (Electronic) -IS - 1465-9921 (Print) -IS - 1465-9921 (Linking) -VI - 25 -IP - 1 -DP - 2024 Jun 21 -TI - Correlation between immune-related adverse events and efficacy of PD-(L)1 - inhibitors in small cell lung cancer: a multi-center retrospective study. -PG - 256 -LID - 10.1186/s12931-024-02890-3 [doi] -LID - 256 -AB - BACKGROUND: Patients receiving PD-(L)1 inhibitors frequently encounter unusual - side effects known as immune-related adverse events (irAEs). However, the - correlation of irAEs development with clinical response in small cell lung cancer - (SCLC) is unknown. METHOD: This retrospective study enrolled 244 stage IV SCLC - patients who receiving PD-(L)1 inhibitors from 3 cancer centers. The correlation - of irAEs with objective response rate (ORR), disease control rate (DCR), - progression-free survival (PFS), and overall survival (OS) were evaluated. - RESULTS: 140 in 244 (57%) patients experienced irAEs, with 122 (87.1%) - experiencing one and 18 (12.9%) experiencing two or more. Compared to patient - without irAEs, those developing irAEs had higher ORR (73.6% vs. 52.9%, P < 0.001) - and DCR (97.9% vs. 79.8%, P < 0.001), as well as prolonged median PFS (8.8 vs. - 4.5 months, P < 0.001) and OS (23.2 vs. 21.6 months, P < 0.05). Among the - different spectra of irAEs, thyroid dysfunction, rash, and pneumonitis were the - most powerful indicator for improved PFS. When analyzed as a time-dependent - covariate, the occurrence of irAEs was associated with significant improvement in - PFS rather than in OS. Furthermore, patients experiencing multisystem irAEs - displayed a longer PFS and OS compared with single-system irAEs and the irAE-free - ones. IrAEs grade and steroid use did not impact the predictive value of irAEs on - PFS. CONCLUSION: The presence of irAEs predicts superior clinical benefit in - SCLC. Patients who develop multi-system irAEs may have an improved survival than - those developed single-system irAEs and no-irAEs. This association persists even - when systemic corticosteroids were used for irAEs management. -CI - © 2024. The Author(s). -FAU - Zhang, Jian -AU - Zhang J -AD - Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, 440 - Jiyan Road, Jinan, 250117, Shandong, China. -FAU - Gao, Aiqin -AU - Gao A -AUID- ORCID: 0009-0009-3596-6669 -AD - Department of Thoracic Radiation Oncology, Shandong Cancer Hospital and - Institute, Shandong First Medical University, Shandong Academy of Medical - Sciences, Jinan, 250117, Shandong, China. -FAU - Wang, Shuyun -AU - Wang S -AD - Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, 440 - Jiyan Road, Jinan, 250117, Shandong, China. -FAU - Sun, Yanxin -AU - Sun Y -AD - School of Clinical Medicine, Weifang Medical University, Weifang, 250117, - Shandong, China. -FAU - Wu, Jiake -AU - Wu J -AD - Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, 440 - Jiyan Road, Jinan, 250117, Shandong, China. -FAU - Wang, Dahai -AU - Wang D -AD - Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, 440 - Jiyan Road, Jinan, 250117, Shandong, China. -FAU - Ge, Yihui -AU - Ge Y -AD - Phase I Clinical Research Center, Shandong University Cancer Center, Jinan, - 250117, Shandong, China. -FAU - Li, Juan -AU - Li J -AD - Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, 440 - Jiyan Road, Jinan, 250117, Shandong, China. -FAU - Sun, Haifeng -AU - Sun H -AD - School of Clinical Medicine, Weifang Medical University, Weifang, 250117, - Shandong, China. -FAU - Cheng, Qinglei -AU - Cheng Q -AD - Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, 440 - Jiyan Road, Jinan, 250117, Shandong, China. -FAU - Sun, Yuping -AU - Sun Y -AUID- ORCID: 0000-0002-0804-6850 -AD - Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, 440 - Jiyan Road, Jinan, 250117, Shandong, China. 13370582181@163.com. -LA - eng -GR - 320.6750.2023-05-51/WU JIEPING MEDICAL FOUNDATION/ -GR - ZR2021MH268/Natural Science Foundation of Shandong Province/ -GR - 82103340/the National Natural Science Foundation of China/ -GR - 202019041,202134041, 202225015/the Jinan Science and Technology Innovation - Program of Clinical Medicine/ -GR - 202019041,202134041, 202225015/the Jinan Science and Technology Innovation - Program of Clinical Medicine/ -GR - 202019041,202134041, 202225015/the Jinan Science and Technology Innovation - Program of Clinical Medicine/ -GR - 20220XG0010510/Key R & D Program of Shandong Province/ -PT - Journal Article -PT - Multicenter Study -DEP - 20240621 -PL - England -TA - Respir Res -JT - Respiratory research -JID - 101090633 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (CD274 protein, human) -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - Retrospective Studies -MH - Male -MH - *Small Cell Lung Carcinoma/drug therapy/immunology/mortality -MH - Female -MH - *Lung Neoplasms/drug therapy/immunology/mortality -MH - Middle Aged -MH - Aged -MH - *Immune Checkpoint Inhibitors/adverse effects/therapeutic use -MH - Adult -MH - Aged, 80 and over -MH - Treatment Outcome -MH - B7-H1 Antigen/antagonists & inhibitors/immunology -MH - Progression-Free Survival -PMC - PMC11193240 -OTO - NOTNLM -OT - Extensive-stage small cell lung cancer (ES-SCLC) -OT - Immune-related adverse events (irAEs) -OT - Immunotherapy -OT - Programmed cell death ligand protein 1 (PD-L1) -OT - Programmed cell death protein 1 (PD-1) -COIS- The authors declare no competing interests. -EDAT- 2024/06/22 05:43 -MHDA- 2024/06/22 05:44 -PMCR- 2024/06/21 -CRDT- 2024/06/21 23:35 -PHST- 2023/12/18 00:00 [received] -PHST- 2024/06/19 00:00 [accepted] -PHST- 2024/06/22 05:44 [medline] -PHST- 2024/06/22 05:43 [pubmed] -PHST- 2024/06/21 23:35 [entrez] -PHST- 2024/06/21 00:00 [pmc-release] -AID - 10.1186/s12931-024-02890-3 [pii] -AID - 2890 [pii] -AID - 10.1186/s12931-024-02890-3 [doi] -PST - epublish -SO - Respir Res. 2024 Jun 21;25(1):256. doi: 10.1186/s12931-024-02890-3. - -PMID- 3020703 -OWN - NLM -STAT- MEDLINE -DCOM- 19861103 -LR - 20180524 -IS - 0093-7754 (Print) -IS - 0093-7754 (Linking) -VI - 13 -IP - 3 Suppl 3 -DP - 1986 Sep -TI - Small-cell lung cancer: a 10-year perspective. -PG - 63-74 -AB - Over the past 10 years, four clinical trials have been conducted with a total of - 528 patients with previously untreated small-cell lung cancer. Trials I to III - were randomized phase III studies testing the value of prophylactic cranial - irradiation, immunotherapy, and etoposide, respectively. They were done in the - setting of combined modality treatment with the same local chest radiotherapy - (3,000 rad in 10 fractions) and combined agent chemotherapy using a nucleus of - CAV (cyclophosphamide, doxorubicin, vincristine). Trial IV was a pilot study - evaluating sequential hemibody radiotherapy in a combined modality treatment - program with CAV. Overall, the best treatment results to date have been observed - following the combination of etoposide with CAV in trial III, particularly for - patients with extensive disease. This combination with or without other agents - also appears to be a common component of many trials that have reported - particularly good survival results in this disease. -FAU - Jackson, D V Jr -AU - Jackson DV Jr -FAU - Case, L D -AU - Case LD -LA - eng -GR - CA-12197/CA/NCI NIH HHS/United States -GR - CA-33499/CA/NCI NIH HHS/United States -PT - Clinical Trial -PT - Journal Article -PT - Research Support, U.S. Gov't, P.H.S. -PT - Review -PL - United States -TA - Semin Oncol -JT - Seminars in oncology -JID - 0420432 -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Carcinoma, Small Cell/*therapy -MH - Clinical Trials as Topic -MH - Combined Modality Therapy -MH - Humans -MH - Lung Neoplasms/*therapy -MH - Prognosis -MH - Remission Induction -RF - 47 -EDAT- 1986/09/01 00:00 -MHDA- 2001/03/28 10:01 -CRDT- 1986/09/01 00:00 -PHST- 1986/09/01 00:00 [pubmed] -PHST- 2001/03/28 10:01 [medline] -PHST- 1986/09/01 00:00 [entrez] -AID - 0093-7754(86)90040-0 [pii] -PST - ppublish -SO - Semin Oncol. 1986 Sep;13(3 Suppl 3):63-74. - -PMID- 37722622 -OWN - NLM -STAT- MEDLINE -DCOM- 20240515 -LR - 20240515 -IS - 1097-685X (Electronic) -IS - 0022-5223 (Linking) -VI - 167 -IP - 6 -DP - 2024 Jun -TI - Induction chemoimmunotherapy with surgery versus concurrent chemoradiation - followed by immunotherapy for stage III-N2 non-small cell lung cancer. -PG - 1895-1905.e2 -LID - S0022-5223(23)00853-X [pii] -LID - 10.1016/j.jtcvs.2023.09.029 [doi] -AB - OBJECTIVE: Despite the growing relevance of immunotherapy for non-small cell lung - cancer (NSCLC), there is limited consensus on the optimal treatment strategy for - locally advanced NSCLC. This study evaluated the overall survival of patients - with stage III-N2 NSCLC undergoing induction chemoimmunotherapy with surgery - (CT/IO+Surgery) and definitive concurrent chemoradiation followed by - immunotherapy (cCRT+IO). METHODS: Patients with cT1-3, N2, M0 NSCLC in the - National Cancer Database (2013 to 2019) were included and stratified by treatment - regimen: CT/IO+Surgery or cCRT+IO. Overall survival was evaluated using - Kaplan-Meier analysis, Cox proportional hazards modeling, and propensity score - matching on 10 prognostic variables. RESULTS: Of the 3382 patients who met the - study eligibility criteria, 3289 (97.3%) received cCRT+IO and 93 (2.8%) received - CT/IO+Surgery. The 3-year overall survival of the entire cohort was 58.2% (95% - CI, 56.2% to 60.1%). Multivariable-adjusted Cox proportional hazards modeling - demonstrated better survival after CT/IO+Surgery than after cCRT+IO (hazard ratio - [HR], 0.52; 95% confidence interval [CI], 0.32 to 0.84; P = .007). In a 3:1 - variable ratio propensity score-matched analysis of 223 patients who received - cCRT+IO and 76 patients who received CT/IO+Surgery, 3-year overall survival was - 63.2% (95% CI, 55.9% to 70.2%) after cCRT+IO and 77.2% (95% CI, 64.6% to 85.7%) - after CT/IO+Surgery (P = .029). CONCLUSIONS: In this national analysis, - multimodal treatment including immunotherapy was associated with a 3-year overall - survival rate of 58.2% for all patients with stage III-N2 NSCLC and 77.2% for - patients who underwent chemoimmunotherapy followed by surgery. These results - should be considered hypothesis-generating and demonstrate the importance of - developing a randomized trial to evaluate the role of surgery versus - chemoradiation for locally advanced NSCLC in the modern immunotherapy era. -CI - Copyright © 2023 The American Association for Thoracic Surgery. Published by - Elsevier Inc. All rights reserved. -FAU - Kumar, Arvind -AU - Kumar A -AD - Icahn School of Medicine at Mount Sinai, New York, NY. -FAU - Srinivasan, Deepti -AU - Srinivasan D -AD - Division of Thoracic Surgery, Department of Surgery, Massachusetts General - Hospital, Boston, Mass. -FAU - Potter, Alexandra L -AU - Potter AL -AD - Division of Thoracic Surgery, Department of Surgery, Massachusetts General - Hospital, Boston, Mass. -FAU - Mathey-Andrews, Camille -AU - Mathey-Andrews C -AD - Division of Thoracic Surgery, Department of Surgery, Massachusetts General - Hospital, Boston, Mass. -FAU - Lanuti, Michael -AU - Lanuti M -AD - Division of Thoracic Surgery, Department of Surgery, Massachusetts General - Hospital, Boston, Mass. -FAU - Martin, Linda W -AU - Martin LW -AD - Division of Thoracic and Cardiovascular Surgery, Department of Surgery, - University of Virginia, Charlottesville, Va. -FAU - Jeffrey Yang, Chi-Fu -AU - Jeffrey Yang CF -AD - Division of Thoracic Surgery, Department of Surgery, Massachusetts General - Hospital, Boston, Mass. Electronic address: cjyang@mgh.harvard.edu. -LA - eng -PT - Comparative Study -PT - Journal Article -DEP - 20230916 -PL - United States -TA - J Thorac Cardiovasc Surg -JT - The Journal of thoracic and cardiovascular surgery -JID - 0376343 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/mortality/pathology/immunology -MH - *Lung Neoplasms/therapy/mortality/pathology/immunology -MH - Female -MH - Male -MH - Middle Aged -MH - Aged -MH - *Neoplasm Staging -MH - *Chemoradiotherapy/mortality -MH - *Pneumonectomy/mortality/adverse effects -MH - Retrospective Studies -MH - Immunotherapy/methods/mortality -MH - Induction Chemotherapy/mortality -MH - Treatment Outcome -MH - Databases, Factual -OTO - NOTNLM -OT - immunotherapy -OT - locally advanced NSCLC -OT - multimodal treatment -OT - non–small cell lung cancer -OT - thoracic surgery -COIS- Conflict of Interest Statement L.M. has received consulting fees from - AstraZeneca, Genentech, Ontarget Laboratories, and Ethicon. The other authors - have no conflicts of interest to report. The Journal policy requires editors and - reviewers to disclose conflicts of interest and to decline handling or reviewing - manuscripts for which they may have a conflict of interest. The editors and - reviewers of this article have no conflicts of interest. -EDAT- 2023/09/19 00:43 -MHDA- 2024/05/16 00:43 -CRDT- 2023/09/18 19:17 -PHST- 2023/05/21 00:00 [received] -PHST- 2023/08/15 00:00 [revised] -PHST- 2023/09/11 00:00 [accepted] -PHST- 2024/05/16 00:43 [medline] -PHST- 2023/09/19 00:43 [pubmed] -PHST- 2023/09/18 19:17 [entrez] -AID - S0022-5223(23)00853-X [pii] -AID - 10.1016/j.jtcvs.2023.09.029 [doi] -PST - ppublish -SO - J Thorac Cardiovasc Surg. 2024 Jun;167(6):1895-1905.e2. doi: - 10.1016/j.jtcvs.2023.09.029. Epub 2023 Sep 16. - -PMID- 37933113 -OWN - NLM -STAT- MEDLINE -DCOM- 20240415 -LR - 20240425 -IS - 2005-9256 (Electronic) -IS - 1598-2998 (Print) -IS - 1598-2998 (Linking) -VI - 56 -IP - 2 -DP - 2024 Apr -TI - Intrathoracic Progression Is Still the Most Dominant Failure Pattern after - First-Line Chemo-immunotherapy in Extensive-Stage Small-Cell Lung Cancer: - Implications for Thoracic Radiotherapy. -PG - 430-441 -LID - 10.4143/crt.2023.931 [doi] -AB - PURPOSE: This study aimed to compare the failure patterns before and after the - introduction of immunotherapy and to determine the role of thoracic radiotherapy - (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) treatment. MATERIALS - AND METHODS: We retrospectively reviewed 294 patients with ES-SCLC, of which - 62.2% underwent chemotherapy alone, 13.3% underwent chemotherapy followed by - consolidative TRT (TRT group), and 24.5% underwent chemotherapy with immune - checkpoint inhibitor (ICI group). We performed propensity-score matching (PSM) to - compare each treatment group. RESULTS: The median follow-up duration was 10.4 - months. At the first relapse, in the cohort showing objective response, the - proportion of cases showing intrathoracic progression was significantly lower in - the TRT group (37.8%) than in the chemotherapy-alone (77.2%, p < 0.001) and the - ICI (60.3%, p=0.03) groups. Furthermore, in the subgroup analysis, TRT showed - benefits related to intrathoracic progression-free survival (PFS) in comparison - with ICI in patients with less than two involved extrathoracic sites (p=0.008) or - without liver metastasis (p=0.02) or pleural metastasis (p=0.005) at diagnosis. - After PSM, the TRT group showed significantly better intrathoracic PFS than both - chemotherapy-alone and ICI groups (p < 0.001 and p=0.04, respectively), but - showed no significant benefit in terms of PFS and overall survival in comparison - with the ICI group (p=0.17 and p=0.31, respectively). CONCLUSION: In ES-SCLC, - intrathoracic progression was the most dominant failure pattern after - immunotherapy. In the era of chemoimmunotherapy, consolidative TRT can still be - considered a useful treatment strategy for locoregional control. -FAU - Kim, Dowook -AU - Kim D -AD - Department of Radiation Oncology, Chungnam National University Hospital, Daejeon, - Korea. -AD - Department of Radiation Oncology, Seoul National University College of Medicine, - Seoul, Korea. -FAU - Kim, Hak Jae -AU - Kim HJ -AD - Department of Radiation Oncology, Seoul National University College of Medicine, - Seoul, Korea. -AD - Cancer Research Institute, Seoul National University, Seoul, Korea. -AD - Department of Radiation Oncology, Seoul National University Hospital, Seoul, - Korea. -FAU - Wu, Hong-Gyun -AU - Wu HG -AD - Department of Radiation Oncology, Seoul National University College of Medicine, - Seoul, Korea. -AD - Cancer Research Institute, Seoul National University, Seoul, Korea. -AD - Department of Radiation Oncology, Seoul National University Hospital, Seoul, - Korea. -FAU - Lee, Joo Ho -AU - Lee JH -AD - Department of Radiation Oncology, Seoul National University College of Medicine, - Seoul, Korea. -AD - Department of Radiation Oncology, Seoul National University Hospital, Seoul, - Korea. -FAU - Kim, Suzy -AU - Kim S -AD - Department of Radiation Oncology, Seoul National University College of Medicine, - Seoul, Korea. -AD - Department of Radiation Oncology, Seoul Metropolitan Government Seoul National - University Boramae Medical Center, Seoul, Korea. -FAU - Kim, Tae Min -AU - Kim TM -AD - Cancer Research Institute, Seoul National University, Seoul, Korea. -AD - Department of Internal Medicine, Seoul National University Hospital, Seoul, - Korea. -FAU - Kim, Jin-Soo -AU - Kim JS -AD - Department of Internal Medicine, Seoul Metropolitan Government-Seoul National - University Boramae Medical Center, Seoul, Korea. -FAU - Kim, Byoung Hyuck -AU - Kim BH -AD - Department of Radiation Oncology, Seoul National University College of Medicine, - Seoul, Korea. -AD - Department of Radiation Oncology, Seoul Metropolitan Government Seoul National - University Boramae Medical Center, Seoul, Korea. -LA - eng -PT - Journal Article -DEP - 20231106 -PL - Korea (South) -TA - Cancer Res Treat -JT - Cancer research and treatment -JID - 101155137 -SB - IM -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Retrospective Studies -MH - Treatment Outcome -MH - *Small Cell Lung Carcinoma/drug therapy/radiotherapy -MH - Immunotherapy -PMC - PMC11016648 -OTO - NOTNLM -OT - Extensive-stage small-cell lung cancer -OT - Patterns of progression -OT - Thoracic radiotherapy -COIS- Conflicts of Interest Conflict of interest relevant to this article was not - reported. -EDAT- 2023/11/07 06:45 -MHDA- 2024/04/15 06:43 -PMCR- 2024/04/01 -CRDT- 2023/11/07 03:02 -PHST- 2023/08/13 00:00 [received] -PHST- 2023/11/03 00:00 [accepted] -PHST- 2024/04/15 06:43 [medline] -PHST- 2023/11/07 06:45 [pubmed] -PHST- 2023/11/07 03:02 [entrez] -PHST- 2024/04/01 00:00 [pmc-release] -AID - crt.2023.931 [pii] -AID - crt-2023-931 [pii] -AID - 10.4143/crt.2023.931 [doi] -PST - ppublish -SO - Cancer Res Treat. 2024 Apr;56(2):430-441. doi: 10.4143/crt.2023.931. Epub 2023 - Nov 6. - -PMID- 39179598 -OWN - NLM -STAT- MEDLINE -DCOM- 20240823 -LR - 20240826 -IS - 2045-2322 (Electronic) -IS - 2045-2322 (Linking) -VI - 14 -IP - 1 -DP - 2024 Aug 23 -TI - Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and - outcomes of durvalumab after chemoradiation in non-small cell lung cancer. -PG - 19596 -LID - 10.1038/s41598-024-70214-y [doi] -LID - 19596 -AB - The usefulness of the derived neutrophil-to-lymphocyte ratio (dNLR) and its - dynamics before/after durvalumab consolidation therapy to predict safety or - efficacy remains unclear. We retrospectively reviewed patients with locally - advanced non-small cell lung cancer treated with durvalumab consolidation therapy - after chemoradiotherapy (D group) or chemoradiotherapy alone (non-D group) at - multiple institutions. We investigated the association between dNLR, or its - dynamics, and pneumonitis, checkpoint inhibitor-related pneumonitis (CIP), irAEs, - and efficacy. Ninety-eight and fifty-six patients were enrolled in the D and - non-D groups, respectively. The dNLR at baseline was significantly lower in - patients who experienced irAEs or CIP than in those who did not. The low dNLR - group, 28 days following durvalumab consolidation therapy (dNLR28 ≤ 3), - demonstrated longer progression-free survival (PFS) and overall survival (OS) - than the high dNLR group (dNLR28 > 3) (PFS, hazard ratio [HR] 0.44, 95% - confidence interval [CI] 0.22-0.88, p = 0.020; OS, HR 0.39, 95% CI 0.16-0.94, - p = 0.037). Among patients with high dNLR at baseline (dNLR > 3), the dNLR28 ≤ 3 - group showed longer PFS than the dNLR28 > 3 group (p = 0.010). The dNLR is a - predictive factor for irAEs and CIP in patients receiving durvalumab - consolidation therapy. The dNLR at 28 days after durvalumab consolidation therapy - and its dynamics predict favorable outcomes. -CI - © 2024. The Author(s). -FAU - Sugimoto, Akira -AU - Sugimoto A -AD - Department of Respiratory Medicine, Graduate School of Medicine, Osaka City - University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -AD - Department of Respiratory Medicine, Graduate School of Medicine, Osaka - Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -FAU - Kaneda, Hiroyasu -AU - Kaneda H -AD - Department of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan - University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. - kaneda.hiroyasu@omu.ac.jp. -FAU - Yoshimoto, Naoki -AU - Yoshimoto N -AD - Department of Respiratory Medicine, Ishikiriseiki Hospital, 18-28 Yayoi-cho, - Higashiosaka, Osaka, 579-8026, Japan. -FAU - Nagata, Kenji -AU - Nagata K -AD - Department of Radiation Oncology, Ishikiriseiki Hospital, 18-28 Yayoi-cho, - Higashiosaka, Osaka, 579-8026, Japan. -FAU - Fujii, Tatsuo -AU - Fujii T -AD - Department of Respiratory Medicine, Osaka General Hospital of West Japan Railway - Company, 1-2-22 Matsuzaki-cho, Abeno-ku, Osaka, 545-0053, Japan. -FAU - Michimoto, Koichi -AU - Michimoto K -AD - Department of Radiation Therapy, Osaka General Hospital of West Japan Railway - Company, 1-2-22 Matsuzaki-cho, Abeno-ku, Osaka, 545-0053, Japan. -FAU - Ueno, Shunsuke -AU - Ueno S -AD - Department of Respiratory Medicine, Yodogawa Christian Hospital, 1-7-50 Kunijima, - Higashiyodogawa-ku, Osaka, 533-0024, Japan. -FAU - Kamimori, Takao -AU - Kamimori T -AD - Department of Respiratory Medicine, Yodogawa Christian Hospital, 1-7-50 Kunijima, - Higashiyodogawa-ku, Osaka, 533-0024, Japan. -FAU - Ishii, Yoshie -AU - Ishii Y -AD - Department of Radiation Therapy, Yodogawa Christian Hospital, 1-7-50 Kunijima, - Higashiyodogawa-ku, Osaka, 533-0024, Japan. -FAU - Sakagami, Mai -AU - Sakagami M -AD - Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan - University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -FAU - Inokuchi, Haruo -AU - Inokuchi H -AD - Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan - University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -FAU - Shibuya, Keiko -AU - Shibuya K -AD - Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan - University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -FAU - Mizutani, Megumi -AU - Mizutani M -AD - Department of Respiratory Medicine, Graduate School of Medicine, Osaka - Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -FAU - Nagamine, Hiroaki -AU - Nagamine H -AD - Department of Respiratory Medicine, Graduate School of Medicine, Osaka - Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -FAU - Nakahama, Kenji -AU - Nakahama K -AD - Department of Respiratory Medicine, Graduate School of Medicine, Osaka - Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -AD - Department of Respiratory Medicine, Ishikiriseiki Hospital, 18-28 Yayoi-cho, - Higashiosaka, Osaka, 579-8026, Japan. -FAU - Matsumoto, Yoshiya -AU - Matsumoto Y -AD - Department of Respiratory Medicine, Graduate School of Medicine, Osaka - Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -FAU - Tani, Yoko -AU - Tani Y -AD - Department of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan - University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -FAU - Sawa, Kenji -AU - Sawa K -AD - Department of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan - University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -FAU - Kawaguchi, Tomoya -AU - Kawaguchi T -AD - Department of Respiratory Medicine, Graduate School of Medicine, Osaka City - University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -AD - Department of Respiratory Medicine, Graduate School of Medicine, Osaka - Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -AD - Department of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan - University, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. -LA - eng -PT - Journal Article -DEP - 20240823 -PL - England -TA - Sci Rep -JT - Scientific reports -JID - 101563288 -RN - 28X28X9OKV (durvalumab) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/therapy/pathology/mortality -MH - Female -MH - Male -MH - *Neutrophils -MH - Aged -MH - *Antibodies, Monoclonal/therapeutic use/adverse effects -MH - *Lung Neoplasms/drug therapy/pathology/therapy/mortality -MH - Middle Aged -MH - *Chemoradiotherapy/adverse effects/methods -MH - *Lymphocytes -MH - Retrospective Studies -MH - Treatment Outcome -MH - Adult -MH - Antineoplastic Agents, Immunological/therapeutic use/adverse effects -MH - Aged, 80 and over -PMC - PMC11343745 -OTO - NOTNLM -OT - Derived neutrophil to lymphocyte ratio -OT - Durvalumab -OT - Immune related adverse event -OT - Non small cell lung cancer -OT - Pneumonitis -COIS- Akira Sugimoto reports a relationship with Chugai Pharmaceutical Co Ltd that - includes speaking and lecture fees. Hiroyasu Kaneda reports a relationship with - AstraZeneca, Chugai Pharmaceutical Co Ltd, Ono Pharmaceutical Co Ltd, and Bristol - Myers Squibb Co that includes speaking and lecture fees. Naoki Yoshimoto reports - a relationship with AstraZeneca, Boehringer Ingelheim Japan Inc, Bristol Myers - Squibb Co, Eli Lilly and Company, Kyowa Kirin Co Ltd, MSD, Nippon Kayaku Co Ltd, - Taiho Pharmaceutical Co Ltd, and Takeda Pharmaceutical Company Limited that - includes speaking and lecture fees. Tatsuo Fujii reports a relationship with - AstraZeneca that includes speaking and lecture fees. Shunsuke Ueno reports a - relationship with MSD and Chugai Pharmaceutical Co Ltd that includes speaking and - lecture fees. Takao Kamimori reports a relationship with AstraZeneca, MSD, Nippon - Boehringer Ingelheim Co Ltd, Novartis Pharma, Sanofi, and Takeda Pharmaceutical - Company Limited that includes speaking and lecture fees. Haruo Inokuchi reports a - relationship with AstraZeneca, Elekta, Boston Scientific Corp, Daiichi Sankyo Co - Ltd, and Regeneron Pharmaceuticals Inc. that includes speaking and lecture fees. - Keiko Shibuya reports a relationship with AstraZeneca, Takeda Pharmaceutical - Company Limited, and Elekta that includes speaking and lecture fees. Yoko Tani - reports a relationship with AstraZeneca, Kyowa Kirin Co Ltd, and Chugai - Pharmaceutical Co Ltd that includes speaking and lecture fees. Kenji Sawa reports - a relationship with Eli Lilly Japan KK, AstraZeneca, Kyowa Kirin Co Ltd, Ono - Pharmaceutical Co Ltd, Nippon Kayaku Co Ltd, Chugai Pharmaceutical Co Ltd, Taiho - Pharmaceutical Co Ltd, and MSD that includes speaking and lecture fees. Tomoya - Kawaguchi reports a relationship with Chugai Pharmaceutical Co Ltd, MSD, - AstraZeneca, Taiho Pharmaceutical Co Ltd, Boehringer Ingelheim, Ono - Pharmaceutical Co Ltd, Bristol Myers Squibb Co, and Pfizer Inc that includes - speaking and lecture fees. The other authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2024/08/24 16:44 -MHDA- 2024/08/24 16:45 -PMCR- 2024/08/23 -CRDT- 2024/08/23 23:18 -PHST- 2024/03/26 00:00 [received] -PHST- 2024/08/13 00:00 [accepted] -PHST- 2024/08/24 16:45 [medline] -PHST- 2024/08/24 16:44 [pubmed] -PHST- 2024/08/23 23:18 [entrez] -PHST- 2024/08/23 00:00 [pmc-release] -AID - 10.1038/s41598-024-70214-y [pii] -AID - 70214 [pii] -AID - 10.1038/s41598-024-70214-y [doi] -PST - epublish -SO - Sci Rep. 2024 Aug 23;14(1):19596. doi: 10.1038/s41598-024-70214-y. - -PMID- 38010059 -OWN - NLM -STAT- MEDLINE -DCOM- 20240116 -LR - 20240117 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 15 -IP - 2 -DP - 2024 Jan -TI - Association of antibiotic exposure with survival in patients with extensive-stage - small cell lung cancer receiving immune checkpoint inhibitor therapy. -PG - 152-162 -LID - 10.1111/1759-7714.15172 [doi] -AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) have dramatically shifted the - therapeutic paradigm of extensive-stage small cell lung cancer (ES-SCLC). - Antibiotic (ATB) exposure before or during ICI therapy can harm the integrity of - the gut microbiome and lead to intestinal dysbiosis, which has a profoundly - negative impact on the treatment response for various malignancies. Whether this - is applicable to ES-SCLC remains unclear. METHODS: We retrospectively reviewed - the electronic medical records of all patients diagnosed with ES-SCLC who were - treated with ICI-based immunotherapies from July 2019 to December 2020 at - Shandong Cancer Hospital and Institute, China. Outcomes with the use of ATBs - before or after the first infusion of ICI, including progression-free survival - (PFS) and overall survival (OS), were investigated using the Kaplan-Meier method. - Multivariate analyses were also conducted using a Cox proportional hazards model. - RESULTS: A total of 214 patients were included, among whom 41 (19.2%) received - ATBs within 2 months before or after the first initiation of ICI therapy and were - assigned to the ATB group. The ATB group showed a shorter median PFS (4.3 vs. - 6.3 months; HR = 1.43, 95% CI: 0.97-2.11; p = 0.043) and a significantly shorter - median OS (6.9 vs. 13 months; HR = 1.47, 95% CI: 0.98-2.20; p = 0.033) than the - non-ATB group. In the multivariate analysis, ATB exposure was markedly associated - with worse PFS (HR = 1.47, 95% CI: 1.03-2.09, p = 0.035) and OS (HR = 1.46, 95% - CI: 1.01-2.11, p = 0.043). CONCLUSIONS: Our results demonstrate that ATB exposure - was significantly associated with worse survival in ES-SCLC patients who received - ICI therapy. -CI - © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Zhong, Jiaqi -AU - Zhong J -AD - Clinical Medical College, Southwest Medical University, Luzhou, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Xiong, Dali -AU - Xiong D -AD - Clinical Medical College, Southwest Medical University, Luzhou, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Liu, Yu -AU - Liu Y -AD - Shandong Provincial Hospital Affiliated to Shandong First Medical University - Digestive Endoscopy Center, Jinan, China. -FAU - Yuan, Shuanghu -AU - Yuan S -AUID- ORCID: 0000-0002-8327-2524 -AD - Clinical Medical College, Southwest Medical University, Luzhou, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -AD - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou - University, Zhengzhou, China. -LA - eng -GR - NSFC82073345/National Natural Science Foundation of China/ -GR - Taishan Scholars Program to Shuanghu Yuan/ -GR - 202019060/Jinan Clinical Medicine Science and Technology Innovation Plan/ -GR - ZR202209010002/Natural Science Innovation and Development Joint Foundation of - Shandong Province/ -PT - Journal Article -DEP - 20231127 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Anti-Bacterial Agents) -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/drug therapy -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Lung Neoplasms/drug therapy -MH - Retrospective Studies -MH - Anti-Bacterial Agents/adverse effects -PMC - PMC10788467 -OTO - NOTNLM -OT - antibiotic -OT - extensive-stage small cell lung cancer -OT - gut microbiome -OT - immune checkpoint inhibitor -COIS- The authors declare no potential conflicts of interest. -EDAT- 2023/11/27 12:43 -MHDA- 2024/01/16 06:42 -PMCR- 2023/11/27 -CRDT- 2023/11/27 09:24 -PHST- 2023/11/09 00:00 [revised] -PHST- 2023/09/04 00:00 [received] -PHST- 2023/11/11 00:00 [accepted] -PHST- 2024/01/16 06:42 [medline] -PHST- 2023/11/27 12:43 [pubmed] -PHST- 2023/11/27 09:24 [entrez] -PHST- 2023/11/27 00:00 [pmc-release] -AID - TCA15172 [pii] -AID - 10.1111/1759-7714.15172 [doi] -PST - ppublish -SO - Thorac Cancer. 2024 Jan;15(2):152-162. doi: 10.1111/1759-7714.15172. Epub 2023 - Nov 27. - -PMID- 34870327 -OWN - NLM -STAT- MEDLINE -DCOM- 20220106 -LR - 20240901 -IS - 1469-493X (Electronic) -IS - 1361-6137 (Linking) -VI - 12 -IP - 12 -DP - 2021 Dec 6 -TI - Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell - lung cancer treated with surgery or radiotherapy with curative intent. -PG - CD011300 -LID - 10.1002/14651858.CD011300.pub3 [doi] -LID - CD011300 -AB - BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common lung cancer, - accounting for approximately 80% to 85% of all cases. For people with localised - NSCLC (stages I to III), it has been speculated that immunotherapy may be helpful - for reducing postoperative recurrence rates, or improving the clinical outcomes - of current treatment for unresectable tumours. This is an update of a Cochrane - Review first published in 2017 and it includes two new randomised controlled - trials (RCTs). OBJECTIVES: To assess the effectiveness and safety of - immunotherapy (excluding checkpoint inhibitors) among  people  with localised - NSCLC of stages I to III who received curative intent of radiotherapy or surgery. - SEARCH METHODS: We searched the following databases (from inception to 19 May - 2021): CENTRAL, MEDLINE, Embase, CINAHL, and five trial registers. We also - searched conference proceedings and reference lists of included trials. SELECTION - CRITERIA: We included RCTs conducted in adults (≥ 18 years) diagnosed with  NSCLC - stage I to III after surgical resection, and those with unresectable locally - advanced stage III NSCLC receiving radiotherapy with curative intent. We included - participants who underwent primary surgical treatment, postoperative radiotherapy - or chemoradiotherapy if the same strategy was provided for both intervention and - control groups. DATA COLLECTION AND ANALYSIS: Two review authors independently - selected eligible trials, assessed risk of bias, and extracted data. We used - survival analysis to pool time-to-event data, using hazard ratios (HRs). We used - risk ratios (RRs) for dichotomous data, and mean differences (MDs) for continuous - data, with 95% confidence intervals (CIs). Due to clinical heterogeneity - (immunotherapeutic agents with different underlying mechanisms), we combined data - by applying random-effects models. MAIN RESULTS: We included 11 RCTs involving - 5128 participants (this included 2 new trials with 188 participants since the - last search dated 20 January 2017). Participants who underwent surgical resection - or received curative radiotherapy were randomised to either an immunotherapy - group or a control group. The immunological interventions were active - immunotherapy Bacillus Calmette-Guérin (BCG) adoptive cell transfer (i.e. - transfer factor (TF), tumour-infiltrating lymphocytes (TIL), dendritic - cell/cytokine-induced killer (DC/CIK), antigen-specific cancer vaccines - (melanoma-associated antigen 3 (MAGE-A3) and L-BLP25), and targeted natural - killer (NK) cells. Seven trials were at high risk of bias for at least one of the - risk of bias domains. Three trials were at low risk of bias across all domains - and one small trial was at unclear risk of bias as it provided insufficient - information. We included data from nine of the 11 trials in the meta-analyses - involving 4863 participants. There was no evidence of a difference between the - immunotherapy agents and the controls on any of the following outcomes: overall - survival (HR 0.94, 95% CI 0.84 to 1.05; P = 0.27; 4 trials, 3848 participants; - high-quality evidence), progression-free survival (HR 0.94, 95% CI 0.86 to 1.03; - P = 0.19; moderate-quality evidence), adverse events (RR 1.12, 95% CI 0.97 to - 1.28; P = 0.11; 4 trials, 4126 evaluated participants; low-quality evidence), and - severe adverse events (RR 1.14, 95% CI 0.92 to 1.40; 6 trials, 4546 evaluated - participants; low-quality evidence).  Survival rates at different time points - showed no evidence of a difference between immunotherapy agents and the controls. - Survival rate at 1-year follow-up (RR 1.02, 95% CI 0.96 to 1.08; I(2) = 57%; 7 - trials, 4420 participants; low-quality evidence), 2-year follow-up (RR 1.02, 95% - CI 0.93 to 1.12; 7 trials, 4420 participants; moderate-quality evidence), 3-year - follow-up (RR 0.99, 95% CI 0.90 to 1.09; 7 trials, 4420 participants; I(2) = 22%; - moderate-quality evidence) and at 5-year follow-up (RR 0.98, 95% CI 0.86 to 1.12; - I(2) = 0%; 7 trials, 4389 participants; moderate-quality evidence).  Only one - trial reported overall response rates. Two trials provided health-related quality - of life results with contradicting results.  AUTHORS' CONCLUSIONS: Based on this - updated review, the current literature does not provide evidence that suggests a - survival benefit from adding immunotherapy (excluding checkpoint inhibitors) to - conventional curative surgery or radiotherapy, for people with localised NSCLC - (stages I to III). Several ongoing trials with immune checkpoints inhibitors - (PD-1/PD-L1) might bring new insights into the role of immunotherapy for people - with stages I to III NSCLC. -CI - Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. -FAU - Zhu, Jianwei -AU - Zhu J -AD - Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, - China. -FAU - Yuan, Yun -AU - Yuan Y -AD - West China Biomedical Big Data Center, West China Hospital, Sichuan University, - Chengdu, China. -FAU - Wan, Xiaoyu -AU - Wan X -AD - West China Biomedical Big Data Center, West China Hospital, Sichuan University, - Chengdu, China. -FAU - Yin, Dan -AU - Yin D -AD - West China Biomedical Big Data Center, West China Hospital, Sichuan University, - Chengdu, China. -FAU - Li, Rui -AU - Li R -AD - Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West - China Hospital, Sichuan University, Chengdu, China. -FAU - Chen, Wenwen -AU - Chen W -AD - West China Biomedical Big Data Center, West China Hospital, Sichuan University, - Chengdu, China. -FAU - Suo, Chen -AU - Suo C -AD - Key Laboratory of Public Health Safety, Fudan University, Ministry of Education, - Shanghai, China. -FAU - Song, Huan -AU - Song H -AD - West China Biomedical Big Data Center, West China Hospital, Sichuan University, - Chengdu, China. -AD - Center of Public Health Sciences, Faculty of Medicine, University of Iceland, - Reykjavík, Iceland. -LA - eng -SI - ClinicalTrials.gov/NCT00409188 -SI - ClinicalTrials.gov/NCT00960115 -SI - ClinicalTrials.gov/NCT00290355 -SI - ClinicalTrials.gov/NCT00480025 -SI - ClinicalTrials.gov/NCT01015443 -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PT - Systematic Review -DEP - 20211206 -PL - England -TA - Cochrane Database Syst Rev -JT - The Cochrane database of systematic reviews -JID - 100909747 -SB - IM -UOF - Cochrane Database Syst Rev. 2017 Dec 16;12:CD011300. doi: - 10.1002/14651858.CD011300.pub2. PMID: 29247502 -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -MH - Progression-Free Survival -MH - Randomized Controlled Trials as Topic -PMC - PMC8647093 -COIS- JZ: declares no conflict of interest YY: declares no conflict of interest XW: - declares no conflict of interest DY: declares no conflict of interest RL: - declares no conflict of interest WC: declares no conflict of interest CS: - declares no conflict of interest HS: declares no conflict of interest -EDAT- 2021/12/07 06:00 -MHDA- 2022/01/07 06:00 -PMCR- 2022/12/06 -CRDT- 2021/12/06 09:33 -PHST- 2021/12/06 09:33 [entrez] -PHST- 2021/12/07 06:00 [pubmed] -PHST- 2022/01/07 06:00 [medline] -PHST- 2022/12/06 00:00 [pmc-release] -AID - CD011300.pub3 [pii] -AID - 10.1002/14651858.CD011300.pub3 [doi] -PST - epublish -SO - Cochrane Database Syst Rev. 2021 Dec 6;12(12):CD011300. doi: - 10.1002/14651858.CD011300.pub3. - -PMID- 36252995 -OWN - NLM -STAT- MEDLINE -DCOM- 20221019 -LR - 20221222 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 10 -IP - 10 -DP - 2022 Oct -TI - Tumor microenvironment shows an immunological abscopal effect in patients with - NSCLC treated with pembrolizumab-radiotherapy combination. -LID - 10.1136/jitc-2022-005248 [doi] -LID - e005248 -AB - BACKGROUND: Immunotherapy is currently part of the standard of care for patients - with advanced-stage non-small cell lung cancer (NSCLC). However, many patients do - not respond to this treatment, therefore combination strategies are being - explored to increase clinical benefit. The PEMBRO-RT trial combined the - therapeutic programmed cell death 1 (PD-1) antibody pembrolizumab with - stereotactic body radiation therapy (SBRT) to increase the overall response rate - and study the effects on the tumor microenvironment (TME). METHODS: Here, immune - infiltrates in the TME of patients included in the PEMBRO-RT trial were - investigated. Tumor biopsies of patients treated with pembrolizumab alone or - combined with SBRT (a biopsy of the non-irradiated site) at baseline and during - treatment were stained with multiplex immunofluorescence for CD3, CD8, CD20, - CD103 and FoxP3 for lymphocytes, pan-cytokeratin for tumors, and HLA-ABC - expression was determined. RESULTS: The total number of lymphocytes increased - significantly after 6 weeks of treatment in the anti-PD-1 group (fold change: - 1.87, 95% CI: 1.06 to 3.29) and the anti-PD-1+SBRT group (fold change: 2.29, 95% - CI: 1.46 to 3.60). The combination of SBRT and anti-PD-1 induced a 4.87-fold - increase (95% CI: 2.45 to 9.68) in CD103(+) cytotoxic T-cells 6 weeks on - treatment and a 2.56-fold increase (95% CI: 1.03 to 6.36) after anti-PD-1 therapy - alone. Responders had a significantly higher number of lymphocytes at baseline - than non-responders (fold difference 1.85, 95% CI: 1.04 to 3.29 for anti-PD-1 and - fold change 1.93, 95% CI: 1.08 to 3.44 for anti-PD-1+SBRT). CONCLUSION: This - explorative study shows that that lymphocyte infiltration in general, instead of - the infiltration of a specific lymphocyte subset, is associated with response to - therapy in patients with NSCLC.Furthermore, anti-PD-1+SBRT combination therapy - induces an immunological abscopal effect in the TME represented by a superior - infiltration of cytotoxic T cells as compared with anti-PD-1 monotherapy. -CI - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - van der Woude, Lieke L -AU - van der Woude LL -AUID- ORCID: 0000-0002-4761-0768 -AD - Department of Tumour Immunology, Radboudumc, Nijmegen, The Netherlands. -AD - Department of Pathology, Radboudumc, Nijmegen, The Netherlands. -AD - Division of Immunotherapy, Oncode Institute, Radboudumc, Nijmegen, the - Netherlands. -FAU - Gorris, Mark A J -AU - Gorris MAJ -AUID- ORCID: 0000-0003-3621-226X -AD - Department of Tumour Immunology, Radboudumc, Nijmegen, The Netherlands. -AD - Division of Immunotherapy, Oncode Institute, Radboudumc, Nijmegen, the - Netherlands. -FAU - Wortel, Inge M N -AU - Wortel IMN -AD - Data Science, Institute for Computing and Information Sciences, Radboud - University, Nijmegen, the Netherlands. -FAU - Creemers, Jeroen H A -AU - Creemers JHA -AUID- ORCID: 0000-0003-0371-8416 -AD - Department of Tumour Immunology, Radboudumc, Nijmegen, The Netherlands. -AD - Division of Immunotherapy, Oncode Institute, Radboudumc, Nijmegen, the - Netherlands. -FAU - Verrijp, Kiek -AU - Verrijp K -AUID- ORCID: 0000-0001-5223-8406 -AD - Department of Tumour Immunology, Radboudumc, Nijmegen, The Netherlands. -AD - Department of Pathology, Radboudumc, Nijmegen, The Netherlands. -AD - Division of Immunotherapy, Oncode Institute, Radboudumc, Nijmegen, the - Netherlands. -FAU - Monkhorst, Kim -AU - Monkhorst K -AD - Department of Pathology, Netherlands Cancer Institute, Amsterdam, The - Netherlands. -FAU - Grünberg, Katrien -AU - Grünberg K -AD - Department of Pathology, Radboudumc, Nijmegen, The Netherlands. -FAU - van den Heuvel, Michel M -AU - van den Heuvel MM -AD - Department of Pulmonary Diseases, Radboudumc, Nijmegen, The Netherlands. -FAU - Textor, Johannes -AU - Textor J -AUID- ORCID: 0000-0002-0459-9458 -AD - Department of Tumour Immunology, Radboudumc, Nijmegen, The Netherlands. -AD - Data Science, Institute for Computing and Information Sciences, Radboud - University, Nijmegen, the Netherlands. -FAU - Figdor, Carl G -AU - Figdor CG -AUID- ORCID: 0000-0002-2366-9212 -AD - Department of Tumour Immunology, Radboudumc, Nijmegen, The Netherlands. -FAU - Piet, Berber -AU - Piet B -AD - Department of Pulmonary Diseases, Radboudumc, Nijmegen, The Netherlands. -FAU - Theelen, Willemijn S M E -AU - Theelen WSME -AD - Department of Pulmonology, Netherlands Cancer Institute, Amsterdam, The - Netherlands. -FAU - de Vries, I Jolanda M -AU - de Vries IJM -AUID- ORCID: 0000-0002-8653-4040 -AD - Department of Tumour Immunology, Radboudumc, Nijmegen, The Netherlands - jolanda.devries@radboudumc.nl. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Forkhead Transcription Factors) -RN - 68238-35-7 (Keratins) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - Forkhead Transcription Factors -MH - Humans -MH - Keratins -MH - *Lung Neoplasms/drug therapy/pathology -MH - Tumor Microenvironment -PMC - PMC9577911 -OTO - NOTNLM -OT - immunotherapy -OT - programmed cell death 1 receptor -OT - radiotherapy -OT - tumor microenvironment -COIS- Competing interests: WSMET reports grants from AstraZeneca, MSD and Sanofi. -EDAT- 2022/10/18 06:00 -MHDA- 2022/10/20 06:00 -PMCR- 2022/10/17 -CRDT- 2022/10/17 20:42 -PHST- 2022/09/17 00:00 [accepted] -PHST- 2022/10/17 20:42 [entrez] -PHST- 2022/10/18 06:00 [pubmed] -PHST- 2022/10/20 06:00 [medline] -PHST- 2022/10/17 00:00 [pmc-release] -AID - jitc-2022-005248 [pii] -AID - 10.1136/jitc-2022-005248 [doi] -PST - ppublish -SO - J Immunother Cancer. 2022 Oct;10(10):e005248. doi: 10.1136/jitc-2022-005248. - -PMID- 39350057 -OWN - NLM -STAT- MEDLINE -DCOM- 20241001 -LR - 20241003 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 24 -IP - 1 -DP - 2024 Sep 30 -TI - Clinical outcomes and synergistic effect between radiotherapy and immunotherapy - in patients with extensive-stage small cell lung cancer: a real-world study. -PG - 1206 -LID - 10.1186/s12885-024-12942-y [doi] -LID - 1206 -AB - BACKGROUND: Patients with extensive-stage small cell lung cancer (ES-SCLC) - experience significant therapeutic challenges and limited survival rates. This - study aimed to investigate the efficacy of combining immunotherapy (IT) with - chemotherapy (CT) for treating ES-SCLC and to explore the synergistic effect - between radiotherapy (RT) and IT. METHODS: This retrospective analysis examined - patients with ES-SCLC who received treatment at three centers. Furthermore, - propensity score-matched (PSM) analysis was conducted. The Kaplan‒Meier method - and Cox proportional hazards regression were used to compare the survival - outcomes. RESULTS: A total of 257 eligible patients with ES-SCLC were included in - the analysis. Among all patients, the median overall survival (mOS) was 18.0 m in - the chemoimmunotherapy (CT + IT) group and 15.7 m in the CT group (p = 0.208). - The median real-world progression-free survival (mrwPFS) was 7.7 m and 6.8 m - (p = 0.043) in the CT + IT and CT group, respectively. Moreover, the mOS was - 22.0 m in the chemoradiotherapy (CT + RT) group and 13.6 m in the CT group - (p < 0.001). The mrwPFS was 7.4 m and 6.0 m (p = 0.175) in the CT + RT group and - CT group, respectively. The multivariate analyses revealed that sex, liver - metastasis and RT were independent prognostic factors for OS (p < 0.05), while - liver metastasis and IT were found to be independent predictive factors of - real-world progression-free survival (rwPFS) (p < 0.05). After PSM, the mOS was - 23.2 m in the CT + IT group and 13.0 m in the CT group (p = 0.008). The mrwPFS - was 7.3 m and 6.2 m (p = 0.096) in the CT + IT group and the CT group, - respectively. Moreover, the mOS was 21.4 m in the CT + RT group and 12.5 m in the - CT group (p < 0.001). The mrwPFS was 7.3 m and 5.2 m (p = 0.220) in the CT + RT - group and the CT group, respectively. Additionally, our study revealed that in - the PD-1 group, RT significantly improved patient survival (36.0 m vs. 15.8 m, - p = 0.041). CONCLUSION: An increasing number of treatment options are being - explored for ES-SCLC, and CT is the cornerstone of treatment for this disease. - Combining CT with IT and RT has demonstrated remarkable efficacy and excellent - safety profiles, and such treatments are worthy of further exploration. -CI - © 2024. The Author(s). -FAU - Sun, Meiling -AU - Sun M -AD - Department of Pulmonary and Critical Care Medicine, Qilu Hospital, Cheeloo - College of Medicine, Shandong University, No. 107 Wenhua Xilu, Jinan, 250012, - Shandong, China. -AD - Department of Respiratory Medicine, Weihai Municipal Hospital, Cheeloo College of - Medicine, Shandong University, 70 Heping Road, Weihai, 264200, Shandong, China. -FAU - Ji, Huaijun -AU - Ji H -AD - Department of Thoracic Surgery, Weihai Municipal Hospital, Cheeloo College of - Medicine, Shandong University, 70 Heping Road, Weihai, 264200, Shandong, China. - sdhzcxjhj@sina.com. -FAU - Deng, Fang -AU - Deng F -AD - Department of Oncology, Qilu Hospital of Shandong University Dezhou Hospital, - Dezhou, 254300, Shandong, China. -FAU - Li, Jingyi -AU - Li J -AD - Department of Radiation Oncology, Weihai Municipal Hospital, Cheeloo College of - Medicine, Shandong University, 70 Heping Road, Weihai, 264200, Shandong, China. -FAU - Xu, Ning -AU - Xu N -AD - Department of Respiratory Medicine, Weihai Municipal Hospital, Cheeloo College of - Medicine, Shandong University, 70 Heping Road, Weihai, 264200, Shandong, China. -FAU - Li, Yu -AU - Li Y -AD - Department of Pulmonary and Critical Care Medicine, Qilu Hospital, Cheeloo - College of Medicine, Shandong University, No. 107 Wenhua Xilu, Jinan, 250012, - Shandong, China. qlliyures@163.com. -LA - eng -PT - Journal Article -DEP - 20240930 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -SB - IM -MH - Humans -MH - Male -MH - Female -MH - *Small Cell Lung Carcinoma/therapy/pathology/radiotherapy/mortality -MH - *Lung Neoplasms/therapy/pathology/mortality/radiotherapy -MH - Retrospective Studies -MH - Middle Aged -MH - Aged -MH - *Immunotherapy/methods -MH - Combined Modality Therapy -MH - Neoplasm Staging -MH - Chemoradiotherapy/methods -MH - Treatment Outcome -MH - Adult -MH - Kaplan-Meier Estimate -MH - Propensity Score -MH - Survival Rate -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -PMC - PMC11441094 -OTO - NOTNLM -OT - Chemotherapy -OT - Extensive-stage small cell lung cancer -OT - Immunotherapy -OT - Propensity score matching -OT - Radiotherapy -COIS- The authors declare no competing interests. -EDAT- 2024/10/01 00:42 -MHDA- 2024/10/01 10:19 -PMCR- 2024/09/30 -CRDT- 2024/09/30 23:55 -PHST- 2024/06/17 00:00 [received] -PHST- 2024/09/12 00:00 [accepted] -PHST- 2024/10/01 10:19 [medline] -PHST- 2024/10/01 00:42 [pubmed] -PHST- 2024/09/30 23:55 [entrez] -PHST- 2024/09/30 00:00 [pmc-release] -AID - 10.1186/s12885-024-12942-y [pii] -AID - 12942 [pii] -AID - 10.1186/s12885-024-12942-y [doi] -PST - epublish -SO - BMC Cancer. 2024 Sep 30;24(1):1206. doi: 10.1186/s12885-024-12942-y. - -PMID- 36952645 -OWN - NLM -STAT- MEDLINE -DCOM- 20230327 -LR - 20230331 -IS - 2473-4284 (Electronic) -IS - 2473-4284 (Linking) -VI - 7 -DP - 2023 Mar -TI - Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With - ROS1-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort - Study. -PG - e2200614 -LID - 10.1200/PO.22.00614 [doi] -AB - PURPOSE: Immune checkpoint inhibitors (ICIs) exert robust antitumor activity in - non-small-cell lung cancer (NSCLC) without actionable mutations. Apart from - isolated case reports, the efficacy of PD-1 blockade in ROS1-rearranged NSCLC is - currently unknown. METHODS: This retrospective cohort study included 23 patients - with ROS1-rearranged advanced lung adenocarcinoma who received ICI plus - chemotherapy regardless of the treatment setting. ICI plus chemotherapy was - received as a later-line regimen by 14 patients, as the first-line regimen by six - patients, and after chemoradiotherapy by three patients. RESULTS: All three - patients who received chemoradiotherapy followed by ICI plus chemotherapy - achieved partial response (PR) and had a progression-free survival (PFS) of >17.9 - months. Of the six patients who received first-line ICI plus chemotherapy, five - patients achieved PR and one had stable disease (SD), with a median PFS of 24.3 - months (95% CI, 4.9 to 43.7). Of the 14 previously treated patients who received - later-line ICI plus chemotherapy, the Objective Response Rate (ORR) was 28.6%, - the Disease Control Rate (DCR) was 92.9%, and the median PFS was 5.8 months (95% - CI, 0.2 to 9.4). The median time on ICI therapy was 10.0 months (95% CI, 1.5 to - 32.5). The duration of response was 24.3 months (95% CI, 5.4 to 43.2) and 4.8 - months (95% CI, 2.3 to 12.7) for first-line (n = 5) and subsequent-line (n = 4) - ICI plus chemotherapy, respectively. Of the 10 patients with brain metastasis - before receiving ICI plus chemotherapy, four patients achieved intracranial PR - and five patients achieved intracranial SD, achieving an intracranial ORR of - 40.0% and an intracranial DCR of 90.0%. CONCLUSION: Our retrospective study - provides real-world clinical evidence that ROS1-rearranged NSCLCs benefit from - ICI plus chemotherapy in any treatment setting, including patients who present - with brain metastasis. -FAU - Huang, Zhe -AU - Huang Z -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -AD - Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical - School, University of South China, Hengyang, Hunan, China. -FAU - Yan, Huan -AU - Yan H -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -AD - Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical - School, University of South China, Hengyang, Hunan, China. -FAU - Zeng, Liang -AU - Zeng L -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Xu, Qinqin -AU - Xu Q -AD - Department of Medical Oncology, Qinghai Provincial People's Hospital, Xining, - China. -FAU - Guo, Wenhuan -AU - Guo W -AD - Department of Pathology, Ninth People's Hospital, Shanghai Jiao Tong University - School of Medicine, Shanghai, China. -FAU - Lin, Shaoding -AU - Lin S -AD - Department of Medical Oncology, The First Affiliated Hospital of Hunan University - of Medicine, Huaihua, China. -FAU - Jiang, Wenjuan -AU - Jiang W -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Wang, Zhan -AU - Wang Z -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Deng, Li -AU - Deng L -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Qin, Haoyue -AU - Qin H -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -AD - Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical - School, University of South China, Hengyang, Hunan, China. -FAU - Zhang, Xing -AU - Zhang X -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -AD - Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical - School, University of South China, Hengyang, Hunan, China. -FAU - Tong, Fan -AU - Tong F -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, China. -FAU - Zhang, Ruiguang -AU - Zhang R -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, China. -FAU - Liu, Zhaoyi -AU - Liu Z -AD - Department of Medical Oncology, the Affiliated Cancer Hospital of Xiangya School - of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China. -FAU - Zhang, Lin -AU - Zhang L -AD - Department of Radiotherapy, the Affiliated Cancer Hospital of Xiangya School of - Medicine, Central South University/Hunan Cancer Hospital, Changsha, China. -FAU - Dong, Xiaorong -AU - Dong X -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, China. -FAU - Yang, Nong -AU - Yang N -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -AD - Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical - School, University of South China, Hengyang, Hunan, China. -FAU - Zhang, Yongchang -AU - Zhang Y -AUID- ORCID: 0000-0002-6829-7176 -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -AD - Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical - School, University of South China, Hengyang, Hunan, China. -LA - eng -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -PL - United States -TA - JCO Precis Oncol -JT - JCO precision oncology -JID - 101705370 -RN - 0 (Immune Checkpoint Inhibitors) -RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) -RN - 0 (Proto-Oncogene Proteins) -RN - EC 2.7.10.1 (ROS1 protein, human) -SB - IM -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use -MH - Retrospective Studies -MH - Protein-Tyrosine Kinases/genetics -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - *Lung Neoplasms/drug therapy/genetics -MH - Proto-Oncogene Proteins/genetics -MH - *Adenocarcinoma of Lung/drug therapy/genetics -MH - *Brain Neoplasms -EDAT- 2023/03/24 06:00 -MHDA- 2023/03/28 06:00 -CRDT- 2023/03/23 16:03 -PHST- 2023/03/23 16:03 [entrez] -PHST- 2023/03/24 06:00 [pubmed] -PHST- 2023/03/28 06:00 [medline] -AID - 10.1200/PO.22.00614 [doi] -PST - ppublish -SO - JCO Precis Oncol. 2023 Mar;7:e2200614. doi: 10.1200/PO.22.00614. - -PMID- 34550461 -OWN - NLM -STAT- MEDLINE -DCOM- 20220106 -LR - 20220813 -IS - 1433-7339 (Electronic) -IS - 0941-4355 (Linking) -VI - 30 -IP - 2 -DP - 2022 Feb -TI - Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy - in advanced non-small-cell lung cancer. -PG - 1633-1641 -LID - 10.1007/s00520-021-06572-4 [doi] -AB - PURPOSE: Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) - inhibitors plus chemotherapy have become the standard first line of treatment in - patients with advanced non-small-cell lung cancer (NSCLC). However, few studies - have explicitly focused on the impact of weight loss on the efficacy of - PD-1/PD-L1 inhibitors plus chemotherapy. Thus, we evaluated the clinical - implications of weight loss on the survival outcomes in patients who received - this treatment. METHODS: We conducted a retrospective review of medical records - of patients with advanced NSCLC who were treated with PD-1/PD-L1 inhibitors plus - chemotherapy from December 2018 to December 2020. Significant weight loss was - defined as an unintentional weight loss of 5% or more over 6 months. We evaluated - the progression-free survival (PFS) and overall survival (OS) of patients with or - without weight loss. RESULTS: Among the 80 included patients, 37 (46%) had weight - loss, and were associated with a lower objective response rate (30 vs 51%, - P < 0.05), poorer PFS (2.3 vs 12.0 months, P < 0.05), and poorer OS (10.8 vs - 23.9 months, P < 0.05) than those without weight loss. The Cox - proportional-hazard ratios (95% confidence interval) of weight loss were 1.77 - (1.01-3.10) for PFS and 2.90 (1.40-6.00) for OS, with adjustments for Eastern - Cooperative Oncology Group performance status, PD-L1 tumour proportion score, - histology, and central nervous system metastases. CONCLUSION: Pre-treatment - weight loss may reduce treatment efficacy and shorten survival time in patients - receiving PD-1/PD-L1 inhibitors plus chemotherapy. Early evaluation and - intervention for weight loss might improve oncological outcomes in patients with - advanced NSCLC. -CI - © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, - part of Springer Nature. -FAU - Miyawaki, Taichi -AU - Miyawaki T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -AD - Department of Respiratory Medicine, Juntendo University Graduate School of - Medicine, Tokyo, Japan. -FAU - Naito, Tateaki -AU - Naito T -AUID- ORCID: 0000-0003-4047-2929 -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. - t.naito@scchr.jp. -FAU - Yabe, Michitoshi -AU - Yabe M -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Kodama, Hiroaki -AU - Kodama H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Nishioka, Naoya -AU - Nishioka N -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Miyawaki, Eriko -AU - Miyawaki E -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Mamesaya, Nobuaki -AU - Mamesaya N -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Kobayashi, Haruki -AU - Kobayashi H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Omori, Shota -AU - Omori S -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Wakuda, Kazushige -AU - Wakuda K -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Ono, Akira -AU - Ono A -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Kenmotsu, Hirotsugu -AU - Kenmotsu H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Murakami, Haruyasu -AU - Murakami H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Mori, Keita -AU - Mori K -AD - Division of Clinical Research Management Office, Shizuoka Cancer Center, - Shizuoka, Japan. -FAU - Harada, Hideyuki -AU - Harada H -AD - Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Takahashi, Kazuhisa -AU - Takahashi K -AD - Department of Respiratory Medicine, Juntendo University Graduate School of - Medicine, Tokyo, Japan. -FAU - Takahashi, Toshiaki -AU - Takahashi T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -LA - eng -PT - Journal Article -DEP - 20210922 -PL - Germany -TA - Support Care Cancer -JT - Supportive care in cancer : official journal of the Multinational Association of - Supportive Care in Cancer -JID - 9302957 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - *Lung Neoplasms/drug therapy -MH - Programmed Cell Death 1 Receptor -MH - Retrospective Studies -MH - Weight Loss -OTO - NOTNLM -OT - Cancer cachexia -OT - Non-small cell lung cancer -OT - PD-1/PD-L1 inhibitor plus chemotherapy -OT - Programmed death-ligand 1 -OT - Weight loss -EDAT- 2021/09/23 06:00 -MHDA- 2022/01/07 06:00 -CRDT- 2021/09/22 12:28 -PHST- 2021/05/14 00:00 [received] -PHST- 2021/09/10 00:00 [accepted] -PHST- 2021/09/23 06:00 [pubmed] -PHST- 2022/01/07 06:00 [medline] -PHST- 2021/09/22 12:28 [entrez] -AID - 10.1007/s00520-021-06572-4 [pii] -AID - 10.1007/s00520-021-06572-4 [doi] -PST - ppublish -SO - Support Care Cancer. 2022 Feb;30(2):1633-1641. doi: 10.1007/s00520-021-06572-4. - Epub 2021 Sep 22. - -PMID- 35412172 -OWN - NLM -STAT- MEDLINE -DCOM- 20220719 -LR - 20220818 -IS - 1573-0646 (Electronic) -IS - 0167-6997 (Linking) -VI - 40 -IP - 4 -DP - 2022 Aug -TI - The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in - patients with advanced non-small-cell lung cancer: a meta-analysis. -PG - 810-817 -LID - 10.1007/s10637-022-01232-8 [doi] -AB - OBJECTIVE: To evaluate the efficacy and safety of immune checkpoint inhibitor - (ICI) and chemotherapy (CT) versus CT alone in advanced non-small-cell lung - cancer (NSCLC). METHODS: Databases (PubMed, Embase and Cochrane Library) were - searched for relevant randomized controlled trials (RCTs). Clinical outcome - measures including overall survival (OS), progression-free survival (PFS), - objective response rate (ORR), and grade 3-5 treatment-related adverse events - (AEs) were analyzed by Stata 15.0 software; significance level was 0.05. RESULTS: - Eight RCTs involving 4227 patients were included. The results showed ICI + CT - significantly improved OS (hazard ratio [HR] = 0.74, 95% CI: 0.62-0.85, - p < 0.001), PFS (HR = 0.66, 95% CI: 0.57 - 0.75, p < 0.001) and ORR (odds ratio - [OR] = 1.89; 95% CI, 1.43-2.49, p < 0.001) compared with CT alone. Subgroup - analysis indicated that significantly longer OS was also observed in subgroups - including combination regimens (pembrolizumab + CT, atezolizumab + CT, - ipilimumab + CT, and nivolumab + ipilimumab + CT) and PD-L1 status [negative - (< 1%), positive (≥ 1%), low (1-49%) and high (≥ 50%)]. However, ICI + CT showed - signifcantly higher grade 3-5 treatment-related AEs than CT (OR = 1.46, 95% CI: - 1.19 - 1.79, p < 0.001). CONCLUSIONS: ICI + CT showed better clinical efficacy - than CT alone in patients with advanced NSCLC, with increased treatment-related - AEs. -CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business - Media, LLC, part of Springer Nature. -FAU - Meng, Li-Fang -AU - Meng LF -AUID- ORCID: 0000-0003-0606-3048 -AD - Respiratory Department, Binyang County People's Hospital, Ren-Ai Street No.137, - Binyang, Guangxi, China. xinfang121627@163.com. -FAU - Huang, Jian-Feng -AU - Huang JF -AD - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical - University, 530000, Nanning, Guangxi, China. -FAU - Luo, Peng-Hui -AU - Luo PH -AD - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical - University, 530000, Nanning, Guangxi, China. -FAU - Huang, Shang-Xiao -AU - Huang SX -AD - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical - University, 530000, Nanning, Guangxi, China. -FAU - Wang, Han-Lei -AU - Wang HL -AD - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical - University, 530000, Nanning, Guangxi, China. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Review -DEP - 20220412 -PL - United States -TA - Invest New Drugs -JT - Investigational new drugs -JID - 8309330 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Ipilimumab) -SB - IM -MH - *Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - Humans -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Ipilimumab/therapeutic use -MH - *Lung Neoplasms/drug therapy/pathology -OTO - NOTNLM -OT - Efficacy and safety -OT - Immune checkpoint inhibitor -OT - Non-small-cell lung cancer -OT - PD-1/PD-L1 -OT - PD-L1 expression level -EDAT- 2022/04/13 06:00 -MHDA- 2022/07/20 06:00 -CRDT- 2022/04/12 12:07 -PHST- 2022/01/12 00:00 [received] -PHST- 2022/03/09 00:00 [accepted] -PHST- 2022/04/13 06:00 [pubmed] -PHST- 2022/07/20 06:00 [medline] -PHST- 2022/04/12 12:07 [entrez] -AID - 10.1007/s10637-022-01232-8 [pii] -AID - 10.1007/s10637-022-01232-8 [doi] -PST - ppublish -SO - Invest New Drugs. 2022 Aug;40(4):810-817. doi: 10.1007/s10637-022-01232-8. Epub - 2022 Apr 12. - -PMID- 34810130 -OWN - NLM -STAT- MEDLINE -DCOM- 20220517 -LR - 20220520 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 23 -IP - 3 -DP - 2022 May -TI - PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites - in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 - NIRVANA-Lung Trial. -PG - e252-e256 -LID - S1525-7304(21)00269-2 [pii] -LID - 10.1016/j.cllc.2021.10.008 [doi] -AB - Advanced non-small cell lung cancer (NSCLC) remains a high unmet medical need. - The first line standard-of-care therapy comprises concurrent - chemotherapy-immunotherapy with pembrolizumab. Concurrent irradiation with - pembrolizumab has been shown to significantly improve survival benefit compared - with immunotherapy alone in a pooled analysis of 2 randomized phase 2 trials. We - present the rationale and study design of the "PD-1 iNhibitor and chemotherapy - with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung - cAncer" (NIRVANA-Lung) trial (ClinicalTrials.gov identifier, NCT03774732). This - study is a national multicenter 1:1 randomized phase III trial testing in 460 - patients, the addition of multisite radiotherapy in advanced NSCLC treated with - standard immune checkpoint inhibitors (pembrolizumab)-chemotherapy in first line. - The primary objective of the trial is to compare the overall survival between the - 2 arms at year 1 of the study. The secondary objective is to compare the - progression-free survival and cancer-specific survival at year 1 and 2, as well - as to determine quality of life, local and distant control in irradiated and - nonirradiated sites at 6 months and year 1. -CI - Copyright © 2021 Elsevier Inc. All rights reserved. -FAU - Doyen, Jérôme -AU - Doyen J -AD - Department of Radiation Oncology, Centre Antoine-Lacassagne, University of Côte - d'Azur, Fédération Claude-Lalanne, Nice, France. Electronic address: - jerome.doyen@nice.unicancer.fr. -FAU - Besse, Benjamin -AU - Besse B -AD - Department of Medical Oncology, Gustave Roussy, Villejuif, France; Université - Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France. -FAU - Texier, Matthieu -AU - Texier M -AD - Department of Statistics, Gutave Roussy, Villejuif, France. -FAU - Bonnet, Naima -AU - Bonnet N -AD - Research Group in Radiotherapy of Unicancer (UNITRAD), UNICANCER, Paris, France. -FAU - Levy, Antonin -AU - Levy A -AD - Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; - Department of Radiation Oncology, International Center for Thoracic Cancers - (CICT), Gustave Roussy, Villejuif, France; Université Paris-Saclay, INSERM U1030, - Molecular Radiotherapy, Villejuif, France. Electronic address: - antonin.levy@gustaveroussy.fr. -LA - eng -SI - ClinicalTrials.gov/NCT03774732 -PT - Clinical Trial, Phase II -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20211024 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Lung/pathology -MH - *Lung Neoplasms/drug therapy -MH - Prospective Studies -MH - Quality of Life -OTO - NOTNLM -OT - Advanced non-small-cell lung cancer -OT - Chemotherapy -OT - Immune checkpoint inhibitors -OT - Multisite radiotherapy -OT - PD-1 -OT - Phase III trial -EDAT- 2021/11/24 06:00 -MHDA- 2022/05/18 06:00 -CRDT- 2021/11/23 05:51 -PHST- 2021/03/25 00:00 [received] -PHST- 2021/10/08 00:00 [revised] -PHST- 2021/10/11 00:00 [accepted] -PHST- 2021/11/24 06:00 [pubmed] -PHST- 2022/05/18 06:00 [medline] -PHST- 2021/11/23 05:51 [entrez] -AID - S1525-7304(21)00269-2 [pii] -AID - 10.1016/j.cllc.2021.10.008 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2022 May;23(3):e252-e256. doi: 10.1016/j.cllc.2021.10.008. Epub - 2021 Oct 24. - -PMID- 32943323 -OWN - NLM -STAT- MEDLINE -DCOM- 20210922 -LR - 20210922 -IS - 1879-0593 (Electronic) -IS - 1368-8375 (Linking) -VI - 112 -DP - 2021 Jan -TI - Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 - inhibitor toripalimab: A case report. -PG - 104992 -LID - S1368-8375(20)30428-0 [pii] -LID - 10.1016/j.oraloncology.2020.104992 [doi] -AB - INTRODUCTION: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of - non-small cell lung carcinoma (NSCLC), which characterized by insensitive to - conventional radiotherapy and chemotherapy and poor prognosis. Except MET exon 14 - alterations and other oncogene mutations, PSC commonly harbor high tumor - mutational burden (TMB) and high level of PD-L1, which provide new therapeutic - opportunities. Toripalimab (JS001) is IgG4 monoclonal antibody targeting PD-1, - which has been approved for treatment of patients with metastatic melanoma after - previous systemic therapy. PD-1 combined with radiotherapy has been tried in - several cancer types. CASE PRESENTATION: We reported a case of a PSC patient with - PD-L1 overexpression responding to toripalimab and after progression the patients - also benefits from toripalimab combined with local radiotherapy, which provides a - promising option for PSC patients. CONCLUSION: This case provides the evidence of - the effective role of toripalimab and PD-1 combined with local radiotherapy in - PSC patients, which was the first application as far as we know. -CI - Copyright © 2020 Elsevier Ltd. All rights reserved. -FAU - Jiao, Yuyan -AU - Jiao Y -AD - Department of Oncology, Taian City Central Hospital, Taian, China. -FAU - Liu, Ming -AU - Liu M -AD - Department of Oncology, Taian City Central Hospital, Taian, China. -FAU - Luo, Ningning -AU - Luo N -AD - The State Key Laboratory of Translational Medicine and Innovative Drug - Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China. -FAU - Guo, Hao -AU - Guo H -AD - The State Key Laboratory of Translational Medicine and Innovative Drug - Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China. -FAU - Li, Jianzhe -AU - Li J -AD - Department of Oncology, Taian City Central Hospital, Taian, China. Electronic - address: lijianzheta@126.com. -LA - eng -PT - Case Reports -PT - Letter -DEP - 20200915 -PL - England -TA - Oral Oncol -JT - Oral oncology -JID - 9709118 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Indoles) -RN - 0 (Quinolines) -RN - 0 (anlotinib) -RN - 8JXN261VVA (toripalimab) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors/metabolism -MH - Carcinoma/*drug therapy/genetics/metabolism -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/metabolism -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Indoles/therapeutic use -MH - Lung Neoplasms/*drug therapy/genetics/metabolism -MH - Male -MH - Mutation Rate -MH - Quinolines/therapeutic use -MH - Rare Diseases/*drug therapy/genetics/metabolism -MH - Treatment Outcome -OTO - NOTNLM -OT - High level of PD-L1 -OT - PD-1 inhibitor -OT - Pulmonary sarcomatoid carcinoma -OT - Toripalimab -OT - Toripalimab combined with thoracic radiotherapy -EDAT- 2020/09/19 06:00 -MHDA- 2021/09/23 06:00 -CRDT- 2020/09/18 05:37 -PHST- 2020/08/27 00:00 [received] -PHST- 2020/08/31 00:00 [accepted] -PHST- 2020/09/19 06:00 [pubmed] -PHST- 2021/09/23 06:00 [medline] -PHST- 2020/09/18 05:37 [entrez] -AID - S1368-8375(20)30428-0 [pii] -AID - 10.1016/j.oraloncology.2020.104992 [doi] -PST - ppublish -SO - Oral Oncol. 2021 Jan;112:104992. doi: 10.1016/j.oraloncology.2020.104992. Epub - 2020 Sep 15. - -PMID- 38311031 -OWN - NLM -STAT- MEDLINE -DCOM- 20240318 -LR - 20240906 -IS - 1879-0887 (Electronic) -IS - 0167-8140 (Print) -IS - 0167-8140 (Linking) -VI - 193 -DP - 2024 Apr -TI - Survival outcomes and toxicity of adjuvant immunotherapy after definitive - concurrent chemotherapy with proton beam radiation therapy for patients with - inoperable locally advanced non-small cell lung carcinoma. -PG - 110121 -LID - S0167-8140(24)00042-2 [pii] -LID - 10.1016/j.radonc.2024.110121 [doi] -AB - INTRODUCTION: Adjuvant immunotherapy (IO) following concurrent chemotherapy and - photon radiation therapy confers an overall survival (OS) benefit for patients - with inoperable locally advanced non-small cell lung carcinoma (LA-NSCLC); - however, outcomes of adjuvant IO after concurrent chemotherapy with proton beam - therapy (CPBT) are unknown. We investigated OS and toxicity after CPBT with - adjuvant IO versus CPBT alone for inoperable LA-NSCLC. MATERIALS AND METHODS: We - analyzed 354 patients with LA-NSCLC who were prospectively treated with CPBT with - or without adjuvant IO from 2009 to 2021. Optimal variable ratio propensity score - matching (PSM) matched CPBT with CPBT + IO patients. Survival was estimated with - the Kaplan-Meier method and compared with log-rank tests. Multivariable Cox - proportional hazards regression evaluated the effect of IO on disease outcomes. - RESULTS: Median age was 70 years; 71 (20%) received CPBT + IO and 283 (80%) - received CPBT only. After PSM, 71 CPBT patients were matched with 71 CPBT + IO - patients. Three-year survival rates for CPBT + IO vs CPBT were: OS 67% vs 30% - (P < 0.001) and PFS 59% vs 35% (P = 0.017). Three-year LRFS (P = 0.137) and DMFS - (P = 0.086) did not differ. Receipt of adjuvant IO was a strong predictor of OS - (HR 0.40, P = 0.001) and PFS (HR 0.56, P = 0.030), but not LRFS (HR 0.61, - P = 0.121) or DMFS (HR 0.61, P = 0.136). There was an increased incidence of - grade ≥3 esophagitis in the CPBT-only group (6% CPBT + IO vs 17% CPBT, - P = 0.037). CONCLUSION: This study, one of the first to investigate CPBT followed - by IO for inoperable LA-NSCLC, showed that IO conferred survival benefits with no - increased rates of toxicity. -CI - Copyright © 2024 Elsevier B.V. All rights reserved. -FAU - Corrigan, Kelsey L -AU - Corrigan KL -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Xu, Ting -AU - Xu T -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. Electronic address: TXu@mdanderson.org. -FAU - Sasaki, Yuki -AU - Sasaki Y -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Lin, Ruitao -AU - Lin R -AD - Department of Biostatics and Computational Science, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Chen, Aileen B -AU - Chen AB -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Welsh, James W -AU - Welsh JW -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Lin, Steven H -AU - Lin SH -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Chang, Joe Y -AU - Chang JY -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Ning, Matthew S -AU - Ning MS -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Gandhi, Saumil -AU - Gandhi S -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - O'Reilly, Michael S -AU - O'Reilly MS -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Gay, Carl M -AU - Gay CM -AD - Department of Thoracic-Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Altan, Mehmet -AU - Altan M -AD - Department of Thoracic-Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Lu, Charles -AU - Lu C -AD - Department of Thoracic-Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Cascone, Tina -AU - Cascone T -AD - Department of Thoracic-Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Koutroumpakis, Efstratios -AU - Koutroumpakis E -AD - Department of Cardiology, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Sheshadri, Ajay -AU - Sheshadri A -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Zhang, Xiaodong -AU - Zhang X -AD - Department of Radiation Physics, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Liao, Li -AU - Liao L -AD - Department of Radiation Physics, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Zhu, X Ronald -AU - Zhu XR -AD - Department of Radiation Physics, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Heymach, John V -AU - Heymach JV -AD - Department of Thoracic-Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Nguyen, Quynh-Nhu -AU - Nguyen QN -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Liao, Zhongxing -AU - Liao Z -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. Electronic address: Zliao@mdanderson.org. -LA - eng -GR - P30 CA016672/CA/NCI NIH HHS/United States -GR - R01 HL157273/HL/NHLBI NIH HHS/United States -PT - Journal Article -DEP - 20240203 -PL - Ireland -TA - Radiother Oncol -JT - Radiotherapy and oncology : journal of the European Society for Therapeutic - Radiology and Oncology -JID - 8407192 -SB - IM -MH - Humans -MH - Aged -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Proton Therapy/adverse effects -MH - Chemotherapy, Adjuvant -MH - *Lung Neoplasms/pathology -MH - Immunotherapy/adverse effects -MH - Retrospective Studies -PMC - PMC10947851 -MID - NIHMS1966693 -COIS- Declaration of Competing Interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2024/02/05 00:42 -MHDA- 2024/03/18 06:44 -PMCR- 2025/04/01 -CRDT- 2024/02/04 19:28 -PHST- 2023/10/09 00:00 [received] -PHST- 2024/01/26 00:00 [revised] -PHST- 2024/01/28 00:00 [accepted] -PHST- 2025/04/01 00:00 [pmc-release] -PHST- 2024/03/18 06:44 [medline] -PHST- 2024/02/05 00:42 [pubmed] -PHST- 2024/02/04 19:28 [entrez] -AID - S0167-8140(24)00042-2 [pii] -AID - 10.1016/j.radonc.2024.110121 [doi] -PST - ppublish -SO - Radiother Oncol. 2024 Apr;193:110121. doi: 10.1016/j.radonc.2024.110121. Epub - 2024 Feb 3. - -PMID- 35105168 -OWN - NLM -STAT- MEDLINE -DCOM- 20220325 -LR - 20220325 -IS - 1744-8301 (Electronic) -IS - 1479-6694 (Linking) -VI - 18 -IP - 7 -DP - 2022 Mar -TI - Cost-effectiveness of immune checkpoint inhibitors in the treatment of - non-small-cell lung cancer as a second line in Taiwan. -PG - 859-870 -LID - 10.2217/fon-2021-0785 [doi] -AB - Objectives: To evaluate the cost-effectiveness of immune checkpoint inhibitors - versus docetaxel in patients with advanced non-small-cell lung cancer. Methods: A - Markov model was constructed to simulate the clinical outcomes and costs of - advanced non-small-cell lung cancer. Clinical outcomes data were derived from - randomized clinical trials. Drug acquisition cost and other health resource use - were obtained from the claim data of a tertiary hospital and the National Health - Insurance. The outcome was an incremental cost-effectiveness ratio expressed as - cost per quality-adjusted life year gained. One-way and probabilistic sensitivity - analyses were performed to evaluate the uncertainty of the model parameters. - Results: In the base case, patients treated with immunotherapies in the second - line were associated with higher costs and higher mean survival. The incremental - costs per quality-adjusted life year gained for pembrolizumab, nivolumab, or - atezolizumab compared to docetaxel were NT$416,102, NT$1,572,912 and - NT$1,580,469, respectively. Conclusion: The results showed that pembrolizumab was - more cost effective than nivolumab and atezolizumab compared with docetaxel as a - second-line regimen for patients with previously treated advanced non-small-cell - lung cancer at willingness to pay threshold in Taiwan. -FAU - Leung, John Hang -AU - Leung JH -AD - Department of Obstetrics & Gynecology, Ditmanson Medical Foundation Chia-Yi - Christian Hospital, Chiayi, 600, Taiwan. -FAU - Chang, Chih-Wen -AU - Chang CW -AD - Institute of Hospital & Healthcare Administration, National Yang Ming Chiao Tung - University, Taipei, 112, Taiwan. -FAU - Chan, Agnes Lf -AU - Chan AL -AUID- ORCID: 0000-0003-4071-8132 -AD - Department of Pharmacy, An-Nan Hospital, China Medical University, Tainan, 709, - Taiwan. -FAU - Lang, Hui-Chu -AU - Lang HC -AUID- ORCID: 0000-0003-2762-4385 -AD - Institute of Hospital & Healthcare Administration, National Yang Ming Chiao Tung - University, Taipei, 112, Taiwan. -LA - eng -PT - Journal Article -DEP - 20220202 -PL - England -TA - Future Oncol -JT - Future oncology (London, England) -JID - 101256629 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 15H5577CQD (Docetaxel) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Cost-Benefit Analysis -MH - Docetaxel/economics -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/*economics -MH - Lung Neoplasms/*drug therapy -MH - Male -MH - Middle Aged -MH - Randomized Controlled Trials as Topic -MH - Taiwan -OAB - Plain language summary Lung cancer is the first leading cause of cancer death in - Taiwan. About 75% of patients have advanced disease at the time of diagnosis - (stage III/IV) with a median survival of 13.2 months. Most non-small-cell lung - cancer (NSCLC) patients are usually diagnosed at a late stage. The conventional - chemotherapy, surgery or radiation regimens may not be of significant benefits. - Fortunately, newer immunotherapies or targeted therapies have improved the 5-year - survival rates of advanced NSCLC from 15 to 50% with high cost. This study aimed - to assess if the newer targeted therapies are cost effective and provide ‘value - for money’ compared with chemotherapy in NSCLC patients with advanced stage. A - cost–effectiveness model was created based on the data from the real-world and - published phase III randomized controlled trials. The results showed that - pembrolizumab is more cost effective than nivolumab and atezolizumab compared - with docetaxel as a second-line regimen for patients with previously treated - advanced NSCLC at willingness to pay threshold in Taiwan. -OABL- eng -OTO - NOTNLM -OT - PD-L1-positive -OT - advanced NSCLC -OT - atezolizumab -OT - cost–effectiveness -OT - nivolumab and docetaxel -OT - pembrolizumab -EDAT- 2022/02/03 06:00 -MHDA- 2022/03/26 06:00 -CRDT- 2022/02/02 05:28 -PHST- 2022/02/03 06:00 [pubmed] -PHST- 2022/03/26 06:00 [medline] -PHST- 2022/02/02 05:28 [entrez] -AID - 10.2217/fon-2021-0785 [doi] -PST - ppublish -SO - Future Oncol. 2022 Mar;18(7):859-870. doi: 10.2217/fon-2021-0785. Epub 2022 Feb - 2. - -PMID- 36330681 -OWN - NLM -STAT- MEDLINE -DCOM- 20230306 -LR - 20230316 -IS - 1878-0261 (Electronic) -IS - 1574-7891 (Print) -IS - 1574-7891 (Linking) -VI - 17 -IP - 3 -DP - 2023 Mar -TI - Atezolizumab and stereotactic body radiotherapy in patients with advanced - non-small cell lung cancer: safety, clinical activity and ctDNA responses-the - ComIT-1 trial. -PG - 487-498 -LID - 10.1002/1878-0261.13330 [doi] -AB - The introduction of immune checkpoint inhibitors has transformed the treatment - landscape of metastatic non-small cell lung cancer. However, challenges remain to - increase the fraction of patients achieving durable clinical responses to these - drugs and to help monitor the treatment effect. In this phase II trial, we - investigated the toxicity, systemic responses and circulating tumour DNA - responses in patients (n = 21) with advanced non-small-cell lung cancer treated - with atezolizumab and stereotactic body radiotherapy in the second or later line. - We found the combined treatment to be safe with grade 3 toxicity reported in - three patients. As the best overall response, four patients had a partial - response, eight had stable disease and five had progressive disease. Median - overall survival time was still not reached after a median follow-up of - 26.5 months and 10/15 patients with programmed death-ligand 1 negative tumours - were alive >18 months after the start of the study treatment. ctDNA was - detectable at baseline in 11 patients. A rapid decline in ctDNA to <30% of - baseline levels was seen in three patients, two of which were radiographic - responders and one was considered clinically benefiting from therapy for almost - 1 year. -CI - © 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on - behalf of Federation of European Biochemical Societies. -FAU - Horndalsveen, Henrik -AU - Horndalsveen H -AUID- ORCID: 0000-0002-6806-6116 -AD - Department of Oncology, Oslo University Hospital, Norway. -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, Norway. -FAU - Alver, Tine Norman -AU - Alver TN -AUID- ORCID: 0000-0002-3681-4511 -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, Norway. -AD - Department of Clinical Medicine, University of Oslo, Norway. -FAU - Dalsgaard, Astrid Marie -AU - Dalsgaard AM -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, Norway. -FAU - Rogg, Lotte Victoria -AU - Rogg LV -AD - Department of Oncology, Oslo University Hospital, Norway. -FAU - Helbekkmo, Nina -AU - Helbekkmo N -AUID- ORCID: 0000-0003-4748-4914 -AD - Department of Pulmonology, University Hospital of North Norway, Tromsø, Norway. -FAU - Grønberg, Bjørn Henning -AU - Grønberg BH -AUID- ORCID: 0000-0001-5744-1534 -AD - Department of Clinical and Molecular Medicine, NTNU, Norwegian University of - Science and Technology, Trondheim, Norway. -AD - Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, - Norway. -FAU - Halvorsen, Tarje Onsøien -AU - Halvorsen TO -AUID- ORCID: 0000-0002-1181-921X -AD - Department of Clinical and Molecular Medicine, NTNU, Norwegian University of - Science and Technology, Trondheim, Norway. -AD - Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, - Norway. -FAU - Ramberg, Christina -AU - Ramberg C -AD - Department of Medical Physics, Oslo University Hospital, Norway. -FAU - Haakensen, Vilde Drageset -AU - Haakensen VD -AUID- ORCID: 0000-0003-0864-3628 -AD - Department of Oncology, Oslo University Hospital, Norway. -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, Norway. -FAU - Öjlert, Åsa Kristina -AU - Öjlert ÅK -AUID- ORCID: 0000-0002-2888-8406 -AD - Department of Oncology, Oslo University Hospital, Norway. -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, Norway. -FAU - Bjaanaes, Maria Moksnes -AU - Bjaanaes MM -AUID- ORCID: 0000-0001-7126-9064 -AD - Department of Oncology, Oslo University Hospital, Norway. -FAU - Helland, Åslaug -AU - Helland Å -AUID- ORCID: 0000-0002-5520-0275 -AD - Department of Oncology, Oslo University Hospital, Norway. -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, Norway. -AD - Department of Clinical Medicine, University of Oslo, Norway. -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20221122 -PL - United States -TA - Mol Oncol -JT - Molecular oncology -JID - 101308230 -RN - 52CMI0WC3Y (atezolizumab) -RN - 0 (Antibodies, Monoclonal, Humanized) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/radiotherapy -MH - *Lung Neoplasms/drug therapy/genetics/radiotherapy -MH - *Radiosurgery -MH - Antibodies, Monoclonal, Humanized/adverse effects -PMC - PMC9980306 -OTO - NOTNLM -OT - NSCLC -OT - circulating tumour DNA -OT - immunotherapy -OT - liquid biopsy -OT - radiotherapy -COIS- Henrik Horndalsveen: Advisory board: Janssen. Honoraria: AstraZeneca, Pfizer, - Roche. Bjørn Henning Grønberg: Advisory board: AstraZeneca, BMS, Debiopharm, Eli - Lilly, Janssen, MSD, Novartis, Pfizer, Roche, Takeda. Honoraria: AstraZeneca, - Bayer, BMS, Bohringer Ingelheim, Debiopharm, Eli Lilly, MSD, Novartis, Pfizer, - Pierre Fabre, Roche, Sanofi, Takeda. Research funding: AstraZeneca, Roche. - Spouse: Employee and shareholder of Eli Lilly and Company. Tarje Onsøien - Halvorsen: Honoraria: AstraZeneca, MSD, Pierre Fabre, Pfizer. Travel support: - AstraZeneca, MSD. Vilde Drageset Haakensen: Advisory boards: Novartis, Astra - Zeneca, Pfizer. Honoraria: BMS, Astra Zeneca, Takeda. Åslaug Helland: Financial - support and/or study drug from AstraZeneca, Roche, Novartis, Incyte, Eli Lilly, - Ultimovacs and BMS, in association with clinical studies. Adv board: AstraZeneca, - BMS, Janssen, MSD, Pfizer, Roche, Takeda, Sanofi, Bayer, Abbvie. The remaining - authors declare that they have no competing interests. -EDAT- 2022/11/05 06:00 -MHDA- 2023/03/07 06:00 -PMCR- 2022/11/22 -CRDT- 2022/11/04 03:43 -PHST- 2022/09/02 00:00 [revised] -PHST- 2022/05/20 00:00 [received] -PHST- 2022/11/01 00:00 [accepted] -PHST- 2022/11/05 06:00 [pubmed] -PHST- 2023/03/07 06:00 [medline] -PHST- 2022/11/04 03:43 [entrez] -PHST- 2022/11/22 00:00 [pmc-release] -AID - MOL213330 [pii] -AID - 10.1002/1878-0261.13330 [doi] -PST - ppublish -SO - Mol Oncol. 2023 Mar;17(3):487-498. doi: 10.1002/1878-0261.13330. Epub 2022 Nov - 22. - -PMID- 30113497 -OWN - NLM -STAT- MEDLINE -DCOM- 20180824 -LR - 20220331 -IS - 1536-5964 (Electronic) -IS - 0025-7974 (Print) -IS - 0025-7974 (Linking) -VI - 97 -IP - 33 -DP - 2018 Aug -TI - Comparative analysis of immune checkpoint inhibitors and chemotherapy in the - treatment of advanced non-small cell lung cancer: A meta-analysis of randomized - controlled trials. -PG - e11936 -LID - 10.1097/MD.0000000000011936 [doi] -LID - e11936 -AB - BACKGROUND: Recently, immune checkpoint inhibitors have shown survival advantage - over chemotherapy in the treatment of advanced non-small cell lung cancer - (NSCLC). This meta-analysis was conducted to gather and analyze the available - evidence (Evidence level I; Randomized Controlled Trials) comparing efficacy and - safety of anti-programmed cell death-1 (PD1)/programmed cell death ligand 1 - (PD-L1) therapies and chemotherapy in the treatment of advanced NSCLC. METHODS: A - search strategy was devised to identify the randomized controlled trials (RCTs) - using electronic databases of PubMed, Cochrane Library, and Web of Science. - Hazard ratios or odds ratios obtained for overall survival (OS), progression-free - survival (PFS), objective response rate (ORR), and treatment related adverse - events (TRAEs) were analyzed using fixed effect model or random effects model. - Additionally, subgroup analysis was also performed. RESULTS: A total of seven - RCTs (n = 3867) were identified and selected for inclusion in this meta-analysis. - Anti-PD1/PD-L1 therapies (nivolumab, pembrolizumab, atezolizumab) resulted in - better OS (HR 0.72 [95% confidence interval [CI] 0.63, 0.82; P < .00001]), PFS - (HR 0.84 [95% CI 0.72, 0.97; P < .02]), and ORR (odds ratio [OR] 1.52 [95% CI - 1.08, 2.14; P < .02]) in comparison to chemotherapy in advanced NSCLC. Improved - safety was observed with anti-PD1/PD-L1 therapies (OR 0.31 [95%CI 0.26, 0.38; - P < .00001]). Subgroups analysis revealed Eastern Cooperative Oncology Group - Performance Status (ECOG PS) 1 (HR 0.76 [95%CI 0.62, 0.93; P = .007]), squamous - cell type (HR 0.76 [95% CI 0.63, 0.92; P = .005]), current/former smoker (HR 0.76 - [95% CI 0.63, 0.92; P = .005]), epidermal growth factor receptor (EGFR) wild type - (HR 0.67 [95% CI 0.60, 0.76; P < .00001]), Kirsten rat sarcoma oncogene mutation - (KRAS) mutant (HR 0.60 [95% CI 0.39, 0.93; P < .02]), and absence of central - nervous system (CNS) metastases (HR 0.71 [95% CI 0.63, 0.80; P < .00001]) were - associated with better overall survival. CONCLUSIONS: Anti-PD1/PD-L1 therapies - are safe and effective treatment option in advanced non-small cell lung cancer - and can be recommended selectively. -FAU - Khan, Muhammad -AU - Khan M -AD - Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of - Guangzhou Medical University Department of Radiation Oncology, Sun Yat-sen - University Cancer Center, Sun Yat-sen Medical University, Guangzhou, Guangdong - Province, People's Republic of China. -FAU - Lin, Jie -AU - Lin J -FAU - Liao, Guixiang -AU - Liao G -FAU - Tian, Yunhong -AU - Tian Y -FAU - Liang, Yingying -AU - Liang Y -FAU - Li, Rong -AU - Li R -FAU - Liu, Mengzhong -AU - Liu M -FAU - Yuan, Yawei -AU - Yuan Y -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Review -PL - United States -TA - Medicine (Baltimore) -JT - Medicine -JID - 2985248R -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 31YO63LBSN (Nivolumab) -RN - 52CMI0WC3Y (atezolizumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - Antineoplastic Agents/*therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology -MH - Cell Cycle Checkpoints/*drug effects -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/immunology -MH - Male -MH - Middle Aged -MH - Nivolumab -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - Randomized Controlled Trials as Topic -MH - Treatment Outcome -PMC - PMC6113026 -COIS- The authors declare no conflict of interest in preparing this article. -EDAT- 2018/08/17 06:00 -MHDA- 2018/08/25 06:00 -PMCR- 2018/08/17 -CRDT- 2018/08/17 06:00 -PHST- 2018/08/17 06:00 [entrez] -PHST- 2018/08/17 06:00 [pubmed] -PHST- 2018/08/25 06:00 [medline] -PHST- 2018/08/17 00:00 [pmc-release] -AID - 00005792-201808170-00048 [pii] -AID - MD-D-18-02043 [pii] -AID - 10.1097/MD.0000000000011936 [doi] -PST - ppublish -SO - Medicine (Baltimore). 2018 Aug;97(33):e11936. doi: 10.1097/MD.0000000000011936. - -PMID- 34072448 -OWN - NLM -STAT- MEDLINE -DCOM- 20210603 -LR - 20210627 -IS - 1648-9144 (Electronic) -IS - 1010-660X (Print) -IS - 1010-660X (Linking) -VI - 57 -IP - 6 -DP - 2021 May 29 -TI - Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung - Cancer after Chemoradiotherapy: Case Report. -LID - 10.3390/medicina57060547 [doi] -LID - 547 -AB - Chemoimmunotherapy has become the standard of care as the first-line treatment of - advanced or recurrent non-small-cell lung cancer (NSCLC). The - bevacizumab-containing chemoimmunotherapy regimen is theoretically more effective - than a non-bevacizumab-containing regimen via two mechanisms: a superior outcome - of bevacizumab-containing chemothrerapy than the standard platinum doublet - regimen, and the synergistic effect of bevacizumab with an immune checkpoint - inhibitor (ICI). Bevacizumab effectively normalizes vascularization, especially - when the vascular bed is damaged by previous treatment. Bevacizumab promotes - immunomodulation when used with ICI. We describe a patient with nonsquamous NSCLC - who returned 2.5 years after definitive chemoradiotherapy for postoperative - locoregional recurrence in the right supraclavicular lymph node. Considering the - destroyed vascular bed due to prior chemoradiotherapy, attaining vascular - normalization was critical for effective drug delivery. The patient was treated - with a bevacizumab-containing chemoimmunotherapy regimen, which resulted in a - complete metabolic response. The patient responded well for 23 months and is - receiving ongoing treatment. Thus, bevacizumab-containing chemoimmunotherapy - could be advantageous in some recurrent cases after chemoradiotherapy. -FAU - Kataoka, Nobutaka -AU - Kataoka N -AD - Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, - Kyoto 602-8031, Japan. -FAU - Kunimatsu, Yusuke -AU - Kunimatsu Y -AD - Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, - Kyoto 602-8031, Japan. -FAU - Tsutsumi, Rei -AU - Tsutsumi R -AD - Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, - Kyoto 602-8031, Japan. -FAU - Tani, Nozomi -AU - Tani N -AD - Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, - Kyoto 602-8031, Japan. -FAU - Sato, Izumi -AU - Sato I -AUID- ORCID: 0000-0003-3310-3615 -AD - Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, - Kyoto 602-8031, Japan. -FAU - Tanimura, Mai -AU - Tanimura M -AD - Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, - Kyoto 602-8031, Japan. -FAU - Nakano, Takayuki -AU - Nakano T -AD - Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, - Kyoto 602-8031, Japan. -FAU - Tanimura, Keiko -AU - Tanimura K -AUID- ORCID: 0000-0002-7826-4466 -AD - Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, - Kyoto 602-8031, Japan. -FAU - Kato, Daishiro -AU - Kato D -AD - Department of Thoracic Surgery, Japanese Red Cross Kyoto Daini Hospital, Kyoto - 602-8031, Japan. -FAU - Takeda, Takayuki -AU - Takeda T -AUID- ORCID: 0000-0002-8375-6940 -AD - Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, - Kyoto 602-8031, Japan. -LA - eng -PT - Case Reports -DEP - 20210529 -PL - Switzerland -TA - Medicina (Kaunas) -JT - Medicina (Kaunas, Lithuania) -JID - 9425208 -RN - 2S9ZZM9Q9V (Bevacizumab) -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Bevacizumab/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Neoplasm Recurrence, Local/drug therapy -PMC - PMC8226573 -OTO - NOTNLM -OT - bevacizumab -OT - chemoimmunotherapy -OT - chemoradiotherapy -OT - non-small-cell lung cancer -OT - recurrence -COIS- The authors declare no conflict of interest. -EDAT- 2021/06/03 06:00 -MHDA- 2021/06/04 06:00 -PMCR- 2021/05/29 -CRDT- 2021/06/02 01:35 -PHST- 2021/04/18 00:00 [received] -PHST- 2021/05/16 00:00 [revised] -PHST- 2021/05/27 00:00 [accepted] -PHST- 2021/06/02 01:35 [entrez] -PHST- 2021/06/03 06:00 [pubmed] -PHST- 2021/06/04 06:00 [medline] -PHST- 2021/05/29 00:00 [pmc-release] -AID - medicina57060547 [pii] -AID - medicina-57-00547 [pii] -AID - 10.3390/medicina57060547 [doi] -PST - epublish -SO - Medicina (Kaunas). 2021 May 29;57(6):547. doi: 10.3390/medicina57060547. - -PMID- 38652815 -OWN - NLM -STAT- MEDLINE -DCOM- 20240701 -LR - 20241010 -IS - 1557-3265 (Electronic) -IS - 1078-0432 (Linking) -VI - 30 -IP - 13 -DP - 2024 Jul 1 -TI - Fraction Dose Escalation of Hypofractionated Radiotherapy with Concurrent - Chemotherapy and Subsequent Consolidation Immunotherapy in Locally Advanced - Non-Small Cell Lung Cancer: A Phase I Study. -PG - 2719-2728 -LID - 10.1158/1078-0432.CCR-23-3600 [doi] -AB - PURPOSE: This phase I trial aimed to determine the maximum tolerated fraction - dose (MTFD) of hypofractionated radiotherapy (hypo-RT) combined with concurrent - chemotherapy and subsequent consolidation immune checkpoint inhibitors (cICI) for - patients with locally advanced non-small cell lung cancer. PATIENTS AND METHODS: - Split-course hypo-RT and hypoboost combined with concurrent chemotherapy was - administered at three dose levels (DL), using a stepwise dose-escalation - protocol. The sophisticated esophagus-sparing technique was implemented to - restrict the dose to the esophagus. Patients who did not experience disease - progression or unresolved ≥grade 2 (G2+) toxicities after RT received cICI. Each - DL aimed to treat six patients. The MTFD was defined as the highest DL at which - ≤2 patients of the six who were treated experienced treatment-related G3+ - toxicity and ≤1 patient experienced G4+ toxicity within 12 months post-RT. - RESULTS: Eighteen patients were enrolled, with six patients in each DL. All - patients completed hypo-RT and concurrent chemotherapy, and 16 (88.9%) received - at least one infusion of cICI, with a median of 10 infusions. Within the 12-month - assessment period, one patient in DL1 experienced G3 pneumonitis, and one patient - in DL3 developed G3 tracheobronchitis. The MTFD was not reached. The objective - response rate was 100%. With a median follow-up of 20.9 months, the 1-year - overall survival and progression-free survival rates were 94.4% and 83.3%, - respectively. CONCLUSIONS: Utilizing the split-course hypo-RT and hypoboost - approach, a fraction dose of 5 Gy to a total dose of 60 Gy, combined with - concurrent chemotherapy and subsequent cICI, was well tolerated and yielded a - promising objective response rate and survival outcomes. -CI - ©2024 American Association for Cancer Research. -FAU - Zhou, Rui -AU - Zhou R -AUID- ORCID: 0000-0003-0678-9009 -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -AD - Lung Cancer Institute of Sun Yat-sen University, Guangzhou, China. -AD - Guangdong Association Study of Thoracic Oncology, Guangzhou, China. -FAU - Liu, FangJie -AU - Liu F -AUID- ORCID: 0000-0002-3771-5566 -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -AD - Lung Cancer Institute of Sun Yat-sen University, Guangzhou, China. -AD - Guangdong Association Study of Thoracic Oncology, Guangzhou, China. -FAU - Zhang, HongMei -AU - Zhang H -AUID- ORCID: 0009-0000-5307-0385 -AD - Air Force Hospital of Southern Theater Command of the People's Liberation Army, - Guangzhou, China. -FAU - Wang, DaQuan -AU - Wang D -AUID- ORCID: 0009-0006-6634-1002 -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -AD - Lung Cancer Institute of Sun Yat-sen University, Guangzhou, China. -AD - Guangdong Association Study of Thoracic Oncology, Guangzhou, China. -FAU - Zhang, PengXin -AU - Zhang P -AUID- ORCID: 0009-0008-1771-2991 -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -AD - Lung Cancer Institute of Sun Yat-sen University, Guangzhou, China. -AD - Guangdong Association Study of Thoracic Oncology, Guangzhou, China. -FAU - Zheng, ShiYang -AU - Zheng S -AUID- ORCID: 0000-0002-8502-249X -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -AD - Lung Cancer Institute of Sun Yat-sen University, Guangzhou, China. -AD - Guangdong Association Study of Thoracic Oncology, Guangzhou, China. -FAU - Liu, YiMei -AU - Liu Y -AUID- ORCID: 0000-0002-5434-4867 -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. -FAU - Chen, Li -AU - Chen L -AUID- ORCID: 0000-0002-9887-3429 -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. -FAU - Guo, JinYu -AU - Guo J -AUID- ORCID: 0009-0008-3811-3971 -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -AD - Lung Cancer Institute of Sun Yat-sen University, Guangzhou, China. -AD - Guangdong Association Study of Thoracic Oncology, Guangzhou, China. -FAU - Zou, YingYi -AU - Zou Y -AUID- ORCID: 0009-0007-4570-0384 -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -AD - Lung Cancer Institute of Sun Yat-sen University, Guangzhou, China. -AD - Guangdong Association Study of Thoracic Oncology, Guangzhou, China. -FAU - Rong, Yu-Ming -AU - Rong YM -AUID- ORCID: 0000-0002-3592-1358 -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -AD - Department of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Liu, Hui -AU - Liu H -AUID- ORCID: 0000-0002-3335-3756 -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -AD - Lung Cancer Institute of Sun Yat-sen University, Guangzhou, China. -AD - Guangdong Association Study of Thoracic Oncology, Guangzhou, China. -FAU - Qiu, Bo -AU - Qiu B -AUID- ORCID: 0000-0001-7264-2203 -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -AD - Lung Cancer Institute of Sun Yat-sen University, Guangzhou, China. -AD - Guangdong Association Study of Thoracic Oncology, Guangzhou, China. -LA - eng -GR - 2022YFC2505800/National Key Research and Development Program of China (NKPs)/ -PT - Clinical Trial, Phase I -PT - Journal Article -PL - United States -TA - Clin Cancer Res -JT - Clinical cancer research : an official journal of the American Association for - Cancer Research -JID - 9502500 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/pathology/drug therapy/mortality -MH - Male -MH - Female -MH - Middle Aged -MH - Aged -MH - *Lung Neoplasms/therapy/pathology/drug therapy/mortality -MH - *Chemoradiotherapy/methods -MH - *Radiation Dose Hypofractionation -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects -MH - Maximum Tolerated Dose -MH - Immune Checkpoint Inhibitors/administration & dosage/therapeutic use/adverse - effects -MH - Adult -MH - Immunotherapy/methods -EDAT- 2024/04/23 18:51 -MHDA- 2024/07/01 06:41 -CRDT- 2024/04/23 14:33 -PHST- 2023/11/18 00:00 [received] -PHST- 2024/01/20 00:00 [revised] -PHST- 2024/04/19 00:00 [accepted] -PHST- 2024/07/01 06:41 [medline] -PHST- 2024/04/23 18:51 [pubmed] -PHST- 2024/04/23 14:33 [entrez] -AID - 743212 [pii] -AID - 10.1158/1078-0432.CCR-23-3600 [doi] -PST - ppublish -SO - Clin Cancer Res. 2024 Jul 1;30(13):2719-2728. doi: 10.1158/1078-0432.CCR-23-3600. - -PMID- 34664091 -OWN - NLM -STAT- MEDLINE -DCOM- 20220426 -LR - 20220428 -IS - 1619-7089 (Electronic) -IS - 1619-7070 (Print) -IS - 1619-7070 (Linking) -VI - 49 -IP - 4 -DP - 2022 Mar -TI - Differential role of residual metabolic tumor volume in inoperable stage III - NSCLC after chemoradiotherapy ± immune checkpoint inhibition. -PG - 1407-1416 -LID - 10.1007/s00259-021-05584-w [doi] -AB - BACKGROUND: The PET-derived metabolic tumor volume (MTV) is an independent - prognosticator in non-small cell lung cancer (NSCLC) patients. We analyzed the - prognostic value of residual MTV (rMTV) after completion of chemoradiotherapy - (CRT) in inoperable stage III NSCLC patients with and without immune checkpoint - inhibition (ICI). METHODS: Fifty-six inoperable stage III NSCLC patients (16 - female, median 65.0 years) underwent (18)F-FDG PET/CT after completion of - standard CRT. rMTV was delineated on (18)F-FDG PET/CT using a standard threshold - (liver SUV(mean) + 2 × standard deviation). 21/56 patients underwent additional - ICI (CRT-IO, 21/56 patients) thereafter. Patients were divided in volumetric - subgroups using median split dichotomization (MTV ≤ 4.3 ml vs. > 4.3 ml). rMTV, - clinical features, and ICI-application were correlated with clinical outcome - parameters (progression-free survival (PFS), local PFS (LPFS), and overall - survival (OS). RESULTS: Overall, median follow-up was 52.0 months. Smaller rMTV - was associated with longer median PFS (29.3 vs. 10.5 months, p = 0.015), LPFS - (49.9 vs. 13.5 months, p = 0.001), and OS (63.0 vs. 23.0 months, p = 0.003). - CRT-IO patients compared to CRT patients showed significantly longer median PFS - (29.3 vs. 11.2 months, p = 0.034), LPFS (median not reached vs. 14.0 months, - p = 0.016), and OS (median not reached vs. 25.2 months, p = 0.007). In the CRT - subgroup, smaller rMTV was associated with longer median PFS (33.5 vs. - 8.6 months, p = 0.001), LPFS (49.9 vs. 10.1 months, p = 0.001), and OS (63.0 vs. - 16.3 months, p = 0.004). In the CRT-IO subgroup, neither PFS, LPFS, nor OS were - associated with MTV (p > 0.05 each). The findings were confirmed in subsequent - multivariate analyses. CONCLUSION: In stage III NSCLC, smaller rMTV is highly - associated with superior clinical outcome, especially in patients undergoing CRT - without ICI. Patients with CRT-IO show significantly improved outcome compared to - CRT patients. Of note, clinical outcome in CRT-IO patients is independent of - residual MTV. Hence, even patients with large rMTV might profit from ICI despite - extensive tumor load. -CI - © 2021. The Author(s). -FAU - Unterrainer, Marcus -AU - Unterrainer M -AUID- ORCID: 0000-0002-8238-1198 -AD - Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, - 81377, Munich, Germany. marcus.unterrainer@med.uni-muenchen.de. -FAU - Taugner, Julian -AU - Taugner J -AD - Department of Radiotherapy and Radiation Oncology, University Hospital, LMU - Munich, Munich, Germany. -FAU - Käsmann, Lukas -AU - Käsmann L -AD - Department of Radiotherapy and Radiation Oncology, University Hospital, LMU - Munich, Munich, Germany. -AD - Member of the German Center for Lung Research (DZL), Comprehensive Pneumology - Center Munich (CPC-M), Munich, Germany. -AD - German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. -FAU - Tufman, Amanda -AU - Tufman A -AD - Member of the German Center for Lung Research (DZL), Comprehensive Pneumology - Center Munich (CPC-M), Munich, Germany. -AD - Department of Internal Medicine V, LMU Munich, Munich, Germany. -FAU - Reinmuth, Niels -AU - Reinmuth N -AD - Asklepios Lung Clinic, Munich-Gauting, Germany. -FAU - Li, Minglun -AU - Li M -AD - Department of Radiotherapy and Radiation Oncology, University Hospital, LMU - Munich, Munich, Germany. -FAU - Mittlmeier, Lena M -AU - Mittlmeier LM -AD - Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany. -FAU - Bartenstein, Peter -AU - Bartenstein P -AD - Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany. -FAU - Kunz, Wolfgang G -AU - Kunz WG -AD - Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, - 81377, Munich, Germany. -FAU - Ricke, Jens -AU - Ricke J -AD - Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, - 81377, Munich, Germany. -FAU - Belka, Claus -AU - Belka C -AD - Department of Radiotherapy and Radiation Oncology, University Hospital, LMU - Munich, Munich, Germany. -AD - Member of the German Center for Lung Research (DZL), Comprehensive Pneumology - Center Munich (CPC-M), Munich, Germany. -AD - German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. -FAU - Eze, Chukwuka -AU - Eze C -AD - Department of Radiotherapy and Radiation Oncology, University Hospital, LMU - Munich, Munich, Germany. -FAU - Manapov, Farkhad -AU - Manapov F -AD - Department of Radiotherapy and Radiation Oncology, University Hospital, LMU - Munich, Munich, Germany. -AD - Member of the German Center for Lung Research (DZL), Comprehensive Pneumology - Center Munich (CPC-M), Munich, Germany. -AD - German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. -LA - eng -PT - Journal Article -DEP - 20211019 -PL - Germany -TA - Eur J Nucl Med Mol Imaging -JT - European journal of nuclear medicine and molecular imaging -JID - 101140988 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/therapy -MH - Chemoradiotherapy -MH - Disease Progression -MH - Female -MH - Fluorodeoxyglucose F18/metabolism -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - *Lung Neoplasms/drug therapy/therapy -MH - Male -MH - Neoplasm, Residual/drug therapy -MH - Positron Emission Tomography Computed Tomography -MH - Prognosis -MH - Retrospective Studies -MH - Tumor Burden -PMC - PMC8921088 -OTO - NOTNLM -OT - Durvalumab -OT - Immunotherapy -OT - Metabolic tumor volume -OT - NSCLC -OT - Nivolumab -COIS- The authors declare no competing interests. -EDAT- 2021/10/20 06:00 -MHDA- 2022/04/27 06:00 -PMCR- 2021/10/19 -CRDT- 2021/10/19 06:29 -PHST- 2021/07/29 00:00 [received] -PHST- 2021/10/09 00:00 [accepted] -PHST- 2021/10/20 06:00 [pubmed] -PHST- 2022/04/27 06:00 [medline] -PHST- 2021/10/19 06:29 [entrez] -PHST- 2021/10/19 00:00 [pmc-release] -AID - 10.1007/s00259-021-05584-w [pii] -AID - 5584 [pii] -AID - 10.1007/s00259-021-05584-w [doi] -PST - ppublish -SO - Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1407-1416. doi: - 10.1007/s00259-021-05584-w. Epub 2021 Oct 19. - -PMID- 30797489 -OWN - NLM -STAT- MEDLINE -DCOM- 20191231 -LR - 20191231 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 129 -DP - 2019 Mar -TI - Nivolumab and brain metastases in patients with advanced non-squamous non-small - cell lung cancer. -PG - 35-40 -LID - S0169-5002(18)30724-4 [pii] -LID - 10.1016/j.lungcan.2018.12.025 [doi] -AB - OBJECTIVES: Brain metastases are common among patients with non-squamous - non-small-cell lung cancer (NSCLC) and result in a poor prognosis. Consequently, - such patients are often excluded from clinical trials. In Italy an expanded - access program (EAP) was used to evaluate nivolumab efficacy and safety in this - subpopulation outside a clinical trial. MATERIALS AND METHODS: In this EAP, - nivolumab was available for patients with non-squamous NSCLC in progression after - at least one systemic treatment for stage IIIB/IV disease. Nivolumab 3 mg/kg was - administered intravenously every 2 weeks. Patients with brain metastases could be - included if they were asymptomatic, neurologically stable and either off - corticosteroids or on a stable or decreasing dose of ≤10 mg/day prednisone. - RESULTS: 409 out of 1588 patients included had asymptomatic or controlled brain - metastases. A median of 7 doses (range 1-45) were delivered. Median follow-up was - 6.1 months (range 0.1-21.9). The disease control rate was 39%: 4 patients had a - complete response, 64 a partial response and 96 showed stable disease. At - baseline, 118 patients were on corticosteroids and 74 were undergoing concomitant - radiotherapy. The median overall survival in this subpopulation was 8.6 months - (95% CI: 6.4-10.8). 337 discontinued treatment for various reasons, 23 (7%) of - whom due to adverse events, in line with that observed in the overall population - and in previous studies. CONCLUSIONS: Our results confirm that nivolumab is - active in non-squamous NSCLC patients with brain metastases, despite their poor - prognosis. Its safety profile is also concordant with results in the EAP overall - population and in patients with other malignancies. -CI - Copyright © 2018 Elsevier B.V. All rights reserved. -FAU - Crinò, Lucio -AU - Crinò L -AD - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, - Meldola, Italy. -FAU - Bronte, Giuseppe -AU - Bronte G -AD - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, - Meldola, Italy. Electronic address: giuseppe.bronte@irst.emr.it. -FAU - Bidoli, Paolo -AU - Bidoli P -AD - Ospedale S. Gerardo, Monza, Italy. -FAU - Cravero, Paola -AU - Cravero P -AD - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, - Meldola, Italy. -FAU - Minenza, Elisa -AU - Minenza E -AD - AO Santa Maria, Terni, Italy. -FAU - Cortesi, Enrico -AU - Cortesi E -AD - Policlinico Umberto I, Rome, Italy. -FAU - Garassino, Marina C -AU - Garassino MC -AD - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. -FAU - Proto, Claudia -AU - Proto C -AD - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. -FAU - Cappuzzo, Federico -AU - Cappuzzo F -AD - AUSL della Romagna, Ravenna, Italy. -FAU - Grossi, Francesco -AU - Grossi F -AD - IRCCS AOU San Martino IST, Genova, Italy. -FAU - Tonini, Giuseppe -AU - Tonini G -AD - Policlinico Universitario Campus Biomedico, Rome, Italy. -FAU - Sarobba, Maria Giuseppina -AU - Sarobba MG -AD - ASL 3 S. Francesco, Nuoro, Italy. -FAU - Pinotti, Graziella -AU - Pinotti G -AD - Ospedale di Circolo e Fondazione Macchi, Varese, Italy. -FAU - Numico, Gianmauro -AU - Numico G -AD - AO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy. -FAU - Samaritani, Riccardo -AU - Samaritani R -AD - Presidio Nuovo Regina Margherita, Rome, Italy. -FAU - Ciuffreda, Libero -AU - Ciuffreda L -AD - AOU Città della salute e della Scienza di Torino, Turin, Italy. -FAU - Frassoldati, Antonio -AU - Frassoldati A -AD - Arcispedale S. Anna, Ferrara, Ferrara, Italy. -FAU - Bregni, Marco -AU - Bregni M -AD - Presidio Ospedaliero di Busto Arsizio, Varese, Italy. -FAU - Santo, Antonio -AU - Santo A -AD - AO Universitaria Integrata di Verona, Verona, Italy. -FAU - Piantedosi, Francovito -AU - Piantedosi F -AD - AO dei Colli, Monaldi- Cotugno-CTO, Naples, Italy. -FAU - Illiano, Alfonso -AU - Illiano A -AD - AO dei Colli, Monaldi- Cotugno-CTO, Naples, Italy. -FAU - De Marinis, Filippo -AU - De Marinis F -AD - European Institute of Oncology, Milan, Italy. -FAU - Tamberi, Stefano -AU - Tamberi S -AD - Degli Infermi Hospital, Faenza, Italy. -FAU - Giannarelli, Diana -AU - Giannarelli D -AD - Regina Elena National Cancer Institute IRCCS, Rome, Italy. -FAU - Delmonte, Angelo -AU - Delmonte A -AD - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, - Meldola, Italy. -LA - eng -PT - Journal Article -DEP - 20190115 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Brain Neoplasms/*epidemiology/mortality/secondary -MH - Carcinoma, Non-Small-Cell Lung/*epidemiology/mortality/secondary -MH - Disease Progression -MH - Female -MH - Humans -MH - Immunotherapy/*methods -MH - Italy/epidemiology -MH - Lung Neoplasms/*epidemiology/mortality/pathology -MH - Male -MH - Middle Aged -MH - Nivolumab/*therapeutic use -MH - Survival Analysis -MH - Treatment Outcome -OTO - NOTNLM -OT - Brain metastasis -OT - Immune checkpoint inhibitors -OT - Nivolumab -OT - Non-small cell lung cancer -OT - Non-squamous -EDAT- 2019/02/25 06:00 -MHDA- 2020/01/01 06:00 -CRDT- 2019/02/25 06:00 -PHST- 2018/09/14 00:00 [received] -PHST- 2018/12/19 00:00 [revised] -PHST- 2018/12/25 00:00 [accepted] -PHST- 2019/02/25 06:00 [entrez] -PHST- 2019/02/25 06:00 [pubmed] -PHST- 2020/01/01 06:00 [medline] -AID - S0169-5002(18)30724-4 [pii] -AID - 10.1016/j.lungcan.2018.12.025 [doi] -PST - ppublish -SO - Lung Cancer. 2019 Mar;129:35-40. doi: 10.1016/j.lungcan.2018.12.025. Epub 2019 - Jan 15. - -PMID- 37498227 -OWN - NLM -STAT- MEDLINE -DCOM- 20230728 -LR - 20230802 -IS - 1473-2300 (Electronic) -IS - 0300-0605 (Print) -IS - 0300-0605 (Linking) -VI - 51 -IP - 7 -DP - 2023 Jul -TI - Late-stage esophageal neuroendocrine carcinoma in a patient treated with - tislelizumab combined with anlotinib: a case report. -PG - 3000605231187942 -LID - 10.1177/03000605231187942 [doi] -LID - 03000605231187942 -AB - Esophageal neuroendocrine carcinoma (ENEC) is an extremely rare tumor with highly - malignant potential, rapid growth, and a poor prognosis. Advanced extrapulmonary - neuroendocrine carcinoma should be treated with chemotherapeutic regimens - suitable for small cell lung cancer. However, ENEC has no clear second-line - treatment options. The clinical application of immunotherapy and targeted therapy - in small cell lung cancer has produced good therapeutic effects. We describe the - case of an elderly woman with multiple metastatic advanced ENEC treated with - tislelizumab combined with anlotinib as second-line therapy, achieving complete - remission in a short period and long-term survival. In total, 21 cycles of - tislelizumab combined with anlotinib were given to this patient. After two - cycles, the patient's neuron-specific enolase level decreased from 181.8 to - 22.9 µg/L and remained at normal levels throughout treatment. Progression-free - survival and overall survival were 16 and 21 months, respectively, in this - patient. No obvious side effects were observed. Thus, tislelizumab and anlotinib - could represent a novel therapeutic option for advanced ENEC. -FAU - Zhang, Yanqi -AU - Zhang Y -AUID- ORCID: 0000-0002-0664-2114 -AD - Department of Oncology, Dezhou People's Hospital (Qilu Hospital of Shandong - University Dezhou Hospital), 1166 Dongfanghong West Road, Dezhou, P.R. China. -FAU - Liu, Xiaoyu -AU - Liu X -AD - Department of Oncology, Dezhou People's Hospital (Qilu Hospital of Shandong - University Dezhou Hospital), 1166 Dongfanghong West Road, Dezhou, P.R. China. -FAU - Liang, Honglu -AU - Liang H -AD - Department of Radiotherapy, Dezhou People's Hospital (Qilu Hospital of Shandong - University Dezhou Hospital), 1166 Dongfanghong West Road, Dezhou, P.R. China. -FAU - Liu, Weihua -AU - Liu W -AD - Department of Gastroenterology, Dezhou People's Hospital (Qilu Hospital of - Shandong University Dezhou Hospital), 1166 Dongfanghong West Road, Dezhou, P.R. - China. -FAU - Wang, Haiyan -AU - Wang H -AD - Department of Infectious Diseases, Dezhou People's Hospital (Qilu Hospital of - Shandong University Dezhou Hospital), 1166 Dongfanghong West Road, Dezhou, P.R. - China. -FAU - Li, Tao -AU - Li T -AUID- ORCID: 0000-0003-0147-3769 -AD - Department of Oncology, Dezhou People's Hospital (Qilu Hospital of Shandong - University Dezhou Hospital), 1166 Dongfanghong West Road, Dezhou, P.R. China. -LA - eng -PT - Case Reports -PT - Journal Article -PL - England -TA - J Int Med Res -JT - The Journal of international medical research -JID - 0346411 -RN - 0 (anlotinib) -RN - 0KVO411B3N (tislelizumab) -SB - IM -MH - Aged -MH - Female -MH - Humans -MH - *Small Cell Lung Carcinoma -MH - *Carcinoma, Neuroendocrine -MH - *Esophageal Neoplasms/drug therapy -MH - *Lung Neoplasms -PMC - PMC10387792 -OTO - NOTNLM -OT - Tislelizumab -OT - anlotinib -OT - case report -OT - chemotherapy -OT - esophageal neuroendocrine carcinoma -OT - immunotherapy -OT - small cell lung cancer -OT - targeted therapy -COIS- The authors declare that they have no conflict of interest. -EDAT- 2023/07/27 13:10 -MHDA- 2023/07/28 06:43 -PMCR- 2023/07/27 -CRDT- 2023/07/27 10:22 -PHST- 2023/07/28 06:43 [medline] -PHST- 2023/07/27 13:10 [pubmed] -PHST- 2023/07/27 10:22 [entrez] -PHST- 2023/07/27 00:00 [pmc-release] -AID - 10.1177_03000605231187942 [pii] -AID - 10.1177/03000605231187942 [doi] -PST - ppublish -SO - J Int Med Res. 2023 Jul;51(7):3000605231187942. doi: 10.1177/03000605231187942. - -PMID- 35305566 -OWN - NLM -STAT- MEDLINE -DCOM- 20220322 -LR - 20220324 -IS - 1471-2377 (Electronic) -IS - 1471-2377 (Linking) -VI - 22 -IP - 1 -DP - 2022 Mar 19 -TI - Longitudinal extensive transverse myelitis after chemoradiation therapy with - durvalumab, a rare complication: case report. -PG - 107 -LID - 10.1186/s12883-022-02576-7 [doi] -LID - 107 -AB - BACKGROUND: Longitudinal extensive transverse myelitis is a rare and potentially - life-threatening complication of chemoradiation. Certain chemotherapy agents have - been proposed to increased neurotoxicity with chemoradiation therapy. One such - agent is durvalumab, a human IgG1 monoclonal antibody that blocks programmed - death ligand 1, allowing T-cells to recognize and kill tumor cells. Durvalumab - and other immune checkpoint inhibitors may also cause transverse myelitis without - concomitant treatment with radiation. Durvalumab is a standard therapy for - non-small cell lung carcinoma. Here we present a case of a 68-year-old male who - presented after chemoradiation and durvalumab therapy with transverse myelitis - extending outside the irradiation site. CASE PRESENTATION: A 68-year-old male - presented to the emergency department with pain and weakness in his feet and - hesitancy of urination. Medical history is significant for non-small cell lung - cancer treated with chemoradiotherapy and consolidation therapy with durvalumab - for one year. His last radiation treatment was 15 months prior, and his last - infusion of durvalumab was 3 months prior. Exam revealed severe weakness of - bilateral legs with absent vibration sensation. MRI showed central longitudinal - extensive transverse myelitis extending from C4-T11. CSF studies showed 8 WBC - with 63% lymphocyte predominance and a protein of 48. Oligoclonal bands and - angiotensin-converting enzyme were negative. Serum Neuromyelitis Optica antibody - (AQP4-IgG) and Myelin oligodendrocyte glycoprotein antibody (MOG-IgG) were - negative. Infectious workup came back negative. The patient was treated with - steroids and plasma exchange with mild improvement. Etiology remained unknown, - but longitudinal extensive transverse myelitis following durvalumab - chemoradiotherapy was thought to be the likely cause. He was discharged on a - high-dose prednisone taper with outpatient follow-up. His condition worsened near - the end of the steroid taper. High-dose prednisone and cyclophosphamide infusions - were started with mild improvement and stabilization of the patient's condition. - He transitioned to methotrexate after completion of six cyclophosphamide - infusions. The patient expired due to complications from his cancer. CONCLUSION: - Longitudinal extensive transverse myelitis is a rare and potentially - life-threatening complication of durvalumab therapy. As durvalumab has become a - standard treatment for non-small cell lung cancer, it is important to be able to - identify and treat side effects. -CI - © 2022. The Author(s). -FAU - Moodie, Travis -AU - Moodie T -AD - University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA. -FAU - Alshaqi, Ola -AU - Alshaqi O -AD - Damascus University, Damascus, Syria. -FAU - Alchaki, Abdul -AU - Alchaki A -AUID- ORCID: 0000-0002-4129-2455 -AD - University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA. - aalchaki@gmail.com. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20220319 -PL - England -TA - BMC Neurol -JT - BMC neurology -JID - 100968555 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal/adverse effects -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Male -MH - *Myelitis, Transverse/chemically induced/therapy -PMC - PMC8933995 -OTO - NOTNLM -OT - Durvalumab -OT - Longitudinal extensive transverse myelitis -COIS- All authors have nothing to declare. No financial or non-financial competing - interests. -EDAT- 2022/03/21 06:00 -MHDA- 2022/03/23 06:00 -PMCR- 2022/03/19 -CRDT- 2022/03/20 20:23 -PHST- 2021/07/05 00:00 [received] -PHST- 2022/02/01 00:00 [accepted] -PHST- 2022/03/20 20:23 [entrez] -PHST- 2022/03/21 06:00 [pubmed] -PHST- 2022/03/23 06:00 [medline] -PHST- 2022/03/19 00:00 [pmc-release] -AID - 10.1186/s12883-022-02576-7 [pii] -AID - 2576 [pii] -AID - 10.1186/s12883-022-02576-7 [doi] -PST - epublish -SO - BMC Neurol. 2022 Mar 19;22(1):107. doi: 10.1186/s12883-022-02576-7. - -PMID- 29398578 -OWN - NLM -STAT- MEDLINE -DCOM- 20190308 -LR - 20210103 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 19 -IP - 3 -DP - 2018 May -TI - Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung - Cancer: A Retrospective Multicenter Analysis. -PG - e349-e358 -LID - S1525-7304(18)30001-9 [pii] -LID - 10.1016/j.cllc.2018.01.001 [doi] -AB - BACKGROUND: Nivolumab, an immune checkpoint inhibitor, is now a standard - treatment for previously treated advanced non-small-cell lung cancer based on the - results from phase III clinical trials. We evaluated the real-world efficacy and - safety of nivolumab in a nonselected population and identified the clinical - characteristics that influence efficacy. MATERIALS AND METHODS: A total of 142 - patients with advanced non-small-cell lung cancer who were administered nivolumab - at Keio University and affiliated hospitals in Japan from January to July 2016 - were enrolled. The treatment efficacy and adverse events were retrospectively - reviewed, and the clinical characteristics associated with the nivolumab response - were evaluated using univariate and stratified analyses and the - Cochran-Mantel-Haenszel test. RESULTS: The objective response rate was 17.0% (95% - confidence interval [CI], 12.0%-24.0%), the median progression-free survival - (PFS) was 58 days (95% CI, 50-67 days), and the proportion of patients with - adverse events of any grade was 45.0%. EGFR/ALK mutation status was inversely - associated with the treatment response (P < .05), and the difference in PFS for - the mutation-positive versus mutation-negative patients was statistically - significant (49 vs. 63 days; hazard ratio, 1.9; 95% CI, 1.1-5.2; P = .029). - Previous radiotherapy also had a positive association with the treatment response - (P = .012). CONCLUSION: The objective response rate, PFS, and adverse event - profiles were comparable to those observed in previous clinical trials. EGFR/ALK - mutation-negative status and previous radiotherapy might be key clinical - characteristics associated with a positive treatment response. Our findings could - aid in the efficient immunotherapeutic management of lung cancer. -CI - Copyright © 2018 Elsevier Inc. All rights reserved. -FAU - Kobayashi, Keigo -AU - Kobayashi K -AD - Division of Pulmonary Medicine, Department of Medicine, Keio University School of - Medicine, Tokyo, Japan. -FAU - Nakachi, Ichiro -AU - Nakachi I -AD - Pulmonary Division, Department Internal Medicine, Saiseikai Utsunomiya Hospital, - Utsunomiya, Japan. Electronic address: nichiro4747@gmail.com. -FAU - Naoki, Katsuhiko -AU - Naoki K -AD - Division of Pulmonary Medicine, Department of Medicine, Keio University School of - Medicine, Tokyo, Japan. -FAU - Satomi, Ryosuke -AU - Satomi R -AD - National Hospital Organization, Tokyo Medical Center, Tokyo, Japan. -FAU - Nakamura, Morio -AU - Nakamura M -AD - Tokyo Saiseikai Central Hospital, Tokyo, Japan. -FAU - Inoue, Takashi -AU - Inoue T -AD - Sano Kousei General Hospital, Sano, Japan. -FAU - Tateno, Hiroki -AU - Tateno H -AD - Saitama City Hospital, Saitama, Japan. -FAU - Sakamaki, Fumio -AU - Sakamaki F -AD - Tokai University Hachioji Hospital, Tokyo, Japan. -FAU - Sayama, Koichi -AU - Sayama K -AD - Kawasaki Municipal Hospital, Kawasaki, Japan. -FAU - Terashima, Takeshi -AU - Terashima T -AD - Tokyo Dental College, Ichikawa General Hospital, Ichikawashi, Japan. -FAU - Koh, Hidefumi -AU - Koh H -AD - Tachikawa Hospital, Tachikawa, Japan. -FAU - Abe, Takayuki -AU - Abe T -AD - Department of Preventive Medicine and Public Health, Keio University School of - Medicine, Tokyo, Japan. -FAU - Nishino, Makoto -AU - Nishino M -AD - Division of Pulmonary Medicine, Department of Medicine, Keio University School of - Medicine, Tokyo, Japan. -FAU - Arai, Daisuke -AU - Arai D -AD - Pulmonary Division, Department Internal Medicine, Saiseikai Utsunomiya Hospital, - Utsunomiya, Japan. -FAU - Yasuda, Hiroyuki -AU - Yasuda H -AD - Division of Pulmonary Medicine, Department of Medicine, Keio University School of - Medicine, Tokyo, Japan. -FAU - Kawada, Ichiro -AU - Kawada I -AD - Division of Pulmonary Medicine, Department of Medicine, Keio University School of - Medicine, Tokyo, Japan. -FAU - Soejima, Kenzo -AU - Soejima K -AD - Division of Pulmonary Medicine, Department of Medicine, Keio University School of - Medicine, Tokyo, Japan. -FAU - Betsuyaku, Tomoko -AU - Betsuyaku T -AD - Division of Pulmonary Medicine, Department of Medicine, Keio University School of - Medicine, Tokyo, Japan. -CN - Keio Lung Oncology Group (KLOG) -LA - eng -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -DEP - 20180105 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality -MH - Female -MH - Humans -MH - Japan -MH - Lung Neoplasms/*drug therapy/mortality -MH - Male -MH - Middle Aged -MH - Nivolumab/*therapeutic use -MH - Progression-Free Survival -MH - Retrospective Studies -MH - Treatment Outcome -OTO - NOTNLM -OT - EGFR mutation -OT - Immunotherapy -OT - NSCLC -OT - Nivolumab -OT - Radiation -EDAT- 2018/02/06 06:00 -MHDA- 2019/03/09 06:00 -CRDT- 2018/02/06 06:00 -PHST- 2017/07/10 00:00 [received] -PHST- 2017/12/20 00:00 [revised] -PHST- 2018/01/01 00:00 [accepted] -PHST- 2018/02/06 06:00 [pubmed] -PHST- 2019/03/09 06:00 [medline] -PHST- 2018/02/06 06:00 [entrez] -AID - S1525-7304(18)30001-9 [pii] -AID - 10.1016/j.cllc.2018.01.001 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2018 May;19(3):e349-e358. doi: 10.1016/j.cllc.2018.01.001. Epub - 2018 Jan 5. - -PMID- 35686586 -OWN - NLM -STAT- MEDLINE -DCOM- 20230331 -LR - 20230331 -IS - 1743-7563 (Electronic) -IS - 1743-7555 (Linking) -VI - 19 -IP - 2 -DP - 2023 Apr -TI - Early administration of durvalumab after chemoradiotherapy increased risk of - pneumonitis in patients with locally advanced non-small cell lung cancer. -PG - e111-e117 -LID - 10.1111/ajco.13803 [doi] -AB - AIMS: Durvalumab (Durva) administration after chemoradiation therapy (CRT) in - locally advanced non-small-cell lung cancer (NSCLC) is the standard of care, - associated with relatively prolonged progression-free (PFS) and overall survival. - However, pneumonitis occurs in 73.6% of Japanese patients. This retrospective - study aimed to identify factors associated with Durva efficacy and safety, - specifically, the risk of pneumonitis. METHODS: This study included data from 26 - consecutive patients with locally advanced NSCLC who underwent CRT followed by - Durva. The rates of adverse events and PFS were examined. RESULTS: The median PFS - time was 15.6 months (95% confidence interval [CI]: 8.7-not available). Patients - developed pneumonitis of grade 1, 2, 3, and 4 at the rate of 62%, 27%, 12%, and - 0%, respectively. The median PFS time was 6.4 months for patients with programmed - death ligand 1 (PD-L1) expression level of <50% and not reached for patients with - PD-L1 expression level of ≥50% (hazard ratio [HR], 0.19; 95% CI: 0.04-0.89), - which was significantly prolonged. The cumulative incidence of pneumonitis grade - 2 or above was significantly higher when the time between the last day of - thoracic radiotherapy (TRT) and the start of Durva therapy was within 14 days - compared to >14 days (HR: 0.19; 95% CI: 0.06-0.59). This association was - statistically significant in multivariate analysis. CONCLUSIONS: The initiation - of Durva therapy within 14 days after TRT may increase the risk of pneumonitis - grade 2 or above. Careful observation and suitable treatment are recommended. -CI - © 2022 John Wiley & Sons Australia, Ltd. -FAU - Harada, Daijiro -AU - Harada D -AUID- ORCID: 0000-0002-5314-2489 -AD - Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer - Center, Matsuyama, Japan. -FAU - Shimonishi, Atsushi -AU - Shimonishi A -AD - Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer - Center, Matsuyama, Japan. -FAU - Saeki, Kazuhiko -AU - Saeki K -AD - Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer - Center, Matsuyama, Japan. -FAU - Ninomiya, Takashi -AU - Ninomiya T -AD - Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer - Center, Matsuyama, Japan. -FAU - Kanzaki, Hiromitsu -AU - Kanzaki H -AD - Department of Radiotherapy, National Hospital Organization Shikoku Cancer Center, - Matsuyama, Japan. -FAU - Nagasaki, Kei -AU - Nagasaki K -AD - Department of Radiotherapy, National Hospital Organization Shikoku Cancer Center, - Matsuyama, Japan. -FAU - Ogura, China -AU - Ogura C -AD - Department of Pharmacy, National Hospital Organization Shikoku Cancer Center, - Matsuyama, Japan. -FAU - Tsutsui, Yoko -AU - Tsutsui Y -AD - Department of Pharmacy, National Hospital Organization Shikoku Cancer Center, - Matsuyama, Japan. -FAU - Kojin, Kazuhiro -AU - Kojin K -AD - Department of Pharmacy, National Hospital Organization Shikoku Cancer Center, - Matsuyama, Japan. -FAU - Hamamoto, Yasushi -AU - Hamamoto Y -AD - Department of Radiotherapy, National Hospital Organization Shikoku Cancer Center, - Matsuyama, Japan. -FAU - Kozuki, Toshiyuki -AU - Kozuki T -AD - Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer - Center, Matsuyama, Japan. -LA - eng -GR - The authors received no specific funding for this work/ -PT - Journal Article -DEP - 20220610 -PL - Australia -TA - Asia Pac J Clin Oncol -JT - Asia-Pacific journal of clinical oncology -JID - 101241430 -RN - 28X28X9OKV (durvalumab) -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - B7-H1 Antigen -MH - Retrospective Studies -MH - Chemoradiotherapy/adverse effects -MH - *Pneumonia/chemically induced -OTO - NOTNLM -OT - chemoradiotherapy -OT - durvalumab -OT - non-small cell lung carcinoma -OT - pneumonitis -EDAT- 2022/06/11 06:00 -MHDA- 2023/03/31 06:42 -CRDT- 2022/06/10 05:22 -PHST- 2021/08/01 00:00 [received] -PHST- 2022/05/15 00:00 [accepted] -PHST- 2023/03/31 06:42 [medline] -PHST- 2022/06/11 06:00 [pubmed] -PHST- 2022/06/10 05:22 [entrez] -AID - 10.1111/ajco.13803 [doi] -PST - ppublish -SO - Asia Pac J Clin Oncol. 2023 Apr;19(2):e111-e117. doi: 10.1111/ajco.13803. Epub - 2022 Jun 10. - -PMID- 36274215 -OWN - NLM -STAT- MEDLINE -DCOM- 20221205 -LR - 20240908 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 13 -IP - 23 -DP - 2022 Dec -TI - An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy - combined with chemotherapy in non-small cell lung cancer. -PG - 3374-3383 -LID - 10.1111/1759-7714.14696 [doi] -AB - BACKGROUND: Immune checkpoint inhibitor (ICI) combined with chemotherapy is one - of the standards of care for advanced non-small cell lung cancer (NSCLC) without - driver mutations. However, the biomarker of combination therapy is still unknown. - Although previous studies have confirmed that low allele frequency adjusted - blood-based tumor mutational burden (LAF-bTMB) is associated with the efficacy of - ICI monotherapy, there has been no report on the correlation between the efficacy - of LAF-bTMB and ICI combined chemotherapy. This study aimed to explore whether - LAF-bTMB can be used as a predictive biomarker for the efficacy of immunotherapy - combined with chemotherapy in advanced NSCLC. METHODS: This study enrolled - patients diagnosed with advanced NSCLC and who received ICI combined with - chemotherapy for first-line therapy from May 2020 to December 2021 at Cancer - Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. - Clinical information, treatment information, survival data, and peripheral blood - samples of every patient before treatment were collected. Next-generation - sequencing was performed on plasma samples to estimate bTMB and LAF-bTMB. - RESULTS: A total of 42 patients with NSCLC were enrolled. In this cohort, 19 - patients achieved partial response (PR), and the objective response rate (ORR) - was 45.2%. The median progression-free survival (PFS) of all patients was - 13.4 months (95% CI, 7.49-19.72). Both PFS and the overall survival (OS) were - significantly longer in the responder (R) group than in the non-responder (NR) - group (median PFS, 16.4 months vs. 7.2 months, p = 0.028; median OS, NE vs. - 9.3 months, p = 0.016). There was no significant difference in bTMB and LAF-BTMB - between the R and NR group. The ORR of patients with LAF-bTMB≤8muts/Mb was - significantly higher than that of patients with LAF-bTMB >8muts/Mb (ORR, 61% vs. - 26%, respectively, p = 0.033). When LAF-bTMB ≤8muts/Mb or > 20muts/Mb, ORR was - significantly higher than that of patients with LAF-bTMB between 8 and 20muts/Mb - (ORR were 57% and 21%, p = 0.047). No correlation has been found between LAF-bTMB - and PFS or OS. CONCLUSIONS: This study confirmed that neither bTMB nor LAF-bTMB - is feasible as a potential predictor of first-line immunochemotherapy for - advanced NSCLC. More suitable biomarkers need to be explored to screen patients - with better efficacy of immunotherapy combined with chemotherapy in the future. -CI - © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Zhang, Shuyang -AU - Zhang S -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, China. -FAU - Yang, Lu -AU - Yang L -AUID- ORCID: 0000-0002-4286-9586 -AD - Department of Medical Oncology and Radiation Sickness, Peking University Third - Hospital, Beijing, China. -FAU - Yang, Yaning -AU - Yang Y -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, China. -FAU - Xin, Ying -AU - Xin Y -AD - The Medical Department, 3D Medicines, Shanghai, China. -FAU - Wang, Yan -AU - Wang Y -AUID- ORCID: 0000-0002-1743-6383 -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, China. -LA - eng -PT - Journal Article -DEP - 20221023 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology -MH - *Lung Neoplasms/drug therapy/genetics -MH - Immunotherapy -MH - Biomarkers, Tumor/genetics -MH - Gene Frequency -PMC - PMC9715764 -OTO - NOTNLM -OT - LAF-bTMB -OT - bTMB -OT - immune checkpoint inhibitor -OT - non-small cell lung cancer -COIS- The authors have no conflicts of interest to declare. -EDAT- 2022/10/25 06:00 -MHDA- 2022/12/06 06:00 -PMCR- 2022/12/01 -CRDT- 2022/10/24 01:02 -PHST- 2022/10/02 00:00 [revised] -PHST- 2022/09/04 00:00 [received] -PHST- 2022/10/03 00:00 [accepted] -PHST- 2022/10/25 06:00 [pubmed] -PHST- 2022/12/06 06:00 [medline] -PHST- 2022/10/24 01:02 [entrez] -PHST- 2022/12/01 00:00 [pmc-release] -AID - TCA14696 [pii] -AID - 10.1111/1759-7714.14696 [doi] -PST - ppublish -SO - Thorac Cancer. 2022 Dec;13(23):3374-3383. doi: 10.1111/1759-7714.14696. Epub 2022 - Oct 23. - -PMID- 34956561 -OWN - NLM -STAT- MEDLINE -DCOM- 20220107 -LR - 20220531 -IS - 2040-2309 (Electronic) -IS - 2040-2295 (Print) -IS - 2040-2295 (Linking) -VI - 2021 -DP - 2021 -TI - Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the - Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on - Serum Tumor Markers. -PG - 2338800 -LID - 10.1155/2021/2338800 [doi] -LID - 2338800 -AB - OBJECTIVE: To explore the safety of anlotinib capsules combined with the PD-1 - inhibitor (camrelizumab) in the third-line treatment of advanced non-small-cell - lung cancer (NSCLC) and their effect on serum tumor markers. METHODS: 88 patients - with advanced NSCLC treated in the Oncology Department of our hospital from - December 2018 to December 2019 were selected as research subjects and randomly - and equally split into the single treatment group (STG) and combined treatment - group (CTG). The levels of serum tumor markers after treatment were detected in - both groups, and the incidence of adverse reactions during treatment was - recorded. RESULTS: Compared with the STG, CTG achieved obviously higher total - effective rate (P < 0.05), lower total incidence of adverse reactions (P < 0.05), - lower levels of serum tumor markers and average CFS score (P < 0.001), and higher - average KPS score (P < 0.001). CONCLUSION: Application of anlotinib capsules - combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of - advanced NSCLC can effectively reduce the levels of serum tumor markers and - cancer fatigue degree of patients, with a better effect than that of simple - anlotinib treatment. In addition, further research of the combined treatment is - helpful to establish a better therapeutic regimen for patients with advanced - NSCLC. -CI - Copyright © 2021 Yinhua Wang et al. -FAU - Wang, Yinhua -AU - Wang Y -AD - Department of Radiotherapy, The Second People's Hospital of Wuhu City, Wuhu, - 241000, Anhui Province, China. -FAU - Shi, Xiuhua -AU - Shi X -AD - Department of Radiotherapy, The Second People's Hospital of Wuhu City, Wuhu, - 241000, Anhui Province, China. -FAU - Qi, Qinghua -AU - Qi Q -AD - Department of Radiotherapy, The Second People's Hospital of Wuhu City, Wuhu, - 241000, Anhui Province, China. -FAU - Ye, Bin -AU - Ye B -AD - Department of Radiotherapy, The Second People's Hospital of Wuhu City, Wuhu, - 241000, Anhui Province, China. -FAU - Zou, Zhaoling -AU - Zou Z -AUID- ORCID: 0000-0003-0146-2146 -AD - Department of Hematology, The Second People's Hospital of Wuhu City, Wuhu, - 241000, Anhui Province, China. -LA - eng -PT - Journal Article -PT - Randomized Controlled Trial -DEP - 20211215 -PL - England -TA - J Healthc Eng -JT - Journal of healthcare engineering -JID - 101528166 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Biomarkers, Tumor) -RN - 0 (Capsules) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Indoles) -RN - 0 (Quinolines) -RN - 0 (anlotinib) -RN - 73096E137E (camrelizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized -MH - Biomarkers, Tumor/therapeutic use -MH - Capsules/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Indoles -MH - *Lung Neoplasms/drug therapy -MH - Quinolines -PMC - PMC8694967 -COIS- The authors declare no conflicts of interest. -EDAT- 2021/12/28 06:00 -MHDA- 2022/01/08 06:00 -PMCR- 2021/12/15 -CRDT- 2021/12/27 06:28 -PHST- 2021/11/04 00:00 [received] -PHST- 2021/11/23 00:00 [revised] -PHST- 2021/11/29 00:00 [accepted] -PHST- 2021/12/27 06:28 [entrez] -PHST- 2021/12/28 06:00 [pubmed] -PHST- 2022/01/08 06:00 [medline] -PHST- 2021/12/15 00:00 [pmc-release] -AID - 10.1155/2021/2338800 [doi] -PST - epublish -SO - J Healthc Eng. 2021 Dec 15;2021:2338800. doi: 10.1155/2021/2338800. eCollection - 2021. - -PMID- 28230005 -OWN - NLM -STAT- MEDLINE -DCOM- 20170316 -LR - 20220331 -IS - 1998-4138 (Electronic) -IS - 1998-4138 (Linking) -VI - 12 -IP - Supplement -DP - 2016 Dec -TI - Current mechanism of acquired resistance to epidermal growth factor - receptor-tyrosine kinase inhibitors and updated therapy strategies in human - nonsmall cell lung cancer. -PG - C131-C137 -LID - 10.4103/0973-1482.200613 [doi] -AB - Lung cancer continues to be a major health problem and the most common - cancer-related mortality worldwide with about 80%-85% patients suffering from - nonsmall cell lung cancer (NSCLC). More than 80% of NSCLC cases are often - diagnosed as advanced stage and harbor epidermal growth factor receptor (EGFR) - activating mutation. Although great success in initial response to EGFR-tyrosine - kinase inhibitors (EGFR-TKIs) are found in EGFR-mutant NSCLC patients, acquired - resistance usually occurs on the continuous treatment. Here, we provide an - overview on the mechanism of acquired resistance to EGFR-TKIs in NSCLC therapy as - well as current preclinical and clinical evidence of new therapy strategies and - inhibitors in the treatment of NSCLC. Many studies have shown that original or - induced T790M mutation, human EGFR 2 amplification, and activated secondary - signaling such as MET amplification or phosphatidylinositol 3-kinase mutation can - lead to acquired resistance to EGFR-TKIs. In addition, transformation from NSCLC - to SCLC or conferred epithelial to mesenchymal transition has also been - identified as mechanisms of acquired resistance to EGFR-TKIs. Increasing evidence - has proven that non-coding RNA including long noncoding RNAs and microRNAs or new - EGFR mutation is involved in acquired resistance. Preclinical and clinical Phase - 1-3 evidence on combination drug therapy or new generation inhibitors with - different tumor-targeting approaches have made those strategies the promising - options for EGFR-TKI-resistant NSCLC therapy. This review aims to get deep - insight into providing a state-of-the-art overview of the recent advances in the - mechanisms of acquired resistance and new strategies for targeted cancer therapy - in EGFR-TKI-resistant NSCLC. -FAU - Zhang, Kaixian -AU - Zhang K -AD - Department of Oncology, Tengzhou Central People's Hospital, Tengzhou, Shangdong, - P.R. China. -FAU - Yuan, Qianqian -AU - Yuan Q -AD - Department of Oncology, Tengzhou Central People's Hospital, Tengzhou, Shangdong, - P.R. China. -LA - eng -PT - Journal Article -PT - Review -PL - India -TA - J Cancer Res Ther -JT - Journal of cancer research and therapeutics -JID - 101249598 -RN - 0 (Antineoplastic Agents) -RN - 0 (Protein Kinase Inhibitors) -RN - 0 (RNA, Long Noncoding) -RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) -RN - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) -RN - EC 2.7.1.137 (PIK3CA protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-met) -SB - IM -MH - Antineoplastic Agents/pharmacology/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/pathology -MH - Class I Phosphatidylinositol 3-Kinases -MH - Drug Discovery -MH - *Drug Resistance, Neoplasm/genetics -MH - Epithelial-Mesenchymal Transition/genetics -MH - ErbB Receptors/*antagonists & inhibitors/genetics -MH - Gene Amplification -MH - Humans -MH - Immunotherapy -MH - Lung Neoplasms/*drug therapy/genetics/pathology -MH - Molecular Targeted Therapy -MH - Multigene Family -MH - Mutation -MH - Phosphatidylinositol 3-Kinases/genetics -MH - Protein Kinase Inhibitors/pharmacology/*therapeutic use -MH - Proto-Oncogene Proteins c-met/antagonists & inhibitors/genetics -MH - RNA, Long Noncoding/genetics -MH - Small Cell Lung Carcinoma/drug therapy/genetics/pathology -EDAT- 2017/02/24 06:00 -MHDA- 2017/03/17 06:00 -CRDT- 2017/02/24 06:00 -PHST- 2017/02/24 06:00 [entrez] -PHST- 2017/02/24 06:00 [pubmed] -PHST- 2017/03/17 06:00 [medline] -AID - JCanResTher_2016_12_7_131_200613 [pii] -AID - 10.4103/0973-1482.200613 [doi] -PST - ppublish -SO - J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: - 10.4103/0973-1482.200613. - -PMID- 39349536 -OWN - NLM -STAT- MEDLINE -DCOM- 20240930 -LR - 20241003 -IS - 2045-2322 (Electronic) -IS - 2045-2322 (Linking) -VI - 14 -IP - 1 -DP - 2024 Sep 30 -TI - Risk stratification and overall survival prediction in extensive stage small cell - lung cancer after chemotherapy with immunotherapy based on CT radiomics. -PG - 22659 -LID - 10.1038/s41598-024-73331-w [doi] -LID - 22659 -AB - The prognosis of extensive-stage small cell lung cancer is usually poor. In this - study, a combined model based on pre-treatment CT radiomics and clinical features - was constructed to predict the OS of extensive-stage small cell lung cancer after - chemotherapy with immunotherapy.Clinical data of 111 patients with extensive - stage small-cell lung cancer who received first-line immunotherapy combined with - chemotherapy in our hospital from December 2019 to December 2021 were - retrospectively collected. Finally, 93 patients were selected for inclusion in - the study, and CT images were obtained through PACS system before treatment. All - patients were randomly divided into a training set (n = 66) and a validation set - (n = 27). Images were imported into ITK-SNAP to outline areas of interest, and - Python software was used to extract radiomics features. A total of 1781 radiomics - features were extracted from each patient's images. The feature dimensions were - reduced by MRMR and LASSO methods, and the radiomics features with the greatest - predictive value were screened. The weight coefficient of radiomics features was - calculated, and the linear combination of the feature parameters and the weight - coefficient was used to calculate Radscore. Univariate cox regression analysis - was used to screen out the factors significantly associated with prognosis from - the radiomics and clinical features, and multivariate cox regression analysis was - performed to establish the prognosis prediction model of extensive stage small - cell lung cancer. The degree of metastases was selected as a significant clinical - prognostic factor by univariate cox regression analysis. Seven radiomics features - with significance were selected by LASSO-COX regression analysis, and the - Radscore was calculated according to the coefficient of the radiomics features. - An alignment diagram survival prediction model was constructed by combining - Radscore with the number of metastatic lesions. The study population was - stratified into those who survived less than 11 months, and those with a greater - than 11 month survival. The C-index was 0.722 (se = 0.044) and 0.68(se = 0.074) - in the training and the validation sets, respectively. The Log_rank test results - of the combination model were as follows: training set: p < 0.0001, validation - set: p = 0.00042. In this study, a combined model based on radiomics and clinical - features could predict OS in patients with extensive stage small cell lung cancer - after chemotherapy with immunotherapy, which could help guide clinical treatment - strategies. -CI - © 2024. The Author(s). -FAU - Wang, Fang -AU - Wang F -AD - Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, - China. -FAU - Chen, Wujie -AU - Chen W -AD - Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, - China. -FAU - Chen, Fangmin -AU - Chen F -AD - Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, - China. -FAU - Lu, Jinlan -AU - Lu J -AD - Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, - China. -FAU - Xu, Yanjun -AU - Xu Y -AD - Department of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, - 310022, Zhejiang, China. -FAU - Fang, Min -AU - Fang M -AD - Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, - Zhejiang, China. -FAU - Jiang, Haitao -AU - Jiang H -AD - Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, - China. jianght@zjcc.org.cn. -LA - eng -GR - 2022KY660/Medical and Health Research Project of Zhejiang Province/ -GR - 2022RC110/Medical and Health Research Project of Zhejiang Province/ -GR - 2022C03072/Natural Science Foundation of Zhejiang Province/ -GR - LTGY24H180015/Natural Science Foundation of Zhejiang Province/ -PT - Journal Article -DEP - 20240930 -PL - England -TA - Sci Rep -JT - Scientific reports -JID - 101563288 -SB - IM -MH - Humans -MH - *Lung Neoplasms/pathology/diagnostic imaging/mortality/therapy/drug therapy -MH - *Small Cell Lung Carcinoma/diagnostic imaging/pathology/therapy/mortality/drug - therapy -MH - Male -MH - Female -MH - Middle Aged -MH - *Immunotherapy/methods -MH - *Tomography, X-Ray Computed/methods -MH - Aged -MH - Prognosis -MH - Retrospective Studies -MH - Neoplasm Staging -MH - Risk Assessment -MH - Adult -MH - Radiomics -PMC - PMC11442625 -OTO - NOTNLM -OT - Computed tomography -OT - Overall survival -OT - Prediction model -OT - Radiomics -OT - Small cell lung cancer -COIS- The authors declare no competing interests. -EDAT- 2024/10/01 00:42 -MHDA- 2024/10/01 00:43 -PMCR- 2024/09/30 -CRDT- 2024/09/30 23:22 -PHST- 2024/03/14 00:00 [received] -PHST- 2024/09/16 00:00 [accepted] -PHST- 2024/10/01 00:43 [medline] -PHST- 2024/10/01 00:42 [pubmed] -PHST- 2024/09/30 23:22 [entrez] -PHST- 2024/09/30 00:00 [pmc-release] -AID - 10.1038/s41598-024-73331-w [pii] -AID - 73331 [pii] -AID - 10.1038/s41598-024-73331-w [doi] -PST - epublish -SO - Sci Rep. 2024 Sep 30;14(1):22659. doi: 10.1038/s41598-024-73331-w. - -PMID- 38457254 -OWN - NLM -STAT- MEDLINE -DCOM- 20240311 -LR - 20240311 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 13 -IP - 4 -DP - 2024 Feb -TI - East Asian patients who received immunotherapy-based therapy associated with - improved survival benefit in advanced non-small cell lung cancer: An updated - meta-analysis. -PG - e7080 -LID - 10.1002/cam4.7080 [doi] -LID - e7080 -AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) combined with chemotherapy have - been recommended as the standard treatment for advanced NSCLC patients without - driver-gene mutations. However, there are different genetic characteristics and - biological traits of tumors between non-East Asian (nEA) and East Asian (EA) - patients with NSCLC, which may contribute to differences in the efficacy of ICIs - in different ethnic populations. Previous findings regarding differences in the - efficacy of ICIs among ethnic groups have been inconsistent. Therefore, we - performed a meta-analysis by collecting published data to investigate the - clinical outcomes of ICIs for EA NSCLC patients compared to nEA patients. - METHODS: Overall survival (OS) and progression-free survival (PFS) were used to - access the difference in survival outcomes between the two populations. Subgroup - analyses were performed based on the line of ICIs, the use of ICIs alone or in - combination, and the type of ICIs. RESULTS: A total of 9826 NSCLC patients from - 21 randomized controlled trials (RCTs) with 4064 EAs were included, which - involved PD-1, PD-L1, and CTLA-4 inhibitors. EA NSCLC patients who received - ICIs-based therapy were associated with significantly improved survival benefits - in OS (p = 0.02) compared with nEA patients. Subgroup analysis indicated that EA - patients receiving first-line ICIs showed significantly superior OS compared with - nEA patients (p = 0.007). Chemo-ICIs treatment showed significant advantages in - terms of OS (p = 0.002) and PFS (p = 0.02) among EA patients compared to nEA - patients. In addition, PD-1 inhibitors were associated with improved OS among - both EA patients and nEA patients compared with PD-L1 inhibitors. CONCLUSION: EA - NSCLC patients who received ICIs-based therapy were associated with significantly - improved survival benefits compared with nEA NSCLC patients. Earlier intervention - with ICIs and combination treatment was more recommended for EA NSCLC patients. - Moreover, PD-1 inhibitors are associated with prolonged survival among both EA - and nEA patients. -CI - © 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Yao, Yueyuan -AU - Yao Y -AD - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Li, Butuo -AU - Li B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Xu, Yiyue -AU - Xu Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Yang, Linlin -AU - Yang L -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Zou, Bing -AU - Zou B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Wang, Linlin -AU - Wang L -AUID- ORCID: 0000-0002-2231-6642 -AD - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -LA - eng -GR - 320.6750.2021-02-51/Clinical Research Special Fund of Wu Jieping Medical - Foundation/ -GR - 320.6750.2021-17-13/Clinical Research Special Fund of Wu Jieping Medical - Foundation/ -GR - 2020-B14/Start-up fund of Shandong Cancer Hospital/ -GR - 82172865/National Natural Science Foundation of China/ -PT - Journal Article -PT - Meta-Analysis -PT - Review -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - East Asian People -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -PMC - PMC10923033 -OTO - NOTNLM -OT - East Asia -OT - chemotherapy -OT - immune checkpoint inhibitors -OT - immunotherapy -OT - meta-analysis -OT - non-East Asia -OT - non-small cell lung cancer -COIS- All authors disclosed no relevant relationship. -EDAT- 2024/03/08 18:42 -MHDA- 2024/03/11 06:44 -PMCR- 2024/03/08 -CRDT- 2024/03/08 12:03 -PHST- 2024/02/16 00:00 [revised] -PHST- 2023/07/30 00:00 [received] -PHST- 2024/02/18 00:00 [accepted] -PHST- 2024/03/11 06:44 [medline] -PHST- 2024/03/08 18:42 [pubmed] -PHST- 2024/03/08 12:03 [entrez] -PHST- 2024/03/08 00:00 [pmc-release] -AID - CAM47080 [pii] -AID - 10.1002/cam4.7080 [doi] -PST - ppublish -SO - Cancer Med. 2024 Feb;13(4):e7080. doi: 10.1002/cam4.7080. - -PMID- 37531737 -OWN - NLM -STAT- MEDLINE -DCOM- 20230904 -LR - 20230907 -IS - 2468-2942 (Electronic) -IS - 2468-2942 (Linking) -VI - 36 -DP - 2023 -TI - Survival outcomes and predicting intracranial metastasis in stage III non-small - cell lung cancer treated with definitive chemoradiation: Real-world data from a - tertiary cancer center. -PG - 100747 -LID - S2468-2942(23)00069-2 [pii] -LID - 10.1016/j.ctarc.2023.100747 [doi] -AB - PURPOSE/OBJECTIVE: Around 30% of patients with non-small cell lung cancers - (NSCLC) are diagnosed with stage III disease at presentation, of which about 50% - are treated with definitive chemoradiation (CRT). Around 65-80% of patients will - eventually develop intracranial metastases (IM), though associated risk factors - are not clearly described. We report survival outcomes and risk factors for - development of IM in a cohort of patients with stage III NSCLC treated with CRT - at a tertiary cancer center. MATERIALS/METHODS: We identified 195 patients with - stage III NSCLC treated with CRT from January 2010 to May 2021. Multivariable - logistic regression was used to generate odds ratios for covariates associated - with development of IM. Kaplan-Meier analysis with the Log Rank test was used for - unadjusted time-to-event analyses. P-value for statistical significance was set - at < 0.05 with a two-sided test. RESULTS: Out of 195 patients, 108 (55.4%) had - stage IIIA disease and 103 (52.8%) had adenocarcinoma histology. The median age - and follow-up (in months) was 67 (IQR 60-74) and 21 (IQR 12-43), respectively. - The dose of radiation was 60 Gy in 30 fractions for148 patients (75.9%). Of the - 77 patients who received treatment since immunotherapy was available and standard - at our cancer center, 45 (58.4%) received at least one cycle. During follow-up, - 84 patients (43.1%) developed any metastasis, and 33 (16.9%) developed IM (either - alone or with extracranial metastasis). 150 patients (76.9%) experienced a - treatment delay (interval between diagnosis and treatment > 4 weeks). Factors - associated with developing any metastasis included higher overall stage at - diagnosis (p = 0.013) and higher prescribed dose (p = 0.022). Factors associated - with developing IM included higher ratio of involved over sampled lymph nodes - (p = 0.001) and receipt of pre-CRT systemic or radiotherapy for any reason - (p = 0.034). On multivariate logistical regression, treatment delay (OR 3.9, - p = 0.036) and overall stage at diagnosis (IIIA vs. IIIB/IIIC) (OR 2.8, p = 0.02) - predicted development of IM. These findings were sustained on sensitivity - analysis using different delay intervals. Median OS was not reached for the - overall cohort, and was 43.1 months for patients with IM and 40.3 months in those - with extracranial-only metastasis (p = 0.968). In patients with any metastasis, - median OS was longer (p = 0.003) for those who experienced a treatment delay - (48.4 months) compared to those that did not (12.2 months), likely due to - expedited diagnosis and treatment in patients with a higher symptom burden - secondary to more advanced disease. CONCLUSIONS: In patients with stage III NSCLC - treated with definitive CRT, the risk of IM appears to increase with overall - stage at diagnosis and, importantly, may be associated with experiencing a - treatment delay (> 4 weeks). Metastatic disease of any kind remains the primary - life-limiting prognostic factor in these patients with advanced lung cancer. In - patients with metastatic disease, treatment delay was associated with better - survival. Patients who experience a treatment delay and those initially diagnosed - at a more advanced overall stage may warrant more frequent surveillance for early - diagnosis and treatment of IM. Healthcare system stakeholders should strive to - mitigate treatment delay in patients with locally NSCLC to reduce the risk of IM. - Further research is needed to better understand factors associated with survival, - treatment delay, and the development of IM after CRT in the immunotherapy era. -CI - Copyright © 2023. Published by Elsevier Ltd. -FAU - Thibodeau, Stephane -AU - Thibodeau S -AD - Department of Oncology, Division of Radiation Oncology, Cancer Centre of - Southeastern Ontario, Kingston Health Sciences Centre, Ontario, Canada; Faculty - of Medicine, Queen's University, Ontario, Canada. Electronic address: - 13st14@queensu.ca. -FAU - Meem, Mahbuba -AU - Meem M -AD - Department of Oncology, Division of Radiation Oncology, Cancer Centre of - Southeastern Ontario, Kingston Health Sciences Centre, Ontario, Canada; Faculty - of Medicine, Queen's University, Ontario, Canada. -FAU - Hopman, Wilma -AU - Hopman W -AD - Faculty of Medicine, Queen's University, Ontario, Canada; Department of Public - Health Sciences, Kingston Health Sciences Research Institute, Ontario, Canada. -FAU - Sandhu, Simran -AU - Sandhu S -AD - Faculty of Medicine, Queen's University, Ontario, Canada. -FAU - Zalay, Osbert -AU - Zalay O -AD - Department of Radiology, Division of Radiation Oncology, Ottawa Hospital Cancer - Centre, Ontario, Canada. -FAU - Fung, Andrea S -AU - Fung AS -AD - Faculty of Medicine, Queen's University, Ontario, Canada; Department of Oncology, - Division of Medical Oncology, Cancer Centre of Southeastern Ontario, Kingston - Health Sciences Centre, Ontario, Canada. -FAU - Kartolo, Adi -AU - Kartolo A -AD - Department of Oncology, Division of Medical Oncology, Juravinski Cancer Centre, - Hamilton Health Sciences, Ontario, Canada. -FAU - Digby, Geneviève C -AU - Digby GC -AD - Faculty of Medicine, Queen's University, Ontario, Canada; Department of Internal - Medicine, Division of Respirology, Kingston Health Sciences Centre, Ontario, - Canada. -FAU - Al-Ghamdi, Shahad -AU - Al-Ghamdi S -AD - Faculty of Medicine, Queen's University, Ontario, Canada; Department of Internal - Medicine, Division of Respirology, Kingston Health Sciences Centre, Ontario, - Canada. -FAU - Robinson, Andrew -AU - Robinson A -AD - Faculty of Medicine, Queen's University, Ontario, Canada; Department of Oncology, - Division of Medical Oncology, Cancer Centre of Southeastern Ontario, Kingston - Health Sciences Centre, Ontario, Canada. -FAU - Ashworth, Allison -AU - Ashworth A -AD - Department of Oncology, Division of Radiation Oncology, Cancer Centre of - Southeastern Ontario, Kingston Health Sciences Centre, Ontario, Canada; Faculty - of Medicine, Queen's University, Ontario, Canada. -FAU - Owen, Timothy -AU - Owen T -AD - Department of Oncology, Division of Radiation Oncology, Cancer Centre of - Southeastern Ontario, Kingston Health Sciences Centre, Ontario, Canada; Faculty - of Medicine, Queen's University, Ontario, Canada. -FAU - Mahmud, Aamer -AU - Mahmud A -AD - Department of Oncology, Division of Radiation Oncology, Cancer Centre of - Southeastern Ontario, Kingston Health Sciences Centre, Ontario, Canada; Faculty - of Medicine, Queen's University, Ontario, Canada. -FAU - Tam, Kit -AU - Tam K -AD - Department of Oncology, Division of Radiation Therapy, Cancer Centre of - Southeastern Ontario, Kingston Health Sciences Centre, Ontario, Canada. -FAU - Olding, Timothy -AU - Olding T -AD - Department of Oncology, Division of Medical Physics, Cancer Centre of - Southeastern Ontario, Kingston Health Sciences Centre, Ontario, Canada. -FAU - de Moraes, Fabio Ynoe -AU - de Moraes FY -AD - Department of Oncology, Division of Radiation Oncology, Cancer Centre of - Southeastern Ontario, Kingston Health Sciences Centre, Ontario, Canada; Faculty - of Medicine, Queen's University, Ontario, Canada. -LA - eng -PT - Journal Article -DEP - 20230726 -PL - England -TA - Cancer Treat Res Commun -JT - Cancer treatment and research communications -JID - 101694651 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Neoplasm Staging -MH - Chemoradiotherapy -MH - *Adenocarcinoma/drug therapy -OTO - NOTNLM -OT - Chemoradiation -OT - Intracranial metastasis -OT - Treatment delay -COIS- Declaration of Competing Interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2023/08/03 01:06 -MHDA- 2023/09/04 06:43 -CRDT- 2023/08/02 18:03 -PHST- 2023/03/27 00:00 [received] -PHST- 2023/07/07 00:00 [revised] -PHST- 2023/07/22 00:00 [accepted] -PHST- 2023/09/04 06:43 [medline] -PHST- 2023/08/03 01:06 [pubmed] -PHST- 2023/08/02 18:03 [entrez] -AID - S2468-2942(23)00069-2 [pii] -AID - 10.1016/j.ctarc.2023.100747 [doi] -PST - ppublish -SO - Cancer Treat Res Commun. 2023;36:100747. doi: 10.1016/j.ctarc.2023.100747. Epub - 2023 Jul 26. - -PMID- 37002471 -OWN - NLM -STAT- MEDLINE -DCOM- 20230428 -LR - 20230428 -IS - 2523-899X (Electronic) -IS - 2523-899X (Linking) -VI - 43 -IP - 2 -DP - 2023 Apr -TI - Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in - Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint - Inhibitors. -PG - 344-359 -LID - 10.1007/s11596-023-2702-0 [doi] -AB - OBJECTIVE: The combination of stereotactic body radiation therapy (SBRT) and - immune checkpoint inhibitors (ICIs) is actively being explored in advanced - non-small-cell lung cancer (NSCLC) patients. However, little is known about the - optimal fractionation and radiotherapy target lesions in this scenario. This - study investigated the effect of SBRT on diverse organ lesions and radiotherapy - dose fractionation regimens on the prognosis of advanced NSCLC patients receiving - ICIs. METHODS: The medical records of advanced NSCLC patients consecutively - treated with ICIs and SBRT were retrospectively reviewed at our institution from - Dec. 2015 to Sep. 2021. Patients were grouped according to radiation sites. - Progression-free survival (PFS) and overall survival (OS) were recorded using the - Kaplan-Meier method and compared between different treatment groups using the - log-rank (Mantel-Cox) test. RESULTS: A total of 124 advanced NSCLC patients - receiving ICIs combined with SBRT were identified in this study. Radiation sites - included lung lesions (lung group, n=43), bone metastases (bone group, n=24), and - brain metastases (brain group, n=57). Compared with the brain group, the mean PFS - (mPFS) in the lung group was significantly prolonged by 13.3 months (8.5 months - vs. 21.8 months, HR=0.51, 95%CI: 0.28-0.92, P=0.0195), and that in the bone group - prolonged by 9.5 months with a 43% reduction in the risk of disease progression - (8.5 months vs. 18.0 months, HR=0.57, 95%CI: 0.29-1.13, P=0.1095). The mPFS in - the lung group was prolonged by 3.8 months as compared with that in the bone - group. The mean OS (mOS) in the lung and bone groups was longer than that of the - brain group, and the risk of death decreased by up to 60% in the lung and bone - groups as compared with that of the brain group. When SBRT was concurrently given - with ICIs, the mPFS in the lung and brain groups were significantly longer than - that of the bone group (29.6 months vs. 16.5 months vs. 12.1 months). When SBRT - with 8-12 Gy per fraction was combined with ICIs, the mPFS in the lung group was - significantly prolonged as compared with that of the bone and brain groups (25.4 - months vs. 15.2 months vs. 12.0 months). Among patients receiving SBRT on lung - lesions and brain metastases, the mPFS in the concurrent group was longer than - that of the SBRT→ICIs group (29.6 months vs. 11.4 months, P=0.0003 and 12.1 - months vs. 8.9 months, P=0.2559). Among patients receiving SBRT with <8 Gy and - 8-12 Gy per fraction, the mPFS in the concurrent group was also longer than that - of the SBRT→ICIs group (20.1 months vs. 5.3 months, P=0.0033 and 24.0 months vs. - 13.4 months, P=0.1311). The disease control rates of the lung, bone, and brain - groups were 90.7%, 83.3%, and 70.1%, respectively. CONCLUSION: The study - demonstrated that the addition of SBRT on lung lesions versus bone and brain - metastases to ICIs improved the prognosis in advanced NSCLC patients. This - improvement was related to the sequence of radiotherapy combined with ICIs and - the radiotherapy fractionation regimens. Dose fractionation regimens of 8-12 Gy - per fraction and lung lesions as radiotherapy targets might be the appropriate - choice for advanced NSCLC patients receiving ICIs combined with SBRT. -CI - © 2023. Huazhong University of Science and Technology. -FAU - Zhu, Kui-Kui -AU - Zhu KK -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. -FAU - Wei, Jie-Lin -AU - Wei JL -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. -FAU - Xu, Yun-Hong -AU - Xu YH -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. -FAU - Li, Jun -AU - Li J -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. -FAU - Rao, Xin-Rui -AU - Rao XR -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. -FAU - Xu, Ying-Zhuo -AU - Xu YZ -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. -FAU - Xing, Bi-Yuan -AU - Xing BY -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. -FAU - Zhang, Si-Jia -AU - Zhang SJ -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. -FAU - Chen, Lei-Chong -AU - Chen LC -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. -FAU - Dong, Xiao-Rong -AU - Dong XR -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. -FAU - Zhang, Sheng -AU - Zhang S -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. -FAU - Li, Zheng-Yu -AU - Li ZY -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. -FAU - Liu, Cui-Wei -AU - Liu CW -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. cuiweiliu19870620@163.com. -FAU - Meng, Rui -AU - Meng R -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. mengruivip@163.com. -FAU - Wu, Gang -AU - Wu G -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, 430022, China. xlzlwg@163.com. -LA - eng -PT - Journal Article -DEP - 20230331 -PL - China -TA - Curr Med Sci -JT - Current medical science -JID - 101729993 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Immune Checkpoint Inhibitors -MH - Retrospective Studies -MH - *Radiosurgery/methods -OTO - NOTNLM -OT - advanced non-small cell lung cancer -OT - dose fractionation regimens -OT - immune checkpoint inhibitors -OT - organ-specific prognoses -OT - stereotactic body radiation therapy -EDAT- 2023/04/01 06:00 -MHDA- 2023/04/28 06:42 -CRDT- 2023/03/31 23:31 -PHST- 2022/04/13 00:00 [received] -PHST- 2022/05/31 00:00 [accepted] -PHST- 2023/04/28 06:42 [medline] -PHST- 2023/04/01 06:00 [pubmed] -PHST- 2023/03/31 23:31 [entrez] -AID - 10.1007/s11596-023-2702-0 [pii] -AID - 10.1007/s11596-023-2702-0 [doi] -PST - ppublish -SO - Curr Med Sci. 2023 Apr;43(2):344-359. doi: 10.1007/s11596-023-2702-0. Epub 2023 - Mar 31. - -PMID- 36209942 -OWN - NLM -STAT- MEDLINE -DCOM- 20221201 -LR - 20240328 -IS - 1879-0887 (Electronic) -IS - 0167-8140 (Linking) -VI - 176 -DP - 2022 Nov -TI - Treatment-related pulmonary adverse events induced by chemoradiation and - Durvalumab affect survival in locally advanced non-small cell lung cancer. -PG - 149-156 -LID - S0167-8140(22)04495-4 [pii] -LID - 10.1016/j.radonc.2022.10.002 [doi] -AB - PURPOSE: We compared treatment-related pulmonary adverse events (TRPAE), - progression-free survival (PFS), and overall survival (OS) among locally advanced - non-small cell lung cancer (NSCLC) patients who received concurrent - chemoradiotherapy (CRT) versus CRT followed by immune check point inhibitor (ICI) - immunotherapy (CRTI). MATERIALS AND METHODS: TRPAE was defined as any pulmonary - events as defined in CTCAE v.5 occurring within 12 months after completion of - radiotherapy. Outcomes were compared between CRT and CTRI by Cox proportional - hazard regression and Kaplan-Meier analyses. We also assessed if TRPAE-induced - discontinuation of ICI affected survival. RESULTS: We analyzed 326 patients - treated between July 2010 and November 2019; 195 patients received CRT and 131 - received CRTI. The incidences of severe grade ≥ 3 TRPAE were similar between the - two groups, however, symptomatic TRPAE was almost doubled in CRTI group (65.7 % - CTRI vs 35.9 % CRT, P < 0.0001). The rates of 4-year OS and PFS were 54.5 % vs - 36.7 % (P = 0.0003) and 43.8 % vs 35.8 % (P = 0.038) in CRT + Durvalumab and CRT - group, respectively. Receipt of ICI Durvalumab was associated with better 4-year - OS (HR 0.53, 95 % CI 0.36-0.78, P = 0.001) and PFS (HR 0.55, 95 % CI 0.38-0.80, - P = 0.002). Patients who discontinued ICI because of TRPAE had worse 4-year OS - (P = 0.001) and higher rates of distant metastasis (P = 0.003) than those who - completed planned ICI after developing TRPAE. CONCLUSION: CRT followed by - adjuvant ICI led to improved 4-year OS and PFS consistent with published data. - CRTI was associated with higher incidence of grade ≥ 2 TRPAE in both high and low - mean lung dose groups without significant difference in grade ≥ 3 TRPAE. - Discontinuation of ICI due to TRPAE was associated with poorer OS and distant - disease control than completing ICI as planned after developing TRPAE. -CI - Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved. -FAU - Xu, Ting -AU - Xu T -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Wu, Lirong -AU - Wu L -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA; Department of Radiation Oncology, Jiangsu Cancer - Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital - of Nanjing Medical University, Nanjing, China. -FAU - Gandhi, Saumil -AU - Gandhi S -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Jing, Wang -AU - Jing W -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Nguyen, Quyhn-Nhu -AU - Nguyen QN -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Chen, Aileen -AU - Chen A -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Chang, Joe Y -AU - Chang JY -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Nurieva, Roza -AU - Nurieva R -AD - Department of Immunology, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Sheshadri, Ajay -AU - Sheshadri A -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Altan, Mehmet -AU - Altan M -AD - Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Lee, Percy P -AU - Lee PP -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Lin, Steven H -AU - Lin SH -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Liao, Zhongxing -AU - Liao Z -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. Electronic address: zliao@mdanderson.org. -LA - eng -GR - R01 HL157273/HL/NHLBI NIH HHS/United States -GR - P30 CA016672/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20221007 -PL - Ireland -TA - Radiother Oncol -JT - Radiotherapy and oncology : journal of the European Society for Therapeutic - Radiology and Oncology -JID - 8407192 -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung -MH - *Lung Neoplasms/pathology -MH - Chemoradiotherapy/adverse effects -MH - Lung/pathology -OTO - NOTNLM -OT - Adjuvant immunotherapy -OT - Concurrent chemoradiotherapy -OT - Disease outcome -OT - Non-small cell lung cancer -OT - Pulmonary toxicities -COIS- Declaration of Competing Interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2022/10/10 06:00 -MHDA- 2022/12/02 06:00 -CRDT- 2022/10/09 19:24 -PHST- 2022/05/16 00:00 [received] -PHST- 2022/09/27 00:00 [revised] -PHST- 2022/10/03 00:00 [accepted] -PHST- 2022/10/10 06:00 [pubmed] -PHST- 2022/12/02 06:00 [medline] -PHST- 2022/10/09 19:24 [entrez] -AID - S0167-8140(22)04495-4 [pii] -AID - 10.1016/j.radonc.2022.10.002 [doi] -PST - ppublish -SO - Radiother Oncol. 2022 Nov;176:149-156. doi: 10.1016/j.radonc.2022.10.002. Epub - 2022 Oct 7. - -PMID- 27393510 -OWN - NLM -STAT- MEDLINE -DCOM- 20171222 -LR - 20220321 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 98 -DP - 2016 Aug -TI - Toxicity of definitive and post-operative radiation following ipilimumab in - non-small cell lung cancer. -PG - 76-78 -LID - S0169-5002(16)30340-3 [pii] -LID - 10.1016/j.lungcan.2016.05.014 [doi] -AB - To determine the feasibility and toxicity of radiation therapy, delivered either - as definitive treatment or following surgery, following neo-adjuvant immune - checkpoint inhibition for locally advanced NSCLC sixteen patients who received - neo-adjuvant chemotherapy including ipilimumab as part of a phase II study were - identified. Patients were analyzed by intent of radiation and toxicity graded - based on CTCAE 4.0. There were seven patients identified who received definitive - radiation and nine who received post-operative radiation. There was no grade 3 or - greater toxicity in the definitive treatment group although one patient stopped - treatment early due to back pain secondary to progression outside of the - treatment field. In the post-operative treatment group, one patient required a - one week break due to grade 2 odynophagia and no grade 3 or greater toxicity was - observed. In this study of radiation as definitive or post-operative treatment - following neo-adjuvant chemotherapy including ipilimumab for locally advanced - NSCLC was feasible and well tolerated with limited toxicity. -CI - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved. -FAU - Boyer, Matthew J -AU - Boyer MJ -AD - Department of Radiation Oncology, Duke University, Durham, NC 27710, USA. - Electronic address: mjb14@dm.duke.edu. -FAU - Gu, Lin -AU - Gu L -AD - Duke Cancer Institute, Department of Biostatistics, Duke University, Durham, NC - 27710, USA. -FAU - Wang, Xiaofei -AU - Wang X -AD - Duke Cancer Institute, Department of Biostatistics, Duke University, Durham, NC - 27710, USA. -FAU - Kelsey, Chris R -AU - Kelsey CR -AD - Department of Radiation Oncology, Duke University, Durham, NC 27710, USA. -FAU - Yoo, David S -AU - Yoo DS -AD - Department of Radiation Oncology, Duke University, Durham, NC 27710, USA. -FAU - Onaitis, Mark W -AU - Onaitis MW -AD - Department of Surgery, Division of Cardiothoracic Surgery, Duke University, - Durham, NC 27710, USA. -FAU - Dunphy, Frank R -AU - Dunphy FR -AD - Department of Medicine, Division of Medical Oncology, Duke University, Durham, NC - 27710, USA. -FAU - Crawford, Jeffrey -AU - Crawford J -AD - Department of Medicine, Division of Medical Oncology, Duke University, Durham, NC - 27710, USA. -FAU - Ready, Neal E -AU - Ready NE -AD - Department of Medicine, Division of Medical Oncology, Duke University, Durham, NC - 27710, USA. -FAU - Salama, Joseph K -AU - Salama JK -AD - Department of Radiation Oncology, Duke University, Durham, NC 27710, USA. -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20160525 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Ipilimumab) -SB - IM -MH - Aged -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/diagnosis/*therapy -MH - Chemotherapy, Adjuvant -MH - Combined Modality Therapy -MH - Dose Fractionation, Radiation -MH - Female -MH - Humans -MH - Ipilimumab/*therapeutic use -MH - Lung Neoplasms/diagnosis/*therapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Postoperative Care/adverse effects/methods -MH - Radiotherapy Dosage -MH - Radiotherapy, Adjuvant/*adverse effects -MH - Treatment Outcome -OTO - NOTNLM -OT - Ipilimumab -OT - Non-small cell lung cancer -OT - Radiation -OT - Toxicity -EDAT- 2016/07/10 06:00 -MHDA- 2017/12/23 06:00 -CRDT- 2016/07/10 06:00 -PHST- 2016/04/05 00:00 [received] -PHST- 2016/04/27 00:00 [revised] -PHST- 2016/05/24 00:00 [accepted] -PHST- 2016/07/10 06:00 [entrez] -PHST- 2016/07/10 06:00 [pubmed] -PHST- 2017/12/23 06:00 [medline] -AID - S0169-5002(16)30340-3 [pii] -AID - 10.1016/j.lungcan.2016.05.014 [doi] -PST - ppublish -SO - Lung Cancer. 2016 Aug;98:76-78. doi: 10.1016/j.lungcan.2016.05.014. Epub 2016 May - 25. - -PMID- 35613998 -OWN - NLM -STAT- MEDLINE -DCOM- 20220621 -LR - 20230703 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Print) -IS - 1525-7304 (Linking) -VI - 23 -IP - 5 -DP - 2022 Jul -TI - Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based - systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell - lung cancer. -PG - e317-e320 -LID - S1525-7304(22)00065-1 [pii] -LID - 10.1016/j.cllc.2022.04.004 [doi] -AB - INTRODUCTION: Treatment of advanced stage non-small cell lung cancer (NSCLC) has - changed dramatically due to immunotherapy. However, patients without Programmed - Death-Ligand 1 (PD-L1) protein expression often benefit less from immunotherapy. - This trial is designed to test if stereotactic body radiation therapy (SBRT) to a - single tumor site can significantly enhance the outcome of patients with advanced - stage PD-L1(-) NSCLC when added to systemic therapy including immunotherapy. - MATERIALS AND METHODS: Alliance A082002 is based on subgroup analysis from the - randomized phase II PEMBRO-RT trial., PEMBRO-RT compared pembrolizumab alone or - with SBRT and revealed improved progression-free and overall survival (PFS and - OS, respectively) in PD-L1(-) patients when adding SBRT (8 Gy x 3 fractions). In - A082002, patients without PD-L1 expression will be randomized to SBRT (8 Gy x3) - plus systemic therapy vs. systemic therapy alone. The primary endpoint of the - phase II portion of the trial is PFS and will require 100 patients. The primary - endpoint of the phase III portion of the trial is OS and will require an - additional 284 patients. This trial will clarify whether adding SBRT to systemic - therapy can improve PFS and OS in a larger multi-institutional cohort. Several - systemic treatment options are allowed including either immunotherapy alone or - chemo-immunotherapy. CONCLUSIONS: This phase II/III Alliance trial A082002 will - test whether the addition of SBRT to a single tumor site will enhance the - anti-tumor activity of systemic immunotherapy or chemo-immunotherapy in patients - with stage IV PD-L1(-) NSCLC. It is now open in the National Clinical Trials - Network (NCTN). -CI - Copyright © 2022 Elsevier Inc. All rights reserved. -FAU - Schild, Steven E -AU - Schild SE -AD - Department of Radiation Oncology, Mayo Clinic, 13400 E. Shea Blvd, Phoenix, AZ, - United States. Electronic address: sschild@mayo.edu. -FAU - Wang, Xiaofei -AU - Wang X -AD - Alliance Statistics and Data Management Center, Duke University, Durham, NC, - United States. -FAU - Bestvina, Christine M -AU - Bestvina CM -AD - Department of Hematology and Oncology, University of Chicago Medicine, Chicago, - IL, United States. -FAU - Williams, Terence -AU - Williams T -AD - Department of Radiation Oncology, City of Hope Comprehensive Cancer Center, - Duarte, CA, United States. -FAU - Masters, Greg -AU - Masters G -AD - Department of Medical Oncology, Christiana Care Hospitals, Newark, DE, United - States. -FAU - Singh, Anurag K -AU - Singh AK -AD - Department of Radiation Oncology, Roswell Park Comprehensive Cancer Center, - Buffalo, NY, United States. -FAU - Stinchcombe, Thomas E -AU - Stinchcombe TE -AD - Department of Medical Oncology, Duke Cancer Institute, Durham, NC, United States. -FAU - Salama, Joseph K -AU - Salama JK -AD - Department of Medical Oncology, Duke Cancer Institute, Durham, NC, United States. -FAU - Wolf, Steven -AU - Wolf S -AD - Department of Medical Oncology, Duke Cancer Institute, Durham, NC, United States. -FAU - Zemla, Tyler -AU - Zemla T -AD - Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, - United States. -FAU - Duma, Narjust -AU - Duma N -AD - Department of Medical Oncology, University of Wisconsin, Madison, WI, United - States. -FAU - Chun, Stephen G -AU - Chun SG -AD - Department of Radiation Oncology, Anderson Cancer Center, Houston, TX, United - States. -FAU - Amini, Arya -AU - Amini A -AD - Department of Radiation Oncology, City of Hope Comprehensive Cancer Center, - Duarte, CA, United States. -FAU - Kozono, David -AU - Kozono D -AD - Department of Radiation Oncology, Dana-Farber/Partners Cancer Care, Boston, MA, - United States. -FAU - Watt, Colleen -AU - Watt C -AD - Alliance Protocol Operations Central Office, University of Chicago, Chicago, IL, - United States. -LA - eng -SI - ClinicalTrials.gov/NCT04929041 -GR - U10 CA180868/CA/NCI NIH HHS/United States -GR - UG1 CA232760/CA/NCI NIH HHS/United States -GR - UG1 CA233180/CA/NCI NIH HHS/United States -GR - UG1 CA233191/CA/NCI NIH HHS/United States -GR - U10 CA180882/CA/NCI NIH HHS/United States -GR - U10 CA180820/CA/NCI NIH HHS/United States -GR - UG1 CA233253/CA/NCI NIH HHS/United States -GR - U10 CA180888/CA/NCI NIH HHS/United States -GR - U10 CA180821/CA/NCI NIH HHS/United States -GR - UG1 CA233277/CA/NCI NIH HHS/United States -PT - Clinical Trial, Phase II -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Randomized Controlled Trial -PT - Research Support, N.I.H., Extramural -DEP - 20220430 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -SB - IM -MH - B7-H1 Antigen -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -MH - *Radiosurgery -PMC - PMC9634857 -MID - NIHMS1844315 -OTO - NOTNLM -OT - Chemotherapy -OT - Immunotherapy -OT - Lung cancer -OT - Stereotactic body radiation therapy -OT - advanced stage non-small cell lung cancer -OT - programmed death-1 ligand negative -EDAT- 2022/05/26 06:00 -MHDA- 2022/06/22 06:00 -PMCR- 2023/07/01 -CRDT- 2022/05/25 22:04 -PHST- 2022/02/28 00:00 [received] -PHST- 2022/04/03 00:00 [accepted] -PHST- 2022/05/26 06:00 [pubmed] -PHST- 2022/06/22 06:00 [medline] -PHST- 2022/05/25 22:04 [entrez] -PHST- 2023/07/01 00:00 [pmc-release] -AID - S1525-7304(22)00065-1 [pii] -AID - 10.1016/j.cllc.2022.04.004 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2022 Jul;23(5):e317-e320. doi: 10.1016/j.cllc.2022.04.004. Epub - 2022 Apr 30. - -PMID- 35379201 -OWN - NLM -STAT- MEDLINE -DCOM- 20220406 -LR - 20220408 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 22 -IP - 1 -DP - 2022 Apr 4 -TI - Durvalumab after chemoradiotherapy for locally advanced non-small cell lung - cancer prolonged distant metastasis-free survival, progression-free survival and - overall survival in clinical practice. -PG - 364 -LID - 10.1186/s12885-022-09354-1 [doi] -LID - 364 -AB - BACKGROUND: In clinical practice, the effect of durvalumab and radiation - pneumonitis (RP) on survival after intensity-modulated radiotherapy (IMRT) is not - fully understood. The purpose of this retrospective study was to investigate - factors related to distant metastasis-free survival (DMFS), progression-free - survival (PFS) and overall survival (OS) after IMRT for locally advanced - non-small cell lung cancer (LA-NSCLC). METHODS: All patients who were treated - with conventional fractionated IMRT for LA-NSCLC between April 2016 and March - 2021 were eligible. Time-to-event data were assessed by using the Kaplan-Meier - estimator, and the Cox proportional hazards model was used for prognostic factor - analyses. Factors that emerged after the start of IMRT, such as durvalumab - administration or the development of RP, were analysed as time-dependent - covariates. RESULTS: A total of 68 consecutive patients treated with conventional - fractionated IMRT for LA-NSCLC were analysed. Sixty-six patients completed - radiotherapy, 50 patients received concurrent chemotherapy, and 36 patients - received adjuvant durvalumab. During the median follow-up period of 14.3 months, - 23 patients died, and tumour progression occurred in 37 patients, including 28 - patients with distant metastases. The 1-year DMFS rate, PFS rate and OS rate were - 59.9%, 48.7% and 84.2%, respectively. Grade 2 RP occurred in 16 patients, grade 3 - in 6 patients and grade 5 in 1 patient. The 1-year cumulative incidences of grade - 2 or higher RP and grade 3 or higher RP were 33.8% and 10.3%, respectively. The - results of multivariate analyses showed that durvalumab had a significantly lower - hazard ratio (HR) for DMFS, PFS and OS (HR 0.31, p < 0.01; HR 0.33, p < 0.01 and - HR 0.32, p = 0.02), respectively. Grade 2 or higher RP showed significance for - DMFS and a nonsignificant trend for OS (HR 2.28, p = 0.04 and HR 2.12, p = 0.13), - respectively, whereas a higher percentage of lung volume receiving 20 Gy or - higher was significant for PFS (HR 2.25, p = 0.01). CONCLUSIONS: In clinical - practice, durvalumab administration following IMRT with concomitant chemotherapy - showed a significant survival benefit. Reducing the risk of grade 2 or higher RP - would also be beneficial. -CI - © 2022. The Author(s). -FAU - Yamamoto, Takaya -AU - Yamamoto T -AD - Department of Radiation Oncology, Tohoku University Graduate School of Medicine, - Sendai, Japan. t.yamamoto@rad.med.tohoku.ac.jp. -FAU - Tsukita, Yoko -AU - Tsukita Y -AD - Department of Respiratory Medicine, Tohoku University Graduate School of - Medicine, Sendai, Japan. -FAU - Katagiri, Yu -AU - Katagiri Y -AD - Department of Radiation Oncology, Tohoku University Graduate School of Medicine, - Sendai, Japan. -FAU - Matsushita, Haruo -AU - Matsushita H -AD - Department of Radiation Oncology, Tohoku University Graduate School of Medicine, - Sendai, Japan. -FAU - Umezawa, Rei -AU - Umezawa R -AD - Department of Radiation Oncology, Tohoku University Graduate School of Medicine, - Sendai, Japan. -FAU - Ishikawa, Yojiro -AU - Ishikawa Y -AD - Department of Radiation Oncology, Tohoku University Graduate School of Medicine, - Sendai, Japan. -FAU - Takahashi, Noriyoshi -AU - Takahashi N -AD - Department of Radiation Oncology, Tohoku University Graduate School of Medicine, - Sendai, Japan. -FAU - Suzuki, Yu -AU - Suzuki Y -AD - Department of Radiation Oncology, Tohoku University Graduate School of Medicine, - Sendai, Japan. -FAU - Takeda, Kazuya -AU - Takeda K -AD - Department of Radiation Oncology, Tohoku University Graduate School of Medicine, - Sendai, Japan. -FAU - Miyauchi, Eisaku -AU - Miyauchi E -AD - Department of Respiratory Medicine, Tohoku University Graduate School of - Medicine, Sendai, Japan. -FAU - Saito, Ryota -AU - Saito R -AD - Department of Respiratory Medicine, Tohoku University Graduate School of - Medicine, Sendai, Japan. -FAU - Katsuta, Yoshiyuki -AU - Katsuta Y -AD - Department of Radiation Oncology, Tohoku University Graduate School of Medicine, - Sendai, Japan. -FAU - Kadoya, Noriyuki -AU - Kadoya N -AD - Department of Radiation Oncology, Tohoku University Graduate School of Medicine, - Sendai, Japan. -FAU - Jingu, Keiichi -AU - Jingu K -AD - Department of Radiation Oncology, Tohoku University Graduate School of Medicine, - Sendai, Japan. -LA - eng -PT - Journal Article -DEP - 20220404 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - Chemoradiotherapy/adverse effects -MH - Disease-Free Survival -MH - Humans -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Progression-Free Survival -MH - Retrospective Studies -PMC - PMC8981776 -OTO - NOTNLM -OT - Chemoradiotherapy -OT - Durvalumab -OT - IMRT -OT - Intensity-modulated radiotherapy -OT - Time-dependent covariate -COIS- TY, YT, YK(1) and RS have received lecturer fees from AstraZeneca KK. EM has - received grants from Chugai Pharmaceutical Co Ltd. and Eli Lily Japan KK., - honouraria from AstraZeneca KK., Taiho Pharmaceutical Co Ltd., Daiichi Sankyo - KK., Boehringer Ingelheim Japan Inc., Bristol Myers Squibb Co Ltd., Novartis - Pharma KK., MSD KK., Kyowa Kirin Co Ltd., Merck Biopharma Co Ltd., Pfizer Inc., - Ono Pharmaceutical Co Ltd., Otsuka Pharmaceutical Co Ltd. and Towa Pharmaceutical - Co. Ltd., and EM has been an advisory board of Chugai Pharmaceutical Co Ltd, - Boehringer Ingelheim Japan Inc and Eli Lilly Japan KK. KJ has received consulting - fees from Varian Medical Systems and Elekta, and honouraria from Shimazu. Co. HM, - RU, YI, NT, YS, YK(2) and NK have no conflicts of interest. -EDAT- 2022/04/06 06:00 -MHDA- 2022/04/07 06:00 -PMCR- 2022/04/04 -CRDT- 2022/04/05 05:27 -PHST- 2022/01/07 00:00 [received] -PHST- 2022/03/02 00:00 [accepted] -PHST- 2022/04/05 05:27 [entrez] -PHST- 2022/04/06 06:00 [pubmed] -PHST- 2022/04/07 06:00 [medline] -PHST- 2022/04/04 00:00 [pmc-release] -AID - 10.1186/s12885-022-09354-1 [pii] -AID - 9354 [pii] -AID - 10.1186/s12885-022-09354-1 [doi] -PST - epublish -SO - BMC Cancer. 2022 Apr 4;22(1):364. doi: 10.1186/s12885-022-09354-1. - -PMID- 36806899 -OWN - NLM -STAT- MEDLINE -DCOM- 20230331 -LR - 20230412 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 178 -DP - 2023 Apr -TI - Safety and tolerability of stereotactic radiotherapy combined with durvalumab - with or without tremelimumab in advanced non-small cell lung cancer, the phase I - SICI trial. -PG - 96-102 -LID - S0169-5002(23)00052-1 [pii] -LID - 10.1016/j.lungcan.2023.02.004 [doi] -AB - INTRODUCTION: This phase I study primarily addresses the safety and tolerability - of Stereotactic radiotherapy on the primary tumor combined with double Immune - Checkpoint Inhibition (SICI) in patients with non-small cell lung cancer (NSCLC). - Increasing the release of neoantigens by radiotherapy might enhance response to - immunotherapy. Especially, by targeting trunk mutations in the primary tumor. - MATERIALS AND METHODS: In three sequential cohorts, immunotherapy regimes - combined with stereotactic body radiotherapy (SBRT) on the primary tumor (1x20 Gy - on 9 cc) were studied in stage IIIB/IV NSCLC patients progressing on - chemotherapy. The first cohort (n = 3) received durvalumab. The second (n = 6) - received a combination of tremelimumab and durvalumab followed by durvalumab - monotherapy. The third cohort (n = 6) was similar except that the combination was - reversed. Descriptive statistics were used to assess safety parameters and the - exploratory outcomes of efficacy. Adverse events were reported using NCI CTCAE - version 4.03. Exhaled breath was analyzed at baseline. RESULTS: Fifteen patients - were included. Median irradiated volume was 9.13 cc, on a median primary tumor - volume of 79 cc. There were seven patients with grade 1-2, and two patients with - grade 3 treatment related adverse events. There was 1 dose limiting toxicity - (colitis) with double immunotherapy. CONCLUSION: The combination of SBRT to the - primary tumor and double immunotherapy in advanced NSCLC patients is safe and - feasible. -CI - Copyright © 2023. Published by Elsevier B.V. -FAU - Kievit, H -AU - Kievit H -AD - Department of Pulmonary Diseases, University of Groningen, University Medical - Center Groningen, Groningen, the Netherlands. -FAU - Muntinghe-Wagenaar, M B -AU - Muntinghe-Wagenaar MB -AD - Department of Pulmonary Diseases, University of Groningen, University Medical - Center Groningen, Groningen, the Netherlands. -FAU - Hijmering-Kappelle, L B M -AU - Hijmering-Kappelle LBM -AD - Department of Pulmonary Diseases, University of Groningen, University Medical - Center Groningen, Groningen, the Netherlands. -FAU - Hiddinga, B I -AU - Hiddinga BI -AD - Department of Pulmonary Diseases, University of Groningen, University Medical - Center Groningen, Groningen, the Netherlands. -FAU - Ubbels, J F -AU - Ubbels JF -AD - Department of Radiation Oncology, University of Groningen, University Medical - Center Groningen, Groningen, the Netherlands. -FAU - Wijsman, R -AU - Wijsman R -AD - Department of Radiation Oncology, University of Groningen, University Medical - Center Groningen, Groningen, the Netherlands. -FAU - Slingers, G -AU - Slingers G -AD - Breathomix BV, Leiden, the Netherlands. -FAU - de Vries, R -AU - de Vries R -AD - Breathomix BV, Leiden, the Netherlands. -FAU - Groen, H J M -AU - Groen HJM -AD - Department of Pulmonary Diseases, University of Groningen, University Medical - Center Groningen, Groningen, the Netherlands. -FAU - Kerstjens, H A M -AU - Kerstjens HAM -AD - Department of Pulmonary Diseases, University of Groningen, University Medical - Center Groningen, Groningen, the Netherlands. -FAU - van der Wekken, A J -AU - van der Wekken AJ -AD - Department of Pulmonary Diseases, University of Groningen, University Medical - Center Groningen, Groningen, the Netherlands. -FAU - Hiltermann, T J N -AU - Hiltermann TJN -AD - Department of Pulmonary Diseases, University of Groningen, University Medical - Center Groningen, Groningen, the Netherlands. Electronic address: - t.j.n.hiltermann@umcg.nl. -LA - eng -PT - Clinical Trial, Phase I -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20230207 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 28X28X9OKV (durvalumab) -RN - QEN1X95CIX (tremelimumab) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Radiosurgery -MH - *Lung Neoplasms/drug therapy/etiology -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -OTO - NOTNLM -OT - Immunotherapy -OT - Non-small cell lung cancer -OT - Resistance -OT - Safety -OT - Stereotactic body radiotherapy -OT - Tolerability -COIS- Declaration of Competing Interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2023/02/23 06:00 -MHDA- 2023/03/31 06:42 -CRDT- 2023/02/22 11:05 -PHST- 2022/11/10 00:00 [received] -PHST- 2022/12/23 00:00 [revised] -PHST- 2023/02/04 00:00 [accepted] -PHST- 2023/03/31 06:42 [medline] -PHST- 2023/02/23 06:00 [pubmed] -PHST- 2023/02/22 11:05 [entrez] -AID - S0169-5002(23)00052-1 [pii] -AID - 10.1016/j.lungcan.2023.02.004 [doi] -PST - ppublish -SO - Lung Cancer. 2023 Apr;178:96-102. doi: 10.1016/j.lungcan.2023.02.004. Epub 2023 - Feb 7. - -PMID- 37005095 -OWN - NLM -STAT- MEDLINE -DCOM- 20230529 -LR - 20230529 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 14 -IP - 15 -DP - 2023 May -TI - Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy - in extensive-stage small cell lung cancer patients: A real-world multicenter - propensity score-matched study. -PG - 1327-1338 -LID - 10.1111/1759-7714.14874 [doi] -AB - OBJECTIVES: Our research aimed to evaluate the effectiveness of first-line immune - checkpoint inhibitors (ICIs) with etoposide and platinum (EP) for extensive-stage - small cell lung cancer (ES-SCLC) and identify prognostic factors, as real-world - outcomes and the inconsistency of PD-1 and PD-L1 inhibitors are uncertain. - METHODS: We selected ES-SCLC patients in three centers and conducted a propensity - score-matched analysis. The Kaplan-Meier method and Cox proportional hazards - regression were conducted to compare the survival outcomes. We also performed - univariate and multivariate Cox regression analyses to investigate predictors. - RESULTS: Among 236 patients included, 83 pairs of cases were matched. The EP plus - ICIs cohort had a longer median overall survival (OS) (17.3 months) than the EP - cohort (13.4 months) (hazard ratio [HR],  0.61 [0.45, 0.83]; p = 0.001). The - median progression-free survival (PFS) was also longer in the EP plus ICIs cohort - (8.3 months) than in the EP cohort (5.9 months) (HR,   0.44 [0.32, 0.60]; - p < 0.001). The EP plus ICIs group had a higher objective response rate (ORR) - (EP: 62.3%, EP + ICIs: 84.3%, p < 0.001). Multivariate analysis presented that - liver metastases (HR, 2.08; p = 0.018) and lymphocyte-monocyte ratio (LMR) (HR, - 0.54; p = 0.049) were independent prognostic factors for OS, and performance - status (PS) (HR, 2.11; p = 0.015), liver metastases (HR, 2.64; p = 0.002), and - neutrophil-lymphocyte ratio (NLR) (HR, 0.45; p = 0.028) were for PFS in patients - with chemo-immunotherapy. CONCLUSION: Our real-world data demonstrated that ICIs - with chemotherapy as the first-line setting for ES-SCLC are effective and safe. - PS, liver metastases, and inflammatory markers could serve as valuable risk - factors. -CI - © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Xie, Jingyuan -AU - Xie J -AD - Department of Respiratory and Critical Care Medicine, Affiliated Jinling - Hospital, Medical School, Nanjing University, Nanjing, China. -FAU - Chen, Mo -AU - Chen M -AUID- ORCID: 0000-0002-4466-3602 -AD - Department of Respiratory and Critical Care Medicine, Jinling Hospital, Jinling - Clinical College of Nanjing Medical University, Nanjing, China. -FAU - Han, Hedong -AU - Han H -AD - Department of Respiratory and Critical Care Medicine, Affiliated Jinling - Hospital, Medical School, Nanjing University, Nanjing, China. -FAU - Xu, Ke -AU - Xu K -AD - Department of Respiratory and Critical Care Medicine, Affiliated Jinling - Hospital, Medical School, Nanjing University, Nanjing, China. -FAU - Qiu, Guihuan -AU - Qiu G -AD - State Key Laboratory of Respiratory Disease, National Clinical Research Centre - for Respiratory Disease, Guangzhou Institute of Respiratory Health, First - Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. -FAU - Lin, Xinqing -AU - Lin X -AUID- ORCID: 0000-0001-9436-2229 -AD - State Key Laboratory of Respiratory Disease, National Clinical Research Centre - for Respiratory Disease, Guangzhou Institute of Respiratory Health, First - Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. -FAU - Song, Yong -AU - Song Y -AUID- ORCID: 0000-0003-4979-4131 -AD - Department of Respiratory and Critical Care Medicine, Affiliated Jinling - Hospital, Medical School, Nanjing University, Nanjing, China. -AD - Department of Respiratory and Critical Care Medicine, Jinling Hospital, Jinling - Clinical College of Nanjing Medical University, Nanjing, China. -FAU - Ye, Jinjun -AU - Ye J -AD - Department of Radiotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer - Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China. -FAU - Lv, Tangfeng -AU - Lv T -AUID- ORCID: 0000-0001-7224-8468 -AD - Department of Respiratory and Critical Care Medicine, Affiliated Jinling - Hospital, Medical School, Nanjing University, Nanjing, China. -AD - Department of Respiratory and Critical Care Medicine, Jinling Hospital, Jinling - Clinical College of Nanjing Medical University, Nanjing, China. -FAU - Zhan, Ping -AU - Zhan P -AUID- ORCID: 0000-0002-7983-976X -AD - Department of Respiratory and Critical Care Medicine, Affiliated Jinling - Hospital, Medical School, Nanjing University, Nanjing, China. -AD - Department of Respiratory and Critical Care Medicine, Jinling Hospital, Jinling - Clinical College of Nanjing Medical University, Nanjing, China. -LA - eng -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -DEP - 20230402 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 6PLQ3CP4P3 (Etoposide) -RN - 49DFR088MY (Platinum) -SB - IM -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use -MH - Programmed Cell Death 1 Receptor -MH - Propensity Score -MH - *Small Cell Lung Carcinoma/drug therapy -MH - Etoposide/pharmacology/therapeutic use -MH - *Liver Neoplasms -MH - Platinum -MH - *Lung Neoplasms/drug therapy -PMC - PMC10212658 -OTO - NOTNLM -OT - PD-1 inhibitors -OT - PD-L1 inhibitors -OT - extensive-stage SCLC -OT - propensity score-matched analysis -OT - risk factors -COIS- The authors declare that they have no known competing financial interests or - personal relationships that could have appeared to influence the work reported in - this paper. -EDAT- 2023/04/03 06:00 -MHDA- 2023/05/29 06:42 -PMCR- 2023/04/02 -CRDT- 2023/04/02 21:52 -PHST- 2023/03/15 00:00 [revised] -PHST- 2023/02/28 00:00 [received] -PHST- 2023/03/16 00:00 [accepted] -PHST- 2023/05/29 06:42 [medline] -PHST- 2023/04/03 06:00 [pubmed] -PHST- 2023/04/02 21:52 [entrez] -PHST- 2023/04/02 00:00 [pmc-release] -AID - TCA14874 [pii] -AID - 10.1111/1759-7714.14874 [doi] -PST - ppublish -SO - Thorac Cancer. 2023 May;14(15):1327-1338. doi: 10.1111/1759-7714.14874. Epub 2023 - Apr 2. - -PMID- 35586668 -OWN - NLM -STAT- MEDLINE -DCOM- 20220520 -LR - 20230916 -IS - 1748-6718 (Electronic) -IS - 1748-670X (Print) -IS - 1748-670X (Linking) -VI - 2022 -DP - 2022 -TI - Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung - Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational - Study. -PG - 2848220 -LID - 10.1155/2022/2848220 [doi] -LID - 2848220 -AB - BACKGROUND: Relapsed and refractory small cell lung cancer (SCLC) accounts for - about 15% of all lung cancers. The prognosis of patients is poor. The 5-year - survival rate is almost 0. The average survival time of patients who refuse to - receive treatment is only 2-4 months. For patients with extensive-stage SCLC, the - current first-line treatment regimens are mainly platinum-containing double-drug - chemotherapy. Poside combined with cisplatin/carboplatin and irinotecan combined - with cisplatin/carboplatin are commonly used clinical regimens for the treatment - of patients with extensive-stage SCLC. Although SCLC is very sensitive to - radiotherapy and chemotherapy, most patients will develop recurrence and - metastasis after initial treatment. Therefore, it is necessary to study - clinically effective therapeutic drugs for relapsed and refractory SCLC. - OBJECTIVE: To investigate the relationship between programmed death receptor-1 - (programmed death receptor-1 (PD-1)) and programmed death receptor-ligand 1 - (programmed death-ligand 1 (PD-L1)) inhibitors and Lung Cancer No. 1 efficacy and - safety of Lung Cancer Fang No. 1 in the treatment of relapsed and refractory - SCLC. METHODS: 80 patients with refractory SCLC were selected and randomly - divided into control group and treatment group with 40 cases in each group. Among - them, the control group received PD-1/PD-L1 inhibitor chemotherapy, and the - treatment group received PD-1/PD-L1 inhibitor chemotherapy combined with Lung - Cancer Fang No. 1 treatment. The differences in immune and tumor marker levels, - clinical efficacy, and prognostic complications between the two groups before and - after treatment were observed and compared. RESULTS: Before treatment, there was - no significant difference in clinical improvement between the two groups. After - treatment, the clinical symptom scores and body weight changes in the treatment - group were significantly improved. The clinical symptom scores in the treatment - group were lower than those in the control group, but the body weight changes - were higher than those in the control group. The difference was statistically - significant (P < 0.05). Before treatment, there was no significant difference in - the levels of tumor markers between the two groups. After treatment, the levels - of CYFRA21-1, CA125, and VGEF in the treatment group were significantly lower - than those in the control group, and the difference was statistically significant - (P < 0.05). There was no significant difference in the immune level between the - two groups before treatment (P > 0.05), while the differences in CD4+, CD3+, and - CD4+/CD8+ after treatment were significant, and the treatment group was higher - than the control group, with statistical significance (P < 0.05). After - treatment, the clinical efficacy of the two groups was significantly improved. - The DCR90.00% of the treatment group was significantly higher than that of the - control group, 67.50%, and the difference was statistically significant (P < - 0.05). The analysis of complications after treatment showed that fatigue, - anorexia, hypertension, hand-foot syndrome, diarrhea, leukopenia, - thrombocytopenia, and urinary protein in the treatment group were significantly - lower than those in the control group, and the difference was statistically - significant (P < 0.05). CONCLUSION: PD-1/PD-L1 inhibitor chemotherapy combined - with Lung Cancer Fang No. 1 has a good and safe effect on SCLC patients. It has a - good curative effect in improving the clinical symptoms of patients. It can - stabilize the tumor, inhibit the development of lung cancer, improve the body's - cellular immune function, adjust the level and expression of tumor markers, - improve the body's material metabolism, and restore the balance of yin and yang - in the body. -CI - Copyright © 2022 Lihua Wang et al. -FAU - Wang, Lihua -AU - Wang L -AD - Department of Respiratory Endology, People's Hospital of Dongxihu District, - Wuhan, Hubei 430040, China. -FAU - Lei, Xiaoxia -AU - Lei X -AD - Second Ward, Department of Respiratory and Critical Care Medicine, Wuhan No. 1 - Hospital, China. -FAU - Wang, Xin -AU - Wang X -AUID- ORCID: 0000-0001-8894-5567 -AD - Department of Infectious Disease, Wuhan Asia General Hospital, China. -LA - eng -PT - Journal Article -PT - Observational Study -PT - Retracted Publication -DEP - 20220509 -PL - United States -TA - Comput Math Methods Med -JT - Computational and mathematical methods in medicine -JID - 101277751 -RN - 0 (Antigens, Neoplasm) -RN - 0 (Biomarkers, Tumor) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Keratin-19) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 0 (Receptors, Death Domain) -RN - 0 (antigen CYFRA21.1) -RN - BG3F62OND5 (Carboplatin) -RN - Q20Q21Q62J (Cisplatin) -SB - IM -RIN - Comput Math Methods Med. 2023 Jun 28;2023:9870685. doi: 10.1155/2023/9870685. - PMID: 37416284 -MH - Antigens, Neoplasm -MH - Biomarkers, Tumor -MH - Body Weight -MH - Carboplatin/therapeutic use -MH - Cisplatin/adverse effects -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Keratin-19 -MH - *Lung Neoplasms/diagnosis -MH - Programmed Cell Death 1 Receptor -MH - Randomized Controlled Trials as Topic -MH - Receptors, Death Domain -MH - *Small Cell Lung Carcinoma/drug therapy -PMC - PMC9110176 -COIS- There are no conflicts of interest. -EDAT- 2022/05/20 06:00 -MHDA- 2022/05/21 06:00 -PMCR- 2022/05/09 -CRDT- 2022/05/19 02:29 -PHST- 2022/01/27 00:00 [received] -PHST- 2022/03/22 00:00 [revised] -PHST- 2022/04/01 00:00 [accepted] -PHST- 2022/05/19 02:29 [entrez] -PHST- 2022/05/20 06:00 [pubmed] -PHST- 2022/05/21 06:00 [medline] -PHST- 2022/05/09 00:00 [pmc-release] -AID - 10.1155/2022/2848220 [doi] -PST - epublish -SO - Comput Math Methods Med. 2022 May 9;2022:2848220. doi: 10.1155/2022/2848220. - eCollection 2022. - -PMID- 37011458 -OWN - NLM -STAT- MEDLINE -DCOM- 20230410 -LR - 20230427 -IS - 1476-5586 (Electronic) -IS - 1522-8002 (Print) -IS - 1476-5586 (Linking) -VI - 39 -DP - 2023 May -TI - Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis - The - challenge to predict and detect overlapping immune-related adverse effects from - evolving laboratory biomarkers and clinical imaging. -PG - 100892 -LID - S1476-5586(23)00017-9 [pii] -LID - 10.1016/j.neo.2023.100892 [doi] -LID - 100892 -AB - The risk of overlapping pulmonary toxicity induced by thoracic - radio(chemo)therapy and immune checkpoint inhibitor therapy in the treatment of - patients suffering from non-small cell lung cancer (NSCLC) is one important - challenge in successful radioimmunotherapy. In the present opinion we highlight - factors that we find important to be considered before treatment initiation, - during the treatment sequence, and after treatment completion combined or - sequential application of radio(chemo)therapy and immune checkpoint inhibitor - therapy. A major aim is to optimize the therapeutic index and to avoid immune - related adverse effects. The goals in the future will be focused not only on - identifying patients already in the pretreatment phase who could benefit from - this complex treatment, but also in identifying patients, who are most likely to - have higher grade toxicity. In this respect, proper assessment of clinical - performance status, monitoring for the presence of certain comorbidities, - evaluation of laboratory parameters such as TGF-α and IL-6 levels, human - leukocyte antigens (HLA), and consideration of other potential biomarkers which - will evolve in near future are essential. Likewise, the critical parameters must - be monitored during the treatment phase and follow-up care to detect potential - side effects in time. With the help of high-end imaging which is already used on - a daily basis in image guided radiotherapy (IGRT) for intensity modulated - radiotherapy (IMRT), its advanced form volumetric modulated arc therapy (VMAT), - and adaptive radiation therapy (ART), clinically relevant changes in lung tissue - can be detected at an early stage of disease. Concurrent radiotherapy and - immunotherapy requires a special focus on adverse events, particularly of the - lung, but, when properly approached and applied, it may offer new perspectives - for patients with locally advanced NSCLC to be seriously considered as a curative - option. -CI - Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. -FAU - Guberina, Nika -AU - Guberina N -AD - Department of Radiation Therapy, West German Cancer Center, University of - Duisburg-Essen, University Hospital Essen, Germany. -FAU - Wirsdörfer, Florian -AU - Wirsdörfer F -AD - Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, - University Hospital Essen, Germany. -FAU - Stuschke, Martin -AU - Stuschke M -AD - Department of Radiation Therapy, West German Cancer Center, University of - Duisburg-Essen, University Hospital Essen, Germany. -FAU - Jendrossek, Verena -AU - Jendrossek V -AD - Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, - University Hospital Essen, Germany. Electronic address: - verena.jendrossek@uk-essen.de. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20230401 -PL - United States -TA - Neoplasia -JT - Neoplasia (New York, N.Y.) -JID - 100886622 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - *Lung Neoplasms/drug therapy -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Radiotherapy, Intensity-Modulated/adverse effects/methods -MH - *Pneumonia/drug therapy/etiology -PMC - PMC10124136 -OTO - NOTNLM -OT - Immune checkpoint inhibitor-induced lung injury -OT - Immune-related adverse effects -OT - Pneumonitis -OT - Pulmonary toxicity -OT - Radiation-induced lung injury -COIS- Declaration of Competing Interest The authors declare the following financial - interests/personal relationships which may be considered as potential competing - interests: AstraZeneca- Advisory board function - Research funding to institution -EDAT- 2023/04/04 06:00 -MHDA- 2023/04/10 06:42 -PMCR- 2023/04/01 -CRDT- 2023/04/03 18:02 -PHST- 2022/06/01 00:00 [received] -PHST- 2023/02/17 00:00 [revised] -PHST- 2023/02/23 00:00 [accepted] -PHST- 2023/04/10 06:42 [medline] -PHST- 2023/04/04 06:00 [pubmed] -PHST- 2023/04/03 18:02 [entrez] -PHST- 2023/04/01 00:00 [pmc-release] -AID - S1476-5586(23)00017-9 [pii] -AID - 100892 [pii] -AID - 10.1016/j.neo.2023.100892 [doi] -PST - ppublish -SO - Neoplasia. 2023 May;39:100892. doi: 10.1016/j.neo.2023.100892. Epub 2023 Apr 1. - -PMID- 33830168 -OWN - NLM -STAT- MEDLINE -DCOM- 20220311 -LR - 20220531 -IS - 2374-2445 (Electronic) -IS - 2374-2437 (Print) -IS - 2374-2437 (Linking) -VI - 7 -IP - 6 -DP - 2021 Jun 1 -TI - Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced - Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized - Clinical Trial. -PG - 910-914 -LID - 10.1001/jamaoncol.2021.0281 [doi] -AB - IMPORTANCE: Severe acute esophagitis occurs in up to 20% of patients with locally - advanced lung cancer treated with chemoradiation therapy to at least 60 Gy once - daily and represents a dose-limiting toxic event associated with poor outcomes. - OBJECTIVE: To assess whether formalized sparing of the contralateral esophagus - (CE) is associated with reduced risk of severe acute esophagitis. DESIGN, - SETTING, AND PARTICIPANTS: This single-center phase 1 nonrandomized clinical - trial assessing an empirical CE-sparing technique enrolled patients from July - 2015 to January 2019. In total, 27 patients with locally advanced non-small cell - lung carcinoma (with or without solitary brain metastasis) or limited-stage small - cell lung carcinoma with gross tumor within 1 cm of the esophagus were eligible. - INTERVENTIONS: Intensity-modulated radiation therapy to 70 Gy at 2 Gy/fraction - concurrent with standard chemotherapy with or without adjuvant durvalumab. The - esophageal wall contralateral to gross tumor was contoured as an avoidance - structure to guide a steep dose falloff gradient. Target coverage was prioritized - over CE sparing, and 99% of internal and planning target volumes had to be - covered by 70 Gy and at least 63 Gy, respectively. MAIN OUTCOMES AND MEASURES: - The primary end point was the rate of at least grade 3 acute esophagitis as - assessed by Common Terminology Criteria for Adverse Events, version 4. RESULTS: - Of 27 patients enrolled, 25 completed chemoradiation therapy. Nineteen patients - had non-small cell lung carcinoma, and 6 had small cell lung carcinoma. The - median age at diagnosis was 67 years (range, 51-81 years), and 15 patients (60%) - were men. Thirteen patients (52%) had stage IIIA cancer, 10 (40%) had stage IIIB - cancer, and 2 (8%) had stage IV cancer. The median CE maximum dose was 66 Gy - (range, 44-71 Gy); the median volume of CE receiving at least 55 Gy was 1.4 cm3 - (range, 0-5.3 cm3), and the median volume of CE receiving at least 45 Gy was 2.7 - cm3 (range, 0-9.2 cm3). The median combined percentage of lung receiving at least - 20 Gy was 25% (range, 11%-37%). The median follow-up was 33.3 months (range, - 11.1-52.2 months). Among the 20 patients who had treatment breaks of 0 to 3 days - and were thus evaluable for the primary end point, the rate of at least grade 3 - esophagitis was 0%. Other toxic events observed among all 25 patients included 7 - (28%) with grade 2 esophagitis, 3 (12%) with at least grade 2 pneumonitis - (including 1 with grade 5), and 2 (8%) with at least grade 3 cardiac toxic event - (including 1 with grade 5). There was no isolated local tumor failure. The 2-year - progression-free survival rate was 57% (95% CI, 33%-75%), and the 2-year overall - survival rate was 67% (95% CI, 45%-82%). CONCLUSIONS AND RELEVANCE: This phase 1 - nonrandomized clinical trial found that the CE-sparing technique was associated - with reduced risk of esophagitis among patients treated uniformly with - chemoradiation therapy (to 70 Gy), with no grade 3 or higher esophagitis despite - tumor within 1 cm of the esophagus. This technique may be translated into - clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: - NCT02394548. -FAU - Kamran, Sophia C -AU - Kamran SC -AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston. -FAU - Yeap, Beow Y -AU - Yeap BY -AD - Department of Medicine, Massachusetts General Hospital, Boston. -FAU - Ulysse, Christine A -AU - Ulysse CA -AD - Department of Medicine, Massachusetts General Hospital, Boston. -FAU - Cronin, Catherine -AU - Cronin C -AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston. -FAU - Bowes, Cynthia L -AU - Bowes CL -AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston. -FAU - Durgin, Brittany -AU - Durgin B -AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston. -FAU - Gainor, Justin F -AU - Gainor JF -AD - Department of Medicine, Massachusetts General Hospital, Boston. -FAU - Khandekar, Melin J -AU - Khandekar MJ -AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston. -FAU - Tansky, Joanna Y -AU - Tansky JY -AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston. -AD - Department of Radiation Oncology, Newton-Wellesley Hospital, Newton, - Massachusetts. -FAU - Keane, Florence K -AU - Keane FK -AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston. -AD - Department of Radiation Oncology, Newton-Wellesley Hospital, Newton, - Massachusetts. -FAU - Olsen, Christine C -AU - Olsen CC -AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston. -AD - Department of Radiation Oncology, Newton-Wellesley Hospital, Newton, - Massachusetts. -FAU - Willers, Henning -AU - Willers H -AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston. -LA - eng -SI - ClinicalTrials.gov/NCT02394548 -PT - Clinical Trial, Phase I -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - United States -TA - JAMA Oncol -JT - JAMA oncology -JID - 101652861 -SB - IM -MH - Aged -MH - Aged, 80 and over -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - Chemoradiotherapy/adverse effects/methods -MH - Esophagus/pathology -MH - Female -MH - Humans -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Male -MH - Middle Aged -MH - Radiotherapy Dosage -PMC - PMC8033505 -COIS- Conflict of Interest Disclosures: Dr Kamran reported having an immediate family - member who is an employee of Sanofi Genzyme. Dr Gainor reported receiving - personal fees from Agios, Alexo, Amgen, Array, Ariad/Takeda, AstraZeneca, - Blueprint, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Gilead, Incyte, - Loxo/Lilly, Merck & Co, Moderna, Novartis, Oncorus, Pfizer, and Regeneron; - receiving research support from Ariad/Takeda, Genentech/Roche, and Novartis; - receiving institutional research support from Adaptimmune, Alexo Array, - Biopharma, Blueprint, Bristol Myers Squibb, Jounce, Merck & Co, Moderna, - Novartis, and Tesaro; and having an immediate family member as an employee of - Ironwood Pharmaceuticals with equity outside the submitted work. Dr Keane - reported receiving personal fees from AstraZeneca, OncLive, and UpToDate. No - other disclosures were reported. -EDAT- 2021/04/09 06:00 -MHDA- 2022/03/12 06:00 -PMCR- 2022/04/08 -CRDT- 2021/04/08 12:38 -PHST- 2021/04/09 06:00 [pubmed] -PHST- 2022/03/12 06:00 [medline] -PHST- 2021/04/08 12:38 [entrez] -PHST- 2022/04/08 00:00 [pmc-release] -AID - 2778095 [pii] -AID - cbr210005 [pii] -AID - 10.1001/jamaoncol.2021.0281 [doi] -PST - ppublish -SO - JAMA Oncol. 2021 Jun 1;7(6):910-914. doi: 10.1001/jamaoncol.2021.0281. - -PMID- 36931040 -OWN - NLM -STAT- MEDLINE -DCOM- 20230410 -LR - 20230412 -IS - 1476-5586 (Electronic) -IS - 1522-8002 (Print) -IS - 1476-5586 (Linking) -VI - 39 -DP - 2023 May -TI - Neural network based ensemble model to predict radiation induced lymphopenia - after concurrent chemo-radiotherapy for non-small cell lung cancer from two - institutions. -PG - 100889 -LID - S1476-5586(23)00014-3 [pii] -LID - 10.1016/j.neo.2023.100889 [doi] -LID - 100889 -AB - The use of adjuvant Immune Checkpoint Inhibitors (ICI) after concurrent - chemo-radiation therapy (CCRT) has become the standard of care for locally - advanced non-small cell lung cancer (LA-NSCLC). However, prolonged radiotherapy - regimens are known to cause radiation-induced lymphopenia (RIL), a long-neglected - toxicity that has been shown to correlate with response to ICIs and survival of - patients treated with adjuvant ICI after CCRT. In this study, we aim to develop a - novel neural network (NN) approach that integrates patient characteristics, - treatment related variables, and differential dose volume histograms (dDVH) of - lung and heart to predict the incidence of RIL at the end of treatment. - Multi-institutional data of 139 LA-NSCLC patients from two hospitals were - collected for training and validation of our suggested model. Ensemble learning - was combined with a bootstrap strategy to stabilize the model, which was - evaluated internally using repeated cross validation. The performance of our - proposed model was compared to conventional models using the same input features, - such as Logistic Regression (LR) and Random Forests (RF), using the Area Under - the Curve (AUC) of Receiver Operating Characteristics (ROC) curves. Our suggested - model (AUC=0.77) outperformed the comparison models (AUC=0.72, 0.74) in terms of - absolute performance, indicating that the convolutional structure of the network - successfully abstracts additional information from the differential DVHs, which - we studied using Gradient-weighted Class Activation Map. This study shows that - clinical factors combined with dDVHs can be used to predict the risk of RIL for - an individual patient and shows a path toward preventing lymphopenia using - patient-specific modifications of the radiotherapy plan. -CI - Copyright © 2023. Published by Elsevier Inc. -FAU - Kim, Yejin -AU - Kim Y -AD - Department of Nuclear and Quantum Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Korea; Department of Radiation Oncology, - Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. -FAU - Chamseddine, Ibrahim -AU - Chamseddine I -AD - Department of Radiation Oncology, Massachusetts General Hospital and Harvard - Medical School, Boston, MA, USA. -FAU - Cho, Yeona -AU - Cho Y -AD - Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University - College of Medicine, Yonsei University Health System, Seoul, Korea. -FAU - Kim, Jin Sung -AU - Kim JS -AD - Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University Health - System, Yonsei University College of Medicine, Seoul, Republic of Korea. -FAU - Mohan, Radhe -AU - Mohan R -AD - Division of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA. -FAU - Shusharina, Nadya -AU - Shusharina N -AD - Department of Radiation Oncology, Massachusetts General Hospital and Harvard - Medical School, Boston, MA, USA. -FAU - Paganetti, Harald -AU - Paganetti H -AD - Department of Radiation Oncology, Massachusetts General Hospital and Harvard - Medical School, Boston, MA, USA. -FAU - Lin, Steven -AU - Lin S -AD - Division of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA. -FAU - Yoon, Hong In -AU - Yoon HI -AD - Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University Health - System, Yonsei University College of Medicine, Seoul, Republic of Korea. - Electronic address: yhi0225@yuhs.ac. -FAU - Cho, Seungryong -AU - Cho S -AD - Department of Nuclear and Quantum Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Korea. Electronic address: scho@kaist.ac.kr. -FAU - Grassberger, Clemens -AU - Grassberger C -AD - Department of Radiation Oncology, Massachusetts General Hospital and Harvard - Medical School, Boston, MA, USA. -LA - eng -GR - P01 CA261669/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20230315 -PL - United States -TA - Neoplasia -JT - Neoplasia (New York, N.Y.) -JID - 100886622 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/radiotherapy/drug therapy -MH - *Lung Neoplasms/radiotherapy/drug therapy -MH - *Lymphopenia/etiology/drug therapy -MH - Chemoradiotherapy/adverse effects -MH - Neural Networks, Computer -PMC - PMC10025955 -OTO - NOTNLM -OT - Chemo-radiotherapy -OT - Immunotherapy -OT - Prediction model -OT - Radiation-induced lymphopenia -COIS- Declaration of Competing Interests The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2023/03/18 06:00 -MHDA- 2023/04/10 06:42 -PMCR- 2023/03/15 -CRDT- 2023/03/17 19:02 -PHST- 2022/09/07 00:00 [received] -PHST- 2022/11/10 00:00 [revised] -PHST- 2023/02/13 00:00 [accepted] -PHST- 2023/04/10 06:42 [medline] -PHST- 2023/03/18 06:00 [pubmed] -PHST- 2023/03/17 19:02 [entrez] -PHST- 2023/03/15 00:00 [pmc-release] -AID - S1476-5586(23)00014-3 [pii] -AID - 100889 [pii] -AID - 10.1016/j.neo.2023.100889 [doi] -PST - ppublish -SO - Neoplasia. 2023 May;39:100889. doi: 10.1016/j.neo.2023.100889. Epub 2023 Mar 15. - -PMID- 32503595 -OWN - NLM -STAT- MEDLINE -DCOM- 20210517 -LR - 20210517 -IS - 1756-8722 (Electronic) -IS - 1756-8722 (Linking) -VI - 13 -IP - 1 -DP - 2020 Jun 5 -TI - IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for - extensive-stage small cell lung cancer. -PG - 69 -LID - 10.1186/s13045-020-00898-y [doi] -LID - 69 -AB - The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients - has not improved in the last 2-3 decades until two recent trials (CASPIAN and - IMpower133) showing the addition of anti-programmed death ligand (PD-L1) therapy - to chemotherapy has survival benefit over chemotherapy alone. However, such - benefit is relatively small and was not even observed in some other trials using - immunotherapy, raising the question of optimal chemoimmunotherapy combination in - the 1st-line setting for ES-SCLC. Here, we discussed several thought-provoking - questions with the focus on IMpower133 and CASPIAN trials. -FAU - Huang, Chengliang -AU - Huang C -AD - Department of Respiratory and Critical Care Medicine II, The Affiliated Hospital - of Southwest Medical University, 25 Taiping Street, Luzhou, 646000, Sichuan, - China. -AD - Division of Medical Oncology, Department of Internal Medicine, University of - Kansas Cancer Center, University of Kansas Medical Center, 3005 Wahl Hall East, - 3901 Rainbow Blvd, Kansas City, KS, 66160, USA. -FAU - Gan, Gregory N -AU - Gan GN -AD - Department of Radiation Oncology, University of Kansas Cancer Center, University - of Kansas Medical Center, 3005 Wahl Hall East, 3901 Rainbow Blvd, Kansas City, - KS, 66160, USA. -AD - Department of Cancer Biology, University of Kansas Cancer Center, University of - Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160, USA. -FAU - Zhang, Jun -AU - Zhang J -AUID- ORCID: 0000-0001-7886-6187 -AD - Division of Medical Oncology, Department of Internal Medicine, University of - Kansas Cancer Center, University of Kansas Medical Center, 3005 Wahl Hall East, - 3901 Rainbow Blvd, Kansas City, KS, 66160, USA. jzhang3@kumc.edu. -AD - Department of Cancer Biology, University of Kansas Cancer Center, University of - Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160, USA. - jzhang3@kumc.edu. -LA - eng -GR - P20 GM130423/GM/NIGMS NIH HHS/United States -PT - Letter -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20200605 -PL - England -TA - J Hematol Oncol -JT - Journal of hematology & oncology -JID - 101468937 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Neoplasm Proteins) -RN - 0 (Organoplatinum Compounds) -RN - 28X28X9OKV (durvalumab) -RN - 6PLQ3CP4P3 (Etoposide) -RN - QEN1X95CIX (tremelimumab) -SB - IM -MH - Antibodies, Monoclonal/administration & dosage -MH - Antibodies, Monoclonal, Humanized/administration & dosage -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors -MH - *Clinical Trials, Phase III as Topic/statistics & numerical data -MH - Double-Blind Method -MH - Drug Synergism -MH - Etoposide/administration & dosage -MH - Humans -MH - Immune Checkpoint Inhibitors/administration & dosage -MH - *Immunotherapy -MH - Lung Neoplasms/*drug therapy -MH - Multicenter Studies as Topic/*statistics & numerical data -MH - Neoplasm Proteins/antagonists & inhibitors -MH - Organoplatinum Compounds/administration & dosage -MH - Progression-Free Survival -MH - Randomized Controlled Trials as Topic/*statistics & numerical data -MH - Small Cell Lung Carcinoma/*drug therapy -MH - Survival Analysis -PMC - PMC7275499 -OTO - NOTNLM -OT - CD155 (PVR) -OT - CD28 -OT - CD80 -OT - CTLA-4 -OT - Extensive-stage small cell lung cancer -OT - Immunotherapy -OT - PD-1 -OT - PD-L1 -OT - Radiation therapy -OT - TIGIT -COIS- The authors report no competing interests. -EDAT- 2020/06/07 06:00 -MHDA- 2021/05/18 06:00 -PMCR- 2020/06/05 -CRDT- 2020/06/07 06:00 -PHST- 2020/01/27 00:00 [received] -PHST- 2020/03/27 00:00 [accepted] -PHST- 2020/06/07 06:00 [entrez] -PHST- 2020/06/07 06:00 [pubmed] -PHST- 2021/05/18 06:00 [medline] -PHST- 2020/06/05 00:00 [pmc-release] -AID - 10.1186/s13045-020-00898-y [pii] -AID - 898 [pii] -AID - 10.1186/s13045-020-00898-y [doi] -PST - epublish -SO - J Hematol Oncol. 2020 Jun 5;13(1):69. doi: 10.1186/s13045-020-00898-y. - -PMID- 23429914 -OWN - NLM -STAT- MEDLINE -DCOM- 20140522 -LR - 20220317 -IS - 1399-3003 (Electronic) -IS - 0903-1936 (Linking) -VI - 42 -IP - 4 -DP - 2013 Oct -TI - Current status of and future strategies for multimodality treatment of - unresectable stage III nonsmall cell lung cancer. -PG - 1119-33 -LID - 10.1183/09031936.00143112 [doi] -AB - Stage III nonsmall cell lung cancer (NSCLC) encompasses a heterogeneous group of - patients, some of whom may be candidates for potentially curative surgery, - although for the majority surgery is not an option. Recommended therapy for - patients with unresectable stage III disease is concurrent treatment with - chemotherapy and thoracic radiotherapy, although even with this dual modality - therapy survival remains disappointing. Novel classes of agents including - targeted therapies have been shown to improve survival in advanced stage NSCLC, - raising the possibility that these agents may have benefits in multimodal therapy - when combined with chemoradiotherapy. Here we consider the rationale for - combining new agents with chemoradiotherapy and the evidence from clinical - studies assessing multimodal strategies for the management of patients with - unresectable stage III NSCLC. -FAU - Huber, Rudolf M -AU - Huber RM -AD - Dept of Medicine, University of Munich - Campus Innenstadt, and Thoracic Oncology - Centre Munich, Munich. -FAU - Reck, Martin -AU - Reck M -FAU - Thomas, Michael -AU - Thomas M -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20130221 -PL - England -TA - Eur Respir J -JT - The European respiratory journal -JID - 8803460 -RN - 0 (Angiogenesis Inhibitors) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents) -RN - 0 (Pyrazoles) -RN - 0 (Pyridines) -RN - 0 (Quinazolines) -RN - 2S9ZZM9Q9V (Bevacizumab) -RN - 53AH36668S (Crizotinib) -RN - DA87705X9K (Erlotinib Hydrochloride) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - PQX0D8J21J (Cetuximab) -RN - S65743JHBS (Gefitinib) -SB - IM -MH - Angiogenesis Inhibitors/therapeutic use -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - Antineoplastic Agents/therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Bevacizumab -MH - Carcinoma, Non-Small-Cell Lung/*therapy -MH - Cetuximab -MH - Chemoradiotherapy/methods -MH - Clinical Trials as Topic -MH - Combined Modality Therapy/*methods -MH - Crizotinib -MH - ErbB Receptors/antagonists & inhibitors -MH - Erlotinib Hydrochloride -MH - Evidence-Based Medicine -MH - Gefitinib -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/*therapy -MH - Pyrazoles/therapeutic use -MH - Pyridines/therapeutic use -MH - Quinazolines/therapeutic use -EDAT- 2013/02/23 06:00 -MHDA- 2014/05/23 06:00 -CRDT- 2013/02/23 06:00 -PHST- 2013/02/23 06:00 [entrez] -PHST- 2013/02/23 06:00 [pubmed] -PHST- 2014/05/23 06:00 [medline] -AID - 09031936.00143112 [pii] -AID - 10.1183/09031936.00143112 [doi] -PST - ppublish -SO - Eur Respir J. 2013 Oct;42(4):1119-33. doi: 10.1183/09031936.00143112. Epub 2013 - Feb 21. - -PMID- 39057143 -OWN - NLM -STAT- MEDLINE -DCOM- 20240726 -LR - 20240728 -IS - 1718-7729 (Electronic) -IS - 1198-0052 (Print) -IS - 1198-0052 (Linking) -VI - 31 -IP - 7 -DP - 2024 Jun 27 -TI - Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer - Leading to 60 Months Overall Survival: A Case Report. -PG - 3682-3689 -LID - 10.3390/curroncol31070271 [doi] -AB - Small-cell lung cancer (SCLC) remains a disease with poor prognosis, particularly - in extensive-stage SCLC (ES-SCLC). Current standard-of-care treatment includes - chemotherapy with platinum agents and etoposide plus immunotherapy with - atezolizumab or durvalumab, which has achieved a mean overall survival of 12-13 - months in clinical trials. However, long-term survival in ES-SCLC, even with the - addition of immunotherapy, continues to be rare. We present the case of a - middle-aged male patient diagnosed with ES-SCLC who was treated with four cycles - of induction chemotherapy (carboplatin and etoposide) and atezolizumab, starting - maintenance atezolizumab every 21 days thereafter, and thoracic radiotherapy. - After 9 months, he experienced mild disease progression and was rechallenged with - six cycles of carboplatin and etoposide with continued atezolizumab. Subsequent - imaging showed near-complete disease resolution which has been sustained since. - He has continued on maintenance atezolizumab since diagnosis and has achieved 60 - months overall survival and 44 months progression-free survival. Throughout - treatment, he has maintained a high functional capacity and only experienced one - immune-related adverse event. Our patient is representative of a small subset who - are capable of achieving durable responses to immunotherapy and his case - highlights the need for further research to elucidate the clinical and biological - factors driving this response. -FAU - Paczkowski, Freeman -AU - Paczkowski F -AUID- ORCID: 0009-0001-5580-6920 -AD - Schulich School of Medicine & Dentistry, Western University, London, ON N6A 3K7, - Canada. -FAU - Raphael, Jacques -AU - Raphael J -AUID- ORCID: 0000-0002-9484-0224 -AD - Division of Medical Oncology, Department of Oncology, London Health Sciences - Centre, Western University, London, ON N6A 5W9, Canada. -FAU - Browne, Claire -AU - Browne C -AD - Division of Medical Oncology, Department of Oncology, London Health Sciences - Centre, Western University, London, ON N6A 5W9, Canada. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20240627 -PL - Switzerland -TA - Curr Oncol -JT - Current oncology (Toronto, Ont.) -JID - 9502503 -RN - 52CMI0WC3Y (atezolizumab) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 6PLQ3CP4P3 (Etoposide) -SB - IM -MH - Humans -MH - *Small Cell Lung Carcinoma/drug therapy -MH - Male -MH - *Antibodies, Monoclonal, Humanized/therapeutic use -MH - *Lung Neoplasms/drug therapy -MH - Middle Aged -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Treatment Outcome -MH - Etoposide/therapeutic use -PMC - PMC11276320 -OTO - NOTNLM -OT - atezolizumab -OT - durable response -OT - extensive-stage small-cell lung cancer -OT - long-term survival -OT - small-cell lung cancer -COIS- J.R. has served on advisory boards for Merck, Lily, AstraZeneca, and Novartis. - The remaining authors declare no conflicts of interest. -EDAT- 2024/07/26 12:46 -MHDA- 2024/07/26 12:47 -PMCR- 2024/06/27 -CRDT- 2024/07/26 08:37 -PHST- 2024/06/04 00:00 [received] -PHST- 2024/06/21 00:00 [revised] -PHST- 2024/06/25 00:00 [accepted] -PHST- 2024/07/26 12:47 [medline] -PHST- 2024/07/26 12:46 [pubmed] -PHST- 2024/07/26 08:37 [entrez] -PHST- 2024/06/27 00:00 [pmc-release] -AID - curroncol31070271 [pii] -AID - curroncol-31-00271 [pii] -AID - 10.3390/curroncol31070271 [doi] -PST - epublish -SO - Curr Oncol. 2024 Jun 27;31(7):3682-3689. doi: 10.3390/curroncol31070271. - -PMID- 37171300 -OWN - NLM -STAT- MEDLINE -DCOM- 20230515 -LR - 20230515 -IS - 1536-5964 (Electronic) -IS - 0025-7974 (Print) -IS - 0025-7974 (Linking) -VI - 102 -IP - 19 -DP - 2023 May 12 -TI - Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the - skin: A case report. -PG - e33788 -LID - 10.1097/MD.0000000000033788 [doi] -LID - e33788 -AB - INTRODUCTION: Surgery is the preferred treatment for basal cell carcinoma (BCC), - locally advanced or metastatic BCC, radiation therapy or systemic therapy can be - considered. Programmed death receptor 1 (PD-1) inhibitors are rarely used to - treat cutaneous BCC. In the present case, we found that tislelizumab, a PD-1 - immunosuppressant, had a positive effect on BCC. PATIENT CONCERNS: A 74-year-old - male patient presented with a mass in the left back in October 2021, which was - surgically removed and diagnosed as BCC. The patient was diagnosed with squamous - lung cancer after presenting with a cough and coughing up a small amount of - white, sticky sputum in December 2021. DIAGNOSIS: BCC and squamous lung cancer. - INTERVENTIONS: Docetaxel + nedaplatin systemic chemotherapy combined with - tislelizumab immunotherapy. OUTCOMES: Both BCC and squamous lung cancer were - significantly reduced in size. CONCLUSION: After 2 cycles of immunotherapy with - tislelizumab, the lung tumor shrank, the back mass disappeared, and the wound - healed. -CI - Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. -FAU - Wu, Ming-Jun -AU - Wu MJ -AUID- ORCID: 0000-0001-5115-2280 -AD - Respiratory, The 940th Hospital of Joint Logistics Support Force of Chinese - People's Liberation Army, Lanzhou, Gansu Province, China. -AD - Respiratory, The Clinical Medical College of Ningxia Medical University, - Yinchuan, Ningxia Hui Autonomous Region, China. -FAU - Chen, Yu-Chun -AU - Chen YC -AD - Respiratory, The 940th Hospital of Joint Logistics Support Force of Chinese - People's Liberation Army, Lanzhou, Gansu Province, China. -AD - Respiratory, The Clinical Medical College of Ningxia Medical University, - Yinchuan, Ningxia Hui Autonomous Region, China. -FAU - Cui, Xiao-Li -AU - Cui XL -AD - Respiratory, The 940th Hospital of Joint Logistics Support Force of Chinese - People's Liberation Army, Lanzhou, Gansu Province, China. -AD - Respiratory, The Clinical Medical College of Ningxia Medical University, - Yinchuan, Ningxia Hui Autonomous Region, China. -FAU - Yang, Qian -AU - Yang Q -AD - Respiratory, The 940th Hospital of Joint Logistics Support Force of Chinese - People's Liberation Army, Lanzhou, Gansu Province, China. -FAU - Xue, Qing-Liang -AU - Xue QL -AD - Respiratory, The 940th Hospital of Joint Logistics Support Force of Chinese - People's Liberation Army, Lanzhou, Gansu Province, China. -LA - eng -PT - Case Reports -PT - Journal Article -PL - United States -TA - Medicine (Baltimore) -JT - Medicine -JID - 2985248R -RN - 0KVO411B3N (tislelizumab) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Male -MH - Humans -MH - Aged -MH - *Skin Neoplasms/complications/drug therapy/pathology -MH - Programmed Cell Death 1 Receptor/therapeutic use -MH - *Carcinoma, Basal Cell/complications/drug therapy/pathology -MH - *Lung Neoplasms/complications/drug therapy/pathology -MH - *Carcinoma, Squamous Cell/complications/drug therapy/pathology -PMC - PMC10174383 -COIS- The authors have no funding and conflicts of interest to disclose. -EDAT- 2023/05/12 13:08 -MHDA- 2023/05/15 06:42 -PMCR- 2023/05/12 -CRDT- 2023/05/12 10:13 -PHST- 2023/05/15 06:42 [medline] -PHST- 2023/05/12 13:08 [pubmed] -PHST- 2023/05/12 10:13 [entrez] -PHST- 2023/05/12 00:00 [pmc-release] -AID - 00005792-202305120-00007 [pii] -AID - 10.1097/MD.0000000000033788 [doi] -PST - ppublish -SO - Medicine (Baltimore). 2023 May 12;102(19):e33788. doi: - 10.1097/MD.0000000000033788. - -PMID- 35616056 -OWN - NLM -STAT- MEDLINE -DCOM- 20220718 -LR - 20220816 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 13 -IP - 14 -DP - 2022 Jul -TI - Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally - advanced non-small cell lung cancer patients receiving durvalumab after - chemoradiotherapy. -PG - 2031-2040 -LID - 10.1111/1759-7714.14484 [doi] -AB - BACKGROUNDS: The PACIFIC trial established durvalumab consolidation therapy after - concurrent chemoradiotherapy (CCRT) as the standard treatment for locally - advanced non-small cell lung cancer (LA-NSCLC). However, little is known about - the predictive factors of durvalumab efficacy in this population. This study - aimed to validate the predictive use of inflammation-related parameters in - patients with LA-NSCLC treated with CCRT plus durvalumab. METHODS: We recruited - 76 LA-NSCLC patients who received CCRT followed by durvalumab from 10 Japanese - institutions. The neutrophil-to-lymphocyte ratio (NLR), C-reactive - protein-to-albumin ratio (CAR), and prognostic nutrition index (PNI) were - measured before (pre-treatment) and 2 months after (post-treatment) durvalumab - induction. Cox proportional hazards analysis was used to examine prognostic - factors associated with progression-free survival (PFS) after durvalumab therapy. - RESULTS: The median follow-up time was 17 (range, 3.3-35.8) months. The median - PFS and overall survival (OS) times were 26.1 and 33.7 months, respectively. - Durvalumab was discontinued in 47 (61.8%) patients, with non-infectious - pneumonitis being the most common reason. Post-treatment CAR (cutoff, 0.2) was a - significant stratifying factor in survival comparison (<0.2 vs. ≥ 0.2, median - PFS, not-reached vs. 9.6 months. Log-rank, p = 0.002). Multivariate analysis with - a Cox proportional hazards model showed that post-treatment CAR was an - independent prognostic factor for PFS (hazard ratio, 3.16, p = 0.003). - CONCLUSIONS: This study suggests that post-treatment CAR has predictive value for - LA-NSCLC patients treated with CCRT plus durvalumab consolidation therapy. -CI - © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Araki, Taisuke -AU - Araki T -AUID- ORCID: 0000-0002-8033-868X -AD - First Department of Internal Medicine, Shinshu University School of Medicine, - Matsumoto, Japan. -FAU - Tateishi, Kazunari -AU - Tateishi K -AUID- ORCID: 0000-0003-4641-640X -AD - First Department of Internal Medicine, Shinshu University School of Medicine, - Matsumoto, Japan. -FAU - Komatsu, Masamichi -AU - Komatsu M -AD - First Department of Internal Medicine, Shinshu University School of Medicine, - Matsumoto, Japan. -FAU - Sonehara, Kei -AU - Sonehara K -AUID- ORCID: 0000-0001-9810-4016 -AD - First Department of Internal Medicine, Shinshu University School of Medicine, - Matsumoto, Japan. -FAU - Wasamoto, Satoshi -AU - Wasamoto S -AD - Department of Respiratory Medicine, Saku Central Hospital Advanced Care Center, - Saku, Japan. -FAU - Koyama, Shigeru -AU - Koyama S -AD - Department of Respiratory Medicine, Japanese Red Cross Society Nagano Hospital, - Nagano, Japan. -FAU - Yoshiike, Fumiaki -AU - Yoshiike F -AD - Department of Respiratory Medicine, Nagano Municipal Hospital, Nagano, Japan. -FAU - Hama, Mineyuki -AU - Hama M -AD - Department of Respiratory Medicine, Japanese Red Cross Society Suwa Hospital, - Suwa, Japan. -FAU - Nishie, Kenichi -AU - Nishie K -AD - Department of Respiratory Medicine, Iida Municipal Hospital, Iida, Japan. -FAU - Kondo, Daichi -AU - Kondo D -AD - Department of Respiratory Medicine, Hokushin General Hospital, Nakano, Japan. -FAU - Agatsuma, Toshihiko -AU - Agatsuma T -AD - Department of Respiratory Medicine, Shinshu Ueda Medical Center, Ueda, Japan. -FAU - Kato, Akane -AU - Kato A -AD - Department of Respiratory Medicine, Ina Central Hospital, Ina, Japan. -FAU - Takata, Munetake -AU - Takata M -AD - Department of Respiratory Medicine, Jiseikai Aizawa Hospital, Matsumoto, Japan. -FAU - Kanda, Shintaro -AU - Kanda S -AUID- ORCID: 0000-0001-7864-3928 -AD - Department of Hematology and Medical Oncology, Shinshu University School of - Medicine, Matsumoto, Japan. -FAU - Hanaoka, Masayuki -AU - Hanaoka M -AD - First Department of Internal Medicine, Shinshu University School of Medicine, - Matsumoto, Japan. -FAU - Koizumi, Tomonobu -AU - Koizumi T -AUID- ORCID: 0000-0002-5182-0960 -AD - Department of Hematology and Medical Oncology, Shinshu University School of - Medicine, Matsumoto, Japan. -LA - eng -PT - Journal Article -DEP - 20220526 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -RN - 9007-41-4 (C-Reactive Protein) -SB - IM -MH - Antibodies, Monoclonal -MH - C-Reactive Protein -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Neoplasm Staging -PMC - PMC9284133 -OTO - NOTNLM -OT - Albumin -OT - C-reactive protein -OT - chemoradiotherapy -OT - durvalumab -OT - non-small cell lung cancer -COIS- The authors have no conflict of interest to declare. -EDAT- 2022/05/27 06:00 -MHDA- 2022/07/19 06:00 -PMCR- 2022/07/01 -CRDT- 2022/05/26 05:13 -PHST- 2022/05/04 00:00 [revised] -PHST- 2022/04/12 00:00 [received] -PHST- 2022/05/05 00:00 [accepted] -PHST- 2022/05/27 06:00 [pubmed] -PHST- 2022/07/19 06:00 [medline] -PHST- 2022/05/26 05:13 [entrez] -PHST- 2022/07/01 00:00 [pmc-release] -AID - TCA14484 [pii] -AID - 10.1111/1759-7714.14484 [doi] -PST - ppublish -SO - Thorac Cancer. 2022 Jul;13(14):2031-2040. doi: 10.1111/1759-7714.14484. Epub 2022 - May 26. - -PMID- 35716632 -OWN - NLM -STAT- MEDLINE -DCOM- 20220810 -LR - 20220817 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 170 -DP - 2022 Aug -TI - Dosimetric predictors of pneumonitis in locally advanced non-small cell lung - cancer patients treated with chemoradiation followed by durvalumab. -PG - 58-64 -LID - S0169-5002(22)00467-6 [pii] -LID - 10.1016/j.lungcan.2022.06.003 [doi] -AB - OBJECTIVES: The incidence and predictors of pneumonitis for patients with - unresectable, locally advanced non-small cell lung cancer (NSCLC) in the era of - consolidation durvalumab have yet to be fully elucidated. In this large single - institution analysis, we report the incidence of and factors associated with - grade 2 + pneumonitis in NSCLC patients treated with the PACIFIC regimen. - MATERIALS AND METHODS: We identified all patients treated at our institution with - definitive CRT followed by durvalumab from 2018 to 2021. Clinical documentation - and imaging studies were reviewed to determine grade 2 + pneumonitis events, - which required the following: 1) pulmonary symptoms warranting prolonged steroid - taper, oxygen dependence, and/or hospital admission and 2) radiographic findings - consistent with pneumonitis. RESULTS: One-hundred ninety patients were included. - The majority received 60 Gray (Gy) in 30 fractions with concurrent carboplatin - and paclitaxel. Median number of durvalumab cycles received was 12 (IQR: 4-22). - At a median follow-up of 14.8 months, 50 (26.3%) patients experienced grade - 2 + pneumonitis with a 1-year cumulative incidence of 27.8% (95% CI: 21.9-35.4). - Seventeen (8.9%) patients experienced grade 3 + pneumonitis and 4 grade 5 (2.1%). - Dosimetric predictors of pneumonitis included ipsilateral and total lung volume - receiving 5 Gy or greater (V5Gy), V10Gy, V20Gy, V40Gy, and mean dose and - contralateral V40Gy. Heart V5Gy, V10Gy, and mean dose were also significant - variables. Overall survival estimates at 1 and 3 years were 87.4% (95% CI: - 82.4-92.8) and 60.3% (95% CI: 47.9-74.4), respectively. CONCLUSION: We report a - risk of pneumonitis higher than that seen on RTOG 0617 and comparable to the - PACIFIC study. Multiple lung and heart dosimetric factors were predictive of - pneumonitis. -CI - Copyright © 2022 Elsevier B.V. All rights reserved. -FAU - Gao, Robert W -AU - Gao RW -AD - Departments of Radiation Oncology and Biostatistics & Information, Mayo Clinic, - 200 1st St SW, Rochester, MN, USA. Electronic address: gao.robert@mayo.edu. -FAU - Day, Courtney N -AU - Day CN -AD - Departments of Biostatistics & Information, Mayo Clinic, 200 1st St SW, - Rochester, MN, USA. Electronic address: day.courtney1@mayo.edu. -FAU - Yu, Nathan Y -AU - Yu NY -AD - Department of Radiation Oncology, Mayo Clinic, 13400 E. Shea Blvd, Scottsdale, - AZ, USA. Electronic address: yu.nathan@mayo.edu. -FAU - Bush, Aaron -AU - Bush A -AD - Department of Radiation Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, - FL, USA. Electronic address: bush.aaron1@mayo.edu. -FAU - Amundson, Adam C -AU - Amundson AC -AD - Departments of Radiation Oncology and Biostatistics & Information, Mayo Clinic, - 200 1st St SW, Rochester, MN, USA. Electronic address: amundson.adam1@mayo.edu. -FAU - Prodduturvar, Pranitha -AU - Prodduturvar P -AD - University of South Alabama, Mitchell Cancer Institute, 1660 Spring Hill Ave, - Mobile, AL, USA. Electronic address: pprodduturvar@health.southalabama.edu. -FAU - Majeed, Umair -AU - Majeed U -AD - Division of Hematology/Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, - FL, USA. Electronic address: majeed.umair@mayo.edu. -FAU - Butts, Emily -AU - Butts E -AD - Department of Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, USA. - Electronic address: butts.emily@mayo.edu. -FAU - Oliver, Thomas -AU - Oliver T -AD - Division of Medical Oncology, Mayo Clinic, 13400 E. Shea Blvd, Scottsdale, AZ, - USA. Electronic address: oliver.thomas@mayo.edu. -FAU - Schwecke, Anna J -AU - Schwecke AJ -AD - Division of Medical Oncology, Mayo Clinic, 200 1st St SW, Rochester, MN, USA. - Electronic address: schwecke.anna@mayo.edu. -FAU - Moffett, Jenesse N -AU - Moffett JN -AD - Division of Medical Oncology, Mayo Clinic, 200 1st St SW, Rochester, MN, USA. - Electronic address: moffett.jenesse@mayo.edu. -FAU - Routman, David M -AU - Routman DM -AD - Departments of Radiation Oncology and Biostatistics & Information, Mayo Clinic, - 200 1st St SW, Rochester, MN, USA. Electronic address: routman.david@mayo.edu. -FAU - Breen, William G -AU - Breen WG -AD - Departments of Radiation Oncology and Biostatistics & Information, Mayo Clinic, - 200 1st St SW, Rochester, MN, USA. Electronic address: breen.william@mayo.edu. -FAU - Potter, Ashley L -AU - Potter AL -AD - Division of Medical Oncology, Mayo Clinic, 200 1st St SW, Rochester, MN, USA. - Electronic address: potter.ashley@mayo.edu. -FAU - Rivera-Concepcion, Joel -AU - Rivera-Concepcion J -AD - Division of Medical Oncology, Mayo Clinic, 200 1st St SW, Rochester, MN, USA. - Electronic address: riveraconcepcion.joel@mayo.edu. -FAU - Hoppe, Bradford S -AU - Hoppe BS -AD - Department of Radiation Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, - FL, USA. Electronic address: hoppe.bradford@mayo.edu. -FAU - Schild, Steven E -AU - Schild SE -AD - Department of Radiation Oncology, Mayo Clinic, 13400 E. Shea Blvd, Scottsdale, - AZ, USA. Electronic address: sschild@mayo.edu. -FAU - Sio, Terence T -AU - Sio TT -AD - Department of Radiation Oncology, Mayo Clinic, 13400 E. Shea Blvd, Scottsdale, - AZ, USA. Electronic address: sio.terence@mayo.edu. -FAU - Lou, Yanyan -AU - Lou Y -AD - Division of Hematology/Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, - FL, USA. Electronic address: lou.yanyan@mayo.edu. -FAU - Ernani, Vinicius -AU - Ernani V -AD - Division of Medical Oncology, Mayo Clinic, 13400 E. Shea Blvd, Scottsdale, AZ, - USA. Electronic address: ernani.vinicius@mayo.edu. -FAU - Ko, Stephen -AU - Ko S -AD - Department of Radiation Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, - FL, USA. Electronic address: ko.stephen@mayo.edu. -FAU - Olivier, Kenneth R -AU - Olivier KR -AD - Departments of Radiation Oncology and Biostatistics & Information, Mayo Clinic, - 200 1st St SW, Rochester, MN, USA. Electronic address: olivier.kenneth@mayo.edu. -FAU - Merrell, Kenneth W -AU - Merrell KW -AD - Departments of Radiation Oncology and Biostatistics & Information, Mayo Clinic, - 200 1st St SW, Rochester, MN, USA. Electronic address: merrell.kenneth@mayo.edu. -FAU - Garces, Yolanda I -AU - Garces YI -AD - Departments of Radiation Oncology and Biostatistics & Information, Mayo Clinic, - 200 1st St SW, Rochester, MN, USA. Electronic address: garces.yolanda@mayo.edu. -FAU - Manochakian, Rami -AU - Manochakian R -AD - Division of Hematology/Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, - FL, USA. Electronic address: manochakian.rami@mayo.edu. -FAU - Harmsen, William S -AU - Harmsen WS -AD - Departments of Biostatistics & Information, Mayo Clinic, 200 1st St SW, - Rochester, MN, USA. Electronic address: harmsen.william@mayo.edu. -FAU - Leventakos, Konstantinos -AU - Leventakos K -AD - Division of Medical Oncology, Mayo Clinic, 200 1st St SW, Rochester, MN, USA. - Electronic address: leventakos.konstantinos@mayo.edu. -FAU - Owen, Dawn -AU - Owen D -AD - Departments of Radiation Oncology and Biostatistics & Information, Mayo Clinic, - 200 1st St SW, Rochester, MN, USA. Electronic address: owen.dawn@mayo.edu. -LA - eng -PT - Journal Article -DEP - 20220613 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy/adverse effects -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - *Pneumonia/complications/etiology -MH - *Radiation Pneumonitis/diagnosis/epidemiology/etiology -MH - Radiotherapy Dosage -OTO - NOTNLM -OT - Chemoradiation -OT - Durvalumab -OT - Non-small cell lung cancer -OT - PACIFIC -OT - Pneumonitis -EDAT- 2022/06/19 06:00 -MHDA- 2022/08/11 06:00 -CRDT- 2022/06/18 18:23 -PHST- 2022/04/18 00:00 [received] -PHST- 2022/05/26 00:00 [revised] -PHST- 2022/06/02 00:00 [accepted] -PHST- 2022/06/19 06:00 [pubmed] -PHST- 2022/08/11 06:00 [medline] -PHST- 2022/06/18 18:23 [entrez] -AID - S0169-5002(22)00467-6 [pii] -AID - 10.1016/j.lungcan.2022.06.003 [doi] -PST - ppublish -SO - Lung Cancer. 2022 Aug;170:58-64. doi: 10.1016/j.lungcan.2022.06.003. Epub 2022 - Jun 13. - -PMID- 35950566 -OWN - NLM -STAT- MEDLINE -DCOM- 20221017 -LR - 20240327 -IS - 1744-8301 (Electronic) -IS - 1479-6694 (Linking) -VI - 18 -IP - 28 -DP - 2022 Sep -TI - LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage - IB-IIIA RET fusion-positive non-small-cell lung cancer. -PG - 3133-3141 -LID - 10.2217/fon-2022-0656 [doi] -AB - Selpercatinib, a first-in-class, highly selective and potent central nervous - system-active RET kinase inhibitor demonstrated clinically meaningful activity - with manageable toxicity in pretreated and treatment-naive advanced/metastatic - RET fusion-positive non-small-cell lung cancer (NSCLC). LIBRETTO-432 is a global, - randomized, double-blind, phase III trial evaluating selpercatinib versus placebo - in stage IB-IIIA, RET fusion-positive NSCLC, previously treated with definitive - surgery or radiation; participants must have undergone available anti-cancer - therapy (including chemotherapy or durvalumab) or not be suitable for it, per - investigator's discretion. The primary end point is investigator-assessed - event-free survival (EFS) in the primary analysis population (stage II-IIIA RET - fusion-positive NSCLC). Key secondary end points include EFS in the overall - population, overall survival, and time to distant disease recurrence in the - central nervous system. -FAU - Tsuboi, Masahiro -AU - Tsuboi M -AUID- ORCID: 0000-0003-3031-5807 -AD - National Cancer Center Hospital East, Kashiwa, Japan. -FAU - Goldman, Jonathan W -AU - Goldman JW -AD - David Geffen School of Medicine, University of California Los Angeles, Los - Angeles, CA 90095, USA. -FAU - Wu, Yi-Long -AU - Wu YL -AUID- ORCID: 0000-0002-3611-0258 -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & - Guangdong Academy of Medical Sciences, Guangzhou, China. -FAU - Johnson, Melissa L -AU - Johnson ML -AD - Sarah Cannon Research Institute, Nashville, TN 37203, USA. -FAU - Paz-Ares, Luis -AU - Paz-Ares L -AD - Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO - Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, Spain. -FAU - Yang, James Chih-Hsin -AU - Yang JC -AD - Department of Oncology, National Taiwan University Hospital & Graduate Institute - of Oncology, National Taiwan University, Taipei, Taiwan. -FAU - Besse, Benjamin -AU - Besse B -AD - Gustave Roussy, Villejuif France & Paris Saclay University, France. -FAU - Su, Weiji -AU - Su W -AD - Eli Lilly & Company, Indianapolis, IN 46225, USA. -FAU - Chao, Bo H -AU - Chao BH -AD - Eli Lilly & Company, New York, NY 10016, USA. -FAU - Drilon, Alexander -AU - Drilon A -AD - Department of Medicine, Memorial Sloan-Kettering Cancer Center & Weill Cornell - Medical College, New York, NY 10065, USA. -LA - eng -SI - ClinicalTrials.gov/NCT04819100 -GR - Eli Lilly and Company/ -PT - Clinical Trial Protocol -PT - Journal Article -DEP - 20220811 -PL - England -TA - Future Oncol -JT - Future oncology (London, England) -JID - 101256629 -RN - 0 (Protein Kinase Inhibitors) -RN - 0 (Pyrazoles) -RN - 0 (Pyridines) -RN - CEGM9YBNGD (selpercatinib) -RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret) -RN - EC 2.7.10.1 (RET protein, human) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Chemotherapy, Adjuvant -MH - Clinical Trials, Phase III as Topic -MH - Humans -MH - *Lung Neoplasms/drug therapy/genetics -MH - Neoplasm Recurrence, Local/pathology -MH - Neoplasm Staging -MH - Protein Kinase Inhibitors/adverse effects -MH - Proto-Oncogene Proteins c-ret/genetics -MH - Pyrazoles -MH - Pyridines -MH - Randomized Controlled Trials as Topic -OAB - Selpercatinib is approved in multiple countries for the treatment of advanced or - metastatic RET-altered lung cancers. Selpercatinib has shown promising efficacy - and safety results in patients with advanced/metastatic RET fusion-positive - NSCLC. This is a summary of the LIBRETTO-432 study which compares selpercatinib - with placebo in patients with earlier stages (stage IB-IIIA) of RET - fusion-positive NSCLC, who have already undergone surgery or radiotherapy and - applicable adjuvant chemotherapy. This study is active and currently recruiting - new participants. This trial will evaluate how long people live without evidence - of cancer recurrence, both during and after treatment. Side effects will also be - evaluated in this study. Clinical Trial Registration: NCT04819100 - (ClinicalTrials.gov). -OABL- eng -OTO - NOTNLM -OT - RET fusion-positive -OT - RET kinase inhibitor -OT - RET rearrangement -OT - adjuvant therapy -OT - early stage -OT - non-small-cell lung cancer -OT - phase III trial -OT - selpercatinib -OT - stage IB -OT - stage II -OT - stage IIIA -OT - targeted therapy -EDAT- 2022/08/12 06:00 -MHDA- 2022/10/18 06:00 -CRDT- 2022/08/11 05:54 -PHST- 2022/08/12 06:00 [pubmed] -PHST- 2022/10/18 06:00 [medline] -PHST- 2022/08/11 05:54 [entrez] -AID - 10.2217/fon-2022-0656 [doi] -PST - ppublish -SO - Future Oncol. 2022 Sep;18(28):3133-3141. doi: 10.2217/fon-2022-0656. Epub 2022 - Aug 11. - -PMID- 35870727 -OWN - NLM -STAT- MEDLINE -DCOM- 20221003 -LR - 20230801 -IS - 1879-0887 (Electronic) -IS - 0167-8140 (Linking) -VI - 174 -DP - 2022 Sep -TI - Impact of radiation dose to the immune cells in unresectable or stage III - non-small cell lung cancer in the durvalumab era. -PG - 133-140 -LID - S0167-8140(22)04211-6 [pii] -LID - 10.1016/j.radonc.2022.07.015 [doi] -AB - BACKGROUND/PURPOSE: Higher estimated radiation doses to immune cells (EDIC) have - correlated with worse overall survival (OS) in patients with locally-advanced - non-small cell lung cancer (NSCLC) prior to the PACIFIC trial, which established - consolidative durvalumab as standard-of-care. Here, we examine the prognostic - impact of EDIC in the durvalumab era. MATERIALS/METHODS: This single-institution, - multi-center study included patients with unresectable stage II/III NSCLC treated - with chemoradiation followed by durvalumab. Associations between EDIC [analyzed - continuously and categorically (≤6 Gy vs > 6 Gy)] and OS, progression-free - survival (PFS), and locoregional control (LRC) were evaluated by Kaplan-Meier and - Cox proportional methods. RESULTS: 100 patients were included with median - follow-up of 23.7 months. The EDIC > 6 Gy group had a significantly greater - percentage of stage IIIB/IIIC disease (76.0 % vs 32.6 %; p < 0.001) and larger - tumor volumes (170 cc vs 42 cc; p < 0.001). There were no differences in early - durvalumab discontinuation from toxicity (24.1 % vs 15.2 %; p = 0.27). Median OS - was shorter among the EDIC > 6 Gy group (29.6 months vs not reached; p < 0.001). - On multivariate analysis, EDIC > 6 Gy correlated with worse OS (HR: 4.15, 95 %CI: - 1.52-11.33; p = 0.006), PFS (HR: 3.79; 95 %CI: 1.80-8.0; p < 0.001), and LRC (HR: - 2.66, 95 %CI: 1.15-6.18; p = 0.023). Analyzed as a continuous variable, higher - EDIC was associated with worse OS (HR: 1.34; 95 %CI: 1.16-1.57; p < 0.001), PFS - (HR: 1.52; 95 %CI: 1.29-1.79; p < 0.001), and LRC (HR: 1.34, 95 %CI: 1.13-1.60; - p = 0.007). CONCLUSIONS: In the immunotherapy era, EDIC is an independent - predictor of OS and disease control in locally advanced NSCLC, warranting - investigation into techniques to reduce dose to the immune compartment. -CI - Copyright © 2022 Elsevier B.V. All rights reserved. -FAU - McCall, Neal S -AU - McCall NS -AD - Winship Cancer Institute of Emory University, Department of Radiation Oncology, - United States. Electronic address: Nsmccal@emory.edu. -FAU - McGinnis, Hamilton S -AU - McGinnis HS -AD - Winship Cancer Institute of Emory University, Department of Radiation Oncology, - United States. -FAU - Janopaul-Naylor, James R -AU - Janopaul-Naylor JR -AD - Winship Cancer Institute of Emory University, Department of Radiation Oncology, - United States. -FAU - Kesarwala, Aparna H -AU - Kesarwala AH -AD - Winship Cancer Institute of Emory University, Department of Radiation Oncology, - United States. -FAU - Tian, Sibo -AU - Tian S -AD - Winship Cancer Institute of Emory University, Department of Radiation Oncology, - United States. -FAU - Stokes, William A -AU - Stokes WA -AD - Winship Cancer Institute of Emory University, Department of Radiation Oncology, - United States. -FAU - Shelton, Joseph W -AU - Shelton JW -AD - Winship Cancer Institute of Emory University, Department of Radiation Oncology, - United States. -FAU - Steuer, Conor E -AU - Steuer CE -AD - Winship Cancer Institute of Emory University, Department of Hematology & Medical - Oncology, United States. -FAU - Carlisle, Jennifer W -AU - Carlisle JW -AD - Winship Cancer Institute of Emory University, Department of Hematology & Medical - Oncology, United States. -FAU - Leal, Ticiana -AU - Leal T -AD - Winship Cancer Institute of Emory University, Department of Hematology & Medical - Oncology, United States. -FAU - Ramalingam, Suresh S -AU - Ramalingam SS -AD - Winship Cancer Institute of Emory University, Department of Hematology & Medical - Oncology, United States. -FAU - Bradley, Jeffrey D -AU - Bradley JD -AD - Winship Cancer Institute of Emory University, Department of Radiation Oncology, - United States. -FAU - Higgins, Kristin A -AU - Higgins KA -AD - Winship Cancer Institute of Emory University, Department of Radiation Oncology, - United States. -LA - eng -PT - Journal Article -PT - Multicenter Study -PT - Research Support, N.I.H., Extramural -DEP - 20220720 -PL - Ireland -TA - Radiother Oncol -JT - Radiotherapy and oncology : journal of the European Society for Therapeutic - Radiology and Oncology -JID - 8407192 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung -MH - Chemoradiotherapy/adverse effects/methods -MH - Humans -MH - *Lung Neoplasms -MH - Radiation Dosage -OTO - NOTNLM -OT - Chemoradiation -OT - Durvalumab -OT - Immunotherapy -OT - Non-small cell lung cancer -EDAT- 2022/07/24 06:00 -MHDA- 2022/10/04 06:00 -CRDT- 2022/07/23 19:27 -PHST- 2022/05/22 00:00 [received] -PHST- 2022/07/12 00:00 [revised] -PHST- 2022/07/15 00:00 [accepted] -PHST- 2022/07/24 06:00 [pubmed] -PHST- 2022/10/04 06:00 [medline] -PHST- 2022/07/23 19:27 [entrez] -AID - S0167-8140(22)04211-6 [pii] -AID - 10.1016/j.radonc.2022.07.015 [doi] -PST - ppublish -SO - Radiother Oncol. 2022 Sep;174:133-140. doi: 10.1016/j.radonc.2022.07.015. Epub - 2022 Jul 20. - -PMID- 36333988 -OWN - NLM -STAT- MEDLINE -DCOM- 20230101 -LR - 20230106 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 13 -IP - 24 -DP - 2022 Dec -TI - Prognostic factors for survival in extensive-stage small cell lung cancer: An - Italian real-world retrospective analysis of 244 patients treated over the last - decade. -PG - 3486-3495 -LID - 10.1111/1759-7714.14712 [doi] -AB - BACKGROUND: Potential relationships with the prognosis of patients with - extensive-stage non-small cell lung cancer (ES-SCLC) have been investigated - without valid results. METHODS: A retrospective analysis of real-world data of - consecutive patients with ES-SCLC admitted to our Medical Thoracic Oncology Unit - was carried out from 2010 to 2020, focusing on identification of prognostic - factors. Kaplan-Meier analysis was used to represent progression-free survival - (PFS) and overall survival (OS). Univariable and multivariable Cox models were - used to investigate prognostic factors. RESULTS: The analysis included 244 - patients. The median OS was 8 months (95% confidence interval [CI]: 8-10) and the - median PFS was 5 months (95% CI: 5-6). The univariable analysis showed that - factors associated with shorter OS were older age (p = 0.047), TNM stage 4 versus - 3 (p < 0.001), Eastern Cooperative Oncology Group (ECOG) performance status (PS) - 1 and 2 versus 0 (p < 0.001), and >2 metastatic sites (p = 0.004). Mediastinal - radiotherapy (RT) (p < 0.001), >1 irradiated site (p = 0.026), 3 and 4 - chemotherapy (CT) lines versus 1 (p = 0.044 and 0.001, respectively), - prophylactic cranial irradiation (PCI) (p < 0.001), and surgery (p = 0.001) - correlated with longer OS. The multivariable analysis revealed statistically - significant associations for TNM, ECOG PS 2 versus 0, number of CT lines, PCI, - and surgery. A total of 23 patients (9.4%) survived ≥24 months, 39% of whom had - received four CT lines and 48% had mediastinal RT. CONCLUSIONS: Our data suggest - that tumor burden, PS, and mediastinal RT strongly correlate with outcome. With - the addition of immunotherapy to CT, the identification of new biomarkers as - predictive factors is urgently required. -CI - © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Longo, Vito -AU - Longo V -AUID- ORCID: 0000-0001-7224-2111 -AD - Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, - Italy. -FAU - Pizzutilo, Pamela -AU - Pizzutilo P -AD - Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, - Italy. -FAU - Catino, Annamaria -AU - Catino A -AD - Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, - Italy. -FAU - Montrone, Michele -AU - Montrone M -AD - Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, - Italy. -FAU - Pesola, Francesco -AU - Pesola F -AD - Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, - Italy. -FAU - Marerch, Ilaria -AU - Marerch I -AD - Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, - Italy. -FAU - Galetta, Domenico -AU - Galetta D -AD - Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, - Italy. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20221105 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy -MH - *Lung Neoplasms/drug therapy -MH - Prognosis -MH - Retrospective Studies -MH - *Small Cell Lung Carcinoma/drug therapy -MH - Italy -PMC - PMC9750807 -OTO - NOTNLM -OT - predictive factors -OT - prognostic factors -OT - small cell lung cancer -COIS- The authors have no conflicts of interest to declare. -EDAT- 2022/11/06 06:00 -MHDA- 2022/12/17 06:00 -PMCR- 2022/12/01 -CRDT- 2022/11/05 05:02 -PHST- 2022/10/15 00:00 [revised] -PHST- 2022/06/13 00:00 [received] -PHST- 2022/10/17 00:00 [accepted] -PHST- 2022/11/06 06:00 [pubmed] -PHST- 2022/12/17 06:00 [medline] -PHST- 2022/11/05 05:02 [entrez] -PHST- 2022/12/01 00:00 [pmc-release] -AID - TCA14712 [pii] -AID - 10.1111/1759-7714.14712 [doi] -PST - ppublish -SO - Thorac Cancer. 2022 Dec;13(24):3486-3495. doi: 10.1111/1759-7714.14712. Epub 2022 - Nov 5. - -PMID- 38228082 -OWN - NLM -STAT- MEDLINE -DCOM- 20240717 -LR - 20240724 -IS - 2005-9256 (Electronic) -IS - 1598-2998 (Print) -IS - 1598-2998 (Linking) -VI - 56 -IP - 3 -DP - 2024 Jul -TI - Contribution of Enhanced Locoregional Control to Improved Overall Survival with - Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced - Non-Small Cell Lung Cancer: Insights from Real-World Data. -PG - 785-794 -LID - 10.4143/crt.2023.1014 [doi] -AB - PURPOSE: This study aimed to assess the real-world clinical outcomes of - consolidative durvalumab in patients with unresectable locally advanced non-small - cell lung cancer (LA-NSCLC) and to explore the role of radiotherapy in the era of - immunotherapy. MATERIALS AND METHODS: This retrospective study assessed 171 - patients with unresectable LA-NSCLC who underwent concurrent chemoradiotherapy - (CCRT) with or without consolidative durvalumab at Asan Medical Center between - May 2018 and May 2021. Primary outcomes included freedom from locoregional - failure (FFLRF), distant metastasis-free survival (DMFS), progression-free - survival (PFS), and overall survival (OS). RESULTS: Durvalumab following CCRT - demonstrated a prolonged median PFS of 20.9 months (p=0.048) and a 3-year FFLRF - rate of 57.3% (p=0.008), compared to 13.7 months and 38.8%, respectively, with - CCRT alone. Furthermore, the incidence of in-field recurrence was significantly - greater in the CCRT-alone group compared to the durvalumab group (26.8% vs. - 12.4%, p=0.027). While median OS was not reached with durvalumab, it was 35.4 - months in patients receiving CCRT alone (p=0.010). Patients positive for - programmed cell death ligand 1 (PD-L1) expression showed notably better outcomes, - including FFLRF, DMFS, PFS, and OS. Adherence to PACIFIC trial eligibility - criteria identified 100 patients (58.5%) as ineligible. The use of durvalumab - demonstrated better survival regardless of eligibility criteria. CONCLUSION: The - use of durvalumab consolidation following CCRT significantly enhanced - locoregional control and OS in patients with unresectable LA-NSCLC, especially in - those with PD-L1-positive tumors, thereby validating the role of durvalumab in - standard care. -FAU - Jang, Jeong Yun -AU - Jang JY -AD - Department of Radiation Oncology, Konkuk University Medical Center, Konkuk - University School of Medicine, Seoul, Korea. -AD - Department of Radiation Oncology, Asan Medical Center, University of Ulsan - College of Medicine, Seoul, Korea. -FAU - Song, Si Yeol -AU - Song SY -AD - Department of Radiation Oncology, Asan Medical Center, University of Ulsan - College of Medicine, Seoul, Korea. -FAU - Shin, Young Seob -AU - Shin YS -AD - Department of Radiation Oncology, Asan Medical Center, University of Ulsan - College of Medicine, Seoul, Korea. -FAU - Kim, Ha Un -AU - Kim HU -AD - Department of Radiation Oncology, Asan Medical Center, University of Ulsan - College of Medicine, Seoul, Korea. -FAU - Choi, Eun Kyung -AU - Choi EK -AD - Department of Radiation Oncology, Asan Medical Center, University of Ulsan - College of Medicine, Seoul, Korea. -FAU - Kim, Sang-We -AU - Kim SW -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, Seoul, Korea. -FAU - Lee, Jae Cheol -AU - Lee JC -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, Seoul, Korea. -FAU - Lee, Dae Ho -AU - Lee DH -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, Seoul, Korea. -FAU - Choi, Chang-Min -AU - Choi CM -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, Seoul, Korea. -AD - Department of Pulmonology and Critical Care Medicine, Asan Medical Center, - University of Ulsan College of Medicine, Seoul, Korea. -FAU - Yoon, Shinkyo -AU - Yoon S -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, Seoul, Korea. -FAU - Kim, Su Ssan -AU - Kim SS -AD - Department of Radiation Oncology, Asan Medical Center, University of Ulsan - College of Medicine, Seoul, Korea. -LA - eng -PT - Journal Article -DEP - 20240116 -PL - Korea (South) -TA - Cancer Res Treat -JT - Cancer research and treatment -JID - 101155137 -RN - 28X28X9OKV (durvalumab) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/mortality/pathology/drug therapy -MH - Male -MH - Female -MH - *Chemoradiotherapy/methods -MH - *Lung Neoplasms/therapy/mortality/pathology/drug therapy -MH - Retrospective Studies -MH - Aged -MH - Middle Aged -MH - *Antibodies, Monoclonal/therapeutic use -MH - Adult -MH - Antineoplastic Agents, Immunological/therapeutic use -MH - Aged, 80 and over -PMC - PMC11261197 -OTO - NOTNLM -OT - Concurrent chemoradiotherapy -OT - Durvalumab -OT - Immunotherapy -OT - Non-small-cell lung carcinoma -OT - Radiotherapy -COIS- Conflicts of Interest Conflict of interest relevant to this article was not - reported. -EDAT- 2024/01/17 00:42 -MHDA- 2024/07/17 06:43 -PMCR- 2024/07/01 -CRDT- 2024/01/16 18:07 -PHST- 2023/09/06 00:00 [received] -PHST- 2024/01/14 00:00 [accepted] -PHST- 2024/07/17 06:43 [medline] -PHST- 2024/01/17 00:42 [pubmed] -PHST- 2024/01/16 18:07 [entrez] -PHST- 2024/07/01 00:00 [pmc-release] -AID - crt.2023.1014 [pii] -AID - crt-2023-1014 [pii] -AID - 10.4143/crt.2023.1014 [doi] -PST - ppublish -SO - Cancer Res Treat. 2024 Jul;56(3):785-794. doi: 10.4143/crt.2023.1014. Epub 2024 - Jan 16. - -PMID- 32877435 -OWN - NLM -STAT- MEDLINE -DCOM- 20201027 -LR - 20201027 -IS - 1932-6203 (Electronic) -IS - 1932-6203 (Linking) -VI - 15 -IP - 9 -DP - 2020 -TI - Cost effectiveness of immune checkpoint inhibitors for treatment of non-small - cell lung cancer: A systematic review. -PG - e0238536 -LID - 10.1371/journal.pone.0238536 [doi] -LID - e0238536 -AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) for treatment of non-small cell - lung cancer (NSCLC) have been rapidly evolving. ICIs are likely to be more - effective but also lead to escalating healthcare costs. OBJECTIVES: The aim of - this study was to evaluate the cost effectiveness of immune checkpoint inhibitors - (ICIs) for treatment of non-small cell lung cancer (NSCLC). METHODS: We searched - the PubMed, Web of Science, and Cochrane Library for studies comparing the cost - effectiveness of ICIs for NSCLC. Potential studies identified were independently - checked for eligibility by two authors, with disagreement resolved by a third - reviewer. Quality of the included studies was evaluated using Consolidated Health - Economic Evaluation Reporting Standards checklists. RESULTS: A total of 22 - economic studies were included. Overall reporting of the identified studies - largely met CHEERS recommendations. In the first-line setting, for advanced or - metastatic NSCLC patients with PD-L1 ≥ 50%, pembrolizumab appeared cost-effective - compared with platinum-based chemotherapy in the US and Hong Kong (China), but - not in the UK and China. The cost-effectiveness of pembrolizumab versus - chemotherapy for first-line treatment of NSCLC in PD-L1 ≥ 1% patients remained - obscure. Regardless of PD-L1 expression status, pembrolizumab in combination with - chemotherapy could be a cost-effective first-line therapy in the US. On the - contrary, addition of atezolizumab to the combination of bevacizumab and - chemotherapy was not cost-effective for patients with metastatic non-squamous - NSCLC from the US payer perspective. In the second-line setting compared with - docetaxel, pembrolizumab was cost-effective; though nivolumab was not - cost-effective in the base case, it could be by increased PD-L1 threshold. - Results of the cost-effectiveness of atezolizumab second-line treatment remained - inconsistent. In addition, the adoption of durvalumab consolidation therapy after - chemoradiotherapy could be cost-effective versus no consolidation therapy for - patients with stage III NSCLC. CONCLUSIONS: Immunotherapy can be a cost-effective - option for treatment of NSCLC in several scenarios. A discount of the agents or - the use of PD-L1 expression as a biomarker improves the cost-effectiveness of - immunotherapy. -FAU - Ding, Haiying -AU - Ding H -AD - Department of Pharmacy, Cancer Hospital of the University of Chinese Academy of - Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic Medicine - (IBMC), Chinese Academy of Sciences, Hangzhou, China. -AD - Department of Pharmacy, The First Affiliated Hospital, College of Medicine, - Zhejiang University, Hangzhou, China. -FAU - Xin, Wenxiu -AU - Xin W -AD - Department of Pharmacy, Cancer Hospital of the University of Chinese Academy of - Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic Medicine - (IBMC), Chinese Academy of Sciences, Hangzhou, China. -FAU - Tong, Yinghui -AU - Tong Y -AD - Department of Pharmacy, Cancer Hospital of the University of Chinese Academy of - Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic Medicine - (IBMC), Chinese Academy of Sciences, Hangzhou, China. -FAU - Sun, Jiao -AU - Sun J -AD - Department of Pharmacy, Cancer Hospital of the University of Chinese Academy of - Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic Medicine - (IBMC), Chinese Academy of Sciences, Hangzhou, China. -FAU - Xu, Gaoqi -AU - Xu G -AD - Department of Pharmacy, Cancer Hospital of the University of Chinese Academy of - Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic Medicine - (IBMC), Chinese Academy of Sciences, Hangzhou, China. -FAU - Ye, Ziqi -AU - Ye Z -AD - Department of Pharmacy, The First Affiliated Hospital, College of Medicine, - Zhejiang University, Hangzhou, China. -FAU - Rao, Yuefeng -AU - Rao Y -AUID- ORCID: 0000-0002-3098-2768 -AD - Department of Pharmacy, The First Affiliated Hospital, College of Medicine, - Zhejiang University, Hangzhou, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Systematic Review -DEP - 20200902 -PL - United States -TA - PLoS One -JT - PloS one -JID - 101285081 -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Antineoplastic Agents, Immunological/economics/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/*economics/*therapy -MH - *Cost-Benefit Analysis -MH - Humans -MH - *Immunotherapy -MH - Lung Neoplasms/drug therapy/*economics/*therapy -PMC - PMC7467260 -COIS- The authors have declared that no competing interests exist. -EDAT- 2020/09/03 06:00 -MHDA- 2020/10/28 06:00 -PMCR- 2020/09/02 -CRDT- 2020/09/03 06:00 -PHST- 2020/04/03 00:00 [received] -PHST- 2020/08/18 00:00 [accepted] -PHST- 2020/09/03 06:00 [entrez] -PHST- 2020/09/03 06:00 [pubmed] -PHST- 2020/10/28 06:00 [medline] -PHST- 2020/09/02 00:00 [pmc-release] -AID - PONE-D-20-09429 [pii] -AID - 10.1371/journal.pone.0238536 [doi] -PST - epublish -SO - PLoS One. 2020 Sep 2;15(9):e0238536. doi: 10.1371/journal.pone.0238536. - eCollection 2020. - -PMID- 27702837 -OWN - NLM -STAT- MEDLINE -DCOM- 20170419 -LR - 20181202 -IS - 1465-3621 (Electronic) -IS - 0368-2811 (Print) -IS - 0368-2811 (Linking) -VI - 46 -IP - 12 -DP - 2016 Dec -TI - Role of multimodality therapy in cIIIA-N2 non-small cell lung cancer: - perspective. -PG - 1174-1178 -AB - A number of promising new approaches for both local and systemic control of - locally advanced non-small cell lung cancer have been examined in clinical - trials, aimed at improving the patient survival. Development of better systemic - therapies by adopting newer agents (such as epidermal growth factor - receptor-tyrosine kinase inhibitors and immune checkpoint inhibitors) from - advanced non-small cell lung cancer is mandatory. As for radiotherapy, adaptive - radiotherapy and proton therapy are under investigation after the RTOG 0617 trial - unexpectedly failed to show the efficacy of high-dose radiotherapy for Stage III - disease. To date, no Phase III trial has clearly shown the benefit of adding - surgery as a part of multimodality therapy for locally advanced non-small cell - lung cancer. Such poor progress in the development of effective treatments for - Stage III non-small cell lung cancer is considered to be attributable to the - existence of heterogeneities in the disease characteristics, including the - biological and anatomic characteristics. Constant effort via well-designed and - well-conducted clinical trials is needed to decipher the heterogeneity of Stage - III non-small cell lung cancer. -CI - © The Author 2015. Published by Oxford University Press. -FAU - Horinouchi, Hidehito -AU - Horinouchi H -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo - hhorinou@ncc.go.jp. -AD - Advanced Clinical Research of Cancer, Juntendo University Graduate School of - Medicine, Tokyo, Japan hhorinou@ncc.go.jp. -LA - eng -PT - Journal Article -DEP - 20161004 -PL - England -TA - Jpn J Clin Oncol -JT - Japanese journal of clinical oncology -JID - 0313225 -RN - 0 (Antineoplastic Agents) -RN - 0 (Protein Kinase Inhibitors) -SB - IM -MH - Antineoplastic Agents/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy/*therapy -MH - Combined Modality Therapy -MH - Humans -MH - Lung Neoplasms/drug therapy/radiotherapy/*therapy -MH - Neoplasm Staging -MH - Protein Kinase Inhibitors/therapeutic use -PMC - PMC5144660 -OTO - NOTNLM -OT - NSCLC -OT - cIIIA-N2 -OT - multimodality therapy -EDAT- 2016/10/06 06:00 -MHDA- 2017/04/20 06:00 -PMCR- 2016/12/08 -CRDT- 2016/10/06 06:00 -PHST- 2016/06/11 00:00 [received] -PHST- 2016/08/17 00:00 [revised] -PHST- 2016/08/19 00:00 [accepted] -PHST- 2016/10/06 06:00 [pubmed] -PHST- 2017/04/20 06:00 [medline] -PHST- 2016/10/06 06:00 [entrez] -PHST- 2016/12/08 00:00 [pmc-release] -AID - hyw131 [pii] -AID - 10.1093/jjco/hyw131 [doi] -PST - ppublish -SO - Jpn J Clin Oncol. 2016 Dec;46(12):1174-1178. doi: 10.1093/jjco/hyw131. Epub 2016 - Oct 4. - -PMID- 35502623 -OWN - NLM -STAT- MEDLINE -DCOM- 20220603 -LR - 20220718 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 13 -IP - 11 -DP - 2022 Jun -TI - Programmed death-ligand 1 expression and use of immune checkpoint inhibitors - among patients with advanced non-small-cell lung cancer in a resource-limited - country. -PG - 1676-1683 -LID - 10.1111/1759-7714.14442 [doi] -AB - INTRODUCTION: Immune checkpoint inhibitor (ICI) therapy is an established - treatment for advanced non-small-cell lung cancer (NSCLC) and programmed death - ligand-1 (PD-L1) expression is a recognized biomarker to determine response to - therapy. We retrospectively analyzed NSCLC patients in the Malaysia Lung Cancer - Registry (MLCR) and report on the clinical characteristics associated with PD-L1 - expression and ICI use in Malaysia, a low- to middle-income country. METHODS: All - 901 NSCLC patients in the MLCR who were diagnosed from January 1, 2017 to - December 31, 2020 from 14 hospitals across the country were analyzed. RESULTS: - Out of 901 patients, 505 had PDL-1 testing done with complete data available only - in 489 patients. The most common histology was adenocarcinoma (84.7%) followed by - squamous cell carcinoma (10.2%). The majority (95%) presented with stage 3 or 4. - The number and percentage of patients with PDL-1 tumor proportion scores of ≥50%, - 1-49%, and <1% were 138 (28.2%), 158 (32.3%), and 193 (39.5%), respectively. In - multivariate analysis, the presence of genomic mutation is the only independent - characteristic associated with negative PD-L1 expression (crude odds ratio 0.579, - 95% confidence interval 0.399-0.840, p = 0.004). Of 292 patients eligible for ICI - therapy, only 100 patients (34.2%) received ICIs. Seventy-eight patients received - ICI therapy as first-line treatment, 15 patients as second-line treatment, and 7 - patients as third-line treatment. CONCLUSIONS: This is the first analysis on - PD-L1 expression and ICI use in Malaysia. Despite the proven efficacy of ICI - therapy, only 56% of our patients had PD-L1 tests performed and only 34.2% of - eligible patients received ICIs. -CI - © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - How, Soon Hin -AU - How SH -AD - Kulliyyah of Medicine, International Islamic University Malaysia, Kuantan, - Malaysia. -FAU - Tho, Lye Mun -AU - Tho LM -AD - Department of Clinical Oncology, Beacon Hospital, Petaling Jaya, Malaysia. -FAU - Liam, Chong Kin -AU - Liam CK -AD - Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. -FAU - Hasbullah, Harissa H -AU - Hasbullah HH -AUID- ORCID: 0000-0002-1956-6536 -AD - Oncology Unit, Faculty of Medicine, Universiti Teknologi Mara, Sungai Buloh, - Malaysia. -AD - Oncology and Radiotherapy Department, General Hospital Kuala Lumpur, Kuala - Lumpur, Malaysia. -FAU - Ho, Gwo Fuang -AU - Ho GF -AD - Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. -FAU - Muhammad Nor, Ibtisam -AU - Muhammad Nor I -AD - Oncology and Radiotherapy Department, General Hospital Kuala Lumpur, Kuala - Lumpur, Malaysia. -FAU - Poh, Mau Ern -AU - Poh ME -AUID- ORCID: 0000-0003-0971-2795 -AD - Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. -FAU - Ho, Kean Fatt -AU - Ho KF -AD - Mount Miriam Cancer Hospital, Penang, Malaysia. -FAU - Thiagarajan, Muthukkumaran -AU - Thiagarajan M -AD - Oncology and Radiotherapy Department, General Hospital Kuala Lumpur, Kuala - Lumpur, Malaysia. -FAU - Samsudin, Azlina -AU - Samsudin A -AD - Hospital Sultanah Nur Zahirah, Kuala Terengganu, Malaysia. -FAU - Omar, Azza -AU - Omar A -AD - Respiratory Unit, Medical Department, Hospital Raja Perempuan Zainab II, Kota - Bharu, Malaysia. -FAU - Ong, Choo Khoon -AU - Ong CK -AD - Gleneagles Penang, George Town, Malaysia. -FAU - Pang, Yong Kek -AU - Pang YK -AD - Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. -FAU - Soon, Sing Yang -AU - Soon SY -AD - Sarawak Heart Centre, Kota Samarahan, Malaysia. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20220503 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - B7-H1 Antigen/metabolism -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use -MH - *Lung Neoplasms/drug therapy/genetics/pathology -MH - Retrospective Studies -PMC - PMC9161340 -OTO - NOTNLM -OT - PDL-1 -OT - immunotherapy -OT - lung cancer -COIS- All authors declare no conflict of interest pertaining to this manuscript -EDAT- 2022/05/04 06:00 -MHDA- 2022/06/07 06:00 -PMCR- 2022/06/01 -CRDT- 2022/05/03 04:43 -PHST- 2022/04/13 00:00 [revised] -PHST- 2022/01/27 00:00 [received] -PHST- 2022/04/13 00:00 [accepted] -PHST- 2022/05/04 06:00 [pubmed] -PHST- 2022/06/07 06:00 [medline] -PHST- 2022/05/03 04:43 [entrez] -PHST- 2022/06/01 00:00 [pmc-release] -AID - TCA14442 [pii] -AID - 10.1111/1759-7714.14442 [doi] -PST - ppublish -SO - Thorac Cancer. 2022 Jun;13(11):1676-1683. doi: 10.1111/1759-7714.14442. Epub 2022 - May 3. - -PMID- 33923355 -OWN - NLM -STAT- MEDLINE -DCOM- 20210924 -LR - 20210924 -IS - 1718-7729 (Electronic) -IS - 1198-0052 (Print) -IS - 1198-0052 (Linking) -VI - 28 -IP - 3 -DP - 2021 Apr 24 -TI - A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy - in Stage III Unresectable Non-Small Cell Lung Cancer. -PG - 1618-1629 -LID - 10.3390/curroncol28030151 [doi] -AB - Stage III non-small cell lung cancer (NSCLC) comprises a highly heterogenous - group of patients with regards to patient fitness and tumour size and - distribution, resulting in a wide range of treatment goals and therapy options. - Curative-intent multimodality treatment should be considered in all patients with - stage III NSCLC. For patients with unresectable disease who are fit, have - adequate lung function, and have a disease that can be encompassed within a - radical radiation volume, concurrent chemoradiation therapy (cCRT) is the - standard of care and can produce cure rates of 20-30%. Recently, consolidation - immunotherapy with durvalumab has been recognized as the standard of care - following cCRT based on significant improvement rates in overall survival at 4 - years. The large heterogeneity of the stage III NSCLC population, along with the - need for extensive staging procedures, multidisciplinary care, intensive cCRT, - and now consolidation therapy makes the delivery of timely and optimal treatment - for these patients complex. Several logistical, communication, and education - factors hinder the delivery of guideline-recommended care to patients with stage - III unresectable NSCLC. This commentary discusses the potential challenges - patients may encounter at different points along their care pathway that can - interfere with delivery of curative-intent therapy and suggests strategies for - improving care delivery. -FAU - Brade, Anthony -AU - Brade A -AD - Department of Radiation Oncology, Peel Regional Cancer Centre, Mississauga, ON - L5M 2N1, Canada. -FAU - Jao, Kevin -AU - Jao K -AD - Department of Hematology and Oncology, Hôpital du Sacré-Coeur de Montréal, - Montreal, QC H4J 1C5, Canada. -FAU - Yu, Simon -AU - Yu S -AD - Department of Medicine, Burnaby Hospital Cancer Centre, Burnaby, BC V5G 2X6, - Canada. -FAU - Cheema, Parneet -AU - Cheema P -AD - Department of Medicine, Division of Medical Oncology, University of Toronto, - Toronto, ON M5S 3H2, Canada. -AD - William Osler Health System, Brampton, ON L6R 3J7, Canada. -FAU - Doucette, Sarah -AU - Doucette S -AD - Senior Medical Writer, IMPACT Medicom Inc., Toronto, ON M6S 3K2, Canada. -FAU - Christofides, Anna -AU - Christofides A -AUID- ORCID: 0000-0001-6421-8728 -AD - Senior Medical Writer, IMPACT Medicom Inc., Toronto, ON M6S 3K2, Canada. -FAU - Schellenberg, Devin -AU - Schellenberg D -AD - Department of Radiation Oncology, BC Cancer Agency, Surrey, BC V2V 1Z2, Canada. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20210424 -PL - Switzerland -TA - Curr Oncol -JT - Current oncology (Toronto, Ont.) -JID - 9502503 -SB - IM -MH - Canada -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Neoplasm Staging -PMC - PMC8161772 -OTO - NOTNLM -OT - care pathway -OT - chemoradiation therapy -OT - curative-intent -OT - immunotherapy -OT - inoperable -OT - stage III non-small cell lung cancer -COIS- We have read and understood Current Oncology’s policy on disclosing conflicts of - interest, and we declare the following interests: A.B. has received honoraria - from AstraZeneca. K.J. has re-ceived honoraria from AstraZeneca, Merck, Pfizer, - Roche, and Bristol Myers Squibb. S.Y. has re-ceived honorarium from AstraZeneca. - P.C. has received honoraria and/or has participated in advisory board meetings - with AstraZeneca, Roche, Merck, Pfizer, Amgen, Bristol Myers Squibb, Takeda, - Novartis, and E.M.D. Serono. D.S. has received grant funding from Varian Medical - Sys-tems, and honoraria from Merck, Pfizer, and AstraZeneca. Medical writing - support provided by S.D. and A.C. of IMPACT Medicom Inc. was funded by - AstraZeneca Canada. -EDAT- 2021/05/01 06:00 -MHDA- 2021/09/25 06:00 -PMCR- 2021/04/24 -CRDT- 2021/04/30 01:24 -PHST- 2021/03/25 00:00 [received] -PHST- 2021/04/19 00:00 [revised] -PHST- 2021/04/21 00:00 [accepted] -PHST- 2021/04/30 01:24 [entrez] -PHST- 2021/05/01 06:00 [pubmed] -PHST- 2021/09/25 06:00 [medline] -PHST- 2021/04/24 00:00 [pmc-release] -AID - curroncol28030151 [pii] -AID - curroncol-28-00151 [pii] -AID - 10.3390/curroncol28030151 [doi] -PST - epublish -SO - Curr Oncol. 2021 Apr 24;28(3):1618-1629. doi: 10.3390/curroncol28030151. - -PMID- 26017283 -OWN - NLM -STAT- MEDLINE -DCOM- 20160511 -LR - 20231213 -IS - 1932-6203 (Electronic) -IS - 1932-6203 (Linking) -VI - 10 -IP - 5 -DP - 2015 -TI - 90Y-Labeled Anti-ROBO1 Monoclonal Antibody Exhibits Antitumor Activity against - Small Cell Lung Cancer Xenografts. -PG - e0125468 -LID - 10.1371/journal.pone.0125468 [doi] -LID - e0125468 -AB - INTRODUCTION: ROBO1 is a membrane protein that contributes to tumor metastasis - and angiogenesis. We previously reported that 90Y-labeled anti-ROBO1 monoclonal - antibody (90Y-anti-ROBO1 IgG) showed an antitumor effect against ROBO1-positive - tumors. In this study, we performed a biodistribution study and - radioimmunotherapy (RIT) against ROBO1-positive small cell lung cancer (SCLC) - models. METHODS: For the biodistribution study, 111In-labeled anti-ROBO1 - monoclonal antibody (111In-anti-ROBO1 IgG) was injected into ROBO1-positive SCLC - xenograft mice via the tail vein. To evaluate antitumor effects, an RIT study was - performed, and SCLC xenograft mice were treated with 90Y-anti-ROBO1 IgG. Tumor - volume and body weight were periodically measured throughout the experiments. The - tumors and organs of mice were then collected, and a pathological analysis was - carried out. RESULTS: As a result of the biodistribution study, we observed tumor - uptake of 111In-anti-ROBO1 IgG. The liver, kidney, spleen, and lung showed - comparably high accumulation of 111In-labeled anti-ROBO1. In the RIT study, - 90Y-anti-ROBO1 IgG significantly reduced tumor volume compared with baseline. - Pathological analyses of tumors revealed coagulation necrosis and fatal - degeneration of tumor cells, significant reduction in the number of - Ki-67-positive cells, and an increase in the number of apoptotic cells. A - transient reduction of hematopoietic cells was observed in the spleen, sternum, - and femur. CONCLUSIONS: These results suggest that RIT with 90Y-anti-ROBO1 IgG is - a promising treatment for ROBO1-positive SCLC. -FAU - Fujiwara, Kentaro -AU - Fujiwara K -AD - Department of Radiology, Graduate School of Medicine, The University of Tokyo, - Bunkyo-ku, Tokyo, Japan. -FAU - Koyama, Keitaro -AU - Koyama K -AD - Department of Radiology, Graduate School of Medicine, The University of Tokyo, - Bunkyo-ku, Tokyo, Japan. -FAU - Suga, Kosuke -AU - Suga K -AD - SANKYO LABO SERVICE Co., Ltd., Edogawaku, Tokyo, Japan. -FAU - Ikemura, Masako -AU - Ikemura M -AD - Department of Pathology, Graduate School of Medicine, The University of Tokyo, - Bunkyo-ku, Tokyo, Japan. -FAU - Saito, Yasutaka -AU - Saito Y -AD - FUJIFILM RI Pharma Co., Ltd., SAMMU-CITY, CHIBA, Japan. -FAU - Hino, Akihiro -AU - Hino A -AD - FUJIFILM RI Pharma Co., Ltd., SAMMU-CITY, CHIBA, Japan. -FAU - Iwanari, Hiroko -AU - Iwanari H -AD - Department of Quantitative Biology and Medicine, Research Center for Advanced - Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan. -FAU - Kusano-Arai, Osamu -AU - Kusano-Arai O -AD - Department of Quantitative Biology and Medicine, Research Center for Advanced - Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan. -FAU - Mitsui, Kenichi -AU - Mitsui K -AD - Department of Quantitative Biology and Medicine, Research Center for Advanced - Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan. -FAU - Kasahara, Hiroyuki -AU - Kasahara H -AD - FUJIFILM RI Pharma Co., Ltd., SAMMU-CITY, CHIBA, Japan. -FAU - Fukayama, Masashi -AU - Fukayama M -AD - Department of Pathology, Graduate School of Medicine, The University of Tokyo, - Bunkyo-ku, Tokyo, Japan. -FAU - Kodama, Tatsuhiko -AU - Kodama T -AD - Department of Systems Biology and Medicine, Research Center for Advanced Science - and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan. -FAU - Hamakubo, Takao -AU - Hamakubo T -AD - Department of Quantitative Biology and Medicine, Research Center for Advanced - Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan. -FAU - Momose, Toshimitsu -AU - Momose T -AD - Department of Radiology, Graduate School of Medicine, The University of Tokyo, - Bunkyo-ku, Tokyo, Japan. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20150527 -PL - United States -TA - PLoS One -JT - PloS one -JID - 101285081 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Nerve Tissue Proteins) -RN - 0 (Receptors, Immunologic) -RN - 0 (Yttrium Radioisotopes) -SB - IM -MH - Animals -MH - Antibodies, Monoclonal/chemistry/immunology/pharmacokinetics/*pharmacology -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology/radiotherapy -MH - Male -MH - Mice, Inbred BALB C -MH - Mice, Nude -MH - Nerve Tissue Proteins/*immunology/metabolism -MH - Radioimmunotherapy/methods -MH - Receptors, Immunologic/*immunology/metabolism -MH - Small Cell Lung Carcinoma/*drug therapy/pathology/radiotherapy -MH - Tissue Distribution -MH - Xenograft Model Antitumor Assays/methods -MH - Yttrium Radioisotopes/chemistry/pharmacokinetics/*therapeutic use -MH - Roundabout Proteins -PMC - PMC4446100 -COIS- Competing Interests: The authors have the following interests: Co-author Kosuke - Suga is employed by SANKYO LABO SERVICE Co., Ltd. Co-authors Yasutaka Saito, - Akihiro Hino and Hiroyuki Kasahara are employed by FUJIFILM RI Pharma Co., Ltd. - FUJIFILM RI Pharma Co., Ltd. joined this study as a collaborating company in the - Japan Society for the Promotion of Science through the “Funding Program for - World-Leading Innovative R&D on Science and Technology.” It was responsible for - radiolabelling of antibodies. There are no patents, products in development or - marketed products to declare. This does not alter the authors' adherence to all - the PLOS ONE policies on sharing data and materials. -EDAT- 2015/05/29 06:00 -MHDA- 2016/05/12 06:00 -PMCR- 2015/05/27 -CRDT- 2015/05/29 06:00 -PHST- 2014/10/06 00:00 [received] -PHST- 2015/03/24 00:00 [accepted] -PHST- 2015/05/29 06:00 [entrez] -PHST- 2015/05/29 06:00 [pubmed] -PHST- 2016/05/12 06:00 [medline] -PHST- 2015/05/27 00:00 [pmc-release] -AID - PONE-D-14-44766 [pii] -AID - 10.1371/journal.pone.0125468 [doi] -PST - epublish -SO - PLoS One. 2015 May 27;10(5):e0125468. doi: 10.1371/journal.pone.0125468. - eCollection 2015. - -PMID- 33211281 -OWN - NLM -STAT- MEDLINE -DCOM- 20211206 -LR - 20211214 -IS - 1699-3055 (Electronic) -IS - 1699-048X (Linking) -VI - 23 -IP - 6 -DP - 2021 Jun -TI - The optimal immune checkpoint inhibitors combined with chemotherapy for advanced - non-small-cell lung cancer: a systematic review and meta-analysis. -PG - 1117-1127 -LID - 10.1007/s12094-020-02502-8 [doi] -AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) plus chemotherapy (CT) have - strikingly expanded the therapeutic landscape for advanced non-small cell lung - cancer (NSCLC), but little is known about which is superior. We performed a - meta-analysis that compared the efficacy and safety of PD-1 inhibitor + CT with - PD-L1 inhibitor + CT. METHODS: PubMed, Embase, Web of Science, Cochrane Library, - and major international scientific meetings were searched for relevant randomized - controlled trials (RCTs), and the indirect analysis was performed for PD-1 + CT - vs PD-L1 + CT. The outcomes included progression-free survival (PFS), overall - survival (OS), objective response rate (ORR) and treatment-related adverse events - (TRAEs). RESULTS: 8 phase III RCTs with 4253 patients comparing PD-1/PD-L1 + CT - in NSCLC were included. The PD-1 + CT led to notably longer OS most in - low/negative expression of PD-L1 for NSCLC patients compared with PD-L1 + CT. In - terms of Grade 3-5 TRAEs, the results showed that PD-1 + CT and PD-L1 + CT - exclusively increased the risk of adverse incidence than CT alone, especially for - PD-L1 + CT (p < 0.00001). For subgroups including female, young patients, - patients with nonsmoker, and EGFR/ALK wild-type, PD-1 + CT was associated with - prolonged OS (p < 0.05). Meanwhile, for no liver metastasis of NSCLC patients, we - found obviously OS advantage for patients treated with PD-1 + CT compared to - PD-L1 + CT. CONCLUSIONS: ICIs + CT seemed to be more effective first-line regimen - and PD-1 + CT could be recommended as the first-rank therapy for advanced NSCLC - patients with low/negative expression of PD-L1. However, we should be - particularly vigilant about the occurrence of the Grade 3-5 TRAEs. -FAU - Yang, Y -AU - Yang Y -AD - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou - University, Dong Ming Road 127#, Zhengzhou, 450008, China. -FAU - Luo, H -AU - Luo H -AD - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou - University, Dong Ming Road 127#, Zhengzhou, 450008, China. -FAU - Zheng, X L -AU - Zheng XL -AD - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou - University, Dong Ming Road 127#, Zhengzhou, 450008, China. -FAU - Ge, H -AU - Ge H -AUID- ORCID: 0000-0002-2958-3866 -AD - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou - University, Dong Ming Road 127#, Zhengzhou, 450008, China. gehong616@126.com. -LA - eng -GR - 81372436/National Natural Science Foundation of China/ -GR - 182106000062/Science and Technology Department of Henan Province/ -PT - Comparative Study -PT - Journal Article -PT - Meta-Analysis -PT - Systematic Review -DEP - 20201119 -PL - Italy -TA - Clin Transl Oncol -JT - Clinical & translational oncology : official publication of the Federation of - Spanish Oncology Societies and of the National Cancer Institute of Mexico -JID - 101247119 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Lung Neoplasms/*drug therapy/pathology -MH - Neoplasm Staging -MH - Treatment Outcome -OTO - NOTNLM -OT - Advanced non-small cell lung cancer (advanced NSCLC) -OT - Chemotherapy -OT - Immune checkpoint inhibitors (ICIs) -OT - Programmed death 1 -OT - Programmed death 1 ligand 1 -EDAT- 2020/11/20 06:00 -MHDA- 2021/12/15 06:00 -CRDT- 2020/11/19 12:16 -PHST- 2020/05/11 00:00 [received] -PHST- 2020/09/15 00:00 [accepted] -PHST- 2020/11/20 06:00 [pubmed] -PHST- 2021/12/15 06:00 [medline] -PHST- 2020/11/19 12:16 [entrez] -AID - 10.1007/s12094-020-02502-8 [pii] -AID - 10.1007/s12094-020-02502-8 [doi] -PST - ppublish -SO - Clin Transl Oncol. 2021 Jun;23(6):1117-1127. doi: 10.1007/s12094-020-02502-8. - Epub 2020 Nov 19. - -PMID- 31605794 -OWN - NLM -STAT- MEDLINE -DCOM- 20210106 -LR - 20230202 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 15 -IP - 2 -DP - 2020 Feb -TI - Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy - for Extensive-Stage Small Cell Lung Cancer. -PG - 266-273 -LID - S1556-0864(19)33525-7 [pii] -LID - 10.1016/j.jtho.2019.10.001 [doi] -AB - INTRUDUCTION: Radiation and immunotherapy have separately been shown to confer - survival advantages to patients with extensive-stage small cell lung cancer - (ESCLC), but failure rates remain high and combination therapy has been - understudied. In this single-arm phase I trial (NCT02402920), we assessed the - safety of combining pembrolizumab with thoracic radiotherapy (TRT) after - induction chemotherapy for SCLC. METHODS: Patients with ESCLC who had completed - chemotherapy received TRT with pembrolizumab. The maximum tolerated dose of - pembrolizumab was assessed by 3+3 dose-escalation; doses began at 100 mg and - increased in 50 mg increments to 200 mg. Pembrolizumab was given every 3 weeks - for up to 16 cycles; TRT was prescribed as 45 Gy in 15 daily fractions. Toxicity - was evaluated with the Common Terminology Criteria for Adverse Events v4.0. The - primary endpoint was safety of the combined therapy based on the incidence of - dose-limiting toxicity in the 35 days following initiation of treatment. RESULTS: - Thirty-eight patients with ESCLC (median age 65 years, range: 37-79 years) were - enrolled from September 2015 through September 2017; 33 received per-protocol - treatment, and all tolerated pembrolizumab at 100 to 200 mg with no dose-limiting - toxicity in the 35-day window. There were no grade 4-5 toxicities; 2 (6%) - patients experienced grade 3 events (n = 1 rash, n = 1 - asthenia/paresthesia/autoimmune disorder) that were unlikely/doubtfully related - to protocol therapy. The median follow-up time was 7.3 months (range: 1-13 - months); median progression-free and overall survival times were 6.1 months (95% - confidence interval: 4.1-8.1) and 8.4 months (95% confidence interval: 6.7-10.1). - CONCLUSIONS: Concurrent pembrolizumab-TRT was tolerated well with few high-grade - adverse events in the short-term; progression-free and overall survival rates are - difficult to interpret due to heterogeneity in eligibility criteria (e.g., - enrolling progressors on induction chemotherapy). Although randomized studies - have shown benefits to TRT alone and immunotherapy alone, the safety of the - combined regimen supports further investigation as a foundational approach for - future prospective studies. -CI - Copyright © 2019 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Welsh, James W -AU - Welsh JW -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. Electronic address: jwelsh@mdanderson.org. -FAU - Heymach, John V -AU - Heymach JV -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Chen, Dawei -AU - Chen D -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas; Department of Radiation Oncology, Shandong Cancer - Hospital affiliated to Shandong University, Jinan, China. -FAU - Verma, Vivek -AU - Verma V -AD - Department of Radiation Oncology, Alleghany General Hospital, Pittsburgh, - Pennsylvania. -FAU - Cushman, Taylor R -AU - Cushman TR -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Hess, Kenneth R -AU - Hess KR -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, Texas. -FAU - Shroff, Girish -AU - Shroff G -AD - Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Tang, Chad -AU - Tang C -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Skoulidis, Ferdinandos -AU - Skoulidis F -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Jeter, Melenda -AU - Jeter M -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Menon, Hari -AU - Menon H -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Nguyen, Quynh-Nhu -AU - Nguyen QN -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Chang, Joe Y -AU - Chang JY -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Altan, Mehmet -AU - Altan M -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Papadimitrakopoulou, Vassiliki A -AU - Papadimitrakopoulou VA -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Simon, George R -AU - Simon GR -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Raju, Uma -AU - Raju U -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Byers, Lauren -AU - Byers L -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Glisson, Bonnie -AU - Glisson B -AD - Department of Thoracic Head & Neck Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -LA - eng -SI - ClinicalTrials.gov/NCT02402920 -PT - Clinical Trial, Phase I -PT - Journal Article -DEP - 20191009 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -CIN - J Thorac Oncol. 2020 Feb;15(2):166-169. doi: 10.1016/j.jtho.2019.12.106. PMID: - 32127183 -MH - Adult -MH - Aged -MH - Antibodies, Monoclonal, Humanized -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Humans -MH - Induction Chemotherapy -MH - *Lung Neoplasms/drug therapy -MH - Middle Aged -MH - Prospective Studies -MH - *Small Cell Lung Carcinoma/drug therapy -OTO - NOTNLM -OT - Extensive stage small cell lung cancer -OT - immunotherapy -OT - pembrolizumab -OT - radiotherapy -EDAT- 2019/10/13 06:00 -MHDA- 2021/01/07 06:00 -CRDT- 2019/10/13 06:00 -PHST- 2019/08/26 00:00 [received] -PHST- 2019/09/27 00:00 [revised] -PHST- 2019/10/01 00:00 [accepted] -PHST- 2019/10/13 06:00 [pubmed] -PHST- 2021/01/07 06:00 [medline] -PHST- 2019/10/13 06:00 [entrez] -AID - S1556-0864(19)33525-7 [pii] -AID - 10.1016/j.jtho.2019.10.001 [doi] -PST - ppublish -SO - J Thorac Oncol. 2020 Feb;15(2):266-273. doi: 10.1016/j.jtho.2019.10.001. Epub - 2019 Oct 9. - -PMID- 37533115 -OWN - NLM -STAT- MEDLINE -DCOM- 20230907 -LR - 20230909 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 14 -IP - 25 -DP - 2023 Sep -TI - Predictors of lung injury during durvalumab maintenance therapy following - concurrent chemoradiotherapy in unresectable locally advanced non-small cell lung - carcinoma. -PG - 2601-2607 -LID - 10.1111/1759-7714.15042 [doi] -AB - BACKGROUND: Based on the results of the PACIFIC trial, maintenance with - durvalumab has emerged as the standard treatment following concurrent - chemoradiotherapy in patients with unresectable locally advanced non-small cell - lung carcinoma (NSCLC). However, adverse events attributed to durvalumab, - especially lung injuries, including immune-related adverse events, and radiation - pneumonitis, are concerning. This study retrospectively investigated the factors - related to lung injury in patients receiving the PACIFIC regimen. METHODS: - Patients with unresectable locally advanced NSCLC who received durvalumab - maintenance therapy following concurrent chemoradiotherapy at Yokohama City - University Medical Centre between July 2018 and March 2022 were included. - Clinical data, volume of normal lung receiving 20 or 5 Gy or more (V20 or V5), - planning target volume (PTV), and relative lung parenchyma volume in - emphysematous lung receiving 20 or 5 Gy or more (RLPV20 or 5; V20 or - V5/100-percentage of low-attenuation volume) were evaluated. RESULTS: Performance - status (PS), V20, V5, PTV, RLPV20, and RLPV5 were significantly higher in the - lung injury group in the univariate analysis. Furthermore, RLPV20 was the most - significant factor in the lung injury group in the multivariate analysis - comprising PS, PTV, V20, and RLPV20. CONCLUSION: RLPV20 and RLPV5 are useful in - estimating lung inflammation. RLPV20 could be considered the most reliable risk - factor for maintenance therapy with durvalumab following concurrent - chemoradiotherapy in patients with unresectable locally advanced NSCLC. -CI - © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Hirama, Nobuyuki -AU - Hirama N -AUID- ORCID: 0000-0003-3585-5589 -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Yamamoto, Masaki -AU - Yamamoto M -AUID- ORCID: 0000-0001-7056-4192 -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Nagaoka, Satoshi -AU - Nagaoka S -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Segawa, Wataru -AU - Segawa W -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Sugimoto, Chihiro -AU - Sugimoto C -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Nagayama, Hirokazu -AU - Nagayama H -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Hiro, Shuntaro -AU - Hiro S -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Kajita, Yukihito -AU - Kajita Y -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Maeda, Chihiro -AU - Maeda C -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Kubo, Sousuke -AU - Kubo S -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Seki, Kenichi -AU - Seki K -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Nagahara, Yoshinori -AU - Nagahara Y -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Teranishi, Shuhei -AU - Teranishi S -AUID- ORCID: 0000-0003-2365-144X -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Tashiro, Ken -AU - Tashiro K -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Hara, Yu -AU - Hara Y -AD - Department of Pulmonology, Yokohama City University Graduate School of Medicine, - Yokohama, Japan. -FAU - Kobayashi, Nobuaki -AU - Kobayashi N -AUID- ORCID: 0000-0002-7064-320X -AD - Department of Pulmonology, Yokohama City University Graduate School of Medicine, - Yokohama, Japan. -FAU - Watanabe, Shigenobu -AU - Watanabe S -AD - Department of Radiation Oncology, Fujisawa City Hospital, Fujisawa, Japan. -FAU - Kudo, Makoto -AU - Kudo M -AD - Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, - Japan. -FAU - Kaneko, Takeshi -AU - Kaneko T -AD - Department of Pulmonology, Yokohama City University Graduate School of Medicine, - Yokohama, Japan. -LA - eng -PT - Journal Article -DEP - 20230802 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Lung Neoplasms/pathology -MH - *Lung Injury/etiology -MH - Retrospective Studies -MH - Chemoradiotherapy/methods -PMC - PMC10481134 -OTO - NOTNLM -OT - concurrent chemoradiotherapy -OT - durvalumab maintenance therapy -OT - lung injury predictors -OT - non-small cell lung carcinoma -COIS- The authors declare no conflicts of interest. -EDAT- 2023/08/03 01:06 -MHDA- 2023/09/07 06:42 -PMCR- 2023/08/02 -CRDT- 2023/08/02 23:41 -PHST- 2023/06/29 00:00 [received] -PHST- 2023/07/06 00:00 [accepted] -PHST- 2023/09/07 06:42 [medline] -PHST- 2023/08/03 01:06 [pubmed] -PHST- 2023/08/02 23:41 [entrez] -PHST- 2023/08/02 00:00 [pmc-release] -AID - TCA15042 [pii] -AID - 10.1111/1759-7714.15042 [doi] -PST - ppublish -SO - Thorac Cancer. 2023 Sep;14(25):2601-2607. doi: 10.1111/1759-7714.15042. Epub 2023 - Aug 2. - -PMID- 37354070 -OWN - NLM -STAT- MEDLINE -DCOM- 20231106 -LR - 20231219 -IS - 1097-0142 (Electronic) -IS - 0008-543X (Linking) -VI - 129 -IP - 23 -DP - 2023 Dec 1 -TI - Safety and efficacy of durvalumab after concurrent chemoradiation in Black - patients with locally advanced non-small cell lung cancer. -PG - 3713-3723 -LID - 10.1002/cncr.34915 [doi] -AB - BACKGROUND: The PACIFIC trial established consolidative durvalumab after - concurrent chemoradiation as standard-of-care in patients with stage III or - unresectable non-small cell lung cancer (NSCLC). Black patients, however, - comprised just 2% (n = 14) of randomized patients in this trial, warranting - real-world evaluation of the PACIFIC regimen in these patients. METHODS: This - single-institution, multi-site study included 105 patients with unresectable - stage II/III NSCLC treated with concurrent chemoradiation followed by durvalumab - between 2017 and 2021. Overall survival (OS), progression-free survival (PFS), - and grade ≥3 pneumonitis-free survival (PNFS) were compared between Black and - non-Black patients using Kaplan-Meier and Cox regression analyses. RESULTS: A - total of 105 patients with a median follow-up of 22.8 months (interquartile - range, 11.3-37.3 months) were identified for analysis, including 57 Black (54.3%) - and 48 (45.7%) non-Black patients. The mean radiation prescription dose was - higher among Black patients (61.5 ± 2.9 Gy vs. 60.5 ± 1.9 Gy; p = .031), but - other treatment characteristics were balanced between groups. The median OS - (not-reached vs. 39.7 months; p = .379) and PFS (31.6 months vs. 19.3 months; p = - .332) were not statistically different between groups. Eight (14.0%) Black - patients discontinued durvalumab due to toxicity compared to 13 (27.1%) non-Black - patients (p = .096). The grade ≥3 pneumonitis rate was similar between Black and - non-Black patients (12.3% vs. 12.5%; p = .973), and there was no significant - difference in time to grade ≥3 PNFS (p = .904). Three (5.3%) Black patients and - one (2.1%) non-Black patient developed grade 5 pneumonitis. CONCLUSIONS: The - efficacy and tolerability of consolidative durvalumab after chemoradiation - appears to be comparable between Black and non-Black patients. -CI - © 2023 American Cancer Society. -FAU - McCall, Neal S -AU - McCall NS -AUID- ORCID: 0000-0001-7571-6984 -AD - Department of Radiation Oncology, Winship Cancer Institute of Emory University, - Atlanta, Georgia, USA. -FAU - Janopaul-Naylor, James R -AU - Janopaul-Naylor JR -AUID- ORCID: 0000-0002-3612-4852 -AD - Department of Radiation Oncology, Winship Cancer Institute of Emory University, - Atlanta, Georgia, USA. -FAU - McGinnis, H Scott -AU - McGinnis HS -AD - Department of Radiation Oncology, Winship Cancer Institute of Emory University, - Atlanta, Georgia, USA. -FAU - Kesarwala, Aparna H -AU - Kesarwala AH -AD - Department of Radiation Oncology, Winship Cancer Institute of Emory University, - Atlanta, Georgia, USA. -FAU - Tian, Sibo -AU - Tian S -AUID- ORCID: 0000-0001-5018-4854 -AD - Department of Radiation Oncology, Winship Cancer Institute of Emory University, - Atlanta, Georgia, USA. -FAU - Stokes, William A -AU - Stokes WA -AD - Department of Radiation Oncology, Winship Cancer Institute of Emory University, - Atlanta, Georgia, USA. -FAU - Shelton, Joseph W -AU - Shelton JW -AD - Department of Radiation Oncology, Winship Cancer Institute of Emory University, - Atlanta, Georgia, USA. -FAU - Steuer, Conor E -AU - Steuer CE -AD - Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory - University, Atlanta, Georgia, USA. -FAU - Carlisle, Jennifer W -AU - Carlisle JW -AUID- ORCID: 0000-0001-7085-4640 -AD - Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory - University, Atlanta, Georgia, USA. -FAU - Leal, Ticiana A -AU - Leal TA -AUID- ORCID: 0000-0002-3735-9063 -AD - Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory - University, Atlanta, Georgia, USA. -FAU - Ramalingam, Suresh S -AU - Ramalingam SS -AUID- ORCID: 0000-0002-0757-3106 -AD - Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory - University, Atlanta, Georgia, USA. -FAU - Bradley, Jeffrey D -AU - Bradley JD -AD - Department of Radiation Oncology, Winship Cancer Institute of Emory University, - Atlanta, Georgia, USA. -FAU - Higgins, Kristin A -AU - Higgins KA -AD - Department of Radiation Oncology, Winship Cancer Institute of Emory University, - Atlanta, Georgia, USA. -LA - eng -GR - P30 CA138292/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20230624 -PL - United States -TA - Cancer -JT - Cancer -JID - 0374236 -RN - 28X28X9OKV (durvalumab) -SB - IM -CIN - Cancer. 2023 Dec 1;129(23):3692-3693. doi: 10.1002/cncr.35013. PMID: 37728029 -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Chemoradiotherapy/adverse effects -MH - *Pneumonia -OTO - NOTNLM -OT - chemoradiation -OT - durvalumab -OT - immunotherapy -OT - non-small cell lung cancer -OT - race -EDAT- 2023/06/24 21:03 -MHDA- 2023/11/06 06:42 -CRDT- 2023/06/24 07:42 -PHST- 2023/02/10 00:00 [revised] -PHST- 2022/12/01 00:00 [received] -PHST- 2023/03/02 00:00 [accepted] -PHST- 2023/11/06 06:42 [medline] -PHST- 2023/06/24 21:03 [pubmed] -PHST- 2023/06/24 07:42 [entrez] -AID - 10.1002/cncr.34915 [doi] -PST - ppublish -SO - Cancer. 2023 Dec 1;129(23):3713-3723. doi: 10.1002/cncr.34915. Epub 2023 Jun 24. - -PMID- 36779488 -OWN - NLM -STAT- MEDLINE -DCOM- 20230417 -LR - 20230417 -IS - 1744-8301 (Electronic) -IS - 1479-6694 (Linking) -VI - 19 -IP - 2 -DP - 2023 Jan -TI - Efficacy and safety of immune checkpoint inhibitors combined with recombinant - human endostatin and chemotherapy as the first-line treatment of advanced - non-small-cell lung cancer. -PG - 147-158 -LID - 10.2217/fon-2022-0861 [doi] -AB - Aim: To assess the efficacy and safety of combination of PD-1 inhibitors, - recombinant human endostatin (Rh-endostatin) and chemotherapy as first-line - treatment for advanced non-small-cell lung cancer (NSCLC). Methods: A total of - 100 patients with advanced NSCLC were retrospectively reviewed and analyzed (58 - in the group receiving PD-1 inhibitors plus Rh-endostatin and chemotherapy; 42 in - the group receiving Rh-endostatin and chemotherapy). The primary end point was - progression-free survival. Results: Patients in the group receiving PD-1 - inhibitors plus Rh-endostatin and chemotherapy had significantly improved - progression-free survival (10.2 vs 6.5 months; p < 0.001) and objective response - rate (67.2 vs 42.9%; p = 0.015), with acceptable toxicity. Conclusion: Our study - showed the superiority of combination therapy of PD-1 inhibitors and - Rh-endostatin as first-line treatment for advanced NSCLC. -FAU - Fu, Silv -AU - Fu S -AUID- ORCID: 0000-0002-0069-0115 -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, 330006, China. -AD - Department of Radiotherapy, Jiangxi Cancer Hospital, Nanchang, 330029, China. -FAU - Huang, Hongxiang -AU - Huang H -AUID- ORCID: 0000-0002-4446-7775 -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, 330006, China. -FAU - Shang, Kai -AU - Shang K -AD - Department of Oncology, Affiliated Hospital of Guizhou Medical University, - Guiyang, 550004, China. -FAU - Tu, Ganjie -AU - Tu G -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, 330006, China. -AD - Department of Radiotherapy, Jiangxi Cancer Hospital, Nanchang, 330029, China. -FAU - Zhong, Peiyuan -AU - Zhong P -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, 330006, China. -FAU - Li, Siling -AU - Li S -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, 330006, China. -FAU - Zhu, Xie -AU - Zhu X -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, 330006, China. -FAU - Peng, Sujuan -AU - Peng S -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, 330006, China. -FAU - Liu, Yangyang -AU - Liu Y -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, 330006, China. -FAU - Lu, Zhihui -AU - Lu Z -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, 330006, China. -FAU - Chen, Li -AU - Chen L -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, 330006, China. -LA - eng -GR - 82103339/National Natural Science Foundation of China/ -PT - Journal Article -DEP - 20230213 -PL - England -TA - Future Oncol -JT - Future oncology (London, England) -JID - 101256629 -RN - 0 (Endostatins) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Endostatins -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - *Lung Neoplasms/drug therapy -MH - Retrospective Studies -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -OAB - This study retrospectively analyzed the effectiveness and safety of PD-1 - inhibitors combined with recombinant human endostatin (Rh-endostatin) and - chemotherapy as first-line treatment for advanced non-small-cell lung cancer. - Among them, 58 patients received a PD-1 inhibitor combined with Rh-endostatin and - chemotherapy (treatment group), and 42 patients received Rh-endostatin combined - with chemotherapy (control group). Patients in the treatment group had a - significantly improved objective response rate (67.2 vs 42.9%; p = 0.015) and - prolonged survival without their disease getting worse (10.2 vs 6.5 months; - p < 0.001). No significant differences were found in the adverse events between - the two groups. -OABL- eng -OTO - NOTNLM -OT - angiogenesis inhibitors -OT - immune checkpoint inhibitors -OT - non-small-cell lung cancer -OT - tumor microenvironments -EDAT- 2023/02/14 06:00 -MHDA- 2023/04/17 06:41 -CRDT- 2023/02/13 06:53 -PHST- 2023/04/17 06:41 [medline] -PHST- 2023/02/14 06:00 [pubmed] -PHST- 2023/02/13 06:53 [entrez] -AID - 10.2217/fon-2022-0861 [doi] -PST - ppublish -SO - Future Oncol. 2023 Jan;19(2):147-158. doi: 10.2217/fon-2022-0861. Epub 2023 Feb - 13. - -PMID- 35256515 -OWN - NLM -STAT- MEDLINE -DCOM- 20220510 -LR - 20240923 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 10 -IP - 3 -DP - 2022 Mar -TI - Novel imaging biomarkers predict outcomes in stage III unresectable non-small - cell lung cancer treated with chemoradiation and durvalumab. -LID - 10.1136/jitc-2021-003778 [doi] -LID - e003778 -AB - BACKGROUND: The landmark study of durvalumab as consolidation therapy in NSCLC - patients (PACIFIC trial) demonstrated significantly longer progression-free - survival (PFS) in patients with locally advanced, unresectable non-small cell - lung cancer (NSCLC) treated with durvalumab (immunotherapy, IO) therapy after - chemoradiotherapy (CRT). In clinical practice in the USA, durvalumab continues to - be used in patients across all levels of programmed cell death ligand-1 (PD-L1) - expression. While immune therapies have shown promise in several cancers, some - patients either do not respond to the therapy or have cancer recurrence after an - initial response. It is not clear so far who will benefit of this therapy or what - the mechanisms behind treatment failure are. METHODS: A total of 133 patients - with unresectable stage III NSCLC who underwent durvalumab after CRT or CRT alone - were included. Patients treated with durvalumab IO after CRT were randomly split - into training (D1=59) and test (D2=59) sets and the remaining 15 patients treated - with CRT alone were grouped in D3. Radiomic textural patterns from within and - around the target nodules were extracted. A radiomic risk score (RRS) was built - and was used to predict PFS and overall survival (OS). Patients were divided into - high-risk and low-risk groups based on median RRS. RESULTS: RRS was found to be - significantly associated with PFS in D1 (HR=2.67, 95% CI 1.85 to 4.13, p<0.05, - C-index=0.78) and D2 (HR=2.56, 95% CI 1.63 to 4, p<0.05, C-index=0.73). - Similarly, RRS was associated with OS in D1 (HR=1.89, 95% CI 1.3 to 2.75, p<0.05, - C-index=0.67) and D2 (HR=2.14, 95% CI 1.28 to 3.6, p<0.05, C-index=0.69), - respectively. RRS was found to be significantly associated with PFS in high PD-L1 - (HR=3.01, 95% CI 1.41 to 6.45, p=0.0044) and low PD-L1 (HR=2.74, 95% CI 1.8 to - 4.14, p=1.77e-06) groups. Moreover, RRS was not significantly associated with OS - in the high PD-L1 group (HR=2.08, 95% CI 0.98 to 4.4, p=0.054) but was - significantly associated with OS in the low PD-L1 group (HR=1.61, 95% CI 1.14 to - 2.28, p=0.0062). In addition, RRS was significantly associated with PFS (HR=2.77, - 95% CI 1.17 to 6.52, p=0.019, C-index=0.77) and OS (HR=2.62, 95% CI 1.25 to 5.51, - p=0.01, C-index=0.77) in D3, respectively. CONCLUSIONS: Tumor radiomics of - pretreatment CT images from patients with stage III unresectable NSCLC were - prognostic of PFS and OS to CRT followed by durvalumab IO and CRT alone. -CI - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Jazieh, Khalid -AU - Jazieh K -AD - Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA. -FAU - Khorrami, Mohammadhadi -AU - Khorrami M -AD - Department of Biomedical Engineering, Case Western Reserve University, Cleveland, - Ohio, USA. -FAU - Saad, Anas -AU - Saad A -AD - Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA. -FAU - Gad, Mohamed -AU - Gad M -AD - Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA. -FAU - Gupta, Amit -AU - Gupta A -AD - Department of Radiology, University Hospitals Cleveland Medical Center, - Cleveland, Ohio, USA. -FAU - Patil, Pradnya -AU - Patil P -AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, - Cleveland Clinic, Cleveland, Ohio, USA. -FAU - Viswanathan, Vidya Sankar -AU - Viswanathan VS -AD - Department of Biomedical Engineering, Case Western Reserve University, Cleveland, - Ohio, USA. -FAU - Rajiah, Prabhakar -AU - Rajiah P -AD - Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA. -FAU - Nock, Charles J -AU - Nock CJ -AD - Louis Stokes Cleveland VA Medical Center Mental Health Services, Cleveland, Ohio, - USA. -FAU - Gilkey, Michael -AU - Gilkey M -AD - Department of Biomedical Engineering, Case Western Reserve University, Cleveland, - Ohio, USA. -FAU - Fu, Pingfu -AU - Fu P -AD - Department of Population and Quantitative Health Sciences, Case Western Reserve - University, Cleveland, Ohio, USA. -FAU - Pennell, Nathan A -AU - Pennell NA -AUID- ORCID: 0000-0002-1458-0064 -AD - Department of Hematology and Medical Oncology, Taussig Cancer Institute, - Cleveland Clinic, Cleveland, Ohio, USA. -FAU - Madabhushi, Anant -AU - Madabhushi A -AUID- ORCID: 0000-0002-5741-0399 -AD - Department of Biomedical Engineering, Case Western Reserve University, Cleveland, - Ohio, USA axm788@case.edu. -AD - Louis Stokes Cleveland VA Medical Center Mental Health Services, Cleveland, Ohio, - USA. -LA - eng -GR - UL1 TR002548/TR/NCATS NIH HHS/United States -GR - R01 CA216579/CA/NCI NIH HHS/United States -GR - C06 RR012463/RR/NCRR NIH HHS/United States -GR - U24 CA199374/CA/NCI NIH HHS/United States -GR - R43 EB028736/EB/NIBIB NIH HHS/United States -GR - U01 CA239055/CA/NCI NIH HHS/United States -GR - R01 CA249992/CA/NCI NIH HHS/United States -GR - R01 CA220581/CA/NCI NIH HHS/United States -GR - R01 CA202752/CA/NCI NIH HHS/United States -GR - R01 CA208236/CA/NCI NIH HHS/United States -GR - U01 CA248226/CA/NCI NIH HHS/United States -GR - I01 BX004121/BX/BLRD VA/United States -GR - R01 CA257612/CA/NCI NIH HHS/United States -GR - U54 CA254566/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, U.S. Gov't, Non-P.H.S. -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers) -RN - 28X28X9OKV (durvalumab) -SB - IM -CIN - J Immunother Cancer. 2022 May;10(5):e004965. doi: 10.1136/jitc-2022-004965. PMID: - 35640929 -CIN - J Immunother Cancer. 2022 May;10(5):e005086. doi: 10.1136/jitc-2022-005086. PMID: - 35640931 -MH - Antibodies, Monoclonal -MH - B7-H1 Antigen/therapeutic use -MH - Biomarkers -MH - *Carcinoma, Non-Small-Cell Lung/diagnostic imaging/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/diagnostic imaging/drug therapy -MH - Neoplasm Recurrence, Local/drug therapy -PMC - PMC8905876 -OTO - NOTNLM -OT - immunotherapy -OT - tumor biomarkers -COIS- Competing interests: AM is an equity holder in Elucid Bioimaging and in - Inspirata. In addition, he has served as a scientific advisory board member for - Inspirata, AstraZeneca, Bristol Meyers Squibb and Merck. Currently he serves on - the advisory board of Aiforia and currently consults for Caris, Roche and - Aiforia. He also has sponsored research agreements with Philips, AstraZeneca, - Boehringer Ingelheim and Bristol Meyers Squibb. His technology has been licensed - to Elucid Bioimaging. He is also involved in a NIH U24 grant with PathCore, and - three different R01 grants with Inspirata. Other authors declare no potential - conflicts of interest. -EDAT- 2022/03/09 06:00 -MHDA- 2022/05/11 06:00 -PMCR- 2022/03/07 -CRDT- 2022/03/08 05:36 -PHST- 2022/01/14 00:00 [accepted] -PHST- 2022/03/08 05:36 [entrez] -PHST- 2022/03/09 06:00 [pubmed] -PHST- 2022/05/11 06:00 [medline] -PHST- 2022/03/07 00:00 [pmc-release] -AID - jitc-2021-003778 [pii] -AID - 10.1136/jitc-2021-003778 [doi] -PST - ppublish -SO - J Immunother Cancer. 2022 Mar;10(3):e003778. doi: 10.1136/jitc-2021-003778. - -PMID- 34679113 -OWN - NLM -STAT- MEDLINE -DCOM- 20211126 -LR - 20211126 -IS - 1932-6203 (Electronic) -IS - 1932-6203 (Linking) -VI - 16 -IP - 10 -DP - 2021 -TI - Prospective observational study of nutritional/immunologic indices as predictive - biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer - (ICI-PREDICT study). -PG - e0258616 -LID - 10.1371/journal.pone.0258616 [doi] -LID - e0258616 -AB - Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and - programmed cell death-ligand 1 (PD-L1) have markedly improved the prognosis of - many patients with advanced non-small cell lung cancer (NSCLC). However, the - relationship between the patient's nutritional/immunologic status and the - outcomes of ICI treatment remains unclear. In previous retrospective studies, we - reported that the controlling nutritional status (CONUT) score, skeletal muscle - area, and neutrophil-to-lymphocyte ratio were independent predictors of the - response of NSCLC patients to anti-PD-1 drugs. The aim of this prospective - multi-center study is to investigate the clinical impact of pre-treatment - nutritional/immunologic indices and early post-treatment changes in the indices - on treatment outcomes in advanced NSCLC. The main inclusion criteria are: (1) - stage IV NSCLC, or stage III NSCLC not applicable for definitive - chemoradiotherapy; (2) treatment with ICIs (monotherapy or combined with - chemotherapy) as first-line therapy; and (3) available data on PD-L1 expression - on tumor cells. A total of 300 patients will be enrolled prospectively. - Enrollment will begin in 2020 and the final analyses will be completed by 2025. -FAU - Takamori, Shinkichi -AU - Takamori S -AUID- ORCID: 0000-0001-8175-6798 -AD - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer - Center, Notame, Minami-ku, Fukuoka, Japan. -FAU - Ohba, Taro -AU - Ohba T -AD - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu - University, Maidashi, Higashi-ku, Fukuoka, Japan. -FAU - Shimokawa, Mototsugu -AU - Shimokawa M -AD - Department of Biostatistics, Yamaguchi University Graduate School of Medicine, - Minamiogushi, Ube-shi, Yamaguchi, Japan. -FAU - Matsubara, Taichi -AU - Matsubara T -AD - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer - Center, Notame, Minami-ku, Fukuoka, Japan. -FAU - Haratake, Naoki -AU - Haratake N -AD - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer - Center, Notame, Minami-ku, Fukuoka, Japan. -FAU - Miura, Naoko -AU - Miura N -AD - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer - Center, Notame, Minami-ku, Fukuoka, Japan. -FAU - Toyozawa, Ryo -AU - Toyozawa R -AD - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer - Center, Notame, Minami-ku, Fukuoka, Japan. -FAU - Yamaguchi, Masafumi -AU - Yamaguchi M -AD - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer - Center, Notame, Minami-ku, Fukuoka, Japan. -FAU - Seto, Takashi -AU - Seto T -AD - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer - Center, Notame, Minami-ku, Fukuoka, Japan. -FAU - Takenoyama, Mitsuhiro -AU - Takenoyama M -AD - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer - Center, Notame, Minami-ku, Fukuoka, Japan. -LA - eng -PT - Journal Article -PT - Multicenter Study -PT - Observational Study -PT - Research Support, Non-U.S. Gov't -DEP - 20211022 -PL - United States -TA - PLoS One -JT - PloS one -JID - 101285081 -RN - 0 (Albumins) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 97C5T2UQ7J (Cholesterol) -SB - IM -MH - Albumins/metabolism -MH - B7-H1 Antigen/*metabolism -MH - Biomarkers/*metabolism -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/pathology -MH - Cholesterol/metabolism -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology/*therapeutic use -MH - Lung Neoplasms/*drug therapy/metabolism/pathology -MH - Lymphocyte Count -MH - Male -MH - Neoplasm Staging -MH - Nutritional Status -MH - Prognosis -MH - Prospective Studies -MH - Treatment Outcome -PMC - PMC8535181 -COIS- The authors declare no conflicts of interest in association with the present - study. -EDAT- 2021/10/23 06:00 -MHDA- 2021/11/27 06:00 -PMCR- 2021/10/22 -CRDT- 2021/10/22 21:05 -PHST- 2020/02/29 00:00 [received] -PHST- 2021/09/04 00:00 [accepted] -PHST- 2021/10/22 21:05 [entrez] -PHST- 2021/10/23 06:00 [pubmed] -PHST- 2021/11/27 06:00 [medline] -PHST- 2021/10/22 00:00 [pmc-release] -AID - PONE-D-20-05915 [pii] -AID - 10.1371/journal.pone.0258616 [doi] -PST - epublish -SO - PLoS One. 2021 Oct 22;16(10):e0258616. doi: 10.1371/journal.pone.0258616. - eCollection 2021. - -PMID- 39226660 -OWN - NLM -STAT- MEDLINE -DCOM- 20241010 -LR - 20241010 -IS - 1476-5586 (Electronic) -IS - 1522-8002 (Print) -IS - 1476-5586 (Linking) -VI - 57 -DP - 2024 Nov -TI - Treatment options for tumor progression after initial immunotherapy in advanced - non-small cell lung cancer: A real-world study. -PG - 101043 -LID - S1476-5586(24)00085-X [pii] -LID - 10.1016/j.neo.2024.101043 [doi] -LID - 101043 -AB - OBJECTIVE: Whether to continue administering immunotherapy to patients with - advanced non-small cell lung cancer (NSCLC) who have experienced tumor - progression remains controversial after immunotherapy. The aims were to explore - survival outcomes after further immunotherapy post-progression and to determine - the optimal combination therapy in such cases. METHODS: Overall, 507 patients - with NSCLC who underwent immunotherapy and experienced tumor progression were - retrospectively divided into Immuno-combination and No-immuno groups according to - whether additional combination therapy involving immunotherapy was administered - post-progression. Progression-free survival (PFS) and overall survival (OS) were - evaluated. Subgroup analyses were performed according to the different treatment - regimens for patients in the Immuno-combination group. RESULTS: After propensity - score matching, there were 150 patients in the No-immuno group and 300 patients - in the Immuno combination group. Superior PFS was observed in the - Immuno-combination group compared with those in the No-immuno group (6-month PFS: - 25.3 % vs. 60.6 %; 12-month PFS: 6.7 % vs. 24.4 %; P < 0.001). Similar intergroup - differences were observed for OS (12-month OS: 22.3 % vs. 69.4 %; 18-month OS: - 6.4 % vs. 40.4 %; P < 0.001). Superior PFS outcomes were observed in the - Immuno+Antiangiogenic group compared with the Immuno+Chemo group (6-month PFS: - 51.3 % vs. 71.5 %; 12-month PFS: 23.1 % vs. 25.7 %; P = 0.017). Similar - differences in OS were observed between those same subgroups (12-month OS: 62.1 % - vs. 77.9 %; 18-month OS: 33.3 % vs. 48.7 %; P = 0.006). CONCLUSION: Patients with - NSCLC experiencing tumor progression post-immunotherapy can still benefit from - further treatment, with immunotherapy combined with antiangiogenic therapy the - most efficacious option. -CI - Copyright © 2024. Published by Elsevier Inc. -FAU - Li, Ying -AU - Li Y -AD - Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, 250000, China. -FAU - Zhao, Junfeng -AU - Zhao J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, 250000, China. -FAU - Li, Ruyue -AU - Li R -AD - Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, - Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, - Weifang Medical University, Weifang, Shan Dong, 261000, China. -FAU - Yao, Xiujing -AU - Yao X -AD - Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, - Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, - Weifang Medical University, Weifang, Shan Dong, 261000, China. -FAU - Dong, Xue -AU - Dong X -AD - Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, 250000, China. -FAU - Zhang, Ruidan -AU - Zhang R -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, 250000, China. -FAU - Li, Yintao -AU - Li Y -AD - Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, 250000, China. Electronic address: yintaoli@fudan.edu.cn. -LA - eng -PT - Journal Article -DEP - 20240902 -PL - United States -TA - Neoplasia -JT - Neoplasia (New York, N.Y.) -JID - 100886622 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/pathology/immunology/mortality/drug - therapy -MH - Male -MH - Female -MH - *Lung Neoplasms/therapy/pathology/immunology/mortality/drug therapy -MH - *Immunotherapy/methods -MH - Aged -MH - Middle Aged -MH - *Disease Progression -MH - Combined Modality Therapy -MH - Retrospective Studies -MH - Neoplasm Staging -MH - Treatment Outcome -MH - Adult -MH - Aged, 80 and over -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -PMC - PMC11403516 -OTO - NOTNLM -OT - Antiangiogenic therapy -OT - Chemotherapy -OT - Immune checkpoint inhibitor -OT - Immunotherapy -OT - Non-small cell lung cancer -COIS- Declaration of competing interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2024/09/04 01:02 -MHDA- 2024/10/11 10:17 -PMCR- 2024/09/02 -CRDT- 2024/09/03 18:02 -PHST- 2024/06/09 00:00 [received] -PHST- 2024/08/14 00:00 [revised] -PHST- 2024/08/22 00:00 [accepted] -PHST- 2024/10/11 10:17 [medline] -PHST- 2024/09/04 01:02 [pubmed] -PHST- 2024/09/03 18:02 [entrez] -PHST- 2024/09/02 00:00 [pmc-release] -AID - S1476-5586(24)00085-X [pii] -AID - 101043 [pii] -AID - 10.1016/j.neo.2024.101043 [doi] -PST - ppublish -SO - Neoplasia. 2024 Nov;57:101043. doi: 10.1016/j.neo.2024.101043. Epub 2024 Sep 2. - -PMID- 34023330 -OWN - NLM -STAT- MEDLINE -DCOM- 20210727 -LR - 20210727 -IS - 1879-0887 (Electronic) -IS - 0167-8140 (Linking) -VI - 160 -DP - 2021 Jul -TI - Intensity-modulated radiation therapy with concurrent chemotherapy followed by - durvalumab for stage III non-small cell lung cancer: A multi-center retrospective - study. -PG - 266-272 -LID - S0167-8140(21)06254-X [pii] -LID - 10.1016/j.radonc.2021.05.016 [doi] -AB - BACKGROUND AND PURPOSE: Intensity-modulated radiation therapy (IMRT) is - increasingly applied in concurrent chemoradiotherapy (CCRT) for locally-advanced - non-small cell lung cancer (NSCLC), with improvement of target coverage and - better sparing of normal tissue. IMRT tends to have a larger low-dose irradiation - volume than 3D conformal radiotherapy, but the incidence of and risk factors for - pneumonitis remain unclear, especially following the approval of durvalumab. - MATERIALS AND METHODS: We retrospectively reviewed the records of NSCLC patients - treated by CCRT using IMRT at seven Japanese institutions. Primary outcomes were - incidence of symptomatic pneumonitis and progression-free survival (PFS). - Multivariate logistic regression analysis was used to identify risk factors for - ≥grade 2 pneumonitis. RESULTS: Median follow-up from the start of CCRT was - 14.3 months (n = 107 patients; median age 70 years, 29% female). Median lung V5 - and V20 was 49.2% and 19.5%, respectively. Durvalumab was administered to 87 - patients (81%). Pneumonitis developed in 95 (89%) patients of which 53% had grade - 1, 28% grade 2, 6.5% grade 3, and 0.9% grade 4. Durvalumab had been discontinued - in 16 patients (18.4%) due to pneumonitis. By multivariate analysis, age - ≥70 years, male sex, and V5 ≥58.9% were identified as significantly associated - with ≥grade 2 pneumonitis (p = 0.0065, 0.036 and 0.0013 respectively). The median - PFS from the start of CCRT was not reached (95% CI, 14.2 months to not reached) - in patients receiving durvalumab. CONCLUSION: CCRT using IMRT followed by - durvalumab was generally effective and tolerable; V5 <60% would be recommended to - avoid symptomatic pneumonitis. -CI - Copyright © 2021 Elsevier B.V. All rights reserved. -FAU - Tsukita, Yoko -AU - Tsukita Y -AD - Department of Respiratory Medicine, Tohoku University Graduate School of - Medicine, Sendai, Japan. Electronic address: y-tsukita@rm.med.tohoku.ac.jp. -FAU - Yamamoto, Takaya -AU - Yamamoto T -AD - Department of Radiation Oncology, Tohoku University Graduate School of Medicine, - Sendai, Japan. -FAU - Mayahara, Hiroshi -AU - Mayahara H -AD - Department of Radiation Oncology, Kobe Minimally-invasive Cancer Center, Kobe, - Japan. -FAU - Hata, Akito -AU - Hata A -AD - Department of Respiratory Medical Oncology, Kobe Minimally-invasive Cancer - Center, Kobe, Japan. -FAU - Takeda, Yuichiro -AU - Takeda Y -AD - Department of Respiratory Medicine, National Center for Global Health and - Medicine, Tokyo, Japan. -FAU - Nakayama, Hidetsugu -AU - Nakayama H -AD - Department of Radiation Oncology, National Center for Global Health and Medicine, - Tokyo, Japan. -FAU - Tanaka, Satoshi -AU - Tanaka S -AD - Department of Respiratory Medicine, Osaka General Medical Center, Osaka, Japan. -FAU - Uchida, Junji -AU - Uchida J -AD - Department of Respiratory Medicine, Osaka General Medical Center, Osaka, Japan. -FAU - Usui, Kazuhiro -AU - Usui K -AD - Division of Respirology, NTT Medical Center Tokyo, Tokyo, Japan. -FAU - Toyoda, Tatsuya -AU - Toyoda T -AD - Department of Radiology, NTT Medical Center Tokyo, Tokyo, Japan. -FAU - Tamiya, Motohiro -AU - Tamiya M -AD - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, - Japan. -FAU - Morimoto, Masahiro -AU - Morimoto M -AD - Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, - Japan. -FAU - Oya, Yuko -AU - Oya Y -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. -FAU - Kodaira, Takeshi -AU - Kodaira T -AD - Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. -FAU - Miyauchi, Eisaku -AU - Miyauchi E -AD - Department of Respiratory Medicine, Tohoku University Graduate School of - Medicine, Sendai, Japan. -FAU - Jingu, Keiichi -AU - Jingu K -AD - Department of Radiation Oncology, Tohoku University Graduate School of Medicine, - Sendai, Japan. -FAU - Sugiura, Hisatoshi -AU - Sugiura H -AD - Department of Respiratory Medicine, Tohoku University Graduate School of - Medicine, Sendai, Japan. -LA - eng -PT - Journal Article -PT - Multicenter Study -DEP - 20210521 -PL - Ireland -TA - Radiother Oncol -JT - Radiotherapy and oncology : journal of the European Society for Therapeutic - Radiology and Oncology -JID - 8407192 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy/adverse effects -MH - Female -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Male -MH - *Radiotherapy, Intensity-Modulated/adverse effects -MH - Retrospective Studies -OTO - NOTNLM -OT - Chemoradiotherapy -OT - Durvalumab -OT - IMRT -OT - NSCLC -OT - Pneumonitis -COIS- Conflict of Interest statement Yoko Tsukita reports personal fees from - AstraZeneca and Chugai Pharmaceutical outside the submitted work. Takaya Yamamoto - reports personal fees from AstraZeneca outside the submitted work. Hiroshi - Mayahara reports personal fees from Accuray Japan Inc., Hitachi, Ltd, Eisai Co., - Ltd., grants from MSD, grants and personal fees from AstraZeneca plc outside the - submitted work. Akito Hata reports grants and personal fees from Eli Lilly, - Boehringer Ingelheim and Astrazeneca, personal fees from Chugai, grants from MSD - outside the submitted work. Yuichiro Takeda reports grants from Chugai and - Boehringer Ingelheim, personal fees from Otsuka Pharmaceutical Co., Ltd outside - the submitted work. Junji Uchida reports personal fees from Astra Zeneca K.K., - Chugai pharmaceutical.co.ltd, Bristol Myers Squibb, Taiho Pharma and Boehringer - Ingelheim outside the submitted work. Kazuhiro Usui reports personal fees from - Astra Zeneca, Chugai, MSD, Pfizer and Boehringer Ingelheim outside the submitted - work. Motohiro Tamiya reports grants and personal fees from Boehringer Ingelheim, - Ono Pharmaceutical and Bristol-Myers Squibb, personal fees from Chugai - Pharmaceutical, MSD, AstraZeneca, Taiho Pharmaceutical, Eli Lilly, Asahi Kasei - Pharmaceutical and Pfizer outside the submitted work. Yuko Oya reports personal - fees from Chugai pharma, Boehringer Ingelheim, Daiichi Sankyo, Astrazeneca, Ono - pharmaceutical and Eli lilly outside the submitted work. Takeshi Kodaira reports - personal fees from Merck Serono Co., Hitachi Co., Bristle Myers Squibb., Accuray - Co., Elekta Co., Ono Pharmaceutical Co., AstraZeneca Co., Taiho Pharmaceutical - Co. and Canon Co. outside the submitted work. Eisaku Miyauchi reports grants and - personal fees from Chugai pharmaceutical co ltd, Ono pharmaceutical co., ltd., - Boehringer Ingelheim and Lilly, personal fees from Astrazeneca, Taiho pharma, - Kyowa kirin, Daiichi sankyo, MSD, Bristol-Meyers Squibb, Novartis and Merck Bio - outside the submitted work. Keiichi Jingu reports personal fees from Varina - Medical Systems, Inc., Elekta K.K., Shimadzu Medical Systems Corporation, - AstraZeneca K.K., Guerbet Japan and grants and personal fees from Eisai Co., - Ltd., grants from Takeda Pharmaceutical Company Limited, TAIHO Phamaceutical Co., - Ltd., outside the submitted work. The remaining authors declare no conflict of - interest. -EDAT- 2021/05/24 06:00 -MHDA- 2021/07/28 06:00 -CRDT- 2021/05/23 20:37 -PHST- 2021/01/12 00:00 [received] -PHST- 2021/05/07 00:00 [revised] -PHST- 2021/05/12 00:00 [accepted] -PHST- 2021/05/24 06:00 [pubmed] -PHST- 2021/07/28 06:00 [medline] -PHST- 2021/05/23 20:37 [entrez] -AID - S0167-8140(21)06254-X [pii] -AID - 10.1016/j.radonc.2021.05.016 [doi] -PST - ppublish -SO - Radiother Oncol. 2021 Jul;160:266-272. doi: 10.1016/j.radonc.2021.05.016. Epub - 2021 May 21. - -PMID- 34260719 -OWN - NLM -STAT- MEDLINE -DCOM- 20220131 -LR - 20220131 -IS - 1349-9157 (Electronic) -IS - 0449-3060 (Print) -IS - 0449-3060 (Linking) -VI - 62 -IP - 5 -DP - 2021 Sep 13 -TI - Feasibility of intensity modulated radiotherapy with involved field radiotherapy - for Japanese patients with locally advanced non-small cell lung cancer. -PG - 894-900 -LID - 10.1093/jrr/rrab063 [doi] -AB - The feasibility of intensity modulated radiotherapy (IMRT) with involved field - radiotherapy (IFRT) for Japanese patients with locally advanced non-small cell - lung cancer (LA-NSCLC) remains unclear. Here we reviewed our initial experience - of IMRT with IFRT for Japanese patients with LA-NSCLC to evaluate the feasibility - of the treatment. Twenty LA-NSCLC patients who were treated with IMRT with IFRT - during November 2019 to October 2020 were retrospectively analyzed. All patients - received 60 Gy in 30 fractions of IMRT and were administered concurrent - platinum-based chemotherapy. The median patient age was 71 years old and the - group included 15 men and 5 women. The patient group included 2 patients with - stage IIB, 11 patients with stage IIIA, 5 patients with stage IIIB, and 2 - patients with stage IIIC disease. Histological diagnosis was squamous cell - carcinoma in 14 patients, adenocarcinoma in 5 patients, and non-small cell lung - cancer in 1 patient. The median follow-up period was 8 months. The incidence of - grade 3 or greater pneumonitis was 5%, and grade 3 or greater esophagitis was not - observed. None of the patients developed regional lymph node, with only - recurrence reported so far. These findings indicate that IMRT with IFRT for - Japanese patients with LA-NSCLC is feasible in terms of acute toxicity. Further - study with a larger number of patients and longer follow-up to clarify the effect - of treatment on patient prognosis is required. -CI - © The Author(s) 2021. Published by Oxford University Press on behalf of The - Japanese Radiation Research Society and Japanese Society for Radiation Oncology. -FAU - Abe, Takanori -AU - Abe T -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -FAU - Iino, Misaki -AU - Iino M -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -FAU - Saito, Satoshi -AU - Saito S -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -FAU - Aoshika, Tomomi -AU - Aoshika T -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -FAU - Ryuno, Yasuhiro -AU - Ryuno Y -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -FAU - Ohta, Tomohiro -AU - Ohta T -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -FAU - Igari, Mitsunobu -AU - Igari M -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -FAU - Hirai, Ryuta -AU - Hirai R -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -FAU - Kumazaki, Yu -AU - Kumazaki Y -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -FAU - Miura, Yu -AU - Miura Y -AD - Department of Respiratory Medicine, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -FAU - Kaira, Kyoichi -AU - Kaira K -AD - Department of Respiratory Medicine, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -FAU - Kagamu, Hiroshi -AU - Kagamu H -AD - Department of Respiratory Medicine, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -FAU - Noda, Shin-Ei -AU - Noda SE -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -FAU - Kato, Shingo -AU - Kato S -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan. -LA - eng -PT - Journal Article -PL - England -TA - J Radiat Res -JT - Journal of radiation research -JID - 0376611 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Organoplatinum Compounds) -RN - 28X28X9OKV (durvalumab) -RN - P88XT4IS4D (Paclitaxel) -SB - IM -MH - Adenocarcinoma/drug therapy/radiotherapy -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal/administration & dosage -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/drug therapy/*radiotherapy -MH - Carcinoma, Squamous Cell/drug therapy/radiotherapy -MH - Combined Modality Therapy -MH - Dose-Response Relationship, Radiation -MH - Feasibility Studies -MH - Female -MH - Humans -MH - Japan -MH - Lung Neoplasms/diagnostic imaging/drug therapy/*radiotherapy -MH - Male -MH - Middle Aged -MH - Multimodal Imaging -MH - Neoplasm Metastasis -MH - Organoplatinum Compounds/administration & dosage -MH - Organs at Risk/radiation effects -MH - Paclitaxel/administration & dosage -MH - Radiation Pneumonitis/etiology -MH - Radiotherapy Planning, Computer-Assisted -MH - Radiotherapy, Conformal -MH - Radiotherapy, Intensity-Modulated/adverse effects/*methods -MH - Retrospective Studies -MH - User-Computer Interface -PMC - PMC8438249 -OTO - NOTNLM -OT - durvalumab -OT - feasibility -OT - intensity modulated radiotherapy -OT - locally advanced non-small cell lung cancer -OT - volumetric modulated arc therapy -EDAT- 2021/07/15 06:00 -MHDA- 2022/02/01 06:00 -PMCR- 2021/07/15 -CRDT- 2021/07/14 17:37 -PHST- 2021/04/20 00:00 [received] -PHST- 2021/05/31 00:00 [revised] -PHST- 2021/07/15 06:00 [pubmed] -PHST- 2022/02/01 06:00 [medline] -PHST- 2021/07/14 17:37 [entrez] -PHST- 2021/07/15 00:00 [pmc-release] -AID - 6321369 [pii] -AID - rrab063 [pii] -AID - 10.1093/jrr/rrab063 [doi] -PST - ppublish -SO - J Radiat Res. 2021 Sep 13;62(5):894-900. doi: 10.1093/jrr/rrab063. - -PMID- 1663661 -OWN - NLM -STAT- MEDLINE -DCOM- 19920303 -LR - 20180524 -IS - 0093-7754 (Print) -IS - 0093-7754 (Linking) -VI - 18 -IP - 6 -DP - 1991 Dec -TI - Neoadjuvant and adjuvant therapy of non-small cell lung cancer. -PG - 536-42 -AB - Present treatment options for non-small cell lung cancer in the adjuvant and - neoadjuvant settings are far from ideal. The bottom line of improvement in - overall survival by any treatment modality used has yet to be achieved. For this - to happen, better drug therapy will be required. Future trials should be - carefully designed with intraoperative staging and stratification of patients by - histology, stage, and potentially immunologic markers, ploidy, and molecular - biologic markers such as growth factors and their receptors. Combination of - individual therapies to maximal toxicity in an attempt to overcome inherent tumor - resistance will be key. The use of colony-stimulating factors, with high-dose - chemotherapy integrated with hyperfractionated radiotherapy, may be seen in - future studies. Combining standard chemotherapy and radiotherapy with cytokines - or immunotherapy using interleukin-1 and -2, or tumor necrosis factor or - monoclonal antibodies to growth factors may be seen in innovative trials. By such - meticulously and intelligently designed trials, progress in adjuvant and - neoadjuvant treatment of the important group of patients with locally advanced - non-small cell lung cancer will occur. -FAU - Rose, L J -AU - Rose LJ -AD - Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107. -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - Semin Oncol -JT - Seminars in oncology -JID - 0420432 -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/pathology/*therapy -MH - Chemotherapy, Adjuvant -MH - Combined Modality Therapy -MH - Humans -MH - Immunotherapy -MH - Lung Neoplasms/pathology/*therapy -MH - Neoplasm Staging -MH - Radiotherapy Dosage -RF - 40 -EDAT- 1991/12/01 00:00 -MHDA- 1991/12/01 00:01 -CRDT- 1991/12/01 00:00 -PHST- 1991/12/01 00:00 [pubmed] -PHST- 1991/12/01 00:01 [medline] -PHST- 1991/12/01 00:00 [entrez] -AID - 0093-7754(91)90011-B [pii] -PST - ppublish -SO - Semin Oncol. 1991 Dec;18(6):536-42. - -PMID- 33356733 -OWN - NLM -STAT- MEDLINE -DCOM- 20210818 -LR - 20210818 -IS - 1651-226X (Electronic) -IS - 0284-186X (Linking) -VI - 60 -IP - 2 -DP - 2021 Feb -TI - Immune checkpoint blockade in the treatment of advanced non-small cell lung - cancer - predictors of response and impact of previous radiotherapy. -PG - 149-156 -LID - 10.1080/0284186X.2020.1854851 [doi] -AB - BACKGROUND: The implementation of immune checkpoint inhibitors (ICI) into the - standard care of advanced non-small cell lung cancer (NSCLC) has improved - prognosis for this group of patients. However, long-term survival is rare. The - aim of the study was to identify predictors of response and, especially, to - investigate the impact radiotherapy might have on duration of response. MATERIAL - AND METHODS: The association between pretreatment patient/tumor characteristics - and progression-free survival (PFS), overall survival (OS), and lung - cancer-specific survival was investigated in 78 patients receiving an ICI as ≥2nd - line treatment for advanced NSCLC, using Cox regression analysis. Due to - competing risk, cause-specific deaths were also examined with cumulative - incidence plots. RESULTS: Median OS was 12.6 months (95% CI 7.8-18.2) and median - PFS 4.1 months (95% CI 3.0-6.2), after median follow-up time of 49.7 months - (range 20.9-51.5). Increasing CRP and neutrophil/lymphocyte ratio (NLR), were - associated with poor PFS (CRP: HR 1.49, 95% CI 1.12-1.98; NLR: HR 1.59, 95% CI - 1.22-1.85) and OS (CRP: HR 1.94, 95% CI 1.47-2.56; NLR: HR 1.54, 95% CI - 1.27-1.87). Radiotherapy prior to immunotherapy was not significantly associated - with patient outcome. However, when the dataset was split at 6 months of - follow-up, to be able to identify early and late predictors of prognosis, we - found that patients receiving radiotherapy <6 months prior to immunotherapy had - better PFS (HR: 0.27, 95% CI 0.09-0.84) and lung cancer-specific survival (HR: - 0.41, 95% CI 0.18-0.95) after the first 6 months of follow-up, while increasing - CRP (PFS: HR1.61, 95% CI 1.21-2.14; OS: HR2.04, 95% CI 1.51-2.74) and NLR (PFS: - HR 1.57, 95% CI 1.29-1.91; OS: HR 1.63, 95% CI 1.35-1.97) were predictors of poor - short-term prognosis. CONCLUSIONS: Radiotherapy may be of importance to achieve a - long-lasting response to immunotherapy, while indicators of systemic inflammation - can help in identifying patients with poor short-term prognosis. -FAU - Öjlert, Åsa Kristina -AU - Öjlert ÅK -AUID- ORCID: 0000-0002-2888-8406 -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, The Norwegian Radium Hospital, Oslo, Norway. -FAU - Nebdal, Daniel -AU - Nebdal D -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, The Norwegian Radium Hospital, Oslo, Norway. -FAU - Lund-Iversen, Marius -AU - Lund-Iversen M -AUID- ORCID: 0000-0002-2025-4062 -AD - Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, - Oslo, Norway. -FAU - Åstrøm Ellefsen, Renée -AU - Åstrøm Ellefsen R -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, The Norwegian Radium Hospital, Oslo, Norway. -FAU - Brustugun, Odd Terje -AU - Brustugun OT -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, The Norwegian Radium Hospital, Oslo, Norway. -AD - Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, - Norway. -FAU - Gran, Jon Michael -AU - Gran JM -AD - Oslo Centre for Biostatistics and Epidemiology, University of Oslo and Oslo - University Hospital, Oslo, Norway. -FAU - Halvorsen, Ann Rita -AU - Halvorsen AR -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, The Norwegian Radium Hospital, Oslo, Norway. -AD - Department of Clinical Medicine, University of Oslo, Oslo, Norway. -FAU - Helland, Åslaug -AU - Helland Å -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, The Norwegian Radium Hospital, Oslo, Norway. -AD - Department of Clinical Medicine, University of Oslo, Oslo, Norway. -AD - Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, - Oslo, Norway. -LA - eng -PT - Journal Article -DEP - 20201224 -PL - Sweden -TA - Acta Oncol -JT - Acta oncologica (Stockholm, Sweden) -JID - 8709065 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -MH - Prognosis -OTO - NOTNLM -OT - Non-small cell lung cancer -OT - immune checkpoint inhibitors -OT - neutrophil-to-lymphocyte ratio -OT - prognosis -OT - radiotherapy -EDAT- 2020/12/29 06:00 -MHDA- 2021/08/19 06:00 -CRDT- 2020/12/28 10:10 -PHST- 2020/12/29 06:00 [pubmed] -PHST- 2021/08/19 06:00 [medline] -PHST- 2020/12/28 10:10 [entrez] -AID - 10.1080/0284186X.2020.1854851 [doi] -PST - ppublish -SO - Acta Oncol. 2021 Feb;60(2):149-156. doi: 10.1080/0284186X.2020.1854851. Epub 2020 - Dec 24. - -PMID- 37519059 -OWN - NLM -STAT- MEDLINE -DCOM- 20230912 -LR - 20230913 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 14 -IP - 26 -DP - 2023 Sep -TI - Identification of predictive factors for early relapse in patients with - unresectable stage III non-small cell lung cancer receiving consolidation - durvalumab after concurrent chemoradiation therapy. -PG - 2657-2664 -LID - 10.1111/1759-7714.15050 [doi] -AB - BACKGROUND: Patients with locally advanced, unresectable, non-small cell lung - cancer (NSCLC) receiving definitive concurrent chemoradiation therapy (CCRT) - benefit from durvalumab consolidation therapy. However, predictive factors for - early relapse during durvalumab maintenance have not yet been identified. - METHODS: The present study included the lung cancer cohort of the Catholic - Medical Centers at the Catholic University of Korea from January 2018 to December - 2021. A total of 51 NSCLC patients treated with durvalumab consolidation therapy - after definitive CCRT were included in the analysis. Early relapse was defined as - patients experiencing relapse within 6 months of starting initial durvalumab - therapy. RESULTS: Among the 51 patients, 15 (29.4%) relapsed during the study - period. Median time from initial therapy of durvalumab to progression was - 451.00 ± 220.87 days (95% confidence interval [CI]: 18.10-883.90) in overall - patients. In multivariate analysis, younger age (adjusted odds ratio [aOR], - 0.792; 95% CI: 0.642-0.977; p = 0.030), higher pack-years (aOR, 1.315; 95% CI: - 1.058-1.635; p = 0.014), non-COPD (aOR, 0.004; 95% CI: 0.000-0.828; p = 0.004) - and anemia (aOR, 234.30; 95% CI: 1.212-45280.24; p = 0.042), were independent - predictive factors for early relapse during durvalumab consolidation therapy. - CONCLUSION: Younger age, higher number of pack-years, non-COPD, and anemia were - independent predictive factors for early relapse during durvalumab consolidation - therapy in patients with unresectable stage III NSCLC after definitive CCRT. - Careful patient selection and clinical attention are needed for high-risk - individuals. -CI - © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Nam, Jung Hyun -AU - Nam JH -AUID- ORCID: 0000-0002-1871-4269 -AD - Division of Pulmonary and Critical Care Medicine, Department of Internal - Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University - of Korea, Seoul, Republic of Korea. -FAU - Yeo, Chang Dong -AU - Yeo CD -AUID- ORCID: 0000-0002-4103-7921 -AD - Division of Pulmonary, Sleep and Critical Care Medicine, Department of Internal - Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic - University of Korea, Seoul, Republic of Korea. -FAU - Park, Chan Kwon -AU - Park CK -AD - Division of Pulmonology and Critical Care Medicine, Department of Internal - Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic - University of Korea, Seoul, Republic of Korea. -FAU - Kim, Sung Kyoung -AU - Kim SK -AD - Division of Pulmonary and Critical Care Medicine, Department of Internal - Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of - Korea, Seoul, Republic of Korea. -FAU - Kim, Ju Sang -AU - Kim JS -AD - Division of Pulmonary and Critical Care Medicine, Department of Internal - Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic - University of Korea, Seoul, Republic of Korea. -FAU - Kim, Yong Hyun -AU - Kim YH -AD - Division of Pulmonary and Critical Care Medicine, Department of Internal - Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic - University of Korea, Seoul, Republic of Korea. -FAU - Kim, Jin Woo -AU - Kim JW -AD - Division of Pulmonary and Critical Care Medicine, Department of Internal - Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic - University of Korea, Seoul, Republic of Korea. -FAU - Kim, Seung Joon -AU - Kim SJ -AUID- ORCID: 0000-0003-4836-8958 -AD - Division of Pulmonary and Critical Care Medicine, Department of Internal - Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University - of Korea, Seoul, Republic of Korea. -FAU - Lee, Sang Haak -AU - Lee SH -AD - Division of Pulmonary, Sleep and Critical Care Medicine, Department of Internal - Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic - University of Korea, Seoul, Republic of Korea. -FAU - Kang, Hye Seon -AU - Kang HS -AUID- ORCID: 0000-0002-2096-7679 -AD - Division of Pulmonary and Critical Care Medicine, Department of Internal - Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic - University of Korea, Seoul, Republic of Korea. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20230730 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 28X28X9OKV (durvalumab) -RN - 0 (Antibodies, Monoclonal) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Chemoradiotherapy -MH - Antibodies, Monoclonal/pharmacology/therapeutic use -PMC - PMC10493476 -OTO - NOTNLM -OT - chemoradiotherapy -OT - durvalumab -OT - non-small cell lung cancer -OT - recurrence -COIS- The authors have no conflicts of interest relevant to this article to report. -EDAT- 2023/07/31 06:42 -MHDA- 2023/09/12 06:41 -PMCR- 2023/07/30 -CRDT- 2023/07/31 02:13 -PHST- 2023/07/10 00:00 [revised] -PHST- 2023/06/30 00:00 [received] -PHST- 2023/07/11 00:00 [accepted] -PHST- 2023/09/12 06:41 [medline] -PHST- 2023/07/31 06:42 [pubmed] -PHST- 2023/07/31 02:13 [entrez] -PHST- 2023/07/30 00:00 [pmc-release] -AID - TCA15050 [pii] -AID - 10.1111/1759-7714.15050 [doi] -PST - ppublish -SO - Thorac Cancer. 2023 Sep;14(26):2657-2664. doi: 10.1111/1759-7714.15050. Epub 2023 - Jul 30. - -PMID- 36640944 -OWN - NLM -STAT- MEDLINE -DCOM- 20230315 -LR - 20230329 -IS - 1879-0887 (Electronic) -IS - 0167-8140 (Linking) -VI - 180 -DP - 2023 Mar -TI - Impact of interstitial lung abnormality on survival after adjuvant durvalumab - with chemoradiotherapy for locally advanced non-small cell lung cancer. -PG - 109454 -LID - S0167-8140(22)04606-0 [pii] -LID - 10.1016/j.radonc.2022.109454 [doi] -AB - INTRODUCTION: Concurrent chemoradiotherapy (CCRT) has been the standard of care - for patients with locally advanced non-small cell lung cancer (LA-NSCLC). - BACKGROUND AND PURPOSE: The results of the PACIFIC trial established the use of - consolidative durvalumab after concurrent chemoradiotherapy (CCRT) as the - standard of care for patients with locally advanced non-small cell lung cancer - (LA-NSCLC). A subgroup analysis of the PACIFIC trial reported a better - progression-free survival (PFS) in Asians. Although real-world data on LA-NSCLC - patients who received CCRT plus durvalumab have been reported, there have been - few large-scale reports on Asians. In this study, we investigated prognostic - factors in the largest real-world data set in Asia of only Japanese LA-NSCLC - patients treated with CCRT plus durvalumab. MATERIALS AND METHODS: One hundred - and thirteen LA-NSCLC patients who received definitive CCRT and consolidative - durvalumab at our institution between May 2018 and April 2021 were analyzed. - Overall survival (OS), cause-specific survival (CSS), PFS, distant - metastasis-free survival (DMFS), and in-field progression-free survival (IFPFS) - were investigated as treatment outcomes using competing risk analyses. RESULTS: - During a median follow-up of 24 months (range, 5-47) after the initiation of - durvalumab therapy, 31 patients died, of whom 23 died of lung cancer. In the - multivariate analysis, the pretreatment factors that correlated with OS were ILA - scores, adenocarcinoma, and performance status at the initiation of durvalumab. - Furthermore, ILA score and programmed cell death ligand 1 (PD-L1) tumor - proportion score (TPS) ≥ 1 % were significantly correlated with CSS, and PD-L1 - TPS ≥ 1 % was significantly correlated with PFS and IFPFS. CONCLUSION: - Pretreatment ILA, adenocarcinoma, and performance status may have an impact on OS - of LA-NSCLC patients receiving CCRT plus durvalumab. -CI - Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved. -FAU - Kashihara, Tairo -AU - Kashihara T -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. Electronic address: tkashiha@ncc.go.jp. -FAU - Nakayama, Yuko -AU - Nakayama Y -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -FAU - Okuma, Kae -AU - Okuma K -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -FAU - Takahashi, Ayaka -AU - Takahashi A -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -FAU - Kaneda, Tomoya -AU - Kaneda T -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -FAU - Katagiri, Mika -AU - Katagiri M -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -FAU - Nakayama, Hiroki -AU - Nakayama H -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -FAU - Kubo, Yuko -AU - Kubo Y -AD - Department of Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, - Tokyo 104-0045, Japan. -FAU - Ito, Kimiteru -AU - Ito K -AD - Department of Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, - Tokyo 104-0045, Japan. -FAU - Nakamura, Satoshi -AU - Nakamura S -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -FAU - Takahashi, Kana -AU - Takahashi K -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -FAU - Inaba, Koji -AU - Inaba K -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -FAU - Murakami, Naoya -AU - Murakami N -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -FAU - Saito, Tetsuo -AU - Saito T -AD - Department of Radiation Oncology, Arao Municipal Hospital, 2600 Arao, Arao-shi - Kumamoto 864-0041, Japan. -FAU - Okamoto, Hiroyuki -AU - Okamoto H -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -FAU - Itami, Jun -AU - Itami J -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -FAU - Kusumoto, Masahiko -AU - Kusumoto M -AD - Department of Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, - Tokyo 104-0045, Japan. -FAU - Ohe, Yuichiro -AU - Ohe Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -FAU - Igaki, Hiroshi -AU - Igaki H -AD - Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, - Chuo-ku, Tokyo 104-0045, Japan. -LA - eng -PT - Journal Article -DEP - 20230111 -PL - Ireland -TA - Radiother Oncol -JT - Radiotherapy and oncology : journal of the European Society for Therapeutic - Radiology and Oncology -JID - 8407192 -RN - 28X28X9OKV (durvalumab) -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - B7-H1 Antigen/metabolism -MH - Neoplasm Staging -MH - *Adenocarcinoma/pathology -MH - Chemoradiotherapy/methods -MH - Lung/pathology -OTO - NOTNLM -OT - Immune checkpoint inhibitor -OT - Interstitial lung disease -OT - Non-small cell lung cancer -OT - Prognosis -OT - Radiotherapy -COIS- Declaration of Competing Interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2023/01/15 06:00 -MHDA- 2023/03/16 06:00 -CRDT- 2023/01/14 19:26 -PHST- 2022/10/16 00:00 [received] -PHST- 2022/12/13 00:00 [revised] -PHST- 2022/12/17 00:00 [accepted] -PHST- 2023/01/15 06:00 [pubmed] -PHST- 2023/03/16 06:00 [medline] -PHST- 2023/01/14 19:26 [entrez] -AID - S0167-8140(22)04606-0 [pii] -AID - 10.1016/j.radonc.2022.109454 [doi] -PST - ppublish -SO - Radiother Oncol. 2023 Mar;180:109454. doi: 10.1016/j.radonc.2022.109454. Epub - 2023 Jan 11. - -PMID- 34970277 -OWN - NLM -STAT- MEDLINE -DCOM- 20220208 -LR - 20220208 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 12 -DP - 2021 -TI - Systemic Immune Activation and Responses of Irradiation to Different Metastatic - Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer. -PG - 803247 -LID - 10.3389/fimmu.2021.803247 [doi] -LID - 803247 -AB - PURPOSE: Considering the limited data, we aimed to identify the greatest immune - activation irradiated site of common metastases and response to immune checkpoint - inhibitors simultaneously in non-small cell lung cancer (NSCLC). METHODS: A total - of 136 patients with advanced NSCLC who had received radiation to a primary or - metastatic solid tumor were enrolled. We recorded blood cell counts in three time - periods, before, during, and after radiotherapy (RT), and derived some blood - index ratios including monocyte-to-lymphocyte ratio (MLR), - neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and - systemic immune-inflammation index (SII). The delta-IBs were calculated as - medio-IBs ÷ pre-IBs - 1. We analyzed the changes before and during RT using - Spearman rank correlation test, Kruskal-Wallis rank sum test, and logistic - regression analyzing their correlation with efficacy. RESULTS: The medians of - delta-MLR and delta-PLR were both the lowest while the median of delta-L was the - highest in brain. Therapeutic effect evaluation showed that the objective - response rate (ORR) of 48.65% (18/37) in the brain irradiation group was the - highest, compared with 17.07% (7/41) in bone and 41.94% (13/31) in lung. - CONCLUSIONS: In this study, results suggested that irradiation to brain has the - best immune activation effect and patient outcome compared with other organs in - NSCLC, and when the earlier-line ICIs were combined with RT, a better patient - outcome was reached. Prospective studies are also necessary to provide more - convincing evidence and standards for clinical irradiation metastases selection. -CI - Copyright © 2021 Wu, Liu, Wu, Liu, Wu, Yu and Meng. -FAU - Wu, Min -AU - Wu M -AD - Cheeloo College of Medicine, Shandong University, Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Liu, Jie -AU - Liu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Wu, Shihao -AU - Wu S -AD - Medical School, Anhui University of Science and Technology, Huainan, China. -FAU - Liu, Jingru -AU - Liu J -AD - Cheeloo College of Medicine, Shandong University, Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Wu, Hui -AU - Wu H -AD - Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou - University, Zhengzhou, China. -FAU - Yu, Jinming -AU - Yu J -AD - Cheeloo College of Medicine, Shandong University, Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Meng, Xue -AU - Meng X -AD - Cheeloo College of Medicine, Shandong University, Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20211214 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Biomarkers, Tumor) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Adult -MH - Aged -MH - Biomarkers, Tumor -MH - Carcinoma, Non-Small-Cell Lung/diagnosis/*immunology/*therapy -MH - Combined Modality Therapy -MH - Disease Susceptibility -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use -MH - *Immunity/drug effects/radiation effects -MH - Immunotherapy/adverse effects/methods -MH - Lung Neoplasms/diagnosis/*immunology/*therapy -MH - Male -MH - Middle Aged -MH - Molecular Targeted Therapy -MH - Neoplasm Metastasis -MH - Neoplasm Staging -MH - Radiotherapy/adverse effects/methods -MH - Treatment Outcome -PMC - PMC8712862 -OTO - NOTNLM -OT - NSCLC -OT - immune activation effect -OT - inflammatory blood indexes -OT - irradiated organs -OT - radioimmunotherapy -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/01/01 06:00 -MHDA- 2022/02/09 06:00 -PMCR- 2021/01/01 -CRDT- 2021/12/31 06:03 -PHST- 2021/10/27 00:00 [received] -PHST- 2021/11/22 00:00 [accepted] -PHST- 2021/12/31 06:03 [entrez] -PHST- 2022/01/01 06:00 [pubmed] -PHST- 2022/02/09 06:00 [medline] -PHST- 2021/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2021.803247 [doi] -PST - epublish -SO - Front Immunol. 2021 Dec 14;12:803247. doi: 10.3389/fimmu.2021.803247. eCollection - 2021. - -PMID- 37099383 -OWN - NLM -STAT- MEDLINE -DCOM- 20230626 -LR - 20230626 -IS - 1532-4281 (Electronic) -IS - 1079-9893 (Linking) -VI - 43 -IP - 2 -DP - 2023 Dec -TI - Hypoxia and acidity regulate immune checkpoint molecule and IFN-β expression in - non-small cell lung cancer cell lines. -PG - 31-36 -LID - 10.1080/10799893.2023.2204944 [doi] -AB - PURPOSE: Non-small cell lung cancer (NSCLC) is one of the most lethal tumors in - humans. Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized - the treatment of patients with advanced diseases. Tumor microenvironment - conditions like hypoxia and low pH may compromise the efficacy of ICIs. MATERIALS - AND METHODS: We report the effect of hypoxia and acidity on the expression levels - of the major checkpoint molecules, namely PD-L1, CD80, and CD47, in the A549 and - H1299 NSCLC cell lines. RESULTS: Hypoxia induces PD-L1 protein and mRNA - expression, represses CD80 mRNA levels, and enhances IFNβ protein expression. An - opposite effect was noticed when cells were exposed to acidic conditions. - Hypoxia-induced the CD47 molecule at protein and mRNA levels. It is concluded - that hypoxia and acidity are important regulators of the expression of PD-L1 and - CD80 immune checkpoint molecules. Acidity contributes to the suppression of the - interferon type I pathway. CONCLUSIONS: These findings suggest that hypoxia and - acidity assist cancer cells in the escape from immune surveillance through direct - effects on cancer cells' ability to present immune checkpoint molecules and - release type I interferons. Targeting hypoxia and acidity may enhance the - activity of ICIs in NSCLC. -FAU - Mitrakas, Achilleas G -AU - Mitrakas AG -AD - Department of Radiotherapy/Oncology, Democritus University of Thrace, - Alexandroupolis, Greece. -FAU - Giatromanolaki, Alexandra -AU - Giatromanolaki A -AD - Department of Pathology, Democritus University of Thrace, Alexandroupolis, - Greece. -FAU - Koukourakis, Michael I -AU - Koukourakis MI -AUID- ORCID: 0000-0002-2324-699X -AD - Department of Radiotherapy/Oncology, Democritus University of Thrace, - Alexandroupolis, Greece. -LA - eng -PT - Journal Article -DEP - 20230426 -PL - England -TA - J Recept Signal Transduct Res -JT - Journal of receptor and signal transduction research -JID - 9509432 -RN - 0 (Immune Checkpoint Proteins) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD47 Antigen) -RN - 0 (RNA, Messenger) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - *Lung Neoplasms/drug therapy/genetics/metabolism -MH - Immune Checkpoint Proteins -MH - B7-H1 Antigen -MH - CD47 Antigen -MH - Hypoxia -MH - RNA, Messenger -MH - Cell Line -MH - Tumor Microenvironment/genetics -OTO - NOTNLM -OT - CD80 -OT - IFN-β -OT - Non-small cell lung cancer -OT - PD-L1 -OT - acidity -OT - hypoxia -EDAT- 2023/04/26 12:42 -MHDA- 2023/06/26 06:41 -CRDT- 2023/04/26 12:03 -PHST- 2023/06/26 06:41 [medline] -PHST- 2023/04/26 12:42 [pubmed] -PHST- 2023/04/26 12:03 [entrez] -AID - 10.1080/10799893.2023.2204944 [doi] -PST - ppublish -SO - J Recept Signal Transduct Res. 2023 Dec;43(2):31-36. doi: - 10.1080/10799893.2023.2204944. Epub 2023 Apr 26. - -PMID- 36153496 -OWN - NLM -STAT- MEDLINE -DCOM- 20220928 -LR - 20221001 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 22 -IP - 1 -DP - 2022 Sep 24 -TI - Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small - cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase - II trial. -PG - 1011 -LID - 10.1186/s12885-022-10074-9 [doi] -LID - 1011 -AB - BACKGROUND: Recently, the combination of the programmed death-ligand 1 (PD-L1) - inhibitor atezolizumab with first-line chemotherapy has demonstrated to improve - outcome for patients with advanced small cell lung cancer (SCLC), leading to - approval of this regimen. At the same time, accumulating (pre-)clinical data - suggest synergisms of radiotherapy and immunotherapy via the radiation-mediated - induction of anti-tumor immunogenicity. Combining the recent findings, the - TREASURE trial aims at further enhancing response to upfront chemo-immunotherapy - by the addition of thoracic radiotherapy (TRT). METHODS/DESIGN: The TREASURE - trial is a randomized, multicenter, phase II clinical trial ( ClinicalTrials.gov - identifier, NCT04462276). One hundred four patients suffering from extensive - disease (ED) SCLC, with any response to the standard of care induction - chemo-immunotherapy will be randomized to receive atezolizumab maintenance - therapy with or without TRT. The primary endpoint of this study is overall - survival (OS). Secondary endpoints include further measures of efficacy, safety, - and the collection of biomarker samples. A safety interim analysis will take - place after n = 23 patients receiving TRT have been observed for three months - after the end of TRT. DISCUSSION: This trial will investigate whether treatment - efficacy can be improved by adding TRT to atezolizumab maintenance therapy in ED - SCLC patients with any response after chemo-immunotherapy. Safety and feasibility - of such a regimen will be evaluated, and biomaterials for a translational - research project will be collected. Together, the results of this trial will - deepen our comprehension of how checkpoint inhibition and radiotherapy interact - and contribute to the evolving landscape of SCLC therapy. TRIAL REGISTRATION: - Clinicaltrials.gov identifier: NCT04462276 (Date of initial registration: 8th - July 2020), https://clinicaltrials.gov/ct2/show/NCT04462276 Eudra-CT Number: - 2019-003916-29 (Date of initial registration: 30th March 2020), - https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003916-29/DE. -CI - © 2022. The Author(s). -FAU - Bozorgmehr, Farastuk -AU - Bozorgmehr F -AUID- ORCID: 0000-0001-8058-8884 -AD - Department of Thoracic Oncology, Thoraxklinik at University Hospital of - Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany. - Farastuk.Bozorgmehr@med.uni-heidelberg.de. -AD - Translational Lung Research Center Heidelberg TLRCH, Member of the German Center - for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany. - Farastuk.Bozorgmehr@med.uni-heidelberg.de. -FAU - Christopoulos, Petros -AU - Christopoulos P -AD - Department of Thoracic Oncology, Thoraxklinik at University Hospital of - Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany. -AD - Translational Lung Research Center Heidelberg TLRCH, Member of the German Center - for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany. -FAU - Chung, Inn -AU - Chung I -AD - Department of Thoracic Oncology, Thoraxklinik at University Hospital of - Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany. -AD - Translational Lung Research Center Heidelberg TLRCH, Member of the German Center - for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany. -FAU - Cvetkovic, Jelena -AU - Cvetkovic J -AD - Department of Thoracic Oncology, Thoraxklinik at University Hospital of - Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany. -AD - Translational Lung Research Center Heidelberg TLRCH, Member of the German Center - for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany. -FAU - Feißt, Manuel -AU - Feißt M -AD - University Hospital of Heidelberg, Institute of Medical Biometry, Im Neuenheimer - Feld 130.3, 69120, Heidelberg, Germany. -FAU - Krisam, Johannes -AU - Krisam J -AD - University Hospital of Heidelberg, Institute of Medical Biometry, Im Neuenheimer - Feld 130.3, 69120, Heidelberg, Germany. -FAU - Schneider, Marc A -AU - Schneider MA -AD - Translational Lung Research Center Heidelberg TLRCH, Member of the German Center - for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany. -AD - Thoraxklinik at University Hospital of Heidelberg, Translational Research Unit - (STF), Röntgenstraße 1, 69126, Heidelberg, Germany. -FAU - Heußel, Claus Peter -AU - Heußel CP -AD - Translational Lung Research Center Heidelberg TLRCH, Member of the German Center - for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany. -AD - Thoraxklinik at University Hospital of Heidelberg, Diagnostic and Interventional - Radiology with Nuclear Medicine, Röntgenstraße 1, 69126, Heidelberg, Germany. -FAU - Kreuter, Michael -AU - Kreuter M -AD - Translational Lung Research Center Heidelberg TLRCH, Member of the German Center - for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany. -AD - Thoraxklinik at University Hospital of Heidelberg, Center for Interstitial and - Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Röntgenstraße 1, - 69126, Heidelberg, Germany. -FAU - Müller, Daniel W -AU - Müller DW -AD - Institute of Clinical Cancer Research IKF GmbH at Northwest Hospital, Steinbacher - Hohl 2-26, 60488, Frankfurt am Main, Germany. -FAU - Thomas, Michael -AU - Thomas M -AD - Department of Thoracic Oncology, Thoraxklinik at University Hospital of - Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany. -AD - Translational Lung Research Center Heidelberg TLRCH, Member of the German Center - for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany. -FAU - Rieken, Stefan -AU - Rieken S -AD - Department of Radiation Oncology, University Medical Center Göttingen, - Robert-Koch-Str. 40, 37075, Göttingen, Germany. -LA - eng -SI - ClinicalTrials.gov/NCT04462276 -PT - Clinical Trial Protocol -PT - Journal Article -DEP - 20220924 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biocompatible Materials) -RN - 52CMI0WC3Y (atezolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - B7-H1 Antigen -MH - Biocompatible Materials/therapeutic use -MH - Clinical Trials, Phase II as Topic -MH - Humans -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Multicenter Studies as Topic -MH - Randomized Controlled Trials as Topic -MH - *Small Cell Lung Carcinoma/drug therapy/radiotherapy -PMC - PMC9509547 -OTO - NOTNLM -OT - Anti-PD-L1 monoclonal antibody -OT - Atezolizumab -OT - Extensive disease small cell lung cancer -OT - First-line therapy -OT - Radioimmuntherapy -OT - SCLC -OT - Thoracic radiotherapy -COIS- There has been no financial support for this work that could have influenced its - outcome. The TREASURE trial receives funding from Roche Pharma AG. However, Roche - Pharma AG has not been involved in study design, data collection, management, - data analysis and interpretation, or in the decision to submit this protocol for - publication. All authors declare that there are no competing conflicts of - interest. -EDAT- 2022/09/25 06:00 -MHDA- 2022/09/28 06:00 -PMCR- 2022/09/24 -CRDT- 2022/09/24 23:30 -PHST- 2022/02/08 00:00 [received] -PHST- 2022/09/09 00:00 [accepted] -PHST- 2022/09/24 23:30 [entrez] -PHST- 2022/09/25 06:00 [pubmed] -PHST- 2022/09/28 06:00 [medline] -PHST- 2022/09/24 00:00 [pmc-release] -AID - 10.1186/s12885-022-10074-9 [pii] -AID - 10074 [pii] -AID - 10.1186/s12885-022-10074-9 [doi] -PST - epublish -SO - BMC Cancer. 2022 Sep 24;22(1):1011. doi: 10.1186/s12885-022-10074-9. - -PMID- 36623605 -OWN - NLM -STAT- MEDLINE -DCOM- 20230605 -LR - 20230606 -IS - 1879-355X (Electronic) -IS - 0360-3016 (Linking) -VI - 116 -IP - 3 -DP - 2023 Jul 1 -TI - Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive - Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small - Cell Lung Cancer. -PG - 590-600 -LID - S0360-3016(22)03693-8 [pii] -LID - 10.1016/j.ijrobp.2022.12.042 [doi] -AB - PURPOSE: In the era of immunotherapy, the treatment for bulky, locally advanced - non-small cell lung cancer (LA-NSCLC) remains challenging. This study explored - the feasibility of induction immune checkpoint inhibitors (ICIs) plus - chemotherapy before definitive chemoradiation therapy (CRT) for bulky LA-NSCLC. - METHODS AND MATERIALS: Patients with bulky, unresectable stage III NSCLC (primary - tumor ≥5 cm in greatest dimension or metastatic lymph nodes ≥2 cm in shortest - diameter) receiving ICIs and chemotherapy before CRT from 2018 to 2022 were - identified. Survival outcomes and toxic effects were analyzed. Radiation therapy - plans on computed tomography images before and after 2 cycles of induction - chemoimmunotherapy were simulated to evaluate dosimetric outcomes. RESULTS: - Seventy-five patients were included. One- and 2-year overall-survival (OS) rates - were 91.5% (95% CI, 85.2%-98.3%) and 75.1% (95% CI, 64.1%-88.0%), respectively. - One- and 2-year progression-free-survival (PFS) rates were 85.8% (95% CI, - 78.0%-94.4%) and 64.2% (95% CI, 52.5%-78.6%), respectively. Median OS was not - reached (NR). Median PFS was 30.6 months (95% CI, 25.9 months to NR). Grade 2 and - ≥3 pneumonitis occurred in 26.7% and 9.3% of patients, respectively. Grade ≥3 - pneumonitis was significantly associated with poorer OS (P = .003) and PFS - (P = .018). Treatment discontinuation was significantly associated with shorter - OS (P = .023) and PFS (P = .047). Patients with consolidation ICIs exhibited - numerically better OS than those without consolidation ICIs (2-year OS, 85.8% vs - 64.2%; P = .170). The objective response rate was 76.1% for induction treatment - and 86.7% for induction treatment plus CRT. The disease control rate after 2 - cycles of induction therapy was significantly greater than after 4 (P = .046) or - more cycles (P = .025). Simulated radiation plans indicated that all target - volumes, mean lung dose, and volume of lung parenchyma receiving ≥5 Gy, ≥20 Gy, - and ≥30 Gy significantly decreased after 2 cycles (all P < .005). CONCLUSIONS: - Two cycles of induction ICIs plus chemotherapy before definitive CRT were - feasible for bulky LA-NSCLC, with significant tumor reduction and normal lung - protection. Further investigations on CRT combined with induction and - consolidation ICIs are warranted. -CI - Copyright © 2023 Elsevier Inc. All rights reserved. -FAU - Wang, Yu -AU - Wang Y -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Zhang, Tao -AU - Zhang T -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Wang, Jianyang -AU - Wang J -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Zhou, Zongmei -AU - Zhou Z -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Liu, Wenyang -AU - Liu W -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Xiao, Zefen -AU - Xiao Z -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Deng, Lei -AU - Deng L -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Feng, Qinfu -AU - Feng Q -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Wang, Xin -AU - Wang X -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Lv, Jima -AU - Lv J -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Ma, Xiangyu -AU - Ma X -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Xue, Qi -AU - Xue Q -AD - Department of Thoracic Surgery, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, China. -FAU - Wang, Jie -AU - Wang J -AD - State Key Laboratory of Molecular Oncology, Department of Medical Oncology, - National Cancer Center/National Clinical Research Center for Cancer/Cancer - Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, - Beijing, China. -FAU - Wang, Zhijie -AU - Wang Z -AD - State Key Laboratory of Molecular Oncology, Department of Medical Oncology, - National Cancer Center/National Clinical Research Center for Cancer/Cancer - Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, - Beijing, China. Electronic address: jie_969@163.com. -FAU - Bi, Nan -AU - Bi N -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. Electronic address: - binan_email@163.com. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20230107 -PL - United States -TA - Int J Radiat Oncol Biol Phys -JT - International journal of radiation oncology, biology, physics -JID - 7603616 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy -MH - *Lung Neoplasms -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Chemoradiotherapy/adverse effects -MH - *Pneumonia -EDAT- 2023/01/10 06:00 -MHDA- 2023/06/05 06:42 -CRDT- 2023/01/09 19:16 -PHST- 2022/08/07 00:00 [received] -PHST- 2022/12/19 00:00 [revised] -PHST- 2022/12/24 00:00 [accepted] -PHST- 2023/06/05 06:42 [medline] -PHST- 2023/01/10 06:00 [pubmed] -PHST- 2023/01/09 19:16 [entrez] -AID - S0360-3016(22)03693-8 [pii] -AID - 10.1016/j.ijrobp.2022.12.042 [doi] -PST - ppublish -SO - Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):590-600. doi: - 10.1016/j.ijrobp.2022.12.042. Epub 2023 Jan 7. - -PMID- 39415565 -OWN - NLM -STAT- MEDLINE -DCOM- 20241017 -LR - 20241017 -IS - 1651-226X (Electronic) -IS - 0284-186X (Linking) -VI - 63 -DP - 2024 Oct 16 -TI - Assessment of radiation pneumonitis and predictive factors in patients with - locally advanced non-small cell lung cancer treated with chemoradiotherapy. -PG - 791-797 -LID - 10.2340/1651-226X.2024.40576 [doi] -AB - PURPOSE: Radiation pneumonitis (RP) is a dose-limiting toxicity associated with - increased mortality for patients with non-small cell lung cancer (NSCLC) treated - with chemoradiotherapy (CRT). This study aims to assess the incidence of - symptomatic RP (grade 2-5), rate of recovery and associated predictive factors. - MATERIAL AND METHODS: We performed a retrospective population-based study - including 602 patients with NSCLC who were treated with CRT between 2002 and - 2016. RP and rate of recovery were analysed using Common Terminology Criteria for - Adverse Events version 4.0. Stepwise logistic regression was performed to analyse - potential predictive factors for the two endpoints RP grade ≥ 2 and RP grade ≥ 3. - RESULTS: A total of 136 (23%) patients developed symptomatic RP and 37 (6%) - developed RP grade ≥ 3. A total of 67 (71%) recovered, whereas the remaining 27 - (29%), with the major proportion of patients belonging to the RP grade ≥ 3 group, - suffered from prevailing sequelae. On multivariable analysis, the selected model - for predicting RP grade ≥ 2 included the factors V20, smoking status, average - fractions per week and chemotherapy agent. V20 and age were selected factors for - RP grade ≥ 3. INTERPRETATION: The results suggest that regardless of all proposed - factors predictive for RP, the most important influenceable significant factor - still is dose to the lung. The main aim should be to avoid RP grade ≥ 3, where a - substantial proportion of patients suffer from prevailing sequalae. Consequently, - the technical improvement and precision of radiotherapy delivery should continue - to focus on lung sparing techniques also in the ongoing immunotherapy-containing - schedules where the risk of pneumonitis may be increased. e factor still is dose - to the lung. Consequently, the technical improvement and precision of - radiotherapy delivery should continue to focus on lung sparing techniques also in - the ongoing immunotherapy-containing schedules where the risk of pneumonitis may - be increased. -FAU - Gunnarsson, Kerstin -AU - Gunnarsson K -AD - Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, - University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. - kerstin.a.gunnarsson@vgregion.se. -FAU - Mövik, Louise -AU - Mövik L -AUID- ORCID: 0000-0003-0880-5041 -AD - Department of Medical Radiation Sciences, Institute of Clinical Sciences, - Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, - Gothenburg, Sweden. -FAU - Pettersson, Niclas -AU - Pettersson N -AUID- ORCID: 0000-0003-4962-0799 -AD - Department of Medical Radiation Sciences, Institute of Clinical Sciences, - Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, - Gothenburg, Sweden. -FAU - Bäck, Anna -AU - Bäck A -AUID- ORCID: 0009-0000-0358-0491 -AD - Department of Medical Radiation Sciences, Institute of Clinical Sciences, - Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, - Gothenburg, Sweden. -FAU - Nyman, Jan -AU - Nyman J -AUID- ORCID: 0000-0002-2314-5902 -AD - Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, - University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. -FAU - Hallqvist, Andreas -AU - Hallqvist A -AUID- ORCID: 0000-0002-3705-194X -AD - Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, - University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. -LA - eng -PT - Journal Article -DEP - 20241016 -PL - Sweden -TA - Acta Oncol -JT - Acta oncologica (Stockholm, Sweden) -JID - 8709065 -SB - IM -MH - Humans -MH - *Radiation Pneumonitis/etiology/epidemiology -MH - *Carcinoma, Non-Small-Cell Lung/therapy/pathology/radiotherapy -MH - Female -MH - Male -MH - *Lung Neoplasms/therapy/pathology/radiotherapy -MH - Aged -MH - Middle Aged -MH - Retrospective Studies -MH - *Chemoradiotherapy/adverse effects/methods -MH - Adult -MH - Aged, 80 and over -MH - Risk Factors -MH - Incidence -EDAT- 2024/10/17 10:05 -MHDA- 2024/10/17 10:06 -CRDT- 2024/10/17 03:02 -PHST- 2024/04/25 00:00 [received] -PHST- 2024/09/20 00:00 [accepted] -PHST- 2024/10/17 10:06 [medline] -PHST- 2024/10/17 10:05 [pubmed] -PHST- 2024/10/17 03:02 [entrez] -AID - 10.2340/1651-226X.2024.40576 [doi] -PST - epublish -SO - Acta Oncol. 2024 Oct 16;63:791-797. doi: 10.2340/1651-226X.2024.40576. - -PMID- 39306923 -OWN - NLM -STAT- MEDLINE -DCOM- 20241011 -LR - 20241011 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 196 -DP - 2024 Oct -TI - Five-year survival in patients with extensive-stage small cell lung cancer - treated with atezolizumab in the Phase III IMpower133 study and the Phase III - IMbrella A extension study. -PG - 107924 -LID - S0169-5002(24)00458-6 [pii] -LID - 10.1016/j.lungcan.2024.107924 [doi] -AB - OBJECTIVES: IMbrella A is a Phase III extension study that allowed rollover from - Roche/Genentech-sponsored atezolizumab trials, including IMpower133, a Phase - I/III trial of first-line atezolizumab or placebo plus carboplatin/etoposide in - extensive-stage small cell lung cancer. We report outcomes from an exploratory - analysis of IMpower133 with extended time-to-event data for patients who rolled - over to IMbrella A. MATERIALS AND METHODS: IMpower133 patients could roll over to - IMbrella A to receive atezolizumab 1200 mg intravenously every three weeks if - they continued to receive atezolizumab at IMpower133 closure or were in survival - follow-up after atezolizumab discontinuation. Overall survival and safety were - assessed; only serious adverse events and AEs of special interest were collected - in IMbrella A. RESULTS: Eighteen of 26 eligible patients rolled over to IMbrella - A. At clinical cutoff (March 16, 2023), median follow-up in the atezolizumab plus - carboplatin/etoposide arm (IMpower133 and IMbrella A) was 59.4 months. The - three-, four-, and five-year overall survival (95 % CI) estimates were 16 % - (11 %-21 %), 13 % (8 %-18 %), and 12 % (7 %-17 %), respectively. In IMbrella A, - serious adverse events occurred in three patients (16.7 %), and one adverse event - of special interest was reported (grade two hypothyroidism). CONCLUSION: This - long-term analysis of patients from IMbrella A previously enrolled in IMpower133 - provides the first report of five-year overall survival outcomes in patients with - extensive-stage small cell lung cancer treated with first-line cancer - immunotherapy and chemotherapy. While limited by small patient numbers and lack - of long-term data for the IMpower133 control arm, exploratory overall survival - analyses in patients treated with atezolizumab plus carboplatin/etoposide - compared favorably with historical data with chemotherapy alone. NCT03148418. -CI - Copyright © 2024. Published by Elsevier B.V. -FAU - Reck, Martin -AU - Reck M -AD - Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung - Research, Grosshansdorf, Germany. Electronic address: m.reck@lungenclinic.de. -FAU - Dziadziuszko, Rafal -AU - Dziadziuszko R -AD - Faculty of Medicine, Department of Oncology and Radiotherapy, Medical University - of Gdańsk, Gdańsk, Poland. -FAU - Sugawara, Shunichi -AU - Sugawara S -AD - Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan. -FAU - Kao, Steven -AU - Kao S -AD - Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, - Australia. -FAU - Hochmair, Maximilian -AU - Hochmair M -AD - Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute - of Lung Research and Pulmonary Oncology, Vienna North Hospital Klinik - Floridsdorf, Vienna, Austria. -FAU - Huemer, Florian -AU - Huemer F -AD - Department of Respiratory Care, Ludwig Boltzmann Institute for Lung Health, - Klinik Penzing, Vienna, Austria. -FAU - de Castro, Gilberto Jr -AU - de Castro G Jr -AD - Clinical Oncology, Instituto de Cancer do Estado de São Paulo, Hospital Das - Clínicas Da FMUSP, São Paulo, Brazil. -FAU - Havel, Libor -AU - Havel L -AD - First Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech - Republic. -FAU - Bernabé Caro, Reyes -AU - Bernabé Caro R -AD - Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, - Spain. -FAU - Losonczy, György -AU - Losonczy G -AD - Faculty of Medicine, Semmelweis University, Budapest, Hungary. -FAU - Lee, Jong-Seok -AU - Lee JS -AD - Department of Internal Medicine, Seoul National University Bundang Hospital, - Seongnam, South Korea. -FAU - Kowalski, Dariusz M -AU - Kowalski DM -AD - Department of Lung Cancer and Chest Tumours, Maria Skłodowska-Curie National - Research Institute of Oncology, Warsaw, Poland. -FAU - Andric, Zoran -AU - Andric Z -AD - Department of Medical Oncology, Clinical Hospital Centre Bezanijska Kosa, - Belgrade, Serbia. -FAU - Califano, Raffaele -AU - Califano R -AD - Department of Medical Oncology, The Christie NHS Foundation Trust and Division of - Cancer Sciences, The University of Manchester, Manchester, UK. -FAU - Veatch, Andrea -AU - Veatch A -AD - Northwest Medical Specialties, Puyallup, WA, USA. -FAU - Gerstner, Gregory -AU - Gerstner G -AD - Illinois Cancer Care, Peoria, IL, USA. -FAU - Batus, Marta -AU - Batus M -AD - Medical Oncology, Rush University Medical Center, Chicago, IL, USA. -FAU - Morris, Stefanie -AU - Morris S -AD - F. Hoffmann-La Roche Ltd, Basel, Switzerland. -FAU - Kaul, Monika -AU - Kaul M -AD - Oncology Product Development Safety, Genentech Inc, South San Francisco, CA, USA. -FAU - Cuchelkar, Vaikunth -AU - Cuchelkar V -AD - Product Development Oncology-Hematology, Genentech, South San Francisco, CA, USA. -FAU - Li, Huafei -AU - Li H -AD - Roche, Product Development China, Shanghai, China. -FAU - Danner, Bradford J -AU - Danner BJ -AD - Genentech, South San Francisco, CA, USA. -FAU - Nabet, Barzin Y -AU - Nabet BY -AD - Computational Sciences, Genentech, South San Francisco, CA, USA. -FAU - Liu, Stephen V -AU - Liu SV -AD - Thoracic Oncology and Developmental Therapeutics, Lombardi Comprehensive Cancer - Center, Georgetown University, Washington, DC, USA. -LA - eng -SI - ClinicalTrials.gov/NCT03148418 -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -DEP - 20240810 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 52CMI0WC3Y (atezolizumab) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - BG3F62OND5 (Carboplatin) -RN - 6PLQ3CP4P3 (Etoposide) -SB - IM -MH - Humans -MH - *Antibodies, Monoclonal, Humanized/therapeutic use/administration & - dosage/adverse effects -MH - *Small Cell Lung Carcinoma/drug therapy/mortality/pathology -MH - *Lung Neoplasms/drug therapy/mortality/pathology -MH - Male -MH - Female -MH - Middle Aged -MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects -MH - Aged -MH - *Carboplatin/administration & dosage/therapeutic use -MH - Neoplasm Staging -MH - Etoposide/administration & dosage/therapeutic use -MH - Follow-Up Studies -MH - Survival Rate -MH - Adult -MH - Aged, 80 and over -OTO - NOTNLM -OT - Atezolizumab -OT - Carboplatin -OT - Clinical Trial -OT - Drug Therapy -OT - Etoposide -OT - Immune Checkpoint Inhibitor -OT - Small Cell Lung Carcinoma -OT - Survival -COIS- Declaration of competing interest The authors declare the following financial - interests/personal relationships which may be considered as potential competing - interests: All authors report editorial support funded by the Sponsor. Martin - Reck reports receiving consulting fees, honoraria and travel support from Amgen, - AstraZeneca, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, - GSK, Mirati, Merck, MSD, Lily, Novartis, Pfizer, Sanofi, Roche, and Regeneron; - and participation on a data safety monitoring or advisory board for Sanofi and - Daiichi Sankyo. Rafal Dziadziuszko reports receiving honoraria from Roche, - AstraZeneca, Amgen, Novartis, MSD, Bristol Myers Squibb, Takeda, and Pfizer; and - materials from Novartis. Shunichi Sugawara reports receiving grants (to - institution) from AstraZeneca, Chugai Pharma, MSD, Bristol Myers Squibb, and Ono - Pharmaceutical; and honoraria from AstraZeneca, Chugai Pharma, MSD, Bristol Myers - Squibb, and Ono Pharmaceutical. Steven Kao reports receiving grants (to - institution) from AstraZeneca; honoraria from AstaZeneca, Pfizer, MSD, Bristol - Myers Squibb, Roche, Amgen, Beigene, and Boehringer Ingelheim; and travel support - from MSD. Maximilian Hochmair reports receiving honoraria from MSD, Roche, Lilly, - AstraZeneca, Takeda, Bristol Myers Squibb, and Amgen. Florian Huemer declares no - conflict of interest. Gilberto de Castro, Jr reports receiving consulting fees - from Daiichi-Sankyo; honoraria from AstraZeneca, Bristol Myers Squibb, Jannsen, - Lilly, MSD, Novartis, Roche, Amgen, and Daiichi-Sankyo; travel support from - Roche, Amgen, Daiichi-Sankyo, MSD, AstraZeneca, and Bristol Myers Squibb; and - participation on a data safety monitoring or advisory board for GlaxoSmithKline, - AstraZeneca, MSD, and Novartis. Libor Havel declares no conflict of interest. - Reyes Bernabé Caro reports receiving an investigational grant from Roche; - honoraria from Roche, Bristol Myers Squibb, Pfizer, MSD, Amgen, Takeda, and - AstraZeneca; and participation in a data safety monitoring or advisory board for - Takeda, Roche, Bristol Myers Squibb, and AstraZeneca. György Losonczy and - Jong-Seok Lee declare no conflict of interest. Dariusz M. Kowalski reports - participation on an advisory board and consultancy for Roche, Boehringer - Ingelheim, Novartis, Bristol Myers Squibb, MSD, Sanofi-Aventis, Takeda, Pfizer, - and Johnson & Johnson. Zoran Andric declares no conflict of interest. Raffaele - Califano reports receiving grants (to institution) from Roche and MSD; consulting - fees from Roche, MSD, Bristol Myers Squibb, and AstraZeneca; and honoraria from - Roche, MSD, and AstraZeneca; membership in the EORTC lung cancer group and ESMO - educational publication working group; and stock or stock options in The Christie - Private Care and Supportive Care UK. Andrea Veatch, Gregory Gerstner, and Marta - Batus declare no conflicts of interest. Stefanie Morris reports employment with - and stock or stock options in Roche. Monika Kaul, Vaikunth Cuchelkar, Huafei Li, - Bradford J. Danner, and Barzin Y. Nabet report employment with Roche. Stephen V. - Liu reports receiving grants from AbbVie, Alkermes, Elevation Oncology, Ellipses, - Genentech, Gilead, Merck, Merus, Nuvalent, RAPT, and Turning Point Therapeutics; - and consulting fees from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, - Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, - Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Merck, - Merus, Mirati, Novartis, Pfizer, Regeneron, Sanofi, Takeda, and Turning Point - Therapeutics; and participation on a data safety monitoring for Candel - Therapeutics. -EDAT- 2024/09/23 03:01 -MHDA- 2024/10/12 13:18 -CRDT- 2024/09/22 18:02 -PHST- 2024/05/23 00:00 [received] -PHST- 2024/07/31 00:00 [revised] -PHST- 2024/08/06 00:00 [accepted] -PHST- 2024/10/12 13:18 [medline] -PHST- 2024/09/23 03:01 [pubmed] -PHST- 2024/09/22 18:02 [entrez] -AID - S0169-5002(24)00458-6 [pii] -AID - 10.1016/j.lungcan.2024.107924 [doi] -PST - ppublish -SO - Lung Cancer. 2024 Oct;196:107924. doi: 10.1016/j.lungcan.2024.107924. Epub 2024 - Aug 10. - -PMID- 34371299 -OWN - NLM -STAT- MEDLINE -DCOM- 20211022 -LR - 20211022 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 160 -DP - 2021 Oct -TI - Prognostic and predictive value of PD-L1 expression and tumour infiltrating - lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous - radiochemotherapy in the randomized, multicenter, phase III German Intergroup - lung Trial (GILT). -PG - 17-27 -LID - S0169-5002(21)00470-0 [pii] -LID - 10.1016/j.lungcan.2021.07.008 [doi] -AB - OBJECTIVES: Immune checkpoint inhibition after radiochemotherapy (RTCT) has - become a new standard of care for locally advanced non-small cell lung cancer - with programmed death-ligand 1 (PD-L1) expression. However, little is known about - the prognostic role of immune response markers in this setting. We analysed PD-L1 - expression and tumour infiltrating lymphocytes (TiLs) in tumour biopsies from the - multicenter German Intergroup Lung Trial (GILT), which previously randomised - patients with stage III NSCLC to RTCT with or without consolidation chemotherapy. - MATERIALS AND METHODS: We retrospectively analyzed tumour biopsies from patients - treated in the GILT trial. PD-L1 expression was analysed using the Ventana SP263 - assay and TiL score (low, intermediate, high) and pattern (excluded, inflamed, - desert) were assessed. The primary endpoint of the biomarker analysis was PFS in - patients with PD-L1 ≥ 1% vs. PD-L1 < 1% NSCLC. Secondary endpoints explored the - prognostic relevance of additional PD-L1 expression levels and TiL score and - pattern. RESULTS: Biopsies were available from 92 patients treated with RTCT. - Patients with available tumor tissue did not differ significantly from the whole - study population. PD-L1 scores from 78 samples were available for analysis. There - was no difference in PFS in the PD-L1 < 1% vs. PD-L1 ≥ 1% subgroups. TiL score - was available in 66 patients. Patients with high TiL score showed favourable - overall survival compared to the low TiL subgroup. This trend was most pronounced - in those patients treated with consolidative chemotherapy. CONCLUSION: In this - analysis, PD-L1 expression did not correlate with PFS following RTCT. However, - patients with TiLs > 10% were found to have longer overall survival, especially - for those patients treated with consolidation chemotherapy after the end of RTCT. - Further analyses to explore the prognostic and predictive relevance of TiLs in - the context of consolidative checkpoint inhibition with durvalumab are required. -CI - Copyright © 2021. Published by Elsevier B.V. -FAU - Tufman, Amanda -AU - Tufman A -AD - Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, - Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich - (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz - 31, 81377 Munich, Germany. Electronic address: Amanda.Tufman@med.uni-muenchen.de. -FAU - Neumann, Jens -AU - Neumann J -AD - Institute of Pathology, Faculty of Medicine, LMU Munich, Thalkirchner Str. 36, - 80337 Munich, Germany. Electronic address: Jens.Neumann@med.uni-muenchen.de. -FAU - Manapov, Farkhad -AU - Manapov F -AD - Department of Radiation Oncology, University Hospital, LMU Munich, - Marchioninistr. 15, 81377 Munich, Germany. Electronic address: - Farkhad.Manapov@med.uni-muenchen.de. -FAU - Sellmer, Laura -AU - Sellmer L -AD - Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, - Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich - (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz - 31, 81377 Munich, Germany. Electronic address: Laura.Sellmer@med.uni-muenchen.de. -FAU - Jung, Andreas -AU - Jung A -AD - Institute of Pathology, Faculty of Medicine, LMU Munich, Thalkirchner Str. 36, - 80337 Munich, Germany. Electronic address: Andreas.Jung@med.uni-muenchen.de. -FAU - Kauffmann-Guerrero, Diego -AU - Kauffmann-Guerrero D -AD - Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, - Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich - (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz - 31, 81377 Munich, Germany. Electronic address: - Diego.KauffmannGuerrero@med.uni-muenchen.de. -FAU - Kahnert, Kathrin -AU - Kahnert K -AD - Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, - Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich - (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz - 31, 81377 Munich, Germany. Electronic address: - Kathrin.Kahnert@med.uni-muenchen.de. -FAU - Mertsch, Pontus -AU - Mertsch P -AD - Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, - Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich - (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz - 31, 81377 Munich, Germany. Electronic address: - Pontus.Mertsch@med.uni-muenchen.de. -FAU - Borgmeier, Astrid -AU - Borgmeier A -AD - Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, - Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich - (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz - 31, 81377 Munich, Germany. Electronic address: - Astrid.Borgmeier@med.uni-muenchen.de. -FAU - Semrau, Sabine -AU - Semrau S -AD - Department of Radiation Oncology, University Hospital Erlangen, Universitätsstr. - 27, 91054 Erlangen, Germany. Electronic address: Sabine.Semrau@uk-erlangen.de. -FAU - Rittmeyer, Achim -AU - Rittmeyer A -AD - Department of Pneumology, Lung Clinic Immenhausen, Robert-Koch-Str. 3, 34376 - Immenhausen, Germany. Electronic address: - arittmeyer@lungenfachklinik-immenhausen.de. -FAU - Ulm, Bernhard -AU - Ulm B -AD - Department of Anaesthesiology and Intensive Care Medicine, School of Medicine, - Technical University of Munich, Munich, Germany. Electronic address: - Bernhard.ulm@tum.de. -FAU - Ulm, Kurt -AU - Ulm K -AD - Institute of Medical Informatics, Statistics and Epidemiology, Technical - University of Munich, Ismaninger Str 22, 81675 Munich, Germany. Electronic - address: kurt.ulm@tum.de. -FAU - Flentje, Michael -AU - Flentje M -AD - Department of Radiation Oncology, University Hospital Würzburg, Josef-Schneider - Str. 2, 97080 Würzburg, Germany. Electronic address: flentje_m@ukw.de. -FAU - Fietkau, Rainer -AU - Fietkau R -AD - Department of Radiation Oncology, University Hospital Erlangen, Universitätsstr. - 27, 91054 Erlangen, Germany. Electronic address: Rainer.Fietkau@uk-erlangen.de. -FAU - Huber, Rudolf Maria -AU - Huber RM -AD - Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, - Ziemssenstr. 1, 80336 Munich, Germany; Comprehensive Pneumology Center Munich - (CPC-M), Member of the German Center for Lung Research (DZL), Max-Lebsche-Platz - 31, 81377 Munich, Germany. Electronic address: Huber@med.uni-meunchen.de. -LA - eng -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -DEP - 20210720 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (B7-H1 Antigen) -SB - IM -MH - B7-H1 Antigen -MH - *Carcinoma, Non-Small-Cell Lung/therapy -MH - Chemoradiotherapy -MH - Humans -MH - Lung -MH - *Lung Neoplasms/therapy -MH - Lymphocytes, Tumor-Infiltrating -MH - Prognosis -MH - Retrospective Studies -OTO - NOTNLM -OT - Checkpoint inhibition -OT - Chemoradiotherapy -OT - PDL1 -OT - Prognostic factors -OT - TiLs -EDAT- 2021/08/10 06:00 -MHDA- 2023/02/25 06:00 -CRDT- 2021/08/09 20:18 -PHST- 2021/03/02 00:00 [received] -PHST- 2021/06/30 00:00 [revised] -PHST- 2021/07/10 00:00 [accepted] -PHST- 2021/08/10 06:00 [pubmed] -PHST- 2023/02/25 06:00 [medline] -PHST- 2021/08/09 20:18 [entrez] -AID - S0169-5002(21)00470-0 [pii] -AID - 10.1016/j.lungcan.2021.07.008 [doi] -PST - ppublish -SO - Lung Cancer. 2021 Oct;160:17-27. doi: 10.1016/j.lungcan.2021.07.008. Epub 2021 - Jul 20. - -PMID- 35641202 -OWN - NLM -STAT- MEDLINE -DCOM- 20220602 -LR - 20240824 -IS - 1549-490X (Electronic) -IS - 1083-7159 (Print) -IS - 1083-7159 (Linking) -VI - 27 -IP - 2 -DP - 2022 Mar 4 -TI - Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of - Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation - With Outcome. -PG - e199-e202 -LID - 10.1093/oncolo/oyab047 [doi] -AB - INTRODUCTION: Data on tumor immune-milieu after chemo-radiation (CT-RT) are - scarce. Noninvasive tools are needed to improve the treatment of non-small cell - lung cancer (NSCLC), especially in the locally advanced (LA) setting. METHODS: We - collected a series of superior-sulcus (SS)- patients with NSCLC referred to our - Institute (2015-2019), eligible for a preoperative CT-RT. We characterized - tumor-infiltrating immune cells (TIICs), determined PD-L1-TPS and the residual - viable tumor cells (RVTC). Radiological and metabolic responses were reviewed. We - calculated pre-surgery neutrophil-to-lymphocyte ratio (NLR) and - platelet-to-lymphocyte ratio (PLR). RESULTS: Eight patients were included. - Radiological responses were 6 disease stabilities (SD) and 2 partial responses - (PR). Metabolic responses were 4 SD and 4 PR. CD68+-TIICs were correlated with - metabolic response and lower RVTC. CD68+-TIICs were associated with higher PLR. - Higher PLR values seemed linked with lower RVTC. CONCLUSIONS: These preliminary - results could be useful for consolidation treatment selection for patients with - LA-NSCLC without evaluable baseline PD-L1 and higher PLR values. -CI - © The Author(s) 2022. Published by Oxford University Press. -FAU - Pavan, Alberto -AU - Pavan A -AUID- ORCID: 0000-0003-4695-0100 -AD - Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. -FAU - Ferro, Alessandra -AU - Ferro A -AD - Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. -AD - Department of Surgery, Oncology and Gastroenterology, University of Padova, - Padova, Italy. -FAU - Fortarezza, Francesco -AU - Fortarezza F -AD - Pathology Division, Department of Cardiac, Thoracic, Vascular Sciences and Public - Health, Padova University Hospital, Padova, Italy. -FAU - Schiavon, Marco -AU - Schiavon M -AD - Thoracic Surgery Division, Department of Cardiac, Thoracic, Vascular Sciences and - Public Health, Padova University Hospital, Padova, Italy. -FAU - Evangelista, Laura -AU - Evangelista L -AD - Nuclear Medicine Unit, Department of Medicine, Padova University Hospital, - Padova, Italy. -FAU - Pezzuto, Federica -AU - Pezzuto F -AD - Pathology Division, Department of Cardiac, Thoracic, Vascular Sciences and Public - Health, Padova University Hospital, Padova, Italy. -FAU - Lunardi, Francesca -AU - Lunardi F -AD - Pathology Division, Department of Cardiac, Thoracic, Vascular Sciences and Public - Health, Padova University Hospital, Padova, Italy. -FAU - Frega, Stefano -AU - Frega S -AD - Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. -FAU - Bonanno, Laura -AU - Bonanno L -AD - Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. -FAU - Rea, Federico -AU - Rea F -AD - Thoracic Surgery Division, Department of Cardiac, Thoracic, Vascular Sciences and - Public Health, Padova University Hospital, Padova, Italy. -FAU - Guarneri, Valentina -AU - Guarneri V -AD - Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. -AD - Department of Surgery, Oncology and Gastroenterology, University of Padova, - Padova, Italy. -FAU - Conte, PierFranco -AU - Conte P -AUID- ORCID: 0000-0002-5210-5344 -AD - Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. -AD - Department of Surgery, Oncology and Gastroenterology, University of Padova, - Padova, Italy. -FAU - Calabrese, Fiorella -AU - Calabrese F -AD - Pathology Division, Department of Cardiac, Thoracic, Vascular Sciences and Public - Health, Padova University Hospital, Padova, Italy. -FAU - Pasello, Giulia -AU - Pasello G -AUID- ORCID: 0000-0002-8741-6038 -AD - Department of Surgery, Oncology and Gastroenterology, University of Padova, - Padova, Italy. -LA - eng -PT - Journal Article -PL - England -TA - Oncologist -JT - The oncologist -JID - 9607837 -RN - 0 (B7-H1 Antigen) -SB - IM -MH - B7-H1 Antigen/metabolism -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Prognosis -PMC - PMC8895738 -OTO - NOTNLM -OT - chemo-radiotherapy -OT - immunotherapy -OT - locally advanced NSCLC -OT - platelet-to-lymphocyte ratio -OT - tumor immune microenvironment -EDAT- 2022/06/01 06:00 -MHDA- 2022/06/03 06:00 -PMCR- 2022/01/31 -CRDT- 2022/05/31 21:24 -PHST- 2021/08/19 00:00 [received] -PHST- 2021/10/28 00:00 [accepted] -PHST- 2022/05/31 21:24 [entrez] -PHST- 2022/06/01 06:00 [pubmed] -PHST- 2022/06/03 06:00 [medline] -PHST- 2022/01/31 00:00 [pmc-release] -AID - 6518014 [pii] -AID - oyab047 [pii] -AID - 10.1093/oncolo/oyab047 [doi] -PST - ppublish -SO - Oncologist. 2022 Mar 4;27(2):e199-e202. doi: 10.1093/oncolo/oyab047. - -PMID- 31031204 -OWN - NLM -STAT- MEDLINE -DCOM- 20200403 -LR - 20220120 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Print) -IS - 1525-7304 (Linking) -VI - 20 -IP - 4 -DP - 2019 Jul -TI - Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in - Patients With Advanced Non-Small-Cell Lung Cancer. -PG - e470-e479 -LID - S1525-7304(19)30068-3 [pii] -LID - 10.1016/j.cllc.2019.02.018 [doi] -AB - PURPOSE: To investigate the relationship between radiotherapy (RT), in particular - chest RT, and development of immune-related (IR) pneumonitis in non-small-cell - lung cancer (NSCLC) patients treated with anti-programmed cell death 1 - (PD-1)/programmed death ligand 1 (PD-L1). PATIENTS AND METHODS: Between June 2011 - and July 2017, NSCLC patients treated with anti-PD-1/PD-L1 at a tertiary-care - academic cancer center were identified. Patient, treatment, prior RT (intent, - technique, timing, courses), and IR pneumonitis details were collected. Treating - investigators diagnosed IR pneumonitis clinically. Diagnostic IR pneumonitis - scans were overlaid with available chest RT plans to describe IR pneumonitis in - relation to prior chest RT. We evaluated associations between patient, treatment, - RT details, and development of IR pneumonitis by Fisher exact and Wilcoxon - rank-sum tests. RESULTS: Of the 188 NSCLC patients we identified, median - follow-up was 6.78 (range, 0.30-79.3) months and median age 66 (range, 39-91) - years; 54% (n = 102) were male; and 42% (n = 79) had stage I-III NSCLC at initial - diagnosis. Patients received anti-PD-1/PD-L1 monotherapy (n = 127, 68%) or - PD-1/PD-L1-based combinations (n = 61, 32%). In the entire cohort, 70% (132/188) - received any RT, 53% (100/188) chest RT, and 37% (70/188) curative-intent chest - RT. Any grade IR pneumonitis occurred in 19% (36/188; 95% confidence interval, - 13.8-25.6). Of those who developed IR pneumonitis and received chest RT (n = 19), - patients were more likely to have received curative-intent versus - palliative-intent chest RT (17/19, 89%, vs. 2/19, 11%; P = .051). Predominant IR - pneumonitis appearances were ground-glass opacities outside high-dose chest RT - regions. CONCLUSION: No RT parameter was significantly associated with IR - pneumonitis. On subset analysis of patients who developed IR pneumonitis and who - had received prior chest RT, IR pneumonitis was more common in patients who - received curative-intent chest RT. Attention should be paid to NSCLC patients - receiving curative-intent RT followed by anti-PD-1/PD-L1 agents. -CI - Copyright © 2019 Elsevier Inc. All rights reserved. -FAU - Voong, Khinh Ranh -AU - Voong KR -AD - Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins - University, Baltimore, MD. Electronic address: Kvoong1@jhmi.edu. -FAU - Hazell, Sarah Z -AU - Hazell SZ -AD - Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins - University, Baltimore, MD. -FAU - Fu, Wei -AU - Fu W -AD - Department of Oncology, Biostatistics, Johns Hopkins University School of - Medicine, Baltimore, MD. -FAU - Hu, Chen -AU - Hu C -AD - Department of Oncology, Biostatistics, Johns Hopkins University School of - Medicine, Baltimore, MD. -FAU - Lin, Cheng Ting -AU - Lin CT -AD - Department of Radiology and Radiological Science, Johns Hopkins University School - of Medicine, Baltimore, MD. -FAU - Ding, Kai -AU - Ding K -AD - Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins - University, Baltimore, MD. -FAU - Suresh, Karthik -AU - Suresh K -AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, - MD. -FAU - Hayman, Jonathan -AU - Hayman J -AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, - MD. -FAU - Hales, Russell K -AU - Hales RK -AD - Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins - University, Baltimore, MD. -FAU - Alfaifi, Salem -AU - Alfaifi S -AD - Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins - University, Baltimore, MD. -FAU - Marrone, Kristen A -AU - Marrone KA -AD - Department of Oncology, Johns Hopkins University, Baltimore, MD; Bloomberg-Kimmel - Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD. -FAU - Levy, Benjamin -AU - Levy B -AD - Department of Oncology, Johns Hopkins University, Baltimore, MD. -FAU - Hann, Christine L -AU - Hann CL -AD - Department of Oncology, Johns Hopkins University, Baltimore, MD. -FAU - Ettinger, David S -AU - Ettinger DS -AD - Department of Oncology, Johns Hopkins University, Baltimore, MD. -FAU - Feliciano, Josephine L -AU - Feliciano JL -AD - Department of Oncology, Johns Hopkins University, Baltimore, MD. -FAU - Peterson, Valerie -AU - Peterson V -AD - Department of Oncology, Johns Hopkins University, Baltimore, MD. -FAU - Kelly, Ronan J -AU - Kelly RJ -AD - Department of Oncology, Johns Hopkins University, Baltimore, MD. -FAU - Brahmer, Julie R -AU - Brahmer JR -AD - Department of Oncology, Johns Hopkins University, Baltimore, MD; Bloomberg-Kimmel - Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD. -FAU - Forde, Patrick M -AU - Forde PM -AD - Department of Oncology, Johns Hopkins University, Baltimore, MD; Bloomberg-Kimmel - Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD. -FAU - Naidoo, Jarushka -AU - Naidoo J -AD - Department of Oncology, Johns Hopkins University, Baltimore, MD; Bloomberg-Kimmel - Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD. -LA - eng -GR - P30 CA006973/CA/NCI NIH HHS/United States -PT - Journal Article -DEP - 20190328 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 28X28X9OKV (durvalumab) -RN - 31YO63LBSN (Nivolumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal/therapeutic use -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/epidemiology/*radiotherapy -MH - Drug-Related Side Effects and Adverse Reactions/*epidemiology -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Lung Neoplasms/drug therapy/epidemiology/*radiotherapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Nivolumab/therapeutic use -MH - Pneumonia/*epidemiology/etiology -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - Survival Analysis -PMC - PMC8767572 -MID - NIHMS1758343 -OTO - NOTNLM -OT - Anti–PD-1/PD-L1 therapy -OT - Nivolumab -OT - Pembrolizumab -OT - Pneumonitis -OT - Radiation -EDAT- 2019/04/30 06:00 -MHDA- 2020/04/04 06:00 -PMCR- 2022/01/19 -CRDT- 2019/04/30 06:00 -PHST- 2018/12/20 00:00 [received] -PHST- 2019/02/04 00:00 [revised] -PHST- 2019/02/21 00:00 [accepted] -PHST- 2019/04/30 06:00 [pubmed] -PHST- 2020/04/04 06:00 [medline] -PHST- 2019/04/30 06:00 [entrez] -PHST- 2022/01/19 00:00 [pmc-release] -AID - S1525-7304(19)30068-3 [pii] -AID - 10.1016/j.cllc.2019.02.018 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2019 Jul;20(4):e470-e479. doi: 10.1016/j.cllc.2019.02.018. Epub - 2019 Mar 28. - -PMID- 34606491 -OWN - NLM -STAT- MEDLINE -DCOM- 20211006 -LR - 20211103 -IS - 1941-5923 (Electronic) -IS - 1941-5923 (Linking) -VI - 22 -DP - 2021 Oct 4 -TI - Chronic Pleuritis and Recurrent Pleural Effusion After Atezolizumab for Small - Cell Lung Cancer. -PG - e933396 -LID - 10.12659/AJCR.933396 [doi] -AB - BACKGROUND As use of immune checkpoint inhibitors consistently grows, so does - knowledge of immune-related adverse events. Pleural complications from PD-L1 - inhibitors such as atezolizumab have never been reported. We describe the first - reported case of biopsy-proven pleuritis manifesting as recurrent pleural - effusion in a patient treated with atezolizumab. CASE REPORT A 66-year-old woman - with history of extensive-stage small cell lung cancer presented with a new - pleural effusion. She was previously treated with carboplatin, etoposide, and - atezolizumab followed by atezolizumab maintenance, but this later was stopped due - to pneumonitis. She had been on no systemic therapy for 6 months prior; radiation - to the chest was completed 1 year earlier. Thoracentesis revealed an exudate with - eosinophilia but no malignancy. She underwent medical thoracoscopy, which showed - normal pleura with no evidence of radiation changes. Random pleural biopsies - revealed only chronic pleuritis. Given normal-appearing pleura, radiation - pleuritis was ruled out. It was felt that the chemotherapy had occurred too long - ago to be a present cause of her pleuritis. As such, after extensive workup, the - eosinophilic pleural effusion was felt to be due to pleuritis from atezolizumab. - The effusion has ultimately recurred 5 times over 1 year, and cytology remains - negative for malignancy. CONCLUSIONS Patients with prior cancer presenting with a - new pleural effusion should undergo an extensive workup to evaluate for - recurrence. When other causes have been ruled out, ongoing immune-related effects - of immunotherapy should be considered. Pleural complications from PD-L1 - inhibitors have not been reported; we present a possible case of chronic - pleuritis and recurrent effusion due to atezolizumab. -FAU - Lin, Julie -AU - Lin J -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Sabath, Bruce Fernando -AU - Sabath BF -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20211004 -PL - United States -TA - Am J Case Rep -JT - The American journal of case reports -JID - 101489566 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 52CMI0WC3Y (atezolizumab) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal, Humanized -MH - Exudates and Transudates -MH - Female -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Neoplasm Recurrence, Local/drug therapy -MH - *Pleural Effusion/chemically induced -MH - *Pleurisy/chemically induced -MH - *Small Cell Lung Carcinoma -PMC - PMC8503793 -COIS- Conflict of interest: None declared -EDAT- 2021/10/05 06:00 -MHDA- 2021/10/07 06:00 -PMCR- 2021/10/04 -CRDT- 2021/10/04 17:26 -PHST- 2021/10/04 17:26 [entrez] -PHST- 2021/10/05 06:00 [pubmed] -PHST- 2021/10/07 06:00 [medline] -PHST- 2021/10/04 00:00 [pmc-release] -AID - 933396 [pii] -AID - 10.12659/AJCR.933396 [doi] -PST - epublish -SO - Am J Case Rep. 2021 Oct 4;22:e933396. doi: 10.12659/AJCR.933396. - -PMID- 36288758 -OWN - NLM -STAT- MEDLINE -DCOM- 20230228 -LR - 20230511 -IS - 1879-355X (Electronic) -IS - 0360-3016 (Linking) -VI - 115 -IP - 4 -DP - 2023 Mar 15 -TI - STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally - Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt - RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II - Trial. -PG - 886-896 -LID - S0360-3016(22)03459-9 [pii] -LID - 10.1016/j.ijrobp.2022.10.025 [doi] -AB - PURPOSE: This is a single arm phase 2 trial (Clinical trials.gov NCT05291780) to - assess local control (LC) and safety of SAbR in patients with unresectable - locally advanced non-small cell lung cancer (LA-NSCLC) unfit for concurrent - chemo-radiation therapy (ChT-RT). METHODS: Neoadjuvant ChT was prescribed in fit - patients. The tumor volume included primary tumor and any regionally positive - node/s. The coprimary study endpoints were LC and safety. RESULTS: Between - December 31, 2015, and December 31, 2020, 50 patients with LA-NSCLC were - enrolled. Histology was squamous cell carcinoma and adenocarcinoma (ADC) in 52% - and 48%, respectively. Forty (80%) patients had ultracentral tumor. Twenty-seven - (54%) received neoadjuvant ChT and 7 (14%) adjuvant durvalumab. Median prescribed - dose was 45 Gy (range, 35-55) and 40 Gy (35-45) in 5 daily fractions to tumor and - node/s, respectively. After a median follow-up of 38 months (range, 12-80), 19 - (38%) patients had experienced local recurrence (LR) at a median time of 13 - months (range, 7-34). The median LR-free survival (FS) was not reached (95% - confidence interval [CI], 28 to not reached). The 1-, 2-, and 3-year LR-FS rates - were 86% ± 5%, 66% ± 7%, and 56% ± 8%, respectively. At last follow-up, 33 (66%) - patients were alive. Median overall survival (OS) was 55 months (95% CI, 43-55 - months). The 1-, 2-, and 3-year OS rates were 94% ± 3%, 79% ± 6%, and 72% ± 7%, - respectively. No patients developed ≥ grade (G) 3 toxicity. ADC (hazard ratio - [HR], 3.61; 95% CI, 1.15-11.35) was a significant predictor of better LC, while - OS was significantly conditioned by smaller planning target volumes (HR, 1.004; - 95% CI, 1.001-1.010) and tumor, node, and metastasis stage (HR, 4.8; 95% CI, - 1.34-17). CONCLUSIONS: Patients with LA-NSCLC treated with SABR had optimal LC - and promising OS in absence of ≥G3 toxicity. Our early outcomes would suggest the - feasibility of using this approach in patients with LA-NSCLC unfit for concurrent - ChT-RT. -CI - Copyright © 2022 Elsevier Inc. All rights reserved. -FAU - Arcidiacono, Fabio -AU - Arcidiacono F -AD - Radiotherapy Oncology Centre. Electronic address: f.arcidiacono@aospterni.it. -FAU - Anselmo, Paola -AU - Anselmo P -AD - Radiotherapy Oncology Centre. -FAU - Casale, Michelina -AU - Casale M -AD - Radiotherapy Oncology Centre. -FAU - Zannori, Cristina -AU - Zannori C -AD - Medical Oncology. -FAU - Ragusa, Mark -AU - Ragusa M -AD - Thoracic Surgery Division. -FAU - Mancioli, Francesco -AU - Mancioli F -AD - Radiology Service. -FAU - Marchetti, Giovanni -AU - Marchetti G -AD - Pathology Unit. -FAU - Loreti, Fabio -AU - Loreti F -AD - Nuclear Medicine Service, "S. Maria" Hospital, Terni, Italy. -FAU - Italiani, Marco -AU - Italiani M -AD - Radiotherapy Oncology Centre. -FAU - Bracarda, Sergio -AU - Bracarda S -AD - Medical Oncology. -FAU - Maranzano, Ernesto -AU - Maranzano E -AD - Radiotherapy Oncology Centre. -FAU - Trippa, Fabio -AU - Trippa F -AD - Radiotherapy Oncology Centre. -LA - eng -SI - ClinicalTrials.gov/NCT05291780 -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20221024 -PL - United States -TA - Int J Radiat Oncol Biol Phys -JT - International journal of radiation oncology, biology, physics -JID - 7603616 -SB - IM -MH - Humans -MH - *Adenocarcinoma/pathology -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Carcinoma, Squamous Cell/pathology -MH - *Lung Neoplasms/pathology -MH - *Radiosurgery -EDAT- 2022/10/27 06:00 -MHDA- 2023/03/03 06:00 -CRDT- 2022/10/26 19:13 -PHST- 2022/08/05 00:00 [received] -PHST- 2022/10/06 00:00 [revised] -PHST- 2022/10/13 00:00 [accepted] -PHST- 2022/10/27 06:00 [pubmed] -PHST- 2023/03/03 06:00 [medline] -PHST- 2022/10/26 19:13 [entrez] -AID - S0360-3016(22)03459-9 [pii] -AID - 10.1016/j.ijrobp.2022.10.025 [doi] -PST - ppublish -SO - Int J Radiat Oncol Biol Phys. 2023 Mar 15;115(4):886-896. doi: - 10.1016/j.ijrobp.2022.10.025. Epub 2022 Oct 24. - -PMID- 35260342 -OWN - NLM -STAT- MEDLINE -DCOM- 20220816 -LR - 20220816 -IS - 1769-6658 (Electronic) -IS - 1278-3218 (Linking) -VI - 26 -IP - 5 -DP - 2022 Sep -TI - Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, - cisplatin, and concurrent radiotherapy in patients with locally advanced, - unresectable, stage III, non-squamous, non-small-cell lung cancer. -PG - 670-677 -LID - S1278-3218(22)00035-X [pii] -LID - 10.1016/j.canrad.2021.12.005 [doi] -AB - PURPOSE: Roughly 20% of patients with non-small-cell lung cancer exhibit locally - advanced, unresectable, stage III disease. Concurrent platinum-based - chemoradiotherapy is the backbone treatment, which is followed by maintenance - immunotherapy, yet with poor long-term prognosis. This phase II trial (IFCT-0803) - sought to evaluate whether adding cetuximab to cisplatin and pemetrexed - chemoradiotherapy would improve its efficacy in these patients. MATERIALS AND - METHODS: Eligible patients received weekly cetuximab (loading dose 400mg/m(2) day - 1; subsequent weekly 250mg/m(2) doses until two weeks postradiotherapy). - Chemotherapy comprised cisplatin (75mg/m(2)) and pemetrexed (500mg/m(2)), both - delivered on day 1 of a 21-day cycle of maximally four. Irradiation with - maximally 66Gy started on day 22. Disease control rate at week 16 was the primary - endpoint. RESULTS: One hundred and six patients were included (99 eligible - patients). Compliance exceeded 95% for day 1 of chemotherapy cycles 1 to 4, with - 76% patients receiving the 12 planned cetuximab doses. Maximal grade 3 toxicity - occurred in 63% patients, and maximal grade 4 in 9.6%. The primary endpoint - involving the first 95 eligible patients comprised two (2.1%) complete responses, - 57 (60.0%) partial responses, and 27 (28.4%) stable diseases. This 90.5% disease - control rate (95% confidence interval [95% CI]: 84.6%-96.4%) was achieved at week - 16. After median 63.0-month follow-up, one-year and two-year survival rates were - 75.8% and 59.5%. Median overall survival was 35.8months (95% CI: 23.5-NR), and - median progression-free survival 14.4months (95% CI: 11.2-18.8), with one-year - and two-year progression-free survival rates of 57.6% and 34.3%. CONCLUSION: - These survival rates compare favourably with published data, thus justifying - further development of cetuximab-based induction chemoradiotherapy. -CI - Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights - reserved. -FAU - Trédaniel, J -AU - Trédaniel J -AD - Department of pneumology, hôpital Saint-Joseph, 75014 Paris, France. Electronic - address: jeantredaniel@gmail.com. -FAU - Barlési, F -AU - Barlési F -AD - Multidisciplinary oncology and therapeutic innovations department, centre - hospitalier universitaire de Marseille, 13000 Marseille, France. -FAU - Le Péchoux, C -AU - Le Péchoux C -AD - Department of radiation oncology, Gustave-Roussy, 94805 Villejuif, France. -FAU - Lerouge, D -AU - Lerouge D -AD - Department of radiation oncology, centre François-Baclesse, 14000 Caen, France. -FAU - Pichon, É -AU - Pichon É -AD - Department of pneumology, centre hospitalier universitaire de Tours, 37000 Tours, - France. -FAU - Le Moulec, S -AU - Le Moulec S -AD - Department of pneumology, institut Bergonié, 33000 Bordeaux, France. -FAU - Moreau, L -AU - Moreau L -AD - Department of pneumology, hôpital Louis-Pasteur, 68024 Colmar, France. -FAU - Friard, S -AU - Friard S -AD - Department of pneumology, hôpital Foch, 92150 Suresnes, France. -FAU - Westeel, V -AU - Westeel V -AD - Department of pneumology, centre hospitalier universitaire de Besançon, 25000 - Besançon, France. -FAU - Petit, L -AU - Petit L -AD - Department of pneumology, centre hospitalier Alpes Léman, 74130 - Contamine-sur-Arve, France. -FAU - Carré, O -AU - Carré O -AD - Department of pneumology, clinique de l'Europe, 80090 Amiens, France. -FAU - Guichard, F -AU - Guichard F -AD - Department of oncology, polyclinique, 33000 Bordeaux, France. -FAU - Raffy, O -AU - Raffy O -AD - Department of pneumology, hôpital de Chartres, 28000 Chartres, France. -FAU - Villa, J -AU - Villa J -AD - Department of pneumology, centre hospitalier universitaire de Grenoble, 38000 - Grenoble, France. -FAU - Prévost, A -AU - Prévost A -AD - Department of pneumology, centre de lutte contre le cancer Jean-Godinot, 51100 - Reims, France. -FAU - Langlais, A -AU - Langlais A -AD - Intergroupe francophone de cancérologie thoracique, 75000 Paris, France. -FAU - Morin, F -AU - Morin F -AD - Intergroupe francophone de cancérologie thoracique, 75000 Paris, France. -FAU - Wislez, M -AU - Wislez M -AD - Department of pneumology, hôpital Cochin, 75014 Paris, France. -FAU - Giraud, P -AU - Giraud P -AD - Department of radiation Oncology, hôpital européen Georges-Pompidou, 75015 Paris, - France. -FAU - Zalcman, G -AU - Zalcman G -AD - Department of pneumology, centre hospitalier universitaire de Caen, 14000 Caen, - France. -FAU - Mornex, F -AU - Mornex F -AD - Department of radiation oncology, centre hospitalier universitaire de Lyon, 69000 - Lyon, France. -CN - French Cooperative Thoracic Intergroup (IFCT) -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20220305 -PL - France -TA - Cancer Radiother -JT - Cancer radiotherapie : journal de la Societe francaise de radiotherapie - oncologique -JID - 9711272 -RN - 04Q9AIZ7NO (Pemetrexed) -RN - PQX0D8J21J (Cetuximab) -RN - Q20Q21Q62J (Cisplatin) -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung -MH - Cetuximab/therapeutic use -MH - Chemoradiotherapy/adverse effects -MH - Cisplatin -MH - Humans -MH - *Lung Neoplasms -MH - Neoplasm Staging -MH - Pemetrexed -OTO - NOTNLM -OT - CPNPC de stade III -OT - Cetuximab -OT - Chimioradiothérapie concomitante -OT - Cisplatin -OT - Cisplatine -OT - Concurrent chemoradiotherapy -OT - Cétuximab -OT - Pemetrexed -OT - Pémétrexed -OT - Stage III NSCLC -EDAT- 2022/03/10 06:00 -MHDA- 2022/08/17 06:00 -CRDT- 2022/03/09 05:33 -PHST- 2021/10/20 00:00 [received] -PHST- 2021/11/24 00:00 [revised] -PHST- 2021/12/12 00:00 [accepted] -PHST- 2022/03/10 06:00 [pubmed] -PHST- 2022/08/17 06:00 [medline] -PHST- 2022/03/09 05:33 [entrez] -AID - S1278-3218(22)00035-X [pii] -AID - 10.1016/j.canrad.2021.12.005 [doi] -PST - ppublish -SO - Cancer Radiother. 2022 Sep;26(5):670-677. doi: 10.1016/j.canrad.2021.12.005. Epub - 2022 Mar 5. - -PMID- 33533013 -OWN - NLM -STAT- MEDLINE -DCOM- 20221012 -LR - 20221028 -IS - 1543-0154 (Electronic) -IS - 0885-8195 (Linking) -VI - 37 -IP - 5 -DP - 2022 Oct -TI - Patterns of Care and Barriers to Utilization of Definitive Concurrent - Chemoradiation Therapy for Stage III Non-Small Cell Lung Cancer in Russia. -PG - 1378-1384 -LID - 10.1007/s13187-021-01966-8 [doi] -AB - BACKGROUND: Definitive concurrent chemoradiation (cCRT) is offered to only 3% of - Russian patients with stage III NSCLC. To determine the patterns of care and - barriers to cCRT utilization in Russia, we conducted a survey of practicing - radiation oncologists (ROs). METHODS: Electronic IRB-approved survey containing - 15 questions was distributed to Russian ROs. Fisher's exact test or - Cochran-Armitage test of trend was used to assess the associations between - clinical experience, practice type, and patterns of care. RESULTS: We analyzed 58 - questionnaires completed by ROs-16 respondents from tertiary referral hospitals, - and 42 from community or private centers. A total of 88% of respondents formulate - treatment recommendations in multi-disciplinary tumor boards. For unresectable - stage III NSCLC, the most common recommendation is sequential CRT (50%), followed - by concurrent CRT (40%), with an observed higher utilization of cCRT in tertiary - centers (9/16, 56% vs 14/42, 33%). Of the respondents, 31% do not offer cCRT to - their pts. Among reasons for avoiding cCRT are (1) poor performance of pts (76%); - (2) high toxicity of therapy (55%); (3) lack of consensus among tumor board - members (33%); and (4) preference for sequential CRT (31%). Only 3% do not - irradiate elective LNs. Eighty-six percent of respondents counsel their NSCLC pts - regarding smoking cessation. CONCLUSIONS: Despite level 1 evidence, cCRT is - rarely used in Russia for pts with locally advanced NSCLC, and preference for - sequential therapy and concerns over high toxicity are the most common barriers. - Education of Russian ROs may increase cCRT utilization, leading to improved - survival, notably in the era of maintenance immunotherapy. -CI - © 2021. American Association for Cancer Education. -FAU - Dengina, Natalia -AU - Dengina N -AD - Department of Radiotherapy, Ulyanovsk Regional Cancer Center, Ulyanovsk, Oblast, - Russia. -FAU - Chernykh, Marina -AU - Chernykh M -AD - PET-Technology Podolsk, Podolsk, Russia. -FAU - Degnin, Catherine -AU - Degnin C -AD - Biostatics Shared Resources, Knight Cancer Institute, Oregon Health & Science - University, Portland, OR, USA. -FAU - Chen, Yiyi -AU - Chen Y -AD - Biostatics Shared Resources, Knight Cancer Institute, Oregon Health & Science - University, Portland, OR, USA. -AD - Department of Radiation Medicine, Knight Cancer Institute, Oregon Health & - Science University, 3181 S.W. Sam Jackson Park Road, KPV4, Portland, OR, 97239, - USA. -FAU - Tsimafeyeu, Ilya -AU - Tsimafeyeu I -AD - Institute of Oncology, Hadassah Medical, Moscow, Russia. -FAU - Karaseva, Vera V -AU - Karaseva VV -AD - Russian Society of Clinical Oncology, Moscow, Russia. -FAU - Tjulandin, Sergei -AU - Tjulandin S -AD - N.N. Blokhin Russian Cancer Center, Moscow, Russia. -FAU - Laktionov, Konstantin -AU - Laktionov K -AD - N.N. Blokhin Russian Cancer Center, Moscow, Russia. -FAU - Thomas, Charles R Jr -AU - Thomas CR Jr -AD - Department of Radiation Medicine, Knight Cancer Institute, Oregon Health & - Science University, 3181 S.W. Sam Jackson Park Road, KPV4, Portland, OR, 97239, - USA. -FAU - Mitin, Timur -AU - Mitin T -AUID- ORCID: 0000-0001-7923-574X -AD - Department of Radiation Medicine, Knight Cancer Institute, Oregon Health & - Science University, 3181 S.W. Sam Jackson Park Road, KPV4, Portland, OR, 97239, - USA. mitin@ohsu.edu. -LA - eng -PT - Journal Article -DEP - 20210202 -PL - England -TA - J Cancer Educ -JT - Journal of cancer education : the official journal of the American Association - for Cancer Education -JID - 8610343 -RN - 0 (Reactive Oxygen Species) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Neoplasm Staging -MH - Reactive Oxygen Species/therapeutic use -OTO - NOTNLM -OT - Chemoradiation therapy -OT - Non-small cell lung cancer -OT - Russia -EDAT- 2021/02/04 06:00 -MHDA- 2022/10/13 06:00 -CRDT- 2021/02/03 06:03 -PHST- 2021/01/24 00:00 [accepted] -PHST- 2021/02/04 06:00 [pubmed] -PHST- 2022/10/13 06:00 [medline] -PHST- 2021/02/03 06:03 [entrez] -AID - 10.1007/s13187-021-01966-8 [pii] -AID - 10.1007/s13187-021-01966-8 [doi] -PST - ppublish -SO - J Cancer Educ. 2022 Oct;37(5):1378-1384. doi: 10.1007/s13187-021-01966-8. Epub - 2021 Feb 2. - -PMID- 167630 -OWN - NLM -STAT- MEDLINE -DCOM- 19751003 -LR - 20190619 -IS - 0003-4819 (Print) -IS - 0003-4819 (Linking) -VI - 83 -IP - 1 -DP - 1975 Jul -TI - Current and future concepts of lung cancer. -PG - 93-106 -AB - We discuss here some of the last decade's diagnostic and therapeutic advances in - the treatment of lung cancer, as well as current and future research objectives. - Roentgenographs from selected patients illustrate the natural history of lung - cancer. We present perspectives concerning selection from the growing diagnostic - armamentarium, with comments upon early detection and localization of "occult" - cancers with the help of flexible bronchoscopy. Operative approaches have changed - over the past 4 decades; we review how and why they evolved, including - perspectives concerning mediastinoscopy. There is a presentation on a - radiotherapeutic research approach to oat-cell cancers and the current status of - immunotherapy. Such issues as animal models available for lung cancer research - emerge in the general discussion, and it becomes clear that lung cancer merits a - truly interdisciplinary approach in order to bring meaningful advances to the - patient's bedside. -FAU - Benfield, J R -AU - Benfield JR -FAU - Julliard, G J -AU - Julliard GJ -FAU - Pilch, Y H -AU - Pilch YH -FAU - Rigler, L G -AU - Rigler LG -FAU - Selecky, P -AU - Selecky P -LA - eng -PT - Journal Article -PL - United States -TA - Ann Intern Med -JT - Annals of internal medicine -JID - 0372351 -SB - IM -MH - Bronchoscopy -MH - Carcinoma/immunology/therapy -MH - Carcinoma, Small Cell/drug therapy/radiotherapy -MH - Cytodiagnosis -MH - Diagnosis, Differential -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/diagnosis/therapy -MH - Male -MH - Mediastinoscopy -MH - Middle Aged -MH - Neoplasm Metastasis -MH - Pneumonectomy -MH - Sputum/cytology -MH - Tomography, X-Ray -EDAT- 1975/07/01 00:00 -MHDA- 1975/07/01 00:01 -CRDT- 1975/07/01 00:00 -PHST- 1975/07/01 00:00 [pubmed] -PHST- 1975/07/01 00:01 [medline] -PHST- 1975/07/01 00:00 [entrez] -AID - 10.7326/0003-4819-83-1-93 [doi] -PST - ppublish -SO - Ann Intern Med. 1975 Jul;83(1):93-106. doi: 10.7326/0003-4819-83-1-93. - -PMID- 30452687 -OWN - NLM -STAT- MEDLINE -DCOM- 20190308 -LR - 20220408 -IS - 1465-3621 (Electronic) -IS - 0368-2811 (Linking) -VI - 49 -IP - 2 -DP - 2019 Feb 1 -TI - Nivolumab and stereotactic radiation therapy for the treatment of patients with - Stage IV non-small-cell lung cancer. -PG - 160-164 -LID - 10.1093/jjco/hyy171 [doi] -AB - BACKGROUND: Radiation therapy might modify the cancer immune environment to - enhance the antitumor effect of immune checkpoint inhibitors. We performed a - feasibility study of nivolumab following stereotactic radiation therapy for - chemotherapy pretreated advanced non-small-cell lung cancer. PATIENTS AND - METHODS: Pretreated advanced/recurrent non-small-cell lung cancer patients - received stereotactic radiation therapy to one of the disease sites. Nivolumab at - a dose of 3 mg/kg was given within 2 weeks after the completion of stereotactic - radiation therapy and continued every 2 weeks thereafter until disease - progression or unacceptable toxicities. The primary endpoint was the occurrence - rate of Grade 3 pneumonitis (within 12 weeks) or other non-hematological toxicity - (within 8 weeks). RESULTS: From September 2016 to September 2017, six patients - were enrolled. Five received stereotactic radiation therapy to their primary - lesions. All patients received nivolumab on the following day after stereotactic - radiation therapy completion. Grade 3 pneumonitis occurred in one patient, but no - other serious adverse events were reported for the other patients. One complete - response and two partial responses were achieved. Four patients had measurable - lesions outside the irradiated area, of whom three patients responded to the - treatment. The initial progression sites were mainly outside the irradiated - field, including one brain metastasis. CONCLUSIONS: Nivolumab therapy immediately - following stereotactic radiation therapy was well tolerated. This sequential - combination warrants further study. -FAU - Miyamoto, Shingo -AU - Miyamoto S -AD - Department of Medical Oncology, Japanese Red Cross Medical Center, Shibuya, - Tokyo, Japan. -FAU - Nomura, Ryutaro -AU - Nomura R -AD - CyberKnife Center, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan. -FAU - Sato, Kengo -AU - Sato K -AD - CyberKnife Center, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan. -FAU - Awano, Nobuyasu -AU - Awano N -AD - Department of Respiratory Medicine, Japanese Red Cross Medical Center, Shibuya, - Tokyo, Japan. -FAU - Kuse, Naoyuki -AU - Kuse N -AD - Department of Respiratory Medicine, Japanese Red Cross Medical Center, Shibuya, - Tokyo, Japan. -FAU - Inomata, Minoru -AU - Inomata M -AD - Department of Respiratory Medicine, Japanese Red Cross Medical Center, Shibuya, - Tokyo, Japan. -FAU - Izumo, Takehiro -AU - Izumo T -AD - Department of Respiratory Medicine, Japanese Red Cross Medical Center, Shibuya, - Tokyo, Japan. -FAU - Terada, Yuriko -AU - Terada Y -AD - Department of Thoracic Surgery, Japanese Red Cross Medical Center, Shibuya, - Tokyo, Japan. -FAU - Furuhata, Yoshiaki -AU - Furuhata Y -AD - Department of Thoracic Surgery, Japanese Red Cross Medical Center, Shibuya, - Tokyo, Japan. -FAU - Bae, Yuan -AU - Bae Y -AD - Department of Pathology, Japanese Red Cross Medical Center, Shibuya, Tokyo, - Japan. -FAU - Kunitoh, Hideo -AU - Kunitoh H -AD - Department of Medical Oncology, Japanese Red Cross Medical Center, Shibuya, - Tokyo, Japan. -LA - eng -PT - Clinical Trial -PT - Journal Article -PL - England -TA - Jpn J Clin Oncol -JT - Japanese journal of clinical oncology -JID - 0313225 -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Aged -MH - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/*drug - therapy/pathology/*radiotherapy -MH - Cohort Studies -MH - Combined Modality Therapy -MH - Female -MH - Humans -MH - Lung Neoplasms/diagnostic imaging/*drug therapy/pathology/*radiotherapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Nivolumab/adverse effects/*therapeutic use -MH - *Radiosurgery/adverse effects -MH - Tomography, X-Ray Computed -MH - Treatment Outcome -EDAT- 2018/11/20 06:00 -MHDA- 2019/03/09 06:00 -CRDT- 2018/11/20 06:00 -PHST- 2018/06/27 00:00 [received] -PHST- 2018/10/31 00:00 [accepted] -PHST- 2018/11/20 06:00 [pubmed] -PHST- 2019/03/09 06:00 [medline] -PHST- 2018/11/20 06:00 [entrez] -AID - 5185662 [pii] -AID - 10.1093/jjco/hyy171 [doi] -PST - ppublish -SO - Jpn J Clin Oncol. 2019 Feb 1;49(2):160-164. doi: 10.1093/jjco/hyy171. - -PMID- 36384755 -OWN - NLM -STAT- MEDLINE -DCOM- 20221121 -LR - 20221121 -IS - 1748-717X (Electronic) -IS - 1748-717X (Linking) -VI - 17 -IP - 1 -DP - 2022 Nov 16 -TI - CT radiomics-based long-term survival prediction for locally advanced non-small - cell lung cancer patients treated with concurrent chemoradiotherapy using - features from tumor and tumor organismal environment. -PG - 184 -LID - 10.1186/s13014-022-02136-w [doi] -LID - 184 -AB - BACKGROUND: Definitive concurrent chemoradiotherapy (CCRT) is the standard - treatment for locally advanced non-small cell lung cancer (LANSCLC) patients, but - the treatment response and survival outcomes varied among these patients. We - aimed to identify pretreatment computed tomography-based radiomics features - extracted from tumor and tumor organismal environment (TOE) for long-term - survival prediction in these patients treated with CCRT. METHODS: A total of 298 - eligible patients were randomly assigned into the training cohort and validation - cohort with a ratio 2:1. An integrated feature selection and model training - approach using support vector machine combined with genetic algorithm was - performed to predict 3-year overall survival (OS). Patients were stratified into - the high-risk and low-risk group based on the predicted survival status. - Pulmonary function test and blood gas analysis indicators were associated with - radiomic features. Dynamic changes of peripheral blood lymphocytes counts before - and after CCRT had been documented. RESULTS: Nine features including 5 - tumor-related features and 4 pulmonary features were selected in the predictive - model. The areas under the receiver operating characteristic curve for the - training and validation cohort were 0.965 and 0.869, and were reduced by 0.179 - and 0.223 when all pulmonary features were excluded. Based on radiomics-derived - stratification, the low-risk group yielded better 3-year OS (68.4% vs. 3.3%, - p < 0.001) than the high-risk group. Patients in the low-risk group had better - baseline FEV1/FVC% (96.3% vs. 85.9%, p = 0.046), less Grade ≥ 3 lymphopenia - during CCRT (63.2% vs. 83.3%, p = 0.031), better recovery of lymphopenia from - CCRT (71.4% vs. 27.8%, p < 0.001), lower incidence of Grade ≥ 2 radiation-induced - pneumonitis (31.6% vs. 53.3%, p = 0.040), superior tumor remission (84.2% vs. - 66.7%, p = 0.003). CONCLUSION: Pretreatment radiomics features from tumor and TOE - could boost the long-term survival forecast accuracy in LANSCLC patients, and the - predictive results could be utilized as an effective indicator for survival risk - stratification. Low-risk patients might benefit more from radical CCRT and - further adjuvant immunotherapy. TRIAL REGISTRATION: retrospectively registered. -CI - © 2022. The Author(s). -FAU - Chen, Nai-Bin -AU - Chen NB -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, No.651 Dongfeng Road East, 510060, Guangzhou, China. -FAU - Xiong, Mai -AU - Xiong M -AD - Department of Cardiac Surgery, The First Affiliated Hospital of Sun Yat-sen - University, Guangzhou, Guangdong, China. -FAU - Zhou, Rui -AU - Zhou R -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, No.651 Dongfeng Road East, 510060, Guangzhou, China. -FAU - Zhou, Yin -AU - Zhou Y -AD - Homology Medical Technologies Inc., Ningbo, Zhejiang, China. -FAU - Qiu, Bo -AU - Qiu B -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, No.651 Dongfeng Road East, 510060, Guangzhou, China. -FAU - Luo, Yi-Feng -AU - Luo YF -AD - Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital - of Sun Yat-sen University, Guangzhou, Guangdong, China. -FAU - Zhou, Su -AU - Zhou S -AD - Guangzhou Xinhua University, Guangzhou, Guangdong, China. -FAU - Chu, Chu -AU - Chu C -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, No.651 Dongfeng Road East, 510060, Guangzhou, China. -FAU - Li, Qi-Wen -AU - Li QW -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, No.651 Dongfeng Road East, 510060, Guangzhou, China. -FAU - Wang, Bin -AU - Wang B -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, No.651 Dongfeng Road East, 510060, Guangzhou, China. -FAU - Jiang, Hai-Hang -AU - Jiang HH -AD - Homology Medical Technologies Inc., Ningbo, Zhejiang, China. -FAU - Guo, Jin-Yu -AU - Guo JY -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, No.651 Dongfeng Road East, 510060, Guangzhou, China. -FAU - Peng, Kang-Qiang -AU - Peng KQ -AD - Department of Imaging Diagnosis and Interventional Center, State Key Laboratory - of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, - Sun Yat-sen University Cancer Center, No.651 Dongfeng Road East, 510060, - Guangzhou, Guangdong, China. -FAU - Xie, Chuan-Miao -AU - Xie CM -AD - Department of Imaging Diagnosis and Interventional Center, State Key Laboratory - of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, - Sun Yat-sen University Cancer Center, No.651 Dongfeng Road East, 510060, - Guangzhou, Guangdong, China. xiechm@sysucc.org.cn. -FAU - Liu, Hui -AU - Liu H -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen - University Cancer Center, No.651 Dongfeng Road East, 510060, Guangzhou, China. - liuhuisysucc@126.com. -LA - eng -GR - 2018YFC0116800/National Key R&D Program of China/ -GR - SYS2018009/Suzhou Municipal Science and Technology Program/ -GR - 82073328/National Natural Science Foundation of China/ -PT - Journal Article -PT - Randomized Controlled Trial -DEP - 20221116 -PL - England -TA - Radiat Oncol -JT - Radiation oncology (London, England) -JID - 101265111 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/diagnostic imaging/therapy -MH - Prognosis -MH - *Lung Neoplasms/diagnostic imaging/therapy -MH - Chemoradiotherapy/adverse effects/methods -MH - Tomography, X-Ray Computed/methods -MH - *Lymphopenia -PMC - PMC9667605 -OTO - NOTNLM -OT - Locally advanced non-small cell lung cancer -OT - Long-term survival prediction -OT - Machine learning -OT - Radiomics -OT - Tumor organismal environment. -COIS- The authors declare that they have no competing interests. -EDAT- 2022/11/18 06:00 -MHDA- 2022/11/22 06:00 -PMCR- 2022/11/16 -CRDT- 2022/11/17 09:58 -PHST- 2022/06/07 00:00 [received] -PHST- 2022/09/28 00:00 [accepted] -PHST- 2022/11/17 09:58 [entrez] -PHST- 2022/11/18 06:00 [pubmed] -PHST- 2022/11/22 06:00 [medline] -PHST- 2022/11/16 00:00 [pmc-release] -AID - 10.1186/s13014-022-02136-w [pii] -AID - 2136 [pii] -AID - 10.1186/s13014-022-02136-w [doi] -PST - epublish -SO - Radiat Oncol. 2022 Nov 16;17(1):184. doi: 10.1186/s13014-022-02136-w. - -PMID- 34390218 -OWN - NLM -STAT- MEDLINE -DCOM- 20220223 -LR - 20220223 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 10 -IP - 18 -DP - 2021 Sep -TI - Three models that predict the efficacy of immunotherapy in Chinese patients with - advanced non-small cell lung cancer. -PG - 6291-6303 -LID - 10.1002/cam4.4171 [doi] -AB - BACKGROUND: Many tools have been developed to predict the efficacy of - immunotherapy, such as lung immune prognostic index (LIPI), EPSILoN [Eastern - Cooperative Oncology Group performance status (ECOG PS), smoking, liver - metastases, lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR)], - and modified lung immune predictive index (mLIPI) scores. The aim of this study - was to determine the ability of three predictive scores to predict the outcomes - in Chinese advanced non-small cell lung cancer (aNSCLC) patients treated with - immune checkpoint inhibitors (ICIs). METHODS: We retrospectively analyzed 429 - patients with aNSCLC treated with ICIs at our institution. The predictive ability - of these models was evaluated using area under the curve (AUC) in receiver - operating characteristic curve (ROC) analysis. Calibration was assessed using the - Hosmer-Lemeshow test (H-L test) and Spearman's correlation coefficient. - Progression-free survival (PFS) and overall survival (OS) curves were generated - using the Kaplan-Meier method. RESULTS: The AUC values of LIPI, mLIPI, and - EPSILoN scores predicting PFS at 6 months were 0.642 [95% confidence interval - (CI):0.590-0.694], 0.720 (95% CI: 0.675-0.762), and 0.633 (95% CI: 0.585-0.679), - respectively (p < 0.001 for all models). The AUC values of LIPI, mLIPI, and - EPSILON scores predicting objective response rate (ORR) were 0.606 (95% CI: - 0.546-0.665), 0.683 (95% CI: 0.637-0.727), and 0.666 (95% CI: 0.620-0.711), - respectively (p < 0.001 for all models). The C-indexes of LIPI, mLIPI, and - EPSILoN scores for PFS were 0.627 (95% CI 0.611-6.643), 0.677 (95% CI - 0.652-0.682), and 0.631 (95% CI 0.617-0.645), respectively. CONCLUSIONS: As mLIPI - scores had the highest accuracy when used to predict the outcomes in Chinese - aNSCLC patients, this tool could be used to guide clinical immunotherapy - decision-making. -CI - © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Zhao, Qian -AU - Zhao Q -AD - Cheeloo College of Medicine, Shandong University, Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute - (Shandong Cancer Hospital, Shandong First Medical University and Shandong Academy - of Medical Sciences, Jinan, China. -FAU - Li, Butuo -AU - Li B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute - (Shandong Cancer Hospital, Shandong First Medical University and Shandong Academy - of Medical Sciences, Jinan, China. -FAU - Xu, Yiyue -AU - Xu Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute - (Shandong Cancer Hospital, Shandong First Medical University and Shandong Academy - of Medical Sciences, Jinan, China. -FAU - Wang, Shijiang -AU - Wang S -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute - (Shandong Cancer Hospital, Shandong First Medical University and Shandong Academy - of Medical Sciences, Jinan, China. -FAU - Zou, Bing -AU - Zou B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute - (Shandong Cancer Hospital, Shandong First Medical University and Shandong Academy - of Medical Sciences, Jinan, China. -FAU - Yu, Jinming -AU - Yu J -AD - Cheeloo College of Medicine, Shandong University, Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute - (Shandong Cancer Hospital, Shandong First Medical University and Shandong Academy - of Medical Sciences, Jinan, China. -FAU - Wang, Linlin -AU - Wang L -AUID- ORCID: 0000-0002-2231-6642 -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute - (Shandong Cancer Hospital, Shandong First Medical University and Shandong Academy - of Medical Sciences, Jinan, China. -LA - eng -GR - 2019ZL002/The Innovation Project of Shandong Academy of Medical Sciences/ -PT - Comparative Study -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20210813 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Aged -MH - Carcinoma, Non-Small-Cell Lung/diagnosis/*drug therapy/mortality -MH - China/epidemiology -MH - Feasibility Studies -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Kaplan-Meier Estimate -MH - Lung Neoplasms/diagnosis/*drug therapy/mortality -MH - Male -MH - Middle Aged -MH - Prognosis -MH - Progression-Free Survival -MH - ROC Curve -MH - Retrospective Studies -MH - Risk Assessment/methods -PMC - PMC8446565 -OTO - NOTNLM -OT - immunotherapy -OT - non-small cell lung cancer (NSCLC) -OT - predictive -OT - score -COIS- The authors have no conflict of interest to declare. -EDAT- 2021/08/15 06:00 -MHDA- 2022/02/24 06:00 -PMCR- 2021/08/13 -CRDT- 2021/08/14 06:43 -PHST- 2021/06/30 00:00 [revised] -PHST- 2020/10/18 00:00 [received] -PHST- 2021/07/01 00:00 [accepted] -PHST- 2021/08/15 06:00 [pubmed] -PHST- 2022/02/24 06:00 [medline] -PHST- 2021/08/14 06:43 [entrez] -PHST- 2021/08/13 00:00 [pmc-release] -AID - CAM44171 [pii] -AID - 10.1002/cam4.4171 [doi] -PST - ppublish -SO - Cancer Med. 2021 Sep;10(18):6291-6303. doi: 10.1002/cam4.4171. Epub 2021 Aug 13. - -PMID- 33796915 -OWN - NLM -STAT- MEDLINE -DCOM- 20211015 -LR - 20240426 -IS - 1432-0851 (Electronic) -IS - 0340-7004 (Print) -IS - 0340-7004 (Linking) -VI - 70 -IP - 11 -DP - 2021 Nov -TI - Assessment of systematic inflammatory and nutritional indexes in extensive-stage - small-cell lung cancer treated with first-line chemotherapy and atezolizumab. -PG - 3199-3206 -LID - 10.1007/s00262-021-02926-3 [doi] -AB - BACKGROUND: The present study aims to investigate the prognostic role of - systematic inflammatory and nutritional indexes in extensive-stage small-cell - lung cancer (ES-SCLC) treated with first-line chemotherapy and atezolizumab. - MATERIALS AND METHODS: Prospective cohort population involving 53 patients were - identified from NCT03041311 trial. The following peripheral blood-derived - inflammatory and nutritional indexes, including neutrophil-lymphocyte ratio - (NLR), platelet lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), systemic - immune-inflammation index (SII), systemic inflammation response index (SIRI), - prognostic nutrition index (PNI), advanced lung cancer inflammation index (ALI), - and lung immune prognostic index (LIPI) were evaluated. RESULTS: The optimal - cut-off values of the ALI, LMR, NLR, PLR, PNI, SII and SIRI were 323.23, 2.73, - 2.57, 119.23, 48, 533.28 and 2.32, respectively. With a median follow-up of - 17.1 months, the 1-year OS and PFS were 56% and 8%, respectively. Multivariate - analysis showed that PLR was the only independent prognostic factors for OS among - ES-SCLC patients treated with chemotherapy and atezolizumab (HR 4.63, 95%CI: - 1.00-21.46, p = 0.05). K-M analysis showed that the OS and PFS for patients with - high PLR (> 119.23) were significantly poorer than these with low PLR (≤ 119.23) - (p = 0.0004 for OS and p = 0.014 for PFS). In external validation set, prognosis - of patients with high PLR was also significantly poorer than these with low PLR - in terms of OS (p = 0.038) and PFS (p = 0.028). CONCLUSION: Pre-treatment PLR - could serve as a valuable independent prognostic factor for ES-SCLC who receive - chemotherapy and immune checkpoint inhibitors. Further, prospective studies are - still needed to confirm our findings. -CI - © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, - part of Springer Nature. -FAU - Qi, Wei-Xiang -AU - Qi WX -AD - Department of Radiation Oncology, Rui Jin Hospital, Shanghai Jiao Tong University - School of Medicine, Shanghai, China. -FAU - Xiang, Yi -AU - Xiang Y -AD - Department of Respiration and Critical Care Medicine, Rui Jin Hospital, Shanghai - Jiao Tong University School of Medicine, Shanghai, China. -FAU - Zhao, Shengguang -AU - Zhao S -AUID- ORCID: 0000-0001-7116-692X -AD - Department of Radiation Oncology, Rui Jin Hospital, Shanghai Jiao Tong University - School of Medicine, Shanghai, China. qwx12055@rjh.com.cn. -FAU - Chen, Jiayi -AU - Chen J -AD - Department of Radiation Oncology, Rui Jin Hospital, Shanghai Jiao Tong University - School of Medicine, Shanghai, China. chenjiayi0188@aliyun.com. -LA - eng -PT - Journal Article -DEP - 20210401 -PL - Germany -TA - Cancer Immunol Immunother -JT - Cancer immunology, immunotherapy : CII -JID - 8605732 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 52CMI0WC3Y (atezolizumab) -SB - IM -MH - Adult -MH - Aged -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Female -MH - Humans -MH - *Inflammation -MH - Leukocyte Count -MH - Lung Neoplasms/*drug therapy -MH - Male -MH - Middle Aged -MH - *Nutrition Assessment -MH - Prognosis -MH - Small Cell Lung Carcinoma/*drug therapy -MH - Treatment Outcome -PMC - PMC10991671 -OTO - NOTNLM -OT - Atezolizumab -OT - Platelet lymphocyte ratio -OT - Prognosis -OT - Small-cell lung cancer -COIS- The author declares that they have no conflict of interest. -EDAT- 2021/04/03 06:00 -MHDA- 2021/10/16 06:00 -PMCR- 2021/04/01 -CRDT- 2021/04/02 06:42 -PHST- 2021/01/12 00:00 [received] -PHST- 2021/03/23 00:00 [accepted] -PHST- 2021/04/03 06:00 [pubmed] -PHST- 2021/10/16 06:00 [medline] -PHST- 2021/04/02 06:42 [entrez] -PHST- 2021/04/01 00:00 [pmc-release] -AID - 10.1007/s00262-021-02926-3 [pii] -AID - 2926 [pii] -AID - 10.1007/s00262-021-02926-3 [doi] -PST - ppublish -SO - Cancer Immunol Immunother. 2021 Nov;70(11):3199-3206. doi: - 10.1007/s00262-021-02926-3. Epub 2021 Apr 1. - -PMID- 36259253 -OWN - NLM -STAT- MEDLINE -DCOM- 20221205 -LR - 20240908 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 13 -IP - 23 -DP - 2022 Dec -TI - A phase II, multicenter study of lazertinib as consolidation therapy in patients - with locally advanced, unresectable, EGFR mutation-positive non-small cell lung - cancer (stage III) who have not progressed following definitive, platinum-based, - chemoradiation therapy (PLATINUM trial). -PG - 3431-3435 -LID - 10.1111/1759-7714.14663 [doi] -AB - INTRODUCTION: The PACIFIC study demonstrated that durvalumab consolidation - therapy significantly improved progression-free survival (PFS) and overall - survival (OS) in patients with unresectable stage III non-small cell lung cancer - (NSCLC) after concurrent chemoradiotherapy (CCRT). However, there was no clinical - benefit in both PFS and OS in epidermal growth factor receptor (EGFR) - mutation-positive patient groups in a post hoc exploratory analysis. Moreover, - the clinical effects of immune checkpoint inhibitors (ICIs) in EGFR - mutation-positive stage IV NSCLC were demonstrated to be poor. Personalized - treatment according to the mutation status is also required in stage III NSCLC. - Lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is newly - developed and approved for use in Korea. METHODS: This prospective, open, - single-arm, multicenter, phase II clinical trial aims to evaluate the efficacy - and safety of lazertinib as a consolidative therapy after CCRT treatment in - unresectable, EGFR mutation-positive NSCLC stage III patients. The primary - endpoint of this study is PFS, and the secondary endpoints are OS, objective - response rate (ORR), duration of response (DoR), time to death or distant - metastasis (TTDM), and safety profiles. DISCUSSION: Our study may extend the - indications for third-generation EGFR-TKIs to treat patients with stage III - NSCLC. Moreover, using this drug to treat stage III NSCLC would emphasize the - value of mutation analysis and personalized medicine. -CI - © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Choi, Juwhan -AU - Choi J -AD - Division of Pulmonary, Allergy, and Critical Care Medicine, Department of - Internal Medicine, Korea University Guro Hospital, Korea University College of - Medicine, Seoul, Republic of Korea. -FAU - Lee, Jeong Eun -AU - Lee JE -AUID- ORCID: 0000-0001-9566-7489 -AD - Division of Pulmonology, Department of Internal Medicine, College of Medicine, - Chungnam National University, Daejeon, Republic of Korea. -FAU - Choi, Chang-Min -AU - Choi CM -AUID- ORCID: 0000-0002-2881-4669 -AD - Department of Pulmonary and Critical Care Medicine, Asan Medical Center, - University of Ulsan College of Medicine, Seoul, Republic of Korea. -FAU - Oh, In-Jae -AU - Oh IJ -AUID- ORCID: 0000-0003-4837-1321 -AD - Department of Internal Medicine, Chonnam National University Medical School and - Hwasun Hospital, Hwasun, Republic of Korea. -FAU - Lee, Kye Young -AU - Lee KY -AD - Department of Pulmonary Medicine, Konkuk University School of Medicine, Seoul, - Republic of Korea. -FAU - Jang, Tae Won -AU - Jang TW -AD - Department of Internal Medicine, Kosin University Medical College, Pusan, - Republic of Korea. -FAU - Lee, Seung Hyeun -AU - Lee SH -AUID- ORCID: 0000-0002-7666-313X -AD - Division of Pulmonary and Critical Care Medicine, Department of Internal - Medicine, Kyung Hee University Medical Center, Kyung Hee University College of - Medicine, Seoul, Republic of Korea. -FAU - Kim, Eun Young -AU - Kim EY -AD - Division of Pulmonology, Department of Internal Medicine, Severance Hospital, - Yonsei University College of Medicine, Seoul, Republic of Korea. -FAU - Park, Dong Won -AU - Park DW -AD - Department of Internal Medicine Hanyang University Hospital, Hanyang University - College of Medicine, Seoul, Republic of Korea. -FAU - Park, Sun Hyo -AU - Park SH -AD - Division of Pulmonology, Respiratory Center, Keimyung University Dongsan - Hospital, Keimyung University School of Medicine, Daegu, Republic of Korea. -FAU - Lee, Sung Yong -AU - Lee SY -AUID- ORCID: 0000-0002-8693-5792 -AD - Division of Pulmonary, Allergy, and Critical Care Medicine, Department of - Internal Medicine, Korea University Guro Hospital, Korea University College of - Medicine, Seoul, Republic of Korea. -LA - eng -SI - ClinicalTrials.gov/NCT05338619 -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -DEP - 20221019 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 4A2Y23XK11 (lazertinib) -RN - 49DFR088MY (Platinum) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (EGFR protein, human) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Platinum/therapeutic use -MH - *Lung Neoplasms/drug therapy/genetics -MH - Prospective Studies -MH - Consolidation Chemotherapy -MH - ErbB Receptors/genetics/therapeutic use -MH - Protein Kinase Inhibitors/therapeutic use -MH - Chemoradiotherapy -MH - Mutation -PMC - PMC9715807 -OTO - NOTNLM -OT - EGFR -OT - chemoradiotherapy -OT - consolidation therapy -OT - lazertinib -COIS- The authors have no conflicts of interest to declare. -EDAT- 2022/10/20 06:00 -MHDA- 2022/12/06 06:00 -PMCR- 2022/12/01 -CRDT- 2022/10/19 04:03 -PHST- 2022/09/04 00:00 [revised] -PHST- 2022/07/20 00:00 [received] -PHST- 2022/09/05 00:00 [accepted] -PHST- 2022/10/20 06:00 [pubmed] -PHST- 2022/12/06 06:00 [medline] -PHST- 2022/10/19 04:03 [entrez] -PHST- 2022/12/01 00:00 [pmc-release] -AID - TCA14663 [pii] -AID - 10.1111/1759-7714.14663 [doi] -PST - ppublish -SO - Thorac Cancer. 2022 Dec;13(23):3431-3435. doi: 10.1111/1759-7714.14663. Epub 2022 - Oct 19. - -PMID- 33737339 -OWN - NLM -STAT- MEDLINE -DCOM- 20211217 -LR - 20211217 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 9 -IP - 3 -DP - 2021 Mar -TI - Primary results from TAIL: a global single-arm safety study of atezolizumab - monotherapy in a diverse population of patients with previously treated advanced - non-small cell lung cancer. -LID - 10.1136/jitc-2020-001865 [doi] -LID - e001865 -AB - BACKGROUND: Atezolizumab treatment improves survival, with manageable safety, in - patients with previously treated advanced/metastatic non-small cell lung cancer. - The global phase III/IV study TAIL (NCT03285763) was conducted to evaluate the - safety and efficacy of atezolizumab monotherapy in a clinically diverse - population of patients with previously treated non-small cell lung cancer, - including those not eligible for pivotal trials. METHODS: Patients with stage - IIIB/IV non-small cell lung cancer whose disease progressed after 1-2 lines of - chemotherapy were eligible for this open-label, single-arm, multicenter study, - including those with severe renal impairment, an Eastern Cooperative Oncology - Group performance status of 2, prior anti-programmed death 1 (PD-1) therapy, and - autoimmune disease. Atezolizumab was administered intravenously (1200 mg every 3 - weeks). Coprimary endpoints were treatment-related serious adverse events and - immune-related adverse events. RESULTS: 619 patients enrolled and 615 received - atezolizumab. At data cutoff, the median follow-up was 12.6 months (95% CI 11.9 - to 13.1). Treatment-related serious adverse events occurred in 7.8% and - immune-related adverse events in 8.3% of all patients and as follows, - respectively, in these subgroups: renal impairment (n=78), 11.5% and 12.8%; - Eastern Cooperative Oncology Group performance status of 2 (n=61), 14.8% and - 8.2%; prior anti-PD-1 therapy (n=39), 5.1% and 7.7%; and autoimmune disease - (n=30), 6.7% and 10.0%. No new safety signals were reported. In the overall - population, the median overall survival was 11.1 months (95% CI 8.9 to 12.9), the - median progression-free survival was 2.7 months (95% CI 2.1 to 2.8) and the - objective response rate was 11%. CONCLUSIONS: This study confirmed the - benefit-risk profile of atezolizumab monotherapy in a clinically diverse - population of patients with previously treated non-small cell lung cancer. These - safety and efficacy outcomes may inform treatment decisions for patients - generally excluded from checkpoint inhibitor trials. -CI - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Ardizzoni, Andrea -AU - Ardizzoni A -AUID- ORCID: 0000-0003-0623-4257 -AD - Department of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di - Bologna, Bologna, Italy andrea.ardizzoni@aosp.bo.it. -FAU - Azevedo, Sergio -AU - Azevedo S -AD - Oncology Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. -FAU - Rubio-Viqueira, Belen -AU - Rubio-Viqueira B -AD - Department of Medical Oncology, Hospital Universitario Quirónsalud Madrid, - Madrid, Spain. -FAU - Rodríguez-Abreu, Delvys -AU - Rodríguez-Abreu D -AD - Department of Medical Oncology, Hospital Universitario Insular de Gran Canaria, - Las Palmas, Canarias, Spain. -FAU - Alatorre-Alexander, Jorge -AU - Alatorre-Alexander J -AD - Thoracic Oncology Clinic, Health Pharma Professional Research, Mexico City, - Mexico. -FAU - Smit, Hans J M -AU - Smit HJM -AD - Department of Pulmonary Diseases, Rijnstate Hospital, Arnhem, The Netherlands. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital, affiliated to - Shandong University, Jinan, Shandong, China. -FAU - Syrigos, Konstantinos -AU - Syrigos K -AD - 3rd Department of Medicine, National and Kapodistrian University of Athens, - Athens, Attica, Greece. -FAU - Trunzer, Kerstin -AU - Trunzer K -AD - Department of Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, - Basel-Stadt, Switzerland. -FAU - Patel, Hina -AU - Patel H -AD - Department of Safety Science Oncology, Genentech Inc, South San Francisco, - California, USA. -FAU - Tolson, Jonathan -AU - Tolson J -AD - Department of Global Product Development, F. Hoffmann-La Roche Ltd, Basel, - Basel-Stadt, Switzerland. -FAU - Cardona, Andres -AU - Cardona A -AD - Department of Product Development Biometrics, F. Hoffmann-La Roche Ltd, Basel, - Basel-Stadt, Switzerland. -FAU - Perez-Moreno, Pablo D -AU - Perez-Moreno PD -AD - Department of Product Development, Genentech Inc, South San Francisco, - California, USA. -FAU - Newsom-Davis, Tom -AU - Newsom-Davis T -AD - Department of Oncology, Chelsea and Westminster Hospital, London, UK. -LA - eng -SI - ClinicalTrials.gov/NCT03285763 -PT - Clinical Trial, Phase III -PT - Clinical Trial, Phase IV -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 52CMI0WC3Y (atezolizumab) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors/immunology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/mortality/secondary -MH - Disease Progression -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects/*therapeutic use -MH - Lung Neoplasms/*drug therapy/immunology/mortality/pathology -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Progression-Free Survival -MH - Prospective Studies -MH - Time Factors -MH - Young Adult -PMC - PMC7978274 -OTO - NOTNLM -OT - PD-L1 inhibitor -OT - checkpoint inhibitor -OT - clinical trials -OT - immunotherapy -OT - lung neoplasms -OT - metastatic -OT - phase IIII clinical trial -OT - subgroup analysis -COIS- Competing interests: Support of the parent study and funding of editorial support - were provided by F. Hoffmann-La Roche/Genentech. AA is a consultant to Merck - Sharpe & Dohme, AstraZeneca, Bristol Myers Squibb, and F. Hoffmann-La Roche and - has received research funding from Bristol Myers Squibb, F. Hoffmann-La Roche, - and Celgene and honoraria from Eli Lilly and Pfizer. SA is a consultant to and - has received research funding, honoraria, and travel expenses from F. Hoffmann-La - Roche, Bristol Myers Squibb, and Celgene, is a consultant to Merck Sharpe & - Dohme, and has received research funding, travel expenses, and honoraria from - Novartis, Eli Lilly, and AstraZeneca. BRV is a consultant to Merck Sharpe & Dohme - and Eli Lilly and has received honoraria and travel expenses from F. Hoffmann-La - Roche, Eli Lilly, Bristol Myers Squibb and Merck Sharpe & Dohme. DR-A is an - advisor to and has received speaker honoraria from Bristol Myers Squibb, - Boehringer Ingelheim, Eli Lilly, Merck Sharpe & Dohme, F. Hoffmann-La Roche, - Pfizer, and AstraZeneca. JA-A is a consultant to, on a speaker bureau for, and - has received travel expenses from Merck Sharpe & Dohme, AstraZeneca, Pfizer, - Boehringer Ingelheim, Eli Lilly, Novartis, F. Hoffmann-La Roche, and Bristol - Myers Squibb. HJMS is a consultant to Merck Sharpe & Dohme, AstraZeneca, and - Bristol Myers Squibb and is secretary of the oncology section of NVALT (Dutch - lung physician’s organization) and president of the Dutch Lung Cancer Audit. JY - has nothing to disclose. KS is on a speaker bureau for Merck Sharpe & Dohme, has - received research funding from F. Hoffmann-La Roche and Novartis, has received - research funding and travel expenses from Bristol Myers Squibb, and has received - travel expenses from Genesis. KT, JT, and AC are employees of F. Hoffmann-La - Roche. HP and PP-M are employees of Genentech. TN-D is a consultant to Amgen, - Bayer, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck - Sharpe & Dohme, Novartis, Otsuka, Pfizer, Roche, and Takeda, and is on a speaker - bureau for AstraZeneca, Merck Sharpe & Dohme, F. Hoffmann-La Roche, and Takeda. -EDAT- 2021/03/20 06:00 -MHDA- 2021/12/18 06:00 -PMCR- 2021/03/18 -CRDT- 2021/03/19 06:34 -PHST- 2020/12/11 00:00 [accepted] -PHST- 2021/03/19 06:34 [entrez] -PHST- 2021/03/20 06:00 [pubmed] -PHST- 2021/12/18 06:00 [medline] -PHST- 2021/03/18 00:00 [pmc-release] -AID - jitc-2020-001865 [pii] -AID - 10.1136/jitc-2020-001865 [doi] -PST - ppublish -SO - J Immunother Cancer. 2021 Mar;9(3):e001865. doi: 10.1136/jitc-2020-001865. - -PMID- 36657815 -OWN - NLM -STAT- MEDLINE -DCOM- 20230123 -LR - 20230206 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 11 -IP - 1 -DP - 2023 Jan -TI - Venous thromboembolism incidence and risk factors associated with immune - checkpoint inhibitors among patients with advanced non-small cell lung cancer. -LID - 10.1136/jitc-2022-006072 [doi] -LID - e006072 -AB - BACKGROUND: Venous thromboembolism (VTE) is a significant cause of morbidity and - mortality in patients with lung cancer. Systemic therapies, such as chemotherapy - (chemo), are associated with increased risk of VTE. Immune checkpoint inhibitors - (ICIs) are a new standard of care for the treatment of lung cancer, but their - association with VTE is not fully understood. We evaluated the incidence of VTE - and risk factors for patients with advanced non-small cell lung cancer (aNSCLC) - treated with first-line ICI-based, chemo-based, or ICI+chemo regimens. METHODS: - This retrospective cohort study used HealthCore Integrated Research Environment - - Oncology data, an integrated database of administrative claims, coupled with - clinical data from a cancer-care quality program. Patients with first-line - treatment of stage IV non-small cell lung cancer from July 2014 to August 2020 - were grouped based on three treatment types: ICI-based, chemo-based, or - ICI+chemo. Patients with VTE before initiation of systemic treatment were - excluded. Newly diagnosed VTE events were identified via inpatient and outpatient - diagnosis codes. Cox proportional hazards models were used to investigate the - factors associated with VTE risk. RESULTS: Among 2299 eligible patients - (ICI-based, n=605; chemo-based, n=1092; ICI+chemo, n=602) with a median follow-up - of 9.1 months, the VTE incidence rates (95% CI) per 100 person-years were 17.8 - (95% CI 16.0 to 19.5) overall, 13.5 (95% CI 10.6 to 16.5) for ICI-based, 18.0 - (95% CI 15.5 to 20.5) for chemo-based, and 22.4 (95% CI 20.2 to 24.5) for - ICI+chemo. The 6-month cumulative incidence of VTE was 8.1% for ICI-based, 10.9% - for chemo-based, and 12.8% for ICI+chemo. Pulmonary embolism was most common, - accounting for 63% of the VTE events. After controlling for baseline patient - characteristics, the risk of VTE was 26% lower for ICI-based regimens than for - chemo-based regimens (HR 0.74, p=0.03). There was no meaningful difference in the - risk between ICI+chemo and chemo-based regimens (HR 1.12, p=0.36). Previous - radiation and severe obesity (body mass index ≥40) were associated with VTE. - CONCLUSIONS: VTE incidence rate per 100 person-years was common across regimens - in patients with aNSCLC, but numerically lower for patients receiving ICI-based - regimens compared with those receiving chemo-based and ICI+chemo regimens. VTE is - a common complication of lung cancer, and there is a continued need for awareness - of VTE as a comorbidity in this population. -CI - © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Khorana, Alok A -AU - Khorana AA -AUID- ORCID: 0000-0002-9509-0998 -AD - Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio, - USA khorana@ccf.org. -FAU - Palaia, Jennell -AU - Palaia J -AD - Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, - Princeton, New Jersey, USA. -FAU - Rosenblatt, Lisa -AU - Rosenblatt L -AD - Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, - Princeton, New Jersey, USA. -FAU - Pisupati, Radhika -AU - Pisupati R -AD - US Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey, USA. -FAU - Huang, Ning -AU - Huang N -AD - Worldwide Patient Safety: Medical Safety Assessment, Bristol Myers Squibb, - Princeton, New Jersey, USA. -FAU - Nguyen, Chi -AU - Nguyen C -AD - Health Economics and Outcomes Research, HealthCore Inc, Wilmington, Delaware, - USA. -FAU - Barron, John -AU - Barron J -AD - Health Economics and Outcomes Research, HealthCore Inc, Wilmington, Delaware, - USA. -FAU - Gallagher, Kerrin -AU - Gallagher K -AD - Health Economics and Outcomes Research, HealthCore Inc, Wilmington, Delaware, - USA. -FAU - Bond, T Christopher -AU - Bond TC -AD - Worldwide Patient Safety: Epidemiology, Bristol Myers Squibb, Princeton, New - Jersey, USA. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/complications/drug therapy/epidemiology -MH - *Venous Thromboembolism/chemically induced/epidemiology -MH - Incidence -MH - *Lung Neoplasms/complications/drug therapy/epidemiology -MH - Immune Checkpoint Inhibitors/adverse effects -MH - Retrospective Studies -MH - Risk Factors -PMC - PMC9853260 -OTO - NOTNLM -OT - Immunotherapy -OT - Lung Neoplasms -OT - Programmed Cell Death 1 Receptor -COIS- Competing interests: AAK reports funding to conduct the study of current - manuscript from Bristol Myers Squibb (BMS); consulting fees from Janssen, Bayer, - BMS, Pfizer, Sanofi, and Anthos; honoraria from WebMD CME; travel support from - Bayer, Pfizer, Sanofi, and Anthos; and an unpaid leadership role as chair from - MASAB of NBCA. NH and KG received funding (institutional) to conduct the study of - the current manuscript from BMS. KG was an employee of HealthCore when the paper - was written. JB reports stock ownership in Anthem. JP, LR, RP, NH, and TCB are - employed by and have stock ownership in BMS. -EDAT- 2023/01/20 06:00 -MHDA- 2023/01/24 06:00 -PMCR- 2023/01/19 -CRDT- 2023/01/19 20:52 -PHST- 2022/12/22 00:00 [accepted] -PHST- 2023/01/19 20:52 [entrez] -PHST- 2023/01/20 06:00 [pubmed] -PHST- 2023/01/24 06:00 [medline] -PHST- 2023/01/19 00:00 [pmc-release] -AID - jitc-2022-006072 [pii] -AID - 10.1136/jitc-2022-006072 [doi] -PST - ppublish -SO - J Immunother Cancer. 2023 Jan;11(1):e006072. doi: 10.1136/jitc-2022-006072. - -PMID- 29567824 -OWN - NLM -STAT- MEDLINE -DCOM- 20190920 -LR - 20190920 -IS - 1549-490X (Electronic) -IS - 1083-7159 (Print) -IS - 1083-7159 (Linking) -VI - 23 -IP - 8 -DP - 2018 Aug -TI - Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced - Non-Small Cell Lung Cancer Patients. -PG - 936-942 -LID - 10.1634/theoncologist.2017-0452 [doi] -AB - BACKGROUND: Rare cases of severe myocarditis are reported during treatment with - nivolumab. Troponin, a biomarker of cardiac damage, is a key component of the - diagnostic workup of many cardiac disorders, including myocarditis. This study - investigates the role of troponin to assess cardiac involvement during nivolumab - therapy for non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We - evaluated 59 NSCLC patients, analyzing serum samples collected within a - translational research study. Troponin above the upper normal limit (0.046 ng/mL) - was defined as Tn+, whereas normal but detectable troponin (0.015-0.045) was - defined as Tn(det). Troponin alterations were interpreted on the grounds of the - following elements: peak values and time curve, cardiac comorbidities, signs and - symptoms coincident to troponin elevation, ECG, echocardiography, and disease - progression. RESULTS: No patient had cardiovascular events. Among 362 available - blood samples, Tn+ (max 0.317 ng/mL) was found in 13 determinations belonging to - 6 patients. Seven other patients had isolated Tn(det). In five patients, Tn+ was - attributed to cardiac comorbidities, disease progression, or worsening clinical - status. One patient without cardiac history and in good clinical condition had a - sustained troponin increase-soon after the start of therapy-and after careful - evaluation of all relevant elements, it was interpreted as a marker of - nivolumab-related subclinical myocarditis. CONCLUSION: Tn+ may occur in NSCLC - patients treated with nivolumab, but in most cases it does not indicate nivolumab - cardiotoxicity. In some cases, however, a careful interpretation of troponin - alteration, especially at the beginning of therapy, enables identification of - subclinical myocarditis, thus allowing early cardiac treatment. IMPLICATIONS FOR - PRACTICE: Myocarditis is a rare but serious adverse event of immune checkpoint - blockade with nivolumab, which needs to be recognized as soon as possible. This - article suggests that troponin, a user-friendly biomarker of myocardial - cytotoxicity, might be useful for early detection of immune-mediated myocarditis. - However, because troponin abnormalities might also be related to a number of - conditions capable of causing myocardial oxygen demand-supply mismatch, a careful - cardiac assessment should be performed in non-small cell lung cancer patients in - order to properly interpret any troponin increase. According to the available - evidence, monitoring troponin during the first weeks of treatment can be - considered reasonable. -CI - © AlphaMed Press 2018. -FAU - Sarocchi, Matteo -AU - Sarocchi M -AUID- ORCID: 0000-0002-8132-8715 -AD - Cardiovascular Disease Unit, San Martino Policlinic Hospital, Genoa, Italy. -AD - Department of Internal Medicine, University of Genoa, Genoa, Italy. -FAU - Grossi, Francesco -AU - Grossi F -AD - Lung Cancer Unit, San Martino Policlinic Hospital, Genoa, Italy. -FAU - Arboscello, Eleonora -AU - Arboscello E -AD - Internal Medicine Unit, San Martino Policlinic Hospital, Genoa, Italy. -FAU - Bellodi, Andrea -AU - Bellodi A -AD - Internal Medicine Unit, San Martino Policlinic Hospital, Genoa, Italy. -FAU - Genova, Carlo -AU - Genova C -AD - Lung Cancer Unit, San Martino Policlinic Hospital, Genoa, Italy. -AD - Department of Internal Medicine, University of Genoa, Genoa, Italy. -FAU - Dal Bello, Maria Giovanna -AU - Dal Bello MG -AD - Lung Cancer Unit, San Martino Policlinic Hospital, Genoa, Italy. -FAU - Rijavec, Erika -AU - Rijavec E -AD - Lung Cancer Unit, San Martino Policlinic Hospital, Genoa, Italy. -FAU - Barletta, Giulia -AU - Barletta G -AD - Lung Cancer Unit, San Martino Policlinic Hospital, Genoa, Italy. -FAU - Rossi, Giovanni -AU - Rossi G -AD - Lung Cancer Unit, San Martino Policlinic Hospital, Genoa, Italy. -FAU - Biello, Federica -AU - Biello F -AD - Lung Cancer Unit, San Martino Policlinic Hospital, Genoa, Italy. -FAU - Ghigliotti, Giorgio -AU - Ghigliotti G -AD - Cardiovascular Disease Unit, San Martino Policlinic Hospital, Genoa, Italy. -AD - Department of Internal Medicine, University of Genoa, Genoa, Italy. -FAU - Canepa, Marco -AU - Canepa M -AD - Cardiovascular Disease Unit, San Martino Policlinic Hospital, Genoa, Italy. -AD - Department of Internal Medicine, University of Genoa, Genoa, Italy. -FAU - Mussap, Michele -AU - Mussap M -AD - Laboratory Medicine Unit, San Martino Policlinic Hospital, Genoa, Italy. -FAU - Brunelli, Claudio -AU - Brunelli C -AD - Cardiovascular Disease Unit, San Martino Policlinic Hospital, Genoa, Italy. -AD - Department of Internal Medicine, University of Genoa, Genoa, Italy. -FAU - Spallarossa, Paolo -AU - Spallarossa P -AD - Cardiovascular Disease Unit, San Martino Policlinic Hospital, Genoa, Italy - paolo.spallarossa@unige.it. -LA - eng -PT - Journal Article -DEP - 20180322 -PL - England -TA - Oncologist -JT - The oncologist -JID - 9607837 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Troponin) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antineoplastic Agents, Immunological/pharmacology/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Cardiotoxicity -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology -MH - Male -MH - Middle Aged -MH - Nivolumab/pharmacology/*therapeutic use -MH - Troponin/*blood -PMC - PMC6156175 -OTO - NOTNLM -OT - Cardiotoxicity -OT - Immunotherapy -OT - Lung cancer -OT - Nivolumab -OT - Troponin -COIS- Disclosures of potential conflicts of interest may be found at the end of this - article. -EDAT- 2018/03/24 06:00 -MHDA- 2019/09/21 06:00 -PMCR- 2019/08/01 -CRDT- 2018/03/24 06:00 -PHST- 2017/09/12 00:00 [received] -PHST- 2018/02/06 00:00 [accepted] -PHST- 2018/03/24 06:00 [pubmed] -PHST- 2019/09/21 06:00 [medline] -PHST- 2018/03/24 06:00 [entrez] -PHST- 2019/08/01 00:00 [pmc-release] -AID - theoncologist.2017-0452 [pii] -AID - ONCO12418 [pii] -AID - 10.1634/theoncologist.2017-0452 [doi] -PST - ppublish -SO - Oncologist. 2018 Aug;23(8):936-942. doi: 10.1634/theoncologist.2017-0452. Epub - 2018 Mar 22. - -PMID- 27650132 -OWN - NLM -STAT- MEDLINE -DCOM- 20170711 -LR - 20181202 -IS - 1744-7682 (Electronic) -IS - 1471-2598 (Linking) -VI - 16 -IP - 12 -DP - 2016 Dec -TI - Immunotherapy of non-small cell lung cancer: report from an international experts - panel meeting of the Italian association of thoracic oncology. -PG - 1479-1489 -AB - The potential long term survival gain, related to immune adaptability and memory, - the potential activity across multiple tumour types through targeting the immune - system, and the opportunity for combinations offered by the unique mechanism of - actions and safety profile of these new agents, all support the role of - immunotherapy in the cancer treatment pathway or paradigm. Areas covered: The - authors discuss the recent advances in the understanding of immunology and - antitumor immune responses that have led to the development of new - immunotherapies, including monoclonal antibodies that inhibit immune checkpoint - pathways, such as Programmed Death-1 (PD-1) and Cytotoxic T-Lymphocyte-Associated - Antigen 4 (CTLA-4). Currently, two PD-1 inhibitors are available in clinical - practice for treatment of advanced non-small cell lung cancer (NSCLC): nivolumab - and pembrolizumab. Expert opinion: Ongoing research will dictate future - strategies, including the potential incorporation of immunotherapy in stage - dependent treatment settings (early stage locally advanced disease and first line - therapy for metastatic disease). Immunotherapy combinations are promising - avenues, and careful selection of patients, doses of each agent and information - supporting strategies (i.e. concomitant or sequential) is still needed. -FAU - Gridelli, Cesare -AU - Gridelli C -AD - a Division of Medical Oncology , 'S. G. Moscati' Hospital , Avellino , Italy. -FAU - Ascierto, Paolo A -AU - Ascierto PA -AD - b Melanoma Unit, Cancer Immunotherapy and Innovative Therapy , Istituto Nazionale - Tumori Fondazione 'G. Pascale' , Napoli , Italy. -FAU - Barberis, Massimo C P -AU - Barberis MC -AD - c Pathology , European Institute of Oncology , Milan , Italy. -FAU - Felip, Enriqueta -AU - Felip E -AD - d Lung Cancer Unit, Oncology Department , Vall d'Hebron University Hospital , - Barcelona , Spain. -FAU - Garon, Edward B -AU - Garon EB -AD - e Department of Hematology/Oncology , David Geffen School of Medicine at the - University of California , Los Angeles , CA , USA. -FAU - O'brien, Mary -AU - O'brien M -AD - f Department of Medicine , Royal Marsden NHS Foundation Trust , London , UK. -FAU - Senan, Suresh -AU - Senan S -AD - g Department of Radiation Oncology , VU University Medical Center , Amsterdam , - The Netherlands. -FAU - Casaluce, Francesca -AU - Casaluce F -AD - a Division of Medical Oncology , 'S. G. Moscati' Hospital , Avellino , Italy. -FAU - Sgambato, Assunta -AU - Sgambato A -AD - a Division of Medical Oncology , 'S. G. Moscati' Hospital , Avellino , Italy. -FAU - Papadimitrakopoulou, Vali -AU - Papadimitrakopoulou V -AD - h Department of Thoracic/Head and Neck Medical Oncology , The University of - Texas, M.D. Anderson Cancer Center , Houston , TX , USA. -FAU - De Marinis, Filippo -AU - De Marinis F -AD - i Thoracic Division, Medical Oncology Department , European Institute of Oncology - , Milan , Italy. -LA - eng -PT - Journal Article -DEP - 20160921 -PL - England -TA - Expert Opin Biol Ther -JT - Expert opinion on biological therapy -JID - 101125414 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents) -RN - 0 (CTLA-4 Antigen) -RN - 0 (CTLA4 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - Antineoplastic Agents/immunology/therapeutic use -MH - CTLA-4 Antigen/immunology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology -MH - Clinical Trials as Topic/methods -MH - Congresses as Topic/trends -MH - Humans -MH - Immunotherapy/adverse effects/*methods/trends -MH - *Internationality -MH - Italy/epidemiology -MH - Lung Neoplasms/*drug therapy/immunology -MH - Nivolumab -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - *Research Report/trends -OTO - NOTNLM -OT - Combination therapies -OT - immune checkpoint inhibitors -OT - immune-related toxicity -OT - nivolumab -OT - pembrolizumab -OT - programmed death-1 (PD-1) -EDAT- 2016/09/22 06:00 -MHDA- 2017/07/14 06:00 -CRDT- 2016/09/22 06:00 -PHST- 2016/09/22 06:00 [pubmed] -PHST- 2017/07/14 06:00 [medline] -PHST- 2016/09/22 06:00 [entrez] -AID - 10.1080/14712598.2016.1234602 [doi] -PST - ppublish -SO - Expert Opin Biol Ther. 2016 Dec;16(12):1479-1489. doi: - 10.1080/14712598.2016.1234602. Epub 2016 Sep 21. - -PMID- 35231913 -OWN - NLM -STAT- MEDLINE -DCOM- 20220606 -LR - 20220606 -IS - 2296-5262 (Electronic) -IS - 2296-5270 (Linking) -VI - 45 -IP - 6 -DP - 2022 -TI - Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and - Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection. -PG - 366-374 -LID - 10.1159/000523854 [doi] -AB - BACKGROUND: Immune checkpoint inhibitors have become new research hot spots in - the treatment of non-small-cell lung cancer (NSCLC), but the efficacy and safety - of immunotherapy for patients with chronic infection are still unclear because - existing clinical trials often exclude those patients. MATERIALS AND METHODS: We - identified 78 locally advanced or advanced NSCLC patients with chronic infection - treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) - inhibitors alone or combined with the chemotherapy/bevacizumab therapy, of whom - 60 with hepatitis B, 2 with hepatitis C, and 16 with syphilis. Objective response - rates were assessed using the RECIST v1.1. Adverse events (AEs) were graded - following the National Cancer Institute Common Terminology Criteria for Adverse - Events v5.0. RESULTS: Objective responses were observed in 19 out of 78 (24.36%) - patients, and the disease control rate was 69.23% (54/78). No patient achieved a - complete response. The median progression-free survival (PFS) was 6.49 months - (95% CI: 3.71-9.27). PFS was 1.44 months (95% CI: 0.00-4.34) for monotherapy - versus 7.34 months (95% CI: 4.50-10.18) for combination therapy (p = 0.053). - Patients in the first-line treatment group revealed relatively higher ORR and - longer PFS (ORR: 48.00% vs. 13.20%, p = 0.001; PFS: 7.67 vs. 5.57 months, p = - 0.129). Patients with combined radiotherapy showed longer PFS than those without - combined radiotherapy (14.07 vs. 4.62, p = 0.027). The incidence of AEs of any - grade was 73.07% (57/78), among which there were 7 cases of grade 4 AEs. The - incidence of leukopenia in any grade of AEs was the highest (57.69%), followed by - anemia (25.64%), elevated alanine aminotransferase or aspartate aminotransferase - (24.36%), and fatigue (21.79%). Hepatic transaminase increased in 26.7% (16/60) - of HBV-infected patients and remained unchanged in 65.0% (39/60) patients. - CONCLUSIONS: The PD-1 inhibitor showed an acceptable toxicity profile and - moderate efficacy on NSCLC patients with chronic infection, but still has the - potential to increase the incidence of hepatitis. -CI - © 2022 S. Karger AG, Basel. -FAU - Zhao, Zhiting -AU - Zhao Z -AD - Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Hu, Ran -AU - Hu R -AD - Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Chen, Yan -AU - Chen Y -AD - Department of Pathology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Zhou, Guoren -AU - Zhou G -AD - Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Yu, Shaorong -AU - Yu S -AD - Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Feng, Jifeng -AU - Feng J -AD - Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -LA - eng -PT - Journal Article -DEP - 20220301 -PL - Switzerland -TA - Oncol Res Treat -JT - Oncology research and treatment -JID - 101627692 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Lung Neoplasms -MH - Persistent Infection -MH - Programmed Cell Death 1 Receptor -OTO - NOTNLM -OT - Chronic infection -OT - Immune checkpoint inhibitors -OT - Non-small-cell lung cancer -OT - Programmed death-1 -EDAT- 2022/03/02 06:00 -MHDA- 2022/06/07 06:00 -CRDT- 2022/03/01 20:19 -PHST- 2021/08/27 00:00 [received] -PHST- 2022/02/19 00:00 [accepted] -PHST- 2022/03/02 06:00 [pubmed] -PHST- 2022/06/07 06:00 [medline] -PHST- 2022/03/01 20:19 [entrez] -AID - 000523854 [pii] -AID - 10.1159/000523854 [doi] -PST - ppublish -SO - Oncol Res Treat. 2022;45(6):366-374. doi: 10.1159/000523854. Epub 2022 Mar 1. - -PMID- 36066161 -OWN - NLM -STAT- MEDLINE -DCOM- 20220908 -LR - 20221214 -IS - 2284-0729 (Electronic) -IS - 1128-3602 (Linking) -VI - 26 -IP - 16 -DP - 2022 Aug -TI - Efficacy of addition immune checkpoint inhibitors to chemotherapy as first-line - treatment for small cell lung cancer patients with liver or brain metastases: a - systematic review and meta-analysis. -PG - 5857-5867 -LID - 29525 [pii] -LID - 10.26355/eurrev_202208_29525 [doi] -AB - OBJECTIVE: Differential organ-specific tumor response to immune checkpoint - inhibitors (ICIs) has been reported in multiple solid tumors. We aim at - investigating the efficacy differences of ICIs combined with chemotherapy (CT) - vs. CT alone as first-line treatment for extensive-stage small-cell lung cancer - (ES-SCLC). MATERIALS AND METHODS: We searched PubMed, Embase, Medline, and China - National Knowledge Infrastructure databases to identify relevant trials comparing - ICIs combined with CT vs. CT alone in ES-SCLC patients with brain or liver - metastases. The primary outcome was overall survival (OS). The secondary outcomes - included progression-free survival (PFS). The pooled hazard ratio (HR) was - analyzed using the fixed or random effects model, according to heterogeneity - among included trials. RESULTS: We identified 5 randomized controlled trials of 8 - studies that involved a total of 1,401 patients, 310 with brain metastases and - 1,091 with liver metastases. The quality of included trials was high. The pooled - results showed that ICIs combined with CT significantly improved OS of ES-SCLC - with liver metastases (HR 0.88, 95%CI: 0.78-1.00, p=0.049), and a tendency to - improve PFS (HR 0.86, 95%CI: 0.68-1.07, p=0.17). For patients with brain - metastases, no survival benefit could be obtained from combination therapy of - ICIs with CT in terms of PFS (HR 0.91, 95%CI: 0.63-1.32, p=0.62) and OS (HR 1.12, - 95%CI: 0.88-1.43, p=0.36). No publication bias was detected. CONCLUSIONS: The - addition of ICIs to CT significantly improves OS in ES-SCLC patients with liver - metastases compared with CT alone. No survival benefit could be obtained from - ICIs and CT combination therapy for ES-SCLC with brain metastases. -FAU - Chen, C-R -AU - Chen CR -AD - Department of Radiation Oncology, The First Affiliated Hospital of Qiqihar - Medical College, Qiqihar, Heilongjiang Province, China. chen.chunrong@qmu.edu.cn. -FAU - Qi, W-X -AU - Qi WX -FAU - Liu, T -AU - Liu T -FAU - Tong, X -AU - Tong X -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Systematic Review -PL - Italy -TA - Eur Rev Med Pharmacol Sci -JT - European review for medical and pharmacological sciences -JID - 9717360 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - *Brain Neoplasms/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - *Liver Neoplasms/drug therapy -MH - *Lung Neoplasms/pathology -MH - *Small Cell Lung Carcinoma/drug therapy -EDAT- 2022/09/07 06:00 -MHDA- 2022/09/09 06:00 -CRDT- 2022/09/06 08:32 -PHST- 2022/09/06 08:32 [entrez] -PHST- 2022/09/07 06:00 [pubmed] -PHST- 2022/09/09 06:00 [medline] -AID - 29525 [pii] -AID - 10.26355/eurrev_202208_29525 [doi] -PST - ppublish -SO - Eur Rev Med Pharmacol Sci. 2022 Aug;26(16):5857-5867. doi: - 10.26355/eurrev_202208_29525. - -PMID- 37217919 -OWN - NLM -STAT- MEDLINE -DCOM- 20230524 -LR - 20230525 -IS - 1748-717X (Electronic) -IS - 1748-717X (Linking) -VI - 18 -IP - 1 -DP - 2023 May 22 -TI - Clinical features and risk factors for interstitial lung disease spreading in - low-dose irradiated areas after definitive radiotherapy with or without - durvalumab consolidation therapy for patients with non-small cell lung cancer. -PG - 87 -LID - 10.1186/s13014-023-02276-7 [doi] -LID - 87 -AB - BACKGROUND: The current standard of care for patients with unresectable locally - advanced non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) combined - with durvalumab consolidation therapy. However, radiotherapy (RT) always carries - the risk of radiation pneumonitis (RP), which can preclude durvalumab - continuation. In particular, the spread of interstitial lung disease (ILD) in - low-dose areas or extending beyond the RT field often makes it difficult to - determine the safety of continuation or rechallenging of durvalumab. Thus, we - retrospectively analyzed ILD/RP after definitive RT with and without durvalumab, - with assessment of radiologic features and dose distribution in RT. METHODS: We - retrospectively evaluated the clinical records, CT imaging, and radiotherapy - planning data of 74 patients with NSCLC who underwent definitive RT at our - institution between July 2016 and July 2020. We assessed the risk factors for - recurrence within one year and occurrence of ILD/RP. RESULTS: Kaplan-Meier method - showed that ≥ 7 cycles of durvalumab significantly improved 1-year progression - free survival (PFS) (p < 0.001). Nineteen patients (26%) were diagnosed with - ≥ Grade 2 and 7 (9.5%) with ≥ Grade 3 ILD/RP after completing RT. There was no - significant correlation between durvalumab administration and ≥ Grade 2 ILD/RP. - Twelve patients (16%) developed ILD/RP that spread outside the high-dose - (> 40 Gy) area, of whom 8 (67%) had ≥ Grade 2 and 3 (25%) had Grade 3 symptoms. - In unadjusted and multivariate Cox proportional-hazards models adjusted for V(20) - (proportion of the lung volume receiving ≥ 20 Gy), high HbA1c level was - significantly correlated with ILD/RP pattern spreading outside the high-dose area - (hazard ratio, 1.842; 95% confidence interval, 1.35-2.51). CONCLUSIONS: - Durvalumab improved 1-year PFS without increasing the risk of ILD/RP. Diabetic - factors were associated with ILD/RP distribution pattern spreading in the lower - dose area or outside RT fields, with a high rate of symptoms. Further study of - the clinical background of patients including diabetes is needed to safely - increase the number of durvalumab doses after CRT. -CI - © 2023. The Author(s). -FAU - Sakagami, Mai -AU - Sakagami M -AD - Department of Radiation Oncology, Graduate School of Medicine, Osaka City - University, Osaka, Japan. o21064c@omu.ac.jp. -FAU - Inokuchi, Haruo -AU - Inokuchi H -AD - Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan - University, Osaka, Japan. -FAU - Mukumoto, Nobutaka -AU - Mukumoto N -AD - Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan - University, Osaka, Japan. -FAU - Itoyama, Hiroshige -AU - Itoyama H -AD - Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan - University, Osaka, Japan. -FAU - Hamaura, Nobunari -AU - Hamaura N -AD - Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan - University, Osaka, Japan. -FAU - Yamagishi, Mutsumi -AU - Yamagishi M -AD - Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan - University, Osaka, Japan. -FAU - Mukumoto, Naoki -AU - Mukumoto N -AD - Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan - University, Osaka, Japan. -FAU - Matsuda, Shogo -AU - Matsuda S -AD - Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan - University, Osaka, Japan. -FAU - Kabata, Daijiro -AU - Kabata D -AD - Department of Medical Statistics, Graduate School of Medicine, Osaka Metropolitan - University, Osaka, Japan. -FAU - Shibuya, Keiko -AU - Shibuya K -AD - Department of Radiation Oncology, Graduate School of Medicine, Osaka Metropolitan - University, Osaka, Japan. -LA - eng -PT - Journal Article -DEP - 20230522 -PL - England -TA - Radiat Oncol -JT - Radiation oncology (London, England) -JID - 101265111 -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/radiotherapy -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Retrospective Studies -MH - Consolidation Chemotherapy/adverse effects -MH - *Lung Diseases, Interstitial/complications -MH - *Radiation Pneumonitis/etiology/epidemiology -MH - Risk Factors -MH - Chemoradiotherapy/adverse effects -PMC - PMC10204233 -OTO - NOTNLM -OT - Chemoradiotherapy -OT - Diabetes -OT - Durvalumab -OT - Interstitial lung disease -OT - Non-small cell lung cancer -OT - Radiation pneumonitis -OT - Radiotherapy -OT - Risk factor -COIS- The authors declare no competing interests. -EDAT- 2023/05/23 01:06 -MHDA- 2023/05/24 06:42 -PMCR- 2023/05/22 -CRDT- 2023/05/22 23:47 -PHST- 2022/08/18 00:00 [received] -PHST- 2023/05/04 00:00 [accepted] -PHST- 2023/05/24 06:42 [medline] -PHST- 2023/05/23 01:06 [pubmed] -PHST- 2023/05/22 23:47 [entrez] -PHST- 2023/05/22 00:00 [pmc-release] -AID - 10.1186/s13014-023-02276-7 [pii] -AID - 2276 [pii] -AID - 10.1186/s13014-023-02276-7 [doi] -PST - epublish -SO - Radiat Oncol. 2023 May 22;18(1):87. doi: 10.1186/s13014-023-02276-7. - -PMID- 35927166 -OWN - NLM -STAT- MEDLINE -DCOM- 20221108 -LR - 20221108 -IS - 1769-6658 (Electronic) -IS - 1278-3218 (Linking) -VI - 26 -IP - 8 -DP - 2022 Nov -TI - Impact of radiotherapy schedule on survival of patients treated with - immune-checkpoint inhibitors for advanced melanoma and non-small cell lung - cancer. -PG - 1045-1053 -LID - S1278-3218(22)00093-2 [pii] -LID - 10.1016/j.canrad.2022.04.005 [doi] -AB - PURPOSE: Preclinical and clinical data suggest a potential benefit in the - addition of radiotherapy (RT) to immune-checkpoint inhibitors (ICI) during the - treatment of advanced cancers. Nevertheless, the ideal patients for this approach - and the optimal RT regimen is still debated. MATERIAL AND METHODS: The aim of - this study was to determine the effect RT schedule has on survival for advanced - non-small cell lung cancer and melanoma patients (pts) treated with ICI (anti-PD1 - or anti-CTLA4) and concomitant RT. RESULTS: A total of 58 pts were identified, of - which 26 received RT concomitantly with ICI while the remaining 32 pts were - treated with RT at the time of progression under ICI. The RT parameters - associated with outcome include dose per fraction, biological effective dose, RT - to all targets and lung irradiation. Independent predictors of improved - progression-free survival were lung irradiation, melanoma histology, - oligometastatic status (<6 metastasis), presence of liver metastasis, - PNN<7000/mm(3) and normal LDH. Independent predictors of improved overall - survival were melanoma histology and normal LDH. Among pts who were irradiated at - progression, 68.7% had an overall clinical benefit and had a median extension of - ICI use by 2.3 months (range: 0-29.1), among which 2 presented with an abscopal - effect. CONCLUSIONS: The irradiation of lung metastases may increase survival in - patients under ICI. RT at progression could prolong the use of ICI, and - neutrophilia and LDH should be considered during patient selection of this - combined RT/ICI approach. -CI - Copyright © 2022 Société française de radiothérapie oncologique (SFRO). Published - by Elsevier Masson SAS. All rights reserved. -FAU - Sumodhee, S -AU - Sumodhee S -AD - Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte - d'Azur, Fédération Claude Lalanne, Nice, France. Electronic address: - shakeel.sumodhee@nice.unicancer.fr. -FAU - Guo, L -AU - Guo L -AD - Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte - d'Azur, Fédération Claude Lalanne, Nice, France; Department of Radiation - Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical - University, Guangzhou, Guangdong, PR China. -FAU - Bouhlel, L -AU - Bouhlel L -AD - Department of Pulmonary Medicine and Oncology, Centre Hospitalier Universitaire, - University Côte d'Azur, CHU de Nice, FHU OncoAge, Nice, France. -FAU - Picard, A -AU - Picard A -AD - Department of Dermatology, Centre Hospitalier Universitaire, University Côte - d'Azur, Nice, France. -FAU - Otto, J -AU - Otto J -AD - Department of Medical Oncology, Centre Antoine-Lacassagne, University Côte - d'Azur, Nice, France. -FAU - Naghavi, A O -AU - Naghavi AO -AD - Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, Florida, United States. -FAU - Richier, Q -AU - Richier Q -AD - Department of Infectious Diseases, Saint Antoine Hospital, Assistance Publique - des Hôpitaux de Paris, Paris, France. -FAU - Lévy, A -AU - Lévy A -AD - Department of Radiation Oncology, Gustave Roussy, Institut d'Oncologie Thoracique - (IOT), Université Paris-Saclay, Villejuif, France; University of Paris Sud, - University Paris-Saclay, Le Kremlin-Bicêtre, France. -FAU - Bondiau, P-Y -AU - Bondiau PY -AD - Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte - d'Azur, Fédération Claude Lalanne, Nice, France. -FAU - Poudenx, M -AU - Poudenx M -AD - Department of Medical Oncology, Centre Antoine-Lacassagne, University Côte - d'Azur, Nice, France. -FAU - Passeron, T -AU - Passeron T -AD - Department of Dermatology, Centre Hospitalier Universitaire, University Côte - d'Azur, Nice, France. -FAU - Lacour, J-P -AU - Lacour JP -AD - Department of Dermatology, Centre Hospitalier Universitaire, University Côte - d'Azur, Nice, France. -FAU - Montaudié, H -AU - Montaudié H -AD - Department of Dermatology, Centre Hospitalier Universitaire, University Côte - d'Azur, Nice, France. -FAU - Doyen, J -AU - Doyen J -AD - Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte - d'Azur, Fédération Claude Lalanne, Nice, France. -LA - eng -PT - Journal Article -DEP - 20220801 -PL - France -TA - Cancer Radiother -JT - Cancer radiotherapie : journal de la Societe francaise de radiotherapie - oncologique -JID - 9711272 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/radiotherapy/drug therapy -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - *Lung Neoplasms/radiotherapy/drug therapy -MH - Immunotherapy/adverse effects -MH - *Melanoma/drug therapy/radiotherapy -MH - Retrospective Studies -OTO - NOTNLM -OT - Abscopal -OT - Advanced melanoma -OT - Advanced non-small cell lung cancer -OT - Cancer bronchique non à petites cellules avancé -OT - Immune checkpoint inhibitor -OT - Inhibiteurs de points de contrôle immunitaire -OT - Mélanome avancé -OT - Radiotherapy -OT - Radiothérapie -EDAT- 2022/08/05 06:00 -MHDA- 2022/11/09 06:00 -CRDT- 2022/08/04 22:07 -PHST- 2021/05/10 00:00 [received] -PHST- 2021/12/30 00:00 [revised] -PHST- 2022/04/03 00:00 [accepted] -PHST- 2022/08/05 06:00 [pubmed] -PHST- 2022/11/09 06:00 [medline] -PHST- 2022/08/04 22:07 [entrez] -AID - S1278-3218(22)00093-2 [pii] -AID - 10.1016/j.canrad.2022.04.005 [doi] -PST - ppublish -SO - Cancer Radiother. 2022 Nov;26(8):1045-1053. doi: 10.1016/j.canrad.2022.04.005. - Epub 2022 Aug 1. - -PMID- 35044093 -OWN - NLM -STAT- MEDLINE -DCOM- 20220323 -LR - 20220323 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 13 -IP - 5 -DP - 2022 Mar -TI - Risk factors for pneumonitis in patients with non-small cell lung cancer treated - with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis. -PG - 724-731 -LID - 10.1111/1759-7714.14308 [doi] -AB - BACKGROUND: Immune checkpoint inhibitor (ICI) therapy plus chemotherapy has - become a standard of care for patients with advanced non-small cell lung cancer - (NSCLC). Pre-existing interstitial lung disease (ILD) is a risk factor for - drug-induced pneumonitis caused by chemotherapy or ICI monotherapy. However, - clinical data in patients with pre-existing ILD who received ICI therapy plus - chemotherapy are limited. This study aimed to identify the risk factors for - drug-induced pneumonitis in patients with NSCLC treated with ICIs plus - chemotherapy. METHODS: We retrospectively reviewed the medical records of 160 - consecutive patients who were diagnosed with NSCLC and treated with ICIs plus - chemotherapy at Aichi Cancer Center Hospital between December 2018 and November - 2020. Patients with a prior history of ICI treatment or thoracic radiotherapy - were excluded from the analysis. RESULTS: Among 125 patients, pre-existing ILD - was observed in 20 patients (16.0%). Drug-induced pneumonitis developed in 17 - patients (13.6%), with a median time to onset of 19.3 weeks (range, - 1.6-108.9 weeks). In multivariate logistic analysis, pre-existing ILD (odds - ratio = 19.07, p = 0.0001) and PEM exposure (odds ratio = 5.67, p = 0.022) were - identified as risk factors for the development of drug-induced pneumonitis. - CONCLUSIONS: Pre-existing ILD and pemetrexed exposure are risk factors for - drug-induced pneumonitis in patients with NSCLC. -CI - © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Yamaguchi, Teppei -AU - Yamaguchi T -AUID- ORCID: 0000-0002-8909-5709 -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, - Japan. -FAU - Shimizu, Junichi -AU - Shimizu J -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, - Japan. -FAU - Oya, Yuko -AU - Oya Y -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, - Japan. -FAU - Watanabe, Naohiro -AU - Watanabe N -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, - Japan. -FAU - Hasegawa, Takaaki -AU - Hasegawa T -AUID- ORCID: 0000-0001-6701-8836 -AD - Department of Diagnostic and Interventional Radiology, Aichi Cancer Center - Hospital, Nagoya, Aichi, Japan. -FAU - Horio, Yoshitsugu -AU - Horio Y -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, - Japan. -FAU - Inaba, Yoshitaka -AU - Inaba Y -AD - Department of Diagnostic and Interventional Radiology, Aichi Cancer Center - Hospital, Nagoya, Aichi, Japan. -FAU - Fujiwara, Yutaka -AU - Fujiwara Y -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, - Japan. -LA - eng -PT - Journal Article -DEP - 20220119 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/complications/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - *Lung Neoplasms/complications/drug therapy -MH - *Pneumonia/chemically induced/drug therapy -MH - Retrospective Studies -MH - Risk Factors -PMC - PMC8888158 -OTO - NOTNLM -OT - immune checkpoint inhibitors -OT - interstitial lung disease -OT - non-small cell lung cancer -OT - pemetrexed -OT - pneumonitis -COIS- TY reported receiving personal fees from Ono Pharmaceutical, Chugai - Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, MSD, and - Bristol‐Meyers Squibb outside the submitted work. JS reported receiving personal - fees from AstraZeneca, Bristol‐Myers Squibb, Ono Pharmaceutical, Chugai - Pharmaceutical, and MSD. YO reported receiving personal fees from AstraZeneca, - Daiichi Sankyo, Ono Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, - Eli Lilly, Bristol‐Myers Squibb, and Amgen outside the submitted work. YF - reported receiving grant from Chugai Pharmaceutical, and personal fees from Astra - Zeneca, Daiichi Sankyo, ONO Pharmaceutical, Otsuka Pharmaceutical, Novartis, and - Yakult outside the submitted work. All other authors have no conflicts of - interest. -EDAT- 2022/01/20 06:00 -MHDA- 2022/03/24 06:00 -PMCR- 2022/03/01 -CRDT- 2022/01/19 09:02 -PHST- 2021/12/22 00:00 [revised] -PHST- 2021/11/04 00:00 [received] -PHST- 2021/12/23 00:00 [accepted] -PHST- 2022/01/20 06:00 [pubmed] -PHST- 2022/03/24 06:00 [medline] -PHST- 2022/01/19 09:02 [entrez] -PHST- 2022/03/01 00:00 [pmc-release] -AID - TCA14308 [pii] -AID - 10.1111/1759-7714.14308 [doi] -PST - ppublish -SO - Thorac Cancer. 2022 Mar;13(5):724-731. doi: 10.1111/1759-7714.14308. Epub 2022 - Jan 19. - -PMID- 33049757 -OWN - NLM -STAT- MEDLINE -DCOM- 20210224 -LR - 20210703 -IS - 1465-3621 (Electronic) -IS - 0368-2811 (Linking) -VI - 51 -IP - 2 -DP - 2021 Feb 8 -TI - Impact of previous thoracsic radiation therapy on the efficacy of immune - checkpoint inhibitors in advanced non-smasll-cell lung cancer. -PG - 279-286 -LID - 10.1093/jjco/hyaa180 [doi] -AB - OBJECTIVES: Studies investigating the association between radiation therapy and - the efficacy of immune checkpoint inhibitors in advanced non-small-cell lung - cancer have provided inconsistent results, likely due to relatively small cohort - sizes. This study investigated the effect of previous thoracic radiation therapy - on the efficacy of immune checkpoint inhibitor therapy in a large non-small-cell - lung cancer cohort. PATIENTS AND METHODS: We conducted a retrospective cohort - study using data from 531 non-small-cell lung cancer patients who received - monotherapy with programmed cell death protein 1/programmed death-ligand 1 - inhibitors at nine institutions. The effects of thoracic radiation therapy on the - efficacy of immune checkpoint inhibitors were investigated. RESULTS: A total of - 531 non-small-cell lung cancer patients treated with immune checkpoint inhibitors - were included in this study. The progression-free survival period was - significantly longer in patients that had received thoracic radiation therapy - before immune checkpoint inhibitor therapy compared to those without previous - thoracic radiation therapy (median progression-free survival 5.0 vs. 3.0 months, - P = 0.0013). A multivariate analysis showed that thoracic radiation therapy was - an independent predictive factor of improved progression-free survival (hazard - ratio of progression-free survival: 0.79, P = 0.049). In contrast, extra-thoracic - radiation therapy was associated with inferior outcomes (median progression-free - survival 3.0 vs. 4.2 months, P = 0.0008). CONCLUSION: Previous thoracic radiation - therapy, but not prior extra-thoracic radiation therapy, enhanced the efficacy of - anti-programmed cell death protein 1/programmed death-ligand 1 therapy in - non-small-cell lung cancer patients. -CI - © The Author(s) 2020. Published by Oxford University Press. All rights reserved. - For permissions, please e-mail: journals.permission@oup.com. -FAU - Hosokawa, Shinobu -AU - Hosokawa S -AD - Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, - Japan. -FAU - Ichihara, Eiki -AU - Ichihara E -AD - Department of Allergy and Respiratory Medicine, Okayama University Hospital, - Okayama, Japan. -FAU - Bessho, Akihiro -AU - Bessho A -AD - Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, - Japan. -FAU - Harada, Daijiro -AU - Harada D -AD - Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer - Center, Matsuyama, Japan. -FAU - Inoue, Koji -AU - Inoue K -AD - Department of Respiratory Medicine, Ehime Prefectural Central Hospital, - Matsuyama, Japan. -FAU - Shibayama, Takuo -AU - Shibayama T -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Okayama, Japan. -FAU - Kishino, Daizo -AU - Kishino D -AD - Department of Respiratory Medicine, Himeji Red Cross Hospital, Himeji, Japan. -FAU - Harita, Shingo -AU - Harita S -AD - Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, - Japan. -FAU - Ochi, Nobuaki -AU - Ochi N -AD - Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, - Japan. -FAU - Oda, Naohiro -AU - Oda N -AD - Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Japan. -FAU - Hara, Naofumi -AU - Hara N -AD - Department of Hematology, Oncology and Respiratory Medicine, Okayama University - Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, - Japan. -FAU - Hotta, Katsuyuki -AU - Hotta K -AD - Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, - Japan. -FAU - Maeda, Yoshinobu -AU - Maeda Y -AD - Department of Hematology, Oncology and Respiratory Medicine, Okayama University - Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, - Japan. -FAU - Kiura, Katsuyuki -AU - Kiura K -AD - Department of Allergy and Respiratory Medicine, Okayama University Hospital, - Okayama, Japan. -LA - eng -PT - Journal Article -PL - England -TA - Jpn J Clin Oncol -JT - Japanese journal of clinical oncology -JID - 0313225 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (Immune Checkpoint Inhibitors) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -EIN - Jpn J Clin Oncol. 2021 Aug 1;51(8):1348. doi: 10.1093/jjco/hyab113. PMID: - 34215885 -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - B7-H1 Antigen/metabolism -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/*radiotherapy -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects/*therapeutic use -MH - Lung Neoplasms/*drug therapy/*radiotherapy -MH - Male -MH - Middle Aged -MH - Multivariate Analysis -MH - Progression-Free Survival -MH - Retrospective Studies -MH - Thorax/*radiation effects -MH - Treatment Outcome -OTO - NOTNLM -OT - PD-1 -OT - PD-L1 -OT - immune checkpoint inhibitor -OT - non-small cell lung cancer -OT - radiation -OT - therapy -EDAT- 2020/10/14 06:00 -MHDA- 2021/02/25 06:00 -CRDT- 2020/10/13 20:17 -PHST- 2020/05/29 00:00 [received] -PHST- 2020/08/23 00:00 [accepted] -PHST- 2020/10/14 06:00 [pubmed] -PHST- 2021/02/25 06:00 [medline] -PHST- 2020/10/13 20:17 [entrez] -AID - 5922678 [pii] -AID - 10.1093/jjco/hyaa180 [doi] -PST - ppublish -SO - Jpn J Clin Oncol. 2021 Feb 8;51(2):279-286. doi: 10.1093/jjco/hyaa180. - -PMID- 35245844 -OWN - NLM -STAT- MEDLINE -DCOM- 20220426 -LR - 20220505 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 166 -DP - 2022 Apr -TI - Characterizing immune-mediated adverse events with durvalumab in patients with - unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. -PG - 84-93 -LID - S0169-5002(22)00043-5 [pii] -LID - 10.1016/j.lungcan.2022.02.003 [doi] -AB - INTRODUCTION: Immune-mediated adverse events (imAEs), including all-cause - immune-mediated pneumonitis, were reported in approximately 25% of patients in - the placebo-controlled, phase III PACIFIC trial of durvalumab monotherapy (for up - to 12 months) in patients with unresectable, stage III NSCLC and no disease - progression after concurrent chemoradiotherapy; only 3.4% of patients experienced - grade 3/4 imAEs. With broad application of the PACIFIC regimen (consolidation - durvalumab after chemoradiotherapy), now standard-of-care in this setting, there - is a need to better characterize the occurrence of imAEs with this regimen. - METHODS: We performed descriptive, post-hoc, exploratory analyses to characterize - the occurrence of imAEs (pneumonitis and non-pneumonitis) in PACIFIC in terms of: - incidence, severity, and timing; clinical management and outcomes; and - associations between the occurrence of imAEs and (1) all-cause AEs and (2) - baseline patient, disease, and treatment characteristics. RESULTS: Any-grade - immune-mediated pneumonitis (9.4%) and non-pneumonitis imAEs (10.7%) occurred - infrequently and were more common with durvalumab versus placebo. Grade 3/4 - immune-mediated pneumonitis (1.9%) and non-pneumonitis imAEs (1.7%) were uncommon - with durvalumab, as were fatal imAEs (0.8%; all pneumonitis). The most common - non-pneumonitis imAEs with durvalumab were thyroid disorders, dermatitis/rash, - and diarrhea/colitis. Dermatitis/rash had the shortest time to onset (from - durvalumab initiation), followed by pneumonitis; dermatitis/rash had the longest - time to resolution, followed by thyroid disorders. Most patients with - immune-mediated pneumonitis (78.4%) and non-pneumonitis imAEs (56.3%) had these - events occur ≤ 3 months after initiating durvalumab. ImAEs were well managed with - administration of systemic corticosteroids, administration of endocrine - replacement therapy, and interruption/discontinuation of durvalumab. Time elapsed - from completion of prior radiotherapy to trial randomization (<14 vs. ≥ 14 days) - did not impact either incidence or severity of imAEs. Durvalumab had a manageable - safety profile broadly irrespective of whether patients experienced imAEs. - CONCLUSION: The risk of imAEs should not deter use of the PACIFIC regimen in - eligible patients, as these events are generally well managed through appropriate - clinical intervention. -CI - Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved. -FAU - Naidoo, Jarushka -AU - Naidoo J -AD - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, - MD, USA; Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, MD, USA; Beaumont Hospital Dublin, RCSI University of - Health Sciences, Dublin, Ireland. Electronic address: jnaidoo1@jhmi.edu. -FAU - Vansteenkiste, Johan F -AU - Vansteenkiste JF -AD - University Hospitals KU Leuven, Leuven, Belgium. -FAU - Faivre-Finn, Corinne -AU - Faivre-Finn C -AD - The University of Manchester and The Christie NHS Foundation Trust, Manchester, - UK. -FAU - Özgüroğlu, Mustafa -AU - Özgüroğlu M -AD - Istanbul University - Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, - Turkey. -FAU - Murakami, Shuji -AU - Murakami S -AD - Kanagawa Cancer Center, Yokohama, Japan. -FAU - Hui, Rina -AU - Hui R -AD - Westmead Hospital and the University of Sydney, Sydney, NSW, Australia. -FAU - Quantin, Xavier -AU - Quantin X -AD - ICM Val d'Aurelle and IRCM U1194, Montpellier University, Montpellier, France. -FAU - Broadhurst, Helen -AU - Broadhurst H -AD - Plus Project Ltd, Alderley Park, Macclesfield, UK. -FAU - Newton, Michael -AU - Newton M -AD - AstraZeneca, Gaithersburg, MD, USA. -FAU - Thiyagarajah, Piruntha -AU - Thiyagarajah P -AD - AstraZeneca, Cambridge, UK. -FAU - Antonia, Scott J -AU - Antonia SJ -AD - H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. -LA - eng -SI - ClinicalTrials.gov/NCT02125461 -SI - EudraCT/EudraCT: 2014-000336-42 -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20220209 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal -MH - *Carcinoma, Non-Small-Cell Lung/therapy -MH - Chemoradiotherapy/adverse effects -MH - *Dermatitis/drug therapy/etiology -MH - *Exanthema/etiology -MH - Humans -MH - *Lung Neoplasms/therapy -MH - *Pneumonia/diagnosis/epidemiology/etiology -OTO - NOTNLM -OT - Chemoradiotherapy -OT - Immune checkpoint inhibition -OT - Locally advanced NSCLC -OT - PACIFIC -OT - Pneumonitis -OT - Thyroid disorders -EDAT- 2022/03/05 06:00 -MHDA- 2022/04/27 06:00 -CRDT- 2022/03/04 20:13 -PHST- 2021/11/16 00:00 [received] -PHST- 2022/02/02 00:00 [revised] -PHST- 2022/02/07 00:00 [accepted] -PHST- 2022/03/05 06:00 [pubmed] -PHST- 2022/04/27 06:00 [medline] -PHST- 2022/03/04 20:13 [entrez] -AID - S0169-5002(22)00043-5 [pii] -AID - 10.1016/j.lungcan.2022.02.003 [doi] -PST - ppublish -SO - Lung Cancer. 2022 Apr;166:84-93. doi: 10.1016/j.lungcan.2022.02.003. Epub 2022 - Feb 9. - -PMID- 34953398 -OWN - NLM -STAT- MEDLINE -DCOM- 20220324 -LR - 20220324 -IS - 2059-7029 (Electronic) -IS - 2059-7029 (Linking) -VI - 7 -IP - 1 -DP - 2022 Feb -TI - IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a - nationwide cohort of patients with advanced non-small-cell lung cancer. -PG - 100353 -LID - S2059-7029(21)00315-X [pii] -LID - 10.1016/j.esmoop.2021.100353 [doi] -LID - 100353 -AB - BACKGROUND: Immunotherapy using inhibitors targeting immune checkpoint programmed - cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the - standard of care in patients with advanced non-small-cell lung cancer (NSCLC). - MATERIALS AND METHODS: We carried out a nationwide cohort retrospective study of - consecutive patients with advanced, refractory NSCLC who received nivolumab as - second to later lines of treatment as part of the expanded access program. Key - objectives were to assess the efficacy and safety of nivolumab and the efficacy - of first post-nivolumab treatment. RESULTS: Nine hundred and two patients were - enrolled: 317 (35%) with squamous cell carcinoma and 585 (65%) with non-squamous - cell carcinoma. Median age was 64 years; there were 630 (70%) men, 795 (88%) - smokers, 723 (81%) patients with an Eastern Cooperative Oncology Group (ECOG) - performance status (PS) of 0/1, 197 (22%) patients with brain metastases, and 212 - (27%) with liver metastases. Best response was partial response for 16.2% and - stable disease (SD) for 30.5%. Progression-free survival and overall survival - (OS) rates at 2, 3, and 5 years were 8% and 25%, 6% and 16%, and 4% and 10%, - respectively. At multivariate analysis, ECOG PS ≥2 [hazard ratio (HR) = 2.13, 95% - confidence interval (95% CI) 1.78-2.55, P < 0.001], squamous histology (HR = - 1.17, 95% CI 1.01-1.36, P = 0.04), and presence of central nervous system - metastases (HR = 1.29, 95% CI 1.08-1.54, P = 0.005) were significantly associated - with lower OS. Four hundred and ninety-two patients received at least one - treatment after discontinuation of nivolumab, consisting of systemic therapies in - 450 (91%). Radiation therapy was delivered to 118 (24%) patients. CONCLUSION: The - CLINIVO cohort represents the largest real-world evidence cohort with the use of - immune checkpoint inhibitor in advanced, metastatic NSCLC after failure of - first-line chemotherapy, with long-term follow-up and analysis of subsequent - therapies. Our data confirm the efficacy of nivolumab in a cohort larger than - that reported in landmark clinical trials and identify prognostic factors, which - reinforces the need for accurate selection of patients for treatment with immune - checkpoint inhibitors. Our data indicate that oligoprogression is frequent after - nivolumab exposure and provide a unique insight into the long-term survival. -CI - Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. -FAU - Molinier, O -AU - Molinier O -AD - Pneumology, Centre Hospitalier Du Mans, Le Mans, France. -FAU - Besse, B -AU - Besse B -AD - Cancer Medicine Department, Gustave Roussy, Villejuif, France; Paris-Saclay - University, Orsay, France. -FAU - Barlesi, F -AU - Barlesi F -AD - Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France; Gustave Roussy - Cancer Campus, Villejuif, France. -FAU - Audigier-Valette, C -AU - Audigier-Valette C -AD - Pneumology Department, Centre Hospitalier Toulon Sainte-Musse, Toulon, France. -FAU - Friard, S -AU - Friard S -AD - Hopital Foch, Chest Department, Suresnes, France. -FAU - Monnet, I -AU - Monnet I -AD - Pneumology Service, CHI Créteil, Créteil, France. -FAU - Jeannin, G -AU - Jeannin G -AD - Pneumology Service, CHU Gabriel Montpied, Clermont-Ferrand, France. -FAU - Mazières, J -AU - Mazières J -AD - Pneumology Service, Centre Hospitalier Universitaire de Toulouse, Hôpital Larrey, - Pôle Voies Respiratoires, Toulouse, France. -FAU - Cadranel, J -AU - Cadranel J -AD - Pneumology Service, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, - France; Sorbonne Universités, UPMC Univ Paris 06, GRC n04, Theranoscan, Paris, - France. -FAU - Hureaux, J -AU - Hureaux J -AD - Pôle Hippocrate, CHU d'Angers, Angers, France. -FAU - Hilgers, W -AU - Hilgers W -AD - Medical Oncology, Sainte Catherine Cancer Institute, Avignon Provence, France. -FAU - Quoix, E -AU - Quoix E -AD - Pneumology Service, Hôpitaux Universitaires de Strasbourg-Unistra, Strasbourg, - France. -FAU - Coudert, B -AU - Coudert B -AD - Medical Oncology Department, Centre Georges-François Leclerc, Dijon, France. -FAU - Moro-Sibilot, D -AU - Moro-Sibilot D -AD - Pneumology and Thoracic Oncology Department, CHU Grenoble-Alpes, La Tronche, - France. -FAU - Fauchon, E -AU - Fauchon E -AD - Pneumology Service, CHI, Saint-Julien-en-Genevois, France. -FAU - Westeel, V -AU - Westeel V -AD - Pneumology Service, Centre Hospitalier Régional Universitaire de Besançon, - Hôpital Jean Minjoz, Besançon, France. -FAU - Brun, P -AU - Brun P -AD - Pneumology Service, CH de Valence, Valence, France. -FAU - Langlais, A -AU - Langlais A -AD - Biostatistic Department, French Cooperative Thoracic Intergroup (IFCT), Paris, - France. -FAU - Morin, F -AU - Morin F -AD - Clinical Research Unit, French Cooperative Thoracic Intergroup (IFCT), Paris, - France. -FAU - Souquet, P J -AU - Souquet PJ -AD - Pneumology Service, Centre hospitalier Lyon-Sud, Pierre-Bénite, France. -FAU - Girard, N -AU - Girard N -AD - Paris-Saclay University, Orsay, France; Institut du Thorax Curie-Montsouris, - Institut Curie, Paris, France. Electronic address: nicolas.girard2@curie.fr. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20211223 -PL - England -TA - ESMO Open -JT - ESMO open -JID - 101690685 -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - Humans -MH - *Lung Neoplasms/pathology -MH - Male -MH - Middle Aged -MH - Nivolumab/pharmacology/therapeutic use -MH - Progression-Free Survival -MH - Retrospective Studies -PMC - PMC8764511 -OTO - NOTNLM -OT - chemotherapy -OT - immunotherapy -OT - lung cancer -OT - non-small-cell lung cancer -OT - real-life evidence -OT - sequence -COIS- Disclosure OM reports personal fees from AstraZeneca, Takeda, BMS, MSD, Novartis, - and AMGEN. NG reports research/grant support from MSD, AstraZeneca, AbbVie, - Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Janssen, Merck, MSD, - Novartis, Pfizer, Sivan, and Trizell, and consultative services for Bristol Myers - Squibb, AstraZeneca, AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann-La - Roche, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi, and Sivan. BB reports - grants from AbbVie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint - Medicines, BMS, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, - Daiichi-Sankyo, Eli Lilly, GSK, Inivata, Janssen, Onxeo, OSE Immunotherapeutics, - Pfizer, Roche-Genentech, Sanofi, Takeda, and Tolero Pharmaceuticals. FB reports - personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer - Ingelheim, Eli Lilly Oncology, ß. Hoffmann-La Roche Ltd, Novartis, Merck, MSD, - Pierre Fabre, Pfizer, and Takeda. CA-V reports personal fees and non-financial - support from Roche, BMS, MSD, AstraZeneca, AbbVie, Pfizer, and Takeda. SF reports - support for attending meetings and/or travel from Boehringer Ingelheim France, - BMS, Leo Pharma, Sandoz, and Novartis Pharma SAS. JM reports personal fees from - Roche, AstraZeneca, Pierre Fabre, Takeda, BMS, MSD, Hengrui, BLUEPRINT, DAIICHI, - and Novartis and grants from Roche, AstraZeneca, Pierre Fabre, and BMS. JC - reports consulting fees from AstraZeneca, Boehringer Ingelheim, BMS, Jansen, MSD, - Pfizer, Roche, and Takeda. WH reports payment or honoraria for lectures, - presentations, speaker's bureaus, manuscript writing, or educational events from - BMS and Astellas and support for attending meetings and/or travel from Astellas, - Pfizer, and Janssen. DM-S reports grants or contracts from Roche, AstraZeneca, - Amgen, AbbVie, Pfizer, Takeda, and Lilly; consulting fees from Roche, - AstraZeneca, Amgen, AbbVie, Pfizer, Takeda, and Lilly; payment or honoraria for - lectures, presentations, speaker's bureaus, manuscript writing, or educational - events from Roche, AstraZeneca, Amgen, AbbVie, Pfizer, Takeda, Lilly, and BMS; - and support for attending meetings and/or travel from Roche, AstraZeneca, Amgen, - AbbVie, Pfizer, Takeda, Lilly, and BMS. VW reports honoraria from Roche, - AstraZeneca, BMS, and MSD and non-financial support from Roche and Pfizer. PJS - reports consulting fees, support for attending meetings and/or travel, payment or - honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or - educational events from BMS and participated on a data safety monitoring board or - advisory board for BMS. The remaining authors have declared no conflicts of - interest. -EDAT- 2021/12/26 06:00 -MHDA- 2022/03/25 06:00 -PMCR- 2021/12/23 -CRDT- 2021/12/25 20:16 -PHST- 2021/10/12 00:00 [received] -PHST- 2021/11/17 00:00 [revised] -PHST- 2021/11/20 00:00 [accepted] -PHST- 2021/12/26 06:00 [pubmed] -PHST- 2022/03/25 06:00 [medline] -PHST- 2021/12/25 20:16 [entrez] -PHST- 2021/12/23 00:00 [pmc-release] -AID - S2059-7029(21)00315-X [pii] -AID - 100353 [pii] -AID - 10.1016/j.esmoop.2021.100353 [doi] -PST - ppublish -SO - ESMO Open. 2022 Feb;7(1):100353. doi: 10.1016/j.esmoop.2021.100353. Epub 2021 Dec - 23. - -PMID- 35558076 -OWN - NLM -STAT- MEDLINE -DCOM- 20220519 -LR - 20231105 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 13 -DP - 2022 -TI - Development and Validation of a Radiomics Nomogram Using Computed Tomography for - Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation - Pneumonitis for Patients With Non-Small Cell Lung Cancer. -PG - 870842 -LID - 10.3389/fimmu.2022.870842 [doi] -LID - 870842 -AB - BACKGROUND: The combination of immunotherapy and chemoradiotherapy has become the - standard therapeutic strategy for patients with unresected locally advance-stage - non-small cell lung cancer (NSCLC) and induced treatment-related adverse effects, - particularly immune checkpoint inhibitor-related pneumonitis (CIP) and radiation - pneumonitis (RP). The aim of this study is to differentiate between CIP and RP by - pretreatment CT radiomics and clinical or radiological parameters. METHODS: A - total of 126 advance-stage NSCLC patients with pneumonitis were enrolled in this - retrospective study and divided into the training dataset (n =88) and the - validation dataset (n = 38). A total of 837 radiomics features were extracted - from regions of interest based on the lung parenchyma window of CT images. A - radiomics signature was constructed on the basis of the predictive features by - the least absolute shrinkage and selection operator. A logistic regression was - applied to develop a radiomics nomogram. Receiver operating characteristics curve - and area under the curve (AUC) were applied to evaluate the performance of - pneumonitis etiology identification. RESULTS: There was no significant difference - between the training and the validation datasets for any clinicopathological - parameters in this study. The radiomics signature, named Rad-score, consisting of - 11 selected radiomics features, has potential ability to differentiate between - CIP and RP with the empirical and α-binormal-based AUCs of 0.891 and 0.896. These - results were verified in the validation dataset with AUC = 0.901 and 0.874, - respectively. The clinical and radiological parameters of bilateral changes (p < - 0.001) and sharp border (p = 0.001) were associated with the identification of - CIP and RP. The nomogram model showed good performance on discrimination in the - training dataset (AUC = 0.953 and 0.950) and in the validation dataset (AUC = - 0.947 and 0.936). CONCLUSIONS: CT-based radiomics features have potential values - for differentiating between patients with CIP and patients with RP. The addition - of bilateral changes and sharp border produced superior model performance on - classifying, which could be a useful method to improve related clinical - decision-making. -CI - Copyright © 2022 Qiu, Xing, Wang, Feng and Wen. -FAU - Qiu, Qingtao -AU - Qiu Q -AD - Department of Radiation Physics and Technology, Shandong Cancer Hospital and - Institute, Shandong First Medical University and Shandong Academy of Medical - Sciences, Jinan, China. -FAU - Xing, Ligang -AU - Xing L -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Wang, Yu -AU - Wang Y -AD - Department of Radiation Oncology, Shandong Provincial Hospital Affiliated to - Shandong First Medical University, Shandong First Medical University, Jinan, - China. -FAU - Feng, Alei -AU - Feng A -AD - Department of Radiation Oncology, Shandong Provincial Hospital Affiliated to - Shandong First Medical University, Shandong First Medical University, Jinan, - China. -FAU - Wen, Qiang -AU - Wen Q -AD - Department of Radiation Oncology, Shandong Provincial Hospital Affiliated to - Shandong First Medical University, Shandong First Medical University, Jinan, - China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20220426 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Lung Neoplasms/pathology -MH - Nomograms -MH - *Pneumonia/complications -MH - *Radiation Pneumonitis/diagnostic imaging/etiology -MH - Retrospective Studies -MH - Tomography, X-Ray Computed/methods -PMC - PMC9088878 -OTO - NOTNLM -OT - NSCLC -OT - differential diagnosis -OT - immune checkpoint inhibitor-related pneumonitis -OT - radiation pneumonitis -OT - radiomics nomogram -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/05/14 06:00 -MHDA- 2022/05/20 06:00 -PMCR- 2022/01/01 -CRDT- 2022/05/13 18:10 -PHST- 2022/02/07 00:00 [received] -PHST- 2022/03/24 00:00 [accepted] -PHST- 2022/05/13 18:10 [entrez] -PHST- 2022/05/14 06:00 [pubmed] -PHST- 2022/05/20 06:00 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2022.870842 [doi] -PST - epublish -SO - Front Immunol. 2022 Apr 26;13:870842. doi: 10.3389/fimmu.2022.870842. eCollection - 2022. - -PMID- 34936940 -OWN - NLM -STAT- MEDLINE -DCOM- 20220421 -LR - 20220616 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 162 -DP - 2022 Feb -TI - Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the - efficacy of durvalumab consolidation therapy after chemoradiotherapy in - unresectable locally advanced patients with non-small-cell lung cancer. -PG - 1-10 -LID - S0959-8049(21)01219-3 [pii] -LID - 10.1016/j.ejca.2021.11.013 [doi] -AB - BACKGROUND: Chemoradiotherapy (CRT) followed by durvalumab treatment improved - prognosis in unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). - This study aimed to evaluate whether the status of the immune-related tumour - microenvironment (TME) at baseline associates with the efficacy. METHODS: This - retrospective study evaluated immune-related TME factors, including programmed - cell death ligand 1 (PD-L1) (clone: 22C3) expression on tumour cells and the - density of CD8-positive tumour-infiltrating lymphocytes (TILs) at pre-CRT in - patients with unresectable LA-NSCLC treated with CRT only (CRT alone group) and - those treated with CRT followed by durvalumab (Durva group). RESULTS: A total of - 551 patients were included (N = 113 in the Durva group). Progression-free - survival (PFS) in the Durva group was significantly greater than that in the CRT - alone group (not reached [NR] vs 12.9 months; p = 0.002). In the CRT alone group, - neither PD-L1 expression nor TIL status affected PFS; in contrast, in the Durva - group, high density of CD8-positive TILs (TIL(High) ≥100/mm(2)) and - PD-L1-positive expression (tumour proportion score ≥1%; PD-L1+) was significantly - associated with longer PFS (TIL: NR vs 9.5 months; p = 0.002; and PD-L1: NR - vs 7.7 months; p = 0.003). On the other hand, in patients with epidermal growth - factor receptor mutations or anaplastic lymphoma kinase rearrangements, there was - no significant difference in PFS between the groups (Durva vs CRT alone: 9.9 - months vs 14.0 months; p = 0.77). CONCLUSIONS: PD-L1+ and TIL(High) at baseline - could be predictive markers of the efficacy of CRT followed by durvalumab. -CI - Copyright © 2021 Elsevier Ltd. All rights reserved. -FAU - Shirasawa, Masayuki -AU - Shirasawa M -AD - Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, - Chuo-ku, Tokyo, 104-0045, Japan; Department of Respiratory Medicine, Kitasato - University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara City, - Kanagawa, 252-0375, Japan. Electronic address: mshirasa@ncc.go.jp. -FAU - Yoshida, Tatsuya -AU - Yoshida T -AD - Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, - Chuo-ku, Tokyo, 104-0045, Japan; Department of Experimental Therapeutics, - National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. - Electronic address: tatyoshi@ncc.go.jp. -FAU - Imabayashi, Tatsuya -AU - Imabayashi T -AD - Department of Endoscopy, Respiratory Endoscopy Division, National Cancer Center - Hospital, Tokyo, 104-0045, Japan. -FAU - Okuma, Kae -AU - Okuma K -AD - Department of Radiation Therapy, National Cancer Center Hospital, Tokyo, - 104-0045, Japan. -FAU - Matsumoto, Yuji -AU - Matsumoto Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, - Chuo-ku, Tokyo, 104-0045, Japan; Department of Endoscopy, Respiratory Endoscopy - Division, National Cancer Center Hospital, Tokyo, 104-0045, Japan. -FAU - Masuda, Ken -AU - Masuda K -AD - Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, - Chuo-ku, Tokyo, 104-0045, Japan. -FAU - Shinno, Yuki -AU - Shinno Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, - Chuo-ku, Tokyo, 104-0045, Japan. -FAU - Okuma, Yusuke -AU - Okuma Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, - Chuo-ku, Tokyo, 104-0045, Japan. -FAU - Goto, Yasushi -AU - Goto Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, - Chuo-ku, Tokyo, 104-0045, Japan. -FAU - Horinouchi, Hidehito -AU - Horinouchi H -AD - Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, - Chuo-ku, Tokyo, 104-0045, Japan. -FAU - Tsuchida, Takaaki -AU - Tsuchida T -AD - Department of Endoscopy, Respiratory Endoscopy Division, National Cancer Center - Hospital, Tokyo, 104-0045, Japan. -FAU - Yamamoto, Noboru -AU - Yamamoto N -AD - Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, - Chuo-ku, Tokyo, 104-0045, Japan; Department of Experimental Therapeutics, - National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. -FAU - Nakayama, Yuko -AU - Nakayama Y -AD - Department of Radiation Therapy, National Cancer Center Hospital, Tokyo, - 104-0045, Japan. -FAU - Watanabe, Shun-Ichi -AU - Watanabe SI -AD - Department of Thoracic Surgery, National Cancer Center Hospital, 5-1-1, Tsukiji, - Chuo-ku, Tokyo, 104-0045, Japan. -FAU - Motoi, Noriko -AU - Motoi N -AD - Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1, - Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. -FAU - Ohe, Yuichiro -AU - Ohe Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, - Chuo-ku, Tokyo, 104-0045, Japan. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20211220 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 28X28X9OKV (durvalumab) -SB - IM -CIN - Eur J Cancer. 2022 May;167:149-151. doi: 10.1016/j.ejca.2022.02.015. PMID: - 35307255 -MH - *Antibodies, Monoclonal/immunology/pharmacology -MH - *B7-H1 Antigen/biosynthesis/immunology -MH - CD8-Positive T-Lymphocytes/immunology -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/immunology/radiotherapy -MH - Chemoradiotherapy -MH - Consolidation Chemotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - *Lymphocytes, Tumor-Infiltrating/immunology -MH - Prognosis -MH - Retrospective Studies -MH - Tumor Microenvironment -OTO - NOTNLM -OT - CD8 -OT - Durvalumab -OT - Locally advanced non-small-cell carcinoma -OT - Tumour-infiltrated lymphocytes -OT - and PD-L1 expression -COIS- Conflict of interest statement Shirasawa has nothing to disclose. Yoshida reports - grants from ONO Pharmaceutical, during the conduct of the study; grants and - personal fees from AstraZeneca, grants and personal fees from Bristol-Myers - Squibb, grants from Takeda, personal fees from Chugai, personal fees from - Novartis, grants from MSD, grants from Abbvie, outside the submitted work. - Imabayashi reports grants from Hitachi High-Tech Corporation, personal fees from - AstraZeneca, personal fees from COOK, personal fees from Chugai Pharma, personal - fees from Eli Lilly Japan, personal fees from MSD, personal fees from Thermo - Fisher Scientific K.K., personal fees from Johnson & Johnson Medical Devices - Companies Personal fees for lectures, personal fees from Olympus Personal fees - for lectures, outside the submitted work. K Okuma has nothing to - disclose. Matsumoto reports grants from National Cancer Centre Research and - Development Fund, grants from Grant-in-Aid for Scientific Research on Innovative - Areas, grants from Hitachi, Ltd., grants from Hitachi High-Technologies, personal - fees from Olympus, personal fees from AstraZeneca, personal fees from Novartis, - personal fees from COOK, personal fees from AMCO INC. outside the submitted - work. Masuda reports personal fees from Chugai, outside the submitted work. - Shinno has nothing to disclose. Y Okuma reports grants from AbbVie, outside the - submitted work. Goto reports grants and personal fees from Eli Lilly, personal - fees from Chugai, grants and personal fees from Taiho Pharmaceutical, personal - fees from Boehringer Ingelheim, grants and personal fees from Pfizer, grants and - personal fees from Novartis, personal fees from AstraZeneca, grants and personal - fees from MSD, grants and personal fees from Guardant Health, grants and personal - fees from Ono Pharmaceutical, grants from Kyorin, grants and personal fees from - Dai-ichi Sankyo, personal fees from Illumina, grants and personal fees from - Bristol Myers Squibb, outside the submitted work. Horinouchi reports grants and - personal fees from BMS, grants and personal fees from MSD, grants and personal - fees from Chugai, grants and personal fees from Taiho, grants and personal fees - from Astra Zeneca, grants from Astellas, grants from Merck Serono, grants from - Genomic Health, grants and personal fees from Lilly, grants and personal fees - from Ono, outside the submitted work. Tsuchida reports personal fees from Nippon - Medical School Foundation, grants from Japan Agency for Medical Research and - Development, grants from Foundation for Promotion Cancer Research, personal fees - from Hamamatsu University School of Medicine, outside the submitted - work;. Yamamoto reports grants from Chugai, grants from Taiho, grants from Eisai, - grants from Lilly, grants from Quintiles, grants from Astellas, grants from BMS, - grants from Novartis, grants from Daiichi-Sankyo, grants from Pfizer, grants from - Boehringer Ingelheim, grants from Kyowa-Hakko Kirin, grants from Bayer, grants - from Ono Pharmaceutical Co. Ltd., grants from Takeda, personal fees from Ono - Pharmaceutical Co. Ltd., personal fees from Chugai, personal fees from - AstraZeneca, personal fees from Pfizer, personal fees from Lilly, personal fees - from BMS, personal fees from Eisai, personal fees from Otsuka, personal fees from - Takeda, personal fees from Boehringer Ingelheim, personal fees from Cimic, grants - from Janssen Pharma, grants from MSD, grants from Merck, personal fees from - Sysmex, grants from GSK, grants from Sumitomo Dainippon, grants from Chiome - Bioscience Inc., outside the submitted work. Nakayama has nothing to - disclose. Watanabe has nothing to disclose. Motoi reports grants and personal - fees from Ono, grants from NEC, personal fees from Miraca Life Sciences, personal - fees from MSD, personal fees from Astra Zeneca, grants and personal fees from - Roche Diagnostics, personal fees from Novartis, personal fees from Taiho, - personal fees from Beckton Dickinson Japan, personal fees from Covidien Japan - Inc, outside the submitted work. Ohe reports grants and personal fees from - Bristol-Myers Squibb, grants and personal fees from ONO Pharmaceutical, grants - and personal fees from MSD, during the conduct of the study; grants and personal - fees from AstraZeneca, grants and personal fees from Amgen, personal fees from - Boehringer Ingelheim, personal fees from Celltrion, grants and personal fees from - Chugai, grants and personal fees from Eli Lilly, grants and personal fees from - Janssen, grants and personal fees from Kyorin, grants from Kissei, grants and - personal fees from Nippon Kayaku, grants and personal fees from Novartis, grants - from Ignyta, grants and personal fees from Taiho, grants and personal fees from - Takeda, personal fees from Pfizer, outside the submitted work. -EDAT- 2021/12/23 06:00 -MHDA- 2022/04/22 06:00 -CRDT- 2021/12/22 20:11 -PHST- 2021/11/05 00:00 [received] -PHST- 2021/11/08 00:00 [accepted] -PHST- 2021/12/23 06:00 [pubmed] -PHST- 2022/04/22 06:00 [medline] -PHST- 2021/12/22 20:11 [entrez] -AID - S0959-8049(21)01219-3 [pii] -AID - 10.1016/j.ejca.2021.11.013 [doi] -PST - ppublish -SO - Eur J Cancer. 2022 Feb;162:1-10. doi: 10.1016/j.ejca.2021.11.013. Epub 2021 Dec - 20. - -PMID- 33453313 -OWN - NLM -STAT- MEDLINE -DCOM- 20210423 -LR - 20210423 -IS - 1879-0887 (Electronic) -IS - 0167-8140 (Linking) -VI - 157 -DP - 2021 Apr -TI - Incidence, risk factors, and CT characteristics of radiation recall pneumonitis - induced by immune checkpoint inhibitor in lung cancer. -PG - 47-55 -LID - S0167-8140(21)00001-3 [pii] -LID - 10.1016/j.radonc.2021.01.001 [doi] -AB - BACKGROUND AND PURPOSE: Radiation recall pneumonitis (RRP) is a delayed - radiation-induced lung toxicity triggered by systemic agents, typically - anticancer drugs. Immune checkpoint inhibitors (ICIs) have recently been - identified as potential causal agents of RRP but its real incidence and potential - risk factors remain unknown. MATERIALS AND METHODS: Medical records and CTs of - patients treated with programmed death 1 (PD-1) or programmed death ligand 1 - (PD-L1) inhibitors for advanced lung cancer between 2014 and 2019 at our tertiary - center, and who had a previous history of lung irradiation were retrospectively - analyzed. We identified RRP as lung CT modifications occurring in the irradiation - field >6 months after conventionally fractionated radiotherapy completion and - >1 year after stereotactic body radiation therapy. Clinical and dosimetric data - were analyzed to identify potential risk factors for RRP. RESULTS: Among 348 - patients treated with ICIs, data from 80 eligible patients were analyzed (median - age, 69 years [interquartile range, 11]; 45 men). Fifteen patients (18.8%) - presented with RRP. Median time between end of radiotherapy and RRP was 450 days - (range, 231-1859). No risk factor was significantly associated with RRP. - ICI-related pneumonitis was associated with RRP in 33.3% of cases (p = 0.0021), - developing either concomitantly or after RRP. Incidence of grade ≥ 3 pneumonitis - in the RRP population was 13.3 %. CONCLUSION: We demonstrated a high incidence of - RRP (18.8%) in our population of previously irradiated patients treated with ICIs - for lung cancer. We identified no risk factors for RRP, but an association was - noted between RRP and ICI-related pneumonitis. -CI - Copyright © 2021 Elsevier B.V. All rights reserved. -FAU - Cousin, François -AU - Cousin F -AD - Department of Nuclear Medicine and Oncological Imaging, Liège, Belgium. - Electronic address: fcousin@chuliege.be. -FAU - Desir, Colin -AU - Desir C -AD - Department of Radiology, Liège, Belgium. -FAU - Ben Mustapha, Selma -AU - Ben Mustapha S -AD - Department of Radiotherapy, University Hospital (CHU) of Liège, Liège, Belgium. -FAU - Mievis, Carole -AU - Mievis C -AD - Department of Radiotherapy, University Hospital (CHU) of Liège, Liège, Belgium. -FAU - Coucke, Philippe -AU - Coucke P -AD - Department of Radiotherapy, University Hospital (CHU) of Liège, Liège, Belgium. -FAU - Hustinx, Roland -AU - Hustinx R -AD - Department of Nuclear Medicine and Oncological Imaging, Liège, Belgium. -LA - eng -PT - Journal Article -DEP - 20210114 -PL - Ireland -TA - Radiother Oncol -JT - Radiotherapy and oncology : journal of the European Society for Therapeutic - Radiology and Oncology -JID - 8407192 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Aged -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Incidence -MH - *Lung Neoplasms/drug therapy -MH - Male -MH - *Pneumonia -MH - *Radiation Pneumonitis/epidemiology/etiology -MH - Retrospective Studies -MH - Risk Factors -MH - Tomography, X-Ray Computed -OTO - NOTNLM -OT - Anti PD-1/PD-L1 -OT - Lung cancer -OT - Radiation pneumonitis -OT - Radiation recall pneumonitis -EDAT- 2021/01/17 06:00 -MHDA- 2021/04/24 06:00 -CRDT- 2021/01/16 20:08 -PHST- 2020/11/18 00:00 [received] -PHST- 2020/12/30 00:00 [revised] -PHST- 2021/01/02 00:00 [accepted] -PHST- 2021/01/17 06:00 [pubmed] -PHST- 2021/04/24 06:00 [medline] -PHST- 2021/01/16 20:08 [entrez] -AID - S0167-8140(21)00001-3 [pii] -AID - 10.1016/j.radonc.2021.01.001 [doi] -PST - ppublish -SO - Radiother Oncol. 2021 Apr;157:47-55. doi: 10.1016/j.radonc.2021.01.001. Epub 2021 - Jan 14. - -PMID- 34297160 -OWN - NLM -STAT- MEDLINE -DCOM- 20220228 -LR - 20240426 -IS - 1432-0851 (Electronic) -IS - 0340-7004 (Print) -IS - 0340-7004 (Linking) -VI - 71 -IP - 3 -DP - 2022 Mar -TI - Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line - treatment with chemotherapy for extensive-stage small-cell lung cancer. -PG - 637-644 -LID - 10.1007/s00262-021-03017-z [doi] -AB - OBJECTIVES: Programmed cell death-ligand 1 inhibitors plus chemotherapy - (PD-L1 + Chemo) have achieved substantial progress in extensive-stage small-cell - lung cancer (ES-SCLC). However, evidence about programmed cell death 1 inhibitors - plus chemotherapy (PD-1 + Chemo) in SCLC is relatively lacking. Whether PD-1 - inhibitors differ from PD-L1 inhibitors in their clinical outcomes remains - controversial. MATERIALS AND METHODS: We performed a meta-analysis to compare - efficacy and safety of PD-L1 + Chemo vs PD-1 + Chemo in ES-SCLC by searching - PubMed, Embase, the Cochrane Library, and major oncology conferences. We examined - overall survival (OS) as the primary outcome. Secondary outcomes included - progression-free survival (PFS), objective response rate (ORR), and - treatment-related adverse events (AEs). RESULTS: We included four randomized - trials (IMpower133, CASPIAN, KEYNOTE-604, and EA5161) with a total of 1553 - patients. Direct comparison showed that PD-L1 + Chemo (PFS: hazard ratio [HR] - 0.79; OS: HR 0.75) and PD-1 + Chemo (PFS: HR 0.72; OS: HR 0.77) significantly - prolonged survival time compared with chemotherapy alone. But PD-L1 + Chemo - (relative risk [RR]: 1.07) and PD-1 + Chemo (RR: 1.13) were not superior to - chemotherapy alone in terms of ORR. Indirect comparison showed no significant - difference in clinical efficacy between PD-L1 + Chemo and PD-1 + Chemo (OS: HR - 0.99; PFS: HR 1.10; ORR: RR 0.95). We further stratified patients according to - subgroups in terms of OS. In the subgroup of patients with brain metastasis, - PD-L1 + Chemo tended to prolong OS (HR: 0.61, 0.28 to 1.32). There were no - significant differences between PD-L1 + Chemo and PD-1 + Chemo regarding safety - analyses. However, PD-L1 + Chemo exhibited a better safety profile in reducing - the risk of treatment discontinuation due to AEs (RR: 0.43, 0.19 to 0.95) and - pneumonia (pneumonia of any grade, RR: 0.59, 0.24 to 1.42; pneumonia of - grade ≥ 3, RR: 0.37, 0.10 to 1.39). CONCLUSIONS: PD-L1 + Chemo and PD-1 + Chemo - provided a significant survival benefit relative to chemotherapy alone for - ES-SCLC. The efficacy and safety of PD-L1 + Chemo and PD-1 + Chemo were similar - based on current evidence. -CI - © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, - part of Springer Nature. -FAU - Yu, Hui -AU - Yu H -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of VIP Region, Sun Yat-Sen University Cancer Center, 651 Dongfeng East - Road, Guangzhou, 510060, China. -FAU - Chen, Ping -AU - Chen P -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of VIP Region, Sun Yat-Sen University Cancer Center, 651 Dongfeng East - Road, Guangzhou, 510060, China. -FAU - Cai, Xiuyu -AU - Cai X -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of VIP Region, Sun Yat-Sen University Cancer Center, 651 Dongfeng East - Road, Guangzhou, 510060, China. -FAU - Chen, Chen -AU - Chen C -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Radiotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, - China. -FAU - Zhang, Xuanye -AU - Zhang X -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. -FAU - He, Lina -AU - He L -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. -FAU - Zhou, Yixin -AU - Zhou Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. - zhouyx@sysucc.org.cn. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. - zhouyx@sysucc.org.cn. -AD - Department of VIP Region, Sun Yat-Sen University Cancer Center, 651 Dongfeng East - Road, Guangzhou, 510060, China. zhouyx@sysucc.org.cn. -FAU - Hong, Shaodong -AU - Hong S -AUID- ORCID: 0000-0002-5632-6857 -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. - hongshd@sysucc.org.cn. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. - hongshd@sysucc.org.cn. -AD - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. hongshd@sysucc.org.cn. -FAU - Zhang, Bei -AU - Zhang B -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. - zhangbei@sysucc.org.cn. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. - zhangbei@sysucc.org.cn. -AD - Department of VIP Region, Sun Yat-Sen University Cancer Center, 651 Dongfeng East - Road, Guangzhou, 510060, China. zhangbei@sysucc.org.cn. -LA - eng -GR - 81903176/National Natural Science Funds of China/ -GR - 2019A1515011596/Science and Technology Program of Guangdong Province/ -GR - C2019110/Medical Scientific Research Foundation of Guangdong Province/ -PT - Journal Article -PT - Meta-Analysis -DEP - 20210723 -PL - Germany -TA - Cancer Immunol Immunother -JT - Cancer immunology, immunotherapy : CII -JID - 8605732 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - Disease Management -MH - Disease Susceptibility -MH - Humans -MH - Immune Checkpoint Inhibitors/administration & dosage -MH - Lung Neoplasms/diagnosis/*drug therapy/etiology/metabolism -MH - Molecular Targeted Therapy -MH - Neoplasm Metastasis -MH - Neoplasm Staging -MH - Odds Ratio -MH - Prognosis -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -MH - Small Cell Lung Carcinoma/*drug therapy/etiology/metabolism/*pathology -MH - Treatment Outcome -PMC - PMC10992902 -OTO - NOTNLM -OT - Efficacy -OT - First-line therapy -OT - PD-1 inhibitors -OT - PD-L1 inhibitors -OT - Small-cell lung cancer -COIS- The authors declare that they have no competing interests. -EDAT- 2021/07/24 06:00 -MHDA- 2022/03/01 06:00 -PMCR- 2021/07/23 -CRDT- 2021/07/23 12:25 -PHST- 2021/02/25 00:00 [received] -PHST- 2021/07/11 00:00 [accepted] -PHST- 2021/07/24 06:00 [pubmed] -PHST- 2022/03/01 06:00 [medline] -PHST- 2021/07/23 12:25 [entrez] -PHST- 2021/07/23 00:00 [pmc-release] -AID - 10.1007/s00262-021-03017-z [pii] -AID - 3017 [pii] -AID - 10.1007/s00262-021-03017-z [doi] -PST - ppublish -SO - Cancer Immunol Immunother. 2022 Mar;71(3):637-644. doi: - 10.1007/s00262-021-03017-z. Epub 2021 Jul 23. - -PMID- 33002543 -OWN - NLM -STAT- MEDLINE -DCOM- 20210701 -LR - 20220202 -IS - 1879-355X (Electronic) -IS - 0360-3016 (Print) -IS - 0360-3016 (Linking) -VI - 109 -IP - 2 -DP - 2021 Feb 1 -TI - Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With - Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small - Cell Lung Cancer. -PG - 425-435 -LID - S0360-3016(20)34303-0 [pii] -LID - 10.1016/j.ijrobp.2020.09.031 [doi] -AB - PURPOSE: Consolidative thoracic radiation therapy (TRT) has been shown to improve - outcomes for patients with extensive stage small cell lung cancer. We - hypothesized that the addition of ipilimumab (IPI) and nivolumab (NIVO) after TRT - would improve outcomes for patients with extensive stage small cell lung cancer. - METHODS AND MATERIALS: Eligibility required stable disease or better after - platinum doublet chemotherapy. Study therapy included consolidative TRT to 30 Gy - in 10 fractions, targeting residual primary tumor and initially involved regional - lymph nodes. Two weeks after TRT, patients received concurrent IPI (3 mg/kg) and - NIVO (1 mg/kg) every 3 weeks for 4 doses followed by NIVO monotherapy (480 mg) - every 4 weeks until progression or up to 1 year. RESULTS: The study enrolled 21 - patients, with 6-month progression-free survival (PFS) of 24% (90% confidence - interval [CI], 11%-40%) and a median PFS of 4.5 months (95% CI, 2.7%-4.6%). The - 12-month overall survival (OS) was 48% (95% CI, 29%-64%) with a median OS of 11.7 - months (95% CI, 4.7%-16.0%). Fifty-two percent of patients had ≥1 possibly - related grade 3 to 4 immune-related adverse event. Grade 3 pulmonary and - gastrointestinal immune-related adverse events were recorded in 19% and 24% of - patients, respectively. Exploratory analysis showed increased cytotoxic T cell - (CD3+CD8+) tumor infiltration was associated with favorable PFS (P = .01) and OS - (P = .02). Reduction in peripheral blood CD3+CD8+ from baseline to after first - dose of IPI/NIVO was associated with improved PFS (P = .02) and OS (P = .02). - CONCLUSIONS: Consolidative IPI and NIVO after platinum-based chemotherapy and TRT - demonstrated a toxicity profile consistent with the known adverse events - attributable to IPI and NIVO. Although the study regimen did not significantly - improve PFS, the OS was higher than historic expectations. CD3+CD8+ tumor - infiltration and migration may identify patients most likely to have improved - outcomes in small cell lung cancer. -CI - Copyright © 2020 Elsevier Inc. All rights reserved. -FAU - Perez, Bradford A -AU - Perez BA -AD - Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research - Institute; Department of Immunology, H Lee Moffitt Cancer Center and Research - Institute; Department of Thoracic Oncology, H Lee Moffitt Cancer Center and - Research Institute. Electronic address: bradford.perez@moffitt.org. -FAU - Kim, Sungjune -AU - Kim S -AD - Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research - Institute; Department of Immunology, H Lee Moffitt Cancer Center and Research - Institute. -FAU - Wang, Minhsuan -AU - Wang M -AD - Department of Immunology, H Lee Moffitt Cancer Center and Research Institute. -FAU - Karimi, Ahmad M -AU - Karimi AM -AD - Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research - Institute. -FAU - Powell, Chase -AU - Powell C -AD - Department of Immunology, H Lee Moffitt Cancer Center and Research Institute. -FAU - Li, Jiannong -AU - Li J -AD - Department of Biostatistics, H Lee Moffitt Cancer Center and Research Institute. -FAU - Dilling, Thomas J -AU - Dilling TJ -AD - Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research - Institute; Department of Thoracic Oncology, H Lee Moffitt Cancer Center and - Research Institute. -FAU - Chiappori, Alberto -AU - Chiappori A -AD - Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research - Institute. -FAU - Latifi, Kujtim -AU - Latifi K -AD - Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research - Institute. -FAU - Rose, Trevor -AU - Rose T -AD - Department of Radiology, H Lee Moffitt Cancer Center and Research Institute. -FAU - Lannon, Austin -AU - Lannon A -AD - Clinical Trials Office, H Lee Moffitt Cancer Center and Research Institute. -FAU - MacMillan, Gretchen -AU - MacMillan G -AD - Clinical Trials Office, H Lee Moffitt Cancer Center and Research Institute. -FAU - Saller, James -AU - Saller J -AD - Department of Pathology, H Lee Moffitt Cancer Center and Research Institute. -FAU - Grass, G Daniel -AU - Grass GD -AD - Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research - Institute. -FAU - Rosenberg, Stephen -AU - Rosenberg S -AD - Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research - Institute; Department of Thoracic Oncology, H Lee Moffitt Cancer Center and - Research Institute. -FAU - Gray, Jhanelle -AU - Gray J -AD - Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research - Institute. -FAU - Haura, Eric -AU - Haura E -AD - Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research - Institute. -FAU - Creelan, Ben -AU - Creelan B -AD - Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research - Institute. -FAU - Tanvetyanon, Tawee -AU - Tanvetyanon T -AD - Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research - Institute. -FAU - Saltos, Andreas -AU - Saltos A -AD - Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research - Institute. -FAU - Shafique, Michael -AU - Shafique M -AD - Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research - Institute. -FAU - Boyle, Theresa A -AU - Boyle TA -AD - Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research - Institute; Department of Pathology, H Lee Moffitt Cancer Center and Research - Institute. -FAU - Schell, Michael J -AU - Schell MJ -AD - Department of Biostatistics, H Lee Moffitt Cancer Center and Research Institute. -FAU - Conejo-Garcia, Jose R -AU - Conejo-Garcia JR -AD - Department of Immunology, H Lee Moffitt Cancer Center and Research Institute. -FAU - Antonia, Scott J -AU - Antonia SJ -AD - Department of Medical Oncology, Duke Cancer Institute, Duke University Medical - Center. -LA - eng -SI - ClinicalTrials.gov/NCT03043599 -GR - K08 CA231454/CA/NCI NIH HHS/United States -GR - P30 CA076292/CA/NCI NIH HHS/United States -GR - R01 CA124515/CA/NCI NIH HHS/United States -GR - R01 CA201124/CA/NCI NIH HHS/United States -PT - Clinical Trial, Phase I -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20200928 -PL - United States -TA - Int J Radiat Oncol Biol Phys -JT - International journal of radiation oncology, biology, physics -JID - 7603616 -RN - 0 (Ipilimumab) -RN - 31YO63LBSN (Nivolumab) -RN - 49DFR088MY (Platinum) -SB - IM -MH - Aged -MH - Antineoplastic Combined Chemotherapy Protocols -MH - Combined Modality Therapy -MH - Female -MH - Humans -MH - Ipilimumab/*therapeutic use -MH - Lung Neoplasms/drug therapy/*pathology/*radiotherapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Nivolumab/*therapeutic use -MH - Platinum/*therapeutic use -MH - Progression-Free Survival -MH - Prospective Studies -MH - Small Cell Lung Carcinoma/drug therapy/*pathology/*radiotherapy -MH - Thorax/radiation effects -PMC - PMC8465780 -MID - NIHMS1633048 -EDAT- 2020/10/02 06:00 -MHDA- 2021/07/02 06:00 -PMCR- 2022/02/01 -CRDT- 2020/10/01 20:11 -PHST- 2020/05/12 00:00 [received] -PHST- 2020/07/28 00:00 [revised] -PHST- 2020/09/13 00:00 [accepted] -PHST- 2020/10/02 06:00 [pubmed] -PHST- 2021/07/02 06:00 [medline] -PHST- 2020/10/01 20:11 [entrez] -PHST- 2022/02/01 00:00 [pmc-release] -AID - S0360-3016(20)34303-0 [pii] -AID - 10.1016/j.ijrobp.2020.09.031 [doi] -PST - ppublish -SO - Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):425-435. doi: - 10.1016/j.ijrobp.2020.09.031. Epub 2020 Sep 28. - -PMID- 34470722 -OWN - NLM -STAT- MEDLINE -DCOM- 20220517 -LR - 20220520 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 23 -IP - 3 -DP - 2022 May -TI - Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II - Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to - Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced - Non-Squamous NSCLC After Chemo-Immunotherapy Induction. -PG - e269-e272 -LID - S1525-7304(21)00185-6 [pii] -LID - 10.1016/j.cllc.2021.07.004 [doi] -AB - BACKGROUND: Improvement in radiotherapy techniques and expected outcomes, as well - as in understanding the underlying biological mechanisms contributing to its - action (immunomodulation in primis), led to the integration of this therapeutical - approach in the current management of advanced non-small cell lung cancer - (NSCLC), not only in oncogene-driven tumors, but also in non-oncogene addicted - NSCLC where the combination of platinum-based chemotherapy plus pembrolizumab - represents nowadays the pivotal strategy. In this light, we have designed a - randomized phase II (ESPERa) trial to evaluate the efficacy and safety of adding - Stereotactic Body Radiotherapy (SBRT) to pembrolizumab-pemetrexed maintenance in - advanced NSCLC patients experiencing disease response or stability after - chemo-immunotherapy induction. PATIENTS AND METHODS: Advanced non-oncogene - addicted NSCLC patients with ECOG performance status of 0 or 1, who obtained - disease response or stability after 4 cycles of platinum-based chemotherapy plus - pembrolizumab will be randomized 2:1 to receive pembrolizumab-pemetrexed - maintenance plus SBRT vs pembrolizumab-pemetrexed alone. The primary endpoint is - progression-free survival (PFS). Concomitant translational researches will be - performed to identify potential prognostic and/or predictive biomarkers, as well - as to analyze and monitor tumour microenvironment and tumor-host interactions. - CONCLUSIONS: Although available data suggest the safety and efficacy of combining - immunotherapy and radiotherapy, their systematic integration in the current - first-line landscape still remains to be explored. If the pre-planned endpoints - of the ESPERa trial will be achieved, the addition of SBRT to - pembrolizumab-pemetrexed maintenance as a strategy to consolidate and ideally - improve the awaited benefit could be considered as a promising strategy in NSCLC - undergoing first-line therapy, as well as an interesting approach to be evaluated - in other disease setting, as well as in other oncological malignancies where - immunotherapy represents nowadays the standard-of-care. -CI - Copyright © 2021 Elsevier Inc. All rights reserved. -FAU - Belluomini, Lorenzo -AU - Belluomini L -AD - Section of Oncology, Department of Medicine, University of Verona School of - Medicine and Verona University Hospital Trust, Verona, Italy. -FAU - Dionisi, Valeria -AU - Dionisi V -AD - Section of Radiotherapy, Department of Surgery and Oncology, University of Verona - School of Medicine and Verona University Hospital Trust, Verona, Italy. -FAU - Palmerio, Silvia -AU - Palmerio S -AD - Section of Oncology, Department of Medicine, University of Verona School of - Medicine and Verona University Hospital Trust, Verona, Italy. -FAU - Vincenzi, Sofia -AU - Vincenzi S -AD - Section of Oncology, Department of Medicine, University of Verona School of - Medicine and Verona University Hospital Trust, Verona, Italy. -FAU - Avancini, Alice -AU - Avancini A -AD - Biomedical, Clinical and Experimental Sciences, Department of Medicine, - University of Verona Hospital Trust, Verona, Italy. -FAU - Casali, Miriam -AU - Casali M -AD - Section of Oncology, Department of Medicine, University of Verona School of - Medicine and Verona University Hospital Trust, Verona, Italy. -FAU - Riva, Silvia Teresa -AU - Riva ST -AD - Section of Oncology, Department of Medicine, University of Verona School of - Medicine and Verona University Hospital Trust, Verona, Italy. -FAU - Menis, Jessica -AU - Menis J -AD - Section of Oncology, Department of Medicine, University of Verona School of - Medicine and Verona University Hospital Trust, Verona, Italy. -FAU - Mazzarotto, Renzo -AU - Mazzarotto R -AD - Section of Radiotherapy, Department of Surgery and Oncology, University of Verona - School of Medicine and Verona University Hospital Trust, Verona, Italy. -FAU - Pilotto, Sara -AU - Pilotto S -AD - Section of Oncology, Department of Medicine, University of Verona School of - Medicine and Verona University Hospital Trust, Verona, Italy. -FAU - Milella, Michele -AU - Milella M -AD - Section of Oncology, Department of Medicine, University of Verona School of - Medicine and Verona University Hospital Trust, Verona, Italy. Electronic address: - michele.milella@univr.it. -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -DEP - 20210720 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 04Q9AIZ7NO (Pemetrexed) -RN - 49DFR088MY (Platinum) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -MH - Pemetrexed/therapeutic use -MH - Platinum/therapeutic use -MH - *Radiosurgery -MH - Tumor Microenvironment -OTO - NOTNLM -OT - Chemo-immunotherapy -OT - Clinical trial -OT - NSCLC -OT - Radiotherapy -OT - SBRT -COIS- Disclosure M.M. reports personal fees from Pfizer, EUSA Pharma and Astra Zeneca, - outside the submitted manuscript. S.P. received honoraria or speakers’ fee from - Astra-Zeneca, Eli-Lilly, BMS, Boehringer Ingelheim, MSD and Roche, outside the - submitted manuscript. All remaining authors have declared no conflicts of - interest. -EDAT- 2021/09/03 06:00 -MHDA- 2022/05/18 06:00 -CRDT- 2021/09/02 05:48 -PHST- 2021/02/03 00:00 [received] -PHST- 2021/07/04 00:00 [accepted] -PHST- 2021/09/03 06:00 [pubmed] -PHST- 2022/05/18 06:00 [medline] -PHST- 2021/09/02 05:48 [entrez] -AID - S1525-7304(21)00185-6 [pii] -AID - 10.1016/j.cllc.2021.07.004 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2022 May;23(3):e269-e272. doi: 10.1016/j.cllc.2021.07.004. Epub - 2021 Jul 20. - -PMID- 12934657 -OWN - NLM -STAT- MEDLINE -DCOM- 20031023 -LR - 20070607 -IS - 1473-7140 (Print) -IS - 1473-7140 (Linking) -VI - 3 -IP - 4 -DP - 2003 Aug -TI - Role of targeted therapy in non-small cell lung cancer: hype or hope? -PG - 443-55 -AB - New cytotoxic therapies, including the taxanes, gemcitabine (Gemzar), vinorelbine - (Navelbine) and irinotecan (Campto), have improved treatment outcome and expanded - treatment options in advanced non-small cell lung cancer. However, despite their - promise, a therapeutic plateau with response rates of 20-30% and 1-year survival - rates of 30-40% has been reached. It is doubtful if exchanging one agent for - another in various combinations will lead to any significant improvement. The - thrust of current research focuses on targeted therapy and its careful - integration into the standard treatment paradigm. These agents include compunds - targeted at growth factor receptors, angiogenesis, cyclooxygenase, farnesyl - transferase and protein kinase C-alpha. Preclinical models have demonstrated - synergy for many of these agents in combination with either chemotherapy or - radiation, although clinical challenges exist. These include the identification - of an optimal biologic dose, the proper integration of these agents into systemic - chemotherapy regimens, and selecting the best setting in which to test the - compounds. -FAU - Langer, Corey J -AU - Langer CJ -AD - Fox Chase Cancer Center, Philadelphia, PA 19111, USA. cj_langer@fccc.edu -LA - eng -PT - Journal Article -PT - Review -PL - England -TA - Expert Rev Anticancer Ther -JT - Expert review of anticancer therapy -JID - 101123358 -RN - 0 (Antineoplastic Agents) -SB - IM -MH - Antineoplastic Agents/administration & dosage/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/therapy -MH - Humans -MH - Immunotherapy -MH - Lung Neoplasms/*drug therapy/therapy -RF - 93 -EDAT- 2003/08/26 05:00 -MHDA- 2003/10/24 05:00 -CRDT- 2003/08/26 05:00 -PHST- 2003/08/26 05:00 [pubmed] -PHST- 2003/10/24 05:00 [medline] -PHST- 2003/08/26 05:00 [entrez] -AID - ERA030405 [pii] -AID - 10.1586/14737140.3.4.443 [doi] -PST - ppublish -SO - Expert Rev Anticancer Ther. 2003 Aug;3(4):443-55. doi: 10.1586/14737140.3.4.443. - -PMID- 37537968 -OWN - NLM -STAT- MEDLINE -DCOM- 20230928 -LR - 20231003 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 12 -IP - 17 -DP - 2023 Sep -TI - A pilot trial of consolidation bevacizumab after hypo-fractionated concurrent - chemoradiotherapy in patients with unresectable locally advanced non-squamous - non-small-cell lung cancer. -PG - 17638-17647 -LID - 10.1002/cam4.6381 [doi] -AB - PURPOSE: To determine the feasibility of incorporating bevacizumab consolidation - into hypo-fractionated concurrent chemoradiotherapy (hypo-CCRT) for patients with - unresectable locally advanced non-squamous non-small-cell lung cancer - (LA-NS-NSCLC). PATIENTS AND METHODS: Eligible patients were treated with hypo-RT - (40Gy in 10 fractions) followed by hypo-boost (24-28Gy in 6-7 fractions), along - with concurrent weekly chemotherapy. Patients who completed the hypo-CCRT without - experiencing ≥G2 toxicities received consolidation bevacizumab every 3 weeks for - up to 1 year, until disease progression or unacceptable treatment-related - toxicities. The primary endpoint was the risk of G4 or higher hemorrhage. - Secondary endpoints included progression-free survival (PFS), overall survival - (OS), locoregional failure-free survival (LRFS), distant metastasis-free survival - (DMFS), and objective response rate (ORR). All time-to-event endpoints (OS, PFS, - LRFS, and DMFS) were measured from the start of radiotherapy. RESULTS: Between - December 2017 and July 2020, a total of 27 patients were included in the - analysis, with a median follow-up duration of 28.0 months. One patient (3.7%) - developed G5 hemorrhage during bevacizumab consolidation. Additionally, seven - patients (25.9%) had G3 cough and three patients (11.1%) experienced G3 - pneumonitis. The ORR for the entire cohort was 92.6%. The median OS was - 37.0 months (95% confidence interval, 8.9-65.1 months), the median PFS was - 16.0 months (95% confidence interval, 14.0-18.0 months), the median LRFS was not - reached, and the median DMFS was 18.0 months. CONCLUSIONS: This pilot study met - its goal of demonstrating the tolerability of consolidation bevacizumab after - hypo-CCRT. Further investigation of antiangiogenic and immunotherapy combinations - in LA-NSCLC is warranted, while the potential for grade 3 respiratory toxicities - should be taken into consideration. -CI - © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Huo, LanQing -AU - Huo L -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer - Center, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -FAU - Chu, Chu -AU - Chu C -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer - Center, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -FAU - Jiang, XiaoBo -AU - Jiang X -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer - Center, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -FAU - Zheng, ShiYang -AU - Zheng S -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer - Center, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -FAU - Zhang, PengXin -AU - Zhang P -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer - Center, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -FAU - Zhou, Rui -AU - Zhou R -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer - Center, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -FAU - Chen, NaiBin -AU - Chen N -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer - Center, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -FAU - Guo, JinYu -AU - Guo J -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer - Center, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -FAU - Qiu, Bo -AU - Qiu B -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer - Center, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -AD - Lung Cancer Institute of Sun Yat-sen University, Guangzhou, China. -AD - Guangdong Association Study of Thoracic Oncology, Guangzhou, China. -FAU - Liu, Hui -AU - Liu H -AUID- ORCID: 0000-0002-6855-6668 -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -AD - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer - Center, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -AD - Lung Cancer Institute of Sun Yat-sen University, Guangzhou, China. -AD - Guangdong Association Study of Thoracic Oncology, Guangzhou, China. -LA - eng -PT - Journal Article -DEP - 20230803 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 2S9ZZM9Q9V (Bevacizumab) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - Bevacizumab/adverse effects -MH - *Lung Neoplasms/pathology -MH - Pilot Projects -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - Neoplasm Staging -MH - Chemoradiotherapy/adverse effects -PMC - PMC10523965 -OTO - NOTNLM -OT - LA-NS-NSCLC -OT - consolidation bevacizumab -OT - hypo-CCRT -OT - treatment-related toxicity -COIS- The authors declared no conflict of interest. -EDAT- 2023/08/04 06:43 -MHDA- 2023/09/28 06:42 -PMCR- 2023/08/03 -CRDT- 2023/08/04 02:43 -PHST- 2023/07/10 00:00 [revised] -PHST- 2023/04/20 00:00 [received] -PHST- 2023/07/16 00:00 [accepted] -PHST- 2023/09/28 06:42 [medline] -PHST- 2023/08/04 06:43 [pubmed] -PHST- 2023/08/04 02:43 [entrez] -PHST- 2023/08/03 00:00 [pmc-release] -AID - CAM46381 [pii] -AID - 10.1002/cam4.6381 [doi] -PST - ppublish -SO - Cancer Med. 2023 Sep;12(17):17638-17647. doi: 10.1002/cam4.6381. Epub 2023 Aug 3. - -PMID- 36697072 -OWN - NLM -STAT- MEDLINE -DCOM- 20230127 -LR - 20230202 -IS - 1791-7530 (Electronic) -IS - 0250-7005 (Linking) -VI - 43 -IP - 2 -DP - 2023 Feb -TI - Comparison of the Efficacy and Toxicity of Concurrent Chemoradiotherapy and - Durvalumab and Concurrent Chemoradiotherapy Alone for Locally Advanced Non-small - Cell Lung Cancer With N3 Lymph Node Metastasis. -PG - 675-682 -LID - 10.21873/anticanres.16205 [doi] -AB - BACKGROUND/AIM: Efficacy and toxicity of concurrent chemoradiotherapy (CCRT) and - durvalumab for locally advanced non-small cell lung cancer (LA-NSCLC) with N3 - lymph node metastasis remain unclear. We aimed to evaluate the clinical outcomes - of patients who received CCRT and durvalumab (durvalumab cohort) and compare - their outcomes with those of patients who received CCRT alone (CCRT-alone - cohort). PATIENTS AND METHODS: The data of patients who had received treatment - between November 2008 and February 2022 and were followed up for at least 3 - months were retrospectively analyzed. Local control, progression-free survival, - and overall survival were evaluated using Kaplan-Meier analysis and compared - using the log-rank test. Toxicity was evaluated using the Common Terminology - Criteria for Adverse Events version 5.0. RESULTS: The data of 29 patients were - analyzed (median follow-up period: 22 months). Among them, 17 received CCRT alone - and 12 received CCRT and durvalumab. There were 14 patients with stage IIIB and - 15 with stage IIIC LA-NSCLC. The durvalumab cohort (89%) had a significantly - higher 1-year local control rate than the CCRT-alone cohort (47%; p=0.035). No - significant difference was observed in either progression-free or overall - survival between the two cohorts. Grade ≥2 pneumonitis was observed in 6 (50%) - and 7 (41%) patients in the durvalumab and CCRT-alone cohorts, respectively. - CONCLUSION: CCRT with durvalumab may be effective against LA-NSCLC with N3 lymph - node metastasis. The incidence of grade 2 pneumonitis was slightly higher in the - durvalumab cohort than in the CCRT-alone cohort, suggesting the need for careful - patient monitoring after treatment. -CI - Copyright © 2023 International Institute of Anticancer Research (Dr. George J. - Delinasios), All rights reserved. -FAU - Abe, Takanori -AU - Abe T -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan; mrtaka100@yahoo.co.jp. -FAU - Iino, Misaki -AU - Iino M -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Saito, Satoshi -AU - Saito S -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Aoshika, Tomomi -AU - Aoshika T -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Ryuno, Yasuhiro -AU - Ryuno Y -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Ohta, Tomohiro -AU - Ohta T -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Igari, Mitsunobu -AU - Igari M -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Hirai, Ryuta -AU - Hirai R -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Kumazaki, Y U -AU - Kumazaki YU -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Miura, Y U -AU - Miura YU -AD - Department of Respiratory Medicine, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Kaira, Kyoichi -AU - Kaira K -AD - Department of Respiratory Medicine, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Kagamu, Hiroshi -AU - Kagamu H -AD - Department of Respiratory Medicine, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Noda, Shin-Ei -AU - Noda SE -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Kato, Shingo -AU - Kato S -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -LA - eng -PT - Journal Article -PL - Greece -TA - Anticancer Res -JT - Anticancer research -JID - 8102988 -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Lymphatic Metastasis -MH - Retrospective Studies -MH - Neoplasm Staging -MH - Chemoradiotherapy/adverse effects -OTO - NOTNLM -OT - Locally advanced non-small cell lung cancer -OT - N3 lymph node metastasis -OT - chemoradiotherapy -OT - durvalumab -EDAT- 2023/01/26 06:00 -MHDA- 2023/01/28 06:00 -CRDT- 2023/01/25 20:53 -PHST- 2022/11/21 00:00 [received] -PHST- 2022/12/05 00:00 [revised] -PHST- 2022/12/06 00:00 [accepted] -PHST- 2023/01/25 20:53 [entrez] -PHST- 2023/01/26 06:00 [pubmed] -PHST- 2023/01/28 06:00 [medline] -AID - 43/2/675 [pii] -AID - 10.21873/anticanres.16205 [doi] -PST - ppublish -SO - Anticancer Res. 2023 Feb;43(2):675-682. doi: 10.21873/anticanres.16205. - -PMID- 35049695 -OWN - NLM -STAT- MEDLINE -DCOM- 20220324 -LR - 20220324 -IS - 1718-7729 (Electronic) -IS - 1198-0052 (Print) -IS - 1198-0052 (Linking) -VI - 29 -IP - 1 -DP - 2022 Jan 7 -TI - Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in - Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional - Experience. -PG - 221-230 -LID - 10.3390/curroncol29010021 [doi] -AB - BACKGROUND: The safety impact of radiotherapy (RT) timing relative to immune - checkpoint inhibitors (ICIs) for advanced non-small-cell lung cancer (NSCLC) is - unclear. We investigated if RT within 14 days (Interval 1) and 90 days (Interval - 2) of ICI use is associated with toxicities compared to RT outside these - intervals. METHODS: Advanced NSCLC patients treated with both RT and ICIs were - reviewed. Toxicities were graded as per CTCAE v4.0 and attributed to either ICIs - or RT by clinicians. Associations between RT timing and Grade ≥2 toxicities were - analyzed using logistic regression models adjusted for patient, disease, and - treatment factors (α = 0.05). RESULTS: Sixty-four patients were identified. - Twenty received RT within Interval 1 and 40 within Interval 2. There were 20 - Grade ≥2 toxicities in 18 (28%) patients; pneumonitis (6) and nausea (2) were - most prevalent. One treatment-related death (immune encephalitis) was observed. - Rates of patients with Grade ≥2 toxicities were 35%/25% in the group with/without - RT within Interval 1 and 30%/25% in the group with/without RT within Interval 2. - No significant association between RT timing relative to ICI use period and Grade - ≥2 toxicities was observed. CONCLUSION: Albeit limited by the small sample size, - the result suggested that pausing ICIs around RT use may not be necessary. -FAU - Tjong, Michael C -AU - Tjong MC -AD - Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Sunnybrook - Hospital, Toronto, ON M4N3M5, Canada. -FAU - Ragulojan, Malavan -AU - Ragulojan M -AD - Faculty of Medicine, McMaster University, Hamilton, ON L8S4L8, Canada. -FAU - Poon, Ian -AU - Poon I -AD - Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Sunnybrook - Hospital, Toronto, ON M4N3M5, Canada. -FAU - Louie, Alexander V -AU - Louie AV -AD - Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Sunnybrook - Hospital, Toronto, ON M4N3M5, Canada. -FAU - Cheng, Susanna Y -AU - Cheng SY -AD - Department of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, - Sunnybrook Hospital, Toronto, ON M4N3M5, Canada. -FAU - Doherty, Mark -AU - Doherty M -AD - Department of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, - Sunnybrook Hospital, Toronto, ON M4N3M5, Canada. -FAU - Zhang, Liying -AU - Zhang L -AD - Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Sunnybrook - Hospital, Toronto, ON M4N3M5, Canada. -FAU - Ung, Yee -AU - Ung Y -AD - Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Sunnybrook - Hospital, Toronto, ON M4N3M5, Canada. -FAU - Cheung, Patrick -AU - Cheung P -AD - Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Sunnybrook - Hospital, Toronto, ON M4N3M5, Canada. -FAU - Cheema, Parneet K -AU - Cheema PK -AD - Department of Medical Oncology and Hematology, William Osler Health System, - Brampton, ON L6R3J7, Canada. -LA - eng -PT - Journal Article -DEP - 20220107 -PL - Switzerland -TA - Curr Oncol -JT - Current oncology (Toronto, Ont.) -JID - 9502503 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Lung Neoplasms/drug therapy/radiotherapy -PMC - PMC8775081 -OTO - NOTNLM -OT - immunotherapy -OT - radiotherapy -OT - safety -OT - timing -OT - toxicity -COIS- A.V.L. reports personal fees from AstraZeneca, personal fees from RefleXion, and - personal fees from Varian Medical Systems Inc. S.Y.C. reported honoraria from - Roche and Boehringer Ingelheim. M.D. reports grants and personal fees from - AstraZeneca, grants and personal fees from Merck, personal fees from Roche, - personal fees from Takeda, personal fees from Boehringer Ingelheim, and personal - fees from Eisai. P.K.C. has been an adviser to and received honoraria from - Boehringer Ingelheim, Bristol–Myers Squibb, AstraZeneca, Merck, Roche, Novartis, - and Takeda. The rest of the authors declare no conflicts of interest. -EDAT- 2022/01/21 06:00 -MHDA- 2022/03/25 06:00 -PMCR- 2022/01/07 -CRDT- 2022/01/20 12:26 -PHST- 2021/11/07 00:00 [received] -PHST- 2022/01/04 00:00 [revised] -PHST- 2022/01/05 00:00 [accepted] -PHST- 2022/01/20 12:26 [entrez] -PHST- 2022/01/21 06:00 [pubmed] -PHST- 2022/03/25 06:00 [medline] -PHST- 2022/01/07 00:00 [pmc-release] -AID - curroncol29010021 [pii] -AID - curroncol-29-00021 [pii] -AID - 10.3390/curroncol29010021 [doi] -PST - epublish -SO - Curr Oncol. 2022 Jan 7;29(1):221-230. doi: 10.3390/curroncol29010021. - -PMID- 39078223 -OWN - NLM -STAT- MEDLINE -DCOM- 20241003 -LR - 20241003 -IS - 1365-2567 (Electronic) -IS - 0019-2805 (Linking) -VI - 173 -IP - 3 -DP - 2024 Nov -TI - Spatial tertiary lymphoid structures imply response to anti-PD-1 plus anlotinib - in advanced non-small cell lung cancer. -PG - 536-551 -LID - 10.1111/imm.13841 [doi] -AB - Despite breakthroughs of immunotherapy synergistically combined with blockade of - vascular endothelial growth factor receptor, several patients with advanced - non-small cell lung cancer (NSCLC) experience non-response or followed relapse. - Organized lymphoid aggregates, termed tertiary lymphoid structures (TLSs), are - found to be associated with improved response to immunotherapy. Here, we explore - the landscapes of TLSs in tumour tissues from a real-world retrospective study. - Our investigation showed that with a median follow-up of 11.2 months, the ORR was - 28.6% (18/63, 95% CI 17.9-41.3) and the median PFS was 6.1 (95% CI 5.5-6.6) - months in NSCLC patients treated with PD-1 blockade combined with anlotinib. By - multiplex immunofluorescence (mIF) analysis, spatially, more TLSs and high CD20+ - B-cell ratio in TLSs were associated with higher ORR. High density of - intratumoral CD8+ T cells showed better ORR and PFS. The numbers of CD8+ T cells - with a distance within 20 μm and 20-50 μm between tumour cells were higher in - responders than non-responders. But responders had significantly higher TLSs - within 20 μm rather than within 20-50 μm of tumour cells than non-responders. The - inflamed immunophenotyping occupied higher proportions in responders and was - associated with better PFS. Besides, tumour cells in non-responders were found - more temporal cell-in-cell structures than responders, which could protect inner - cells from T-cell attacks. Taken together, landscape of TLSs and proximity - architecture may imply superior responses to PD-1 blockade combined with - anlotinib for patients with advanced non-small cell lung cancer. -CI - © 2024 John Wiley & Sons Ltd. -FAU - Ma, Jianli -AU - Ma J -AD - Department of Radiation Oncology, Harbin Medical University Cancer Hospital, - Harbin, Heilongjiang Province, People's Republic of China. -FAU - Deng, Yuwei -AU - Deng Y -AD - Department of Medical Oncology, Harbin Medical University Cancer Hospital, - Harbin, Heilongjiang Province, People's Republic of China. -FAU - Zhang, Minghui -AU - Zhang M -AD - Department of Medical Oncology, Harbin Medical University Cancer Hospital, - Harbin, Heilongjiang Province, People's Republic of China. -FAU - Zhang, Qingyuan -AU - Zhang Q -AUID- ORCID: 0000-0001-8116-5293 -AD - Department of Medical Oncology, Harbin Medical University Cancer Hospital, - Harbin, Heilongjiang Province, People's Republic of China. -LA - eng -PT - Journal Article -DEP - 20240730 -PL - England -TA - Immunology -JT - Immunology -JID - 0374672 -RN - 0 (anlotinib) -RN - 0 (Indoles) -RN - 0 (Quinolines) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (PDCD1 protein, human) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/immunology/pathology -MH - *Lung Neoplasms/drug therapy/immunology/pathology -MH - Male -MH - Female -MH - *Indoles/therapeutic use -MH - *Quinolines/therapeutic use/administration & dosage -MH - Middle Aged -MH - Aged -MH - *Programmed Cell Death 1 Receptor/antagonists & inhibitors/metabolism -MH - *Immune Checkpoint Inhibitors/therapeutic use/pharmacology -MH - *Tertiary Lymphoid Structures/immunology -MH - Retrospective Studies -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - CD8-Positive T-Lymphocytes/immunology -MH - Lymphocytes, Tumor-Infiltrating/immunology/drug effects/metabolism -MH - Treatment Outcome -MH - Tumor Microenvironment/drug effects/immunology -MH - Adult -MH - Aged, 80 and over -OTO - NOTNLM -OT - PD‐1 blockade -OT - advanced non‐small cell lung cancer -OT - anlotinib -OT - cell‐in‐cell structures -OT - tertiary lymphoid structure -EDAT- 2024/07/30 12:44 -MHDA- 2024/10/03 06:58 -CRDT- 2024/07/30 09:24 -PHST- 2023/08/13 00:00 [received] -PHST- 2024/07/11 00:00 [accepted] -PHST- 2024/10/03 06:58 [medline] -PHST- 2024/07/30 12:44 [pubmed] -PHST- 2024/07/30 09:24 [entrez] -AID - 10.1111/imm.13841 [doi] -PST - ppublish -SO - Immunology. 2024 Nov;173(3):536-551. doi: 10.1111/imm.13841. Epub 2024 Jul 30. - -PMID- 31911323 -OWN - NLM -STAT- MEDLINE -DCOM- 20210406 -LR - 20210406 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 140 -DP - 2020 Feb -TI - Effects of checkpoint inhibitors in advanced non-small cell lung cancer at - population level from the National Immunotherapy Registry. -PG - 107-112 -LID - S0169-5002(19)30775-5 [pii] -LID - 10.1016/j.lungcan.2019.12.011 [doi] -AB - OBJECTIVE: Phase III studies of checkpoint inhibitors changed the therapeutic - landscape for lung cancer. In 2015 the Dutch Society of Chest Physicians (NVALT) - introduced a national immunotherapy registry for patients with lung cancer; - quality standards for hospitals were implemented. At population level we studied - clinical benefit in daily practice and in patients who are underrepresented in - phase III trials. MATERIALS AND METHODS: From the initial introduction of - checkpoint inhibitors in the Netherlands patients were centrally registered. - Educational programs and quality control were provided under supervision of - NVALT. The largest immunotherapy providing hospitals were compared to hospitals - who provided less checkpoint inhibitors as marker of experience. Patients - characteristics, treatment and side effects, response rate and survival were - studied. RESULTS: A total of 2676 patients were registered, 2302 with follow up - data were evaluated. Between October 2015 and December 2017 a gradual increase - from 12 to 30 qualified hospitals showed no major toxicity differences. Toxicity - led to a hospital admission rate of 9.1 with an average duration of 10.4 days. - Overall tumor response was 21.8 % and median overall survival 12.6 months. - Overall survival was not significantly different for patients aged ≥ 75 years, - those having brain metastases or selected auto-immune diseases before start - checkpoint inhibitors compared to younger patients or those without, - respectively. Survival outcomes were worse in patients with PS 2+, non-smokers, - and patients who received any palliative radiotherapy (HR 2.1, 95 % CI 1.7-2.7; - 1.3, 95 % CI 1.0-1.6 and 1.2, 95 % CI 1.1-1.4, respectively). CONCLUSIONS: - Changes in the therapeutic landscape did not lead to major differences in quality - of care between hospitals. Elderly patients, those with brain metastases or - selected auto-immune disease underrepresented in clinical trials did not do worse - on checkpoint inhibitors, except for those with PS 2 + . -CI - Copyright © 2020 Elsevier B.V. All rights reserved. -FAU - Smit, H J M -AU - Smit HJM -AD - Department of Pulmonary Diseases, Rijnstate Hospital, Arnhem, the Netherlands. -FAU - Aerts, J -AU - Aerts J -AD - Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, the - Netherlands. -FAU - van den Heuvel, M -AU - van den Heuvel M -AD - Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, - the Netherlands. -FAU - Hiltermann, T J N -AU - Hiltermann TJN -AD - Department of Pulmonary Diseases, University of Groningen and University Medical - Center Groningen, Groningen, the Netherlands. -FAU - Bahce, I -AU - Bahce I -AD - Department of Pulmonary Diseases, Amsterdam University Medical Center, Amsterdam, - the Netherlands. -FAU - Smit, E F -AU - Smit EF -AD - Department of Thoracic Oncology, Antoni Van Leeuwenhoek Hospital, Amsterdam, the - Netherlands. -FAU - Dingemans, A-M C -AU - Dingemans AC -AD - Department of Pulmonary Diseases, University Medical Center Maastricht, - Maastricht, the Netherlands. -FAU - Hendriks, L E -AU - Hendriks LE -AD - Department of Pulmonary Diseases, University Medical Center Maastricht, - Maastricht, the Netherlands. -FAU - Stigt, J A -AU - Stigt JA -AD - Department of Pulmonary Diseases, Isala Hospital, Zwolle, the Netherlands. -FAU - Schramel, F M N H -AU - Schramel FMNH -AD - Department of Pulmonary Diseases, St. Antonius Hospital, Nieuwegein, the - Netherlands. -FAU - van Tinteren, H -AU - van Tinteren H -AD - Department of Thoracic Oncology, Antoni Van Leeuwenhoek Hospital, Amsterdam, the - Netherlands. -FAU - Groen, H J M -AU - Groen HJM -AD - Department of Pulmonary Diseases, University of Groningen and University Medical - Center Groningen, Groningen, the Netherlands. Electronic address: - h.j.m.groen@umcg.nl. -CN - all participants of NVALT Immunotherapy Register (see addendum) -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20191228 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Adenocarcinoma of Lung/drug therapy/immunology/pathology -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Brain Neoplasms/*drug therapy/immunology/secondary -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/pathology -MH - Carcinoma, Squamous Cell/drug therapy/immunology/pathology -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Immunotherapy/*methods -MH - Lung Neoplasms/*drug therapy/immunology/pathology -MH - Male -MH - Middle Aged -MH - Netherlands -MH - Prognosis -MH - Registries/*statistics & numerical data -MH - Small Cell Lung Carcinoma/*drug therapy/immunology/pathology -MH - Survival Rate -OTO - NOTNLM -OT - Advanced non-small cell lung cancer -OT - Check point inhibitors -OT - Immunotherapy -OT - Population study -OT - Underrepresented population -EDAT- 2020/01/09 06:00 -MHDA- 2021/04/07 06:00 -CRDT- 2020/01/09 06:00 -PHST- 2019/06/14 00:00 [received] -PHST- 2019/12/11 00:00 [revised] -PHST- 2019/12/18 00:00 [accepted] -PHST- 2020/01/09 06:00 [pubmed] -PHST- 2021/04/07 06:00 [medline] -PHST- 2020/01/09 06:00 [entrez] -AID - S0169-5002(19)30775-5 [pii] -AID - 10.1016/j.lungcan.2019.12.011 [doi] -PST - ppublish -SO - Lung Cancer. 2020 Feb;140:107-112. doi: 10.1016/j.lungcan.2019.12.011. Epub 2019 - Dec 28. - -PMID- 10068267 -OWN - NLM -STAT- MEDLINE -DCOM- 19990303 -LR - 20041117 -IS - 1078-0432 (Print) -IS - 1078-0432 (Linking) -VI - 3 -IP - 12 Pt 2 -DP - 1997 Dec -TI - Combined modality therapy of lung cancer. -PG - 2638-47 -AB - Combined modality therapy for lung cancer was first demonstrated to be successful - in limited-stage small cell lung cancer. Concurrent administration of - chemotherapy with chest and elective brain irradiation appears to produce the - best results, with cisplatin/etoposide as the core chemotherapy. Using such - programs, 2-year survival in the 40% range and 5-year survivals in excess of 20% - may be expected, based on the results of multiple studies. Attempts to improve on - these results through the use of altered schemes of chest irradiation or the - delivery of high-dose consolidation chemotherapy are ongoing but to date have not - been shown to affect survival significantly. We remain at a plateau in the - effectiveness of combined modality therapy for small cell lung cancer, with - little evidence that it impacts survival at all in extensive-stage disease. The - incorporation of new agents in combination chemotherapy regimens, more "specific" - immunotherapy directed at tumor-associated antigens, and the potential adjunctive - use of broad-spectrum neuropeptide antagonists offer promise for the future. In - non-small cell lung cancer, the sequential use of platinum-based chemotherapy and - chest irradiation appears superior in survival to standard, daily fractionated - radiation therapy used alone, with long-term survival increased from 5-10% to - 15-20%. Concurrent administration of chemotherapy with cisplatin/etoposide and - chest irradiation produces 2-year survival in the range of 30%, about twice that - would be expected for radiation therapy alone, but has not been compared to it in - the setting of a randomized trial. Low-dose cisplatin on a daily basis has been - combined as a "sensitizer" with chest irradiation, producing initial results that - appeared encouraging. However, these have not been reproduced in subsequent, - randomized trials. Another approach to combined modalities has been to give - chemotherapy or chemotherapy/radiation therapy as induction, followed by surgical - resection, with or without subsequent additional treatment. Most patients - (80-85%) can be resected, with encouraging survival at 2 and 3 years in the - Southwest Oncology Group experience (37 and 26%, respectively). However, toxicity - is greater, and such an approach is associated with an overall mortality risk in - the range of 10%. A current intergroup study attempts to define the role of - surgery in this setting. The major recent development that is likely to influence - the future of combined modality therapy for this disease is the advent of - multiple new chemotherapeutic agents, such as the taxanes, gemcitabine, - vinorelbine, and the topoisomerase-I inhibitors, which have activity in stage IV - disease. The immediate challenge is how to combine these agents with platinum - analogues, radiation, and surgery. Aiding this process may be the use of - molecular biological "markers" that may predict the chance of success or failure - with a given systemic agent. The next decade is likely to see substantial - improvements in the outcome of treatment for patients with stages I-III non-small - cell lung cancer, based on the systemic exploration of combined modalities. -FAU - Livingston, R B -AU - Livingston RB -AD - Division of Oncology, University of Washington, Seattle, 98195, USA. -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - Clin Cancer Res -JT - Clinical cancer research : an official journal of the American Association for - Cancer Research -JID - 9502500 -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/mortality/*therapy -MH - Carcinoma, Small Cell/mortality/*therapy -MH - Combined Modality Therapy -MH - Disease-Free Survival -MH - Humans -MH - Lung Neoplasms/mortality/*therapy -MH - Survival Analysis -RF - 94 -EDAT- 1999/03/06 00:00 -MHDA- 1999/03/06 00:01 -CRDT- 1999/03/06 00:00 -PHST- 1999/03/06 00:00 [pubmed] -PHST- 1999/03/06 00:01 [medline] -PHST- 1999/03/06 00:00 [entrez] -PST - ppublish -SO - Clin Cancer Res. 1997 Dec;3(12 Pt 2):2638-47. - -PMID- 33302114 -OWN - NLM -STAT- MEDLINE -DCOM- 20210423 -LR - 20210423 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 143 -DP - 2021 Jan -TI - Dynamic changes in circulating PD-1(+)CD8(+) T lymphocytes for predicting - treatment response to PD-1 blockade in patients with non-small-cell lung cancer. -PG - 113-126 -LID - S0959-8049(20)31315-0 [pii] -LID - 10.1016/j.ejca.2020.10.028 [doi] -AB - BACKGROUND: The predictive value of immune monitoring with circulating CD8(+) T - lymphocytes for treatment response to programmed cell death protein 1 (PD-1) - inhibitors has not been explored in non-small-cell lung cancer (NSCLC), prompting - us to investigate whether dynamic changes in PD-1(+)CD8(+) T lymphocytes have - predictive value for durable clinical benefit (DCB) and survival after PD-1 - blockade. METHODS: Patients with recurrent and/or metastatic NSCLC treated with - PD-1 inhibitors were enrolled (discovery cohort; n = 94). Peripheral blood was - obtained immediately before and after one cycle of treatment with PD-1 blockade. - Phenotyping of circulating CD8(+) T lymphocytes was conducted using multi-colour - flow cytometry. Predictive values of dynamic changes in circulating PD-1(+)CD8(+) - T lymphocytes during the first cycle were validated in an independent cohort - (validation cohort; n = 54) of a prospective trial with a PD-1 inhibitor - (NCT03486119). RESULTS: Circulating PD-1(+)CD8(+) T lymphocytes were enriched - with effector/memory populations with elevated expression of activation- and - exhaustion-related markers. Reduction in the frequency of PD-1(+) cells among - CD8(+) T lymphocytes after one cycle of treatment was associated with a higher - probability of DCB and superior survival outcomes in the discovery cohort. - Similar results were obtained in the analysis of tumour antigen NY-ESO-1-specific - CD8(+) T lymphocytes and the validation cohort. Mechanistically, PD-1 molecule - expression on CD8(+) T lymphocytes suppresses the effector functions of tumour - antigen-specific CD8(+) T lymphocytes. CONCLUSIONS: Dynamic changes in - circulating PD-1(+)CD8(+) T lymphocytes predict clinical, and survival benefit - from PD-1 blockade treatment in NSCLC, providing a useful tool to identify - patient subgroups who will optimally benefit from PD-1 inhibitors. -CI - Copyright © 2020 Elsevier Ltd. All rights reserved. -FAU - Kim, Chang Gon -AU - Kim CG -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea; Division of Medical Oncology, - Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College - of Medicine, Seoul, Republic of Korea. -FAU - Hong, Min Hee -AU - Hong MH -AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer - Center, Yonsei University College of Medicine, Seoul, Republic of Korea. -FAU - Kim, Kyung Hwan -AU - Kim KH -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea; Department of Radiation - Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, - Republic of Korea. -FAU - Seo, In-Ho -AU - Seo IH -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. -FAU - Ahn, Beung-Chul -AU - Ahn BC -AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer - Center, Yonsei University College of Medicine, Seoul, Republic of Korea. -FAU - Pyo, Kyoung-Ho -AU - Pyo KH -AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer - Center, Yonsei University College of Medicine, Seoul, Republic of Korea; JE-UK - Institute for Cancer Research, JEUK Co. Ltd., Gumi, Republic of Korea. -FAU - Synn, Chun-Bong -AU - Synn CB -AD - Severance Biomedical Science Institute, Yonsei University College of Medicine, - Seoul, Republic of Korea. -FAU - Yoon, Hong In -AU - Yoon HI -AD - Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College - of Medicine, Seoul, Republic of Korea. -FAU - Shim, Hyo Sup -AU - Shim HS -AD - Department of Pathology, Severance Hospital, Yonsei University College of - Medicine, Seoul, Republic of Korea. -FAU - Lee, Yong Il -AU - Lee YI -AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer - Center, Yonsei University College of Medicine, Seoul, Republic of Korea. -FAU - Choi, Seong Jin -AU - Choi SJ -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. -FAU - Lee, Yun Jeong -AU - Lee YJ -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. -FAU - Kim, Ellen Janine -AU - Kim EJ -AD - Department of Biological Engineering, Massachusetts Institute of Technology, - Cambridge, MA, USA. -FAU - Kim, Youngun -AU - Kim Y -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. -FAU - Kwak, Jeong-Eun -AU - Kwak JE -AD - Biomedical Science and Engineering Interdisciplinary Program, Korea Advanced - Institute of Science and Technology, Daejeon, Republic of Korea. -FAU - Jung, Jaehyung -AU - Jung J -AD - Biomedical Science and Engineering Interdisciplinary Program, Korea Advanced - Institute of Science and Technology, Daejeon, Republic of Korea. -FAU - Park, Su-Hyung -AU - Park SH -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. -FAU - Paik, Soonmyung -AU - Paik S -AD - Severance Biomedical Science Institute, Yonsei University College of Medicine, - Seoul, Republic of Korea. -FAU - Shin, Eui-Cheol -AU - Shin EC -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. Electronic address: - ecshin@kaist.ac.kr. -FAU - Kim, Hye Ryun -AU - Kim HR -AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer - Center, Yonsei University College of Medicine, Seoul, Republic of Korea. - Electronic address: nobelg@yuhs.ac. -LA - eng -SI - ClinicalTrials.gov/NCT03486119 -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20201207 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - CD8-Positive T-Lymphocytes/*metabolism -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology/*therapeutic use -MH - Lung Neoplasms/*drug therapy -MH - Male -MH - Middle Aged -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -OTO - NOTNLM -OT - Anti-programmed cell death-1 treatment -OT - Biomarker -OT - CD8(+) T lymphocytes -OT - Non-small-cell lung cancer -COIS- Conflict of interest statement None to declare. -EDAT- 2020/12/11 06:00 -MHDA- 2021/04/24 06:00 -CRDT- 2020/12/10 20:12 -PHST- 2020/07/19 00:00 [received] -PHST- 2020/10/04 00:00 [revised] -PHST- 2020/10/08 00:00 [accepted] -PHST- 2020/12/11 06:00 [pubmed] -PHST- 2021/04/24 06:00 [medline] -PHST- 2020/12/10 20:12 [entrez] -AID - S0959-8049(20)31315-0 [pii] -AID - 10.1016/j.ejca.2020.10.028 [doi] -PST - ppublish -SO - Eur J Cancer. 2021 Jan;143:113-126. doi: 10.1016/j.ejca.2020.10.028. Epub 2020 - Dec 7. - -PMID- 33415571 -OWN - NLM -STAT- MEDLINE -DCOM- 20210323 -LR - 20220531 -IS - 1437-7772 (Electronic) -IS - 1341-9625 (Linking) -VI - 26 -IP - 4 -DP - 2021 Apr -TI - Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with - unresectable stage III non-small cell lung cancer receiving chemoradiotherapy. -PG - 659-669 -LID - 10.1007/s10147-020-01856-x [doi] -AB - BACKGROUND: The expression of programmed cell death-ligand 1 (PD-L1) is a - biomarker for administering immune check point inhibitors in patients with - advanced stage non-small cell lung cancer. Although the consolidation therapy of - durvalumab after definitive chemoradiotherapy has become the new standard of care - for patients with unresectable stage III non-small cell lung cancer, the - prevalence and prognostic role of PD-L1 expression in this population remain - unclear. METHODS: We retrospectively reviewed data from patients with - unresectable stage III non-small cell lung cancer who received definitive - chemoradiotherapy at our institution between 2012 and 2017. Levels of PD-L1 were - assessed using 22C3 antibody, and associations of progression-free and overall - survival rates with PD-L1 statuses at a tumor proportion score cutoff of 1% were - analyzed. RESULTS: Among the 104 patients enrolled, PD-L1 statuses were as - follows: tumor proportion score < 1%, 73 (70.2%); 1-49%, 21 (20.2%); and ≥ 50%, - 10 (9.6%). The number of patients with stage III non-small cell lung cancer with - pretreatment PD-L1 tumor proportion score ≥ 1% was less than the number with - advanced stage disease. There was no association between patient characteristics - and PD-L1 status, and no significant differences were observed in - progression-free and overall survival rates relative to PD-L1 status. CONCLUSION: - Expression of PD-L1 in patients with stage III non-small cell cancer before - chemoradiotherapy should be assessed because of the low prevalence of tumors with - tumor proportion scores ≥ 1%. Further studies are needed to clarify whether - durvalumab improves survival after definitive chemoradiotherapy, irrespective of - tumor PD-L1 expression. -FAU - Mamesaya, Nobuaki -AU - Mamesaya N -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -AD - Division of Respiratory Medicine, Nihon University School of Medicine, Tokyo, - Japan. -FAU - Muramatsu, Koji -AU - Muramatsu K -AD - Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Yabe, Michitoshi -AU - Yabe M -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Kodama, Hiroaki -AU - Kodama H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Nishioka, Naoya -AU - Nishioka N -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Miyawaki, Taichi -AU - Miyawaki T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Miyawaki, Eriko -AU - Miyawaki E -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Kobayashi, Haruki -AU - Kobayashi H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Omori, Shota -AU - Omori S -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Wakuda, Kazushige -AU - Wakuda K -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Ono, Akira -AU - Ono A -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Kenmotsu, Hirotsugu -AU - Kenmotsu H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Naito, Tateaki -AU - Naito T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Murakami, Haruyasu -AU - Murakami H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Harada, Hideyuki -AU - Harada H -AD - Division of Radiation Therapy, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Sugino, Takashi -AU - Sugino T -AD - Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Shimizu, Tetsuo -AU - Shimizu T -AD - Division of Respiratory Medicine, Nihon University School of Medicine, Tokyo, - Japan. -FAU - Gon, Yasuhiro -AU - Gon Y -AD - Division of Respiratory Medicine, Nihon University School of Medicine, Tokyo, - Japan. -FAU - Takahashi, Toshiaki -AU - Takahashi T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. t.takahashi@scchr.jp. -LA - eng -PT - Journal Article -DEP - 20210107 -PL - Japan -TA - Int J Clin Oncol -JT - International journal of clinical oncology -JID - 9616295 -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -RN - 0 (CD274 protein, human) -RN - 0 (Ligands) -SB - IM -MH - Apoptosis -MH - B7-H1 Antigen/analysis -MH - Biomarkers, Tumor/analysis -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - Chemoradiotherapy -MH - Humans -MH - Ligands -MH - *Lung Neoplasms/drug therapy -MH - Retrospective Studies -OTO - NOTNLM -OT - Chemoradiotherapy -OT - Immunohistochemistry -OT - PD-L1 expression -OT - Unresectable stage III non-small cell lung cancer -EDAT- 2021/01/09 06:00 -MHDA- 2021/03/24 06:00 -CRDT- 2021/01/08 06:16 -PHST- 2020/08/14 00:00 [received] -PHST- 2020/12/15 00:00 [accepted] -PHST- 2021/01/09 06:00 [pubmed] -PHST- 2021/03/24 06:00 [medline] -PHST- 2021/01/08 06:16 [entrez] -AID - 10.1007/s10147-020-01856-x [pii] -AID - 10.1007/s10147-020-01856-x [doi] -PST - ppublish -SO - Int J Clin Oncol. 2021 Apr;26(4):659-669. doi: 10.1007/s10147-020-01856-x. Epub - 2021 Jan 7. - -PMID- 35799182 -OWN - NLM -STAT- MEDLINE -DCOM- 20220711 -LR - 20220716 -IS - 1748-717X (Electronic) -IS - 1748-717X (Linking) -VI - 17 -IP - 1 -DP - 2022 Jul 7 -TI - Locally advanced NSCLC: a plea for sparing the ipsilateral normal - lung-prospective, clinical trial with DART-bid (dose-differentiated accelerated - radiation therapy, 1.8 Gy twice daily) by VMAT. -PG - 120 -LID - 10.1186/s13014-022-02083-6 [doi] -LID - 120 -AB - BACKGROUND: In radiation treatment of locally advanced non-small cell lung cancer - (LA-NSCLC), 'margins' from internal target volumes to planning target volumes in - the range of 12 to 23 mm are reported, and avoiding exposure of the contralateral - lung is common practice. We investigated prospectively an approach with tight - margins (7 mm) and maximal sparing of the ipsilateral normal lung. Mature results - for the first endpoint (pneumonitis) and further toxicities are reported. - METHODS: Primary tumors were treated by VMAT with 73.8-90.0 Gy in positive - correlation to tumor volumes, nodes with 61.2 Gy, a restricted volume of nodes - electively with 45 Gy. Fractional doses of 1.8 Gy bid, interval 8 h. Before - radiotherapy, two cycles platin-based chemotherapy were given. 12 patients - finished maintenance therapy with Durvalumab. Median follow up time for all - patients is 19.4 months, for patients alive 27.0 months (3.4-66.5 months). - RESULTS: 100 consecutive, unselected patients with LA-NSCLC in stages II through - IVA were enrolled (UICC/AJCC, 8th edition). No acute grade 4/5 toxicity occurred. - Pneumonitis grade 2 and 3 was observed in 12% and 2% of patients, respectively; - lowering the risk of pneumonitis grade ≥ 2 in comparison to the largest study in - the literature investigating pneumonitis in LA-NSCLC, is significant - (p < 0.0006). Acute esophageal toxicity grade 1, 2 and 3 occurred in 12%, 57% and - 3% of patients, respectively. Two patients showed late bronchial - stricture/atelectasis grade 2. In two patients with lethal pulmonary haemorrhages - a treatment correlation cannot be excluded. Median overall survival for all stage - III patients, and for those with 'RTOG 0617 inclusion criteria' is 46.6 and - 50.0 months, respectively. CONCLUSIONS: Overall toxicity is low. In comparison to - results in the literature, maximal sparing the ipsilateral normal lung lowers the - risk for pneumonitis significantly. TRIAL REGISTRATION: Ethics committee of - Vorarlberg, Austria; EK-0.04-105, Registered 04/09/2017-Retrospectively - registered. http://www.ethikkommission-vorarlberg.at. -CI - © 2022. The Author(s). -FAU - Wurstbauer, Karl -AU - Wurstbauer K -AUID- ORCID: 0000-0003-3628-7907 -AD - Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, - 6800, Feldkirch, Austria. karl.wurstbauer@lkhf.at. -FAU - Kazil, Margit -AU - Kazil M -AD - Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, - 6800, Feldkirch, Austria. -FAU - Meinschad, Marco -AU - Meinschad M -AD - Academic Teaching Hospital, Institute of Medical Physics, Feldkirch, Austria. -FAU - Pinter, Raoul -AU - Pinter R -AD - Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, - 6800, Feldkirch, Austria. -FAU - De Vries, Catharina -AU - De Vries C -AD - Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, - 6800, Feldkirch, Austria. -FAU - Clemens, Patrick -AU - Clemens P -AD - Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, - 6800, Feldkirch, Austria. -FAU - Kreuter, Christof -AU - Kreuter C -AD - Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, - 6800, Feldkirch, Austria. -FAU - Hernler, Tamara -AU - Hernler T -AD - Department for Pneumology, Academic Teaching Hospital, Hohenems, Austria. -FAU - Hitzl, Wolfgang -AU - Hitzl W -AD - Team Biostatistics and Publication of Clincial Studies, FM&TT, Paracelsus Medical - University, Salzburg, Austria. -FAU - Cerkl, Peter -AU - Cerkl P -AD - Department for Pneumology, Academic Teaching Hospital, Hohenems, Austria. -FAU - Künzler, Thomas -AU - Künzler T -AD - Academic Teaching Hospital, Institute of Medical Physics, Feldkirch, Austria. -FAU - De Vries, Alexander -AU - De Vries A -AD - Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, - 6800, Feldkirch, Austria. -LA - eng -PT - Journal Article -DEP - 20220707 -PL - England -TA - Radiat Oncol -JT - Radiation oncology (London, England) -JID - 101265111 -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung -MH - Humans -MH - Lung/pathology -MH - *Lung Neoplasms -MH - Prospective Studies -MH - Radiotherapy Dosage -PMC - PMC9264580 -OTO - NOTNLM -OT - DART-bid -OT - Locally advanced NSCLC -OT - Lung cancer -OT - Margins -OT - Planning -OT - QUANTEC -OT - Radiation dose intensification -OT - VMAT -COIS- The authors declare that they have no competing interests. -EDAT- 2022/07/08 06:00 -MHDA- 2022/07/12 06:00 -PMCR- 2022/07/07 -CRDT- 2022/07/07 23:46 -PHST- 2021/12/08 00:00 [received] -PHST- 2022/06/14 00:00 [accepted] -PHST- 2022/07/07 23:46 [entrez] -PHST- 2022/07/08 06:00 [pubmed] -PHST- 2022/07/12 06:00 [medline] -PHST- 2022/07/07 00:00 [pmc-release] -AID - 10.1186/s13014-022-02083-6 [pii] -AID - 2083 [pii] -AID - 10.1186/s13014-022-02083-6 [doi] -PST - epublish -SO - Radiat Oncol. 2022 Jul 7;17(1):120. doi: 10.1186/s13014-022-02083-6. - -PMID- 32770608 -OWN - NLM -STAT- MEDLINE -DCOM- 20201224 -LR - 20201224 -IS - 1349-7006 (Electronic) -IS - 1347-9032 (Print) -IS - 1347-9032 (Linking) -VI - 111 -IP - 12 -DP - 2020 Dec -TI - Efficacy of local therapy for oligoprogressive disease after programmed cell - death 1 blockade in advanced non-small cell lung cancer. -PG - 4442-4452 -LID - 10.1111/cas.14605 [doi] -AB - Immune checkpoint inhibitors (ICIs) have dramatically changed the strategy used - to treat patients with non-small-cell lung cancer (NSCLC); however, the vast - majority of patients eventually develop progressive disease (PD) and acquire - resistance to ICIs. Some patients experience oligoprogressive disease. Few - retrospective studies have evaluated clinical efficacy in patients with - oligometastatic progression who received local therapy after ICI treatment. We - conducted a retrospective analysis of advanced NSCLC patients who received PD-1 - inhibitor monotherapy with nivolumab or pembrolizumab to evaluate the effects of - ICIs on the patterns of progression and the efficacy of local therapy for - oligoprogressive disease. Of the 307 patients treated with ICIs, 148 were - evaluated in our study; 42 were treated with pembrolizumab, and 106 were treated - with nivolumab. Thirty-eight patients showed oligoprogression. Male sex, a lack - of driver mutations, and smoking history were significantly correlated with the - risk of oligoprogression. Primary lesions were most frequently detected at - oligoprogression sites (15 patients), and 6 patients experienced abdominal lymph - node (LN) oligoprogression. Four patients showed evidence of new abdominal LN - oligometastases. There was no significant difference in overall survival (OS) - between the local therapy group and the switch therapy group (reached vs. not - reached, P = .456). We summarized clinical data on the response of - oligoprogressive NSCLC to ICI therapy. The results may help to elucidate the - causes of ICI resistance and indicate that the use of local therapy as the - initial treatment in this setting is feasible treatment option. -CI - © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd - on behalf of Japanese Cancer Association. -FAU - Kagawa, Yusuke -AU - Kagawa Y -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. -AD - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City - University Graduate School of Medicine Sciences, Nagoya, Japan. -FAU - Furuta, Hiromi -AU - Furuta H -AUID- ORCID: 0000-0001-7027-0354 -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. -FAU - Uemura, Takehiro -AU - Uemura T -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. -AD - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City - University Graduate School of Medicine Sciences, Nagoya, Japan. -FAU - Watanabe, Naohiro -AU - Watanabe N -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. -FAU - Shimizu, Junichi -AU - Shimizu J -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. -FAU - Horio, Yoshitsugu -AU - Horio Y -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. -FAU - Kuroda, Hiroaki -AU - Kuroda H -AD - Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan. -FAU - Inaba, Yoshitaka -AU - Inaba Y -AD - Department of Diagnostic and Interventional Radiology, Aichi Cancer Center - Hospital, Nagoya, Japan. -FAU - Kodaira, Takeshi -AU - Kodaira T -AD - Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. -FAU - Masago, Katsuhiro -AU - Masago K -AD - Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, - Nagoya, Japan. -FAU - Fujita, Shiro -AU - Fujita S -AD - Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, - Nagoya, Japan. -FAU - Niimi, Akio -AU - Niimi A -AD - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City - University Graduate School of Medicine Sciences, Nagoya, Japan. -FAU - Hida, Toyoaki -AU - Hida T -AUID- ORCID: 0000-0003-3537-0020 -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. -LA - eng -GR - Kyowa Hakko Kirin/ -GR - Chugai Pharmaceutical/ -GR - Bristol-Myers Squibb/ -GR - Taiho Pharmaceutical/ -GR - Merck Sharp and Dohme/ -GR - Astellas Pharma/ -GR - AbbVie/ -GR - Ono Pharmaceutical/ -GR - Clovis Oncology/ -GR - Daiichi Sankyo Company/ -GR - Pfizer/ -GR - Novartis Pharma/ -GR - Takeda Pharmaceutical Company/ -GR - AstraZeneca/ -GR - Boehringer Ingelheim/ -PT - Journal Article -DEP - 20201031 -PL - England -TA - Cancer Sci -JT - Cancer science -JID - 101168776 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 31YO63LBSN (Nivolumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - *Ablation Techniques -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/immunology/mortality/pathology/*therapy -MH - Combined Modality Therapy/methods -MH - Disease Progression -MH - Feasibility Studies -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology/*therapeutic use -MH - Lung Neoplasms/immunology/pathology/*therapy -MH - Male -MH - Middle Aged -MH - Nivolumab/pharmacology/therapeutic use -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - Progression-Free Survival -MH - Retrospective Studies -PMC - PMC7734009 -OTO - NOTNLM -OT - local therapy -OT - nivolumab -OT - oligometastasis -OT - oligoprogression -OT - pembrolizumab -COIS- Dr. Niimi has a financial relationship as a lecturer with Eli Lily Inc, Novartis - Pharma Inc, AstraZeneca Inc, MSD Inc, Ono Pharmaceutical Industries, Kyorin - Pharmaceutical Inc, Daiichi Sankyo Inc, Boehringer Ingelheim Inc, Kyowa Hakko - Kirin Inc, Taiho Pharmaceutical Inc, GlaxoSmithKline, and Sanofi Inc, and has - received grants from Eli Lily Inc and Novartis Pharma Inc. Dr. Hida has received - grants from Pfizer, MSD, Kissei, AstraZeneca, Clovis Oncology, Novartis, Ono - Pharmaceutical Co., Ignyta, Merck Serono, Daiichi Sankyo, Nippon Boehringer - Ingelheim, Eisai, Kyowa Hakko Kirin, Taiho Pharmaceutical Co., Bristol‐Meyers - Squibb, Chugai Pharmaceutical Co., Astellas, AbbVie, Takeda Pharmaceutical Co., - and Dainippon Sumitomo Pharma. Other authors (than Dr. Niimi and Dr. Hida) have - no conflict of interest. -EDAT- 2020/08/10 06:00 -MHDA- 2020/12/29 06:00 -PMCR- 2020/12/01 -CRDT- 2020/08/10 06:00 -PHST- 2020/03/23 00:00 [received] -PHST- 2020/07/10 00:00 [revised] -PHST- 2020/07/23 00:00 [accepted] -PHST- 2020/08/10 06:00 [pubmed] -PHST- 2020/12/29 06:00 [medline] -PHST- 2020/08/10 06:00 [entrez] -PHST- 2020/12/01 00:00 [pmc-release] -AID - CAS14605 [pii] -AID - 10.1111/cas.14605 [doi] -PST - ppublish -SO - Cancer Sci. 2020 Dec;111(12):4442-4452. doi: 10.1111/cas.14605. Epub 2020 Oct 31. - -PMID- 34340919 -OWN - NLM -STAT- MEDLINE -DCOM- 20211125 -LR - 20211125 -IS - 1433-2981 (Electronic) -IS - 0936-6555 (Linking) -VI - 33 -IP - 12 -DP - 2021 Dec -TI - Dose-dense Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy for Stage - IIB/IIIA Non-small Cell Lung Cancer - A Phase II trial. -PG - e553-e560 -LID - S0936-6555(21)00267-3 [pii] -LID - 10.1016/j.clon.2021.07.008 [doi] -AB - AIMS: The approach to potentially resectable non-small cell lung cancer (NSCLC) - remains controversial. There is a benefit of neoadjuvant chemotherapy (NACT), but - the ideal regimen is unknown. We evaluated the efficacy and safety of dose-dense - NACT in potentially resectable NSCLC in this phase II trial. MATERIALS AND - METHODS: Paclitaxel at 80 mg/m(2) on days 1, 8 and 15 with AUC-6 carboplatin on - day 1, 3 weekly for four cycles was evaluated as NACT. Patients with Eastern - Cooperative Oncology Group performance status 0-2, stage IIB and IIIA (with only - non-bulky N2 nodes) were included. The primary end point was the objective - response rate. Secondary end points included toxicity, progression-free survival, - recurrence-free survival, complete resection rate and overall survival. The - relative dose intensity (RDI) was calculated to define tolerability - (CTRI/2016/05/006916). RESULTS: In total, 37 patients were enrolled (median age - 55 years). Most (78.8%) were smokers. Most patients had adenocarcinoma (57.6%) - and stage IIIA disease (81.0%) according to the seventh American Joint Committee - on Cancer staging system. Seventy-eight per cent of patients completed four - cycles. The objective response rate was 75.6% with a complete response in 10.8%. - The mean RDI of paclitaxel was 88.61%, with 68.0% of patients able to maintain an - RDI ≥85.0%. In total, 187 toxicity events were recorded (120 grade 1, 64 grade 2 - and three grade 3 events). Common toxicities were peripheral neuropathy (20.3%), - myalgia (19.8%), nausea (15.7%) and neutropenia (10.2%). There were no - treatment-related deaths. Seventeen patients underwent surgery (lobectomy 82.4%). - After a median follow-up of 47 months (95% confidence interval 27-50.7 months), - the median progression-free survival was 9.6 months (7.4-17.4) and overall - survival was 29.2 months (16.0-37.2). CONCLUSION: Dose-dense - paclitaxel-carboplatin is feasible, safe and efficacious and should be evaluated - further in potentially resectable NSCLC. -CI - Copyright © 2021 The Royal College of Radiologists. Published by Elsevier Ltd. - All rights reserved. -FAU - Mittal, A -AU - Mittal A -AD - Department of Medical Oncology, All India Institute of Medical Sciences, Ansari - Nagar, New Delhi, India. -FAU - Malik, P S -AU - Malik PS -AD - Department of Medical Oncology, All India Institute of Medical Sciences, Ansari - Nagar, New Delhi, India. Electronic address: drprabhatsm@gmail.com. -FAU - Kumar, S -AU - Kumar S -AD - Department of Surgical Oncology, All India Institute of Medical Sciences, Ansari - Nagar, New Delhi, India. -FAU - Saikia, J -AU - Saikia J -AD - Department of Surgical Oncology, All India Institute of Medical Sciences, Ansari - Nagar, New Delhi, India. -FAU - Chitikela, S -AU - Chitikela S -AD - Department of Medical Oncology, All India Institute of Medical Sciences, Ansari - Nagar, New Delhi, India. -FAU - Khurana, S -AU - Khurana S -AD - Department of Medical Oncology, All India Institute of Medical Sciences, Ansari - Nagar, New Delhi, India. -FAU - Bharti, S -AU - Bharti S -AD - Department of Oncoanaesthesia and Palliative Medicine, All India Institute of - Medical Sciences, Ansari Nagar, New Delhi, India. -FAU - Jain, D -AU - Jain D -AD - Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, - New Delhi, India. -FAU - Pathy, S -AU - Pathy S -AD - Department of Radiation Oncology, All India Institute of Medical Sciences, Ansari - Nagar, New Delhi, India. -FAU - Thulkar, S -AU - Thulkar S -AD - Department of Radiodiagnosis, All India Institute of Medical Sciences, Ansari - Nagar, New Delhi, India. -FAU - Kumar, R -AU - Kumar R -AD - Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari - Nagar, New Delhi, India. -FAU - Madan, K -AU - Madan K -AD - Department of Pulmonary Medicine, All India Institute of Medical Sciences, Ansari - Nagar, New Delhi, India. -FAU - Mohan, A -AU - Mohan A -AD - Department of Pulmonary Medicine, All India Institute of Medical Sciences, Ansari - Nagar, New Delhi, India. -LA - eng -SI - CTRI/CTRI/2016/05/006916 -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20210731 -PL - England -TA - Clin Oncol (R Coll Radiol) -JT - Clinical oncology (Royal College of Radiologists (Great Britain)) -JID - 9002902 -RN - BG3F62OND5 (Carboplatin) -RN - P88XT4IS4D (Paclitaxel) -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - Carboplatin/adverse effects -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Middle Aged -MH - Neoadjuvant Therapy -MH - Paclitaxel/adverse effects -OTO - NOTNLM -OT - chemoimmunotherapy -OT - dose-dense chemotherapy -OT - locally advanced NSCLC -OT - objective response rate -OT - potentially resectable NSCLC -EDAT- 2021/08/04 06:00 -MHDA- 2021/11/26 06:00 -CRDT- 2021/08/03 05:45 -PHST- 2021/01/26 00:00 [received] -PHST- 2021/06/02 00:00 [revised] -PHST- 2021/07/14 00:00 [accepted] -PHST- 2021/08/04 06:00 [pubmed] -PHST- 2021/11/26 06:00 [medline] -PHST- 2021/08/03 05:45 [entrez] -AID - S0936-6555(21)00267-3 [pii] -AID - 10.1016/j.clon.2021.07.008 [doi] -PST - ppublish -SO - Clin Oncol (R Coll Radiol). 2021 Dec;33(12):e553-e560. doi: - 10.1016/j.clon.2021.07.008. Epub 2021 Jul 31. - -PMID- 37365076 -OWN - NLM -STAT- MEDLINE -DCOM- 20231103 -LR - 20231107 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 24 -IP - 7 -DP - 2023 Nov -TI - Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage - Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3. -PG - 591-597 -LID - S1525-7304(23)00107-9 [pii] -LID - 10.1016/j.cllc.2023.05.005 [doi] -AB - BACKGROUND: Studies demonstrated that chemoimmunotherapy prolongs - progression-free survival (PFS) and overall survival (OS) in patients with - extensive-stage small-cell lung cancer (ES-SCLC) and an Eastern Cooperative - Oncology Group performance status (ECOG PS) 0 or 1. However, there is little data - regarding chemoimmunotherapy in patients with ES-SCLC and an ECOG PS 2 or 3. This - study aims to evaluate the benefits of chemoimmunotherapy compared to - chemotherapy in the first-line treatment of patients with ES-SCLC and ECOG PS 2 - or 3. MATERIALS AND METHODS: This retrospective study analyzed 46 adults treated - at Mayo Clinic between 2017 and 2020 with de novo ES-SCLC and an ECOG PS 2 or 3. - Twenty patients received platinum-etoposide and 26 patients received - platinum-etoposide and atezolizumab. Progression-free survival (PFS) and Overall - survival (OS) were calculated using Kaplan-Meier methods. RESULTS: PFS was longer - in the chemoimmunotherapy group compared to the chemotherapy group, 4.1 months - (95% confidence interval [CI]: 3.8-6.9) vs. 3.2 months (95% CI: 0.6-4.8), - respectively; P = 0.0491. However, there was no statistically significant - difference in the OS between the chemoimmunotherapy and chemotherapy group, 9.3 - months (95% CI: : 4.9-12.8) vs. 7.6 months (95% CI: 0.6-11.9), - respectively; P = .21. CONCLUSION: Chemoimmunotherapy prolongs PFS compared to - chemotherapy in patients with newly diagnosed ES-SCLC and an ECOG PS 2 or 3.  No - OS difference was observed among the chemoimmunotherapy and chemotherapy groups; - nevertheless, this may be attributed due to the small sample size of the study. -CI - Published by Elsevier Inc. -FAU - Agarwal, Muskan -AU - Agarwal M -AD - Department of Internal Medicine, Mayo Clinic, Phoenix, AZ. -FAU - Liu, Alex -AU - Liu A -AD - Division of Hematology-Oncology, Mayo Clinic Cancer Center, Phoenix, AZ. -FAU - Langlais, Blake T -AU - Langlais BT -AD - Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ. -FAU - Leventakos, Konstantinos -AU - Leventakos K -AD - Department of Hematology-Oncology, Mayo Clinic Cancer Center, Rochester, MN. -FAU - Yu, Nathan Y -AU - Yu NY -AD - Department of Radiation Oncology, Mayo Clinic Cancer Center, Phoenix, AZ. -FAU - Almquist, Daniel -AU - Almquist D -AD - Department of Hematology-Oncology, Sanford Roger Maris Cancer Center, Fargo, ND. -FAU - Manochakian, Rami -AU - Manochakian R -AD - Division of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, FL. -FAU - Ernani, Vinicius -AU - Ernani V -AD - Division of Hematology-Oncology, Mayo Clinic Cancer Center, Phoenix, AZ. - Electronic address: Ernani.Vinicius@mayo.edu. -LA - eng -PT - Journal Article -DEP - 20230526 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 6PLQ3CP4P3 (Etoposide) -RN - 49DFR088MY (Platinum) -SB - IM -MH - Adult -MH - Humans -MH - *Lung Neoplasms/drug therapy/etiology -MH - Etoposide -MH - Platinum/therapeutic use -MH - Retrospective Studies -MH - *Small Cell Lung Carcinoma/drug therapy -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -OTO - NOTNLM -OT - Chemotherapy -OT - Eastern Cooperative Oncology Group Performance Status -OT - Overall Survival -OT - Progression-Free Survival -OT - Small Cell Lung Cancer -COIS- Disclosure Dr. Ernani participated in advisory boards for AstraZeneca, Daiichi - Sankyo, Pfizer, Bayer, Jazz Pharmaceuticals, Novocure and BioAtla. Dr. - Manochakian participated in advisory boards for Guardant Health, AstraZeneca, - Novocure, Janssen, Takeda, Turning Points. There are no conflicts of interests - for any of the other  authors. -EDAT- 2023/06/27 01:06 -MHDA- 2023/11/03 06:43 -CRDT- 2023/06/26 21:54 -PHST- 2022/05/29 00:00 [received] -PHST- 2023/05/21 00:00 [revised] -PHST- 2023/05/22 00:00 [accepted] -PHST- 2023/11/03 06:43 [medline] -PHST- 2023/06/27 01:06 [pubmed] -PHST- 2023/06/26 21:54 [entrez] -AID - S1525-7304(23)00107-9 [pii] -AID - 10.1016/j.cllc.2023.05.005 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2023 Nov;24(7):591-597. doi: 10.1016/j.cllc.2023.05.005. Epub - 2023 May 26. - -PMID- 36206101 -OWN - NLM -STAT- MEDLINE -DCOM- 20221019 -LR - 20221216 -IS - 1473-5741 (Electronic) -IS - 0959-4973 (Linking) -VI - 33 -IP - 10 -DP - 2022 Nov 1 -TI - Thoracic radiotherapy may improve the outcome of extensive stage small cell lung - carcinoma patients treated with first-line immunotherapy plus chemotherapy. -PG - e842-e849 -LID - 10.1097/CAD.0000000000001374 [doi] -AB - OBJECTIVE: Immunotherapy plus etoposide and platinum (EP)-based chemotherapy is - the standard of care for patients with extensive stage-small cell lung carcinoma - (ES-SCLC). In the era of immunotherapy, the role of thoracic radiotherapy for - ES-SCLC remains unclear. METHODS: We retrospectively included ES-SCLC patients - treated with first-line EP-based chemotherapy plus atezolizumab or durvalumab at - Taichung Veterans General Hospital to evaluate the prognostic role and safety of - thoracic radiotherapy. RESULTS: A total of 22 patients were included. The median - age was 64 years and most of them were male and smokers. Sixteen patients (72.7%) - received durvalumab, while the other 6 patients (27.3%) underwent atezolizumab - treatment. Among these patients, 11 (50.0%) had a history of thoracic - radiotherapy. There was no significant difference in baseline characteristics - between patients with and without thoracic radiotherapy. In the overall - population, the objective response rate to immunotherapy plus chemotherapy was - 73.7%. The progression-free survival and overall survival were 6.0 months (95% - CI: 4.0-7.9) and 13.8 months (95% CI: 8.0-19.6), respectively. The overall - survival was significantly longer in patients with thoracic radiotherapy - (not-reached [NR] [95% CI NR-NR] vs. 9.6 months [95% CI 2.5-16.6]), respectively - ( P value by log-rank test <0.001). Both multivariate analysis and subgroup - analysis specifically comparing patients with consolidative thoracic radiotherapy - and patients with clinical benefits to systemic therapy who did not undergo - thoracic radiotherapy indicated that thoracic radiotherapy improved survival. - CONCLUSION: The real-world efficacy of EP-based chemotherapy plus atezolizumab or - durvalumab was comparable with that of clinical trials. Thoracic radiotherapy may - improve the outcome of ES-SCLC. -CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. -FAU - Wu, Jia-Jun -AU - Wu JJ -AD - Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans - General Hospital, Taichung. -AD - Taipei Veterans General Hospital Taoyuan Branch, Taoyuan. -FAU - Huang, Jing-Wen -AU - Huang JW -AD - Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans - General Hospital, Taichung. -AD - Institute of Biomedical Sciences, National Chung Hsing University. -FAU - Hsu, Kuo-Hsuan -AU - Hsu KH -AD - Division of Critical Care and Respiratory Therapy, Department of Internal - Medicine, Taichung Veterans General Hospital. -FAU - Huang, Yen-Hsiang -AU - Huang YH -AD - Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans - General Hospital, Taichung. -AD - Institute of Biomedical Sciences, National Chung Hsing University. -AD - College of Medicine, National Yang Ming Chiao Tung University, Taipei. -FAU - Chen, Kun-Chieh -AU - Chen KC -AD - Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan - Medical University Hospital, Taichung. -AD - School of Medicine, Chung Shan Medical University, Taichung. -AD - Institute of Medicine, Chung Shan Medical University. -FAU - Tseng, Jeng-Sen -AU - Tseng JS -AD - Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans - General Hospital, Taichung. -AD - Institute of Biomedical Sciences, National Chung Hsing University. -AD - College of Medicine, National Yang Ming Chiao Tung University, Taipei. -AD - Department of Post-Baccalaureate Medicine, College of Medicine, National Chung - Hsing University. -FAU - Yang, Tsung-Ying -AU - Yang TY -AD - Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans - General Hospital, Taichung. -AD - Division of Critical Care and Respiratory Therapy, Department of Internal - Medicine, Taichung Veterans General Hospital. -AD - Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan. -FAU - Chang, Gee-Chen -AU - Chang GC -AD - Institute of Biomedical Sciences, National Chung Hsing University. -AD - Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan - Medical University Hospital, Taichung. -AD - School of Medicine, Chung Shan Medical University, Taichung. -AD - Institute of Medicine, Chung Shan Medical University. -LA - eng -PT - Journal Article -DEP - 20220929 -PL - England -TA - Anticancer Drugs -JT - Anti-cancer drugs -JID - 9100823 -RN - 49DFR088MY (Platinum) -RN - 6PLQ3CP4P3 (Etoposide) -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Etoposide -MH - Female -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Male -MH - Middle Aged -MH - Platinum -MH - Retrospective Studies -MH - *Small Cell Lung Carcinoma/drug therapy/radiotherapy -EDAT- 2022/10/08 06:00 -MHDA- 2022/10/20 06:00 -CRDT- 2022/10/07 12:13 -PHST- 2022/10/08 06:00 [pubmed] -PHST- 2022/10/20 06:00 [medline] -PHST- 2022/10/07 12:13 [entrez] -AID - 00001813-202211000-00018 [pii] -AID - 10.1097/CAD.0000000000001374 [doi] -PST - ppublish -SO - Anticancer Drugs. 2022 Nov 1;33(10):e842-e849. doi: 10.1097/CAD.0000000000001374. - Epub 2022 Sep 29. - -PMID- 33610454 -OWN - NLM -STAT- MEDLINE -DCOM- 20220106 -LR - 20220106 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 22 -IP - 4 -DP - 2021 Jul -TI - Association of Immune-Related Adverse Events and Efficacy Outcomes With - Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable - Stage III Non-Small-Cell Lung Cancer. -PG - 274-281 -LID - S1525-7304(21)00002-4 [pii] -LID - 10.1016/j.cllc.2020.12.014 [doi] -AB - BACKGROUND: Many patients with non-small-cell lung cancer (NSCLC) treated with - immunotherapy experience immune-related adverse events (irAEs). Patients with - metastatic NSCLC who receive checkpoint inhibitors (CPI) and experience irAEs - generally receive fewer cycles of CPI without decreased efficacy. However, the - association between irAEs and efficacy outcomes in patients with locally advanced - NSCLC treated with curative intent with CPI after chemoradiation has never been - reported. Here we report a retrospective analysis of the association between - irAEs and efficacy outcomes from the Hoosier Cancer Research Network (HCRN) LUN - 14-179 single-arm phase 2 trial of consolidation pembrolizumab after - chemoradiation in patients with stage III NSCLC. PATIENTS AND METHODS: A total of - 92 eligible patients were enrolled from March 2015 to November 2016. - Demographics, disease characteristics, and number of pembrolizumab cycles - received were reported in patients with and without irAEs. Chi-square test was - used for comparisons for categorical variables and Wilcoxon test for continuous - variables. The Kaplan-Meier method was used to analyze time to metastatic disease - or death (TMDD), progression-free survival (PFS), and overall survival (OS). A - log-rank test was used to compare groups. RESULTS: Any grade irAEs occurred in - 55.4% of patients. There was no significant difference in number of pembrolizumab - cycles received, TMDD, OS, or PFS in patients with and without irAEs. Patients - who discontinued pembrolizumab early because of irAEs received significantly - fewer cycles of pembrolizumab (5 vs 15, P = .0016) without a significant - difference in TMDD, PFS, or OS. Similarly, patients who received - immunosuppressive therapy received fewer numbers of cycles of pembrolizumab (4 vs - 16, P < .001) without significantly reduced TMDD, PFS, or OS. CONCLUSION: irAEs - due to pembrolizumab, regardless of grade or number of irAEs, were not associated - with decreased efficacy outcomes. Furthermore, early discontinuation of - pembrolizumab because of irAEs and/or treatment of irAEs with immunosuppressive - therapy was not associated with a decrease in treatment efficacy. -CI - Copyright © 2021 Elsevier Inc. All rights reserved. -FAU - Shukla, Nikhil Atul -AU - Shukla NA -AD - Department of Hematology/Oncology. Electronic address: nashukla@iu.edu. -FAU - Althouse, Sandra -AU - Althouse S -AD - Department of Biostatistics, Indiana University Melvin and Bren Simon Cancer - Center, Indianapolis, IN. -FAU - Meyer, Zachary -AU - Meyer Z -AD - Department of Internal Medicine, Indiana University School of Medicine, - Indianapolis, IN. -FAU - Hanna, Nasser -AU - Hanna N -AD - Department of Hematology/Oncology. -FAU - Durm, Greg -AU - Durm G -AD - Department of Hematology/Oncology. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20210123 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects -MH - Antineoplastic Agents, Immunological/administration & dosage/adverse effects -MH - Carcinoma, Non-Small-Cell Lung/pathology/*therapy -MH - Chemoradiotherapy/adverse effects/methods -MH - Female -MH - Humans -MH - Immune System Diseases/epidemiology/etiology -MH - Immunotherapy/adverse effects/*methods -MH - Lung Neoplasms/pathology/*therapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Progression-Free Survival -MH - Retrospective Studies -MH - Survival Rate -OTO - NOTNLM -OT - Consolidation therapy -OT - Immune-related adverse events -OT - Immunotherapy -OT - Inoperable stage III NSCLC -EDAT- 2021/02/22 06:00 -MHDA- 2022/01/07 06:00 -CRDT- 2021/02/21 20:28 -PHST- 2020/10/04 00:00 [received] -PHST- 2020/12/09 00:00 [revised] -PHST- 2020/12/23 00:00 [accepted] -PHST- 2021/02/22 06:00 [pubmed] -PHST- 2022/01/07 06:00 [medline] -PHST- 2021/02/21 20:28 [entrez] -AID - S1525-7304(21)00002-4 [pii] -AID - 10.1016/j.cllc.2020.12.014 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2021 Jul;22(4):274-281. doi: 10.1016/j.cllc.2020.12.014. Epub - 2021 Jan 23. - -PMID- 8052874 -OWN - NLM -STAT- MEDLINE -DCOM- 19940908 -LR - 20071115 -IS - 0093-7754 (Print) -IS - 0093-7754 (Linking) -VI - 21 -IP - 3 Suppl 6 -DP - 1994 Jun -TI - The treatment of non-small cell lung cancer: current perspectives and - controversies, future directions. -PG - 49-59 -AB - The projected cure rate for patients who develop lung cancer in 1993 is only 13%. - The majority of these patients have metastatic disease at the time of diagnosis, - and are therefore ineligible for curative surgery. Among the minority of patients - who undergo surgical therapy with curative intent, the majority experience - relapse in metastatic sites. Patients with metastatic disease cannot be cured - with currently available therapies. Recent randomized studies suggest that - cisplatin-based chemotherapy regimens can prolong survival in patients with - metastatic non-small cell lung cancer and small cell lung cancer. It was thus - logical to evaluate cisplatin-based chemotherapy in early disease stages. Many - randomized studies have compared radiation therapy alone with radiation plus - cisplatin-based chemotherapy in locally advanced, inoperable, stages IIIA and - IIIB non-small cell lung cancer. Most, but not all, of these studies show a - survival benefit for the combined-modality approach. Although the improvement in - median length of survival in these studies is modest, long-term survival rates - are often doubled or tripled. The optimal chemoradiotherapy combination is - unknown. Fewer randomized trials have evaluated cisplatin-based chemotherapy as - an adjuvant to surgery in operable stages I through IIIA disease. A trial of the - Lung Cancer Study Group comparing postoperative - cyclophosphamide/doxorubicin/cisplatin with immunotherapy in stages II and IIIA - adenocarcinoma and large cell carcinoma showed a small survival advantage for the - chemotherapy. A European postoperative randomized study comparing cisplatin-based - chemotherapy with no therapy also showed a survival advantage for chemotherapy, - as did a small ongoing study from M.D. Anderson Cancer Center (Houston, TX) with - preoperative chemotherapy. However, there are many negative randomized studies - evaluating postoperative chemotherapy, especially with non-cisplatin-based - regimens, and further studies are obviously needed. Many new agents have produced - exciting preliminary results. Response rates in excess of 20% were reported for - paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), irinotecan - (CPT-11), topotecan, and gemcitabine. Studies in the next few years will help to - define the ultimate role of these agents. Further developments in understanding - the biology (and molecular biology) of lung cancer are leading to preclinical - studies of antigrowth factors and genetic therapy. -FAU - Bunn, P A Jr -AU - Bunn PA Jr -AD - University of Colorado Cancer Center, Denver 80262. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Research Support, Non-U.S. Gov't -PL - United States -TA - Semin Oncol -JT - Seminars in oncology -JID - 0420432 -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*mortality/secondary/*therapy -MH - Clinical Trials as Topic -MH - Combined Modality Therapy -MH - Forecasting -MH - Humans -MH - Lung Neoplasms/*mortality/pathology/*therapy -MH - Medical Oncology/*trends -MH - Neoplasm Staging -MH - Survival Rate -EDAT- 1994/06/01 00:00 -MHDA- 2001/03/28 10:01 -CRDT- 1994/06/01 00:00 -PHST- 1994/06/01 00:00 [pubmed] -PHST- 2001/03/28 10:01 [medline] -PHST- 1994/06/01 00:00 [entrez] -PST - ppublish -SO - Semin Oncol. 1994 Jun;21(3 Suppl 6):49-59. - -PMID- 34461420 -OWN - NLM -STAT- MEDLINE -DCOM- 20211122 -LR - 20211122 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 156 -DP - 2021 Oct -TI - Prospective trial of immuno(chemo)therapy before resection, definitive - chemoradiotherapy or palliative therapy in patients with locally advanced or - oligometastatic non-small cell lung cancer without a primary curative option. -PG - 175-186 -LID - S0959-8049(21)00493-7 [pii] -LID - 10.1016/j.ejca.2021.07.035 [doi] -AB - BACKGROUND: Recent phase II-III trials of immuno(chemo)therapy before resection - in locally advanced resectable non-small cell lung cancer (NSCLC) report high - rates of pathological response and promising survival. However, primarily, - patients who did not undergo resection were excluded from these studies. - Moreover, there are no data on chemoradiotherapy (CRT) after immuno(chemo)therapy - in patients who are primarily not amenable to CRT. We hypothesised that induction - immuno(chemo)therapy may enable patients with NSCLC with a potentially curative - stage (III-IVA), for whom primary curative treatment (either resection or CRT) is - not possible for anatomical or functional reasons, to receive curative treatment. - PATIENTS AND METHODS: We enrolled 35 patients with NSCLC with aforementioned - characteristics into a prospective real-world trial of induction - immuno(chemo)therapy followed by morphologic and metabolic reassessment and - multidisciplinary board-guided curative treatment (resection [preferred] or CRT) - or palliative therapy. The primary end-point was the proportion of patients - receiving curative treatment. RESULTS: Thirty-two patients (91%) received - curative treatment (11 resections and 21 CRT). 73% and 64% of patients who - underwent resection had a major or complete pathological response, respectively. - There were 14 recurrences: 2 (18%) in patients who underwent resection, 9 (43%) - in patients who received CRT and 3 (100%) in patients who received palliative - therapy (median follow-up 17 months). Eight tumour-related deaths occurred: 5 - (24%) in patients who received CRT; and 3 (100%) in patients who received - palliative therapy. There were no treatment-related deaths. CONCLUSIONS: In - locally advanced or oligometastatic NSCLC without a primary curative option, - induction immuno(chemo)therapy results in a high rate of curative treatment with - promising early survival data. patients who underwent resection achieved a high - rate of prognostically favourable pathological response. -CI - Copyright © 2021 Elsevier Ltd. All rights reserved. -FAU - Faehling, Martin -AU - Faehling M -AD - Klinik für Kardiologie und Pneumologie, Klinikum Esslingen, Germany. Electronic - address: m.faehling@klinikum-esslingen.de. -FAU - Fallscheer, Sabine -AU - Fallscheer S -AD - Klinik für Kardiologie und Pneumologie, Klinikum Esslingen, Germany. -FAU - Kramberg, Sebastian -AU - Kramberg S -AD - Klinik für Kardiologie und Pneumologie, Klinikum Esslingen, Germany. -FAU - Sträter, Jörn -AU - Sträter J -AD - Institut für Pathologie, Esslingen, Germany. -FAU - Eschmann, Susanne -AU - Eschmann S -AD - MVZ Nuklearmedizin, Marienhospital, Stuttgart, Germany. -FAU - Sätzler, Rainer -AU - Sätzler R -AD - Klinik für Gefäß- und Thoraxchirurgie, Klinikum Esslingen, Germany. -FAU - Heinzelmann, Frank -AU - Heinzelmann F -AD - MVZ Strahlentherapie, Klinikum Esslingen, Germany. -LA - eng -PT - Clinical Study -PT - Comparative Study -PT - Journal Article -DEP - 20210827 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 31YO63LBSN (Nivolumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/mortality/secondary -MH - *Chemoradiotherapy/adverse effects/mortality -MH - Chemotherapy, Adjuvant -MH - Female -MH - Germany -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects/*therapeutic use -MH - Lung Neoplasms/*drug therapy/immunology/mortality/pathology -MH - Male -MH - Middle Aged -MH - *Neoadjuvant Therapy/adverse effects/mortality -MH - Nivolumab/adverse effects/*therapeutic use -MH - *Palliative Care -MH - *Pneumonectomy/adverse effects/mortality -MH - Prospective Studies -MH - Time Factors -MH - Treatment Outcome -OTO - NOTNLM -OT - Checkpoint inhibitor -OT - NSCLC -OT - PD-L1 -OT - Real-world -OT - Survival -COIS- Conflict of interest statement The authors declare the following financial - interests/personal relationships which may be considered as potential competing - interests: MF has received speaker's honoraria and served on advisory boards of - AstraZeneca, BMS, MSD and Roche and is the principle investigator of phase II–III - clinical studies by AstraZeneca, BMS, MSD and Roche. SK has received speaker's - honoraria Roche. The other authors have declared no conflict of interest to - disclose. -EDAT- 2021/08/31 06:00 -MHDA- 2021/11/23 06:00 -CRDT- 2021/08/30 20:20 -PHST- 2021/06/29 00:00 [received] -PHST- 2021/07/21 00:00 [accepted] -PHST- 2021/08/31 06:00 [pubmed] -PHST- 2021/11/23 06:00 [medline] -PHST- 2021/08/30 20:20 [entrez] -AID - S0959-8049(21)00493-7 [pii] -AID - 10.1016/j.ejca.2021.07.035 [doi] -PST - ppublish -SO - Eur J Cancer. 2021 Oct;156:175-186. doi: 10.1016/j.ejca.2021.07.035. Epub 2021 - Aug 27. - -PMID- 34526044 -OWN - NLM -STAT- MEDLINE -DCOM- 20220120 -LR - 20220120 -IS - 1748-717X (Electronic) -IS - 1748-717X (Linking) -VI - 16 -IP - 1 -DP - 2021 Sep 15 -TI - Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony - stimulating factor as second-line therapy for advanced non-small cell lung - cancer: safety run-in results of a multicenter, single-arm, phase II trial. -PG - 177 -LID - 10.1186/s13014-021-01905-3 [doi] -LID - 177 -AB - OBJECTIVES: The SWORD trial is the first multicenter, single arm, phase II study - assessing the safety and efficacy of a PD-1 inhibitor (Sintilimab), stereotactic - body radiotherapy (SBRT) and granulocyte-macrophage colony stimulating factor - (GM-CSF) in advanced non-small cell lung cancer (NSCLC) without sensitizing - driver mutations. A safety run-in phase was conducted to determine the - tolerability of the experimental treatment. MATERIALS AND METHODS: Twenty - metastatic NSCLC patients who failed first-line chemotherapy were enrolled, and - they received SBRT (8 Gy × 3) to one lesion, followed by Sintilimab (200 mg d1, - every 3 weeks, until disease progression, unacceptable toxicity, or up to 35 - cycles) and GM-CSF (125 μg/m(2) d1-d14, cycle 1) within 2 weeks after SBRT. In - addition, blood and tissue samples were serially collected for translational - research. RESULTS: Median age of the patients was 61 and all of them had more - than 5 lesions at baseline. The sites of SBRT included lung (n = 11), mediastinal - lymph node (n = 5), liver (n = 1), abdominal lymph node (n = 1), pleural nodule - (n = 1) and vertebra (n = 1). No patients had dose-limiting toxicities (DLTs) and - 18 patients experienced treatment-related adverse event (TRAE). The most common - TRAEs were fatigue (50%), fever (30%), and ostealgia (20%), and they all were - grade 1. Only 2 grade 3 TRAEs were observed, including elevation of liver enzymes - in one and transient acute heart failure in another. No grade 4 or 5 AE was - observed. CONCLUSION: Sintilimab, SBRT and GM-CSF for advanced NSCLC is safe with - manageable TRAEs and the trial continues to recruit participants. Trial - registration ClinicalTrials.gov, NCT04106180. Registered 26 September 2019, SBRT - in Combination With Sintilimab and GM-CSF for the Treatment of Advanced - NSCLC-Tabular View-ClinicalTrials.gov. -CI - © 2021. The Author(s). -FAU - Ni, Jianjiao -AU - Ni J -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 - Dong An Road, Shanghai, 200032, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Zhou, Yue -AU - Zhou Y -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 - Dong An Road, Shanghai, 200032, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Wu, Lin -AU - Wu L -AD - The Second Department of Thoracic Oncology, Hunan Cancer Hospital, The Affiliated - Cancer Hospital of Xiangya School of Medicine, Central South University, - Changsha, China. -FAU - Ai, Xinghao -AU - Ai X -AD - Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong - University, Shanghai, China. -FAU - Dong, Xiaorong -AU - Dong X -AD - Cancer Center, Union Hospital, Tongji Medical School, Huazhong University of - Science and Technology, Wuhan, China. -FAU - Chu, Qian -AU - Chu Q -AD - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong - University of Science and Technology, Wuhan, China. -FAU - Han, Chengbo -AU - Han C -AD - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, - China. -FAU - Wang, Xiaofei -AU - Wang X -AD - Department of Biostatistics and Bioinformatics, Duke University School of - Medicine, Durham, USA. -FAU - Zhu, Zhengfei -AU - Zhu Z -AUID- ORCID: 0000-0001-7537-3619 -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 - Dong An Road, Shanghai, 200032, China. fuscczzf@163.com. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. fuscczzf@163.com. -AD - Institute of Thoracic Oncology, Fudan University, 270 Dong An Road, Shanghai, - 200032, China. fuscczzf@163.com. -LA - eng -SI - ClinicalTrials.gov/NCT04106180 -GR - SHDC2020CR4010/Clinical Research Plan of SHDC/ -GR - Y-XD2019-050/CSCO Foundation/ -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Multicenter Study -DEP - 20210915 -PL - England -TA - Radiat Oncol -JT - Radiation oncology (London, England) -JID - 101265111 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor) -RN - 8FU7FQ8UPK (sintilimab) -SB - IM -MH - Adult -MH - Aged -MH - Antibodies, Monoclonal, Humanized/*adverse effects -MH - Carcinoma, Non-Small-Cell Lung/*therapy -MH - Combined Modality Therapy -MH - Female -MH - Granulocyte-Macrophage Colony-Stimulating Factor/*adverse effects -MH - Humans -MH - Lung Neoplasms/*therapy -MH - Male -MH - Middle Aged -MH - Prospective Studies -MH - Radiosurgery/*adverse effects -PMC - PMC8444553 -OTO - NOTNLM -OT - Granulocyte–macrophage colony stimulating factor (GM-CSF) -OT - Non-small cell lung cancer (NSCLC) -OT - Sintilimab -OT - Stereotactic body radiotherapy (SBRT) -OT - Treatment-related adverse event (TRAE) -COIS- The authors declare that they have no competing interests. -EDAT- 2021/09/17 06:00 -MHDA- 2022/01/21 06:00 -PMCR- 2021/09/15 -CRDT- 2021/09/16 05:45 -PHST- 2021/05/31 00:00 [received] -PHST- 2021/09/01 00:00 [accepted] -PHST- 2021/09/16 05:45 [entrez] -PHST- 2021/09/17 06:00 [pubmed] -PHST- 2022/01/21 06:00 [medline] -PHST- 2021/09/15 00:00 [pmc-release] -AID - 10.1186/s13014-021-01905-3 [pii] -AID - 1905 [pii] -AID - 10.1186/s13014-021-01905-3 [doi] -PST - epublish -SO - Radiat Oncol. 2021 Sep 15;16(1):177. doi: 10.1186/s13014-021-01905-3. - -PMID- 36572596 -OWN - NLM -STAT- MEDLINE -DCOM- 20230223 -LR - 20230321 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 24 -IP - 2 -DP - 2023 Mar -TI - The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III - Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation. -PG - 130-136 -LID - S1525-7304(22)00266-2 [pii] -LID - 10.1016/j.cllc.2022.11.008 [doi] -AB - INTRODUCTION: Chemoradiotherapy (CRT) is the standard of care in inoperable - non-small-cell lung cancer (NSCLC) patients, favoring concurrent (cCRT) over - sequential CRT (seqCRT), with adjuvant immunotherapy in responders. Elderly and - frail NSCLC patients have generally been excluded from trials in the past. In - elderly patients however, the higher treatment related morbidity of cCRT, may - outweigh the possible lower tumor control of seqCRT. For elderly patients with - locally advanced NSCLC real-world data is essential to be able to balance - treatment toxicity and treatment outcome. The aim of this study is to analyze - acute toxicity and 3-month mortality of curative chemoradiation (CRT) in patients - with stage III NSCLC and to analyze whether cCRT for elderly stage III NSCLC - patients is safe. METHODS: The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R) is a - national lung cancer audit that started in 2013 for patients treated with - curative intent radiotherapy. All Dutch patients treated for stage III NSCLC - between 2015 and 2018 with seqCRT or cCRT for (primary or recurrent) stage III - lung cancer are included in this population-based study. Information was - collected on patient, tumor- and treatment characteristics and the incidence and - severity of acute non-hematological toxicity (CTCAE-4 version 4.03) and mortality - within 3 months after the end of radiotherapy. To evaluate the association - between prognostic factors and outcome (acute toxicity and mortality within 3 - months), an univariable and multivariable analysis was performed. The definition - of cCRT was:radiotherapy started within 30 days after the start of chemotherapy. - RESULTS: Out of all 20 Dutch departments of radiation oncology, 19 centers - participated in the registry. A total of 2942 NSCLC stage III patients were - treated with CRT. Of these 67.2% (n = 1977) were treated with cCRT (median age 66 - years) and 32.8% (n = 965) were treated with seqCRT (median age 69 years). Good - performance status (WHO 0-1) was scored in 88.6% for patients treated with cCRT - and in 71.0% in the patients treated with seqCRT. Acute nonhematological 3-month - toxicity (CTCAE grade ≥3 or radiation pneumonitis grade ≥2) was scored in 21.9% - of the patients treated with cCRT and in 17.7% of the patients treated with - seqCRT. The univariable analysis for acute toxicity showed significantly - increased toxicity for cCRT (P = .008), WHO ≥2 (P = .006), and TNM IIIC - (P = .031). The multivariable analysis for acute toxicity was significant for - cCRT (P = .015), WHO ≥2 (P = .001) and TNM IIIC (P = .016). The univariable - analysis for 3-month mortality showed significance for seqCRT (P = .025), WHO ≥2 - (P < .001), higher cumulative radiotherapy dose (P < .001), higher gross tumor - volume total (P = .020) and male patients (p < .001). None of these variables - reached significance in the multivariable analysis for 3-month mortality. - CONCLUSION: In this national lung cancer audit of inoperable NSCLC patients, - 3-month toxicity was significantly higher in patients treated with cCRT (21.9% - vs. 17.7% for seqCRT) higher TNM stage IIIC, and poor performance (WHO≥2) - patients.The 3-months mortality was not significantly different for tested - parameters. Age was not a risk factor for acute toxicity, nor 3 months mortality. -CI - Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. -FAU - Dieleman, Edith -AU - Dieleman E -AD - Amsterdam UMC location AMC, Radiation Oncology, Amsterdam, The Netherlands. -FAU - van der Woude, Lisa -AU - van der Woude L -AD - RadboudUMC, Cardiothoracic surgery, Nijmegen, The Netherlands; Dutch Institute - for Clinical Auditing, Leiden, The Netherlands. -FAU - van Os, Rob -AU - van Os R -AD - Amsterdam UMC location AMC, Radiation Oncology, Amsterdam, The Netherlands. -FAU - van Bockel, Liselotte -AU - van Bockel L -AD - Haga ziekenhuis, Radiation Oncology, Den Haag, The Netherlands. -FAU - Coremans, Ida -AU - Coremans I -AD - LUMC, Radiation Oncology, Leiden, The Netherlands. -FAU - van Es, Corine -AU - van Es C -AD - UMCU, Radiation Oncology, Utrecht, The Netherlands. -FAU - De Jaeger, Katrien -AU - De Jaeger K -AD - Catharina Ziekenhuis, Radiation Oncology, Eindhoven, The Netherlands. -FAU - Knol, Hans Peter -AU - Knol HP -AD - Noordwest Ziekenhuis groep, Radiation Oncology, Alkmaar, The Netherlands. -FAU - Kolff, Willemijn -AU - Kolff W -AD - Amsterdam UMC location AMC, Radiation Oncology, Amsterdam, The Netherlands. -FAU - Koppe, Frederike -AU - Koppe F -AD - Instituut Verbeeten, Radiation Oncology, Tilburg, The Netherlands. -FAU - Pomp, Jacqueline -AU - Pomp J -AD - Medisch Spectrum Twente, Radiation Oncology, Enschede, The Netherlands. -FAU - Reymen, Bart -AU - Reymen B -AD - Maastro, Radiation Oncology, Maastricht, The Netherlands. -FAU - Schinagl, Dominic -AU - Schinagl D -AD - RadboudUMC, Radiation Oncology, Nijmegen, The Netherlands. -FAU - Spoelstra, Femke -AU - Spoelstra F -AD - Amsterdam UMC location VUMC, Radiation Oncology, Amsterdam, The Netherlands. -FAU - Tissing-Tan, Caroline -AU - Tissing-Tan C -AD - Radiotherapiegroep, Radiation Oncology, Arnhem, The Netherlands. -FAU - van der Voort van Zyp, Noelle -AU - van der Voort van Zyp N -AD - Haaglanden MC, Radiation oncology, Den Haag, The Netherlands. -FAU - van der Wel, Antoinet -AU - van der Wel A -AD - Radiotherapeutisch Instituut Friesland, Radiation Oncology, Leeuwarden, The - Netherlands. -FAU - Wijsman, Robin -AU - Wijsman R -AD - UMCG, Radiation Oncology, Groningen, The Netherlands. -FAU - Dielwart, Michel -AU - Dielwart M -AD - ZRTI, Radiation Oncology, Vlissingen, The Netherlands. -FAU - Wiegman, Erwin -AU - Wiegman E -AD - Isala, Radiation Oncology, Zwolle, The Netherlands. -FAU - Damhuis, Ronald -AU - Damhuis R -AD - Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, - The Netherlands. -FAU - Belderbos, Jose -AU - Belderbos J -AD - Netherlands Cancer Institute, Radiation Oncology, Amsterdam, The Netherlands. -LA - eng -PT - Journal Article -DEP - 20221125 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -SB - IM -MH - Humans -MH - Male -MH - Aged -MH - Infant -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - *Radiation Oncology -MH - Neoplasm Staging -MH - Chemoradiotherapy/adverse effects -OTO - NOTNLM -OT - Elderly -OT - Mortality -OT - National audit -OT - Toxicity -EDAT- 2022/12/27 06:00 -MHDA- 2023/02/25 06:00 -CRDT- 2022/12/26 21:53 -PHST- 2022/07/06 00:00 [received] -PHST- 2022/10/23 00:00 [revised] -PHST- 2022/11/16 00:00 [accepted] -PHST- 2022/12/27 06:00 [pubmed] -PHST- 2023/02/25 06:00 [medline] -PHST- 2022/12/26 21:53 [entrez] -AID - S1525-7304(22)00266-2 [pii] -AID - 10.1016/j.cllc.2022.11.008 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2023 Mar;24(2):130-136. doi: 10.1016/j.cllc.2022.11.008. Epub - 2022 Nov 25. - -PMID- 32160383 -OWN - NLM -STAT- MEDLINE -DCOM- 20210315 -LR - 20210315 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 11 -IP - 5 -DP - 2020 May -TI - Chemoradiotherapy followed by durvalumab in patients with unresectable advanced - non-small cell lung cancer: Management of adverse events. -PG - 1280-1287 -LID - 10.1111/1759-7714.13394 [doi] -AB - BACKGROUND: Chemoradiotherapy followed by durvalumab is the standard treatment - for the patients with local advanced non-small cell lung cancer (NSCLC). There is - a real-world data about the management of adverse events, such as pneumonitis, - according to the different institutions. Here, we present the experience - regarding the management of adverse events after the initiation of durvalumab as - daily practice. METHODS: From July 2018 to August 2019, 41 patients with locally - advanced NSCLC, who underwent chemoradiotherapy followed by durvalumab, were - retrospectively analyzed in the study using our medical records. RESULTS: The - median age of patients was 72 years (range: 51-80 years). A total of 33 patients - were male and eight were female, and 40 patients (98%) received a total radiation - dose of 60 Gy as concomitant chemoradiotherapy. The median V20 for the entire - cohort was 18.9% (range: 3.5-29.9). Any adverse events during chemoradiotherapy - and durvalumab were observed in 32 patients (78.0%), while three patients (7.3%) - experienced grade 3 toxicities. In total, 25 (61.0%) patients experienced - pneumonitis, four (9.8%) thyroid dysfunction, three (7.3%) myopathy, two (4.9%) - rash or eruption, one (2.4%) bowel disease and one (2.4%) malaise. Grade 3 - pneumonitis, thyroid dysfunction and myopathy were observed in one (2.4%), one - (2.4%) and one (2.4%), respectively. A total of 22 (53.7%) patients were unable - to continue durvalumab due to pneumonitis. However, durvalumab was finally - readministered to six patients. CONCLUSIONS: The adherence to lung dose - constraints such as V20 as well as close treatment monitoring are a prerequisite - for the management of pneumonitis during maintenance therapy with durvalumab. -CI - © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Miura, Yu -AU - Miura Y -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Mouri, Atsuto -AU - Mouri A -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Kaira, Kyoichi -AU - Kaira K -AUID- ORCID: 0000-0001-5548-7686 -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Yamaguchi, Ou -AU - Yamaguchi O -AUID- ORCID: 0000-0001-7194-6459 -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Shiono, Ayako -AU - Shiono A -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Hashimoto, Kosuke -AU - Hashimoto K -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Nishihara, Fuyumi -AU - Nishihara F -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Shinomiya, Shun -AU - Shinomiya S -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Akagami, Tomoe -AU - Akagami T -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Murayama, Yoshitake -AU - Murayama Y -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Abe, Takanori -AU - Abe T -AD - Department of Radiation Oncology, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Noda, Shin-Ei -AU - Noda SE -AD - Department of Radiation Oncology, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Kato, Shingo -AU - Kato S -AD - Department of Radiation Oncology, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Kobayashi, Kunihiko -AU - Kobayashi K -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -FAU - Kagamu, Hiroshi -AU - Kagamu H -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Saitama, Japan. -LA - eng -PT - Journal Article -DEP - 20200311 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Adenocarcinoma of Lung/pathology/therapy -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal/*adverse effects -MH - Antineoplastic Agents, Immunological/adverse effects -MH - Carcinoma, Non-Small-Cell Lung/pathology/*therapy -MH - Carcinoma, Squamous Cell/pathology/therapy -MH - Chemoradiotherapy/*adverse effects -MH - Disease Management -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Lung Neoplasms/pathology/*therapy -MH - Male -MH - Middle Aged -MH - Neoplasm Recurrence, Local/pathology/*therapy -MH - Pneumonia/chemically induced/*drug therapy/pathology -MH - Prognosis -MH - Retrospective Studies -MH - Survival Rate -PMC - PMC7180558 -OTO - NOTNLM -OT - Chemoradiotherapy -OT - durvalumab -OT - non-small cell lung cancer -OT - radiation pneumonitis -OT - real-world experience -EDAT- 2020/03/12 06:00 -MHDA- 2021/03/16 06:00 -PMCR- 2020/05/01 -CRDT- 2020/03/12 06:00 -PHST- 2020/01/24 00:00 [received] -PHST- 2020/02/23 00:00 [revised] -PHST- 2020/02/24 00:00 [accepted] -PHST- 2020/03/12 06:00 [pubmed] -PHST- 2021/03/16 06:00 [medline] -PHST- 2020/03/12 06:00 [entrez] -PHST- 2020/05/01 00:00 [pmc-release] -AID - TCA13394 [pii] -AID - 10.1111/1759-7714.13394 [doi] -PST - ppublish -SO - Thorac Cancer. 2020 May;11(5):1280-1287. doi: 10.1111/1759-7714.13394. Epub 2020 - Mar 11. - -PMID- 30678553 -OWN - NLM -STAT- MEDLINE -DCOM- 20200204 -LR - 20220410 -IS - 1750-7448 (Electronic) -IS - 1750-743X (Linking) -VI - 11 -IP - 4 -DP - 2019 Mar -TI - First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a - pair-wise and network meta-analysis. -PG - 311-320 -LID - 10.2217/imt-2018-0107 [doi] -AB - AIM: To estimate efficacy of checkpoint inhibitors and rank treatment effects in - non-small-cell lung cancer. MATERIALS & METHODS: Prospective randomized trials - were included. p-score was used to rank treatment effects. RESULTS: A total of - nine trials were identified, involving 5504 patients and three checkpoint - inhibitors. Pembrolizumab plus chemotherapy had the highest p-score of 0.95 among - all the treatments, and was superior to pembrolizumab alone (hazard ratio: 0.87; - 95% CI: 0.79-0.95). Combination therapy had more grade 3-5 adverse events; but - toxicity-related discontinuation and treatment-related death did not increase. - CONCLUSION: Pembrolizumab plus chemotherapy was likely to be the most effective - treatment for patients with wild-type advanced NSCLC. -FAU - Wang, Xiao-Jian -AU - Wang XJ -AD - Department of Pharmacy, Shantou Central Hospital, Shantou, China. -FAU - Lin, Jia-Zhou -AU - Lin JZ -AD - Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University - Medical College, Shantou, China. -FAU - Yu, Shu-Han -AU - Yu SH -AD - Department of Medical Oncology, Shantou Central Hospital, Shantou, China. -FAU - Wu, Sheng-Xi -AU - Wu SX -AD - Department of Radiation Oncology, Shantou Central Hospital, Shantou, China. -FAU - Luo, He-San -AU - Luo HS -AD - Department of Radiation Oncology, Shantou Central Hospital, Shantou, China. -FAU - Du, Ze-Sen -AU - Du ZS -AD - Department of Surgical Oncology, Shantou Central Hospital, Shantou, China. -FAU - Li, Xu-Yuan -AU - Li XY -AD - Department of Medical Oncology, Shantou Central Hospital, Shantou, China. -LA - eng -PT - Comparative Study -PT - Evaluation Study -PT - Journal Article -PT - Meta-Analysis -PL - England -TA - Immunotherapy -JT - Immunotherapy -JID - 101485158 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 31YO63LBSN (Nivolumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/mortality -MH - Humans -MH - Immunotherapy/*methods -MH - Lung Neoplasms/*drug therapy/mortality -MH - Neoplasm Staging -MH - Network Meta-Analysis -MH - Nivolumab/*therapeutic use -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - Randomized Controlled Trials as Topic -MH - Survival Analysis -OTO - NOTNLM -OT - biomarker -OT - checkpoint inhibitor -OT - meta-analysis -OT - non-small-cell lung cancer -OT - programmed death-1 -OT - wild-type -EDAT- 2019/01/27 06:00 -MHDA- 2020/02/06 06:00 -CRDT- 2019/01/26 06:00 -PHST- 2019/01/26 06:00 [entrez] -PHST- 2019/01/27 06:00 [pubmed] -PHST- 2020/02/06 06:00 [medline] -AID - 10.2217/imt-2018-0107 [doi] -PST - ppublish -SO - Immunotherapy. 2019 Mar;11(4):311-320. doi: 10.2217/imt-2018-0107. - -PMID- 33735884 -OWN - NLM -STAT- MEDLINE -DCOM- 20210602 -LR - 20210602 -IS - 1423-0232 (Electronic) -IS - 0030-2414 (Linking) -VI - 99 -IP - 6 -DP - 2021 -TI - An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of - Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line - Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer. -PG - 389-396 -LID - 10.1159/000514577 [doi] -AB - BACKGROUND: Before the approval of first-line immune checkpoint inhibitors, - platinum doublets were the standard of care in patients with treatment-naïve - advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. - Pemetrexed-platinum combinations are preferred in non-squamous NSCLC. However, - there has been no direct comparison to paclitaxel-carboplatin. METHODS: This - open-label randomized trial was designed to compare pemetrexed-carboplatin with - (weekly) paclitaxel-carboplatin in treatment-naïve advanced/metastatic - non-squamous NSCLC without driver mutations. Patients received either pemetrexed - 500 mg/m2 and carboplatin AUC 5 every 3 weeks, or paclitaxel 80 mg/m2 on day 1, - day 8, and day 15 with carboplatin AUC 5 every 4 weeks for 4 cycles. Patients in - both arms were allowed to receive pemetrexed maintenance. RESULTS: A total of 180 - patients were enrolled. The study was terminated early; however, at the time of - analysis 75.8% of the required events had occurred. Finally, 164 patients were - evaluable, 83 in the pemetrexed arm and 81 in the paclitaxel arm. After a median - follow-up of 17 months, progression-free survival (PFS) rates at 6 months were - not different in the two treatment arms (47.45 vs. 48.64%, p = 0.88). The median - PFS values were 5.67 months (95% CI 3.73-7.3) and 5.03 months (95% CI 2.63-7.43) - in each arm, respectively (HR 1.13, 95% CI 0.81-1.59, p = 0.44). The median - overall survival was also not different: 14.83 months (95% CI 9.5-18.73) and 11.3 - (95% CI 8.3-19.7; HR 1.19, 95% CI 0.8-1.78, p = 0.37). All grade toxicities were - similar except for alopecia and peripheral neuropathy, which were higher in the - paclitaxel arm. CONCLUSION: Pemetrexed-carboplatin is not superior to (weekly) - paclitaxel-carboplatin as the first-line regimen in advanced non-squamous NSCLC - in terms of PFS. -CI - © 2021 S. Karger AG, Basel. -FAU - Yadav, Ajay -AU - Yadav A -AD - Department of Medical Oncology, Dr. BRAIRCH, All India Institute of Medical - Sciences, New Delhi, India. -FAU - Malik, Prabhat Singh -AU - Malik PS -AD - Department of Medical Oncology, Dr. BRAIRCH, All India Institute of Medical - Sciences, New Delhi, India, drprabhatsm@gmail.com. -FAU - Khurana, Sachin -AU - Khurana S -AD - Department of Medical Oncology, Dr. BRAIRCH, All India Institute of Medical - Sciences, New Delhi, India. -FAU - Jain, Deepali -AU - Jain D -AD - Department of Pathology, All India Institute of Medical Sciences, New Delhi, - India. -FAU - Vishnubhatla, Sreenivas -AU - Vishnubhatla S -AD - Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, - India. -FAU - Yadav, Mukesh -AU - Yadav M -AD - Department of Radiology, Dr. BRAIRCH, All India Institute of Medical Sciences, - New Delhi, India. -FAU - Pathy, Sushmita -AU - Pathy S -AD - Department of Radiation Oncology, Dr. BRAIRCH, All India Institute of Medical - Sciences, New Delhi, India. -FAU - Mohan, Anant -AU - Mohan A -AD - Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of - Medical Sciences, New Delhi, India. -FAU - Kumar, Lalit -AU - Kumar L -AD - Department of Medical Oncology, Dr. BRAIRCH, All India Institute of Medical - Sciences, New Delhi, India. -LA - eng -PT - Comparative Study -PT - Equivalence Trial -PT - Journal Article -PT - Randomized Controlled Trial -DEP - 20210318 -PL - Switzerland -TA - Oncology -JT - Oncology -JID - 0135054 -RN - 04Q9AIZ7NO (Pemetrexed) -RN - BG3F62OND5 (Carboplatin) -RN - P88XT4IS4D (Paclitaxel) -SB - IM -MH - Academic Medical Centers -MH - Adult -MH - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse - effects -MH - Carboplatin/*administration & dosage/adverse effects -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Drug Administration Schedule -MH - Female -MH - Humans -MH - India -MH - Lung Neoplasms/*drug therapy -MH - Male -MH - Middle Aged -MH - Paclitaxel/*administration & dosage/adverse effects -MH - Pemetrexed/*administration & dosage/adverse effects -MH - Survival Analysis -MH - Tertiary Care Centers -MH - Treatment Outcome -EDAT- 2021/03/19 06:00 -MHDA- 2021/06/03 06:00 -CRDT- 2021/03/18 20:27 -PHST- 2020/11/16 00:00 [received] -PHST- 2020/12/30 00:00 [accepted] -PHST- 2021/03/19 06:00 [pubmed] -PHST- 2021/06/03 06:00 [medline] -PHST- 2021/03/18 20:27 [entrez] -AID - 000514577 [pii] -AID - 10.1159/000514577 [doi] -PST - ppublish -SO - Oncology. 2021;99(6):389-396. doi: 10.1159/000514577. Epub 2021 Mar 18. - -PMID- 32646604 -OWN - NLM -STAT- MEDLINE -DCOM- 20201001 -LR - 20201001 -IS - 1769-6917 (Electronic) -IS - 0007-4551 (Linking) -VI - 107 -IP - 9 -DP - 2020 Sep -TI - Occurrence and number of immune-related adverse events are independently - associated with survival in advanced non-small-cell lung cancer treated by - nivolumab. -PG - 946-958 -LID - S0007-4551(20)30263-0 [pii] -LID - 10.1016/j.bulcan.2020.04.019 [doi] -AB - It has been found that occurrence of immune-related adverse events (irAEs) is - associated with outcome in the treatment of advanced non-small-cell lung cancer - (NSCLC) with anti-programmed cell death (PD)-1 or anti-PDL1 agents. Independent - correlation with survival was not consistently demonstrated and correlation with - the number of toxicities was also not previously described. All patients treated - with nivolumab for advanced NSCLC, in the second line setting, were - retrospectively reviewed in a single-center from March 2015 to March 2017. - Sixty-nine patients were identified. After a median follow-up of 13 months - (95% CI: 10.8; 15.3), there were 46 tumor progressions and 37 deaths. The 6-month - and one-year progression-free survival (PFS) and overall survival (OS) rates were - 29%/61% and 24%/49%, respectively. Thirty-one patients (44.9%) presented irAEs. - Patients presenting tumor response to previous chemotherapy had a higher rate of - irAEs (P=0.01) and a better OS (HR=2, P=0.04). Occurrence of irAEs correlated - with OS in multivariate analysis (HR=0.4, 95% CI [0.19; 0.8], P=0.02). The number - of irAEs correlated with tumor response, PFS and OS in univariate analysis. - Having≥2 irAEs correlated with better outcome compared with one irAE, which - correlated with better tumor response and PFS in comparison with 0 irAE, in - multivariate analysis. In this study, irAEs was associated with a better outcome - in patients treated with nivolumab for advanced NSCLC in the second line setting. - Interestingly, the number of irAEs correlated with tumor response and PFS. -CI - Copyright © 2020 Société Française du Cancer. Published by Elsevier Masson SAS. - All rights reserved. -FAU - Bouhlel, Linda -AU - Bouhlel L -AD - University Côte d'Azur, CHU of Nice, FHU OncoAge, department of pulmonary - medicine and oncology, 30, voie Romaine, 06000 Nice, France. -FAU - Doyen, Jérôme -AU - Doyen J -AD - University of Côte d'Azur, Centre Antoine-Lacassagne, Fédération Claude-Lalanne, - department of radiation oncology, 33, avenue de Valombrose, 06189 Nice, France. - Electronic address: jerome.doyen@nice.unicancer.fr. -FAU - Chamorey, Emmanuel -AU - Chamorey E -AD - University of Côte d'Azur, Centre Antoine-Lacassagne, department of - biostatistics, 33, avenue de Valombrose, 06189 Nice, France. -FAU - Poudenx, Michel -AU - Poudenx M -AD - University of Côte d'Azur, Centre Antoine-Lacassagne, department medical - oncology, 33, avenue de Valombrose, 06189 Nice, France. -FAU - Ilie, Marius -AU - Ilie M -AD - University of Côte d'Azur, CHU of Nice, department of pathology, 30, voie - Romaine, 06000 Nice, France. -FAU - Gal, Jocelyn -AU - Gal J -AD - University of Côte d'Azur, Centre Antoine-Lacassagne, department of - biostatistics, 33, avenue de Valombrose, 06189 Nice, France. -FAU - Guigay, Joël -AU - Guigay J -AD - University of Côte d'Azur, Centre Antoine-Lacassagne, department medical - oncology, 33, avenue de Valombrose, 06189 Nice, France. -FAU - Benzaquen, Jonathan -AU - Benzaquen J -AD - University Côte d'Azur, CHU of Nice, FHU OncoAge, department of pulmonary - medicine and oncology, 30, voie Romaine, 06000 Nice, France. -FAU - Marquette, Charles-Hugo -AU - Marquette CH -AD - University Côte d'Azur, CHU of Nice, FHU OncoAge, department of pulmonary - medicine and oncology, 30, voie Romaine, 06000 Nice, France. -FAU - Berthet, Jean-Philippe -AU - Berthet JP -AD - University of Côte d'Azur, CHU of Nice, department of thoracic surgery, 30, voie - Romaine, 06000 Nice, France. -FAU - Mouroux, Jérôme -AU - Mouroux J -AD - University of Côte d'Azur, CHU of Nice, department of thoracic surgery, 30, voie - Romaine, 06000 Nice, France. -FAU - Schiappa, Renaud -AU - Schiappa R -AD - University of Côte d'Azur, Centre Antoine-Lacassagne, department of - biostatistics, 33, avenue de Valombrose, 06189 Nice, France. -FAU - Padovani, Bernard -AU - Padovani B -AD - University of Côte d'Azur, CHU of Nice, department of radiology, 30, voie - Romaine, 06000 Nice, France. -FAU - Hofman, Paul -AU - Hofman P -AD - University of Côte d'Azur, CHU of Nice, department of pathology, 30, voie - Romaine, 06000 Nice, France. -FAU - Otto, Josiane -AU - Otto J -AD - University of Côte d'Azur, Centre Antoine-Lacassagne, department medical - oncology, 33, avenue de Valombrose, 06189 Nice, France. -LA - eng -PT - Journal Article -DEP - 20200706 -PL - France -TA - Bull Cancer -JT - Bulletin du cancer -JID - 0072416 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antineoplastic Agents, Immunological/*adverse effects/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/*mortality/pathology -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/immunology/*mortality/pathology -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Nivolumab/*adverse effects/therapeutic use -MH - Progression-Free Survival -MH - Retrospective Studies -MH - Survival Rate -OTO - NOTNLM -OT - Carcinome bronchique non à petites cellules -OT - Effets indésirables immuns -OT - Immune-related adverse events -OT - Nivolumab -OT - Non-small cell lung cancer -OT - Survie -OT - Survival -EDAT- 2020/07/11 06:00 -MHDA- 2020/10/02 06:00 -CRDT- 2020/07/11 06:00 -PHST- 2019/12/24 00:00 [received] -PHST- 2020/04/13 00:00 [revised] -PHST- 2020/04/27 00:00 [accepted] -PHST- 2020/07/11 06:00 [pubmed] -PHST- 2020/10/02 06:00 [medline] -PHST- 2020/07/11 06:00 [entrez] -AID - S0007-4551(20)30263-0 [pii] -AID - 10.1016/j.bulcan.2020.04.019 [doi] -PST - ppublish -SO - Bull Cancer. 2020 Sep;107(9):946-958. doi: 10.1016/j.bulcan.2020.04.019. Epub - 2020 Jul 6. - -PMID- 35331196 -OWN - NLM -STAT- MEDLINE -DCOM- 20220404 -LR - 20220405 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 22 -IP - 1 -DP - 2022 Mar 24 -TI - Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC - patients treated with concurrent chemoradiotherapy followed by maintenance - treatment with durvalumab. -PG - 317 -LID - 10.1186/s12885-022-09395-6 [doi] -LID - 317 -AB - BACKGROUND: Investigating dynamic changes in blood-parameters and weight in - patients with locally advanced non-small cell lung cancer (NSCLC) receiving - durvalumab maintenance therapy after chemoradiotherapy (cCRT). Laboratory - outcomes were determined based on the number of durvalumab administrations - received. METHODS: Twenty-two patients completed platinum-based cCRT followed by - maintenance treatment with durvalumab. Different parameters such as hemoglobin - (Hb), leukocytes, Lactate dehydrogenase (LDH), C-reactive protein (CRP), body - weight and albumin were analyzed before cCRT, after cCRT, 3, 6, 9 and 12 months - after starting durvalumab maintenance. RESULTS: Sixteen (72.7%) patients were - male; twelve (54.5%) and fifteen (68.2%) patients had non-squamous histology and - Union for International Cancer Control (UICC) stage IIIB-C disease, respectively. - Median follow-up time was 24.4 months; 12- and 18-months- progression-free and - overall-survival rates were 55.0% and 45.0 as well as 90.2 and 85.0%, - respectively. During maintenance treatment Hb increased by 1.93 mg/dl (17.53%) - after 9 months (p < 0.001) and 2.02 mg/dl (18.46%) after 12 months compared to - the start of durvalumab (p < 0.001). LDH decreased by 29.86 U/l (- 11.74%) after - 3 months (p = 0.022). Receipt of at least 12 cycles of durvalumab was beneficial - in terms of Hb-recovery (Hb 6 months: 12.64 vs. 10.86 [mg/dl]; Hb 9 months: 13.33 - vs 11.74 [mg/dl]; (p = 0.03)). Median weight change [kilogram (kg)] was + 6.06% - (range: - 8.89 - + 18.75%) after 12 months. The number of durvalumab cycles - significantly correlated with total weight gain [kg] (Spearman-Rho-correlation: - r = 0.502*). CONCLUSION: In the investigated cohort, no severe hematologic - toxicity occurred by laboratory blood tests within 1 year of durvalumab - maintenance therapy after cCRT for unresectable stage III NSCLC. Receiving at - least 12 cycles of durvalumab appears to have a significant effect on recovery of - hemoglobin levels and body weight. -CI - © 2022. The Author(s). -FAU - Guggenberger, J -AU - Guggenberger J -AD - Department of Radiation Oncology, University Hospital, LMU Munich, Munich, - Germany. -FAU - Kenndoff, S -AU - Kenndoff S -AD - Department of Radiation Oncology, University Hospital, LMU Munich, Munich, - Germany. -FAU - Taugner, J -AU - Taugner J -AD - Department of Radiation Oncology, University Hospital, LMU Munich, Munich, - Germany. -FAU - Käsmann, L -AU - Käsmann L -AUID- ORCID: 0000-0002-4372-3597 -AD - Department of Radiation Oncology, University Hospital, LMU Munich, Munich, - Germany. Lukas.Kaesmann@med.uni-muenchen.de. -AD - Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for - Lung Research (DZL), Munich, Germany. Lukas.Kaesmann@med.uni-muenchen.de. -AD - German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. - Lukas.Kaesmann@med.uni-muenchen.de. -FAU - Flörsch, B -AU - Flörsch B -AD - Department of Radiation Oncology, University Hospital, LMU Munich, Munich, - Germany. -FAU - Belka, C -AU - Belka C -AD - Department of Radiation Oncology, University Hospital, LMU Munich, Munich, - Germany. -AD - Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for - Lung Research (DZL), Munich, Germany. -AD - German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. -FAU - Eze, C -AU - Eze C -AD - Department of Radiation Oncology, University Hospital, LMU Munich, Munich, - Germany. -FAU - Manapov, F -AU - Manapov F -AD - Department of Radiation Oncology, University Hospital, LMU Munich, Munich, - Germany. -AD - Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for - Lung Research (DZL), Munich, Germany. -AD - German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. -LA - eng -PT - Journal Article -DEP - 20220324 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy/pathology -MH - Male -MH - Neoplasm Staging -PMC - PMC8944024 -OTO - NOTNLM -OT - Blood parameters -OT - Durvalumab -OT - Dynamic changes -OT - NSCLC -OT - Prognostic factors -COIS- The authors declare no conflict of interest. FM receives an Institutional - research grant for participating or running clinical studies from Astrazeneca - (outside of the study mentioned in the manuscript). -EDAT- 2022/03/26 06:00 -MHDA- 2022/04/05 06:00 -PMCR- 2022/03/24 -CRDT- 2022/03/25 05:30 -PHST- 2021/08/08 00:00 [received] -PHST- 2022/03/09 00:00 [accepted] -PHST- 2022/03/25 05:30 [entrez] -PHST- 2022/03/26 06:00 [pubmed] -PHST- 2022/04/05 06:00 [medline] -PHST- 2022/03/24 00:00 [pmc-release] -AID - 10.1186/s12885-022-09395-6 [pii] -AID - 9395 [pii] -AID - 10.1186/s12885-022-09395-6 [doi] -PST - epublish -SO - BMC Cancer. 2022 Mar 24;22(1):317. doi: 10.1186/s12885-022-09395-6. - -PMID- 33791360 -OWN - NLM -STAT- MEDLINE -DCOM- 20210525 -LR - 20240331 -IS - 2314-6141 (Electronic) -IS - 2314-6133 (Print) -VI - 2021 -DP - 2021 -TI - The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung - Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and - Meta-Analysis. -PG - 1780860 -LID - 10.1155/2021/1780860 [doi] -LID - 1780860 -AB - BACKGROUND: Nonsmall cell lung cancer (NSCLC) is the most common type of lung - cancer, and the majority of NSCLC patients are diagnosed at the advanced stage. - Chemotherapy is still the main treatment at present, and the overall prognosis is - poor. In recent years, immunotherapy has developed rapidly. Immune checkpoint - inhibitors (ICIs) as the representative have been extensively applied for - treating various types of cancers. Tumor mutation burden (TMB) as a potential - biomarker is used to screen appropriate patients for treatment of ICIs. To verify - the predictive efficacy of TMB, a systematic review and meta-analysis were - conducted to explore the association between TMB and ICIs. METHOD: PubMed, - EMBASE, Cochrane Library, and son on were systematically searched from inception - to April 2020. Objective response rate (ORR), progression-free survival (PFS), - and overall survival (OS) were estimated. RESULTS: A total of 11 studies - consisting of 1525 nonsmall cell lung cancer (NSCLC) patients were included. - Comparison of high and low TMB: pooled HRs for OS, 0.57 (95% CI 0.32 to 0.99; P = - 0.046); PFS, 0.48 (95% CI 0.33 to 0.69; P < 0.001); ORR, 3.15 (95% CI 2.29 to - 4.33; P < 0.001). Subgroup analysis values: pooled HRs for OS, 0.75 (95% CI 0.29 - to 1.92, P = 0.548) for blood TMB (bTMB), 0.44 (95% CI 0.26 to 0.75, P = 0.003) - for tissue TMB (tTMB); for PFS, 0.54 (95% CI 0.29 to 0.98, P = 0.044) and 0.43 - (95% CI 0.26 to 0.71, P = 0.001), respectively. CONCLUSIONS: These findings imply - that NSCLC patients with high TMB possess significant clinical benefits from ICIs - compared to those with low TMB. As opposed to bTMB, tTMB was thought more - appropriate for stratifying NSCLC patients for ICI treatment. -CI - Copyright © 2021 Zhang Nan et al. -FAU - Nan, Zhang -AU - Nan Z -AUID- ORCID: 0000-0001-6154-0383 -AD - Department of Clinical Laboratory, First Teaching Hospital of Tianjin University - of Traditional Chinese Medicine, China. -FAU - Guoqing, Wang -AU - Guoqing W -AD - Tianjin Key Laboratory of Oral and Maxillofacial Function Reconstruction; Tianjin - Stomatological Hospital; Hospital of Stomatology, Nankai University, China. -FAU - Xiaoxu, Yu -AU - Xiaoxu Y -AD - Tianjin Central Hospital of Gynecology Obstetrics, China. -FAU - Yin, Mi -AU - Yin M -AD - Department of Radiotherapy, First Affiliated Hospital of Zhengzhou University, - China. -FAU - Xin, He -AU - Xin H -AD - Department of Clinical Laboratory, First Teaching Hospital of Tianjin University - of Traditional Chinese Medicine, China. -FAU - Xue, Li -AU - Xue L -AD - School of Medical Laboratory, Tianjin Medical University, China. -FAU - Rong, Wang -AU - Rong W -AUID- ORCID: 0000-0003-3502-5446 -AD - School of Medical Laboratory, Tianjin Medical University, China. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Systematic Review -DEP - 20210313 -PL - United States -TA - Biomed Res Int -JT - BioMed research international -JID - 101600173 -RN - 0 (Biomarkers, Tumor) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Biomarkers, Tumor/*metabolism -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/metabolism/mortality -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - *Lung Neoplasms/drug therapy/genetics/metabolism/mortality -MH - Progression-Free Survival -MH - Survival Rate -PMC - PMC7984892 -COIS- The authors declare that there are no conflicts of interest. -EDAT- 2021/04/02 06:00 -MHDA- 2021/05/26 06:00 -PMCR- 2021/03/13 -CRDT- 2021/04/01 06:31 -PHST- 2020/08/13 00:00 [received] -PHST- 2021/02/20 00:00 [revised] -PHST- 2021/03/01 00:00 [accepted] -PHST- 2021/04/01 06:31 [entrez] -PHST- 2021/04/02 06:00 [pubmed] -PHST- 2021/05/26 06:00 [medline] -PHST- 2021/03/13 00:00 [pmc-release] -AID - 10.1155/2021/1780860 [doi] -PST - epublish -SO - Biomed Res Int. 2021 Mar 13;2021:1780860. doi: 10.1155/2021/1780860. eCollection - 2021. - -PMID- 34481329 -OWN - NLM -STAT- MEDLINE -DCOM- 20211029 -LR - 20211103 -IS - 2059-7029 (Electronic) -IS - 2059-7029 (Linking) -VI - 6 -IP - 5 -DP - 2021 Oct -TI - Association of the advanced lung cancer inflammation index (ALI) with immune - checkpoint inhibitor efficacy in patients with advanced non-small-cell lung - cancer. -PG - 100254 -LID - S2059-7029(21)00216-7 [pii] -LID - 10.1016/j.esmoop.2021.100254 [doi] -LID - 100254 -AB - BACKGROUND: The advanced lung cancer inflammation index [ALI: body mass index × - serum albumin/neutrophil-to-lymphocyte ratio (NLR)] reflects systemic host - inflammation, and is easily reproducible. We hypothesized that ALI could assist - guidance of non-small-cell lung cancer (NSCLC) treatment with immune checkpoint - inhibitors (ICIs). PATIENTS AND METHODS: This retrospective study included 672 - stage IV NSCLC patients treated with programmed death-ligand 1 (PD-L1) inhibitors - alone or in combination with chemotherapy in 25 centers in Greece and Germany, - and a control cohort of 444 stage IV NSCLC patients treated with platinum-based - chemotherapy without subsequent targeted or immunotherapy drugs. The association - of clinical outcomes with biomarkers was analyzed with Cox regression models, - including cross-validation by calculation of the Harrell's C-index. RESULTS: High - ALI values (>18) were significantly associated with longer overall survival (OS) - for patients receiving ICI monotherapy [hazard ratio (HR) = 0.402, P < 0.0001, - n = 460], but not chemo-immunotherapy (HR = 0.624, P = 0.111, n = 212). Similar - positive correlations for ALI were observed for objective response rate (36% - versus 24%, P = 0.008) and time-on-treatment (HR = 0.52, P < 0.001), in case of - ICI monotherapy only. In the control cohort of chemotherapy, the association - between ALI and OS was weaker (HR = 0.694, P = 0.0002), and showed a significant - interaction with the type of treatment (ICI monotherapy versus chemotherapy, P < - 0.0001) upon combined analysis of the two cohorts. In multivariate analysis, ALI - had a stronger predictive effect than NLR, PD-L1 tumor proportion score, lung - immune prognostic index, and EPSILoN scores. Among patients with PD-L1 tumor - proportion score ≥50% receiving first-line ICI monotherapy, a high ALI score >18 - identified a subset with longer OS and time-on-treatment (median 35 and 16 - months, respectively), similar to these under chemo-immunotherapy. CONCLUSIONS: - The ALI score is a powerful prognostic and predictive biomarker for patients with - advanced NSCLC treated with PD-L1 inhibitors alone, but not in combination with - chemotherapy. Its association with outcomes appears to be stronger than that of - other widely used parameters. For PD-L1-high patients, an ALI score >18 could - assist the selection of cases that do not need addition of chemotherapy. -CI - Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. -FAU - Mountzios, G -AU - Mountzios G -AD - Fourth Oncology Department and Clinical Trials Unit, Henry Dunant Hospital - Center, Athens, Greece. Electronic address: gmountzios@gmail.com. -FAU - Samantas, E -AU - Samantas E -AD - Second Oncology Department, Metropolitan Hospital, Pireaus, Athens, Greece. -FAU - Senghas, K -AU - Senghas K -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany. -FAU - Zervas, E -AU - Zervas E -AD - 7th Pneumonology Department 'Sotiria' Hospital, Athens, Greece. -FAU - Krisam, J -AU - Krisam J -AD - Institute of Medical Biometry and Statistics, Heidelberg University Hospital, - Heidelberg, Germany. -FAU - Samitas, K -AU - Samitas K -AD - Department of Medical Oncology, University of Irakleion School of Medicine, - Iraklion, Greece. -FAU - Bozorgmehr, F -AU - Bozorgmehr F -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany. -FAU - Kuon, J -AU - Kuon J -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany. -FAU - Agelaki, S -AU - Agelaki S -AD - Department of Medical Oncology, University of Irakleion School of Medicine, - Iraklion, Greece. -FAU - Baka, S -AU - Baka S -AD - Department of Medical Oncology, Interbalkan Medical Center, Thessaloniki, Greece. -FAU - Athanasiadis, I -AU - Athanasiadis I -AD - Department of Medical Oncology, 'Mitera' Hospital, Athens, Greece. -FAU - Gaissmaier, L -AU - Gaissmaier L -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg, - German Center for Lung Research (DZL), Heidelberg, Germany. -FAU - Elshiaty, M -AU - Elshiaty M -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg, - German Center for Lung Research (DZL), Heidelberg, Germany. -FAU - Daniello, L -AU - Daniello L -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany. -FAU - Christopoulou, A -AU - Christopoulou A -AD - Department of Medical Oncology, General Hospital of Patras 'Agios Andreas', - Patras, Greece. -FAU - Pentheroudakis, G -AU - Pentheroudakis G -AD - Department of Medical Oncology, University of Ioannina School of Medicine, - Ioannina, Greece. -FAU - Lianos, E -AU - Lianos E -AD - Department of Medical Oncology, 'Metaxa' Cancer Hospital, Pireaus, Greece. -FAU - Linardou, H -AU - Linardou H -AD - Fourth Oncology Department, Metropolitan Hospital, Pireaus, Athens, Greece. -FAU - Kriegsmann, K -AU - Kriegsmann K -AD - Department of Hematology, Oncology and Rheumatology, University Hospital - Heidelberg, Heidelberg, Germany. -FAU - Kosmidis, P -AU - Kosmidis P -AD - Second Oncology Department, 'Hygeia' Hospital, Athens, Greece. -FAU - El Shafie, R -AU - El Shafie R -AD - Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, - Germany. -FAU - Kriegsmann, M -AU - Kriegsmann M -AD - Translational Lung Research Center Heidelberg, German Center for Lung Research - (DZL), Heidelberg, Germany; Department of Hematology, Oncology and Rheumatology, - University Hospital Heidelberg, Heidelberg, Germany. -FAU - Psyrri, A -AU - Psyrri A -AD - Department of Medical Oncology, 'Attikon' University Hospital, Athens, Greece. -FAU - Andreadis, C -AU - Andreadis C -AD - Third Department of Medical Oncology, 'Theageneion' Cancer Hospital, - Thessaloniki, Greece. -FAU - Fountzilas, E -AU - Fountzilas E -AD - Department of Medical Oncology, 'Euromedica' Clinic, Thessaloniki, Greece. -FAU - Heussel, C-P -AU - Heussel CP -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg, - German Center for Lung Research (DZL), Heidelberg, Germany. -FAU - Herth, F J -AU - Herth FJ -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg, - German Center for Lung Research (DZL), Heidelberg, Germany. -FAU - Winter, H -AU - Winter H -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg, - German Center for Lung Research (DZL), Heidelberg, Germany. -FAU - Emmanouilides, C -AU - Emmanouilides C -AD - Department of Medical Oncology, Interbalkan Medical Center, Thessaloniki, Greece. -FAU - Oikonomopoulos, G -AU - Oikonomopoulos G -AD - Second Oncology Department, Metropolitan Hospital, Pireaus, Athens, Greece. -FAU - Meister, M -AU - Meister M -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg, - German Center for Lung Research (DZL), Heidelberg, Germany. -FAU - Muley, T -AU - Muley T -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg, - German Center for Lung Research (DZL), Heidelberg, Germany. -FAU - Bischoff, H -AU - Bischoff H -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany. -FAU - Saridaki, Z -AU - Saridaki Z -AD - Department of Medical Oncology, 'Asclepius' Clinic, Iraklion, Greece. -FAU - Razis, E -AU - Razis E -AD - Third Department of Medical Oncology, Hygeia Hospital, Athens, Greece. -FAU - Perdikouri, E-I -AU - Perdikouri EI -AD - Department of Medical Oncology, 'Achilopouleio' General Hospital of Volos, Volos, - Greece. -FAU - Stenzinger, A -AU - Stenzinger A -AD - Translational Lung Research Center Heidelberg, German Center for Lung Research - (DZL), Heidelberg, Germany; Department of Hematology, Oncology and Rheumatology, - University Hospital Heidelberg, Heidelberg, Germany. -FAU - Boukovinas, I -AU - Boukovinas I -AD - Department of Medical Oncology, 'Bioclinica' Hospital, Thessaloniki, Greece. -FAU - Reck, M -AU - Reck M -AD - LungenClinic Großhansdorf GmbH, Großhansdorf, Germany; Airway Research Center - North, German Center for Lung Research, Großhansdorf, Germany. -FAU - Syrigos, K -AU - Syrigos K -AD - Department of Medical Oncology, Sotiria General Hospital of Athens, Athens, - Greece. -FAU - Thomas, M -AU - Thomas M -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg, - German Center for Lung Research (DZL), Heidelberg, Germany. -FAU - Christopoulos, P -AU - Christopoulos P -AD - Thoraxklinik and National Center for Tumor Diseases at Heidelberg University - Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg, - German Center for Lung Research (DZL), Heidelberg, Germany. Electronic address: - petros.christopoulos@med.uni-heidelberg.de. -LA - eng -PT - Journal Article -DEP - 20210901 -PL - England -TA - ESMO Open -JT - ESMO open -JID - 101690685 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Inflammation -MH - *Lung Neoplasms/drug therapy -MH - Retrospective Studies -PMC - PMC8417333 -OTO - NOTNLM -OT - PD-L1 -OT - advanced lung cancer inflammation index -OT - immunotherapy -OT - neutrophil-to-lymphocyte ratio -OT - non-small-cell lung cancer -COIS- Disclosure GM reports advisory/consultation fees from Roche, AstraZeneca, Bristol - Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Takeda, Pfizer, Amgen, and Merck - outside from the submitted work. ES reports advisory/consultation fees from - Roche, AstraZeneca, BMS, MSD, Pfizer, Amgen, and Merck outside from the submitted - work. EZ reports advisory/consultation fees from MSD and Roche outside from the - submitted work. KS reports advisory/consultation fees from MSD and Roche outside - from the submitted work. SA reports advisory/consultation fees from Roche, - AstraZeneca, BMS, MSD, Takeda, Pfizer, Amgen, and Merck outside from the - submitted work. SB reports advisory/consultation fees from Roche, AstraZeneca, - BMS, MSD, Takeda, Pfizer, and Amgen outside from the submitted work. IA reports - advisory/consultation fees from Roche, AstraZeneca, BMS, MSD, Pfizer, Amgen, and - Merck outside from the submitted work. AC reports advisory/consultation fees from - Roche, AstraZeneca, BMS, MSD, Pfizer, and Amgen outside from the submitted work. - GP reports advisory/consultation fees from Roche, AstraZeneca, BMS, MSD, Pfizer, - Amgen, and Merck outside from the submitted work. EL reports - advisory/consultation fees from Roche, AstraZeneca, MSD, and Pfizer outside from - the submitted work. HL reports advisory/consultation fees from Roche, - AstraZeneca, BMS, MSD, Pfizer, Amgen, and Merck outside from the submitted work. - PK reports advisory/consultation fees from Roche, AstraZeneca, BMS, MSD, Pfizer, - Amgen, and Merck outside from the submitted work. AP reports - advisory/consultation fees from Roche, AstraZeneca, BMS, MSD, Pfizer, Amgen, and - Merck outside from the submitted work. CA reports advisory/consultation fees from - Roche, AstraZeneca, BMS, MSD, Pfizer, Amgen, and Merck outside from the submitted - work. EF reports advisory/consultation fees from Roche, AstraZeneca, BMS, MSD, - Pfizer, Amgen, and Merck outside from the submitted work. FJH reports advisory - board fees and honoraria from Lilly, Roche, AstraZeneca, Novartis, Boehringer, - Chiesi, Teva, Pulmonx BTG, and Olympus, as well as research funding from Lilly, - Roche, AstraZeneca, Novartis, Boehringer, Chiesi, and Teva, outside of the - submitted work. CE reports advisory/consultation fees from Roche, AstraZeneca, - BMS, MSD, Pfizer, Amgen, and Merck outside from the submitted work. GO reports - advisory/consultation fees from Roche, AstraZeneca, BMS, and MSD outside from the - submitted work. TM reports research funding from Roche and patents with Roche, - outside from the submitted work. ZS reports advisory/consultation fees from - Roche, AstraZeneca, BMS, MSD, Pfizer, Amgen, and Merck outside from the submitted - work. ER reports advisory/consultation fees from Roche, AstraZeneca, BMS, MSD, - Pfizer, and Amgen outside from the submitted work. AS reports advisory board - honoraria from BMS, AstraZeneca, ThermoFisher, Novartis, speaker's honoraria from - BMS, Illumina, AstraZeneca, Novartis, ThermoFisher, MSD, Roche, and research - funding from Chugai, outside from the submitted work. IB reports - advisory/consultation fees from Roche, AstraZeneca, BMS, MSD, Pfizer, and Amgen - outside from the submitted work. MR reports personal fees from Amgen, - AstraZeneca, BMS, Boehringer-Ingelheim, Lilly, Merck, MSD, Novartis, Pfizer, - Roche, and Samsung, outside the submitted work. KS reports advisory/consultation - fees from Roche, AstraZeneca, BMS, and MSD. MT reports advisory board honoraria - from Novartis, Lilly, BMS, MSD, Roche, Celgene, Takeda, AbbVie, Boehringer, - speaker's honoraria from Lilly, MSD, Takeda, research funding from AstraZeneca, - BMS, Celgene, Novartis, Roche, and travel grants from BMS, MSD, Novartis, - Boehringer, outside from the submitted work. PC reports research funding from - AstraZeneca, Novartis, Roche, Takeda, and advisory board/lecture fees from - AstraZeneca, Boehringer Ingelheim, Chugai, Novartis, Pfizer, Roche, Takeda. All - other authors have declared no conflicts of interest. -EDAT- 2021/09/05 06:00 -MHDA- 2021/10/30 06:00 -PMCR- 2021/09/01 -CRDT- 2021/09/04 20:27 -PHST- 2021/04/29 00:00 [received] -PHST- 2021/07/08 00:00 [revised] -PHST- 2021/08/01 00:00 [accepted] -PHST- 2021/09/05 06:00 [pubmed] -PHST- 2021/10/30 06:00 [medline] -PHST- 2021/09/04 20:27 [entrez] -PHST- 2021/09/01 00:00 [pmc-release] -AID - S2059-7029(21)00216-7 [pii] -AID - 100254 [pii] -AID - 10.1016/j.esmoop.2021.100254 [doi] -PST - ppublish -SO - ESMO Open. 2021 Oct;6(5):100254. doi: 10.1016/j.esmoop.2021.100254. Epub 2021 Sep - 1. - -PMID- 33289347 -OWN - NLM -STAT- MEDLINE -DCOM- 20211119 -LR - 20221005 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 12 -IP - 2 -DP - 2021 Jan -TI - Effect of durvalumab on local control after concurrent chemoradiotherapy for - locally advanced non-small cell lung cancer in comparison with chemoradiotherapy - alone. -PG - 245-250 -LID - 10.1111/1759-7714.13764 [doi] -AB - BACKGROUND: Durvalumab after concurrent chemoradiotherapy (CCRT) for locally - advanced non-small cell lung cancer (LA-NSCLC) has been found to significantly - improve overall survival (OS). However, the effect of durvalumab on local control - remains unclear. Here, we evaluated the effect of the durvalumab on local control - in comparison with the clinical result of patients treated with CCRT alone. - METHODS: A total of 120 LA-NSCLC patients including 76 patients with CCRT alone - and 44 patients with CCRT followed by durvalumab were analyzed. Baseline patient - characteristics of CCRT alone cohort and durvalumab cohort were compared with - student's t test or Mann-Whitney U test for continuous variables and with - chi-squared test for categorical variables. Local control (LC), progression free - survival (PFS) and OS rates were estimated using the Kaplan-Meier method and - compared with the log-rank test. RESULTS: There were 19 patients with stage II - disease and 101 patients with stage III disease. Age, sex, histopathological - type, T classification, N classification, clinical stage, tumor volume and dose - fractionation schedule were not significantly different between the CCRT alone - and durvalumab cohorts. The one-year LC rate was significantly higher in the - durvalumab cohort (86%) compared with the CCRT alone cohort (62%) (P = 0.005), - whereas no significant difference was observed in either PFS (P = 0.864) or OS (P - = 0.443) between the CCRT and durvalumab cohorts. CONCLUSIONS: The one-year LC - rate was significantly higher in the durvalumab cohort compared with the CCRT - alone cohort. Although the follow-up period was too short to draw definitive - conclusions, the study revealed that durvalumab might have a significant effect - on LC. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Effect of durvalumab on - local control after chemoradiotherapy for locally advanced non-small cell lung - cancer is unclear WHAT THIS STUDY ADDS: The one-year local control rate of - chemoradiotherapy followed by durvalumab was significantly higher compared with - chemoradiotherapy alone. -CI - © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Abe, Takanori -AU - Abe T -AUID- ORCID: 0000-0001-6209-9446 -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Saito, Satoshi -AU - Saito S -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Iino, Misaki -AU - Iino M -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Aoshika, Tomomi -AU - Aoshika T -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Ryuno, Yasuhiro -AU - Ryuno Y -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Ohta, Tomohiro -AU - Ohta T -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Igari, Mitsunobu -AU - Igari M -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Hirai, Ryuta -AU - Hirai R -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Kumazaki, Yu -AU - Kumazaki Y -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Miura, Yu -AU - Miura Y -AD - Department of Respiratory Medicine, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Kaira, Kyoichi -AU - Kaira K -AUID- ORCID: 0000-0001-5548-7686 -AD - Department of Respiratory Medicine, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Kagamu, Hiroshi -AU - Kagamu H -AD - Department of Respiratory Medicine, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Noda, Shin-Ei -AU - Noda SE -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -FAU - Kato, Shingo -AU - Kato S -AD - Department of Radiation Oncology, International Medical Center, Saitama Medical - University, Hidaka, Japan. -LA - eng -PT - Journal Article -DEP - 20201201 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/*radiotherapy -MH - Chemoradiotherapy/methods -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology/*radiotherapy -MH - Male -MH - Middle Aged -PMC - PMC7812072 -OTO - NOTNLM -OT - Concurrent chemoradiotherapy -OT - durvalumab -OT - local control -OT - locally advanced non-small cell lung cancer -EDAT- 2020/12/09 06:00 -MHDA- 2021/11/20 06:00 -PMCR- 2021/01/01 -CRDT- 2020/12/08 05:50 -PHST- 2020/10/05 00:00 [received] -PHST- 2020/11/10 00:00 [revised] -PHST- 2020/11/15 00:00 [accepted] -PHST- 2020/12/09 06:00 [pubmed] -PHST- 2021/11/20 06:00 [medline] -PHST- 2020/12/08 05:50 [entrez] -PHST- 2021/01/01 00:00 [pmc-release] -AID - TCA13764 [pii] -AID - 10.1111/1759-7714.13764 [doi] -PST - ppublish -SO - Thorac Cancer. 2021 Jan;12(2):245-250. doi: 10.1111/1759-7714.13764. Epub 2020 - Dec 1. - -PMID- 32798130 -OWN - NLM -STAT- MEDLINE -DCOM- 20211229 -LR - 20240329 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 22 -IP - 3 -DP - 2021 May -TI - Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With - Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With - Chemoradiation and Atezolizumab. -PG - e451-e465 -LID - S1525-7304(20)30210-2 [pii] -LID - 10.1016/j.cllc.2020.06.016 [doi] -AB - BACKGROUND: Cancer-associated macrophage-like cells (CAMLs) are a potential - peripheral blood biomarker for disease progression. This study used data from a - phase 2 clinical trial to evaluate prognostic utility of CAMLs for locally - advanced non-small-cell lung cancer treated with definitive chemoradiotherapy - (CRT) and atezolizumab (DETERRED; ClinicalTrials.gov NCT02525757). PATIENTS AND - METHODS: Sample collection occurred at baseline (T0), during CRT (T1), at end of - CRT (T2), and at first follow-up (T3). CAMLs were captured and quantified by the - CellSieve system using multiplex immunostaining. Giant CAMLs were defined as - characteristic CAMLs ≥ 50 μm. Kaplan-Meier methodology estimated progression-free - survival, distant failure-free survival, relapse-free survival, and overall - survival at 30 months. RESULTS: Thirty-nine patients were evaluated between - December 2015 and March 2018. Median follow-up was 27 months. Most disease was - stage III (85%) and comprised squamous-cell carcinoma (38%) or adenocarcinoma - (59%). In total, 267 blood samples were analyzed. Giant CAMLs were identified in - 57%, 60%, 64%, and 63% of patients at T0, T1, T2, and T3, respectively. Patients - with giant CAMLs at T3, occurring at a median of 30 days after completion of CRT, - had significantly worse distant failure-free survival (hazard ratio [HR] 4.9, P = - .015), progression-free survival (HR 2.5, P = .025), recurrence-free survival (HR - 2.4, P = .036), and overall survival (HR 3.5, P = .034) compared to patients with - small or no CAMLs. CONCLUSIONS: Presence of giant CAMLs after CRT completion was - associated with development of metastatic disease and poorer survival despite the - use of maintenance immunotherapy. Monitoring CAMLs may help risk-stratify - patients for adaptive treatment strategies. -CI - Copyright © 2020 Elsevier Inc. All rights reserved. -FAU - Augustyn, Alexander -AU - Augustyn A -AD - Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, - Houston, TX. -FAU - Adams, Daniel L -AU - Adams DL -AD - Creatv MicroTech Inc, Monmouth Junction, NJ. -FAU - He, Jianzhong -AU - He J -AD - Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, - Houston, TX. -FAU - Qiao, Yawei -AU - Qiao Y -AD - Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, - Houston, TX. -FAU - Verma, Vivek -AU - Verma V -AD - Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA. -FAU - Liao, Zhongxing -AU - Liao Z -AD - Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, - Houston, TX. -FAU - Tang, Cha-Mei -AU - Tang CM -AD - Creatv MicroTech Inc, Rockville, MD. -FAU - Heymach, John V -AU - Heymach JV -AD - Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD - Anderson Cancer Center, Houston, TX. -FAU - Tsao, Anne S -AU - Tsao AS -AD - Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD - Anderson Cancer Center, Houston, TX. -FAU - Lin, Steven H -AU - Lin SH -AD - Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, - Houston, TX. Electronic address: shlin@mdanderson.org. -LA - eng -SI - ClinicalTrials.gov/NCT02525757 -GR - R43 CA206840/CA/NCI NIH HHS/United States -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20200620 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 52CMI0WC3Y (atezolizumab) -SB - IM -CIN - Front Immunol. 2023 Nov 16;14:1295257. doi: 10.3389/fimmu.2023.1295257. PMID: - 38035101 -MH - Adenocarcinoma of Lung/pathology/therapy -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/*administration & dosage -MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage -MH - Carcinoma, Non-Small-Cell Lung/pathology/*therapy -MH - Carcinoma, Squamous Cell/pathology/therapy -MH - Chemoradiotherapy/methods -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Lung Neoplasms/pathology/*therapy -MH - Male -MH - Middle Aged -MH - Neoplasm Recurrence, Local -MH - Neoplasm Staging -MH - Neoplastic Cells, Circulating/*metabolism -MH - Prognosis -MH - Progression-Free Survival -MH - Prospective Studies -MH - Survival Rate -OTO - NOTNLM -OT - Biomarker -OT - CAML -OT - Chemoradiation -OT - Immunotherapy -OT - NSCLC -EDAT- 2020/08/17 06:00 -MHDA- 2021/12/30 06:00 -CRDT- 2020/08/17 06:00 -PHST- 2020/03/19 00:00 [received] -PHST- 2020/06/09 00:00 [revised] -PHST- 2020/06/13 00:00 [accepted] -PHST- 2020/08/17 06:00 [pubmed] -PHST- 2021/12/30 06:00 [medline] -PHST- 2020/08/17 06:00 [entrez] -AID - S1525-7304(20)30210-2 [pii] -AID - 10.1016/j.cllc.2020.06.016 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2021 May;22(3):e451-e465. doi: 10.1016/j.cllc.2020.06.016. Epub - 2020 Jun 20. - -PMID- 33302668 -OWN - NLM -STAT- MEDLINE -DCOM- 20210514 -LR - 20210514 -IS - 2224-5839 (Electronic) -IS - 2224-5820 (Linking) -VI - 9 -IP - 6 -DP - 2020 Nov -TI - The efficiency and safety of immune checkpoint inhibitors in the treatment of - small cell lung cancer: a meta-analysis. -PG - 4081-4088 -LID - 10.21037/apm-20-2011 [doi] -AB - BACKGROUND: Small cell lung cancer (SCLC) is highly invasive and fatal, sensitive - to chemotherapy and radiotherapy but prone to relapse, with a poor overall - survival rate. It is particularly urgent for SCLC patients to receive effective - follow-up treatment. In the past 20 years, there has been no breakthrough in - clinical treatment of SCLC. Currently, clinical studies on immunotherapy for SCLC - with extensive stage disease (ED) have achieved good efficacy, bringing new hope - for the treatment of small-cell lung cancer. PD-1 inhibitors used to treat small - cell lung cancer include Pembrolizumab and Nivolumab. PD-L1 inhibitors mainly - include Atezolizumab and Durvalumab. Other PD-1/PD-L1 inhibitors, such as - Avelumab, are currently being tried for SCLC and the results have not yet been - published. This study is to evaluate the efficacy and safety of immunotherapy in - patients with ED SCLC. METHODS: A literature search of the PubMed, Embase, and - Cochrane Library databases were performed. Two reviewers independently screened - the literature, extracted the data, and evaluated the risk of bias of the - included studies. RevMan 5.3 software was used for meta-analysis. RESULTS: Four - studies involving 1,981 patients with ED SCLC were included. Both overall - survival (OS) [hazard ratio (HR) =0.80, 95% confidence interval (CI) (0.68, - 0.95), P=0.009] and progression-free survival (PFS) [HR =0.82, 95% CI (0.75, - 0.90), P<0.00001] were longer in the immunotherapy group than in the chemotherapy - group. The incidence of total treatment-related adverse events in the - immunotherapy group were lower than those in the chemotherapy group [relative - risk (RR) =1.050, 95% CI (1.010, 1.080), P=0.007], and the differences were - statistically significant. CONCLUSIONS: Immunotherapy has better efficacy and - safety than chemotherapy for the treatment of ED SCLC. -FAU - Zhang, Shanshan -AU - Zhang S -AD - Department of Oncology, the First Affiliated Hospital of Bengbu Medical College, - Bengbu, China. -FAU - Bi, Minghong -AU - Bi M -AD - Department of Oncology, the First Affiliated Hospital of Bengbu Medical College, - Bengbu, China. bmh2003@126.com. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PL - China -TA - Ann Palliat Med -JT - Annals of palliative medicine -JID - 101585484 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -MH - *Small Cell Lung Carcinoma/drug therapy -OTO - NOTNLM -OT - Immunotherapy -OT - chemotherapy -OT - small cell lung cancer -EDAT- 2020/12/12 06:00 -MHDA- 2021/05/15 06:00 -CRDT- 2020/12/11 05:33 -PHST- 2020/09/14 00:00 [received] -PHST- 2020/11/06 00:00 [accepted] -PHST- 2020/12/11 05:33 [entrez] -PHST- 2020/12/12 06:00 [pubmed] -PHST- 2021/05/15 06:00 [medline] -AID - 10.21037/apm-20-2011 [doi] -PST - ppublish -SO - Ann Palliat Med. 2020 Nov;9(6):4081-4088. doi: 10.21037/apm-20-2011. - -PMID- 33728436 -OWN - NLM -STAT- MEDLINE -DCOM- 20210517 -LR - 20210517 -IS - 1465-3621 (Electronic) -IS - 0368-2811 (Linking) -VI - 51 -IP - 5 -DP - 2021 Apr 30 -TI - A multi-institutional randomized phase III study comparing weekly carboplatin - plus nab-paclitaxel and daily low-dose carboplatin as regimens for concurrent - chemoradiotherapy in elderly patients with unresectable locally advanced - non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG1914. -PG - 836-841 -LID - 10.1093/jjco/hyab025 [doi] -AB - Daily low-dose carboplatin plus concurrent thoracic radiotherapy is the standard - treatment for elderly patients with unresectable clinical stage (c-Stage) III - non-small cell lung cancer (NSCLC) in Japan. However, a phase I study by Omori et - al. suggests that weekly carboplatin and nab-paclitaxel plus concurrent thoracic - radiotherapy have comparable efficacy outcomes with more manageable adverse - events. In December 2020, we initiated a randomized controlled trial in Japan to - confirm whether the weekly carboplatin plus nab-paclitaxel regimen is noninferior - to the daily low-dose carboplatin regimen for concurrent chemoradiotherapy in - elderly patients with unresectable c-Stage III NSCLC. We plan to enroll 166 - patients from 50 institutions in 3.5 years. The primary endpoint is overall - survival. The secondary endpoints are progression-free survival, response rate, - proportion of patients starting maintenance durvalumab therapy, adverse events, - site of progression, Functional Assessment of Cancer Therapy-Trial Outcome Index - deterioration and Instrumental Activities of Daily Living deterioration. -CI - © The Author(s) 2021. Published by Oxford University Press. All rights reserved. - For permissions, please e-mail: journals.permission@oup.com. -FAU - Shimoyama, Ryo -AU - Shimoyama R -AD - JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, - Japan. -FAU - Omori, Shota -AU - Omori S -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Nomura, Shogo -AU - Nomura S -AD - JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, - Japan. -FAU - Kenmotsu, Hirotsugu -AU - Kenmotsu H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Takahashi, Toshiaki -AU - Takahashi T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Harada, Hideyuki -AU - Harada H -AD - Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Ishikura, Satoshi -AU - Ishikura S -AD - Department of Radiology, Nagoya City University Graduate School of Medical - Sciences, Aichi, Japan. -FAU - Mizutani, Tomonori -AU - Mizutani T -AD - Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, - Japan. -FAU - Ando, Masahiko -AU - Ando M -AD - Department of Advanced Medicine, Nagoya University Hospital, Aichi, Japan. -FAU - Kataoka, Tomoko -AU - Kataoka T -AD - JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, - Japan. -FAU - Fukuda, Haruhiko -AU - Fukuda H -AD - JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, - Japan. -FAU - Ohe, Yuichiro -AU - Ohe Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -CN - Lung Cancer Study Group in the Japan Clinical Oncology Group -LA - eng -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -PL - England -TA - Jpn J Clin Oncol -JT - Japanese journal of clinical oncology -JID - 0313225 -RN - 0 (130-nm albumin-bound paclitaxel) -RN - 0 (Albumins) -RN - BG3F62OND5 (Carboplatin) -RN - P88XT4IS4D (Paclitaxel) -SB - IM -MH - Aged -MH - Albumins/pharmacology/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use -MH - Carboplatin/administration & dosage/pharmacology/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Chemoradiotherapy/*methods -MH - Female -MH - Humans -MH - Japan -MH - Lung Neoplasms/*drug therapy/pathology -MH - Male -MH - Paclitaxel/pharmacology/*therapeutic use -OTO - NOTNLM -OT - carboplatin -OT - nab-paclitaxel -OT - non-small cell lung cancer -OT - radiotherapy -OT - randomized controlled trial -EDAT- 2021/03/18 06:00 -MHDA- 2021/05/18 06:00 -CRDT- 2021/03/17 06:54 -PHST- 2020/12/09 00:00 [received] -PHST- 2021/02/01 00:00 [revised] -PHST- 2021/02/04 00:00 [accepted] -PHST- 2021/03/18 06:00 [pubmed] -PHST- 2021/05/18 06:00 [medline] -PHST- 2021/03/17 06:54 [entrez] -AID - 6174321 [pii] -AID - 10.1093/jjco/hyab025 [doi] -PST - ppublish -SO - Jpn J Clin Oncol. 2021 Apr 30;51(5):836-841. doi: 10.1093/jjco/hyab025. - -PMID- 34663250 -OWN - NLM -STAT- MEDLINE -DCOM- 20220128 -LR - 20240610 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 21 -IP - 1 -DP - 2021 Oct 18 -TI - Phase II study of multidisciplinary therapy combined with pembrolizumab for - patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO - study (WJOG11118L). -PG - 1121 -LID - 10.1186/s12885-021-08851-z [doi] -LID - 1121 -AB - BACKGROUND: Synchronous oligometastatic non-small cell lung cancer (NSCLC) is - generally characterised by the limited number of metastases at the time of - diagnosis. Several clinical trials have shown that local ablative therapy (LAT) - at all sites of the disease might be beneficial for patients with oligometastatic - NSCLC. In recent years, the combination of programmed cell death 1 (PD-1) - inhibitors or programmed cell death ligand 1 with cytotoxic chemotherapy has - become a new standard treatment for patients with metastatic NSCLC. Furthermore, - multisite LAT would inherently reduce the overall tumour burden, and this could - promote T cell reinvigoration to enhance the efficacy of PD-1 inhibitors. Few - studies have evaluated the efficacy of the combination of PD-1 inhibitors with - LAT at all sites of disease. The aim of the present multicentre single-arm phase - II study is to evaluate the efficacy of LAT at all sites of disease following - standard platinum doublet chemotherapy with pembrolizumab in patients with - oligometastatic NSCLC. METHODS: Thirty patients with synchronous oligometastatic - NSCLC will be enrolled in the trial. All patients will receive 2-4 cycles of a - systemic treatment including pembrolizumab and chemotherapy as induction therapy. - Patients who will receive LAT will be determined by a multidisciplinary tumour - board, including medical oncologists, radiation oncologists, and thoracic - surgeons. LAT will be administered at all sites of disease within 21-56 days of - the last dose of induction therapy and will be followed by maintenance therapy - within 42 days of the last day of LAT. The primary endpoint is the - progression-free survival (PFS) rate of 24 months from the date of initiation of - LAT. The secondary endpoints are toxicity, response to induction therapy, PFS, - overall survival, and the frequency of LAT. DISCUSSION: This study will provide - novel data on the efficacy and safety profile of the combination of LAT and - chemotherapy plus immune-checkpoint inhibitors in patients with synchronous - oligometastatic NSCLC. If the primary endpoint of this study is met, extensive - phase III studies further assessing this strategy will be recommended. TRIAL - REGISTRATION: jRCT identifier: jRCTs041200046 (date of initial registration: 28 - October 2020). -CI - © 2021. The Author(s). -FAU - Miyawaki, Taichi -AU - Miyawaki T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -AD - Department of Respiratory Medicine, Juntendo University Graduate School of - Medicine, Tokyo, Japan. -FAU - Kenmotsu, Hirotsugu -AU - Kenmotsu H -AUID- ORCID: 0000-0003-0590-9259 -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. h.kenmotsu@scchr.jp. -FAU - Harada, Hideyuki -AU - Harada H -AD - Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Ohde, Yasuhisa -AU - Ohde Y -AD - Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Chiba, Yasutaka -AU - Chiba Y -AD - Clinical Research Center, Kindai University Hospital, Osaka-sayama, Japan. -FAU - Haratani, Koji -AU - Haratani K -AD - Department of Medical Oncology, Kindai University Faculty of Medicine, - Osaka-sayama, Japan. -FAU - Okimoto, Tamio -AU - Okimoto T -AD - Department of Internal Medicine, Division of Medical Oncology & Respiratory - Medicine, Shimane University Faculty of Medicine, Izumo, Japan. -FAU - Sakamoto, Tomohiro -AU - Sakamoto T -AD - Division of Respiratory Medicine and Rheumatology, Department of - Multidisciplinary Internal Medicine, Tottori University, Yonago city, Japan. -FAU - Wakuda, Kazushige -AU - Wakuda K -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Ito, Kentaro -AU - Ito K -AD - Respiratory Centor, Matsusaka Municipal Hospital, Matsusaka, Japan. -FAU - Uemura, Takehiro -AU - Uemura T -AD - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City - University Graduate School of Medical Sciences, Nagoya, Japan. -FAU - Sakata, Shinya -AU - Sakata S -AD - Department of Respiratory Medicine, Kumamoto University Hospital, Kumamoto, - Japan. -FAU - Kogure, Yoshihito -AU - Kogure Y -AD - Department of Respiratory Medicine, National Hospital Organization Nagoya Medical - Center, Nagoya, Japan. -FAU - Nishimura, Yasumasa -AU - Nishimura Y -AD - Department of Radiation Oncology, Kindai University Faculty of Medicine, - Osaka-sayama, Japan. -FAU - Nakagawa, Kazuhiko -AU - Nakagawa K -AD - Department of Medical Oncology, Kindai University Faculty of Medicine, - Osaka-sayama, Japan. -FAU - Yamamoto, Nobuyuki -AU - Yamamoto N -AD - Internal Medicine III, Wakayama Medical University, Wakayama, Japan. -LA - eng -PT - Clinical Trial Protocol -PT - Journal Article -DEP - 20211018 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (130-nm albumin-bound paclitaxel) -RN - 0 (Albumins) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - BG3F62OND5 (Carboplatin) -RN - Q20Q21Q62J (Cisplatin) -RN - 0 (Immune Checkpoint Inhibitors) -RN - P88XT4IS4D (Paclitaxel) -RN - DPT0O3T46P (pembrolizumab) -RN - 04Q9AIZ7NO (Pemetrexed) -SB - IM -MH - Adult -MH - Aged -MH - Humans -MH - Middle Aged -MH - Albumins/administration & dosage -MH - Antibodies, Monoclonal, Humanized/administration & dosage -MH - Antineoplastic Agents, Immunological/administration & dosage -MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Carboplatin/administration & dosage -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology/secondary -MH - Carcinoma, Squamous Cell/drug therapy/pathology/secondary -MH - Cisplatin/administration & dosage -MH - Drug Administration Schedule -MH - *Immune Checkpoint Inhibitors/therapeutic use -MH - Induction Chemotherapy/methods -MH - Japan -MH - *Lung Neoplasms/drug therapy/pathology -MH - Maintenance Chemotherapy/methods -MH - Paclitaxel/administration & dosage -MH - Pemetrexed/administration & dosage -MH - Progression-Free Survival -MH - Clinical Trials, Phase II as Topic -MH - Multicenter Studies as Topic -PMC - PMC8524804 -OTO - NOTNLM -OT - Clinical trial -OT - Local ablative therapy -OT - Oligometastatic disease -OT - Programmed cell death 1 inhibitor -OT - Progression-free survival -COIS- Dr. Kenmotsu reports grants and personal fees from AstraZeneca K.K., grants and - personal fees from Chugai Pharmaceutical Co, Ltd., personal fees from Ono - Pharmaceutical Co, Ltd., grants and personal fees from Boehringer Ingelheim, - personal fees from Eli Lilly K. K, personal fees from Kyowa Hakko Kirin Co., - Ltd., personal fees from Bristol-Myers Squibb, personal fees from MSD, grants and - personal fees from Novartis Pharma K.K., grants and personal fees from - Daiichi-Sankyo Co., Ltd., personal fees from Pfizer, and personal fees from Taiho - Pharma, outside the submitted work. Dr. Harada reports personal fees from Daiichi - Sankyo pharmaceutical Co., during the conduct of the study; personal fees from - Daiichi Sankyo pharmaceutical co., personal fees from AstraZneca pharmaceutical - co., personal fees from Brain labo co., personal fees from Chugai Pharmaceutical - Co., grants from Japan Agency for Medical Research and Development, grants from - The National Cancer Center Research and Development fund, outside the submitted - work. Dr. Chiba reports personal fees from Chugai Pharmaceutical Co., Ltd., - outside the submitted work. Dr. Haratani reports personal fees from AS ONE - Corporation, grants and personal fees from AstraZeneca K.K., personal fees from - Bristol-Myers Squibb Co. Ltd., personal fees from Chugai Pharmaceutical Co. Ltd., - grants and personal fees from MSD K.K. 2018/11, personal fees from Ono - Pharmaceutical Co. Ltd., and personal fees from Pfizer Japan Inc., outside the - submitted work. Dr. Sakamoto reports personal fees from AstraZeneca K.K., - personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Merck - KGaA, personal fees from Eli Lilly Japan K.K., personal fees from Novartis Pharma - K.K., and personal fees from Kyowa Kirin Co., Ltd., outside the submitted work. - Dr. Wakuda reports grants and personal fees from Chugai Pharmaceutical Co., Ltd., - personal fees from Taiho Pharmaceutical, personal fees from Boehringer Ingelheim, - personal fees from Eli Lilly K.K., personal fees from Ono Pharmaceutical, - personal fees from MSD, grants from Novartis, grants from AbbVie, grants and - personal fees from AstraZeneca, outside the submitted work. Dr. Ito reports - personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, personal - fees from Pfizer, Eli Lilly, personal fees from Chugai Pharmaceutical, personal - fees from Merk Sharp & Dohme (MSD), personal fees from Ono Pharmaceutical, - personal fees from Taiho Pharmaceutical, during the conduct of the study. Dr. - Uemura reports personal fees from Chugai Pharmaceutical Co., Ltd., outside the - submitted work. Dr. Kogure reports personal fees from AstraZeneca K.K., Chugai - Pharmaceutical Co, Ltd., Eli Lilly K. K, and Boehringer Ingelheim., grants and - personal fees from MSD, which are unrelated to the submitted work. Dr. Nakagawa - reports grants and personal fees from AstraZeneca K.K., grants and personal fees - from Astellas Pharma Inc., grants and personal fees from MSD K.K., grants, - personal fees and other from Ono Pharmaceutical Co., Ltd., grants and personal - fees from Nippon Boehringer Ingelheim Co., Ltd., grants and personal fees from - Novartis Pharma K.K., grants, personal fees and other from Pfizer Japan Inc., - grants and personal fees from Bristol-Myers Squibb Company, grants, personal fees - and other from Eli Lilly Japan K.K., grants and personal fees from Chugai - Pharmaceutical Co., Ltd., grants and personal fees from Daiichi Sankyo Co., Ltd., - grants and personal fees from Merck Serono Co., Ltd./ Merck Biopharma Co., Ltd., - during the conduct of the study; personal fees from Clinical Trial Co., Ltd., - personal fees from MEDICUS SHUPPAN, Publishers Co., Ltd., personal fees from Care - Net, Inc., personal fees from Reno. Medical K.K., personal fees and other from - KYORIN Pharmaceutical Co., Ltd., personal fees from Medical Review Co., Ltd., - personal fees from Roche Diagnostics K.K., personal fees from Bayer Yakuhin, - Ltd., personal fees from Medical Mobile Communications co., Ltd., personal fees - from 3H Clinical Trial Inc., personal fees from Nichi-Iko Pharmaceutical Co., - Ltd., grants, personal fees and other from Takeda Pharmaceutical Co., Ltd., - grants and personal fees from Taiho Pharmaceutical Co., Ltd., grants and personal - fees from SymBio Pharmaceuticals Limited., personal fees from NANZANDO Co., Ltd., - personal fees from YODOSHA CO., LTD., personal fees from Nikkei Business - Publications, Inc., personal fees from Thermo Fisher Scientific K.K., personal - fees from YOMIURI TELECASTING CORPORATION., personal fees from Nippon Kayaku Co., - Ltd., grants and personal fees from AbbVie Inc., grants from inVentiv Health - Japan, grants from ICON Japan K.K., grants from GRITSONE ONCOLOGY.INC, grants - from PAREXEL International Corp., grants from Kissei Pharmaceutical Co., Ltd., - grants from EPS Corporation., grants from Syneos Health., grants from Pfizer R&D - Japan G.K., grants from A2 Healthcare Corp., grants from Quintiles Inc. / IQVIA - Services JAPAN K.K., grants from EP-CRSU CO., LTD., grants from Linical Co., - Ltd., grants from Eisai Co., Ltd., grants from CMIC Shift Zero K.K., grants from - Kyowa Hakko Kirin Co., Ltd., grants from Bayer Yakuhin, Ltd., grants from EPS - International Co., Ltd.,., grants from Otsuka Pharmaceutical Co., Ltd., outside - the submitted work. Dr. Yamamoto reports grants and personal fees from MSD K.K., - grants and personal fees from AstraZeneca, grants and personal fees from ONO - PHARMACEUTICAL CO., LTD., personal fees from Thermo Fisher Scientific, grants and - personal fees from Daiichi Sankyo Co., Ltd., grants and personal fees from TAIHO - PHARMACEUTICAL CO., LTD., grants and personal fees from Takeda Pharmaceutical - CO., LTD., grants and personal fees from Chugai Pharmaceutical Co., LTD., grants - and personal fees from Eli Lilly Japan K.K., grants and personal fees from - Boehringer Ingelheim, grants and personal fees from Novartis, grants and personal - fees from Pfizer Inc., personal fees from Bristol-Myers Squibb, personal fees - from Life Technologies Japan Ltd., personal fees from NIPPON KAYAKU, personal - fees from Merk Biopharma, grants from Astellas Pharma Inc., grants from TSUMURA & - CO., grants from SHIONOGI Co., Ltd., grants from AbbVie G.K., grants from Amgen - Inc., grants from KYORIN Pharmaceutical Co., Ltd., grants from Eisai Co., Ltd., - grants from TERUMO CORPORATION, grants from Toppan Printing Co., Ltd., grants - from TOSOH, outside the submitted work. -EDAT- 2021/10/20 06:00 -MHDA- 2022/01/29 06:00 -PMCR- 2021/10/18 -CRDT- 2021/10/19 05:35 -PHST- 2021/02/04 00:00 [received] -PHST- 2021/10/08 00:00 [accepted] -PHST- 2021/10/19 05:35 [entrez] -PHST- 2021/10/20 06:00 [pubmed] -PHST- 2022/01/29 06:00 [medline] -PHST- 2021/10/18 00:00 [pmc-release] -AID - 10.1186/s12885-021-08851-z [pii] -AID - 8851 [pii] -AID - 10.1186/s12885-021-08851-z [doi] -PST - epublish -SO - BMC Cancer. 2021 Oct 18;21(1):1121. doi: 10.1186/s12885-021-08851-z. - -PMID- 34331065 -OWN - NLM -STAT- MEDLINE -DCOM- 20220304 -LR - 20220304 -IS - 1873-734X (Electronic) -IS - 1010-7940 (Linking) -VI - 60 -IP - 6 -DP - 2021 Dec 1 -TI - Two centres experience of lung cancer resection in patients with advanced - non-small cell lung cancer upon treatment with immune checkpoint inhibitors: - safety and clinical outcomes. -PG - 1297-1305 -LID - 10.1093/ejcts/ezab340 [doi] -AB - OBJECTIVES: Recent trials have begun to explore immune checkpoint inhibitors for - non-small cell lung cancer in the neoadjuvant setting, but data on tumour - response and surgical outcome remain limited. METHODS: Retrospective evaluation - of clinical data from patients with non-small cell lung cancer treated with - immune checkpoint inhibitors followed by lung resection was performed at 2 large - volume institutions (1 North American, 1 European). Data were analysed using - Chi-squared, Fisher's and Wilcoxon rank-sum tests where appropriate. RESULTS: - Thirty-seven patients were identified from 2017 to 2019. Forty-nine per cent were - Stage IIIB and IV. Forty-six per cent received immunotherapy alone and 54% in - combination with chemo- and/or radiotherapy. Sixteen per cent of cases were - successfully performed minimally invasively. Twenty patients were operated with - lobectomy (6 of these with wedges or segments of a neighbouring lobe, 2 with - sleeve resections and 1 with a chest wall resection), 4 with bilobectomies, 11 - with pneumonectomy (including 5 extrapleural pneumonectomies and 1 atrial - resection) and 1 with a wedge resection. Overall, 10 patients (27%) developed - postoperative complications and the 90-day mortality was zero. One-year - recurrence-free survival was 73% for stage II/IIIA and 55% for stage IIIB/stage - IV. The major pathologic response rate was 34%. CONCLUSION: In this retrospective - study, lung resection after immunotherapy (alone or in combination) is safe, - although often requires complex surgery. Due to increasing number of clinical - trials adopting immunotherapy in the neoadjuvant setting, it is likely that this - therapy will become part of standard of care. Immunotherapy may also allow - surgery to have a role for selected patients with advanced disease. -CI - © The Author(s) 2021. Published by Oxford University Press on behalf of the - European Association for Cardio-Thoracic Surgery. All rights reserved. -FAU - Beattie, Rory -AU - Beattie R -AUID- ORCID: 0000-0001-6827-1833 -AD - Department of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA, USA. -FAU - Furrer, Katarzyna -AU - Furrer K -AD - Department of Thoracic Surgery, University Hospital of Zurich, Zürich, - Switzerland. -FAU - Dolan, Daniel P -AU - Dolan DP -AUID- ORCID: 0000-0003-2747-505X -AD - Department of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA, USA. -FAU - Curioni-Fontecedro, Alessandra -AU - Curioni-Fontecedro A -AD - Department of Medical Oncology and Hematology, University Hospital Zurich, - Zürich, Switzerland. -FAU - Lee, Daniel N -AU - Lee DN -AD - Department of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA, USA. -FAU - Frauenfelder, Thomas -AU - Frauenfelder T -AD - Department of Diagnostic and Interventional Radiology, University Hospital - Zurich, Zürich, Switzerland. -FAU - Hoeller, Sylvia -AU - Hoeller S -AD - Department of Pathology and Molecular Pathology, University Hospital Zurich, - Zürich, Switzerland. -FAU - Weder, Walter -AU - Weder W -AD - Department of Thoracic Surgery, University Hospital of Zurich, Zürich, - Switzerland. -FAU - Bueno, Raphael -AU - Bueno R -AD - Department of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA, USA. -FAU - Opitz, Isabelle -AU - Opitz I -AUID- ORCID: 0000-0001-5900-9040 -AD - Department of Thoracic Surgery, University Hospital of Zurich, Zürich, - Switzerland. -FAU - Swanson, Scott -AU - Swanson S -AD - Department of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA, USA. -LA - eng -PT - Journal Article -PL - Germany -TA - Eur J Cardiothorac Surg -JT - European journal of cardio-thoracic surgery : official journal of the European - Association for Cardio-thoracic Surgery -JID - 8804069 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -CIN - Eur J Cardiothorac Surg. 2021 Dec 1;60(6):1306-1307. doi: 10.1093/ejcts/ezab399. - PMID: 34435637 -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/surgery -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects -MH - Lung/pathology -MH - *Lung Neoplasms/drug therapy/surgery -MH - Neoplasm Staging -MH - Pneumonectomy/adverse effects -MH - Retrospective Studies -OTO - NOTNLM -OT - Immunotherapy -OT - Lung cancer -OT - Lung resection -EDAT- 2021/08/01 06:00 -MHDA- 2022/03/05 06:00 -CRDT- 2021/07/31 07:58 -PHST- 2020/11/30 00:00 [received] -PHST- 2021/06/22 00:00 [revised] -PHST- 2021/06/23 00:00 [accepted] -PHST- 2021/08/01 06:00 [pubmed] -PHST- 2022/03/05 06:00 [medline] -PHST- 2021/07/31 07:58 [entrez] -AID - 6332634 [pii] -AID - 10.1093/ejcts/ezab340 [doi] -PST - ppublish -SO - Eur J Cardiothorac Surg. 2021 Dec 1;60(6):1297-1305. doi: 10.1093/ejcts/ezab340. - -PMID- 35014762 -OWN - NLM -STAT- MEDLINE -DCOM- 20220322 -LR - 20230917 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 13 -IP - 3 -DP - 2022 Feb -TI - Successful immune checkpoint inhibitor-based rechallenge in a patient with - advanced esophageal squamous cell cancer: A case report. -PG - 497-501 -LID - 10.1111/1759-7714.14279 [doi] -AB - Immune checkpoint inhibitors (ICIs) have been shown to improve survival in - patients with advanced or metastatic esophageal cancer. However, ICI-based - rechallenges after recovery from fatal adverse events (AEs) are equivocal, - especially in patients who have already undergone treatment-related AEs. In this - study, we report the case of a patient with advanced esophageal squamous cell - cancer (ESCC) who developed a treatment-related tracheoesophageal fistula (TEF) - after two cycles of ICI administration, provided in combination with traditional - chemotherapeutics. After spontaneous healing of the TEF, the patient was again - treated with ICIs and achieved a durable clinical response without any signs of - fistula recurrence. Successful ICI-based rechallenges after fistula healing have - rarely been reported. Therefore, ICI-based rechallenge in patients with - esophageal cancer having an Eastern Cooperative Oncology Group (ECOG) performance - status (PS) 0-1 after serious AEs may serve as a clinically viable treatment - strategy that should be administered under close monitoring. -CI - © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Yao, Yanhong -AU - Yao Y -AUID- ORCID: 0000-0003-0499-5554 -AD - Department of Medical Oncology and Radiation Sickness, Peking University Third - Hospital, Beijing, China. -FAU - Liu, Zhentao -AU - Liu Z -AD - Department of Medical Oncology and Radiation Sickness, Peking University Third - Hospital, Beijing, China. -FAU - Li, Qian -AU - Li Q -AUID- ORCID: 0000-0002-7204-0429 -AD - Department of Medical Oncology and Radiation Sickness, Peking University Third - Hospital, Beijing, China. -FAU - Cao, Baoshan -AU - Cao B -AD - Department of Medical Oncology and Radiation Sickness, Peking University Third - Hospital, Beijing, China. -FAU - Wang, Mopei -AU - Wang M -AD - Department of Medical Oncology and Radiation Sickness, Peking University Third - Hospital, Beijing, China. -LA - eng -PT - Case Reports -DEP - 20220111 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Carcinoma, Squamous Cell/drug therapy -MH - Epithelial Cells/metabolism -MH - *Esophageal Neoplasms/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Lung Neoplasms/pathology -PMC - PMC8807265 -OTO - NOTNLM -OT - esophageal squamous cell cancer (ESCC) -OT - immune checkpoint inhibitors (ICIs) -OT - rechallenge -OT - tracheoesophageal fistula (TEF) -COIS- The authors report no conflict of interest. -EDAT- 2022/01/12 06:00 -MHDA- 2022/03/23 06:00 -PMCR- 2022/02/01 -CRDT- 2022/01/11 08:55 -PHST- 2021/11/29 00:00 [revised] -PHST- 2021/09/20 00:00 [received] -PHST- 2021/11/30 00:00 [accepted] -PHST- 2022/01/12 06:00 [pubmed] -PHST- 2022/03/23 06:00 [medline] -PHST- 2022/01/11 08:55 [entrez] -PHST- 2022/02/01 00:00 [pmc-release] -AID - TCA14279 [pii] -AID - 10.1111/1759-7714.14279 [doi] -PST - ppublish -SO - Thorac Cancer. 2022 Feb;13(3):497-501. doi: 10.1111/1759-7714.14279. Epub 2022 - Jan 11. - -PMID- 14644533 -OWN - NLM -STAT- MEDLINE -DCOM- 20040330 -LR - 20190922 -IS - 0169-5002 (Print) -IS - 0169-5002 (Linking) -VI - 42 Suppl 2 -DP - 2003 Dec -TI - Adjuvant therapy for locally advanced non-small cell lung cancer. -PG - S29-34 -FAU - Keller, Steven M -AU - Keller SM -AD - Department of Cardiothoracic Surgery, Montefiore Medical Center, Albert Einstein - College of Medicine, 3400 Bainbridge Ave, Suite 5B, Bronx, NY 10467, USA. - skeller@montefiore.org -LA - eng -PT - Journal Article -PT - Review -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/*radiotherapy/surgery -MH - Chemotherapy, Adjuvant -MH - Combined Modality Therapy -MH - Drug Administration Schedule -MH - Humans -MH - Immunotherapy -MH - Lung Neoplasms/*drug therapy/*radiotherapy/surgery -MH - Prognosis -MH - Radiotherapy, Adjuvant -RF - 37 -EDAT- 2003/12/04 05:00 -MHDA- 2004/03/31 05:00 -CRDT- 2003/12/04 05:00 -PHST- 2003/12/04 05:00 [pubmed] -PHST- 2004/03/31 05:00 [medline] -PHST- 2003/12/04 05:00 [entrez] -AID - S0169500203003970 [pii] -AID - 10.1016/j.lungcan.2003.08.008 [doi] -PST - ppublish -SO - Lung Cancer. 2003 Dec;42 Suppl 2:S29-34. doi: 10.1016/j.lungcan.2003.08.008. - -PMID- 28373005 -OWN - NLM -STAT- MEDLINE -DCOM- 20170810 -LR - 20220409 -IS - 1474-5488 (Electronic) -IS - 1470-2045 (Print) -IS - 1470-2045 (Linking) -VI - 18 -IP - 5 -DP - 2017 May -TI - Avelumab for patients with previously treated metastatic or recurrent - non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a - multicentre, open-label, phase 1b trial. -PG - 599-610 -LID - S1470-2045(17)30240-1 [pii] -LID - 10.1016/S1470-2045(17)30240-1 [doi] -AB - BACKGROUND: Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and - approved in the USA for the treatment of metastatic Merkel cell carcinoma, has - shown antitumour activity and an acceptable safety profile in patients with - advanced solid tumours in a dose-escalation phase 1a trial. In this - dose-expansion cohort of that trial, we assess avelumab treatment in a cohort of - patients with advanced, platinum-treated non-small-cell lung cancer (NSCLC). - METHODS: In this dose-expansion cohort of a multicentre, open-label, phase 1 - study, patients with progressive or platinum-resistant metastatic or recurrent - NSCLC were enrolled at 58 cancer treatment centres and academic hospitals in the - USA. Eligible patients had confirmed stage IIIB or IV NSCLC with squamous or - non-squamous histology, measurable disease by Response Evaluation Criteria In - Solid Tumors version 1.1 (RECIST v1.1), tumour biopsy or archival sample for - biomarker assessment, and Eastern Cooperative Oncology Group performance status 0 - or 1, among other criteria. Patient selection was not based on PD-L1 expression - or expression of other biomarkers, including EGFR or KRAS mutation or ALK - translocation status. Patients received infusional avelumab monotherapy 10 mg/kg - every 2 weeks until disease progression or toxicity. The primary objective was to - assess safety and tolerability. This trial is registered with ClinicalTrials.gov, - number NCT01772004; enrolment in this cohort is closed and the trial is ongoing. - FINDINGS: Between Sept 10, 2013, and June 24, 2014, 184 patients were enrolled - and initiated treatment with avelumab. Median follow-up duration was 8·8 months - (IQR 7·2-11·9). The most common treatment-related adverse events of any grade - were fatigue (46 [25%] of 184 patients), infusion-related reaction (38 [21%]), - and nausea (23 [13%]). Grade 3 or worse treatment-related adverse events occurred - in 23 (13%) of 184 patients; the most common (occurring in more than two - patients) were infusion-related reaction (four [2%] patients) and increased - lipase level (three [2%]). 16 (9%) of 184 patients had a serious adverse event - related to treatment with avelumab, with infusion-related reaction (in four [2%] - patients) and dyspnoea (in two [1%]) occurring in more than one patient. Serious - adverse events irrespective of cause occurred in 80 (44%) of 184 patients. Those - occurring in more than five patients (≥3%) were dyspnoea (ten patients [5%]), - pneumonia (nine [5%]), and chronic obstructive pulmonary disease (six [3%]). - Immune-related treatment-related events occurred in 22 patients (12%). Of 184 - patients, 22 (12% [95% CI 8-18]) achieved a confirmed objective response, - including one complete response and 21 partial responses. 70 (38%) had stable - disease. Overall, 92 (50%) of 184 patients achieved disease control (they had a - confirmed response or stable disease as their best overall response). One patient - was initially thought to have died from grade 5 radiation pneumonitis during the - study; however, this adverse event was subsequently regraded to grade 3 and the - death was attributed to disease progression. INTERPRETATION: Avelumab showed an - acceptable safety profile and antitumour activity in patients with progressive or - treatment-resistant NSCLC, providing a rationale for further studies of avelumab - in this disease setting. FUNDING: Merck KGaA and Pfizer. -CI - Copyright © 2017 Elsevier Ltd. All rights reserved. -FAU - Gulley, James L -AU - Gulley JL -AD - Genitourinary Malignancies Branch, National Cancer Institute, National Institutes - of Health, Bethesda, MD, USA; Laboratory of Tumor Immunology and Biology, Center - for Cancer Research, National Cancer Institute, National Institutes of Health, - Bethesda, MD, USA. Electronic address: gulleyj@mail.nih.gov. -FAU - Rajan, Arun -AU - Rajan A -AD - Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, - National Institutes of Health, Bethesda, MD, USA. -FAU - Spigel, David R -AU - Spigel DR -AD - Sarah Cannon Research Institute Tennessee Oncology, North Nashville, TN, USA. -FAU - Iannotti, Nicholas -AU - Iannotti N -AD - Hematology Oncology Associates of the Treasure Coast, Port St Lucie, FL, USA. -FAU - Chandler, Jason -AU - Chandler J -AD - West Cancer Center, Memphis, TN, USA. -FAU - Wong, Deborah J L -AU - Wong DJL -AD - Department of Medicine, University of California, Los Angeles, CA, USA. -FAU - Leach, Joseph -AU - Leach J -AD - Virginia Piper Cancer Institute, Minneapolis, MN, USA. -FAU - Edenfield, W Jeff -AU - Edenfield WJ -AD - Institute for Translational Oncology Research, Greenville, SC, USA. -FAU - Wang, Ding -AU - Wang D -AD - Henry Ford Hospital, Detroit, MI, USA. -FAU - Grote, Hans Juergen -AU - Grote HJ -AD - Merck KGaA, Darmstadt, Germany. -FAU - Heydebreck, Anja von -AU - Heydebreck AV -AD - Merck KGaA, Darmstadt, Germany. -FAU - Chin, Kevin -AU - Chin K -AD - EMD Serono, Billerica, MA, USA. -FAU - Cuillerot, Jean-Marie -AU - Cuillerot JM -AD - EMD Serono, Billerica, MA, USA. -FAU - Kelly, Karen -AU - Kelly K -AD - University of California-Davis, Comprehensive Cancer Center, Sacramento, CA, USA. -LA - eng -SI - ClinicalTrials.gov/NCT01772004 -GR - Z01 BC010666-04/Intramural NIH HHS/United States -PT - Clinical Trial, Phase I -PT - Journal Article -PT - Multicenter Study -DEP - 20170331 -PL - England -TA - Lancet Oncol -JT - The Lancet. Oncology -JID - 100957246 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents) -RN - 0 (Platinum Compounds) -RN - EC 3.1.1.3 (Lipase) -RN - KXG2PJ551I (avelumab) -SB - IM -CIN - Lancet Oncol. 2017 May;18(5):556-557. doi: 10.1016/S1470-2045(17)30227-9. PMID: - 28373006 -CIN - Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S35-S38. doi: - 10.21037/tlcr.2017.11.01. PMID: 29299406 -CIN - Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S41-S43. doi: - 10.21037/tlcr.2017.10.15. PMID: 29299408 -MH - Aged -MH - Antibodies, Monoclonal/administration & dosage/*adverse effects -MH - Antibodies, Monoclonal, Humanized -MH - Antineoplastic Agents/administration & dosage/*adverse effects -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/secondary -MH - Disease Progression -MH - Drug Resistance, Neoplasm -MH - Dyspnea/chemically induced -MH - Fatigue/chemically induced -MH - Female -MH - Humans -MH - Infusions, Intravenous/adverse effects -MH - Lipase/blood -MH - Lung Neoplasms/*drug therapy/pathology -MH - Male -MH - Middle Aged -MH - Nausea/chemically induced -MH - Neoplasm Recurrence, Local/*drug therapy -MH - Platinum Compounds/therapeutic use -MH - Pneumonia/chemically induced -MH - Pulmonary Disease, Chronic Obstructive/chemically induced -MH - Response Evaluation Criteria in Solid Tumors -MH - Retreatment -PMC - PMC5522719 -MID - NIHMS866690 -COIS- Conflict of Interest Statement: D.J.L.W. reports research grant funding from - Merck Serono. J.L. is an employee at PRA Health Sciences. J.L. reports - institutional research funding from EMD Serono, relevant to the submitted work. - J.L. reports institutional research funding from AstraZeneca, Genentech, and - Clovis, outside the submitted work. W.J.E. reports participation in Speaker’s - Bureau’s for Astellas and Novartis, outside the submitted work. H.J.G. and A.vH. - are employees at Merck KGaA. A.vH. is a stockholder at Merck KGaA. K.C. is an - employee at EMD Serono. J-M.C. was an employee of Merck KGaA. J-M.C. is an - employee and stockholder at Angenus Bio. All other authors declare no competing - interests. -EDAT- 2017/04/05 06:00 -MHDA- 2017/08/11 06:00 -PMCR- 2018/05/01 -CRDT- 2017/04/05 06:00 -PHST- 2016/11/14 00:00 [received] -PHST- 2017/01/20 00:00 [revised] -PHST- 2017/01/24 00:00 [accepted] -PHST- 2017/04/05 06:00 [pubmed] -PHST- 2017/08/11 06:00 [medline] -PHST- 2017/04/05 06:00 [entrez] -PHST- 2018/05/01 00:00 [pmc-release] -AID - S1470-2045(17)30240-1 [pii] -AID - 10.1016/S1470-2045(17)30240-1 [doi] -PST - ppublish -SO - Lancet Oncol. 2017 May;18(5):599-610. doi: 10.1016/S1470-2045(17)30240-1. Epub - 2017 Mar 31. - -PMID- 33962592 -OWN - NLM -STAT- MEDLINE -DCOM- 20211018 -LR - 20240327 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 21 -IP - 1 -DP - 2021 May 7 -TI - Checkpoint inhibition in combination with an immunoboost of external beam - radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, - randomized controlled trial. -PG - 514 -LID - 10.1186/s12885-021-08088-w [doi] -LID - 514 -AB - BACKGROUND: While the introduction of checkpoint inhibitors (CPIs) as standard of - care treatment for various tumor types has led to considerable improvements in - clinical outcome, the majority of patients still fail to respond. Preclinical - data suggest that stereotactic body radiotherapy (SBRT) could work - synergistically with CPIs by acting as an in situ cancer vaccine, thus - potentially increasing response rates and prolonging disease control. Though SBRT - administered concurrently with CPIs has been shown to be safe, evidence of its - efficacy from large randomized trials is still lacking. The aim of this - multicenter randomized phase II trial is to assess whether SBRT administered - concurrently with CPIs could prolong progression-free survival as compared to - standard of care in patients with advanced solid tumors. METHODS/DESIGN: - Ninety-eight patients with locally advanced or metastatic disease will be - randomized in a 1:1 fashion to receive CPI treatment combined with SBRT (Arm A) - or CPI monotherapy (Arm B). Randomization will be stratified according to tumor - histology (melanoma, renal, urothelial, head and neck squamous cell or non-small - cell lung carcinoma) and disease burden (≤ or > 3 cancer lesions). The - recommended SBRT dose is 24Gy in 3 fractions, which will be administered to a - maximum of 3 lesions and is to be completed prior to the second or third CPI - cycle (depending on CPI treatment schedule). The study's primary endpoint is - progression-free survival as per iRECIST. Secondary endpoints include overall - survival, objective response, local control, quality of life and toxicity. - Translational analyses will be performed using blood, fecal and tissue samples. - DISCUSSION: The CHEERS trial will provide further insights into the clinical and - immunological impact of SBRT when combined with CPIs in patients with advanced - solid tumors. Furthermore, study results will inform the design of future - immuno-radiotherapy trials. TRIAL REGISTRATION: Clinicaltrials.gov identifier: - NCT03511391 . Registered 17 April 2018. -FAU - Spaas, Mathieu -AU - Spaas M -AD - Radiation Oncology, Ghent University Hospital, C. Heymanslaan 10, B-9000, Ghent, - Belgium. mathieu.spaas@uzgent.be. -FAU - Sundahl, Nora -AU - Sundahl N -AD - Radiation Oncology, Ghent University Hospital, C. Heymanslaan 10, B-9000, Ghent, - Belgium. -FAU - Hulstaert, Eva -AU - Hulstaert E -AD - Dermatology, Ghent University Hospital, Ghent, Belgium. -AD - Center for Medical Genetics (CMGG), Ghent University, Ghent, Belgium. -AD - Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium. -FAU - Kruse, Vibeke -AU - Kruse V -AD - Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium. -AD - Medical Oncology, Ghent University Hospital, Ghent, Belgium. -FAU - Rottey, Sylvie -AU - Rottey S -AD - Medical Oncology, Ghent University Hospital, Ghent, Belgium. -FAU - De Maeseneer, Daan -AU - De Maeseneer D -AD - Medical Oncology, Ghent University Hospital, Ghent, Belgium. -AD - Medical Oncology, AZ Sint-Lucas, Bruges, Belgium. -FAU - Surmont, Veerle -AU - Surmont V -AD - Pulmonary Medicine, Ghent University Hospital, Ghent, Belgium. -FAU - Meireson, Annabel -AU - Meireson A -AD - Dermatology, Ghent University Hospital, Ghent, Belgium. -AD - Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium. -FAU - Brochez, Lieve -AU - Brochez L -AD - Dermatology, Ghent University Hospital, Ghent, Belgium. -AD - Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium. -FAU - Reynders, Dries -AU - Reynders D -AD - Department of Applied Mathematics, Computer Science and Statistics & Stat-Gent - CRESCENDO Consortium, Ghent University, Ghent, Belgium. -FAU - Goetghebeur, Els -AU - Goetghebeur E -AD - Department of Applied Mathematics, Computer Science and Statistics & Stat-Gent - CRESCENDO Consortium, Ghent University, Ghent, Belgium. -FAU - Van den Begin, Robbe -AU - Van den Begin R -AD - Radiation Oncology, Jules Bordet Insitute, Université Libre de Bruxelles, - Brussels, Belgium. -FAU - Van Gestel, Dirk -AU - Van Gestel D -AD - Radiation Oncology, Jules Bordet Insitute, Université Libre de Bruxelles, - Brussels, Belgium. -FAU - Renard, Vincent -AU - Renard V -AD - Medical Oncology, AZ Sint-Lucas, Ghent, Belgium. -FAU - Dirix, Piet -AU - Dirix P -AD - Radiation Oncology, Iridium Cancer Network, Wilrijk, Belgium. -FAU - Mestdagh, Pieter -AU - Mestdagh P -AD - Center for Medical Genetics (CMGG), Ghent University, Ghent, Belgium. -AD - Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium. -FAU - Ost, Piet -AU - Ost P -AD - Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium. -AD - Radiation Oncology, Iridium Cancer Network, Wilrijk, Belgium. -LA - eng -SI - ClinicalTrials.gov/NCT03511391 -GR - KW/1892/RTH/003/013/Kom op tegen Kanker/ -GR - KW/1992/RTH/008/013/Varian Medical Systems/ -PT - Clinical Trial Protocol -PT - Journal Article -DEP - 20210507 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - Combined Modality Therapy -MH - *Immune Checkpoint Inhibitors/therapeutic use -MH - *Neoplasms/mortality/therapy -MH - *Radiosurgery/methods -MH - Randomized Controlled Trials as Topic -MH - Clinical Trials, Phase II as Topic -PMC - PMC8106163 -OTO - NOTNLM -OT - Checkpoint inhibitor -OT - Clinical trial -OT - Head and neck squamous cell carcinoma -OT - Immunotherapy -OT - Melanoma -OT - Non-small-cell lung carcinoma -OT - Renal cell carcinoma -OT - Stereotactic body radiotherapy -OT - Survival -OT - Transitional cell carcinoma -COIS- MS has received travel grants from Astellas, unrelated to this research project. - NS has received travel grants from Merck Sharpe & Dohme, Astellas, Bayer and - Bristol-Myers Squibb, all unrelated to this research project. VK has served on - advisory boards for and received travel grants from Bristol-Myers Squibb and - Merck Sharpe & Dohme, unrelated to this research project. SR has received - honoraria from Bristol-Myers Squibb, Merck and Roche, as well as grant funding - from Merck and Roche, all unrelated to this research project. DVG has received - consultancy fees from Sanofi, Merck, Takeda, Novartis. PD has received honoraria - from Bayer, Ferring Pharmaceuticals, Ipsen, Janssen, Astellas, as well as grant - funding from Janssen, all unrelated to this research project. PO has received - research funding from Merck and Varian, has consulted for Ferring - Pharmaceuticals, Bayer AG and Janssen, and has received travel grants from Ipsen - and Ferring Pharmaceuticals, all unrelated to this research project. The other - authors declare that they have no competing interests. -EDAT- 2021/05/09 06:00 -MHDA- 2021/10/21 06:00 -PMCR- 2021/05/07 -CRDT- 2021/05/08 06:07 -PHST- 2020/10/26 00:00 [received] -PHST- 2021/03/23 00:00 [accepted] -PHST- 2021/05/08 06:07 [entrez] -PHST- 2021/05/09 06:00 [pubmed] -PHST- 2021/10/21 06:00 [medline] -PHST- 2021/05/07 00:00 [pmc-release] -AID - 10.1186/s12885-021-08088-w [pii] -AID - 8088 [pii] -AID - 10.1186/s12885-021-08088-w [doi] -PST - epublish -SO - BMC Cancer. 2021 May 7;21(1):514. doi: 10.1186/s12885-021-08088-w. - -PMID- 31615633 -OWN - NLM -STAT- MEDLINE -DCOM- 20210414 -LR - 20211204 -IS - 1879-0887 (Electronic) -IS - 0167-8140 (Print) -IS - 0167-8140 (Linking) -VI - 143 -DP - 2020 Feb -TI - Are unsatisfactory outcomes after concurrent chemoradiotherapy for locally - advanced non-small cell lung cancer due to treatment-related immunosuppression? -PG - 51-57 -LID - S0167-8140(19)33009-9 [pii] -LID - 10.1016/j.radonc.2019.07.016 [doi] -AB - BACKGROUND AND PURPOSE: We test the hypothesis that unsatisfactory outcomes after - concurrent chemoradiotherapy (RT) for locally advanced non-small cell lung cancer - (LA-NSCLC) are due to treatment-related immunosuppression. MATERIALS AND METHODS: - White blood cells (WBCs) data were retrospectively collected for all stage IIIA/B - LA-NSCLC patients before and after (after RT: two weeks, two months, four months) - concurrent chemotherapy and intensity-modulated RT in which patients were treated - to a median of 63 Gy (1.8-2.0 Gy/fractions) in 2004-2014 (N = 155). Nine WBC - variables were generated from pre-RT normalized absolute number of lymphocytes - and neutrophils (L, N) and the N/L thereof. A WBC variable was considered a - predictor for overall survival and recurrence (distant/local/nodal/regional) if - p ≤ 0.006 (corrected for 9 variables) from Cox regression and competing risk - analyses, respectively; both conducted using bootstrap resampling. Finally, a WBC - variable predicting any of the outcomes was linearly associated with each of - eleven disease/patient/treatment characteristics (p ≤ 0.005; corrected for 11 - characteristics). RESULTS: At the three post-RT time points both L and N - significantly decreased (p < 0.0003). Overall survival was associated with N and - N/L four months post-RT (p = 0.00001, 0.0003); regional recurrence was associated - with L two months post-RT (p < 0.0001). None of the disease/patient/treatment - characteristics was significantly associated with any of the three WBC variables - that predicted OS or recurrence (lowest p-value: p = 0.006 for tumour stage,). - CONCLUSION: Significantly lower WBC levels after concurrent chemo-RT for LA-NSCLC - are associated with worse long-term outcomes. The mechanism behind this - treatment-related immunosuppression requires further analysis likely including - other characteristics as no statistically significant association was established - between any WBC variable and the disease/patient/treatment characteristics. -CI - Copyright © 2019. Published by Elsevier B.V. -FAU - Thor, Maria -AU - Thor M -AD - Dept of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, United - States. -FAU - Montovano, Margaret -AU - Montovano M -AD - Dept of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, - United States. -FAU - Hotca, Alexandra -AU - Hotca A -AD - Dept of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, - United States. -FAU - Luo, Leo -AU - Luo L -AD - Dept of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, - United States. -FAU - Jackson, Andrew -AU - Jackson A -AD - Dept of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, United - States. -FAU - Wu, Abraham J -AU - Wu AJ -AD - Dept of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, - United States. -FAU - Deasy, Joseph O -AU - Deasy JO -AD - Dept of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, United - States. Electronic address: deasyj@mskcc.org. -FAU - Rimner, Andreas -AU - Rimner A -AD - Dept of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, - United States. -LA - eng -GR - P30 CA008748/CA/NCI NIH HHS/United States -GR - R01 CA198121/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20191012 -PL - Ireland -TA - Radiother Oncol -JT - Radiotherapy and oncology : journal of the European Society for Therapeutic - Radiology and Oncology -JID - 8407192 -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy/adverse effects -MH - Humans -MH - Immunosuppression Therapy -MH - *Lung Neoplasms/drug therapy -MH - Neoplasm Recurrence, Local -MH - Retrospective Studies -PMC - PMC8356254 -MID - NIHMS1617003 -OTO - NOTNLM -OT - Dose -OT - Immune -OT - Lung cancer -OT - Radiotherapy -OT - Survival -OT - Toxicity -COIS- Declaration of Competing Interest None. AR reports relevant grants outside the - submitted work from Varian Medical Systems, Boehringer Ingelheim, Pfizer, and - AztraZeneca, personal fees from AztraZeneca, Merck, Research to Practice, and - Cybrexa, as well as non-financial support from Philips/Elekta. -EDAT- 2019/10/17 06:00 -MHDA- 2021/04/15 06:00 -PMCR- 2021/08/11 -CRDT- 2019/10/17 06:00 -PHST- 2019/04/26 00:00 [received] -PHST- 2019/07/09 00:00 [revised] -PHST- 2019/07/12 00:00 [accepted] -PHST- 2019/10/17 06:00 [pubmed] -PHST- 2021/04/15 06:00 [medline] -PHST- 2019/10/17 06:00 [entrez] -PHST- 2021/08/11 00:00 [pmc-release] -AID - S0167-8140(19)33009-9 [pii] -AID - 10.1016/j.radonc.2019.07.016 [doi] -PST - ppublish -SO - Radiother Oncol. 2020 Feb;143:51-57. doi: 10.1016/j.radonc.2019.07.016. Epub 2019 - Oct 12. - -PMID- 34488412 -OWN - NLM -STAT- MEDLINE -DCOM- 20210908 -LR - 20210908 -IS - 2224-5839 (Electronic) -IS - 2224-5820 (Linking) -VI - 10 -IP - 8 -DP - 2021 Aug -TI - Pneumonitis, appendicitis, and biliary obstruction during toripalimab treatment - in a patient with extensive-stage small-cell lung cancer: a case report. -PG - 9267-9275 -LID - 10.21037/apm-21-858 [doi] -AB - In recent years, immune checkpoint inhibitors (ICIs) have become a standard - treatment for patients with advanced lung cancers. With the widespread use of - immunotherapy in clinical practice, immune-related adverse events (irAEs) have - become increasingly common. This case report details a 72-year-old man with - small-cell lung cancer (SCLC) who developed pneumonitis, appendicitis, and - biliary obstruction during treatment with toripalimab. The patient was initially - diagnosed with limited-stage SCLC in January 2019 and completed 5 sequential - cycles of etoposide/cisplatin (EP) and radiotherapy (60 Gy/30 F). The overall - response was complete response (CR) after first line treatment. He developed - radiation pneumonitis after completion of radiotherapy, which responded well to - symptomatic treatment. Due to newly diagnosed bone metastasis, he was - administered toripalimab intravenously every 3 weeks and 12 mg anlotinib orally - once a day from January 2020. By the third cycle, the patient presented with - electrocardiographic abnormalities, gingival swelling and pain, and hoarseness, - and consequently, the anlotinib was suspended. After 4 cycles, he developed - suppurative appendicitis, which was managed successfully with anti-inflammatory - agents. He then presented with shortness of breath on exertion and after a - comprehensive examination, he was diagnosed with ICI-related-pneumonitis. After 6 - weeks of treatment with methylprednisolone, the shortness of breath was mostly - relieved and treatment continued. In June 2020, the patient developed severe - vomiting. Computed tomography (CT) indicated biliary obstruction, and at - endoscopic retrograde cholangiopancreatography (ERCP) there was edema of the - major papilla of the duodenum. The patient's symptoms were relieved after - treatment with gastric acid suppression and antiemetics. Re-examination by - magnetic resonance imaging (MRI) showed that the biliary obstruction had been - resolved. Although the disease progressed after immunotherapy, no tumor tissue - related to the biliary obstruction was detected, and this was therefore - classified as an irAE. -FAU - Qu, Yanli -AU - Qu Y -AD - Department of Thoracic Radiation Oncology, Cancer Hospital of China Medical - University, Liaoning Cancer Hospital & Institute, Shenyang, China. -FAU - Wang, Zheng -AU - Wang Z -AD - Department of Thoracic Surgery, Cancer Hospital of China Medical University, - Liaoning Cancer Hospital & Institute, Shenyang, China. -FAU - Feng, Jilong -AU - Feng J -AD - Department of Radiation Oncology, Fifth People's Hospital of Shenyang, Shenyang, - China. -FAU - Wang, Lijun -AU - Wang L -AD - Department of Radiation Oncology, Fifth People's Hospital of Shenyang, Shenyang, - China. -FAU - Liu, Hangyu -AU - Liu H -AD - Department of Thoracic Radiation Oncology, Cancer Hospital of China Medical - University, Liaoning Cancer Hospital & Institute, Shenyang, China. -FAU - Liu, Dan -AU - Liu D -AD - Department of Radiation Oncology, Fourth Hospital Afflicted to China Medical - University, Shenyang, China. -FAU - Zhao, Yuxia -AU - Zhao Y -AD - Department of Radiation Oncology, Fourth Hospital Afflicted to China Medical - University, Shenyang, China. -FAU - Yu, Ruoxi -AU - Yu R -AD - Department of Thoracic Radiation Oncology, Cancer Hospital of China Medical - University, Liaoning Cancer Hospital & Institute, Shenyang, China. -FAU - Li, Wang -AU - Li W -AD - Department of Thoracic Radiation Oncology, Cancer Hospital of China Medical - University, Liaoning Cancer Hospital & Institute, Shenyang, China. -FAU - Sun, Deyu -AU - Sun D -AD - Department of Gastrointestinal and Urinary and Musculoskeletal Cancer Radiation - Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & - Institute, Shenyang, China. -FAU - Yu, Hong -AU - Yu H -AD - Department of Thoracic Radiation Oncology, Cancer Hospital of China Medical - University, Liaoning Cancer Hospital & Institute, Shenyang, China. -LA - eng -PT - Case Reports -PL - China -TA - Ann Palliat Med -JT - Annals of palliative medicine -JID - 101585484 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 8JXN261VVA (toripalimab) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal, Humanized -MH - *Appendicitis -MH - *Cholestasis -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Male -MH - *Pneumonia/chemically induced/drug therapy -OTO - NOTNLM -OT - Small-cell lung cancer (SCLC) -OT - case report -OT - immune checkpoint inhibitors (ICIs) -OT - immune-related adverse events (irAEs) -EDAT- 2021/09/08 06:00 -MHDA- 2021/09/09 06:00 -CRDT- 2021/09/07 05:44 -PHST- 2021/03/13 00:00 [received] -PHST- 2021/05/17 00:00 [accepted] -PHST- 2021/09/07 05:44 [entrez] -PHST- 2021/09/08 06:00 [pubmed] -PHST- 2021/09/09 06:00 [medline] -AID - 10.21037/apm-21-858 [doi] -PST - ppublish -SO - Ann Palliat Med. 2021 Aug;10(8):9267-9275. doi: 10.21037/apm-21-858. - -PMID- 30362811 -OWN - NLM -STAT- MEDLINE -DCOM- 20200207 -LR - 20200207 -IS - 1936-2692 (Electronic) -IS - 1088-0224 (Linking) -VI - 24 -IP - 20 Suppl -DP - 2018 Oct -TI - Understanding total cost of care in advanced non-small cell lung cancer pre- and - postapproval of immuno-oncology therapies. -PG - S439-S447 -AB - This study assesses resource utilization and total direct medical cost among - patients in the United States starting systemic antineoplastic therapy (ST) pre- - and postapproval of immuno-oncology (IO) agents for advanced non-small cell lung - cancer. Adults diagnosed with lung cancer initiating first-line ST within 6 - months of diagnosis during either the pre- (March 2013-March 2014) or post-IO - (March 2015-December 2016) approval period were identified in a US-based - multipayer administrative claims database. Excluded were patients with small cell - lung cancer, secondary malignancies, less than 1 month follow-up, and those in - clinical trials. Total cost (TC) was calculated from the date of initiation of - treatment until the last follow-up. Propensity score matching was adjusted for - differences in patient cohorts, including follow-up time. Binary multiple - logistic regression assessed predictors of high TC (above mean) pre- and post IO. - Mean TC per patient was higher pre-IO versus post IO in both unmatched ($165,548 - vs $95,715) and matched analyses($129,977 vs $113,177). Hospitalization and - emergency department (ED) visit rates were higher pre-IO versus postapproval. - Predictors of high TC pre-IO included use of first-line combination therapy, - radiation, targeted therapy, maintenance therapy, biomarker testing, more - comorbidities, longer follow-up, first-line hospitalization, first-line cost - above mean, and age 65 years and older. In the post-IO period, additional - predictors of higher TC included use of IO, having mild liver disease or - hemiplegia, and longer time to ST initiation. Early data show lower ED visit and - hospitalization rates and associated lower TC in the post-IO era. -FAU - Korytowsky, Beata -AU - Korytowsky B -AD - Bristol-Myers Squibb, Lawrenceville, NJ. Email: beata.korytowsky@bms.com. -FAU - Radtchenko, Janna -AU - Radtchenko J -FAU - Nwokeji, Esmond D -AU - Nwokeji ED -FAU - Tuell, Kenneth W -AU - Tuell KW -FAU - Kish, Jonathan K -AU - Kish JK -FAU - Feinberg, Bruce A -AU - Feinberg BA -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - United States -TA - Am J Manag Care -JT - The American journal of managed care -JID - 9613960 -RN - 0 (Antineoplastic Agents) -MH - Adult -MH - Aged -MH - Antineoplastic Agents/*economics/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/*economics -MH - Female -MH - Health Care Costs/*statistics & numerical data -MH - Humans -MH - Immunotherapy/*economics -MH - Lung Neoplasms/*drug therapy/*economics -MH - Male -MH - Middle Aged -MH - Propensity Score -MH - United States -MH - Utilization Review -EDAT- 2018/10/27 06:00 -MHDA- 2020/02/08 06:00 -CRDT- 2018/10/27 06:00 -PHST- 2018/10/27 06:00 [entrez] -PHST- 2018/10/27 06:00 [pubmed] -PHST- 2020/02/08 06:00 [medline] -AID - 87777 [pii] -PST - ppublish -SO - Am J Manag Care. 2018 Oct;24(20 Suppl):S439-S447. - -PMID- 29200082 -OWN - NLM -STAT- MEDLINE -DCOM- 20190911 -LR - 20190911 -IS - 1537-4513 (Electronic) -IS - 1524-9557 (Linking) -VI - 41 -IP - 2 -DP - 2018 Feb/Mar -TI - Pneumonitis in Irradiated Lungs After Nivolumab: A Brief Communication and Review - of the Literature. -PG - 96-99 -LID - 10.1097/CJI.0000000000000198 [doi] -AB - Nivolumab is a feasible therapy option in patients with advanced non-small cell - lung cancer (NSCLC) who progress on first-line treatment. However, there is - limited information about an overlapping toxicity of PD-1 inhibitors when - administered following thoracic radiotherapy (TRT). Three of 25 patients with - advanced NSCLC were treated with palliative or curative intent. Nivolumab was - initiated as second or third-line therapy after TRT for recurrent or progressive - disease. All 3 patients developed grade 3 pneumonitis at some point during - nivolumab therapy. Herein, we describe 3 cases of pneumonitis in patients with - NSCLC started on nivolumab following TRT. Imaging analysis was strongly - consistent with heterogenous lung parenchyma changes in the irradiated lung - volume receiving a total dose of 15-20 Gy. Pulmonary toxicity was manageable; - however, interruption of immunotherapy was necessary. -FAU - Manapov, Farkhad -AU - Manapov F -AD - Department of Radiation Oncology, University Hospital, LMU Munich. -AD - Comprehensive Pneumology Center Munich (CPC-M), Munich, Germany. -FAU - Roengvoraphoj, Olarn -AU - Roengvoraphoj O -AD - Department of Radiation Oncology, University Hospital, LMU Munich. -FAU - Dantes, Maurice -AU - Dantes M -AD - Department of Radiation Oncology, University Hospital, LMU Munich. -FAU - Marschner, Sebastian -AU - Marschner S -AD - Department of Radiation Oncology, University Hospital, LMU Munich. -FAU - Li, Minglun -AU - Li M -AD - Department of Radiation Oncology, University Hospital, LMU Munich. -FAU - Eze, Chukwuka -AU - Eze C -AD - Department of Radiation Oncology, University Hospital, LMU Munich. -LA - eng -PT - Case Reports -PT - Journal Article -PT - Meta-Analysis -PL - United States -TA - J Immunother -JT - Journal of immunotherapy (Hagerstown, Md. : 1997) -JID - 9706083 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Aged -MH - Antineoplastic Agents, Immunological/*adverse effects/therapeutic use -MH - Female -MH - Humans -MH - Lung Neoplasms/*complications/drug therapy/radiotherapy -MH - Male -MH - Nivolumab/*adverse effects/therapeutic use -MH - Pneumonia/*diagnosis/*etiology -MH - *Radiation, Ionizing -MH - Radiotherapy/adverse effects -MH - Tomography, X-Ray Computed/adverse effects -EDAT- 2017/12/05 06:00 -MHDA- 2019/09/12 06:00 -CRDT- 2017/12/05 06:00 -PHST- 2017/12/05 06:00 [pubmed] -PHST- 2019/09/12 06:00 [medline] -PHST- 2017/12/05 06:00 [entrez] -AID - 10.1097/CJI.0000000000000198 [doi] -PST - ppublish -SO - J Immunother. 2018 Feb/Mar;41(2):96-99. doi: 10.1097/CJI.0000000000000198. - -PMID- 31943163 -OWN - NLM -STAT- MEDLINE -DCOM- 20201015 -LR - 20230510 -IS - 1097-0142 (Electronic) -IS - 0008-543X (Print) -IS - 0008-543X (Linking) -VI - 126 -IP - 5 -DP - 2020 Mar 1 -TI - Real-world use and survival outcomes of immune checkpoint inhibitors in older - adults with non-small cell lung cancer. -PG - 978-985 -LID - 10.1002/cncr.32624 [doi] -AB - BACKGROUND: Limited data exist regarding the characteristics and survival - outcomes of older adults with non-small cell lung cancer (NSCLC) who receive - immune checkpoint inhibitors in routine oncology practice. METHODS: Using the - Surveillance, Epidemiology, and End Results-Medicare linked database, we - identified 1256 patients aged ≥65 years who were diagnosed with pathologically - confirmed stage I to stage IV NSCLC between 2002 and 2015 and initiated nivolumab - or pembrolizumab in 2016. We examined patient characteristics and overall - survival from the time of immune checkpoint inhibitor initiation through December - 31, 2017. RESULTS: The median patient age at the time of immune checkpoint - inhibitor initiatiton was 75.3 years (interquartile range, 8.5). A substantial - percentage of patients were initially diagnosed with stage IV disease (42.6%) and - had ≥2 comorbid conditions (48.7%). Using a claims-based proxy, 11.5% of patients - had poor performance status and 12.6% had a history of autoimmune conditions. The - median overall survival after initiation of immune checkpoint inhibitor was - 9.3 months (95% CI, 8.5-10.5 months). The 1-year survival rate was 43.0% (95% CI, - 40.2-45.7%). In multivariable analyses, multiple comorbid conditions, squamous - histology, a history of nonplatinum doublet systemic therapy, recent - radiotherapy, and a shorter time from initial diagnosis to treatment initiation - were found to be statistically significantly associated with an increased hazard - of death. Demographics, poor performance status, and prior autoimmune conditions - were not significantly associated with the hazard of death. CONCLUSIONS: Many - older adults with NSCLC who initiated immune checkpoint inhibitors had multiple - comorbidities, a history of autoimmune disease, or poor performance status. - Factors associated with poor prognosis among patients with advanced NSCLC were - also associated with worse survival in older adults treated with immune - checkpoint inhibitors. -CI - © 2020 American Cancer Society. -FAU - Youn, Bora -AU - Youn B -AUID- ORCID: 0000-0003-2870-976X -AD - Department of Health Services, Policy, and Practice, Brown University School of - Public Health, Providence, Rhode Island. -FAU - Trikalinos, Nikolaos A -AU - Trikalinos NA -AUID- ORCID: 0000-0001-8611-2182 -AD - Division of Oncology, Washington University in St Louis, St Louis, Missouri. -FAU - Mor, Vincent -AU - Mor V -AD - Department of Health Services, Policy, and Practice, Brown University School of - Public Health, Providence, Rhode Island. -AD - Providence Veterans Affairs Medical Center, Providence, Rhode Island. -FAU - Wilson, Ira B -AU - Wilson IB -AD - Department of Health Services, Policy, and Practice, Brown University School of - Public Health, Providence, Rhode Island. -FAU - Dahabreh, Issa J -AU - Dahabreh IJ -AUID- ORCID: 0000-0002-2215-9931 -AD - Department of Health Services, Policy, and Practice, Brown University School of - Public Health, Providence, Rhode Island. -AD - Center for Evidence Synthesis in Health, Brown University, Providence, Rhode - Island. -AD - Department of Epidemiology, Brown University School of Public Health, Providence, - Rhode Island. -LA - eng -GR - U54 GM115677/GM/NIGMS NIH HHS/United States -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20200114 -PL - United States -TA - Cancer -JT - Cancer -JID - 0374236 -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -CIN - Cancer. 2020 Mar 1;126(5):931-934. doi: 10.1002/cncr.32625. PMID: 31943149 -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/immunology/*mortality/pathology -MH - Carcinoma, Squamous Cell/drug therapy/immunology/*mortality/pathology -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Lung Neoplasms/drug therapy/immunology/*mortality/pathology -MH - Male -MH - Middle Aged -MH - Prognosis -MH - SEER Program -MH - Survival Rate -PMC - PMC10167638 -MID - NIHMS1892630 -OTO - NOTNLM -OT - immune checkpoint inhibitor -OT - nivolumab -OT - non-small cell lung cancer -OT - older adults -OT - pembrolizumab -OT - prognosis -OT - survival -COIS- CONFLICT OF INTEREST DISCLOSURES Vincent Mor reports serving as chair on an - independent quality committee of HCR ManorCare, serving as chair of a scientific - advisory board at naviHealth Inc, and serving as the former director of - PointRight Inc. The other authors made no disclosures. -EDAT- 2020/01/17 06:00 -MHDA- 2020/10/21 06:00 -PMCR- 2023/05/09 -CRDT- 2020/01/17 06:00 -PHST- 2019/03/30 00:00 [received] -PHST- 2019/06/13 00:00 [revised] -PHST- 2019/08/03 00:00 [accepted] -PHST- 2020/01/17 06:00 [pubmed] -PHST- 2020/10/21 06:00 [medline] -PHST- 2020/01/17 06:00 [entrez] -PHST- 2023/05/09 00:00 [pmc-release] -AID - 10.1002/cncr.32624 [doi] -PST - ppublish -SO - Cancer. 2020 Mar 1;126(5):978-985. doi: 10.1002/cncr.32624. Epub 2020 Jan 14. - -PMID- 38910009 -OWN - NLM -STAT- MEDLINE -DCOM- 20240623 -LR - 20240818 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 12 -IP - 6 -DP - 2024 Jun 23 -TI - Correlation of K(trans) derived from dynamic contrast-enhanced MRI with treatment - response and survival in locally advanced NSCLC patients undergoing induction - immunochemotherapy and concurrent chemoradiotherapy. -LID - 10.1136/jitc-2023-008574 [doi] -LID - e008574 -AB - PURPOSE: This study aimed to investigate the prognostic significance of - pretreatment dynamic contrast-enhanced (DCE)-MRI parameters concerning tumor - response following induction immunochemotherapy and survival outcomes in patients - with locally advanced non-small cell lung cancer (NSCLC) who underwent - immunotherapy-based multimodal treatments. MATERIAL AND METHODS: Unresectable - stage III NSCLC patients treated by induction immunochemotherapy, concurrent - chemoradiotherapy (CCRT) with or without consolidative immunotherapy from two - prospective clinical trials were screened. Using the two-compartment Extend Tofts - model, the parameters including K(trans), K(ep), V(e), and V(p) were calculated - from DCE-MRI data. The apparent diffusion coefficient was calculated from - diffusion-weighted-MRI data. The receiver operating characteristic (ROC) curve - and the area under the curve (AUC) were used to assess the predictive performance - of MRI parameters. The Cox regression model was used for univariate and - multivariate analysis. RESULTS: 111 unresectable stage III NSCLC patients were - enrolled. Patients received two cycles of induction immunochemotherapy and CCRT, - with or without consolidative immunotherapy. With the median follow-up of 22.3 - months, the median progression-free survival (PFS) and overall survival (OS) were - 16.3 and 23.8 months. The multivariate analysis suggested that Eastern - Cooperative Oncology Group score, TNM stage and the response to induction - immunochemotherapy were significantly related to both PFS and OS. After induction - immunochemotherapy, 67 patients (59.8%) achieved complete response or partial - response and 44 patients (40.2%) had stable disease or progressive disease. The - K(trans) of primary lung tumor before induction immunochemotherapy yielded the - best performance in predicting the treatment response, with an AUC of 0.800. - Patients were categorized into two groups: high-K(trans) group (n=67, - K(trans)>164.3×10(-3)/min) and low-K(trans) group (n=44, - K(trans)≤164.3×10(-3)/min) based on the ROC analysis. The high-K(trans) group had - a significantly higher objective response rate than the low-K(trans) group (85.1% - (57/67) vs 22.7% (10/44), p<0.001). The high-K(trans) group also presented better - PFS (median: 21.1 vs 11.3 months, p=0.002) and OS (median: 34.3 vs 15.6 months, - p=0.035) than the low-K(trans) group. CONCLUSIONS: Pretreatment K(trans) value - emerged as a significant predictor of the early response to induction - immunochemotherapy and survival outcomes in unresectable stage III NSCLC patients - who underwent immunotherapy-based multimodal treatments. Elevated K(trans) values - correlated positively with enhanced treatment response, leading to extended PFS - and OS durations. -CI - © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Wang, DaQuan -AU - Wang D -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, - Guangdong, China. -FAU - Liu, SongRan -AU - Liu S -AD - Department of Pathology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, - Guangdong, China. -FAU - Fu, Jia -AU - Fu J -AD - Department of Pathology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, - Guangdong, China. -FAU - Zhang, PengXin -AU - Zhang P -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, - Guangdong, China. -FAU - Zheng, ShiYang -AU - Zheng S -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, - Guangdong, China. -FAU - Qiu, Bo -AU - Qiu B -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, - Guangdong, China. -FAU - Liu, Hui -AU - Liu H -AD - United Imaging Healthcare, ShangHai, China. -FAU - Ye, YongQuan -AU - Ye Y -AD - United Imaging of Healthcare America, Houston, Texas, USA. -FAU - Guo, JinYu -AU - Guo J -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, - Guangdong, China. -FAU - Zhou, Yin -AU - Zhou Y -AD - SuZhou TongDiao Company, Suzhou, China. -FAU - Jiang, HaiHang -AU - Jiang H -AD - SuZhou TongDiao Company, Suzhou, China. -FAU - Yin, ShaoHan -AU - Yin S -AD - Department of Radiology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, - Guangdong, China. -FAU - He, HaoQiang -AU - He H -AD - Department of Radiology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, - Guangdong, China liuhuisysucc@126.com xiechm@sysucc.org.cn hehq@sysucc.org.cn. -FAU - Xie, ChuanMiao -AU - Xie C -AD - Department of Radiology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, - Guangdong, China liuhuisysucc@126.com xiechm@sysucc.org.cn hehq@sysucc.org.cn. -FAU - Liu, Hui -AU - Liu H -AUID- ORCID: 0000-0002-3335-3756 -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, - Guangdong, China liuhuisysucc@126.com xiechm@sysucc.org.cn hehq@sysucc.org.cn. -LA - eng -PT - Journal Article -DEP - 20240623 -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Contrast Media) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/mortality/diagnostic imaging/drug - therapy/pathology -MH - Female -MH - Male -MH - *Chemoradiotherapy/methods -MH - *Lung Neoplasms/therapy/mortality/diagnostic imaging/drug therapy/pathology -MH - Middle Aged -MH - Aged -MH - *Immunotherapy/methods -MH - Adult -MH - Magnetic Resonance Imaging/methods -MH - Contrast Media -MH - Treatment Outcome -MH - Induction Chemotherapy -MH - Neoplasm Staging -MH - Prospective Studies -PMC - PMC11328668 -OTO - NOTNLM -OT - Dynamic contrast-enhanced MRI -OT - Ktrans -OT - immunotherapy -OT - lung cancer -OT - treatment response -COIS- Competing interests: None declared. -EDAT- 2024/06/24 00:42 -MHDA- 2024/06/24 00:43 -PMCR- 2024/06/22 -CRDT- 2024/06/23 20:52 -PHST- 2024/05/30 00:00 [accepted] -PHST- 2024/06/24 00:43 [medline] -PHST- 2024/06/24 00:42 [pubmed] -PHST- 2024/06/23 20:52 [entrez] -PHST- 2024/06/22 00:00 [pmc-release] -AID - jitc-2023-008574 [pii] -AID - 10.1136/jitc-2023-008574 [doi] -PST - epublish -SO - J Immunother Cancer. 2024 Jun 23;12(6):e008574. doi: 10.1136/jitc-2023-008574. - -PMID- 32900864 -OWN - NLM -STAT- MEDLINE -DCOM- 20211014 -LR - 20211014 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 8 -IP - 2 -DP - 2020 Sep -TI - Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line - treatment for patients with extensive-stage small cell lung cancer. -LID - 10.1136/jitc-2020-001300 [doi] -LID - e001300 -AB - We performed a meta-analysis to comprehensively investigate the efficacy and - safety of immune-checkpoint inhibitors (ICIs) plus chemotherapy in patients with - extensive-stage small cell lung cancer (ES-SCLC). The primary outcome was overall - survival (OS). The secondary outcomes included progression-free survival (PFS), - objective response rate (ORR) and ≥grade 3 adverse events (AEs). A total of six - studies involving 2905 patients were identified, including 469 patients receiving - program death ligand 1 (PD-L1) inhibitor plus chemotherapy, 308 receiving PD-1 - inhibitors plus chemotherapy, 563 receiving CTLA-4 inhibitors plus chemotherapy, - 268 receiving PD-L1/CTLA-4 inhibitors plus chemotherapy, and 1297 receiving - chemotherapy alone. 10.8% (283/2615) patients had baseline brain metastases - (BMs). Notably, ICIs plus chemotherapy was associated with significantly improved - OS (HR, 0.82; 95% CI, 0.75 to 0.89). Subgroup analyses revealed that PD-1 - inhibitors (HR, 0.77; 95% CI, 0.64 to 0.92) and PD-L1 inhibitors (HR, 0.73; 95% - CI, 0.63 to 0.85) plus chemotherapy yielded a statistically significant - improvement in OS while CTLA-4 inhibitors did not (HR, 0.92; 95% CI, 0.81 to - 1.06). In patients with baseline BMs, ICIs plus chemotherapy showed no survival - benefits over chemotherapy alone (HR, 1.23; 95% CI, 0.92 to 1.64). ICIs plus - chemotherapy also significantly prolonged PFS (HR, 0.81; 95% CI, 0.75 to 0.87) - while the pooled ORRs were comparable between ICIs plus chemotherapy and - chemotherapy alone (RR, 1.04; 95% CI, 0.99 to 1.10). Patients treated with CTLA-4 - inhibitors (relative risk (RR), 1.12; 95% CI, 0.99 to 1.28) experienced - more≥grade 3 AEs than those treated with PD-1/PD-L1 inhibitors (RR, 1.03; 95% CI, - 0.96 to 1.11). The addition of PD-1/PD-L1 inhibitors to chemotherapy resulted in - significant improvements in both PFS and OS for patients with treatment-naïve - ES-SCLC, not at the cost of increased AEs. -CI - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Zhou, Fei -AU - Zhou F -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, China. -FAU - Zhao, Wencheng -AU - Zhao W -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, China. -FAU - Gong, Xiaomei -AU - Gong X -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, China. -FAU - Ren, Shengxiang -AU - Ren S -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, China. -FAU - Su, Chunxia -AU - Su C -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, China. -FAU - Jiang, Tao -AU - Jiang T -AD - Department of Pulmonary Medicine, Shanghai Respiratory Research Institute, - Zhongshan Hospital, Fudan University, Shanghai, China caicunzhou_dr@163.com - tonyjiangdr@163.com. -FAU - Zhou, Caicun -AU - Zhou C -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, China - caicunzhou_dr@163.com tonyjiangdr@163.com. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Research Support, Non-U.S. Gov't -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology/*therapeutic use -MH - Immunotherapy/*methods -MH - Lung Neoplasms/*drug therapy -MH - Neoplasm Staging -MH - Small Cell Lung Carcinoma/*drug therapy -PMC - PMC7477983 -OTO - NOTNLM -OT - lung neoplasms -COIS- Competing interests: None declared. -EDAT- 2020/09/10 06:00 -MHDA- 2021/10/15 06:00 -PMCR- 2020/09/07 -CRDT- 2020/09/09 05:25 -PHST- 2020/08/14 00:00 [accepted] -PHST- 2020/09/09 05:25 [entrez] -PHST- 2020/09/10 06:00 [pubmed] -PHST- 2021/10/15 06:00 [medline] -PHST- 2020/09/07 00:00 [pmc-release] -AID - jitc-2020-001300 [pii] -AID - 10.1136/jitc-2020-001300 [doi] -PST - ppublish -SO - J Immunother Cancer. 2020 Sep;8(2):e001300. doi: 10.1136/jitc-2020-001300. - -PMID- 32502055 -OWN - NLM -STAT- MEDLINE -DCOM- 20200625 -LR - 20221005 -IS - 1536-5964 (Electronic) -IS - 0025-7974 (Print) -IS - 0025-7974 (Linking) -VI - 99 -IP - 23 -DP - 2020 Jun 5 -TI - First-line albumin-bound paclitaxel/carboplatin plus apatinib in advanced - pulmonary sarcomatoid carcinoma: A case series and review of the literature. -PG - e20667 -LID - 10.1097/MD.0000000000020667 [doi] -LID - e20667 -AB - RATIONALE: Pulmonary sarcomatoid carcinoma (PSC) is an uncommon type of non-small - cell lung cancer, exhibiting aggressive behavior and resistance to the - conventional chemoradiotherapy. To date, the optimal treatment for PSC has not - been elucidated. PATIENT CONCERNS: Three male patients including a 69-year-old - smoker (Case 1), a 45-year-old non-smoker (Case 2), and a 69-year-old smoker - (Case 3) were admitted because of cough, back pain, and loss of body weight - respectively. DIAGNOSES: Radiographical examinations in these patients showed - bulky intrathoracic lesions, which were pathologically diagnosed as PSC staging - III-IV by computed tomography-guided percutaneous biopsy and endoscopy. - INTERVENTIONS: Immunotherapy was not covered by their health insurance and they - refused immune checkpoint inhibitors for financial reasons. In addition, a - radical resection was not appropriate due to the advanced staging of these - lesions. Therefore, first-line albumin-bound paclitaxel (nab-paclitaxel, 260 mg/m - of the body surface area) and carboplatin (area under curve 5) combined with oral - apatinib (425 mg, daily) were administered empirically. OUTCOMES: Two patients - achieved a partial response and the other case showed stable disease lasting for - more than 6 months. However, 1 of them indicated progression on the 7-month - follow up. LESSONS: Nab-paclitaxel/carboplatin plus apatinib showed limited - short-term efficacy in advanced, unresectable PSC. The rapid resistance of PSC to - the current therapeutic regimen necessitates further researches, as more - effective agents are urgently needed. -FAU - Kong, Feng-Wei -AU - Kong FW -AD - Department of General Surgery, Xuzhou Infectious Disease Hospital. -FAU - Wang, Wei-Min -AU - Wang WM -AD - Department of General Surgery, Xuzhou Infectious Disease Hospital. -FAU - Liu, Lei -AU - Liu L -AD - Department of Gastroenterology, Yichang Central People's Hospital, Institute of - Digestive Disease, China Three Gorges University, Yichang. -FAU - Wu, Wen-Bin -AU - Wu WB -AD - Department of Surgery, Xuzhou Central Hospital, Xuzhou, China. -FAU - Wang, Xiang -AU - Wang X -AD - Department of Surgery, Xuzhou Central Hospital, Xuzhou, China. -FAU - Zhang, Miao -AU - Zhang M -AUID- ORCID: 0000-0001-7431-5986 -AD - Department of Surgery, Xuzhou Central Hospital, Xuzhou, China. -LA - eng -PT - Case Reports -PT - Journal Article -PT - Review -PL - United States -TA - Medicine (Baltimore) -JT - Medicine -JID - 2985248R -RN - 0 (130-nm albumin-bound paclitaxel) -RN - 0 (Albumins) -RN - 0 (Antineoplastic Agents) -RN - 0 (Pyridines) -RN - 5S371K6132 (apatinib) -RN - BG3F62OND5 (Carboplatin) -RN - P88XT4IS4D (Paclitaxel) -SB - IM -MH - Aged -MH - Albumins/*administration & dosage -MH - Antineoplastic Agents/*administration & dosage -MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage -MH - Biopsy -MH - Carboplatin/*administration & dosage -MH - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/*drug therapy/pathology -MH - Humans -MH - Lung Neoplasms/diagnostic imaging/*drug therapy/pathology -MH - Male -MH - Middle Aged -MH - Non-Smokers -MH - Paclitaxel/*administration & dosage -MH - Pyridines/*administration & dosage -MH - Smokers -MH - Tomography, X-Ray Computed -PMC - PMC7306366 -COIS- The authors have no conflicts of interest to disclose. -EDAT- 2020/06/06 06:00 -MHDA- 2020/06/26 06:00 -PMCR- 2020/06/05 -CRDT- 2020/06/06 06:00 -PHST- 2020/06/06 06:00 [entrez] -PHST- 2020/06/06 06:00 [pubmed] -PHST- 2020/06/26 06:00 [medline] -PHST- 2020/06/05 00:00 [pmc-release] -AID - 00005792-202006050-00093 [pii] -AID - MD-D-20-00715 [pii] -AID - 10.1097/MD.0000000000020667 [doi] -PST - ppublish -SO - Medicine (Baltimore). 2020 Jun 5;99(23):e20667. doi: 10.1097/MD.0000000000020667. - -PMID- 31756415 -OWN - NLM -STAT- MEDLINE -DCOM- 20210405 -LR - 20210405 -IS - 1879-355X (Electronic) -IS - 0360-3016 (Linking) -VI - 108 -IP - 1 -DP - 2020 Sep 1 -TI - A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation - Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. -PG - 170-177 -LID - S0360-3016(19)34007-6 [pii] -LID - 10.1016/j.ijrobp.2019.10.047 [doi] -AB - PURPOSE: Preclinical data and subset analyses from immunotherapy clinical trials - indicate that prior radiation therapy was associated with better progression-free - survival and overall survival when combined with immune checkpoint inhibitors in - patients with non-small cell lung cancer. We present a prospective study of - hypofractionated image guided radiation therapy (HIGRT) to a single site of - metastatic disease concurrently with atezolizumab in patients with metastatic - non-small cell lung cancer. METHODS AND MATERIALS: Patients meeting eligibility - criteria received 1200 mg of atezolizumab intravenously every 3 weeks with - concurrent 3- or 5-fraction HIGRT starting no later than the second cycle. The - 3-fraction regimen employed a minimum of 8 Gy per fraction compared with 6 Gy for - the 5-fraction regimen. Imaging was obtained every 12 weeks to assess response. - RESULTS: From October 2015 to February 2017, 12 patients were enrolled in the - study (median age 64; range, 55-77 years). The best response by the Response - Evaluation in Solid Tumors criteria was partial response in 3 and stable disease - in 3, for a disease control rate of 50%. Five patients had a grade 3 - immune-related adverse event, including choreoretinitis (n = 1), pneumonitis (n = - 1), transaminitis (n = 1), fatigue (n = 1), and peripheral neuropathy (n = 1). - The median progression-free survival was 2.3 months, and the median overall - survival was 6.9 months (range, 0.4-not reached). There was no clear association - between peripheral blood T cell repertoire characteristics at baseline, PD-L1, or - tumor mutations and response or outcome. One long-term survivor exhibited - oligoclonal T cell populations in a baseline tumor biopsy that were consistently - detected in peripheral blood over the entire course of the study. CONCLUSIONS: - HIGRT plus atezolizumab resulted in an overall response rate of 25% and disease - control rate of 50% in this pilot study. The incidence of grade 3 adverse events - was similar to that of atezolizumab alone. Alhough it was a pilot study with - limited sample size, the results generated hypotheses worthy of further - investigation. -CI - Copyright © 2019 Elsevier Inc. All rights reserved. -FAU - Qin, Angel -AU - Qin A -AD - Department of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, - Michigan. -FAU - Rengan, Ramesh -AU - Rengan R -AD - Department of Radiation Oncology, University of Washington, Seattle, Washington; - Clinical Research Division, Fred Hutchinson Cancer Research Center. -FAU - Lee, Sylvia -AU - Lee S -AD - Clinical Research Division, Fred Hutchinson Cancer Research Center; Department of - Medicine, University of Washington, Seattle, Washington. -FAU - Santana-Davila, Rafael -AU - Santana-Davila R -AD - Clinical Research Division, Fred Hutchinson Cancer Research Center; Department of - Medicine, University of Washington, Seattle, Washington. -FAU - Goulart, Bernardo H L -AU - Goulart BHL -AD - Clinical Research Division, Fred Hutchinson Cancer Research Center; Department of - Medicine, University of Washington, Seattle, Washington. -FAU - Martins, Renato -AU - Martins R -AD - Clinical Research Division, Fred Hutchinson Cancer Research Center; Department of - Medicine, University of Washington, Seattle, Washington. -FAU - Baik, Christina -AU - Baik C -AD - Clinical Research Division, Fred Hutchinson Cancer Research Center; Department of - Medicine, University of Washington, Seattle, Washington. -FAU - Kalemkerian, Gregory P -AU - Kalemkerian GP -AD - Department of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, - Michigan. -FAU - Hassan, Khaled A -AU - Hassan KA -AD - Department of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, - Michigan. -FAU - Schneider, Bryan J -AU - Schneider BJ -AD - Department of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, - Michigan. -FAU - Hayman, James A -AU - Hayman JA -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Jolly, Shruti -AU - Jolly S -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Hearn, Jason -AU - Hearn J -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Lawrence, Theodore S -AU - Lawrence TS -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Towlerton, Andrea M H -AU - Towlerton AMH -AD - Clinical Research Division, Fred Hutchinson Cancer Research Center. -FAU - Tewari, Muneesh -AU - Tewari M -AD - Department of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, - Michigan. -FAU - Thomas, Dafydd -AU - Thomas D -AD - Department of Pathology, University of Michigan, Ann Arbor, Michigan. -FAU - Zhao, Lili -AU - Zhao L -AD - Department of Biostatistics, University of Michigan, Ann Arbor, Michigan. -FAU - Brown, Noah -AU - Brown N -AD - Department of Pathology, University of Michigan, Ann Arbor, Michigan. -FAU - Frankel, Timothy L -AU - Frankel TL -AD - Department of Surgery, University of Michigan, Ann Arbor, Michigan. -FAU - Warren, Edus H -AU - Warren EH -AD - Clinical Research Division, Fred Hutchinson Cancer Research Center; Department of - Medicine, University of Washington, Seattle, Washington. -FAU - Ramnath, Nithya -AU - Ramnath N -AD - Department of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, - Michigan. Electronic address: nithyar@med.umich.edu. -LA - eng -GR - P30 CA046592/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20191119 -PL - United States -TA - Int J Radiat Oncol Biol Phys -JT - International journal of radiation oncology, biology, physics -JID - 7603616 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 52CMI0WC3Y (atezolizumab) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - B7-H1 Antigen/metabolism -MH - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/*drug - therapy/pathology/*radiotherapy -MH - Combined Modality Therapy -MH - Female -MH - Gene Expression Regulation, Neoplastic/drug effects/radiation effects -MH - Humans -MH - Lung Neoplasms/diagnostic imaging/*drug therapy/pathology/*radiotherapy -MH - Male -MH - Middle Aged -MH - Pilot Projects -MH - *Radiation Dose Hypofractionation -MH - *Radiotherapy, Image-Guided -MH - Safety -MH - Treatment Outcome -EDAT- 2019/11/23 06:00 -MHDA- 2021/04/07 06:00 -CRDT- 2019/11/23 06:00 -PHST- 2019/08/07 00:00 [received] -PHST- 2019/10/23 00:00 [revised] -PHST- 2019/10/25 00:00 [accepted] -PHST- 2019/11/23 06:00 [pubmed] -PHST- 2021/04/07 06:00 [medline] -PHST- 2019/11/23 06:00 [entrez] -AID - S0360-3016(19)34007-6 [pii] -AID - 10.1016/j.ijrobp.2019.10.047 [doi] -PST - ppublish -SO - Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):170-177. doi: - 10.1016/j.ijrobp.2019.10.047. Epub 2019 Nov 19. - -PMID- 33126091 -OWN - NLM -STAT- MEDLINE -DCOM- 20210621 -LR - 20210621 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 150 -DP - 2020 Dec -TI - Durvalumab after definitive chemoradiotherapy in locally advanced unresectable - non-small cell lung cancer (NSCLC): Real-world data on survival and safety from - the German expanded-access program (EAP). -PG - 114-122 -LID - S0169-5002(20)30654-1 [pii] -LID - 10.1016/j.lungcan.2020.10.006 [doi] -AB - BACKGROUND: Following the PACIFIC trial, durvalumab has been approved by the - European Medicines Agency (EMA) for consolidation of locally advanced - PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with - durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its - efficacy and safety. METHODS: Data from 56 centres were analysed for adverse - events (AE), progression-free survival (PFS), overall survival (OS). RESULTS: 126 - patients actually received at least 1 cycle durvalumab. Compared to the PACIFIC - trial, the EAP population had more advanced stage and included "oligometastatic" - stage IV patients and patients with autoimmune disease. PFS (20.1 months) and OS - (not reached) were similar in the EAP and the PACIFIC trial. 42.9 % completed 12 - months of durvalumab without deaths during FU. Stage IV patients (n = 7) had - encouraging OS (not reached at 27 months). Autoimmune disease did not affect - survival. PFS and OS were similar in PD-L1-negative patients (n = 32) and - PD-L1-positive patients (n = 79). CONCLUSIONS: Survival in the EAP was comparable - to the PACIFIC trial. Selected stage IV patients and patients with autoimmune - disease may benefit from durvalumab consolidation and should be included in - future immuno-oncological trials. PD-L1 did not predict survival challenging the - exclusion of PD-L1-negative patients from durvalumab consolidation. In summary, - durvalumab consolidation is safe and effective in a European real-world setting. -CI - Copyright © 2020 Elsevier B.V. All rights reserved. -FAU - Faehling, Martin -AU - Faehling M -AD - Klinik für Kardiologie und Pneumologie, Klinikum Esslingen, 73730 Esslingen, - Germany. -FAU - Schumann, Christian -AU - Schumann C -AD - Klinik für Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedizin, Klinikum - Kempten, 87439 Kempten, Germany. -FAU - Christopoulos, Petros -AU - Christopoulos P -AD - Thoraxklinik-Heidelberg, 69126 Heidelberg, Germany. -FAU - Hoffknecht, Petra -AU - Hoffknecht P -AD - Klinik für Thoraxonkologie und Palliativstation, Franziskus-Hospital Harderberg, - 49124 Georgsmarienhütte, Germany. -FAU - Alt, Jürgen -AU - Alt J -AD - III. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, 55131 - Mainz, Germany. -FAU - Horn, Marlitt -AU - Horn M -AD - LungenClinic Grosshansdorf, Großhansdorf, Germany. -FAU - Eisenmann, Stephan -AU - Eisenmann S -AD - Universitätsklinik und Poliklinik für Innere Medizin I (Gastroenterologie & - Pneumologie), Universitätsklinikum Halle (Saale), 06120 Halle, Germany. -FAU - Schlenska-Lange, Anke -AU - Schlenska-Lange A -AD - Klinik für Onkologie und Hämatologie, Krankenhaus Barmherzige Brüder Regensburg, - 93049 Regensburg, Germany. -FAU - Schütt, Philipp -AU - Schütt P -AD - Onkologische Gemeinschaftspraxis, Gütersloh, Germany. -FAU - Steger, Felix -AU - Steger F -AD - Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Regensburg, - 93053 Regensburg, Germany. -FAU - Brückl, Wolfgang M -AU - Brückl WM -AD - Klinik für Innere Medizin 3, Klinikum Nürnberg Nord, 90419 Nürnberg, Germany. -FAU - Christoph, Daniel C -AU - Christoph DC -AD - Klinik für Internistische Onkologie und Hämatologie mit integrierter - Palliativmedizin, Evang. Kliniken Essen-Mitte, 45136 Essen, Germany. -LA - eng -PT - Journal Article -DEP - 20201021 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy -OTO - NOTNLM -OT - Checkpoint inhibitor -OT - NSCLC -OT - PD-L1 -OT - Real world -OT - Survival -EDAT- 2020/10/31 06:00 -MHDA- 2021/06/22 06:00 -CRDT- 2020/10/30 20:13 -PHST- 2020/08/05 00:00 [received] -PHST- 2020/09/26 00:00 [revised] -PHST- 2020/10/09 00:00 [accepted] -PHST- 2020/10/31 06:00 [pubmed] -PHST- 2021/06/22 06:00 [medline] -PHST- 2020/10/30 20:13 [entrez] -AID - S0169-5002(20)30654-1 [pii] -AID - 10.1016/j.lungcan.2020.10.006 [doi] -PST - ppublish -SO - Lung Cancer. 2020 Dec;150:114-122. doi: 10.1016/j.lungcan.2020.10.006. Epub 2020 - Oct 21. - -PMID- 36532013 -OWN - NLM -STAT- MEDLINE -DCOM- 20221220 -LR - 20240909 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 13 -DP - 2022 -TI - Long-term survival in extensive-stage small-cell lung cancer treated with - different immune checkpoint inhibitors in multiple-line therapies: A case report - and literature review. -PG - 1059331 -LID - 10.3389/fimmu.2022.1059331 [doi] -LID - 1059331 -AB - BACKGROUND: Extensive-stage small-cell lung cancer (ES-SCLC) is highly malignant, - is highly prone to recurrence, and has a short survival period. It is very - difficult to achieve long-term survival in ES-SCLC, which has not been - significantly improved in the last 20 years. For a long time, platinum-based - chemotherapy has occupied the core position in the treatment of small-cell lung - cancer (SCLC), but there are few options for treatment drugs or regimens, and if - disease progression occurs, the options for follow-up regimens are obviously - limited. The advent of immunotherapy has changed this situation to some extent, - and immunotherapy has shown some effects in improving efficiency and prolonging - survival, whether in first- or third-line therapy, but it is still - unsatisfactory. CASE PRESENTATION: A 57-year-old patient with ES-SCLC experienced - disease progression after four lines of treatment including synchronous - radiotherapy, chemotherapy, and antiangiogenesis. However, the patient still - benefited when switching to the programmed cell death receptor-1 (PD-1) inhibitor - toripalimab in combination with chemotherapy in the fifth line. Even after the - development of immune resistance, the patient still benefited after switching to - tislelizumab in combination with different chemotherapy regimens or alone in the - sixth and seventh lines. Following the progression of tislelizumab in combination - with chemotherapy, the patient again profited after switching to durvalumab in - combination with anlotinib and again achieved a progressive-free survival (PFS) - of 11 months. Overall, the patient achieved a total of 45 months of PFS and 50 - months of overall survival (OS), with a shocking and exciting 30 months of PFS - achieved in the immune combination phase alone. CONCLUSION: We report a patient - with ES-SCLC who achieved long-term survival after at least eight lines of - therapy including chemotherapy, antiangiogenesis, and different immune checkpoint - inhibitors (ICIs). This suggests that long-term survival in SCLC is possible with - aggressive, combined, and standardized treatment. Otherwise, immunotherapy - postline enablement can still benefit patients, rechallenge after immune - resistance is also possible in SCLC, and combination with chemotherapy or - antiangiogenic therapy can improve the efficacy and prolong the survival. This - will provide new ideas and options for the selection of treatment options for - SCLC. -CI - Copyright © 2022 Zhang, Zheng, Niu, Xue, Yu, Tan and Cui. -FAU - Zhang, Xu -AU - Zhang X -AD - Graduate School, Beijing University of Chinese Medicine, Beijing, China. -FAU - Zheng, Jiabin -AU - Zheng J -AD - Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, - China. -FAU - Niu, Yun -AU - Niu Y -AD - Department of Pathology, China-Japan Friendship Hospital, Beijing, China. -FAU - Xue, Chongxiang -AU - Xue C -AD - Graduate School, Beijing University of Chinese Medicine, Beijing, China. -FAU - Yu, Yixuan -AU - Yu Y -AD - Graduate School, Beijing University of Chinese Medicine, Beijing, China. -FAU - Tan, Kexin -AU - Tan K -AD - Graduate School, Beijing University of Chinese Medicine, Beijing, China. -FAU - Cui, Huijuan -AU - Cui H -AD - Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, - China. -LA - eng -PT - Case Reports -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20221130 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - Middle Aged -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - *Lung Neoplasms/pathology -MH - *Small Cell Lung Carcinoma/drug therapy/pathology -MH - Immunotherapy -MH - Disease Progression -PMC - PMC9747940 -OTO - NOTNLM -OT - ES-SCLC -OT - ICIs -OT - combined regimens -OT - long-term survival -OT - re-challenge -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/12/20 06:00 -MHDA- 2022/12/21 06:00 -PMCR- 2022/01/01 -CRDT- 2022/12/19 04:05 -PHST- 2022/10/01 00:00 [received] -PHST- 2022/11/10 00:00 [accepted] -PHST- 2022/12/19 04:05 [entrez] -PHST- 2022/12/20 06:00 [pubmed] -PHST- 2022/12/21 06:00 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2022.1059331 [doi] -PST - epublish -SO - Front Immunol. 2022 Nov 30;13:1059331. doi: 10.3389/fimmu.2022.1059331. - eCollection 2022. - -PMID- 32094063 -OWN - NLM -STAT- MEDLINE -DCOM- 20210218 -LR - 20210218 -IS - 0929-6646 (Print) -IS - 0929-6646 (Linking) -VI - 119 -IP - 12 -DP - 2020 Dec -TI - Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell - lung cancer, radical radiotherapy-ineligible patients: A phase II study in - Taiwan. -PG - 1817-1826 -LID - S0929-6646(20)30008-5 [pii] -LID - 10.1016/j.jfma.2020.01.004 [doi] -AB - BACKGROUND/PURPOSE: There is a lack of data on nivolumab treatment outcomes in - Taiwanese patients with advanced or recurrent non-small cell lung cancer (NSCLC) - ineligible for radical radiotherapy and resistant to platinum-based chemotherapy. - We investigated the safety and efficacy of nivolumab in this population. METHODS: - In this ongoing, multicenter, open-label, single-arm, phase II study, patients - aged ≥20 years with a performance status of 0-1 and stage IIIB/IV or recurrent - NSCLC received nivolumab 3 mg/kg every 2 weeks in 6-week cycles. Interim data - obtained between 27 January 2016 and 21 May 2017 were analyzed. Safety, based on - adverse event (AE) reporting, was the primary endpoint. Efficacy assessment - parameters included overall response rate (ORR), overall survival (OS), and - progression-free survival (PFS). RESULTS: Among 53 treated patients with advanced - NSCLC (median age 61.0 years; 62.3% male), mean treatment duration was 99.7 days. - AEs (any grade) and serious AEs were reported by 92.5% and 47.2% of patients, - respectively. Adverse drug reactions (ADRs; any) occurred in 58.5% of patients; - grade ≥3 ADRs occurred in 13.2% of patients. Five deaths occurred; two cases - (neoplasm progression and septic shock) were considered treatment-emergent. - Common ADRs were fatigue (17.0%) and rash (13.2%). Common immune-related - treatment-emergent AEs were rash (17.0%) and pruritus (13.2%). The centrally - assessed ORR was 9.4% (5/53). The median OS and median PFS were 11.5 months and - 1.4 months, respectively. CONCLUSION: Nivolumab appeared to be safe and effective - in Taiwanese patients. These interim results suggest that nivolumab is a suitable - treatment option for this population. CLINICAL TRIAL REGISTRATION: NCT02582125. -CI - Copyright © 2020. Published by Elsevier B.V. -FAU - Chen, Yuh-Min -AU - Chen YM -AD - Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, - Taiwan; Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, - Taiwan. -FAU - Chih-Hsin Yang, James -AU - Chih-Hsin Yang J -AD - Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. -FAU - Su, Wu-Chou -AU - Su WC -AD - Department of Internal Medicine, National Cheng Kung University Hospital, College - of Medicine, National Cheng Kung University, Tainan, Taiwan. -FAU - Chong, Inn-Wen -AU - Chong IW -AD - Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University - Hospital, Kaohsiung, Taiwan. -FAU - Hsia, Te-Chun -AU - Hsia TC -AD - China Medical University Hospital and Department of Respiratory Therapy, China - Medical University, Taichung, Taiwan. -FAU - Lin, Meng-Chih -AU - Lin MC -AD - Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, - Kaohsiung, Taiwan; Department of Internal Medicine, Chang Gung University, - Taoyuan, Taiwan. -FAU - Chang, Gee-Chen -AU - Chang GC -AD - Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, - Taiwan; Division of Chest Medicine, Department of Internal Medicine, Taichung - Veterans General Hospital, Taichung, Taiwan. -FAU - Chiu, Chao-Hua -AU - Chiu CH -AD - Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, - Taiwan; Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, - Taiwan. -FAU - Ho, Chao-Chi -AU - Ho CC -AD - Department of Internal Medicine, National Taiwan University Hospital, Taipei, - Taiwan. -FAU - Wu, Shang-Yin -AU - Wu SY -AD - Department of Internal Medicine, National Cheng Kung University Hospital, College - of Medicine, National Cheng Kung University, Tainan, Taiwan. -FAU - Hung, Jen-Yu -AU - Hung JY -AD - Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University - Hospital, Kaohsiung, Taiwan. -FAU - Wang, Chin-Chou -AU - Wang CC -AD - Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, - Kaohsiung, Taiwan; Department of Internal Medicine, Chang Gung University, - Taoyuan, Taiwan. -FAU - Yang, Tsung-Ying -AU - Yang TY -AD - Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, - Taiwan; Division of Chest Medicine, Department of Internal Medicine, Taichung - Veterans General Hospital, Taichung, Taiwan. -FAU - Yu, Chong-Jen -AU - Yu CJ -AD - Department of Internal Medicine, National Taiwan University Hospital, Taipei, - Taiwan. Electronic address: jefferycjyu@ntu.edu.tw. -LA - eng -SI - ClinicalTrials.gov/NCT02582125 -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Multicenter Study -DEP - 20200222 -PL - Singapore -TA - J Formos Med Assoc -JT - Journal of the Formosan Medical Association = Taiwan yi zhi -JID - 9214933 -RN - 31YO63LBSN (Nivolumab) -RN - 49DFR088MY (Platinum) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/therapy -MH - Chemoradiotherapy -MH - Drug Resistance, Neoplasm -MH - Female -MH - Humans -MH - *Lung Neoplasms/therapy -MH - Male -MH - Middle Aged -MH - Neoplasm Recurrence, Local -MH - Nivolumab/adverse effects/*therapeutic use -MH - Platinum -MH - Taiwan -OTO - NOTNLM -OT - Monoclonal antibodies -OT - Non-small cell lung carcinoma -OT - Programmed cell death 1 receptor -OT - Safety -OT - Taiwan -COIS- Declaration of competing interest Yuh-Min Chen, Wu-Chou Su, Inn-Wen Chong, - Te-Chun Hsia, Meng-Chih Lin, Gee-Chen Chang, Shang-Yin Wu, Jen-Yu Hung, Chin-Chou - Wang, Tsung-Ying Yang, and Chong-Jen Yu have no conflicts of interest to declare - in relation to the present work. James Chih-Hsin Yang declares having received - personal fees as honoraria for advisory board participation or speaker bureaus - from Boehringer Ingelheim, Eli Lilly, Roche/Genentech, Chugai, Astellas, MSD, - Merck Serono, Pfizer, Novartis, Celgene, Merrimack, Yuhan Pharmaceuticals, BMS, - Ono Pharmaceutical, Daiichi Sankyo, AstraZeneca, Hansoh Pharmaceuticals, and - Takeda Pharmaceuticals. Chao-Hua Chiu declares having received personal fees as - honoraria from BMS, MSD Roche, AstraZeneca, Novartis, and Pfizer. Chao-Chi Ho - declares having received grants from AstraZeneca. -EDAT- 2020/02/26 06:00 -MHDA- 2021/02/20 06:00 -CRDT- 2020/02/26 06:00 -PHST- 2019/06/06 00:00 [received] -PHST- 2019/12/20 00:00 [revised] -PHST- 2020/01/07 00:00 [accepted] -PHST- 2020/02/26 06:00 [pubmed] -PHST- 2021/02/20 06:00 [medline] -PHST- 2020/02/26 06:00 [entrez] -AID - S0929-6646(20)30008-5 [pii] -AID - 10.1016/j.jfma.2020.01.004 [doi] -PST - ppublish -SO - J Formos Med Assoc. 2020 Dec;119(12):1817-1826. doi: 10.1016/j.jfma.2020.01.004. - Epub 2020 Feb 22. - -PMID- 32537926 -OWN - NLM -STAT- MEDLINE -DCOM- 20210427 -LR - 20210427 -IS - 1445-5994 (Electronic) -IS - 1444-0903 (Linking) -VI - 50 -IP - 6 -DP - 2020 Jun -TI - Case of post-progression prolongation of survival after cessation of - pembrolizumab in advanced non-small-cell lung cancer. -PG - 771-773 -LID - 10.1111/imj.14852 [doi] -FAU - Liu, Jia -AU - Liu J -AD - Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, - Australia. -AD - Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, - Australia. -AD - University of Sydney, Sydney, New South Wales, Australia. -FAU - Wong, Kirby -AU - Wong K -AD - Department of Radiology, Royal Prince Alfred Hospital, Sydney, New South Wales, - Australia. -FAU - Patanjali, Nitya -AU - Patanjali N -AD - Department of Radiation Oncology, Chris O'Brien Lifehouse, Sydney, New South - Wales, Australia. -FAU - Boyer, Michael -AU - Boyer M -AD - Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, - Australia. -FAU - Kao, Steven -AU - Kao S -AUID- ORCID: 0000-0003-4531-7397 -AD - Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, - Australia. -LA - eng -PT - Letter -PL - Australia -TA - Intern Med J -JT - Internal medicine journal -JID - 101092952 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - *Antineoplastic Agents, Immunological/adverse effects -MH - Antineoplastic Combined Chemotherapy Protocols -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - *Lung Neoplasms/drug therapy -EDAT- 2020/06/17 06:00 -MHDA- 2021/04/28 06:00 -CRDT- 2020/06/16 06:00 -PHST- 2019/08/13 00:00 [received] -PHST- 2019/09/24 00:00 [revised] -PHST- 2019/09/27 00:00 [accepted] -PHST- 2020/06/16 06:00 [entrez] -PHST- 2020/06/17 06:00 [pubmed] -PHST- 2021/04/28 06:00 [medline] -AID - 10.1111/imj.14852 [doi] -PST - ppublish -SO - Intern Med J. 2020 Jun;50(6):771-773. doi: 10.1111/imj.14852. - -PMID- 32518972 -OWN - NLM -STAT- MEDLINE -DCOM- 20201006 -LR - 20201006 -IS - 1432-1335 (Electronic) -IS - 0171-5216 (Linking) -VI - 146 -IP - 11 -DP - 2020 Nov -TI - Overall survival benefit of continuing immune checkpoint inhibitors treatment - post dissociated response in patients with advanced lung cancer. -PG - 2979-2988 -LID - 10.1007/s00432-020-03282-y [doi] -AB - PURPOSE: Dissociated response (DR, reduction at baseline or increase < 20% in - target lesions compared with nadir in the presence of new lesions) was observed - in 20-34% of patients treated with immune checkpoint inhibitors (ICIs). DRs were - defined as progression disease (PD) per response evaluation criteria in solid - tumors (RECIST v1.1), while evaluation criteria related to immunotherapy - incorporated the new lesions into the total tumor burden or conducted further - evaluation after 4-8 weeks rather than declaring PD immediately. The main - objective of this study is to compare survival between people who continuing - initial ICIs treatment and those who switched to other anticancer therapy at the - time of DR. PATIENTS AND METHODS: 235 patients with advanced lung cancer (LC) - treated with ICIs were evaluated. Propensity score matching (PSM) was used to - minimize potential confounding factors. Post-DR OS, target lesion changes were - evaluated. RESULTS: 52 patients had been estimated as DRs. After PSM, the - continuing ICIs treatment Post-DR cohort still had a significantly longer median - post-DR OS than discontinuing ICIs treatment Post-DR cohort, 10.63 months (95% CI - 6.27-NA) versus 4.33 months (95% CI 1.77-NA), respectively (p = 0.016). - CONCLUSION: Within the limitations of this single-center retrospective analysis, - clinically stable patients who were judged by clinicians to be eligible for - continuing ICIs treatment post-DR derived apparent OS benefit than discontinuing - counterpart. -FAU - Zhou, Huijie -AU - Zhou H -AD - Department of Thoracic Oncology, West China Hospital/West China Medical Center, - Sichuan University, Chengdu, China. -FAU - Sun, Yu -AU - Sun Y -AD - Department of Radiation Oncology, West China Hospital, Sichuan University, - Chengdu, China. -FAU - Xiu, Weigang -AU - Xiu W -AD - Department of Thoracic Oncology, West China Hospital, Sichuan University, - Chengdu, China. -FAU - Han, Jialong -AU - Han J -AD - Department of Thoracic Oncology, West China Hospital/West China Medical Center, - Sichuan University, Chengdu, China. -FAU - Zhong, Lili -AU - Zhong L -AD - Department of Thoracic Oncology, West China Hospital/West China Medical Center, - Sichuan University, Chengdu, China. -FAU - Suo, Jiaojiao -AU - Suo J -AD - Department of Thoracic Oncology, West China Hospital/West China Medical Center, - Sichuan University, Chengdu, China. -FAU - Wei, Hao -AU - Wei H -AD - Department of Thoracic Oncology, West China Hospital/West China Medical Center, - Sichuan University, Chengdu, China. -FAU - Wang, Yan -AU - Wang Y -AD - Department of IVF, West China 2nd Hospital, Sichuan University, Chengdu, China. -FAU - Zhu, Jiang -AU - Zhu J -AUID- ORCID: 0000-0002-5496-8450 -AD - Department of Thoracic Oncology, West China Hospital, Sichuan University, - Chengdu, China. zhujiang@wchscu.cn. -LA - eng -PT - Journal Article -DEP - 20200609 -PL - Germany -TA - J Cancer Res Clin Oncol -JT - Journal of cancer research and clinical oncology -JID - 7902060 -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Adult -MH - Aged -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/*pathology -MH - Disease Progression -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/mortality/*pathology -MH - Male -MH - Middle Aged -MH - Retrospective Studies -OTO - NOTNLM -OT - Dissociated response -OT - Immunotherapy -OT - Lung cancer -OT - Overall survival -EDAT- 2020/06/11 06:00 -MHDA- 2020/10/07 06:00 -CRDT- 2020/06/11 06:00 -PHST- 2020/04/01 00:00 [received] -PHST- 2020/05/30 00:00 [accepted] -PHST- 2020/06/11 06:00 [pubmed] -PHST- 2020/10/07 06:00 [medline] -PHST- 2020/06/11 06:00 [entrez] -AID - 10.1007/s00432-020-03282-y [pii] -AID - 10.1007/s00432-020-03282-y [doi] -PST - ppublish -SO - J Cancer Res Clin Oncol. 2020 Nov;146(11):2979-2988. doi: - 10.1007/s00432-020-03282-y. Epub 2020 Jun 9. - -PMID- 33023530 -OWN - NLM -STAT- MEDLINE -DCOM- 20210422 -LR - 20220417 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 20 -IP - 1 -DP - 2020 Oct 6 -TI - A phase II study of daily carboplatin plus irradiation followed by durvalumab for - stage III non-small cell lung cancer patients with PS 2 up to 74 years old and - patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress). -PG - 961 -LID - 10.1186/s12885-020-07406-y [doi] -LID - 961 -AB - BACKGROUND: Durvalumab is a standard drug used during maintenance therapy after - chemoradiotherapy in patients with locally advanced non-small cell lung cancer - (LA-NSCLC). However, little is known about the clinical benefits of durvalumab - after chemoradiotherapy in patients with LA-NSCLC with a performance status (PS) - of 2 and/or aged > 75 years. As daily carboplatin plus concurrent thoracic - radiotherapy is recommended for elderly patients according to guideline, the - current phase II study aims to investigate the effect of daily carboplatin plus - radiotherapy followed by durvalumab for patients with stage III NSCLC who have a - PS of 2 and/or are older. METHODS: Daily carboplatin plus radiotherapy followed - by durvalumab is performed for the patients with stage III NSCLC who have a PS of - 2 and/or are older. This is a trial in progress manuscript. STUDY TREATMENT: - Daily, intravenous, low-dose carboplatin (30 mg/m(2) in a 30-min infusion) is - administered to patients 1 h before radiotherapy for the first 20 fractions. - Radiotherapy for all patients consisted of 60 Gy administered as 30 fractions - over 6 weeks. Durvalumab at a dose of 10 mg/kg/body is intravenously administered - every 2 weeks for up to 12 months after chemoradiotherapy. EXPLORATORY - ASSESSMENT: In the future, an exploratory investigation will be performed to - determine whether the combined assessment of T-cell markers, PD-L1 expression, - and tumor mutation burden could predict the outcomes of the regimen. DISCUSSION: - The results of our study will exhibit the efficacy and tolerability of durvalumab - as maintenance therapy after daily carboplatin plus radiotherapy. TRIAL - REGISTRATION: During the first registration (before induction chemoradiotherapy), - 70 patients will be included; then, we include 58 patients during the second - registration (before durvalumab treatment after chemoradiotherapy). - https://jcrb.niph.go.jp/ . PRIMARY ENDPOINT: The primary endpoint of the current - study is the 12-month progression-free survival (PFS) rate after the initiation - of durvalumab. SECONDARY ENDPOINTS: The secondary endpoints are the feasibility, - objective response, PFS, overall survival, and adverse events. -FAU - Kaira, Kyoichi -AU - Kaira K -AUID- ORCID: 0000-0001-5548-7686 -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-City, Saitama, - 350-1298, Japan. kkaira1970@yahoo.co.jp. -FAU - Mouri, Atsuto -AU - Mouri A -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-City, Saitama, - 350-1298, Japan. -FAU - Kato, Shingo -AU - Kato S -AD - Department of Radiation Oncology, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-City, Saitama, - 350-1298, Japan. -FAU - Yoshimura, Kenichi -AU - Yoshimura K -AD - Center for Integrated Medical Research, Hiroshima University Hospital, Hiroshima - University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 732-8551, Japan. -FAU - Kagamu, Hiroshi -AU - Kagamu H -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-City, Saitama, - 350-1298, Japan. -FAU - Kobayashi, Kunihiko -AU - Kobayashi K -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-City, Saitama, - 350-1298, Japan. -LA - eng -GR - N/A/AstraZeneca company/ -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20201006 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -RN - BG3F62OND5 (Carboplatin) -SB - IM -MH - Adolescent -MH - Adult -MH - Aged -MH - Antibodies, Monoclonal/administration & dosage/pharmacology -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carboplatin/administration & dosage -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/*radiotherapy -MH - Chemoradiotherapy -MH - Child -MH - Child, Preschool -MH - Female -MH - Humans -MH - Infant -MH - Infant, Newborn -MH - Lung Neoplasms/*drug therapy/pathology/*radiotherapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Prospective Studies -MH - Young Adult -PMC - PMC7542352 -OTO - NOTNLM -OT - Carboplatin -OT - Chemoradiotherapy -OT - Durvalumab -OT - Elderly -OT - Immune checkpoint inhibitor -OT - Locally advanced non-small cell lung cancer -OT - PD-L1 antibody -OT - PS 2 -COIS- K. Kaira has received research grants and a speaker honorarium from Ono - Pharmaceutical Company, Boehringer Ingelheim, Chugai Pharmaceutical, Taiho - Pharmaceutical, Eli Lilly Japan and AstraZeneca. AM has received a speaker - honorarium from Eli Lilly, Taiho Pharmaceutical, Pfizer, Chugai Pharmaceutical - and AstraZeneca. KY has received a speaker honorarium from AstraZeneca. HK has - received research grants and a speaker honorarium from Ono Pharmaceutical - Company, Bristol-Myers Company, Boehringer Ingelheim, MSD, Daiichi Sankyo - Company, Chugai Pharmaceutical, Taiho Pharmaceutical, Merck Biopharma Company, - Eli Lilly Japan and AstraZeneca. K. Kobayashi has received research grants and a - speaker honorarium from Boehringer Ingelheim, AstraZeneca and Bristol-Myers - Company. SK has no conflicts of interest. -EDAT- 2020/10/08 06:00 -MHDA- 2021/04/23 06:00 -PMCR- 2020/10/06 -CRDT- 2020/10/07 05:32 -PHST- 2020/04/03 00:00 [received] -PHST- 2020/09/14 00:00 [accepted] -PHST- 2020/10/07 05:32 [entrez] -PHST- 2020/10/08 06:00 [pubmed] -PHST- 2021/04/23 06:00 [medline] -PHST- 2020/10/06 00:00 [pmc-release] -AID - 10.1186/s12885-020-07406-y [pii] -AID - 7406 [pii] -AID - 10.1186/s12885-020-07406-y [doi] -PST - epublish -SO - BMC Cancer. 2020 Oct 6;20(1):961. doi: 10.1186/s12885-020-07406-y. - -PMID- 27923550 -OWN - NLM -STAT- MEDLINE -DCOM- 20180309 -LR - 20181202 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Print) -IS - 1525-7304 (Linking) -VI - 18 -IP - 3 -DP - 2017 May -TI - Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide - Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced - Non-Small-Cell Lung Cancer (RTOG 3505). -PG - 333-339 -LID - S1525-7304(16)30352-7 [pii] -LID - 10.1016/j.cllc.2016.10.009 [doi] -AB - Radiation Therapy Oncology Group (RTOG) 3505 is a randomized phase 3 study of - concurrent chemoradiation followed by immune checkpoint inhibitor therapy or - placebo in patients with locally advanced non-small-cell lung cancer (NSCLC). - Patients with surgically unresectable stage 3 NSCLC will receive thoracic - radiotherapy to 60 Gy with concurrent cisplatin 50 mg/m(2) intravenously (I.V.) - on days 1, 8, 29, and 36, and etoposide 50 mg/m(2) I.V. on days 1 to 5 and days - 29 to 33. Between 4 and 12 weeks after completion of concurrent chemoradiation, - eligible patients will be randomized to the anti-programmed death 1 (PD-1) - monoclonal antibody nivolumab 240 mg I.V. or placebo every 2 weeks for up to 1 - year. The primary end points are overall survival (OS) and progression-free - survival (PFS), as determined by central independent radiology review. Secondary - objectives include toxicity assessment, patient-reported outcomes and quality of - life, and OS and PFS in programmed death ligand 1 (PD-L1) expressors (≥ 1%) and - PD-L1 nonexpressors (< 1%). Assuming a rate of 16.7% due to ineligibility and - dropout before randomization, a total of 660 patients will be enrolled to ensure - 550 patients will be randomized after completion of chemoradiation. This sample - size will provide ≥ 90% power to detect a hazard ratio of 0.7 for OS with 2-sided - type I error of 0.04, and to detect a hazard ratio of 0.667 for PFS 2-sided type - I error of 0.01. (NCT02768558). -CI - Copyright © 2016 Elsevier Inc. All rights reserved. -FAU - Gerber, David E -AU - Gerber DE -AD - Harold C. Simmons Comprehensive Cancer Center at University of Texas Southwestern - Medical Center, Dallas, TX. Electronic address: david.gerber@utsouthwestern.edu. -FAU - Urbanic, James J -AU - Urbanic JJ -AD - University of California San Diego, San Diego, CA. -FAU - Langer, Corey -AU - Langer C -AD - University of Pennsylvania, Philadelphia, PA. -FAU - Hu, Chen -AU - Hu C -AD - Johns Hopkins University, Baltimore, MD; RTOG Foundation, Philadelphia, PA. -FAU - Chang, I-Fen -AU - Chang IF -AD - Bristol-Myers Squibb, New York, NY. -FAU - Lu, Bo -AU - Lu B -AD - Thomas Jefferson University, Philadelphia, PA. -FAU - Movsas, Benjamin -AU - Movsas B -AD - Henry Ford Hospital, Detroit, MI. -FAU - Jeraj, Robert -AU - Jeraj R -AD - University of Wisconsin Carbone Cancer Center, Madison, WI. -FAU - Curran, Walter J -AU - Curran WJ -AD - Emory University Medical Center, Atlanta, GA. -FAU - Bradley, Jeffrey D -AU - Bradley JD -AD - Washington University School of Medicine, St. Louis, Mo. -LA - eng -SI - ClinicalTrials.gov/NCT02768558 -GR - K24 CA201543/CA/NCI NIH HHS/United States -GR - U10 CA180833/CA/NCI NIH HHS/United States -GR - U10 CA180870/CA/NCI NIH HHS/United States -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Randomized Controlled Trial -DEP - 20161026 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Antibodies, Monoclonal) -RN - 31YO63LBSN (Nivolumab) -RN - 6PLQ3CP4P3 (Etoposide) -RN - Q20Q21Q62J (Cisplatin) -SB - IM -CIN - J Thorac Dis. 2017 Oct;9(10):3525-3528. doi: 10.21037/jtd.2017.09.12. PMID: - 29268332 -CIN - J Thorac Dis. 2017 Dec;9(12):4908-4911. doi: 10.21037/jtd.2017.11.103. PMID: - 29312689 -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/mortality/*therapy -MH - *Chemoradiotherapy -MH - Cisplatin/*therapeutic use -MH - Combined Modality Therapy -MH - Etoposide/*therapeutic use -MH - Humans -MH - Immunotherapy/*methods -MH - Lung Neoplasms/mortality/*therapy -MH - Middle Aged -MH - Neoplasm Staging -MH - Nivolumab -MH - Placebo Effect -MH - Proportional Hazards Models -MH - Research Design -MH - Survival Analysis -MH - Young Adult -PMC - PMC5406261 -MID - NIHMS825595 -OTO - NOTNLM -OT - Abscopal effect -OT - Checkpoint inhibitor -OT - Coprimary end points -OT - Immunotherapy -OT - Programmed death 1 (PD-1) -EDAT- 2016/12/08 06:00 -MHDA- 2018/03/10 06:00 -PMCR- 2018/05/01 -CRDT- 2016/12/08 06:00 -PHST- 2016/10/13 00:00 [received] -PHST- 2016/10/18 00:00 [accepted] -PHST- 2016/12/08 06:00 [pubmed] -PHST- 2018/03/10 06:00 [medline] -PHST- 2016/12/08 06:00 [entrez] -PHST- 2018/05/01 00:00 [pmc-release] -AID - S1525-7304(16)30352-7 [pii] -AID - 10.1016/j.cllc.2016.10.009 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2017 May;18(3):333-339. doi: 10.1016/j.cllc.2016.10.009. Epub - 2016 Oct 26. - -PMID- 32449125 -OWN - NLM -STAT- MEDLINE -DCOM- 20210712 -LR - 20210712 -IS - 1699-3055 (Electronic) -IS - 1699-048X (Linking) -VI - 22 -IP - 12 -DP - 2020 Dec -TI - Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in - stage III non-small cell lung cancer treated with chemoradiotherapy. -PG - 2333-2340 -LID - 10.1007/s12094-020-02396-6 [doi] -AB - PURPOSE: Locally advanced non-small cell lung cancer (LA-NSCLC) is frequently - treated with chemoradiotherapy (CRT). Despite the efforts, long-term outcomes are - poor, and novel therapies have been introduced to improve results. Biomarkers are - needed to detect early treatment failure and plan future follow-up and therapies. - Our aim is to evaluate the role of dynamics of neutrophil-to-lymphocyte ratio - (NLR) in patients with locally advanced NSCLC treated with CRT. METHODS: We - retrospectively reviewed patients diagnosed with LA-NSCLC receiving definitive - CRT at our center from 2010 to 2015. Baseline and post-treatment NLR were - collected from our center database. NLR was dichotomized (threshold = 4) and - patients were divided into two groups based on the variation from baseline to - post-treatment NLR. The prognostic role and association with response were - examined with logistic regression and multivariate Cox regression model, - respectively. RESULTS: Ninety-two patients were included. Our analysis shows that - NLR after treatment is associated with response to treatment [OR in the - multivariate analysis 4.94 (1.01-24.48); p value = 0.048]. Furthermore, NLR and - ECOG are independent prognostic factors for progression-free survival (PFS) and - overall survival (OS). Specifically, PFS was 25.79 months for the good prognosis - group and 12.09 for the poor prognosis group [HR 2.98 (CI 95% = 1.74-5.10), - p < 0.001]; and OS was 42.94 months and 18.86 months, respectively [HR 2.81 (CI - 95% = 1.62-4.90), p < 0.001]. CONCLUSION: Dynamics of NLR have a prognostic value - in stage III NSCLC treated with definitive CRT. Pre- and post-CRT NLR should be - evaluated in prospective clinical trials involving consolidation treatment with - immunotherapy. -FAU - Palomar-Abril, V -AU - Palomar-Abril V -AUID- ORCID: 0000-0002-6753-7377 -AD - Department of Medical Oncology, Hospital Universitario Doctor Peset, Comunitat - Valenciana, 46017, Valencia, Spain. vicente.palomar.abril@gmail.com. -FAU - Soria-Comes, T -AU - Soria-Comes T -AUID- ORCID: 0000-0003-1125-7824 -AD - Department of Medical Oncology, Hospital Universitario Doctor Peset, Comunitat - Valenciana, 46017, Valencia, Spain. -FAU - Campos, S T -AU - Campos ST -AUID- ORCID: 0000-0001-5346-1407 -AD - Department of Applied Statistics, Operations Research and Quality, Universitat - Politècnica de València, Comunitat Valenciana, Valencia, Spain. -FAU - Ureste, M M -AU - Ureste MM -AD - Department of Medical Oncology, Hospital Universitario Doctor Peset, Comunitat - Valenciana, 46017, Valencia, Spain. -FAU - Bosch, V G -AU - Bosch VG -AUID- ORCID: 0000-0003-1375-4461 -AD - Centre for Quality and Change Management, Universitat Politècnica de València, - Comunitat Valenciana, Valencia, Spain. -FAU - Maiques, I C M -AU - Maiques ICM -AUID- ORCID: 0000-0002-7901-0900 -AD - Department of Medical Oncology, Hospital Universitario Doctor Peset, Comunitat - Valenciana, 46017, Valencia, Spain. -LA - eng -PT - Journal Article -DEP - 20200524 -PL - Italy -TA - Clin Transl Oncol -JT - Clinical & translational oncology : official publication of the Federation of - Spanish Oncology Societies and of the National Cancer Institute of Mexico -JID - 101247119 -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*blood/mortality/pathology/therapy -MH - Chemoradiotherapy -MH - Female -MH - Humans -MH - Leukocyte Count -MH - Logistic Models -MH - Lung Neoplasms/*blood/mortality/pathology/therapy -MH - Lymphocyte Count -MH - Lymphocytes/*cytology -MH - Male -MH - Middle Aged -MH - Neutrophils/*cytology -MH - Prognosis -MH - Progression-Free Survival -MH - Proportional Hazards Models -MH - Retrospective Studies -MH - Treatment Outcome -OTO - NOTNLM -OT - Chemoradiotherapy -OT - Neutrophil-to-lymphocyte ratio -OT - Non-small cell lung cancer -OT - Stage III -OT - Survival outcomes -EDAT- 2020/05/26 06:00 -MHDA- 2021/07/13 06:00 -CRDT- 2020/05/26 06:00 -PHST- 2020/03/12 00:00 [received] -PHST- 2020/05/12 00:00 [accepted] -PHST- 2020/05/26 06:00 [pubmed] -PHST- 2021/07/13 06:00 [medline] -PHST- 2020/05/26 06:00 [entrez] -AID - 10.1007/s12094-020-02396-6 [pii] -AID - 10.1007/s12094-020-02396-6 [doi] -PST - ppublish -SO - Clin Transl Oncol. 2020 Dec;22(12):2333-2340. doi: 10.1007/s12094-020-02396-6. - Epub 2020 May 24. - -PMID- 32873573 -OWN - NLM -STAT- MEDLINE -DCOM- 20211123 -LR - 20211123 -IS - 1557-3265 (Electronic) -IS - 1078-0432 (Linking) -VI - 26 -IP - 20 -DP - 2020 Oct 15 -TI - Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of - Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical - Trial. -PG - 5368-5379 -LID - 10.1158/1078-0432.CCR-20-1141 [doi] -AB - PURPOSE: Non-small cell lung cancer (NSCLC) is a fatal disease with poor - prognosis. A membrane-bound form of Hsp70 (mHsp70) which is selectively expressed - on high-risk tumors serves as a target for mHsp70-targeting natural killer (NK) - cells. Patients with advanced mHsp70-positive NSCLC may therefore benefit from a - therapeutic intervention involving mHsp70-targeting NK cells. The randomized - phase II clinical trial (EudraCT2008-002130-30) explores tolerability and - efficacy of ex vivo-activated NK cells in patients with NSCLC after - radiochemotherapy (RCT). PATIENTS AND METHODS: Patients with unresectable, - mHsp70-positive NSCLC (stage IIIa/b) received 4 cycles of autologous NK cells - activated ex vivo with TKD/IL2 [interventional arm (INT)] after RCT (60-70 Gy, - platinum-based chemotherapy) or RCT alone [control arm (CTRL)]. The primary - objective was progression-free survival (PFS), and secondary objectives were the - assessment of quality of life (QoL, QLQ-LC13), toxicity, and immunobiological - responses. RESULTS: The NK-cell therapy after RCT was well tolerated, and no - differences in QoL parameters between the two study arms were detected. Estimated - 1-year probabilities for PFS were 67% [95% confidence interval (CI), 19%-90%] for - the INT arm and 33% (95% CI, 5%-68%) for the CTRL arm (P = 0.36, 1-sided log-rank - test). Clinical responses in the INT group were associated with an increase in - the prevalence of activated NK cells in their peripheral blood. CONCLUSIONS: Ex - vivo TKD/IL2-activated, autologous NK cells are well tolerated and deliver - positive clinical responses in patients with advanced NSCLC after RCT. -CI - ©2020 American Association for Cancer Research. -FAU - Multhoff, Gabriele -AU - Multhoff G -AD - Department Radiation Oncology, Klinikum rechts der Isar, TU München, (TUM), - Munich, Germany. gabriele.multhoff@tum.de. -AD - Radiation Immuno-Oncology, Center for Translational Cancer Research TUM - (TranslaTUM), Munich, Germany. -FAU - Seier, Sophie -AU - Seier S -AD - Department Radiation Oncology, Klinikum rechts der Isar, TU München, (TUM), - Munich, Germany. -FAU - Stangl, Stefan -AU - Stangl S -AD - Radiation Immuno-Oncology, Center for Translational Cancer Research TUM - (TranslaTUM), Munich, Germany. -FAU - Sievert, Wolfgang -AU - Sievert W -AD - Radiation Immuno-Oncology, Center for Translational Cancer Research TUM - (TranslaTUM), Munich, Germany. -FAU - Shevtsov, Maxim -AU - Shevtsov M -AUID- ORCID: 0000-0002-8539-2239 -AD - Radiation Immuno-Oncology, Center for Translational Cancer Research TUM - (TranslaTUM), Munich, Germany. -AD - Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg, - Russia. -FAU - Werner, Caroline -AU - Werner C -AD - Radiation Immuno-Oncology, Center for Translational Cancer Research TUM - (TranslaTUM), Munich, Germany. -FAU - Pockley, A Graham -AU - Pockley AG -AUID- ORCID: 0000-0001-9593-6431 -AD - John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, - United Kingdom; and multimmune GmbH, Munich, Germany. -FAU - Blankenstein, Christiane -AU - Blankenstein C -AD - Münchner Studienzentrum CCC, TUM, Munich, Germany. -FAU - Hildebrandt, Martin -AU - Hildebrandt M -AD - TUMCells, TUM School of Medicine, Munich, Germany. -FAU - Offner, Robert -AU - Offner R -AD - Department of Transfusion Medicine, University Hospital Regensburg, Regensburg, - Germany. -FAU - Ahrens, Norbert -AU - Ahrens N -AUID- ORCID: 0000-0002-4680-2688 -AD - Department of Transfusion Medicine, University Hospital Regensburg, Regensburg, - Germany. -FAU - Kokowski, Konrad -AU - Kokowski K -AD - Pneumology and Pneumologic Oncology, Klinikum Bogenhausen, Munich, Germany. -FAU - Hautmann, Matthias -AU - Hautmann M -AUID- ORCID: 0000-0002-1039-0677 -AD - Department of Radiation Oncology, University Hospital Regensburg, Regensburg, - Germany. -FAU - Rödel, Claus -AU - Rödel C -AD - Department of Radiotherapy and Oncology, Goethe University Frankfurt, Frankfurt, - Germany. -FAU - Fietkau, Rainer -AU - Fietkau R -AD - Department of Radiation Oncology, Friedrich-Alexander-Universität - Erlangen-Nürnberg (FAU), Erlangen, Germany. -FAU - Lubgan, Dorota -AU - Lubgan D -AUID- ORCID: 0000-0002-2569-3814 -AD - Department of Radiation Oncology, Friedrich-Alexander-Universität - Erlangen-Nürnberg (FAU), Erlangen, Germany. -FAU - Huber, Rudolf -AU - Huber R -AUID- ORCID: 0000-0001-7041-6368 -AD - Division of Respiratory Medicine and Thoracic Oncology Centre Munich and Thoracic - Oncology Centre Munich, University München, LMU, Munich, Germany. -FAU - Hautmann, Hubert -AU - Hautmann H -AUID- ORCID: 0000-0002-1039-0677 -AD - Pneumology Group Med I, Klinikum rechts der Isar, TUM, Munich, Germany. -FAU - Duell, Thomas -AU - Duell T -AD - Asklepios Lung Hospital München-Gauting, Thoracal Pneumology, LMU, Munich, - Germany. -FAU - Molls, Michael -AU - Molls M -AD - Department Radiation Oncology, Klinikum rechts der Isar, TU München, (TUM), - Munich, Germany. -FAU - Specht, Hanno -AU - Specht H -AD - Department Radiation Oncology, Klinikum rechts der Isar, TU München, (TUM), - Munich, Germany. -FAU - Haller, Bernhard -AU - Haller B -AD - Institute of Medical Informatics, Statistics and Epidemiology, TUM, Munich, - Germany. -FAU - Devecka, Michal -AU - Devecka M -AD - Department Radiation Oncology, Klinikum rechts der Isar, TU München, (TUM), - Munich, Germany. -FAU - Sauter, Andreas -AU - Sauter A -AUID- ORCID: 0000-0003-4394-862X -AD - Institute of Radiology, TUM, Munich, Germany. -FAU - Combs, Stephanie E -AU - Combs SE -AD - Department Radiation Oncology, Klinikum rechts der Isar, TU München, (TUM), - Munich, Germany. -AD - Institute of Radiation Medicine (IRM), Helmholtz Zentrum München (HMGU), - Neuherberg, Germany. -AD - Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site - Munich, Germany. -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20200901 -PL - United States -TA - Clin Cancer Res -JT - Clinical cancer research : an official journal of the American Association for - Cancer Research -JID - 9502500 -RN - 0 (HSP70 Heat-Shock Proteins) -RN - 49DFR088MY (Platinum) -SB - IM -MH - Adult -MH - Aged -MH - Carcinoma, Non-Small-Cell Lung/blood/*drug therapy/pathology/*radiotherapy -MH - *Chemoradiotherapy -MH - Combined Modality Therapy -MH - Female -MH - HSP70 Heat-Shock Proteins/*blood -MH - Humans -MH - Immunotherapy, Adoptive/adverse effects -MH - Killer Cells, Natural/drug effects/immunology/radiation effects -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Platinum/*administration & dosage/adverse effects -MH - Progression-Free Survival -EDAT- 2020/09/03 06:00 -MHDA- 2021/11/24 06:00 -CRDT- 2020/09/03 06:00 -PHST- 2020/03/27 00:00 [received] -PHST- 2020/05/15 00:00 [revised] -PHST- 2020/07/21 00:00 [accepted] -PHST- 2020/09/03 06:00 [pubmed] -PHST- 2021/11/24 06:00 [medline] -PHST- 2020/09/03 06:00 [entrez] -AID - 1078-0432.CCR-20-1141 [pii] -AID - 10.1158/1078-0432.CCR-20-1141 [doi] -PST - ppublish -SO - Clin Cancer Res. 2020 Oct 15;26(20):5368-5379. doi: - 10.1158/1078-0432.CCR-20-1141. Epub 2020 Sep 1. - -PMID- 32281272 -OWN - NLM -STAT- MEDLINE -DCOM- 20210311 -LR - 20210311 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 11 -IP - 6 -DP - 2020 Jun -TI - Consolidation treatment of durvalumab after chemoradiation in real-world patients - with stage III unresectable non-small cell lung cancer. -PG - 1541-1549 -LID - 10.1111/1759-7714.13426 [doi] -AB - BACKGROUND: Treatment for stage III non-small cell lung cancer (NSCLC) of - unresectable disease mainly involves concurrent chemoradiation (CRT). Post-CRT - consolidation treatment with durvalumab is a major therapeutic advance that - provides survival benefit in this group of patients. However, the performance of - this treatment strategy remains to be studied in a real-world setting. METHODS: A - total of 31 patients who had disease control post-CRT were included in the - durvalumab early access program (EAP) as an intent-to-treat cohort and - retrospectively reviewed for post-CRT progression-free survival (PFS) and time to - metastatic disease or death (TMDD). The neutrophil-to-lymphocyte ratio (NLR) at - the initiation of durvalumab was analyzed in 29 patients. RESULTS: The median - time from the completion of concurrent CRT to the initiation of durvalumb was 2.8 - months. The objective response was 25.8% and the 12 month PFS and TMDD-free rate - were 56.4% and 66.9%, respectively. The low NLR patients showed a significantly - longer post-CRT PFS (not reach vs. 12.0 months [95% CI: 5.5-not estimable]; P = - 0.040; the hazard ratio for disease progression or death, 0.23 [95% CI: - 0.05-1.00]; P = 0.048) and the 12 month post-CRT PFS rate (82.5 vs. 42.6%). The - post-CRT TMDD (not reach vs. 12.6 months, [95% CI: 10.8-not estimable]; P = - 0.010; the hazard ratio for distant metastasis or death, 0.11 [95% CI: - 0.01-0.88]; P = 0.037) and 12 month post-CRT TMDD-free rate (90.9 vs. 57.1%) were - also significantly higher in the low NLR patients. CONCLUSIONS: Durvalumab - consolidation treatment in real-world patients showed substantial efficacy and - the correlation with the NLR level warrants further investigation. -CI - © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Chu, Chia-Hsun -AU - Chu CH -AD - Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung - Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan City, - Taiwan. -AD - Thoracic Oncology Unit, Chang Gung Memorial Hospital Cancer Center, Taoyuan City, - Taiwan. -FAU - Chiu, Tzu-Hsuan -AU - Chiu TH -AD - Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung - Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan City, - Taiwan. -AD - Thoracic Oncology Unit, Chang Gung Memorial Hospital Cancer Center, Taoyuan City, - Taiwan. -FAU - Wang, Chin-Chou -AU - Wang CC -AD - Division of Pulmonary & Critical Care Medicine, Kaohsiung Chang Gung Memorial - Hospital, Kaohsiung, Taiwan. -FAU - Chang, Wen-Chen -AU - Chang WC -AD - Thoracic Oncology Unit, Chang Gung Memorial Hospital Cancer Center, Taoyuan City, - Taiwan. -AD - Department of Medical Oncology, Chang Gung Memorial Hospital, Chang Gung - University, Taoyuan City, Taiwan. -FAU - Huang, Allen Chung-Cheng -AU - Huang AC -AD - Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung - Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan City, - Taiwan. -AD - Thoracic Oncology Unit, Chang Gung Memorial Hospital Cancer Center, Taoyuan City, - Taiwan. -FAU - Liu, Chien-Ying -AU - Liu CY -AD - Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung - Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan City, - Taiwan. -AD - Thoracic Oncology Unit, Chang Gung Memorial Hospital Cancer Center, Taoyuan City, - Taiwan. -FAU - Wang, Chih-Liang -AU - Wang CL -AD - Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung - Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan City, - Taiwan. -AD - Thoracic Oncology Unit, Chang Gung Memorial Hospital Cancer Center, Taoyuan City, - Taiwan. -FAU - Ko, Ho-Wen -AU - Ko HW -AD - Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung - Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan City, - Taiwan. -AD - Thoracic Oncology Unit, Chang Gung Memorial Hospital Cancer Center, Taoyuan City, - Taiwan. -FAU - Chung, Fu-Tsai -AU - Chung FT -AD - Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung - Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan City, - Taiwan. -AD - Thoracic Oncology Unit, Chang Gung Memorial Hospital Cancer Center, Taoyuan City, - Taiwan. -FAU - Hsu, Ping-Chih -AU - Hsu PC -AUID- ORCID: 0000-0003-0173-7509 -AD - Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung - Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan City, - Taiwan. -AD - Thoracic Oncology Unit, Chang Gung Memorial Hospital Cancer Center, Taoyuan City, - Taiwan. -FAU - Guo, Yi-Ke -AU - Guo YK -AD - Data Science Institute, Department of Computing, Imperial College London, London, - UK. -FAU - Kuo, Chih-Hsi S -AU - Kuo CS -AUID- ORCID: 0000-0003-3309-937X -AD - Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung - Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan City, - Taiwan. -AD - Thoracic Oncology Unit, Chang Gung Memorial Hospital Cancer Center, Taoyuan City, - Taiwan. -AD - Data Science Institute, Department of Computing, Imperial College London, London, - UK. -FAU - Yang, Cheng-Ta -AU - Yang CT -AD - Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung - Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan City, - Taiwan. -AD - Thoracic Oncology Unit, Chang Gung Memorial Hospital Cancer Center, Taoyuan City, - Taiwan. -LA - eng -GR - CORPG3J0331/Chang Gung Medical Foundation/International -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20200413 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Biomarkers, Tumor) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Adenocarcinoma of Lung/drug therapy/*mortality/pathology -MH - Aged -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antineoplastic Agents, Immunological/therapeutic use -MH - Biomarkers, Tumor/*analysis -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/*mortality/pathology -MH - Carcinoma, Squamous Cell/drug therapy/*mortality/pathology -MH - Chemoradiotherapy/*mortality -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Lung Neoplasms/drug therapy/*mortality/pathology -MH - Lymphocytes/pathology -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Neutrophils/pathology -MH - Retrospective Studies -MH - *Salvage Therapy -MH - Survival Rate -PMC - PMC7262925 -OTO - NOTNLM -OT - Chemoradiation -OT - consolidation -OT - durvalumab -EDAT- 2020/04/14 06:00 -MHDA- 2021/03/12 06:00 -PMCR- 2020/06/01 -CRDT- 2020/04/14 06:00 -PHST- 2020/02/16 00:00 [received] -PHST- 2020/03/18 00:00 [revised] -PHST- 2020/03/20 00:00 [accepted] -PHST- 2020/04/14 06:00 [pubmed] -PHST- 2021/03/12 06:00 [medline] -PHST- 2020/04/14 06:00 [entrez] -PHST- 2020/06/01 00:00 [pmc-release] -AID - TCA13426 [pii] -AID - 10.1111/1759-7714.13426 [doi] -PST - ppublish -SO - Thorac Cancer. 2020 Jun;11(6):1541-1549. doi: 10.1111/1759-7714.13426. Epub 2020 - Apr 13. - -PMID- 38390854 -OWN - NLM -STAT- MEDLINE -DCOM- 20240325 -LR - 20240325 -IS - 1532-4192 (Electronic) -IS - 0735-7907 (Linking) -VI - 42 -IP - 2 -DP - 2024 Feb -TI - NGS-based Tissue-Blood TMB Comparison and Blood-TMB Monitoring in Stage-III - Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. -PG - 165-175 -LID - 10.1080/07357907.2024.2316297 [doi] -AB - In this study, we analyzed the blood-based TMB (b-TMB) and its dynamic changes in - patients with locally advanced non-small cell lung cancer (LA-NSCLC) who received - concurrent chemoradiotherapy. Baseline tissue and blood TMB from 15 patients - showed a strong positive correlation (Pearson correlation = 0.937), and nearly - all mutations were markedly reduced in the later course of treatment, indicating - a treatment-related response. This study suggests that in patients with LA-NSCLC, - b-TMB is a reliable biomarker, and its dynamic monitoring can help distinguish - patients who might benefit most from the consolidated immunotherapy. -FAU - Ye, Luxi -AU - Ye L -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Chu, Xiao -AU - Chu X -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Ni, Jianjiao -AU - Ni J -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Chu, Li -AU - Chu L -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Yang, Xi -AU - Yang X -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Zhu, Zhengfei -AU - Zhu Z -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -AD - Institute of Thoracic Oncology, Fudan University, Shanghai, China. -LA - eng -PT - Journal Article -DEP - 20240223 -PL - England -TA - Cancer Invest -JT - Cancer investigation -JID - 8307154 -RN - 0 (Biomarkers) -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - *Lung Neoplasms/drug therapy/genetics -MH - Biomarkers -MH - Mutation -MH - Chemoradiotherapy -MH - Biomarkers, Tumor/genetics -OTO - NOTNLM -OT - CtDNA -OT - NSCLC -OT - TMB -OT - chemoradiotherapy -OT - immunotherapy -EDAT- 2024/02/23 12:42 -MHDA- 2024/03/25 06:42 -CRDT- 2024/02/23 07:58 -PHST- 2024/03/25 06:42 [medline] -PHST- 2024/02/23 12:42 [pubmed] -PHST- 2024/02/23 07:58 [entrez] -AID - 10.1080/07357907.2024.2316297 [doi] -PST - ppublish -SO - Cancer Invest. 2024 Feb;42(2):165-175. doi: 10.1080/07357907.2024.2316297. Epub - 2024 Feb 23. - -PMID- 32759049 -OWN - NLM -STAT- MEDLINE -DCOM- 20210527 -LR - 20210527 -IS - 1878-1705 (Electronic) -IS - 1567-5769 (Linking) -VI - 87 -DP - 2020 Oct -TI - The relative and absolute benefit of programmed death receptor-1 vs programmed - death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic - review and meta-analysis. -PG - 106852 -LID - S1567-5769(20)31682-9 [pii] -LID - 10.1016/j.intimp.2020.106852 [doi] -AB - INTRODUCTION: Programmed death receptor-1 (PD-1) and its ligand (PD-L1) - inhibitors have shown promising results in treating advanced non-small-cell lung - cancer (NSCLC). Our objective was to compare the relative and absolute benefits - between PD-1 and PD-L1 inhibitors in advanced NSCLC. MATERIALS AND METHODS: - PubMed, EMBASE and the Cochrane Library were searched up to Dec 1, 2019, for - randomized controlled trials of PD-1/PD-L1 inhibitors that had available overall - survival (OS) data in NSCLC. Random-effects models were used to calculate the - pooled estimates. RESULTS: Twenty-three randomized controlled trials (15,797 - patients) of PD-1/PD-L1 inhibitors were included in the analysis. PD-1 inhibitors - significantly extended OS compared with standard of care therapy (difference in - means, 4.80 months, 95% CI 3.41-6.18; HR 0.72, 95% CI 0.66-0.78; P < 0.01 for - both). PD-L1 inhibitors also significantly improved OS compared with standard of - care therapy (difference in means, 2.59 months 95% CI 1.47-3.71; HR 0.83, 95% CI - 0.79-0.88; P < 0.01 for both). More importantly, PD-1 inhibitors had - significantly higher OS than PD-L1 inhibitors (difference in means, P = 0.015; - HR, P = 0.006). The same increased OS benefit was observed in patients with PD-L1 - ≥1% (P = 0.035) and PD-L1 <1% (P = 0.007). However, OS did not differ between - PD-1 and PD-L1 inhibitors in patients with an EGFR mutation-positive status - (P = 0.724) and who were never smokers (P = 0.999). CONCLUSIONS: PD-1 inhibitors - showed superior relative and absolute OS benefits compared with PD-L1 inhibitors - in the treatment of advanced NSCLC. These findings have implications for - treatment selection in current clinical practice and future study design. -CI - Copyright © 2020 Elsevier B.V. All rights reserved. -FAU - Yi, Kun -AU - Yi K -AD - Department of Lymphoma and Hematology, Jiangxi Cancer Hospital of Nanchang - University, Nanchang, People's Republic of China. -FAU - Zhu, Qian -AU - Zhu Q -AD - Department of Intensive Care Unit, Sun Yat-sen University Cancer Center, - Guangzhou, People's Republic of China. -FAU - Kuang, Yu-Kang -AU - Kuang YK -AD - Department of Thoracic Surgery, Jiangxi Cancer Hospital of Nanchang University, - Nanchang, People's Republic of China. -FAU - Jiang, Si-Cong -AU - Jiang SC -AD - Department of Thoracic Surgery, Jiangxi Cancer Hospital of Nanchang University, - Nanchang, People's Republic of China. Electronic address: jiangsicong666@163.com. -FAU - Hu, Hao -AU - Hu H -AD - Department of Radiation Therapy, General Hospital of Southern Theater Command of - Chinese People's Liberation Army, Guangzhou, People's Republic of China. - Electronic address: qianhe89513@163.com. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Systematic Review -DEP - 20200803 -PL - Netherlands -TA - Int Immunopharmacol -JT - International immunopharmacology -JID - 100965259 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Lung Neoplasms/*drug therapy/immunology -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -MH - Randomized Controlled Trials as Topic -OTO - NOTNLM -OT - Meta-analysis -OT - Non-small-cell lung cancer -OT - Overall survival -OT - Programmed death ligand 1 -OT - Programmed death receptor-1 -COIS- Declaration of Competing Interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2020/08/08 06:00 -MHDA- 2021/05/28 06:00 -CRDT- 2020/08/08 06:00 -PHST- 2020/05/24 00:00 [received] -PHST- 2020/07/07 00:00 [revised] -PHST- 2020/07/26 00:00 [accepted] -PHST- 2020/08/08 06:00 [pubmed] -PHST- 2021/05/28 06:00 [medline] -PHST- 2020/08/08 06:00 [entrez] -AID - S1567-5769(20)31682-9 [pii] -AID - 10.1016/j.intimp.2020.106852 [doi] -PST - ppublish -SO - Int Immunopharmacol. 2020 Oct;87:106852. doi: 10.1016/j.intimp.2020.106852. Epub - 2020 Aug 3. - -PMID- 32779372 -OWN - NLM -STAT- MEDLINE -DCOM- 20210812 -LR - 20210812 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 11 -IP - 10 -DP - 2020 Oct -TI - Adverse impact of bone metastases on clinical outcomes of patients with advanced - non-small cell lung cancer treated with immune checkpoint inhibitors. -PG - 2812-2819 -LID - 10.1111/1759-7714.13597 [doi] -AB - BACKGROUND: Bone metastasis (BoM) is common in patients with advanced non-small - cell lung cancer (NSCLC) and considered as one of the negative prognostic - factors. However, the impact of BoM on clinical outcomes of patients with - advanced NSCLC treated with immune checkpoint inhibitors (ICIs) remains unclear. - METHODS: A total of 103 patients treated with ICI monotherapy and 101 patients - treated with ICIs combined with chemotherapy or antiangiogenesis therapy were - retrospectively analyzed. The differences in progression-free survival (PFS), - overall survival (OS) and objective response rate (ORR) between BoM+ and BoM- - were investigated. RESULTS: Of those 101 patients who received combination - therapy, no significant difference between BoM- and BoM+ in terms of both median - PFS and median OS (median PFS, 10.1 vs. 12.1 months, P = 0.6; median OS, NR vs. - 24.6 months, P = 0.713) was determined. In contrast, of the 103 patients who - received ICI monotherapy, BoM+ patients had an inferior PFS (4.2 vs. 6.7 months, - P = 0.0484) and OS (12.5 vs. 23.9 months, P = 0.0036) compared with BoM- - patients. The univariate and multivariate analysis in the ICI monotherapy group - also identified BoM as an independent factor attenuating the efficacy of ICI - monotherapy. Of all BoM+ patients who received ICI monotherapy, neither - palliative radiotherapy nor bisphosphonate drugs improved OS (palliative - radiotherapy: 12.5 vs. 16.7 months, P = 0.487; bisphosphonate drugs: 12.5 vs. - 9.7 months, P = 0.568). CONCLUSIONS: BoM attenuated the efficacy of ICI - monotherapy in patients with advanced NSCLC. Of BoM+ patients who received ICI - monotherapy, neither palliative radiotherapy nor bisphosphonate drugs improved - OS. Other therapeutic strategies are needed for patients with BoM. -CI - © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Li, Xing -AU - Li X -AUID- ORCID: 0000-0002-6892-6737 -AD - Medical Oncology Department, Tongji University School of Medicine Affiliated - Shanghai Pulmonary Hospital, Shanghai, China. -AD - Department of Immuno-oncology, Fourth Hospital of Hebei Medical University, - Shijiazhuang, China. -FAU - Wang, Lei -AU - Wang L -AD - Medical Oncology Department, Tongji University School of Medicine Affiliated - Shanghai Pulmonary Hospital, Shanghai, China. -FAU - Chen, Shanhao -AU - Chen S -AD - Medical Oncology Department, Tongji University School of Medicine Affiliated - Shanghai Pulmonary Hospital, Shanghai, China. -FAU - Zhou, Fei -AU - Zhou F -AUID- ORCID: 0000-0002-5865-0052 -AD - Medical Oncology Department, Tongji University School of Medicine Affiliated - Shanghai Pulmonary Hospital, Shanghai, China. -FAU - Zhao, Jing -AU - Zhao J -AD - Medical Oncology Department, Tongji University School of Medicine Affiliated - Shanghai Pulmonary Hospital, Shanghai, China. -FAU - Zhao, Wencheng -AU - Zhao W -AD - Medical Oncology Department, Tongji University School of Medicine Affiliated - Shanghai Pulmonary Hospital, Shanghai, China. -FAU - Su, Chunxia -AU - Su C -AD - Medical Oncology Department, Tongji University School of Medicine Affiliated - Shanghai Pulmonary Hospital, Shanghai, China. -LA - eng -GR - 81874036 81703020 81702865/National Natural Science Foundation of - China/International -PT - Journal Article -DEP - 20200811 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Aged -MH - Bone Neoplasms/*secondary -MH - Carcinoma, Non-Small-Cell Lung/*complications/*drug therapy/pathology -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology/*therapeutic use -MH - Lung Neoplasms/*complications/*drug therapy/pathology -MH - Male -MH - Neoplasm Metastasis -MH - Retrospective Studies -MH - Treatment Outcome -PMC - PMC7529562 -OTO - NOTNLM -OT - Bone metastasis -OT - immune checkpoint inhibitor -OT - non-small cell lung cancer -OT - outcomes -EDAT- 2020/08/12 06:00 -MHDA- 2021/08/13 06:00 -PMCR- 2020/10/01 -CRDT- 2020/08/12 06:00 -PHST- 2020/05/27 00:00 [received] -PHST- 2020/07/09 00:00 [revised] -PHST- 2020/07/12 00:00 [accepted] -PHST- 2020/08/12 06:00 [pubmed] -PHST- 2021/08/13 06:00 [medline] -PHST- 2020/08/12 06:00 [entrez] -PHST- 2020/10/01 00:00 [pmc-release] -AID - TCA13597 [pii] -AID - 10.1111/1759-7714.13597 [doi] -PST - ppublish -SO - Thorac Cancer. 2020 Oct;11(10):2812-2819. doi: 10.1111/1759-7714.13597. Epub 2020 - Aug 11. - -PMID- 31704279 -OWN - NLM -STAT- MEDLINE -DCOM- 20210204 -LR - 20210204 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 139 -DP - 2020 Jan -TI - Hyper-progressive disease in a patient with advanced non-small cell lung cancer - on immune checkpoint inhibitor therapy: A case report and literature review. -PG - 18-21 -LID - S0169-5002(19)30707-X [pii] -LID - 10.1016/j.lungcan.2019.10.026 [doi] -AB - OBJECTIVES: While immune checkpoint inhibitor (ICI) therapy has excellent - efficacy in treating multiple cancers, some patients experience accelerated - disease progression, defined as hyper-progressive disease (HPD). However, the - characteristics of HPD, especially in patients with non-small-cell lung cancer - (NSCLC), remain to be elucidated. MATERIALS AND METHODS: We report about an - advanced NSCLC patient with striking disease progression, defined as HPD by - existing standards, after the administration of pembrolizumab. We also reviewed - related studies to discuss the definition, relative factors, and prognosis of - HPD. RESULTS AND CONCLUSION: This case of NSCLC with HPD had a series of - characteristics not widely described in HPD cases previously reported, suggesting - the potential complexity of this phenomenon and the necessity to study its - characteristics and to more closely monitor patients who are administered ICIs. -CI - Copyright © 2019 Elsevier B.V. All rights reserved. -FAU - Zhang, Dongxiao -AU - Zhang D -AD - School of Medicine, Shandong University, Jinan, Shandong, China; Department of - Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, - Jinan, Shandong, China. -FAU - Zhang, Yan -AU - Zhang Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong - University, Jinan, Shandong, China. -FAU - Huang, Yong -AU - Huang Y -AD - Department of Radiology, Shandong Cancer Hospital Affiliated to Shandong - University, Jinan, Shandong, China. -FAU - Kong, Li -AU - Kong L -AD - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong - University, Jinan, Shandong, China. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong - University, Jinan, Shandong, China. Electronic address: sdyujinming@163.com. -LA - eng -PT - Case Reports -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20191031 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Immune Checkpoint Inhibitors) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Adult -MH - Antibodies, Monoclonal, Humanized/*adverse effects -MH - Antineoplastic Agents, Immunological/*adverse effects -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Disease Progression -MH - Drug-Related Side Effects and Adverse Reactions/etiology/*pathology -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/*adverse effects -MH - Lung Neoplasms/*drug therapy/pathology -MH - Prognosis -OTO - NOTNLM -OT - Checkpoint inhibitor -OT - Hyper-progressive disease -OT - Immunotherapy -OT - Non-small-cell lung cancer -EDAT- 2019/11/11 06:00 -MHDA- 2021/02/05 06:00 -CRDT- 2019/11/10 06:00 -PHST- 2018/06/13 00:00 [received] -PHST- 2019/10/16 00:00 [revised] -PHST- 2019/10/24 00:00 [accepted] -PHST- 2019/11/11 06:00 [pubmed] -PHST- 2021/02/05 06:00 [medline] -PHST- 2019/11/10 06:00 [entrez] -AID - S0169-5002(19)30707-X [pii] -AID - 10.1016/j.lungcan.2019.10.026 [doi] -PST - ppublish -SO - Lung Cancer. 2020 Jan;139:18-21. doi: 10.1016/j.lungcan.2019.10.026. Epub 2019 - Oct 31. - -PMID- 38635049 -OWN - NLM -STAT- MEDLINE -DCOM- 20240619 -LR - 20240808 -IS - 1439-099X (Electronic) -IS - 0179-7158 (Linking) -VI - 200 -IP - 7 -DP - 2024 Jul -TI - [Radiotherapy plus durvalumab for the treatment of locally advanced non-small - cell lung cancer-The DOLPHIN trial]. -PG - 646-648 -LID - 10.1007/s00066-024-02231-9 [doi] -FAU - Trommer, Maike -AU - Trommer M -AD - Klinik und Poliklinik für Radioonkologie, Cyberknife- und Strahlentherapie, - Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), - Medizinische Fakultät und Universitätsklinikum Köln, Köln, Deutschland. - maike.trommer@uk-koeln.de. -AD - Department of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research - Centre, Austin Health, Melbourne, Australien. maike.trommer@uk-koeln.de. -AD - Center for Molecular Medicine Cologne (CMMC), Universitätsklinikum Köln, Köln, - Deutschland. maike.trommer@uk-koeln.de. -LA - ger -PT - Clinical Trial, Phase II -PT - Controlled Clinical Trial -PT - Journal Article -PT - Multicenter Study -TT - Radiotherapie plus Durvalumab beim lokal fortgeschrittenen NSCLC: die - DOLPHIN-Studie. -DEP - 20240418 -PL - Germany -TA - Strahlenther Onkol -JT - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et - al] -JID - 8603469 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Aged -MH - Female -MH - Humans -MH - Male -MH - Middle Aged -MH - *Antibodies, Monoclonal/therapeutic use -MH - Antineoplastic Agents, Immunological/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/radiotherapy/therapy/drug therapy/pathology -MH - *Chemoradiotherapy -MH - *Lung Neoplasms/radiotherapy/pathology/therapy/drug therapy -MH - Neoplasm Staging -EDAT- 2024/04/18 12:44 -MHDA- 2024/06/20 00:42 -CRDT- 2024/04/18 11:13 -PHST- 2024/03/21 00:00 [accepted] -PHST- 2024/06/20 00:42 [medline] -PHST- 2024/04/18 12:44 [pubmed] -PHST- 2024/04/18 11:13 [entrez] -AID - 10.1007/s00066-024-02231-9 [pii] -AID - 10.1007/s00066-024-02231-9 [doi] -PST - ppublish -SO - Strahlenther Onkol. 2024 Jul;200(7):646-648. doi: 10.1007/s00066-024-02231-9. - Epub 2024 Apr 18. - -PMID- 35144339 -OWN - NLM -STAT- MEDLINE -DCOM- 20220214 -LR - 20220214 -IS - 0376-2491 (Print) -IS - 0376-2491 (Linking) -VI - 102 -IP - 6 -DP - 2022 Feb 15 -TI - [Expression and prognostic value of programmed cell death ligand 1 in patients - with locally advanced and non-EGFR-mutated non-small cell lung cancer receiving - concurrent chemoradiotherapy]. -PG - 406-411 -LID - 10.3760/cma.j.cn112137-20211002-02207 [doi] -AB - Objective: To explore the expression of programmed cell death ligand 1 (PD-L1) in - patients with locally advanced and non-EGFR-mutated non-small cell lung cancer - (LA-NSCLC) undergoing concurrent chemoradiotherapy (cCRT) and its association - with clinical outcome of patients. Methods: The basic clinical information of 19 - patients with unresectable, non-EGFR mutated LA-NSCLC receiving radical cCRT in - Cancer Hospital Chinese Academy of Medical Sciences from January 2016 to December - 2017 was retrospectively analyzed. The rabbit monoclonal antibody SP263 was used - for immunohistochemical analysis to detect the expression of PD-L1 in LA-NSCLC - tissues and the tumor proportion score (TPS) equal to or greater than 1% was - defined as PD-L1 positive. The associations between PD-L1 ≥1% and PD-L1 ≥25% with - the clinical characteristics and clinical outcome of LA-NSCLC patients were - evaluated respectively. Results: Among 19 LA-NSCLC patients, 13 had PD-L1 - positive expression, and 4 had PD-L1 expression greater than or equal to 25%. No - significant difference was observed between patients with PD-L1 positive and - negative expressions regarding the distribution of age, smoking history, - pathological classification, and TNM staging (P>0.05). A total of 15 patients - could be evaluated for therapeutic effect, including 7 patients with partial - response (PR), 7 patients with stable disease (SD), and 1 patient with - progressive disease (PD). In the group with PD-L1 expression<1%, 3 patients were - in objective response, and 4 patients were in disease control. In the group with - PD-L1 expression ≥1%, 4 patients were in objective response, and 10 patients were - in disease control. When the PD-L1 expression was less than 25%, 6 patients - gained the objective response, and 11 patients gained the disease control. When - the PD-L1 expression was greater than or equal to 25%, 1 patient gained the - objective response, and 3 patients gained the disease control. The median overall - survival (OS) was 35 (95%CI: 12.7-57.3) months for patients with PD-L1 ≥1% and 40 - (95%CI: not reaching the end point) months for patients with PD-L1<1% (P=0.284). - Patients with PD-L1 ≥25% had a median survival time of 12 (95%CI:0.0-34.5) - months, and patients with PD-L1<25% had a median survival time of 40 (95%CI: - 27.4-52.6) months (P=0.241). Conclusions: The prognosis of LA-NSCLC patients with - PD-L1 positive and no-EGFR mutation receiving concurrent chemoradiation has a - trend of poor prognosis. A larger sample size study is warranted to explore the - prognostic value of PD-L1 expression in inoperable LA-NSCLC patients and to - further explore the effect of immunotherapy on patients with different PD-L1 - expression levels. -FAU - Xue, W J -AU - Xue WJ -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing 100021, China. -FAU - Bi, N -AU - Bi N -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing 100021, China. -FAU - Yang, L -AU - Yang L -AD - Department of Pathology, National Cancer Center/National Clinical Research Center - for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing 100021, China. -FAU - Wang, X -AU - Wang X -AD - Department of Pathology, National Cancer Center/National Clinical Research Center - for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing 100021, China. -FAU - Dong, J Y -AU - Dong JY -AD - Department of Pathology, National Cancer Center/National Clinical Research Center - for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing 100021, China. -FAU - Zhang, T -AU - Zhang T -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing 100021, China. -FAU - Wu, L F -AU - Wu LF -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing 100021, China. -FAU - Wang, L H -AU - Wang LH -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy - of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China. -LA - chi -GR - SZSM201612063/the Sanming Project of Medicine in Shenzhen/ -PT - Journal Article -PL - China -TA - Zhonghua Yi Xue Za Zhi -JT - Zhonghua yi xue za zhi -JID - 7511141 -RN - 0 (B7-H1 Antigen) -RN - 0 (Ligands) -SB - IM -MH - Apoptosis -MH - B7-H1 Antigen/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/genetics/therapy -MH - Chemoradiotherapy -MH - Humans -MH - Ligands -MH - *Lung Neoplasms/drug therapy/therapy -MH - Prognosis -MH - Retrospective Studies -EDAT- 2022/02/11 06:00 -MHDA- 2022/02/15 06:00 -CRDT- 2022/02/10 21:42 -PHST- 2022/02/10 21:42 [entrez] -PHST- 2022/02/11 06:00 [pubmed] -PHST- 2022/02/15 06:00 [medline] -AID - 10.3760/cma.j.cn112137-20211002-02207 [doi] -PST - ppublish -SO - Zhonghua Yi Xue Za Zhi. 2022 Feb 15;102(6):406-411. doi: - 10.3760/cma.j.cn112137-20211002-02207. - -PMID- 38238648 -OWN - NLM -STAT- MEDLINE -DCOM- 20240122 -LR - 20240202 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 24 -IP - 1 -DP - 2024 Jan 18 -TI - Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for - advanced non-small cell lung cancer: a multicenter, retrospective real-world - study. -PG - 107 -LID - 10.1186/s12885-024-11860-3 [doi] -LID - 107 -AB - BACKGROUND: Paclitaxel liposome (Lipusu) is known to be effective in non-small - cell lung cancer (NSCLC) as first-line treatment. This study aimed to evaluate - the effectiveness and safety of paclitaxel liposome based chemotherapy plus - PD-1/PD-L1 inhibitor in patients with advanced NSCLC. METHODS: In this - multicenter, retrospective, real-world study, patients with advanced NSCLC who - were administered paclitaxel liposome based chemotherapy plus PD-1/PD-L1 - inhibitor in three centers (Peking University People's Hospital as the lead - center) in China between 2016 and 2022 were included. Progression-free survival - (PFS), overall survival (OS), objective response rate, disease control rate, and - adverse events (AEs) were evaluated. RESULTS: A total of 49 patients were - included, with 33 (67.3%) receiving paclitaxel liposome based chemotherapy plus - PD-1/PD-L1 inhibitor as first-line treatment. There were 34 patients (69.4%) - diagnosed with squamous cell carcinoma and 15 (30.6%) with adenocarcinoma. The - median follow-up was 20.5 (range: 3.1-41.1) months. The median PFS and OS of all - patients were 9.7 months (95% confidence interval [CI], 7.0-12.4) and 30.5 months - (95% CI, not evaluable-not evaluable), respectively. Patients with squamous cell - carcinoma and adenocarcinoma had median PFS of 11 months (95%CI, 6.5-15.5) and - 9.3 months (95%CI, 7.0-12.4), respectively. The median PFS was 9.9 months (95%CI, - 7.1-12.7) in patients who received the combined regimen as first-line treatment. - Treatment-related AEs of any grade were observed in 25 (51.0%) patients, and AEs - of grade 3 or worse were observed in nine patients (18.4%). The most common - treatment-related AEs were myelosuppression (14.3%) and fever (10.2%). - CONCLUSIONS: Paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor - prolonged the PFS in advanced NSCLC with acceptable safety, which was worthy of - clinical application. -CI - © 2024. The Author(s). -FAU - Li, Ran -AU - Li R -AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking - University People's Hospital, No.11 Xizhimen South Street, Xicheng District, - 100044, Beijing, China. -FAU - Liang, Hongge -AU - Liang H -AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking - University People's Hospital, No.11 Xizhimen South Street, Xicheng District, - 100044, Beijing, China. -FAU - Li, Jun -AU - Li J -AD - Department of Oncology, The First Affiliated Hospital of Nanjing Medical - University, 210029, Nanjing, China. -FAU - Shao, Zhenyu -AU - Shao Z -AD - Department of Radiation Oncology, Qilu Hospital of Shandong University, 250012, - Jinan, China. -FAU - Yang, Donghong -AU - Yang D -AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking - University People's Hospital, No.11 Xizhimen South Street, Xicheng District, - 100044, Beijing, China. -FAU - Bao, Jing -AU - Bao J -AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking - University People's Hospital, No.11 Xizhimen South Street, Xicheng District, - 100044, Beijing, China. -FAU - Wang, Keqiang -AU - Wang K -AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking - University People's Hospital, No.11 Xizhimen South Street, Xicheng District, - 100044, Beijing, China. -FAU - Xi, Wen -AU - Xi W -AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking - University People's Hospital, No.11 Xizhimen South Street, Xicheng District, - 100044, Beijing, China. -FAU - Gao, Zhancheng -AU - Gao Z -AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking - University People's Hospital, No.11 Xizhimen South Street, Xicheng District, - 100044, Beijing, China. -FAU - Guo, Renhua -AU - Guo R -AD - Department of Oncology, The First Affiliated Hospital of Nanjing Medical - University, 210029, Nanjing, China. -FAU - Mu, Xinlin -AU - Mu X -AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking - University People's Hospital, No.11 Xizhimen South Street, Xicheng District, - 100044, Beijing, China. xinlin169@163.com. -LA - eng -PT - Journal Article -PT - Multicenter Study -DEP - 20240118 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - P88XT4IS4D (Paclitaxel) -RN - 0 (Liposomes) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - Paclitaxel -MH - *Lung Neoplasms/pathology -MH - Liposomes -MH - Immune Checkpoint Inhibitors/adverse effects -MH - Programmed Cell Death 1 Receptor/therapeutic use -MH - Retrospective Studies -MH - Immunotherapy/adverse effects -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - *Adenocarcinoma/drug therapy -MH - *Carcinoma, Squamous Cell/drug therapy -PMC - PMC10797919 -OTO - NOTNLM -OT - Immune checkpoint inhibitor -OT - Immunotherapy -OT - Non-small cell lung cancer -OT - Paclitaxel liposome -COIS- The authors declare no competing interests. -EDAT- 2024/01/19 00:42 -MHDA- 2024/01/22 06:43 -PMCR- 2024/01/18 -CRDT- 2024/01/18 23:33 -PHST- 2023/06/03 00:00 [received] -PHST- 2023/12/20 00:00 [accepted] -PHST- 2024/01/22 06:43 [medline] -PHST- 2024/01/19 00:42 [pubmed] -PHST- 2024/01/18 23:33 [entrez] -PHST- 2024/01/18 00:00 [pmc-release] -AID - 10.1186/s12885-024-11860-3 [pii] -AID - 11860 [pii] -AID - 10.1186/s12885-024-11860-3 [doi] -PST - epublish -SO - BMC Cancer. 2024 Jan 18;24(1):107. doi: 10.1186/s12885-024-11860-3. - -PMID- 31200833 -OWN - NLM -STAT- MEDLINE -DCOM- 20200305 -LR - 20200305 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 133 -DP - 2019 Jul -TI - Safety evaluation of nivolumab added concurrently to radiotherapy in a standard - first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The - ETOP NICOLAS trial. -PG - 83-87 -LID - S0169-5002(19)30441-6 [pii] -LID - 10.1016/j.lungcan.2019.05.001 [doi] -AB - OBJECTIVES: Chemo-radiotherapy (CRT) and concurrent PD-1 inhibition has shown - promising results in pre-clinical models. So far, the feasibility of delivering - concurrent CRT and PD-1/PD-L1 inhibition has never been assessed in a clinical - trial. MATERIAL AND METHODS: NICOLAS is a phase-II trial evaluating the safety - and efficacy of nivolumab combined with CRT in stage III NSCLC. Patients received - 3 cycles of platinum-based chemotherapy and concurrent RT (66 Gy/33fractions). - Nivolumab started concurrently with RT. The primary endpoint was 6-month post-RT - rate of grade-≥3-pneumonitis. A formal interim safety analysis (IA) was scheduled - when the first 21 patients reached 3 months follow-up post-RT. An early positive - safety conclusion would be reached at IA if there were no grade ≥3-pneumonitis in - those patients. Efficacy evaluation was planned provided the safety conclusion - was reached. RESULTS AND CONCLUSION: As of 13 December 2018, 82 patients were - recruited with median follow-up of 13.4 months. The most frequent adverse events - (AEs) were anaemia, fatigue and pneumonitis. No unexpected AEs or increased - toxicities were observed. For the first 21 patients, no grade-≥3-pneumonitis was - observed by the end of the 3-month post-RT follow-up period. The early safety IA - provides evidence that the addition of nivolumab to concurrent CRT is safe and - tolerable regarding the 6-month rate of pneumonitis grade ≥3 at the one-sided - significance level of 5%. Following that, the 1-year progression-free survival - will be evaluated in an expanded patient cohort. NICOLAS trial creates the - opportunity for assessing the activity of the combination of checkpoint with - concurrent CRT in larger prospective trials for locally advanced NSCLC. -CI - Copyright © 2019 Elsevier B.V. All rights reserved. -FAU - Peters, S -AU - Peters S -AD - Centre Hospitalier Universitaire Vaudois (CHUV), Département d'Oncologie, - Lausanne, Switzerland. -FAU - Felip, E -AU - Felip E -AD - Vall d'Hebron University Hospital, Institute of Oncology (VHIO), Barcelona, - Spain. -FAU - Dafni, U -AU - Dafni U -AD - Frontier Science Foundation-Hellas & National and Kapodistrian University of - Athens, Greece. -FAU - Belka, C -AU - Belka C -AD - Department of Radiation Oncology and DZL Munich, University Hospital, LMU Munich, - Germany. -FAU - Guckenberger, M -AU - Guckenberger M -AD - University Hospital Zurich, Department for Radiation Oncology, University of - Zurich, Switzerland. -FAU - Irigoyen, A -AU - Irigoyen A -AD - Hospital Virgen De La Salud, Department of Medical Oncology, Toledo, Spain. -FAU - Nadal, E -AU - Nadal E -AD - Catalan Institute of Oncology, Department of Medical Oncology, IDIBELL - L'Hospitalet, Barcelona, Spain. -FAU - Becker, A -AU - Becker A -AD - Amsterdam University Medical Center, Department of Respiratory Diseases, - Amsterdam, the Netherlands. -FAU - Vees, H -AU - Vees H -AD - Clinic Hirslanden, Radiation Oncology, Zürich, Switzerland. -FAU - Pless, M -AU - Pless M -AD - Cantonal Hospital Winterthur, Medical Oncology, Winterthur, Switzerland. -FAU - Martinez-Marti, A -AU - Martinez-Marti A -AD - Vall d'Hebron University Hospital, Institute of Oncology (VHIO), Barcelona, - Spain. -FAU - Tufman, A -AU - Tufman A -AD - Ludwig Maximilian University of Munich (LMU), Medizinische Klinik and Poliklinik - V, German Center for Lung Research, Munich, Germany. -FAU - Lambrecht, M -AU - Lambrecht M -AD - University Hospitals Gasthuisberg, Department of Radiotherapy-Oncology, Leuven, - Belgium. -FAU - Andratschke, N -AU - Andratschke N -AD - University Hospital Zurich, Department for Radiation Oncology, University of - Zurich, Switzerland. -FAU - Piguet, A C -AU - Piguet AC -AD - European Thoracic Oncology Platform (ETOP), Bern, Switzerland. -FAU - Kassapian, M -AU - Kassapian M -AD - Frontier Science Foundation-Hellas, Athens, Greece. -FAU - Roschitzki-Voser, H -AU - Roschitzki-Voser H -AD - European Thoracic Oncology Platform (ETOP), Bern, Switzerland. -FAU - Rabaglio-Poretti, M -AU - Rabaglio-Poretti M -AD - European Thoracic Oncology Platform (ETOP), Bern, Switzerland. -FAU - Stahel, R A -AU - Stahel RA -AD - University Hospital Zurich, Department of Haematology and Oncology, Switzerland. -FAU - Vansteenkiste, J -AU - Vansteenkiste J -AD - University Hospitals Gasthuisberg, Department of Respiratory Diseases, Leuven, - Belgium. -FAU - De Ruysscher, D -AU - De Ruysscher D -AD - Maastro Clinic, Department of Radiation Oncology Maastricht, the Netherlands. - Electronic address: dirk.deruysscher@maastro.nl. -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20190503 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Platinum Compounds) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Adult -MH - Aged -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/radiotherapy -MH - Chemoradiotherapy -MH - Cohort Studies -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/mortality/radiotherapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Nivolumab/*therapeutic use -MH - Platinum Compounds/*therapeutic use -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - Survival Analysis -MH - Treatment Outcome -OTO - NOTNLM -OT - Cancer immunotherapy -OT - Chemotherapy -OT - Combination treatment -OT - Immune checkpoint inhibitors -OT - NSCLC -OT - Nivolumab -OT - Non-small cell lung cancer -OT - PD-1 inhibitor -OT - Radiotherapy -EDAT- 2019/06/16 06:00 -MHDA- 2020/03/07 06:00 -CRDT- 2019/06/16 06:00 -PHST- 2019/03/17 00:00 [received] -PHST- 2019/04/25 00:00 [revised] -PHST- 2019/05/03 00:00 [accepted] -PHST- 2019/06/16 06:00 [entrez] -PHST- 2019/06/16 06:00 [pubmed] -PHST- 2020/03/07 06:00 [medline] -AID - S0169-5002(19)30441-6 [pii] -AID - 10.1016/j.lungcan.2019.05.001 [doi] -PST - ppublish -SO - Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 - May 3. - -PMID- 30577837 -OWN - NLM -STAT- MEDLINE -DCOM- 20191014 -LR - 20240413 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 6 -IP - 1 -DP - 2018 Dec 22 -TI - Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy - for first-line treatment in advanced non-small cell lung carcinoma: a systematic - review and meta-analysis. -PG - 155 -LID - 10.1186/s40425-018-0477-9 [doi] -LID - 155 -AB - BACKGROUND: Immune-checkpoint inhibitors plus chemotherapy are emerging as - effective first-line treatment in advanced non-small-cell lung carcinoma (NSCLC), - but little is known about the magnitude of benefits and potential clinical - predictors. METHODS: We performed a meta-analysis of randomized trials that - compared PD-1/PD-L1 inhibitor plus chemotherapy with chemotherapy in first line - of treatment for advanced NSCLC. The outcomes included progression-free survival - (PFS), overall survival (OS), objective response rate (ORR) and treatment-related - adverse events (AEs). A fixed-effect or random-effects model was adopted - depending on between-study heterogeneity. RESULTS: Six trials involving 3144 - patients were included. PD-1/PD-L1 inhibitor plus chemotherapy was significantly - associated with improvement of PFS (hazards ratio [HR], 0.62; 95% CI 0.57-0.67; - P < .001), OS (HR, 0.68; 95% CI 0.53-0.87; P = .002) and ORR (relative ratio - [RR], 1.56; 95% CI 1.29-1.89; P < .001), irrespective of PD-L1 expression level. - The significant predictor(s) for treatment benefit with combination therapy - versus chemotherapy alone were PD-L1 expression level for PFS (P < .001); types - of checkpoint inhibitor for ORR (P < .001); histology (P = .025), age (P = .038), - gender (P < .001), and types of checkpoint inhibitor (P < .001) for OS. In safety - analyses, PD-1/PD-L1 inhibitor plus chemotherapy had significantly higher - incidence of adverse events (AEs) of grade 3 or higher (RR, 1.14; P = .007), AEs - leading to treatment discontinuation (RR, 1.29; P = .022), serious AEs (RR 1.70; - P = .006), immune mediated AEs of any grade (RR, 2.37; P < .001), and immune - mediated AEs of grade 3 or higher (RR, 3.71; P < .001). CONCLUSIONS: PD-1/PD-L1 - inhibitor plus chemotherapy, compared with chemotherapy, is associated with - significantly improved PFS, ORR, and OS in first-line therapy in NSCLC, at the - expense of increased treatment-related AEs. -FAU - Zhou, Yixin -AU - Zhou Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of VIP region, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Chen, Chen -AU - Chen C -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, - China. -FAU - Zhang, Xuanye -AU - Zhang X -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. -FAU - Fu, Sha -AU - Fu S -AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene - Regulation, Pathology Department, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen - University, Guangzhou, China. -FAU - Xue, Cong -AU - Xue C -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. -FAU - Ma, Yuxiang -AU - Ma Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. -FAU - Fang, Wenfeng -AU - Fang W -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. -FAU - Yang, Yunpeng -AU - Yang Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. -FAU - Hou, Xue -AU - Hou X -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. -FAU - Huang, Yan -AU - Huang Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. -FAU - Zhao, Hongyun -AU - Zhao H -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. -FAU - Hong, Shaodong -AU - Hong S -AUID- ORCID: 0000-0002-5632-6857 -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. - hongshd@sysucc.org.cn. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. - hongshd@sysucc.org.cn. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. hongshd@sysucc.org.cn. -FAU - Zhang, Li -AU - Zhang L -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. - zhangli6@mail.sysu.edu.cn. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. - zhangli6@mail.sysu.edu.cn. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. zhangli6@mail.sysu.edu.cn. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Research Support, Non-U.S. Gov't -PT - Systematic Review -DEP - 20181222 -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -RN - 0 (CD274 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antineoplastic Agents, Immunological/administration & dosage/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors -MH - Biomarkers, Tumor -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/metabolism/pathology -MH - Clinical Trials as Topic -MH - Humans -MH - Lung Neoplasms/*drug therapy/immunology/metabolism/pathology -MH - *Molecular Targeted Therapy -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - Treatment Outcome -PMC - PMC6303974 -OTO - NOTNLM -OT - Chemotherapy -OT - Immune checkpoint inhibitor -OT - Non-small cell lung carcinoma -OT - Predict -OT - Programmed death 1 -OT - Programmed death 1 ligand 1 -COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR - PUBLICATION: Not applicable. COMPETING INTERESTS: Li Zhang has received research - support from AstraZeneca, Eli Lilly and company, and Roche. No other disclosures - were reported. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to - jurisdictional claims in published maps and institutional affiliations. -EDAT- 2018/12/24 06:00 -MHDA- 2019/10/15 06:00 -PMCR- 2018/12/22 -CRDT- 2018/12/23 06:00 -PHST- 2018/08/15 00:00 [received] -PHST- 2018/12/06 00:00 [accepted] -PHST- 2018/12/23 06:00 [entrez] -PHST- 2018/12/24 06:00 [pubmed] -PHST- 2019/10/15 06:00 [medline] -PHST- 2018/12/22 00:00 [pmc-release] -AID - 10.1186/s40425-018-0477-9 [pii] -AID - 477 [pii] -AID - 10.1186/s40425-018-0477-9 [doi] -PST - epublish -SO - J Immunother Cancer. 2018 Dec 22;6(1):155. doi: 10.1186/s40425-018-0477-9. - -PMID- 6303542 -OWN - NLM -STAT- MEDLINE -DCOM- 19830708 -LR - 20161123 -IS - 0008-428X (Print) -IS - 0008-428X (Linking) -VI - 26 -IP - 3 -DP - 1983 May -TI - Symposium on the diagnosis and treatment of common cancers. 1. Lung cancer--1983. -PG - 266-8 -AB - The frequency of lung cancer, common in both men and women, seems to be - increasing rapidly, particularly in women. The main causative factor appears to - be cigarette smoking. Diagnosis and staging have not changed notably in the last - few years, although the advent of computerized tomography and gallium scanning - have been of some help in identifying mediastinal tumours, which are - unresectable. Further refinements in these techniques may allow us to avoid - mediastinoscopy but, at present, this is still usually necessary before operation - for lung cancer. Operation is the major form of therapy for non-small cell cancer - when this is medically and technically possible. Adjuvant therapy in the - treatment of this type of lung cancer has so far been of little help. - Radiotherapy as primary treatment, although occasionally curative, should be used - only if patients refuse operation or clearly have medical contraindications for - thoracotomy. Radiotherapy is very useful for palliation. Chemotherapy is of - little value in treating advanced, non-small cell lung cancer, although responses - can be seen in up to 40% of patients. This does not translate into important, - long-term survival, but responders do survive longer than non-responders. - Patients with small cell lung cancer should be treated with combination - chemotherapy, with or without thoracic irradiation and with or without cranial - irradiation. The latter two modalities have not yet been proved to prolong - survival, but may reduce the morbidity. Immunotherapy has not been shown to - benefit those with non-small cell lung cancer. Thymosin was beneficial in one - controlled trial in patients with small cell lung cancer, but this must be - confirmed. In the future, many new approaches will be necessary to control or - eradicate this steadily increasing cause of cancer death. -FAU - Feld, R -AU - Feld R -LA - eng -PT - Comparative Study -PT - Journal Article -PL - Canada -TA - Can J Surg -JT - Canadian journal of surgery. Journal canadien de chirurgie -JID - 0372715 -RN - 0 (Antineoplastic Agents) -SB - IM -MH - Antineoplastic Agents/therapeutic use -MH - Biopsy, Needle -MH - *Carcinoma, Small Cell/diagnosis/radiotherapy/surgery -MH - Female -MH - Humans -MH - Lung/diagnostic imaging/surgery -MH - *Lung Neoplasms/diagnosis/radiotherapy/surgery -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Radiography -EDAT- 1983/05/01 00:00 -MHDA- 1983/05/01 00:01 -CRDT- 1983/05/01 00:00 -PHST- 1983/05/01 00:00 [pubmed] -PHST- 1983/05/01 00:01 [medline] -PHST- 1983/05/01 00:00 [entrez] -PST - ppublish -SO - Can J Surg. 1983 May;26(3):266-8. - -PMID- 32807654 -OWN - NLM -STAT- MEDLINE -DCOM- 20211011 -LR - 20220125 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Print) -IS - 1525-7304 (Linking) -VI - 21 -IP - 6 -DP - 2020 Nov -TI - Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After - Chemoradiation in Patients With Unresectable Stage III Non-Squamous - Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research - Group (E6508). -PG - 520-526 -LID - S1525-7304(20)30189-3 [pii] -LID - 10.1016/j.cllc.2020.06.007 [doi] -AB - INTRODUCTION: Although chemoradiotherapy (CRT) is the standard of care for - patients with unresectable stage III non-small-cell lung cancer (LA-NSCLC), most - patients relapse. Tecemotide is a MUC1 antigen-specific cancer immunotherapy - vaccine. Bevacizumab improves survival in advanced nonsquamous (NS)-NSCLC and has - a role in immune modulation. This phase II trial tested the combination of - tecemotide and bevacizumab following CRT in patients with LA-NSCLC. PATIENTS AND - METHODS: Subjects with stage III NS-NSCLC suitable for CRT received - carboplatin/paclitaxel weekly + 66 Gy followed by 2 cycles of consolidation - carboplatin/paclitaxel ≤ 4 weeks of completion of CRT (Step 1). Patients with - partial response/stable disease after consolidation therapy were registered onto - step 2, which was 6 weekly tecemotide injections followed by every 6 weekly - injections and bevacizumab every 3 weeks for up to 34 doses. The primary endpoint - was to determine the safety of this regimen. RESULTS: Seventy patients were - enrolled; 68 patients (median age, 63 years; 56% male; 57% stage IIIA) initiated - therapy, but only 39 patients completed CRT and consolidation therapy per - protocol, primarily owing to disease progression or toxicity. Thirty-three - patients (median age, 61 years; 58% male; 61% stage IIIA) were registered to step - 2 (tecemotide + bevacizumab). The median number of step 2 cycles received was 11 - (range, 2-25). Step 2 worst toxicity included grade 3, N = 9; grade 4, N = 1; and - grade 5, N = 1. Grade 5 toxicity in step 2 was esophageal perforation attributed - to bevacizumab. Among the treated and eligible patients (n = 32) who were treated - on step 2, the median overall survival was 42.7 months (95% confidence interval, - 21.7-63.3 months), and the median progression-free survival was 14.9 months (95% - confidence interval, 11.0-20.9 months) from step 1 registration. CONCLUSIONS: - This cooperative group trial met its endpoint, demonstrating tolerability of - bevacizumab + tecemotide after CRT and consolidation. In this selected group of - patients, the median progression-free survival and overall survival are - encouraging. Given that consolidation immunotherapy is now a standard of care - following CRT in patients with LA-NSCLC, these results support a role for - continued investigation of antiangiogenic and immunotherapy combinations in - LA-NSCLC. -CI - Copyright © 2020 Elsevier Inc. All rights reserved. -FAU - Patel, Jyoti D -AU - Patel JD -AD - Division of Hematology/Oncology, Northwestern University, Chicago, IL. Electronic - address: jd-patel@northwestern.edu. -FAU - Lee, Ju-Whei -AU - Lee JW -AD - Data Science, Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, - Boston, MA. -FAU - Carbone, David P -AU - Carbone DP -AD - Department of Medicine, Ohio State University Comprehensive Cancer Center, - Columbus, OH. -FAU - Wagner, Henry -AU - Wagner H -AD - Department of Radiation Oncology, Penn State Cancer Institute, Hersey, PA. -FAU - Shanker, Anil -AU - Shanker A -AD - Department of Biochemistry and Cancer Biology, Meharry Medical College, - Nashville, TN. -FAU - de Aquino, Maria Teresa P -AU - de Aquino MTP -AD - Department of Biochemistry and Cancer Biology, Meharry Medical College, - Nashville, TN. -FAU - Horn, Leora -AU - Horn L -AD - Department of Medicine, Vanderbilt University, Nashville, TN. -FAU - Johnson, Melissa L -AU - Johnson ML -AD - Department of Medicine, Sarah Cannon Research Institute, Nashville, TN. -FAU - Gerber, David E -AU - Gerber DE -AD - Department of Medicine, UT Southwestern/Simmons Cancer Center, Dallas, TX. -FAU - Liu, Jane Jijun -AU - Liu JJ -AD - Illinois Cancer Care, Peoria, IL. -FAU - Das, Millie S -AU - Das MS -AD - Department of Medicine, VA Palo Alto Health Care, Palo Alto, CA. -FAU - Al-Nsour, Mohammed Ali -AU - Al-Nsour MA -AD - Mercy Cancer Centers, Toledo, OH. -FAU - Dakhil, Christopher S R -AU - Dakhil CSR -AD - Wichita NCORP, Wichita, KS. -FAU - Ramalingam, Suresh -AU - Ramalingam S -AD - Department of Medicine, Emory University, Atlanta, GA. -FAU - Schiller, Joan H -AU - Schiller JH -AD - Inova Cancer Institute, Fairfax, VA. -LA - eng -GR - UG1 CA189873/CA/NCI NIH HHS/United States -GR - SC1 CA182843/CA/NCI NIH HHS/United States -GR - U24 CA196172/CA/NCI NIH HHS/United States -GR - R01 CA175370/CA/NCI NIH HHS/United States -GR - UG1 CA233302/CA/NCI NIH HHS/United States -GR - UG1 CA189830/CA/NCI NIH HHS/United States -GR - UG1 CA233327/CA/NCI NIH HHS/United States -GR - U10 CA180820/CA/NCI NIH HHS/United States -GR - U10 CA180870/CA/NCI NIH HHS/United States -GR - K24 CA201543/CA/NCI NIH HHS/United States -GR - UG1 CA233270/CA/NCI NIH HHS/United States -GR - UG1 CA233331/CA/NCI NIH HHS/United States -GR - UG1 CA233247/CA/NCI NIH HHS/United States -GR - UG1 CA189808/CA/NCI NIH HHS/United States -GR - U10 CA180794/CA/NCI NIH HHS/United States -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20200612 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Cancer Vaccines) -RN - 0 (L-BLP25) -RN - 0 (Membrane Glycoproteins) -RN - 2S9ZZM9Q9V (Bevacizumab) -RN - BG3F62OND5 (Carboplatin) -RN - P88XT4IS4D (Paclitaxel) -SB - IM -MH - Adenocarcinoma of Lung/*drug therapy/immunology/pathology -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Bevacizumab/administration & dosage -MH - Cancer Vaccines/administration & dosage -MH - Carboplatin/administration & dosage -MH - Carcinoma, Large Cell/*drug therapy/immunology/pathology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/pathology -MH - Chemoradiotherapy/*methods -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Immunotherapy/*methods -MH - Lung Neoplasms/*drug therapy/immunology/pathology -MH - Male -MH - Membrane Glycoproteins/administration & dosage -MH - Middle Aged -MH - Paclitaxel/administration & dosage -MH - Prognosis -MH - Survival Rate -PMC - PMC7606595 -MID - NIHMS1622760 -OTO - NOTNLM -OT - Angiogenesis -OT - Locally advanced NSCLC -OT - Radiation -OT - Vaccine -EDAT- 2020/08/19 06:00 -MHDA- 2021/10/12 06:00 -PMCR- 2021/11/01 -CRDT- 2020/08/19 06:00 -PHST- 2020/02/24 00:00 [received] -PHST- 2020/05/19 00:00 [revised] -PHST- 2020/06/04 00:00 [accepted] -PHST- 2020/08/19 06:00 [pubmed] -PHST- 2021/10/12 06:00 [medline] -PHST- 2020/08/19 06:00 [entrez] -PHST- 2021/11/01 00:00 [pmc-release] -AID - S1525-7304(20)30189-3 [pii] -AID - 10.1016/j.cllc.2020.06.007 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2020 Nov;21(6):520-526. doi: 10.1016/j.cllc.2020.06.007. Epub - 2020 Jun 12. - -PMID- 29336998 -OWN - NLM -STAT- MEDLINE -DCOM- 20190308 -LR - 20220408 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 19 -IP - 3 -DP - 2018 May -TI - Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell - Lung Cancer Patients Treated With Nivolumab. -PG - 280-288.e4 -LID - S1525-7304(17)30346-7 [pii] -LID - 10.1016/j.cllc.2017.12.007 [doi] -AB - INTRODUCTION: Despite significant improvement of clinical outcomes of advanced - non-small-cell lung cancer (NSCLC) patients treated with immunotherapy, our - knowledge of optimal biomarkers is still limited. PATIENTS AND METHODS: We - retrospectively evaluated 159 advanced NSCLC patients in our institution treated - with nivolumab after disease progression during platinum-based chemotherapy. We - correlated several variables with progression-free survival (PFS) to develop the - immunotherapy, Sex, Eastern Cooperative Oncology Group performance status, - Neutrophil-to-lymphocyte ratio (NLR), and Delta NLR (iSEND) model. We categorized - patients into iSEND good, intermediate, and poor risk groups and evaluated their - clinical outcomes. Performance of iSEND at 3, 6, 9, and 12 months was evaluated - according to receiver operating characteristic (ROC) curves and internally - validated using bootstrapping. The association of iSEND risk groups with clinical - benefit was evaluated using logistic regression. RESULTS: Median follow-up was - 11.5 months (95% confidence interval [CI], 9.4-13.1). There were 50 deaths and 43 - with disease progression without death. PFS rates at 3, 6, 9, and 12 months were - 78.4%, 63.7%, 55.3%, and 52.2% in iSEND good; 79.4%, 44.3%, 25.9%, and 19.2% in - iSEND intermediate; and 65%, 25.9%, 22.8%, and 17.8% in iSEND poor. - Time-dependent area under ROC curves of iSEND for PFS at 3, 6, 9, and 12 months - were 0.718, 0.74, 0.746, and 0.774. The iSEND poor group was significantly - associated with progressive disease at 12 ± 2 weeks (odds ratio, 9.59; 95% CI, - 3.8-26.9; P < .0001). CONCLUSION: The iSEND model is an algorithmic model that - can characterize clinical outcomes of advanced NSCLC patients receiving nivolumab - into good, intermediate, or poor risk groups and might be useful as a predictive - model if validated independently. -CI - Copyright © 2017 Elsevier Inc. All rights reserved. -FAU - Park, Wungki -AU - Park W -AD - Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller - School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, - Miami, FL. Electronic address: wungkipark@gmail.com. -FAU - Kwon, Deukwoo -AU - Kwon D -AD - Biostatistics and Bioinformatics Core, Sylvester Comprehensive Cancer Center, - Miami, FL. -FAU - Saravia, Diana -AU - Saravia D -AD - Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller - School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, - Miami, FL. -FAU - Desai, Amrita -AU - Desai A -AD - Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller - School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, - Miami, FL. -FAU - Vargas, Fernando -AU - Vargas F -AD - Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller - School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, - Miami, FL. -FAU - El Dinali, Mohamed -AU - El Dinali M -AD - Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller - School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, - Miami, FL. -FAU - Warsch, Jessica -AU - Warsch J -AD - Department of Radiology, Miller School of Medicine, University of Miami, - Sylvester Comprehensive Cancer Center, Miami, FL. -FAU - Elias, Roy -AU - Elias R -AD - Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller - School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, - Miami, FL. -FAU - Chae, Young Kwang -AU - Chae YK -AD - Developmental Therapeutics Program of Division of Hematology Oncology, Feinberg - School of Medicine, Northwestern University, Chicago, IL. -FAU - Kim, Dae Won -AU - Kim DW -AD - Division of Medical Oncology, Department of Medical Oncology, Moffitt Cancer - Center, Tampa, FL. -FAU - Warsch, Sean -AU - Warsch S -AD - Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller - School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, - Miami, FL. -FAU - Ishkanian, Adrian -AU - Ishkanian A -AD - Department of Radiation Oncology, Miller School of Medicine, University of Miami, - Sylvester Comprehensive Cancer Center, Miami, FL. -FAU - Ikpeazu, Chukwuemeka -AU - Ikpeazu C -AD - Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller - School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, - Miami, FL. -FAU - Mudad, Raja -AU - Mudad R -AD - Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller - School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, - Miami, FL. -FAU - Lopes, Gilberto -AU - Lopes G -AD - Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller - School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, - Miami, FL. -FAU - Jahanzeb, Mohammad -AU - Jahanzeb M -AD - Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller - School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, - Miami, FL. -LA - eng -PT - Journal Article -DEP - 20171221 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - *Algorithms -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality -MH - Female -MH - *Health Status Indicators -MH - Humans -MH - Lung Neoplasms/*drug therapy/mortality -MH - Male -MH - Middle Aged -MH - Nivolumab/*therapeutic use -MH - Progression-Free Survival -MH - Proportional Hazards Models -MH - Treatment Outcome -OTO - NOTNLM -OT - Advanced non-small cell lung cancer -OT - Algorithm -OT - Biomarker model -OT - Clinical outcome -OT - Immunotherapy -EDAT- 2018/01/18 06:00 -MHDA- 2019/03/09 06:00 -CRDT- 2018/01/17 06:00 -PHST- 2017/09/22 00:00 [received] -PHST- 2017/11/29 00:00 [revised] -PHST- 2017/12/17 00:00 [accepted] -PHST- 2018/01/18 06:00 [pubmed] -PHST- 2019/03/09 06:00 [medline] -PHST- 2018/01/17 06:00 [entrez] -AID - S1525-7304(17)30346-7 [pii] -AID - 10.1016/j.cllc.2017.12.007 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2018 May;19(3):280-288.e4. doi: 10.1016/j.cllc.2017.12.007. - Epub 2017 Dec 21. - -PMID- 31754795 -OWN - NLM -STAT- MEDLINE -DCOM- 20210514 -LR - 20210514 -IS - 1619-7089 (Electronic) -IS - 1619-7070 (Linking) -VI - 47 -IP - 5 -DP - 2020 May -TI - Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced - NSCLC patients treated with immune checkpoint inhibitors. -PG - 1147-1157 -LID - 10.1007/s00259-019-04615-x [doi] -AB - PURPOSE: We aimed to evaluate if imaging biomarkers on FDG PET are associated - with clinical outcomes in patients with advanced non-small cell lung cancer - (NSCLC) treated with immune checkpoint inhibitors (ICIs). METHODS: In this - retrospective monocentric study, we included 109 patients with advanced NSCLC who - underwent baseline FDG PET/CT before ICI initiation between July 2013 and - September 2018. Clinical, biological (including dNLR = neutrophils/[leukocytes - minus neutrophils]), pathological and PET parameters (tumor SUVmax, total - metabolic tumor volume [TMTV]) were evaluated. A multivariate prediction model - was developed using Cox models for progression-free survival (PFS) and overall - survival (OS). The association between biomarkers on FDG PET/CT and disease - clinical benefit (DCB) was tested using logistic regression. RESULTS: Eighty - patients were eligible. Median follow-up was 11.6 months (95%CI 7.7-15.5). - Sixty-four and 52 patients experienced progression and death, respectively. DCB - was 40%. In multivariate analyses, TMTV > 75 cm(3) and dNLR > 3 were associated - with shorter OS (HR 2.5, 95%CI 1.3-4.7 and HR 3.3, 95%CI 1.6-6.4) and absence of - DCB (OR 0.3, 95%CI 0.1-0.9 and OR 0.4, 95%CI 0.2-0.9). Unlike TMTV, dNLR was a - significant prognostic factor for PFS (HR 1.9, 95%CI 1.1-3.3) along with anemia - (HR 1.9, 95%CI 1.2-3.8). No association was observed between tumor SUVmax and PFS - or OS. CONCLUSION: Baseline tumor burden (TMTV) on FDG PET/CT scans and - inflammatory status (dNLR) were associated with poor OS and absence of DCB for - ICI treatment in advanced NSCLC patients, unlike tumor SUVmax, and may be used - together to improve the selection of appropriate candidates. -FAU - Seban, Romain-David -AU - Seban RD -AD - Gustave Roussy, Department of Nuclear Medicine and Endocrine Oncology, Université - Paris-Saclay, Villejuif, France. -FAU - Mezquita, Laura -AU - Mezquita L -AD - Gustave Roussy, Department of Medical Oncology, Thoracic Unit, Villejuif, France. -FAU - Berenbaum, Arnaud -AU - Berenbaum A -AD - Gustave Roussy, Department of Nuclear Medicine and Endocrine Oncology, Université - Paris-Saclay, Villejuif, France. -FAU - Dercle, Laurent -AU - Dercle L -AD - Gustave Roussy Cancer Campus, UMR1015, Université Paris Saclay, Villejuif, - France. -FAU - Botticella, Angela -AU - Botticella A -AD - Gustave Roussy, Department of Radiation Oncology, Villejuif, France. -FAU - Le Pechoux, Cécile -AU - Le Pechoux C -AD - Gustave Roussy, Department of Radiation Oncology, Villejuif, France. -FAU - Caramella, Caroline -AU - Caramella C -AD - Gustave Roussy, Department of Radiology, Université Paris-Saclay, Villejuif, - France. -FAU - Deutsch, Eric -AU - Deutsch E -AD - Gustave Roussy, Department of Radiation Oncology, Villejuif, France. -AD - Gustave Roussy Cancer Campus INSERM U1030Radiomics team, 94800, Villejuif, - France. -AD - Gustave Roussy Drug Development Department (DITEP), Villejuif, France. -FAU - Grimaldi, Serena -AU - Grimaldi S -AD - Gustave Roussy, Department of Nuclear Medicine and Endocrine Oncology, Université - Paris-Saclay, Villejuif, France. -FAU - Adam, Julien -AU - Adam J -AD - Gustave Roussy, Department of Pathology, Université Paris-Saclay, Villejuif, - France. -FAU - Ammari, Samy -AU - Ammari S -AD - Gustave Roussy, Department of Radiology, Université Paris-Saclay, Villejuif, - France. -FAU - Planchard, David -AU - Planchard D -AD - Gustave Roussy, Department of Medical Oncology, Thoracic Unit, Villejuif, France. -FAU - Leboulleux, Sophie -AU - Leboulleux S -AD - Gustave Roussy, Department of Nuclear Medicine and Endocrine Oncology, Université - Paris-Saclay, Villejuif, France. -FAU - Besse, Benjamin -AU - Besse B -AD - Gustave Roussy, Department of Medical Oncology, Thoracic Unit, Villejuif, France. - Benjamin.BESSE@gustaveroussy.fr. -AD - Gustave Roussy Drug Development Department (DITEP), Villejuif, France. - Benjamin.BESSE@gustaveroussy.fr. -LA - eng -PT - Journal Article -DEP - 20191121 -PL - Germany -TA - Eur J Nucl Med Mol Imaging -JT - European journal of nuclear medicine and molecular imaging -JID - 101140988 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) -SB - IM -CIN - Eur J Nucl Med Mol Imaging. 2020 May;47(5):1019-1021. doi: - 10.1007/s00259-020-04702-4. PMID: 31996974 -MH - *Carcinoma, Non-Small-Cell Lung/diagnostic imaging/drug therapy -MH - Fluorodeoxyglucose F18 -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - *Lung Neoplasms/diagnostic imaging/drug therapy -MH - Positron Emission Tomography Computed Tomography -MH - Prognosis -MH - Retrospective Studies -MH - Tumor Burden -OTO - NOTNLM -OT - Advanced non-small-cell lung carcinoma -OT - Derived neutrophil to lymphocyte ratio -OT - Fluorodeoxyglucose F18-positron emission tomography computed tomography -OT - Immune checkpoint inhibitors -EDAT- 2019/11/23 06:00 -MHDA- 2021/05/15 06:00 -CRDT- 2019/11/23 06:00 -PHST- 2019/08/06 00:00 [received] -PHST- 2019/11/11 00:00 [accepted] -PHST- 2019/11/23 06:00 [pubmed] -PHST- 2021/05/15 06:00 [medline] -PHST- 2019/11/23 06:00 [entrez] -AID - 10.1007/s00259-019-04615-x [pii] -AID - 10.1007/s00259-019-04615-x [doi] -PST - ppublish -SO - Eur J Nucl Med Mol Imaging. 2020 May;47(5):1147-1157. doi: - 10.1007/s00259-019-04615-x. Epub 2019 Nov 21. - -PMID- 32205040 -OWN - NLM -STAT- MEDLINE -DCOM- 20211011 -LR - 20211011 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 21 -IP - 5 -DP - 2020 Sep -TI - Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint - Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer. -PG - e405-e414 -LID - S1525-7304(20)30037-1 [pii] -LID - 10.1016/j.cllc.2020.02.012 [doi] -AB - BACKGROUND: Programmed cell death 1 (PD-1) inhibitors have become a standard - treatment, albeit not completely effective, for patients with advanced - non-small-cell lung cancer (NSCLC). Previous studies of advanced melanoma have - revealed that the tumor burden predicted the response to PD-1 inhibitors, - although this relationship has remained unclear for NSCLC. PATIENTS AND METHODS: - The present single-center retrospective study evaluated 163 patients with - advanced NSCLC who had received PD-1/programmed cell death ligand 1 (PD-L1) - inhibitor monotherapy from December 2015 to December 2018. The clinical tumor - burden was estimated using the baseline sum of the target lesions' longest - diameters (BSLDs), measured according to the Response Evaluation Criteria for - Solid Tumors, and the baseline number of metastatic lesions (BNMLs). RESULTS: The - optimal cutoff values for predicting progression-free survival (PFS) were 5 for - the BNMLs and 76 mm for the BSLDs, using the minimum P value method. The low-BNML - group included 73 patients (44.8%). The median PFS was 12.2 months in the - low-BNML group and 2.8 months in the high-BNML group (hazard ratio, 0.51; P = - .0005). The low-BSLD group included 92 patients (56.4%). The median PFS was 9.6 - months in the low-BSLD group and 3.4 months in the high-BSLD group (hazard ratio, - 0.52; P = .0006). Multivariable analysis revealed that low-BSLD, low-BNML, - nonsquamous histologic type and a PD-L1 tumor proportion score of ≥ 50% were - independently associated with prolonged PFS. CONCLUSIONS: PD-L1 expression and - the clinical tumor burden can predict the efficacy of PD-1/PD-L1 inhibitor - monotherapy for NSCLC. -CI - Copyright © 2020 Elsevier Inc. All rights reserved. -FAU - Miyawaki, Taichi -AU - Miyawaki T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan; - Department of Respiratory Medicine, Juntendo University Graduate School of - Medicine, Tokyo, Japan. -FAU - Kenmotsu, Hirotsugu -AU - Kenmotsu H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan. - Electronic address: h.kenmotsu@scchr.jp. -FAU - Mori, Keita -AU - Mori K -AD - Division of Clinical Research Promotion Unit, Shizuoka Cancer Center, Nagaizumi, - Japan. -FAU - Miyawaki, Eriko -AU - Miyawaki E -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan. -FAU - Mamesaya, Nobuaki -AU - Mamesaya N -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan. -FAU - Kawamura, Takahisa -AU - Kawamura T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan. -FAU - Kobayashi, Haruki -AU - Kobayashi H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan. -FAU - Omori, Shota -AU - Omori S -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan. -FAU - Wakuda, Kazushige -AU - Wakuda K -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan. -FAU - Ono, Akira -AU - Ono A -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan. -FAU - Naito, Tateaki -AU - Naito T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan. -FAU - Murakami, Haruyasu -AU - Murakami H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan. -FAU - Harada, Hideyuki -AU - Harada H -AD - Radiation and Proton Therapy Center, Shizuoka Cancer Center, Nagaizumi, Japan. -FAU - Endo, Masahiro -AU - Endo M -AD - Division of Diagnostic Radiology, Shizuoka Cancer Center, Nagaizumi, Japan. -FAU - Ohde, Yasuhisa -AU - Ohde Y -AD - Division of Thoracic Surgery, Shizuoka Cancer Center, Nagaizumi, Japan. -FAU - Takahashi, Kazuhisa -AU - Takahashi K -AD - Department of Respiratory Medicine, Juntendo University Graduate School of - Medicine, Tokyo, Japan. -FAU - Takahashi, Toshiaki -AU - Takahashi T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan. -LA - eng -PT - Clinical Trial -PT - Journal Article -DEP - 20200226 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Adenocarcinoma of Lung/drug therapy/metabolism/*mortality/pathology -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - B7-H1 Antigen/*metabolism -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/metabolism/*mortality/pathology -MH - Carcinoma, Squamous Cell/drug therapy/metabolism/*mortality/pathology -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Lung Neoplasms/drug therapy/metabolism/*mortality/pathology -MH - Male -MH - Middle Aged -MH - Prognosis -MH - Retrospective Studies -MH - Survival Rate -MH - Tumor Burden/*drug effects -OTO - NOTNLM -OT - Baseline number of metastatic lesions -OT - Baseline sum of target lesions’ longest diameters -OT - Clinical biomarker -OT - Programmed cell death 1 inhibitors -OT - Programmed cell death ligand 1 inhibitors -EDAT- 2020/03/25 06:00 -MHDA- 2021/10/12 06:00 -CRDT- 2020/03/25 06:00 -PHST- 2019/05/09 00:00 [received] -PHST- 2020/02/04 00:00 [revised] -PHST- 2020/02/13 00:00 [accepted] -PHST- 2020/03/25 06:00 [pubmed] -PHST- 2021/10/12 06:00 [medline] -PHST- 2020/03/25 06:00 [entrez] -AID - S1525-7304(20)30037-1 [pii] -AID - 10.1016/j.cllc.2020.02.012 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2020 Sep;21(5):e405-e414. doi: 10.1016/j.cllc.2020.02.012. Epub - 2020 Feb 26. - -PMID- 32991393 -OWN - NLM -STAT- MEDLINE -DCOM- 20210902 -LR - 20210902 -IS - 1537-4513 (Electronic) -IS - 1524-9557 (Linking) -VI - 43 -IP - 9 -DP - 2020 Nov/Dec -TI - Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain - Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%. -PG - 299-306 -LID - 10.1097/CJI.0000000000000340 [doi] -AB - The authors conducted a multicenter retrospective study on the outcome of - programmed death-ligand 1 tumor proportion score≥50% advanced non-small cell lung - cancer patients treated with first-line pembrolizumab according to the - presence/absence of brain metastases. A total of 282 patients were included, of - whom 56 had brain metastases that were treated with upfront local radiation - therapy in 80.3% of cases. The overall response rate was 39.2% and 44.4% in - patients with and without brain metastases (P=0.48), respectively, while - intracranial response rate and intracranial disease control rate were 67.5% and - 85.0%, respectively. The median time-to-treatment failure (TTF) and overall - survival (OS) were 4.2 and 9.9 months versus 10.8 and 26.5 months for patients - with and without brain metastases (P=0.06 and 0.05, respectively). Drug - discontinuation rate due to treatment-related adverse events was 10.7% and 10.2% - in patients with and without brain metastases, respectively. Multivariate - analysis showed that baseline steroids was an independent predictor for a worse - OS (P<0.001), while performance status (PS)≥2 was an independent predictor for a - poorer TTF (P<0.001) and OS (P<0.001). In patients with brain metastases, only PS - ≥2 was predicted for a worse TTF (P=0.02) and OS (P=0.03). Pembrolizumab has - activity against brain metastases from non-small cell lung cancers with - programmed death-ligand 1≥50%. Presence of brain metastases per se does not - appear to be prognostic, and PS ≥2 seems to be the only factor associated with a - worse outcome in patients with brain metastases. -FAU - Metro, Giulio -AU - Metro G -AD - Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia. -FAU - Banna, Giuseppe Luigi -AU - Banna GL -AD - Department of Oncology, United Lincolnshire Hospitals NHS trust, Lincoln, UK. -FAU - Signorelli, Diego -AU - Signorelli D -AD - Department of Medical Oncology, National Cancer Institute, Milan. -FAU - Gili, Alessio -AU - Gili A -AD - Public Health Section, Department of Experimental Medicine, University of - Perugia, Perugia. -FAU - Galetta, Domenico -AU - Galetta D -AD - Thoracic Oncology Unit, "Giovanni Paolo II" Cancer Institute, Bari. -FAU - Galli, Giulia -AU - Galli G -AD - Department of Medical Oncology, National Cancer Institute, Milan. -FAU - Economopoulou, Panagiota -AU - Economopoulou P -AD - Oncology Department, Attikon University Hospital. -FAU - Roila, Fausto -AU - Roila F -AD - Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia. -FAU - Friedlaender, Alex -AU - Friedlaender A -AD - Department of Oncology, Geneva University Hospital, Geneva, Switzerland. -FAU - Camerini, Andrea -AU - Camerini A -AD - Oncology Unit, Lido di Camaiore (LU). -FAU - Christopoulou, Athina -AU - Christopoulou A -AD - Department of Medical Oncology, Agios Andreas General Hospital of Patras, Patras, - Greece. -FAU - Cantale, Ornella -AU - Cantale O -AD - Department of Oncology, United Lincolnshire Hospitals NHS trust, Lincoln, UK. -FAU - De Toma, Alessandro -AU - De Toma A -AD - Department of Medical Oncology, National Cancer Institute, Milan. -FAU - Pizzutilo, Pamela -AU - Pizzutilo P -AD - Thoracic Oncology Unit, "Giovanni Paolo II" Cancer Institute, Bari. -FAU - Jimenez, Beatriz -AU - Jimenez B -AD - Department of Medical Oncology, University Hospital HM Sanchinarro. -FAU - Collazo-Lorduy, Ana -AU - Collazo-Lorduy A -AD - Department of Medical Oncology, University Hospital HM Sanchinarro. -FAU - Calles, Antonio -AU - Calles A -AD - Division of Medical Oncology, University General Hospital Gregorio Maranon, - Madrid, Spain. -FAU - Baxevanos, Panagiotis -AU - Baxevanos P -AD - Second Department of Medical Oncology, Saint Savvas Anti-Cancer Hospital. -FAU - Linardou, Helena -AU - Linardou H -AD - 4th Oncology Department, Metropolitan Hospital. -FAU - Kosmidis, Paris -AU - Kosmidis P -AD - Second Department of Medical Oncology, Hygeia Hospital. -FAU - Giannarelli, Diana -AU - Giannarelli D -AD - Biostatistical Unit, Regina Elena National Cancer Institute, IRCCS, Rome, Italy. -FAU - Mountzios, Giannis -AU - Mountzios G -AD - Second Department of Medical Oncology, Henry Dunant Hospital Center, Athens. -FAU - Addeo, Alfredo -AU - Addeo A -AD - Department of Oncology, Geneva University Hospital, Geneva, Switzerland. -LA - eng -PT - Journal Article -PL - United States -TA - J Immunother -JT - Journal of immunotherapy (Hagerstown, Md. : 1997) -JID - 9706083 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized/administration & dosage/adverse - effects/*therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors/genetics/metabolism -MH - Brain Neoplasms/*drug therapy/*secondary -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/etiology/*pathology -MH - Disease Management -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/administration & dosage/adverse effects/*therapeutic - use -MH - Lung Neoplasms/*drug therapy/etiology/*pathology -MH - Male -MH - Molecular Targeted Therapy -MH - Neoplasm Staging -MH - Prognosis -MH - Treatment Outcome -EDAT- 2020/09/30 06:00 -MHDA- 2021/09/03 06:00 -CRDT- 2020/09/29 17:13 -PHST- 2020/09/30 06:00 [pubmed] -PHST- 2021/09/03 06:00 [medline] -PHST- 2020/09/29 17:13 [entrez] -AID - 00002371-202011000-00006 [pii] -AID - 10.1097/CJI.0000000000000340 [doi] -PST - ppublish -SO - J Immunother. 2020 Nov/Dec;43(9):299-306. doi: 10.1097/CJI.0000000000000340. - -PMID- 29678530 -OWN - NLM -STAT- MEDLINE -DCOM- 20190415 -LR - 20210126 -IS - 1879-355X (Electronic) -IS - 0360-3016 (Linking) -VI - 101 -IP - 3 -DP - 2018 Jul 1 -TI - Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 - Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With - Brain Metastases. -PG - 624-629 -LID - S0360-3016(18)30542-X [pii] -LID - 10.1016/j.ijrobp.2018.02.175 [doi] -AB - PURPOSE: Despite the emerging role of programmed cell death-1 (PD-1) pathway - inhibitors for patients with advanced lung cancer, a paucity of data are - available on the activity of these agents among patients with brain metastases. - We investigated the outcomes of PD-1 pathway inhibitors and stereotactic - radiosurgery (SRS) for the treatment of patients with brain metastases from lung - cancer. METHODS AND MATERIALS: We retrospectively reviewed the medical records of - non-small-cell lung cancer patients with brain metastases consecutively treated - with PD-1 pathway inhibitors and SRS at our institution from 2012 to 2017. - Overall survival (OS), distant brain failure (DBF), and local control (LC) were - assessed using Kaplan-Meier estimates and Cox regression models. RESULTS: We - identified 37 patients treated with SRS to 85 lesions (90.6% intact and 9.4% - resected) and a median total of 7 doses of PD-1 pathway inhibitors (83.8% - nivolumab, 10.8% atezolizumab, 5.4% pembrolizumab). Most lesions were treated - with 18 Gy in a single fraction (n = 61; 71.8%). Patients treated with concurrent - SRS and PD-1 pathway inhibitors had longer OS and reduced rates of DBF compared - with patients treated with SRS before or after PD-1 pathway inhibitor therapy - (1-year OS, 87.3% vs 70.0% vs 0%, P = .008; 1-year DBF, 38.5% vs 65.8% vs 100%, - P = .042). LC was favorable among lesions treated with SRS concurrent with or - after PD-1 pathway inhibitor therapy compared with before PD-1 pathway inhibitor - therapy (1-year LC, 100% vs 72.3%, P = .016). Three lesions transiently enlarged - after SRS and then had partially or completely resolved on follow-up imaging. - Four patients required steroids for SRS-associated toxicity. No patient - experienced grade ≥ 4 toxicity. CONCLUSIONS: Concurrent treatment with SRS and - PD-1 pathway inhibitors was associated with favorable OS and locoregional disease - control. This combination of therapy was well tolerated and merits further - evaluation in larger cohorts in a prospective setting. -CI - Copyright © 2018 Elsevier Inc. All rights reserved. -FAU - Schapira, Emily -AU - Schapira E -AD - Harvard Medical School, Boston, Massachusetts; Department of Radiation Oncology, - Massachusetts General Hospital, Boston, Massachusetts. -FAU - Hubbeling, Harper -AU - Hubbeling H -AD - Harvard Medical School, Boston, Massachusetts; Department of Medicine, - Massachusetts General Hospital, Boston, Massachusetts. -FAU - Yeap, Beow Y -AU - Yeap BY -AD - Harvard Medical School, Boston, Massachusetts; Department of Medicine, - Massachusetts General Hospital, Boston, Massachusetts. -FAU - Mehan, William A Jr -AU - Mehan WA Jr -AD - Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts. -FAU - Shaw, Alice T -AU - Shaw AT -AD - Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. -FAU - Oh, Kevin -AU - Oh K -AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston, - Massachusetts. -FAU - Gainor, Justin F -AU - Gainor JF -AD - Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. -FAU - Shih, Helen A -AU - Shih HA -AD - Department of Radiation Oncology, Massachusetts General Hospital, Boston, - Massachusetts. Electronic address: hshih@mgh.harvard.edu. -LA - eng -GR - C06 CA059267/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20180322 -PL - United States -TA - Int J Radiat Oncol Biol Phys -JT - International journal of radiation oncology, biology, physics -JID - 7603616 -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Brain Neoplasms/drug therapy/radiotherapy/*secondary/*therapy -MH - Combined Modality Therapy -MH - Female -MH - Humans -MH - Kaplan-Meier Estimate -MH - Lung Neoplasms/*pathology -MH - Male -MH - Middle Aged -MH - Molecular Targeted Therapy -MH - Programmed Cell Death 1 Receptor/*metabolism -MH - *Radiosurgery -MH - Retrospective Studies -EDAT- 2018/04/22 06:00 -MHDA- 2019/04/16 06:00 -CRDT- 2018/04/22 06:00 -PHST- 2017/10/06 00:00 [received] -PHST- 2018/01/30 00:00 [revised] -PHST- 2018/02/08 00:00 [accepted] -PHST- 2018/04/22 06:00 [pubmed] -PHST- 2019/04/16 06:00 [medline] -PHST- 2018/04/22 06:00 [entrez] -AID - S0360-3016(18)30542-X [pii] -AID - 10.1016/j.ijrobp.2018.02.175 [doi] -PST - ppublish -SO - Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):624-629. doi: - 10.1016/j.ijrobp.2018.02.175. Epub 2018 Mar 22. - -PMID- 31992521 -OWN - NLM -STAT- MEDLINE -DCOM- 20210402 -LR - 20210402 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 21 -IP - 2 -DP - 2020 Mar -TI - Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With - Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis. -PG - 106-113.e5 -LID - S1525-7304(19)30321-3 [pii] -LID - 10.1016/j.cllc.2019.11.004 [doi] -AB - Randomized trials showed inconsistent survival benefit with immune checkpoint - inhibitors (ICIs) in patients with advanced non-small-cell lung cancer with low - programmed death-ligand 1 (PD-L1) tumors (< 1%) and in elderly patients (> 65 - years old) and never-smokers. We conducted a systematic review and meta-analysis - to assess the efficacy of single agent ICIs in these pre-defined subgroups. The - electronic databases PubMed and EMBASE were searched for relevant randomized - trials. Pooled hazard ratios (HRs) for overall survival (OS) and progression-free - survival (PFS) were meta-analyzed using the generic inverse variance method. Nine - studies were included. Compared with chemotherapy, the use of single agent ICIs - in the second-line setting reduced the risk of death independent of PD-L1 - expression (HR, 0.79; 95% confidence interval [CI], 0.66-0.96 and HR, 0.75; 95% - CI, 0.61-0.85 for patients with PD-L1-negative and -positive tumors, - respectively). Yet, a PFS benefit was only seen in patients with PD-L1-positive - tumors. Similarly, an OS benefit was seen in patients independent of age (HR, - 0.79; 95% CI, 0.69-0.89 and HR, 0.76; 95% CI, 0.66-0.88 for elderly and - non-elderly patients, respectively). Conversely, an OS benefit was only seen in - ever-smokers (HR, 0.78; 95% CI, 0.68-0.89) and a detrimental effect on PFS in - never-smokers (HR, 1.68; 95% CI, 1.07-2.63). Patients with advanced - non-small-cell lung cancer derive a survival benefit from ICIs independent of - tumor PD-L1 expression and age, particularly in the second line, whereas - never-smokers do not. Caution should be exercised when offering single-agent ICIs - to elderly patients in the first line, and other treatment options should be - considered in never-smokers. -CI - Copyright © 2019 Elsevier Inc. All rights reserved. -FAU - Raphael, Jacques -AU - Raphael J -AD - Division of Medical Oncology, Department of Oncology, London Regional Cancer - Program, Western University, London, ON, Canada; Institute of Health Policy, - Management, and Evaluation, University of Toronto, Toronto, ON, Canada. - Electronic address: jacques.raphael@lhsc.on.ca. -FAU - Batra, Anupam -AU - Batra A -AD - Division of Medical Oncology, Department of Oncology, London Regional Cancer - Program, Western University, London, ON, Canada. -FAU - Boldt, Gabriel -AU - Boldt G -AD - Division of Medical Oncology, Department of Oncology, London Regional Cancer - Program, Western University, London, ON, Canada. -FAU - Shah, Prakesh S -AU - Shah PS -AD - Institute of Health Policy, Management, and Evaluation, University of Toronto, - Toronto, ON, Canada; Department of Pediatrics Mount Sinai Hospital, Toronto, - Toronto, ON, Canada. -FAU - Blanchette, Phillip -AU - Blanchette P -AD - Division of Medical Oncology, Department of Oncology, London Regional Cancer - Program, Western University, London, ON, Canada. -FAU - Rodrigues, George -AU - Rodrigues G -AD - Division of Radiation Oncology, Department of Oncology, London Regional Cancer - Program, Western University, London, ON, Canada. -FAU - Vincent, Mark D -AU - Vincent MD -AD - Division of Medical Oncology, Department of Oncology, London Regional Cancer - Program, Western University, London, ON, Canada. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Systematic Review -DEP - 20200103 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Biomarkers, Tumor) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Biomarkers, Tumor/*metabolism -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/metabolism/*mortality/pathology -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Lung Neoplasms/drug therapy/metabolism/*mortality/pathology -MH - Prognosis -MH - Survival Rate -OTO - NOTNLM -OT - Age -OT - Lung neoplasm -OT - PD-L1 -OT - Pooled analysis -OT - Smoking -EDAT- 2020/01/30 06:00 -MHDA- 2021/04/07 06:00 -CRDT- 2020/01/30 06:00 -PHST- 2019/07/15 00:00 [received] -PHST- 2019/10/15 00:00 [revised] -PHST- 2019/11/10 00:00 [accepted] -PHST- 2020/01/30 06:00 [pubmed] -PHST- 2021/04/07 06:00 [medline] -PHST- 2020/01/30 06:00 [entrez] -AID - S1525-7304(19)30321-3 [pii] -AID - 10.1016/j.cllc.2019.11.004 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2020 Mar;21(2):106-113.e5. doi: 10.1016/j.cllc.2019.11.004. - Epub 2020 Jan 3. - -PMID- 32077891 -OWN - NLM -STAT- MEDLINE -DCOM- 20210122 -LR - 20210220 -IS - 2374-2445 (Electronic) -IS - 2374-2437 (Print) -IS - 2374-2437 (Linking) -VI - 6 -IP - 6 -DP - 2020 Jun 1 -TI - Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy - for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled - Trial. -PG - 848-855 -LID - 10.1001/jamaoncol.2019.6731 [doi] -AB - IMPORTANCE: Consolidative programmed death ligand-1 (PD-L) inhibition after - chemoradiotherapy improves overall survival and progression-free survival (PFS) - for stage III non-small cell lung cancer (NSCLC) and requires safety evaluation - for incorporation of programmed cell death 1 (PD-1) inhibition at the onset of - chemoradiotherapy. OBJECTIVE: To determine the safety and tolerability of PD-1 - inhibition concurrently with definitive chemoradiotherapy for NSCLC. DESIGN, - SETTING, AND PARTICIPANTS: This phase 1 prospective multicenter nonrandomized - controlled trial using a 3 plus 3 design was performed from August 30, 2016, to - October 24, 2018, with a median follow-up of 16.0 (95% CI, 12.0-22.6) months and - data locked on July 25, 2019. Twenty-one participants had locally advanced, - unresectable, stage III NSCLC as determined by multidisciplinary review, Eastern - Cooperative Oncology Group performance status 0 or 1, and adequate hematologic, - renal, and hepatic function. Data were analyzed from October 17, 2016, to July - 19, 2019. INTERVENTIONS: Pembrolizumab was combined with concurrent - chemoradiotherapy (weekly carboplatin and paclitaxel with 60 Gy of radiation in 2 - Gy per d). Dose cohorts evaluated included full-dose pembrolizumab (200 mg - intravenously every 3 weeks) 2 to 6 weeks after chemoradiotherapy (cohort 1); - reduced-dose pembrolizumab (100 mg intravenously every 3 weeks) starting day 29 - of chemoradiotherapy (cohort 2); full-dose pembrolizumab starting day 29 of - chemoradiotherapy (cohort 3); reduced-dose pembrolizumab starting day 1 of - chemoradiotherapy (cohort 4); and full-dose pembrolizumab starting day 1 of - chemoradiotherapy (cohort 5). A safety expansion cohort of 6 patients was planned - based on the maximum tolerated dose of pembrolizumab. Dose-limiting toxic effects - were defined as pneumonitis of at least grade 4 within cycle 1 of pembrolizumab - treatment. MAIN OUTCOMES AND MEASURES: Safety and tolerability of PD-1 inhibition - with chemoradiotherapy for NSCLC. Secondary outcomes included PFS and pneumonitis - rates. RESULTS: Among the 21 patients included in the analysis (11 female [52%]; - median age, 69.5 [range, 53.0-85.0] years), no dose-limiting toxic effects in any - cohort were observed. One case of grade 5 pneumonitis occurred in the safety - expansion cohort with the cohort 5 regimen. Immune-related adverse events of at - least grade 3 occurred in 4 patients (18%). Median PFS for patients who received - at least 1 dose of pembrolizumab (n = 21) was 18.7 (95% CI, 11.8-29.4) months, - and 6- and 12-month PFS were 81.0% (95% CI, 64.1%-97.7%) and 69.7% (95% CI, - 49.3%-90.2%), respectively. Median PFS for patients who received at least 2 doses - of pembrolizumab (n = 19) was 21.0 (95% CI, 15.3 to infinity) months. CONCLUSIONS - AND RELEVANCE: These findings suggest that combined treatment with PD-1 - inhibitors and chemoradiotherapy for stage III NSCLC is tolerable, with promising - PFS of 69.7% at 12 months, and requires further study. TRIAL REGISTRATION: - ClinicalTrials.gov Identifier: NCT02621398. -FAU - Jabbour, Salma K -AU - Jabbour SK -AD - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert - Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey. -FAU - Berman, Abigail T -AU - Berman AT -AD - Department of Radiation Oncology, Abramson Cancer Center, Perelman School of - Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. -FAU - Decker, Roy H -AU - Decker RH -AD - Department of Therapeutic Radiology, Smilow Cancer Center, Yale School of - Medicine, Yale University, New Haven, Connecticut. -FAU - Lin, Yong -AU - Lin Y -AD - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert - Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey. -AD - Department of Biostatistics and Epidemiology, Rutgers School of Public Health, - Piscataway, New Jersey. -AD - Biometrics Division, Rutgers Cancer Institute of New Jersey, Rutgers University, - Piscataway, New Jersey. -FAU - Feigenberg, Steven J -AU - Feigenberg SJ -AD - Department of Radiation Oncology, Abramson Cancer Center, Perelman School of - Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. -FAU - Gettinger, Scott N -AU - Gettinger SN -AD - Section of Medical Oncology, Department of Medicine, Smilow Cancer Center, Yale - School of Medicine, Yale University, New Haven, Connecticut. -FAU - Aggarwal, Charu -AU - Aggarwal C -AD - Division of Hematology Oncology, Department of Medicine, Abramson Cancer Center, - Perelman School of Medicine, University of Pennsylvania, Philadelphia. -FAU - Langer, Corey J -AU - Langer CJ -AD - Division of Hematology Oncology, Department of Medicine, Abramson Cancer Center, - Perelman School of Medicine, University of Pennsylvania, Philadelphia. -FAU - Simone, Charles B 2nd -AU - Simone CB 2nd -AD - Department of Radiation Oncology, New York Proton Center, New York, New York. -FAU - Bradley, Jeffrey D -AU - Bradley JD -AD - Department of Radiation Oncology, Winship Cancer Institute, Emory School of - Medicine, Emory University Atlanta, Georgia. -FAU - Aisner, Joseph -AU - Aisner J -AD - Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers - Robert Wood Johnson Medical School, Rutgers University. -FAU - Malhotra, Jyoti -AU - Malhotra J -AD - Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers - Robert Wood Johnson Medical School, Rutgers University. -LA - eng -SI - ClinicalTrials.gov/NCT02621398 -GR - UL1 TR001863/TR/NCATS NIH HHS/United States -PT - Clinical Trial, Phase I -PT - Controlled Clinical Trial -PT - Journal Article -PL - United States -TA - JAMA Oncol -JT - JAMA oncology -JID - 101652861 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - BG3F62OND5 (Carboplatin) -RN - DPT0O3T46P (pembrolizumab) -RN - P88XT4IS4D (Paclitaxel) -SB - IM -CIN - JAMA Oncol. 2020 Oct 1;6(10):1634-1635. doi: 10.1001/jamaoncol.2020.2722. PMID: - 32761104 -CIN - JAMA Oncol. 2020 Oct 1;6(10):1634. doi: 10.1001/jamaoncol.2020.2698. PMID: - 32761136 -CIN - J Thorac Dis. 2020 Aug;12(8):4549-4552. doi: 10.21037/jtd-20-1672. PMID: 32944372 -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use -MH - Antineoplastic Agents, Immunological/adverse effects/*therapeutic use -MH - Carboplatin/adverse effects/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/mortality/pathology/*therapy -MH - *Chemoradiotherapy -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects/*therapeutic use -MH - Lung Neoplasms/mortality/pathology/*therapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Paclitaxel/adverse effects/*therapeutic use -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -MH - Treatment Outcome -PMC - PMC7042914 -COIS- Conflict of Interest Disclosures: Dr Jabbour reported receiving grants and - personal fees from Merck & Co during the conduct of the study and grants and - personal fees from Merck & Co outside the submitted work. Dr Berman reported - receiving nonfinancial support from Merck & Co during the conduct of the study - and personal fees from IMX Medical, Varian Medical Systems, AstraZeneca, and - Imedex outside the submitted work. Dr Decker reported receiving grants from Merck - & Co during the conduct of the study and grants and personal fees from - AstraZeneca and personal fees from Regeneron Pharmaceuticals, Inc outside the - submitted work. Dr Gettinger reported receiving personal fees from Merck & Co - during the conduct of the study and other from Bristol-Myers Squibb, Nektar, - Genentech/Roche, and Iovance outside the submitted work. Dr Aggarwal reported - receiving consulting fees from Bristol-Myers Squibb, AstraZeneca, Roche, Merck & - Co, Eli Lilly and Company, and Celgene during the conduct of the study. Dr Langer - reported receiving grants and personal fees from Merck & Co during the conduct of - the study, personal fees from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, - and Eli Lilly and Company, and grants from Advantagene, Inc, Inovio - Pharmaceuticals, Inc, and Trizell, Ltd, outside the submitted work; and serving - on data-safety monitoring committees for Eli Lilly and Company and SWOG (formerly - Southwest Oncology Group). Dr Simone reported receiving an honorarium from Varian - Medical Systems outside the submitted work. Dr Bradley reported receiving - personal fees from AstraZeneca outside the submitted work. Dr Aisner reported - receiving grants from Merck & Co during the conduct of the study and personal - fees from Serono AG outside the submitted work. Dr Malhotra reported receiving - personal fees from Pfizer, Inc, and AstraZeneca outside the submitted work. No - other disclosures were reported. -EDAT- 2020/02/23 06:00 -MHDA- 2021/01/23 06:00 -PMCR- 2021/02/20 -CRDT- 2020/02/21 06:00 -PHST- 2020/02/23 06:00 [pubmed] -PHST- 2021/01/23 06:00 [medline] -PHST- 2020/02/21 06:00 [entrez] -PHST- 2021/02/20 00:00 [pmc-release] -AID - 2761665 [pii] -AID - coi190116 [pii] -AID - 10.1001/jamaoncol.2019.6731 [doi] -PST - ppublish -SO - JAMA Oncol. 2020 Jun 1;6(6):848-855. doi: 10.1001/jamaoncol.2019.6731. - -PMID- 31053172 -OWN - NLM -STAT- MEDLINE -DCOM- 20200527 -LR - 20200527 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 7 -IP - 1 -DP - 2019 May 3 -TI - First-line treatment for patients with advanced non-small cell lung carcinoma and - high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. -PG - 120 -LID - 10.1186/s40425-019-0600-6 [doi] -LID - 120 -AB - Pembrolizumab monotherapy has become the preferred treatment for patients with - advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand - 1 (PD-L1) tumor proportion score (TPS) of at least 50%. However, little is known - about the value of adding chemotherapy to pembrolizumab in this setting. - Therefore, we performed an indirect comparison for pembrolizumab plus - chemotherapy versus pembrolizumab, using the frequentist methods. The primary - outcomes were overall survival (OS), progression-free survival (PFS) and - objective response rate (ORR). Data were retrieved from randomized trials - comparing pembrolizumab plus chemotherapy or pembrolizumab monotherapy against - chemotherapy. Five trials involving 1289 patients were included. Direct - meta-analysis showed that both pembrolizumab plus chemotherapy (ORR: relative - risk (RR) 2.16; PFS: hazard ratio (HR) 0.36; OS: HR 0.51) and pembrolizumab alone - (ORR: RR 1.33; PFS: HR, 0.65; OS: HR 0.67) improved clinical outcomes compared - with chemotherapy. Indirect comparison showed that pembrolizumab plus - chemotherapy was superior to pembrolizumab alone, in terms of ORR (RR 1.62, - 1.18-2.23) and PFS (HR 0.55, 0.32-0.97). A trend towards improved OS was also - observed (HR 0.76, 0.51-1.14). In conclusion, the addition of chemotherapy to - pembrolizumab further improves the outcomes of patients with advanced NSCLC and a - PD-L1 TPS of at least 50%. -FAU - Zhou, Yixin -AU - Zhou Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of VIP region, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Lin, Zuan -AU - Lin Z -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, - China. -FAU - Zhang, Xuanye -AU - Zhang X -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. -FAU - Chen, Chen -AU - Chen C -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, - China. -FAU - Zhao, Hongyun -AU - Zhao H -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, - China. -FAU - Hong, Shaodong -AU - Hong S -AUID- ORCID: 0000-0002-5632-6857 -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. - hongshd@sysucc.org.cn. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. - hongshd@sysucc.org.cn. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. hongshd@sysucc.org.cn. -FAU - Zhang, Li -AU - Zhang L -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. - zhangli6@mail.sysu.edu.cn. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. - zhangli6@mail.sysu.edu.cn. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 - Dongfeng East Road, Guangzhou, 510060, China. zhangli6@mail.sysu.edu.cn. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Research Support, Non-U.S. Gov't -DEP - 20190503 -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized/administration & dosage/adverse - effects/therapeutic use -MH - Antineoplastic Agents, Immunological/administration & dosage/adverse - effects/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors/genetics/metabolism -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/metabolism/pathology -MH - Humans -MH - Lung Neoplasms/*drug therapy/genetics/metabolism/pathology -MH - *Molecular Targeted Therapy/methods -MH - Neoplasm Staging -MH - Randomized Controlled Trials as Topic -MH - Treatment Outcome -PMC - PMC6500047 -OTO - NOTNLM -OT - Chemotherapy -OT - First-line -OT - Non-small cell lung cancer -OT - Pembrolizumab -OT - Programmed cell death-ligand 1 -COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR - PUBLICATION: Not applicable. COMPETING INTERESTS: Li Zhang has received research - support from AstraZeneca, Eli Lilly and company, and Roche. No other disclosures - were reported. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to - jurisdictional claims in published maps and institutional affiliations. -EDAT- 2019/05/06 06:00 -MHDA- 2020/05/28 06:00 -PMCR- 2019/05/03 -CRDT- 2019/05/05 06:00 -PHST- 2019/01/02 00:00 [received] -PHST- 2019/04/23 00:00 [accepted] -PHST- 2019/05/05 06:00 [entrez] -PHST- 2019/05/06 06:00 [pubmed] -PHST- 2020/05/28 06:00 [medline] -PHST- 2019/05/03 00:00 [pmc-release] -AID - 10.1186/s40425-019-0600-6 [pii] -AID - 600 [pii] -AID - 10.1186/s40425-019-0600-6 [doi] -PST - epublish -SO - J Immunother Cancer. 2019 May 3;7(1):120. doi: 10.1186/s40425-019-0600-6. - -PMID- 2548520 -OWN - NLM -STAT- MEDLINE -DCOM- 19891005 -LR - 20191029 -IS - 1046-7416 (Print) -IS - 1046-7416 (Linking) -VI - 1 -DP - 1989 -TI - Surgical adjuvant therapy of non-small-cell lung cancer. -PG - 26-33 -AB - Results of several studies by the Lung Cancer Study Group have shown that - postoperative adjuvant chemotherapy enhances survival following surgery for lung - cancer. The 18-month disease-free survival almost doubled in one study using - cyclophosphamide, doxorubicin, cisplatin (CAP) chemotherapy postoperatively. The - recurrence rate remained significant, however. Patients with more advanced - resectable disease seem to benefit most from postoperative chemotherapy. Results - also suggest that CAP delays recurrences more effectively in patients with - nonsquamous vs. squamous lung carcinoma. There has been considerable interest in - the use of preoperative adjuvant therapy as well. Findings from studies of - preoperative or induction therapy--either chemotherapy alone or in combination - with radiation therapy--have shown high response rates and that patients with - unresectable disease can be converted to technically resectable. Although - preoperative therapy can cause difficulties with surgical dissection, surgical - morbidity is acceptable. Preoperative chemotherapy and radiotherapy followed by - surgical resection clearly eliminates local recurrence. Systemic recurrences - remain a significant problem. The evidence, as yet, does not indicate that - preoperative adjuvant therapy prolongs survival. -FAU - Holmes, E C -AU - Holmes EC -AD - Department of Surgery/Oncology, UCLA School of Medicine 90024-1782. -LA - eng -PT - Comparative Study -PT - Journal Article -PT - Review -PL - United States -TA - J Surg Oncol Suppl -JT - Journal of surgical oncology. Supplement -JID - 8912976 -RN - 0 (Phosphoramide Mustards) -RN - 80168379AG (Doxorubicin) -RN - Q20Q21Q62J (Cisplatin) -RN - CAP protocol 1 -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*therapy -MH - Carcinoma, Squamous Cell/*therapy -MH - Cisplatin/therapeutic use -MH - Combined Modality Therapy -MH - Doxorubicin/therapeutic use -MH - Female -MH - Humans -MH - Immunotherapy -MH - Lung Neoplasms/surgery/*therapy -MH - Male -MH - Middle Aged -MH - Phosphoramide Mustards/therapeutic use -MH - Postoperative Care -MH - Preoperative Care -RF - 21 -EDAT- 1989/01/01 00:00 -MHDA- 1989/01/01 00:01 -CRDT- 1989/01/01 00:00 -PHST- 1989/01/01 00:00 [pubmed] -PHST- 1989/01/01 00:01 [medline] -PHST- 1989/01/01 00:00 [entrez] -AID - 10.1002/jso.2930420507 [doi] -PST - ppublish -SO - J Surg Oncol Suppl. 1989;1:26-33. doi: 10.1002/jso.2930420507. - -PMID- 31703637 -OWN - NLM -STAT- MEDLINE -DCOM- 20200406 -LR - 20200408 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 19 -IP - 1 -DP - 2019 Nov 8 -TI - Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in - advanced non-small cell lung cancer - study protocol of the FORCE trial. -PG - 1074 -LID - 10.1186/s12885-019-6205-0 [doi] -LID - 1074 -AB - BACKGROUND: Hypofractionated palliative radiotherapy for metastatic lung cancer - patients is frequently used in order to ease pain, to increase bone stability, to - treat local mass effects, or to prolong progression-free survival at critical - sites. Recently introduced, immunotherapy for patients with non-squamous - non-small cell lung carcinoma (NSCLC) has significantly improved outcome in this - cohort. Preclinical and early clinical data suggest that the combination of - photon radiation with programmed death-1 (PD-1) targeting immunotherapies may - promote a strong and durable immune response against tumor manifestations both - within and beyond radiation targets. METHODS/DESIGN: In the present prospective, - two-group, non-randomized, open-label phase II trial, 130 patients with stage IV - non-squamous NSCLC in 2nd-line or 3rd-line treatment will be included. 65 - patients with a clinical indication for palliative radiotherapy to - non-cerebral/non-pulmonary metastatic sites will receive 240 mg nivolumab - followed by palliative radiotherapy with 5 × 4 Gray (Gy) = 20 Gy photon - radiation, which will be initiated within 72 h after first nivolumab - administration (Group A). 65 patients without an indication for radiotherapy will - only receive nivolumab (Group B). Nivolumab will be further administered every - two weeks in both groups and will be continued until progression and loss of - clinical benefit or until occurrence of limiting toxicities. The primary endpoint - will be the objective response rate (ORR) according to response evaluation - criteria in solid tumors (RECIST) 1.1. Secondary endpoints will be - progression-free survival (PFS) according to RECIST 1.1, overall survival, - descriptive subgroup analyses according to PD-L1 expression, toxicity and quality - of life. Since response patterns following immunotherapies differ from those - after conventional cytostatic agents, both objective response rate and - progression-free survival will additionally be assessed according to - immune-related RECIST (irRECIST) criteria. DISCUSSION: The FORCE study will - prospectively investigate response rates, progression-free and overall survival - (OS), and toxicity of nivolumab with and without hypofractionated palliative - radiotherapy in a group of 130 patients with metastatic non-small cell lung - cancer (non-squamous histology) in 2nd-line or 3rd-line treatment. This trial - will contribute prospective data to the repeatedly published observation that the - combination of hypofractionated photon radiotherapy and medical immunotherapy is - not only safe but will also promote antitumoral immune responses. TRIAL - REGISTRATION: Clinicaltrials.gov identifier: NCT03044626 (Date of initial - registration: 05 January 2017). Eudra-CT Number: 2015-005741-31 (Date of initial - registration: 18 December 2015). -FAU - Bozorgmehr, Farastuk -AU - Bozorgmehr F -AUID- ORCID: 0000-0001-8058-8884 -AD - Department of Thoracic Oncology, Thoraxklinik at University Hospital of - Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany. -AD - Translational Lung Research Center Heidelberg TLRCH, Member of the German Center - for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany. -FAU - Hommertgen, Adriane -AU - Hommertgen A -AD - Department of Radiation Oncology, University Hospital of Heidelberg, Im - Neuenheimer Feld 400, 69120, Heidelberg, Germany. -AD - German Cancer Research Center, Abteilung für Molekulare Radioonkologie, Im - Neuenheimer Feld 280, 69120, Heidelberg, Germany. -AD - Heidelberg Institute of Radiation Oncology HIRO, Im Neuenheimer Feld 280, 69120, - Heidelberg, Germany. -FAU - Krisam, Johannes -AU - Krisam J -AD - Institute of Medical Biometry and Informatics, University Hospital of Heidelberg, - Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany. -FAU - Lasitschka, Felix -AU - Lasitschka F -AD - Translational Lung Research Center Heidelberg TLRCH, Member of the German Center - for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany. -AD - University Hospital of Heidelberg, Institute of Pathology, Im Neuenheimer Feld - 430, 69120, Heidelberg, Germany. -FAU - Kuon, Jonas -AU - Kuon J -AD - Department of Thoracic Oncology, Thoraxklinik at University Hospital of - Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany. -FAU - Maenz, Martin -AU - Maenz M -AD - AIO-Studien gGmbH, Berlin, Germany. -FAU - Huber, Peter E -AU - Huber PE -AD - German Cancer Research Center, Abteilung für Molekulare Radioonkologie, Im - Neuenheimer Feld 280, 69120, Heidelberg, Germany. -AD - Heidelberg Institute of Radiation Oncology HIRO, Im Neuenheimer Feld 280, 69120, - Heidelberg, Germany. -FAU - König, Laila -AU - König L -AD - Department of Radiation Oncology, University Hospital of Heidelberg, Im - Neuenheimer Feld 400, 69120, Heidelberg, Germany. -AD - Heidelberg Institute of Radiation Oncology HIRO, Im Neuenheimer Feld 280, 69120, - Heidelberg, Germany. -FAU - Kieser, Meinhard -AU - Kieser M -AD - Institute of Medical Biometry and Informatics, University Hospital of Heidelberg, - Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany. -FAU - Debus, Juergen -AU - Debus J -AD - Department of Radiation Oncology, University Hospital of Heidelberg, Im - Neuenheimer Feld 400, 69120, Heidelberg, Germany. -AD - German Cancer Research Center, Abteilung für Molekulare Radioonkologie, Im - Neuenheimer Feld 280, 69120, Heidelberg, Germany. -AD - Heidelberg Institute of Radiation Oncology HIRO, Im Neuenheimer Feld 280, 69120, - Heidelberg, Germany. -FAU - Thomas, Michael -AU - Thomas M -AD - Department of Thoracic Oncology, Thoraxklinik at University Hospital of - Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany. -AD - Translational Lung Research Center Heidelberg TLRCH, Member of the German Center - for Lung Research DZL, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany. -FAU - Rieken, Stefan -AU - Rieken S -AD - Department of Radiation Oncology, University Hospital of Heidelberg, Im - Neuenheimer Feld 400, 69120, Heidelberg, Germany. - Stefan.Rieken@med.uni-heidelberg.de. -AD - Heidelberg Institute of Radiation Oncology HIRO, Im Neuenheimer Feld 280, 69120, - Heidelberg, Germany. Stefan.Rieken@med.uni-heidelberg.de. -LA - eng -SI - ClinicalTrials.gov/NCT03044626 -GR - CA209-430/Bristol-Myers Squibb(BMS)/ -GR - NCT3.0/Federal Ministry of Education and Research/ -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20191108 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -RN - 0 (CD274 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Antineoplastic Agents, Immunological/administration & dosage/adverse - effects/pharmacology/*therapeutic use -MH - B7-H1 Antigen/analysis -MH - Biomarkers, Tumor/analysis -MH - Carcinoma, Non-Small-Cell Lung/*radiotherapy/*therapy -MH - Cohort Studies -MH - Combined Modality Therapy/methods -MH - Follow-Up Studies -MH - Humans -MH - *Immunotherapy -MH - Lung Neoplasms/*radiotherapy/*therapy -MH - Nivolumab/administration & dosage/adverse effects/pharmacology/*therapeutic use -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -MH - Progression-Free Survival -MH - Prospective Studies -MH - Quality of Life -MH - Radiation Dose Hypofractionation -MH - Response Evaluation Criteria in Solid Tumors -PMC - PMC6842256 -OTO - NOTNLM -OT - Abscopal effect -OT - Immunotherapy -OT - Nivolumab -OT - Non-small cell lung cancer -OT - PD-1 -OT - Palliative radiotherapy -OT - Radioimmunotherapy -COIS- The FORCE trial received funding from Bristol-Myers Squibb GmbH & Co.KGaA (BMS). - BMS has not been involved in the study design, and has no role in data - collection, management, data analysis and interpretation, or in the decision to - submit this protocol for publication. All authors declare that there are no - competing conflicts of interest. -EDAT- 2019/11/11 06:00 -MHDA- 2020/04/09 06:00 -PMCR- 2019/11/08 -CRDT- 2019/11/10 06:00 -PHST- 2018/10/30 00:00 [received] -PHST- 2019/09/25 00:00 [accepted] -PHST- 2019/11/10 06:00 [entrez] -PHST- 2019/11/11 06:00 [pubmed] -PHST- 2020/04/09 06:00 [medline] -PHST- 2019/11/08 00:00 [pmc-release] -AID - 10.1186/s12885-019-6205-0 [pii] -AID - 6205 [pii] -AID - 10.1186/s12885-019-6205-0 [doi] -PST - epublish -SO - BMC Cancer. 2019 Nov 8;19(1):1074. doi: 10.1186/s12885-019-6205-0. - -PMID- 29477100 -OWN - NLM -STAT- MEDLINE -DCOM- 20190111 -LR - 20240210 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 93 -DP - 2018 Apr -TI - Diversity of brain metastases screening and management in non-small cell lung - cancer in Europe: Results of the European Organisation for Research and Treatment - of Cancer Lung Cancer Group survey. -PG - 37-46 -LID - S0959-8049(18)30081-9 [pii] -LID - 10.1016/j.ejca.2018.01.067 [doi] -AB - BACKGROUND: Brain metastases (BM) are frequent in non-small cell lung cancer - (NSCLC) patients, but there is a lack of evidence-based management of this - patient group. We aimed to capture a snapshot of routine BM management in Europe - to identify relevant research questions for future clinical trials. METHODS: An - EORTC Lung Cancer Group (LCG) online survey containing questions on NSCLC BM - screening and treatment was distributed between 16/02/17 and 15/06/17 to - worldwide EORTC LCG members, and through several European scientific societies in - the thoracic oncology field. RESULTS: A total of 462 European physician responses - (394 institutions) were analysed (radiation oncologist: 53% [n = 247], - pulmonologist: 26% [n = 119], medical oncologist: 18% [n = 84]; 84% with >5 - years' experience in NSCLC). Italy (18%, n = 85), Netherlands (15%, n = 68), UK - (14%, n = 66), and France (12%, n = 55) contributed most. 393 physicians (85%) - screened neurologically asymptomatic patients for BM at diagnosis (52% using - magnetic resonance imaging). Most often screened patients were those with a - driver mutation (MUT+; 51%, n = 234), stage III (63%, n = 289), and IV (43%, - n = 199). 158 physicians (34%) used a prognostic classification to guide initial - treatment decisions, and in 50%, lowest prognostic-score threshold to receive - treatment differed between MUT+ and non-driver mutation (MUT-) patients. - MUT+ patients with >4 BM were more likely to receive stereotactic radiosurgery - (SRS) compared with MUT- (27% versus. 21%; p < 0.01). Most physicians (90%) had - access to SRS. After single BM surgery, 50% systematically prescribed SRS or - WBRT, and 45% only in case of incomplete resection. The preferred treatment in - neurologically asymptomatic treatment-naive patients diagnosed with >5 BM was - systemic treatment (79%). Of all, 45%/49% physicians stated that all tyrosine - kinase inhibitors and immune checkpoint blockers were discontinued (timing - varied) during SRS/WBRT, respectively. Drugs most often continued during SRS/WBRT - were erlotinib (44%/40%), gefitinib (39%/34%), afatinib (29%/25%), crizotinib - (33%/26%) and anti-PD-(L)-1 (28%/22%). CONCLUSION: BM management is highly - variable in Europe: screening is not uniform, prognostic classifications are not - often used and MUT+ NSCLC patients generally receive more intensive local - treatment. Prospective assessment of BM management in MUT+ NSCLC patients is - required. -CI - Copyright © 2018 Elsevier Ltd. All rights reserved. -FAU - Levy, Antonin -AU - Levy A -AD - Department of Radiation Oncology, Gustave Roussy, Institut d'Oncologie Thoracique - (IOT), INSERM U1030 Molecular Radiotherapy, Université Paris-Saclay, F-94805, - Villejuif, France; Univ Paris Sud, Université Paris-Saclay, F-94270, Le - Kremlin-Bicêtre, France. Electronic address: antonin.levy@gustaveroussy.fr. -FAU - Faivre-Finn, Corinne -AU - Faivre-Finn C -AD - Manchester Academic Health Science Centre, Institute of Cancer Sciences, - Manchester Cancer Research Centre (MCRC), University of Manchester, Manchester, - UK. -FAU - Hasan, Baktiar -AU - Hasan B -AD - European Organisation for Research and Treatment of Cancer, Brussels, Belgium. -FAU - De Maio, Eleonora -AU - De Maio E -AD - European Organisation for Research and Treatment of Cancer, Brussels, Belgium. -FAU - Berghoff, Anna S -AU - Berghoff AS -AD - Department of Medicine I and Comprehensive Cancer Center CNS Unit (CCC-CNS), - Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. -FAU - Girard, Nicolas -AU - Girard N -AD - Department of Medical Oncology, Institut Curie, Paris, France. -FAU - Greillier, Laurent -AU - Greillier L -AD - Multidisciplinary Oncology and Therapeutic Innovations, Assistance Publique - Hôpitaux de Marseille, Aix Marseille University, Marseille, France. -FAU - Lantuéjoul, Sylvie -AU - Lantuéjoul S -AD - Department of Biopathology, Centre Léon Bérard UNICANCER, Lyon, Université - Grenoble Alpes, INSERM U1209/CNRS 5309 Institute for Advanced Biosciences, - Grenoble France. -FAU - O'Brien, Mary -AU - O'Brien M -AD - Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK. -FAU - Reck, Martin -AU - Reck M -AD - LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung - Research, Grosshansdorf, Germany. -FAU - Dingemans, Anne-Marie C -AU - Dingemans AC -AD - Department of Pulmonary Diseases, GROW - School for Oncology and Developmental - Biology, Maastricht University Medical Center+, Maastricht, The Netherlands. -FAU - Novello, Silvia -AU - Novello S -AD - Oncology Department, University of Turin, AOU San Luigi, Orbassano (TO), Italy. -FAU - Berghmans, Thierry -AU - Berghmans T -AD - Department of Intensive Care and Oncological Emergencies & Thoracic Oncology, - Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. -FAU - Besse, Benjamin -AU - Besse B -AD - Univ Paris Sud, Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France; - Department of Medical Oncology, Gustave Roussy, Institut d'Oncologie Thoracique - (IOT), Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France. -FAU - Hendriks, Lizza -AU - Hendriks L -AD - Department of Pulmonary Diseases, GROW - School for Oncology and Developmental - Biology, Maastricht University Medical Center+, Maastricht, The Netherlands. - Electronic address: lizza.hendriks@mumc.nl. -CN - Young Investigators EORTC Lung Cancer Group (YI EORTC LCG) -LA - eng -GR - 20465/CRUK_/Cancer Research UK/United Kingdom -PT - Journal Article -DEP - 20180221 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -RN - 0 (Biomarkers, Tumor) -RN - 0 (Protein Kinase Inhibitors) -SB - IM -CIN - Eur Respir J. 2020 Jan 2;55(1):1901686. doi: 10.1183/13993003.01686-2019. PMID: - 31896679 -MH - Biomarkers, Tumor/*genetics -MH - Brain Neoplasms/*drug therapy/genetics/*secondary -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology -MH - DNA Mutational Analysis -MH - Early Detection of Cancer/*methods -MH - Europe -MH - Humans -MH - Lung Neoplasms/drug therapy/genetics/pathology -MH - *Mutation -MH - *Oncologists -MH - Prognosis -MH - Protein Kinase Inhibitors/*therapeutic use -MH - Surveys and Questionnaires -OTO - NOTNLM -OT - Guideline -OT - Lung cancer -OT - Radiation -OT - Stereotactic radiosurgery -OT - Targeted therapy -EDAT- 2018/02/25 06:00 -MHDA- 2019/01/12 06:00 -CRDT- 2018/02/25 06:00 -PHST- 2017/11/27 00:00 [received] -PHST- 2018/01/03 00:00 [revised] -PHST- 2018/01/04 00:00 [accepted] -PHST- 2018/02/25 06:00 [pubmed] -PHST- 2019/01/12 06:00 [medline] -PHST- 2018/02/25 06:00 [entrez] -AID - S0959-8049(18)30081-9 [pii] -AID - 10.1016/j.ejca.2018.01.067 [doi] -PST - ppublish -SO - Eur J Cancer. 2018 Apr;93:37-46. doi: 10.1016/j.ejca.2018.01.067. Epub 2018 Feb - 21. - -PMID- 32795284 -OWN - NLM -STAT- MEDLINE -DCOM- 20210414 -LR - 20210414 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 20 -IP - 1 -DP - 2020 Aug 14 -TI - Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients - with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: - the INCREASE trial. -PG - 764 -LID - 10.1186/s12885-020-07263-9 [doi] -LID - 764 -AB - BACKGROUND: The likelihood of a tumor recurrence in patients with T3-4N0-1 - non-small cell lung cancer following multimodality treatment remains substantial, - mainly due distant metastases. As pathological complete responses (pCR) in - resected specimens are seen in only a minority (28-38%) of patients following - chemoradiotherapy, we designed the INCREASE trial (EudraCT-Number: - 2019-003454-83; Netherlands Trial Register number: NL8435) to assess if pCR rates - could be further improved by adding short course immunotherapy to induction - chemoradiotherapy. Translational studies will correlate changes in loco-regional - and systemic immune status with patterns of recurrence. METHODS/DESIGN: This - single-arm, prospective phase II trial will enroll 29 patients with either - resectable, or borderline resectable, T3-4N0-1 NSCLC. The protocol was approved - by the institutional ethics committee. Study enrollment commenced in February - 2020. On day 1 of guideline-recommended concurrent chemoradiotherapy (CRT), - ipilimumab (IPI, 1 mg/kg IV) and nivolumab (NIVO, 360 mg flat dose IV) will be - administered, followed by nivolumab (360 mg flat dose IV) after 3 weeks. - Radiotherapy consists of once-daily doses of 2 Gy to a total of 50 Gy, and - chemotherapy will consist of a platinum-doublet. An anatomical pulmonary - resection is planned 6 weeks after the last day of radiotherapy. The primary - study objective is to establish the safety of adding IPI/NIVO to pre-operative - CRT, and its impact on pathological tumor response. Secondary objectives are to - assess the impact of adding IPI/NIVO to CRT on disease free and overall survival. - Exploratory objectives are to characterize tumor inflammation and the immune - contexture in the tumor and tumor-draining lymph nodes (TDLN), and to explore the - effects of IPI/NIVO and CRT and surgery on distribution and phenotype of - peripheral blood immune subsets. DISCUSSION: The INCREASE trial will evaluate the - safety and local efficacy of a combination of 4 modalities in patients with - resectable, T3-4N0-1 NSCLC. Translational research will investigate the - mechanisms of action and drug related adverse events. TRIAL REGISTRATION: - Netherlands Trial Registration (NTR): NL8435 , Registered 03 March 2020. -FAU - Dickhoff, Chris -AU - Dickhoff C -AUID- ORCID: 0000-0002-6396-8372 -AD - Department of Surgery and Cardiothoracic Surgery, Amsterdam University Medical - Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, - Amsterdam, the Netherlands. c.dickhoff@amsterdamumc.nl. -FAU - Senan, Suresh -AU - Senan S -AD - Department of Radiation Oncology, Amsterdam University Medical Center, location - VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the - Netherlands. -FAU - Schneiders, Famke L -AU - Schneiders FL -AD - Department of Radiation Oncology, Amsterdam University Medical Center, location - VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the - Netherlands. -FAU - Veltman, Joris -AU - Veltman J -AD - Department of Pulmonary Diseases, Amsterdam University Medical Center, location - VUmcCancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the - Netherlands. -FAU - Hashemi, Sayed -AU - Hashemi S -AD - Department of Pulmonary Diseases, Amsterdam University Medical Center, location - VUmcCancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the - Netherlands. -FAU - Daniels, Johannes M A -AU - Daniels JMA -AD - Department of Pulmonary Diseases, Amsterdam University Medical Center, location - VUmcCancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the - Netherlands. -FAU - Fransen, Marieke -AU - Fransen M -AD - Department of Pulmonary Diseases, Amsterdam University Medical Center, location - VUmcCancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the - Netherlands. -FAU - Heineman, David J -AU - Heineman DJ -AD - Department of Surgery and Cardiothoracic Surgery, Amsterdam University Medical - Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, - Amsterdam, the Netherlands. -FAU - Radonic, Teodora -AU - Radonic T -AD - Department of Pathology, Amsterdam University Medical Center, location VUmc, - Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the Netherlands. -FAU - van de Ven, Peter M -AU - van de Ven PM -AD - Department of Epidemiology and Biostatistics, Amsterdam University Medical - Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, - Amsterdam, the Netherlands. -FAU - Bartelink, Imke H -AU - Bartelink IH -AD - Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical - Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, - Amsterdam, the Netherlands. -FAU - Meijboom, Lilian J -AU - Meijboom LJ -AD - Department of Radiology and Nuclear Medicine, Amsterdam University Medical - Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, - Amsterdam, the Netherlands. -FAU - Garcia-Vallejo, Juan J -AU - Garcia-Vallejo JJ -AD - Department of Molecular Cell Biology & Immunology, Amsterdam University Medical - Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, - Amsterdam, the Netherlands. -FAU - Oprea-Lager, Daniela E -AU - Oprea-Lager DE -AD - Department of Radiology and Nuclear Medicine, Amsterdam University Medical - Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, - Amsterdam, the Netherlands. -FAU - de Gruijl, Tanja D -AU - de Gruijl TD -AD - Department of Medical Oncology, Amsterdam University Medical Center, location - VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the - Netherlands. -FAU - Bahce, Idris -AU - Bahce I -AD - Department of Pulmonary Diseases, Amsterdam University Medical Center, location - VUmcCancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the - Netherlands. -LA - eng -PT - Clinical Trial Protocol -PT - Journal Article -DEP - 20200814 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Ipilimumab) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Adult -MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse - effects -MH - Carcinoma, Non-Small-Cell Lung/diagnosis/immunology/mortality/*therapy -MH - Chemoradiotherapy, Adjuvant/adverse effects/methods -MH - Clinical Trials, Phase II as Topic -MH - Disease-Free Survival -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Immune Checkpoint Inhibitors/administration & dosage/*adverse effects -MH - Ipilimumab/administration & dosage/*adverse effects -MH - Lung/diagnostic imaging/pathology/surgery -MH - Lung Neoplasms/diagnosis/immunology/mortality/*therapy -MH - Male -MH - Neoadjuvant Therapy/*adverse effects/methods -MH - Neoplasm Staging -MH - Netherlands -MH - Nivolumab/administration & dosage/adverse effects -MH - Pneumonectomy -MH - Prospective Studies -MH - Tomography, X-Ray Computed -PMC - PMC7427738 -OTO - NOTNLM -OT - Locally advanced -OT - NSCLC -OT - Neoadjuvant immunotherapy -OT - Pathological response -OT - Thoracic surgery -COIS- CD, FS, JV, SH, JD, MF, DH, PV, IHB, LM, JGV and DOLdeclare no competing - interests. TG receives consultation fees from TILT Biotherapeutics, DCPrime, - Macrophage Pharma and Partner Therapeutics, and receives research support from - Marcrophage Pharma and Idera Pharmaceuticals, outside the submitted work. TR - reports research support from Abbvie Pharmaceuticals ad participates in advisory - boards of Roche, MSD, and Abbvie. Suresh Senan reports consulting/advisory fees - from AstraZeneca, Merck, Celgene and Eli Lilly. His department has received - research funding from AstraZeneca, ViewRay Inc. and Varian, outside the submitted - work. IB reports consulting/advisory fees from AstraZeneca, MSD, Boehringer - Ingelheim, Pfizer, Takeda, Celgene, Roche, BMS and Eli Lilly. His department has - received research funding from AstraZeneca, BMS, Boehringer Ingelheim, - HeatBiologics, Roche and MSD outside the submitted work. -EDAT- 2020/08/17 06:00 -MHDA- 2021/04/15 06:00 -PMCR- 2020/08/14 -CRDT- 2020/08/16 06:00 -PHST- 2020/03/23 00:00 [received] -PHST- 2020/08/05 00:00 [accepted] -PHST- 2020/08/16 06:00 [entrez] -PHST- 2020/08/17 06:00 [pubmed] -PHST- 2021/04/15 06:00 [medline] -PHST- 2020/08/14 00:00 [pmc-release] -AID - 10.1186/s12885-020-07263-9 [pii] -AID - 7263 [pii] -AID - 10.1186/s12885-020-07263-9 [doi] -PST - epublish -SO - BMC Cancer. 2020 Aug 14;20(1):764. doi: 10.1186/s12885-020-07263-9. - -PMID- 38346736 -OWN - NLM -STAT- MEDLINE -DCOM- 20241014 -LR - 20241014 -IS - 1349-7235 (Electronic) -IS - 0918-2918 (Linking) -VI - 63 -IP - 20 -DP - 2024 Oct 15 -TI - Real-world Prognostic Data on Unresectable Stage III Non-small-cell Lung Cancer - Treated with Concurrent Chemoradiation Therapy by Histological Type. -PG - 2757-2765 -LID - 10.2169/internalmedicine.3097-23 [doi] -AB - Objective The current standard treatment for locally advanced, unresectable stage - III non-small-cell lung cancer (NSCLC) is concurrent chemoradiation therapy - (CCRT) and durvalumab administration. Although reports have indicated that the - prognosis of squamous cell carcinoma is poorer than that of adenocarcinoma, - real-world data are currently inadequate. Methods The present study analyzed - patients with stage III NSCLC who received CCRT at the study center between April - 2018 and February 2022. These patients were retrospectively classified into - adenocarcinoma and squamous cell carcinoma groups for an analysis of the - progression-free survival (PFS), overall survival (OS), and patient background - factors, including the age, performance status, smoking history, and pre-CCRT - laboratory data. Results A total of 109 patients were included for the analysis; - 25 were excluded, and 44 and 40 patients were classified into the adenocarcinoma - and squamous cell carcinoma groups, respectively. The median PFS was - significantly longer in the adenocarcinoma group than in the squamous cell - carcinoma group [27.9 (95% confidence interval (CI): 15.2-not achieved) vs. 9.63 - (95% CI: 5.88-13.9) months; p<0.01]. Similarly, the median OS was significantly - longer in the adenocarcinoma group than in the squamous cell carcinoma group [not - achieved (95% CI: 48.1-not achieved) vs. 23.8 (95% CI; 14.6-not achieved) months; - p<0.01]. In the multivariate Cox proportional hazard analysis, the histological - type was the only prognostic factor for the PFS (p<0.05) and OS (p<0.05). - Conclusion The median PFS and OS were poorer in patients with squamous cell - carcinoma than in those with stage III NSCLC treated with CCRT and durvalumab. - The histological type was an independent factor affecting the PFS and OS. -FAU - Toriyama, Kazutoshi -AU - Toriyama K -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, Japan. -FAU - Yomota, Makiko -AU - Yomota M -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, Japan. -FAU - Asai, Maiko -AU - Asai M -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, Japan. -FAU - Hashimoto, Kana -AU - Hashimoto K -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, Japan. -FAU - Mirokuji, Kie -AU - Mirokuji K -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, Japan. -FAU - Kawai, Shoko -AU - Kawai S -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, Japan. -FAU - Watanabe, Kageaki -AU - Watanabe K -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, Japan. -FAU - Narita, Kosuke -AU - Narita K -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, Japan. -FAU - Hosomi, Yukio -AU - Hosomi Y -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, Japan. -LA - eng -PT - Journal Article -DEP - 20240212 -PL - Japan -TA - Intern Med -JT - Internal medicine (Tokyo, Japan) -JID - 9204241 -RN - 28X28X9OKV (durvalumab) -RN - 0 (Antibodies, Monoclonal) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/pathology/mortality -MH - Male -MH - Female -MH - *Lung Neoplasms/therapy/pathology/mortality -MH - Middle Aged -MH - Aged -MH - *Chemoradiotherapy -MH - Retrospective Studies -MH - *Carcinoma, Squamous Cell/therapy/pathology/mortality -MH - *Neoplasm Staging -MH - Prognosis -MH - Adenocarcinoma/therapy/pathology/mortality -MH - Progression-Free Survival -MH - Adult -MH - Aged, 80 and over -MH - Antibodies, Monoclonal/therapeutic use/administration & dosage -OTO - NOTNLM -OT - chemoradiation therapy -OT - durvalumab -OT - immune checkpoint inhibitor -OT - non-small-cell lung cancer -EDAT- 2024/02/13 00:42 -MHDA- 2024/10/15 00:20 -CRDT- 2024/02/12 20:33 -PHST- 2024/10/15 00:20 [medline] -PHST- 2024/02/13 00:42 [pubmed] -PHST- 2024/02/12 20:33 [entrez] -AID - 10.2169/internalmedicine.3097-23 [doi] -PST - ppublish -SO - Intern Med. 2024 Oct 15;63(20):2757-2765. doi: 10.2169/internalmedicine.3097-23. - Epub 2024 Feb 12. - -PMID- 36189237 -OWN - NLM -STAT- MEDLINE -DCOM- 20221004 -LR - 20221004 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 13 -DP - 2022 -TI - Case report: Pneumonia with clinical symptoms precedes imaging evidence after - immune checkpoint inhibitors combined with radiotherapy in lung squamous cell - cancer. -PG - 998516 -LID - 10.3389/fimmu.2022.998516 [doi] -LID - 998516 -AB - Immune-checkpoint inhibitors (ICI) targeting programmed cell death 1 (PD-1) and - its ligand 1 (PD-L1) have quickly changed the treatment landscape in advanced - non-small cell lung cancer. However, any patient treated with an immune - checkpoint inhibitor is at risk for immune-related adverse events (irAEs). - Checkpoint inhibitor pneumonitis (CIP) is a rare but potentially severe pulmonary - toxicity of immunotherapy. Since the imaging features and symptoms are not - specific, the diagnosis of CIP is challenging. In addition, CIP may mimic other - lung diseases. Due to these characteristics, proper patient management may be - delayed. So, a comprehensive understanding of imaging features is essential for a - prompt detection and correct management of these drug-induced lung diseases. We - presented a patient with lung squamous cell cancer who has clinical symptoms - preceding imaging evidence of pneumonitis after immunotherapy and radiotherapy. - We also discussed the safety of immunotherapy, the complexity and management of - immune pneumonitis. -CI - Copyright © 2022 Wang, Wang, Yu and Meng. -FAU - Wang, Yao -AU - Wang Y -AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of - Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, China. -AD - Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, - China. -FAU - Wang, Yimeng -AU - Wang Y -AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of - Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, China. -AD - Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, - China. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of - Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, China. -AD - Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, - China. -FAU - Meng, Xiangjiao -AU - Meng X -AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of - Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, China. -AD - Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, - China. -LA - eng -PT - Case Reports -PT - Research Support, Non-U.S. Gov't -DEP - 20220915 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (B7-H1 Antigen) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Ligands) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - B7-H1 Antigen -MH - *Carcinoma, Non-Small-Cell Lung -MH - *Carcinoma, Squamous Cell -MH - Epithelial Cells -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects -MH - Ligands -MH - Lung -MH - *Lung Neoplasms -MH - *Pneumonia/chemically induced/drug therapy -MH - Programmed Cell Death 1 Receptor -PMC - PMC9520566 -OTO - NOTNLM -OT - cancer immunotherapy -OT - immune checkpoint inhibitors (ICI) -OT - immune-related adverse event(irAE) -OT - pneumonitis -OT - programmed cell death 1 inhibitor -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/10/04 06:00 -MHDA- 2022/10/05 06:00 -PMCR- 2022/01/01 -CRDT- 2022/10/03 05:18 -PHST- 2022/07/20 00:00 [received] -PHST- 2022/09/01 00:00 [accepted] -PHST- 2022/10/03 05:18 [entrez] -PHST- 2022/10/04 06:00 [pubmed] -PHST- 2022/10/05 06:00 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2022.998516 [doi] -PST - epublish -SO - Front Immunol. 2022 Sep 15;13:998516. doi: 10.3389/fimmu.2022.998516. eCollection - 2022. - -PMID- 36159875 -OWN - NLM -STAT- MEDLINE -DCOM- 20220928 -LR - 20220928 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 13 -DP - 2022 -TI - Case report: A persistently expanded T cell response in an exceptional responder - to radiation and atezolizumab for metastatic non-small cell lung cancer. -PG - 961105 -LID - 10.3389/fimmu.2022.961105 [doi] -LID - 961105 -AB - Most patients with advanced non-small cell lung cancer (NSCLC) do not achieve a - durable remission after treatment with immune checkpoint inhibitors. Here we - report the clinical history of an exceptional responder to radiation and - anti-program death-ligand 1 (PD-L1) monoclonal antibody, atezolizumab, for - metastatic NSCLC who remains in a complete remission more than 8 years after - treatment. Sequencing of the patient's T cell repertoire from a metastatic lesion - and the blood before and after anti-PD-L1 treatment revealed oligoclonal T cell - expansion. Characterization of the dominant T cell clone, which comprised 10% of - all clones and increased 10-fold in the blood post-treatment, revealed an - activated CD8(+) phenotype and reactivity against 4 HLA-A2 restricted neopeptides - but not viral or wild-type human peptides, suggesting tumor reactivity. We - hypothesize that the patient's exceptional response to anti-PD-L1 therapy may - have been achieved by increased tumor immunogenicity promoted by pre-treatment - radiation therapy as well as long-term persistence of oligoclonal expanded - circulating T cells. -CI - Copyright © 2022 Coffey, Xu, Towlerton, Kowanetz, Hegde, Darwish, Yadav, - Blanchette, Ruppert, Bertino, Xu, Ferretti, Weinheimer, Hellmann, Qin, Thomas, - Warren and Ramnath. -FAU - Coffey, David G -AU - Coffey DG -AD - Department of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, United - States. -AD - Department of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, United - States. -FAU - Xu, Yuexin -AU - Xu Y -AD - Department of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, United - States. -FAU - Towlerton, Andrea M H -AU - Towlerton AMH -AD - Department of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, United - States. -FAU - Kowanetz, Marcin -AU - Kowanetz M -AD - ArriVent Biopharma, Newtown Square, PA, United States. -FAU - Hegde, Priti -AU - Hegde P -AD - Foundation Medicine, Cambridge, MA, United States. -FAU - Darwish, Martine -AU - Darwish M -AD - Genentech, San Francisco, CA, United States. -FAU - Yadav, Mahesh -AU - Yadav M -AD - Genentech, San Francisco, CA, United States. -FAU - Blanchette, Craig -AU - Blanchette C -AD - Genentech, San Francisco, CA, United States. -FAU - Ruppert, Shannon M -AU - Ruppert SM -AD - Genentech, San Francisco, CA, United States. -FAU - Bertino, Sarah -AU - Bertino S -AD - TScan Therapeutics, Waltham, MA, United States. -FAU - Xu, Qikai -AU - Xu Q -AD - TScan Therapeutics, Waltham, MA, United States. -FAU - Ferretti, Andrew -AU - Ferretti A -AD - TScan Therapeutics, Waltham, MA, United States. -FAU - Weinheimer, Adam -AU - Weinheimer A -AD - TScan Therapeutics, Waltham, MA, United States. -FAU - Hellmann, Matthew -AU - Hellmann M -AD - AstraZeneca, Wilmington, DE, United States. -FAU - Qin, Angel -AU - Qin A -AD - Department of Medicine, University of Michigan, Ann Arbor, MI, United States. -FAU - Thomas, Dafydd -AU - Thomas D -AD - Department of Pathology, University of Michigan, Ann Arbor, MI, United States. -FAU - Warren, Edus H -AU - Warren EH -AD - Department of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, United - States. -FAU - Ramnath, Nithya -AU - Ramnath N -AD - Department of Medicine, University of Michigan, Ann Arbor, MI, United States. -AD - Precision Oncology Program, Veterans Affairs, Ann Arbor Healthcare System, Ann - Arbor, MI, United States. -LA - eng -GR - P30 CA015704/CA/NCI NIH HHS/United States -GR - S10 OD028685/OD/NIH HHS/United States -PT - Case Reports -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20220909 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (HLA-A2 Antigen) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 52CMI0WC3Y (atezolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - HLA-A2 Antigen -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - *Lung Neoplasms/drug therapy/genetics -MH - T-Lymphocytes -PMC - PMC9500393 -OTO - NOTNLM -OT - case report -OT - immunotherapy -OT - lung neoplasms -OT - programmed death-ligand 1 -OT - t lymphocytes -COIS- MK was employed by ArriVent. PH was employed by Foundation Medicine. MD, MY, CB, - and SB were employed by Genetech. QX, AF, AW were employed by Tscan. The - remaining authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/09/27 06:00 -MHDA- 2022/09/28 06:00 -PMCR- 2022/01/01 -CRDT- 2022/09/26 17:41 -PHST- 2022/06/03 00:00 [received] -PHST- 2022/08/22 00:00 [accepted] -PHST- 2022/09/26 17:41 [entrez] -PHST- 2022/09/27 06:00 [pubmed] -PHST- 2022/09/28 06:00 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2022.961105 [doi] -PST - epublish -SO - Front Immunol. 2022 Sep 9;13:961105. doi: 10.3389/fimmu.2022.961105. eCollection - 2022. - -PMID- 28711032 -OWN - NLM -STAT- MEDLINE -DCOM- 20180221 -LR - 20180221 -IS - 1878-1705 (Electronic) -IS - 1567-5769 (Linking) -VI - 50 -DP - 2017 Sep -TI - Influence of the number and interval of treatment cycles on cytokine-induced - killer cells and their adjuvant therapeutic effects in advanced non-small-cell - lung cancer (NSCLC). -PG - 263-269 -LID - S1567-5769(17)30272-2 [pii] -LID - 10.1016/j.intimp.2017.07.006 [doi] -AB - OBJECTIVE: Cytokine-induced killer (CIK) cells have important therapeutic effects - in adoptive cell transfer (ACT) for the treatment of various malignancies. In - this study, we focused on in vitro expansion of CIK cells and their clinical - efficacy in combination with chemotherapy in patients with advanced - non-small-cell lung cancer (NSCLC). METHODS: A total of 64 patients with NSCLC - (enrolled from 2011 to 2012), including 32 patients who received chemotherapy - alone or with sequential radiotherapy (conventional treatment, control group) and - 32 patients who received conventional treatment and sequential CIK infusion - (study group), were retrospectively analyzed. The time to progression (TTP), - overall survival (OS) and adverse effects were analyzed and the phenotype of - lymphocytes in CIK population was also determined by flow cytometry. RESULTS: - After in vitro expansion, the average percentage of CIK cells was 26.35%. During - the 54-month follow up, the median OS and TTP were significantly longer in the - study group than in the control group (P=0.0189 and P=0.0129, respectively). The - median OS of the ACT≥4cycles subgroup was significantly longer than that of the - ACT<4cycles subgroup (P=0.0316). The percentage of CIK cells in patients who - received ≥4cycles of ACT was higher than that in patients treated with <4cycles - of ACT (P=0.0376). Notably, CIK cells were difficult to expand in vitro in some - patients after the first ACT cycle but became much easier as the treatment cycles - increased monthly. Longer treatment interval negatively impacted the expansion of - CIK cells. CONCLUSIONS: Systematic immune levels can be increasingly boosted by - reinfusion of ACT. Conventional treatment plus CIK cells is an effective - therapeutic strategy to prevent progression and prolong survival of patients with - advanced NSCLC. -CI - Copyright © 2017. Published by Elsevier B.V. -FAU - Gu, Yuanlong -AU - Gu Y -AD - Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer - Hospital, Harbin 150081, China. -FAU - Lv, Huimin -AU - Lv H -AD - Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150081, - China. -FAU - Zhao, Juan -AU - Zhao J -AD - Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150081, - China. -FAU - Li, Qi -AU - Li Q -AD - Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150081, - China. -FAU - Mu, Guannan -AU - Mu G -AD - Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150081, - China. -FAU - Li, Jiade -AU - Li J -AD - Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150081, - China. -FAU - Wuyang, Jiazi -AU - Wuyang J -AD - Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150081, - China. -FAU - Lou, Ge -AU - Lou G -AD - Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin - 150081, China. -FAU - Wang, Ruitao -AU - Wang R -AD - Department of Internal medicine, Harbin Medical University Cancer Hospital, - Harbin 150081, China. -FAU - Zhang, Yanqiao -AU - Zhang Y -AD - Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer - Hospital, Harbin 150081, China. Electronic address: - yanqiaozhang@ems.hrbmu.edu.cn. -FAU - Huang, Xiaoyi -AU - Huang X -AD - Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150081, - China; Center of Translational Medicine, Harbin Medical University, Harbin - 150086, China. Electronic address: xyhuang@hrbmu.edu.cn. -LA - eng -PT - Journal Article -DEP - 20170712 -PL - Netherlands -TA - Int Immunopharmacol -JT - International immunopharmacology -JID - 100965259 -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Carcinoma, Non-Small-Cell Lung/mortality/pathology/*therapy -MH - Cell Proliferation -MH - Cells, Cultured -MH - Chemoradiotherapy, Adjuvant/*methods -MH - Combined Modality Therapy -MH - Cytokine-Induced Killer Cells/*immunology/transplantation -MH - Female -MH - Humans -MH - Immunotherapy, Adoptive/*methods -MH - Lung Neoplasms/mortality/pathology/*therapy -MH - Lymphocyte Count -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Retrospective Studies -MH - Survival Analysis -MH - Treatment Outcome -OTO - NOTNLM -OT - Adoptive cell transfer -OT - Advanced non-small-cell lung cancer -OT - Cytokine-induced killer cells -OT - Overall survival -OT - Time to transfer -EDAT- 2017/07/16 06:00 -MHDA- 2018/02/22 06:00 -CRDT- 2017/07/16 06:00 -PHST- 2017/05/04 00:00 [received] -PHST- 2017/07/01 00:00 [revised] -PHST- 2017/07/07 00:00 [accepted] -PHST- 2017/07/16 06:00 [pubmed] -PHST- 2018/02/22 06:00 [medline] -PHST- 2017/07/16 06:00 [entrez] -AID - S1567-5769(17)30272-2 [pii] -AID - 10.1016/j.intimp.2017.07.006 [doi] -PST - ppublish -SO - Int Immunopharmacol. 2017 Sep;50:263-269. doi: 10.1016/j.intimp.2017.07.006. Epub - 2017 Jul 12. - -PMID- 29948974 -OWN - NLM -STAT- MEDLINE -DCOM- 20190514 -LR - 20200225 -IS - 1699-3055 (Electronic) -IS - 1699-048X (Linking) -VI - 21 -IP - 2 -DP - 2019 Feb -TI - The absolute lymphocyte count can predict the overall survival of patients with - non-small cell lung cancer on nivolumab: a clinical study. -PG - 206-212 -LID - 10.1007/s12094-018-1908-2 [doi] -AB - INTRODUCTION: The neutrophil-to-lymphocyte (ANC/ALC) ratio is associated with - worse prognosis in patients with NSCLC on immunotherapies, but the role of ALC - remains unclear. The previous radiation therapy causes lymphopenia, and given - approaches of combining radiation with immunotherapies, it is critical to better - understand the impact of peripheral lymphocytes. PATIENTS AND METHODS: We - evaluated retrospectively 22 patients with advanced NSCLC treated with nivolumab - at Boston Medical Center from January 2014 to September 2016 and correlated the - peripheral blood counts with the overall survival (OS) and overall time on - treatment. We assessed the effect of the previous radiation on peripheral blood - counts and clinical outcomes. RESULTS: Baseline ALC and ANC/ALC ratios are - positively and negatively correlated, respectively, with the OS on nivolumab. The - ALC and ALC/WBC ratios at 6 weeks on treatment are positively associated with the - OS. Kaplan-Meier analysis at baseline and at 6 weeks showed significantly - increased OS in the group of patients with the highest ALC. The previous - radiation therapy was positively correlated with the ANC and negatively - correlated with the ALC/WBC ratio at 8 weeks after the initiation of nivolumab. - CONCLUSION: Our finding that ALC at baseline and at 6 weeks on treatment is - positively correlated with the OS provides an easily obtained predictive marker. - Our result that the previous radiation is associated with higher ANC and lower - ALC during treatment supports that the combination of radiation therapy with - immunotherapy should be carefully applied and potentially peripheral blood counts - can be utilized to stratify patients for this approach. -FAU - Karantanos, T -AU - Karantanos T -AUID- ORCID: 0000-0002-6792-8298 -AD - Medical Oncology Department, Sidney Kimmel Comprehensive Cancer Center, Johns - Hopkins University Hospital, 401 North Broadway Ave, Baltimore, MD, 21287, USA. - Theodoroskarantanosmd@gmail.com. -AD - General Internal Medicine Department, Boston Medical Center, Boston University - School of Medicine, 850 Harrison Ave, Boston, MA, 02118, USA. - Theodoroskarantanosmd@gmail.com. -FAU - Karanika, S -AU - Karanika S -AD - General Internal Medicine Department, Boston Medical Center, Boston University - School of Medicine, 850 Harrison Ave, Boston, MA, 02118, USA. -FAU - Seth, B -AU - Seth B -AD - General Internal Medicine Department, Boston Medical Center, Boston University - School of Medicine, 850 Harrison Ave, Boston, MA, 02118, USA. -FAU - Gignac, G -AU - Gignac G -AD - Hematology-Oncology, Department of Internal Medicine, Boston Medical Center, - Boston University School of Medicine, 820 Harrison Ave, FGH Building, 1st Floor, - Boston, MA, 02118, USA. -LA - eng -PT - Clinical Study -PT - Journal Article -DEP - 20180613 -PL - Italy -TA - Clin Transl Oncol -JT - Clinical & translational oncology : official publication of the Federation of - Spanish Oncology Societies and of the National Cancer Institute of Mexico -JID - 101247119 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Biomarkers, Tumor) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Adult -MH - Aged -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Biomarkers, Tumor/blood/immunology -MH - Carcinoma, Non-Small-Cell Lung/*immunology/mortality/*therapy -MH - Chemoradiotherapy/methods -MH - Female -MH - Humans -MH - Kaplan-Meier Estimate -MH - Lung Neoplasms/*immunology/mortality/*therapy -MH - Lymphocyte Count -MH - Male -MH - Middle Aged -MH - Nivolumab/*therapeutic use -MH - Prognosis -MH - Retrospective Studies -MH - Treatment Outcome -OTO - NOTNLM -OT - Lung cancer -OT - Lymphocytes -OT - Nivolumab -OT - Peripheral blood counts -OT - Radiation therapy -EDAT- 2018/06/28 06:00 -MHDA- 2019/05/15 06:00 -CRDT- 2018/06/28 06:00 -PHST- 2018/03/15 00:00 [received] -PHST- 2018/06/04 00:00 [accepted] -PHST- 2018/06/28 06:00 [pubmed] -PHST- 2019/05/15 06:00 [medline] -PHST- 2018/06/28 06:00 [entrez] -AID - 10.1007/s12094-018-1908-2 [pii] -AID - 10.1007/s12094-018-1908-2 [doi] -PST - ppublish -SO - Clin Transl Oncol. 2019 Feb;21(2):206-212. doi: 10.1007/s12094-018-1908-2. Epub - 2018 Jun 13. - -PMID- 37596831 -OWN - NLM -STAT- MEDLINE -DCOM- 20231003 -LR - 20231006 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 14 -IP - 28 -DP - 2023 Oct -TI - Investigation of the efficacy and feasibility of combined therapy of - PD-L1-enhanced exogenous peripatetic adoptive natural killer (NK) cells in - combination with antiangiogenic targeted therapy in the treatment of - extensive-stage small cell lung cancer. -PG - 2877-2885 -LID - 10.1111/1759-7714.15040 [doi] -AB - A 67-year-old male patient presented with extensive-stage small cell lung cancer - with the primary lesion located in the right upper lung, accompanied by multiple - metastases to the pleura and abdominal cavity with enlarged mediastinal lymph - nodes. A combination therapy approach was used to target the patient's multiple - systemic metastases after localized radiotherapy. The approach involved adoptive - transfer of programmed death ligand 1 (PD-L1) enhanced exogenous natural killer - (NK) cells, along with antiangiogenic treatment. Allogeneic cord blood NK cells - were infused back into the patient over two consecutive days. On the first day, - the treatment was followed by a dose of 1200 mg of atezolizumab. Subsequently, - the patient received a daily dose of 10 mg of anlotinib administered orally for - 14 days. This was followed by a 7-day break, and each cycle lasted 21 days. After - delivering localized radiation to the primary lesion in the right lung and - metastatic mediastinal lymph nodes, complete remission was achieved in the local - lesion, effectively avoiding the risk of superior vena cava syndrome. Following - six cycles of combined therapy, most of the metastatic lesions had disappeared, - and the remaining metastatic lesions had significantly reduced in size. The - recent therapeutic effect resulted in partial remission. The combination therapy - of immune checkpoint inhibitor PD-L1-enhanced exogenous adoptive transfer NK - cells, along with antiangiogenic targeted treatment, demonstrated a satisfactory - short-term effect, with disappearance of most of the metastases and noticeable - shrinkage in the remaining metastatic lesions. -CI - © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Wang, Zhizhen -AU - Wang Z -AD - Tianjin Medical University Cancer Institute & Hospital, National Clinical - Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, - Tianjin, China. -FAU - Zhang, Ruiping -AU - Zhang R -AUID- ORCID: 0000-0001-5506-7016 -AD - Tianjin Medical University Cancer Institute & Hospital, National Clinical - Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, - Tianjin, China. -FAU - Cao, Yuchan -AU - Cao Y -AD - Brown University School of Public Health, Brown University, Providence, Rhode - Island, USA. -FAU - Chen, Yang -AU - Chen Y -AD - Tianjin Medical University Cancer Institute & Hospital, National Clinical - Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, - Tianjin, China. -FAU - Huang, Sheng -AU - Huang S -AD - Tianjin Medical University Cancer Institute & Hospital, National Clinical - Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, - Tianjin, China. -FAU - Luo, Yan'an -AU - Luo Y -AD - Nankai University, Tianjin, China. -LA - eng -PT - Case Reports -PT - Research Support, Non-U.S. Gov't -DEP - 20230819 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (CD274 protein, human) -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Male -MH - Humans -MH - Aged -MH - *Lung Neoplasms/drug therapy/pathology -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - B7-H1 Antigen -MH - *Small Cell Lung Carcinoma/drug therapy/pathology -MH - Feasibility Studies -MH - *Superior Vena Cava Syndrome/pathology -MH - Killer Cells, Natural -PMC - PMC10542463 -OTO - NOTNLM -OT - PD-1/PD-L1 -OT - antiangiogenesis -OT - extensive-stage small-cell lung cancer -OT - immune checkpoint inhibitor -OT - radiotherapy -COIS- The authors declare that they have no competing interests. -EDAT- 2023/08/19 11:43 -MHDA- 2023/10/03 06:47 -PMCR- 2023/08/19 -CRDT- 2023/08/19 03:43 -PHST- 2023/07/04 00:00 [revised] -PHST- 2023/06/05 00:00 [received] -PHST- 2023/07/05 00:00 [accepted] -PHST- 2023/10/03 06:47 [medline] -PHST- 2023/08/19 11:43 [pubmed] -PHST- 2023/08/19 03:43 [entrez] -PHST- 2023/08/19 00:00 [pmc-release] -AID - TCA15040 [pii] -AID - 10.1111/1759-7714.15040 [doi] -PST - ppublish -SO - Thorac Cancer. 2023 Oct;14(28):2877-2885. doi: 10.1111/1759-7714.15040. Epub 2023 - Aug 19. - -PMID- 32128667 -OWN - NLM -STAT- MEDLINE -DCOM- 20210902 -LR - 20210902 -IS - 1573-0646 (Electronic) -IS - 0167-6997 (Print) -IS - 0167-6997 (Linking) -VI - 38 -IP - 5 -DP - 2020 Oct -TI - Clinical and radiation dose-volume factors related to pneumonitis after treatment - with radiation and durvalumab in locally advanced non-small cell lung cancer. -PG - 1612-1617 -LID - 10.1007/s10637-020-00917-2 [doi] -AB - Introduction Durvalumab has been shown to confer a survival benefit after - definitive chemoradiotherapy in the patients with locally advanced non-small cell - lung cancer, but no studies have attempted to identify risk factors for - pneumonitis after durvalumab therapy. The purpose of this study was to - investigate associations between clinical and radiation dose-volume factors, and - the severity of pneumonitis. Methods We retrospectively assessed the cases of 30 - patients who had been started on durvalumab therapy between July 2018 and - February 2019. In this study we evaluated the percentage of lung volume receiving - radiation dose in excess of 20 Gy (V20) as radiation dose-volume factor. We - compared V20 and some baseline factors between a grade 0 or 1 (Gr 0/1) - pneumonitis group and a grade 2 or more (≥Gr 2) pneumonitis group, and we - performed a logistic regression analysis to establish the associations between - variables and ≥ Gr 2 pneumonitis. Results Pneumonitis had developed in 22 - patients (73.3%): Gr 1/2/3-5 in 8 (26.7%)/14 (46.7%) /0 (0%), respectively. The - difference in V20 between the Gr 0/1 group and Gr 2 group (median: 20.5% vs. - 23.5%, p = 0.505) was not statistically significant, and thus V20 was not a risk - factor for Gr 2 pneumonitis (odds ratio: 1.047, p = 0.303). None of the clinical - factors, including sex, age, smoking history, presence of baseline pneumonitis, - type of radiation therapy, location of lesion and facility, were risk factors. - Conclusions Our study suggest that the severity of pneumonitis after durvalumab - is unrelated to V20 or any of the clinical factors assessed in this study. -FAU - Inoue, Hiroto -AU - Inoue H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Ono, Akira -AU - Ono A -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. a.ono@scchr.jp. -FAU - Kawabata, Takanori -AU - Kawabata T -AD - Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Mamesaya, Nobuaki -AU - Mamesaya N -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Kawamura, Takahisa -AU - Kawamura T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Kobayashi, Haruki -AU - Kobayashi H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Omori, Shota -AU - Omori S -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Wakuda, Kazushige -AU - Wakuda K -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Kenmotsu, Hirotsugu -AU - Kenmotsu H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Naito, Tateaki -AU - Naito T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Murakami, Haruyasu -AU - Murakami H -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. -FAU - Yasui, Kazuaki -AU - Yasui K -AD - Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Ogawa, Hirofumi -AU - Ogawa H -AD - Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Onoe, Tsuyoshi -AU - Onoe T -AD - Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Endo, Masahiro -AU - Endo M -AD - Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Harada, Hideyuki -AU - Harada H -AD - Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Takahashi, Toshiaki -AU - Takahashi T -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. -LA - eng -PT - Journal Article -DEP - 20200303 -PL - United States -TA - Invest New Drugs -JT - Investigational new drugs -JID - 8309330 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 28X28X9OKV (durvalumab) -SB - IM -EIN - Invest New Drugs. 2021 Jun;39(3):899. doi: 10.1007/s10637-020-00969-4. PMID: - 32591973 -MH - Aged -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*therapy -MH - *Chemoradiotherapy -MH - Female -MH - Humans -MH - Lung Neoplasms/*therapy -MH - Male -MH - Middle Aged -MH - Pneumonia/*etiology -MH - Radiation Dosage -MH - Retrospective Studies -PMC - PMC7497668 -OTO - NOTNLM -OT - Chemoradiotherapy -OT - Durvalumab -OT - Locally advanced non-small cell lung cancer -OT - Pneumonitis -OT - Risk factor -OT - V20 -COIS- H Inoue declares that he has no conflict of interest. A Ono received honoraria - from AstraZeneca. T Kawabata declares that he has no conflict of interest. N - mamesaya received honoraria from AstraZeneca. T Kawamura declares that he has no - conflict of interest. H Kobayashi declares that he has no conflict of interest. S - Omori received honoraria from AstraZeneca. K Wakuda received honoraria from - AstraZeneca. H Kenmotsu received honoraria and research funding to our - institution from AstraZeneca. T Naito declares that he has no conflict of - interest. H Murakami received honoraria and research funding to our institution - from AstraZeneca. K Yasui declares that he has no conflict of interest. H Ogawa - declares that he has no conflict of interest. T Onoe declares that he has no - conflict of interest. M Endo received honoraria from AstraZeneca. H Harada - received honoraria from AstraZeneca. T Takahashi received honoraria and research - funding to our institution from AstraZeneca. -EDAT- 2020/03/05 06:00 -MHDA- 2021/09/03 06:00 -PMCR- 2020/03/03 -CRDT- 2020/03/05 06:00 -PHST- 2020/01/17 00:00 [received] -PHST- 2020/02/25 00:00 [accepted] -PHST- 2020/03/05 06:00 [pubmed] -PHST- 2021/09/03 06:00 [medline] -PHST- 2020/03/05 06:00 [entrez] -PHST- 2020/03/03 00:00 [pmc-release] -AID - 10.1007/s10637-020-00917-2 [pii] -AID - 917 [pii] -AID - 10.1007/s10637-020-00917-2 [doi] -PST - ppublish -SO - Invest New Drugs. 2020 Oct;38(5):1612-1617. doi: 10.1007/s10637-020-00917-2. Epub - 2020 Mar 3. - -PMID- 37728607 -OWN - NLM -STAT- MEDLINE -DCOM- 20231216 -LR - 20231216 -IS - 1473-5628 (Electronic) -IS - 0143-3636 (Print) -IS - 0143-3636 (Linking) -VI - 45 -IP - 1 -DP - 2024 Jan 1 -TI - The tyrosine kinase inhibitor nintedanib enhances the efficacy of 90 Y-labeled - B5209B radioimmunotherapy targeting ROBO1 without increased toxicity in - small-cell lung cancer xenograft mice. -PG - 68-76 -LID - 10.1097/MNM.0000000000001775 [doi] -AB - BACKGROUND: Small cell lung cancer (SCLC) has a poor prognosis, and Roundabout - homolog 1 (ROBO1) is frequently expressed in SCLC. ROBO1-targeted - radioimmunotherapy (RIT) previously showed tumor shrinkage, but regrowth with - fibroblast infiltration was observed. The fibroblasts would support tumor - survival by secreting growth factors and cytokines. Inhibition of fibroblasts - offers a candidate strategy for increasing RIT efficacy. Here, we evaluated the - efficacy of combination therapy with 90 Y-labeled anti-ROBO1 antibody B5209B ( 90 - Y-B5209B) and the tyrosine kinase inhibitor nintedanib in SCLC xenograft mice. - METHODS: Subcutaneous NCI-H69 SCLC xenograft mice were divided into four groups: - saline, nintedanib alone, RIT alone, and a combination of RIT with nintedanib - (combination). A single dose of 7.4 MBq of 90 Y-B5209B was injected - intravenously. Nintedanib was orally administered at a dose of 400 µg five times - a week for 4 weeks. Tumor volumes and body weights were measured regularly. Tumor - sections were stained with hematoxylin and eosin or Masson trichrome. RESULTS: - All six tumors in the combination therapy group disappeared, and four tumors - showed no regrowth. Although RIT alone induced similar tumor shrinkage, regrowth - was observed. Prolonged survival in the combination therapy group was found - compared with the other groups. Temporary body weight loss was observed in RIT - and combination therapy. There is no difference in fibroblast infiltration - between RIT alone and the combination. CONCLUSION: Nintedanib significantly - enhanced the anti-tumor effects of RIT with the 90 Y-B5209B without an increase - in toxicity. These findings encourage further research into the potential - clinical application of combining RIT with nintedanib. -CI - Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. -FAU - Fujiwara, Kentaro -AU - Fujiwara K -AD - Department of Molecular Imaging and Theranostics, iQMS, National Institutes for - Quantum Science and Technology, Chiba, . -FAU - Tsuji, Atsushi B -AU - Tsuji AB -AD - Department of Molecular Imaging and Theranostics, iQMS, National Institutes for - Quantum Science and Technology, Chiba, . -FAU - Sudo, Hitomi -AU - Sudo H -AD - Department of Molecular Imaging and Theranostics, iQMS, National Institutes for - Quantum Science and Technology, Chiba, . -FAU - Sugyo, Aya -AU - Sugyo A -AD - Department of Molecular Imaging and Theranostics, iQMS, National Institutes for - Quantum Science and Technology, Chiba, . -FAU - Hamakubo, Takao -AU - Hamakubo T -AD - Department of Protein-protein Interaction Research, Institute for Advanced - Medical Sciences, Nippon Medical School and . -AD - Department of Quantitative Biology and Medicine, Research Center for Advanced - Science and Technology, The University of Tokyo, Tokyo, Japan. -FAU - Higashi, Tatsuya -AU - Higashi T -AD - Department of Molecular Imaging and Theranostics, iQMS, National Institutes for - Quantum Science and Technology, Chiba, . -LA - eng -PT - Journal Article -DEP - 20230921 -PL - England -TA - Nucl Med Commun -JT - Nuclear medicine communications -JID - 8201017 -RN - 0 (Nerve Tissue Proteins) -RN - G6HRD2P839 (nintedanib) -RN - 0 (Tyrosine Kinase Inhibitors) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Receptors, Immunologic) -SB - IM -MH - Humans -MH - Animals -MH - Mice -MH - Radioimmunotherapy -MH - *Small Cell Lung Carcinoma/drug therapy/radiotherapy -MH - Nerve Tissue Proteins -MH - Tyrosine Kinase Inhibitors -MH - Antibodies, Monoclonal/therapeutic use -MH - *Lung Neoplasms/drug therapy -MH - Heterografts -MH - Receptors, Immunologic -PMC - PMC10718214 -COIS- There are no conflicts of interest. -EDAT- 2023/09/20 12:52 -MHDA- 2023/12/17 09:46 -PMCR- 2023/12/13 -CRDT- 2023/09/20 11:00 -PHST- 2023/12/17 09:46 [medline] -PHST- 2023/09/20 12:52 [pubmed] -PHST- 2023/09/20 11:00 [entrez] -PHST- 2023/12/13 00:00 [pmc-release] -AID - 00006231-990000000-00211 [pii] -AID - 10.1097/MNM.0000000000001775 [doi] -PST - ppublish -SO - Nucl Med Commun. 2024 Jan 1;45(1):68-76. doi: 10.1097/MNM.0000000000001775. Epub - 2023 Sep 21. - -PMID- 38155421 -OWN - NLM -STAT- MEDLINE -DCOM- 20240220 -LR - 20240220 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 15 -IP - 5 -DP - 2024 Feb -TI - Comparison of primary and metastatic site-related PD-L1 expression in predicting - ORR in patients with advanced NSCLC who received ICB-based therapy. -PG - 379-385 -LID - 10.1111/1759-7714.15201 [doi] -AB - BACKGROUND: Whether the value of PD-L1 expression from metastatic sites to - predict the efficacy of immune checkpoint blockade (ICB)-based treatment is - equivalent to that from a primary tumor is uncertain. This study aimed to compare - the utility of PD-L1 TPS from a primary lung tumor and metastatic sites to - predict the overall response rate (ORR) of first-line ICB-based treatment. - METHODS: This study included 249 patients with advanced non-small cell lung - cancer (NSCLC) who received first-line ICB-based treatment. All subjects - underwent PD-L1 testing prior to ICB-based treatment and were divided into two - cohorts corresponding to the different biopsy sites: lung primary site-sampled - cohort (PT cohort, n = 167) and metastatic site-sampled cohort (MT cohort, - n = 82). RESULTS: There was no statistical significance in PD-L1 TPS distribution - between the two cohorts (p = 0.742). PD-L1 TPS ≥50% was also related to high ORR - compared with PD-L1 < 50% in the PT cohort (34.3% vs. 14.1%, p = 0.004). In - contrast, ICB-based therapy could bring comparable ORR (35.1% vs. 33.3%, - p = 0.871) in the MT cohort regardless of PD-L1 TPS status (≥50%, or <50%). As - supported, when the cutoff value of TPS was selected as 50%, it was suggested - that PT-related PD-L1 was the independent predictor of ORR (OR 2.870, 95% CI: - 1.231-6.694, p = 0.015) rather than MT-related PD-L1 (OR 0.689, 95% CI: - 0.236-2.013, p = 0.495). Furthermore, ROC proved that PT-related PD-L1 expression - manifested a better AUC of 0.621 (p = 0.026) than that of MT-related PD-L1 - (AUC = 0.565, p = 0.362). CONCLUSION: Compared with PT-related PD-L1 expression, - MT-related PD-L1 expression showed limited value in predicting ORR in patients - with advanced NSCLC receiving ICB-based therapy. It was concluded that even - patients with low MT-related PD-L1 expression could benefit from ICB-based - therapy. -CI - © 2023 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, - Ltd. -FAU - Zhou, Danhong -AU - Zhou D -AD - Department of Respiratory and Critical Medicine, The First Affiliated Hospital of - Soochow University, Suzhou, China. -FAU - Wang, Yang -AU - Wang Y -AD - Department of Respiratory and Critical Medicine, The First Affiliated Hospital of - Soochow University, Suzhou, China. -FAU - Ning, Weiwei -AU - Ning W -AD - Department of Respiratory and Critical Medicine, The First Affiliated Hospital of - Soochow University, Suzhou, China. -FAU - Chen, Cheng -AU - Chen C -AUID- ORCID: 0000-0002-9583-7991 -AD - Department of Respiratory and Critical Medicine, The First Affiliated Hospital of - Soochow University, Suzhou, China. -LA - eng -GR - 81672280/National Natural Science Foundation of China/ -GR - SYS2021042/Natural Science Foundation of Suzhou Municipality/ -PT - Comparative Study -PT - Journal Article -DEP - 20231228 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - Antibodies, Monoclonal, Humanized -MH - B7-H1 Antigen/metabolism -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - *Lung Neoplasms/drug therapy/genetics -MH - Radioimmunotherapy -PMC - PMC10864116 -OTO - NOTNLM -OT - PD-L1 -OT - comparison -OT - metastatic sites -OT - predictive -OT - primary site -COIS- All authors declare no financial or nonfinancial competing interests. -EDAT- 2023/12/29 06:43 -MHDA- 2024/02/15 06:43 -PMCR- 2023/12/28 -CRDT- 2023/12/29 00:33 -PHST- 2023/12/04 00:00 [revised] -PHST- 2023/09/24 00:00 [received] -PHST- 2023/12/07 00:00 [accepted] -PHST- 2024/02/15 06:43 [medline] -PHST- 2023/12/29 06:43 [pubmed] -PHST- 2023/12/29 00:33 [entrez] -PHST- 2023/12/28 00:00 [pmc-release] -AID - TCA15201 [pii] -AID - 10.1111/1759-7714.15201 [doi] -PST - ppublish -SO - Thorac Cancer. 2024 Feb;15(5):379-385. doi: 10.1111/1759-7714.15201. Epub 2023 - Dec 28. - -PMID- 36532056 -OWN - NLM -STAT- MEDLINE -DCOM- 20221220 -LR - 20231106 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 13 -DP - 2022 -TI - Case report: Brain metastasis necrosis with immune checkpoint inhibitors plus - chemotherapy for advanced non-small cell lung cancer. -PG - 1064596 -LID - 10.3389/fimmu.2022.1064596 [doi] -LID - 1064596 -AB - The emergence of immune checkpoint inhibitors (ICIs) has reshaped the landscape - of advanced lung cancer treatment. The brain is the most common metastatic site - for lung cancer. Whether conventional criteria can evaluate the intracranial - response of ICIs remains unclear. Here, we report a well-documented case of - intracranial necrosis confirmed by post-operative pathology after only one cycle - of chemo-immunotherapy without any radiation therapy, which suggests that - immunotherapy elicits strong anti-tumor responses for intracranial metastasis and - promotes intracranial necrosis, resulting in a temporary increase in size of the - target lesions. Still, the specific mechanisms and management strategies need to - be further explored. -CI - Copyright © 2022 Niu, Li, Meng, Zhang, Wan, Jing, Zhou and Zhou. -FAU - Niu, Lishui -AU - Niu L -AD - Department of Oncology, Xiangya Hospital, Central South University, Changsha, - China. -FAU - Li, Xiang -AU - Li X -AD - Department of Pathology, Xiangya Hospital, Central South University, Changsha, - China. -FAU - Meng, Li -AU - Meng L -AD - Department of Radiology, Xiangya Hospital, Central South University, Changsha, - China. -FAU - Zhang, Yingying -AU - Zhang Y -AD - Department of Oncology, Xiangya Hospital, Central South University, Changsha, - China. -FAU - Wan, Xin -AU - Wan X -AD - Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, - China. -FAU - Jing, Di -AU - Jing D -AD - Department of Oncology, Xiangya Hospital, Central South University, Changsha, - China. -FAU - Zhou, Qin -AU - Zhou Q -AD - Department of Oncology, Xiangya Hospital, Central South University, Changsha, - China. -FAU - Zhou, Rongrong -AU - Zhou R -AD - Department of Oncology, Xiangya Hospital, Central South University, Changsha, - China. -AD - Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, - China. -AD - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, - Central South University, Changsha, China. -LA - eng -PT - Case Reports -PT - Research Support, Non-U.S. Gov't -DEP - 20221201 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/metabolism -MH - *Lung Neoplasms/drug therapy/metabolism -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Brain Neoplasms/drug therapy -MH - Necrosis/drug therapy -PMC - PMC9752014 -OTO - NOTNLM -OT - brain metastasis -OT - brain necrosis -OT - case report -OT - immune checkpoint inhibitors -OT - lung cancer -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/12/20 06:00 -MHDA- 2022/12/21 06:00 -PMCR- 2022/01/01 -CRDT- 2022/12/19 04:05 -PHST- 2022/10/08 00:00 [received] -PHST- 2022/11/16 00:00 [accepted] -PHST- 2022/12/19 04:05 [entrez] -PHST- 2022/12/20 06:00 [pubmed] -PHST- 2022/12/21 06:00 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2022.1064596 [doi] -PST - epublish -SO - Front Immunol. 2022 Dec 1;13:1064596. doi: 10.3389/fimmu.2022.1064596. - eCollection 2022. - -PMID- 30888716 -OWN - NLM -STAT- MEDLINE -DCOM- 20200312 -LR - 20200312 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 10 -IP - 4 -DP - 2019 Apr -TI - Radiotherapy is an independent prognostic marker of favorable prognosis in - non-small cell lung cancer patients after treatment with the immune checkpoint - inhibitor, nivolumab. -PG - 992-1000 -LID - 10.1111/1759-7714.13044 [doi] -AB - BACKGROUND: It remains unclear why radiation clinically provides a synergistic - effect when combined with immune checkpoint inhibitors such as nivolumab. The - purpose of our study was to retrospectively evaluate whether the therapeutic - efficacy of nivolumab is improved as a result of a history of radiotherapy (RT) - in patients with previously treated advanced non-small cell lung cancer (NSCLC). - METHODS: From February 2016 to December 2017, 124 consecutive patients were - administered nivolumab for pretreated advanced NSCLC. The patients were divided - into RT and non-RT groups. RESULTS: Sixty-six (53%) of the 124 patients had been - administered RT before the initiation of nivolumab, 52 (42%) received - extracranial RT, and 40 (32%) were treated with thoracic RT. The median number of - nivolumab cycles was 4 (range: 1-43). The overall response rate (ORR) and disease - control rate (DCR) of nivolumab in all patients were 28.0% and 58.4%, - respectively. The ORR (36.4%) was significantly higher in patients who had - received previous RT than in patients who had not received any RT (19%). The - therapeutic efficacy of nivolumab was particularly noteworthy in patients with - non-adenocarcinoma and squamous cell carcinoma histology administered - extracranial RT, with ORRs of 48.3% and 52.6%, and DCRs of 87.1% and 84.2%, - respectively. CONCLUSION: Previous RT was an independent prognostic marker of - favorable prognosis after nivolumab administration and improved the response rate - to nivolumab treatment. Previous RT was clinically identified to have a - synergistic effect with nivolumab treatment, increasing the response rate and - improving the outcome of patients with advanced NSCLC. -CI - © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Yamaguchi, Ou -AU - Yamaguchi O -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Hidaka-City, Japan. -FAU - Kaira, Kyoichi -AU - Kaira K -AUID- ORCID: 0000-0001-5548-7686 -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Hidaka-City, Japan. -FAU - Hashimoto, Kosuke -AU - Hashimoto K -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Hidaka-City, Japan. -FAU - Mouri, Atsuto -AU - Mouri A -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Hidaka-City, Japan. -FAU - Miura, Yu -AU - Miura Y -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Hidaka-City, Japan. -FAU - Shiono, Ayako -AU - Shiono A -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Hidaka-City, Japan. -FAU - Nishihara, Fuyumi -AU - Nishihara F -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Hidaka-City, Japan. -FAU - Murayama, Yoshitake -AU - Murayama Y -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Hidaka-City, Japan. -FAU - Noda, Shin-Ei -AU - Noda SE -AD - Department of Radiation Oncology, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Hidaka-City, Japan. -FAU - Kato, Shingo -AU - Kato S -AD - Department of Radiation Oncology, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Hidaka-City, Japan. -FAU - Kobayashi, Kunihiko -AU - Kobayashi K -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Hidaka-City, Japan. -FAU - Kagamu, Hiroshi -AU - Kagamu H -AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International - Medical Center, Saitama Medical University, Hidaka-City, Japan. -LA - eng -PT - Journal Article -DEP - 20190319 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Antibodies, Monoclonal) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Administration, Intravenous -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal/*administration & dosage/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/*radiotherapy -MH - Chemoradiotherapy -MH - Drug Administration Schedule -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology/*radiotherapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -MH - Nivolumab/*administration & dosage/therapeutic use -MH - Prognosis -MH - Retrospective Studies -MH - Survival Analysis -MH - Treatment Outcome -PMC - PMC6449241 -OTO - NOTNLM -OT - NSCLC -OT - Nivolumab -OT - PD-1 -OT - radiotherapy -OT - synergistic effect -EDAT- 2019/03/20 06:00 -MHDA- 2020/03/13 06:00 -PMCR- 2019/04/01 -CRDT- 2019/03/20 06:00 -PHST- 2019/01/24 00:00 [received] -PHST- 2019/02/23 00:00 [revised] -PHST- 2019/02/24 00:00 [accepted] -PHST- 2019/03/20 06:00 [pubmed] -PHST- 2020/03/13 06:00 [medline] -PHST- 2019/03/20 06:00 [entrez] -PHST- 2019/04/01 00:00 [pmc-release] -AID - TCA13044 [pii] -AID - 10.1111/1759-7714.13044 [doi] -PST - ppublish -SO - Thorac Cancer. 2019 Apr;10(4):992-1000. doi: 10.1111/1759-7714.13044. Epub 2019 - Mar 19. - -PMID- 33587349 -OWN - NLM -STAT- MEDLINE -DCOM- 20211207 -LR - 20211214 -IS - 1473-5741 (Electronic) -IS - 0959-4973 (Linking) -VI - 32 -IP - 4 -DP - 2021 Apr 1 -TI - Combination of radiation therapy for brain metastasis and anti-PD-1/PD-L1 - treatment in non-small cell lung cancer: two cases and review of the literature. -PG - 460-464 -LID - 10.1097/CAD.0000000000000996 [doi] -AB - Lung cancer is the most frequent cause of cancer-related death worldwide and is - usually diagnosed in advanced stages. Among those, approximately 7.4% of - non-small cell lung cancer (NSCLC) patients will have brain metastasis (BM) at - presentation, and 25-30% will develop BM during the course of their disease. To - date, patients with BMs are increasingly considered for combined treatment using - systemic immune checkpoint inhibition (ICI) and cranial radiation therapy (RT); - yet, there is limited data regarding the safety of this approach. Here, we report - two cases of NSCLC patients treated with two different types of cranial RT and - ICIs. -CI - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. -FAU - Nigro, Olga -AU - Nigro O -AD - Medical Oncology Department, ASST Sette Laghi, Ospedale di Circolo. -FAU - Tuzi, Alessandro -AU - Tuzi A -AD - Medical Oncology Department, ASST Sette Laghi, Ospedale di Circolo. -FAU - Coppola, Andrea -AU - Coppola A -AD - Department of Diagnostic and Interventional Radiology, University of Insubria, - Ospedale di Circolo e Fondazione Macchi, Varese, Italy. -FAU - Tartaro, Tiziana -AU - Tartaro T -AD - Medical Oncology Department, ASST Sette Laghi, Ospedale di Circolo. -FAU - Chini, Claudio -AU - Chini C -AD - Medical Oncology Department, ASST Sette Laghi, Ospedale di Circolo. -FAU - Pinotti, Graziella -AU - Pinotti G -AD - Medical Oncology Department, ASST Sette Laghi, Ospedale di Circolo. -LA - eng -PT - Case Reports -PT - Journal Article -PT - Review -PL - England -TA - Anticancer Drugs -JT - Anti-cancer drugs -JID - 9100823 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized/administration & dosage -MH - B7-H1 Antigen/antagonists & inhibitors -MH - Brain Neoplasms/drug therapy/radiotherapy/*secondary/*therapy -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/*radiotherapy -MH - Chemoradiotherapy -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/administration & dosage -MH - Lung Neoplasms/*drug therapy/pathology/*radiotherapy -MH - Male -MH - Middle Aged -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - Radiosurgery -EDAT- 2021/02/16 06:00 -MHDA- 2021/12/15 06:00 -CRDT- 2021/02/15 13:18 -PHST- 2021/02/16 06:00 [pubmed] -PHST- 2021/12/15 06:00 [medline] -PHST- 2021/02/15 13:18 [entrez] -AID - 00001813-202104000-00012 [pii] -AID - 10.1097/CAD.0000000000000996 [doi] -PST - ppublish -SO - Anticancer Drugs. 2021 Apr 1;32(4):460-464. doi: 10.1097/CAD.0000000000000996. - -PMID- 38378870 -OWN - NLM -STAT- MEDLINE -DCOM- 20240222 -LR - 20240224 -IS - 2045-2322 (Electronic) -IS - 2045-2322 (Linking) -VI - 14 -IP - 1 -DP - 2024 Feb 20 -TI - Neutrophil to lymphocyte ratio may predict efficacy of anti-PD-1 inhibitors in - advanced EGFR-mutant non-small cell lung cancer: retrospective cohort study. -PG - 4165 -LID - 10.1038/s41598-024-54557-0 [doi] -LID - 4165 -AB - This study aimed to investigate the associations between the clinical - characteristics and effectiveness of anti-PD-1 inhibitors in patients with - EGFR-sensitive mutations, aiming to identify the potential subgroup of patients - who might benefit from anti-PD-1 inhibitor treatment. Patients with advanced - non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor - (EGFR)-sensitive mutations who received subsequent anti-PD-1 inhibitors in - combination with chemotherapy/antiangiogenic agents or alone after progression to - tyrosine kinase inhibitors (TKIs) were screened. Clinical characteristics, - including hematological parameters, were investigated for potential correlations - with clinical outcomes. Subgroup and multivariate analyses were used for further - confirmation of the relationship. Kaplan-Meier curves and Cox survival regression - models using the log-rank test were used for progression-free survival (PFS) and - overall survival (OS) assessments between the groups. Multiple regression - analysis was performed using the standard regression coefficient values. The - Wilcoxon test was used for the analysis of the variation in NLR. P ≤ 0.05 was - considered to indicate statistical significance. This study was a retrospective - study. Twenty-two patients met the inclusion criteria and were included in the - study. The median PFS was 3.05 months (95% CI, 2.9-10.2 months). The median OS - was 7.30 months (95% CI, 5.2-18.1 months). PFS in low neutrophil to lymphocyte - ratio (NLR ≤ 4) was significantly longer than high NLR (NLR > 4, 5.7 months - versus 2.0 months, HR, 0.35, 95% CI, 0.08-0.63, P = 0.0083). The OS in the low - NLR group was also significantly better than that in the high NLR group (OS, - 21.3 months versus 5.0 months, HR, 0.33; 95% CI, 0.09-0.74; P = 0.0163). In the - multivariate analysis, NLR was the only significant factor for OS benefits - (β = 3.535, 95% CI, 1.175-10.636, P = 0.025). Further investigation revealed that - front-line TKIs exposure may contribute to the elevation or decrease of NLR, and - finally lead to different efficacy outcomes by anti-PD-1 inhibitors. The findings - suggest that a portion of advanced NSCLC patients with low NLR characteristics - (NLR ≤ 4), even those harboring EGFR-sensitive mutations, could benefit from - anti-PD-1 inhibitors as further line treatment after progression to EGFR-TKIs. -CI - © 2024. The Author(s). -FAU - Chen, Jianxin -AU - Chen J -AD - Department of Medical Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical - University, Quzhou People's Hospital, Quzhou, 324000, Zhejiang, China. -FAU - Zheng, Qinhong -AU - Zheng Q -AD - Department of Medical Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical - University, Quzhou People's Hospital, Quzhou, 324000, Zhejiang, China. -FAU - Zhu, Shijian -AU - Zhu S -AD - Department of Medical Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical - University, Quzhou People's Hospital, Quzhou, 324000, Zhejiang, China. -FAU - Qiu, Dan -AU - Qiu D -AD - Department of Medical Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical - University, Quzhou People's Hospital, Quzhou, 324000, Zhejiang, China. -FAU - Wang, Junhui -AU - Wang J -AD - Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou - Medical University, Quzhou People's Hospital, Quzhou, 324000, Zhejiang, China. - wangjunhui7526@163.com. -LA - eng -GR - 2020057/2021005/Instructional Project of Quzhou/ -GR - 2022K48/Science and Technology Key Project of Quzhou/ -PT - Journal Article -DEP - 20240220 -PL - England -TA - Sci Rep -JT - Scientific reports -JID - 101563288 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Antineoplastic Agents) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (EGFR protein, human) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Retrospective Studies -MH - *Lung Neoplasms/drug therapy/genetics -MH - Neutrophils -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Prognosis -MH - *Antineoplastic Agents/therapeutic use -MH - Lymphocytes -MH - ErbB Receptors -MH - Mutation -MH - Protein Kinase Inhibitors/therapeutic use -PMC - PMC10879166 -OTO - NOTNLM -OT - Anti-PD-1 inhibitor -OT - Efficacy -OT - Epidermal growth factor receptor -OT - Neutrophil to lymphocyte ratio -OT - Non-small cell lung cancer -COIS- The authors declare no competing interests. -EDAT- 2024/02/21 11:15 -MHDA- 2024/02/22 12:11 -PMCR- 2024/02/20 -CRDT- 2024/02/20 23:57 -PHST- 2023/09/26 00:00 [received] -PHST- 2024/02/14 00:00 [accepted] -PHST- 2024/02/22 12:11 [medline] -PHST- 2024/02/21 11:15 [pubmed] -PHST- 2024/02/20 23:57 [entrez] -PHST- 2024/02/20 00:00 [pmc-release] -AID - 10.1038/s41598-024-54557-0 [pii] -AID - 54557 [pii] -AID - 10.1038/s41598-024-54557-0 [doi] -PST - epublish -SO - Sci Rep. 2024 Feb 20;14(1):4165. doi: 10.1038/s41598-024-54557-0. - -PMID- 32758347 -OWN - NLM -STAT- MEDLINE -DCOM- 20210719 -LR - 20210719 -IS - 1999-6187 (Electronic) -IS - 1009-3419 (Print) -IS - 1009-3419 (Linking) -VI - 23 -IP - 8 -DP - 2020 Aug 20 -TI - [Management of Drug Therapy for Leptomeningeal Metastasis of Sensitive Driver - Gene Positive Non-small Cell Lung Cancer]. -PG - 710-718 -LID - 10.3779/j.issn.1009-3419.2020.102.18 [doi] -AB - Leptomeningeal metastasis (LM) is one of the serious complications of advanced - non-small cell lung cancer (NSCLC), although the incidence is not high, the - clinical symptoms are severe and the prognosis is poor. LM is prone to occur in - patients with positive driver gene than negative. At present, the treatment of LM - mainly includes molecular targeted therapy, systemic chemotherapy, whole brain - radiotherapy, intrathecal chemotherapy and immunotherapy. Although there are many - treatments, the efficacy of LM is still unsatisfactory. This article reviews the - drug therapy of sensitive driver gene positive NSCLC LM. -FAU - Lu, Zhiqin -AU - Lu Z -AD - Department of Oncology, The Second Affiliated of Nanchang University, Nanchang - 330006, China. -FAU - Cai, Jing -AU - Cai J -AD - Department of Oncology, The Second Affiliated of Nanchang University, Nanchang - 330006, China. -AD - Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang - 330006, China. -FAU - Zeng, Zhimin -AU - Zeng Z -AD - Department of Oncology, The Second Affiliated of Nanchang University, Nanchang - 330006, China. -AD - Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang - 330006, China. -FAU - Liu, Anwen -AU - Liu A -AD - Department of Oncology, The Second Affiliated of Nanchang University, Nanchang - 330006, China. -AD - Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang - 330006, China. -LA - chi -PT - Journal Article -DEP - 20200806 -PL - China -TA - Zhongguo Fei Ai Za Zhi -JT - Zhongguo fei ai za zhi = Chinese journal of lung cancer -JID - 101126433 -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/*complications/*drug therapy/therapy -MH - Humans -MH - Lung Neoplasms/*complications/*drug therapy/therapy -MH - Meningeal Neoplasms/*drug therapy/*secondary/therapy -PMC - PMC7467993 -OTO - NOTNLM -OT - Driver gene positive -OT - Drug therapy -OT - Leptomeningeal metastasis -OT - Lung neoplasms -EDAT- 2020/08/08 06:00 -MHDA- 2021/07/20 06:00 -PMCR- 2020/08/20 -CRDT- 2020/08/08 06:00 -PHST- 2020/08/08 06:00 [pubmed] -PHST- 2021/07/20 06:00 [medline] -PHST- 2020/08/08 06:00 [entrez] -PHST- 2020/08/20 00:00 [pmc-release] -AID - zgfazz-23-8-710 [pii] -AID - 10.3779/j.issn.1009-3419.2020.102.18 [doi] -PST - ppublish -SO - Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):710-718. doi: - 10.3779/j.issn.1009-3419.2020.102.18. Epub 2020 Aug 6. - -PMID- 6282482 -OWN - NLM -STAT- MEDLINE -DCOM- 19820826 -LR - 20190829 -IS - 0344-5704 (Print) -IS - 0344-5704 (Linking) -VI - 7 -IP - 2-3 -DP - 1982 -TI - Doxorubicin, Cyclophosphamide and VP16-213 (ACE) in the treatment of small cell - lung cancer. -PG - 187-93 -AB - Small cell lung cancer requires aggressive combination chemotherapy. The three - active agents, doxorubicin (A) 45 mg/m2 i.v. day 1, cyclophosphamide (C) 1.0 - mg/m2 i.v. day 1 and VP16-213 (E) 50 mg/m2/day i.v. days 1-5 were given together. - The combination (ACE) was given every 21 days without chest irradiation. One - hundred and seventy-four patients have been stratified for extent of disease and - randomized on three sequential studies testing ACE vs ACE + MER immunotherapy (38 - patients), or ACE vs ACE alternating with CCNU, methotrexate, vincristine and - procarbazine (109 patients), or ACE vs ACE II (ACE with continuous VP16-213 - 100 - mg/m2/day X 5 days - 27 patients - ongoing). The immunotherapy and the - alternating non-cross resistant combination have not proven beneficial with - respect to response or survival. The ACE combination, regardless of additional - treatments, has produced greater than 90% response overall. In limited disease - the complete response (CR) frequency is 65%. The median survival for limited - disease overall is 14 months and 18 months for patients achieving CR. In - extensive disease the CR frequency is 40% with a median survival of 9 months - overall and 13 months for patients achieving CR. Response frequency and survival - are identical in the first two studies and 20-30% of patients with limited - disease are long-term survivors with one late relapse (greater than 3 years). - Patients who achieved CR had a significantly longer survival regardless of other - factors such as performance status or extent of disease. Prophylactic cranial - irradiation was demonstrated to be useful in prevention or delaying CNS - metastases in patients who achieved CR. The third generation study of high-dose - VP16-213 infusion seeks to increase the CR frequency. ACE chemotherapy without - chest irradiation is a highly effective treatment for all patients with small - cell lung cancer and compares favorably with all other studies with or without - adjuvant radiotherapy. -FAU - Aisner, J -AU - Aisner J -FAU - Whitacre, M -AU - Whitacre M -FAU - VanEcho, D A -AU - VanEcho DA -FAU - Wesley, M -AU - Wesley M -FAU - Wiernik, P H -AU - Wiernik PH -LA - eng -GR - 1 P50CA 32107-01/CA/NCI NIH HHS/United States -PT - Clinical Trial -PT - Controlled Clinical Trial -PT - Journal Article -PT - Research Support, U.S. Gov't, P.H.S. -PL - Germany -TA - Cancer Chemother Pharmacol -JT - Cancer chemotherapy and pharmacology -JID - 7806519 -RN - 6PLQ3CP4P3 (Etoposide) -RN - 80168379AG (Doxorubicin) -RN - 8N3DW7272P (Cyclophosphamide) -RN - L36H50F353 (Podophyllotoxin) -SB - IM -MH - Adult -MH - Aged -MH - Brain Neoplasms/prevention & control/radiotherapy -MH - Carcinoma, Small Cell/*drug therapy -MH - Cyclophosphamide/adverse effects/*therapeutic use -MH - Doxorubicin/adverse effects/*therapeutic use -MH - Drug Therapy, Combination -MH - Etoposide/adverse effects/*therapeutic use -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy -MH - Male -MH - Middle Aged -MH - Podophyllotoxin/*analogs & derivatives -EDAT- 1982/01/01 00:00 -MHDA- 1982/01/01 00:01 -CRDT- 1982/01/01 00:00 -PHST- 1982/01/01 00:00 [pubmed] -PHST- 1982/01/01 00:01 [medline] -PHST- 1982/01/01 00:00 [entrez] -AID - 10.1007/BF00254546 [doi] -PST - ppublish -SO - Cancer Chemother Pharmacol. 1982;7(2-3):187-93. doi: 10.1007/BF00254546. - -PMID- 34405563 -OWN - NLM -STAT- MEDLINE -DCOM- 20220131 -LR - 20220131 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 12 -IP - 20 -DP - 2021 Oct -TI - Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy - in a non-small cell lung cancer patient: A case report. -PG - 2811-2814 -LID - 10.1111/1759-7714.14106 [doi] -AB - We describe a case of a 60-year-old man with a prolonged thrombocytopenia during - a durvalumab maintenance therapy after chemoradiotherapy for locally advanced - non-small cell lung carcinoma. Bone marrow specimen was normoplastic with the - marked megakaryocyte depletion, which was assumed to be an acquired - amegakaryocytic thrombocytopenic purpura. Although hematological disorders as - immune-related adverse events (irAE) are rare, we should pay more attention to - hematological disorders with durvalumab especially after concurrent - chemoradiotherapy. -CI - © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Makiguchi, Tomonori -AU - Makiguchi T -AUID- ORCID: 0000-0001-9249-7904 -AD - Department of Respiratory Medicine, Hirosaki University Graduate School of - Medicine, Hirosaki, Japan. -FAU - Tanaka, Hisashi -AU - Tanaka H -AUID- ORCID: 0000-0003-2009-0210 -AD - Department of Respiratory Medicine, Hirosaki University Graduate School of - Medicine, Hirosaki, Japan. -FAU - Kamata, Kosuke -AU - Kamata K -AD - Department of Gastroenterology and Hematology, Hirosaki University Graduate - School of Medicine, Hirosaki, Japan. -FAU - Taima, Kageaki -AU - Taima K -AD - Department of Respiratory Medicine, Hirosaki University Graduate School of - Medicine, Hirosaki, Japan. -FAU - Kurose, Akira -AU - Kurose A -AD - Department of Pathology, Hirosaki University Graduate School of Medicine, - Hirosaki, Japan. -FAU - Tasaka, Sadatomo -AU - Tasaka S -AD - Department of Respiratory Medicine, Hirosaki University Graduate School of - Medicine, Hirosaki, Japan. -LA - eng -PT - Case Reports -DEP - 20210817 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal/*adverse effects/*therapeutic use -MH - Antineoplastic Agents, Immunological/adverse effects/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/radiotherapy -MH - Chemoradiotherapy/methods -MH - Humans -MH - Lung Neoplasms/*drug therapy/radiotherapy -MH - Male -MH - Middle Aged -MH - Thrombocytopenia/*chemically induced/immunology -PMC - PMC8520809 -OTO - NOTNLM -OT - amegakaryocytic thrombocytopenic purpura -OT - concurrent chemoradiotherapy -OT - immune checkpoint inhibitor -OT - immune-mediated thrombocytopenia -EDAT- 2021/08/19 06:00 -MHDA- 2022/02/01 06:00 -PMCR- 2021/10/01 -CRDT- 2021/08/18 06:54 -PHST- 2021/07/27 00:00 [revised] -PHST- 2021/06/01 00:00 [received] -PHST- 2021/07/28 00:00 [accepted] -PHST- 2021/08/19 06:00 [pubmed] -PHST- 2022/02/01 06:00 [medline] -PHST- 2021/08/18 06:54 [entrez] -PHST- 2021/10/01 00:00 [pmc-release] -AID - TCA14106 [pii] -AID - 10.1111/1759-7714.14106 [doi] -PST - ppublish -SO - Thorac Cancer. 2021 Oct;12(20):2811-2814. doi: 10.1111/1759-7714.14106. Epub 2021 - Aug 17. - -PMID- 39230871 -OWN - NLM -STAT- MEDLINE -DCOM- 20241015 -LR - 20241015 -IS - 1865-8652 (Electronic) -IS - 0741-238X (Linking) -VI - 41 -IP - 11 -DP - 2024 Nov -TI - Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the - First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A - Randomized, Double-Blind, Phase III Study. -PG - 4032-4048 -LID - 10.1007/s12325-024-02965-z [doi] -AB - INTRODUCTION: SCT510 is a biosimilar to bevacizumab (Avastin) reference product - (RP) that is approved for various metastatic cancers. In this study, we aimed to - demonstrate the equivalence of SCT510 and bevacizumab in terms of efficacy, - safety, immunogenicity and pharmacokinetics (PK) in patients with advanced - non-squamous non-small cell lung cancer (NSCLC). METHODS: Patients with - non-squamous NSCLC were randomized equally to the SCT510 group (comprising - SCT510, paclitaxel, and carboplatin) and the bevacizumab group (comprising - bevacizumab, paclitaxel, and carboplatin) for 4-6 cycles, followed by maintenance - monotherapy with SCT510. The primary endpoint was the objective response rate - (ORR) at week 12. Secondary endpoints included 18-week ORR, disease control rate - (DCR), duration of response (DoR), progression-free survival (PFS), overall - survival (OS), and 1-year survival rate, as well as assessments of safety, - immunogenicity, and multi-dose PK analysis. RESULTS: Between March 29, 2019, and - April 27, 2021, 989 patients were screened and 567 eligible patients were - randomly assigned to the SCT510 group (285 patients) and the bevacizumab group - (282 patients). The ORR at week 12 was 52.6% [95% confidence interval (CI) - 46.66-58.55%] in the SCT510 group and 52.5% (95% CI 46.47-58.47%) in the - bevacizumab group. The ORR at week 18 was 55.4% (95% CI 49.46-61.30%) for SCT510 - and 55.7% (95% CI 49.68-61.62%) for bevacizumab. The ORR risk ratio (RR) at weeks - 12 and 18 was 0.99 (90% CI 0.873-1.133) and 0.99 (90% CI 0.872-1.114), - respectively, both within the pre-specified equivalence margin of 0.75-1.33. - There were no differences between the two groups in relation to other secondary - endpoints, specifically DCR, DOR, PFS, OS, and 1-year survival rate. The overall - safety findings were similar between the two treatment groups, and both SCT510 - and bevacizumab RP exhibited low immunogenicity. CONCLUSIONS: SCT510 is similar - to bevacizumab in clinical efficacy, safety, immunogenicity, and PK in patients - with advanced non-squamous NSCLC. The totality of the evidence supports the - clinical equivalence of SCT510 and bevacizumab. TRIAL REGISTRATION: NCT03792074. -CI - © 2024. The Author(s), under exclusive licence to Springer Healthcare Ltd., part - of Springer Nature. -FAU - Cheng, Ying -AU - Cheng Y -AD - Jilin Cancer Hospital, 1066 Jinhu Road, High-Tech Zone, Changchun, Changchun, - 130000, China. jl.cheng@163.com. -FAU - Pan, Zhanyu -AU - Pan Z -AD - Tianjin Cancer Hospital, Tianjin, China. -FAU - Wu, Lin -AU - Wu L -AD - The Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer - Hospital, Central South University, Changsha, China. -FAU - Zhu, Bo -AU - Zhu B -AD - The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. -FAU - Yu, Yan -AU - Yu Y -AD - Harbin Medical University Cancer Hospital, Harbin, China. -FAU - Zang, Kai -AU - Zang K -AD - Henan Cancer Hospital, Zhengzhou, China. -FAU - Zhuang, Wu -AU - Zhuang W -AD - Fujian Cancer Hospital, Fuzhou, China. -FAU - Liu, Lianke -AU - Liu L -AD - Jiang Su Province Hospital, Nanjing, China. -FAU - Gu, Kangsheng -AU - Gu K -AD - The First Affiliated Hospital of Anhui Medical University, Hefei, China. -FAU - Lian, Juanwen -AU - Lian J -AD - Xi'an Chest Hospital, Xi'an, China. -FAU - Chen, Rixin -AU - Chen R -AD - Liuzhou People's Hospital, Liuzhou, China. -FAU - Bian, Tao -AU - Bian T -AD - Wuxi People's Hospital, Wuxi, China. -FAU - Lin, Dang -AU - Lin D -AD - The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China. -FAU - Sun, Shenghua -AU - Sun S -AD - The Third Xiangya Hospital of Central South University, Changsha, China. -FAU - Li, Wei -AU - Li W -AD - The First Affiliated Hospital of Bengbu Medical College, Bengbu, China. -FAU - Hang, Xiaosheng -AU - Hang X -AD - Affiliated Hospital of Jiangnan University, Wuxi, China. -FAU - Jiang, Ou -AU - Jiang O -AD - The Second People's Hospital of Neijiang, Neijiang, China. -FAU - Zhong, Fukuan -AU - Zhong F -AD - The Second People's Hospital of Lianyungang, Lianyungang, China. -FAU - Wang, Rui -AU - Wang R -AD - Anhui Chest Hospital, Hefei, China. -FAU - Luo, Hui -AU - Luo H -AD - Jiangxi Cancer Hospital Thoracic Oncology Radiotherapy Department, Nanchang, - China. -FAU - Shi, Huaqiu -AU - Shi H -AD - The First Affiliated Hospital of Gannan Medical College, Ganzhou, China. -FAU - Wei, Zonghui -AU - Wei Z -AD - Chongqing Nanchuan District People's Hospital, Chongqing, China. -FAU - Zhao, Li -AU - Zhao L -AD - Shengjing Hospital of China Medical University, Liaoning, China. -FAU - Chen, Shaoshui -AU - Chen S -AD - Binzhou Medical University Hospital, Binzhou, China. -FAU - Sun, Hongmei -AU - Sun H -AD - Jiamusi Cancer Hospital, Jiamusi, China. -FAU - Li, Xingya -AU - Li X -AD - The First Affiliated Hospital of Zhengzhou University Oncology Department, - Zhengzhou, China. -FAU - Sun, Debin -AU - Sun D -AD - The Central Hospital of Lishui City, Lishui, China. -FAU - Ren, Tiejun -AU - Ren T -AD - Luoyang Central Hospital, Luoyang, China. -FAU - Lei, Kaijian -AU - Lei K -AD - The Second People's Hospital of Yibin, Yibin, China. -FAU - He, Miao -AU - He M -AD - Deyang People's Hospital, Deyang, China. -FAU - Li, Gaofeng -AU - Li G -AD - The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor - Hospital), Kunming, China. -FAU - Liu, Hailong -AU - Liu H -AD - The First People's Hospital of Chenzhou, Chenzhou, China. -FAU - Li, Runpu -AU - Li R -AD - Baoding Second Central Hospital, Zhuozhou, China. -FAU - Hu, Chunhong -AU - Hu C -AD - The Second Xiangya Hospital of Central South University, Changsha, China. -FAU - Kong, Li -AU - Kong L -AD - Shandong Cancer Hospital, Jinan, China. -FAU - Sun, Meili -AU - Sun M -AD - Jinan Central Hospital, Jinan, China. -FAU - Xie, Liangzhi -AU - Xie L -AD - Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., - Beijing, China. -FAU - Gai, Wenlin -AU - Gai W -AD - Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., - Beijing, China. -FAU - Chen, Weiqiu -AU - Chen W -AD - Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., - Beijing, China. -FAU - Huang, Zhe -AU - Huang Z -AD - Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., - Beijing, China. -FAU - Ren, Wenwen -AU - Ren W -AD - Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., - Beijing, China. -FAU - Su, Huo -AU - Su H -AD - Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., - Beijing, China. -LA - eng -SI - ClinicalTrials.gov/NCT03792074 -GR - 2018ZX09736002/National Science and Technology Major Projects of China/ -PT - Clinical Trial, Phase III -PT - Comparative Study -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -DEP - 20240904 -PL - United States -TA - Adv Ther -JT - Advances in therapy -JID - 8611864 -RN - 2S9ZZM9Q9V (Bevacizumab) -RN - 0 (Biosimilar Pharmaceuticals) -RN - P88XT4IS4D (Paclitaxel) -RN - BG3F62OND5 (Carboplatin) -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Bevacizumab/therapeutic use -MH - Male -MH - Female -MH - *Lung Neoplasms/drug therapy -MH - *Biosimilar Pharmaceuticals/therapeutic use -MH - Middle Aged -MH - Aged -MH - Double-Blind Method -MH - Adult -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Paclitaxel/therapeutic use/administration & dosage -MH - Carboplatin/therapeutic use/administration & dosage -MH - Antineoplastic Agents, Immunological/therapeutic use -OTO - NOTNLM -OT - Immunotherapy -OT - Non-small cell lung cancer -OT - Randomized controlled trial -OT - SCT510 -EDAT- 2024/09/04 12:42 -MHDA- 2024/10/15 12:24 -CRDT- 2024/09/04 11:19 -PHST- 2024/05/28 00:00 [received] -PHST- 2024/08/06 00:00 [accepted] -PHST- 2024/10/15 12:24 [medline] -PHST- 2024/09/04 12:42 [pubmed] -PHST- 2024/09/04 11:19 [entrez] -AID - 10.1007/s12325-024-02965-z [pii] -AID - 10.1007/s12325-024-02965-z [doi] -PST - ppublish -SO - Adv Ther. 2024 Nov;41(11):4032-4048. doi: 10.1007/s12325-024-02965-z. Epub 2024 - Sep 4. - -PMID- 30683299 -OWN - NLM -STAT- MEDLINE -DCOM- 20200408 -LR - 20200408 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 14 -IP - 2 -DP - 2019 Feb -TI - Refractory Severe Esophagitis During Durvalumab Therapy in a Patient With Locally - Advanced NSCLC. -PG - e40-e42 -LID - S1556-0864(18)33388-4 [pii] -LID - 10.1016/j.jtho.2018.10.153 [doi] -FAU - Utsumi, Takahiro -AU - Utsumi T -AD - Department of Respiratory Medicine, Japan Community Health Care Organization - Kyushu Hospital, Fukuoka, Japan. -FAU - Tsubouchi, Kazuya -AU - Tsubouchi K -AD - Department of Respiratory Medicine, Japan Community Health Care Organization - Kyushu Hospital, Fukuoka, Japan. Electronic address: tubouchi@med.kyushu-u.ac.jp. -FAU - Harada, Taishi -AU - Harada T -AD - Department of Respiratory Medicine, Japan Community Health Care Organization - Kyushu Hospital, Fukuoka, Japan. -LA - eng -PT - Case Reports -PT - Letter -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Adrenal Cortex Hormones) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Adrenal Cortex Hormones/therapeutic use -MH - Aged -MH - Antibodies, Monoclonal/*adverse effects -MH - Antineoplastic Agents, Immunological/*adverse effects -MH - Carcinoma, Non-Small-Cell Lung/*therapy -MH - Chemoradiotherapy/adverse effects -MH - Esophagitis/drug therapy/*etiology -MH - Humans -MH - Lung Neoplasms/*therapy -MH - Male -MH - Radiation Injuries/*chemically induced/drug therapy -EDAT- 2019/01/27 06:00 -MHDA- 2020/04/09 06:00 -CRDT- 2019/01/27 06:00 -PHST- 2018/10/15 00:00 [received] -PHST- 2018/10/16 00:00 [revised] -PHST- 2018/10/16 00:00 [accepted] -PHST- 2019/01/27 06:00 [entrez] -PHST- 2019/01/27 06:00 [pubmed] -PHST- 2020/04/09 06:00 [medline] -AID - S1556-0864(18)33388-4 [pii] -AID - 10.1016/j.jtho.2018.10.153 [doi] -PST - ppublish -SO - J Thorac Oncol. 2019 Feb;14(2):e40-e42. doi: 10.1016/j.jtho.2018.10.153. - -PMID- 27765756 -OWN - NLM -STAT- MEDLINE -DCOM- 20171226 -LR - 20221207 -IS - 1569-8041 (Electronic) -IS - 0923-7534 (Print) -IS - 0923-7534 (Linking) -VI - 27 -IP - 12 -DP - 2016 Dec -TI - Safety and efficacy of nivolumab and standard chemotherapy drug combination in - patients with advanced non-small-cell lung cancer: a four arms phase Ib study. -PG - 2242-2250 -LID - 10.1093/annonc/mdw416 [doi] -AB - BACKGROUND: The human IgG4 monoclonal antibody nivolumab targets programmed cell - death-1 (PD-1) and promotes antitumor response by blocking the interaction of - PD-1 with its ligands. This single-center phase Ib study investigated the - tolerability, safety, and pharmacokinetics of nivolumab combined with standard - chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). - PATIENTS AND METHODS: Patients who had stage IIIB without indication for - definitive radiotherapy, stage IV, or recurrent NSCLC were eligible. Regimens - were nivolumab 10 mg/kg + gemcitabine/cisplatin (arm A), pemetrexed/cisplatin - (arm B), paclitaxel/carboplatin/bevacizumab (arm C), or docetaxel (arm D). - Regimens A, B, and D were repeated every 3 weeks for up to four cycles and - regimen C was repeated for up to six cycles; nivolumab alone (arm A), with - pemetrexed (arm B), bevacizumab (arm C), or docetaxel (arm D) was continued every - 3 weeks as maintenance therapy until disease progression or unacceptable - toxicity. Dose-limiting toxicity (DLT) was evaluated during the first treatment - cycle. RESULTS: As of March 2014, six patients were enrolled in each arm. The - combination of nivolumab 10 mg/kg and chemotherapy was well tolerated. DLT was - observed in only one patient in arm A (alanine aminotransferase increased). - Select adverse events (those with a potential immunologic cause) of any grade - were observed in six, four, six, and five patients in arms A, B, C, and D, - respectively. Three, three, six, and one patient achieved partial response while - median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 - months in arms A, B, C, and D, respectively. CONCLUSIONS: Combination of - nivolumab 10 mg/kg and chemotherapy showed an acceptable toxicity profile and - encouraging antitumor activity in patients with advanced NSCLC. CLINICAL TRIALS - NUMBER: Japanese Pharmaceutical Information Center Clinical Trials Information - (JapicCTI)-132071. -CI - © The Author 2016. Published by Oxford University Press on behalf of the European - Society for Medical Oncology. -FAU - Kanda, S -AU - Kanda S -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo - skanda@ncc.go.jp. -FAU - Goto, K -AU - Goto K -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo. -FAU - Shiraishi, H -AU - Shiraishi H -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo. -FAU - Kubo, E -AU - Kubo E -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo. -FAU - Tanaka, A -AU - Tanaka A -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo. -FAU - Utsumi, H -AU - Utsumi H -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo. -FAU - Sunami, K -AU - Sunami K -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo. -FAU - Kitazono, S -AU - Kitazono S -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo. -FAU - Mizugaki, H -AU - Mizugaki H -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo. -FAU - Horinouchi, H -AU - Horinouchi H -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo. -FAU - Fujiwara, Y -AU - Fujiwara Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo. -FAU - Nokihara, H -AU - Nokihara H -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo. -FAU - Yamamoto, N -AU - Yamamoto N -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo. -FAU - Hozumi, H -AU - Hozumi H -AD - ONO Pharmaceutical Co. Ltd, Osaka, Japan. -FAU - Tamura, T -AU - Tamura T -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo. -LA - eng -SI - JapicCTI/132071 -PT - Clinical Trial, Phase I -PT - Journal Article -PT - Randomized Controlled Trial -DEP - 20161020 -PL - England -TA - Ann Oncol -JT - Annals of oncology : official journal of the European Society for Medical - Oncology -JID - 9007735 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Taxoids) -RN - 04Q9AIZ7NO (Pemetrexed) -RN - 0W860991D6 (Deoxycytidine) -RN - 15H5577CQD (Docetaxel) -RN - 2S9ZZM9Q9V (Bevacizumab) -RN - 31YO63LBSN (Nivolumab) -RN - BG3F62OND5 (Carboplatin) -RN - P88XT4IS4D (Paclitaxel) -RN - Q20Q21Q62J (Cisplatin) -RN - 0 (Gemcitabine) -SB - IM -MH - Adult -MH - Aged -MH - Antibodies, Monoclonal/*administration & dosage/adverse effects -MH - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse - effects -MH - Bevacizumab -MH - Carboplatin/administration & dosage -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/radiotherapy -MH - Cisplatin/administration & dosage -MH - Deoxycytidine/administration & dosage/analogs & derivatives -MH - Disease-Free Survival -MH - Docetaxel -MH - Female -MH - Humans -MH - Male -MH - Middle Aged -MH - Neoplasm Recurrence, Local/*drug therapy/pathology/radiotherapy -MH - Neoplasm Staging -MH - Nivolumab -MH - Paclitaxel/administration & dosage -MH - Pemetrexed/administration & dosage -MH - Taxoids/administration & dosage -MH - Gemcitabine -PMC - PMC5178141 -OTO - NOTNLM -OT - chemotherapy -OT - combination -OT - nivolumab -OT - non-small-cell lung cancer -EDAT- 2016/10/22 06:00 -MHDA- 2017/12/27 06:00 -PMCR- 2016/12/22 -CRDT- 2016/10/22 06:00 -PHST- 2016/04/19 00:00 [received] -PHST- 2016/07/23 00:00 [revised] -PHST- 2016/08/16 00:00 [accepted] -PHST- 2016/10/22 06:00 [pubmed] -PHST- 2017/12/27 06:00 [medline] -PHST- 2016/10/22 06:00 [entrez] -PHST- 2016/12/22 00:00 [pmc-release] -AID - S0923-7534(19)36539-1 [pii] -AID - mdw416 [pii] -AID - 10.1093/annonc/mdw416 [doi] -PST - ppublish -SO - Ann Oncol. 2016 Dec;27(12):2242-2250. doi: 10.1093/annonc/mdw416. Epub 2016 Oct - 20. - -PMID- 36577398 -OWN - NLM -STAT- MEDLINE -DCOM- 20230914 -LR - 20230914 -IS - 1421-9794 (Electronic) -IS - 0009-3157 (Linking) -VI - 68 -IP - 3 -DP - 2023 -TI - Initial Therapeutic Approach with Pembrolizumab in Synchronous Multiple Cancers, - Including Non-Small Cell Lung Cancer, Highly Positive for Programmed Death-Ligand - 1 Expression. -PG - 160-167 -LID - 10.1159/000528592 [doi] -AB - Treatment of synchronous multiple primary cancers is clinically difficult. We - report four cases of synchronous primary cancers, including advanced and - metastatic non-small cell lung cancer (NSCLCs) highly positive for programmed - death ligand-1 (PD-L1) expression and initially treated with pembrolizumab. - Pembrolizumab was efficacious in 2 patients with NSCLC lesions, followed by - chemoradiotherapy for esophageal cancer (case 1) and chemotherapy for gastric - cancer (case 2). Both cancers in case 1 showed a complete response for 3 years, - while progression of the accompanying gastric cancer resulted in mortality at 20 - months in case 2. Both NSCLC and gastric cancer in case 3 failed to respond to - pembrolizumab, but the accompanying laryngeal cancer in case 4 showed a complete - response, and cytotoxic chemotherapy for NSCLC was continued for 18.0 months. Our - clinical experience suggests that pembrolizumab is a useful therapeutic approach - for patients with synchronous cancers, including NSCLC that highly expresses - PD-L1. -CI - © 2022 S. Karger AG, Basel. -FAU - Koizumi, Tomonobu -AU - Koizumi T -AD - Department of Hematology and Medical Oncology, Shinshu University School of - Medicine, Matsumoto, Japan. -FAU - Kanda, Shintaro -AU - Kanda S -AD - Department of Hematology and Medical Oncology, Shinshu University School of - Medicine, Matsumoto, Japan. -FAU - Kobayashi, Takashi -AU - Kobayashi T -AD - Department of Hematology and Medical Oncology, Shinshu University School of - Medicine, Matsumoto, Japan. -FAU - Iwasa, Yoh-Ichiro -AU - Iwasa YI -AD - Department of Otolaryngology, Shinshu University School of Medicine, Matsumoto, - Japan. -FAU - Matsuo, Akemi -AU - Matsuo A -AD - Department of Pulmonary Medicine, Minami Nagano Iryou Center, Shinonoi Hospital, - Nagano, Japan. -LA - eng -PT - Case Reports -DEP - 20221228 -PL - Switzerland -TA - Chemotherapy -JT - Chemotherapy -JID - 0144731 -RN - 0 (CD274 protein, human) -RN - 0 (B7-H1 Antigen) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - B7-H1 Antigen/metabolism -MH - *Lung Neoplasms/drug therapy/pathology -MH - *Stomach Neoplasms -OTO - NOTNLM -OT - Double cancers -OT - Immune checkpoint inhibitor -OT - Multiple primary malignancy -OT - Programmed death ligand-1 -EDAT- 2022/12/29 06:00 -MHDA- 2023/09/14 06:42 -CRDT- 2022/12/28 18:23 -PHST- 2022/10/07 00:00 [received] -PHST- 2022/11/27 00:00 [accepted] -PHST- 2023/09/14 06:42 [medline] -PHST- 2022/12/29 06:00 [pubmed] -PHST- 2022/12/28 18:23 [entrez] -AID - 000528592 [pii] -AID - 10.1159/000528592 [doi] -PST - ppublish -SO - Chemotherapy. 2023;68(3):160-167. doi: 10.1159/000528592. Epub 2022 Dec 28. - -PMID- 32646546 -OWN - NLM -STAT- MEDLINE -DCOM- 20210127 -LR - 20210127 -IS - 1879-114X (Electronic) -IS - 0149-2918 (Linking) -VI - 42 -IP - 8 -DP - 2020 Aug -TI - Clinical Application of Iodine-125 Seed Brachytherapy Combined with Anti-PD-1 - Antibodies in the Treatment of Lung Cancer. -PG - 1612-1616 -LID - S0149-2918(20)30280-0 [pii] -LID - 10.1016/j.clinthera.2020.05.018 [doi] -AB - PURPOSE: The purpose of this case report was to investigate the clinical efficacy - and tolerability of anti-programmed cell death protein (PD)-1 antibody combined - with iodine (I)-125 seed brachytherapy in lung cancer treatment. METHODS: Three - patients with advanced PD-L1-positive non-small-cell lung cancer were treated - first with I-125 seed brachytherapy and then with anti-PD-1 antibody. Clinical - efficacy was evaluated with Response Evaluation Criteria in Solid Tumors. - FINDINGS: All 3 patients had complete response or partial response. None of the 3 - patients had reported obvious adverse events. IMPLICATIONS: Encouraging - preliminary results provide important support for further clinical treatment of - lung cancer using anti-PD-1 antibody combined with I-125 seed brachytherapy. -CI - Copyright © 2020. Published by Elsevier Inc. -FAU - Sui, Aixia -AU - Sui A -AD - Department of Oncology, Hebei General Hospital, Shijiazhuang, China. Electronic - address: allen_sui77@sina.com. -FAU - Song, Huiling -AU - Song H -AD - Department of Oncology, Hebei General Hospital, Shijiazhuang, China; North China - University of Science and Technology, Tang shan, China. -FAU - Yu, Huimin -AU - Yu H -AD - Department of Oncology, Hebei General Hospital, Shijiazhuang, China. -FAU - Zhang, Hongtao -AU - Zhang H -AD - Department of Oncology, Hebei General Hospital, Shijiazhuang, China. -FAU - Hu, Qilu -AU - Hu Q -AD - Department of Oncology, Hebei General Hospital, Shijiazhuang, China. -FAU - Lei, Yuying -AU - Lei Y -AD - Department of Oncology, Hebei General Hospital, Shijiazhuang, China. -FAU - Zhang, Lijuan -AU - Zhang L -AD - Department of Oncology, Hebei General Hospital, Shijiazhuang, China. -FAU - Wang, Juan -AU - Wang J -AD - Department of Oncology, Hebei General Hospital, Shijiazhuang, China. -LA - eng -PT - Case Reports -PT - Research Support, Non-U.S. Gov't -DEP - 20200707 -PL - United States -TA - Clin Ther -JT - Clinical therapeutics -JID - 7706726 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Iodine Radioisotopes) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 31YO63LBSN (Nivolumab) -RN - DPT0O3T46P (pembrolizumab) -RN - GVO776611R (Iodine-125) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - *Brachytherapy -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Iodine Radioisotopes/*therapeutic use -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Male -MH - Middle Aged -MH - Nivolumab/*therapeutic use -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -MH - Treatment Outcome -OTO - NOTNLM -OT - anti–PD-1 antibody -OT - combined treatment -OT - iodine-125 seed brachytherapy -OT - lung cancer -EDAT- 2020/07/11 06:00 -MHDA- 2021/01/28 06:00 -CRDT- 2020/07/11 06:00 -PHST- 2020/02/29 00:00 [received] -PHST- 2020/05/25 00:00 [revised] -PHST- 2020/05/30 00:00 [accepted] -PHST- 2020/07/11 06:00 [pubmed] -PHST- 2021/01/28 06:00 [medline] -PHST- 2020/07/11 06:00 [entrez] -AID - S0149-2918(20)30280-0 [pii] -AID - 10.1016/j.clinthera.2020.05.018 [doi] -PST - ppublish -SO - Clin Ther. 2020 Aug;42(8):1612-1616. doi: 10.1016/j.clinthera.2020.05.018. Epub - 2020 Jul 7. - -PMID- 36135056 -OWN - NLM -STAT- MEDLINE -DCOM- 20220923 -LR - 20221020 -IS - 1718-7729 (Electronic) -IS - 1198-0052 (Print) -IS - 1198-0052 (Linking) -VI - 29 -IP - 9 -DP - 2022 Aug 29 -TI - Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced - Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case - Report. -PG - 6203-6210 -LID - 10.3390/curroncol29090487 [doi] -AB - Durvalumab consolidation therapy is the standard treatment after concurrent - chemoradiotherapy for patients with surgically unresectable stage IIIA (N2) - non-small-cell lung cancer (NSCLC). Neoadjuvant therapy followed by surgery could - reduce locoregional and distant recurrence and improve the survival rate for - surgically resectable NSCLC. However, the value of neoadjuvant therapy in locally - advanced potentially resectable NSCLC remains controversial. Herein, we report a - locally advanced potentially resectable NSCLC case with a history of breast - cancer who achieved a pathologic complete response (pCR) after preoperative - treatment with pembrolizumab and chemotherapy. A 50-year-old woman developed - squamous cell carcinoma (SCC) (left lower lobe of the lung, stage IIIA-N2) after - two years of chemotherapy and anti-HER2 therapy following a diagnosis of - HER2-overexpressing breast cancer. Surgical resection was attempted despite an - MDT classification as unamenable to curative surgical resection. After two cycles - of neoadjuvant chemotherapy combined with anti-PD1 immunotherapy, the tumor - significantly shrank, then the patient underwent a left lower lobectomy. Complete - resection with negative margins (R0 resection) was achieved in the patient. The - patient experienced grade 1-2 adverse effects and no grade 3 or worse adverse - effects occurred. Cardiotoxicity did not occur in the patient despite prior - anti-HER2 treatment for breast cancer. Our case study contributes to the existing - evidence on the feasibility, efficacy, and safety of neoadjuvant immunotherapy - combined with chemotherapy in locally advanced unresectable NSCLC. Furthermore, - future studies are needed to determine which patients can benefit from - immunoadjuvant therapy and the duration and course of preoperative and - postoperative immunotherapy. -FAU - Yang, Rui-Xia -AU - Yang RX -AD - Department of Oncology, Xijing Hospital of Air Force Military Medical University, - Xi'an 710032, China. -FAU - Hei, Yue -AU - Hei Y -AD - Department of Oncology, Xijing Hospital of Air Force Military Medical University, - Xi'an 710032, China. -FAU - Zhu, Wen-Ting -AU - Zhu WT -AD - Department of Oncology, Xijing Hospital of Air Force Military Medical University, - Xi'an 710032, China. -FAU - Wang, Qian-Rong -AU - Wang QR -AD - Department of Oncology, Xijing Hospital of Air Force Military Medical University, - Xi'an 710032, China. -FAU - Zhang, Hong-Mei -AU - Zhang HM -AUID- ORCID: 0000-0002-3991-3750 -AD - Department of Oncology, Xijing Hospital of Air Force Military Medical University, - Xi'an 710032, China. -FAU - Chen, Yan -AU - Chen Y -AD - Department of Oncology, Xijing Hospital of Air Force Military Medical University, - Xi'an 710032, China. -LA - eng -PT - Case Reports -PT - Research Support, Non-U.S. Gov't -DEP - 20220829 -PL - Switzerland -TA - Curr Oncol -JT - Current oncology (Toronto, Ont.) -JID - 9502503 -RN - 0 (Adjuvants, Immunologic) -SB - IM -MH - Adjuvants, Immunologic/therapeutic use -MH - *Breast Neoplasms/drug therapy/pathology -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - Female -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy/pathology -MH - Middle Aged -MH - Neoadjuvant Therapy -MH - Neoplasm Staging -PMC - PMC9497472 -OTO - NOTNLM -OT - Neoadjuvant immunotherapy -OT - non-small-cell lung cancer -OT - pathologic complete response -COIS- All authors have completed the uniform disclosure form. The authors have no - conflict of interest to declare. -EDAT- 2022/09/23 06:00 -MHDA- 2022/09/24 06:00 -PMCR- 2022/08/29 -CRDT- 2022/09/22 08:14 -PHST- 2022/07/27 00:00 [received] -PHST- 2022/08/12 00:00 [revised] -PHST- 2022/08/25 00:00 [accepted] -PHST- 2022/09/22 08:14 [entrez] -PHST- 2022/09/23 06:00 [pubmed] -PHST- 2022/09/24 06:00 [medline] -PHST- 2022/08/29 00:00 [pmc-release] -AID - curroncol29090487 [pii] -AID - curroncol-29-00487 [pii] -AID - 10.3390/curroncol29090487 [doi] -PST - epublish -SO - Curr Oncol. 2022 Aug 29;29(9):6203-6210. doi: 10.3390/curroncol29090487. - -PMID- 28870955 -OWN - NLM -STAT- MEDLINE -DCOM- 20170918 -LR - 20181202 -IS - 1791-7530 (Electronic) -IS - 0250-7005 (Linking) -VI - 37 -IP - 9 -DP - 2017 Sep -TI - Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of - Interstitial Lung Disease and Progression-free Survival of Patients with - Pre-treated Advanced Non-small Cell Lung Cancer. -PG - 5199-5205 -AB - BACKGROUND/AIM: Nivolumab has a promising efficacy for patients with - non-small-cell lung cancer (NSCLC) as second-line or later treatment, and after - radiotherapy as abscopal effect. However, the effects of radiation pneumonitis - history before nivolumab have not been clarified. Therefore, we retrospectively - analyzed the correlation of a history of radiation pneumonitis before nivolumab - with onset of interstitial lung disease (ILD) and progression-free survival (PFS) - after nivolumab treatment in patients with previously treated NSCLC. PATIENTS AND - METHODS: A total of 201 patients treated with nivolumab were retrospectively - reviewed. We collected clinical data of patients at the time of starting - nivolumab and we evaluated ILD incidence and PFS in relation to patient - characteristics, including radiation pneumonitis history. RESULTS: The median age - was 68 years; 135 patients were men, 157 had a smoking history, and 153 had - performance status of 0 or 1. Thirty-four patients experienced radiation - pneumonitis before nivolumab, and 50 patients received radiotherapy to the chest - (31 patients received curative radiotherapy). The overall median PFS was 2.8 - months and the overall ILD rate was 12.4%. Higher ILD incidence was observed in - the group with a history of radiation pneumonitis (26.5%) compared to the group - without radiation pneumonitis (9.6%). The median PFS was 3.6 and 2.3 months, - respectively. On multivariate analysis, a history of radiation pneumonitis was - also significantly correlated with good PFS (p=0.023). CONCLUSION: Although - increasing the risk of ILD, a history of radiation pneumonitis before nivolumab - also contributes to the prolongation of PFS after nivolumab. -CI - Copyright© 2017, International Institute of Anticancer Research (Dr. George J. - Delinasios), All rights reserved. -FAU - Tamiya, Akihiro -AU - Tamiya A -AD - Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest - Medical Center, Osaka, Japan atamiya@kch.hosp.go.jp. -FAU - Tamiya, Motohiro -AU - Tamiya M -AD - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, - Japan. -FAU - Nakahama, Kenji -AU - Nakahama K -AD - Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest - Medical Center, Osaka, Japan. -FAU - Taniguchi, Yoshihiko -AU - Taniguchi Y -AD - Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest - Medical Center, Osaka, Japan. -FAU - Shiroyama, Takayuki -AU - Shiroyama T -AD - Department of Thoracic Malignancy, Osaka Habikino Medical Center, Osaka, Japan. -FAU - Isa, Shun-Ichi -AU - Isa SI -AD - Department of Clinical Research Center, National Hospital Organization Kinki-chuo - Chest Medical Center, Osaka, Japan. -FAU - Inoue, Takako -AU - Inoue T -AD - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, - Japan. -FAU - Okishio, Kyoichi -AU - Okishio K -AD - Department of Clinical Research Center, National Hospital Organization Kinki-chuo - Chest Medical Center, Osaka, Japan. -FAU - Nishino, Kazumi -AU - Nishino K -AD - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, - Japan. -FAU - Kumagai, Toru -AU - Kumagai T -AD - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, - Japan. -FAU - Suzuki, Hidekazu -AU - Suzuki H -AD - Department of Thoracic Malignancy, Osaka Habikino Medical Center, Osaka, Japan. -FAU - Hirashima, Tomonori -AU - Hirashima T -AD - Department of Thoracic Malignancy, Osaka Habikino Medical Center, Osaka, Japan. -FAU - Imamura, Fumio -AU - Imamura F -AD - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, - Japan. -FAU - Atagi, Shinji -AU - Atagi S -AD - Department of Clinical Research Center, National Hospital Organization Kinki-chuo - Chest Medical Center, Osaka, Japan. -LA - eng -PT - Journal Article -PL - Greece -TA - Anticancer Res -JT - Anticancer research -JID - 8102988 -RN - 0 (Antibodies, Monoclonal) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Disease-Free Survival -MH - Female -MH - Humans -MH - Kaplan-Meier Estimate -MH - Lung Diseases, Interstitial/*etiology -MH - Lung Neoplasms/*drug therapy/pathology -MH - Male -MH - Middle Aged -MH - Multivariate Analysis -MH - Neoplasm Staging -MH - Nivolumab -MH - Proportional Hazards Models -MH - Radiation Pneumonitis/*complications -MH - Treatment Outcome -OTO - NOTNLM -OT - Nivolumab -OT - interstitial lung disease -OT - progression-free survival -OT - radiation pneumonitis -EDAT- 2017/09/06 06:00 -MHDA- 2017/09/19 06:00 -CRDT- 2017/09/06 06:00 -PHST- 2017/06/21 00:00 [received] -PHST- 2017/08/05 00:00 [revised] -PHST- 2017/08/08 00:00 [accepted] -PHST- 2017/09/06 06:00 [entrez] -PHST- 2017/09/06 06:00 [pubmed] -PHST- 2017/09/19 06:00 [medline] -AID - 37/9/5199 [pii] -AID - 10.21873/anticanres.11943 [doi] -PST - ppublish -SO - Anticancer Res. 2017 Sep;37(9):5199-5205. doi: 10.21873/anticanres.11943. - -PMID- 30911841 -OWN - NLM -STAT- MEDLINE -DCOM- 20190612 -LR - 20200225 -IS - 1432-1335 (Electronic) -IS - 0171-5216 (Print) -IS - 0171-5216 (Linking) -VI - 145 -IP - 6 -DP - 2019 Jun -TI - Comprehensive analysis of the characteristics and treatment outcomes of patients - with non-small cell lung cancer treated with anti-PD-1 therapy in real-world - practice. -PG - 1613-1623 -LID - 10.1007/s00432-019-02899-y [doi] -AB - PURPOSE: Immune checkpoint inhibitors (ICI) have shown marked responses in - patients with non-small cell lung cancer (NSCLC) in clinical trials. However, - because such trials comprise cohorts selected based on specific criteria, it is - unclear if their results represent routine clinical practice. METHODS: We - examined 155 patients with advanced NSCLC who were administered either nivolumab - or pembrolizumab at Yonsei Cancer Center, Korea between March 2014 and January - 2019. Patient characteristics, EGFR/ALK mutation status, metastatic locations, - response to ICIs, and adverse events were retrospectively analyzed. RESULTS: The - median age was 64 years and 72.9% of patients were male; former or current - smokers constituted 67.1% of the subjects. Adenocarcinoma was predominant - (67.7%), and 50.3% of the patients underwent ≥ 2 previous treatments. - Twenty-three patients (14.8%) were EGFR mutation- or ALK rearrangement-positive. - The objective response rate (ORR) was 23.9% [95% confidence interval (CI) - 17.4-31.4%]; the median progression-free survival (PFS) and overall survival (OS) - were 3.06 (95% CI 1.893-4.21) and 10.25 (95% CI 5.39-15.11) months, respectively. - Multivariate analysis identified ECOG performance status, EGFR mutation/ALK - rearrangement status, liver metastasis and PD-L1 proportion as independent - predictors of OS. Furthermore, 61.9% of the patients had adverse events of any - grade; 38.1% had immune-related adverse events that were associated with PFS and - OS on multivariate analysis. CONCLUSIONS: The real-world ORR, PFS, OS, and - adverse event profiles were comparable to previous clinical trials despite the - patients' different baseline characteristics. Our findings can aid in - establishing effective immunotherapeutic management of NSCLC in routine clinical - practice. -FAU - Ahn, Beung-Chul -AU - Ahn BC -AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer - Center, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, - 120-752, Republic of Korea. -FAU - Pyo, Kyoung-Ho -AU - Pyo KH -AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer - Center, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, - 120-752, Republic of Korea. -AD - Severance Biomedical Science Institute, Yonsei University College of Medicine, - Seoul, Republic of Korea. -FAU - Xin, Chun-Feng -AU - Xin CF -AD - Severance Biomedical Science Institute, Yonsei University College of Medicine, - Seoul, Republic of Korea. -FAU - Jung, Dongmin -AU - Jung D -AD - Severance Biomedical Science Institute, Yonsei University College of Medicine, - Seoul, Republic of Korea. -FAU - Shim, Hyo Sup -AU - Shim HS -AD - Department of Pathology, Severance Hospital, Yonsei University College of - Medicine, Seoul, Republic of Korea. -FAU - Lee, Chang Young -AU - Lee CY -AD - Department of Thoracic and Cardiovascular Surgery, Yonsei University College of - Medicine, Seoul, Republic of Korea. -FAU - Park, Seong Yong -AU - Park SY -AD - Department of Thoracic and Cardiovascular Surgery, Yonsei University College of - Medicine, Seoul, Republic of Korea. -FAU - Yoon, Hong In -AU - Yoon HI -AD - Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College - of Medicine, Seoul, Republic of Korea. -FAU - Hong, Min Hee -AU - Hong MH -AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer - Center, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, - 120-752, Republic of Korea. -FAU - Cho, Byoung Chul -AU - Cho BC -AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer - Center, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, - 120-752, Republic of Korea. cbc1971@yuhs.ac. -FAU - Kim, Hye Ryun -AU - Kim HR -AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer - Center, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, - 120-752, Republic of Korea. nobelg@yuhs.ac. -LA - eng -GR - 2017R1D1A1B03029874/National Research Foundation of Republic of Korea/ -GR - 2017M3A9E8029717/National Research Foundation of Republic of Korea/ -GR - 2017M3A9E9072669/National Research Foundation of Republic of Korea/ -GR - 2016M3C9A4922809/National Research Foundation of Republic of Korea/ -PT - Journal Article -DEP - 20190325 -PL - Germany -TA - J Cancer Res Clin Oncol -JT - Journal of cancer research and clinical oncology -JID - 7902060 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 31YO63LBSN (Nivolumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/*administration & dosage -MH - Antineoplastic Agents, Immunological/administration & dosage -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/pathology -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/immunology/pathology -MH - Male -MH - Middle Aged -MH - Nivolumab/*administration & dosage -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors/immunology -MH - Retrospective Studies -MH - Treatment Outcome -PMC - PMC6527531 -OTO - NOTNLM -OT - Immunotherapy -OT - Non-small cell lung cancer -OT - PD-1 -OT - Real-world setting -OT - Survival -COIS- The authors declare no potential conflicts of interest. -EDAT- 2019/03/27 06:00 -MHDA- 2019/06/14 06:00 -PMCR- 2019/03/25 -CRDT- 2019/03/27 06:00 -PHST- 2018/12/25 00:00 [received] -PHST- 2019/03/18 00:00 [accepted] -PHST- 2019/03/27 06:00 [pubmed] -PHST- 2019/06/14 06:00 [medline] -PHST- 2019/03/27 06:00 [entrez] -PHST- 2019/03/25 00:00 [pmc-release] -AID - 10.1007/s00432-019-02899-y [pii] -AID - 2899 [pii] -AID - 10.1007/s00432-019-02899-y [doi] -PST - ppublish -SO - J Cancer Res Clin Oncol. 2019 Jun;145(6):1613-1623. doi: - 10.1007/s00432-019-02899-y. Epub 2019 Mar 25. - -PMID- 33545805 -OWN - NLM -STAT- MEDLINE -DCOM- 20210514 -LR - 20210514 -IS - 2224-5839 (Electronic) -IS - 2224-5820 (Linking) -VI - 10 -IP - 1 -DP - 2021 Jan -TI - Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and - platinum for extensive-stage small cell lung cancer: a case report. -PG - 828-835 -LID - 10.21037/apm-20-2574 [doi] -AB - The conventional etoposide-platinum (EP) regimen and adjuvant radiotherapy remain - the gold-standard treatment for small cell lung cancer (SCLC). However, most - patients already have multiple metastases when they are first diagnosed with - SCLC. The objective response rate (ORR) and 1-year survival rate are low in these - patients despite active radiotherapy and chemotherapy. SCLC is oncologically - featured by the high tumor mutational burden (TMB) of multiple genes, which makes - immunotherapy a possible new treatment strategy for SCLC. New data from the - IMpower133 and CASPIAN trials will shed new light on the treatment of SCLC. In - 2020, the results from the phase 3 CASPIAN trial have already suggested that - programmed cell death-ligand 1 (PD-L1) inhibitors may represent breakthroughs in - the management of SCLC. Here, we report a patient with extensive-stage SCLC - (ES-SCLC) treated with first-line anti-PD-L1 immune checkpoint inhibitor (PD-L1 - inhibitor) (i.e., durvalumab) combined with the EP regimen for 6 cycles. The - patient consistently achieved partial response (PR) [nearly complete response - (CR)], and no immune-related adverse events were noted during this period. The - Karnofsky performance status (PS) score maintained at 1-2 points. We further - review the history of SCLC treatment and elucidate the role of combination with - immunotherapy in treating SCLC in the coming years. -FAU - Xue, Lei -AU - Xue L -AD - Department of Thoracic Surgery, The Third Affiliated Hospital of Southern Medical - University, Guangzhou, China. -FAU - Chen, Baishen -AU - Chen B -AD - Department of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen - University, Guangzhou, China. -FAU - Lin, Junshuang -AU - Lin J -AD - Department of Thoracic Surgery, The Third Affiliated Hospital of Southern Medical - University, Guangzhou, China. -FAU - Peng, Jiangzhou -AU - Peng J -AD - Department of Thoracic Surgery, The Third Affiliated Hospital of Southern Medical - University, Guangzhou, China. Email: academycn@foxmail.com. -LA - eng -PT - Case Reports -PT - Journal Article -PL - China -TA - Ann Palliat Med -JT - Annals of palliative medicine -JID - 101585484 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 49DFR088MY (Platinum) -RN - 6PLQ3CP4P3 (Etoposide) -SB - IM -MH - Etoposide/therapeutic use -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - *Lung Neoplasms/drug therapy -MH - Platinum/therapeutic use -MH - *Small Cell Lung Carcinoma/drug therapy -OTO - NOTNLM -OT - PD-L1 expression -OT - Small cell lung cancer (SCLC) -OT - programmed cell death-ligand 1 (PD-L1) -OT - programmed death-1 (PD-1) -OT - tumor mutation burden (TMB) -EDAT- 2021/02/07 06:00 -MHDA- 2021/05/15 06:00 -CRDT- 2021/02/06 01:00 -PHST- 2020/11/12 00:00 [received] -PHST- 2021/01/11 00:00 [accepted] -PHST- 2021/02/06 01:00 [entrez] -PHST- 2021/02/07 06:00 [pubmed] -PHST- 2021/05/15 06:00 [medline] -AID - 10.21037/apm-20-2574 [doi] -PST - ppublish -SO - Ann Palliat Med. 2021 Jan;10(1):828-835. doi: 10.21037/apm-20-2574. - -PMID- 38697848 -OWN - NLM -STAT- MEDLINE -DCOM- 20241015 -LR - 20241015 -IS - 2005-9256 (Electronic) -IS - 1598-2998 (Linking) -VI - 56 -IP - 4 -DP - 2024 Oct -TI - Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer - Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, - Open-Label, Single-Arm, Phase 2 Trial. -PG - 1084-1095 -LID - 10.4143/crt.2024.084 [doi] -AB - PURPOSE: Optimal treatment for stage IIIA/N2 non-small cell lung cancer (NSCLC) - is controversial. We aimed to assess the efficacy and safety of adjuvant - pembrolizumab for stage IIIA/N2 NSCLC completely resected after neoadjuvant - concurrent chemoradiation therapy (CCRT). MATERIALS AND METHODS: In this - open-label, single-center, single-arm phase 2 trial, patients with stage IIIA/N2 - NSCLC received adjuvant pembrolizumab for up to 2 years after complete resection - following neoadjuvant CCRT. The primary endpoint was disease-free survival (DFS). - Secondary endpoints included overall survival (OS) and safety. As an exploratory - biomarker analysis, we evaluated the proliferative response of blood - CD39+PD-1+CD8+ T cells using fold changes in the percentage of proliferating - Ki-67+ cells from days 1 to 7 of cycle 1 (Ki-67D7/D1). RESULTS: Between October - 2017 and October 2018, 37 patients were enrolled. Twelve (32%) and three (8%) - patients harbored EGFR and ALK alterations, respectively. Of 34 patients with - programmed cell death ligand 1 assessment, 21 (62%), nine (26%), and four (12%) - had a tumor proportion score of < 1%, 1%-50%, and ≥ 50%, respectively. The median - follow-up was 71 months. The median DFS was 22.4 months in the overall - population, with a 5-year DFS rate of 29%. The OS rate was 86% at 2 years and 76% - at 5 years. Patients with tumor recurrence within 6 months had a significantly - lower Ki-67D7/D1 among CD39+PD-1+CD8+ T cells than those without (p=0.036). No - new safety signals were identified. CONCLUSION: Adjuvant pembrolizumab may offer - durable disease control in a subset of stage IIIA/N2 NSCLC patients after - neoadjuvant CCRT and surgery. -FAU - Shin, Junghoon -AU - Shin J -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Korea. -FAU - Park, Sehhoon -AU - Park S -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Korea. -FAU - Kim, Kyung Hwan -AU - Kim KH -AD - Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy - Research Institute, Yonsei University College of Medicine, Seoul, Korea. -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Korea. -FAU - Shin, Eui-Cheol -AU - Shin EC -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Korea. -FAU - Jung, Hyun Ae -AU - Jung HA -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Korea. -FAU - Cho, Jong Ho -AU - Cho JH -AD - Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Korea. -FAU - Sun, Jong-Mu -AU - Sun JM -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Korea. -FAU - Lee, Se-Hoon -AU - Lee SH -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Korea. -FAU - Choi, Yong Soo -AU - Choi YS -AD - Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Korea. -FAU - Ahn, Jin Seok -AU - Ahn JS -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Korea. -FAU - Kim, Jhingook -AU - Kim J -AD - Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Korea. -FAU - Park, Keunchil -AU - Park K -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Korea. -FAU - Shim, Young Mog -AU - Shim YM -AD - Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Korea. -FAU - Kim, Hong Kwan -AU - Kim HK -AD - Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Korea. -FAU - Noh, Jae Myoung -AU - Noh JM -AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University - School of Medicine, Seoul, Korea. -FAU - Ahn, Yong Chan -AU - Ahn YC -AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University - School of Medicine, Seoul, Korea. -FAU - Pyo, Hongryull -AU - Pyo H -AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University - School of Medicine, Seoul, Korea. -FAU - Ahn, Myung-Ju -AU - Ahn MJ -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Korea. -LA - eng -GR - Merck Sharp & Dohme Corp./ -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20240430 -PL - Korea (South) -TA - Cancer Res Treat -JT - Cancer research and treatment -JID - 101155137 -RN - DPT0O3T46P (pembrolizumab) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/pathology/mortality -MH - Female -MH - Male -MH - Middle Aged -MH - *Antibodies, Monoclonal, Humanized/therapeutic use/administration & dosage -MH - *Lung Neoplasms/therapy/pathology/mortality -MH - Aged -MH - *Neoadjuvant Therapy/methods -MH - Prospective Studies -MH - *Neoplasm Staging -MH - *Chemoradiotherapy/methods -MH - Adult -MH - Chemotherapy, Adjuvant/methods -MH - Antineoplastic Agents, Immunological/therapeutic use/pharmacology -OTO - NOTNLM -OT - Adjuvant chemotherapy -OT - Chemoradiotherapy -OT - Non-small-cell lung carcinoma -OT - Pembrolizumab -EDAT- 2024/05/03 00:50 -MHDA- 2024/10/15 10:17 -CRDT- 2024/05/02 21:50 -PHST- 2024/01/23 00:00 [received] -PHST- 2024/04/28 00:00 [accepted] -PHST- 2024/10/15 10:17 [medline] -PHST- 2024/05/03 00:50 [pubmed] -PHST- 2024/05/02 21:50 [entrez] -AID - crt.2024.084 [pii] -AID - 10.4143/crt.2024.084 [doi] -PST - ppublish -SO - Cancer Res Treat. 2024 Oct;56(4):1084-1095. doi: 10.4143/crt.2024.084. Epub 2024 - Apr 30. - -PMID- 38714983 -OWN - NLM -STAT- MEDLINE -DCOM- 20240508 -LR - 20240510 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 24 -IP - 1 -DP - 2024 May 7 -TI - Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior - immunotherapy in patients with driver-gene negative advanced non-small cell lung - cancer. -PG - 569 -LID - 10.1186/s12885-024-12315-5 [doi] -LID - 569 -AB - BACKGROUND: No definite conclusion has yet to be reached for immunotherapy beyond - progression(IBP) of first-line immunotherapy as the second-line treatment for - advanced NSCLC patients with negative driver genes. Therefore a retrospective - study was conducted to evaluate the efficacy of IBP in this population and - investigated whether the cycles best response and progressive mode of first-line - immunotherapy could affect the results. PATIENTS AND METHODS: The clinical data - of patients with advanced NSCLC whose response was evaluated as progressive - disease (PD) after receiving a PD-1/PD-L1 inhibitors as first-line therapy were - retrospectively collected and the patients were assigned to the IBP and non-IBP - groups. The overall survival (OS), progression-free survival (PFS) were evaluated - between the two groups. The survival effects of cycles best response and - progressive mode of first-line immunotherapy were also evaluated. RESULTS: - Between January 2019 and January 2022, a total of 121 patients was evaluated as - PD after first-line immunotherapy in our institution; 53 (43.8%) patients were - included in the IBP group and 68 (56.2%) patients were included in the non-IBP - group. The OS and PFS were no significantly different between the two groups in - whole population. Further analysis revealed the OS was prolonged with the - prolongation of first-line medication cycle. The median OS was 15.4m (15.4 vs - 10.8 p=0.047) 16.1m (16.1 vs 10.8 p=0.039), 16.3m (16.3 vs 10.9 p=0.029) for - patients with ≥4, ≥6, ≥8 cycles in first-line immunotherapy, respectively. The - advantages of OS and PFS were also seen in the subgroup of PR (best response) and - oligo progression of first-line immunotherapy. CONCLUSIONS: The clinical outcomes - of IBP were similar to those of non-IBP in patients with PD after first-line - immnuotherapy in advanced NSCLC. But more cycles, PR as best response and oligo - progression in first-line was benefit. -CI - © 2024. The Author(s). -FAU - Wang, Min -AU - Wang M -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, - 250117, Shandong Province, China. -FAU - Jing, Xuquan -AU - Jing X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, - 250117, Shandong Province, China. -FAU - Chen, Feihu -AU - Chen F -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, - 250117, Shandong Province, China. -FAU - Lu, Shuangqing -AU - Lu S -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, - 250117, Shandong Province, China. -FAU - Sun, Yulan -AU - Sun Y -AD - Department of Medical Oncology, Shandong First Medical University and Shandong - Academy of Medical Sciences, Shandong Cancer Hospital and Institute, 440 Jiyan - Road, Jinan, 250117, Shandong Province, China. 306920775@qq.com. -LA - eng -GR - Y-2019AZZD-0352/CSCO-Pilot Cancer Research/ -GR - Y-2019AZZD-0352/CSCO-Pilot Cancer Research/ -GR - Y-2019AZZD-0352/CSCO-Pilot Cancer Research/ -GR - Y-2019AZZD-0352/CSCO-Pilot Cancer Research/ -GR - Y-2019AZZD-0352/CSCO-Pilot Cancer Research/ -PT - Journal Article -DEP - 20240507 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (B7-H1 Antigen) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug - therapy/immunology/mortality/genetics/therapy/pathology -MH - *Immune Checkpoint Inhibitors/therapeutic use -MH - Male -MH - Female -MH - *Lung Neoplasms/drug therapy/mortality/pathology/immunology/genetics/therapy -MH - Middle Aged -MH - Retrospective Studies -MH - Aged -MH - *Immunotherapy/methods -MH - Disease Progression -MH - Progression-Free Survival -MH - Adult -MH - Aged, 80 and over -MH - B7-H1 Antigen/antagonists & inhibitors -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -PMC - PMC11075238 -OTO - NOTNLM -OT - Best response -OT - Cycles -OT - Immunotherapy -OT - NSCLC -OT - Progrssion -COIS- The authors declare no competing interests. -EDAT- 2024/05/08 02:06 -MHDA- 2024/05/08 06:45 -PMCR- 2024/05/07 -CRDT- 2024/05/07 23:48 -PHST- 2024/01/09 00:00 [received] -PHST- 2024/04/26 00:00 [accepted] -PHST- 2024/05/08 06:45 [medline] -PHST- 2024/05/08 02:06 [pubmed] -PHST- 2024/05/07 23:48 [entrez] -PHST- 2024/05/07 00:00 [pmc-release] -AID - 10.1186/s12885-024-12315-5 [pii] -AID - 12315 [pii] -AID - 10.1186/s12885-024-12315-5 [doi] -PST - epublish -SO - BMC Cancer. 2024 May 7;24(1):569. doi: 10.1186/s12885-024-12315-5. - -PMID- 30996212 -OWN - NLM -STAT- MEDLINE -DCOM- 20190809 -LR - 20190809 -IS - 1349-3329 (Electronic) -IS - 0040-8727 (Linking) -VI - 247 -IP - 4 -DP - 2019 Apr -TI - Development of Hepatocellular Carcinoma During Nivolumab Treatment for Recurrent - Non-Small Cell Lung Cancer: A Case Report. -PG - 247-250 -LID - 10.1620/tjem.247.247 [doi] -AB - Nivolumab, a monoclonal antibody targeting programmed cell death 1 (PD-1), is the - standard second-line therapy for advanced non-small cell lung cancer (NSCLC). In - the current immunotherapy era, it is often difficult to evaluate the therapeutic - effect, disease progression, and pseudo-enlargement of the tumor or the emergence - of another etiology. In the present report, we describe a 79-year-old patient - with hepatocellular carcinoma (HCC) newly detected during nivolumab treatment for - recurrent NSCLC. When the patient was 73 years old, he had suffered from NSCLC - and received concurrent chemoradiotherapy comprising cisplatin and docetaxel, - achieving a complete response. Six years after the chemoradiotherapy, the patient - had multiple lung and hepatic lesions. We thus started the treatment with - nivolumab for recurrent NSCLC. All those lesions responded to nivolumab over nine - cycles. By contrast, a lesion was newly detected in the medial segment of left - hepatic lobe, liver segment 4 (S4), and was gradually getting larger, as judged - by computed tomographic scan. Liver biopsy revealed the growing lesion to be a - well-differentiated HCC. Consequently, the patient was treated with - radiofrequency ablation to HCC, while nivolumab treatment was continued for - NSCLC. Immunohistochemical analysis of the HCC specimens revealed nuclear - accumulation of β-catenin compared with normal liver cells and undetectable - expression of program death ligand 1 (PD-L1). Such expression profiles of - β-catenin and PD-L1 in HCC may be responsible for the resistance against - nivolumab treatment. Immunohistochemical features of the biopsy specimens may be - predictive of the effectiveness of the immunotherapy in HCC. -FAU - Nishikawa, Koji -AU - Nishikawa K -AD - Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases - Center Komagome Hospital. -FAU - Okuma, Yusuke -AU - Okuma Y -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center Komagome Hospital. -FAU - Hashimoto, Kana -AU - Hashimoto K -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center Komagome Hospital. -FAU - Kashima, Jumpei -AU - Kashima J -AD - Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center - Komagome Hospital. -LA - eng -PT - Case Reports -PT - Journal Article -PL - Japan -TA - Tohoku J Exp Med -JT - The Tohoku journal of experimental medicine -JID - 0417355 -RN - 31YO63LBSN (Nivolumab) -MH - Aged -MH - Carcinoma, Hepatocellular/diagnostic imaging/*drug therapy/pathology -MH - Chemoradiotherapy -MH - Humans -MH - Lung Neoplasms/diagnostic imaging/*drug therapy/pathology -MH - Male -MH - Neoplasm Recurrence, Local/pathology -MH - Nivolumab/*therapeutic use -MH - Tomography, X-Ray Computed -OTO - NOTNLM -OT - hepatocellular carcinoma -OT - nivolumab -OT - non-small cell lung carcinoma -OT - program death ligand 1 -OT - β-catenin -EDAT- 2019/04/19 06:00 -MHDA- 2019/08/10 06:00 -CRDT- 2019/04/19 06:00 -PHST- 2019/04/19 06:00 [entrez] -PHST- 2019/04/19 06:00 [pubmed] -PHST- 2019/08/10 06:00 [medline] -AID - 10.1620/tjem.247.247 [doi] -PST - ppublish -SO - Tohoku J Exp Med. 2019 Apr;247(4):247-250. doi: 10.1620/tjem.247.247. - -PMID- 28138869 -OWN - NLM -STAT- MEDLINE -DCOM- 20170313 -LR - 20220408 -IS - 1559-131X (Electronic) -IS - 1357-0560 (Linking) -VI - 34 -IP - 3 -DP - 2017 Mar -TI - Risk of tumor flare after nivolumab treatment in patients with irradiated field - recurrence. -PG - 34 -LID - 10.1007/s12032-017-0895-4 [doi] -AB - Nivolumab offers a statistically superior survival benefit over docetaxel in - patients with advanced, previously treated squamous and non-squamous - non-small-cell lung cancer (NSCLC). However, we unexpectedly encountered "tumor - flare" that was associated with initially increased tumor lesion size and - subsequently decreased tumor burden in patients with NSCLC treated with - nivolumab, which is known as pseudoprogression. Tumor flare with rapid - progression related to accelerated progression after nivolumab treatment has also - been observed. Here we report two patients having early irradiated field - recurrence who experienced "tumor flare" that showed pseudoprogression and rapid - progression. In addition, we present a brief literature review on "tumor flare" - after nivolumab treatment. -FAU - Yoshida, Tatsuya -AU - Yoshida T -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1, Kanokoden, - Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. t.yoshida@aichi-cc.jp. -FAU - Furuta, Hiromi -AU - Furuta H -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1, Kanokoden, - Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. -FAU - Hida, Toyoaki -AU - Hida T -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1, Kanokoden, - Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. -LA - eng -PT - Case Reports -PT - Letter -DEP - 20170130 -PL - United States -TA - Med Oncol -JT - Medical oncology (Northwood, London, England) -JID - 9435512 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal/*adverse effects/therapeutic use -MH - Antineoplastic Agents/adverse effects/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/*pathology/radiotherapy -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/*pathology/radiotherapy -MH - Male -MH - Middle Aged -MH - Neoplasm Recurrence, Local/drug therapy/pathology/radiotherapy -MH - Nivolumab -MH - Tumor Burden -OTO - NOTNLM -OT - Nivolumab -OT - Non-small cell lung cancer -OT - Pseudoprogression -OT - Tumor flare -EDAT- 2017/02/01 06:00 -MHDA- 2017/03/14 06:00 -CRDT- 2017/02/01 06:00 -PHST- 2016/12/30 00:00 [received] -PHST- 2017/01/19 00:00 [accepted] -PHST- 2017/02/01 06:00 [entrez] -PHST- 2017/02/01 06:00 [pubmed] -PHST- 2017/03/14 06:00 [medline] -AID - 10.1007/s12032-017-0895-4 [pii] -AID - 10.1007/s12032-017-0895-4 [doi] -PST - ppublish -SO - Med Oncol. 2017 Mar;34(3):34. doi: 10.1007/s12032-017-0895-4. Epub 2017 Jan 30. - -PMID- 33302686 -OWN - NLM -STAT- MEDLINE -DCOM- 20210514 -LR - 20210514 -IS - 2224-5839 (Electronic) -IS - 2224-5820 (Linking) -VI - 9 -IP - 6 -DP - 2020 Nov -TI - A case report of sustained clinical remission in patients with locally advanced - lung adenocarcinoma after sequential immunotherapy following concurrent - chemoradiotherapy. -PG - 4346-4352 -LID - 10.21037/apm-20-1773 [doi] -AB - Lung cancer is the most common cause of cancer-related deaths worldwide. - Pathologically, lung cancer can be non-small cell lung cancer (NSCLC) or small - cell lung cancer (SCLC), while NSCLC accounts for approximately 85% of lung - cancer patients. Stage III NSCLC represents a heterogeneous group of disease - entities that are potentially curable and are usually dealt with multimodality - treatments involving radiotherapy, chemotherapy, and surgical resection. Immune - checkpoint inhibitors (ICIs) target programmed cell death receptor-1 (PD-1) and - programmed death-ligand 1 (PD-L1). Studies have shown that ICIs have excellent - and long-lasting anti-cancer effects in many cancers. The PACIFIC study is the - first in the systemic treatment of stage III unresectable NSCLC in the past few - decades that both progression-free survival (PFS) and overall survival (OS) have - obtained positive results, However, the performance of this treatment strategy - remains to be studied in a real-world setting. Such as who will benefit from - treatment is still worthy of our continuous exp loration. In this paper, a - patient with locally advanced unresectable NSCLC who underwent concurrent - chemoradiotherapy followed by sequential immunotherapy (durvalumab) was reported. - The patient obtained sustained clinical benefits despite low PD-L1 expression. - This case report may serve as a reference for clinicians to make diagnostic and - treatment decisions in clinical practice. -FAU - Chen, Weilin -AU - Chen W -AD - Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical - University, Zhangzhou, China. cwlqiao@163.com. -FAU - Zhang, Haoyi -AU - Zhang H -AD - Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical - University, Zhangzhou, China. -FAU - Huang, Weifeng -AU - Huang W -AD - Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical - University, Zhangzhou, China. -FAU - Lan, Tingting -AU - Lan T -AD - Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical - University, Zhangzhou, China. -LA - eng -PT - Case Reports -PT - Journal Article -PL - China -TA - Ann Palliat Med -JT - Annals of palliative medicine -JID - 101585484 -SB - IM -MH - *Adenocarcinoma of Lung/therapy -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -OTO - NOTNLM -OT - Lung adenocarcinoma -OT - clinical remission -OT - concurrent chemoradiotherapy -OT - immunotherapy -EDAT- 2020/12/12 06:00 -MHDA- 2021/05/15 06:00 -CRDT- 2020/12/11 05:33 -PHST- 2020/06/16 00:00 [received] -PHST- 2020/10/24 00:00 [accepted] -PHST- 2020/12/11 05:33 [entrez] -PHST- 2020/12/12 06:00 [pubmed] -PHST- 2021/05/15 06:00 [medline] -AID - 10.21037/apm-20-1773 [doi] -PST - ppublish -SO - Ann Palliat Med. 2020 Nov;9(6):4346-4352. doi: 10.21037/apm-20-1773. - -PMID- 7979413 -OWN - NLM -STAT- MEDLINE -DCOM- 19941209 -LR - 20071115 -IS - 0385-0684 (Print) -IS - 0385-0684 (Linking) -VI - 21 -IP - 15 -DP - 1994 Nov -TI - [Combined multimodality treatment for non-small cell lung cancer--with special - reference to pre- and post-operative adjuvant therapy]. -PG - 2555-63 -AB - Surgical resection is the treatment of choice for patients with localized - non-small cell lung cancer. However, the long-term survival rate of patients - after such surgery is disappointing. Even in stage I patients who have undergone - potentially curative operation, over 30% of them recur within five years. Most of - the recurrences are caused by hematogenous metastases to the distant organs. - However, all of the comparative study to evaluate postoperative adjuvant therapy, - ie, chemotherapy, immunotherapy, radiotherapy, or their combination, showed - negative results, except for a few positive outcomes. To date, there is no - evidence that pre- and postoperative adjuvant therapy have shown a favorable - impact on survival of postoperative patients with stage I disease. LCSG has had - reportedly favorable results on survival of stage II and III adenocarcinoma and - large cell carcinoma by postoperative CAP-chemotherapy. Postoperative - chemotherapy and/or radiotherapy showed no impact on survival of stage III - patients who underwent surgical intervention. However, preoperative induction - therapy (IT) using combination chemotherapy (with or without radiotherapy) has - improved the survival of patients with resected stage III disease, although most - reports are of phase II trial or interim results. It seems to be true that the IT - can render an advanced lung cancer resectable and also can control pre-existing - micro-metastases in the distant organs. However, randomized prospective trials - are required for evaluating an impact on the survival rate of the advanced - non-small cell lung cancer. -FAU - Watanabe, Y -AU - Watanabe Y -AD - Dept. of Surgery I, Kanazawa University School of Medicine. -LA - jpn -PT - English Abstract -PT - Journal Article -PT - Review -PL - Japan -TA - Gan To Kagaku Ryoho -JT - Gan to kagaku ryoho. Cancer & chemotherapy -JID - 7810034 -SB - IM -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/mortality/radiotherapy/*therapy -MH - Chemotherapy, Adjuvant -MH - Clinical Trials as Topic -MH - Combined Modality Therapy -MH - Humans -MH - Lung Neoplasms/mortality/radiotherapy/*therapy -MH - *Pneumonectomy -MH - Radiotherapy, Adjuvant -MH - Survival Rate -RF - 33 -EDAT- 1994/11/01 00:00 -MHDA- 1994/11/01 00:01 -CRDT- 1994/11/01 00:00 -PHST- 1994/11/01 00:00 [pubmed] -PHST- 1994/11/01 00:01 [medline] -PHST- 1994/11/01 00:00 [entrez] -PST - ppublish -SO - Gan To Kagaku Ryoho. 1994 Nov;21(15):2555-63. - -PMID- 25130084 -OWN - NLM -STAT- MEDLINE -DCOM- 20150610 -LR - 20201219 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 86 -IP - 1 -DP - 2014 Oct -TI - A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) - non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. -PG - 59-66 -LID - S0169-5002(14)00318-3 [pii] -LID - 10.1016/j.lungcan.2014.07.018 [doi] -AB - OBJECTIVES: The immunological and clinical responses of patients with NSCLC - treated, in the context of an expanded action program, with the cryptic - hTERT-targeting Vx-001 vaccine are presented. MATERIALS AND METHODS: Forty-six - HLA-A*0201-positive patients with advanced NSCLC and residual (n=27) or - progressive (n=19) disease following front-line treatment received two - subcutaneous injections of the optimized TERT572Y peptide followed by four - injections of the native TERT572 peptide, every 3 weeks. Peptide-specific immune - responses were monitored by enzyme-linked immunosorbent spot assay at baseline, - and after the 2nd and the 6th vaccinations. Thirty-eight HLA-A*0201-positive - matched patients were used as historical controls. RESULTS: Twenty-three patients - (50%) completed the vaccination protocol and 87% received at least two - administrations. Twelve patients (26%) without disease progression after the 6th - vaccination received boost vaccinations. Three (7%) patients achieved a partial - response and 13 (28%) disease stabilization. The disease control rate was - significantly higher in patients with non-squamous histology compared to those - with squamous-cell histology [n=14 (45%) versus n=2 (13%); p=0.03]. The median - progression-free survival (PFS) and overall survival (OS) was 3.8 (range, - 0.7-99.4) and 19.8 months (range, 0.7-99.4), respectively. Patients who developed - immune response had a numerically higher PFS compared to those who failed to - mount any (6.7 versus 2.7 months; p=0.090). However, the median OS for the - immune-responders was significantly prolonged compared to non-responders (40.0 - versus 9.2 months, respectively; p=0.02). Toxicity was or =18 years, Eastern Cooperative - Oncology Group performance status 0-1, at stage IIIB (pleural effusion)/IV or - with recurrent disease not suitable for primary surgical treatment, with no - palliative chemotherapy or radiotherapy to the chest or immunotherapy or biologic - therapy, the presence of measurable disease by RECIST, and who had given signed - written informed consent, were eligible. Treatment consisted of irinotecan 65 - mg/m(2) on days 1 and 8 and oxaliplatin 130 mg/m(2) on day 1, repeated every 3 - weeks. RESULTS: A total of 18 patients were enrolled in June and August 2007, the - median age was 59 years (47-73). In total, 71 cycles were administered with a - median of 4 cycles per patient (range, 1-6 cycles) and 18 patients were evaluable - for treatment response. An independent review of tumor responses gave an overall - response rate of 27.7% (CR: 0, PR: 5/18; 95% CI, 7-48.4%) by intent-to-treat - analysis. The median overall survival of all patients was 14 months and the - median time-to-progression was 4.2 months (95% CI, 1.959-6.441). The most common - grade 3/4 toxicities were diarrhea (7% of all cycles) and neutropenia (5.6% of - all cycles). Grade 3 peripheral neuropathy occurred in one patient and one - patient died due to sepsis. CONCLUSION: This study suggests that IrOx combination - therapy has moderate activity with a tolerable toxicity profile. However, it was - not warranted to evaluate further this regimen as first-line treatment for - patients with advanced or metastatic NSCLC using the current dosages and - schedule. -FAU - Chang, Myung Hee -AU - Chang MH -AD - Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, - Seoul, South Korea. -FAU - Kim, Kyoung Ha -AU - Kim KH -FAU - Jun, Hyun Jung -AU - Jun HJ -FAU - Kim, Hyo Song -AU - Kim HS -FAU - Yi, Seong Yoon -AU - Yi SY -FAU - Uhm, Ji Eun -AU - Uhm JE -FAU - Park, Min Jae -AU - Park MJ -FAU - Lim, Do Hyoung -AU - Lim DH -FAU - Ji, Sang Hoon -AU - Ji SH -FAU - Hwang, In Gyu -AU - Hwang IG -FAU - Lee, Jeeyun -AU - Lee J -FAU - Park, Yeon Hee -AU - Park YH -FAU - Ahn, Jin Seok -AU - Ahn JS -FAU - Ahn, Myung-Ju -AU - Ahn MJ -FAU - Park, Keunchil -AU - Park K -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20090217 -PL - Germany -TA - Cancer Chemother Pharmacol -JT - Cancer chemotherapy and pharmacology -JID - 7806519 -RN - 0 (Antineoplastic Agents) -RN - 0 (Antineoplastic Agents, Phytogenic) -RN - 0 (Organoplatinum Compounds) -RN - 04ZR38536J (Oxaliplatin) -RN - 7673326042 (Irinotecan) -RN - EC 2.4.1.17 (Glucuronosyltransferase) -RN - XT3Z54Z28A (Camptothecin) -SB - IM -MH - Aged -MH - Antineoplastic Agents/administration & dosage -MH - Antineoplastic Agents, Phytogenic/administration & dosage -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use -MH - Camptothecin/administration & dosage/analogs & derivatives -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/pathology -MH - Disease Progression -MH - Female -MH - Genotype -MH - Glucuronosyltransferase/genetics -MH - Humans -MH - Irinotecan -MH - Lung Neoplasms/*drug therapy/genetics/pathology -MH - Male -MH - Middle Aged -MH - Neoplasm Metastasis -MH - Organoplatinum Compounds/administration & dosage -MH - Oxaliplatin -MH - Polymorphism, Genetic -MH - Survival Analysis -EDAT- 2009/02/18 09:00 -MHDA- 2009/09/15 06:00 -CRDT- 2009/02/18 09:00 -PHST- 2008/11/12 00:00 [received] -PHST- 2009/01/19 00:00 [accepted] -PHST- 2009/02/18 09:00 [entrez] -PHST- 2009/02/18 09:00 [pubmed] -PHST- 2009/09/15 06:00 [medline] -AID - 10.1007/s00280-009-0943-7 [doi] -PST - ppublish -SO - Cancer Chemother Pharmacol. 2009 Oct;64(5):917-24. doi: - 10.1007/s00280-009-0943-7. Epub 2009 Feb 17. - -PMID- 36353627 -OWN - NLM -STAT- MEDLINE -DCOM- 20221111 -LR - 20240907 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 13 -DP - 2022 -TI - Immune-related arthritis following pelvic radiation therapy in a patient with - lung cancer receiving long-term immune checkpoint blocker treatment: Case report. -PG - 920130 -LID - 10.3389/fimmu.2022.920130 [doi] -LID - 920130 -AB - Radiotherapy can trigger immune-related out-of-field "abscopal" response. We - report a patient with advanced NSCLC (non-small cell lung cancer) receiving - long-term anti-PD1 (programmed cell death protein 1) who have developed - out-of-field immune-related arthritis following pelvic irradiation. -CI - Copyright © 2022 Aldea, Belkhir, Colomba, Blanchard, Danlos, Botticella, - Terlizzi, Deutsch, Le Péchoux, Planchard, Michot, Besse and Levy. -FAU - Aldea, Mihaela -AU - Aldea M -AD - Department of Medical Oncology, International Center for Thoracic Cancers (CICT), - Université Paris-Saclay, Gustave Roussy, Villejuif, France. -FAU - Belkhir, Rakiba -AU - Belkhir R -AD - Rheumatology, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, - Le Kremlin-Bicêtre, France. -FAU - Colomba, Emeline -AU - Colomba E -AD - Department of Medical Oncology, International Center for Thoracic Cancers (CICT), - Université Paris-Saclay, Gustave Roussy, Villejuif, France. -FAU - Blanchard, Pierre -AU - Blanchard P -AD - Department of Radiation Oncology, International Center for Thoracic Cancers - (CICT), Université Paris-Saclay, Gustave Roussy, Villejuif, France. -FAU - Danlos, Francois-Xavier -AU - Danlos FX -AD - Department of Medical Oncology, International Center for Thoracic Cancers (CICT), - Université Paris-Saclay, Gustave Roussy, Villejuif, France. -FAU - Botticella, Angela -AU - Botticella A -AD - Department of Radiation Oncology, International Center for Thoracic Cancers - (CICT), Université Paris-Saclay, Gustave Roussy, Villejuif, France. -FAU - Terlizzi, Mario -AU - Terlizzi M -AD - Department of Radiation Oncology, International Center for Thoracic Cancers - (CICT), Université Paris-Saclay, Gustave Roussy, Villejuif, France. -FAU - Deutsch, Eric -AU - Deutsch E -AD - Department of Radiation Oncology, International Center for Thoracic Cancers - (CICT), Université Paris-Saclay, Gustave Roussy, Villejuif, France. -AD - INSERM U1030, Molecular Radiotherapy, Université Paris-Saclay, Villejuif, France. -FAU - Le Péchoux, Cecile -AU - Le Péchoux C -AD - Department of Radiation Oncology, International Center for Thoracic Cancers - (CICT), Université Paris-Saclay, Gustave Roussy, Villejuif, France. -FAU - Planchard, David -AU - Planchard D -AD - Department of Medical Oncology, International Center for Thoracic Cancers (CICT), - Université Paris-Saclay, Gustave Roussy, Villejuif, France. -FAU - Michot, Jean-Marie -AU - Michot JM -AD - DITEP (Département des Innovations Thérapeutiques et Essais Précoces), Université - Paris-Saclay, Gustave Roussy, Villejuif, France. -FAU - Besse, Benjamin -AU - Besse B -AD - Department of Medical Oncology, International Center for Thoracic Cancers (CICT), - Université Paris-Saclay, Gustave Roussy, Villejuif, France. -FAU - Levy, Antonin -AU - Levy A -AD - Department of Radiation Oncology, International Center for Thoracic Cancers - (CICT), Université Paris-Saclay, Gustave Roussy, Villejuif, France. -AD - INSERM U1030, Molecular Radiotherapy, Université Paris-Saclay, Villejuif, France. -LA - eng -PT - Case Reports -DEP - 20221024 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Lung Neoplasms -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Arthritis -PMC - PMC9637658 -OTO - NOTNLM -OT - adverse (side) effects -OT - anti-PD(L)1 -OT - immunoradiotherapy -OT - immunotherapy -OT - radiation therapy -OT - toxicity -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/11/11 06:00 -MHDA- 2022/11/15 06:00 -PMCR- 2022/01/01 -CRDT- 2022/11/10 02:24 -PHST- 2022/04/14 00:00 [received] -PHST- 2022/10/05 00:00 [accepted] -PHST- 2022/11/10 02:24 [entrez] -PHST- 2022/11/11 06:00 [pubmed] -PHST- 2022/11/15 06:00 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2022.920130 [doi] -PST - epublish -SO - Front Immunol. 2022 Oct 24;13:920130. doi: 10.3389/fimmu.2022.920130. eCollection - 2022. - -PMID- 6262887 -OWN - NLM -STAT- MEDLINE -DCOM- 19810709 -LR - 20190904 -IS - 0080-0015 (Print) -IS - 0080-0015 (Linking) -VI - 76 -DP - 1981 -TI - Small cell lung carcinoma - recent advances and current challenges. -PG - 267-75 -FAU - Livingston, R B -AU - Livingston RB -LA - eng -PT - Journal Article -PT - Review -PL - Germany -TA - Recent Results Cancer Res -JT - Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans - les recherches sur le cancer -JID - 0044671 -RN - 0 (Antineoplastic Agents) -SB - IM -MH - Antineoplastic Agents/therapeutic use -MH - Carcinoma, Small Cell/drug therapy/radiotherapy/*therapy -MH - Drug Therapy, Combination -MH - Humans -MH - Immunotherapy -MH - Lung Neoplasms/drug therapy/radiotherapy/*therapy -RF - 42 -EDAT- 1981/01/01 00:00 -MHDA- 1981/01/01 00:01 -CRDT- 1981/01/01 00:00 -PHST- 1981/01/01 00:00 [pubmed] -PHST- 1981/01/01 00:01 [medline] -PHST- 1981/01/01 00:00 [entrez] -AID - 10.1007/978-3-642-81565-2_24 [doi] -PST - ppublish -SO - Recent Results Cancer Res. 1981;76:267-75. doi: 10.1007/978-3-642-81565-2_24. - -PMID- 33725780 -OWN - NLM -STAT- MEDLINE -DCOM- 20210514 -LR - 20220531 -IS - 2224-5839 (Electronic) -IS - 2224-5820 (Linking) -VI - 10 -IP - 2 -DP - 2021 Feb -TI - Anlotinib combined with durvalumab in a patient with recurrent multifocal brain - metastases of small cell lung cancer after definitive concurrent - chemoradiotherapy and palliative radiotherapy of the lung and brain: a case - report. -PG - 2379-2386 -LID - 10.21037/apm-20-2390 [doi] -AB - The brain is a common metastatic site of small cell lung cancer (SCLC), but - systematic treatment options are limited by the blood-brain barrier. Currently, - the optimal treatment regimen remains controversial, especially for patients - already treated by brain radiotherapy. Anlotinib is a novel oral multitarget - tyrosine kinase inhibitor which has shown significant improvement in - progression-free survival and overall survival in third-line or beyond therapy of - advanced SCLC in a randomized, double-blind phase II study (ALTER1202 trial) - based on a Chinese population sample. Emerging data has also suggested that - immunotherapy, such as the programmed death ligand 1 (PD-L1) inhibitor, has a - relatively high response rate in brain metastatic SCLC, although there is a lack - of large sample-size studies. Integrating anlotinib and immunotherapy for - recurrent or relapsing brain metastases (BMs) of SCLC has not been previously - reported, but it is possible that these two treatments may have synergistic - effects and provide even better outcomes. Here, we present a case of stage III - SCLC who developed lung and BMs after concurrent chemoradiotherapy (cCRT) and - achieved radiographic locally complete regression following whole brain - irradiation (WBI) with a simultaneous integrated boost (SIB) technique. - Durvalumab was delivered as maintenance therapy. Asymptomatic multifocal - recurrence of BMs occurred after the administration of the second dose of - durvalumab. After administration of combined durvalumab and anlotinib, the BMs - achieved near-complete regression and no severe toxicity was reported. This - suggests a potential synergistic effect of combined durvalumab and anlotinib in - previously treated BMs in a patient with SCLC and may provide a direction for - future clinical decisions. -FAU - Wu, Yuqi -AU - Wu Y -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Zhang, Tao -AU - Zhang T -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Liu, Yutao -AU - Liu Y -AD - Department of Oncology, National Cancer Center/National Clinical Research Center - for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union - Medical College, Beijing, China. -FAU - Wang, Jianyang -AU - Wang J -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. -FAU - Bi, Nan -AU - Bi N -AD - Department of Radiation Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science - and Peking Union Medical College, Beijing, China. binan_email@163.com. -LA - eng -PT - Case Reports -PT - Journal Article -PL - China -TA - Ann Palliat Med -JT - Annals of palliative medicine -JID - 101585484 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Indoles) -RN - 0 (Quinolines) -RN - 0 (anlotinib) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal -MH - Brain -MH - *Brain Neoplasms -MH - Chemoradiotherapy -MH - Humans -MH - Indoles -MH - Lung -MH - *Lung Neoplasms/drug therapy -MH - Quinolines -MH - *Small Cell Lung Carcinoma/drug therapy -OTO - NOTNLM -OT - Small cell lung cancer (SCLC) -OT - anlotinib -OT - brain metastases (BMs) -OT - case report -OT - durvalumab -EDAT- 2021/03/18 06:00 -MHDA- 2021/05/15 06:00 -CRDT- 2021/03/17 01:00 -PHST- 2020/10/16 00:00 [received] -PHST- 2021/02/03 00:00 [accepted] -PHST- 2021/03/17 01:00 [entrez] -PHST- 2021/03/18 06:00 [pubmed] -PHST- 2021/05/15 06:00 [medline] -AID - 10.21037/apm-20-2390 [doi] -PST - ppublish -SO - Ann Palliat Med. 2021 Feb;10(2):2379-2386. doi: 10.21037/apm-20-2390. - -PMID- 32161221 -OWN - NLM -STAT- MEDLINE -DCOM- 20201019 -LR - 20240329 -IS - 1349-7235 (Electronic) -IS - 0918-2918 (Print) -IS - 0918-2918 (Linking) -VI - 59 -IP - 11 -DP - 2020 Jun 1 -TI - Whole-brain Radiation and Pembrolizumab Treatment for a Non-small-cell Lung - Cancer Patient with Meningeal Carcinomatosis Lacking Driver Oncogenes Led to a - Long-term Survival. -PG - 1433-1435 -LID - 10.2169/internalmedicine.4232-19 [doi] -AB - We herein report a 66-year-old woman with advanced lung adenocarcinoma - [programmed cell death and its ligand 1 (PD-L1) tumor proportion score 60%] - lacking driver oncogenes in whom meningeal carcinomatosis, along with sudden - onset dizziness, deafness, and consciousness disturbance, appeared after - second-line chemotherapy. Whole-brain radiation therapy (WBRT) and Pembrolizumab - were subsequently administered, and third-line chemotherapy with Pembrolizumab is - now ongoing. At the time of writing, the patient has achieved a 23-month survival - without disease progression. Our findings suggest that the combination of WBRT - and an immune checkpoint inhibitor is effective for non-small-cell lung cancer - patients lacking driver oncogenes who develop meningeal carcinomatosis. -FAU - Nakashima, Koki -AU - Nakashima K -AD - Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan. -FAU - Demura, Yoshiki -AU - Demura Y -AD - Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan. -FAU - Oi, Masahiro -AU - Oi M -AD - Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan. -FAU - Tabata, Mio -AU - Tabata M -AD - Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan. -FAU - Tada, Toshihiko -AU - Tada T -AD - Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan. -FAU - Shiozaki, Kohei -AU - Shiozaki K -AD - Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan. -FAU - Akai, Masaya -AU - Akai M -AD - Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan. -FAU - Ishizuka, Tamotsu -AU - Ishizuka T -AD - Third Department of Internal Medicine, Faculty of Medical Sciences, University of - Fukui, Japan. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20200312 -PL - Japan -TA - Intern Med -JT - Internal medicine (Tokyo, Japan) -JID - 9204241 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Brain Neoplasms/*radiotherapy -MH - Carcinoma, Non-Small-Cell Lung/*complications/*drug therapy/genetics -MH - Female -MH - Humans -MH - Lung Neoplasms/*complications/*drug therapy/genetics -MH - Meningeal Carcinomatosis/etiology/*radiotherapy -MH - Oncogenes -MH - Treatment Outcome -PMC - PMC7332633 -OTO - NOTNLM -OT - Pembrolizumab -OT - immune checkpoint inhibitor -OT - meningeal carcinomatosis -OT - non-small-cell lung cancer -OT - whole-brain radiation therapy -COIS- The authors state that they have no Conflict of Interest (COI). -EDAT- 2020/03/13 06:00 -MHDA- 2020/10/21 06:00 -PMCR- 2020/06/01 -CRDT- 2020/03/13 06:00 -PHST- 2020/03/13 06:00 [pubmed] -PHST- 2020/10/21 06:00 [medline] -PHST- 2020/03/13 06:00 [entrez] -PHST- 2020/06/01 00:00 [pmc-release] -AID - 10.2169/internalmedicine.4232-19 [doi] -PST - ppublish -SO - Intern Med. 2020 Jun 1;59(11):1433-1435. doi: 10.2169/internalmedicine.4232-19. - Epub 2020 Mar 12. - -PMID- 32648466 -OWN - NLM -STAT- MEDLINE -DCOM- 20210427 -LR - 20210427 -IS - 2224-5839 (Electronic) -IS - 2224-5820 (Linking) -VI - 9 -IP - 5 -DP - 2020 Sep -TI - Successful treatment of a patient with non-small cell lung cancer and - interstitial lung disease with durvalumab: a case report. -PG - 3623-3628 -LID - 10.21037/apm-20-1134 [doi] -AB - For patients with advanced non-small cell lung cancer (NSCLC), immune checkpoint - inhibitors (ICIs) can offer an effective treatment. However, despite their - potential benefits, the use of ICIs can lead to inflammation in various organs, - including pneumonitis. Interstitial lung disease (ILD), which is a common - complication in patients with NSCLC, can increase the risk of pneumonitis. For - NSCLC patients with ILD, the safety of ICIs has yet to be established. Durvalumab - is a selective, high-affinity, engineered, human IgG1 monoclonal antibody, which - showed durable response and manageable side effects in stage III NSCLC patients - after definitive chemoradiotherapy. Pneumonitis in patients who received - durvalumab was mostly low grade, given the potential applications in NSCLC with - ILD. A 77-year-old man was diagnosed with Stage IV lung squamous carcinoma and - ILD at our hospital. The PD-L1 expression assessed by VENTANA PD-L1 (SP263) Assay - showed about 60% of tumor cells exhibit positive. Because the patient refused - chemotherapy, he was given durvalumab at 20 mg/kg every 4 weeks as first-line - anti-tumor therapy. After four cycles of therapy, the patient achieved partial - remission, and complete remission(CR) had been achieved after 6 cycles of therapy - and maintained over two years. No immune-related adverse events were reported. In - this case, PD-L1 inhibitors were used to safely treat an NSCLC patient with ILD, - which presents the need for further evaluation of their use. -FAU - Tao, Haitao -AU - Tao H -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Li, Fangfang -AU - Li F -AD - Department of State Guest, Institute of Health Management, The Second Medical - Center of Chinese PLA General Hospital, Beijing, China. -FAU - Li, Ruixin -AU - Li R -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Han, Xiao -AU - Han X -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Hu, Yi -AU - Hu Y -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. huyi0401@aliyun.com. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20200709 -PL - China -TA - Ann Palliat Med -JT - Annals of palliative medicine -JID - 101585484 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - *Lung Diseases, Interstitial/chemically induced/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Male -OTO - NOTNLM -OT - Non-small cell lung cancer (NSCLC) -OT - case report -OT - immune checkpoint inhibitors (ICIs) -OT - interstitial lung disease (ILD) -OT - pneumonitis -EDAT- 2020/07/11 06:00 -MHDA- 2021/04/28 06:00 -CRDT- 2020/07/11 06:00 -PHST- 2020/04/17 00:00 [received] -PHST- 2020/06/30 00:00 [accepted] -PHST- 2020/07/11 06:00 [pubmed] -PHST- 2021/04/28 06:00 [medline] -PHST- 2020/07/11 06:00 [entrez] -AID - apm-20-1134 [pii] -AID - 10.21037/apm-20-1134 [doi] -PST - ppublish -SO - Ann Palliat Med. 2020 Sep;9(5):3623-3628. doi: 10.21037/apm-20-1134. Epub 2020 - Jul 9. - -PMID- 15735129 -OWN - NLM -STAT- MEDLINE -DCOM- 20050325 -LR - 20220309 -IS - 0732-183X (Print) -IS - 0732-183X (Linking) -VI - 23 -IP - 7 -DP - 2005 Mar 1 -TI - Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment - radioimmunotherapy in patients with advanced lung cancer. -PG - 1538-47 -AB - PURPOSE: Tumor necrosis treatment (TNT) uses degenerating tumor cells and - necrotic regions of tumors as targets for radioimmunotherapy. Previous studies in - animal tumor models and clinical trials have demonstrated that when linked to the - therapeutic radionuclide iodine-131, recombinant chimeric TNT antibody - ((131)I-chTNT) can deliver therapeutic doses to tumors regardless of the location - or type of malignancy. Therapeutic efficacy and toxicity of (131)I-chTNT in - advanced lung cancer patients were studied in this pivotal registration trial. - PATIENTS AND METHODS: Patients with advanced lung cancer were treated with - systemic or intratumoral injection of (131)I-chTNT in eight oncology centers in - China. The objective response rate (ORR) was assessed as the primary end point. - RESULTS: All 107 patients who were entered onto the study and completed therapy - had experienced treatment failure after prior radiotherapy or chemotherapy a mean - of three times. The results showed an ORR of 34.6% (complete response, 3.7%; - partial response, 30.8%; no change, 55.1%; and progressive disease, 10.3%) in all - patients and 33% in 97 non-small-cell lung cancer patients. A biodistribution - study demonstrated excellent localization of the radioactivity in tumors in both - systemically and intratumorally injected patients. The most obvious adverse side - effect was mild and reversible bone marrow suppression. CONCLUSION: - Radioimmunotherapy with (131)I-chTNT was well tolerated and can be used - systemically or locally to treat refractory tumors of the lung. -FAU - Chen, Shaoliang -AU - Chen S -AD - Zhongshan Hospital and Tumor Hospital, Fudan University, Shanghai, China. -FAU - Yu, Like -AU - Yu L -FAU - Jiang, Changying -AU - Jiang C -FAU - Zhao, Yan -AU - Zhao Y -FAU - Sun, Da -AU - Sun D -FAU - Li, Shenyu -AU - Li S -FAU - Liao, Guoqing -AU - Liao G -FAU - Chen, Yangchun -AU - Chen Y -FAU - Fu, Qing -AU - Fu Q -FAU - Tao, Qun -AU - Tao Q -FAU - Ye, Dan -AU - Ye D -FAU - Hu, Peisheng -AU - Hu P -FAU - Khawli, Leslie A -AU - Khawli LA -FAU - Taylor, Clive R -AU - Taylor CR -FAU - Epstein, Alan L -AU - Epstein AL -FAU - Ju, Dian Wen -AU - Ju DW -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - United States -TA - J Clin Oncol -JT - Journal of clinical oncology : official journal of the American Society of - Clinical Oncology -JID - 8309333 -RN - 0 (Antibodies, Neoplasm) -RN - 0 (Immunotoxins) -RN - 0 (Iodine Radioisotopes) -SB - IM -MH - Adult -MH - Aged -MH - Antibodies, Neoplasm -MH - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/pathology/*radiotherapy -MH - Female -MH - Humans -MH - Immunotoxins/administration & dosage -MH - Iodine Radioisotopes/*administration & dosage/toxicity -MH - Lung Neoplasms/diagnostic imaging/pathology/*radiotherapy -MH - Male -MH - Middle Aged -MH - Necrosis -MH - Positron-Emission Tomography -MH - Radioimmunotherapy/adverse effects/*methods -MH - Tissue Distribution -EDAT- 2005/03/01 09:00 -MHDA- 2005/03/26 09:00 -CRDT- 2005/03/01 09:00 -PHST- 2005/03/01 09:00 [pubmed] -PHST- 2005/03/26 09:00 [medline] -PHST- 2005/03/01 09:00 [entrez] -AID - 23/7/1538 [pii] -AID - 10.1200/JCO.2005.06.108 [doi] -PST - ppublish -SO - J Clin Oncol. 2005 Mar 1;23(7):1538-47. doi: 10.1200/JCO.2005.06.108. - -PMID- 6262886 -OWN - NLM -STAT- MEDLINE -DCOM- 19810709 -LR - 20190904 -IS - 0080-0015 (Print) -IS - 0080-0015 (Linking) -VI - 76 -DP - 1981 -TI - Combined modality studies on small cell carcinoma of the lung - current status in - Japan. -PG - 257-66 -AB - Sixty-two patients with small cell carcinoma in three institutes were carefully - divided into limited and extensive disease categories. Median survival time of - limited-disease patients was longer than those with extensive disease. In - relation to the survival rate, the degree of response to initial chemotherapy was - studied on 75 patients treated in our institute. The complete responders had a - significantly better survival rate than the partial responders and nonresponders. - Best survival was achieved by multidisciplinary treatment, including - polychemotherapy, subsequent radiotherapy, and immunotherapy using BCG-CWS or - Nocardia-CWS. Combination chemotherapy with concurrent small-dose radiation - therapy for the purpose of intensifying the effect of chemotherapy was - introduced. This method significantly improved the response rate without causing - any of the side effects associated with radiotherapy. Cytomorphological studies - on the correlation with better survival rates of small cell carcinoma patients - were described. -FAU - Ikegami, H -AU - Ikegami H -FAU - Horai, T -AU - Horai T -FAU - Hattori, S -AU - Hattori S -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - Germany -TA - Recent Results Cancer Res -JT - Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans - les recherches sur le cancer -JID - 0044671 -RN - 0 (Antineoplastic Agents) -SB - IM -MH - Antineoplastic Agents/*therapeutic use -MH - Carcinoma, Small Cell/*drug therapy/pathology/radiotherapy -MH - Drug Therapy, Combination -MH - Humans -MH - Japan -MH - Lung Neoplasms/*drug therapy/pathology/radiotherapy -EDAT- 1981/01/01 00:00 -MHDA- 1981/01/01 00:01 -CRDT- 1981/01/01 00:00 -PHST- 1981/01/01 00:00 [pubmed] -PHST- 1981/01/01 00:01 [medline] -PHST- 1981/01/01 00:00 [entrez] -AID - 10.1007/978-3-642-81565-2_23 [doi] -PST - ppublish -SO - Recent Results Cancer Res. 1981;76:257-66. doi: 10.1007/978-3-642-81565-2_23. - -PMID- 32820489 -OWN - NLM -STAT- MEDLINE -DCOM- 20201210 -LR - 20201214 -IS - 1438-8790 (Electronic) -IS - 0934-8387 (Linking) -VI - 74 -IP - 11 -DP - 2020 Nov -TI - [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) - after Neoadjuvant Therapy with Immune Checkpoint Inhibition]. -PG - 766-772 -LID - 10.1055/a-1199-2029 [doi] -AB - BACKGROUND:  The blockade of immune escape mechanisms (e. g. PD1 /PD-L1) using - immune checkpoint inhibition (ICI) can significantly prolong survival and induce - remission in patients with advanced non-small cell lung cancer (NSCLC). Less is - known about neoadjuvant ICI in patients with resectable (UICC stage III) or - oligometastatic (UICC stage IVa) NSCLC. METHODS:  Tissue biopsies from patients - with advanced or oligometastatic NSCLC were screened for PD-L1 expression. In - case of PD-L1-expression > 50 %, ECOG status of 0 or 1 and expected operability, - patients received ICI. After about four weeks, patients underwent thoracic - surgical resection. In all patients, a complete staging, including PET-CT, cMRI, - and endobronchial ultrasound, was performed. The tolerability, the radiological - and the histopathological tumor response as well as the surgical and oncological - outcomes were analyzed. FINDINGS:  Four patients (2 male, 2 female, age 56 - 78 - years, n = 3 adenocarcinoma, n = 1 squamous cell carcinoma) with local advanced - tumors received ICI before surgical resection. In three cases the mediastinal - lymph nodes were positive. One patient had a single cerebral metastasis which was - treated with radiotherapy. All four patients underwent therapy with two to six - cycles of ICI (3 × pembrolizumab, 1 × atezolizumab) without any complication, and - ICI did not delay the time of surgical resection. According to iRECIST, three - patients showed partial response (PR), one patient had stable disease (SD). All - tumors were completely resected. The thoracic surgical procedures proved to be - technically unproblematic despite inflammatory changes. There were neither - treatment-related deaths nor perioperative complications. In the resectates, - complete pathological response (CPR, regression grade III ) and regression grade - IIb were detected twice. The average time of follow-up was 12 (1 - 24) months. - Patients with PPR developed distant metastasis after six months or a local - recurrence after four months. The CPR patient is relapse free to date. - CONCLUSION:  In selected patients, neoadjuvant therapy with ICI is well tolerated - and can induce a complete remission of the tumor. Treatment with ICI has no - negative impact on the surgical procedure. Prognosis seems to be promising in CPR - and limited in PPR. -CI - Thieme. All rights reserved. -FAU - Lücke, E -AU - Lücke E -AD - Klinik für Pneumologie, Otto-von-Guericke-Universität Magdeburg, Magdeburg. -FAU - Ganzert, C -AU - Ganzert C -AD - Klinik für Pneumologie, Otto-von-Guericke-Universität Magdeburg, Magdeburg. -FAU - Föllner, S -AU - Föllner S -AD - Klinik für Pneumologie, Otto-von-Guericke-Universität Magdeburg, Magdeburg. -FAU - Wäsche, A -AU - Wäsche A -AD - Klinik für Pneumologie, Otto-von-Guericke-Universität Magdeburg, Magdeburg. -FAU - Jechorek, D -AU - Jechorek D -AD - Institut für Pathologie, Otto-von-Guericke-Universität Magdeburg, Magdeburg. -FAU - Schoeder, V -AU - Schoeder V -AD - Institut für Pathologie, Otto-von-Guericke-Universität Magdeburg, Magdeburg. -FAU - Walles, T -AU - Walles T -AD - Klinik für Herz- und Thoraxchirurgie, Abteilung Thoraxchirurgie, - Otto-von-Guericke-Universität Magdeburg, Magdeburg. -FAU - Genseke, P -AU - Genseke P -AD - Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke-Universität - Magdeburg, Magdeburg. -FAU - Schreiber, J -AU - Schreiber J -AD - Klinik für Pneumologie, Otto-von-Guericke-Universität Magdeburg, Magdeburg. -LA - ger -PT - Journal Article -TT - Operabilität und pathologisches Ansprechen des Lungenkarzinoms nach neoadjuvanter - Therapie mit Immun-Checkpoint-Inhibitoren. -DEP - 20200820 -PL - Germany -TA - Pneumologie -JT - Pneumologie (Stuttgart, Germany) -JID - 8906641 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Antineoplastic Agents, Immunological/*adverse effects/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/immunology/*pathology/*surgery -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Immunotherapy/*adverse effects -MH - Lung Neoplasms/drug therapy/immunology/*pathology/*surgery -MH - Male -MH - Neoadjuvant Therapy -MH - Neoplasm Staging -MH - Positron Emission Tomography Computed Tomography -MH - Treatment Outcome -COIS- Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht. -EDAT- 2020/08/21 06:00 -MHDA- 2020/12/15 06:00 -CRDT- 2020/08/22 06:00 -PHST- 2020/08/21 06:00 [pubmed] -PHST- 2020/12/15 06:00 [medline] -PHST- 2020/08/22 06:00 [entrez] -AID - 10.1055/a-1199-2029 [doi] -PST - ppublish -SO - Pneumologie. 2020 Nov;74(11):766-772. doi: 10.1055/a-1199-2029. Epub 2020 Aug 20. - -PMID- 31635973 -OWN - NLM -STAT- MEDLINE -DCOM- 20200923 -LR - 20200923 -IS - 1879-0593 (Electronic) -IS - 1368-8375 (Linking) -VI - 101 -DP - 2020 Feb -TI - Immune checkpoint inhibitors: For how long do we need to release the brakes to - achieve the optimum acceleration of immune-mediated anti-tumor response? -PG - 104435 -LID - S1368-8375(19)30336-7 [pii] -LID - 10.1016/j.oraloncology.2019.09.027 [doi] -AB - In recent years, cancer immunotherapy has emerged as the fourth pillar of cancer - therapy alongside surgery, chemotherapy and radiotherapy. We here report an - unusual scenario of a patient with advanced metastatic non-small cell lung cancer - who was lost to follow up after two cycles of chemo-immunotherapy who later - returned to clinic with complete response; suggesting that in some, all that was - needed may have been just a few doses of therapy to "release the breaks." -CI - Copyright © 2019. Published by Elsevier Ltd. -FAU - Sukari, Ammar -AU - Sukari A -AD - Department of Oncology, Karmanos Cancer Institute/Wayne State University, - Detroit, MI, USA. Electronic address: sukaria@karmanos.org. -FAU - Nagasaka, Misako -AU - Nagasaka M -AD - Department of Oncology, Karmanos Cancer Institute/Wayne State University, - Detroit, MI, USA; Department of Advanced Medical Innovation, St. Marianna - University Graduate School of Medicine, Kawasaki, Japan. -LA - eng -PT - Case Reports -PT - Letter -DEP - 20191018 -PL - England -TA - Oral Oncol -JT - Oral oncology -JID - 9709118 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Antineoplastic Agents, Immunological/administration & dosage/adverse - effects/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use -MH - Biomarkers, Tumor -MH - Carcinoma, Non-Small-Cell Lung/diagnosis/*drug therapy/etiology -MH - *Duration of Therapy -MH - Humans -MH - Lung Neoplasms/diagnosis/*drug therapy/etiology -MH - Male -MH - Middle Aged -MH - *Molecular Targeted Therapy/adverse effects/methods -MH - Multimodal Imaging -MH - Treatment Outcome -OTO - NOTNLM -OT - Chemo-immunotherapy -OT - Complete response -OT - Duration of therapy -COIS- Declaration of Competing Interest The authors have not received any funding for - this study and declare no direct conflict of interest. Dr. Sukari serves on the - advisory board for Eisai and a speaker for Merck and Eisai. He has received study - funding from Eisai. Dr. Nagasaka serves on the advisory board for AstraZeneca and - has received research support from Tempus. -EDAT- 2019/10/23 06:00 -MHDA- 2020/09/24 06:00 -CRDT- 2019/10/23 06:00 -PHST- 2019/09/24 00:00 [received] -PHST- 2019/09/25 00:00 [revised] -PHST- 2019/09/28 00:00 [accepted] -PHST- 2019/10/23 06:00 [pubmed] -PHST- 2020/09/24 06:00 [medline] -PHST- 2019/10/23 06:00 [entrez] -AID - S1368-8375(19)30336-7 [pii] -AID - 10.1016/j.oraloncology.2019.09.027 [doi] -PST - ppublish -SO - Oral Oncol. 2020 Feb;101:104435. doi: 10.1016/j.oraloncology.2019.09.027. Epub - 2019 Oct 18. - -PMID- 30266109 -OWN - NLM -STAT- MEDLINE -DCOM- 20190815 -LR - 20190815 -IS - 1001-9294 (Print) -IS - 1001-9294 (Linking) -VI - 33 -IP - 3 -DP - 2018 Sep 20 -TI - Treatment of Skin Reaction Induced by Nivolumab Combined with Radiotherapy in - Non-small Cell Lung Cancer: A Case Report. -PG - 183-187 -LID - 10.24920/31805 [doi] -AB - Skin reaction or dermatological toxicities induced by immunotherapy is common. It - usually manifests skin rash or erythema and can be cured by skin lotion or - steroid. Nivolumab, a human IgG4 programmed cell death protein 1 (PD-1) - inhibitor, blocks T cells activation preventing signal and allows the immune - system to clear cancer cells. Nivolumab was approved in the second-line therapy - in squamous cell lung cancer by FDA, with less than 10% unusual skin reaction, - like sensory neuropathy, peeling skin, erythema multiforme, vitiligo, and - psoriasis. Radiotherapy could aggravate this skin reaction through inflammatory - response and promotion of immunity. The combined treatment of anti-PD-1 and - radiotherapy represented a new promising therapeutic approach in many studies, - but the risk of side effects may be high. We reported a patient with advanced - squamous cell lung cancer who suffered from serious skin immune-related adverse - events when he was treated with nivolumab and radiotherapy. The immune - overreaction of the treatment of anti-PD-1 treatment and radiotherapy might cause - these serious skin adverse events. Our report warranted careful workup to reduce - the risk of side effects by combinative therapy with anti-PD-1 and radiotherapy. -FAU - Zhao, Zhi-Mei -AU - Zhao ZM -AD - Department of Oncology, Affiliated Qingdao Central Hospital of Qingdao - University, Qingdao, Shandong 266042, China. -FAU - Liu, Shi-Chao -AU - Liu SC -AD - Department of Oncology, Qingdao Cancer Hospital, Qingdao, Shandong 266042, China. -FAU - Xu, Xia-Juan -AU - Xu XJ -AD - Department of Oncology, Affiliated Qingdao Central Hospital of Qingdao - University, Qingdao, Shandong 266042, China. -FAU - Zhang, Zhong-Fa -AU - Zhang ZF -AD - Department of Oncology, Qingdao Cancer Hospital, Qingdao, Shandong 266042, China. -FAU - Nie, Ke-Ke -AU - Nie KK -AD - Department of Oncology, Qingdao Cancer Hospital, Qingdao, Shandong 266042, China. -FAU - Ji, You-Xin -AU - Ji YX -AD - Department of Oncology, Affiliated Qingdao Central Hospital of Qingdao - University, Qingdao, Shandong 266042, China. -LA - eng -PT - Case Reports -PT - Journal Article -PL - China -TA - Chin Med Sci J -JT - Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih -JID - 9112559 -RN - 31YO63LBSN (Nivolumab) -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/*radiotherapy -MH - Combined Modality Therapy -MH - Humans -MH - Lung Neoplasms/*drug therapy/*radiotherapy -MH - Male -MH - Middle Aged -MH - Nivolumab/*adverse effects/*therapeutic use -MH - Skin/drug effects/*pathology/radiation effects -EDAT- 2018/09/30 06:00 -MHDA- 2019/08/16 06:00 -CRDT- 2018/09/30 06:00 -PHST- 2018/09/30 06:00 [entrez] -PHST- 2018/09/30 06:00 [pubmed] -PHST- 2019/08/16 06:00 [medline] -AID - 10.24920/31805 [doi] -PST - ppublish -SO - Chin Med Sci J. 2018 Sep 20;33(3):183-187. doi: 10.24920/31805. - -PMID- 10687149 -OWN - NLM -STAT- MEDLINE -DCOM- 20000511 -LR - 20191103 -IS - 1524-9557 (Print) -IS - 1524-9557 (Linking) -VI - 23 -IP - 1 -DP - 2000 Jan -TI - Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the - postoperative treatment of advanced non-small-cell lung cancer. -PG - 161-7 -AB - The association of adoptive immunotherapy (AI) and radiotherapy has been shown to - be effective in the control of residual intrathoracic disease, while having no - systemic advantages, in patients operated on for locally advanced non-small-cell - lung cancer (NSCLC). The potential synergy of coupling immunotherapy and - chemotherapy has been emphasized in several tumors including NSCLC. The aim of - this work was to determine the feasibility and activity of a combined therapeutic - program, including AI, chemotherapy, and radiotherapy in patients who had - undergone incomplete resections for NSCLC. In a phase II trial, 13 patients - received the combined treatment. AI was given from week 4 after surgery until - week 8. Concurrent chemo-(cisplatin and etoposide)-radiotherapy (60 Gy) was given - from week 9 to week 14. Twenty eligible patients received chemoradiotherapy only - and were used as a non-randomized concomitant group for merely descriptive - purposes. At 9-month follow-up, 10 of the 13 patients had progression of disease - and the study was stopped. Progression-free survival and survival were similar to - those of the chemoradiotherapy group. The present study showed that the sequence - of immunotherapy followed by chemotherapy is not effective as adjuvant treatment - in patients operated on for stage III NSCLC, at least when used according to the - adopted schedule. -FAU - Ratto, G B -AU - Ratto GB -AD - Cattedra di Chirurgia Toracica, University of Genoa, Italy. -FAU - Cafferata, M A -AU - Cafferata MA -FAU - Scolaro, T -AU - Scolaro T -FAU - Bruzzi, P -AU - Bruzzi P -FAU - Alloisio, A -AU - Alloisio A -FAU - Costa, R -AU - Costa R -FAU - Spessa, E -AU - Spessa E -FAU - Semino, C -AU - Semino C -FAU - Melioli, G -AU - Melioli G -LA - eng -PT - Clinical Trial -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - United States -TA - J Immunother -JT - Journal of immunotherapy (Hagerstown, Md. : 1997) -JID - 9706083 -RN - 0 (Antineoplastic Agents) -RN - 6PLQ3CP4P3 (Etoposide) -RN - Q20Q21Q62J (Cisplatin) -SB - IM -MH - Adult -MH - Aged -MH - Antineoplastic Agents/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy/surgery/*therapy -MH - Cisplatin/*therapeutic use -MH - Combined Modality Therapy -MH - Etoposide/*therapeutic use -MH - Female -MH - Humans -MH - Immunotherapy -MH - Lung Neoplasms/drug therapy/radiotherapy/surgery/*therapy -MH - Male -MH - Middle Aged -MH - Postoperative Care -MH - Treatment Outcome -EDAT- 2000/02/25 09:00 -MHDA- 2000/05/16 09:00 -CRDT- 2000/02/25 09:00 -PHST- 2000/02/25 09:00 [pubmed] -PHST- 2000/05/16 09:00 [medline] -PHST- 2000/02/25 09:00 [entrez] -AID - 10.1097/00002371-200001000-00019 [doi] -PST - ppublish -SO - J Immunother. 2000 Jan;23(1):161-7. doi: 10.1097/00002371-200001000-00019. - -PMID- 29681240 -OWN - NLM -STAT- MEDLINE -DCOM- 20180928 -LR - 20181114 -IS - 1752-1947 (Electronic) -IS - 1752-1947 (Linking) -VI - 12 -IP - 1 -DP - 2018 Apr 23 -TI - Pembrolizumab combined with stereotactic body radiotherapy in a patient with - human immunodeficiency virus and advanced non-small cell lung cancer: a case - report. -PG - 104 -LID - 10.1186/s13256-018-1667-2 [doi] -LID - 104 -AB - BACKGROUND: Pembrolizumab has significantly improved outcomes in patients with - advanced non-small cell lung cancer. Combining programmed death-1 inhibitor with - stereotactic body radiotherapy showed a slight toxicity and good benefits in - recent clinical trials. However, patients infected with human immunodeficiency - virus were excluded from most trials because it was assumed that their anti-tumor - immunity was compromised compared with immunocompetent patients. CASE - PRESENTATION: In June 2016, a 52-year-old Chinese man presented with human - immunodeficiency virus and lung adenocarcinoma (T1bN3M1b). From November 2016 to - December 2016, systemic chemotherapy and palliative radiotherapy for bone - metastasis of femoral neck were carried out, but the tumor progressed. In January - 2017, after immunochemistry detection of programmed death-1 and programmed - death-ligand 1 expression (both > 50%), pembrolizumab was started. Three weeks - after pembrolizumab, we combined stereotactic body radiotherapy for the primary - lung tumor. He received no comfort and his CD4 lymphocyte count was stable. Human - immunodeficiency virus-ribonucleic acid remained below the limits of detection. - In March 2017, after three cycles of pembrolizumab and 5 weeks of stereotactic - body radiotherapy therapy, he suddenly presented with palpitations. Emergency - computed tomography scanning showed massive pericardial effusion and interstitial - pneumonia. So we interrupted the pembrolizumab use and initiated treatment with - prednisolone 1 mg/kg; however, the tumor progressed. Then, his CD4 lymphocyte - count declined. Finally he died in June 2017 due to dyscrasia. CONCLUSIONS: - Pembrolizumab combined with SBRT therapy for patients with human immunodeficiency - virus infection and non-small cell lung cancer may lead to serious immune-related - adverse events and more clinical trials are needed. -FAU - Li, Dongqi -AU - Li D -AD - Bone and Soft Tissue Tumors Research Center of Yunnan Province, Department of - Orthopaedics, The Third Affiliated Hospital of Kunming Medical University (Tumor - Hospital of Yunnan Province), Kunming, Yunnan, 650118, People's Republic of - China. -FAU - He, Chuanchun -AU - He C -AD - Bone and Soft Tissue Tumors Research Center of Yunnan Province, Department of - Orthopaedics, The Third Affiliated Hospital of Kunming Medical University (Tumor - Hospital of Yunnan Province), Kunming, Yunnan, 650118, People's Republic of - China. -FAU - Xia, Yaoxiong -AU - Xia Y -AD - Department of Radiotherapy, The Third Affiliated Hospital of Kunming Medical - University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, 650118, People's - Republic of China. -FAU - Du, Yaxi -AU - Du Y -AD - Lung Cancer Research Center, The Third Affiliated Hospital of Kunming Medical - University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, 650118, People's - Republic of China. -FAU - Zhang, Jing -AU - Zhang J -AD - Bone and Soft Tissue Tumors Research Center of Yunnan Province, Department of - Orthopaedics, The Third Affiliated Hospital of Kunming Medical University (Tumor - Hospital of Yunnan Province), Kunming, Yunnan, 650118, People's Republic of - China. zhangjingnmlimit@tom.com. -LA - eng -GR - 81302343/the National Natural Science Foundation of China/ -GR - 81760486/the National Natural Science Foundation of China/ -PT - Case Reports -PT - Journal Article -DEP - 20180423 -PL - England -TA - J Med Case Rep -JT - Journal of medical case reports -JID - 101293382 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Adenocarcinoma/complications/diagnostic imaging/*drug therapy/*therapy -MH - Antibodies, Monoclonal, Humanized/*adverse effects -MH - Antineoplastic Agents, Immunological/*adverse effects -MH - CD4 Lymphocyte Count -MH - Carcinoma, Non-Small-Cell Lung/complications/diagnostic - imaging/secondary/*therapy -MH - Fatal Outcome -MH - Femoral Neoplasms/secondary -MH - HIV Infections/complications -MH - Humans -MH - Lung Diseases, Interstitial/etiology -MH - Male -MH - Middle Aged -MH - Pericardial Effusion/etiology -MH - Radiosurgery/*adverse effects -MH - Tomography, X-Ray Computed -PMC - PMC5911965 -OTO - NOTNLM -OT - HIV -OT - Immune-related adverse events -OT - Non-small cell lung cancer -OT - Pembrolizumab -OT - Stereotactic body radiotherapy -COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR - PUBLICATION: Written informed consent was obtained from the patient’s wife for - publication of this case report and any accompanying images. A copy of the - written consent is available for review by the Editor-in-Chief of this journal. - COMPETING INTERESTS: The authors declare that they have no competing interests. - PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional - claims in published maps and institutional affiliations. -EDAT- 2018/04/24 06:00 -MHDA- 2018/10/03 06:00 -PMCR- 2018/04/23 -CRDT- 2018/04/24 06:00 -PHST- 2018/01/10 00:00 [received] -PHST- 2018/03/23 00:00 [accepted] -PHST- 2018/04/24 06:00 [entrez] -PHST- 2018/04/24 06:00 [pubmed] -PHST- 2018/10/03 06:00 [medline] -PHST- 2018/04/23 00:00 [pmc-release] -AID - 10.1186/s13256-018-1667-2 [pii] -AID - 1667 [pii] -AID - 10.1186/s13256-018-1667-2 [doi] -PST - epublish -SO - J Med Case Rep. 2018 Apr 23;12(1):104. doi: 10.1186/s13256-018-1667-2. - -PMID- 38756778 -OWN - NLM -STAT- MEDLINE -DCOM- 20240517 -LR - 20240518 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 15 -DP - 2024 -TI - Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for - metastatic bone tumor resection in patients with PSC. -PG - 1372279 -LID - 10.3389/fimmu.2024.1372279 [doi] -LID - 1372279 -AB - BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of - non-small-cell lung cancer (NSCLC), which is resistant to chemotherapy and - radiotherapy with a poor prognosis. PSC is highly malignant and is prone to - recurrence even after surgery. The programmed death-ligand 1 (PD-L1) tumor cell - proportion score (TPS) 5%, TERT and TP53 gene mutations were detected in this - patient accompanied by multiple metastatic sites. The anlotinib is a novel - multitarget tyrosine kinase inhibitor (TKI) that could be effective for advanced - NSCLC and some sarcoma patients. Limited clinical trials and case reports have - shown that PSC patients with gene mutations and PD-L1 expression have good - responses to multitarget antiangiogenic drug and immune checkpoint inhibitors - (ICIs). In this article, we reported a case with metastatic PSC diagnosed by - Computed Tomography (CT)-guided needle biopsy treated with immunotherapy combined - with antiangiogenic drugs as a neoadjuvant chemotherapy (NACT). PSC is controlled - and the patient achieves successfully limb salvage treatment by surgical - resection. Therefore, targeted therapy and immunotherapy can provide sufficient - surgical opportunities for limb salvage in the treatment of metastatic PSC - patients. CASE SUMMARY: A 69-year-old male diagnosed with malignant bone tumor in - the proximal femur was admitted to our hospital in June 2022 with recurrent fever - as well as swelling and pain in the left thigh for twenty days. The initial - computed tomography (CT) scan of the chest showed a pulmonary cavity (20 mm × - 30 mm) and scattered lung masses. Subsequently, he underwent a CT-guided needle - biopsy to distinguish the essence of osteolytic bone destruction and soft tissue - mass in the left proximal femur which showed metastatic sarcomatoid carcinoma - histology. Genetic testing revealed TERT c.-124C mutation (abundance 8.81%), TP53 - p.R342 mutation (abundance 11.35%), tumor mutational burden (TMB) 7.09 muts/Mb, - microsatellite stability (MSS), and PD-L1 (SP263) TPS 5% were also detected. The - patient was tentatively treated with a combination of antiangiogenic drug and - PD-1 inhibitor. After one course, the tumor volume significantly reduced in - magnetic resonance imaging (MRI) and pathological fracture occurred in the femur - after combined treatment. The patient received proximal femoral tumor resection - and prosthesis replacement after defervescence. Sequentially sintilimab with - anlotinib were administered for over 1 year. Finally, the local tumor was well - controlled, and no obvious drug-related adverse reactions were observed. The - lesions in the lung remained in partial response (PR) for more than 16 months and - complete response (CR) of metastatic tumor in the proximal femur was observed - through imaging examinations. CONCLUSION: This is the first reported case of a - metastatic PSC in femur showing a favorable response to the treatment consisting - of anlotinib combined with sintilimab. This case suggests that antiangiogenic - therapy combined with immunotherapy may benefit patients with metastatic PSC in - the preoperative adjuvant therapy for limb salvage. -CI - Copyright © 2024 Bao, Yu, Zheng, Zhai, Cui and Xu. -FAU - Bao, Zheming -AU - Bao Z -AD - Orthopedics Department, 960th Hospital of People's Liberation Army (PLA) Joint - Service Support Force, Jinan, China. -FAU - Yu, Xiuchun -AU - Yu X -AD - Orthopedics Department, 960th Hospital of People's Liberation Army (PLA) Joint - Service Support Force, Jinan, China. -FAU - Zheng, Kai -AU - Zheng K -AD - Orthopedics Department, 960th Hospital of People's Liberation Army (PLA) Joint - Service Support Force, Jinan, China. -FAU - Zhai, Kai -AU - Zhai K -AD - Orthopedics Department, 960th Hospital of People's Liberation Army (PLA) Joint - Service Support Force, Jinan, China. -FAU - Cui, Haocheng -AU - Cui H -AD - Orthopedics Department, 960th Hospital of People's Liberation Army (PLA) Joint - Service Support Force, Jinan, China. -FAU - Xu, Ming -AU - Xu M -AD - Orthopedics Department, 960th Hospital of People's Liberation Army (PLA) Joint - Service Support Force, Jinan, China. -LA - eng -PT - Case Reports -DEP - 20240502 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (anlotinib) -RN - 0 (sintilimab) -SB - IM -MH - Humans -MH - *Antibodies, Monoclonal, Humanized/therapeutic use/administration & - dosage/adverse effects -MH - *Bone Neoplasms/secondary/drug therapy/therapy -MH - *Lung Neoplasms/secondary/drug therapy -MH - *Quinolines/therapeutic use/administration & dosage -MH - *Neoadjuvant Therapy -MH - Male -MH - *Indoles/therapeutic use/administration & dosage -MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/therapy -MH - Aged -MH - Treatment Outcome -MH - Immune Checkpoint Inhibitors/therapeutic use/adverse effects -PMC - PMC11096473 -OTO - NOTNLM -OT - anlotinib -OT - neoadjuvant chemotherapy -OT - non-small-cell lung cancer -OT - programmed death-ligand 1 -OT - pulmonary sarcomatoid carcinoma -OT - sintilimab -OT - tyrosine kinase inhibitor -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2024/05/17 06:43 -MHDA- 2024/05/17 06:44 -PMCR- 2024/01/01 -CRDT- 2024/05/17 03:54 -PHST- 2024/01/17 00:00 [received] -PHST- 2024/04/17 00:00 [accepted] -PHST- 2024/05/17 06:44 [medline] -PHST- 2024/05/17 06:43 [pubmed] -PHST- 2024/05/17 03:54 [entrez] -PHST- 2024/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2024.1372279 [doi] -PST - epublish -SO - Front Immunol. 2024 May 2;15:1372279. doi: 10.3389/fimmu.2024.1372279. - eCollection 2024. - -PMID- 8673999 -OWN - NLM -STAT- MEDLINE -DCOM- 19960815 -LR - 20201215 -IS - 0008-543X (Print) -IS - 0008-543X (Linking) -VI - 78 -IP - 2 -DP - 1996 Jul 15 -TI - A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes - and interleukin-2 versus standard therapy in the postoperative treatment of - resected nonsmall cell lung carcinoma. -PG - 244-51 -AB - BACKGROUND: A previous pilot study from our group suggested that: (1) adoptive - immunotherapy (A1) with tumor-infiltrating lymphocytes (TIL) and recombinant - interleukin-2 (rIL-2) may be applied with safety to more than 80% of the patients - who had surgery for Stage III nonsmall cell lung carcinoma (NSCLC); and (2) AI - could be useful in patients with locally advanced disease. The present randomized - study was planned to assess the efficacy of AI in the postoperative treatment of - Stage II, IIIa, or IIIb NSCLC: METHODS: TIL were expanded in vitro from tissue - samples obtained from the surgically removed specimens of 131 patients. Eighteen - cultures yielded no growth of TIL. The remaining 113 patients were stratified - according to disease stage and randomized to receive AI or standard - chemoradiotherapy. TIL were infused intravenously 6 to 8 weeks after surgery, - rIL-2 was administered subcutaneously at escalating doses for 2 weeks, and then - at reduced doses for 2 weeks and then for 2 to 3 months. RESULTS: Three-year - survival was significantly better (P < 0.05) for patients who underwent AI than - for controls. AI was of no benefit to patients with Stage II NSCLC, potentially - useful to patients with Stage IIIa NSCLC (P = 0.06), and significantly - advantageous to patients with Stage IIIb (T4) NSCLC (P < 0.01). For patients with - Stage III NSCLC, local relapse (but not distant relapse) was significantly - reduced following AI (P < 0.05). CONCLUSIONS: AI should be considered when - designing future adjuvant therapy protocols for the treatment of NSCLC: -FAU - Ratto, G B -AU - Ratto GB -AD - Istituto Patologia Chirurgica, University of Genoa, Italy. -FAU - Zino, P -AU - Zino P -FAU - Mirabelli, S -AU - Mirabelli S -FAU - Minuti, P -AU - Minuti P -FAU - Aquilina, R -AU - Aquilina R -FAU - Fantino, G -AU - Fantino G -FAU - Spessa, E -AU - Spessa E -FAU - Ponte, M -AU - Ponte M -FAU - Bruzzi, P -AU - Bruzzi P -FAU - Melioli, G -AU - Melioli G -LA - eng -PT - Clinical Trial -PT - Journal Article -PT - Randomized Controlled Trial -PL - United States -TA - Cancer -JT - Cancer -JID - 0374236 -RN - 0 (Antineoplastic Agents) -RN - 0 (Interleukin-2) -SB - IM -CIN - Cancer. 1996 Jul 15;78(2):195-8. doi: - 10.1002/(SICI)1097-0142(19960715)78:2<195::AID-CNCR1>3.0.CO;2-L. PMID: 8673991 -MH - Antineoplastic Agents/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/radiotherapy/surgery/*therapy -MH - Combined Modality Therapy -MH - Follow-Up Studies -MH - Humans -MH - *Immunotherapy, Adoptive -MH - Infusions, Intravenous -MH - Injections, Subcutaneous -MH - Interleukin-2/administration & dosage/adverse effects/*therapeutic use -MH - Lung Neoplasms/radiotherapy/surgery/*therapy -MH - Lymphocytes, Tumor-Infiltrating/*immunology -MH - Middle Aged -MH - Multivariate Analysis -MH - Neoplasm Recurrence, Local/pathology/prevention & control -MH - Neoplasm Staging -MH - Neoplasm, Residual -MH - *Pneumonectomy -MH - Postoperative Care -MH - Survival Rate -MH - Treatment Outcome -EDAT- 1996/07/15 00:00 -MHDA- 2000/06/20 09:00 -CRDT- 1996/07/15 00:00 -PHST- 1996/07/15 00:00 [pubmed] -PHST- 2000/06/20 09:00 [medline] -PHST- 1996/07/15 00:00 [entrez] -AID - 10.1002/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L [pii] -AID - 10.1002/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L [doi] -PST - ppublish -SO - Cancer. 1996 Jul 15;78(2):244-51. doi: - 10.1002/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L. - -PMID- 38326053 -OWN - NLM -STAT- MEDLINE -DCOM- 20240209 -LR - 20240209 -IS - 0376-2491 (Print) -IS - 0376-2491 (Linking) -VI - 104 -IP - 6 -DP - 2024 Feb 6 -TI - [Chinese expert consensus on evaluation and treatment of advanced non-small cell - lung cancer with negative driver genes after first-line immunotherapy resistance - (2024 edition)]. -PG - 411-426 -LID - 10.3760/cma.j.cn112137-20230927-00589 [doi] -AB - Immunotherapy has become the standard first-line treatment for advanced non-small - cell lung cancer (NSCLC) with negative driver genes, which has significantly - improved the prognosis of patients. However, there is still a lack of consistent - guidelines or consensus on evaluation and treatment regimens after first-line - immunotherapy resistance. The Committee of Non-Small Cell Lung Cancer of Chinese - Society of Clinical Oncology organized multidisciplinary experts from medical - oncology, respiratory medicine, thoracic surgery, radiotherapy, and imaging to - conduct an in-depth discussion on the definition and classification of primary - resistance and secondary resistance, evaluation criteria of immunotherapy, - subsequent treatment strategies of oligo-progression or extensive progression - after first-line immunotherapy, re-challenges of immunotherapy and clinical - research of new drugs in advanced NSCLC patients with negative driver genes - according to the existing evidence. After the consensus meeting, an expert - consensus on evaluation and treatment strategy of advanced NSCLC with negative - driver genes after first-line immunotherapy resistance was formed, aiming to - provide standardized guidance for clinical practice of Chinese clinicians. -CN - Committee of Non-Small Cell Lung Cancer of Chinese Society of Clinical Oncology -LA - chi -PT - English Abstract -PT - Journal Article -PL - China -TA - Zhonghua Yi Xue Za Zhi -JT - Zhonghua yi xue za zhi -JID - 7511141 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy -MH - *Lung Neoplasms/therapy/drug therapy -MH - Consensus -MH - Immunotherapy -MH - Medical Oncology -EDAT- 2024/02/08 00:42 -MHDA- 2024/02/09 06:42 -CRDT- 2024/02/07 21:35 -PHST- 2024/02/09 06:42 [medline] -PHST- 2024/02/08 00:42 [pubmed] -PHST- 2024/02/07 21:35 [entrez] -AID - 10.3760/cma.j.cn112137-20230927-00589 [doi] -PST - ppublish -SO - Zhonghua Yi Xue Za Zhi. 2024 Feb 6;104(6):411-426. doi: - 10.3760/cma.j.cn112137-20230927-00589. - -PMID- 9093708 -OWN - NLM -STAT- MEDLINE -DCOM- 19970926 -LR - 20200203 -IS - 0923-7534 (Print) -IS - 0923-7534 (Linking) -VI - 8 -IP - 1 -DP - 1997 Jan -TI - Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin - (VIP-E) in 107 consecutive patients with limited- and extensive-stage - non-small-cell lung cancer. -PG - 57-64 -AB - BACKGROUND: We conducted a phase I/II trial to assess the feasibility and - activity of combination chemotherapy with etoposide, ifosfamide, cisplatin, and - epirubicin in limited-stage (LS, stage I-IIIB) and extensive-stage (ES, stage IV) - non-small-cell lung cancer (NSCLC). End-points were treatment-related morbidity - and mortality, response rate, duration of response, and survival. PATIENTS AND - METHODS: Chemotherapy followed by granulocyte colony-stimulating factor was given - at a dose of etoposide (500 mg/m2), ifosfamide (4000 mg/m2), cisplatin (50 - mg/m2), and epirubicin (50 mg/m2) (VIP-E) to 107 patients with NSCLC. Twenty-five - patients with qualifying responses proceeded to high-dose chemotherapy with - autologous peripheral blood stem cell transplantation after etoposide (1500 - mg/m2), ifosfamide (12,000 mg/m2), carboplatin (750 mg/m2) and epirubicin (150 - mg/m2) (VIC-E) conditioning. RESULTS OF CONVENTIONAL-DOSE VIP-E: 35 of 102 (34%) - evaluable patients responded (2 CR's, 33 PR's), 33/102 patients (33%) showed no - change (NC); the remainder of patients progressed with therapy (PD). Objective - response rate was 68% (4% CR, 64% PR) in LS-NSCLC and 23% (1.4% CR, 21.4% PR) in - ES-NSCLC. Median duration of survival was 13 months in LS-NSCLC and 5.5 months in - ES-NSCLC. Two-year survival was 26% in LS and 2% in ES-NSCLC. RESULTS OF - HIGH-DOSE VIC-E: 23 of 24 evaluable patients improved or maintained prior - responses (92%), I patient showed NC. Treatment mortality was 4%. Median duration - of survival was 17 months in LS-NSCLC and 10 months in ES-NSCLC. Two-year - survival was 30% in LS and 8% in ES-NSCLC. CONCLUSION: Response-rates and - survival after conventional-dose VIP-E chemotherapy are comparable to other - published trials of combination chemotherapy in NSCLC. Toxicity and mortality is - acceptable in limited stage, but unacceptably high in extensive stage NSCLC. - Although better response-rates were achieved in the high-dose arm, they did not - translate into improved survival. Most stage IV NSCLC-patients will neither - benefit from VIP-E conventional dose, nor from VIC-E high dose chemotherapy. - Whether selected LS-patients with partial or complete responses to VIP-E - induction chemotherapy could benefit from dose intensification in an adjuvant or - neo-adjuvant setting remains to be determined. -FAU - Fetscher, S -AU - Fetscher S -AD - Department of Internal Medicine, University of Freiburg Medical Center, Freiburg - im Breisgau, Germany. -FAU - Brugger, W -AU - Brugger W -FAU - Engelhardt, R -AU - Engelhardt R -FAU - Kanz, L -AU - Kanz L -FAU - Hasse, J -AU - Hasse J -FAU - Frommhold, H -AU - Frommhold H -FAU - Wenger, M -AU - Wenger M -FAU - Lange, W -AU - Lange W -FAU - Mertelsmann, R -AU - Mertelsmann R -LA - eng -PT - Clinical Trial -PT - Clinical Trial, Phase I -PT - Clinical Trial, Phase II -PT - Journal Article -PL - England -TA - Ann Oncol -JT - Annals of oncology : official journal of the European Society for Medical - Oncology -JID - 9007735 -RN - 3Z8479ZZ5X (Epirubicin) -RN - 6PLQ3CP4P3 (Etoposide) -RN - BG3F62OND5 (Carboplatin) -RN - Q20Q21Q62J (Cisplatin) -RN - UM20QQM95Y (Ifosfamide) -RN - VIC-E protocol -RN - VIP-E protocol -SB - IM -MH - Adult -MH - Aged -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use -MH - Bone Marrow Diseases/chemically induced/therapy -MH - Bone Neoplasms/radiotherapy/secondary -MH - Carboplatin/administration & dosage -MH - Carcinoma, Non-Small-Cell Lung/*drug - therapy/mortality/pathology/radiotherapy/secondary/surgery -MH - Chemotherapy, Adjuvant -MH - Cisplatin/administration & dosage/adverse effects -MH - Combined Modality Therapy -MH - Disease-Free Survival -MH - Epirubicin/administration & dosage/adverse effects -MH - Etoposide/administration & dosage/adverse effects -MH - Feasibility Studies -MH - Female -MH - Hematopoietic Stem Cell Transplantation -MH - Humans -MH - Ifosfamide/administration & dosage/adverse effects -MH - Life Tables -MH - Lung Neoplasms/*drug therapy/mortality/pathology/surgery -MH - Male -MH - Middle Aged -MH - Palliative Care -MH - Pneumonectomy -MH - Remission Induction -MH - Salvage Therapy -MH - Survival Analysis -MH - Transplantation Conditioning -MH - Treatment Outcome -EDAT- 1997/01/01 00:00 -MHDA- 1997/01/01 00:01 -CRDT- 1997/01/01 00:00 -PHST- 1997/01/01 00:00 [pubmed] -PHST- 1997/01/01 00:01 [medline] -PHST- 1997/01/01 00:00 [entrez] -AID - S0923-7534(19)48087-3 [pii] -AID - 10.1023/a:1008209713568 [doi] -PST - ppublish -SO - Ann Oncol. 1997 Jan;8(1):57-64. doi: 10.1023/a:1008209713568. - -PMID- 36156016 -OWN - NLM -STAT- MEDLINE -DCOM- 20220928 -LR - 20220928 -IS - 0385-0684 (Print) -IS - 0385-0684 (Linking) -VI - 49 -IP - 9 -DP - 2022 Sep -TI - [A Case of Advanced Squamous Cell Carcinoma of the Lung 19 Years after - Chemoradiotherapy of Limited-Disease Small-Cell Lung Cancer]. -PG - 969-971 -AB - A 65-year-old man was referred to our hospital because of a fever and cough 19 - years after chemoradiotherapy for small-cell lung cancer(SCLC)in the right middle - lobe. Computed tomography(CT)revealed a normal right middle lobe, but found - pneumonia and a tumor at the bronchial entrance of the right upper lobe. After - treating the pneumonia with antibiotics and prednisolone, transbronchial - biopsies(TBBs)revealed the tumor to be squamous cell carcinoma(SCC). Eight lines - of chemotherapy including immune checkpoint inhibitors(ICIs)were completed with a - 42-month survival following the initiation of chemotherapy for SCC, after which - he ultimately died of hemoptysis. Survival of over 10 years from small- cell - cancer is rare. We herein report the prognosis of SCLC and the treatment of - subsequent primary lung cancer. -FAU - Kato, Akane -AU - Kato A -AD - Dept. of Respirology, Ina Central Hospital. -FAU - Shiina, Takayuki -AU - Shiina T -FAU - Takasuna, Keiichiro -AU - Takasuna K -FAU - Takeuchi, Nobumichi -AU - Takeuchi N -FAU - Shinoda, Atsunori -AU - Shinoda A -FAU - Morita, Masashige -AU - Morita M -FAU - Hirose, Yoshiki -AU - Hirose Y -LA - jpn -PT - Case Reports -PT - Journal Article -PL - Japan -TA - Gan To Kagaku Ryoho -JT - Gan to kagaku ryoho. Cancer & chemotherapy -JID - 7810034 -RN - 0 (Anti-Bacterial Agents) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 9PHQ9Y1OLM (Prednisolone) -SB - IM -MH - Aged -MH - Anti-Bacterial Agents/therapeutic use -MH - *Carcinoma, Small Cell/drug therapy -MH - *Carcinoma, Squamous Cell/drug therapy -MH - Chemoradiotherapy -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - Lung/metabolism/pathology -MH - *Lung Neoplasms/drug therapy/metabolism -MH - Male -MH - Prednisolone/therapeutic use -MH - *Small Cell Lung Carcinoma/drug therapy -EDAT- 2022/09/27 06:00 -MHDA- 2022/09/28 06:00 -CRDT- 2022/09/26 16:09 -PHST- 2022/09/26 16:09 [entrez] -PHST- 2022/09/27 06:00 [pubmed] -PHST- 2022/09/28 06:00 [medline] -PST - ppublish -SO - Gan To Kagaku Ryoho. 2022 Sep;49(9):969-971. - -PMID- 9093707 -OWN - NLM -STAT- MEDLINE -DCOM- 19970926 -LR - 20200203 -IS - 0923-7534 (Print) -IS - 0923-7534 (Linking) -VI - 8 -IP - 1 -DP - 1997 Jan -TI - Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin - (VIP-E) in 100 consecutive patients with limited- and extensive-disease - small-cell lung cancer. -PG - 49-56 -AB - BACKGROUND: We conducted a phase I/II trial to assess the feasibility and - activity of VIP-E chemotherapy in small-cell lung cancer. End-points were - treatment-related morbidity and mortality, response to treatment. duration of - response, and survival. PATIENTS AND METHODS: Two cycles of combination - chemotherapy followed by granulocyte colony-stimulating factor (G-CSF) were given - at a dose of etoposide (500 mg/m2), ifosfamide (4000 mg/m2), cisplatin (50 - mg/m2), and epirubicin (50 mg/m2) to 100 consecutive patients with SCLC. Thirty - patients (19 with LD, and 11 with ED SCLC) proceeded to VIC-E high-dose - chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) - at a cumulative dose of etoposide 1500 mg/m2, ifosfamide 12,000 mg/m2, - carboplatin 750 mg/m2 and epirubicin 150 mg/m2 (VIC-E). Surgical resection of - primary tumor was attempted at the earliest feasible point. Thoracic irradiation - was given after completion of chemotherapy. RESULTS of conventional-dose VIP-E: - 97 patients were evaluable for response. Objective response rate was 81% in - LD-SCLC (33% CR, 48% PR; excluding patients in surgical CR) and 77% in ED-SCLC - (18% CR, 58% PR). Treatment mortality was 2%. Median survival was 19 months in - LD-SCLC and 6 months in ED-SCLC. Two-year survival was 36% in LD and 0% in ED - SCLC. RESULTS OF HIGH-DOSE VIC-E: All 30 patients improved on or maintained prior - responses. Four patients (13%) died of treatment-related complications. Median - survival was 26 months in LD-SCLC and 8 months in ED-SCLC. Two-year survival was - 53% in LD and 9% in ED SCLC. CONCLUSION: VIP-E chemotherapy is an effective - induction therapy for SCLC. Compared with traditional protocols such as ACO or - carboplatin/etoposide, response rates are slightly improved, while survival is - not different. In the LD SCLC subgroup, high-dose chemotherapy improved response - rates and survival, especially for patients in surgical CR prior to high-dose - therapy. In ED SCLC, however, higher response-rates did not translate into - improved survival. Selected LD-SCLC patients with good partial or complete - remissions after prior therapy may benefit from HDC and PBSCT. -FAU - Fetscher, S -AU - Fetscher S -AD - Department of Internal Medicine, University of Freiburg Medical Center, Freiburg - im Breisgau, Germany. -FAU - Brugger, W -AU - Brugger W -FAU - Engelhardt, R -AU - Engelhardt R -FAU - Kanz, L -AU - Kanz L -FAU - Hasse, J -AU - Hasse J -FAU - Frommhold, H -AU - Frommhold H -FAU - Wenger, M -AU - Wenger M -FAU - Lange, W -AU - Lange W -FAU - Mertelsmann, R -AU - Mertelsmann R -LA - eng -PT - Clinical Trial -PT - Clinical Trial, Phase I -PT - Clinical Trial, Phase II -PT - Comparative Study -PT - Journal Article -PL - England -TA - Ann Oncol -JT - Annals of oncology : official journal of the European Society for Medical - Oncology -JID - 9007735 -RN - 3Z8479ZZ5X (Epirubicin) -RN - 6PLQ3CP4P3 (Etoposide) -RN - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor) -RN - BG3F62OND5 (Carboplatin) -RN - Q20Q21Q62J (Cisplatin) -RN - UM20QQM95Y (Ifosfamide) -RN - VIC-E protocol -RN - VIP-E protocol -SB - IM -MH - Adult -MH - Aged -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use -MH - Bone Marrow Diseases/chemically induced/therapy -MH - Carboplatin/administration & dosage/adverse effects -MH - Carcinoma, Small Cell/*drug therapy/mortality/pathology/surgery -MH - Cardiovascular Diseases/chemically induced/mortality -MH - Cisplatin/administration & dosage/adverse effects -MH - Combined Modality Therapy -MH - Disease-Free Survival -MH - Epirubicin/administration & dosage/adverse effects -MH - Etoposide/administration & dosage/adverse effects -MH - Feasibility Studies -MH - Female -MH - Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use -MH - Hematopoietic Stem Cell Transplantation -MH - Humans -MH - Ifosfamide/administration & dosage/adverse effects -MH - Lung Neoplasms/*drug therapy/mortality/pathology/surgery -MH - Male -MH - Middle Aged -MH - Neoplasm Metastasis -MH - Pneumonectomy -MH - Remission Induction -MH - Survival Analysis -MH - Transplantation Conditioning -MH - Treatment Outcome -EDAT- 1997/01/01 00:00 -MHDA- 1997/01/01 00:01 -CRDT- 1997/01/01 00:00 -PHST- 1997/01/01 00:00 [pubmed] -PHST- 1997/01/01 00:01 [medline] -PHST- 1997/01/01 00:00 [entrez] -AID - S0923-7534(19)48086-1 [pii] -AID - 10.1023/a:1008232329498 [doi] -PST - ppublish -SO - Ann Oncol. 1997 Jan;8(1):49-56. doi: 10.1023/a:1008232329498. - -PMID- 12954119 -OWN - NLM -STAT- MEDLINE -DCOM- 20040325 -LR - 20071114 -IS - 1084-9785 (Print) -IS - 1084-9785 (Linking) -VI - 18 -IP - 3 -DP - 2003 Jun -TI - Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody - in patients with advanced non-small cell lung cancer: clinical effects and - hematologic toxicity. -PG - 317-25 -AB - The purpose of this retrospective analysis was to evaluate the hematologic - toxicity and clinical outcome of salvage chemotherapy following (90)Y-CC49 - radioimmunotherapy (RIT) in patients with non-small cell lung cancer (NSCLC). - Sixteen patients from a total of 37 who were enrolled in a phase I trial of - (90)Y-CC49 monoclonal therapy were treated with post-RIT salvage chemotherapy at - our institution. Five patients had received chest radiation therapy prior to RIT, - and seven patients had prior chemotherapy. The majority of these patients were - treated with doses of (90)Y of >/= 14 mCi/m(2) (8-20 mCi/m(2)), and four of them - received concurrent 96-hour taxol infusion. The maximum tolerated dose of this - study was exceeded at 17 mCi/m(2), and grade 4 thrombocytopenia/neutropenia were - the dose-limiting toxicities. Twelve patients received one chemotherapy regimen - as salvage therapy, and four patients had more than one regimen. Four patients - (25%) experienced reversible grade 4 neutropenia, but no grade 4 thrombocytopenia - was observed. Five patients had stable disease. The median survival from start of - salvage therapy was 5.5 months. Our data suggest that therapy with RIT did not - significantly affect survival of these patients. Taking into consideration the - potential clinical relevance of integration of RIT with other treatment - modalities, it is important to expand this clinical experience in order to - support combined modality strategies. -FAU - Robert, Francisco -AU - Robert F -AD - Department of Medicine, Division of Hematology/Oncology and Comprehensive Cancer - Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA. - pacorobertuab@cs.com -FAU - Busby, Elizabeth M -AU - Busby EM -FAU - LoBuglio, Albert F -AU - LoBuglio AF -LA - eng -GR - 5 U01 CA 743392/CA/NCI NIH HHS/United States -PT - Clinical Trial -PT - Clinical Trial, Phase I -PT - Journal Article -PT - Research Support, U.S. Gov't, P.H.S. -PL - United States -TA - Cancer Biother Radiopharm -JT - Cancer biotherapy & radiopharmaceuticals -JID - 9605408 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Neoplasm) -RN - 0 (B72.3 antibody) -RN - 0 (Yttrium Radioisotopes) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal/therapeutic use -MH - Antibodies, Neoplasm/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/radiotherapy -MH - Combined Modality Therapy -MH - Drug Tolerance -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/radiotherapy -MH - Male -MH - Maximum Tolerated Dose -MH - Middle Aged -MH - *Radioimmunotherapy -MH - Retrospective Studies -MH - Salvage Therapy -MH - Treatment Outcome -MH - Yttrium Radioisotopes/*therapeutic use -EDAT- 2003/09/05 05:00 -MHDA- 2004/03/26 05:00 -CRDT- 2003/09/05 05:00 -PHST- 2003/09/05 05:00 [pubmed] -PHST- 2004/03/26 05:00 [medline] -PHST- 2003/09/05 05:00 [entrez] -AID - 10.1089/108497803322285071 [doi] -PST - ppublish -SO - Cancer Biother Radiopharm. 2003 Jun;18(3):317-25. doi: - 10.1089/108497803322285071. - -PMID- 6254629 -OWN - NLM -STAT- MEDLINE -DCOM- 19810226 -LR - 20190620 -IS - 0008-543X (Print) -IS - 0008-543X (Linking) -VI - 46 -IP - 11 -DP - 1980 Dec 1 -TI - Combination chemotherapy, radiotherapy, and BCG immunotherapy in extensive - (metastatic) small cell carcinoma of the lung. A Southwest Oncology Group study. -PG - 2335-40 -AB - From November 1976 to November 1978, the Southwest Oncology Group treated 254 - patients with extensive (metastatic) small cell carcinoma of the lung with - combination chemotherapy and radiotherapy with and without BCG immunotherapy. - Patients receiving BCG achieved a response rate of 50% versus those patients not - receiving BCG of 46% (P = .704). Response duration was 20 weeks for the BCG arms - and 23 weeks for the no-BCG arms; survival was 28 weeks for the BCG arms versus - 29 weeks for the no-BCG arms. An adverse effect in patients surviving more than - one year was detected; those continuing to receive BCG had significantly shorter - survival, 60 weeks versus 85 weeks (P = .019). Toxicities of the programs were - not affected by the addition of BCG immunotherapy. It appears that BCG - immunotherapy has no beneficial effect on response rate or duration of response - in programs using chemotherapy and radiotherapy for control of metastatic small - cell carcinoma of the lung. In addition, because of the adverse effect on - long-term survival, we do not recommend the addition of BCG immunotherapy as a - treatment modality in this tumor type. -FAU - McCracken, J D -AU - McCracken JD -FAU - Heilbrun, L -AU - Heilbrun L -FAU - White, J -AU - White J -FAU - Reed, R -AU - Reed R -FAU - Samson, M -AU - Samson M -FAU - Saiers, J H -AU - Saiers JH -FAU - Stephens, R -AU - Stephens R -FAU - Stuckey, W J -AU - Stuckey WJ -FAU - Bickers, J -AU - Bickers J -FAU - Livingston, R -AU - Livingston R -LA - eng -GR - CA-04915+/CA/NCI NIH HHS/United States -GR - CA-04919/CA/NCI NIH HHS/United States -GR - CA-13392/CA/NCI NIH HHS/United States -PT - Comparative Study -PT - Journal Article -PT - Research Support, U.S. Gov't, P.H.S. -PL - United States -TA - Cancer -JT - Cancer -JID - 0374236 -RN - 0 (Antineoplastic Agents) -RN - 0 (BCG Vaccine) -SB - IM -MH - Antineoplastic Agents/*administration & dosage -MH - BCG Vaccine/*therapeutic use -MH - Carcinoma, Small Cell/radiotherapy/*therapy -MH - Drug Administration Schedule -MH - Drug Therapy, Combination -MH - Evaluation Studies as Topic -MH - Humans -MH - Lung Neoplasms/radiotherapy/*therapy -MH - Neoplasm Metastasis -MH - Prognosis -MH - Time Factors -EDAT- 1980/12/01 00:00 -MHDA- 1980/12/01 00:01 -CRDT- 1980/12/01 00:00 -PHST- 1980/12/01 00:00 [pubmed] -PHST- 1980/12/01 00:01 [medline] -PHST- 1980/12/01 00:00 [entrez] -AID - 10.1002/1097-0142(19801201)46:11<2335::aid-cncr2820461102>3.0.co;2-g [doi] -PST - ppublish -SO - Cancer. 1980 Dec 1;46(11):2335-40. doi: - 10.1002/1097-0142(19801201)46:11<2335::aid-cncr2820461102>3.0.co;2-g. - -PMID- 28774862 -OWN - NLM -STAT- MEDLINE -DCOM- 20181102 -LR - 20181202 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 12 -IP - 11 -DP - 2017 Nov -TI - Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced - Non-Small Cell Lung Cancer. -PG - 1733-1736 -LID - S1556-0864(17)30656-1 [pii] -LID - 10.1016/j.jtho.2017.07.025 [doi] -FAU - Furuta, Hiromi -AU - Furuta H -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan. -FAU - Yoshida, Tatsuya -AU - Yoshida T -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan. - Electronic address: t.yoshida@aichi-cc.jp. -FAU - Shimizu, Junichi -AU - Shimizu J -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan. -FAU - Tomita, Natsuo -AU - Tomita N -AD - Department of Radiation Oncology, Aichi Cancer Center Hospital, Aichi, Japan. -FAU - Yatabe, Yasushi -AU - Yatabe Y -AD - Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, - Aichi, Japan. -FAU - Hida, Toyoaki -AU - Hida T -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20170731 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal/pharmacology/*therapeutic use -MH - Antineoplastic Agents/pharmacology/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Humans -MH - Inflammation/*drug therapy/pathology -MH - Lung Neoplasms/*drug therapy/pathology -MH - Male -MH - Nivolumab -EDAT- 2017/08/05 06:00 -MHDA- 2018/11/06 06:00 -CRDT- 2017/08/05 06:00 -PHST- 2017/07/02 00:00 [received] -PHST- 2017/07/19 00:00 [revised] -PHST- 2017/07/24 00:00 [accepted] -PHST- 2017/08/05 06:00 [pubmed] -PHST- 2018/11/06 06:00 [medline] -PHST- 2017/08/05 06:00 [entrez] -AID - S1556-0864(17)30656-1 [pii] -AID - 10.1016/j.jtho.2017.07.025 [doi] -PST - ppublish -SO - J Thorac Oncol. 2017 Nov;12(11):1733-1736. doi: 10.1016/j.jtho.2017.07.025. Epub - 2017 Jul 31. - -PMID- 38758372 -OWN - NLM -STAT- MEDLINE -DCOM- 20240517 -LR - 20240617 -IS - 1432-0851 (Electronic) -IS - 0340-7004 (Print) -IS - 0340-7004 (Linking) -VI - 73 -IP - 7 -DP - 2024 May 17 -TI - The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib - in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center - retrospective study. -PG - 134 -LID - 10.1007/s00262-024-03712-7 [doi] -LID - 134 -AB - BACKGROUND: Effective treatment after EGFR-TKI resistance is of great clinical - concern. We aimed to investigate the efficacy and safety of anlotinib in - combination with an anti-PD-1/PD-L1 antibody in later-line therapy for - EGFR-mutant NSCLC patients after TKI treatment failure and to explore the - independent predictive factors of therapeutic efficacy. METHODS: A total of 71 - patients with confirmed advanced EGFR-mutated NSCLC who progressed after previous - standard EGFR-TKI therapy but still failed after multiline treatments were - included retrospectively in this study. Most of the patients had previously - received at least three lines of treatment. All were treated with anlotinib - combined with anti-PD-1 or anti-PD-L1 therapy. The safety of this combined - treatment was assessed by the incidence of adverse events. The efficacy of the - regimens was evaluated by survival analysis (OS, PFS, ORR, DCR). RESULTS: The - median follow-up period was 28.6 months (range: 2.3-54.0 months), and the median - number of treatment lines was 4. The overall response rate (ORR) and disease - control rate (DCR) were 19.7% and 77.5%, respectively. The median PFS was - 5.8 months (95% CI 4.2-7.4 months), and the median OS was 17.1 months (95% CI - 12.0-22.3 months). Patients who received immune checkpoint inhibitors plus - anlotinib had an encouraging intracranial ORR of 38.5% and a DCR of 80.8%. ECOG - performance status < 2 at baseline was independent protective factors of PFS. - Metastatic organs and ECOG performance status were independent parameters in - predicting OS. Treatment-related adverse events occurred in 66 (93.0%) patients; - most of the adverse events were Grade 1-2, and no increase in adverse events was - observed compared to monotherapy. CONCLUSION: Anlotinib combined with an - anti-PD-1/PD-L1-based regimen exhibited promising efficacy and tolerance in NSCLC - patients with EGFR mutations after previous TKI failure. The efficacy of this - combined regimen in patients with EGFR mutations should be further evaluated. -CI - © 2024. The Author(s). -FAU - Yin, Xiaoyan -AU - Yin X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Liu, Xinchao -AU - Liu X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Ren, Fei -AU - Ren F -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Meng, Xiangjiao -AU - Meng X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. mengxiangjiao@sina.com. -LA - eng -GR - No.81972796/National Natural Science Foundation of China/ -PT - Journal Article -DEP - 20240517 -PL - Germany -TA - Cancer Immunol Immunother -JT - Cancer immunology, immunotherapy : CII -JID - 8605732 -RN - 0 (anlotinib) -RN - 0 (B7-H1 Antigen) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Indoles) -RN - 0 (Protein Kinase Inhibitors) -RN - 0 (Quinolines) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Female -MH - Humans -MH - Male -MH - Middle Aged -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects -MH - B7-H1 Antigen/antagonists & inhibitors -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/mortality/pathology -MH - *Drug Resistance, Neoplasm -MH - ErbB Receptors/genetics/antagonists & inhibitors -MH - *Immune Checkpoint Inhibitors/therapeutic use/adverse effects -MH - *Indoles/therapeutic use/adverse effects/administration & dosage -MH - *Lung Neoplasms/drug therapy/genetics/pathology -MH - *Mutation -MH - *Protein Kinase Inhibitors/therapeutic use/adverse effects -MH - *Quinolines/therapeutic use/adverse effects/administration & dosage -MH - Retrospective Studies -PMC - PMC11101402 -OTO - NOTNLM -OT - Anlotinib -OT - EGFR-TKI resistance -OT - Efficacy -OT - Immune checkpoint inhibitor -OT - Non-small cell lung cancer -OT - Safety -COIS- The authors declare that they have no competing interests. -EDAT- 2024/05/17 12:44 -MHDA- 2024/05/17 12:45 -PMCR- 2024/05/17 -CRDT- 2024/05/17 11:15 -PHST- 2024/02/14 00:00 [received] -PHST- 2024/04/21 00:00 [accepted] -PHST- 2024/05/17 12:45 [medline] -PHST- 2024/05/17 12:44 [pubmed] -PHST- 2024/05/17 11:15 [entrez] -PHST- 2024/05/17 00:00 [pmc-release] -AID - 10.1007/s00262-024-03712-7 [pii] -AID - 3712 [pii] -AID - 10.1007/s00262-024-03712-7 [doi] -PST - epublish -SO - Cancer Immunol Immunother. 2024 May 17;73(7):134. doi: - 10.1007/s00262-024-03712-7. - -PMID- 31436226 -OWN - NLM -STAT- MEDLINE -DCOM- 20200210 -LR - 20200210 -IS - 1998-4138 (Electronic) -IS - 1998-4138 (Linking) -VI - 15 -IP - 4 -DP - 2019 -TI - Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and - future directions. -PG - 743-750 -LID - 10.4103/jcrt.JCRT_903_18 [doi] -AB - The development of inhibitors of immune checkpoints has revolutionized the - treatment for a subset of patients with advanced nonsmall cell lung cancer - (NSCLC), resulting in promising clinical outcomes and durable responses. - Pembrolizumab, a humanized anti-programmed cell death-1 (PD-1) antibody, has been - approved as a first-line treatment for patients with advanced NSCLC with PD-L1 - expression of ≥50% and as a second-line treatment for PD-L1 expression of ≥1%. - Pembrolizumab in combination with standard chemotherapy has shown better clinical - outcomes than chemotherapy as a first-line therapy in patients with advanced - NSCLC without targetable mutations, regardless of PD-L1 expression. In this - review, we summarized the current indications of pembrolizumab for NSCLC, briefly - described immune-relevant pneumonitis and discussed potential biomarkers to - predict clinical efficacy. -FAU - Qin, Qin -AU - Qin Q -AD - Department of Oncology, The Second Clinical Medical College, Jingzhou Central - Hospital, Yangtze University, Jingzhou, Hubei 434020, China. -FAU - Li, Baosheng -AU - Li B -AD - Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and - Institute, Shandong University, Jinan, Shandong 250117, China. -LA - eng -PT - Journal Article -PT - Review -PL - India -TA - J Cancer Res Ther -JT - Journal of cancer research and therapeutics -JID - 101249598 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Humans -MH - Lung Neoplasms/*drug therapy -MH - Treatment Outcome -OTO - NOTNLM -OT - Immune checkpoint inhibitor -OT - nonsmall cell lung cancer -OT - pembrolizumab -OT - programmed cell death-1 -COIS- None -EDAT- 2019/08/23 06:00 -MHDA- 2020/02/11 06:00 -CRDT- 2019/08/23 06:00 -PHST- 2019/08/23 06:00 [entrez] -PHST- 2019/08/23 06:00 [pubmed] -PHST- 2020/02/11 06:00 [medline] -AID - JCanResTher_2019_15_4_743_264310 [pii] -AID - 10.4103/jcrt.JCRT_903_18 [doi] -PST - ppublish -SO - J Cancer Res Ther. 2019;15(4):743-750. doi: 10.4103/jcrt.JCRT_903_18. - -PMID- 29773328 -OWN - NLM -STAT- MEDLINE -DCOM- 20190307 -LR - 20190307 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 19 -IP - 4 -DP - 2018 Jul -TI - Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of - Current and Future Therapies and Technologies. -PG - 331-339 -LID - S1525-7304(18)30056-1 [pii] -LID - 10.1016/j.cllc.2018.03.014 [doi] -AB - Patients with non-small-cell lung cancer, including squamous-cell lung cancer - (SqCLC), typically present at an advanced stage. The current treatment landscape, - which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted - agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular - and immune biomarker testing can serve to guide optimal treatment choices, and - immune biomarker testing is becoming more important for this patient population. - In this review we provide an overview of current and emerging practices and - technologies for molecular and immune biomarker testing in advanced - non-small-cell lung cancer, with a focus on SqCLC. -CI - Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved. -FAU - Hirsch, Fred R -AU - Hirsch FR -AD - Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO. - Electronic address: fred.hirsch@ucdenver.edu. -FAU - Kerr, Keith M -AU - Kerr KM -AD - Department of Pathology, University of Aberdeen School of Medicine and Aberdeen - Royal Infirmary, Aberdeen, Scotland. -FAU - Bunn, Paul A Jr -AU - Bunn PA Jr -AD - Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO. -FAU - Kim, Edward S -AU - Kim ES -AD - Levine Cancer Institute, Atrium Health, Charlotte, NC. -FAU - Obasaju, Coleman -AU - Obasaju C -AD - Eli Lilly and Company, Indianapolis, IN. -FAU - Pérol, Maurice -AU - Pérol M -AD - Department of Medical Oncology, Centre Léon Bérard, Lyon, France. -FAU - Bonomi, Philip -AU - Bonomi P -AD - Department of Hematology and Oncology, Rush University Medical Center, Chicago, - IL. -FAU - Bradley, Jeffrey D -AU - Bradley JD -AD - Department of Radiation Oncology, Washington University School of Medicine, St. - Louis, MO. -FAU - Gandara, David -AU - Gandara D -AD - Department of Hematology and Oncology, UC Davis Comprehensive Cancer Center, - Sacramento, CA. -FAU - Jett, James R -AU - Jett JR -AD - Department of Oncology, formerly of National Jewish Health, Denver, CO. -FAU - Langer, Corey J -AU - Langer CJ -AD - Department of Thoracic Oncology, University of Pennsylvania Abramson Cancer - Center, Philadelphia, PA. -FAU - Natale, Ronald B -AU - Natale RB -AD - Cedars-Sinai Comprehensive Cancer Center, West Hollywood, CA. -FAU - Novello, Silvia -AU - Novello S -AD - Department of Oncology, University of Turin, Turin, Italy. -FAU - Paz-Ares, Luis -AU - Paz-Ares L -AD - Department of Medical Oncology, Hospital Universitario Doce de Octubre, - Universidad Complutense, CIBERONC and CNIO, Madrid, Spain. -FAU - Ramalingam, Suresh S -AU - Ramalingam SS -AD - Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory - University, Atlanta, GA. -FAU - Reck, Martin -AU - Reck M -AD - Lung Clinic Grosshansdorf, Airway Research Center North, Member of the German - Center for Lung Research, Grosshansdorf, Germany. -FAU - Reynolds, Craig H -AU - Reynolds CH -AD - Florida Cancer Specialists, Ocala, FL. -FAU - Smit, Egbert F -AU - Smit EF -AD - Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The - Netherlands. -FAU - Socinski, Mark A -AU - Socinski MA -AD - Florida Hospital Cancer Institute, Orlando, FL. -FAU - Spigel, David R -AU - Spigel DR -AD - Sarah Cannon Research Institute, Nashville, TN. -FAU - Stinchcombe, Thomas E -AU - Stinchcombe TE -AD - Division of Medical Oncology, Duke Cancer Institute, Durham, NC. -FAU - Vansteenkiste, Johan F -AU - Vansteenkiste JF -AD - Respiratory Oncology Unit, Department of Respiratory Medicine, University - Hospital KU Leuven, Leuven, Belgium. -FAU - Wakelee, Heather -AU - Wakelee H -AD - Department of Medicine (Oncology), Stanford Cancer Institute and Stanford - University School of Medicine, Stanford, CA. -FAU - Thatcher, Nick -AU - Thatcher N -AD - Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, - United Kingdom. -LA - eng -PT - Journal Article -PT - Review -DEP - 20180321 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Biomarkers, Tumor/*analysis -MH - Carcinoma, Squamous Cell/*drug therapy -MH - Humans -MH - Immunotherapy/*methods/trends -MH - Lung Neoplasms/*drug therapy -MH - Molecular Targeted Therapy/*methods/trends -OTO - NOTNLM -OT - Immune-oncology -OT - Molecular testing -OT - Non–small-cell lung cancer -OT - PD-L1 -OT - Pathology -OT - Targeted treatment -EDAT- 2018/05/19 06:00 -MHDA- 2019/03/08 06:00 -CRDT- 2018/05/19 06:00 -PHST- 2018/01/03 00:00 [received] -PHST- 2018/03/12 00:00 [revised] -PHST- 2018/03/13 00:00 [accepted] -PHST- 2018/05/19 06:00 [pubmed] -PHST- 2019/03/08 06:00 [medline] -PHST- 2018/05/19 06:00 [entrez] -AID - S1525-7304(18)30056-1 [pii] -AID - 10.1016/j.cllc.2018.03.014 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2018 Jul;19(4):331-339. doi: 10.1016/j.cllc.2018.03.014. Epub - 2018 Mar 21. - -PMID- 33896153 -OWN - NLM -STAT- MEDLINE -DCOM- 20211005 -LR - 20240402 -IS - 1999-6187 (Electronic) -IS - 1009-3419 (Print) -IS - 1009-3419 (Linking) -VI - 24 -IP - 4 -DP - 2021 Apr 20 -TI - [Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell - Lung Cancer (2020 Version)]. -PG - 217-235 -LID - 10.3779/j.issn.1009-3419.2021.101.13 [doi] -AB - Non-small cell lung cancer (NSCLC) is the most common pathological type of lung - cancer. The systemic antitumor therapy of advanced NSCLC has undergone - renovations of chemotherapy, targeted therapy and immunotherapy, which results in - greatly improved survival for patients with advanced NSCLC. Immune checkpoint - inhibitors (ICIs), especially targeting programmed cell death protein 1 - (PD-1)/programmed death-ligand 1 (PD-L1), has changed the treatment paradigm of - NSCLC. ICIs have become the standard treatment for advanced NSCLC without - epidermal growth factor receptor(EGFR) mutation or anaplastic lymphomakinase(ALK) - translocation in the first- or second-line setting, and for locally advanced - NSCLC following concurrent radiotherapy and chemotherapy. ICIs are also promising - in adjuvant/neoadjuvant therapy. More and more ICIs have been approved - domestically for the treatment of NSCLC. Led by the NSCLC expert committee of - Chinese Society of Clinical Oncology (CSCO), this consensus was developed and - updated based on thoroughly reviewing domestic and foreign literatures, clinical - trial data, systematic reviews, experts' discussion and the consensus(2019 - version). This consensus will aid domestic clinicians in the treatment of NSCLC - with ICIs.
. -FAU - Zhou, Caicun -AU - Zhou C -AD - Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai - 200433, China. -FAU - Wang, Jie -AU - Wang J -AD - National Cancer Center/National Clinical Research Center for Cancer/Cancer - Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, - Beijing 100021, China. -FAU - Wang, Baocheng -AU - Wang B -AD - No. 960 Hospital of PLA, Jinan 250031, China. -FAU - Cheng, Ying -AU - Cheng Y -AD - Jilin Cancer Hospital, Changchun 130012, China. -FAU - Wang, Zhehai -AU - Wang Z -AD - Shandong Cancer Hospital and Institute, Jinan 250117, China. -FAU - Han, Baohui -AU - Han B -AD - Shanghai Chest Hospital, Shanghai 200030, China. -FAU - Lu, You -AU - Lu Y -AD - West China Hospital, Sichuan University, Chengdu 610041, China. -FAU - Wu, Gang -AU - Wu G -AD - Union Hospital, Tongji Medical College, Huazhong University of Science and - Technology, Wuhan 430022, China. -FAU - Zhang, Li -AU - Zhang L -AD - Peking Union Medical College Hospital, Beijing 100010, China. -FAU - Song, Yong -AU - Song Y -AD - General Hospital of Eastern Theater Command, Nanjing 210002, China. -FAU - Zhu, Bo -AU - Zhu B -AD - Xinqiao Hospital, The Army Medical University, Chongqing 400037, China. -FAU - Hu, Yi -AU - Hu Y -AD - Chinese PLA General Hospital, Beijing 100853, China. -FAU - Wang, Ziping -AU - Wang Z -AD - Beijing Cancer Hospital, Beijing 100142, China. -FAU - Song, Qibin -AU - Song Q -AD - Renmin Hospital of Wuhan University, Wuhan 430060, China. -FAU - Ren, Shengxiang -AU - Ren S -AD - Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai - 200433, China. -FAU - He, Yayi -AU - He Y -AD - Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai - 200433, China. -FAU - Hu, Xiaohua -AU - Hu X -AD - The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, - China. -FAU - Zhang, Jian -AU - Zhang J -AD - Xijing Hospital, Xi'an 710032, China. -FAU - Yao, Yu -AU - Yao Y -AD - The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. -FAU - Zhao, Hongyun -AU - Zhao H -AD - Sun Yat-sen University Cancer Center, Guangzhou 510060, China. -FAU - Wang, Zhijie -AU - Wang Z -AD - National Cancer Center/National Clinical Research Center for Cancer/Cancer - Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, - Beijing 100021, China. -FAU - Chu, Qian -AU - Chu Q -AD - Tongji Hospital of Tongji Medical College, Huazhong University of Science and - Technology, Wuhan 430030, China. -FAU - Duan, Jianchun -AU - Duan J -AD - National Cancer Center/National Clinical Research Center for Cancer/Cancer - Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, - Beijing 100021, China. -FAU - Liu, Jingjing -AU - Liu J -AD - Jilin Cancer Hospital, Changchun 130012, China. -FAU - Qin, Shukui -AU - Qin S -AD - Cancer Center, Eastern Theater General Hospital of the Chinese PLA, Nanjing - 210002, China. -LA - chi -PT - Consensus Development Conference -PT - Journal Article -DEP - 20210426 -PL - China -TA - Zhongguo Fei Ai Za Zhi -JT - Zhongguo fei ai za zhi = Chinese journal of lung cancer -JID - 101126433 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antineoplastic Agents, Immunological/*administration & dosage -MH - B7-H1 Antigen/administration & dosage -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - China -MH - Consensus -MH - Humans -MH - Immune Checkpoint Inhibitors/*administration & dosage -MH - Immunotherapy -MH - Lung Neoplasms/*drug therapy -MH - Programmed Cell Death 1 Receptor/administration & dosage -PMC - PMC8105610 -OTO - NOTNLM -OT - Expert consensus -OT - Immunotherapy -OT - Lung neoplasms -OT - Programmed cell death protein 1/Programmed death-ligand 1 -EDAT- 2021/04/26 06:00 -MHDA- 2021/10/06 06:00 -PMCR- 2021/04/20 -CRDT- 2021/04/25 22:42 -PHST- 2021/04/26 06:00 [pubmed] -PHST- 2021/10/06 06:00 [medline] -PHST- 2021/04/25 22:42 [entrez] -PHST- 2021/04/20 00:00 [pmc-release] -AID - zgfazz-24-4-217 [pii] -AID - 10.3779/j.issn.1009-3419.2021.101.13 [doi] -PST - ppublish -SO - Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):217-235. doi: - 10.3779/j.issn.1009-3419.2021.101.13. Epub 2021 Apr 26. - -PMID- 33872981 -OWN - NLM -STAT- MEDLINE -DCOM- 20211018 -LR - 20211018 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 149 -DP - 2021 May -TI - BRAF mutations and BRAF mutation functional class have no negative impact on the - clinical outcome of advanced NSCLC and associate with susceptibility to - immunotherapy. -PG - 211-221 -LID - S0959-8049(21)00144-1 [pii] -LID - 10.1016/j.ejca.2021.02.036 [doi] -AB - OBJECTIVE: BRAF mutations have been subtyped in three functional classes with - different oncogenic modes of action. The clinical impact of BRAF mutational - subtypes in non-small-cell lung cancer (NSCLC) remains to be defined. So far, - ambiguous results were reported from analyses of heterogeneous patient cohorts. - METHODS: We studied patients with metastatic or recurrent NSCLC who were - sequentially enrolled in precision oncology programs at two large German lung - cancer centres from 2009 to 2019. The study period allowed evaluating the - specific impact of BRAF V600E-targeting. RESULTS: In a cohort of 72 patients, - BRAF mutation subtyping revealed p.V600E mutations in 31 cases (43%), whereas 41 - cases (57%) harboured 18 different BRAF mutational subtypes of functional classes - II/III. Functionally relevant comutations were observed in 6.4% of class I, and - 24.4% of class II/III BRAF mutations. Most patients were treated with - chemotherapy. Targeted therapy was administered in 11 patients with a response - rate of 72.7%. PD-1/PD-L1-immunotherapy was given in 14 patients with a response - rate of 28.6%. Overall survival of patients with BRAF-mutated NSCLC was inferior - (HR 1.38, p = 0.048) as compared to patients with BRAF wild-type cancers. Median - time-to-treatment-failure with BRAF-targeting agents was shorter as compared to - approved targeted therapy of other oncogenic drivers (HR 1.97, p = 0.05). - Survival outcomes were not impacted by BRAF mutation subtype functional class. - CONCLUSIONS: Patients with BRAF-mutated NSCLC have an inferior prognosis, which - is not determined by BRAF mutation functional class. In contrast to NSCLC with - other tractable driver mutations, BRAF-mutated NSCLC exhibit high susceptibility - to immune checkpoint inhibitors. -CI - Copyright © 2021 Elsevier Ltd. All rights reserved. -FAU - Wiesweg, Marcel -AU - Wiesweg M -AD - Department of Medical Oncology, West German Cancer Center, University Hospital - Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West - German Cancer Center, University Medicine Essen - Ruhrlandklinik, University - Duisburg-Essen, Germany. Electronic address: marcel.wiesweg@uk-essen.de. -FAU - Preuß, Cedric -AU - Preuß C -AD - Department of Medical Oncology, West German Cancer Center, University Hospital - Essen, University Duisburg-Essen, Germany. -FAU - Roeper, Julia -AU - Roeper J -AD - Department of Hematology and Oncology, University Department Internal - Medicine-Oncology, Pius Hospital, Medical Campus University of Oldenburg, - Oldenburg, Germany; Lung Cancer Network NOWEL, Oldenburg, Germany. -FAU - Metzenmacher, Martin -AU - Metzenmacher M -AD - Department of Medical Oncology, West German Cancer Center, University Hospital - Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West - German Cancer Center, University Medicine Essen - Ruhrlandklinik, University - Duisburg-Essen, Germany. -FAU - Eberhardt, Wilfried -AU - Eberhardt W -AD - Department of Medical Oncology, West German Cancer Center, University Hospital - Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West - German Cancer Center, University Medicine Essen - Ruhrlandklinik, University - Duisburg-Essen, Germany. -FAU - Stropiep, Ursula -AU - Stropiep U -AD - Department of Hematology and Oncology, University Department Internal - Medicine-Oncology, Pius Hospital, Medical Campus University of Oldenburg, - Oldenburg, Germany; Lung Cancer Network NOWEL, Oldenburg, Germany. -FAU - Wedeken, Katrin -AU - Wedeken K -AD - Department of Hematology and Oncology, University Department Internal - Medicine-Oncology, Pius Hospital, Medical Campus University of Oldenburg, - Oldenburg, Germany; Lung Cancer Network NOWEL, Oldenburg, Germany. -FAU - Reis, Henning -AU - Reis H -AD - Institute of Pathology, West German Cancer Center, University Hospital Essen, - University Duisburg-Essen, Germany. -FAU - Herold, Thomas -AU - Herold T -AD - Institute of Pathology, West German Cancer Center, University Hospital Essen, - University Duisburg-Essen, Germany. -FAU - Darwiche, Kaid -AU - Darwiche K -AD - Department of Pulmonary Medicine, Section of Interventional Pneumology, West - German Cancer Center, University Medicine Essen - Ruhrlandklinik, University - Duisburg-Essen, Germany. -FAU - Aigner, Clemens -AU - Aigner C -AD - Department of Thoracic Surgery and Endoscopy, West German Cancer Center, - University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany; - German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, - Germany. -FAU - Stuschke, Martin -AU - Stuschke M -AD - Department of Radiotherapy, West German Cancer Center, University Hospital Essen, - University Duisburg-Essen, Germany; German Cancer Consortium (DKTK), Partner Site - University Hospital Essen, Essen, Germany. -FAU - Schildhaus, Hans-Ulrich -AU - Schildhaus HU -AD - Institute of Pathology, West German Cancer Center, University Hospital Essen, - University Duisburg-Essen, Germany. -FAU - Schmid, Kurt W -AU - Schmid KW -AD - Institute of Pathology, West German Cancer Center, University Hospital Essen, - University Duisburg-Essen, Germany; German Cancer Consortium (DKTK), Partner Site - University Hospital Essen, Essen, Germany. -FAU - Falk, Markus -AU - Falk M -AD - Institute for Hematopathology Hamburg, Hamburg, Germany; Lung Cancer Network - NOWEL, Oldenburg, Germany. -FAU - Heukamp, Lukas -AU - Heukamp L -AD - Institute for Hematopathology Hamburg, Hamburg, Germany; Lung Cancer Network - NOWEL, Oldenburg, Germany. -FAU - Tiemann, Markus -AU - Tiemann M -AD - Institute for Hematopathology Hamburg, Hamburg, Germany; Lung Cancer Network - NOWEL, Oldenburg, Germany. -FAU - Griesinger, Frank -AU - Griesinger F -AD - Department of Hematology and Oncology, University Department Internal - Medicine-Oncology, Pius Hospital, Medical Campus University of Oldenburg, - Oldenburg, Germany; Lung Cancer Network NOWEL, Oldenburg, Germany. -FAU - Schuler, Martin -AU - Schuler M -AD - Department of Medical Oncology, West German Cancer Center, University Hospital - Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West - German Cancer Center, University Medicine Essen - Ruhrlandklinik, University - Duisburg-Essen, Germany; German Cancer Consortium (DKTK), Partner Site University - Hospital Essen, Essen, Germany. -LA - eng -PT - Journal Article -PT - Multicenter Study -DEP - 20210416 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - EC 2.7.11.1 (BRAF protein, human) -RN - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - B7-H1 Antigen/*antagonists & inhibitors/immunology -MH - Biomarkers, Tumor/*genetics -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/immunology/mortality -MH - Databases, Factual -MH - Female -MH - Germany -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects/*therapeutic use -MH - Lung Neoplasms/*drug therapy/genetics/immunology/mortality -MH - Male -MH - Middle Aged -MH - *Mutation -MH - Precision Medicine -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors/immunology -MH - Proto-Oncogene Proteins B-raf/*genetics -MH - Time Factors -MH - Treatment Outcome -OTO - NOTNLM -OT - BRAF mutation functional class -OT - BRAF mutation subtype -OT - BRAF-Mutated lung cancer -OT - BRAF-Targeted therapy -OT - NSCLC immunotherapy -COIS- Conflict of interest statement Marcel Wiesweg—Honoraria: Boehringer Ingelheim, - Novartis, Roche, Takeda. Research funding: Bristol-Myers Squibb, Takeda. Julia - Roeper—Honoraria: Astra-Zeneca, Boehringer Ingelheim, Roche. Henning - Reis—Consulting and advisory role: Bristol-Myers Squibb. Honoraria: Roche and - Bristol-Myers Squibb. Travel support: Philips, Roche, Bristol-Myers Squibb. - Research funding: Bristol-Myers Squibb. Share ownership: Bayer. Martin - Metzenmacher—Honoraria: Merck, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, - Takeda. Wilfried Ernst Erich Eberhardt—Research funding to institution: - Bristol-Myers Squibb, Astra Zeneca and Eli Lilly. Honoraria: Astra Zeneca, - Bristol-Myers Squibb, Merck, Roche, Pfizer, Novartis, Boehringer Ingelheim, - Takeda, Abbvie, Bayer, Johnson & Johnson, Amgen, Daichi Sankyo, Eli Lilly, - Honoraria for educational lectures from Astra Zeneca, Bristol-Myers Squibb, - Merck, Roche, Pfizer, Boehringer Ingelheim, Takeda, Amgen, Eli Lilly. Clemens - Aigner—Research funding: Bristol-Myers Squibb. Kaid Darwiche—Consultancy/Advisory - role: Boehringer Ingelheim, Novartis. Honoraria: Boehringer Ingelheim. - Hans-Ulrich Schildhaus—Research grant: Novartis, Takeda. Honoraria: Pfizer, - Novartis, Roche. Markus Tiemann—Honoraria: AstraZeneca, Boehringer Ingelheim, - Roche, Pfizer, Takeda, Bristol-Myers Squibb, Merck. Frank Griesinger—Research - funding to institution: Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, - Celgene, Lilly, Merck, Novartis, Pfizer, Roche, Takeda, Siemens. Honoraria for - educational lectures: Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, - Celgene, Lilly, Merck, Novartis, Pfizer, Roche, Takeda, Ariad, Abbvie, Siemens, - Tesaro/GlaxoSmithKline, Amgen, Honoraria: Astra Zeneca, Boehringer Ingelheim, - Bristol-Myers Squibb, Celgene, Lilly, Merck, Novartis, Pfizer, Roche, Takeda, - Ariad, Abbvie, Tesaro/GlaxoSmithKline, Siemens, Amgen. Martin Schuler—Consultant - honoraria from Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, - Novartis, Roche, Takeda. Honoraria for educational lectures: Amgen, Boehringer - Ingelheim, Bristol-Myers Squibb, Janssen, Merck, Novartis. Research funding to - institution: Astra Zeneca, Boehringer Ingelheim, Bristol Myers-Squibb, Novartis. - Other: Universität Duisburg-Essen (Patents). All remaining authors declared no - conflicts of interest. -EDAT- 2021/04/20 06:00 -MHDA- 2021/10/21 06:00 -CRDT- 2021/04/19 20:21 -PHST- 2021/01/18 00:00 [received] -PHST- 2021/02/17 00:00 [revised] -PHST- 2021/02/22 00:00 [accepted] -PHST- 2021/04/20 06:00 [pubmed] -PHST- 2021/10/21 06:00 [medline] -PHST- 2021/04/19 20:21 [entrez] -AID - S0959-8049(21)00144-1 [pii] -AID - 10.1016/j.ejca.2021.02.036 [doi] -PST - ppublish -SO - Eur J Cancer. 2021 May;149:211-221. doi: 10.1016/j.ejca.2021.02.036. Epub 2021 - Apr 16. - -PMID- 34409252 -OWN - NLM -STAT- MEDLINE -DCOM- 20220228 -LR - 20220228 -IS - 2515-5091 (Electronic) -IS - 2515-5091 (Linking) -VI - 5 -IP - 4 -DP - 2021 Aug -TI - Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of - Non-Small Cell Lung Cancer. -LID - 10.1093/jncics/pkab048 [doi] -LID - pkab048 -AB - BACKGROUND: Immunotherapy yields survival benefit for some advanced stage - non-small cell lung cancer (NSCLC) patients. Because highly predictive biomarkers - of immunotherapy response are an unmet clinical need, we used pretreatment - radiomics and clinical data to train and validate a parsimonious model associated - with survival outcomes among NSCLC patients treated with immunotherapy. METHODS: - Three cohorts of NSCLC patients treated with immunotherapy were analyzed: - training (n = 180), validation 1 (n = 90), and validation 2 (n = 62). The most - informative clinical and radiomic features were subjected to decision tree - analysis, which stratified patients into risk groups of low, moderate, high, and - very high risk of death after initiation of immunotherapy. All statistical tests - were 2-sided. RESULTS: The very high-risk group was associated with extremely - poor overall survival (OS) in validation cohorts 1 (hazard ratio [HR] = 5.35, 95% - confidence interval [CI] = 2.14 to 13.36; 1-year OS = 11.1%, 95% CI = 1.9% to - 29.8%; 3-year OS = 0%) and 2 (HR = 13.81, 95% CI = 2.58 to 73.93; 1-year - OS = 47.6%, 95% CI = 18.2% to 72.4%; 3-year OS = 0%) when compared with the - low-risk group (HR = 1.00) in validation cohorts 1 (1-year OS = 85.0%, 95% - CI = 60.4% to 94.9%; 3-year OS = 38.9%, 95% CI = 17.1% to 60.3%) and 2 (1-year - OS = 80.2%, 95% CI = 40.3% to 94.8%; 3-year OS = 40.1%, 95% CI = 1.3% to 83.5%). - The most informative radiomic feature, gray-level co-occurrence matrix (GLCM) - inverse difference, was positively associated with hypoxia-related carbonic - anhydrase 9 using gene-expression profiling and immunohistochemistry. CONCLUSION: - Utilizing standard-of-care imaging and clinical data, we identified and validated - a novel parsimonious model associated with survival outcomes among NSCLC patients - treated with immunotherapy. Based on this model, clinicians can identify patients - who are unlikely to respond to immunotherapy. -CI - © The Author(s) 2021. Published by Oxford University Press. -FAU - Tunali, Ilke -AU - Tunali I -AUID- ORCID: 0000-0002-2565-4030 -AD - Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, FL, USA. -FAU - Tan, Yan -AU - Tan Y -AD - Department of Radiology, First Hospital of Shanxi Medical University, Taiyuan, - Shanxi Province, China. -FAU - Gray, Jhanelle E -AU - Gray JE -AD - Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, FL, USA. -FAU - Katsoulakis, Evangelia -AU - Katsoulakis E -AUID- ORCID: 0000-0003-3462-6303 -AD - Department of Radiation Oncology, James A. Haley Veterans' Hospital, Tampa, FL, - USA. -FAU - Eschrich, Steven A -AU - Eschrich SA -AUID- ORCID: 0000-0002-9833-2788 -AD - Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and - Research Institute, Tampa, FL, USA. -FAU - Saller, James -AU - Saller J -AUID- ORCID: 0000-0001-5040-4482 -AD - Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, FL, USA. -FAU - Aerts, Hugo J W L -AU - Aerts HJWL -AD - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber - Cancer Institute, Harvard Medical School, Boston, MA, USA. -FAU - Boyle, Theresa -AU - Boyle T -AD - Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, FL, USA. -FAU - Qi, Jin -AU - Qi J -AD - Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, FL, USA. -FAU - Guvenis, Albert -AU - Guvenis A -AUID- ORCID: 0000-0003-0490-5184 -AD - Institute of Biomedical Engineering, Bogazici University, Istanbul, Turkey. -FAU - Gillies, Robert J -AU - Gillies RJ -AUID- ORCID: 0000-0002-8888-7747 -AD - Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, FL, USA. -FAU - Schabath, Matthew B -AU - Schabath MB -AUID- ORCID: 0000-0003-3241-3216 -AD - Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research - Institute, Tampa, FL, USA. -LA - eng -GR - P30 CA076292/CA/NCI NIH HHS/United States -GR - U01 CA143062/CA/NCI NIH HHS/United States -GR - U01 CA200464/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20210513 -PL - England -TA - JNCI Cancer Spectr -JT - JNCI cancer spectrum -JID - 101721827 -RN - 0 (Antigens, Neoplasm) -RN - 0 (Immune Checkpoint Inhibitors) -RN - EC 4.2.1.1 (CA9 protein, human) -RN - EC 4.2.1.1 (Carbonic Anhydrase IX) -MH - Aged -MH - Antigens, Neoplasm/genetics -MH - Carbonic Anhydrase IX/genetics -MH - Carcinoma, Non-Small-Cell Lung/*diagnostic imaging/genetics/mortality/*therapy -MH - Cohort Studies -MH - Confidence Intervals -MH - Decision Trees -MH - Female -MH - Gene Expression Profiling -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Lung Neoplasms/*diagnostic imaging/genetics/mortality/*therapy -MH - Male -MH - Middle Aged -MH - Proportional Hazards Models -MH - Risk -MH - Tomography, X-Ray Computed -MH - Treatment Outcome -MH - *Tumor Hypoxia -PMC - PMC8363765 -EDAT- 2021/08/20 06:00 -MHDA- 2021/08/20 06:01 -PMCR- 2021/05/13 -CRDT- 2021/08/19 06:46 -PHST- 2020/12/23 00:00 [received] -PHST- 2021/03/30 00:00 [revised] -PHST- 2021/04/16 00:00 [accepted] -PHST- 2021/08/19 06:46 [entrez] -PHST- 2021/08/20 06:00 [pubmed] -PHST- 2021/08/20 06:01 [medline] -PHST- 2021/05/13 00:00 [pmc-release] -AID - pkab048 [pii] -AID - 10.1093/jncics/pkab048 [doi] -PST - epublish -SO - JNCI Cancer Spectr. 2021 May 13;5(4):pkab048. doi: 10.1093/jncics/pkab048. - eCollection 2021 Aug. - -PMID- 35718373 -OWN - NLM -STAT- MEDLINE -DCOM- 20220621 -LR - 20220819 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 10 -IP - 6 -DP - 2022 Jun -TI - Longitudinal plasma proteomic profiling of patients with non-small cell lung - cancer undergoing immune checkpoint blockade. -LID - 10.1136/jitc-2022-004582 [doi] -LID - e004582 -AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the cancer - therapy landscape due to long-term benefits in patients with advanced metastatic - disease. However, robust predictive biomarkers for response are still lacking and - treatment resistance is not fully understood. METHODS: We profiled approximately - 800 pre-treatment and on-treatment plasma proteins from 143 ICI-treated patients - with non-small cell lung cancer (NSCLC) using ELISA-based arrays. Different - clinical parameters were collected from the patients including specific - mutations, smoking habits, and body mass index, among others. Machine learning - algorithms were used to identify a predictive signature for response. - Bioinformatics tools were used for the identification of patient subtypes and - analysis of differentially expressed proteins and pathways in each response - group. RESULTS: We identified a predictive signature for response to treatment - comprizing two proteins (CXCL8 and CXCL10) and two clinical parameters (age and - sex). Bioinformatic analysis of the proteomic profiles identified three distinct - patient clusters that correlated with multiple parameters such as response, sex - and TNM (tumors, nodes, and metastasis) staging. Patients who did not benefit - from ICI therapy exhibited significantly higher plasma levels of several proteins - on-treatment, and enrichment in neutrophil-related proteins. CONCLUSIONS: Our - study reveals potential biomarkers in blood plasma for predicting response to ICI - therapy in patients with NSCLC and sheds light on mechanisms underlying therapy - resistance. -CI - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Harel, Michal -AU - Harel M -AD - OncoHost Ltd, Binyamina, Israel. -FAU - Lahav, Coren -AU - Lahav C -AD - OncoHost Ltd, Binyamina, Israel. -FAU - Jacob, Eyal -AU - Jacob E -AD - OncoHost Ltd, Binyamina, Israel. -FAU - Dahan, Nili -AU - Dahan N -AD - OncoHost Ltd, Binyamina, Israel. -FAU - Sela, Itamar -AU - Sela I -AD - OncoHost Ltd, Binyamina, Israel. -FAU - Elon, Yehonatan -AU - Elon Y -AD - OncoHost Ltd, Binyamina, Israel. -FAU - Raveh Shoval, Shani -AU - Raveh Shoval S -AD - OncoHost Ltd, Binyamina, Israel. -FAU - Yahalom, Galit -AU - Yahalom G -AD - OncoHost Ltd, Binyamina, Israel. -FAU - Kamer, Iris -AU - Kamer I -AD - Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel. -FAU - Zer, Alona -AU - Zer A -AD - Oncology Center, Rambam Health Care Campus, Haifa, Israel. -FAU - Sharon, Ofer -AU - Sharon O -AD - OncoHost Ltd, Binyamina, Israel. -FAU - Carbone, David P -AU - Carbone DP -AD - James Thoracic Oncology Center, Ohio State University Medical Center, Columbus, - Ohio, USA. -FAU - Dicker, Adam P -AU - Dicker AP -AD - Radiation Oncology, Thomas Jefferson University Sidney Kimmel Medical College, - Philadelphia, Pennsylvania, USA. -FAU - Bar, Jair -AU - Bar J -AD - Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel. -AD - Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel. -FAU - Shaked, Yuval -AU - Shaked Y -AUID- ORCID: 0000-0001-9037-3895 -AD - Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, - Israel yshaked@technion.ac.il. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Biomarkers) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - *Antineoplastic Agents, Immunological/adverse effects -MH - Biomarkers -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - *Lung Neoplasms/pathology -MH - Plasma -MH - Proteomics -PMC - PMC9207924 -OTO - NOTNLM -OT - lung neoplasms -OT - translational medical research -OT - tumor biomarkers -COIS- Competing interests: MH, CL, EJ, IS, YE, SRS, GY, and OS are employees of - OncoHost. ND, AZ, DC, AD, and YS are advisors to OncoHost. IK declares no - potential conflicts of interest. OncoHost holds patents on predicting therapeutic - outcome based on plasma proteins. DPC reports personal fees from the following: - AbbVie, Adaptimmune, Agenus, Amgen, Ariad, AstraZeneca, Biocept, Boehringer - Ingelheim, Celgene, Clovis, Daiichi Sankyo (DSI), EMD Serono, Flame Biosciences, - Foundation Medicine, G1Therapeutics/Intellisphere, GenePlus, Genentech/Roche, - GlaxoSmithKline, Gloria Biosciences, Gritstone, Guardant Health, Humana, Incyte, - Inivata, Inovio, Janssen, Kyowa Kirin, Loxo Oncology, Merck, MSD, Nexus Oncology, - Novartis, Oncocyte, Palobiofarma, Pfizer, prIME Oncology, Stemcentrx, Takeda - Oncology and Teva. AD reports personal fees from the following: Roche, Janssen, - Self Care Catalysts, Albert Einstein Medical College, Alcimed, Oranomed, IBA, - Deallus, Genentech, CVS. JB reports grants and personal fees from Merck Sharp and - Dohme (MSD), AbbVie, AstraZeneca, Pfizer, Takeda, and Roche, grants from Bristol - Myers Squibb (BMS), personal fees from Boehringer Ingelheim (BI), VBL, Novartis, - Bayer, and Lilly. -EDAT- 2022/06/20 06:00 -MHDA- 2022/06/22 06:00 -PMCR- 2022/06/19 -CRDT- 2022/06/19 21:04 -PHST- 2022/05/09 00:00 [accepted] -PHST- 2022/06/19 21:04 [entrez] -PHST- 2022/06/20 06:00 [pubmed] -PHST- 2022/06/22 06:00 [medline] -PHST- 2022/06/19 00:00 [pmc-release] -AID - jitc-2022-004582 [pii] -AID - 10.1136/jitc-2022-004582 [doi] -PST - ppublish -SO - J Immunother Cancer. 2022 Jun;10(6):e004582. doi: 10.1136/jitc-2022-004582. - -PMID- 30819829 -OWN - NLM -STAT- MEDLINE -DCOM- 20200302 -LR - 20200309 -IS - 1549-490X (Electronic) -IS - 1083-7159 (Print) -IS - 1083-7159 (Linking) -VI - 24 -IP - Suppl 1 -DP - 2019 Feb -TI - PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current - Status and Future Directions. -PG - S31-S41 -LID - 10.1634/theoncologist.2019-IO-S1-s05 [doi] -AB - The use of immune checkpoint inhibitors (ICIs) has become one of the most - promising approaches in the field of cancer therapy. Unlike the current therapies - that target tumor cells, such as chemotherapy, radiotherapy, or targeted therapy, - ICIs directly restore the exhausted host antitumor immune responses mediated by - the tumors. Among multiple immune modulators identified, the programmed cell - death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis - leading to the exhaustion of T-cell immunity in chronic infections and tumors has - been widely investigated. Therefore, blocking antibodies targeting PD-1 or PD-L1 - have been developed and approved for the treatment of various advanced cancers, - including non-small-cell lung cancer (NSCLC), making them the most successful - ICIs. Compared with chemotherapy or radiotherapy, PD-1/PD-L1 blockade therapy - significantly improves the durable response rate and prolongs long-term survival - with limited adverse effects in both monotherapy and combination therapy for - advanced NSCLC. However, extensive challenges exist for further clinical - applications, such as a small fraction of benefit population, primary and - acquired resistance, the lack of predictive and prognostic biomarkers, and - treatment-related adverse effects. In this article, we summarize the latest - clinical applications of PD-1/PD-L1 blockade therapy in advanced NSCLC worldwide, - as well as in China, and discuss the bottlenecks related to the use of this - therapy in clinical practice. An exploration of the underlying mechanism of - PD-1/PD-L1 blockade therapy and biomarker identification will maximize the - application of ICIs in advanced NSCLC and facilitate bedside-to-bench studies in - cancer immunotherapy as well. IMPLICATIONS FOR PRACTICE: Immune checkpoint - inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed - cell death protein ligand 1 (PD-L1) display apparent benefits for the treatment - of advanced non-small-cell lung cancer (NSCLC). However, the clinical - applications of these therapies are challenged by the limited benefit population - with additional high economic burden and adverse events. This review discusses - the bottlenecks of ICI therapy in clinical practice and provides appropriate - guidance in the development of predictive biomarkers, the establishment of the - criteria for combining PD-1/PD-L1 blockade therapy with the existing therapies, - and the management of adverse events observed both in monotherapy and combination - therapy, which will help maximize the applications of ICIs in advanced NSCLC. -CI - © AlphaMed Press 2019. -FAU - Xia, Liliang -AU - Xia L -AD - Shanghai Institute of Immunology, Department of Immunology and Microbiology, - Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of - China. -FAU - Liu, Yuanyong -AU - Liu Y -AD - Shanghai Institute of Immunology, Department of Immunology and Microbiology, - Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of - China. -AD - School of Life Science and Technology, Changchun University of Science and - Technology, Changchun, People's Republic of China. -FAU - Wang, Ying -AU - Wang Y -AD - Shanghai Institute of Immunology, Department of Immunology and Microbiology, - Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of - China ywang@sibs.ac.cn. -AD - Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National - Human Genome Center at Shanghai, Shanghai, People's Republic of China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - England -TA - Oncologist -JT - The oncologist -JID - 9607837 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antibodies, Monoclonal/immunology/*therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors/immunology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology -MH - China -MH - Clinical Trials as Topic -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/*drug therapy/immunology -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors/immunology -MH - Randomized Controlled Trials as Topic -PMC - PMC6394772 -OTO - NOTNLM -OT - Clinical trials -OT - Combination therapy -OT - Immune checkpoint inhibitors -OT - Non‐small‐cell lung cancer -OT - PD‐1/PD‐L1 -COIS- Disclosures of potential conflicts of interest may be found at the end of this - article. -EDAT- 2019/03/02 06:00 -MHDA- 2020/03/03 06:00 -PMCR- 2019/02/28 -CRDT- 2019/03/02 06:00 -PHST- 2018/11/06 00:00 [received] -PHST- 2018/11/09 00:00 [accepted] -PHST- 2019/03/02 06:00 [entrez] -PHST- 2019/03/02 06:00 [pubmed] -PHST- 2020/03/03 06:00 [medline] -PHST- 2019/02/28 00:00 [pmc-release] -AID - 24/Suppl_1/S31 [pii] -AID - ONCO12760 [pii] -AID - 10.1634/theoncologist.2019-IO-S1-s05 [doi] -PST - ppublish -SO - Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: - 10.1634/theoncologist.2019-IO-S1-s05. - -PMID- 38780929 -OWN - NLM -STAT- MEDLINE -DCOM- 20240620 -LR - 20240620 -IS - 2374-2445 (Electronic) -IS - 2374-2437 (Print) -IS - 2374-2437 (Linking) -VI - 10 -IP - 6 -DP - 2024 Jun 1 -TI - Body Composition in Advanced Non-Small Cell Lung Cancer Treated With - Immunotherapy. -PG - 773-783 -LID - 10.1001/jamaoncol.2024.1120 [doi] -AB - IMPORTANCE: The association between body composition (BC) and cancer outcomes is - complex and incompletely understood. Previous research in non-small-cell lung - cancer (NSCLC) has been limited to small, single-institution studies and yielded - promising, albeit heterogeneous, results. OBJECTIVES: To evaluate the association - of BC with oncologic outcomes in patients receiving immunotherapy for advanced or - metastatic NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This comprehensive - multicohort analysis included clinical data from cohorts receiving treatment at - the Dana-Farber Brigham Cancer Center (DFBCC) who received immunotherapy given - alone or in combination with chemotherapy and prospectively collected data from - the phase 1/2 Study 1108 and the chemotherapy arm of the phase 3 MYSTIC trial. - Baseline and follow-up computed tomography (CT) scans were collected and analyzed - using deep neural networks for automatic L3 slice selection and body compartment - segmentation (skeletal muscle [SM], subcutaneous adipose tissue [SAT], and - visceral adipose tissue). Outcomes were compared based on baseline BC measures or - their change at the first follow-up scan. The data were analyzed between July - 2022 and April 2023. MAIN OUTCOMES AND MEASURES: Hazard ratios (HRs) for the - association of BC measurements with overall survival (OS) and progression-free - survival (PFS). RESULTS: A total of 1791 patients (878 women [49%]) with NSCLC - were analyzed, of whom 487 (27.2%) received chemoimmunotherapy at DFBCC - (DFBCC-CIO), 825 (46.1%) received ICI monotherapy at DFBCC (DFBCC-IO), 222 - (12.4%) were treated with durvalumab monotherapy on Study 1108, and 257 (14.3%) - were treated with chemotherapy on MYSTIC; median (IQR) ages were 65 (58-74), 66 - (57-71), 65 (26-87), and 63 (30-84) years, respectively. A loss in SM mass, as - indicated by a change in the L3 SM area, was associated with worse oncologic - outcome across patient groups (HR, 0.59 [95% CI, 0.43-0.81] and 0.61 [95% CI, - 0.47-0.79] for OS and PFS, respectively, in DFBCC-CIO; HR, 0.74 [95% CI, - 0.60-0.91] for OS in DFBCC-IO; HR, 0.46 [95% CI, 0.33-0.64] and 0.47 [95% CI, - 0.34-0.64] for OS and PFS, respectively, in Study 1108; HR, 0.76 [95% CI, - 0.61-0.96] for PFS in the MYSTIC trial). This association was most prominent - among male patients, with a nonsignificant association among female patients in - the MYSTIC trial and DFBCC-CIO cohorts on Kaplan-Meier analysis. An increase of - more than 5% in SAT density, as quantified by the average CT attenuation in - Hounsfield units of the SAT compartment, was associated with poorer OS in 3 - patient cohorts (HR, 0.61 [95% CI, 0.43-0.86] for DFBCC-CIO; HR, 0.62 [95% CI, - 0.49-0.79] for DFBCC-IO; and HR, 0.56 [95% CI, 0.40-0.77] for Study 1108). The - change in SAT density was also associated with PFS for DFBCC-CIO (HR, 0.73; 95% - CI, 0.54-0.97). This was primarily observed in female patients on Kaplan-Meier - analysis. CONCLUSIONS AND RELEVANCE: The results of this multicohort study - suggest that loss in SM mass during systemic therapy for NSCLC is a marker of - poor outcomes, especially in male patients. SAT density changes are also - associated with prognosis, particularly in female patients. Automated CT-derived - BC measurements should be considered in determining NSCLC prognosis. -FAU - Chaunzwa, Tafadzwa L -AU - Chaunzwa TL -AD - Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard - Medical School, Boston, Massachusetts. -AD - Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and - Women's Hospital, Harvard Medical School, Boston, Massachusetts. -FAU - Qian, Jack M -AU - Qian JM -AD - Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and - Women's Hospital, Harvard Medical School, Boston, Massachusetts. -FAU - Li, Qin -AU - Li Q -AD - AstraZeneca, Cambridge, England and Waltham, Massachusetts. -FAU - Ricciuti, Biagio -AU - Ricciuti B -AD - Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, - Massachusetts. -FAU - Nuernberg, Leonard -AU - Nuernberg L -AD - Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard - Medical School, Boston, Massachusetts. -AD - Radiology and Nuclear Medicine, CARIM & GROW, Maastricht University, Maastricht, - the Netherlands. -FAU - Johnson, Justin W -AU - Johnson JW -AD - Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard - Medical School, Boston, Massachusetts. -FAU - Weiss, Jakob -AU - Weiss J -AD - Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard - Medical School, Boston, Massachusetts. -AD - Department of Diagnostic and Interventional Radiology, University Freiburg, - Freiburg im Breisgau, Germany. -FAU - Zhang, Zhongyi -AU - Zhang Z -AD - Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard - Medical School, Boston, Massachusetts. -FAU - MacKay, Jamie -AU - MacKay J -AD - AstraZeneca, Cambridge, England and Waltham, Massachusetts. -FAU - Kagiampakis, Ioannis -AU - Kagiampakis I -AD - AstraZeneca, Cambridge, England and Waltham, Massachusetts. -FAU - Bikiel, Damian -AU - Bikiel D -AD - AstraZeneca, Cambridge, England and Waltham, Massachusetts. -FAU - Di Federico, Alessandro -AU - Di Federico A -AD - Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, - Massachusetts. -FAU - Alessi, Joao V -AU - Alessi JV -AD - Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, - Massachusetts. -FAU - Mak, Raymond H -AU - Mak RH -AD - Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard - Medical School, Boston, Massachusetts. -AD - Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and - Women's Hospital, Harvard Medical School, Boston, Massachusetts. -FAU - Jacob, Etai -AU - Jacob E -AD - AstraZeneca, Cambridge, England and Waltham, Massachusetts. -FAU - Awad, Mark M -AU - Awad MM -AD - Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, - Massachusetts. -FAU - Aerts, Hugo J W L -AU - Aerts HJWL -AD - Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard - Medical School, Boston, Massachusetts. -AD - Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and - Women's Hospital, Harvard Medical School, Boston, Massachusetts. -AD - Radiology and Nuclear Medicine, CARIM & GROW, Maastricht University, Maastricht, - the Netherlands. -LA - eng -PT - Journal Article -PL - United States -TA - JAMA Oncol -JT - JAMA oncology -JID - 101652861 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/therapy/pathology -MH - *Lung Neoplasms/drug therapy/therapy/pathology/mortality -MH - Female -MH - Male -MH - *Immunotherapy/methods -MH - *Body Composition -MH - Middle Aged -MH - Aged -MH - Progression-Free Survival -MH - Adult -PMC - PMC11117154 -COIS- Conflict of Interest Disclosures: Drs Li and MacKay reported employment with and - stock ownership in AstraZeneca. Dr Ricciuti reported personal fees from Amgen, - AstraZeneca, and Targeted Oncology outside the submitted work. Dr Bikiel reported - employment with AstraZeneca. Dr Alessi reported personal fees from BMS during the - conduct of the study. Dr Mak reported personal fees from AstraZeneca, Novartis, - Sio Capital Management, and Varian Medical Systems and grants from ViewRay - outside the submitted work. Dr Awad reported personal fees from Merck, Pfizer, - Novartis, Mirati, Foundation Medicine, Gritstone, EMD Serono, Regeneron, Johnson - & Johnson, Affini-T, Genentech, Lilly, personal fees and grants from - Bristol-Myers Squib, and grants from Amgen outside the submitted work. Dr Aerts - reported grants from the European Union and National Institutes of Health and - personal fees from Sphera, Onc.Ai, and Love outside the submitted work. No other - disclosures were reported. -EDAT- 2024/05/23 12:44 -MHDA- 2024/06/20 12:44 -PMCR- 2025/05/23 -CRDT- 2024/05/23 11:33 -PHST- 2025/05/23 00:00 [pmc-release] -PHST- 2024/06/20 12:44 [medline] -PHST- 2024/05/23 12:44 [pubmed] -PHST- 2024/05/23 11:33 [entrez] -AID - 2819050 [pii] -AID - coi240011 [pii] -AID - 10.1001/jamaoncol.2024.1120 [doi] -PST - ppublish -SO - JAMA Oncol. 2024 Jun 1;10(6):773-783. doi: 10.1001/jamaoncol.2024.1120. - -PMID- 34553354 -OWN - NLM -STAT- MEDLINE -DCOM- 20220120 -LR - 20220120 -IS - 1439-4413 (Electronic) -IS - 0012-0472 (Linking) -VI - 146 -IP - 19 -DP - 2021 Oct -TI - [Advances in Lung Cancer Treatment]. -PG - 1283-1286 -LID - 10.1055/a-1393-7697 [doi] -AB - IMMUNO-ONCOLOGIC MONOTHERAPY FOR NSCLC: 5-year survival data from the KEYNOTE-024 - trial confirm the sustained efficacy of immuno-oncologic monotherapy in patients - with NSCLC with high PD-L1 expression (≥ 50 %). DUAL IMMUNOTHERAPY IN COMBINATION - WITH CHEMOTHERAPY AS FIRST-LINE THERAPY FOR NSCLC:  Nivolumab plus impilimumab in - combination with 2 cycles of platinum-containing chemotherapy improves survival - in NSCLC patients. NOVEL TARGETS AND TREATMENT OPTIONS: Entrectinib and - larotrectinib with efficacy in NTRK fusion-positive NSCLC. Selpercatinib and - pralsetinib with efficacy in RET fusion-positive NSCLC. Mobocertinib with - efficacy in EGFRex20ins mutation of the EGFR gene. Sotorasib with efficacy in - kRAS-G12C mutation of NSCLC. NATIONAL NETWORK GENOMIC MEDICINE LUNG CANCER - (NNGM): The nationwide network nNGM provides NSCLC patients with access to - state-of-the-art molecular diagnostics and the latest treatment options. -CI - Thieme. All rights reserved. -FAU - Schulz, Christian -AU - Schulz C -AD - Klinik und Poliklinik für Innere Medizin II, Bereich Pneumologie, Klinikum der - Universität Regensburg. -LA - ger -PT - Journal Article -TT - Therapiekonzepte des fortgeschrittenen Lungenkarzinoms im Stadium IV. -DEP - 20210922 -PL - Germany -TA - Dtsch Med Wochenschr -JT - Deutsche medizinische Wochenschrift (1946) -JID - 0006723 -RN - 0 (Antineoplastic Agents) -RN - 0 (Pyrazoles) -RN - 0 (Pyridines) -RN - 0 (Pyrimidines) -RN - 0 (pralsetinib) -RN - CEGM9YBNGD (selpercatinib) -SB - IM -MH - Antineoplastic Agents/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/mortality -MH - Genomic Medicine/*methods -MH - Humans -MH - *Lung Neoplasms/drug therapy/genetics/mortality -MH - Pyrazoles/therapeutic use -MH - Pyridines/therapeutic use -MH - Pyrimidines/therapeutic use -COIS- C. Schulz hat Berater- und Vortragshonorare der Firmen Amgen, MSD, Roche und - Takeda erhalten. -EDAT- 2021/09/24 06:00 -MHDA- 2022/01/21 06:00 -CRDT- 2021/09/23 07:05 -PHST- 2021/09/23 07:05 [entrez] -PHST- 2021/09/24 06:00 [pubmed] -PHST- 2022/01/21 06:00 [medline] -AID - 10.1055/a-1393-7697 [doi] -PST - ppublish -SO - Dtsch Med Wochenschr. 2021 Oct;146(19):1283-1286. doi: 10.1055/a-1393-7697. Epub - 2021 Sep 22. - -PMID- 32332901 -OWN - NLM -STAT- MEDLINE -DCOM- 20211227 -LR - 20220418 -IS - 2042-0226 (Electronic) -IS - 1672-7681 (Print) -IS - 1672-7681 (Linking) -VI - 18 -IP - 2 -DP - 2021 Feb -TI - PD-1 blockade-unresponsive human tumor-infiltrating CD8(+) T cells are marked by - loss of CD28 expression and rescued by IL-15. -PG - 385-397 -LID - 10.1038/s41423-020-0427-6 [doi] -AB - Blockade of programmed death-1 (PD-1) reinvigorates exhausted CD8(+) T cells, - resulting in tumor regression in cancer patients. Recently, reinvigoration of - exhausted CD8(+) T cells following PD-1 blockade was shown to be CD28-dependent - in mouse models. Herein, we examined the role of CD28 in anti-PD-1 - antibody-induced human T cell reinvigoration using tumor-infiltrating CD8(+) T - cells (CD8(+) TILs) obtained from non-small-cell lung cancer patients. - Single-cell analysis demonstrated a distinct expression pattern of CD28 between - mouse and human CD8(+) TILs. Furthermore, we found that human CD28(+)CD8(+) but - not CD28(-)CD8(+) TILs responded to PD-1 blockade irrespective of B7/CD28 - blockade, indicating that CD28 costimulation in human CD8(+) TILs is dispensable - for PD-1 blockade-induced reinvigoration and that loss of CD28 expression serves - as a marker of anti-PD-1 antibody-unresponsive CD8(+) TILs. Transcriptionally and - phenotypically, PD-1 blockade-unresponsive human CD28(-)PD-1(+)CD8(+) TILs - exhibited characteristics of terminally exhausted CD8(+) T cells with low TCF1 - expression. Notably, CD28(-)PD-1(+)CD8(+) TILs had preserved machinery to respond - to IL-15, and IL-15 treatment enhanced the proliferation of CD28(-)PD-1(+)CD8(+) - TILs as well as CD28(+)PD-1(+)CD8(+) TILs. Taken together, these results show - that loss of CD28 expression is a marker of PD-1 blockade-unresponsive human - CD8(+) TILs with a TCF1(-) signature and provide mechanistic insights into - combining IL-15 with anti-PD-1 antibodies. -FAU - Kim, Kyung Hwan -AU - Kim KH -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. -AD - Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College - of Medicine, Seoul, Republic of Korea. -FAU - Kim, Hong Kwan -AU - Kim HK -AD - Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. -FAU - Kim, Hyung-Don -AU - Kim HD -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. -FAU - Kim, Chang Gon -AU - Kim CG -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. -FAU - Lee, Hoyoung -AU - Lee H -AD - Biomedical Science and Engineering Interdisciplinary Program, Korea Advanced - Institute of Science and Technology, Daejeon, Republic of Korea. -FAU - Han, Ji Won -AU - Han JW -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. -FAU - Choi, Seong Jin -AU - Choi SJ -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. -FAU - Jeong, Seongju -AU - Jeong S -AD - Biomedical Science and Engineering Interdisciplinary Program, Korea Advanced - Institute of Science and Technology, Daejeon, Republic of Korea. -FAU - Jeon, Minwoo -AU - Jeon M -AD - Biomedical Science and Engineering Interdisciplinary Program, Korea Advanced - Institute of Science and Technology, Daejeon, Republic of Korea. -FAU - Kim, Hyunglae -AU - Kim H -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. -FAU - Koh, Jiae -AU - Koh J -AD - Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan - University School of Medicine, Seoul, Republic of Korea. -AD - Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, - Seoul, Republic of Korea. -FAU - Ku, Bo Mi -AU - Ku BM -AD - Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan - University School of Medicine, Seoul, Republic of Korea. -FAU - Park, Su-Hyung -AU - Park SH -AUID- ORCID: 0000-0001-6363-7736 -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. -FAU - Ahn, Myung-Ju -AU - Ahn MJ -AD - Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, - Seoul, Republic of Korea. silkahn@skku.edu. -AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. - silkahn@skku.edu. -FAU - Shin, Eui-Cheol -AU - Shin EC -AUID- ORCID: 0000-0002-6308-9503 -AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of - Science and Technology, Daejeon, Republic of Korea. ecshin@kaist.ac.kr. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20200424 -PL - China -TA - Cell Mol Immunol -JT - Cellular & molecular immunology -JID - 101242872 -RN - 0 (CD28 Antigens) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Interleukin-15) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Animals -MH - CD28 Antigens/*metabolism -MH - CD8-Positive T-Lymphocytes/*immunology -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/*immunology/metabolism/pathology -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology -MH - Interleukin-15/*metabolism -MH - Lung Neoplasms/drug therapy/*immunology/metabolism/pathology -MH - Lymphocytes, Tumor-Infiltrating/*immunology -MH - Mice -MH - Mice, Inbred C57BL -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -PMC - PMC8027446 -OTO - NOTNLM -OT - CD28 -OT - IL-15 -OT - T cells -OT - TCF1 -OT - anti-PD-1 -COIS- The authors declare no competing interests. -EDAT- 2020/04/26 06:00 -MHDA- 2021/12/28 06:00 -PMCR- 2022/02/01 -CRDT- 2020/04/26 06:00 -PHST- 2019/11/12 00:00 [received] -PHST- 2020/03/22 00:00 [accepted] -PHST- 2020/04/26 06:00 [pubmed] -PHST- 2021/12/28 06:00 [medline] -PHST- 2020/04/26 06:00 [entrez] -PHST- 2022/02/01 00:00 [pmc-release] -AID - 10.1038/s41423-020-0427-6 [pii] -AID - 427 [pii] -AID - 10.1038/s41423-020-0427-6 [doi] -PST - ppublish -SO - Cell Mol Immunol. 2021 Feb;18(2):385-397. doi: 10.1038/s41423-020-0427-6. Epub - 2020 Apr 24. - -PMID- 32997195 -OWN - NLM -STAT- MEDLINE -DCOM- 20210325 -LR - 20221207 -IS - 1432-1335 (Electronic) -IS - 0171-5216 (Linking) -VI - 147 -IP - 4 -DP - 2021 Apr -TI - Morphological, immune and genetic features in biopsy sample associated with the - efficacy of pembrolizumab in patients with non-squamous non-small cell lung - cancer. -PG - 1227-1237 -LID - 10.1007/s00432-020-03413-5 [doi] -AB - INTRODUCTION: The usefulness of the histopathology of biopsy samples for - predicting the efficacy of immunotherapy in non-squamous, non-small cell lung - cancer (NSq NSCLC) patients remains unclear. METHODS: We retrospectively - investigated the associations between the histopathological features in biopsy - samples and survival outcomes in advanced NSq NSCLC patients receiving - pembrolizumab. NSq NSCLC was classified histopathologically as morphological - adenocarcinoma or non-small cell carcinoma (NSCC: absence of definitive features - of either adenocarcinoma or a squamous morphology). We investigated the - association between the tumor morphological features and immune/genetic features - by examining the tumor PD-L1 expression and tumor mutation burden (TMB). RESULTS: - Among 33 advanced NSq NSCLC patients with tumor PD-L1 scores ≥ 50% receiving - pembrolizumab as first-line therapy, a biopsy diagnosis of NSCC was associated - with a significantly longer progression-free survival [median 16.8 vs. - 2.3 months; hazard ratio (HR) 0.26; 95% CI 0.10-0.62, P = 0.01] and overall - survival (median NR vs. 10.1 months; HR 0.35; 0.12-0.97, P = 0.04) as compared to - that of morphological adenocarcinoma. In an analysis of 367 biopsy samples, the - NSCC group showed a higher percentage of samples with PD-L1 scores ≥ 50% than the - morphological adenocarcinoma group (35% vs. 10%). The NSCC group (n = 8) also - showed a significantly higher TMB than the morphological adenocarcinoma group - (n = 7) (median 236 vs. 25 mutations/whole exome, P = 0.01). CONCLUSION: Absence - of definitive morphological features in a biopsy sample could be a useful - predictor of the efficacy of pembrolizumab in NSq NSCLC patients with tumor PD-L1 - scores ≥ 50%, as these tumors are likely to show high tumor PD-L1 expression and - high TMB. -FAU - Sakai, Tetsuya -AU - Sakai T -AD - Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 - Kashiwanoha, Kashiwa, Chiba, 277-0882, Japan. -AD - Course of Advanced Clinical Research of Cancer, Juntendo University Graduate - School of Medicine, Tokyo, Japan. -AD - Department of Pathology and Clinical Laboratories, National Cancer Center - Hospital East, Kashiwa, Japan. -FAU - Udagawa, Hibiki -AU - Udagawa H -AUID- ORCID: 0000-0001-8822-2684 -AD - Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 - Kashiwanoha, Kashiwa, Chiba, 277-0882, Japan. hudagawa@east.ncc.go.jp. -FAU - Matsumoto, Shingo -AU - Matsumoto S -AD - Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 - Kashiwanoha, Kashiwa, Chiba, 277-0882, Japan. -FAU - Yoh, Kiyotaka -AU - Yoh K -AD - Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 - Kashiwanoha, Kashiwa, Chiba, 277-0882, Japan. -FAU - Nosaki, Kaname -AU - Nosaki K -AD - Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 - Kashiwanoha, Kashiwa, Chiba, 277-0882, Japan. -FAU - Ikeda, Takaya -AU - Ikeda T -AD - Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 - Kashiwanoha, Kashiwa, Chiba, 277-0882, Japan. -FAU - Zenke, Yoshitaka -AU - Zenke Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 - Kashiwanoha, Kashiwa, Chiba, 277-0882, Japan. -FAU - Kirita, Keisuke -AU - Kirita K -AD - Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 - Kashiwanoha, Kashiwa, Chiba, 277-0882, Japan. -FAU - Niho, Seiji -AU - Niho S -AD - Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 - Kashiwanoha, Kashiwa, Chiba, 277-0882, Japan. -FAU - Akimoto, Tetsuo -AU - Akimoto T -AD - Course of Advanced Clinical Research of Cancer, Juntendo University Graduate - School of Medicine, Tokyo, Japan. -AD - Department of Radiation Oncology and Particle Therapy, National Cancer Center - Hospital East, Kashiwa, Japan. -FAU - Goto, Koichi -AU - Goto K -AD - Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 - Kashiwanoha, Kashiwa, Chiba, 277-0882, Japan. -FAU - Ishii, Genichiro -AU - Ishii G -AD - Course of Advanced Clinical Research of Cancer, Juntendo University Graduate - School of Medicine, Tokyo, Japan. -AD - Department of Pathology and Clinical Laboratories, National Cancer Center - Hospital East, Kashiwa, Japan. -LA - eng -PT - Journal Article -DEP - 20200930 -PL - Germany -TA - J Cancer Res Clin Oncol -JT - Journal of cancer research and clinical oncology -JID - 7902060 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -RN - 0 (CD274 protein, human) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Adenocarcinoma of Lung/drug therapy/genetics/immunology/*pathology -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - Antineoplastic Agents, Immunological/therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors/immunology -MH - Biomarkers, Tumor/*genetics -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/immunology/*pathology -MH - Female -MH - Follow-Up Studies -MH - Gene Expression Regulation, Neoplastic -MH - Humans -MH - Lung Neoplasms/drug therapy/genetics/immunology/*pathology -MH - Male -MH - Middle Aged -MH - Neoplasm Recurrence, Local/drug therapy/genetics/immunology/*pathology -MH - Prognosis -MH - Retrospective Studies -MH - Survival Rate -MH - Exome Sequencing -OTO - NOTNLM -OT - Lung cancer -OT - Morphological features -OT - PD-L1 -OT - Pembrolizumab -OT - TMB -EDAT- 2020/10/01 06:00 -MHDA- 2021/03/26 06:00 -CRDT- 2020/09/30 12:16 -PHST- 2020/08/05 00:00 [received] -PHST- 2020/09/24 00:00 [accepted] -PHST- 2020/10/01 06:00 [pubmed] -PHST- 2021/03/26 06:00 [medline] -PHST- 2020/09/30 12:16 [entrez] -AID - 10.1007/s00432-020-03413-5 [pii] -AID - 10.1007/s00432-020-03413-5 [doi] -PST - ppublish -SO - J Cancer Res Clin Oncol. 2021 Apr;147(4):1227-1237. doi: - 10.1007/s00432-020-03413-5. Epub 2020 Sep 30. - -PMID- 33323401 -OWN - NLM -STAT- MEDLINE -DCOM- 20220210 -LR - 20220210 -IS - 1557-3265 (Electronic) -IS - 1078-0432 (Linking) -VI - 27 -IP - 5 -DP - 2021 Mar 1 -TI - Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in - Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. -PG - 1296-1304 -LID - 10.1158/1078-0432.CCR-20-3136 [doi] -AB - PURPOSE: Our preclinical work suggests that appropriate angiogenesis inhibition - could potentiate PD-1/PD-L1 blockade via alleviating hypoxia, increasing - infiltration of CD8(+) T cells and reducing recruitment of tumor-associated - macrophages. We hereby conducted a clinical trial to evaluate this combination in - pretreated patients with advanced non-small cell lung cancer (NSCLC). PATIENTS - AND METHODS: The study included phase Ib apatinib dose-escalation and phase II - expansion cohorts. Patients received apatinib at doses of 250-500 mg orally once - daily, in combination with camrelizumab 200 mg intravenously every 2 weeks. - RESULTS: From March 2017 to October 2018, 105 chemotherapy-pretreated patients - with nonsquamous NSCLC were enrolled and received apatinib 250 mg (recommended - phase II dose) and camrelizumab. Among them, one (1.0%) complete response, 28 - (26.7%) partial responses, and 48 (45.7%) stable diseases were observed. In the - efficacy-evaluable population (n = 94), objective response rate (ORR) was 30.9% - [95% confidence interval (CI), 21.7-41.2]. The median progression-free survival - was 5.7 months (95% CI, 4.5-8.8) and overall survival was 15.5 months (95% CI, - 10.9-24.5). Efficacy of combination therapy was evident across all PD-L1 and - tumor mutation burden subgroups, and appeared to be improved in patients with - STK11/KEAP1 mutation (mutant vs. wild-type, ORR: 42.9% vs. 28.1%; 1-year survival - rate: 85.1% vs. 53.1%). No unexpected adverse events were observed. CONCLUSIONS: - Combined apatinib and camrelizumab showed encouraging antitumor activity and - acceptable toxicity in chemotherapy-pretreated patients with advanced nonsquamous - NSCLC. Patients with STK11/KEAP1 mutation might derive more benefits from this - combination. We will validate these results in an ongoing phase III trial - (NCT04203485). -CI - ©2020 American Association for Cancer Research. -FAU - Zhou, Caicun -AU - Zhou C -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, - Shanghai, P.R. China. -FAU - Wang, Yina -AU - Wang Y -AD - Department of Oncology, The First Affiliated Hospital Zhejiang University, - Hangzhou, P.R. China. -FAU - Zhao, Jun -AU - Zhao J -AD - Department of Oncology, Beijing Cancer Hospital, Beijing, P.R. China. -FAU - Chen, Gongyan -AU - Chen G -AD - Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, P.R. - China. -FAU - Liu, Zhihua -AU - Liu Z -AD - Thoracic Tumor Radiotherapy Department, Jiangxi Cancer Hospital, Nanchang, P.R. - China. -FAU - Gu, Kangsheng -AU - Gu K -AD - Department of Oncology, The First Affiliated Hospital of Anhui Medical - University, Hefei, P.R. China. -FAU - Huang, Meijuan -AU - Huang M -AD - Department of Thoracic Oncology, West China Hospital of Sichuan University, - Chengdu, P.R. China. -FAU - He, Jianxing -AU - He J -AD - Thoracic Surgery Department, The First Affiliated Hospital of Guangzhou Medical - University, Guangzhou, P.R. China. -FAU - Chen, Jianhua -AU - Chen J -AD - Department of Medical Oncology, Hunan Cancer Hospital, Changsha, P.R. China. -FAU - Ma, Zhiyong -AU - Ma Z -AD - Department of Oncology, Henan Cancer Hospital, Zhengzhou, P.R. China. -FAU - Feng, Jifeng -AU - Feng J -AD - Department of Medical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of - Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, - Nanjing, P.R. China. -FAU - Shi, Jianhua -AU - Shi J -AD - Department of Oncology, Linyi Cancer Hospital, Linyi, P.R. China. -FAU - Yu, Xinmin -AU - Yu X -AD - Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, P.R. China. -FAU - Cheng, Ying -AU - Cheng Y -AD - Department of Medical Oncology, Jilin Cancer Hospital, Changchun, P.R. China. -FAU - Yao, Yu -AU - Yao Y -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, P.R. China. -FAU - Chen, Yuan -AU - Chen Y -AD - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong - University of Science and Technology, Wuhan, P.R. China. -FAU - Guo, Renhua -AU - Guo R -AUID- ORCID: 0000-0003-4475-8617 -AD - Department of Oncology, Jiangsu Province Hospital, Nanjing, P.R. China. -FAU - Lin, Xiaoyan -AU - Lin X -AD - Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, P.R. - China. -FAU - Wang, Zhehai -AU - Wang Z -AD - Department of Oncology, Shandong Cancer Hospital, Jinan, P.R. China. -FAU - Gao, Guanghui -AU - Gao G -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, - Shanghai, P.R. China. -FAU - Wang, Quanren -AU - Wang Q -AD - Department of Clinical Research and Development, Jiangsu Hengrui Medicine Co. - Ltd., Shanghai, P.R. China. -FAU - Li, Weixia -AU - Li W -AD - Department of Clinical Research and Development, Jiangsu Hengrui Medicine Co. - Ltd., Shanghai, P.R. China. -FAU - Yang, Xinfeng -AU - Yang X -AD - Department of Clinical Research and Development, Jiangsu Hengrui Medicine Co. - Ltd., Shanghai, P.R. China. -FAU - Wu, Lihong -AU - Wu L -AD - Genecast Precision Medicine Technology Institute, Beijing, P.R. China. -FAU - Zhang, Jun -AU - Zhang J -AD - Division of Medical Oncology, Department of Internal Medicine, Department of - Cancer Biology, University of Kansas Cancer Center (KUCC), University of Kansas - Medical Center (KUMC), Overland Park, Kansas. -FAU - Ren, Shengxiang -AU - Ren S -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, - Shanghai, P.R. China. harry_ren@tongji.edu.cn. -LA - eng -SI - ClinicalTrials.gov/NCT04203485 -PT - Clinical Trial, Phase I -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -DEP - 20201215 -PL - United States -TA - Clin Cancer Res -JT - Clinical cancer research : an official journal of the American Association for - Cancer Research -JID - 9502500 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Biomarkers, Tumor) -RN - 0 (Pyridines) -RN - 5S371K6132 (apatinib) -RN - 73096E137E (camrelizumab) -SB - IM -MH - Adolescent -MH - Adult -MH - Aged -MH - Antibodies, Monoclonal, Humanized/administration & dosage -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Biomarkers, Tumor/*metabolism -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/pathology -MH - Case-Control Studies -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Lung Neoplasms/*drug therapy/metabolism/pathology -MH - Male -MH - Middle Aged -MH - Prognosis -MH - Pyridines/administration & dosage -MH - Retrospective Studies -MH - Survival Rate -MH - Young Adult -EDAT- 2020/12/17 06:00 -MHDA- 2022/02/11 06:00 -CRDT- 2020/12/16 05:27 -PHST- 2020/08/09 00:00 [received] -PHST- 2020/10/16 00:00 [revised] -PHST- 2020/12/10 00:00 [accepted] -PHST- 2020/12/17 06:00 [pubmed] -PHST- 2022/02/11 06:00 [medline] -PHST- 2020/12/16 05:27 [entrez] -AID - 1078-0432.CCR-20-3136 [pii] -AID - 10.1158/1078-0432.CCR-20-3136 [doi] -PST - ppublish -SO - Clin Cancer Res. 2021 Mar 1;27(5):1296-1304. doi: 10.1158/1078-0432.CCR-20-3136. - Epub 2020 Dec 15. - -PMID- 35304712 -OWN - NLM -STAT- MEDLINE -DCOM- 20220815 -LR - 20220815 -IS - 1863-6713 (Electronic) -IS - 1863-6705 (Linking) -VI - 70 -IP - 9 -DP - 2022 Sep -TI - Safety of salvage lung resection after immunotherapy for unresectable non-small - cell lung cancer. -PG - 812-817 -LID - 10.1007/s11748-022-01798-3 [doi] -AB - BACKGROUND: The safety of salvage lung resection after immune checkpoint - inhibitor (ICI) therapy in patients with advanced non-small cell lung cancer - (NSCLC) is not well understood. METHODS: In this retrospective multicenter study, - we reviewed perioperative morbidity and mortality rates in 11 patients (8 men, 3 - women; median age 70 years) who underwent salvage lung resection for unresectable - NSCLC after ICI therapy in the 4 years since 2017. Operative factors were also - compared according to operating time (> 6 h, n = 7; < 6 h, n = 4). RESULTS: The - clinical stage at the time of diagnosis was IIIA in 2 patients, IIIB in 4, IVA in - 2, and IVB in 3. Eight patients received pembrolizumab and 3 received durvalumab. - Two patients received an ICI agent alone, 3 underwent chemoradiotherapy, and 6 - received chemotherapy. Lobectomy was performed in 10 cases and bilobectomy in 1 - case. All patients underwent complete resection. Median operating time was 429 - (range 169-570) min with a median blood loss of 199 (range 10-5, 140) mL. The - only intraoperative complication was damage to the pulmonary artery. The - perioperative morbidity and mortality rates were 27% and 0%, respectively. The - 90-day mortality rate was 9% (1 patient died of acute exacerbation of - interstitial pneumonia). Patients in whom the operating time was > 6 h more - frequently had lymph node metastasis at the time of initial diagnosis (100% vs - 25%, p = 0.02). CONCLUSIONS: Salvage lung resection was tolerated after ICI - therapy in these patients. Lymph node metastasis at the time of initial diagnosis - might make salvage surgery difficult. -CI - © 2022. The Author(s), under exclusive licence to The Japanese Association for - Thoracic Surgery. -FAU - Ueno, Tsuyoshi -AU - Ueno T -AUID- ORCID: 0000-0002-7629-2834 -AD - Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer - Center, Matsuyama, Japan. ueno.tsuyoshi.qz@mail.hosp.go.jp. -FAU - Yamashita, Motohiro -AU - Yamashita M -AD - Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer - Center, Matsuyama, Japan. -FAU - Yamashita, Natsumi -AU - Yamashita N -AD - Department of Clinical Research Center, National Hospital Organization Shikoku - Cancer Center, Matsuyama, Japan. -FAU - Uomoto, Masashi -AU - Uomoto M -AD - Department of Thoracic Surgery, Matsuyama Shimin Hospital, Matsuyama, Japan. -FAU - Kawamata, Osamu -AU - Kawamata O -AD - Department of Surgery, Onomichi Municipal Hospital, Onomichi, Japan. -FAU - Sano, Yoshifumi -AU - Sano Y -AD - Department of Cardiovascular and Thoracic Surgery, Ehime University Medical - School, Toon, Japan. -FAU - Inokawa, Hidetoshi -AU - Inokawa H -AD - Division of Thoracic Surgery, National Hospital Organization Yamaguchi-Ube - Medical Center, Ube, Japan. -FAU - Hirayama, Shin -AU - Hirayama S -AD - Department of Thoracic Surgery, Nozaki Tokushukai Hospital, Daitou, Japan. -FAU - Okazaki, Mikio -AU - Okazaki M -AD - Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan. -FAU - Toyooka, Shinichi -AU - Toyooka S -AD - Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan. -LA - eng -PT - Journal Article -PT - Review -DEP - 20220319 -PL - Japan -TA - Gen Thorac Cardiovasc Surg -JT - General thoracic and cardiovascular surgery -JID - 101303952 -SB - IM -MH - Aged -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/surgery -MH - Female -MH - Humans -MH - Immunotherapy -MH - Lung/pathology -MH - *Lung Neoplasms/surgery -MH - Lymphatic Metastasis -MH - Male -MH - Multicenter Studies as Topic -MH - Neoplasm Staging -MH - Retrospective Studies -MH - Salvage Therapy/adverse effects -OTO - NOTNLM -OT - Immunotherapy -OT - Non-small cell lung cancer -OT - Salvage surgery -EDAT- 2022/03/20 06:00 -MHDA- 2022/08/16 06:00 -CRDT- 2022/03/19 05:33 -PHST- 2022/01/13 00:00 [received] -PHST- 2022/03/01 00:00 [accepted] -PHST- 2022/03/20 06:00 [pubmed] -PHST- 2022/08/16 06:00 [medline] -PHST- 2022/03/19 05:33 [entrez] -AID - 10.1007/s11748-022-01798-3 [pii] -AID - 10.1007/s11748-022-01798-3 [doi] -PST - ppublish -SO - Gen Thorac Cardiovasc Surg. 2022 Sep;70(9):812-817. doi: - 10.1007/s11748-022-01798-3. Epub 2022 Mar 19. - -PMID- 32313723 -OWN - NLM -STAT- MEDLINE -DCOM- 20210728 -LR - 20240330 -IS - 2162-4011 (Print) -IS - 2162-402X (Electronic) -IS - 2162-4011 (Linking) -VI - 9 -IP - 1 -DP - 2020 -TI - Identifying optimal first-line interventions for advanced non-small cell lung - carcinoma according to PD-L1 expression: a systematic review and network - meta-analysis. -PG - 1746112 -LID - 10.1080/2162402X.2020.1746112 [doi] -LID - 1746112 -AB - This network meta-analysis (NMA), based on one phase II and nine phase III - studies, involving 6,124 patients with metastatic NSCLC, indirectly compares - Atezolizumab + Bevacizumab + chemotherapy (ABC), Atezolizumab + chemotherapy - (AC), Pembrolizumab + chemotherapy (PC), Pembrolizumab alone, Bevacizumab + - chemotherapy (BC) and chemotherapy alone. Each of these is recommended as - front-line interventions, according to the US FDA and the European Medicines - Agency (EMA) for advanced NSCLC without EGFR mutation or ALK rearrangement. - Studies were identified through PubMed, EMBASE, the Cochrane Library, Medline, - and abstracts found in oncology articles. Primary endpoints, i.e., - progression-free survival (PFS) and overall survival (OS) with corresponding - hazard ratios (HR), objective response rates (ORR) and adverse event (AEs) with - odds risk (OR) were pooled according to frequentist network meta-analytical - techniques. PD-L1 expression thresholds, as well as non-squamous/squamous were - used to determine subgroups. Immunotherapy plus chemotherapy appeared superior to - Pembrolizumab alone for PD-L1-high (i.e., TPS≥50%) NSCLC patients. BC might also - be specifically recommended as an initial first-line treatment for PD-L1-high, - non-squamous NSCLC patients, since BC was not inferior to Pembrolizumab alone. PC - and ABC might be preferred for NSCLC patients with intermediate PD-L1 (1% ≤PD-L1, - TPS<50%) expression. BC can also be tentatively recommended specifically for - PD-L1-intermediate, non-squamous NSCLC patients. Combined immunotherapies can all - be recommended for PD-L1-negative (i.e., TPS<1%) NSCLC patients, although - especially the ABC combination for non-squamous NSCLC patients, which was - superior to PC in regards of PFS. However, PC performed comparable to ABC in the - whole population and in all subgroup save this one. More predictive biomarkers - could be factored into further analyses to help identifying the most effective - treatment regimens for specific patient groups. -CI - © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. -FAU - Liu, Jie -AU - Liu J -AD - School of Medicine and Life Sciences, University of Jinan-Shandong Academy of - Medical Sciences, Jinan, Shandong, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Li, Chengming -AU - Li C -AD - School of Medicine and Life Sciences, University of Jinan-Shandong Academy of - Medical Sciences, Jinan, Shandong, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Seery, Samuel -AU - Seery S -AD - Department of Humanities, Peking Union Medical College, Chinese Academy of - Medical Sciences and Peking Union Medical College, Beijing, China. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Meng, Xue -AU - Meng X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Research Support, Non-U.S. Gov't -PT - Review -PT - Systematic Review -DEP - 20200407 -PL - United States -TA - Oncoimmunology -JT - Oncoimmunology -JID - 101570526 -RN - 0 (B7-H1 Antigen) -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - B7-H1 Antigen/genetics -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Network Meta-Analysis -PMC - PMC7153822 -OTO - NOTNLM -OT - Non-Small-Cell-Lung-Carcinoma -OT - PD-L1 -OT - adverse events -OT - cancer -OT - combined -OT - expression -OT - interventions -OT - network meta-analysis -OT - survival -OT - systematic review -EDAT- 2020/04/22 06:00 -MHDA- 2020/04/22 06:01 -PMCR- 2020/04/07 -CRDT- 2020/04/22 06:00 -PHST- 2019/10/27 00:00 [received] -PHST- 2020/02/06 00:00 [revised] -PHST- 2020/02/06 00:00 [accepted] -PHST- 2020/04/22 06:00 [entrez] -PHST- 2020/04/22 06:00 [pubmed] -PHST- 2020/04/22 06:01 [medline] -PHST- 2020/04/07 00:00 [pmc-release] -AID - 1746112 [pii] -AID - 10.1080/2162402X.2020.1746112 [doi] -PST - epublish -SO - Oncoimmunology. 2020 Apr 7;9(1):1746112. doi: 10.1080/2162402X.2020.1746112. - eCollection 2020. - -PMID- 37153619 -OWN - NLM -STAT- MEDLINE -DCOM- 20230510 -LR - 20230510 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 14 -DP - 2023 -TI - Research progress of extracellular vesicles as biomarkers in immunotherapy for - non-small cell lung cancer. -PG - 1114041 -LID - 10.3389/fimmu.2023.1114041 [doi] -LID - 1114041 -AB - Lung cancer is one of the most severe forms of malignancy and a leading cause of - cancer-related death worldwide, of which non-small cell lung cancer (NSCLC) is - the most primary type observed in the clinic. NSCLC is mainly treated with - surgery, radiotherapy, and chemotherapy. Additionally, targeted therapy and - immunotherapy have also shown promising results. Several immunotherapies, - including immune checkpoint inhibitors, have been developed for clinical use and - have benefited patients with NSCLC. However, immunotherapy faces several - challenges like poor response and unknown effective population. It is essential - to identify novel predictive markers to further advance precision immunotherapy - for NSCLC. Extracellular vesicles (EVs) present an important research direction. - In this review, we focus on the role of EVs as a biomarker in NSCLC immunotherapy - considering various perspectives, including the definition and properties of EVs, - their role as biomarkers in current NSCLC immunotherapy, and different EV - components as biomarkers in NSCLC immunotherapy research. We describe the - cross-talk between the role of EVs as biomarkers and novel technical approaches - or research concepts in NSCLC immunotherapy, such as neoadjuvants, multi-omics - analysis, and the tumour microenvironment. This review will provide a reference - for future research to improve the benefits of immunotherapy for patients with - NSCLC. -CI - Copyright © 2023 Ge, Ye, Fu, Jiang, Song, Liu, Wang and Wang. -FAU - Ge, Yang -AU - Ge Y -AD - Graduate School, Anhui University of Chinese Medicine, Hefei, China. -FAU - Ye, Ting -AU - Ye T -AD - Graduate School, Anhui University of Chinese Medicine, Hefei, China. -FAU - Fu, Siyun -AU - Fu S -AD - Department of Cellular and Molecular Biology, Beijing Chest Hospital, Capital - Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, - Beijing, China. -FAU - Jiang, Xiaoying -AU - Jiang X -AD - Department of Science and Technology, Beijing Chest Hospital, Capital Medical - University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, - China. -FAU - Song, Hang -AU - Song H -AD - School of Integrated Chinese and Western Medicine, Anhui University of Chinese - Medicine, Hefei, China. -FAU - Liu, Bin -AU - Liu B -AD - Department of Cellular and Molecular Biology, Beijing Chest Hospital, Capital - Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, - Beijing, China. -FAU - Wang, Guoquan -AU - Wang G -AD - School of Integrated Chinese and Western Medicine, Anhui University of Chinese - Medicine, Hefei, China. -FAU - Wang, Jinghui -AU - Wang J -AD - Department of Cellular and Molecular Biology, Beijing Chest Hospital, Capital - Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, - Beijing, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20230421 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Biomarkers) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Biomarkers -MH - Immunotherapy/methods -MH - *Extracellular Vesicles/metabolism -MH - Tumor Microenvironment -PMC - PMC10162406 -OTO - NOTNLM -OT - EV -OT - NSCLC -OT - TME -OT - biomarker -OT - chemoimmunotherapy -OT - immunotherapy -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2023/05/08 06:42 -MHDA- 2023/05/10 06:42 -PMCR- 2023/01/01 -CRDT- 2023/05/08 04:17 -PHST- 2022/12/02 00:00 [received] -PHST- 2023/04/07 00:00 [accepted] -PHST- 2023/05/10 06:42 [medline] -PHST- 2023/05/08 06:42 [pubmed] -PHST- 2023/05/08 04:17 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2023.1114041 [doi] -PST - epublish -SO - Front Immunol. 2023 Apr 21;14:1114041. doi: 10.3389/fimmu.2023.1114041. - eCollection 2023. - -PMID- 28403675 -OWN - NLM -STAT- MEDLINE -DCOM- 20170605 -LR - 20240210 -IS - 1744-8328 (Electronic) -IS - 1473-7140 (Linking) -VI - 17 -IP - 6 -DP - 2017 Jun -TI - Advances in the use of surgery and multimodality treatment for N2 non-small cell - lung cancer. -PG - 555-561 -LID - 10.1080/14737140.2017.1319766 [doi] -AB - Stage IIIA-N2 non-small cell lung cancer (NSCLC) represents a heterogeneous group - of bronchogenic carcinomas with locoregional involvement. Different categories of - N2 disease exist, ranging from unexpectedly encountered N2 involvement after - detailed preoperative staging or 'surprise' N2, to potentially resectable disease - treated within a combined modality setting, and finally, bulky N2 involvement - treated by chemoradiation. Areas covered: Large randomised controlled trials and - meta-analyses on stage IIIA-N2 NSCLC have been published but their implications - for treatment remain a matter of debate. No definite recommendations can be - provided as diagnostic and therapeutic algorithms vary according to local, - national or international guidelines. Expert commentary: From the literature, it - is clear that patients with stage IIIA-N2 NSCLC should be treated by combined - modality therapy including chemotherapy, radiotherapy and surgery. The relative - contribution of each modality has not been firmly established. For patients - undergoing induction therapy, adequate restaging is important as only down-staged - patients will clearly benefit from surgical resection. Each patient should be - discussed within a multidisciplinary team to determine the best diagnostic and - therapeutic approach according to the specific local expertise. In the near - future, it might be expected that targeted therapies and immunotherapy will be - incorporated as possible therapeutic options. -FAU - Van Schil, Paul E -AU - Van Schil PE -AD - a Department of Thoracic and Vascular Surgery , Antwerp University Hospital , - Edegem (Antwerp) , Belgium. -FAU - Yogeswaran, Krishan -AU - Yogeswaran K -AD - a Department of Thoracic and Vascular Surgery , Antwerp University Hospital , - Edegem (Antwerp) , Belgium. -FAU - Hendriks, Jeroen M -AU - Hendriks JM -AD - a Department of Thoracic and Vascular Surgery , Antwerp University Hospital , - Edegem (Antwerp) , Belgium. -FAU - Lauwers, Patrick -AU - Lauwers P -AD - a Department of Thoracic and Vascular Surgery , Antwerp University Hospital , - Edegem (Antwerp) , Belgium. -FAU - Faivre-Finn, Corinne -AU - Faivre-Finn C -AD - b Division of Molecular and Clinical Cancer Sciences , University of Manchester , - Manchester , UK. -LA - eng -GR - 20465/CRUK_/Cancer Research UK/United Kingdom -PT - Journal Article -PT - Review -DEP - 20170421 -PL - England -TA - Expert Rev Anticancer Ther -JT - Expert review of anticancer therapy -JID - 101123358 -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/pathology/*therapy -MH - Combined Modality Therapy -MH - Humans -MH - Lung Neoplasms/pathology/*therapy -MH - Neoplasm Staging -MH - Patient Care Team/*organization & administration -MH - Randomized Controlled Trials as Topic -OTO - NOTNLM -OT - Lung cancer -OT - chemotherapy -OT - induction therapy -OT - multimodality therapy -OT - prognosis -OT - radiotherapy -OT - stage IIIA-N2 -OT - surgery -OT - treatment -EDAT- 2017/04/14 06:00 -MHDA- 2017/06/06 06:00 -CRDT- 2017/04/14 06:00 -PHST- 2017/04/14 06:00 [pubmed] -PHST- 2017/06/06 06:00 [medline] -PHST- 2017/04/14 06:00 [entrez] -AID - 10.1080/14737140.2017.1319766 [doi] -PST - ppublish -SO - Expert Rev Anticancer Ther. 2017 Jun;17(6):555-561. doi: - 10.1080/14737140.2017.1319766. Epub 2017 Apr 21. - -PMID- 33125909 -OWN - NLM -STAT- MEDLINE -DCOM- 20210104 -LR - 20220413 -IS - 1474-5488 (Electronic) -IS - 1470-2045 (Print) -IS - 1470-2045 (Linking) -VI - 21 -IP - 12 -DP - 2020 Dec -TI - Biomarker-driven therapies for previously treated squamous non-small-cell lung - cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. -PG - 1589-1601 -LID - S1470-2045(20)30475-7 [pii] -LID - 10.1016/S1470-2045(20)30475-7 [doi] -AB - BACKGROUND: The Lung Cancer Master Protocol (Lung-MAP; S1400) is a completed - biomarker-driven master protocol designed to address an unmet need for better - therapies for squamous non-small-cell lung cancer. Lung-MAP (S1400) was created - to establish an infrastructure for biomarker screening and rapid regulatory - intent evaluation of targeted therapies and was the first biomarker-driven master - protocol initiated with the US National Cancer Institute (NCI). METHODS: Lung-MAP - (S1400) was done within the National Clinical Trials Network of the NCI using a - public-private partnership. Eligible patients were aged 18 years or older, had - stage IV or recurrent squamous non-small-cell lung cancer, had previously been - treated with platinum-based chemotherapy, and had an Eastern Cooperative Oncology - Group (ECOG) performance status of 0-2. The study included a screening component - using the FoundationOne assay (Foundation Medicine, Cambridge, MA, USA) for - next-generation sequencing, and a clinical trial component with biomarker-driven - substudies and non-match substudies for patients who were ineligible for - biomarker-driven substudies. Patients were pre-screened and received their - substudy assignment upon progression, or they were screened at progression and - received their substudy assignment upon completion of testing. Patients could - enrol onto additional substudies after progression on a substudy. The study is - registered with ClinicalTrials.gov, NCT02154490, and all research related to - Lung-MAP (S1400) is completed. FINDINGS: Between June 16, 2014, and Jan 28, 2019, - 1864 patients enrolled and 1841 (98·9%) submitted tissue. 1674 (90·9%) of 1841 - patients had biomarker results, and 1404 (83·9%) of 1674 patients received a - substudy assignment. Of the assigned patients, 655 (46·7%) registered to a - substudy. The biomarker-driven substudies evaluated taselisib (targeting PIK3CA - alterations), palbociclib (cell cycle gene alterations), AZD4547 (FGFR - alteration), rilotumumab plus erlotinib (MET), talazoparib (homologous - recombination repair deficiency), and telisotuzumab vedotin (MET). The non-match - substudies evaluated durvalumab, and nivolumab plus ipilimumab for anti-PD-1 or - anti-PD-L1-naive disease, and durvalumab plus tremelimumab for anti-PD-1 or - anti-PD-L1 relapsed disease. Combining data from the substudies, ten (7·0%) of - 143 patients responded to targeted therapy, 53 (16·8%) of 315 patients responded - to anti-PD-1 or anti-PD-L1 therapy for immunotherapy-naive disease, and three - (5·4%) of 56 responded to docetaxel in the second line of therapy. Median overall - survival was 5·9 months (95% CI 4·8-7·8) for the targeted therapy groups, 7·7 - months (6·7-9·2) for the docetaxel groups, and 10·8 months (9·4-12·3) for the - anti-PD-1 or anti-PD-L1-containing groups. Median progression-free survival was - 2·5 months (95% CI 1·7-2·8) for the targeted therapy groups, 2·7 months (1·9-2·9) - for the docetaxel groups, and 3·0 months (2·7-3·9) for the anti-PD-1 or - anti-PD-L1-containing groups. INTERPRETATION: Lung-MAP (S1400) met its goal to - quickly address biomarker-driven therapy questions in squamous non-small-cell - lung cancer. In early 2019, a new screening protocol was implemented expanding to - all histological types of non-small-cell lung cancer and to add focus on - immunotherapy combinations for anti-PD-1 and anti-PD-L1 therapy-relapsed disease. - With these changes, Lung-MAP continues to meet its goal to focus on unmet needs - in the treatment of advanced lung cancers. FUNDING: US National Institutes of - Health, and AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Genentech, and - Pfizer through the Foundation for the National Institutes of Health. -CI - Copyright © 2020 Elsevier Ltd. All rights reserved. -FAU - Redman, Mary W -AU - Redman MW -AD - SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research - Center, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer - Research Center, Seattle, WA, USA. Electronic address: mredman@fredhutch.org. -FAU - Papadimitrakopoulou, Vassiliki A -AU - Papadimitrakopoulou VA -AD - Department of Thoracic Head and Neck Medical Oncology, Division of Cancer - Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. -FAU - Minichiello, Katherine -AU - Minichiello K -AD - SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research - Center, Seattle, WA, USA; Public Health Sciences Division, Fred Hutchinson Cancer - Research Center, Seattle, WA, USA. -FAU - Hirsch, Fred R -AU - Hirsch FR -AD - Department of Medicine, Division of Hematology and Oncology, Tisch Cancer - Institute at Mount Sinai, New York, NY, USA. -FAU - Mack, Philip C -AU - Mack PC -AD - Department of Medicine, Division of Hematology and Oncology, Tisch Cancer - Institute at Mount Sinai, New York, NY, USA. -FAU - Schwartz, Lawrence H -AU - Schwartz LH -AD - Department of Radiology, Division of Abdominal Imaging, Columbia University - Medical College, New York, NY, USA. -FAU - Vokes, Everett -AU - Vokes E -AD - Department of Medicine, University of Chicago, Chicago, IL, USA. -FAU - Ramalingam, Suresh -AU - Ramalingam S -AD - Department of Hematology and Oncology, Emory University, Atlanta, GA, USA. -FAU - Leighl, Natasha -AU - Leighl N -AD - Princess Margaret Hospital, Toronto, ON, Canada. -FAU - Bradley, Jeff -AU - Bradley J -AD - Department of Radiation Oncology, Emory University, Atlanta, GA, USA. -FAU - Miao, Jieling -AU - Miao J -AD - SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research - Center, Seattle, WA, USA; Public Health Sciences Division, Fred Hutchinson Cancer - Research Center, Seattle, WA, USA. -FAU - Moon, James -AU - Moon J -AD - SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research - Center, Seattle, WA, USA; Public Health Sciences Division, Fred Hutchinson Cancer - Research Center, Seattle, WA, USA. -FAU - Highleyman, Louise -AU - Highleyman L -AD - SWOG Data Operations Center, Cancer Research and Biostatistics, Seattle, WA, USA. -FAU - Miwa, Crystal -AU - Miwa C -AD - SWOG Operations Office, San Antonio, TX, USA. -FAU - LeBlanc, Michael L -AU - LeBlanc ML -AD - SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research - Center, Seattle, WA, USA; Public Health Sciences Division, Fred Hutchinson Cancer - Research Center, Seattle, WA, USA. -FAU - Malik, Shakun -AU - Malik S -AD - National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. -FAU - Miller, Vincent A -AU - Miller VA -AD - Foundation Medicine, Cambridge, MA, USA. -FAU - Sigal, Ellen V -AU - Sigal EV -AD - Friends of Cancer Research, Washington, DC, USA. -FAU - Adam, Stacey -AU - Adam S -AD - Foundation for the National Institutes of Health, Bethesda, MD, USA. -FAU - Wholley, David -AU - Wholley D -AD - Foundation for the National Institutes of Health, Bethesda, MD, USA. -FAU - Sigman, Caroline -AU - Sigman C -AD - CCS Associates, San Jose, CA, USA. -FAU - Smolich, Beverly -AU - Smolich B -AD - CCS Associates, San Jose, CA, USA. -FAU - Blanke, Charles D -AU - Blanke CD -AD - SWOG Group Chair's Office and Knight Cancer Institute, School of Medicine, Oregon - Health and Science University, Portland, OR, USA. -FAU - Kelly, Karen -AU - Kelly K -AD - Department of Internal Medicine, UC Davis Comprehensive Cancer Center, - Sacramento, CA, USA. -FAU - Gandara, David R -AU - Gandara DR -AD - Department of Internal Medicine, UC Davis Comprehensive Cancer Center, - Sacramento, CA, USA. -FAU - Herbst, Roy S -AU - Herbst RS -AD - Department of Medicine, Yale Cancer Center, New Haven, CT, USA. -LA - eng -SI - ClinicalTrials.gov/NCT02154490 -GR - P30 CA093373/CA/NCI NIH HHS/United States -GR - UG1 CA189971/CA/NCI NIH HHS/United States -GR - UL1 TR001863/TR/NCATS NIH HHS/United States -GR - U10 CA180821/CA/NCI NIH HHS/United States -GR - UG1 CA189858/CA/NCI NIH HHS/United States -GR - UG1 CA189830/CA/NCI NIH HHS/United States -GR - UG1 CA239767/CA/NCI NIH HHS/United States -GR - U10 CA180828/CA/NCI NIH HHS/United States -GR - UG1 CA233340/CA/NCI NIH HHS/United States -GR - U10 CA180820/CA/NCI NIH HHS/United States -GR - U10 CA180888/CA/NCI NIH HHS/United States -GR - U10 CA180819/CA/NCI NIH HHS/United States -GR - U10 CA180868/CA/NCI NIH HHS/United States -GR - U10 CA180826/CA/NCI NIH HHS/United States -GR - UG1 CA233329/CA/NCI NIH HHS/United States -GR - UG1 CA189821/CA/NCI NIH HHS/United States -GR - U10 CA180858/CA/NCI NIH HHS/United States -GR - U10 CA180846/CA/NCI NIH HHS/United States -PT - Clinical Trial -PT - Journal Article -PT - Multicenter Study -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20201027 -PL - England -TA - Lancet Oncol -JT - The Lancet. Oncology -JID - 100957246 -RN - 0 (Biomarkers, Tumor) -SB - IM -CIN - Lancet Oncol. 2020 Dec;21(12):1539-1541. doi: 10.1016/S1470-2045(20)30553-2. - PMID: 33125908 -CIN - Signal Transduct Target Ther. 2021 Apr 1;6(1):141. doi: - 10.1038/s41392-021-00557-9. PMID: 33795635 -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Biomarkers, Tumor/*genetics -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/mortality/pathology -MH - Carcinoma, Squamous Cell/*drug therapy/genetics/mortality/pathology -MH - Clinical Decision-Making -MH - Disease Progression -MH - Female -MH - *High-Throughput Nucleotide Sequencing -MH - Humans -MH - Lung Neoplasms/*drug therapy/genetics/mortality/pathology -MH - Male -MH - Middle Aged -MH - *Molecular Targeted Therapy -MH - Neoplasm Recurrence, Local -MH - Neoplasm Staging -MH - *Precision Medicine -MH - Predictive Value of Tests -MH - Progression-Free Survival -MH - Time Factors -MH - Young Adult -PMC - PMC8109255 -MID - NIHMS1644275 -EDAT- 2020/10/31 06:00 -MHDA- 2021/01/05 06:00 -PMCR- 2021/12/01 -CRDT- 2020/10/30 20:08 -PHST- 2020/06/02 00:00 [received] -PHST- 2020/07/30 00:00 [revised] -PHST- 2020/08/05 00:00 [accepted] -PHST- 2020/10/31 06:00 [pubmed] -PHST- 2021/01/05 06:00 [medline] -PHST- 2020/10/30 20:08 [entrez] -PHST- 2021/12/01 00:00 [pmc-release] -AID - S1470-2045(20)30475-7 [pii] -AID - 10.1016/S1470-2045(20)30475-7 [doi] -PST - ppublish -SO - Lancet Oncol. 2020 Dec;21(12):1589-1601. doi: 10.1016/S1470-2045(20)30475-7. Epub - 2020 Oct 27. - -PMID- 37574133 -OWN - NLM -STAT- MEDLINE -DCOM- 20231027 -LR - 20231027 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 18 -IP - 11 -DP - 2023 Nov -TI - Current and Future Treatment Options in the Management of Stage III NSCLC. -PG - 1478-1491 -LID - S1556-0864(23)00731-1 [pii] -LID - 10.1016/j.jtho.2023.08.011 [doi] -AB - For much of the past two decades, the treatment options for patients with stage - III NSCLC were mostly stagnant. In the past 5 years, ongoing innovations have - dovetailed alongside advances in biomarker testing, novel therapeutics, precision - surgery, and radiotherapy, all of which are leading to an increase in more - personalized option for the treatment. This review article will focus on several - completed and ongoing initiatives involving treatment of patients with stage III - NSCLC. First, it will tackle the progress made in curative treatment of - unresectable stage III NSCLC, starting with PACIFIC, and branching out into - topics such as concurrent immunotherapy and chemoradiation, intensification of - consolidative immunotherapy, dual immunotherapy consolidation, and a reflection - on those subpopulations that may not benefit from consolidative immunotherapy. - Second, there will be discussion of novel strategies in the setting of resectable - stage III disease, most notably neoadjuvant therapy using combined - chemoimmunotherapy and immunotherapy alone before surgical resection. Third, it - will delve into recent data evaluating adjuvant immunotherapy for resectable - stage III NSCLC, including adjuvant targeted therapy (for those harboring driver - mutations) and postoperative radiotherapy. Finally, a look to future - trials/initiatives will be interspersed throughout the review, to reveal the - ongoing efforts being made to continue to improve outcomes in this group of - patients. -CI - Copyright © 2023 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Li, Yuchen -AU - Li Y -AD - Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, - Ontario, Canada. -FAU - Juergens, Rosalyn Anne -AU - Juergens RA -AD - Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, - Ontario, Canada. -FAU - Finley, Christian -AU - Finley C -AD - Department of Surgery, McMaster University, St. Joseph's Healthcare Hamilton, - Ontario, Canada. -FAU - Swaminath, Anand -AU - Swaminath A -AD - Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, - Ontario, Canada. Electronic address: swaminath@hhsc.ca. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230811 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -SB - IM -MH - Humans -MH - *Lung Neoplasms/pathology -MH - Neoplasm Staging -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - Combined Modality Therapy -MH - Neoadjuvant Therapy -MH - Immunotherapy -OTO - NOTNLM -OT - Chemotherapy -OT - Immunotherapy -OT - Non–small cell lung cancer -OT - Radiotherapy -OT - Stage III -OT - Surgery -EDAT- 2023/08/14 00:42 -MHDA- 2023/10/27 06:42 -CRDT- 2023/08/13 19:27 -PHST- 2023/03/07 00:00 [received] -PHST- 2023/07/31 00:00 [revised] -PHST- 2023/08/08 00:00 [accepted] -PHST- 2023/10/27 06:42 [medline] -PHST- 2023/08/14 00:42 [pubmed] -PHST- 2023/08/13 19:27 [entrez] -AID - S1556-0864(23)00731-1 [pii] -AID - 10.1016/j.jtho.2023.08.011 [doi] -PST - ppublish -SO - J Thorac Oncol. 2023 Nov;18(11):1478-1491. doi: 10.1016/j.jtho.2023.08.011. Epub - 2023 Aug 11. - -PMID- 30445271 -OWN - NLM -STAT- MEDLINE -DCOM- 20190107 -LR - 20190610 -IS - 1532-1967 (Electronic) -IS - 0305-7372 (Linking) -VI - 72 -DP - 2019 Jan -TI - EGFR-directed monoclonal antibodies in combination with chemotherapy for - treatment of non-small-cell lung cancer: an updated review of clinical trials and - new perspectives in biomarkers analysis. -PG - 15-27 -LID - S0305-7372(18)30137-3 [pii] -LID - 10.1016/j.ctrv.2018.08.002 [doi] -AB - Lung cancer still represents one of the most common and fatal neoplasm, - accounting for nearly 30% of all cancer-related deaths. Targeted therapies based - on molecular tumor features and programmed death-1 (PD-1)/programmed death - ligand-1 (PDL-1) blockade immunotherapy have offered new therapeutic options for - patients with advanced non-small-cell lung cancer (NSCLC). Activation of the - epidermal growth factor receptor (EGFR)-pathway promotes tumor growth and - progression, including angiogenesis, invasion, metastasis and inhibition of - apoptosis, providing a strong rationale for targeting this pathway. EGFR - expression is detected in up to 85% of NSCLC and has been demonstrated to be - associated with poor prognosis. Two approaches for blocking EGFR signaling are - available: prevention of ligand binding to the extracellular domain with - monoclonal antibodies (mAbs) and inhibition of the intracellular tyrosine kinase - activity with small molecules. There is a strong rationale to consider the - tumor's level of EGFR expression as one of the most significant predictive - biomarkers in this setting. In this paper we provide an update focusing on the - current status of EGFR-directed mAbs use for the treatment of patients with - advanced NSCLC, through a review of all clinical trials involving anti-EGFR mAbs - in combination with chemotherapy (CT) for advanced disease and with - chemo-radiotherapy for stage III disease. Here we also discuss the current status - of predictive biomarkers for anti-EGFR mAbs when added to first-line CT in - patients with advanced NSCLC. Finally, we focused on the relevance of EGFR - fluorescence in situ hybridization (FISH)+ and immunohistochemistry - (IHC)-Score ≥ 200 as predictive biomarkers for the selection of patients who - would be most likely to derive a clinical benefit from treatment with CT in - combination with anti-EGFR mAbs, with particular reference also to histology. -CI - Copyright © 2018. Published by Elsevier Ltd. -FAU - Agustoni, Francesco -AU - Agustoni F -AD - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, - Aurora, CO, United States. -FAU - Suda, Kenichi -AU - Suda K -AD - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, - Aurora, CO, United States; Division of Thoracic Surgery, Department of Surgery, - Kindai University, Faculty of Medicine, Osaka-Sayama, Japan. -FAU - Yu, Hui -AU - Yu H -AD - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, - Aurora, CO, United States. -FAU - Ren, Shengxiang -AU - Ren S -AD - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, - Aurora, CO, United States; Department of Medical Oncology, Shanghai Pulmonary - Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, - Shanghai, China. -FAU - Rivard, Christopher J -AU - Rivard CJ -AD - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, - Aurora, CO, United States. -FAU - Ellison, Kim -AU - Ellison K -AD - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, - Aurora, CO, United States. -FAU - Caldwell, Charles Jr -AU - Caldwell C Jr -AD - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, - Aurora, CO, United States. -FAU - Rozeboom, Leslie -AU - Rozeboom L -AD - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, - Aurora, CO, United States. -FAU - Brovsky, Kristine -AU - Brovsky K -AD - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, - Aurora, CO, United States. -FAU - Hirsch, Fred R -AU - Hirsch FR -AD - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, - Aurora, CO, United States. Electronic address: fred.hirsch@ucdenver.edu. -LA - eng -GR - U10 CA180888/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Review -DEP - 20180804 -PL - Netherlands -TA - Cancer Treat Rev -JT - Cancer treatment reviews -JID - 7502030 -RN - 0 (Antineoplastic Agents) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Biomarkers, Tumor) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Antineoplastic Agents/*therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Biomarkers, Tumor/*analysis -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - ErbB Receptors/antagonists & inhibitors -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/*drug therapy -OTO - NOTNLM -OT - Biomarker -OT - Chemotherapy -OT - EGFR -OT - FISH -OT - IHC -OT - Monoclonal antibodies -OT - NSCLC -EDAT- 2018/11/18 06:00 -MHDA- 2019/01/08 06:00 -CRDT- 2018/11/17 06:00 -PHST- 2017/11/22 00:00 [received] -PHST- 2018/07/30 00:00 [revised] -PHST- 2018/08/03 00:00 [accepted] -PHST- 2018/11/18 06:00 [pubmed] -PHST- 2019/01/08 06:00 [medline] -PHST- 2018/11/17 06:00 [entrez] -AID - S0305-7372(18)30137-3 [pii] -AID - 10.1016/j.ctrv.2018.08.002 [doi] -PST - ppublish -SO - Cancer Treat Rev. 2019 Jan;72:15-27. doi: 10.1016/j.ctrv.2018.08.002. Epub 2018 - Aug 4. - -PMID- 31683094 -OWN - NLM -STAT- MEDLINE -DCOM- 20200901 -LR - 20200901 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 138 -DP - 2019 Dec -TI - Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in - Macau and multimodality treatment for advanced disease. -PG - 116-123 -LID - S0169-5002(19)30674-9 [pii] -LID - 10.1016/j.lungcan.2019.10.004 [doi] -AB - OBJECTIVE: Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare type of - non-small cell lung cancer. The clinical course and prognosis of advanced LELC - are largely unknown. Few reports have discussed multimodality treatment for LELC. - MATERIALS AND METHODS: This retrospective study identified records from 2007 to - 2018 of pulmonary LELCs and other lung cancer subtypes from hospital information - systems and collected demographic, treatment, and survival data. RESULTS: In this - cohort of 69 LELCs (median age: 55.4), more female, non-smokers, and fewer right - upper lobe tumors (4.3%) were observed in the LELC subgroup compared with others. - The median overall survival (OS) of LELCs was 40 months, superior to other - subtypes (p < 0.05), except adenocarcinoma (p = 0.062). Patients with early stage - disease and primary tumor resection tended to have better OS in univariate - analysis, but surgery was the independent predictor in multivariate analysis - (0.042). The median OS of 52 advanced LELCs was 22.7 months. Platinum-based - chemotherapy and radiotherapy with curative purpose were independent predictors - for OS of advanced LELCs (p = 0.004 and 0.003, respectively). For patients who - received multimodality treatment in advanced setting, the median line of - treatments was two. The overall response and disease-control rates were 61.8% and - 80.6%, respectively. There were no differences in response or survival between - patients receiving taxane-combined and non-taxane-combined chemotherapy. However, - patients treated with radiotherapy in upfront settings had significantly - favorable response and progression-free survival compared with those without. One - case with PD-L1 positivity had pembrolizumab in the 4(th) line and achieved tumor - shrinkage and stable disease for 12 months. CONCLUSION: Patients who underwent - radical resection of primary tumors had better prognoses. Patients with advanced - LELC could achieve satisfactory survival by receiving multimodality treatment, - including platinum-based chemotherapy and/or radiotherapy. Immune checkpoint - inhibitors may be part of future therapies. A well-organized clinical trial - should be performed to determine the optimal treatment regimen. -CI - Copyright © 2019 Elsevier B.V. All rights reserved. -FAU - Zhou, Na -AU - Zhou N -AD - Department of medical oncology, Peking Union Medical College Hospital, No. 1, - Shuaifuyuan, Wangfujing, Dongcheng district, Beijing, China. -FAU - Lin, Yi -AU - Lin Y -AD - Department of oncology, Centro Hospitalar Conde de Sao Januario, Estrada do - Visconde de S. Januario, Macau, China. -FAU - Peng, Xianghong -AU - Peng X -AD - Department of oncology, Centro Hospitalar Conde de Sao Januario, Estrada do - Visconde de S. Januario, Macau, China. -FAU - Wang, Yingyi -AU - Wang Y -AD - Department of medical oncology, Peking Union Medical College Hospital, No. 1, - Shuaifuyuan, Wangfujing, Dongcheng district, Beijing, China. Electronic address: - wangyingyi7363@163.com. -FAU - Wang, Yuzhou -AU - Wang Y -AD - Department of oncology, Centro Hospitalar Conde de Sao Januario, Estrada do - Visconde de S. Januario, Macau, China. Electronic address: Yuzhouw@yahoo.com. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20191011 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/epidemiology/mortality/*therapy -MH - Combined Modality Therapy -MH - Female -MH - Humans -MH - Lung Neoplasms/epidemiology/mortality/*therapy -MH - Macau/epidemiology -MH - Male -MH - Middle Aged -MH - Retrospective Studies -MH - Surveys and Questionnaires -MH - Survival Rate -MH - Treatment Outcome -OTO - NOTNLM -OT - Chemotherapy -OT - Lung cancer -OT - Lymphoepithelioma-like carcinoma -OT - Multimodal treatment -OT - Radiotherapy -OT - Thorough survey -EDAT- 2019/11/05 06:00 -MHDA- 2020/09/02 06:00 -CRDT- 2019/11/05 06:00 -PHST- 2019/07/10 00:00 [received] -PHST- 2019/09/02 00:00 [revised] -PHST- 2019/10/07 00:00 [accepted] -PHST- 2019/11/05 06:00 [pubmed] -PHST- 2020/09/02 06:00 [medline] -PHST- 2019/11/05 06:00 [entrez] -AID - S0169-5002(19)30674-9 [pii] -AID - 10.1016/j.lungcan.2019.10.004 [doi] -PST - ppublish -SO - Lung Cancer. 2019 Dec;138:116-123. doi: 10.1016/j.lungcan.2019.10.004. Epub 2019 - Oct 11. - -PMID- 37268451 -OWN - NLM -STAT- MEDLINE -DCOM- 20230703 -LR - 20240921 -IS - 2589-7500 (Electronic) -IS - 2589-7500 (Linking) -VI - 5 -IP - 7 -DP - 2023 Jul -TI - Predicting benefit from immune checkpoint inhibitors in patients with - non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective - study. -PG - e404-e420 -LID - S2589-7500(23)00082-1 [pii] -LID - 10.1016/S2589-7500(23)00082-1 [doi] -AB - BACKGROUND: Only around 20-30% of patients with non-small-cell lung cancer - (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although - tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue - availability, and tumour heterogeneity, radiographic images might holistically - capture the underlying cancer biology. We aimed to investigate the application of - deep learning on chest CT scans to derive an imaging signature of response to - immune checkpoint inhibitors and evaluate its added value in the clinical - context. METHODS: In this retrospective modelling study, 976 patients with - metastatic, EGFR/ALK negative NSCLC treated with immune checkpoint inhibitors at - MD Anderson and Stanford were enrolled from Jan 1, 2014, to Feb 29, 2020. We - built and tested an ensemble deep learning model on pretreatment CTs (Deep-CT) to - predict overall survival and progression-free survival after treatment with - immune checkpoint inhibitors. We also evaluated the added predictive value of the - Deep-CT model in the context of existing clinicopathological and radiological - metrics. FINDINGS: Our Deep-CT model demonstrated robust stratification of - patient survival of the MD Anderson testing set, which was validated in the - external Stanford set. The performance of the Deep-CT model remained significant - on subgroup analyses stratified by PD-L1, histology, age, sex, and race. In - univariate analysis, Deep-CT outperformed the conventional risk factors, - including histology, smoking status, and PD-L1 expression, and remained an - independent predictor after multivariate adjustment. Integrating the Deep-CT - model with conventional risk factors demonstrated significantly improved - prediction performance, with overall survival C-index increases from 0·70 - (clinical model) to 0·75 (composite model) during testing. On the other hand, the - deep learning risk scores correlated with some radiomics features, but radiomics - alone could not reach the performance level of deep learning, indicating that the - deep learning model effectively captured additional imaging patterns beyond known - radiomics features. INTERPRETATION: This proof-of-concept study shows that - automated profiling of radiographic scans through deep learning can provide - orthogonal information independent of existing clinicopathological biomarkers, - bringing the goal of precision immunotherapy for patients with NSCLC closer. - FUNDING: National Institutes of Health, Mark Foundation Damon Runyon Foundation - Physician Scientist Award, MD Anderson Strategic Initiative Development Program, - MD Anderson Lung Moon Shot Program, Andrea Mugnaini, and Edward L C Smith. -CI - Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access - article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights - reserved. -FAU - Saad, Maliazurina B -AU - Saad MB -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Hong, Lingzhi -AU - Hong L -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA; Department of Thoracic/Head and Neck Medical Oncology, The - University of Texas MD Anderson Cancer Center, Houston, TX, USA. -FAU - Aminu, Muhammad -AU - Aminu M -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Vokes, Natalie I -AU - Vokes NI -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The - University of Texas MD Anderson Cancer Center, Houston, TX, USA. -FAU - Chen, Pingjun -AU - Chen P -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Salehjahromi, Morteza -AU - Salehjahromi M -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Qin, Kang -AU - Qin K -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Sujit, Sheeba J -AU - Sujit SJ -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Lu, Xuetao -AU - Lu X -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Young, Elliana -AU - Young E -AD - Department of Enterprise Data Engineering and Analytics, The University of Texas - MD Anderson Cancer Center, Houston, TX, USA. -FAU - Al-Tashi, Qasem -AU - Al-Tashi Q -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Qureshi, Rizwan -AU - Qureshi R -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Wu, Carol C -AU - Wu CC -AD - Department of Thoracic Imaging, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Carter, Brett W -AU - Carter BW -AD - Department of Thoracic Imaging, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Lin, Steven H -AU - Lin SH -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Lee, Percy P -AU - Lee PP -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA; Department of Radiation Oncology, City of Hope National - Medical Center, Los Angeles, CA, USA. -FAU - Gandhi, Saumil -AU - Gandhi S -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Chang, Joe Y -AU - Chang JY -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Li, Ruijiang -AU - Li R -AD - Department of Radiation Oncology, Stanford University School of Medicine, Palo - Alto, CA, USA. -FAU - Gensheimer, Michael F -AU - Gensheimer MF -AD - Department of Radiation Oncology, Stanford University School of Medicine, Palo - Alto, CA, USA. -FAU - Wakelee, Heather A -AU - Wakelee HA -AD - Department of Medicine, Division of Oncology, Stanford University School of - Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford, CA, USA. -FAU - Neal, Joel W -AU - Neal JW -AD - Department of Medicine, Division of Oncology, Stanford University School of - Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford, CA, USA. -FAU - Lee, Hyun-Sung -AU - Lee HS -AD - Systems Onco-Immunology Laboratory, David J Sugarbaker Division of Thoracic - Surgery, Michael E DeBakey Department of Surgery, Baylor College of Medicine, - Houston, TX, USA. -FAU - Cheng, Chao -AU - Cheng C -AD - Institute for Clinical and Translational Research, Baylor College of Medicine, - Houston, TX, USA. -FAU - Velcheti, Vamsidhar -AU - Velcheti V -AD - Department of Hematology and Oncology, New York University Langone Health, New - York, NY, USA. -FAU - Lou, Yanyan -AU - Lou Y -AD - Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA. -FAU - Petranovic, Milena -AU - Petranovic M -AD - Department of Radiology, Massachusetts General Hospital, Boston, MA, USA. -FAU - Rinsurongkawong, Waree -AU - Rinsurongkawong W -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Le, Xiuning -AU - Le X -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Rinsurongkawong, Vadeerat -AU - Rinsurongkawong V -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Spelman, Amy -AU - Spelman A -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Elamin, Yasir Y -AU - Elamin YY -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Negrao, Marcelo V -AU - Negrao MV -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Skoulidis, Ferdinandos -AU - Skoulidis F -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Gay, Carl M -AU - Gay CM -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Cascone, Tina -AU - Cascone T -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Antonoff, Mara B -AU - Antonoff MB -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Sepesi, Boris -AU - Sepesi B -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Lewis, Jeff -AU - Lewis J -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Wistuba, Ignacio I -AU - Wistuba II -AD - Department of Translational Molecular Pathology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Hazle, John D -AU - Hazle JD -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Chung, Caroline -AU - Chung C -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA; Department of Neuroradiology, The University of Texas - MD Anderson Cancer Center, Houston, TX, USA. -FAU - Jaffray, David -AU - Jaffray D -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA; Department of Radiation Physics, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Gibbons, Don L -AU - Gibbons DL -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Vaporciyan, Ara -AU - Vaporciyan A -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Lee, J Jack -AU - Lee JJ -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Heymach, John V -AU - Heymach JV -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. Electronic address: - jheymach@mdanderson.org. -FAU - Zhang, Jianjun -AU - Zhang J -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The - University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic - address: jzhang20@mdanderson.org. -FAU - Wu, Jia -AU - Wu J -AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA; Department of Thoracic/Head and Neck Medical Oncology, The - University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic - address: jwu11@mdanderson.org. -LA - eng -GR - P30 CA016672/CA/NCI NIH HHS/United States -GR - P50 CA070907/CA/NCI NIH HHS/United States -GR - R00 CA218667/CA/NCI NIH HHS/United States -GR - R01 CA262425/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20230531 -PL - England -TA - Lancet Digit Health -JT - The Lancet. Digital health -JID - 101751302 -RN - 0 (B7-H1 Antigen) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -CIN - Lancet Digit Health. 2023 Jul;5(7):e396-e397. doi: 10.1016/S2589-7500(23)00086-9. - PMID: 37268450 -EIN - Lancet Digit Health. 2023 Jul;5(7):e403. doi: 10.1016/S2589-7500(23)00110-3. - PMID: 37391264 -MH - United States -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/diagnostic imaging/drug therapy -MH - B7-H1 Antigen -MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use -MH - Retrospective Studies -MH - *Deep Learning -MH - *Lung Neoplasms/diagnostic imaging/drug therapy -PMC - PMC10330920 -MID - NIHMS1913223 -COIS- Declaration of interests NIV receives consulting fees from Sanofi, Regeneron, - Oncocyte, and Eli Lilly; and research funding from Mirati, outside the submitted - work. SHL reports research funding from STCube Pharmaceuticals, Beyond Spring - Pharmaceuticals, and Nektar Therapeutics; being on an advisory board for - AstraZeneca and Creatv Microtech; and receiving consultation fees from XRAD - Therapeutics, all outside the submitted work. PPL reports personal fees from - Viewray and AstraZeneca; personal fees and non-financial support from Varian; and - personal fees from Genentech, outside the submitted work. SG reports research - support from AstraZeneca, BMS, and Millenium Pharmaceuticals, all outside the - submitted work. JYC reports research funding from BMS-MDACC and consultation fees - from Legion Healthcare Partners. MFG reports research support from Varian Medical - Systems and RefleXion Medical. HAW reports research funding from ACEA - Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, BMS, Clovis Oncology, - Genentech/Roche, Merck, Novartis, SeaGen, Xcovery, and Helsinn; being on an - advisory board for AstraZeneca, Blueprint, Mirati, Merck, and Genentech/Roche; - and has leadership roles with the International Association for the Study of Lung - Cancer, and ECOG-ACRIN. JWN reports honoraria from CME Matters, Clinical Care - Options Continuing Medical Education (CME), Research to Practice CME, Medscape - CME, Biomedical Learning Institute CME, MLI Peerview CME, Prime Oncology CME, - Projects in Knowledge CME, Rockpointe CME, MJH Life Sciences CME, Medical - Educator Consortium, and HMP Education; consulting or advisory roles for - AstraZeneca, Genentech/Roche, Exelixis, Jounce Therapeutics, Takeda - Pharmaceuticals, Eli Lilly, Calithera Biosciences, Amgen, Iovance - Biotherapeutics, Blueprint Pharmaceuticals, Regeneron Pharmaceuticals, Natera, - Sanofi/Regeneron, D2G Oncology, Surface Oncology, Turning Point Therapeutics, - Mirati Therapeutics, Gilead Sciences, and AbbVie; and research funding from - Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar - Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GSK, Janssen, and AbbVie. H-SL - reports research funding from Samyang Biopharmaceutical USA. VV reports - consulting fees from BMS, Merck, Novartis, Amgen, Foundation Medicine, and - AstraZeneca. YL reports research funding from Merck, MacroGenics, Tolero - Pharmaceuticals, AstraZeneca, Vaccinex, Blueprint Medicines, Harpoon - Therapeutics, Sun Pharma Advanced Research, Bristol Myers Squibb, Kyowa - Pharmaceuticals, Tesaro, Bayer HealthCare, Mirati Therapeutics, and Daiichi - Sankyo; has been on scientific advisory boards for AstraZeneca Pharmaceuticals, - Janssen Pharmaceutical, Lilly Oncology, and Turning Point Therapeutics; has - received consultation fees from AstraZeneca; and has received honoraria from - Clarion Health Care. MP reports research funding from Novartis Institutes for - Biomedical Research. XLe reports research funding from Eli Lilly, EMD Serono, - Regeneron, and Boehringer Ingelheim; and consultant fees from EMD Serono (Merck - KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Eli Lilly, Boehringer - Ingelheim, Hengrui Therapeutics, Janssen, Blueprint Medicines, Sensei - Biotherapeutics, and AbbVie, outside the submitted work. YYE discloses research - support from AstraZeneca, Takeda, Eli Lilly, Xcovery, Tuning Point Therapeutics, - Blueprint, Elevation Oncology, Spectrum, and Nuvalent; having advisory roles for - AstraZeneca, Eli Lilly, Takeda, Specturm, Bristol Myers Squibb, and Turning Point - Therapeutics; and accommodation expenses from Eli Lilly. MVN has been on - scientific advisory boards for Mirati, Merck/MSD, and Genentech; and has received - research funding from Mirati, Novartis, Checkmate, Alaunos/Ziopharm, AstraZeneca, - Pfizer, and Genentech. FS reports consulting fees and advisory roles from Amgen, - AstraZeneca Pharmaceuticals, Novartis, BeiGene, Tango Therapeutics, Calithera - Biosciences, Navire Pharma, Medscape, Intellisphere, Guardant Health, and - BergenBio; speaker fees from BMS, RV Mais Promoção e Eventos, Visiting Speakers - Programme in Oncology at McGill University and the Université de Montréal, AIM - Group International, and ESMO; fees for travel, food, and beverages from Tango - Therapeutics, AstraZeneca Pharmaceuticals, Amgen, Guardant Health, and Dava - Oncology; stock or stock options in BioNTech and Moderna; research grants (to - institution) from Amgen, Mirati Therapeutics, Boehringer Ingelheim, Merck & Co, - and Novartis; study chair funds (to institution) from Pfizer; and research grants - (spouse, to institution) from Almmune. CMG reports fees for advisory committees - from AstraZeneca, Bristol Myers Squibb, Jazz Pharmaceuticals, and Monte Rosa - Therapeutics; research support from AstraZeneca; and speaker's fees from - AstraZeneca and Beigene. TC reports speaker fees and honoraria from The Society - for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape, and PeerView; - having an advisory role or receiving consulting fees from AstraZeneca, Bristol - Myers Squibb, EMD Serono, Merck & Co, Genentech, and Arrowhead Pharmaceuticals; - and institutional research funding from AstraZeneca, Bristol Myers Squibb, and - EMD Serono. IIW reports grants and personal fees from Genentech/Roche, Bayer, - Bristol Myers Squibb, AstraZeneca, Pfizer, HTG Molecular, Merck, Guardant Health, - Novartis, and Amgen; personal fees from GSK, Flame, Sanofi, Daiichi Sankyo, - Oncocyte, Janssen, MSD, and Platform Health; and grants from Adaptimmune, - Adaptive, 4D, EMD Serono, Takeda, Karus, Iovance, Johnson & Johnson, and Akoya - outside the submitted work. JDH is on the Scientific Advisory Board of Imagion - Biosystems. DLG reports honoraria for scientific advisory boards from - AstraZeneca, Sanofi, Alethia Biotherapeutics, Menarini, Eli Lilly, 4D Pharma, and - Onconova; and research support from Janssen, Takeda, Astellas, Ribon - Therapeutics, NGM Biopharmaceuticals, Boehringer Ingelheim, Mirati Therapeutics, - and AstraZeneca. JVH reports being on scientific advisory boards for AstraZeneca, - Boehringer Ingelheim, Genentech, GlaxoSmithKline, Eli Lilly, Novartis, Spectrum, - EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, and Janssen Global - Services; receiving research support from AstraZeneca, Takeda, Boehringer - Ingelheim, and Spectrum; and receiving licensing fees from Spectrum. JZ reports - research funding from Merck, Johnson & Johnson, and Novartis; and consultant fees - from BMS, Johnson & Johnson, AstraZeneca, Geneplus, OrigMed, Novartis, and - Innovent, outside the submitted work. CCW reports research support from Medical - Imaging and Data Resource Center from NIBIB/University of Chicago and royalties - from Elsevier. All other authors declare no competing interests. -EDAT- 2023/06/03 11:42 -MHDA- 2023/07/03 06:42 -PMCR- 2023/07/10 -CRDT- 2023/06/02 21:57 -PHST- 2022/09/16 00:00 [received] -PHST- 2023/01/28 00:00 [revised] -PHST- 2023/04/04 00:00 [accepted] -PHST- 2023/07/03 06:42 [medline] -PHST- 2023/06/03 11:42 [pubmed] -PHST- 2023/06/02 21:57 [entrez] -PHST- 2023/07/10 00:00 [pmc-release] -AID - S2589-7500(23)00082-1 [pii] -AID - 10.1016/S2589-7500(23)00082-1 [doi] -PST - ppublish -SO - Lancet Digit Health. 2023 Jul;5(7):e404-e420. doi: 10.1016/S2589-7500(23)00082-1. - Epub 2023 May 31. - -PMID- 31752884 -OWN - NLM -STAT- MEDLINE -DCOM- 20200429 -LR - 20200429 -IS - 1465-993X (Electronic) -IS - 1465-9921 (Print) -IS - 1465-9921 (Linking) -VI - 20 -IP - 1 -DP - 2019 Nov 21 -TI - Analysis of key clinical features for achieving complete remission in stage III - and IV non-small cell lung cancer patients. -PG - 263 -LID - 10.1186/s12931-019-1235-3 [doi] -LID - 263 -AB - BACKGROUND: Although development of immune checkpoint inhibitors and various - molecular target agents has extended overall survival time (OS) in advanced - non-small cell lung cancer (NSCLC), a complete cure remains rare. We aimed to - identify features and treatment modalities of complete remission (CR) cases in - stages III and IV NSCLC by analyzing long-term survivors whose OS exceeded 3 - years. METHODS: From our hospital database, 1,699 patients, registered as lung - cancer between 1(st) Mar 2004 and 30(th) Apr 2011, were retrospectively examined. - Stage III or IV histologically or cytologically confirmed NSCLC patients with - chemotherapy initiated during this period were enrolled. A Cox proportion hazards - regression model was used. Data collection was closed on 13(th) Feb 2017. - RESULTS: There were 164 stage III and 279 stage IV patients, including 37 (22.6%) - and 51 (18.3%) long-term survivors and 12 (7.3%) and 5 (1.8%) CR patients, - respectively. The long-term survivors were divided into three groups: 3 ≤ OS < 5 - years, 5 years ≤ OS with tumor, and 5 years ≤ OS without tumor (CR). The median - OS of these groups were 1,405, 2,238, and 2,876 days in stage III and 1,368, - 2,503, and 2,643 days in stage IV, respectively. The mean chemotherapy cycle - numbers were 16, 20, and 10 in stage III and 24, 25, and 5 in stage IV, - respectively. In the stage III CR group, all patients received chemoradiation, - all oligometastases were controlled by radiation, and none had brain metastases. - Compared with non-CR patients, the stage IV CR patients had smaller primary - tumors and fewer metastases, which were independent prognostic factors for OS - among long-term survivors. The 80% stage IV CR patients received radiation or - surgery for controlling primary tumors, and the surgery rate for oligometastases - was high. Pathological findings in the stage IV CR patients revealed that - numerous inflammatory cells existed around and inside resected lung and brain - tumors, indicating strong immune response. CONCLUSIONS: Multiple line - chemotherapies with primary and oligometastatic controls by surgery and/or - radiation might achieve cure in certain advanced NSCLC. Cure strategies must be - changed according to stage III or IV. This study was retrospectively registered - on 16(th) Jun 2019 in UMIN Clinical Trials Registry (number UMIN000037078). -FAU - Aoki, Takuya -AU - Aoki T -AUID- ORCID: 0000-0002-1299-4220 -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. ZWQ00221@nifty.ne.jp. -FAU - Akiba, Takeshi -AU - Akiba T -AD - Department of Radiation Oncology, Tokai University School of Medicine, Isehara, - Kanagawa, 259-1193, Japan. -FAU - Nishiyama, Jun -AU - Nishiyama J -AD - Department of Neurosurgery, Tokai University School of Medicine, Isehara, - Kanagawa, 259-1193, Japan. -FAU - Tajiri, Sakurako -AU - Tajiri S -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. -FAU - Hayama, Naoki -AU - Hayama N -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. -FAU - Takahashi, Genki -AU - Takahashi G -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. -FAU - Tanaka, Jun -AU - Tanaka J -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. -FAU - Sato, Masako -AU - Sato M -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. -FAU - Takiguchi, Hiroto -AU - Takiguchi H -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. -FAU - Tomomatsu, Hiromi -AU - Tomomatsu H -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. -FAU - Tomomatsu, Katsuyoshi -AU - Tomomatsu K -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. -FAU - Takihara, Takahisa -AU - Takihara T -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. -FAU - Niimi, Kyoko -AU - Niimi K -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. -FAU - Oguma, Tsuyoshi -AU - Oguma T -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. -FAU - Kohno, Mitsutomo -AU - Kohno M -AD - Department of Thoracic Surgery, Tokai University School of Medicine, Isehara, - Kanagawa, 259-1193, Japan. -FAU - Masuda, Ryota -AU - Masuda R -AD - Department of Thoracic Surgery, Tokai University School of Medicine, Isehara, - Kanagawa, 259-1193, Japan. -FAU - Urano, Tetsuya -AU - Urano T -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. -FAU - Itoh, Hitoshi -AU - Itoh H -AD - Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa, - 259-1193, Japan. -FAU - Kajiwara, Hiroshi -AU - Kajiwara H -AD - Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa, - 259-1193, Japan. -FAU - Nakamura, Naoya -AU - Nakamura N -AD - Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa, - 259-1193, Japan. -FAU - Kunieda, Etsuo -AU - Kunieda E -AD - Department of Radiation Oncology, Tokai University School of Medicine, Isehara, - Kanagawa, 259-1193, Japan. -FAU - Matsumae, Mitsunori -AU - Matsumae M -AD - Department of Neurosurgery, Tokai University School of Medicine, Isehara, - Kanagawa, 259-1193, Japan. -FAU - Iwazaki, Masayuki -AU - Iwazaki M -AD - Department of Thoracic Surgery, Tokai University School of Medicine, Isehara, - Kanagawa, 259-1193, Japan. -FAU - Asano, Koichiro -AU - Asano K -AD - Respiratory Division, Department of Internal Medicine, Tokai University School of - Medicine, Isehara, Kanagawa, 259-1193, Japan. -LA - eng -GR - JP16K09555/Japan Society for the Promotion of Science/ -PT - Journal Article -DEP - 20191121 -PL - England -TA - Respir Res -JT - Respiratory research -JID - 101090633 -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Carcinoma, Non-Small-Cell Lung/*diagnostic imaging/mortality/*therapy -MH - Disease-Free Survival -MH - Female -MH - Humans -MH - Lung Neoplasms/*diagnostic imaging/mortality/*therapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging/methods/trends -MH - Remission Induction/methods -MH - Retrospective Studies -PMC - PMC6873580 -OTO - NOTNLM -OT - advanced non-small cell lung cancer -OT - complete remission -OT - oligometastases -OT - radiation -OT - surgery -COIS- The authors declare no conflicts of interest. -EDAT- 2019/11/23 06:00 -MHDA- 2020/04/30 06:00 -PMCR- 2019/11/21 -CRDT- 2019/11/23 06:00 -PHST- 2019/09/01 00:00 [received] -PHST- 2019/11/07 00:00 [accepted] -PHST- 2019/11/23 06:00 [entrez] -PHST- 2019/11/23 06:00 [pubmed] -PHST- 2020/04/30 06:00 [medline] -PHST- 2019/11/21 00:00 [pmc-release] -AID - 10.1186/s12931-019-1235-3 [pii] -AID - 1235 [pii] -AID - 10.1186/s12931-019-1235-3 [doi] -PST - epublish -SO - Respir Res. 2019 Nov 21;20(1):263. doi: 10.1186/s12931-019-1235-3. - -PMID- 16248762 -OWN - NLM -STAT- MEDLINE -DCOM- 20060227 -LR - 20151119 -IS - 1084-9785 (Print) -IS - 1084-9785 (Linking) -VI - 20 -IP - 5 -DP - 2005 Oct -TI - Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced - non-small cell lung cancer: effect of chelating agents and paclitaxel - co-administration. -PG - 467-78 -AB - PURPOSE: This trial was designed to evaluate strategies to improve the efficacy - of a radiolabeled monoclonal antibody (mCC49) against tumor-associated - glycoprotein-72 (TAG-72) in patients with non-small cell lung cancer (NSCLC). The - aims of this study were to determine: safety and maximum tolerated dose (MTD) of - (90)Y-mCC49 in combination with interferon alpha2beta (IFN); whether calcium - disodium versonate (EDTA) or diethylenetriamine penta-acetic acid (DTPA) could - reduce myelosuppression; and safety and MTD of paclitaxel (Taxol) in combination - with (90)Y-mCC49. EXPERIMENTAL DESIGN: Patients with advanced (TAG-72 positive) - non-small cell lung cancer were entered in three phases; the first was the dose - escalation of a single agent (90)Y-mCC49. In the second phase, the dose - escalation of (90)Y-mCC49 was attempted with concurrent EDTA or DTPA chelator - therapy. In the third phase, radiosensitization with a continuous infusion of - paclitaxel (96-hour) was administered with (90)Y-mCC49. All patients received IFN - for TAG-72 up-regulation. RESULTS: Thirty-four patients were evaluable. - Reversible Grade 4 neutropenia and thrombocytopenia were the dose-limiting - toxicities (DLTs). The MTD of (90)Y-mCC49/IFN was 14 mCi/m(2). EDTA did not alter - toxicity, while there was a modest reduction of myelosuppression with DTPA. The - MTD of continuous infusion paclitaxel in combination with 14 mCi/m(2) of - (90)Y-CC49 was 60 mg/m(2). There were no objective tumor responses. CONCLUSIONS: - (90)Y-mCC49/IFN was well tolerated at a dose of 14 mCi/m(2). The clinical effect - of adjunctive chelating therapy with DTPA was modest. The MTD of coadministered - continuous infusion (96-hour) paclitaxel was 60 mg/m(2). Because of the - immunogenicity of the murine compound, future studies are planned using a - humanized version of CC49. -FAU - Forero, Andres -AU - Forero A -AD - Department of Medicine, Comprehensive Cancer Center, University of Alabama at - Birmingham, 1824 Sixth Avenue South, Birmingham, AL 35294-3300, USA. - Andres.Forero@cc.uab.edu -FAU - Meredith, Ruby F -AU - Meredith RF -FAU - Khazaeli, M B -AU - Khazaeli MB -FAU - Shen, Sui -AU - Shen S -FAU - Grizzle, William E -AU - Grizzle WE -FAU - Carey, Delicia -AU - Carey D -FAU - Busby, Elizabeth -AU - Busby E -FAU - LoBuglio, Albert F -AU - LoBuglio AF -FAU - Robert, Francisco -AU - Robert F -LA - eng -GR - 5U01 CA 743392/CA/NCI NIH HHS/United States -GR - K12 CA 76937/CA/NCI NIH HHS/United States -GR - M01 RR 00032/RR/NCRR NIH HHS/United States -PT - Clinical Trial, Phase I -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PL - United States -TA - Cancer Biother Radiopharm -JT - Cancer biotherapy & radiopharmaceuticals -JID - 9605408 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Neoplasm) -RN - 0 (Antigens, Neoplasm) -RN - 0 (Antineoplastic Agents) -RN - 0 (B72.3 antibody) -RN - 0 (Chelating Agents) -RN - 0 (Glycoproteins) -RN - 0 (Yttrium Radioisotopes) -RN - 0 (tumor-associated antigen 72) -RN - 7A314HQM0I (Pentetic Acid) -RN - 9G34HU7RV0 (Edetic Acid) -RN - P88XT4IS4D (Paclitaxel) -SB - IM -MH - Adult -MH - Aged -MH - Antibodies, Monoclonal/chemistry -MH - Antibodies, Neoplasm/*therapeutic use -MH - Antigens, Neoplasm/chemistry -MH - Antineoplastic Agents/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Chelating Agents/*administration & dosage/pharmacology -MH - Clinical Trials as Topic -MH - Disease Progression -MH - Edetic Acid/pharmacology -MH - Female -MH - Glycoproteins/chemistry -MH - Humans -MH - Lung Neoplasms/*drug therapy/metabolism -MH - Male -MH - Maximum Tolerated Dose -MH - Middle Aged -MH - Neutropenia -MH - Paclitaxel/*administration & dosage/pharmacology/therapeutic use -MH - Pentetic Acid/pharmacology -MH - Radioimmunotherapy -MH - Radiometry -MH - Thrombocytopenia -MH - Treatment Outcome -MH - Up-Regulation -MH - Yttrium Radioisotopes/*therapeutic use -EDAT- 2005/10/27 09:00 -MHDA- 2006/02/28 09:00 -CRDT- 2005/10/27 09:00 -PHST- 2005/10/27 09:00 [pubmed] -PHST- 2006/02/28 09:00 [medline] -PHST- 2005/10/27 09:00 [entrez] -AID - 10.1089/cbr.2005.20.467 [doi] -PST - ppublish -SO - Cancer Biother Radiopharm. 2005 Oct;20(5):467-78. doi: 10.1089/cbr.2005.20.467. - -PMID- 31203193 -OWN - NLM -STAT- MEDLINE -DCOM- 20200601 -LR - 20200601 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 116 -DP - 2019 Jul -TI - Survival of patients with non-small cell lung cancer having leptomeningeal - metastases treated with immune checkpoint inhibitors. -PG - 182-189 -LID - S0959-8049(19)30322-3 [pii] -LID - 10.1016/j.ejca.2019.05.019 [doi] -AB - INTRODUCTION: Patients with non-small cell lung cancer (NSCLC) experience - leptomeningeal metastases (LM) in 3-9% of cases. Because overall survival (OS) - and performance status are very poor, they are mostly excluded from clinical - trials. Here, we evaluated survival of patients with NSCLC having LM treated with - immune checkpoint inhibitors (ICIs). METHODS: A prospectively collected list of - patients with advanced NSCLC treated with ICIs between November 2012 and July - 2018 in 7 European centres was merged. All patients with LM before ICI start were - selected, data were retrospectively added and patients were classified according - to the National Comprehensive Cancer Network (NCCN) LM prognostic classification - (good/poor). Progression-free survival (PFS) and OS on ICIs were evaluated. - RESULTS: Nineteen of 1288 (1.5%) patients had LM; 73.7% had synchronous brain - metastases; 73.7% had neurological symptoms at the start of ICIs and 52.6% were - in the NCCN LM good prognosis group. Programmed death ligand-1 (PD-L1) expression - was known for 42.1% of patients (87.5% positive). Median follow-up was 13 months - from the start of ICIs, and median (95% confidence interval [CI]) PFS on ICIs was - 2.0 (1.8-2.2) months. Six-month PFS rate was 21.0% and was significantly higher - in the NCCN good versus poor prognostic group: 40% vs 0% (p = 0.05). Twelve-month - PFS rate was 0%. Median (95% CI) OS from the start of ICIs was 3.7 (0.9-6.6) - months. Six-month OS rate was 36.8%, and 12-month OS rate was 21.1%; both were - not statistically significantly different for the good versus poor NCCN - prognostic group (p = 0.40 and p = 0.56, respectively). CONCLUSION: Some patients - with NSCLC having LM do benefit from ICI treatment; specifically, those in the - NCCN LM good prognosis group can obtain a long survival. -CI - Copyright © 2019 Elsevier Ltd. All rights reserved. -FAU - Hendriks, Lizza E L -AU - Hendriks LEL -AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Institut - d'Oncologie Thoracique (IOT), Gustave Roussy, Université Paris-Saclay, F-94805, - Villejuif, France; Department of Pulmonary Diseases, GROW - School for Oncology - and Developmental Biology, Maastricht University Medical Center+, Maastricht, the - Netherlands. Electronic address: lizza.hendriks@mumc.nl. -FAU - Bootsma, Gerben -AU - Bootsma G -AD - Department of Pulmonary Diseases, Zuyderland Hospital, Location Heerlen, the - Netherlands. Electronic address: G.bootsma@zuyderland.nl. -FAU - Mourlanette, Jean -AU - Mourlanette J -AD - Department of Pulmonary Diseases, Centre Hospitalier Universitaire de Toulouse, - Université Paul Sabatier, Toulouse, France. Electronic address: - Jean.mourlanette@orange.fr. -FAU - Henon, Clemence -AU - Henon C -AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Institut - d'Oncologie Thoracique (IOT), Gustave Roussy, Université Paris-Saclay, F-94805, - Villejuif, France. Electronic address: clemence.HENON@gustaveroussy.fr. -FAU - Mezquita, Laura -AU - Mezquita L -AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Institut - d'Oncologie Thoracique (IOT), Gustave Roussy, Université Paris-Saclay, F-94805, - Villejuif, France. Electronic address: laura.MEZQUITA@gustaveroussy.fr. -FAU - Ferrara, Roberto -AU - Ferrara R -AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Institut - d'Oncologie Thoracique (IOT), Gustave Roussy, Université Paris-Saclay, F-94805, - Villejuif, France. Electronic address: Roberto.Ferrara@istitutotumori.mi.it. -FAU - Audigier-Valette, Clarisse -AU - Audigier-Valette C -AD - Department of Pulmonary Diseases, Centre Hospitalier Toulon Sainte-Musse, Toulon, - France. Electronic address: Clarisse.Audigier-Valette@ch-toulon.fr. -FAU - Mazieres, Julien -AU - Mazieres J -AD - Department of Pulmonary Diseases, Centre Hospitalier Universitaire de Toulouse, - Université Paul Sabatier, Toulouse, France. Electronic address: - mazieres.j@chu-toulouse.fr. -FAU - Lefebvre, Corentin -AU - Lefebvre C -AD - Department of Pulmonary Diseases, Centre Hospitalier Universitaire de Toulouse, - Université Paul Sabatier, Toulouse, France. Electronic address: - corentin.lefebvre@hotmail.com. -FAU - Duchemann, Boris -AU - Duchemann B -AD - Department of Pulmonary Diseases, Hopital Avicenne, Paris, France. Electronic - address: Boris.duchemann@aphp.fr. -FAU - Cousin, Sophie -AU - Cousin S -AD - Department of Medical Oncology, Institut Bergonie, Bordeaux, France. Electronic - address: s.cousin@bordeaux.unicancer.fr. -FAU - le Pechoux, Cecile -AU - le Pechoux C -AD - Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, - France. Electronic address: Cecile.LEPECHOUX@gustaveroussy.fr. -FAU - Botticella, Angela -AU - Botticella A -AD - Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, - France. Electronic address: angela.BOTTICELLA@gustaveroussy.fr. -FAU - De Ruysscher, Dirk -AU - De Ruysscher D -AD - Department of Radiation Oncology (MAASTRO Clinic), GROW School for Oncology and - Developmental Biology, Maastricht University Medical Center+, Maastricht, the - Netherlands. Electronic address: Dirk.deruysscher@maastro.nl. -FAU - Dingemans, Anne-Marie C -AU - Dingemans AC -AD - Department of Pulmonary Diseases, GROW - School for Oncology and Developmental - Biology, Maastricht University Medical Center+, Maastricht, the Netherlands. - Electronic address: a.dingemans@mumc.nl. -FAU - Besse, Benjamin -AU - Besse B -AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Institut - d'Oncologie Thoracique (IOT), Gustave Roussy, Université Paris-Saclay, F-94805, - Villejuif, France; Paris-Sud University, Orsay, France. Electronic address: - Benjamin.BESSE@gustaveroussy.fr. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20190613 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Adult -MH - Aged -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/mortality/pathology -MH - Male -MH - Meningeal Carcinomatosis/*drug therapy/mortality -MH - Middle Aged -MH - Retrospective Studies -MH - Treatment Outcome -OTO - NOTNLM -OT - Immune checkpoint inhibition -OT - Leptomeningeal metastases -OT - NSCLC -EDAT- 2019/06/17 06:00 -MHDA- 2020/06/02 06:00 -CRDT- 2019/06/17 06:00 -PHST- 2019/03/15 00:00 [received] -PHST- 2019/05/04 00:00 [revised] -PHST- 2019/05/12 00:00 [accepted] -PHST- 2019/06/17 06:00 [pubmed] -PHST- 2020/06/02 06:00 [medline] -PHST- 2019/06/17 06:00 [entrez] -AID - S0959-8049(19)30322-3 [pii] -AID - 10.1016/j.ejca.2019.05.019 [doi] -PST - ppublish -SO - Eur J Cancer. 2019 Jul;116:182-189. doi: 10.1016/j.ejca.2019.05.019. Epub 2019 - Jun 13. - -PMID- 36248782 -OWN - NLM -STAT- MEDLINE -DCOM- 20221018 -LR - 20221020 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 13 -DP - 2022 -TI - Association between immune-related adverse events and the efficacy of PD-1 - inhibitors in advanced esophageal cancer. -PG - 931429 -LID - 10.3389/fimmu.2022.931429 [doi] -LID - 931429 -AB - INTRODUCTION: Recent developments in immune checkpoint inhibitors (ICIs) have - improved the treatment outcomes of esophageal cancer (EC); however, it may - initiate immune-related adverse events (irAEs) in some patients. The ICIs' - therapeutic efficacy is associated with irAEs in patients with non-small cell - lung cancer or renal cell carcinoma, although this association is unknown in EC. - The purpose of this study was to explore the association between irAEs and the - efficacy of programmed death 1 (PD-1) inhibitors in EC patients. PATIENTS AND - METHODS: This study included patients with advanced EC treated with PD-1 - inhibitors. The patients were divided into two groups according to the occurrence - of irAEs. Afterward, the efficacy was compared between the irAE-negative and - irAE-positive groups, and we analyzed the predictive factors of irAEs and - survival. RESULTS: Overall, 295 patients were included in this study. Baseline - characteristics were balanced in the irAE-negative and irAE-positive groups. In - total, 143 (48.47%) patients experienced irAEs. The most frequent irAEs were - anemia (49, 16.61%), hyperthyroidism (45, 15.25%), and pneumonitis (44, 14.92%). - In total, 33 (11.19%) patients had grade ≥ 3 irAEs and pneumonitis have 15 - (5.08%). No grade 5 adverse events were observed. A total of 52 (17.63%) and 91 - (30.85%) patients had single and multiple irAEs, respectively. Compared with - patients without irAEs, those with irAEs had significantly higher objective - response rate (ORR) (37.76% vs. 25.00%, p = 0.018) and disease control rate (DCR) - (92.31% vs. 83.55%, p = 0.022). Univariate Cox analyses indicated the significant - association between irAEs and improved median progression-free survival (PFS) - (10.27 vs. 6.2 months, p < 0.001) and overall survival (OS) (15.4 vs. 9.2 months, - p < 0.001). In multivariate analyses, irAEs were independently associated with - longer PFS (p = 0.011) and OS (p = 0.002). Moreover, multivariate analysis - revealed that cycles > 8, radiation, as well as antiangiogenic therapy were - strongly associated with irAEs development (p < 0.001, p = 0.002, and p = 0.025, - respectively). CONCLUSION: In advanced EC, patients with irAEs showed markedly - better efficacy in ORR, DCR, PFS, and OS compared with patients without irAEs. -CI - Copyright © 2022 Qin, Yang, Fan, Zou, Duan, Li and Wang. -FAU - Qin, Wenru -AU - Qin W -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Yang, Linlin -AU - Yang L -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Fan, Bingjie -AU - Fan B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Zou, Bing -AU - Zou B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Duan, Yanan -AU - Duan Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -AD - Department of Oncology, Shandong First Medical University, Jinan, China. -FAU - Li, Butuo -AU - Li B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Wang, Linlin -AU - Wang L -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20220928 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung -MH - *Drug-Related Side Effects and Adverse Reactions/drug therapy -MH - *Esophageal Neoplasms/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Immune System Diseases/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Programmed Cell Death 1 Receptor -MH - Retrospective Studies -PMC - PMC9554876 -OTO - NOTNLM -OT - PD-1 inhibitors -OT - esophageal cancer -OT - immune checkpoint inhibitors -OT - immune-related adverse events -OT - prognostic marker -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/10/18 06:00 -MHDA- 2022/10/19 06:00 -PMCR- 2022/01/01 -CRDT- 2022/10/17 05:12 -PHST- 2022/04/29 00:00 [received] -PHST- 2022/09/12 00:00 [accepted] -PHST- 2022/10/17 05:12 [entrez] -PHST- 2022/10/18 06:00 [pubmed] -PHST- 2022/10/19 06:00 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2022.931429 [doi] -PST - epublish -SO - Front Immunol. 2022 Sep 28;13:931429. doi: 10.3389/fimmu.2022.931429. eCollection - 2022. - -PMID- 32400223 -OWN - NLM -STAT- MEDLINE -DCOM- 20210127 -LR - 20220416 -IS - 1744-764X (Electronic) -IS - 1474-0338 (Linking) -VI - 19 -IP - 7 -DP - 2020 Jul -TI - The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung - cancer. -PG - 775-783 -LID - 10.1080/14740338.2020.1767584 [doi] -AB - INTRODUCTION: Atezolizumab is a humanized monoclonal antibody against PD-L1 - capable of enhancing antitumor immune activity, with a demonstrated activity as - single agent in patients with advanced non-small-cell lung cancer (NSCLC). AREAS - COVERED: This review summarizes the clinical data emerging from randomized - clinical studies with atezolizumab in NSCLC and small-cell lung cancer (SCLC), - focusing in particular on the efficacy and safety data regarding the combinations - of atezolizumab plus chemotherapy in the IMpower studies. EXPERT OPINION: A - significant improvement in progression-free survival and in overall survival was - observed in IMpower 130 and 150 (NSCLC non-squamous) and 133 (SCLC), with an - acceptable safety profile. In particular, the most common immune-related adverse - events were rash (18-28% of patients), hypothyroidism (8-15%), hepatitis (5-17%), - pneumonitis (2-7%), and colitis (1.5-2.3%). The safety profile of atezolizumab in - combination with chemotherapy was consistent with the known adverse events - related to single-agent atezolizumab and no new adverse events were observed. - Ongoing studies will evaluate the role of atezolizumab in other settings - (adjuvant and neoadjuvant) and in combination with chemotherapy and radiotherapy - for patients with locally advanced NSCLC and the role of predictive factors - (B-FAST study). -FAU - Manzo, Anna -AU - Manzo A -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione - G.Pascale"-IRCCS , Napoli, Italy. -FAU - Carillio, Guido -AU - Carillio G -AD - Department of Oncology & Hematology, Azienda Ospedaliera Pugliese-Ciaccio , - Catanzaro, Italy. -FAU - Montanino, Agnese -AU - Montanino A -AUID- ORCID: 0000-0003-4271-8275 -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione - G.Pascale"-IRCCS , Napoli, Italy. -FAU - Sforza, Vincenzo -AU - Sforza V -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione - G.Pascale"-IRCCS , Napoli, Italy. -FAU - Palumbo, Giuliano -AU - Palumbo G -AD - Oncology, Ospedale S.Maria Della Pietà , Napoli, Italy. -FAU - Esposito, Giovanna -AU - Esposito G -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione - G.Pascale"-IRCCS , Napoli, Italy. -FAU - Costanzo, Raffaele -AU - Costanzo R -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione - G.Pascale"-IRCCS , Napoli, Italy. -FAU - Sandomenico, Claudia -AU - Sandomenico C -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione - G.Pascale"-IRCCS , Napoli, Italy. -FAU - La Manna, Carmine -AU - La Manna C -AD - Thoracic Surgery, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , - Napoli, Italy. -FAU - Martucci, Nicola -AU - Martucci N -AD - Thoracic Surgery, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , - Napoli, Italy. -FAU - La Rocca, Antonello -AU - La Rocca A -AD - Thoracic Surgery, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , - Napoli, Italy. -FAU - De Luca, Giuseppe -AU - De Luca G -AD - Thoracic Surgery, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , - Napoli, Italy. -FAU - Piccirillo, Maria Carmela -AU - Piccirillo MC -AD - Clinical Trials Unit, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , - Napoli, Italy. -FAU - De Cecio, Rossella -AU - De Cecio R -AD - Pathology, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , Napoli, - Italy. -FAU - Botti, Gerardo -AU - Botti G -AD - Scientific Directorate, Istituto Nazionale Tumori, "Fondazione G. Pascale" - - IRCCS , Naples, Italy. -FAU - Totaro, Giuseppe -AU - Totaro G -AD - Radiotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS , Naples, - Italy. -FAU - Muto, Paolo -AU - Muto P -AD - Radiotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS , Naples, - Italy. -FAU - Picone, Carmine -AU - Picone C -AD - Radiology, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , Napoli, - Italy. -FAU - Normanno, Nicola -AU - Normanno N -AD - Cell Biology and Biotherapy, Istituto Nazionale Tumori, "Fondazione G.Pascale" - - IRCCS , Napoli, Italy. -FAU - Morabito, Alessandro -AU - Morabito A -AUID- ORCID: 0000-0002-1319-9608 -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione - G.Pascale"-IRCCS , Napoli, Italy. -LA - eng -PT - Journal Article -PT - Review -DEP - 20200526 -PL - England -TA - Expert Opin Drug Saf -JT - Expert opinion on drug safety -JID - 101163027 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 52CMI0WC3Y (atezolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects -MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse - effects -MH - B7-H1 Antigen/immunology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Disease-Free Survival -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology -MH - Randomized Controlled Trials as Topic -MH - Survival Rate -OTO - NOTNLM -OT - NSCLC -OT - PD-1 -OT - PD-L1 -OT - SCLC -OT - atezolizumab -OT - chemotherapy -OT - safety -EDAT- 2020/05/14 06:00 -MHDA- 2021/01/28 06:00 -CRDT- 2020/05/14 06:00 -PHST- 2020/05/14 06:00 [pubmed] -PHST- 2021/01/28 06:00 [medline] -PHST- 2020/05/14 06:00 [entrez] -AID - 10.1080/14740338.2020.1767584 [doi] -PST - ppublish -SO - Expert Opin Drug Saf. 2020 Jul;19(7):775-783. doi: 10.1080/14740338.2020.1767584. - Epub 2020 May 26. - -PMID- 25030654 -OWN - NLM -STAT- MEDLINE -DCOM- 20150212 -LR - 20211203 -IS - 1534-6269 (Electronic) -IS - 1523-3790 (Linking) -VI - 16 -IP - 9 -DP - 2014 Sep -TI - Immunotherapeutic agents in non-small-cell lung cancer finally coming to the - front lines. -PG - 400 -LID - 10.1007/s11912-014-0400-6 [doi] -AB - Non-small-cell lung cancer usually carries a dismal prognosis. Novel treatment - approaches are clearly warranted. Immunotherapy has emerged as a promising area - of research developing agents that manipulate the immune system to induce - antitumor responses while avoiding major toxicity. New vaccines and checkpoint - inhibitors are currently undergoing investigation in phase II and phase III - clinical trials. In advanced non-small-cell lung cancer (NSCLC), - belagenpumatucel-L, an allogeneic cell vaccine directed against transforming - growth factor β in the tumor microenvironment, knocks down the immune suppression - caused by the tumor and has demonstrated a dose- and time-dependent efficacy in - some subgroups of patients. L-BLP25 and TG4010 are both antigenic vaccines that - target mucin 1, whose encoding proto-oncogene is commonly mutated in solid - tumors. The L-BLP25 vaccine achieved a significant improvement in overall - survival in the subgroup of patients with stage IIIB NSCLC treated with - chemoradiotherapy. TG4010 vaccination resulted in better progression-free - survival when added to cisplatin-gemcitabine chemotherapy. These results are - being addressed in the currently ongoing phase III TIME trial. In the adjuvant - setting, MAGE-A3, an antigen-based vaccine, showed promising results in - melanoma-associated antigen A3 positive lung cancer patients who underwent - resection in the phase II study; however, no improvement in progression-free - survival was observed in the phase III MAGRIT study. CIMAVax is a recombinant - human epidermal growth factor (EGF) vaccine that induces anti-EGF antibody - production and prevents EGF from binding to its receptor. It has improved overall - survival in patients with advanced NSCLC who achieve seroconversion. Ipilimumab, - an immune checkpoint inhibitor that targets cytotoxic T-lymphocyte antigen 4, - demonstrated improved progression-free survival in advanced NSCLC patients who - received the drug after chemotherapy in a phased regimen. Finally, - anti-programmed death receptor 1 agents have achieved durable response rates in - phase I studies. This review gives an overview of the current data and the most - promissory immunotherapeutic agents for NSCLC. -FAU - Ruiz, Rossana -AU - Ruiz R -AD - Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades - Neoplásicas, Angamos Este 2520, Surquilllo, Lima, Peru, - rossana.ruiz.mendoza@gmail.com. -FAU - Hunis, Brian -AU - Hunis B -FAU - Raez, Luis E -AU - Raez LE -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - Curr Oncol Rep -JT - Current oncology reports -JID - 100888967 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antigens, Neoplasm) -RN - 0 (Cancer Vaccines) -RN - 0 (Immunologic Factors) -RN - 0 (MAS1 protein, human) -RN - 0 (Proto-Oncogene Mas) -RN - 62229-50-9 (Epidermal Growth Factor) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - Antigens, Neoplasm/immunology -MH - Cancer Vaccines/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology -MH - Clinical Trials as Topic -MH - Epidermal Growth Factor/immunology -MH - Humans -MH - Immunologic Factors/*therapeutic use -MH - Immunotherapy, Active/*methods -MH - Lung Neoplasms/*drug therapy/immunology -MH - Proto-Oncogene Mas -EDAT- 2014/07/18 06:00 -MHDA- 2015/02/13 06:00 -CRDT- 2014/07/18 06:00 -PHST- 2014/07/18 06:00 [entrez] -PHST- 2014/07/18 06:00 [pubmed] -PHST- 2015/02/13 06:00 [medline] -AID - 10.1007/s11912-014-0400-6 [doi] -PST - ppublish -SO - Curr Oncol Rep. 2014 Sep;16(9):400. doi: 10.1007/s11912-014-0400-6. - -PMID- 28467720 -OWN - NLM -STAT- MEDLINE -DCOM- 20180131 -LR - 20231213 -IS - 1747-6356 (Electronic) -IS - 1747-6348 (Linking) -VI - 11 -IP - 6 -DP - 2017 Jun -TI - Second-line therapy of squamous non-small cell lung cancer: an evolving - landscape. -PG - 469-479 -LID - 10.1080/17476348.2017.1326822 [doi] -AB - The treatment of lung cancer has radically changed over the last few years. The - discovery of druggable oncogenic alterations and the introduction of - immunotherapy have provided lung cancer patients with the possibility of more - efficient and less toxic therapeutic alternatives than chemotherapy. In the case - of lung squamous cell carcinoma (LSCC), the treatment progress is slower than - adenocarcinoma, for which several targeted agents have been already approved. The - standard first-line therapy for LSCC, in most sites of the world, is - platinum-based chemotherapy. After disease progression, these patients now have - novel treatment options, including antiangiogenic agents and immune checkpoint - blockade. Areas covered: We provide a summary of the recent novelties for the - second-line therapy of LSCC, emphasizing on the results of the most important - clinical trials that have led to regulatory approvals. Expert commentary: Immune - checkpoint inhibitors have changed the therapeutic algorithm for LSCC patients. - Other treatment options in the second-line setting include ramucirumab in - combination with docetaxel and afatinib. However, we still lack biomarkers to - predict which patients could respond better to each treatment. Despite the - identification of several actionable molecular alterations, there are no approved - targeted agents specific for advanced LSCC. Results from ongoing biomarker-driven - studies are eagerly awaited to establish effective treatments for molecularly - selected subgroups of patients. -FAU - Lazzari, Chiara -AU - Lazzari C -AD - a Department of Oncology, Division of Experimental Medicine , IRCCS San Raffaele - , Milan , Italy. -FAU - Karachaliou, Niki -AU - Karachaliou N -AD - b Medical Oncology Department , Institute of Oncology Rosell (IOR), University - Hospital Sagrat Cor , Barcelona , Spain. -FAU - Gregorc, Vanesa -AU - Gregorc V -AD - a Department of Oncology, Division of Experimental Medicine , IRCCS San Raffaele - , Milan , Italy. -FAU - Bulotta, Alessandra -AU - Bulotta A -AD - a Department of Oncology, Division of Experimental Medicine , IRCCS San Raffaele - , Milan , Italy. -FAU - Gonzalez-Cao, Maria -AU - Gonzalez-Cao M -AD - c Translational Cancer Research Unit, Instituto Oncológico Dr Rosell , Dexeus - University Hospital-Quirónsalud Group , Barcelona , Spain. -FAU - Verlicchi, Alberto -AU - Verlicchi A -AD - d S.C. Oncologia , Fondazione IRCCS Policlinico San Matteo , Pavia , Italy. -FAU - Altavilla, Giuseppe -AU - Altavilla G -AD - e Medical Oncology Unit, Department of Human Pathology "G. Barresi" , University - of Messina , Messina , Italy. -FAU - Rosell, Rafael -AU - Rosell R -AD - c Translational Cancer Research Unit, Instituto Oncológico Dr Rosell , Dexeus - University Hospital-Quirónsalud Group , Barcelona , Spain. -AD - f Germans Trias i Pujol Research Institute , Badalona , Spain. -AD - g Catalan Institute of Oncology , Germans Trias i Pujol University Hospital , - Badalona , Spain. -FAU - Santarpia, Mariacarmela -AU - Santarpia M -AD - e Medical Oncology Unit, Department of Human Pathology "G. Barresi" , University - of Messina , Messina , Italy. -LA - eng -PT - Journal Article -PT - Review -DEP - 20170515 -PL - England -TA - Expert Rev Respir Med -JT - Expert review of respiratory medicine -JID - 101278196 -RN - 0 (Angiogenesis Inhibitors) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents) -RN - 0 (Quinazolines) -RN - 0 (Radiation-Sensitizing Agents) -RN - 0 (Taxoids) -RN - 15H5577CQD (Docetaxel) -RN - 41UD74L59M (Afatinib) -SB - IM -MH - Afatinib -MH - Angiogenesis Inhibitors/*therapeutic use -MH - Antibodies, Monoclonal/therapeutic use -MH - Antibodies, Monoclonal, Humanized -MH - Antineoplastic Agents/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols -MH - Carcinoma, Squamous Cell/*drug therapy/pathology -MH - Docetaxel -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology -MH - Quinazolines/therapeutic use -MH - Radiation-Sensitizing Agents/*therapeutic use -MH - Retreatment -MH - Taxoids/therapeutic use -MH - Ramucirumab -OTO - NOTNLM -OT - Lung Squamous Cell Carcinoma (LSCC) -OT - antiangiogenic agents -OT - immune checkpoint inhibitors -OT - immunotherapy -OT - targeted therapies -EDAT- 2017/05/04 06:00 -MHDA- 2018/02/01 06:00 -CRDT- 2017/05/04 06:00 -PHST- 2017/05/04 06:00 [pubmed] -PHST- 2018/02/01 06:00 [medline] -PHST- 2017/05/04 06:00 [entrez] -AID - 10.1080/17476348.2017.1326822 [doi] -PST - ppublish -SO - Expert Rev Respir Med. 2017 Jun;11(6):469-479. doi: - 10.1080/17476348.2017.1326822. Epub 2017 May 15. - -PMID- 38145428 -OWN - NLM -STAT- MEDLINE -DCOM- 20240521 -LR - 20240710 -IS - 1699-3055 (Electronic) -IS - 1699-048X (Linking) -VI - 26 -IP - 6 -DP - 2024 Jun -TI - Continuation of immunotherapy beyond progression is beneficial to the survival of - advanced non-small-cell lung cancer. -PG - 1357-1367 -LID - 10.1007/s12094-023-03360-w [doi] -AB - PURPOSE: To investigate the potential clinical importance of continuing - immunotherapy beyond progression in patients with advanced non-small-cell lung - cancer (aNSCLC). METHODS: The data of patients with aNSCLC who experienced - progressive disease after receiving first-line immunotherapy plus chemotherapy - were collected from multiple centers for the period from January 1, 2018 to May - 31, 2022. According to the second-line treatment, the patients were classified - into two groups: the continuation of immunotherapy beyond progression (CIBP) - group and the discontinuation of immunotherapy beyond progression (DIBP) group. - The efficacy and safety of the treatment were compared between the groups. - RESULTS: Overall, data from 169 patients were analyzed; 93 patients were enrolled - in the CIBP group and 76 patients were in the DIBP group. The median second-line - progression-free survival was 5.5 months in the CIBP group, which for the DIBP - group was 3.4 (p = 0.011). The median overall survival of the CIBP group was - 13.3 months, whereas that of the DIBP group was 8.8 months (p = 0.031). The - disease control rate of the CIBP group (79.57%) was observably higher than that - of the DIBP group (64.47%; p = 0.028). Among patients who responded better - (complete or partial response) to prior therapy, the median progression-free - survival was 5.5 months and 3.3 months in the CIBP and DIBP groups respectively - (p = 0.022), and the median overall survival was 14.8 months and 8.8 months in - the CIBP and DIBP groups respectively (p = 0.046). CONCLUSIONS: Continuing - immunotherapy as a second-line treatment could be beneficial to the survival of - patients with aNSCLC with disease progression beyond initial chemotherapy - combined with immunotherapy. -CI - © 2023. The Author(s), under exclusive licence to Federación de Sociedades - Españolas de Oncología (FESEO). -FAU - Cheng, Yuanyuan -AU - Cheng Y -AD - Department of Oncology, The First Affiliated Hospital of Wenzhou Medical - University, 2 Fuxue Road, Wenzhou, Zhejiang, 325000, People's Republic of China. -FAU - Ye, Zhe -AU - Ye Z -AD - Department of Radiation Oncology, Ruian City People's Hospital, Wenzhou, - Zhejiang, People's Republic of China. -FAU - Xie, Yanru -AU - Xie Y -AD - Department of Oncology, Lishui Municipal Central Hospital, Lishui, Zhejiang, - People's Republic of China. -FAU - Du, Xuedan -AU - Du X -AD - Department of Oncology, Lishui Municipal Central Hospital, Lishui, Zhejiang, - People's Republic of China. -FAU - Song, Siqi -AU - Song S -AD - Department of Oncology, The First Affiliated Hospital of Wenzhou Medical - University, 2 Fuxue Road, Wenzhou, Zhejiang, 325000, People's Republic of China. -FAU - Ding, Xiaobo -AU - Ding X -AD - Department of Oncology, The First Affiliated Hospital of Wenzhou Medical - University, 2 Fuxue Road, Wenzhou, Zhejiang, 325000, People's Republic of China. -FAU - Lin, Chuchu -AU - Lin C -AD - Department of Oncology, The First Affiliated Hospital of Wenzhou Medical - University, 2 Fuxue Road, Wenzhou, Zhejiang, 325000, People's Republic of China. -FAU - Wang, Bin -AU - Wang B -AD - Department of Oncology, The First Affiliated Hospital of Wenzhou Medical - University, 2 Fuxue Road, Wenzhou, Zhejiang, 325000, People's Republic of China. -FAU - Li, Wenfeng -AU - Li W -AUID- ORCID: 0000-0002-8669-4976 -AD - Department of Oncology, The First Affiliated Hospital of Wenzhou Medical - University, 2 Fuxue Road, Wenzhou, Zhejiang, 325000, People's Republic of China. - liwenfeng@wmu.edu.cn. -FAU - Zhang, Chunhong -AU - Zhang C -AD - Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical - University, 2 Fuxue Road, Wenzhou, Zhejiang, People's Republic of China. - zch760217@163.com. -LA - eng -GR - 2021KY207/the General program of Health Commission of Zhejiang Province/ -PT - Journal Article -PT - Multicenter Study -DEP - 20231225 -PL - Italy -TA - Clin Transl Oncol -JT - Clinical & translational oncology : official publication of the Federation of - Spanish Oncology Societies and of the National Cancer Institute of Mexico -JID - 101247119 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/mortality/pathology -MH - *Lung Neoplasms/mortality/therapy/pathology -MH - Male -MH - Female -MH - Aged -MH - Middle Aged -MH - *Disease Progression -MH - *Immunotherapy/methods -MH - *Progression-Free Survival -MH - Adult -MH - Retrospective Studies -MH - Aged, 80 and over -MH - Survival Rate -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -OTO - NOTNLM -OT - Immune checkpoint inhibitors -OT - Independent prognostic factors -OT - Negative driver genes -OT - Rechallenge of immunotherapy -OT - Safety and efficacy -EDAT- 2023/12/25 12:42 -MHDA- 2024/05/21 12:44 -CRDT- 2023/12/25 11:04 -PHST- 2023/09/27 00:00 [received] -PHST- 2023/11/21 00:00 [accepted] -PHST- 2024/05/21 12:44 [medline] -PHST- 2023/12/25 12:42 [pubmed] -PHST- 2023/12/25 11:04 [entrez] -AID - 10.1007/s12094-023-03360-w [pii] -AID - 10.1007/s12094-023-03360-w [doi] -PST - ppublish -SO - Clin Transl Oncol. 2024 Jun;26(6):1357-1367. doi: 10.1007/s12094-023-03360-w. - Epub 2023 Dec 25. - -PMID- 28366756 -OWN - NLM -STAT- MEDLINE -DCOM- 20180213 -LR - 20181113 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Print) -IS - 1525-7304 (Linking) -VI - 18 -IP - 5 -DP - 2017 Sep -TI - Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans - With Advanced Non-Small-Cell Lung Cancer. -PG - 559-564 -LID - S1525-7304(17)30041-4 [pii] -LID - 10.1016/j.cllc.2017.01.012 [doi] -AB - BACKGROUND: Because of the prevalence of smoking in the veteran population, - non-small-cell lung cancer (NSCLC) remains a significant cause of morbidity and - mortality. The objectives of our study were to evaluate the extent of durable - clinical benefit (DCB) to pembrolizumab in veterans with metastatic NSCLC and to - identify clinical determinants of DCB. MATERIALS AND METHODS: Prospective - clinical data on veterans receiving pembrolizumab were collected. Duration of - response was calculated from the first date of infusion until date of disease - progression on computed tomography scans, defined according to Response - Evaluation Criteria in Solid Tumors version 1.1 (CTCAE). RESULTS: As of the - censor date, 25 veterans consented and 24 were evaluable. The response rate was - 25% (6 of 24 patients), with all achieving a partial response. Four patients - received palliative radiation because of focal progression and continued to - receive pembrolizumab, leading to a DCB rate of 41% (10 of 24 patients). The mean - duration of response at the censor date was 12.9 months (95% confidence interval - [CI], 9.9-15.9) and 2.7 months (95% CI, 1.9-4.3) for those with and without DCB, - respectively. Patients without DCB had a higher pack-year smoking history (P = - .007). An increase in peripheral blood absolute lymphocyte count (ALC) during - therapy was seen in patients with DCB (P = .073). There were no CTCAE Grade > 3 - adverse events. All immune-related adverse events occurred in patients with DCB. - CONCLUSION: Nearly half of the veterans exhibited DCB and pembrolizumab therapy - was well tolerated. An increase in ALC from baseline and occurrence of autoimmune - phenomena might be associated with DCB. Immunotherapy with pembrolizumab is a - promising therapeutic strategy in veterans with advanced NSCLC. -CI - Copyright © 2017 Elsevier Inc. All rights reserved. -FAU - Qin, Angel -AU - Qin A -AD - Division of Hematology and Oncology, Department of Medicine, University of - Michigan Hospital, Ann Arbor, MI. Electronic address: qina@med.umich.edu. -FAU - Street, Lindsay -AU - Street L -AD - VA Ann Arbor Healthcare System, Ann Arbor, MI. -FAU - Cease, Kemp -AU - Cease K -AD - Division of Hematology and Oncology, Department of Medicine, University of - Michigan Hospital, Ann Arbor, MI; VA Ann Arbor Healthcare System, Ann Arbor, MI. -FAU - Viglianti, Benjamin L -AU - Viglianti BL -AD - VA Ann Arbor Healthcare System, Ann Arbor, MI; Department of Radiology, - University of Michigan Hospital, Ann Arbor, MI. -FAU - Warren, Edus H -AU - Warren EH -AD - Clinical Research Division, Program in Immunology, Fred Hutchinson Cancer - Research Center, Seattle, WA; Division of Medical Oncology, Department of - Medicine, University of Washington Medical Center, Seattle, WA. -FAU - Zhao, Lili -AU - Zhao L -AD - Department of Biostatistics, University of Michigan, Ann Arbor, MI. -FAU - Ramnath, Nithya -AU - Ramnath N -AD - Division of Hematology and Oncology, Department of Medicine, University of - Michigan Hospital, Ann Arbor, MI; VA Ann Arbor Healthcare System, Ann Arbor, MI. -LA - eng -GR - I01 CX001560/CX/CSRD VA/United States -GR - T32 CA009357/CA/NCI NIH HHS/United States -PT - Clinical Trial -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, U.S. Gov't, Non-P.H.S. -DEP - 20170209 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/blood/diagnostic imaging/*drug therapy -MH - Comorbidity -MH - Disease Progression -MH - Humans -MH - Lung Neoplasms/blood/diagnostic imaging/*drug therapy -MH - Lymphocyte Count -MH - Male -MH - Middle Aged -MH - Prospective Studies -MH - Response Evaluation Criteria in Solid Tumors -MH - Smoking -MH - Tomography, X-Ray Computed -MH - Veterans -PMC - PMC6037992 -MID - NIHMS971772 -OTO - NOTNLM -OT - Checkpoint inhibitors -OT - Immunotherapy -OT - Lymphocyte count -OT - NSCLC -OT - Response rate -COIS- Disclosure The authors have stated that they have no conflicts of interest to - disclose. -EDAT- 2017/04/04 06:00 -MHDA- 2018/02/14 06:00 -PMCR- 2018/07/10 -CRDT- 2017/04/04 06:00 -PHST- 2016/12/04 00:00 [received] -PHST- 2017/01/26 00:00 [revised] -PHST- 2017/01/31 00:00 [accepted] -PHST- 2017/04/04 06:00 [pubmed] -PHST- 2018/02/14 06:00 [medline] -PHST- 2017/04/04 06:00 [entrez] -PHST- 2018/07/10 00:00 [pmc-release] -AID - S1525-7304(17)30041-4 [pii] -AID - 10.1016/j.cllc.2017.01.012 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2017 Sep;18(5):559-564. doi: 10.1016/j.cllc.2017.01.012. Epub - 2017 Feb 9. - -PMID- 35806080 -OWN - NLM -STAT- MEDLINE -DCOM- 20220712 -LR - 20220716 -IS - 1422-0067 (Electronic) -IS - 1422-0067 (Linking) -VI - 23 -IP - 13 -DP - 2022 Jun 25 -TI - Immunotherapy in NSCLC Patients with Brain Metastases. -LID - 10.3390/ijms23137068 [doi] -LID - 7068 -AB - Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients - develop brain metastases (BMs) during their disease, with considerable morbidity - and mortality. The management of BMs in patients with NSCLC is a clinical - challenge and requires a multidisciplinary approach to gain effective - intracranial disease control. Over the last decade, immune checkpoint inhibitors - (ICIs) have emerged as a game-changer in the treatment landscape of advanced - NSCLC, with significant improvements in survival outcomes, although patients with - BMs are mostly underrepresented in randomized clinical trials. Moreover, the - safety and activity of ICIs and radiotherapy combinations compared with - single-agent or sequential modalities is still under evaluation to establish the - optimal management of these patients. The aim of this review is to summarize the - state-of-the-art of clinical evidence of ICIs intracranial activity and the main - challenges of incorporating these agents in the treatment armamentarium of NSCLC - patients with BMs. -FAU - Buriolla, Silvia -AU - Buriolla S -AUID- ORCID: 0000-0001-8076-856X -AD - Department of Medicine (DAME), University of Udine, 33100 Udine, Italy. -FAU - Pelizzari, Giacomo -AU - Pelizzari G -AUID- ORCID: 0000-0003-1224-9906 -AD - Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), - 33100 Udine, Italy. -FAU - Corvaja, Carla -AU - Corvaja C -AD - Department of Medicine (DAME), University of Udine, 33100 Udine, Italy. -FAU - Alberti, Martina -AU - Alberti M -AD - Department of Medicine (DAME), University of Udine, 33100 Udine, Italy. -FAU - Targato, Giada -AU - Targato G -AUID- ORCID: 0000-0002-2079-1829 -AD - Department of Medicine (DAME), University of Udine, 33100 Udine, Italy. -FAU - Bortolot, Martina -AU - Bortolot M -AD - Department of Medicine (DAME), University of Udine, 33100 Udine, Italy. -FAU - Torresan, Sara -AU - Torresan S -AD - Department of Medicine (DAME), University of Udine, 33100 Udine, Italy. -FAU - Cortiula, Francesco -AU - Cortiula F -AUID- ORCID: 0000-0002-2719-3653 -AD - Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), - 33100 Udine, Italy. -FAU - Fasola, Gianpiero -AU - Fasola G -AUID- ORCID: 0000-0002-1254-4705 -AD - Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), - 33100 Udine, Italy. -FAU - Follador, Alessandro -AU - Follador A -AUID- ORCID: 0000-0002-2168-4574 -AD - Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), - 33100 Udine, Italy. -LA - eng -PT - Journal Article -PT - Review -DEP - 20220625 -PL - Switzerland -TA - Int J Mol Sci -JT - International journal of molecular sciences -JID - 101092791 -SB - IM -MH - *Brain Neoplasms/drug therapy/secondary -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy/pathology -PMC - PMC9267075 -OTO - NOTNLM -OT - NSCLC -OT - brain -OT - immunotherapy -OT - metastases -COIS- G.P. has served on advisory boards for MSD and AstraZeneca. The other authors - declare no conflict of interest. -EDAT- 2022/07/10 06:00 -MHDA- 2022/07/14 06:00 -PMCR- 2022/06/25 -CRDT- 2022/07/09 01:11 -PHST- 2022/05/15 00:00 [received] -PHST- 2022/06/16 00:00 [revised] -PHST- 2022/06/23 00:00 [accepted] -PHST- 2022/07/09 01:11 [entrez] -PHST- 2022/07/10 06:00 [pubmed] -PHST- 2022/07/14 06:00 [medline] -PHST- 2022/06/25 00:00 [pmc-release] -AID - ijms23137068 [pii] -AID - ijms-23-07068 [pii] -AID - 10.3390/ijms23137068 [doi] -PST - epublish -SO - Int J Mol Sci. 2022 Jun 25;23(13):7068. doi: 10.3390/ijms23137068. - -PMID- 30862891 -OWN - NLM -STAT- MEDLINE -DCOM- 20200928 -LR - 20210109 -IS - 2045-2322 (Electronic) -IS - 2045-2322 (Linking) -VI - 9 -IP - 1 -DP - 2019 Mar 12 -TI - Real-world evidenceand clinical observations of the treatment of advanced - non-small cell lung cancer with PD-1/PD-L1 inhibitors. -PG - 4278 -LID - 10.1038/s41598-019-40748-7 [doi] -LID - 4278 -AB - To summarize the therapeutic effects of PD-1/PD-L1 inhibitors on patients with - advanced non-small cell lung cancer (NSCLC) in a real-world setting, we attempted - to identify potential molecular biomarkers or clinical factors that reflected the - therapeutic effect. The medical records of patients with non-small cell lung - cancer who were treated with PD-1/PD-L1 inhibitors were obtained from the - outpatient department or inpatient department of Peking Union Medical College - Hospital from August 1, 2015, to January 1, 2018. Our follow-up continued until - May 1,2018. We chose overall survival (OS) as the primary observation endpoint - and progression-free survival (PFS), objective response rate (ORR), disease - control rate (DCR), and safety as the secondary observation endpoints. Efficacy - was evaluated according to the Response Evaluation Criteria in Solid Tumors - (RECIST) 1.1. The Kaplan-Meier method was used to generate survival curves, and - we compared the influence of different factors on PFS and OS by the log-rank - test. The median follow-up time was 11 months. At the end of the follow-up, 24 - patients (61.5%) were still undergoing immunotherapy, and 7 patients (17.9%) had - died. Twenty-six cases (66.7%) employed PD-1/PD-L1 inhibitors as first-line - treatment, and 7 cases (17.9%) employed PD-1/PD-L1 inhibitors as second-line - treatment. Only 6 cases (15.4%) employed PD-1/PD-L1 inhibitors as third-line - treatment. Therapeutic effect evaluation: Complete response (CR): 1 case (2.6%). - Partial response (PR): 10 cases (25.6%). Stable disease (SD): 16 cases (41.0%). - Progressive disease (PD): 12 cases (30.8%). The ORR was 28.2%, and DCR was 69.2%. - The median PFS was 25.5 months (95% CI 6.8-44.1 months), which failed to reach - the median OS. PD-1/PD-L1 inhibitor treatment is more effective for advanced - non-small cell lung cancer patients in a real-world setting than in clinical - trials; PD-1/PD-L1 inhibitor treatment is more effective for people who are over - 70 than for people who are under 70. Additionally, patients who are over 75 years - old have a higher response rate, suggesting that elderly patients may receive - more benefits from immunotherapy; Patients who have an epidermal growth factor - receptor (EGFR) mutation (+) may benefit from immunotherapy after treatment with - a tyrosine kinase inhibitor (TKI). It is essential to identify these potential - patients from the entire patient pool; PD-1 may have a certain curative effect on - brain metastases from NSCLC. Local radiotherapy may help to improve PD-1 - intracranial efficacy. -FAU - Song, Peng -AU - Song P -AD - Department of Respiratory Medicine, Peking Union Medical College Hospital, - Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, - China. -FAU - Zhang, Jingcheng -AU - Zhang J -AD - Department of Internal Medicine, Peking Union Medical College Hospital, Chinese - Academy of Medical Sciences & Peking Union Medical College, Beijing, China. -FAU - Shang, Congcong -AU - Shang C -AD - Department of allergy, Henan Provincial People's Hospital, Zhengzhou, China. - 471613851@qq.com. -FAU - Zhang, Li -AU - Zhang L -AD - Department of Respiratory Medicine, Peking Union Medical College Hospital, - Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, - China. zhanglipumch@aliyun.com. -LA - eng -PT - Journal Article -DEP - 20190312 -PL - England -TA - Sci Rep -JT - Scientific reports -JID - 101563288 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Enzyme Inhibitors) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -EIN - Sci Rep. 2020 Jan 27;10(1):1525. doi: 10.1038/s41598-020-58487-5. PMID: 31988322 -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - B7-H1 Antigen/antagonists & inhibitors/*metabolism -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/therapy -MH - Enzyme Inhibitors/*therapeutic use -MH - ErbB Receptors/genetics/metabolism -MH - Female -MH - Humans -MH - Immunotherapy -MH - Kaplan-Meier Estimate -MH - Lung Neoplasms/*drug therapy/metabolism/therapy -MH - Magnetic Resonance Imaging -MH - Male -MH - Middle Aged -MH - Positron Emission Tomography Computed Tomography -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors/*metabolism -MH - Progression-Free Survival -MH - T-Lymphocyte Subsets/metabolism -PMC - PMC6414649 -COIS- The authors declare no competing interests. -EDAT- 2019/03/14 06:00 -MHDA- 2020/09/29 06:00 -PMCR- 2019/03/12 -CRDT- 2019/03/14 06:00 -PHST- 2018/10/24 00:00 [received] -PHST- 2019/02/19 00:00 [accepted] -PHST- 2019/03/14 06:00 [entrez] -PHST- 2019/03/14 06:00 [pubmed] -PHST- 2020/09/29 06:00 [medline] -PHST- 2019/03/12 00:00 [pmc-release] -AID - 10.1038/s41598-019-40748-7 [pii] -AID - 40748 [pii] -AID - 10.1038/s41598-019-40748-7 [doi] -PST - epublish -SO - Sci Rep. 2019 Mar 12;9(1):4278. doi: 10.1038/s41598-019-40748-7. - -PMID- 35881197 -OWN - NLM -STAT- MEDLINE -DCOM- 20230125 -LR - 20240123 -IS - 1432-0851 (Electronic) -IS - 0340-7004 (Print) -IS - 0340-7004 (Linking) -VI - 72 -IP - 2 -DP - 2023 Feb -TI - Comparison of the tumor immune microenvironment and checkpoint blockade - biomarkers between stage III and IV non-small cell lung cancer. -PG - 339-350 -LID - 10.1007/s00262-022-03252-y [doi] -AB - BACKGROUND: Adjuvant immune checkpoint blockade (ICB) following chemoradiotherapy - and adding ICB to chemotherapy have been key advances for stages III-IV non-small - cell lung cancer (NSCLC) treatment. However, known biomarkers like PD-L1 are not - consistently indicative of ICB response. Other markers within the tumor immune - microenvironment (TIME) may better reflect ICB response and/or resistance - mechanisms, but an understanding of how TIMEs differ between stage III and IV - NSCLC has not been explored. METHODS: Real-world data from unresectable, stage - III-IV, non-squamous, pretreatment NSCLCs (stage III n = 106, stage IV n = 285) - were retrospectively analyzed. PD-L1 immunohistochemistry (IHC) was compared to - CD274 gene expression. Then, differential gene expression levels, pathway - enrichment, and immune infiltrate between stages were calculated from - whole-transcriptome RNA-seq. Analyses were stratified by EGFR status. RESULTS: - PD-L1 IHC and CD274 expression in tumor cells were highly correlated (n = 295, - P < 2.2e-16, ⍴ = 0.74). CTLA4 expression was significantly increased in stage III - tumors (P = 1.32e-04), while no differences were observed for other ICB-related - genes. Metabolic pathway activity was significantly enriched in stage IV tumors - (P = 0.004), whereas several immune-related KEGG pathways were enriched in stage - III. Stage IV tumors had significantly increased macrophage infiltration - (P = 0.0214), and stage III tumors had a significantly higher proportion of - CD4 + T cells (P = 0.017). CD4 + T cells were also relatively more abundant in - EGFR-mutant tumors vs. wild-type (P = 0.0081). CONCLUSION: Directly comparing the - TIMEs of stage III and IV NSCLC, these results carry implications for further - studies of ICB response in non-resectable stage III NSCLC and guide further - research of prognostic biomarkers and therapeutic targets. -CI - © 2022. The Author(s). -FAU - Gao, Yinjie -AU - Gao Y -AD - Tempus Labs, Chicago, IL, 60654, USA. -FAU - Stein, Michelle M -AU - Stein MM -AD - Tempus Labs, Chicago, IL, 60654, USA. -FAU - Kase, Matthew -AU - Kase M -AD - Tempus Labs, Chicago, IL, 60654, USA. -FAU - Cummings, Amy L -AU - Cummings AL -AD - UCLA School of Medicine, Los Angeles, CA, 90095, USA. -FAU - Bharanikumar, Ramit -AU - Bharanikumar R -AD - Tempus Labs, Chicago, IL, 60654, USA. -FAU - Lau, Denise -AU - Lau D -AD - Tempus Labs, Chicago, IL, 60654, USA. -FAU - Garon, Edward B -AU - Garon EB -AD - UCLA School of Medicine, Los Angeles, CA, 90095, USA. -FAU - Patel, Sandip P -AU - Patel SP -AD - UC San Diego Health, La Jolla, San Diego, CA, 92093, USA. SPatel@Health.UCSD.edu. -LA - eng -GR - P30 CA016042/CA/NCI NIH HHS/United States -PT - Journal Article -DEP - 20220726 -PL - Germany -TA - Cancer Immunol Immunother -JT - Cancer immunology, immunotherapy : CII -JID - 8605732 -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers) -RN - 0 (Immune Checkpoint Inhibitors) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - B7-H1 Antigen/metabolism -MH - Retrospective Studies -MH - Biomarkers -MH - Tumor Microenvironment -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - ErbB Receptors -MH - Biomarkers, Tumor -PMC - PMC9870967 -OTO - NOTNLM -OT - Checkpoint blockade -OT - Immunotherapy -OT - Non-small cell lung cancer -OT - PD-L1 -OT - Transcriptomics -OT - Tumor immune microenvironment -COIS- Y.G., M.M.S., M.K., D.L., and R.B. are all employees of Tempus Labs. S.P. reports - grants and personal fees from AstraZeneca, grants and personal fees from - Bristol-Myers Squibb, grants and personal fees from Eli Lilly, personal fees from - Illumina, personal fees from Rakuten, grants and personal fees from Tempus, - grants from Merck, grants from Pfizer, grants from Roche/Genentech, grants from - Fate, grants from Genocea, from Iovance, grants from Novartis, outside the - submitted work. A.L.C. reports institutional payments from Amgen, a consulting - role for Tempus Labs, and serving as an unpaid data chair for the University of - California Lung Cancer Consortium Steering Committee. E.B.G. reports a consulting - or advisory role for Merck, Bristol-Meyers Squibb, Shionogi, GlaxoSmithKline, - Regeneron/Sanofi, Gilead Sciences, Novartis, Personalis, Boehringer Ingelheim, - ABL Bio, Xilio, Natera, Eli Lilly, and Eisai. E.B.G also reports research funding - from AstraZeneca, Bristol-Myers Squibb, Genentech, Neon Therapeutics, Dynavax, - Iovance Biotherapeutics, ABL Bio, Novartis, Lilly, EMD Serono, Merck, and Mirati - Therapeutics, outside the submitted work. -EDAT- 2022/07/27 06:00 -MHDA- 2023/01/26 06:00 -PMCR- 2022/07/26 -CRDT- 2022/07/26 11:15 -PHST- 2022/03/30 00:00 [received] -PHST- 2022/07/03 00:00 [accepted] -PHST- 2022/07/27 06:00 [pubmed] -PHST- 2023/01/26 06:00 [medline] -PHST- 2022/07/26 11:15 [entrez] -PHST- 2022/07/26 00:00 [pmc-release] -AID - 10.1007/s00262-022-03252-y [pii] -AID - 3252 [pii] -AID - 10.1007/s00262-022-03252-y [doi] -PST - ppublish -SO - Cancer Immunol Immunother. 2023 Feb;72(2):339-350. doi: - 10.1007/s00262-022-03252-y. Epub 2022 Jul 26. - -PMID- 33232786 -OWN - NLM -STAT- MEDLINE -DCOM- 20210430 -LR - 20210430 -IS - 1872-7980 (Electronic) -IS - 0304-3835 (Linking) -VI - 498 -DP - 2021 Feb 1 -TI - TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in - non-small cell lung cancer via down-regulation of CSF-1R and enhances the - anti-tumor effects of anti-PD-1. -PG - 142-151 -LID - S0304-3835(20)30577-2 [pii] -LID - 10.1016/j.canlet.2020.10.043 [doi] -AB - Recent advances in immune checkpoint inhibition, which augment T-cell immune - responses, have highlighted the potential of exploiting one's immune system to - combat cancer. However, only a relatively small number of non-small cell lung - cancer (NSCLC) patients benefit from immune checkpoint blockade due to the - immunosuppressive tumor microenvironment. Therefore, combination immunotherapies - are now being developed to achieve maximal therapeutic benefits. In this study, - we assessed whether a novel erlotinib derivative, TD-92, which possesses - anti-tumor effects across several cancer cell lines, could enhance anti-PD-1 - treatment. Our results demonstrated that the combined treatment of anti-PD-1 and - TD-92 resulted in a potent anti-tumor response in a Lewis lung carcinoma cancer - model, as evidenced by the reduced tumor growth and increased survival. Analysis - of immune cell population counts revealed that TD-92 reduced the number of - pro-tumorigenic CD11b(+) F4/80(+) tumor-associated macrophages, without - significantly affecting the total numbers of other major immunocytes. Further - experiments showed that TD-92 induced a marked decline in colony stimulating - factor 1 receptor (CSF-1R) expression in macrophage cell lines. The results also - suggested that c-Cbl-mediated proteasome degradation was involved in - TD-92-mediated CSF-1R downregulation. Our data paves the way for the development - of additional combination immunotherapies for NSCLC patients. -CI - Copyright © 2020 Elsevier B.V. All rights reserved. -FAU - Shih, Chi-Ting -AU - Shih CT -AD - Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, - Taiwan. -FAU - Shiau, Chung-Wai -AU - Shiau CW -AD - Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, - Taiwan. -FAU - Chen, Yen-Lin -AU - Chen YL -AD - Department of Pathology, Cardinal Tien Hospital, School of Medicine, Fu Jen - Catholic University, New Taipei city, Taiwan. -FAU - Chen, Li-Ju -AU - Chen LJ -AD - Department of Medical Research, National Taiwan University Hospital, Taipei, - Taiwan. -FAU - Chao, Tzu-I -AU - Chao TI -AD - SupremeCure Pharma Inc., Taipei, Taiwan. -FAU - Wang, Cheng-Yi -AU - Wang CY -AD - Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, - College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. - Electronic address: cywang@mospital.com. -FAU - Huang, Chao-Yuan -AU - Huang CY -AD - Division of Radiation Oncology, Department of Oncology, National Taiwan - University Hospital and National Taiwan University College of Medicine, Taipei, - Taiwan. Electronic address: cyhuang999@ntu.edu.tw. -FAU - Hung, Man-Hsin -AU - Hung MH -AD - Division of Medical Oncology, Department of Oncology, Taipei Veterans General - Hospital, Taipei, Taiwan; School of Medicine, National Yang-Ming University, - Taipei, Taiwan; Laboratory of Human Carcinogenesis, Center for Cancer Research, - National Cancer Institute, Bethesda, MD, USA. Electronic address: - manhsin.hung@nih.gov. -FAU - Chen, Kuen-Feng -AU - Chen KF -AD - SupremeCure Pharma Inc., Taipei, Taiwan. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20201121 -PL - Ireland -TA - Cancer Lett -JT - Cancer letters -JID - 7600053 -RN - 0 (Antineoplastic Agents) -RN - 0 (Biomarkers, Tumor) -RN - 0 (Csf1r protein, mouse) -RN - 0 (Pdcd1 protein, mouse) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 0 (Receptors, Granulocyte-Macrophage Colony-Stimulating Factor) -RN - DA87705X9K (Erlotinib Hydrochloride) -SB - IM -MH - Animals -MH - Antineoplastic Agents/*pharmacology -MH - Biomarkers, Tumor/metabolism -MH - Carcinoma, Lewis Lung/drug therapy/metabolism -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism -MH - Cell Line, Tumor -MH - Down-Regulation/*drug effects -MH - Erlotinib Hydrochloride/*pharmacology -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/*drug therapy/metabolism -MH - Male -MH - Mice -MH - Mice, Inbred BALB C -MH - Mice, Inbred C57BL -MH - Programmed Cell Death 1 Receptor/*metabolism -MH - Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/*metabolism -MH - Tumor Microenvironment/drug effects -MH - Tumor-Associated Macrophages/*drug effects/metabolism -OTO - NOTNLM -OT - Anti-PD-1 -OT - CSF-1R -OT - Immunotherapy -OT - NSCLC -OT - TAMs -OT - TD-92 -EDAT- 2020/11/25 06:00 -MHDA- 2021/05/01 06:00 -CRDT- 2020/11/24 20:08 -PHST- 2020/02/28 00:00 [received] -PHST- 2020/10/15 00:00 [revised] -PHST- 2020/10/26 00:00 [accepted] -PHST- 2020/11/25 06:00 [pubmed] -PHST- 2021/05/01 06:00 [medline] -PHST- 2020/11/24 20:08 [entrez] -AID - S0304-3835(20)30577-2 [pii] -AID - 10.1016/j.canlet.2020.10.043 [doi] -PST - ppublish -SO - Cancer Lett. 2021 Feb 1;498:142-151. doi: 10.1016/j.canlet.2020.10.043. Epub 2020 - Nov 21. - -PMID- 29905778 -OWN - NLM -STAT- MEDLINE -DCOM- 20191223 -LR - 20210109 -IS - 1569-8041 (Electronic) -IS - 0923-7534 (Print) -IS - 0923-7534 (Linking) -VI - 29 -IP - 8 -DP - 2018 Aug 1 -TI - Predictive biomarkers for response to EGFR-directed monoclonal antibodies for - advanced squamous cell lung cancer. -PG - 1701-1709 -LID - S0923-7534(19)34117-1 [pii] -LID - 10.1093/annonc/mdy196 [doi] -AB - BACKGROUND: Upregulated expression and aberrant activation of the epidermal - growth-factor receptor (EGFR) are found in lung cancer, making EGFR a relevant - target for non-small-cell lung cancer (NSCLC). Treatment with anti-EGFR - monoclonal antibodies (mAbs) is associated with modest improvement in overall - survival in patients with squamous cell lung cancer (SqCLC) who have a - significant unmet need for effective treatment options. While there is evidence - that using EGFR gene copy number, EGFR mutation, and EGFR protein expression as - biomarkers can help select patients who respond to treatment, it is important to - consider biomarkers for response in patients treated with combination therapies - that include EGFR mAbs. DESIGN: Randomized trials of EGFR-directed mAbs cetuximab - and necitumumab in combination with chemotherapy, immunotherapy, or - antiangiogenic therapy in patients with advanced NSCLC, including SqCLC, were - searched in the literature. Results of associations of potential biomarkers and - outcomes were summarized. RESULTS: Data from phase III clinical trials indicate - that patients with NSCLC, including SqCLC, whose tumors express high levels of - EGFR protein (H-score of ≥200) and/or gene copy numbers of EGFR (e.g. ≥40% cells - with ≥4 EGFR copies as detected by fluorescence in situ hybridization; gene - amplification in ≥10% of analyzed cells) derive greater therapeutic benefits from - EGFR-directed mAbs. Biomarker data are limited for EGFR mAbs used in combination - with immunotherapy and are absent when used in combination with antiangiogenic - agents. CONCLUSIONS: Therapy with EGFR-directed mAbs in combination with - chemotherapy is associated with greater clinical benefits in patients with NSCLC, - including SqCLC, whose tumors express high levels of EGFR protein and/or have - increased EGFR gene copy number. These data support validating the role of these - as biomarkers to identify those patients who derive the greatest clinical benefit - from EGFR mAb therapy. However, data on biomarkers for EGFR-directed mAbs - combined with immunotherapy or antiangiogenic agents remain limited. -FAU - Bonomi, P D -AU - Bonomi PD -AD - Department of Internal Medicine, Rush University Medical Center, Chicago, USA. - Electronic address: pbonomi@rush.edu. -FAU - Gandara, D -AU - Gandara D -AD - Department of Hematology and Oncology, UC Davis Comprehensive Cancer Center, - Sacramento, USA. -FAU - Hirsch, F R -AU - Hirsch FR -AD - University of Colorado Cancer Center, Aurora, USA. -FAU - Kerr, K M -AU - Kerr KM -AD - Department of Pathology, Aberdeen University Medical School and Aberdeen Royal - Infirmary Foresterhill, Aberdeen, UK. -FAU - Obasaju, C -AU - Obasaju C -AD - Eli Lilly and Company, Indianapolis, USA. -FAU - Paz-Ares, L -AU - Paz-Ares L -AD - Hospital Universitario Doce de Octubre, Universidad Complutense, CiberOnc & CNIO, - Madrid, Spain. -FAU - Bellomo, C -AU - Bellomo C -AD - Intermountain Cancer Center, Cedar City Hospital, Cedar City, USA. -FAU - Bradley, J D -AU - Bradley JD -AD - Department of Radiation Oncology, Washington University School of Medicine, St. - Louis, USA. -FAU - Bunn, P A Jr -AU - Bunn PA Jr -AD - University of Colorado Cancer Center, Aurora, USA. -FAU - Culligan, M -AU - Culligan M -AD - Division of Thoracic Surgery, University of Maryland School of Medicine, - Baltimore, USA. -FAU - Jett, J R -AU - Jett JR -AD - Emeritus, National Jewish Health, Denver, USA. -FAU - Kim, E S -AU - Kim ES -AD - Levine Cancer Institute, Atrium Health, Charlotte, USA. -FAU - Langer, C J -AU - Langer CJ -AD - Department of Thoracic Oncology, University of Pennsylvania Abramson Cancer - Center, Philadelphia, USA. -FAU - Natale, R B -AU - Natale RB -AD - Cedars-Sinai Comprehensive Cancer Center, West Hollywood, USA. -FAU - Novello, S -AU - Novello S -AD - Department of Oncology, University of Turin, Turin, Italy. -FAU - Pérol, M -AU - Pérol M -AD - Department of Medical Oncology, Centre Léon Bérard, Lyon, France. -FAU - Ramalingam, S S -AU - Ramalingam SS -AD - Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory - University, Atlanta, USA. -FAU - Reck, M -AU - Reck M -AD - Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the - German Center for Lung Research (DZL), Grosshansdorf, Germany. -FAU - Reynolds, C H -AU - Reynolds CH -AD - Florida Cancer Specialists, Ocala, USA. -FAU - Smit, E F -AU - Smit EF -AD - Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, the - Netherlands. -FAU - Socinski, M A -AU - Socinski MA -AD - Florida Hospital Cancer Institute, Orlando, USA. -FAU - Spigel, D R -AU - Spigel DR -AD - Sarah Cannon Research Institute, Nashville, USA. -FAU - Vansteenkiste, J F -AU - Vansteenkiste JF -AD - Respiratory Oncology Unit, Department of Respiratory Medicine, University - Hospital KU Leuven, Leuven, Belgium. -FAU - Wakelee, H -AU - Wakelee H -AD - Stanford University School of Medicine, Stanford, USA. -FAU - Thatcher, N -AU - Thatcher N -AD - The Christie NHS Foundation Trust, Manchester, UK. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - England -TA - Ann Oncol -JT - Annals of oncology : official journal of the European Society for Medical - Oncology -JID - 9007735 -RN - 0 (Angiogenesis Inhibitors) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Biomarkers, Tumor) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Angiogenesis Inhibitors/pharmacology/therapeutic use -MH - Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use -MH - Antineoplastic Agents, Immunological/pharmacology/therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/*pharmacology/therapeutic use -MH - Biomarkers, Tumor/*analysis/genetics/metabolism -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/pathology -MH - Drug Resistance, Neoplasm/drug effects/genetics -MH - ErbB Receptors/antagonists & inhibitors/genetics/metabolism -MH - Gene Dosage -MH - Humans -MH - Lung/pathology -MH - Lung Neoplasms/*drug therapy/genetics/pathology -MH - Mutation -MH - Randomized Controlled Trials as Topic -MH - Treatment Outcome -PMC - PMC6128180 -EDAT- 2018/06/16 06:00 -MHDA- 2019/12/24 06:00 -PMCR- 2018/06/14 -CRDT- 2018/06/16 06:00 -PHST- 2018/06/16 06:00 [pubmed] -PHST- 2019/12/24 06:00 [medline] -PHST- 2018/06/16 06:00 [entrez] -PHST- 2018/06/14 00:00 [pmc-release] -AID - S0923-7534(19)34117-1 [pii] -AID - mdy196 [pii] -AID - 10.1093/annonc/mdy196 [doi] -PST - ppublish -SO - Ann Oncol. 2018 Aug 1;29(8):1701-1709. doi: 10.1093/annonc/mdy196. - -PMID- 37095004 -OWN - NLM -STAT- MEDLINE -DCOM- 20230614 -LR - 20230619 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 14 -IP - 17 -DP - 2023 Jun -TI - Correlations between pathogenic variants in DNA repair genes and anticancer - treatment efficacy in stage IV non-small cell lung cancer: A large real-world - cohort and review of the literature. -PG - 1589-1596 -LID - 10.1111/1759-7714.14902 [doi] -AB - BACKGROUND: Mutations in genes involved in DNA damage repair (DDR), a hallmark of - cancer, are associated with increased cancer cell sensitivity to certain - therapies. This study sought to evaluate the association of DDR pathogenic - variants with treatment efficacy in patients with advanced non-small cell lung - cancer (NSCLC). METHODS: A retrospective cohort of consecutive patients with - advanced NSCLC attending a tertiary medical center who underwent next-generation - sequencing in 01/2015-8/2020 were clustered according to DDR gene status and - compared for overall response rate (ORR), progression-free survival (PFS) - (patients receiving systemic therapy), local PFS (patients receiving definitive - radiotherapy), and overall survival (OS) using log-rank and Cox regression - analyses. RESULTS: Of 225 patients with a clear tumor status, 42 had a - pathogenic/likely pathogenic DDR variant (pDDR), and 183 had no DDR variant - (wtDDR). Overall survival was similar in the two groups (24.2 vs. 23.1 months, - p = 0.63). The pDDR group had a higher median local PFS after radiotherapy - (median 45 months vs. 9.9 months, respectively; p = 0.044), a higher ORR (88.9% - vs. 36.2%, p = 0.04), and a longer median PFS (not reached vs. 6.0 months, - p = 0.01) in patients treated with immune checkpoint blockade. There was no - difference in ORR, median PFS, and median OS in patients treated with - platinum-based chemotherapy. CONCLUSION: Our retrospective data suggest that in - patients with stage 4 NSCLC, pathogenic variants in DDR pathway genes may be - associated with higher efficacy of radiotherapy and immune checkpoint inhibitors - (ICIs). This should be further explored prospectively. -CI - © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Averbuch, Itamar -AU - Averbuch I -AUID- ORCID: 0000-0003-1784-4528 -AD - Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. -FAU - Tschernichovsky, Roi -AU - Tschernichovsky R -AD - Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. -FAU - Icht, Oded -AU - Icht O -AD - Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. -FAU - Goldstein, Daniel A -AU - Goldstein DA -AD - Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. -FAU - Mutai, Raz -AU - Mutai R -AD - Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. -FAU - Dudnik, Elizabeth -AU - Dudnik E -AD - Oncology Division, Assuta Medical Center, Tel Aviv, Israel. -FAU - Rotem, Ofer -AU - Rotem O -AD - Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. -FAU - Peled, Nir -AU - Peled N -AD - Oncology Division, Shaare Zedek Medical Center, Jerusalem, Israel. -FAU - Allen, Aaron M -AU - Allen AM -AD - Oncology Division, Shaare Zedek Medical Center, Jerusalem, Israel. -FAU - Laufer-Geva, Smadar -AU - Laufer-Geva S -AD - Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. -FAU - Goldberg, Yael -AU - Goldberg Y -AD - The Raphael Recanati Genetic Institute, Rabin Medical Center, Petah Tikva, - Israel. -FAU - Zer, Alona -AU - Zer A -AD - Fishman Oncology Institute, Rambam Health Care Campus, Haifa, Israel. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230424 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung -MH - Retrospective Studies -MH - *Lung Neoplasms -MH - Treatment Outcome -MH - DNA Repair -MH - Immune Checkpoint Inhibitors -PMC - PMC10260479 -OTO - NOTNLM -OT - DNA damage repair mutations -OT - immunotherapy -OT - non-small cell lung cancer -OT - platinum-based chemotherapy -OT - radiotherapy -COIS- IA, RT, OI, RM, OR, YG, AMA and SL declares no conflicts of interest. ED declares - the following interests: Grants or contracts (Astra Zeneca), Consulting fees - (Roche, Astra Zeneca, Pfizer, Merck Sharpe & Dohme, Bristol Myers Squibb, - Novartis, Takeda, Sanofi, Merck Serono, Medison Pharma, Janssen Israel), Payment - or honoraria (Roche, Astra Zeneca, Pfizer, Merck Sharpe & Dohme, Bristol Myers - Squibb, Novartis, Takeda, Sanofi, Merck Serono, Medison Pharma, Janssen Israel), - Support (Merck Serono, Medison Pharma). DAG declares the following interests: - institutional research funding (Merck, Bristol Myers Squibb and Jannsen); - consulting fees (VIVIO Health); stock ownership (VIVIO Health and TailorMed). NP - declares the following interests: Advisor, Honorarium & Research (AstraZeneca, - Bayer, Boehringer Ingelheim, Bristol‐Myers Squibb, Eli Lilly, Foundation - Medicine, Guardant360, Merk, MSD, Novartis, NovellusDx, Pfizer, Roche, Takeda) - and Support for attending meetings and/or travel (AstraZeneca, Bayer, Boehringer - Ingelheim, Bristol‐Myers Squibb, Eli Lilly, Foundation Medicine, Guardant360, - Merk, MSD, Novartis, NovellusDx, Pfizer, Roche, Takeda). AZ declares the - following interests: Consulting fees from Roche, MSD, AstraZeneca, Novartis, - Pfizer. Honoraria from Roche, Takeda, AstraZeneca. Participation in Advisory - boards ‐ AstraZeneca, Novartis. Stock Options ‐ Nixio. -EDAT- 2023/04/25 00:41 -MHDA- 2023/06/14 06:42 -PMCR- 2023/04/24 -CRDT- 2023/04/24 09:52 -PHST- 2023/04/01 00:00 [revised] -PHST- 2023/02/07 00:00 [received] -PHST- 2023/04/03 00:00 [accepted] -PHST- 2023/06/14 06:42 [medline] -PHST- 2023/04/25 00:41 [pubmed] -PHST- 2023/04/24 09:52 [entrez] -PHST- 2023/04/24 00:00 [pmc-release] -AID - TCA14902 [pii] -AID - 10.1111/1759-7714.14902 [doi] -PST - ppublish -SO - Thorac Cancer. 2023 Jun;14(17):1589-1596. doi: 10.1111/1759-7714.14902. Epub 2023 - Apr 24. - -PMID- 29738824 -OWN - NLM -STAT- MEDLINE -DCOM- 20190903 -LR - 20220330 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 13 -IP - 7 -DP - 2018 Jul -TI - Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell - Lung Cancer. -PG - 978-986 -LID - S1556-0864(18)30536-7 [pii] -LID - 10.1016/j.jtho.2018.04.010 [doi] -AB - INTRODUCTION: Anti-programmed cell death protein 1 (PD-1) therapy can lead to - unconventional tumor responses, including radiologic pseudoprogression. Here we - have determined the real-world incidence of radiologic pseudoprogression in - advanced NSCLC and compared radiologic response criteria for assessment of - disease response. METHODS: The electronic medical records of all patients with - NSCLC who were receiving anti-PD-1 therapy at our institution over a 3-year - period were retrospectively reviewed, and patients with clinically suspected - radiologic pseudoprogression were identified. Patients without available - follow-up imaging or clinical data were excluded. Imaging examinations were then - analyzed to determine whether progression was confirmed on subsequent reimaging. - Assessments of tumor response by the Response Evaluation Criteria in Solid Tumors - (RECIST), version 1.1 (RECIST 1.1), the unidimensional immune-related response - criteria (iRRC), and the iRECIST criteria for all patients were performed and - compared. RESULTS: A total of 228 consecutive patients began receiving anti-PD-1 - therapy over a 3-year period. Of the 166 of these patients who were evaluable, - most (80%) received nivolumab. Fifteen patients (9%) were clinically suspected of - having radiologic pseudoprogression on account of tumor enlargement and/or - development of new lesions on computed tomography images during the first 4 to 6 - weeks of therapy, and they continued receiving anti-PD-1 therapy. Three of these - patients (2%) demonstrated evidence of radiologic pseudoprogression at first - reimaging. The iRRC and immune RECIST criteria were more accurate in classifying - radiologic pseudoprogression as nonprogression; none of the three cases were - deemed progression by the iRRC or immune RECIST, whereas all three cases were - determined to be progression according to the Response Evaluation Criteria in - Solid Tumors, version 1.1. CONCLUSIONS: Radiologic pseudoprogression is a - clinical challenge but an uncommon occurrence in patients with NSCLC who are - receiving anti-PD-1 therapy. -CI - Copyright © 2018 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Katz, Sharyn I -AU - Katz SI -AD - Department of Radiology, University of Pennsylvania Perelman School of Medicine, - Philadelphia, Pennsylvania. Electronic address: sharyn.katz@uphs.upenn.edu. -FAU - Hammer, Mark -AU - Hammer M -AD - Department of Radiology, University of Pennsylvania Perelman School of Medicine, - Philadelphia, Pennsylvania; Department of Radiology, Brigham and Women's - Hospital, Boston, Massachusetts. -FAU - Bagley, Stephen J -AU - Bagley SJ -AD - Department of Medicine, University of Pennsylvania Perelman School of Medicine, - Philadelphia, Pennsylvania. -FAU - Aggarwal, Charu -AU - Aggarwal C -AD - Department of Medicine, University of Pennsylvania Perelman School of Medicine, - Philadelphia, Pennsylvania. -FAU - Bauml, Joshua M -AU - Bauml JM -AD - Department of Medicine, University of Pennsylvania Perelman School of Medicine, - Philadelphia, Pennsylvania. -FAU - Thompson, Jeffrey C -AU - Thompson JC -AD - Department of Medicine, University of Pennsylvania Perelman School of Medicine, - Philadelphia, Pennsylvania. -FAU - Nachiappan, Arun C -AU - Nachiappan AC -AD - Department of Radiology, University of Pennsylvania Perelman School of Medicine, - Philadelphia, Pennsylvania. -FAU - Simone, Charles B 2nd -AU - Simone CB 2nd -AD - Department of Radiation Oncology, University of Maryland Medical Center, - Baltimore, Maryland. -FAU - Langer, Corey J -AU - Langer CJ -AD - Department of Medicine, University of Pennsylvania Perelman School of Medicine, - Philadelphia, Pennsylvania. -LA - eng -PT - Journal Article -DEP - 20180505 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 31YO63LBSN (Nivolumab) -SB - IM -CIN - J Thorac Oncol. 2018 Jul;13(7):880-882. doi: 10.1016/j.jtho.2018.05.011. PMID: - 29935844 -CIN - J Thorac Dis. 2018 Nov;10(Suppl 33):S3930-S3932. doi: 10.21037/jtd.2018.09.129. - PMID: 30631519 -MH - Adenocarcinoma/diagnostic imaging/drug therapy/*pathology -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antineoplastic Agents, Immunological/therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/drug therapy/*pathology -MH - Carcinoma, Squamous Cell/diagnostic imaging/drug therapy/*pathology -MH - Disease Progression -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Lung Neoplasms/diagnostic imaging/drug therapy/*pathology -MH - Male -MH - Middle Aged -MH - Nivolumab/*therapeutic use -MH - *Response Evaluation Criteria in Solid Tumors -MH - Retrospective Studies -MH - Tomography, X-Ray Computed -MH - Treatment Outcome -OTO - NOTNLM -OT - Anti–PD-1 therapy -OT - Immune-related response criteria -OT - NSCLC -OT - Pseudoprogression -EDAT- 2018/05/09 06:00 -MHDA- 2019/09/04 06:00 -CRDT- 2018/05/09 06:00 -PHST- 2017/07/08 00:00 [received] -PHST- 2018/04/01 00:00 [revised] -PHST- 2018/04/06 00:00 [accepted] -PHST- 2018/05/09 06:00 [pubmed] -PHST- 2019/09/04 06:00 [medline] -PHST- 2018/05/09 06:00 [entrez] -AID - S1556-0864(18)30536-7 [pii] -AID - 10.1016/j.jtho.2018.04.010 [doi] -PST - ppublish -SO - J Thorac Oncol. 2018 Jul;13(7):978-986. doi: 10.1016/j.jtho.2018.04.010. Epub - 2018 May 5. - -PMID- 34740922 -OWN - NLM -STAT- MEDLINE -DCOM- 20220407 -LR - 20240902 -IS - 1557-3265 (Electronic) -IS - 1078-0432 (Print) -IS - 1078-0432 (Linking) -VI - 28 -IP - 4 -DP - 2022 Feb 15 -TI - Adding Base-Excision Repair Inhibitor TRC102 to Standard - Pemetrexed-Platinum-Radiation in Patients with Advanced Nonsquamous Non-Small - Cell Lung Cancer: Results of a Phase I Trial. -PG - 646-652 -LID - 10.1158/1078-0432.CCR-21-2025 [doi] -AB - PURPOSE: TRC102, a small-molecule base-excision repair inhibitor, potentiates the - cytotoxicity of pemetrexed and reverses resistance by binding to - chemotherapy-induced abasic sites in DNA. We conducted a phase I clinical trial - combining pemetrexed and TRC102 with cisplatin-radiation in stage III nonsquamous - non-small cell lung cancer (NS-NSCLC). PATIENTS AND METHODS: Fifteen patients - were enrolled from 2015 to 2019. The primary objective was to determine the - dose-limiting toxicity and maximum tolerated dose of TRC102 in combination with - pemetrexed, cisplatin, and radiotherapy. Secondary objectives were to assess - toxicity, tumor response, and progression-free survival at 6 months. Based on our - preclinical experiments, pemetrexed-TRC102 was given on day 1, and - cisplatin/radiotherapy was initiated on day 3. This schedule was duplicated in - the second cycle. After completion, two additional cycles of pemetrexed-cisplatin - were given. Toxicities were assessed using NCI CTACAE versions 4/5. RESULTS: The - median age was 69 years (45-79) with the median follow-up of 25.7 months (range, - 7.9-47.4). No dose-limiting toxicities and no grade 5 toxicity were seen. - Hematologic and gastrointestinal toxicities were the most common side effects. No - clinical radiation pneumonitis was seen. Of 15 evaluable patients, three had - complete response (20%), and 12 had partial response (80%). The 6-month - progression-free survival was 80%, and the 2-year overall survival was 83%. - CONCLUSIONS: Pemetrexed-TRC102 combined with cisplatin/radiotherapy in NS-NSCLC - is safe and well tolerated. The recommended phase II dose is 200 mg TRC102 along - with cisplatin-pemetrexed. No additional safety signal was seen beyond the - expected CRT risks. A phase II trial, integrating post-CRT immunotherapy with - this aggressive DNA-damaging regimen, is warranted. -CI - ©2021 The Authors; Published by the American Association for Cancer Research. -FAU - Biswas, Tithi -AU - Biswas T -AUID- ORCID: 0000-0002-9074-733X -AD - University Hospitals Seidman Cancer Center, Cleveland, Ohio. -AD - Case Western Reserve University, Cleveland, Ohio. -FAU - Dowlati, Afshin -AU - Dowlati A -AD - University Hospitals Seidman Cancer Center, Cleveland, Ohio. -AD - Case Western Reserve University, Cleveland, Ohio. -FAU - Kunos, Charles A -AU - Kunos CA -AD - National Cancer Institute, Rockville, Maryland. -FAU - Pink, John J -AU - Pink JJ -AD - Case Western Reserve University, Cleveland, Ohio. -AD - Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, - Ohio. -FAU - Oleinick, Nancy L -AU - Oleinick NL -AD - Case Western Reserve University, Cleveland, Ohio. -FAU - Malik, Shakun -AU - Malik S -AD - National Cancer Institute, Rockville, Maryland. -FAU - Fu, Pingfu -AU - Fu P -AD - Case Western Reserve University, Cleveland, Ohio. -AD - Department of Population and Quantitative Health Sciences, Case Western Reserve - University, Cleveland, Ohio. -FAU - Cao, Shufen -AU - Cao S -AD - Case Western Reserve University, Cleveland, Ohio. -AD - Department of Population and Quantitative Health Sciences, Case Western Reserve - University, Cleveland, Ohio. -FAU - Bruno, Debora S -AU - Bruno DS -AD - University Hospitals Seidman Cancer Center, Cleveland, Ohio. -AD - Case Western Reserve University, Cleveland, Ohio. -FAU - Bajor, David L -AU - Bajor DL -AUID- ORCID: 0000-0003-2702-5008 -AD - University Hospitals Seidman Cancer Center, Cleveland, Ohio. -AD - Case Western Reserve University, Cleveland, Ohio. -FAU - Patel, Monaliben -AU - Patel M -AD - University Hospitals Seidman Cancer Center, Cleveland, Ohio. -AD - Case Western Reserve University, Cleveland, Ohio. -FAU - Gerson, Stanton L -AU - Gerson SL -AD - Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, - Ohio. -AD - School of Medicine, Case Western Reserve University, Cleveland, Ohio. -FAU - Machtay, Mitchell -AU - Machtay M -AD - Pennsylvania State University, State College, Pennsylvania. -LA - eng -GR - P30 CA043703/CA/NCI NIH HHS/United States -PT - Clinical Trial, Phase I -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - United States -TA - Clin Cancer Res -JT - Clinical cancer research : an official journal of the American Association for - Cancer Research -JID - 9502500 -RN - 0 (Glutamates) -RN - 04Q9AIZ7NO (Pemetrexed) -RN - 49DFR088MY (Platinum) -RN - 5Z93L87A1R (Guanine) -RN - Q20Q21Q62J (Cisplatin) -SB - IM -MH - Aged -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - Cisplatin -MH - DNA Repair -MH - Glutamates/adverse effects -MH - Guanine/adverse effects -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Pemetrexed/adverse effects -MH - Platinum/therapeutic use -PMC - PMC8866206 -MID - NIHMS1755145 -EDAT- 2021/11/07 06:00 -MHDA- 2022/04/08 06:00 -PMCR- 2022/08/15 -CRDT- 2021/11/06 05:37 -PHST- 2021/06/04 00:00 [received] -PHST- 2021/09/01 00:00 [revised] -PHST- 2021/10/29 00:00 [accepted] -PHST- 2021/11/07 06:00 [pubmed] -PHST- 2022/04/08 06:00 [medline] -PHST- 2021/11/06 05:37 [entrez] -PHST- 2022/08/15 00:00 [pmc-release] -AID - 1078-0432.CCR-21-2025 [pii] -AID - CCR-21-2025 [pii] -AID - 10.1158/1078-0432.CCR-21-2025 [doi] -PST - ppublish -SO - Clin Cancer Res. 2022 Feb 15;28(4):646-652. doi: 10.1158/1078-0432.CCR-21-2025. - -PMID- 39097705 -OWN - NLM -STAT- MEDLINE -DCOM- 20240803 -LR - 20240806 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 24 -IP - 1 -DP - 2024 Aug 3 -TI - Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in - non-small-cell lung cancer patients with uncommon driver gene alterations. -PG - 952 -LID - 10.1186/s12885-024-12748-y [doi] -LID - 952 -AB - BACKGROUND: Limited data exists on the efficacy of immune checkpoint inhibitor - (ICI) combinations in non-small-cell lung cancer (NSCLC) with uncommon driver - alterations in genes such as ERBB2, BRAF, RET, and MET. This study - retrospectively assessed ICI-combination therapy outcomes in this molecular - subset of NSCLC. METHODS: We retrospectively analyzed patients with advanced - NSCLC confirmed with driver alterations in genes including ERBB2, BRAF, RET or - MET, and received ICI combined with chemotherapy (ICI + chemo) and/or targeted - therapy (ICI + chemo/TT) as first-line (1L) or second- or third-line (≥ 2L) - treatment at Hunan Cancer Hospital between January 2018 and May 2024. RESULTS: Of - the 181 patients included in the study, 131 patients received 1L-ICI + chemo - (ERBB2, n = 64; BRAF, n = 34; RET, n = 23; and MET, n = 10), and 50 patients - received ≥ 2L-ICI + chemo/TT (ERBB2, n = 16; BRAF, n = 7; RET, n = 14; MET, - n = 13). The full cohort had an overall response rate (ORR) of 45.9% and disease - control rate of 84.0%. Among patients who received 1L-ICI + chemo, ORR ranged - between 51.6% and 60.0%, with the median progression-free survival (mPFS) and - overall survival (mOS) of 8.2 and 21.0 months for those with ERBB2-altered - tumors, 10.0 and 15.0 months for BRAF-altered tumors, 12.1 months and OS not - reached for RET-altered tumors, and 6.2 and 28.0 months for MET-altered tumors, - respectively. Additionally, ORR ranged between 14.3% and 30.8% - for ≥ 2L-ICI + chemo/TT; mPFS and mOS were 5.4 and 16.2 months for patients with - ERBB2-altered tumors, 2.7 and 5.0 months for BRAF-altered tumors, 6.2 and - 14.3 months for RET-altered tumors, and 5.7 and 11.5 months for MET-altered - tumors, respectively. CONCLUSION: ICI-based combination therapies, regardless of - treatment line, were effective in treating patients with advanced NSCLC harboring - driver alterations in ERBB2, BRAF, RET, or MET. This suggests their potential as - alternative treatment options in this patient population. -CI - © 2024. The Author(s). -FAU - Qin, Haoyue -AU - Qin H -AD - Hengyang Medical School, Graduate Collaborative Training Base of Hunan Cancer - Hospital, University of South China, Hengyang, 421001, Hunan, China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, The - Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, - Central South University, Changsha, 410013, China. -FAU - Yan, Huan -AU - Yan H -AD - Hengyang Medical School, Graduate Collaborative Training Base of Hunan Cancer - Hospital, University of South China, Hengyang, 421001, Hunan, China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, The - Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, - Central South University, Changsha, 410013, China. -FAU - Chen, Yangqian -AU - Chen Y -AD - Hengyang Medical School, Graduate Collaborative Training Base of Hunan Cancer - Hospital, University of South China, Hengyang, 421001, Hunan, China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, The - Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, - Central South University, Changsha, 410013, China. -FAU - Xu, Qinqin -AU - Xu Q -AD - Department of Medical Oncology, Qinghai Provincial People's Hospital, Xining, - 810000, China. -FAU - Huang, Zhe -AU - Huang Z -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, The - Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, - Central South University, Changsha, 410013, China. -FAU - Jiang, Wenjuan -AU - Jiang W -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, The - Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, - Central South University, Changsha, 410013, China. -FAU - Wang, Zhan -AU - Wang Z -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, The - Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, - Central South University, Changsha, 410013, China. -FAU - Deng, Li -AU - Deng L -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, The - Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, - Central South University, Changsha, 410013, China. -FAU - Zhang, Xing -AU - Zhang X -AD - Hengyang Medical School, Graduate Collaborative Training Base of Hunan Cancer - Hospital, University of South China, Hengyang, 421001, Hunan, China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, The - Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, - Central South University, Changsha, 410013, China. -FAU - Zhang, Lin -AU - Zhang L -AD - Department of Radiotherapy, The Affiliated Cancer Hospital of Xiangya School of - Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410008, - Hunan, China. -FAU - Yang, Nong -AU - Yang N -AD - Hengyang Medical School, Graduate Collaborative Training Base of Hunan Cancer - Hospital, University of South China, Hengyang, 421001, Hunan, China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, The - Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, - Central South University, Changsha, 410013, China. -FAU - Zeng, Liang -AU - Zeng L -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, The - Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, - Central South University, Changsha, 410013, China. 530490930@qq.com. -FAU - Zhang, Yongchang -AU - Zhang Y -AD - Hengyang Medical School, Graduate Collaborative Training Base of Hunan Cancer - Hospital, University of South China, Hengyang, 421001, Hunan, China. - zhangyongchang@csu.edu.cn. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, The - Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, - Central South University, Changsha, 410013, China. zhangyongchang@csu.edu.cn. -AD - Early Clinical Trial Center, The Affiliated Cancer Hospital of Xiangya School of - Medicine, Hunan Cancer Hospital, Central South University, Changsha, 410013, - Hunan, China. zhangyongchang@csu.edu.cn. -AD - Furong Laboratory, Changsha, 410013, Hunan, China. zhangyongchang@csu.edu.cn. -LA - eng -PT - Journal Article -DEP - 20240803 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Immune Checkpoint Inhibitors) -RN - EC 2.7.10.1 (Receptor, ErbB-2) -RN - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) -RN - EC 2.7.10.1 (ERBB2 protein, human) -RN - EC 2.7.11.1 (BRAF protein, human) -RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret) -RN - EC 2.7.10.1 (RET protein, human) -RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-met) -RN - EC 2.7.10.1 (MET protein, human) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/mortality/pathology -MH - *Immune Checkpoint Inhibitors/therapeutic use -MH - Male -MH - Female -MH - *Lung Neoplasms/drug therapy/genetics/mortality/pathology -MH - Middle Aged -MH - Aged -MH - Retrospective Studies -MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Adult -MH - *Receptor, ErbB-2/genetics/metabolism -MH - Aged, 80 and over -MH - Proto-Oncogene Proteins B-raf/genetics -MH - Proto-Oncogene Proteins c-ret/genetics -MH - Treatment Outcome -MH - Mutation -MH - Proto-Oncogene Proteins c-met/genetics -PMC - PMC11297614 -OTO - NOTNLM -OT - BRAF -OT - ERBB2 -OT - Immune checkpoint inhibitor -OT - MET -OT - RET -COIS- The authors declare no competing interests. -EDAT- 2024/08/04 13:44 -MHDA- 2024/08/04 13:45 -PMCR- 2024/08/03 -CRDT- 2024/08/03 23:24 -PHST- 2024/02/18 00:00 [received] -PHST- 2024/08/01 00:00 [accepted] -PHST- 2024/08/04 13:45 [medline] -PHST- 2024/08/04 13:44 [pubmed] -PHST- 2024/08/03 23:24 [entrez] -PHST- 2024/08/03 00:00 [pmc-release] -AID - 10.1186/s12885-024-12748-y [pii] -AID - 12748 [pii] -AID - 10.1186/s12885-024-12748-y [doi] -PST - epublish -SO - BMC Cancer. 2024 Aug 3;24(1):952. doi: 10.1186/s12885-024-12748-y. - -PMID- 32652370 -OWN - NLM -STAT- MEDLINE -DCOM- 20210621 -LR - 20210621 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 147 -DP - 2020 Sep -TI - Pembrolizumab-induced severe oral mucositis in a patient with squamous cell - carcinoma of the lung: A case study. -PG - 21-25 -LID - S0169-5002(20)30507-9 [pii] -LID - 10.1016/j.lungcan.2020.06.033 [doi] -AB - BACKGROUND: Immune checkpoint inhibitors, such as pembrolizumab, a humanized - monoclonal antibody against programmed death-1, elicit antitumor activity in - various types of cancers, including lung cancer. However, pembrolizumab has been - reported to cause diverse immune-related adverse events associated with T-cell - activation. CASE PRESENTATION: We present the case of a 61-year-old man with - advanced non-small cell lung cancer who was administered pembrolizumab as - first-line treatment. After the first dose, radiotherapy was also administered - because of rapid progression of dyspnea due to bronchial obstruction by the - tumor. After the fourth cycle of pembrolizumab treatment, the patient presented - with severe oral pain and multiple oral ulcers on the lips and throughout the - oral cavity. Diagnostic tests including viral serology, fungal cultures, and - esophagogastroscopy did not provide conclusive results. A biopsy of the damaged - oral mucosa showed infiltration of inflammatory cells with no other specific - findings. In addition, multiple skin rashes were observed on various areas of the - patient's body, most notably in the area that had previously been irradiated. - Given that there was no other apparent cause, the patient's symptoms were - considered to be an immune-related adverse event due to pembrolizumab treatment. - The oral mucositis and skin rash gradually improved over a month with - corticosteroid treatment. CONCLUSION: Immune checkpoint inhibitors have recently - been introduced into the clinical practice. Their use is gradually increasing as - monotherapy or in combination with other cytotoxic chemotherapeutic agents. Since - immune check point inhibitors such as pembrolizumab have not been used in the - clinical setting for very long, we wish to share this case report in order to - build a better understating of the rare and unknown side effects of treatment - with immune check point inhibitors. The potential side effects of combined - therapy must be monitored carefully. -CI - Copyright © 2020 Elsevier B.V. All rights reserved. -FAU - Yoon, Soo-Young -AU - Yoon SY -AD - Division of Medical Oncology-Hematology, Department of Internal Medicine, Kyung - Hee University Hospital, College of Medicine, Kyung Hee University, Seoul, - Republic of Korea. -FAU - Han, Jae Joon -AU - Han JJ -AD - Division of Medical Oncology-Hematology, Department of Internal Medicine, Kyung - Hee University Hospital, College of Medicine, Kyung Hee University, Seoul, - Republic of Korea. -FAU - Baek, Sun Kyung -AU - Baek SK -AD - Division of Medical Oncology-Hematology, Department of Internal Medicine, Kyung - Hee University Hospital, College of Medicine, Kyung Hee University, Seoul, - Republic of Korea. -FAU - Kim, Hong Jun -AU - Kim HJ -AD - Division of Medical Oncology-Hematology, Department of Internal Medicine, Kyung - Hee University Hospital, College of Medicine, Kyung Hee University, Seoul, - Republic of Korea. -FAU - Maeng, Chi Hoon -AU - Maeng CH -AD - Division of Medical Oncology-Hematology, Department of Internal Medicine, Kyung - Hee University Hospital, College of Medicine, Kyung Hee University, Seoul, - Republic of Korea. Electronic address: mchihoon@khu.ac.kr. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20200630 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized -MH - *Antineoplastic Agents, Immunological/adverse effects -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Carcinoma, Squamous Cell -MH - Humans -MH - Lung -MH - *Lung Neoplasms/drug therapy -MH - Male -MH - Middle Aged -MH - *Stomatitis -OTO - NOTNLM -OT - Immune-related adverse events -OT - Oral mucositis -OT - Pembrolizumab -EDAT- 2020/07/12 06:00 -MHDA- 2021/06/22 06:00 -CRDT- 2020/07/12 06:00 -PHST- 2020/04/21 00:00 [received] -PHST- 2020/06/19 00:00 [revised] -PHST- 2020/06/26 00:00 [accepted] -PHST- 2020/07/12 06:00 [pubmed] -PHST- 2021/06/22 06:00 [medline] -PHST- 2020/07/12 06:00 [entrez] -AID - S0169-5002(20)30507-9 [pii] -AID - 10.1016/j.lungcan.2020.06.033 [doi] -PST - ppublish -SO - Lung Cancer. 2020 Sep;147:21-25. doi: 10.1016/j.lungcan.2020.06.033. Epub 2020 - Jun 30. - -PMID- 34939294 -OWN - NLM -STAT- MEDLINE -DCOM- 20220317 -LR - 20220317 -IS - 1445-5994 (Electronic) -IS - 1444-0903 (Linking) -VI - 51 -IP - 12 -DP - 2021 Dec -TI - Developments in systemic therapies for the management of lung cancer. -PG - 2012-2020 -LID - 10.1111/imj.15609 [doi] -AB - Lung cancer accounts for approximately 1 in 10 new cancer diagnoses annually and - is responsible for the most cancer-associated deaths in Australia. Despite such - figures, there is reason for optimism with many practice-changing developments to - report for the management of patients with thoracic malignancies over the last - few years. We outline such changes, including the emerging role of immunotherapy - in the neoadjuvant and adjuvant setting for patients with localised - non-small-cell lung cancer, as well as the established standard of consolidation - immunotherapy following definitive chemoradiotherapy for those with locally - advanced disease. In the metastatic setting, combination - chemotherapy-immunotherapy approaches have become the new paradigm for most - patients in the absence of a recognised driver mutation. A range of novel - targeted therapies now exist and are Pharmaceutical Benefits Scheme - (PBS)-subsidised for targets such as EGFR, ALK and ROS1, with many others, such - as KRAS G12C, NTRK, MET, RET and HER2, also with therapies rapidly being - developed. Even among patients with small-cell lung cancer, who account for the - worst prognoses and until recently have received a chemotherapy regimen that has - remained unchanged in over 20 years, there is a new standard-of-care in - combination chemotherapy-immunotherapy. Furthermore, immunotherapy and - potentially anti-vascular endothelial growth factor agents now also play a role - in mesothelioma treatment. Last, given recent developments in immunotherapy, - targeted therapy and combination approaches in the non-small-cell lung cancer - space, there is an increasing recognition of the diversity of lived experience - for such patients and need for survivorship programmes to acknowledge such - nuances. -CI - © 2021 Royal Australasian College of Physicians. -FAU - Heynemann, Sarah -AU - Heynemann S -AUID- ORCID: 0000-0003-2205-5320 -AD - Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, - Australia. -FAU - Mitchell, Paul -AU - Mitchell P -AD - Department of Medical Oncology, Olivia Newton-John Cancer Wellness and Research - Centre, Austin Health, Melbourne, Victoria, Australia. -AD - Department of Medicine, Austin Health, The University of Melbourne, Melbourne, - Victoria, Australia. -LA - eng -PT - Journal Article -PL - Australia -TA - Intern Med J -JT - Internal medicine journal -JID - 101092952 -RN - 0 (Proto-Oncogene Proteins) -RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Humans -MH - *Lung Neoplasms/drug therapy/genetics -MH - Molecular Targeted Therapy -MH - Protein-Tyrosine Kinases -MH - Proto-Oncogene Proteins/therapeutic use -OTO - NOTNLM -OT - lung cancer -OT - mesothelioma -OT - non-small cell lung cancer -OT - small cell lung cancer -EDAT- 2021/12/24 06:00 -MHDA- 2022/03/18 06:00 -CRDT- 2021/12/23 06:11 -PHST- 2021/09/20 00:00 [revised] -PHST- 2021/07/11 00:00 [received] -PHST- 2021/10/01 00:00 [accepted] -PHST- 2021/12/23 06:11 [entrez] -PHST- 2021/12/24 06:00 [pubmed] -PHST- 2022/03/18 06:00 [medline] -AID - 10.1111/imj.15609 [doi] -PST - ppublish -SO - Intern Med J. 2021 Dec;51(12):2012-2020. doi: 10.1111/imj.15609. - -PMID- 21843081 -OWN - NLM -STAT- MEDLINE -DCOM- 20111202 -LR - 20171116 -IS - 1750-7448 (Electronic) -IS - 1750-743X (Linking) -VI - 3 -IP - 8 -DP - 2011 Aug -TI - Development of bavituximab, a vascular targeting agent with immune-modulating - properties, for lung cancer treatment. -PG - 933-44 -LID - 10.2217/imt.11.87 [doi] -AB - Bavituximab is a chimeric monoclonal antibody directed against the membrane - phospholipid phosphatidylserine. Phosphatidylserine exposure is increased on - endothelial cells and apoptotic cancer cells in solid tumors, allowing - tumor-specific targeting of bavituximab. Bavituximab binding results in tumor - vessel occlusion and enhanced antitumor immunity. Preclinical investigations have - demonstrated efficacy as monotherapy and in combination with other modalities - against multiple cancer types. Phase I clinical trials of bavituximab monotherapy - and in combination with chemotherapy in adults with refractory solid tumors have - been completed. Phase II trials of bavituximab in combination with chemotherapy - for the first- and second-line treatment of advanced non-small-cell lung cancer - are currently ongoing. This article summarizes the preclinical development and - clinical experience with bavituximab in non-small-cell lung cancer. -FAU - DeRose, Paul -AU - DeRose P -AD - Department of Radiation Oncology, University of Texas Southwestern Medical - Center, Dallas, TX, USA. -FAU - Thorpe, Philip E -AU - Thorpe PE -FAU - Gerber, David E -AU - Gerber DE -LA - eng -GR - KL2RR024983/RR/NCRR NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - England -TA - Immunotherapy -JT - Immunotherapy -JID - 101485158 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Phosphatidylserines) -RN - Q16CT95N25 (bavituximab) -SB - IM -MH - Animals -MH - Antibodies, Monoclonal/*administration & dosage/adverse effects -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/pathology -MH - Clinical Trials, Phase II as Topic -MH - Drug Evaluation, Preclinical -MH - Endothelium, Vascular/drug effects/immunology/metabolism -MH - Humans -MH - Lung Neoplasms/*drug therapy/immunology/pathology -MH - Phosphatidylserines/*immunology -EDAT- 2011/08/17 06:00 -MHDA- 2011/12/13 00:00 -CRDT- 2011/08/17 06:00 -PHST- 2011/08/17 06:00 [entrez] -PHST- 2011/08/17 06:00 [pubmed] -PHST- 2011/12/13 00:00 [medline] -AID - 10.2217/imt.11.87 [doi] -PST - ppublish -SO - Immunotherapy. 2011 Aug;3(8):933-44. doi: 10.2217/imt.11.87. - -PMID- 36601768 -OWN - NLM -STAT- MEDLINE -DCOM- 20230110 -LR - 20230204 -IS - 1791-2423 (Electronic) -IS - 1019-6439 (Print) -IS - 1019-6439 (Linking) -VI - 62 -IP - 2 -DP - 2023 Feb -TI - Dual inhibition of EGFR‑VEGF: An effective approach to the treatment of advanced - non‑small cell lung cancer with EGFR mutation (Review). -LID - 26 [pii] -LID - 10.3892/ijo.2023.5474 [doi] -AB - On a global scale, the incidence and mortality rates of lung cancer are gradually - increasing year by year. A number of bad habits and environmental factors are - associated with lung cancer, including smoking, second‑hand smoke exposure, - occupational exposure, respiratory diseases and genetics. At present, low‑dose - spiral computed tomography is routinely the first choice in the diagnosis of lung - cancer. However, pathological examination is still the gold standard for the - diagnosis of lung cancer. Based on the classification and stage of the cancer, - treatment options such as surgery, radiotherapy, chemotherapy, targeted therapy - and immunotherapy are available. The activation of the EGFR pathway can promote - the survival and proliferation of tumor cells, and the VEGF pathway can promote - the formation of blood vessels, thereby promoting tumor growth. In non‑small cell - lung cancer (NSCLC) with EGFR mutation, EGFR activation can promote tumor growth - by promoting VEGF upregulation through a hypoxia‑independent mechanism. The - upregulation of VEGF can make tumor cells resistant to EGFR inhibitors. In - addition, the expression of the VEGF signal is also affected by other factors. - Therefore, the use of a single EGFR inhibitor cannot completely inhibit the - expression of the VEGF signal. In order to overcome this problem, the combination - of VEGF inhibitors and EGFR inhibitors has become the method of choice. Dual - inhibition can not only overcome the resistance of tumor cells to EGFR - inhibitors, but also significantly increase the progression‑free survival time of - patients with NSCLC. The present review discusses the associations between the - EGFR and VEGF pathways, and the characteristics of dual inhibition of the - EGFR‑VEGF pathway. -FAU - Wang, Qian -AU - Wang Q -AD - School of Medical and Life Sciences, Chengdu University of Traditional Chinese - Medicine, Chengdu, Sichuan 611137, P.R. China. -FAU - Zeng, Anqi -AU - Zeng A -AD - Institute of Translational Pharmacology and Clinical Application, Sichuan Academy - of Chinese Medical Science, Chengdu, Sichuan 610041, P.R. China. -FAU - Zhu, Min -AU - Zhu M -AD - School of Medical and Life Sciences, Chengdu University of Traditional Chinese - Medicine, Chengdu, Sichuan 611137, P.R. China. -FAU - Song, Linjiang -AU - Song L -AD - School of Medical and Life Sciences, Chengdu University of Traditional Chinese - Medicine, Chengdu, Sichuan 611137, P.R. China. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230105 -PL - Greece -TA - Int J Oncol -JT - International journal of oncology -JID - 9306042 -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - 0 (Protein Kinase Inhibitors) -RN - 0 (Vascular Endothelial Growth Factor A) -RN - 0 (VEGFA protein, human) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology -MH - Drug Resistance, Neoplasm -MH - ErbB Receptors/genetics/metabolism -MH - *Lung Neoplasms/drug therapy/genetics/metabolism -MH - Mutation -MH - Protein Kinase Inhibitors/pharmacology/therapeutic use -MH - Vascular Endothelial Growth Factor A/genetics/metabolism -PMC - PMC9851127 -OTO - NOTNLM -OT - EGFR -OT - VEGF -OT - combination therapy -OT - dual inhibition -OT - non‑small cell lung cancer -OT - targeted therapy -COIS- All authors declare that they have no competing interests. -EDAT- 2023/01/06 06:00 -MHDA- 2023/01/07 06:00 -PMCR- 2023/01/03 -CRDT- 2023/01/05 03:45 -PHST- 2022/10/12 00:00 [received] -PHST- 2022/12/01 00:00 [accepted] -PHST- 2023/01/05 03:45 [entrez] -PHST- 2023/01/06 06:00 [pubmed] -PHST- 2023/01/07 06:00 [medline] -PHST- 2023/01/03 00:00 [pmc-release] -AID - 26 [pii] -AID - ijo-62-2-05474 [pii] -AID - 10.3892/ijo.2023.5474 [doi] -PST - ppublish -SO - Int J Oncol. 2023 Feb;62(2):26. doi: 10.3892/ijo.2023.5474. Epub 2023 Jan 5. - -PMID- 32587591 -OWN - NLM -STAT- MEDLINE -DCOM- 20210401 -LR - 20221207 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 11 -DP - 2020 -TI - Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese - Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint - Inhibitors. -PG - 1173 -LID - 10.3389/fimmu.2020.01173 [doi] -LID - 1173 -AB - Background: Serum tumor markers carcinoembryonic antigen (CEA), cancer antigen - 125 (CA125), cytokeratin 19 fragment (CYFRA21-1) and squamous-cell - carcinoma-related antigen (SCC-Ag) are routinely used for monitoring the response - to chemotherapy or targeted therapy in advanced-stage non-small cell lung cancer - (NSCLC), however their role in immunotherapy remains unclear. The aim of this - study was to investigate whether dynamics of these serum markers were associated - with the efficacy and prognosis of Chinese late-stage NSCLC patients treated with - programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors. - Methods: We initiated a longitudinal prospective study on advanced NSCLC patients - treated with PD-1/PD-L1 inhibitors in Chinese PLA general hospital (Beijing, - China). Blood samples of baseline and after 6 weeks' treatment were collected. CT - scan were used by all patients to evaluate treatment efficacy according to RECIST - 1.1. Serum tumor markers levels were measured with an electrochemical - luminescence for SCC-Ag and with a chemiluminescent microparticle immunoassay for - serum CEA, CA125, and CYFRA21-1. At least 20% decreases of the biomarkers from - baseline were considered as meaningful improvements after 6 weeks of treatment - with immune checkpoint inhibitors (ICIs). Optimization-based method was used to - balance baseline covariates between different groups. Associations between serum - tumor biomarker improvements and objective response rate (ORR), progression-free - survival (PFS), and overall survival (OS) were analyzed. Results: A total of 308 - Chinese patients with advanced NSCLC were enrolled in the study. After balancing - baseline covariates, patients with meaningful improvements in <2 out of 4 - biomarkers (CEA, CA125, CYFRA21-1, and SCC-Ag) was ended up with lower ORR (0.08 - vs. 0.35, p < 0.001), shorten PFS (median: 5.4 vs. 12.5 months, p < 0.001), and - OS (median: 11.7 vs. 25.6 months, p < 0.001) in the total population. Subgroup - analysis of patients with adenocarcinoma revealed that patients with meaningful - improvements in <2 out of 4 biomarkers had significant lower ORR (0.06 vs. 0.36, - p < 0.001), shorten PFS (median: 4.1 vs. 11.9 months, p < 0.001), and OS (median: - 11.9 vs. 24.2 months, p < 0.001). So as in patients with squamous cell carcinoma, - meaningful improvements in at least 2 out of 4 biomarkers were linked to better - ORR (0.42 vs. 0.08, p = 0.014), longer PFS (median: 13.1 vs. 5.6 months, p = - 0.001), and OS (median: 25.6 vs. 10.9 months, p = 0.06). Conclusions: The dynamic - change of CEA, CA125, CYFRA21-1, and SCC-Ag from baseline have prognostic value - for late-stage NSCLC patients treated with PD-1/PD-L1 inhibitors. Decrease of - associated biomarkers serum levels were associated with favorable clinical - outcomes. -CI - Copyright © 2020 Zhang, Yuan, Chen, Li, Ma, Yan, Wang, Zhang, Tao, Guo, Huang, - Zhang, Li, Zhi, Ge, Hu and Wang. -FAU - Zhang, Zhibo -AU - Zhang Z -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -AD - Medical School of Chinese PLA, Beijing, China. -AD - The 78th Group Army Hospital of Chinese PLA, Mudanjiang, China. -FAU - Yuan, Fang -AU - Yuan F -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Chen, Runzhe -AU - Chen R -AD - Departments of Thoracic/Head and Neck Medical Oncology and Genomic Medicine, The - University of Texas MD Anderson Cancer Center, Houston, TX, United States. -FAU - Li, Ye -AU - Li Y -AD - Department of Radiotherapy, The First Medical Center of Chinese PLA General - Hospital, Beijing, China. -FAU - Ma, Junxun -AU - Ma J -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Yan, Xiang -AU - Yan X -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Wang, Lijie -AU - Wang L -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Zhang, Fan -AU - Zhang F -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Tao, Haitao -AU - Tao H -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Guo, Dong -AU - Guo D -AD - BeiGene (Shanghai) Co., Ltd., Shanghai, China. -FAU - Huang, Zhiyue -AU - Huang Z -AD - BeiGene (Shanghai) Co., Ltd., Shanghai, China. -FAU - Zhang, Sujie -AU - Zhang S -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Li, Xiaoyan -AU - Li X -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Zhi, Xiaoyu -AU - Zhi X -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -AD - Medical School of Chinese PLA, Beijing, China. -FAU - Ge, Xiangwei -AU - Ge X -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -AD - Medical School of Chinese PLA, Beijing, China. -FAU - Hu, Yi -AU - Hu Y -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Wang, Jinliang -AU - Wang J -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -LA - eng -PT - Journal Article -PT - Observational Study -DEP - 20200610 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Antigens, Neoplasm) -RN - 0 (Biomarkers, Tumor) -RN - 0 (CA-125 Antigen) -RN - 0 (Carcinoembryonic Antigen) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Keratin-19) -RN - 0 (MUC16 protein, human) -RN - 0 (Membrane Proteins) -RN - 0 (antigen CYFRA21.1) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antigens, Neoplasm/blood -MH - Asian People -MH - Biomarkers, Tumor/*blood -MH - CA-125 Antigen/blood -MH - Carcinoembryonic Antigen/blood -MH - Carcinoma, Non-Small-Cell Lung/*blood/drug therapy -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Keratin-19/blood -MH - Lung Neoplasms/*blood/drug therapy -MH - Male -MH - Membrane Proteins/blood -MH - Middle Aged -MH - Prognosis -MH - *Treatment Outcome -PMC - PMC7298878 -OTO - NOTNLM -OT - Chinese patients -OT - immune checkpoint inhibitors -OT - non-small cell lung cancer -OT - prognostic biomarker -OT - serum tumor markers -EDAT- 2020/06/27 06:00 -MHDA- 2021/04/02 06:00 -PMCR- 2020/01/01 -CRDT- 2020/06/27 06:00 -PHST- 2020/03/12 00:00 [received] -PHST- 2020/05/12 00:00 [accepted] -PHST- 2020/06/27 06:00 [entrez] -PHST- 2020/06/27 06:00 [pubmed] -PHST- 2021/04/02 06:00 [medline] -PHST- 2020/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2020.01173 [doi] -PST - epublish -SO - Front Immunol. 2020 Jun 10;11:1173. doi: 10.3389/fimmu.2020.01173. eCollection - 2020. - -PMID- 36804711 -OWN - NLM -STAT- MEDLINE -DCOM- 20230501 -LR - 20230518 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 24 -IP - 3 -DP - 2023 May -TI - The Association of Improved Overall Survival with NSAIDs in Non-Small Cell Lung - Cancer Patients Receiving Immune Checkpoint Inhibitors. -PG - 287-294 -LID - S1525-7304(23)00001-3 [pii] -LID - 10.1016/j.cllc.2022.12.013 [doi] -AB - BACKGROUND: Immune checkpoint inhibitors (ICI) are commonly used in the - management of patients with advanced non-small cell lung cancer (NSCLC), but - response is suboptimal. Preclinical data suggest ICI efficacy may be enhanced - with concomitant nonsteroidal anti-inflammatory (NSAID) medications. PATIENTS AND - METHODS: In this retrospective study, the Veterans Health Administration - Corporate Data Warehouse was queried for patients diagnosed with NSCLC and - treated with ICI from 2010 to 2018. Concomitant NSAID use was defined as NSAID - dispensation by a VA pharmacy within 90 days of the any ICI infusion. To mitigate - immortal time bias, patients who started NSAIDs 60 or more days after ICI - initiation were excluded from analysis. Survival was measured from start of ICI. - RESULTS: We identified 3634 patients with NSCLC receiving ICI; 2336 (64.3%) were - exposed to concomitant NSAIDs. On multivariable analysis, NSAIDs were associated - with better overall survival (HR = 0.90; 95% CI, 0.83-0.98; P = .010). When - stratifying by NSAID type, diclofenac was the only NSAID with significant - association with overall survival (HR = 0.75; 95% CI, 0.68-0.83; P < .001). - Propensity score matching of the original cohort yielded 1251 patients per cohort - balanced in characteristics. NSAIDs remained associated with improved overall - survival (HR = 0.85; 95% CI, 0.78-0.92; P < .001). CONCLUSION: This study of - Veterans with NSCLC treated with ICI demonstrated that concomitant NSAIDs are - associated with longer OS. This may indicate that NSAIDs can enhance ICI-induced - antitumor immunity and should prospectively validated. -CI - Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. -FAU - Sebastian, Nikhil T -AU - Sebastian NT -AD - Department of Radiation Oncology, Emory University, Atlanta, GA; Winship Cancer - Institute, Emory University, Atlanta, GA. Electronic address: - Nikhil.Sebastian@emory.edu. -FAU - Stokes, William A -AU - Stokes WA -AD - Department of Radiation Oncology, Emory University, Atlanta, GA; Winship Cancer - Institute, Emory University, Atlanta, GA. -FAU - Behera, Madhusmita -AU - Behera M -AD - Winship Cancer Institute, Emory University, Atlanta, GA. -FAU - Jiang, Renjian -AU - Jiang R -AD - Winship Cancer Institute, Emory University, Atlanta, GA. -FAU - Gutman, David A -AU - Gutman DA -AD - Winship Cancer Institute, Emory University, Atlanta, GA; Atlanta Veterans Affairs - Health Care System, Decatur, GA. -FAU - Huang, Zhonglu -AU - Huang Z -AD - Winship Cancer Institute, Emory University, Atlanta, GA. -FAU - Burns, Abigail -AU - Burns A -AD - Atlanta Veterans Affairs Health Care System, Decatur, GA. -FAU - Sukhatme, Vidula -AU - Sukhatme V -AD - Morningside Center for Innovative and Affordable Medicine, Emory University, - Atlanta, GA; GlobalCures, Inc, Newton, MA. -FAU - Lowe, Michael C -AU - Lowe MC -AD - Morningside Center for Innovative and Affordable Medicine, Emory University, - Atlanta, GA; Division of Surgical Oncology, Emory University, Atlanta, GA. -FAU - Ramalingam, Suresh S -AU - Ramalingam SS -AD - Winship Cancer Institute, Emory University, Atlanta, GA; Department of Hematology - and Medical Oncology, Emory University, Atlanta, GA. -FAU - Sukhatme, Vikas P -AU - Sukhatme VP -AD - Morningside Center for Innovative and Affordable Medicine, Emory University, - Atlanta, GA. -FAU - Moghanaki, Drew -AU - Moghanaki D -AD - Department of Radiation Oncology, University of California Los Angeles, Los - Angeles, CA. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20230121 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Retrospective Studies -MH - *Lung Neoplasms/drug therapy -OTO - NOTNLM -OT - Immunotherapy -OT - Metastatic -OT - NSCLC -OT - Nonsteroidal anti-inflammatory drugs -OT - Veterans -COIS- Disclosure NTS has no disclosures. WAS has no disclosures. MB has no disclosures. - RJ has no disclosures. DAG has no disclosures. ZH has no disclosures. AB has no - disclosures. VS has no disclosures. MCL has no disclosures. SSR has received - grant funding and/or other support (for consultancy) from Amgen, AstraZeneca, - Bristol-Myers Squibb, Merck, Takeda, Tesaro, Advaxis, AbbVie, and - Genentech/Roche. VPS is on the SAB of BERG and HiFiBio Therapeutics, and an - equity holder in Aggamin Pharmaceuticals and Victa Biotherapeutics. DM has - received travel support and speaking honoraria from Varian Medical Systems. -EDAT- 2023/02/23 06:00 -MHDA- 2023/05/01 06:42 -CRDT- 2023/02/22 08:59 -PHST- 2022/11/02 00:00 [received] -PHST- 2022/12/22 00:00 [revised] -PHST- 2022/12/25 00:00 [accepted] -PHST- 2023/05/01 06:42 [medline] -PHST- 2023/02/23 06:00 [pubmed] -PHST- 2023/02/22 08:59 [entrez] -AID - S1525-7304(23)00001-3 [pii] -AID - 10.1016/j.cllc.2022.12.013 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2023 May;24(3):287-294. doi: 10.1016/j.cllc.2022.12.013. Epub - 2023 Jan 21. - -PMID- 35935943 -OWN - NLM -STAT- MEDLINE -DCOM- 20220809 -LR - 20220822 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 13 -DP - 2022 -TI - Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current - status, possible mechanisms and application prospects. -PG - 940288 -LID - 10.3389/fimmu.2022.940288 [doi] -LID - 940288 -AB - Immune checkpoint inhibitors (ICIs) are effective against advanced and even - perioperative non-small-cell lung cancer (NSCLC) and result in durable clinical - benefit, regardless of programmed death ligand-1 (PD-L1) expression status in - cancer. Existing clinical evidence shows that the effect of immunotherapy in - patients with EGFR-mutant NSCLC after the development of tyrosine kinase - inhibitor (TKI) resistance is not satisfactory. However, compared with - monotherapy, ICIs combined with chemotherapy can improve the efficacy. - Encouragingly, compared with that of patients with sensitive mutations, the - progression-free survival of patients with rare mutations who were treated with - ICIs was increased. Adequately maximizing the efficacy of ICIs in EGFR-mutant - NSCLC patients is worth exploring. In this review, we described preclinical and - clinical studies of ICIs or combined therapy for EGFR-mutant NSCLC. We further - focused on EGFR mutations and the cancer immune response, with particular - attention given to the role of EGFR activation in the cancer-immunity cycle. The - mechanisms for the natural resistance to ICIs were explored to identify - corresponding countermeasures that made more EGFR-mutant NSCLC patients benefit - from ICIs. -CI - Copyright © 2022 Shi, Wang, Xue and Zhou. -FAU - Shi, Chunyan -AU - Shi C -AD - Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan - University, Chengdu, China. -AD - The Department of Oncology, Jiujiang No.1 People's Hospital, Jiujiang, China. -FAU - Wang, Yan -AU - Wang Y -AD - Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan - University, Chengdu, China. -FAU - Xue, Jianxin -AU - Xue J -AD - Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan - University, Chengdu, China. -AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan - University, Chengdu, China. -AD - Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, - Chengdu, China. -FAU - Zhou, Xiaojuan -AU - Zhou X -AD - Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan - University, Chengdu, China. -AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan - University, Chengdu, China. -LA - eng -PT - Journal Article -PT - Review -DEP - 20220722 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Immunologic Factors) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - ErbB Receptors/metabolism -MH - Humans -MH - Immunologic Factors/therapeutic use -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy/genetics -MH - Protein Kinase Inhibitors/pharmacology/therapeutic use -PMC - PMC9353115 -OTO - NOTNLM -OT - EGFR mutation -OT - immune checkpoint inhibitors -OT - non-small-cell lung cancer -OT - programmed cell death 1 -OT - programmed cell death ligand 1 -OT - tumor microenvironment -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/08/09 06:00 -MHDA- 2022/08/10 06:00 -PMCR- 2022/01/01 -CRDT- 2022/08/08 03:41 -PHST- 2022/05/10 00:00 [received] -PHST- 2022/07/04 00:00 [accepted] -PHST- 2022/08/08 03:41 [entrez] -PHST- 2022/08/09 06:00 [pubmed] -PHST- 2022/08/10 06:00 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2022.940288 [doi] -PST - epublish -SO - Front Immunol. 2022 Jul 22;13:940288. doi: 10.3389/fimmu.2022.940288. eCollection - 2022. - -PMID- 35468364 -OWN - NLM -STAT- MEDLINE -DCOM- 20220621 -LR - 20220621 -IS - 1878-1705 (Electronic) -IS - 1567-5769 (Linking) -VI - 109 -DP - 2022 Aug -TI - Neuropilin-1 is a valuable biomarker for predicting response of advanced - non-small cell lung cancer patients to hypofractionated radiotherapy and PD-1 - blockade. -PG - 108732 -LID - S1567-5769(22)00216-8 [pii] -LID - 10.1016/j.intimp.2022.108732 [doi] -AB - Programmed death-1 (PD-1) blockade promoted the combination therapy of advanced - non-small cell lung cancer (NSCLC), induces changes in peripheral memory T cell - subsets. Neuropilin-1 (NRP1) is a new T cell memory checkpoint, its association - with the clinical prognosis of NSCLC is less reported. Here, we detected the - expression of NRP1 and the depletion-associated factor thymocyte - selection-associated HMG box protein (TOX) in peripheral T cell subsets with - responders treated with hypofractionated radiotherapy (HFRT) combined with PD-1 - blockade and chemoimmunotherapy, aimed to explore their association with the - prognosis of advanced NSCLC. NRP1 and TOX expression was localized on - tissue-infiltrating T cells by immunofluorescence assay in nine patients who had - undergone surgery. Flow cytometry was used to detect the expression of NRP1 and - TOX in peripheral circulating T cells in patients with advanced NSCLC before and - after HFRT combined with PD-1 blockade (HFRT+PD-1) and chemoimmunotherapy in - thirty-nine patients. NSCLC patients showed an increase in NRP1 and TOX in - peripheral T cells as compared to that in healthy controls. The expression of - NRP1 and TOX in CD8(+) T cells was higher in tumor tissues than in uninvolved - tissues. Patients who responded to HFRT+PD-1 blockade showed a reduction in - NRP1(+)CD8(+), TOX(+)CD4(+), and TOX(+)CD8(+) levels, chemoimmunotherapy - responders showed decreased expression of NRP1 in the CD4(+) T cell - subpopulation. In conclusion, lower expression levels of NRP1 and TOX in - peripheral circulating CD8(+) T cells were associated with a better prognosis for - advanced NSCLC patients treated with HFRT+PD-1 blockade. -CI - Copyright © 2022 Elsevier B.V. All rights reserved. -FAU - Kang, Pengyuan -AU - Kang P -AD - Immune Mechanism and Therapy of Major Diseases of Luzhou Key Laboratory, Public - Center of Experimental Technology, School of Basic Medical Sciences, Southwest - Medical University, Luzhou 646000, China. -FAU - Li, Yunfei -AU - Li Y -AD - Department of Oncology, The Affiliated Hospital of Southwest Medical University, - China. -FAU - Hu, Zhi -AU - Hu Z -AD - Department of Thoracic Surgery, The Affiliated Hospital of South West Medical - University, China. -FAU - Lei, Ming -AU - Lei M -AD - Key Laboratory of Medical Electrophysiology of Ministry of Education, Institute - of Cardiovascular Research, Southwest Medical University, China. -FAU - Cheng, Jun -AU - Cheng J -AD - Key Laboratory of Medical Electrophysiology of Ministry of Education, Institute - of Cardiovascular Research, Southwest Medical University, China. -FAU - Guo, Xiyuan -AU - Guo X -AD - Immune Mechanism and Therapy of Major Diseases of Luzhou Key Laboratory, Public - Center of Experimental Technology, School of Basic Medical Sciences, Southwest - Medical University, Luzhou 646000, China. -FAU - Zhang, Lulu -AU - Zhang L -AD - Immune Mechanism and Therapy of Major Diseases of Luzhou Key Laboratory, Public - Center of Experimental Technology, School of Basic Medical Sciences, Southwest - Medical University, Luzhou 646000, China. -FAU - Lin, Sheng -AU - Lin S -AD - Department of Oncology, The Affiliated Hospital of Southwest Medical University, - China. Electronic address: linsheng@swmu.edu.cn. -FAU - Yuan, Qing -AU - Yuan Q -AD - Immune Mechanism and Therapy of Major Diseases of Luzhou Key Laboratory, Public - Center of Experimental Technology, School of Basic Medical Sciences, Southwest - Medical University, Luzhou 646000, China. Electronic address: - qingyuan@swmu.edu.cn. -LA - eng -PT - Journal Article -DEP - 20220422 -PL - Netherlands -TA - Int Immunopharmacol -JT - International immunopharmacology -JID - 100965259 -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 144713-63-3 (Neuropilin-1) -SB - IM -MH - CD8-Positive T-Lymphocytes/metabolism -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology/radiotherapy -MH - Humans -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Neuropilin-1 -MH - Programmed Cell Death 1 Receptor/metabolism -OTO - NOTNLM -OT - Chemoimmunotherapy -OT - Hypofractionated radiotherapy -OT - NRP1 -OT - TOX -EDAT- 2022/04/26 06:00 -MHDA- 2022/06/22 06:00 -CRDT- 2022/04/25 20:15 -PHST- 2022/02/15 00:00 [received] -PHST- 2022/03/17 00:00 [revised] -PHST- 2022/03/22 00:00 [accepted] -PHST- 2022/04/26 06:00 [pubmed] -PHST- 2022/06/22 06:00 [medline] -PHST- 2022/04/25 20:15 [entrez] -AID - S1567-5769(22)00216-8 [pii] -AID - 10.1016/j.intimp.2022.108732 [doi] -PST - ppublish -SO - Int Immunopharmacol. 2022 Aug;109:108732. doi: 10.1016/j.intimp.2022.108732. Epub - 2022 Apr 22. - -PMID- 35034046 -OWN - NLM -STAT- MEDLINE -DCOM- 20220509 -LR - 20230901 -IS - 1537-4513 (Electronic) -IS - 1524-9557 (Print) -IS - 1524-9557 (Linking) -VI - 45 -IP - 3 -DP - 2022 Apr 1 -TI - Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients - Treated With the PD-1 Inhibitor Budigalimab. -PG - 167-179 -LID - 10.1097/CJI.0000000000000408 [doi] -AB - Budigalimab, a novel anti-PD-1 monoclonal antibody, demonstrated efficacy and - biomarker pharmacodynamics in patients with head and neck squamous cell carcinoma - (HNSCC) or non-small cell lung cancer (NSCLC) consistent with those reported by - other PD-1 inhibitors. Herein are presented additional outcomes of biomarker - analyses from the phase 1 study of budigalimab monotherapy in patients with HNSCC - and NSCLC (NCT03000257). PD-1 inhibitor naive patients with advanced HNSCC (n=41) - or NSCLC (n=40) received budigalimab intravenously at 250 mg every 2 weeks (Q2W) - or 500 mg Q4W until progression. Archival tumor specimens were evaluated by - immunohistochemistry for CD8 and tumor PD-1 ligand 1 (PD-L1) expression, RNA, and - whole-exome sequencing. Serum and whole blood samples were acquired at baseline - and at select on-treatment time points. As of October 2019, best overall response - of 15% in HNSCC and 18% in NSCLC was observed in all treated patients; both - cohorts reported responses in PD-L1+ and PD-L1- tumors. Treatment with - budigalimab was associated with increases in multiple soluble biomarkers - including interferon gamma-induced chemokines. Expanded overall T-cell counts, - total CD8 T-cell counts, and percentages of CD8+CD45RA-CD62L- effector memory T - cells were observed at cycle 1, day 15 in responders. Univariate analysis - demonstrated an association between prolonged progression-free survival and - higher tumor mutational burden/neoantigen load, smaller tumor size, lower - platelet-lymphocyte ratios, lower CCL23, lower colony-stimulating factor 1, and - lower interleukin-6 levels at baseline. The biomarker analysis presented herein - identified additional early pharmacodynamic biomarkers associated with anti-PD-1 - activity and improved clinical responses to budigalimab in patients with advanced - HNSCC and NSCLC. -CI - Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. -FAU - Lambert, Stacie L -AU - Lambert SL -AD - Oncology Early Development. -FAU - Zhang, Chun -AU - Zhang C -AD - Discovery and Exploratory Statistics. -FAU - Guo, Claire -AU - Guo C -AD - Discovery and Exploratory Statistics. -FAU - Turan, Tolga -AU - Turan T -AD - Genomics Research Center. -FAU - Masica, David L -AU - Masica DL -AD - Genomics Research Center. -FAU - Englert, Stefan -AU - Englert S -AD - Data and Statistical Sciences, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, - Germany. -FAU - Fang, Yuni -AU - Fang Y -AD - Drug Metabolism, Pharmacokinetics, AbbVie Inc, Redwood City, CA. -FAU - Sheridan, James -AU - Sheridan J -AD - Drug Metabolism, Pharmacokinetics, AbbVie Inc, Redwood City, CA. -FAU - McLaughlin, Robert Tyler -AU - McLaughlin RT -AD - Genomics Research Center. -FAU - Tribouley, Catherine -AU - Tribouley C -AD - Oncology Early Development. -FAU - Vosganian, Greg -AU - Vosganian G -AD - Oncology Early Development. -FAU - Afar, Daniel -AU - Afar D -AD - Oncology Early Development. -LA - eng -SI - ClinicalTrials.gov/NCT03000257 -PT - Clinical Trial -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - United States -TA - J Immunother -JT - Journal of immunotherapy (Hagerstown, Md. : 1997) -JID - 9706083 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers) -RN - 0 (Biomarkers, Tumor) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (budigalimab) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - Antibodies, Monoclonal, Humanized -MH - *Antineoplastic Agents/therapeutic use -MH - B7-H1 Antigen -MH - Biomarkers -MH - Biomarkers, Tumor/metabolism -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Head and Neck Neoplasms/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - *Lung Neoplasms/genetics -MH - Squamous Cell Carcinoma of Head and Neck/drug therapy -PMC - PMC8906246 -COIS- AbbVie Inc. provided financial support for the study (NCT03000257) and - participated in the design, study conduct, as well as the writing, review, and - approval of the manuscript. Data analysis and interpretation was conducted by - employees of AbbVie Inc. S.L.L., C.Z., C.G., T.T., D.L.M., S.E., Y.F., J.S., - R.T.M., C.T., and D.A.: AbbVie employees and may own stock. G.V.: former employee - of AbbVie and may own stock. -EDAT- 2022/01/17 06:00 -MHDA- 2022/05/10 06:00 -PMCR- 2022/03/09 -CRDT- 2022/01/16 21:10 -PHST- 2021/01/04 00:00 [received] -PHST- 2021/10/22 00:00 [accepted] -PHST- 2022/01/17 06:00 [pubmed] -PHST- 2022/05/10 06:00 [medline] -PHST- 2022/01/16 21:10 [entrez] -PHST- 2022/03/09 00:00 [pmc-release] -AID - 00002371-202204000-00004 [pii] -AID - 10.1097/CJI.0000000000000408 [doi] -PST - ppublish -SO - J Immunother. 2022 Apr 1;45(3):167-179. doi: 10.1097/CJI.0000000000000408. - -PMID- 36758475 -OWN - NLM -STAT- MEDLINE -DCOM- 20230228 -LR - 20230325 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 182 -DP - 2023 Mar -TI - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients - with advanced non-small cell lung cancer. -PG - 107-114 -LID - S0959-8049(23)00015-1 [pii] -LID - 10.1016/j.ejca.2023.01.007 [doi] -AB - BACKGROUND: We aimed to determine whether immune checkpoint inhibitors (ICI) - time-of-day infusion might influence the survival of patients with advanced - non-small cell lung cancer (NSCLC). METHODS: We retrospectively analysed patients - who received single-agent anti-PD-(L)1 therapy in any line between 2016 and 2021. - We calculated by Cox regression models the association between the proportion of - ICI infusions received after 16:30h and overall survival (OS) and - progression-free survival (PFS). RESULTS: 180 patients were included, 77% - received ICI as second- or further-line (median of 12 infusions/patient). The - median age was 65 years (IQR 57-70), 112 patients (62%) were male, 165 (92%) were - current or former tobacco smokers, 140 (78%) had performance status (PS) 0 or 1, - 26 (14%) were on steroid therapy at ICI initiation. Histology was non-squamous - for 139 (77%), the median number of metastatic sites was 3, and 33% had brain - metastases. Patients who received at least 20% of ICI infusions after 16:30h (65 - out of 180, 36%) had a statistically significant shorter median PFS as compared - with patients receiving less than 20% of infusions in the evening (4.9 vs 9.4 - months, log-rank p = 0.020), while numerical but not statistical shorter OS was - observed (14.0 vs 26.2 months, log-rank p = 0.090). In the multivariate analysis, - receiving at least 20% of evening infusions did not significantly increase the - risk of death, while PS and line of treatment were significantly correlated with - the OS. On the contrary, a proportion of ICI administration after 16:30h ≥20% - conferred an HR for the PFS of 1.44 (95% CI: 1.01-2.05, p = 0.043), but this - prognostic effect was not found when including in the model the total number of - ICI infusions received (HR 1.20, 95% CI: 0.83-1.75, p = 0.329). CONCLUSION: - Time-of-day infusion of ICI may impact the survival of patients with advanced - NSCLC. Underlying prognostic characteristics and the number of infusions received - could represent conceivable confounding factors, linked to increased variance - related to ICI infusion timing. Nonetheless, further studies may unravel - chronobiological mechanisms modulating ICI efficacy. -CI - Copyright © 2023 Elsevier Ltd. All rights reserved. -FAU - Rousseau, Adrien -AU - Rousseau A -AD - Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Tagliamento, Marco -AU - Tagliamento M -AD - Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France; - Department of Internal Medicine and Medical Specialties (DiMI), University of - Genova, Genova, Italy. -FAU - Auclin, Edouard -AU - Auclin E -AD - Medical Oncology Department, Hôpital Européen Georges Pompidou, AP-HP Centre, - Université Paris Cité, Paris, France. -FAU - Aldea, Mihaela -AU - Aldea M -AD - Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Frelaut, Maxime -AU - Frelaut M -AD - Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Levy, Antonin -AU - Levy A -AD - Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, - France; Paris-Saclay University, Orsay, France. -FAU - Benitez, Jose C -AU - Benitez JC -AD - Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Naltet, Charles -AU - Naltet C -AD - Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Lavaud, Pernelle -AU - Lavaud P -AD - Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Botticella, Angela -AU - Botticella A -AD - Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, - France. -FAU - Grecea, Miruna -AU - Grecea M -AD - Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Chaput, Nathalie -AU - Chaput N -AD - Laboratory of Immunomonitoring in Oncology, Gustave Roussy Cancer Campus, - Villejuif, France; Paris-Saclay University, UFR Pharmacy, Orsay, France. -FAU - Barlesi, Fabrice -AU - Barlesi F -AD - Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Planchard, David -AU - Planchard D -AD - Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Besse, Benjamin -AU - Besse B -AD - Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France; - Paris-Saclay University, Orsay, France. Electronic address: - Benjamin.BESSE@gustaveroussy.fr. -LA - eng -PT - Journal Article -DEP - 20230113 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Humans -MH - Male -MH - Aged -MH - Female -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - *Lung Neoplasms/drug therapy -MH - Retrospective Studies -MH - *Antineoplastic Agents, Immunological/adverse effects -OTO - NOTNLM -OT - Anti-PD-1 -OT - Anti-PD-L1 -OT - Chronomodulation -OT - Chronotherapy -OT - Immune checkpoint inhibitors -OT - Lung cancer -OT - NSCLC -OT - Time-of-day infusion -COIS- Conflict of interest statement The authors declare the following financial - interests/personal relationships which may be considered as potential competing - interests: MT: Travel, accommodation, expenses: Roche, Bristol-Myers Squibb, - AstraZeneca, Takeda, Eli Lilly. Honoraria as medical writer: Novartis, Amgen, - MSD. None related to the current manuscript. ED: Honoraria/Board: Amgen and - Sanofi Genzyme. MA: Expenses: Sandoz; Advisory Board: Viatris; Research funding: - Sandoz. AL: Grants for academic research from Amgen, BeiGene, Astra Zeneca, - Roche. None related to the current manuscript. NC: Grants: BMS, Sanofi, Astra - Zeneca, GSK. Personal fees: Astra Zeneca, Servier. None related to the current - manuscript. FB: Consultancy fees: AstraZeneca, Astex, Clovis, GSK, GamaMabs, Eli - Lilly, MSD, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, - Roche/Genentech, Sanofi, Servier, Symphogen, and Takeda. None related to the - current manuscript. DP: Consulting, advisory role, or lectures: AstraZeneca, - Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, - Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, Janssen, AbbVie; - honoraria from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, - Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, Janssen, and - AbbVie; clinical trial research as principal or co-investigator (institutional - financial interests): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, - Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmune, Sanofi-Aventis, Taiho - Pharma, Novocure, Daiichi Sankyo, Janssen, and AbbVie; travel, accommodations, - and expenses: AstraZeneca, Roche, Novartis, and Pfizer. None related to the - current manuscript. BB: Sponsored Research at Gustave Roussy Cancer Center: 4D - Pharma, Abbvie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint - Medicines, BMS, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, - Daiichi-Sankyo, Eli Lilly, GSK, Inivata, Janssen, Onxeo, OSE immunotherapeutics, - Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals. None related to - the current manuscript. The other authors declared no conflicts of interest. -EDAT- 2023/02/10 06:00 -MHDA- 2023/03/03 06:00 -CRDT- 2023/02/09 18:21 -PHST- 2022/08/01 00:00 [received] -PHST- 2022/12/20 00:00 [revised] -PHST- 2023/01/10 00:00 [accepted] -PHST- 2023/02/10 06:00 [pubmed] -PHST- 2023/03/03 06:00 [medline] -PHST- 2023/02/09 18:21 [entrez] -AID - S0959-8049(23)00015-1 [pii] -AID - 10.1016/j.ejca.2023.01.007 [doi] -PST - ppublish -SO - Eur J Cancer. 2023 Mar;182:107-114. doi: 10.1016/j.ejca.2023.01.007. Epub 2023 - Jan 13. - -PMID- 36401404 -OWN - NLM -STAT- MEDLINE -DCOM- 20221122 -LR - 20230103 -IS - 1536-5964 (Electronic) -IS - 0025-7974 (Print) -IS - 0025-7974 (Linking) -VI - 101 -IP - 46 -DP - 2022 Nov 18 -TI - Therapeutic effectiveness and safety of sequential ICIs with radiotherapy for - symptomatic brain and bone metastases in NSCLC patients. -PG - e31665 -LID - 10.1097/MD.0000000000031665 [doi] -LID - e31665 -AB - In advanced non-small cell lung cancer (NSCLC), the brain and bones are common - metastatic sites, and the disease seriously affects the survival time and quality - of life. For metastatic lesions with symptoms, local treatment often precedes - systemic treatment. However, in clinical trials, patients with symptomatic brain - or bone metastases are often excluded. Therefore, limited data are available on - the efficacy of immune checkpoint inhibitors (ICIs) in those patients. We aimed - to evaluate the effectiveness and safety of local radiotherapy followed by ICIs - in driver gene-negative NSCLC patients with symptomatic local metastasis in the - brain and bone. This is a 29-month 2 centered retrospective cohort study - performed in China between March 2019 and August 2021. A total of 22 patients - with advanced NSCLC were included. All patients received radiotherapy in the - brain or bone before the administration of ICIs. For all patients, the overall - response rate was 59.09%, the median progression-free survival (PFS) was 7.5 - months, the PFS rate at 6 months was 72.73%, and the PFS rate at 1 year was - 13.64%. Waterfall plots showed that tumor size was mostly reduced compared with - baseline. The spider map showed that the tumor continued to shrink. In terms of - symptom improvement, 100% pain control and 83.33% improvement were observed in - epilepsy and neurological function. Sequential ICIs with local radiotherapy is - effective for the treatment of patients with symptomatic brain and bone - metastases of driver gene-negative NSCLC, which will benefit patients and improve - their symptoms. -CI - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. -FAU - Tang, Cuiping -AU - Tang C -AUID- ORCID: 0000-0002-4817-2405 -AD - The Second Clinical College of Chongqing Medical University, Chongqing, China. -AD - Department of Oncology, the second affiliated hospital of Chongqing Medical - University, Chongqing, China. -FAU - Qin, Si -AU - Qin S -AD - Department of Oncology, Xinqiao Hospital, Army Military Medical University, - Chongqing, China. -FAU - Li, Qian -AU - Li Q -AD - Department of Pathology, Southwest Hospital, Army Military Medical University, - Chongqing, China. -FAU - Huang, Yusheng -AU - Huang Y -AD - Department of Oncology, the second affiliated hospital of Chongqing Medical - University, Chongqing, China. -LA - eng -PT - Journal Article -PL - United States -TA - Medicine (Baltimore) -JT - Medicine -JID - 2985248R -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/radiotherapy -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Retrospective Studies -MH - Quality of Life -MH - *Bone Neoplasms/radiotherapy -MH - Brain/pathology -PMC - PMC9678514 -COIS- The authors have no conflicts of interest to disclose. -EDAT- 2022/11/20 06:00 -MHDA- 2022/11/23 06:00 -PMCR- 2022/11/18 -CRDT- 2022/11/19 01:04 -PHST- 2022/11/19 01:04 [entrez] -PHST- 2022/11/20 06:00 [pubmed] -PHST- 2022/11/23 06:00 [medline] -PHST- 2022/11/18 00:00 [pmc-release] -AID - 00005792-202211180-00043 [pii] -AID - 10.1097/MD.0000000000031665 [doi] -PST - ppublish -SO - Medicine (Baltimore). 2022 Nov 18;101(46):e31665. doi: - 10.1097/MD.0000000000031665. - -PMID- 38814640 -OWN - NLM -STAT- MEDLINE -DCOM- 20240530 -LR - 20240603 -IS - 2574-3805 (Electronic) -IS - 2574-3805 (Linking) -VI - 7 -IP - 5 -DP - 2024 May 1 -TI - International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small - Cell Lung Cancer. -PG - e2413938 -LID - 10.1001/jamanetworkopen.2024.13938 [doi] -LID - e2413938 -AB - IMPORTANCE: Standard of care for unresectable locally advanced non-small cell - lung cancer (NSCLC) involves definitive chemoradiotherapy followed by maintenance - therapy with durvalumab. However, the cost of durvalumab has been cited as a - barrier to its use in various health systems. OBJECTIVE: To evaluate the - cost-effectiveness of durvalumab vs placebo as maintenance therapy in patients - with unresectable stage III NSCLC from 4 international payer perspectives (US, - Brazil, Singapore, and Spain). DESIGN, SETTING, AND PARTICIPANTS: In this - economic evaluation, a Markov model was designed to compare the lifetime - cost-effectiveness of maintenance durvalumab for unresectable stage III NSCLC - with that of placebo, using 5-year outcomes data from the PACIFIC randomized - placebo-controlled trial. Individual patient data were extracted from the - PACIFIC, KEYNOTE-189, ADAURA, ALEX, and REVEL randomized clinical trials to - develop a decision-analytic model to determine the cost-effectiveness of - durvalumab compared with placebo maintenance therapy over a 10-year time horizon. - Direct costs, adverse events, and patient characteristics were based on - country-specific payer perspectives and demographic characteristics. The study - was conducted from June 1, 2022, through December 27, 2023. MAIN OUTCOMES AND - MEASURES: Life-years, quality-adjusted life years (QALYs), lifetime costs, and - incremental cost-effectiveness ratios (ICERs) were estimated at country-specific - willingness-to-pay thresholds ([data reported in US$] US: $150 000 per QALY; - Brazil: $22 251 per QALY; Singapore: $55 288 per QALY, and Spain: $107 069 per - QALY). One-way and probabilistic sensitivity analyses were performed to account - for parameters of uncertainty. A cost-threshold analysis was also performed. - RESULTS: The US base-case model found that treatment with durvalumab was - associated with an increased cost of $114 394 and improved effectiveness of 0.50 - QALYs compared with placebo, leading to an ICER of $228 788 per QALY. Incremental - cost-effectiveness ratios, according to base-case models, were $141 146 for - Brazil, $153 461 for Singapore, and $125 193 for Spain. Durvalumab price - adjustments to the PACIFIC data improved cost-effectiveness in Singapore, with an - ICER of $45 164. The model was most sensitive to the utility of durvalumab. - CONCLUSIONS AND RELEVANCE: In this cost-effectiveness analysis of durvalumab as - maintenance therapy for unresectable stage III NSCLC, the therapy was found to be - cost-prohibitive from the perspective of various international payers according - to country-specific willingness-to-pay thresholds per QALY. The findings of the - study suggest that discounted durvalumab acquisition costs, as possible in - Singapore, might improve cost-effectiveness globally. -FAU - Kareff, Samuel A -AU - Kareff SA -AD - University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial - Hospital, Miami, Florida. -FAU - Han, Sunwoo -AU - Han S -AD - University of Miami Miller School of Medicine, Miami, Florida. -FAU - Haaland, Benjamin -AU - Haaland B -AD - Pentara Corporation, Salt Lake City, Utah. -FAU - Jani, Chinmay J -AU - Jani CJ -AD - University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial - Hospital, Miami, Florida. -FAU - Kohli, Rhea -AU - Kohli R -AD - Case Western University School of Medicine, Cleveland, Ohio. -FAU - Aguiar, Pedro Nazareth Jr -AU - Aguiar PN Jr -AD - Oncoclínicas, São Paulo, São Paulo, Brazil. -FAU - Huang, Yiqing -AU - Huang Y -AD - National University Cancer Institute, Singapore. -FAU - Soo, Ross A -AU - Soo RA -AD - National University Cancer Institute, Singapore. -FAU - Rodríguez-Perez, Ángel -AU - Rodríguez-Perez Á -AD - Fundación Jiménez Díaz University Hospital, Madrid, Spain. -FAU - García-Foncillas, Jesús -AU - García-Foncillas J -AD - Fundación Jiménez Díaz University Hospital, Madrid, Spain. -FAU - Dómine, Manuel -AU - Dómine M -AD - Fundación Jiménez Díaz University Hospital, Madrid, Spain. -FAU - de Lima Lopes, Gilberto -AU - de Lima Lopes G -AD - University of Miami Miller School of Medicine, Miami, Florida. -LA - eng -PT - Journal Article -DEP - 20240501 -PL - United States -TA - JAMA Netw Open -JT - JAMA network open -JID - 101729235 -RN - 28X28X9OKV (durvalumab) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/economics -MH - *Cost-Benefit Analysis -MH - *Lung Neoplasms/drug therapy/economics -MH - *Antibodies, Monoclonal/therapeutic use/economics -MH - Brazil -MH - Spain -MH - Quality-Adjusted Life Years -MH - Male -MH - Singapore -MH - Female -MH - United States -MH - Middle Aged -MH - Neoplasm Staging -MH - Aged -MH - Antineoplastic Agents, Immunological/therapeutic use/economics -MH - Markov Chains -MH - Cost-Effectiveness Analysis -PMC - PMC11140532 -COIS- Conflict of Interest Disclosures: Dr Kareff reported receiving honoraria from the - Academy of Continued Healthcare Education, Integrity Continuing Education, - Healthcourse Inc, Precisca, and Research to Practice; speaker’s fees from i3 - Health; travel grants from the Florida Society of Clinical Oncology and the - International Association for the Study of Lung Cancer outside the submitted - work; and consultant fees from Pathway Medical. Dr Haaland reported being a - full-time employee of Pentara Corporation outside the submitted work. Dr Soo - reported receiving personal fees from Amgen, AstraZeneca, Bayer, BMS, Boehringer - Ingelheim, J INTS BIO, Janssen, Lily, Merck, Merck Serono, Novartis, Pfizer, - Puma, Roche, Sanofi, Taiho, Takeda, Thermofisher, Yuhan, and Daiichi Sankyo; and - grants from AstraZeneca, Boehringer Ingelheim, and Pfizer outside the submitted - work. Dr Dómine reported receiving advisory board fees from Amgen; and lecture - and advisory board fees from AstraZeneca, BMS, and Boehringer; advisory board - fees from Janssen Cilag; and lecture and advisory board fees from MSD, Pfizer, - Roche, Sanofi, and Takeda outside the submitted work. Dr Lopes reported receiving - funding from AstraZeneca, Lucence, Xilis, E.R. Squibb Sons, LLC, Merck Sharp & - Dohme, EMD Serono, Blueprint Medicines, Tesaro, Bavarian Nordic, Novartis, G1 - Therapeutics, Adaptimmune, BMS, GSK, Abbvie, Rgenix, Pfizer, Roche, Genentech, - Lilly, Janssen; Stock and Other Ownership Interests from Xilis, Biomab, - Morphometrix, CDR-Life; Honoraria from Boehringer Ingelheim, Blueprint Medicines, - AstraZeneca, Merck, Janssen; consultant or advisory role with Pfizer, - AstraZeneca; Travel, Accommodations Expenses from Boehringer Ingelheim, Pfizer, - E.R. Squibb Sons, LLC, Janssen, Seattle Genetics, Celgene, Ibsen, Pharmacyclics, - Merck, AstraZeneca, Seagen, all outside the submitted work. No other disclosures - were reported. -EDAT- 2024/05/30 12:43 -MHDA- 2024/05/30 12:44 -PMCR- 2024/05/30 -CRDT- 2024/05/30 11:35 -PHST- 2024/05/30 12:44 [medline] -PHST- 2024/05/30 12:43 [pubmed] -PHST- 2024/05/30 11:35 [entrez] -PHST- 2024/05/30 00:00 [pmc-release] -AID - 2819200 [pii] -AID - zoi240479 [pii] -AID - 10.1001/jamanetworkopen.2024.13938 [doi] -PST - epublish -SO - JAMA Netw Open. 2024 May 1;7(5):e2413938. doi: - 10.1001/jamanetworkopen.2024.13938. - -PMID- 35698820 -OWN - NLM -STAT- MEDLINE -DCOM- 20220714 -LR - 20220902 -IS - 1750-7448 (Electronic) -IS - 1750-743X (Linking) -VI - 14 -IP - 11 -DP - 2022 Aug -TI - Immunotherapy in advanced non-small-cell lung cancer (NSCLC) after progression on - chemotherapy: real-world results from a prospective institutional cohort. -PG - 851-858 -LID - 10.2217/imt-2021-0170 [doi] -AB - Objective: To analyze the outcomes of patients receiving immunotherapy (IO) with - advanced non-driver mutated non-small-cell lung cancer (NSCLC) after progression - on systemic treatment. Methods: The overall survival (OS), progression-free - survival (PFS) and best response to IO of 64 patients who met our inclusion - criteria were analyzed. Results: Median follow-up, OS and PFS were 35.9, 7.1 and - 3.2 months, respectively. On uni- and multi-variable analysis, better ECOG PS and - fewer extra-thoracic metastases were associated with prolonged OS and PFS. - Response to IO was associated with prolonged OS, while thoracic radiotherapy and - isolated CNS involvement were associated with prolonged PFS. ECOG PS, thoracic - radiotherapy and PDL1 status significantly influenced the likelihood of response - to IO. Overall, 30% patients experienced any grade toxicity. Conclusion: Our - results are concordant with reported trial outcomes and support the application - of IO in Indian patients. -FAU - Batra, Ullas -AU - Batra U -AUID- ORCID: 0000-0003-3306-9824 -AD - Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre, - New Delhi, 110085, India. -FAU - Chufal, Kundan Singh -AU - Chufal KS -AD - Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research - Centre, New Delhi, 110085, India. -FAU - Nathany, Shrinidhi -AU - Nathany S -AD - Department of Molecular Diagnostics, Rajiv Gandhi Cancer Institute & Research - Centre, New Delhi, 110085, India. -FAU - Ahmad, Irfan -AU - Ahmad I -AUID- ORCID: 0000-0003-2944-6797 -AD - Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research - Centre, New Delhi, 110085, India. -FAU - Chowdhary, Rahul Lal -AU - Chowdhary RL -AD - Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research - Centre, New Delhi, 110085, India. -FAU - Sharma, Mansi -AU - Sharma M -AD - Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre, - New Delhi, 110085, India. -FAU - Jain, Praveen -AU - Jain P -AD - Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre, - New Delhi, 110085, India. -FAU - Gairola, Munish -AU - Gairola M -AD - Department of Radiation Oncology, Rajiv Gandhi Cancer Institute & Research - Centre, New Delhi, 110085, India. -LA - eng -PT - Journal Article -DEP - 20220614 -PL - England -TA - Immunotherapy -JT - Immunotherapy -JID - 101485158 -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung -MH - Humans -MH - Immunotherapy/methods -MH - *Lung Neoplasms/pathology -MH - Progression-Free Survival -MH - Prospective Studies -MH - Retrospective Studies -OAB - Several clinical trials have demonstrated favorable results with immunotherapy in - patients with lung cancer who do not have a mutation in their tumors. However, - clinical trials are often designed to provide the best chance for a trial - drug/intervention to demonstrate effectiveness. Therefore, they usually include - relatively healthier patients compared to what clinicians see in their practice. - To demonstrate the efficacy of a drug outside a clinical trial, a real-world - analysis is performed, which is reported in this article. We analyzed lung cancer - patients treated with immunotherapy at our institution and found comparable - efficacy to reported clinical trials. This was important because the trials did - not include any patients from our country. We also found that patients with fewer - sites of involvement outside the lung and those who received radiotherapy to the - lung (either during or before receiving immunotherapy) survived longer without - disease progression. -OABL- eng -OTO - NOTNLM -OT - PD-L1 -OT - immunotherapy -OT - nivolumab -OT - radiotherapy -EDAT- 2022/06/15 06:00 -MHDA- 2022/07/15 06:00 -CRDT- 2022/06/14 03:13 -PHST- 2022/06/15 06:00 [pubmed] -PHST- 2022/07/15 06:00 [medline] -PHST- 2022/06/14 03:13 [entrez] -AID - 10.2217/imt-2021-0170 [doi] -PST - ppublish -SO - Immunotherapy. 2022 Aug;14(11):851-858. doi: 10.2217/imt-2021-0170. Epub 2022 Jun - 14. - -PMID- 35848053 -OWN - NLM -STAT- MEDLINE -DCOM- 20230131 -LR - 20230226 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 12 -IP - 2 -DP - 2023 Jan -TI - Clinical impact of tumour burden on the efficacy of PD-1/PD-L1 inhibitors plus - chemotherapy in non-small-cell lung cancer. -PG - 1451-1460 -LID - 10.1002/cam4.5035 [doi] -AB - BACKGROUND: Programmed cell death 1 (PD-1)/programmed cell death ligand (PD-L1) - inhibitors plus chemotherapy (ICI + Chemo) is the standard treatment for advanced - non-small-cell lung cancer (NSCLC). However, the impact of tumour burden on the - efficacy of ICI + Chemo remains unknown. METHODS: We retrospectively evaluated 92 - patients with advanced NSCLC treated with ICI + Chemo. Tumour burden was assessed - as the sum of the longest diameter of the target lesion (BSLD) and number of - metastatic lesions (BNMLs). We categorised the patients into three groups based - on the combined BSLD and BNML values. RESULTS: Sixty-eight patients (74%) had - progressive disease or died. Forty-four patients (48%) in the low-BSLD group had - a median progression-free survival (PFS) of 9.5 months, whereas patients in the - high-BSLD group had a median PFS of 4.6 months (hazard ratio [HR] = 0.54, - p = 0012). Twenty-five patients (27%) in the low-BNML group had a median PFS of - 9.6 months, whereas patients in the high-BNML group had a median PFS of - 6.5 months (HR = 0.51, p = 0.029). Low-BSLD and low-BNML were associated - independently with improved PFS in multivariate analysis. Analysis of the tumour - burden combined with BSLD and BNML revealed a trend towards improved PFS as the - tumour burden decreased, with median PFS of 22.3, 8.7, and 3.9 months in the low- - (N = 13), medium- (N = 42) and high-burden (N = 37) groups respectively. - CONCLUSIONS: Our findings demonstrated that a high tumour burden negatively - impacts the efficacy of ICI + Chemo in patients with advanced NSCLC. -CI - © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Miyawaki, Taichi -AU - Miyawaki T -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -AD - Department of Respiratory Medicine, Juntendo University Graduate School of - Medicine, Tokyo, Japan. -FAU - Kenmotsu, Hirotsugu -AU - Kenmotsu H -AUID- ORCID: 0000-0003-0590-9259 -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Doshita, Kosei -AU - Doshita K -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Kodama, Hiroaki -AU - Kodama H -AUID- ORCID: 0000-0002-0953-3183 -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Nishioka, Naoya -AU - Nishioka N -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Iida, Yuko -AU - Iida Y -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Miyawaki, Eriko -AU - Miyawaki E -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Mamesaya, Nobuaki -AU - Mamesaya N -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Kobayashi, Haruki -AU - Kobayashi H -AUID- ORCID: 0000-0002-3386-8063 -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Omori, Shota -AU - Omori S -AUID- ORCID: 0000-0003-1407-9779 -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Ko, Ryo -AU - Ko R -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Wakuda, Kazushige -AU - Wakuda K -AUID- ORCID: 0000-0002-6369-2388 -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Ono, Akira -AU - Ono A -AUID- ORCID: 0000-0001-5705-9423 -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Naito, Tateaki -AU - Naito T -AUID- ORCID: 0000-0003-4047-2929 -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Murakami, Haruyasu -AU - Murakami H -AUID- ORCID: 0000-0003-2416-546X -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Mori, Keita -AU - Mori K -AD - Clinical Research Support Center, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Harada, Hideyuki -AU - Harada H -AD - Radiation and Proton Therapy Centre, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Endo, Masahiro -AU - Endo M -AD - Division of Diagnostic Radiology, Shizuoka Cancer Centre, Shizuoka, Japan. -FAU - Takahashi, Kazuhisa -AU - Takahashi K -AD - Department of Respiratory Medicine, Juntendo University Graduate School of - Medicine, Tokyo, Japan. -FAU - Takahashi, Toshiaki -AU - Takahashi T -AD - Division of Thoracic Oncology, Shizuoka Cancer Centre, Shizuoka, Japan. -LA - eng -PT - Journal Article -DEP - 20220718 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Lung Neoplasms/pathology -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Programmed Cell Death 1 Receptor -MH - Retrospective Studies -MH - Tumor Burden -MH - B7-H1 Antigen/metabolism -PMC - PMC9883568 -OTO - NOTNLM -OT - clinical cancer research -OT - immunology -OT - lung cancer -OT - metastasis -OT - non-small-cell lung cancer -COIS- Dr. Kenmotsu reports grants and personal fees from Chugai Pharmaceutical Co., - Ltd., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from - Boehringer Ingelheim, personal fees from Eli Lilly K.K, personal fees from Kyowa - Hakko Kirin Co., Ltd., personal fees from Bristol‐Myers Squibb, personal fees - from MSD, grants and personal fees from Novartis Pharma K.K., grants and personal - fees from Daiichi‐Sankyo Co., Ltd., grants and personal fees from AstraZeneca - K.K., personal fees from Pfizer, personal fees from Taiho Pharma, outside the - submitted work. Dr. Mamesaya reports personal fees from AstraZeneca K.K., Pfizer - Japan, Inc., personal fees from Chugai Pharmaceutical Co., Ltd., grants and - personal fees from Boehringer Ingelheim, personal fees from MSD K.K., personal - fees from Taiho Pharmaceutical Co., Ltd., personal fees from Oon Pharmaceutical - Co., Ltd., outside the submitted work. Dr. Kobayashi reports personal fees from - Eli Lilly K.K, personal fees from Taiho Pharmaceutical, personal fees from - AstraZeneca, outside the submitted work. Dr. Omori reports personal fees from - Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical, AstraZeneca K.K., Boehringer - Ingelheim, Taiho Pharmaceutical, and MSD, which are unrelated to the submitted - work. Dr. Ko reports grants and personal fees from Boehringer Ingelheim, grants - and personal fees from AstraZeneca, personal fees from Taiho Pharmaceutical, - personal fees from Chugai Pharmaceutical, personal fees from Ono Pharmaceutical, - personal fees from Pfizer, personal fees from Lilly, outside the submitted work. - Dr. Wakuda reports grants and personal fees from Chugai Pharmaceutical Co., Ltd., - personal fees from Taiho Pharmaceutical, personal fees from Boehringer Ingelheim, - personal fees from Eli Lilly K.K., personal fees from Ono Pharmaceutical, - personal fees from MSD, grants and personal fees from AstraZeneca, grants from - Novartis, grants from Abbvie, outside the submitted work. Dr. Ono reports grants - from Taiho Pharmaceutical, grants from Ono Pharmaceutical, grants from Chugai - Pharmaceutical Co., Ltd., grants from Novartis Pharma K.K., outside the submitted - work. Dr. Murakami reports personal fees from AstraZeneca K.K., Ono - Pharmaceutical, Bristol‐Myers Squibb Japan, Chugai Pharmaceutical Co., Ltd., - Pfizer Inc., Novartis Pharma K.K., Boehringer Ingelheim, Taiho Pharmaceutical, - Eli Lilly K.K., and MSD, which are unrelated to the submitted work. Dr. Harada - reports personal fees from Daiichi‐Sankyo Pharmaceutical Co. during the conduct - of the study as well as personal fees from Daiichi‐Sankyo Pharmaceutical Co., - AstraZeneca K.K., Brain Labo Co., and Chugai Pharmaceutical Co. and grants from - the Japan Agency for Medical Research and Development and the National Cancer - Center Research and Development Fund, which are unrelated to the submitted work. - Dr. Endo reports personal fees from Ono Pharmaceutical, personal fees from - AstraZeneca, personal fees from Takeda Pharmaceutical Co., Ltd., personal fees - from Daiichi‐Sankyo Co., Ltd., outside the submitted work. Dr. Kazuhisa Takahashi - reports grants and personal fees from AstraZeneca K.K., Pfizer Japan, Inc., Eli - Lilly K.K., MSD, and Boehringer Ingelheim as well as grants from Takeda - Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical - Co., Ltd., KYORIN Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., - GlaxoSmithKline Consumer Healthcare Japan K.K., Shionogi & Co., Ltd., and - Novartis Pharma K.K., which are not related to the submitted work. Dr. Toshiaki - Takahashi reports grants and personal fees from AstraZeneca K.K., Pfizer Japan, - Inc., grants and personal fees from Eli Lilly Japan K.K., grants and personal - fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Ono - Pharmaceutical Co., Ltd., grants and personal fees from MSD K.K., grants and - personal fees from Boehringer Ingelheim Japan, Inc., grants and personal fees - from Pfizer Japan, Inc., personal fees from Roche Diagnostics K.K., outside the - submitted work. The remaining authors declare no conflict of interest. -EDAT- 2022/07/19 06:00 -MHDA- 2023/02/01 06:00 -PMCR- 2022/07/18 -CRDT- 2022/07/18 04:24 -PHST- 2022/06/27 00:00 [revised] -PHST- 2022/01/25 00:00 [received] -PHST- 2022/06/29 00:00 [accepted] -PHST- 2022/07/19 06:00 [pubmed] -PHST- 2023/02/01 06:00 [medline] -PHST- 2022/07/18 04:24 [entrez] -PHST- 2022/07/18 00:00 [pmc-release] -AID - CAM45035 [pii] -AID - 10.1002/cam4.5035 [doi] -PST - ppublish -SO - Cancer Med. 2023 Jan;12(2):1451-1460. doi: 10.1002/cam4.5035. Epub 2022 Jul 18. - -PMID- 28285695 -OWN - NLM -STAT- MEDLINE -DCOM- 20171227 -LR - 20191210 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 106 -DP - 2017 Apr -TI - Optimal management of ALK-positive NSCLC progressing on crizotinib. -PG - 58-66 -LID - S0169-5002(17)30035-1 [pii] -LID - 10.1016/j.lungcan.2017.02.003 [doi] -AB - Crizotinib is an anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor - (-TKI) that represents the standard first-line treatment of patients with - ALK-rearranged (ALK-positive) advanced non-small cell lung cancer (NSCLC). In - this setting, crizotinib has demonstrated a response rate of roughly 75% and a - median progression-free survival just under one year. However, acquired - resistance will emerge in virtually all crizotinib-treated patients, whose - management may require a diversified approach according to the pace of the - disease and/or the site(s) of disease progression. Crizotinib beyond disease - progression is an option in patients with oligoprogressive disease, especially in - presence of isolated central nervous system (CNS) relapse, provided that local - ablative therapy (mainly radiotherapy) to the brain is administered. On the other - hand, novel more potent and highly selective ALK-TKIs with demonstrated - anti-tumor activity (CNS included) in crizotinib-refractory patients have been - made available in recent years. Therefore, clinicians may well consider switching - to a second-generation ALK-TKI as treatment option in case of progression on - crizotinib. Therapeutic chances are more limited for patients who progress after - crizotinib and a second-generation ALK-TKI, for whom both a third-generation - ALK-TKI or pemetrexed-based chemotherapy could prove beneficial, while evidence - in support of the use of immunotherapy in patients pretreated with ≥1 ALK-TKI is - lacking. -CI - Copyright © 2017 Elsevier B.V. All rights reserved. -FAU - Metro, Giulio -AU - Metro G -AD - Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di - Perugia, Perugia, Italy. Electronic address: giulio.metro@yahoo.com. -FAU - Tazza, Marco -AU - Tazza M -AD - Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di - Perugia, Perugia, Italy. -FAU - Matocci, Roberta -AU - Matocci R -AD - Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di - Perugia, Perugia, Italy. -FAU - Chiari, Rita -AU - Chiari R -AD - Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di - Perugia, Perugia, Italy. -FAU - Crinò, Lucio -AU - Crinò L -AD - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, - Meldola (FC), Italy. -LA - eng -PT - Journal Article -PT - Review -DEP - 20170206 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Carbazoles) -RN - 0 (Organophosphorus Compounds) -RN - 0 (Piperidines) -RN - 0 (Protein Kinase Inhibitors) -RN - 0 (Pyrazoles) -RN - 0 (Pyridines) -RN - 0 (Pyrimidines) -RN - 0 (Sulfones) -RN - 53AH36668S (Crizotinib) -RN - EC 2.7.10.1 (ALK protein, human) -RN - EC 2.7.10.1 (Anaplastic Lymphoma Kinase) -RN - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) -RN - HYW8DB273J (brigatinib) -RN - K418KG2GET (ceritinib) -RN - LIJ4CT1Z3Y (alectinib) -SB - IM -MH - Anaplastic Lymphoma Kinase -MH - Brain Neoplasms/drug therapy/radiotherapy/secondary -MH - Carbazoles/administration & dosage/pharmacology -MH - Carcinoma, Non-Small-Cell Lung/complications/*drug therapy/*genetics/pathology -MH - Crizotinib -MH - Disease Progression -MH - Disease-Free Survival -MH - Drug Resistance, Neoplasm/genetics -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/drug therapy/genetics/pathology -MH - Organophosphorus Compounds/administration & dosage/pharmacology -MH - Piperidines/administration & dosage/pharmacology -MH - Prevalence -MH - Protein Kinase Inhibitors/therapeutic use -MH - Pyrazoles/administration & dosage/*pharmacology -MH - Pyridines/administration & dosage/*pharmacology -MH - Pyrimidines/administration & dosage/pharmacology -MH - Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors/therapeutic use -MH - Sulfones/administration & dosage/pharmacology -OTO - NOTNLM -OT - ALK-TKI -OT - Alectinib -OT - Brigatinib -OT - Ceritinib -OT - Crizotinib -OT - Non-small cell lung cancer -EDAT- 2017/03/14 06:00 -MHDA- 2017/12/28 06:00 -CRDT- 2017/03/14 06:00 -PHST- 2017/02/02 00:00 [received] -PHST- 2017/02/04 00:00 [accepted] -PHST- 2017/03/14 06:00 [entrez] -PHST- 2017/03/14 06:00 [pubmed] -PHST- 2017/12/28 06:00 [medline] -AID - S0169-5002(17)30035-1 [pii] -AID - 10.1016/j.lungcan.2017.02.003 [doi] -PST - ppublish -SO - Lung Cancer. 2017 Apr;106:58-66. doi: 10.1016/j.lungcan.2017.02.003. Epub 2017 - Feb 6. - -PMID- 34742684 -OWN - NLM -STAT- MEDLINE -DCOM- 20220103 -LR - 20220103 -IS - 1872-7786 (Electronic) -IS - 0009-2797 (Linking) -VI - 351 -DP - 2022 Jan 5 -TI - A review on epidermal growth factor receptor's role in breast and non-small cell - lung cancer. -PG - 109735 -LID - S0009-2797(21)00373-2 [pii] -LID - 10.1016/j.cbi.2021.109735 [doi] -AB - Epithelial growth factor receptor (EGFR) is a cell surface transmembrane receptor - that mediates the tyrosine signaling pathway to carry the extracellular messages - inside the cell and thereby alter the function of nucleus. This leads to the - generation of various protein products to up or downregulate the cellular - function. It is encoded by cell erythroblastosis virus oncogene B1, so called - C-erb B1/ERBB2/HER-2 gene that acts as a proto-oncogene. It belongs to the HER-2 - receptor-family in breast cancer and responds best with anti-Herceptin therapy - (anti-tyrosine kinase monoclonal antibody). HER-2 positive breast cancer patient - exhibits worse prognosis without Herceptin therapy. Similar incidence and - prognosis are reported in other epithelial neoplasms like EGFR + lung non-small - cell carcinoma and glioblastoma (grade IV brain glial tumor). Present study - highlights the role and connectivity of EGF with various cancers via signaling - pathways, cell surface receptors mechanism, macromolecules, mitochondrial genes - and neoplasm. Present study describes the EGFR associated gene expression - profiling (in breast cancer and NSCLC), relation between mitrochondrial genes and - carcinoma, and several in vitro and in vivo models to screen the synergistic - effect of various combination treatments. According to this study, although - clinical studies including targeted treatments, immunotherapies, radiotherapy, - TKi-EGFR combined targeted therapy have been carried out to investigate the - synergism of combination therapy; however still there is a gap to apply the - scenarios of experimental and clinical studies for further developments. This - review will give an idea about the transition from experimental to most advanced - clinical studies with different combination drug strategies to treat cancer. -CI - Copyright © 2021 Elsevier B.V. All rights reserved. -FAU - Subramaniyan, Vetriselvan -AU - Subramaniyan V -AD - Faculty of Medicine, Bioscience and Nursing, MAHSA University, Jalan SP 2, Bandar - Saujana Putra, 42610, Jenjarom, Selangor, Malaysia. -FAU - Fuloria, Shivkanya -AU - Fuloria S -AD - Faculty of Pharmacy & Centre of Excellence for Biomaterials Engineering, AIMST - University, Bedong 08100, Kedah, Malaysia. -FAU - Gupta, Gaurav -AU - Gupta G -AD - Department of Pharmacology, Suresh Gyan Vihar University, Mahal Road, Jagatpura, - Jaipur, India; Department of Pharmacology, Saveetha Dental College and Hospitals, - Saveetha Institute of Medical Sciences, Saveetha University, Chennai, India. -FAU - Kumar, Darnal Hari -AU - Kumar DH -AD - Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, - Selngor, 47500, Malaysia. -FAU - Sekar, Mahendran -AU - Sekar M -AD - Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, - Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh, 30450, Malaysia. -FAU - Sathasivam, Kathiresan V -AU - Sathasivam KV -AD - Faculty of Applied Science & Centre of Excellence for Biomaterials Engineering, - AIMST University, Bedong 08100, Kedah, Malaysia. -FAU - Sudhakar, Kalvatala -AU - Sudhakar K -AD - School of Pharmaceutical Sciences (LIT-Pharmacy), Lovely Professional University, - Jalandhar, 144411, India. -FAU - Alharbi, Khalid Saad -AU - Alharbi KS -AD - Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, - Al-Jouf, Saudi Arabia. -FAU - Al-Malki, Waleed Hassan -AU - Al-Malki WH -AD - Department of Pharmacology, College of Pharmacy, Umm Al-Qura University, Makkah, - Saudi Arabia. -FAU - Afzal, Obaid -AU - Afzal O -AD - Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam - BinAbdulaziz University, AlKharj, 11942, Saudi Arabia. -FAU - Kazmi, Imran -AU - Kazmi I -AD - Department of Biochemistry, Faculty of Science, King Abdulaziz University, - Jeddah, 21589, Saudi Arabia. -FAU - Al-Abbasi, Fahad A -AU - Al-Abbasi FA -AD - Department of Biochemistry, Faculty of Science, King Abdulaziz University, - Jeddah, 21589, Saudi Arabia. -FAU - Altamimi, Abdulmalik Saleh Alfawaz -AU - Altamimi ASA -AD - Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam - BinAbdulaziz University, AlKharj, 11942, Saudi Arabia. -FAU - Fuloria, Neeraj Kumar -AU - Fuloria NK -AD - Faculty of Pharmacy & Centre of Excellence for Biomaterials Engineering, AIMST - University, Bedong 08100, Kedah, Malaysia. Electronic address: - nfulorias@gmail.com. -LA - eng -PT - Journal Article -PT - Review -DEP - 20211103 -PL - Ireland -TA - Chem Biol Interact -JT - Chemico-biological interactions -JID - 0227276 -RN - 0 (Antineoplastic Agents) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Animals -MH - Antineoplastic Agents/therapeutic use -MH - Breast Neoplasms/genetics/*physiopathology -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/*physiopathology -MH - ErbB Receptors/antagonists & inhibitors/*metabolism -MH - Gene Expression Profiling -MH - Genes, Mitochondrial -MH - Humans -MH - Lung Neoplasms/drug therapy/genetics/*physiopathology -MH - Protein Kinase Inhibitors/therapeutic use -MH - Signal Transduction/genetics/physiology -OTO - NOTNLM -OT - Breast cancer -OT - Combination drugs -OT - EGFR -OT - NSCLC -OT - Treatment strategies -EDAT- 2021/11/08 06:00 -MHDA- 2022/01/04 06:00 -CRDT- 2021/11/07 20:33 -PHST- 2021/08/22 00:00 [received] -PHST- 2021/09/28 00:00 [revised] -PHST- 2021/11/01 00:00 [accepted] -PHST- 2021/11/08 06:00 [pubmed] -PHST- 2022/01/04 06:00 [medline] -PHST- 2021/11/07 20:33 [entrez] -AID - S0009-2797(21)00373-2 [pii] -AID - 10.1016/j.cbi.2021.109735 [doi] -PST - ppublish -SO - Chem Biol Interact. 2022 Jan 5;351:109735. doi: 10.1016/j.cbi.2021.109735. Epub - 2021 Nov 3. - -PMID- 37345618 -OWN - NLM -STAT- MEDLINE -DCOM- 20230816 -LR - 20230816 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 14 -IP - 23 -DP - 2023 Aug -TI - Integrating POLE/POLD1 mutated for immunotherapy treatment planning of advanced - stage non-small cell lung cancer. -PG - 2269-2274 -LID - 10.1111/1759-7714.15012 [doi] -AB - BACKGROUND: In this study, we evaluated the potential of DNA polymerase epsilon - (POLE) and DNA polymerase delta 1 (POLD1) as prognostic biomarkers for immune - checkpoint inhibitor (ICI) treatment in patients with advanced stage non-small - cell lung cancer (NSCLC). METHODS: Disease stage, PD-L1 positivity, histological - subtypes, POLE/POLD1 mutation status, tumor mutation burden (TMB), and response - to ICIs in NSCLC cases were derived from AACR GENIE dataset (n = 24 120), - TCGA-Pan Lung Cancer dataset (n = 1144), AACR GENIE BPC NSCLC v2.0-public - (n = 2004), and Memorial Sloan Kettering-Integrated Mutation Profiling of - Actionable Cancer Targets dataset (n = 350). The smoking history from TCGA and - AACR GENIE datasets was grouped into current, former or never-smokers. RESULTS: - POLE and POLD1 genetic alterations were identified in 5% and 2.6% of NSCLC - patients, respectively. Current smokers had 9% and 4% of POLE/POLD1 mutations, - respectively, versus 1.7% for both POLE and POLD1 mutations prevalence in - never-smokers. POLE/POLD1 mutations were associated with elevated mutation counts - than those with wild-type (median mutation counts 16 vs. 7, p < 0.0001), more - advanced disease stages (stage I disease 15.19% vs. 29.42%), more prevalent - squamous histology subtype (21.69% vs. 9.05%, p = 0.0427), and a higher - percentage of PD-L1 positivity (66.67% vs. 43.87%, p < 0.001). Treatment with - ICIs improved survival in patients with both POLE/POLD1 mutated and those with - TMB > 18 (p < 0.001). CONCLUSION: Current smokers have a five-fold increased risk - of having POLE mutations than never-smokers. POLE/POLD1 mutation status and - TMB > 18 can be a composite biomarker for selecting NSCLC patients with survival - benefits to ICI treatment. -CI - © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Zheng, Shuhua -AU - Zheng S -AUID- ORCID: 0000-0003-3903-3080 -AD - Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center of - Northwestern University, Chicago, Illinois, USA. -FAU - Cao, Yenong -AU - Cao Y -AD - Division of Hematology/Oncology, Tufts Medical Center, Boston, Massachusetts, - USA. -FAU - Randall, James -AU - Randall J -AD - Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center of - Northwestern University, Chicago, Illinois, USA. -FAU - Yu, Haomin -AU - Yu H -AD - Department of Mathematics, University of California, Santa Barbara, California, - USA. -FAU - Thomas, Tarita O -AU - Thomas TO -AD - Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center of - Northwestern University, Chicago, Illinois, USA. -LA - eng -PT - Journal Article -DEP - 20230622 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -RN - EC 2.7.7.- (POLD1 protein, human) -RN - EC 2.7.7.7 (DNA Polymerase III) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - *Lung Neoplasms/drug therapy/genetics -MH - B7-H1 Antigen/genetics -MH - Mutation -MH - Biomarkers, Tumor/genetics -MH - Immunotherapy -MH - DNA Polymerase III/genetics -PMC - PMC10423654 -OTO - NOTNLM -OT - POLE -OT - immunotherapy -OT - lung cancer -OT - tumor mutation burden -COIS- The authors declare no conflict of interest. -EDAT- 2023/06/22 06:42 -MHDA- 2023/08/16 06:42 -PMCR- 2023/06/22 -CRDT- 2023/06/22 05:53 -PHST- 2023/06/08 00:00 [revised] -PHST- 2023/04/26 00:00 [received] -PHST- 2023/06/11 00:00 [accepted] -PHST- 2023/08/16 06:42 [medline] -PHST- 2023/06/22 06:42 [pubmed] -PHST- 2023/06/22 05:53 [entrez] -PHST- 2023/06/22 00:00 [pmc-release] -AID - TCA15012 [pii] -AID - 10.1111/1759-7714.15012 [doi] -PST - ppublish -SO - Thorac Cancer. 2023 Aug;14(23):2269-2274. doi: 10.1111/1759-7714.15012. Epub 2023 - Jun 22. - -PMID- 35844547 -OWN - NLM -STAT- MEDLINE -DCOM- 20220719 -LR - 20220719 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 13 -DP - 2022 -TI - Elucidation of the Application of Blood Test Biomarkers to Predict Immune-Related - Adverse Events in Atezolizumab-Treated NSCLC Patients Using Machine Learning - Methods. -PG - 862752 -LID - 10.3389/fimmu.2022.862752 [doi] -LID - 862752 -AB - BACKGROUND: Development of severe immune-related adverse events (irAEs) is a - major predicament to stop treatment with immune checkpoint inhibitors, even - though tumor progression is suppressed. However, no effective early phase - biomarker has been established to predict irAE until now. METHOD: This study - retrospectively used the data of four international, multi-center clinical trials - to investigate the application of blood test biomarkers to predict irAEs in - atezolizumab-treated advanced non-small cell lung cancer (NSCLC) patients. Seven - machine learning methods were exploited to dissect the importance score of 21 - blood test biomarkers after 1,000 simulations by the training cohort consisting - of 80%, 70%, and 60% of the combined cohort with 1,320 eligible patients. - RESULTS: XGBoost and LASSO exhibited the best performance in this study with - relatively higher consistency between the training and test cohorts. The best - area under the curve (AUC) was obtained by a 10-biomarker panel using the XGBoost - method for the 8:2 training:test cohort ratio (training cohort AUC = 0.692, test - cohort AUC = 0.681). This panel could be further narrowed down to a - three-biomarker panel consisting of C-reactive protein (CRP), - platelet-to-lymphocyte ratio (PLR), and thyroid-stimulating hormone (TSH) with a - small median AUC difference using the XGBoost method [for the 8:2 training:test - cohort ratio, training cohort AUC difference = -0.035 (p < 0.0001), and test - cohort AUC difference = 0.001 (p=0.965)]. CONCLUSION: Blood test biomarkers - currently do not have sufficient predictive power to predict irAE development in - atezolizumab-treated advanced NSCLC patients. Nevertheless, biomarkers related to - adaptive immunity and liver or thyroid dysfunction warrant further investigation. -CI - Copyright © 2022 Zhou, Wong, Wang, Tan, Chen, Jin, He, Shen, Wang, Frey, Fietkau, - Hecht, Ma and Gaipl. -FAU - Zhou, Jian-Guo -AU - Zhou JG -AD - Department of Oncology, The Second Affiliated Hospital of Zunyi Medical - University, Zunyi, China. -AD - Translational Radiobiology, Department of Radiation Oncology, - Universitätsklinikum Erlangen, Erlangen, Germany. -AD - Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, - Germany. -AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. -FAU - Wong, Ada Hang-Heng -AU - Wong AH -AD - AW Medical Company Limited, Macau, Macau SAR, China. -FAU - Wang, Haitao -AU - Wang H -AD - Thoracic Surgery Branch, National Cancer Institute, National Institutes of - Health, Bethesda, MD, United States. -FAU - Tan, Fangya -AU - Tan F -AD - Department of Analytics, Harrisburg University of Science & Technology, - Harrisburg, PA, United States. -FAU - Chen, Xiaofei -AU - Chen X -AD - Department of Biostat & Programming, Sanofi, Bridgewater, NJ, United States. -FAU - Jin, Su-Han -AU - Jin SH -AD - Department of Orthodontics, School of Stomatology, Zunyi Medical University, - Zunyi, China. -FAU - He, Si-Si -AU - He SS -AD - Department of Oncology, The Second Affiliated Hospital of Zunyi Medical - University, Zunyi, China. -FAU - Shen, Gang -AU - Shen G -AD - Department of Oncology, The Second Affiliated Hospital of Zunyi Medical - University, Zunyi, China. -FAU - Wang, Yun-Jia -AU - Wang YJ -AD - Department of Oncology, The Second Affiliated Hospital of Zunyi Medical - University, Zunyi, China. -FAU - Frey, Benjamin -AU - Frey B -AD - Translational Radiobiology, Department of Radiation Oncology, - Universitätsklinikum Erlangen, Erlangen, Germany. -AD - Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, - Germany. -AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. -FAU - Fietkau, Rainer -AU - Fietkau R -AD - Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, - Germany. -AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. -FAU - Hecht, Markus -AU - Hecht M -AD - Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, - Germany. -AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. -FAU - Ma, Hu -AU - Ma H -AD - Department of Oncology, The Second Affiliated Hospital of Zunyi Medical - University, Zunyi, China. -FAU - Gaipl, Udo S -AU - Gaipl US -AD - Translational Radiobiology, Department of Radiation Oncology, - Universitätsklinikum Erlangen, Erlangen, Germany. -AD - Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, - Germany. -AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20220630 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Biomarkers) -RN - 52CMI0WC3Y (atezolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized -MH - Biomarkers -MH - *Carcinoma, Non-Small-Cell Lung -MH - Hematologic Tests -MH - Humans -MH - *Immune System Diseases -MH - *Lung Neoplasms/diagnosis/drug therapy/pathology -MH - Machine Learning -MH - Retrospective Studies -PMC - PMC9284319 -OTO - NOTNLM -OT - NSCLC -OT - atezolizumab -OT - blood test -OT - irAE prediction -OT - machine learning -COIS- AHW is a founder and shareholder of AW Medical Company Limited. MH reports - collaborations with Merck Serono (advisory role, speakers’ bureau, honoraria, - travel expenses, and research funding), MSD (advisory role, speakers’ bureau, - honoraria, travel expenses, and research funding), AstraZeneca (research - funding), Novartis (research funding), BMS (advisory role, honoraria, and - speakers’ bureau), and Teva (travel expenses). UG and RF received support for - presentation activities for Dr Sennewald Medizintechnik GmbH, have received - support for investigator initiated clinical studies (IITs) from MSD and - AstraZeneca, and contributed at Advisory Boards Meetings of AstraZeneca and - Bristol-Myers Squibb. The remaining authors declare that the research was - conducted in the absence of any commercial or financial relationships that could - be construed as a potential conflict of interest. -EDAT- 2022/07/19 06:00 -MHDA- 2022/07/20 06:00 -PMCR- 2022/01/01 -CRDT- 2022/07/18 03:38 -PHST- 2022/01/26 00:00 [received] -PHST- 2022/05/24 00:00 [accepted] -PHST- 2022/07/18 03:38 [entrez] -PHST- 2022/07/19 06:00 [pubmed] -PHST- 2022/07/20 06:00 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2022.862752 [doi] -PST - epublish -SO - Front Immunol. 2022 Jun 30;13:862752. doi: 10.3389/fimmu.2022.862752. eCollection - 2022. - -PMID- 31666118 -OWN - NLM -STAT- MEDLINE -DCOM- 20200408 -LR - 20231104 -IS - 1756-994X (Electronic) -IS - 1756-994X (Linking) -VI - 11 -IP - 1 -DP - 2019 Oct 30 -TI - pTuneos: prioritizing tumor neoantigens from next-generation sequencing data. -PG - 67 -LID - 10.1186/s13073-019-0679-x [doi] -LID - 67 -AB - BACKGROUND: Cancer neoantigens are expressed only in cancer cells and presented - on the tumor cell surface in complex with major histocompatibility complex (MHC) - class I proteins for recognition by cytotoxic T cells. Accurate and rapid - identification of neoantigens play a pivotal role in cancer immunotherapy. - Although several in silico tools for neoantigen prediction have been presented, - limitations of these tools exist. RESULTS: We developed pTuneos, a computational - pipeline for prioritizing tumor neoantigens from next-generation sequencing data. - We tested the performance of pTuneos on the melanoma cancer vaccine cohort data - and tumor-infiltrating lymphocyte (TIL)-recognized neopeptide data. pTuneos is - able to predict the MHC presentation and T cell recognition ability of the - candidate neoantigens, and the actual immunogenicity of single-nucleotide variant - (SNV)-based neopeptides considering their natural processing and presentation, - surpassing the existing tools with a comprehensive and quantitative benchmark of - their neoantigen prioritization performance and running time. pTuneos was further - tested on The Cancer Genome Atlas (TCGA) cohort data as well as the melanoma and - non-small cell lung cancer (NSCLC) cohort data undergoing checkpoint blockade - immunotherapy. The overall neoantigen immunogenicity score proposed by pTuneos is - demonstrated to be a powerful and pan-cancer marker for survival prediction - compared to traditional well-established biomarkers. CONCLUSIONS: In summary, - pTuneos provides the state-of-the-art one-stop and user-friendly solution for - prioritizing SNV-based candidate neoepitopes, which could help to advance - research on next-generation cancer immunotherapies and personalized cancer - vaccines. pTuneos is available at https://github.com/bm2-lab/pTuneos , with a - Docker version for quick deployment at - https://cloud.docker.com/u/bm2lab/repository/docker/bm2lab/ptuneos . -FAU - Zhou, Chi -AU - Zhou C -AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital; - Bioinformatics Department, School of Life Sciences and Technology, Tongji - University, Shanghai, 200092, China. -AD - Department of Ophthalmology, Ninghai First Hospital, Ninghai, 310000, Zhejiang, - China. -FAU - Wei, Zhiting -AU - Wei Z -AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital; - Bioinformatics Department, School of Life Sciences and Technology, Tongji - University, Shanghai, 200092, China. -AD - Department of Ophthalmology, Ninghai First Hospital, Ninghai, 310000, Zhejiang, - China. -FAU - Zhang, Zhanbing -AU - Zhang Z -AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital; - Bioinformatics Department, School of Life Sciences and Technology, Tongji - University, Shanghai, 200092, China. -AD - Department of Ophthalmology, Ninghai First Hospital, Ninghai, 310000, Zhejiang, - China. -FAU - Zhang, Biyu -AU - Zhang B -AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital; - Bioinformatics Department, School of Life Sciences and Technology, Tongji - University, Shanghai, 200092, China. -AD - Department of Ophthalmology, Ninghai First Hospital, Ninghai, 310000, Zhejiang, - China. -FAU - Zhu, Chenyu -AU - Zhu C -AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital; - Bioinformatics Department, School of Life Sciences and Technology, Tongji - University, Shanghai, 200092, China. -AD - Department of Ophthalmology, Ninghai First Hospital, Ninghai, 310000, Zhejiang, - China. -FAU - Chen, Ke -AU - Chen K -AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital; - Bioinformatics Department, School of Life Sciences and Technology, Tongji - University, Shanghai, 200092, China. -AD - Department of Ophthalmology, Ninghai First Hospital, Ninghai, 310000, Zhejiang, - China. -FAU - Chuai, Guohui -AU - Chuai G -AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital; - Bioinformatics Department, School of Life Sciences and Technology, Tongji - University, Shanghai, 200092, China. -AD - Department of Ophthalmology, Ninghai First Hospital, Ninghai, 310000, Zhejiang, - China. -FAU - Qu, Sheng -AU - Qu S -AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital; - Bioinformatics Department, School of Life Sciences and Technology, Tongji - University, Shanghai, 200092, China. -AD - Department of Ophthalmology, Ninghai First Hospital, Ninghai, 310000, Zhejiang, - China. -FAU - Xie, Lu -AU - Xie L -AD - Shanghai Center for Bioinformation Technology, Shanghai, 201203, China. -FAU - Gao, Yong -AU - Gao Y -AD - Department of Digestive Oncology, Shanghai East Hospital, Tongji University, - Shanghai, 200120, China. -FAU - Liu, Qi -AU - Liu Q -AUID- ORCID: 0000-0003-2578-1221 -AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital; - Bioinformatics Department, School of Life Sciences and Technology, Tongji - University, Shanghai, 200092, China. qiliu@tongji.edu.cn. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20191030 -PL - England -TA - Genome Med -JT - Genome medicine -JID - 101475844 -RN - 0 (Antigens, Neoplasm) -RN - 0 (Cancer Vaccines) -SB - IM -MH - Antigens, Neoplasm/analysis/genetics/*immunology -MH - Cancer Vaccines/genetics/*immunology -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/*immunology -MH - Cohort Studies -MH - Genome -MH - High-Throughput Nucleotide Sequencing/*methods -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/drug therapy/genetics/*immunology -MH - Melanoma/drug therapy/genetics/*immunology -MH - *Software -MH - T-Lymphocytes, Cytotoxic -PMC - PMC6822339 -OTO - NOTNLM -OT - Biomarker -OT - Cancer neoantigen -OT - Immune checkpoint blockade -OT - Immunotherapy -OT - Next-generation sequencing -COIS- The authors declare that they have no competing interests. -EDAT- 2019/11/02 06:00 -MHDA- 2020/04/09 06:00 -PMCR- 2019/10/30 -CRDT- 2019/11/01 06:00 -PHST- 2019/02/05 00:00 [received] -PHST- 2019/10/15 00:00 [accepted] -PHST- 2019/11/01 06:00 [entrez] -PHST- 2019/11/02 06:00 [pubmed] -PHST- 2020/04/09 06:00 [medline] -PHST- 2019/10/30 00:00 [pmc-release] -AID - 10.1186/s13073-019-0679-x [pii] -AID - 679 [pii] -AID - 10.1186/s13073-019-0679-x [doi] -PST - epublish -SO - Genome Med. 2019 Oct 30;11(1):67. doi: 10.1186/s13073-019-0679-x. - -PMID- 39330007 -OWN - NLM -STAT- MEDLINE -DCOM- 20240927 -LR - 20240929 -IS - 1718-7729 (Electronic) -IS - 1198-0052 (Print) -IS - 1198-0052 (Linking) -VI - 31 -IP - 9 -DP - 2024 Aug 30 -TI - Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene - Alterations: An Evolving Scenario. -PG - 5121-5139 -LID - 10.3390/curroncol31090379 [doi] -AB - The ever-growing knowledge regarding NSCLC molecular biology has brought - innovative therapies into clinical practice; however, the treatment situation in - the non-metastatic setting is rapidly evolving. Indeed, immunotherapy-based - perioperative treatments are currently considered the standard of care for - patients with resectable NSCLC in the absence of EGFR mutations or ALK gene - rearrangements. Recently, data have been presented on the use of tyrosine kinase - inhibitors (TKIs) in the adjuvant and locally advanced setting for patients with - NSCLC harboring such driver gene alterations. The aim of the current work is to - review the available evidence on the use of targeted treatments in the - non-metastatic setting, together with a summary of the ongoing trials designed - for actionable gene alterations other than EGFR and ALK. To date, 3-year adjuvant - osimertinib treatment has been demonstrated to improve DFS and OS and to reduce - CNS recurrence in resected EGFR-mutated NSCLC in stage IB-IIIA (TNM 7th edition). - The use of osimertinib after chemo-radiation in stage III unresectable - EGFR-mutated NSCLC showed the relevant PFS improvement. In the ALK-positive - setting, 2-year alectinib treatment was shown to clearly improve DFS compared to - adjuvant standard chemotherapy in resected NSCLC with stage IB (≥4 cm)-IIIA (TNM - 7th edition). Several trials are ongoing to establish the optimal adjuvant TKI - treatment duration, as well as neoadjuvant TKI strategies in EGFR- and - ALK-positive disease, and (neo)adjuvant targeted treatments in patients with - actionable gene alterations other than EGFR or ALK. In conclusion, our review - depicts how the current treatment scenario is expected to rapidly change in the - context of non-metastatic NSCLC with actionable gene alterations, hence - appropriate molecular testing from the early stages has become crucial to - establish the most adequate approaches both in the perioperative and the locally - advanced disease. -FAU - Fuorivia, Valeria -AU - Fuorivia V -AD - Division of Thoracic Oncology, European Institute of Oncology IRCCS, 20141 Milan, - Italy. -FAU - Attili, Ilaria -AU - Attili I -AUID- ORCID: 0000-0003-1333-6622 -AD - Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, - Italy. -FAU - Corvaja, Carla -AU - Corvaja C -AD - Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, - Italy. -FAU - Asnaghi, Riccardo -AU - Asnaghi R -AD - Division of Thoracic Oncology, European Institute of Oncology IRCCS, 20141 Milan, - Italy. -FAU - Carnevale Schianca, Ambra -AU - Carnevale Schianca A -AUID- ORCID: 0009-0007-9864-8284 -AD - Division of Thoracic Oncology, European Institute of Oncology IRCCS, 20141 Milan, - Italy. -FAU - Trillo Aliaga, Pamela -AU - Trillo Aliaga P -AUID- ORCID: 0000-0002-4341-003X -AD - Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, - Italy. -FAU - Del Signore, Ester -AU - Del Signore E -AD - Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, - Italy. -FAU - Spitaleri, Gianluca -AU - Spitaleri G -AUID- ORCID: 0000-0003-3742-9962 -AD - Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, - Italy. -FAU - Passaro, Antonio -AU - Passaro A -AUID- ORCID: 0000-0002-7575-3870 -AD - Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, - Italy. -FAU - de Marinis, Filippo -AU - de Marinis F -AD - Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, - Italy. -LA - eng -GR - N/A/This work was partially supported by the Italian Ministry of Health with - "Ricerca Corrente", "5 × 1000"/ -PT - Journal Article -PT - Review -DEP - 20240830 -PL - Switzerland -TA - Curr Oncol -JT - Current oncology (Toronto, Ont.) -JID - 9502503 -RN - 0 (Protein Kinase Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/genetics/drug therapy/therapy -MH - *Lung Neoplasms/genetics/drug therapy/pathology/therapy -MH - Protein Kinase Inhibitors/therapeutic use -MH - Mutation -PMC - PMC11431721 -OTO - NOTNLM -OT - NSCLC -OT - adjuvant -OT - driver gene -OT - early stage -OT - locally advanced -OT - neoadjuvant -OT - perioperative -OT - targeted treatments -OT - tyrosine kinase inhibitors (TKI) -COIS- I. Attili received consulting fees from Bristol-Myers Squibb, outside the - submitted work. F. de Marinis received honoraria or consulting fees from - AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, - Pfizer, Novartis, Takeda, Xcovery and Roche, outside the submitted work. A. - Passaro reports personal fees, as speaker bureau or advisor, for AstraZeneca, - Agilent/Dako, Boehringer Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Merck Sharp - & Dohme, Janssen, Novartis, Pfizer and Roche Genentech, outside the submitted - work. The authors have no other relevant affiliations or financial involvement - with any organization or entity with a financial interest in or financial - conflict with the subject matter or materials discussed in the manuscript apart - from those disclosed. -EDAT- 2024/09/27 16:17 -MHDA- 2024/09/27 16:18 -PMCR- 2024/08/30 -CRDT- 2024/09/27 09:26 -PHST- 2024/07/23 00:00 [received] -PHST- 2024/08/21 00:00 [revised] -PHST- 2024/08/28 00:00 [accepted] -PHST- 2024/09/27 16:18 [medline] -PHST- 2024/09/27 16:17 [pubmed] -PHST- 2024/09/27 09:26 [entrez] -PHST- 2024/08/30 00:00 [pmc-release] -AID - curroncol31090379 [pii] -AID - curroncol-31-00379 [pii] -AID - 10.3390/curroncol31090379 [doi] -PST - epublish -SO - Curr Oncol. 2024 Aug 30;31(9):5121-5139. doi: 10.3390/curroncol31090379. - -PMID- 33594771 -OWN - NLM -STAT- MEDLINE -DCOM- 20210705 -LR - 20240425 -IS - 1549-490X (Electronic) -IS - 1083-7159 (Print) -IS - 1083-7159 (Linking) -VI - 26 -IP - 6 -DP - 2021 Jun -TI - A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer - and the Rationale for the ECOG-ACRIN EA5181 Study. -PG - 523-532 -LID - 10.1002/onco.13725 [doi] -AB - ECOG-ACRIN EA5181 is a phase III prospective, randomized trial that randomizes - patients undergoing chemo/radiation for locally advanced non-small cell lung - cancer (LA-NSCLC) to concomitant durvalumab or no additional therapy, with both - arms receiving 1 year of consolidative durvalumab. Radiation dose escalation - failed to improve overall survival in RTOG 0617. However, conventionally - fractionated radiation to 60 Gy with concomitant chemotherapy is associated with - a high risk of local failure (38%-46%). It is hoped that concomitant - immunotherapy during chemo/radiation can help decrease the risk of local failure, - thereby improving overall survival and progression-free survival with acceptable - toxicity. In this article, we review conventional chemo/radiation therapy for - LA-NSCLC, as well as the quickly evolving world of immunotherapy in the treatment - of non-small cell lung cancer and discuss the rationale and study design of - EA5181. IMPLICATIONS FOR PRACTICE: This article provides an up-to-date assessment - of how immunotherapy is reshaping the landscape of metastatic non-small cell lung - cancer (NSCLC) and how the impact of this therapy is now rapidly moving into the - treatment of patients with locally advanced NSCLC who are presenting for curative - treatment. This article reviews the recent publications of chemo/radiation as - well as those combining immunotherapy with chemotherapy and chemo/radiation, and - provides a strategy for improving overall survival of patients with locally - advanced NSCLC by using concomitant immunotherapy with standard concurrent - chemo/radiation. -CI - © 2021 AlphaMed Press. -FAU - Varlotto, John M -AU - Varlotto JM -AD - Division of Radiation Oncology, Marshall University, Huntington, West Virginia, - USA. -FAU - Sun, Zhuoxin -AU - Sun Z -AD - Dana Farber Cancer Institute, Boston, Massachusetts, USA. -AD - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts, USA. -FAU - Ky, Bonnie -AU - Ky B -AD - Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, - Pennsylvania, USA. -FAU - Upshaw, Jenica -AU - Upshaw J -AD - Department of Medicine, Tufts University, Boston, Massachusetts, USA. -FAU - Katz, Sharyn I -AU - Katz SI -AD - Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA. -FAU - Fitzgerald, Thomas J -AU - Fitzgerald TJ -AD - Imaging and Radiation Oncology Core (IROC), Lincoln, Rhode Island, USA. -FAU - Wakelee, Heather -AU - Wakelee H -AD - Division of Oncology, Stanford University, Stanford, California, USA. -FAU - Diehn, Maximilian -AU - Diehn M -AD - Department of Radiation Oncology, Stanford University, Stanford, California, USA. -FAU - Mankoff, David A -AU - Mankoff DA -AD - Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA. -FAU - Lovely, Christine -AU - Lovely C -AD - Division of Hematology Oncology, Vanderbilt University, Nashville, Tennessee, - USA. -FAU - Belani, Chandra -AU - Belani C -AD - Department of Medical Oncology, Penn State Cancer Institute, Hershey, - Pennsylvania, USA. -FAU - Oettel, Kurt -AU - Oettel K -AD - Department of Medical Oncology, Gundersen Lutheran Medical Center, La Crosse, - Wisconsin, USA. -FAU - Masters, Gregory -AU - Masters G -AD - Delaware/Christiana Care NCORP, Newark, Delaware, USA. -FAU - Ramalingam, Suresh -AU - Ramalingam S -AD - Division of Medical Oncology, Emory University, Atlanta, Georgia, USA. -FAU - Pennell, Nathan A -AU - Pennell NA -AD - Department of Hematology Oncology, Cleveland Clinic, Cleveland, Ohio, USA. -LA - eng -GR - U10 CA180868/CA/NCI NIH HHS/United States -GR - UG1 CA233270/CA/NCI NIH HHS/United States -GR - UG1 CA233234/CA/NCI NIH HHS/United States -GR - UG1 CA189956/CA/NCI NIH HHS/United States -GR - K08 HL146959/HL/NHLBI NIH HHS/United States -GR - UG1 CA189828/CA/NCI NIH HHS/United States -GR - UG1 CA189819/CA/NCI NIH HHS/United States -GR - U10 CA180820/CA/NCI NIH HHS/United States -GR - R01 HL148272/HL/NHLBI NIH HHS/United States -GR - UG1 CA233247/CA/NCI NIH HHS/United States -GR - U10 CA180794/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20210311 -PL - England -TA - Oncologist -JT - The oncologist -JID - 9607837 -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/therapy -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/therapy -MH - Prospective Studies -MH - Randomized Controlled Trials as Topic -PMC - PMC8176975 -OTO - NOTNLM -OT - Chemo/radiation -OT - Immunotherapy -OT - Locally advanced lung cancer -OT - Radiation pneumonitis -OT - Radiation-related cardiac morbidity -COIS- Disclosures of potential conflicts of interest may be found at the end of this - article. -EDAT- 2021/02/18 06:00 -MHDA- 2021/07/06 06:00 -PMCR- 2021/06/01 -CRDT- 2021/02/17 06:02 -PHST- 2020/08/24 00:00 [received] -PHST- 2021/02/09 00:00 [accepted] -PHST- 2021/02/18 06:00 [pubmed] -PHST- 2021/07/06 06:00 [medline] -PHST- 2021/02/17 06:02 [entrez] -PHST- 2021/06/01 00:00 [pmc-release] -AID - ONCO13725 [pii] -AID - 10.1002/onco.13725 [doi] -PST - ppublish -SO - Oncologist. 2021 Jun;26(6):523-532. doi: 10.1002/onco.13725. Epub 2021 Mar 11. - -PMID- 34315390 -OWN - NLM -STAT- MEDLINE -DCOM- 20220510 -LR - 20220531 -IS - 1875-5992 (Electronic) -IS - 1871-5206 (Linking) -VI - 22 -IP - 7 -DP - 2022 -TI - Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: - Analysis of Prognostic Factors of Outcomes. -PG - 1278-1285 -LID - 10.2174/1871520621666210727112212 [doi] -AB - BACKGROUND: In advanced non-small-cell lung cancer, without activating mutations - and with PD-L1≥50%, Pembrolizumab monotherapy is the therapeutic standard in - Europe. OBJECTIVE: To evaluate retrospectively the safety and efficacy of this - drug and to investigate potential prognostic factors in daily clinical practice. - METHODS: From September 2017 to September 2019, 205 consecutive patients from 14 - Italian Medical Oncology Units were enrolled in the study. Gender, Age (> or <70 - years), ECOG-PS (0-1 or 2), histology (squamous or nonsquamous), presence of - brain, bone and liver metastases at baseline, PD-L1 score (>90% or <90%), smoking - status (never or former or current) were applied to the stratified log-rank. - Cox's proportional hazards model was used for multivariate analysis. RESULTS: At - a median follow-up of 15.2 months, median progression-free and overall survival - (mPFS and mOS) were 9.2 months (95% C.I., 4.8-13.5) and 15.9 months (95% C.I., - not yet evaluable), respectively. Patients with Eastern Cooperative Oncology - Group performance status (ECOG-PS) 2 had mPFS of 2.8 months (95% C.I., 2.1-3.4) - and mOS of 3.9 months (95% C.I., 2.5-5.3). Patients with liver metastases at - diagnosis had an mPFS of 3.2 months (95% C.I., 0.6-5.8) and an mOS of 6.0 months - (95% C.I., 3.7-8.4). At multivariate analysis for OS gender, ECOG-PS 2, and - presence of liver metastases were independent prognostic factors. CONCLUSION: - Patients with ECOG-PS 2 derived little benefit from the use of first-line - pembrolizumab. In patients with liver metastases, the association of - pembrolizumab with platinum-based chemotherapy could be a better option than - pembrolizumab alone. -CI - Copyright© Bentham Science Publishers; For any queries, please email at - epub@benthamscience.net. -FAU - Tibaldi, Carmelo -AU - Tibaldi C -AD - Department of Oncology, S.Luca Hospital, Lucca, Italy. -FAU - Mazzoni, Francesca -AU - Mazzoni F -AD - Department of Oncology, Careggi University Hospital, Firenze, Italy. -FAU - Scotti, Vieri -AU - Scotti V -AD - Department of Oncology, Radiation Oncology Unit, Azienda - Ospedaliero-Universitaria Careggi, Florence, Italy. -FAU - Vasile, Enrico -AU - Vasile E -AD - Department of Oncology, Azienda Ospedaliero-Universitaria, Pisa, Italy. -FAU - Pozzessere, Daniele -AU - Pozzessere D -AD - Division of Medical Oncology, S. Stefano Hospital, Prato, Italy. -FAU - Stasi, Irene -AU - Stasi I -AD - Division of Medical Oncology, Civil Hospital, Livorno, Italy. -FAU - Camerini, Andrea -AU - Camerini A -AD - Department of Oncology, Versilia Hospital, Lido di Camaiore, Italy. -FAU - Federici, Francesca -AU - Federici F -AD - Division of Medical Oncology, Apuane Hospital, Massa, Italy. -FAU - Meoni, Giulia -AU - Meoni G -AD - Department of Oncology, S. Giovanni di Dio Hospital, Firenze, Italy. -FAU - Caparello, Chiara -AU - Caparello C -AD - Division of Medical Oncology, Piombino, Italy. -FAU - Turrini, Marianna -AU - Turrini M -AD - Department of Oncology, S. Maria alla Gruccia Hospital, Montevarchi, Italy. -FAU - Rossi, Virginia -AU - Rossi V -AD - Department of Oncology, Careggi University Hospital, Firenze, Italy. -FAU - Ciccone, Lucia Pia -AU - Ciccone LP -AD - Department of Oncology, Radiation Oncology Unit, Azienda - Ospedaliero-Universitaria Careggi, Florence, Italy. -FAU - Pecora, Irene -AU - Pecora I -AD - Department of Oncology, Azienda Ospedaliero-Universitaria, Pisa, Italy. -FAU - Fantechi, Beatrice -AU - Fantechi B -AD - Division of Medical Oncology, S. Stefano Hospital, Prato, Italy. -FAU - Antonuzzo, Lorenzo -AU - Antonuzzo L -AD - Department of Oncology, Careggi University Hospital, Firenze, Italy. -FAU - Giannarelli, Diana -AU - Giannarelli D -AD - Biostatistical Unit, Regina Elena National Cancer Institute, IRCCS, Rome, Italy. -FAU - Baldini, Editta -AU - Baldini E -AD - Department of Oncology, S.Luca Hospital, Lucca, Italy. -LA - eng -PT - Journal Article -PL - Netherlands -TA - Anticancer Agents Med Chem -JT - Anti-cancer agents in medicinal chemistry -JID - 101265649 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal, Humanized -MH - B7-H1 Antigen -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - Humans -MH - *Liver Neoplasms/drug therapy -MH - *Lung Neoplasms/drug therapy/pathology -MH - Prognosis -MH - Retrospective Studies -OTO - NOTNLM -OT - NSCLC -OT - PD-L1 -OT - liver metastases -OT - pembrolizumab -OT - platinum-based chemotherapy -OT - prognostic factors -EDAT- 2021/07/29 06:00 -MHDA- 2022/05/11 06:00 -CRDT- 2021/07/28 05:31 -PHST- 2020/11/16 00:00 [received] -PHST- 2021/03/05 00:00 [revised] -PHST- 2021/03/30 00:00 [accepted] -PHST- 2021/07/29 06:00 [pubmed] -PHST- 2022/05/11 06:00 [medline] -PHST- 2021/07/28 05:31 [entrez] -AID - ACAMC-EPUB-116869 [pii] -AID - 10.2174/1871520621666210727112212 [doi] -PST - ppublish -SO - Anticancer Agents Med Chem. 2022;22(7):1278-1285. doi: - 10.2174/1871520621666210727112212. - -PMID- 37310427 -OWN - NLM -STAT- MEDLINE -DCOM- 20231023 -LR - 20240101 -IS - 1619-7089 (Electronic) -IS - 1619-7070 (Linking) -VI - 50 -IP - 11 -DP - 2023 Sep -TI - Patlak-Ki derived from ultra-high sensitivity dynamic total body [(18)F]FDG - PET/CT correlates with the response to induction immuno-chemotherapy in locally - advanced non-small cell lung cancer patients. -PG - 3400-3413 -LID - 10.1007/s00259-023-06298-x [doi] -AB - PURPOSE: This study aimed to investigate the predictive value of metabolic - features in response to induction immuno-chemotherapy in patients with locally - advanced non-small cell cancer (LA-NSCLC), using ultra-high sensitivity dynamic - total body [(18)F]FDG PET/CT. METHODS: The study analyzed LA-NSCLC patients who - received two cycles of induction immuno-chemotherapy and underwent a 60-min - dynamic total body [(18)F]FDG PET/CT scan before treatment. The primary tumors - (PTs) were manually delineated, and their metabolic features, including the - Patlak-Ki, Patlak-Intercept, maximum SUV (SUV(max)), metabolic tumor volume (MTV) - and total lesion glycolysis (TLG) were evaluated. The overall response rate (ORR) - to induction immuno-chemotherapy was evaluated according to RECIST 1.1 criteria. - The Patlak-Ki of PTs was calculated from the 20-60 min frames using the Patlak - graphical analysis. The best feature was selected using Laplacian feature - importance scores, and an unsupervised K-Means method was applied to cluster - patients. ROC curve was used to examine the effect of selected metabolic feature - in predicting tumor response to treatment. The targeted next generation - sequencing on 1021 genes was conducted. The expressions of CD68, CD86, CD163, - CD206, CD33, CD34, Ki67 and VEGFA were assayed through immunohistochemistry. The - independent samples t test and the Mann-Whitney U test were applied in the - intergroup comparison. Statistical significance was considered at P < 0.05. - RESULTS: Thirty-seven LA-NSCLC patients were analyzed between September 2020 and - November 2021. All patients received two cycles of induction chemotherapy - combined with Nivolumab/ Camrelizumab. The Laplacian scores showed that the - Patlak-Ki of PTs had the highest importance for patient clustering, and the - unsupervised K-Means derived decision boundary of Patlak-Ki was - 2.779 ml/min/100 g. Patients were categorized into two groups based on their - Patlak-Ki values: high FDG Patlak-Ki (H-FDG-Ki, Patlak-Ki > 2.779 ml/min/100 g) - group (n = 23) and low FDG Patlak-Ki (L-FDG-Ki, Patlak-Ki ≤ 2.779 ml/min/100 g) - group (n = 14). The ORR to induction immuno-chemotherapy was 67.6% (25/37) in the - whole cohort, with 87% (20/23) in H-FDG-Ki group and 35.7% (5/14) in L-FDG-Ki - group (P = 0.001). The sensitivity and specificity of Patlak-Ki in predicting the - treatment response were 80% and 75%, respectively [AUC = 0.775 (95%CI - 0.605-0.945)]. The expression of CD3(+)/CD8(+) T cells and - CD86(+)/CD163(+)/CD206(+) macrophages were higher in the H-FDG-Ki group, while - Ki67, CD33(+) myeloid cells, CD34(+) micro-vessel density (MVD) and tumor - mutation burden (TMB) were comparable between the two groups. CONCLUSIONS: The - total body [(18)F]FDG PET/CT scanner performed a dynamic acquisition of the - entire body and clustered LA-NSCLC patients into H-FDG-Ki and L-FDG-Ki groups - based on the Patlak-Ki. Patients with H-FDG-Ki demonstrated better response to - induction immuno-chemotherapy and higher levels of immune cell infiltration in - the PTs compared to those with L-FDG-Ki. Further studies with a larger patient - cohort are required to validate these findings. -CI - © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, - part of Springer Nature. -FAU - Wang, DaQuan -AU - Wang D -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University - Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's - Republic of China. -FAU - Qiu, Bo -AU - Qiu B -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University - Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's - Republic of China. -FAU - Liu, QianWen -AU - Liu Q -AD - Department of Thoracic Surgery, State Key Laboratory of Oncology in South China, - Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer - Center, Guangzhou, China. -FAU - Xia, LiangPing -AU - Xia L -AD - Department of VIP, State Key Laboratory of Oncology in South China, Collaborative - Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, - Guangzhou, China. -FAU - Liu, SongRan -AU - Liu S -AD - Department of Pathology, State Key Laboratory of Oncology in South China, - Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer - Center, Guangzhou, China. -FAU - Zheng, ChaoJie -AU - Zheng C -AD - United Imaging Healthcare, Shanghai, China. -FAU - Liu, Hui -AU - Liu H -AD - United Imaging Healthcare, Shanghai, China. -FAU - Mo, YiWen -AU - Mo Y -AD - Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, - Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer - Center, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's Republic - of China. -FAU - Zhang, Xu -AU - Zhang X -AD - Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, - Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer - Center, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's Republic - of China. -FAU - Hu, YingYing -AU - Hu Y -AD - Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, - Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer - Center, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's Republic - of China. -FAU - Zheng, ShiYang -AU - Zheng S -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University - Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's - Republic of China. -FAU - Zhou, Yin -AU - Zhou Y -AD - SuZhou TongDiao Company, Suzhou, China. -FAU - Fu, Jia -AU - Fu J -AD - Department of Pathology, State Key Laboratory of Oncology in South China, - Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer - Center, Guangzhou, China. -FAU - Chen, NaiBin -AU - Chen N -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University - Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's - Republic of China. -FAU - Liu, FangJie -AU - Liu F -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University - Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's - Republic of China. -FAU - Zhou, Rui -AU - Zhou R -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University - Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's - Republic of China. -FAU - Guo, JinYu -AU - Guo J -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University - Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's - Republic of China. -FAU - Fan, Wei -AU - Fan W -AD - Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, - Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer - Center, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's Republic - of China. fanwei@sysucc.org.cn. -FAU - Liu, Hui -AU - Liu H -AD - Department of Radiation Oncology, State Key Laboratory of Oncology in South - China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University - Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's - Republic of China. liuhuisysucc@126.com. -LA - eng -GR - 82073328/National Natural Science Foundation of China/ -PT - Journal Article -DEP - 20230613 -PL - Germany -TA - Eur J Nucl Med Mol Imaging -JT - European journal of nuclear medicine and molecular imaging -JID - 101140988 -RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) -RN - 0 (Ki-67 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/diagnostic imaging/drug therapy/metabolism -MH - Positron Emission Tomography Computed Tomography/methods -MH - Fluorodeoxyglucose F18 -MH - *Lung Neoplasms/diagnostic imaging/drug therapy/metabolism -MH - Ki-67 Antigen/metabolism -MH - Induction Chemotherapy -MH - CD8-Positive T-Lymphocytes/metabolism/pathology -MH - Tumor Burden -OTO - NOTNLM -OT - Dynamic total body PET -OT - FDG -OT - Immunotherapy -OT - Ki -OT - Lung cancer -EDAT- 2023/06/13 13:12 -MHDA- 2023/10/23 00:45 -CRDT- 2023/06/13 11:03 -PHST- 2023/02/19 00:00 [received] -PHST- 2023/06/01 00:00 [accepted] -PHST- 2023/10/23 00:45 [medline] -PHST- 2023/06/13 13:12 [pubmed] -PHST- 2023/06/13 11:03 [entrez] -AID - 10.1007/s00259-023-06298-x [pii] -AID - 10.1007/s00259-023-06298-x [doi] -PST - ppublish -SO - Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3400-3413. doi: - 10.1007/s00259-023-06298-x. Epub 2023 Jun 13. - -PMID- 36142866 -OWN - NLM -STAT- MEDLINE -DCOM- 20220926 -LR - 20220928 -IS - 1422-0067 (Electronic) -IS - 1422-0067 (Linking) -VI - 23 -IP - 18 -DP - 2022 Sep 19 -TI - Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic - Review. -LID - 10.3390/ijms231810948 [doi] -LID - 10948 -AB - Immune checkpoint inhibitors (ICIs) are an important advancement in the field of - cancer treatment, significantly improving the survival of patients with a series - of advanced malignancies, like melanoma, non-small cell lung cancer (NSCLC), - hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and Hodgkin lymphoma. - ICIs act upon T lymphocytes and antigen-presenting cells, targeting programmed - cell death protein 1 (PD1), programmed cell death protein ligand 1 (PD-L1), and - cytotoxic T-lymphocyte antigen 4 (CTLA-4), breaking the immune tolerance of the T - cells against malignant cells and enhancing the body's own immune response. A - variety of cardiac-adverse effects are associated with ICI-based treatment, - including pericarditis, arrhythmias, cardiomyopathy, and acute coronary syndrome, - with myocarditis being the most studied due to its often-unexpected onset and - severity. Overall, Myocarditis is rare but presents an immune-related adverse - event (irAE) that has a high fatality rate. Considering the rising number of - oncological patients treated with ICIs and the severity of their potential - adverse effects, a good understanding and continuous investigation of cardiac - irAEs is of the utmost importance. This systematic review aimed to revise recent - publications (between 2016-2022) on ICI-induced cardiac toxicities and highlight - the therapeutical approach and evolution in the selected cases. -FAU - Cozma, Angela -AU - Cozma A -AD - Department of Internal Medicine, Iuliu Hatieganu University of Medicine and - Pharmacy, 400012 Cluj-Napoca, Romania. -FAU - Sporis, Nicolae Dan -AU - Sporis ND -AD - Department of Medical Oncology, Prof. Dr. I. Chiricuta Oncology Institute, 400015 - Cluj-Napoca, Romania. -FAU - Lazar, Andrada Luciana -AU - Lazar AL -AUID- ORCID: 0000-0001-8428-8088 -AD - Department of Dermatology, Iuliu Hatieganu University of Medicine and Pharmacy, - 400012 Cluj-Napoca, Romania. -FAU - Buruiana, Andrei -AU - Buruiana A -AD - Department of Medical Oncology, Prof. Dr. I. Chiricuta Oncology Institute, 400015 - Cluj-Napoca, Romania. -FAU - Ganea, Andreea Maria -AU - Ganea AM -AD - Department of Internal Medicine, Iuliu Hatieganu University of Medicine and - Pharmacy, 400012 Cluj-Napoca, Romania. -FAU - Malinescu, Toma Vlad -AU - Malinescu TV -AD - Department of Internal Medicine, Iuliu Hatieganu University of Medicine and - Pharmacy, 400012 Cluj-Napoca, Romania. -FAU - Berechet, Bianca Mihaela -AU - Berechet BM -AD - Department of Internal Medicine, Iuliu Hatieganu University of Medicine and - Pharmacy, 400012 Cluj-Napoca, Romania. -FAU - Fodor, Adriana -AU - Fodor A -AUID- ORCID: 0000-0002-1124-6984 -AD - Clinical Centre of Diabetes, Nutrition and Metabolic Disease, Iuliu Hatieganu - University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. -FAU - Sitar-Taut, Adela Viviana -AU - Sitar-Taut AV -AUID- ORCID: 0000-0001-8590-4583 -AD - Department of Internal Medicine, Iuliu Hatieganu University of Medicine and - Pharmacy, 400012 Cluj-Napoca, Romania. -FAU - Vlad, Vasile Calin -AU - Vlad VC -AD - Department of Internal Medicine, Iuliu Hatieganu University of Medicine and - Pharmacy, 400012 Cluj-Napoca, Romania. -FAU - Negrean, Vasile -AU - Negrean V -AD - Department of Internal Medicine, Iuliu Hatieganu University of Medicine and - Pharmacy, 400012 Cluj-Napoca, Romania. -FAU - Orasan, Olga Hilda -AU - Orasan OH -AD - Department of Internal Medicine, Iuliu Hatieganu University of Medicine and - Pharmacy, 400012 Cluj-Napoca, Romania. -LA - eng -PT - Journal Article -PT - Review -PT - Systematic Review -DEP - 20220919 -PL - Switzerland -TA - Int J Mol Sci -JT - International journal of molecular sciences -JID - 101092791 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Apoptosis Regulatory Proteins) -RN - 0 (B7-H1 Antigen) -RN - 0 (CTLA-4 Antigen) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Ligands) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - *Antineoplastic Agents, Immunological/therapeutic use -MH - Apoptosis Regulatory Proteins -MH - B7-H1 Antigen -MH - CTLA-4 Antigen -MH - *Carcinoma, Hepatocellular/chemically induced -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Cardiotoxicity/etiology -MH - *Drug-Related Side Effects and Adverse Reactions -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects -MH - Ligands -MH - *Liver Neoplasms/chemically induced -MH - *Lung Neoplasms/drug therapy -MH - *Myocarditis/chemically induced -MH - Programmed Cell Death 1 Receptor -PMC - PMC9502843 -OTO - NOTNLM -OT - arrythmia -OT - cardiomyopathy -OT - immune checkpoint inhibitors -OT - myocarditis -OT - pericarditis -COIS- The authors declare no conflict of interest. -EDAT- 2022/09/24 06:00 -MHDA- 2022/09/28 06:00 -PMCR- 2022/09/19 -CRDT- 2022/09/23 01:26 -PHST- 2022/08/15 00:00 [received] -PHST- 2022/09/09 00:00 [revised] -PHST- 2022/09/16 00:00 [accepted] -PHST- 2022/09/23 01:26 [entrez] -PHST- 2022/09/24 06:00 [pubmed] -PHST- 2022/09/28 06:00 [medline] -PHST- 2022/09/19 00:00 [pmc-release] -AID - ijms231810948 [pii] -AID - ijms-23-10948 [pii] -AID - 10.3390/ijms231810948 [doi] -PST - epublish -SO - Int J Mol Sci. 2022 Sep 19;23(18):10948. doi: 10.3390/ijms231810948. - -PMID- 37769653 -OWN - NLM -STAT- MEDLINE -DCOM- 20231003 -LR - 20231012 -IS - 1424-3997 (Electronic) -IS - 0036-7672 (Linking) -VI - 153 -DP - 2023 Sep 1 -TI - Prognostic implication of PD-L1 in early-stage non-small cell lung cancer: a - retrospective single-centre study. -PG - 40110 -LID - 10.57187/smw.2023.40110 [doi] -AB - BACKGROUND: The prognostic role of programmed death-ligand 1 (PD-L1) expression - in patients with localised and locally advanced non-small cell lung cancer has - not been fully elucidated. This information could help to better interpret recent - and upcoming results of phase III adjuvant or neoadjuvant anti-PD-1/PD-L1 - immunotherapy studies. METHODS: In a cohort of 146 patients with early or locally - advanced non-small cell lung cancer treated with curative intent (by surgery or - radiotherapy), we investigated the prognostic value of PD-L1 expression and its - correlation with other biological and clinical features. PD-L1 expression was - stratified by quartiles. Primary endpoints were overall and disease-free - survival. We also analysed the prognostic impact of the presence of actionable - mutations, implemented treatment modality and completion of the treatment plan. - Neither type of patient received neoadjuvant or adjuvant immunotherapy or target - therapy. RESULTS: Of the 146 selected patients, 32 (21.9%) presented disease - progression and 15 died (10.3%) at a median follow-up of 20 months. In a - univariable analysis, PD-L1 expression ≥25% was associated with significantly - lower disease-free survival (hazard ratio [HR]) 1.9, 95% confidence interval [CI] - 1.0-3.9, p = 0.049). PD-L1 expression ≥50% did not lead to disease-free survival - or overall survival benefits (HR 1.2 and 1.1, respectively; 95% CI 0.6-2.6 and - 0.3-3.4, respectively; pnot significant). In a multivariate analysis, a stage >I - (HR 2.7, 95% CI 1.2-6, p = 0.012) and having an inoperable tumour (HR 3.2, 95% CI - 1.4-7.4, p = 0.005) were associated with lower disease-free survival. CONCLUSION: - The population of patients with early-stage non-small cell lung cancer and PD-L1 - expression ≥25% who were treated with curative intent during the - pre-immunotherapy era exhibited a worse prognosis. This finding provides - justification for the utilisation of adjuvant immunotherapy in this subgroup of - patients, based on the current evidence derived from disease-free survival - outcomes. However, for patients with PD-L1 expression <25%, opting to wait for - the availability of the overall survival results may be a prudent choice. -FAU - Cekani, Elona -AU - Cekani E -AD - Istituto Oncologico della Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale - (EOC), Bellinzona, Switzerland. -FAU - Martorell, Carolina -AU - Martorell C -AD - Istituto Oncologico della Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale - (EOC), Bellinzona, Switzerland. -FAU - Martucci, Francesco -AU - Martucci F -AD - Istituto Oncologico della Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale - (EOC), Bellinzona, Switzerland. -FAU - Patella, Miriam -AU - Patella M -AD - Thoracic Surgery Department, Ente Ospedaliero Cantonale (EOC), Bellinzona, - Switzerland. -FAU - Cafarotti, Stefano -AU - Cafarotti S -AD - Thoracic Surgery Department, Ente Ospedaliero Cantonale (EOC), Bellinzona, - Switzerland. -FAU - Valenti, Antonio -AU - Valenti A -AD - Pneumology Department, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland. -FAU - Freguia, Stefania -AU - Freguia S -AD - Institute of Pathology EOC, Locarno, Switzerland. -FAU - Molinari, Francesca -AU - Molinari F -AD - Institute of Pathology EOC, Locarno, Switzerland. -FAU - Froesch, Patrizia -AU - Froesch P -AD - Istituto Oncologico della Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale - (EOC), Bellinzona, Switzerland. -FAU - Frattini, Milo -AU - Frattini M -AD - Institute of Pathology EOC, Locarno, Switzerland. -FAU - Stathis, Anastasios -AU - Stathis A -AD - Istituto Oncologico della Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale - (EOC), Bellinzona, Switzerland. -FAU - Wannesson, Luciano -AU - Wannesson L -AD - Istituto Oncologico della Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale - (EOC), Bellinzona, Switzerland. -LA - eng -PT - Journal Article -DEP - 20230901 -PL - Switzerland -TA - Swiss Med Wkly -JT - Swiss medical weekly -JID - 100970884 -RN - 0 (CD274 protein, human) -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy -MH - *Lung Neoplasms/therapy/drug therapy -MH - B7-H1 Antigen -MH - Prognosis -MH - Retrospective Studies -EDAT- 2023/09/29 00:42 -MHDA- 2023/10/03 06:47 -CRDT- 2023/09/28 19:26 -PHST- 2023/10/03 06:47 [medline] -PHST- 2023/09/29 00:42 [pubmed] -PHST- 2023/09/28 19:26 [entrez] -AID - 40110 [pii] -AID - 10.57187/smw.2023.40110 [doi] -PST - epublish -SO - Swiss Med Wkly. 2023 Sep 1;153:40110. doi: 10.57187/smw.2023.40110. - -PMID- 36248788 -OWN - NLM -STAT- MEDLINE -DCOM- 20221018 -LR - 20221020 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 13 -DP - 2022 -TI - PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the - first-line treatment of locally advanced or metastatic pulmonary - lymphoepithelioma-like carcinoma. -PG - 1015444 -LID - 10.3389/fimmu.2022.1015444 [doi] -LID - 1015444 -AB - BACKGROUND: Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a distinctive - subtype of non-small cell lung carcinoma that was not well presented in clinical - studies. The management of advanced PLELC remains an important, unmet need due to - the paucity of high-grade evidence. Herein, we carried out a multicenter, - retrospective study to assess the effectiveness and tolerability of PD-1/PD-L1 - inhibitor plus chemotherapy versus chemotherapy alone for patients with advanced - PLELC in the first-line setting. PATIENTS AND METHODS: This retrospective study - enrolled patients with advanced PLELC receiving first-line treatment with PD-1 - inhibition plus chemotherapy (IO-Chemo group) or chemotherapy alone (Chemo group) - in three medical centers in China. The survival outcomes, efficacy, and safety - profile were investigated. The primary endpoint was progression-free survival - (PFS). Secondary endpoints included objective response rate (ORR), overall - survival (OS), and adverse events (AEs). RESULTS: A total of 133 patients were - enrolled. PFS was significantly longer in the IO-Chemo group (median 12.8 months - [95% CI 5.2-20.4]) than that in the Chemo group (median 7.7 months [95% CI - 6.8-8.6]; hazard ratio [HR] 0.48 [95% CI 0.31-0.74]; P=0.001). ORR was 74.5% (95% - CI, 63.0-86.1) in the IO-Chemo group and 34.6% (95% CI, 24.1-45.2) in the Chemo - group (P<0.001). The median OS was not reached in the IO-Chemo group versus 35.7 - months (95% CI 26.7-44.8) in the Chemo group (HR 0.47 [95% CI 0.20-1.07]; - P=0.065). Multivariate analysis revealed that PD-1/PD-L1 inhibitor combination - was independently associated with longer PFS (HR 0.40 [95% CI 0.25-0.63]; - P<0.001). Grade 3 or higher AEs occurred in 36 (65.5%) patients in the IO-Chemo - group and 56 (71.8%) patients in the Chemo group, respectively. CONCLUSIONS: In - patients with advanced PLELC, adding PD-1/PD-L1 inhibitor to platinum-based - chemotherapy significantly increased PFS and ORR with a tolerable safety profile. -CI - Copyright © 2022 Zhang, Zhou, Chen, Chen, Lin, He, Du, Chen, Hong and Fu. -FAU - Zhang, Xuanye -AU - Zhang X -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, - China. -FAU - Zhou, Yixin -AU - Zhou Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Very Important Person (VIP) Region, Sun Yat-sen University Cancer - Center, Guangzhou, China. -FAU - Chen, Hualin -AU - Chen H -AD - Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical - University, Zhanjiang, China. -FAU - Chen, Chen -AU - Chen C -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, - Guangzhou, China. -FAU - Lin, Zuan -AU - Lin Z -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, - China. -FAU - He, Li-Na -AU - He LN -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, - China. -FAU - Du, Wei -AU - Du W -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, - China. -FAU - Chen, Tao -AU - Chen T -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, Guangzhou, - China. -FAU - Hong, Shaodong -AU - Hong S -AD - State Key Laboratory of Oncology in South China, Guangzhou, China. -AD - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, - China. -FAU - Fu, Sha -AU - Fu S -AD - Department of Cellular and Molecular Diagnostics Center, Sun Yat-Sen Memorial - Hospital, Sun Yat-Sen University, Guangzhou, China. -AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene - Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, - China. -LA - eng -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -DEP - 20220929 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 49DFR088MY (Platinum) -SB - IM -MH - *Carcinoma, Squamous Cell/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Lung Neoplasms/pathology -MH - Platinum/therapeutic use -MH - Programmed Cell Death 1 Receptor -MH - Retrospective Studies -PMC - PMC9559223 -OTO - NOTNLM -OT - PD-1 -OT - PD-L1 -OT - chemotherapy -OT - immunotherapy -OT - pulmonary lymphoepithelioma-like carcinoma -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/10/18 06:00 -MHDA- 2022/10/19 06:00 -PMCR- 2022/01/01 -CRDT- 2022/10/17 05:12 -PHST- 2022/08/09 00:00 [received] -PHST- 2022/09/14 00:00 [accepted] -PHST- 2022/10/17 05:12 [entrez] -PHST- 2022/10/18 06:00 [pubmed] -PHST- 2022/10/19 06:00 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2022.1015444 [doi] -PST - epublish -SO - Front Immunol. 2022 Sep 29;13:1015444. doi: 10.3389/fimmu.2022.1015444. - eCollection 2022. - -PMID- 35256282 -OWN - NLM -STAT- MEDLINE -DCOM- 20220531 -LR - 20220714 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 23 -IP - 4 -DP - 2022 Jun -TI - Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for - Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations. -PG - 333-344 -LID - S1525-7304(22)00015-8 [pii] -LID - 10.1016/j.cllc.2022.02.001 [doi] -AB - INTRODUCTION: Therapeutic options for stage III non-small-cell lung cancer - (NSCLC) consist of definitive chemoradiation, surgery combined with - neoadjuvant/adjuvant chemotherapy, and trimodality therapy. More recently, - biologically driven systemic therapy options, including immunotherapy and - targeted therapy, have become increasingly available. METHODS: A customized, - case-based survey was designed and distributed to members of the International - Association for the Study of Lung Cancer (IASLC) to determine practice habits and - preferences for NSCLC patients with stage III disease and N2 to N3 nodal - involvement. RESULTS: Data were compiled from 87 respondents from 31 countries, - including medical oncologists (49%), surgical oncologists (24%), and radiation - oncologists (21%). Definitive chemoradiation was more likely to be recommended - for stage IIIC (98.2%) or stage IIIB (75.8%) scenarios compared with stage IIIA - (59.6%) without actionable driver alterations (P < .0001 and .0003, - respectively); and chemoradiation was more likely for stage IIIB (57.7%) compared - to stage IIIA (39.9%) with actionable EGFR/ALK alterations (P = .008). Surgery - was more likely to be recommended in the presence of an actionable alteration - (38.7% vs. 19%, P < .0001). Surgeons were more likely than medical oncologists to - recommend surgical approaches in scenarios without actionable alterations (25.6% - vs. 11.2%, P < .0001) or with actionable alterations (57.5% vs. 31.1%, - P = .0001). DISCUSSION: The dominant recommended strategy for stage III NSCLC was - chemoradiation, although respondents were more likely to recommend surgical - approaches in the presence of actionable alterations. Despite the lack of - reported clinical trial data, many IASLC lung cancer experts favored targeted - therapy when actionable driver alterations were present. -CI - Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. -FAU - Harris, Jeremy P -AU - Harris JP -AD - Department of Radiation Oncology, University of California Irvine, Orange, CA. - Electronic address: jeremy.harris@uci.edu. -FAU - Fujimoto, Dylann K -AU - Fujimoto DK -AD - Department of Radiation Oncology, University of California Irvine, Orange, CA. -FAU - Nagasaka, Misako -AU - Nagasaka M -AD - Division of Hematology/Oncology, Department of Medicine, University of California - Irvine, Orange, CA. -FAU - Ku, Eric -AU - Ku E -AD - Department of Radiation Oncology, University of California Irvine, Orange, CA. -FAU - Harada, Garrett -AU - Harada G -AD - Department of Radiation Oncology, University of California Irvine, Orange, CA. -FAU - Keshava, Hari -AU - Keshava H -AD - Division of Pulmonary Diseases and Critical Care Medicine, Department of - Medicine, University of California Irvine, Orange, CA. -FAU - Mahtabifard, Ali -AU - Mahtabifard A -AD - Division of Pulmonary Diseases and Critical Care Medicine, Department of - Medicine, University of California Irvine, Orange, CA. -FAU - Longoria, Javier -AU - Longoria J -AD - Division of Cardiothoracic Surgery, Department of Surgery, University of - California Irvine, Orange, CA. -FAU - Patel, Niral -AU - Patel N -AD - Division of Cardiothoracic Surgery, Department of Surgery, University of - California Irvine, Orange, CA. -FAU - Seyedin, Steven -AU - Seyedin S -AD - Department of Radiation Oncology, University of California Irvine, Orange, CA. -FAU - Simon, Aaron -AU - Simon A -AD - Department of Radiation Oncology, University of California Irvine, Orange, CA. -FAU - Chen, Allen -AU - Chen A -AD - Department of Radiation Oncology, University of California Irvine, Orange, CA. -LA - eng -PT - Journal Article -DEP - 20220210 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Combined Modality Therapy -MH - Cost of Illness -MH - Humans -MH - *Lung Neoplasms/pathology -MH - Neoplasm Staging -OTO - NOTNLM -OT - ALK -OT - Chemoradiation -OT - EGFR -OT - Locally advanced -OT - Surgery -EDAT- 2022/03/09 06:00 -MHDA- 2022/06/01 06:00 -CRDT- 2022/03/08 05:35 -PHST- 2021/11/26 00:00 [received] -PHST- 2022/01/28 00:00 [revised] -PHST- 2022/02/03 00:00 [accepted] -PHST- 2022/03/09 06:00 [pubmed] -PHST- 2022/06/01 06:00 [medline] -PHST- 2022/03/08 05:35 [entrez] -AID - S1525-7304(22)00015-8 [pii] -AID - 10.1016/j.cllc.2022.02.001 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2022 Jun;23(4):333-344. doi: 10.1016/j.cllc.2022.02.001. Epub - 2022 Feb 10. - -PMID- 31214620 -OWN - NLM -STAT- MEDLINE -DCOM- 20191209 -LR - 20240717 -IS - 2314-6141 (Electronic) -IS - 2314-6133 (Print) -VI - 2019 -DP - 2019 -TI - Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients - with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis. -PG - 9853701 -LID - 10.1155/2019/9853701 [doi] -LID - 9853701 -AB - OBJECTIVES: Despite the fact that it is widely acknowledged that immune - checkpoint inhibitors (ICIs) rely on the presence of immune response to take - their antitumor effect, little is known whether there is an influence exerted on - the efficacy of ICIs based on patients' age. We performed a systematic review and - meta-analysis to explore the efficacy of ICIs between younger and older patients. - MATERIALS AND METHODS: We searched online database and major conference - proceedings for randomized controlled trials (RCTs) published of ICIs and - included RCTs that conducted subgroup comparisons of age with available - combination of hazard ratios (HRs) and 95% confidence interval (95%CI). - Subsequently, we figured out the pooled HR and 95%CI in younger and older - patients with a random-effects model and evaluated the within-study heterogeneity - by using subgroup, sensitivity, and meta-regression analysis. RESULTS AND - CONCLUSION: A total of 12 eligible RCTs included in our study, which reported OS - according to patients' age. The overall estimated random-effects for HR was 0.75 - with 95% CI of 0.65-0.87 in younger arm versus 0.81 with 95% CI of 0.72-0.92 in - older arm. ICIs can improve OS for patients with advanced or metastatic lung - cancer when compared to controls, especially for those patients with NSCLC, - anti-PD-1/PD-L1 inhibitors, non-squamous, Pembrolizumab or Atezolizumab used as - well as subsequent-line setting, and the magnitude of benefit in OS had - comparable efficacy in both younger and older arms using a cut-off of 65 yr. - Conversely, we also drew a statically significant conclusion that older patients - failed to acquire benefit from ICIs when subdivided with a further cut-off of - 75 yr. -FAU - Zhang, Leyin -AU - Zhang L -AUID- ORCID: 0000-0002-7211-7094 -AD - The First Clinical Medical College of Zhejiang Chinese Medical University, - Hangzhou 310053, Zhejiang, China. -FAU - Sun, Leitao -AU - Sun L -AUID- ORCID: 0000-0002-1441-3899 -AD - The First Clinical Medical College of Zhejiang Chinese Medical University, - Hangzhou 310053, Zhejiang, China. -FAU - Yu, Jieru -AU - Yu J -AD - College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou - 310053, Zhejiang, China. -FAU - Shan, Feiyu -AU - Shan F -AUID- ORCID: 0000-0001-8115-4965 -AD - The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, - Zhejiang, China. -FAU - Zhang, Kai -AU - Zhang K -AD - The First Clinical Medical College of Zhejiang Chinese Medical University, - Hangzhou 310053, Zhejiang, China. -FAU - Pang, Xi -AU - Pang X -AD - The First Clinical Medical College of Zhejiang Chinese Medical University, - Hangzhou 310053, Zhejiang, China. -FAU - Ma, Chenghao -AU - Ma C -AD - The First Clinical Medical College of Zhejiang Chinese Medical University, - Hangzhou 310053, Zhejiang, China. -FAU - Zhang, Yinan -AU - Zhang Y -AD - The First Clinical Medical College of Zhejiang Chinese Medical University, - Hangzhou 310053, Zhejiang, China. -FAU - Shen, Minhe -AU - Shen M -AUID- ORCID: 0000-0001-7321-3830 -AD - Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese - Medical University, Hangzhou 310006, Zhejiang, China. -FAU - Ma, Shenglin -AU - Ma S -AD - Department of Radiotherapy, The Fourth Clinical Medical College of Zhejiang - Chinese Medical University, Hangzhou 310006, Zhejiang, China. -FAU - Ruan, Shanming -AU - Ruan S -AUID- ORCID: 0000-0003-1061-5255 -AD - Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese - Medical University, Hangzhou 310006, Zhejiang, China. -LA - eng -PT - Comparative Study -PT - Journal Article -PT - Meta-Analysis -PT - Systematic Review -DEP - 20190513 -PL - United States -TA - Biomed Res Int -JT - BioMed research international -JID - 101600173 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents) -RN - 52CMI0WC3Y (atezolizumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Age Factors -MH - *Aging -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - Antineoplastic Agents/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Clinical Trials as Topic -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy -MH - Male -MH - *Models, Biological -PMC - PMC6535828 -EDAT- 2019/06/20 06:00 -MHDA- 2019/12/18 06:00 -PMCR- 2019/05/13 -CRDT- 2019/06/20 06:00 -PHST- 2018/12/19 00:00 [received] -PHST- 2019/04/19 00:00 [revised] -PHST- 2019/04/28 00:00 [accepted] -PHST- 2019/06/20 06:00 [entrez] -PHST- 2019/06/20 06:00 [pubmed] -PHST- 2019/12/18 06:00 [medline] -PHST- 2019/05/13 00:00 [pmc-release] -AID - 10.1155/2019/9853701 [doi] -PST - epublish -SO - Biomed Res Int. 2019 May 13;2019:9853701. doi: 10.1155/2019/9853701. eCollection - 2019. - -PMID- 38219795 -OWN - NLM -STAT- MEDLINE -DCOM- 20240215 -LR - 20240216 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 15 -IP - 5 -DP - 2024 Feb -TI - Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung - cancer. -PG - 419-426 -LID - 10.1111/1759-7714.15209 [doi] -AB - Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer - (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge - can be divided into three categories: adverse events (AEs); resistance to ICIs, - and rechallenge becomes compulsive because of tumor relapse while the patients - had completed a 2 year course of immunotherapy. However, these categories are - still controversial and should be explored further. Through voting at the 6th - Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of - 147 experts in ICI rechallenges. A total of 97.74% experts agreed to rechallenge; - 48.87% experts rechallenge with the original drug, and the others rechallenge - with a different drug; 40.3% agreed to rechallenge directly after progression; - 88.06% experts agreed to ICI rechallenge with a combination regimen; and factors - such as previous performance status score, PD-1 expression, and age should also - be considered. Understanding the the clinical studies in ICI rechallenge could - bring us one step closer to understanding the consensus. In patients with - advanced NSCLC who have suffered recurrent or distant metastasis after - immunotherapy, the option of rechallenge with ICIs is a promising treatment - option. -CI - © 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, - Ltd. -FAU - Lin, Gen -AU - Lin G -AUID- ORCID: 0000-0001-6793-552X -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, China. -FAU - Wang, Zhijie -AU - Wang Z -AD - Department of Medical Oncology, National Cancer Center, National Clinical - Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Chu, Qian -AU - Chu Q -AD - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong - University of Science and Technology, Wuhan, China. -FAU - Hu, Yi -AU - Hu Y -AUID- ORCID: 0000-0001-9319-5692 -AD - Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China. -FAU - Huang, Dingzhi -AU - Huang D -AUID- ORCID: 0000-0002-2798-9459 -AD - Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and - Hospital, Tianjin, China. -FAU - Wang, Jun -AU - Wang J -AUID- ORCID: 0000-0003-3941-2507 -AD - Department of Oncology, The First Affiliated Hospital of Shandong First Medical - University & Shandong Provincial Qianfoshan Hospital, Ji'nan, China. -FAU - Yang, Fan -AU - Yang F -AD - Department of Thoracic Surgery, Peking University People's Hospital, Beijing, - China. -FAU - Zhong, Wenzhao -AU - Zhong W -AUID- ORCID: 0000-0002-8917-8635 -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, - Guangdong Academy of Medical Sciences, Guangzhou, China. -FAU - Zhou, Chengzhi -AU - Zhou C -AUID- ORCID: 0000-0003-0029-6879 -AD - Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, - National Clinical Research Center for Respiratory Disease, National Center for - Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First - Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. -FAU - Zhu, Bo -AU - Zhu B -AD - Institute of Cancer, Xinqiao Hospital, Army Medical University, Chongqing, China. -FAU - Ai, Xinghao -AU - Ai X -AD - Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong - University School of Medicine, Shanghai, China. -FAU - Cao, Baoshan -AU - Cao B -AD - Department of Medical Oncology and Radiation Sickness, Cancer Center, Peking - University Third Hospital, Beijing, China. -FAU - Cao, Yabing -AU - Cao Y -AD - Department of oncology, Kiang Wu Hospital, Macau, China. -FAU - Chen, Mingqiu -AU - Chen M -AD - Department of Thoracic Radiation Oncology, Clinical Oncology School of Fujian - Medical University, Fujian Cancer Hospital, Fuzhou, China. -FAU - Chen, Xiaohui -AU - Chen X -AD - Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, China. -FAU - Chu, Tianqing -AU - Chu T -AD - Respiratory Department, Shanghai Chest Hospital, Shanghai Jiao Tong University - School of Medicine, Shanghai, China. -FAU - Duan, Jianchun -AU - Duan J -AUID- ORCID: 0000-0003-1479-2304 -AD - Department of Medical Oncology, National Cancer Center, National Clinical - Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Fan, Yun -AU - Fan Y -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. -FAU - Fang, Yong -AU - Fang Y -AD - Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhenjiang University - School of Medicine, Hangzhou, China. -FAU - Feng, Shuitu -AU - Feng S -AD - Department of Medical Oncology, Fudan University Shanghai Cancer Center Xiamen - Hospital, Xiamen, China. -FAU - Feng, Weineng -AU - Feng W -AD - Department of Pulmonary Oncology, The First People's Hospital of Foshan, Foshan, - China. -FAU - Guo, Hui -AU - Guo H -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, China. -FAU - Han, Chengbo -AU - Han C -AUID- ORCID: 0000-0001-8391-6134 -AD - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, - China. -FAU - He, Yong -AU - He Y -AUID- ORCID: 0000-0002-9404-798X -AD - Department of Respiratory Medicine, Xinqiao Hospital, Army Medical University, - Chongqing, China. -FAU - Hong, Shaodong -AU - Hong S -AD - State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer - Center, Guangzhou, China. -FAU - Hu, Jie -AU - Hu J -AD - Shanghai Geriatric Center, Zhongshan Hospital, Fudan University, Shanghai, China. -FAU - Huang, Meijuan -AU - Huang M -AUID- ORCID: 0000-0002-3390-9697 -AD - Division of Thoracic Tumor Multimodality Treatment and Department of Medical - Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Huang, Yan -AU - Huang Y -AD - State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer - Center, Guangzhou, China. -FAU - Jiang, Da -AU - Jiang D -AD - Department of Oncology, The Fourth Affiliated Hospital of Hebei Medical - University, Shijiazhuang, China. -FAU - Jiang, Kan -AU - Jiang K -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, China. -FAU - Jiang, Richeng -AU - Jiang R -AD - Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and - Hospital, Tianjin, China. -FAU - Jin, Bo -AU - Jin B -AD - Department of Medical Oncology, The First affiliated hospital of China Medical - University, Shenyang, China. -FAU - Jin, Shi -AU - Jin S -AUID- ORCID: 0000-0002-4462-2931 -AD - National Cancer Center/National Clinical Research Cencer for Cancer/Cancer - Hospital &Shenzhen Hospital, Chinese Academy of Medical Sciences and Perking - Union Medical College, Shenzhen, China. -FAU - Li, Jisheng -AU - Li J -AUID- ORCID: 0000-0002-4186-6228 -AD - Department of Medical Oncology, Qilu Hospital of Shandong University, Ji'nan, - China. -FAU - Li, Min -AU - Li M -AD - Department of Respiratory Medicine, Xiangya Hospital, Central South University, - Changsha, China. -FAU - Li, Ziming -AU - Li Z -AD - Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong - University School of Medicine, Shanghai, China. -FAU - Li, Chao -AU - Li C -AD - Department of Pathology, Clinical Oncology School of Fujian Medical University, - Fujian Cancer Hospital, Fuzhou, China. -FAU - Lin, Jie -AU - Lin J -AD - Department of Medical Oncology, The Second Affiliated Hospital of Kunming Medical - University, Kunming, China. -FAU - Liu, Anwen -AU - Liu A -AD - Department of Medical Oncology, The Second Affiliated Hospital of Nanchang - University, Nanchang, China. -FAU - Liu, Si-Yang Maggie -AU - Liu SM -AD - Department of Hematology, First Affiliated Hospital, Ji'nan University, - Guangzhou, China. -FAU - Yutao, Liu -AU - Yutao L -AD - Department of Medical Oncology, National Cancer Center, National Clinical - Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Liu, Zhefeng -AU - Liu Z -AD - Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China. -FAU - Liu, Zhe -AU - Liu Z -AD - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical - University, Beijing, China. -FAU - Liu, Zhenhua -AU - Liu Z -AD - Department of Oncology, Shengli Clinical Medical College of Fujian Medical - University, Fujian Provincial Hospital, Fuzhou, China. -FAU - Liu, Zhentian -AU - Liu Z -AD - Department of Thoracic Oncology, Jiangxi Cancer Hospital, Nanchang, China. -FAU - Liu, Zhigang -AU - Liu Z -AD - Cancer Center, The 10th Affiliated Hospital of Southern Medical University, - Dongguan, China. -FAU - Lu, Yuping -AU - Lu Y -AD - Department of Abdominal Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, China. -FAU - Lv, Tangfeng -AU - Lv T -AUID- ORCID: 0000-0001-7224-8468 -AD - Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School - of Nanjing University, Nanjing, China. -FAU - Ma, Zhiyong -AU - Ma Z -AD - Department of Respiratory Medicine, Henan cancer Hospital, Affiliated Cancer - Hospital of Zhengzhou University, Zhengzhou, China. -FAU - Miao, Qian -AU - Miao Q -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, China. -FAU - Peng, Min -AU - Peng M -AUID- ORCID: 0000-0001-6648-945X -AD - Cancer cenrter, Renmin Hospital of Wuhan University, Wuhan, China. -FAU - Pu, Xingxiang -AU - Pu X -AD - Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated - Cancer Hospital of Xiangya School of Medicine, Central South University, - Changsha, China. -FAU - Ren, Xiu Bao -AU - Ren XB -AD - Department of Biotherapy, Tianjin Medical University Cancer Institute and - Hospital, Tianjin, China. -FAU - Shan, Jianzhen -AU - Shan J -AD - Department of Medical Oncology, The First Affiliated Hospital of Zhejiang - University, Zhejiang, China. -FAU - Shan, Jinlu -AU - Shan J -AD - Department of Medical Oncology, Daping Hospital, Army Medical University, - Chongqing, China. -FAU - Shen, Peng -AU - Shen P -AD - Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, - China. -FAU - Shen, Bo -AU - Shen B -AUID- ORCID: 0000-0001-5709-5213 -AD - Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of - Cancer Research and Affiliated Cancer Hospital of Nanjing Medical University, - Nanjing, China. -FAU - Shi, Meiqi -AU - Shi M -AD - Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of - Cancer Research and Affiliated Cancer Hospital of Nanjing Medical University, - Nanjing, China. -FAU - Song, Yong -AU - Song Y -AUID- ORCID: 0000-0003-4979-4131 -AD - Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School - of Nanjing University, Nanjing, China. -FAU - Song, Zhengbo -AU - Song Z -AD - Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China. -FAU - Su, ChunXia -AU - Su C -AD - Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, - Tongji University School of Medicine, Shanghai, China. -FAU - Sun, Jianguo -AU - Sun J -AD - Institute of Cancer, Xinqiao Hospital, Army Medical University, Chongqing, China. -FAU - Tian, Panwen -AU - Tian P -AUID- ORCID: 0000-0002-6313-3228 -AD - Precision Medicine Key Laboratory of Sichuan Province, Department of Pulmonary - and Critical Care Medicine, Lung Cancer Center, West China Hospital, Sichuan - University, Chengdu, China. -FAU - Wang, Jinliang -AU - Wang J -AD - Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China. -FAU - Wang, Feng -AU - Wang F -AD - Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, China. -FAU - Wang, Huijuan -AU - Wang H -AD - Department of Respiratory Medicine, Henan cancer Hospital, Affiliated Cancer - Hospital of Zhengzhou University, Zhengzhou, China. -FAU - Wang, Jialei -AU - Wang J -AD - Department of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -FAU - Wang, Qian -AU - Wang Q -AD - Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of - Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China. -FAU - Wang, Wenxian -AU - Wang W -AUID- ORCID: 0000-0002-3047-4149 -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. -FAU - Wang, Yan -AU - Wang Y -AUID- ORCID: 0000-0002-1743-6383 -AD - Department of Medical Oncology, National Cancer Center, National Clinical - Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Wu, Lin -AU - Wu L -AD - Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated - Cancer Hospital of Xiangya School of Medicine, Central South University, - Changsha, China. -FAU - Wu, Fang -AU - Wu F -AUID- ORCID: 0000-0002-6627-3437 -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, China. -FAU - Xia, Yang -AU - Xia Y -AUID- ORCID: 0000-0003-2487-2244 -AD - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital - of Zhejiang University School of Medicine, Hangzhou, China. -FAU - Xie, Congying -AU - Xie C -AUID- ORCID: 0000-0002-1693-9034 -AD - Department of Radiation and Medical Oncology, Second Affiliated Hospital of - Wenzhou Medical University, Wenzhou, China. -FAU - Xie, Conghua -AU - Xie C -AUID- ORCID: 0000-0001-6623-9864 -AD - Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, - China. -FAU - Xin, Tao -AU - Xin T -AD - Department of Oncology, The Second Affiliated Hospital of Harbin Medical - University, Harbin, China. -FAU - Xiong, Jianping -AU - Xiong J -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, China. -FAU - Xu, Haipeng -AU - Xu H -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, China. -FAU - Xu, Song -AU - Xu S -AUID- ORCID: 0000-0001-6153-387X -AD - Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, - Tianjin, China. -FAU - Xu, Yiquan -AU - Xu Y -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, China. -FAU - Xu, Bin -AU - Xu B -AD - Cancer cenrter, Renmin Hospital of Wuhan University, Wuhan, China. -FAU - Xu, Chunwei -AU - Xu C -AUID- ORCID: 0000-0002-9021-6731 -AD - Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School - of Nanjing University, Nanjing, China. -FAU - Yan, Xiaolong -AU - Yan X -AD - Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, - Xi'an, China. -FAU - Yang, Zhenzhou -AU - Yang Z -AD - Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical - University, Chongqing, China. -FAU - Yao, Wenxiu -AU - Yao W -AD - Department of Medical Oncology, Sichuan Cancer Hospital, University of Electronic - Science and Technology of China, Chengdu, China. -FAU - Yu, Yao -AU - Yu Y -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, China. -FAU - Feng, Ye -AU - Feng Y -AD - Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug - Transformation Research, The First Affiliated Hospital of Xiamen University, - School of Medicine, Xiamen University, Xiamen, China. -FAU - Yu, Zongyang -AU - Yu Z -AD - Department of Respiratory Medicine, The 900th Hospital of the Joint Logistic - Support Force, People's Liberation Army of China, Fuzhou, China. -FAU - Yu, Yongfeng -AU - Yu Y -AD - Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong - University School of Medicine, Shanghai, China. -FAU - Yue, Dongsheng -AU - Yue D -AD - Department of Lung Cancer, Tianjin Medical University Cancer Institute and - Hospital, Tianjin, China. -FAU - Zhang, Haibo -AU - Zhang H -AD - Department of Oncology, Guangdong Provicial Hospital of Chinese Medicine, - Guangzhou, China. -FAU - Zhang, HongMei -AU - Zhang H -AD - Department of Clinical Oncology, Xijing Hospital, Air Force Medical University, - Xi'an, China. -FAU - Zhang, Li -AU - Zhang L -AD - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong - University of Science and Technology, Wuhan, China. -FAU - Zhang, Longfeng -AU - Zhang L -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, China. -FAU - Zhang, Qiuyu -AU - Zhang Q -AD - Institute of Immunotherapy, Fujian Medical University, Fuzhou, China. -FAU - Zhang, Tongmei -AU - Zhang T -AUID- ORCID: 0000-0003-4271-3773 -AD - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical - University, Beijing, China. -FAU - Zhang, Bicheng -AU - Zhang B -AD - Cancer cenrter, Renmin Hospital of Wuhan University, Wuhan, China. -FAU - Zhao, Jun -AU - Zhao J -AUID- ORCID: 0000-0003-1464-7158 -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer - Hospital and Institute, Beijing, China. -FAU - Zhao, Mingfang -AU - Zhao M -AD - Department of Medical Oncology, The First affiliated hospital of China Medical - University, Shenyang, China. -FAU - Zheng, Xiaobin -AU - Zheng X -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, China. -FAU - Zhong, Qiaofeng -AU - Zhong Q -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, China. -FAU - Zhou, Jin -AU - Zhou J -AD - Department of Medical Oncology, Sichuan Cancer Hospital, University of Electronic - Science and Technology of China, Chengdu, China. -FAU - Zhou, Penghui -AU - Zhou P -AD - State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer - Center, Guangzhou, China. -FAU - Zhu, Zhengfei -AU - Zhu Z -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -FAU - Zou, Juntao -AU - Zou J -AD - Department of Respiratory Medicine, The First Affiliated Hospital of Nanchang - University, Nanchang, China. -FAU - Zou, Zihua -AU - Zou Z -AUID- ORCID: 0000-0003-0677-3998 -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, China. -LA - eng -PT - Journal Article -DEP - 20240114 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use -MH - Consensus -MH - Immunotherapy -PMC - PMC10864121 -OTO - NOTNLM -OT - ICI -OT - NSCLC -OT - re-challenge -COIS- The authors declare no conflicts of interest. -EDAT- 2024/01/15 00:42 -MHDA- 2024/02/15 06:42 -PMCR- 2024/01/14 -CRDT- 2024/01/14 19:32 -PHST- 2023/11/27 00:00 [received] -PHST- 2023/12/12 00:00 [accepted] -PHST- 2024/02/15 06:42 [medline] -PHST- 2024/01/15 00:42 [pubmed] -PHST- 2024/01/14 19:32 [entrez] -PHST- 2024/01/14 00:00 [pmc-release] -AID - TCA15209 [pii] -AID - 10.1111/1759-7714.15209 [doi] -PST - ppublish -SO - Thorac Cancer. 2024 Feb;15(5):419-426. doi: 10.1111/1759-7714.15209. Epub 2024 - Jan 14. - -PMID- 31698333 -OWN - NLM -STAT- MEDLINE -DCOM- 20210204 -LR - 20210204 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 139 -DP - 2020 Jan -TI - Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small - cell lung carcinomas: A case series. -PG - 9-12 -LID - S0169-5002(19)30701-9 [pii] -LID - 10.1016/j.lungcan.2019.10.020 [doi] -AB - OBJECTIVES: to report outcomes of four cases of chemo-refractory RET-rearranged - non-small cell lung carcinomas (NSCLCs) treated with alectinib in a single - center. MATERIALS AND METHODS: we retrospectively assessed and reported the - activity and tolerability of alectinib 600 mg twice daily in advanced and - chemo-refractory RET-rearranged NSCLC patients treated in a Brazilian - institution. Identification of RET rearrangements was performed using the - FoundationOne® next-generation sequencing (NGS) platform. RESULTS: The four - patients herein reported were white, female and non-smokers, ranging between - 59-66 years of age. All patients had been previously treated with chemotherapy - and were TKI naïve; three of them presented disease progression to nivolumab as - well. Molecular tumor profiling showed a KIF5B-RET fusion in three patients and a - CCDC6-RET in the fourth. One patient exhibited disease progression and clinical - deterioration two months after treatment initiation. Disease control was - documented in two patients with PFS ranging from 4 to 5 months (one partial - metabolic response and one stable disease). In one of the cases, which developed - oligoprogression on alectinib, radiation therapy plus post-progression alectinib - were able to provide additional disease control for 9 more months. No grade 3/4 - adverse events, dose reductions or discontinuation due to toxicity were - documented. CONCLUSION: Although this is a small single center evaluation, - alectinib was well tolerated and demonstrated clinical activity against advanced - RET-rearranged NSCLCs, suggesting its potential role in this specific subset of - malignancies. Clinical trials addressing its efficacy and the optimal dosing - schedule in the present context are underway, and results are eagerly awaited. -CI - Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved. -FAU - Ribeiro, Maurício Fernando Silva Almeida -AU - Ribeiro MFSA -AD - Oncology Center, Hospital Sírio-Libanês, Rua Dona Adma Jafet, 91, 01308-050, São - Paulo, SP, Brazil. Electronic address: mauricio.fsaribeiro@hsl.org.br. -FAU - Alessi, João Victor Machado -AU - Alessi JVM -AD - Oncology Center, Hospital Sírio-Libanês, Rua Dona Adma Jafet, 91, 01308-050, São - Paulo, SP, Brazil. -FAU - Oliveira, Leandro Jonata Carvalho -AU - Oliveira LJC -AD - Oncology Center, Hospital Sírio-Libanês, Rua Dona Adma Jafet, 91, 01308-050, São - Paulo, SP, Brazil. -FAU - Gongora, Aline Bobato Lara -AU - Gongora ABL -AD - Oncology Center, Hospital Sírio-Libanês, Rua Dona Adma Jafet, 91, 01308-050, São - Paulo, SP, Brazil. -FAU - Sacardo, Karina Perez -AU - Sacardo KP -AD - Oncology Center, Hospital Sírio-Libanês, Rua Dona Adma Jafet, 91, 01308-050, São - Paulo, SP, Brazil. -FAU - Zucchetti, Bruna Migliavacca -AU - Zucchetti BM -AD - Oncology Center, Hospital Sírio-Libanês, Rua Dona Adma Jafet, 91, 01308-050, São - Paulo, SP, Brazil. -FAU - Shimada, Andrea Kazumi -AU - Shimada AK -AD - Oncology Center, Hospital Sírio-Libanês, Rua Dona Adma Jafet, 91, 01308-050, São - Paulo, SP, Brazil. -FAU - de Galiza Barbosa, Felipe -AU - de Galiza Barbosa F -AD - Nuclear Medicine Center, Hospital Sírio-Libanês, Rua Dona Adma Jafet, 91, - 01308-050, São Paulo, SP, Brazil. -FAU - Feher, Olavo -AU - Feher O -AD - Oncology Center, Hospital Sírio-Libanês, Rua Dona Adma Jafet, 91, 01308-050, São - Paulo, SP, Brazil. -FAU - Katz, Artur -AU - Katz A -AD - Oncology Center, Hospital Sírio-Libanês, Rua Dona Adma Jafet, 91, 01308-050, São - Paulo, SP, Brazil. -LA - eng -PT - Case Reports -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20191024 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Carbazoles) -RN - 0 (Piperidines) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret) -RN - EC 2.7.10.1 (RET protein, human) -RN - LIJ4CT1Z3Y (alectinib) -SB - IM -MH - Aged -MH - Carbazoles/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/secondary -MH - Drug Resistance, Neoplasm/*drug effects -MH - Female -MH - Follow-Up Studies -MH - *Gene Rearrangement -MH - Humans -MH - Lung Neoplasms/*drug therapy/genetics/pathology -MH - Middle Aged -MH - Piperidines/*therapeutic use -MH - Prognosis -MH - Protein Kinase Inhibitors/therapeutic use -MH - Proto-Oncogene Proteins c-ret/*genetics -MH - Retrospective Studies -OTO - NOTNLM -OT - Adenocarcinoma -OT - Alectinib -OT - Lung cancer -OT - RET-rearranged -OT - Targeted-therapy -EDAT- 2019/11/08 06:00 -MHDA- 2021/02/05 06:00 -CRDT- 2019/11/08 06:00 -PHST- 2019/08/10 00:00 [received] -PHST- 2019/09/24 00:00 [revised] -PHST- 2019/10/21 00:00 [accepted] -PHST- 2019/11/08 06:00 [pubmed] -PHST- 2021/02/05 06:00 [medline] -PHST- 2019/11/08 06:00 [entrez] -AID - S0169-5002(19)30701-9 [pii] -AID - 10.1016/j.lungcan.2019.10.020 [doi] -PST - ppublish -SO - Lung Cancer. 2020 Jan;139:9-12. doi: 10.1016/j.lungcan.2019.10.020. Epub 2019 Oct - 24. - -PMID- 36136277 -OWN - NLM -STAT- MEDLINE -DCOM- 20230719 -LR - 20230719 -IS - 1432-1335 (Electronic) -IS - 0171-5216 (Linking) -VI - 149 -IP - 8 -DP - 2023 Jul -TI - Central nervous systemic efficacy of immune checkpoint inhibitors and concordance - between intra/extracranial response in non-small cell lung cancer patients with - brain metastasis. -PG - 4523-4532 -LID - 10.1007/s00432-022-04251-3 [doi] -AB - PURPOSE: Immune checkpoint inhibitors (ICIs) markedly improve the clinical - outcomes of advanced non-small-cell lung cancer (NSCLC). However, the - intracranial efficacy of ICI is not well elucidated, and previous studies showed - discordant outcomes of ICI between intracranial and extracranial diseases. We - aimed to evaluate the clinical outcomes and the intracranial and extracranial - response of patients with NSCLC and brain metastasis who were treated with ICI in - the real-world setting. METHODS: A total of 55 patients (median age, 63 years - [range 42-80]; male, 78%) who had NSCLC with brain metastasis and treated with - ICI monotherapy were retrospectively analyzed. We separately assessed the - response rates of brain lesions and systemic lesions, and estimated the overall - survival (OS) and progression-free survival (PFS). RESULTS: The median OS and - overall PFS were 17.0 months (95% CI 10.3-25.6) and 3.19 months (95% CI - 2.24-5.03), respectively. The intracranial objective response rate and disease - control rate of ICI were 36 and 54%, respectively. Among the 44 patients who - showed disease progression, only 32% (n = 14) showed concordant outcomes and 9 - patients (20%) showed opposing discordant outcomes. Eight patients continued ICI - with local brain therapy after intracranial progression, and their median - extracranial PFS and OS were 15 months (95% CI 5.0-not assessed [NA]) and - 23.8 months (95% CI 14.7-NA), respectively. CONCLUSIONS: ICI monotherapy had a - clinically meaningful intracranial efficacy in NSCLC patients with brain - metastasis. Watchful waiting and close monitoring without local radiotherapy - might be feasible in NSCLC patients with asymptomatic active brain metastasis. -CI - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, - part of Springer Nature. -FAU - Kang, Sora -AU - Kang S -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. -AD - Division of hemato-oncology, Department of Internal Medicine, Chungnam National - University Hospital, Daejeon, 35015, South Korea. -FAU - Jeong, Hyehyun -AU - Jeong H -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. -FAU - Park, Ji Eun -AU - Park JE -AD - Department of Radiology and Research Institute of Radiology, Asan Medical Center, - University of Ulsan College of Medicine, Seoul, South Korea. -FAU - Kim, Ho Sung -AU - Kim HS -AD - Department of Radiology and Research Institute of Radiology, Asan Medical Center, - University of Ulsan College of Medicine, Seoul, South Korea. -FAU - Kim, Young-Hoon -AU - Kim YH -AD - Department of Neurological Surgery, Asan Medical Center, University of Ulsan - College of Medicine, Seoul, South Korea. -FAU - Lee, Dae Ho -AU - Lee DH -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. -FAU - Kim, Sang-We -AU - Kim SW -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. -FAU - Lee, Jae Cheol -AU - Lee JC -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. -FAU - Choi, Chang Min -AU - Choi CM -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. -FAU - Yoon, Shinkyo -AU - Yoon S -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. - shinkyoyoon@amc.seoul.kr. -LA - eng -GR - HI22C1234/Korea Health Technology R&D Project through the Korea Health Industry - Development Institute (KHIDI), the Ministry of Health & Welfare, Republic of - Korea/ -PT - Journal Article -DEP - 20220922 -PL - Germany -TA - J Cancer Res Clin Oncol -JT - Journal of cancer research and clinical oncology -JID - 7902060 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - Male -MH - Adult -MH - Middle Aged -MH - Aged -MH - Aged, 80 and over -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Lung Neoplasms/pathology -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Retrospective Studies -MH - *Brain Neoplasms/drug therapy/secondary -OTO - NOTNLM -OT - Brain metastasis -OT - Immunotherapy -OT - Non-small cell lung cancer -OT - RANO-BM -OT - mRECIST -EDAT- 2022/09/23 06:00 -MHDA- 2023/07/19 06:42 -CRDT- 2022/09/22 11:20 -PHST- 2022/03/29 00:00 [received] -PHST- 2022/08/02 00:00 [accepted] -PHST- 2023/07/19 06:42 [medline] -PHST- 2022/09/23 06:00 [pubmed] -PHST- 2022/09/22 11:20 [entrez] -AID - 10.1007/s00432-022-04251-3 [pii] -AID - 10.1007/s00432-022-04251-3 [doi] -PST - ppublish -SO - J Cancer Res Clin Oncol. 2023 Jul;149(8):4523-4532. doi: - 10.1007/s00432-022-04251-3. Epub 2022 Sep 22. - -PMID- 31264531 -OWN - NLM -STAT- MEDLINE -DCOM- 20190708 -LR - 20190708 -IS - 2038-2529 (Electronic) -IS - 0300-8916 (Linking) -VI - 105 -IP - 5_suppl -DP - 2019 Jul -TI - Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the - Italian Association of Medical Oncology (AIOM). -PG - 3-14 -LID - 10.1177/0300891619857418 [doi] -AB - The treatment landscape of metastatic non-small cell lung cancer (NSCLC) has - dramatically evolved in recent years, since the recognition of several - clinical-biological entities requiring personalized treatment approaches, leading - to significant improvements in patients' survival outcomes. In particular, - targeted therapies acting against EGFR, ALK, and ROS1, and immunotherapeutic - agents modulating the PD-1/PD-L1 axis, represent new milestones in the treatment - of advanced disease, supporting a chemotherapy backbone within a - multidisciplinary model. The Italian Association of Medical Oncology (AIOM) has - developed evidence-based guidelines for the management of lung tumors. Given the - epidemiologic relevance, this report is dedicated to the treatment of - advanced/metastatic NSCLC. These guidelines serve as a practical tool for - oncologists, physicians, and other healthcare professionals to easily embrace the - updated key points of NSCLC treatment strategies. Considering the upcoming - introduction of potential new standards of care in several disease settings, - these guidelines represent a benchmark from which to move forward. -FAU - Facchinetti, Francesco -AU - Facchinetti F -AD - 1 INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, - France. -FAU - Pilotto, Sara -AU - Pilotto S -AD - 2 Medical Oncology, University of Verona, Verona University Hospital, Verona, - Italy. -FAU - Metro, Giulio -AU - Metro G -AD - 3 Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera - di Perugia, Perugia, Italy. -FAU - Baldini, Editta -AU - Baldini E -AD - 4 Department of Oncology, S. Luca Hospital, Lucca, Italy. -FAU - Bertolaccini, Luca -AU - Bertolaccini L -AD - 5 Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, - Italy. -FAU - Cappuzzo, Federico -AU - Cappuzzo F -AD - 6 Department of Oncology and Hematology, AUSL Romagna, Ravenna, Italy. -FAU - Delmonte, Angelo -AU - Delmonte A -AD - 7 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, - Meldola, Italy. -FAU - Gasparini, Stefano -AU - Gasparini S -AD - 8 Department of Biologic Sciences and Public Health, Polytechnic University of - Marche Region; Pulmonary Diseases Unit, Azienda Ospedali Riuniti, Ancona, Italy. -FAU - Inno, Alessandro -AU - Inno A -AD - 9 Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Verona, - Italy. -FAU - Marchetti, Antonio -AU - Marchetti A -AD - 10 Center of Predictive Molecular Medicine, Center of Excellence on Aging - University-Foundation, Chieti, Italy. -FAU - Passiglia, Francesco -AU - Passiglia F -AD - 11 Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, - Italy. -FAU - Puma, Francesco -AU - Puma F -AD - 12 Division of Thoracic Surgery, S. Maria della Misericordia Hospital, University - of Perugia Medical School, Perugia, Italy. -FAU - Ricardi, Umberto -AU - Ricardi U -AD - 13 Radiation Oncology, Department of Oncology, University of Torino, Torino, - Italy. -FAU - Rossi, Antonio -AU - Rossi A -AD - 14 Division of Medical Oncology, Fondazione IRCCS "Casa Sollievo della - Sofferenza," San Giovanni Rotondo, Foggia, Italy. -FAU - Crinò, Lucio -AU - Crinò L -AD - 7 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, - Meldola, Italy. -FAU - Novello, Silvia -AU - Novello S -AD - 11 Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, - Italy. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Systematic Review -PL - United States -TA - Tumori -JT - Tumori -JID - 0111356 -RN - 0 (Antineoplastic Agents) -SB - IM -MH - Antineoplastic Agents/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Health Personnel/standards -MH - Humans -MH - Italy -MH - Lung Neoplasms/*drug therapy -MH - Medical Oncology/*standards -OTO - NOTNLM -OT - AIOM -OT - guidelines -OT - non-small cell lung cancer -OT - recommendations -EDAT- 2019/07/03 06:00 -MHDA- 2019/07/10 06:00 -CRDT- 2019/07/03 06:00 -PHST- 2019/07/03 06:00 [entrez] -PHST- 2019/07/03 06:00 [pubmed] -PHST- 2019/07/10 06:00 [medline] -AID - 10.1177/0300891619857418 [doi] -PST - ppublish -SO - Tumori. 2019 Jul;105(5_suppl):3-14. doi: 10.1177/0300891619857418. - -PMID- 37035884 -OWN - NLM -STAT- MEDLINE -DCOM- 20230411 -LR - 20230419 -IS - 1999-6187 (Electronic) -IS - 1009-3419 (Print) -IS - 1009-3419 (Linking) -VI - 26 -IP - 3 -DP - 2023 Mar 20 -TI - [A Real-world Study on the Expression Characteristics of PD-L1 in Patients 
with - Advanced EGFR Positive NSCLC and Its Relationship with the 
Therapeutic Efficacy - of EGFR-TKIs]. -PG - 217-227 -LID - 10.3779/j.issn.1009-3419.2023.101.09 [doi] -AB - BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors - (EGFR-TKIs) is the first choice for first-line treatment of advanced patients - with EGFR positive non-small cell lung cancer (NSCLC). For advanced NSCLC - patients with negative drive gene and positive programmed cell death ligand 1 - (PD-L1) or highly expressed NSCLC patients, the first-line treatment recommends - immune checkpoint inhibitors (ICIs) monotherapy or ICIs combined chemotherapy. - Therefore, the first-line treatment strategy for advanced NSCLC patients with - EGFR positive at different PD-L1 expression levels is worth further exploring. - Many previous studies have suggested that the expression of PD-L1 is obviously - affected by EGFR mutation, and the expression of PD-L1 is likely to be related to - the mechanism of EGFR-TKIs resistance. The purpose of this study was to analyze - the expression characteristics of PD-L1 in patients with advanced EGFR positive - NSCLC and its relationship with the efficacy of EGFR-TKIs. METHODS: 159 patients - with newly diagnosed advanced NSCLC with EGFR positive (including 141 patients - with EGFR sensitive mutations) were enrolled to analyze the relationship between - clinicopathological characteristics and PD-L1 expression. The factors affecting - the therapeutic effect of EGFR-TKIs in 141 patients with EGFR sensitive mutations - were also explored. RESULTS: The PD-L1 expression of the included patients was - classified according to the tumor promotion score (TPS): negative (TPS<1%) - accounted for 47.2%, low expression (1%≤TPS<50%) accounted for 32.1%, and high - expression (TPS≥50%) accounted for 20.7%. Among them, patients with solid - predominant cancer cell pathomorphology classification are more likely to have - high expression of PD-L1, accounting for 52.9% (P<0.0001). The median - progression-free survival (mPFS) of patients with PD-L1 negative expression, low - expression and high expression who received first generation EGFR-TKIs treatment - were 12.4 months, 10.5 months and 3.7 months, respectively, with significant - statistical difference (P<0.0001). During the EGFR-TKIs treatment, patients with - a history of radiotherapy for lung lesions have a longer PFS benefit than those - without a history of radiotherapy (mPFS: 17.0 months vs 9.3 months, P<0.0001). - CONCLUSIONS: The expression level of PD-L1 in advanced EGFR positive NSCLC - patients was significantly correlated with the pathomorphology classification of - cancer cells. The efficacy of EGFR-TKIs in patients with PD-L1 overexpression - NSCLC was significantly poor. PFS can be significantly prolonged during targeted - therapy combined with radiotherapy of lung lesions. -FAU - Chen, Ran -AU - Chen R -AD - Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of - Medicine, Xiangyang 441000, China. -AD - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical - University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing - 101149, China. -FAU - Gao, Xiang -AU - Gao X -AD - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical - University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing - 101149, China. -FAU - Xu, Fudong -AU - Xu F -AD - Department of Pathology, Beijing Chest Hospital, Capital Medical University, - 
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, - China. -FAU - Zhang, Shucai -AU - Zhang S -AD - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical - University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing - 101149, China. -FAU - Ma, Li -AU - Ma L -AD - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical - University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing - 101149, China. -FAU - Hu, Bo -AU - Hu B -AD - Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of - Medicine, Xiangyang 441000, China. -LA - chi -PT - English Abstract -PT - Journal Article -PL - China -TA - Zhongguo Fei Ai Za Zhi -JT - Zhongguo fei ai za zhi = Chinese journal of lung cancer -JID - 101126433 -RN - 0 (B7-H1 Antigen) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (EGFR protein, human) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology -MH - *Lung Neoplasms/drug therapy/genetics/pathology -MH - B7-H1 Antigen/metabolism -MH - ErbB Receptors/metabolism -MH - Mutation -MH - Protein Kinase Inhibitors/therapeutic use/pharmacology -PMC - PMC10106801 -OTO - NOTNLM -OT - Epidermal growth factor receptor mutation -OT - Lung neoplasms -OT - Programmed cell death ligand 1 expression -OT - Targeted treatment -EDAT- 2023/04/11 06:00 -MHDA- 2023/04/11 06:42 -PMCR- 2023/03/20 -CRDT- 2023/04/10 04:29 -PHST- 2023/04/11 06:42 [medline] -PHST- 2023/04/10 04:29 [entrez] -PHST- 2023/04/11 06:00 [pubmed] -PHST- 2023/03/20 00:00 [pmc-release] -AID - 10.3779/j.issn.1009-3419.2023.101.09 [doi] -PST - ppublish -SO - Zhongguo Fei Ai Za Zhi. 2023 Mar 20;26(3):217-227. doi: - 10.3779/j.issn.1009-3419.2023.101.09. - -PMID- 35797413 -OWN - NLM -STAT- MEDLINE -DCOM- 20220711 -LR - 20220726 -IS - 1932-6203 (Electronic) -IS - 1932-6203 (Linking) -VI - 17 -IP - 7 -DP - 2022 -TI - Splenic volume as a predictor of treatment response in patients with non-small - cell lung cancer receiving immunotherapy. -PG - e0270950 -LID - 10.1371/journal.pone.0270950 [doi] -LID - e0270950 -AB - INTRODUCTION: The spleen is a lymphoid organ and we hypothesize that clinical - benefit to immunotherapy may present with an increase in splenic volume during - treatment. The purpose of this study was to investigate whether changes in - splenic volume could be observed in those showing clinical benefit versus those - not showing clinical benefit to pembrolizumab treatment in non-small cell lung - cancer (NSCLC) patients. MATERIALS AND METHODS: In this study, 70 patients with - locally advanced or metastatic NSCLC treated with pembrolizumab; and who - underwent baseline CT scan within 2 weeks before treatment and follow-up CT - within 3 months after commencing immunotherapy were retrospectively evaluated. - The splenic volume on each CT was segmented manually by outlining the splenic - contour on every image and the total volume summated. We compared the splenic - volume in those achieving a clinical benefit and those not achieving clinical - benefit, using non-parametric Wilcoxon signed-rank test. Clinical benefit was - defined as stable disease or partial response lasting for greater than 24 weeks. - A p-value of <0.05 was considered statistically significant. RESULTS: There were - 23 responders and 47 non-responders based on iRECIST criteria and 35 patients - with clinical benefit and 35 without clinical benefit. There was no significant - difference in the median pre-treatment volume (175 vs 187 cm3, p = 0.34), - post-treatment volume (168 vs 167 cm3, p = 0.39) or change in splenic volume - (-0.002 vs 0.0002 cm3, p = 0.97) between the two groups. No significant - differences were also found between the splenic volume of patients with partial - response, stable disease or progressive disease (p>0.017). Moreover, there was no - statistically significant difference between progression-free survival and time - to disease progression when the splenic volume was categorized as smaller or - larger than the median pre-treatment or post-treatment volume (p>0.05). - CONCLUSION: No significant differences were observed in the splenic volume of - those showing clinical benefit versus those without clinical benefit to - pembrolizumab treatment in NSCLC patients. CT splenic volume cannot be used as a - potentially simple biomarker of response to immunotherapy. -FAU - Castagnoli, Francesca -AU - Castagnoli F -AUID- ORCID: 0000-0003-2407-7451 -AD - Department of Radiology, Royal Marsden Hospital, Sutton, United Kingdom. -FAU - Doran, Simon -AU - Doran S -AD - Division of Radiotherapy and Imaging, Institute of Cancer Research, London, - United Kingdom. -FAU - Lunn, Jason -AU - Lunn J -AUID- ORCID: 0000-0001-9214-6645 -AD - Division of Radiotherapy and Imaging, Institute of Cancer Research, London, - United Kingdom. -FAU - Minchom, Anna -AU - Minchom A -AD - Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, United - Kingdom. -FAU - O'Brien, Mary -AU - O'Brien M -AD - Lung Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, United - Kingdom. -FAU - Popat, Sanjay -AU - Popat S -AD - Lung Unit, Royal Marsden Hospital/Institute of Cancer Research, London, United - Kingdom. -FAU - Messiou, Christina -AU - Messiou C -AD - Department of Radiology, Royal Marsden Hospital, Sutton, United Kingdom. -FAU - Koh, Dow-Mu -AU - Koh DM -AD - Department of Radiology, Royal Marsden Hospital, Sutton, United Kingdom. -LA - eng -GR - DH_/Department of Health/United Kingdom -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20220707 -PL - United States -TA - PLoS One -JT - PloS one -JID - 101285081 -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/diagnostic imaging/drug therapy -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/diagnostic imaging/drug therapy -MH - Retrospective Studies -MH - Spleen/diagnostic imaging/pathology -PMC - PMC9262211 -COIS- I have read the journal’s policy and one of the authors of this manuscript (Anna - Minchom) have the following competing interests: has served on advisory boards - for Janssen Pharmaceuticals and Merck Pharmaceuticals, has received honoraria - from Chugai Pharmaceuticals, Novartis Oncology, Faron Pharmaceuticals, Bayer - Pharmaceuticals, has received expenses from Amgen Pharmaceuticals and LOXO - Oncology. The other authors have declared that no competing interests exist. that - this does not alter our adherence to PLOS ONE policies on sharing data and - materials. -EDAT- 2022/07/08 06:00 -MHDA- 2022/07/12 06:00 -PMCR- 2022/07/07 -CRDT- 2022/07/07 13:53 -PHST- 2022/01/21 00:00 [received] -PHST- 2022/06/22 00:00 [accepted] -PHST- 2022/07/07 13:53 [entrez] -PHST- 2022/07/08 06:00 [pubmed] -PHST- 2022/07/12 06:00 [medline] -PHST- 2022/07/07 00:00 [pmc-release] -AID - PONE-D-22-01786 [pii] -AID - 10.1371/journal.pone.0270950 [doi] -PST - epublish -SO - PLoS One. 2022 Jul 7;17(7):e0270950. doi: 10.1371/journal.pone.0270950. - eCollection 2022. - -PMID- 30267842 -OWN - NLM -STAT- MEDLINE -DCOM- 20191001 -LR - 20191001 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 13 -IP - 12 -DP - 2018 Dec -TI - Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint - Immunotherapy: Incidence and Risk Factors. -PG - 1930-1939 -LID - S1556-0864(18)33118-6 [pii] -LID - 10.1016/j.jtho.2018.08.2035 [doi] -AB - Checkpoint inhibitor pneumonitis (CIP) is an immune-related adverse event that - can occur after initiation of anti-programmed death 1/programmed death ligand 1 - immune checkpoint inhibitor (ICI) therapy for the treatment of multiple - malignancies, including NSCLC. However, the incidence of CIP has not been - previously examined in a population that included both trial-enrolled and - non-trial-enrolled patients with advanced NSCLC. Furthermore, risk factors and - other clinical characteristics associated with CIP severity are not known. In - this study, we retrospectively examined clinical characteristics, incidence, and - risk factors for CIP in a cohort of 205 patients with NSCLC, all of whom received - anti-programmed death 1/programmed death ligand 1 ICIs. Our results demonstrate a - higher incidence of CIP (19%) than previously reported in clinical trials - (3%-5%). Our data also suggest that tumor histologic type may be a risk factor - for CIP development. We observed a wide range of time to onset of CIP (median 82 - days), with high morbidity and mortality associated with higher-grade - CIP regardless of degree of immunosuppression. Our data provide new insight into - the epidemiology and clinical characteristics of CIP. Further studies are needed - to increase CIP pharmacovigilance, improve risk stratification, and refine - diagnostic algorithms for the diagnosis and management of this potential - life-threatening complication of ICI therapy. -CI - Copyright © 2018 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Suresh, Karthik -AU - Suresh K -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. Electronic address: ksuresh2@jhmi.edu. -FAU - Voong, Khinh Ranh -AU - Voong KR -AD - Department of Radiation Oncology, Johns Hopkins University School of Medicine, - Baltimore, Maryland. -FAU - Shankar, Bairavi -AU - Shankar B -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland. -FAU - Forde, Patrick M -AU - Forde PM -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Ettinger, David S -AU - Ettinger DS -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland. -FAU - Marrone, Kristen A -AU - Marrone KA -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Kelly, Ronan J -AU - Kelly RJ -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Hann, Christine L -AU - Hann CL -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Levy, Benjamin -AU - Levy B -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Feliciano, Josephine L -AU - Feliciano JL -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Brahmer, Julie R -AU - Brahmer JR -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Feller-Kopman, David -AU - Feller-Kopman D -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. -FAU - Lerner, Andrew D -AU - Lerner AD -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. -FAU - Lee, Hans -AU - Lee H -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. -FAU - Yarmus, Lonny -AU - Yarmus L -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. -FAU - D'Alessio, Franco -AU - D'Alessio F -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. -FAU - Hales, Russell K -AU - Hales RK -AD - Department of Radiation Oncology, Johns Hopkins University School of Medicine, - Baltimore, Maryland. -FAU - Lin, Cheng Ting -AU - Lin CT -AD - Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, - Maryland. -FAU - Psoter, Kevin J -AU - Psoter KJ -AD - Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, - Maryland. -FAU - Danoff, Sonye K -AU - Danoff SK -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. -FAU - Naidoo, Jarushka -AU - Naidoo J -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -LA - eng -GR - K08 HL132055/HL/NHLBI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20180926 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -SB - IM -CIN - J Thorac Oncol. 2018 Dec;13(12):1812-1814. doi: 10.1016/j.jtho.2018.10.007. PMID: - 30467044 -MH - Adenocarcinoma of Lung/*drug therapy/immunology/pathology -MH - Adolescent -MH - Adult -MH - Aged -MH - Antineoplastic Agents, Immunological/*adverse effects -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/pathology -MH - Carcinoma, Squamous Cell/*drug therapy/immunology/pathology -MH - Child -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Immunotherapy/*adverse effects -MH - Incidence -MH - Lung Neoplasms/drug therapy/immunology/pathology -MH - Male -MH - Maryland/epidemiology -MH - Middle Aged -MH - Pneumonia/chemically induced/*epidemiology -MH - Prognosis -MH - Retrospective Studies -MH - Risk Factors -MH - Young Adult -OTO - NOTNLM -OT - Checkpoint inhibitor pneumonitis -OT - Checkpoint inhibitors -OT - Immune-related adverse events -OT - Immunotherapy -OT - NSCLC -EDAT- 2018/09/30 06:00 -MHDA- 2019/10/02 06:00 -CRDT- 2018/09/30 06:00 -PHST- 2018/07/05 00:00 [received] -PHST- 2018/08/22 00:00 [revised] -PHST- 2018/08/27 00:00 [accepted] -PHST- 2018/09/30 06:00 [pubmed] -PHST- 2019/10/02 06:00 [medline] -PHST- 2018/09/30 06:00 [entrez] -AID - S1556-0864(18)33118-6 [pii] -AID - 10.1016/j.jtho.2018.08.2035 [doi] -PST - ppublish -SO - J Thorac Oncol. 2018 Dec;13(12):1930-1939. doi: 10.1016/j.jtho.2018.08.2035. Epub - 2018 Sep 26. - -PMID- 30367809 -OWN - NLM -STAT- MEDLINE -DCOM- 20190930 -LR - 20200309 -IS - 1581-3207 (Electronic) -IS - 1318-2099 (Print) -IS - 1318-2099 (Linking) -VI - 52 -IP - 4 -DP - 2018 Oct 18 -TI - Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung - cancer patients treated with immunotherapy. -PG - 365-369 -LID - 10.2478/raon-2018-0037 [doi] -AB - Background Uncommon response during immunotherapy is a new challenging issue in - oncology practice. Recently, new criteria for evaluation of response to - immunotherapy immune response evaluation criteria in solid tumors (iRECIST) were - accepted. According to iRECIST, worsening of performance status (PS) accompanied - to pseudoprogression reflects most probably the true progression of the malignant - disease. Methods A systematic review of the literature was made by using several - electronic database with the following search criteria: symptomatic - pseudoprogression, atypical response, immunotherapy and lung cancer. Results In - the literature, we identified five reports of seven patients treated with - immunotherapy that met the inclusion criteria. We also report our experience of - patient with pseudoprogression and almost complete response after one dose of - immunotherapy. Conclusions As seen from our review, iRECIST criteria might be - insufficient in distinguishing true progression from pseudoprogression in some - patients with advanced NSCLC treated with immunotherapy. More precise assessment - methods are urgently needed. -FAU - Vrankar, Martina -AU - Vrankar M -AD - Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, Slovenia. -FAU - Unk, Mojca -AU - Unk M -AD - Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, - Slovenia. -LA - eng -PT - Journal Article -PT - Systematic Review -DEP - 20181018 -PL - Poland -TA - Radiol Oncol -JT - Radiology and oncology -JID - 9317213 -RN - 0 (Immunologic Factors) -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Disease Progression -MH - Humans -MH - Immunologic Factors/*therapeutic use -MH - Immunotherapy/*methods -MH - Lung Neoplasms/*drug therapy -MH - Response Evaluation Criteria in Solid Tumors -PMC - PMC6287173 -OTO - NOTNLM -OT - atypical response -OT - immunotherapy -OT - lung cancer -OT - symptomatic pseudoprogression -EDAT- 2018/10/28 06:00 -MHDA- 2019/10/01 06:00 -PMCR- 2018/12/01 -CRDT- 2018/10/28 06:00 -PHST- 2018/02/05 00:00 [received] -PHST- 2018/03/12 00:00 [accepted] -PHST- 2018/10/28 06:00 [pubmed] -PHST- 2019/10/01 06:00 [medline] -PHST- 2018/10/28 06:00 [entrez] -PHST- 2018/12/01 00:00 [pmc-release] -AID - /j/raon.ahead-of-print/raon-2018-0037/raon-2018-0037.xml [pii] -AID - raon-2018-0037 [pii] -AID - 10.2478/raon-2018-0037 [doi] -PST - epublish -SO - Radiol Oncol. 2018 Oct 18;52(4):365-369. doi: 10.2478/raon-2018-0037. - -PMID- 37076834 -OWN - NLM -STAT- MEDLINE -DCOM- 20230421 -LR - 20230422 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 23 -IP - 1 -DP - 2023 Apr 19 -TI - Improved uptake and survival with systemic treatments for metastatic non-small - cell lung cancer: younger versus older adults. -PG - 360 -LID - 10.1186/s12885-023-10800-x [doi] -LID - 360 -AB - BACKGROUND: Over the past decade, there has been increasing availability of novel - therapeutics with improved tolerability and efficacy for advanced non-small cell - lung cancer (NSCLC). The study goals were: to compare the uptake of systemic - therapy (ST) before and after the availability of targeted tyrosine kinase - inhibitors (TKI) and immunotherapy and to examine the changes in overall survival - (OS) over time between younger and older adults with advanced NSCLC. METHODS: All - patients with advanced NSCLC referred to British Columbia (BC) Cancer in 2009, - 2011, 2015 and 2017 were included. One-year time points were based on molecular - testing implementation and funded drug availability: baseline (2009), epidermal - growth factor receptor TKI (2011), anaplastic lymphoma kinase TKI (2015) and - Programed Death-1 (PD-1) inhibitors (2017). Age groups were <70years and - ≥70years. Baseline demographics, simplified comorbidity scores (SCS), disease - characteristics, and ST details were collected retrospectively. Variables were - compared using X2, Fisher's exact tests and logistic-regression analysis. OS was - calculated using the Kaplan-Meier method and compared using the log-rank test. - RESULTS: 3325 patients were identified. Baseline characteristics were compared - between ages < 70 years and ≥ 70 years for each time cohort with significant - differences noted in baseline Eastern Cooperative Oncology Group (ECOG) - performance status and SCS. The rate of ST delivery trended upwards over time - with age <70 years: 2009 44%, 2011 53%, 2015 50% and 2017 52% and age ≥70 years: - 22%, 25%, 28% and 29% respectively. Predictors for decreased use of ST for - age <70 years: ECOG ≥2, SCS ≥9, year 2011, and smoking history; and age ≥70 - years: ECOG ≥2, years 2011 and 2015, and smoking history. The median OS of - patients who received ST improved from 2009 to 2017: age <70 years 9.1 m vs. - 15.5 m and age ≥70 years 11.4 m vs. 15.0 m. CONCLUSIONS: There was an increased - uptake of ST for both age groups with the introduction of novel therapeutics. - Although a smaller proportion of older adults received ST, those who received - treatment had comparable OS to their young counterpart. The benefit of ST in both - age groups was seen across the different types of treatments. With careful - assessment and selection of appropriate candidates, older adults with advanced - NSCLC appear to benefit from ST. -CI - © 2023. The Author(s). -FAU - Leung, Bonnie -AU - Leung B -AD - Department of Medical Oncology, BC Cancer - Vancouver Centre, 600 10th Avenue - West, Vancouver, BC, V5Z 4E6, Canada. Bonnie.Leung@bccancer.bc.ca. -FAU - Shokoohi, Aria -AU - Shokoohi A -AD - Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. -FAU - Al-Hashami, Zamzam -AU - Al-Hashami Z -AD - Department of Medicine, Sultan Qaboos Comprehensive Cancer Care and Research - Center, Muscat, Oman. -FAU - Moore, Sara -AU - Moore S -AD - The Ottawa Hospital Cancer Centre, Ottawa Hospital Research Institute, Ottawa, - ON, Canada. -FAU - Pender, Alexandra -AU - Pender A -AD - Royal Free London NHS Foundation Trust, London, UK. -FAU - Wong, Selina K -AU - Wong SK -AD - University of British Columbia Faculty of Medicine, Vancouver, BC, Canada. -AD - Department of Medical Oncology, BC Cancer, Victoria, BC, Canada. -FAU - Wang, Ying -AU - Wang Y -AD - Department of Medical Oncology, BC Cancer - Vancouver Centre, 600 10th Avenue - West, Vancouver, BC, V5Z 4E6, Canada. -AD - University of British Columbia Faculty of Medicine, Vancouver, BC, Canada. -FAU - Wu, Jonn -AU - Wu J -AD - University of British Columbia Faculty of Medicine, Vancouver, BC, Canada. -AD - Department of Radiation Oncology, BC Cancer, Vancouver, BC, Canada. -FAU - Ho, Cheryl -AU - Ho C -AD - Department of Medical Oncology, BC Cancer - Vancouver Centre, 600 10th Avenue - West, Vancouver, BC, V5Z 4E6, Canada. -AD - University of British Columbia Faculty of Medicine, Vancouver, BC, Canada. -LA - eng -PT - Journal Article -DEP - 20230419 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Protein Kinase Inhibitors) -SB - IM -MH - Humans -MH - Aged -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Lung Neoplasms/pathology -MH - Retrospective Studies -MH - Neoplasm Staging -MH - Immunotherapy/methods -MH - Protein Kinase Inhibitors/therapeutic use -PMC - PMC10114445 -OTO - NOTNLM -OT - Aging -OT - Cancer Treatment -OT - Geriatrics -OT - Lung cancer -OT - Older adults -OT - Overall survival -OT - Systemic therapy -COIS- Bonnie Leung reports receiving personal fees from AstraZeneca, outside of the - submitted work. Cheryl Ho reports receiving personal fees from Abbvie, Amgen, - AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Jazz, Merck, Novartis, - Pfizer, Roche, and Takeda; all outside of the submitted work. Ying Wang reports - receiving personal fees from AstraZeneca, Merck, and Takeda; all outside of the - submitted work. All other authors declare that they have no known competing - financial interests or personal relationships that could have appeared to - influence the work reported in this paper. -EDAT- 2023/04/20 00:41 -MHDA- 2023/04/21 06:41 -PMCR- 2023/04/19 -CRDT- 2023/04/19 23:55 -PHST- 2022/11/24 00:00 [received] -PHST- 2023/03/31 00:00 [accepted] -PHST- 2023/04/21 06:41 [medline] -PHST- 2023/04/20 00:41 [pubmed] -PHST- 2023/04/19 23:55 [entrez] -PHST- 2023/04/19 00:00 [pmc-release] -AID - 10.1186/s12885-023-10800-x [pii] -AID - 10800 [pii] -AID - 10.1186/s12885-023-10800-x [doi] -PST - epublish -SO - BMC Cancer. 2023 Apr 19;23(1):360. doi: 10.1186/s12885-023-10800-x. - -PMID- 36600554 -OWN - NLM -STAT- MEDLINE -DCOM- 20230106 -LR - 20230717 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 10 -IP - 12 -DP - 2022 Dec -TI - Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab - plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis - from a single-arm, phase 2 trial. -LID - 10.1136/jitc-2022-004952 [doi] -LID - e004952 -AB - OBJECTIVE: Robust biomarker predicting efficacy of immunotherapy is limited. - Circulating tumor DNA (ctDNA) sought to effectively monitor therapeutic response - as well as disease progression. This study aims to investigate predictive role of - ctDNA short-term dynamic change (6 weeks postimmunotherapy) in a single-arm, - phase 2 trial of sintilimab plus docetaxel for previously treated advanced - non-small cell lung cancer (NSCLC) patients. METHODS: A total of 33 patients with - advanced NSCLC with disease progression during or after any first-line treatment - were prospectively enrolled between 2019 and 2020. Patients received sintilimab - (200 mg, day 1, every 3 weeks) plus docetaxel (75 mg/m(2), day 3, every 3 weeks) - for 4-6 cycles, followed by maintenance therapy with sintilimab (200 mg, day 1, - every 3 weeks) until disease progression or unacceptable toxic effects. Blood - samples were prospectively collected at baseline, and after 2 cycles of treatment - (6 weeks post-treatment). All samples were subjected to targeted next-generation - sequencing with a panel of 448 cancer-related genes. The landscape of - high-frequency genomic profile of baseline and 6th week was described. Major - molecular characteristics in preselected genes of interest associated with - response to second-line chemoimmunotherapy were analyzed. The curative effects - and prognosis of patients were evaluated. RESULTS: Patients with ctDNA clearance - at 6th week had decreased tumor volume, while most patients with positive ctDNA - at 6th-week experienced an increase in tumor volume. Positive 6th-week ctDNA was - associated with significantly shorter progression-free survival (PFS) (91 vs NR - days; p<0.0001) and overall survival (47 vs 467 days; p =0.0039). Clearance of - clonal mutations and none new clonal formation at 6th week were associated with - longer PFS (mPFS 89 vs 266 days, p =0.003). ctDNA clearance at 6th week was an - independent risk factor for progression or death (HR=100 (95% CI 4.10 to - 2503.00), p=0.005). CONCLUSION: ctDNA status and ctDNA mutation clearance - putatively serve as predictive biomarkers for sintilimab combined with docetaxel - chemotherapy in pretreated advanced NSCLC patients. -CI - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Han, Xiao -AU - Han X -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Tang, Xiaoyong -AU - Tang X -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Zhu, Hui -AU - Zhu H -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Zhu, Dongyuan -AU - Zhu D -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Zhang, Xiqin -AU - Zhang X -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Meng, Xiangjiao -AU - Meng X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute Shandong - First Medical University and Shandong Academy of Medical Sciences, Jinan, China. -FAU - Hua, Ying -AU - Hua Y -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Wang, Zhongtang -AU - Wang Z -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Zhang, Yan -AU - Zhang Y -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Huang, Wei -AU - Huang W -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Wang, Linlin -AU - Wang L -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Yuan, Shuanghu -AU - Yuan S -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Zhang, Pinliang -AU - Zhang P -AD - Internal Medicine Department, Shandong Cancer Hospital and Institute, Jinan, - Shandong, China. -FAU - Gong, Heyi -AU - Gong H -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Sun, Yulan -AU - Sun Y -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Zhang, Yingjie -AU - Zhang Y -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China. -FAU - Liu, Zengjun -AU - Liu Z -AD - Internal Medicine Department, Shandong Cancer Hospital and Institute, Jinan, - Shandong, China. -FAU - Dong, Xiaomeng -AU - Dong X -AD - Medical Department, Amoy Diagnostics Co Ltd, Xiamen, Fujian, China. -FAU - Gai, Fei -AU - Gai F -AD - Medical Department, Amoy Diagnostics Co Ltd, Xiamen, Fujian, China. -FAU - Huang, Zhan -AU - Huang Z -AD - Medical Department, Amoy Diagnostics Co Ltd, Xiamen, Fujian, China. -FAU - Zhu, Changbin -AU - Zhu C -AD - Medical Department, Amoy Diagnostics Co Ltd, Xiamen, Fujian, China. -FAU - Guo, Jun -AU - Guo J -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China zhwang@sdfmu.edu.cn jngj2005@126.com. -FAU - Wang, Zhehai -AU - Wang Z -AUID- ORCID: 0000-0002-5021-8580 -AD - Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, - Jinan, Shandong, China zhwang@sdfmu.edu.cn jngj2005@126.com. -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 15H5577CQD (Docetaxel) -RN - 0 (Circulating Tumor DNA) -RN - 8FU7FQ8UPK (sintilimab) -SB - IM -EIN - J Immunother Cancer. 2023 Jul;11(7):e004952corr1. doi: - 10.1136/jitc-2022-004952corr1. PMID: 37460251 -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology -MH - Docetaxel/therapeutic use -MH - *Circulating Tumor DNA/genetics -MH - *Lung Neoplasms/drug therapy/genetics/pathology -MH - Disease Progression -PMC - PMC9730395 -OTO - NOTNLM -OT - Biomarkers, Tumor -OT - Genetic Markers -OT - Immunotherapy -OT - Lung Neoplasms -COIS- Competing interests: XD, FG, ZH, and CZ were employed by Amoy Diagnostics. No - other potential conflicts of interest relevant to this article were reported. -EDAT- 2023/01/06 06:00 -MHDA- 2023/01/07 06:00 -PMCR- 2022/12/06 -CRDT- 2023/01/05 01:13 -PHST- 2022/11/10 00:00 [accepted] -PHST- 2023/01/05 01:13 [entrez] -PHST- 2023/01/06 06:00 [pubmed] -PHST- 2023/01/07 06:00 [medline] -PHST- 2022/12/06 00:00 [pmc-release] -AID - jitc-2022-004952 [pii] -AID - 10.1136/jitc-2022-004952 [doi] -PST - ppublish -SO - J Immunother Cancer. 2022 Dec;10(12):e004952. doi: 10.1136/jitc-2022-004952. - -PMID- 37668890 -OWN - NLM -STAT- MEDLINE -DCOM- 20231216 -LR - 20231216 -IS - 2038-3312 (Electronic) -IS - 2038-131X (Linking) -VI - 75 -IP - 8 -DP - 2023 Dec -TI - Predictors, surrogate, and patient-reported outcomes in immunotherapy and salvage - surgery for unresectable lung cancer: a single-center retrospective study. -PG - 2355-2363 -LID - 10.1007/s13304-023-01644-y [doi] -AB - Medical treatment has changed drastically in recent years, especially for - advanced stages of non-small-cell lung cancer (NSCLC), for which the development - of immunotherapy and molecular targeted therapy significantly increased survival - and quality of life. This single-center retrospective study aimed to analyze the - outcome predictors, the surrogate outcomes, and the patient-reported outcomes - after neoadjuvant immunotherapy for initially unresectable NSCLC. Patients - affected by an initially unresectable NSCLC and identified between March 2014 and - December 2021 who received immunotherapy alone or in combination with - platinum-based chemotherapy and/or radiotherapy were collected. Overall survival - (OS) and disease-free survival (DFS) were estimated according to the Kaplan-Meier - method. Patient-reported outcomes were recorded using the European Organization - for Research and Treatment of Cancer (EORTC) Quality-of-Life (QoL) Group - questionnaire-Lung Cancer 29 Module to compare differences in symptoms and QoL at - two different times, 30 days and 1 year after surgery. Surgical, pathological - records, and patient-reported outcomes (at 30 days and 1 year after surgery) were - reviewed. Complete pathological remission was achieved in 7 patients (36.8%) and - major pathological remission in 3 patients (15.7%). The median overall survival - in the study group is 19 months (range: 2-57.4). Of 19 patients, 16 (84.2%) are - alive to date, of which 2 (10.5%) have a local recurrence. At 30 days from - surgery, the main symptoms reported by EORTC Module were coughing, shortness of - breath, the side effect of treatment, fear of progression, and surgery-related - problems. Induction immunotherapy with or without chemotherapy can be considered - for unresectable locally advanced NSCLC, and after the downstaging, the - possibility of surgery could be re-evaluated in a multidisciplinary setting with - high rates of R0 resection. In this selected and highly motivated group of - patients, the QoL and symptoms after salvage surgeries are acceptable and even - better than those reported in the literature. -CI - © 2023. Italian Society of Surgery (SIC). -FAU - Mohamed, Shehab -AU - Mohamed S -AD - Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, - Italy. -FAU - Bertolaccini, Luca -AU - Bertolaccini L -AUID- ORCID: 0000-0002-1153-3334 -AD - Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, - Italy. luca.bertolaccini@gmail.com. -AD - Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Via - Ripamonti 435, 20141, Milan, Italy. luca.bertolaccini@gmail.com. -FAU - Casiraghi, Monica -AU - Casiraghi M -AD - Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, - Italy. -AD - Unit of Interventional Pneumology, IEO, European Institute of Oncology IRCCS, - Milan, Italy. -FAU - Petrella, Francesco -AU - Petrella F -AD - Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, - Italy. -AD - Unit of Interventional Pneumology, IEO, European Institute of Oncology IRCCS, - Milan, Italy. -FAU - Galetta, Domenico -AU - Galetta D -AD - Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, - Italy. -AD - Unit of Interventional Pneumology, IEO, European Institute of Oncology IRCCS, - Milan, Italy. -FAU - Guarize, Juliana -AU - Guarize J -AD - Department of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, - Milan, Italy. -FAU - de Marinis, Filippo -AU - de Marinis F -AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. -FAU - Spaggiari, Lorenzo -AU - Spaggiari L -AD - Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, - Italy. -AD - Unit of Interventional Pneumology, IEO, European Institute of Oncology IRCCS, - Milan, Italy. -LA - eng -GR - 5 x 1000/Ministero della Salute/ -GR - Ricerca Corrente/Ministero della Salute/ -PT - Journal Article -DEP - 20230905 -PL - Italy -TA - Updates Surg -JT - Updates in surgery -JID - 101539818 -SB - IM -MH - Humans -MH - *Lung Neoplasms/therapy/pathology -MH - *Carcinoma, Non-Small-Cell Lung/surgery -MH - Retrospective Studies -MH - Quality of Life -MH - Immunotherapy -MH - Patient Reported Outcome Measures -MH - Neoplasm Staging -OTO - NOTNLM -OT - Immuno-oncology -OT - Lung cancer -OT - Patient-reported outcomes -OT - Predictive study -EDAT- 2023/09/05 12:42 -MHDA- 2023/12/17 09:42 -CRDT- 2023/09/05 11:19 -PHST- 2023/05/12 00:00 [received] -PHST- 2023/08/28 00:00 [accepted] -PHST- 2023/12/17 09:42 [medline] -PHST- 2023/09/05 12:42 [pubmed] -PHST- 2023/09/05 11:19 [entrez] -AID - 10.1007/s13304-023-01644-y [pii] -AID - 10.1007/s13304-023-01644-y [doi] -PST - ppublish -SO - Updates Surg. 2023 Dec;75(8):2355-2363. doi: 10.1007/s13304-023-01644-y. Epub - 2023 Sep 5. - -PMID- 38132391 -OWN - NLM -STAT- MEDLINE -DCOM- 20231225 -LR - 20240524 -IS - 1718-7729 (Electronic) -IS - 1198-0052 (Print) -IS - 1198-0052 (Linking) -VI - 30 -IP - 12 -DP - 2023 Dec 9 -TI - Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small - Cell Lung Cancer: A Real-World Population Study. -PG - 10396-10407 -LID - 10.3390/curroncol30120757 [doi] -AB - The PACIFIC trial led to a new standard of care for patients with locally - advanced lung cancer, but real-world practice has demonstrated that immune - checkpoint inhibitor (ICI) pneumonitis can lead to significant clinical - complications. This study aimed to examine the clinical predictors, outcomes, and - healthcare utilization data in patients who received consolidation durvalumab. - Using the Alberta Immunotherapy Database, NSCLC patients who received durvalumab - in Alberta, Canada, from January 2018 to December 2021 were retrospectively - evaluated. We examined incidence and predictive values of severe pneumonitis, - with overall survival (OS) and time-to-treatment failure (TTF) using exploratory - multivariate analyses. Of 189 patients, 91% were ECOG 0-1 and 85% had a partial - response from chemoradiation prior to durvalumab. Median TTF and OS were not - reached; 1-year OS was 82%. An amount of 26% developed any grade of pneumonitis; - 9% had ≥grade 3 pneumonitis. Male gender and a pre-existing autoimmune condition - were associated with severe pneumonitis. V20 was associated with any grade of - pneumonitis. Pneumonitis development was found to be an independent risk factor - for worse OS (p = 0.038) and TTF (p = 0.007). Our results suggest clinical and - dosimetric predictive factors of durvalumab-associated pneumonitis. These results - affirm the importance of careful patient selection for safe completion of - consolidation durvalumab in real-world LA-NSCLC population. -FAU - Lim, Chloe Ahryung -AU - Lim CA -AUID- ORCID: 0000-0001-6506-1742 -AD - Internal Medicine Residency Program, University of Calgary, Calgary, AB T2N 4N1, - Canada. -FAU - Ghosh, Sunita -AU - Ghosh S -AD - Cross Cancer Institute, University of Alberta, Edmonton, AB T2S 3C3, Canada. -FAU - Morrison, Hali -AU - Morrison H -AUID- ORCID: 0000-0001-8915-8506 -AD - Tom Baker Cancer Center, University of Calgary, Calgary, AB T2N 4N2, Canada. -FAU - Meyers, Daniel -AU - Meyers D -AUID- ORCID: 0000-0002-7619-7327 -AD - Internal Medicine Residency Program, University of Calgary, Calgary, AB T2N 4N1, - Canada. -FAU - Stukalin, Igor -AU - Stukalin I -AD - Internal Medicine Residency Program, University of Calgary, Calgary, AB T2N 4N1, - Canada. -FAU - Kerba, Marc -AU - Kerba M -AD - Tom Baker Cancer Center, University of Calgary, Calgary, AB T2N 4N2, Canada. -FAU - Hao, Desiree -AU - Hao D -AD - Tom Baker Cancer Center, University of Calgary, Calgary, AB T2N 4N2, Canada. -FAU - Pabani, Aliyah -AU - Pabani A -AUID- ORCID: 0009-0006-7605-8497 -AD - Tom Baker Cancer Center, University of Calgary, Calgary, AB T2N 4N2, Canada. -LA - eng -PT - Journal Article -DEP - 20231209 -PL - Switzerland -TA - Curr Oncol -JT - Current oncology (Toronto, Ont.) -JID - 9502503 -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Humans -MH - Male -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Retrospective Studies -MH - *Pneumonia -MH - Alberta -PMC - PMC10742980 -OTO - NOTNLM -OT - durvalumab-associated pneumonitis -OT - immunotherapy toxicity -OT - radiation pneumonitis -COIS- The authors declare no conflict of interest. -EDAT- 2023/12/22 12:43 -MHDA- 2023/12/25 06:42 -PMCR- 2023/12/09 -CRDT- 2023/12/22 09:06 -PHST- 2023/10/13 00:00 [received] -PHST- 2023/12/05 00:00 [revised] -PHST- 2023/12/05 00:00 [accepted] -PHST- 2023/12/25 06:42 [medline] -PHST- 2023/12/22 12:43 [pubmed] -PHST- 2023/12/22 09:06 [entrez] -PHST- 2023/12/09 00:00 [pmc-release] -AID - curroncol30120757 [pii] -AID - curroncol-30-00757 [pii] -AID - 10.3390/curroncol30120757 [doi] -PST - epublish -SO - Curr Oncol. 2023 Dec 9;30(12):10396-10407. doi: 10.3390/curroncol30120757. - -PMID- 18971836 -OWN - NLM -STAT- MEDLINE -DCOM- 20090305 -LR - 20081030 -IS - 0761-8425 (Print) -IS - 0761-8425 (Linking) -VI - 25 -IP - 8 Pt 2 -DP - 2008 Oct -TI - [Stage IV NSCLC. Biological treatments of lung cancer in 2008... and in the near - future]. -PG - 3S119-26 -AB - Nowadays, biological cancer treatments represent the major advance in non-small - cell lung cancer therapeutic strategies. During the last decade, more than 15 - randomized trials associating chemo with biological treatments, in first line - setting, have included more than 12,073 NSCLC patients, and as much in phase 2-3 - trials in second and third line setting. Very few were positive, but currently - anti-angiogenic strategy using the humanized monoclonal antibody bevacizumab has - been approved in association with chemotherapy, in first line treatment of - carefully selected NSCLC patients (with non proximal tumors, without cerebral - metastasis, and of non-squamous histology). On the same way, monotherapy by the - EGFR tyrosine kinase inhibitor erlotinib has been approved in second and third - line setting, with comparable results as chemotherapy. 2008 was the year of new - targeted therapies with cetuximab, the chimeric monoclonal antibody directed - against EFGR, in association with chemotherapy in first line setting, whereas - EGFR TKI are also tested in first line, in patients selected on the ground of the - molecular properties of their tumors (with EGFR mutation or positive EGFR FISH). - New generation EGFR TKI (more potent if not more selective) are developed in new - settings (neo-adjuvant or adjuvant treatment), with promising results in phase 2 - trials, whereas active immunotherapy directed toward MUC1 or MAGE-A3 are tested - in large phase 3 randomized trials in adjuvant setting (post-surgery or - post-radiotherapy), since phase 2 results were appealing. Therefore, during the - last few years, targeted therapies quit science-fiction to enter in our current - practice, leading clinicians to learn how to treat new kinds of toxicities and to - select patients on molecular grounds. -FAU - Bergot, E -AU - Bergot E -AD - Service de Pneumologie, Pôle Coeur-Poumons-Vaisseaux, Université de - Basse-Normandie, CHU de Caen, 1 Avenue de la Côte de Nacre, Caen cedex 05, - France. -FAU - Levallet, G -AU - Levallet G -FAU - Zalcman, G -AU - Zalcman G -LA - fre -PT - English Abstract -PT - Journal Article -TT - Les traitements biologiques du cancer bronchique en 2008... et dans un futur - proche. -PL - France -TA - Rev Mal Respir -JT - Revue des maladies respiratoires -JID - 8408032 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Vascular Endothelial Growth Factor A) -RN - 62229-50-9 (Epidermal Growth Factor) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - Biological Therapy -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Epidermal Growth Factor/*antagonists & inhibitors -MH - Forecasting -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology -MH - Neoplasm Staging -MH - Vascular Endothelial Growth Factor A/*antagonists & inhibitors -EDAT- 2008/11/26 09:00 -MHDA- 2009/03/06 09:00 -CRDT- 2008/11/26 09:00 -PHST- 2008/11/26 09:00 [pubmed] -PHST- 2009/03/06 09:00 [medline] -PHST- 2008/11/26 09:00 [entrez] -AID - MDOI-RMR-10-2008-25-8-C2-01761-8425-101019-200720314 [pii] -PST - ppublish -SO - Rev Mal Respir. 2008 Oct;25(8 Pt 2):3S119-26. - -PMID- 7577450 -OWN - NLM -STAT- MEDLINE -DCOM- 19951226 -LR - 20190515 -IS - 0007-0920 (Print) -IS - 1532-1827 (Electronic) -IS - 0007-0920 (Linking) -VI - 72 -IP - 5 -DP - 1995 Nov -TI - Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: - effect of co-administration with doxorubicin. -PG - 1076-82 -AB - The efficacy of radioimmunotherapy of tumours with radiolabelled monoclonal - antibodies (MAbs) depends on the amount of antibody taken up by the tumour and on - its intratumoral distribution. In the case of MAbs directed against intracellular - antigens, increasing the permeability of the cytoplasmic membrane may augment the - bioavailability of the antigen for the antibody. This raises the question whether - the induction of tumour necrosis by chemotherapy can enhance the tumour uptake of - radiolabelled monoclonal antibodies. In this work, the effect of doxorubicin on - the biodistribution of Po66, an MAb directed against an intracellular antigen, - was studied in nude mice grafted with the human non-small-cell lung carcinoma - cell line SK-MES-1. After injection on day 0 of 125I-labelled Po66, tumour - radioactivity increased up to days 3-5, and then remained unchanged to day 14. - The combined administration of 125I-labelled Po66 with 8 mg kg-1 doxorubicin, in - two doses separated by 7 days, doubled the radioactivity retained by the tumour. - Histological and historadiographic analysis showed, however, that the drug - induced cellular damage. In the absence of doxorubicin, the accumulation of Po66 - was restricted to some necrotic areas, whereas with doxorubicin the necrosis was - more extensive and the antibody more evenly distributed. These results suggest - that chemotherapy and immunoradiotherapy combined would enhance tumour uptake of - radioisotope and promote more homogenous distribution of the radiolabelled MAb. - This would promote eradication of the remaining drug-resistant cells in tumours. -FAU - Desrues, B -AU - Desrues B -AD - Service de Pneumologie, Centre Hospitalier Régional et Universitaire, Hôpital - Pontchaillou, Rennes, France. -FAU - Léna, H -AU - Léna H -FAU - Brichory, F -AU - Brichory F -FAU - Ramée, M P -AU - Ramée MP -FAU - Toujas, L -AU - Toujas L -FAU - Delaval, P -AU - Delaval P -FAU - Dazord, L -AU - Dazord L -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - England -TA - Br J Cancer -JT - British journal of cancer -JID - 0370635 -RN - 0 (Antibiotics, Antineoplastic) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Neoplasm) -RN - 0 (Antigens, Neoplasm) -RN - 0 (Immunoconjugates) -RN - 0 (Immunoglobulin G) -RN - 80168379AG (Doxorubicin) -RN - DQY03U61EJ (Polonium) -SB - IM -MH - Animals -MH - Antibiotics, Antineoplastic/administration & dosage/*pharmacokinetics/therapeutic - use -MH - Antibodies, Monoclonal/administration & - dosage/immunology/*pharmacokinetics/therapeutic use -MH - Antibodies, Neoplasm/administration & dosage/immunology/*therapeutic use -MH - Antigens, Neoplasm/immunology -MH - Carcinoma, Squamous Cell/drug therapy/immunology/*metabolism/radiotherapy -MH - Combined Modality Therapy -MH - Doxorubicin/administration & dosage/*pharmacokinetics/therapeutic use -MH - Drug Administration Schedule -MH - Female -MH - Humans -MH - Immunoconjugates/administration & dosage/*pharmacokinetics/therapeutic use -MH - Immunoglobulin G/administration & dosage/immunology/therapeutic use -MH - Intracellular Fluid/immunology -MH - Lung Neoplasms/drug therapy/immunology/*metabolism/radiotherapy -MH - Mice -MH - Mice, Inbred BALB C -MH - Mice, Nude -MH - Neoplasm Transplantation -MH - Polonium/administration & dosage/*pharmacokinetics/therapeutic use -MH - *Radioimmunotherapy -MH - Tissue Distribution/drug effects -PMC - PMC2033938 -EDAT- 1995/11/01 00:00 -MHDA- 1995/11/01 00:01 -CRDT- 1995/11/01 00:00 -PHST- 1995/11/01 00:00 [pubmed] -PHST- 1995/11/01 00:01 [medline] -PHST- 1995/11/01 00:00 [entrez] -AID - 10.1038/bjc.1995.468 [doi] -PST - ppublish -SO - Br J Cancer. 1995 Nov;72(5):1076-82. doi: 10.1038/bjc.1995.468. - -PMID- 36602799 -OWN - NLM -STAT- MEDLINE -DCOM- 20230110 -LR - 20230317 -IS - 2574-3805 (Electronic) -IS - 2574-3805 (Linking) -VI - 6 -IP - 1 -DP - 2023 Jan 3 -TI - Analysis of Tumor Mutational Burden, Progression-Free Survival, and - Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung - Cancer Treated With Chemoradiation and Durvalumab. -PG - e2249591 -LID - 10.1001/jamanetworkopen.2022.49591 [doi] -LID - e2249591 -AB - IMPORTANCE: The addition of consolidative durvalumab to chemoradiation has - improved disease control and survival in locally advanced non-small cell lung - cancer (NSCLC). However, there remains a need to identify biomarkers for response - to this therapy to allow for risk adaptation and personalization. OBJECTIVES: To - evaluate whether TMB or other variants associated with radiation response are - also associated with outcomes following definitive chemoradiation and adjuvant - durvalumab among patients with locally advanced unresectable NSCLC. DESIGN, - SETTING, AND PARTICIPANTS: This cohort study included consecutive patients with - unresectable locally advanced NSCLC treated with chemoradiation and adjuvant - durvalumab between November 2013 and March 2020 who had prospective comprehensive - genomic profiling. This study was completed at a multisite tertiary cancer - center. The median (IQR) follow-up time was 26 (21-36) months. Statistical - analysis was conducted from April to October 2022. EXPOSURES: Patients were - grouped into TMB-high (≥10 mutations/megabase [mt/Mb]) and TMB-low (<10 mt/Mb) - groups and were additionally evaluated by the presence of somatic alterations - associated with radiation resistance (KEAP1/NFE2L2) or radiation sensitivity (DNA - damage repair pathway). MAIN OUTCOMES AND MEASURES: The primary outcomes were - 24-month local-regional failure (LRF) and progression-free survival (PFS). - RESULTS: In this cohort study of 81 patients (46 [57%] male patients; median - [range] age, 67 [45-85] years), 36 patients (44%) had TMB-high tumors (≥10 - mt/Mb). Patients with TMB-high vs TMB-low tumors had markedly lower 24-month LRF - (9% [95% CI, 0%-46%] vs 51% [95% CI, 36%-71%]; P = .001) and improved 24-month - PFS (66% [95% CI, 54%-84%] vs 27% [95% CI, 13%-40%]; P = .003). The 24-month LRF - was 52% (95% CI, 25%-84%) among patients with KEAP1/NFE2L2-altered tumors - compared with 27% (95% CI, 17%-42%) among patients with KEAP1/NFE2L2-wildtype - tumors (P = .05). On Cox analysis, only TMB status was associated with LRF - (hazard ratio [HR], 0.17; 95% CI, 0.03-0.64; P = .02) and PFS (HR, 0.45; 95% CI, - 0.21-0.90; P = .03). Histology, disease stage, Eastern Cooperative Oncology Group - status, programmed cell death ligand 1 expression, and pathogenic KEAP1/NFE2L2, - KRAS, and DNA damage repair pathway alterations were not significantly associated - with LRF or PFS. CONCLUSIONS AND RELEVANCE: In this cohort study, TMB-high status - was associated with improved local-regional control and PFS after definitive - chemoradiation and adjuvant durvalumab. TMB status may facilitate risk-adaptive - radiation strategies in unresectable locally advanced NSCLC. -FAU - Lebow, Emily S -AU - Lebow ES -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, New York. -FAU - Shepherd, Annemarie -AU - Shepherd A -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, New York. -FAU - Eichholz, Jordan E -AU - Eichholz JE -AD - Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of - Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. -FAU - Offin, Michael -AU - Offin M -AD - Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of - Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. -FAU - Gelblum, Daphna Y -AU - Gelblum DY -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, New York. -FAU - Wu, Abraham J -AU - Wu AJ -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, New York. -FAU - Simone, Charles B 2nd -AU - Simone CB 2nd -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, New York. -FAU - Schoenfeld, Adam J -AU - Schoenfeld AJ -AD - Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of - Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. -FAU - Jones, David R -AU - Jones DR -AD - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New - York. -FAU - Rimner, Andreas -AU - Rimner A -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, New York. -FAU - Chaft, Jamie E -AU - Chaft JE -AD - Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of - Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. -FAU - Riaz, Nadeem -AU - Riaz N -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, New York. -FAU - Gomez, Daniel R -AU - Gomez DR -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, New York. -FAU - Shaverdian, Narek -AU - Shaverdian N -AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New - York, New York. -LA - eng -GR - P30 CA008748/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20230103 -PL - United States -TA - JAMA Netw Open -JT - JAMA network open -JID - 101729235 -RN - 0 (Biomarkers, Tumor) -RN - 28X28X9OKV (durvalumab) -RN - 0 (Kelch-Like ECH-Associated Protein 1) -RN - 0 (NF-E2-Related Factor 2) -SB - IM -MH - Aged -MH - Female -MH - Humans -MH - Male -MH - Biomarkers, Tumor/genetics -MH - *Carcinoma, Non-Small-Cell Lung/genetics/therapy -MH - Cohort Studies -MH - Kelch-Like ECH-Associated Protein 1 -MH - *Lung Neoplasms/genetics/therapy -MH - NF-E2-Related Factor 2 -MH - Progression-Free Survival -MH - Middle Aged -MH - Aged, 80 and over -PMC - PMC9856786 -COIS- Conflict of Interest Disclosures: Dr Lebow reported having an equity interest and - fiduciary role in Oncia Technologies outside the submitted work. Dr Shepherd - reported receiving honoraria from the American Society of Clinical Oncology - outside the submitted work. Dr Offin reported receiving honoraria from Bristol - Myers Squibb, Merck Sharp and Dohme, Jazz Pharmaceuticals, Novartis, Targeted - Oncology, and the American Society for Radiation Oncology; receiving grants from - the Druckenmiller Foundation and LUNGevity; and serving in an advisory role for - PharMar, Novartis, and Targeted Oncology outside the submitted work. Dr Wu - reported receiving grants from CivaTech Oncology; receiving personal fees from - MoreHealth, AstraZeneca, and Nanovi; receiving travel expenses from AlphaTau; and - serving on the scientific advisory board of Simphotek outside the submitted work. - Dr Simone II reported receiving honoraria from Varian Medical Systems outside the - submitted work. Dr Schoenfeld reported receiving personal fees from Johnson & - Johnson, KSQ Therapeutics, Bristol Myers Squibb, Merck, Enara Bio, Perceptive - Advisors, Oppenheimer and Co, Umoja Biopharma, Legend Biotech, Iovance - Biotherapeutics, Lyell Immunopharma, Heat Biologics, and Amgen and receiving - grants to the institution from GlaxoSmithKline, PACT Pharma, Iovance - Biotherapeutics, Achilles Therapeutics, Merck, Bristol Myers Squibb, Harpoon - Therapeutics, and Amgen outside the submitted work. Dr Jones reported serving as - a consultant for AstraZeneca; serving on a clinical trial steering committee for - Merck; and serving as a senior medical advisor for Diffusion Pharmaceuticals - outside the submitted work. Dr Rimner reported receiving grants from AstraZeneca, - Merck, Pfizer, Boehringer Ingelheim, Varian Medical Systems; receiving personal - fees from Cybrexa, Research to Practice, MoreHealth, AstraZeneca, and Merck; and - receiving travel expenses from Philips/Elektra outside the submitted work. Dr - Chaft reported receiving personal fees from Bristol Myers Squibb, AstraZeneca, - Genentech, Merck, Regeneron, Guardant Health, Flame Biosciences, and Arcus - Biosciences and receiving grants from Bristol Myers Squibb, AstraZeneca, Merck, - Genentech, and Novartis outside the submitted work. Dr Riaz reported receiving - honoraria from PeerView; consulting for Mirati Therapeuatics and REPARE - Therapeutics; receiving grants from Bristol Myers Squibb, Pfizer, Invitae, and - REPARE Therapuetics; and receiving travel expenses from Varian Medical Systems - outside the submitted work. Dr Gomez reported receiving grants from Merck, - AstraZeneca, Varian Medical Systems, and Bristol Myers Squibb during the conduct - of the study and receiving personal fees from Bristol Myers Squibb, Reflexsion, - Merck, Medscape, Vindico, US Oncology, MedLearning Group, AstraZeneca, GRAIL, - Medtronic, Johnson & Johnson, and Varian Medical Systems outside the submitted - work. Dr Shaverdian reported receiving research funding from Novartis outside the - submitted work. No other disclosures were reported. -EDAT- 2023/01/06 06:00 -MHDA- 2023/01/10 06:00 -PMCR- 2023/01/05 -CRDT- 2023/01/05 11:33 -PHST- 2023/01/05 11:33 [entrez] -PHST- 2023/01/06 06:00 [pubmed] -PHST- 2023/01/10 06:00 [medline] -PHST- 2023/01/05 00:00 [pmc-release] -AID - 2800082 [pii] -AID - zoi221408 [pii] -AID - 10.1001/jamanetworkopen.2022.49591 [doi] -PST - epublish -SO - JAMA Netw Open. 2023 Jan 3;6(1):e2249591. doi: - 10.1001/jamanetworkopen.2022.49591. - -PMID- 30503891 -OWN - NLM -STAT- MEDLINE -DCOM- 20200416 -LR - 20200416 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 14 -IP - 3 -DP - 2019 Mar -TI - Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients - Receiving Immune Checkpoint Immunotherapy. -PG - 494-502 -LID - S1556-0864(18)33493-2 [pii] -LID - 10.1016/j.jtho.2018.11.016 [doi] -AB - With increasing use of immune checkpoint inhibitors (ICIs) for advanced NSCLC, - there is increasing recognition of immune-related adverse events associated with - ICI use. We recently reported increased incidence of checkpoint inhibitor - pneumonitis (CIP) in ICI-treated NSCLC patients. Since development of - immune-related adverse events in other organ systems has been associated with - either no change or even improvement in tumor response/cancer outcomes, we sought - to better understand the impact of CIP development on overall survival in - ICI-treated NSCLC patients. Using baseline and follow-up data collected on a - cohort of 205 ICI-treated NSCLC patients, we used a multi-state modeling approach - to understand the effect of developing CIP on the risk of death. We observed - time-dependent changes in risk of developing and recovery from CIP, with an - increased risk of both developing and recovering from CIP in the first year after - initiating ICI. We found that developing CIP independently increased the risk of - transitioning to death in both adjusted and unadjusted models. In the - multivariate model, we found that the increase in mortality associated with CIP - was only seen in patients with adenocarcinoma tumor histology. Collectively, - these findings suggest that in NSCLC, development of CIP worsens survival in - patients receiving immunotherapy. -CI - Copyright © 2018 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Suresh, Karthik -AU - Suresh K -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. Electronic address: ksuresh2@jhmi.edu. -FAU - Psoter, Kevin J -AU - Psoter KJ -AD - Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, - Maryland. -FAU - Voong, Khinh Ranh -AU - Voong KR -AD - Department of Radiation Oncology, Johns Hopkins University School of Medicine, - Baltimore, Maryland. -FAU - Shankar, Bairavi -AU - Shankar B -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland. -FAU - Forde, Patrick M -AU - Forde PM -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Ettinger, David S -AU - Ettinger DS -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland. -FAU - Marrone, Kristen A -AU - Marrone KA -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Kelly, Ronan J -AU - Kelly RJ -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Hann, Christine L -AU - Hann CL -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Levy, Benjamin -AU - Levy B -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Feliciano, Josephine L -AU - Feliciano JL -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Brahmer, Julie R -AU - Brahmer JR -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -FAU - Feller-Kopman, David -AU - Feller-Kopman D -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. -FAU - Lerner, Andrew D -AU - Lerner AD -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. -FAU - Lee, Hans -AU - Lee H -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. -FAU - Yarmus, Lonny -AU - Yarmus L -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. -FAU - Hales, Russell K -AU - Hales RK -AD - Department of Radiation Oncology, Johns Hopkins University School of Medicine, - Baltimore, Maryland. -FAU - D'Alessio, Franco -AU - D'Alessio F -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. -FAU - Danoff, Sonye K -AU - Danoff SK -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University School of - Medicine, Baltimore, Maryland. -FAU - Naidoo, Jarushka -AU - Naidoo J -AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, - Maryland; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins - University, Baltimore, Maryland. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20181130 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -CIN - J Thorac Oncol. 2019 Mar;14(3):332-335. doi: 10.1016/j.jtho.2018.12.017. PMID: - 30782379 -MH - Adenocarcinoma of Lung/drug therapy/immunology/mortality/pathology -MH - Aged -MH - Antineoplastic Agents, Immunological/*adverse effects -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/immunology/*mortality/pathology -MH - Carcinoma, Squamous Cell/drug therapy/immunology/mortality/pathology -MH - Cell Cycle Checkpoints/*drug effects -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Immunotherapy/*adverse effects -MH - Incidence -MH - Lung Neoplasms/drug therapy/immunology/*mortality/pathology -MH - Male -MH - Maryland/epidemiology -MH - Pneumonia/chemically induced/*epidemiology/pathology -MH - Prognosis -MH - Retrospective Studies -MH - Survival Rate -EDAT- 2018/12/07 06:00 -MHDA- 2020/04/17 06:00 -CRDT- 2018/12/04 06:00 -PHST- 2018/10/02 00:00 [received] -PHST- 2018/11/12 00:00 [revised] -PHST- 2018/11/14 00:00 [accepted] -PHST- 2018/12/07 06:00 [pubmed] -PHST- 2020/04/17 06:00 [medline] -PHST- 2018/12/04 06:00 [entrez] -AID - S1556-0864(18)33493-2 [pii] -AID - 10.1016/j.jtho.2018.11.016 [doi] -PST - ppublish -SO - J Thorac Oncol. 2019 Mar;14(3):494-502. doi: 10.1016/j.jtho.2018.11.016. Epub - 2018 Nov 30. - -PMID- 24777612 -OWN - NLM -STAT- MEDLINE -DCOM- 20140930 -LR - 20240426 -IS - 1432-0851 (Electronic) -IS - 0340-7004 (Print) -IS - 0340-7004 (Linking) -VI - 63 -IP - 7 -DP - 2014 Jul -TI - Pilot study of a novel combination of two therapeutic vaccines in advanced - non-small-cell lung cancer patients. -PG - 737-47 -LID - 10.1007/s00262-014-1552-9 [doi] -AB - Cancer vaccines contain tumor antigens in a pro-inflammatory context with the - purpose to generate potent antitumor immune responses. However, tumor cells - develop different immunosuppressive mechanisms that limit the effectiveness of an - anticancer immune response. Therefore, therapeutic vaccine treatment alone is - usually not sufficient to generate tumor regression or survival improvement, - especially in the advanced disease scenario in which most clinical studies have - been conducted. Combining cancer vaccines with different anticancer therapies - such as chemotherapy, radiotherapy and other immunotherapeutic agents has had - different levels of success. However, the combination of cancer vaccines with - different mechanisms of action has not been explored in clinical trials. To - address this issue, the current review summarizes the main clinical and - immunological results obtained with two different therapeutic vaccines used in - advanced non-small-cell lung cancer patients, inducing an immune response against - epidermal growth factor (CIMAvax-EGF) and NGcGM3 ganglioside (racotumomab). We - also discuss preliminary findings obtained in a trial of combination of these two - vaccines and future challenges with these therapies. -FAU - Herrera, Zaima Mazorra -AU - Herrera ZM -AD - Clinical Immunology Department at Clinical Direction, Center of Molecular - Immunology, Street 216 Corner 15, PO box 16040, Havana, Cuba, zaima@cim.sld.cu. -FAU - Ramos, Tania Crombet -AU - Ramos TC -LA - eng -PT - Journal Article -PT - Review -DEP - 20140429 -PL - Germany -TA - Cancer Immunol Immunother -JT - Cancer immunology, immunotherapy : CII -JID - 8605732 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Murine-Derived) -RN - 0 (CIMAvax EGF) -RN - 0 (Cancer Vaccines) -RN - 52G405U1E5 (racotumomab) -SB - IM -MH - Animals -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antibodies, Monoclonal, Murine-Derived -MH - Cancer Vaccines/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/immunology/*therapy -MH - Humans -MH - Lung Neoplasms/immunology/*therapy -MH - Pilot Projects -MH - Randomized Controlled Trials as Topic -PMC - PMC11028931 -COIS- The authors declare that they have no conflict of interest. -EDAT- 2014/04/30 06:00 -MHDA- 2014/10/01 06:00 -PMCR- 2014/04/29 -CRDT- 2014/04/30 06:00 -PHST- 2013/09/24 00:00 [received] -PHST- 2014/04/11 00:00 [accepted] -PHST- 2014/04/30 06:00 [entrez] -PHST- 2014/04/30 06:00 [pubmed] -PHST- 2014/10/01 06:00 [medline] -PHST- 2014/04/29 00:00 [pmc-release] -AID - 1552 [pii] -AID - 10.1007/s00262-014-1552-9 [doi] -PST - ppublish -SO - Cancer Immunol Immunother. 2014 Jul;63(7):737-47. doi: 10.1007/s00262-014-1552-9. - Epub 2014 Apr 29. - -PMID- 36442353 -OWN - NLM -STAT- MEDLINE -DCOM- 20221227 -LR - 20230106 -IS - 2059-7029 (Electronic) -IS - 2059-7029 (Linking) -VI - 7 -IP - 6 -DP - 2022 Dec -TI - Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of - advanced non-small-cell lung cancer patients treated with programmed cell death - protein 1 axis inhibitor. -PG - 100630 -LID - S2059-7029(22)00264-2 [pii] -LID - 10.1016/j.esmoop.2022.100630 [doi] -LID - 100630 -AB - BACKGROUND: Tumor growth rate (TGR), denoted as percentage change in tumor size - per month, is a well-established indicator of tumor growth kinetics. The - predictive value of early on-treatment TGR (EOT-TGR) for immunotherapy remains - unclear. We sought to establish and validate the association of EOT-TGR with - treatment outcomes in patients with advanced non-small-cell lung cancer (aNSCLC) - undergoing anti-PD-1/PD-L1 (programmed cell death protein 1/programmed - death-ligand 1) therapy. PATIENTS AND METHODS: This bicenter retrospective cohort - study included a training cohort, a contemporaneously treated internal validation - cohort, and an external validation cohort. Computed tomography images were - retrieved to calculate EOT-TGR, denoted as tumor burden change per month during a - period between baseline and the first imaging evaluation after immunotherapy. - Kaplan-Meier methodology and Cox regression analysis were conducted for survival - analyses. RESULTS: In the pooled cohort (n = 172), 125 patients (72.7%) were - males; median age at diagnosis was 58 (range 28-79) years. Based on the training - cohort, we determined the optimal cut-off value for EOT-TGR as 10.4%/month. - Higher EOT-TGR was significantly associated with inferior overall survival [OS; - hazard ratio (HR) 2.93, 95% confidence interval (CI) 1.47-5.83; P = 0.002], worse - progression-free survival (PFS; HR 2.44, 95% CI 1.46-4.08; P = 0.001), and lower - objective response rate (3.3% versus 20.9%; P = 0.040) and durable clinical - benefit rate (6.7% versus 41.9%; P = 0.001). Results were reproducible in the two - validation cohorts for OS and PFS. Among 43 patients who had a best response of - progressive disease in the training cohort, those with high EOT-TGR had worse OS - (HR 2.64; P = 0.041) and were more likely to progress due to target lesions at - the first tumor evaluation (85.2% versus 0.0%; P <0.001). CONCLUSIONS: Higher - EOT-TGR was associated with inferior OS and immunotherapeutic response in - patients with aNSCLC undergoing anti-PD-1/PD-L1 therapy. This easy-to-calculate - radiologic biomarker may help evaluate the abilities of immunotherapy to prolong - survival and assist in tailoring patients' management. TRIAL REGISTRATION: - ClinicalTrials.govNCT04722406; https://clinicaltrials.gov/ct2/show/NCT04722406. -CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. -FAU - He, L-N -AU - He LN -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Fu, S -AU - Fu S -AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene - Regulation of Sun Yat-Sen University; Department of Cellular & Molecular - Diagnostics Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, - Guangzhou, China. -FAU - Ma, H -AU - Ma H -AD - Department of Oncology, the Second Affiliated Hospital of Guangzhou University of - Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, - China; Guangdong Provincial Key Laboratory of Clinical Research on Traditional - Chinese Medicine Syndrome, Guangzhou, China. -FAU - Chen, C -AU - Chen C -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Departments of Radiation - Oncology, Guangzhou, China. -FAU - Zhang, X -AU - Zhang X -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Li, H -AU - Li H -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Du, W -AU - Du W -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Chen, T -AU - Chen T -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Nuclear Medicine, - Guangzhou, China. -FAU - Jiang, Y -AU - Jiang Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Nuclear Medicine, - Guangzhou, China. -FAU - Wang, Y -AU - Wang Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Wang, Y -AU - Wang Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Endoscopy, Guangzhou, - China. -FAU - Zhou, Y -AU - Zhou Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; VIP Region, Guangzhou, - China. -FAU - Lin, Z -AU - Lin Z -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Clinical Research, Sun - Yat-sen University Cancer Center, Guangzhou, China. -FAU - Yang, Y -AU - Yang Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Huang, Y -AU - Huang Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Zhao, H -AU - Zhao H -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Clinical Research, Sun - Yat-sen University Cancer Center, Guangzhou, China. -FAU - Fang, W -AU - Fang W -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Zhang, H -AU - Zhang H -AD - Department of Oncology, the Second Affiliated Hospital of Guangzhou University of - Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, - China; Guangdong Provincial Key Laboratory of Clinical Research on Traditional - Chinese Medicine Syndrome, Guangzhou, China. Electronic address: - haibozh@gzucm.edu.cn. -FAU - Zhang, L -AU - Zhang L -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic - address: zhangli6@mail.sysu.edu.cn. -FAU - Hong, S -AU - Hong S -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic - address: hongshd@sysucc.org.cn. -LA - eng -SI - ClinicalTrials.gov/NCT04722406 -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20221125 -PL - England -TA - ESMO Open -JT - ESMO open -JID - 101690685 -RN - 0 (B7-H1 Antigen) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Male -MH - Humans -MH - Adult -MH - Middle Aged -MH - Aged -MH - Female -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - B7-H1 Antigen -MH - Programmed Cell Death 1 Receptor -MH - *Lung Neoplasms/drug therapy -MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use -MH - Retrospective Studies -MH - Treatment Outcome -PMC - PMC9808481 -OTO - NOTNLM -OT - biomarker -OT - immunotherapy -OT - non-small-cell lung cancer -OT - prognosis -OT - tumor growth rate -COIS- Disclosure The authors have declared no conflicts of interest. Data sharing All - data and material relevant to the study are included within the article and its - additional file. Raw data of this study are available from the corresponding - authors upon reasonable request. Ethics statement This study was approved by the - Institutional Review Boards of Sun Yat-sen University Cancer Center (SYSUCC; - SL-B2020-402-02) and Guangdong Provincial Hospital of Chinese Medicine - (BE2020-247-01). The requirement for written informed consent was waived because - of the retrospective design. Role of the funding source The funders had no role - in the design and conduct of the study; collection, management, analysis, and - interpretation of the data; preparation, review, or approval of the manuscript; - and decision to submit the manuscript for publication. -EDAT- 2022/11/29 06:00 -MHDA- 2022/12/28 06:00 -PMCR- 2022/11/25 -CRDT- 2022/11/28 18:20 -PHST- 2022/05/14 00:00 [received] -PHST- 2022/10/02 00:00 [revised] -PHST- 2022/10/09 00:00 [accepted] -PHST- 2022/11/29 06:00 [pubmed] -PHST- 2022/12/28 06:00 [medline] -PHST- 2022/11/28 18:20 [entrez] -PHST- 2022/11/25 00:00 [pmc-release] -AID - S2059-7029(22)00264-2 [pii] -AID - 100630 [pii] -AID - 10.1016/j.esmoop.2022.100630 [doi] -PST - ppublish -SO - ESMO Open. 2022 Dec;7(6):100630. doi: 10.1016/j.esmoop.2022.100630. Epub 2022 Nov - 25. - -PMID- 36075183 -OWN - NLM -STAT- MEDLINE -DCOM- 20220920 -LR - 20231002 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Print) -IS - 0169-5002 (Linking) -VI - 172 -DP - 2022 Oct -TI - Complete pathologic response to short-course neoadjuvant alectinib in mediastinal - node positive (N2) ALK rearranged lung cancer. -PG - 124-126 -LID - S0169-5002(22)00604-3 [pii] -LID - 10.1016/j.lungcan.2022.08.014 [doi] -AB - OBJECTIVES: Neoadjuvant therapy prior to surgical resection for locally advanced - lung cancer has evolved to incorporate systemic cytotoxic chemotherapy +/- - immunotherapy +/- radiotherapy. The role of neoadjuvant precision therapies - remains understudied. MATERIALS AND METHODS: We report cases with major and - complete pathologic responses to off-label neoadjuvant alectinib. RESULTS: A case - with stage IIIA (cT1b cN2 cM0) EML4-ALK variant 3a/b lung adenocarcinoma received - 6 weeks of alectinib followed by R0 left upper lobectomy with complete - pathological response (ypT0 ypN0). Another case with stage IIIA (cT3 cN2 cM0) - EML4-ALK variant 2 received 12 weeks of alectinib followed by R0 right middle - lobectomy with a major pathologic response (ypT1a ypN0) but systemic recurrence - 12 months post-operatively. CONCLUSION: Ongoing clinical trials are evaluating - the role of both neoadjuvant and adjuvant ALK-directed therapy. Our cases support - the completion of ongoing trials (ALINA: NCT03456076 and ALNEO: NCT05015010), and - highlight the ability of second generation ALK inhibitors to induce major and - complete pathologic responses in the neoadjuvant setting plus the likely role of - long-term adjuvant kinase inhibitor therapy to prevent radiographic/clinical - recurrence. -CI - Copyright © 2022 Elsevier B.V. All rights reserved. -FAU - Sentana-Lledo, Daniel -AU - Sentana-Lledo D -AD - Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess - Medical Center, Harvard Medical School, Boston, MA, United States. -FAU - Viray, Hollis -AU - Viray H -AD - Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess - Medical Center, Harvard Medical School, Boston, MA, United States. -FAU - Piper-Vallillo, Andrew J -AU - Piper-Vallillo AJ -AD - Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess - Medical Center, Harvard Medical School, Boston, MA, United States; Department of - Medicine, Division of Hematology/Oncology, Lahey Hospital & Medical Center, - Burlington, MA, United States. -FAU - Widick, Page -AU - Widick P -AD - Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess - Medical Center, Harvard Medical School, Boston, MA, United States. -FAU - Rangachari, Deepa -AU - Rangachari D -AD - Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess - Medical Center, Harvard Medical School, Boston, MA, United States. -FAU - Wilson, Jennifer L -AU - Wilson JL -AD - Department of Surgery, Division of Thoracic Surgery, Beth Israel Deaconess - Medical Center, Harvard Medical School, Boston, MA, United States. -FAU - Gangadharan, Sidharta P -AU - Gangadharan SP -AD - Department of Surgery, Division of Thoracic Surgery, Beth Israel Deaconess - Medical Center, Harvard Medical School, Boston, MA, United States. -FAU - Aronovitz, Joseph A -AU - Aronovitz JA -AD - Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard - Medical School, Boston, MA, United States. -FAU - Berman, Stuart M -AU - Berman SM -AD - Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard - Medical School, Boston, MA, United States. -FAU - VanderLaan, Paul A -AU - VanderLaan PA -AD - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical - School, Boston, MA, United States. -FAU - Costa, Daniel B -AU - Costa DB -AD - Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess - Medical Center, Harvard Medical School, Boston, MA, United States. Electronic - address: dbcosta@bidmc.harvard.edu. -LA - eng -GR - R37 CA218707/CA/NCI NIH HHS/United States -PT - Case Reports -DEP - 20220824 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Carbazoles) -RN - 0 (Piperidines) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) -RN - LIJ4CT1Z3Y (alectinib) -SB - IM -MH - Carbazoles -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology -MH - Clinical Trials as Topic -MH - Humans -MH - *Lung Neoplasms/drug therapy/genetics/pathology -MH - Neoadjuvant Therapy -MH - Piperidines -MH - Protein Kinase Inhibitors/therapeutic use -MH - Receptor Protein-Tyrosine Kinases/therapeutic use -PMC - PMC9719796 -MID - NIHMS1853951 -OTO - NOTNLM -OT - ALK -OT - Alectinib -OT - Complete pathologic response -OT - Lung cancer -OT - Neoadjuvant -COIS- Declaration of Competing Interest Dr. Costa reports receiving consulting fees and - honoraria from Takeda/Millennium Pharmaceuticals, AstraZeneca, Pfizer, Blueprint - Medicines, and Janssen, institutional research support from Takeda/Millennium - Pharmaceuticals, AstraZeneca, Pfizer, Merck Sharp and Dohme, Merrimack - Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, Spectrum Pharmaceuticals, - Tesaro and Daiichi Sankyo, and consulting fees from Teladoc and Grand Rounds by - Included Health. Dr. Rangachari reports receiving consulting fees and honoraria - from AstraZeneca, institutional research support from Bristol Myers Squibb, - Novocure, and AbbVie/Stemcentrx, and consulting fees from Teladoc and DynaMed. - Dr. VanderLaan reports receiving consulting fees from Gala Therapeutics, - Galvanize Therapeutics, and Ruby Robotics. The other authors declare that they - have no known competing financial interests or personal relationships that could - have appeared to influence the work reported in this paper. -EDAT- 2022/09/09 06:00 -MHDA- 2022/09/21 06:00 -PMCR- 2023/10/01 -CRDT- 2022/09/08 18:19 -PHST- 2022/08/15 00:00 [received] -PHST- 2022/08/20 00:00 [accepted] -PHST- 2022/09/09 06:00 [pubmed] -PHST- 2022/09/21 06:00 [medline] -PHST- 2022/09/08 18:19 [entrez] -PHST- 2023/10/01 00:00 [pmc-release] -AID - S0169-5002(22)00604-3 [pii] -AID - 10.1016/j.lungcan.2022.08.014 [doi] -PST - ppublish -SO - Lung Cancer. 2022 Oct;172:124-126. doi: 10.1016/j.lungcan.2022.08.014. Epub 2022 - Aug 24. - -PMID- 32474768 -OWN - NLM -STAT- MEDLINE -DCOM- 20201022 -LR - 20240426 -IS - 1432-0851 (Electronic) -IS - 0340-7004 (Print) -IS - 0340-7004 (Linking) -VI - 69 -IP - 11 -DP - 2020 Nov -TI - Clinicopathologic correlates of first-line pembrolizumab effectiveness in - patients with advanced NSCLC and a PD-L1 expression of ≥ 50. -PG - 2209-2221 -LID - 10.1007/s00262-020-02613-9 [doi] -AB - BACKGROUND: Single-agent pembrolizumab represents the standard first-line option - for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 - (programmed death-ligand 1) expression of ≥ 50%. METHODS: We conducted a - multicenter retrospective study aimed at evaluating the clinicopathologic - correlates of pembrolizumab effectiveness in patients with treatment-naïve NSCLC - and a PD-L1 expression of ≥ 50%. RESULTS: One thousand and twenty-six consecutive - patients were included. The objective response rate (ORR) was 44.5% (95% CI - 40.2-49.1), while the median progression free survival (PFS) and overall survival - (OS) were 7.9 months (95% CI 6.9-9.5; 599 events) and 17.2 months (95% CI - 15.3-22.3; 598 censored patients), respectively. ECOG-PS ≥ 2 (p < 0.0001) and - bone metastases (p = 0.0003) were confirmed to be independent predictors of a - worse ORR. Former smokers (p = 0.0002), but not current smokers (p = 0.0532) were - confirmed to have a significantly prolonged PFS compared to never smokers at - multivariate analysis. ECOG-PS (p < 0.0001), bone metastases (p < 0.0001) and - liver metastases (p < 0.0001) were also confirmed to be independent predictors of - a worse PFS. Previous palliative RT was significantly related to a shortened OS - (p = 0.0104), while previous non-palliative RT was significantly related to a - prolonged OS (p = 0.0033). Former smokers (p = 0.0131), but not current smokers - (p = 0.3433) were confirmed to have a significantly prolonged OS compared to - never smokers. ECOG-PS (p < 0.0001), bone metastases (p < 0.0001) and liver - metastases (p < 0.0001) were also confirmed to be independent predictors of a - shortened OS. A PD-L1 expression of ≥ 90%, as assessed by recursive partitioning, - was associated with significantly higher ORR (p = 0.0204), and longer and OS - (p = 0.0346) at multivariable analysis. CONCLUSION: Pembrolizumab was effective - in a large cohort of NSCLC patients treated outside of clinical trials. Questions - regarding the effectiveness in clinical subgroups, such as patients with poorer - PS and with liver/bone metastases, still remain to be addressed. We confirmed - that the absence of tobacco exposure, and the presence of bone and liver - metastasis are associated with worse clinical outcomes to pembrolizumab. - Increasing levels of PD-L1 expression may help identifying a subset of patients - who derive a greater benefit from pembrolizumab monotherapy. -FAU - Cortellini, Alessio -AU - Cortellini A -AUID- ORCID: 0000-0002-1209-5735 -AD - Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy. - alessiocortellini@gmail.com. -AD - Department of Biotechnological and Applied Clinical Sciences, University of - L'Aquila, Via Vetoio, 67100, L'Aquila, Italy. alessiocortellini@gmail.com. -FAU - Tiseo, Marcello -AU - Tiseo M -AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. -AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. -FAU - Banna, Giuseppe L -AU - Banna GL -AD - Oncology Department, United Lincolnshire Hospital NHS Trust, Lincoln, UK. -FAU - Cappuzzo, Federico -AU - Cappuzzo F -AD - Department of Oncology and Hematology, AUSL Romagna, Ravenna, Italy. -FAU - Aerts, Joachim G J V -AU - Aerts JGJV -AD - Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, The - Netherlands. -FAU - Barbieri, Fausto -AU - Barbieri F -AD - Department of Oncology and Hematology, Modena University Hospital, Modena, Italy. -FAU - Giusti, Raffaele -AU - Giusti R -AD - Medical Oncology Unit, Sant' Andrea Hospital fo Rome, Rome, Italy. -FAU - Bria, Emilio -AU - Bria E -AD - Comprehensive Cancer Center, Fondazione Policlinico Universitario "A. Gemelli" - IRCCS, Rome, Italy. -AD - Department of Translational Medicine and Surgery, Università Cattolica del Sacro - Cuore, Rome, Italy. -FAU - Cortinovis, Diego -AU - Cortinovis D -AD - Medical Oncology, Ospedale San Gerardo, Monza, Italy. -FAU - Grossi, Francesco -AU - Grossi F -AD - Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, - Milan, Italy. -FAU - Migliorino, Maria R -AU - Migliorino MR -AD - Pneumo-Oncology Unit, St. Camillo-Forlanini Hospital, Rome, Italy. -FAU - Galetta, Domenico -AU - Galetta D -AD - Thoracic Oncology Unit, Clinical Cancer Center, IRCCS Istituto Tumori "Giovanni - Paolo II", Bari, Italy. -FAU - Passiglia, Francesco -AU - Passiglia F -AD - Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, - Orbassano, TO, Italy. -FAU - Santini, Daniele -AU - Santini D -AD - Medical Oncology, Campus Bio-Medico University, Rome, Italy. -FAU - Berardi, Rossana -AU - Berardi R -AD - Oncology Clinic, Ospedali Riuniti Di Ancona, Università Politecnica Delle Marche, - Ancona, Italy. -FAU - Morabito, Alessandro -AU - Morabito A -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori 'Fondazione G Pascale', - IRCCS, Naples, Italy. -FAU - Genova, Carlo -AU - Genova C -AD - Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. -FAU - Mazzoni, Francesca -AU - Mazzoni F -AD - Department of Oncology, Careggi University Hospital, Florence, Italy. -FAU - Di Noia, Vincenzo -AU - Di Noia V -AD - Medical Oncology, University Hospital of Foggia, Foggia, Italy. -FAU - Signorelli, Diego -AU - Signorelli D -AD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, - Milan, Italy. -FAU - Tuzi, Alessandro -AU - Tuzi A -AD - Medical Oncology, ASST-Sette Laghi, Varese, Italy. -FAU - Gelibter, Alain -AU - Gelibter A -AD - Medical Oncology (B), Policlinico Umberto I, "Sapienza" University of Rome, Rome, - Italy. -FAU - Marchetti, Paolo -AU - Marchetti P -AD - Medical Oncology Unit, Sant' Andrea Hospital fo Rome, Rome, Italy. -AD - Medical Oncology (B), Policlinico Umberto I, "Sapienza" University of Rome, Rome, - Italy. -AD - Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, - Rome, Italy. -FAU - Macerelli, Marianna -AU - Macerelli M -AD - Department of Oncology, University Hospital Santa Maria Della Misericordia, - Udine, Italy. -FAU - Rastelli, Francesca -AU - Rastelli F -AD - Medical Oncology, Fermo Area Vasta 4, Fermo, Italy. -FAU - Chiari, Rita -AU - Chiari R -AD - Medical Oncology, Ospedali Riuniti Padova Sud "Madre Teresa Di Calcutta", - Monselice, Italy. -FAU - Rocco, Danilo -AU - Rocco D -AD - Pneumo-Oncology Unit, Monaldi Hospital, Naples, Italy. -FAU - Gori, Stefania -AU - Gori S -AD - Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, VR, Italy. -FAU - De Tursi, Michele -AU - De Tursi M -AD - Department of Medical, Oral and Biotechnological Sciences, University G. - D'Annunzio, Chieti-Pescara, Chieti, Italy. -FAU - Mansueto, Giovanni -AU - Mansueto G -AD - Medical Oncology, F. Spaziani Hospital, Frosinone, Italy. -FAU - Zoratto, Federica -AU - Zoratto F -AD - Medical Oncology, Santa Maria Goretti Hospital, Latina, Italy. -FAU - Santoni, Matteo -AU - Santoni M -AD - Department of Oncology, Macerata Hospital, Macerata, Italy. -FAU - Tudini, Marianna -AU - Tudini M -AD - Medical Oncology, AV2 Fabriano ASUR Marche, Fabriano, Italy. -FAU - Rijavec, Erika -AU - Rijavec E -AD - Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, - Milan, Italy. -FAU - Filetti, Marco -AU - Filetti M -AD - Medical Oncology Unit, Sant' Andrea Hospital fo Rome, Rome, Italy. -FAU - Catino, Annamaria -AU - Catino A -AD - Thoracic Oncology Unit, Clinical Cancer Center, IRCCS Istituto Tumori "Giovanni - Paolo II", Bari, Italy. -FAU - Pizzutilo, Pamela -AU - Pizzutilo P -AD - Thoracic Oncology Unit, Clinical Cancer Center, IRCCS Istituto Tumori "Giovanni - Paolo II", Bari, Italy. -FAU - Sala, Luca -AU - Sala L -AD - Medical Oncology, Ospedale San Gerardo, Monza, Italy. -FAU - Citarella, Fabrizio -AU - Citarella F -AD - Medical Oncology, Campus Bio-Medico University, Rome, Italy. -FAU - Marco, Russano -AU - Marco R -AD - Medical Oncology, Campus Bio-Medico University, Rome, Italy. -FAU - Torniai, Mariangela -AU - Torniai M -AD - Oncology Clinic, Ospedali Riuniti Di Ancona, Università Politecnica Delle Marche, - Ancona, Italy. -FAU - Cantini, Luca -AU - Cantini L -AD - Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, The - Netherlands. -AD - Oncology Clinic, Ospedali Riuniti Di Ancona, Università Politecnica Delle Marche, - Ancona, Italy. -FAU - Targato, Giada -AU - Targato G -AD - Department of Oncology, University Hospital Santa Maria Della Misericordia, - Udine, Italy. -FAU - Sforza, Vincenzo -AU - Sforza V -AD - Thoracic Medical Oncology, Istituto Nazionale Tumori 'Fondazione G Pascale', - IRCCS, Naples, Italy. -FAU - Nigro, Olga -AU - Nigro O -AD - Medical Oncology, ASST-Sette Laghi, Varese, Italy. -FAU - Ferrara, Miriam G -AU - Ferrara MG -AD - Comprehensive Cancer Center, Fondazione Policlinico Universitario "A. Gemelli" - IRCCS, Rome, Italy. -AD - Department of Translational Medicine and Surgery, Università Cattolica del Sacro - Cuore, Rome, Italy. -FAU - D'Argento, Ettore -AU - D'Argento E -AD - Comprehensive Cancer Center, Fondazione Policlinico Universitario "A. Gemelli" - IRCCS, Rome, Italy. -FAU - Buti, Sebastiano -AU - Buti S -AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. -FAU - Bordi, Paola -AU - Bordi P -AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. -FAU - Antonuzzo, Lorenzo -AU - Antonuzzo L -AD - Department of Oncology, Careggi University Hospital, Florence, Italy. -FAU - Scodes, Simona -AU - Scodes S -AD - Department of Oncology and Hematology, AUSL Romagna, Ravenna, Italy. -FAU - Landi, Lorenza -AU - Landi L -AD - Department of Oncology and Hematology, AUSL Romagna, Ravenna, Italy. -FAU - Guaitoli, Giorgia -AU - Guaitoli G -AD - Department of Oncology and Hematology, Modena University Hospital, Modena, Italy. -FAU - Baldessari, Cinzia -AU - Baldessari C -AD - Department of Oncology and Hematology, Modena University Hospital, Modena, Italy. -FAU - Della Gravara, Luigi -AU - Della Gravara L -AD - Pneumo-Oncology Unit, Monaldi Hospital, Naples, Italy. -FAU - Dal Bello, Maria Giovanna -AU - Dal Bello MG -AD - Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. -FAU - Belderbos, Robert A -AU - Belderbos RA -AD - Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, The - Netherlands. -FAU - Bironzo, Paolo -AU - Bironzo P -AD - Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, - Orbassano, TO, Italy. -FAU - Carnio, Simona -AU - Carnio S -AD - Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, - Orbassano, TO, Italy. -FAU - Ricciardi, Serena -AU - Ricciardi S -AD - Pneumo-Oncology Unit, St. Camillo-Forlanini Hospital, Rome, Italy. -FAU - Grieco, Alessio -AU - Grieco A -AD - Pneumo-Oncology Unit, St. Camillo-Forlanini Hospital, Rome, Italy. -FAU - De Toma, Alessandro -AU - De Toma A -AD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, - Milan, Italy. -FAU - Proto, Claudia -AU - Proto C -AD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, - Milan, Italy. -FAU - Friedlaender, Alex -AU - Friedlaender A -AD - Oncology Department, University Hospital of Geneva, Geneva, Switzerland. -FAU - Cantale, Ornella -AU - Cantale O -AD - Oncology Department, United Lincolnshire Hospital NHS Trust, Lincoln, UK. -FAU - Ricciuti, Biagio -AU - Ricciuti B -AD - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. -AD - Division of Medical Oncology, S.Orsola-Malpighi Hospital, University of Bologna, - 40138, Bologna, Italy. -FAU - Addeo, Alfredo -AU - Addeo A -AD - Oncology Department, University Hospital of Geneva, Geneva, Switzerland. -FAU - Metro, Giulio -AU - Metro G -AD - Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda - Ospedaliera di Perugia, Perugia, Italy. -FAU - Ficorella, Corrado -AU - Ficorella C -AD - Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy. -AD - Department of Biotechnological and Applied Clinical Sciences, University of - L'Aquila, Via Vetoio, 67100, L'Aquila, Italy. -FAU - Porzio, Giampiero -AU - Porzio G -AD - Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy. -AD - Department of Biotechnological and Applied Clinical Sciences, University of - L'Aquila, Via Vetoio, 67100, L'Aquila, Italy. -LA - eng -PT - Journal Article -PT - Multicenter Study -DEP - 20200530 -PL - Germany -TA - Cancer Immunol Immunother -JT - Cancer immunology, immunotherapy : CII -JID - 8605732 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Adult -MH - Aged -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - B7-H1 Antigen/biosynthesis -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/pathology -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy/metabolism/pathology -MH - Male -MH - Middle Aged -MH - Progression-Free Survival -MH - Retrospective Studies -PMC - PMC11027629 -OTO - NOTNLM -OT - Bone metastases -OT - Liver metastases -OT - PD-L1 -OT - Performance status -OT - Radiotherapy -OT - Smoking status -COIS- Dr. Alessio Cortellini received speaker fees and grant consultancies by - Astrazeneca, MSD, BMS, Roche, Novartis, Istituto Gentili, Astellas and Ipsen. Dr. - Emilio Bria received speaker and travel fees from MSD, Astra-Zeneca, Pfizer, - Helsinn, Eli-Lilly, BMS, Novartis and Roche. Dr. Emilio Bria received grant - consultancies by Roche and Pfizer. Dr. Marcello Tiseo received speaker fees and - grant consultancies by Astrazeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, - Boehringer Ingelheim, Otsuka, Takeda and Pierre Fabre. Dr. Alessandro Morabito - received speaker fees by Astra, Roche, BMS, MSD, Boehringer, Pfizer, Takeda. Dr. - Francesca Mazzoni received grant consultancies by MSD and Takeda. Dr. Raffaele - Gisti received speaker fees and grant consultancies by Astrazeneca and Roche. Dr. - Francesco Passiglia received grant consultancies by MSD and Astrazeneca. Dr. - Paolo Bironzo received grant consultancies by Astrazeneca and - Boehringer-Ingelheim. Dr. Alex Friedlaender received grant consultancies by - Roche, Pfizer, Astellas and BMS. Dr. Alfredo Addeo received grant consultancies - by Takeda, MSD, BMJ, Astrazeneca, Roche and Pfizer. Dr. Rita Chiari received - speaker fees by BMS, MSD, Takeda, Pfizer, Roche and Astrazeneca. Dr. Carlo Genova - received speaker fees/grant consultancies by Astrazeneca, BMS, - Boehringer-Ingelheim, Roche and MSD. -EDAT- 2020/06/01 06:00 -MHDA- 2020/10/23 06:00 -PMCR- 2020/05/30 -CRDT- 2020/06/01 06:00 -PHST- 2020/04/05 00:00 [received] -PHST- 2020/05/15 00:00 [accepted] -PHST- 2020/06/01 06:00 [pubmed] -PHST- 2020/10/23 06:00 [medline] -PHST- 2020/06/01 06:00 [entrez] -PHST- 2020/05/30 00:00 [pmc-release] -AID - 10.1007/s00262-020-02613-9 [pii] -AID - 2613 [pii] -AID - 10.1007/s00262-020-02613-9 [doi] -PST - ppublish -SO - Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: - 10.1007/s00262-020-02613-9. Epub 2020 May 30. - -PMID- 36453575 -OWN - NLM -STAT- MEDLINE -DCOM- 20230113 -LR - 20230303 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 14 -IP - 2 -DP - 2023 Jan -TI - Co-occurring KEAP1 and TP53 mutations in lung squamous cell carcinoma induced - primary resistance to thoracic radiotherapy: A case report. -PG - 206-209 -LID - 10.1111/1759-7714.14751 [doi] -AB - In lung squamous cell carcinoma, KEAP1 mutations frequently coexist with TP53 - mutations. A preclinical model showed that mutations leading to the activation of - the KEAP1-NRF2 pathway contribute to clinical radioresistance. However, there - have been few clinical reports on the association between the presence of KEAP1 - and TP53 mutations in patients with lung squamous cell carcinoma. Here, we report - the case of a 62-year-old patient with advanced lung squamous cell carcinoma with - KEAP1 and TP53 mutations who experienced primary resistance to thoracic - radiotherapy. She was administered pembrolizumab in combination with cytotoxic - agents as the first-line treatment and the best response was a partial response. - However, the mediastinal lymph node metastases regrew 11 months after the - chemotherapy. Thus, she received thoracic radiation therapy for localized - lesions. However, the lesions within the radiation field had apparently - progressed. Although she received subsequent chemotherapy, the lesion rapidly - progressed. Treatment strategies including radiotherapy based on genetic - stratification, such as KEAP1 and TP53 mutation status, should be implemented for - lung squamous cell carcinoma. -CI - © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Nishimura, Rumi -AU - Nishimura R -AUID- ORCID: 0000-0002-1185-9369 -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -FAU - Yoshida, Tatsuya -AU - Yoshida T -AUID- ORCID: 0000-0003-4896-5824 -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -FAU - Torasawa, Masahiro -AU - Torasawa M -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -FAU - Kashihara, Tairo -AU - Kashihara T -AD - Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan. -FAU - Ohe, Yuichiro -AU - Ohe Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -LA - eng -PT - Case Reports -DEP - 20221201 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (Kelch-Like ECH-Associated Protein 1) -RN - 0 (NF-E2-Related Factor 2) -RN - 0 (TP53 protein, human) -RN - 0 (Tumor Suppressor Protein p53) -RN - 0 (KEAP1 protein, human) -SB - IM -MH - Female -MH - Humans -MH - Middle Aged -MH - *Lung Neoplasms/drug therapy/genetics/radiotherapy -MH - Kelch-Like ECH-Associated Protein 1/genetics/metabolism -MH - NF-E2-Related Factor 2/genetics/metabolism -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Carcinoma, Squamous Cell/drug therapy/genetics/radiotherapy -MH - Lung/pathology -MH - Mutation -MH - Tumor Suppressor Protein p53/genetics -PMC - PMC9834690 -OTO - NOTNLM -OT - KEAP -OT - TP53 -OT - lung squamous cell carcinoma -OT - next-generation sequencing -OT - thoracic radiotherapy -COIS- Dr. Yoshida reports grants from ONO Pharmaceutical, grants and personal fees from - Bristol‐Myers Squibb, and grants from MSD during the conduct of the study; grants - and personal fees from AstraZeneca, grants from Takeda, personal fees from - Chugai, personal fees from Novartis, and grants from Abbvie outside the submitted - work. Dr. Ohe reports grants and personal fees from Bristol‐Myers Squibb, grants - and personal fees from ONO Pharmaceutical, and grants and personal fees from MSD - during the conduct of the study, grants and personal fees from AstraZeneca, - grants and personal fees from Amgen, personal fees from Boehringer Ingelheim, - personal fees from Celtrion, grants and personal fees from Chugai, grants and - personal fees from Eli Lilly, grants and personal fees from Janssen, grants and - personal fees from Kyorin, grants from Kissei, grants and personal fees from - Nippon Kayaku, grants and personal fees from Novartis, grants and personal fees - from Pfizer, grants and personal fees from Taiho, and grants and personal fees - from Takeda Pharmaceutical outside the submitted work. The remaining authors - declare no competing interests. -EDAT- 2022/12/02 06:00 -MHDA- 2023/01/14 06:00 -PMCR- 2022/12/01 -CRDT- 2022/12/01 06:13 -PHST- 2022/11/14 00:00 [revised] -PHST- 2022/10/08 00:00 [received] -PHST- 2022/11/15 00:00 [accepted] -PHST- 2022/12/02 06:00 [pubmed] -PHST- 2023/01/14 06:00 [medline] -PHST- 2022/12/01 06:13 [entrez] -PHST- 2022/12/01 00:00 [pmc-release] -AID - TCA14751 [pii] -AID - 10.1111/1759-7714.14751 [doi] -PST - ppublish -SO - Thorac Cancer. 2023 Jan;14(2):206-209. doi: 10.1111/1759-7714.14751. Epub 2022 - Dec 1. - -PMID- 33478192 -OWN - NLM -STAT- MEDLINE -DCOM- 20210901 -LR - 20210901 -IS - 1999-6187 (Electronic) -IS - 1009-3419 (Print) -IS - 1009-3419 (Linking) -VI - 24 -IP - 1 -DP - 2021 Jan 20 -TI - [Research Progress of Small Molecule Anti-angiogenic Drugs 
in Non-small Cell - Lung Cancer]. -PG - 56-62 -LID - 10.3779/j.issn.1009-3419.2021.102.02 [doi] -AB - Lung cancer is one of the cancers with the highest incidence in the world, and - there is no standard treatment plan after second-line progression. Tumor - angiogenesis has now been identified as an important therapeutic target for - malignant tumors. Small molecule multi-target vascular kinase inhibitors can - inhibit tumor angiogenesis by inhibiting angiogenesis-related signal pathways. At - present, a lot of clinical trials of small molecule anti-angiogenic drugs for the - treatment of non-small cell lung cancer (NSCLC) have been carried out, and some - vascular endothelial growth factor receptor-tyrosine kinase inhibitors - (VEGFR-TKIs) have been approved for the treatment of advanced NSCLC. Based on the - development status of multiple small molecule anti-angiogenic drugs at home and - abroad for the treatment of NSCLC, this article summarizes the efficacy and - safety studies of multiple VEGFR-TKIs and fibroblast growth factor receptor - (FGFR)-TKI single agents or combination treatments [including combined with - chemotherapy, epidermal growth factor receptor (EGFR)-TKIs, immunotherapy, and - radiotherapy, etc.] for NSCLC, and at the same time discussed the possible - existence of VEGFR-TKIs drug resistance mechanisms and efficacy predictors, etc., - and prospect the future development trend and potential problems of anti-vascular - treatment of NSCLC, and provide new ideas for the follow-up precision and - individualized treatment of lung cancer.
. -FAU - Dou, Yan -AU - Dou Y -AD - Department of Oncology, The Fourth Hospital of Hebei Medical University, - Shijiazhuang 050011, China. -FAU - Jiang, Da -AU - Jiang D -AD - Department of Oncology, The Fourth Hospital of Hebei Medical University, - Shijiazhuang 050011, China. -LA - chi -PT - Journal Article -PT - Review -PL - China -TA - Zhongguo Fei Ai Za Zhi -JT - Zhongguo fei ai za zhi = Chinese journal of lung cancer -JID - 101126433 -RN - 0 (Angiogenesis Inhibitors) -RN - 0 (Receptors, Fibroblast Growth Factor) -RN - 0 (Vascular Endothelial Growth Factor A) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Angiogenesis Inhibitors/*administration & dosage -MH - Animals -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/metabolism -MH - ErbB Receptors/genetics/metabolism -MH - Humans -MH - Lung Neoplasms/*drug therapy/genetics/metabolism -MH - Receptors, Fibroblast Growth Factor/genetics/metabolism -MH - Signal Transduction/drug effects -MH - Vascular Endothelial Growth Factor A/genetics/metabolism -PMC - PMC7849040 -OTO - NOTNLM -OT - Angiogenesis inhibitors -OT - Lung neoplasms -OT - Progress -OT - Small molecular tyrosine kinase inhibitors -EDAT- 2021/01/23 06:00 -MHDA- 2021/09/02 06:00 -PMCR- 2021/01/20 -CRDT- 2021/01/22 01:05 -PHST- 2021/01/22 01:05 [entrez] -PHST- 2021/01/23 06:00 [pubmed] -PHST- 2021/09/02 06:00 [medline] -PHST- 2021/01/20 00:00 [pmc-release] -AID - zgfazz-24-1-56 [pii] -AID - 10.3779/j.issn.1009-3419.2021.102.02 [doi] -PST - ppublish -SO - Zhongguo Fei Ai Za Zhi. 2021 Jan 20;24(1):56-62. doi: - 10.3779/j.issn.1009-3419.2021.102.02. - -PMID- 36410966 -OWN - NLM -STAT- MEDLINE -DCOM- 20221123 -LR - 20221220 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 17 -IP - 12 -DP - 2022 Dec -TI - Immune Checkpoint Inhibition for Locally Advanced NSCLC: Time to Ask New - Questions? -PG - 1330-1332 -LID - S1556-0864(22)01585-4 [pii] -LID - 10.1016/j.jtho.2022.08.019 [doi] -FAU - Bogart, Jeffrey A -AU - Bogart JA -AD - Department of Radiation Oncology, State University of New York Upstate Medical - University, Syracuse, New York. Electronic address: BogartJ@upstate.edu. -LA - eng -PT - Comment -PT - Editorial -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (B7-H1 Antigen) -SB - IM -CON - J Thorac Oncol. 2022 Dec;17(12):1415-1427. doi: 10.1016/j.jtho.2022.07.1148. - PMID: 35961520 -MH - Humans -MH - Immune Checkpoint Inhibitors -MH - *Lung Neoplasms/drug therapy -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - B7-H1 Antigen/therapeutic use -EDAT- 2022/11/22 06:00 -MHDA- 2022/11/24 06:00 -CRDT- 2022/11/21 21:08 -PHST- 2022/08/29 00:00 [received] -PHST- 2022/08/30 00:00 [accepted] -PHST- 2022/11/21 21:08 [entrez] -PHST- 2022/11/22 06:00 [pubmed] -PHST- 2022/11/24 06:00 [medline] -AID - S1556-0864(22)01585-4 [pii] -AID - 10.1016/j.jtho.2022.08.019 [doi] -PST - ppublish -SO - J Thorac Oncol. 2022 Dec;17(12):1330-1332. doi: 10.1016/j.jtho.2022.08.019. - -PMID- 37936698 -OWN - NLM -STAT- MEDLINE -DCOM- 20231109 -LR - 20231109 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 14 -DP - 2023 -TI - Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary - sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and - literature review. -PG - 1274937 -LID - 10.3389/fimmu.2023.1274937 [doi] -LID - 1274937 -AB - BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a unique subtype of - non-small cell lung cancer (NSCLC) with a high degree of malignancy and poor - therapeutic effects. With the widespread use of immune checkpoint inhibitors - (ICIs) in recent years, few studies have reported that immunotherapy is effective - against PSC. As a multi-target anti-vascular targeting agent, anlotinib showed a - better anti-tumor effect in various cancer species. The paper reported the - therapeutic and side effects of pembrolizumab combined with anlotinib in a - patient with advanced PSC. CASE PRESENTATION: This is a 73 year old female - patient who underwent thoracoscopy right upper lobectomy and was diagnosed as - locally advanced PSC. However, the patient experienced tumor recurrence and - metastasis 7 weeks after surgery and was unable to tolerate chemoradiotherapy. - Moreover, she detected TP53 mutation and found that tumor mutation burden (TMB) - and PD-L1 were high expression. Therefore, the patient received pembrolizumab - combined with anlotinib treatment. After 15 cycles of treatment, the tumor - significantly shrank with no tumor activity. The evaluation of tumor efficacy is - partial response (PR). During the treatment period, she experienced one-degree - thyroid-stimulating hormone elevation and two-degree hand-foot syndrome. - Pembrolizumab and anlotinib was continued for two years as a maintenance - treatment. The patient had a good quality of life and no disease progression was - observed. Currently, the patient is still alive without tumor progression and has - overall survival exceeding 45 months and toxic side effects were tolerable. - CONCLUSIONS: Combining ICIs and anti-angiogenic targeted therapy has brought new - hope in treating advanced PSC. Additionally, TMB and PD-L1 expression could be - potential predictive biomarkers of the efficacy in advanced PSC with - immunotherapy. -CI - Copyright © 2023 Wu, Wu, Liao, Zhou, Qiu, Wang and Zhong. -FAU - Wu, Shugui -AU - Wu S -AD - Department of Oncology, The Affiliated Ganzhou Hospital of Nanchang University, - Ganzhou, China. -AD - Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical - University, Ganzhou, China. -FAU - Wu, Shanlian -AU - Wu S -AD - Department of Pathology, Ganzhou Hospital-Nanfang Hospital, Southern Medical - University, Ganzhou, China. -FAU - Liao, Xiaohong -AU - Liao X -AD - Department of Oncology, The Affiliated Ganzhou Hospital of Nanchang University, - Ganzhou, China. -AD - Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical - University, Ganzhou, China. -FAU - Zhou, Chaoming -AU - Zhou C -AD - Department of Oncology, The Affiliated Ganzhou Hospital of Nanchang University, - Ganzhou, China. -AD - Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical - University, Ganzhou, China. -FAU - Qiu, Feng -AU - Qiu F -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, China. -FAU - Wang, Chen -AU - Wang C -AD - Department of Oncology, The Affiliated Ganzhou Hospital of Nanchang University, - Ganzhou, China. -AD - Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical - University, Ganzhou, China. -FAU - Zhong, Wenjuan -AU - Zhong W -AD - Department of Oncology, The First Affiliated Hospital of Gannan Medical - University, Ganzhou, China. -LA - eng -PT - Case Reports -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20231023 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - DPT0O3T46P (pembrolizumab) -RN - 0 (anlotinib) -RN - 0 (B7-H1 Antigen) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Female -MH - Humans -MH - Aged -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Lung Neoplasms/pathology -MH - B7-H1 Antigen -MH - Quality of Life -MH - *Antineoplastic Agents, Immunological/adverse effects -MH - Neoplasm Recurrence, Local/drug therapy -MH - Biomarkers, Tumor/genetics -MH - *Carcinoma/drug therapy -PMC - PMC10626500 -OTO - NOTNLM -OT - anlotinib -OT - case report -OT - pembrolizumab -OT - pulmonary sarcomatoid carcinoma -OT - tumor mutation burden -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2023/11/08 06:43 -MHDA- 2023/11/09 06:42 -PMCR- 2023/01/01 -CRDT- 2023/11/08 03:52 -PHST- 2023/08/09 00:00 [received] -PHST- 2023/09/28 00:00 [accepted] -PHST- 2023/11/09 06:42 [medline] -PHST- 2023/11/08 06:43 [pubmed] -PHST- 2023/11/08 03:52 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2023.1274937 [doi] -PST - epublish -SO - Front Immunol. 2023 Oct 23;14:1274937. doi: 10.3389/fimmu.2023.1274937. - eCollection 2023. - -PMID- 34830123 -OWN - NLM -STAT- MEDLINE -DCOM- 20211220 -LR - 20211220 -IS - 1422-0067 (Electronic) -IS - 1422-0067 (Linking) -VI - 22 -IP - 22 -DP - 2021 Nov 12 -TI - Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung - Cancer: A Narrative Review. -LID - 10.3390/ijms222212244 [doi] -LID - 12244 -AB - New drugs, including immune checkpoint inhibitors and targeted therapy, have - changed the prognosis in a subset of patients with advanced lung cancer, and are - now actively investigated in a number of trials with neoadjuvant and adjuvant - regimens. However, no phase III randomized studies were published yet. The - current narrative review proves that targeted therapies are safe in neoadjuvant - approach. Unsurprisingly, administration of therapy is related to an acceptable - toxicity profile. Severe adverse events' rate that rarely compromises outcomes of - patients with advanced lung cancer is not that commonly accepted in early lung - cancer as it may lead to missing the chance of curative surgery. Among those - complications, the most important factors that may limit the use of targeted - therapies are severe respiratory adverse events precluding the resection - occurring after treatment with some anaplastic lymphoma kinase and rarely after - epidermal growth factor receptor tyrosine kinase inhibitors. At this point, in - the presented literature assessing the feasibility of neoadjuvant therapies with - anaplastic lymphoma kinase and epidermal growth factor receptor tyrosine kinase - inhibitors, we did not find any unexpected intraoperative events that would be of - special interest to a thoracic surgeon. Moreover, the postoperative course was - associated with typical rate of complications. -FAU - Marjanski, Tomasz -AU - Marjanski T -AUID- ORCID: 0000-0002-1260-3269 -AD - Thoracic Surgery Department, Medical University of Gdansk, Sklodowskiej-Curie 3A, - 80-211 Gdansk, Poland. -FAU - Dziedzic, Robert -AU - Dziedzic R -AD - Thoracic Surgery Department, Medical University of Gdansk, Sklodowskiej-Curie 3A, - 80-211 Gdansk, Poland. -FAU - Kowalczyk, Anna -AU - Kowalczyk A -AD - Department of Oncology and Radiotherapy, Medical University of Gdansk, - Sklodowskiej-Curie 3A, 80-211 Gdansk, Poland. -FAU - Rzyman, Witold -AU - Rzyman W -AUID- ORCID: 0000-0002-9044-7791 -AD - Thoracic Surgery Department, Medical University of Gdansk, Sklodowskiej-Curie 3A, - 80-211 Gdansk, Poland. -LA - eng -PT - Journal Article -PT - Review -DEP - 20211112 -PL - Switzerland -TA - Int J Mol Sci -JT - International journal of molecular sciences -JID - 101092791 -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (Anaplastic Lymphoma Kinase) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Anaplastic Lymphoma Kinase/*antagonists & inhibitors/metabolism -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/surgery -MH - Diarrhea/chemically induced -MH - ErbB Receptors/*antagonists & inhibitors/metabolism -MH - Humans -MH - Lung Neoplasms/*drug therapy/enzymology/surgery -MH - Molecular Targeted Therapy/*methods -MH - Nausea/chemically induced -MH - Neoadjuvant Therapy/methods -MH - Protein Kinase Inhibitors/adverse effects/*therapeutic use -PMC - PMC8622767 -OTO - NOTNLM -OT - ALK-TKIs -OT - EGFR-TKIs -OT - adverse events -OT - complications -OT - lung cancer -OT - neoadjuvant therapy -OT - non-small cell lung cancer -OT - safety -OT - surgery -OT - toxicity -COIS- Tomasz Marjanski reports having an advisory/consultancy and speaker bureau/expert - testimony role with Roche/Genentech. Robert Dziedzic, Anna Kowalczyk, and Witold - Rzyman declare noconflict of interest. -EDAT- 2021/11/28 06:00 -MHDA- 2021/12/21 06:00 -PMCR- 2021/11/12 -CRDT- 2021/11/27 01:10 -PHST- 2021/09/30 00:00 [received] -PHST- 2021/11/07 00:00 [revised] -PHST- 2021/11/10 00:00 [accepted] -PHST- 2021/11/27 01:10 [entrez] -PHST- 2021/11/28 06:00 [pubmed] -PHST- 2021/12/21 06:00 [medline] -PHST- 2021/11/12 00:00 [pmc-release] -AID - ijms222212244 [pii] -AID - ijms-22-12244 [pii] -AID - 10.3390/ijms222212244 [doi] -PST - epublish -SO - Int J Mol Sci. 2021 Nov 12;22(22):12244. doi: 10.3390/ijms222212244. - -PMID- 39068144 -OWN - NLM -STAT- MEDLINE -DCOM- 20240907 -LR - 20240907 -IS - 1879-4076 (Electronic) -IS - 1879-4068 (Linking) -VI - 15 -IP - 7 -DP - 2024 Sep -TI - Real-world overview of therapeutic strategies and prognosis of older patients - with advanced or metastatic non-small cell lung cancer from the ESME database. -PG - 101819 -LID - S1879-4068(24)00117-6 [pii] -LID - 10.1016/j.jgo.2024.101819 [doi] -AB - INTRODUCTION: In France, 40% of patients diagnosed with lung cancer are ≥70 years - old, but these are under-represented in clinical trials. Using data from the - French Epidemiological Strategy and Medical Economics (ESME) platform on Lung - Cancer (LC), the objective is to provide an overview of the management and the - prognosis of older patients with advanced or metastatic non-small cell lung - cancer (AM-NSCLC) in a real-world context. MATERIALS AND METHODS: From the - ESME-LC database, we selected patients with AM-NSCLC (stage IIIB, IIIC, and IV), - diagnosed between 2015 and 2019, and who received first-line systemic treatment. - Demographics, tumour characteristics, and treatment received were described in - patients ≥70, and compared to younger ones. Real-world progression-free survival - (rwPFS) and overall survival (OS) were evaluated using the multivariable Cox - model. RESULTS: Among 10,002 patients with AM-NSCLC, the median age was 64 years, - with 2,754 (27.5%) aged ≥70. In comparison with patients <70, older patients were - more often male, with worse performance status and more comorbidities, but they - were less underweight and more often non-smokers. The proportion of EGFR mutated - non-squamous NSCLC was higher in older patients (25.0% vs 12.8%, p < 0.001), - particularly among smokers and former smokers (12.7% vs 7.3%, p < 0.001). Among - patients ≥70, 76.6% received first-line chemotherapy (including 67.0% treated - with a platinum-based doublet), 15.0% received only targeted therapy, and 11.0% - received immunotherapy (alone or in combination). Median first-line rwPFS was - 5.1 months (95% confidence interval [CI] = [4.8;5.4]) for patients ≥70 and - 4.6 months (95%CI = [4.4;4.8]) for patients <70, but age was not associated with - rwPFS in multivariable analysis. Median OS was 14.8 months (95%CI = [13.9;16.1]) - for patients ≥70 and 16.7 months (95%CI = [15.9;17.5]) for patients <70, with a - significant effect of age in multivariable analysis for patients treated with - chemotherapy and/or with targeted therapy, but not for patients treated with - immunotherapy (alone or in combination with chemotherapy). DISCUSSION: In this - real-world cohort of patients with AM-NSCLC, age was not associated with - first-line rwPFS regardless of treatment received, nor with OS for patients - receiving immunotherapy. However, OS was significantly shorter for patients aged - ≥70 treated with chemotherapy or with targeted therapy alone. -CI - Copyright © 2024 Elsevier Ltd. All rights reserved. -FAU - Cabart, Mathilde -AU - Cabart M -AD - Institut Bergonié, Department of Medical Oncology, Bordeaux, France. Electronic - address: m.cabart@bordeaux.unicancer.fr. -FAU - Mourey, Loïc -AU - Mourey L -AD - Oncopole Claudius Regaud - IUCT-O, Department of Medical Oncology, Toulouse, - France. -FAU - Pasquier, David -AU - Pasquier D -AD - Centre Oscar Lambret, Lille University, Academic Department of Radiation - Oncology, Lille, France. -FAU - Schneider, Sophie -AU - Schneider S -AD - Centre Hospitalier de la Côte Basque, Pneumology, Bayonne, France. -FAU - Léna, Hervé -AU - Léna H -AD - Centre Hospitalier Universitaire, Pneumology, Rennes, France. -FAU - Girard, Nicolas -AU - Girard N -AD - Institut Curie, Department of Medical Oncology, Paris, France. -FAU - Chouaid, Christos -AU - Chouaid C -AD - Centre Hospitalier Intercommunal, Pneumology, Créteil, France. -FAU - Schott, Roland -AU - Schott R -AD - Institut de Cancérologie Strasbourg Europe ICANS, Department of Medical Oncology, - Strasbourg, France. -FAU - Hiret, Sandrine -AU - Hiret S -AD - Institut de Cancérologie de l'Ouest, Department of Medical Oncology, Nantes, - France. -FAU - Debieuvre, Didier -AU - Debieuvre D -AD - Groupe Hospitalier Région Mulhouse et Sud Alsace, Pneumology, Mulhouse, France. -FAU - Quantin, Xavier -AU - Quantin X -AD - Montpellier Cancer Institute (ICM) and Montpellier Cancer Research Institute - (IRCM), INSERM U1194, University of Montpellier, Montpellier, France. -FAU - Madroszyk, Anne -AU - Madroszyk A -AD - Institut Paoli-Calmettes, Department of Medical Oncology, Marseille, France. -FAU - Dubray-Longeras, Pascale -AU - Dubray-Longeras P -AD - Centre Jean Perrin, Department of Medical Oncology, Clermont-Ferrand, France. -FAU - Pichon, Eric -AU - Pichon E -AD - Centre Hospitalier Régional Universitaire, Pneumology, Tours, France. -FAU - Baranzelli, Anne -AU - Baranzelli A -AD - Centre Hospitalier Métropole Savoie, Pneumology, Chambéry, France. -FAU - Justeau, Grégoire -AU - Justeau G -AD - Centre Hospitalier Universitaire, Pneumology, Angers, France. -FAU - Pérol, Maurice -AU - Pérol M -AD - Centre Léon Bérard, Department of Medical Oncology, Lyon, France. -FAU - Bosquet, Lise -AU - Bosquet L -AD - Unicancer, Health data and partnerships department, Paris, France. -FAU - Cabarrou, Bastien -AU - Cabarrou B -AD - Oncopole Claudius Regaud - IUCT-O, Biostatistics & Health Data Science Unit, - Toulouse, France. -LA - eng -PT - Journal Article -DEP - 20240726 -PL - Netherlands -TA - J Geriatr Oncol -JT - Journal of geriatric oncology -JID - 101534770 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/therapy/mortality/pathology -MH - *Lung Neoplasms/therapy/drug therapy/mortality/pathology -MH - Male -MH - Aged -MH - Female -MH - Middle Aged -MH - France/epidemiology -MH - Aged, 80 and over -MH - Prognosis -MH - *Databases, Factual -MH - Progression-Free Survival -MH - Age Factors -OTO - NOTNLM -OT - Chemotherapy -OT - EGFR mutation -OT - Immunotherapy -OT - Non-small cell lung cancer -OT - Older patients -OT - Pattern of care -OT - Prognosis -OT - Targeted therapy -COIS- Declaration of Competing Interest Mathilde Cabart reports non-financial support - from Janssen, non-financial support from Pfizer, outside the submitted work. Loïc - Mourey reports personal fees and non-financial support from Sanofi, personal fees - from Astellas, personal fees and non-financial support from Janssen, personal - fees and non-financial support from MSD, personal fees and non-financial support - from BMS, personal fees and non-financial support from Ipsen, personal fees and - non-financial support from Astra-Zeneca, personal fees and non-financial support - from Pfizer, personal fees from Merck, outside the submitted work. David Pasquier - has nothing to disclose. Sophie Schneider has nothing to disclose. Hervé Léna - reports personal fees and non-financial support from Roche, personal fees from - Astrazeneca, personal fees and non-financial support from MSD, personal fees and - non-financial support from Novartis, personal fees and non-financial support from - Takeda, personal fees from BMS, personal fees and non-financial support from - Pfizer, non-financial support from Lilly, personal fees and non-financial support - from Amgen, outside the submitted work. Nicolas Girard reports grants and - personal fees from AstraZeneca, personal fees from Daiichi, grants and personal - fees from Roche, grants and personal fees from MSD, grants and personal fees from - BMS, grants and personal fees from Pfizer, grants and personal fees from Janssen, - grants and personal fees from Boehringer Ingelheim, grants and personal fees from - Takeda, grants and personal fees from Novartis, grants and personal fees from - Sanofi, outside the submitted work; and Family Member employee of AstraZeneca. - Christos Chouaid reports grants, personal fees and non-financial support from - AstraZeneca, grants, personal fees and non-financial support from Boehringer - Ingelheim, grants, personal fees and non-financial support from GSK, grants, - personal fees and non-financial support from Roche, grants, personal fees and - non-financial support from Sanofi Aventis, grants, personal fees and - non-financial support from BMS, grants, personal fees and non-financial support - from MSD, grants, personal fees and non-financial support from Lilly, grants, - personal fees and non-financial support from Novartis, grants, personal fees and - non-financial support from Pfizer, grants, personal fees and non-financial - support from Takeda, grants, personal fees and non-financial support from Bayer, - grants, personal fees and non-financial support from Janssen, grants, personal - fees and non-financial support from Viatris, grants, personal fees and - non-financial support from Chugai, grants, personal fees and non-financial - support from Pierre Fabre, grants, personal fees and non-financial support from - Amgen, outside the submitted work. Roland Schott reports personal fees and - non-financial support from Roche, non-financial support from Takeda, personal - fees and non-financial support from AstraZeneca, personal fees and non-financial - support from Pfizer, non-financial support from IPSEN, personal fees and - non-financial support from BMS, outside the submitted work. Sandrine Hiret - reports non-financial support from Roche, non-financial support from Novartis, - other from Sanofi, other from Astra Zeneca, other from Takeda, other from BMS, - outside the submitted work. Didier Debieuvre has nothing to disclose. Xavier - Quantin has nothing to disclose. Anne Madroszyk has nothing to disclose. Pascale - Dubray-Longeras reports personal fees from MSD, personal fees from AstraZeneca, - personal fees and non-financial support from Takeda, non-financial support from - Pfizer, outside the submitted work. Eric Pichon reports personal fees and - non-financial support from Takeda, personal fees from AstraZeneca, personal fees - from MSD, outside the submitted work. Anne Baranzelli has nothing to disclose. - Grégoire Justeau has nothing to disclose. Maurice Pérol reports personal fees and - non-financial support from Takeda, personal fees from Janssen, personal fees and - non-financial support from AstraZeneca, outside the submitted work. Lise Bosquet - has nothing to disclose. Bastien Cabarrou has nothing to disclose. -EDAT- 2024/07/28 14:50 -MHDA- 2024/09/08 13:50 -CRDT- 2024/07/27 21:56 -PHST- 2023/12/26 00:00 [received] -PHST- 2024/05/27 00:00 [revised] -PHST- 2024/06/24 00:00 [accepted] -PHST- 2024/09/08 13:50 [medline] -PHST- 2024/07/28 14:50 [pubmed] -PHST- 2024/07/27 21:56 [entrez] -AID - S1879-4068(24)00117-6 [pii] -AID - 10.1016/j.jgo.2024.101819 [doi] -PST - ppublish -SO - J Geriatr Oncol. 2024 Sep;15(7):101819. doi: 10.1016/j.jgo.2024.101819. Epub 2024 - Jul 26. - -PMID- 38035069 -OWN - NLM -STAT- MEDLINE -DCOM- 20231204 -LR - 20240325 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 14 -DP - 2023 -TI - Harnessing the power of traditional Chinese medicine monomers and compound - prescriptions to boost cancer immunotherapy. -PG - 1277243 -LID - 10.3389/fimmu.2023.1277243 [doi] -LID - 1277243 -AB - At present, cancer is the largest culprit that endangers human health. The - current treatment options for cancer mainly include surgical resection, adjuvant - radiotherapy and chemotherapy, but their therapeutic effects and long-term - prognosis are unsatisfactory. Immunotherapy is an emerging therapy that has - completely transformed the therapeutic landscape of advanced cancers, and has - tried to occupy a place in the neoadjuvant therapy of resectable tumors. However, - not all patients respond to immunotherapy due to the immunological and molecular - features of the tumors. Traditional Chinese Medicine (TCM) provides a new - perspective for cancer treatment and is considered to have the potential as - promising anti-tumor drugs considering its immunoregulatory properties. This - review concludes commonly used TCM monomers and compounds from the perspective of - immune regulatory pathways, aiming to clearly introduce the basic mechanisms of - TCM in boosting cancer immunotherapy and mechanisms of several common TCM. In - addition, we also summarized closed and ongoing trials and presented prospects - for future development. Due to the significant role of immunotherapy in the - treatment of non-small cell lung cancer (NSCLC), TCM combined with immunotherapy - should be emphasized in NSCLC. -CI - Copyright © 2023 Miao, Liu, Xu, Qian and Zhang. -FAU - Miao, Keyan -AU - Miao K -AD - Medical College, Soochow University, Suzhou, Jiangsu, China. -FAU - Liu, Weici -AU - Liu W -AD - Department of Thoracic Surgery, The Affiliated Wuxi People's Hospital of Nanjing - Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical - University, Wuxi, Jiangsu, China. -FAU - Xu, Jingtong -AU - Xu J -AD - The First School of Clinical Medicine, Nanjing Medical University. Nanjing, - Jiangsu, China. -FAU - Qian, Zhengtao -AU - Qian Z -AD - Department of Clinical Laboratory, Changshu Medicine Examination Institute, - Changshu, Jiangsu, China. -FAU - Zhang, Qinglin -AU - Zhang Q -AD - Department of Gastroenterology, The Affiliated Wuxi People's Hospital of Nanjing - Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical - University, Wuxi, Jiangsu, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20231115 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Medicine, Chinese Traditional -MH - *Lung Neoplasms/pathology -MH - Immunotherapy -MH - Prescriptions -PMC - PMC10684919 -OTO - NOTNLM -OT - cancer immunotherapy -OT - cytokines -OT - immunomodulators -OT - natural products -OT - traditional Chinese medicine -OT - tumor immunity -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2023/11/30 18:45 -MHDA- 2023/12/04 12:41 -PMCR- 2023/01/01 -CRDT- 2023/11/30 17:43 -PHST- 2023/08/14 00:00 [received] -PHST- 2023/10/30 00:00 [accepted] -PHST- 2023/12/04 12:41 [medline] -PHST- 2023/11/30 18:45 [pubmed] -PHST- 2023/11/30 17:43 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2023.1277243 [doi] -PST - epublish -SO - Front Immunol. 2023 Nov 15;14:1277243. doi: 10.3389/fimmu.2023.1277243. - eCollection 2023. - -PMID- 10389914 -OWN - NLM -STAT- MEDLINE -DCOM- 19990930 -LR - 20201215 -IS - 1078-0432 (Print) -IS - 1078-0432 (Linking) -VI - 5 -IP - 6 -DP - 1999 Jun -TI - Long survival of patients with small cell lung cancer after adjuvant treatment - with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. -PG - 1319-23 -AB - Despite active therapies for small cell lung cancer (SCLC), most patients relapse - and die of the disease. The present study evaluates immunization using the - anti-idiotypic antibody BEC2, which mimics the ganglioside GD3 expressed on the - surface of most SCLC tumors, combined with Bacillus Calmette-Guérin (BCG) as an - immune adjuvant. We hypothesized that active immunization could alter the natural - history of the disease. Fifteen patients who had completed standard therapy for - SCLC received a series of five intradermal immunizations consisting of 2.5 mg of - BEC2 plus BCG over a 10-week period. Blood was collected for serological - analysis, and outcome was monitored. All patients developed anti-BEC2 antibodies, - despite having received chemotherapy with or without thoracic radiation. We - detected anti-GD3 antibodies in five patients, including those with the longest - relapse-free survival. The median relapse-free survival for patients with - extensive stage disease is 11 months and has not been reached for patients with - limited stage disease (>47 months), with only one of seven patients having - relapsed after a median follow-up of 47 months. Immunization of patients with - SCLC after standard therapy using BEC2 plus BCG can induce anti-GD3 antibodies - and is safe. The survival and relapse-free survival in this group of patients are - substantially better than those observed in a prior group of similar patients. A - Phase III trial is being conducted to evaluate BEC2 plus BCG as adjuvant therapy - after chemotherapy and irradiation. -FAU - Grant, S C -AU - Grant SC -AD - Department of Medicine, Memorial Sloan-Kettering Cancer Center and Joan and - Sanford I. Weill Medical College of Cornell University, New York, New York 10021, - USA. -FAU - Kris, M G -AU - Kris MG -FAU - Houghton, A N -AU - Houghton AN -FAU - Chapman, P B -AU - Chapman PB -LA - eng -GR - CA-33409/CA/NCI NIH HHS/United States -PT - Clinical Trial -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Research Support, U.S. Gov't, P.H.S. -PL - United States -TA - Clin Cancer Res -JT - Clinical cancer research : an official journal of the American Association for - Cancer Research -JID - 9502500 -RN - 0 (Adjuvants, Immunologic) -RN - 0 (Antibodies, Anti-Idiotypic) -RN - 0 (BCG Vaccine) -RN - 0 (Gangliosides) -RN - 0 (Immunoglobulin G) -RN - 0 (Immunoglobulin M) -RN - 62010-37-1 (ganglioside, GD3) -SB - IM -MH - Adjuvants, Immunologic/adverse effects/*therapeutic use -MH - Adult -MH - Aged -MH - Antibodies, Anti-Idiotypic/adverse effects/*therapeutic use -MH - BCG Vaccine/*therapeutic use -MH - Carcinoma, Small Cell/immunology/mortality/*therapy -MH - Disease-Free Survival -MH - Female -MH - Gangliosides/immunology -MH - Humans -MH - Immunoglobulin G/blood -MH - Immunoglobulin M/blood -MH - Immunotherapy, Active -MH - Lung Neoplasms/immunology/mortality/*therapy -MH - Male -MH - Middle Aged -MH - Survival Rate -EDAT- 1999/07/02 00:00 -MHDA- 1999/07/02 00:01 -CRDT- 1999/07/02 00:00 -PHST- 1999/07/02 00:00 [pubmed] -PHST- 1999/07/02 00:01 [medline] -PHST- 1999/07/02 00:00 [entrez] -PST - ppublish -SO - Clin Cancer Res. 1999 Jun;5(6):1319-23. - -PMID- 33450361 -OWN - NLM -STAT- MEDLINE -DCOM- 20210804 -LR - 20210804 -IS - 1872-7980 (Electronic) -IS - 0304-3835 (Linking) -VI - 502 -DP - 2021 Apr 1 -TI - Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: - Mechanisms, advances, and challenges. -PG - 166-179 -LID - S0304-3835(21)00008-2 [pii] -LID - 10.1016/j.canlet.2020.12.043 [doi] -AB - The brain is one of the most common metastatic sites in non-small cell lung - cancer (NSCLC), which is associated with an extremely poor prognosis. Despite the - availability of several therapeutic options, the treatment efficacy remains - unsatisfactory for NSCLC brain metastases. Anti-programmed cell death-1 (PD-1) - and its ligand (PD-L1) monoclonal antibodies have reshaped therapeutic strategies - in advanced NSCLC. Preliminary evidence has shown that anti-PD-(L)1 monotherapy - is also effective in NSCLC patients with brain metastases. However, the - traditional view asserted that these therapeutic antibodies were incapable of - crossing the blood-brain barrier (BBB) with large molecular size, thus most - patients with brain metastases were excluded from most studies on anti-PD-(L)1 - immunotherapy. Therefore, the efficacy and its mechanisms of action of - anti-PD-(L)1 immunotherapy against brain metastases in NSCLC have not been - clarified. In this review, we will survey the underlying mechanisms and current - clinical advances of anti-PD-(L)1 immunotherapy in the treatment of brain - metastases in NSCLC. The trafficking of activated cytotoxic T cells that are - mainly derived from the primary tumor and deep cervical lymph nodes is critical - for the intracranial response to anti-PD-(L)1 immunotherapy, which is driven by - interferon-γ (IFN-γ). Additionally, promising combined strategies with the - rationale in the treatment of brain metastases will be presented to provide - future directions for clinical study design. Several significant challenges in - the preclinical and clinical studies of brain metastases, as well as potential - solutions, will also be discussed. -CI - Copyright © 2021. Published by Elsevier B.V. -FAU - Zhou, Shujie -AU - Zhou S -AD - Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Xie, Jingjing -AU - Xie J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Huang, Zhaoqin -AU - Huang Z -AD - Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong - First Medical University, Jinan, Shandong, China. -FAU - Deng, Liufu -AU - Deng L -AD - Shanghai Institute of Immunology; Department of Immunology and Microbiology, - Shanghai Jiao Tong University School of Medicine, Shanghai, China. -FAU - Wu, Leilei -AU - Wu L -AD - Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Yu, Jinming -AU - Yu J -AD - Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. Electronic address: sdyujinming@126.com. -FAU - Meng, Xiangjiao -AU - Meng X -AD - Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. Electronic address: mengxiangjiao@126.com. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20210113 -PL - Ireland -TA - Cancer Lett -JT - Cancer letters -JID - 7600053 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antibodies, Monoclonal/pharmacology/*therapeutic use -MH - Antineoplastic Agents, Immunological/pharmacology/therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors -MH - Brain Neoplasms/*drug therapy/immunology/*secondary -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology -MH - Clinical Trials as Topic -MH - Gene Expression Regulation, Neoplastic/drug effects -MH - Humans -MH - Immunotherapy -MH - Lung Neoplasms/*drug therapy/immunology -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -OTO - NOTNLM -OT - Combination therapies -OT - Efficacy -OT - Immune checkpoint inhibitors -OT - Metastatic brain tumors -OT - Non-small cell lung cancer -EDAT- 2021/01/16 06:00 -MHDA- 2021/08/05 06:00 -CRDT- 2021/01/15 20:09 -PHST- 2020/10/09 00:00 [received] -PHST- 2020/12/01 00:00 [revised] -PHST- 2020/12/26 00:00 [accepted] -PHST- 2021/01/16 06:00 [pubmed] -PHST- 2021/08/05 06:00 [medline] -PHST- 2021/01/15 20:09 [entrez] -AID - S0304-3835(21)00008-2 [pii] -AID - 10.1016/j.canlet.2020.12.043 [doi] -PST - ppublish -SO - Cancer Lett. 2021 Apr 1;502:166-179. doi: 10.1016/j.canlet.2020.12.043. Epub 2021 - Jan 13. - -PMID- 37776047 -OWN - NLM -STAT- MEDLINE -DCOM- 20231102 -LR - 20231103 -IS - 1747-6356 (Electronic) -IS - 1747-6348 (Linking) -VI - 17 -IP - 9 -DP - 2023 Jul-Dec -TI - Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: - improving prognostics. -PG - 743-751 -LID - 10.1080/17476348.2023.2265810 [doi] -AB - INTRODUCTION: KRAS is the most frequently mutated oncogene in cancer and encodes - a key signaling protein in tumors. Due to its high affinity for GTP and the lack - of a large binding pocket that allosteric inhibitors can occupy, KRAS has long - been considered 'non-druggable.' Finding effective treatment measures for - patients with KRAS mutations is our top priority. AREAS COVERED: In this article, - we will provide an overview of the KRAS pathway and review the current state of - therapeutic strategies for targeting oncogenic KRAS, as well as their potential - to improve outcomes in patients with KRAS-mutant malignancies. We will also - discuss the development of these strategies and gave an outlook on prospects. - EXPERT OPINION: KRAS mutations have posed a significant challenge in the - treatment of advanced non-small cell lung cancer (NSCLC) over the past few - decades. However, the emergence of immunotherapy and KRAS inhibitors, such as - Sotorasib (AMG 510) and Adagrasib (MRTX849), has marked a new era in cancer - therapy. As more research and clinical trials continue, we anticipate the - development of more effective treatment strategies and better options for lung - cancer patients. -FAU - Zhang, Yuda -AU - Zhang Y -AD - Department of Oncology, Graduate Collaborative Training Base of Hunan Cancer - Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, - China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Zeng, Fanxu -AU - Zeng F -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Peng, Shixuan -AU - Peng S -AD - Department of Oncology, Graduate Collaborative Training Base of Hunan Cancer - Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, - China. -AD - Department of Oncology, Graduate Collaborative Training Base of The First - People's Hospital of Xiangtan City, Hengyang Medical school, University of South - China, Hengyang, Hunan, China. -FAU - Chen, Yangqian -AU - Chen Y -AD - Department of Oncology, Graduate Collaborative Training Base of Hunan Cancer - Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, - China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Jiang, Wenjuan -AU - Jiang W -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Wang, Zhan -AU - Wang Z -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Deng, Li -AU - Deng L -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Huang, Zhe -AU - Huang Z -AD - Department of Oncology, Graduate Collaborative Training Base of Hunan Cancer - Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, - China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Qin, Haoyue -AU - Qin H -AD - Department of Oncology, Graduate Collaborative Training Base of Hunan Cancer - Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, - China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Yan, Huan -AU - Yan H -AD - Department of Oncology, Graduate Collaborative Training Base of Hunan Cancer - Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, - China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Zhang, Xing -AU - Zhang X -AD - Department of Oncology, Graduate Collaborative Training Base of Hunan Cancer - Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, - China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Zhang, Lin -AU - Zhang L -AD - Department of Radiotherapy, the Affiliated Cancer Hospital of Xiangya School of - Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, China. -FAU - Yang, Nong -AU - Yang N -AD - Department of Oncology, Graduate Collaborative Training Base of Hunan Cancer - Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, - China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Gong, Qian -AU - Gong Q -AD - Early Clinical Trial Center, Office of National Drug Clinical Trial Institution, - Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of - Medicine, Central South University, Changsha, Hunan, China. -FAU - Zeng, Liang -AU - Zeng L -AD - Department of Oncology, Graduate Collaborative Training Base of Hunan Cancer - Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, - China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -FAU - Zhang, Yongchang -AU - Zhang Y -AUID- ORCID: 0000-0002-6829-7176 -AD - Department of Oncology, Graduate Collaborative Training Base of Hunan Cancer - Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, - China. -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. -AD - Early Clinical Trial Center, Office of National Drug Clinical Trial Institution, - Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of - Medicine, Central South University, Changsha, Hunan, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20231027 -PL - England -TA - Expert Rev Respir Med -JT - Expert review of respiratory medicine -JID - 101278196 -RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) -RN - 8EOO6HQF8Y (adagrasib) -RN - 0 (KRAS protein, human) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Prognosis -MH - Proto-Oncogene Proteins p21(ras)/genetics -MH - *Lung Neoplasms/drug therapy/genetics -MH - Mutation -OTO - NOTNLM -OT - Adagrasib -OT - KRAS mutation -OT - Sotorasib -OT - immunotherapy -OT - lung cancer -OT - targeted therapy -EDAT- 2023/09/30 09:43 -MHDA- 2023/09/30 09:44 -CRDT- 2023/09/30 02:53 -PHST- 2023/09/30 09:44 [medline] -PHST- 2023/09/30 09:43 [pubmed] -PHST- 2023/09/30 02:53 [entrez] -AID - 10.1080/17476348.2023.2265810 [doi] -PST - ppublish -SO - Expert Rev Respir Med. 2023 Jul-Dec;17(9):743-751. doi: - 10.1080/17476348.2023.2265810. Epub 2023 Oct 27. - -PMID- 12738716 -OWN - NLM -STAT- MEDLINE -DCOM- 20040112 -LR - 20220225 -IS - 1078-0432 (Print) -IS - 1078-0432 (Linking) -VI - 9 -IP - 5 -DP - 2003 May -TI - A Phase I dose-escalation study of sibrotuzumab in patients with advanced or - metastatic fibroblast activation protein-positive cancer. -PG - 1639-47 -AB - PURPOSE: The purpose of this research was to determine the safety, - immunogenicity, pharmacokinetics, biodistribution, and tumor uptake of repeat - infusions of a complementarity-determining region grafted humanized antibody - (sibrotuzumab) directed against human fibroblast activation protein (FAP). - EXPERIMENTAL DESIGN: A Phase I open-label dose escalation study was conducted in - patients with cancers epidemiologically known to be FAP positive. Patients were - entered into one of four dosage tiers of 5, 10, 25, or 50 mg/m(2) sibrotuzumab, - administered weekly for 12 weeks, with trace labeling with 8-10 mCi of (131)I in - weeks 1, 5, and 9. RESULTS: A total of 26 patients were entered into the trial - (15 males and 11 females; mean age, 59.9 years; age range, 41-81 years). Twenty - patients had colorectal carcinoma, and 6 patients had non-small cell lung cancer. - A total of 218 infusions of sibrotuzumab were administered during the first 12 - weeks of the study, with 24 patients being evaluable. One patient received an - additional 96 infusions on continued-use phase for a total of 108 infusions over - a 2-year period, and 1 patient received an additional 6 infusions on continued - use. There were no objective tumor responses. Only one episode of dose-limiting - toxicity was observed. Therefore, a maximum tolerated dose was not reached. - Treatment-related adverse events were observed in 6 patients during the - infusional monitoring period. Four of the 6 patients, 3 of whom had associated - positive serum human antihuman antibody, were removed from the study because of - clinical immune responses. Gamma camera images of [(131)I]sibrotuzumab - demonstrated no normal organ uptake of sibrotuzumab, with tumor uptake evident - within 24-48 h after infusion. Analysis of pharmacokinetics demonstrated a - similar mean terminal t(1/2) of 1.4-2.6 days at the 5, 10, and 25 mg/m(2) dose - levels, and with a longer mean t(1/2) of 4.9 days at the 50 mg/m(2) dose level. - CONCLUSION: Repeat infusions of the humanized anti-FAP antibody sibrotuzumab can - be administered safely to patients with advanced FAP-positive cancer. -FAU - Scott, Andrew M -AU - Scott AM -AD - Ludwig Institute for Cancer Research, Melbourne Tumour Biology, Austin, and - Repatriation Medical Centre, 3084 Australia. ams@austin.unimelb.edu.au -FAU - Wiseman, Greg -AU - Wiseman G -FAU - Welt, Sydney -AU - Welt S -FAU - Adjei, Alex -AU - Adjei A -FAU - Lee, Fook-Thean -AU - Lee FT -FAU - Hopkins, Wendie -AU - Hopkins W -FAU - Divgi, Chaitan R -AU - Divgi CR -FAU - Hanson, Lorelei H -AU - Hanson LH -FAU - Mitchell, Paul -AU - Mitchell P -FAU - Gansen, Denise N -AU - Gansen DN -FAU - Larson, Steven M -AU - Larson SM -FAU - Ingle, James N -AU - Ingle JN -FAU - Hoffman, Eric W -AU - Hoffman EW -FAU - Tanswell, Paul -AU - Tanswell P -FAU - Ritter, Gerd -AU - Ritter G -FAU - Cohen, Leonard S -AU - Cohen LS -FAU - Bette, Peter -AU - Bette P -FAU - Arvay, Lisa -AU - Arvay L -FAU - Amelsberg, Andree -AU - Amelsberg A -FAU - Vlock, Dan -AU - Vlock D -FAU - Rettig, Wolfgang J -AU - Rettig WJ -FAU - Old, Lloyd J -AU - Old LJ -LA - eng -PT - Clinical Trial -PT - Clinical Trial, Phase I -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - United States -TA - Clin Cancer Res -JT - Clinical cancer research : an official journal of the American Association for - Cancer Research -JID - 9502500 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antigens, Neoplasm) -RN - 0 (Biomarkers, Tumor) -RN - 0 (Iodine Radioisotopes) -RN - 0 (Membrane Proteins) -RN - 0 (sibrotuzumab) -RN - EC 3.4.- (Endopeptidases) -RN - EC 3.4.21.- (Serine Endopeptidases) -RN - EC 3.4.21.- (fibroblast activation protein alpha) -RN - EC 3.4.24.- (Gelatinases) -SB - IM -CIN - Clin Cancer Res. 2003 May;9(5):1590-5. PMID: 12738710 -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal/adverse effects/pharmacokinetics/*therapeutic use -MH - Antibodies, Monoclonal, Humanized -MH - Antigens, Neoplasm/immunology/*metabolism -MH - Biomarkers, Tumor/immunology/*metabolism -MH - Carcinoma, Non-Small-Cell Lung/blood/drug therapy/secondary -MH - Colorectal Neoplasms/blood/*drug therapy/secondary -MH - Dose-Response Relationship, Drug -MH - Endopeptidases -MH - Female -MH - Follow-Up Studies -MH - Gelatinases -MH - Humans -MH - Infusions, Intravenous -MH - Iodine Radioisotopes -MH - Lung Neoplasms/blood/drug therapy/secondary -MH - Male -MH - Maximum Tolerated Dose -MH - Membrane Proteins -MH - Middle Aged -MH - Radioimmunotherapy -MH - Serine Endopeptidases/immunology/*metabolism -MH - Treatment Outcome -EDAT- 2003/05/10 05:00 -MHDA- 2004/01/13 05:00 -CRDT- 2003/05/10 05:00 -PHST- 2003/05/10 05:00 [pubmed] -PHST- 2004/01/13 05:00 [medline] -PHST- 2003/05/10 05:00 [entrez] -PST - ppublish -SO - Clin Cancer Res. 2003 May;9(5):1639-47. - -PMID- 34454057 -OWN - NLM -STAT- MEDLINE -DCOM- 20211012 -LR - 20211012 -IS - 1879-0461 (Electronic) -IS - 1040-8428 (Linking) -VI - 166 -DP - 2021 Oct -TI - Dynamics of eligibility criteria for central nervous system metastases in - non-small cell lung cancer randomized clinical trials over time: A systematic - review. -PG - 103460 -LID - S1040-8428(21)00247-X [pii] -LID - 10.1016/j.critrevonc.2021.103460 [doi] -AB - Although central nervous system (CNS) metastases frequently occur in patients - with non-small cell lung cancer (NSCLC), historically these patients have been - excluded from clinical trials. However, due to improving NSCLC prognosis, time to - develop CNS metastases increases and information on CNS efficacy of systemic - treatment is important. We performed a systematic PubMed review (2000-2020) to - describe CNS related eligibility and screening criteria over time. Randomized - phase III, and for tyrosine kinase inhibitors (TKIs) also randomized phase II - trials enrolling advanced/metastatic NSCLC patients were included. 256/1195 - trials were included. In 71 %, CNS metastases were eligible, but in only 3% - regardless of symptoms/treatment. Only 37 % required baseline CNS screening (most - often TKI and immunotherapy trials), without significant increase over time. A - CNS endpoint was pre-specified in 4%. CONCLUSION: CNS screening and eligibility - criteria are heterogenous across trials, and CNS related endpoints are rare. - These criteria and endpoints should be improved and harmonized. -CI - Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved. -FAU - Schoenmaekers, Janna Josephus Anna Oda -AU - Schoenmaekers JJAO -AD - Dept. of Pulmonary Diseases, GROW - School for Oncology and Developmental - Biology, Maastricht University Medical Center+, Maastricht, the Netherlands. - Electronic address: J.schoenmaekers@mumc.nl. -FAU - Dursun, Safiye -AU - Dursun S -AD - Dept. of Pulmonary Diseases, Maastricht University Medical Center +, Maastricht, - the Netherlands. Electronic address: Safiye.dursun@mumc.nl. -FAU - Biesmans, Charlotte -AU - Biesmans C -AD - Maastricht University, Maastricht, the Netherlands. Electronic address: - charlotte.biesmans@student.maastrichtuniversity.nl. -FAU - De Ruysscher, Dirk Karel Maria -AU - De Ruysscher DKM -AD - Dept. of Radiation Oncology (MAASTRO), GROW - School for Oncology and - Developmental Biology, Maastricht University Medical Center+, Maastricht, the - Netherlands. Electronic address: Dirk.deruysscher@maastro.nl. -FAU - Broen, Martinus Petrus Gertrudis -AU - Broen MPG -AD - Department of Neurology, Maastricht University Medical Center+, Maastricht, the - Netherlands. Electronic address: Martijn.broen@mumc.nl. -FAU - Remon, Jordi -AU - Remon J -AD - Department of Medical Oncology, Centro Integral Oncológico Clara Campal - (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain. Electronic - address: jremon@hmhospitales.com. -FAU - Dingemans, Anne-Marie Clasina -AU - Dingemans AC -AD - Dept. of Pulmonary Diseases, GROW - School for Oncology and Developmental - Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; - Department of Pulmonary Diseases, Erasmus Medical Centre, Rotterdam, the - Netherlands. Electronic address: A.dingemans@erasmusmc.nl. -FAU - Hendriks, Lizza Elisabeth Lucia -AU - Hendriks LEL -AD - Dept. of Pulmonary Diseases, GROW - School for Oncology and Developmental - Biology, Maastricht University Medical Center+, Maastricht, the Netherlands. - Electronic address: https://www.twitter.com/HendriksLizza. -LA - eng -PT - Journal Article -PT - Review -PT - Systematic Review -DEP - 20210826 -PL - Netherlands -TA - Crit Rev Oncol Hematol -JT - Critical reviews in oncology/hematology -JID - 8916049 -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/diagnosis/drug therapy -MH - Central Nervous System -MH - Clinical Trials, Phase II as Topic -MH - ErbB Receptors -MH - Humans -MH - *Lung Neoplasms/diagnosis/drug therapy -MH - Protein Kinase Inhibitors/therapeutic use -MH - Randomized Controlled Trials as Topic -OTO - NOTNLM -OT - Brain metastases -OT - Clinical trials -OT - Eligibility -OT - NSCLC -OT - Screening -EDAT- 2021/08/29 06:00 -MHDA- 2021/10/13 06:00 -CRDT- 2021/08/28 20:11 -PHST- 2021/08/01 00:00 [received] -PHST- 2021/08/23 00:00 [accepted] -PHST- 2021/08/29 06:00 [pubmed] -PHST- 2021/10/13 06:00 [medline] -PHST- 2021/08/28 20:11 [entrez] -AID - S1040-8428(21)00247-X [pii] -AID - 10.1016/j.critrevonc.2021.103460 [doi] -PST - ppublish -SO - Crit Rev Oncol Hematol. 2021 Oct;166:103460. doi: - 10.1016/j.critrevonc.2021.103460. Epub 2021 Aug 26. - -PMID- 30895304 -OWN - NLM -STAT- MEDLINE -DCOM- 20200806 -LR - 20210109 -IS - 1569-8041 (Electronic) -IS - 0923-7534 (Print) -IS - 0923-7534 (Linking) -VI - 30 -IP - 6 -DP - 2019 Jun 1 -TI - Predicting response to cancer immunotherapy using noninvasive radiomic - biomarkers. -PG - 998-1004 -LID - S0923-7534(19)31202-5 [pii] -LID - 10.1093/annonc/mdz108 [doi] -AB - INTRODUCTION: Immunotherapy is regarded as one of the major breakthroughs in - cancer treatment. Despite its success, only a subset of patients responds-urging - the quest for predictive biomarkers. We hypothesize that artificial intelligence - (AI) algorithms can automatically quantify radiographic characteristics that are - related to and may therefore act as noninvasive radiomic biomarkers for - immunotherapy response. PATIENTS AND METHODS: In this study, we analyzed 1055 - primary and metastatic lesions from 203 patients with advanced melanoma and - non-small-cell lung cancer (NSCLC) undergoing anti-PD1 therapy. We carried out an - AI-based characterization of each lesion on the pretreatment contrast-enhanced CT - imaging data to develop and validate a noninvasive machine learning biomarker - capable of distinguishing between immunotherapy responding and nonresponding. To - define the biological basis of the radiographic biomarker, we carried out gene - set enrichment analysis in an independent dataset of 262 NSCLC patients. RESULTS: - The biomarker reached significant performance on NSCLC lesions (up to 0.83 AUC, - P < 0.001) and borderline significant for melanoma lymph nodes (0.64 AUC, - P = 0.05). Combining these lesion-wide predictions on a patient level, - immunotherapy response could be predicted with an AUC of up to 0.76 for both - cancer types (P < 0.001), resulting in a 1-year survival difference of 24% - (P = 0.02). We found highly significant associations with pathways involved in - mitosis, indicating a relationship between increased proliferative potential and - preferential response to immunotherapy. CONCLUSIONS: These results indicate that - radiographic characteristics of lesions on standard-of-care imaging may function - as noninvasive biomarkers for response to immunotherapy, and may show utility for - improved patient stratification in both neoadjuvant and palliative settings. -CI - © The Author(s) 2019. Published by Oxford University Press on behalf of the - European Society for Medical Oncology. -FAU - Trebeschi, S -AU - Trebeschi S -AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam; GROW School of - Oncology and Developmental Biology, Maastricht, The Netherlands; Departments of - Radiation Oncology; Radiology, Dana Farber Cancer Institute, Brigham and Women's - Hospital, Harvard Medical School, Boston, USA. -FAU - Drago, S G -AU - Drago SG -AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam; Department of - Radiology, Milano-Bicocca University, San Gerardo Hospital, Monza, Italy. -FAU - Birkbak, N J -AU - Birkbak NJ -AD - The Francis Crick Institute, London; University College London, London, UK; - Department of Molecular Medicine, Aarhus University, Aarhus, Denmark. -FAU - Kurilova, I -AU - Kurilova I -AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam; GROW School of - Oncology and Developmental Biology, Maastricht, The Netherlands. -FAU - Cǎlin, A M -AU - Cǎlin AM -AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam; Affidea - Romania, Cluj-Napoca, Romania. -FAU - Delli Pizzi, A -AU - Delli Pizzi A -AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam; ITAB Institute - for Advanced Biomedical Technologies, University G. d'Annunzio, Chieti, Italy. -FAU - Lalezari, F -AU - Lalezari F -AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam. -FAU - Lambregts, D M J -AU - Lambregts DMJ -AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam. -FAU - Rohaan, M W -AU - Rohaan MW -AD - Departments of Medical Oncology. -FAU - Parmar, C -AU - Parmar C -AD - Departments of Radiation Oncology; Radiology, Dana Farber Cancer Institute, - Brigham and Women's Hospital, Harvard Medical School, Boston, USA. -FAU - Rozeman, E A -AU - Rozeman EA -AD - Departments of Medical Oncology. -FAU - Hartemink, K J -AU - Hartemink KJ -AD - Surgery. -FAU - Swanton, C -AU - Swanton C -AD - The Francis Crick Institute, London; University College London, London, UK. -FAU - Haanen, J B A G -AU - Haanen JBAG -AD - Departments of Medical Oncology. -FAU - Blank, C U -AU - Blank CU -AD - Departments of Medical Oncology. -FAU - Smit, E F -AU - Smit EF -AD - Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. -FAU - Beets-Tan, R G H -AU - Beets-Tan RGH -AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam; GROW School of - Oncology and Developmental Biology, Maastricht, The Netherlands. -FAU - Aerts, H J W L -AU - Aerts HJWL -AD - Department of Radiology, Netherlands Cancer Institute, Amsterdam; Departments of - Radiation Oncology; Radiology, Dana Farber Cancer Institute, Brigham and Women's - Hospital, Harvard Medical School, Boston, USA. Electronic address: - Hugo_Aerts@dfci.harvard.edu. -LA - eng -GR - U24 CA194354/CA/NCI NIH HHS/United States -GR - U01 CA190234/CA/NCI NIH HHS/United States -GR - CRUK_/Cancer Research UK/United Kingdom -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -PL - England -TA - Ann Oncol -JT - Annals of oncology : official journal of the European Society for Medical - Oncology -JID - 9007735 -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -CIN - Ann Oncol. 2019 Jun 1;30(6):879-881. doi: 10.1093/annonc/mdz150. PMID: 31124559 -CIN - Technol Cancer Res Treat. 2019 Jan 1;18:1533033819875766. doi: - 10.1177/1533033819875766. PMID: 31537168 -MH - Algorithms -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - *Artificial Intelligence -MH - Carcinoma, Non-Small-Cell Lung/*diagnostic imaging/*drug - therapy/immunology/pathology -MH - Follow-Up Studies -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/*diagnostic imaging/*drug therapy/immunology/pathology -MH - Machine Learning -MH - Melanoma/diagnostic imaging/*drug therapy/immunology/*pathology -MH - Predictive Value of Tests -MH - Prognosis -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology -MH - Survival Rate -MH - Tomography, X-Ray Computed/methods -PMC - PMC6594459 -OTO - NOTNLM -OT - artificial intelligence -OT - immunotherapy -OT - machine learning -OT - medical imaging -OT - radiomics -OT - response prediction -EDAT- 2019/03/22 06:00 -MHDA- 2020/08/07 06:00 -PMCR- 2019/03/21 -CRDT- 2019/03/22 06:00 -PHST- 2019/03/22 06:00 [pubmed] -PHST- 2020/08/07 06:00 [medline] -PHST- 2019/03/22 06:00 [entrez] -PHST- 2019/03/21 00:00 [pmc-release] -AID - S0923-7534(19)31202-5 [pii] -AID - mdz108 [pii] -AID - 10.1093/annonc/mdz108 [doi] -PST - ppublish -SO - Ann Oncol. 2019 Jun 1;30(6):998-1004. doi: 10.1093/annonc/mdz108. - -PMID- 31749060 -OWN - NLM -STAT- MEDLINE -DCOM- 20200422 -LR - 20200422 -IS - 1179-1950 (Electronic) -IS - 0012-6667 (Linking) -VI - 79 -IP - 18 -DP - 2019 Dec -TI - Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance - for Cure? -PG - 1937-1945 -LID - 10.1007/s40265-019-01222-w [doi] -AB - Immune checkpoint inhibition of programmed-death receptor 1 (PD-1) or its ligand - (PD-L1) has become a standard in the treatment of metastatic non-small cell lung - cancer, either as monotherapy or in combination. Recently, it could be shown that - immunotherapy works as consolidation after chemoradiotherapy in locally advanced - disease if the tumours express PD-L1. A significant and meaningful survival - benefit for consolidation with durvalumab after chemoradiotherapy compared to - chemoradiotherapy alone was observed in the PACIFIC trial. In addition, there is - a growing body of evidence that this treatment modality is also effective in a - neoadjuvant setting in early stages, whereas the role as adjuvant treatment after - surgery needs to be determined. The impact of combination therapies in - non-metastatic stages-either neoadjuvant or adjuvant-needs to be evaluated in - future trials. It is yet unclear whether PD-L1 and tumour mutational burden are - predictive biomarkers as randomised trials are missing. -FAU - Heigener, David F -AU - Heigener DF -AD - Department of Pulmonary Medicine, Helios Klinik Schleswig, Schleswig, Germany. -AD - University of Kiel, School of Medicine, Kiel, Germany. -FAU - Reck, Martin -AU - Reck M -AUID- ORCID: 0000-0002-5348-4462 -AD - Department of Oncology, LungenClinic Grosshansdorf, Woehrendamm 80, - Grosshansdorf, Germany. M.reck@lungenclinic.de. -AD - Airway Research Center North in the German Center for Lung Research (DZL), - Grosshansdorf, Germany. M.reck@lungenclinic.de. -LA - eng -PT - Journal Article -PT - Review -PL - New Zealand -TA - Drugs -JT - Drugs -JID - 7600076 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Immunologic Factors) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - B7-H1 Antigen/*antagonists & inhibitors/genetics/metabolism -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism -MH - Combined Modality Therapy -MH - Humans -MH - Immunologic Factors/*pharmacology -MH - *Immunotherapy -MH - Lung Neoplasms/*drug therapy/metabolism -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors/genetics/metabolism -EDAT- 2019/11/22 06:00 -MHDA- 2020/04/23 06:00 -CRDT- 2019/11/22 06:00 -PHST- 2019/11/22 06:00 [pubmed] -PHST- 2020/04/23 06:00 [medline] -PHST- 2019/11/22 06:00 [entrez] -AID - 10.1007/s40265-019-01222-w [pii] -AID - 10.1007/s40265-019-01222-w [doi] -PST - ppublish -SO - Drugs. 2019 Dec;79(18):1937-1945. doi: 10.1007/s40265-019-01222-w. - -PMID- 32768387 -OWN - NLM -STAT- MEDLINE -DCOM- 20211108 -LR - 20240801 -IS - 1932-7420 (Electronic) -IS - 1550-4131 (Print) -IS - 1550-4131 (Linking) -VI - 32 -IP - 3 -DP - 2020 Sep 1 -TI - Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of - Tumor-Reactive T Cells. -PG - 420-436.e12 -LID - S1550-4131(20)30366-1 [pii] -LID - 10.1016/j.cmet.2020.07.008 [doi] -AB - Dysregulated metabolism is a key driver of maladaptive tumor-reactive T - lymphocytes within the tumor microenvironment. Actionable targets that rescue the - effector activity of antitumor T cells remain elusive. Here, we report that the - Sirtuin-2 (Sirt2) NAD(+)-dependent deacetylase inhibits T cell metabolism and - impairs T cell effector functions. Remarkably, upregulation of Sirt2 in human - tumor-infiltrating lymphocytes (TILs) negatively correlates with response to TIL - therapy in advanced non-small-cell lung cancer. Mechanistically, Sirt2 suppresses - T cell metabolism by targeting key enzymes involved in glycolysis, tricarboxylic - acid-cycle, fatty acid oxidation, and glutaminolysis. Accordingly, - Sirt2-deficient murine T cells exhibit increased glycolysis and oxidative - phosphorylation, resulting in enhanced proliferation and effector functions and - subsequently exhibiting superior antitumor activity. Importantly, pharmacologic - inhibition of Sirt2 endows human TILs with these superior metabolic fitness and - effector functions. Our findings unveil Sirt2 as an unexpected actionable target - for reprogramming T cell metabolism to augment a broad spectrum of cancer - immunotherapies. -CI - Copyright © 2020 Elsevier Inc. All rights reserved. -FAU - Hamaidi, Imene -AU - Hamaidi I -AD - Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. -FAU - Zhang, Lin -AU - Zhang L -AD - Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. -FAU - Kim, Nayoung -AU - Kim N -AD - Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. -FAU - Wang, Min-Hsuan -AU - Wang MH -AD - Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. -FAU - Iclozan, Cristina -AU - Iclozan C -AD - Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. -FAU - Fang, Bin -AU - Fang B -AD - Proteomics and Metabolomics Core, H. Lee Moffitt Cancer Center, Tampa, FL 33612, - USA. -FAU - Liu, Min -AU - Liu M -AD - Proteomics and Metabolomics Core, H. Lee Moffitt Cancer Center, Tampa, FL 33612, - USA. -FAU - Koomen, John M -AU - Koomen JM -AD - Proteomics and Metabolomics Core, H. Lee Moffitt Cancer Center, Tampa, FL 33612, - USA; Department of Molecular Oncology, H. Lee Moffitt Cancer Center, Tampa, FL - 33612, USA. -FAU - Berglund, Anders E -AU - Berglund AE -AD - Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, - Tampa, FL 33612, USA. -FAU - Yoder, Sean J -AU - Yoder SJ -AD - Molecular Genomics Core, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. -FAU - Yao, Jiqiang -AU - Yao J -AD - Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, - Tampa, FL 33612, USA. -FAU - Engelman, Robert W -AU - Engelman RW -AD - Pediatrics, Pathology & Cell Biology, University of South of Florida, Tampa, FL - 33612, USA. -FAU - Creelan, Ben C -AU - Creelan BC -AD - Department of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, - USA. -FAU - Conejo-Garcia, Jose R -AU - Conejo-Garcia JR -AD - Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. -FAU - Antonia, Scott J -AU - Antonia SJ -AD - Department of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, - USA. -FAU - Mulé, James J -AU - Mulé JJ -AD - Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. -FAU - Kim, Sungjune -AU - Kim S -AD - Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA; - Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, - USA. Electronic address: sungjune.kim@moffitt.org. -LA - eng -GR - K08 CA194273/CA/NCI NIH HHS/United States -GR - R01 CA076379/CA/NCI NIH HHS/United States -GR - P30 CA076292/CA/NCI NIH HHS/United States -GR - R01 CA124515/CA/NCI NIH HHS/United States -GR - R01 CA157664/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20200807 -PL - United States -TA - Cell Metab -JT - Cell metabolism -JID - 101233170 -RN - 0 (Antineoplastic Agents) -RN - 0 (Enzyme Inhibitors) -RN - EC 3.5.1.- (SIRT2 protein, human) -RN - EC 3.5.1.- (Sirtuin 2) -SB - IM -MH - Animals -MH - Antineoplastic Agents/chemistry/*pharmacology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism -MH - Cells, Cultured -MH - Enzyme Inhibitors/chemistry/*pharmacology -MH - Humans -MH - Lung Neoplasms/*drug therapy/metabolism -MH - Mice -MH - Mice, Inbred C57BL -MH - Sirtuin 2/*antagonists & inhibitors/deficiency/metabolism -MH - T-Lymphocytes/*drug effects/metabolism -PMC - PMC7484212 -MID - NIHMS1615038 -OTO - NOTNLM -OT - FAO -OT - OxPhos -OT - Sirt2 -OT - T cells -OT - antitumor immunity -OT - deacetylase -OT - dysregulated metabolism -OT - glutaminolysis -OT - glycolysis -OT - metabolic checkpoint -COIS- Declaration of Interests The authors declare no competing interests. -EDAT- 2020/08/10 06:00 -MHDA- 2021/11/09 06:00 -PMCR- 2021/09/01 -CRDT- 2020/08/10 06:00 -PHST- 2019/11/22 00:00 [received] -PHST- 2020/05/21 00:00 [revised] -PHST- 2020/07/15 00:00 [accepted] -PHST- 2020/08/10 06:00 [pubmed] -PHST- 2021/11/09 06:00 [medline] -PHST- 2020/08/10 06:00 [entrez] -PHST- 2021/09/01 00:00 [pmc-release] -AID - S1550-4131(20)30366-1 [pii] -AID - 10.1016/j.cmet.2020.07.008 [doi] -PST - ppublish -SO - Cell Metab. 2020 Sep 1;32(3):420-436.e12. doi: 10.1016/j.cmet.2020.07.008. Epub - 2020 Aug 7. - -PMID- 38705930 -OWN - NLM -STAT- MEDLINE -DCOM- 20240505 -LR - 20240509 -IS - 2045-2322 (Electronic) -IS - 2045-2322 (Linking) -VI - 14 -IP - 1 -DP - 2024 May 5 -TI - Novel therapeutic strategies for rare mutations in non-small cell lung cancer. -PG - 10317 -LID - 10.1038/s41598-024-61087-2 [doi] -LID - 10317 -AB - Lung cancer is still the leading cause of cancer-related mortality. Over the past - two decades, the management of non-small cell lung cancer (NSCLC) has undergone a - significant revolution. Since the first identification of activating mutations in - the epidermal growth factor receptor (EGFR) gene in 2004, several genetic - aberrations, such as anaplastic lymphoma kinase rearrangements (ALK), - neurotrophic tropomyosin receptor kinase (NTRK) and hepatocyte growth factor - receptor (MET), have been found. With the development of gene sequencing - technology, the development of targeted drugs for rare mutations, such as - multikinase inhibitors, has provided new strategies for treating lung cancer - patients with rare mutations. Patients who harbor this type of oncologic driver - might acquire a greater survival benefit from the use of targeted therapy than - from the use of chemotherapy and immunotherapy. To date, more new agents and - regimens can achieve satisfactory results in patients with NSCLC. In this review, - we focus on recent advances and highlight the new approval of molecular targeted - therapy for NSCLC patients with rare oncologic drivers. -CI - © 2024. The Author(s). -FAU - Gou, Qitao -AU - Gou Q -AD - Department of Radiation Oncology and Department of Head & Neck Oncology, Cancer - Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Gou, Qiheng -AU - Gou Q -AD - Department of Radiation Oncology and Department of Head & Neck Oncology, Cancer - Center, West China Hospital, Sichuan University, Chengdu, China. - gouqiheng513@wchscu.cn. -FAU - Gan, Xiaochuan -AU - Gan X -AD - Department of Oncology, The First Affiliated Hospital of Chongqing Medical - University, Chongqing, China. -FAU - Xie, Yuxin -AU - Xie Y -AD - Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan - University, Chengdu, China. -LA - eng -GR - 2022SCUH0032/Sichuan University Education Foundation/ -GR - 2021MSXM318/Chongqing Science and Health Joint Medical Research Project/ -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20240505 -PL - England -TA - Sci Rep -JT - Scientific reports -JID - 101563288 -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 2.7.10.1 (Anaplastic Lymphoma Kinase) -RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-met) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - 0 (Antineoplastic Agents) -RN - EC 2.7.10.1 (ALK protein, human) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/genetics/drug therapy -MH - *Lung Neoplasms/genetics/drug therapy -MH - *Mutation -MH - *Molecular Targeted Therapy/methods -MH - Protein Kinase Inhibitors/therapeutic use -MH - ErbB Receptors/genetics/antagonists & inhibitors -MH - Anaplastic Lymphoma Kinase/genetics/antagonists & inhibitors -MH - Proto-Oncogene Proteins c-met/genetics -MH - Antineoplastic Agents/therapeutic use -PMC - PMC11070427 -OTO - NOTNLM -OT - Non-small cell lung cancer -OT - Oncologic driver -OT - Rare mutations -OT - Target therapy -COIS- The authors declare no competing interests. -EDAT- 2024/05/06 00:52 -MHDA- 2024/05/06 00:53 -PMCR- 2024/05/05 -CRDT- 2024/05/05 23:06 -PHST- 2023/12/27 00:00 [received] -PHST- 2024/04/30 00:00 [accepted] -PHST- 2024/05/06 00:53 [medline] -PHST- 2024/05/06 00:52 [pubmed] -PHST- 2024/05/05 23:06 [entrez] -PHST- 2024/05/05 00:00 [pmc-release] -AID - 10.1038/s41598-024-61087-2 [pii] -AID - 61087 [pii] -AID - 10.1038/s41598-024-61087-2 [doi] -PST - epublish -SO - Sci Rep. 2024 May 5;14(1):10317. doi: 10.1038/s41598-024-61087-2. - -PMID- 38637495 -OWN - NLM -STAT- MEDLINE -DCOM- 20240422 -LR - 20240426 -IS - 2059-3635 (Electronic) -IS - 2095-9907 (Print) -IS - 2059-3635 (Linking) -VI - 9 -IP - 1 -DP - 2024 Apr 19 -TI - The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground - glass opacity lesions: insights from a single-arm, phase II trial. -PG - 93 -LID - 10.1038/s41392-024-01799-z [doi] -LID - 93 -AB - Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) protein - significantly improve survival in patients with advanced non-small-cell lung - cancer (NSCLC), but its impact on early-stage ground-glass opacity (GGO) lesions - remains unclear. This is a single-arm, phase II trial (NCT04026841) using Simon's - optimal two-stage design, of which 4 doses of sintilimab (200 mg per 3 weeks) - were administrated in 36 enrolled multiple primary lung cancer (MPLC) patients - with persistent high-risk (Lung-RADS category 4 or had progressed within 6 - months) GGOs. The primary endpoint was objective response rate (ORR). T/B/NK-cell - subpopulations, TCR-seq, cytokines, exosomal RNA, and multiplexed - immunohistochemistry (mIHC) were monitored and compared between responders and - non-responders. Finally, two intent-to-treat (ITT) lesions (pure-GGO or - GGO-predominant) showed responses (ORR: 5.6%, 2/36), and no patients had - progressive disease (PD). No grade 3-5 TRAEs occurred. The total response rate - considering two ITT lesions and three non-intent-to-treat (NITT) lesions - (pure-solid or solid-predominant) was 13.9% (5/36). The proportion of CD8(+) T - cells, the ratio of CD8(+)/CD4(+), and the TCR clonality value were significantly - higher in the peripheral blood of responders before treatment and decreased over - time. Correspondingly, the mIHC analysis showed more CD8(+) T cells infiltrated - in responders. Besides, responders' cytokine concentrations of EGF and CTLA-4 - increased during treatment. The exosomal expression of fatty acid metabolism and - oxidative phosphorylation gene signatures were down-regulated among responders. - Collectively, PD-1 inhibitor showed certain activity on high-risk pulmonary GGO - lesions without safety concerns. Such effects were associated with specific - T-cell re-distribution, EGF/CTLA-4 cytokine compensation, and regulation of - metabolism pathways. -CI - © 2024. The Author(s). -FAU - Cheng, Bo -AU - Cheng B -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Li, Caichen -AU - Li C -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Li, Jianfu -AU - Li J -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Gong, Longlong -AU - Gong L -AUID- ORCID: 0000-0002-5844-6078 -AD - Medical Department, Genecast Biotechnology Co., Ltd, Wuxi, China. -FAU - Liang, Peng -AU - Liang P -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Chen, Ying -AU - Chen Y -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Zhan, Shuting -AU - Zhan S -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Xiong, Shan -AU - Xiong S -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Zhong, Ran -AU - Zhong R -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Liang, Hengrui -AU - Liang H -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Feng, Yi -AU - Feng Y -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Wang, Runchen -AU - Wang R -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Wang, Haixuan -AU - Wang H -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Zheng, Hongbo -AU - Zheng H -AD - Medical Department, Genecast Biotechnology Co., Ltd, Wuxi, China. -FAU - Liu, Jun -AU - Liu J -AUID- ORCID: 0000-0002-9001-9498 -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Zhou, Chengzhi -AU - Zhou C -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Shao, Wenlong -AU - Shao W -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Qiu, Yuan -AU - Qiu Y -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Sun, Jiancong -AU - Sun J -AD - Department of Radiation Oncology, the First Affiliated Hospital of Guangzhou - Medical University, Guangzhou, China. -FAU - Xie, Zhanhong -AU - Xie Z -AD - Department of Respiratory Medicine, the First Affiliated Hospital of Guangzhou - Medical University, Guangzhou Institute of Respiratory Health, State Key - Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - Liang, Zhu -AU - Liang Z -AD - Department of Cardiothoracic Surgery, Affiliated Hospital of Guangdong Medical - University, Zhanjiang, China. -FAU - Yang, Chenglin -AU - Yang C -AD - Department of Thoracic Surgery, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical - Sciences and Peking Union Medical College, Shenzhen, China. -FAU - Cai, Xiuyu -AU - Cai X -AD - Department of VIP Inpatient, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, China. -FAU - Su, Chunxia -AU - Su C -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, - Tongji University, Shanghai, China. -FAU - Wang, Wei -AU - Wang W -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. -FAU - He, Jianxing -AU - He J -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. drjianxing.he@gmail.com. -FAU - Liang, Wenhua -AU - Liang W -AD - Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of - Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State - Key Laboratory of Respiratory Disease, National Clinical Research Center for - Respiratory Disease, Guangzhou, China. liangwh1987@163.com. -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20240419 -PL - England -TA - Signal Transduct Target Ther -JT - Signal transduction and targeted therapy -JID - 101676423 -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 0 (CTLA-4 Antigen) -RN - 62229-50-9 (Epidermal Growth Factor) -RN - 0 (Receptors, Antigen, T-Cell) -RN - 0 (Cytokines) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - *Lung Neoplasms/drug therapy/genetics -MH - Programmed Cell Death 1 Receptor/genetics -MH - CTLA-4 Antigen/therapeutic use -MH - CD8-Positive T-Lymphocytes -MH - Epidermal Growth Factor -MH - Tomography, X-Ray Computed -MH - Lung/pathology -MH - Receptors, Antigen, T-Cell -MH - Cytokines -PMC - PMC11026465 -COIS- The authors declare no competing interests. -EDAT- 2024/04/19 00:44 -MHDA- 2024/04/22 06:42 -PMCR- 2024/04/19 -CRDT- 2024/04/18 23:23 -PHST- 2023/11/24 00:00 [received] -PHST- 2024/03/10 00:00 [accepted] -PHST- 2024/02/26 00:00 [revised] -PHST- 2024/04/22 06:42 [medline] -PHST- 2024/04/19 00:44 [pubmed] -PHST- 2024/04/18 23:23 [entrez] -PHST- 2024/04/19 00:00 [pmc-release] -AID - 10.1038/s41392-024-01799-z [pii] -AID - 1799 [pii] -AID - 10.1038/s41392-024-01799-z [doi] -PST - epublish -SO - Signal Transduct Target Ther. 2024 Apr 19;9(1):93. doi: - 10.1038/s41392-024-01799-z. - -PMID- 34429332 -OWN - NLM -STAT- MEDLINE -DCOM- 20220105 -LR - 20240814 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 9 -IP - 8 -DP - 2021 Aug -TI - Phase II study of durvalumab plus tremelimumab as therapy for patients with - previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer - (Lung-MAP substudy S1400F, NCT03373760). -LID - 10.1136/jitc-2021-002973 [doi] -LID - e002973 -AB - INTRODUCTION: S1400F is a non-match substudy of Lung Cancer Master Protocol - (Lung-MAP) evaluating the immunotherapy combination of durvalumab and - tremelimumab to overcome resistance to anti-programmed death ligand 1 (PD-(L)1) - therapy in patients with advanced squamous lung carcinoma (sq non-small-cell lung - cancer (NSCLC)). METHODS: Patients with previously treated sqNSCLC with disease - progression after anti-PD-(L)1 monotherapy, who did not qualify for any active - molecularly targeted Lung-MAP substudies, were eligible. Patients received - tremelimumab 75 mg plus durvalumab 1500 mg once every 28 days for four cycles - then durvalumab alone every 28 days until disease progression. The primary - endpoint was the objective response rate (RECIST V.1.1). Primary and acquired - resistance cohorts, defined as disease progression within 24 weeks versus ≥24 - weeks of starting prior anti-PD-(L)1 therapy, were analyzed separately and an - interim analysis for futility was planned after 20 patients in each cohort were - evaluable for response. RESULTS: A total of 58 eligible patients received drug, - 28 with primary resistance and 30 with acquired resistance to anti-PD-(L)1 - monotherapy. Grade ≥3 adverse events at least possibly related to treatment were - seen in 20 (34%) patients. The response rate in the primary resistance cohort was - 7% (95% CI 0% to 17%), with one complete and one partial response. No responses - were seen in the acquired resistance cohort. In the primary and resistance - cohorts the median progression-free survival was 2.0 months (95% CI 1.6 to 3.0) - and 2.1 months (95% CI 1.6 to 3.2), respectively, and overall survival was 7.7 - months (95% CI 4.0 to 12.0) and 7.6 months (95% CI 5.3 to 10.2), respectively. - CONCLUSION: Durvalumab plus tremelimumab had minimal activity in patients with - advanced sqNSCLC progressing on prior anti-PD-1 therapy.Trial registration - numberNCT03373760. -CI - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Leighl, Natasha B -AU - Leighl NB -AUID- ORCID: 0000-0002-3249-4602 -AD - Division of Medical Oncology/Hematology, Princess Margaret Hospital Cancer - Centre, Toronto, Ontario, Canada natasha.leighl@uhn.ca. -FAU - Redman, Mary W -AU - Redman MW -AD - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, - Washington, USA. -FAU - Rizvi, Naiyer -AU - Rizvi N -AD - Thoracic Oncology, Columbia University Irving Medical Center, New York, New York, - USA. -FAU - Hirsch, Fred R -AU - Hirsch FR -AD - Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine - Mount Sinai, New York, New York, USA. -FAU - Mack, Philip C -AU - Mack PC -AD - Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine - Mount Sinai, New York, New York, USA. -FAU - Schwartz, Lawrence H -AU - Schwartz LH -AD - Department of Radiology, NewYork-Presbyterian/Columbia University Medical Center, - New York, New York, USA. -FAU - Wade, James L -AU - Wade JL -AD - Medical Oncology, Heartland NCORP, Decatur, Illinois, USA. -FAU - Irvin, William J -AU - Irvin WJ -AD - Hematology Oncology, Bon Secours Cancer Institute, Richmond, Virginia, USA. -FAU - Reddy, Sreekanth C -AU - Reddy SC -AD - Medical Oncology/Hematology, Atlanta Cancer Care Centers, Atlanta, Georgia, USA. -FAU - Crawford, Jeffrey -AU - Crawford J -AD - Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA. -FAU - Bradley, Jeffrey D -AU - Bradley JD -AD - Department of Radiation Oncology, Washington University in St Louis School of - Medicine, St Louis, Missouri, USA. -FAU - Stinchcombe, Thomas E -AU - Stinchcombe TE -AD - Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA. -FAU - Ramalingam, Suresh S -AU - Ramalingam SS -AD - Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory - University, Atlanta, Georgia, USA. -FAU - Miao, Jieling -AU - Miao J -AD - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, - Washington, USA. -FAU - Minichiello, Katherine -AU - Minichiello K -AD - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, - Washington, USA. -FAU - Herbst, Roy S -AU - Herbst RS -AD - Medical Oncology, Yale Cancer Center | Yale School of Medicine | Smilow Cancer - Hospital at Yale New Haven, New Haven, Connecticut, USA. -FAU - Papadimitrakopoulou, Vassiliki A -AU - Papadimitrakopoulou VA -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, Texas, USA. -FAU - Kelly, Karen -AU - Kelly K -AUID- ORCID: 0000-0002-2235-6636 -AD - Divison of Hematology and Oncology, Department of Medicine, University of - California Davis Comprehensive Cancer Center, Sacramento, California, USA. -FAU - Gandara, David R -AU - Gandara DR -AUID- ORCID: 0000-0003-1784-048X -AD - Division of Hematology/Oncology, Department of Medicine, UC Davis Comprehensive - Cancer Center, Sacramento, California, USA. -LA - eng -SI - ClinicalTrials.gov/NCT03373760 -GR - U10 CA180868/CA/NCI NIH HHS/United States -GR - P30 CA093373/CA/NCI NIH HHS/United States -GR - UL1 TR001863/TR/NCATS NIH HHS/United States -GR - U10 CA180821/CA/NCI NIH HHS/United States -GR - U10 CA180863/CA/NCI NIH HHS/United States -GR - U10 CA180820/CA/NCI NIH HHS/United States -GR - U10 CA180888/CA/NCI NIH HHS/United States -GR - U10 CA180819/CA/NCI NIH HHS/United States -GR - UG1 CA233340/CA/NCI NIH HHS/United States -GR - P30 CA014236/CA/NCI NIH HHS/United States -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Multicenter Study -PT - Research Support, N.I.H., Extramural -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 28X28X9OKV (durvalumab) -RN - QEN1X95CIX (tremelimumab) -SB - IM -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal/administration & dosage -MH - Antibodies, Monoclonal, Humanized/administration & dosage -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Carcinoma, Squamous Cell/*drug therapy -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/administration & dosage -MH - Immunotherapy/*methods -MH - Lung Neoplasms/*drug therapy -MH - Male -MH - Middle Aged -MH - Neoplasm Staging -PMC - PMC8386207 -OTO - NOTNLM -OT - CTLA-4 antigen -OT - combination -OT - drug therapy -OT - immunotherapy -OT - lung neoplasms -COIS- Competing interests: The authors’ financial disclosures include: NBL received - travel support and institutional research funding from Astra Zeneca and personal - fees (CME lectures) from MSD and BMS, unrelated to the study. MR salary support - from Hope Foundation, participation on DMSB for AstraZeneca, unrelated to study. - NR received personal fees from Abbvie, Apricity, AstraZeneca, Boehringer - Ingelheim, Calithera, Dracen, Editas, Eli Lilly, EMD Serono, G1 Therapeutics, - Genentech, Gilead, GlaxoSmith Kline, Illumina, Merck, Neogenomics, Novartis and - Takeda, and personal fees and stock options from Arcus, Belicum, Brooklyn - ImmunoTherapeutics, and Gritstone; royalties for patent filed by MSKCC - identifying determinants of cancer response to immunotherapy (PCT/US2015/062208 - licensed to Personal Genome Diagnostics; PM reports personal fees from Guardant - Health. LHS research support from Merck, Bristol-Myers-Squibb, and Boehringer, - participating in DSMB for Regeneron, patent with Varian. SCR fees for expert - testimony. JC reports consulting fees from Amgen, AstraZeneca, Coherus, Merck, - NCCN, Pfizer and travel support from AstraZeneca, GI Therapeutics, participating - on DSMB or Ad Board for Beyond Spring, Celegene, G1 Therapeutics, Janssen, - Merrimack, Mylan, Roche. JDB is principal investigator of AstraZeneca sponsored - trial (PACIFIC 2), research support and consulting fees from Varian. TS - institutional grants from Genentech/Roche, Blueprint Medicines, AstraZeneca, - Takeda, Advaxis, Regeneron, participation on DSMB or ad board for Takeda, - AstraZeneca, Genentech/Roche, Foundation Medicine, Pfizer, EMD Serono, Novartis, - Daiichi Sankyo, Lilly, Puma Biotechnology, Janssen Oncology, Regeneron. SR grants - from Tesaro, Merck, AstraZeneca, Advaxis, BMS, Amgen, Takeda, Genmab, GSK, - consult fees from Amgen, BMS, Genentech/Roche, Merck, AstraZeneca, Takeda, Eisai, - Daiichi Sankyo, Sanofi, GSK, Lilly. RSH reports membership in board of directors - for Immunocore Holdings Ltd, Junshi Pharmaceuticals, consulting including travel - support from AstraZeneca, Genentech/Roche, Merck, Ventana Medical Systems, Inc., - consulting with ARMO Biosciences, Bayer Healthcare Pharmaceuticals, Bolt - Biotherapeutics, Bristol-Myers Squibb, Candel Therapeutics, Cybrexa Therapeutics, - eFFECTOR Therapeutics, Eli Lilly and Company, EMD Serono, Foundation Medicine, - Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, - Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Mirati Therapeutics, Nektar, - Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Oncternal Therapeutics, - Pfizer, Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum - Pharmaceuticals, STCube Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen, - Ventana Medical Systems, WindMIL Therapeutics, Xencor. Research support from - AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck. VP research funding - from AstraZeneca, BMS, Eli Lilly, Novartis, Merck, F. Hoffman-La Roche, Nektar - Therapeutics, Janssen, Bristol-Myers-Squibb, Checkmate, Incyte, consulting fees - from AbbVie, Araxes, Arrys Therapeutics, Bolt Therapeutics, Clovis Oncology, - Exelixis, G2 Innovation, Gritstone, Ideaya, Leeds Biolabs, Loxo Oncology, Takeda, - Tesaro, TRM Oncology, AstraZeneca, BMS, Eli Lilly, Novartis, Merck, F. Hoffman-La - Roche, Nektar Therapeutics, Janssen, Bristol-Myers-Squibb, personal fees from F. - Hoffman-La Roche, employee of Pfizer. KK travel and consultant fees from - AstraZeneca.DRG consultant and participation on advisory boards for AstraZeneca - (institutional), Roche-Genentech (institutional), Guardant Health - (institutional), IO Biotech (institutional) and Oncocyte (institutional) fees - paid to institution, research funding from Amgen, AstraZeneca, Genentech and - Merck, personal fees from Inivata, Lilly, Merck and Novartis.The following - investigators have no financial disclosures to report: FH, JW, WjI, KM, JM. -EDAT- 2021/08/26 06:00 -MHDA- 2022/01/06 06:00 -PMCR- 2021/08/24 -CRDT- 2021/08/25 05:45 -PHST- 2021/07/19 00:00 [accepted] -PHST- 2021/08/25 05:45 [entrez] -PHST- 2021/08/26 06:00 [pubmed] -PHST- 2022/01/06 06:00 [medline] -PHST- 2021/08/24 00:00 [pmc-release] -AID - jitc-2021-002973 [pii] -AID - 10.1136/jitc-2021-002973 [doi] -PST - ppublish -SO - J Immunother Cancer. 2021 Aug;9(8):e002973. doi: 10.1136/jitc-2021-002973. - -PMID- 37031653 -OWN - NLM -STAT- MEDLINE -DCOM- 20230828 -LR - 20230828 -IS - 1773-0449 (Electronic) -IS - 1156-5233 (Linking) -VI - 33 -IP - 3 -DP - 2023 Aug -TI - Instillation of Amphotericin B by bronchoscopy combined with systemic - voriconazole in advanced non-small cell lung cancer patients with chronic - cavitary pulmonary aspergillosis: A case series and literature review. -PG - 101385 -LID - S1156-5233(23)00029-X [pii] -LID - 10.1016/j.mycmed.2023.101385 [doi] -AB - Although the treatment of aspergillosis has been studied for years, the optimal - nonsurgical treatment of chronic cavitary pulmonary aspergillosis (CCPA) remains - unsatisfactory, especially in lung cancer. We report two advanced non-small cell - lung cancer (NSCLC) patients who recovered from CCPA following instillation of - Amphotericin B (AmB) by bronchoscopy combined with systemic voriconazole. The - first patient was diagnosed with lung adenocarcinoma after right upper lobe - resection and was treated with anaplastic lymphoma kinase-targeted therapy. Chest - computed tomography (CT) revealed a right pulmonary cavity containing solid - materials. The second patient was diagnosed with squamous cell carcinoma and - received immunotherapy following surgery, chemotherapy, and radiotherapy. Chest - CT tomography revealed a mass in the right lung cavity. Both patients' cultures - and next-generation sequencing of their bronchoalveolar lavage (BAL) samples - revealed presence of Aspergillus fumigatus. In addition, the galactomannan test - of both patients BAL samples was positive. Systemic voriconazole was prescribed - based on in vitro susceptibility testing. The chest images and clinical symptoms - of both patients did not improve after one month of voriconazole therapy within - the therapeutic blood concentration. Considering the low local concentrations of - antifungals against CCPA, AmB instillation by bronchoscopy combined with systemic - voriconazole was utilized. The chest CT images and clinical symptoms of both - patients markedly improved in the following third month. Instillation of AmB - combined with systemic voriconazole may be a promising treatment option for NSCLC - patients with CCPA who fail voriconazole monotherapy. -CI - Copyright © 2023. Published by Elsevier Masson SAS. -FAU - Wu, Hongxia -AU - Wu H -AD - Department of Respiratory and Critical Care Medicine, West China Hospital, - Sichuan University, Chengdu, China. -FAU - Xiong, Xiaofeng -AU - Xiong X -AD - Department of Respiratory and Critical Care Medicine, West China Hospital, - Sichuan University, Chengdu, China. -FAU - Han, Qingbing -AU - Han Q -AD - Department of Respiratory and Critical Care Medicine, West China Hospital, - Sichuan University, Chengdu, China. -FAU - Zhuo, Kaiquan -AU - Zhuo K -AD - Department of Neurosurgery, Suining Municipal Hospital of TCM, Suining, China. -FAU - Wang, Ke -AU - Wang K -AD - Department of Respiratory and Critical Care Medicine, West China Hospital, - Sichuan University, Chengdu, China. Electronic address: 442620720@qq.com. -FAU - Cheng, Deyun -AU - Cheng D -AD - Department of Respiratory and Critical Care Medicine, West China Hospital, - Sichuan University, Chengdu, China. Electronic address: zhuokq2014@163.com. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230405 -PL - France -TA - J Mycol Med -JT - Journal de mycologie medicale -JID - 9425651 -RN - JFU09I87TR (Voriconazole) -RN - 7XU7A7DROE (Amphotericin B) -RN - 0 (Antifungal Agents) -SB - IM -MH - Humans -MH - Voriconazole/therapeutic use -MH - Amphotericin B/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/complications/drug therapy -MH - Bronchoscopy -MH - *Lung Neoplasms/complications -MH - Antifungal Agents/therapeutic use -MH - *Pulmonary Aspergillosis/diagnosis/drug therapy -OTO - NOTNLM -OT - Amphotericin -OT - Aspergillosis -OT - Aspergillus -OT - Azoles -OT - Fungi -OT - Non-small cell lung cancer -COIS- Declaration of Competing Interest The authors have no conflict of interest. -EDAT- 2023/04/10 06:00 -MHDA- 2023/08/28 06:42 -CRDT- 2023/04/09 18:08 -PHST- 2022/04/20 00:00 [received] -PHST- 2023/03/04 00:00 [revised] -PHST- 2023/04/01 00:00 [accepted] -PHST- 2023/08/28 06:42 [medline] -PHST- 2023/04/10 06:00 [pubmed] -PHST- 2023/04/09 18:08 [entrez] -AID - S1156-5233(23)00029-X [pii] -AID - 10.1016/j.mycmed.2023.101385 [doi] -PST - ppublish -SO - J Mycol Med. 2023 Aug;33(3):101385. doi: 10.1016/j.mycmed.2023.101385. Epub 2023 - Apr 5. - -PMID- 34144405 -OWN - NLM -STAT- MEDLINE -DCOM- 20210803 -LR - 20210803 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 158 -DP - 2021 Aug -TI - Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 - - Systematic review and meta-analysis. -PG - 97-106 -LID - S0169-5002(21)00431-1 [pii] -LID - 10.1016/j.lungcan.2021.06.004 [doi] -AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) are standard of care in advanced - non-small cell lung cancer (NSCLC), however their status in patients with poor - performance status (PS) is poorly defined. We aimed to evaluate the efficacy and - safety of ICIs in NSCLC patients with PS ≥ 2. METHODS: We conducted a systematic - review and meta-analysis of interventional and observational studies, which - reported efficacy and safety data on ICIs in PS ≥ 2 comparing to PS ≤ 1 NSCLC - patients. Efficacy endpoints included: Objective Response Rate (ORR), - Disease-Control Rate (DCR), Overall Survival (OS), Progression-Free Survival - (PFS). Safety endpoint was the incidence of severe (grade≥3) Adverse Events (AE). - Random-effects model was applied for meta-analysis. Heterogeneity was assessed - using I(2). The review is registered on PROSPERO (CRD42020162668). FINDINGS: - Sixty-seven studies (n = 26,442 patients) were included. In PS ≥ 2 vs. PS ≤ 1 - patients, the pooled odds ratios were: for ORR 0.46 (95 %CI: 0.39-0.54, I(2):0 - %); for DCR 0.39 (95 %CI: 0.33-0.48, I(2):50 %) and for AEs 1.12 (95 %CI: - 0.84-1.48, I(2):39 %). The pooled hazard ratio for PFS was 2.17 (95 %CI: - 1.96-2.39, I(2):65 %) and for OS was 2.76 (95 %CI: 2.43-3.14, I(2):76 %). The - safety profile was comparable regardless of the PS status. INTERPRETATION: - Patients with impaired PS status are, on average, twice less likely to achieve a - response when exposed to ICIs when compared with representative PS ≤ 1 - population. For lung cancer patients treated with ICIs, the impaired PS is not - only prognostic, but also predictive for response, while the safety profile is - not affected. Prospective randomized studies are indispensable to determine - whether poor PS patients derive benefit from ICIs. -CI - Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved. -FAU - Tomasik, Bartłomiej -AU - Tomasik B -AD - Department of Biostatistics and Translational Medicine, Medical University of - Łódź, 15 Mazowiecka Street, 92-215 Łódź, Poland; Department of Radiation - Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, - USA. -FAU - Bieńkowski, Michał -AU - Bieńkowski M -AD - Department of Pathomorphology, Medical University of Gdańsk, 17 Smoluchowskiego - Street, 80-214 Gdańsk, Poland. -FAU - Braun, Marcin -AU - Braun M -AD - Department of Pathology, Chair of Oncology, Medical University of Łódź, Pomorska - 251 Street, 92-213 Łódź, Poland. -FAU - Popat, Sanjay -AU - Popat S -AD - Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK; The Institute of Cancer - Research, 123 Old Brompton Road, London SW7 3RP, UK; National Hearth and Lung - Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK. -FAU - Dziadziuszko, Rafał -AU - Dziadziuszko R -AD - Department of Oncology and Radiotherapy, Medical University of Gdańsk, 7 Debinki - Street, 80-211 Gdańsk, Poland. Electronic address: rafald@gumed.edu.pl. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Research Support, Non-U.S. Gov't -PT - Systematic Review -DEP - 20210606 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -MH - Progression-Free Survival -MH - Prospective Studies -OTO - NOTNLM -OT - Effectiveness and safety -OT - Immunotherapy -OT - Meta-analysis -OT - Non-small cell lung cancer -OT - Performance status -EDAT- 2021/06/19 06:00 -MHDA- 2021/08/04 06:00 -CRDT- 2021/06/18 20:24 -PHST- 2021/03/28 00:00 [received] -PHST- 2021/05/08 00:00 [revised] -PHST- 2021/06/03 00:00 [accepted] -PHST- 2021/06/19 06:00 [pubmed] -PHST- 2021/08/04 06:00 [medline] -PHST- 2021/06/18 20:24 [entrez] -AID - S0169-5002(21)00431-1 [pii] -AID - 10.1016/j.lungcan.2021.06.004 [doi] -PST - ppublish -SO - Lung Cancer. 2021 Aug;158:97-106. doi: 10.1016/j.lungcan.2021.06.004. Epub 2021 - Jun 6. - -PMID- 24441502 -OWN - NLM -STAT- MEDLINE -DCOM- 20140929 -LR - 20140206 -IS - 1531-703X (Electronic) -IS - 1040-8746 (Linking) -VI - 26 -IP - 2 -DP - 2014 Mar -TI - Vaccination therapy for non-small-cell lung cancer. -PG - 165-70 -LID - 10.1097/CCO.0000000000000052 [doi] -AB - PURPOSE OF REVIEW: Recent advances in our understanding of cancer immunology - resulted in the development of promising therapeutic agents for either - nonantigen-specific immunotherapy, for example, monoclonal antibodies targeting - immune checkpoints on the T-cell lymphocyte, and antigen-specific immunotherapy - or vaccination. Here, we review the recently reported results from randomized - controlled trials (RCTs) with the latter approach. RECENT FINDINGS: Several - trials indicated feasibility, safety, and potential for better patient outcomes. - In resected early stage non-small-cell lung cancer, a phase II RCT with the - MAGE-A3 vaccine showed a trend for improved disease-free interval (hazard ratio - 0.75), now further evaluated in the large MAGRIT (MAGE-A3 as Adjuvant NSCLC - Immunotherapy Trial) study. In stage III after chemoradiotherapy, the phase III - START (Stimulating Targeted Antigenic Responses to NSCLC) trial with L-BLP25 - vaccine resulted in a remarkable 10-month improvement in median survival in the - concurrent chemoradiotherapy subgroup. In the advanced setting, the phase III - study with the allogeneic tumor cell vaccine belagenpumatucel-L did not improve - survival in the whole study, but interesting effects were seen in subgroups. - SUMMARY: Recent non-small-cell lung cancer vaccination trials did not meet their - primary endpoint, but showed clear patient benefits in subgroup analyses. - Confirmatory trials and identifying patients who will benefit using predictive - factors, will hopefully bring these approaches in the clinic in the near future. -FAU - Cuppens, Kristof -AU - Cuppens K -AD - Respiratory Oncology Unit (Department of Pulmonology) and Leuven Lung Cancer - Group, University Hospital KU Leuven, Leuven, Belgium. -FAU - Vansteenkiste, Johan -AU - Vansteenkiste J -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - Curr Opin Oncol -JT - Current opinion in oncology -JID - 9007265 -RN - 0 (Cancer Vaccines) -SB - IM -MH - Cancer Vaccines/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Humans -MH - Lung Neoplasms/*drug therapy -MH - Randomized Controlled Trials as Topic -MH - Survival Analysis -MH - Treatment Outcome -MH - Vaccination/*methods -EDAT- 2014/01/21 06:00 -MHDA- 2014/09/30 06:00 -CRDT- 2014/01/21 06:00 -PHST- 2014/01/21 06:00 [entrez] -PHST- 2014/01/21 06:00 [pubmed] -PHST- 2014/09/30 06:00 [medline] -AID - 10.1097/CCO.0000000000000052 [doi] -PST - ppublish -SO - Curr Opin Oncol. 2014 Mar;26(2):165-70. doi: 10.1097/CCO.0000000000000052. - -PMID- 38307589 -OWN - NLM -STAT- MEDLINE -DCOM- 20240205 -LR - 20240206 -IS - 1791-7530 (Electronic) -IS - 0250-7005 (Linking) -VI - 44 -IP - 2 -DP - 2024 Feb -TI - Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution - Study. -PG - 605-612 -LID - 10.21873/anticanres.16849 [doi] -AB - BACKGROUND/AIM: The PACIFIC trial demonstrated improved survival in patients with - unresectable stage III non-small cell lung cancer (NSCLC) treated with durvalumab - following definitive concurrent chemoradiotherapy (CRT). This study sought to - explore real-world outcomes with durvalumab consolidation therapy at our - institution. PATIENTS AND METHODS: We retrospectively identified patients - diagnosed with stage III NSCLC at our institution from January 2012 to January - 2022. We created two cohorts: one who received durvalumab following definitive - CRT and a historical one who did not. Primary outcomes of interest included - median progression-free survival (PFS) and overall survival (OS). Additionally, - we performed subgroup analysis on the durvalumab cohort to explore the - associations between survival and time to durvalumab initiation, PD-L1 - expression, and neutrophil-to-lymphocyte ratio (NLR). RESULTS: We identified 79 - patients with locally advanced NSCLC who were not surgical candidates. Patients - treated with durvalumab (n=44) had significantly improved survival compared to - the historical cohort (n=35) including a median PFS of 17.4 months versus 8.0 - months (p=0.0019) and a median OS of 37.0 months versus 17.0 months (log-rank - p-value=0.07, Wilcoxon p-value=0.02). Within the durvalumab group, outcomes did - not significantly differ between those who initiated therapy before or after 42 - days of finishing CRT, between various PD-L1 expression levels, or between high - or low NLR. CONCLUSION: Patients who received durvalumab as consolidation therapy - following definitive CRT demonstrated significantly improved survival compared to - a historical cohort who did not receive durvalumab. Furthermore, durvalumab - appears to benefit patients regardless of time to initiation, PD-L1 expression, - or NLR. -CI - Copyright © 2024 International Institute of Anticancer Research (Dr. George J. - Delinasios), All rights reserved. -FAU - Trinh, Jonathan Q -AU - Trinh JQ -AD - Department of Internal Medicine, University of Nebraska Medical Center, Omaha, - NE, U.S.A.; jtrinh@unmc.edu. -FAU - Xiong, Ying -AU - Xiong Y -AD - Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, - U.S.A. -FAU - Smith, Lynette M -AU - Smith LM -AD - Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, - U.S.A. -FAU - Abughanimeh, Omar -AU - Abughanimeh O -AD - Department of Internal Medicine, University of Nebraska Medical Center, Omaha, - NE, U.S.A. -AD - Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, - Omaha, NE, U.S.A. -FAU - Marr, Alissa S -AU - Marr AS -AD - Department of Internal Medicine, University of Nebraska Medical Center, Omaha, - NE, U.S.A. -AD - Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, - Omaha, NE, U.S.A. -FAU - Ganti, Apar K -AU - Ganti AK -AD - Department of Internal Medicine, University of Nebraska Medical Center, Omaha, - NE, U.S.A. -AD - Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, - Omaha, NE, U.S.A. -AD - Department of Internal Medicine, VA Nebraska Western Iowa Health System, Omaha, - NE, U.S.A. -LA - eng -PT - Journal Article -PL - Greece -TA - Anticancer Res -JT - Anticancer research -JID - 8102988 -RN - 28X28X9OKV (durvalumab) -RN - 0 (B7-H1 Antigen) -RN - 0 (Antibodies, Monoclonal) -SB - IM -MH - Humans -MH - B7-H1 Antigen -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Retrospective Studies -MH - *Antibodies, Monoclonal -OTO - NOTNLM -OT - PD-L1 -OT - Stage III non-small cell lung cancer -OT - durvalumab -OT - immunotherapy -OT - neutrophil-to-lymphocyte ratio -EDAT- 2024/02/03 00:42 -MHDA- 2024/02/05 06:43 -CRDT- 2024/02/02 20:34 -PHST- 2023/12/22 00:00 [received] -PHST- 2024/01/08 00:00 [revised] -PHST- 2024/01/09 00:00 [accepted] -PHST- 2024/02/05 06:43 [medline] -PHST- 2024/02/03 00:42 [pubmed] -PHST- 2024/02/02 20:34 [entrez] -AID - 44/2/605 [pii] -AID - 10.21873/anticanres.16849 [doi] -PST - ppublish -SO - Anticancer Res. 2024 Feb;44(2):605-612. doi: 10.21873/anticanres.16849. - -PMID- 36427429 -OWN - NLM -STAT- MEDLINE -DCOM- 20221216 -LR - 20231213 -IS - 2468-2942 (Electronic) -IS - 2468-2942 (Linking) -VI - 33 -DP - 2022 -TI - Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy - in unresectable stage III EGFR-mutated non-small cell lung cancer. -PG - 100659 -LID - S2468-2942(22)00150-2 [pii] -LID - 10.1016/j.ctarc.2022.100659 [doi] -AB - INTRODUCTION: Increasing evidence suggests that consolidation durvalumab confers - limited benefits for patients with stage III EGFR-mutated NSCLC. Induction or - maintenance EGFR tyrosine kinase inhibitors (TKIs) added to concurrent - chemoradiotherapy (CRT) may optimize definitive treatment, but there are limited - data supporting an induction TKI strategy. METHODS: We evaluated the efficacy and - safety of induction EGFR TKIs administered before concurrent CRT in a - retrospective series of patients with unresectable locally advanced EGFR-mutated - NSCLC. Circulating tumor DNA (ctDNA) analysis was performed on a patient subset - using CAPP-seq and correlated with outcomes. RESULTS: Of six patients, three - received erlotinib and three osimertinib as induction therapy before CRT. - Induction TKIs were administered for a median of 2.5 months. The objective - response rate after induction TKI was 83%. One patient had a complete response to - induction erlotinib and continued erlotinib for 4 years until local progression, - which was treated with CRT. Two patients completed maintenance erlotinib after - CRT, and another received consolidation durvalumab. After a median follow-up of - 20.5 months, only one patient developed disease recurrence, with rising ctDNA - coinciding with recurrence. ctDNA remained undetectable in patients without - recurrence, or low-level in a patient receiving maintenance erlotinib. Adverse - events were mild and expected, and none developed pneumonitis. CONCLUSION: - Induction EGFR TKI before CRT may achieve high disease control rates with - promising signs of durability in patients with locally advanced EGFR-mutated - NSCLC. ctDNA analysis after CRT can correlate well with clinical outcomes. - Prospective studies are needed to define the role of induction EGFR TKIs in this - setting. -CI - Copyright © 2022. Published by Elsevier Ltd. -FAU - Aredo, Jacqueline V -AU - Aredo JV -AD - Department of Medicine, University of California, San Francisco, CA, 94143, USA; - Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford - University School of Medicine, Stanford, CA, 94305, USA. -FAU - Wakelee, Heather A -AU - Wakelee HA -AD - Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford - University School of Medicine, Stanford, CA, 94305, USA. -FAU - Hui, Angela Bik-Yu -AU - Hui AB -AD - Department of Radiation Oncology, Stanford Cancer Institute, Stanford University - School of Medicine, Stanford, CA, 94305, USA. -FAU - Padda, Sukhmani K -AU - Padda SK -AD - Division of Oncology, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, - Los Angeles, CA, 90048, USA. -FAU - Joshi, Nitin D -AU - Joshi ND -AD - University Healthcare Alliance, Stanford Healthcare, Newark, CA, 94560, USA. -FAU - Guo, H Henry -AU - Guo HH -AD - Department of Radiology, Stanford University School of Medicine, Stanford, CA, - 94305, USA. -FAU - Chaudhuri, Aadel -AU - Chaudhuri A -AD - Department of Radiation Oncology, Washington University School of Medicine in St. - Louis, St. Louis, MO, 63110, USA. -FAU - Diehn, Maximilian -AU - Diehn M -AD - Department of Radiation Oncology, Stanford Cancer Institute, Stanford University - School of Medicine, Stanford, CA, 94305, USA. -FAU - Loo, Billy W Jr -AU - Loo BW Jr -AD - Department of Radiation Oncology, Stanford Cancer Institute, Stanford University - School of Medicine, Stanford, CA, 94305, USA. -FAU - Neal, Joel W -AU - Neal JW -AD - Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford - University School of Medicine, Stanford, CA, 94305, USA. Electronic address: - jwneal@stanford.edu. -LA - eng -PT - Journal Article -DEP - 20221117 -PL - England -TA - Cancer Treat Res Commun -JT - Cancer treatment and research communications -JID - 101694651 -RN - 0 (Tyrosine Kinase Inhibitors) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - 0 (Protein Kinase Inhibitors) -RN - DA87705X9K (Erlotinib Hydrochloride) -RN - EC 2.7.10.1 (EGFR protein, human) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Tyrosine Kinase Inhibitors -MH - *Lung Neoplasms/drug therapy/genetics -MH - ErbB Receptors/genetics -MH - Retrospective Studies -MH - Protein Kinase Inhibitors/adverse effects -MH - Neoplasm Recurrence, Local/drug therapy -MH - Erlotinib Hydrochloride/therapeutic use -OTO - NOTNLM -OT - Concurrent chemoradiotherapy -OT - EGFR mutation -OT - Erlotinib -OT - Induction EGFR TKI -OT - Osimertinib -COIS- Declaration of Competing Interest Dr. Aredo reports grants from the Conquer - Cancer Foundation of ASCO. Dr. Wakelee reports grants to institution from ACEA - Biosciences, Arrys Therapeutics, AztraZeneca/MedImmune, BMS, Celgene, Clovis - Oncology, Exelixis, Genentech/Roche, Gilead, Merck, Novartis, Pharmacyclics, - Seattle Genetics, Xcovery, Eli Lilly, Pfizer; honoraria from Novartis, - AstraZeneca; and is on the advisory boards of AstraZeneca, Xcovery, Janssen, - Daiichi Sankyo, Blueprint, Mirati, Helsinn, Merck (uncompensated), Takeda - (uncompensated), Genentech/Roche (uncompensated), Cellworks (uncompensated), all - outside the submitted work. Dr. Padda reports personal fees from Pfizer, G1 - Therapeutics, Blueprint Medicines, AstraZeneca, Abbvie, Janssen Pharmaceuticals; - grants to institution from Epicentrx, Bayer, Boehringer Ingelheim, Forty Seven - Inc., all outside the submitted work. Dr. Guo reports grants to institution from - Pliant Pharmaceuticals; consulting fees from Exact Sciences, BioMind.ai, Arterys, - MORE Health; stock from Exact Sciences, all outside the submitted work. Dr. Diehn - reports personal fees from Roche, AstraZeneca, Novartis, Genentech, BioNTech, - RefleXion, Gritstone Oncology; grants from Varian Medical Systems and - AstraZeneca; is on the advisory boards of AstraZeneca, Illumina, Gritstone - Oncology, Genentech; other leadership roles of CiberMed, Foresight Diagnostics; - non-financial support from Illumina, all outside the submitted work. In addition, - Dr. Diehn has a patent related to cancer biomarkers with royalties paid to Roche - and Foresight Diagnostics, outside the submitted work. Dr. Loo reports grants - from Varian Medical Systems and is a board member of TibaRay, all outside the - submitted work. Dr. Neal reports personal fees from Research to Practice, MLI - Peerview, Medscape, Biomedical Learning Institute, Prime Oncology, Rockpointe, - CME Matters, MJH Life Sciences, AstraZeneca, Jounce Therapeutics, Eli Lilly and - Company, Calithera Biosciences, Amgen, Iovance Biotherapeutics, Genentech/Roche, - Exelixis, Takeda Pharmaceuticals, UpToDate; grants from Genentech/Roche, - Exelixis, Takeda Pharmaceuticals, Merck, Novartis, Boehringer Ingelheim, Nektar - Therapeutics, Adaptimmune, GSK, AbbVie, all outside the submitted work. All - remaining authors have declared no conflicts of interest. -EDAT- 2022/11/26 06:00 -MHDA- 2022/12/15 06:00 -CRDT- 2022/11/25 18:21 -PHST- 2022/09/15 00:00 [received] -PHST- 2022/11/13 00:00 [revised] -PHST- 2022/11/14 00:00 [accepted] -PHST- 2022/11/26 06:00 [pubmed] -PHST- 2022/12/15 06:00 [medline] -PHST- 2022/11/25 18:21 [entrez] -AID - S2468-2942(22)00150-2 [pii] -AID - 10.1016/j.ctarc.2022.100659 [doi] -PST - ppublish -SO - Cancer Treat Res Commun. 2022;33:100659. doi: 10.1016/j.ctarc.2022.100659. Epub - 2022 Nov 17. - -PMID- 31283253 -OWN - NLM -STAT- MEDLINE -DCOM- 20200625 -LR - 20200625 -IS - 1543-8392 (Electronic) -IS - 1543-8384 (Linking) -VI - 16 -IP - 8 -DP - 2019 Aug 5 -TI - Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET - Imaging. -PG - 3469-3476 -LID - 10.1021/acs.molpharmaceut.9b00307 [doi] -AB - Accumulating evidence has suggested that the tumor microenvironment of - nonsmall-cell lung cancer (NSCLC) may be impacted by chemotherapy, radiotherapy, - or epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). - PD-L1 is an important biomarker in the tumor microenvironment that can predict - patient response to immunotherapies. Therefore, it is highly desirable to achieve - a real-time, noninvasive assessment of PD-L1 expression, which can provide - critical information for recruiting patients as well as monitoring therapeutic - efficacy. We herein studied the EGFR-TKI-induced effects on PD-L1 levels in NSCLC - tumor models using immuno-PET imaging with (89)Zr-Df-KN035, an imaging tracer - previously established by our group. A549 human NSCLC xenografts were established - in BALB/c nude mice and treated with different doses of an EGFR-TKI gefitinib. - PET imaging with (89)Zr-Df-KN035 was performed before and after the treatment to - evaluate PD-L1 expression, which was further verified by immunohistochemical - staining. Our results demonstrate that (89)Zr-Df-KN035 can specifically evaluate - PD-L1 levels in NSCLC tumor models. Compared to the untreated control, the high - dose of gefitinib inhibited tumor growth and lowered the tumor uptake of - (89)Zr-Df-KN035. In comparison, the low dose of gefitinib did not affect tumor - growth, although the extensive tumor necrosis also led to the lower uptake of - (89)Zr-Df-KN035. In conclusion, our results demonstrate that immuno-PET imaging - with (89)Zr-Df-KN035 is a promising tool to noninvasively monitor PD-L1 - expression in NSCLC treated with EGFR-TKIs and can be used to optimize treatment - plans for immunotherapy. -FAU - Li, Dan -AU - Li D -AD - Department of Nuclear Medicine , Tongji Hospital, Tongji Medical College, - Huazhong University of Science and Technology , Wuhan 430030 , China. -FAU - Zou, Sijuan -AU - Zou S -AD - Department of Nuclear Medicine , Tongji Hospital, Tongji Medical College, - Huazhong University of Science and Technology , Wuhan 430030 , China. -FAU - Cheng, Siyuan -AU - Cheng S -AD - Department of Nuclear Medicine , Tongji Hospital, Tongji Medical College, - Huazhong University of Science and Technology , Wuhan 430030 , China. -FAU - Song, Shuang -AU - Song S -AD - Department of Nuclear Medicine , Tongji Hospital, Tongji Medical College, - Huazhong University of Science and Technology , Wuhan 430030 , China. -FAU - Wang, Pilin -AU - Wang P -AD - Alphamab Co. Ltd. , Suzhou 215000 , China. -FAU - Zhu, Xiaohua -AU - Zhu X -AUID- ORCID: 0000-0003-0495-9510 -AD - Department of Nuclear Medicine , Tongji Hospital, Tongji Medical College, - Huazhong University of Science and Technology , Wuhan 430030 , China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20190708 -PL - United States -TA - Mol Pharm -JT - Molecular pharmaceutics -JID - 101197791 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Protein Kinase Inhibitors) -RN - 0 (Radioactive Tracers) -RN - 0 (Radioisotopes) -RN - C6V6S92N3C (Zirconium) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - NTM296JU95 (Zirconium-89) -RN - S65743JHBS (Gefitinib) -SB - IM -MH - A549 Cells -MH - Animals -MH - B7-H1 Antigen/*analysis/immunology/metabolism -MH - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/*drug therapy/pathology -MH - Dose-Response Relationship, Drug -MH - Down-Regulation/drug effects -MH - Drug Monitoring/*methods -MH - Drug Resistance, Neoplasm -MH - ErbB Receptors/antagonists & inhibitors -MH - Gefitinib/pharmacology/therapeutic use -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/diagnostic imaging/*drug therapy/pathology -MH - Mice -MH - Mice, Nude -MH - Molecular Imaging/methods -MH - Positron-Emission Tomography/methods -MH - Protein Kinase Inhibitors/*pharmacology/therapeutic use -MH - Radioactive Tracers -MH - Radioisotopes/administration & dosage -MH - Tumor Microenvironment/drug effects -MH - Xenograft Model Antitumor Assays -MH - Zirconium/administration & dosage -OTO - NOTNLM -OT - EGFR-TKIs -OT - NSCLC -OT - PD-L1 -OT - PET imaging -EDAT- 2019/07/10 06:00 -MHDA- 2020/06/26 06:00 -CRDT- 2019/07/09 06:00 -PHST- 2019/07/10 06:00 [pubmed] -PHST- 2020/06/26 06:00 [medline] -PHST- 2019/07/09 06:00 [entrez] -AID - 10.1021/acs.molpharmaceut.9b00307 [doi] -PST - ppublish -SO - Mol Pharm. 2019 Aug 5;16(8):3469-3476. doi: 10.1021/acs.molpharmaceut.9b00307. - Epub 2019 Jul 8. - -PMID- 35238161 -OWN - NLM -STAT- MEDLINE -DCOM- 20221121 -LR - 20221121 -IS - 1743-7563 (Electronic) -IS - 1743-7555 (Linking) -VI - 18 -IP - 6 -DP - 2022 Dec -TI - The systemic management of central nervous system metastases and leptomeningeal - disease from advanced lung, melanoma, and breast cancer with molecular drivers: - An Australian perspective. -PG - 515-525 -LID - 10.1111/ajco.13759 [doi] -AB - The advent of systemic therapies with high intracranial efficacy in recent years - is changing the therapeutic paradigm and renewing interest in the management of - central nervous system (CNS) and leptomeningeal metastases from solid organ - tumors. CNS metastases have traditionally heralded a dismal prognosis with median - survival of 3-10 months, and were primarily treated with local therapeutic - modalities, such as surgery or radiation therapy. Although these modalities still - have a role in the management of CNS disease, newer agents, such as small - molecule tyrosine kinase inhibitors and immune-checkpoint inhibitors, are now - paving the way as an alternative therapeutic option for those with - oligometastatic or low-volume intracranial disease, potentially eliminating or - delaying the need for local treatment modalities in this setting. Herein, we - summarize the systemic treatments with proven intracranial efficacy, currently - approved for use in Australia for advanced mutation-driven non-small cell lung - cancer, melanoma, and breast cancer, as well as novel agents in preclinical and - clinical trial development. -CI - © 2022 John Wiley & Sons Australia, Ltd. -FAU - Senko, Clare -AU - Senko C -AD - Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, - Melbourne, Victoria, Australia. -AD - La Trobe University School of Molecular Sciences, Melbourne, Victoria, Australia. -FAU - Gunjur, Ashray -AU - Gunjur A -AD - Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, - Melbourne, Victoria, Australia. -FAU - Balasubramanian, Adithya -AU - Balasubramanian A -AD - Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, - Melbourne, Victoria, Australia. -FAU - Gan, Hui K -AU - Gan HK -AD - Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, - Melbourne, Victoria, Australia. -AD - La Trobe University School of Cancer Medicine, Melbourne, Victoria, Australia. -AD - Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia. -FAU - Parakh, Sagun -AU - Parakh S -AUID- ORCID: 0000-0003-3891-2489 -AD - Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, - Melbourne, Victoria, Australia. -AD - La Trobe University School of Cancer Medicine, Melbourne, Victoria, Australia. -FAU - Cher, Lawrence -AU - Cher L -AD - Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, - Melbourne, Victoria, Australia. -LA - eng -PT - Journal Article -PT - Review -DEP - 20220303 -PL - Australia -TA - Asia Pac J Clin Oncol -JT - Asia-Pacific journal of clinical oncology -JID - 101241430 -SB - IM -MH - Humans -MH - Female -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Breast Neoplasms/drug therapy/genetics/pathology -MH - *Lung Neoplasms/drug therapy/genetics/pathology -MH - Australia -MH - *Central Nervous System Neoplasms/drug therapy -MH - *Melanoma/drug therapy/genetics/pathology -MH - *Meningeal Neoplasms/genetics/therapy -MH - *Neoplasms, Second Primary -MH - Lung/pathology -MH - Central Nervous System/pathology -OTO - NOTNLM -OT - CNS -OT - breast -OT - leptomeningeal -OT - lung -OT - melanoma -EDAT- 2022/03/04 06:00 -MHDA- 2022/11/22 06:00 -CRDT- 2022/03/03 05:40 -PHST- 2021/08/01 00:00 [received] -PHST- 2022/01/14 00:00 [accepted] -PHST- 2022/03/04 06:00 [pubmed] -PHST- 2022/11/22 06:00 [medline] -PHST- 2022/03/03 05:40 [entrez] -AID - 10.1111/ajco.13759 [doi] -PST - ppublish -SO - Asia Pac J Clin Oncol. 2022 Dec;18(6):515-525. doi: 10.1111/ajco.13759. Epub 2022 - Mar 3. - -PMID- 37723846 -OWN - NLM -STAT- MEDLINE -DCOM- 20231023 -LR - 20231213 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 12 -IP - 19 -DP - 2023 Oct -TI - The efficacy and safety of chemo-free therapy in epidermal growth factor receptor - tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A - single-arm, phase II study. -PG - 19438-19448 -LID - 10.1002/cam4.6545 [doi] -AB - OBJECTIVES: The purpose of this study was to explore the efficacy and safety of - toripalimab combined with anlotinib in patients with advanced non-small cell lung - cancer (NSCLC) who acquired resistance to epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs). MATERIALS AND METHODS: Patients who - developed resistance after using first- or second-generation EGFR-TKIs as their - first-line regimen without EGFR T790M mutation or had disease progression after - being treated with third-generation EGFR-TKIs as first- or second-line therapy - were enrolled. All patients received toripalimab (240 mg/day on Day 1, - intravenously) combined with anlotinib (12 mg/day, Days 1-14, orally) once every - 3 weeks. Treatment continued until disease progression, or if toxicity was - intolerable. The primary endpoint was the objective response rate (ORR) assessed - by the investigator. The secondary endpoint was the progression-free survival - (PFS). RESULTS: In total, 19 patients were enrolled between May 2020 and October - 2021.The ORR was 0%, and a median PFS was 2.1 months (95% CI 0.251-3.949). Grade - ≥3 treatment-related adverse events (AEs) occurred in 11% patients. Common - adverse events included hypothyroidism (12/19), fatigue (9/19), and hypertension - (8/19). Patients in stable disease (SD) group had lower abundance of EGFR - mutation allele frequency (AF) before enrollment than those in progressive - disease (PD) group (p = 0.031). Patients without detectable EGFR mutation (EGFR-) - had longer PFS compared to the ones with EGFR mutations (p = 0.059). Patients - with high levels of soluble programmed cell death ligand 1 (PD-L1) at baseline - also tended to have longer PFS (p = 0.160). CONCLUSION: Toripalimab combined with - anlotinib was tolerable in EGFR-TKI-resistant advanced NSCLC patients not - previously treated with chemotherapy. Patients without detectable EGFR mutation - and high soluble PD-L1 levels may benefit from this chemotherapy-free treatment. -CI - © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Zhang, Shuyang -AU - Zhang S -AD - Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, - China. -FAU - Yang, Lu -AU - Yang L -AUID- ORCID: 0000-0002-4286-9586 -AD - Department of Medical Oncology and Radiation Sickness, Peking University Third - Hospital, Beijing, China. -FAU - Yang, Yaning -AU - Yang Y -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, China. -FAU - Yang, Guangjian -AU - Yang G -AD - Department of Respiratory Medicine, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Xu, Haiyan -AU - Xu H -AD - Department of Comprehensive Oncology, National Cancer Center/National Clinical - Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences - and Peking Union Medical College, Beijing, China. -FAU - Niu, Xueliang -AU - Niu X -AD - Department of Medical Affairs, Shanghai Junshi Biosciences Co., Ltd., Shanghai, - China. -FAU - Wang, Yan -AU - Wang Y -AUID- ORCID: 0000-0002-1743-6383 -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, China. -LA - eng -SI - ChiCTR/ChiCTR1900028112 -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20230918 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (Tyrosine Kinase Inhibitors) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - 0 (B7-H1 Antigen) -RN - 0 (Protein Kinase Inhibitors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - *Lung Neoplasms/drug therapy/genetics -MH - Tyrosine Kinase Inhibitors -MH - ErbB Receptors/genetics -MH - B7-H1 Antigen/genetics -MH - Protein Kinase Inhibitors/adverse effects -MH - Mutation -MH - Disease Progression -PMC - PMC10587943 -OTO - NOTNLM -OT - EGFR gene mutation -OT - antiangiogenic agents -OT - chemo-free therapy -OT - immune checkpoint inhibitors -OT - non-small cell lung cancer -COIS- The authors declare no conflict of interest. -EDAT- 2023/09/19 06:42 -MHDA- 2023/10/23 01:18 -PMCR- 2023/09/18 -CRDT- 2023/09/19 01:23 -PHST- 2023/09/04 00:00 [revised] -PHST- 2023/04/28 00:00 [received] -PHST- 2023/09/05 00:00 [accepted] -PHST- 2023/10/23 01:18 [medline] -PHST- 2023/09/19 06:42 [pubmed] -PHST- 2023/09/19 01:23 [entrez] -PHST- 2023/09/18 00:00 [pmc-release] -AID - CAM46545 [pii] -AID - 10.1002/cam4.6545 [doi] -PST - ppublish -SO - Cancer Med. 2023 Oct;12(19):19438-19448. doi: 10.1002/cam4.6545. Epub 2023 Sep - 18. - -PMID- 38870979 -OWN - NLM -STAT- MEDLINE -DCOM- 20240801 -LR - 20240827 -IS - 2213-2619 (Electronic) -IS - 2213-2600 (Linking) -VI - 12 -IP - 8 -DP - 2024 Aug -TI - Garsorasib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in - China: an open-label, multicentre, single-arm, phase 2 trial. -PG - 589-598 -LID - S2213-2600(24)00110-3 [pii] -LID - 10.1016/S2213-2600(24)00110-3 [doi] -AB - BACKGROUND: Garsorasib (D-1553; InventisBio, Shangai, China), a potent KRAS(G12C) - inhibitor, has shown promising antitumour activity in patients with - KRAS(G12C)-mutated (ie, Gly12Cys) non-small-cell lung cancer (NSCLC) in a phase 1 - study. We report results from a phase 2 study conducted to evaluate the efficacy - and safety of garsorasib in patients with locally advanced or metastatic - KRAS(G12C)-mutated NSCLC. METHODS: This open-label, multicentre, single-arm, - phase 2 trial enrolled adult patients with KRAS(G12C)-mutated NSCLC who had - previously been treated with platinum-based chemotherapy and immune checkpoint - inhibitors from 43 hospitals in China. Participants received 600 mg garsorasib - orally twice per day. Tumour assessments were performed at baseline, at the end - of every two cycles (of 21 days) for the first eight cycles, and at the end of - every three cycles thereafter. The primary endpoint was objective response rate - (ORR) as assessed by an independent review committee (IRC) following the - guidelines in Response Evaluation Criteria in Solid Tumours, version 1.1. - Efficacy and safety were assessed in all patients who received at least one dose - of garsorasib. This trial is registered at ClinicalTrials.gov, NCT05383898, and - is active but no longer recruiting. FINDINGS: From June 17, 2022, to May 17, - 2023, of 225 patients screened for eligibility, 123 patients were enrolled and - treated with garsorasib. Of these 123 participants, the median age was 64 years - (IQR 59-68), 108 (88%) were male and 15 (12%) were female. At data cutoff (Nov - 17, 2023), the median follow-up duration was 7·9 months (IQR 6·3-10·4), and 82 - (67%) of 123 patients had discontinued treatment. The IRC-confirmed ORR was 50% - (61 of 123 patients; 95% CI 41-59). 117 (95%) of 123 patients reported - treatment-related adverse events, with 61 (50%) experiencing grade 3 or higher - events. The most common types of adverse events of grade 3 or higher associated - with garsorasib were hepatic and gastrointestinal events, including increased - liver enzymes, such as aspartate aminotransferase (21 [17%] of 123 participants), - alanine aminotransferase (19 [15%] of 123 participants), and - gamma-glutamyltransferase (28 [23%] of 123 participants); nausea (2 [2%] of 123 - participants); and vomiting (2 [2%] of 123 participants). No new safety signals - were identified, and most of the adverse events were well managed. - INTERPRETATION: The results show that garsorasib has a high response rate, long - duration of response, and an acceptable and manageable safety profile in patients - with previously treated KRAS(G12C)-mutated NSCLC. Garsorasib potentially provides - a promising treatment option for this patient population. FUNDING: InventisBio. -CI - Copyright © 2024 Published by Elsevier Ltd. All rights are reserved, including - those for text and data mining, AI training, and similar technologies. -FAU - Li, Ziming -AU - Li Z -AD - Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong - University School of Medicine, Shanghai, China. -FAU - Dang, Xiaomin -AU - Dang X -AD - Department of Respiratory Medicine, The First Affiliated Hospital of Xi'an - Jiaotong University, Xi'an, China. -FAU - Huang, Dingzhi -AU - Huang D -AD - Pulmonary Oncology Department, Tianjin Medical University Cancer Institute & - Hospital, Tianjin, China. -FAU - Jin, Shi -AU - Jin S -AD - Department of Oncology, Cancer Hospital and Shenzhen Hospital, Chinese Academy of - Medical Sciences and Peking Union Medical College, Shenzhen, China. -FAU - Li, Weiwei -AU - Li W -AD - The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China. -FAU - Shi, Jianhua -AU - Shi J -AD - Department of Medical Oncology II, Linyi Cancer Hospital, Linyi, China. -FAU - Wang, Xicheng -AU - Wang X -AD - Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical - University, Guangzhou, China. -FAU - Zhang, Yiping -AU - Zhang Y -AD - Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Cancer - Hospital of the University of Chinese Academy of Sciences, Hangzhou, China. -FAU - Song, Zhengbo -AU - Song Z -AD - Department of Clinical Trial, Zhejiang Cancer Hospital, Cancer Hospital of the - University of Chinese Academy of Sciences, Hangzhou, China. -FAU - Zhang, Junping -AU - Zhang J -AD - Shanxi Bethune Hospital, The Affiliated Bethune Hospital of Shanxi Medical - University, Taiyuan, China. -FAU - Zhuang, Wu -AU - Zhuang W -AD - Department of Thoracic Oncology, Fujian Provincial Cancer Hospital, Fuzhou, - China. -FAU - Liu, Xuewen -AU - Liu X -AD - Department of Oncology, The Third Xiangya Hospital of Central South University, - Changsha, China. -FAU - Jiang, Liyan -AU - Jiang L -AD - Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong - University School of Medicine, Shanghai, China. -FAU - Meng, Xiangjiao -AU - Meng X -AD - The Four Wards of Thoracic Radiotherapy, Shandong Cancer Hospital, Jinan, China. -FAU - Zhao, Mingfang -AU - Zhao M -AD - Oncology, Medical Ward 2, The First Hospital of China Medical University, - Shenyang, China. -FAU - Zhou, Jianying -AU - Zhou J -AD - Department of Respiratory Medicine, The First Affiliated Hospital of Zhejiang - University School of Medicine, Hangzhou, China. -FAU - Zhang, Liangming -AU - Zhang L -AD - Department of Medical Oncology I, Yantai Yuhuangding Hospital, Yantai, China. -FAU - Wang, Pingli -AU - Wang P -AD - Department of Respiratory Medicine, The Second Affiliated Hospital of Zhejiang - University School of Medicine, Hangzhou, China. -FAU - Luo, Hui -AU - Luo H -AD - Department of Thoracic Cancer Radiotherapy, Jiangxi Cancer Hospital, Nanchang, - China. -FAU - Yang, Junquan -AU - Yang J -AD - Department 1 of Chemoradiotherapy, Tangshan Cancer Hospital, Tangshan, China. -FAU - Cang, Shundong -AU - Cang S -AD - Department of Oncology, Henan Provincial People's Hospital, Zhengzhou, China. -FAU - Wang, Xiang -AU - Wang X -AD - Department of Oncology, Xuzhou Central Hospital, Xuzhou, China. -FAU - Zhang, Ling -AU - Zhang L -AD - InventisBio, Shanghai, China. -FAU - Lu, Shun -AU - Lu S -AD - Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong - University School of Medicine, Shanghai, China. Electronic address: - shunlu@sjtu.edu.cn. -CN - D1553–102 Study Group -LA - eng -SI - ClinicalTrials.gov/NCT05383898 -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Multicenter Study -DEP - 20240610 -PL - England -TA - Lancet Respir Med -JT - The Lancet. Respiratory medicine -JID - 101605555 -RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) -RN - 0 (KRAS protein, human) -RN - 0 (Antineoplastic Agents) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Male -MH - Female -MH - *Lung Neoplasms/drug therapy/genetics -MH - Middle Aged -MH - Aged -MH - *Proto-Oncogene Proteins p21(ras)/genetics -MH - China -MH - *Mutation -MH - Treatment Outcome -MH - Antineoplastic Agents/therapeutic use/adverse effects -COIS- Declaration of interests ZL has received speaker fees from AstraZeneca, Roche, - and Hansoh. SL has received research grants from AstraZeneca, Hutchison, BMS, - Heng Rui, and Roche; has received consulting fees from AstraZeneca, Boehringer - Ingelheim, Hutchison MediPharma, Simcere, ZaiLab, GenomiCare, and Roche; and has - received speaker fees from AstraZeneca, Roche, and Hansoh. LJ, JZ, and PW have - received research grants and speaker fees from InventisBio, and have served as - advisors and consultants for InventisBio. LinZ is employed by InventisBio and - report stocks in InventisBio. All other authors declare no competing interests. -FIR - Li, Ziming -IR - Li Z -FIR - Dang, Xiaomin -IR - Dang X -FIR - Huang, Dingzhi -IR - Huang D -FIR - Jin, Shi -IR - Jin S -FIR - Li, Weiwei -IR - Li W -FIR - Shi, Jianhua -IR - Shi J -FIR - Wang, Xicheng -IR - Wang X -FIR - Zhang, Yiping -IR - Zhang Y -FIR - Song, Zhengbo -IR - Song Z -FIR - Zhang, Junping -IR - Zhang J -FIR - Zhuang, Wu -IR - Zhuang W -FIR - Liu, Xuewen -IR - Liu X -FIR - Jiang, Liyan -IR - Jiang L -FIR - Meng, Xiangjiao -IR - Meng X -FIR - Zhao, Mingfang -IR - Zhao M -FIR - Zhou, Jianying -IR - Zhou J -FIR - Zhang, Liangming -IR - Zhang L -FIR - Wang, Pingli -IR - Wang P -FIR - Luo, Hui -IR - Luo H -FIR - Yang, Junquan -IR - Yang J -FIR - Cang, Shundong -IR - Cang S -FIR - Wang, Xiang -IR - Wang X -FIR - Wang, Jing -IR - Wang J -FIR - Cui, Jiuwei -IR - Cui J -FIR - Yu, Yan -IR - Yu Y -FIR - Zhang, Zhihong -IR - Zhang Z -FIR - Lu, Junguo -IR - Lu J -FIR - Yang, Weihua -IR - Yang W -FIR - Li, Gaofeng -IR - Li G -FIR - Feng, Jifeng -IR - Feng J -FIR - Lv, Dongqing -IR - Lv D -FIR - Wu, Lin -IR - Wu L -FIR - Fang, Yong -IR - Fang Y -FIR - Wang, Yan -IR - Wang Y -FIR - Zhao, Yanqiu -IR - Zhao Y -FIR - Cao, Baoshan -IR - Cao B -FIR - Zhu, Wei -IR - Zhu W -FIR - Zhuang, Zhixiang -IR - Zhuang Z -FIR - Li, Qingshan -IR - Li Q -FIR - Wang, Mingxi -IR - Wang M -FIR - Zhou, Huan -IR - Zhou H -FIR - Dong, Xiaorong -IR - Dong X -FIR - Hu, Sheng -IR - Hu S -FIR - Fang, Jian -IR - Fang J -FIR - Xu, Chun-Wei -IR - Xu CW -FIR - Zhang, Yihong -IR - Zhang Y -FIR - Wang, Wenjia -IR - Wang W -FIR - Xiang, Ziyong -IR - Xiang Z -FIR - Shi, Zhe -IR - Shi Z -FIR - Wang, Yaolin -IR - Wang Y -FIR - Zhang, Ling -IR - Zhang L -FIR - Lu, Shun -IR - Lu S -EDAT- 2024/06/14 00:42 -MHDA- 2024/08/02 00:46 -CRDT- 2024/06/13 18:52 -PHST- 2023/12/29 00:00 [received] -PHST- 2024/03/11 00:00 [revised] -PHST- 2024/03/20 00:00 [accepted] -PHST- 2024/08/02 00:46 [medline] -PHST- 2024/06/14 00:42 [pubmed] -PHST- 2024/06/13 18:52 [entrez] -AID - S2213-2600(24)00110-3 [pii] -AID - 10.1016/S2213-2600(24)00110-3 [doi] -PST - ppublish -SO - Lancet Respir Med. 2024 Aug;12(8):589-598. doi: 10.1016/S2213-2600(24)00110-3. - Epub 2024 Jun 10. - -PMID- 10970684 -OWN - NLM -STAT- MEDLINE -DCOM- 20001002 -LR - 20181113 -IS - 0007-0920 (Print) -IS - 1532-1827 (Electronic) -IS - 0007-0920 (Linking) -VI - 83 -IP - 7 -DP - 2000 Oct -TI - A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with - chemotherapy in patients with advanced inoperable non-small-cell lung cancer and - mesothelioma. -PG - 853-7 -AB - Mycobacterial preparations have been used with limited success against cancer - apart from superficial bladder cancer. Recently, a therapeutic vaccine derived - from Mycobacterium vaccae has been given to patients with prostate cancer and - melanoma indicating a possible beneficial effect on disease activity in such - patients. We have recently initiated a series of randomized studies to test the - feasibility and toxicity of combining a preparation of heat-killed Mycobacterium - vaccae (designated SRL172) with a multidrug chemotherapy regimen to treat - patients with inoperable non-small cell lung cancer (NSCLC) and mesothelioma. 28 - evaluable patients with previously untreated symptomatic NSCLC and mesothelioma - were randomized to receive either 3 weekly intravenous combination chemotherapy - alone, or chemotherapy given with monthly intra-dermal injections of SRL172. - Safety and tolerability were scored by common toxicity criteria and efficacy was - evaluated by survival of patients and by tumour response assessed by CT scanning. - The toxicity of chemotherapy was similar in the two groups. SRL172 caused mild - inflammation at the injection site. In the group of patients randomized to - receive chemotherapy combined with SRL172, there was a trend towards improved - response rate (54% vs. 33%) with more patients in the combined arm receiving - radical surgery and radiotherapy, improved median survival (9.7 months vs. 7.5 - months) and improved 1 year survival (42% vs. 18%). SRL172 appeared to improve - sleep (P = 0.08) and improved appetite (P = 0.01). There was no detectable change - in serum cytokine levels for gamma-interferon and TNF-alpha before and after - treatment. In patients with NSCLC and mesothelioma, there may be a beneficial - interaction when chemotherapy is administered in combination with SRL172. - Confirmation of this effect and further investigation is underway in a randomized - phase III trial and in laboratory models. -CI - Copyright 2000 Cancer Research Campaign. -FAU - O'Brien, M E -AU - O'Brien ME -AD - Royal Marsden Hospital NHS Trust, Sutton, Surrey, SM2 5PT, UK. -FAU - Saini, A -AU - Saini A -FAU - Smith, I E -AU - Smith IE -FAU - Webb, A -AU - Webb A -FAU - Gregory, K -AU - Gregory K -FAU - Mendes, R -AU - Mendes R -FAU - Ryan, C -AU - Ryan C -FAU - Priest, K -AU - Priest K -FAU - Bromelow, K V -AU - Bromelow KV -FAU - Palmer, R D -AU - Palmer RD -FAU - Tuckwell, N -AU - Tuckwell N -FAU - Kennard, D A -AU - Kennard DA -FAU - Souberbielle, B E -AU - Souberbielle BE -LA - eng -PT - Clinical Trial -PT - Clinical Trial, Phase II -PT - Comparative Study -PT - Journal Article -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -PL - England -TA - Br J Cancer -JT - British journal of cancer -JID - 0370635 -RN - 0 (Adjuvants, Immunologic) -RN - 0 (Bacterial Vaccines) -RN - 0 (Cancer Vaccines) -RN - 0 (Tumor Necrosis Factor-alpha) -RN - 0 (Vaccines, Inactivated) -RN - 130068-27-8 (Interleukin-10) -RN - 50SG953SK6 (Mitomycin) -RN - 5V9KLZ54CY (Vinblastine) -RN - 82115-62-6 (Interferon-gamma) -RN - Q20Q21Q62J (Cisplatin) -SB - IM -MH - Adjuvants, Immunologic/adverse effects/therapeutic use -MH - Adult -MH - Aged -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use -MH - Bacterial Vaccines/adverse effects/immunology/*therapeutic use -MH - Cancer Vaccines/adverse effects/immunology/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/immunology/*therapy -MH - Cisplatin/administration & dosage/adverse effects -MH - Combined Modality Therapy -MH - Female -MH - Humans -MH - Immunotherapy, Active -MH - Interferon-gamma/blood -MH - Interleukin-10/blood -MH - Lung Neoplasms/drug therapy/immunology/*therapy -MH - Male -MH - Mesothelioma/drug therapy/immunology/*therapy -MH - Middle Aged -MH - Mitomycin/administration & dosage/adverse effects -MH - Mycobacterium/*immunology -MH - Tumor Necrosis Factor-alpha/metabolism -MH - Vaccines, Inactivated/adverse effects/immunology/therapeutic use -MH - Vinblastine/administration & dosage/adverse effects -PMC - PMC2374669 -EDAT- 2000/09/06 11:00 -MHDA- 2000/10/07 11:01 -PMCR- 2001/09/04 -CRDT- 2000/09/06 11:00 -PHST- 2000/09/06 11:00 [pubmed] -PHST- 2000/10/07 11:01 [medline] -PHST- 2000/09/06 11:00 [entrez] -PHST- 2001/09/04 00:00 [pmc-release] -AID - S0007092000914010 [pii] -AID - 10.1054/bjoc.2000.1401 [doi] -PST - ppublish -SO - Br J Cancer. 2000 Oct;83(7):853-7. doi: 10.1054/bjoc.2000.1401. - -PMID- 37093348 -OWN - NLM -STAT- MEDLINE -DCOM- 20230731 -LR - 20230731 -IS - 1432-1335 (Electronic) -IS - 0171-5216 (Linking) -VI - 149 -IP - 11 -DP - 2023 Sep -TI - Mutant-allele dispersion correlates with prognosis risk in patients with advanced - non-small cell lung cancer. -PG - 8545-8555 -LID - 10.1007/s00432-023-04801-3 [doi] -AB - BACKGROUND: Intra-tumor heterogeneity (ITH) contributes to lung cancer - progression and resistance to therapy. To evaluate ITH and determine whether it - may be employed as a predictive biomarker of prognosis in patients with advanced - non-small cell lung cancer (NSCLC), we used a novel algorithm called - mutant-allele dispersion (MAD). METHODS: In the study, 103 patients with advanced - NSCLC were enrolled. Using a panel of 425 cancer-related genes, next-generation - sequencing (NGS) was performed on tumor specimens that had been collected. From - NGS data, we derived MAD values, and we next looked into their relationships with - clinical variables and different mutation subtypes. RESULTS: The median MAD among - 103 NSCLC patients was 0.73. EGFR mutation, tyrosine kinase inhibitor (TKI) - therapy, radiotherapy, and chemotherapy cycles were all substantially correlated - with the MAD score. In patients with lung adenocarcinoma (LUAD), correlation - analysis revealed that the MAD score was substantially linked with Notch pathway - mutation (P = 0.021). A significant relationship between high MAD and shorter - progression-free survival (PFS) was found (HR = 2.004, 95%CI 1.269-3.163, - P = 0.003). In patients with advanced NSCLC, histological type (P = 0.004), - SMARCA4 mutation (P = 0.038), and LRP1B mutation (P = 0.006) were all - independently associated with prognosis. The disease control rate was - considerably greater in the low MAD group compared to the high MAD group in 19 - LUAD patients receiving immunotherapy (92.9% vs. 40%, P = 0.037). TKI-PFS was - longer in 37 patients with low MAD who received first-line TKI therapy - (P = 0.014). CONCLUSION: Our findings suggested that MAD is a practical and - simple algorithm for assessing ITH, and populations with high MAD values are more - likely to have EGFR mutations. MAD can be used as a potential biomarker to - predict not only the prognosis of NSCLC but also the efficacy of immunotherapy - and TKI therapy in patients with advanced NSCLC. -CI - © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, - part of Springer Nature. -FAU - Wang, Chen-Xu -AU - Wang CX -AD - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, - Zhengzhou, 450052, Henan, China. -FAU - Yan, Jie -AU - Yan J -AD - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, - Zhengzhou, 450052, Henan, China. -FAU - Lin, Shan -AU - Lin S -AD - Department of Oncology, Zhongshan Hospital Affiliated to Xiamen University, - Xiamen, 361004, Fujian, China. -FAU - Ding, Yi -AU - Ding Y -AD - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, - Zhengzhou, 450052, Henan, China. -FAU - Qin, Yan-Ru -AU - Qin YR -AD - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, - Zhengzhou, 450052, Henan, China. yanruqin@163.com. -LA - eng -GR - 81872264/National Natural Science Foundation of China/ -PT - Journal Article -DEP - 20230424 -PL - Germany -TA - J Cancer Res Clin Oncol -JT - Journal of cancer research and clinical oncology -JID - 7902060 -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 3.6.1.- (SMARCA4 protein, human) -RN - EC 3.6.4.- (DNA Helicases) -RN - 0 (Nuclear Proteins) -RN - 0 (Transcription Factors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - *Lung Neoplasms/drug therapy/genetics -MH - Alleles -MH - Protein Kinase Inhibitors/pharmacology -MH - Prognosis -MH - *Adenocarcinoma of Lung/genetics -MH - Mutation -MH - ErbB Receptors/genetics -MH - DNA Helicases/genetics -MH - Nuclear Proteins/genetics -MH - Transcription Factors/genetics -OTO - NOTNLM -OT - EGFR -OT - Immunotherapy -OT - Intra-tumor heterogeneity -OT - Mutant-allele dispersion -OT - Non-small cell lung cancer -EDAT- 2023/04/24 12:42 -MHDA- 2023/07/31 06:42 -CRDT- 2023/04/24 11:17 -PHST- 2022/11/29 00:00 [received] -PHST- 2023/04/17 00:00 [accepted] -PHST- 2023/07/31 06:42 [medline] -PHST- 2023/04/24 12:42 [pubmed] -PHST- 2023/04/24 11:17 [entrez] -AID - 10.1007/s00432-023-04801-3 [pii] -AID - 10.1007/s00432-023-04801-3 [doi] -PST - ppublish -SO - J Cancer Res Clin Oncol. 2023 Sep;149(11):8545-8555. doi: - 10.1007/s00432-023-04801-3. Epub 2023 Apr 24. - -PMID- 37649021 -OWN - NLM -STAT- MEDLINE -DCOM- 20230901 -LR - 20231118 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 23 -IP - 1 -DP - 2023 Aug 30 -TI - Baseline serum tumor markers predict the survival of patients with advanced - non-small cell lung cancer receiving first-line immunotherapy: a multicenter - retrospective study. -PG - 812 -LID - 10.1186/s12885-023-11312-4 [doi] -LID - 812 -AB - BACKGROUND: This study aimed to investigate the association between baseline - serum tumor markers (STMs) (carcinoembryonic antigen [CEA], neuron-specific - enolase [NSE], cytokeratin-19 fragment [CYFRA21-1], carbohydrate antigen 19-9 - [CA19-9], and carbohydrate antigen 125 [CA125]) and the efficacy of first-line - immunotherapy in patients with advanced non-small cell lung cancer. METHODS: This - multicenter retrospective study evaluated patients who received first-line - immunotherapy between July 2017 and July 2022. The endpoints were - progression-free survival (PFS) and overall survival (OS), as defined by the - Response Evaluation Criteria in Solid Tumors version 1.1. We divided the patients - into three groups based on STM levels: Group A ≥ threefold upper limit of normal, - threefold upper limit of normal > Group B > upper limit of normal, and Group - C ≤ upper limit of normal. RESULTS: In total, 716 patients were included in this - study. In Cox proportional hazards analyses, the STM levels in Group C were - independently associated with superior PFS and OS in patients with lung - adenocarcinoma (LUAD). Except for CA19-9 level, the STM levels in Group C were - independently associated with superior PFS and OS in patients with lung squamous - carcinoma (LUSC). Except for CEA and CA19-9 levels, the levels in Group A were - independently associated with inferior PFS and OS in patients with LUAD and LUSC. - CONCLUSIONS: Serum CEA, NSE, CYFRA21-1, and CA125 levels can predict PFS and OS - in patients with LUAD and LUSC, and serum CA19-9 levels can predict PFS and OS in - patients with LUAD. The higher the serum NSE, CYFRA21-1, and CA125 levels, the - worse the PFS and OS in patients with LUAD and LUSC. In addition, the higher the - serum CA19-9 level, the worse the OS in patients with LUAD. -CI - © 2023. BioMed Central Ltd., part of Springer Nature. -FAU - Huang, Jian -AU - Huang J -AD - Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, Jiangxi, - China. -FAU - Xiao, Yi -AU - Xiao Y -AD - Department of Cardio-Thoracic Surgery, Third Affiliated Hospital of Sun Yat-Sen - University, Guangzhou, Guangdong, China. -FAU - Zhou, Yubin -AU - Zhou Y -AD - Department of Cardio-Thoracic Surgery, Third Affiliated Hospital of Sun Yat-Sen - University, Guangzhou, Guangdong, China. -FAU - Deng, Huiyin -AU - Deng H -AD - Department of Anesthesiology, Third Xiangya Hospital, Central South University, - Changsha, Hunan, China. -FAU - Yuan, Zihao -AU - Yuan Z -AD - The Second Clinical Medical College, Guangdong Medical University, Dongguan, - Guangdong, China. -FAU - Dong, Longyan -AU - Dong L -AD - The Second Clinical Medical College, Guangdong Medical University, Dongguan, - Guangdong, China. -FAU - Lan, Jun -AU - Lan J -AD - Department of General Surgery, the People's Hospital of Gaoan City. Gaoan, - Jiangxi, China. -FAU - Li, Xiane -AU - Li X -AD - Jiangxi Cancer Hospital, Nanchang, Jiangxi, China. -FAU - Liu, Gaijiao -AU - Liu G -AD - Department of Anesthesiology, Shenzhen Second People's Hospital, Guangzhou, - China. -FAU - Hu, Hao -AU - Hu H -AD - Department of Radiation Therapy, General Hospital of Southern Theater Command, - Guangzhou, Guangdong, China. qianhe89513@163.com. -FAU - Huang, Shaohong -AU - Huang S -AD - Department of Cardio-Thoracic Surgery, Third Affiliated Hospital of Sun Yat-Sen - University, Guangzhou, Guangdong, China. hshaoh@mail.sysu.edu.cn. -FAU - Yang, Xiongwen -AU - Yang X -AD - Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, Jiangxi, - China. mcyangxiongwen300@mail.scut.edu.cn. -AD - School of Medicine, South China University of Technology, Guangzhou, Guangdong, - China. mcyangxiongwen300@mail.scut.edu.cn. -LA - eng -PT - Journal Article -PT - Multicenter Study -DEP - 20230830 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Biomarkers, Tumor) -RN - 0 (antigen CYFRA21.1) -RN - 0 (Carcinoembryonic Antigen) -RN - 0 (CA-19-9 Antigen) -RN - 0 (CA-125 Antigen) -RN - 0 (Carbohydrates) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Biomarkers, Tumor -MH - Carcinoembryonic Antigen -MH - Retrospective Studies -MH - CA-19-9 Antigen -MH - *Lung Neoplasms/therapy -MH - *Adenocarcinoma of Lung -MH - *Carcinoma, Squamous Cell -MH - Immunotherapy -MH - CA-125 Antigen -MH - Carbohydrates -PMC - PMC10466830 -OTO - NOTNLM -OT - Baseline serum tumor markers -OT - Immunotherapy -OT - Non-small cell lung cancer -OT - Overall survival -OT - Progression-free survival -COIS- The authors declare no competing interests. -EDAT- 2023/08/31 00:41 -MHDA- 2023/09/01 06:42 -PMCR- 2023/08/30 -CRDT- 2023/08/30 23:40 -PHST- 2023/01/02 00:00 [received] -PHST- 2023/08/17 00:00 [accepted] -PHST- 2023/09/01 06:42 [medline] -PHST- 2023/08/31 00:41 [pubmed] -PHST- 2023/08/30 23:40 [entrez] -PHST- 2023/08/30 00:00 [pmc-release] -AID - 10.1186/s12885-023-11312-4 [pii] -AID - 11312 [pii] -AID - 10.1186/s12885-023-11312-4 [doi] -PST - epublish -SO - BMC Cancer. 2023 Aug 30;23(1):812. doi: 10.1186/s12885-023-11312-4. - -PMID- 34088726 -OWN - NLM -STAT- MEDLINE -DCOM- 20220401 -LR - 20240211 -IS - 1557-3265 (Electronic) -IS - 1078-0432 (Print) -IS - 1078-0432 (Linking) -VI - 27 -IP - 15 -DP - 2021 Aug 1 -TI - Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung - Cancers on the LIBRETTO-001 Trial. -PG - 4160-4167 -LID - 10.1158/1078-0432.CCR-21-0800 [doi] -AB - PURPOSE: We report the intracranial efficacy of selpercatinib, a highly potent - and selective RET inhibitor, approved in the United States for RET - fusion-positive non-small cell lung cancers (NSCLC). PATIENTS AND METHODS: In the - global phase 1/2 LIBRETTO-001 trial (NCT03157128) in advanced RET-altered solid - tumors, selpercatinib was dosed orally (160 mg twice every day) in 28-day cycles. - Patients with baseline intracranial metastases had MRI/CT scans every 8 weeks for - 1 year (12 weeks thereafter). In this pre-planned analysis of patients with RET - fusion-positive NSCLC with baseline intracranial metastases, the primary endpoint - was independently assessed intracranial objective response rate (ORR) per RECIST - 1.1. Secondary endpoints included intracranial disease control rate, intracranial - duration of response, and intracranial progression-free survival (PFS) - independently reviewed. RESULTS: Eighty patients with NSCLC had brain metastases - at baseline. Patients were heavily pretreated (median = 2 systemic therapies, - range = 0-10); 56% of patients received ≥1 course of intracranial radiation (14% - whole brain radiotherapy, 45% stereotactic radiosurgery). Among 22 patients with - measurable intracranial disease at baseline, intracranial ORR was 82% [95% - confidence interval (CI), 60-95], including 23% with complete responses. Among - all intracranial responders (measurable and nonmeasurable, n = 38), median - duration of intracranial response was not reached (95% CI, 9.3-NE) at a median - duration of follow-up of 9.5 months (IQR = 5.7, 12.0). At 12 months, 55% of - intracranial responses were ongoing. In all 80 patients, median intracranial PFS - was 13.7 months (95% CI, 10.9-NE) at a median duration of follow-up of 11.0 - months (IQR = 7.4, 16.5). No new safety signals were revealed in patients with - brain metastases compared with the full NSCLC trial population. CONCLUSIONS: - Selpercatinib has robust and durable intracranial efficacy in patients with RET - fusion-positive NSCLC. -CI - ©2021 The Authors; Published by the American Association for Cancer Research. -FAU - Subbiah, Vivek -AU - Subbiah V -AUID- ORCID: 0000-0002-6064-6837 -AD - The University of Texas, MD Anderson Cancer Center, Houston, Texas. - vsubbiah@mdanderson.org. -FAU - Gainor, Justin F -AU - Gainor JF -AD - Massachusetts General Hospital Cancer Center, Boston, Massachusetts. -FAU - Oxnard, Geoffrey R -AU - Oxnard GR -AD - Dana-Farber Cancer Institute, Boston, Massachusetts. -FAU - Tan, Daniel S W -AU - Tan DSW -AD - National Cancer Centre Singapore, Duke-NUS Medical School, Singapore. -FAU - Owen, Dwight H -AU - Owen DH -AUID- ORCID: 0000-0002-6598-4886 -AD - The Ohio State University, Columbus, Ohio. -FAU - Cho, Byoung Chul -AU - Cho BC -AUID- ORCID: 0000-0002-5562-270X -AD - Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of - Korea. -FAU - Loong, Herbert H -AU - Loong HH -AUID- ORCID: 0000-0002-6607-1106 -AD - The Chinese University of Hong Kong, Hong Kong, PR China. -FAU - McCoach, Caroline E -AU - McCoach CE -AD - University of California San Francisco, Helen Diller Family Comprehensive Cancer - Center, San Francisco, California. -FAU - Weiss, Jared -AU - Weiss J -AD - University of North Carolina, Chapel Hill, North Carolina. -FAU - Kim, Yu Jung -AU - Kim YJ -AUID- ORCID: 0000-0002-5037-0523 -AD - Seoul National University Bundang Hospital, Seoul National University College of - Medicine, Seongnam, Gyeonggi-do, Republic of Korea. -FAU - Bazhenova, Lyudmila -AU - Bazhenova L -AUID- ORCID: 0000-0001-8764-4359 -AD - University of California, San Diego Moores Cancer Center, San Diego, California. -FAU - Park, Keunchil -AU - Park K -AUID- ORCID: 0000-0002-4846-7449 -AD - Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, - Republic of Korea. -FAU - Daga, Haruko -AU - Daga H -AD - Osaka City General Hospital, Osaka, Japan. -FAU - Besse, Benjamin -AU - Besse B -AD - Institut Gustav Roussy, Villejuif, France; Paris-Saclay University, Orsay, - France. -FAU - Gautschi, Oliver -AU - Gautschi O -AD - University of Berne and Cantonal Hospital of Lucerne, Lucerne, Switzerland. -FAU - Rolfo, Christian -AU - Rolfo C -AUID- ORCID: 0000-0002-5109-0267 -AD - Greenebaum Comprehensive Cancer Center, University of Maryland School of - Medicine, Baltimore, Maryland. -AD - Center for Thoracic Oncology, Tisch Cancer Institute Mount Sinai Medical System- - Icahn School of Medicine, Mount Sinai, New York, New York. -FAU - Zhu, Edward Y -AU - Zhu EY -AD - Loxo Oncology, a subsidiary of Eli Lilly and Company, Indianapolis, Indiana. -FAU - Kherani, Jennifer F -AU - Kherani JF -AD - Loxo Oncology, a subsidiary of Eli Lilly and Company, Indianapolis, Indiana. -FAU - Huang, Xin -AU - Huang X -AD - Loxo Oncology, a subsidiary of Eli Lilly and Company, Indianapolis, Indiana. -FAU - Kang, Suhyun -AU - Kang S -AD - Eli Lilly and Company, Indianapolis, Indiana. -FAU - Drilon, Alexander -AU - Drilon A -AUID- ORCID: 0000-0001-6806-9061 -AD - Memorial Sloan Kettering Cancer Center, New York, New York. -AD - Weill Cornell Medical College, New York, New York. -LA - eng -SI - ClinicalTrials.gov/NCT03157128 -GR - P30 CA008748/CA/NCI NIH HHS/United States -GR - P30 CA016672/CA/NCI NIH HHS/United States -GR - R01 CA242845/CA/NCI NIH HHS/United States -PT - Clinical Trial, Phase I -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20210604 -PL - United States -TA - Clin Cancer Res -JT - Clinical cancer research : an official journal of the American Association for - Cancer Research -JID - 9502500 -RN - 0 (Pyrazoles) -RN - 0 (Pyridines) -RN - CEGM9YBNGD (selpercatinib) -RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret) -RN - EC 2.7.10.1 (RET protein, human) -SB - IM -CIN - Clin Cancer Res. 27(15):4131. -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Brain Neoplasms/*pathology/*secondary -MH - Carcinoma, Non-Small-Cell Lung/chemistry/*drug therapy/*secondary -MH - Female -MH - Humans -MH - Lung Neoplasms/chemistry/*pathology -MH - Male -MH - Middle Aged -MH - *Proto-Oncogene Proteins c-ret/analysis -MH - Pyrazoles/*therapeutic use -MH - Pyridines/*therapeutic use -MH - Treatment Outcome -PMC - PMC8447251 -MID - NIHMS1714118 -COIS- V. Subbiah reports grants from Eli Lilly/Loxo Oncology and grant and advisory - board/consultant position with Eli Lilly/Loxo Oncology during the conduct of the - study, as well as research grants from Roche/Genentech, Bayer, GlaxoSmithKline, - Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, - Fujifilm, D3, Pfizer, Multivir, Amgen, AbbVie, Alfa-sigma, Agensys, Boston - Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, - Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, - UT MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, - Novartis, Pharmamar, and Medimmune; employment with Helsinn, Incyte, QED Pharma, - Daiichi-Sankyo, Signant Health, Novartis, and Medimmune; travel funds from - Pharmamar, Incyte, ASCO, and ESMO; and other support from Medscape outside the - submitted work. J.F. Gainor reports personal fees and other support from - Bristol-Myers Squibb, Merck, Genentech/Roche, Lilly/Loxo, Blueprint, Helsinn, and - Jounce; personal fees from AstraZeneca, Mirati, Amgen, iTeos, GlydeBio, Pfizer, - Takeda; grants, personal fees, and other support from Novartis; and other support - from Ironwood outside the submitted work. G.R. Oxnard reports personal fees from - Foundation Medicine and Roche outside the submitted work. D.S.W. Tan reports - grants and personal fees from Amgen, Pfizer, Novartis, and AstraZeneca and - personal fees from Bayer, Boehringer Ingelheim, C4 Therapeutics, MSD, and Merck - outside the submitted work. D.H. Owen reports grants from BMS, Merck, - Palobiofarma, and Genentech and personal fees from themednet.org outside the - submitted work. B.C. Cho reports grants from Novartis, Bayer, AstraZeneca, MOGAM - Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD, - AbbVie, Medpacto, GIInnovation, Eli Lilly, Blueprint Medicines, and Interpark Bio - Convergence Corp; personal fees from Novartis, AstraZeneca, Boehringer-Ingelheim, - Roche, BMS, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD, Medpacto, - Blueprint Medicines, TheraCanVac Inc., Gencurix Inc., Bridgebio Therapeutics, - KANAPH Therapeutic Inc., Cyrus Therapeutics, Interpark Bio Convergence Corp. - Guardant Health, and Oscotec Inc.; and other support from Interpark Bio - Convergence Corp., Champions Oncology, and DAAN Biotherapeutics outside the - submitted work. H.H. Loong reports personal fees from Boehringer-Ingelheim, Eli - Lilly, Illumina, Novartis, Takeda, Eisai, Guardant Health, and Bayer and grants - from MSD outside the submitted work. C.E. McCoach reports personal fees from - AstraZeneca, Takeda, and Guardant Health; grants and personal fees from Novartis; - grants from Revolution Medicines; and personal fees and other support from - Genentech outside the submitted work, as well as employment with Genentech Inc. - J. Weiss reports grants from Eli Lilly during the conduct of the study and - personal fees from Eli Lilly outside the submitted work. L. Bazhenova reports - personal fees from Johnson and Johnson, Novartis, Neuvogen, Daiichi Sankyo, - Boehringer Ingelheim, BMS, Merck, and Regeneron outside the submitted work. K. - Park reports other support from Eli Lilly during the conduct of the study and - other support from Eli Lilly and Loxo outside the submitted work. H. Daga reports - personal fees from Chugai outside the submitted work. B. Besse reports grants - from 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint - Medicines, BMS, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, - Daiichi-Sankyo, Eli Lilly, GSK, Inivata, Janssen, Onxeo, OSE Immunotherapeutics, - Pfizer, Roche-Genentech, Sanofi, Takeda, and Tolero Pharmaceuticals during the - conduct of the study. O. Gautschi reports other support from Lilly, Amgen, Bayer, - and Novartis during the conduct of the study. C. Rolfo reports personal fees from - AstraZeneca, MSD, Roche, Inivata, ArcherDX, MD Serono, BMS, Novartis, Boston - Pharmaceuticals, and Pfizer outside the submitted work. E.Y. Zhu reports other - support from Loxo Oncology during the conduct of the study. J.F. Kherani reports - other support from Loxo Oncology at Lilly during the conduct of the study and - other support from Loxo Oncology at Lilly outside the submitted work. X. Huang - reports other support from Loxo Oncology during the conduct of the study. A. - Drilon reports personal fees from Loxo/Lilly during the conduct of the study; - personal fees from Ignyta/Genentech/Roche, Bayer, Takeda/Ariad/Millenium, TP - Therapeutics, AstraZeneca, Pfizer, Beigene, BergenBio, Hengrui, Exelixis, Tyra, - Verastem, MORE Health, AbbVie, 14ner/Elevation, Remedica, ArcherDX, Monopteros, - Novartis, EMD Serono, Melendi, GlaxoSmithKlein, Teva, Taiho, PharmaMar, and - Foundation Medicine outside the submitted work. No disclosures were reported by - the other authors. -EDAT- 2021/06/06 06:00 -MHDA- 2022/04/02 06:00 -PMCR- 2021/06/04 -CRDT- 2021/06/05 05:35 -PHST- 2021/03/09 00:00 [received] -PHST- 2021/04/30 00:00 [revised] -PHST- 2021/06/02 00:00 [accepted] -PHST- 2021/06/06 06:00 [pubmed] -PHST- 2022/04/02 06:00 [medline] -PHST- 2021/06/05 05:35 [entrez] -PHST- 2021/06/04 00:00 [pmc-release] -AID - 1078-0432.CCR-21-0800 [pii] -AID - CCR-21-0800 [pii] -AID - 10.1158/1078-0432.CCR-21-0800 [doi] -PST - ppublish -SO - Clin Cancer Res. 2021 Aug 1;27(15):4160-4167. doi: 10.1158/1078-0432.CCR-21-0800. - Epub 2021 Jun 4. - -PMID- 30780002 -OWN - NLM -STAT- MEDLINE -DCOM- 20200625 -LR - 20200625 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 14 -IP - 7 -DP - 2019 Jul -TI - Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated - with Checkpoint Inhibitors. -PG - 1244-1254 -LID - S1556-0864(19)30117-0 [pii] -LID - 10.1016/j.jtho.2019.02.009 [doi] -AB - INTRODUCTION: Although frequent in NSCLC, patients with brain metastases (BMs) - are often excluded from immune checkpoint inhibitor (ICI) trials. We evaluated BM - outcome in a less-selected NSCLC cohort. METHODS: Data from consecutive patients - with advanced ICI-treated NSCLC were collected. Active BMs were defined as new - and/or growing lesions without any subsequent local treatment before the start of - ICI treatment. Objective response rate (ORR), progression-free survival, and - overall survival (OS) were evaluated. Multivariate analyses were performed by - using a Cox proportional hazards model and logistic regression. RESULTS: A total - of 1025 patients were included; the median follow-up time from start of ICI - treatment was 15.8 months. Of these patients, 255 (24.9%) had BMs (39.2% active, - 14.3% symptomatic, and 27.4% being treated with steroids). Disease-specific - Graded Prognostic Assessment (ds-GPA) score was known for 94.5% of patients - (35.7% with a score of 0-1, 58.5% with a score of 1.5-2.5, and 5.8% with a score - of 3). The ORRs with BM versus without BM were similar: 20.6% (with BM) versus - 22.7% (without BM) (p = 0.484). The intracranial ORR (active BM with follow-up - brain imaging [n = 73]) was 27.3%. The median progression-free survival times - were 1.7 (95% confidence interval [CI]: 1.5-2.1) and 2.1 (95% CI: 1.9-2.5) - months, respectively (p = 0.009). Of the patients with BMs, 12.7% had a - dissociated cranial-extracranial response and two (0.8%) had brain - pseudoprogression. Brain progression occurred more in active BM than in stable BM - (54.2% versus 30% [p < 0.001]). The median OS times were 8.6 months (95% CI: - 6.8-12.0) with BM and 11.4 months (95% CI: 8.6-13.8) months with no BM (p = - 0.035). In the BM subgroup multivariate analysis, corticosteroid use (hazard - ratio [HR] = 2.37) was associated with poorer OS, whereas stable BMs (HR = 0.62) - and higher ds-GPA classification (HR = 0.48-0.52) were associated with improved - OS. CONCLUSION: In multivariate analysis BMs are not associated with a poorer - survival in patients with ICI-treated NSCLC. Stable patients with BM without - baseline corticosteroids and a good ds-GPA classification have the best - prognosis. -CI - Copyright © 2019 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Hendriks, Lizza E L -AU - Hendriks LEL -AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Institut - d'Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, Villejuif, - France; Department of Pulmonary Diseases, GROW School for Oncology and - Developmental Biology, Maastricht University Medical Center+, Maastricht, The - Netherlands. Electronic address: lizza.hendriks@mumc.nl. -FAU - Henon, Clemence -AU - Henon C -AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Institut - d'Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, Villejuif, - France. -FAU - Auclin, Edouard -AU - Auclin E -AD - Gastrointestinal and Medical Oncology Department, Hôpital Européen Georges - Pompidou, Paris, France. -FAU - Mezquita, Laura -AU - Mezquita L -AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Institut - d'Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, Villejuif, - France. -FAU - Ferrara, Roberto -AU - Ferrara R -AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Institut - d'Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, Villejuif, - France. -FAU - Audigier-Valette, Clarisse -AU - Audigier-Valette C -AD - Department of Pulmonary Diseases, Centre Hospitalier Toulon Sainte-Musse, Toulon, - France. -FAU - Mazieres, Julien -AU - Mazieres J -AD - Department of Pulmonary Diseases, Centre Hospitalier Universitaire de Toulouse, - Université Paul Sabatier, Toulouse, France. -FAU - Lefebvre, Corentin -AU - Lefebvre C -AD - Department of Pulmonary Diseases, Centre Hospitalier Universitaire de Toulouse, - Université Paul Sabatier, Toulouse, France. -FAU - Rabeau, Audrey -AU - Rabeau A -AD - Department of Pulmonary Diseases, Centre Hospitalier Universitaire de Toulouse, - Université Paul Sabatier, Toulouse, France. -FAU - Le Moulec, Sylvestre -AU - Le Moulec S -AD - Department of Medical Oncology, Institut Bergonie, Bordeaux, France. -FAU - Cousin, Sophie -AU - Cousin S -AD - Department of Medical Oncology, Institut Bergonie, Bordeaux, France. -FAU - Duchemann, Boris -AU - Duchemann B -AD - Department of Pulmonary Diseases, Hopital Avicenne, Paris, France. -FAU - le Pechoux, Cecile -AU - le Pechoux C -AD - Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, - France. -FAU - Botticella, Angela -AU - Botticella A -AD - Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, - France. -FAU - Ammari, Samy -AU - Ammari S -AD - Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, - Villejuif, France; Imagerie par Résonance Magnétique Médicale et Multi-Modalités, - IR4M, CNRS, Université Paris-Sud, Université Paris-Saclay, Orsay, France. -FAU - Gazzah, Anas -AU - Gazzah A -AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Institut - d'Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, Villejuif, - France; Department of Drug Development, Gustave Roussy Cancer Campus, Villejuif, - France. -FAU - Caramella, Caroline -AU - Caramella C -AD - Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, - Villejuif, France. -FAU - Adam, Julien -AU - Adam J -AD - Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Lechapt, Emmanuèle -AU - Lechapt E -AD - Department of Pathology, Centre Hospitalier Sainte Anne, Paris, France. -FAU - Planchard, David -AU - Planchard D -AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Institut - d'Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, Villejuif, - France. -FAU - De Ruysscher, Dirk -AU - De Ruysscher D -AD - Department of Radiation Oncology, MAASTRO Clinic, GROW School for Oncology and - Developmental Biology, Maastricht University Medical Center+, Maastricht, The - Netherlands. -FAU - Dingemans, Anne-Marie -AU - Dingemans AM -AD - Department of Pulmonary Diseases, GROW School for Oncology and Developmental - Biology, Maastricht University Medical Center+, Maastricht, The Netherlands. -FAU - Besse, Benjamin -AU - Besse B -AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Institut - d'Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, Villejuif, - France; Paris-Sud University, Orsay, France. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20190216 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -CIN - J Thorac Oncol. 2019 Jul;14(7):1119-1121. doi: 10.1016/j.jtho.2019.03.013. PMID: - 31235031 -MH - Adenocarcinoma of Lung/drug therapy/immunology/*mortality/pathology -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors/immunology -MH - Brain Neoplasms/drug therapy/immunology/*mortality/secondary -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/immunology/*mortality/pathology -MH - Carcinoma, Squamous Cell/drug therapy/immunology/*mortality/pathology -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Lung Neoplasms/drug therapy/immunology/mortality/pathology -MH - Male -MH - Middle Aged -MH - Prognosis -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors/immunology -MH - Retrospective Studies -MH - Survival Rate -OTO - NOTNLM -OT - Brain metastases -OT - Checkpoint inhibition -OT - Disease specific Graded Prognostic Assessment -OT - NSCLC -OT - survival -EDAT- 2019/02/20 06:00 -MHDA- 2020/06/26 06:00 -CRDT- 2019/02/20 06:00 -PHST- 2018/11/22 00:00 [received] -PHST- 2019/02/01 00:00 [revised] -PHST- 2019/02/12 00:00 [accepted] -PHST- 2019/02/20 06:00 [pubmed] -PHST- 2020/06/26 06:00 [medline] -PHST- 2019/02/20 06:00 [entrez] -AID - S1556-0864(19)30117-0 [pii] -AID - 10.1016/j.jtho.2019.02.009 [doi] -PST - ppublish -SO - J Thorac Oncol. 2019 Jul;14(7):1244-1254. doi: 10.1016/j.jtho.2019.02.009. Epub - 2019 Feb 16. - -PMID- 33828112 -OWN - NLM -STAT- MEDLINE -DCOM- 20211115 -LR - 20211115 -IS - 2045-2322 (Electronic) -IS - 2045-2322 (Linking) -VI - 11 -IP - 1 -DP - 2021 Apr 7 -TI - Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer - patients. -PG - 7633 -LID - 10.1038/s41598-021-85797-z [doi] -LID - 7633 -AB - Tyrosine kinase inhibitors (TKIs), VEGF/VEGF receptor inhibitors (VEGFIs) and - immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced - cancers including non-small-cell lung cancer (NSCLC). This study aims to evaluate - the utility of plasma cell-free DNA (cfDNA) as a prognostic biomarker and - efficacy predictor of chemotherapy (CT) with or without these precision therapies - in NSCLC patients. Peripheral cfDNA levels in 154 NSCLC patients were quantified - before and after the first target cycle of chemotherapy. The correlations of - cfDNA with tumor burden, clinical characteristics, progression-free survival - (PFS)/disease-free survival (DFS), objective response ratio (ORR), and therapy - regimens were analyzed respectively. Baseline cfDNA, but not - post-chemotherapeutic cfDNA, positively correlates with tumor burden. Notably, - cfDNA kinetics (cfDNA Ratio, the ratio of post-chemotherapeutic cfDNA to baseline - cfDNA) well distinguished responsive individuals (CR/PR) from the non-responsive - (PD/SD). Additionally, cfDNA Ratio was found negatively correlated with PFS in - lung adenocarcinoma (LUAD), but not lung squamous-cell carcinoma (LUSC) which may - be due to a limited number of LUSC patients in this cohort. LUAD patients with - low cfDNA Ratio have prolonged PFS and improved ORR, compared to those with high - cfDNA Ratio. When stratified by therapy regimen, the predictive value of cfDNA - Ratio is significant in patients with chemotherapy plus VEGFIs, while more - patients need be included to validate the value of cfDNA Ratio in other regimens. - Thus, the kinetics of plasma cfDNA during chemotherapy may function as a - prognostic biomarker and efficacy predictor for NSCLC patients. -FAU - Zhou, Xiaorong -AU - Zhou X -AD - Jiangsu Cancer Hospital, Institute of Cancer Research, The Affiliated Cancer - Hospital of Nanjing Medical University, Nanjing, 210009, Jiangsu, China. -FAU - Li, Chenchen -AU - Li C -AD - Jiangsu Cancer Hospital, Institute of Cancer Research, The Affiliated Cancer - Hospital of Nanjing Medical University, Nanjing, 210009, Jiangsu, China. -FAU - Zhang, Zhao -AU - Zhang Z -AD - DiaCarta, Inc., 2600 Hilltop Drive, Richmond, CA, 94806, USA. -FAU - Li, Daniel Y -AU - Li DY -AD - DiaCarta, Inc., 2600 Hilltop Drive, Richmond, CA, 94806, USA. -FAU - Du, Jinwei -AU - Du J -AD - DiaCarta, Inc., 2600 Hilltop Drive, Richmond, CA, 94806, USA. -FAU - Ding, Ping -AU - Ding P -AD - DiaCarta, Inc., 2600 Hilltop Drive, Richmond, CA, 94806, USA. -FAU - Meng, Haiyan -AU - Meng H -AD - DiaCarta, Inc., 2600 Hilltop Drive, Richmond, CA, 94806, USA. -FAU - Xu, Hui -AU - Xu H -AD - DiaCarta, Inc., 2600 Hilltop Drive, Richmond, CA, 94806, USA. -FAU - Li, Ronglei -AU - Li R -AD - Genesmile, Inc., Nanjing, Jiangsu, China. -FAU - Ho, Effie -AU - Ho E -AD - DiaCarta, Inc., 2600 Hilltop Drive, Richmond, CA, 94806, USA. -FAU - Zhang, Aiguo -AU - Zhang A -AD - DiaCarta, Inc., 2600 Hilltop Drive, Richmond, CA, 94806, USA. -FAU - Okunieff, Paul -AU - Okunieff P -AD - Department of Radiation Oncology, University of Florida, Gainesville, USA. -FAU - Lu, Jianwei -AU - Lu J -AD - Jiangsu Cancer Hospital, Institute of Cancer Research, The Affiliated Cancer - Hospital of Nanjing Medical University, Nanjing, 210009, Jiangsu, China. - lujw@medmail.com.cn. -FAU - Sha, Michael Y -AU - Sha MY -AD - DiaCarta, Inc., 2600 Hilltop Drive, Richmond, CA, 94806, USA. msha@diacarta.com. -LA - eng -PT - Journal Article -DEP - 20210407 -PL - England -TA - Sci Rep -JT - Scientific reports -JID - 101563288 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Biomarkers, Pharmacological) -RN - 0 (Biomarkers, Tumor) -RN - 0 (Cell-Free Nucleic Acids) -RN - 0 (Protein Kinase Inhibitors) -SB - IM -MH - Adult -MH - Aged -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Biomarkers, Pharmacological/blood -MH - Biomarkers, Tumor/blood/genetics -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/*genetics/mortality -MH - Carcinoma, Squamous Cell/drug therapy/genetics -MH - Cell-Free Nucleic Acids/analysis/*genetics -MH - Disease-Free Survival -MH - Female -MH - Humans -MH - Kinetics -MH - Lung Neoplasms/genetics/pathology -MH - Male -MH - Middle Aged -MH - Plasma/metabolism -MH - Prognosis -MH - Progression-Free Survival -MH - Protein Kinase Inhibitors/therapeutic use -MH - Retrospective Studies -MH - Tumor Burden/genetics -PMC - PMC8027214 -COIS- The authors declare no competing interests. -EDAT- 2021/04/09 06:00 -MHDA- 2021/11/16 06:00 -PMCR- 2021/04/07 -CRDT- 2021/04/08 06:00 -PHST- 2020/11/06 00:00 [received] -PHST- 2021/02/19 00:00 [accepted] -PHST- 2021/04/08 06:00 [entrez] -PHST- 2021/04/09 06:00 [pubmed] -PHST- 2021/11/16 06:00 [medline] -PHST- 2021/04/07 00:00 [pmc-release] -AID - 10.1038/s41598-021-85797-z [pii] -AID - 85797 [pii] -AID - 10.1038/s41598-021-85797-z [doi] -PST - epublish -SO - Sci Rep. 2021 Apr 7;11(1):7633. doi: 10.1038/s41598-021-85797-z. - -PMID- 36450379 -OWN - NLM -STAT- MEDLINE -DCOM- 20221202 -LR - 20221213 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 10 -IP - 11 -DP - 2022 Nov -TI - Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse - population of patients with previously treated advanced non-small cell lung - cancer. -LID - 10.1136/jitc-2022-005581 [doi] -LID - e005581 -AB - In patients with previously treated advanced or metastatic non-small cell lung - cancer (NSCLC), atezolizumab therapy improves survival with manageable safety. - The open-label, single-arm phase III/IV TAIL study (NCT03285763) evaluated - atezolizumab monotherapy in patients with previously treated NSCLC, including - those with Eastern Cooperative Oncology Group performance status of 2, severe - renal impairment, prior anti-programmed death 1 therapy, autoimmune disease, and - age ≥75 years. Patients received atezolizumab intravenously (1200 mg) every 3 - weeks. At data cut-off for final analysis, the median follow-up was 36.1 (range - 0.0-42.3) months. Treatment-related (TR) serious adverse events (SAEs) and TR - immune-related adverse events (irAEs) were the coprimary endpoints. Secondary - endpoints included overall survival (OS), progression-free survival (PFS), - overall response rate, and duration of response. Safety and efficacy in key - patient subgroups were also assessed. TR SAEs and TR irAEs occurred in 8.0% and - 9.4% of patients, respectively. No new safety signals were documented. In the - overall population, median OS and PFS (95% CI) were 11.2 months (8.9 to 12.7) and - 2.7 months (2.3 to 2.8), respectively. TAIL showed that atezolizumab has a - similar risk-benefit profile in clinically diverse patients with previously - treated NSCLC, which may guide treatment decisions for patients generally - excluded from pivotal clinical trials. -CI - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Ardizzoni, Andrea -AU - Ardizzoni A -AUID- ORCID: 0000-0003-0623-4257 -AD - Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, - Italy andrea.ardizzoni@aosp.bo.it. -FAU - Azevedo, Sergio -AU - Azevedo S -AD - Oncology Service, Unidade de Pesquisa Clinica, Hospital de Clínicas de Porto - Alegre, Bologna, Italy. -FAU - Rubio-Viqueira, Belen -AU - Rubio-Viqueira B -AD - Department of Medical Oncology, Hospital Universitario Quirónsalud Madrid, - Madrid, Spain. -FAU - Rodriguez-Abreu, Delvys -AU - Rodriguez-Abreu D -AD - Department of Medical Oncology, Hospital Universitario Insular de Gran Canaria, - Las Palmas, Spain. -FAU - Alatorre-Alexander, Jorge -AU - Alatorre-Alexander J -AD - Thoracic Oncology Clinic, Health Pharma Professional Research, Mexico City, - Mexico. -FAU - Smit, Hans J M -AU - Smit HJM -AD - Department of Pulmonary Diseases, Rijnstate Hospital, Arnhem, The Netherlands. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong - University, Jinan, Shandong, China. -FAU - Syrigos, Konstantinos -AU - Syrigos K -AD - 3rd Department of Medicine, National and Kapodistrian University of Athens, - Athens, Greece. -FAU - Höglander, Elen -AU - Höglander E -AD - F Hoffmann-La Roche Ltd, Basel, Switzerland. -FAU - Kaul, Monika -AU - Kaul M -AD - Genentech Inc, South San Francisco, California, USA. -FAU - Tolson, Jonathan -AU - Tolson J -AD - F Hoffmann-La Roche Ltd, Basel, Switzerland. -FAU - Hu, Youyou -AU - Hu Y -AD - F Hoffmann-La Roche Ltd, Basel, Switzerland. -FAU - Vollan, Hans Kristian -AU - Vollan HK -AD - F Hoffmann-La Roche Ltd, Basel, Switzerland. -FAU - Newsom-Davis, Thomas -AU - Newsom-Davis T -AD - Department of Oncology, Chelsea and Westminster Hospital, London, UK. -LA - eng -SI - ClinicalTrials.gov/NCT03285763 -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 52CMI0WC3Y (atezolizumab) -RN - 0 (Antibodies, Monoclonal, Humanized) -SB - IM -MH - Humans -MH - Aged -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use -MH - Progression-Free Survival -PMC - PMC9716834 -OTO - NOTNLM -OT - Immunotherapy -OT - Lung Neoplasms -COIS- Competing interests: AA reports personal honoraria for lectures from BMS, Astra - Zeneca, and MSD; advisory board participation for Roche, Astra Zeneca, BMS, - Sanofi, and Eli Lilly. BR-V reports honoraria for educational events for Janssen, - MSD, and Bristol-Myers Squibb; advisory board participation for MSD and Takeda. - DR-A reports personal and/or other fees from BMS, MSD, Roche/Genentech, Novartis, - Astra Zeneca, and Boehringer-Ingelheim. JA-A reports advisory board participation - for Astra Zeneca, Roche, MSD, BMS, Takeda, and Pfizer; speaker bureau for Roche, - MSD, BMS, Takeda, and Pfizer. HJMS reports payment for expert testimony from BMS - for immune-oncology educational website advice; advisory board participation for - MSD. EH reports employment by Roche and stockholding in Roche. MK reports - employment by Genentech and stockholding in Roche. JT reports former employment - by Roche and stockholding in Roche. YH reports employment by Roche and - stockholding in Roche. HKV reports employment by Roche and stockholding in Roche. - TN-D reports personal consulting fees from Takeda, Pfizer, Roche, Amgen, Astra - Zeneca, Bayer, BMS, Boehringer-Ingelheim, Chugai, Janssen, Lilly, Merck, MSD, - Novartis, and Otsuka; personal honoraria for lectures/presentations from Takeda, - Pfizer, Roche, Amgen, Astra Zeneca, Bayer, BMS, Boehringer-Ingelheim, Chugai, - Janssen, Lilly, Merck, MSD, Novartis, and Otsuka; support for attending meetings - and/or travel from Astra Zeneca, BMS, Boehringer-Ingelheim, MSD, Roche, and - Takeda; chair of the independent monitoring committee for Roche and BluePrint - Medicines. SA, JY, and KS report no competing interests. -EDAT- 2022/12/01 06:00 -MHDA- 2022/12/03 06:00 -PMCR- 2022/11/30 -CRDT- 2022/11/30 20:33 -PHST- 2022/10/12 00:00 [accepted] -PHST- 2022/11/30 20:33 [entrez] -PHST- 2022/12/01 06:00 [pubmed] -PHST- 2022/12/03 06:00 [medline] -PHST- 2022/11/30 00:00 [pmc-release] -AID - jitc-2022-005581 [pii] -AID - 10.1136/jitc-2022-005581 [doi] -PST - ppublish -SO - J Immunother Cancer. 2022 Nov;10(11):e005581. doi: 10.1136/jitc-2022-005581. - -PMID- 34244308 -OWN - NLM -STAT- MEDLINE -DCOM- 20220110 -LR - 20230617 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 9 -IP - 7 -DP - 2021 Jul -TI - Neoantigen vaccination induces clinical and immunologic responses in non-small - cell lung cancer patients harboring EGFR mutations. -LID - 10.1136/jitc-2021-002531 [doi] -LID - e002531 -AB - BACKGROUND: Neoantigen (NeoAg) peptides displayed at the tumor cell surface by - human leukocyte antigen molecules show exquisite tumor specificity and can elicit - T cell mediated tumor rejection. However, few NeoAgs are predicted to be shared - between patients, and none to date have demonstrated therapeutic value in the - context of vaccination. METHODS: We report here a phase I trial of personalized - NeoAg peptide vaccination (PPV) of 24 stage III/IV non-small cell lung cancer - (NSCLC) patients who had previously progressed following multiple conventional - therapies, including surgery, radiation, chemotherapy, and tyrosine kinase - inhibitors (TKIs). Primary endpoints of the trial evaluated feasibility, - tolerability, and safety of the personalized vaccination approach, and secondary - trial endpoints assessed tumor-specific immune reactivity and clinical responses. - Of the 16 patients with epidermal growth factor receptor (EGFR) mutations, nine - continued TKI therapy concurrent with PPV and seven patients received PPV alone. - RESULTS: Out of 29 patients enrolled in the trial, 24 were immunized with - personalized NeoAg peptides. Aside from transient rash, fatigue and/or fever - observed in three patients, no other treatment-related adverse events were - observed. Median progression-free survival and overall survival of the 24 - vaccinated patients were 6.0 and 8.9 months, respectively. Within 3-4 months - following initiation of PPV, seven RECIST-based objective clinical responses - including one complete response were observed. Notably, all seven clinical - responders had EGFR-mutated tumors, including four patients that had continued - TKI therapy concurrently with PPV. Immune monitoring showed that five of the - seven responding patients demonstrated vaccine-induced T cell responses against - EGFR NeoAg peptides. Furthermore, two highly shared EGFR mutations (L858R and - T790M) were shown to be immunogenic in four of the responding patients, all of - whom demonstrated increases in peripheral blood neoantigen-specific CD8+ T cell - frequencies during the course of PPV. CONCLUSIONS: These results show that - personalized NeoAg vaccination is feasible and safe for advanced-stage NSCLC - patients. The clinical and immune responses observed following PPV suggest that - EGFR mutations constitute shared, immunogenic neoantigens with promising - immunotherapeutic potential for large subsets of NSCLC patients. Furthermore, PPV - with concurrent EGFR inhibitor therapy was well tolerated and may have - contributed to the induction of PPV-induced T cell responses. -CI - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Li, Fenge -AU - Li F -AUID- ORCID: 0000-0003-3666-010X -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Deng, Ligang -AU - Deng L -AD - Tianjin HengJia Biotechnology Development Co Ltd, Tianjin, China. -FAU - Jackson, Kyle R -AU - Jackson KR -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Talukder, Amjad H -AU - Talukder AH -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Katailiha, Arjun S -AU - Katailiha AS -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Bradley, Sherille D -AU - Bradley SD -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Zou, Qingwei -AU - Zou Q -AD - Tianjin HengJia Biotechnology Development Co Ltd, Tianjin, China. -FAU - Chen, Caixia -AU - Chen C -AD - Tianjin HengJia Biotechnology Development Co Ltd, Tianjin, China. -FAU - Huo, Chong -AU - Huo C -AD - Tianjin HengJia Biotechnology Development Co Ltd, Tianjin, China. -FAU - Chiu, Yulun -AU - Chiu Y -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Stair, Matthew -AU - Stair M -AD - Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, USA. -FAU - Feng, Weihong -AU - Feng W -AD - Department of Oncology, Tianjin Beichen Hospital, Tianjin, China. -FAU - Bagaev, Aleksander -AU - Bagaev A -AD - BostonGene Corporation, Waltham, Massachusetts, USA. -FAU - Kotlov, Nikita -AU - Kotlov N -AD - BostonGene Corporation, Waltham, Massachusetts, USA. -FAU - Svekolkin, Viktor -AU - Svekolkin V -AD - BostonGene Corporation, Waltham, Massachusetts, USA. -FAU - Ataullakhanov, Ravshan -AU - Ataullakhanov R -AD - BostonGene Corporation, Waltham, Massachusetts, USA. -FAU - Miheecheva, Natalia -AU - Miheecheva N -AD - BostonGene Corporation, Waltham, Massachusetts, USA. -FAU - Frenkel, Felix -AU - Frenkel F -AD - BostonGene Corporation, Waltham, Massachusetts, USA. -FAU - Wang, Yaling -AU - Wang Y -AD - Tianjin HengJia Biotechnology Development Co Ltd, Tianjin, China. -FAU - Zhang, Minying -AU - Zhang M -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Hawke, David -AU - Hawke D -AD - Department of Systems Biology, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Han, Ling -AU - Han L -AD - Department of Oncology, Tianjin Beichen Hospital, Tianjin, China. -FAU - Zhou, Shuo -AU - Zhou S -AD - Provincial Clinical College, Fujian Medical University, Fujian, China. -FAU - Zhang, Yan -AU - Zhang Y -AD - State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, - China. -FAU - Wang, Zhenglu -AU - Wang Z -AD - Biological Sample Resource Sharing Center, Tianjin First Central Hospital, - Tianjin, China. -FAU - Decker, William K -AU - Decker WK -AD - Department of Immunology, Baylor College of Medicine, Houston, Texas, USA. -FAU - Sonnemann, Heather M -AU - Sonnemann HM -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Roszik, Jason -AU - Roszik J -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Forget, Marie-Andree -AU - Forget MA -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Davies, Michael A -AU - Davies MA -AUID- ORCID: 0000-0002-0977-0912 -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Bernatchez, Chantale -AU - Bernatchez C -AUID- ORCID: 0000-0001-5926-3460 -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Yee, Cassian -AU - Yee C -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Bassett, Roland -AU - Bassett R -AD - Department of Immunology, The University of Texas M.D. Anderson Cancer Center, - Houston, Texas, USA. -FAU - Hwu, Patrick -AU - Hwu P -AUID- ORCID: 0000-0003-0554-2856 -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Du, Xueming -AU - Du X -AD - Department of Oncology, Tianjin Beichen Hospital, Tianjin, China - glizee@mdanderson.org dudaming73@163.com. -FAU - Lizee, Gregory -AU - Lizee G -AUID- ORCID: 0000-0003-4449-7461 -AD - Department of Melanoma, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA glizee@mdanderson.org dudaming73@163.com. -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -LA - eng -GR - R01 AI127387/AI/NIAID NIH HHS/United States -PT - Journal Article -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Cancer Vaccines) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -EIN - J Immunother Cancer. 2021 Sep;9(9):1. doi: 10.1136/jitc-2021-002531corr1. PMID: - 34479927 -MH - Aged -MH - Aged, 80 and over -MH - Cancer Vaccines/pharmacology/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - ErbB Receptors/metabolism -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology -MH - Male -MH - Middle Aged -MH - Mutation -PMC - PMC8268925 -OTO - NOTNLM -OT - EGFR -OT - EGFR inhibitor -OT - neoantigen vaccine -OT - non-small cell lung cancer -OT - tumor regression -COIS- Competing interests: CH and FL are shareholders of Tianjin HengJia Biotechnology - Development (‘HengJia Biotech’). GL was a consultant for HengJia Neoantigen - Biotechnology (Tianjin), a branch company of HengJia Biotech. LD, QZ, CC, and CH - are employees of HengJia Biotech. MD is a consultant for Novartis, - Roche/Genentech, GSK, Array, Sanofi-Aventis, and Astrazeneca, and part of his - research grants were from Roche/Genentech, GSK, Sanofi-Aventis, and Astrazeneca. - United States patent applications have been filed on aspects of the described - work, entitled: 'Immunogenic EGFR peptide compositions and their use in the - treatment of cancer' (FL, GL), and 'Engineered T cell receptors targeting EGFR - antigens and methods of use' (FL, GL). Chinese patent applications have been - filed on aspects of the described work, entitled: ‘The clinical application of - specific T cell receptors based on EGFR-L858R mutation’ (XD, LD, CH, and QZ), and - ‘Method for identifying tumor-specific T cell receptors’ (XD). The remaining - authors declare no competing financial interests. -EDAT- 2021/07/11 06:00 -MHDA- 2022/01/11 06:00 -PMCR- 2021/07/08 -CRDT- 2021/07/10 05:41 -PHST- 2021/06/07 00:00 [accepted] -PHST- 2021/07/10 05:41 [entrez] -PHST- 2021/07/11 06:00 [pubmed] -PHST- 2022/01/11 06:00 [medline] -PHST- 2021/07/08 00:00 [pmc-release] -AID - jitc-2021-002531 [pii] -AID - 10.1136/jitc-2021-002531 [doi] -PST - ppublish -SO - J Immunother Cancer. 2021 Jul;9(7):e002531. doi: 10.1136/jitc-2021-002531. - -PMID- 35970032 -OWN - NLM -STAT- MEDLINE -DCOM- 20220920 -LR - 20221108 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 174 -DP - 2022 Oct -TI - Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in - patients with advanced thymic carcinoma: A multicentre retrospective study. -PG - 21-30 -LID - S0959-8049(22)00411-7 [pii] -LID - 10.1016/j.ejca.2022.06.059 [doi] -AB - BACKGROUND: Immunotherapy has demonstrated good efficacy and survival outcomes in - solid tumours. However, efficacy data for immune checkpoint inhibitors (ICIs) in - advanced thymic carcinoma are lacking. The present study aimed to assess the - activity of ICIs in advanced thymic carcinoma. METHODS: A multicentre - retrospective study was conducted to explore the efficacy and safety of ICIs for - advanced thymic carcinoma. Objective response rate (ORR), progression-free - survival (PFS), overall survival, and immune-related adverse events (irAEs) were - analysed. In addition, factors independently associated with treatment efficacy - and survival outcomes were evaluated. RESULTS: A total of 77 patients with - advanced thymic carcinoma were enrolled between March 2016 and September 2021. - The ORR was existing the difference between ICIs monotherapy (n = 23) and ICIs - combined with chemotherapy (n = 54) (17.4% versus 44.4%, P = 0.024). The ICIs - combination treatments were associated with better median PFS (mPFS) compared to - ICIs monotherapy (12.7 months versus 2.1 months, P < 0.001). Notably, liver or - brain metastasis was a poor prognostic factor of mPFS (1.8 months versus 3.5 - months, P = 0.012) in the ICIs monotherapy group. In addition, mPFS for the - first-line treatment (n = 27) was longer than that for ICIs as the second- or - posterior-line treatment (n = 50) (P < 0.001). The incidence of irAEs was - 54.5% (42/77) in the 77 enrolled patients. The incidence of grade 3-4 irAE was - 15.6% (12/77). CONCLUSIONS: Immunotherapy is effective in advanced thymic - carcinoma, especially for combination with chemotherapy showed promising - antitumour activity, which indicates worthy of combination treatment strategy for - further study. IrAEs also require close monitoring and management. -CI - Copyright © 2022 Elsevier Ltd. All rights reserved. -FAU - Wang, Wenxian -AU - Wang W -AD - Department of Medical Oncology, The Cancer Hospital of the University of Chinese - Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; Institute of - Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China. -FAU - Lin, Gen -AU - Lin G -AD - Department of Thoracic Oncology, Fujian Medical University Cancer Hospital, - Fujian Cancer Hospital, Fuzhou, China. -FAU - Hao, Yue -AU - Hao Y -AD - Department of Medical Oncology, The Cancer Hospital of the University of Chinese - Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. -FAU - Guan, Yelan -AU - Guan Y -AD - Department of Medical Oncology, The Cancer Hospital of the University of Chinese - Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. -FAU - Zhang, Yuxin -AU - Zhang Y -AD - Department of Radiotherapy, Hangzhou Cancer Hospital, Hangzhou, China. -FAU - Xu, Chunwei -AU - Xu C -AD - Department of Respiratory Medicine, Jinling Hospital, Nanjing University School - of Medicine, Nanjing, China. -FAU - Wang, Qian -AU - Wang Q -AD - Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of - Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China. -FAU - Wang, Dong -AU - Wang D -AD - Department of Respiratory Medicine, Jinling Hospital, Nanjing University School - of Medicine, Nanjing, China. -FAU - Jiang, Zhansheng -AU - Jiang Z -AD - Department of Integrative Oncology, Tianjin Medical University Cancer Institute - and Hospital, National Clinical Research Center for Cancer; Key Laboratory of - Cancer Prevention and Therapy, Tianjin, China. -FAU - Cai, Jing -AU - Cai J -AD - Department of Oncology, Second Affiliated Hospital of Nanchang University, - Nanchang, China. -FAU - Lou, Guangyuan -AU - Lou G -AD - Department of Medical Oncology, The Cancer Hospital of the University of Chinese - Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; Institute of - Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China. -FAU - Song, Zhengbo -AU - Song Z -AD - Department of Medical Oncology, The Cancer Hospital of the University of Chinese - Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; Institute of - Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China. - Electronic address: zheng_bo_song@163.com. -FAU - Zhang, Yongchang -AU - Zhang Y -AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan - Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, - Central South University, Changsha, China. Electronic address: - zhangyongchang@csu.edu.cn. -LA - eng -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -DEP - 20220812 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - *Antineoplastic Agents, Immunological/adverse effects -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Lung Neoplasms/drug therapy -MH - Prognosis -MH - Retrospective Studies -MH - *Thymoma/drug therapy -MH - *Thymus Neoplasms/drug therapy -MH - Treatment Outcome -OTO - NOTNLM -OT - Efficacy -OT - Immune-related adverse events -OT - Immunotherapy -OT - PD-1 -OT - Thymic carcinoma -EDAT- 2022/08/16 06:00 -MHDA- 2022/09/21 06:00 -CRDT- 2022/08/15 18:23 -PHST- 2022/06/17 00:00 [received] -PHST- 2022/06/30 00:00 [accepted] -PHST- 2022/08/16 06:00 [pubmed] -PHST- 2022/09/21 06:00 [medline] -PHST- 2022/08/15 18:23 [entrez] -AID - S0959-8049(22)00411-7 [pii] -AID - 10.1016/j.ejca.2022.06.059 [doi] -PST - ppublish -SO - Eur J Cancer. 2022 Oct;174:21-30. doi: 10.1016/j.ejca.2022.06.059. Epub 2022 Aug - 12. - -PMID- 37623024 -OWN - NLM -STAT- MEDLINE -DCOM- 20230828 -LR - 20230831 -IS - 1718-7729 (Electronic) -IS - 1198-0052 (Print) -IS - 1198-0052 (Linking) -VI - 30 -IP - 8 -DP - 2023 Aug 8 -TI - Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment - Received and PD-L1 Expression. -PG - 7499-7507 -LID - 10.3390/curroncol30080543 [doi] -AB - Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for - unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory - analysis of PACIFIC revealed no OS benefit in the PD-L1 < 1% subgroup. This - retrospective analysis assesses the real-world impact of durvalumab on OS - according to PD-L1 tumor proportion score (TPS). Patients with stage III, - unresectable NSCLC treated by CRT, with available PD-L1 TPS, from 1 March 2018 to - 31 December 2020, at BC Cancer, British Columbia, Canada were included. Patients - were divided into two groups, CRT + durvalumab and CRT alone. OS and PFS were - analyzed in the PD-L1 ≥ 1% and <1% subgroups. A total of 134 patients were - included in the CRT + durvalumab group and 117, in the CRT alone group. Median OS - was 35.9 months in the CRT + durvalumab group and 27.4 months in the CRT alone - group [HR 0.59 (95% CI 0.42-0.83), p = 0.003]. Durvalumab improved OS in the - PD-L1 ≥ 1% [HR 0.53 (95% CI 0.34-0.81), p = 0.003, n = 175], but not in the <1% - subgroup [HR 0.79 (95% CI 0.44-1.42), p = 0.4, n = 76]. This retrospective study - demonstrates a statistically significant improvement in OS associated with - durvalumab after CRT in PD-L1 ≥ 1%, but not PD-L1 < 1% NSCLC. Variables not - accounted for may have biased the survival analysis. A prospective study would - bring more insight. -FAU - Denault, Marie-Hélène -AU - Denault MH -AUID- ORCID: 0000-0002-8210-6364 -AD - BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. -AD - Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie - de Québec, 2725 Ch Ste-Foy, Québec, QC G1V 4G5, Canada. -FAU - Feng, Jamie -AU - Feng J -AUID- ORCID: 0009-0002-3017-1567 -AD - BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. -FAU - Kuang, Shelley -AU - Kuang S -AD - BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. -FAU - Shokoohi, Aria -AU - Shokoohi A -AUID- ORCID: 0000-0002-2093-7381 -AD - BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. -FAU - Leung, Bonnie -AU - Leung B -AUID- ORCID: 0000-0003-3319-8343 -AD - BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. -FAU - Liu, Mitchell -AU - Liu M -AD - BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. -FAU - Berthelet, Eric -AU - Berthelet E -AD - BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. -FAU - Laskin, Janessa -AU - Laskin J -AD - BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. -FAU - Sun, Sophie -AU - Sun S -AD - BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. -FAU - Zhang, Tina -AU - Zhang T -AD - BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. -FAU - Ho, Cheryl -AU - Ho C -AUID- ORCID: 0000-0002-5922-3984 -AD - BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. -FAU - Melosky, Barbara -AU - Melosky B -AUID- ORCID: 0000-0003-2865-659X -AD - BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. -LA - eng -PT - Journal Article -DEP - 20230808 -PL - Switzerland -TA - Curr Oncol -JT - Current oncology (Toronto, Ont.) -JID - 9502503 -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Humans -MH - Retrospective Studies -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Prospective Studies -MH - *Lung Neoplasms/drug therapy -MH - British Columbia -PMC - PMC10453050 -OTO - NOTNLM -OT - PD-L1 -OT - adjuvant -OT - durvalumab -OT - immune checkpoint inhibitors -OT - locally advanced non-small cell lung cancer -COIS- Marie-Hélène Denault has received speaker honoraria from Astra Zeneca and - Janssen, and travel funding from Astra Zeneca to attend ESMO 2022. Jamie Feng has - received speaker honoraria from Astra Zeneca. Bonnie Leung has received honoraria - from Astra Zeneca. Janessa Laskin has received honoraria from Roche, Pfizer, - Takeda and Lilly; she has also received research funding to her institution from - Roche. Tina Zhang has received speaker honoraria from Ipsen Biopharmaceuticals - and Pfizer. Cheryl Ho has received research grants paid to her institution from - Astra Zeneca, EMD Serono and Roche. Cheryl Ho has received honoraria from Abbvie, - Amgen, Astra Zeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Jazz, Merck, - Novartis, Pfizer, Roche, Sanofi and Takeda. Barbara Melosky has been on advisory - boards for Astra Zeneca, BMS, Boehringer Ingelheim, Jazz, Merck, Novartis, - Pfizer, Roche and Takeda. Shelley Kuang, Aria Shokoohi, Mitchell Liu, Eric - Berthelet and Sophie Sun do not have any interest to declare. -EDAT- 2023/08/25 12:43 -MHDA- 2023/08/28 06:42 -PMCR- 2023/08/08 -CRDT- 2023/08/25 08:53 -PHST- 2023/06/05 00:00 [received] -PHST- 2023/07/20 00:00 [revised] -PHST- 2023/08/03 00:00 [accepted] -PHST- 2023/08/28 06:42 [medline] -PHST- 2023/08/25 12:43 [pubmed] -PHST- 2023/08/25 08:53 [entrez] -PHST- 2023/08/08 00:00 [pmc-release] -AID - curroncol30080543 [pii] -AID - curroncol-30-00543 [pii] -AID - 10.3390/curroncol30080543 [doi] -PST - epublish -SO - Curr Oncol. 2023 Aug 8;30(8):7499-7507. doi: 10.3390/curroncol30080543. - -PMID- 36271595 -OWN - NLM -STAT- MEDLINE -DCOM- 20230323 -LR - 20230326 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 12 -IP - 5 -DP - 2023 Mar -TI - Immunotherapy combined with chemotherapy improved clinical outcomes over - bevacizumab combined with chemotherapy as first-line therapy in adenocarcinoma - patients. -PG - 5352-5363 -LID - 10.1002/cam4.5356 [doi] -AB - PURPOSE: No definite conclusion has yet to be reached for the first-line - treatment combined with chemotherapy for advanced adenocarcinoma NSCLC patients - with negative driver genes. This study sought to compare the clinical outcomes of - Beva+ChT and IO+ChT as first-line treatment for this population and investigated - whether the statuses of BM, PD-L1 expression, and KRAS and TP53 mutations could - influence the results. PATIENTS AND METHODS: The clinical data of patients with - adenocarcinoma NSCLC who received first-line therapy were retrospectively - collected and the patients were assigned to the IO+ChT and Beva+ChT groups. The - disease control rate (DCR), progression-free survival (PFS), and overall survival - (OS) were evaluated between the two groups. The survival effects of BM, PD-L1 - expression, and KRAS and TP53 mutations were also evaluated. RESULTS: From April - 2018 to October 2020, a total of 105 patients with first-line therapy were - included in our analysis; 54 (51.4%) patients were included in the IO+ChT group - and 51 (48.6%) patients were included in the Beva+ChT group. The results showed - that OS (NR vs. 18.3 m, p = 0.011) and PFS (14.9 m vs. 6.3 m, p < 0.001) were - superior in patients in the IO+ChT group than in patients in the Beva+ChT group. - Further analysis revealed that the OS (median OS: NR vs. 14.7 months, p = 0.039) - and PFS (median PFS: 18.5 vs. 5.5 months, p < 0.001) advantages of the IO+ChT - group were also seen in the PD-L1 > 1% subgroup but were not seen in the - PD-L1 < 1%, BM or KRAS mutation subgroups. CONCLUSIONS: ICIs combined with ChT - improved clinical outcomes over Beva combined with ChT as first-line therapy for - adenocarcinoma patients without driver gene alterations, especially in patients - with PD-L1 ≥ 1%. -CI - © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Wang, Min -AU - Wang M -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Li, Ji -AU - Li J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Xu, Shuhui -AU - Xu S -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Li, Yuying -AU - Li Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Li, Jiatong -AU - Li J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Tang, Xiaoyong -AU - Tang X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute - affiliated of Shandong University, Jinan, Shandong, China. -FAU - Zhu, Hui -AU - Zhu H -AUID- ORCID: 0000-0001-9422-3886 -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute - affiliated of Shandong University, Jinan, Shandong, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20221021 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 2S9ZZM9Q9V (Bevacizumab) -RN - 0 (B7-H1 Antigen) -RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Humans -MH - *Lung Neoplasms/drug therapy/genetics/pathology -MH - Bevacizumab/therapeutic use -MH - B7-H1 Antigen -MH - Retrospective Studies -MH - Proto-Oncogene Proteins p21(ras)/genetics -MH - *Antineoplastic Agents, Immunological/adverse effects -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Adenocarcinoma/drug therapy/genetics -MH - Immunotherapy/methods -PMC - PMC10028054 -OTO - NOTNLM -OT - NSCLC -OT - adenocarcinoma -OT - bevacizumab -OT - first-line therapy -OT - immunotherapy -EDAT- 2022/10/23 06:00 -MHDA- 2023/03/24 06:00 -PMCR- 2022/10/21 -CRDT- 2022/10/22 01:12 -PHST- 2022/08/18 00:00 [revised] -PHST- 2022/01/27 00:00 [received] -PHST- 2022/10/05 00:00 [accepted] -PHST- 2022/10/23 06:00 [pubmed] -PHST- 2023/03/24 06:00 [medline] -PHST- 2022/10/22 01:12 [entrez] -PHST- 2022/10/21 00:00 [pmc-release] -AID - CAM45356 [pii] -AID - 10.1002/cam4.5356 [doi] -PST - ppublish -SO - Cancer Med. 2023 Mar;12(5):5352-5363. doi: 10.1002/cam4.5356. Epub 2022 Oct 21. - -PMID- 27163312 -OWN - NLM -STAT- MEDLINE -DCOM- 20170522 -LR - 20170522 -IS - 1878-7401 (Electronic) -IS - 0928-7329 (Linking) -VI - 24 Suppl 2 -DP - 2016 Apr 29 -TI - 131I-chTNT injection to relieve tracheal obstruction in advanced NSCLC patient. -PG - S513-9 -LID - 10.3233/THC-161176 [doi] -AB - OBJECTIVE: To relieve large airway obstruction in a patient with advanced - non-small cell lung cancer (NSCLC) by injecting the mouse-human chimeric - monoclonal antibody radiolabeled with iodine 131 chimeric tumor necrotic - treatment (131I-chTNT) and to study the irradiation absorption in the tumor and - critical organs. METHODS: A 50-year-old patient with NSCLC was treated with - radioimmunotherapy. His airway was still obstructed in spite of intensive - chemotherapy and radiotherapy.131I-chTNT was injected into the tumor at the right - bronchus through a fiberscope. A131I scan was performed during treatment, and a - computed tomography (CT) scan of the chest and fiberscope were performed pre- and - post-treatment.131I-chTNT distribution in tissues was followed for up to 4 weeks - using gamma camera imaging. RESULTS: The radiation material accumulated notably - in the tumor, relieving the patient's symptoms by suppressing the tumor. - Recanalization of the airway was achieved so that the patient was able to breathe - easily and cough. CONCLUSION: As a new type of radioimmunotherapy,131I-chTNT may - be helpful in treatment of advanced lung cancer. -FAU - He, Mengzhang -AU - He M -FAU - Li, Shiyue -AU - Li S -FAU - Chen, Yu -AU - Chen Y -FAU - Ouyang, Ming -AU - Ouyang M -FAU - Chen, Ping -AU - Chen P -FAU - Zhang, Jiexia -AU - Zhang J -LA - eng -PT - Case Reports -PT - Journal Article -PL - Netherlands -TA - Technol Health Care -JT - Technology and health care : official journal of the European Society for - Engineering and Medicine -JID - 9314590 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Tumor Necrosis Factor-alpha) -SB - IM -MH - Airway Obstruction/*drug therapy -MH - Antibodies, Monoclonal -MH - Carcinoma, Non-Small-Cell Lung/*pathology -MH - Humans -MH - Injections -MH - Male -MH - Middle Aged -MH - *Radioimmunotherapy -MH - Tomography, X-Ray Computed -MH - Trachea/*physiopathology -MH - Treatment Outcome -MH - Tumor Necrosis Factor-alpha/*therapeutic use -OTO - NOTNLM -OT - Antibodies -OT - NSCLC -OT - iodine radioisotopes -OT - monoclonal -OT - radioimmunotherapy -EDAT- 2016/05/11 06:00 -MHDA- 2017/05/23 06:00 -CRDT- 2016/05/11 06:00 -PHST- 2016/05/11 06:00 [entrez] -PHST- 2016/05/11 06:00 [pubmed] -PHST- 2017/05/23 06:00 [medline] -AID - THC1176 [pii] -AID - 10.3233/THC-161176 [doi] -PST - ppublish -SO - Technol Health Care. 2016 Apr 29;24 Suppl 2:S513-9. doi: 10.3233/THC-161176. - -PMID- 33130353 -OWN - NLM -STAT- MEDLINE -DCOM- 20210621 -LR - 20210621 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 150 -DP - 2020 Dec -TI - Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: - The multicenter retrospective CLARITY study. -PG - 123-131 -LID - S0169-5002(20)30658-9 [pii] -LID - 10.1016/j.lungcan.2020.10.008 [doi] -AB - OBJECTIVES: In the most of cases, for non-small cell lung cancer (NSCLC) patients - who progressed to previous immune checkpoint inhibitors (CKI) administered as - first- or as second-line therapy, chemotherapy (CT) remains the only viable - options in the absence of "druggable" mutations. We aimed to explore the efficacy - of salvage chemotherapy after immunotherapy (SCAI) in advanced NSCLC patients. - MATERIALS AND METHODS: We designed a retrospective, multicenter study, involving - 20 Italian centers, with the primary objective of describing the clinical outcome - of advanced NSCLC patients treated with SCAI at the participating institutions - from November 2013 to July 2019. The primary endpoint of the study was - represented by overall survival (OS), defined as the time from CT initiation to - death. Secondary outcome endpoints of the SCAI (progression free survival, PFS, - objective response rate, ORR and toxicity) and explorative biomarkers (lactate - dehydrogenase, LDH, and neutrophil-to-lymphocyte ratio, NLR during immunotherapy) - were also analyzed. RESULTS: In our study population of 342 NSCLC patients, SCAI - obtained a median OS of 6.8 months (95 % confidence interval, CI 5.5-8.1), median - PFS of 4.1 months (95 % CI 3.4-4.8) and ORR of 22.8 %. A "Post-CKI score" was - constructed by combining significant predictors of OS at the multivariate - analyses (sex, ECOG PS, disease control with prior immunotherapy), Harrell'C was - 0.65, (95 % CI:0.59-0.71). CONCLUSIONS: Despite the late-line settings, our - findings support the hypothesis that previous immunotherapy might increase the - sensitivity of the tumor to the subsequent chemotherapy. The "Post-CKI score" was - clinically effective in successfully discriminating three distinct prognostic - subgroups of patients after the failure of CKI, representing a possibly useful - tool for the tailored decision-making process of advanced treatment-line settings - in NSCLC. -CI - Copyright © 2020 Elsevier B.V. All rights reserved. -FAU - Bersanelli, Melissa -AU - Bersanelli M -AD - Medicine and Surgery Department, University of Parma, Parma, Italy; Medical - Oncology Unit, University Hospital of Parma, Parma, Italy. Electronic address: - bersamel@libero.it. -FAU - Buti, Sebastiano -AU - Buti S -AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. -FAU - Giannarelli, Diana -AU - Giannarelli D -AD - Regina Elena National Cancer Institute, IRCCS, Biostatistical Unit, Roma, Italy. -FAU - Leonetti, Alessandro -AU - Leonetti A -AD - Medicine and Surgery Department, University of Parma, Parma, Italy; Medical - Oncology Unit, University Hospital of Parma, Parma, Italy. -FAU - Cortellini, Alessio -AU - Cortellini A -AD - Department of Biotechnology and Applied Clinical Science, University of L'Aquila, - L'Aquila, Italy; Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy. -FAU - Russo, Giuseppe Lo -AU - Russo GL -AD - Oncologia Toracica, Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto - Nazionale dei Tumori di Milano, Italy. -FAU - Signorelli, Diego -AU - Signorelli D -AD - Oncologia Toracica, Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto - Nazionale dei Tumori di Milano, Italy. -FAU - Toschi, Luca -AU - Toschi L -AD - Medical Oncology, Humanitas Clinical and Research Center - IRCCS, Rozzano, - Milano, Italy. -FAU - Milella, Michele -AU - Milella M -AD - Section of Oncology, Department of Medicine, University of Verona School of - Medicine and Verona University Hospital Trust, Verona, Italy. -FAU - Pilotto, Sara -AU - Pilotto S -AD - Section of Oncology, Department of Medicine, University of Verona School of - Medicine and Verona University Hospital Trust, Verona, Italy. -FAU - Bria, Emilio -AU - Bria E -AD - Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino - Gemelli IRCCS, and Dipartimento di Medicina e Chirurgia Traslazionale, Università - Cattolica del Sacro Cuore, Roma, Italy. -FAU - Proto, Claudia -AU - Proto C -AD - Oncologia Toracica, Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto - Nazionale dei Tumori di Milano, Italy. -FAU - Marinello, Arianna -AU - Marinello A -AD - Medical Oncology, Humanitas Clinical and Research Center - IRCCS, Rozzano, - Milano, Italy. -FAU - Randon, Giovanni -AU - Randon G -AD - Oncologia Toracica, Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto - Nazionale dei Tumori di Milano, Italy. -FAU - Rossi, Sabrina -AU - Rossi S -AD - Medical Oncology, Humanitas Clinical and Research Center - IRCCS, Rozzano, - Milano, Italy. -FAU - Vita, Emanuele -AU - Vita E -AD - Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino - Gemelli IRCCS, and Dipartimento di Medicina e Chirurgia Traslazionale, Università - Cattolica del Sacro Cuore, Roma, Italy. -FAU - Sartori, Giulia -AU - Sartori G -AD - Section of Oncology, Department of Medicine, University of Verona School of - Medicine and Verona University Hospital Trust, Verona, Italy. -FAU - D'Argento, Ettore -AU - D'Argento E -AD - Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino - Gemelli IRCCS, and Dipartimento di Medicina e Chirurgia Traslazionale, Università - Cattolica del Sacro Cuore, Roma, Italy. -FAU - Qako, Eva -AU - Qako E -AD - Medicine and Surgery Department, University of Parma, Parma, Italy. -FAU - Giaiacopi, Elisa -AU - Giaiacopi E -AD - Medicine and Surgery Department, University of Parma, Parma, Italy. -FAU - Ghilardi, Laura -AU - Ghilardi L -AD - UO di Oncologia medica, ASST PAPA Giovanni XXIII Bergamo, Italy. -FAU - Bettini, Anna Cecilia -AU - Bettini AC -AD - UO di Oncologia medica, ASST PAPA Giovanni XXIII Bergamo, Italy. -FAU - Rapacchi, Elena -AU - Rapacchi E -AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. -FAU - Mazzoni, Francesca -AU - Mazzoni F -AD - Oncology Department, Careggi University Hospital, Firenze, Italy. -FAU - Lavacchi, Daniele -AU - Lavacchi D -AD - Oncology Department, Careggi University Hospital, Firenze, Italy. -FAU - Scotti, Vieri -AU - Scotti V -AD - Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria - Careggi, Firenze, Italy. -FAU - Ciccone, Lucia Pia -AU - Ciccone LP -AD - Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria - Careggi, Firenze, Italy. -FAU - De Tursi, Michele -AU - De Tursi M -AD - Dipartimento di Scienze mediche, orali e biotecnologiche, Sezione di Oncologia, - Università G. D'Annunzio, Chieti, Italy. -FAU - Di Marino, Pietro -AU - Di Marino P -AD - Dipartimento di Scienze mediche, orali e biotecnologiche, Sezione di Oncologia, - Università G. D'Annunzio, Chieti, Italy. -FAU - Santini, Daniele -AU - Santini D -AD - Oncologia Medica, Università Campus Bio-Medico, Roma, Italy. -FAU - Russano, Marco -AU - Russano M -AD - Oncologia Medica, Università Campus Bio-Medico, Roma, Italy. -FAU - Bordi, Paola -AU - Bordi P -AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. -FAU - Di Maio, Massimo -AU - Di Maio M -AD - Department of Oncology, University of Turin, AO Ordine Mauriziano Hospital, - Torino, Italy. -FAU - Audisio, Marco -AU - Audisio M -AD - Department of Oncology, University of Turin, AO Ordine Mauriziano Hospital, - Torino, Italy. -FAU - Filetti, Marco -AU - Filetti M -AD - Medical Oncology Unit, Azienda Ospedaliero-Universitaria Sant'Andrea, Roma, - Italy. -FAU - Giusti, Raffaele -AU - Giusti R -AD - Medical Oncology Unit, Azienda Ospedaliero-Universitaria Sant'Andrea, Roma, - Italy. -FAU - Berardi, Rossana -AU - Berardi R -AD - Clinica Oncologica, Università Politecnica delle Marche - Ospedali Riuniti, - Ancona, Italy. -FAU - Fiordoliva, Ilaria -AU - Fiordoliva I -AD - Clinica Oncologica, Università Politecnica delle Marche - Ospedali Riuniti, - Ancona, Italy. -FAU - Cerea, Giulio -AU - Cerea G -AD - Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy. -FAU - Pizzutilo, Elio Gregory -AU - Pizzutilo EG -AD - Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy. -FAU - Bearz, Alessandra -AU - Bearz A -AD - Centro di Riferimento Oncologico, CRO-IRCCS, Aviano, Italy. -FAU - De Carlo, Elisa -AU - De Carlo E -AD - Centro di Riferimento Oncologico, CRO-IRCCS, Aviano, Italy. -FAU - Cecere, Fabiana -AU - Cecere F -AD - Regina Elena National Cancer Institute, IRCCS, Oncology Unit, Roma, Italy. -FAU - Renna, Davide -AU - Renna D -AD - Regina Elena National Cancer Institute, IRCCS, Oncology Unit, Roma, Italy. -FAU - Camisa, Roberta -AU - Camisa R -AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. -FAU - Caruso, Giuseppe -AU - Caruso G -AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. -FAU - Ficorella, Corrado -AU - Ficorella C -AD - Department of Biotechnology and Applied Clinical Science, University of L'Aquila, - L'Aquila, Italy; Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy. -FAU - Banna, Giuseppe Luigi -AU - Banna GL -AD - Portsmouth Hospitals NHS Trust, Portsmouth, UK. -FAU - Cortinovis, Diego -AU - Cortinovis D -AD - SC Oncologia/SS Lung Unit Asst H S Gerardo, Monza, Italy. -FAU - Brighenti, Matteo -AU - Brighenti M -AD - Medical Oncology Department, ASST Cremona, Cremona, Italy. -FAU - Garassino, Marina Chiara -AU - Garassino MC -AD - Oncologia Toracica, Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto - Nazionale dei Tumori di Milano, Italy. -FAU - Tiseo, Marcello -AU - Tiseo M -AD - Medicine and Surgery Department, University of Parma, Parma, Italy; Medical - Oncology Unit, University Hospital of Parma, Parma, Italy. -LA - eng -PT - Journal Article -PT - Multicenter Study -DEP - 20201022 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy -MH - Prognosis -MH - Retrospective Studies -OTO - NOTNLM -OT - CLARITY -OT - Chemotherapy after immunotherapy -OT - Immune checkpoint inhibitors -OT - NSCLC -OT - Salvage chemotherapy -EDAT- 2020/11/02 06:00 -MHDA- 2021/06/22 06:00 -CRDT- 2020/11/01 20:33 -PHST- 2020/07/27 00:00 [received] -PHST- 2020/10/11 00:00 [revised] -PHST- 2020/10/14 00:00 [accepted] -PHST- 2020/11/02 06:00 [pubmed] -PHST- 2021/06/22 06:00 [medline] -PHST- 2020/11/01 20:33 [entrez] -AID - S0169-5002(20)30658-9 [pii] -AID - 10.1016/j.lungcan.2020.10.008 [doi] -PST - ppublish -SO - Lung Cancer. 2020 Dec;150:123-131. doi: 10.1016/j.lungcan.2020.10.008. Epub 2020 - Oct 22. - -PMID- 38651178 -OWN - NLM -STAT- MEDLINE -DCOM- 20240425 -LR - 20240426 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 13 -IP - 8 -DP - 2024 Apr -TI - Survival and safety analysis of COVID-19 vaccine in Chinese patients with - non-small cell lung cancer. -PG - e7032 -LID - 10.1002/cam4.7032 [doi] -LID - e7032 -AB - BACKGROUND: Severe acute respiratory syndrome coronavirus 2 disease (COVID-19) - has caused a worldwide challenging and threatening pandemic. We aimed to assess - the safety and efficacy of the COVID-19 vaccines in Non-Small Cell Lung Cancer - (NSCLC) patients. METHODS: Patient self-reported adverse events related to - vaccines were recorded by follow-up through a uniform questionnaire. Survival - analysis was performed by Kaplan-Meier method. A multivariate analysis was - performed by the Cox proportional hazard regression model to determine the effect - of each variable on the survival of lung cancer patients. RESULTS: A total of 860 - patients with NSCLC on treatment were enrolled. Mean age was 57 years in patients - with early stage group and 62 years in advanced stage group. The vaccination rate - was 71.11% for early-stage patients and 19.48% for advanced-stage patients; most - of them (86.5%) received the COVID-19 inactivated virus (Vero cell) vaccine - (Coronavac; Sinovac). The most common systemic adverse reaction was weakness. The - main reason for vaccine refusal in those unvaccinated patients was concern about - the safety of vaccination in the presence of a tumor and undergoing treatment - (56.9% and 53.4%). The 1-year disease-free survival (DFS) rate was 100% for - vaccinated and 97.4% for unvaccinated early-stage patients. Then we compared the - progression-free survival (PFS) of vaccinated (median PFS 9.0 months) and - unvaccinated (median PFS 7.0 months) advanced stage patients (p = 0.815). - Advanced NSCLC patients continued to be divided into groups receiving - radio-chemotherapy, immunotherapy, and targeted therapy, with no statistical - difference in PFS between the groups (p > 0.05). The median overall survival (OS) - of vaccinated patients was 20.5 months, and that of unvaccinated patients was - 19.0 months (p = 0.478) in advanced NSCLC patients. CONCLUSIONS: COVID-19 - vaccination is safe for Chinese NSCLC patients actively receiving different - antitumor treatments without increasing the incidence of adverse reactions, and - vaccination does not affect cancer patient survival. -CI - © 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Xu, Wei -AU - Xu W -AUID- ORCID: 0000-0002-9725-4335 -AD - Department of Medical Oncology, Shandong Provincial Hospital Affiliated to - Shandong First Medical University, Jinan, Shandong, China. -AD - Department of Medical Oncology, Shandong Provincial Hospital, Cheeloo College of - Medicine, Shandong University, Jinan, Shandong, China. -FAU - Zhao, Jing -AU - Zhao J -AD - Department of Medical Oncology, Shandong Provincial Hospital Affiliated to - Shandong First Medical University, Jinan, Shandong, China. -FAU - Luan, Fang -AU - Luan F -AD - Department of Medical Oncology, Shandong Provincial Hospital Affiliated to - Shandong First Medical University, Jinan, Shandong, China. -FAU - Zhang, Zhizhao -AU - Zhang Z -AD - Department of Medical Oncology, Shandong Provincial Hospital Affiliated to - Shandong First Medical University, Jinan, Shandong, China. -FAU - Liu, Lei -AU - Liu L -AD - Department of Medical Oncology, Shandong Provincial Hospital Affiliated to - Shandong First Medical University, Jinan, Shandong, China. -FAU - Zhao, Hui -AU - Zhao H -AD - Department of Medical Oncology, Shandong Provincial Hospital Affiliated to - Shandong First Medical University, Jinan, Shandong, China. -FAU - Feng, Bin -AU - Feng B -AD - Department of Medical Oncology, Shandong Provincial Hospital Affiliated to - Shandong First Medical University, Jinan, Shandong, China. -FAU - Fu, Guobin -AU - Fu G -AD - Department of Medical Oncology, Shandong Provincial Hospital Affiliated to - Shandong First Medical University, Jinan, Shandong, China. -AD - Department of Medical Oncology, Shandong Provincial Hospital, Cheeloo College of - Medicine, Shandong University, Jinan, Shandong, China. -AD - Department of Medical Oncology, The Third Affiliated Hospital of Shandong First - Medical University, Jinan, Shandong, China. -LA - eng -GR - tsqn202103179/Taishan Scholar Foundation of Shandong Province/ -GR - YXH2022ZX02176/2021 Shandong Medical Association Clinical Research Fund/ -GR - 81802284/National Natural Science Foundation of China/ -GR - Y-HR2022MS-0257/Beijing Xisike Clinical Oncology Research Foundation/ -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (COVID-19 Vaccines) -SB - IM -MH - Adult -MH - Aged -MH - Female -MH - Humans -MH - Male -MH - Middle Aged -MH - *Carcinoma, Non-Small-Cell Lung/mortality/therapy -MH - China/epidemiology -MH - *COVID-19/prevention & control/epidemiology -MH - *COVID-19 Vaccines/adverse effects/administration & dosage -MH - East Asian People -MH - *Lung Neoplasms/mortality/therapy -MH - Neoplasm Staging -MH - Vaccination -PMC - PMC11036071 -OTO - NOTNLM -OT - COVID‐19 vaccine safety -OT - non‐small cell lung cancer -OT - safety -OT - severe acute respiratory syndrome coronavirus 2 -OT - survival analysis -COIS- All authors declare that there is no conflict of interest. -EDAT- 2024/04/23 15:04 -MHDA- 2024/04/25 06:49 -PMCR- 2024/04/23 -CRDT- 2024/04/23 03:49 -PHST- 2024/01/17 00:00 [revised] -PHST- 2023/09/10 00:00 [received] -PHST- 2024/02/08 00:00 [accepted] -PHST- 2024/04/25 06:49 [medline] -PHST- 2024/04/23 15:04 [pubmed] -PHST- 2024/04/23 03:49 [entrez] -PHST- 2024/04/23 00:00 [pmc-release] -AID - CAM47032 [pii] -AID - 10.1002/cam4.7032 [doi] -PST - ppublish -SO - Cancer Med. 2024 Apr;13(8):e7032. doi: 10.1002/cam4.7032. - -PMID- 34839373 -OWN - NLM -STAT- MEDLINE -DCOM- 20220614 -LR - 20240426 -IS - 1432-0851 (Electronic) -IS - 0340-7004 (Print) -IS - 0340-7004 (Linking) -VI - 71 -IP - 7 -DP - 2022 Jul -TI - Baseline tumour size is an independent prognostic factor for overall survival in - PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line - pembrolizumab. -PG - 1747-1756 -LID - 10.1007/s00262-021-03108-x [doi] -AB - BACKGROUND: Advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumour - proportion score ≥ 50% can be treated with pembrolizumab alone. Our aim was to - assess the impact of baseline tumour size (BTS) on overall survival (OS) in NSCLC - patients treated with pembrolizumab versus chemotherapy. METHODS: This - retrospective, multicentre study included all patients with untreated advanced - NSCLC receiving either pembrolizumab (PD-L1 ≥ 50%) or platinum-based chemotherapy - (any PD-L1). The primary endpoint was the impact of BTS (defined as the sum of - the dimensions of baseline target lesions according to RECIST v1.1 criteria) on - OS. RESULTS: Between 09-2016 and 06-2020, 188 patients were included, 96 in the - pembrolizumab (P-group) and 92 in the chemotherapy group (CT-group). The median - follow-up was 26.9 months (range 0.13-37.91) and 44.4 months (range 0.23-48.62), - respectively, while the median BTS was similar, 85.5 mm (IQR 57.2-113.2) and - 86.0 mm (IQR 53.0-108.5), respectively (p = 0.42). The median P-group OS was - 18.2 months [95% CI 12.2-not reached (NR)] for BTS > 86 mm versus NR (95% CI - 27.2-NR) for BTS ≤ 86 mm (p = 0.0026). A high BTS was associated with a shorter - OS in univariate analyses (p = 0.009) as well as after adjustment on confounding - factors (HR 2.16, [95% CI 1.01-4.65], p = 0.048). The CT-group OS was not - statistically different between low and high BTS patients, in univariate and - multivariate analyses (p = 0.411). CONCLUSIONS: After adjustment on major - baseline clinical prognostic factors, BTS was an independent prognostic factor - for OS in PD-L1 ≥ 50% advanced NSCLC patients treated first-line with - pembrolizumab. -CI - © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, - part of Springer Nature. -FAU - Bureau, Mathilde -AU - Bureau M -AD - Medical Oncology Unit, Hôpital Laennec, CHU de Nantes, University Hospital of - Nantes, Boulevard Professeur Jacques Monod, Saint Herblain, 44800, Nantes, - France. -FAU - Chatellier, Thierry -AU - Chatellier T -AD - Medical Oncology Unit, Clinique Mutualiste de l'Estuaire, Saint-Nazaire, France. -FAU - Perennec, Tanguy -AU - Perennec T -AD - Department of Radiation Oncology, Institut de Cancerologie de L'Ouest, - Saint-Herblain, France. -FAU - Goronflot, Thomas -AU - Goronflot T -AD - INSERM, University Hospital of Nantes, CIC 1413, PHU 11, Data Clinic, Nantes, - France. -FAU - Greilsamer, Charlotte -AU - Greilsamer C -AD - Medical Oncology Unit, Hospital of La Roche-sur-Yon, La Roche-sur-Yon, France. -FAU - Chene, Anne-Laure -AU - Chene AL -AD - Pneumology Unit, University Hospital of Nantes, Nantes, France. -FAU - Affi, Raafet -AU - Affi R -AD - Medical Oncology Unit, Hôpital Laennec, CHU de Nantes, University Hospital of - Nantes, Boulevard Professeur Jacques Monod, Saint Herblain, 44800, Nantes, - France. -FAU - Frampas, Eric -AU - Frampas E -AD - Radiology Unit, University Hospital of Nantes, Nantes, France. -FAU - Bennouna, Jaafar -AU - Bennouna J -AD - Medical Oncology Unit, Hôpital Laennec, CHU de Nantes, University Hospital of - Nantes, Boulevard Professeur Jacques Monod, Saint Herblain, 44800, Nantes, - France. -AD - INSERM, CRCINA, Nantes, France. -FAU - Pons-Tostivint, Elvire -AU - Pons-Tostivint E -AUID- ORCID: 0000-0003-4478-0523 -AD - Medical Oncology Unit, Hôpital Laennec, CHU de Nantes, University Hospital of - Nantes, Boulevard Professeur Jacques Monod, Saint Herblain, 44800, Nantes, - France. elvire.pons@chu-nantes.fr. -AD - INSERM, CRCINA, Nantes, France. elvire.pons@chu-nantes.fr. -LA - eng -PT - Journal Article -PT - Multicenter Study -DEP - 20211128 -PL - Germany -TA - Cancer Immunol Immunother -JT - Cancer immunology, immunotherapy : CII -JID - 8605732 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized -MH - B7-H1 Antigen/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - Humans -MH - *Lung Neoplasms/pathology -MH - Prognosis -MH - Retrospective Studies -PMC - PMC10992007 -OTO - NOTNLM -OT - Baseline tumour size -OT - Immune checkpoint inhibitor -OT - Non-small cell lung cancer -OT - Pembrolizumab -COIS- The authors declare that they do not have any conflict of interest. -EDAT- 2021/11/29 06:00 -MHDA- 2022/06/15 06:00 -PMCR- 2021/11/28 -CRDT- 2021/11/28 21:13 -PHST- 2021/07/17 00:00 [received] -PHST- 2021/11/05 00:00 [accepted] -PHST- 2021/11/29 06:00 [pubmed] -PHST- 2022/06/15 06:00 [medline] -PHST- 2021/11/28 21:13 [entrez] -PHST- 2021/11/28 00:00 [pmc-release] -AID - 10.1007/s00262-021-03108-x [pii] -AID - 3108 [pii] -AID - 10.1007/s00262-021-03108-x [doi] -PST - ppublish -SO - Cancer Immunol Immunother. 2022 Jul;71(7):1747-1756. doi: - 10.1007/s00262-021-03108-x. Epub 2021 Nov 28. - -PMID- 39134529 -OWN - NLM -STAT- MEDLINE -DCOM- 20240812 -LR - 20240815 -IS - 2059-3635 (Electronic) -IS - 2095-9907 (Print) -IS - 2059-3635 (Linking) -VI - 9 -IP - 1 -DP - 2024 Aug 13 -TI - Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase - inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer - (FL-ALTER): a multicenter phase III trial. -PG - 215 -LID - 10.1038/s41392-024-01927-9 [doi] -LID - 215 -AB - Dual inhibition of vascular endothelial growth factor and epidermal growth factor - receptor (EGFR) signaling pathways offers the prospect of improving the - effectiveness of EFGR-targeted therapy. In this phase 3 study (ClinicalTrial.gov: - NCT04028778), 315 patients with treatment-naïve, EGFR-mutated, advanced non-small - cell lung cancer (NSCLC) were randomized (1:1) to receive anlotinib or placebo - plus gefitinib once daily on days 1-14 per a 3-week cycle. At the prespecified - final analysis of progression-free survival (PFS), a significant improvement in - PFS was observed for the anlotinib arm over the placebo arm (hazards ratio - [HR] = 0.64, 95% CI, 0.48-0.80, P = 0.003). Particularly, patients with brain - metastasis and those harboring EGFR amplification or high tumor mutation load - gained significant more benefits in PFS from gefitinib plus anlotinib. The - incidence of grade 3 or higher treatment-emergent adverse events was 49.7% of the - patients receiving gefitinib plus anlotinib versus 31.0% of the patients - receiving gefitinib plus placebo. Anlotinib plus gefitinib significantly improves - PFS in patients with treatment-naïve, EGFR-mutated, advanced NSCLC, with a - manageable safety profile. -CI - © 2024. The Author(s). -FAU - Zhou, Hua-Qiang -AU - Zhou HQ -AUID- ORCID: 0000-0003-3538-4481 -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center for Cancer Medicine, - Guangzhou, 510060, China. -FAU - Zhang, Ya-Xiong -AU - Zhang YX -AUID- ORCID: 0000-0002-3632-0300 -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center for Cancer Medicine, - Guangzhou, 510060, China. -FAU - Chen, Gang -AU - Chen G -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center for Cancer Medicine, - Guangzhou, 510060, China. -FAU - Yu, Qi-Tao -AU - Yu QT -AD - Department of Medical Oncology of Respirotary, Affiliated Tumor Hospital of - Guangxi Medical University, Nanning, 530021, China. -FAU - Zhang, Hua -AU - Zhang H -AD - Department of Urogenital Oncology, the First People's Hospital of Foshan, Foshan, - 52800, China. -FAU - Wu, Guo-Wu -AU - Wu GW -AD - Department of Medical Oncology, Meizhou People's Hospital (Huangtang Hospital), - Meizhou, 514031, China. -FAU - Wu, Di -AU - Wu D -AD - Department of Respiratory and Critical Care Medicine, Shenzhen people's Hospital, - Shenzhen, 518020, China. -FAU - Lin, Ying-Cheng -AU - Lin YC -AD - Department of Medical Oncology of Respirotary, Cancer Hospital of Shantou - University Medical College, Shantou, 515031, China. -FAU - Zhu, Jun-Fei -AU - Zhu JF -AD - Department of Respiratory and Critical Care Medicine, Taizhou Central Hospital, - Taizhou, 318000, China. -FAU - Chen, Jian-Hua -AU - Chen JH -AD - Department of Medical Oncology, Hunan Provincial Cancer Hospital, Changsha, - 410031, China. -FAU - Hu, Xiao-Hua -AU - Hu XH -AD - Department of Medical Oncology, the First Affiliated Hospital of Guangxi Medical - University, Nanning, 530021, China. -FAU - Lan, Bin -AU - Lan B -AD - Department of Cardiothoracic Surgery, Shantou Central Hospital, Shantou, 515031, - China. -FAU - Zhou, Ze-Qiang -AU - Zhou ZQ -AD - Department of Oncology, the 2nd People's Hospital of Shenzhen, Shenzhen, 518025, - China. -FAU - Lin, Hai-Feng -AU - Lin HF -AD - Department of Medical Oncology, the Second Affiliated Hospital of Hainan Medical - University, Haikou, 570216, China. -FAU - Wang, Zi-Bing -AU - Wang ZB -AD - Department of Immunotherapy, Henan Cancer Hospital, Zhengzhou, 450003, China. -FAU - Lei, Xiao-Lin -AU - Lei XL -AD - Department of Oncology, Affiliated Hospital of Panzhihua University, Panzhihua, - 617099, China. -FAU - Pan, Suo-Ming -AU - Pan SM -AD - Department of Radiotherapy, Yuebei People's Hospital, Shaoguan, 512099, China. -FAU - Chen, Li-Ming -AU - Chen LM -AD - Department of Oncology, the First Affiliated Hospital of Shantou University - Medicine College, Shantou, 515041, China. -FAU - Zhang, Jian -AU - Zhang J -AD - Department of Oncology, ZhuJiang Hospital of Southern Medical University (The - Second Clinical Medical College), Guangzhou, 510280, China. -FAU - Kong, Tian-Dong -AU - Kong TD -AD - Department of Respiratory Oncology, the Third People's Hospital of Zhengzhou, - Zhengzhou, 450001, China. -FAU - Yao, Ji-Cheng -AU - Yao JC -AD - Shanghai OrigiMed Co., Ltd, Shanghai, China. -FAU - Zheng, Xin -AU - Zheng X -AD - Shanghai OrigiMed Co., Ltd, Shanghai, China. -FAU - Li, Feng -AU - Li F -AD - Shanghai OrigiMed Co., Ltd, Shanghai, China. -FAU - Zhang, Li -AU - Zhang L -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center for Cancer Medicine, - Guangzhou, 510060, China. zhangli@sysucc.org.cn. -FAU - Fang, Wen-Feng -AU - Fang WF -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Guangdong Provincial Clinical Research - Center for Cancer, Collaborative Innovation Center for Cancer Medicine, - Guangzhou, 510060, China. fangwf@sysucc.org.cn. -LA - eng -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -DEP - 20240813 -PL - England -TA - Signal Transduct Target Ther -JT - Signal transduction and targeted therapy -JID - 101676423 -RN - 0 (anlotinib) -RN - S65743JHBS (Gefitinib) -RN - 0 (Quinolines) -RN - 0 (Indoles) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - 0 (Protein Kinase Inhibitors) -RN - 0 (Tyrosine Kinase Inhibitors) -SB - IM -MH - Humans -MH - *Gefitinib/administration & dosage/adverse effects/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology -MH - *Quinolines/administration & dosage/adverse effects/therapeutic use -MH - *Indoles/administration & dosage/therapeutic use/adverse effects -MH - Male -MH - Female -MH - *ErbB Receptors/genetics/antagonists & inhibitors -MH - Middle Aged -MH - Aged -MH - *Mutation -MH - *Lung Neoplasms/drug therapy/genetics/pathology -MH - *Protein Kinase Inhibitors/adverse effects/therapeutic use/administration & - dosage -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects -MH - Adult -MH - Aged, 80 and over -MH - Tyrosine Kinase Inhibitors -PMC - PMC11319491 -COIS- L.Z. has received research support from Chia Tai Tianqing Pharmaceutical Group - Co., Ltd, Eli Lilly, Novartis, Roche, and Bristol-Myers Squibb. Other authors - declare no competing interests. -EDAT- 2024/08/13 00:42 -MHDA- 2024/08/13 00:43 -PMCR- 2024/08/13 -CRDT- 2024/08/12 23:14 -PHST- 2024/02/05 00:00 [received] -PHST- 2024/07/19 00:00 [accepted] -PHST- 2024/06/12 00:00 [revised] -PHST- 2024/08/13 00:43 [medline] -PHST- 2024/08/13 00:42 [pubmed] -PHST- 2024/08/12 23:14 [entrez] -PHST- 2024/08/13 00:00 [pmc-release] -AID - 10.1038/s41392-024-01927-9 [pii] -AID - 1927 [pii] -AID - 10.1038/s41392-024-01927-9 [doi] -PST - epublish -SO - Signal Transduct Target Ther. 2024 Aug 13;9(1):215. doi: - 10.1038/s41392-024-01927-9. - -PMID- 35144431 -OWN - NLM -STAT- MEDLINE -DCOM- 20220214 -LR - 20220214 -IS - 2224-5839 (Electronic) -IS - 2224-5820 (Linking) -VI - 11 -IP - 1 -DP - 2022 Jan -TI - Sintilimab plus chemotherapy achieved symptom relief in stage IV lung squamous - cell carcinoma with superior vena cava syndrome: a case report. -PG - 401-406 -LID - 10.21037/apm-21-3674 [doi] -AB - Lung cancer is the second most common and mortality disease in the world. Most - patients with lung cancer are already at the advanced stage when diagnosed. There - are multiple treatments for advanced lung cancer. Among them, immunotherapy plus - chemotherapy has gradually become the first-line treatment. Lung cancer has - multiple complications, superior vena cava syndrome (SVCS) is a common - complication of patients with advanced lung cancer. The current treatments - include radiotherapy, chemotherapy, and stent implantation. Stent implantation - has the disadvantages of invasiveness and poor efficacy. Immunotherapy, as an - emerging treatment for tumors, has shown significant advantages in treating - patients with advanced lung cancer. However, the treatment of advanced lung - cancer with SVCS using immunotherapy has rarely been reported. Here, we reported - a 48-year-old male patient with stage IV (T4N3M1) lung squamous cell carcinoma. - After receiving 1 cycle (3 weeks) of comprehensive treatment with sintilimab plus - chemotherapy, the tumor mass shrank by 30% to achieve partial response (PR), - collateral circulation was formed, and most of the symptoms caused by SVCS - disappeared. After 3 cycles of treatment, the tumor shrank by nearly 90%, and the - superior and inferior vena cava opened larger than before. Our case provides a - novel treatment strategy for such patients. -FAU - Guo, Liuning -AU - Guo L -AD - Department of Thoracic Surgery, The Affiliated Hospital of Zunyi Medical - University, Zunyi, China. -FAU - Qu, Wendong -AU - Qu W -AD - Department of Thoracic Surgery, The Affiliated Hospital of Zunyi Medical - University, Zunyi, China. -FAU - Wei, Yating -AU - Wei Y -AD - Department of Thoracic Surgery, The Affiliated Hospital of Zunyi Medical - University, Zunyi, China. -FAU - Liang, Lubiao -AU - Liang L -AD - Department of Thoracic Surgery, The Affiliated Hospital of Zunyi Medical - University, Zunyi, China. -FAU - Tang, Yang -AU - Tang Y -AD - Department of Thoracic Surgery, The Affiliated Hospital of Zunyi Medical - University, Zunyi, China. -FAU - Chen, Cheng -AU - Chen C -AD - Department of Thoracic Surgery, The Affiliated Hospital of Zunyi Medical - University, Zunyi, China. -FAU - Ke, Xixian -AU - Ke X -AD - Department of Thoracic Surgery, The Affiliated Hospital of Zunyi Medical - University, Zunyi, China. -LA - eng -PT - Case Reports -PL - China -TA - Ann Palliat Med -JT - Annals of palliative medicine -JID - 101585484 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 8FU7FQ8UPK (sintilimab) -SB - IM -MH - Antibodies, Monoclonal, Humanized -MH - *Carcinoma, Non-Small-Cell Lung -MH - *Carcinoma, Squamous Cell/drug therapy -MH - Humans -MH - Lung -MH - *Lung Neoplasms/drug therapy -MH - Male -MH - Middle Aged -MH - *Superior Vena Cava Syndrome/etiology -OTO - NOTNLM -OT - Lung squamous cell carcinoma -OT - case report -OT - immunotherapy -OT - sintilimab -OT - superior vena cava syndrome (SVCS) -EDAT- 2022/02/12 06:00 -MHDA- 2022/02/15 06:00 -CRDT- 2022/02/11 05:29 -PHST- 2021/11/18 00:00 [received] -PHST- 2022/01/14 00:00 [accepted] -PHST- 2022/02/11 05:29 [entrez] -PHST- 2022/02/12 06:00 [pubmed] -PHST- 2022/02/15 06:00 [medline] -AID - 10.21037/apm-21-3674 [doi] -PST - ppublish -SO - Ann Palliat Med. 2022 Jan;11(1):401-406. doi: 10.21037/apm-21-3674. - -PMID- 38224815 -OWN - NLM -STAT- MEDLINE -DCOM- 20240212 -LR - 20240212 -IS - 1879-0631 (Electronic) -IS - 0024-3205 (Linking) -VI - 339 -DP - 2024 Feb 15 -TI - The analysis of multiple omics and examination of pathological images revealed - the prognostic and therapeutic significances of CD93 in lung squamous cell - carcinoma. -PG - 122422 -LID - S0024-3205(24)00011-0 [pii] -LID - 10.1016/j.lfs.2024.122422 [doi] -AB - As a potent pro-angiogenic factor, the role of CD93 in the prognosis and - therapeutic outcomes of lung squamous cell carcinoma (LUSC) merits exploration. - In this study, we systematically collected transcriptomic, genomic, and clinical - data from various public databases, as well as pathological images from - hospital-operated patients. Employing statistical analysis software like R - (Version 4.2.2) and GraphPad (Version 8.0), we conducted comprehensive analyses - of multi-omics data. The results revealed elevated CD93 expression in LUSC - tissues, closely associated with various cancer-related pathways. High CD93 - expression indicated advanced clinical stage and poorer prognosis. Furthermore, - CD93 contributed to resistance against chemotherapy and immunotherapy by - enhancing tumor cell stemness, reducing immune cell infiltration, and inducing T - cell exhaustion. Patients with low CD93 expression exhibited higher response - rates to both chemotherapy and immunotherapy. Immunohistochemistry validated the - significance of CD93 in LUSC. CD93 emerges as a biomarker signaling unfavorable - prognosis and influencing therapeutic outcomes, suggesting a potential LUSC - treatment avenue. -CI - Copyright © 2024. Published by Elsevier Inc. -FAU - Qu, Jialin -AU - Qu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan - 250117, Shandong, China. -FAU - Lin, Li -AU - Lin L -AD - Department of Respiratory Medicine, Shandong Provincial Chest Hospital, Shandong - Public Health Clinical Center, Jinan 250117, Shandong, China. -FAU - Fu, Guangming -AU - Fu G -AD - Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao - University, Qingdao 266003, China. -FAU - Zheng, Mei -AU - Zheng M -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan - 250117, Shandong, China. -FAU - Geng, Jiaxiao -AU - Geng J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan - 250117, Shandong, China. -FAU - Sun, Xiaorong -AU - Sun X -AD - Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong - First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, - Shandong, China. Electronic address: xrsun@sdfmu.edu.cn. -FAU - Xing, Ligang -AU - Xing L -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan - 250117, Shandong, China. Electronic address: xinglg@medmail.com.cn. -LA - eng -PT - Journal Article -DEP - 20240113 -PL - Netherlands -TA - Life Sci -JT - Life sciences -JID - 0375521 -RN - 0 (complement 1q receptor) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung -MH - *Carcinoma, Squamous Cell/drug therapy/genetics -MH - Lung -MH - *Lung Neoplasms/drug therapy/genetics -MH - Prognosis -OTO - NOTNLM -OT - CD93 -OT - Chemotherapy -OT - Immunotherapy -OT - Lung squamous cell carcinoma -OT - Multi-omics -COIS- Declaration of competing interest All authors report no conflicts of interest in - this work. -EDAT- 2024/01/16 00:42 -MHDA- 2024/02/05 06:42 -CRDT- 2024/01/15 19:32 -PHST- 2023/08/14 00:00 [received] -PHST- 2023/12/31 00:00 [revised] -PHST- 2024/01/08 00:00 [accepted] -PHST- 2024/02/05 06:42 [medline] -PHST- 2024/01/16 00:42 [pubmed] -PHST- 2024/01/15 19:32 [entrez] -AID - S0024-3205(24)00011-0 [pii] -AID - 10.1016/j.lfs.2024.122422 [doi] -PST - ppublish -SO - Life Sci. 2024 Feb 15;339:122422. doi: 10.1016/j.lfs.2024.122422. Epub 2024 Jan - 13. - -PMID- 38349001 -OWN - NLM -STAT- MEDLINE -DCOM- 20240221 -LR - 20240221 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 13 -IP - 2 -DP - 2024 Jan -TI - Efficacy of first-line treatment options beyond RET-TKIs in advanced - RET-rearranged non-small cell lung cancer: A multi-center real-world study. -PG - e6960 -LID - 10.1002/cam4.6960 [doi] -LID - e6960 -AB - BACKGROUND: Although RET-tyrosine kinase inhibitors (RET-TKIs) are the preferred - first-line therapy for advanced RET-arranged NSCLC, most patients cannot afford - them. In this population, bevacizumab, immunotherapy, and chemotherapy are the - most commonly used regimens. However, the optimal scheme beyond RET-TKIs has not - been defined in the first-line setting. METHODS: This retrospective study - included 86 stage IV NSCLC patients harboring RET rearrangement from six cancer - centers between May 2017 and October 2022. RET-TKIs, chemotherapy, or one of the - combination therapies (including immune checkpoint inhibitor (ICI) combined with - chemotherapy (I + C), bevacizumab combined with chemotherapy (B + C), ICI and - bevacizumab combined with chemotherapy (I + B + C)), were used as the first-line - therapeutics. The clinical outcomes and safety were evaluated. RESULTS: Fourteen - of the 86 patients received RET-TKIs, 57 received combination therapies, and 15 - received chemotherapy alone. Their medium PFS (mPFS) were 16.92 months (95% CI: - 5.9-27.9 months), 8.7 months (95% CI: 6.5-11.0 months), and 5.55 months (95% CI: - 2.4-8.7 months) respectively. Among all the combination schemes, B + C - (p = 0.007) or I + B + C (p = 0.025) gave beneficial PFS compared with - chemotherapy, while I + C treatment (p = 0.169) generated comparable PFS with - chemotherapy. In addition, I + B + C treatment had a numerically longer mPFS - (12.21 months) compared with B + C (8.74 months) or I + C (7.89 months) schemes. - In terms of safety, I + B + C treatment led to the highest frequency of - hematological toxicity (50%) and vomiting (75%), but no ≥G3 adverse effect was - observed. CONCLUSIONS: I + B + C might be a preferred option beyond RET-TKIs in - the first-line therapy of RET-arranged NSCLC. Combination with Bevacizumab rather - than with ICIs offered favorable survival compared with chemotherapy alone. -CI - © 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Ge, Yihui -AU - Ge Y -AD - Phase I Clinical Research Center, Shandong University Cancer Center, Jinan, - China. -FAU - Li, Juan -AU - Li J -AUID- ORCID: 0000-0002-0992-2699 -AD - Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Gong, Wenjing -AU - Gong W -AD - Medical Department, The Affiliated Yantai Yuhuangding Hospital of Qingdao - University, Yantai, China. -FAU - Wang, Jian -AU - Wang J -AD - Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, - China. -FAU - Wei, Xiaojuan -AU - Wei X -AD - Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, - China. -FAU - Liu, Jing -AU - Liu J -AD - Department of Oncology, Affiliated Hospital of Weifang Medical University, - Weifang, P. R. China. -FAU - Wang, Shuyun -AU - Wang S -AD - Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Wang, Leirong -AU - Wang L -AD - Phase I Clinical Research Center, Shandong University Cancer Center, Jinan, - China. -FAU - Sun, Haifeng -AU - Sun H -AD - Weifang Medical University, Weifang, China. -FAU - Cheng, Qinglei -AU - Cheng Q -AD - Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Sun, Yanxin -AU - Sun Y -AD - Weifang Medical University, Weifang, China. -FAU - Dang, Qi -AU - Dang Q -AD - Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Sun, Yuping -AU - Sun Y -AUID- ORCID: 0000-0002-0804-6850 -AD - Phase I Clinical Research Center, Shandong University Cancer Center, Jinan, - China. -FAU - Gao, Aiqin -AU - Gao A -AUID- ORCID: 0000-0003-1157-6104 -AD - Department of Thoracic Radiation Oncology, Shandong University Cancer Center, - Jinan, China. -LA - eng -GR - 202134041/Jinan Science and Technology Innovation Program of Clinical Medicine/ -GR - 202225015/Jinan Science and Technology Innovation Program of Clinical Medicine/ -GR - 2021M700054/China Postdoctoral Science Foundation/ -GR - ZR2021MH268/Natural Science Foundation of Shandong Province/ -GR - 82103340/National Natural Science Foundation of China/ -PT - Journal Article -PT - Multicenter Study -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 2S9ZZM9Q9V (Bevacizumab) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret) -RN - EC 2.7.10.1 (RET protein, human) -SB - IM -MH - Humans -MH - Bevacizumab/adverse effects/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Immunotherapy -MH - *Lung Neoplasms/drug therapy/genetics -MH - Protein Kinase Inhibitors/therapeutic use -MH - Proto-Oncogene Proteins c-ret/genetics -MH - Retrospective Studies -PMC - PMC10832335 -OTO - NOTNLM -OT - RET rearrangement -OT - combination schemes -OT - efficacy -OT - first-line therapy -OT - non-small cell lung cancer -COIS- All authors have completed the ICMJE uniform disclosure form. The authors have no - conflicts of interest to declare. -EDAT- 2024/02/13 12:45 -MHDA- 2024/02/14 12:46 -PMCR- 2024/02/01 -CRDT- 2024/02/13 08:28 -PHST- 2023/12/21 00:00 [revised] -PHST- 2023/09/27 00:00 [received] -PHST- 2024/01/12 00:00 [accepted] -PHST- 2024/02/14 12:46 [medline] -PHST- 2024/02/13 12:45 [pubmed] -PHST- 2024/02/13 08:28 [entrez] -PHST- 2024/02/01 00:00 [pmc-release] -AID - CAM46960 [pii] -AID - 10.1002/cam4.6960 [doi] -PST - ppublish -SO - Cancer Med. 2024 Jan;13(2):e6960. doi: 10.1002/cam4.6960. - -PMID- 26497482 -OWN - NLM -STAT- MEDLINE -DCOM- 20160815 -LR - 20220419 -IS - 1875-9114 (Electronic) -IS - 0277-0008 (Linking) -VI - 35 -IP - 10 -DP - 2015 Oct -TI - Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. -PG - 963-76 -LID - 10.1002/phar.1643 [doi] -AB - The treatment of cancer has largely relied on killing tumor cells with - nonspecific cytotoxic therapies and radiotherapy. This approach, however, has - limitations including severe systemic toxicities, bystander effects on normal - cells, recurrence of drug-resistant tumor cells, and the inability to target - micrometastases or subclinical disease. An increased understanding of the - critical role of the immune system in cancer development and progression has led - to new treatment strategies using various immunotherapies. It is now recognized - that established tumors have numerous mechanisms of suppressing the antitumor - immune response including production of inhibitory cytokines, recruitment of - immunosuppressive immune cells, and upregulation of coinhibitory receptors known - as immune checkpoints. This review focuses on the immune checkpoint inhibitors, a - novel class of immunotherapy first approved in 2011. Our objective is to - highlight similarities and differences among the three immune checkpoint - inhibitors approved by the U.S. Food and Drug Administration-ipilimumab, - pembrolizumab, and nivolumab-to facilitate therapeutic decision making. We - conducted a review of the published literature and conference proceedings and - present a critical appraisal of the clinical evidence supporting their use in the - treatment of metastatic melanoma and advanced squamous non-small cell lung cancer - (NSCLC). We also compare and contrast their current place in cancer therapy and - patterns of immune-related toxicities, and discuss the role of dual immune - checkpoint inhibition and strategies for the management of immune-related adverse - events. The immune checkpoint inhibitors have demonstrated a dramatic improvement - in overall survival in patients with advanced melanoma and squamous NSCLC, along - with acceptable toxicity profiles. These agents have a clear role in the - first-line treatment of advanced melanoma and in the second-line treatment of - advanced squamous NSCLC. -CI - © 2015 Pharmacotherapy Publications, Inc. -FAU - La-Beck, Ninh M -AU - La-Beck NM -AD - Department of Immunotherapeutics and Biotechnology, Texas Tech University Health - Sciences Center School of Pharmacy, Abilene, Texas. -FAU - Jean, Gary W -AU - Jean GW -AD - Department of Pharmacy Practice, Texas Tech University Health Sciences Center - School of Pharmacy, Dallas, Texas. -FAU - Huynh, Cindy -AU - Huynh C -AD - Department of Immunotherapeutics and Biotechnology, Texas Tech University Health - Sciences Center School of Pharmacy, Abilene, Texas. -FAU - Alzghari, Saeed K -AU - Alzghari SK -AD - Department of Immunotherapeutics and Biotechnology, Texas Tech University Health - Sciences Center School of Pharmacy, Abilene, Texas. -FAU - Lowe, Devin B -AU - Lowe DB -AD - Department of Immunotherapeutics and Biotechnology, Texas Tech University Health - Sciences Center School of Pharmacy, Abilene, Texas. -AD - Experimmune, A Center for Immunotherapeutic Development, Texas Tech University - Health Sciences Center, Abilene, Texas. -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - Pharmacotherapy -JT - Pharmacotherapy -JID - 8111305 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (CTLA-4 Antigen) -RN - 0 (Ipilimumab) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 0 (Receptors, Antigen, T-Cell) -RN - 31YO63LBSN (Nivolumab) -RN - DPT0O3T46P (pembrolizumab) -RN - EC 2.7.11.1 (BRAF protein, human) -RN - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) -SB - IM -EIN - Pharmacotherapy. 2015 Dec;35(12):1205. doi: 10.1002/phar.1679. PMID: 26684559 -MH - Antibodies, Monoclonal/administration & dosage/adverse - effects/*pharmacology/*therapeutic use -MH - Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use -MH - CTLA-4 Antigen/*antagonists & inhibitors -MH - Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Humans -MH - Immunotherapy -MH - Ipilimumab -MH - Lung Neoplasms/drug therapy -MH - Major Histocompatibility Complex/physiology -MH - Melanoma/*drug therapy/genetics/pathology -MH - Neoplasm Metastasis -MH - Nivolumab -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -MH - Proto-Oncogene Proteins B-raf/genetics -MH - Randomized Controlled Trials as Topic -MH - Receptors, Antigen, T-Cell/metabolism -MH - United States -OTO - NOTNLM -OT - cancer -OT - cytotoxic lymphocyte-associated protein 4 -OT - immune checkpoint -OT - immunotherapy -OT - ipilimumab -OT - nivolumab -OT - pembrolizumab -OT - programmed cell death protein 1 -EDAT- 2015/10/27 06:00 -MHDA- 2016/08/16 06:00 -CRDT- 2015/10/27 06:00 -PHST- 2015/10/27 06:00 [entrez] -PHST- 2015/10/27 06:00 [pubmed] -PHST- 2016/08/16 06:00 [medline] -AID - 10.1002/phar.1643 [doi] -PST - ppublish -SO - Pharmacotherapy. 2015 Oct;35(10):963-76. doi: 10.1002/phar.1643. - -PMID- 37629023 -OWN - NLM -STAT- MEDLINE -DCOM- 20230828 -LR - 20230829 -IS - 1422-0067 (Electronic) -IS - 1422-0067 (Linking) -VI - 24 -IP - 16 -DP - 2023 Aug 16 -TI - Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer - with BRAF or cMET Exon 14 Skipping Mutations. -LID - 10.3390/ijms241612840 [doi] -LID - 12840 -AB - BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment - sequence in these cases for the first and second line is not clear. An - international registry was created for patients with advanced NSCLC harboring - BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June - 2022. Clinicopathological and molecular data and treatment patterns were - recorded. Data on 58 patients, from eight centers across five countries, were - included in the final analysis. We found that 40 patients had the cMET exon 14 - skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 - patients received first- and second-line treatments, respectively, among which - 52.8% received targeted therapy (TT) in the first line and 53.5% in the second - line. The overall response rate (ORR) and disease control rate (DCR) for - first-line treatment with TT vs. other treatment such as immune checkpoint - inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (p = 0.0084) and 66.7% - vs. 39.1% (p = 0.04), respectively. The type of treatment in first-line TT vs. - other affected time to treatment discontinuation (TTD) was 11.6 m vs. 4.6 m (p= - 0.006). The overall survival for the whole group was 15.4 m and was not - statistically affected by the type of treatment (19.2 m vs. 13.5 m; p = 0.83). -FAU - Janzic, Urska -AU - Janzic U -AUID- ORCID: 0000-0001-9232-1431 -AD - Department of Medical Oncology, University Clinic Golnik, 4204 Golnik, Slovenia. -AD - Medical Faculty Ljubljana, University of Ljubljana, 1000 Ljubljana, Slovenia. -FAU - Shalata, Walid -AU - Shalata W -AUID- ORCID: 0000-0002-7570-4550 -AD - The Legacy Heritage Cancer Center & Dr. Larry Norton Institute, Soroka Medical - Center, Ben Gurion University, Beer Sheva 84105, Israel. -FAU - Szymczak, Katarzyna -AU - Szymczak K -AD - Department of Oncology and Radiotherapy and Early Phase Clinical Trials Centre, - Medical University of Gdańsk, 80-210 Gdańsk, Poland. -FAU - Dziadziuszko, Rafał -AU - Dziadziuszko R -AD - Department of Oncology and Radiotherapy and Early Phase Clinical Trials Centre, - Medical University of Gdańsk, 80-210 Gdańsk, Poland. -FAU - Jakopovic, Marko -AU - Jakopovic M -AUID- ORCID: 0000-0002-4815-7512 -AD - Department for Respiratory Diseases Jordanovac, University Hospital Centre - Zagreb, 10 000 Zagreb, Croatia. -FAU - Mountzios, Giannis -AU - Mountzios G -AUID- ORCID: 0000-0002-7780-7836 -AD - Clinical Trials Unit, Fourth Oncology Department, Henry Dunant Hospital Center, - 115 26 Athens, Greece. -FAU - Płużański, Adam -AU - Płużański A -AD - Department of Lung Cancer and Chest Tumours, The Maria Skłodowska-Curie National - Research Institute of Oncology, 00-001 Warsaw, Poland. -FAU - Araujo, Antonio -AU - Araujo A -AUID- ORCID: 0000-0002-7267-3584 -AD - Department of Medical Oncology, CHUPorto-University Hospitalar Center of Porto, - 4099-001 Porto, Portugal. -FAU - Charpidou, Andriani -AU - Charpidou A -AUID- ORCID: 0000-0002-5107-6430 -AD - Oncology Unit, 3rd Department of Medicine, "Sotiria" Hospital for Diseases of the - Chest, National and Kapodistrian University of Athens, 106 79 Athens, Greece. -FAU - Agbarya, Abed -AU - Agbarya A -AUID- ORCID: 0000-0002-3330-2959 -AD - Department of Oncology, Bnai-Zion Medical Center, 47 Golomb Avenue, Haifa 31048, - Israel. -LA - eng -PT - Journal Article -DEP - 20230816 -PL - Switzerland -TA - Int J Mol Sci -JT - International journal of molecular sciences -JID - 101092791 -RN - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) -RN - EC 2.7.11.1 (BRAF protein, human) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Proto-Oncogene Proteins B-raf/genetics -MH - *Lung Neoplasms/drug therapy/genetics -MH - Exons/genetics -MH - Mutation -PMC - PMC10454089 -OTO - NOTNLM -OT - BRAF V600E mutation -OT - cMET exon 14 skipping mutation -OT - first-line treatment -OT - non-small-cell lung cancer -OT - real-world data -OT - targeted therapy -COIS- U.J. reports honoraria for consultancy or lectures from MSD, AstraZeneca, Roche, - Takeda, Pfizer, Novartis, BMS, Amgen and Boehringer Ingelheim. W.S. reports - honoraria for consultancy or lectures from AstraZeneca, Roche, Novartis, MSD, - Pfizer, Merck and Bristol Myers Squibb. K.S. reports honoraria for consultancy or - lectures from Roche, AstraZeneca, MSD, Novartis, BMS, Amgen and Vipharm. R.D. - reports honoraria for consultancy or lectures from AstraZeneca, Roche, Novartis, - MSD, Takeda, Pfizer, Amgen and Bristol Myers Squibb. M.J. reports honoraria for - consultancy or lectures from AstraZeneca, Roche, Novartis, MSD, Takeda, Pfizer, - Amgen, Boehringer Ingelheim and Bristol Myers Squibb. G.M. reports honoraria for - consultancy or lectures from Roche, MSD, BMS, Amgen, AstraZeneca, Sanofi, - Novartis, Takeda, Pfizer, Amgen and Janssen. A.P. reports honoraria for - consultancy or lectures from BMS, MSD, AstraZeneca and Roche. A.A. (Antonio - Araujo) reports honoraria for consultancy or lectures from Merck, IPSEN, Roche, - Eli Lily, Pfizer, Janssen and Servier. A.A. (Abed Agbarya) reports honoraria for - consultancy or lectures from AstraZeneca, Roche, Novartis, MSD, Takeda, Pfizer, - Amgen and Bristol Myers Squibb. -EDAT- 2023/08/26 10:44 -MHDA- 2023/08/28 07:16 -PMCR- 2023/08/16 -CRDT- 2023/08/26 01:16 -PHST- 2023/07/15 00:00 [received] -PHST- 2023/08/12 00:00 [revised] -PHST- 2023/08/15 00:00 [accepted] -PHST- 2023/08/28 07:16 [medline] -PHST- 2023/08/26 10:44 [pubmed] -PHST- 2023/08/26 01:16 [entrez] -PHST- 2023/08/16 00:00 [pmc-release] -AID - ijms241612840 [pii] -AID - ijms-24-12840 [pii] -AID - 10.3390/ijms241612840 [doi] -PST - epublish -SO - Int J Mol Sci. 2023 Aug 16;24(16):12840. doi: 10.3390/ijms241612840. - -PMID- 38889498 -OWN - NLM -STAT- MEDLINE -DCOM- 20240706 -LR - 20240718 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 193 -DP - 2024 Jul -TI - Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after - progression on first-line osimertinib in advanced EGFR-mutated NSCLC. -PG - 107856 -LID - S0169-5002(24)00390-8 [pii] -LID - 10.1016/j.lungcan.2024.107856 [doi] -AB - OBJECTIVES: First-line pemetrexed-platinum - chemotherapy + osimertinib(Pem-Plat-Osi) improves progression-free survival as - compared to osimertinib alone in advanced epidermal growth factor (EGFR)-mutated - non-small cell lung cancer (NSCLC). However, many patients are hesitant to - commence chemotherapy upfront. We describe outcomes to Pem-Plat-Osi after - first-line osimertinib failure. MATERIALS AND METHODS: Patients with advanced - EGFR-mutated (ex19del/L858R) NSCLC who had Pem-Plat-Osi between - 1/7/2018-30/9/2023 after progression on first-line osimertinib at National Cancer - Centre Singapore, Prince of Wales Hospital and Chinese University of Hong Kong - were identified. Key endpoints were time to treatment failure (TTF) and overall - survival (OS). RESULTS: A total of 60 patients were included. Median age at - diagnosis was 62, 53.3 % (32/60) were male and 76.7 % (46/60) were never smokers. - Ex19del comprised 56.7 % (34/60) and L858R 43.3 % (26/60). Baseline central - nervous system (CNS) metastases were present in 66.7 % (40/60). Median TTF on - osimertinib (TTF1) was 14.4 months(m) and median time to initiation of - Pem-Plat-Osi was 41 days(d) (range 0-652) after progression on osimertinib. - Partial response (PR) or stable disease to Pem-Plat-Osi was achieved in - 81.7 %(49/60). Intracranial disease control was achieved in 90.6 % (29/32) of - patients with measurable CNS metastases, including those who did not undergo - brain radiotherapy. At median follow up of 31.2 m, median TTF on Pem-Plat-Osi - (TTF2) was 6.6 m. Median TTF1 + TTF2 was 23.4 m and median OS was 34.2 m. - Survival outcomes were similar comparing ex19del and L858R (median TTF1 + TTF2 - 21.8 m vs 23.5 m, p = 0.90; median OS 34.2 m vs 36.8 m, p = 0.37) and in patients - without/with baseline CNS metastases (median TTF1 + TTF2 21.8 m vs 23.4 m, - p = 0.44; median OS 36.2 m vs 31.9 m, p = 0.65). TTF1 duration was not - significantly associated with TTF2 (p = 0.76). Patients who started Pem-Plat-Osi - within 20d of progression on osimertinib had significantly longer TTF2 as - compared to patients who started after 20d (median 8.4 m versus 6.0 months, - p = 0.03), which remained statistically significant on multivariable analysis. - CONCLUSIONS: Our real-world data supports the efficacy of Pem-Plat-Osi after - progression on first-line osimertinib, including L858R and baseline CNS - metastases. Chemotherapy initiation within 20d of Osi progression was predictive - of superior TTF2. -CI - Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. -FAU - Saw, Stephanie P L -AU - Saw SPL -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore; - Duke-NUS Medical School, National University of Singapore, Singapore. Electronic - address: stephanie.saw.p.l@singhealth.com.sg. -FAU - Low, Yi Fen -AU - Low YF -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore. -FAU - Lai, Gillianne G Y -AU - Lai GGY -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore; - Duke-NUS Medical School, National University of Singapore, Singapore. -FAU - Chan, Landon L -AU - Chan LL -AD - Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, - China. -FAU - Wong, Wesley K Y -AU - Wong WKY -AD - Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China. -FAU - Tsui, Giselle -AU - Tsui G -AD - Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China. -FAU - Chen, Olivia H -AU - Chen OH -AD - Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China. -FAU - Seet, Amanda O L -AU - Seet AOL -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore; - Duke-NUS Medical School, National University of Singapore, Singapore. -FAU - Tan, Wei Chong -AU - Tan WC -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore; - Duke-NUS Medical School, National University of Singapore, Singapore. -FAU - Tan, Aaron C -AU - Tan AC -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore; - Duke-NUS Medical School, National University of Singapore, Singapore. -FAU - Chan, Johan W K -AU - Chan JWK -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore; - Duke-NUS Medical School, National University of Singapore, Singapore. -FAU - Teh, Yi Lin -AU - Teh YL -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore; - Duke-NUS Medical School, National University of Singapore, Singapore. -FAU - Tan, Wan-Ling -AU - Tan WL -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore; - Duke-NUS Medical School, National University of Singapore, Singapore. -FAU - Ng, Quan Sing -AU - Ng QS -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore; - Duke-NUS Medical School, National University of Singapore, Singapore. -FAU - Ang, Mei-Kim -AU - Ang MK -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore; - Duke-NUS Medical School, National University of Singapore, Singapore. -FAU - Kanesvaran, Ravindran -AU - Kanesvaran R -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore; - Duke-NUS Medical School, National University of Singapore, Singapore. -FAU - Lim, Darren W T -AU - Lim DWT -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore; - Duke-NUS Medical School, National University of Singapore, Singapore. -FAU - Tan, Daniel S W -AU - Tan DSW -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore; - Duke-NUS Medical School, National University of Singapore, Singapore. -FAU - Mok, Tony S K -AU - Mok TSK -AD - Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, - China. -FAU - Li, Molly S C -AU - Li MSC -AD - Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, - China. -LA - eng -PT - Journal Article -DEP - 20240615 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (Acrylamides) -RN - 0 (Aniline Compounds) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - 0 (Indoles) -RN - 3C06JJ0Z2O (osimertinib) -RN - 04Q9AIZ7NO (Pemetrexed) -RN - 49DFR088MY (Platinum) -RN - 0 (Pyrimidines) -SB - IM -MH - Female -MH - Humans -MH - Male -MH - Middle Aged -MH - *Acrylamides/therapeutic use -MH - *Aniline Compounds/therapeutic use -MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/mortality/pathology -MH - Disease Progression -MH - *ErbB Receptors/genetics -MH - Indoles -MH - *Lung Neoplasms/drug therapy/genetics/mortality/pathology -MH - *Mutation -MH - *Pemetrexed/therapeutic use/administration & dosage -MH - Platinum/therapeutic use/administration & dosage -MH - Pyrimidines -MH - Retrospective Studies -MH - Treatment Outcome -OTO - NOTNLM -OT - EGFR -OT - NSCLC -OT - Osimertinib -COIS- Declaration of competing interest The authors declare the following financial - interests/personal relationships which may be considered as potential competing - interests: [Dr Saw reports grants from Astra Zeneca, consulting fees from Pfizer, - Bayer, Astra Zeneca and Daiichi Sankyo, honoraria from Astra Zeneca, MSD, - Bristol-Myers Squibb, Daiichi Sankyo, Roche and Takeda, meeting support from MSD - and Astra Zeneca from Pfizer, advisory board participation from Astra Zeneca, - Daiichi Sankyo and Pfizer, outside the submitted work. Dr Lai reports grants from - Astra Zeneca, Roche and Amgen and meeting support from Astra Zeneca, outside the - submitted work. Dr Chan reports meeting support from Roche, Astra Zeneca and - Ipsen, outside the submitted work. Dr W.C. Tan reports grants from Singhealth, - honoraria from Merck & Co, MSD and Astra Zeneca, meeting support from Ipsen - Pharmaceuticals and Merck & Co, outside the submitted work. Dr A. Tan reports - consulting fees from Amgen, Bayer and Pfizer, honoraria from Amgen, Guardant - Health, Takeda, Juniper Biologics and Astra Zeneca, outside the submitted work. - Dr W.L. Tan reports grants from Astra Zeneca, honoraria from Novartis and Merck, - meeting support from Astra Zeneca, MSD, Boehringer Ingelheim and Ipsen, outside - the submitted work. Dr Kanesvaran reports honoraria from Astellas, MSD and Ipsen, - leadership roles in ESMO and SIOG, outside the submitted work. Dr Lim reports - grants from Taiho Pharmaceuticals, consulting fees from Daiichi Sankyo, Amgen, - Janssen and Alentis Therapeutics, honoraria from MSD and Takeda, meeting support - from Astra Zeneca and Alentis Therapeutics, outside the submitted work. Dr. Tan - reports grants from ACM Biolabs, Amgen, Astra Zeneca, Bayer and Pfizer, - consulting fees from Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, DKSH, - GlaxoSmithKline, Merck, Novartis, Pfizer, Roche and Takeda, honoraria from Amgen, - Bayer, Merck, Pfizer, Novartis, Boehringer Ingelheim, Roche, Takeda, Beigene, - Regeneron, Zymeworks, meeting support from Bayer, Merck, Pfizer, Regeneron and - Zymeworks, outside the submitted work. Dr Mok reportsgrantsfrom AstraZeneca, - Bristol Myers Squibb, G1 Therapeutics, Merck Sharp & Dohme, Merck Serono, - Novartis, Pfizer, Roche, SFJ, Takeda, XCovery, consulting fees from Abbvie Inc, - ACEA Pharma, Adagene, Alentis Therapeutics AG, Alpha Biopharma Co., Ltd, Amgen, - Amoy Diagnostics Co,AnHeart Therapeutics Inc,AVEO Pharmaceuticals, Inc,Bayer - Healthcare Pharmaceuticals Ltd,BeiGene,BerGenBio ASA,Berry Oncology,Boehringer - Ingelheim,Blueprint Medicines Corporation,Bristol Myers Squibb,Bowtie Life - Insurance Company Limited,Bridge Biotherapeutics Inc,Covidien LP,C4 Therapeutics - Inc,Cirina Ltd,CStone Pharmaceuticals,Curio Science,D3 Bio Ltd,Da - Volterra,Daiichi Sankyo,Eisai,Elevation Oncology,F. Hoffmann-La Roche Ltd./ - Genentech,Fishawack Facilitate Ltd,G1 Therapeutics Inc,geneDecode Co., Ltd,Gilead - Sciences, Inc,GLG’s Healthcare,Gritstone Oncology, Inc,Guardant Health,Hengrui - Therapeutics Inc,HiberCell, Inc.,HutchMed,Ignyta Inc.,Illumina - Inc.,IncyteCorporation,Inivata,IQVIA,Janssen,Lakeshore Biotech Ltd,Lilly,Lunit - USA, Inc,Loxo-Oncology,Lucence Health Inc,Medscape LLC/ WebMD,Medtronic,Merck - Serono,MSD,Mirati Therapeutics Inc,MiRXES,MoreHealth,Novartis,Novocure GmbH,Omega - Therapeutics Inc,OrigiMed,OSE Immunotherapeutics,PeerVoice,Pfizer,PrIME - Oncology,Prenetics Global Limited,Puma Biotechnology Inc,Qiming Development (HK) - Ltd,Regen Medtech Holdings Limited,Regeneron Pharmaceuticals Inc.,Roche - Pharmaceuticals/ Diagnostics/ Foundation One,Sanofi-Aventis,SFJ Pharmaceutical - Ltd,Simcere of America Inc,Synergy Research,Summit Therapeutics Sub, Inc,Takeda - Pharmaceuticals HK Ltd,Tigermed,Vertex Pharmaceuticals,Virtus Medical - Group,XENCOR, Inc,Yuhan Corporation,honorariafromACEA Pharma,Alpha Biopharma - Co.Ltd,Amgen,Amoy Diagnostics Co. Ltd,AstraZeneca (before - 1/1/19),BeiGene,BI,BMS,Daiichi Sankyo,Daz Group,Fishawack Facilitate Ltd.,InMed - Medical Communication,Janssen Pharmaceutica NV,Jiahui Holdings Co. - Limited,LiangYiHui Healthcare,Lilly,Lucence Health Inc.,MD Health Brazil,Medscape - LLC,Merck Pharmaceuticals HK Ltd.,Merck Sharp & Dohme,MiRXES,Novartis,OrigiMed - Co. Ltd.,P. Permanyer SL,PeerVoice, Physicians’ Education Resource,Pfizer,PrIME - Oncology,Research to Practice,Roche Pharmaceuticals/ Diagnostics/ Foundation - One,Sanofi-Aventis,Shanghai BeBirds Translation & Consulting Co. Ltd,Taiho - Pharmaceutical Co. Ltd,Takeda Oncology,Touch Independent Medical Education - Ltd,meeting support fromNovartis,Roche,Pfizer, AstraZeneca,Daiichi - Sankyo,BI,MiRXES,BMS,MSD,Abbvie,Zai Lab,Liangyihui,advisory boardforAbbVie - Inc.,ACEA Pharma,Amgen,AstraZeneca,Alentis Therapeutics AG,BerGenBio ASA,Berry - Oncology,Blueprint Medicines Corporation,Boehringer Ingelheim,Bowtie Life - Insurance Co Ltd,Bristol Myers Squibb,C4 Therapeutics Inc,Covidien LP,CStone - Pharmaceuticals,Curio Science,D3 Bio Ltd.,Daiichi Sankyo Inc.,Eisai,Fishawack - Facilitate Ltd.,G1 Therapeutics Inc.,Gilead Sciences Inc.,Gritstone Oncology - Inc,Guardant Health,geneDecode Co. Ltd. (uncompensated),Hengrui Therapeutics - Inc.,HutchMed,Ignyta Inc.,Incyte Corporation,Imagene AI - Ltd.,Inivata,IQVIA,Janssen,Lakeshore Biotech,Lily,Loxo-Oncology Inc.,Lunit - Inc,Merck Serono,Merck Sharp & Dohme,Mirati Therapeutics Inc.,MiRXES - Group,Novartis,OrigiMed,Pfizer,Prenetics Global Limited,Puma Biotechnology - Inc.,Roche/Genentech,Regeneron Pharmaceuticals Inc,Sanofi-Aventis R&D,SFJ - Pharmaceutical,Simcere of America Inc.,Simcere Zaiming, Inc.,Takeda,Vertex - Pharmaceuticals,Virtus Medical Group,XENCOR, Inc,Yuhan Corporation,being member - in the Board of DirectorsforAstraZeneca PLC,HutchMed,Aurora,Insighta,holding - stock / stock optionofAstraZeneca,Aurora Tele-Oncology Ltd.,Biolidics - Ltd.,HutchMed,Prenetics Global Limited,D3 Bio,Lunit,Bowtie Life Insurance, - Lakeshore Biotech Ltd,Loxo-oncology,Virtus Medical Group,Yinson Capital Pte. - Ltd.,Phanes Therapeutics, Inc.,Insighta,Alentis Therapeutics AG, outside the - submitted work. Dr Li reports grants from Gilead, MSD and Astra Zeneca, honoraria - from Astra Zeneca, Novartis, Amgen, Pfizer. Takeda, ACE Oncology, Merck, Guardant - Health, Gilead, Janssen and MSD, meeting support from Astra Zeneca, Pfizer, - Daiichi Sankyo, MSD, Amgen, advisory board for Astra Zeneca, Pfizer, AnHeart - Therapeutics, Amgen, Takeda, Yuhan and Blossomhill therapeutics, outside the - submitted work. No other conflicts of interest were declared.]. -EDAT- 2024/06/19 00:44 -MHDA- 2024/07/07 00:42 -CRDT- 2024/06/18 18:02 -PHST- 2024/04/24 00:00 [received] -PHST- 2024/06/12 00:00 [revised] -PHST- 2024/06/14 00:00 [accepted] -PHST- 2024/07/07 00:42 [medline] -PHST- 2024/06/19 00:44 [pubmed] -PHST- 2024/06/18 18:02 [entrez] -AID - S0169-5002(24)00390-8 [pii] -AID - 10.1016/j.lungcan.2024.107856 [doi] -PST - ppublish -SO - Lung Cancer. 2024 Jul;193:107856. doi: 10.1016/j.lungcan.2024.107856. Epub 2024 - Jun 15. - -PMID- 34613418 -OWN - NLM -STAT- MEDLINE -DCOM- 20220420 -LR - 20240426 -IS - 1432-0851 (Electronic) -IS - 0340-7004 (Print) -IS - 0340-7004 (Linking) -VI - 71 -IP - 5 -DP - 2022 May -TI - A brief report on incidence, radiographic feature and prognostic significance of - brain MRI changes after anti-PD-1/PD-L1 therapy in advanced non-small cell lung - cancer. -PG - 1275-1280 -LID - 10.1007/s00262-021-03070-8 [doi] -AB - INTRODUCTION: Neurologic immune-related adverse events (nirAEs) are uncommon but - potentially lethal complications of immune checkpoint inhibitor (ICI) treatment. - However, the incidence, radiographic features and prognostic significance of - brain magnetic resonance imaging (MRI) changes after ICI treatment remain largely - unknown. METHODS: Consecutive patients with advanced non-small cell lung cancer - (NSCLC) at three participating institutions receiving anti-PD-1/PD-L1 therapy - from June 2017 to September 2020 were screened, and those who received brain MRI - within 6 weeks before ICI initiation and at least one follow-up brain MRI after - ICI treatment were included. Serial brain MRI images were independently reviewed - by two experienced radiologists. RESULTS: With a median follow-up of 13.2 months, - 27 (20.0%) of the 135 enrolled patients developed certain kind of brain MRI - aberration. The 1-, 2- and 3-year cumulative incidence of brain MRI aberration - was 17.1%, 36.3% and 52.2%, respectively. Brain MRI aberration indicative of - stroke, mimicking typical white matter lesions and presenting as - T2-hyperintensity suggestive of CNS vasculitis or encephalitis, was documented in - 11, 9 and 4 patients, respectively. Patients with brain MRI aberration had higher - clinical benefit rate (p = 0.030), longer progression-free survival (p = 0.015) - and a tendency of improved overall survival (p = 0.054). CONCLUSIONS: Brain MRI - aberrations developed after ICI treatment are not uncommon, and their - manifestations vary a lot. Patients developing brain MRI aberrations tended to - have better prognosis, which needed to be further investigated. -CI - © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, - part of Springer Nature. -FAU - Ni, Jianjiao -AU - Ni J -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Zhou, Yue -AU - Zhou Y -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Wang, Shengping -AU - Wang S -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -AD - Department of Radiology, Fudan University Shanghai Cancer Center, 270 Dong An - Road, Shanghai, 200032, China. -FAU - Guo, Tiantian -AU - Guo T -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Hu, Jie -AU - Hu J -AD - Department of Pulmonary Medicine, Shanghai Respiratory Research Institute, - Zhongshan Hospital, Fudan University, Shanghai, China. -FAU - Chu, Qian -AU - Chu Q -AD - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong - University of Science and Technology, Wuhan, China. -FAU - Yang, Xi -AU - Yang X -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Chu, Li -AU - Chu L -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Chu, Xiao -AU - Chu X -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Li, Yida -AU - Li Y -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. -FAU - Zhu, Zhengfei -AU - Zhu Z -AUID- ORCID: 0000-0003-4012-4270 -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, China. fuscczzf@163.com. -AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, - China. fuscczzf@163.com. -AD - Institute of Thoracic Oncology, Fudan University, 270 Dong An Road, Shanghai, - 200032, China. fuscczzf@163.com. -LA - eng -GR - Y-BMS2019082/chinese society of clinical oncology/ -PT - Journal Article -DEP - 20211006 -PL - Germany -TA - Cancer Immunol Immunother -JT - Cancer immunology, immunotherapy : CII -JID - 8605732 -RN - 0 (B7-H1 Antigen) -SB - IM -MH - B7-H1 Antigen/metabolism -MH - Brain/diagnostic imaging/pathology -MH - *Carcinoma, Non-Small-Cell Lung/diagnostic imaging/drug therapy -MH - Humans -MH - Incidence -MH - *Lung Neoplasms/pathology -MH - Magnetic Resonance Imaging -MH - Prognosis -PMC - PMC10991942 -OTO - NOTNLM -OT - Brain magnetic resonance imaging (MRI) -OT - Neurologic immune-related adverse events (nirAEs) -OT - Non-small cell lung cancer (NSCLC) -COIS- The authors declare that there is no conflict of interest that could be perceived - as prejudicing the impartiality of the research reported. -EDAT- 2021/10/07 06:00 -MHDA- 2022/04/21 06:00 -PMCR- 2021/10/06 -CRDT- 2021/10/06 12:30 -PHST- 2021/06/12 00:00 [received] -PHST- 2021/09/26 00:00 [accepted] -PHST- 2021/10/07 06:00 [pubmed] -PHST- 2022/04/21 06:00 [medline] -PHST- 2021/10/06 12:30 [entrez] -PHST- 2021/10/06 00:00 [pmc-release] -AID - 10.1007/s00262-021-03070-8 [pii] -AID - 3070 [pii] -AID - 10.1007/s00262-021-03070-8 [doi] -PST - ppublish -SO - Cancer Immunol Immunother. 2022 May;71(5):1275-1280. doi: - 10.1007/s00262-021-03070-8. Epub 2021 Oct 6. - -PMID- 30711957 -OWN - NLM -STAT- MEDLINE -DCOM- 20190220 -LR - 20191204 -IS - 1791-7530 (Electronic) -IS - 0250-7005 (Print) -IS - 0250-7005 (Linking) -VI - 39 -IP - 2 -DP - 2019 Feb -TI - Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A - Retrospective Analysis of Real-life Experience at a Single Institution. -PG - 781-790 -LID - 10.21873/anticanres.13175 [doi] -AB - BACKGROUND: Data on the characteristics of patients who are likely to experience - adverse events, both immune-related and non-immune-related, from programmed cell - death-1 (PD1) inhibitors are limited. PATIENTS AND METHODS: Data from patients - who received ≥1 dose of single-agent PD1 inhibitor between August 3, 2011 and - August 31, 2016 were obtained from our Institution's pharmacy database. AEs were - graded using Common Terminology Criteria for Adverse Events version 4. RESULTS: - One hundred and eighty-two patients received at least one dose of single-agent - PD1 inhibitor prior to data cut-off. After excluding 14 patients with uncommon - malignancies, the total number of patients were 168. The median age was 63 - (range=24-92) years. There were 87 (52%) cases of non-small cell lung cancer - (NSCLC), 35 (21%) of renal cell carcinoma (RCC), 12 (7%) of melanoma, 18 (11%) of - Hodgkin's lymphomas, eight (5%) of head and neck squamous cell carcinoma (HNSCC) - and eight (5%) of small cell lung cancer. Considering grade 2 or more AEs, 30 - (18%) patients had kidney injury, 34 (20%) hypothyroidism, 36 (21%) - transaminitis, 20 (12%) pneumonitis, and 18 (11%) colitis. Patients with RCC had - higher odds of experiencing grade 2 or more kidney injury than patients with - other primary tumor types (adjusted p=0.025), whereas patients with Hodgkin's - lymphoma and HNSCC had higher odds of grade 2 hypothyroidism (adjusted p=0.005). - Patients with NSCLC had higher risk of death with pneumonitis than those whose - primary cancer was not NSCLC (adjusted p=0.005). DISCUSSION: The increased odds - of patients with Hodgkin's lymphoma and HNSCC experiencing grade 2 or more - hypothyroidism may be related to previous radiation exposure. Most patients with - RCC had undergone nephrectomy, making them more susceptible to acute kidney - injury. When pneumonitis occurred in patients with primary NSCLC, the overall - survival was significantly worse. The duration of PD1 therapy was significantly - associated with onset of pneumonitis (p=0.007). CONCLUSION: The site of primary - tumor or metastasis may help predict the most common AEs in patients treated with - PD1 inhibitors. -CI - Copyright© 2019, International Institute of Anticancer Research (Dr. George J. - Delinasios), All rights reserved. -FAU - Sukari, Ammar -AU - Sukari A -AD - Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State - University School of Medicine, Detroit, MI, U.S.A. sukaria@karmanos.org. -FAU - Nagasaka, Misako -AU - Nagasaka M -AD - Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State - University School of Medicine, Detroit, MI, U.S.A. -AD - Department of Advanced Medical Innovation, St. Marianna University Graduate - School of Medicine, Kawasaki, Japan. -FAU - Alhasan, Roba -AU - Alhasan R -AD - Department of Hematology and Oncology, Michigan State University, Lansing, MI, - U.S.A. -FAU - Patel, Dhaval -AU - Patel D -AD - Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State - University School of Medicine, Detroit, MI, U.S.A. -FAU - Wozniak, Antoinette -AU - Wozniak A -AD - Department of Oncology, University of Pittsburgh, Pittsburgh, PA, U.S.A. -FAU - Ramchandren, Radhakrishnan -AU - Ramchandren R -AD - Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State - University School of Medicine, Detroit, MI, U.S.A. -FAU - Vaishampayan, Ulka -AU - Vaishampayan U -AD - Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State - University School of Medicine, Detroit, MI, U.S.A. -FAU - Weise, Amy -AU - Weise A -AD - Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State - University School of Medicine, Detroit, MI, U.S.A. -FAU - Flaherty, Lawrence -AU - Flaherty L -AD - Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State - University School of Medicine, Detroit, MI, U.S.A. -FAU - Jang, Hyejeong -AU - Jang H -AD - Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State - University School of Medicine, Detroit, MI, U.S.A. -FAU - Kim, Seongho -AU - Kim S -AD - Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State - University School of Medicine, Detroit, MI, U.S.A. -FAU - Gadgeel, Shirish -AU - Gadgeel S -AD - Department of Internal Medicine, Division of Hematology/Oncology, University of - Michigan, Ann Arbor, MI, U.S.A. -LA - eng -GR - P30 CA022453/CA/NCI NIH HHS/United States -PT - Journal Article -PL - Greece -TA - Anticancer Res -JT - Anticancer research -JID - 8102988 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 31YO63LBSN (Nivolumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/*adverse effects -MH - Antineoplastic Agents/*adverse effects -MH - Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Carcinoma, Renal Cell/drug therapy/immunology -MH - Female -MH - Hodgkin Disease/drug therapy/immunology -MH - Humans -MH - *Immune System -MH - Kidney Neoplasms/drug therapy/immunology -MH - Lung Neoplasms/drug therapy/immunology -MH - Male -MH - Melanoma/drug therapy/immunology -MH - Middle Aged -MH - Neoplasms/*drug therapy/immunology -MH - Nivolumab/*adverse effects -MH - Odds Ratio -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -MH - Retrospective Studies -MH - Skin Neoplasms/drug therapy/immunology -PMC - PMC6886239 -MID - NIHMS1057932 -OTO - NOTNLM -OT - Immunotherapy -OT - PD1 inhibitor -OT - hypothyroidism -OT - immune related toxicities -OT - immune-related side-effects -OT - pneumonitis -OT - primary tumor -OT - renal insufficiency -COIS- Conflicts of Interest The Authors declare no competing interest related to this - study. -EDAT- 2019/02/04 06:00 -MHDA- 2019/03/21 06:00 -PMCR- 2019/12/02 -CRDT- 2019/02/04 06:00 -PHST- 2018/10/29 00:00 [received] -PHST- 2018/12/17 00:00 [revised] -PHST- 2018/12/20 00:00 [accepted] -PHST- 2019/02/04 06:00 [entrez] -PHST- 2019/02/04 06:00 [pubmed] -PHST- 2019/03/21 06:00 [medline] -PHST- 2019/12/02 00:00 [pmc-release] -AID - 39/2/781 [pii] -AID - 10.21873/anticanres.13175 [doi] -PST - ppublish -SO - Anticancer Res. 2019 Feb;39(2):781-790. doi: 10.21873/anticanres.13175. - -PMID- 15991677 -OWN - NLM -STAT- MEDLINE -DCOM- 20050722 -LR - 20181201 -IS - 0030-6002 (Print) -IS - 0030-6002 (Linking) -VI - 146 -IP - 21 -DP - 2005 May 22 -TI - [New therapies for non-small cell lung cancer]. -PG - 1135-41 -AB - Lung cancer is one of the most frequent causes of death from cancer. Non-small - cell lung cancer represents approximately 80% of the total pulmonary - malignancies. Unfortunately, most non-small cell lung cancer patients present - advanced disease at diagnosis and a very poor prognosis. Despite advances in our - understanding of the molecular and genetic basis of non-small cell lung cancer, - and improvement in therapy with surgery, conventional chemotherapy, and - radiation, 5-year survival for patients with this diagnosis remains poor and the - disease remains a clinical challenge. However, strategies of molecular based - therapies are in development and it is hoped that these new approaches will - continue to improve survival for patients with advanced lung cancer. Any - categorization of these drugs is hard, with overlap in several features. The main - investigated agents are epidermal growth factor receptor (EGFR) family - inhibitors, angiogenesis inhibitors and antivascular drugs, signal transduction - inhibitors, apoptosis inducers, eicosanoid pathway inhibitors and - immunotherapeutic drugs. To date, few of these new drugs can offer trust of a - substantial influence on the natural history of non-small cell lung cancer, and - disappointing results are more commonly reported than encouraging ones. - Nevertheless, tailored treatment for non-small cell lung cancer patients may - represent a further chance of tumor control and symptom palliation. This review - presents an overview of molecular targeted therapy in non-small cell lung cancer. -FAU - Ostoros, Gyula -AU - Ostoros G -AD - Országos Korányi Tbc es Pulmonológiai Intézet, Budapest. ostorosgyula@freemail.hu -FAU - Kovács, Gábor -AU - Kovács G -FAU - Szondy, Klára -AU - Szondy K -FAU - Döme, Balázs -AU - Döme B -LA - hun -PT - Journal Article -PT - Review -TT - Uj terápiás lehetoségek a nem kissejtes tüdorák kezelésében. -PL - Hungary -TA - Orv Hetil -JT - Orvosi hetilap -JID - 0376412 -RN - 0 (Angiogenesis Inhibitors) -RN - 0 (Antineoplastic Agents) -RN - 0 (Drugs, Investigational) -RN - 0 (Eicosanoids) -RN - 0 (Immunologic Factors) -RN - 0 (Matrix Metalloproteinase Inhibitors) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) -RN - EC 2.7.10.1 (Receptor, ErbB-2) -SB - IM -MH - Angiogenesis Inhibitors/therapeutic use -MH - Animals -MH - Antineoplastic Agents/*therapeutic use -MH - Apoptosis/drug effects -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Drugs, Investigational/therapeutic use -MH - Eicosanoids/therapeutic use -MH - ErbB Receptors/antagonists & inhibitors -MH - Humans -MH - Immunologic Factors/therapeutic use -MH - Lung Neoplasms/*drug therapy -MH - Matrix Metalloproteinase Inhibitors -MH - Protein-Tyrosine Kinases/antagonists & inhibitors -MH - Receptor, ErbB-2/antagonists & inhibitors -MH - Signal Transduction/drug effects -MH - Survival Analysis -MH - Treatment Outcome -RF - 50 -EDAT- 2005/07/05 09:00 -MHDA- 2005/07/23 09:00 -CRDT- 2005/07/05 09:00 -PHST- 2005/07/05 09:00 [pubmed] -PHST- 2005/07/23 09:00 [medline] -PHST- 2005/07/05 09:00 [entrez] -PST - ppublish -SO - Orv Hetil. 2005 May 22;146(21):1135-41. - -PMID- 38022521 -OWN - NLM -STAT- MEDLINE -DCOM- 20231201 -LR - 20240401 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 14 -DP - 2023 -TI - Novel nomogram for predicting survival in advanced non-small cell lung cancer - receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy. -PG - 1297188 -LID - 10.3389/fimmu.2023.1297188 [doi] -LID - 1297188 -AB - BACKGROUND: This study aimed to develop and validate a novel nomogram to predict - survival in advanced non-small cell lung cancer (NSCLC) receiving programmed cell - death 1 (PD-1) inhibitor plus chemotherapy with or without antiangiogenic - therapy. METHODS: A total of 271 patients with advanced NSCLC who received - anti-PD-1 plus chemotherapy with or without antiangiogenic therapy were enrolled - in our center and randomized into the training cohort (n = 133) and the internal - validation cohort (n = 138). Forty-five patients from another center were - included as an independent external validation cohort. The nomogram was created - based on the multivariate Cox regression analysis to predict overall survival - (OS) and progression-free survival (PFS). The performance of the nomogram was - assessed using the concordance index (C-index), the time-dependent area under the - receiver operating (ROC) curves (AUCs), calibration curves, and decision curve - analysis (DCA). RESULTS: Four factors significantly associated with OS were - utilized to create a nomogram to predict OS: Eastern Cooperative Oncology Group - performance status (ECOG PS), programmed cell death-ligand 1 (PD-L1) expression, - chemotherapy cycle, and pretreatment lactate dehydrogenase-albumin ratio (LAR). - Six variables significantly associated with PFS were incorporated into the - development of a nomogram for predicting PFS: ECOG PS, histology, PD-L1 - expression, chemotherapy cycle, pretreatment platelet to lymphocyte (PLR), and - pretreatment LAR. The C-indexes of the nomogram for predicting OS and PFS were - 0.750 and 0.747, respectively. The AUCs for predicting the 6-month, 12-month, and - 18-month OS and PFS were 0.847, 0.791, and 0.776 and 0.810, 0.787, and 0.861, - respectively. The calibration curves demonstrated a good agreement between - predictions and actual observations. The DCA curves indicated that the nomograms - had good net benefits. Furthermore, the nomogram model was well-validated in the - internal and external cohorts. CONCLUSION: The novel nomogram for predicting the - prognosis of advanced NSCLC receiving anti-PD-1 plus chemotherapy with or without - antiangiogenic therapy may help guide clinical treatment decisions. -CI - Copyright © 2023 Wu, Lv, Lin, Hong, Du, Yao, Zhu, Ji, Li and Lai. -FAU - Wu, Yahua -AU - Wu Y -AD - Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, - China. -FAU - Lv, Chengliu -AU - Lv C -AD - Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, - China. -FAU - Lin, Mingqian -AU - Lin M -AD - Department of Radiation Oncology, Fujian Medical University Cancer Hospital, - Fuzhou, China. -FAU - Hong, Yaping -AU - Hong Y -AD - Department of Radiation Oncology, Fujian Medical University Cancer Hospital, - Fuzhou, China. -FAU - Du, Bin -AU - Du B -AD - Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, - China. -FAU - Yao, Na -AU - Yao N -AD - Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, - China. -FAU - Zhu, Yingjiao -AU - Zhu Y -AD - Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, - China. -FAU - Ji, Xiaohui -AU - Ji X -AD - Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, - China. -FAU - Li, Jiancheng -AU - Li J -AD - Department of Radiation Oncology, Fujian Medical University Cancer Hospital, - Fuzhou, China. -FAU - Lai, Jinhuo -AU - Lai J -AD - Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, - China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20231108 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - 0 (B7-H1 Antigen) -RN - 0 (Albumins) -SB - IM -MH - Humans -MH - Nomograms -MH - B7-H1 Antigen -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Albumins -PMC - PMC10663364 -OTO - NOTNLM -OT - advanced NSCLC -OT - anti-PD-1 -OT - combined therapy -OT - nomogram -OT - survival -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2023/11/29 18:42 -MHDA- 2023/12/01 06:44 -PMCR- 2023/01/01 -CRDT- 2023/11/29 15:25 -PHST- 2023/09/19 00:00 [received] -PHST- 2023/10/20 00:00 [accepted] -PHST- 2023/12/01 06:44 [medline] -PHST- 2023/11/29 18:42 [pubmed] -PHST- 2023/11/29 15:25 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2023.1297188 [doi] -PST - epublish -SO - Front Immunol. 2023 Nov 8;14:1297188. doi: 10.3389/fimmu.2023.1297188. - eCollection 2023. - -PMID- 36994945 -OWN - NLM -STAT- MEDLINE -DCOM- 20230612 -LR - 20231122 -IS - 1097-0142 (Electronic) -IS - 0008-543X (Linking) -VI - 129 -IP - 13 -DP - 2023 Jul 1 -TI - Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A - systematic review and meta-analysis. -PG - 1969-1985 -LID - 10.1002/cncr.34755 [doi] -AB - BACKGROUND: Neoadjuvant immunotherapy (nIT) is a rapidly emerging paradigm for - advanced resectable non-small cell lung cancer (NSCLC). The objectives of this - PRISMA/MOOSE/PICOD-guided systematic review and meta-analysis were (1) to assess - the safety and efficacy of nIT, (2) to compare the safety and efficacy of - neoadjuvant chemoimmunotherapy (nCIT) versus chemotherapy alone (nCT), and (3) to - explore predictors of pathologic response with nIT and their association with - outcomes. METHODS: Eligibility was resectable stage I-III NSCLC and the receipt - of programmed death-1/programmed cell death ligand-1 (PD-L1)/cytotoxic - T-lymphocyte-associated antigen-4 inhibitors before resection; other forms and - modalities of neoadjuvant and/or adjuvant therapies were allowed. For statistical - analysis, the Mantel-Haenszel fixed-effect or random-effect model was used, - depending on the heterogeneity (I(2) ). RESULTS: Sixty-six articles met the - criteria (eight randomized studies, 39 prospective nonrandomized studies, and 19 - retrospective studies). The pooled pathologic complete response (pCR) rate was - 28.1%. The estimated grade ≥3 toxicity rate was 18.0%. Compared with nCT, nCIT - achieved higher rates of pCR (odds ratio [OR], 7.63; 95% confidence interval - [CI], 4.49-12.97; p < .001), progression-free survival (PFS) (hazard ratio [HR] - 0.51; 95% CI, 0.38-0.67; p < .001), and overall survival (OS) (HR, 0.51; 95% CI, - 0.36-0.74; p = .0003) but yielded similar toxicity rates (OR, 1.01; 95% CI, - 0.67-1.52; p = .97). The results remained robust on sensitivity analysis when all - retrospective publications were removed. pCR was associated with improved PFS - (HR, 0.25; 0.15-0.43; p < .001) and OS (HR, 0.26; 95% CI, 0.10-0.67; p = .005). - PD-L1 expressors (≥1%) were more likely to achieve a pCR (OR, 2.93; 95% CI, - 1.22-7.03; p = .02). CONCLUSIONS: In patients with advanced resectable NSCLC, - neoadjuvant immunotherapy was safe and efficacious. nCIT improved pathologic - response rates and PFS/OS over nCT, particularly in patients who had tumors that - expressed PD-L1, without increasing toxicities. PLAIN LANGUAGE SUMMARY: This - meta-analysis of 66 studies showed that neoadjuvant immunotherapy for advanced - resectable non-small cell lung cancer is safe and efficacious. Compared with - chemotherapy alone, chemoimmunotherapy improved pathologic response rates and - survival, particularly for patients who had tumors that expressed programmed cell - death ligand-1, without increasing toxicities. -CI - © 2023 American Cancer Society. -FAU - Wu, Yajing -AU - Wu Y -AD - Department of Radiation Oncology, The Fourth Hospital of Hebei Medical - University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, - China. -FAU - Verma, Vivek -AU - Verma V -AUID- ORCID: 0000-0002-5863-6023 -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas, USA. -FAU - Gay, Carl M -AU - Gay CM -AD - Department of Head/Neck and Thoracic Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, Texas, USA. -FAU - Chen, Yujia -AU - Chen Y -AD - Department of Radiation Oncology, The Fourth Hospital of Hebei Medical - University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, - China. -FAU - Liang, Fei -AU - Liang F -AUID- ORCID: 0000-0002-4184-7844 -AD - Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, - China. -FAU - Lin, Qiang -AU - Lin Q -AD - Department of Oncology, North China Petroleum Bureau General Hospital, Hebei - Medical University, Renqiu, China. -FAU - Wang, Jianing -AU - Wang J -AD - Department of Radiation Oncology, The Fourth Hospital of Hebei Medical - University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, - China. -FAU - Zhang, Wei -AU - Zhang W -AD - Department of Radiation Oncology, The Fourth Hospital of Hebei Medical - University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, - China. -FAU - Hui, Zhouguang -AU - Hui Z -AUID- ORCID: 0000-0002-7189-4692 -AD - Department of VIP Medical Services & Radiation Oncology, National Cancer - Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese - Academy of Medical Sciences and Peking Union Medical, Beijing, China. -FAU - Zhao, Min -AU - Zhao M -AD - Department of Oncology, Hebei Chest Hospital, Shijiazhuang, China. -FAU - Wang, Jun -AU - Wang J -AD - Department of Radiation Oncology, The Fourth Hospital of Hebei Medical - University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, - China. -FAU - Chang, Joe Y -AU - Chang JY -AUID- ORCID: 0000-0002-8435-2083 -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, Texas, USA. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Research Support, Non-U.S. Gov't -PT - Systematic Review -DEP - 20230330 -PL - United States -TA - Cancer -JT - Cancer -JID - 0374236 -RN - 0 (B7-H1 Antigen) -RN - 0 (Ligands) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Neoadjuvant Therapy -MH - B7-H1 Antigen -MH - Ligands -MH - Prospective Studies -MH - Retrospective Studies -MH - Immunotherapy/adverse effects/methods -OTO - NOTNLM -OT - immunotherapy -OT - neoadjuvant -OT - non-small cell lung cancer -OT - pathologic response -OT - survival -EDAT- 2023/03/31 06:00 -MHDA- 2023/06/12 06:42 -CRDT- 2023/03/30 07:33 -PHST- 2023/02/16 00:00 [revised] -PHST- 2022/10/18 00:00 [received] -PHST- 2023/02/22 00:00 [accepted] -PHST- 2023/06/12 06:42 [medline] -PHST- 2023/03/31 06:00 [pubmed] -PHST- 2023/03/30 07:33 [entrez] -AID - 10.1002/cncr.34755 [doi] -PST - ppublish -SO - Cancer. 2023 Jul 1;129(13):1969-1985. doi: 10.1002/cncr.34755. Epub 2023 Mar 30. - -PMID- 35666500 -OWN - NLM -STAT- MEDLINE -DCOM- 20220608 -LR - 20230426 -IS - 2574-3805 (Electronic) -IS - 2574-3805 (Linking) -VI - 5 -IP - 6 -DP - 2022 Jun 1 -TI - Association of Driver Oncogene Variations With Outcomes in Patients With Locally - Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative - Durvalumab. -PG - e2215589 -LID - 10.1001/jamanetworkopen.2022.15589 [doi] -LID - e2215589 -AB - IMPORTANCE: Consolidative durvalumab after definitive chemoradiation for - unresectable locally advanced non-small cell lung cancer (NSCLC) can - significantly improve progression-free survival (PFS) and overall survival (OS), - as shown in the PACIFIC trial. However, whether patients with driver variations - derive equal benefit from this regimen remains unclear. OBJECTIVES: To compare - outcomes of patients with locally advanced NSCLC with and without driver - variations treated with the PACIFIC regimen. DESIGN, SETTING, AND PARTICIPANTS: - This cohort study examined 104 patients with unresectable locally advanced NSCLC - with mutational profiling treated at a tertiary cancer center with definitive - chemoradiation and consolidative durvalumab from June 2017 through May 2020. - Patients with recurrent disease or those receiving postoperative therapy were - excluded. Outcomes were analyzed with Kaplan-Meier and multivariate regression - analyses. EXPOSURES: Patients were grouped according to the presence of non-KRAS - driver variations (EGFR exon 19 deletion, EGFR exon 20 insertion, EGFR exon 21 - mutation [L858R], ERBB2 exon 20 insertion, EML4-ALK fusion, MET exon 14 skipping, - NTRK2 fusion), KRAS driver variations, or no driver variations. MAIN OUTCOMES AND - MEASURES: The primary outcomes were PFS, OS, and second progression-free survival - (PFS2) times. RESULTS: The 104 patients had a median (IQR) age of 65.1 (9.8) - years, with 55 females (53%) and 85 former or current smokers (88%). There were - 43 patients (41%) with driver variations with a median PFS time of 8.4 months vs - 40.1 months for patients without driver variations (hazard ratio [HR], 2.75; 95% - CI, 1.64-4.62; log-rank P < .001). Both patients with non-KRAS and KRAS driver - variations had worse PFS. No difference in OS was found between patients with and - without driver variations (log rank P = .24). Among the 63 patients who developed - progressive disease, those with non-KRAS driver variations had a median PFS2 time - of 13.7 months vs 4.4 months for all other patients (HR, 0.37; 95% CI, 0.21-0.64; - log-rank P = .001). Rates of overall grade 2 toxic effects or higher did not - differ by driver mutation status. CONCLUSIONS AND RELEVANCE: In this cohort - study, driver variations in patients with unresectable locally advanced NSCLC - were associated with significantly shorter PFS time after definitive - chemoradiation and consolidative durvalumab. These findings suggest the need to - consider additional or alternative treatment options to the PACIFIC regimen for - patients with driver variations. -FAU - Liu, Yufei -AU - Liu Y -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston. -FAU - Zhang, Zhe -AU - Zhang Z -AD - Department of Sociology, Rice University, Houston, Texas. -FAU - Rinsurongkawong, Waree -AU - Rinsurongkawong W -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston. -FAU - Gay, Carl M -AU - Gay CM -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston. -FAU - Le, Xiuning -AU - Le X -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston. -FAU - Ning, Matthew S -AU - Ning MS -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston. -FAU - Lewis, Jeff -AU - Lewis J -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston. -FAU - Rinsurongkawong, Vadeerat -AU - Rinsurongkawong V -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston. -FAU - Lee, J Jack -AU - Lee JJ -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston. -FAU - Roth, Jack -AU - Roth J -AD - Department of Thoracic and Cardiothoracic Surgery, The University of Texas MD - Anderson Cancer Center, Houston. -FAU - Swisher, Stephen -AU - Swisher S -AD - Department of Thoracic and Cardiothoracic Surgery, The University of Texas MD - Anderson Cancer Center, Houston. -FAU - Gandhi, Saumil -AU - Gandhi S -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston. -FAU - Lee, Percy P -AU - Lee PP -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston. -FAU - Gibbons, Don L -AU - Gibbons DL -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston. -FAU - Vaporciyan, Ara A -AU - Vaporciyan AA -AD - Department of Thoracic and Cardiothoracic Surgery, The University of Texas MD - Anderson Cancer Center, Houston. -FAU - Heymach, John V -AU - Heymach JV -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston. -FAU - Zhang, Jianjun -AU - Zhang J -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston. -FAU - Lin, Steven H -AU - Lin SH -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston. -LA - eng -GR - P30 CA016672/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20220601 -PL - United States -TA - JAMA Netw Open -JT - JAMA network open -JID - 101729235 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal -MH - *Carcinoma, Non-Small-Cell Lung/genetics/therapy -MH - Cohort Studies -MH - ErbB Receptors/genetics -MH - Female -MH - Humans -MH - *Lung Neoplasms/genetics/therapy -MH - Oncogenes -MH - Proto-Oncogene Proteins p21(ras)/genetics -PMC - PMC9171557 -COIS- Conflict of Interest Disclosures: Dr Gay reported receiving grants from - AstraZeneca and personal fees from AstraZeneca, Bristol Myers Squibb, and Jazz - Pharmaceuticals outside the submitted work. Dr Le reported receiving grants from - Eli Lilly and personal fees from EMD Serono, Astra Zeneca, Spectrum, Novartis, - Eli Lilly, Boehringer Ingelheim, Hengrui, Janssen, Abbvie, Regeneron outside the - submitted work. Dr Roth reported receiving grants and personal fees from Genprex - and personal fees from Genprex outside the submitted work, having a patent for - gene therapy licensed, and having a pending patent for overcoming TKI resistance. - Dr Gandhi reported receiving grants from Bristol Myers Squibb and Gateway - Foundation outside the submitted work. Dr P. P. Lee reported receiving grants - from AstraZeneca, personal fees from AstraZeneca, Genentech, and Varian, and - nonfinancial support from Viewray outside the submitted work. Dr Gibbons reported - receiving grants from AstraZeneca and personal fees from Eli Lilly, Sanofi, and - Menarini Ricerche, and grants from AstraZeneca during the conduct of the study - and receiving grants from Janssen, Takeda, Astellas, Ribon Therapeutics, and NGM - Biopharmaceuticals outside the submitted work. Dr Heymach reported receiving - personal fees from AstraZeneca and Spectrum during the conduct of the study. Dr - J. Zhang reported receiving grants from Johnson and Johnson, personal fees from - AstraZeneca, Geneplus Institute, Innovent, Johnson and Johnson, and Novartis, and - other support from Merck Clinical trial and Novartis Clinical trial outside the - submitted work. Dr Lin reported receiving grants from STCube Pharmaceuticals, - Nektar Therapeutics, Beyond Spring Pharmaceuticals, personal fees from - AstraZeneca and Varian Systems, and nonfinancial support from Creatv Microtech - and being a cofounder of Scenexo Inc outside the submitted work. No other - disclosures were reported. -EDAT- 2022/06/07 06:00 -MHDA- 2022/06/09 06:00 -PMCR- 2022/06/06 -CRDT- 2022/06/06 15:38 -PHST- 2022/06/06 15:38 [entrez] -PHST- 2022/06/07 06:00 [pubmed] -PHST- 2022/06/09 06:00 [medline] -PHST- 2022/06/06 00:00 [pmc-release] -AID - 2793016 [pii] -AID - zoi220458 [pii] -AID - 10.1001/jamanetworkopen.2022.15589 [doi] -PST - epublish -SO - JAMA Netw Open. 2022 Jun 1;5(6):e2215589. doi: - 10.1001/jamanetworkopen.2022.15589. - -PMID- 35607930 -OWN - NLM -STAT- MEDLINE -DCOM- 20230119 -LR - 20230207 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 12 -IP - 1 -DP - 2023 Jan -TI - Impact of concomitant fibrates on immunotherapy outcomes for advanced non-small - cell lung cancer. -PG - 358-367 -LID - 10.1002/cam4.4847 [doi] -AB - BACKGROUND: Peroxisome proliferator-activated receptor agonists such as fibrates - restore oxidative metabolism in cytotoxic T-lymphocytes, thereby enhancing - response to immune checkpoint inhibitors (ICI) in preclinical models. However, - there is no evidence in humans on the clinical impact of fibrates as an adjunct - to ICI. METHODS: In this cohort study of Veterans with non-small cell lung cancer - (NSCLC) receiving ICI, fibrate exposure was defined as a prescription filled - within 90 days of an ICI infusion. Overall survival (OS), measured from the start - of ICI, was compared between exposed and unexposed Veterans. Cox multivariable - analysis (MVA) was used to identify factors associated with OS. A sensitivity - analysis of Veterans with stage IV NSCLC who received docetaxel without ICI was - similarly performed. RESULTS: The ICI cohort included 3593 Veterans, of whom 301 - (8.5%) coincidentally received a fibrate. Veterans receiving fibrates were more - likely to be older, white, male, and married, and to have greater comorbidity - burden, but less likely to receive chemotherapy. Coincidental fibrates were - associated with improved OS both on MVA (HR 0.86, 95%CI 0.75-0.99) and in a - matched subset (HR 0.75, 95%CI 0.63-0.90). In contrast, among the cohort of 968 - Veterans treated with chemotherapy, fibrates did not have a significant impact on - OS by MVA (HR 0.99, 95%CI 0.79-1.25) or in a matched subset (HR 1.02, 95%CI CI - 0.75-1.39). CONCLUSIONS: Concomitant fibrates are associated with improved OS - among NSCLC patients receiving ICI but not among those receiving chemotherapy. - This hypothesis-generating observation supports a potential role for fibrates as - an adjunct to immunotherapy. -CI - © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Stokes, William A -AU - Stokes WA -AUID- ORCID: 0000-0002-1616-7046 -AD - Department of Radiation Oncology, Emory University, Atlanta, Georgia, USA. -AD - Winship Cancer Institute, Emory University, Atlanta, Georgia, USA. -FAU - Behera, Madhusmita -AU - Behera M -AD - Winship Cancer Institute, Emory University, Atlanta, Georgia, USA. -FAU - Jiang, Renjian -AU - Jiang R -AD - Winship Cancer Institute, Emory University, Atlanta, Georgia, USA. -FAU - Gutman, David A -AU - Gutman DA -AD - Winship Cancer Institute, Emory University, Atlanta, Georgia, USA. -AD - Atlanta Veterans Affairs Health Care System, Decatur, Georgia, USA. -FAU - Huang, Zhonglu -AU - Huang Z -AD - Winship Cancer Institute, Emory University, Atlanta, Georgia, USA. -FAU - Burns, Abigail -AU - Burns A -AD - Atlanta Veterans Affairs Health Care System, Decatur, Georgia, USA. -FAU - Sebastian, Nikhil T -AU - Sebastian NT -AUID- ORCID: 0000-0002-3977-7867 -AD - Department of Radiation Oncology, Emory University, Atlanta, Georgia, USA. -AD - Winship Cancer Institute, Emory University, Atlanta, Georgia, USA. -FAU - Sukhatme, Vidula -AU - Sukhatme V -AD - Morningside Center for Innovative and Affordable Medicine, Emory University, - Atlanta, Georgia, USA. -AD - GlobalCures, Inc, Newton, Massachusetts, USA. -FAU - Lowe, Michael C -AU - Lowe MC -AD - Morningside Center for Innovative and Affordable Medicine, Emory University, - Atlanta, Georgia, USA. -AD - Division of Surgical Oncology, Emory University, Atlanta, Georgia, USA. -FAU - Ramalingam, Suresh S -AU - Ramalingam SS -AD - Winship Cancer Institute, Emory University, Atlanta, Georgia, USA. -AD - Department of Hematology and Medical Oncology, Emory University, Atlanta, - Georgia, USA. -FAU - Sukhatme, Vikas P -AU - Sukhatme VP -AD - Morningside Center for Innovative and Affordable Medicine, Emory University, - Atlanta, Georgia, USA. -FAU - Moghanaki, Drew -AU - Moghanaki D -AD - Department of Radiation Oncology, University of California Los Angeles, Los - Angeles, California, USA. -LA - eng -GR - U.S. Department of Veterans Affairs/ -PT - Journal Article -PT - Research Support, U.S. Gov't, Non-P.H.S. -DEP - 20220524 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (Fibric Acids) -SB - IM -MH - Humans -MH - Male -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Cohort Studies -MH - *Lung Neoplasms/drug therapy -MH - Immunotherapy -MH - Fibric Acids/therapeutic use -MH - Retrospective Studies -PMC - PMC9844615 -OTO - NOTNLM -OT - fibrates -OT - immune checkpoint inhibitors -OT - peroxisome proliferator-activated receptor (PPAR) agonists -COIS- William A. Stokes has no disclosures. Madhusmita Behera has no disclosures. - Renjian Jiang has no disclosures. David A. Gutman has no disclosures. Zhonglu - Huang has no disclosures. Abigail Burns has no disclosures. Nikhil T. Sebastian - has no disclosures. Vidula Sukhatme has no disclosures. Michael C. Lowe has no - disclosures. Suresh S. Ramalingam has received grant funding and/or other support - (for consultancy) from Amgen, AstraZeneca, Bristol‐Myers Squibb, Merck, Takeda, - Tesaro, Advaxis, AbbVie, and Genentech/Roche. Vikas P. Sukhatme is on the SAB of - BERG and HiFiBio Therapeutics, and an equity holder in Aggamin Pharmaceuticals - and Victa Biotherapeutics. Drew Moghanaki has received travel support and - speaking honoraria from Varian Medical Systems. -EDAT- 2022/05/25 06:00 -MHDA- 2023/01/20 06:00 -PMCR- 2022/05/24 -CRDT- 2022/05/24 04:13 -PHST- 2022/05/05 00:00 [revised] -PHST- 2022/02/26 00:00 [received] -PHST- 2022/05/11 00:00 [accepted] -PHST- 2022/05/25 06:00 [pubmed] -PHST- 2023/01/20 06:00 [medline] -PHST- 2022/05/24 04:13 [entrez] -PHST- 2022/05/24 00:00 [pmc-release] -AID - CAM44847 [pii] -AID - 10.1002/cam4.4847 [doi] -PST - ppublish -SO - Cancer Med. 2023 Jan;12(1):358-367. doi: 10.1002/cam4.4847. Epub 2022 May 24. - -PMID- 37963454 -OWN - NLM -STAT- MEDLINE -DCOM- 20231205 -LR - 20231217 -IS - 1759-7714 (Electronic) -IS - 1759-7706 (Print) -IS - 1759-7706 (Linking) -VI - 14 -IP - 34 -DP - 2023 Dec -TI - Clinical definition of secondary resistance to immunotherapy in non-small cell - lung cancer. -PG - 3421-3429 -LID - 10.1111/1759-7714.15157 [doi] -AB - Immune checkpoint inhibitors (PD-1/PD-L1 and CTLA-4 blockade) have revolutionized - the treatment landscape in non-small cell lung cancer (NSCLC). Secondary - resistance to immunotherapy (IO), which poses a substantial challenge in clinical - settings, occurs in several initial responders. Currently, new treatment - approaches have been extensively evaluated in investigational studies for these - patients to tackle this difficult problem; however, the lack of consistency in - clinical definition, uniform criteria for enrollment in clinical trials, and - interpretation of results remain significant hurdles to progress. Thus, our - expert panel comprehensively synthesized data from current studies to propose a - practical clinical definition of secondary resistance to immunotherapy in NSCLC - in metastatic and neoadjuvant settings. In addition to patients who received IO - alone (including IO-IO combinations), we also generated a definition for patients - treated with chemotherapy plus IO. This consensus aimed to provide guidance for - clinical trial design and facilitate future discussions with investigators. It - should be noted that additional updates in this consensus are required when new - data is available. -CI - © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and - John Wiley & Sons Australia, Ltd. -FAU - Huang, Dingzhi -AU - Huang D -AUID- ORCID: 0000-0002-2798-9459 -AD - Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and - Hospital, Tianjin, People's Republic of China. -FAU - Lin, Gen -AU - Lin G -AUID- ORCID: 0000-0001-6793-552X -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. -FAU - Chu, Qian -AU - Chu Q -AD - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong - University of Science and Technology, Wuhan, People's Republic of China. -FAU - Hu, Yi -AU - Hu Y -AUID- ORCID: 0000-0001-9319-5692 -AD - Senior Department of Oncology, Chinese PLA General Hospital, Beijing, People's - Republic of China. -FAU - Wang, Jun -AU - Wang J -AUID- ORCID: 0000-0003-3941-2507 -AD - Department of Oncology, The First Affiliated Hospital of Shandong First Medical - University & Shandong Provincial Qianfoshan Hospital, Ji'nan, People's Republic - of China. -FAU - Wang, Zhijie -AU - Wang Z -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, People's Republic of China. -FAU - Yang, Fan -AU - Yang F -AD - Department of Thoracic Surgery, Peking University People Hospital, Beijing, - People's Republic of China. -FAU - Zhong, Wenzhao -AU - Zhong W -AUID- ORCID: 0000-0002-8917-8635 -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, - Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. -FAU - Zhou, Chengzhi -AU - Zhou C -AUID- ORCID: 0000-0003-0029-6879 -AD - Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, - National Clinical Research Center for Respiratory Disease, National Center for - Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First - Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic - of China. -FAU - Zhu, Bo -AU - Zhu B -AD - Institute of Cancer, Xinqiao Hospital, Army Medical University, Chongqing, - People's Republic of China. -FAU - Ai, Xinghao -AU - Ai X -AD - Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong - University School of Medicine, Shanghai, People's Republic of China. -FAU - Cao, Baoshan -AU - Cao B -AD - Cancer center, Peking University Third Hospital/ Department of medical oncology - and radiation sickness, Peking University Third Hospital, Beijing, People's - Republic of China. -FAU - Cao, Yabing -AU - Cao Y -AD - Department of oncology, Kiang Wu Hospital, Macau, People's Republic of China. -FAU - Chen, Mingqiu -AU - Chen M -AD - Department of Thoracic Radiation Oncology, Clinical Oncology School of Fujian - Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. -FAU - Chen, Xiaohui -AU - Chen X -AD - Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. -FAU - Chu, Tianqing -AU - Chu T -AD - Respiratory Department, Shanghai Chest Hospital, Shanghai Jiao Tong University - School of Medicine, Shanghai, People's Republic of China. -FAU - Duan, Jianchun -AU - Duan J -AUID- ORCID: 0000-0003-1479-2304 -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, People's Republic of China. -FAU - Fan, Yun -AU - Fan Y -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People's - Republic of China. -FAU - Fang, Yong -AU - Fang Y -AD - Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhenjiang University - School of Medicine, Hangzhou, People's Republic of China. -FAU - Feng, Shuitu -AU - Feng S -AD - Department of Medical Oncology, Fudan University Shanghai Cancer Center Xiamen - Hospital, Xiamen, People's Republic of China. -FAU - Feng, Weineng -AU - Feng W -AD - Department of Pulmonary Oncology, The First People's Hospital of Foshan, Foshan, - People's Republic of China. -FAU - Guo, Hui -AU - Guo H -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, People's Republic of China. -FAU - Han, Chengbo -AU - Han C -AUID- ORCID: 0000-0001-8391-6134 -AD - Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, - People's Republic of China. -FAU - He, Yong -AU - He Y -AUID- ORCID: 0000-0002-9404-798X -AD - Department of Respiratory Medicine, Xinqiao Hospital, Army Medical University, - Chongqing, People's Republic of China. -FAU - Hong, Shaodong -AU - Hong S -AD - State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer - Center, Guangzhou, People's Republic of China. -FAU - Hu, Jie -AU - Hu J -AD - Zhongshan Hospital, Fudan University, Shanghai Geriatric Center, Shanghai, - People's Republic of China. -FAU - Huang, Meijuan -AU - Huang M -AUID- ORCID: 0000-0002-3390-9697 -AD - Division of Thoracic Tumor Multimodality Treatment and Department of Medical - Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, - People's Republic of China. -FAU - Huang, Yan -AU - Huang Y -AD - State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer - Center, Guangzhou, People's Republic of China. -FAU - Jiang, Da -AU - Jiang D -AD - Department of Oncology, The Fourth Affiliated Hospital of Hebei Medical - University, Shijiazhuang, People's Republic of China. -FAU - Jiang, Kan -AU - Jiang K -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. -FAU - Jiang, Richeng -AU - Jiang R -AD - Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and - Hospital, Tianjin, People's Republic of China. -FAU - Jin, Bo -AU - Jin B -AD - Department of Medical Oncology, The First affiliated hospital of China Medical - University, Shenyang, People's Republic of China. -FAU - Jin, Shi -AU - Jin S -AUID- ORCID: 0000-0002-4462-2931 -AD - National Cancer Center/National Clinical Research Center for Cancer/Cancer - Hospital &Shenzhen Hospital, Chinese Academy of Medical Sciences and Perking - Union Medical College, Shenzhen, People's Republic of China. -FAU - Li, Jisheng -AU - Li J -AUID- ORCID: 0000-0002-4186-6228 -AD - Department of Medical Oncology, Qilu Hospital of Shandong University, Ji'nan, - People's Republic of China. -FAU - Li, Min -AU - Li M -AD - Department of Respiratory Medicine, Xiangya Hospital, Central South University, - Changsha, People's Republic of China. -FAU - Li, Ziming -AU - Li Z -AD - Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong - University School of Medicine, Shanghai, People's Republic of China. -FAU - Li, Chao -AU - Li C -AD - Department of Pathology, Clinical Oncology School of Fujian Medical University, - Fujian Cancer Hospital, Fuzhou, People's Republic of China. -FAU - Lin, Jie -AU - Lin J -AD - Department of Medical Oncology, The Second Affiliated Hospital of Kunming Medical - University, Kunming, People's Republic of China. -FAU - Liu, Anwen -AU - Liu A -AD - Department of Medical Oncology, The Second Affiliated Hospital of Nanchang - University, Nanchang, People's Republic of China. -FAU - Liu, Si-Yang Maggie -AU - Liu SM -AD - Department of Hematology, First Affiliated Hospital, Ji'nan University, - Guangzhou, People's Republic of China. -FAU - Liu, Yutao -AU - Liu Y -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, People's Republic of China. -FAU - Liu, Zhefeng -AU - Liu Z -AD - Senior Department of Oncology, Chinese PLA General Hospital, Beijing, People's - Republic of China. -FAU - Liu, Zhe -AU - Liu Z -AD - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical - University, Beijing, People's Republic of China. -FAU - Liu, Zhenhua -AU - Liu Z -AD - Department of Oncology, Shengli Clinical Medical College of Fujian Medical - University, Fujian Provincial Hospital, Fuzhou, People's Republic of China. -FAU - Liu, Zhentian -AU - Liu Z -AD - Department of Thoracic Oncology,Jiangxi Cancer Hospital, Nanchang, People's - Republic of China. -FAU - Liu, Zhigang -AU - Liu Z -AD - Cancer Center, The 10th Affiliated Hospital of Southern Medical University, - Dongguan, People's Republic of China. -FAU - Lu, Yuping -AU - Lu Y -AD - Department of Abdominal Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. -FAU - Lv, Tangfeng -AU - Lv T -AUID- ORCID: 0000-0001-7224-8468 -AD - Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School - of Nanjing University, Nanjing, People's Republic of China. -FAU - Ma, Zhiyong -AU - Ma Z -AD - Department of Respiratory Medicine, Henan Cancer Hospital /Affiliated Cancer - Hospital of Zhengzhou University, Zhengzhou, People's Republic of China. -FAU - Miao, Qian -AU - Miao Q -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. -FAU - Peng, Min -AU - Peng M -AUID- ORCID: 0000-0001-6648-945X -AD - Cancer center, Renmin Hospital of Wuhan University, Wuhan, People's Republic of - China. -FAU - Pu, Xingxiang -AU - Pu X -AD - Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated - Cancer Hospital of Xiangya School of Medicine, Central South University, - Changsha, People's Republic of China. -FAU - Ren, Xiu Bao -AU - Ren XB -AD - Department of Biotherapy, Tianjin Medical University Cancer Institute and - Hospital, Tianjin, People's Republic of China. -FAU - Shan, Jianzhen -AU - Shan J -AD - Department of Medical Oncology, The First Affiliated Hospital of Zhejiang - University, Zhejiang, People's Republic of China. -FAU - Shan, Jinlu -AU - Shan J -AD - Department of Medical Oncology, Daping Hospital, Army Medical University, - Chongqing, People's Republic of China. -FAU - Shen, Peng -AU - Shen P -AD - Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, - People's Republic of China. -FAU - Shen, Bo -AU - Shen B -AUID- ORCID: 0000-0001-5709-5213 -AD - Department of Medical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of - Cancer Research and Affiliated Cancer Hospital of Nanjing Medical University, - Nanjing, People's Republic of China. -FAU - Shi, Meiqi -AU - Shi M -AUID- ORCID: 0000-0002-3578-4082 -AD - Department of Medical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of - Cancer Research and Affiliated Cancer Hospital of Nanjing Medical University, - Nanjing, People's Republic of China. -FAU - Song, Yong -AU - Song Y -AUID- ORCID: 0000-0003-4979-4131 -AD - Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School - of Nanjing University, Nanjing, People's Republic of China. -FAU - Song, Zhengbo -AU - Song Z -AD - Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, People's - Republic of China. -FAU - Su, ChunXia -AU - Su C -AD - Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, - Tongji University School of Medicine, Shanghai, People's Republic of China. -FAU - Sun, Jianguo -AU - Sun J -AD - Institute of Cancer, Xinqiao Hospital, Army Medical University, Chongqing, - People's Republic of China. -FAU - Tian, Panwen -AU - Tian P -AUID- ORCID: 0000-0002-6313-3228 -AD - Department of Pulmonary and Critical Care Medicine, Lung Cancer Center, West - China Hospital, Sichuan University, Precision Medicine Key Laboratory of Sichuan - Province, Chengdu, People's Republic of China. -FAU - Wang, Jinliang -AU - Wang J -AD - Senior Department of Oncology, Chinese PLA General Hospital, Beijing, People's - Republic of China. -FAU - Wang, Feng -AU - Wang F -AD - Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. -FAU - Wang, Huijuan -AU - Wang H -AD - Department of Respiratory Medicine, Henan Cancer Hospital /Affiliated Cancer - Hospital of Zhengzhou University, Zhengzhou, People's Republic of China. -FAU - Wang, Jialei -AU - Wang J -AD - Department of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, - Shanghai, People's Republic of China. -FAU - Wang, Qian -AU - Wang Q -AD - Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of - Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, - People's Republic of China. -FAU - Wang, Wenxian -AU - Wang W -AUID- ORCID: 0000-0002-3047-4149 -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People's - Republic of China. -FAU - Wang, Yan -AU - Wang Y -AUID- ORCID: 0000-0002-1743-6383 -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking - Union Medical College, Beijing, People's Republic of China. -FAU - Wu, Lin -AU - Wu L -AD - Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated - Cancer Hospital of Xiangya School of Medicine, Central South University, - Changsha, People's Republic of China. -FAU - Wu, Fang -AU - Wu F -AUID- ORCID: 0000-0002-6627-3437 -AD - Department of Oncology, The Second Xiangya Hospital, Central South University, - Changsha, People's Republic of China. -FAU - Xia, Yang -AU - Xia Y -AUID- ORCID: 0000-0003-2487-2244 -AD - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital - of Zhejiang University School of Medicine, Hangzhou, People's Republic of China. -FAU - Xie, Congying -AU - Xie C -AUID- ORCID: 0000-0002-1693-9034 -AD - Department of Radiation and Medical Oncology, Second Affiliated Hospital of - Wenzhou Medical University, Wenzhou, People's Republic of China. -FAU - Xie, Conghua -AU - Xie C -AUID- ORCID: 0000-0001-6623-9864 -AD - Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, - People's Republic of China. -FAU - Xin, Tao -AU - Xin T -AD - Department of Oncology, The Second Affiliated Hospital of Harbin Medical - University, Harbin, People's Republic of China. -FAU - Xiong, Jianping -AU - Xiong J -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, People's Republic of China. -FAU - Xu, Haipeng -AU - Xu H -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. -FAU - Xu, Song -AU - Xu S -AUID- ORCID: 0000-0001-6153-387X -AD - Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, - Tianjin, People's Republic of China. -FAU - Xu, Yiquan -AU - Xu Y -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. -FAU - Xu, Bin -AU - Xu B -AD - Cancer center, Renmin Hospital of Wuhan University, Wuhan, People's Republic of - China. -FAU - Xu, Chunwei -AU - Xu C -AUID- ORCID: 0000-0002-9021-6731 -AD - Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School - of Nanjing University, Nanjing, People's Republic of China. -FAU - Yan, Xiaolong -AU - Yan X -AD - Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, - Xi'an, People's Republic of China. -FAU - Yang, Zhenzhou -AU - Yang Z -AD - Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical - University, Chongqing, People's Republic of China. -FAU - Yao, Wenxiu -AU - Yao W -AD - Department of Medical Oncology, Sichuan Cancer Hospital, University of Electronic - Science and Technology of China, Chengdu, People's Republic of China. -FAU - Yu, Yao -AU - Yu Y -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, People's Republic of China. -FAU - Feng, Ye -AU - Feng Y -AD - Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug - Transformation Research, The First Affiliated Hospital of Xiamen University, - School of Medicine, Xiamen University, Xiamen, People's Republic of China. -FAU - Yu, Zongyang -AU - Yu Z -AD - Department of Respiratory Medicine, The 900th Hospital of the Joint Logistic - Support Force, People's Liberation Army of China, Fuzhou, People's Republic of - China. -FAU - Yu, Yongfeng -AU - Yu Y -AD - Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong - University School of Medicine, Shanghai, People's Republic of China. -FAU - Yue, Dongsheng -AU - Yue D -AD - Department of Lung Cancer, Tianjin Medical University Cancer Institute and - Hospital, Tianjin, People's Republic of China. -FAU - Zhang, Haibo -AU - Zhang H -AD - Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, - Guangzhou, People's Republic of China. -FAU - Zhang, HongMei -AU - Zhang H -AD - Department of Clinical Oncology, Xijing Hospital, Air Force Medical University, - Xi'an, People's Republic of China. -FAU - Zhang, Li -AU - Zhang L -AD - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong - University of Science and Technology, Wuhan, People's Republic of China. -FAU - Zhang, Longfeng -AU - Zhang L -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. -FAU - Zhang, Qiuyu -AU - Zhang Q -AD - Institute of Immunotherapy, Fujian Medical University, Fuzhou, People's Republic - of China. -FAU - Zhang, Tongmei -AU - Zhang T -AUID- ORCID: 0000-0003-4271-3773 -AD - Department of Medical Oncology, Beijing Chest Hospital, Capital Medical - University, Beijing, People's Republic of China. -FAU - Zhang, Bicheng -AU - Zhang B -AD - Cancer center, Renmin Hospital of Wuhan University, Wuhan, People's Republic of - China. -FAU - Zhao, Jun -AU - Zhao J -AUID- ORCID: 0000-0003-1464-7158 -AD - Key Laboratory of Carcinogenesis and Translational Research(Ministry of - Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer - Hospital and Institute, Beijing, People's Republic of China. -FAU - Zhao, Mingfang -AU - Zhao M -AD - Department of Medical Oncology, The First affiliated hospital of China Medical - University, Shenyang, People's Republic of China. -FAU - Zheng, Xiaobin -AU - Zheng X -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. -FAU - Zhong, Fengqiao -AU - Zhong F -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. -FAU - Zhou, Jin -AU - Zhou J -AD - Department of Medical Oncology, Sichuan Cancer Hospital, University of Electronic - Science and Technology of China, Chengdu, People's Republic of China. -FAU - Zhou, Penghui -AU - Zhou P -AD - State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer - Center, Guangzhou, People's Republic of China. -FAU - Zhu, Zhengfei -AU - Zhu Z -AD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, - Shanghai, People's Republic of China. -FAU - Zou, Juntao -AU - Zou J -AD - Department of Respiratory Medicine, The First Affiliated Hospital of Nanchang - University, Nanchang, People's Republic of China. -FAU - Zou, Zihua -AU - Zou Z -AUID- ORCID: 0000-0003-0677-3998 -AD - Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, People's Republic of China. -LA - eng -PT - Journal Article -DEP - 20231114 -PL - Singapore -TA - Thorac Cancer -JT - Thoracic cancer -JID - 101531441 -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - *Lung Neoplasms/drug therapy/pathology -MH - Immunotherapy/methods -MH - Neoadjuvant Therapy -MH - B7-H1 Antigen -PMC - PMC10693946 -OTO - NOTNLM -OT - NSCLC -OT - immunotherapy -OT - secondary resistance -COIS- The authors report no conflicts of interest related to this study. -EDAT- 2023/11/15 00:41 -MHDA- 2023/12/05 17:44 -PMCR- 2023/11/14 -CRDT- 2023/11/14 18:35 -PHST- 2023/10/25 00:00 [received] -PHST- 2023/10/29 00:00 [accepted] -PHST- 2023/12/05 17:44 [medline] -PHST- 2023/11/15 00:41 [pubmed] -PHST- 2023/11/14 18:35 [entrez] -PHST- 2023/11/14 00:00 [pmc-release] -AID - TCA15157 [pii] -AID - 10.1111/1759-7714.15157 [doi] -PST - ppublish -SO - Thorac Cancer. 2023 Dec;14(34):3421-3429. doi: 10.1111/1759-7714.15157. Epub 2023 - Nov 14. - -PMID- 38446596 -OWN - NLM -STAT- MEDLINE -DCOM- 20240322 -LR - 20240702 -IS - 1945-4589 (Electronic) -IS - 1945-4589 (Linking) -VI - 16 -IP - 5 -DP - 2024 Mar 5 -TI - HOXC9 characterizes a suppressive tumor immune microenvironment and integration - with multiple immune biomarkers predicts response to PD-1 blockade plus - chemotherapy in lung adenocarcinoma. -PG - 4841-4861 -LID - 10.18632/aging.205637 [doi] -AB - BACKGROUND: The quest for dependable biomarkers to predict responses to immune - checkpoint inhibitors (ICIs) combined with chemotherapy in advanced non-small - cell lung cancer remains unfulfilled. HOXC9, known for its role in oncogenesis - and creating a suppressive tumor microenvironment (TME), shows promise in - enhancing predictive precision when included as a TME biomarker. This study - explores the predictive significance of HOXC9 for ICI plus chemotherapy efficacy - in lung adenocarcinoma (LUAD). METHODS: Following the bioinformatic findings, - assays were performed to ascertain the effects of Hoxc9 on oncogenesis and - response to programmed death 1 (PD-1) blockade. Furthermore, a cohort of LUAD - patients were prospectively enrolled to receive anti-PD-1 plus chemotherapy. - Based on the expression levels, baseline characteristics, and clinical outcomes, - the predictive potential of HOXC9, PD-L1, CD4, CD8, CD68, and FOXP3 was - integrally analyzed. HOXC9 not only mediated oncogenesis, but also corelated with - suppressive TME. CMT167 and LLC cell lines unveiled the impacts of Hoxc9 on - proliferation, invasion, and migration. Subsequently, tumor-bearing murine models - were established to validate the inverse relationship between Hoxc9 expression - and effective CD8+ T cells. RESULTS: Inhibition of Hoxc9 significantly curtailed - tumor growth (P<0.05), independent of PD-1 blockade. In patient studies, while - individual markers fell short in prognosticating survival, a notable elevation in - CD8-positive expression was observed in responders (P=0.042). Yet, the - amalgamation of HOXC9 with other markers provided a more distinct differentiation - between responders and non-responders. Notably, patients displaying PD-L1+/HOXC9- - and CD8+/HOXC9- phenotypes exhibited significantly prolonged progression-free - survival. CONCLUSIONS: The expression of HOXC9 may serve as a biomarker to - amplifying predictive efficacy for ICIs plus chemotherapy, which is also a viable - oncogene and therapeutic target for immunotherapy in LUAD. -FAU - Liu, Liang -AU - Liu L -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of - Medicine, Tongji University, Shanghai 200433, China. -FAU - Zhang, Zhenshan -AU - Zhang Z -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of - Medicine, Tongji University, Shanghai 200433, China. -AD - Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan - University Cancer Hospital, Shanghai 201315, China. -FAU - Jiang, Chenxue -AU - Jiang C -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of - Medicine, Tongji University, Shanghai 200433, China. -FAU - Zhu, Yaoyao -AU - Zhu Y -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of - Medicine, Tongji University, Shanghai 200433, China. -FAU - Han, Ruiqin -AU - Han R -AD - State Key Laboratory of Common Mechanism Research for Major Disease, Institute of - Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing 100191, China. -FAU - Wu, Leilei -AU - Wu L -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of - Medicine, Tongji University, Shanghai 200433, China. -FAU - Xu, Yaping -AU - Xu Y -AD - Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of - Medicine, Tongji University, Shanghai 200433, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20240305 -PL - United States -TA - Aging (Albany NY) -JT - Aging -JID - 101508617 -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -RN - 0 (Homeodomain Proteins) -RN - 0 (Hoxc9 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 0 (Hoxc9 protein, mouse) -RN - 0 (PDCD1 protein, human) -RN - 0 (Pdcd1 protein, mouse) -SB - IM -MH - Animals -MH - Humans -MH - Mice -MH - *Adenocarcinoma of Lung/drug therapy -MH - B7-H1 Antigen -MH - Biomarkers, Tumor -MH - Carcinogenesis -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - Homeodomain Proteins/genetics -MH - *Lung Neoplasms/pathology -MH - Programmed Cell Death 1 Receptor -MH - Tumor Microenvironment -PMC - PMC10968688 -OTO - NOTNLM -OT - HOXC9 -OT - LUAD -OT - TME -OT - biomarker -OT - immunotherapy -COIS- CONFLICTS OF INTEREST: The authors declare that they have no conflicts of - interest. -EDAT- 2024/03/06 18:42 -MHDA- 2024/03/22 06:44 -PMCR- 2024/03/15 -CRDT- 2024/03/06 12:13 -PHST- 2023/09/28 00:00 [received] -PHST- 2024/02/13 00:00 [accepted] -PHST- 2024/03/22 06:44 [medline] -PHST- 2024/03/06 18:42 [pubmed] -PHST- 2024/03/06 12:13 [entrez] -PHST- 2024/03/15 00:00 [pmc-release] -AID - 205637 [pii] -AID - 10.18632/aging.205637 [doi] -PST - ppublish -SO - Aging (Albany NY). 2024 Mar 5;16(5):4841-4861. doi: 10.18632/aging.205637. Epub - 2024 Mar 5. - -PMID- 17218777 -OWN - NLM -STAT- MEDLINE -DCOM- 20070831 -LR - 20200930 -IS - 1538-4047 (Print) -IS - 1538-4047 (Linking) -VI - 6 -IP - 2 -DP - 2007 Feb -TI - Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell - lung cancer: report of a phase I trial. -PG - 145-50 -AB - 1E10 is an anti-idiotype murine monoclonal antibody (Ab2 MAb) specific to an Ab1 - MAb which reacts with NeuGc-containing gangliosides, sulfatides and with antigens - expressed in some human tumors. Preparations containing this Ab2 were capable to - induce a strong anti-metastatic effect in tumor-bearing mice. We conducted a - Phase I clinical trial to evaluate the toxicity and humoral immune response - elicited by 1E10 vaccine in patients with small cell lung cancer (SCLC). Eligible - patients were those who after received chemotherapy and/or radiotherapy had - partial or complete response to treatment. Patients received four biweekly - injections with 2 mg of aluminum hydroxide-precipitated 1E10 MAb, then other six - doses at 28-day intervals, and later the patients who maintained a good - performance status were reimmunized. Six patients with limited-stage disease and - three with extensive-stage disease were enrolled in the study. Most of the - patients who received at least four doses of 1E10 vaccine developed strong - specific antibody responses against 1E10 MAb and NeuGc-GM3 ganglioside. - Antibodies able to react with lung carcinoma tissue sections were detected in - sera from vaccinated patients. A prolonged survival was observed in several - patients treated with the anti-idiotype vaccine. No evidence of serious adverse - effects was found. -FAU - Neninger, Elia -AU - Neninger E -AD - Hermanos Amejeiras Hospital, Havana City, Cuba 10300. nenin@infomed.sld.cu -FAU - Díaz, Rosa M -AU - Díaz RM -FAU - de la Torre, Ana -AU - de la Torre A -FAU - Rives, Rolando -AU - Rives R -FAU - Díaz, Alain -AU - Díaz A -FAU - Saurez, Giselle -AU - Saurez G -FAU - Gabri, Mariano R -AU - Gabri MR -FAU - Alonso, Daniel F -AU - Alonso DF -FAU - Wilkinson, Barbara -AU - Wilkinson B -FAU - Alfonso, Angel M -AU - Alfonso AM -FAU - Combet, Tania -AU - Combet T -FAU - Pérez, Rolando -AU - Pérez R -FAU - Vázquez, Ana M -AU - Vázquez AM -LA - eng -PT - Clinical Trial, Phase I -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20070205 -PL - United States -TA - Cancer Biol Ther -JT - Cancer biology & therapy -JID - 101137842 -RN - 0 (Antibodies, Anti-Idiotypic) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Neoplasm) -RN - 0 (Cancer Vaccines) -RN - 0 (G(M3) Ganglioside) -SB - IM -CIN - Cancer Biol Ther. 2007 Feb;6(2):151-2. doi: 10.4161/cbt.6.2.4027. PMID: 17426436 -MH - Aged -MH - Animals -MH - Antibodies, Anti-Idiotypic/*therapeutic use -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antibodies, Neoplasm/*therapeutic use -MH - Antibody Specificity -MH - Binding Sites, Antibody -MH - Cancer Vaccines/immunology/therapeutic use -MH - Carcinoma, Small Cell/*drug therapy -MH - Female -MH - G(M3) Ganglioside/immunology -MH - Humans -MH - Immunohistochemistry -MH - Immunotherapy, Active -MH - Lung Neoplasms/*drug therapy -MH - Male -MH - Mice -MH - Middle Aged -MH - Treatment Outcome -EDAT- 2007/01/16 09:00 -MHDA- 2007/09/01 09:00 -CRDT- 2007/01/16 09:00 -PHST- 2007/01/16 09:00 [pubmed] -PHST- 2007/09/01 09:00 [medline] -PHST- 2007/01/16 09:00 [entrez] -AID - 3574 [pii] -AID - 10.4161/cbt.6.2.3574 [doi] -PST - ppublish -SO - Cancer Biol Ther. 2007 Feb;6(2):145-50. doi: 10.4161/cbt.6.2.3574. Epub 2007 Feb - 5. - -PMID- 26903265 -OWN - NLM -STAT- MEDLINE -DCOM- 20161013 -LR - 20191210 -IS - 1744-7682 (Electronic) -IS - 1471-2598 (Linking) -VI - 16 -IP - 4 -DP - 2016 -TI - Racotumomab for treating lung cancer and pediatric refractory malignancies. -PG - 573-8 -LID - 10.1517/14712598.2016.1157579 [doi] -AB - INTRODUCTION: Racotumomab (originally known as 1E10 mAb) is an anti-idiotype - murine IgG1 directed to membrane glycoconjugates expressed in aggressive solid - tumors. It was developed as a mirror image of the idiotype of another antibody - against N-glycolyl-containing molecules, such as the NeuGcGM3 ganglioside. After - a successful phase II/III study, racotumomab formulated in alum was conditionally - approved in Latin American countries as maintenance therapy for advanced - non-small cell lung cancer. AREAS COVERED: This review analyzes the biology of - the target antigen, summarizes preclinical studies and discusses clinical trials - in adults and the pediatric experience with racotumomab. EXPERT OPINION: Proper - patient selection and combination with chemotherapy, radiotherapy or checkpoint - inhibitors appear to be critical issues to maximize the effects of racotumomab - vaccination in lung cancer. In a recent phase I clinical trial in children with - relapsed or resistant neuroectodermal malignancies, racotumomab was well - tolerated and immunogenic, and its evaluation as immunotherapy for high-risk - neuroblastoma is warranted. -FAU - Gabri, Mariano R -AU - Gabri MR -AD - a Laboratory of Molecular Oncology , National University of Quilmes , Buenos - Aires , Argentina. -FAU - Cacciavillano, Walter -AU - Cacciavillano W -AD - b Hematology-Oncology Service , Pediatric Hospital Professor Dr. Juan P. Garrahan - , Buenos Aires , Argentina. -FAU - Chantada, Guillermo L -AU - Chantada GL -AD - b Hematology-Oncology Service , Pediatric Hospital Professor Dr. Juan P. Garrahan - , Buenos Aires , Argentina. -FAU - Alonso, Daniel F -AU - Alonso DF -AD - a Laboratory of Molecular Oncology , National University of Quilmes , Buenos - Aires , Argentina. -LA - eng -PT - Journal Article -PT - Review -PL - England -TA - Expert Opin Biol Ther -JT - Expert opinion on biological therapy -JID - 101125414 -RN - 0 (Antibodies, Anti-Idiotypic) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Murine-Derived) -RN - 0 (Cancer Vaccines) -RN - 0 (G(M3) Ganglioside) -RN - 52G405U1E5 (racotumomab) -RN - 69345-49-9 (N-glycolylneuraminyllactosylceramide) -SB - IM -MH - Animals -MH - Antibodies, Anti-Idiotypic/therapeutic use -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antibodies, Monoclonal, Murine-Derived -MH - Cancer Vaccines/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Child -MH - G(M3) Ganglioside/analogs & derivatives/immunology -MH - Humans -MH - Lung Neoplasms/*drug therapy -OTO - NOTNLM -OT - Immunotherapy -OT - N-glycolylated gangliosides -OT - anti-idiotype antibody -OT - neuroblastoma -OT - non-small cell lung cancer -OT - vaccine -EDAT- 2016/02/24 06:00 -MHDA- 2016/10/14 06:00 -CRDT- 2016/02/24 06:00 -PHST- 2016/02/24 06:00 [entrez] -PHST- 2016/02/24 06:00 [pubmed] -PHST- 2016/10/14 06:00 [medline] -AID - 10.1517/14712598.2016.1157579 [doi] -PST - ppublish -SO - Expert Opin Biol Ther. 2016;16(4):573-8. doi: 10.1517/14712598.2016.1157579. - -PMID- 37675730 -OWN - NLM -STAT- MEDLINE -DCOM- 20230908 -LR - 20230908 -IS - 1998-4138 (Electronic) -IS - 1998-4138 (Linking) -VI - 19 -IP - 4 -DP - 2023 Aug -TI - Comparison of first-line immunotherapy efficacy between advanced lung squamous - cell carcinoma and pulmonary lymphoepithelioma-like carcinoma: A propensity score - matching multicenter study. -PG - 1011-1018 -LID - 10.4103/jcrt.jcrt_2711_22 [doi] -AB - BACKGROUND: Compared with other lung squamous cell carcinomas (LUSC), pulmonary - lymphoepithelioma-like carcinoma (pLELC) is closely associated with Epstein-Barr - virus (EBV) infections with a unique molecular profile and immune - microenvironment. This study was thus established to compare the treatment - response and effectiveness of immunotherapy between pLELC and LUSC. MATERIAL AND - METHODS: We enrolled 31 patients with pLELC and 116 with LUSC receiving - first-line immunotherapy at three centers in China and compared the treatment - response and effectiveness of immunotherapy. Propensity score matching (PSM) was - used to balance the differences in baseline data between the two groups. RESULTS: - Before PSM, progression-free survival and overall survival were longer in the - pLELC group than in the LUSC group (progression-free survival: hazard ratio (HR), - 1.67, 95% CI: 1.05-2.63, P = 0.028; overall survival: HR, 1.90, 95% CI: - 1.06-3.40, P = 0.028). This remained unchanged after PSM (progression-free - survival: HR, 1.79, 95% CI: 1.02-3.15, P = 0.044; overall survival: HR, 2.20; 95% - CI: 1.10-4.37, P = 0.022). CONCLUSION: pLELC showed a clinically meaningful - survival benefit compared with traditional LUSC following immunotherapy. - Subsequent studies should consider the role of the EBV in the tumor immune - microenvironment of pLELC. -FAU - Zhou, YuBin -AU - Zhou Y -AD - Department of Cardio-Thoracic Surgery, the Third Affiliated Hospital of Sun - Yat-sen University, Guangzhou, Guangdong; The University of Hongkong-ShenZhen - Hospital, Shenzhen, 518000, China. -FAU - Huang, Jian -AU - Huang J -AD - Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, Jiangxi, - China. -FAU - Lan, Jun -AU - Lan J -AD - Department of General Surgery, the People's Hospital of Gaoan City. Gaoan, - Jiangxi, China. -FAU - Hu, Hao -AU - Hu H -AD - Department of Radiation Therapy, General Hospital of Southern Theater Command, - Guangzhou, Guangdong, China. -FAU - Yuan, Zihao -AU - Yuan Z -AD - The Second Clinical Medical College of Guangdong Medical University, Dongguan, - Guangdong, China. -FAU - Dong, Longyan -AU - Dong L -AD - The Second Clinical Medical College of Guangdong Medical University, Dongguan, - Guangdong, China. -FAU - Deng, Huiyin -AU - Deng H -AD - Department of Anesthesiology, the Third Xiangya Hospital, Central South - University, Chang-sha, Hunan, China. -FAU - Yue, Li-Ao -AU - Yue LA -AD - Huafa Community Health Service Center, Shenzhen, Zhuhai, China. -FAU - Xiao, Yi -AU - Xiao Y -AD - Department of Cardio-Thoracic Surgery, the Third Affiliated Hospital of Sun - Yat-sen University, Guangzhou, Guangdong, China. -FAU - Yang, Xiongwen -AU - Yang X -AD - Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, Jiangxi; - School of Medicine, South China University of Technology, Guangzhou, Guangdong, - China. -LA - eng -PT - Journal Article -PT - Multicenter Study -PL - India -TA - J Cancer Res Ther -JT - Journal of cancer research and therapeutics -JID - 101249598 -SB - IM -MH - Humans -MH - *Epstein-Barr Virus Infections/complications -MH - Propensity Score -MH - Herpesvirus 4, Human -MH - *Carcinoma, Non-Small-Cell Lung -MH - *Carcinoma, Squamous Cell/drug therapy -MH - Immunotherapy -MH - *Lung Neoplasms/therapy -MH - Lung -MH - Tumor Microenvironment -OTO - NOTNLM -OT - Immunotherapy -OT - lung squamous cell carcinoma -OT - prognosis -OT - pulmonary lymphoepithelioma-like carcinoma -EDAT- 2023/09/07 06:42 -MHDA- 2023/09/08 06:43 -CRDT- 2023/09/07 05:45 -PHST- 2023/09/08 06:43 [medline] -PHST- 2023/09/07 06:42 [pubmed] -PHST- 2023/09/07 05:45 [entrez] -AID - JCanResTher_2023_19_4_1011_384520 [pii] -AID - 10.4103/jcrt.jcrt_2711_22 [doi] -PST - ppublish -SO - J Cancer Res Ther. 2023 Aug;19(4):1011-1018. doi: 10.4103/jcrt.jcrt_2711_22. - -PMID- 6266642 -OWN - NLM -STAT- MEDLINE -DCOM- 19811029 -LR - 20190620 -IS - 0008-543X (Print) -IS - 0008-543X (Linking) -VI - 47 -IP - 12 -DP - 1981 Jun 15 -TI - Combination chemotherapy with and without the methanol-extracted residue of - bacillus Calmette-Guerin (MER) in extensive non-small-cell lung cancer: a - prospective randomized study for the Piedmont Oncology Association. -PG - 2827-32 -AB - One-hundred-three patients with extensive non-small-cell lung cancer were entered - into a prospective, randomized trial to determine the value of MER as an adjuvant - to chemotherapy. Patients were stratified according to histology and performance - status. All patients received CCNU, methotrexate, and Adriamycin with 48 patients - also receiving MER. All patients had a performance status of 2 or less (less than - 50% bedridden), 49% had prior radiation therapy, only one patient had prior - chemotherapy, and all had extensive disease. Of the patients, 42% had epidermoid - cancer, 21% had large cell cancer, 32% had adenocarcinoma, and 4% had mixed - adenosquamous or undifferentiated carcinoma. The response rates and response - durations of the two treatment regimens were similar. Of the patients, 18% had an - objective response; in 4% it was complete. An additional 29% had a stable - response. Median duration of response ranged from 21 to 23 weeks. Median survival - rates for non-MER and MER treatment groups were 21.5 and 18.6 weeks, - respectively. The four complete responders have a survival of 24, 85, 86+, and - 129 weeks. MER did not improve response for hematopoietic tolerance, was - associated with significant morbidity, and was poorly tolerated. The value of - immunotherapy in lung cancer remains to be established. -FAU - Richards, F 2nd -AU - Richards F 2nd -FAU - Howard, V -AU - Howard V -FAU - Shore, A -AU - Shore A -FAU - Muss, H B -AU - Muss HB -FAU - White, D R -AU - White DR -FAU - Jackson, D V -AU - Jackson DV -FAU - Cooper, M R -AU - Cooper MR -FAU - Bearden, J -AU - Bearden J -FAU - Stuart, J J -AU - Stuart JJ -FAU - Sartiano, G -AU - Sartiano G -FAU - Rhyne, A L -AU - Rhyne AL -FAU - Spurr, C L -AU - Spurr CL -LA - eng -GR - CA-03927/CA/NCI NIH HHS/United States -GR - CA-12197/CA/NCI NIH HHS/United States -GR - CA-19439/CA/NCI NIH HHS/United States -PT - Clinical Trial -PT - Comparative Study -PT - Journal Article -PT - Randomized Controlled Trial -PT - Research Support, U.S. Gov't, P.H.S. -PL - United States -TA - Cancer -JT - Cancer -JID - 0374236 -RN - 0 (Antineoplastic Agents) -RN - 0 (BCG Vaccine) -RN - 0 (methanol extraction residue (MER) tubercle bacillus fraction) -RN - 7BRF0Z81KG (Lomustine) -RN - 80168379AG (Doxorubicin) -RN - YL5FZ2Y5U1 (Methotrexate) -SB - IM -MH - Adenocarcinoma/therapy -MH - Adult -MH - Aged -MH - Antineoplastic Agents/*administration & dosage -MH - BCG Vaccine/*therapeutic use -MH - Carcinoma, Small Cell/therapy -MH - Carcinoma, Squamous Cell/therapy -MH - Doxorubicin/administration & dosage -MH - Drug Administration Schedule -MH - Drug Therapy, Combination -MH - Female -MH - Humans -MH - Lomustine/administration & dosage -MH - Lung Neoplasms/*therapy -MH - Male -MH - Methotrexate/administration & dosage -MH - Middle Aged -MH - Mycobacterium tuberculosis -MH - Prospective Studies -MH - Random Allocation -EDAT- 1981/06/15 00:00 -MHDA- 1981/06/15 00:01 -CRDT- 1981/06/15 00:00 -PHST- 1981/06/15 00:00 [pubmed] -PHST- 1981/06/15 00:01 [medline] -PHST- 1981/06/15 00:00 [entrez] -AID - 10.1002/1097-0142(19810615)47:12<2827::aid-cncr2820471212>3.0.co;2-d [doi] -PST - ppublish -SO - Cancer. 1981 Jun 15;47(12):2827-32. doi: - 10.1002/1097-0142(19810615)47:12<2827::aid-cncr2820471212>3.0.co;2-d. - -PMID- 35115705 -OWN - NLM -STAT- MEDLINE -DCOM- 20220426 -LR - 20221026 -IS - 1546-170X (Electronic) -IS - 1078-8956 (Print) -IS - 1078-8956 (Linking) -VI - 28 -IP - 2 -DP - 2022 Feb -TI - Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in - patients with advanced non-small-cell lung cancer. -PG - 315-324 -LID - 10.1038/s41591-021-01655-5 [doi] -AB - Aside from PD-L1 expression, biomarkers of response to immune checkpoint - inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. In a previous - retrospective analysis, we documented that fecal Akkermansia muciniphila (Akk) - was associated with clinical benefit of ICI in patients with NSCLC or kidney - cancer. In the current study, we performed shotgun-metagenomics-based microbiome - profiling in a large cohort of patients with advanced NSCLC (n = 338) treated - with first- or second-line ICIs to prospectively validate the predictive value of - fecal Akk. Baseline stool Akk was associated with increased objective response - rates and overall survival in multivariate analyses, independent of PD-L1 - expression, antibiotics, and performance status. Intestinal Akk was accompanied - by a richer commensalism, including Eubacterium hallii and Bifidobacterium - adolescentis, and a more inflamed tumor microenvironment in a subset of patients. - However, antibiotic use (20% of cases) coincided with a relative dominance of Akk - above 4.8% accompanied with the genus Clostridium, both associated with - resistance to ICI. Our study shows significant differences in relative abundance - of Akk that may represent potential biomarkers to refine patient stratification - in future studies. -CI - © 2022. The Author(s), under exclusive licence to Springer Nature America, Inc. -FAU - Derosa, Lisa -AU - Derosa L -AUID- ORCID: 0000-0003-0527-2964 -AD - Gustave Roussy Cancer Campus, Villejuif, France. -AD - Cancer Medicine Department, Gustave Roussy, Villejuif, France. -AD - Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe - Labellisée, Ligue Nationale contre le Cancer, Villejuif, France. -AD - Université Paris-Saclay, Ile-de-France, France. -FAU - Routy, Bertrand -AU - Routy B -AUID- ORCID: 0000-0003-1955-9149 -AD - Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), - Hematology-Oncology Division, Montréal, Quebec, Canada. -AD - Centre de Recherche du CHUM (CRCHUM), Montréal, Quebec, Canada. -FAU - Thomas, Andrew Maltez -AU - Thomas AM -AUID- ORCID: 0000-0001-5789-3354 -AD - Department CIBIO, University of Trento, Trento, Italy. -AD - European Institute of Oncology (IEO) IRCCS, Milan, Italy. -FAU - Iebba, Valerio -AU - Iebba V -AD - Department of Medical, Surgical and Health Sciences, University of Trieste, - Trieste, Italy. -FAU - Zalcman, Gerard -AU - Zalcman G -AUID- ORCID: 0000-0002-0343-9575 -AD - Thoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude - Bernard, AP-HP, Université Paris-Diderot, Paris, France. -FAU - Friard, Sylvie -AU - Friard S -AD - Pneumology Department, Foch Hospital, Suresnes, France. -FAU - Mazieres, Julien -AU - Mazieres J -AUID- ORCID: 0000-0002-5921-7613 -AD - Department of Pneumology, Toulouse University Hospital, Toulouse, France. -FAU - Audigier-Valette, Clarisse -AU - Audigier-Valette C -AD - Pneumology Department, Centre Hospitalier Toulon Sainte-Musse, Toulon, France. -FAU - Moro-Sibilot, Denis -AU - Moro-Sibilot D -AUID- ORCID: 0000-0001-6776-8610 -AD - Department of Thoracic Oncology, Centre Hospitalier Universitaire, Grenoble, - France. -FAU - Goldwasser, François -AU - Goldwasser F -AD - UPR 4466, Paris Descartes University, Sorbonne Paris Cité, Paris, France. -AD - Department of Medical Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de - Paris, Paris, France. -AD - Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France. -FAU - Silva, Carolina Alves Costa -AU - Silva CAC -AD - Gustave Roussy Cancer Campus, Villejuif, France. -AD - Cancer Medicine Department, Gustave Roussy, Villejuif, France. -FAU - Terrisse, Safae -AU - Terrisse S -AD - Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Bonvalet, Melodie -AU - Bonvalet M -AUID- ORCID: 0000-0003-2692-5338 -AD - Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Scherpereel, Arnaud -AU - Scherpereel A -AD - Department of Pulmonary and Thoracic Oncology, University of Lille, University - Hospital (CHU), Lille, France. -FAU - Pegliasco, Hervé -AU - Pegliasco H -AD - Pulmonary Department, European Hospital, Marseille, France. -FAU - Richard, Corentin -AU - Richard C -AD - Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), - Hematology-Oncology Division, Montréal, Quebec, Canada. -AD - Centre de Recherche du CHUM (CRCHUM), Montréal, Quebec, Canada. -FAU - Ghiringhelli, François -AU - Ghiringhelli F -AUID- ORCID: 0000-0002-5465-8305 -AD - Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France. -AD - Centre de Recherche INSERM LNC-UMR1231, Dijon, France. -AD - Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. -FAU - Elkrief, Arielle -AU - Elkrief A -AD - Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), - Hematology-Oncology Division, Montréal, Quebec, Canada. -AD - Centre de Recherche du CHUM (CRCHUM), Montréal, Quebec, Canada. -FAU - Desilets, Antoine -AU - Desilets A -AUID- ORCID: 0000-0002-9382-7597 -AD - Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), - Hematology-Oncology Division, Montréal, Quebec, Canada. -AD - Centre de Recherche du CHUM (CRCHUM), Montréal, Quebec, Canada. -FAU - Blanc-Durand, Felix -AU - Blanc-Durand F -AD - Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Cumbo, Fabio -AU - Cumbo F -AD - Department CIBIO, University of Trento, Trento, Italy. -FAU - Blanco, Aitor -AU - Blanco A -AUID- ORCID: 0000-0001-7386-5572 -AD - Department CIBIO, University of Trento, Trento, Italy. -FAU - Boidot, Romain -AU - Boidot R -AUID- ORCID: 0000-0001-9956-1737 -AD - Unit of Molecular Biology, Department of Biology and Pathology of Tumors, - Georges-François Leclerc Cancer Center, UNICANCER, Dijon, France. -FAU - Chevrier, Sandy -AU - Chevrier S -AD - Unit of Molecular Biology, Department of Biology and Pathology of Tumors, - Georges-François Leclerc Cancer Center, UNICANCER, Dijon, France. -FAU - Daillère, Romain -AU - Daillère R -AD - EverImmune, Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Kroemer, Guido -AU - Kroemer G -AUID- ORCID: 0000-0002-9334-4405 -AD - Gustave Roussy Cancer Campus, Villejuif, France. -AD - UPR 4466, Paris Descartes University, Sorbonne Paris Cité, Paris, France. -AD - Centre de Recherche des Cordeliers, INSERM U1138, Equipe labellisée-Ligue contre - le cancer, Université de Paris, Institut Universitaire de France, Paris, France. -AD - Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, - France. -AD - Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France. -FAU - Alla, Laurie -AU - Alla L -AD - Université Paris-Saclay, INRAE, MGP, Jouy en Josas, France. -FAU - Pons, Nicolas -AU - Pons N -AD - Université Paris-Saclay, INRAE, MGP, Jouy en Josas, France. -FAU - Le Chatelier, Emmanuelle -AU - Le Chatelier E -AUID- ORCID: 0000-0002-2724-0536 -AD - Université Paris-Saclay, INRAE, MGP, Jouy en Josas, France. -FAU - Galleron, Nathalie -AU - Galleron N -AD - Université Paris-Saclay, INRAE, MGP, Jouy en Josas, France. -FAU - Roume, Hugo -AU - Roume H -AD - Université Paris-Saclay, INRAE, MGP, Jouy en Josas, France. -FAU - Dubuisson, Agathe -AU - Dubuisson A -AUID- ORCID: 0000-0002-7526-0769 -AD - Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Bouchard, Nicole -AU - Bouchard N -AD - Centre Hospitalier de Sherbrooke, Sherbrooke, Quebec, Canada. -FAU - Messaoudene, Meriem -AU - Messaoudene M -AD - Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), - Hematology-Oncology Division, Montréal, Quebec, Canada. -AD - Centre de Recherche du CHUM (CRCHUM), Montréal, Quebec, Canada. -FAU - Drubay, Damien -AU - Drubay D -AUID- ORCID: 0000-0002-9997-9727 -AD - INSERM U1018, Oncostat, Villejuif, France. -FAU - Deutsch, Eric -AU - Deutsch E -AUID- ORCID: 0000-0002-8223-3697 -AD - Gustave Roussy Cancer Campus, Villejuif, France. -AD - Université Paris-Saclay, Ile-de-France, France. -AD - Department of Radiation Oncology, Gustave Roussy, Villejuif, France. -AD - INSERM U1030, Radiothérapie Moléculaire et Innovation Thérapeutique, Villejuif, - France. -FAU - Barlesi, Fabrice -AU - Barlesi F -AD - Gustave Roussy Cancer Campus, Villejuif, France. -AD - Cancer Medicine Department, Gustave Roussy, Villejuif, France. -FAU - Planchard, David -AU - Planchard D -AD - Gustave Roussy Cancer Campus, Villejuif, France. -AD - Cancer Medicine Department, Gustave Roussy, Villejuif, France. -FAU - Segata, Nicola -AU - Segata N -AUID- ORCID: 0000-0002-1583-5794 -AD - Department CIBIO, University of Trento, Trento, Italy. -AD - European Institute of Oncology (IEO) IRCCS, Milan, Italy. -FAU - Martinez, Stéphanie -AU - Martinez S -AD - Service des Maladies Respiratoires, Centre Hospitalier d'Aix-en-Provence, - Aix-en-Provence, France. -FAU - Zitvogel, Laurence -AU - Zitvogel L -AUID- ORCID: 0000-0003-1596-0998 -AD - Gustave Roussy Cancer Campus, Villejuif, France. - laurence.zitvogel@gustaveroussy.fr. -AD - Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe - Labellisée, Ligue Nationale contre le Cancer, Villejuif, France. - laurence.zitvogel@gustaveroussy.fr. -AD - Université Paris-Saclay, Ile-de-France, France. - laurence.zitvogel@gustaveroussy.fr. -AD - Center of Clinical Investigations in Biotherapies of Cancer (BIOTHERIS) 1428, - Villejuif, France. laurence.zitvogel@gustaveroussy.fr. -FAU - Soria, Jean-Charles -AU - Soria JC -AD - Gustave Roussy Cancer Campus, Villejuif, France. -FAU - Besse, Benjamin -AU - Besse B -AD - Gustave Roussy Cancer Campus, Villejuif, France. -AD - Cancer Medicine Department, Gustave Roussy, Villejuif, France. -AD - Université Paris-Saclay, Ile-de-France, France. -LA - eng -GR - R01 CA230551/CA/NCI NIH HHS/United States -GR - U01 CA230551/CA/NCI NIH HHS/United States -GR - CIHR/Canada -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20220203 -PL - United States -TA - Nat Med -JT - Nature medicine -JID - 9502015 -RN - 0 (B7-H1 Antigen) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - Akkermansia muciniphila -SB - IM -CIN - Cell Rep Med. 2022 May 17;3(5):100642. doi: 10.1016/j.xcrm.2022.100642. PMID: - 35584634 -MH - Akkermansia -MH - B7-H1 Antigen -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/metabolism -MH - Humans -MH - *Lung Neoplasms/drug therapy/genetics -MH - Programmed Cell Death 1 Receptor -MH - Retrospective Studies -MH - Tumor Microenvironment -PMC - PMC9330544 -MID - NIHMS1807276 -COIS- CONFLICTS OF INTEREST LZ received research contract from Kaleido and Innovate - Pharma and Pilege. LD had consulting, and advisory role for BMS, Sanofi and was - supported by Philantropia Fondation Gustave Roussy. GZ received a research grant - from Fondation Roche, received fees from Roche, MSD, BMS, Astra-Zeneca and is - consultant for Da Volterra & Inventiva. ED reports grants and personal fees from - Roche Genentech, grants from Boehringer, grants from Astrazeneca, grants and - personal fees from Merck Serono, grants from BMS, and grants from MSD. PD had - consulting, and advisory role for AstraZeneca, Bristol-Myers Squibb, Boehringer - Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME - Oncology, Peer CME, Roche, Samsung, as well as honoraria from AstraZeneca, - Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, - Pfizer, prIME Oncology, Peer CME, Roche, Samsung. PD ran clinical trials as - principal or co-investigator for AstraZeneca, Bristol-Myers Squibb, Boehringer - Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, - Taiho Pharma, Novocure, Daiichi Sankyo, and received Travel, Accommodation, - Expenses: from AstraZeneca, Roche, Novartis, prIME Oncology, Pfizer. FG received - honoraria from Amgen,Sanofi, Merk Serono, MSD, BMS, Astra Zeneca, had a - consultancy or advisory role for Roche, Enterome and received direct research - fundings from Roche, Enterome, Astra Zeneca, Servier and traveling supports from - Servier, Amgen, Roche. JCS In the last 2 years consultancy fees from Relay - Therapeutics, Gritstone are holds shares from Hookipa, Gritstone, AstraZeneca, - Daiichi Sankyo and was a full time employee for AstraZeneca 2017–2019. -EDAT- 2022/02/05 06:00 -MHDA- 2022/04/27 06:00 -PMCR- 2022/08/03 -CRDT- 2022/02/04 05:46 -PHST- 2020/12/15 00:00 [received] -PHST- 2021/12/06 00:00 [accepted] -PHST- 2022/02/05 06:00 [pubmed] -PHST- 2022/04/27 06:00 [medline] -PHST- 2022/02/04 05:46 [entrez] -PHST- 2022/08/03 00:00 [pmc-release] -AID - 10.1038/s41591-021-01655-5 [pii] -AID - 10.1038/s41591-021-01655-5 [doi] -PST - ppublish -SO - Nat Med. 2022 Feb;28(2):315-324. doi: 10.1038/s41591-021-01655-5. Epub 2022 Feb - 3. - -PMID- 35749385 -OWN - NLM -STAT- MEDLINE -DCOM- 20220628 -LR - 20220718 -IS - 1932-6203 (Electronic) -IS - 1932-6203 (Linking) -VI - 17 -IP - 6 -DP - 2022 -TI - Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients - with locally advanced, unresectable, stage Ⅲ nsclc in china. -PG - e0270118 -LID - 10.1371/journal.pone.0270118 [doi] -LID - e0270118 -AB - OBJECTIVE: The aim of this study was to evaluate the cost-effectiveness of - durvalumab compared with Best supportive care (BSC) after chemoradiotherapy in - patients with stage III non-small cell lung cancer from healthcare system - perspective in China. METHODS: A dynamic state transition model was adopted to - simulate life time, direct medical costs and QALYs. In the base case scenario, - for patients with unresectable, stage Ⅲ non-small cell lung cancer whose disease - has not progressed after platinum-based chemoradiation therapy, the treatment - group would use durvalumab whereas the control group would use BSC. Clinical data - and health utility were derived from the patient-level data of Asian ethnicity in - the PACIFIC trial. Cost of drug acquisition, follow-up, medical service, - inspection, terminal care and adverse event treatment were considered in this - model. The cost of durvalumab was calculated based on retail prices and Patient - Assistance Program. RESULTS: In the base case, the durvalumab group yielded an - additional 2.60 LYs and 2.37QALYs (discounted), causing an additional cost of - 0.459 million RMB and 0.109 million RMB without and with PAP, so the ICER was - 193,898 RMB/QALY and 46,093.12 RMB/QALY respectively. CONCLUSIONS: This study - demonstrated that durvalumab can improve the survival of patients with - unresectable, stage Ⅲ non-small cell lung cancer whose disease has not progressed - after platinum-based chemoradiation therapy and would be a cost-effective option - compared with BSC at a willingness to pay (WTP) threshold of 212676 RMB (three - times GDP per capita of China in 2019). -FAU - Jiang, Xiaotong -AU - Jiang X -AD - Institute of Medical Information, Chinese Academy of Medical Sciences, Beijing, - China. -FAU - Chen, Jinyu -AU - Chen J -AUID- ORCID: 0000-0002-0534-7543 -AD - China Health Economics Association, Beijing, China. -AD - National Center for Medicine and Health Technology Assessment, Beijing, China. -FAU - Zheng, Min -AU - Zheng M -AD - Shenyang Pharmaceutical University, Shenyang, China. -FAU - Jia, Hanxue -AU - Jia H -AD - Shenyang Pharmaceutical University, Shenyang, China. -LA - eng -PT - Journal Article -DEP - 20220624 -PL - United States -TA - PLoS One -JT - PloS one -JID - 101285081 -RN - 0 (Antibodies, Monoclonal) -RN - 28X28X9OKV (durvalumab) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung -MH - China -MH - Cost-Benefit Analysis -MH - Humans -MH - *Lung Neoplasms -MH - Quality-Adjusted Life Years -PMC - PMC9231800 -COIS- The authors have declared that no competing interests exist. -EDAT- 2022/06/25 06:00 -MHDA- 2022/06/29 06:00 -PMCR- 2022/06/24 -CRDT- 2022/06/24 13:43 -PHST- 2021/08/27 00:00 [received] -PHST- 2022/06/06 00:00 [accepted] -PHST- 2022/06/24 13:43 [entrez] -PHST- 2022/06/25 06:00 [pubmed] -PHST- 2022/06/29 06:00 [medline] -PHST- 2022/06/24 00:00 [pmc-release] -AID - PONE-D-21-27815 [pii] -AID - 10.1371/journal.pone.0270118 [doi] -PST - epublish -SO - PLoS One. 2022 Jun 24;17(6):e0270118. doi: 10.1371/journal.pone.0270118. - eCollection 2022. - -PMID- 31527660 -OWN - NLM -STAT- MEDLINE -DCOM- 20201029 -LR - 20210110 -IS - 2045-2322 (Electronic) -IS - 2045-2322 (Linking) -VI - 9 -IP - 1 -DP - 2019 Sep 16 -TI - (18)F-FDG uptake in PET/CT is a potential predictive biomarker of response to - anti-PD-1 antibody therapy in non-small cell lung cancer. -PG - 13362 -LID - 10.1038/s41598-019-50079-2 [doi] -LID - 13362 -AB - To examine the association between (18)F-fluorodeoxyglucose ((18)F-FDG) uptake in - positron emission tomography/computed tomography (PET/CT) and the response to - anti-programmed cell death-1 (PD-1) monoclonal antibody therapy in non-small cell - lung cancer (NSCLC) patients, 89 patients with advanced or recurrent NSCLC were - retrospectively analysed. Maximum standardized uptake value (SUVmax) in (18)F-FDG - PET/CT and the response to anti-PD-1 antibodies were recorded. A cut-off value of - SUVmax was determined by receiver operating characteristic curve analysis for - patient stratification. Among the 89 patients evaluated, 24 were classified as - responders (all partial response), and 65 as non-responders. The average SUVmax - of the responders was 15.60 (range, 6.44-51.10), which was significantly higher - than that of the non-responders (11.61; range, 2.13-32.75; P = 0.0168, Student's - t-test). The cut-off SUVmax value selected for stratification was 11.16 - (sensitivity and specificity, 0.792 and 0.585, respectively). The response rate - of patients with SUVmax value ≥ 11.16 (41.3% [19/46]) was significantly higher - than that of patients with SUVmax < 11.16 (11.6% [5/43], P = 0.0012, Chi-squared - test). The SUVmax in (18)F-FDG PET/CT is a potential predictive marker of - response to anti-PD-1 antibody therapy in NSCLC patients. Further prospective - studies of large populations are necessary to validate these results. -FAU - Takada, Kazuki -AU - Takada K -AUID- ORCID: 0000-0001-6377-9291 -AD - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu - University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. - k_takada@surg2.med.kyushu-u.ac.jp. -FAU - Toyokawa, Gouji -AU - Toyokawa G -AD - Department of Thoracic Surgery, National Kyushu Medical Center, 1-8-1 Jigyohama, - Chuo-ku, Fukuoka, 810-8563, Japan. -FAU - Yoneshima, Yasuto -AU - Yoneshima Y -AD - Research Institute for Diseases of the Chest, Graduate School of Medical - Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, - Japan. -FAU - Tanaka, Kentaro -AU - Tanaka K -AD - Research Institute for Diseases of the Chest, Graduate School of Medical - Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, - Japan. -FAU - Okamoto, Isamu -AU - Okamoto I -AD - Research Institute for Diseases of the Chest, Graduate School of Medical - Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, - Japan. -FAU - Shimokawa, Mototsugu -AU - Shimokawa M -AD - Clinical Research Institute, National Kyushu Cancer Center, 3-1-1 Notame, - Minami-ku, Fukuoka, 811-1395, Japan. -FAU - Wakasu, Sho -AU - Wakasu S -AD - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu - University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. -FAU - Haro, Akira -AU - Haro A -AD - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu - University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. -FAU - Osoegawa, Atsushi -AU - Osoegawa A -AD - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu - University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. -FAU - Tagawa, Tetsuzo -AU - Tagawa T -AD - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu - University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. -FAU - Oda, Yoshinao -AU - Oda Y -AD - Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu - University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. -FAU - Nakanishi, Yoichi -AU - Nakanishi Y -AD - Research Institute for Diseases of the Chest, Graduate School of Medical - Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, - Japan. -FAU - Mori, Masaki -AU - Mori M -AD - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu - University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. -LA - eng -PT - Journal Article -DEP - 20190916 -PL - England -TA - Sci Rep -JT - Scientific reports -JID - 101563288 -RN - 0 (Biomarkers, Pharmacological) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 0 (Radiopharmaceuticals) -RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Biomarkers, Pharmacological/*metabolism -MH - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/*drug therapy -MH - Female -MH - Fluorodeoxyglucose F18/*metabolism -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/drug therapy -MH - Lymph Nodes/diagnostic imaging -MH - Lymphatic Metastasis/radiotherapy -MH - Male -MH - Middle Aged -MH - Neoplasm Recurrence, Local/diagnostic imaging -MH - Positron Emission Tomography Computed Tomography/methods -MH - Programmed Cell Death 1 Receptor/immunology -MH - ROC Curve -MH - Radiopharmaceuticals -MH - Sensitivity and Specificity -PMC - PMC6746703 -COIS- The authors declare no competing interests. -EDAT- 2019/09/19 06:00 -MHDA- 2020/10/30 06:00 -PMCR- 2019/09/16 -CRDT- 2019/09/19 06:00 -PHST- 2019/03/19 00:00 [received] -PHST- 2019/09/05 00:00 [accepted] -PHST- 2019/09/19 06:00 [entrez] -PHST- 2019/09/19 06:00 [pubmed] -PHST- 2020/10/30 06:00 [medline] -PHST- 2019/09/16 00:00 [pmc-release] -AID - 10.1038/s41598-019-50079-2 [pii] -AID - 50079 [pii] -AID - 10.1038/s41598-019-50079-2 [doi] -PST - epublish -SO - Sci Rep. 2019 Sep 16;9(1):13362. doi: 10.1038/s41598-019-50079-2. - -PMID- 37076159 -OWN - NLM -STAT- MEDLINE -DCOM- 20230421 -LR - 20230426 -IS - 2044-6055 (Electronic) -IS - 2044-6055 (Linking) -VI - 13 -IP - 4 -DP - 2023 Apr 19 -TI - Assessing the impact of digital patient monitoring on health outcomes and - healthcare resource usage in addition to the feasibility of its combination with - at-home treatment, in participants receiving systemic anticancer treatment in - clinical practice: protocol for an interventional, open-label, multicountry - platform study (ORIGAMA). -PG - e063242 -LID - 10.1136/bmjopen-2022-063242 [doi] -LID - e063242 -AB - INTRODUCTION: Digital patient monitoring (DPM) tools can enable more effective - clinical care and improved patient outcomes in cancer. However, their broad - adoption requires ease of use and demonstration of real-world clinical - utility/impact. ORIGAMA (MO42720) is an interventional, open-label, multicountry - platform study investigating the clinical utility of DPM tools and specific - treatments. ORIGAMA will begin with two cohorts that aim to assess the impact of - the atezolizumab-specific Roche DPM Module (hosted on the Kaiku Health DPM - platform (Helsinki, Finland)) on health outcomes and healthcare resource usage, - and its feasibility to support at-home treatment administration, in participants - receiving systemic anticancer treatment. Other digital health solutions may be - added to future cohorts. METHODS AND ANALYSIS: In Cohort A, participants with - metastatic non-small cell lung cancer (NSCLC), extensive-stage SCLC or Child Pugh - A unresectable hepatocellular carcinoma will be randomised to a locally approved - anticancer regimen containing intravenous atezolizumab (TECENTRIQ, F. Hoffmann-La - Roche Ltd/Genentech) and local standard-of-care support, with/without the Roche - DPM Module. Cohort B will assess the feasibility of the Roche DPM Module in - supporting administration of three cycles of subcutaneous atezolizumab (1875 mg; - Day 1 of each 21-day cycle) in the hospital, followed by 13 cycles at home by a - healthcare professional (ie, flexible care), in participants with programmed - cell-death ligand 1-positive, early-stage NSCLC. The primary endpoints are the - mean difference in change of the participant-reported Total Symptom Interference - Score at Week 12 from baseline (Cohort A) and flexible care adoption rate at - Cycle 6 (Cohort B). ETHICS AND DISSEMINATION: This study will be conducted - according to the Declaration of Helsinki, and/or the applicable laws and - regulations of the country in which the research is conducted, whichever affords - the greater protection to the individual. The study received its first Ethics - Committee approval in Spain in October 2022. Participants will provide written - informed consent in a face-to-face setting. The results of this study will be - presented at national and/or international congresses and disseminated via - publication in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT05694013. -CI - © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Iivanainen, Sanna -AU - Iivanainen S -AUID- ORCID: 0000-0003-1075-1134 -AD - Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland. -FAU - Baird, Anne-Marie -AU - Baird AM -AD - Trinity Translational Medicine Institute, Trinity College Dublin School of - Medicine, Dublin, Ireland. -AD - Lung Cancer Europe, Bern, Switzerland. -FAU - Balas, Bogdana -AU - Balas B -AD - Product Development Safety, F Hoffmann-La Roche Ltd, Basel, Switzerland. -FAU - Bustillos, Alberto -AU - Bustillos A -AD - Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland. -FAU - Castro Sanchez, Amparo Yovanna -AU - Castro Sanchez AY -AD - Product Development Data Sciences, F Hoffmann-La Roche Ltd, Basel, Switzerland. -FAU - Eicher, Manuela -AU - Eicher M -AD - Institute of Higher Education and Research in Health Care, Faculty of Biology and - Medicine, University of Lausanne, Lausanne, Switzerland. -AD - Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland. -FAU - Golding, Sophie -AU - Golding S -AD - Product Development Data Sciences, F Hoffmann-La Roche Ltd, Basel, Switzerland. -FAU - Mueller-Ohldach, Mathis -AU - Mueller-Ohldach M -AD - Product Development Global, F Hoffmann-La Roche Ltd, Basel, Switzerland. -FAU - Reig, Maria -AU - Reig M -AUID- ORCID: 0000-0002-5711-9534 -AD - BCLC Group, Liver Unit, Hospital Clínic de Barcelona, IDIBAPS, Universidad de - Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y - Digestivas (CIBERehd), Barcelona, Spain. -FAU - Welslau, Manfred -AU - Welslau M -AD - Department of Oncology, Medical Care Center, Hospital Aschaffenburg GmbH, - Aschaffenburg, Germany. -FAU - Ammann, Johannes -AU - Ammann J -AUID- ORCID: 0000-0002-4656-0949 -AD - Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland - johannes.ammann@roche.com. -LA - eng -SI - ClinicalTrials.gov/NCT05694013 -PT - Clinical Trial Protocol -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20230419 -PL - England -TA - BMJ Open -JT - BMJ open -JID - 101552874 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Delivery of Health Care -MH - Feasibility Studies -MH - *Liver Neoplasms -MH - *Lung Neoplasms/drug therapy -MH - Monitoring, Physiologic -MH - Treatment Outcome -MH - Randomized Controlled Trials as Topic -MH - Multicenter Studies as Topic -PMC - PMC10124208 -OTO - NOTNLM -OT - Information management -OT - ONCOLOGY -OT - Telemedicine -COIS- Competing interests: SI has acted in a consultancy and advisory role for - Bristol-Myers Squibb, Roche and Merck Sharp & Dohme; has participated in a - speaker bureau or provided expert testimony for Boehringer Ingelheim; is an - employee at an institution that has received a research grant or funding from - Roche; and has received travel and accommodation expenses from Boehringer - Ingelheim, Merck Sharp & Dohme, Roche, Novartis and Kaiku Health. A-MB: has - received honoraria for participation in an advisory board for Roche (Ireland), - has received institutional research funding to Lung Cancer Europe (LuCE) from - Amgen, AstraZeneca, Bayer, Blueprint Medicines, BMS, Boehringer Ingelheim, - Daiichi Sankyo, Eli Lilly, Merck, MSD, Novartis, Pfizer, Regeneron, Roche, - Sanofi, Takeda and Thermo Fisher, has received institutional honoraria to LuCE - from Janssen, and has participated in various meetings, presentations and - advisory boards, on behalf of LuCE. BB, AB, and AYCS are employees of and have - stocks/other ownership in F. Hoffmann-La Roche Ltd. ME has acted in a consultancy - and advisory role for Roche, is an employee at an institution that has received - research grants from Novartis, Roche, BMS and Kaiku Health, and has received - travel and accommodation expenses from Vifor. SG and MM-O are employees of and - have stocks/other ownership in F. Hoffmann-La Roche Ltd. MR has received grants - or contracts from Bayer and Ipsen, has received consulting fees from Bayer, BMS, - Roche, Ipsen, AstraZeneca, Eli Lilly, BTG and Universal DX, and has received - payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript - writing or educational events, from Bayer, BMS, Gilead Sciences, Eli Lilly, Roche - and Eisai. MW has received research funding from Roche for conduct of the study. - JA is an employee of and has stocks/other ownership in F. Hoffmann-La Roche Ltd. -EDAT- 2023/04/20 00:41 -MHDA- 2023/04/21 06:41 -PMCR- 2023/04/19 -CRDT- 2023/04/19 20:43 -PHST- 2023/04/21 06:41 [medline] -PHST- 2023/04/20 00:41 [pubmed] -PHST- 2023/04/19 20:43 [entrez] -PHST- 2023/04/19 00:00 [pmc-release] -AID - bmjopen-2022-063242 [pii] -AID - 10.1136/bmjopen-2022-063242 [doi] -PST - epublish -SO - BMJ Open. 2023 Apr 19;13(4):e063242. doi: 10.1136/bmjopen-2022-063242. - -PMID- 31063864 -OWN - NLM -STAT- MEDLINE -DCOM- 20200723 -LR - 20200723 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 14 -IP - 8 -DP - 2019 Aug -TI - Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell - Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC - Screened for the ATLANTIC Study. -PG - 1390-1399 -LID - S1556-0864(19)30360-0 [pii] -LID - 10.1016/j.jtho.2019.04.025 [doi] -AB - INTRODUCTION: We evaluated the impact of patient characteristics, sample types, - and prior non-immunotherapy treatment on tumor cell (TC) programmed cell death - ligand 1 (PD-L1) expression using samples from patients with advanced NSCLC. - METHODS: Patients (N = 1590) screened for the ATLANTIC study submitted a recently - acquired (≤3 months) or archival (>3 months to >3 years old) tumor sample for - PD-L1 assessment using the VENTANA PD-L1 (SP263) Assay with a cutoff of ≥25% of - TCs expressing PD-L1 (TC ≥25%). Samples were acquired either before or after the - two or more treatment regimens required for study entry and sample age varied - among patients. A subset of patients (n = 123) provided both recent and archival - samples. RESULTS: A total of 517 of 1590 (32.5%) patients had TC greater than or - equal to 25%: prevalence was greater in smokers versus nonsmokers (p = 0.0005) - and those with EGFR- versus EGFR+ tumors (p = 0.0002); these effects were - independent. Prevalence of TC greater than or equal to 25% was increased in - recent metastatic versus primary (p = 0.005) and recent versus archival (p = - 0.039) samples. Chemotherapy or radiotherapy, but not tyrosine kinase inhibition, - before sampling was associated with significantly increased PD-L1 prevalence. - PD-L1 status (TC ≥25% cutoff) remained unchanged in 74.0% of patients with recent - and archival samples; where PD-L1 status changed, it was more likely to increase - than decrease over time or with intervening treatment. CONCLUSIONS: Several - factors potentially impact PD-L1 TC greater than or equal to 25% prevalence in - advanced NSCLC; however, no characteristic can be considered a surrogate for - PD-L1 expression. Fresh biopsy may provide more accurate assessment of current - tumoral PD-L1 expression where a low/negative result is seen in an archival - sample, especially if the patient has received intervening therapy. -CI - Copyright © 2019 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Boothman, Anne-Marie -AU - Boothman AM -AD - Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, - United Kingdom. Electronic address: Anne-Marie.Boothman@astrazeneca.com. -FAU - Scott, Marietta -AU - Scott M -AD - Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, - United Kingdom. -FAU - Ratcliffe, Marianne -AU - Ratcliffe M -AD - Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, - United Kingdom. -FAU - Whiteley, Jessica -AU - Whiteley J -AD - Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, - United Kingdom. -FAU - Dennis, Phillip A -AU - Dennis PA -AD - Global Medicines Development, AstraZeneca, Gaithersburg, Maryland. -FAU - Wadsworth, Catherine -AU - Wadsworth C -AD - Global Medicines Development, AstraZeneca, Alderley Park, United Kingdom. -FAU - Sharpe, Alan -AU - Sharpe A -AD - Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom. -FAU - Rizvi, Naiyer A -AU - Rizvi NA -AD - Division of Hematology and Oncology, Columbia University Medical Center, New - York, New York. -FAU - Garassino, Marina Chiara -AU - Garassino MC -AD - Thoracic Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto - Nazionale dei Tumori, Milan, Italy. -FAU - Walker, Jill -AU - Walker J -AD - Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, - United Kingdom. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20190504 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 28X28X9OKV (durvalumab) -SB - IM -CIN - J Thorac Oncol. 2019 Sep;14(9):e211. doi: 10.1016/j.jtho.2019.05.034. PMID: - 31445743 -CIN - J Thorac Oncol. 2019 Sep;14(9):e212-e213. doi: 10.1016/j.jtho.2019.06.022. PMID: - 31445744 -MH - Aged -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - B7-H1 Antigen/*biosynthesis/immunology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/*immunology/pathology -MH - Clinical Trials, Phase II as Topic -MH - Female -MH - Humans -MH - Immunohistochemistry -MH - Lung Neoplasms/*drug therapy/*immunology/pathology -MH - Male -MH - Middle Aged -OTO - NOTNLM -OT - Diagnostic test -OT - Immunohistochemistry -OT - Immunotherapy -OT - NSCLC -OT - Programmed cell death ligand 1 -EDAT- 2019/05/08 06:00 -MHDA- 2020/07/24 06:00 -CRDT- 2019/05/08 06:00 -PHST- 2019/02/15 00:00 [received] -PHST- 2019/03/28 00:00 [revised] -PHST- 2019/04/19 00:00 [accepted] -PHST- 2019/05/08 06:00 [pubmed] -PHST- 2020/07/24 06:00 [medline] -PHST- 2019/05/08 06:00 [entrez] -AID - S1556-0864(19)30360-0 [pii] -AID - 10.1016/j.jtho.2019.04.025 [doi] -PST - ppublish -SO - J Thorac Oncol. 2019 Aug;14(8):1390-1399. doi: 10.1016/j.jtho.2019.04.025. Epub - 2019 May 4. - -PMID- 33277857 -OWN - NLM -STAT- MEDLINE -DCOM- 20210820 -LR - 20210820 -IS - 2241-6293 (Electronic) -IS - 1107-0625 (Linking) -VI - 25 -IP - 5 -DP - 2020 Sep-Oct -TI - Efficacy of dendritic cell-cytokine induced killer cells combined with concurrent - chemoradiotherapy on locally advanced non-small cell lung cancer. -PG - 2364-2370 -AB - PURPOSE: To explore the efficacy and safety of docetaxel/cisplatin concurrent - chemoradiotherapy (CCRT) combined with dendritic cell-cytokine induced killer - cell (DC-CIK) immunotherapy in the treatment of locally advanced non-small cell - lung cancer (LANSCLC). METHODS: The clinical data of 142 LANSCLC patients treated - in our hospital from March 2014 to March 2016 were retrospectively analyzed. 71 - patients were treated with docetaxel/cisplatin CCRT (CCRT group), while the - remaining 71 patients underwent CCRT combined with DC-CIK immunotherapy (DC-CIK - group). The clinical data of all patients were collected, the short-term - efficacy, the changes in serum immunological indexes and quality of life before - and after treatment, and the incidence of adverse reactions were compared between - the two groups, and the overall survival (OS) and progression-free survival (PFS) - were recorded during the follow-up of patients. RESULTS: After treatment, the - level of cluster of differentiation 3+ (CD3+) CD4+ T lymphocytes, CD4/CD8 ratio - and CD56+ natural killer (NK) cell ratio significantly rose, while the level of - CD3+ CD8+ T lymphocytes significantly declined in both groups compared with those - before treatment. After treatment, the level of CD3+ CD4+ T lymphocytes, CD4/CD8 - ratio and CD56+ NK cell ratio were obviously higher, while the level of CD3+ CD8+ - T lymphocytes was obviously lower in DC-CIK group than those in CCRT group. At 12 - months after treatment, both Karnofsky performance scale (KPS) score and quality - of life (QOL) score in DC-CIK group were evidently higher than those in CCRT - group. In CCRT group and DC-CIK group, 1-year OS was 74.6% and 83.1%, and 1-year - PFS was 70.4% and 73.2%, respectively. 2-year OS was 45.1% and 57.7%, and 2-year - PFS was 38.0% and 46.5%), respectively. 3-year OS was 26.8% and 40.8%, and 3-year - PFS was 15.5% and 22.5%, respectively. It can be seen that both OS and PFS in - DC-CIK group were remarkably superior to those in CCRT group. CONCLUSION: - Docetaxel/cisplatin CCRT combined with DC-CIK can significantly enhance the - cellular immunity, improve the long-term survival rate and raise the quality of - life of LANSCLC patients, with tolerable adverse reactions. -FAU - Tian, Lin -AU - Tian L -AD - Department of Respirology, Affiliated Hospital of Changchun University of - Traditional Chinese Medicine, Changchun 130021, China. -FAU - Wang, Wei -AU - Wang W -FAU - Yu, Bin -AU - Yu B -FAU - Zhang, Guoxia -AU - Zhang G -LA - eng -PT - Journal Article -PL - Cyprus -TA - J BUON -JT - Journal of B.U.ON. : official journal of the Balkan Union of Oncology -JID - 100883428 -SB - IM -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Cytokine-Induced Killer Cells/*immunology -MH - Dendritic Cells/*immunology -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy -MH - Male -MH - Middle Aged -EDAT- 2020/12/06 06:00 -MHDA- 2021/08/21 06:00 -CRDT- 2020/12/05 05:35 -PHST- 2020/12/05 05:35 [entrez] -PHST- 2020/12/06 06:00 [pubmed] -PHST- 2021/08/21 06:00 [medline] -PST - ppublish -SO - J BUON. 2020 Sep-Oct;25(5):2364-2370. - -PMID- 35606756 -OWN - NLM -STAT- MEDLINE -DCOM- 20220525 -LR - 20220716 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 22 -IP - 1 -DP - 2022 May 24 -TI - Efficacy and safety of maintenance immune checkpoint inhibitors with or without - pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective - study. -PG - 576 -LID - 10.1186/s12885-022-09674-2 [doi] -LID - 576 -AB - BACKGROUND: Advanced non-squamous non-small cell lung cancer (NS-NSCLC) patients - without driver gene mutations are usually treated with immune checkpoint - inhibitors (ICIs) plus pemetrexed as maintenance therapy after first-line ICIs - plus 4-6 cycles of pemetrexed/platinum. Some patients in the real world receive - ICIs monotherapy as maintenance therapy. No clinical study has compared the - efficacy and safety of ICIs with or without pemetrexed as maintenance therapy. - METHODS: We performed a retrospective study analyzing clinical data of patients - with NS-NSCLC who were diagnosed in Zhejiang Cancer Hospital from September 2018 - to May 2021 and received maintenance therapy after 4-6 cycles of ICIs plus - pemetrexed/platinum. Patients were divided into ICIs plus pemetrexed group and - ICIs monotherapy group. Progression Free Survival 1 (PFS1) and PFS2, defined as - the interval from the date of initial treatment and maintenance therapy to the - date of systemic progression/death or the last follow-up, respectively. RESULTS: - A total of 120 patients received ICIs with or without pemetrexed as maintenance - therapy. Eighty-two patients received ICIs plus pemetrexed as maintenance - therapy, and 38 patients received ICIs monotherapy. There were no statistically - significant difference in median PFS1 between the ICIs monotherapy group and ICIs - plus pemetrexed group (12.00 months vs. 12.07 months, P = 0.979). Among patients - with PD-L1 TPS < 1%, the median PFS1 was worse with ICIs monotherapy (9.50 months - vs. 14.20 months, P = 0.039). Among patients with PD-L1 TPS ≥50% or 1-49%, the - median PFS1 in both groups was not statistically significant (P = 0.866, - P = 0.589, respectively). Results for median PFS2 were similar to median PFS1, - with statistically significantly different only in patients with PD-L1 TPS < 1% - (P = 0.008). The 2-year survival rates of the two groups were similar (66.7% vs. - 69.5%, P = 0.812). The incidence of fatigue was significantly higher in the ICIs - plus pemetrexed group (P = 0.023). CONCLUSIONS: ICIs with or without pemetrexed - can be used as maintenance therapy after first-line ICIs plus 4-6 cycles of - pemetrexed/platinum in patients with advanced NS-NSCLC based on PD-L1 expression. -CI - © 2022. The Author(s). -FAU - Gu, Xiaodong -AU - Gu X -AD - The Second Clinical Medical College of Zhejiang Chinese Medical University, - Hangzhou, 310053, Zhejiang, China. -AD - Department of Thoracic Medical Oncology, Chinese Academy of Sciences University - Cancer Hospital (Zhejiang Cancer Hospital), No.1 Banshan East Street, Gongshu - District, Hangzhou, 310022, China. -AD - Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, - Hangzhou, 310022, Zhejiang, China. -FAU - Shi, Zhiyong -AU - Shi Z -AD - Department of Thoracic Medical Oncology, Chinese Academy of Sciences University - Cancer Hospital (Zhejiang Cancer Hospital), No.1 Banshan East Street, Gongshu - District, Hangzhou, 310022, China. -AD - Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, - Hangzhou, 310022, Zhejiang, China. -FAU - Shao, Lan -AU - Shao L -AD - Department of Thoracic Medical Oncology, Chinese Academy of Sciences University - Cancer Hospital (Zhejiang Cancer Hospital), No.1 Banshan East Street, Gongshu - District, Hangzhou, 310022, China. -AD - Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, - Hangzhou, 310022, Zhejiang, China. -FAU - Zhang, Yuxin -AU - Zhang Y -AD - Department of Radiotherapy, Hangzhou Cancer Hospital, Hangzhou, 310002, Zhejiang, - China. -FAU - Zhang, Yiping -AU - Zhang Y -AD - Department of Thoracic Medical Oncology, Chinese Academy of Sciences University - Cancer Hospital (Zhejiang Cancer Hospital), No.1 Banshan East Street, Gongshu - District, Hangzhou, 310022, China. -AD - Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, - Hangzhou, 310022, Zhejiang, China. -FAU - Song, Zhengbo -AU - Song Z -AD - Department of Thoracic Medical Oncology, Chinese Academy of Sciences University - Cancer Hospital (Zhejiang Cancer Hospital), No.1 Banshan East Street, Gongshu - District, Hangzhou, 310022, China. -AD - Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, - Hangzhou, 310022, Zhejiang, China. -FAU - Wang, Wenxian -AU - Wang W -AD - Department of Thoracic Medical Oncology, Chinese Academy of Sciences University - Cancer Hospital (Zhejiang Cancer Hospital), No.1 Banshan East Street, Gongshu - District, Hangzhou, 310022, China. helen-0407@163.com. -AD - Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, - Hangzhou, 310022, Zhejiang, China. helen-0407@163.com. -FAU - Lou, Guangyuan -AU - Lou G -AD - Department of Thoracic Medical Oncology, Chinese Academy of Sciences University - Cancer Hospital (Zhejiang Cancer Hospital), No.1 Banshan East Street, Gongshu - District, Hangzhou, 310022, China. lougy@zjcc.org.cn. -AD - Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, - Hangzhou, 310022, Zhejiang, China. lougy@zjcc.org.cn. -LA - eng -GR - 2021ZQ013/Zhejiang Chinese Medical Science and Technology Foundation/ -GR - 2022KY644/Zhejiang Medical and Health Science and Technology Program/ -PT - Journal Article -DEP - 20220524 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 04Q9AIZ7NO (Pemetrexed) -RN - 49DFR088MY (Platinum) -SB - IM -MH - Antibodies, Monoclonal, Humanized -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - B7-H1 Antigen/metabolism -MH - *Carcinoma, Non-Small-Cell Lung -MH - Humans -MH - Immune Checkpoint Inhibitors/adverse effects -MH - *Lung Neoplasms -MH - Pemetrexed -MH - Platinum/therapeutic use -MH - Retrospective Studies -PMC - PMC9128194 -OTO - NOTNLM -OT - Adverse events -OT - Immune checkpoint inhibitors -OT - Maintenance therapy -OT - Non-squamous non-small cell lung cancer -OT - Pemetrexed -COIS- The authors declare that they have no competing interests. -EDAT- 2022/05/24 06:00 -MHDA- 2022/05/26 06:00 -PMCR- 2022/05/24 -CRDT- 2022/05/23 23:47 -PHST- 2022/03/31 00:00 [received] -PHST- 2022/05/18 00:00 [accepted] -PHST- 2022/05/23 23:47 [entrez] -PHST- 2022/05/24 06:00 [pubmed] -PHST- 2022/05/26 06:00 [medline] -PHST- 2022/05/24 00:00 [pmc-release] -AID - 10.1186/s12885-022-09674-2 [pii] -AID - 9674 [pii] -AID - 10.1186/s12885-022-09674-2 [doi] -PST - epublish -SO - BMC Cancer. 2022 May 24;22(1):576. doi: 10.1186/s12885-022-09674-2. - -PMID- 36039980 -OWN - NLM -STAT- MEDLINE -DCOM- 20220929 -LR - 20221101 -IS - 1750-7448 (Electronic) -IS - 1750-743X (Linking) -VI - 14 -IP - 15 -DP - 2022 Oct -TI - Herpes zoster in patients with lung cancer treated with PD-1/PD-L1 antibodies. -PG - 1211-1217 -LID - 10.2217/imt-2021-0318 [doi] -AB - Background: There are no available clinical data on immunotherapy and the risk of - herpes zoster. Materials & methods: This retrospective study included patients - with recurrent or advanced lung cancer who were inoperable and ineligible for - radiotherapy and were treated with either a PD-1/PD-L1 antibody (136 patients) or - an EGFR tyrosine kinase inhibitor (149 patients) at Jichi Medical University - Hospital between January 2016 and December 2018. Results: Herpes zoster-free - survival was significantly shorter in the PD-1/PD-L1 antibody-treated group - compared with the EGFR tyrosine kinase inhibitor-treated group (hazard ratio: - 0.20; 95% CI: 0.048-0.84; p = 0.016). PD-1/PD-L1 antibody administration was - independently and significantly associated with herpes zoster occurrence. - Conclusion: Clinicians should anticipate herpes zoster in patients with lung - cancer during treatment with PD-1/PD-L1 antibodies. -FAU - Nagai, Yoshiaki -AU - Nagai Y -AD - Division of Respiratory Medicine, Department of Internal Medicine, Jichi Medical - University Hospital, 3311-1 Yakushi-ji, Shimotsuke-shi, Tochigi-ken, 329-0431, - Japan. -FAU - Sata, Masafumi -AU - Sata M -AD - Division of Respiratory Medicine, Department of Internal Medicine, Jichi Medical - University Hospital, 3311-1 Yakushi-ji, Shimotsuke-shi, Tochigi-ken, 329-0431, - Japan. -FAU - Ohta, Hiromitsu -AU - Ohta H -AD - Department of Respiratory Medicine, Jichi Medical University Saitama Medical - Center, Saitama, Japan. -FAU - Onuki, Tsugitoshi -AU - Onuki T -AD - Division of Respiratory Medicine, Department of Internal Medicine, Jichi Medical - University Hospital, 3311-1 Yakushi-ji, Shimotsuke-shi, Tochigi-ken, 329-0431, - Japan. -FAU - Saito, Tatsuya -AU - Saito T -AD - Division of Respiratory Medicine, Department of Internal Medicine, Jichi Medical - University Hospital, 3311-1 Yakushi-ji, Shimotsuke-shi, Tochigi-ken, 329-0431, - Japan. -FAU - Uchiyama, Ayumi -AU - Uchiyama A -AD - Division of Respiratory Medicine, Department of Internal Medicine, Jichi Medical - University Hospital, 3311-1 Yakushi-ji, Shimotsuke-shi, Tochigi-ken, 329-0431, - Japan. -FAU - Kurosaki, Ayako -AU - Kurosaki A -AD - Division of Respiratory Medicine, Department of Internal Medicine, Jichi Medical - University Hospital, 3311-1 Yakushi-ji, Shimotsuke-shi, Tochigi-ken, 329-0431, - Japan. -FAU - Yoshizumi, Naoko -AU - Yoshizumi N -AD - Division of Respiratory Medicine, Department of Internal Medicine, Jichi Medical - University Hospital, 3311-1 Yakushi-ji, Shimotsuke-shi, Tochigi-ken, 329-0431, - Japan. -FAU - Takigami, Ayako -AU - Takigami A -AD - Division of Respiratory Medicine, Department of Internal Medicine, Jichi Medical - University Hospital, 3311-1 Yakushi-ji, Shimotsuke-shi, Tochigi-ken, 329-0431, - Japan. -FAU - Nakazawa, Shoko -AU - Nakazawa S -AD - Division of Respiratory Medicine, Department of Internal Medicine, Jichi Medical - University Hospital, 3311-1 Yakushi-ji, Shimotsuke-shi, Tochigi-ken, 329-0431, - Japan. -FAU - Nakayama, Masayuki -AU - Nakayama M -AD - Division of Respiratory Medicine, Department of Internal Medicine, Jichi Medical - University Hospital, 3311-1 Yakushi-ji, Shimotsuke-shi, Tochigi-ken, 329-0431, - Japan. -FAU - Yamaguchi, Hironori -AU - Yamaguchi H -AD - Department of Clinical Oncology, Jichi Medical University Hospital, 3311-1 - Yakushi-ji, Shimotsuke-shi, Tochigi-ken, 329-0431, Japan. -FAU - Hagiwara, Koichi -AU - Hagiwara K -AUID- ORCID: 0000-0001-8079-7811 -AD - Division of Respiratory Medicine, Department of Internal Medicine, Jichi Medical - University Hospital, 3311-1 Yakushi-ji, Shimotsuke-shi, Tochigi-ken, 329-0431, - Japan. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20220830 -PL - England -TA - Immunotherapy -JT - Immunotherapy -JID - 101485158 -RN - 0 (B7-H1 Antigen) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - B7-H1 Antigen -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - ErbB Receptors -MH - *Herpes Zoster/epidemiology -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Programmed Cell Death 1 Receptor -MH - Protein Kinase Inhibitors/therapeutic use -MH - Retrospective Studies -OAB - There are no available clinical data on immunotherapy and the risk of herpes - zoster. This retrospective study included patients with recurrent or advanced - lung cancer who were inoperable and ineligible for radiotherapy and were treated - with either an immune checkpoint inhibitor (136 patients) or an EGFR tyrosine - kinase inhibitor (149 patients) through the authors' university between January - 2016 and December 2018. The herpes zoster-free period was significantly shorter - in the immune checkpoint inhibitor-treated group compared with the EGFR tyrosine - kinase inhibitor-treated group (hazard ratio: 0.20; 95% CI: 0.048–0.84; p = - 0.016). Immune checkpoint inhibitor antibody administration was independently and - significantly associated with herpes zoster occurrence. Clinicians should be - cautious of herpes zoster in patients with lung cancer during treatment with - immune checkpoint inhibitors. -OABL- eng -OTO - NOTNLM -OT - EGFR tyrosine kinase inhibitor -OT - PD-1 -OT - PD-L1 -OT - herpes zoster -OT - lung cancer -EDAT- 2022/08/31 06:00 -MHDA- 2022/09/30 06:00 -CRDT- 2022/08/30 07:33 -PHST- 2022/08/31 06:00 [pubmed] -PHST- 2022/09/30 06:00 [medline] -PHST- 2022/08/30 07:33 [entrez] -AID - 10.2217/imt-2021-0318 [doi] -PST - ppublish -SO - Immunotherapy. 2022 Oct;14(15):1211-1217. doi: 10.2217/imt-2021-0318. Epub 2022 - Aug 30. - -PMID- 35410334 -OWN - NLM -STAT- MEDLINE -DCOM- 20220413 -LR - 20220613 -IS - 1741-7015 (Electronic) -IS - 1741-7015 (Linking) -VI - 20 -IP - 1 -DP - 2022 Apr 12 -TI - Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in - advanced non-small cell lung cancer: applicability from clinical trials to - real-world practice. -PG - 120 -LID - 10.1186/s12916-022-02315-2 [doi] -LID - 120 -AB - BACKGROUND: Organ-specific metastatic context has not been incorporated into the - clinical practice of guiding programmed death-(ligand) 1 [PD-(L)1] blockade, due - to a lack of understanding of its predictive versus prognostic value. We aim at - delineating and then incorporating both the predictive and prognostic effects of - the metastatic-organ landscape to dissect PD-(L)1 blockade efficacy in non-small - cell lung cancer (NSCLC). METHODS: A total of 2062 NSCLC patients from a - double-arm randomized trial (OAK), two immunotherapy trials (FIR, BIRCH), and a - real-world cohort (NFyy) were included. The metastatic organs were stratified - into two categories based on their treatment-dependent predictive significance - versus treatment-independent prognosis. A metastasis-based scoring system - (METscore) was developed and validated for guiding PD-(L)1 blockade in clinical - trials and real-world practice. RESULTS: Patients harboring various - organ-specific metastases presented significantly different responses to - immunotherapy, and those with brain and adrenal gland metastases survived longer - than others [overall survival (OS), p = 0.0105; progression-free survival (PFS), - p = 0.0167]. In contrast, survival outcomes were similar in chemotherapy-treated - patients regardless of metastatic sites (OS, p = 0.3742; PFS, p = 0.8242). - Intriguingly, the immunotherapeutic predictive significance of the - metastatic-organ landscape was specifically presented in PD-L1-positive - populations (PD-L1 > 1%). Among them, a paradoxical coexistence of a favorable - predictive effect coupled with an unfavorable prognostic effect was observed in - metastases to adrenal glands, brain, and liver (category I organs), whereas - metastases to bone, pleura, pleural effusion, and mediastinum yielded consistent - unfavorable predictive and prognostic effects (category II organs). METscore was - capable of integrating both predictive and prognostic effects of the entire - landscape and dissected OS outcome of NSCLC patients received PD-(L)1 blockade (p - < 0.0001) but not chemotherapy (p = 0.0805) in the OAK training cohort. - Meanwhile, general performance of METscore was first validated in FIR (p = - 0.0350) and BIRCH (p < 0.0001), and then in the real-world NFyy cohort (p = - 0.0181). Notably, METscore was also applicable to patients received PD-(L)1 - blockade as first-line treatment both in the clinical trials (OS, p = 0.0087; - PFS, p = 0.0290) and in the real-world practice (OS, p = 0.0182; PFS, p = - 0.0045). CONCLUSIONS: Organ-specific metastatic landscape served as a potential - predictor of immunotherapy, and METscore might enable noninvasive forecast of - PD-(L)1 blockade efficacy using baseline radiologic assessments in advanced - NSCLC. -CI - © 2022. The Author(s). -FAU - Ma, Si-Cong -AU - Ma SC -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, China. -AD - Information Management and Big Data Center, Nanfang Hospital, Southern Medical - University, Guangzhou, China. -FAU - Bai, Xue -AU - Bai X -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, China. -FAU - Guo, Xue-Jun -AU - Guo XJ -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, China. -FAU - Liu, Li -AU - Liu L -AD - Information Management and Big Data Center, Nanfang Hospital, Southern Medical - University, Guangzhou, China. -AD - Department of Medical Quality Management, Nanfang Hospital, Southern Medical - University, Guangzhou, China. -AD - Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Hepatology Unit - and Department of Infectious Diseases, Nanfang Hospital, Southern Medical - University, Guangzhou, China. -FAU - Xiao, Lu-Shan -AU - Xiao LS -AD - Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Hepatology Unit - and Department of Infectious Diseases, Nanfang Hospital, Southern Medical - University, Guangzhou, China. -FAU - Lin, Yan -AU - Lin Y -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, China. -FAU - Tan, Jia-Le -AU - Tan JL -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, China. -FAU - Cai, Xiao-Ting -AU - Cai XT -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, China. -FAU - Wen, Yu-Xiang -AU - Wen YX -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, China. -FAU - Ma, Hu -AU - Ma H -AD - Department of Oncology, The Second Affiliated Hospital of Zunyi Medical - University, Zunyi, China. -FAU - Fu, Q John -AU - Fu QJ -AD - Department of Community Health, Tufts University, Medford, USA. -FAU - Leng, Meng-Xin -AU - Leng MX -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, China. -FAU - Zhang, Yan-Pei -AU - Zhang YP -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, China. -AD - Information Management and Big Data Center, Nanfang Hospital, Southern Medical - University, Guangzhou, China. -FAU - Long, Li-Li -AU - Long LL -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, China. -FAU - Guo, Ze-Qin -AU - Guo ZQ -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, China. -FAU - Wu, De-Hua -AU - Wu DH -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, China. 18602062748@163.com. -FAU - Zhou, Jian-Guo -AU - Zhou JG -AD - Department of Oncology, The Second Affiliated Hospital of Zunyi Medical - University, Zunyi, China. jianguo.zhou@yahoo.com. -AD - Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, - Germany. jianguo.zhou@yahoo.com. -AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. - jianguo.zhou@yahoo.com. -FAU - Dong, Zhong-Yi -AU - Dong ZY -AUID- ORCID: 0000-0001-9967-0060 -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, China. dongzy1317@foxmail.com. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20220412 -PL - England -TA - BMC Med -JT - BMC medicine -JID - 101190723 -RN - 0 (B7-H1 Antigen) -SB - IM -MH - B7-H1 Antigen -MH - *Carcinoma, Non-Small-Cell Lung -MH - Clinical Trials as Topic -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms/pathology -MH - Progression-Free Survival -PMC - PMC9004108 -OTO - NOTNLM -OT - Immune checkpoint inhibitor -OT - Metastatic-organ landscape -OT - Non-small cell lung cancer -OT - Programmed death-(ligand) 1 -COIS- The authors have no actual or potential conflicts of interest to declare. -EDAT- 2022/04/13 06:00 -MHDA- 2022/04/14 06:00 -PMCR- 2022/04/12 -CRDT- 2022/04/12 05:18 -PHST- 2021/12/04 00:00 [received] -PHST- 2022/02/24 00:00 [accepted] -PHST- 2022/04/12 05:18 [entrez] -PHST- 2022/04/13 06:00 [pubmed] -PHST- 2022/04/14 06:00 [medline] -PHST- 2022/04/12 00:00 [pmc-release] -AID - 10.1186/s12916-022-02315-2 [pii] -AID - 2315 [pii] -AID - 10.1186/s12916-022-02315-2 [doi] -PST - epublish -SO - BMC Med. 2022 Apr 12;20(1):120. doi: 10.1186/s12916-022-02315-2. - -PMID- 26950292 -OWN - NLM -STAT- MEDLINE -DCOM- 20170712 -LR - 20231213 -IS - 1744-7682 (Electronic) -IS - 1471-2598 (Linking) -VI - 16 -IP - 6 -DP - 2016 Jun -TI - Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell - lung cancer. -PG - 747-58 -LID - 10.1517/14712598.2016.1163333 [doi] -AB - INTRODUCTION: In recent years, several clinical trials have evaluated the - efficacy and safety of biological therapies in lung cancer. Epidermal growth - factor receptor (EGFR) and the axis vascular endothelial growth factor receptor - (VEGF/VEGFR) are targeted by small molecules and monoclonal antibodies (mAbs), - especially in non-squamous non-small-cell lung cancer (NSCLC). AREAS COVERED: The - current state of the art of anti-EGFR and antiangiogenic monoclonal antibodies in - metastatic NSCLC is reviewed and discussed. EXPERT OPINION: Bevacizumab and - cetuximab are the most studied mAbs in NSCLC, but only bevacizumab is in clinical - practice in the first-line setting. Necitumumab is a new anti-EGFR monoclonal - antibody that improves survival when combined to cisplatin/gemcitabine - chemotherapy and has been approved in first-line advanced NSCLC. Ramucirumab, an - antiangiogenic drug binding with high affinity to VEGFR-2, improves the results - of chemotherapy alone when administered with docetaxel and has been approved in - second-line setting. Moreover, the novel combination of bevacizumab and erlotinib - is very promising for the treatment of patients with NSCLC harbouring EGFR - mutations. The association of antiangiogenic mAbs and immunotherapy is under - investigation too. -FAU - Losanno, Tania -AU - Losanno T -AD - a Department of Experimental Medicine , University 'Sapienza' , Rome , Italy. -FAU - Rossi, Antonio -AU - Rossi A -AD - b Division of Medical Oncology , S.G. Moscati Hospital , Avellino , Italy. -FAU - Maione, Paolo -AU - Maione P -AD - b Division of Medical Oncology , S.G. Moscati Hospital , Avellino , Italy. -FAU - Napolitano, Alba -AU - Napolitano A -AD - c Division of Pharmacy , S.G. Moscati Hospital , Avellino , Italy. -FAU - Gridelli, Cesare -AU - Gridelli C -AD - b Division of Medical Oncology , S.G. Moscati Hospital , Avellino , Italy. -LA - eng -PT - Journal Article -PT - Review -DEP - 20160322 -PL - England -TA - Expert Opin Biol Ther -JT - Expert opinion on biological therapy -JID - 101125414 -RN - 0 (Angiogenesis Inhibitors) -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Vascular Endothelial Growth Factor A) -RN - 2BT4C47RUI (necitumumab) -RN - 2S9ZZM9Q9V (Bevacizumab) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2) -SB - IM -MH - Angiogenesis Inhibitors/pharmacology/*therapeutic use -MH - Animals -MH - Antibodies, Monoclonal/pharmacology/*therapeutic use -MH - Antibodies, Monoclonal, Humanized -MH - Bevacizumab/pharmacology/therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism -MH - ErbB Receptors/*antagonists & inhibitors/immunology/metabolism -MH - Humans -MH - Immunotherapy/methods -MH - Lung Neoplasms/*drug therapy/metabolism -MH - Vascular Endothelial Growth Factor A/antagonists & inhibitors/metabolism -MH - Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors/metabolism -MH - Ramucirumab -OTO - NOTNLM -OT - EGFR -OT - NSCLC -OT - VEGF -OT - VEGFR -OT - bevacizumab -OT - cetuximab -OT - monoclonal antibodies -OT - necitumumab -OT - ramucirumab -EDAT- 2016/03/08 06:00 -MHDA- 2017/07/14 06:00 -CRDT- 2016/03/08 06:00 -PHST- 2016/03/08 06:00 [entrez] -PHST- 2016/03/08 06:00 [pubmed] -PHST- 2017/07/14 06:00 [medline] -AID - 10.1517/14712598.2016.1163333 [doi] -PST - ppublish -SO - Expert Opin Biol Ther. 2016 Jun;16(6):747-58. doi: 10.1517/14712598.2016.1163333. - Epub 2016 Mar 22. - -PMID- 38380327 -OWN - NLM -STAT- MEDLINE -DCOM- 20240222 -LR - 20240415 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 15 -DP - 2024 -TI - Case report: Clinical complete response in advanced ALK-positive lung squamous - cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs - failure. -PG - 1360671 -LID - 10.3389/fimmu.2024.1360671 [doi] -LID - 1360671 -AB - In patients with advanced lung adenocarcinoma (LADC) harboring the echinoderm - microtubule-associated protein-like 4 (EML4) -anaplastic lymphoma kinase (ALK) - rearrangement, targeted therapy typically demonstrates superior efficacy as an - initial treatment compared to chemotherapy. Following resistance to ALK-tyrosine - kinase inhibitors (TKIs), regimens incorporating platinum-based dual agents or - combined with bevacizumab often show effectiveness. However, therapeutic - alternatives become constrained after resistance develops to both TKIs and - platinum-based therapies. Given that the majority of ALK-positive non-small cell - lung carcinomas (NSCLC) are LADC, the benefits of TKIs for patients with - ALK-positive lung squamous cell carcinoma (LSCC) and the optimal treatment - strategy for these patients remain a subject of debate. In this case study, we - report on a patient with advanced LSCC, in whom the EML4-ALK rearrangement was - identified via ARMS-PCR (Amplification Refractory Mutation System-Polymerase - Chain Reaction). The patient underwent oral treatment with crizotinib and - alectinib, showing effectiveness in both first-line and second-line ALK-TKI - therapies, albeit with limited progression-free survival (PFS). Subsequent - resistance to second-generation TKI was followed by the detection of tumors in - the left neck region via computed tomography (CT). Biopsy pathology revealed - non-squamous cell carcinoma, and subsequent treatment with platinum-based - double-drug therapy proved ineffective. Further analysis through next-generation - sequencing (NGS) indicated ALK negativity but a high expression of programmed - death-ligand 1 (PD-L1). Immunotherapy was then initiated, resulting in a PFS of - over 29 months and clinical complete remission (cCR). This case underscores the - potential benefit of ALK-TKIs in patients with ALK-positive LSCC. Resistance to - second-generation TKIs may lead to ALK negativity and histological - transformation, highlighting the necessity of repeated biopsies post-TKI - resistance for informed treatment decision-making. As of November 2023, imaging - studies continue to indicate cCR in the patient, with a survival time exceeding - 47 months. -CI - Copyright © 2024 Yang, Zeng, Zha, Li, Wang, Zhao, Li and Zhang. -FAU - Yang, Chen -AU - Yang C -AD - Zhongshan City People's Hospital, Xinxiang Medical University, Xinxiang, China. -AD - Department of Radiotherapy, Zhongshan City People's Hospital, Zhongshan, China. -FAU - Zeng, Rui -AU - Zeng R -AD - Department of Radiotherapy, Zhongshan City People's Hospital, Zhongshan, China. -FAU - Zha, Yawen -AU - Zha Y -AD - Department of Radiotherapy, Zhongshan City People's Hospital, Zhongshan, China. -FAU - Li, Yani -AU - Li Y -AD - Department of Radiotherapy, Zhongshan City People's Hospital, Zhongshan, China. -FAU - Wang, Ting -AU - Wang T -AD - Department of Radiotherapy, Zhongshan City People's Hospital, Zhongshan, China. -FAU - Zhao, Ruolan -AU - Zhao R -AD - Department of Imaging, Zhongshan City People's Hospital, Zhongshan, China. -FAU - Li, Minying -AU - Li M -AD - Department of Radiotherapy, Zhongshan City People's Hospital, Zhongshan, China. -FAU - Zhang, Jingjing -AU - Zhang J -AD - Department of Radiotherapy, Zhongshan City People's Hospital, Zhongshan, China. -LA - eng -PT - Case Reports -PT - Comment -PT - Research Support, Non-U.S. Gov't -DEP - 20240206 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -RN - EC 2.7.10.1 (Anaplastic Lymphoma Kinase) -RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) -RN - 0 (Antineoplastic Agents) -RN - 0 (Protein Kinase Inhibitors) -SB - IM -CON - Zhongguo Fei Ai Za Zhi. 2022 Sep 20;25(9):696-700. doi: - 10.3779/j.issn.1009-3419.2022.102.29. PMID: 36172736 -MH - Humans -MH - Anaplastic Lymphoma Kinase/genetics/metabolism -MH - *Lung Neoplasms/diagnosis/drug therapy/genetics -MH - Protein-Tyrosine Kinases -MH - *Carcinoma, Non-Small-Cell Lung/diagnosis/drug therapy/genetics -MH - *Antineoplastic Agents/therapeutic use -MH - Protein Kinase Inhibitors/therapeutic use/pharmacology -MH - *Carcinoma, Squamous Cell/diagnosis/drug therapy/genetics -MH - *Adenocarcinoma of Lung/drug therapy -MH - Immunotherapy -MH - Lung/pathology -PMC - PMC10876774 -OTO - NOTNLM -OT - ALK-TKI -OT - ALK-positive -OT - clinical complete response -OT - immunotherapy -OT - lung squamous cell carcinoma -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2024/02/21 11:15 -MHDA- 2024/02/22 06:42 -PMCR- 2024/01/01 -CRDT- 2024/02/21 04:08 -PHST- 2023/12/23 00:00 [received] -PHST- 2024/01/16 00:00 [accepted] -PHST- 2024/02/22 06:42 [medline] -PHST- 2024/02/21 11:15 [pubmed] -PHST- 2024/02/21 04:08 [entrez] -PHST- 2024/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2024.1360671 [doi] -PST - epublish -SO - Front Immunol. 2024 Feb 6;15:1360671. doi: 10.3389/fimmu.2024.1360671. - eCollection 2024. - -PMID- 28063623 -OWN - NLM -STAT- MEDLINE -DCOM- 20170626 -LR - 20240210 -IS - 1433-2981 (Electronic) -IS - 0936-6555 (Linking) -VI - 29 -IP - 4 -DP - 2017 Apr -TI - Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity? -PG - 207-217 -LID - S0936-6555(16)30459-9 [pii] -LID - 10.1016/j.clon.2016.12.003 [doi] -AB - Lung cancer remains the leading cause of cancer-related death worldwide, with - non-small cell lung cancer accounting for 85% of the disease. Over 70% - of patients present with locally advanced, non-resectable or metastatic disease - and despite improvements in chemoradiotherapy regimens and the development of - molecularly targeted agents, 5 year survival rates remain poor, with acquired - resistance to novel targeted therapies becoming a growing concern. Currently - there remains an unmet need in effectively treating and inducing durable - responses in advanced disease. Targeting the immune system has, however, recently - given hope of improving therapeutic outcomes for these patients. The notion that - the immune system is capable of recognising and eliminating cancer cells is now a - widely accepted phenomenon and growing evidence suggests lung cancer is an - attractive target for such intervention. Recent success targeting the programmed - death-1/programmed death-ligand 1 (PD-1/PD-L1) axis of immune checkpoint - inhibition suggests a major immunotherapeutic advance in treating lung cancer and - unheralded opportunity for such approaches to further improve outcome for - patients. Currently there is considerable interest in combining anti-PD-1 or - PD-L1 monoclonal antibodies with established standard of care therapies such as - radiotherapy. Radiotherapy is known to be immunostimulatory and efforts are - underway to combine and augment the efficacy of the immune checkpoint inhibitors - further. This review outlines the interaction between lung cancer and the immune - system, summarises current evidence supporting the use of monoclonal antibodies - targeting the PD-1 axis in lung cancer and explores the potential of combining - radiotherapy with immunotherapy to augment anti-tumour immune responses. -CI - Copyright © 2016 The Royal College of Radiologists. Published by Elsevier Ltd. - All rights reserved. -FAU - Marshall, R -AU - Marshall R -AD - Institute of Cancer Sciences, The University of Manchester, Manchester Academic - Health Science Centre, Manchester, UK. -FAU - Popple, A -AU - Popple A -AD - Institute of Cancer Sciences, The University of Manchester, Manchester Academic - Health Science Centre, Manchester, UK. -FAU - Kordbacheh, T -AU - Kordbacheh T -AD - Institute of Cancer Sciences, The University of Manchester, Manchester Academic - Health Science Centre, Manchester, UK. -FAU - Honeychurch, J -AU - Honeychurch J -AD - Institute of Cancer Sciences, The University of Manchester, Manchester Academic - Health Science Centre, Manchester, UK. -FAU - Faivre-Finn, C -AU - Faivre-Finn C -AD - Institute of Cancer Sciences, The University of Manchester, Manchester Academic - Health Science Centre, Manchester, UK; The Christie NHS Foundation Trust, - Manchester, UK. -FAU - Illidge, T -AU - Illidge T -AD - Institute of Cancer Sciences, The University of Manchester, Manchester Academic - Health Science Centre, Manchester, UK; The Christie NHS Foundation Trust, - Manchester, UK. Electronic address: tmi@manchester.ac.uk. -LA - eng -GR - 17737/CRUK_/Cancer Research UK/United Kingdom -PT - Journal Article -PT - Review -DEP - 20170104 -PL - England -TA - Clin Oncol (R Coll Radiol) -JT - Clinical oncology (Royal College of Radiologists (Great Britain)) -JID - 9002902 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents) -RN - 0 (B7-H1 Antigen) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antineoplastic Agents/*therapeutic use -MH - B7-H1 Antigen/therapeutic use -MH - Humans -MH - Immunotherapy/*methods -MH - Lung Neoplasms/*drug therapy/immunology -MH - Programmed Cell Death 1 Receptor/*drug effects -MH - Treatment Outcome -OTO - NOTNLM -OT - Immune checkpoint -OT - immunotherapy -OT - non-small cell lung cancer -OT - programmed death-1 -OT - radiotherapy -OT - tumour microenvironment -EDAT- 2017/01/09 06:00 -MHDA- 2017/06/27 06:00 -CRDT- 2017/01/09 06:00 -PHST- 2016/06/24 00:00 [received] -PHST- 2016/10/04 00:00 [revised] -PHST- 2016/11/01 00:00 [accepted] -PHST- 2017/01/09 06:00 [pubmed] -PHST- 2017/06/27 06:00 [medline] -PHST- 2017/01/09 06:00 [entrez] -AID - S0936-6555(16)30459-9 [pii] -AID - 10.1016/j.clon.2016.12.003 [doi] -PST - ppublish -SO - Clin Oncol (R Coll Radiol). 2017 Apr;29(4):207-217. doi: - 10.1016/j.clon.2016.12.003. Epub 2017 Jan 4. - -PMID- 37704166 -OWN - NLM -STAT- MEDLINE -DCOM- 20231002 -LR - 20231015 -IS - 1569-8041 (Electronic) -IS - 0923-7534 (Linking) -VI - 34 -IP - 10 -DP - 2023 Oct -TI - Randomized open-label controlled study of cancer vaccine OSE2101 versus - chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer - with resistance to immunotherapy: ATALANTE-1. -PG - 920-933 -LID - S0923-7534(23)00790-1 [pii] -LID - 10.1016/j.annonc.2023.07.006 [doi] -AB - BACKGROUND: Patients with advanced non-small-cell lung cancer (NSCLC) treated - with immune checkpoint blockers (ICBs) ultimately progress either rapidly - (primary resistance) or after durable benefit (secondary resistance). The cancer - vaccine OSE2101 may invigorate antitumor-specific immune responses after ICB - failure. The objective of ATALANTE-1 was to evaluate its efficacy and safety in - these patients. PATIENTS AND METHODS: ATALANTE-1 was a two-step open-label study - to evaluate the efficacy and safety of OSE2101 compared to standard-of-care (SoC) - chemotherapy (CT). Patients with human leukocyte antigen (HLA)-A2-positive - advanced NSCLC without actionable alterations, failing sequential or concurrent - CT and ICB were randomized (2 : 1) to OSE2101 or SoC (docetaxel or pemetrexed). - Primary endpoint was overall survival (OS). Interim OS futility analysis was - planned as per Fleming design. In April 2020 at the time of interim analysis, a - decision was taken to prematurely stop the accrual due to coronavirus disease - 2019 (COVID-19). Final analysis was carried out in all patients and in the - subgroup of patients with ICB secondary resistance defined as failure after ICB - monotherapy second line ≥12 weeks. RESULTS: Two hundred and nineteen patients - were randomized (139 OSE2101, 80 SoC); 118 had secondary resistance to sequential - ICB. Overall, median OS non-significantly favored OSE2101 over SoC {hazard ratio - (HR) [95% confidence interval (CI)] 0.86 [0.62-1.19], P = 0.36}. In the secondary - resistance subgroup, OSE2101 significantly improved median OS versus SoC [11.1 - versus 7.5 months; HR (95% CI) 0.59 (0.38-0.91), P = 0.017], and significantly - improved post-progression survival (HR 0.46, P = 0.004), time to Eastern - Cooperative Oncology Group (ECOG) performance status deterioration (HR 0.43, P = - 0.006) and Quality of Life Questionnaire Core 30 (QLQ-C30) global health status - compared to SoC (P = 0.045). Six-month disease control rates and progression-free - survival were similar between groups. Grade ≥3 adverse effects occurred in 11.4% - of patients with OSE2101 and 35.1% in SoC (P = 0.002). CONCLUSIONS: In - HLA-A2-positive patients with advanced NSCLC and secondary resistance to - immunotherapy, OSE2101 increased survival with better safety compared to CT. - Further evaluation in this population is warranted. -CI - Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. -FAU - Besse, B -AU - Besse B -AD - Paris-Saclay University, Cancer Medicine Department, Institut Gustave Roussy, - Villejuif, France. Electronic address: Benjamin.BESSE@gustaveroussy.fr. -FAU - Felip, E -AU - Felip E -AD - Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron - Institute of Oncology, Barcelona. -FAU - Garcia Campelo, R -AU - Garcia Campelo R -AD - Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, - Biomedical Research Institute, INIBIC, A Coruña. -FAU - Cobo, M -AU - Cobo M -AD - Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University - Hospitals, IBIMA, Málaga, Spain. -FAU - Mascaux, C -AU - Mascaux C -AD - Pneumology Department, Hôpitaux Universitaires de Strasbourg-Nouvel Hôpital - Civil, Strasbourg. -FAU - Madroszyk, A -AU - Madroszyk A -AD - Medical Oncology Department, IPC-Institut Paoli-Calmettes, Marseille, France. -FAU - Cappuzzo, F -AU - Cappuzzo F -AD - Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy. -FAU - Hilgers, W -AU - Hilgers W -AD - Medical Oncology Department, Sainte Catherine Cancer Center, Avignon, France. -FAU - Romano, G -AU - Romano G -AD - Medical Oncology Department, Ospedale Vito Fazzi-ASL Lecce, Lecce, Italy. -FAU - Denis, F -AU - Denis F -AD - Medical Oncology Department, Institut Inter-Régional de Cancérologie Jean - Bernard-Elsan, Le Mans, France. -FAU - Viteri, S -AU - Viteri S -AD - Medical Oncology Department, Instituto Oncológico Dr. Rosell, Hospital - Universitario Dexeus, Grupo Quironsalud, Barcelona, Spain. -FAU - Debieuvre, D -AU - Debieuvre D -AD - Pneumology Department, Groupe Hospitalier de la Région Mulhouse Sud Alsace, - Mulhouse, France. -FAU - Galetta, D -AU - Galetta D -AD - Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari. -FAU - Baldini, E -AU - Baldini E -AD - Oncology Department, Ospedale San Luca, Lucca, Italy. -FAU - Razaq, M -AU - Razaq M -AD - Oncology Department, Stephenson Cancer Center, Oklahoma City, USA. -FAU - Robinet, G -AU - Robinet G -AD - Oncology Department, Centre Hospitalier Régional Universitaire Morvan, Brest, - France. -FAU - Maio, M -AU - Maio M -AD - Department of Oncology, University of Siena and Center for Immuno-Oncology, - University Hospital, Siena. -FAU - Delmonte, A -AU - Delmonte A -AD - Thoracic Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino - Amadori" (IRST), Meldola, Italy. -FAU - Roch, B -AU - Roch B -AD - Thoracic Oncology Unit, Montpellier University, University Hospital of - Montpellier, Montpellier. -FAU - Masson, P -AU - Masson P -AD - Pneumology Department, Centre Hospitalier de Cholet, Cholet, France. -FAU - Schuette, W -AU - Schuette W -AD - Medical Oncology Department, Hospital Martha-Maria Halle-Doelau, Halle, Germany. -FAU - Zer, A -AU - Zer A -AD - Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Petah - Tikva, Israel. -FAU - Remon, J -AU - Remon J -AD - Paris-Saclay University, Cancer Medicine Department, Institut Gustave Roussy, - Villejuif, France. -FAU - Costantini, D -AU - Costantini D -AD - Medical Development Department, OSE Immunotherapeutics, Paris, France. -FAU - Vasseur, B -AU - Vasseur B -AD - Medical Development Department, OSE Immunotherapeutics, Paris, France. -FAU - Dziadziuszko, R -AU - Dziadziuszko R -AD - Oncology and Radiotherapy Department and Early Phase Clinical Trials Centre, - Medical University of Gdansk, Gdansk, Poland. -FAU - Giaccone, G -AU - Giaccone G -AD - Meyer Cancer Center, Weill Cornell Medicine, New York, USA. -CN - ATALANTE-1 study group -LA - eng -PT - Journal Article -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20230911 -PL - England -TA - Ann Oncol -JT - Annals of oncology : official journal of the European Society for Medical - Oncology -JID - 9007735 -RN - 0 (Cancer Vaccines) -RN - 0 (HLA-A2 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Cancer Vaccines/adverse effects -MH - HLA-A2 Antigen/therapeutic use -MH - *Lung Neoplasms/drug therapy/etiology -MH - Quality of Life -MH - Treatment Outcome -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects -MH - *COVID-19/etiology -MH - Immunotherapy -OTO - NOTNLM -OT - advanced NSCLC -OT - cancer vaccine -OT - immunotherapy resistance -OT - quality of life -COIS- Disclosure BB: research funding, institution: Abbvie, Amgen, AstraZeneca, Chugai - pharmaceutical, Daiichi-Sankyo, Ellipse pharma, EISAI, Genmab, Genzyme - Corporation, Hedera Dx, Inivata, IPSEN, Janssen, MSD, Pharmamar, Roche-Genentech, - Sanofi, Socar research, Taiho Oncology, Turning Point Therapeutics. EF: - consulting or advisory role, personal: Amgen, AstraZeneca, Bayer, Bristol-Myers - Squibb, Lilly, GlaxoSmithKline, Janssen, Merck Serono, Novartis, Pfizer, Sanofi, - Takeda, Peptomyc, Daiichi Sankyo Europe GmbH, F. Hoffmann LaRoche, Merck Sharp & - Dohme; speakers’ bureau, personal: AstraZeneca, Bristol-Myers Squibb, Lilly, - Medscape, Merck Sharp & Dohme, PeerVoice, Pfizer, Takeda, Amgen, F. Hoffmann - LaRoche, Janssen, Medical Trends, Merck Serono, Sanofi, Touch ONCOLOGY; other - relationship, personal: GRIFOLS; research funding, institution: Merck, Merck - KGaA. RGC: consulting or advisory role, personal: Roche/Genentech, MSD Oncology, - AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Takeda, Boehringer - Ingelheim, Janssen Oncology; speakers’ bureau, personal: Roche, AstraZeneca, - Bristol-Myers Squibb, Pfizer, Novartis, Takeda, Boehringer Ingelheim, MSD - Oncology, Sanofi/Aventis, Janssen Oncology, Amgen, Lilly; travel, accommodations, - expenses, personal: Roche/Genentech, MSD Oncology, Pfizer. CM: consulting or - advisory role, personal: Roche, Sanofi, Takeda, Pfizer, Bristol-Myers Squibb, - MSD, AstraZeneca, Kephren, AMGEN, Janssen, GlaxoSmithKline; honoraria, personal: - Roche, AstraZeneca, Kephren, Bristol-Myers Squibb, Pfizer, Sanofi, MSD, Takeda, - Janssen; travel, accommodations, expenses, personal: MSD; other, uncompensated - relationships: Boehringer Ingelheim. FC: consulting or advisory role, personal: - Roche/Genentech, AstraZeneca/MedImmune, Pfizer, Bristol-Myers Squibb, Takeda, - Lilly, MSD Oncology, Bayer, Amgen, Sanofi, PharmaMar, Novocure; honoraria, - personal: Pfizer, Roche/Genentech, AstraZeneca/MedImmune, Lilly, MSD Oncology, - Bristol-Myers Squibb, Takeda, Bayer, Amgen, Sanofi, PharmaMar, Novocure; travel, - accommodations, expenses, personal: OSE Immunotherapeutics. WH: consulting or - advisory role, personal: AstraZeneca, Janssen; honoraria, personal: MSD Oncology. - FD: consulting or advisory role, institution: SIVAN Innovation; honoraria, - personal: AstraZeneca, MSD, Ipsen, Roche Belgium, Pfizer/EMD Serono, Takeda; - stock and other ownership interests, institution: Kelindi; other relationship, - personal: Takeda, Novartis, Ipsen, Janssen-Cilag, Merck Serono, Chugai Pharma, - Ferring. SV: consulting or advisory role, personal: Roche; company: Bristol-Myers - Squibb, Janssen, Takeda, Reddy Pharma Iberia, Merck KGaA, Puma Biotechnology; - speakers’ bureau, personal: Bristol-Myers Squibb, Roche, MSD, AstraZeneca Spain; - travel, accommodations, expenses, personal: Roche, MSD, Merck KGaA. DD: - consulting or advisory role, personal: BMS, OSE Immunotherapeutics, Amgen, - AstraZeneca; honoraria, personal: AstraZeneca, BMS, Janssen, Amgen, Novartis, - Sanofi Aventis, Ipsen, MSD, GSK, Hoffmann-La Roche, Pfizer, OSE - Immunotherapeutics; research funding, institution: AstraZeneca, Chugaï, - Hoffmann-La Roche, Lilly, BMS, MSD, Boehringer-Ingelheim, Pfizer, Takeda, Bayer, - Janssen, Sanofi-Aventis; travel, accommodations, expenses, personal: Amgen, BMS, - AstraZeneca, MSD, Novartis, Roche, Pfizer, Janssen, Takeda. DG: consulting or - advisory role, personal: Eli Lilly, Novartis, AZ, BMS, Pfizer; speakers’ bureau, - personal: Eli Lilly, Takeda, Novartis, BMS, MSD, Roche; travel, accommodations, - expenses, personal: Amgen. GR: consulting or advisory role, personal: MSD, Astra - Zeneca, BMS; honoraria, personal: Roche, MSD, Astra Zeneca; research funding, - institution: Roche; travel, accommodations, expenses, personal: Roche, MSD, Astra - Zeneca. MM: consulting or advisory role, personal: Alfasigma, Amgen, AstraZeneca, - Bristol-Myers Squibb, GlaxoSmithKline, Incyte, Lilly, Merck Serono, MSD, Pierre - Fabre, Roche, Sanofi; honoraria: Alfasigma, Amgen, AstraZeneca, Bristol-Myers - Squibb, GlaxoSmithKline, Lilly, Merck Serono, MSD, Pierre Fabre, Roche, Sanofi, - SciClone; stock and other ownership interests: Epigen Therapeutics, Theravance. - AD: consulting or advisory role, personal: Novartis, Pfizer, Immunocore; research - funding, institution: MSD; travel, accommodations, expenses, personal: MSD. BR: - consulting or advisory role, personal: Amgen, AstraZeneca, BMS, Chugaï, Lilly, - Roche, Takeda; speaker’s bureau: BMS, Roche; travel, accommodations, expenses, - personal: BMS, Amgen, MSD, Roche, Novartis. WS: consulting or advisory role, - personal: Roche, MSD, Novartis; honoraria, personal: Roche, MSD, Novartis. AZ: - consulting or advisory role, personal: Boehringer Ingelheim, Roche, MSD, - Oncotest/Rhenium, Lilly; honoraria, personal: MSD, Roche, AstraZeneca, Takeda, - Novartis; stock and other ownership interests, personal: Nixio; research funding, - institution: Bristol-Myers Squibb; travel, accommodations, expenses, personal: - AstraZeneca, MSD, Roche. DC: employment, personal: OSE Immunotherapeutics; - leadership, personal: OSE Immunotherapeutics; stock and other ownership - interests, personal: OSE Immunotherapeutics. BV: employment, personal: OSE - Immunotherapeutics; patents, royalties, other intellectual property, personal: - uses of anti-SIRPa antibodies in the treatment of cancer; stock and other - ownership interests, personal: OSE Immunotherapeutics. RD: consulting or advisory - role, personal: Regeneron, Karyopharm Therapeutics; honoraria, personal: - Roche/Genentech, Novartis, Pfizer, Bristol-Myers Squibb, Takeda, AstraZeneca, MSD - Oncology, Boehringer Ingelheim, Seattle Genetics; travel, accommodations, - expenses, personal: Roche, AstraZeneca. GG: consulting or advisory role, - personal: Daiichi Sankyo, Novartis, Radiomics, Janssen Oncology, Sanofi, Eisai, - Spectrum Pharmaceuticals, Sanofi/Regeneron; research funding, institution: - MedImmune, Karyopharm Therapeutics, Cantargia AB; starting in September 2022, - employee of Amgen. All other authors have declared no conflicts of interest. -FIR - Zemanová, M -IR - Zemanová M -FIR - Besse, B -IR - Besse B -FIR - Bonnet, C -IR - Bonnet C -FIR - Cadranel, J -IR - Cadranel J -FIR - Chouaid, C -IR - Chouaid C -FIR - Cortot, A -IR - Cortot A -FIR - Debieuvre, D -IR - Debieuvre D -FIR - Delclaux, B -IR - Delclaux B -FIR - Denis, F -IR - Denis F -FIR - Duchemann, B -IR - Duchemann B -FIR - El Kouri, C -IR - El Kouri C -FIR - Ferrand, F R -IR - Ferrand FR -FIR - Ginoux, M -IR - Ginoux M -FIR - Hilgers, W -IR - Hilgers W -FIR - Madroszyk, A -IR - Madroszyk A -FIR - Masson, P -IR - Masson P -FIR - Mazieres, J -IR - Mazieres J -FIR - Molinier, O -IR - Molinier O -FIR - Moro-Sibilot, D -IR - Moro-Sibilot D -FIR - Pichon, E -IR - Pichon E -FIR - Mascaux, C -IR - Mascaux C -FIR - Robinet, G -IR - Robinet G -FIR - Roch, B -IR - Roch B -FIR - Zalcman, G -IR - Zalcman G -FIR - Schmidtke-Schrezenmeier, G -IR - Schmidtke-Schrezenmeier G -FIR - Schuette, W -IR - Schuette W -FIR - Urban, L -IR - Urban L -FIR - Gottfried, M -IR - Gottfried M -FIR - Nechushtan, H -IR - Nechushtan H -FIR - Peled, N -IR - Peled N -FIR - Wollner, M -IR - Wollner M -FIR - Zer, A -IR - Zer A -FIR - Baldini, E -IR - Baldini E -FIR - Bonanno, L -IR - Bonanno L -FIR - Bonetti, A -IR - Bonetti A -FIR - Cappuzzo, F -IR - Cappuzzo F -FIR - Delmonte, A -IR - Delmonte A -FIR - Galetta, D -IR - Galetta D -FIR - Maio, M -IR - Maio M -FIR - Minotti, V -IR - Minotti V -FIR - Rea, A -IR - Rea A -FIR - Romano, G -IR - Romano G -FIR - Tassinari, D -IR - Tassinari D -FIR - Tonini, G -IR - Tonini G -FIR - Dziadziuszko, R -IR - Dziadziuszko R -FIR - Karaszewska, B -IR - Karaszewska B -FIR - Szczęsna, A -IR - Szczęsna A -FIR - Cobo, M -IR - Cobo M -FIR - De Castro, J -IR - De Castro J -FIR - Felip, E -IR - Felip E -FIR - Garcia Campelo, M R -IR - Garcia Campelo MR -FIR - Hernández, A -IR - Hernández A -FIR - Moran, T -IR - Moran T -FIR - Provencio, M -IR - Provencio M -FIR - Viteri, S -IR - Viteri S -FIR - Dasgupta, A -IR - Dasgupta A -FIR - Gabrail, N -IR - Gabrail N -FIR - Giaccone, G -IR - Giaccone G -FIR - Harshad, A -IR - Harshad A -FIR - Liu, S -IR - Liu S -FIR - Oubre, D -IR - Oubre D -FIR - Panikkar, R -IR - Panikkar R -FIR - Razaq, M -IR - Razaq M -FIR - Sanborn, R -IR - Sanborn R -EDAT- 2023/09/14 00:42 -MHDA- 2023/10/02 06:42 -CRDT- 2023/09/13 19:18 -PHST- 2023/04/04 00:00 [received] -PHST- 2023/07/04 00:00 [revised] -PHST- 2023/07/05 00:00 [accepted] -PHST- 2023/10/02 06:42 [medline] -PHST- 2023/09/14 00:42 [pubmed] -PHST- 2023/09/13 19:18 [entrez] -AID - S0923-7534(23)00790-1 [pii] -AID - 10.1016/j.annonc.2023.07.006 [doi] -PST - ppublish -SO - Ann Oncol. 2023 Oct;34(10):920-933. doi: 10.1016/j.annonc.2023.07.006. Epub 2023 - Sep 11. - -PMID- 33472433 -OWN - NLM -STAT- MEDLINE -DCOM- 20220202 -LR - 20220202 -IS - 1750-7448 (Electronic) -IS - 1750-743X (Linking) -VI - 13 -IP - 5 -DP - 2021 Apr -TI - Clinical efficacy of immune checkpoint inhibitors in patients with brain - metastases. -PG - 419-432 -LID - 10.2217/imt-2020-0208 [doi] -AB - Brain metastases (BMs) represent a negative prognostic factor for patients with - solid malignancies. BMs are generally approached with loco-regional treatments - and the blood-brain barrier limits the efficacy of some systemic drugs. The aim - of this review is to summarize current knowledge about the role of immune - checkpoint inhibitors for the management of brain metastases in patients with - solid malignancies. We performed a review of available literature. Immune - checkpoint inhibitors represent the standard treatment for several advanced solid - malignancies. However, with the exception of melanoma their clinical role in - other solid malignancies is not completely clear due to the exclusion of patients - with BM from approval clinical trials. Immune-checkpoint inhibitors may be an - effective treatment of brain metastases of melanoma while their clinical role on - brain metastases from other solid malignancies is uncertain. -FAU - Nunno, Vincenzo Di -AU - Nunno VD -AUID- ORCID: 0000-0003-4441-9834 -AD - Department of Medical Oncology, Azienda USL, Bologna, Italy. -FAU - Nuvola, Giacomo -AU - Nuvola G -AD - Department of Specialized, Experimental & Diagnostic Medicine, S. Orsola-Malpighi - University Hospital, Alma Mater Studiorum University of Bologna. -FAU - Mosca, Mirta -AU - Mosca M -AD - Department of Specialized, Experimental & Diagnostic Medicine, S. Orsola-Malpighi - University Hospital, Alma Mater Studiorum University of Bologna. -FAU - Maggio, Ilaria -AU - Maggio I -AD - Department of Medical Oncology, Azienda USL, Bologna, Italy. -FAU - Gatto, Lidia -AU - Gatto L -AD - Department of Medical Oncology, Azienda USL, Bologna, Italy. -FAU - Tosoni, Alicia -AU - Tosoni A -AD - Department of Medical Oncology, Azienda USL, Bologna, Italy. -FAU - Lodi, Raffaele -AU - Lodi R -AUID- ORCID: 0000-0003-3878-304X -AD - IRCCS Istituto delle Scienze Neurologiche di Bologna. -FAU - Franceschi, Enrico -AU - Franceschi E -AUID- ORCID: 0000-0001-9332-4677 -AD - Department of Medical Oncology, Azienda USL, Bologna, Italy. -FAU - Brandes, Alba Ariela -AU - Brandes AA -AUID- ORCID: 0000-0002-2503-9089 -AD - Department of Medical Oncology, Azienda USL, Bologna, Italy. -LA - eng -PT - Journal Article -PT - Review -DEP - 20210121 -PL - England -TA - Immunotherapy -JT - Immunotherapy -JID - 101485158 -RN - 0 (Biomarkers, Tumor) -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Biomarkers, Tumor/genetics -MH - Brain Neoplasms/*drug therapy/genetics/immunology/*secondary -MH - Breast Neoplasms/drug therapy/genetics/immunology/pathology -MH - Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/immunology/secondary -MH - Carcinoma, Renal Cell/drug therapy/genetics/immunology/secondary -MH - Combined Modality Therapy -MH - Humans -MH - Immune Checkpoint Inhibitors/*therapeutic use -MH - Kidney Neoplasms/drug therapy/genetics/immunology/pathology -MH - Lung Neoplasms/drug therapy/genetics/immunology/pathology -MH - Melanoma/drug therapy/genetics/immunology/secondary -MH - Mutation -MH - Radiotherapy -MH - Treatment Outcome -OTO - NOTNLM -OT - CTLA-4 -OT - NSCLC -OT - PD-1 -OT - PD-L1 -OT - brain metastases -OT - immune checkpoint inhibitors -OT - melanoma -OT - renal cell carcinoma -EDAT- 2021/01/22 06:00 -MHDA- 2022/02/03 06:00 -CRDT- 2021/01/21 05:23 -PHST- 2021/01/22 06:00 [pubmed] -PHST- 2022/02/03 06:00 [medline] -PHST- 2021/01/21 05:23 [entrez] -AID - 10.2217/imt-2020-0208 [doi] -PST - ppublish -SO - Immunotherapy. 2021 Apr;13(5):419-432. doi: 10.2217/imt-2020-0208. Epub 2021 Jan - 21. - -PMID- 34311110 -OWN - NLM -STAT- MEDLINE -DCOM- 20211203 -LR - 20211214 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 16 -IP - 12 -DP - 2021 Dec -TI - Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or - Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. -PG - 2040-2050 -LID - S1556-0864(21)02321-2 [pii] -LID - 10.1016/j.jtho.2021.07.008 [doi] -AB - INTRODUCTION: The Blood First Assay Screening Trial is an ongoing open-label, - multicohort study, prospectively evaluating the relationship between blood-based - next-generation sequencing (NGS) detection of actionable genetic alterations and - activity of targeted therapies or immunotherapy in treatment-naive advanced or - metastatic NSCLC. We present data from the ALK-positive cohort. METHODS: Patients - aged more than or equal to 18 years with stage IIIB or IV NSCLC and ALK - rearrangements detected by blood-based NGS using hybrid capture technology - (FoundationACT) received alectinib 600 mg twice daily. Asymptomatic or treated - central nervous system (CNS) metastases were permitted. Primary end point was - investigator-assessed objective response rate (ORR; Response Evaluation Criteria - in Solid Tumors version 1.1). Secondary end points were independent review - facility-assessed ORR, duration of response, progression-free survival (PFS), - overall survival, and safety. Exploratory end points were investigator-assessed - ORR in patients with baseline CNS metastases and relationship between circulating - biomarkers and response. RESULTS: In total, 2219 patients were screened and - blood-based NGS yielded results in 98.6% of the cases. Of these, 119 patients - (5.4%) had ALK-positive disease; 87 were enrolled and received alectinib. Median - follow-up was 12.6 months (range: 2.6-18.7). Confirmed ORR was 87.4% (95% - confidence interval [CI]: 78.5-93.5) by investigator and 92.0% (95% CI: - 84.1-96.7) by independent review facility. Investigator-confirmed 12-month - duration of response was 75.9% (95% CI: 63.6-88.2). In 35 patients (40%) with - baseline CNS disease, investigator-assessed ORR was 91.4% (95% CI: 76.9-98.2). - Median PFS was not reached; 12-month investigator-assessed PFS was 78.4% (95% CI: - 69.1-87.7). Safety data were consistent with the known tolerability profile of - alectinib. CONCLUSIONS: These results reveal the clinical application of - blood-based NGS as a method to inform clinical decision-making in ALK-positive - NSCLC. -CI - Copyright © 2021 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Dziadziuszko, Rafal -AU - Dziadziuszko R -AD - Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, - Poland. -FAU - Mok, Tony -AU - Mok T -AD - State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, - Shatin, Hong Kong. -FAU - Peters, Solange -AU - Peters S -AD - Oncology Department, University Hospital (CHUV), University of Lausanne, - Switzerland. -FAU - Han, Ji-Youn -AU - Han JY -AD - Center for Lung Cancer, National Cancer Center, Goyang, South Korea. -FAU - Alatorre-Alexander, Jorge -AU - Alatorre-Alexander J -AD - Thoracic Oncology Clinic, Health Pharma Professional Research, Mexico City, - Mexico. -FAU - Leighl, Natasha -AU - Leighl N -AD - Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, - Canada. -FAU - Sriuranpong, Virote -AU - Sriuranpong V -AD - Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial - Hospital, Bangkok, Thailand. -FAU - Pérol, Maurice -AU - Pérol M -AD - Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France. -FAU - de Castro Junior, Gilberto -AU - de Castro Junior G -AD - Division of Clinical Oncology, Instituto do Cancer do Estado de São Paulo, São - Paulo, Brazil. -FAU - Nadal, Ernest -AU - Nadal E -AD - Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain. -FAU - de Marinis, Filippo -AU - de Marinis F -AD - European Institute of Oncology, Istituto di Ricovero e Cura a Carattere - Scientifico (IRCCS), Milan, Italy. -FAU - Frontera, Osvaldo Arén -AU - Frontera OA -AD - Centro de Investigación Clínica Bradford Hill, Santiago, Chile. -FAU - Tan, Daniel S W -AU - Tan DSW -AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore. -FAU - Lee, Dae Ho -AU - Lee DH -AD - Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. -FAU - Kim, Hye Ryun -AU - Kim HR -AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer - Centre, Yonsei University College of Medicine, Seoul, South Korea. -FAU - Yan, Mark -AU - Yan M -AD - F. Hoffmann-La Roche, Mississauga, Canada. -FAU - Riehl, Todd -AU - Riehl T -AD - Genentech, Inc., South San Francisco, California. -FAU - Schleifman, Erica -AU - Schleifman E -AD - Genentech, Inc., South San Francisco, California. -FAU - Paul, Sarah M -AU - Paul SM -AD - Genentech, Inc., South San Francisco, California. -FAU - Mocci, Simonetta -AU - Mocci S -AD - Genentech, Inc., South San Francisco, California. -FAU - Patel, Rajesh -AU - Patel R -AD - Genentech, Inc., South San Francisco, California. -FAU - Assaf, Zoe June -AU - Assaf ZJ -AD - Genentech, Inc., South San Francisco, California. -FAU - Shames, David S -AU - Shames DS -AD - Genentech, Inc., South San Francisco, California. -FAU - Mathisen, Michael S -AU - Mathisen MS -AD - Genentech, Inc., South San Francisco, California. -FAU - Gadgeel, Shirish M -AU - Gadgeel SM -AD - Department of Internal Medicine, Henry Ford Cancer Institute, Henry Ford Health - System, Detroit, Michigan. Electronic address: sgadgee1@hfhs.org. -LA - eng -PT - Clinical Trial, Phase II -PT - Journal Article -DEP - 20210724 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Protein Kinase Inhibitors) -RN - 53AH36668S (Crizotinib) -RN - EC 2.7.10.1 (Anaplastic Lymphoma Kinase) -SB - IM -MH - Anaplastic Lymphoma Kinase/genetics -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics -MH - Cohort Studies -MH - Crizotinib -MH - Humans -MH - *Lung Neoplasms/drug therapy/genetics -MH - Protein Kinase Inhibitors/therapeutic use -OTO - NOTNLM -OT - ALK-positive -OT - Alectinib -OT - Blood-based assay -OT - NSCLC -OT - Next-generation sequencing -EDAT- 2021/07/27 06:00 -MHDA- 2021/12/15 06:00 -CRDT- 2021/07/26 20:13 -PHST- 2021/06/03 00:00 [received] -PHST- 2021/07/02 00:00 [revised] -PHST- 2021/07/04 00:00 [accepted] -PHST- 2021/07/27 06:00 [pubmed] -PHST- 2021/12/15 06:00 [medline] -PHST- 2021/07/26 20:13 [entrez] -AID - S1556-0864(21)02321-2 [pii] -AID - 10.1016/j.jtho.2021.07.008 [doi] -PST - ppublish -SO - J Thorac Oncol. 2021 Dec;16(12):2040-2050. doi: 10.1016/j.jtho.2021.07.008. Epub - 2021 Jul 24. - -PMID- 31248647 -OWN - NLM -STAT- MEDLINE -DCOM- 20210702 -LR - 20210702 -IS - 1879-1476 (Electronic) -IS - 0385-8146 (Linking) -VI - 47 -IP - 3 -DP - 2020 Jun -TI - Efficacy of chemotherapy after progression with nivolumab in squamous cell - carcinoma of the head and neck. -PG - 485-488 -LID - S0385-8146(19)30273-1 [pii] -LID - 10.1016/j.anl.2019.06.004 [doi] -AB - Nivolumab, a programmed death-1 (PD-1) inhibitor, has shown promising results - against squamous cell carcinoma of the head and neck (SCCHN) in cases of - recurrence or in a metastatic setting after platinum-based therapy. However, - treatment alternatives for patients with nivolumab-refractory are limited, and a - constant opinion is not provided. Recently, accumulating studies have - demonstrated that chemotherapy after immune checkpoint inhibitor treatment may - induce better objective responses in patients with advanced non-small cell lung - cancer. However, there are few reports on the increased effect of chemotherapy - after nivolumab treatment in SCCHN. Therefore, cases must be accumulated to - identify patients with nivolumab-refractory SCCHN who may benefit from - chemotherapy. Here, we present patients with SCCHN who exhibited a significant - response to chemotherapy after nivolumab treatment. -CI - Copyright © 2019 Oto-Rhino-Laryngological Society of Japan Inc. Published by - Elsevier B.V. All rights reserved. -FAU - Suzuki, Shinsuke -AU - Suzuki S -AD - Department of Otorhinolaryngology & Head and Neck Surgery, Akita University - Graduate School of Medicine, Akita 010-8543, Japan. Electronic address: - suzukis@med.akita-u.ac.jp. -FAU - Toyoma, Satoshi -AU - Toyoma S -AD - Department of Otorhinolaryngology & Head and Neck Surgery, Akita University - Graduate School of Medicine, Akita 010-8543, Japan. -FAU - Tomizawa, Hiroki -AU - Tomizawa H -AD - Department of Otorhinolaryngology & Head and Neck Surgery, Akita University - Graduate School of Medicine, Akita 010-8543, Japan. -FAU - Yamada, Toshiki -AU - Yamada T -AD - Department of Otorhinolaryngology & Head and Neck Surgery, Akita University - Graduate School of Medicine, Akita 010-8543, Japan. -FAU - Iikawa, Nobuko -AU - Iikawa N -AD - Department of Otorhinolaryngology & Head and Neck Surgery, Akita University - Graduate School of Medicine, Akita 010-8543, Japan. -FAU - Shiina, Kazuhiro -AU - Shiina K -AD - Department of Otorhinolaryngology & Head and Neck Surgery, Akita University - Graduate School of Medicine, Akita 010-8543, Japan. -FAU - Saito, Hidekazu -AU - Saito H -AD - Department of Otorhinolaryngology & Head and Neck Surgery, Akita University - Graduate School of Medicine, Akita 010-8543, Japan. -FAU - Koizumi, Koh -AU - Koizumi K -AD - Department of Otorhinolaryngology & Head and Neck Surgery, Akita University - Graduate School of Medicine, Akita 010-8543, Japan. -FAU - Kawasaki, Yohei -AU - Kawasaki Y -AD - Department of Otorhinolaryngology & Head and Neck Surgery, Akita University - Graduate School of Medicine, Akita 010-8543, Japan. -FAU - Yamada, Takechiyo -AU - Yamada T -AD - Department of Otorhinolaryngology & Head and Neck Surgery, Akita University - Graduate School of Medicine, Akita 010-8543, Japan. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20190625 -PL - Netherlands -TA - Auris Nasus Larynx -JT - Auris, nasus, larynx -JID - 7708170 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Aged -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Chemoradiotherapy -MH - Disease Progression -MH - Head and Neck Neoplasms/*drug therapy/therapy -MH - Humans -MH - Male -MH - Middle Aged -MH - Neoplasm Recurrence, Local/drug therapy -MH - Nivolumab/*therapeutic use -MH - Squamous Cell Carcinoma of Head and Neck/*drug therapy/therapy -OTO - NOTNLM -OT - Chemotherapy -OT - Head and neck squamous cell carcinoma -OT - Immune checkpoint inhibitor -OT - Metastasis -OT - Nivolumab -OT - Recurrence -EDAT- 2019/06/30 06:00 -MHDA- 2021/07/03 06:00 -CRDT- 2019/06/29 06:00 -PHST- 2019/03/17 00:00 [received] -PHST- 2019/05/31 00:00 [revised] -PHST- 2019/06/12 00:00 [accepted] -PHST- 2019/06/30 06:00 [pubmed] -PHST- 2021/07/03 06:00 [medline] -PHST- 2019/06/29 06:00 [entrez] -AID - S0385-8146(19)30273-1 [pii] -AID - 10.1016/j.anl.2019.06.004 [doi] -PST - ppublish -SO - Auris Nasus Larynx. 2020 Jun;47(3):485-488. doi: 10.1016/j.anl.2019.06.004. Epub - 2019 Jun 25. - -PMID- 35524294 -OWN - NLM -STAT- MEDLINE -DCOM- 20220510 -LR - 20220716 -IS - 1471-2466 (Electronic) -IS - 1471-2466 (Linking) -VI - 22 -IP - 1 -DP - 2022 May 6 -TI - Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in - the treatment of elder patients with non-small-cell lung cancer: a retrospective - study. -PG - 179 -LID - 10.1186/s12890-022-01981-5 [doi] -LID - 179 -AB - BACKGROUND: Anlotinib is a multitarget tyrosine kinase inhibitor for treating - patients with advanced non-small cell lung cancer (NSCLC). We aimed to assess the - efficacy and safety of anlotinib in elder patients with advanced NSCLC. METHODS: - Elder patients with advanced NSCLC who received anlotinib were enrolled. They - were all age ≥ 65 years and with demonstrated records of EGFR gene status. All - patients had received treatment with anlotinib or immune checkpoint inhibitors - (ICIs)/EGFR-TKIs. The efficacy was evaluated according to the efficacy evaluation - criteria for solid tumors (RECIST 1.1). Common Adverse Events Evaluation Criteria - (CTCAE 4.03) were used to evaluate adverse drug reactions. RESULTS: A total of 91 - patients were included in this study. We divided the patients into two groups - (EGFR wild type: 60 patients; EGFR mutation: 31 patients). Among EGFR negative - patients, the progression-free survival (PFS) for anlotinib monotherapy and - anlotinib combination ICI therapy was 3.2 months and 5.0 months, respectively - (P = 0.012). The difference in overall survival (OS) between monotherapy and - combination therapy was also significant (9.5 vs. 18.4 months, respectively - P = 0.010). Interestingly, we further analyzed differences between patients with - hypertension and without hypertension, and found that hypertension was associated - with better prognosis (5.7 vs. 1.4 months, P < 0.0001). In the EGFR mutation - group, the PFS for anlotinib and EGFR-TKI combination treatment indicated better - efficacy than that of anlotinib monotherapy (1.83 months vs. 7.03 months, - respectively, P = 0.001). The median OS for monotherapy and combination therapy - in the EGFR mutation group showed no statistical difference (28.34 months vs. - 31.37 months, P = 0.223). The most common adverse reactions were hypertension, - fatigue, and hand-foot syndrome, mainly of grade 1 or 2. No significant increase - in adverse reactions was observed in patients  ≥ 70 years of age. CONCLUSIONS: - Anlotinib treatment and combination regimens resulted in good efficacy and - controllable adverse reactions in elder patients with advanced NSCLC. -CI - © 2022. The Author(s). -FAU - Wang, Wenxian -AU - Wang W -AD - The Second Affiliated Hospital of Soochow University, Suzhou, China. -AD - Department of Medical Oncology, The Cancer Hospital of the University of Chinese - Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. -FAU - Shao, Lan -AU - Shao L -AD - Department of Medical Oncology, The Cancer Hospital of the University of Chinese - Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. -AD - Institute of Cancer and Basic Medicine(IBMC), Chinese Academy of Sciences, - Hangzhou, China. -FAU - Xu, Yibing -AU - Xu Y -AD - Department of Medical Oncology, The Cancer Hospital of the University of Chinese - Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. -FAU - Song, Zhengbo -AU - Song Z -AD - Department of Medical Oncology, The Cancer Hospital of the University of Chinese - Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. -AD - Institute of Cancer and Basic Medicine(IBMC), Chinese Academy of Sciences, - Hangzhou, China. -FAU - Lou, Guangyuan -AU - Lou G -AD - Department of Medical Oncology, The Cancer Hospital of the University of Chinese - Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. -AD - Institute of Cancer and Basic Medicine(IBMC), Chinese Academy of Sciences, - Hangzhou, China. -FAU - Zhang, Yiping -AU - Zhang Y -AD - Department of Medical Oncology, The Cancer Hospital of the University of Chinese - Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. -AD - Institute of Cancer and Basic Medicine(IBMC), Chinese Academy of Sciences, - Hangzhou, China. -FAU - Chen, Ming -AU - Chen M -AD - Department of Radiotherapy Oncology, The Second Affiliated Hospital of Soochow - University, 1055 Sanxiang Road, Suzhou, 215004, Jiangsu Province, China. - chen_ming_dr@163.com. -LA - eng -GR - 2019ZYC-A76/Scientific Research Foundation of Zhejiang Medical Association/ -PT - Journal Article -DEP - 20220506 -PL - England -TA - BMC Pulm Med -JT - BMC pulmonary medicine -JID - 100968563 -RN - 0 (Indoles) -RN - 0 (Protein Kinase Inhibitors) -RN - 0 (Quinolines) -RN - 0 (anlotinib) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Aged -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - ErbB Receptors/genetics -MH - Humans -MH - *Hypertension -MH - Immunotherapy -MH - Indoles -MH - *Lung Neoplasms/pathology -MH - Protein Kinase Inhibitors/adverse effects -MH - Quinolines -MH - Retrospective Studies -PMC - PMC9074279 -OTO - NOTNLM -OT - Angiogenesis -OT - Non-small cell lung cancer -OT - Prognosis -OT - Tyrosine kinase inhibitors -COIS- The authors declare that they have no conflicts of interest. -EDAT- 2022/05/08 06:00 -MHDA- 2022/05/11 06:00 -PMCR- 2022/05/06 -CRDT- 2022/05/07 00:00 -PHST- 2021/09/26 00:00 [received] -PHST- 2022/05/03 00:00 [accepted] -PHST- 2022/05/07 00:00 [entrez] -PHST- 2022/05/08 06:00 [pubmed] -PHST- 2022/05/11 06:00 [medline] -PHST- 2022/05/06 00:00 [pmc-release] -AID - 10.1186/s12890-022-01981-5 [pii] -AID - 1981 [pii] -AID - 10.1186/s12890-022-01981-5 [doi] -PST - epublish -SO - BMC Pulm Med. 2022 May 6;22(1):179. doi: 10.1186/s12890-022-01981-5. - -PMID- 37409360 -OWN - NLM -STAT- MEDLINE -DCOM- 20230901 -LR - 20230902 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 12 -IP - 15 -DP - 2023 Aug -TI - A nomogram model for predicting the risk of checkpoint inhibitor-related - pneumonitis for patients with advanced non-small-cell lung cancer. -PG - 15998-16010 -LID - 10.1002/cam4.6244 [doi] -AB - OBJECTIVE: Immunotherapy extensively treats advanced non-small-cell lung cancer - (NSCLC). Although immunotherapy is generally better tolerated than chemotherapy, - it can cause multiple immune-related adverse events (irAEs) involving multiple - organs. Checkpoint inhibitor-related pneumonitis (CIP) is a relatively uncommon - irAE that, in severe cases, can be fatal. Potential risk factors for the - occurrence of CIP are currently poorly understood. This study sought to develop a - novel scoring system for predicting the risk of CIP based on a nomogram model. - METHODS: We retrospectively collected advanced NSCLC patients who received - immunotherapy at our institution between January 1, 2018, and December 30, 2021. - All patients who met the criteria were randomly divided into the training set and - testing set (in a ratio of 7:3), and cases fulfilling the CIP diagnostic criteria - were screened. The patients' baseline clinical characteristics, laboratory tests, - imaging, and treatment information were extracted from the electronic medical - records. The risk factors associated with the occurrence of CIP were identified - based on the results of logistic regression analysis on the training set, and a - nomogram prediction model was developed. The discrimination and prediction - accuracy of the model was evaluated using the receiver operating characteristic - (ROC) curve, the concordance index (C-index), and the calibration curve. Decision - curve analysis (DCA) was used to evaluate the clinical applicability of the - model. RESULTS: The training set comprised 526 (CIP: 42 cases), and the testing - set comprised 226 (CIP: 18 cases) patients, respectively. In the training set, - the final multivariate regression analysis revealed that age (p = 0.014; odds - ratio [OR] = 1.056; 95% Confidence Interval [CI] =1.011-1.102), Eastern - Cooperative Oncology Group performance status (p = 0.002; OR = 6.170; 95% - CI = 1.943-19.590), history of prior radiotherapy (p < 0.001; OR = 4.005; 95% - CI = 1.920-8.355), baseline white blood cell count (WBC) (p < 0.001; OR = 1.604; - 95% CI = 1.250-2.059), and baseline absolute lymphocyte count (ALC) (p = 0.034; - OR = 0.288; 95% CI = 0.091-0.909) were identified as independent risk factors for - the occurrence of CIP. A prediction nomogram model was developed based on these - five parameters. The area under the ROC curve and C-index of the prediction model - in the training set and testing set were 0.787 (95% CI: 0.716-0.857) and 0.874 - (95% CI: 0.792-0.957), respectively. The calibration curves are in good - agreement. The DCA curves indicate that the model has good clinical utility. - CONCLUSION: We developed a nomogram model that proved to be a good assistant tool - for predicting the risk of CIP in advanced NSCLC. This model has the potential - power to help clinicians in making treatment decisions. -CI - © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Zhang, Yao -AU - Zhang Y -AUID- ORCID: 0000-0001-9278-935X -AD - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, - Shanghai Jiao Tong University School of Medicine, Shanghai, China. -FAU - Zhang, Lincheng -AU - Zhang L -AD - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, - Shanghai Jiao Tong University School of Medicine, Shanghai, China. -FAU - Cao, Shuhui -AU - Cao S -AD - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, - Shanghai Jiao Tong University School of Medicine, Shanghai, China. -FAU - Wang, Yue -AU - Wang Y -AD - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, - Shanghai Jiao Tong University School of Medicine, Shanghai, China. -FAU - Ling, Xuxinyi -AU - Ling X -AD - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, - Shanghai Jiao Tong University School of Medicine, Shanghai, China. -FAU - Zhou, Yan -AU - Zhou Y -AD - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, - Shanghai Jiao Tong University School of Medicine, Shanghai, China. -FAU - Zhong, Hua -AU - Zhong H -AD - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, - Shanghai Jiao Tong University School of Medicine, Shanghai, China. -LA - eng -PT - Journal Article -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20230706 -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - Nomograms -MH - Retrospective Studies -MH - *Pneumonia/chemically induced/diagnosis/epidemiology -PMC - PMC10469710 -OTO - NOTNLM -OT - checkpoint inhibitor-related pneumonitis (CIP) -OT - immunotherapy -OT - nomogram -OT - non-small-cell lung cancer (NSCLC) -OT - predict -COIS- The authors declare no conflicts of interest. -EDAT- 2023/07/06 06:42 -MHDA- 2023/09/01 06:43 -PMCR- 2023/07/06 -CRDT- 2023/07/06 04:26 -PHST- 2023/05/08 00:00 [revised] -PHST- 2022/12/02 00:00 [received] -PHST- 2023/06/02 00:00 [accepted] -PHST- 2023/09/01 06:43 [medline] -PHST- 2023/07/06 06:42 [pubmed] -PHST- 2023/07/06 04:26 [entrez] -PHST- 2023/07/06 00:00 [pmc-release] -AID - CAM46244 [pii] -AID - 10.1002/cam4.6244 [doi] -PST - ppublish -SO - Cancer Med. 2023 Aug;12(15):15998-16010. doi: 10.1002/cam4.6244. Epub 2023 Jul 6. - -PMID- 32354698 -OWN - NLM -STAT- MEDLINE -DCOM- 20211027 -LR - 20211027 -IS - 1557-3265 (Electronic) -IS - 1078-0432 (Linking) -VI - 26 -IP - 16 -DP - 2020 Aug 15 -TI - PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical - Practice. -PG - 4186-4197 -LID - 10.1158/1078-0432.CCR-20-0798 [doi] -AB - Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced - non-small cell lung cancer (NSCLC). However, most pivotal phase III trials - systematically excluded patients with active brain metastases, precluding the - generalization of the results. Although theoretically restricted from crossing - the blood-brain barrier, the novel pharmacokinetic/pharmacodynamic profiles of - anti-PD-1/PD-L1 drugs have prompted studies to evaluate their activity in - patients with NSCLC with active central nervous system (CNS) involvement. - Encouraging results have suggested that ICI could be active in the CNS in - selected patients with driver-negative advanced NSCLC with high PD-L1 expression - and low CNS disease burden. Single-agent CNS response rates around 30% have been - reported. Beyond this particular setting, anti-PD-1/PD-L1 antibodies have been - evaluated in patients receiving local therapy for brain metastases (BM), - addressing concerns about potential neurologic toxicity risks associated with - radiotherapy, more specifically, radionecrosis (RN). Accordingly, a variety of - clinical and imaging strategies are being appropriately developed to evaluate - tumor response and to rule out pseudoprogression or radionecrosis. Our purpose is - to critically summarize the advances regarding the role of systemic - anti-PD-1/PD-L1 antibodies for the treatment of NSCLC BM. Data were collected - from the PubMed database, reference lists, and abstracts from the latest - scientific meetings. Recent reports suggest anti-PD-1/PD-L1 agents are active in - a subset of patients with NSCLC with BM showing acceptable toxicity. These - advances are expected to change soon the management of these patients but - additional research is required to address concerns regarding radionecrosis and - the appropriate sequencing of local and systemic therapy combinations. -CI - ©2020 American Association for Cancer Research. -FAU - Eguren-Santamaria, Iñaki -AU - Eguren-Santamaria I -AUID- ORCID: 0000-0003-1581-3728 -AD - Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. -AD - University of Navarra, Center for Applied Medical Research, Program of Immunology - and Immunotherapy, Pamplona, Spain. -FAU - Sanmamed, Miguel F -AU - Sanmamed MF -AUID- ORCID: 0000-0002-7295-6074 -AD - Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. -AD - University of Navarra, Center for Applied Medical Research, Program of Immunology - and Immunotherapy, Pamplona, Spain. -AD - IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. -AD - Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. -FAU - Goldberg, Sarah B -AU - Goldberg SB -AD - Yale University School of Medicine and Yale Cancer Center, New Haven, - Connecticut. -FAU - Kluger, Harriet M -AU - Kluger HM -AD - Yale University School of Medicine and Yale Cancer Center, New Haven, - Connecticut. -FAU - Idoate, Miguel A -AU - Idoate MA -AUID- ORCID: 0000-0002-1596-1192 -AD - Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain. -FAU - Lu, Benjamin Y -AU - Lu BY -AD - Yale University School of Medicine and Yale Cancer Center, New Haven, - Connecticut. -FAU - Corral, Jesús -AU - Corral J -AD - Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. -FAU - Schalper, Kurt A -AU - Schalper KA -AD - Department of Pathology, Yale University School of Medicine, New Haven, - Connecticut. -FAU - Herbst, Roy S -AU - Herbst RS -AD - Yale University School of Medicine and Yale Cancer Center, New Haven, - Connecticut. -FAU - Gil-Bazo, Ignacio -AU - Gil-Bazo I -AD - Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. - igbazo@unav.es. -AD - IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. -AD - Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. -AD - University of Navarra, Center for Applied Medical Research, Program of Solid - Tumors, Pamplona, Spain. -LA - eng -GR - P50 CA121974/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20200430 -PL - United States -TA - Clin Cancer Res -JT - Clinical cancer research : an official journal of the American Association for - Cancer Research -JID - 9502500 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - B7-H1 Antigen/*genetics -MH - Brain Neoplasms/drug therapy/genetics/pathology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/immunology/pathology -MH - Central Nervous System Neoplasms/*drug therapy/genetics/immunology/secondary -MH - Humans -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Neoplasm Metastasis -MH - Programmed Cell Death 1 Receptor/*genetics -EDAT- 2020/05/02 06:00 -MHDA- 2021/10/28 06:00 -CRDT- 2020/05/02 06:00 -PHST- 2020/03/02 00:00 [received] -PHST- 2020/03/26 00:00 [revised] -PHST- 2020/04/28 00:00 [accepted] -PHST- 2020/05/02 06:00 [pubmed] -PHST- 2021/10/28 06:00 [medline] -PHST- 2020/05/02 06:00 [entrez] -AID - 1078-0432.CCR-20-0798 [pii] -AID - 10.1158/1078-0432.CCR-20-0798 [doi] -PST - ppublish -SO - Clin Cancer Res. 2020 Aug 15;26(16):4186-4197. doi: - 10.1158/1078-0432.CCR-20-0798. Epub 2020 Apr 30. - -PMID- 39242330 -OWN - NLM -STAT- Publisher -LR - 20240906 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -DP - 2024 Aug 13 -TI - DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage - Small Cell Lung Cancer. -LID - S1525-7304(24)00159-1 [pii] -LID - 10.1016/j.cllc.2024.08.004 [doi] -AB - BACKGROUND: Immunotherapy in combination with chemotherapy is first-line - treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC). - Growing evidence suggests that radiation, specifically stereotactic body - radiation therapy (SBRT), may enhance the immunogenic response as well as - cytoreduce tumor burden. The primary objective of the study is to determine the - progression free survival for patients with newly diagnosed ES-SCLC treated with - combination multisite SBRT and chemo-immunotherapy (carboplatin, etoposide, and - durvalumab). METHODS: This is a multicenter, single arm, phase 2 study. Patients - with treatment-naïve, ES-SCLC will be eligible for this study. Patients will - receive durvalumab 1500mg IV q3w, carboplatin AUC 5 to 6 mg/mL q3w, and etoposide - 80 to 100 mg/m2 on days 1 to 3 q3w for four cycles, followed by durvalumab 1500mg - IV q4w until disease progression or unacceptable toxicity. Ablative radiation - will be delivered 1 to 4 extracranial sites in 3 or 5 fractions, determined by - location, during cycle 2. The primary endpoint is progression-free survival, - measured from day 1 of chemoimmunotherapy. Secondary endpoints include grade ≥3 - toxicity by CTCAE v5.0 within three months of RT, overall survival, response - rate, time to second line systemic therapy, and time to new distant progression. - CONCLUSIONS: Now that immunotherapy is an established part of ES-SCLC management, - it is important to further optimize its use and effect. This study will - investigate the progression-free survival of combined SBRT and - chemo-immunotherapy in patients with ES-SCLC. In addition, the data from this - study may further inform the immunogenic role of SBRT with chemo-immunotherapy, - as well as identify clinical, biological, or radiomic prognostic features. -CI - Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. -FAU - Bestvina, Christine M -AU - Bestvina CM -AD - Department of Medicine, Section of Hematology and Oncology, The University of - Chicago Medicine, Chicago, IL. -FAU - Hara, Jared H L -AU - Hara JHL -AD - Department of Radiation Oncology, The Queen's Medical Center, Honolulu, HI. -FAU - Karrison, Theodore -AU - Karrison T -AD - Department of Public Health Sciences, The University of Chicago, Chicago, IL. -FAU - Bowar, Benjamen -AU - Bowar B -AD - Department of Pharmacy, University of Chicago Medical Center, Chicago, IL. -FAU - Chin, Janet -AU - Chin J -AD - Department of Medicine, Section of Hematology and Oncology, The University of - Chicago Medicine, Chicago, IL. -FAU - Garassino, Marina C -AU - Garassino MC -AD - Department of Medicine, Section of Hematology and Oncology, The University of - Chicago Medicine, Chicago, IL. -FAU - Pitroda, Sean P -AU - Pitroda SP -AD - Department of Radiation and Cellular Oncology, The University of Chicago - Medicine, Chicago, IL. -FAU - Thawani, Rajat -AU - Thawani R -AD - Department of Medicine, Section of Hematology and Oncology, The University of - Chicago Medicine, Chicago, IL. -FAU - Vokes, Everett E -AU - Vokes EE -AD - Department of Medicine, Section of Hematology and Oncology, The University of - Chicago Medicine, Chicago, IL. -FAU - Gan, Gregory -AU - Gan G -AD - Department of Radiation Oncology, Department of Cancer Biology, University of - Kansas Medical Center, Kansas City, KS. -FAU - Zhang, Jun -AU - Zhang J -AD - Department of Internal Medicine, Division of Medical Oncology; Department of - Cancer Biology, University of Kansas Medical Center, Kansas City, KS. -FAU - Baschnagel, Andrew M -AU - Baschnagel AM -AD - Department of Human Oncology, University of Wisconsin School of Medicine and - Public Health, Madison, WI. -FAU - Campbell, Toby C -AU - Campbell TC -AD - Department of Medicine, University of Wisconsin-Madison, Madison, WI. -FAU - Chmura, Steven -AU - Chmura S -AD - Department of Radiation and Cellular Oncology, The University of Chicago - Medicine, Chicago, IL. -FAU - Juloori, Aditya -AU - Juloori A -AD - Department of Radiation and Cellular Oncology, The University of Chicago - Medicine, Chicago, IL. Electronic address: ajuloori@radonc.uchicago.edu. -LA - eng -PT - Journal Article -DEP - 20240813 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -SB - IM -OTO - NOTNLM -OT - Chemoimmunotherapy -OT - Durvalumab -OT - Extensive stage small cell lung cancer -OT - Immunotherapy -OT - Stereotactic Body Radiation Therapy -EDAT- 2024/09/07 14:42 -MHDA- 2024/09/07 14:42 -CRDT- 2024/09/06 22:04 -PHST- 2024/05/31 00:00 [received] -PHST- 2024/08/09 00:00 [revised] -PHST- 2024/08/09 00:00 [accepted] -PHST- 2024/09/07 14:42 [medline] -PHST- 2024/09/07 14:42 [pubmed] -PHST- 2024/09/06 22:04 [entrez] -AID - S1525-7304(24)00159-1 [pii] -AID - 10.1016/j.cllc.2024.08.004 [doi] -PST - aheadofprint -SO - Clin Lung Cancer. 2024 Aug 13:S1525-7304(24)00159-1. doi: - 10.1016/j.cllc.2024.08.004. - -PMID- 32046999 -OWN - NLM -STAT- MEDLINE -DCOM- 20210913 -LR - 20210913 -IS - 1557-3265 (Electronic) -IS - 1078-0432 (Print) -IS - 1078-0432 (Linking) -VI - 26 -IP - 12 -DP - 2020 Jun 15 -TI - Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term - Response to PD-(L)1 Blockade in NSCLC. -PG - 2849-2858 -LID - 10.1158/1078-0432.CCR-19-3418 [doi] -AB - PURPOSE: Treatment with PD-(L)1 blockade can produce remarkably durable responses - in patients with non-small cell lung cancer (NSCLC). However, a significant - fraction of long-term responders ultimately progress and predictors of late - progression are unknown. We hypothesized that circulating tumor DNA (ctDNA) - analysis of long-term responders to PD-(L)1 blockade may differentiate those who - will achieve ongoing benefit from those at risk of eventual progression. - EXPERIMENTAL DESIGN: In patients with advanced NSCLC achieving long-term benefit - from PD-(L)1 blockade (progression-free survival ≥ 12 months), plasma was - collected at a surveillance timepoint late during/after treatment to interrogate - ctDNA by Cancer Personalized Profiling by Deep Sequencing. Tumor tissue was - available for 24 patients and was profiled by whole-exome sequencing (n = 18) or - by targeted sequencing (n = 6). RESULTS: Thirty-one patients with NSCLC with - long-term benefit to PD-(L)1 blockade were identified, and ctDNA was analyzed in - surveillance blood samples collected at a median of 26.7 months after initiation - of therapy. Nine patients also had baseline plasma samples available, and all had - detectable ctDNA prior to therapy initiation. At the surveillance timepoint, 27 - patients had undetectable ctDNA and 25 (93%) have remained progression-free; in - contrast, all 4 patients with detectable ctDNA eventually progressed [Fisher P < - 0.0001; positive predictive value = 1, 95% confidence interval (CI), 0.51-1; - negative predictive value = 0.93 (95% CI, 0.80-0.99)]. CONCLUSIONS: ctDNA - analysis can noninvasively identify minimal residual disease in patients with - long-term responses to PD-(L)1 blockade and predict the risk of eventual - progression. If validated, ctDNA surveillance may facilitate personalization of - the duration of immune checkpoint blockade and enable early intervention in - patients at high risk for progression. -CI - ©2020 American Association for Cancer Research. -FAU - Hellmann, Matthew D -AU - Hellmann MD -AUID- ORCID: 0000-0002-2670-9777 -AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New - York. diehn@stanford.edu arasha@stanford.edu hellmanm@mskcc.org. -AD - Weill Cornell School of Medicine, New York, New York. -AD - Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer - Center, New York, New York. -AD - Parker Center for Cancer Immunotherapy, San Francisco, California. -FAU - Nabet, Barzin Y -AU - Nabet BY -AUID- ORCID: 0000-0002-4824-3533 -AD - Department of Radiation Oncology, Stanford University, Stanford, California. -AD - Stanford Cancer Institute, Stanford University, Stanford, California. -FAU - Rizvi, Hira -AU - Rizvi H -AD - Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer - Center, New York, New York. -FAU - Chaudhuri, Aadel A -AU - Chaudhuri AA -AUID- ORCID: 0000-0003-3115-3061 -AD - Department of Radiation Oncology, Washington University School of Medicine, St. - Louis, Missouri. -FAU - Wells, Daniel K -AU - Wells DK -AD - Parker Center for Cancer Immunotherapy, San Francisco, California. -FAU - Dunphy, Mark P S -AU - Dunphy MPS -AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New - York. -FAU - Chabon, Jacob J -AU - Chabon JJ -AD - Department of Radiation Oncology, Stanford University, Stanford, California. -AD - Stanford Cancer Institute, Stanford University, Stanford, California. -FAU - Liu, Chih Long -AU - Liu CL -AD - Stanford Cancer Institute, Stanford University, Stanford, California. -AD - Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford - University, Stanford, California. -FAU - Hui, Angela B -AU - Hui AB -AD - Department of Radiation Oncology, Stanford University, Stanford, California. -AD - Stanford Cancer Institute, Stanford University, Stanford, California. -FAU - Arbour, Kathryn C -AU - Arbour KC -AUID- ORCID: 0000-0001-5951-8427 -AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New - York. -AD - Weill Cornell School of Medicine, New York, New York. -AD - Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer - Center, New York, New York. -FAU - Luo, Jia -AU - Luo J -AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New - York. -FAU - Preeshagul, Isabel R -AU - Preeshagul IR -AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New - York. -FAU - Moding, Everett J -AU - Moding EJ -AUID- ORCID: 0000-0001-7913-5351 -AD - Department of Radiation Oncology, Stanford University, Stanford, California. -AD - Stanford Cancer Institute, Stanford University, Stanford, California. -FAU - Almanza, Diego -AU - Almanza D -AD - Department of Radiation Oncology, Stanford University, Stanford, California. -AD - Stanford Cancer Institute, Stanford University, Stanford, California. -FAU - Bonilla, Rene F -AU - Bonilla RF -AD - Department of Radiation Oncology, Stanford University, Stanford, California. -FAU - Sauter, Jennifer L -AU - Sauter JL -AUID- ORCID: 0000-0001-6987-2294 -AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New - York. -FAU - Choi, Hyejin -AU - Choi H -AD - Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering - Cancer Center, New York, New York. -FAU - Tenet, Megan -AU - Tenet M -AD - Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer - Center, New York, New York. -FAU - Abu-Akeel, Mohsen -AU - Abu-Akeel M -AD - Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering - Cancer Center, New York, New York. -FAU - Plodkowski, Andrew J -AU - Plodkowski AJ -AUID- ORCID: 0000-0002-3772-370X -AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New - York. -FAU - Perez Johnston, Rocio -AU - Perez Johnston R -AD - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New - York. -FAU - Yoo, Christopher H -AU - Yoo CH -AUID- ORCID: 0000-0003-2132-8956 -AD - Department of Radiation Oncology, Stanford University, Stanford, California. -FAU - Ko, Ryan B -AU - Ko RB -AUID- ORCID: 0000-0002-2123-9702 -AD - Department of Radiation Oncology, Stanford University, Stanford, California. -FAU - Stehr, Henning -AU - Stehr H -AD - Department of Pathology, Stanford University, Stanford, California. -FAU - Gojenola, Linda -AU - Gojenola L -AD - Department of Pathology, Stanford University, Stanford, California. -FAU - Wakelee, Heather A -AU - Wakelee HA -AD - Stanford Cancer Institute, Stanford University, Stanford, California. -AD - Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford - University, Stanford, California. -FAU - Padda, Sukhmani K -AU - Padda SK -AD - Stanford Cancer Institute, Stanford University, Stanford, California. -AD - Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford - University, Stanford, California. -FAU - Neal, Joel W -AU - Neal JW -AD - Stanford Cancer Institute, Stanford University, Stanford, California. -AD - Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford - University, Stanford, California. -FAU - Chaft, Jamie E -AU - Chaft JE -AUID- ORCID: 0000-0002-5838-9982 -AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New - York. -AD - Weill Cornell School of Medicine, New York, New York. -AD - Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer - Center, New York, New York. -FAU - Kris, Mark G -AU - Kris MG -AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New - York. -AD - Weill Cornell School of Medicine, New York, New York. -AD - Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer - Center, New York, New York. -FAU - Rudin, Charles M -AU - Rudin CM -AUID- ORCID: 0000-0001-5204-3465 -AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New - York. -AD - Weill Cornell School of Medicine, New York, New York. -AD - Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer - Center, New York, New York. -FAU - Merghoub, Taha -AU - Merghoub T -AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New - York. -AD - Weill Cornell School of Medicine, New York, New York. -AD - Parker Center for Cancer Immunotherapy, San Francisco, California. -AD - Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering - Cancer Center, New York, New York. -FAU - Li, Bob T -AU - Li BT -AUID- ORCID: 0000-0001-6661-8733 -AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New - York. -AD - Weill Cornell School of Medicine, New York, New York. -AD - Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer - Center, New York, New York. -FAU - Alizadeh, Ash A -AU - Alizadeh AA -AUID- ORCID: 0000-0002-5153-5625 -AD - Stanford Cancer Institute, Stanford University, Stanford, California. - diehn@stanford.edu arasha@stanford.edu hellmanm@mskcc.org. -AD - Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford - University, Stanford, California. -FAU - Diehn, Maximilian -AU - Diehn M -AD - Department of Radiation Oncology, Stanford University, Stanford, California. - diehn@stanford.edu arasha@stanford.edu hellmanm@mskcc.org. -AD - Stanford Cancer Institute, Stanford University, Stanford, California. -AD - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, - Stanford, California. -LA - eng -GR - DP2 CA186569/CA/NCI NIH HHS/United States -GR - R25 CA180993/CA/NCI NIH HHS/United States -GR - T32 CA009207/CA/NCI NIH HHS/United States -GR - P30 CA008748/CA/NCI NIH HHS/United States -GR - KL2 TR002385/TR/NCATS NIH HHS/United States -GR - R01 CA188298/CA/NCI NIH HHS/United States -GR - R25 CA020449/CA/NCI NIH HHS/United States -GR - T32 CA009302/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20200211 -PL - United States -TA - Clin Cancer Res -JT - Clinical cancer research : an official journal of the American Association for - Cancer Research -JID - 9502500 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -RN - 0 (CD274 protein, human) -RN - 0 (Circulating Tumor DNA) -SB - IM -MH - Antineoplastic Agents, Immunological/*adverse effects -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - Biomarkers, Tumor/*blood/genetics -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology -MH - Circulating Tumor DNA/*blood/genetics -MH - Disease Progression -MH - Drug-Related Side Effects and Adverse Reactions/blood/*diagnosis/etiology -MH - Follow-Up Studies -MH - Humans -MH - Lung Neoplasms/*drug therapy/pathology -MH - Prognosis -PMC - PMC7299781 -MID - NIHMS1560746 -EDAT- 2020/02/13 06:00 -MHDA- 2021/09/14 06:00 -PMCR- 2020/12/15 -CRDT- 2020/02/13 06:00 -PHST- 2019/10/17 00:00 [received] -PHST- 2020/02/05 00:00 [revised] -PHST- 2020/02/06 00:00 [accepted] -PHST- 2020/02/13 06:00 [pubmed] -PHST- 2021/09/14 06:00 [medline] -PHST- 2020/02/13 06:00 [entrez] -PHST- 2020/12/15 00:00 [pmc-release] -AID - 1078-0432.CCR-19-3418 [pii] -AID - 10.1158/1078-0432.CCR-19-3418 [doi] -PST - ppublish -SO - Clin Cancer Res. 2020 Jun 15;26(12):2849-2858. doi: - 10.1158/1078-0432.CCR-19-3418. Epub 2020 Feb 11. - -PMID- 32220780 -OWN - NLM -STAT- MEDLINE -DCOM- 20201123 -LR - 20201123 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 130 -DP - 2020 May -TI - First-line pembrolizumab in advanced non-small cell lung cancer patients with - poor performance status. -PG - 155-167 -LID - S0959-8049(20)30096-4 [pii] -LID - 10.1016/j.ejca.2020.02.023 [doi] -AB - BACKGROUND: Pembrolizumab is the first-line standard of care for advanced - non-small cell lung cancer (NSCLC) with a PD-L1 tumour proportion score - (TPS) ≥ 50%. Eastern Cooperative Oncology Group performance status (PS) 2 - patients may receive pembrolizumab, despite the absence of sustaining evidence. - PATIENTS AND METHODS: GOIRC-2018-01 is a multicentre, retrospective, - observational study. PS 2 NSCLC patients with a PD-L1 TPS ≥50% receiving - first-line pembrolizumab from June 2017 to December 2018 at 21 Italian - institutions were included. Clinical-pathological characteristics were correlated - with disease response and survival outcomes; adverse events were recorded. The - primary objective was 6-months progression-free rate (6-months PFR). RESULTS: One - hundred fifty-three patients (median age 70 years) were enrolled. At a median - follow-up of 18.2 months, median progression-free survival (PFS) and overall - survival (OS) were 2.4 (95% confidence interval, 95% CI, 1.6-2.5) and 3.0 months - (95% CI 2.4-3.5), respectively. 6-months PFR was 27% (95% CI 21-35%). Patients - with a PS 2 determined by comorbidities (n = 41) had significantly better - outcomes compared with disease burden-induced PS 2 (n = 112). Indeed, 6-months - PFR was 49% versus 19%, median PFS 5.6 versus 1.8 months and OS 11.8 versus 2.8 - months, respectively. Additional potential prognostic factors (radiotherapy, - antibiotics, steroids received before pembrolizumab) correlated with clinical - outcomes. The determinant of PS 2 resulted the only factor independently - impacting on both PFS and OS. No toxicity issues emerged. CONCLUSIONS: Outcomes - of PS 2 NSCLC patients with PD-L1 TPS ≥50% receiving first-line pembrolizumab - were globally dismal but strongly dependent on the reason conditioning the poor - PS itself. -CI - Copyright © 2020 Elsevier Ltd. All rights reserved. -FAU - Facchinetti, Francesco -AU - Facchinetti F -AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Université - Paris-Saclay, Institut Gustave Roussy, Inserm, Biomarqueurs Prédictifs et - Nouvelles Stratégies Thérapeutiques en Oncologie, 94800, Villejuif, France. - Electronic address: francescofacchietti2@gmail.com. -FAU - Mazzaschi, Giulia -AU - Mazzaschi G -AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. -FAU - Barbieri, Fausto -AU - Barbieri F -AD - Division of Medical Oncology, Azienda Ospedaliero-Universitaria Policlinico, - Modena, Italy. -FAU - Passiglia, Francesco -AU - Passiglia F -AD - Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, - Italy. -FAU - Mazzoni, Francesca -AU - Mazzoni F -AD - Medical Oncology Unit, Department of Oncology, Careggi University Hospital, - Firenze, Italy. -FAU - Berardi, Rossana -AU - Berardi R -AD - Oncology Clinic, Università Politecnica Delle Marche, Ospedali Riuniti di Ancona, - Ancona, Italy. -FAU - Proto, Claudia -AU - Proto C -AD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, - Milan, Italy. -FAU - Cecere, Fabiana Letizia -AU - Cecere FL -AD - IRCCS Regina Elena National Cancer Institute, Rome, Italy. -FAU - Pilotto, Sara -AU - Pilotto S -AD - Section of Medical Oncology, Department of Medicine, University of Verona, - Verona, Italy. -FAU - Scotti, Vieri -AU - Scotti V -AD - Radiation Therapy Unit, Department of Oncology, Careggi University Hospital, - Firenze, Italy. -FAU - Rossi, Sabrina -AU - Rossi S -AD - Department of Oncology & Hematology, Humanitas Clinical & Research Center, - Rozzano, Milan, Italy. -FAU - Del Conte, Alessandro -AU - Del Conte A -AD - Medical Oncology and Immuno-Related Tumors, Centro di Riferimento Oncologico di - Aviano (CRO) IRCCS, Aviano, Italy. -FAU - Vita, Emanuele -AU - Vita E -AD - Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino - Gemelli, IRCCS, Università Cattolica Del Sacro Cuore, Rome, Italy. -FAU - Bennati, Chiara -AU - Bennati C -AD - Onco-Hematology Department, S Maria Delle Croci Hospital Ravenna, Italy. -FAU - Ardizzoni, Andrea -AU - Ardizzoni A -AD - Department of Oncology, Policlinico S. Orsola-Malpighi, University of Bologna, - Bologna, Italy. -FAU - Cerea, Giulio -AU - Cerea G -AD - Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy. -FAU - Migliorino, Maria Rita -AU - Migliorino MR -AD - Pneumologia Oncologica, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy. -FAU - Sala, Elisa -AU - Sala E -AD - Oncology Unit, Ospedale S. Gerardo, Monza, Italy. -FAU - Camerini, Andrea -AU - Camerini A -AD - Medical Oncology, Azienda USL Toscana Nord-ovest, Ospedale Versilia, Italy. -FAU - Bearz, Alessandra -AU - Bearz A -AD - Medical Oncology and Immuno-Related Tumors, Centro di Riferimento Oncologico di - Aviano (CRO) IRCCS, Aviano, Italy. -FAU - De Carlo, Elisa -AU - De Carlo E -AD - Medical Oncology and Immuno-Related Tumors, Centro di Riferimento Oncologico di - Aviano (CRO) IRCCS, Aviano, Italy. -FAU - Zanelli, Francesca -AU - Zanelli F -AD - Oncology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio - Emilia, Italy. -FAU - Guaitoli, Giorgia -AU - Guaitoli G -AD - Division of Medical Oncology, Azienda Ospedaliero-Universitaria Policlinico, - Modena, Italy. -FAU - Garassino, Marina Chiara -AU - Garassino MC -AD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, - Milan, Italy. -FAU - Ciccone, Lucia Pia -AU - Ciccone LP -AD - Radiation Therapy Unit, Department of Oncology, Careggi University Hospital, - Firenze, Italy. -FAU - Sartori, Giulia -AU - Sartori G -AD - Section of Medical Oncology, Department of Medicine, University of Verona, - Verona, Italy. -FAU - Toschi, Luca -AU - Toschi L -AD - Department of Oncology & Hematology, Humanitas Clinical & Research Center, - Rozzano, Milan, Italy. -FAU - Dall'Olio, Filippo Gustavo -AU - Dall'Olio FG -AD - Department of Oncology, Policlinico S. Orsola-Malpighi, University of Bologna, - Bologna, Italy. -FAU - Landi, Lorenza -AU - Landi L -AD - Onco-Hematology Department, S Maria Delle Croci Hospital Ravenna, Italy. -FAU - Pizzutilo, Elio Gregory -AU - Pizzutilo EG -AD - Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy; - Department of Oncology and Hemato-Oncology, Università Degli Studi di Milano, - Milan, Italy. -FAU - Bartoli, Gabriele -AU - Bartoli G -AD - Pneumologia Oncologica, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy. -FAU - Baldessari, Cinzia -AU - Baldessari C -AD - Division of Medical Oncology, Azienda Ospedaliero-Universitaria Policlinico, - Modena, Italy. -FAU - Novello, Silvia -AU - Novello S -AD - Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, - Italy. -FAU - Bria, Emilio -AU - Bria E -AD - Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino - Gemelli, IRCCS, Università Cattolica Del Sacro Cuore, Rome, Italy. -FAU - Cortinovis, Diego Luigi -AU - Cortinovis DL -AD - Oncology Unit, Ospedale S. Gerardo, Monza, Italy. -FAU - Rossi, Giulio -AU - Rossi G -AD - Pathology Unit, S. Maria Delle Croci Hospital, Ravenna, Italy. -FAU - Rossi, Antonio -AU - Rossi A -AD - Division of Medical Oncology, Fondazione IRCCS Casa Sollievo Della Sofferenza, - San Giovanni Rotondo (FG), Italy. -FAU - Banna, Giuseppe Luigi -AU - Banna GL -AD - United Lincolnshire Hospitals NHS Trust, Lincoln, UK. -FAU - Camisa, Roberta -AU - Camisa R -AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy. -FAU - Di Maio, Massimo -AU - Di Maio M -AD - Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Torino, - Italy. -FAU - Tiseo, Marcello -AU - Tiseo M -AD - Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Department of - Medicine and Surgery, University of Parma, Parma, Italy. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20200325 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal, Humanized/pharmacology/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Female -MH - Humans -MH - Lung Neoplasms/*drug therapy -MH - Male -MH - Programmed Cell Death 1 Receptor/*therapeutic use -MH - Retrospective Studies -OTO - NOTNLM -OT - ECOG PS 2 -OT - Immune checkpoint inhibitors -OT - Immunotherapy -OT - NSCLC -OT - PD-1 -COIS- Conflict of interest statement F.F. declares he has attended editorial activities - sponsored by Roche and BMS. F.P. declares having attended advisory boards and - having performed consultant activities from MSD. C.P. declares honoraria and - travel accommodation from BMS; travel accommodation from MSD: advisory board and - travel accommodation from Roche; speaker's bureau from Eli Lilly. S.P. received - honoraria or speakers’ fee from AstraZeneca, BMS, Boehringer Ingelheim, MSD, - Roche and Istituto Gentili. V.S. declares speakers’ fees and advisory boards from - MSD. A.D.C. declares speakers’ fees from MSD. A.A. declares advisory board and - research grants from BMS; advisory board from MSD; speakers' fees from Eli Lilly; - advisory boards from Boehringer Ingelheim; speakers’ fees from Pfizer; research - grants from Celgene. A.B. declares advisor and speaker services for Takeda, - Boehringer Ingelheim, Novartis, Pfizer, MSD, travel grants from Jansen, Roche, - MSD, BMS. M.C.G. declares personal financial interests with the following - organizations: AstraZeneca, MSD International GmbH, BMS, Boehringer Ingelheim - Italia S.p.A, Celgene, Eli Lilly, Ignyta, Incyte, Inivata, MedImmune, Novartis, - Pfizer, Roche and Takeda. S.N. declares speaker bureau/advisory boards for - AstraZeneca, Boehringer Ingelheim, MSD, Pfizer, Bayer, Takeda, Abbvie, Eli Lilly, - Roche, BMS. E.B. declares consulting, scientific advisory board, speaker's fees - from Roche, MSD, AstraZeneca, Pfizer, Eli Lilly, BMS, Novartis; research funding - from AstraZeneca and Roche. A.R. declares advisory boards and honoraria as - speaker's bureau from MSD, Eli Lilly, AstraZeneca, Roche, Boehringer Ingelheim. - M.D.M. received honoraria and had roles as consultant or advisor for AstraZeneca, - Eli Lilly, BMS, MSD and Janssen. M.T. declares advisory boards and speakers’ fees - from AstraZeneca, Pfizer, Eli Lilly, BMS, Novartis, Roche, MSD, Boehringer - Ingelheim, Otsuka, Takeda, Pierre Fabre; research grants from AstraZeneca and - Boehringer Ingelheim. All other authors declare they have no conflict of interest - to disclose. -EDAT- 2020/03/30 06:00 -MHDA- 2020/11/24 06:00 -CRDT- 2020/03/30 06:00 -PHST- 2020/01/12 00:00 [received] -PHST- 2020/02/20 00:00 [revised] -PHST- 2020/02/20 00:00 [accepted] -PHST- 2020/03/30 06:00 [pubmed] -PHST- 2020/11/24 06:00 [medline] -PHST- 2020/03/30 06:00 [entrez] -AID - S0959-8049(20)30096-4 [pii] -AID - 10.1016/j.ejca.2020.02.023 [doi] -PST - ppublish -SO - Eur J Cancer. 2020 May;130:155-167. doi: 10.1016/j.ejca.2020.02.023. Epub 2020 - Mar 25. - -PMID- 33552685 -OWN - NLM -STAT- MEDLINE -DCOM- 20210728 -LR - 20240809 -IS - 2162-402X (Electronic) -IS - 2162-4011 (Print) -IS - 2162-4011 (Linking) -VI - 10 -IP - 1 -DP - 2021 Jan 28 -TI - Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy - in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) - ≥50%: real-world data. -PG - 1865653 -LID - 10.1080/2162402X.2020.1865653 [doi] -LID - 1865653 -AB - Both pembrolizumab (P) and combination of pembrolizumab with platinum-based - chemotherapy (PCT) represent standard 1(st)-line options for advanced non-small - cell lung cancer (aNSCLC) with PD-L1 tumor proportion score (TPS) ≥50%. The two - strategies have never been compared in a randomized trial. 256 consecutive - patients with EGFR/ALK/ROS1-wild-type PD-L1 TPS ≥50% aNSCLC receiving P (group P, - n = 203) or PCT (group PCT, n = 53) as a 1(st)-line treatment were identified in - the electronic databases of 4 Israeli cancer centers. Time-to-treatment - discontinuation (TTD) and overall survival (OS) were assessed. Baseline - characteristics were well balanced, except for age and ECOG PS differences in - favor of group PCT. Median (m)TTD was 4.9 months (mo) (95% CI, 3.1-7.6) vs 8.0mo - (95% CI, 4.7-15.6) (p-0.09), mOS was 12.5mo (95% CI, 9.8-16.4) vs 20.4mo (95% CI, - 10.8-NR) (p-0.08), with P and PCT, respectively. In the propensity score matching - analysis (n = 106; 53 patients in each group matched for age, sex and ECOG PS), - mTTD was 7.9mo (95% CI, 2.8-12.7) vs 8.0mo (95% CI, 4.7-15.6) (p-0.41), and mOS - was 13.3mo (95% CI, 6.8-20.3) vs 20.4mo (95% CI, 10.8-NR) (p-0.18), with P and - PCT, respectively. Among various subgroups of patients examined, only in females - (n = 86) mOS differed significantly between treatments (10.2mo (95% CI, 6.8-17.2) - with P vs NR (95% CI, 11.4-NR) with PCT; p-0.02). In the real-world setting, no - statistically significant differences in long-term outcomes with P vs PCT were - observed; a prospective randomized trial addressing the comparative efficacy of P - and PCT in different patient subgroups is highly anticipated.List of - abbreviations: AE - adverse events; ALK - anaplastic lymphoma kinase gene; ALT - - alanine aminotransferase; (a)NSCLC - (advanced) non-small cell lung cancer; AST - - aspartate aminotransferase; BRAF - v-Raf murine sarcoma viral oncogene homolog B; - BRCA2 - BReast CAncer gene 2; c-Met - tyrosine-protein kinase Met; CTCAE, v. 4.03 - - Common Terminology Criteria for Adverse Events, version 4.03; CTLA-4 - - cytotoxic T-lymphocyte-associated protein 4; ECOG PS - Eastern Cooperative - Oncology Group performance status; EGFR - epidermal growth factor receptor gene; - FISH - fluorescent in situ hybridization; HER2 - human epidermal growth factor - receptor 2; IC - tumor-infiltrating immune cells; ICI - immune check-point - inhibitors; IHC - immunohistochemistry; IQR - interquartile range; irAE - immune - related adverse events; ISCORT - Israeli Society for Clinical Oncology and - Radiotherapy; KRAS - Kirsten rat sarcoma viral oncogene homolog; (m)TTD -(median) - time-to-treatment discontinuation; mo - months; (m)OS - (median) overall - survival; (m)PFS - (median) progression-free survival; muts/Mb - mutations per - megabase; NA - not specified/not available; NOS - not otherwise specified; NR - - not reported/not reached; ORR - objective response rate; P - pembrolizumab; PCR - - polymerase chain reaction; PCT - combination of pembrolizumab with platinum-based - chemotherapy; PD - progression of disease; PD-1 - programmed cell death-1; PD-L1 - - programmed cell death ligand-1; pts - patients; RET - proto-oncogene RET; ROS1 - - proto-oncogene tyrosine-protein kinase ROS1; SD - standard deviation; STK11 - - serine/threonine kinase 11; TC - tumor cells; TMB - Tumor mutation burden; TPS - - tumor proportion score. -CI - © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. -FAU - Dudnik, Elizabeth -AU - Dudnik E -AUID- ORCID: 0000-0001-6971-3576 -AD - Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Beilinson - Campus, Petah Tikva, Israel. -AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. -FAU - Moskovitz, Mor -AU - Moskovitz M -AD - Oncology Department, Thoracic Cancer Service, Rambam Health Care Campus, Haifa, - Israel. -FAU - Rottenberg, Yakir -AU - Rottenberg Y -AD - Oncology Department, Hadassah Medical Center, Jerusalem, Israel. -AD - Hebrew University of Jerusalem, Hadassah Medical Center, Jerusalem, Israel. -FAU - Lobachov, Anastasiya -AU - Lobachov A -AD - Thoracic Cancer Service, Institute of Oncology, Sheba Medical Center, Ramat Gan, - Israel. -FAU - Mandelboim, Rinat -AU - Mandelboim R -AD - Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Beilinson - Campus, Petah Tikva, Israel. -FAU - Shochat, Tzippy -AU - Shochat T -AD - Statistical Consulting Unit, Rabin Medical Center, Beilinson Campus, Petah Tikva, - Israel. -FAU - Urban, Damien -AU - Urban D -AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. -AD - Thoracic Cancer Service, Institute of Oncology, Sheba Medical Center, Ramat Gan, - Israel. -FAU - Wollner, Mira -AU - Wollner M -AD - Oncology Department, Thoracic Cancer Service, Rambam Health Care Campus, Haifa, - Israel. -FAU - Nechushtan, Hovav -AU - Nechushtan H -AD - Oncology Department, Hadassah Medical Center, Jerusalem, Israel. -AD - Hebrew University of Jerusalem, Hadassah Medical Center, Jerusalem, Israel. -FAU - Rotem, Ofer -AU - Rotem O -AD - Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Beilinson - Campus, Petah Tikva, Israel. -FAU - Zer, Alona -AU - Zer A -AD - Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Beilinson - Campus, Petah Tikva, Israel. -AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. -FAU - Daher, Sameh -AU - Daher S -AD - Thoracic Cancer Service, Institute of Oncology, Sheba Medical Center, Ramat Gan, - Israel. -FAU - Bar, Jair -AU - Bar J -AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. -AD - Thoracic Cancer Service, Institute of Oncology, Sheba Medical Center, Ramat Gan, - Israel. -CN - Israel Lung Cancer Group -LA - eng -PT - Journal Article -DEP - 20210128 -PL - United States -TA - Oncoimmunology -JT - Oncoimmunology -JID - 101570526 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (B7-H1 Antigen) -RN - 0 (MAS1 protein, human) -RN - 0 (Proto-Oncogene Mas) -RN - 0 (Proto-Oncogene Proteins) -RN - 49DFR088MY (Platinum) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized -MH - B7-H1 Antigen/genetics -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Female -MH - Humans -MH - In Situ Hybridization, Fluorescence -MH - *Lung Neoplasms/drug therapy -MH - Platinum -MH - Prospective Studies -MH - Proto-Oncogene Mas -MH - Proto-Oncogene Proteins/genetics -PMC - PMC7849771 -OTO - NOTNLM -OT - PD-L1 -OT - Pembrolizumab -OT - lung cancer -OT - pembrolizumab chemotherapy -OT - real world -EDAT- 2021/02/09 06:00 -MHDA- 2021/07/29 06:00 -PMCR- 2021/01/28 -CRDT- 2021/02/08 05:40 -PHST- 2021/02/08 05:40 [entrez] -PHST- 2021/02/09 06:00 [pubmed] -PHST- 2021/07/29 06:00 [medline] -PHST- 2021/01/28 00:00 [pmc-release] -AID - 1865653 [pii] -AID - 10.1080/2162402X.2020.1865653 [doi] -PST - epublish -SO - Oncoimmunology. 2021 Jan 28;10(1):1865653. doi: 10.1080/2162402X.2020.1865653. - -PMID- 34087538 -OWN - NLM -STAT- MEDLINE -DCOM- 20210803 -LR - 20220531 -IS - 1872-8332 (Electronic) -IS - 0169-5002 (Linking) -VI - 158 -DP - 2021 Aug -TI - Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival - outcomes in advanced non-small cell lung cancer patients treated with - Anti-PD-1/PD-L1 monotherapy. -PG - 1-8 -LID - S0169-5002(21)00410-4 [pii] -LID - 10.1016/j.lungcan.2021.05.030 [doi] -AB - BACKGROUND: Systemic inflammation plays an important role in carcinogenesis and - is associated with overall survival in patients with different cancer types, - including those treated with immune checkpoint blockade (ICB). Serum Amyloid A - (SAA) is an acute-phase protein and a marker of persistent inflammation. We - hypothesized that circulating SAA may predict outcomes in advanced non-small cell - lung (aNSCLC) patients treated with PD-1/PD-L1 ICB. MATERIALS AND METHODS: This - retrospective study included 91 aNSCLC patients who received anti-PD-(L)1 - monotherapy in Sun Yat-sen University Cancer Center (Guangzhou, China) between - August 2016 and June 2018. We examined the impact of circulating SAA at baseline - and 8 (±2) weeks later on overall survival (OS). X-tile program was used to - determine the cut-off values which optimized the significance of the split - between Kaplan-Meier survival curves. Kaplan-Meier methodology and Cox regression - analyses were conducted for survival analyses. RESULTS: The optimal cut-off value - of baseline SAA for OS stratification was 137.6 mg/L. In univariate analysis, - both high level of baseline SAA (hazard ratio [HR], 2.76; 95% confidence interval - [CI], 1.47-5.18; P = 0.002) and lack of early SAA descent (HR, 1.51; 95% CI, - 1.11-2.06; P = 0.009) were significantly associated with inferior OS. In - multivariate analysis, gender, smoking status, performance status, liver - metastasis, neutrophil-to-lymphocyte ratio, baseline SAA and early changes in SAA - independently predicted OS (all with P < 0.05). A combined baseline SAA ≥ 137.6 - mg/L and without early SAA descent identified a small cohort with remarkably - worse OS (median, 3.2 months). CONCLUSIONS: Both high baseline and lack of early - decline in circulating SAA are significantly associated with inferior outcomes in - aNSCLC patients treated with PD-1/PD-L1 ICB. Combined these two SAA indexes - provided improved risk stratification. The prognostic value of this simple, - readily-available, and cost-effective biomarker warrants larger, prospective - validation before definitive recommendation can be made. -CI - Copyright © 2021. Published by Elsevier B.V. -FAU - He, Li-Na -AU - He LN -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Fu, Sha -AU - Fu S -AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene - Regulation, Pathology Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen - University, Guangzhou, China. -FAU - Zhang, Xuanye -AU - Zhang X -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Hu, Qiaozhen -AU - Hu Q -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Du, Wei -AU - Du W -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Li, Haifeng -AU - Li H -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Chen, Tao -AU - Chen T -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Nuclear - Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Chen, Chen -AU - Chen C -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Radiation - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Jiang, Yongluo -AU - Jiang Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Nuclear - Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Zhou, Yixin -AU - Zhou Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of VIP - Region, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Lin, Zuan -AU - Lin Z -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Clinical - Research, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Yang, Yunpeng -AU - Yang Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Huang, Yan -AU - Huang Y -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Zhao, Hongyun -AU - Zhao H -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Clinical - Research, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Fang, Wenfeng -AU - Fang W -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. -FAU - Zhang, Li -AU - Zhang L -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic - address: zhangli6@mail.sysu.edu.cn. -FAU - Hong, Shaodong -AU - Hong S -AD - State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative - Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical - Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic - address: hongshd@sysucc.org.cn. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20210528 -PL - Ireland -TA - Lung Cancer -JT - Lung cancer (Amsterdam, Netherlands) -JID - 8800805 -RN - 0 (B7-H1 Antigen) -RN - 0 (Serum Amyloid A Protein) -SB - IM -MH - B7-H1 Antigen -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - China -MH - Humans -MH - *Lung Neoplasms/drug therapy -MH - Prospective Studies -MH - Retrospective Studies -MH - Serum Amyloid A Protein -OTO - NOTNLM -OT - Biomarker -OT - Immunotherapy -OT - Non-small cell lung cancer -OT - Overall survival -OT - Serum amyloid A -EDAT- 2021/06/05 06:00 -MHDA- 2021/08/04 06:00 -CRDT- 2021/06/04 20:18 -PHST- 2021/03/29 00:00 [received] -PHST- 2021/05/18 00:00 [revised] -PHST- 2021/05/25 00:00 [accepted] -PHST- 2021/06/05 06:00 [pubmed] -PHST- 2021/08/04 06:00 [medline] -PHST- 2021/06/04 20:18 [entrez] -AID - S0169-5002(21)00410-4 [pii] -AID - 10.1016/j.lungcan.2021.05.030 [doi] -PST - ppublish -SO - Lung Cancer. 2021 Aug;158:1-8. doi: 10.1016/j.lungcan.2021.05.030. Epub 2021 May - 28. - -PMID- 37156009 -OWN - NLM -STAT- MEDLINE -DCOM- 20231108 -LR - 20240210 -IS - 1549-490X (Electronic) -IS - 1083-7159 (Print) -IS - 1083-7159 (Linking) -VI - 28 -IP - 11 -DP - 2023 Nov 2 -TI - Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors - in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. -PG - e1065-e1074 -LID - 10.1093/oncolo/oyad118 [doi] -AB - INTRODUCTION: Immune checkpoint inhibitor (ICI) pneumonitis causes substantial - morbidity and mortality. Estimates of real-world incidence and reported risk - factors vary substantially. METHODS: We conducted a retrospective review of 419 - patients with advanced non-small cell lung cancer (NSCLC) who were treated with - anti-PD-(L)1 with or without anti-CTLA-4 therapy. Clinical, imaging, and - microbiological data were evaluated by multidisciplinary adjudication teams. The - primary outcome of interest was grade ≥2 (CTCAEv5) pneumonitis. Clinicopathologic - variables, tobacco use, cancer therapies, and preexisting lung disease were - assessed for univariate effects using Cox proportional hazards models. We created - multivariate Cox proportional hazards models to assess risk factors for - pneumonitis and mortality. Pneumonitis, pneumonia, and progression were modeled - as time-dependent variables in mortality models. RESULTS: We evaluated 419 - patients between 2013 and 2021. The cumulative incidence of pneumonitis was 9.5% - (40/419). In a multivariate model, pneumonitis increased the risk for mortality - (HR 1.6, 95% CI, 1.0-2.5), after adjustment for disease progression (HR 1.6, 95% - CI, 1.4-1.8) and baseline shortness of breath (HR 1.5, 95% CI, 1.2-2.0). - Incomplete resolution was more common with more severe pneumonitis. Interstitial - lung disease was associated with higher risk for pneumonitis (HR 5.4, 95% CI, - 1.1-26.6), particularly in never smokers (HR 26.9, 95% CI, 2.8-259.0). - CONCLUSION: Pneumonitis occurred at a high rate and significantly increased - mortality. Interstitial lung disease, particularly in never smokers, increased - the risk for pneumonitis. -CI - © The Author(s) 2023. Published by Oxford University Press. -FAU - Altan, Mehmet -AU - Altan M -AUID- ORCID: 0000-0001-9229-156X -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Soto, Felipe -AU - Soto F -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Zhong, Linda L -AU - Zhong LL -AD - Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Akhmedzhanov, Fechukwu O -AU - Akhmedzhanov FO -AD - Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Wilson, Nathaniel R -AU - Wilson NR -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Zarifa, Abdulrazzak -AU - Zarifa A -AD - Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Albittar, Aya A -AU - Albittar AA -AD - Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Yang, Vincent -AU - Yang V -AD - Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Lewis, Jeff -AU - Lewis J -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Rinsurongkawong, Waree -AU - Rinsurongkawong W -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Jack Lee, J -AU - Jack Lee J -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Rinsurongkawong, Vadeerat -AU - Rinsurongkawong V -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Zhang, Jianjun -AU - Zhang J -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Gibbons, Don L -AU - Gibbons DL -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Vaporciyan, Ara A -AU - Vaporciyan AA -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Jennings, Kristofer -AU - Jennings K -AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Khawaja, Fareed -AU - Khawaja F -AD - Department of Infectious Disease, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Faiz, Saadia A -AU - Faiz SA -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Shannon, Vickie R -AU - Shannon VR -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Shroff, Girish -AU - Shroff G -AD - Department of Thoracic Imaging, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Godoy, Myrna C B -AU - Godoy MCB -AD - Department of Thoracic Imaging, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Daver, Naval G -AU - Daver NG -AD - Department of Leukemia, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Gandhi, Saumil -AU - Gandhi S -AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Mendoza, Tito R -AU - Mendoza TR -AD - Department of Symptom Research, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Naing, Aung -AU - Naing A -AD - Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Daniel-MacDougall, Carrie -AU - Daniel-MacDougall C -AD - Department of Epidemiology, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Heymach, John V -AU - Heymach JV -AUID- ORCID: 0000-0001-9068-8942 -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD - Anderson Cancer Center, Houston, TX, USA. -FAU - Sheshadri, Ajay -AU - Sheshadri A -AD - Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -LA - eng -GR - K23 AI117024/AI/NIAID NIH HHS/United States -GR - P30 CA016672/CA/NCI NIH HHS/United States -GR - NH/NIH HHS/United States -PT - Journal Article -PL - England -TA - Oncologist -JT - The oncologist -JID - 9607837 -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Incidence -MH - *Lung Neoplasms/drug therapy -MH - *Pneumonia/epidemiology -MH - Risk Factors -MH - *Lung Diseases, Interstitial/complications -MH - Retrospective Studies -PMC - PMC10628566 -OTO - NOTNLM -OT - immune checkpoint inhibitors -OT - non-small cell lung cancer -OT - pneumonitis -COIS- M.A. reports receiving research funding (to institution) from Genentech, Nektar - Therapeutics, Merck, GlaxoSmithKline, Novartis, Jounce Therapeutics, Bristol - Myers Squibb, Eli Lilly, Adaptimmune, and Shattuck Lab and receives consultant - and advisor fees from GlaxoSmithKline, Shattuck Lab, and AstraZeneca outside of - the submitted work. J.Z. reports grants from Merck, Johnson and Johnson, and - Novartis, and personal fees from Bristol Myers Squibb, AstraZeneca, GenePlus, - Innovent, Hengrui, Johnson and Johnson, and Novartis, outside the submitted work. - D.L.G. serves on scientific advisory committees for AstraZeneca, GlaxoSmithKline, - Sanofi, Lilly, Alethia Biotherapeutics, and Janssen and has received research - support from Janssen, Takeda, Ribon Therapeutics, Astellas, NGM - Biopharmaceuticals, and AstraZeneca outside of the submitted work. Fareed Khawaja - reported honorarium from Merck and personal fees from MEDSCAPE outside of the - submitted work. N.G. reported research funding (to institution) from - Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, - Astellas, Daiichi-Sankyo, Abbvie, Hanmi, Trovagene, FATE Therapeutics, Amgen, - Novimmune, Glycomimetics, Trillium, and ImmunoGen and has served in a consulting - or advisory role for Daiichi-Sankyo, Bristol-Myers Squibb, Arog, Pfizer, - Novartis, Jazz, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, - Trillium, Gilead, Amgen, Shattuck Labs, and Agios outside of the submitted work. - S.G. reported research funding (to institution) from Bristol Myers Squibb. A.N. - reported research funding (to the institution) from NCI, EMD Serono, MedImmune, - Healios Onc. Nutrition, Atterocor/Millendo, Amplimmune, ARMO BioSciences, - Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol-Myers - Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, - TopAlliance Biosciences, Eli Lilly, Kymab, PsiOxus, Arcus Biosciences, - NeoImmuneTech, Immune-Onc Therapeutics, Surface Oncology, Monopteros - Therapeutics, BioNTech SE, Seven & Eight Biopharma, and SOTIO Biotech AG; - personal fees and other support from Deka Biosciences, NGM Bio, PsiOxus - Therapeutics, Immune-Onc Therapeutics, STCube Pharmaceuticals, OncoSec - KEYNOTE-695, Pharming, Genome & Company, Horizon Therapeutics, CytomX - Therapeutics, and Kymab; consulting for Nouscom, Merck Sharp & Dohme Corp., - Genome & Company, OncoNano, Servier, and Lynx Health; travel and accommodation - expenses from ARMO BioSciences, NeoImmuneTech; speaker fees from AKH Inc., The - Lynx Group, Society for Immunotherapy of Cancer (SITC), Korean Society of Medical - Oncology (KSMO), Scripps Cancer Care Symposium, ASCO Direct Oncology Highlights, - European Society for Medical Oncology (ESMO), European Society for - Immunodeficiencies (ESID), and CME Outfitters. J.V.H. has served on Advisory - Committees for Genentech, Mirati Therapeutics, Eli Lilly & Co, Janssen - Pharmaceuticals, Boehringer-Ingelheim Pharmaceuticals, Regeneron, Takeda - Pharmaceuticals, BerGenBio, Jazz Pharmaceuticals, Curio Science, Novartis, - AstraZeneca Pharmaceuticals, BioAlta, Sanofi, Spectrum Pharmaceuticals, - GlaxoSmithKline, EMD Serono, BluePrint Medicine, and Chugai Pharmaceutical; - received research support from AstraZeneca, Boehringer-Ingelheim, Spectrum, - Mirati, Bristol-Myer Squibb, and Takeda, and Licensing/Royalties from Spectrum. - A.S. reported consulting for Enanta Pharmaceuticals and research funding from NIH - (NHLBI) and Gateway for Cancer Research Foundation. The other authors indicated - no financial relationships. -EDAT- 2023/05/08 18:42 -MHDA- 2023/11/08 06:41 -PMCR- 2023/05/08 -CRDT- 2023/05/08 17:25 -PHST- 2022/11/07 00:00 [received] -PHST- 2023/03/22 00:00 [accepted] -PHST- 2023/11/08 06:41 [medline] -PHST- 2023/05/08 18:42 [pubmed] -PHST- 2023/05/08 17:25 [entrez] -PHST- 2023/05/08 00:00 [pmc-release] -AID - 7157070 [pii] -AID - oyad118 [pii] -AID - 10.1093/oncolo/oyad118 [doi] -PST - ppublish -SO - Oncologist. 2023 Nov 2;28(11):e1065-e1074. doi: 10.1093/oncolo/oyad118. - -PMID- 37261356 -OWN - NLM -STAT- MEDLINE -DCOM- 20230605 -LR - 20230606 -IS - 1664-3224 (Electronic) -IS - 1664-3224 (Linking) -VI - 14 -DP - 2023 -TI - Efficacy of radiotherapy in combination with first-line immunotherapy and - chemotherapy for advanced lung squamous cell carcinoma: a propensity score - analysis. -PG - 1138025 -LID - 10.3389/fimmu.2023.1138025 [doi] -LID - 1138025 -AB - AIM: To compare the efficacy and safety of radiotherapy in combination with - immunotherapy after achieving disease control from the first-line combination - therapy of platinum-based chemotherapy and immunotherapy for advanced lung - squamous cell carcinoma (LUSC). METHODS: This study retrospectively evaluated the - patients with advanced LUSC treated with the combination of radiotherapy with - immunotherapy and chemotherapy (ICRT group, n = 52) or immunotherapy and - chemotherapy (ICT group, n = 63) as the first-line treatment from April 2018 to - April 2022. Using propensity score matching (PSM), 50 pairs were created, while - the confounders and bias were controlled. The objective response rate (ORR), - duration of overall response (DOR), progression-free survival (PFS), overall - survival (OS), and adverse events were analyzed in the two groups. The PFS and OS - were re-analyzed separately for patients treated with thoracic radiotherapy. - RESULTS: After PSM, the median PFS (12.23 vs. 7.43 months; P <0.001) and median - OS (19.7 vs. 12.9 months; P <0.001) were significantly longer in the ICRT group - than those in the ICT group. Both the PFS and OS rates were also significantly - higher in the ICRT group than those in the ICT group, except for the OS rates in - the 6th and 12th months. The mDOR of the ICRT group patients (17.10 vs. 8.27 - months; P <0.001) was significantly higher than that of the ICT group patients. - The median PFS, median OS, and local control rate were significantly longer in - the thoracic radiotherapy group than in the control group. Radiation pneumonia - was the most common adverse effect after radiotherapy; however, no - treatment-related deaths occurred. The Cox regression analysis showed that ECOG - scores 0-1, presence of necrosis in the tumor, radiotherapy, and optimal efficacy - better than the stable disease (SD) were independent factors, affecting the PFS, - while the patients with recurrent post-operative, pre-treatment NLR, - radiotherapy, and optimal efficacy better than SD were the independent factors, - affecting the OS. CONCLUSIONS: The combination of radiotherapy with systematic - immunotherapy and chemotherapy for the advanced LUSC was effective with tolerable - adverse effects. -CI - Copyright © 2023 Qin, Yi, Zhou, Zeng, Zou, Zeng, Yang and Huang. -FAU - Qin, Jian -AU - Qin J -AD - Department of Oncology, the Second Affiliated Hospital of Chongqing Medical - University, Chongqing, China. -FAU - Yi, Shouhui -AU - Yi S -AD - Department of Oncology, the Second Affiliated Hospital of Chongqing Medical - University, Chongqing, China. -FAU - Zhou, Hanjing -AU - Zhou H -AD - Department of Oncology, the First Affiliated Hospital of Chongqing Medical - University, Chongqing, China. -FAU - Zeng, Chuan -AU - Zeng C -AD - Department of Oncology, the Second Affiliated Hospital of Chongqing Medical - University, Chongqing, China. -FAU - Zou, Minghua -AU - Zou M -AD - Department of Oncology, the Second Affiliated Hospital of Chongqing Medical - University, Chongqing, China. -FAU - Zeng, Xuan -AU - Zeng X -AD - Department of Oncology, the Second Affiliated Hospital of Chongqing Medical - University, Chongqing, China. -FAU - Yang, Zhenzhou -AU - Yang Z -AD - Department of Oncology, the Second Affiliated Hospital of Chongqing Medical - University, Chongqing, China. -FAU - Huang, Yusheng -AU - Huang Y -AD - Department of Oncology, the Second Affiliated Hospital of Chongqing Medical - University, Chongqing, China. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20230516 -PL - Switzerland -TA - Front Immunol -JT - Frontiers in immunology -JID - 101560960 -SB - IM -MH - Humans -MH - Retrospective Studies -MH - Propensity Score -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Carcinoma, Squamous Cell/therapy/etiology -MH - *Drug-Related Side Effects and Adverse Reactions/etiology -MH - *Lung Neoplasms/drug therapy -MH - Immunotherapy/adverse effects -MH - Lung/pathology -PMC - PMC10227428 -OTO - NOTNLM -OT - ICIs -OT - LUSC -OT - NSCLC -OT - immunotherapy -OT - radiotherapy -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2023/06/01 13:09 -MHDA- 2023/06/05 06:42 -PMCR- 2023/01/01 -CRDT- 2023/06/01 10:40 -PHST- 2023/01/05 00:00 [received] -PHST- 2023/05/02 00:00 [accepted] -PHST- 2023/06/05 06:42 [medline] -PHST- 2023/06/01 13:09 [pubmed] -PHST- 2023/06/01 10:40 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fimmu.2023.1138025 [doi] -PST - epublish -SO - Front Immunol. 2023 May 16;14:1138025. doi: 10.3389/fimmu.2023.1138025. - eCollection 2023. - -PMID- 27831000 -OWN - NLM -STAT- MEDLINE -DCOM- 20170424 -LR - 20200306 -IS - 2164-554X (Electronic) -IS - 2164-5515 (Print) -IS - 2164-5515 (Linking) -VI - 13 -IP - 4 -DP - 2017 Apr 3 -TI - Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal - antibodies and biological inhibitors. -PG - 843-853 -LID - 10.1080/21645515.2016.1249551 [doi] -AB - The usual treatments for patients with non-small-cell lung cancer (NSCLC), such - as advanced lung adenocarcinoma, are unspecific and aggressive, and include lung - resection, radiotherapy and chemotherapy. Recently, treatment with monoclonal - antibodies and biological inhibitors has emerged as an effective alternative, - generating effective results with few side effects. In recent years, several - clinical trials using monoclonal antibodies presented potential benefits to - NSCLC, and 4 of them are already approved for the treatment of NSCLC, such as - cetuximab, bevacizumab, nivolumab and pembrolizumab. Also, biological inhibitors - are attractive tolls for biological applications. Among the approved inhibitors - are crizotinib, erlotinib, afatinib and gefitinib, and side effects are usually - mild to intense. Nevertheless, biological molecule treatments are under - development, and several new monoclonal antibodies and biological inhibitors are - in trial to treat NSCLC. Also under trial study are as follows: anti-epidermal - growth factor receptor (EGFR) antibodies (nimotuzumab and ficlatuzumab), anti-IGF - 1 receptor (IGF-1R) monoclonal antibody (figitumumab), anti-NR-LU-10 monoclonal - antibody (nofetumomab) as well as antibodies directly affecting the cytotoxic - T-lymphocyte-associated antigen 4 (CTLA-4) molecule (ipilimumab and - tremelimumab), to receptor activator of nuclear factor-kappa B ligand (RANKL) - (denosumab) or to polymerase enzyme (veliparib and olaparib). Among new - inhibitors under investigation are poly-ADP ribose polymerase (PARP) inhibitors - (veliparib and olaparib) and phosphatidylinositol 3-kinase (PI3K) inhibitor - (buparlisib). However, the success of immunotherapies still requires extensive - research and additional controlled trials to evaluate the long-term benefits and - side effects. -FAU - Silva, Ana P S -AU - Silva AP -AD - a Department of Biomedical Science , Faculty of Americana , Americana , SP , - Brazil. -FAU - Coelho, Priscila V -AU - Coelho PV -AD - a Department of Biomedical Science , Faculty of Americana , Americana , SP , - Brazil. -FAU - Anazetti, Maristella -AU - Anazetti M -AD - a Department of Biomedical Science , Faculty of Americana , Americana , SP , - Brazil. -AD - b Department of Health Science , Faculty DeVry Metrocamp , Campinas , SP , - Brazil. -FAU - Simioni, Patricia U -AU - Simioni PU -AD - a Department of Biomedical Science , Faculty of Americana , Americana , SP , - Brazil. -AD - c Department of Genetics , Evolution and Bioagents, Institute of Biology, - University of Campinas (UNICAMP) , Campinas , SP , Brazil. -AD - d Department of Biochemistry and Microbiology , Institute of Biosciences, - Universidade Estadual Paulista, UNESP , Rio Claro , SP , Brazil. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20161110 -PL - United States -TA - Hum Vaccin Immunother -JT - Human vaccines & immunotherapeutics -JID - 101572652 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents) -RN - 0 (Immunologic Factors) -SB - IM -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antineoplastic Agents/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/*therapy -MH - Clinical Trials as Topic -MH - Drug Discovery/trends -MH - Humans -MH - Immunologic Factors/*therapeutic use -MH - Immunotherapy/*methods -MH - Molecular Targeted Therapy/*methods -PMC - PMC5404364 -OTO - NOTNLM -OT - biological inhibitor -OT - biological therapy -OT - carcinogenesis -OT - lung cancer -OT - monoclonal antibody -OT - non- small- cell lung cancer -EDAT- 2016/11/11 06:00 -MHDA- 2017/04/25 06:00 -PMCR- 2016/11/10 -CRDT- 2016/11/11 06:00 -PHST- 2016/11/11 06:00 [pubmed] -PHST- 2017/04/25 06:00 [medline] -PHST- 2016/11/11 06:00 [entrez] -PHST- 2016/11/10 00:00 [pmc-release] -AID - 1249551 [pii] -AID - 10.1080/21645515.2016.1249551 [doi] -PST - ppublish -SO - Hum Vaccin Immunother. 2017 Apr 3;13(4):843-853. doi: - 10.1080/21645515.2016.1249551. Epub 2016 Nov 10. - -PMID- 33849133 -OWN - NLM -STAT- MEDLINE -DCOM- 20210514 -LR - 20210514 -IS - 2224-5839 (Electronic) -IS - 2224-5820 (Linking) -VI - 10 -IP - 3 -DP - 2021 Mar -TI - Neoadjuvant treatment of pembrolizumab plus platinum-doublet chemotherapy in - stage IIIA squamous cell carcinoma of the lung: a case report. -PG - 3510-3517 -LID - 10.21037/apm-21-335 [doi] -AB - With the popularity of neoadjuvant therapy as first-line treatment, especially - for advanced squamous cell carcinoma (SCC), the focus has become accurate - individualized treatment. Specifically, toxic side effects of traditional - platinum-doublet chemotherapy are high, so treatment with pembrolizumab plus - platinum-doublet chemotherapy is safer and more effective. Pembrolizumab is a - humanized monoclonal IgG4 kappa anti-PD1 antibody. It is devoid of any cytotoxic - activity among the drug effect. Pembrolizumab has been tested clinically in a - series of KEYNOTE studies and 12 categories of malignancies have been tested to - determine their clinical effects. A 64-year-old man with IIIA SCC of the lung - without any surgical contraindications in the preoperative period successfully - underwent radical resection and had a great prognosis after neoadjuvant - treatment. Chest computed tomography (CT) showed that the left upper lung lesion, - hilar and mediastinal lymph nodes were obviously smaller than before, meanwhile, - obstructive pneumonia was significantly absorbed. No sign of metastasis was - detected by head-abdominopelvic CT and bone scan. Although radiation pneumonitis - was an adverse event after postoperative adjuvant therapy, symptoms were relieved - with low-dose glucocorticoids. In conclusion, traditional chemotherapy with - single agents alone has been gradually replaced by pembrolizumab plus - platinum-doublet chemotherapy as a first-line therapy now. -FAU - Zhang, Chengpeng -AU - Zhang C -AD - Department of Thoracic Surgery, The First Affiliated Hospital of Soochow - University, Suzhou, China. -FAU - Jiang, Wei -AU - Jiang W -AD - Department of Thoracic Surgery, The First Affiliated Hospital of Soochow - University, Suzhou, China. -FAU - Li, Guangbin -AU - Li G -AD - Department of Thoracic Surgery, The First Affiliated Hospital of Soochow - University, Suzhou, China. -FAU - Li, Jiaxi -AU - Li J -AD - Department of Thoracic Surgery, The First Affiliated Hospital of Soochow - University, Suzhou, China. -FAU - Kang, Yunteng -AU - Kang Y -AD - Department of Thoracic Surgery, The First Affiliated Hospital of Soochow - University, Suzhou, China. -FAU - Yu, Xiaojun -AU - Yu X -AD - Department of Thoracic Surgery, The First Affiliated Hospital of Soochow - University, Suzhou, China. -FAU - Ma, Haitao -AU - Ma H -AD - Department of Thoracic Surgery, The First Affiliated Hospital of Soochow - University, Suzhou, China. mht7403@163.com. -FAU - Feng, Yu -AU - Feng Y -AD - Department of Thoracic Surgery, The First Affiliated Hospital of Soochow - University, Suzhou, China. fengyu1@suda.edu.cn. -LA - eng -PT - Case Reports -PT - Journal Article -PL - China -TA - Ann Palliat Med -JT - Annals of palliative medicine -JID - 101585484 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 49DFR088MY (Platinum) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Carcinoma, Squamous Cell/drug therapy -MH - Humans -MH - Lung -MH - *Lung Neoplasms/drug therapy -MH - Male -MH - Middle Aged -MH - Neoadjuvant Therapy -MH - Platinum/therapeutic use -OTO - NOTNLM -OT - Case report -OT - immune-related adverse events (irAEs) -OT - neoadjuvant treatment -OT - programmed death ligand 1 (PD-L1) -OT - squamous cell carcinoma (SCC) -EDAT- 2021/04/15 06:00 -MHDA- 2021/05/15 06:00 -CRDT- 2021/04/14 01:00 -PHST- 2021/01/20 00:00 [received] -PHST- 2021/03/20 00:00 [accepted] -PHST- 2021/04/14 01:00 [entrez] -PHST- 2021/04/15 06:00 [pubmed] -PHST- 2021/05/15 06:00 [medline] -AID - 10.21037/apm-21-335 [doi] -PST - ppublish -SO - Ann Palliat Med. 2021 Mar;10(3):3510-3517. doi: 10.21037/apm-21-335. - -PMID- 31327829 -OWN - NLM -STAT- MEDLINE -DCOM- 20200210 -LR - 20200210 -IS - 1349-7235 (Electronic) -IS - 0918-2918 (Print) -IS - 0918-2918 (Linking) -VI - 58 -IP - 22 -DP - 2019 Nov 15 -TI - Bilateral Testicular Metastases from Lung Adenocarcinoma Showing an Objective - Response to Nivolumab: A Case Report and Review of the Literature. -PG - 3277-3282 -LID - 10.2169/internalmedicine.2927-19 [doi] -AB - A 69-year-old man who had undergone chemoradiotherapy for advanced pulmonary - adenocarcinoma had bilateral testicular and adrenal gland masses on a routine - follow-up examination. We performed left orchiectomy, and the histopathological - examination confirmed metastatic pulmonary adenocarcinoma involving the extracted - testis. He was treated for disease progression with nivolumab after unsuccessful - cytotoxic chemotherapy, which resulted in regression of recurrent adrenal and - right testicular tumors. We reviewed the existing literature on metastatic - testicular tumors and found that testicular metastasis from lung cancer is rare - and poses a chemotherapeutic challenge. Based on our experience, immune - checkpoint inhibitors seem to have good efficacy for treating testicular - metastasis. -FAU - Ozeki, Taichi -AU - Ozeki T -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Japan. -FAU - Fujiwara, Keiichi -AU - Fujiwara K -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Japan. -FAU - Shimonishi, Atsushi -AU - Shimonishi A -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Japan. -FAU - Nishimura, Jun -AU - Nishimura J -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Japan. -FAU - Okawa, Sachi -AU - Okawa S -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Japan. -FAU - Takada, Kenji -AU - Takada K -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Japan. -FAU - Kayatani, Hiroe -AU - Kayatani H -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Japan. -FAU - Minami, Daisuke -AU - Minami D -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Japan. -FAU - Sato, Ken -AU - Sato K -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Japan. -FAU - Shibayama, Takuo -AU - Shibayama T -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Japan. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20190722 -PL - Japan -TA - Intern Med -JT - Internal medicine (Tokyo, Japan) -JID - 9204241 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Adenocarcinoma of Lung/*pathology/therapy -MH - Aged -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - Humans -MH - Lung Neoplasms/*pathology/therapy -MH - Male -MH - Nivolumab/*therapeutic use -MH - Orchiectomy -MH - Testicular Neoplasms/*drug therapy/*secondary -PMC - PMC6911762 -OTO - NOTNLM -OT - adenocarcinoma -OT - immune checkpoint inhibitors -OT - nivolumab -OT - non-small cell lung cancer -OT - testicular metastasis -COIS- Author's disclosure of potential Conflicts of Interest (COI). Keiichi Fujiwara: - Research funding, Hisamitsu Pharmaceutical. -EDAT- 2019/07/23 06:00 -MHDA- 2020/02/11 06:00 -PMCR- 2019/11/15 -CRDT- 2019/07/23 06:00 -PHST- 2019/07/23 06:00 [pubmed] -PHST- 2020/02/11 06:00 [medline] -PHST- 2019/07/23 06:00 [entrez] -PHST- 2019/11/15 00:00 [pmc-release] -AID - 10.2169/internalmedicine.2927-19 [doi] -PST - ppublish -SO - Intern Med. 2019 Nov 15;58(22):3277-3282. doi: 10.2169/internalmedicine.2927-19. - Epub 2019 Jul 22. - -PMID- 35227966 -OWN - NLM -STAT- MEDLINE -DCOM- 20220503 -LR - 20220716 -IS - 2059-7029 (Electronic) -IS - 2059-7029 (Linking) -VI - 7 -IP - 2 -DP - 2022 Apr -TI - Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the - IFCT-1803 LORLATU study. -PG - 100418 -LID - S2059-7029(22)00039-4 [pii] -LID - 10.1016/j.esmoop.2022.100418 [doi] -LID - 100418 -AB - INTRODUCTION: ROS1-rearranged (ROS1+) non-small-cell lung cancer (NSCLC) is a - rare lung cancer with limited treatment options. Phase I-II studies with - ROS1-tyrosine kinase inhibitors (TKIs) included small numbers of patients and - real-world data are lacking. We investigate the efficacy and safety of - lorlatinib, a third-generation TKI targeting ALK and ROS1, in patients with ROS1+ - NSCLC treated through an expanded access program. METHODS: Consecutive patients - with advanced ROS1+ NSCLC treated with lorlatinib between October 2015 and June - 2019 were included. Data were collected from medical records. The primary - endpoint was progression-free survival. RESULTS: Out of the 80 patients included, - 47(59%) were female, 49(62%) never smokers (less than 100 cigarettes over the - lifetime), and 68(85%) had stage IV NSCLC at diagnosis. Most frequent histology - was adenocarcinoma (95%) and median age was 58.2 years. At the time of lorlatinib - initiation, 51(64%) patients had brain metastases and 55(81%) were PS 0-1. - Lorlatinib was administered as second/third/fourth/fifth+ line in 29%/28%/18%/26% - of patients. All patients previously received at least one ROS1 TKI, and 55(69%) - previously received chemotherapy. Median follow-up from lorlatinib initiation was - 22.2 months. Median progression-free survival and overall survival from - lorlatinib initiation were 7.1 months [95% confidence interval (CI) 5.0-9.9 - months] and 19.6 months (95% CI 12.3-27.5 months). Median duration of treatment - with lorlatinib was 7.4 months (95% CI 6.5-13.1 months). Overall response and - disease control rates were 45% and 82%, respectively. The central nervous system - response rate was 72%. Treatment was stopped due to toxicity in 10 patients - (13%). The safety profile was consistent with previously published data. - CONCLUSIONS: Lorlatinib is a major treatment option for advanced refractory ROS1+ - NSCLC in treatment strategy. -CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. -FAU - Girard, N -AU - Girard N -AD - Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; Université - Versailles Saint Quentin, Paris Saclay Campus, Versailles, France. Electronic - address: nicolas.girard2@curie.fr. -FAU - Galland-Girodet, S -AU - Galland-Girodet S -AD - Service d'Oncologie - Radiothérapie, Polyclinique Bordeaux Nord Aquitaine, - Bordeaux, France. -FAU - Avrillon, V -AU - Avrillon V -AD - Service d'Oncologie Médicale, Centre Léon Bérard, Lyon, France. -FAU - Besse, B -AU - Besse B -AD - Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France; - Paris-Saclay University, Orsay, France. -FAU - Duruisseaux, M -AU - Duruisseaux M -AD - Unité de Recherche Commune en Oncologie Thoracique (URCOT), Institut de - Cancérologie des Hospices Civils de Lyon, Lyon, France; Service de Pneumologie, - Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France; Oncopharmacology - Laboratory, Cancer Research Center of Lyon, Inserm 1052, CNRS 5286, Lyon, France; - Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France. -FAU - Cadranel, J -AU - Cadranel J -AD - Chest Department, AP-HP Hôpital Tenon and GRC#4 Theranoscan Sorbonne Université - Paris, Paris, France. -FAU - Otto, J -AU - Otto J -AD - Oncologie, Centre Anticancer Antoine Lacassagne, Nice, France. -FAU - Prevost, A -AU - Prevost A -AD - Institut Godinot, Reims, France. -FAU - Roch, B -AU - Roch B -AD - Unité d'Oncologie Thoracique, Département de Pneumologie, CHU Montpellier, - Montpellier, France; Institut de Recherche en Cancérologie de Montpellier, U1194, - Campus Val d'Aurelle, Montpellier, France; Université de Montpellier, - Montpellier, France. -FAU - Bennouna, J -AU - Bennouna J -AD - Thoracic Oncology Unit, University Hospital of Nantes, Nantes, France. -FAU - Bouledrak, K -AU - Bouledrak K -AD - Oncologie Médicale et Pneumologie, Hôpital Privé Jean Mermoz, Lyon, France. -FAU - Coudurier, M -AU - Coudurier M -AD - Pneumologie, Centre hospitalier Métropole Savoie, Chambery, France. -FAU - Egenod, T -AU - Egenod T -AD - Thoracic Oncology Department, CHU Limoges - Hôpital Dupuytren, Limoges, France. -FAU - Lamy, R -AU - Lamy R -AD - Oncologie, GHBS, Lorient, France. -FAU - Ricordel, C -AU - Ricordel C -AD - Department of Pulmonary Medicine, CHU Pontchaillou, Rennes, France. -FAU - Moro-Sibilot, D -AU - Moro-Sibilot D -AD - Thoracic Oncology, CHU de Grenoble, Hôpital Michallon, La Tronche, France. -FAU - Odier, L -AU - Odier L -AD - Pneumology, L'Hôpital Nord Ouest Villefranche-Sur-Saône, Gleize, France. -FAU - Tillon-Strozyk, J -AU - Tillon-Strozyk J -AD - Clinique Pneumologique, Hôpital Charles Nicolle, Rouen, France. -FAU - Zalcman, G -AU - Zalcman G -AD - Department of Thoracic Oncology and CIC1425, Hôpital Bichat-Claude Bernard, - Assistance Publique Hôpitaux de Paris, Université Paris-Diderot, Paris, France. -FAU - Missy, P -AU - Missy P -AD - French Cooperative Thoracic Intergroup, Paris, France. -FAU - Westeel, V -AU - Westeel V -AD - Oncologie Thoracique et Allergologie Respiratoire, CHRU Besancon - Hôpital Jean - Minjoz, Besançon, France. -FAU - Baldacci, S -AU - Baldacci S -AD - Lille University, CHU Lille, Thoracic Oncology Department, CNRS, Inserm, Institut - Pasteur de Lille, UMR9020 - UMR-S 1277 - Canther, Lille, France. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20220226 -PL - England -TA - ESMO Open -JT - ESMO open -JID - 101690685 -RN - 0 (Aminopyridines) -RN - 0 (Lactams) -RN - 0 (Lactams, Macrocyclic) -RN - 0 (Proto-Oncogene Proteins) -RN - 0 (Pyrazoles) -RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) -RN - EC 2.7.10.1 (ROS1 protein, human) -RN - OSP71S83EU (lorlatinib) -SB - IM -MH - Aminopyridines -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology -MH - Female -MH - Humans -MH - Lactams -MH - Lactams, Macrocyclic/pharmacology/therapeutic use -MH - *Lung Neoplasms/pathology -MH - Male -MH - Middle Aged -MH - Protein-Tyrosine Kinases/therapeutic use -MH - Proto-Oncogene Proteins/genetics/therapeutic use -MH - Pyrazoles -PMC - PMC9058895 -OTO - NOTNLM -OT - NSCLC -OT - ROS1 -OT - brain metastases -OT - chemotherapy -COIS- Role of the funder The funding source had no role in the design, data collection, - analysis, or interpretation of the study, or in the preparation of this - manuscript. Disclosure SB reports non-financial support from Lilly, - GlaxoSmithKline, Roche, Pfizer, personal fees from Roche, Boehringer Ingelheim, - grants from Intergroupe Francophone de Cancérologie Thoracique. BB reports grants - from Abbvie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, - Bristol Myers Squibb (BMS), Boehringer Ingelheim, Celgene, Cergentis, Cristal - Therapeutics, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Inivata, Janssen, - Onxeo, OSE Immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero - Pharmaceuticals. DMS reports grants from Pfizer, Roche, AstraZeneca, BMS, Merck - Sharp & Dohme (MSD), personal fees from Pfizer, Roche, Takeda, AstraZeneca, - Lilly, BMS, MSD, Novartis, Amgen, Abbvie, Becton Dickinson, and non-financial - support from Pfizer, Roche, Takeda, AstraZeneca, BMS, MSD. JC reports personal - fees from Pfizer, Roche, Takeda, Novartis, AstraZeneca, MSD, BMS, and Boehringer - Ingelheim. VW reports honoraria from Roche, AstraZeneca, BMS, MSD and - non-financial support from Roche, Pfizer. BR reports grants or contracts from - Chugai, consulting fees from BMS, AstraZeneca, Roche, support for attending - meetings and/or travel from BMS, Amgen, MSD, Roche. JB reports personal fees for - advisory boards and educational symposia from AstraZeneca, Bayer, BMS, MSD, - Roche, Daichii, and Servier. All other authors have declared no conflicts of - interest. -EDAT- 2022/03/02 06:00 -MHDA- 2022/05/04 06:00 -PMCR- 2022/02/26 -CRDT- 2022/03/01 05:49 -PHST- 2021/10/18 00:00 [received] -PHST- 2022/01/10 00:00 [revised] -PHST- 2022/02/02 00:00 [accepted] -PHST- 2022/03/02 06:00 [pubmed] -PHST- 2022/05/04 06:00 [medline] -PHST- 2022/03/01 05:49 [entrez] -PHST- 2022/02/26 00:00 [pmc-release] -AID - S2059-7029(22)00039-4 [pii] -AID - 100418 [pii] -AID - 10.1016/j.esmoop.2022.100418 [doi] -PST - ppublish -SO - ESMO Open. 2022 Apr;7(2):100418. doi: 10.1016/j.esmoop.2022.100418. Epub 2022 Feb - 26. - -PMID- 35973745 -OWN - NLM -STAT- MEDLINE -DCOM- 20220818 -LR - 20220910 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 10 -IP - 8 -DP - 2022 Aug -TI - Neoadjuvant immunotherapy of locoregionally advanced solid tumors. -LID - 10.1136/jitc-2022-005036 [doi] -LID - e005036 -AB - Definitive management of locoregionally advanced solid tumors presents a major - challenge and often consists of a combination of surgical, radiotherapeutic and - systemic therapy approaches. Upfront surgical treatment with or without adjuvant - radiotherapy carries the risks of significant morbidities and potential - complications that could be lasting. In addition, these patients continue to have - a high risk of local or distant disease relapse despite the use of standard - adjuvant therapy. Preoperative neoadjuvant systemic therapy has the potential to - significantly improve clinical outcomes, particularly in this era of expanding - immunotherapeutic agents that have transformed the care of patients with - metastatic/unresectable malignancies. Tremendous progress has been made with - neoadjuvant immunotherapy in the treatment of several locoregionally advanced - resectable solid tumors leading to ongoing phase 3 trials and change in clinical - practice. The promise of neoadjuvant immunotherapy has been supported by the high - pathologic tumor response rates in early trials as well as the durability of - these responses making cure a more achievable potential outcome compared with - other forms of systemic therapy. Furthermore, neoadjuvant studies allow the - assessment of radiologic and pathological responses and the access to - biospecimens before and during systemic therapy. Pathological responses may guide - future treatment decisions, and biospecimens allow the conduct of mechanistic and - biomarker studies that may guide future drug development. On behalf of the - National Cancer Institute Early Drug Development Neoadjuvant Immunotherapy - Working Group, this article summarizes the current state of neoadjuvant - immunotherapy of solid tumors focusing primarily on locoregionally advanced - melanoma, gynecologic malignancies, gastrointestinal malignancies, non-small cell - lung cancer and head and neck cancer including recent advances and our expert - recommendations related to future neoadjuvant trial designs and associated - clinical and translational research questions. -CI - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Tarhini, Ahmad A -AU - Tarhini AA -AUID- ORCID: 0000-0002-3193-9702 -AD - Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research - Institute, University of South Florida Morsani College of Medicine, Tampa, - Florida, USA ahmad.tarhini@moffitt.org. -FAU - Eads, Jennifer R -AU - Eads JR -AD - Medicine, University of Pennsylvania Abramson Cancer Center, Philadelphia, - Pennsylvania, USA. -FAU - Moore, Kathleen N -AU - Moore KN -AD - Gynecologic Oncology, The University of Oklahoma Stephenson Cancer Center, - Oklahoma City, Oklahoma, USA. -FAU - Tatard-Leitman, Valerie -AU - Tatard-Leitman V -AD - The Emmes Company LLC, Rockville, Maryland, USA. -FAU - Wright, John -AU - Wright J -AD - National Cancer Institute, Bethesda, Maryland, USA. -FAU - Forde, Patrick M -AU - Forde PM -AD - Oncology, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, - Baltimore, Maryland, USA. -FAU - Ferris, Robert L -AU - Ferris RL -AD - Otolaryngology and Immunology, University of Pittsburgh & UPMC Hillman Cancer - Center, Pittsburgh, Pennsylvania, USA. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -SB - IM -MH - *Carcinoma, Non-Small-Cell Lung -MH - Female -MH - Humans -MH - Immunotherapy -MH - *Lung Neoplasms -MH - *Melanoma/pathology -MH - Neoadjuvant Therapy -PMC - PMC9386211 -OTO - NOTNLM -OT - Gastrointestinal Neoplasms -OT - Genital Neoplasms, Female -OT - Head and Neck Neoplasms -OT - Immunotherapy -OT - Melanoma -COIS- Competing interests: AAT reports grants from Bristol Myers Squib, grants from - Genentech-Roche, grants from Regeneron, grants from Sanofi-Genzyme, grants from - Nektar, grants from Clinigen, grants from Merck, grants from Acrotech, grants - from Pfizer, grants from Checkmate, grants from OncoSec, personal fees from - Bristol Myers Squibb, personal fees from Merck, personal fees from Easai, - personal fees from Instil Bio, personal fees from Clinigin, personal fees from - Regeneron, personal fees from Sanofi-Genzyme, personal fees from Novartis, - personal fees from Partner Therapeutics, personal fees from Genentech/Roche, - personal fees from BioNTech, outside the submitted work. RLF reports grants from - AstraZeneca/MedImmune, grants from Bristol Myers Squibb, grants from Merck, - grants from Novasenta, grants from Tesaro, stock from Novasenta, personal fees - from Aduro Biotech, personal fees from Bicara Therapeutics, personal fees from - Bristol Myers Squibb, personal fees from Brooklyn Immunotherapeutics, personal - fees from Catenion, personal fees from Coherus BioSciences, personal fees from - Everest Clinical Research Corporation, personal fees from F. Hoffmann-La Roche, - personal fees from Genocea Biosciences, personal fees from Hookipa Biotech, - personal fees from Instil Bio, personal fees from Kowa Research Institute, - personal fees from Lifescience Dynamics Limited, personal fees from MacroGenics, - personal fees from Merck, personal fees from Mirati Therapeutics, personal fees - from Mirror Biologics, personal fees from Nanobiotix, personal fees from - Novasenta, personal fees from Numab Therapeutics AG, personal fees from OncoCyte - Corporation, personal fees from Pfizer, personal fees from PPD Development LP, - personal fees from Rakuten Medical, personal fees from Sanofi, personal fees from - Seagen, personal fees from Vir Biotechnology, personal fees from Zymeworks, - outside of the submitted work. KNM reports advisory board participation and - reimbursement from Aravive, Alkemeres, AstraZeneca, Blueprint pharma, Eisai, - EMD/Serono, GSK/Tesaro, Genentech/Roche, Hengrui, Immunogen, IMXmed, IMab, Lilly, - Mersana, Mereo, Myriad, Merck, Novarits, OncXerna, Onconova, VBL Therapeutics. - Research funding from PTC therapeutics, Lilly, Merck, GSK/Tesaro. GOG Partners - Associate director. VT-L does not have any competing interest to report. PMF - reports advisory board participation and reimbursement from Amgen, AstraZeneca, - BMS, Daiichi, F-Star, G1, Genentech, Iteos, Janssen, Merck, Novartis, Sanofi, - Surface, and research grants to his institution from AstraZeneca, BioNTech, BMS, - Corvus, Kyowa, Novartis, and Regeneron. JRE reports employment at Bristol Meyers - Squibb (spouse) and Janssen (spouse), honoraria for Pfizer, consulting for - Lexicon, advisory boards for Ipsen, Advanced Accelerator Applications, and - research support from Xencor, Tarveda, Genentech, Amgen, AstraZeneca, Medimmune, - Hutchison, Incyte, Oncolys, Seagen. Neither JW nor members of his immediate - family have a financial interest or obligation related to the information - transmitted in this publication. None of them have received any compensation, - salary, gifts, promises of employment or reimbursement for travel. -EDAT- 2022/08/17 06:00 -MHDA- 2022/08/19 06:00 -PMCR- 2022/08/16 -CRDT- 2022/08/16 20:52 -PHST- 2022/07/23 00:00 [accepted] -PHST- 2022/08/16 20:52 [entrez] -PHST- 2022/08/17 06:00 [pubmed] -PHST- 2022/08/19 06:00 [medline] -PHST- 2022/08/16 00:00 [pmc-release] -AID - jitc-2022-005036 [pii] -AID - 10.1136/jitc-2022-005036 [doi] -PST - ppublish -SO - J Immunother Cancer. 2022 Aug;10(8):e005036. doi: 10.1136/jitc-2022-005036. - -PMID- 37907645 -OWN - NLM -STAT- MEDLINE -DCOM- 20231211 -LR - 20240926 -IS - 1432-0851 (Electronic) -IS - 0340-7004 (Print) -IS - 0340-7004 (Linking) -VI - 72 -IP - 12 -DP - 2023 Dec -TI - A retrospective real-world study: the efficacy of immune-related combination - therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs. -PG - 4355-4365 -LID - 10.1007/s00262-023-03570-9 [doi] -AB - BACKGROUND: Whether patients with advanced non-small cell lung cancer (NSCLC) - should choose an immune-combination therapy regimen after EGFR-tyrosine kinase - inhibitors (EGFR-TKIs) resistance is currently unclear. METHODS: We evaluated 118 - NSCLC patients treated by immune checkpoint inhibitors (ICIs) + chemotherapy - (I + C), ICIs + chemotherapy + antiangiogenic therapy (I + C + A), - chemotherapy + antiangiogenic therapy (C + A) after inefficacy of EGFR-TKIs. We - assessed the objective remission rate (ORR), disease control rate (DCR), and - progression-free survival (PFS) of these treatments. RESULTS: The ORR was 26.1% - vs 38.2% vs 16.3% in the three groups (P = 0.093). The divergence in DCR was also - statistically significant (65.2% vs 85.3% vs 74.4%, P = 0.209). The median PFS - was no statistically significant difference in PFS (3.09 vs 6.31 vs 5.91 months, - P = 0.809), but the Kaplan-Meier survival curve of 12-month-PFS indicated an - apparent survival advantage in the I + C + A group (P = 0.001). In addition, the - I + C/I + C + A group showed higher median PFS than the C + A group in patients - with brain metastases (median PFS, 6.44 vs 4.21 months, P = 0.022). The - divergence in ORR of patients in the brain group was also statistically - significant (P = 0.045). The I + C + A group showed superior efficacy in patients - with liver metastases (median PFS, 0.95 vs 6.44 vs 3.48 months, P < 0.0001). The - Cox proportional hazard modeling analysis suggested that the age, brain - metastases, and liver metastases were all connected with the prognosis. - CONCLUSIONS: This study suggests that advanced NSCLC patients after resistance to - EGFR-TKIs may achieve better outcomes from triple therapy. Patients with brain - metastases favor ICIs-related combination therapies and patients with liver - metastases prefer I + C + A therapy. -CI - © 2023. The Author(s). -FAU - Cai, Ruoxue -AU - Cai R -AD - Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Baiziting 42, 210009, Nanjing, People's Republic of China. -FAU - Liu, Ying -AU - Liu Y -AD - Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Baiziting 42, 210009, Nanjing, People's Republic of China. -FAU - Yu, Mingyan -AU - Yu M -AD - Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - 210009, Nanjing, People's Republic of China. -FAU - Sha, Huanhuan -AU - Sha H -AD - Department of Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer - Research, The Affiliated Cancer Hospital of Nanjing Medical University, 210009, - Nanjing, People's Republic of China. -FAU - Guo, Mengya -AU - Guo M -AD - Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Baiziting 42, 210009, Nanjing, People's Republic of China. -FAU - Chen, Yue -AU - Chen Y -AD - Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Baiziting 42, 210009, Nanjing, People's Republic of China. -FAU - Ye, Jinjun -AU - Ye J -AD - Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - 210009, Nanjing, People's Republic of China. -FAU - Zhou, Guoren -AU - Zhou G -AD - Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Baiziting 42, 210009, Nanjing, People's Republic of China. zhouguoren888@163.com. -FAU - Fang, Ying -AU - Fang Y -AD - Department of Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer - Research, The Affiliated Cancer Hospital of Nanjing Medical University, 210009, - Nanjing, People's Republic of China. fangyingnj@163.com. -FAU - Shen, Bo -AU - Shen B -AD - Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Baiziting 42, 210009, Nanjing, People's Republic of China. -LA - eng -GR - 82273162/the National Natural Science Foundation of China/ -GR - 82272863/the National Natural Science Foundation of China/ -GR - ZD2021019/2021 Key Projects of Jiangsu Provincial Healthcare Commission's - Scientific Research Programs/ -PT - Journal Article -DEP - 20231031 -PL - Germany -TA - Cancer Immunol Immunother -JT - Cancer immunology, immunotherapy : CII -JID - 8605732 -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 2.7.10.1 (EGFR protein, human) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/pathology -MH - *Lung Neoplasms/pathology -MH - Retrospective Studies -MH - Protein Kinase Inhibitors/pharmacology -MH - *Brain Neoplasms/secondary -MH - ErbB Receptors/genetics -MH - *Liver Neoplasms/drug therapy -MH - Mutation -PMC - PMC10700213 -OTO - NOTNLM -OT - Brain metastasis -OT - Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) - resistance -OT - Immune checkpoint inhibitors (ICIs) -OT - Liver metastasis -OT - Non-small cell lung cancer (NSCLC) -COIS- The authors have no relevant financial or non-financial interests to disclose. -EDAT- 2023/11/01 06:43 -MHDA- 2023/12/11 12:41 -PMCR- 2023/10/31 -CRDT- 2023/11/01 00:41 -PHST- 2023/08/14 00:00 [received] -PHST- 2023/10/21 00:00 [accepted] -PHST- 2023/12/11 12:41 [medline] -PHST- 2023/11/01 06:43 [pubmed] -PHST- 2023/11/01 00:41 [entrez] -PHST- 2023/10/31 00:00 [pmc-release] -AID - 10.1007/s00262-023-03570-9 [pii] -AID - 3570 [pii] -AID - 10.1007/s00262-023-03570-9 [doi] -PST - ppublish -SO - Cancer Immunol Immunother. 2023 Dec;72(12):4355-4365. doi: - 10.1007/s00262-023-03570-9. Epub 2023 Oct 31. - -PMID- 38742347 -OWN - NLM -STAT- MEDLINE -DCOM- 20240514 -LR - 20240514 -IS - 0376-2491 (Print) -IS - 0376-2491 (Linking) -VI - 104 -IP - 18 -DP - 2024 May 14 -TI - [Effect of peripheral blood inflammatory indicators on the efficacy of - immunotherapy in patients with advanced non-small cell lung cancer and chronic - obstructive pulmonary disease]. -PG - 1601-1609 -LID - 10.3760/cma.j.cn112137-20231130-01247 [doi] -AB - Objective: To investigate the impact of peripheral blood inflammatory indicators - on the efficacy of immunotherapy in patients with advanced non-small cell lung - cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD). - Methods: A retrospective cohort study was performed to include 178 patients with - Ⅲ-Ⅳ NSCLC complicated with COPD who received at least 2 times of immunotherapy in - Xinqiao Hospital of the Army Medical University from January 2019 to August 2021. - Baseline peripheral blood inflammatory indicators such as interleukin-6 (IL-6), - interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α) were collected within 2 - weeks before the first treatment, with the last one being on or before February - 7, 2022. X-tile software was used to determine the optimal cut-off value of - peripheral blood inflammatory indicators. The Cox multivariate regression models - were used to analyze the factors affecting progression free survival (PFS) and - overall survival (OS). Results: Among the 178 patients, there were 174 males - (97.8%) and 4 females (2.2%); the age ranged from 42 to 86 (64.3±8.3) years - old.There were 30 cases (16.9%) of immunotherapy monotherapy, 114 cases (64.0%) - of immunotherapy combined with chemotherapy, 21 cases (11.8%) of immunotherapy - combined with antivascular therapy, and 13 cases (7.3%) of immunotherapy combined - with radiotherapy. The median follow-up period was 14.5 months (95%CI: 13.6-15.3 - months). The objective response rate (ORR) and disease control rate (DCR) were - 44.9% (80/178) and 90.4% (161/178) for the whole group, the median PFS was 14.6 - months (95%CI: 11.6-17.6 months), and the median OS was 25.7 months (95%CI: - 18.0-33.4 months). The results of Cox multivariate analysis showed that IL-6>9.9 - ng/L (HR=5.885, 95%CI: 2.558-13.543, P<0.01), TNF-α>8.8 ng/L (HR=3.213, 95%CI: - 1.468-7.032, P=0.003), IL-8>202 ng/L (HR=2.614, 95%CI: 1.054-6.482, P=0.038), - systemic immune inflammatory index (SII)>2 003.95 (HR=2.976, 95%CI: 1.647-5.379, - P<0.001) were risk factors for PFS, and advanced lung cancer inflammation index - (ALI)>171.15 was protective factor for PFS (HR=0.545, 95%CI: 0.344-0.863, - P=0.010). IL-6>9.9 ng/L(HR=6.124, 95%CI: 1.950-19.228, P<0.002), lactate - dehydrogenase (LDH)>190.7 U/L (HR=2.776, 95%CI: 1.020-7.556, P=0.046), SII>2 - 003.95 (HR=4.521, 95%CI: 2.241-9.120, P<0.001) were risk factors for OS, and - ALI>171.15 was a protective factor for OS (HR=0.434, 95%CI: 0.243-0.778, - P=0.005). Conclusion: Baseline high levels of IL-6, TNF-α, IL-8, SII, LDH, and - low levels of ALI are risk factors for poor prognosis in patients with advanced - NSCLC-COPD receiving immunotherapy. -FAU - Bi, Z K -AU - Bi ZK -AD - Department of Respiratory and Critical Care Medicine, Xinqiao Hospital, Army - Medical University, Chongqing 400037, China. -FAU - Xu, Y -AU - Xu Y -AD - Department of Oncology, Army Specialty Medical Center, Army Medical University, - Chongqing 400010, China. -FAU - Guo, L -AU - Guo L -AD - Department of Respiratory and Critical Care Medicine, Xinqiao Hospital, Army - Medical University, Chongqing 400037, China. -FAU - Zhang, W J -AU - Zhang WJ -AD - Department of Respiratory and Critical Care Medicine, Xinqiao Hospital, Army - Medical University, Chongqing 400037, China. -FAU - You, Y T -AU - You YT -AD - Department of Respiratory and Critical Care Medicine, Xinqiao Hospital, Army - Medical University, Chongqing 400037, China. -FAU - Li, J W -AU - Li JW -AD - Department of Respiratory and Critical Care Medicine, Xinqiao Hospital, Army - Medical University, Chongqing 400037, China. -FAU - Zhao, C L -AU - Zhao CL -AD - Department of Respiratory and Critical Care Medicine, Xinqiao Hospital, Army - Medical University, Chongqing 400037, China. -FAU - Shan, Y F -AU - Shan YF -AD - Department of Epidemiology, Faculty of Military Preventive Medicine, Army Medical - University, Chongqing 400037, China. -FAU - Xia, T T -AU - Xia TT -AD - Department of Epidemiology, Faculty of Military Preventive Medicine, Army Medical - University, Chongqing 400037, China. -FAU - Li, Y F -AU - Li YF -AD - Department of Epidemiology, Faculty of Military Preventive Medicine, Army Medical - University, Chongqing 400037, China. -FAU - Xu, Z -AU - Xu Z -AD - Department of Respiratory and Critical Care Medicine, Xinqiao Hospital, Army - Medical University, Chongqing 400037, China. -FAU - Fan, Y -AU - Fan Y -AD - Department of Respiratory and Critical Care Medicine, Xinqiao Hospital, Army - Medical University, Chongqing 400037, China. -FAU - Bai, L -AU - Bai L -AD - Department of Respiratory and Critical Care Medicine, Xinqiao Hospital, Army - Medical University, Chongqing 400037, China. -LA - chi -GR - 2022ZDXM023/Chongqing Science and Health Joint Major Project/ -PT - English Abstract -PT - Journal Article -PL - China -TA - Zhonghua Yi Xue Za Zhi -JT - Zhonghua yi xue za zhi -JID - 7511141 -SB - IM -MH - Humans -MH - Male -MH - Female -MH - *Carcinoma, Non-Small-Cell Lung/therapy -MH - *Pulmonary Disease, Chronic Obstructive/therapy/blood -MH - Middle Aged -MH - *Lung Neoplasms/therapy/blood -MH - Aged -MH - Retrospective Studies -MH - *Immunotherapy -MH - *Interleukin-6/blood -MH - Adult -MH - *Tumor Necrosis Factor-alpha/blood -MH - Inflammation -MH - Interleukin-8/blood -MH - Aged, 80 and over -EDAT- 2024/05/14 06:42 -MHDA- 2024/05/14 06:43 -CRDT- 2024/05/14 04:15 -PHST- 2024/05/14 06:43 [medline] -PHST- 2024/05/14 06:42 [pubmed] -PHST- 2024/05/14 04:15 [entrez] -AID - 10.3760/cma.j.cn112137-20231130-01247 [doi] -PST - ppublish -SO - Zhonghua Yi Xue Za Zhi. 2024 May 14;104(18):1601-1609. doi: - 10.3760/cma.j.cn112137-20231130-01247. - -PMID- 38451530 -OWN - NLM -STAT- MEDLINE -DCOM- 20240419 -LR - 20240419 -IS - 2374-2445 (Electronic) -IS - 2374-2437 (Print) -IS - 2374-2437 (Linking) -VI - 10 -IP - 4 -DP - 2024 Apr 1 -TI - Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell - Lung Cancer. -PG - 439-447 -LID - 10.1001/jamaoncol.2023.6277 [doi] -LID - e236277 -AB - IMPORTANCE: Immune checkpoint inhibitor (ICI) plus chemotherapy combination - treatment (ICI-chemotherapy) is now a standard treatment for non-small cell lung - cancer (NSCLC) without targetable oncogene alterations, but there are few data on - ICI-chemotherapy for patients 75 years and older. OBJECTIVE: To inform the choice - of first-line drugs in clinical practice and assess the safety and efficacy of - ICI-chemotherapy combination treatment in older adult patients with previously - untreated advanced NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective - cohort study included 58 centers in Japan. The cohort consisted of patients 75 - years and older with clinical stage IIIB, IIIC, IV, postoperative or radiotherapy - recurrent NSCLC. Patients started first-line systemic therapy between December - 2018 and March 2021. Those receiving first-line molecular targeted drugs were - excluded. The data were analyzed from February 2022 to October 2022. EXPOSURES: - Systemic therapy. MAIN OUTCOMES AND MEASURES: The main outcomes were overall - survival (OS), progression-free survival (PFS), and safety. RESULTS: A total of - 1245 patients (median [range] age, 78 [75-95] years; 967 [78%] male) with NSCLC - were included in the cohort. Programmed death ligand-1 (PD-L1) expression of less - than 1% occurred in 268 tumors (22%); 1% to 49% in 387 tumors (31%); 50% and - higher in 410 tumors (33%), and unknown expression in 180 tumors (14%). Median OS - was 20.0 (95% CI, 17.1-23.6) months for the 354 patients receiving - ICI-chemotherapy (28%); 19.8 (95% CI, 16.5-23.8) months for the 425 patients - receiving ICI alone (34%); 12.8 (95% CI, 10.7-15.6) months for the 311 patients - receiving platinum-doublet chemotherapy (25%); and 9.5 (95% CI, 7.4-13.4) months - for the 155 patients receiving single-agent chemotherapy (12%). After propensity - score matching, no differences in OS and PFS were found between the patients - receiving ICI-chemotherapy vs ICI alone. Each group consisted of 118 patients. - For PD-L1 expression of 1% and higher the OS hazard ratio (HR) was 0.98 (95% CI, - 0.67-1.42; P = .90), and the PFS HR was 0.92 (95% CI, 0.67-1.25; P = .59). - Significance was also not reached when separately analyzed for lower or higher - PD-L1 expression (1%-49% or ≥50%). However, grade 3 or higher immune-related - adverse events occurred in 86 patients (24.3%) treated with ICI-chemotherapy and - 76 (17.9%) with ICI alone (P = .03). CONCLUSIONS AND RELEVANCE: In this study, - ICI-chemotherapy combination treatment did not improve survival and increased the - incidence of grade 3 and higher immune-related adverse events compared with ICI - alone in patients 75 years and older. Based on these results, ICI alone may be - recommended for older adult patients with PD-L1-positive NSCLC. -FAU - Tsukita, Yoko -AU - Tsukita Y -AD - Department of Respiratory Medicine, Tohoku University Graduate School of - Medicine, Sendai, Japan. -FAU - Tozuka, Takehiro -AU - Tozuka T -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, Tokyo, Japan. -FAU - Kushiro, Kohei -AU - Kushiro K -AD - Department of Respiratory Medicine and Infectious Diseases, Niigata University - Graduate School of Medical and Dental Sciences, Niigata, Japan. -FAU - Hosokawa, Shinobu -AU - Hosokawa S -AD - Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, - Japan. -FAU - Sumi, Toshiyuki -AU - Sumi T -AD - Department of Respiratory Medicine, Hakodate Goryoukaku Hospital, Hakodate, - Japan. -FAU - Uematsu, Mao -AU - Uematsu M -AD - Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan - Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. -FAU - Honjo, Osamu -AU - Honjo O -AD - Department of Respiratory Medicine, Sapporo Minami-Sanjo Hospital, Sapporo, - Japan. -FAU - Yamaguchi, Ou -AU - Yamaguchi O -AD - Department of Respiratory Medicine, Saitama Medical University International - Medical Center, Hidaka, Saitama, Japan. -FAU - Asao, Tetsuhiko -AU - Asao T -AD - Department of Respiratory Medicine, Juntendo University Graduate School of - Medicine, Tokyo, Japan. -FAU - Sugisaka, Jun -AU - Sugisaka J -AD - Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan. -FAU - Saito, Go -AU - Saito G -AD - Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, - Japan. -FAU - Shiihara, Jun -AU - Shiihara J -AD - Department of Respiratory Medicine, Jichi Medical University Saitama Medical - Center, Saitama, Japan. -FAU - Morita, Ryo -AU - Morita R -AD - Department of Respiratory Medicine, Akita Kousei Medical Center, Akita, Japan. -FAU - Katakura, Seigo -AU - Katakura S -AD - Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan. -FAU - Yasuda, Takehiro -AU - Yasuda T -AD - Department of Respiratory Medicine, Yokosuka Kyosai Hospital, Yokosuka, Japan. -FAU - Hisakane, Kakeru -AU - Hisakane K -AD - Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School - Tamanagayama Hospital, Tokyo, Japan. -FAU - Miyauchi, Eisaku -AU - Miyauchi E -AD - Department of Respiratory Medicine, Tohoku University Graduate School of - Medicine, Sendai, Japan. -FAU - Morita, Satoshi -AU - Morita S -AD - Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate - School of Medicine, Kyoto, Japan. -FAU - Kobayashi, Kunihiko -AU - Kobayashi K -AD - Department of Respiratory Medicine, Saitama Medical University International - Medical Center, Hidaka, Saitama, Japan. -FAU - Asahina, Hajime -AU - Asahina H -AD - Department of Respiratory Medicine, Hokkaido University Graduate School of - Medicine, Sapporo, Japan. -LA - eng -PT - Comment -PT - Journal Article -PL - United States -TA - JAMA Oncol -JT - JAMA oncology -JID - 101652861 -RN - 0 (B7-H1 Antigen) -SB - IM -CON - JAMA Oncol. 2024 Apr 1;10(4):433-434. doi: 10.1001/jamaoncol.2023.5855. PMID: - 38451519 -MH - Male -MH - Humans -MH - Aged -MH - Female -MH - B7-H1 Antigen -MH - *Carcinoma, Non-Small-Cell Lung -MH - Retrospective Studies -MH - *Lung Neoplasms -MH - Neoplasm Recurrence, Local -MH - Immunotherapy -PMC - PMC10921348 -COIS- Conflict of Interest Disclosures: Dr Tsukita reported personal fees from - AstraZeneca, personal fees from Chugai Pharmaceutical, personal fees from Taiho - Pharmaceutical, personal fees from Daiichi Sankyo, personal fees from Eli Lilly, - personal fees from Bristol-Meyers Squibb, personal fees from MSD, personal fees - from Nippon Boehringer Ingelheim, and personal fees from Eisai outside the - submitted work. Dr Tozuka reported personal fees from AstraZeneca and personal - fees from Chugai Pharmaceutical outside the submitted work. Dr Kushiro reported - personal fees from Kyowa Kirin Co., Ltd., personal fees from CHUGAI - PHARMACEUTICAL CO., LTD., personal fees from AstraZeneca, personal fees from - Merck Biopharma Co., Ltd., and personal fees from Takeda Pharmaceutical Co., Ltd. - outside the submitted work. Dr Hosokawa reported personal fees from - Bristol-Meyers Squibb, personal fees from AstraZeneca, personal fees from Chugai - Pharmaceutical, and personal fees from Ono Pharmaceutical outside the submitted - work. Dr Sumi reported personal fees from Ono Pharmaceutical outside the - submitted work. Dr Honjo reported personal fees from Bristol-Meyers Squibb - outside the submitted work. Dr Yamaguchi reported personal fees from Ono - Pharmaceutical, personal fees from Bristol-Meyers Squibb, and personal fees from - Chugai Pharmaceutical outside the submitted work. Dr Asao reported personal fees - from AstraZeneca, personal fees from Chugai Pharmaceutical, personal fees from - Eli Lilly Japan, personal fees from MSD, personal fees from Nippon Kayaku, - personal fees from Pfizer, personal fees from Takeda Pharmaceutical, personal - fees from Bristol-Myers Squibb, personal fees from Daiich Sankyo, personal fees - from Merck Biopharma, personal fees from Nippon Boehringer Ingelheim, personal - fees from Ono Pharmaceutical, and personal fees from Taiho Pharmaceutical outside - the submitted work. Dr Saito reported personal fees from Ono Pharmaceutical, - personal fees from Chugai Pharmaceutical, personal fees from AstraZeneca, - personal fees from Novartis, personal fees from MSD K.K., personal fees from - Pfizer, personal fees from Daiichi Sankyo Company, and personal fees from Taiho - Pharmaceutical outside the submitted work. Dr Shiihara reported personal fees - from Chugai Pharmaceutical, personal fees from Daiichi Sankyo, personal fees from - Taiho Pharmaceutical, and personal fees from Takeda Pharmaceutical outside the - submitted work. Dr Yasuda reported personal fees from AstraZeneca, personal fees - from Chugai Pharmaceutical, personal fees from Nippon Kayaku, personal fees from - Ono Pharmaceutical, and personal fees from Sanofi outside the submitted work. Dr - Miyauchi reported grants from Chugai Pharmaceutical Co Ltd, grants from Eli Lily - Japan KK, personal fees from Taiho Pharmaceutical Co Ltd, personal fees from - Bristol Myers Squibb Co Ltd, personal fees from MSD KK, personal fees from Ono - Pharmaceutical Co Ltd, personal fees from Daiichi Sankyo KK, personal fees from - Boehringer Ingelheim Japan Inc, personal fees from Novartis Pharma KK, personal - fees from Kyowa Kirin Co Ltd, personal fees from Merck Biopharma Co Ltd, personal - fees from Pfizer Inc, personal fees from Eisai Co Ltd, personal fees from Otsuka - pharmaceutical Co Ltd, personal fees from Amgen Inc, personal fees from Thermo - Fisher Scientific K.K., personal fees from Takeda Pharmaceutical Co Ltd, personal - fees from Nippon Kayaku Co., Ltd., personal fees from Sysmex Co, personal fees - from AstraZeneca K.K., personal fees from Chugai Pharmaceutical Co Ltd, and - personal fees from Eli Lily Japan KK outside the submitted work. Dr S. Morita - reported personal fees from AstraZeneca, personal fees from Bristol-Myers Squibb, - personal fees from Chugai Pharmaceutical, personal fees from Taiho - Pharmaceutical, personal fees from Eli Lily Japan, personal fees from Merck Sharp - & Dohme, personal fees from Nippon Boehringer Ingelheim, personal fees from Ono - Pharmaceutical, personal fees from Pfizer, personal fees from Eisai, personal - fees from Novartis, and personal fees from Kyowa Kirin outside the submitted - work. Dr Kobayashi reported personal fees from Astra Zeneca speech fee, personal - fees from Takeda Pharmaceutical Company speech fee, and personal fees from - Daiichi Sankyo Co. speech fee outside the submitted work. Dr Asahina reported - grants from AstraZeneca, personal fees from AstraZeneca, personal fees from - Chugai Pharmaceutical, personal fees from Ono Pharmaceutical, personal fees from - MSD, personal fees from Eli Lilly, personal fees from Kyowa Hakko Kirin, personal - fees from Merck, personal fees from Taiho Pharmaceutical outside the submitted - work. No other disclosures were reported. -EDAT- 2024/03/07 12:43 -MHDA- 2024/04/19 06:43 -PMCR- 2025/03/07 -CRDT- 2024/03/07 11:34 -PHST- 2025/03/07 00:00 [pmc-release] -PHST- 2024/04/19 06:43 [medline] -PHST- 2024/03/07 12:43 [pubmed] -PHST- 2024/03/07 11:34 [entrez] -AID - 2815671 [pii] -AID - coi230082 [pii] -AID - 10.1001/jamaoncol.2023.6277 [doi] -PST - ppublish -SO - JAMA Oncol. 2024 Apr 1;10(4):439-447. doi: 10.1001/jamaoncol.2023.6277. - -PMID- 33595888 -OWN - NLM -STAT- MEDLINE -DCOM- 20210304 -LR - 20210304 -IS - 1096-9098 (Electronic) -IS - 0022-4790 (Linking) -VI - 123 -IP - 3 -DP - 2021 Mar -TI - Immunotherapy in lung cancer. -PG - 718-729 -LID - 10.1002/jso.26347 [doi] -AB - Immunotherapy has emerged as an important treatment modality throughout oncology - with a particularly important role in the treatment of lung cancer. Early signals - showed responses could be achieved in nonsmall cell lung cancer and small cell - lung cancer and these monoclonal antibodies have become standards of care for - advanced stage disease. They have also shown promise in earlier-stage disease as - complements to radiation or surgery, offering the potential for durable, - meaningful survival gains. -CI - © 2020 Wiley Periodicals LLC. -FAU - Montenegro, Gabriela Bravo -AU - Montenegro GB -AD - Division of Medical Oncology, Georgetown University, Washington, District of - Columbia, USA. -FAU - Farid, Saira -AU - Farid S -AD - Department of Medicine, Washington Hospital Center, Washington, District of - Columbia, USA. -FAU - Liu, Stephen V -AU - Liu SV -AD - Division of Medical Oncology, Georgetown University, Washington, District of - Columbia, USA. -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - J Surg Oncol -JT - Journal of surgical oncology -JID - 0222643 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - B7-H1 Antigen/antagonists & inhibitors/immunology -MH - Clinical Trials, Phase III as Topic -MH - Humans -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Immunotherapy/*methods -MH - Lung Neoplasms/drug therapy/immunology/*therapy -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology -MH - Randomized Controlled Trials as Topic -OTO - NOTNLM -OT - PD-1 -OT - PD-L1 -OT - checkpoint inhibitors -OT - chemo-immunotherapy -OT - neoadjuvant -EDAT- 2021/02/18 06:00 -MHDA- 2021/03/05 06:00 -CRDT- 2021/02/17 12:16 -PHST- 2020/11/13 00:00 [received] -PHST- 2020/11/20 00:00 [revised] -PHST- 2020/11/21 00:00 [accepted] -PHST- 2021/02/17 12:16 [entrez] -PHST- 2021/02/18 06:00 [pubmed] -PHST- 2021/03/05 06:00 [medline] -AID - 10.1002/jso.26347 [doi] -PST - ppublish -SO - J Surg Oncol. 2021 Mar;123(3):718-729. doi: 10.1002/jso.26347. - -PMID- 36126410 -OWN - NLM -STAT- MEDLINE -DCOM- 20221020 -LR - 20221020 -IS - 1878-1705 (Electronic) -IS - 1567-5769 (Linking) -VI - 112 -DP - 2022 Nov -TI - Benefits of combination therapy with immune checkpoint inhibitors and predictive - role of tumour mutation burden in hepatocellular carcinoma: A systematic review - and meta-analysis. -PG - 109244 -LID - S1567-5769(22)00728-7 [pii] -LID - 10.1016/j.intimp.2022.109244 [doi] -AB - OBJECTIVES: To investigate the clinical benefits of combination therapy with - immune checkpoint inhibitors (ICIs) and best combination regimen for people with - advanced hepatocellular carcinoma (HCC) and to explore the predictive performance - of tumour mutation burden (TMB). METHODS: We conducted a systematic literature - search to identify clinical trials. Meta-analysis and subgroup analyses were - performed to estimate the benefits of combination regimens with PD-1/PD-L1 - inhibitors for patients with advanced HCC and compare the effectiveness of - PD-1/PD-L1 inhibitors and sorafenib as first-line therapy. Individualized - analysis and Kaplan-Meier were used to assess the prognostic value of TMB. - RESULTS: A total of 29 studies with 5396 patients were included. ICIs' - combination therapy had higher ORR (26 % vs 15 %) and DCR (73 % vs 55 %), longer - PFS (5.5 vs 3.1 months) and OS (15.9 vs 12.6 months) compared to monotherapy. - Anti-PD-1/PD-L1 agents provided improved ORR, DCR, PFS and OS compared to - sorafenib. The overall ORs of ORR and DCR in subgroup analysis were 3.49 (95 % CI - 2.36-5.17, p < 0.01) and 1.60 (95 % CI 1.15-2.21, p < 0.01). The overall HRs of - PFS and OS were 0.68 (95 % CI 0.48-0.96, p = 0.03) and 0.73 (95 % CI 0.62-0.85, - p < 0.01). PD-1/PD-L1 inhibitors plus anti-VEGF agents had an advantage in DCR - (0.80 vs 0.48, meta-regression =  - 0.32, P < 0.001), but an equal ORR (0.29 vs - 0.26) compared to dual immune checkpoint inhibitors. The total OS in Dua-ICIs - were 16.5 months (95 % CI 14.2-18.7), yet not reached in the major studies of ICI - plus anti-VEGF regimen. In individualized analysis, the 1-year OS was superior - for patients who had high-TMB (>10, mutations/Mb) than moderate-TMB (1-10, - mutations/Mb; 28 % vs 15 %, P = 0.025). CONCLUSION: Immune checkpoint inhibitors' - combination therapy improved clinical outcomes in the management of advanced - hepatocellular carcinoma. However, the overall objective response rate still did - not exceed 30%. PD-1/PD-L1 inhibitors plus anti-angiogenic agents and dual - immunotherapy provided significantly increased survival over sorafenib, which - also pose new challenges for future research, and more appropriate and guided - control regimens are required. Also, TMB may be a promising prognostic biomarker - for immunotherapy in HCC. However, the validation of prospective and large sample - studies is needed. -CI - Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved. -FAU - Zheng, Jiaxi -AU - Zheng J -AD - Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of - Digestive System Tumour of Zhejiang Province, Taizhou, China; Key Laboratory of - Radiation Oncology of Taizhou, Radiation Oncology Institute of Enze Medical - Health Academy, Department of Radiation Oncology, Taizhou Hospital Affiliated to - Wenzhou Medical University, Taizhou, China. -FAU - Shao, Minghai -AU - Shao M -AD - Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of - Digestive System Tumour of Zhejiang Province, Taizhou, China; Key Laboratory of - Radiation Oncology of Taizhou, Radiation Oncology Institute of Enze Medical - Health Academy, Department of Radiation Oncology, Taizhou Hospital Affiliated to - Wenzhou Medical University, Taizhou, China. -FAU - Yang, Weifang -AU - Yang W -AD - Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of - Digestive System Tumour of Zhejiang Province, Taizhou, China; Key Laboratory of - Radiation Oncology of Taizhou, Radiation Oncology Institute of Enze Medical - Health Academy, Department of Radiation Oncology, Taizhou Hospital Affiliated to - Wenzhou Medical University, Taizhou, China. -FAU - Ren, Justin -AU - Ren J -AD - Biological Sciences, Northwestern University, Evanston, Evanston, IL, USA. -FAU - Chen, Xiaofeng -AU - Chen X -AD - Department of Radiation Oncology, Indiana University School of Medicine, - Indianapolis, IU, USA. Electronic address: xiaof.chen@yahoo.com. -FAU - Yang, Haihua -AU - Yang H -AD - Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of - Digestive System Tumour of Zhejiang Province, Taizhou, China; Key Laboratory of - Radiation Oncology of Taizhou, Radiation Oncology Institute of Enze Medical - Health Academy, Department of Radiation Oncology, Taizhou Hospital Affiliated to - Wenzhou Medical University, Taizhou, China. Electronic address: - yhh93181@hotmail.com. -LA - eng -PT - Journal Article -PT - Meta-Analysis -PT - Review -PT - Systematic Review -DEP - 20220918 -PL - Netherlands -TA - Int Immunopharmacol -JT - International immunopharmacology -JID - 100965259 -RN - 0 (B7-H1 Antigen) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 9ZOQ3TZI87 (Sorafenib) -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Humans -MH - B7-H1 Antigen/genetics -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - *Carcinoma, Hepatocellular/drug therapy/genetics -MH - *Lung Neoplasms/drug therapy -MH - *Antineoplastic Agents, Immunological/therapeutic use -MH - Sorafenib/therapeutic use -MH - Prospective Studies -MH - *Liver Neoplasms/drug therapy/genetics -MH - Biomarkers, Tumor/genetics -MH - Mutation -OTO - NOTNLM -OT - Biomarker -OT - Hepatocellular carcinoma -OT - Immune checkpoint inhibitor -OT - PD-1/PD-L1 -OT - Sorafenib -OT - Tumour mutation burden -COIS- Declaration of Competing Interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2022/09/21 06:00 -MHDA- 2022/10/21 06:00 -CRDT- 2022/09/20 18:18 -PHST- 2022/06/26 00:00 [received] -PHST- 2022/09/04 00:00 [revised] -PHST- 2022/09/07 00:00 [accepted] -PHST- 2022/09/21 06:00 [pubmed] -PHST- 2022/10/21 06:00 [medline] -PHST- 2022/09/20 18:18 [entrez] -AID - S1567-5769(22)00728-7 [pii] -AID - 10.1016/j.intimp.2022.109244 [doi] -PST - ppublish -SO - Int Immunopharmacol. 2022 Nov;112:109244. doi: 10.1016/j.intimp.2022.109244. Epub - 2022 Sep 18. - -PMID- 28533476 -OWN - NLM -STAT- MEDLINE -DCOM- 20180316 -LR - 20240326 -IS - 1549-490X (Electronic) -IS - 1083-7159 (Print) -IS - 1083-7159 (Linking) -VI - 22 -IP - 6 -DP - 2017 Jun -TI - Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally - Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined - Modality Therapy. -PG - 737-742 -LID - 10.1634/theoncologist.2016-0443 [doi] -AB - BACKGROUND: Neutrophil-lymphocyte ratio (NLR) is a measure of systemic - inflammation that appears prognostic in localized and advanced non-small cell - lung cancer (NSCLC). Increased systemic inflammation portends a poorer prognosis - in cancer patients. We hypothesized that low NLR at diagnosis is associated with - improved overall survival (OS) in locally advanced NSCLC (LANSCLC) patients. - PATIENTS AND METHODS: Records from 276 patients with stage IIIA and IIIB NSCLC - treated with definitive chemoradiation with or without surgery between 2000 and - 2010 with adequate data were retrospectively reviewed. Baseline demographic data - and pretreatment peripheral blood absolute neutrophil and lymphocyte counts were - collected. Patients were grouped into quartiles based on NLR. OS was estimated - using the Kaplan-Meier method. The log-rank test was used to compare mortality - between groups. A linear test-for-trend was used for the NLR quartile groups. The - Cox proportional hazards model was used for multivariable analysis. RESULTS: The - NLR was prognostic for OS (p < .0001). Median survival in months (95% confidence - interval) for the first, second, third, and fourth quartile groups of the - population distribution of NLR were 27 (19-36), 28 (22-34), 22 (12-31), and 10 - (8-12), respectively. NLR remained prognostic for OS after adjusting for race, - sex, stage, performance status, and chemoradiotherapy approach (p = .004). - CONCLUSION: To our knowledge, our series is the largest to demonstrate that - baseline NLR is a significant prognostic indicator in LANSCLC patients who - received definitive chemoradiation with or without surgery. As an indicator of - inflammatory response, it should be explored as a potential predictive marker in - the context of immunotherapy and radiation therapy. IMPLICATIONS FOR PRACTICE: - Neutrophil-lymphocyte ratio measured at the time of diagnosis was associated with - improved overall survival in 276 patients with stage IIIA and IIIB non-small cell - lung cancer (NSCLC) treated with definitive chemoradiation with or without - surgery. To our knowledge, our series is the largest to demonstrate that baseline - neutrophil-lymphocyte ratio is a significant prognostic indicator in locally - advanced NSCLC patients who received definitive chemoradiation with or without - surgery. Neutrophil-lymphocyte ratio is an inexpensive biomarker that may be - easily utilized by clinicians at the time of locally advanced NSCLC diagnosis to - help predict life expectancy. -CI - © AlphaMed Press 2017. -FAU - Scilla, Katherine A -AU - Scilla KA -AD - University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer - Center, Baltimore, Maryland, USA. -FAU - Bentzen, Søren M -AU - Bentzen SM -AD - University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer - Center, Baltimore, Maryland, USA. -FAU - Lam, Vincent K -AU - Lam VK -AD - University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer - Center, Baltimore, Maryland, USA. -FAU - Mohindra, Pranshu -AU - Mohindra P -AD - University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer - Center, Baltimore, Maryland, USA. -FAU - Nichols, Elizabeth M -AU - Nichols EM -AD - University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer - Center, Baltimore, Maryland, USA. -FAU - Vyfhuis, Melissa A -AU - Vyfhuis MA -AD - University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer - Center, Baltimore, Maryland, USA. -FAU - Bhooshan, Neha -AU - Bhooshan N -AD - University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer - Center, Baltimore, Maryland, USA. -FAU - Feigenberg, Steven J -AU - Feigenberg SJ -AD - University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer - Center, Baltimore, Maryland, USA. -FAU - Edelman, Martin J -AU - Edelman MJ -AD - University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer - Center, Baltimore, Maryland, USA. -FAU - Feliciano, Josephine L -AU - Feliciano JL -AD - Johns Hopkins School of Medicine, Baltimore, Maryland, USA jfelici4@jhmi.edu. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20170522 -PL - England -TA - Oncologist -JT - The oncologist -JID - 9607837 -RN - 0 (Biomarkers, Tumor) -SB - IM -CIN - J Thorac Dis. 2017 Sep;9(9):2782-2785. doi: 10.21037/jtd.2017.08.27. PMID: - 29221239 -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Biomarkers, Tumor/*blood -MH - Carcinoma, Non-Small-Cell Lung/*blood/drug therapy/pathology/radiotherapy -MH - Combined Modality Therapy/adverse effects -MH - Disease-Free Survival -MH - Female -MH - Humans -MH - Lymphocytes/*pathology -MH - Male -MH - Middle Aged -MH - Neoplasm Recurrence, Local/*blood/drug therapy/pathology/radiotherapy -MH - Neoplasm Staging -MH - Neutrophils/*pathology -MH - Prognosis -PMC - PMC5469587 -OTO - NOTNLM -OT - Locally advanced -OT - Neutrophil‐lymphocyte ratio -OT - Non‐small cell lung cancer -OT - Prognosis -COIS- Disclosures of potential conflicts of interest may be found at the end of this - article. -EDAT- 2017/05/24 06:00 -MHDA- 2018/03/17 06:00 -PMCR- 2018/06/01 -CRDT- 2017/05/24 06:00 -PHST- 2016/11/07 00:00 [received] -PHST- 2017/01/20 00:00 [accepted] -PHST- 2017/05/24 06:00 [pubmed] -PHST- 2018/03/17 06:00 [medline] -PHST- 2017/05/24 06:00 [entrez] -PHST- 2018/06/01 00:00 [pmc-release] -AID - theoncologist.2016-0443 [pii] -AID - ONCO12119 [pii] -AID - 10.1634/theoncologist.2016-0443 [doi] -PST - ppublish -SO - Oncologist. 2017 Jun;22(6):737-742. doi: 10.1634/theoncologist.2016-0443. Epub - 2017 May 22. - -PMID- 38347487 -OWN - NLM -STAT- MEDLINE -DCOM- 20240214 -LR - 20240215 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 24 -IP - 1 -DP - 2024 Feb 13 -TI - Molecular alterations and clinical prognostic factors in resectable non-small - cell lung cancer. -PG - 200 -LID - 10.1186/s12885-024-11934-2 [doi] -LID - 200 -AB - BACKGROUND: EGFR inhibitor and immunotherapy have been approved for adjuvant - treatment in resectable non-small cell lung cancer (NSCLC). Limited reports of - molecular and clinical characteristics as prognostic factors in NSCLC have been - published. METHODS: Medical records of patients with resectable NSCLC stage I-III - diagnosed during 2015-2020 were reviewed. Real time-PCR (RT-PCR) was performed - for EGFR mutations (EGFRm). Immunohistochemistry staining was conducted for ALK - and PD-L1 expression. Categorical variables were compared using chi-square test - and Fisher's exact test. Survival analysis was done by cox-regression method. - RESULTS: Total 441 patients were included. The prevalence of EGFRm, ALK fusion, - and PD-L1 expression were 57.8%, 1.9%, and 20.5% (SP263), respectively. The most - common EGFRm were Del19 (43%) and L858R (41%). There was no significant - difference of recurrence free survival (RFS) by EGFRm status whereas patients - with PD-L1 expression (PD-L1 positive patients) had lower RFS compared to without - PD-L1 expression (PD-L1 negative patients) (HR = 1.75, P = 0.036). Patients with - both EGFRm and PD-L1 expression had worse RFS compared with EGFRm and PD-L1 - negative patients (HR = 3.38, P = 0.001). Multivariable analysis showed higher - CEA at cut-off 3.8 ng/ml, pT4, pN2, pStage II, and margin were significant poor - prognostic factors for RFS in the overall population, which was similar to EGFRm - population (exception of pT and pStage). Only pStage was a significant poor - prognostic factor for PD-L1 positive patients. The predictive score for - predicting of recurrence were 6 for all population (63% sensitivity and 86% - specificity) and 5 for EGFRm population (62% sensitivity and 93% specificity). - CONCLUSION: The prevalence and types of EGFRm were similar between early stage - and advanced stage NSCLC. While lower prevalence of PD-L1 expression was found in - early stage disease. Patients with both EGFRm and PD-L1 expression had poorer - outcome. Thus PD-L1 expression would be one of the prognostic factor in EGFRm - patients. Validation of the predictive score should be performed in a larger - cohort. -CI - © 2024. The Author(s). -FAU - Thamrongjirapat, T -AU - Thamrongjirapat T -AD - Division of Medical Oncology, Department of Medicine, Faculty of Medicine - Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. -AD - Ramathibodi Lung Cancer Consortium (RLC), Faculty of Medicine Ramathibodi - Hospital, Mahidol University, Bangkok, Thailand. -FAU - Muntham, D -AU - Muntham D -AD - Department of Mathematics, Faculty of Science and Technology, Rajamangala - University of Technology Suvarnabhumi, Bangkok, Thailand. -FAU - Incharoen, P -AU - Incharoen P -AD - Ramathibodi Lung Cancer Consortium (RLC), Faculty of Medicine Ramathibodi - Hospital, Mahidol University, Bangkok, Thailand. -AD - Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol - University, Bangkok, Thailand. -FAU - Trachu, N -AU - Trachu N -AD - Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, - Bangkok, Thailand. -FAU - Sae-Lim, P -AU - Sae-Lim P -AD - Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol - University, Bangkok, Thailand. -FAU - Sarachai, N -AU - Sarachai N -AD - Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol - University, Bangkok, Thailand. -FAU - Khiewngam, K -AU - Khiewngam K -AD - Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol - University, Bangkok, Thailand. -FAU - Monnamo, N -AU - Monnamo N -AD - Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, - Bangkok, Thailand. -FAU - Kantathut, N -AU - Kantathut N -AD - Division of Thoracic Surgery, Department of Surgery, Faculty of Medicine - Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. -FAU - Ngodngamthaweesuk, M -AU - Ngodngamthaweesuk M -AD - Ramathibodi Lung Cancer Consortium (RLC), Faculty of Medicine Ramathibodi - Hospital, Mahidol University, Bangkok, Thailand. -AD - Division of Thoracic Surgery, Department of Surgery, Faculty of Medicine - Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. -FAU - Ativitavas, T -AU - Ativitavas T -AD - Division of Medical Oncology, Department of Medicine, Faculty of Medicine - Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. -AD - Ramathibodi Lung Cancer Consortium (RLC), Faculty of Medicine Ramathibodi - Hospital, Mahidol University, Bangkok, Thailand. -FAU - Chansriwong, P -AU - Chansriwong P -AD - Division of Medical Oncology, Department of Medicine, Faculty of Medicine - Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. -AD - Ramathibodi Lung Cancer Consortium (RLC), Faculty of Medicine Ramathibodi - Hospital, Mahidol University, Bangkok, Thailand. -FAU - Nitiwarangkul, C -AU - Nitiwarangkul C -AD - Ramathibodi Lung Cancer Consortium (RLC), Faculty of Medicine Ramathibodi - Hospital, Mahidol University, Bangkok, Thailand. -AD - Division of Diagnostic Radiology, Department of Diagnostic and Therapeutic - Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, - Thailand. -FAU - Ruangkanchanasetr, R -AU - Ruangkanchanasetr R -AD - Ramathibodi Lung Cancer Consortium (RLC), Faculty of Medicine Ramathibodi - Hospital, Mahidol University, Bangkok, Thailand. -AD - Radiation and Oncology Unit, Department of Diagnostic and Therapeutic Radiology, - Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. -FAU - Kositwattanarerk, A -AU - Kositwattanarerk A -AD - Ramathibodi Lung Cancer Consortium (RLC), Faculty of Medicine Ramathibodi - Hospital, Mahidol University, Bangkok, Thailand. -AD - Division of Nuclear Medicine, Department of Diagnostic and Therapeutic Radiology, - Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. -FAU - Sirachainan, E -AU - Sirachainan E -AD - Division of Medical Oncology, Department of Medicine, Faculty of Medicine - Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. -AD - Ramathibodi Lung Cancer Consortium (RLC), Faculty of Medicine Ramathibodi - Hospital, Mahidol University, Bangkok, Thailand. -FAU - Dejthevaporn, T -AU - Dejthevaporn T -AD - Division of Medical Oncology, Department of Medicine, Faculty of Medicine - Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. -AD - Ramathibodi Lung Cancer Consortium (RLC), Faculty of Medicine Ramathibodi - Hospital, Mahidol University, Bangkok, Thailand. -FAU - Reungwetwattana, T -AU - Reungwetwattana T -AD - Division of Medical Oncology, Department of Medicine, Faculty of Medicine - Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. - thanyanan.reu@mahidol.ac.th. -AD - Ramathibodi Lung Cancer Consortium (RLC), Faculty of Medicine Ramathibodi - Hospital, Mahidol University, Bangkok, Thailand. thanyanan.reu@mahidol.ac.th. -LA - eng -PT - Journal Article -DEP - 20240213 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (B7-H1 Antigen) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - B7-H1 Antigen/metabolism -MH - Prognosis -MH - ErbB Receptors/genetics/therapeutic use -MH - Mutation -PMC - PMC10863204 -OTO - NOTNLM -OT - EGFR mutation -OT - Molecular alterations -OT - Prognostic factors -OT - Resectable NSCLC -COIS- The authors declare no competing interests. -EDAT- 2024/02/13 00:42 -MHDA- 2024/02/13 06:45 -PMCR- 2024/02/13 -CRDT- 2024/02/12 23:41 -PHST- 2023/08/28 00:00 [received] -PHST- 2024/01/29 00:00 [accepted] -PHST- 2024/02/13 06:45 [medline] -PHST- 2024/02/13 00:42 [pubmed] -PHST- 2024/02/12 23:41 [entrez] -PHST- 2024/02/13 00:00 [pmc-release] -AID - 10.1186/s12885-024-11934-2 [pii] -AID - 11934 [pii] -AID - 10.1186/s12885-024-11934-2 [doi] -PST - epublish -SO - BMC Cancer. 2024 Feb 13;24(1):200. doi: 10.1186/s12885-024-11934-2. - -PMID- 36336841 -OWN - NLM -STAT- MEDLINE -DCOM- 20221220 -LR - 20230123 -IS - 2523-3548 (Electronic) -IS - 2523-3548 (Linking) -VI - 42 -IP - 12 -DP - 2022 Dec -TI - Sintilimab versus docetaxel as second-line treatment in advanced or metastatic - squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 - trial (ORIENT-3). -PG - 1314-1330 -LID - 10.1002/cac2.12385 [doi] -AB - BACKGROUND: Treatment options for Chinese patients with locally advanced or - metastatic squamous-cell non-small-cell lung cancer (sqNSCLC) after failure of - first-line chemotherapy are limited. This study (ORIENT-3) aimed to evaluate the - efficacy and safety of sintilimab versus docetaxel as second-line treatment in - patients with locally advanced or metastatic sqNSCLC. METHODS: ORIENT-3 was an - open-label, multicenter, randomized controlled phase 3 trial that recruited - patients with stage IIIB/IIIC/IV sqNSCLC after failure with first-line - platinum-based chemotherapy. Patients were randomized in a 1:1 ratio to receive - either 200 mg of sintilimab or 75 mg/m(2) of docetaxel intravenously every 3 - weeks, stratified by the Eastern Cooperative Oncology Group performance status. - The primary endpoint was overall survival (OS) in the full analysis set (FAS). - Secondary endpoints included progression-free survival (PFS), objective response - rate (ORR), disease control rate (DCR), duration of response (DoR) and safety. - RESULTS: Between August 25, 2017, and November 7, 2018, 290 patients were - randomized. For FAS, 10 patients from the docetaxel arm were excluded. The median - OS was 11.79 (n = 145; 95% confidence interval [CI], 10.28-15.57) months with - sintilimab versus 8.25 (n = 135; 95% CI, 6.47-9.82) months with docetaxel (hazard - ratio [HR]: 0.74; 95% CI, 0.56-0.96; P = 0.025). Sintilimab treatment - significantly prolonged PFS (median 4.30 vs. 2.79 months; HR: 0.52; 95% CI, - 0.39-0.68; P < 0.001) and showed higher ORR (25.50% vs. 2.20%, P < 0.001) and DCR - (65.50% vs. 37.80%, P < 0.001) than the docetaxel arm. The median DoR was 12.45 - (95% CI, 4.86-25.33) months in the sintilimab arm and 4.14 (95% CI, 1.41-7.23) - months in the docetaxel arm (P = 0.045). Treatment-related adverse events of - grade ≥ 3 were reported in 26 (18.1%) patients in the sintilimab arm and 47 - (36.2%) patients in the docetaxel arm. Exploratory biomarker analysis showed - potential predictive values of expression levels of two transcription factors, - including OVOL2 (HR: 0.35; P < 0.001) and CTCF (HR: 3.50; P < 0.001),for - sintilimab treatment. CONCLUSIONS: Compared with docetaxel, sintilimab - significantly improved the OS, PFS, and ORR of Chinese patients with previously - treated locally advanced or metastatic sqNSCLC. -CI - © 2022 The Authors. Cancer Communications published by John Wiley & Sons - Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center. -FAU - Shi, Yuankai -AU - Shi Y -AUID- ORCID: 0000-0002-3342-4964 -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking - Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer - Molecular Targeted Drugs, Beijing, P. R. China. -FAU - Wu, Lin -AU - Wu L -AUID- ORCID: 0000-0001-7078-7767 -AD - Department II of Thoracic Medicine, Hunan Cancer Hospital, Changsha, Hunan, P. R. - China. -FAU - Yu, Xinmin -AU - Yu X -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. - R. China. -FAU - Xing, Puyuan -AU - Xing P -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking - Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer - Molecular Targeted Drugs, Beijing, P. R. China. -FAU - Wang, Yan -AU - Wang Y -AD - Department of Medical Oncology, National Cancer Center/National Clinical Research - Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking - Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer - Molecular Targeted Drugs, Beijing, P. R. China. -FAU - Zhou, Jianying -AU - Zhou J -AD - Department of Respiratory Diseases, The First Affiliated Hospital, College of - Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China. -FAU - Wang, Airong -AU - Wang A -AD - The Third Department of Chemotherapy, Weihai Municipal Hospital, Weihai, - Shandong, P. R. China. -FAU - Shi, Jianhua -AU - Shi J -AD - Department of Medical Oncology, Linyi Cancer Hospital, Linyi, Shandong, P. R. - China. -FAU - Hu, Yi -AU - Hu Y -AD - Oncology Department, General Hospital of Chinese People's Liberation Army, - Beijing, P. R. China. -FAU - Wang, Ziping -AU - Wang Z -AD - Department of Chest Medicine, Beijing Cancer Hospital, Beijing, P. R. China. -FAU - An, Guangyu -AU - An G -AD - Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, - Beijing, P. R. China. -FAU - Fang, Yong -AU - Fang Y -AD - Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, - Hangzhou, Zhejiang, P. R. China. -FAU - Sun, Sanyuan -AU - Sun S -AD - Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou Medical - University, Xuzhou, Jiangsu, P. R. China. -FAU - Zhou, Caicun -AU - Zhou C -AUID- ORCID: 0000-0002-6958-0766 -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, - Shanghai, P. R. China. -FAU - Wang, Changli -AU - Wang C -AD - Department of Lung Cancer, Tianjin Medical University Cancer Institute and - Hospital, Tianjin, P. R. China. -FAU - Ye, Feng -AU - Ye F -AD - Department of Medical Oncology, Cancer Hospital, The First Affiliated Hospital of - Xiamen University, School of Medicine, Xiamen University, The Third Clinical - Medical College, Fujian Medical University, Xiamen, Fujian, P. R. China. -FAU - Li, Xingya -AU - Li X -AD - Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou - University, Zhengzhou, Henan, P. R. China. -FAU - Wang, Junye -AU - Wang J -AD - Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, - Shandong, P. R. China. -FAU - Wang, Mengzhao -AU - Wang M -AUID- ORCID: 0000-0002-9226-5393 -AD - Department of Respiratory and Critical Care Medicine, Peking Union Medical - College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical - College, Beijing, P. R. China. -FAU - Liu, Yunpeng -AU - Liu Y -AD - Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy - of Liaoning Province, The First Hospital of China Medical University, Shenyang, - Liaoning, P. R. China. -FAU - Zhao, Yanqiu -AU - Zhao Y -AD - Department of Internal Medicine, Henan Cancer Hospital, Affiliated Cancer - Hospital of Zhengzhou University, Zhengzhou, Henan, P. R. China. -FAU - Yuan, Ying -AU - Yuan Y -AD - Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang - University School of Medicine, Hangzhou, Zhejiang, P. R. China. -FAU - Feng, Jifeng -AU - Feng J -AD - Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of - Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, - Nanjing, Jiangsu, P. R. China. -FAU - Chen, Zhendong -AU - Chen Z -AD - Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, - Anhui, P. R. China. -FAU - Shi, Jindong -AU - Shi J -AD - Department of Respiratory Medicine, Shanghai Fifth' People's Hospital, Fudan - University, Shanghai, P. R. China. -FAU - Sun, Tao -AU - Sun T -AD - Department of Medical Oncology, Cancer Hospital of China Medical University, - Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China. -FAU - Wu, Gang -AU - Wu G -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, Hubei, P. R. China. -FAU - Shu, Yongqian -AU - Shu Y -AUID- ORCID: 0000-0003-2103-0877 -AD - Department of Oncology, The First Affiliated Hospital of Nanjing Medical - University, Nanjing, Jiangsu, P. R. China. -FAU - Guo, Qisen -AU - Guo Q -AD - Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong - University, Shandong Academy of Medical Sciences, Shandong Cancer Hospital and - Institute, Jinan, Shandong, P. R. China. -FAU - Zhang, Yi -AU - Zhang Y -AD - Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, - Beijing, P. R. China. -FAU - Song, Yong -AU - Song Y -AD - Department of Respiratory and Critical Care Medicine, The General Hospital of the - Eastern Theater Command of PLA, Nanjing, Jiangsu, P. R. China. -FAU - Zhang, Shucai -AU - Zhang S -AD - Department of Oncology, Beijing Chest Hospital, Capital Medical University, - Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, P. R. China. -FAU - Chen, Yuan -AU - Chen Y -AD - Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong - University of Science and Technology, Wuhan, Hubei, P. R. China. -FAU - Li, Wei -AU - Li W -AD - Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, P. R. - China. -FAU - Niu, Hongrui -AU - Niu H -AD - Department of Oncology, The First Affiliated Hospital of Xinxiang Medical - University, Xinxiang, Henan, P. R. China. -FAU - Hu, Wenwei -AU - Hu W -AD - Department of Oncology, The First People's Hospital of Changzhou, Changzhou, - Jiangsu, P. R. China. -FAU - Wang, Lijun -AU - Wang L -AD - Department of Tumor Radiotherapy, The Second Affiliated Hospital of Xingtai - Medical College, Xingtai, Hebei, P. R. China. -FAU - Huang, Jianan -AU - Huang J -AD - Department of Respiratory Medicine, The First Affiliated Hospital of Soochow - University, Suzhou, Jiangsu, P. R. China. -FAU - Zhang, Yang -AU - Zhang Y -AD - Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, - Liaoning, P. R. China. -FAU - Cheng, Ying -AU - Cheng Y -AD - Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, Jilin, P. R. - China. -FAU - Wu, Zhengdong -AU - Wu Z -AD - Department of Oncology, Jiangsu Taizhou People's Hospital, Taizhou, Jiangsu, P. - R. China. -FAU - Peng, Bo -AU - Peng B -AD - New Drug Biology and Translational Medicine, Innovent Biologics, Inc., Suzhou, - Jiangsu, P. R. China. -FAU - Sun, Jiya -AU - Sun J -AD - New Drug Biology and Translational Medicine, Innovent Biologics, Inc., Suzhou, - Jiangsu, P. R. China. -FAU - Mancao, Christoph -AU - Mancao C -AD - New Drug Biology and Translational Medicine, Innovent Biologics, Inc., Suzhou, - Jiangsu, P. R. China. -FAU - Wang, Yanqi -AU - Wang Y -AD - Medical Science and Strategy Oncology, Innovent Biologics, Inc., Suzhou, Jiangsu, - P. R. China. -FAU - Sun, Luyao -AU - Sun L -AD - Medical Science and Strategy Oncology, Innovent Biologics, Inc., Suzhou, Jiangsu, - P. R. China. -LA - eng -SI - ClinicalTrials.gov/NCT03150875 -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Multicenter Study -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20221106 -PL - United States -TA - Cancer Commun (Lond) -JT - Cancer communications (London, England) -JID - 101723675 -RN - 15H5577CQD (Docetaxel) -RN - 8FU7FQ8UPK (sintilimab) -RN - 0 (Taxoids) -RN - 0 (Ovol2 protein, human) -RN - 0 (Transcription Factors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung -MH - Docetaxel/adverse effects -MH - *Lung Neoplasms/pathology -MH - Taxoids/adverse effects -MH - *Carcinoma, Squamous Cell/drug therapy -MH - Transcription Factors -PMC - PMC9759762 -OTO - NOTNLM -OT - Carcinoma, squamous cell -OT - Immunotherapy -OT - Non-small cell lung cancer -OT - Randomized controlled trial -OT - Sintilimab -OT - Survival -COIS- Disclosure: Bo Peng, Jiya Sun, Christoph Mancao, Yanqi Wang and Luyao Sun are - full‐time employees of Innovent Biologics,Inc. The other authors declare that - they have no competing interests. -EDAT- 2022/11/08 06:00 -MHDA- 2022/12/21 06:00 -PMCR- 2022/11/06 -CRDT- 2022/11/07 00:42 -PHST- 2022/09/20 00:00 [revised] -PHST- 2021/12/15 00:00 [received] -PHST- 2022/10/21 00:00 [accepted] -PHST- 2022/11/08 06:00 [pubmed] -PHST- 2022/12/21 06:00 [medline] -PHST- 2022/11/07 00:42 [entrez] -PHST- 2022/11/06 00:00 [pmc-release] -AID - CAC212385 [pii] -AID - 10.1002/cac2.12385 [doi] -PST - ppublish -SO - Cancer Commun (Lond). 2022 Dec;42(12):1314-1330. doi: 10.1002/cac2.12385. Epub - 2022 Nov 6. - -PMID- 33358698 -OWN - NLM -STAT- MEDLINE -DCOM- 20210623 -LR - 20211204 -IS - 1872-7980 (Electronic) -IS - 0304-3835 (Print) -IS - 0304-3835 (Linking) -VI - 500 -DP - 2021 Mar 1 -TI - Targeting NPM1 in irradiated cells inhibits NPM1 binding to RAD51, RAD51 foci - formation and radiosensitizes NSCLC. -PG - 220-227 -LID - S0304-3835(20)30683-2 [pii] -LID - 10.1016/j.canlet.2020.12.023 [doi] -AB - The ability of chemo-radiation therapy to control locally advanced stage III - non-small cell lung cancer (NSCLC) is poor. While addition of consolidation - immunotherapy has improved outcomes in subsets of patients there is still an - urgent need for new therapeutic targets. Emerging research indicates that - nucleophosmin1 (NPM1) is over-expressed in NSCLC, promotes tumor growth and that - over-expression correlates with a lower survival probability. NPM1 is critical - for APE1 base excision activity and for RAD51-mediated repair of DNA double - strand breaks (DSBs). YTR107 is a small molecule radiation sensitizer that has - been shown to bind to NPM1, suppressing pentamer formation. Here we show that in - irradiated cells YTR107 inhibits SUMOylated NPM1 from associating with RAD51, - RAD51 foci formation and repair of DSBs. YTR107 acts synergistically with the - PARP1/2 inhibitor ABT 888 to increase replication stress and radiation-induced - cell lethality. YTR107 was found to radiosensitize tumor initiating cells. - Congruent with this knowledge, adding YTR107 to a fractionated irradiation - regimen diminished NSCLC xenograft growth and increased overall survival. These - data support the hypothesis that YTR107 represents a therapeutic target for - control of NSCLC. -CI - Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved. -FAU - Traver, Geri -AU - Traver G -AD - Department of Radiation Oncology, Vanderbilt University Medical Center, - Nashville, TN, 37232, USA. -FAU - Sekhar, Konjeti R -AU - Sekhar KR -AD - Department of Radiation Oncology, Vanderbilt University Medical Center, - Nashville, TN, 37232, USA. -FAU - Crooks, Peter A -AU - Crooks PA -AD - Department of Pharmaceutical Sciences, College of Pharmacy, University of - Arkansas for Medical Sciences, Little Rock, AR72205, USA. -FAU - Keeney, Diane S -AU - Keeney DS -AD - Cumberland Emerging Technologies, Inc., 2525 West End Ave, Suite 950, Nashville, - TN, 37203-1608, USA. -FAU - Freeman, Michael L -AU - Freeman ML -AD - Department of Radiation Oncology, Vanderbilt University Medical Center, - Nashville, TN, 37232, USA. Electronic address: michael.freeman@vumc.org. -LA - eng -GR - R44 CA228756/CA/NCI NIH HHS/United States -GR - P30 DK058404/DK/NIDDK NIH HHS/United States -GR - P30 HD015052/HD/NICHD NIH HHS/United States -GR - P30 EY008126/EY/NEI NIH HHS/United States -GR - P30 DK020593/DK/NIDDK NIH HHS/United States -GR - P30 CA068485/CA/NCI NIH HHS/United States -GR - U24 DK059637/DK/NIDDK NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20201221 -PL - Ireland -TA - Cancer Lett -JT - Cancer letters -JID - 7600053 -RN - 0 (5-((N-benzyl-1H-indol-3-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)trione) -RN - 0 (Barbiturates) -RN - 0 (Indoles) -RN - 0 (NPM1 protein, human) -RN - 0 (Nuclear Proteins) -RN - 0 (Radiation-Sensitizing Agents) -RN - 117896-08-9 (Nucleophosmin) -RN - EC 2.4.2.30 (Poly (ADP-Ribose) Polymerase-1) -RN - EC 2.7.7.- (Rad51 Recombinase) -RN - EC 4.2.99.18 (APEX1 protein, human) -RN - EC 4.2.99.18 (DNA-(Apurinic or Apyrimidinic Site) Lyase) -SB - IM -MH - Barbiturates/pharmacology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/pathology/*radiotherapy -MH - Cell Line, Tumor -MH - Cell Proliferation/drug effects -MH - DNA Breaks, Double-Stranded/radiation effects -MH - DNA Repair/drug effects/radiation effects -MH - DNA-(Apurinic or Apyrimidinic Site) Lyase/*genetics -MH - Humans -MH - Indoles/pharmacology -MH - Neoplasm Recurrence, Local/drug therapy/genetics/pathology/radiotherapy -MH - Nuclear Proteins/*genetics -MH - Nucleophosmin -MH - Poly (ADP-Ribose) Polymerase-1/antagonists & inhibitors/genetics -MH - Rad51 Recombinase/*genetics -MH - Radiation Tolerance/drug effects -MH - Radiation-Sensitizing Agents/pharmacology -MH - Sumoylation/drug effects/radiation effects -PMC - PMC7822076 -MID - NIHMS1658200 -OTO - NOTNLM -OT - NSCLC -OT - Nucleophosmin1 -OT - RAD51 -OT - Radiation sensitization -OT - YTR107 -COIS- Declaration of competing interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2020/12/29 06:00 -MHDA- 2021/06/24 06:00 -PMCR- 2021/03/01 -CRDT- 2020/12/28 10:39 -PHST- 2020/10/26 00:00 [received] -PHST- 2020/12/14 00:00 [revised] -PHST- 2020/12/16 00:00 [accepted] -PHST- 2020/12/29 06:00 [pubmed] -PHST- 2021/06/24 06:00 [medline] -PHST- 2020/12/28 10:39 [entrez] -PHST- 2021/03/01 00:00 [pmc-release] -AID - S0304-3835(20)30683-2 [pii] -AID - 10.1016/j.canlet.2020.12.023 [doi] -PST - ppublish -SO - Cancer Lett. 2021 Mar 1;500:220-227. doi: 10.1016/j.canlet.2020.12.023. Epub 2020 - Dec 21. - -PMID- 37158938 -OWN - NLM -STAT- MEDLINE -DCOM- 20230515 -LR - 20230612 -IS - 1756-8722 (Electronic) -IS - 1756-8722 (Linking) -VI - 16 -IP - 1 -DP - 2023 May 8 -TI - First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual - blocker, in patients with advanced solid tumors. -PG - 50 -LID - 10.1186/s13045-023-01445-1 [doi] -LID - 50 -AB - BACKGROUND: QL1706 (PSB205) is a single bifunctional MabPair (a novel technical - platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 - IgG4 and anti-CTLA-4 IgG1), with a shorter elimination half-life (t(1/2)) for - CTLA-4. We report results from a phase I/Ib study of QL1706 in patients with - advanced solid tumors who failed standard therapies. METHODS: In the phase I - study, QL1706 was administered intravenously once every 3 weeks at one of five - doses ranging from 0.3 to 10 mg/kg, and the maximum tolerated dose, recommended - phase 2 dose (RP2D), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of - QL1706 were investigated. In the phase Ib study, QL1706 was administered at the - RP2D intravenously every 3 weeks, and the preliminary efficacies in non-small - cell lung cancer (NSCLC), nasopharyngeal carcinoma (NPC), cervical cancer (CC), - and other solid tumors were evaluated. RESULTS: Between March 2020 and July 2021, - 518 patients with advanced solid tumors were enrolled (phase I, n = 99; phase Ib, - n = 419). For all patients, the three most common treatment-related adverse - events (TRAEs) were rash (19.7%), hypothyroidism (13.5%), and pruritus (13.3%). - The TRAEs and immune-related adverse events (irAEs) of grade ≥ 3 occurred in - 16.0% and 8.1% of patients, respectively. In phase I, 2 of 6 patients in the - 10mg/kg group experienced dose-limiting toxicities (DLTs) (grade 3 - thrombocytopenia and grade 4 immune-mediated nephritis), so the maximum tolerated - dose (MTD) was reached at 10 mg/kg. The RP2D was determined to be 5 mg/kg based - on comprehensive analysis of tolerability, PK/PD, and efficacy. For all patients - who received QL1706 at the RP2D, the objective response rate (ORR) and median - duration of response were 16.9% (79/468) and 11.7 months (8.3-not reached [NR]), - respectively; and the ORRs were 14.0% (17/121) in NSCLC, 24.5% (27/110) in NPC, - 27.3% (15/55) in CC, 7.4% (2/27) in colorectal cancer, 23.1% (6/26) in small cell - lung cancer. For immunotherapy-naive patients, QL1706 exhibited promising - antitumor activities, especially in NSCLC, NPC, and CC, with ORRs of 24.2%, - 38.7%, and 28.3%, respectively. CONCLUSIONS: QL1706 was well tolerated and - demonstrated promising antitumor activity in solid tumors, especially in NSCLC, - NPC, and CC patients. It is currently being evaluated in randomized phase II - (NCT05576272, NCT05179317) and phase III (NCT05446883, NCT05487391) trials. Trial - Registration ClinicalTrials.gov Identifier: NCT04296994 and NCT05171790. -CI - © 2023. The Author(s). -FAU - Zhao, Yuanyuan -AU - Zhao Y -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer - Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and - Therapy, No. 651 Dongfeng East Road, Guangzhou, 510060, China. -FAU - Ma, Yuxiang -AU - Ma Y -AD - Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer - Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and - Therapy, No. 651 Dongfeng East Road, Guangzhou, 510060, China. -FAU - Zang, Aimin -AU - Zang A -AD - Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, - 071000, China. -FAU - Cheng, Ying -AU - Cheng Y -AD - Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, 130012, China. -FAU - Zhang, Yiping -AU - Zhang Y -AD - The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang - Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy - of Sciences, Hangzhou, 310022, Zhejiang, China. -FAU - Wang, Xiangcai -AU - Wang X -AD - Department of Oncology, First Affiliated Hospital of Gannan Medical University, - Ganzhou, 341001, China. -FAU - Chen, Zhendong -AU - Chen Z -AD - Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical - University, Hefei, 230093, China. -FAU - Qu, Song -AU - Qu S -AD - Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, - Cancer Institute of Guangxi, Nanning, 530021, Guangxi, China. -FAU - He, Jianbo -AU - He J -AD - Department of Medical Oncology of Respiratory, Guangxi Medical University Cancer - Hospital, Cancer Institute of Guangxi, Nanning, 530021, Guangxi, China. -FAU - Chen, Chuanben -AU - Chen C -AD - Department of Head and Neck Radiation Oncology, Fujian Cancer Hospital, Fuzhou, - 350000, China. -FAU - Jin, Chuan -AU - Jin C -AD - Department of Medical Oncology, Affiliated Cancer Hospital and Institute of - Guangzhou Medical University, Guangzhou, 510095, China. -FAU - Zhu, Dongyuan -AU - Zhu D -AD - Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, - China. -FAU - Li, Qingshan -AU - Li Q -AD - Department of Oncology, Affiliated Hospital of Chengde Medical University, - Chengde, 067000, China. -FAU - Liu, Xianling -AU - Liu X -AD - Department of Oncology, Second Xiangya Hospital, Central South University, - Changsha, 410011, China. -FAU - Su, Wuyun -AU - Su W -AD - Department of Medical Oncology, Affiliated Hospital of Inner Mongolia Medical - University, Huhhot, 010050, Inner Mongolia, China. -FAU - Ba, Yi -AU - Ba Y -AD - Tianjin Medical University Cancer Institute and Hospital, National Clinical - Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, - Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China. -FAU - Hao, Yanrong -AU - Hao Y -AD - Department of Oncology, Clinical Oncology Center, The People's Hospital of - Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, - 530021, China. -FAU - Chen, Junmin -AU - Chen J -AD - Department of Medical Oncology, Hainan General Hospital, Haikou, 570100, China. -FAU - Zhang, Guoping -AU - Zhang G -AD - Department of Medical Oncology, Yuebei People's Hospital, Shaoguan, 512025, - China. -FAU - Qu, Shenhong -AU - Qu S -AD - Department of Otolaryngology & Head and Neck, The People's Hospital of Guangxi - Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, 530021, - China. -FAU - Li, Yong -AU - Li Y -AD - Department of Medical Oncology, The First Affiliated Hospital of Nanchang - University, Nanchang, 330000, China. -FAU - Feng, Weineng -AU - Feng W -AD - Department of Head and Neck/Thoracic Medical Oncology, The First People's - Hospital of Foshan, Foshan City, 528010, China. -FAU - Yang, Mengxiang -AU - Yang M -AD - Oncology Department, Liaocheng People's Hospital, Liaocheng, 252004, China. -FAU - Liu, Baorui -AU - Liu B -AD - The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing - University and Clinical Cancer Institute of Nanjing University, Nanjing, 210008, - China. -FAU - Ouyang, Weiwei -AU - Ouyang W -AD - Department of Oncology, The Affiliated Cancer Hospital of Guizhou Medical - University, Guiyang, 550001, China. -FAU - Liang, Jin -AU - Liang J -AD - Department of Oncology, The First Affiliated Hospital of Kunming Medical - University, Kunming, 650032, China. -FAU - Yu, Zhuang -AU - Yu Z -AD - Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, - 266003, China. -FAU - Kang, Xiaoyan -AU - Kang X -AD - Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, 250000, China. -FAU - Xue, Shilin -AU - Xue S -AD - Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, 250000, China. -FAU - Yang, Guihong -AU - Yang G -AD - Department of Clinical Pharmacology, Qilu Pharmaceutical Co., Ltd., Jinan, - 250000, China. -FAU - Yan, Wei -AU - Yan W -AD - Sound Biologics, 21720 23rd Drive SE, Suite200, Bothell, WA, 98021, USA. -FAU - Yang, Yingying -AU - Yang Y -AD - Department of Non-Clinical, Qilu Pharmaceutical Co., Ltd., Jinan, 250001, China. -FAU - Liu, Zhi -AU - Liu Z -AD - Sound Biologics, 21720 23rd Drive SE, Suite200, Bothell, WA, 98021, USA. -FAU - Peng, Yufeng -AU - Peng Y -AD - Sound Biologics, 21720 23rd Drive SE, Suite200, Bothell, WA, 98021, USA. -FAU - Fanslow, Bill -AU - Fanslow B -AD - Sound Biologics, 21720 23rd Drive SE, Suite200, Bothell, WA, 98021, USA. -FAU - Huang, Xian -AU - Huang X -AD - Sound Biologics, 21720 23rd Drive SE, Suite200, Bothell, WA, 98021, USA. -FAU - Zhang, Li -AU - Zhang L -AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer - Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and - Therapy, No. 651 Dongfeng East Road, Guangzhou, 510060, China. - zhangli@sysucc.org.cn. -FAU - Zhao, Hongyun -AU - Zhao H -AD - Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key - Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer - Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and - Therapy, No. 651 Dongfeng East Road, Guangzhou, 510060, China. - zhaohy@sysucc.org.cn. -LA - eng -SI - ClinicalTrials.gov/NCT04296994 -SI - ClinicalTrials.gov/NCT05171790 -SI - ClinicalTrials.gov/NCT05487391 -SI - ClinicalTrials.gov/NCT05446883 -SI - ClinicalTrials.gov/NCT05171790 -SI - ClinicalTrials.gov/NCT05179317 -SI - ClinicalTrials.gov/NCT04296994 -PT - Clinical Trial, Phase I -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20230508 -PL - England -TA - J Hematol Oncol -JT - Journal of hematology & oncology -JID - 101468937 -RN - 0 (Antibodies, Bispecific) -RN - 0 (Antineoplastic Agents) -RN - 0 (CTLA-4 Antigen) -RN - 0 (CTLA4 protein, human) -RN - 0 (Immunoglobulin G) -SB - IM -MH - Female -MH - Humans -MH - *Antibodies, Bispecific -MH - *Antineoplastic Agents -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *CTLA-4 Antigen/antagonists & inhibitors -MH - Immunoglobulin G -MH - *Lung Neoplasms/drug therapy -MH - *Uterine Cervical Neoplasms/drug therapy -MH - *Nasopharyngeal Carcinoma/drug therapy -PMC - PMC10169367 -OTO - NOTNLM -OT - Bifunctional PD-1 -OT - CTLA4 antibody -OT - Cervical cancer -OT - MabPair -OT - Nasopharyngeal carcinoma -OT - Phase I trial -COIS- Li Zhang reports receiving research support from Jiangsu Hengrui Pharmaceuticals, - Eli Lilly, Novartis, Roche, and Bristol-Myers Squibb. Zhi Liu, Yufeng Peng, Bill - Fanslow, Xian Huang, and Wei Yan are employees of Sound Biologics. Xiaoyan Kang, - Shilin Xue, Guihong Yang, and Yingying Yang are employees of Qilu Pharma Ltd. All - other authors declare no potential competing interests. -EDAT- 2023/05/09 13:42 -MHDA- 2023/05/11 06:42 -PMCR- 2023/05/08 -CRDT- 2023/05/09 10:50 -PHST- 2022/12/27 00:00 [received] -PHST- 2023/04/26 00:00 [accepted] -PHST- 2023/05/11 06:42 [medline] -PHST- 2023/05/09 13:42 [pubmed] -PHST- 2023/05/09 10:50 [entrez] -PHST- 2023/05/08 00:00 [pmc-release] -AID - 10.1186/s13045-023-01445-1 [pii] -AID - 1445 [pii] -AID - 10.1186/s13045-023-01445-1 [doi] -PST - epublish -SO - J Hematol Oncol. 2023 May 8;16(1):50. doi: 10.1186/s13045-023-01445-1. - -PMID- 29358503 -OWN - NLM -STAT- MEDLINE -DCOM- 20190930 -LR - 20190930 -IS - 1557-3265 (Electronic) -IS - 1078-0432 (Linking) -VI - 24 -IP - 6 -DP - 2018 Mar 15 -TI - Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in - Stage III Lung Cancer. -PG - 1271-1276 -LID - 10.1158/1078-0432.CCR-17-3269 [doi] -AB - Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is - standard-of-care therapy for patients with stage III unresectable non-small cell - lung cancer (NSCLC). Although cCRT is potentially curative, 5-year overall - survival has hovered around 20%, despite extensive efforts to improve outcomes - with increasing doses of conformal radiation and intensification of systemic - therapy with either induction or consolidation chemotherapy. PD-1/PD-L1 immune - checkpoint inhibitors have demonstrated unprecedented efficacy in patients with - stage IV NSCLC. In addition, preclinical and early clinical evidence suggests - that chemotherapy and radiation may work synergistically with anti-PD-1/PD-L1 - therapy to promote antitumor immunity, which has led to the initiation of - clinical trials testing these drugs in patients with stage III NSCLC. A - preliminary report of a randomized phase III trial, the PACIFIC trial, - demonstrated an impressive increase in median progression-free survival with - consolidative durvalumab, a PD-L1 inhibitor, compared with observation after - cCRT. Here, we discuss the clinical and translational implications of integrating - PD-1/PD-L1 inhibitors in the management of patients with unresectable stage III - NSCLC. Clin Cancer Res; 24(6); 1271-6. ©2018 AACR. -CI - ©2018 American Association for Cancer Research. -FAU - McCall, Neal S -AU - McCall NS -AD - Department of Radiation Oncology, Thomas Jefferson University Hospitals, - Philadelphia, Pennsylvania. -FAU - Dicker, Adam P -AU - Dicker AP -AD - Department of Radiation Oncology, Thomas Jefferson University Hospitals, - Philadelphia, Pennsylvania. -FAU - Lu, Bo -AU - Lu B -AD - Department of Radiation Oncology, Thomas Jefferson University Hospitals, - Philadelphia, Pennsylvania. bo.lu@jefferson.edu. -LA - eng -GR - R21 CA178229/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -PT - Research Support, U.S. Gov't, Non-P.H.S. -PT - Review -DEP - 20180122 -PL - United States -TA - Clin Cancer Res -JT - Clinical cancer research : an official journal of the American Association for - Cancer Research -JID - 9502500 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -RN - 0 (CD274 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antineoplastic Agents, Immunological/pharmacology/therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors -MH - Biomarkers, Tumor -MH - Chemoradiotherapy/adverse effects/methods -MH - Combined Modality Therapy -MH - Humans -MH - Molecular Targeted Therapy -MH - Neoplasm Metastasis -MH - Neoplasm Staging -MH - Neoplasms/diagnosis/etiology/mortality/*therapy -MH - Patient Selection -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - Treatment Outcome -EDAT- 2018/01/24 06:00 -MHDA- 2019/10/01 06:00 -CRDT- 2018/01/24 06:00 -PHST- 2017/11/07 00:00 [received] -PHST- 2017/12/18 00:00 [revised] -PHST- 2018/01/09 00:00 [accepted] -PHST- 2018/01/24 06:00 [pubmed] -PHST- 2019/10/01 06:00 [medline] -PHST- 2018/01/24 06:00 [entrez] -AID - 1078-0432.CCR-17-3269 [pii] -AID - 10.1158/1078-0432.CCR-17-3269 [doi] -PST - ppublish -SO - Clin Cancer Res. 2018 Mar 15;24(6):1271-1276. doi: 10.1158/1078-0432.CCR-17-3269. - Epub 2018 Jan 22. - -PMID- 31378235 -OWN - NLM -STAT- MEDLINE -DCOM- 20200109 -LR - 20200109 -IS - 1942-5546 (Electronic) -IS - 0025-6196 (Linking) -VI - 94 -IP - 8 -DP - 2019 Aug -TI - Current Diagnosis and Management of Small-Cell Lung Cancer. -PG - 1599-1622 -LID - S0025-6196(19)30126-0 [pii] -LID - 10.1016/j.mayocp.2019.01.034 [doi] -AB - Small-cell lung cancer (SCLC) is an aggressive disease with distinct - pathological, clinical, and molecular characteristics from non-small-cell lung - cancer. SCLC has high metastatic potential, resulting in a clinically poor - prognosis. Early concurrent chemo-radiation is the standard of care for - limited-stage SCLC (LS-SCLC). Prophylactic cranial irradiation (PCI) is - recommended for patients with LS-SCLC without progression of disease after - initial therapy. A combination of etoposide and cisplatin or carboplatin remains - the mainstay of first-line treatment for ES-SCLC, with the addition of - atezolizumab, now becoming standard. Most SCLCs initially respond to therapy but - almost invariably recur. Topotecan and amrubicin (in Japan) remain the primary - chemotherapy options for relapsed SCLC. Immunotherapy, including nivolumab with - or without ipilimumab, is now available for refractory disease. In general, the - poor prognosis of SCLC has not improved significantly for more than 3 decades. - Recently, next-generation molecular profiling studies have identified new - therapeutic targets for SCLC. A variety of proapoptotic agents, compounds - capitalizing on DNA-repair defects, immunotherapy agents, and antibody-drug - conjugates are being evaluated in SCLC, with a number of them showing early - promise. -CI - Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by - Elsevier Inc. All rights reserved. -FAU - Wang, Shuhang -AU - Wang S -AD - Peking University Cancer Hospital, Beijing, China. -FAU - Zimmermann, Stefan -AU - Zimmermann S -AD - Département d'Oncologie, service d'Immuno-Oncologie, CHUV, Lausanne, Switzerland. -FAU - Parikh, Kaushal -AU - Parikh K -AD - Mayo Clinic, Rochester, MN. -FAU - Mansfield, Aaron S -AU - Mansfield AS -AD - Mayo Clinic, Rochester, MN. -FAU - Adjei, Alex A -AU - Adjei AA -AD - Mayo Clinic, Rochester, MN. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - England -TA - Mayo Clin Proc -JT - Mayo Clinic proceedings -JID - 0405543 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Biological Products) -RN - 52CMI0WC3Y (atezolizumab) -SB - IM -MH - Aged -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols -MH - Biological Products/*therapeutic use -MH - Carcinoma, Non-Small-Cell Lung/diagnosis/*mortality/*therapy -MH - Chemoradiotherapy/methods -MH - Disease Management -MH - Disease-Free Survival -MH - Female -MH - Humans -MH - Immunotherapy/*methods -MH - Japan -MH - Lung Neoplasms/diagnosis/*drug therapy/*mortality -MH - Male -MH - Middle Aged -MH - Neoplasm Invasiveness/pathology -MH - Neoplasm Staging -MH - Prognosis -MH - Risk Assessment -MH - Survival Analysis -EDAT- 2019/08/06 06:00 -MHDA- 2020/01/10 06:00 -CRDT- 2019/08/06 06:00 -PHST- 2018/09/04 00:00 [received] -PHST- 2019/01/05 00:00 [revised] -PHST- 2019/01/31 00:00 [accepted] -PHST- 2019/08/06 06:00 [entrez] -PHST- 2019/08/06 06:00 [pubmed] -PHST- 2020/01/10 06:00 [medline] -AID - S0025-6196(19)30126-0 [pii] -AID - 10.1016/j.mayocp.2019.01.034 [doi] -PST - ppublish -SO - Mayo Clin Proc. 2019 Aug;94(8):1599-1622. doi: 10.1016/j.mayocp.2019.01.034. - -PMID- 33899782 -OWN - NLM -STAT- MEDLINE -DCOM- 20240724 -LR - 20240724 -IS - 1473-5628 (Electronic) -IS - 0143-3636 (Print) -IS - 0143-3636 (Linking) -VI - 42 -IP - 9 -DP - 2021 Sep 1 -TI - Feasibility of semiquantitative 18F-fluorodeoxyglucose PET/computed tomography in - patients with advanced lung cancer for interim treatment evaluation of combining - immunotherapy and chemotherapy. -PG - 1017-1023 -LID - 10.1097/MNM.0000000000001428 [doi] -AB - OBJECTIVE: This study aimed to investigate the prognosis value of - 18F-fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) in advanced lung - cancer patients with immunotherapy combined with chemotherapy. METHODS: Fifty-one - advanced lung cancer patients were included in this retrospective study, who - underwent 18F-FDG PET/CT imaging before four cycles of immunotherapy combined - with chemotherapy at our institution between January 2018 and January 2020. The - following PET/CT parameters were calculated: standardized uptake value SUVmax, - SUVmean, SUVpeak, SUVsd, metabolic tumor volume (MTV), total lesion glycolysis - (TLG), MTV25%, MTV42%, MTV50%, MTV75%, global lung glycolysis (GLG), - target-to-background ratio (TBR), SUVpeakwb, MTVwb, TLGwb, SUVmeanwb, SUVmaxwb. - Logistics regression analyses were used for assessing the association between - baseline metabolic parameters and response to treatment. Kaplan-Meier estimator - curves and the log-rank test were constructed for survival analyses. RESULTS: - According to RECIST, nine patients (18%) showed partial response, 25 (49%) had - SD, and 17 (33%) had progressive disease. The mean ± SD of SUVmax, SUVpeak, MTV - were lower in clinical benefit (CB) group than no-clinical benefit (no-CB) group - (all P < 0.05). Median PFS was 3.7 months in no-CB group and 9.9 months in CB - group (P < 0.001). Multivariate logistic analysis indicated that SUVmax and - histology were independent factors significantly related to the evaluation of - therapeutic efficiency. Furthermore, SUVmax is an independent predictor of - efficacy in non-small cell lung cancer. CONCLUSION: SUVmax can be used to predict - interim treatment response of immunotherapy combination with chemotherapy for - advanced lung cancer. Moreover, the combination of SUVmax and histology may - predict treatment response with acceptable reliability. However, a large - prospective multicenter trial is still needed to examine the above finding for - lacking limited evidence. -CI - Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. -FAU - Ke, Linping -AU - Ke L -AD - Department of Clinical Medicine, Weifang Medical University, Weifang. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences. -FAU - Wu, Leilei -AU - Wu L -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences. -AD - Department of Radiation Oncology, School of Medicine, Shandong University, Jinan, - Shandong, China. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences. -FAU - Meng, Xue -AU - Meng X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences. -LA - eng -PT - Journal Article -PL - England -TA - Nucl Med Commun -JT - Nuclear medicine communications -JID - 8201017 -RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) -MH - Humans -MH - *Fluorodeoxyglucose F18 -MH - *Positron Emission Tomography Computed Tomography -MH - Male -MH - *Lung Neoplasms/diagnostic imaging/therapy/drug therapy/pathology -MH - Female -MH - Middle Aged -MH - *Feasibility Studies -MH - Retrospective Studies -MH - Aged -MH - *Immunotherapy -MH - Adult -MH - Treatment Outcome -MH - Combined Modality Therapy -PMC - PMC8357040 -COIS- There are no conflicts of interest. -EDAT- 2021/04/27 06:00 -MHDA- 2022/01/07 06:00 -PMCR- 2021/08/11 -CRDT- 2021/04/26 09:05 -PHST- 2021/04/27 06:00 [pubmed] -PHST- 2022/01/07 06:00 [medline] -PHST- 2021/04/26 09:05 [entrez] -PHST- 2021/08/11 00:00 [pmc-release] -AID - 00006231-202109000-00011 [pii] -AID - 10.1097/MNM.0000000000001428 [doi] -PST - ppublish -SO - Nucl Med Commun. 2021 Sep 1;42(9):1017-1023. doi: 10.1097/MNM.0000000000001428. - -PMID- 36764316 -OWN - NLM -STAT- MEDLINE -DCOM- 20230307 -LR - 20240920 -IS - 1474-547X (Electronic) -IS - 0140-6736 (Linking) -VI - 401 -IP - 10378 -DP - 2023 Mar 4 -TI - Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with - KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. -PG - 733-746 -LID - S0140-6736(23)00221-0 [pii] -LID - 10.1016/S0140-6736(23)00221-0 [doi] -AB - BACKGROUND: Sotorasib is a specific, irreversible inhibitor of the GTPase - protein, KRAS(G12C). We compared the efficacy and safety of sotorasib with a - standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) - with the KRAS(G12C) mutation who had been previously treated with other - anticancer drugs. METHODS: We conducted a randomised, open-label phase 3 trial at - 148 centres in 22 countries. We recruited patients aged at least 18 years with - KRAS(G12C)-mutated advanced NSCLC, who progressed after previous platinum-based - chemotherapy and a PD-1 or PD-L1 inhibitor. Key exclusion criteria included new - or progressing untreated brain lesions or symptomatic brain lesions, previously - identified oncogenic driver mutation other than KRAS(G12C) for which an approved - therapy is available (eg EGFR or ALK), previous treatment with docetaxel - (neoadjuvant or adjuvant docetaxel was allowed if the tumour did not progress - within 6 months after the therapy was terminated), previous treatment with a - direct KRAS(G12C) inhibitor, systemic anticancer therapy within 28 days of study - day 1, and therapeutic or palliative radiation therapy within 2 weeks of - treatment initiation. We randomly assigned (1:1) patients to oral sotorasib (960 - mg once daily) or intravenous docetaxel (75 mg/m(2) once every 3 weeks) in an - open-label manner using interactive response technology. Randomisation was - stratified by number of previous lines of therapy in advanced disease (1 vs 2 vs - >2), ethnicity (Asian vs non-Asian), and history of CNS metastases (present or - absent). Treatment continued until an independent central confirmation of disease - progression, intolerance, initiation of another anticancer therapy, withdrawal of - consent, or death, whichever occurred first. The primary endpoint was - progression-free survival, which was assessed by a blinded, independent central - review in the intention-to-treat population. Safety was assessed in all treated - patients. This trial is registered at ClinicalTrials.gov, NCT04303780, and is - active but no longer recruiting. FINDINGS: Between June 4, 2020, and April 26, - 2021, 345 patients were randomly assigned to receive sotorasib (n=171 [50%]) or - docetaxel (n=174 [50%]). 169 (99%) patients in the sotorasib group and 151 (87%) - in the docetaxel group received at least one dose. After a median follow-up of - 17·7 months (IQR 16·4-20·1), the study met its primary endpoint of a - statistically significant increase in the progression-free survival for - sotorasib, compared with docetaxel (median progression-free survival 5·6 months - [95% CI 4·3-7·8] vs 4·5 months [3·0-5·7]; hazard ratio 0·66 [0·51-0·86]; - p=0·0017). Sotorasib was well tolerated, with fewer grade 3 or worse (n=56 [33%] - vs n=61 [40%]) and serious treatment-related adverse events compared with - docetaxel (n=18 [11%] vs n=34 [23%]). For sotorasib, the most common - treatment-related adverse events of grade 3 or worse were diarrhoea (n= 20 - [12%]), alanine aminotransferase increase (n=13 [8%]), and aspartate - aminotransferase increase (n=9 [5%]). For docetaxel, the most common - treatment-related adverse events of grade 3 or worse were neutropenia (n=13 - [9%]), fatigue (n=9 [6%]), and febrile neutropenia (n=8 [5%]). INTERPRETATION: - Sotorasib significantly increased progression-free survival and had a more - favourable safety profile, compared with docetaxel, in patients with advanced - NSCLC with the KRAS(G12C) mutation and who had been previously treated with other - anticancer drugs. FUNDING: Amgen. -CI - Copyright © 2023 Elsevier Ltd. All rights reserved. -FAU - de Langen, Adrianus Johannes -AU - de Langen AJ -AD - Netherlands Cancer Institute, Amsterdam, Netherlands. -FAU - Johnson, Melissa L -AU - Johnson ML -AD - Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA. -FAU - Mazieres, Julien -AU - Mazieres J -AD - Centre Hospitalier Universitaire de Toulouse, Toulouse, France. -FAU - Dingemans, Anne-Marie C -AU - Dingemans AC -AD - Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands. -FAU - Mountzios, Giannis -AU - Mountzios G -AD - Henry Dunant Hospital Center, Athens, Greece. -FAU - Pless, Miklos -AU - Pless M -AD - Department of Medical Oncology, Cancer Center Kantonsspital Winterthur, - Winterthur, Switzerland. -FAU - Wolf, Jürgen -AU - Wolf J -AD - Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany. -FAU - Schuler, Martin -AU - Schuler M -AD - West German Cancer Center, University Hospital Essen, Essen, Germany. -FAU - Lena, Hervé -AU - Lena H -AD - Centre Hospitalier Universitaire de Rennes-Hopital Pontchaillou, Rennes, France. -FAU - Skoulidis, Ferdinandos -AU - Skoulidis F -AD - University of Texas MD Anderson Cancer Center, Houston, TX, USA. -FAU - Yoneshima, Yasuto -AU - Yoneshima Y -AD - Kyushu University Hospital, Fukuoka, Japan. -FAU - Kim, Sang-We -AU - Kim SW -AD - Asan Medical Center, Seoul, South Korea. -FAU - Linardou, Helena -AU - Linardou H -AD - Metropolitan Hospital, Athens, Greece. -FAU - Novello, Silvia -AU - Novello S -AD - Department of Oncology, Università Degli Studi Di Torino-San Luigi Hospital - Orbassano, Italy. -FAU - van der Wekken, Anthonie J -AU - van der Wekken AJ -AD - Department of Pulmonology and Tuberculosis, University of Groningen, Medical - Centre Groningen, Groningen, Netherlands. -FAU - Chen, Yuanbin -AU - Chen Y -AD - Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI, USA. -FAU - Peters, Solange -AU - Peters S -AD - Oncology Department-CHUV, Lausanne University, Lausanne, Switzerland. -FAU - Felip, Enriqueta -AU - Felip E -AD - Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain. -FAU - Solomon, Benjamin J -AU - Solomon BJ -AD - Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. -FAU - Ramalingam, Suresh S -AU - Ramalingam SS -AD - Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA. -FAU - Dooms, Christophe -AU - Dooms C -AD - Department of Respiratory Diseases, University Hospitals KU Leuven, Leuven, - Belgium. -FAU - Lindsay, Colin R -AU - Lindsay CR -AD - Division of Cancer Sciences, University of Manchester, Manchester, UK; The - Christie NHS Foundation Trust, Manchester, UK. -FAU - Ferreira, Carlos Gil -AU - Ferreira CG -AD - Oncoclinicas, Rio De Janeiro, Brazil. -FAU - Blais, Normand -AU - Blais N -AD - Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, - QC, Canada. -FAU - Obiozor, Cynthia C -AU - Obiozor CC -AD - Amgen, Thousand Oaks, CA, USA. -FAU - Wang, Yang -AU - Wang Y -AD - Amgen, Thousand Oaks, CA, USA. -FAU - Mehta, Bhakti -AU - Mehta B -AD - Amgen, Thousand Oaks, CA, USA. -FAU - Varrieur, Tracy -AU - Varrieur T -AD - Amgen, Thousand Oaks, CA, USA. -FAU - Ngarmchamnanrith, Gataree -AU - Ngarmchamnanrith G -AD - Amgen, Thousand Oaks, CA, USA. -FAU - Stollenwerk, Björn -AU - Stollenwerk B -AD - Amgen (Europe), Rotkreuz, Switzerland. -FAU - Waterhouse, David -AU - Waterhouse D -AD - Oncology Hematology Care, Cincinnati, OH, USA. -FAU - Paz-Ares, Luis -AU - Paz-Ares L -AD - Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Complutense - University and Ciberonc, Madrid, Spain. Electronic address: lpazaresr@seom.org. -CN - CodeBreaK 200 Investigators -LA - eng -SI - ClinicalTrials.gov/NCT04303780 -PT - Clinical Trial, Phase III -PT - Journal Article -PT - Randomized Controlled Trial -PT - Research Support, Non-U.S. Gov't -DEP - 20230207 -PL - England -TA - Lancet -JT - Lancet (London, England) -JID - 2985213R -RN - 15H5577CQD (Docetaxel) -RN - 2B2VM6UC8G (sotorasib) -RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) -RN - 0 (Antineoplastic Agents) -RN - 0 (KRAS protein, human) -SB - IM -CIN - Lancet. 2023 Mar 4;401(10378):706-707. doi: 10.1016/S0140-6736(23)00288-X. PMID: - 36774937 -CIN - Lancet. 2024 Jan 13;403(10422):145. doi: 10.1016/S0140-6736(23)02035-4. PMID: - 38218611 -CIN - Transl Cancer Res. 2024 Jan 31;13(1):15-21. doi: 10.21037/tcr-23-1477. PMID: - 38410207 -MH - Humans -MH - Adolescent -MH - Adult -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - Docetaxel/therapeutic use -MH - Proto-Oncogene Proteins p21(ras)/genetics/therapeutic use -MH - *Lung Neoplasms/drug therapy -MH - *Antineoplastic Agents/therapeutic use -MH - Mutation -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Disease-Free Survival -COIS- Declaration of interests AJdL reports financial interests, institutional, - research grant from BMS, MSD, Boehringer, AstraZeneca; non-financial interests, - other from Merck Serono, Roche. MLJ reports financial interests, institutional, - research grant from AbbVie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus - Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, - BerGenBio, BioAtla, Boehringer Ingelheim, Calithera Biosciences, Corvus - Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, - Lilly, EMD Serono, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, - Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, - Harpoon, Helsinn Healthcare, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA - Biosciences, IGM Biosciences, Immunocore, Incyte, Janssen, Kadmon - Pharmaceuticals, Loxo Oncology, Lycera, Memorial Sloan-Kettering, Merck, Merus, - NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, Nuvalent, OncoMed - Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Regeneron Pharmaceuticals, Relay - Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, - Sanofi, Seven and Eight Biopharmaceuticals/Birdie Biopharmaceuticals, Shattuck - Labs, Silicon Therapeutics, Stem CentRx, Syndax Pharmaceuticals, Takeda - Pharmaceuticals, Tarveda Therapeutics, TCR2 Therapeutics, Tempest Therapeutics, - Tizona Therapeutics, Tmunity Therapeutics, Turning Point Therapeutics, University - of Michigan, Vyriad, WindMIL, Y-mAbs Therapeutics, Black Diamond, Carisma - Therapeutics, Elicio Therapeutics, EQRx, Immunitas Therapeutics, Kartos - Therapeutics, Mirati Therapeutics, Palleon Pharmaceuticals, Rain Therapeutics; - financial interests, institutional, consulting fees from AbbVie, Amgen, Astellas, - AstraZeneca, Axelia Oncology, Black Diamond, Calithera Biosciences, Checkpoint - Therapeutics, CytomX Therapeutics, Daiichi Sankyo, EcoR1, Editas Medicine, Eisai, - Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone - Oncology, IDEAYA Biosciences, iTeos Therapeutics, Janssen, Lilly, Merck, Mirati - Therapeutics, Molecular Axiom, Novartis, Oncorus, Regeneron Pharmaceuticals, - Ribon Therapeutics, Sanofi-Aventis, Turning Point Therapeutics, VBL Therapeutics, - Takeda Pharmaceuticals, Arrivant, Pyramid Biosciences, Revolution Medicines, - Seagen. JM reports financial interests, personal fees from Amgen, AstraZeneca, - Roche, Pierre Fabre, Pfizer; financial interests, institutional, research grant - from AstraZeneca, Roche, Pierre Fabre; advisory board for Merck, Roche, - AstraZeneca, MSD, BMS, Pfizer, Hengrui Therapeutics, Daiichi, Boehringer, Pierre - Fabre, Amgen. A MCD reports other, institutional, advisory board for Amgen, - Bayer, Boehringer Ingelheim, Roche, Sanofi; other, institutional, invited speaker - for AstraZeneca, Janssen, Eli Lilly, Pfizer, Takeda; financial interests, - institutional, research grant from Amgen; financial interests, institutional, - principal investigator, local PI for Amgen, Daiichi, JNJ, Eli Lilly, Mirati - Therapeutics; financial interests, institutional, principal investigator, - coordinating PI for Roche; financial interests, institutional, other, steering - committee member for Roche. GM reports financial interests, personal, other, - consulting fees from Roche Hellas, Novartis Greece, BMS Greece, MSD Greece, - AstraZeneca Greece, Takeda Hellas, Janssen Greece, GSK Greece, Amgen Hellas, - Sanofi Greece, Boehringer Greece; financial interests, personal, other, payment - or honoraria for lectures, presentations, speakers bureaus, manuscript writing or - educational events from Roche Hellas, Novartis Greece, BMS Greece, MSD Greece, - AstraZeneca Greece, Takeda Hellas, Pierre Fabre Greece, Janssen Greece, GSK - Greece, Amgen Hellas, Sanofi Greece, Boehringer Greece; financial interests, - personal, other, payment for expert testimony from Roche Hellas, Novartis Greece, - BMS Greece, MSD Greece, AstraZeneca Greece, Takeda Hellas, Pierre Fabre Greece, - Janssen Greece, GSK Greece, Amgen Hellas, Sanofi Greece, Boehringer Greece; - financial interests, personal, other, support for attending meetings and/or - travel from Roche Hellas, Novartis Greece, BMS Greece, MSD Greece, AstraZeneca - Greece, Takeda Hellas, Pierre Fabre Greece, Janssen Greece, GSK Greece, Amgen - Hellas, Sanofi Greece, Boehringer Greece; financial interests, personal, other, - participation on a data safety monitoring board or advisory board for Roche - Hellas, Novartis Greece, BMS Greece, MSD Greece, AstraZeneca Greece, Takeda - Hellas, Janssen Greece, GSK Greece, Amgen Hellas, Sanofi Greece, Boehringer - Greece; financial interests, personal, other, leadership or fiduciary role in - other board, society, committee or advocacy group, unpaid for European Society - for Medical Oncology working groups (Educational Publication Working Group, - Adolescents and Young Adults working group); financial interests, institutional, - principal investigator for Roche Hellas, Novartis Greece, BMS Greece, MSD Greece, - AstraZeneca Greece, Gilead Greece, GSK Greece, Amgen Hellas, Sanofi Greece. MP - reports financial interests, personal, advisory board for AbbVie, AstraZeneca, - BMS, Boehringer Ingelheim, Eisei, MSD, Novartis, Pfizer, Roche, Takeda, Merck, - Sanofi, Bayer, Amgen; financial interests, personal, other, travel grant from - AstraZeneca, BMS, Boehringer Ingelheim, Roche, Takeda, Vifor; financial - interests, personal, speaker fees from Janssen, Nestle. JW reports financial - interests, personal, advisory board, lectures fees from Amgen, AstraZeneca, - Bayer, Blueprint, BMS, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Merck, - Janssen, Lilly, Loxo, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda, - Turning Point, Nuvalent; financial interests, institutional, research grant from - BMS, Janssen, Novartis, Pfizer. MS reports financial interests, institutional, - research grant from AstraZeneca, Bristol Myers Squibb; financial interests, - personal, consulting fees from Amgen, AstraZeneca, BIOCAD, Boehringer Ingelheim, - Bristol Myers Squibb, GlaxoSmithKline, Janssen, Merck Serono, Novartis, Roche, - Sanofi, Takeda; financial interests, personal, payment or honoraria for lectures, - presentations, speakers bureaus, manuscript writing or educational events from - Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis; financial - interests, personal, support for attending meetings and/or travel from BIOCAD, - Bristol Myers Squibb, Boehringer Ingelheim, Janssen, Novartis; financial - interests, personal, participation on a data safety monitoring board or advisory - board for Amgen, Bristol Myers Squibb, Novartis, Sanofi, GlaxoSmithKline, Merck - Serono. HL reports financial interests, other, personal fees from Daiichi Sankyo, - AstraZeneca, Pfizer, Novartis, Amgen, MSD, Roche, BMS, Eli Lilly, Boehringer - Ingelheim. FS reports financial interests, personal, other, consulting fees from - AstraZeneca, Amgen, Novartis, BeiGene Guardant Health, BerGenBio, Navire Pharma, - Tango Therapeutics, Calithera Biosciences; financial interests, personal, other, - lecture fees from European Society for Medical Oncology, Japanese Lung Cancer - Society, Medscape, Intellisphere, VSPO McGill Universite de Montreal, RV Mais - Promoção Eventos Ltda, MJH Life Sciences, IDEOlogy Health, MI&T, PER, LLC, CURIO; - financial interests, personal, other, fees for travel, food and beverage from - Dava Oncology, Tango Therapeutics, American Association for Cancer Research, - International Association for the Study of Lung Cancer (IASLC), MJH Life - Sciences, IDEOlogy Health, MI&T, PER, LLC, CURIO; financial interests, personal, - stocks/shares, stock or stock options for BioNTech SE, Moderna (completed 2020); - financial interests, institutional, research grant from Amgen, Mirati - Therapeutics, Revolution Medicines, Pfizer, Novartis, Merck & Co; participation - on a data safety monitoring board or advisory board for AstraZeneca, Amgen, - Novartis, BeiGene, Guardant Health, BerGenBio; Calithera Biosciences. YY reports - no relationships to disclose. S-WK reports no relationships to disclose. HL - reports financial interests, personal, other, consulting fees from Roche, - Novartis, BMS, MSD, AstraZeneca, Takeda, GSK, Merck, Amgen, Boehringer, Pfizer, - Lilly; financial interests, personal, other, payment or honoraria for lectures, - presentations, speakers bureaus, manuscript writing or educational events from - Roche, Novartis, BMS, MSD, AstraZeneca, Takeda, AbbVie, GSK, Amgen, Boehringer, - Pfizer, Lilly; financial interests, personal, other, payment for expert testimony - from Roche, Novartis, BMS, MSD, AstraZeneca, Takeda, GSK, Amgen, Boehringer, - Pfizer, Lilly; financial interests, personal, other, support for attending - meetings and/or travel from Roche, Novartis, BMS, MSD, AstraZeneca, GSK, Amgen, - Boehringer, Pfizer; financial interests, personal, participation on a data safety - monitoring board or advisory board for Roche, Novartis, BMS, MSD, AstraZeneca, - Takeda, GSK, Amgen, Boehringer, Pfizer, Lilly; other, personal, leadership role, - W4O Core Committee – Unpaid for European Society for Medical Oncology; other, - personal, leadership role, President of the Scientific Committee and Member of - the Board of Directors – Unpaid for Hellenic Cooperative Oncology Group; other, - personal, leadership role, member of board of directors – unpaid for Hellenic - Foundation for Cancer Research, FairLife LCC; Other, personal, leadership role, - legal representative member of board of directors - unpaid for W4O-Hellas; - financial interests, personal and institutional, principal investigator, pi in - sponsored clinical trials, personal and institutional fees from Bristol Myers - Squibb, Boehringer Ingelheim, Roche, AbbVie, Lilly, Novartis, AstraZeneca, Amgen, - PPD, Parexel ILR, Qualitis, Health Data Specialist. SN reports financial - interests, personal, advisor/speaker bureau for AstraZeneca, BI, MSD, Roche, - Sanofi, Pfizer, Takeda, Thermo Fisher, Novartis; financial interests, personal, - speaker bureau for BeiGene. AJvdW reports financial interests, institutional, - research grant from AstraZeneca, Boehringer-Ingelheim, Pfizer, Roche, Takeda; - financial interests, fees to institution from AstraZeneca, Boehringer-Ingelheim, - Pfizer, Roche, Takeda, Janssen Cilag, Lilly, Amgen, Merck. YC reports other, - personal, speaker faculty for Amgen, AstraZeneca, Bristol Myers Squibb, Guardant - Health, Jazz Pharmaceuticals, Pfizer, Takeda; other, personal, advisory board for - AstraZeneca, Bristol Myers Squibb, Mirati Therapeutics; financial interests, - institutional, principal investigator, local PI for Amgen, AstraZeneca, Bristol - Myers Squibb, EMD/Serono, Helsinn, Ipsen, Merck. SP reports financial interests, - institutional, support for study conduct and medical writing from AstraZeneca; - financial interests, institutional, principal investigator, coordinating PI for - Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Merck Sharp - and Dohme, Roche/Genentech. Financial interests, institutional, consulting fees - from AbbVie, AiCME, Amgen, Arcus, AstraZeneca, Bayer, BeiGene, Biocartis, - BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, - Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, F-Star, - Fishawack, Foundation Medicine, Genzyme, Gilead, GlaxoSmithKline, Illumina, - Imedex, IQVIA, Incyte, Ipsen, iTeos, Janssen, Medscape, Medtoday, Merck Sharp and - Dohme, Merck Serono, Merrimack, Novartis, Novocure, OncologyEducation, Pharma - Mar, Phosplatin Therapeutics, PER, PeerView, Pfizer, PRIME, Regeneron, RMEI, - Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda, Vaccibody; financial - interests, institution, other, payment or honoraria for lectures, presentations, - speakers bureaus, manuscript writing or educational events from AiCME, - AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, ecancer, Eli Lilly, - Foundation Medicine, Illumina, Imedex, Medscape, Merck Sharp and Dohme, Mirati - Therapeutics, Novartis, PeerView, PER, Pfizer, Prime, Roche/Genentech, RTP, - Sanofi, Takeda; financial interests, institutional, other, support for attending - meetings and/or travel from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, - Eli Lilly, Merck Sharp and Dohme, Novartis, Pfizer, Roche/Genentech, Takeda; - financial interests, institutional, other, participation on a data safety - monitoring board or advisory board for AbbVie, AiCME, Amgen, Arcus, AstraZeneca, - Bayer, BeiGene, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, - Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, - Elsevier, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GSK, Illumina, - Imedex, IQVIA, Incyte, Ipsen, iTeos, Janssen, Medscape, Medtoday, Merck Sharp and - Dohme, Merck Serono, Merrimack, Novartis, Novocure, OncologyEducation, Pharma - Mar, Phosplatin Therapeutics, PER, PeerView, Pfizer, PRIME, Regeneron, RMEI, - Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda, Vaccibody. EF reports - financial interests, institutional, research grant from Merck Healthcare KGaA - (grant for oncology innovation), Fundación Merck Salud; financial interests, - institutional, consulting fees from Amgen, AstraZeneca, Bayer, Bristol Myers - Squibb, Daichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Janssen, - Merck Serono, Merck Sharp & Dohme, Novartis, Peptomyc, Pfizer, Sanofi, Takeda, - BerGenBio; financial interests, institutional, payment or honoraria for lectures, - presentations, speakers bureaus, manuscript writing or educational events from - Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, - Janssen, Medical Trends, Medscape, Merck Serono, Merck Sharp & Dohme, PeerVoice, - Pfizer, Sanofi, Takeda, Touch Oncology; other financial/non-financial interests, - board member for Grífols. BJS reports financial interests, institutional, - funding, institutional funding for conduct of clinical trial from Amgen; - financial interests, personal, advisory board/honoraria from Amgen, - Roche-Genentech, Novartis, Pfizer, AstraZeneca, Bristol Myers Squibb, Takeda, Eli - Lilly, Merck Sharp Dohme, Janssen. SSR reports financial interests, personal, - research grant from Amgen, AstraZeneca; financial interests, personal, advisory - board for AstraZeneca, Mirati Therapeutics, Merck, BMS, GlaxoSmithKline, Genmab. - CD reports no relationships to disclose. CL reports financial interests, - personal, advisory board from Amgen; financial interests, personal, educational - presentation/workshop from Amgen; financial interests, institutional, advisory - board for CBPartners; non-financial interests, institutional, principal - investigator, coordinating PI for Amgen, BI, Mirati Therapeutics, Revolution - Medicines, Roche; non-financial interests, institutional, principal investigator, - local PI Apollomics. CGF reports financial interests, other, consulting fees from - AstraZeneca, Janssen; advisory board for IASCL; financial interests, personal, - stocks/shares, stock or stock options in Oncoclínicas - Brazil. NB reports - financial interests, other, consulting fees/honoraria from Amgen. CCO, YW, BM, - TV, GN, BS report financial interests, personal, current or former full-time - employment, employee and stockholder/shareholder in Amgen. DW reports financial - interests, personal, invited speaker, advisory event, travel for BMS; financial - interests, personal, invited speaker, advisory event for AstraZeneca, Janssen, - EMD Serono; financial interests, personal, invited speaker, advisory event, - consultant for Amgen, Merck; financial interest, personal, advisory event, - consultant for Jazz Pharmaceuticals, Fresenius Kbi; financial interests, - personal, advisory event for Pfizer, Mirati Therapeutics, Regeneron/Sanofi; - financial interests, personal, advisory event for Exelixis, Eisai, Pfizer, Mirati - Therapeutics, Regeneron/Sanofi, Lilly, Sanofi, Astellas, Gilead. LPA reports - financial interests, research grant from MSD, AstraZeneca, Pfizer, BMS; financial - interests, consulting fees from Lilly, MSD, Roche, PharmaMar, Merck, AstraZeneca, - Novartis, Servier, Amgen, Pfizer, Sanofi, Bayer, BMS, Mirati Therapeutics, GSK, - Janssen, Takeda, Daiichi Sankyo; financial interests, payment/honoraria for - lectures, presentations, speakers bureau from AstraZeneca, Janssen, Merck, Mirati - Therapeutics. All other authors declare no competing interests. -EDAT- 2023/02/11 06:00 -MHDA- 2023/03/08 06:00 -CRDT- 2023/02/10 18:53 -PHST- 2022/12/22 00:00 [received] -PHST- 2023/01/20 00:00 [revised] -PHST- 2023/01/23 00:00 [accepted] -PHST- 2023/02/11 06:00 [pubmed] -PHST- 2023/03/08 06:00 [medline] -PHST- 2023/02/10 18:53 [entrez] -AID - S0140-6736(23)00221-0 [pii] -AID - 10.1016/S0140-6736(23)00221-0 [doi] -PST - ppublish -SO - Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub - 2023 Feb 7. - -PMID- 28812378 -OWN - NLM -STAT- MEDLINE -DCOM- 20180814 -LR - 20180814 -IS - 1744-8301 (Electronic) -IS - 1479-6694 (Linking) -VI - 13 -IP - 28 -DP - 2017 Dec -TI - Bevacizumab in advanced lung cancer: state of the art. -PG - 2515-2535 -LID - 10.2217/fon-2017-0302 [doi] -AB - Despite recent advances in metastatic lung cancer treatment with the advent of - immune checkpoint inhibitors and molecules targeting addictive genomic - abnormalities, prognosis of most of the patients remains unfavorable. Combination - approaches with older drugs, such as bevacizumab, should be thus envisioned. - Bevacizumab is a monoclonal anti-VEGF antibody, approved by the US FDA and - the EMA in first-line and maintenance settings of advanced nonsquamous - non-small-cell lung cancer (NSCLC) treatment, in association with platinum-based - chemotherapy. In the years to come, bevacizumab might be associated with new - molecular therapies or immuno-oncology drugs, in order to optimize response rates - and overcome resistances. This review summarizes the pharmacologic properties, - clinical efficacy and safety of bevacizumab in advanced lung cancer treatment, - with a focus on NSCLC, EGFR-mutant NSCLC and small-cell lung cancer. -FAU - Assoun, Sandra -AU - Assoun S -AD - Department of Thoracic Oncology & CIC 1425/CLIP2 Paris-Nord, Bichat-Claude - Bernard Hospital, APHP, Paris, France. -FAU - Brosseau, Solenn -AU - Brosseau S -AD - Department of Thoracic Oncology & CIC 1425/CLIP2 Paris-Nord, Bichat-Claude - Bernard Hospital, APHP, Paris, France. -AD - University Paris-Diderot, Paris, France. -FAU - Steinmetz, Christelle -AU - Steinmetz C -AD - Pharmacy Department, Bichat-Claude Bernard Hospital, APHP, 46, rue Henri Huchard, - 75877 Paris Cedex 18, Paris, France. -FAU - Gounant, Valérie -AU - Gounant V -AD - Department of Thoracic Oncology & CIC 1425/CLIP2 Paris-Nord, Bichat-Claude - Bernard Hospital, APHP, Paris, France. -FAU - Zalcman, Gérard -AU - Zalcman G -AD - Department of Thoracic Oncology & CIC 1425/CLIP2 Paris-Nord, Bichat-Claude - Bernard Hospital, APHP, Paris, France. -AD - University Paris-Diderot, Paris, France. -LA - eng -PT - Journal Article -PT - Review -DEP - 20170816 -PL - England -TA - Future Oncol -JT - Future oncology (London, England) -JID - 101256629 -RN - 0 (Angiogenesis Inhibitors) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Biomarkers) -RN - 2S9ZZM9Q9V (Bevacizumab) -SB - IM -MH - Angiogenesis Inhibitors/chemistry/pharmacology/*therapeutic use -MH - Animals -MH - Antineoplastic Agents, Immunological/chemistry/pharmacology/*therapeutic use -MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use -MH - Bevacizumab/chemistry/pharmacology/*therapeutic use -MH - Biomarkers -MH - Clinical Trials as Topic -MH - Disease Progression -MH - Drug Evaluation, Preclinical -MH - Humans -MH - Lung Neoplasms/*drug therapy/genetics/mortality/*pathology -MH - Molecular Targeted Therapy -MH - Product Surveillance, Postmarketing -MH - Randomized Controlled Trials as Topic -MH - Retreatment -MH - Treatment Outcome -OTO - NOTNLM -OT - angiogenesis inhibitor -OT - bevacizumab -OT - lung cancer -EDAT- 2017/08/16 06:00 -MHDA- 2018/08/15 06:00 -CRDT- 2017/08/17 06:00 -PHST- 2017/08/16 06:00 [pubmed] -PHST- 2018/08/15 06:00 [medline] -PHST- 2017/08/17 06:00 [entrez] -AID - 10.2217/fon-2017-0302 [doi] -PST - ppublish -SO - Future Oncol. 2017 Dec;13(28):2515-2535. doi: 10.2217/fon-2017-0302. Epub 2017 - Aug 16. - -PMID- 32368177 -OWN - NLM -STAT- MEDLINE -DCOM- 20210607 -LR - 20240328 -IS - 1718-7729 (Electronic) -IS - 1198-0052 (Print) -IS - 1198-0052 (Linking) -VI - 27 -IP - Suppl 2 -DP - 2020 Apr -TI - Immuno-oncology-the new paradigm of lung cancer treatment. -PG - S78-S86 -LID - 10.3747/co.27.5183 [doi] -AB - Systemic therapy is an essential part of treatment for all patients with - small-cell lung cancer (sclc) and for most patients with non-small-cell lung - cancer (nsclc). Standards of care have evolved dramatically since 2009, - especially in the setting of incurable or advanced nsclc. Part of that evolution - has been the incorporation of immuno-oncology drugs, especially immune checkpoint - inhibitors (icis) into multiple therapeutic scenarios. In the present review, we - discuss the role of the immune system in lung cancer and the previous failures of - immunotherapy for patients with lung cancer. We then provide an overview of the - existing evidence for the use of icis in patients with advanced nsclc that is - either treatment-naïve or pretreated, for consolidative treatment after - chemoradiotherapy in stage iii nsclc, and for palliative therapy in patients with - sclc. Finally, we discuss duration of treatment, special populations, and the - future of immuno-oncology for patients with lung cancer. Overall, we provide an - evidence-based snapshot of immuno-oncology agents in the treatment of lung cancer - up to early 2019. -CI - 2020 Multimed Inc. -FAU - Dawe, D E -AU - Dawe DE -AD - Department of Medical Oncology and Hematology, CancerCare Manitoba, and - Department of Internal Medicine, University of Manitoba, Winnipeg, MB. -FAU - Harlos, C H -AU - Harlos CH -AD - Department of Medical Oncology and Hematology, CancerCare Manitoba, and - Department of Internal Medicine, University of Manitoba, Winnipeg, MB. -FAU - Juergens, R A -AU - Juergens RA -AD - Department of Oncology, Juravinski Cancer Centre, Hamilton, ON. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20200401 -PL - Switzerland -TA - Curr Oncol -JT - Current oncology (Toronto, Ont.) -JID - 9502503 -SB - IM -MH - Humans -MH - Immunotherapy/*methods -MH - Lung Neoplasms/*drug therapy -PMC - PMC7194003 -OTO - NOTNLM -OT - Immuno-oncology -OT - PD-1 -OT - PD-L1 -OT - immunotherapy -OT - lung cancer -COIS- CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s - policy on disclosing conflicts of interest, and we declare the following - interests: DED has participated on advisory boards for AstraZeneca and Merck and - has received an honorarium from Boehringer Ingelheim for providing educational - content. RAJ has received honoraria from Bristol–Myers Squib, AstraZeneca, Roche - Canada, Merck Sharp and Dohme, Novartis Canada Pharmaceuticals Inc., Amgen, and - Boehringer Ingelheim, and has consulted or advised for AstraZeneca, Bristol–Myers - Squib, Novartis, Pfizer, Roche Canada, Takeda, AbbVie, and Fusion - Pharmaceuticals. CHH has no conflicts to disclose. -EDAT- 2020/05/06 06:00 -MHDA- 2021/06/08 06:00 -PMCR- 2020/04/01 -CRDT- 2020/05/06 06:00 -PHST- 2020/05/06 06:00 [entrez] -PHST- 2020/05/06 06:00 [pubmed] -PHST- 2021/06/08 06:00 [medline] -PHST- 2020/04/01 00:00 [pmc-release] -AID - conc-27-e78 [pii] -AID - 10.3747/co.27.5183 [doi] -PST - ppublish -SO - Curr Oncol. 2020 Apr;27(Suppl 2):S78-S86. doi: 10.3747/co.27.5183. Epub 2020 Apr - 1. - -PMID- 36774235 -OWN - NLM -STAT- MEDLINE -DCOM- 20230530 -LR - 20230604 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -VI - 24 -IP - 4 -DP - 2023 Jun -TI - Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in - Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy. -PG - 295-304 -LID - S1525-7304(23)00002-5 [pii] -LID - 10.1016/j.cllc.2023.01.004 [doi] -AB - BACKGROUND: Antibiotic treatment may reduce the efficacy of cancer immunotherapy - by disrupting gut microbiome. We aimed to study the association of antibiotics - and survival outcomes in advanced cutaneous melanoma and non-small-cell lung - cancer (NSCLC) patients who had received anti-PD-1/L1 monotherapy. PATIENTS AND - METHODS: A total of 222 melanoma and 199 NSCLC patients had received anti-PD-1/L1 - monotherapy in 5 Finnish hospitals between January 2014 and December 2020. - Clinical characteristics, antibiotic and corticosteroid treatment, and survival - outcomes were retrospectively collected from hospital and national medical - records. RESULTS: There were 32% of melanoma and 31% of NSCLC patients who had - received antibiotic treatment (ABT) 3 months before to 1 month after the first - anti-PD-1/L1 antibody infusion. In survival analyses, early antibiotic treatment - was associated with inferior overall survival (OS) (ABT 19.2 [17.6-43.7] vs. no - ABT 35.6 [29.3-NA] months, P = .033) but not with inferior progression-free - survival (PFS) (ABT 5.8 [3.0-12.6] vs. no ABT 10.2 [7.7-15.3] months, P = .3) in - melanoma patients and with inferior OS (ABT 8.6 [6.4-12.3] vs. no ABT 18.5 - [15.1-21.6] months, P < .001) and PFS (ABT 2.8 [2.1-4.5] vs. no ABT 5.6 [4.4-8.0] - months, P = .0081) in NSCLC patients. In multivariable analyses, ABT was not an - independent risk-factor for inferior OS and PFS in melanoma but was associated - with inferior OS (hazard ratio [HR] 2.12 [1.37-3.28]) and PFS (HR 1.65 - [1.10-2.47]) in NSCLC after adjusted for other risk factors. CONCLUSIONS: Early - ABT was an independent poor risk factor in NSCLC patients who had received - anti-PD-1/L1 monotherapy but not in melanoma patients. The weight of ABT as a - poor risk factor might depend on other prognostic factors in different cancers. -CI - Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. -FAU - Vihinen, Hannes -AU - Vihinen H -AD - Department of Oncology and Radiotherapy and Fican West Cancer Centre, University - of Turku and Turku University Hospital, POB 52, FIN-20521 Turku, Finland. -FAU - Jokinen, Artturi -AU - Jokinen A -AD - Department of Oncology and Radiotherapy and Fican West Cancer Centre, University - of Turku and Turku University Hospital, POB 52, FIN-20521 Turku, Finland. -FAU - Laajala, Teemu D -AU - Laajala TD -AD - Department of Mathematics and Statistics, University of Turku, Turku, Finland. -FAU - Wahid, Nesna -AU - Wahid N -AD - Department of Oncology and Radiotherapy Vaasa Central Hospital, Vaasa Finland. -FAU - Peltola, Lotta -AU - Peltola L -AD - Department of Oncology and Radiotherapy Vaasa Central Hospital, Vaasa Finland. -FAU - Kettunen, Tiia -AU - Kettunen T -AD - Center of Oncology, Kuopio University Hospital, Kuopio, Finland. -FAU - Rönkä, Aino -AU - Rönkä A -AD - Center of Oncology, Kuopio University Hospital, Kuopio, Finland. -FAU - Tiainen, Leena -AU - Tiainen L -AD - Department of Oncology, Tays Cancer Centre, Tampere University Hospital and - Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. -FAU - Skyttä, Tanja -AU - Skyttä T -AD - Department of Oncology, Tays Cancer Centre, Tampere University Hospital and - Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. -FAU - Kohtamäki, Laura -AU - Kohtamäki L -AD - Comprehensive Cancer Center, Helsinki University Hospital and University of - Helsinki, Helsinki, Finland. -FAU - Tulokas, Sanni -AU - Tulokas S -AD - Comprehensive Cancer Center, Helsinki University Hospital and University of - Helsinki, Helsinki, Finland. -FAU - Karhapää, Hanna -AU - Karhapää H -AD - Comprehensive Cancer Center, Helsinki University Hospital and University of - Helsinki, Helsinki, Finland. -FAU - Hernberg, Micaela -AU - Hernberg M -AD - Comprehensive Cancer Center, Helsinki University Hospital and University of - Helsinki, Helsinki, Finland. -FAU - Silvoniemi, Maria -AU - Silvoniemi M -AD - Department of Respiratory Medicine, Turku University Hospital and University of - Turku, Turku, Finland. -FAU - Mattila, Kalle E -AU - Mattila KE -AD - Department of Oncology and Radiotherapy and Fican West Cancer Centre, University - of Turku and Turku University Hospital, POB 52, FIN-20521 Turku, Finland; - InFLAMES Research Flagship Center, University of Turku. Electronic address: - kalle.mattila@tyks.fi. -LA - eng -PT - Journal Article -DEP - 20230124 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -RN - 0 (Anti-Bacterial Agents) -RN - 0 (B7-H1 Antigen) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung -MH - *Lung Neoplasms -MH - *Melanoma/drug therapy -MH - Retrospective Studies -MH - *Skin Neoplasms/drug therapy -MH - Anti-Bacterial Agents/therapeutic use -MH - B7-H1 Antigen -OTO - NOTNLM -OT - Antibiotics -OT - Immune checkpoint inhibitors -OT - Overall survival -OT - Prognostic factor -OT - Progression-free survival -EDAT- 2023/02/12 06:00 -MHDA- 2023/05/30 06:42 -CRDT- 2023/02/11 22:00 -PHST- 2022/11/10 00:00 [received] -PHST- 2023/01/03 00:00 [revised] -PHST- 2023/01/04 00:00 [accepted] -PHST- 2023/05/30 06:42 [medline] -PHST- 2023/02/12 06:00 [pubmed] -PHST- 2023/02/11 22:00 [entrez] -AID - S1525-7304(23)00002-5 [pii] -AID - 10.1016/j.cllc.2023.01.004 [doi] -PST - ppublish -SO - Clin Lung Cancer. 2023 Jun;24(4):295-304. doi: 10.1016/j.cllc.2023.01.004. Epub - 2023 Jan 24. - -PMID- 35988454 -OWN - NLM -STAT- MEDLINE -DCOM- 20221024 -LR - 20240324 -IS - 2059-7029 (Electronic) -IS - 2059-7029 (Linking) -VI - 7 -IP - 5 -DP - 2022 Oct -TI - Diagnostic work-up and systemic treatment for advanced non-squamous - non-small-cell lung cancer in four Southeast Asian countries. -PG - 100560 -LID - S2059-7029(22)00188-0 [pii] -LID - 10.1016/j.esmoop.2022.100560 [doi] -LID - 100560 -AB - BACKGROUND: Lung cancer is the second most common cancer and leading cause of - cancer mortality worldwide. Recent advances in molecular testing and targeted - therapy have improved survival among patients with metastatic non-small-cell lung - cancer (NSCLC). We sought to quantify and describe molecular testing among - metastatic non-squamous NSCLC cases in selected Southeast Asian countries and - describe first-line therapy chosen. PATIENTS AND METHODS: A retrospective study - was conducted based on incident lung cancer cases diagnosed between 2017 and 2019 - in Lampang (Thailand), Penang (Malaysia), Singapore and Yogyakarta (Indonesia). - Cases (n = 3413) were defined using the International Classification of Diseases - for Oncology third edition. In Singapore, a clinical series obtained from the - National Cancer Centre was used to identify patients, while corresponding - population-based cancer registries were used elsewhere. Tumor and clinical - information were abstracted by chart review according to a predefined study - protocol. Molecular testing of epidermal growth factor receptor (EGFR), - anaplastic lymphoma kinase (ALK) gene rearrangement, ROS1 gene rearrangement and - BRAF V600 mutation was recorded. RESULTS: Among 2962 cases with a specified - pathological diagnosis (86.8%), most patients had non-squamous NSCLC (75.8%). For - cases with staging information (92.1%), the majority presented with metastatic - disease (71.3%). Overall, molecular testing rates in the 1528 patients with stage - IV non-squamous NSCLC were 67.0% for EGFR, 42.3% for ALK, 39.1% for ROS1, 7.8% - for BRAF and 36.1% for PD-L1. Among these patients, first-line systemic treatment - included chemotherapy (25.9%), targeted therapy (35.6%) and immunotherapy (5.9%), - with 31% of patients having no record of antitumor treatment. Molecular testing - and the proportion of patients receiving treatment were highly heterogenous - between the regions. CONCLUSIONS: This first analysis of data from a clinically - annotated registry for lung cancer from four settings in Southeast Asia has - demonstrated the feasibility of integrating clinical data within population-based - cancer registries. Our study results identify areas where further development - could improve patient access to optimal treatment. -CI - Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. -FAU - Soo, R -AU - Soo R -AD - Department of Hematology-Oncology, National University Hospital, Singapore, - Singapore. -FAU - Mery, L -AU - Mery L -AD - Section of Cancer Surveillance, International Agency for Research on Cancer, - Lyon, France. -FAU - Bardot, A -AU - Bardot A -AD - Section of Cancer Surveillance, International Agency for Research on Cancer, - Lyon, France. -FAU - Kanesvaran, R -AU - Kanesvaran R -AD - Division of Medical Oncology, National Cancer Centre, Singapore, Singapore. -FAU - Keong, T C -AU - Keong TC -AD - Division of Medical Oncology, National Cancer Centre, Singapore, Singapore. -FAU - Pongnikorn, D -AU - Pongnikorn D -AD - Cancer Registry Unit, Lampang Cancer Hospital, Lampang, Thailand. -FAU - Prasongsook, N -AU - Prasongsook N -AD - Medical Oncology Division, Department of Internal Medicine, Phramongkutklao - Hospital, Bangkok, Thailand. -FAU - Hutajulu, S H -AU - Hutajulu SH -AD - Division of Hematology and Medical Oncology, Department of Internal Medicine, - Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. - Sardjito General Hospital, Yogyakarta, Indonesia. -FAU - Irawan, C -AU - Irawan C -AD - Division of Hematology and Medical Oncology, Department of Internal Medicine, - Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General - Hospital, Jakarta, Indonesia. -FAU - Manan, A Ab -AU - Manan AA -AD - Malaysian National Cancer Registry Department, National Cancer Institute, - Ministry of Health Malaysia, Putrajaya, Malaysia. -FAU - Thiagarajan, M -AU - Thiagarajan M -AD - Department of Radiotherapy and Oncology, Kuala Lumpur Hospital, Kuala Lumpur, - Malaysia. -FAU - Sripan, P -AU - Sripan P -AD - Research Institute for Health Sciences, Chiang Mai University, Chiangmai, - Thailand. -FAU - Peters, S -AU - Peters S -AD - Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, - Switzerland. -FAU - Storm, H -AU - Storm H -AD - Danish Cancer Society, Copenhagen, Denmark. -FAU - Bray, F -AU - Bray F -AD - Section of Cancer Surveillance, International Agency for Research on Cancer, - Lyon, France. -FAU - Stahel, R -AU - Stahel R -AD - ETOP IBCSG Partners Foundation, Bern, Switzerland. Electronic address: - Rolf.Stahel@etop.ibcsg.org. -LA - eng -GR - 001/WHO_/World Health Organization/International -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20220818 -PL - England -TA - ESMO Open -JT - ESMO open -JID - 101690685 -RN - 0 (B7-H1 Antigen) -RN - EC 2.7.10.1 (Anaplastic Lymphoma Kinase) -RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) -RN - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) -RN - 0 (Proto-Oncogene Proteins) -RN - EC 2.7.10.1 (ErbB Receptors) -SB - IM -MH - Humans -MH - *Carcinoma, Non-Small-Cell Lung/drug therapy -MH - *Lung Neoplasms/drug therapy -MH - B7-H1 Antigen -MH - Anaplastic Lymphoma Kinase/genetics -MH - Protein-Tyrosine Kinases/genetics/therapeutic use -MH - Proto-Oncogene Proteins B-raf/genetics -MH - Retrospective Studies -MH - Mutation -MH - Proto-Oncogene Proteins/genetics/therapeutic use -MH - Thailand -MH - ErbB Receptors/genetics -PMC - PMC9588878 -OTO - NOTNLM -OT - Asia -OT - NSCLC -OT - lung cancer -OT - molecular testing -OT - population-based cancer registry -COIS- Disclosure RS is involved in advisory boards for Amgen, AstraZeneca, Bayer, BMS, - Boehringer Ingelheim, Janssen, Lily, Merck, Merck Serono, Novartis, Pfizer, Puma, - Roche, Taiho, Takeda, Yuhan and has received research grants from AstraZeneca and - Boehringer Ingelheim. RK has been an advisor/speaker or received honorarium from - AstraZeneca, Pfizer, Merck, MSD, BMS, J&J, Ipsen, Eisai, Amgen, Novartis, Lucence - Therapeutics and Astellas. NP has consulting or advisory roles with AstraZeneca, - Novartis and Roche. SP has consulting/advisory roles with AbbVie, Amgen, Arcus, - AstraZeneca, Bayer, Beigene, Biocartis, BioInvent, Blueprint Medicines, - Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, - ecancer, Eli Lilly, Elsevier, F-Star, Fishawack, Foundation Medicine, Genzyme, - Gilead, GSK, Illumina, Imedex, IQVIA, Incyte, iTeos, Janssen, Medscape, Merck - Sharp and Dohme, Merck Serono, Merrimack, Novartis, Novocure, Oncology Education, - Pharma Mar, Phosplatin Therapeutics, PER, Pfizer, PRIME, Regeneron, RMEI, - Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda and Vaccibody; has talked - in organized public events for AstraZeneca, Boehringer Ingelheim, Bristol-Myers - Squibb, ecancer, Eli Lilly, Foundation Medicine, Illumina, Imedex, Medscape, - Merck Sharp and Dohme, Mirati, Novartis, PER, Pfizer, Prime, Roche/Genentech, - RTP, Sanofi and Takeda; has been a principal investigator in trials - (institutional financial support for clinical trials) sponsored by Amgen, - AstraZeneca, Beigene, Bristol-Myers Squibb, GSK, Merck Sharp and Dohme, and - Roche/Genentech. RSt has been an invited speaker for Amgen, AstraZeneca, - Blueprint, Bristol-Myers Squibb, Boehringer Ingelheim, GSK, MSD, Novartis and - Roche; has been on advisory boards for AstraZeneca, BMS, Boehringer Ingelheim, - GSK, MSD, Pfizer, Roche, Sandoz, Seattle Genetics and Takeda; has received - institutional support (ETOP, IBCSG) from AstraZeneca, Bristol-Myers Squibb, - Daiichi Sankyo, Celgene, Ipsen, Janssen, Mirati, MSD, Novartis, Pfizer, Pierre - Fabre and Roche. All other authors have declared no conflicts of interest. Where - authors are identified as personnel of the International Agency for Research on - Cancer/World Health Organization, the authors alone are responsible for the views - expressed in this article, and they do not necessarily represent the decisions, - policy, or views of the International Agency for Research on Cancer/World Health - Organization. -EDAT- 2022/08/22 06:00 -MHDA- 2022/10/25 06:00 -PMCR- 2022/08/18 -CRDT- 2022/08/21 18:25 -PHST- 2022/05/03 00:00 [received] -PHST- 2022/07/04 00:00 [revised] -PHST- 2022/07/06 00:00 [accepted] -PHST- 2022/08/22 06:00 [pubmed] -PHST- 2022/10/25 06:00 [medline] -PHST- 2022/08/21 18:25 [entrez] -PHST- 2022/08/18 00:00 [pmc-release] -AID - S2059-7029(22)00188-0 [pii] -AID - 100560 [pii] -AID - 10.1016/j.esmoop.2022.100560 [doi] -PST - ppublish -SO - ESMO Open. 2022 Oct;7(5):100560. doi: 10.1016/j.esmoop.2022.100560. Epub 2022 Aug - 18. - -PMID- 30813943 -OWN - NLM -STAT- MEDLINE -DCOM- 20200331 -LR - 20200331 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 7 -IP - 1 -DP - 2019 Feb 27 -TI - Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with - pembrolizumab: a case report. -PG - 59 -LID - 10.1186/s40425-019-0534-z [doi] -LID - 59 -AB - BACKGROUND: Pembrolizumab, an anti-programmed cell death-1 protein monoclonal - antibody, is effective for patients with advanced non-small-cell lung cancer. - However, immune checkpoint inhibitors such as pembrolizumab induce various - immune-related adverse events, involving the lung, liver, gastrointestinal, - endocrine system, and skin. Intralymphatic histiocytosis (ILH) is a rare, chronic - cutaneous disorder with a reactive inflammatory component, which often occurs in - patients with rheumatoid arthritis. CASE PRESENTATION: We present a 67-year-old - man with lung adenocarcinoma who developed ILH associated with pembrolizumab - treatment. He was treated with palliative thoracic radiotherapy for superior vena - cava syndrome. Subsequently, he received four cycles of pembrolizumab. - Approximately 2.5 months after the initiation of pembrolizumab, he developed - erythema on the trunk of his body. Based on findings of skin biopsies, he was - diagnosed with pembrolizumab-induced ILH. Moreover, the upregulation of tumor - necrosis factor-α was observed during pembrolizumab therapy. CONCLUSIONS: This is - the first report of ILH induced by pembrolizumab in a patient with lung - adenocarcinoma. -FAU - Sugano, Teppei -AU - Sugano T -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. -FAU - Seike, Masahiro -AU - Seike M -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. - mseike@nms.ac.jp. -FAU - Funasaka, Yoko -AU - Funasaka Y -AD - Department of Dermatology, Nippon Medical School, Tokyo, Japan. -FAU - Yoshida, Mai -AU - Yoshida M -AD - Department of Dermatology, Nippon Medical School, Tokyo, Japan. -FAU - Takayama, Ryoko -AU - Takayama R -AD - Department of Dermatology, Nippon Medical School, Tokyo, Japan. -FAU - Okamura, Ken -AU - Okamura K -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. -FAU - Nakanishi, Asuka -AU - Nakanishi A -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. -FAU - Tanaka, Toru -AU - Tanaka T -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. -FAU - Takeuchi, Susumu -AU - Takeuchi S -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. -FAU - Noro, Rintaro -AU - Noro R -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. -FAU - Minegishi, Yuji -AU - Minegishi Y -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. -FAU - Kubota, Kaoru -AU - Kubota K -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. -FAU - Saeki, Hidehisa -AU - Saeki H -AD - Department of Dermatology, Nippon Medical School, Tokyo, Japan. -FAU - Gemma, Akihiko -AU - Gemma A -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20190227 -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Adenocarcinoma of Lung/*drug therapy -MH - Aged -MH - Antibodies, Monoclonal, Humanized/*adverse effects -MH - Antineoplastic Agents, Immunological/*adverse effects -MH - Histiocytosis/*chemically induced -MH - Humans -MH - Lung Neoplasms/*drug therapy -MH - Male -PMC - PMC6391791 -OTO - NOTNLM -OT - Intralymphatic histiocytosis -OT - Lung adenocarcinoma -OT - Pembrolizumab -COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Written informed consent was obtained - from the patient for the analysis of the samples and the tissues. CONSENT FOR - PUBLICATION: Consent for publication was obtained from the patient. A copy of the - written consent is available for review. COMPETING INTERESTS: Masahiro Seike, - Kaoru Kubota, and Akihiko Gemma have received honorarium from Merck Sharp & - Dohme. The authors report no other conflicts of interest in this work. - PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional - claims in published maps and institutional affiliations. -EDAT- 2019/03/01 06:00 -MHDA- 2020/04/01 06:00 -PMCR- 2019/02/27 -CRDT- 2019/03/01 06:00 -PHST- 2018/10/11 00:00 [received] -PHST- 2019/02/12 00:00 [accepted] -PHST- 2019/03/01 06:00 [entrez] -PHST- 2019/03/01 06:00 [pubmed] -PHST- 2020/04/01 06:00 [medline] -PHST- 2019/02/27 00:00 [pmc-release] -AID - 10.1186/s40425-019-0534-z [pii] -AID - 534 [pii] -AID - 10.1186/s40425-019-0534-z [doi] -PST - epublish -SO - J Immunother Cancer. 2019 Feb 27;7(1):59. doi: 10.1186/s40425-019-0534-z. - -PMID- 34116229 -OWN - NLM -STAT- MEDLINE -DCOM- 20211021 -LR - 20220531 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Linking) -VI - 16 -IP - 10 -DP - 2021 Oct -TI - Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced - NSCLC With EGFR Mutation; West Japan Oncology Group 6911L. -PG - 1745-1752 -LID - S1556-0864(21)02190-0 [pii] -LID - 10.1016/j.jtho.2021.05.019 [doi] -AB - INTRODUCTION: About 10% of patients with locally advanced NSCLC (LA-NSCLC) harbor - EGFR mutation and recent reports suggested the declined benefit with an immune - checkpoint inhibitor in this population. The attempt that introduces EGFR - tyrosine kinase inhibitor into the treatment of LA-NSCLC with EGFR mutation has - been warranted. METHODS: Chemotherapy-naive patients with unresectable LA-NSCLC - with sensitive EGFR mutation (exon 19 deletion or exon 21 L858R point mutation) - were enrolled. Patients were treated with gefitinib (250 mg/d for 2 y) plus - concurrent thoracic radiotherapy (64 Gy/32 fractions). The primary end point was - progression-free survival (PFS) at 2 years (trial identifier, UMIN000008366). - RESULTS: Between August 2012 and November 2017, a total of 28 patients were - enrolled and 27 were eligible. The median age was 67 years (range: 45-74); - never/current or former smoker in 15/12 patients, respectively; Eastern - Cooperative Oncology Group performance status of 0/1 in 19/8; EGFR exon 19 - deletion/exon 21 L858R in 13/14; and c-stage IIIA/IIIB in 14/13. The PFS rate at - 2 years by independent review was 29.6% (one-sided 95% confidence interval [CI]: - 17.6%-). The overall response rate was 81.5% (95% CI: 63.3%-91.3%), median PFS - was 18.6 months (95% CI: 12.0-24.5 mo), and median overall survival was 61.1 - months (95% CI: 38.1 mo-not reached). Approximately half of the patients - exhibited solitary brain metastasis as their first site of relapse. Adverse - events greater than or equal to grade 3 were fatigue, skin reaction, and appetite - loss (3.7% each). CONCLUSIONS: This prospective study revealed the tolerability - and the possible efficacy of gefitinib plus concurrent thoracic radiotherapy in - patients with LA-NSCLC having EGFR mutation. -CI - Copyright © 2021 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Akamatsu, Hiroaki -AU - Akamatsu H -AD - Department of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan; - Internal Medicine III, Wakayama Medical University, Wakayama, Japan. Electronic - address: hiroakiakamatsu@gmail.com. -FAU - Murakami, Haruyasu -AU - Murakami H -AD - Department of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Harada, Hideyuki -AU - Harada H -AD - Department of Radiation Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, - Nagaizumi-cho, Sunto-gun, Shizuoka, Japan. -FAU - Shimizu, Junichi -AU - Shimizu J -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. -FAU - Hayashi, Hidetoshi -AU - Hayashi H -AD - Department of Medical Oncology, Kindai University Faculty of Medicine, - Osakasayama, Japan. -FAU - Daga, Haruko -AU - Daga H -AD - Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan. -FAU - Hasegawa, Yoshikazu -AU - Hasegawa Y -AD - Department of Medical Oncology, Izumi City General Hospital, Izumi, Japan. -FAU - Kim, Young Hak -AU - Kim YH -AD - Department of Respiratory Medicine, Kyoto University, Kyoto, Japan. -FAU - Kato, Terufumi -AU - Kato T -AD - Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan. -FAU - Tokunaga, Shoji -AU - Tokunaga S -AD - Medical Information Center, Kyushu University Hospital, Fukuoka, Japan. -FAU - Nishimura, Yasumasa -AU - Nishimura Y -AD - Department of Radiation Oncology, Kindai University Faculty of Medicine, - Osakasayama, Japan. -FAU - Yamamoto, Nobuyuki -AU - Yamamoto N -AD - Internal Medicine III, Wakayama Medical University, Wakayama, Japan. -FAU - Nakagawa, Kazuhiko -AU - Nakagawa K -AD - Department of Medical Oncology, Kindai University Faculty of Medicine, - Osakasayama, Japan. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20210609 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -RN - 0 (Protein Kinase Inhibitors) -RN - 0 (Quinazolines) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - S65743JHBS (Gefitinib) -SB - IM -CIN - J Thorac Oncol. 2021 Oct;16(10):1607-1609. doi: 10.1016/j.jtho.2021.06.026. PMID: - 34561033 -MH - Aged -MH - Disease-Free Survival -MH - ErbB Receptors/genetics -MH - *Gefitinib/therapeutic use -MH - Humans -MH - Japan -MH - *Lung Neoplasms/drug therapy/radiotherapy -MH - Middle Aged -MH - Mutation -MH - Neoplasm Recurrence, Local -MH - Prospective Studies -MH - Protein Kinase Inhibitors/therapeutic use -MH - Quinazolines -OTO - NOTNLM -OT - Chemoradiotherapy -OT - Epidermal growth factor receptor mutation -OT - Gefitinib -OT - Locally advanced non–small cell lung cancer -EDAT- 2021/06/12 06:00 -MHDA- 2021/10/26 06:00 -CRDT- 2021/06/11 20:15 -PHST- 2021/03/24 00:00 [received] -PHST- 2021/05/12 00:00 [revised] -PHST- 2021/05/20 00:00 [accepted] -PHST- 2021/06/12 06:00 [pubmed] -PHST- 2021/10/26 06:00 [medline] -PHST- 2021/06/11 20:15 [entrez] -AID - S1556-0864(21)02190-0 [pii] -AID - 10.1016/j.jtho.2021.05.019 [doi] -PST - ppublish -SO - J Thorac Oncol. 2021 Oct;16(10):1745-1752. doi: 10.1016/j.jtho.2021.05.019. Epub - 2021 Jun 9. - -PMID- 38923311 -OWN - NLM -STAT- MEDLINE -DCOM- 20240626 -LR - 20240722 -IS - 2045-7634 (Electronic) -IS - 2045-7634 (Linking) -VI - 13 -IP - 12 -DP - 2024 Jun -TI - A retrospective study of first-line therapy and subsequent pyrotinib treatment in - advanced lung adenocarcinoma with HER2 mutations. -PG - e7335 -LID - 10.1002/cam4.7335 [doi] -LID - e7335 -AB - OBJECTIVES: HER2 is an infrequently mutated driver gene in non-small cell lung - cancer (NSCLC). At present, there has been no comprehensive large-scale clinical - study to establish the optimal first-line treatment strategy for advanced lung - adenocarcinoma (LUAD) with HER2-Mutant. Besides that, the effectiveness and - safety of pyrotinib, a pan-HER inhibitor, in the context of NSCLC are still - undergoing investigation. MATERIALS AND METHODS: In this study, we conducted a - retrospective data collection of HER2-Mutated advanced LUAD who received - first-line treatment and pyrotinib between May 2014 and June 2023. Patients - treated with chemotherapy, chemotherapy + immune checkpoint inhibitors (ICIs), - chemotherapy + bevacizumab and pyrotinib in first-line treatment. Furthermore, we - collected data on the efficacy and safety of pyrotinib in these patients after - disease progression. The main endpoint of the study was progression-free survival - (PFS). RESULTS: In the final analysis, 89 patients were included in the - first-line cohort and 30 patients were included in the pyrotinib cohort. In the - first-line treatment cohort, chemotherapy + ICIs, chemotherapy + bevacizumab, and - pyrotinib exhibited notable survival benefits compared to chemotherapy (median - PFS: 9.87 vs. 7.77 vs. 7.10 vs. 5.40 months, p-value < 0.05). Furthermore, - patients with a first-line treatment PFS of less than 6 months may potentially - benefit from subsequent treatment with pyrotinib (median PFS: 7.467 vs. 3.000, - p-value = 0.0490). CONCLUSIONS: In the first-line treatment of HER2-Mutant LUAD, - regimens involving combinations like chemotherapy + ICIs, - chemotherapy + bevacizumab, and pyrotinib may confer enhanced survival advantages - compared to chemotherapy. Nevertheless, no significant distinctions were observed - among these three treatment strategies, underscoring the imperative to identify - biomarkers for the discerning selection of suitable therapeutic modalities. - Moreover, patients with suboptimal response to first-line treatment may - potentially derive more benefit from pyrotinib. -CI - © 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. -FAU - Wang, Li -AU - Wang L -AUID- ORCID: 0000-0002-6433-1605 -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, People's Republic of - China. -FAU - Wu, Yueran -AU - Wu Y -AD - Department of Chronic Disease Prevention and Control, Jiujiang City Center for - Disease Control and Prevention, Jiangxi, China. -FAU - Ren, Zhixuan -AU - Ren Z -AD - Department of Radiation Oncology, Huadong Hospital Affiliated to Fudan - University, Shanghai, People's Republic of China. -FAU - Chu, Xiangling -AU - Chu X -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, People's Republic of - China. -FAU - Chen, Jianing -AU - Chen J -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, People's Republic of - China. -FAU - Liu, Li -AU - Liu L -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, People's Republic of - China. -FAU - Zhao, Jing -AU - Zhao J -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, People's Republic of - China. -FAU - Yu, Xin -AU - Yu X -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, People's Republic of - China. -FAU - Xie, Mengqing -AU - Xie M -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, People's Republic of - China. -FAU - Su, Chunxia -AU - Su C -AUID- ORCID: 0000-0003-1632-9487 -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer - Institute, Tongji University School of Medicine, Shanghai, People's Republic of - China. -LA - eng -GR - SHDC2022CRD048/Shanghai Shenkang development research physician project/ -GR - 2023YFC2508605/National Key R&D Program of China/ -GR - 82072568/National Natural Science Foundation of China/ -GR - 82373320/National Natural Science Foundation of China/ -PT - Journal Article -PL - United States -TA - Cancer Med -JT - Cancer medicine -JID - 101595310 -RN - 0 (pyrotinib) -RN - EC 2.7.10.1 (Receptor, ErbB-2) -RN - 0 (Acrylamides) -RN - EC 2.7.10.1 (ERBB2 protein, human) -RN - 0 (Aminoquinolines) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 2S9ZZM9Q9V (Bevacizumab) -SB - IM -MH - Humans -MH - Female -MH - Retrospective Studies -MH - Male -MH - Middle Aged -MH - Aged -MH - *Lung Neoplasms/drug therapy/genetics/pathology/mortality -MH - *Receptor, ErbB-2/genetics/metabolism -MH - *Mutation -MH - *Acrylamides/therapeutic use -MH - *Adenocarcinoma of Lung/drug therapy/genetics/pathology/mortality -MH - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects -MH - Progression-Free Survival -MH - Adult -MH - Aminoquinolines/therapeutic use/administration & dosage -MH - Immune Checkpoint Inhibitors/therapeutic use -MH - Bevacizumab/therapeutic use/administration & dosage -MH - Aged, 80 and over -PMC - PMC11194746 -OTO - NOTNLM -OT - HER2‐mutant -OT - efficacy -OT - first‐line treatment -OT - lung adenocarcinoma -OT - pyrotinib -COIS- All authors declare no conflict of interest. -EDAT- 2024/06/26 18:42 -MHDA- 2024/06/26 18:43 -PMCR- 2024/06/24 -CRDT- 2024/06/26 12:46 -PHST- 2024/05/09 00:00 [revised] -PHST- 2024/02/27 00:00 [received] -PHST- 2024/05/14 00:00 [accepted] -PHST- 2024/06/26 18:43 [medline] -PHST- 2024/06/26 18:42 [pubmed] -PHST- 2024/06/26 12:46 [entrez] -PHST- 2024/06/24 00:00 [pmc-release] -AID - CAM47335 [pii] -AID - 10.1002/cam4.7335 [doi] -PST - ppublish -SO - Cancer Med. 2024 Jun;13(12):e7335. doi: 10.1002/cam4.7335. - -PMID- 3993837 -OWN - NLM -STAT- MEDLINE -DCOM- 19850620 -LR - 20220408 -IS - 0002-9610 (Print) -IS - 0002-9610 (Linking) -VI - 149 -IP - 5 -DP - 1985 May -TI - Carcinoma of the lung in patients under 40 years of age. -PG - 602-5 -AB - Bronchogenic carcinoma in the young population (40 years of age or less) is - reported to present in an advanced stage and to have a virulent course. Between - 1969 and 1979, 101 patients (65 men and 36 women) presented with cancer of the - lung. Their mean age was 36.2 +/- 3.9 years (range 18 to 40 years). Eighty-seven - percent had a history of cigarette smoking. Fifty percent of the patients had a - strong familial history of malignancy of several organs. The interval between - onset of symptoms and diagnosis was 4.01 +/- 3.48 months (3.56 +/- 3.34 for the - surgically treated group and 4.16 +/- 3.53 for the nonoperated or unresectable - group). Diagnosis was made at bronchoscopy in 32 patients, during thoracotomy in - 30 patients, during nodal biopsy in 28 patients, and on cytologic examination of - the sputum in 9 patients. The most common cell types were adenocarcinoma in 39 - patients, squamous carcinoma in 29 patients, and oat cell carcinoma in 18 - patients. Eighty-six patients (the majority) presented in stage III, whereas 9 - were in stage I and 6 were in stage II. Twenty-seven patients (26.7 percent) - underwent resection for cure, whereas 18 patients were inoperable at surgery. - Eighteen of the surgical patients had adjuvant radiotherapy, and chemotherapy, - immunotherapy, or both. The average length of survival for the nonresected - patients was 7.12 +/- 5.9 months (range 1 to 36 months) and the actuarial - survival was 1.5 percent at 36 months. The survival for the surgically managed - patients was 56.1 +/- 52.6 months (range 3 to 168 months) or 48 percent at 36 - months. At 46 to 168 months after treatment, the only survivors were 13 patients - who were surgically managed. Stage III patients had longer survival after surgery - (24.1 +/- 24.6 months to 7.09 +/- 5.90 months; range 3 to 74 months and 1 to 36 - months, respectively). The survival at 5 years for patients with stage I disease - was 78.8 percent, stage II disease 66.6 percent, and stage III disease, 3.6 - percent. Early diagnosis and aggressive surgical management are necessary to - improve the survival of patients with bronchogenic carcinoma under 40 years of - age. -FAU - Larrieu, A J -AU - Larrieu AJ -FAU - Jamieson, W R -AU - Jamieson WR -FAU - Nelems, J M -AU - Nelems JM -FAU - Fowler, R -AU - Fowler R -FAU - Yamamoto, B -AU - Yamamoto B -FAU - Leriche, J -AU - Leriche J -FAU - Murray, N -AU - Murray N -LA - eng -PT - Journal Article -PL - United States -TA - Am J Surg -JT - American journal of surgery -JID - 0370473 -SB - IM -MH - Adolescent -MH - Adult -MH - Age Factors -MH - Female -MH - Humans -MH - *Lung Neoplasms/epidemiology/mortality/therapy -MH - Male -EDAT- 1985/05/01 00:00 -MHDA- 1985/05/01 00:01 -CRDT- 1985/05/01 00:00 -PHST- 1985/05/01 00:00 [pubmed] -PHST- 1985/05/01 00:01 [medline] -PHST- 1985/05/01 00:00 [entrez] -AID - S0002-9610(85)80135-5 [pii] -AID - 10.1016/s0002-9610(85)80135-5 [doi] -PST - ppublish -SO - Am J Surg. 1985 May;149(5):602-5. doi: 10.1016/s0002-9610(85)80135-5. - -PMID- 32156781 -OWN - NLM -STAT- MEDLINE -DCOM- 20201111 -LR - 20201111 -IS - 1538-7445 (Electronic) -IS - 0008-5472 (Linking) -VI - 80 -IP - 11 -DP - 2020 Jun 1 -TI - BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders - That Potently Induce Apoptosis through Suppression of Mcl-1. -PG - 2380-2393 -LID - 10.1158/0008-5472.CAN-19-3674 [doi] -AB - Lung cancer consists of approximately 80% non-small cell lung cancer (NSCLC) and - 20% small cell lung cancer (SCLC) and remains the leading cause of cancer-related - deaths worldwide despite advances in early diagnosis, targeted therapy, and - immunotherapy. Thus, novel therapies are still urgently needed. Bromodomain and - extraterminal (BET) proteins, primarily comprised of BRD2, BRD3, and BRD4 - proteins, function as epigenetic readers and master transcription coactivators - and are now recognized cancer therapeutic targets. BET degraders such as ZBC260 - and dBET represent a novel class of BET inhibitors that act by inducing BET - degradation. The current study demonstrates the therapeutic efficacies of BET - degraders, particularly ZBC260, against lung cancer, as well as understanding the - underlying mechanisms and identifying molecular markers that determine cell - sensitivity to BET degraders. A panel of NSCLC cell lines possessed similar - response patterns to ZBC260 and dBET but different responses to BET inhibitor - JQ-1. BRD levels, particularly BRD4, correlated positively with high sensitivity - to BET degraders but not to JQ-1. BET degraders potently induced apoptosis in - sensitive NSCLC cells and were accompanied by reduction of Mcl-1 and c-FLIP - levels, which are critical for mediating induction of apoptosis and enhancement - of TRAIL-induced apoptosis. Accordingly, ZBC260 exerted more potent activity than - JQ-1 in vivo against the growth of NSCLC xenografts and patient-derived - xenografts. These findings warrant future clinical validation of the efficacy of - BET degraders in NSCLC, particularly those with high levels of BRD proteins, - especially BRD4. SIGNIFICANCE: The current study demonstrates the potential of - novel BET degraders in the treatment of lung cancer and warrants clinical - validation of BET degraders in lung cancer with high levels of BRD4. -CI - ©2020 American Association for Cancer Research. -FAU - Zong, Dan -AU - Zong D -AD - Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing - Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer - Research, Nanjing, Jiangsu, P. R. China. -AD - Department of Hematology and Medical Oncology, Emory University School of - Medicine and Winship Cancer Institute, Atlanta, Georgia. -FAU - Gu, Jiajia -AU - Gu J -AUID- ORCID: 0000-0001-8929-6976 -AD - Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing - Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer - Research, Nanjing, Jiangsu, P. R. China. -AD - Department of Hematology and Medical Oncology, Emory University School of - Medicine and Winship Cancer Institute, Atlanta, Georgia. -FAU - Cavalcante, Giovanna C -AU - Cavalcante GC -AUID- ORCID: 0000-0001-9814-4819 -AD - Department of Hematology and Medical Oncology, Emory University School of - Medicine and Winship Cancer Institute, Atlanta, Georgia. -AD - Laboratory of Human and Medical Genetics, Federal University of Pará, Belém, - Pará, Brazil. -FAU - Yao, Weilong -AU - Yao W -AUID- ORCID: 0000-0001-7534-0323 -AD - Department of Hematology and Medical Oncology, Emory University School of - Medicine and Winship Cancer Institute, Atlanta, Georgia. -AD - Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical - University, Beijing, P. R. China. -FAU - Zhang, Guojing -AU - Zhang G -AD - Department of Hematology and Medical Oncology, Emory University School of - Medicine and Winship Cancer Institute, Atlanta, Georgia. -FAU - Wang, Shaomeng -AU - Wang S -AD - Departments of Medicinal Chemistry, Pharmacology and Internal Medicine, - University of Michigan, Ann Arbor, Michigan. -FAU - Owonikoko, Taofeek K -AU - Owonikoko TK -AD - Department of Hematology and Medical Oncology, Emory University School of - Medicine and Winship Cancer Institute, Atlanta, Georgia. -FAU - He, Xia -AU - He X -AD - Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing - Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer - Research, Nanjing, Jiangsu, P. R. China. ssun@emory.edu hexiabm@163.com. -FAU - Sun, Shi-Yong -AU - Sun SY -AD - Department of Hematology and Medical Oncology, Emory University School of - Medicine and Winship Cancer Institute, Atlanta, Georgia. ssun@emory.edu - hexiabm@163.com. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20200310 -PL - United States -TA - Cancer Res -JT - Cancer research -JID - 2984705R -RN - 0 ((+)-JQ1 compound) -RN - 0 (Azepines) -RN - 0 (BRD4 protein, human) -RN - 0 (Cell Cycle Proteins) -RN - 0 (MCL1 protein, human) -RN - 0 (Myeloid Cell Leukemia Sequence 1 Protein) -RN - 0 (Proteins) -RN - 0 (Transcription Factors) -RN - 0 (Triazoles) -RN - 0 (bromodomain and extra-terminal domain protein, human) -RN - 4Z8R6ORS6L (Thalidomide) -SB - IM -MH - Animals -MH - Apoptosis/drug effects -MH - Azepines/*pharmacology -MH - Cell Cycle Proteins/*metabolism -MH - Cell Line, Tumor -MH - Humans -MH - Lung Neoplasms/*drug therapy/*metabolism/pathology -MH - Mice -MH - Myeloid Cell Leukemia Sequence 1 Protein/*antagonists & inhibitors/metabolism -MH - Proteins/*metabolism -MH - Thalidomide/*analogs & derivatives/pharmacology -MH - Transcription Factors/*metabolism -MH - Triazoles/*pharmacology -MH - Xenograft Model Antitumor Assays -EDAT- 2020/03/12 06:00 -MHDA- 2020/11/12 06:00 -CRDT- 2020/03/12 06:00 -PHST- 2019/11/21 00:00 [received] -PHST- 2020/02/12 00:00 [revised] -PHST- 2020/03/06 00:00 [accepted] -PHST- 2020/03/12 06:00 [pubmed] -PHST- 2020/11/12 06:00 [medline] -PHST- 2020/03/12 06:00 [entrez] -AID - 0008-5472.CAN-19-3674 [pii] -AID - 10.1158/0008-5472.CAN-19-3674 [doi] -PST - ppublish -SO - Cancer Res. 2020 Jun 1;80(11):2380-2393. doi: 10.1158/0008-5472.CAN-19-3674. Epub - 2020 Mar 10. - -PMID- 31747941 -OWN - NLM -STAT- MEDLINE -DCOM- 20200415 -LR - 20240722 -IS - 1476-4598 (Electronic) -IS - 1476-4598 (Linking) -VI - 18 -IP - 1 -DP - 2019 Nov 20 -TI - EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 - expression. -PG - 165 -LID - 10.1186/s12943-019-1073-4 [doi] -LID - 165 -AB - BACKGROUND: The ATLANTIC trial reported that higher PD-L1 expression in tumors - was involved in a higher objective response in patients with EGFR(+)/ALK(+) - non-small cell lung cancer (NSCLC), indicating the possibility of anti-PD-1/PD-L1 - therapy as a third-line (or later) treatment for advanced NSCLC. Therefore, the - determination of status and regulatory mechanisms of PD-L1 in EGFR mutant NSCLC - before and after acquired EGFR-TKIs resistance are meaningful. METHODS: The - correlation among PD-L1, c-MET, and HGF was analyzed based on TCGA datasheets and - paired NSCLC specimens before and after acquired EGFR-TKI resistance. EGFR-TKI - resistant NSCLC cells with three well-known mechanisms, c-MET amplification, - hepatocyte growth factor (HGF), and EGFR-T790M, were investigated to determinate - PD-L1 expression status and immune escape ability. PD-L1-deleted EGFR-TKIs - sensitive and resistant cells were used to evaluate the immune escape ability of - tumors in mice xenograft models. RESULTS: Positive correlations were found - among PD-L1, c-MET, and HGF, based on TCGA datasheets and paired NSCLC specimens. - Moreover, the above three resistant mechanisms increased PD-L1 expression and - attenuated activation and cytotoxicity of lymphocytes in vitro and in vivo, and - downregulation of PD-L1 partially restored the cytotoxicity of lymphocytes. Both - MAPK and PI3K pathways were involved in the three types of resistance - mechanism-induced PD-L1 overexpression, whereas the NF-kappa B pathway was only - involved in T790M-induced PD-L1 expression. CONCLUSIONS: HGF, MET-amplification, - and EGFR-T790M upregulate PD-L1 expression in NSCLC and promote the immune escape - of tumor cells through different mechanisms. -FAU - Peng, Shunli -AU - Peng S -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, People's Republic of China. -FAU - Wang, Rong -AU - Wang R -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, People's Republic of China. -FAU - Zhang, Xiaojuan -AU - Zhang X -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, People's Republic of China. -FAU - Ma, Yueyun -AU - Ma Y -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, People's Republic of China. -FAU - Zhong, Longhui -AU - Zhong L -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, People's Republic of China. -FAU - Li, Ke -AU - Li K -AD - Center for Clinical Medicine Research, Nanfang Hospital, Southern Medical - University, Guangzhou, 510515, People's Republic of China. -FAU - Nishiyama, Akihiro -AU - Nishiyama A -AD - Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, - Kanazawa, Ishikawa, Japan. -FAU - Arai, Sachiko -AU - Arai S -AD - Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, - Kanazawa, Ishikawa, Japan. -FAU - Yano, Seiji -AU - Yano S -AD - Divisions of Medical Oncology, Cancer Research Institute, Kanazawa University, - Kanazawa, Ishikawa, Japan. syano@staff.kanazawau.ac.jp. -FAU - Wang, Wei -AU - Wang W -AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, - Guangzhou, People's Republic of China. wangwei9500@hotmail.com. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -DEP - 20191120 -PL - England -TA - Mol Cancer -JT - Molecular cancer -JID - 101147698 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Protein Kinase Inhibitors) -RN - EC 2.7.10.1 (EGFR protein, human) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) -SB - IM -MH - Animals -MH - B7-H1 Antigen/*genetics -MH - Cell Line, Tumor -MH - Disease Models, Animal -MH - Drug Resistance, Neoplasm/*genetics -MH - ErbB Receptors/antagonists & inhibitors/metabolism -MH - Gene Expression Regulation, Neoplastic/*drug effects -MH - Humans -MH - Lung Neoplasms/drug therapy/*etiology/*metabolism/pathology -MH - Mice -MH - Molecular Targeted Therapy -MH - Phosphatidylinositol 3-Kinases/metabolism -MH - Protein Kinase Inhibitors/*pharmacology -MH - Proto-Oncogene Proteins c-akt/metabolism -MH - Signal Transduction/drug effects -MH - T-Lymphocytes/immunology/metabolism -MH - Tumor Escape/*genetics -MH - Xenograft Model Antitumor Assays -PMC - PMC6864970 -OTO - NOTNLM -OT - EGFR-TKIs resistance -OT - Immunotherapy -OT - Lung cancer -OT - PD-L1 -OT - Signaling pathways -COIS- The authors declare that they have no competing interests. -EDAT- 2019/11/22 06:00 -MHDA- 2020/04/16 06:00 -PMCR- 2019/11/20 -CRDT- 2019/11/22 06:00 -PHST- 2019/03/17 00:00 [received] -PHST- 2019/09/12 00:00 [accepted] -PHST- 2019/11/22 06:00 [entrez] -PHST- 2019/11/22 06:00 [pubmed] -PHST- 2020/04/16 06:00 [medline] -PHST- 2019/11/20 00:00 [pmc-release] -AID - 10.1186/s12943-019-1073-4 [pii] -AID - 1073 [pii] -AID - 10.1186/s12943-019-1073-4 [doi] -PST - epublish -SO - Mol Cancer. 2019 Nov 20;18(1):165. doi: 10.1186/s12943-019-1073-4. - -PMID- 38221913 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240116 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 13 -DP - 2023 -TI - Treating patients with platinum-sensitive extensive-stage small-cell lung cancer - in a real-world setting. -PG - 1161931 -LID - 10.3389/fonc.2023.1161931 [doi] -LID - 1161931 -AB - Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive disease with - poor 5-year survival. The first-line standard-of-care for ES-SCLC is platinum - plus etoposide, along with 1 of the immune checkpoint inhibitors atezolizumab or - durvalumab. Although SCLC first-line therapy often leads to rapid responses, - treatment becomes more challenging at progression, particularly for those with a - chemotherapy-free interval (CTFI) of ≤6 months. The NCCN Clinical Practice - Guidelines in Oncology (NCCN Guidelines(®)) for SCLC no longer specify treatment - recommendations in this setting, but options approved by the US Food and Drug - Administration include topotecan and lurbinectedin. Participation in a clinical - trial is recommended as an option regardless of CTFI. Other NCCN-recommended - regimens are paclitaxel, irinotecan, temozolomide, and - cyclophosphamide/doxorubicin/vincristine, among others. Nivolumab and - pembrolizumab are options in those not previously treated with a checkpoint - inhibitor. For patients with platinum-sensitive SCLC (CTFI >6 months), preferred - treatment per the NCCN Guidelines(®) for SCLC is retreatment with platinum and - etoposide, although the use of immune checkpoint inhibitors is discouraged if - there is progression on a drug in this class. Further research on immunotherapies - and combination regimens is ongoing, and continuing work on the - subcharacterization of SCLC may lead to better precision of therapies that - promote more durable responses in individual patients with ES-SCLC. -CI - Copyright © 2023 Sands and Subramanian. -FAU - Sands, Jacob -AU - Sands J -AD - Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States. -FAU - Subramanian, Janakiraman -AU - Subramanian J -AD - Division of Oncology, Saint Luke's Cancer Institute, Kansas City, MO, United - States. -AD - Center for Precision Oncology, Saint Luke's Cancer Institute, Kansas City, MO, - United States. -LA - eng -PT - Journal Article -DEP - 20231222 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC10786446 -OTO - NOTNLM -OT - SCLC -OT - chemotherapy -OT - immune checkpoint inhibitors -OT - immunotherapy -OT - platinum resistant -OT - platinum sensitive -OT - radiotherapy -OT - small-cell lung cancer -COIS- JSa is a consultant or advisory board member for Arcus, AstraZeneca, Curadev, - Daiichi Sankyo, Guardant Health, Jazz Pharmaceuticals, Medtronic, PharmaMar, and - Sanofi. JSu is an advisory board member for AstraZeneca, Boehringer Ingelheim, - Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Janssen, Jazz Pharmaceuticals, - Novartis, Pfizer, and Takeda; and has received speaker honoraria from - AstraZeneca, Boehringer Ingelheim, G1 Therapeutics, Janssen, and Jazz - Pharmaceuticals. -EDAT- 2024/01/15 06:42 -MHDA- 2024/01/15 06:43 -PMCR- 2023/01/01 -CRDT- 2024/01/15 04:24 -PHST- 2023/02/08 00:00 [received] -PHST- 2023/10/09 00:00 [accepted] -PHST- 2024/01/15 06:43 [medline] -PHST- 2024/01/15 06:42 [pubmed] -PHST- 2024/01/15 04:24 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2023.1161931 [doi] -PST - epublish -SO - Front Oncol. 2023 Dec 22;13:1161931. doi: 10.3389/fonc.2023.1161931. eCollection - 2023. - -PMID- 11142486 -OWN - NLM -STAT- MEDLINE -DCOM- 20010322 -LR - 20220409 -IS - 0923-7534 (Print) -IS - 0923-7534 (Linking) -VI - 11 -IP - 11 -DP - 2000 Nov -TI - Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An - update after long-term follow-up from two centers of the European Intergroup - study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical - Center, Germany and St. Anna Kinderspital, Vienna, Austria. -PG - 1451-62 -AB - BACKGROUND: An update of results from the High Risk Protocol of the Meta-EICESS - Study, conducted at the Pediatric Stem-Cell Transplant Centers of Düsseldorf and - Vienna. In order to evaluate a possible therapeutic benefit after allogeneic SCT - in patients with advanced Ewing tumors (AET), we compared outcome after - autologous and allogeneic stem-cell transplantation (SCT). PATIENTS AND METHODS: - We analyzed 36 patients treated with the myeloablative Hyper-ME protocol - (hyperfractionated total body irradiation, melphalan, etoposide +/- carboplatin) - between November 1986 and December 1994. Minimal follow-up for all patients was - five years. All patients underwent remission induction chemotherapy and local - treatment before myeloablative therapy. Seventeen of thirty-six patients had - multifocal primary Ewing's tumor, eighteen of thirty-six had early, multiple or - multifocal relapse, one of thirty-six patients had unifocal late relapse. - Twenty-six of thirty-six were treated with autologous and ten of thirty-six with - allogeneic hematopoietic stem cells. We analyzed the following risk factors, that - could possibly influence the event-free survival (EFS): number of involved bones, - degree of remission at time of SCT, type of graft, indication for SCT, bone - marrow infiltration, bone with concomitant lung disease, age at time of - diagnosis, pelvic involvement, involved compartment radiation, histopathological - diagnosis. RESULTS: EFS for the 36 patients was 0.24 (0.21) +/- 0.07. Eighteen of - thirty-six patients suffered relapse or died of disease, nine of thirty-six died - of treatment related toxicity (DOC). Nine of thirty-six patients are alive in CR. - Age > or = 17 years at initial diagnosis (P < 0.005) significantly deteriorated - outcome. According to the type of graft, EFS was 0.25 +/- 0.08 after autologous - and 0.20 +/- 0.13 after allogeneic SCT. Incidence of DOC was more than twice as - high after allogeneic (40%) compared to autologous (19%) SCT, even though the - difference did not reach significance (P = 0.08, Fisher's exact test). - CONCLUSIONS: Because of the rather short observation period. secondary malignant - neoplasms (SMN) may complicate the future clinical course of some of our patients - who are currently viewed as event-free survivors. EFS in AET is not improved by - allogeneic SCT due to a higher complication rate. The patient group was to small - to analyze for a possible graft-versus-tumor effect. -FAU - Burdach, S -AU - Burdach S -AD - Division of Pediatric Hematology/Oncology, Children' s Hospital Medical Center, - Martin Luther University Halle-Wittenberg, Halle, Germany. - stefan.burdach@medizin.uni-halle.de -FAU - van Kaick, B -AU - van Kaick B -FAU - Laws, H J -AU - Laws HJ -FAU - Ahrens, S -AU - Ahrens S -FAU - Haase, R -AU - Haase R -FAU - Körholz, D -AU - Körholz D -FAU - Pape, H -AU - Pape H -FAU - Dunst, J -AU - Dunst J -FAU - Kahn, T -AU - Kahn T -FAU - Willers, R -AU - Willers R -FAU - Engel, B -AU - Engel B -FAU - Dirksen, U -AU - Dirksen U -FAU - Kramm, C -AU - Kramm C -FAU - Nürnberger, W -AU - Nürnberger W -FAU - Heyll, A -AU - Heyll A -FAU - Ladenstein, R -AU - Ladenstein R -FAU - Gadner, H -AU - Gadner H -FAU - Jürgens, H -AU - Jürgens H -FAU - Go el, U -AU - Go el U -LA - eng -PT - Comparative Study -PT - Journal Article -PT - Multicenter Study -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - England -TA - Ann Oncol -JT - Annals of oncology : official journal of the European Society for Medical - Oncology -JID - 9007735 -RN - 0 (Immunologic Factors) -RN - 0 (Interleukin-2) -SB - IM -MH - Adolescent -MH - Adult -MH - Age Factors -MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use -MH - Bone Neoplasms/drug therapy/mortality/surgery/*therapy -MH - Case Management -MH - Cause of Death -MH - Child -MH - Combined Modality Therapy -MH - Disease-Free Survival -MH - Dose Fractionation, Radiation -MH - Female -MH - Follow-Up Studies -MH - *Hematopoietic Stem Cell Transplantation -MH - Humans -MH - Immunologic Factors/therapeutic use -MH - Interleukin-2/therapeutic use -MH - Male -MH - Myelodysplastic Syndromes/etiology -MH - Neoplasm Metastasis -MH - Neoplasms, Second Primary/epidemiology -MH - Prognosis -MH - Radiotherapy, Adjuvant -MH - Remission Induction -MH - Risk Factors -MH - Sarcoma, Ewing/drug therapy/mortality/surgery/*therapy -MH - Survival Analysis -MH - Transplantation Conditioning -MH - Transplantation, Autologous -MH - Transplantation, Homologous -MH - Treatment Outcome -RF - 56 -EDAT- 2001/01/06 11:00 -MHDA- 2001/03/27 10:01 -CRDT- 2001/01/06 11:00 -PHST- 2001/01/06 11:00 [pubmed] -PHST- 2001/03/27 10:01 [medline] -PHST- 2001/01/06 11:00 [entrez] -AID - S0923-7534(19)55708-8 [pii] -AID - 10.1023/a:1026539908115 [doi] -PST - ppublish -SO - Ann Oncol. 2000 Nov;11(11):1451-62. doi: 10.1023/a:1026539908115. - -PMID- 32312286 -OWN - NLM -STAT- MEDLINE -DCOM- 20210112 -LR - 20240328 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 20 -IP - 1 -DP - 2020 Apr 20 -TI - TENERGY: multicenter phase II study of Atezolizumab monotherapy following - definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with - unresectable locally advanced esophageal squamous cell carcinoma. -PG - 336 -LID - 10.1186/s12885-020-06716-5 [doi] -LID - 336 -AB - BACKGROUND: The standard treatment for patients with unresectable locally - advanced esophageal squamous cell carcinoma (ESCC) is definitive - chemoradiotherapy (CRT) using 5-FU plus cisplatin. However, complete response - (CR) rates are low at 11-25%, resulting in 9-10 months of median overall survival - (OS). An improved therapeutic efficacy by combining immunotherapy with radiation - has been reported in patients with locally advanced non-small cell lung cancer. - The results using ESCC cell lines suggest sequential treatment with anti-PD-L1 - agents soon after completion of CRT is the most effective combination. METHODS: - TENERGY trial is a multicenter, phase II, proof-of-concept study to assess the - efficacy and safety of atezolizumab following definitive CRT in patients with - locally advanced ESCC. The main inclusion criteria are unresectable locally - advanced ESCC without distant metastasis, completion of 60 Gy of radiation plus - two concomitant cycles of chemotherapy (cisplatin 70 mg/m(2) on day 1 and 5-FU - 700 mg/m(2) on days 1-4, every 28 days), and adequate organ function. Within - 6 weeks after CRT, participants will start taking 1200 mg of atezolizumab every - three weeks and continue until 12 months or disease progression. The primary - endpoint is the confirmed CR rate by the investigator's assessment. Secondary - endpoints include overall response rate, progression-free survival (PFS), OS, - adverse events, and confirmed CR rate by central assessment. We will enroll 50 - patients (40 with primary locally advanced ESCC and 10 with postoperative - locoregionally recurrent ESCC). We will obtain biopsies from the primary site and - will collect blood at 3 time points (before CRT, after CRT, and four weeks after - the start of atezolizumab) for an exploratory biomarker study. We will analyze - the phenotype of immune-competent cells, neoantigens, tumor mutational burden, - PD-L1 status, and Human Leukocyte Antigen haplotyping. DISCUSSION: The - synergistic efficacies of the sequential combination of CRT and atezolizumab - should improve the CR rate, resulting in survival improvement for patients with - unresectable locally advanced ESCC. Because CRT is a standard treatment option - for patients with early stage to locally advanced ESCC, the sequential - combination of CRT and atezolizumab has the potential to change the standard ESCC - treatments. TRIAL REGISTRATION: UMIN000034373, 10/04/2018 and EPOC1802. -FAU - Bando, Hideaki -AU - Bando H -AD - Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. -FAU - Kotani, Daisuke -AU - Kotani D -AD - Department of Gastroenterology and Gastrointestinal Oncology, National Cancer - Center Hospital East, Kashiwa, Japan. -FAU - Tsushima, Takahiro -AU - Tsushima T -AD - Division of Gastrointestinal Oncology Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Hara, Hiroki -AU - Hara H -AD - Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan. -FAU - Kadowaki, Shigenori -AU - Kadowaki S -AD - Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. -FAU - Kato, Ken -AU - Kato K -AD - Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, - Tokyo, Japan. -FAU - Chin, Keisho -AU - Chin K -AD - Department of Gastroenterological Medicine, Cancer Institute Hospital of Japanese - Foundation for Cancer Research, Tokyo, Japan. -FAU - Yamaguchi, Kensei -AU - Yamaguchi K -AD - Department of Gastroenterological Medicine, Cancer Institute Hospital of Japanese - Foundation for Cancer Research, Tokyo, Japan. -FAU - Kageyama, Shun-Ichiro -AU - Kageyama SI -AD - Division of Radiation Oncology and Particle Therapy, National Cancer Center - Hospital East, Kashiwa, Japan. -FAU - Hojo, Hidehiro -AU - Hojo H -AD - Division of Radiation Oncology and Particle Therapy, National Cancer Center - Hospital East, Kashiwa, Japan. -FAU - Nakamura, Masaki -AU - Nakamura M -AD - Division of Radiation Oncology and Particle Therapy, National Cancer Center - Hospital East, Kashiwa, Japan. -FAU - Tachibana, Hidenobu -AU - Tachibana H -AD - Division of Radiation Oncology and Particle Therapy, National Cancer Center - Hospital East, Kashiwa, Japan. -FAU - Wakabayashi, Masashi -AU - Wakabayashi M -AD - Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, - Japan. -FAU - Fukutani, Miki -AU - Fukutani M -AD - Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, - Japan. -FAU - Togashi, Yosuke -AU - Togashi Y -AD - Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial - Center, National Cancer Center Hospital East, Kashiwa, Japan. -FAU - Fuse, Nozomu -AU - Fuse N -AD - Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, - Japan. -FAU - Nishikawa, Hiroyoshi -AU - Nishikawa H -AD - Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial - Center, National Cancer Center Hospital East, Kashiwa, Japan. -FAU - Kojima, Takashi -AU - Kojima T -AD - Department of Gastroenterology and Gastrointestinal Oncology, National Cancer - Center Hospital East, Kashiwa, Japan. takojima@east.ncc.go.jp. -LA - eng -GR - 18ck0106420h0001/Japan Agency for Medical Research and Development/ -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Multicenter Study -DEP - 20200420 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 52CMI0WC3Y (atezolizumab) -RN - Q20Q21Q62J (Cisplatin) -RN - U3P01618RT (Fluorouracil) -SB - IM -MH - Adult -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/administration & dosage -MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use -MH - Chemoradiotherapy/*mortality -MH - Cisplatin/administration & dosage -MH - Esophageal Neoplasms/pathology/*therapy -MH - Esophageal Squamous Cell Carcinoma/pathology/*therapy -MH - Female -MH - Fluorouracil/administration & dosage -MH - Follow-Up Studies -MH - Humans -MH - Male -MH - Middle Aged -MH - Neoadjuvant Therapy/*mortality -MH - Prognosis -MH - Survival Rate -MH - Young Adult -PMC - PMC7168951 -OTO - NOTNLM -OT - Atezolizumab -OT - Chemoradiotherapy -OT - Esophageal squamous cell carcinoma -OT - Unresectable locally advanced -COIS- HB reports research funding from AstraZeneca and Sysmex, and honoraria from - Taiho. DK reports receiving honoraria from Takeda, Chugai, Lilly, Merck - Biopharma, Taiho, and Sysmex. TT reports no competing interests. HH reports paid - consulting or advisory roles for Chugai, Merck Biopharma, Ono and MSD; honoraria - from Chugai, Taiho, Merck Biopharma, Yakult, Lilly, Takeda, Bristol-Myers Squibb, - Sanofi, Ono and MSD; and research funding from Astellas, AstraZeneca, Merck - Biopharma, Takeda, Boehringer Ingelheim, Lilly, Ono, Sumitomo Dainippon, Daiichi - Sankyo, Taiho, Chugai, MSD, Pfizer, Incyte, Beigene, LSK BioPharma and Eisai. SK - reports research funding from Taiho, Lilly, and Ono, and honoraria from Taiho, - Lilly, Ono, Bristol-Myers Squibb, Yakult, Chugai, Bayer, and Merck BioPharma. KK - and KC reports no competing interests. KY, SK, and HH reports no competing - interests. MN reports personal fees from MSD and AstraZeneca. HT, MW, and MF - report no competing interests. YT reports honoraria from Ono, Bristol-Myers - Squibb, Chugai, MSD, and AstraZeneca. NF and HN reports no competing interests. - TK reports paid consulting or advisory roles for Bristol-Myers Squibb, honoraria - from Oncolys BioPharma, and research funding from Ono, MSD, Oncolys BioPharma, - Sihonogi, Chugai and Astellas Amgen BioPharma. -EDAT- 2020/04/22 06:00 -MHDA- 2021/01/13 06:00 -PMCR- 2020/04/20 -CRDT- 2020/04/22 06:00 -PHST- 2020/01/10 00:00 [received] -PHST- 2020/03/05 00:00 [accepted] -PHST- 2020/04/22 06:00 [entrez] -PHST- 2020/04/22 06:00 [pubmed] -PHST- 2021/01/13 06:00 [medline] -PHST- 2020/04/20 00:00 [pmc-release] -AID - 10.1186/s12885-020-06716-5 [pii] -AID - 6716 [pii] -AID - 10.1186/s12885-020-06716-5 [doi] -PST - epublish -SO - BMC Cancer. 2020 Apr 20;20(1):336. doi: 10.1186/s12885-020-06716-5. - -PMID- 39252865 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240912 -IS - 2589-5370 (Electronic) -IS - 2589-5370 (Linking) -VI - 75 -DP - 2024 Sep -TI - Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line - therapy for extensive-stage small-cell lung cancer (ES-SCLC): a phase II trial. -PG - 102795 -LID - 10.1016/j.eclinm.2024.102795 [doi] -LID - 102795 -AB - BACKGROUND: This phase II prospective trial aimed to investigate the efficacy and - safety of adebrelimab (PD-L1 antibody) plus first-line chemotherapy followed by - sequential thoracic radiotherapy (TRT) combined with adebrelimab in - extensive-stage small-cell lung cancer (ES-SCLC). Biomarkers associated with - potential therapeutic effects were also explored. METHODS: Patients with - previously untreated ES-SCLC were enrolled at Shandong Cancer Hospital and - Institute (Jinan, China). Patients received 4-6 cycles of adebrelimab (20 mg/kg, - D1, Q3W) combined with EP/EC (etoposide, 100 mg/m(2), D1-3, Q3W and cisplatin, - 75 mg/m(2), D1, Q3W or carboplatin, AUC = 5, D1, Q3W). Then patients with - response sequentially underwent consolidative TRT (≥30 Gy in 10 fractions - or ≥50 Gy in 25 fractions, involved-field irradiation), and maintenance - adebrelimab until disease progression or intolerable adverse events (AEs). The - primary endpoint was overall survival (OS). Genomic and circulating tumour DNA - (ctDNA) profiling were also analyzed with tumour tissues and peripheral blood. - This trial was registered with ClinicalTrials.gov, NCT04562337. FINDINGS: From - October 2020 to April 2023, 67 patients diagnosed with ES-SCLC were enrolled and - received at least one dose of study treatment. All patients were included in the - efficacy and safety analyses. 45 patients received sequential TRT as planned. The - median OS and progression-free survival (PFS) was 21.4 months (95% CI: 17.2-not - reached months) and 10.1 months (95% CI: 6.9-15.5 months), respectively. The - confirmed objective response rate was 71.6% (48/67, 95% CI: 59.3-82.0%) and - disease control rate was 89.6% (60/67, 95% CI: 79.7-95.7%). There were no - treatment-related deaths. The most common grade 3 or higher treatment-related - adverse events (TRAEs) were hematological toxicities. The incidence of any grade - and G3+ pneumonitis was 25% (17/67) and 6% (4/67), respectively. No unexpected - adverse events were observed. Patients without co-mutations of TP53/RB1 in both - tissue and peripheral blood displayed longer PFS (tissue, P = 0.071; ctDNA, - P = 0.060) and OS (tissue, P = 0.032; ctDNA, P = 0.031). INTERPRETATION: - Adebrelimab plus chemotherapy and sequential TRT as first-line therapy for - ES-SCLC showed promising efficacy and acceptable safety. FUNDING: This study was - funded by the National Natural Science Foundation of China (82172865), Jiangsu - Hengrui Pharmaceuticals Co., Ltd. and Amoy Diagnostics Co., Ltd. -CI - © 2024 The Authors. -FAU - Chen, Dawei -AU - Chen D -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Zou, Bing -AU - Zou B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Li, Butuo -AU - Li B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Gao, Aiqin -AU - Gao A -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Huang, Wei -AU - Huang W -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Shao, Qian -AU - Shao Q -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Meng, Xiangjiao -AU - Meng X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Zhang, Pinliang -AU - Zhang P -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Tang, Xiaoyong -AU - Tang X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Hu, Xudong -AU - Hu X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Zhang, Yan -AU - Zhang Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Guo, Jun -AU - Guo J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Zhao, Changhong -AU - Zhao C -AD - Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China. -FAU - Yuan, Jiajia -AU - Yuan J -AD - Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China. -FAU - Li, Qian -AU - Li Q -AD - Amoy Diagnostics Co., Ltd., Xiamen, Fujian, China. -FAU - Zhu, Changbin -AU - Zhu C -AD - Amoy Diagnostics Co., Ltd., Xiamen, Fujian, China. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Wang, Linlin -AU - Wang L -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -LA - eng -SI - ClinicalTrials.gov/NCT04562337 -PT - Journal Article -DEP - 20240821 -PL - England -TA - EClinicalMedicine -JT - EClinicalMedicine -JID - 101733727 -PMC - PMC11381814 -OTO - NOTNLM -OT - Adebrelimab -OT - ES-SCLC -OT - Immunotherapy -OT - Predictive biomarker -OT - Radiotherapy -COIS- CHZ and JJY are employees of Jiangsu Hengrui Pharmaceuticals. CBZ and QL are - employees of Amoy Diagnostics. All other authors declare that they have no - competing interests. -EDAT- 2024/09/10 06:43 -MHDA- 2024/09/10 06:44 -PMCR- 2024/08/21 -CRDT- 2024/09/10 04:26 -PHST- 2024/04/18 00:00 [received] -PHST- 2024/08/05 00:00 [revised] -PHST- 2024/08/06 00:00 [accepted] -PHST- 2024/09/10 06:44 [medline] -PHST- 2024/09/10 06:43 [pubmed] -PHST- 2024/09/10 04:26 [entrez] -PHST- 2024/08/21 00:00 [pmc-release] -AID - S2589-5370(24)00374-2 [pii] -AID - 102795 [pii] -AID - 10.1016/j.eclinm.2024.102795 [doi] -PST - epublish -SO - EClinicalMedicine. 2024 Aug 21;75:102795. doi: 10.1016/j.eclinm.2024.102795. - eCollection 2024 Sep. - -PMID- 29769148 -OWN - NLM -STAT- MEDLINE -DCOM- 20191025 -LR - 20230223 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 6 -IP - 1 -DP - 2018 May 16 -TI - Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade - immunotherapy in cancer; lessons learned from clinical trials with melanoma and - non-small cell lung cancer (NSCLC). -PG - 39 -LID - 10.1186/s40425-018-0349-3 [doi] -LID - 39 -AB - Immunotherapy is among the most rapidly evolving treatment strategies in - oncology. The therapeutic potential of immune-checkpoint inhibitors is - exemplified by the recent hail of Food and Drug Administration (FDA) approvals - for their use in various malignancies. Continued efforts to enhance outcomes with - immunotherapy agents have led to the formulation of advanced treatment - strategies. Recent evidence from pre-clinical studies evaluating - immune-checkpoint inhibitors in various cancer cell-lines has suggested that - combinatorial approaches may have superior survival outcomes compared to - single-agent immunotherapy regimens. Preliminary trials assessing combination - therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 immune-checkpoint inhibitors have - documented considerable advantages in survival indices over single-agent - immunotherapy. The therapeutic potential of combinatorial approaches is - highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients - with advanced melanoma. Presently, dual-immune checkpoint inhibition with - anti-programmed death receptor-1/programmed cell death receptor- ligand-1 - (anti-PD-1/PD-L1) plus anti-cytotoxic T lymphocyte associated antigen-4 - (anti-CTLA-4) monoclonal antibodies (MoAbs) is being evaluated for a wide range - of tumor histologies. Furthermore, several ongoing clinical trials are - investigating combination checkpoint inhibition in association with traditional - treatment modalities such as chemotherapy, surgery, and radiation. In this - review, we summarize the current landscape of combination therapy with - anti-PD-1/PD-L1 plus anti-CTLA-4 MoAbs for patients with melanoma and non-small - cell lung cancer (NSCLC). We present a synopsis of the prospects for expanding - the indications of dual immune-checkpoint inhibition therapy to a more diverse - set of tumor histologies. -FAU - Chae, Young Kwang -AU - Chae YK -AD - Developmental Therapeutics Program of the Division of Hematology Oncology, Early - Phase Clinical Trials Unit, 645 N. Michigan Avenue, Suite 1006, Chicago, IL, - 60611, USA. young.chae@northwestern.edu. -AD - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 645 N. - Michigan Avenue, Suite 1006, Chicago, IL, 60611, USA. - young.chae@northwestern.edu. -AD - Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, - Suite 1006, Chicago, IL, 60611, USA. young.chae@northwestern.edu. -FAU - Arya, Ayush -AU - Arya A -AD - Developmental Therapeutics Program of the Division of Hematology Oncology, Early - Phase Clinical Trials Unit, 645 N. Michigan Avenue, Suite 1006, Chicago, IL, - 60611, USA. -FAU - Iams, Wade -AU - Iams W -AD - Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, - Suite 1006, Chicago, IL, 60611, USA. -FAU - Cruz, Marcelo R -AU - Cruz MR -AD - Developmental Therapeutics Program of the Division of Hematology Oncology, Early - Phase Clinical Trials Unit, 645 N. Michigan Avenue, Suite 1006, Chicago, IL, - 60611, USA. -FAU - Chandra, Sunandana -AU - Chandra S -AD - Developmental Therapeutics Program of the Division of Hematology Oncology, Early - Phase Clinical Trials Unit, 645 N. Michigan Avenue, Suite 1006, Chicago, IL, - 60611, USA. -AD - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 645 N. - Michigan Avenue, Suite 1006, Chicago, IL, 60611, USA. -AD - Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, - Suite 1006, Chicago, IL, 60611, USA. -FAU - Choi, Jaehyuk -AU - Choi J -AD - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 645 N. - Michigan Avenue, Suite 1006, Chicago, IL, 60611, USA. -AD - Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, - Suite 1006, Chicago, IL, 60611, USA. -FAU - Giles, Francis -AU - Giles F -AD - Developmental Therapeutics Program of the Division of Hematology Oncology, Early - Phase Clinical Trials Unit, 645 N. Michigan Avenue, Suite 1006, Chicago, IL, - 60611, USA. -AD - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 645 N. - Michigan Avenue, Suite 1006, Chicago, IL, 60611, USA. -AD - Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, - Suite 1006, Chicago, IL, 60611, USA. -LA - eng -GR - K12 CA090625/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Review -DEP - 20180516 -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (CTLA-4 Antigen) -RN - 0 (CTLA4 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - CTLA-4 Antigen/*antagonists & inhibitors/immunology -MH - Carcinoma, Non-Small-Cell Lung/*drug therapy -MH - Humans -MH - Immunotherapy/*methods -MH - Melanoma/*drug therapy -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors/*therapeutic use -PMC - PMC5956851 -COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. COMPETING INTERESTS: - The authors declare that they have no competing interests. PUBLISHER’S NOTE: - Springer Nature remains neutral with regard to jurisdictional claims in published - maps and institutional affiliations. -EDAT- 2018/05/18 06:00 -MHDA- 2019/10/28 06:00 -PMCR- 2018/05/16 -CRDT- 2018/05/18 06:00 -PHST- 2017/10/01 00:00 [received] -PHST- 2018/05/02 00:00 [accepted] -PHST- 2018/05/18 06:00 [entrez] -PHST- 2018/05/18 06:00 [pubmed] -PHST- 2019/10/28 06:00 [medline] -PHST- 2018/05/16 00:00 [pmc-release] -AID - 10.1186/s40425-018-0349-3 [pii] -AID - 349 [pii] -AID - 10.1186/s40425-018-0349-3 [doi] -PST - epublish -SO - J Immunother Cancer. 2018 May 16;6(1):39. doi: 10.1186/s40425-018-0349-3. - -PMID- 36540201 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20221222 -IS - 1179-1322 (Print) -IS - 1179-1322 (Electronic) -IS - 1179-1322 (Linking) -VI - 14 -DP - 2022 -TI - Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small - Cell Lung Cancer with Brain Metastases. -PG - 3449-3453 -LID - 10.2147/CMAR.S391220 [doi] -AB - BACKGROUND: The standard of care for extensive-stage small cell lung cancer - (ES-SCLC) is an immune checkpoint inhibitor (ICI) combined with - platinum-etoposide (PE) chemotherapy. At initial diagnosis, about 25% of ES-SCLC - patients have brain metastases, which are associated with a poor prognosis. The - decision as to whether to treat brain metastases with local therapies such as - surgery or radiotherapy before initiation of systemic chemoimmunotherapy is based - on symptoms due to the brain lesions and the general condition of the patient. - Subset analysis of the CASPIAN study showed that combination therapy with PE plus - durvalumab (MEDI4736) is promising for ES-SCLC with brain metastases. However, - data required in daily clinical practice, such as intracranial response rate and - duration of intracranial response, are insufficient for such patients. PATIENTS - AND METHODS: We have designed a single-arm phase II trial of durvalumab plus PE - for patients aged ≥20 years with chemotherapy-naïve ES-SCLC and at least one - brain metastasis ≥5 mm in size that has not been previously treated. Patients - receive durvalumab intravenously combined with four cycles of PE. Enrollment of - 50 patients over 2 years at 25 oncology facilities in Japan is planned. The - primary endpoint is intracranial response rate. CONCLUSION: This is the first - prospective study to evaluate the effects of an ICI with PE specifically in - ES-SCLC patients with brain metastases. If it demonstrates intracranial efficacy, - this regimen will be a potential treatment option for such individuals, and - radiation therapy or surgery for brain metastases can be avoided or postponed. -CI - © 2022 Shiraishi et al. -FAU - Shiraishi, Yoshimasa -AU - Shiraishi Y -AD - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu - University, Fukuoka, Japan. -FAU - Shimose, Takayuki -AU - Shimose T -AD - Department of Statistics and Data Center, Clinical Research Support Center - Kyushu, Fukuoka, Japan. -FAU - Tsuchiya-Kawano, Yuko -AU - Tsuchiya-Kawano Y -AD - Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, - Kitakyushu, Japan. -FAU - Ishii, Hidenobu -AU - Ishii H -AD - Division of Respirology, Neurology, and Rheumatology, Department of Internal - Medicine, Kurume University School of Medicine, Fukuoka, Japan. -FAU - Daga, Haruko -AU - Daga H -AD - Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan. -FAU - Ito, Kentaro -AU - Ito K -AD - Respiratory Center, Matsusaka Municipal Hospital, Mie, Japan. -FAU - Saruwatari, Koichi -AU - Saruwatari K -AD - Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life - Sciences, Kumamoto University, Kumamoto, Japan. -FAU - Okamoto, Isamu -AU - Okamoto I -AD - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu - University, Fukuoka, Japan. -LA - eng -PT - Journal Article -DEP - 20221214 -PL - New Zealand -TA - Cancer Manag Res -JT - Cancer management and research -JID - 101512700 -PMC - PMC9760036 -OTO - NOTNLM -OT - PD-L1 -OT - immune checkpoint inhibitor -OT - intracranial metastasis -OT - intracranial response rate -OT - platinum-etoposide -COIS- Dr. Shiraishi has received research grants from Chugai Pharma as well as - honoraria from Chugai Pharma, Eli Lilly, Ono Pharmaceutical, AstraZeneca, and - Taiho Pharmaceutical, all outside the submitted work. Dr. Tsuchiya-Kawano has - received honoraria from AstraZeneca, Bristol-Myers Squibb, Taiho Pharmaceutical, - Chugai Pharma, Ono Pharmaceutical, and Kyowa Kirin, all outside the submitted - work. Dr. Ishii has received honoraria from AstraZeneca, Chugai Pharma, Ono - Pharmaceutical, Bristol-Myers Squibb, MSD Oncology, and AMCO, all outside the - submitted work. Dr. Daga has received honoraria from AstraZeneca, Chugai Pharma, - and Eli Lilly, all outside the submitted work. Dr. Ito has received honoraria - from TAKEDA, Boehringer-Ingelheim, Eli Lilly, Chugai Pharma, AstraZeneca, Pfizer, - Taiho Pharmaceutical, Ono Pharmaceutical, MSD, and Daiichi-Sankyo, all outside - the submitted work. Dr. Okamoto has received research grants and personal fees - from AstraZeneca, Taiho Pharmaceutical, Chugai Pharma, Boehringer-Ingelheim, Ono - Pharmaceutical, MSD Oncology, Eli Lilly, and Bristol-Myers Squibb; research - grants from Astellas Pharma, Novartis, and AbbVie; and personal fees from Pfizer, - all outside the submitted work. The remaining authors have declared no competing - interests in this work. -EDAT- 2022/12/22 06:00 -MHDA- 2022/12/22 06:01 -PMCR- 2022/12/14 -CRDT- 2022/12/21 02:06 -PHST- 2022/10/10 00:00 [received] -PHST- 2022/11/19 00:00 [accepted] -PHST- 2022/12/21 02:06 [entrez] -PHST- 2022/12/22 06:00 [pubmed] -PHST- 2022/12/22 06:01 [medline] -PHST- 2022/12/14 00:00 [pmc-release] -AID - 391220 [pii] -AID - 10.2147/CMAR.S391220 [doi] -PST - epublish -SO - Cancer Manag Res. 2022 Dec 14;14:3449-3453. doi: 10.2147/CMAR.S391220. - eCollection 2022. - -PMID- 38807763 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240530 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 14 -DP - 2024 -TI - Progression-free survival estimation of docetaxel-based second-line treatment for - advanced non-small cell lung cancer: a pooled analysis from 18 randomized control - trials. -PG - 1298786 -LID - 10.3389/fonc.2024.1298786 [doi] -LID - 1298786 -AB - BACKGROUND: Lung cancer is the foremost cause of cancer-related death globally, - with non-small cell lung cancer (NSCLC) accounting for 85-90% of cases. Targeted - therapy is the most essential therapeutic option for NSCLC, other common - treatments include radiation therapy, surgery, chemotherapy, and immunotherapy. - OBJECTIVE: Our study objective was to estimate whether progression-free survival - (PFS) is an outcome of NSCLC extracted from 18 randomized control trials (RCTs) - with docetaxel as experimental group and antineoplastic agent, kinase inhibitor, - and monoclonal antibodies as a control group. METHODS: We selected relevant - studies published between 2011 and 2022 using Google Scholar, PubMed, Scopus, - Science Direct, and Cochrane Library. Advanced NSCLC, chemotherapy, RCT, - docetaxel, and second-line treatment were the terms included in the search. A - total of 9738 patients were evaluated from the 18 identified studies. We used the - meta package of R Studio to perform the meta-analysis. Graphical funnel plots - were used to evaluate publication bias visually. RESULTS: Patients who underwent - docetaxel-based therapy had a considerably longer PFS than those who got - antineoplastic agents, kinase inhibitors, or monoclonal antibodies-based - treatment. Patients in the standard treatment arm had a slightly longer PFS than - those in the experimental therapy arm in the overall meta-analysis. CONCLUSION: - Docetaxel outperformed monoclonal antibodies, antineoplastic agents, and kinase - inhibitors in the second-line therapy of advanced NSCLC since PFS was extensively - utilized. -CI - Copyright © 2024 N, Jain, C, Shreevatsa, Rajendrasozhan, Dharmashekar, Suresh, - Patil, Singh, Vishwanath, Srinivasa, Kollur and Shivamallu. -FAU - N, Chaithra -AU - N C -AD - Division of Medical Statistics, Life Sciences and Natural Sciences Departments, - JSS Academy of Higher Education and Research, Mysuru, Karnataka, India. -FAU - Jain, Anisha -AU - Jain A -AD - Department of Microbiology, JSS Academy of Higher Education and Research, Mysuru, - Karnataka, India. -FAU - C, Sahana -AU - C S -AD - Division of Medical Statistics, Life Sciences and Natural Sciences Departments, - JSS Academy of Higher Education and Research, Mysuru, Karnataka, India. -FAU - Shreevatsa, Bhargav -AU - Shreevatsa B -AD - Department of Biotechnology and Bioinformatics, JSS Academy of Higher Education - and Research, Mysuru, Karnataka, India. -AD - Pathology, Microbiology and Immunology Department, School of Medicine, University - of South Carolina, Columbia, SC, United States. -FAU - Rajendrasozhan, Saravanan -AU - Rajendrasozhan S -AD - Department of Chemistry, Faculty of Science, University of Hail, Hail, Saudi - Arabia. -FAU - Dharmashekar, Chandan -AU - Dharmashekar C -AD - Department of Biotechnology and Bioinformatics, JSS Academy of Higher Education - and Research, Mysuru, Karnataka, India. -FAU - Suresh, Kuralayanapalya Puttahonnappa -AU - Suresh KP -AD - Department of Spatial Epidemiology, ICAR-National Institute of Veterinary - Epidemiology and Disease Informatics, Bengaluru, Karnataka, India. -FAU - Patil, Sharanagouda S -AU - Patil SS -AD - ICAR-National Institute of Veterinary Epidemiology and Disease Informatics, - Bengaluru, Karnataka, India. -FAU - Singh, Pranav -AU - Singh P -AD - Department of Medicine, Kasturba Medical College, Manipal Academy of Higher - Education, Udupi, Karnataka, India. -FAU - Vishwanath, Prashant -AU - Vishwanath P -AD - Center of Excellence in Molecular Biology and Regenerative Medicine, Department - of Biochemistry, JSS Medical College, JSS Academy of Higher Education and - Research, Mysore, India. -FAU - Srinivasa, Chandrashekar -AU - Srinivasa C -AD - Department of Studies in Biotechnology, Davangere University, Davangere, - Karnataka, India. -FAU - Kollur, Shiva Prasad -AU - Kollur SP -AD - School of Physical Sciences, Amrita Vishwa Vidyapeetham, Mysuru, Karnataka, - India. -FAU - Shivamallu, Chandan -AU - Shivamallu C -AD - Department of Biotechnology and Bioinformatics, JSS Academy of Higher Education - and Research, Mysuru, Karnataka, India. -LA - eng -PT - Systematic Review -DEP - 20240514 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC11130461 -OTO - NOTNLM -OT - lung neoplasms -OT - meta analysis -OT - non-small cell lung carcinoma -OT - progression-free survival -OT - randomized control trials -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2024/05/29 06:42 -MHDA- 2024/05/29 06:43 -PMCR- 2024/01/01 -CRDT- 2024/05/29 03:37 -PHST- 2023/09/22 00:00 [received] -PHST- 2024/04/02 00:00 [accepted] -PHST- 2024/05/29 06:43 [medline] -PHST- 2024/05/29 06:42 [pubmed] -PHST- 2024/05/29 03:37 [entrez] -PHST- 2024/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2024.1298786 [doi] -PST - epublish -SO - Front Oncol. 2024 May 14;14:1298786. doi: 10.3389/fonc.2024.1298786. eCollection - 2024. - -PMID- 26582228 -OWN - NLM -STAT- MEDLINE -DCOM- 20160912 -LR - 20181113 -IS - 1999-6187 (Electronic) -IS - 1009-3419 (Print) -IS - 1009-3419 (Linking) -VI - 18 -IP - 11 -DP - 2015 Nov -TI - [Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the - Treatment of Lung Cancer]. -PG - 706-13 -LID - 10.3779/j.issn.1009-3419.2015.11.09 [doi] -AB - Recently, the immune checkpoint inhibitors which target programmed death-1 - (PD-1)/PD-1 ligand (PD-L1) have made a breakthrough in the treatment of advanced - non-small cell lung cancer. Researches on immune checkpoint inhibitors have been - rapidly implemented in various types of lung cancer, such as small cell lung - cancer and locally advanced non-small cell lung cancer. These inhibitors have - been applied in combination with other treatment strategies, including - chemotherapy, targeting therapy and radiotherapy. However, there are still many - problems to be solved, such as searching for ideal biomarkers, exploring - different combination treatment models, and identifying the potential mechanisms - of primary or secondary drug resistance. Along with these problems to be - successfully solved, the immune checkpoint inhibitors will have broader - applications in lung cancer therapy. -FAU - Huang, Zhiyu -AU - Huang Z -AD - Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou - 310022, China. -FAU - Li, Hui -AU - Li H -AD - Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou - 310022, China. -FAU - Fan, Yun -AU - Fan Y -AD - Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou - 310022, China. -LA - chi -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - China -TA - Zhongguo Fei Ai Za Zhi -JT - Zhongguo fei ai za zhi = Chinese journal of lung cancer -JID - 101126433 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antibodies, Monoclonal/adverse effects/*therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - Humans -MH - Lung Neoplasms/*drug therapy -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -PMC - PMC6000315 -EDAT- 2015/11/20 06:00 -MHDA- 2016/09/13 06:00 -PMCR- 2015/11/20 -CRDT- 2015/11/20 06:00 -PHST- 2015/11/20 06:00 [entrez] -PHST- 2015/11/20 06:00 [pubmed] -PHST- 2016/09/13 06:00 [medline] -PHST- 2015/11/20 00:00 [pmc-release] -AID - zgfazz-18-11-706 [pii] -AID - 10.3779/j.issn.1009-3419.2015.11.09 [doi] -PST - ppublish -SO - Zhongguo Fei Ai Za Zhi. 2015 Nov;18(11):706-13. doi: - 10.3779/j.issn.1009-3419.2015.11.09. - -PMID- 39033607 -OWN - NLM -STAT- Publisher -LR - 20240721 -IS - 2590-0412 (Electronic) -IS - 2590-0412 (Linking) -VI - 86 -DP - 2024 Jul 1 -TI - Real-world comparison of chemo-immunotherapy and chemotherapy alone in the - treatment of extensive-stage small-cell lung cancer. -PG - 101125 -LID - S2590-0412(24)00041-2 [pii] -LID - 10.1016/j.resmer.2024.101125 [doi] -AB - INTRODUCTION: Small cell lung cancer (SCLC) is a high-grade neuroendocrine - carcinoma responsible for 200,000 deaths per year worldwide. - Platinum-etoposide-based chemotherapy has been the standard of treatment for the - past 40 years, with an overall survival of 10 months. Since 2019, the addition of - immunotherapy (atezolizumab or durvalumab) to chemotherapy has become the - standard of care for first-line treatment of extensive-stage SCLC following the - demonstration of an improvement in overall survival in phase 3 studies. We aimed - to evaluate the efficacy and safety of chemo-immunotherapy compared with - chemotherapy alone in a "real-world" setting. METHODS: Retrospective - observational study including patients undergoing first-line treatment for - extensive-stage SCLC between 2014 and 2022. We separated the study population - into two arms (chemo-immunotherapy/chemotherapy). For each arm, progression-free - survival (PFS), overall survival (OS) and serious side effects were collected. - Associations between treatments and survival outcomes were adjusted for potential - confounders. Consolidative palliative thoracic radiotherapy was introduced in the - models as a time-dependent variable. RESULTS: A total of 118 patients with a - median age of 63 years were included. 65.2 % of patients were performance status - 0 or 1. In univariate analysis, PFS and OS were not significantly different - between the chemo-immunotherapy and chemotherapy alone groups (p = 0.70 and 0.24 - respectively). In multivariate analysis, the addition of immunotherapy to - chemotherapy was not significantly associated with better PFS (HR 0.76, IC (0.49 - - 1.19), p = 0.23), but it was significantly associated with better OS (HR 0.61, - IC (0.38 - 0.98), p = 0.04). Consolidative palliative thoracic radiotherapy - (time-dependent variable), when applied (almost only in the chemotherapy alone - group), was significantly associated with better PFS and OS. DISCUSSION: In this - real-world study, chemo-immunotherapy was associated with slightly better OS - compared to chemotherapy alone as a first-line treatment in ES-SCLC patients in - multivariate analysis, which is not explained by a benefit in PFS. However, - consolidative palliative thoracic radiotherapy seems to be significantly - associated with better OS and PFS, suggesting that we should also consider using - it in patients receiving chemo-immunotherapy. -CI - Copyright © 2024 The Author(s). Published by Elsevier Masson SAS.. All rights - reserved. -FAU - Déborah, Lamy -AU - Déborah L -AD - Service d'Oncologie Thoracique et Service de Pneumologie et Soins Intensifs - Respiratoire, Hôpital Dijon-Bourgogne, Dijon, France. -FAU - Pierre, Mouillot -AU - Pierre M -AD - Service d'Oncologie Thoracique et Service de Pneumologie et Soins Intensifs - Respiratoire, Hôpital Dijon-Bourgogne, Dijon, France; University of Burgundy, - Faculty of Medicine and Pharmacy, Dijon, France; INSERM U1231 CTM, Labex LIPSTIC - and label of excellence from la Ligue National contre le cancer, France. -FAU - Anne-Sophie, Mariet -AU - Anne-Sophie M -AD - University of Burgundy, Faculty of Medicine and Pharmacy, Dijon, France; CHU - Dijon Bourgogne, Service de Biostatistiques et d'information médicale, Dijon, - France; INSERM, Université de Bourgogne, CHU Dijon Bourgogne, CIC 1432, Module - Épidémiologie Clinique, Dijon, France; CHU Dijon-Bourgogne, ResAM, Dijon, France. -FAU - Robby, Barnestein -AU - Robby B -AD - Service d'Oncologie Thoracique et Service de Pneumologie et Soins Intensifs - Respiratoire, Hôpital Dijon-Bourgogne, Dijon, France. -FAU - Fleur-Marie, Quilot -AU - Fleur-Marie Q -AD - Service d'Oncologie Thoracique et Service de Pneumologie et Soins Intensifs - Respiratoire, Hôpital Dijon-Bourgogne, Dijon, France. -FAU - Cléa, Fraisse -AU - Cléa F -AD - CHU Dijon-Bourgogne, ResAM, Dijon, France. -FAU - François, Ghiringhelli -AU - François G -AD - University of Burgundy, Faculty of Medicine and Pharmacy, Dijon, France; CHU - Dijon-Bourgogne, ResAM, Dijon, France; INSERM U1231 CTM, Labex LIPSTIC and label - of excellence from la Ligue National contre le cancer, France. -FAU - Philippe, Bonniaud -AU - Philippe B -AD - Service d'Oncologie Thoracique et Service de Pneumologie et Soins Intensifs - Respiratoire, Hôpital Dijon-Bourgogne, Dijon, France; University of Burgundy, - Faculty of Medicine and Pharmacy, Dijon, France; INSERM U1231 CTM, Labex LIPSTIC - and label of excellence from la Ligue National contre le cancer, France. - Electronic address: philippe.bonniaud@chu-dijon.fr. -FAU - Ayoube, Zouak -AU - Ayoube Z -AD - Service d'Oncologie Thoracique et Service de Pneumologie et Soins Intensifs - Respiratoire, Hôpital Dijon-Bourgogne, Dijon, France. -FAU - Pascal, Foucher -AU - Pascal F -AD - Service d'Oncologie Thoracique et Service de Pneumologie et Soins Intensifs - Respiratoire, Hôpital Dijon-Bourgogne, Dijon, France. -LA - eng -PT - Journal Article -DEP - 20240701 -PL - France -TA - Respir Med Res -JT - Respiratory medicine and research -JID - 101746324 -SB - IM -OTO - NOTNLM -OT - Atezolizumab -OT - Durvalumab -OT - Immunotherapy -OT - Small cell lung cancer -COIS- Declaration of competing interest The authors declare that they have no known - competing financial interests or personal relationships that could have appeared - to influence the work reported in this paper. -EDAT- 2024/07/22 00:42 -MHDA- 2024/07/22 00:42 -CRDT- 2024/07/21 18:03 -PHST- 2024/02/07 00:00 [received] -PHST- 2024/06/19 00:00 [revised] -PHST- 2024/06/20 00:00 [accepted] -PHST- 2024/07/22 00:42 [medline] -PHST- 2024/07/22 00:42 [pubmed] -PHST- 2024/07/21 18:03 [entrez] -AID - S2590-0412(24)00041-2 [pii] -AID - 10.1016/j.resmer.2024.101125 [doi] -PST - aheadofprint -SO - Respir Med Res. 2024 Jul 1;86:101125. doi: 10.1016/j.resmer.2024.101125. - -PMID- 33096269 -OWN - NLM -STAT- MEDLINE -DCOM- 20210401 -LR - 20220102 -IS - 1556-1380 (Electronic) -IS - 1556-0864 (Print) -IS - 1556-0864 (Linking) -VI - 16 -IP - 1 -DP - 2021 Jan -TI - Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T - Cell, and B Cell Infiltration in Resectable NSCLC. -PG - 127-139 -LID - S1556-0864(20)30813-3 [pii] -LID - 10.1016/j.jtho.2020.09.027 [doi] -AB - INTRODUCTION: The combination of programmed cell death protein-1 or programmed - death-ligand 1 immune checkpoint blockade and chemotherapy has revolutionized the - treatment of advanced NSCLC, but the mechanisms underlying this synergy remain - incompletely understood. In this study, we explored the relationships between - neoadjuvant chemotherapy and the immune microenvironment (IME) of resectable - NSCLC to identify novel mechanisms by which chemotherapy may enhance the effect - of immune checkpoint blockade. METHODS: Genomic, transcriptomic, and immune - profiling data of 511 patients treated with neoadjuvant chemotherapy followed by - surgery (NCT) versus upfront surgery (US) were compared with determined - differential characteristics of the IMEs derived from whole-exome sequencing - (NCT = 18; US = 73), RNA microarray (NCT = 45; US = 202), flow cytometry (NCT = - 17; US = 39), multiplex immunofluorescence (NCT = 10; US = 72), T-cell receptor - sequencing (NCT = 16 and US = 63), and circulating cytokines (NCT = 18; US = 73). - RESULTS: NCT was associated with increased infiltration of cytotoxic CD8(+) T - cells and CD20(+) B cells. Moreover, NCT was associated with increases in - CD8(+)CD103(+) and CD4(+)CD103(+)PD-1(+)TIM3(-) tissue resident memory T cells. - Gene expression profiling supported memory function of CD8(+) and CD4(+) T cells. - However, NCT did not affect T-cell receptor clonality, richness, or tumor - mutational burden. Finally, NCT was associated with decreased plasma BDNF (TrkB) - at baseline and week 4 after surgery. CONCLUSIONS: Our study supports that, in - the context of resectable NSCLC, neoadjuvant chemotherapy promotes antitumor - immunity through T and B cell recruitment in the IME and through a phenotypic - change toward cytotoxic and memory CD8(+) and CD4(+) memory helper T cells. -CI - Copyright © 2020 International Association for the Study of Lung Cancer. - Published by Elsevier Inc. All rights reserved. -FAU - Gaudreau, Pierre-Olivier -AU - Gaudreau PO -AD - Department of Oncology, Queens' University and the Canadian Cancer Trials Group, - Kingston, Ontario, Canada. -FAU - Negrao, Marcelo V -AU - Negrao MV -AD - Department of Thoracic and Head & Neck Medical Oncology, The University of Texas - MD Anderson Cancer Center, Houston, Texas. -FAU - Mitchell, Kyle G -AU - Mitchell KG -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, Texas. -FAU - Reuben, Alexandre -AU - Reuben A -AD - Department of Thoracic and Head & Neck Medical Oncology, The University of Texas - MD Anderson Cancer Center, Houston, Texas. -FAU - Corsini, Erin M -AU - Corsini EM -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, Texas. -FAU - Li, Jun -AU - Li J -AD - Department of Genomic Medicine, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Karpinets, Tatiana V -AU - Karpinets TV -AD - Department of Genomic Medicine, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Wang, Qi -AU - Wang Q -AD - Department of Bioinformatics and Computational Biology, The University of Texas - MD Anderson Cancer Center, Houston, Texas. -FAU - Diao, Lixia -AU - Diao L -AD - Department of Bioinformatics and Computational Biology, The University of Texas - MD Anderson Cancer Center, Houston, Texas. -FAU - Wang, Jing -AU - Wang J -AD - Department of Bioinformatics and Computational Biology, The University of Texas - MD Anderson Cancer Center, Houston, Texas. -FAU - Federico, Lorenzo -AU - Federico L -AD - Department of Melanoma Medical Oncology, The University of Texas MD Anderson - Cancer Center, Houston, Texas. -FAU - Parra-Cuentas, Edwin R -AU - Parra-Cuentas ER -AD - Department of Translational Molecular Pathology, The University of Texas MD - Anderson Cancer Center, Houston, Texas. -FAU - Khairullah, Roohussaba -AU - Khairullah R -AD - Department of Thoracic and Head & Neck Medical Oncology, The University of Texas - MD Anderson Cancer Center, Houston, Texas. -FAU - Behrens, Carmen -AU - Behrens C -AD - Department of Thoracic and Head & Neck Medical Oncology, The University of Texas - MD Anderson Cancer Center, Houston, Texas. -FAU - Correa, Arlene M -AU - Correa AM -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, Texas. -FAU - Gomez, Daniel -AU - Gomez D -AD - Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New - York, New York. -FAU - Little, Latasha -AU - Little L -AD - Department of Genomic Medicine, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Gumbs, Curtis -AU - Gumbs C -AD - Department of Genomic Medicine, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Kadara, Humam N -AU - Kadara HN -AD - Department of Translational Molecular Pathology, The University of Texas MD - Anderson Cancer Center, Houston, Texas. -FAU - Fujimoto, Junya -AU - Fujimoto J -AD - Department of Translational Molecular Pathology, The University of Texas MD - Anderson Cancer Center, Houston, Texas. -FAU - McGrail, Daniel J -AU - McGrail DJ -AD - Department of Systems Biology, The University of Texas MD Anderson Cancer Center, - Houston, Texas, USA. -FAU - Vaporciyan, Ara A -AU - Vaporciyan AA -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, Texas. -FAU - Swisher, Stephen G -AU - Swisher SG -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, Texas. -FAU - Walsh, Garrett -AU - Walsh G -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, Texas. -FAU - Antonoff, Mara B -AU - Antonoff MB -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, Texas. -FAU - Weissferdt, Annikka -AU - Weissferdt A -AD - Department of Pathology, The University of Texas MD Anderson Cancer Center, - Houston, Texas. -FAU - Tran, Hai -AU - Tran H -AD - Department of Thoracic and Head & Neck Medical Oncology, The University of Texas - MD Anderson Cancer Center, Houston, Texas. -FAU - Roarty, Emily -AU - Roarty E -AD - Department of Thoracic and Head & Neck Medical Oncology, The University of Texas - MD Anderson Cancer Center, Houston, Texas. -FAU - Haymaker, Cara -AU - Haymaker C -AD - Department of Translational Molecular Pathology, The University of Texas MD - Anderson Cancer Center, Houston, Texas. -FAU - Bernatchez, Chantale -AU - Bernatchez C -AD - Biologics Development Department, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Zhang, Jianhua -AU - Zhang J -AD - Department of Genomic Medicine, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Futreal, P Andrew -AU - Futreal PA -AD - Department of Genomic Medicine, The University of Texas MD Anderson Cancer - Center, Houston, Texas. -FAU - Wistuba, Ignacio I -AU - Wistuba II -AD - Department of Translational Molecular Pathology, The University of Texas MD - Anderson Cancer Center, Houston, Texas. -FAU - Cascone, Tina -AU - Cascone T -AD - Department of Thoracic and Head & Neck Medical Oncology, The University of Texas - MD Anderson Cancer Center, Houston, Texas. -FAU - Heymach, John V -AU - Heymach JV -AD - Department of Thoracic and Head & Neck Medical Oncology, The University of Texas - MD Anderson Cancer Center, Houston, Texas. -FAU - Sepesi, Boris -AU - Sepesi B -AD - Department of Thoracic and Cardiovascular Surgery, The University of Texas MD - Anderson Cancer Center, Houston, Texas. -FAU - Zhang, Jianjun -AU - Zhang J -AD - Department of Thoracic and Head & Neck Medical Oncology, The University of Texas - MD Anderson Cancer Center, Houston, Texas; Department of Genomic Medicine, The - University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic - address: jzhang20@mdanderson.org. -FAU - Gibbons, Don L -AU - Gibbons DL -AD - Department of Oncology, Queens' University and the Canadian Cancer Trials Group, - Kingston, Ontario, Canada; Department of Molecular and Cellular Oncology, The - University of Texas MD Anderson Cancer Center, Houston, Texas. -LA - eng -GR - P30 CA008748/CA/NCI NIH HHS/United States -GR - P30 CA016672/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20201021 -PL - United States -TA - J Thorac Oncol -JT - Journal of thoracic oncology : official publication of the International - Association for the Study of Lung Cancer -JID - 101274235 -SB - IM -MH - B-Lymphocytes -MH - CD8-Positive T-Lymphocytes -MH - Humans -MH - Immunologic Memory -MH - *Lung Neoplasms/drug therapy -MH - *Neoadjuvant Therapy -MH - Tumor Microenvironment -PMC - PMC7775914 -MID - NIHMS1639397 -OTO - NOTNLM -OT - B cell -OT - Cytotoxic T cell -OT - Neoadjuvant chemotherapy -OT - Non–small cell lung cancer -OT - Tissue resident memory T cell -EDAT- 2020/10/24 06:00 -MHDA- 2021/04/02 06:00 -PMCR- 2022/01/01 -CRDT- 2020/10/23 20:11 -PHST- 2020/03/26 00:00 [received] -PHST- 2020/07/31 00:00 [revised] -PHST- 2020/09/18 00:00 [accepted] -PHST- 2020/10/24 06:00 [pubmed] -PHST- 2021/04/02 06:00 [medline] -PHST- 2020/10/23 20:11 [entrez] -PHST- 2022/01/01 00:00 [pmc-release] -AID - S1556-0864(20)30813-3 [pii] -AID - 10.1016/j.jtho.2020.09.027 [doi] -PST - ppublish -SO - J Thorac Oncol. 2021 Jan;16(1):127-139. doi: 10.1016/j.jtho.2020.09.027. Epub - 2020 Oct 21. - -PMID- 32783627 -OWN - NLM -STAT- MEDLINE -DCOM- 20201029 -LR - 20220417 -IS - 1748-880X (Electronic) -IS - 0007-1285 (Print) -IS - 0007-1285 (Linking) -VI - 93 -IP - 1115 -DP - 2020 Nov 1 -TI - Clinical and radiological features of immune checkpoint inhibitor-related - pneumonitis in lung cancer and non-lung cancers. -PG - 20200409 -LID - 10.1259/bjr.20200409 [doi] -LID - 20200409 -AB - OBJECTIVE: To investigate the clinical and radiological features of immune - checkpoint inhibitor-related pneumonitis (ICI-P), a rare but serious pulmonary - complication of cancer immunotherapy and to evaluate key differences between lung - cancer (LC) and non-LC patients. METHODS: 247 patients (LC, n = 151) treated with - ICI for malignancies were retrospectively screened in a single institute. The - number of patients, history of other immune-related adverse events (irAE), the - onset, serum KL-6 levels, and chest CT features (types of pneumonitis, symmetry, - laterality, location) were recorded for the ICI-P population and compared for LC - and non-LC groups. RESULTS: ICI-P was identified in 26 patients in total (LC, n = - 19; non-LC, n = 7). The incidence of other irAE was significantly higher in ICI-P - group (63%) compared with patients without ICI-P (34%) (p = 0.0056). An earlier - onset of ICI-P was recorded in LC (78 days) compared to non-LC patients (186 - days) (p = 0.0034). Serum KL-6 was significantly elevated only in the non-LC - group when ICI-P was noticed (p = 0.029). Major CT findings of ICI-P, - irrespective of primary disease, were organizing pneumonia pattern and ground - glass opacities. LC patients commonly exhibited consolidation and traction - bronchiectasis and were prone to asymmetrical shadows (p < 0.001). Non-LC - patients were more likely to exhibit symmetrical infiltrations. A small fraction - of both groups experienced relapse or moving patterns of ICI-P. CONCLUSION: ICI-P - patients more often experienced other irAE prior to the development of ICI-P. The - characteristics of ICI-P can differ in terms of the onset, KL-6 reliability, and - chest CT findings between LC and non-LC patients. ADVANCES IN KNOWLEDGE: In ICI-P - patients, a history of other irAE can be more frequently observed. Differences in - disease onset and radiological patterns between LC and non-LC patients might be - helpful to make a diagnosis of ICI-P; however, longitudinal observation of chest - CT scans is advised to observe the pneumonitis activity irrespective of cancer - types. -FAU - Nobashi, Tomomi W -AU - Nobashi TW -AUID- ORCID: 0000-0001-9781-7321 -AD - Department of Radiology, Tenri Hospital, Nara, Japan. -FAU - Nishimoto, Yuko -AU - Nishimoto Y -AD - Department of Radiology, Tenri Hospital, Nara, Japan. -FAU - Kawata, Yujiro -AU - Kawata Y -AD - Department of Radiology, Tenri Hospital, Nara, Japan. -FAU - Yutani, Hidetaka -AU - Yutani H -AD - Department of Radiology, Tenri Hospital, Nara, Japan. -FAU - Nakamura, Masaki -AU - Nakamura M -AD - Department of Radiology, Tenri Hospital, Nara, Japan. -FAU - Tsuji, Yuichi -AU - Tsuji Y -AD - Department of Radiology, Tenri Hospital, Nara, Japan. -FAU - Yoshida, Atsushi -AU - Yoshida A -AD - Department of Radiology, Tenri Hospital, Nara, Japan. -FAU - Sugimoto, Akihiko -AU - Sugimoto A -AD - Department of Radiology, Tenri Hospital, Nara, Japan. -FAU - Yamamoto, Takayuki -AU - Yamamoto T -AD - Department of Radiology, Tenri Hospital, Nara, Japan. -FAU - Alam, Israt S -AU - Alam IS -AD - Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford - University School of Medicine, Stanford, CA, USA. -FAU - Noma, Satoshi -AU - Noma S -AD - Department of Radiology, Tenri Hospital, Nara, Japan. -LA - eng -PT - Journal Article -DEP - 20200812 -PL - England -TA - Br J Radiol -JT - The British journal of radiology -JID - 0373125 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (CTLA-4 Antigen) -RN - 0 (CTLA4 protein, human) -RN - 0 (K6-antigen) -RN - 0 (Polysaccharides, Bacterial) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 31YO63LBSN (Nivolumab) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Aged -MH - Aged, 80 and over -MH - Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use -MH - Antineoplastic Agents, Immunological/*adverse effects/therapeutic use -MH - Bronchiectasis/diagnostic imaging -MH - CTLA-4 Antigen/antagonists & inhibitors -MH - Cryptogenic Organizing Pneumonia/chemically induced/diagnostic imaging -MH - Female -MH - Humans -MH - Lung Neoplasms/therapy -MH - Male -MH - Middle Aged -MH - Neoplasms/*therapy -MH - Nivolumab/adverse effects/therapeutic use -MH - Pneumonia/*chemically induced/*diagnostic imaging -MH - Polysaccharides, Bacterial/blood -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - Radiation Pneumonitis/diagnostic imaging -MH - Retrospective Studies -MH - Tomography, X-Ray Computed -PMC - PMC8519648 -EDAT- 2020/08/14 06:00 -MHDA- 2020/10/30 06:00 -PMCR- 2021/11/01 -CRDT- 2020/08/14 06:00 -PHST- 2020/08/14 06:00 [pubmed] -PHST- 2020/10/30 06:00 [medline] -PHST- 2020/08/14 06:00 [entrez] -PHST- 2021/11/01 00:00 [pmc-release] -AID - 10.1259/bjr.20200409 [doi] -PST - ppublish -SO - Br J Radiol. 2020 Nov 1;93(1115):20200409. doi: 10.1259/bjr.20200409. Epub 2020 - Aug 12. - -PMID- 34488792 -OWN - NLM -STAT- MEDLINE -DCOM- 20220124 -LR - 20220124 -IS - 1477-3155 (Electronic) -IS - 1477-3155 (Linking) -VI - 19 -IP - 1 -DP - 2021 Sep 6 -TI - Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively - turns tumor-associated macrophages against tumor cells. -PG - 268 -LID - 10.1186/s12951-021-01017-w [doi] -LID - 268 -AB - BACKGROUND: Tumor-associated macrophages (TAMs) are the most abundant stromal - cells in the tumor microenvironment. Turning the TAMs against their host tumor - cells is an intriguing therapeutic strategy particularly attractive for patients - with immunologically "cold" tumors. This concept was mechanistically demonstrated - on in vitro human and murine lung cancer cells and their corresponding TAM models - through combinatorial use of nanodiamond-doxorubicin conjugates (Nano-DOX) and a - PD-L1 blocking agent BMS-1. Nano-DOX are an agent previously proved to be able to - stimulate tumor cells' immunogenicity and thereby reactivate the TAMs into the - anti-tumor M1 phenotype. RESULTS: Nano-DOX were first shown to stimulate the - tumor cells and the TAMs to release the cytokine HMGB1 which, regardless of its - source, acted through the RAGE/NF-κB pathway to induce PD-L1 in the tumor cells - and PD-L1/PD-1 in the TAMs. Interestingly, Nano-DOX also induced NF-κB-dependent - RAGE expression in the tumor cells and thus reinforced HMGB1's action thereon. - Then, BMS-1 was shown to enhance Nano-DOX-stimulated M1-type activation of TAMs - both by blocking Nano-DOX-induced PD-L1 in the TAMs and by blocking tumor cell - PD-L1 ligation with TAM PD-1. The TAMs with enhanced M1-type repolarization both - killed the tumor cells and suppressed their growth. BMS-1 could also potentiate - Nano-DOX's action to suppress tumor cell growth via blocking of Nano-DOX-induced - PD-L1 therein. Finally, Nano-DOX and BMS-1 achieved synergistic therapeutic - efficacy against in vivo tumor grafts in a TAM-dependent manner. CONCLUSIONS: - PD-L1/PD-1 upregulation mediated by autocrine and paracrine activation of the - HMGB1/RAGE/NF-κB signaling is a key response of lung cancer cells and their TAMs - to stress, which can be induced by Nano-DOX. Blockade of Nano-DOX-induced PD-L1, - both in the cancer cells and the TAMs, achieves enhanced activation of - TAM-mediated anti-tumor response. -CI - © 2021. The Author(s). -FAU - Xu, Hua-Zhen -AU - Xu HZ -AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, - Donghu Avenue No.185, Wuhan, 430072, China. -AD - Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, - 430071, China. -FAU - Li, Tong-Fei -AU - Li TF -AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, - Donghu Avenue No.185, Wuhan, 430072, China. -AD - Department of Pharmacology, School of Basic Medical Sciences, Hubei University of - Medicine, Hubei Key Laboratory of Embryonic Stem Cell Research, Taihe Hospital of - Shiyan, Hubei University of Medicine, Renmin road No. 30, Shiyan, 442000, Hubei, - China. -FAU - Wang, Chao -AU - Wang C -AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, - Donghu Avenue No.185, Wuhan, 430072, China. -FAU - Ma, Yan -AU - Ma Y -AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, - Donghu Avenue No.185, Wuhan, 430072, China. -FAU - Liu, Yan -AU - Liu Y -AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, - Donghu Avenue No.185, Wuhan, 430072, China. -FAU - Zheng, Mei-Yan -AU - Zheng MY -AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, - Donghu Avenue No.185, Wuhan, 430072, China. -FAU - Liu, Zhang-Jun-Yan -AU - Liu ZJ -AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, - Donghu Avenue No.185, Wuhan, 430072, China. -FAU - Chen, Jin-Bo -AU - Chen JB -AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, - Donghu Avenue No.185, Wuhan, 430072, China. -FAU - Li, Ke -AU - Li K -AD - Demonstration Center for Experimental Basic Medicine Education, School of Basic - Medical Sciences, Wuhan University, Donghu Avenue No.185, Wuhan, 430072, China. -FAU - Sun, Shi-Kuan -AU - Sun SK -AD - School of Material Science and Energy Engineering, Foshan University, Foshan, - 528000, Guangdong, China. -FAU - Komatsu, Naoki -AU - Komatsu N -AD - Graduate School of Human and Environmental Studies, Kyoto University, Sakyo-ku, - Kyoto, 606-8501, Japan. -FAU - Xu, Yong-Hong -AU - Xu YH -AD - Institute of Ophthalmological Research, Department of Ophthalmology, Renmin - Hospital of Wuhan University, Wuhan, 430060, China. -FAU - Zhao, Li -AU - Zhao L -AD - State Key Laboratory of Radiation Medicine and Protection, School of Radiation - Medicine and Protection & School for Radiological and Interdisciplinary Sciences - (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher - Education Institutions, Soochow University, Suzhou, 215123, Jiangsu, China. - lizhao@suda.edu.cn. -FAU - Chen, Xiao -AU - Chen X -AUID- ORCID: 0000-0001-5474-0205 -AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, - Donghu Avenue No.185, Wuhan, 430072, China. chen-xiao-1976@hotmail.com. -AD - Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, - 430071, China. chen-xiao-1976@hotmail.com. -LA - eng -GR - 81671818/national natural science foundation of china/ -GR - WJ2019Z010/hubei province health and family planning scientific research project, - china/ -GR - 2017060201010148/science and technology program of wuhan, china/ -GR - TFJC2018003/medical science advancement program (basic medical science) of wuhan - university, china/ -GR - 2020CFB152/hubei provincial natural science foundation/ -GR - 2020QDJZR002/cultivating project for young scholar at hubei university of - medicine/ -GR - 202010929005/national training program of innovation and entrepreneurship for - undergraduates/ -GR - S202013249001/national training program of innovation and entrepreneurship for - undergraduates/ -GR - YC2021016/Innovative Research Program for Graduates of Hubei University of - Medicine/ -PT - Journal Article -DEP - 20210906 -PL - England -TA - J Nanobiotechnology -JT - Journal of nanobiotechnology -JID - 101152208 -RN - 0 (B7-H1 Antigen) -RN - 0 (Cd274 protein, mouse) -RN - 0 (Cytokines) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (Nanodiamonds) -RN - 80168379AG (Doxorubicin) -SB - IM -MH - A549 Cells -MH - Animals -MH - B7-H1 Antigen/*drug effects/genetics -MH - Cell Line, Tumor -MH - Cytokines/metabolism -MH - Doxorubicin/*pharmacology -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/*pharmacology -MH - Lung Neoplasms/drug therapy -MH - Mice -MH - Mice, Inbred BALB C -MH - Mice, Nude -MH - Nanodiamonds/*chemistry -MH - Tumor Microenvironment/drug effects -MH - *Tumor-Associated Macrophages -PMC - PMC8422639 -OTO - NOTNLM -OT - HMGB1/RAGE/NF-κB signaling -OT - Nanodiamond–doxorubicin conjugates -OT - Non-small cell lung cancer -OT - PD-L1/PD-1 -OT - Tumor-associated macrophages -COIS- The authors declare that they have no competing interests. -EDAT- 2021/09/08 06:00 -MHDA- 2022/01/27 06:00 -PMCR- 2021/09/06 -CRDT- 2021/09/07 05:59 -PHST- 2021/07/13 00:00 [received] -PHST- 2021/08/28 00:00 [accepted] -PHST- 2021/09/07 05:59 [entrez] -PHST- 2021/09/08 06:00 [pubmed] -PHST- 2022/01/27 06:00 [medline] -PHST- 2021/09/06 00:00 [pmc-release] -AID - 10.1186/s12951-021-01017-w [pii] -AID - 1017 [pii] -AID - 10.1186/s12951-021-01017-w [doi] -PST - epublish -SO - J Nanobiotechnology. 2021 Sep 6;19(1):268. doi: 10.1186/s12951-021-01017-w. - -PMID- 27315066 -OWN - NLM -STAT- MEDLINE -DCOM- 20170807 -LR - 20210103 -IS - 1534-6277 (Electronic) -IS - 1534-6277 (Linking) -VI - 17 -IP - 8 -DP - 2016 Aug -TI - Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and - Potential Biomarkers. -PG - 40 -LID - 10.1007/s11864-016-0419-z [doi] -AB - The discovery and antibody targeting of immune regulatory molecules such as - programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen 4 - (CTLA-4) pathways have led to clinically meaningful anti-cancer results. Rapid - advances are being made in a variety of tumor types resulting in regulatory - approvals in melanoma, non small cell lung cancer, and renal cell cancer. - Numerous ongoing studies are expected to establish the worth of PD-1 pathway - inhibitors in other tumor types as well as in combinations with approved agents. - Head and neck squamous cell carcinoma (HNSCC) represents a complex group of - malignancies characterized by profound immunosuppression and is an excellent - candidate for investigation in this exciting field. However, given the fact that - a subset of patients will likely benefit, it is critical to focus on biomarker - development for appropriate patient selection and facilitation of trial design. - As immunotherapy is settling in cancer treatment, immune checkpoint inhibitors - are emerging as one of the most promising agents. -FAU - Economopoulou, Panagiota -AU - Economopoulou P -AD - Department of Internal Medicine, Section of Medical Oncology, Attikon University - Hospital, National Kapodistrian University of Athens, School of Medicine, 1St - Rimini St, 12462, Haidari, Athens, Greece. panagiota_oiko@hotmail.com. -FAU - Kotsantis, Ioannis -AU - Kotsantis I -AD - Department of Internal Medicine, Section of Medical Oncology, Attikon University - Hospital, National Kapodistrian University of Athens, School of Medicine, 1St - Rimini St, 12462, Haidari, Athens, Greece. -FAU - Psyrri, Amanda -AU - Psyrri A -AD - Department of Internal Medicine, Section of Medical Oncology, Attikon University - Hospital, National Kapodistrian University of Athens, School of Medicine, 1St - Rimini St, 12462, Haidari, Athens, Greece. dpsyrri@med.uoa.gr. -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - Curr Treat Options Oncol -JT - Current treatment options in oncology -JID - 100900946 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents) -RN - 0 (B7-H1 Antigen) -RN - 0 (Biomarkers, Tumor) -RN - 0 (CTLA-4 Antigen) -RN - 0 (CTLA4 protein, human) -RN - 0 (Immunologic Factors) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Antibodies, Monoclonal/therapeutic use -MH - Antineoplastic Agents/*therapeutic use -MH - B7-H1 Antigen/antagonists & inhibitors -MH - *Biomarkers, Tumor -MH - CTLA-4 Antigen/antagonists & inhibitors -MH - Clinical Trials as Topic -MH - Combined Modality Therapy -MH - Head and Neck Neoplasms/diagnosis/*drug therapy/immunology/*metabolism -MH - Humans -MH - Immunologic Factors/therapeutic use -MH - Immunomodulation/drug effects -MH - Immunotherapy -MH - *Molecular Targeted Therapy -MH - Programmed Cell Death 1 Receptor/antagonists & inhibitors -MH - Radiotherapy -MH - Treatment Outcome -OTO - NOTNLM -OT - Biomarkers -OT - CTLA-4 -OT - Head and neck cancer -OT - Monoclonal antibodies -OT - PD-1 -OT - PD-L1 -EDAT- 2016/06/18 06:00 -MHDA- 2017/08/08 06:00 -CRDT- 2016/06/18 06:00 -PHST- 2016/06/18 06:00 [entrez] -PHST- 2016/06/18 06:00 [pubmed] -PHST- 2017/08/08 06:00 [medline] -AID - 10.1007/s11864-016-0419-z [pii] -AID - 10.1007/s11864-016-0419-z [doi] -PST - ppublish -SO - Curr Treat Options Oncol. 2016 Aug;17(8):40. doi: 10.1007/s11864-016-0419-z. - -PMID- 36672383 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230328 -IS - 2072-6694 (Print) -IS - 2072-6694 (Electronic) -IS - 2072-6694 (Linking) -VI - 15 -IP - 2 -DP - 2023 Jan 10 -TI - Thoracic Radiotherapy in Extensive Disease Small Cell Lung Cancer: Multicenter - Prospective Observational TRENDS Study. -LID - 10.3390/cancers15020434 [doi] -LID - 434 -AB - (1) Introduction: Small cell lung cancer (SCLC) is an aggressive tumor type, - accounting for about 15% of all lung cancers. Radiotherapy (RT) plays a - fundamental role in both early and advanced stages. Currently, in advanced - disease, the use of consolidative chest RT should be recommended for patients - with good response to platinum-based first-line chemotherapy, but its use has not - yet been standardized. The present prospective study aims to evaluate the pattern - of care of consolidative chest RT in patients with advanced stage SCLC, and its - effectiveness in terms of disease control and tolerability. (2) Materials and - methods: This study was a multicenter prospective observational trial, proposed - and conducted within the AIRO lung study group to evaluate the pattern of care of - consolidative chest RT after first-line chemotherapy in patients with advanced - SCLC. The patient and tumor characteristics, doses, fractionation and volumes of - thoracic RT and prophylactic cranial irradiation (PCI), as well as the thoracic - and extrathoracic response to the treatment, toxicity and clinical outcomes, were - collected and analyzed. (3) Results: From January 2017 to December 2019, - sixty-four patients were enrolled. Median follow-up was 33 months. The median age - was 68 years (range 42-81); 38 patients (59%) were male and 26 (41%) female. - Carboplatin + etoposide for 6 cycles was the most commonly used first-line - therapeutic scheme (42%). With regard to consolidative chest RT, 56% of patients - (35) received 30 Gy in 10 factions and 16 patients (26%) received 45 Gy in 15 - sessions. The modulated intensity technique was used in 84.5% of cases, and - post-chemotherapy macroscopic residual disease was the target volume in 87.5% of - patients. Forty-four patients (69%) also underwent PCI. At the last follow-up, - over 60% of patients did not experience chest disease progression, while 67% - showed extrathoracic progression. At the first radiological evaluation after RT, - complete response and stable disease were recorded in 6% and 46% of the cases, - respectively. Two patients had a long-term complete response to the combined - treatment. The brain was the first site of extrathoracic progression in 28%. 1y - and 2y OS and PFS were 67%, 19%, 28% and 6%, respectively. Consolidative chest RT - was well-tolerated in the majority of patients; it was interrupted in three cases - (due to G2 pulmonary toxicity, disease progression and clinical decay, - respectively). Only 1 patient developed G3 asthenia. (4) Conclusions: - Consolidative chest RT has been shown to be useful in reducing the risk of - thoracic disease progression and is absolutely well-tolerated in patients with - advanced stage SCLC with good response after first-line chemotherapy. Among the - Italian centers that participated in this study, there is still variability in - the choice of fractionation and target volumes, although the guidelines contain - clear recommendations. The aim of future research should be to clarify the role - and modalities of chest RT in the era of immunotherapy in advanced-stage SCLC. -FAU - Cozzi, Salvatore -AU - Cozzi S -AUID- ORCID: 0000-0002-8890-3460 -AD - Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, - Italy. -AD - Radiation Oncology Department, Centre Lèon Bèrard, 693736 Lyon, France. -FAU - Bruni, Alessio -AU - Bruni A -AD - Radiation Therapy Unit, Department of Oncology and Hematology, University - Hospital of Modena, 41125 Modena, Italy. -FAU - Ruggieri, Maria Paola -AU - Ruggieri MP -AD - Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, - Italy. -FAU - Borghetti, Paolo -AU - Borghetti P -AUID- ORCID: 0000-0001-7275-7908 -AD - Radiation Oncology Department, ASST Spedali Civili and University of Brescia, - 25123 Brescia, Italy. -FAU - Scotti, Vieri -AU - Scotti V -AD - Radiation Oncology Unit, Oncology Department AOU Careggi Firenze, 50134 Florence, - Italy. -FAU - Franceschini, Davide -AU - Franceschini D -AUID- ORCID: 0000-0003-1142-2439 -AD - Radiation Therapy Unit, IRCCS Humanitas Cancer Center, 20089 Milan, Italy. -FAU - Fiore, Michele -AU - Fiore M -AUID- ORCID: 0000-0003-1889-4578 -AD - Radiation Oncology, Campus Bio-Medico University, Fondazione Policlinico - Universitario Campus Bio-Medico, 00128 Rome, Italy. -FAU - Taraborrelli, Maria -AU - Taraborrelli M -AD - Radiation Oncology Unit, "SS Annunziata" Hospital, "G. D'Annunzio" University, - 66100 Chieti, Italy. -FAU - Salvi, Fabrizio -AU - Salvi F -AD - Radiation Oncology Unit, Bellaria Hospital, 40139 Bologna, Italy. -FAU - Galaverni, Marco -AU - Galaverni M -AD - Radiotherapy Unit, Azienda Ospedaliera Universitaria, 43126 Parma, Italy. -FAU - Savoldi, Luisa -AU - Savoldi L -AD - Research and Statistics Infrastructure, Azienda Unità Sanitaria Locale-IRCCS di - Reggio Emilia, 42123 Reggio Emilia, Italy. -FAU - Braglia, Luca -AU - Braglia L -AD - Research and Statistics Infrastructure, Azienda Unità Sanitaria Locale-IRCCS di - Reggio Emilia, 42123 Reggio Emilia, Italy. -FAU - Botti, Andrea -AU - Botti A -AUID- ORCID: 0000-0003-0768-3249 -AD - Medical Physics Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, - Italy. -FAU - Finocchi Ghersi, Sebastiano -AU - Finocchi Ghersi S -AD - Radiation Oncolgy Unit, AOU Sant'Andrea, Facoltà di Medicina e Psicologia, - Università La Sapienza, 00185 Rome, Italy. -FAU - Niccolò, Giaj-Levra -AU - Niccolò GL -AD - Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, - Cancer Care Center, 37024 Verona, Italy. -FAU - Lohr, Frank -AU - Lohr F -AD - Radiation Oncology Department, Centre Lèon Bèrard, 693736 Lyon, France. -AD - Department of Medical and Surgical Science, University of Modena and Reggio - Emilia, 41125 Modena, Italy. -FAU - Iotti, Cinzia -AU - Iotti C -AD - Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, - Italy. -FAU - Ciammella, Patrizia -AU - Ciammella P -AD - Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, - Italy. -LA - eng -PT - Journal Article -DEP - 20230110 -PL - Switzerland -TA - Cancers (Basel) -JT - Cancers -JID - 101526829 -PMC - PMC9857193 -OTO - NOTNLM -OT - SCLC -OT - consolidative radiotherapy -OT - immunotherapy -OT - lung cancer -OT - radiotherapy -OT - small cell lung cancer -OT - target therapy -COIS- The authors declare no conflict of interest. -EDAT- 2023/01/22 06:00 -MHDA- 2023/01/22 06:01 -PMCR- 2023/01/10 -CRDT- 2023/01/21 01:12 -PHST- 2022/11/09 00:00 [received] -PHST- 2022/12/19 00:00 [revised] -PHST- 2023/01/06 00:00 [accepted] -PHST- 2023/01/21 01:12 [entrez] -PHST- 2023/01/22 06:00 [pubmed] -PHST- 2023/01/22 06:01 [medline] -PHST- 2023/01/10 00:00 [pmc-release] -AID - cancers15020434 [pii] -AID - cancers-15-00434 [pii] -AID - 10.3390/cancers15020434 [doi] -PST - epublish -SO - Cancers (Basel). 2023 Jan 10;15(2):434. doi: 10.3390/cancers15020434. - -PMID- 27895920 -OWN - NLM -STAT- MEDLINE -DCOM- 20180201 -LR - 20240603 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 4 -DP - 2016 -TI - PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous - cell carcinoma: a case report. -PG - 83 -LID - 83 -AB - BACKGROUND: Immunotherapy targeting the checkpoint PD1 (programmed cell death - protein 1) or PDL1 (programmed death ligand 1) has led to advances in the - treatment of melanoma and non-small cell lung cancer (NSCLC). The use of such - therapies has also been introduced into the treatment of other malignancies, - including head and neck cancer. The combined effects of checkpoint inhibitors and - anti-PD1(L1) antibodies and radiation therapy have not yet been sufficiently - investigated. CASE PRESENTATION: We report a case of locally relapsed - non-resectable oral cavity squamous cell carcinoma, with excellent local control - after pembrolizumab (MK3475) followed by radiotherapy. CONCLUSION: T cell - activation induced by checkpoint inhibition may dramatically improve tumor - response to radiation. More data are needed to identify the toxicity and efficacy - of sequential or concurrent checkpoint inhibitors and radiotherapy. -FAU - Nagasaka, Misako -AU - Nagasaka M -AD - Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State - University School of Medicine, Detroit, MI USA. -FAU - Zaki, Mark -AU - Zaki M -AD - Division of Radiation Oncology, Department of Oncology, Barbara Ann Karmanos - Cancer Center, Wayne State University School of Medicine, Detroit, MI USA. -FAU - Kim, Harold -AU - Kim H -AD - Division of Radiation Oncology, Department of Oncology, Barbara Ann Karmanos - Cancer Center, Wayne State University School of Medicine, Detroit, MI USA. -FAU - Raza, S Naweed -AU - Raza SN -AD - Department of Otolaryngology-Head and Neck Surgery, Barbara Ann Karmanos Cancer - Institute, Wayne State University School of Medicine, Detroit, MI USA. -FAU - Yoo, George -AU - Yoo G -AD - Department of Otolaryngology-Head and Neck Surgery, Barbara Ann Karmanos Cancer - Institute, Wayne State University School of Medicine, Detroit, MI USA. -FAU - Lin, Ho-Sheng -AU - Lin HS -AD - Department of Otolaryngology-Head and Neck Surgery, Barbara Ann Karmanos Cancer - Institute, Wayne State University School of Medicine, Detroit, MI USA. -FAU - Sukari, Ammar -AU - Sukari A -AD - Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State - University School of Medicine, Detroit, MI USA. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20161115 -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 0 (Radiation-Sensitizing Agents) -SB - IM -MH - Aged -MH - Antineoplastic Agents, Immunological/pharmacology/*therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - Carcinoma, Squamous Cell/diagnosis/*drug therapy/mortality/radiotherapy -MH - Combined Modality Therapy -MH - Disease Progression -MH - Female -MH - Head and Neck Neoplasms/diagnosis/*drug therapy/mortality/radiotherapy -MH - Humans -MH - Molecular Targeted Therapy -MH - Neoplasm Staging -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -MH - Radiation-Sensitizing Agents/pharmacology/*therapeutic use -MH - Recurrence -MH - Squamous Cell Carcinoma of Head and Neck -MH - Tomography, X-Ray Computed -MH - Treatment Outcome -PMC - PMC5109767 -OTO - NOTNLM -OT - Oral cancer -OT - PD1/PDL1 inhibitor -OT - Radiation therapy -EDAT- 2016/11/30 06:00 -MHDA- 2018/02/02 06:00 -PMCR- 2016/11/15 -CRDT- 2016/11/30 06:00 -PHST- 2016/08/24 00:00 [received] -PHST- 2016/11/01 00:00 [accepted] -PHST- 2016/11/30 06:00 [entrez] -PHST- 2016/11/30 06:00 [pubmed] -PHST- 2018/02/02 06:00 [medline] -PHST- 2016/11/15 00:00 [pmc-release] -AID - 187 [pii] -AID - 10.1186/s40425-016-0187-0 [doi] -PST - epublish -SO - J Immunother Cancer. 2016 Nov 15;4:83. doi: 10.1186/s40425-016-0187-0. - eCollection 2016. - -PMID- 34287275 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20210724 -IS - 2039-7275 (Print) -IS - 2039-7283 (Electronic) -IS - 2039-7275 (Linking) -VI - 11 -IP - 3 -DP - 2021 Jul 6 -TI - Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage - Small-Cell Lung Cancer. -PG - 441-454 -LID - 10.3390/clinpract11030059 [doi] -AB - Small-cell lung cancer (SCLC) is an aggressive subtype of lung cancer - characterized by a rapid initial response and early development of resistance to - systemic therapy and radiation. The management of SCLC significantly changed for - the first time in decades with the introduction of immune checkpoint inhibitors. - Pembrolizumab, a humanized IgG4 isotype antibody, targets the programmed cell - death protein 1 (PD-1) pathway to restore anti-tumor immunity. Prospective trials - of pembrolizumab in patients with previously treated SCLC showed significant - durability of responses. These results led to the U.S. Food and Drug - Administration (FDA) granting pembrolizumab accelerated approval as second- or - third-line monotherapy for patients with extensive-stage (ES) SCLC. In a recent - clinical trial that included patients with previously untreated ES-SCLC, - pembrolizumab in combination with platinum/etoposide met its progression-free - survival endpoint, but overall survival (OS) did not cross the threshold for - superiority. With the therapeutic landscape for SCLC rapidly evolving, we review - prior experience and future directions of pembrolizumab in ES-SCLC. -FAU - Riano, Ivy -AU - Riano I -AD - Department of Medicine, MetroWest Medical Center, Tufts University School of - Medicine, Framingham, MA 01702, USA. -FAU - Patel, Shruti R -AU - Patel SR -AD - Department of Medicine, Mayo Clinic, Rochester, MN 55902, USA. -FAU - Liu, Stephen V -AU - Liu SV -AD - Department of Medical Oncology, Lombardi Comprehensive Cancer Center, Georgetown - University, Washington, DC 20057, USA. -FAU - Duma, Narjust -AU - Duma N -AD - Division of Medical Oncology, Hematology and Palliative Care, University of - Wisconsin, Madison, WI 53706, USA. -LA - eng -PT - Journal Article -PT - Review -DEP - 20210706 -PL - Switzerland -TA - Clin Pract -JT - Clinics and practice -JID - 101563282 -PMC - PMC8293071 -OTO - NOTNLM -OT - PD-1 -OT - checkpoint inhibitor -OT - immunotherapy -OT - pembrolizumab -OT - small-cell lung cancer -COIS- N.D. reports consulting and/or advisory board fees from Inivata and AstraZeneca. - S.V.L. reports consulting and/or advisory board fees from AstraZeneca, Beigene, - Blueprint, Bristol-Myers Squibb, Celgene, G1 Therapeutics, Genentech/Roche, - Guardant Health, Inivata, Janssen, Lilly, Merck/MSD, PharmaMar, Pfizer, - Regeneron, and Takeda/Ariad and research funding (to institution) from Alkermes, - AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Corvus, Debiopharm, - Genentech, Lilly, Lycera, Merck, Pfizer, Rain Therapeutics, RAPT, Spectrum, and - Turning Point Therapeutics. The other authors have no conflict of interest to - declare. -EDAT- 2021/07/22 06:00 -MHDA- 2021/07/22 06:01 -PMCR- 2021/07/06 -CRDT- 2021/07/21 12:47 -PHST- 2021/05/08 00:00 [received] -PHST- 2021/06/12 00:00 [revised] -PHST- 2021/07/02 00:00 [accepted] -PHST- 2021/07/21 12:47 [entrez] -PHST- 2021/07/22 06:00 [pubmed] -PHST- 2021/07/22 06:01 [medline] -PHST- 2021/07/06 00:00 [pmc-release] -AID - clinpract11030059 [pii] -AID - clinpract-11-00059 [pii] -AID - 10.3390/clinpract11030059 [doi] -PST - epublish -SO - Clin Pract. 2021 Jul 6;11(3):441-454. doi: 10.3390/clinpract11030059. - -PMID- 33086574 -OWN - NLM -STAT- MEDLINE -DCOM- 20210223 -LR - 20210223 -IS - 1422-0067 (Electronic) -IS - 1422-0067 (Linking) -VI - 21 -IP - 20 -DP - 2020 Oct 19 -TI - Single-Dose Cisplatin Pre-Treatment Enhances Efficacy of ROBO1-Targeted - Radioimmunotherapy. -LID - 10.3390/ijms21207728 [doi] -LID - 7728 -AB - We previously reported that radioimmunotherapy (RIT) using (90)Y-labeled - anti-ROBO1 IgG ((90)Y-B5209B) achieved significant anti-tumor effects against - small-cell lung cancer (SCLC) xenografts. However, subsequent tumor regrowth - suggested the necessity for more effective therapy. Here, we evaluated the - efficacy of combination (90)Y-B5209B and cisplatin therapy in NCI-H69 SCLC - xenograft mice. Mice were divided into four therapeutic groups: saline, cisplatin - only, RIT only, or combination therapy. Either saline or cisplatin was - administered by injection one day prior to the administration of either saline or - (90)Y-B5209B. Tumor volume, body weight, and blood cell counts were monitored. - The pathological analysis was performed on day seven post injection of - (90)Y-B5209B. The survival duration of the combination therapy group was - significantly longer than that of the group treated with RIT alone. No - significant survival benefit was observed following the isolated administration - of cisplatin (relative to saline). Pathological changes following combination - therapy were more significant than those following the isolated administration of - RIT. Although combination therapy was associated with an increase of several - adverse effects such as weight loss and pancytopenia, these were transient. Thus, - cisplatin pre-treatment can potentially enhance the efficacy of (90)Y-B5209B, - making it a promising therapeutic strategy for SCLC. -FAU - Fujiwara, Kentaro -AU - Fujiwara K -AD - National Institute of Radiological Sciences, National Institutes for Quantum and - Radiological Science and Technology (QST-NIRS), Chiba 263-8555, Japan. -FAU - Koyama, Keitaro -AU - Koyama K -AD - Department of Radiology, Faculty of Medicine, International University of Health - and Welfare, Chiba 286-8686, Japan. -FAU - Tsuji, Atsushi B -AU - Tsuji AB -AD - National Institute of Radiological Sciences, National Institutes for Quantum and - Radiological Science and Technology (QST-NIRS), Chiba 263-8555, Japan. -FAU - Iwanari, Hiroko -AU - Iwanari H -AD - Department of Quantitative Biology and Medicine, Research Center for Advanced - Science and Technology, The University of Tokyo, Tokyo 153-8904, Japan. -FAU - Kusano-Arai, Osamu -AU - Kusano-Arai O -AD - Department of Quantitative Biology and Medicine, Research Center for Advanced - Science and Technology, The University of Tokyo, Tokyo 153-8904, Japan. -FAU - Higashi, Tatsuya -AU - Higashi T -AD - National Institute of Radiological Sciences, National Institutes for Quantum and - Radiological Science and Technology (QST-NIRS), Chiba 263-8555, Japan. -FAU - Momose, Toshimitsu -AU - Momose T -AD - Department of Radiology, Faculty of Medicine, International University of Health - and Welfare, Chiba 286-8686, Japan. -FAU - Hamakubo, Takao -AU - Hamakubo T -AD - Department of Quantitative Biology and Medicine, Research Center for Advanced - Science and Technology, The University of Tokyo, Tokyo 153-8904, Japan. -AD - Department of Protein-protein Interaction Research, Institute for Advanced - Medical Sciences, Nippon Medical School, Kanagawa 211-8533, Japan. -LA - eng -GR - JP16K19809, JP18K15335, 18K07778, 17K10497, 18H02774, and 20K08148/Japan Society - for the Promotion of Science/ -GR - P06009/New Energy and Industrial Technology Development Organization/ -GR - the Funding Program for World-Leading Innovative R&D on Science and Technology - (FIRST Program)/Japan Society for the Promotion of Science/ -PT - Journal Article -DEP - 20201019 -PL - Switzerland -TA - Int J Mol Sci -JT - International journal of molecular sciences -JID - 101092791 -RN - Q20Q21Q62J (Cisplatin) -SB - IM -MH - Animals -MH - Cell Line, Tumor -MH - Cisplatin/*pharmacology -MH - Dose-Response Relationship, Drug -MH - Humans -MH - Male -MH - Mice -MH - Mice, Inbred BALB C -MH - Mice, Nude -MH - Neoplasms/pathology/*therapy -MH - *Radioimmunotherapy -MH - Treatment Outcome -PMC - PMC7589062 -OTO - NOTNLM -OT - ROBO1 -OT - cisplatin -OT - combination therapy -OT - radioimmunotherapy -OT - small-cell lung cancer -COIS- The authors declare no conflicts of interest associated with this manuscript. -EDAT- 2020/10/23 06:00 -MHDA- 2021/02/24 06:00 -PMCR- 2020/10/01 -CRDT- 2020/10/22 01:01 -PHST- 2020/09/18 00:00 [received] -PHST- 2020/10/09 00:00 [revised] -PHST- 2020/10/13 00:00 [accepted] -PHST- 2020/10/22 01:01 [entrez] -PHST- 2020/10/23 06:00 [pubmed] -PHST- 2021/02/24 06:00 [medline] -PHST- 2020/10/01 00:00 [pmc-release] -AID - ijms21207728 [pii] -AID - ijms-21-07728 [pii] -AID - 10.3390/ijms21207728 [doi] -PST - epublish -SO - Int J Mol Sci. 2020 Oct 19;21(20):7728. doi: 10.3390/ijms21207728. - -PMID- 33040640 -OWN - NLM -STAT- MEDLINE -DCOM- 20210317 -LR - 20220418 -IS - 1744-7658 (Electronic) -IS - 1354-3784 (Linking) -VI - 29 -IP - 12 -DP - 2020 Dec -TI - Emerging and investigational targeted chemotherapy and immunotherapy agents for - metastatic brain tumors. -PG - 1389-1406 -LID - 10.1080/13543784.2020.1836154 [doi] -AB - INTRODUCTION: Metastases to the central nervous system are the most common cause - of malignant intracranial tumors in adults. Current standard of care includes - surgery and radiation, but overall survival remains poor. A range of systemic - therapies are emerging as promising treatment options for these patients. AREAS - COVERED: This study reviews novel drug regimens that are under investigation in - phase 1 and 2 clinical trials. To identify relevant therapies under clinical - investigation, a search was performed on http://clinicaltrials.gov and Pubmed - with the keywords brain metastasis, Phase I clinical trial, and Phase II clinical - trial from 2016 to 2020. The authors detail the mechanisms of action of all trial - agents, outline evidence for their utility, and summarize the current state of - the field. EXPERT OPINION: Current advancements in the medical management of - brain metastases can be categorized into targeted therapies, methods of - overcoming treatment resistance, novel combinations of therapies, and modulation - of the tumor microenvironment with a specific focus on immunotherapy. Each of - these realms holds great promise for the field going forward. A more streamlined - structure for enrollment into clinical trials will be a crucial step in - accelerating progress in this area. -FAU - McMahon, J Tanner -AU - McMahon JT -AD - Department of Neurosurgery, Emory University , Atlanta, GA, USA. -FAU - Faraj, Razan R -AU - Faraj RR -AD - Department of Neurosurgery, Emory University , Atlanta, GA, USA. -FAU - Adamson, David Cory -AU - Adamson DC -AD - Department of Neurosurgery, Emory University , Atlanta, GA, USA. -AD - Department of Neurosurgery, Atlanta VA Medical Center , Decatur, GA. -LA - eng -PT - Journal Article -PT - Review -DEP - 20201026 -PL - England -TA - Expert Opin Investig Drugs -JT - Expert opinion on investigational drugs -JID - 9434197 -RN - 0 (Antineoplastic Agents) -SB - IM -MH - Adult -MH - Animals -MH - Antineoplastic Agents/administration & dosage/pharmacology -MH - Brain Neoplasms/pathology/secondary/*therapy -MH - Humans -MH - Immunotherapy/*methods -MH - *Molecular Targeted Therapy -MH - Survival Rate -MH - Tumor Microenvironment -OTO - NOTNLM -OT - Brain metastasis -OT - breast cancer -OT - clinical trials -OT - early phase trial -OT - immunotherapy -OT - lung cancer -OT - melanoma -OT - renal cell carcinoma -OT - small molecule inhibitors -OT - tyrosine kinase inhibitors -EDAT- 2020/10/13 06:00 -MHDA- 2021/03/18 06:00 -CRDT- 2020/10/12 05:19 -PHST- 2020/10/13 06:00 [pubmed] -PHST- 2021/03/18 06:00 [medline] -PHST- 2020/10/12 05:19 [entrez] -AID - 10.1080/13543784.2020.1836154 [doi] -PST - ppublish -SO - Expert Opin Investig Drugs. 2020 Dec;29(12):1389-1406. doi: - 10.1080/13543784.2020.1836154. Epub 2020 Oct 26. - -PMID- 34877555 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220429 -IS - 2666-3643 (Electronic) -IS - 2666-3643 (Linking) -VI - 2 -IP - 12 -DP - 2021 Dec -TI - A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in - Patients With Extensive-Stage SCLC in Canada. -PG - 100249 -LID - 10.1016/j.jtocrr.2021.100249 [doi] -LID - 100249 -AB - INTRODUCTION: The real-world data evaluating treatment outcomes of atezolizumab - plus carboplatin-etoposide chemotherapy (atezolizumab) for extensive-stage SCLC - (ESCLC) are lacking. Our objective was to evaluate real-world outcomes of ESCLC - treated with atezolizumab. METHODS: A retrospective analysis of provincial - patients with ESCLC who started first-line (1L) systemic treatment was conducted. - We primarily evaluated the progression-free survival (PFS) and overall survival - (OS) outcomes in association with atezolizumab compared with platinum-etoposide - chemotherapy (chemotherapy) while adjusting for relevant demographic and clinical - factors. Adverse events (AEs) during 1L were evaluated. RESULTS: A total of 67 - patients were identified. Of the 34 patients who received atezolizumab, 24% had - Eastern Cooperative Oncology Group performance status greater than or equal to 2, - approximately 50% were more than or equal to 65 years, 21% received - cisplatin-etoposide chemotherapy before atezolizumab, and 12% had thoracic - radiation (tRT).Within the atezolizumab versus chemotherapy group, the median PFS - equals to 6.0 versus 4.3 months (p = 0.03) whereas OS = 12.8 versus 7.1 months - (p = 0.01). Relative to chemotherapy, the hazard ratio (95% confidence interval) - for PFS was 0.53 (0.28-1.02) and OS was 0.42 (0.20-0.88) with atezolizumab. tRT - compared with no tRT receipt correlated with reduced death risk (hazard ratio - [95% confidence interval] = 0.33 [0.13-0.88]).AE-related treatment withdrawal - with atezolizumab was 32% and 15% with chemotherapy (p = 0.02). Within the tRT - subgroup, 25% versus 20% in atezolizumab versus chemotherapy group, respectively, - discontinued 1L owing to AE. CONCLUSIONS: This is the first real-world study - revealing comparable survival with that in the IMpower133 trial. Treatment - discontinuation from AEs was higher with atezolizumab among Canadian patients - with ESCLC. Our data suggest safe use of tRT and chemoimmunotherapy, but its - efficacy for ESCLC warrants further study. -CI - © 2021 by the International Association for the Study of Lung Cancer. -FAU - Elegbede, Anifat A -AU - Elegbede AA -AD - Department of Oncology, University of Calgary, Calgary, Alberta, Canada. -FAU - Gibson, Amanda J -AU - Gibson AJ -AD - Department of Oncology, University of Calgary, Calgary, Alberta, Canada. -FAU - Fung, Andrea S -AU - Fung AS -AD - Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Kingston, - Ontario, Canada. -FAU - Cheung, Winson Y -AU - Cheung WY -AD - Department of Oncology, University of Calgary, Calgary, Alberta, Canada. -AD - Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alberta, Canada. -FAU - Dean, Michelle L -AU - Dean ML -AD - Department of Oncology, University of Calgary, Calgary, Alberta, Canada. -FAU - Bebb, D Gwyn -AU - Bebb DG -AD - Department of Oncology, University of Calgary, Calgary, Alberta, Canada. -AD - Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alberta, Canada. -FAU - Pabani, Aliyah -AU - Pabani A -AD - Department of Oncology, University of Calgary, Calgary, Alberta, Canada. -AD - Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alberta, Canada. -LA - eng -PT - Journal Article -DEP - 20211028 -PL - United States -TA - JTO Clin Res Rep -JT - JTO clinical and research reports -JID - 101769967 -PMC - PMC8628038 -OTO - NOTNLM -OT - Chemo-immunotherapy -OT - Extensive stage SCLC -OT - Survival outcomes -OT - Thoracic radiation -EDAT- 2021/12/09 06:00 -MHDA- 2021/12/09 06:01 -PMCR- 2021/10/28 -CRDT- 2021/12/08 06:36 -PHST- 2021/08/06 00:00 [received] -PHST- 2021/09/25 00:00 [revised] -PHST- 2021/10/19 00:00 [accepted] -PHST- 2021/12/08 06:36 [entrez] -PHST- 2021/12/09 06:00 [pubmed] -PHST- 2021/12/09 06:01 [medline] -PHST- 2021/10/28 00:00 [pmc-release] -AID - S2666-3643(21)00108-9 [pii] -AID - 100249 [pii] -AID - 10.1016/j.jtocrr.2021.100249 [doi] -PST - epublish -SO - JTO Clin Res Rep. 2021 Oct 28;2(12):100249. doi: 10.1016/j.jtocrr.2021.100249. - eCollection 2021 Dec. - -PMID- 29268332 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20201001 -IS - 2072-1439 (Print) -IS - 2077-6624 (Electronic) -IS - 2072-1439 (Linking) -VI - 9 -IP - 10 -DP - 2017 Oct -TI - Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy - followed by nivolumab or placebo for locally advanced non-small cell lung cancer - (RTOG 3505). -PG - 3525-3528 -LID - 10.21037/jtd.2017.09.12 [doi] -FAU - Yoon, Shinkyo -AU - Yoon S -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, Seoul, South Korea. -FAU - Lee, Dae Ho -AU - Lee DH -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, Seoul, South Korea. -FAU - Kim, Sang-We -AU - Kim SW -AD - Department of Oncology, Asan Medical Center, University of Ulsan College of - Medicine, Seoul, South Korea. -LA - eng -PT - Comment -PT - Editorial -PL - China -TA - J Thorac Dis -JT - Journal of thoracic disease -JID - 101533916 -CON - Clin Lung Cancer. 2017 May;18(3):333-339. doi: 10.1016/j.cllc.2016.10.009. PMID: - 27923550 -PMC - PMC5723812 -COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. -EDAT- 2017/12/23 06:00 -MHDA- 2017/12/23 06:01 -PMCR- 2017/10/01 -CRDT- 2017/12/23 06:00 -PHST- 2017/12/23 06:00 [entrez] -PHST- 2017/12/23 06:00 [pubmed] -PHST- 2017/12/23 06:01 [medline] -PHST- 2017/10/01 00:00 [pmc-release] -AID - jtd-09-10-3525 [pii] -AID - 10.21037/jtd.2017.09.12 [doi] -PST - ppublish -SO - J Thorac Dis. 2017 Oct;9(10):3525-3528. doi: 10.21037/jtd.2017.09.12. - -PMID- 37805442 -OWN - NLM -STAT- MEDLINE -DCOM- 20231101 -LR - 20231101 -IS - 0253-3766 (Print) -IS - 0253-3766 (Linking) -VI - 45 -IP - 9 -DP - 2023 Sep 23 -TI - [Effect of SLC7A11 gene downregulation on the gefitinib resistance of lung - adenocarcinoma PC9/GR cells and its mechanism]. -PG - 779-786 -LID - 10.3760/cma.j.cn112152-20220715-00493 [doi] -AB - Objective: To screen the key genes involved in gefitinib resistance of lung - adenocarcinoma PC9/GR cells which harbored 19 exon mutation of epidermal growth - factor receptor (EGFR) gene, and discuss the effect and mechanism of - downregulation of solute carrier family 7 member 11 (SLC7A11) on the gefitinib - resistance of PC9/GR cells. Methods: RNA microarray was conducted to detect the - gene expressions in PC9 and PC9/GR cells. The differently expressed genes were - screened by using limma package of R language and analyzed by Kyoto encyclopedia - of genes and genomes (KEGG) pathway enrichment analysis. Western blotting was - performed to determine the expression of SLC7A11 protein in PC9 and PC9/GR cells. - PC9/GR cells were infected with lentivirus plasmid containing short hairpin RNA - (shRNA) targeting SLC7A11 or negative control shRNA (sh-NC), respectively. - Real-time quantitative polymerase chain reaction (RT-qPCR) was performed to - evaluate the efficacy of shRNA on the expression of SLC7A11 mRNA. Cell counting - kit-8 (CCK-8) assay was conducted to determine the suppressing effect of - gefitinib on PC9/GR cells. Mito-Tracker Red CMXRos probe and malondialdehyde - (MDA) assay kit were used to evaluate gefitinib-induced ferroptosis in PC9/GR - cells. Immunohistochemistry (IHC) was conducted to detect the expression of - SLC7A11 protein in the tumor tissues of advanced stage lung adenocarcinoma - patients harboring 19 exon mutation of EGFR gene. Thirty-six advanced stage lung - adenocarcinoma patients who received EGFR-tyrosihe kinase inhibitor(TKI) as - first-line treatment in Fourth Hospital of Hebei Medical Unviersity were - enrolled. Kaplan-Meier survival curve was drawn to analyze the correlation - between SLC7A11 expression and progression-free survival (PFS) of the patients. - Results: RNA array demonstrated that 2 888 genes were differently expressed - between PC9 and PC9/GR cells. KEGG analysis showed that ferroptosis-related gene - was one of the most enriched region of the differently expressed genes between - PC9 and PC9/GR cells. These ferroptosis-related gene cohort contained 13 genes, - among which SLC7A11 exhibited the most significant difference. Western blotting - showed that the expression of SLC7A11 protein in PC9/GR cells was significantly - higher than that in PC9 cells (0.76±0.03 vs. 0.19±0.02, P<0.001). The 50% - inhibiting concentration (IC(50)) of gefitinib was 35.08 μmol/L and 64.01 μmol/L - for sh-SLC7A11 and sh-NC group PC9/GR cells, respectively. PC9/GR cells in - sh-SLC7A11 group exhibited significantly lower density of mitochondria - fluorescence after gefitinib treatment, compared to the sh-NC group (213.77±26.50 - vs. 47.88±4.55, P<0.001). In addition, PC9/GR cells in sh-SLC7A11 group exhibited - significantly higher MDA after gefitinib treatment, compared to the sh-NC group - [(15.43±1.60) μmol/mg vs. (82.18±7.77) μmol/mg, P<0.001]. The PFS of the patients - with low expression of SLC7A11 (n=18) was significantly longer than the patients - with high expression of SLC7A11 (n=18, 16.77 months vs. 9.14 months, P<0.001). - Conclusion: Downregulation of SLC7A11 could increase the sensitivity of PC9/GR - cells to gefitinib by promoting ferroptosis. -FAU - Jia, Y L -AU - Jia YL -AD - Department of Tumor Immunotherapy, Fourth Hospital of Hebei Medical University, - Shijiazhuang 050011, China. -FAU - Zhao, Y -AU - Zhao Y -AD - Department of Medical Oncology, Fourth Hospital of Hebei Medical University, - Shijiazhuang 050011, China. -FAU - Zhen, S M -AU - Zhen SM -AD - Department of Radiotherapy, Fourth Hospital of Hebei Medical University, - Shijiazhuang 050011, China. -FAU - Cheng, Z S -AU - Cheng ZS -AD - Department of Tumor Immunotherapy, Fourth Hospital of Hebei Medical University, - Shijiazhuang 050011, China. -FAU - Zheng, B Y -AU - Zheng BY -AD - Department of Tumor Immunotherapy, Fourth Hospital of Hebei Medical University, - Shijiazhuang 050011, China. -FAU - Liu, Y P -AU - Liu YP -AD - Department of Pathology, Fourth Hospital of Hebei Medical University, - Shijiazhuang 050011, China. -FAU - Liu, L H -AU - Liu LH -AD - Department of Tumor Immunotherapy, Fourth Hospital of Hebei Medical University, - Shijiazhuang 050011, China. -LA - chi -GR - 81871894/National Natural Science Foundation of China/ -GR - H2021206070/Precision Medicine United Fund Key Program of Hebei Natural Science - Foundation/ -GR - H2020206236/Hebei Natural Science Fund for Young Scholars/ -GR - CXZZBS2022084/Graduate Innovation Program of Degree Office of Hebei Education - Department/ -PT - English Abstract -PT - Journal Article -PL - China -TA - Zhonghua Zhong Liu Za Zhi -JT - Zhonghua zhong liu za zhi [Chinese journal of oncology] -JID - 7910681 -RN - S65743JHBS (Gefitinib) -RN - 0 (Antineoplastic Agents) -RN - 0 (Quinazolines) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - 0 (Protein Kinase Inhibitors) -RN - 0 (RNA, Small Interfering) -RN - 0 (SLC7A11 protein, human) -RN - 0 (Amino Acid Transport System y+) -SB - IM -MH - Humans -MH - Gefitinib/pharmacology/therapeutic use -MH - *Antineoplastic Agents/pharmacology/therapeutic use -MH - *Lung Neoplasms/pathology -MH - Down-Regulation -MH - Quinazolines/pharmacology/therapeutic use -MH - Drug Resistance, Neoplasm/genetics -MH - ErbB Receptors/metabolism -MH - *Adenocarcinoma of Lung -MH - Protein Kinase Inhibitors/therapeutic use -MH - RNA, Small Interfering/genetics -MH - Cell Line, Tumor -MH - Amino Acid Transport System y+/genetics/metabolism -OTO - NOTNLM -OT - Adenocarcinoma -OT - Ferroptosis -OT - Gefitinib -OT - Lung neoplasms -OT - Solute carrier family 7 member 11 -OT - Treatment-resistance -EDAT- 2023/10/08 02:42 -MHDA- 2023/11/01 12:42 -CRDT- 2023/10/07 22:44 -PHST- 2023/11/01 12:42 [medline] -PHST- 2023/10/08 02:42 [pubmed] -PHST- 2023/10/07 22:44 [entrez] -AID - 10.3760/cma.j.cn112152-20220715-00493 [doi] -PST - ppublish -SO - Zhonghua Zhong Liu Za Zhi. 2023 Sep 23;45(9):779-786. doi: - 10.3760/cma.j.cn112152-20220715-00493. - -PMID- 30016784 -OWN - NLM -STAT- MEDLINE -DCOM- 20190314 -LR - 20190314 -IS - 1423-002X (Electronic) -IS - 0378-7346 (Linking) -VI - 84 -IP - 1 -DP - 2019 -TI - Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and - Review of the Literature. -PG - 94-98 -LID - 10.1159/000491090 [doi] -AB - Advanced vulvar cancer is associated with a very poor prognosis. Surgical - resection is the mainstay of treatment, with radiation indicated for areas at - high risk for recurrence. When surgical and radiation options have been - exhausted, the effectiveness of systemic chemotherapy is poor. No biologic or - targeted agents have been approved for the management of advanced or recurrent - vulvar cancer. Pembrolizumab, a humanized monoclonal antibody against programmed - death 1 (PD-1), has been successfully used as a target of tumor immune therapy in - small cell lung cancer and melanoma. We present the first case in the literature - of a patient with recurrent vulvar cancer who was treated successfully with - pembrolizumab. Caris next-generation testing revealed a PD-L1 and PD-1 mutation - (PD-L1 positive, 2+, 100%). She attained a complete clinical remission after 2 - cycles, and a CT scan after 6 cycles revealed a significant response by RECIST - criteria. After completing 10 cycles, treatment was stopped due to complications - of severe malnutrition related to narcotic abuse. A CT scan 10 weeks after the - final treatment revealed no adenopathy. Pembrolizumab is a safe and effective - chemotherapeutic agent to treat recurrent vulvar carcinoma. -CI - © 2018 S. Karger AG, Basel. -FAU - Shields, Lisa B E -AU - Shields LBE -AD - Norton Neuroscience Institute, Norton Healthcare, Louisville, Kentucky, - USALBES@earthlink.net. -FAU - Gordinier, Mary E -AU - Gordinier ME -AD - Norton Cancer Institute, Norton Healthcare, Louisville, Kentucky, USA. -LA - eng -PT - Case Reports -PT - Journal Article -PT - Review -DEP - 20180717 -PL - Switzerland -TA - Gynecol Obstet Invest -JT - Gynecologic and obstetric investigation -JID - 7900587 -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - DPT0O3T46P (pembrolizumab) -SB - IM -MH - Antibodies, Monoclonal, Humanized/*therapeutic use -MH - Antineoplastic Agents, Immunological/*therapeutic use -MH - B7-H1 Antigen/genetics -MH - Carcinoma, Squamous Cell/genetics/*therapy -MH - Female -MH - Humans -MH - Middle Aged -MH - Neoplasm Recurrence, Local/*drug therapy/genetics -MH - Programmed Cell Death 1 Receptor/genetics -MH - Vulvar Neoplasms/genetics/*therapy -OTO - NOTNLM -OT - Chemotherapy -OT - Gynecology -OT - Oncology -OT - Pembrolizumab -OT - Toxicity -OT - Vulvar cancer -EDAT- 2018/07/18 06:00 -MHDA- 2019/03/15 06:00 -CRDT- 2018/07/18 06:00 -PHST- 2018/04/30 00:00 [received] -PHST- 2018/06/18 00:00 [accepted] -PHST- 2018/07/18 06:00 [pubmed] -PHST- 2019/03/15 06:00 [medline] -PHST- 2018/07/18 06:00 [entrez] -AID - 000491090 [pii] -AID - 10.1159/000491090 [doi] -PST - ppublish -SO - Gynecol Obstet Invest. 2019;84(1):94-98. doi: 10.1159/000491090. Epub 2018 Jul - 17. - -PMID- 30249211 -OWN - NLM -STAT- MEDLINE -DCOM- 20181211 -LR - 20230928 -IS - 1471-2407 (Electronic) -IS - 1471-2407 (Linking) -VI - 18 -IP - 1 -DP - 2018 Sep 24 -TI - Phase II study of neoadjuvant checkpoint blockade in patients with surgically - resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. -PG - 913 -LID - 10.1186/s12885-018-4829-0 [doi] -LID - 913 -AB - BACKGROUND: Soft tissue sarcomas are a heterogeneous and rare group of solid - tumors of mesenchymal origin that can arise anywhere in the body. Although - surgical resection is the mainstay of treatment for patients with localized - disease, disease recurrence is common and 5-year overall survival is poor - (~ 65%). Both radiation therapy and conventional chemotherapy are used to reduce - local and distant recurrence. However, the utility of radiation therapy is often - limited by disease location (in the case of retroperitoneal sarcomas, for - instance) while systemic therapy with conventional lines of chemotherapy offer - limited efficacy and are often poorly tolerated and associated with significant - toxicity. Within the past decade, major advances have been made in the treatment - of other malignancies including melanoma, renal cell carcinoma, and non-small - cell lung carcinoma with the advent of immune-checkpoint inhibitors such as - ipilimumab (anti-CTLA4), pembrolizumab (anti-PD1), and nivolumab (anti-PD1). The - recently published SARC028 (NCT02301039), an open label, phase II, multicenter - trial of pembrolizumab in patients with advanced bone and soft tissue sarcomas - reported promising activity in select histologic subtypes of advanced STS, - including undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. - METHODS: There is a clear need for novel and effective adjuncts in the treatment - of STS. We hypothesize that immune checkpoint blockade will be effective in - patients with surgically resectable primary or locally recurrent dedifferentiated - liposarcoma and undifferentiated pleomorphic sarcoma when administered in the - neoadjuvant setting. The primary aim of this phase II, single-center, open label, - randomized non-comparative trial is to determine the pathologic response to - neoadjuvant nivolumab monotherapy and combination nivolumab/ipilimumab in - patients with resectable dedifferentiated liposarcoma of the retroperitoneum or - undifferentiated pleomorphic sarcoma of the trunk or extremity treated with - concurrent standard of care neoadjuvant radiation therapy. DISCUSSION: This study - will help define the role of single agent anti-PD1 and combination anti-CTLA4 and - anti-PD1 therapy in patients with surgically resectable dedifferentiated - liposarcoma and undifferentiated pleomorphic sarcoma. TRIAL REGISTRATION: - ClinicalTrials.gov NCT03307616 , registered October 12, 2017. -FAU - Keung, Emily Z -AU - Keung EZ -AD - Departments of Surgical Oncology, The University of Texas MD Anderson Cancer - Center, 1400 Pressler St., FCT17.6054, Unit 1484, Houston, TX, 77030, USA. -FAU - Lazar, Alexander J -AU - Lazar AJ -AD - Departments of Pathology, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -AD - Departments of Genomic Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Torres, Keila E -AU - Torres KE -AD - Departments of Surgical Oncology, The University of Texas MD Anderson Cancer - Center, 1400 Pressler St., FCT17.6054, Unit 1484, Houston, TX, 77030, USA. -AD - Departments of Genomic Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Wang, Wei-Lien -AU - Wang WL -AD - Departments of Pathology, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Cormier, Janice N -AU - Cormier JN -AD - Departments of Surgical Oncology, The University of Texas MD Anderson Cancer - Center, 1400 Pressler St., FCT17.6054, Unit 1484, Houston, TX, 77030, USA. -FAU - Ashleigh Guadagnolo, B -AU - Ashleigh Guadagnolo B -AD - Departments of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Bishop, Andrew J -AU - Bishop AJ -AD - Departments of Radiation Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Lin, Heather -AU - Lin H -AD - Departments of Biostatistics, The University of Texas MD Anderson Cancer Center, - Houston, TX, USA. -FAU - Hunt, Kelly K -AU - Hunt KK -AD - Departments of Surgical Oncology, The University of Texas MD Anderson Cancer - Center, 1400 Pressler St., FCT17.6054, Unit 1484, Houston, TX, 77030, USA. -FAU - Bird, Justin -AU - Bird J -AD - Departments of Orthopaedic Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Lewis, Valerae O -AU - Lewis VO -AD - Departments of Orthopaedic Oncology, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Patel, Shreyaskumar R -AU - Patel SR -AD - Departments of Sarcoma Medical Oncology, The University of Texas MD Anderson - Cancer Center, Houston, TX, USA. -FAU - Wargo, Jennifer A -AU - Wargo JA -AD - Departments of Surgical Oncology, The University of Texas MD Anderson Cancer - Center, 1400 Pressler St., FCT17.6054, Unit 1484, Houston, TX, 77030, USA. -AD - Departments of Genomic Medicine, The University of Texas MD Anderson Cancer - Center, Houston, TX, USA. -FAU - Somaiah, Neeta -AU - Somaiah N -AD - Departments of Sarcoma Medical Oncology, The University of Texas MD Anderson - Cancer Center, Houston, TX, USA. -FAU - Roland, Christina L -AU - Roland CL -AD - Departments of Surgical Oncology, The University of Texas MD Anderson Cancer - Center, 1400 Pressler St., FCT17.6054, Unit 1484, Houston, TX, 77030, USA. - clroland@mdanderson.org. -LA - eng -SI - ClinicalTrials.gov/NCT03307616 -GR - K12 CA088084/CA/NCI NIH HHS/United States -GR - P30 CA016672/CA/NCI NIH HHS/United States -GR - T32 CA009599/CA/NCI NIH HHS/United States -PT - Clinical Trial, Phase II -PT - Journal Article -PT - Randomized Controlled Trial -DEP - 20180924 -PL - England -TA - BMC Cancer -JT - BMC cancer -JID - 100967800 -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Antineoplastic Agents, Immunological/pharmacology/*therapeutic use -MH - *Clinical Protocols -MH - Cohort Studies -MH - Humans -MH - Liposarcoma/*drug therapy/pathology -MH - *Molecular Targeted Therapy -MH - Neoadjuvant Therapy -MH - Neoplasm Grading -MH - Neoplasm Staging -MH - Sarcoma/*drug therapy/pathology -PMC - PMC6154892 -OTO - NOTNLM -OT - CTLA4 -OT - Immunotherapy -OT - Ipilimumab -OT - Liposarcoma -OT - Neoadjuvant -OT - Nivolumab -OT - PD-1 -OT - Pembrolizumab -OT - Soft tissue sarcoma -OT - Undifferentiated pleomorphic sarcoma -COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This study was approved by The - University of Texas MD Anderson Cancer Center Institutional Review Board (IRB; - IRB reference number 2017–0143) and will be conducted in agreement with the - requirements of the Code of Federal Regulations and the Institutional Review - Board. All patients will be required to sign an IRB-approved consent form, - indicating their agreement to participate. The consent form includes the nature, - objectives, and potential risks and benefits of the study and details the - required length of follow-up, required tissue biopsies and blood sample - collections, supportive care, the name of the principal investigator (CLR) - responsible for the protocol. The consent additionally specifies the patient’s - right to accept or refuse treatment and to terminate participation and withdraw - from the protocol. All data collection with be performed in accordance with the - human subjects research policies of MD Anderson Cancer Center. CONSENT FOR - PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they - have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral - with regard to jurisdictional claims in published maps and institutional - affiliations. -EDAT- 2018/09/27 06:00 -MHDA- 2018/12/12 06:00 -PMCR- 2018/09/24 -CRDT- 2018/09/26 06:00 -PHST- 2017/12/21 00:00 [received] -PHST- 2018/09/18 00:00 [accepted] -PHST- 2018/09/26 06:00 [entrez] -PHST- 2018/09/27 06:00 [pubmed] -PHST- 2018/12/12 06:00 [medline] -PHST- 2018/09/24 00:00 [pmc-release] -AID - 10.1186/s12885-018-4829-0 [pii] -AID - 4829 [pii] -AID - 10.1186/s12885-018-4829-0 [doi] -PST - epublish -SO - BMC Cancer. 2018 Sep 24;18(1):913. doi: 10.1186/s12885-018-4829-0. - -PMID- 37699402 -OWN - NLM -STAT- MEDLINE -DCOM- 20240930 -LR - 20240930 -IS - 1940-1574 (Electronic) -IS - 0003-3197 (Linking) -VI - 75 -IP - 10 -DP - 2024 Nov-Dec -TI - Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will - Go. -PG - 909-920 -LID - 10.1177/00033197231201929 [doi] -AB - Immune checkpoint inhibitors (ICIs) are specific monoclonal antibodies directed - against inhibitory targets of the immune system, mainly represented by programmed - death-1 (PD1) ligand-1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), - thus enabling an amplified T-cell-mediated immune response against cancer cells. - These drugs have significantly improved prognosis in patients with advanced - metastatic cancer (e.g., melanoma, non-small cell lung cancer, renal cell - carcinoma). However, uncontrolled activation of anti-tumor T-cells could trigger - an excessive immune response, possibly responsible for multi-organ damage, - including, among others, lymphocytic myocarditis. The incidence of ICIs-induced - myocarditis is underestimated and the patients affected are poorly characterized. - The diagnosis and management of this condition are mainly based on expert opinion - and case reports. EKG and ultrasound are tests that can help identify patients at - risk of myocarditis during treatment by red flags, such as QRS complex - enlargement and narrowing of global longitudinal strain (GLS). Therapy of - ICI-related myocarditis is based on immunosuppressors, monoclonal antibodies and - fusion proteins. A future strategy could involve the use of microRNAs. This - review considers the current state of the art of immune-related adverse - cardiovascular events, focusing on histological and clinical features, diagnosis - and management, including current treatments and future pharmacological targets. -FAU - Vergara, Andrea -AU - Vergara A -AUID- ORCID: 0000-0001-5217-7754 -AD - Department of Translational Medical Sciences, University of Campania 'Luigi - Vanvitelli', Caserta, Italy. RINGGOLD: 18994 -AD - Division of Clinical Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano', Caserta, - Italy. RINGGOLD: 165520 -FAU - De Felice, Marco -AU - De Felice M -AUID- ORCID: 0000-0002-3798-9698 -AD - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", - Caserta, Italy. RINGGOLD: 18994 -AD - Division of Oncology, A.O.R.N. 'Sant'Anna e San Sebastiano', Caserta, Italy. - RINGGOLD: 165520 -FAU - Cesaro, Arturo -AU - Cesaro A -AD - Department of Translational Medical Sciences, University of Campania 'Luigi - Vanvitelli', Caserta, Italy. RINGGOLD: 18994 -AD - Division of Clinical Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano', Caserta, - Italy. RINGGOLD: 165520 -FAU - Gragnano, Felice -AU - Gragnano F -AUID- ORCID: 0000-0002-6943-278X -AD - Department of Translational Medical Sciences, University of Campania 'Luigi - Vanvitelli', Caserta, Italy. RINGGOLD: 18994 -AD - Division of Clinical Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano', Caserta, - Italy. RINGGOLD: 165520 -FAU - Pariggiano, Ivana -AU - Pariggiano I -AD - Division of Clinical Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano', Caserta, - Italy. RINGGOLD: 165520 -FAU - Golia, Enrica -AU - Golia E -AD - Division of Clinical Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano', Caserta, - Italy. RINGGOLD: 165520 -FAU - De Pasquale, Antonio -AU - De Pasquale A -AD - Department of Translational Medical Sciences, University of Campania 'Luigi - Vanvitelli', Caserta, Italy. RINGGOLD: 18994 -AD - Division of Clinical Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano', Caserta, - Italy. RINGGOLD: 165520 -FAU - Blasi, Ettore -AU - Blasi E -AD - Department of Translational Medical Sciences, University of Campania 'Luigi - Vanvitelli', Caserta, Italy. RINGGOLD: 18994 -AD - Division of Clinical Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano', Caserta, - Italy. RINGGOLD: 165520 -FAU - Fimiani, Fabio -AU - Fimiani F -AD - Unit of Inherited and Rare Cardiovascular Diseases, A.O.R.N. Dei Colli "V. - Monaldi", Naples, Italy. RINGGOLD: 92712 -FAU - Monda, Emanuele -AU - Monda E -AD - Department of Translational Medical Sciences, University of Campania 'Luigi - Vanvitelli', Caserta, Italy. RINGGOLD: 18994 -AD - Unit of Inherited and Rare Cardiovascular Diseases, A.O.R.N. Dei Colli "V. - Monaldi", Naples, Italy. RINGGOLD: 92712 -FAU - Limongelli, Giuseppe -AU - Limongelli G -AD - Department of Translational Medical Sciences, University of Campania 'Luigi - Vanvitelli', Caserta, Italy. RINGGOLD: 18994 -AD - Unit of Inherited and Rare Cardiovascular Diseases, A.O.R.N. Dei Colli "V. - Monaldi", Naples, Italy. RINGGOLD: 92712 -FAU - Calabrò, Paolo -AU - Calabrò P -AD - Department of Translational Medical Sciences, University of Campania 'Luigi - Vanvitelli', Caserta, Italy. RINGGOLD: 18994 -AD - Division of Clinical Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano', Caserta, - Italy. RINGGOLD: 165520 -LA - eng -PT - Journal Article -PT - Review -DEP - 20230912 -PL - United States -TA - Angiology -JT - Angiology -JID - 0203706 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -MH - Humans -MH - *Immune Checkpoint Inhibitors/adverse effects/therapeutic use -MH - *Myocarditis/chemically induced/therapy/diagnosis/immunology -MH - Neoplasms/drug therapy/immunology -OTO - NOTNLM -OT - cardio-oncology -OT - heart failure -OT - immune checkpoint inhibitors -OT - myocarditis -COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts - of interest with respect to the research, authorship, and/or publication of this - article. -EDAT- 2023/09/13 00:42 -MHDA- 2024/09/30 18:52 -CRDT- 2023/09/12 18:42 -PHST- 2024/09/30 18:52 [medline] -PHST- 2023/09/13 00:42 [pubmed] -PHST- 2023/09/12 18:42 [entrez] -AID - 10.1177/00033197231201929 [doi] -PST - ppublish -SO - Angiology. 2024 Nov-Dec;75(10):909-920. doi: 10.1177/00033197231201929. Epub 2023 - Sep 12. - -PMID- 27777770 -OWN - NLM -STAT- MEDLINE -DCOM- 20180201 -LR - 20190112 -IS - 2051-1426 (Print) -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 4 -DP - 2016 -TI - Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or - hepatic dysfunction. -PG - 60 -LID - 60 -AB - BACKGROUND: Anti-PD-1 therapy is increasingly used in various advanced - malignancies. Patients with baseline organ dysfunction are largely excluded from - clinical trials. Therefore it is unclear whether anti-PD-1 therapy is safe or - effective in this setting. Further, these patients are often not candidates for - other anti-cancer therapies, highlighting their need for active treatment - options. METHODS: We performed a retrospective analysis of patients from multiple - centers with advanced solid tumors and baseline organ dysfunction who received - anti-PD-1 therapy. Organ dysfunction was defined as cardiac (left ventricular - ejection fraction ≤45 %), renal (creatinine ≥2 mg/dL or GFR ≤30 ml/min) or - hepatic dysfunction (evidence of cirrhosis on imaging or AST, ALT or bilirubin - ≥3x ULN). We assessed change in organ dysfunction, immune related adverse events - (irAEs), response rate, progression free survival (PFS) and overall survival - (OS). RESULTS: We identified 27 patients eligible for inclusion with the - following diseases: renal cell carcinoma (n = 8), melanoma (10), non-small cell - lung cancer (3), small cell lung cancer (2) and urothelial bladder cancer (4). - Baseline organ dysfunction included renal dysfunction (n = 17), hepatic - dysfunction (7), cardiac dysfunction (11), including >1 organ dysfunction (8). - Worsening organ dysfunction requiring hospitalization or dose delays occurred in - 8 patients (30 %) although in most cases this was thought not-drug related and - resolved with supportive care. Grade 3 irAEs occurred in 2 pts (7 %; hepatitis - and colitis). Thirteen of 27 patients had ongoing treatment benefit (objective - response or stable disease) at data collection (48 %). Eleven patients had - primary progressive disease (41 %), 11 had stable disease (41 %), 4 had partial - responses (15 %), and one had a complete response (4 %). Overall, median PFS was - 168 days. Median OS was not reached. CONCLUSIONS: In our experience, anti-PD-1 - agents in this group of patients with cardiac, hepatic or renal dysfunction were - associated with tolerable irAEs and infrequent manageable worsening of organ - dysfunction. Further, objective responses and prolonged PFS were observed in a - number of patients. Thus, patients with baseline organ dysfunction may be - considered for anti-PD-1 therapy with appropriate clinical monitoring. -FAU - Kanz, Bridgette A -AU - Kanz BA -AD - Departments of Pharmaceutical Services, Vanderbilt Ingram Cancer Center, 2220 - Pierce Avenue, Nashville, TN 37232 USA. -FAU - Pollack, Megan H -AU - Pollack MH -AD - Departments of Pharmaceutical Services, Vanderbilt Ingram Cancer Center, 2220 - Pierce Avenue, Nashville, TN 37232 USA. -FAU - Johnpulle, Romany -AU - Johnpulle R -AD - Departments of Medicine, Vanderbilt Ingram Cancer Center, 777 PRB, 2220 Pierce - Ave., Nashville, TN 37232 USA. -FAU - Puzanov, Igor -AU - Puzanov I -AD - Department of Medicine, Roswell Park Cancer Institute, Elm @ Carlton Streets, - Buffalo, NY 14263 USA. -FAU - Horn, Leora -AU - Horn L -AD - Departments of Medicine, Vanderbilt Ingram Cancer Center, 777 PRB, 2220 Pierce - Ave., Nashville, TN 37232 USA. -FAU - Morgans, Alicia -AU - Morgans A -AD - Departments of Medicine, Vanderbilt Ingram Cancer Center, 777 PRB, 2220 Pierce - Ave., Nashville, TN 37232 USA. -FAU - Sosman, Jeffrey A -AU - Sosman JA -AD - Departments of Medicine, Vanderbilt Ingram Cancer Center, 777 PRB, 2220 Pierce - Ave., Nashville, TN 37232 USA. -FAU - Rapisuwon, Suthee -AU - Rapisuwon S -AD - Department of Oncology, Georgetown Lombardi Cancer Center, 3970 Reservoir Road - NW, Washington, DC 20007 USA. -FAU - Conry, R Martin -AU - Conry RM -AD - Department of Medicine, University of Alabama at Birmingham, 1824 6th Avenue S, - Birmingham, AL 35233 USA. -FAU - Eroglu, Zeynep -AU - Eroglu Z -AD - Department of Cutaneous Oncology, Moffitt Cancer Center, 12902 USF Magnolia - Drive, Tampa, FL 33612 USA. -FAU - Johnson, Douglas B -AU - Johnson DB -AD - Departments of Medicine, Vanderbilt Ingram Cancer Center, 777 PRB, 2220 Pierce - Ave., Nashville, TN 37232 USA. -LA - eng -GR - K12 CA090625/CA/NCI NIH HHS/United States -GR - K23 CA204726/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Multicenter Study -DEP - 20161018 -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Aged -MH - Aged, 80 and over -MH - Antineoplastic Agents, Immunological/*adverse effects/therapeutic use -MH - Cardiotoxicity -MH - Female -MH - Heart/*drug effects/physiopathology -MH - Heart Function Tests -MH - Humans -MH - Kidney/*drug effects/physiopathology -MH - Kidney Function Tests -MH - Liver/*drug effects/physiopathology -MH - Liver Function Tests -MH - Male -MH - Middle Aged -MH - Molecular Targeted Therapy/*adverse effects -MH - Neoplasm Staging -MH - Neoplasms/complications/diagnosis/drug therapy/mortality -MH - Positron Emission Tomography Computed Tomography -MH - Programmed Cell Death 1 Receptor/*administration & dosage -MH - Retrospective Studies -MH - Treatment Outcome -PMC - PMC5067899 -OTO - NOTNLM -OT - Anti-PD-1 -OT - Cardiac -OT - Dysfunction -OT - Hepatic -OT - Melanoma -OT - Nivolumab -OT - Organ -OT - Pembrolizumab -OT - Renal -EDAT- 2016/10/26 06:00 -MHDA- 2018/02/02 06:00 -PMCR- 2016/10/18 -CRDT- 2016/10/26 06:00 -PHST- 2016/07/22 00:00 [received] -PHST- 2016/09/13 00:00 [accepted] -PHST- 2016/10/26 06:00 [pubmed] -PHST- 2018/02/02 06:00 [medline] -PHST- 2016/10/26 06:00 [entrez] -PHST- 2016/10/18 00:00 [pmc-release] -AID - 166 [pii] -AID - 10.1186/s40425-016-0166-5 [doi] -PST - epublish -SO - J Immunother Cancer. 2016 Oct 18;4:60. doi: 10.1186/s40425-016-0166-5. - eCollection 2016. - -PMID- 33521371 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220420 -IS - 2424-810X (Electronic) -IS - 2382-6533 (Print) -IS - 2382-6533 (Linking) -VI - 6 -IP - 4 -DP - 2020 Oct 29 -TI - Current status and future directions in unresectable stage III non-small cell - lung cancer. -PG - 109-120 -AB - BACKGROUND: Patients with unresectable stage III non-small-cell lung cancer - constitute a heterogeneous group in which the available treatments may range from - radical therapies with radio-chemotherapy to supportive treatments depending on - the extent of the disease and comorbidities present. For years the standard - treatment based on the combination of chemotherapy and radiotherapy (RT) has - remained unchanged and survival outcomes have been poor. AIM: Recent advances in - molecular biology and RT technology have resulted in improved survival. This - article reviews the treatments that constitute current standard treatment in - unresectable advanced lung cancer and the situations and indications for the - management of patients who are not candidates for radical therapy. RELEVANCE FOR - PATIENTS: Although unresectable lung cancer does not have a good prognosis, new - drugs and new technologies in radiation oncology can offer treatment options - adapted to the patient's clinical situation, ranging from therapies administered - with radical intent to others aimed mainly at improving the patient's quality of - life, which, judiciously chosen, will provide optimal management of the patient. -CI - Copyright: © Whioce Publishing Pte. Ltd. -FAU - Arellano, Esperanza Arriola -AU - Arellano EA -AD - Department Medical Oncology, Universitary Hospital Puerta del Mar, Cádiz, Spain. -FAU - Díaz, Verónica Díaz -AU - Díaz VD -AD - Department of Radiation Oncology, Universitary Hospital Puerta del Mar, Cádiz, - Spain. -FAU - Rodríguez, Joaquín José Cabrera -AU - Rodríguez JJC -AD - Department of Radiation Oncology, Universitary Hospital of Badajoz, Badajoz, - Spain. -LA - eng -PT - Journal Article -PT - Review -DEP - 20201029 -PL - Singapore -TA - J Clin Transl Res -JT - Journal of clinical and translational research -JID - 101667205 -PMC - PMC7837736 -OTO - NOTNLM -OT - Non-small cell lung cancer -OT - advanced cancer -OT - image-guided radiotherapy -OT - immunotherapy -OT - intensity-modulated radiotherapy -OT - radio-chemotherapy -OT - radiotherapy -COIS- All the authors have no conflicts of interest. -EDAT- 2021/02/02 06:00 -MHDA- 2021/02/02 06:01 -PMCR- 2020/10/29 -CRDT- 2021/02/01 06:01 -PHST- 2020/06/08 00:00 [received] -PHST- 2020/09/10 00:00 [revised] -PHST- 2020/10/09 00:00 [accepted] -PHST- 2021/02/01 06:01 [entrez] -PHST- 2021/02/02 06:00 [pubmed] -PHST- 2021/02/02 06:01 [medline] -PHST- 2020/10/29 00:00 [pmc-release] -AID - jctres.06.2020S4.006 [pii] -PST - epublish -SO - J Clin Transl Res. 2020 Oct 29;6(4):109-120. eCollection 2020 Oct 29. - -PMID- 38304743 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240203 -IS - 2589-5370 (Electronic) -IS - 2589-5370 (Linking) -VI - 68 -DP - 2024 Feb -TI - Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with - chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung - cancer: Neo-Pre-IC, a single-arm phase 2 trial. -PG - 102422 -LID - 10.1016/j.eclinm.2024.102422 [doi] -LID - 102422 -AB - BACKGROUND: Some locally advanced (IIIA/IIIB) non-small cell lung cancers - (NSCLCs) might have surgical options available. However, information regarding - the effectiveness of neoadjuvant immunotherapy for potentially resectable - IIIA/IIIB NSCLC is limited. The intent of this investigation was to offer a more - favourable alternative to the standard approach of chemoradiotherapy (concurrent - or sequential chemoradiotherapy) followed by immunotherapy for potentially - resectable stage III NSCLC. METHODS: This prospective, single-arm, phase 2 - clinical trial (NCT04326153) enrolled treatment-naïve patients with 'potentially - resectable' IIIA/IIIB NSCLC who were deemed unsuitable for complete (R0) - resection upon initial diagnosis. The study period was between March 20, 2020, - and August 20, 2021. Patients underwent neoadjuvant chemoimmunotherapy - (sintilimab combined with nab-paclitaxel and carboplatin) for two to three cycles - prior to surgical resection of the lung carcinoma and systematic nodal dissection - within 30-45 days. The primary endpoint was the 2-year disease-free survival - (DFS) rate, with secondary endpoints encompassing major pathological response - (MPR) rate, pathological complete response (pCR) rate, overall survival, - objective response rate (ORR), downstaging rate, and adverse events (AEs). Tumour - immune cell infiltrates, identified via immunohistochemistry, were assessed as - biomarkers at baseline and after surgery. FINDINGS: Among 30 patients who - received neoadjuvant chemoimmunotherapy, 20 underwent complete resection. The - disease control rate was 96.7% (95% CI: 90.3%-99.99%), with an ORR of 55% (95% - CI: 37.2%-72.8%) and a downstaging rate of 80% (95% CI: 65.7%-94.3%). In the - subgroup of 20 patients who underwent surgery, the MPR rate was 65% (95% CI: - 43.3%-82.9%), and the pCR rate was 40% (95% CI: 21.2%-46.3%). The 2-year DFS rate - in the surgical group was 75% (95% CI 56%-94%). Notably, the MPR group - demonstrated significantly prolonged DFS compared with the non-MPR group - (p = 0.00024). A significant increase in pretreatment CD8 expression correlated - with improved DFS (p = 0.00019). Three patients (10%) experienced grade 3 or - higher immune-related AEs-one case of grade 3 elevated myocardial enzymes, one - case of grade 3 interstitial pneumonia, and one case of grade 5 bronchopleural - fistula. INTERPRETATION: Neoadjuvant immunotherapy markedly enhanced the rate of - pathological response and 2-year DFS in patients with potentially resectable - IIIA/IIIB NSCLC. Overexpression of CD8 before treatment (H score≥3) may serve as - a potential predictive biomarker for DFS. Consequently, the treatment landscape - for potentially resectable IIIA/IIIB NSCLC could undergo changes. FUNDING: This - study did not receive any financial support. -CI - © 2024 The Authors. -FAU - Sun, Chao -AU - Sun C -AD - Cancer Centre, The First Hospital of Jilin University, Changchun, Jilin, 130021, - China. -FAU - Wang, Xu -AU - Wang X -AD - Cancer Centre, The First Hospital of Jilin University, Changchun, Jilin, 130021, - China. -FAU - Xu, Yinghui -AU - Xu Y -AD - Cancer Centre, The First Hospital of Jilin University, Changchun, Jilin, 130021, - China. -FAU - Shao, Guoguang -AU - Shao G -AD - Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, - Jilin, 130021, China. -FAU - Chen, Xi -AU - Chen X -AD - Cancer Centre, The First Hospital of Jilin University, Changchun, Jilin, 130021, - China. -FAU - Liu, Yunpeng -AU - Liu Y -AD - Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, - Jilin, 130021, China. -FAU - Zhang, Peng -AU - Zhang P -AD - Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, - Jilin, 130021, China. -FAU - Lin, Xingyu -AU - Lin X -AD - Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, - Jilin, 130021, China. -FAU - Ma, Xiaobo -AU - Ma X -AD - Pathological Department, The First Hospital of Jilin University, Changchun, - Jilin, 130021, China. -FAU - Qiu, Shi -AU - Qiu S -AD - Cancer Centre, The First Hospital of Jilin University, Changchun, Jilin, 130021, - China. -FAU - He, Hua -AU - He H -AD - Cancer Centre, The First Hospital of Jilin University, Changchun, Jilin, 130021, - China. -FAU - Yang, Zhiguang -AU - Yang Z -AD - Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, - Jilin, 130021, China. -FAU - Ma, Kewei -AU - Ma K -AD - Cancer Centre, The First Hospital of Jilin University, Changchun, Jilin, 130021, - China. -LA - eng -PT - Journal Article -DEP - 20240119 -PL - England -TA - EClinicalMedicine -JT - EClinicalMedicine -JID - 101733727 -PMC - PMC10831803 -OTO - NOTNLM -OT - Chemoimmunotherapy -OT - Locally advanced -OT - Neoadjuvant -OT - Non-small cell lung cancer -OT - Potentially resectable -COIS- The authors declare that they have no conflicts of interest or competing - interests. -EDAT- 2024/02/02 06:42 -MHDA- 2024/02/02 06:43 -PMCR- 2024/01/19 -CRDT- 2024/02/02 04:12 -PHST- 2023/10/10 00:00 [received] -PHST- 2024/01/01 00:00 [revised] -PHST- 2024/01/02 00:00 [accepted] -PHST- 2024/02/02 06:43 [medline] -PHST- 2024/02/02 06:42 [pubmed] -PHST- 2024/02/02 04:12 [entrez] -PHST- 2024/01/19 00:00 [pmc-release] -AID - S2589-5370(24)00001-4 [pii] -AID - 102422 [pii] -AID - 10.1016/j.eclinm.2024.102422 [doi] -PST - epublish -SO - EClinicalMedicine. 2024 Jan 19;68:102422. doi: 10.1016/j.eclinm.2024.102422. - eCollection 2024 Feb. - -PMID- 28603200 -OWN - NLM -STAT- MEDLINE -DCOM- 20170919 -LR - 20181202 -IS - 1349-7413 (Electronic) -IS - 0911-4300 (Linking) -VI - 40 -IP - 2 -DP - 2017 -TI - [Immune-related adverse events of immune checkpoint inhibitors]. -PG - 102-108 -LID - 10.2177/jsci.40.102 [doi] -AB - Development and application of anti-CTLA-4 antibody and anti-PD-1 antibody to - cancer immunotherapy brought great survival benefits to advanced cancer patients. - They have been applied to various cancers such as melanoma, non-small cell lung - cancer, renal cell cancer, Hodgkin's disease, and head and neck cancers, and - there is no doubt that immunotherapy is becoming a standard therapy as well as - surgery, chemotherapy, and radiotherapy. On the other hand, immune-related - adverse events (irAEs) have been increasingly reported. Nevertheless, mechanisms - of the immune-mediated toxicities are still unclear. There has been a growing - interest in the elucidation of the mechanisms. This review describes the general - characteristics of irAEs induced by immune checkpoint inhibitors, especially 1. - Heterogeneity, 2. Multiplicity, 3. Durability, and 4. Correlativity. -FAU - Tadano, Hiroki -AU - Tadano H -AD - Department of Pathology, Sapporo Medical University School of Medicine. -FAU - Torigoe, Toshihiko -AU - Torigoe T -AD - Department of Pathology, Sapporo Medical University School of Medicine. -LA - jpn -PT - Journal Article -PT - Review -PL - Japan -TA - Nihon Rinsho Meneki Gakkai Kaishi -JT - Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology -JID - 9505992 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (CTLA-4 Antigen) -RN - 0 (Ipilimumab) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -RN - 31YO63LBSN (Nivolumab) -SB - IM -MH - Animals -MH - Antibodies, Monoclonal/*adverse effects/therapeutic use -MH - CTLA-4 Antigen/immunology -MH - Digestive System Diseases/etiology -MH - Endocrine System Diseases/etiology -MH - Humans -MH - Immunotherapy/*adverse effects -MH - Ipilimumab -MH - Liver Diseases/etiology -MH - Lung Diseases, Interstitial/etiology -MH - Mice -MH - Neoplasms/*drug therapy -MH - Nivolumab -MH - Programmed Cell Death 1 Receptor/immunology -MH - Skin Diseases/etiology -OTO - NOTNLM -OT - CTLA-4 -OT - PD-1 -OT - adverse events -OT - cancer immunotherapy -OT - immune checkpoint -EDAT- 2017/06/13 06:00 -MHDA- 2017/09/20 06:00 -CRDT- 2017/06/13 06:00 -PHST- 2017/06/13 06:00 [entrez] -PHST- 2017/06/13 06:00 [pubmed] -PHST- 2017/09/20 06:00 [medline] -AID - 10.2177/jsci.40.102 [doi] -PST - ppublish -SO - Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(2):102-108. doi: 10.2177/jsci.40.102. - -PMID- 37298023 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230612 -IS - 2077-0383 (Print) -IS - 2077-0383 (Electronic) -IS - 2077-0383 (Linking) -VI - 12 -IP - 11 -DP - 2023 Jun 2 -TI - Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line - Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer. -LID - 10.3390/jcm12113828 [doi] -LID - 3828 -AB - (1) Background: At present, the efficacy and safety of thoracic radiotherapy - (TRT) after chemo-immunotherapy (CT-IT) in patients with extensive-stage - small-cell lung cancer (ES-SCLC) still remain unclear. The purpose of this study - was to evaluate the role of TRT after CT-IT in patients with ES-SCLC. (2) - Methods: From January 2020 to October 2021, patients with ES-SCLC treated with - first-line anti-PD-L1 antibody plus platinum-etoposide chemotherapy were enrolled - retrospectively. The survival data and adverse events data of patients treated - with or without TRT after CT-IT were collected for analysis. (3) Results: A total - of 118 patients with ES-SCLC treated with first-line CT-IT were retrospectively - enrolled, with 45 patients with TRT and 73 patients without TRT after CT-IT. The - median PFS and OS in the CT-IT + TRT group and CT-IT only group were 8.0 months - versus 5.9 months (HR = 0.64, p = 0.025) and 22.7 months versus 14.7 months (HR = - 0.52, p = 0.015), respectively. The median PFS and OS in all 118 patients treated - with first-line CT-IT were 7.2 and 19.8 months with an ORR of 72.0%. In - multivariate analyses, liver metastasis and response to CT-IT were shown to be - independent prognostic factors of PFS (p < 0.05), while liver metastasis and bone - metastasis were independent predictive factors of OS (p < 0.05). Although TRT was - significantly associated with better PFS and OS in univariate analysis, the - association of TRT and OS failed to reach statistical significance (HR = 0.564, p - = 0.052) in multivariate analysis. There was no significant difference in adverse - events (AEs) between two treatment groups (p = 0.58). (4) Conclusions: ES-SCLC - patients treated with TRT after first-line CT-IT had prolonged PFS and OS with an - acceptable safety profile. Further prospective randomized studies are necessary - to explore the efficacy and safety of this treatment modality for ES-SCLC in - future. -FAU - Xie, Zhaoliang -AU - Xie Z -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan - 250117, China. -FAU - Liu, Jingru -AU - Liu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong University Cancer Center, Jinan 250117, China. -FAU - Wu, Min -AU - Wu M -AD - Suzhou Cancer Center Core Laboratory, The Affiliated Suzhou Hospital of Nanjing - Medical University, Suzhou 215000, China. -FAU - Wang, Xiaohan -AU - Wang X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan - 250117, China. -FAU - Lu, Yuhan -AU - Lu Y -AD - Department of Emergency Medicine, The First People's Hospital of Neijiang, - Neijiang 641099, China. -FAU - Han, Chunyan -AU - Han C -AD - Department of Radiotherapy, The Third Affiliated Hospital of Shandong First - Medical University, Jinan 250031, China. -FAU - Cong, Lei -AU - Cong L -AD - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First - Medical University, Jinan 250117, China. -FAU - Li, Jisheng -AU - Li J -AUID- ORCID: 0000-0002-4186-6228 -AD - Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan - 250012, China. -FAU - Meng, Xue -AU - Meng X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan - 250117, China. -LA - eng -GR - 2019KJL001/Science and Technology Support Plan for Youth Innovation Teams of - Universities in Shandong Province/ -GR - flzh202106/Bethune · Translational Medicine Research Foundation for Tumor - Radiotherapy/ -GR - 81972864 and 82172720/National Natural Science Foundation of China/ -PT - Journal Article -DEP - 20230602 -PL - Switzerland -TA - J Clin Med -JT - Journal of clinical medicine -JID - 101606588 -PMC - PMC10253710 -OTO - NOTNLM -OT - adverse event -OT - chemo-immunotherapy (CT-IT) -OT - extensive-stage small-cell lung cancer (ES-SCLC) -OT - survival -OT - thoracic radiotherapy (TRT) -COIS- The authors declared that there was no conflict of interest regarding the - publication of this paper. -EDAT- 2023/06/10 15:13 -MHDA- 2023/06/10 15:14 -PMCR- 2023/06/02 -CRDT- 2023/06/10 01:10 -PHST- 2023/02/08 00:00 [received] -PHST- 2023/05/04 00:00 [revised] -PHST- 2023/05/22 00:00 [accepted] -PHST- 2023/06/10 15:14 [medline] -PHST- 2023/06/10 15:13 [pubmed] -PHST- 2023/06/10 01:10 [entrez] -PHST- 2023/06/02 00:00 [pmc-release] -AID - jcm12113828 [pii] -AID - jcm-12-03828 [pii] -AID - 10.3390/jcm12113828 [doi] -PST - epublish -SO - J Clin Med. 2023 Jun 2;12(11):3828. doi: 10.3390/jcm12113828. - -PMID- 37621004 -OWN - NLM -STAT- Publisher -LR - 20231024 -IS - 1537-453X (Electronic) -IS - 0277-3732 (Linking) -VI - 46 -IP - 11 -DP - 2023 Nov 1 -TI - Correlation of Lung Immune Prognostic Index With Efficacy of PD-1/PD-L1 Inhibitor - Combined With Chemotherapy and Prognosis in Patients With Advanced Non-Small Cell - Lung Cancer. -PG - 496-502 -LID - 10.1097/COC.0000000000001035 [doi] -AB - OBJECTIVE: Non-small cell lung cancer (NSCLC) is a devastating but universal - class of lung carcinoma with an unfavorable prognosis. This paper mainly - investigated the correlation between lung immune prognostic index (LIPI) score - and combined treatment of immune checkpoint inhibitor and chemotherapy (CHT) in - patients with advanced NSCLC. METHODS: Totally, 301 advanced NSCLC patients with - programmed death-ligand 1 (PD-L1) expression ≥1% were assigned into good LIPI - group (N=113), intermediate LIPI group (N=101), and poor LIPI group (N=87) based - on LIPI scoring system, followed by treatment of CHT plus programmed cell death-1 - (PD-1)/PD-L1 inhibitor. The differences in clinical parameters between subgroups - of NSCLC patients were analyzed by χ 2 test, 1-way analysis of variance, and - Kruskal-Wallis H test. All patients were followed up until June 30, 2022, and - objective response rate, disease control rate, progression-free survival (PFS), - and overall survival (OS) were recorded. The independent associations of LIPI - score with PFS and OS were assessed via the Cox regression model. RESULTS: There - were evident differences in clinical stage and lymphocyte among the 3 subgroups - of NSCLC patients. The efficacy of PD-1/PD-L1 inhibitor combined with CHT was - better in patients with good LIPI score, manifested by higher objective response - rate and disease control rate. Moreover, LIPI score was an independent factor - influencing PFS and OS in patients with advanced NSCLC, with longer PFS and OS in - patients with good LIPI score. CONCLUSION: LIPI score has a predictive value for - combination therapy of PD-1/PD-L1 blockade and CHT in advanced NSCLC patients. -CI - Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. -FAU - Zhu, Zhongxiu -AU - Zhu Z -AD - Departments of Radiotherapy. -FAU - Zhang, Aixia -AU - Zhang A -AD - Oncology, The Third Affiliated Hospital of Shandong First Medical University - (Affiliated Hospital of Shandong Academy of Medical Sciences), Jinan, Shandong - Province, China. -LA - eng -PT - Journal Article -DEP - 20230825 -PL - United States -TA - Am J Clin Oncol -JT - American journal of clinical oncology -JID - 8207754 -SB - IM -COIS- The authors declare no conflicts of interest. -EDAT- 2023/08/25 06:42 -MHDA- 2023/08/25 06:42 -CRDT- 2023/08/25 00:02 -PHST- 2023/08/25 06:42 [pubmed] -PHST- 2023/08/25 06:42 [medline] -PHST- 2023/08/25 00:02 [entrez] -AID - 00000421-990000000-00123 [pii] -AID - 10.1097/COC.0000000000001035 [doi] -PST - ppublish -SO - Am J Clin Oncol. 2023 Nov 1;46(11):496-502. doi: 10.1097/COC.0000000000001035. - Epub 2023 Aug 25. - -PMID- 28975081 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220420 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 7 -DP - 2017 -TI - Radiotherapy for Oligometastatic Lung Cancer. -PG - 210 -LID - 10.3389/fonc.2017.00210 [doi] -LID - 210 -AB - Non-small cell lung cancer (NSCLC) typically presents at an advanced stage, which - is often felt to be incurable, and such patients are usually treated with a - palliative approach. Accumulating retrospective and prospective clinical - evidence, including a recently completed randomized trial, support the existence - of an oligometastatic disease state wherein select individuals with advanced - NSCLC may experience historically unprecedented prolonged survival with - aggressive local treatments, consisting of radiotherapy and/or surgery, to - limited sites of metastatic disease. This is reflected in the most recent AJCC - staging subcategorizing metastatic disease into intra-thoracic (M1a), a single - extra thoracic site (M1b), and more diffuse metastases (M1c). In the field of - radiation oncology, recent technological advances have allowed for the delivery - of very high, potentially ablative, doses of radiotherapy to both intra- and - extra-cranial disease sites, referred to as stereotactic radiosurgery and - stereotactic body radiotherapy (or SABR), in much shorter time periods compared - to conventional radiation and with minimal associated toxicity. At the same time, - significant improvements in systemic therapy, including platinum-based doublet - chemotherapy, molecular agents targeting oncogene-addicted NSCLC, and - immunotherapy in the form of checkpoint inhibitors, have led to improved control - of micro-metastatic disease and extended survival sparking newfound interest in - combining these agents with ablative local therapies to provide additive, and in - the case of radiation and immunotherapy, potentially synergistic, effects in - order to further improve progression-free and overall survival. Currently, - despite the tantalizing potential associated with aggressive local therapy in the - setting of oligometastatic NSCLC, well-designed prospective randomized controlled - trials sufficiently powered to detect and measure the possible added benefit - afforded by this approach are desperately needed. -FAU - Bergsma, Derek P -AU - Bergsma DP -AD - Department of Radiation Oncology, University of Rochester Medical Center, - Rochester, NY, United States. -FAU - Salama, Joseph K -AU - Salama JK -AD - Department of Radiation Oncology, Duke University Health System, Raleigh, NC, - United States. -FAU - Singh, Deepinder P -AU - Singh DP -AD - Department of Radiation Oncology, University of Rochester Medical Center, - Rochester, NY, United States. -FAU - Chmura, Steven J -AU - Chmura SJ -AD - Department of Radiation and Cellular Oncology, University of Chicago, Chicago, - IL, United States. -FAU - Milano, Michael T -AU - Milano MT -AD - Department of Radiation Oncology, University of Rochester Medical Center, - Rochester, NY, United States. -LA - eng -PT - Journal Article -PT - Review -DEP - 20170919 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC5610690 -OTO - NOTNLM -OT - lung cancer -OT - non-small cell lung cancer -OT - oligometastases -OT - oligometastatic disease -OT - stereotactic body radiotherapy -EDAT- 2017/10/05 06:00 -MHDA- 2017/10/05 06:01 -PMCR- 2017/01/01 -CRDT- 2017/10/05 06:00 -PHST- 2017/07/28 00:00 [received] -PHST- 2017/08/28 00:00 [accepted] -PHST- 2017/10/05 06:00 [entrez] -PHST- 2017/10/05 06:00 [pubmed] -PHST- 2017/10/05 06:01 [medline] -PHST- 2017/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2017.00210 [doi] -PST - epublish -SO - Front Oncol. 2017 Sep 19;7:210. doi: 10.3389/fonc.2017.00210. eCollection 2017. - -PMID- 32554618 -OWN - NLM -STAT- MEDLINE -DCOM- 20210820 -LR - 20240515 -IS - 2051-1426 (Electronic) -IS - 2051-1426 (Linking) -VI - 8 -IP - 1 -DP - 2020 Jun -TI - Chronic immune checkpoint inhibitor pneumonitis. -LID - 10.1136/jitc-2020-000840 [doi] -LID - e000840 -AB - BACKGROUND: Pneumonitis from immune checkpoint inhibitors (ICI) is a potentially - fatal immune-related adverse event (irAE) from antiprogrammed death 1/programmed - death ligand 1 immunotherapy. Most cases of ICI pneumonitis improve or resolve - with 4-6 weeks of corticosteroid therapy. Herein, we report the incidence, - clinicopathological features and management of patients with non-small cell lung - cancer (NSCLC) and melanoma who developed chronic ICI pneumonitis that warrants - ≥12 weeks of immunosuppression. METHODS: Patients with ICI pneumonitis were - identified from institutional databases of ICI-treated patients with advanced - melanoma and NSCLC between January 2011 and July 2018. ICI pneumonitis was - defined as clinical/radiographic evidence of lung inflammation without - alternative diagnoses, adjudicated by a multidisciplinary team. Chronic ICI - pneumonitis was defined as pneumonitis that persists or worsens with steroid - tapering, and necessitates ≥12 weeks of immunosuppression, after ICI - discontinuation. Serial chest CT was used to assess radiological features, and - tumor response by Response EvaluationCriteria for Solid Tumors V.1.1. - Bronchoalveolar lavage fluid (BALF) samples were assessed by cell differential. - Lung biopsy samples were evaluated by H&E staining and multiplex - immunofluorescence (mIF), where available. RESULTS: Among 299 patients, 44 - developed ICI pneumonitis (NSCLC: 5/205; melanoma: 1/94), and of these, 6 - experienced chronic ICI pneumonitis. The overall incidence of chronic ICI - pneumonitis was thus 2%. Of those who developed chronic ICI pneumonitis: the - majority had NSCLC (5/6), all sustained disease control from ICIs, and none had - other concurrent irAEs. Timing of chronic ICI pneumonitis development was - variable (range: 0-50 months), and occurred at a median of 12 months post ICI - start. Recrudescence of ICI pneumonitis occurred at a median of 6 weeks after - initial steroid start (range: 3-12 weeks), with all patients requiring steroid - reintroduction when tapered to ≤10 mg prednisone/equivalent. The median total - duration of steroids was 37 weeks (range: 16-43+weeks). Re-emergence of - radiographic ICI pneumonitis occurred in the same locations on chest CT, in most - cases (5/6). All patients who developed chronic ICI pneumonitis had BALF - lymphocytosis on cell differential and organising pneumonia on lung biopsy at - initial ICI pneumonitis presentation, with persistent BALF lymphocytosis and - brisk CD8+ infiltration on mIF at pneumonitis re-emergence during steroid taper. - CONCLUSIONS: A subset of patients who develop pneumonitis from ICIs will develop - chronic ICI pneumonitis, that warrants long-term immunosuppression of ≥12 weeks, - and has distinct clinicopathological features. -CI - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No - commercial re-use. See rights and permissions. Published by BMJ. -FAU - Naidoo, Jarushka -AU - Naidoo J -AUID- ORCID: 0000-0002-3470-8686 -AD - Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, - Baltimore, Maryland, USA jnaidoo1@jhmi.edu. -AD - The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins - University, Baltimore, Maryland, USA. -FAU - Cottrell, Tricia R -AU - Cottrell TR -AD - Pathology, Queen's University, Kingston, Ontario, Canada. -FAU - Lipson, Evan J -AU - Lipson EJ -AUID- ORCID: 0000-0003-2976-0911 -AD - Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, - Baltimore, Maryland, USA. -AD - The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins - University, Baltimore, Maryland, USA. -FAU - Forde, Patrick M -AU - Forde PM -AD - Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, - Baltimore, Maryland, USA. -AD - The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins - University, Baltimore, Maryland, USA. -FAU - Illei, Peter B -AU - Illei PB -AD - Pathology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, - Baltimore, Maryland, USA. -FAU - Yarmus, Lonny B -AU - Yarmus LB -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University, - Baltimore, Maryland, USA. -FAU - Voong, K Ranh -AU - Voong KR -AD - Radiation Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer - Center, Baltimore, Maryland, USA. -FAU - Feller-Kopman, David -AU - Feller-Kopman D -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University, - Baltimore, Maryland, USA. -FAU - Lee, Hans -AU - Lee H -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University, - Baltimore, Maryland, USA. -FAU - Riemer, Joanne -AU - Riemer J -AD - Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, - Baltimore, Maryland, USA. -FAU - Wang, Daphne -AU - Wang D -AD - Pathology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, - Baltimore, Maryland, USA. -FAU - Taube, Janis M -AU - Taube JM -AD - Pathology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, - Baltimore, Maryland, USA. -FAU - Brahmer, Julie R -AU - Brahmer JR -AD - Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, - Baltimore, Maryland, USA. -AD - The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins - University, Baltimore, Maryland, USA. -FAU - Lin, Cheng Ting -AU - Lin CT -AD - Radiology, Johns Hopkins University, Baltimore, Maryland, USA. -FAU - Danoff, Sonye K -AU - Danoff SK -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University, - Baltimore, Maryland, USA. -FAU - D'Alessio, Franco R -AU - D'Alessio FR -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University, - Baltimore, Maryland, USA. -FAU - Suresh, Karthik -AU - Suresh K -AD - Division of Pulmonary Critical Care Medicine, Johns Hopkins University, - Baltimore, Maryland, USA. -LA - eng -GR - K08 HL132055/HL/NHLBI NIH HHS/United States -GR - R01 HL151530/HL/NHLBI NIH HHS/United States -GR - T32 CA193145/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PL - England -TA - J Immunother Cancer -JT - Journal for immunotherapy of cancer -JID - 101620585 -RN - 0 (Immune Checkpoint Inhibitors) -SB - IM -EIN - J Immunother Cancer. 2020 Nov;8(2):e000840corr1. doi: - 10.1136/jitc-2020-000840corr1. PMID: 33188039 -MH - Aged -MH - Female -MH - Humans -MH - Immune Checkpoint Inhibitors/pharmacology/*therapeutic use -MH - Male -MH - Middle Aged -MH - Pneumonia/*drug therapy/pathology -MH - Retrospective Studies -PMC - PMC7304886 -OTO - NOTNLM -OT - inflammation -OT - lung neoplasms -OT - melanoma -OT - programmed cell death 1 receptor -COIS- Competing interests: JN: research funding: AstraZeneca, Merck, - Consulting/Advisory Board: AstraZeneca, Merck, Bristol-Myers Squibb, Honoraria: - AstraZeneca, Merck, Bristol-Myers Squibb. EL: research funding: Bristol-Myers - Squibb, Merck, Regeneron, Consulting/Advisory Board: Bristol-Myers Squibb, Merck, - Novartis, EMD Serono, Array BioPharma, MacroGenics, Sanofi. PMF: research - funding: AstraZeneca, Bristol-Myers Squibb, Corvus, Kyowa, Novartis, - Consulting/Advisory Board: AstraZeneca, Bristol-Myers Squibb, Janssen, Merck, - Novartis, Lilly, Boehringer. LBY: research funding: Rocket Medical, - Consulting/Advisory Board: Boston Scientific. HL: Consulting/Advisory Board: - Boston Scientific; DFK/Advisory Board: Consulting: Boston Scientific. JT: - research funding: Bristol-Myers Squibb, Consulting/Advisory Board: Bristol-Myers - Squibb, Merck, AstraZeneca. JRB: research funding: Bristol-Myers Squibb, - Consulting/Advisory Board: Bristol-Myers Squibb, Merck, AstraZeneca, and - Genentech, and reports receiving commercial. -EDAT- 2020/06/20 06:00 -MHDA- 2021/08/21 06:00 -PMCR- 2020/06/17 -CRDT- 2020/06/20 06:00 -PHST- 2020/05/07 00:00 [accepted] -PHST- 2020/06/20 06:00 [entrez] -PHST- 2020/06/20 06:00 [pubmed] -PHST- 2021/08/21 06:00 [medline] -PHST- 2020/06/17 00:00 [pmc-release] -AID - jitc-2020-000840 [pii] -AID - 10.1136/jitc-2020-000840 [doi] -PST - ppublish -SO - J Immunother Cancer. 2020 Jun;8(1):e000840. doi: 10.1136/jitc-2020-000840. - -PMID- 34148378 -OWN - NLM -STAT- MEDLINE -DCOM- 20220210 -LR - 20220210 -IS - 1744-8042 (Electronic) -IS - 1462-2416 (Linking) -VI - 22 -IP - 10 -DP - 2021 Jul -TI - KRAS-targeted therapies in advanced solid cancers: drug the undruggable? -PG - 587-590 -LID - 10.2217/pgs-2021-0045 [doi] -FAU - Saleh, Khalil -AU - Saleh K -AUID- ORCID: 0000-0002-2985-2202 -AD - Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France. -FAU - Kordahi, Manal -AU - Kordahi M -AD - Department of Pathology, National Institute of Pathology, Baabda, 1003, Lebanon. -FAU - Felefly, Tony -AU - Felefly T -AD - Department of Radiation Oncology, Hotel-Dieu de France University Hospital, - School of Medicine, Saint-Joseph University, Beirut, 1100, Lebanon. -FAU - Kourie, Hampig Raphael -AU - Kourie HR -AD - Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University, - Beirut, 1100, Lebanon. -FAU - Khalife, Nadine -AU - Khalife N -AD - Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, - France. -LA - eng -PT - Editorial -DEP - 20210621 -PL - England -TA - Pharmacogenomics -JT - Pharmacogenomics -JID - 100897350 -RN - 0 (Acetonitriles) -RN - 0 (Antineoplastic Agents) -RN - 0 (Immune Checkpoint Inhibitors) -RN - 0 (KRAS protein, human) -RN - 0 (Piperazines) -RN - 0 (Pyridines) -RN - 0 (Pyrimidines) -RN - 2B2VM6UC8G (sotorasib) -RN - 8EOO6HQF8Y (adagrasib) -RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) -SB - IM -MH - Acetonitriles/administration & dosage -MH - Antineoplastic Agents/*administration & dosage -MH - Drug Delivery Systems/*methods/trends -MH - Drug Resistance, Neoplasm/drug effects/physiology -MH - Humans -MH - Immune Checkpoint Inhibitors/*administration & dosage -MH - Neoplasms/*drug therapy/genetics/metabolism -MH - Piperazines/administration & dosage -MH - Proto-Oncogene Proteins p21(ras)/*antagonists & inhibitors/genetics/metabolism -MH - Pyridines/administration & dosage -MH - Pyrimidines/administration & dosage -OTO - NOTNLM -OT - KRASG12C mutations -OT - RAS -OT - adagrasib -OT - colorectal cancer -OT - non-small-cell lung cancer -OT - sotorasib -EDAT- 2021/06/22 06:00 -MHDA- 2022/02/11 06:00 -CRDT- 2021/06/21 05:20 -PHST- 2021/06/22 06:00 [pubmed] -PHST- 2022/02/11 06:00 [medline] -PHST- 2021/06/21 05:20 [entrez] -AID - 10.2217/pgs-2021-0045 [doi] -PST - ppublish -SO - Pharmacogenomics. 2021 Jul;22(10):587-590. doi: 10.2217/pgs-2021-0045. Epub 2021 - Jun 21. - -PMID- 38410608 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240229 -IS - 2072-1439 (Print) -IS - 2077-6624 (Electronic) -IS - 2072-1439 (Linking) -VI - 16 -IP - 1 -DP - 2024 Jan 30 -TI - Phase I/II study to evaluate consolidative hypofractionated radiation therapy for - boosting the residual primary disease in combination with durvalumab after - definitive chemoradiation therapy for stage III non-small cell lung cancer - (NSCLC): study protocol for a prospective trial. -PG - 750-759 -LID - 10.21037/jtd-23-304 [doi] -AB - BACKGROUND: Recent advancements in the management of non-small cell lung cancer - (NSCLC) have confirmed the utility of adding adjuvant immunotherapy to concurrent - chemoradiotherapy in stage III disease but intrathoracic progression remains at - high rate. Additional studies have sought to investigate the synergistic - relationship of immunotherapy and radiation therapy (RT). The goal of this study - is to evaluate the safety and efficacy of combining consolidative - hypofractionated radiation therapy (hfRT) using stereotactic body radiotherapy - (SBRT) technique for boosting the residual primary lung cancer with adjuvant - anti-programmed death-ligand 1 (PD-L1) therapy concurrently after completion of - definitive chemoradiation therapy (dCRT) in the rates of tumor control - locoregionally and distantly. METHODS: Eligible subjects with stage III NSCLC - must have gross residual tumor that is smaller than 5.0 cm in maximal dimension - following dCRT. Consolidative hfRT will be delivered 1 to 2 months after - finishing dCRT and concurrently with adjuvant anti-PD-L1 therapy using - durvalumab. Consolidative hfRT will start from 6.5 Gy ×2 fractions and dose - escalate to 10 Gy ×2 fractions in a 3+3 design. At the final determined - consolidative hfRT dose level, a total of 32 subjects with pathologically - documented stage III NSCLC treated with two or more cycles of platinum-based - doublet chemotherapy concurrently with RT will be enrolled for data analyses. - DISCUSSION: We hypothesize that the use of consolidative hfRT directed to the - residual primary lung tumor in combination with adjuvant anti-PD-L1 therapy will - provide additional immunostimulation and therefore improved locoregional and - distant control when compared to either modality used independently. - REGISTRATION: Clinicaltrials.gov: NCT04748419. -CI - 2024 Journal of Thoracic Disease. All rights reserved. -FAU - Coutu, Brendan -AU - Coutu B -AD - Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, - NE, USA. -FAU - Lawrence, Elliot -AU - Lawrence E -AD - Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, - NE, USA. -FAU - Ganti, Apar Kishor -AU - Ganti AK -AD - Division of Hematology/Oncology, Department of Medicine, VA Nebraska Western Iowa - Health Care System, Omaha, NE, USA. -AD - Division of Hematology/Oncology, Department of Medicine, University of Nebraska - Medical Center, Omaha, NE, USA. -FAU - Marr, Alissa -AU - Marr A -AD - Division of Hematology/Oncology, Department of Medicine, University of Nebraska - Medical Center, Omaha, NE, USA. -FAU - Wichman, Chris -AU - Wichman C -AD - Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, - USA. -FAU - Zhang, Chi -AU - Zhang C -AD - Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, - NE, USA. -LA - eng -SI - ClinicalTrials.gov/NCT04748419 -PT - Journal Article -DEP - 20240129 -PL - China -TA - J Thorac Dis -JT - Journal of thoracic disease -JID - 101533916 -PMC - PMC10894375 -OTO - NOTNLM -OT - Consolidative radiation therapy -OT - hypofractionated radiation therapy (hfRT) -OT - non-small cell lung cancer (NSCLC) -OT - stereotactic body radiotherapy (SBRT) -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://jtd.amegroups.com/article/view/10.21037/jtd-23-304/coif). C.Z. received - grand funding from AstraZeneca, Inc., clinical trial research funding from - BioMiMetix, and travel support from GTMedical Technologies. C.Z. reports a US - Provisional patent (63/164,215) issued which is unrelated to the current study. - A.K.G. reports Grants to his institution from Veterans Health Administration - Office of Research and Development, Merck, TAB Biosciences, NEKTAR Therapeutics, - Mirati Therapeutics, IOVANCE Therapeutics, Apexigen; Royalties from Oxford - University Press; Consulting fees from AstraZeneca, Flagship Biosciences, G1 - Therapeutics, Jazz Pharmaceuticals, Cardinal Health, Mirati Therapeutics, Beigene - Ltd., Sanofi Genzyme, Blueprint Medicines, Regeneron Pharmaceuticals; Honoraria - for lectures from MedLearning Group and Plexus Communications; DSMB for YmAbs - Therapeutics; Leadership roles in Academic and Community Cancer Research United - (ACCRU) and A Breath of Hope for Lung Cancer (ABOHLC); Receipt of drugs to the - institution from Takeda Pharmaceuticals and Chimerx. C.W. reports funding from - Chi Zhang’s grant (PI Astra Zeneca Pharmaceuticals IIT Grant; UNMC project number - MEDI4736). The other authors have no conflicts of interest to declare. -EDAT- 2024/02/27 06:45 -MHDA- 2024/02/27 06:46 -PMCR- 2024/01/30 -CRDT- 2024/02/27 03:41 -PHST- 2023/02/28 00:00 [received] -PHST- 2023/11/03 00:00 [accepted] -PHST- 2024/02/27 06:46 [medline] -PHST- 2024/02/27 06:45 [pubmed] -PHST- 2024/02/27 03:41 [entrez] -PHST- 2024/01/30 00:00 [pmc-release] -AID - jtd-16-01-750 [pii] -AID - 10.21037/jtd-23-304 [doi] -PST - ppublish -SO - J Thorac Dis. 2024 Jan 30;16(1):750-759. doi: 10.21037/jtd-23-304. Epub 2024 Jan - 29. - -PMID- 32030268 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220412 -IS - 2072-1439 (Print) -IS - 2077-6624 (Electronic) -IS - 2072-1439 (Linking) -VI - 11 -IP - 12 -DP - 2019 Dec -TI - Extended resections for the treatment of patients with T4 stage IIIA non-small - cell lung cancer (NSCLC) (T(4)N(0-1)M(0)) with or without cardiopulmonary bypass: - a 15-year two-center experience. -PG - 5489-5501 -LID - 10.21037/jtd.2019.11.33 [doi] -AB - BACKGROUND: Stage IIIA non-small cell lung cancer (NSCLC) is a heterogeneous - group of patients, often requiring variable and individualized approaches. The - dilemma to operate or not frequently arises, since more than 75% of the cases of - NSCLC are diagnosed in advanced stages (IIIA). The main objective of this study - was to assess whether the benefits outweigh surgical risks for the T(4)N(0-1)M(0) - subgroup. METHODS: Data from 857 patients with locally advanced T4 NSCLC were - retrospectively collected from two different institutions, between 2002 and 2017. - Clinical data that were retrieved and analyzed, included demographics, - comorbidities, surgical details, neoadjuvant or/and adjuvant therapy and - postoperative complications. RESULTS: Twelve patients were in the cardiopulmonary - bypass (CPB) group and thirty in the non-CPB. The most common types of lung - cancer were squamous cell carcinoma (50.0%) and adenocarcinoma (35.7%). The most - frequent invasion of the tumor was seen in main pulmonary artery and the superior - vena cava. Significantly more patients of the CPB group underwent pneumonectomy - as their primary lung resection (P=0.006). In all patients R0 resection was - achieved according to histological reports. The overall 5-year survival was 60%, - while the median overall survival was 22.5 months. Analysis revealed that patient - age (P=0.027), preoperative chronic obstructive pulmonary disease (COPD) - (P=0.001), tumor size (4.0 vs. 6.0 cm) (P=0.001), postoperative respiratory - dysfunction (P=0.001) and postoperative atelectasis (P=0.036) are possible - independent variables that are significantly correlated with patient outcome. - CONCLUSIONS: We suggest that in patients with stage IIIA/T4 NSCLC, complete - resection of the T4 tumor, although challenging, can be performed in highly - selected patients. Such an approach seems to result in improved long-term - survival. More specific studies on this area of NSCLC probably will further - enlighten this field, and may result in even better outcomes, as advanced - systemic perioperative approaches such as modern chemotherapy, immunotherapy and - improvements in radiation therapy have been incorporated in daily practice. -CI - 2019 Journal of Thoracic Disease. All rights reserved. -FAU - Filippou, Dimitrios -AU - Filippou D -AD - Cardiothoracic Department of European Interbalkan Medical Center of Thessaloniki, - Thessaloniki, Greece. -FAU - Kleontas, Athanasios -AU - Kleontas A -AD - Cardiothoracic Department of European Interbalkan Medical Center of Thessaloniki, - Thessaloniki, Greece. -FAU - Tentzeris, Vasilios -AU - Tentzeris V -AD - Thoracic Department of St. James University Hospital, Leeds, UK. -FAU - Emmanouilides, Christos -AU - Emmanouilides C -AD - Oncology Department of European Interbalkan Medical Center of Thessaloniki, - Thessaloniki, Greece. -FAU - Tryfon, Stavros -AU - Tryfon S -AD - Pulmonology Department of "Papanikolaou" General Hospital of Thessaloniki, - Thessaloniki, Greece. -FAU - Baka, Sofia -AU - Baka S -AD - Oncology Department of European Interbalkan Medical Center of Thessaloniki, - Thessaloniki, Greece. -FAU - Filippou, Ioanna -AU - Filippou I -AD - Pulmonology Department of "Papanikolaou" General Hospital of Thessaloniki, - Thessaloniki, Greece. -FAU - Papagiannopoulos, Kostas -AU - Papagiannopoulos K -AD - Thoracic Department of St. James University Hospital, Leeds, UK. -LA - eng -PT - Journal Article -PL - China -TA - J Thorac Dis -JT - Journal of thoracic disease -JID - 101533916 -PMC - PMC6987995 -OTO - NOTNLM -OT - Extended resection -OT - carcinoma -OT - cardiopulmonary bypass (CPB) -OT - non-small cell lung cancer (NSCLC) -COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. -EDAT- 2020/02/08 06:00 -MHDA- 2020/02/08 06:01 -PMCR- 2019/12/01 -CRDT- 2020/02/08 06:00 -PHST- 2020/02/08 06:00 [entrez] -PHST- 2020/02/08 06:00 [pubmed] -PHST- 2020/02/08 06:01 [medline] -PHST- 2019/12/01 00:00 [pmc-release] -AID - jtd-11-12-5489 [pii] -AID - 10.21037/jtd.2019.11.33 [doi] -PST - ppublish -SO - J Thorac Dis. 2019 Dec;11(12):5489-5501. doi: 10.21037/jtd.2019.11.33. - -PMID- 36647464 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230118 -IS - 2072-1439 (Print) -IS - 2077-6624 (Electronic) -IS - 2072-1439 (Linking) -VI - 14 -IP - 12 -DP - 2022 Dec -TI - Efficacy and safety comparison of PD-1 inhibitors vs. PD-L1 inhibitors in - extensive-stage small-cell lung cancer: a retrospective comparative cohort study. -PG - 4925-4937 -LID - 10.21037/jtd-22-1682 [doi] -AB - BACKGROUND: Evidence from clinical research and meta-analyses have suggested that - programmed cell death 1 (PD-1) inhibitors and programmed cell death ligand 1 - (PD-L1) inhibitors plus chemotherapy could achieve a significant survival benefit - for extensive-stage small-cell lung cancer (ES-SCLC) patients. However clinical - researches concerned about the comparation between the PD-1 and PD-L1 inhibitors - were relatively lacking. METHODS: We collected the data of ES-SCLC patients - treated with PD-1 inhibitors or PD-L1 inhibitors. The primary endpoints were - overall survival (OS) and progression-free survival (PFS). Secondary endpoint - included adverse events (AEs). RESULTS: The data of 221 ES-SCLC patients treated - with PD-1 (n=146) or PD-L1 inhibitors (n=75) between February 2017 and June 2020 - were retrospectively collected. The median OS (mOS) and median PFS (mPFS) were - 19.07 and 8.27 months, respectively, in patients treated with PD-1 inhibitors. In - the PD-L1 group, mOS has not been reached, and mPFS was 7.95 months. No - significant differences were observed between the 2 groups in OS [hazard ratio - (HR), 1.472; 95% confidence interval (CI), 0.847-2.220; P=0.198] and PFS (HR, - 0.816; 95% CI, 0.577-1.155; P=0.251). The rates of patients showed AEs of any - grade treated with PD-1 or PD-L1 were 67.12% and 64.00%, with no significant - difference (P=0.642, χ(2)=0.216), ≥3 grade AEs occurred in 42 (28.76%) and 16 - (21.33%) patients treated with PD-1 and PD-L1 inhibitors separately, also no - significant difference (P=0.234, χ(2)=1.415) was observed. According to subgroup - analysis, camrelizumab revealed a longer mPFS (15.17 months) compared with other - immune-checkpoint inhibitors (ICIs). PD-1 and PD-L1 inhibitors revealed - comparable efficacy in ES-SCLC patients with brain metastases, with no - significant differences in OS (HR, 1.505; 95% CI, 0.684-3.311; P=0.309) and PFS - (HR, 0.649; 95% CI, 0.356-1.182; P=0.157). CONCLUSIONS: PD-1 and PD-L1 inhibitors - might achieved comparable survival benefit and safety in ES-SCLC patients. A - longer PFS was observed in patients treated with PD-1 inhibitors in the - first-line treatment, and the PD-1 inhibitor camrelizumab might have achieved a - better PFS compared with other ICIs. -CI - 2022 Journal of Thoracic Disease. All rights reserved. -FAU - Yang, Guanghui -AU - Yang G -AD - Cheeloo College of Medicine, Shandong University, Jinan, China. -AD - Department of Oncology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, - Shandong University, Qingdao, China. -FAU - Sun, Hongfu -AU - Sun H -AD - Cheeloo College of Medicine, Shandong University, Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Sun, Nini -AU - Sun N -AD - Radiotherapy Center, Xi'an International Medical Center Hospital, Xi'an, China. -FAU - Huang, Wei -AU - Huang W -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Wang, Zhongtang -AU - Wang Z -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Zhang, Huawei -AU - Zhang H -AD - Department of Ultrasound in Medicine, Provincial Hospital Affiliated to Shandong - First Medical University, Jinan, China. -FAU - Liu, Chengxin -AU - Liu C -AD - Cheeloo College of Medicine, Shandong University, Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -LA - eng -PT - Journal Article -PL - China -TA - J Thorac Dis -JT - Journal of thoracic disease -JID - 101533916 -PMC - PMC9840043 -OTO - NOTNLM -OT - Extensive-stage small-cell lung cancer (ES-SCLC) -OT - immune-checkpoint inhibitors (ICIs) -OT - programmed cell death 1 (PD-1) inhibitors -OT - programmed cell death ligand 1 (PD-L1) inhibitors -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://jtd.amegroups.com/article/view/10.21037/jtd-22-1682/coif). The authors - have no conflicts of interest to declare. -EDAT- 2023/01/18 06:00 -MHDA- 2023/01/18 06:01 -PMCR- 2022/12/01 -CRDT- 2023/01/17 01:46 -PHST- 2022/11/02 00:00 [received] -PHST- 2022/12/19 00:00 [accepted] -PHST- 2023/01/17 01:46 [entrez] -PHST- 2023/01/18 06:00 [pubmed] -PHST- 2023/01/18 06:01 [medline] -PHST- 2022/12/01 00:00 [pmc-release] -AID - jtd-14-12-4925 [pii] -AID - 10.21037/jtd-22-1682 [doi] -PST - ppublish -SO - J Thorac Dis. 2022 Dec;14(12):4925-4937. doi: 10.21037/jtd-22-1682. - -PMID- 34475934 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220426 -IS - 1682-024X (Print) -IS - 1681-715X (Electronic) -IS - 1681-715X (Linking) -VI - 37 -IP - 5 -DP - 2021 Sep-Oct -TI - Effect of Intensity Modulated Radiotherapy (IMRT) on the immunity, physical - status and clinical effect of locally advanced NSCLC patients. -PG - 1480-1485 -LID - 10.12669/pjms.37.5.4188 [doi] -AB - OBJECTIVES: To evaluate the clinical value of radiotherapy combined with - Camrelizumab in treating locally advanced non-small cell lung cancer (NSCLC) - patients. METHODS: 80 locally advanced NSCLC patients were randomly divided into - two groups (n=40). The control group was administered with intensity modulated - radiation therapy (IMRT), whereas the experimental group with Camrelizumab in - addition to IMRT. All the patients underwent clinical efficacy evaluation in - terms of adverse drug reaction (ADR), physical status improvement after the - treatment, and changes in T lymphocyte subpopulations (incl. CD3(+), CD4(+), - CD8(+), CD4(+)/CD8(+)). RESULTS: The efficacy was found to be 70% and 47.5 in - experimental group and control group, respectively, with the former being - significantly better than the latter (p=0.03). The ADR rates were 50% and 37.5% - in the experimental group and control group, respectively; but the difference - remained insignificant (p=0.26). As for physical status improvement, experimental - group evidently excelled the control group (p=0.04). The post-treatment - indicators such as CD3(+), CD4(+), CD8(+), CD4(+)/CD8(+) were significantly more - improved in the experimental group than the control group (CD3(+), p=0.02; - CD4(+), p=0.00; and CD4(+)/CD8(+), p=0.01). However, the changes in CD8+ were not - significant at all (p=0.46). CONCLUSIONS: The combined therapy of IMRT with - Camrelizumab appeared effective in dealing with the locally advanced NSCLC - patients, as such patients presented significantly better immune state and - physical status improvement but not increased ADR. The therapy is both safe and - effective. -CI - Copyright: © Pakistan Journal of Medical Sciences. -FAU - Xu, Jun-Kai -AU - Xu JK -AD - Jun-kai Xu Department of Radiotherapy, The Affiliated Hospital (Group) of Putian - University, Putian, 351100, P.R. China. -LA - eng -PT - Journal Article -PL - Pakistan -TA - Pak J Med Sci -JT - Pakistan journal of medical sciences -JID - 100913117 -PMC - PMC8377908 -OTO - NOTNLM -OT - Camrelizumab -OT - IMRT -OT - NSCLC -OT - locally advanced -OT - treatment -COIS- Conflict of interest: The authors declare that there is no conflict of interest. -EDAT- 2021/09/04 06:00 -MHDA- 2021/09/04 06:01 -PMCR- 2021/09/01 -CRDT- 2021/09/03 06:49 -PHST- 2021/01/12 00:00 [received] -PHST- 2021/04/20 00:00 [revised] -PHST- 2021/04/28 00:00 [accepted] -PHST- 2021/09/03 06:49 [entrez] -PHST- 2021/09/04 06:00 [pubmed] -PHST- 2021/09/04 06:01 [medline] -PHST- 2021/09/01 00:00 [pmc-release] -AID - PJMS-37-1480 [pii] -AID - 10.12669/pjms.37.5.4188 [doi] -PST - ppublish -SO - Pak J Med Sci. 2021 Sep-Oct;37(5):1480-1485. doi: 10.12669/pjms.37.5.4188. - -PMID- 36262804 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20221101 -IS - 1178-6930 (Print) -IS - 1178-6930 (Electronic) -IS - 1178-6930 (Linking) -VI - 15 -DP - 2022 -TI - Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in - Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a - Year After Standard Treatment. -PG - 1221-1228 -LID - 10.2147/OTT.S380615 [doi] -AB - PURPOSE: As for local advanced non-small cell lung cancer (NSCLC), synchronous - radiotherapy and chemotherapy is the standard treatment mode. But for patients - with progress in half a year, which means the second-line chemotherapy effect is - not ideal for them. We observed the efficacy and safety of anlotinib - hydrochloride combined with PD-1 blockade as the second-line treatment for those - patients in this trial. PATIENTS AND METHODS: From January 2018 to December 2019, - 57 patients with the progress of local advanced NSCLC treated with anlotinib plus - PD-1 blockade until disease progression or intolerance as a result of adverse - events. Patients have been assessed using computed tomography prior to treatment - and during follow-up every 2 months until disease progression or death. The - primary endpoint was objective response rate (ORR). The secondary endpoints - included overall survival (OS), progression-free survival (PFS) and safety. - Survival curves were created using the Kaplan-Meier method. RESULTS: 57 patients - were enrolled. The median age was 64 years, and 61.4% of the patients were men. - The ORR was 50.9% with a median OS time of 14 months and the 1-year OS rates and - PFS rates were 81.8% and 33.3%, respectively. The patients with squamous cell - carcinoma, no brain or liver metastases had longer PFS than patients with liver - metastasis. When the PFS was calculated from the time of second treatment, the - median PFS was 9 months. Most adverse events (AEs) were grade 1-3, one - drug-related death was noted. CONCLUSION: The expected outcome of this study is - that anlotinib combined with PD-1 blockade has tolerable toxicity and better ORR, - OS than second-line chemotherapy. The results may indicate additional treatment - options for patients with progress of local advance NSCLC in half a year after - standard treatment. -CI - © 2022 Yu et al. -FAU - Yu, Chengqi -AU - Yu C -AD - School of Basic Medical Science, Capital Medical University, Beijing, 100069, - People's Republic of China. -FAU - Jiang, Leilei -AU - Jiang L -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department of Radiation Oncology, Peking University Cancer - Hospital and Institute, Beijing, People's Republic of China. -FAU - Yang, Dan -AU - Yang D -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department of Radiation Oncology, Peking University Cancer - Hospital and Institute, Beijing, People's Republic of China. -FAU - Dong, Xin -AU - Dong X -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department of Radiation Oncology, Peking University Cancer - Hospital and Institute, Beijing, People's Republic of China. -FAU - Yu, Rong -AU - Yu R -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department of Radiation Oncology, Peking University Cancer - Hospital and Institute, Beijing, People's Republic of China. -FAU - Yu, Huiming -AU - Yu H -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education/Beijing), Department of Radiation Oncology, Peking University Cancer - Hospital and Institute, Beijing, People's Republic of China. -LA - eng -PT - Journal Article -DEP - 20221017 -PL - New Zealand -TA - Onco Targets Ther -JT - OncoTargets and therapy -JID - 101514322 -PMC - PMC9575589 -OTO - NOTNLM -OT - PD-1 blockade -OT - angiogenesis -OT - anlotinib -OT - immunotherapy -OT - local advanced non-small cell lung cancer -COIS- The authors report no conflicts of interest in this work. -EDAT- 2022/10/21 06:00 -MHDA- 2022/10/21 06:01 -PMCR- 2022/10/17 -CRDT- 2022/10/20 02:45 -PHST- 2022/07/04 00:00 [received] -PHST- 2022/10/01 00:00 [accepted] -PHST- 2022/10/20 02:45 [entrez] -PHST- 2022/10/21 06:00 [pubmed] -PHST- 2022/10/21 06:01 [medline] -PHST- 2022/10/17 00:00 [pmc-release] -AID - 380615 [pii] -AID - 10.2147/OTT.S380615 [doi] -PST - epublish -SO - Onco Targets Ther. 2022 Oct 17;15:1221-1228. doi: 10.2147/OTT.S380615. - eCollection 2022. - -PMID- 39357279 -OWN - NLM -STAT- Publisher -LR - 20241002 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 212 -DP - 2024 Sep 29 -TI - Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with - untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK - 2004). -PG - 115052 -LID - S0959-8049(24)01018-9 [pii] -LID - 10.1016/j.ejca.2024.115052 [doi] -AB - BACKGROUND: The effect of dual immunotherapy combined with platinum-based - chemotherapy on untreated brain metastases derived from non-small cell lung - cancer (NSCLC) has remained unclear. METHODS: This multicenter single-arm phase 2 - study enrolled patients with chemotherapy-naïve advanced NSCLC and at least one - brain metastasis ≥ 5 mm in size that had not been previously treated. Patients - received nivolumab plus ipilimumab combined with platinum-doublet chemotherapy - (two cycles), followed by nivolumab-ipilimumab alone. The primary endpoint of the - study was intracranial response rate as determined by modified Response - Evaluation Criteria in Solid Tumors (RECIST) for brain metastases of ≥ 5 mm as - target lesions. RESULTS: A total of 30 patients from 18 institutions was enrolled - in this study. The median age was 66.5 years (range, 47-83 years), and 26 - patients (87 %) had a non-squamous cell carcinoma histology. The median size of - all target brain lesions was 8.4 mm, with a range of 5-39 mm. The intracranial - response rate assessed by modified RECIST was 50.0 % (95 % CI, 33.2-66.8 %), with - the rate of complete response being 20.0 %, and the study met its primary - endpoint. The systemic response rate was 53.3 % (95 % CI, 36.1-69.8 %), and - responses for intracranial and extracranial lesions were generally consistent. - The median intracranial progression-free survival was 8.1 months, and both the - median intracranial duration of response and time to brain radiotherapy were not - reached. CONCLUSION: Nivolumab plus ipilimumab combined with platinum-based - chemotherapy showed promising intracranial activity in NSCLC patients with - untreated brain metastases. TRIAL REGISTRATION: jRCT071210019. -CI - Copyright © 2024 Elsevier Ltd. All rights reserved. -FAU - Tsuchiya-Kawano, Yuko -AU - Tsuchiya-Kawano Y -AD - Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, 2-1-1 - Bashaku, Kokurakita-ku, Kitakyushu, Fukuoka 802-0077, Japan. -FAU - Shiraishi, Yoshimasa -AU - Shiraishi Y -AD - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu - University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. -FAU - Tanaka, Kentaro -AU - Tanaka K -AD - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu - University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. -FAU - Tachihara, Motoko -AU - Tachihara M -AD - Division of Respiratory Medicine, Department of Internal Medicine, Kobe - University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo - 650-0017, Japan. -FAU - Saito, Ryota -AU - Saito R -AD - Department of Respiratory Medicine, Tohoku University, 1-1 Seiryo-machi, Aoba-ku, - Sendai, Miyagi 980-8574, Japan. -FAU - Okamoto, Tatsuro -AU - Okamoto T -AD - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer - Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan. -FAU - Sugasaki, Nanae -AU - Sugasaki N -AD - Department of Respiratory Medicine, Nagasaki Prefecture Shimabara Hospital, 7895 - Shimokawashiri-machi, Shimabara, Nagasaki 855-0861, Japan. -FAU - Nakatomi, Keita -AU - Nakatomi K -AD - Department of Respiratory Medicine, Kyushu Central Hospital, 3-23-1 Shiobaru, - Minami-ku, Fukuoka 815-0032, Japan. -FAU - Kiyomi, Fumiaki -AU - Kiyomi F -AD - Clinical Research Support Center Kyushu, 3-1-1 Maidashi, Higashi-ku, Fukuoka - 812-8582, Japan. -FAU - Okamoto, Isamu -AU - Okamoto I -AD - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu - University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Electronic - address: okamoto.isamu.290@m.kyushu-u.ac.jp. -LA - eng -PT - Journal Article -DEP - 20240929 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -SB - IM -OTO - NOTNLM -OT - Immunotherapy -OT - Nivolumab plus ipilimumab with chemotherapy -OT - Non–small cell lung cancer (NSCLC) -OT - Untreated brain metastases -COIS- Declaration of Competing Interest The authors declare the following financial - interests/personal relationships which may be considered as potential competing - interests: Y Tsuchiya-Kawano has received personal fees from Bristol-Myers - Squibb, Taiho Pharmaceutical, Chugai Pharmaceutical, AstraZeneca, Kyowa hakko - Kirin, MSD, Ono Pharmaceutical, and Takeda Pharmaceutical outside the submitted - work. Y Shiraishi has received grants and personal fees from Chugai - Pharmaceutical as well as personal fees from Ono Pharmaceutical, Taiho - Pharmaceutical, AstraZeneca, Bristol-Myers Squibb, and Kyowa Kirin outside the - submitted work. K Tanaka has received personal fees from Chugai Pharmaceutical, - Ono Pharmaceutical, AstraZeneca, Daiichi Sankyo, Eli Lilly, Merck, Takeda - Pharmaceutical, Pfizer, MSD, Novartis, and Bristol-Myers Squibb outside the - submitted work. M Tachihara has received grants from AstraZeneca, Chugai - Pharmaceutical, and Eli Lilly as well as personal fees from Eli Lilly, Ono - Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, AstraZeneca, MSD, - Novartis Pharmaceuticals, Takeda Pharmaceutical, Taiho Pharmaceutical, Boehringer - Ingelheim, Daiichi Sankyo, Pfizer, and Janssen Pharmaceutical outside the - submitted work. T Okamoto has received grants from Chugai Pharmaceutical, - AstraZeneca, Boehringer Ingelheim, MSD, Eli Lilly, and Bristol-Myers Squibb as - well as personal fees from AstraZeneca, Boehringer Ingelheim, Chugai - Pharmaceutical, Ono Pharmaceutical, MSD, Eli Lilly, and Bristol-Myers Squibb - outside the submitted work. I Okamoto has received grants from Chugai - Pharmaceutical, AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, Ono - Pharmaceutical, MSD, Eli Lilly, Astellas, Bristol-Myers Squibb, Novartis, Pfizer, - and AbbVie; consulting fees from AstraZeneca, Bristol-Myers Squibb, and AbbVie; - and personal fees from AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, - Chugai Pharmaceutical, Ono Pharmaceutical, MSD, Eli Lilly, Bristol-Myers Squibb, - Novartis, and Pfizer outside the submitted work. All other authors declare no - competing interests. -EDAT- 2024/10/03 00:42 -MHDA- 2024/10/03 00:42 -CRDT- 2024/10/02 18:07 -PHST- 2024/07/15 00:00 [received] -PHST- 2024/09/04 00:00 [revised] -PHST- 2024/09/23 00:00 [accepted] -PHST- 2024/10/03 00:42 [medline] -PHST- 2024/10/03 00:42 [pubmed] -PHST- 2024/10/02 18:07 [entrez] -AID - S0959-8049(24)01018-9 [pii] -AID - 10.1016/j.ejca.2024.115052 [doi] -PST - aheadofprint -SO - Eur J Cancer. 2024 Sep 29;212:115052. doi: 10.1016/j.ejca.2024.115052. - -PMID- 39077862 -OWN - NLM -STAT- Publisher -LR - 20240730 -IS - 2532-5264 (Electronic) -IS - 1122-0643 (Linking) -DP - 2024 Jul 26 -TI - Survival among patients with lung cancer managed at a tertiary care center in - North India. -LID - 10.4081/monaldi.2024.3045 [doi] -AB - Though there has been advancement in the management of lung cancer, it is not - well utilized due to its limited availability and high cost. This is a - prospective observational study done at a tertiary care center from January 2014 - to December 2022, involving patients with primary lung cancer. After - tumor-node-metastasis staging and molecular testing, the patients received - chemotherapy, radiotherapy, surgery, targeted therapy, and immunotherapy in - various combinations as per the prevailing National Comprehensive Cancer Network - Guidelines. 92 patients were enrolled in the study, with the mean age being - 58.94±10.33 and 72 (78.26%) being males. 69 (75%) patients were either current or - former smokers. 78 (84.78%) patients had an Eastern Cooperative Oncology Group - (ECOG) score of 0-2 while the remaining had an ECOG of 3-4. 80 (86.95%) patients - had non-small cell lung cancer (NSCLC) [44 (47.83%) adenocarcinoma, 25 (27.17%) - squamous cell carcinoma, and 11 (11.95%) NSCLC: not otherwise specified], while - 12 (13.04%) patients had small cell lung cancer. One (1.08%) patient each - presented in stage I and stage II, 31 (33.69%) patients presented in stage III, - and 59 (64.13%) patients presented in stage IV. 44 patients with adenocarcinoma - were subjected to mutational analysis, and an epidermal growth factor receptor - mutation was found in 13 (29.5%) patients. None of the patients had ALK mutation, - ROS-1 rearrangement, or BRAF mutation. PD-L1 expression was evaluated in 9 - patients with NSCLC, and it was found in 6 (66.66%) patients. The overall mean - survival was 12.7 months. The mean survival for patients with stages I, II, III, - and IV was 70, 96, 8.1, and 12.7 months, respectively. Survival in stage IV was - better than in stage III, as the eligible patients received targeted therapy and - immunotherapy. Targeted therapy and immunotherapy have improved survival. - Molecular analysis should be done whenever indicated, and eligible patients must - be administered targeted therapy and immunotherapy. -FAU - Kumar, Rahul -AU - Kumar R -AD - Department of Pulmonary, Critical Care and Sleep Medicine, ESI-PGIMSR, - Basaidarapur, New Delhi. rahul1205@gmail.com. -FAU - Gothi, Dipti -AU - Gothi D -AD - Department of Pulmonary, Critical Care and Sleep Medicine, ESI-PGIMSR, - Basaidarapur, New Delhi. diptigothi@gmail.com. -FAU - Anand, Shweta -AU - Anand S -AD - Department of Chest and Respiratory Medicine, Delhi State Cancer Institute, - Delhi. drshwetaanand89@gmail.com. -FAU - Khan, Shazia -AU - Khan S -AD - Department of Pulmonary Medicine, American International Institute of Medical - Sciences, Udaipur, Rajasthan. kshazia129@gmail.com. -FAU - Malhotra, Nipun -AU - Malhotra N -AD - Department of Pulmonary, Critical Care and Sleep Medicine, ESI-PGIMSR, - Basaidarapur, New Delhi. therightpad@gmail.com. -LA - eng -PT - Journal Article -DEP - 20240726 -PL - Italy -TA - Monaldi Arch Chest Dis -JT - Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace -JID - 9307314 -SB - IM -EDAT- 2024/07/30 12:43 -MHDA- 2024/07/30 12:43 -CRDT- 2024/07/30 06:04 -PHST- 2024/05/02 00:00 [received] -PHST- 2024/05/24 00:00 [accepted] -PHST- 2024/07/30 12:43 [medline] -PHST- 2024/07/30 12:43 [pubmed] -PHST- 2024/07/30 06:04 [entrez] -AID - 10.4081/monaldi.2024.3045 [doi] -PST - aheadofprint -SO - Monaldi Arch Chest Dis. 2024 Jul 26. doi: 10.4081/monaldi.2024.3045. - -PMID- 36299962 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230106 -IS - 2168-8184 (Print) -IS - 2168-8184 (Electronic) -IS - 2168-8184 (Linking) -VI - 14 -IP - 9 -DP - 2022 Sep -TI - Four-Phase, Definitive Chemoradiation for a Real-World (Poor Risk and/or Elderly) - Patient Population With Locally Advanced Non-small Cell Lung Cancer. -PG - e29423 -LID - 10.7759/cureus.29423 [doi] -LID - e29423 -AB - Introduction With the incorporation of modernized radiotherapy, chemotherapy, and - immunotherapy, treatment outcomes have improved for patients with locally - advanced, unresectable diseases. Elderly or poor performance status patients - comprise more than half of non-small cell lung cancer (NSCLC) patients, but they - are often underrepresented or excluded in clinical trials. Split-course - concurrent chemoradiotherapy can be an effective treatment, showing good - adherence and a favorable toxicity profile for unresectable, locally advanced - NSCLC. Method We identified locally advanced NSCLC cancer patients via a single - institution retrospective study. Patients were treated using a four-phase, - split-course external beam radiotherapy approach with concurrent chemotherapy. - The primary endpoints analyzed were completion rate, incidence, and severity of - treatment-related toxicities, progression-free survival (PFS), and median overall - survival (OS). Results Thirty-nine locally advanced lung cancer patients were - treated with split-course chemoradiation (CRT). The median age at diagnosis was - 73 years old. Seventeen patients had an Eastern Cooperative Oncology Group (ECOG) - performance score of 2. Twenty-three patients had a clinical diagnosis of chronic - obstructive pulmonary disease (COPD), and 10 patients were on home oxygen at the - time of diagnosis. All patients completed 6000 centigrays (cGy) of radiation, and - 95% of the patients completed at least three cycles of concurrent chemotherapy. - No patients experienced grade 3 to 5 acute thoracic toxicities. Overall median - survival was 12.7 months, and PFS was 7.5 months. Conclusion Our retrospective - analysis of 39 poor risk and/or elderly patients with locoregional NSCLC treated - with concurrent CRT via a split-course regimen suggests favorable oncologic - outcomes and superb treatment completion rates and toleration. -CI - Copyright © 2022, Zhou et al. -FAU - Zhou, Yu M -AU - Zhou YM -AD - Radiation Oncology, Rush University Medical Center, Chicago, USA. -FAU - Shin, Jacob -AU - Shin J -AD - Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York City, USA. -FAU - Jelinek, Michael -AU - Jelinek M -AD - Medical Oncology, Rush University Medical Center, Chicago, USA. -FAU - Fidler, Mary J -AU - Fidler MJ -AD - Medical Oncology, Rush University Medical Center, Chicago, USA. -FAU - Batus, Marta -AU - Batus M -AD - Medical Oncology, Rush University Medical Center, Chicago, USA. -FAU - Bonomi, Philip D -AU - Bonomi PD -AD - Medical Oncology, Rush University Medical Center, Chicago, USA. -FAU - Marwaha, Gaurav -AU - Marwaha G -AD - Radiation Oncology, Rush University Medical Center, Chicago, USA. -LA - eng -GR - P30 CA008748/CA/NCI NIH HHS/United States -PT - Journal Article -DEP - 20220921 -PL - United States -TA - Cureus -JT - Cureus -JID - 101596737 -PMC - PMC9586742 -OTO - NOTNLM -OT - advanced non-small-cell lung cancer -OT - concurrent chemoradiation therapy -OT - geriatric medicine -OT - intensity modulated radiotherapy -OT - palliative radiation therapy -COIS- The authors have declared that no competing interests exist. -EDAT- 2022/10/28 06:00 -MHDA- 2022/10/28 06:01 -PMCR- 2022/09/21 -CRDT- 2022/10/27 02:38 -PHST- 2022/09/15 00:00 [accepted] -PHST- 2022/10/27 02:38 [entrez] -PHST- 2022/10/28 06:00 [pubmed] -PHST- 2022/10/28 06:01 [medline] -PHST- 2022/09/21 00:00 [pmc-release] -AID - 10.7759/cureus.29423 [doi] -PST - epublish -SO - Cureus. 2022 Sep 21;14(9):e29423. doi: 10.7759/cureus.29423. eCollection 2022 - Sep. - -PMID- 27073525 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220408 -IS - 1792-1074 (Print) -IS - 1792-1082 (Electronic) -IS - 1792-1074 (Linking) -VI - 11 -IP - 4 -DP - 2016 Apr -TI - Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment - of advanced non-small cell lung cancer. -PG - 2605-2610 -AB - The present study aimed to evaluate the survival time, immune response and safety - of a dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell therapy - (DC-CIK) in advanced non-small cell lung cancer (NSCLC). The present - retrospective study enrolled 507 patients with advanced NSCLC; 99 patients - received DC-CIK [immunotherapy group (group I)] and 408 matched patients did not - receive DC-CIK, and acted as the control [non-immunotherapy group (group NI)]. - Delayed-type hypersensitivity (DTH), quality of life (QOL) and safety were - analyzed in group I. The follow-up period for the two groups was 489.2±160.4 - days. The overall survival (OS) time was calculated using the Kaplan-Meier - method. DTH was observed in 59 out of 97 evaluated patients (60.8%) and 67 out of - 98 evaluated patients (68.4%) possessed an improved QOL. Fever and a skin rash - occurred in 36 out of 98 patients (36.7%) and 7 out of 98 patients (7.1%) in - group I. DTH occurred more frequently in patients with squamous cell carcinoma - compared with patients with adenocarcinoma (77.1 vs. 40.4%; P=0.0013). - Radiotherapy was not associated with DC-CIK-induced DTH (72.7 vs. 79.6%; P=0.18), - but chemotherapy significantly reduced the rate of DTH (18.2 vs. 79.6%; P=0.00). - The OS time was significantly increased in group I compared with group NI - (P=0.03). In conclusion, DC-CIK may induce an immune response against NSCLC, - improve the QOL, and prolong the OS time of patients, without adverse effects. - Therefore, the present study recommends DC-CIK for the treatment of patients with - advanced NSCLC. -FAU - Zhang, Lihong -AU - Zhang L -AD - School of Medicine, Nankai University, Tianjin 300071, P.R. China; Department of - Oncology, Tianjin Union Medicine Centre, Tianjin 300121, P.R. China. -FAU - Yang, Xuejing -AU - Yang X -AD - Department of Oncology, Tianjin Union Medicine Centre, Tianjin 300121, P.R. - China; Shanghai Claison Biotechnology Co., Ltd., Shanghai 201201, P.R. China. -FAU - Sun, Zhen -AU - Sun Z -AD - Department of Oncology, Tianjin Union Medicine Centre, Tianjin 300121, P.R. - China; Shanghai Claison Biotechnology Co., Ltd., Shanghai 201201, P.R. China. -FAU - Li, Jiali -AU - Li J -AD - Department of Oncology, Tianjin Union Medicine Centre, Tianjin 300121, P.R. - China. -FAU - Zhu, Hui -AU - Zhu H -AD - Department of Oncology, Tianjin Union Medicine Centre, Tianjin 300121, P.R. - China. -FAU - Li, Jing -AU - Li J -AD - Department of Oncology, Tianjin Union Medicine Centre, Tianjin 300121, P.R. - China. -FAU - Pang, Yan -AU - Pang Y -AD - Department of Oncology, Tianjin Union Medicine Centre, Tianjin 300121, P.R. - China. -LA - eng -PT - Journal Article -DEP - 20160224 -PL - Greece -TA - Oncol Lett -JT - Oncology letters -JID - 101531236 -PMC - PMC4812113 -OTO - NOTNLM -OT - cytokine-induced killer cells -OT - dendritic cell vaccine -OT - immunotherapy -OT - non-small cell lung cancer -EDAT- 2016/04/14 06:00 -MHDA- 2016/04/14 06:01 -PMCR- 2016/02/24 -CRDT- 2016/04/14 06:00 -PHST- 2015/02/03 00:00 [received] -PHST- 2016/01/26 00:00 [accepted] -PHST- 2016/04/14 06:00 [entrez] -PHST- 2016/04/14 06:00 [pubmed] -PHST- 2016/04/14 06:01 [medline] -PHST- 2016/02/24 00:00 [pmc-release] -AID - OL-0-0-4273 [pii] -AID - 10.3892/ol.2016.4273 [doi] -PST - ppublish -SO - Oncol Lett. 2016 Apr;11(4):2605-2610. doi: 10.3892/ol.2016.4273. Epub 2016 Feb - 24. - -PMID- 28761384 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20200930 -IS - 1179-2728 (Print) -IS - 1179-2728 (Electronic) -IS - 1179-2728 (Linking) -VI - 8 -DP - 2017 -TI - New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab. -PG - 67-78 -LID - 10.2147/LCTT.S113177 [doi] -AB - The era of immunotherapy has changed the face of how we approach treatment for - many oncologic and hematologic malignancies. Lung cancer has been in the - forefront of checkpoint inhibition for the past 2 years and has paved the path - for other subspecialties. While PD-1 inhibitors nivolumab and pembrolizumab have - been approved for non-small cell lung cancer (NSCLC), this review focuses on - atezolizumab, its landmark studies, and ongoing trials. Atezolizumab is the first - programmed death ligand 1 (PD-L1) inhibitor to receive US Food and Drug - Administration (FDA) approval for metastatic NSCLC patients who have progressed - on frontline chemotherapy. This approval was based on two open-label Phase II - multicenter trials, POPLAR (NCT01903993) and BIRCH (NCT02031458). Both studies - revealed a benefit in overall survival (OS), progression-free survival, and - response rate in the atezolizumab arm when compared to single-agent docetaxol. - There were also fewest Grade 3-5 treatment-related adverse events (TRAEs) in the - atezolizumab cohort. The open-label randomized Phase III OAK trial (NCT02008227) - further established the role of atezolizumab in previously treated NSCLC. This - study compared atezolizumab with docetaxel in patients with advanced NSCLC - (squamous or nonsquamous histologies) who had progressed on one to two prior - chemotherapy regimens. OS in the PD-L1-enriched population was superior in the - atezolizumab arm (n=241) at 15.7 months compared with docetaxel (n=222) at 10.3 - months (hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.58-0.93; - p=0.0102). Patients lacking PD-L1 also had survival benefit with atezolizumab - with a median OS (mOS) of 12.6 months versus 8.9 months with chemotherapy (HR - 0.75, 95% CI 0.59-0.96). Benefit was noted in both squamous and nonsquamous NSCLC - subsets and regardless of PD-L1 expressivity. As seen in the POPLAR and BIRCH - studies, the toxicity profile was significantly better with immunotherapy. The - future is unfolding rapidly as new checkpoint inhibitors are gaining FDA - approval. It is still not known if these agents will be used in combination with - chemotherapy, with other immune-modulating agents, radiation therapy, or all of - the above. The results of these studies investigating their use in combination - with chemotherapy agents, with other immunotherapy agents such as CTLA-4 - inhibitors, and with radiation therapy, are eagerly awaited. -FAU - Seetharamu, Nagashree -AU - Seetharamu N -AD - Monter Cancer Center, Hofstra-Northwell Health School of Medicine, Lake Success, - NY, USA. -FAU - Preeshagul, Isabel R -AU - Preeshagul IR -AD - Monter Cancer Center, Hofstra-Northwell Health School of Medicine, Lake Success, - NY, USA. -FAU - Sullivan, Kevin M -AU - Sullivan KM -AD - Monter Cancer Center, Hofstra-Northwell Health School of Medicine, Lake Success, - NY, USA. -LA - eng -PT - Journal Article -PT - Review -DEP - 20170713 -PL - New Zealand -TA - Lung Cancer (Auckl) -JT - Lung Cancer (Auckland, N.Z.) -JID - 101632521 -PMC - PMC5516873 -OTO - NOTNLM -OT - ADCC -OT - CDC -OT - PD-1 -OT - PD-L1 -OT - checkpoint inhibition -COIS- Disclosure The authors report no conflicts of interest in this work. -EDAT- 2017/08/02 06:00 -MHDA- 2017/08/02 06:01 -PMCR- 2017/07/13 -CRDT- 2017/08/02 06:00 -PHST- 2017/08/02 06:00 [entrez] -PHST- 2017/08/02 06:00 [pubmed] -PHST- 2017/08/02 06:01 [medline] -PHST- 2017/07/13 00:00 [pmc-release] -AID - lctt-8-067 [pii] -AID - 10.2147/LCTT.S113177 [doi] -PST - epublish -SO - Lung Cancer (Auckl). 2017 Jul 13;8:67-78. doi: 10.2147/LCTT.S113177. eCollection - 2017. - -PMID- 22820413 -OWN - NLM -STAT- MEDLINE -DCOM- 20130328 -LR - 20181202 -IS - 1531-703X (Electronic) -IS - 1040-8746 (Linking) -VI - 24 -IP - 6 -DP - 2012 Nov -TI - Targeted therapy in brain metastasis. -PG - 679-86 -LID - 10.1097/CCO.0b013e3283571a1c [doi] -AB - PURPOSE OF REVIEW: To review the state of the art and new developments in the - field of targeted agents for brain metastases. RECENT FINDINGS: The huge amount - of information on new molecular compounds and the advances in understanding the - molecular pathways that mediate brain colonization have led to an increase of - interest in preclinical and clinical investigations in the field of brain - metastases. Targeted therapies can be employed either on established brain - metastases or in a prevention setting. Targeting angiogenesis is an attractive - approach. Up to date, large clinical trial datasets have shown that - antiangiogenic agents do not increase the risk of bleeding into the brain. - Bevacizumab (an anti-VEGF agent) is undergoing investigation in clinical trials - on brain metastases from non-small cell lung cancer (NSCLC), breast cancer and - melanoma. Sunitinib, a multitarget small molecule tyrosine kinase inhibitor - (TKI), is a promising agent in brain metastases from renal cell cancer. The EGFR - inhibitors gefitinib and erlotinib have a definite activity in brain metastases - from NSCLC with activating EGFR mutations. Regarding HER2-positive breast cancer - patients with established brain metastases, lapatinib (small molecule TKI) seems - particularly active in association with capecitabine. Lapatinib alone is - attractive in the prevention setting. Brain metastases from melanoma with BRAF - V600E mutations respond to a specific inhibitor, such as vemurafenib. The - immunomodulator ipilimumab is also active on brain metastases from melanoma. - SUMMARY: The use of targeted agents in brain metastases from solid tumors is - promising. The setting of prevention will be probably expanded in the next years. - Well designed clinical trials with proper endpoints are needed. -FAU - Soffietti, Riccardo -AU - Soffietti R -AD - Division of Neuro-oncology, Department of Neuroscience, University and San - Giovanni Battista Hospital, Torino, Italy. riccardo.soffietti@unito.it -FAU - Trevisan, Elisa -AU - Trevisan E -FAU - Rudà, Roberta -AU - Rudà R -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - Curr Opin Oncol -JT - Current opinion in oncology -JID - 9007265 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antineoplastic Agents) -RN - 0 (Ipilimumab) -RN - 0 (Quinazolines) -RN - 0VUA21238F (Lapatinib) -RN - NQU9IPY4K9 (cediranib) -SB - IM -MH - Animals -MH - Antibodies, Monoclonal/pharmacology/therapeutic use -MH - Antineoplastic Agents/pharmacology/therapeutic use -MH - Brain Neoplasms/blood supply/*drug therapy/*secondary -MH - Clinical Trials as Topic -MH - Humans -MH - Ipilimumab -MH - Lapatinib -MH - *Molecular Targeted Therapy -MH - Neovascularization, Pathologic/prevention & control -MH - Quinazolines/pharmacology/therapeutic use -EDAT- 2012/07/24 06:00 -MHDA- 2013/03/30 06:00 -CRDT- 2012/07/24 06:00 -PHST- 2012/07/24 06:00 [entrez] -PHST- 2012/07/24 06:00 [pubmed] -PHST- 2013/03/30 06:00 [medline] -AID - 10.1097/CCO.0b013e3283571a1c [doi] -PST - ppublish -SO - Curr Opin Oncol. 2012 Nov;24(6):679-86. doi: 10.1097/CCO.0b013e3283571a1c. - -PMID- 32021337 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220412 -IS - 1178-6981 (Print) -IS - 1178-6981 (Electronic) -IS - 1178-6981 (Linking) -VI - 12 -DP - 2020 -TI - Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who - Received Two or More Lines of Therapy in Europe. -PG - 23-33 -LID - 10.2147/CEOR.S223760 [doi] -AB - PURPOSE: Advanced non-small-cell lung cancer (aNSCLC; stage IIIB/IV) presents a - substantial clinical burden to society; reliable estimates of its economic burden - are lacking. Therefore, this study aimed to quantify real-world health care - resource utilization (HCRU) and costs of patients with squamous (SQ) and non-SQ - (NSQ) aNSCLC who received two or more lines of treatment (2L+) in Europe, and to - describe cost-predictors. METHODS: The LENS (Leading the Evaluation of - Non-squamous and Squamous NSCLC) retrospective chart review study collected data - from 2L+ patients with aNSCLC diagnosed between 07/2009 and 08/2011 (wave 1) or - 07/2010 and 09/2012 (wave 2) in France, Germany, Italy, Spain, England, the - Netherlands, and Sweden. Patients were followed from diagnosis through most - recent visit/death. A weighted average of country-specific unit costs (2018 Euro) - was applied to systemic anti-cancer therapy usage and HCRU (hospital/emergency - department visit, surgery, radiotherapy, ancillary care, biomarker testing) to - determine the total cost from aNSCLC diagnosis to death. Generalized linear - models (gamma distribution, log link) were used to assess clinical and - demographic predictors. RESULTS: Of 973 2L+ aNSCLC patients, median overall - survival (OS) was 1.5 years from advanced diagnosis (range: 0.2-5.3; median OS: - 1.4 [SQ], 1.6 [NSQ]), 79.0% died during follow-up. Weighted mean total - per-patient costs were €21,273, ranging from €17,761 (England) to €30,854 - (Sweden), and €15,446 (SQ) to €26,477 (NSQ). Systemic drug costs comprised 77.4% - of total costs. Insurance status, presence of epidermal growth factor receptor - (EGFR) mutation, SQ histology, age, alcohol abuse, and year of diagnosis were - significant predictors for lower total costs per patient-month, Eastern - Cooperative Oncology Group performance status (ECOG PS) ≥1 and country for higher - costs. CONCLUSION: In the era pre-immunotherapy, HCRU and costs were substantial - in aNSCLC 2L+ patients, with most of the costs accrued prior to start of 2L. NSQ - patients incurred significantly higher total costs than SQ patients in all - participating countries. -CI - © 2020 Verleger et al. -FAU - Verleger, Katharina -AU - Verleger K -AD - Pharmerit International, Berlin, Germany. -FAU - Penrod, John R -AU - Penrod JR -AD - Bristol-Myers Squibb, Princeton, NJ, USA. -FAU - Manley Daumont, Melinda -AU - Manley Daumont M -AD - Bristol-Myers Squibb, Braine-L'alleud, Belgium. -FAU - Solem, Caitlyn -AU - Solem C -AUID- ORCID: 0000-0002-4914-8052 -AD - Pharmerit International, Bethesda, MD, USA. -FAU - Luo, Linlin -AU - Luo L -AD - Pharmerit International, Bethesda, MD, USA. -FAU - Macahilig, Cynthia -AU - Macahilig C -AD - Medical Data Analytics, Parsippany, NJ, USA. -FAU - Hertel, Nadine -AU - Hertel N -AD - Bristol-Myers Squibb, Uxbridge, UK. -LA - eng -PT - Journal Article -DEP - 20200115 -PL - New Zealand -TA - Clinicoecon Outcomes Res -JT - ClinicoEconomics and outcomes research : CEOR -JID - 101560564 -PMC - PMC6970261 -OTO - NOTNLM -OT - carcinoma -OT - cost of illness -OT - health care costs -OT - non-small-cell lung -OT - observational study -COIS- Katharina Verleger, Caitlyn Solem, and Linlin Luo are employees of Pharmerit, - which was contracted by Bristol-Myers Squibb to conduct the retrospective chart - review study. Cynthia Macahilig is an employee of Medical Data Analytics, which - was contracted by Bristol-Myers Squibb to collect and consolidate the data for - this study. Nadine Hertel, Melinda Manley Daumont, and John R Penrod are - employees of Bristol-Myers Squibb, a global biopharmaceutical company that - researches and develops medicines for NSCLC. The authors report no other - conflicts of interest in this work. -EDAT- 2020/02/06 06:00 -MHDA- 2020/02/06 06:01 -PMCR- 2020/01/15 -CRDT- 2020/02/06 06:00 -PHST- 2019/07/18 00:00 [received] -PHST- 2019/12/10 00:00 [accepted] -PHST- 2020/02/06 06:00 [entrez] -PHST- 2020/02/06 06:00 [pubmed] -PHST- 2020/02/06 06:01 [medline] -PHST- 2020/01/15 00:00 [pmc-release] -AID - 223760 [pii] -AID - 10.2147/CEOR.S223760 [doi] -PST - epublish -SO - Clinicoecon Outcomes Res. 2020 Jan 15;12:23-33. doi: 10.2147/CEOR.S223760. - eCollection 2020. - -PMID- 37456701 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240922 -IS - 1507-1367 (Print) -IS - 2083-4640 (Electronic) -IS - 1507-1367 (Linking) -VI - 28 -IP - 2 -DP - 2023 -TI - Locally advanced non-small cell lung cancer: current issues and recent trends. -PG - 286-303 -LID - 10.5603/RPOR.a2023.0019 [doi] -AB - The focus of this paper was to review and summarise the current issues and recent - trends within the framework of locally advanced (LA) non-small cell lung cancer - (NSCLC). The recently proposed 8(th) tumour-node-metastases (TNM) staging system - exhibited significant amendments in the distribution of the T and M descriptors. - Every revision to the TNM classification should contribute to clinical - improvement. This is particularly necessary regarding LA NSCLC stratification, - therapy and outcomes. While several studies reported the superiority of the 8(th) - TNM edition in comparison to the previous 7(th) TNM edition, in terms of both the - discrimination ability among the various T subgroups and clinical outcomes, - others argued against this interpretation. Synergistic cytotoxic chemotherapy - with radiotherapy is most prevalent in treating LA NSCLC. Clinical trial - experience from multiple references has reported that the risk of locoregional - relapse and distant metastasis was less evident for patients treated with - concomitant radiochemotherapy than radiotherapy alone. Nevertheless, concern - persists as to whether major incidences of toxicity may occur due to the addition - of chemotherapy. Cutting-edge technologies such as four-dimensional computed - tomography (4D-CT) and volumetric modulated arc therapy (VMAT) should yield - therapeutic gains due to their capability to conform radiation doses to tumours. - On the basis of the preceding notion, the optimum radiotherapy technique for LA - NSCLC has been a controversial and much-disputed subject within the field of - radiation oncology. Notably, no single-perspective research has been undertaken - to determine the optimum radiotherapy modality for LA NSCLC. The landscape of - immunotherapy in lung cancer is rapidly expanding. Currently, the standard of - care for patients with inoperable LA NSCLC is concurrent chemoradiotherapy - followed by maintenance durvalumab according to clinical outcomes from the - PACIFIC trial. An estimated 42.9% of patients randomly assigned to durvalumab - remained alive at five years, and free of disease progression, thereby - establishing a new benchmark for the standard of care in this setting. -CI - © 2023 Greater Poland Cancer Centre. -FAU - Alaswad, Mohammed -AU - Alaswad M -AD - Comprehensive Cancer Centre, Radiation Oncology, King Fahad Medical City, Riyadh, - Kingdom of Saudi Arabia. -AD - Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230626 -PL - Poland -TA - Rep Pract Oncol Radiother -JT - Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer - Center in Poznan and Polish Society of Radiation Oncology -JID - 100885761 -PMC - PMC10348324 -OTO - NOTNLM -OT - concurrent radiochemotherapy -OT - immune checkpoint inhibitors -OT - immunotherapy -OT - locally advanced-non-small cell lung cancer -OT - passive scattering proton therapy -OT - proton therapy -OT - radiotherapy -OT - sequential radiochemotherapy -OT - tumour node metastases -OT - volumetric modulated arc therapy -COIS- Conflict of interest None declared -EDAT- 2023/07/17 06:42 -MHDA- 2023/07/17 06:43 -PMCR- 2023/06/26 -CRDT- 2023/07/17 04:27 -PHST- 2022/08/16 00:00 [received] -PHST- 2023/03/29 00:00 [accepted] -PHST- 2023/07/17 06:43 [medline] -PHST- 2023/07/17 06:42 [pubmed] -PHST- 2023/07/17 04:27 [entrez] -PHST- 2023/06/26 00:00 [pmc-release] -AID - rpor-28-2-286 [pii] -AID - 10.5603/RPOR.a2023.0019 [doi] -PST - epublish -SO - Rep Pract Oncol Radiother. 2023 Jun 26;28(2):286-303. doi: - 10.5603/RPOR.a2023.0019. eCollection 2023. - -PMID- 35321433 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220829 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 12 -DP - 2022 -TI - Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage - Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case - Report. -PG - 846597 -LID - 10.3389/fonc.2022.846597 [doi] -LID - 846597 -AB - Small-cell lung cancer (SCLC) is a highly malignant, rapidly developing group of - diseases with poor biological behavior. Most patients have extensive-stage SCLC - (ES-SCLC) when they are first diagnosed. Standard chemotherapy is prone to - relapse in a short period of time, and the patients' median overall survival (OS) - can reach only 13 months when chemotherapy is given in combination with PD-L1 - inhibitors. To date, no studies have verified the efficacy and safety of the - composite treatment of ES-SCLC with penpulimab and anlotinib despite some - recognized data and advantages related to this regimen. Penpulimab, a novel PD-1 - inhibitor with an IgG1 subtype, has a structural modification of the Fc segment - which can prevent the immune cells from being phagocytosed or killed and can - steadily avoid tumor immune escape. This case report describes a 71-year-old man - who had ES-SCLC for 7 years which progressed after receiving standard systemic - chemotherapy combined with radiotherapy. The third-line treatment of four cycles - of anlotinib and carilizumab was discontinued because of grade 2 immune-related - pneumonia despite the efficacy being evaluated as stable disease. After - maintaining 22 months of progression-free survival, the patient relapsed and - switched to a safer regimen of penpulimab combined with anlotinib to continue the - treatment for four cycles. Partial response evaluation was confirmed twice, and - the patient remained in good general condition. The combination of penpulimab and - anlotinib can positively regulate the therapeutic effect by simultaneously acting - on the tumor microenvironment and promoting blood vessel normalization. In - general, this case provides support for the successful possibility of a - rechallenge with immune checkpoint inhibitors, the better clinical efficacy of - cross-line therapy with anlotinib, and the drug safety of penpulimab, suggesting - a beneficial therapy for the clinical treatment of ES-SCLC. -CI - Copyright © 2022 Zhang, Li, Dong, Li, Zhang, Zhang and Cui. -FAU - Zhang, Zibo -AU - Zhang Z -AD - Graduate School of Dalian Medical University, Dalian Medical University, Dalian, - China. -FAU - Li, Yujun -AU - Li Y -AD - Graduate School of Dalian Medical University, Dalian Medical University, Dalian, - China. -FAU - Dong, Yan -AU - Dong Y -AD - Department of Oncology, The First Affiliated Hospital of Dalian Medical - University, Dalian Medical University, Dalian, China. -FAU - Li, Jia -AU - Li J -AD - Department of Oncology, The First Affiliated Hospital of Dalian Medical - University, Dalian Medical University, Dalian, China. -FAU - Zhang, Bin -AU - Zhang B -AD - Department of Oncology, The First Affiliated Hospital of Dalian Medical - University, Dalian Medical University, Dalian, China. -FAU - Zhang, Chunxia -AU - Zhang C -AD - Department of Oncology, The First Affiliated Hospital of Dalian Medical - University, Dalian Medical University, Dalian, China. -FAU - Cui, Xiaonan -AU - Cui X -AD - Department of Oncology, The First Affiliated Hospital of Dalian Medical - University, Dalian Medical University, Dalian, China. -LA - eng -PT - Case Reports -DEP - 20220307 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -EIN - Front Oncol. 2022 Aug 02;12:980842. doi: 10.3389/fonc.2022.980842. PMID: 36033531 -PMC - PMC8937034 -OTO - NOTNLM -OT - ICI rechallenge -OT - anlotinib -OT - case report -OT - penpulimab -OT - small-cell lung cancer -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/03/25 06:00 -MHDA- 2022/03/25 06:01 -PMCR- 2022/01/01 -CRDT- 2022/03/24 05:14 -PHST- 2021/12/31 00:00 [received] -PHST- 2022/02/03 00:00 [accepted] -PHST- 2022/03/24 05:14 [entrez] -PHST- 2022/03/25 06:00 [pubmed] -PHST- 2022/03/25 06:01 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2022.846597 [doi] -PST - epublish -SO - Front Oncol. 2022 Mar 7;12:846597. doi: 10.3389/fonc.2022.846597. eCollection - 2022. - -PMID- 38854944 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240611 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 13 -IP - 5 -DP - 2024 May 31 -TI - A novel HLA-DQB2::MET gene fusion variant in lung adenocarcinoma with prolonged - response to tepotinib: a case report. -PG - 1163-1168 -LID - 10.21037/tlcr-24-34 [doi] -AB - BACKGROUND: MET rearrangements are infrequently observed in non-small cell lung - cancer (NSCLC). Advanced genomic detection techniques have unveiled such - infrequent genomic variations, particularly MET fusions in approximately 0.5% of - NSCLC patients. Tyrosine kinase inhibitors (TKIs) have revolutionized the - standard of care in lung cancer and more recently a second generation MET TKI - tepotinib received Food and Drug Administration (FDA) approval for MET exon 14 - alterations in metastatic NSCLC. Despite this, the therapeutic landscape for - MET-rearranged NSCLC patients remains significantly unexplored. The aim of our - report is to detail a unique case of a patient with metastatic lung - adenocarcinoma with a novel HLA-DQB2::MET fusion detected by next-generation - sequencing (NGS) following previous treatment resistance. CASE DESCRIPTION: A - 73-year-old female was initially started on carboplatin, pemetrexed and - pembrolizumab with maintenance, but eventually had progression in the left upper - lobe (LUL). Upon progression she was enrolled in a clinical trial of a monoclonal - antibody with or without a PD-1 inhibitor, but brain metastasis progression was - eventually detected by magnetic resonance imaging (MRI) requiring stereotactic - radiosurgery (SRS) and a craniotomy. The trial drug was eventually discontinued - due to progression and toxicity and NGS on bronchoscopy tissue revealed - HLA-DQB2::MET fusion. The patient was initiated on tepotinib and continues with - clinical and radiological stable disease for over 12 months. The patient's - response to a MET inhibitor, tepotinib, underscores the potential efficacy of - selective MET inhibitors for individuals with previously unexplored MET fusions. - CONCLUSIONS: The positive response to tepotinib of a patient with NSCLC harboring - a novel MET-Fusion underscores the importance of the use of comprehensive - next-generational sequencing-based panels and highlights the necessity for - additional research and clinical exploration of selective MET inhibitors for - managing NSCLC with MET rearrangements. -CI - 2024 Translational Lung Cancer Research. All rights reserved. -FAU - Dias E Silva, Douglas -AU - Dias E Silva D -AD - Department of Medical Oncology and Therapeutic Research, City of Hope National - Medical Center, Duarte, CA, USA. -AD - Department of Medical Oncology, Hospital Israelita Albert Einstein, Sao Paulo, - Brazil. -FAU - Mambetsariev, Isa -AU - Mambetsariev I -AD - Department of Medical Oncology and Therapeutic Research, City of Hope National - Medical Center, Duarte, CA, USA. -FAU - Fricke, Jeremy -AU - Fricke J -AD - Department of Medical Oncology and Therapeutic Research, City of Hope National - Medical Center, Duarte, CA, USA. -FAU - Babikian, Razmig -AU - Babikian R -AD - Department of Medical Oncology and Therapeutic Research, City of Hope National - Medical Center, Duarte, CA, USA. -FAU - Dingal, Shaira Therese -AU - Dingal ST -AD - Department of Medical Oncology and Therapeutic Research, City of Hope National - Medical Center, Duarte, CA, USA. -FAU - Mazdisnian, Farhad -AU - Mazdisnian F -AD - Department of Medicine, City of Hope, Duarte, CA, USA. -FAU - Badie, Behnam -AU - Badie B -AD - Department of Surgery, City of Hope, Duarte, CA, USA. -FAU - Arvanitis, Leonidas -AU - Arvanitis L -AD - Department of Pathology, City of Hope, Duarte, CA, USA. -FAU - Afkhami, Michelle -AU - Afkhami M -AD - Department of Pathology, City of Hope, Duarte, CA, USA. -FAU - Villalona-Calero, Miguel -AU - Villalona-Calero M -AD - Department of Medical Oncology and Therapeutic Research, City of Hope National - Medical Center, Duarte, CA, USA. -FAU - Salgia, Ravi -AU - Salgia R -AUID- ORCID: 0000-0001-9643-7626 -AD - Department of Medical Oncology and Therapeutic Research, City of Hope National - Medical Center, Duarte, CA, USA. -LA - eng -PT - Case Reports -PT - Journal Article -DEP - 20240529 -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -PMC - PMC11157375 -OTO - NOTNLM -OT - HLA-DQB2::MET fusion -OT - Non-small cell lung cancer (NSCLC) -OT - case report -OT - targeted therapy -OT - tepotinib -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-34/coif). The authors - have no conflicts of interest to declare. -EDAT- 2024/06/10 06:42 -MHDA- 2024/06/10 06:43 -PMCR- 2024/05/31 -CRDT- 2024/06/10 05:29 -PHST- 2024/01/11 00:00 [received] -PHST- 2024/03/20 00:00 [accepted] -PHST- 2024/06/10 06:43 [medline] -PHST- 2024/06/10 06:42 [pubmed] -PHST- 2024/06/10 05:29 [entrez] -PHST- 2024/05/31 00:00 [pmc-release] -AID - tlcr-13-05-1163 [pii] -AID - 10.21037/tlcr-24-34 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2024 May 31;13(5):1163-1168. doi: 10.21037/tlcr-24-34. - Epub 2024 May 29. - -PMID- 29875199 -OWN - NLM -STAT- MEDLINE -DCOM- 20190322 -LR - 20190322 -IS - 2046-2441 (Electronic) -IS - 2046-2441 (Linking) -VI - 8 -IP - 6 -DP - 2018 Jun -TI - Cancer immunotherapy: broadening the scope of targetable tumours. -LID - 10.1098/rsob.180037 [doi] -LID - 180037 -AB - Cancer immunotherapy has experienced remarkable advances in recent years. - Striking clinical responses have been achieved for several types of solid cancers - (e.g. melanoma, non-small cell lung cancer, bladder cancer and mismatch - repair-deficient cancers) after treatment of patients with T-cell checkpoint - blockade therapies. These have been shown to be particularly effective in the - treatment of cancers with high mutation burden, which places tumour-mutated - antigens (neo-antigens) centre stage as targets of tumour immunity and cancer - immunotherapy. With current technologies, neo-antigens can be identified in a - short period of time, which may support the development of complementary, - personalized approaches that increase the number of tumours amenable to - immunotherapeutic intervention. In addition to reviewing the state of the art in - cancer immunotherapy, we discuss potential avenues that can bring the - immunotherapy revolution to a broader patient group including cancers with low - mutation burden. -CI - © 2018 The Authors. -FAU - van den Bulk, Jitske -AU - van den Bulk J -AUID- ORCID: 0000-0002-2056-9478 -AD - Department of Pathology, LUMC, Leiden, The Netherlands. -FAU - Verdegaal, Els Me -AU - Verdegaal EM -AD - Department of Clinical Oncology, LUMC, Leiden, The Netherlands. -FAU - de Miranda, Noel Fcc -AU - de Miranda NF -AD - Department of Pathology, LUMC, Leiden, The Netherlands n.f.de_miranda@lumc.nl. -LA - eng -PT - Journal Article -PT - Research Support, Non-U.S. Gov't -PT - Review -PL - England -TA - Open Biol -JT - Open biology -JID - 101580419 -RN - 0 (Antigens, Neoplasm) -RN - 0 (Antineoplastic Agents, Immunological) -SB - IM -MH - Antigens, Neoplasm/metabolism -MH - Antineoplastic Agents, Immunological/pharmacology/*therapeutic use -MH - Clinical Trials as Topic -MH - Humans -MH - Immunotherapy/*methods -MH - Molecular Targeted Therapy -MH - Mutation -MH - Neoplasms/*drug therapy/genetics/immunology -MH - Precision Medicine -PMC - PMC6030119 -OTO - NOTNLM -OT - checkpoint blockade -OT - combination therapies -OT - immunogenicity -OT - immunotherapy -OT - mutation burden -OT - neo-antigens -COIS- We declare we have no competing interests. -EDAT- 2018/06/08 06:00 -MHDA- 2019/03/23 06:00 -PMCR- 2018/06/06 -CRDT- 2018/06/08 06:00 -PHST- 2018/02/26 00:00 [received] -PHST- 2018/05/11 00:00 [accepted] -PHST- 2018/06/08 06:00 [entrez] -PHST- 2018/06/08 06:00 [pubmed] -PHST- 2019/03/23 06:00 [medline] -PHST- 2018/06/06 00:00 [pmc-release] -AID - rsob.180037 [pii] -AID - rsob180037 [pii] -AID - 10.1098/rsob.180037 [doi] -PST - ppublish -SO - Open Biol. 2018 Jun;8(6):180037. doi: 10.1098/rsob.180037. - -PMID- 31099649 -OWN - NLM -STAT- MEDLINE -DCOM- 20191112 -LR - 20240717 -IS - 1548-8756 (Electronic) -IS - 1548-8748 (Print) -IS - 1548-8748 (Linking) -VI - 39 -DP - 2019 Jan -TI - Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging - Strategies and Combination Therapies. -PG - 165-174 -LID - 10.1200/EDBK_237987 [doi] -AB - Emerging immunotherapeutic approaches have revolutionized the treatment of - multiple malignancies. Immune checkpoint blockers (ICBs) have enabled - never-before-seen success rates in durable tumor control and enhanced survival - benefit in patients with advanced cancers. However, this effect is not universal, - resulting in responder and nonresponder populations not only between, but also - within solid tumor types. Although ICBs are thought to be most effective against - tumors with more genetic mutations and higher antigen loads, this is not always - the case for all cancers or for all patients within a cancer subtype. - Furthermore, debilitating and sometimes deadly immune-related adverse events - (irAEs) have resulted from aberrant activation of T-cell responses following - immunotherapy. Thus, we must identify new ways to overcome resistance to - ICB-based immunotherapies and limit irAEs. In fact, preclinical and clinical data - have identified abnormalities in the tumor microenvironment (TME) that can thwart - the efficacy of immunotherapies such as ICBs. Here, we will discuss how - reprogramming various facets of the TME (blood vessels, myeloid cells, and - regulatory T cells [Tregs]) may overcome TME-instigated resistance mechanisms to - immunotherapy. We will discuss clinical applications of this strategic approach, - including the recent successful phase III trial combining bevacizumab with - atezolizumab and chemotherapy for metastatic nonsquamous non-small cell lung - cancer that led to rapid approval by the U.S. Food and Drug Administration of - this regimen for first-line treatment. Given the accelerated testing and approval - of ICBs combined with various targeted therapies in larger numbers of patients - with cancer, we will discuss how these concepts and approaches can be - incorporated into clinical practice to improve immunotherapy outcomes. -FAU - Datta, Meenal -AU - Datta M -AD - 1 Department of Radiation Oncology, Massachusetts General Hospital, Harvard - Medical School, Boston, MA. -FAU - Coussens, Lisa M -AU - Coussens LM -AD - 2 Department of Cell, Developmental & Cancer Biology, Knight Cancer Institute, - Oregon Health & Science University, Portland, OR. -FAU - Nishikawa, Hiroyoshi -AU - Nishikawa H -AD - 3 From the Division of Cancer Immunology, Research Institute, Exploratory - Oncology Research & Clinical Trial Center, National Cancer Center Japan, Tokyo, - Japan. -FAU - Hodi, F Stephen -AU - Hodi FS -AD - 4 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical - School, Boston, MA. -FAU - Jain, Rakesh K -AU - Jain RK -AD - 1 Department of Radiation Oncology, Massachusetts General Hospital, Harvard - Medical School, Boston, MA. -LA - eng -GR - P01 CA080124/CA/NCI NIH HHS/United States -GR - R01 CA208205/CA/NCI NIH HHS/United States -GR - R35 CA197743/CA/NCI NIH HHS/United States -GR - U01 CA224348/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Review -DEP - 20190517 -PL - United States -TA - Am Soc Clin Oncol Educ Book -JT - American Society of Clinical Oncology educational book. American Society of - Clinical Oncology. Annual Meeting -JID - 101233985 -RN - 0 (Angiogenesis Inhibitors) -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Angiogenesis Inhibitors/pharmacology/therapeutic use -MH - Animals -MH - Antineoplastic Agents, Immunological/pharmacology/therapeutic use -MH - Biomarkers, Tumor -MH - Cellular Reprogramming/*genetics/*immunology -MH - Combined Modality Therapy -MH - Disease Progression -MH - Humans -MH - Immunomodulation -MH - Immunotherapy -MH - Molecular Targeted Therapy -MH - Myeloid Cells/immunology/metabolism -MH - Neoplasms/*etiology/*pathology/therapy -MH - Neovascularization, Pathologic/genetics/immunology -MH - T-Lymphocyte Subsets/immunology/metabolism -MH - T-Lymphocytes, Regulatory/immunology/metabolism -MH - Treatment Outcome -MH - Tumor Microenvironment/*genetics/*immunology -PMC - PMC6596289 -MID - NIHMS1034608 -COIS- AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY - STATEMENT Disclosures provided by the authors and data availability (if - applicable) are available with this article at DOI - https://doi.org/10.1200/EDBK_237987. -EDAT- 2019/05/18 06:00 -MHDA- 2019/11/13 06:00 -PMCR- 2019/11/17 -CRDT- 2019/05/18 06:00 -PHST- 2019/05/18 06:00 [entrez] -PHST- 2019/05/18 06:00 [pubmed] -PHST- 2019/11/13 06:00 [medline] -PHST- 2019/11/17 00:00 [pmc-release] -AID - 10.1200/EDBK_237987 [doi] -PST - ppublish -SO - Am Soc Clin Oncol Educ Book. 2019 Jan;39:165-174. doi: 10.1200/EDBK_237987. Epub - 2019 May 17. - -PMID- 39267061 -OWN - NLM -STAT- MEDLINE -DCOM- 20240913 -LR - 20240915 -IS - 1477-3155 (Electronic) -IS - 1477-3155 (Linking) -VI - 22 -IP - 1 -DP - 2024 Sep 12 -TI - Preparation and effects of functionalized liposomes targeting breast cancer - tumors using chemotherapy, phototherapy, and immunotherapy. -PG - 558 -LID - 10.1186/s12951-024-02838-1 [doi] -LID - 558 -AB - Breast cancer therapy has significantly advanced by targeting the programmed cell - death-ligand 1/programmed cell death-1 (PD-L1/PD-1) pathway. BMS-202 (a - smallmolecule PD-L1 inhibitor) induces PD-L1 dimerization to block PD-1/PD-L1 - interactions, allowing the T-cell-mediated immune response to kill tumor cells. - However, immunotherapy alone has limited effects. Clinically approved - photodynamic therapy (PDT) activates immunity and selectively targets malignant - cells. However, PDT aggravates hypoxia, which may compromise its therapeutic - efficacy and promote tumor metastasis. We designed a tumor-specific delivery - nanoplatform of liposomes that encapsulate the hypoxia-sensitive antitumor drug - tirapazamine (TPZ) and the small-molecule immunosuppressant BMS. New indocyanine - green (IR820)-loaded polyethylenimine-folic acid (PEI-FA) was complexed with TPZ - and BMS-loaded liposomes via electrostatic interactions to form lipid - nanocomposites. This nanoplatform can be triggered by near-infrared irradiation - to induce PDT, resulting in a hypoxic tumor environment and activation of the - prodrug TPZ to achieve efficient chemotherapy. The in vitro and in vivo studies - demonstrated excellent combined PDT, chemotherapy, and immunotherapy effects on - the regression of distant tumors and lung metastases, providing a reference - method for the preparation of targeted agents for treating breast cancer. -CI - © 2024. The Author(s). -FAU - Zeng, Bowen -AU - Zeng B -AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -FAU - Pian, Lina -AU - Pian L -AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -AD - Department of Gynecology and Obstetrics, Yanbian University Hospital, Yanji, - Jilin, 133000, People's Republic of China. -FAU - Liu, Yanhong -AU - Liu Y -AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -FAU - Wang, Shuangqing -AU - Wang S -AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -AD - Department of Pharmacy, Yanbian University, Yanji Jilin, 133000, P.R. China. -FAU - Wang, Nuoya -AU - Wang N -AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -AD - Department of Pharmacy, Yanbian University, Yanji Jilin, 133000, P.R. China. -FAU - Liu, Chao -AU - Liu C -AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -FAU - Wu, Hao -AU - Wu H -AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -FAU - Wan, Hongshuang -AU - Wan H -AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -FAU - Chen, Liqing -AU - Chen L -AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -FAU - Huang, Wei -AU - Huang W -AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. -FAU - Gao, Zhonggao -AU - Gao Z -AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. zggao@imm.ac.cn. -AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. zggao@imm.ac.cn. -FAU - Yin, Xuezhe -AU - Yin X -AD - Department of Gynecology and Obstetrics, Yanbian University Hospital, Yanji, - Jilin, 133000, People's Republic of China. yinxz123@126.com. -FAU - Jin, Mingji -AU - Jin M -AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. jinmingji@imm.ac.cn. -AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, - Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union - Medical College, Beijing, 100050, China. jinmingji@imm.ac.cn. -LA - eng -GR - 82073778/National Natural Science Foundation of China/ -GR - 82104106/National Natural Science Fund for Distinguished Young Scholars/ -PT - Journal Article -DEP - 20240912 -PL - England -TA - J Nanobiotechnology -JT - Journal of nanobiotechnology -JID - 101152208 -RN - 0 (Liposomes) -RN - IX6J1063HV (Indocyanine Green) -RN - 1UD32YR59G (Tirapazamine) -RN - 0 (Antineoplastic Agents) -RN - 0 (IR 820) -SB - IM -MH - *Liposomes/chemistry -MH - Female -MH - *Breast Neoplasms/drug therapy/therapy -MH - *Immunotherapy/methods -MH - Animals -MH - Mice -MH - Humans -MH - Cell Line, Tumor -MH - Photochemotherapy/methods -MH - Indocyanine Green/chemistry/therapeutic use/analogs & derivatives -MH - Mice, Inbred BALB C -MH - Tirapazamine/chemistry/pharmacology -MH - Antineoplastic Agents/pharmacology/chemistry/therapeutic use -MH - Phototherapy/methods -PMC - PMC11391708 -OTO - NOTNLM -OT - Breast cancer -OT - Folate receptor tumor targeting -OT - Immune checkpoint blockade -OT - Immunotherapy -OT - Photodynamic therapy -COIS- The authors declare no competing interests. -EDAT- 2024/09/13 00:46 -MHDA- 2024/09/14 15:46 -PMCR- 2024/09/12 -CRDT- 2024/09/12 23:49 -PHST- 2024/03/26 00:00 [received] -PHST- 2024/09/05 00:00 [accepted] -PHST- 2024/09/14 15:46 [medline] -PHST- 2024/09/13 00:46 [pubmed] -PHST- 2024/09/12 23:49 [entrez] -PHST- 2024/09/12 00:00 [pmc-release] -AID - 10.1186/s12951-024-02838-1 [pii] -AID - 2838 [pii] -AID - 10.1186/s12951-024-02838-1 [doi] -PST - epublish -SO - J Nanobiotechnology. 2024 Sep 12;22(1):558. doi: 10.1186/s12951-024-02838-1. - -PMID- 38496686 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240319 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 13 -IP - 2 -DP - 2024 Feb 29 -TI - Intracranial response pattern, tolerability and biomarkers associated with brain - metastases in non-small cell lung cancer treated by tislelizumab plus - chemotherapy. -PG - 269-279 -LID - 10.21037/tlcr-23-687 [doi] -AB - BACKGROUND: Programmed cell death protein-1/programmed cell death protein-ligand - 1 (PD-1/PD-L1) inhibitor and chemotherapy are the standard treatment for advanced - non-small cell lung cancer (NSCLC) without sensitizing mutations. However, - patients with untreated, symptomatic or recently-irradiated brain metastases - (BMs) are mostly excluded from immunochemotherapy trials. This study aims to - evaluate the intracranial response pattern, tolerability and biomarkers of - tislelizumab plus chemotherapy in NSCLC with untreated, symptomatic or - recently-irradiated BM. METHODS: This multicenter, single-arm, phase 2 trial - enrolled patients with treatment-naïve, brain-metastasized NSCLC. BM could be - untreated or irradiated. Symptomatic or recently-irradiated BMs that were deemed - clinically stable were allowed. Patients received tislelizumab (200 mg) plus - pemetrexed (500 mg/m(2)) and carboplatin (AUC =5) on day 1 every 3 weeks for 4 - cycles, followed by maintenance with tislelizumab plus pemetrexed. Primary - endpoint was 1-year progression-free survival (PFS) rate. Secondary endpoints - included intracranial efficacy and tolerability. PD-L1 expression, tumor - mutational burden (TMB) and genomic alterations were evaluated as potential - biomarkers. RESULTS: A total of 36 patients were enrolled, 19.2% had prior brain - radiotherapy, 8.3% had symptomatic BMs that required corticosteroids ≤10 mg/d or - antiepileptics. Confirmed systemic and intracranial ORR (iORR) was 43.8% and - 46.7%, respectively. One-year systematic PFS rate and One-year iPFS rate was - 36.8% and 55.8%, respectively. About 41.7% patients had neurological adverse - events, 90% patients had concordant intracranial-extracranial responses. No - intracranial pseudoprogression or hyperprogression occurred. Patients with prior - brain radiation trended towards higher systemic (83.3% vs. 34.6%) and iORR (75.0% - vs. 42.3%). Similar intracranial efficacy was observed in tumors with different - PD-L1 and TMB levels, while alterations in cytokine receptors pathway predicted - higher iORR (P=0.081), prolonged systematic PFS [hazard ratio (HR) =0.16, - P=0.021] and overall survival (OS) (HR =0.71, P=0.029). CONCLUSIONS: Untreated or - irradiated BMs in NSCLC follows a conventional response and progression pattern - under immunochemotherapy with altered cytokine receptors pathway being a - potential biomarker for systemic and intracranial outcomes. -CI - 2024 Translational Lung Cancer Research. All rights reserved. -FAU - Zhao, Shen -AU - Zhao S -AD - Department of Medical Oncology, State Key Laboratory of Oncology in South China, - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -FAU - Jiang, Wei -AU - Jiang W -AD - Department of Oncology, Guangxi Medical University Cancer Hospital, Nanning, - China. -FAU - Yang, Nong -AU - Yang N -AD - Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China. -FAU - Liu, Li -AU - Liu L -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, China. -FAU - Yu, Yan -AU - Yu Y -AD - Department of Oncology, Harbin Medical University Cancer Hospital, Heilongjiang, - China. -FAU - Wang, Qiming -AU - Wang Q -AD - Department of Medical Oncology, Henan Cancer Hospital, Zhengzhou, China. -FAU - Zhao, Yuanyuan -AU - Zhao Y -AD - Department of Medical Oncology, State Key Laboratory of Oncology in South China, - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -FAU - Yang, Yunpeng -AU - Yang Y -AD - Department of Medical Oncology, State Key Laboratory of Oncology in South China, - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -FAU - Ma, Shuxiang -AU - Ma S -AD - Department of Medical Oncology, Henan Cancer Hospital, Zhengzhou, China. -FAU - Yu, Qitao -AU - Yu Q -AD - Department of Oncology, Guangxi Medical University Cancer Hospital, Nanning, - China. -FAU - Zhang, Li -AU - Zhang L -AD - Department of Medical Oncology, State Key Laboratory of Oncology in South China, - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -FAU - Huang, Yan -AU - Huang Y -AD - Department of Medical Oncology, State Key Laboratory of Oncology in South China, - Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University - Cancer Center, Guangzhou, China. -LA - eng -PT - Journal Article -DEP - 20240223 -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -PMC - PMC10938101 -OTO - NOTNLM -OT - Non-small cell lung cancer (NSCLC) -OT - brain metastasis (BM) -OT - immunochemotherapy -OT - predictive biomarker -OT - response evaluation -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-687/coif). L.Z. received - research fund and support from BeiGene Ltd. and Geneseeq Technology Inc. L.Z. - also reports that BeiGene provided the research fund and the investigated drugs, - and that Geneseeq Technology offered genomic sequencing analysis. The other - authors have no conflicts of interest to declare. -EDAT- 2024/03/18 06:43 -MHDA- 2024/03/18 06:44 -PMCR- 2024/02/29 -CRDT- 2024/03/18 04:41 -PHST- 2023/10/25 00:00 [received] -PHST- 2024/01/22 00:00 [accepted] -PHST- 2024/03/18 06:44 [medline] -PHST- 2024/03/18 06:43 [pubmed] -PHST- 2024/03/18 04:41 [entrez] -PHST- 2024/02/29 00:00 [pmc-release] -AID - tlcr-13-02-269 [pii] -AID - 10.21037/tlcr-23-687 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2024 Feb 29;13(2):269-279. doi: 10.21037/tlcr-23-687. - Epub 2024 Feb 23. - -PMID- 30777100 -OWN - NLM -STAT- MEDLINE -DCOM- 20190529 -LR - 20231006 -IS - 1756-9966 (Electronic) -IS - 0392-9078 (Print) -IS - 0392-9078 (Linking) -VI - 38 -IP - 1 -DP - 2019 Feb 18 -TI - Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for - glioblastoma. -PG - 87 -LID - 10.1186/s13046-019-1085-3 [doi] -LID - 87 -AB - PD-1/PD-L1 checkpoint blockades have achieved significant progress in several - kinds of tumours. Pembrolizumab, which targets PD-1, has been approved as a - first-line treatment for advanced non-small cell lung cancer (NSCLC) patients - with positive PD-L1 expression. However, PD-1/PD-L1 checkpoint blockades have not - achieved breakthroughs in treating glioblastoma because glioblastoma has a low - immunogenic response and an immunosuppressive microenvironment caused by the - precise crosstalk between cytokines and immune cells. A phase III clinical trial, - Checkmate 143, reported that nivolumab, which targets PD-1, did not demonstrate - survival benefits compared with bavacizumab in recurrent glioblastoma patients. - Thus, the combination of a PD-1/PD-L1 checkpoint blockade with RT, TMZ, - antibodies targeting other inhibitory or stimulatory molecules, targeted therapy, - and vaccines may be an appealing solution aimed at achieving optimal clinical - benefit. There are many ongoing clinical trials exploring the efficacy of various - approaches based on PD-1/PD-L1 checkpoint blockades in primary or recurrent - glioblastoma patients. Many challenges need to be overcome, including the - identification of discrepancies between different genomic subtypes in their - response to PD-1/PD-L1 checkpoint blockades, the selection of PD-1/PD-L1 - checkpoint blockades for primary versus recurrent glioblastoma, and the - identification of the optimal combination and sequence of combination therapy. In - this review, we describe the immunosuppressive molecular characteristics of the - tumour microenvironment (TME), candidate biomarkers of PD-1/PD-L1 checkpoint - blockades, ongoing clinical trials and challenges of PD-1/PD-L1 checkpoint - blockades in glioblastoma. -FAU - Wang, Xin -AU - Wang X -AD - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei - Province, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong - University, Shandong Academy of Medical Sciences, Jinan, 250117, Shandong - Province, China. -FAU - Guo, Gaochao -AU - Guo G -AD - Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, - China. -AD - Key Laboratory of Post-Trauma Neuro-Repair and Regeneration in Central Nervous - System, Ministry of Education, Tianjin, China. -AD - Tianjin Key Laboratory of Injuries, Variations and Regeneration of Nervous - System, Tianjin, China. -FAU - Guan, Hui -AU - Guan H -AD - Department of Radiation Oncology, The Fourth People's Hospital of Jinan, Jinan, - Shandong Province, China. -FAU - Yu, Yang -AU - Yu Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong - University, Shandong Academy of Medical Sciences, Jinan, 250117, Shandong - Province, China. -FAU - Lu, Jie -AU - Lu J -AD - Department of Neurosurgery, Shandong Province Qianfoshan Hospital of Shandong - University, Shandong Province, Jinan, 250014, China. Dr_peterluu@163.com. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong - University, Shandong Academy of Medical Sciences, Jinan, 250117, Shandong - Province, China. sdyujinming@163.com. -LA - eng -PT - Journal Article -PT - Review -DEP - 20190218 -PL - England -TA - J Exp Clin Cancer Res -JT - Journal of experimental & clinical cancer research : CR -JID - 8308647 -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (PDCD1 protein, human) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - Brain Neoplasms/*drug therapy -MH - Glioblastoma/*drug therapy -MH - Humans -MH - Immunotherapy/*methods -MH - Molecular Targeted Therapy/methods -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors -PMC - PMC6380009 -OTO - NOTNLM -OT - Glioblastoma multiforme -OT - Nivolumab -OT - Temozolomide -OT - Tumour infiltrating lymphocytes -OT - Tumour mutation load -COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR - PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they - have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral - with regard to jurisdictional claims in published maps and institutional - affiliations. -EDAT- 2019/02/20 06:00 -MHDA- 2019/05/30 06:00 -PMCR- 2019/02/18 -CRDT- 2019/02/20 06:00 -PHST- 2018/12/07 00:00 [received] -PHST- 2019/02/06 00:00 [accepted] -PHST- 2019/02/20 06:00 [entrez] -PHST- 2019/02/20 06:00 [pubmed] -PHST- 2019/05/30 06:00 [medline] -PHST- 2019/02/18 00:00 [pmc-release] -AID - 10.1186/s13046-019-1085-3 [pii] -AID - 1085 [pii] -AID - 10.1186/s13046-019-1085-3 [doi] -PST - epublish -SO - J Exp Clin Cancer Res. 2019 Feb 18;38(1):87. doi: 10.1186/s13046-019-1085-3. - -PMID- 31850192 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20201001 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 9 -DP - 2019 -TI - Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and - Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced - Non-small Cell Lung Cancer. -PG - 1256 -LID - 10.3389/fonc.2019.01256 [doi] -LID - 1256 -AB - Introduction: Multicenter, phase I study of concurrent and delayed nivolumab plus - nab-paclitaxel/carboplatin in advanced non-small cell lung cancer (NSCLC). - Methods: Chemotherapy-naive patients with advanced NSCLC (ineligible for - potentially curative radiation or surgery) received nab-paclitaxel 100 mg/m(2) - (days 1, 8, 15) and carboplatin area under the curve 6 (day 1) intravenously - every 21 days (first 4 cycles); nivolumab 5 mg/kg was administered intravenously - (day 15) beginning in cycle 1 (concurrent) or cycle 3 (delayed) in separate - cohorts and continued beyond the 4 chemotherapy cycles. The primary objective was - to assess safety. Secondary objectives were to assess tolerability and explore - antitumor activity. Results: All 32 patients received chemotherapy; 20 of 22 and - 6 of 10 patients also received concurrent or delayed nivolumab, respectively. No - dose-limiting toxicities were reported in the concurrent cohort; 1 dose-limiting - toxicity was reported in the delayed cohort. In the concurrent cohort, 20 - patients (91%) had ≥1 grade 3/4 treatment-emergent adverse event (TEAE), and 7 - (32%) discontinued treatment due to TEAEs. In the delayed cohort, all patients - had ≥1 grade 3/4 TEAE, and 2 (20%) discontinued due to TEAEs. The median - progression-free and overall survival, respectively, were 10.5 and 29.3 months in - the concurrent cohort and 4.1 and 8.2 months in the delayed cohort. Conclusions: - The safety profile of the combination was consistent with that of individual - agents and generally similar in the 2 cohorts. Efficacy outcomes in the - concurrent cohort, but not in the delayed cohort, were encouraging and support - the rationale for concurrent administration of nivolumab with - nab-paclitaxel/carboplatin for the treatment of advanced NSCLC. Clinical Trial - Registration: www.ClinicalTrials.gov, identifier: NCT02309177. -CI - Copyright © 2019 Goldman, Waterhouse, George, O'Dwyer, Bhore, Banerjee, Lyons, - Louis, Ong and Kelly. -FAU - Goldman, Jonathan W -AU - Goldman JW -AD - David Geffen School of Medicine at the University of California, Los Angeles, Los - Angeles, CA, United States. -FAU - Waterhouse, David M -AU - Waterhouse DM -AD - Oncology Hematology Care, Cincinnati, OH, United States. -FAU - George, Ben -AU - George B -AD - Froedtert & the Medical College of Wisconsin, Milwaukee, WI, United States. -FAU - O'Dwyer, Peter J -AU - O'Dwyer PJ -AD - Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United - States. -FAU - Bhore, Rafia -AU - Bhore R -AD - Celgene Corporation, Summit, NJ, United States. -FAU - Banerjee, Sibabrata -AU - Banerjee S -AD - Celgene Corporation, Summit, NJ, United States. -FAU - Lyons, Larry -AU - Lyons L -AD - Celgene Corporation, Summit, NJ, United States. -FAU - Louis, Chrystal U -AU - Louis CU -AD - Celgene Corporation, Summit, NJ, United States. -FAU - Ong, Teng Jin -AU - Ong TJ -AD - Celgene Corporation, Summit, NJ, United States. -FAU - Kelly, Karen -AU - Kelly K -AD - Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, - United States. -LA - eng -SI - ClinicalTrials.gov/NCT02309177 -PT - Journal Article -DEP - 20191126 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC6901975 -OTO - NOTNLM -OT - carboplatin -OT - nab-paclitaxel -OT - nivolumab -OT - non-small cell lung cancer -OT - treatment beyond progression -EDAT- 2019/12/19 06:00 -MHDA- 2019/12/19 06:01 -PMCR- 2019/01/01 -CRDT- 2019/12/19 06:00 -PHST- 2019/08/07 00:00 [received] -PHST- 2019/10/31 00:00 [accepted] -PHST- 2019/12/19 06:00 [entrez] -PHST- 2019/12/19 06:00 [pubmed] -PHST- 2019/12/19 06:01 [medline] -PHST- 2019/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2019.01256 [doi] -PST - epublish -SO - Front Oncol. 2019 Nov 26;9:1256. doi: 10.3389/fonc.2019.01256. eCollection 2019. - -PMID- 38971385 -OWN - NLM -STAT- Publisher -LR - 20240925 -IS - 1879-355X (Electronic) -IS - 0360-3016 (Linking) -DP - 2024 Jul 4 -TI - Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation - Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer. -LID - S0360-3016(24)00749-1 [pii] -LID - 10.1016/j.ijrobp.2024.06.018 [doi] -AB - PURPOSE: Local failure rates after treatment for locally advanced non-small cell - lung cancer (NSCLC) remain high. Efforts to improve local control with a uniform - dose escalation or dose escalation to midtreatment positron emission tomography - (PET)-avid residual disease have been limited by heightened toxicity. This trial - aimed to refine response-based adaptive radiation therapy (RT) and minimize - toxicity by incorporating fluorodeoxyglucose-PET (FDG-PET) and - ventilation-perfusion single-photon emission computed tomography (SPECT) imaging - midtreatment. METHODS AND MATERIALS: A total of 47 patients with stage IIA to III - unresectable NSCLC were prospectively enrolled in this single-institution trial - (NCT02492867). Patients received concurrent chemoradiation therapy with - personalized response-based adaptive RT over 30 fractions incorporating - ventilation-perfusion single-photon emission computed tomography and FDG-PET. The - first 21 fractions (46.2 Gy at 2.2 Gy/fraction) were delivered to the tumor while - minimizing the dose to the SPECT-defined functional lung. The plan was then - adapted for the final 9 fractions (2.2-3.8 Gy/fraction) up to a total of 80.4 Gy, - based on the midtreatment FDG-PET tumor response to escalate the dose to the - residual tumor while minimizing the dose to the SPECT-defined functional lung. - Nonprogressing patients received consolidative carboplatin, paclitaxel, or - durvalumab. The primary endpoint of the study was ≥ grade 2 lung and esophageal - toxicities. Secondary endpoints included time to local progression, tumor - response, and overall survival. RESULTS: At 1 year posttreatment, the rates of - grade 2 and grade 3 pneumonitis were 21.3% and 2.1%, respectively, with no - difference in pneumonitis rates among patients who received and did not receive - adjuvant durvalumab (P = .74). Although there were no grade 3 esophageal-related - toxicities, 66.0% of patients experienced grade 2 esophagitis. The 1- and 2-year - local control rates were 94.5% (95% CI, 87.4%-100%) and 87.5% (95% CI, - 76.7%-100%), respectively. Overall survival was 82.8% (95% CI, 72.6%-94.4%) at 1 - year and 62.3% (95% CI, 49.6%-78.3%) at 2 years. CONCLUSIONS: Response-based - adaptive dose-escalation accounting for tumor change and normal tissue function - during treatment provided excellent local control, comparable toxicity to - standard chemoradiation therapy, and did not increase toxicity with adjuvant - immunotherapy. -CI - Copyright © 2024 Elsevier Inc. All rights reserved. -FAU - Edwards, Donna M -AU - Edwards DM -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Schonewolf, Caitlin A -AU - Schonewolf CA -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Rice, John D -AU - Rice JD -AD - Department of Biostatistics, University of Michigan, Ann Arbor, Michigan. -FAU - Schipper, Matthew -AU - Schipper M -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; - Department of Biostatistics, University of Michigan, Ann Arbor, Michigan. -FAU - Haken, Randall K Ten -AU - Haken RKT -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Matuszak, Martha -AU - Matuszak M -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Balter, James -AU - Balter J -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Jarema, David -AU - Jarema D -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Arenberg, Douglas A -AU - Arenberg DA -AD - Department of Medicine, Pulmonology, University of Michigan, Ann Arbor, Michigan. -FAU - Piert, Morand -AU - Piert M -AD - Department of Radiology, University of Michigan, Ann Arbor, Michigan. -FAU - Qin, Angel -AU - Qin A -AD - Department of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, - Michigan. -FAU - Kalemkerian, Gregory P -AU - Kalemkerian GP -AD - Department of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, - Michigan. -FAU - Schneider, Bryan J -AU - Schneider BJ -AD - Department of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, - Michigan. -FAU - Ramnath, Nithya -AU - Ramnath N -AD - Department of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, - Michigan; Section of Hematology Oncology, Veterans Affairs Ann Arbor Healthcare - System, Ann Arbor, Michigan. -FAU - Chapman, Christina H -AU - Chapman CH -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; - Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, - Ann Arbor, Michigan; Department of Radiation Oncology, Baylor College of - Medicine, Houston, Texas. -FAU - Elliott, David A -AU - Elliott DA -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; - Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, - Ann Arbor, Michigan. -FAU - Lawrence, Theodore S -AU - Lawrence TS -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Hearn, Jason -AU - Hearn J -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Hayman, James A -AU - Hayman JA -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Jolly, Shruti -AU - Jolly S -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. - Electronic address: shrutij@med.umich.edu. -LA - eng -PT - Journal Article -DEP - 20240704 -PL - United States -TA - Int J Radiat Oncol Biol Phys -JT - International journal of radiation oncology, biology, physics -JID - 7603616 -SB - IM -EDAT- 2024/07/07 00:42 -MHDA- 2024/07/07 00:42 -CRDT- 2024/07/06 19:28 -PHST- 2023/11/15 00:00 [received] -PHST- 2024/04/22 00:00 [revised] -PHST- 2024/06/18 00:00 [accepted] -PHST- 2024/07/07 00:42 [pubmed] -PHST- 2024/07/07 00:42 [medline] -PHST- 2024/07/06 19:28 [entrez] -AID - S0360-3016(24)00749-1 [pii] -AID - 10.1016/j.ijrobp.2024.06.018 [doi] -PST - aheadofprint -SO - Int J Radiat Oncol Biol Phys. 2024 Jul 4:S0360-3016(24)00749-1. doi: - 10.1016/j.ijrobp.2024.06.018. - -PMID- 33209631 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240902 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 9 -IP - 5 -DP - 2020 Oct -TI - Radiotherapy for non-small cell lung cancer in the immunotherapy era: the - opportunity and challenge-a narrative review. -PG - 2120-2136 -LID - 10.21037/tlcr-20-827 [doi] -AB - Immunotherapy has radically changed the clinical management of patients with - cancer in recent years. Immune checkpoint inhibitors (ICIs) reversing the - immunosuppressive effects of the tumor microenvironment are one type of - immunotherapy, several of which are approved by the US Food and Drug - Administration (FDA) as first-line treatments for patients with non-small cell - lung cancer (NSCLC). However, response rates to ICIs are around 19-47% among - patients with advanced NSCLC. As a result, the development of combined ICI and - radiotherapy has begun with the aim of strengthening patients' antitumor - immunity. Radiotherapy with substantial technological improvements not only - achieves local tumor control through the induction of deoxyribonucleic acid (DNA) - damage in irradiated regions, but also has the potential to mediate - immunostimulatory effects that could result in tumor regression beyond irradiated - regions. At present, numerous preclinical and clinical research are investigating - the efficiency and safety of combining ICI with radiotherapy. The PACIFIC trial - showed that combining chemoradiotherapy with ICI could improve clinical outcomes. - In this review, we summarize the rationale for combining radiotherapy with - immunotherapy. We also discuss the opportunities and challenges of combination - therapy, including the timing of radiotherapy, optimal dose and fractionations, - radiotherapy target and target volume, acquired resistance, patient selection, - and radioimmunotherapy toxicity. -CI - 2020 Translational Lung Cancer Research. All rights reserved. -FAU - Xia, Wu-Yan -AU - Xia WY -AD - Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong - University, Shanghai 200030, China. -FAU - Feng, Wen -AU - Feng W -AD - Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong - University, Shanghai 200030, China. -FAU - Zhang, Chen-Chen -AU - Zhang CC -AD - Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong - University, Shanghai 200030, China. -FAU - Shen, Yu-Jia -AU - Shen YJ -AD - Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong - University, Shanghai 200030, China. -FAU - Zhang, Qin -AU - Zhang Q -AD - Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong - University, Shanghai 200030, China. -FAU - Yu, Wen -AU - Yu W -AD - Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong - University, Shanghai 200030, China. -FAU - Cai, Xu-Wei -AU - Cai XW -AD - Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong - University, Shanghai 200030, China. -FAU - Fu, Xiao-Long -AU - Fu XL -AD - Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong - University, Shanghai 200030, China. -LA - eng -PT - Journal Article -PT - Review -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -PMC - PMC7653139 -OTO - NOTNLM -OT - Radiotherapy -OT - immune checkpoint inhibitor (ICI) -OT - immunotherapy -OT - non-small cell lung cancer (NSCLC) -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at http://dx.doi.org/10.21037/tlcr-20-827). The authors report - grants from the National Key Research and Development Program of China - (2016YFC0905502), grants from the Shanghai Shen Kang Hospital Development Center - Clinical Research Plan of SHDC (16CR1016A), grants from the Project of Shanghai - Science and Technology Commission (18YF1421500), during the conduct of the study. -EDAT- 2020/11/20 06:00 -MHDA- 2020/11/20 06:01 -PMCR- 2020/10/01 -CRDT- 2020/11/19 05:46 -PHST- 2020/11/19 05:46 [entrez] -PHST- 2020/11/20 06:00 [pubmed] -PHST- 2020/11/20 06:01 [medline] -PHST- 2020/10/01 00:00 [pmc-release] -AID - tlcr-09-05-2120 [pii] -AID - 10.21037/tlcr-20-827 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2020 Oct;9(5):2120-2136. doi: 10.21037/tlcr-20-827. - -PMID- 28929083 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20201001 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 7 -DP - 2017 -TI - Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body - Radiation Therapy and Immunotherapy. -PG - 197 -LID - 10.3389/fonc.2017.00197 [doi] -LID - 197 -AB - The current standard of care for locally advanced non-small cell lung cancer - (NSCLC) includes radiation, chemotherapy, and surgery in certain individualized - cases. In unresectable NSCLC, chemoradiation has been the standard of care for - the past three decades. Local and distant failure remains high in this group of - patients, so dose escalation has been studied in both single institution and - national clinical trials. Though initial studies showed a benefit to dose - escalation, phase III studies examining dose escalation using standard - fractionation or hyperfractionation have failed to show a benefit. Over the last - 17 years, stereotactic body radiation therapy (SBRT) has shown a high degree of - safety and local control for stage I lung cancers and other localized - malignancies. More recently, phase I/II studies using SBRT for dose escalation - after conventional chemoradiation in locally advanced NSCLC have been promising - with good apparent safety. Immunotherapy also offers opportunities to address - distant disease and preclinical data suggest immunotherapy in tandem with SBRT - may be a rational way to induce an "abscopal effect" although there are little - clinical data as yet. By building on the proven concept of conventional - chemoradiation for patients with locally advanced NSCLC with a subsequent - radiation dose intensification to residual disease with SBRT concurrent with - immunotherapy, we hope address the issues of metastatic and local failures. This - "quadmodality" approach is still in its infancy but appears to be a safe and - rational approach to the improving the outcome of NSCLC therapy. -FAU - Kumar, Sameera S -AU - Kumar SS -AD - Department of Radiation Medicine, University of Kentucky, Lexington, KY, United - States. -FAU - Higgins, Kristin A -AU - Higgins KA -AD - Department of Radiation Oncology, Winship Cancer Institute of Emory University, - The Emory Clinic, Atlanta, GA, United States. -FAU - McGarry, Ronald C -AU - McGarry RC -AD - Department of Radiation Medicine, University of Kentucky, Lexington, KY, United - States. -LA - eng -PT - Journal Article -PT - Review -DEP - 20170904 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC5591326 -OTO - NOTNLM -OT - immunotherapy -OT - non-small cell lung cancer -OT - radiation therapy -OT - stage III -OT - stereotactic body radiation therapy -EDAT- 2017/09/21 06:00 -MHDA- 2017/09/21 06:01 -PMCR- 2017/01/01 -CRDT- 2017/09/21 06:00 -PHST- 2017/07/31 00:00 [received] -PHST- 2017/08/17 00:00 [accepted] -PHST- 2017/09/21 06:00 [entrez] -PHST- 2017/09/21 06:00 [pubmed] -PHST- 2017/09/21 06:01 [medline] -PHST- 2017/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2017.00197 [doi] -PST - epublish -SO - Front Oncol. 2017 Sep 4;7:197. doi: 10.3389/fonc.2017.00197. eCollection 2017. - -PMID- 22863361 -OWN - NLM -STAT- MEDLINE -DCOM- 20121217 -LR - 20181201 -IS - 1768-3114 (Electronic) -IS - 0369-8114 (Linking) -VI - 60 -IP - 4 -DP - 2012 Aug -TI - [Therapeutic monoclonal antibodies in oncology]. -PG - 223-8 -LID - 10.1016/j.patbio.2012.05.008 [doi] -AB - Advances in bioengineering have lead to the possibility to conduct large scale - production of monoclonal antibodies (MoAB) and to reduce progressively the murine - component from 30% (chimeric MoAB) to 5% (humanized MoAB) to 0% (human MoAB). - Three types of extracellular components are targeted in solid tumours: (1) Growth - factors with transmembrane tyrosine kinase receptors either of tumour cells - (IGF1) or endothelial cells (Bevacizumab). Bevacizumab has activity additive to - that of chemotherapy in advanced colorectal, non squamous lung, ovarian, - metastatic breast cancers and glioblastomas; (2) Extracellular domain of those - transmembrane receptors: EGFR in colorectal cancer if no activating of KRAS with - cetuximab and panitumumab, head and neck carcinomas with radiotherapy, and - probably squamous lung cancers. Anti-ERBB2 MoAb are now a constitutive part of - therapy of ERBB2 positive breast cancers at any stage; (3) Differentiation - cluster regulating relationship ot tumour and stromal cells and in particular - immunologic effectors. This is the case of anti-CTLA4 MoAB ipilimumab which - activates and amplifies immunological cytotoxic response against melanoma with - improved survival. These activities are achieved to the expense of class, target - related toxicity conditioned by expression of the target on normal cells and or - mechanism of action (immunological toxicity with ipilimumab). Of note a - synergistic or additive activity with valid treatment regimens of targeted - cancers and now targeted small molecules. -CI - Copyright © 2012. Published by Elsevier SAS. -FAU - Bouzid, K -AU - Bouzid K -AD - Service d'oncologie médicale, centre Pierre-et-Marie-Curie, Alger, Algérie. - naima.bedairia@sls.aphp.fr -FAU - Bedairia, N -AU - Bedairia N -FAU - Marty, M -AU - Marty M -LA - fre -PT - Journal Article -PT - Review -TT - Anticorps monoclonaux thérapeutiques en cancérologie. -PL - France -TA - Pathol Biol (Paris) -JT - Pathologie-biologie -JID - 0265365 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antibodies, Monoclonal, Humanized) -RN - 0 (Ipilimumab) -RN - 2S9ZZM9Q9V (Bevacizumab) -RN - 6A901E312A (Panitumumab) -RN - EC 2.7.10.1 (ErbB Receptors) -RN - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) -RN - PQX0D8J21J (Cetuximab) -SB - IM -MH - Animals -MH - Antibodies, Monoclonal/*therapeutic use -MH - Antibodies, Monoclonal, Humanized/therapeutic use -MH - Bevacizumab -MH - Cetuximab -MH - ErbB Receptors/drug effects/immunology -MH - Humans -MH - Ipilimumab -MH - Mice -MH - Molecular Targeted Therapy -MH - Neoplasms/*drug therapy -MH - Panitumumab -MH - Receptor Protein-Tyrosine Kinases/drug effects -EDAT- 2012/08/07 06:00 -MHDA- 2012/12/18 06:00 -CRDT- 2012/08/07 06:00 -PHST- 2012/03/22 00:00 [received] -PHST- 2012/04/25 00:00 [accepted] -PHST- 2012/08/07 06:00 [entrez] -PHST- 2012/08/07 06:00 [pubmed] -PHST- 2012/12/18 06:00 [medline] -AID - S0369-8114(12)00089-2 [pii] -AID - 10.1016/j.patbio.2012.05.008 [doi] -PST - ppublish -SO - Pathol Biol (Paris). 2012 Aug;60(4):223-8. doi: 10.1016/j.patbio.2012.05.008. - -PMID- 26958509 -OWN - NLM -STAT- PubMed-not-MEDLINE -DCOM- 20160309 -LR - 20200929 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 5 -IP - 1 -DP - 2016 Feb -TI - Immunotherapy in locally-advanced non-small cell lung cancer: releasing the - brakes on consolidation? -PG - 138-42 -LID - 10.3978/j.issn.2218-6751.2016.01.11 [doi] -AB - Locally-advanced non-small cell lung cancer (LA-NSCLC) is optimally treated with - definitive chemoradiation or surgery in combination with chemotherapy or - chemoradiation. Prognosis, however, remains poor, and attempts to improve - outcomes using consolidation or maintenance chemotherapy have not improved - overall survival. Given the limited success of traditional cytotoxic - chemotherapies as maintenance therapy for LA-NSCLC, recent studies have - investigated the role of novel agents such as maintenance or consolidation, - including antiangiogenic agents and molecular targeted therapy. With multiple - newly reported trials demonstrating improved outcomes with immunotherapy over - cytotoxic chemotherapy for stage IV NSCLC, integrating immunotherapy with - definitive chemoradiation regimens or as consolidative therapy for LA-NSCLC is an - attractive option. The recently published START trial is the first to test - immunotherapy in LA-NSCLC in a randomized, phase III setting. In that trial, the - administration of maintenance tecemotide (L-BLP25), which induces a T-cell - response to the mucin 1 (MUC1) glycoprotein, was found to be well tolerated and - improve overall survival compared with placebo among patients receiving - concurrent, but not sequential, chemoradiation. Despite the promising findings of - this trial, numerous questions regarding immunotherapy for LA-NSCLC remain, and - several additional immunotherapy trials are underway or planned in this patient - population. -FAU - Berman, Abigail T -AU - Berman AT -AD - Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA - 19104, USA. -FAU - Simone, Charles B 2nd -AU - Simone CB 2nd -AD - Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA - 19104, USA. -LA - eng -PT - Journal Article -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -CON - Lancet Oncol. 15:59. PMID: 24331154 -PMC - PMC4758973 -OTO - NOTNLM -OT - Adjuvant therapy -OT - immunotherapy -OT - lung cancer -OT - radiation therapy -OT - stereotactic body radiation therapy -COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. -EDAT- 2016/03/10 06:00 -MHDA- 2016/03/10 06:01 -PMCR- 2016/02/01 -CRDT- 2016/03/10 06:00 -PHST- 2016/03/10 06:00 [entrez] -PHST- 2016/03/10 06:00 [pubmed] -PHST- 2016/03/10 06:01 [medline] -PHST- 2016/02/01 00:00 [pmc-release] -AID - tlcr-05-01-138 [pii] -AID - 10.3978/j.issn.2218-6751.2016.01.11 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2016 Feb;5(1):138-42. doi: - 10.3978/j.issn.2218-6751.2016.01.11. - -PMID- 35051703 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240923 -IS - 2468-2942 (Electronic) -IS - 2468-2942 (Linking) -VI - 30 -DP - 2022 -TI - Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for - KRAS-Mutated Non-Small Cell Lung Cancer. -PG - 100514 -LID - S2468-2942(22)00006-5 [pii] -LID - 10.1016/j.ctarc.2022.100514 [doi] -AB - OBJECTIVE: This phase I trial (NCT01912625) evaluated the safety and - pharmacokinetics of definitive concurrent chemoradiotherapy (cCRT) and the - radiosensitizer trametinib (MEK1/2 inhibitor) for KRAS-mutated nonmetastatic - non-small cell lung cancer (NSCLC). METHODS: Patients received cCRT - (carboplatin/paclitaxel and 60 Gy/30 fractions radiotherapy); oral trametinib (7 - days/week) commenced on day 1 and completed on the final day of radiotherapy. - Dose-finding of trametinib was done using the time-to-event continual - reassessment method (TiTE-CRM); dose levels were 0.5mg (level -1), 1mg (initial, - level 1), 1.5mg (level 2), and 2mg (level 3). Progression-free (PFS) and overall - survival (OS) times were also recorded. RESULTS: Fifteen patients (stage III, - variety of KRAS mutations) were treated, with 1/5/4/5 at dose levels -1/1/2/3, - respectively. Five patients received dose reductions (n=2, levels 2 and 3; n=1, - level 1). Twelve patients completed the full cCRT course. One patient (following - 12d trametinib) was taken off protocol for an unrelated/unresolved grade 1 event - and later experienced grade 5 sepsis/respiratory failure. There was one grade 4 - retinal detachment; grade 3 events included skin rash (n=2) and ventricular - dysfunction, pneumonitis, pain, fatigue, and diarrhea (n=1 each). The final dose - selected by the TiTE-CRM of trametinib was 1.5 mg. Pharmacokinetic profiles were - elucidated and extensively described. At median follow-up of 70 months, median - PFS was 11 months and median OS was 38 months. CONCLUSIONS: The MTD for - trametinib when combined with cCRT is 1.5 mg, with encouraging preliminary - outcomes. This combination merits further study to combine with consolidation - durvalumab in non-metastatic KRAS mutant NSCLC. -CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. -FAU - Lin, Steven H -AU - Lin SH -AD - Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer - Center, Houston, TX, USA. Electronic address: shlin@mdanderson.org. -FAU - Lin, Heather Y -AU - Lin HY -AD - Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, - Houston, TX, USA. -FAU - Verma, Vivek -AU - Verma V -AD - Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer - Center, Houston, TX, USA. -FAU - Xu-Welliver, Meng -AU - Xu-Welliver M -AD - Department of Radiation Oncology, Ohio State University, Columbus, OH, USA. -FAU - Thall, Peter F -AU - Thall PF -AD - Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, - Houston, TX, USA. -FAU - Yao, Luyang -AU - Yao L -AD - Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer - Center, Houston, TX, USA. -FAU - Kim, Peter Y -AU - Kim PY -AD - Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, - Houston, TX, USA. -FAU - Gombos, Dan S -AU - Gombos DS -AD - Department of Ophthalmology, The University of Texas M.D. Anderson Cancer Center, - Houston, TX, USA. -FAU - Kawedia, Jitesh D -AU - Kawedia JD -AD - Clinical Pharmacy Research, The University of Texas M.D. Anderson Cancer Center, - Houston, TX, USA. -FAU - Komaki, Ritsuko -AU - Komaki R -AD - Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer - Center, Houston, TX, USA. -FAU - Gomez, Daniel R -AU - Gomez DR -AD - Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer - Center, Houston, TX, USA. -FAU - Nguyen, Quynh-Nhu -AU - Nguyen QN -AD - Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer - Center, Houston, TX, USA. -FAU - O'Reilly, Michael S -AU - O'Reilly MS -AD - Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer - Center, Houston, TX, USA. -FAU - Lu, Charles -AU - Lu C -AD - Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson - Cancer Center, Houston, TX, USA. -FAU - Fossella, Frank V -AU - Fossella FV -AD - Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson - Cancer Center, Houston, TX, USA. -FAU - Skoulidis, Ferdinandos -AU - Skoulidis F -AD - Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson - Cancer Center, Houston, TX, USA. -FAU - Zhang, Jianjun -AU - Zhang J -AD - Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson - Cancer Center, Houston, TX, USA. -FAU - Tsao, Anne S -AU - Tsao AS -AD - Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson - Cancer Center, Houston, TX, USA. -FAU - Heymach, John V -AU - Heymach JV -AD - Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson - Cancer Center, Houston, TX, USA. -FAU - Blumenschein, George R -AU - Blumenschein GR -AD - Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson - Cancer Center, Houston, TX, USA. -LA - eng -GR - P30 CA016672/CA/NCI NIH HHS/United States -GR - UM1 CA186688/CA/NCI NIH HHS/United States -GR - UM1 CA186712/CA/NCI NIH HHS/United States -PT - Journal Article -DEP - 20220107 -PL - England -TA - Cancer Treat Res Commun -JT - Cancer treatment and research communications -JID - 101694651 -SB - IM -PMC - PMC9259763 -MID - NIHMS1771101 -OTO - NOTNLM -OT - KRAS -OT - MEK -OT - Non-small cell lung cancer -OT - chemoradiotherapy -OT - trametinib -COIS- Dr. Lin receives research funding from Beyond Spring Pharmaceuticals, STCube - Pharmaceuticals, Nektar Therapeutics, serves as a consultant for XRAD - Therapeutics; and received honorarium from Varian Medical Systems and - AstraZeneca. Dr. Xu-Welliver received honorarium from Novocure. Dr. Gomez - receives grant support from Varian Medical Systems, AstraZeneca, Merck, Bristol - Myers Squibb, personal fees from Varian Medical systems, AstraZeneca, Merck, US - Oncology, Bristol Myers Squibb, Reflexion, WebMD, Vindico, Medscape; Dr. - Skoulidis receives research funding from Pfizer and Merck; Dr. Zhang receives - research funding from Merck, Johnson and Johnson, Novartis, and consultant fees - from Bristol-Myers Squibb, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed - and Innovent; Dr. Heymach receives grant support from AstraZeneca and Spectrum, - and serves on the advisory boards for Genentech, Bristol Myers Squibb, Merck, - AstraZeneca, EMD Serono, Eli Lilly, Sanofi Aventis, Boehringer Ingelheim, - Novartis, GSK, Pfizer, and Spectrum; Dr. Tsao receives grant support from - Polaris, Epizyme, Merck, Eli Lilly, Millennium/Takeda, Seattle Genetics, grants - and personal fees from Genentech, Bristol Myers Squibb, Ariad, - Boehringer-Ingelheim, AstraZeneca, and personal fees from Roche, and Huron; Dr. - Blumenschein reports personal fees from Abbvie, Adicet, Amgen, Ariad, Clovis - Oncology, Virogin Biotech, Johnson & Johnson/Janssen, Maverick Therapeutics, - grants and personal fees from Bayer, AstraZeneca, Bristol Myers Squibb, Celgene, - Genentech, MedImmune, Merck, Novartis, Roche, Xcovery, and grants from - Adaptimmune, Elelixis, GlaxoSmithKline (GSK), Immatics, Immunocore, Incyte, Kite - Pharma, Macrogenics, Torque. The remaining authors declare no conflicts of - interest. -EDAT- 2022/01/21 06:00 -MHDA- 2022/01/21 06:01 -PMCR- 2023/07/07 -CRDT- 2022/01/20 20:20 -PHST- 2021/11/13 00:00 [received] -PHST- 2022/01/04 00:00 [revised] -PHST- 2022/01/05 00:00 [accepted] -PHST- 2022/01/21 06:01 [medline] -PHST- 2022/01/21 06:00 [pubmed] -PHST- 2022/01/20 20:20 [entrez] -PHST- 2023/07/07 00:00 [pmc-release] -AID - S2468-2942(22)00006-5 [pii] -AID - 10.1016/j.ctarc.2022.100514 [doi] -PST - ppublish -SO - Cancer Treat Res Commun. 2022;30:100514. doi: 10.1016/j.ctarc.2022.100514. Epub - 2022 Jan 7. - -PMID- 33209624 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220910 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 9 -IP - 5 -DP - 2020 Oct -TI - A narrative review of toxicity of chemoradiation and immunotherapy for - unresectable, locally advanced non-small cell lung cancer. -PG - 2040-2050 -LID - 10.21037/tlcr-20-638 [doi] -AB - Despite declining smoking rates, lung cancer remains the second most common - malignancy in the United States and the leading cause of cancer-related - mortality. Non-small cell lung cancer (NSCLC) comprises roughly 85% of cases, and - patients tend to present with advanced disease. Historically, concurrent - chemoradiotherapy (CRT) has been the standard of care for stage III unresectable - NSCLC but outcomes even with multimodal therapy have remained relatively poor. - Efforts to improve outcomes through radiation dose escalation with conventional - dose fractionation were unsuccessful with RTOG 0617, demonstrating significantly - decreased overall survival (OS) with high dose radiation with respect to standard - therapy. The recent PACIFIC trial established a new role for consolidative immune - checkpoint blockade therapy after CRT using the programmed death ligand 1 (PD-L1) - inhibitor durvalumab, by demonstrating significantly improved progression free - survival and OS. Although promising, the addition of immunotherapy to multimodal - therapy has generated debate regarding the most effective immune pathways to - target, appropriate sequencing of therapy, most effective radiation techniques, - and toxicity-related concerns. This review will highlight recent and ongoing - trials in unresectable, locally advanced NSCLC that incorporate chemotherapy, - radiation, and immunotherapy with an emphasis on analysis of treatment-related - toxicities and implications for future study design. -CI - 2020 Translational Lung Cancer Research. All rights reserved. -FAU - Prasad, Rahul N -AU - Prasad RN -AD - Department of Radiation Oncology, The Ohio State University Comprehensive Cancer - Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, - Columbus, Ohio, USA. -FAU - Williams, Terence M -AU - Williams TM -AD - Department of Radiation Oncology, The Ohio State University Comprehensive Cancer - Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, - Columbus, Ohio, USA. -LA - eng -PT - Journal Article -PT - Review -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -PMC - PMC7653152 -OTO - NOTNLM -OT - Chemoradiation -OT - immune checkpoint blockade -OT - immunotherapy -OT - locally advanced unresectable non-small cell lung cancer (NSCLC) -OT - stage III non-small cell lung cancer -COIS- Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure - form (available at http://dx.doi.org/10.21037/tlcr-20-638). The authors have no - conflicts of interest to declare. -EDAT- 2020/11/20 06:00 -MHDA- 2020/11/20 06:01 -PMCR- 2020/10/01 -CRDT- 2020/11/19 05:46 -PHST- 2020/11/19 05:46 [entrez] -PHST- 2020/11/20 06:00 [pubmed] -PHST- 2020/11/20 06:01 [medline] -PHST- 2020/10/01 00:00 [pmc-release] -AID - tlcr-09-05-2040 [pii] -AID - 10.21037/tlcr-20-638 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2020 Oct;9(5):2040-2050. doi: 10.21037/tlcr-20-638. - -PMID- 30173878 -OWN - NLM -STAT- MEDLINE -DCOM- 20190611 -LR - 20190613 -IS - 1535-6345 (Electronic) -IS - 0147-0272 (Linking) -VI - 42 -IP - 4 -DP - 2018 Jul -TI - Cardiotoxicities associated with immune checkpoint inhibitors. -PG - 422-432 -LID - S0147-0272(18)30078-3 [pii] -LID - 10.1016/j.currproblcancer.2018.07.002 [doi] -AB - This review provides an overview of clinical manifestations, diagnostic - approaches, and management strategies for cardiotoxicities associated with the - use of immune checkpoint inhibitors (ICI). ICI therapy represents a novel - treatment modality for advanced-stage malignancies, including melanoma, - metastatic renal cell cancer, and non-small cell lung cancers. ICIs have been - shown to provide significant mortality benefit and are generally well-tolerated. - The major adverse effects associated with ICIs are immune-mediated toxicities, - which can affect multiple different organ systems. Immune-mediated cardiotoxicity - is quickly gaining recognition as a rare but devastating consequence of ICI - therapy. ICI-associated cardiotoxicity can manifest in a variety of ways, - including fulminant lymphocytic myocarditis, supraventricular and ventricular - arrhythmias, pericardial disease, and even Takotsubo-like cardiomyopathy. While - not entirely clear, the primary mechanism of injury has been hypothesized to - involve hyperactivation and infiltration of cytotoxic T-cells into cardiovascular - tissue. The diagnosis is typically made using cardiac biomarkers and imaging, in - conjunction with endomyocardial biopsy when necessary. Treatment options remain - limited and generally focus on immunosuppression. -CI - Copyright © 2018 Elsevier Inc. All rights reserved. -FAU - Yang, Shu -AU - Yang S -AD - Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, - Massachusetts. Electronic address: syang2@bidmc.harvard.edu. -FAU - Asnani, Aarti -AU - Asnani A -AD - CardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, - Massachusetts. Electronic address: aasnani@bidmc.harvard.edu. -LA - eng -PT - Journal Article -PT - Review -DEP - 20180718 -PL - United States -TA - Curr Probl Cancer -JT - Current problems in cancer -JID - 7702986 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Biomarkers) -SB - IM -MH - Antibodies, Monoclonal/*adverse effects -MH - Biomarkers/analysis -MH - Cardiotoxicity/diagnosis/*etiology -MH - Humans -MH - Immunotherapy/*adverse effects -MH - Neoplasms/*drug therapy -MH - Prognosis -MH - Risk Factors -OTO - NOTNLM -OT - Immune checkpoint inhibitor -OT - cardiotoxicity -OT - immunotherapy -OT - myocarditis -EDAT- 2018/09/04 06:00 -MHDA- 2019/06/14 06:00 -CRDT- 2018/09/04 06:00 -PHST- 2018/03/21 00:00 [received] -PHST- 2018/07/03 00:00 [revised] -PHST- 2018/07/09 00:00 [accepted] -PHST- 2018/09/04 06:00 [pubmed] -PHST- 2019/06/14 06:00 [medline] -PHST- 2018/09/04 06:00 [entrez] -AID - S0147-0272(18)30078-3 [pii] -AID - 10.1016/j.currproblcancer.2018.07.002 [doi] -PST - ppublish -SO - Curr Probl Cancer. 2018 Jul;42(4):422-432. doi: - 10.1016/j.currproblcancer.2018.07.002. Epub 2018 Jul 18. - -PMID- 33312885 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240330 -IS - 2218-4333 (Print) -IS - 2218-4333 (Electronic) -IS - 2218-4333 (Linking) -VI - 11 -IP - 11 -DP - 2020 Nov 24 -TI - Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung - cancer to avoid shipwreck. -PG - 898-917 -LID - 10.5306/wjco.v11.i11.898 [doi] -AB - After publication of the PACIFIC trial results, immune checkpoint inhibitor-based - immunotherapy was included in the treatment algorithm of locally advanced - non-small cell lung cancer (NSCLC). The PACIFIC trial demonstrated that 12 mo of - durvalumab consolidation therapy after radical-intent platinum doublet - chemotherapy with concomitant radiotherapy improved both progression-free - survival and overall survival in patients with unresectable stage III NSCLC. This - is the first treatment in decades to successfully improve survival in this - clinical setting, with manageable toxicity and without deterioration in quality - of life. The integration of durvalumab in the management of locally advanced - NSCLC accentuates the need for multidisciplinary, coordinated decision-making - among lung cancer specialists, bringing new challenges and controversies as well - as important changes in clinical work routines. The aim of the present article is - to review-from a practical, multidisciplinary perspective-the findings and - implications of the PACIFIC trial. We evaluate the immunobiological basis of - durvalumab as well as practical aspects related to programmed cell death ligand 1 - determination. In addition, we comprehensively assess the efficacy and toxicity - data from the PACIFIC trial and discuss the controversies and practical aspects - of incorporating durvalumab into routine clinical practice. Finally, we discuss - unresolved questions and future challenges. In short, the present document aims - to provide clinicians with a practical guide for the application of the PACIFIC - regimen in routine clinical practice. -CI - ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights - reserved. -FAU - Mielgo-Rubio, Xabier -AU - Mielgo-Rubio X -AD - Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, Madrid - 28922, Spain. xmielgo@hotmail.com. -FAU - Rojo, Federico -AU - Rojo F -AD - Department of Pathology, IIS-Jiménez Díaz-CIBERONC Foundation, Madrid 28040, - Spain. -FAU - Mezquita-Pérez, Laura -AU - Mezquita-Pérez L -AD - Department of Medical Oncology, Hospital Clinic, Laboratory of Translational - Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona 08036, - Spain. -FAU - Casas, Francesc -AU - Casas F -AD - Department of Radiation Oncology, Hospital Clinic, Barcelona 08036, Spain. -FAU - Wals, Amadeo -AU - Wals A -AD - Department of Radiation Oncology, Hospital Universitario Virgen Macarena, Sevilla - 41009, Spain. -FAU - Juan, Manel -AU - Juan M -AD - Department of Immunology Service, Hospital Clínic, Universitat de Barcelona, - Barcelona 08036, Spain. -FAU - Aguado, Carlos -AU - Aguado C -AD - Department of Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid - 28040, Spain. -FAU - Garde-Noguera, Javier -AU - Garde-Noguera J -AD - Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia 46015, - Spain. -FAU - Vicente, David -AU - Vicente D -AD - Department of Medical Oncology, Hospital Universitario Virgen Macarena, Sevilla - 49001, Spain. -FAU - Couñago, Felipe -AU - Couñago F -AD - Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, - Hospital La Luz, Universidad Europea de Madrid, Madrid 28028, Spain. -LA - eng -PT - Journal Article -PT - Review -PL - United States -TA - World J Clin Oncol -JT - World journal of clinical oncology -JID - 101549149 -PMC - PMC7701908 -OTO - NOTNLM -OT - Anti-programmed cell death ligand 1 -OT - Consolidation therapy -OT - Durvalumab -OT - Immune checkpoint inhibitors -OT - Immunotherapy -OT - Non-small cell lung cancer -OT - PACIFIC -OT - Unresectable stage III lung cancer -COIS- Conflict-of-interest statement: Authors declare no conflict of interests for this - article. -EDAT- 2020/12/15 06:00 -MHDA- 2020/12/15 06:01 -PMCR- 2020/11/24 -CRDT- 2020/12/14 10:58 -PHST- 2020/06/23 00:00 [received] -PHST- 2020/07/30 00:00 [revised] -PHST- 2020/10/12 00:00 [accepted] -PHST- 2020/12/14 10:58 [entrez] -PHST- 2020/12/15 06:00 [pubmed] -PHST- 2020/12/15 06:01 [medline] -PHST- 2020/11/24 00:00 [pmc-release] -AID - 10.5306/wjco.v11.i11.898 [doi] -PST - ppublish -SO - World J Clin Oncol. 2020 Nov 24;11(11):898-917. doi: 10.5306/wjco.v11.i11.898. - -PMID- 35694698 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240826 -IS - 2516-1571 (Electronic) -IS - 2096-5303 (Print) -IS - 2516-1571 (Linking) -VI - 2 -IP - 1 -DP - 2019 Mar -TI - Synergistic effect of immunotherapy and radiotherapy in non-small cell lung - cancer: current clinical trials and prospective challenges. -PG - 57-70 -LID - 10.1093/pcmedi/pbz004 [doi] -AB - Lately, the success of ICIs has drastically changed the landscape of cancer - treatment, and several immune checkpoint inhibitors (ICIs) have been approved by - the US Food and Drug Administration (FDA) for advanced non-small cell lung cancer - (NSCLC). However, numerous patients are resistant to ICIs and require additional - procedures for better efficacy results. Thus, combination therapy is urgently - needed to strengthen the anti-tumor immunity. A variety of preclinical and - clinical studies combining ICIs with radiotherapy (RT) have demonstrated that the - combination could induce synergistic effects, as RT overcomes the resistance to - ICIs. However, the underlying mechanism of the synergistic effect and the optimal - arrangement of the combination therapy are indecisive now. Hence, this review was - conducted to provide an update on the current clinical trial results and - highlighted the ongoing trials. We also discussed the optimal parameters in - clinical trials, including radiation dose, radiation fractionation, radiation - target field, and sequencing of combination therapy. In this review, we found - that combination therapy showed stronger anti-tumor immunity with tolerable - toxicities in clinical trials. However, the best combination mode and potential - biomarkers for the target patients in combination therapy are still unclear. -CI - © The Author(s) [2019]. Published by Oxford University Press on behalf of West - China School of Medicine & West China Hospital of Sichuan University. -FAU - Yang, Hui -AU - Yang H -AUID- ORCID: 0000-0003-2489-7572 -AD - Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan - University, Chengdu, China. -FAU - Jin, Tao -AU - Jin T -AD - Department of Urology, Institute of Urology (Laboratory of Reconstructive - Urology), West China Hospital, Sichuan University, Chengdu, China. -FAU - Li, Mengqian -AU - Li M -AD - Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan - University, Chengdu, China. -FAU - Xue, Jianxin -AU - Xue J -AD - Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan - University, Chengdu, China. -FAU - Lu, Bo -AU - Lu B -AD - Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, - USA. -LA - eng -PT - Journal Article -PT - Review -DEP - 20190313 -PL - England -TA - Precis Clin Med -JT - Precision clinical medicine -JID - 101739592 -PMC - PMC8985786 -OTO - NOTNLM -OT - combination -OT - immune checkpoints -OT - immunotherapy -OT - non-small cell lung cancer -OT - radiotherapy -EDAT- 2019/03/01 00:00 -MHDA- 2019/03/01 00:01 -PMCR- 2019/03/13 -CRDT- 2022/06/13 03:36 -PHST- 2019/01/05 00:00 [received] -PHST- 2019/01/31 00:00 [revised] -PHST- 2019/02/02 00:00 [accepted] -PHST- 2022/06/13 03:36 [entrez] -PHST- 2019/03/01 00:00 [pubmed] -PHST- 2019/03/01 00:01 [medline] -PHST- 2019/03/13 00:00 [pmc-release] -AID - pbz004 [pii] -AID - 10.1093/pcmedi/pbz004 [doi] -PST - ppublish -SO - Precis Clin Med. 2019 Mar;2(1):57-70. doi: 10.1093/pcmedi/pbz004. Epub 2019 Mar - 13. - -PMID- 25621841 -OWN - NLM -STAT- MEDLINE -DCOM- 20160101 -LR - 20210102 -IS - 1879-0372 (Electronic) -IS - 0952-7915 (Linking) -VI - 33 -DP - 2015 Apr -TI - The evolution of checkpoint blockade as a cancer therapy: what's here, what's - next? -PG - 23-35 -LID - S0952-7915(15)00007-2 [pii] -LID - 10.1016/j.coi.2015.01.006 [doi] -AB - Unleashing the immune system to fight cancer has become one of the main treatment - modalities since the anti-CTLA-4 antibody, ipilimumab was approved for patients - with advanced melanoma in 2011. Pembrolizumab and nivolumab, two anti-PD-1 - antibodies recently approved for the treatment of patients with metastatic - melanoma, are being actively investigated for the treatment of multiple caners - including lung, breast, bladder and renal cancers along with other anti-PD-1/L1 - antibodies. Early results of combining of anti-CTLA-4 antibody and anti-PD-1 - antibody treatment for advanced melanoma patients are showing impressive response - rates with manageable toxicity profiles. There are several other checkpoint - molecules that are likely potential inhibitory targets. The outcome of blocking - some of these negative immune regulators, such as LAG-3 or TIM-3, is being - pursued in the clinic or about to enter clinical development. Blockade of these - molecules is demonstrating promising preclinical activity alone or when combined - with anti-PD-1/L1. Future studies will define bio-markers of these therapies and - how to target them alone or in combination with other immunotherapies, - chemotherapy, radiotherapy and small molecule inhibitors. -CI - Copyright © 2015. Published by Elsevier Ltd. -FAU - Shin, Daniel Sanghoon -AU - Shin DS -AD - Department of Medicine, Division of Hematology-Oncology, University of California - Los Angeles (UCLA), Los Angeles, CA, USA; Department of Molecular, Cellular and - Integrative Physiology, UCLA, Los Angeles, CA, USA. -FAU - Ribas, Antoni -AU - Ribas A -AD - Department of Medicine, Division of Hematology-Oncology, University of California - Los Angeles (UCLA), Los Angeles, CA, USA; Department of Molecular and Medical - Pharmacology, UCLA, Los Angeles, CA, USA; Department of Surgery, Division of - Surgical-Oncology, UCLA, Los Angeles, CA, USA; Jonsson Comprehensive Cancer - Center at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA; - Department of Molecular, Cellular and Integrative Physiology, UCLA, Los Angeles, - CA, USA. Electronic address: aribas@mednet.ucla.edu. -LA - eng -GR - 2U54 CA151819/CA/NCI NIH HHS/United States -GR - 5T32AR058921-05/AR/NIAMS NIH HHS/United States -GR - 5T32CA009297-30/CA/NCI NIH HHS/United States -GR - P01 CA132681/CA/NCI NIH HHS/United States -GR - P01 CA168585/CA/NCI NIH HHS/United States -GR - R01CA170689/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -PT - Review -DEP - 20150123 -PL - England -TA - Curr Opin Immunol -JT - Current opinion in immunology -JID - 8900118 -RN - 0 (Antibodies, Monoclonal) -RN - 0 (Antigens, CD) -RN - 0 (Antineoplastic Agents) -RN - 0 (B7-H1 Antigen) -RN - 0 (CTLA-4 Antigen) -RN - 0 (Costimulatory and Inhibitory T-Cell Receptors) -RN - 0 (Programmed Cell Death 1 Receptor) -SB - IM -MH - Animals -MH - Antibodies, Monoclonal/*pharmacology/*therapeutic use -MH - Antigens, CD/metabolism -MH - Antineoplastic Agents/pharmacology/therapeutic use -MH - B7-H1 Antigen/*antagonists & inhibitors/metabolism -MH - CTLA-4 Antigen/antagonists & inhibitors -MH - Clinical Trials as Topic -MH - Costimulatory and Inhibitory T-Cell Receptors/antagonists & inhibitors -MH - Drug Evaluation, Preclinical -MH - Humans -MH - Neoplasms/*drug therapy/*immunology/metabolism -MH - Programmed Cell Death 1 Receptor/*antagonists & inhibitors/metabolism -MH - Signal Transduction/drug effects -MH - T-Lymphocyte Subsets/drug effects/immunology/metabolism -EDAT- 2015/01/27 06:00 -MHDA- 2016/01/02 06:00 -CRDT- 2015/01/27 06:00 -PHST- 2014/12/19 00:00 [received] -PHST- 2015/01/09 00:00 [revised] -PHST- 2015/01/11 00:00 [accepted] -PHST- 2015/01/27 06:00 [entrez] -PHST- 2015/01/27 06:00 [pubmed] -PHST- 2016/01/02 06:00 [medline] -AID - S0952-7915(15)00007-2 [pii] -AID - 10.1016/j.coi.2015.01.006 [doi] -PST - ppublish -SO - Curr Opin Immunol. 2015 Apr;33:23-35. doi: 10.1016/j.coi.2015.01.006. Epub 2015 - Jan 23. - -PMID- 37795434 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240926 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 13 -DP - 2023 -TI - Real-world predictors of survival in patients with extensive-stage small-cell - lung cancer in Manitoba, Canada: a retrospective cohort study. -PG - 1191855 -LID - 10.3389/fonc.2023.1191855 [doi] -LID - 1191855 -AB - BACKGROUND: Extensive-stage small-cell lung cancer (ES-SCLC) is an incurable - cancer with poor prognosis in which characteristics predictive of long-term - survival are debated. The utility of agents such as immune checkpoint inhibitors - highlights the importance of identifying key characteristics and treatment - strategies that contribute to long-term survival and could help guide therapeutic - decisions. OBJECTIVE: This real-world analysis examines the characteristics, - treatment patterns, and clinical outcomes of patients receiving chemotherapy - without immunotherapy for ES-SCLC in Manitoba, Canada. METHODS: A retrospective - cohort study assessed patient characteristics, treatment, and survival duration - (short: <6 months; medium: 6-24 months; long: >24 months) using the Manitoba - Cancer Registry and CancerCare Manitoba records. Eligible patients were aged >18 - years with cytologically confirmed ES-SCLC diagnosed between January 1, 2004, and - December 31, 2018, and received cytotoxic chemotherapy (CT). The one-, two-, and - five-year probabilities of overall survival (OS) were assessed relative to - patient, disease, and treatment characteristics using Kaplan-Meier methods and - Cox proportional hazards models. RESULTS: This analysis included 537 patients. - Cisplatin was used in 56.1% of patients, 45.6% received thoracic radiotherapy - (RT), and few received prophylactic cranial irradiation (PCI). In the overall - cohort, one-, two- and five-year OS rates were 26%, 8%, and 3%, respectively. For - patients with Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, - OS rates at one, two, and five years were 43%, 17%, and 10%, respectively, vs. - 27%, 8%, and 2% for those with ECOG PS 1-2, and 16%, 3%, and 3% for those with - ECOG PS 3-4. In long-term survivors, ECOG PS scores were lower and abnormal - laboratory test results were less frequent. Overall, 74.4% of long-term survivors - received thoracic RT and 53.5% received PCI. Known poor prognostic factors - - including brain/liver metastases, high lactate dehydrogenase (LDH), abnormal - sodium, and low hemoglobin levels - were less common but still seen in long-term - survivors. CONCLUSION: Although rare, patients with ES-SCLC may experience - long-term survival with CT ± thoracic RT ± PCI. Factors predicting long-term - survival include traditional prognostic factors such as ECOG PS, LDH level, and - receipt of thoracic RT or PCI. These findings support current treatment - algorithms for ES-SCLC and provide baseline survival estimates to assess the - real-world impact of adding immune checkpoint inhibitors in the future. -CI - Copyright © 2023 Dawe, Rittberg, Syed, Shanahan, Moldaver, Bucher, Galloway, - Reynolds, Paul, Harlos, Kim and Banerji. -FAU - Dawe, David E -AU - Dawe DE -AD - Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. -AD - Department of Hematology and Medical Oncology, CancerCare Manitoba, Winnipeg, MB, - Canada. -AD - CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, MB, - Canada. -FAU - Rittberg, Rebekah -AU - Rittberg R -AD - Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. -AD - Department of Hematology and Medical Oncology, CancerCare Manitoba, Winnipeg, MB, - Canada. -FAU - Syed, Iqra -AU - Syed I -AD - AstraZeneca Canada, Mississauga, ON, Canada. -FAU - Shanahan, Mary Kate -AU - Shanahan MK -AD - AstraZeneca Canada, Mississauga, ON, Canada. -FAU - Moldaver, Daniel -AU - Moldaver D -AD - AstraZeneca Canada, Mississauga, ON, Canada. -FAU - Bucher, Oliver -AU - Bucher O -AD - Department of Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, - MB, Canada. -FAU - Galloway, Katie -AU - Galloway K -AD - Department of Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, - MB, Canada. -FAU - Reynolds, Kayla -AU - Reynolds K -AD - Department of Cellular & Physiological Sciences, University of British Columbia, - Vancouver, BC, Canada. -FAU - Paul, James T -AU - Paul JT -AD - Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. -AD - Department of Hematology and Medical Oncology, CancerCare Manitoba, Winnipeg, MB, - Canada. -FAU - Harlos, Craig -AU - Harlos C -AD - Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. -AD - Department of Hematology and Medical Oncology, CancerCare Manitoba, Winnipeg, MB, - Canada. -FAU - Kim, Julian O -AU - Kim JO -AD - Department of Radiology, University of Manitoba, Winnipeg, MB, Canada. -AD - Department of Radiation Oncology, CancerCare Manitoba, Winnipeg, MB, Canada. -FAU - Banerji, Shantanu -AU - Banerji S -AD - Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. -AD - Department of Hematology and Medical Oncology, CancerCare Manitoba, Winnipeg, MB, - Canada. -AD - CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, MB, - Canada. -LA - eng -PT - Journal Article -DEP - 20230918 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC10545857 -OTO - NOTNLM -OT - extensive stage (ES) -OT - long-term survival -OT - overall survival (OS) -OT - performance status (ECOG-PS) -OT - radiotherapy (RT) -OT - real world -OT - small cell lung cancer (SCLC) -COIS- IS and MS are employees and shareholders of AstraZeneca. DM was an employee of - AstraZeneca at the time of this study. DD reports advisory board attendance for - Merck Canada, Novartis, Jazz Pharmaceuticals, Pfizer, and AstraZeneca, honoraria - for education content from Boehringer-Ingelheim and Bristol Myers Squibb, grants - from Canadian Institutes of Health Research, CancerCare Manitoba Foundation, and - Manitoba Medical Services Foundation. RR reports grant funding received from - AstraZeneca. SB reports advisory board attendance for AstraZeneca, Bayer, Bristol - Myers Squibb, Jazz Pharmaceuticals, Merck Canada, Novartis Janssen, Pfizer, and - Roche, clinical trial funding from AstraZeneca, Bayer, and Roche, grants from - Canadian Institutes of Health Research, grants from CancerCare Manitoba - Foundation, and grants from Genome Canada, outside the submitted work. The - remaining authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. The authors declare that this study received funding from - AstraZeneca Canada. The funder had the following involvement with the study: - study design, writing of this article, data interpretation and decision to submit - it for publication. The funder was not involved in data analysis and did not have - access to patient data. -EDAT- 2023/10/05 06:44 -MHDA- 2023/10/05 06:45 -PMCR- 2023/01/01 -CRDT- 2023/10/05 04:12 -PHST- 2023/03/22 00:00 [received] -PHST- 2023/08/07 00:00 [accepted] -PHST- 2023/10/05 06:45 [medline] -PHST- 2023/10/05 06:44 [pubmed] -PHST- 2023/10/05 04:12 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2023.1191855 [doi] -PST - epublish -SO - Front Oncol. 2023 Sep 18;13:1191855. doi: 10.3389/fonc.2023.1191855. eCollection - 2023. - -PMID- 33102221 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240329 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 10 -DP - 2020 -TI - Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later - Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung - Cancer. -PG - 556275 -LID - 10.3389/fonc.2020.556275 [doi] -LID - 556275 -AB - BACKGROUND: Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor - monotherapy has been approved as second-line or later therapy in advanced - non-small-cell lung cancer (NSCLC). The study aimed to compare the clinical - outcomes of PD-1 inhibitor plus chemotherapy with PD-1/PD-L1 inhibitor - monotherapy as second-line or later therapy in advanced NSCLC. METHODS: The - clinical data of patients with advanced NSCLC who received PD-1/PD-L1 inhibitors - as second-line or later line therapy was retrospectively collected. Patients were - assigned to one of the two groups according to the therapeutic modality used: - PD-1/PD-L1 inhibitor monotherapy group or PD-1 inhibitor plus chemotherapy - combination therapy group. Disease control rate (DCR), progression-free survival - (PFS), and overall survival (OS) were evaluated between the two groups. The - prognostic effect of the derived neutrophil-to-lymphocyte ratio (dNLR) and - lactate dehydrogenase (LDH) on the outcomes was also evaluated. RESULTS: From - April 2017 to October 2019, a total of 84 patients were enrolled in the current - study. Twenty-six patients (PD-1 inhibitor, n = 25; PD-L1 inhibitor, n = 1) - received PD-1/PD-L1 inhibitor monotherapy, and fifty-eight patients received PD-1 - inhibitor plus chemotherapy. The chemotherapy regimens used were as follows: - liposome paclitaxel (n = 15); nab-paclitaxel (n = 12); docetaxel (n = 9); - pemetrexed (n = 6); and others (n = 16). The DCR and OS were not significantly - different between the two groups. The PFS of the monotherapy group was longer - than that of the combination therapy group (mPFS: 9.6 vs. 4.6 months, P = 0.01). - Univariate and multivariate analyses suggested that LDH and sex were independent - prognostic factors of PFS. In the second-line therapy subgroup of 38 patients, OS - and PFS were not significantly different between the two groups. In the subgroup - of 46 patients treated beyond the 2nd line, the monotherapy group had a longer - PFS (mPFS: 9.6 vs. 4.2 months, P = 0.01). The incidence of any-grade adverse - events was not significantly different between the monotherapy group and the - combination therapy group (19.2 vs. 18.9%, P = 1.000). One patient in the PD-1 - inhibitor plus chemotherapy group died of immune-related pneumonitis. CONCLUSION: - The clinical outcomes of PD-1 inhibitor plus chemotherapy as second-line or later - therapy were similar to those of PD-1/PD-L1 inhibitor alone in advanced NSCLC. -CI - Copyright © 2020 Zhai, Jing, Li, Tian, Xu, Wang and Zhu. -FAU - Zhai, Xiaoyang -AU - Zhai X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Jing, Xuquan -AU - Jing X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Li, Ji -AU - Li J -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Tian, Yaru -AU - Tian Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute - Affiliated of Shandong University, Jinan, China. -FAU - Xu, Shuhui -AU - Xu S -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Wang, Min -AU - Wang M -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -FAU - Zhu, Hui -AU - Zhu H -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, China. -LA - eng -PT - Journal Article -DEP - 20200930 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC7554577 -OTO - NOTNLM -OT - PD-1 -OT - PD-L1 -OT - immune-related adverse events -OT - non-small-cell lung cancer -OT - second-line or later therapy -EDAT- 2020/10/27 06:00 -MHDA- 2020/10/27 06:01 -PMCR- 2020/01/01 -CRDT- 2020/10/26 05:26 -PHST- 2020/04/27 00:00 [received] -PHST- 2020/09/04 00:00 [accepted] -PHST- 2020/10/26 05:26 [entrez] -PHST- 2020/10/27 06:00 [pubmed] -PHST- 2020/10/27 06:01 [medline] -PHST- 2020/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2020.556275 [doi] -PST - epublish -SO - Front Oncol. 2020 Sep 30;10:556275. doi: 10.3389/fonc.2020.556275. eCollection - 2020. - -PMID- 27846884 -OWN - NLM -STAT- MEDLINE -DCOM- 20171020 -LR - 20231104 -IS - 1479-5876 (Electronic) -IS - 1479-5876 (Linking) -VI - 14 -IP - 1 -DP - 2016 Nov 15 -TI - Future perspectives in melanoma research : Meeting report from the "Melanoma - Bridge". Napoli, December 1st-4th 2015. -PG - 313 -LID - 313 -AB - The sixth "Melanoma Bridge Meeting" took place in Naples, Italy, December - 1st-4th, 2015. The four sessions at this meeting were focused on: (1) molecular - and immune advances; (2) combination therapies; (3) news in immunotherapy; and 4) - tumor microenvironment and biomarkers. Recent advances in tumor biology and - immunology has led to the development of new targeted and immunotherapeutic - agents that prolong progression-free survival (PFS) and overall survival (OS) of - cancer patients. Immunotherapies in particular have emerged as highly successful - approaches to treat patients with cancer including melanoma, non-small cell lung - cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin's - disease. Specifically, many clinical successes have been using checkpoint - receptor blockade, including T cell inhibitory receptors such as cytotoxic - T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death-1 (PD-1) - and its ligand PD-L1. Despite demonstrated successes, responses to immunotherapy - interventions occur only in a minority of patients. Attempts are being made to - improve responses to immunotherapy by developing biomarkers. Optimizing - biomarkers for immunotherapy could help properly select patients for treatment - and help to monitor response, progression and resistance that are critical - challenges for the immuno-oncology (IO) field. Importantly, biomarkers could help - to design rational combination therapies. In addition, biomarkers may help to - define mechanism of action of different agents, dose selection and to sequence - drug combinations. However, biomarkers and assays development to guide cancer - immunotherapy is highly challenging for several reasons: (i) multiplicity of - immunotherapy agents with different mechanisms of action including - immunotherapies that target activating and inhibitory T cell receptors (e.g., - CTLA-4, PD-1, etc.); adoptive T cell therapies that include tissue infiltrating - lymphocytes (TILs), chimeric antigen receptors (CARs), and T cell receptor (TCR) - modified T cells; (ii) tumor heterogeneity including changes in antigenic - profiles over time and location in individual patient; and (iii) a variety of - immune-suppressive mechanisms in the tumor microenvironment (TME) including T - regulatory cells (Treg), myeloid derived suppressor cells (MDSC) and - immunosuppressive cytokines. In addition, complex interaction of tumor-immune - system further increases the level of difficulties in the process of biomarkers - development and their validation for clinical use. Recent clinical trial results - have highlighted the potential for combination therapies that include - immunomodulating agents such as anti-PD-1 and anti-CTLA-4. Agents targeting other - immune inhibitory (e.g., Tim-3) or immune stimulating (e.g., CD137) receptors on - T cells and other approaches such as adoptive cell transfer are tested for - clinical efficacy in melanoma as well. These agents are also being tested in - combination with targeted therapies to improve upon shorter-term responses thus - far seen with targeted therapy. Various locoregional interventions that - demonstrate promising results in treatment of advanced melanoma are also - integrated with immunotherapy agents and the combinations with cytotoxic - chemotherapy and inhibitors of angiogenesis are changing the evolving landscape - of therapeutic options and are being evaluated to prevent or delay resistance and - to further improve survival rates for melanoma patients' population. This - meeting's specific focus was on advances in immunotherapy and combination therapy - for melanoma. The importance of understanding of melanoma genomic background for - development of novel therapies and biomarkers for clinical application to predict - the treatment response was an integral part of the meeting. The overall emphasis - on biomarkers supports novel concepts toward integrating biomarkers into - personalized-medicine approach for treatment of patients with melanoma across the - entire spectrum of disease stage. Translation of the knowledge gained from the - biology of tumor microenvironment across different tumors represents a bridge to - impact on prognosis and response to therapy in melanoma. We also discussed the - requirements for pre-analytical and analytical as well as clinical validation - process as applied to biomarkers for cancer immunotherapy. The concept of the - fit-for-purpose marker validation has been introduced to address the challenges - and strategies for analytical and clinical validation design for specific assays. -FAU - Ascierto, Paolo A -AU - Ascierto PA -AD - IRCCS Istituto Nazionale Tumori, Fondazione "G. Pascale", Naples, Italy. - paolo.ascierto@gmail.com. -AD - Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio - e la Cura dei Tumori "Fondazione G. Pascale", Via Mariano Semmola, 80131, Naples, - Italy. paolo.ascierto@gmail.com. -FAU - Agarwala, Sanjiv -AU - Agarwala S -AD - Department of Oncology and Hematology, St. Luke's University Hospital and Temple - University, Bethlehem, PA, USA. -FAU - Botti, Gerardo -AU - Botti G -AD - IRCCS Istituto Nazionale Tumori, Fondazione "G. Pascale", Naples, Italy. -FAU - Cesano, Alessandra -AU - Cesano A -AD - Nanostring Inc., 500 Fairview Avenue N, Seattle, WA, 98109, USA. -FAU - Ciliberto, Gennaro -AU - Ciliberto G -AD - IRCCS Istituto Nazionale Tumori, Fondazione "G. Pascale", Naples, Italy. -FAU - Davies, Michael A -AU - Davies MA -AD - Division of Cancer Medicine, Department of Melanoma Medical Oncology, The - University of Texas MD Anderson Cancer Center, Houston, TX, USA. -FAU - Demaria, Sandra -AU - Demaria S -AD - Departments of Radiation Oncology and Pathology, Weill Cornell Medical College, - New York, NY, USA. -FAU - Dummer, Reinhard -AU - Dummer R -AD - Skin Cancer Unit, Department of Dermatology, University Hospital Zürich, 8091, - Zurich, Switzerland. -FAU - Eggermont, Alexander M -AU - Eggermont AM -AD - Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. -FAU - Ferrone, Soldano -AU - Ferrone S -AD - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, - Boston, MA, USA. -FAU - Fu, Yang Xin -AU - Fu YX -AD - Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA. -FAU - Gajewski, Thomas F -AU - Gajewski TF -AD - Departments of Medicine and of Pathology, Immunology and Cancer Program, The - University of Chicago Medicine, Chicago, IL, USA. -FAU - Garbe, Claus -AU - Garbe C -AD - Department of Dermatology, Center for Dermato Oncology, University of Tübingen, - Tübingen, Germany. -FAU - Huber, Veronica -AU - Huber V -AD - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. -FAU - Khleif, Samir -AU - Khleif S -AD - Georgia Regents University Cancer Center, Georgia Regents University, Augusta, - GA, USA. -FAU - Krauthammer, Michael -AU - Krauthammer M -AD - Yale University School of Medicine, New Haven, CT, USA. -FAU - Lo, Roger S -AU - Lo RS -AD - Departments of Medicine and Molecular and Medical Pharmacology, David Geffen - School of Medicine and Jonsson Comprehensive Cancer Center at the University of - California Los Angeles (UCLA), Los Angeles, CA, USA. -FAU - Masucci, Giuseppe -AU - Masucci G -AD - Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. -FAU - Palmieri, Giuseppe -AU - Palmieri G -AD - Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research - Council, Sassari, Italy. -FAU - Postow, Michael -AU - Postow M -AD - Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell - Medical College, New York, NY, USA. -FAU - Puzanov, Igor -AU - Puzanov I -AD - Department of Medicine, Early Phase Clinical Trials Program, Roswell Park Cancer - Institute, New York, NY, USA. -FAU - Silk, Ann -AU - Silk A -AD - University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA. -FAU - Spranger, Stefani -AU - Spranger S -AD - University of Chicago, Chicago, IL, USA. -FAU - Stroncek, David F -AU - Stroncek DF -AD - Cell Processing Section, Department of Transfusion Medicine, Clinical Center, - NIH, Bethesda, MD, USA. -FAU - Tarhini, Ahmad -AU - Tarhini A -AD - Departments of Medicine, Immunology and Dermatology, University of Pittsburgh, - Pittsburgh, PA, USA. -FAU - Taube, Janis M -AU - Taube JM -AD - Department of Dermatology, Johns Hopkins University SOM, Baltimore, MD, USA. -FAU - Testori, Alessandro -AU - Testori A -AD - Istituto Europeo di Oncologia, Milan, Italy. -FAU - Wang, Ena -AU - Wang E -AD - Division of Translational Medicine, Sidra Medical and Research Center, Doha, - Qatar. -FAU - Wargo, Jennifer A -AU - Wargo JA -AD - Genomic Medicine and Surgical Oncology, The University of Texas MD Anderson - Cancer Center, Houston, TX, USA. -FAU - Yee, Cassian -AU - Yee C -AD - The University of Texas MD Anderson Cancer Center, Houston, TX, USA. -FAU - Zarour, Hassane -AU - Zarour H -AD - Departments of Medicine, Immunology and Dermatology, University of Pittsburgh, - Pittsburgh, PA, USA. -FAU - Zitvogel, Laurence -AU - Zitvogel L -AD - Gustave Roussy Cancer Center, U1015 INSERM, Villejuif, France. -AD - University Paris XI, Kremlin Bicêtre, France. -FAU - Fox, Bernard A -AU - Fox BA -AD - Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, - Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA. -AD - Department of Molecular Microbiology and Immunology, Oregon Health and Science - University, Portland, OR, USA. -FAU - Mozzillo, Nicola -AU - Mozzillo N -AD - IRCCS Istituto Nazionale Tumori, Fondazione "G. Pascale", Naples, Italy. -FAU - Marincola, Francesco M -AU - Marincola FM -AD - The University of Texas MD Anderson Cancer Center, Houston, TX, USA. -FAU - Thurin, Magdalena -AU - Thurin M -AD - Cancer Diagnosis Program, National Cancer Institute, NIH, Bethesda, MD, USA. - thurinm@mail.nih.gov. -LA - eng -GR - K08 CA160692/CA/NCI NIH HHS/United States -GR - UL1 TR001863/TR/NCATS NIH HHS/United States -PT - Congress -DEP - 20161115 -PL - England -TA - J Transl Med -JT - Journal of translational medicine -JID - 101190741 -RN - 0 (Biomarkers, Tumor) -SB - IM -MH - Animals -MH - Biomarkers, Tumor/metabolism -MH - *Biomedical Research -MH - Clinical Trials as Topic -MH - Combined Modality Therapy -MH - Humans -MH - Immunotherapy -MH - Italy -MH - Melanoma/genetics/immunology/*pathology/therapy -MH - Tumor Microenvironment -PMC - PMC5111349 -EDAT- 2016/11/17 06:00 -MHDA- 2017/10/21 06:00 -PMCR- 2016/11/15 -CRDT- 2016/11/17 06:00 -PHST- 2016/09/19 00:00 [received] -PHST- 2016/10/27 00:00 [accepted] -PHST- 2016/11/17 06:00 [entrez] -PHST- 2016/11/17 06:00 [pubmed] -PHST- 2017/10/21 06:00 [medline] -PHST- 2016/11/15 00:00 [pmc-release] -AID - 10.1186/s12967-016-1070-y [pii] -AID - 1070 [pii] -AID - 10.1186/s12967-016-1070-y [doi] -PST - epublish -SO - J Transl Med. 2016 Nov 15;14(1):313. doi: 10.1186/s12967-016-1070-y. - -PMID- 32536981 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220415 -IS - 1758-8340 (Print) -IS - 1758-8359 (Electronic) -IS - 1758-8340 (Linking) -VI - 12 -DP - 2020 -TI - Rationale and design of a phase II trial of durvalumab treatment in patients with - NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy - (SPIRAL-RT study). -PG - 1758835920927841 -LID - 10.1177/1758835920927841 [doi] -LID - 1758835920927841 -AB - BACKGROUND: In the PACIFIC study, progression-free survival (PFS) and overall - survival (OS) of patients with unresectable, locally advanced, stage III - non-small cell lung cancer (NSCLC) were prolonged by durvalumab as maintenance - therapy after radical concurrent chemoradiotherapy using platinum-based antitumor - agents. However, no data were obtained to reveal the efficacy of durvalumab after - radiation monotherapy in patients unsuitable for chemoradiotherapy. Here, we - describe an ongoing single-arm, prospective, open-label, multicenter phase II - trial of durvalumab in patients with NSCLC ineligible for stage III - chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). METHODS: - Durvalumab at 10 mg/kg body weight is administered every 2 weeks after radiation - therapy until individual patients meet the discontinuation criteria. The - treatment duration is up to 12 months. The primary endpoint is the 1-year PFS - rate. Secondary endpoints are response rate, PFS, OS, and safety. Durvalumab - treatment after radiation monotherapy is expected to prolong 1-year PFS rate and - have acceptable adverse events. DISCUSSION: We are conducting an intervention - study to investigate the safety and efficacy of durvalumab treatment in patients - with NSCLC ineligible for stage III chemoradiotherapy following radiation - monotherapy. -CI - © The Author(s), 2020. -FAU - Yamada, Tadaaki -AU - Yamada T -AUID- ORCID: 0000-0002-6945-281X -AD - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, - Kyoto, Japan. -FAU - Uchino, Junji -AU - Uchino J -AUID- ORCID: 0000-0003-0651-7767 -AD - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, 465 - Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto 602-0857, Japan. -FAU - Chihara, Yusuke -AU - Chihara Y -AD - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, - Kyoto, Japan. -FAU - Shimamoto, Takayuki -AU - Shimamoto T -AD - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, - Kyoto, Japan. -FAU - Iwasaku, Masahiro -AU - Iwasaku M -AD - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, - Kyoto, Japan. -FAU - Tamiya, Nobuyo -AU - Tamiya N -AD - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, - Kyoto, Japan. -FAU - Kaneko, Yoshiko -AU - Kaneko Y -AD - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, - Kyoto, Japan. -FAU - Kiyomi, Fumiaki -AU - Kiyomi F -AD - Statistics and Data Center, Clinical Research Support Center Kyushu, Fukuoka, - Japan. -FAU - Takayama, Koichi -AU - Takayama K -AD - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, - Kyoto, Japan. -LA - eng -PT - Journal Article -DEP - 20200528 -PL - England -TA - Ther Adv Med Oncol -JT - Therapeutic advances in medical oncology -JID - 101510808 -PMC - PMC7268142 -OTO - NOTNLM -OT - 1-year progression-free survival rate -OT - anti-programmed death-ligand 1 antibody -OT - maintenance therapy -OT - non-small cell lung cancer -OT - radiotherapy -COIS- Conflict of interest statement: TY obtained grants from Nippon Boehringer - Ingelheim and Ono Pharmaceutical for different work. JU obtained grants from Eli - Lilly Japan K.K. for different work. KT obtained grants from Chugai-Roche and Ono - Pharmaceutical, personal fees from AstraZeneca K.K., Chugai-Roche, MSD-Merck, Eli - Lilly, Boehringer Ingelheim, and Daiichi-Sankyo for different work. -EDAT- 2020/06/17 06:00 -MHDA- 2020/06/17 06:01 -PMCR- 2020/05/28 -CRDT- 2020/06/16 06:00 -PHST- 2019/08/29 00:00 [received] -PHST- 2020/04/28 00:00 [accepted] -PHST- 2020/06/16 06:00 [entrez] -PHST- 2020/06/17 06:00 [pubmed] -PHST- 2020/06/17 06:01 [medline] -PHST- 2020/05/28 00:00 [pmc-release] -AID - 10.1177_1758835920927841 [pii] -AID - 10.1177/1758835920927841 [doi] -PST - epublish -SO - Ther Adv Med Oncol. 2020 May 28;12:1758835920927841. doi: - 10.1177/1758835920927841. eCollection 2020. - -PMID- 39040456 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240724 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 14 -DP - 2024 -TI - Camrelizumab combined with anlotinib as second-line therapy for metastatic or - recurrent small cell lung cancer: a retrospective cohort study. -PG - 1391828 -LID - 10.3389/fonc.2024.1391828 [doi] -LID - 1391828 -AB - INTRODUCTION: This retrospective study evaluates the efficacy of camrelizumab - combined with anlotinib versus chemotherapy in patients with extensive-stage - small-cell lung cancer (ES-SCLC) undergoing second-line treatment. METHODS: Data - were sourced from medical records at a Chinese medical facility, involving 34 - patients diagnosed with ES-SCLC after failing first-line treatment. Patients were - divided into two groups: one received camrelizumab (200 mg every 3 weeks) with - anlotinib (12 mg daily for 14 days followed by a 7-day rest), while the other - group received physician-chosen chemotherapy administered every 3 weeks. The - primary endpoint was progression-free survival (PFS), with secondary endpoints - including overall survival (OS), objective response rate (ORR), and disease - control rate (DCR). RESULTS: The combination therapy group showed a significant - improvement in PFS compared to the chemotherapy group (median PFS: 7 months vs. 3 - months; hazard ratio (HR): 0.34; 95% confidence interval (CI): 0.15-0.77; - p<0.001). However, there was no statistically significant difference in OS - between the groups (16.3 months vs. 17.3 months; p=0.82). The ORR was 52.9% in - the combination therapy group versus 23.5% in the chemotherapy group (p=0.08), - and the DCR was 82.4% compared to 58.8% (p=0.26). Grade 3 or higher adverse - events were observed in 17.6% of the combination therapy group and 29.4% of the - chemotherapy group. CONCLUSIONS: The findings suggest that the combination of - camrelizumab and anlotinib offers a superior anti-tumor response with a - manageable safety profile in a second-line setting for ES-SCLC patients. This - combination regimen may be a viable option for second-line ES-SCLC treatment. -CI - Copyright © 2024 Shen, Li, Guo, Xu and Yan. -FAU - Shen, Shujing -AU - Shen S -AD - Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou - University, Zhengzhou, China. -FAU - Li, Xingya -AU - Li X -AD - Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou - University, Zhengzhou, China. -FAU - Guo, Sanxing -AU - Guo S -AD - Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou - University, Zhengzhou, China. -FAU - Xu, Liang -AU - Xu L -AD - Prevention and Cure Center of Breast Disease, The Third Hospital of Nanchang - City, Nanchang, Jiangxi, China. -FAU - Yan, Ningning -AU - Yan N -AD - Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou - University, Zhengzhou, China. -LA - eng -PT - Journal Article -DEP - 20240708 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC11261159 -OTO - NOTNLM -OT - anlotinib -OT - camrelizumab -OT - extensive stage -OT - second-line setting -OT - small-cell lung cancer -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2024/07/23 06:42 -MHDA- 2024/07/23 06:43 -PMCR- 2024/01/01 -CRDT- 2024/07/23 04:18 -PHST- 2024/04/23 00:00 [received] -PHST- 2024/06/24 00:00 [accepted] -PHST- 2024/07/23 06:43 [medline] -PHST- 2024/07/23 06:42 [pubmed] -PHST- 2024/07/23 04:18 [entrez] -PHST- 2024/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2024.1391828 [doi] -PST - epublish -SO - Front Oncol. 2024 Jul 8;14:1391828. doi: 10.3389/fonc.2024.1391828. eCollection - 2024. - -PMID- 35236356 -OWN - NLM -STAT- MEDLINE -DCOM- 20220331 -LR - 20220401 -IS - 1477-3155 (Electronic) -IS - 1477-3155 (Linking) -VI - 20 -IP - 1 -DP - 2022 Mar 2 -TI - IR792-MCN@ZIF-8-PD-L1 siRNA drug delivery system enhances photothermal - immunotherapy for triple-negative breast cancer under near-infrared laser - irradiation. -PG - 96 -LID - 10.1186/s12951-022-01255-6 [doi] -LID - 96 -AB - BACKGROUND: Despite extensive investigations on photothermal therapy, the - clinical application is restricted due to poor stability, low therapeutic - efficacy of photothermal therapy agents and its affinity loss in the multistep - synthesis of delivery carriers. To address this, we designed an - IR792-MCN@ZIF-8-PD-L1 siRNA (IM@ZP) nanoparticle drug delivery system. IM@ZP was - prepared by in situ synthesis and physical adsorption, followed by - characterization. Photothermal conversion ability of IM@ZP was assessed by - irradiation of near-infrared (NIR) laser, followed by analysis of its effect on - 4T1 cell viability, maturation of dendritic cells (DCs) and the secretion of - related cytokines in vitro, and the changes of tumor infiltrating T cells and - natural killer (NK) cells in vivo. Subcutaneous 4T1 tumor-bearing mouse and lung - metastasis models were established to investigate the role of IM@ZP in killing - tumor and inhibiting metastasis in vivo. RESULTS: IM@ZP was uniform nanoparticles - of 81.67 nm with the characteristic UV absorption peak of IR792, and could - effectively adsorb PD-L1 siRNA. Under the irradiation of 808 nm laser, IM@ZP - exhibited excellent photothermal performance. IM@ZP could be efficiently uptaken - by 4T1 cells, and had high transfection efficiency of PD-L1 siRNA. Upon NIR laser - irradiation, IM@ZP effectively killed 4T1 cells, upregulated HSP70 expression, - induced DC maturation and increased secretion of TNF-α and IL-6 in vitro. - Moreover, in vivo experimental results revealed that IM@ZP enhanced photothermal - immunotherapy as shown by promoted tumor infiltrating CD8 +  and CD4 +  T cells - and NK cells, and inhibited tumor growth and lung metastasis. CONCLUSION: - Together, biocompatible IM@ZP nanoparticles result in high photothermal - immunotherapy efficiency and may have a great potential as a delivery system for - sustained cancer therapy. -CI - © 2022. The Author(s). -FAU - Wang, Yongmei -AU - Wang Y -AD - Breast Disease Center, The Affiliated Hospital of Qingdao University, No. 59, - Haier Road, Qingdao, 266071, Shandong, People's Republic of China. - qdfywym@163.com. -FAU - Wang, Haibo -AU - Wang H -AD - Breast Disease Center, The Affiliated Hospital of Qingdao University, No. 59, - Haier Road, Qingdao, 266071, Shandong, People's Republic of China. -FAU - Song, Yuhua -AU - Song Y -AD - Breast Disease Center, The Affiliated Hospital of Qingdao University, No. 59, - Haier Road, Qingdao, 266071, Shandong, People's Republic of China. -FAU - Lv, Meng -AU - Lv M -AD - Breast Disease Center, The Affiliated Hospital of Qingdao University, No. 59, - Haier Road, Qingdao, 266071, Shandong, People's Republic of China. -FAU - Mao, Yan -AU - Mao Y -AD - Breast Disease Center, The Affiliated Hospital of Qingdao University, No. 59, - Haier Road, Qingdao, 266071, Shandong, People's Republic of China. -FAU - Song, Hongming -AU - Song H -AD - Breast Disease Center, The Affiliated Hospital of Qingdao University, No. 59, - Haier Road, Qingdao, 266071, Shandong, People's Republic of China. -FAU - Wang, Yuanyuan -AU - Wang Y -AD - Breast Disease Center, The Affiliated Hospital of Qingdao University, No. 59, - Haier Road, Qingdao, 266071, Shandong, People's Republic of China. -FAU - Nie, Gang -AU - Nie G -AD - Breast Disease Center, The Affiliated Hospital of Qingdao University, No. 59, - Haier Road, Qingdao, 266071, Shandong, People's Republic of China. -FAU - Liu, Xiaoyi -AU - Liu X -AD - Breast Disease Center, The Affiliated Hospital of Qingdao University, No. 59, - Haier Road, Qingdao, 266071, Shandong, People's Republic of China. -FAU - Cui, Jian -AU - Cui J -AD - Breast Disease Center, The Affiliated Hospital of Qingdao University, No. 59, - Haier Road, Qingdao, 266071, Shandong, People's Republic of China. -FAU - Zou, Xueqing -AU - Zou X -AD - Department of Anesthesiology, The Affiliated Hospital of Qingdao University, No. - 59, Haier Road, Qingdao, 266071, Shandong, People's Republic of China. - qdfyzxq@163.com. -LA - eng -GR - 19-6-2-56-cg/the foundation of the applied basic research program of qingdao/ -GR - ZR2018BH023/natural science doctoral funding of shandong province/ -GR - ZR2017BH061/natural science doctoral funding of shandong province/ -GR - ZR2019BH013/natural science doctoral funding of shandong province/ -PT - Journal Article -DEP - 20220302 -PL - England -TA - J Nanobiotechnology -JT - Journal of nanobiotechnology -JID - 101152208 -RN - 0 (B7-H1 Antigen) -RN - 0 (RNA, Small Interfering) -RN - 80168379AG (Doxorubicin) -SB - IM -MH - Animals -MH - B7-H1 Antigen -MH - Cell Line, Tumor -MH - Doxorubicin/pharmacology -MH - Drug Delivery Systems -MH - Humans -MH - Immunotherapy -MH - Lasers -MH - Mice -MH - *Nanoparticles -MH - Phototherapy/methods -MH - RNA, Small Interfering/therapeutic use -MH - *Triple Negative Breast Neoplasms/drug therapy -PMC - PMC8889783 -OTO - NOTNLM -OT - Dendritic cell -OT - HSP70 -OT - IR792 -OT - Mesoporous carbon nanocomposite -OT - Near-infrared laser irradiation -OT - PD-L1 siRNA -OT - Triple-negative breast cancer -OT - Zeolitic imidazolate frameworks-8 -COIS- The authors declare that they have no competing interests. -EDAT- 2022/03/04 06:00 -MHDA- 2022/04/01 06:00 -PMCR- 2022/03/02 -CRDT- 2022/03/03 05:30 -PHST- 2021/04/27 00:00 [received] -PHST- 2022/01/09 00:00 [accepted] -PHST- 2022/03/03 05:30 [entrez] -PHST- 2022/03/04 06:00 [pubmed] -PHST- 2022/04/01 06:00 [medline] -PHST- 2022/03/02 00:00 [pmc-release] -AID - 10.1186/s12951-022-01255-6 [pii] -AID - 1255 [pii] -AID - 10.1186/s12951-022-01255-6 [doi] -PST - epublish -SO - J Nanobiotechnology. 2022 Mar 2;20(1):96. doi: 10.1186/s12951-022-01255-6. - -PMID- 26487966 -OWN - NLM -STAT- PubMed-not-MEDLINE -DCOM- 20151021 -LR - 20240323 -IS - 2095-3941 (Print) -IS - 2095-3941 (Linking) -VI - 12 -IP - 3 -DP - 2015 Sep -TI - Advances in immunotherapy for treatment of lung cancer. -PG - 209-22 -LID - 10.7497/j.issn.2095-3941.2015.0032 [doi] -AB - Different approaches for treating lung cancer have been developed over time, - including chemotherapy, radiotherapy and targeted therapies against activating - mutations. Lately, better understanding of the role of the immunological system - in tumor control has opened multiple doors to implement different strategies to - enhance immune response against cancer cells. It is known that tumor cells elude - immune response by several mechanisms. The development of monoclonal antibodies - against the checkpoint inhibitor programmed cell death protein 1 (PD-1) and its - ligand (PD-L1), on T cells, has led to high activity in cancer patients with long - lasting responses. Nivolumab, an anti PD-1 inhibitor, has been recently approved - for the treatment of squamous cell lung cancer patients, given the survival - advantage demonstrated in a phase III trial. Pembrolizumab, another anti PD-1 - antibody, has received FDA breakthrough therapy designation for treatment of - non-small cell lung cancer (NSCLC), supported by data from a phase I trial. - Clinical trials with anti PD-1/PD-L1 antibodies in NSCLC have demonstrated very - good tolerability and activity, with response rates around 20% and a median - duration of response of 18 months. -FAU - Bustamante Alvarez, Jean G -AU - Bustamante Alvarez JG -AD - 1 Albert Einstein Medical Center, Philadelphia 19141, USA ; 2 Translational - Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University - Hospital, Barcelona 08028, Spain ; 3 Medical Oncology Unit, Human Pathology - Department, University of Messina, Messina 98100, Italy ; 4 Pangaea Biotech S.L, - Barcelona 08028, Spain ; 5 Cancer Biology & Precision Medicine Program, Catalan - Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and - Hospital, Campus Can Ruti, Badalona, Barcelona 08916, Spain ; 6 Fundación - Molecular Oncology Research, Barcelona 08028, Spain. -FAU - González-Cao, María -AU - González-Cao M -AD - 1 Albert Einstein Medical Center, Philadelphia 19141, USA ; 2 Translational - Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University - Hospital, Barcelona 08028, Spain ; 3 Medical Oncology Unit, Human Pathology - Department, University of Messina, Messina 98100, Italy ; 4 Pangaea Biotech S.L, - Barcelona 08028, Spain ; 5 Cancer Biology & Precision Medicine Program, Catalan - Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and - Hospital, Campus Can Ruti, Badalona, Barcelona 08916, Spain ; 6 Fundación - Molecular Oncology Research, Barcelona 08028, Spain. -FAU - Karachaliou, Niki -AU - Karachaliou N -AD - 1 Albert Einstein Medical Center, Philadelphia 19141, USA ; 2 Translational - Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University - Hospital, Barcelona 08028, Spain ; 3 Medical Oncology Unit, Human Pathology - Department, University of Messina, Messina 98100, Italy ; 4 Pangaea Biotech S.L, - Barcelona 08028, Spain ; 5 Cancer Biology & Precision Medicine Program, Catalan - Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and - Hospital, Campus Can Ruti, Badalona, Barcelona 08916, Spain ; 6 Fundación - Molecular Oncology Research, Barcelona 08028, Spain. -FAU - Santarpia, Mariacarmela -AU - Santarpia M -AD - 1 Albert Einstein Medical Center, Philadelphia 19141, USA ; 2 Translational - Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University - Hospital, Barcelona 08028, Spain ; 3 Medical Oncology Unit, Human Pathology - Department, University of Messina, Messina 98100, Italy ; 4 Pangaea Biotech S.L, - Barcelona 08028, Spain ; 5 Cancer Biology & Precision Medicine Program, Catalan - Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and - Hospital, Campus Can Ruti, Badalona, Barcelona 08916, Spain ; 6 Fundación - Molecular Oncology Research, Barcelona 08028, Spain. -FAU - Viteri, Santiago -AU - Viteri S -AD - 1 Albert Einstein Medical Center, Philadelphia 19141, USA ; 2 Translational - Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University - Hospital, Barcelona 08028, Spain ; 3 Medical Oncology Unit, Human Pathology - Department, University of Messina, Messina 98100, Italy ; 4 Pangaea Biotech S.L, - Barcelona 08028, Spain ; 5 Cancer Biology & Precision Medicine Program, Catalan - Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and - Hospital, Campus Can Ruti, Badalona, Barcelona 08916, Spain ; 6 Fundación - Molecular Oncology Research, Barcelona 08028, Spain. -FAU - Teixidó, Cristina -AU - Teixidó C -AD - 1 Albert Einstein Medical Center, Philadelphia 19141, USA ; 2 Translational - Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University - Hospital, Barcelona 08028, Spain ; 3 Medical Oncology Unit, Human Pathology - Department, University of Messina, Messina 98100, Italy ; 4 Pangaea Biotech S.L, - Barcelona 08028, Spain ; 5 Cancer Biology & Precision Medicine Program, Catalan - Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and - Hospital, Campus Can Ruti, Badalona, Barcelona 08916, Spain ; 6 Fundación - Molecular Oncology Research, Barcelona 08028, Spain. -FAU - Rosell, Rafael -AU - Rosell R -AD - 1 Albert Einstein Medical Center, Philadelphia 19141, USA ; 2 Translational - Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University - Hospital, Barcelona 08028, Spain ; 3 Medical Oncology Unit, Human Pathology - Department, University of Messina, Messina 98100, Italy ; 4 Pangaea Biotech S.L, - Barcelona 08028, Spain ; 5 Cancer Biology & Precision Medicine Program, Catalan - Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and - Hospital, Campus Can Ruti, Badalona, Barcelona 08916, Spain ; 6 Fundación - Molecular Oncology Research, Barcelona 08028, Spain. -LA - eng -PT - Journal Article -PT - Review -PL - China -TA - Cancer Biol Med -JT - Cancer biology & medicine -JID - 101588850 -PMC - PMC4607819 -OTO - NOTNLM -OT - Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) -OT - immune checkpoint inhibitors -OT - lung cancer -OT - programmed cell death protein 1 (PD-1) -OT - programmed cell death protein ligand-1 (PD-L1) -COIS- No potential conflicts of interest are disclosed. -EDAT- 2015/10/22 06:00 -MHDA- 2015/10/22 06:01 -PMCR- 2015/09/01 -CRDT- 2015/10/22 06:00 -PHST- 2015/10/22 06:00 [entrez] -PHST- 2015/10/22 06:00 [pubmed] -PHST- 2015/10/22 06:01 [medline] -PHST- 2015/09/01 00:00 [pmc-release] -AID - cbm-12-03-209 [pii] -AID - 10.7497/j.issn.2095-3941.2015.0032 [doi] -PST - ppublish -SO - Cancer Biol Med. 2015 Sep;12(3):209-22. doi: 10.7497/j.issn.2095-3941.2015.0032. - -PMID- 36237270 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20221015 -IS - 2219-6803 (Electronic) -IS - 2218-676X (Print) -IS - 2218-676X (Linking) -VI - 11 -IP - 9 -DP - 2022 Sep -TI - Is immunotherapy at reduced dose and radiotherapy for older patients with locally - advanced non-small lung cancer feasible?-a narrative review by the international - geriatric radiotherapy group. -PG - 3298-3308 -LID - 10.21037/tcr-22-821 [doi] -AB - BACKGROUND AND OBJECTIVE: The standard of care for locally advanced non-small - cell lung cancer (NSCLC) is either surgery followed by adjuvant chemotherapy with - or without radiotherapy or concurrent chemotherapy and radiotherapy. However, - older patients (70 years old or above) with multiple co-morbidities may not be - able to tolerate the combined treatment due to its toxicity. Since lung cancer - prevalence increases significantly with age, a new algorithm needs to be - investigated to allow curative treatment for those with locally advanced disease. - METHODS: A literature search of the literature was conducted through PubMed and - Google Scholar using search terms such as locally advanced NSCLC, older cancer - patients, immunotherapy with check point inhibitors (CPI), and image-guided - radiotherapy (IGRT). Abstracts were screened, full articles fitting the article - topic were reviewed, and duplicated and non-English articles were excluded. KEY - CONTENT AND FINDINGS: Recently, CPI has been introduced and proven effective for - selected patients with increased program death ligand 1 (PD-L1) expression (50% - or above). A reduced dose for CPI (RDCPI) may be as effective as a full dose and - may decrease treatment cost. New radiation technique such as IGRT may also - minimize radiotherapy complication through normal lung and cardiac sparing. - CONCLUSIONS: IGRT and RDCPI may be an innovative option for older patients with - locally advanced NSCLC and high PD-L1 expression and needs to be investigated in - future prospective studies. -CI - 2022 Translational Cancer Research. All rights reserved. -FAU - Vinh-Hung, Vincent -AU - Vinh-Hung V -AD - Department of Radiation Oncology, Centre Hospitalier de la Polynesie Francaise, - Papeete, Tahiti, French Polynesia. -FAU - Gorobets, Olena -AU - Gorobets O -AD - Department of Oral Surgery, Centre Hospitalier Universitaire de Martinique, Le - Lamentin, Martinique, France. -FAU - Duerinkcx, Andre -AU - Duerinkcx A -AD - Department of Radiology, Howard University, Washington DC, USA. -FAU - Dutta, Suresh -AU - Dutta S -AD - Department of Radiation Oncology, International Geriatric Radiotherapy Group, - Washington DC, USA. -FAU - Oboite, Eromosele -AU - Oboite E -AD - Department of Radiology, Howard University, Washington DC, USA. -FAU - Oboite, Joan -AU - Oboite J -AD - Department of Radiology, Howard University, Washington DC, USA. -FAU - Ali, Ahmed -AU - Ali A -AD - Department of Radiology, Howard University, Washington DC, USA. -FAU - Mazibuko, Thandeka -AU - Mazibuko T -AD - Department of Radiation Oncology, International Geriatric Radiotherapy Group, - Washington DC, USA. -FAU - Karlsson, Ulf -AU - Karlsson U -AD - Department of Radiation Oncology, International Geriatric Radiotherapy Group, - Washington DC, USA. -FAU - Chi, Alexander -AU - Chi A -AD - Department of Radiation Oncology, Beijing Chest Hospital, Capital Medical - University, Beijing, China. -FAU - Lehrman, David -AU - Lehrman D -AD - Department of Radiation Oncology, International Geriatric Radiotherapy Group, - Washington DC, USA. -FAU - Mohammed, Omer Hashim -AU - Mohammed OH -AD - Department of Radiation Oncology, Port Sudan Oncology, Khartoum, Sudan. -FAU - Mohammadianpanah, Mohammad -AU - Mohammadianpanah M -AD - Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical - Sciences, Shiraz, Iran. -FAU - Loganadane, Gokoulakrichenane -AU - Loganadane G -AD - Department of Radiation Oncology, CHU Mondor, University Paris Est Creteil, - Creteil, France. -FAU - Migliore, Natalia -AU - Migliore N -AD - Barretos School of Health Sciences Dr. Paulo Prata, Barretos, Sao Paulo, Brazil. -FAU - Vasileiou, Maria -AU - Vasileiou M -AD - Department of Pharmacy, School of Health Sciences, National and Kapodistrian - University of Athens, Athens, Greece. -FAU - Nguyen, Nam P -AU - Nguyen NP -AD - Department of Radiology, Howard University, Washington DC, USA. -FAU - Giap, Huan -AU - Giap H -AD - Department of Radiation Oncology, Medical University of South Carolina, - Charleston, SC, USA. -LA - eng -PT - Journal Article -PT - Review -PL - China -TA - Transl Cancer Res -JT - Translational cancer research -JID - 101585958 -PMC - PMC9552052 -OTO - NOTNLM -OT - Older -OT - cancer patients -OT - image-guided radiotherapy (IGRT) -OT - locally advanced -OT - reduced dose for check point inhibitor (RDCPI) -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://tcr.amegroups.com/article/view/10.21037/tcr-22-821/coif). VVH received - travel support from Ipsen. VVH reports a patent USPTO 62/608,751, WO/2019/014384 - pending. TM is the executive director of Black Women in Oncology, and the - executive director of SinomusaNothando Community Development Inc. HG serves as - Co-Editor-in-Chief of Translational Cancer Research. The other authors have no - conflicts of interest to declare. -EDAT- 2022/10/15 06:00 -MHDA- 2022/10/15 06:01 -PMCR- 2022/09/01 -CRDT- 2022/10/14 02:46 -PHST- 2022/03/26 00:00 [received] -PHST- 2022/08/26 00:00 [accepted] -PHST- 2022/10/14 02:46 [entrez] -PHST- 2022/10/15 06:00 [pubmed] -PHST- 2022/10/15 06:01 [medline] -PHST- 2022/09/01 00:00 [pmc-release] -AID - tcr-11-09-3298 [pii] -AID - 10.21037/tcr-22-821 [doi] -PST - ppublish -SO - Transl Cancer Res. 2022 Sep;11(9):3298-3308. doi: 10.21037/tcr-22-821. - -PMID- 32099495 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20200928 -IS - 1179-2728 (Print) -IS - 1179-2728 (Electronic) -IS - 1179-2728 (Linking) -VI - 10 -DP - 2019 -TI - Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III - Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives. -PG - 161-170 -LID - 10.2147/LCTT.S184380 [doi] -AB - There has been no improvement in outcome for patients with unresectable locally - advanced (stage III) non-small cell lung cancer (NSCLC) for more than 10 years. - The standard treatment for these patients is definitive concurrent chemotherapy - and radiation (CCRT). Although the goal of treatment in this setting is to - achieve a cure, most patients progress and their prognosis is poor, with a 5-year - survival rate of 15-30%. There is thus an urgent need for the development of - novel anticancer treatments in this patient population. Recent advances in cancer - immunotherapy have led to a marked improvement in clinical outcome for advanced - NSCLC. Such immunotherapy mainly consists of the administration of immune - checkpoint inhibitors (ICIs) such as antibodies to cytotoxic T - lymphocyte-associated protein-4 (CTLA-4) or to either programmed cell death-1 - (PD-1) or its ligand PD-L1. Durvalumab (MEDI4736) is a high-affinity human - immunoglobulin G1 monoclonal antibody that blocks the binding of PD-L1 on tumor - cells or antigen-presenting cells to PD-1 on T cells. The PACIFIC study recently - evaluated consolidation immunotherapy with durvalumab versus placebo administered - after concurrent chemoradiotherapy (CCRT) in patients with unresectable stage III - NSCLC. It revealed a significant improvement in both progression-free and overall - survival with durvalumab, and this improvement was associated with a favorable - safety profile. This achievement has made durvalumab a standard of care for - consolidation after CCRT in patients with unresectable stage III NSCLC, and it - has now been approved in this setting by regulatory agencies in the United - States, Canada, Japan, Australia, Switzerland, Malaysia, Singapore, India, and - the United Arab Emirates. In this review, we briefly summarize the results of the - PACIFIC trial, including those of post hoc analysis, and we address possible - molecular mechanisms, perspectives, and remaining questions related to combined - treatment with CCRT and ICIs in this patient population. -CI - © 2019 Inoue and Okamoto. -FAU - Inoue, Hiroyuki -AU - Inoue H -AD - Research Institute for Diseases of the Chest, Graduate School of Medical - Sciences, Kyushu University, Fukuoka, Japan. -AD - Center for Clinical and Translational Research, Kyushu University Hospital, - Fukuoka, Japan. -FAU - Okamoto, Isamu -AU - Okamoto I -AD - Research Institute for Diseases of the Chest, Graduate School of Medical - Sciences, Kyushu University, Fukuoka, Japan. -LA - eng -PT - Journal Article -PT - Review -DEP - 20191231 -PL - New Zealand -TA - Lung Cancer (Auckl) -JT - Lung Cancer (Auckland, N.Z.) -JID - 101632521 -PMC - PMC6997215 -OTO - NOTNLM -OT - PD-L1 -OT - durvalumab -OT - immunogenic cell death -OT - lung cancer -COIS- Dr Isamu Okamoto reports grants, personal fees from AstraZenaca, during the - conduct of the study; grants from Boehringer Ingelheim, Astellas Pharma, - Novartis, and AbbVie; grants, personal fees from Taiho Pharmaceutical, Ono - Pharmaceutical, MSD, Eli Lilly, Bristol-Myers Squibb, Chugai Pharma; personal - fees from Pfizer, outside the submitted work. The authors report no other - conflicts of interest in this work. -EDAT- 2020/02/27 06:00 -MHDA- 2020/02/27 06:01 -PMCR- 2019/12/31 -CRDT- 2020/02/27 06:00 -PHST- 2019/11/02 00:00 [received] -PHST- 2019/12/20 00:00 [accepted] -PHST- 2020/02/27 06:00 [entrez] -PHST- 2020/02/27 06:00 [pubmed] -PHST- 2020/02/27 06:01 [medline] -PHST- 2019/12/31 00:00 [pmc-release] -AID - 184380 [pii] -AID - 10.2147/LCTT.S184380 [doi] -PST - epublish -SO - Lung Cancer (Auckl). 2019 Dec 31;10:161-170. doi: 10.2147/LCTT.S184380. - eCollection 2019. - -PMID- 34086039 -OWN - NLM -STAT- Publisher -LR - 20240222 -IS - 2374-2445 (Electronic) -IS - 2374-2437 (Print) -IS - 2374-2437 (Linking) -VI - 7 -IP - 9 -DP - 2021 Jun 4 -TI - Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With - Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 - KEYNOTE-799 Nonrandomized Trial. -PG - 1-9 -LID - 10.1001/jamaoncol.2021.2301 [doi] -AB - IMPORTANCE: Administration of pembrolizumab plus concurrent chemoradiation - therapy (cCRT) may provide treatment benefit to patients with locally advanced, - stage III non-small cell lung cancer (NSCLC). OBJECTIVE: To evaluate treatment - outcomes and safety of pembrolizumab plus cCRT in stage III NSCLC. DESIGN, - SETTING, AND PARTICIPANTS: The phase 2, nonrandomized, 2-cohort, open-label - KEYNOTE-799 study enrolled patients between November 5, 2018, and July 31, 2020, - from 52 academic facilities and community-based institutions across 10 countries. - As of October 28, 2020, median (range) follow-up was 18.5 (13.6-23.8) months in - cohort A and 13.7 (2.9-23.5) months in cohort B. Of 301 patients screened, 216 - eligible patients with previously untreated, unresectable, and - pathologically/radiologically confirmed stage IIIA/IIIB/IIIC NSCLC with - measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 - (RECIST v1.1) were enrolled. INTERVENTIONS: Patients in cohort A - (squamous/nonsquamous) received 1 cycle (3 weeks) of carboplatin (area under the - curve [AUC] 6 mg/mL/min), paclitaxel (200 mg/m2), and pembrolizumab (200 mg), - followed by carboplatin (AUC 2 mg/mL/min) and paclitaxel (45 mg/m2) once weekly - for 6 weeks and 2 cycles of pembrolizumab plus standard thoracic radiotherapy. - Patients in cohort B (nonsquamous) received 3 cycles of cisplatin (75 mg/m2), - pemetrexed (500 mg/m2), and pembrolizumab (200 mg) every 3 weeks and thoracic - radiotherapy in cycles 2 and 3. Patients received 14 additional cycles of - pembrolizumab. MAIN OUTCOMES AND MEASURES: Coprimary end points were objective - response rate per RECIST v1.1 by blinded independent central review and incidence - of grade 3 to 5 pneumonitis. RESULTS: A total of 112 patients received treatment - in cohort A (76 men [67.9%]; median [range] age, 66.0 [46-90] years; 66 patients - [58.9%] with programmed cell death ligand 1 [PD-L1] tumor proportion score ≥1%) - and 102 patients received treatment in cohort B (62 men [60.8%]; median [range] - age, 64.0 [35-81] years; 40 patients [39.2%] with PD-L1 tumor proportion score - ≥1%). Objective response rate was 70.5% (79 of 112; 95% CI, 61.2%-78.8%) in - cohort A and 70.6% (72 of 102; 95% CI, 60.7%-79.2%) in cohort B. Median duration - of response was not reached, but 79.7% and 75.6%, respectively, had response - duration of 12 months or longer. Grade 3 or higher pneumonitis occurred in 9 of - 112 patients (8.0%) in cohort A and 7 of 102 (6.9%) in cohort B. Grade 3 to 5 - treatment-related adverse events occurred in 72 of 112 (64.3%) and 51 of 102 - (50.0%) patients, respectively. CONCLUSIONS AND RELEVANCE: The findings of this - phase 2, nonrandomized, 2-cohort study suggest promising antitumor activity of - pembrolizumab plus cCRT and manageable safety in patients with previously - untreated, locally advanced, stage III NSCLC. -FAU - Jabbour, Salma K -AU - Jabbour SK -AD - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers - Robert Wood Johnson Medical School, Rutgers University, New Brunswick. -FAU - Lee, Ki Hyeong -AU - Lee KH -AD - Chungbuk National University Hospital, Chungbuk National University College of - Medicine, Cheongju, South Korea. -FAU - Frost, Nikolaj -AU - Frost N -AD - Department of Infectious Diseases and Respiratory Medicine, - Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, - Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. -FAU - Breder, Valeriy -AU - Breder V -AD - N.N. Blokhin Russian Cancer Research Center, Moscow, Russia. -FAU - Kowalski, Dariusz M -AU - Kowalski DM -AD - The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, - Poland. -FAU - Pollock, Theodore -AU - Pollock T -AD - Northeastern Health System, Tahlequah, Oklahoma. -FAU - Levchenko, Evgeny -AU - Levchenko E -AD - N.N. Petrov National Medical Research Center of Oncology, St Petersburg, Russia. -FAU - Reguart, Noemi -AU - Reguart N -AD - Thoracic Oncology Unit, Department of Medical Oncology, IDIBAPS, Hospital Clínic, - Barcelona, Spain. -FAU - Martinez-Marti, Alex -AU - Martinez-Marti A -AD - Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, - Barcelona, Spain. -FAU - Houghton, Baerin -AU - Houghton B -AD - Mid North Coast Cancer Institute, Port Macquarie Base Hospital, Port Macquarie, - New South Wales, Australia. -FAU - Paoli, Jean-Baptiste -AU - Paoli JB -AD - Radiotherapie, Clinique Clairval, Marseille, France. -FAU - Safina, Sufia -AU - Safina S -AD - Medical Oncology, Republican Dispensary of Tatarstan Ministry of Healthcare, - Kazan, Russia. -FAU - Park, Keunchil -AU - Park K -AD - Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University - School of Medicine, Seoul, South Korea. -FAU - Komiya, Takefumi -AU - Komiya T -AD - Hematology/Medical Oncology, Parkview Cancer Institute, Fort Wayne, Indiana. -FAU - Sanford, Amy -AU - Sanford A -AD - Sanford Health, Sioux Falls, South Dakota. -FAU - Boolell, Vishal -AU - Boolell V -AD - Ballarat Health Services, Ballarat, Victoria, Australia. -FAU - Liu, Hong -AU - Liu H -AD - Merck & Co, Inc, Kenilworth, New Jersey. -FAU - Samkari, Ayman -AU - Samkari A -AD - Merck & Co, Inc, Kenilworth, New Jersey. -FAU - Keller, Steven M -AU - Keller SM -AD - Merck & Co, Inc, Kenilworth, New Jersey. -FAU - Reck, Martin -AU - Reck M -AD - LungenClinic, Airway Research Center North, German Center for Lung Research, - Grosshansdorf, Germany. -LA - eng -PT - Journal Article -DEP - 20210604 -PL - United States -TA - JAMA Oncol -JT - JAMA oncology -JID - 101652861 -SB - IM -CIN - JAMA Oncol. 2022 Jan 1;8(1):168-169. doi: 10.1001/jamaoncol.2021.5611. PMID: - 34734971 -CIN - JAMA Oncol. 2022 Jan 1;8(1):167-168. doi: 10.1001/jamaoncol.2021.5605. PMID: - 34734980 -CIN - JAMA Oncol. 2022 Jan 1;8(1):168. doi: 10.1001/jamaoncol.2021.5608. PMID: 34734982 -PMC - PMC8446818 -COIS- Conflict of Interest Disclosures: Dr Jabbour reported receiving grants, personal - fees, and nonfinancial support from Merck & Co during the conduct of the study; - and receiving grants from the National Cancer Institute and grants to institution - from Merck & Co outside the submitted work. Dr Lee reported receiving personal - fees for advisory board meetings from Bristol Myers Squibb, Merck Sharp & Dohme, - AstraZeneca, Pfizer, and Eli Lilly outside the submitted work. Dr Frost reported - receiving personal fees and nonfinancial support from Merck Sharp & Dohme during - the conduct of the study; and receiving personal fees from Boehringer Ingelheim, - Bristol Myers Squibb, Roche, Pfizer, Takeda, Novartis, and AbbVie, Berlin-Chemie, - Sanofi, and BeiGene; travel grants from Takeda, AstraZeneca, Bristol Myers - Squibb, AbbVie, and Eli Lilly; and nonfinancial support from Bristol Myers Squibb - outside the submitted work. Dr Kowalski reported serving on advisory boards for - Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, - Pfizer, Takeda, and Roche outside the submitted work. Dr Reguart reported - receiving grants from Novartis and Pfizer, personal fees (advisory panels, - invited speaker, congress registration) from Merck Sharp & Dohme, Eli Lilly, - Roche, Takeda, Novartis, Pfizer, and Janssen, and personal fees (advisory panels, - invited speaker) from Bristol Myers Squibb outside the submitted work. Dr - Martinez-Marti reported receiving personal fees and travel expenses from Bristol - Myers Squibb, F. Hoffmann-La Roche, Merck Sharp & Dohme, Pfizer, Boehringer - Ingelheim, Merck Sharp & Dohme Oncology, and AstraZeneca outside the submitted - work. Dr Houghton reported receiving personal fees (trial funding) from Merck - during the conduct of the study; and receiving personal fees (advisory board) - from Merck outside the submitted work. Dr Paoli reported receiving nonfinancial - support from Merck Sharp & Dohme during the conduct of the study; and receiving - personal fees from Bristol Myers Squibb and AstraZeneca and nonfinancial support - from Merck Sharp & Dohme France, Fresenius Kabi France, Ipsen Pharma, Boehringer - Ingelheim France, Pierre Fabre Medicament, Eisai SAS, Janssen-Cilag, Pfizer SAS, - Roche SAS, Isis Méditerranée, Novartis Pharma SAS, Mundipharma, Vifor France SA, - Sandoz, Kyowa Kirin, Bristol Myers Squibb, and AstraZeneca outside the submitted - work. Dr Park reported receiving grants (research funding) from Merck Sharp & - Dohme outside the submitted work; and serving as an advisor for Merck Sharp & - Dohme outside the submitted work. Dr Sanford reported receiving grants to - institution from Merck during the conduct of the study; and receiving grants from - Eli Lilly, NantWorks, and QuantumLeap Health outside the submitted work. Drs Liu, - Samkari, and Keller reported being an employee of Merck. Dr Reck reported - receiving personal fees (honoraria for lectures and consultancy) from Amgen, - AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, - Mirati, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Samsung Bioepis outside - the submitted work. No other disclosures were reported. -EDAT- 2021/06/05 06:00 -MHDA- 2021/06/05 06:00 -PMCR- 2021/06/04 -CRDT- 2021/06/04 12:19 -PHST- 2021/06/04 12:19 [entrez] -PHST- 2021/06/05 06:00 [pubmed] -PHST- 2021/06/05 06:00 [medline] -PHST- 2021/06/04 00:00 [pmc-release] -AID - 2780855 [pii] -AID - coi210037 [pii] -AID - 10.1001/jamaoncol.2021.2301 [doi] -PST - aheadofprint -SO - JAMA Oncol. 2021 Jun 4;7(9):1-9. doi: 10.1001/jamaoncol.2021.2301. - -PMID- 38516099 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240323 -IS - 2589-5370 (Electronic) -IS - 2589-5370 (Linking) -VI - 70 -DP - 2024 Apr -TI - Sintilimab plus anlotinib as second or further-line therapy for extensive disease - small cell lung cancer: a phase 2 investigator-initiated non-randomized - controlled trial. -PG - 102543 -LID - 10.1016/j.eclinm.2024.102543 [doi] -LID - 102543 -AB - BACKGROUND: Treatment options remain rather limited for extensive disease small - cell lung cancer (ED-SCLC) patients in second or further-line setting. METHODS: - The phase 2 investigator-initiated non-randomized study enrolled patients who had - disease progression on at least one line of platinum-based chemotherapy. - Participants received intravenous sintilimab 200 mg on day one and oral daily - anlotinib 12 mg on days 1-14 once every three weeks per cycle. The primary - endpoint was progression-free survival (PFS). The secondary endpoints included - overall survival (OS), objective response rate (ORR), disease control rate (DCR) - and safety. This study is registered with ClinicalTrials.gov (NCT04055792). - FINDINGS: Forty-two patients were enrolled between August 29, 2019 and December - 26, 2021 at Henan Cancer Hospital in China. 37 patients were evaluable for - efficacy. The median follow-up was 24.8 months (IQR: 16.9-28.2). The median PFS - was 6.1 months (95% CI: 5.0-7.3). The OS was 12.7 months (95% CI: 7.1-18.2). The - ORR was 56.8% (21/37, 95% CI: 40.0-73.5) and the DCR was 89.2% (33/37, 95% CI: - 78.7-99.7). Forty patients (40/42, 95%) had at least one treatment-related - adverse event (TRAE). Immune-related adverse events (irAEs) were reported in 39 - patients (39/42, 93%), while grade 3 or higher irAEs occurred in 11 patients - (11/42, 26%). The most frequent irAEs were hypothyroidism (16/42, 38%), elevated - gamma-glutamyl transpeptidase (15/42, 36%) and elevated creatine kinase MB - (15/42, 36%). The most frequent grade 3 or higher irAEs were elevated - gamma-glutamyl transpeptidase (5/42, 12%) and increased aspartate - aminotransferase (3/42, 7%). INTERPRETATION: Sintilimab plus anlotinib - demonstrated promising antitumor activities as second or further-line therapy for - ED-SCLC and had manageable toxicities. The findings support further randomized - controlled trials of this combination regimen for ED-SCLC. FUNDING: Henan - Province Health and Youth Subject Leader Training Project, Henan Health Science - and Technology Innovation Talents, ZHONGYUAN QIANREN JIHUA, Henan International - Joint Laboratory of drug resistance and reversal of targeted therapy for lung - cancer, Tumor Research Fund of Anti-Angiogenesis Targeted Therapy of China - Anti-Cancer Association. -CI - © 2024 The Authors. -FAU - Ma, Shuxiang -AU - Ma S -AD - Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou - University & Henan Cancer Hospital, Zhengzhou, 450008, China. -FAU - He, Zhen -AU - He Z -AD - Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou - University & Henan Cancer Hospital, Zhengzhou, 450008, China. -FAU - Liu, Yang -AU - Liu Y -AD - Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou - University & Henan Cancer Hospital, Zhengzhou, 450008, China. -FAU - Wang, Lili -AU - Wang L -AD - Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou - University & Henan Cancer Hospital, Zhengzhou, 450008, China. -FAU - Yang, Sen -AU - Yang S -AD - Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou - University & Henan Cancer Hospital, Zhengzhou, 450008, China. -FAU - Wu, Yufeng -AU - Wu Y -AD - Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou - University & Henan Cancer Hospital, Zhengzhou, 450008, China. -FAU - Chen, Haiyang -AU - Chen H -AD - Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou - University & Henan Cancer Hospital, Zhengzhou, 450008, China. -FAU - Wu, Yingxi -AU - Wu Y -AD - Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou - University & Henan Cancer Hospital, Zhengzhou, 450008, China. -FAU - Wang, Qiming -AU - Wang Q -AD - Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou - University & Henan Cancer Hospital, Zhengzhou, 450008, China. -LA - eng -SI - ClinicalTrials.gov/NCT04055792 -PT - Journal Article -DEP - 20240314 -PL - England -TA - EClinicalMedicine -JT - EClinicalMedicine -JID - 101733727 -PMC - PMC10955204 -OTO - NOTNLM -OT - Anti-angiogenesis -OT - Extensive-disease small cell lung cancer -OT - PD-1 inhibitor -OT - Transcription factors -COIS- The authors declare no competing interests. -EDAT- 2024/03/22 06:44 -MHDA- 2024/03/22 06:45 -PMCR- 2024/03/14 -CRDT- 2024/03/22 04:05 -PHST- 2023/10/09 00:00 [received] -PHST- 2024/02/16 00:00 [revised] -PHST- 2024/02/27 00:00 [accepted] -PHST- 2024/03/22 06:45 [medline] -PHST- 2024/03/22 06:44 [pubmed] -PHST- 2024/03/22 04:05 [entrez] -PHST- 2024/03/14 00:00 [pmc-release] -AID - S2589-5370(24)00122-6 [pii] -AID - 102543 [pii] -AID - 10.1016/j.eclinm.2024.102543 [doi] -PST - epublish -SO - EClinicalMedicine. 2024 Mar 14;70:102543. doi: 10.1016/j.eclinm.2024.102543. - eCollection 2024 Apr. - -PMID- 39302841 -OWN - NLM -STAT- Publisher -LR - 20240920 -IS - 1473-5709 (Electronic) -IS - 0959-8278 (Linking) -DP - 2024 Sep 20 -TI - Effects of antibiotics on immunotherapy in patients with metastatic nonsmall cell - lung cancer. -LID - 10.1097/CEJ.0000000000000912 [doi] -AB - To investigate the effects of antibiotic exposure on the prognosis of patients - with advanced metastatic non-small cell lung cancer (m-NSCLC) who received immune - checkpoint inhibitors (ICIs). This study retrospectively included 199 patients - diagnosed with m-NSCLC in Shandong Cancer Hospital and Institute from December - 2017 to October 2021, all patients received ICIs for the first time. The basic - clinical characteristics of patients before the first treatment of ICIs, whether - antibiotics were used during treatment, progression-free survival (PFS), and - overall survival (OS) were collected. The survival among different groups was - compared by the Kaplan-Meier method. The median follow-up time of m-NSCLC - patients was 33.79 months, mPFS was 11.67 months, and mOS was 21.55 months. - Univariate analysis showed that antibiotic use, radiotherapy, and targeted drug - resistance influenced PFS and OS (P < 0.05). Multivariate analysis showed that - antibiotic use, radiotherapy, and targeted resistance remained independent - factors of PFS, and targeted resistance was an independent factor of OS - (P < 0.05). Subgroup analysis found that antibiotic use within 30 days before and - after immunotherapy could decrease the PFS and OS (P < 0.05). Kaplan-Meier - analysis showed that patients without radiotherapy had shorter PFS (mPFS, 12.89 - vs. 8.13 months; P = 0.0258) and OS (mOS, 26.94 vs. 16.43 months; P = 0.0465). - The mPFS (16.17 vs. 9.19 months; P = 0.0151) and mOS (27.27 vs. 18.65 months; - P = 0.0437) of patients in the antibiotic group were shorter. Patients in the - targeted drug-resistant group had shorter PFS (mPFS, 40.66 vs. 7.77 months, - P < 0.001) and OS (mOS, 41.98 vs. 16.89 months, P < 0.001) compared with patients - who did not receive targeted treatment. Antibiotics and radiation therapy are - associated with the prognosis of m-NSCLC who are newly treated with ICIs. - Effectively reducing antibiotic use in 1 month before and after ICIs treatment - may help improve the immunotherapy efficacy of patients with m-NSCLC. -CI - Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. -FAU - Hu, Tao -AU - Hu T -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences. -FAU - Li, Li -AU - Li L -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences. -FAU - Cui, Jinfeng -AU - Cui J -AD - Center for Medical Integration and Practice, Shandong University, Jinan. -FAU - Song, Xiaoyu -AU - Song X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences. -FAU - Zhu, He -AU - Zhu H -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences. -FAU - Hou, Zhi Wei -AU - Hou ZW -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences. -FAU - Yuan, Shuanghu -AU - Yuan S -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences. -AD - Division of Life Sciences and Medicine, Department of Radiation Oncology, The - First Affiliated Hospital of USTC, University of Science and Technology of China. -AD - Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui, - China. -LA - eng -GR - This study was supported in part by the National Natural Science Foundation of - China (NSFC82073345), Natural Science Innovation and Development Joint Foundation - of Shandong Province (ZR202209010002), Jinan Clinical Medicine Science and - Technology Innovation Plan (202019060) and the Taishan Scholars Program/ -PT - Journal Article -DEP - 20240920 -PL - England -TA - Eur J Cancer Prev -JT - European journal of cancer prevention : the official journal of the European - Cancer Prevention Organisation (ECP) -JID - 9300837 -SB - IM -EDAT- 2024/09/20 19:08 -MHDA- 2024/09/20 19:08 -CRDT- 2024/09/20 12:42 -PHST- 2024/09/20 19:08 [medline] -PHST- 2024/09/20 19:08 [pubmed] -PHST- 2024/09/20 12:42 [entrez] -AID - 00008469-990000000-00174 [pii] -AID - 10.1097/CEJ.0000000000000912 [doi] -PST - aheadofprint -SO - Eur J Cancer Prev. 2024 Sep 20. doi: 10.1097/CEJ.0000000000000912. - -PMID- 38778819 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240524 -IS - 2452-1094 (Print) -IS - 2452-1094 (Electronic) -IS - 2452-1094 (Linking) -VI - 9 -IP - 4 -DP - 2024 Apr -TI - Differential Effect of Consolidative Thoracic Radiation Therapy in - Extensive-Stage Small Cell Lung Cancer Based on Sex. -PG - 101413 -LID - 10.1016/j.adro.2023.101413 [doi] -LID - 101413 -AB - PURPOSE: The landmark randomized trial on chest irradiation in extensive disease - small cell lung cancer (CREST) demonstrated that consolidative thoracic radiation - therapy (cTRT) improved overall (OS) and progression-free survival (PFS) after - initial chemotherapy (chemo) in extensive-stage small cell lung cancer, with - potentially increased benefit in women compared with men. It is unknown whether - similar findings would apply after chemoimmunotherapy became the standard - first-line treatment. In this analysis, we report national practice patterns and - survival outcomes of cTRT according to patient sex. METHODS AND MATERIALS: We - included patients from de-identified electronic health record-derived database - diagnosed with stage IV small cell lung cancer (2014-2021) who completed 4 to 6 - cycles of first-line systemic therapy (platinum-doublet chemotherapy or - chemoimmunotherapy). We evaluated OS and PFS using multivariable Cox proportional - hazards regression with receipt of cTRT as an independent variable and stratified - by sex. As a sensitivity analysis, we weighted the models by the inverse - probability of receiving cTRT. RESULTS: A total of 1227 patients were included - (850 chemotherapy, 377 chemoimmunotherapy). There were no statistically - significant differences in baseline characteristics between patients who did and - did not receive cTRT. Among women, cTRT was associated with superior OS (adjusted - hazard ratio [HR], 0.67; 95% CI, 0.52-0.87) and PFS (HR, 0.63; 95% CI, 0.49-0.82) - compared with those not receiving cTRT. Conversely, no OS or PFS benefit with - cTRT was observed in men (OS HR, 1.03; 95% CI, 0.80-1.31; PFS HR, 1.12; 95% CI, - 0.85-1.47). Findings were similar in weighted analyses. CONCLUSIONS: The survival - efficacy of cTRT may be moderated by sex, with female patients appearing more - likely to benefit than male patients. These findings reflect sex-based survival - trends with similar effect sizes to those observed in the CREST trial. Although - the underpinnings of this association need to be elucidated, stratification by - sex should be considered for randomized-controlled trials studying cTRT in - extensive-stage small cell lung cancer. -CI - © 2023 The Authors. -FAU - Jairam, Vikram -AU - Jairam V -AD - Department of Radiation Oncology, Sutter Medical Group, Sacramento, California. -FAU - Soulos, Pamela R -AU - Soulos PR -AD - Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale - School of Medicine, New Haven, Connecticut. -FAU - K C, Madhav -AU - K C M -AD - Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale - School of Medicine, New Haven, Connecticut. -FAU - Gross, Cary P -AU - Gross CP -AD - Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale - School of Medicine, New Haven, Connecticut. -AD - Section of General Internal Medicine, Department of Medicine, Yale School of - Medicine, New Haven, Connecticut. -FAU - Slotman, Ben J -AU - Slotman BJ -AD - Department of Radiation Oncology, Amsterdam University Medical Center, De - Boelelaan, Amsterdam, The Netherlands. -FAU - Chiang, Anne C -AU - Chiang AC -AD - Section of Medical Oncology, Department of Medicine, Yale School of Medicine, New - Haven, Connecticut. -FAU - Park, Henry S -AU - Park HS -AD - Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale - School of Medicine, New Haven, Connecticut. -AD - Department of Therapeutic Radiology, Yale School of Medicine, New Haven, - Connecticut. -LA - eng -PT - Journal Article -DEP - 20231203 -PL - United States -TA - Adv Radiat Oncol -JT - Advances in radiation oncology -JID - 101677247 -PMC - PMC11110031 -COIS- Pamela R. Soulos reported receiving consulting fees from TARGET PharmaSolutions - outside of the submitted work. Cary P. Gross reported receiving grants or - contracts from Johnson & Johnson, the National Comprehensive Cancer Network, and - Genentech, and a leadership role in the American Society of Clinical Oncology - (ASCO)-Quality Annual Meeting planning committee, outside of the submitted work. - Anne C. Chiang reported receiving research funding from Bristol Myers Squibb, - AbbeVie, and Genentech, and is on the advisory board or consultant to Genentech, - AstraZeneca, Regeneron, and Daichi, outside the submitted work. Henry S. Park - reported receiving research funding from RefleXion and Merck, consulting fees - from AstraZeneca and RefleXion, honoraria from Bristol Myers Squibb and G1 - Therapeutics, and serving on the advisory board for AstraZeneca and Galera, - outside the submitted work. Vikram Jairam, Ben J. Slotman, and K.C. Madhav - reported no disclosures. -EDAT- 2024/05/23 06:44 -MHDA- 2024/05/23 06:45 -PMCR- 2023/12/03 -CRDT- 2024/05/23 03:36 -PHST- 2023/08/07 00:00 [received] -PHST- 2023/11/19 00:00 [accepted] -PHST- 2024/05/23 06:45 [medline] -PHST- 2024/05/23 06:44 [pubmed] -PHST- 2024/05/23 03:36 [entrez] -PHST- 2023/12/03 00:00 [pmc-release] -AID - S2452-1094(23)00241-5 [pii] -AID - 101413 [pii] -AID - 10.1016/j.adro.2023.101413 [doi] -PST - epublish -SO - Adv Radiat Oncol. 2023 Dec 3;9(4):101413. doi: 10.1016/j.adro.2023.101413. - eCollection 2024 Apr. - -PMID- 29760563 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20201001 -IS - 1179-1322 (Print) -IS - 1179-1322 (Electronic) -IS - 1179-1322 (Linking) -VI - 10 -DP - 2018 -TI - Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell - lung cancer. -PG - 931-940 -LID - 10.2147/CMAR.S148009 [doi] -AB - Lung cancer is the most common cancer worldwide and the most common cause of - cancer-related death. Non-small-cell lung cancer comprises ~87% of newly - diagnosed cases of lung cancer, and nearly one-third of these patients have stage - III disease. Despite improvements in the treatment of stage IV lung cancer, - particularly with the introduction and dissemination of checkpoint inhibitors, - very little progress has been made in the treatment of stage III lung cancer. In - this article, we discuss the general staging criteria and treatment options for - stage III lung cancer. We review how concurrent radiation and chemotherapy can - have immunomodulatory effects, supporting the rationale for incorporating - immunotherapy into existing treatment paradigms. Finally, we discuss the results - of the PACIFIC trial and implications for the treatment of stage III lung cancer. - In the PACIFIC trial, adding durvalumab as a maintenance therapy following the - completion of chemoradiotherapy improved progression-free survival in patients - with locally advanced unresectable stage III lung cancer. On the strength of - these results, durvalumab has been approved by the US Food and Drug - Administration for use in this setting, representing the first advance in the - treatment of stage III lung cancer in nearly a decade. -FAU - Shafique, Michael R -AU - Shafique MR -AD - Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research - Institute, Tampa, FL, USA. -FAU - Robinson, Lary A -AU - Robinson LA -AD - Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research - Institute, Tampa, FL, USA. -FAU - Antonia, Scott -AU - Antonia S -AD - Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research - Institute, Tampa, FL, USA. -LA - eng -PT - Journal Article -PT - Review -DEP - 20180501 -PL - New Zealand -TA - Cancer Manag Res -JT - Cancer management and research -JID - 101512700 -PMC - PMC5937504 -OTO - NOTNLM -OT - chemoradiation -OT - durvalumab -OT - immunotherapy -OT - maintenance therapy -OT - non-small-cell lung cancer -OT - staging -OT - surgery-ineligible -COIS- Disclosure SA serves on the advisory boards of Astra Zeneca/Med Immune, - Bristol-Myers Squibb, Novartis, Merck, CBMG, Boehringer Ingelheim, Memgen, and - FLX Bio. He also performs contracted research for Novartis. MRS serves on the - advisory board of GlaxoSmithKline. LAR reports no conflicts of interest in this - work. -EDAT- 2018/05/16 06:00 -MHDA- 2018/05/16 06:01 -PMCR- 2018/05/01 -CRDT- 2018/05/16 06:00 -PHST- 2018/05/16 06:00 [entrez] -PHST- 2018/05/16 06:00 [pubmed] -PHST- 2018/05/16 06:01 [medline] -PHST- 2018/05/01 00:00 [pmc-release] -AID - cmar-10-931 [pii] -AID - 10.2147/CMAR.S148009 [doi] -PST - epublish -SO - Cancer Manag Res. 2018 May 1;10:931-940. doi: 10.2147/CMAR.S148009. eCollection - 2018. - -PMID- 37841212 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20231020 -IS - 2040-6223 (Print) -IS - 2040-6231 (Electronic) -IS - 2040-6223 (Linking) -VI - 14 -DP - 2023 -TI - Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC - lacking driver gene mutations: a systematic review and Bayesian network - meta-analysis. -PG - 20406223231189224 -LID - 10.1177/20406223231189224 [doi] -LID - 20406223231189224 -AB - BACKGROUND: Numerous first-line immune checkpoint inhibitors (ICI) were developed - for patients with advanced non-small cell lung cancer (NSCLC) lacking driver gene - mutations. However, this group consists of a heterogeneous patient population, - for whom the optimal therapeutic choice is yet to be confirmed. OBJECTIVE: To - identify the best first-line immunotherapy regimen for overall advanced NSCLC - patients and different subgroups. DESIGN: Systematic review and Bayesian network - meta-analysis (NMA). METHODS: We searched several databases to retrieve relevant - literature. We performed Bayesian NMA for the overall survival (OS), - progression-free survival (PFS), objective response rate (ORR), and - treatment-related adverse events (tr-AEs) with a grade equal or more than 3 - (grade ⩾ 3 tr-AEs). Subgroup analysis was conducted according to programed death - ligand 1 (PD-L1) levels, histologic type, central nervous system (CNS) metastases - and tobacco use history. RESULTS: For the PD-L1 non-selective patients, - sintilimab plus chemotherapy (sinti-chemo) provided the best OS [hazard ratio - (HR) = 0.59, 95% confidence interval (CI):0.42-0.83]. Nivolumab plus bevacizumab - plus chemotherapy (nivo-bev-chemo) was comparable to atezolizumab plus - bevacizumab plus chemotherapy (atezo-bev-chemo) in prolonging PFS (HR = 0.99, 95% - CI: 0.51-1.91). Atezo-bev-chemo remarkably elevated the ORR than chemotherapy - (OR = 3.13, 95% CI: 1.51-6.59). Subgroup analysis showed pembrolizumab plus - chemotherapy (pembro-chemo) ranked first in OS in subgroups of PD-L1 < 1%, - non-squamous, no CNS metastases, with or without smoking history, and ranked - second in OS in subgroups of PD-L1 ⩾ 1% and PD-L1 1-49%. Cemiplimab and - sugemalimab plus chemotherapy ranked first in OS and PFS for squamous subgroup, - respectively. For patients with CNS metastases, nivolumab plus ipilimumab plus - chemotherapy (nivo-ipili-chemo) and camrelizumab plus chemotherapy provided the - best OS and PFS, respectively. CONCLUSIONS: Sinti-chemo and nivo-bev-chemo were - two effective first-line regimens ranked first in OS and PFS for overall - patients, respectively. Pembro-chemo was favorable for patients in subgroups of - PD-L1 < 1%, PD-L1 ⩾ 1%, PD-L1 1-49%, non-squamous, no CNS metastases, with or - without smoking history. Addition of bevacizumab consistently provided with - favorable PFS results in patients of all PD-L1 levels. Cemiplimab was the best - option in squamous subgroup and nivo-ipili-chemo in CNS metastases subgroup due - to their advantages in OS. -CI - © The Author(s), 2023. -FAU - Wenfan, Fu -AU - Wenfan F -AUID- ORCID: 0000-0002-4478-6290 -AD - Department of Chest Surgery, Affiliated Cancer Hospital & Institute of Guangzhou - Medical University, Guangzhou, Guangdong, China. -AD - Southern Medical University, Guangzhou, Guangdong, China. -AD - Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong - Academy of Medical Sciences, Guangzhou, Guangdong, China. -FAU - Manman, Xu -AU - Manman X -AD - Department of Gynecology, the First Affiliated Hospital, Sun Yat-sen University, - Guangzhou, Guangdong, China. -FAU - Xingyuan, Shi -AU - Xingyuan S -AD - Department of Radiotherapy, the Fifth Affiliated Hospital of Guangzhou Medical - University, Guangzhou, Guangdong, China. -FAU - Zeyong, Jiang -AU - Zeyong J -AD - Department of Chest Surgery, Affiliated Cancer Hospital & Institute of Guangzhou - Medical University, Guangzhou, Guangdong, China. -FAU - Jian, Zhao -AU - Jian Z -AD - Department of Chest Surgery, Affiliated Cancer Hospital & Institute of Guangzhou - Medical University, Guangzhou, Guangdong, China. -FAU - Lu, Dai -AU - Lu D -AD - Department of Chest Surgery, Affiliated Cancer Hospital & Institute of Guangzhou - Medical University, 78 Hengzhigang Road, Guangzhou, Guangdong 510095, China. -LA - eng -PT - Journal Article -DEP - 20231011 -PL - United States -TA - Ther Adv Chronic Dis -JT - Therapeutic advances in chronic disease -JID - 101532140 -PMC - PMC10568994 -OAB - First-line PD-1/PD-L1 inhibitors for advanced NSCLC patients lacking driver gene - mutations Patients with advance non-small cell lung cancer (NSCLC) lacking driver - gene mutations are a group of heterogeneous people. Although numerous therapeutic - regimens were developed, the optimal choice for advanced NSCLC patients and - specific subgroups is yet to be identified.We conducted a Bayesian network - meta-analysis with the currently available data, and performed subgroup analyses - according to programed death ligand 1 (PD-L1) levels, histologic type, CNS - metastases and tobacco use history.Our key findings were as follows: (1) in - non-selective PD-L1 groups, sinti-chemo and pembro-chemo provided the best OS - outcome; nivo-bev-chemo and atezo-bev-chemo resulted in the most prolonged PFS; - atezo-bev-chemo and pembro-chemo yielded significantly improved ORR; (2) - pembro-chemo was favorable for patients in subgroups of PD-L1 < 1%, PD-L1 ⩾ 1%, - PD-L1 1–49%, non-squamous, no CNS metastases, with or without smoking history; - (3) immunochemotherapies involving anti-PD-1 agents generally exhibited potential - advantages over those with anti-PD-L1 drugs; (4) addition of anti-VEGF drugs to - immunochemotherapies consistently provided with favorable PFS results in advanced - NSCLC patients with or without PD-L1 selection; (5) in patients with squamous - NSCLC, cemiplimab and suge-chemo were the optimal drugs for improving OS and PFS, - respectively; in patients with non-squamous NSCLC, pembro-chemo provided the best - OS, while nivo-bev-chemo, atezo-bev-chemo, sinti-chemo, and pembro-chemo showed - comparable advantages in improving PFS; (6) for patients with CNS metastases, - nivo-ipili-chemo and camre-chemo provided the best OS and PFS, respectively.Our - findings provide evidence for a more precise selection of first-line - immunotherapy regimen for advanced NSCLC patients. -OABL- eng -OTO - NOTNLM -OT - PD-1/PD-L1 inhibitors -OT - bevacizumab -OT - immunotherapy -OT - network meta-analysis -OT - non-small cell lung cancer -COIS- The authors declare that there is no conflict of interest. -EDAT- 2023/10/16 06:48 -MHDA- 2023/10/16 06:49 -PMCR- 2023/10/11 -CRDT- 2023/10/16 04:29 -PHST- 2022/12/19 00:00 [received] -PHST- 2023/06/08 00:00 [accepted] -PHST- 2023/10/16 06:49 [medline] -PHST- 2023/10/16 06:48 [pubmed] -PHST- 2023/10/16 04:29 [entrez] -PHST- 2023/10/11 00:00 [pmc-release] -AID - 10.1177_20406223231189224 [pii] -AID - 10.1177/20406223231189224 [doi] -PST - epublish -SO - Ther Adv Chronic Dis. 2023 Oct 11;14:20406223231189224. doi: - 10.1177/20406223231189224. eCollection 2023. - -PMID- 28789381 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20201001 -IS - 1792-1074 (Print) -IS - 1792-1082 (Electronic) -IS - 1792-1074 (Linking) -VI - 14 -IP - 2 -DP - 2017 Aug -TI - Comparative beneficiary effects of immunotherapy against chemotherapy in patients - with advanced NSCLC: Meta-analysis and systematic review. -PG - 1568-1580 -LID - 10.3892/ol.2017.6274 [doi] -AB - Lung cancer is the most commonly diagnosed cancer among men and it is the third - ranked in women. There are two major types of lung cancer, namely, small cell - lung cancer (SCLC), which accounts for ~20% of the cases, and non-small cell lung - cancer (NSCLC), which is the most common. Chemotherapy and chemoradiotherapy have - been used as the first-line therapies but suffer from lack of efficacy and also - of several toxic adverse effects. Immunotherapeutic approaches including tumor - antigen vaccination, monoclonal antibodies targeting checkpoint pathways and also - activated immune cells are being developed and have been shown to be effective in - treating NSCLC. Despite their promise, efficacy of several immunotherapies has - not been consistent. We undertook this meta-analysis study to analyze results - from clinical trials that compared efficacy and safety of immunotherapies with - placebo or chemotherapy/radiotherapy in improving overall survival (OS) and - progression-free survival (PFS) of NSCLC patients. Various databases were - searched to identify randomized clinical studies examining the efficacy and - safety of antibody- and vaccine-based immunotherapies in NSCLC patients in - comparison to chemotherapy or chemoradiotherapy or placebo. Effects on OS and PFS - and also adverse events have been compared. In accordance with the selection - criteria, a total of 13 studies with 3,513 patients in immunotherapy and 3,072 - patients in chemotherapy/placebo, were selected. PFS (odds ratio 1.81, 95% CI - 1.36, 2.42; P<0.0001) and OS (P<0.0001) are found to be greatly improved by - immunotherapies. Immunotherapy of NSCLC patients was also found to prevent - several adverse effects and to improve daily living ability of the patients. The - present meta-analysis strongly suggests that immunotherapy improves OS and PFS of - patients with NSCLC. -FAU - Yu, Da-Ping -AU - Yu DP -AD - Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical - University, Beijing 101149, P.R. China. -FAU - Cheng, Xu -AU - Cheng X -AD - Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical - University, Beijing 101149, P.R. China. -FAU - Liu, Zhi-Dong -AU - Liu ZD -AD - Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical - University, Beijing 101149, P.R. China. -FAU - Xu, Shao-Fa -AU - Xu SF -AD - Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical - University, Beijing 101149, P.R. China. -LA - eng -PT - Journal Article -DEP - 20170529 -PL - Greece -TA - Oncol Lett -JT - Oncology letters -JID - 101531236 -PMC - PMC5529907 -OTO - NOTNLM -OT - antibody therapy -OT - chemotherapy -OT - immune checkpoint inhibitors -OT - immunotherapy -OT - lung cancer -OT - non-small cell lung cancer -OT - overall survival -OT - progression-free survival -OT - vaccine therapy -EDAT- 2017/08/10 06:00 -MHDA- 2017/08/10 06:01 -PMCR- 2017/05/29 -CRDT- 2017/08/10 06:00 -PHST- 2017/02/07 00:00 [received] -PHST- 2017/05/04 00:00 [accepted] -PHST- 2017/08/10 06:00 [entrez] -PHST- 2017/08/10 06:00 [pubmed] -PHST- 2017/08/10 06:01 [medline] -PHST- 2017/05/29 00:00 [pmc-release] -AID - OL-0-0-6274 [pii] -AID - 10.3892/ol.2017.6274 [doi] -PST - ppublish -SO - Oncol Lett. 2017 Aug;14(2):1568-1580. doi: 10.3892/ol.2017.6274. Epub 2017 May - 29. - -PMID- 35942069 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220810 -IS - 1179-1322 (Print) -IS - 1179-1322 (Electronic) -IS - 1179-1322 (Linking) -VI - 14 -DP - 2022 -TI - The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A - Multicenter Real-World Study. -PG - 2273-2287 -LID - 10.2147/CMAR.S364125 [doi] -AB - PURPOSE: Anlotinib, an antiangiogenic multi-target tyrosine kinase inhibitor - (TKI), has shown favorable anticancer efficacy and acceptable safety in treating - extensive-stage small cell lung cancer (ES-SCLC) in some clinical studies. This - research aimed to explore the real-world efficacy and safety of anlotinib in - ES-SCLC. METHODS: Pathologically confirmed ES-SCLC patients receiving anlotinib - were enrolled for this retrospective study. The primary endpoint of this study - was progression-free survival (PFS), and secondary endpoints included overall - survival (OS), objective response rate (ORR), disease control rate (DCR), and - adverse reactions. RESULTS: In total, 202 patients were included in this study. - The median PFS of all patients was 4.8 months [95% confidence interval (CI): - 3.9-5.7], and the median OS was 7.6 months (95% CI 6.5-8.7). Respectively, the - overall ORR and DCR were 30.2% and 87.1%. The univariate and multivariate Cox - regression analyses revealed that patients with Eastern Cooperative Oncology - Group Performance Status (ECOG PS) ≤1, plus chemotherapy or immunotherapy, plus - radiotherapy, and post-medication hypertension might have longer PFS and OS. The - PFS and OS were significantly prolonged in combination group than that in - monotherapy group [PFS 6.0 vs 3.6 months, hazards ratio (HR)=0.49, 95% CI - 0.34-0.70, P < 0.001; OS 9.2 vs 4.8 months, HR = 0.48, 95% CI 0.32-0.72, P < - 0.001]. The main treatment-related adverse reactions were generally tolerated. - The incidence of adverse reactions in combination group was higher than that in - monotherapy group (75.0% vs 52.6%, P = 0.001). The most common adverse reaction - was hypertension, followed by hand-foot syndrome and fatigue, regardless of - monotherapy or combination group. CONCLUSION: Anlotinib is effective and well - tolerated in patients with ES-SCLC in the real-world. The clinical efficacy of - anlotinib combined with chemotherapy or immunotherapy is better than that of - monotherapy. Further investigations are needed for prospective studies with - larger sample size. -CI - © 2022 Zheng et al. -FAU - Zheng, Hao-Ran -AU - Zheng HR -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, Shaanxi, People's Republic of China. -AD - Department of Medical Oncology, Xi'an No.3 Hospital, Xi'an, Shaanxi, People's - Republic of China. -FAU - Jiang, Ai-Min -AU - Jiang AM -AUID- ORCID: 0000-0002-4092-342X -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, Shaanxi, People's Republic of China. -FAU - Gao, Huan -AU - Gao H -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, Shaanxi, People's Republic of China. -FAU - Liu, Na -AU - Liu N -AUID- ORCID: 0000-0003-2276-3108 -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, Shaanxi, People's Republic of China. -FAU - Zheng, Xiao-Qiang -AU - Zheng XQ -AUID- ORCID: 0000-0001-7150-2575 -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, Shaanxi, People's Republic of China. -FAU - Fu, Xiao -AU - Fu X -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, Shaanxi, People's Republic of China. -FAU - Zhang, Rui -AU - Zhang R -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, Shaanxi, People's Republic of China. -FAU - Ruan, Zhi-Ping -AU - Ruan ZP -AUID- ORCID: 0000-0001-9467-7466 -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, Shaanxi, People's Republic of China. -FAU - Tian, Tao -AU - Tian T -AUID- ORCID: 0000-0002-2033-1291 -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, Shaanxi, People's Republic of China. -FAU - Liang, Xuan -AU - Liang X -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, Shaanxi, People's Republic of China. -FAU - Yao, Yu -AU - Yao Y -AD - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong - University, Xi'an, Shaanxi, People's Republic of China. -LA - eng -PT - Journal Article -DEP - 20220802 -PL - New Zealand -TA - Cancer Manag Res -JT - Cancer management and research -JID - 101512700 -PMC - PMC9356751 -OTO - NOTNLM -OT - anlotinib -OT - efficacy -OT - real-world -OT - safety -OT - small cell lung cancer -COIS- The authors declare that they have no competing interests. -EDAT- 2022/08/10 06:00 -MHDA- 2022/08/10 06:01 -PMCR- 2022/08/02 -CRDT- 2022/08/09 02:01 -PHST- 2022/03/31 00:00 [received] -PHST- 2022/07/19 00:00 [accepted] -PHST- 2022/08/09 02:01 [entrez] -PHST- 2022/08/10 06:00 [pubmed] -PHST- 2022/08/10 06:01 [medline] -PHST- 2022/08/02 00:00 [pmc-release] -AID - 364125 [pii] -AID - 10.2147/CMAR.S364125 [doi] -PST - epublish -SO - Cancer Manag Res. 2022 Aug 2;14:2273-2287. doi: 10.2147/CMAR.S364125. eCollection - 2022. - -PMID- 35693282 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240214 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 11 -IP - 5 -DP - 2022 May -TI - Efficacy and safety of apatinib as second or later-line therapy in - extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, - multi-center clinical trial. -PG - 832-844 -LID - 10.21037/tlcr-22-313 [doi] -AB - BACKGROUND: A paucity of strategies exist for extensive-stage small cell lung - cancer (ES-SCLC) patients who fail the first-line chemotherapy. Apatinib is a - tyrosine kinase inhibitor (TKI) that selectively inhibits vascular endothelial - growth factor receptor-2 (VEGFR-2), which has been demonstrated to have active - anti-tumor activity in ES-SCLC when used only or combined with PD-1 inhibitors or - chemotherapy with good tolerance. However, the efficacy and safety of apatinib - monotherapy is unclear in second-line or beyond treatment of ES-SCLC. METHODS: In - this prospective, exploratory, single-arm, multi-center study, eligible patients - were aged 18 years or older with histologically confirmed ES-SCLC, and had - progressed on, or were intolerant to previous systemic treatment. Patients - received apatinib 500 mg (orally qd, every 4 weeks a cycle). The efficacy was - assessed after 1 cycle and then every 2 cycles based on computed tomography - imaging per the Response Evaluation Criteria in Solid Tumors (RECIST, version - 1.1). The primary endpoint was progression-free survival (PFS). The adverse - events (AEs) were assessed per the National Cancer Institute Common Terminology - Criteria for Adverse Events 4.0 (NCI-CTCAE 4.0). This study is registered in the - Chinese Clinical Trial Registry, number ChiCTR-OPC-17013964. RESULTS: From 28 - July 2017 to 21 June 2019, 62 patients were screened for eligibility, among whom - 57 patients were available for efficacy and safety analysis. The objective - response rate (ORR) was 14.3% and disease control rate (DCR) was 79.6%. The - median PFS was 5.6 months [95% confidence interval (CI): 3.3-8.0 months] and the - median overall survival (OS) was 11.2 months (95% CI: 7.5-24.0 months). Among the - participants who received apatinib as second-line treatment, the median PFS and - OS were 6.1 months (95% CI: 2.6-7.6 months) and 12.0 months (95% CI: 7.9 months - to not reached), respectively. The most common AEs of all grades were anemia - (36.8%), hypertension (33.3%), fatigue (31.6%), blood bilirubin increased - (22.8%), elevated transaminase (19.3%), and hand-foot syndrome (17.54%). Grade 3 - AEs included 2 (3.5%) cases of hypertension and 1 (1.8%) case of fatigue. No - grade 4/5 AEs were observed. CONCLUSIONS: Apatinib showed encouraging anti-tumor - activity in pretreated ES-SCLC patients with tolerable toxicities. Further larger - scale studies are warranted to demonstrate the efficacy of apatinib. -CI - 2022 Translational Lung Cancer Research. All rights reserved. -FAU - Liu, Quan -AU - Liu Q -AD - Department of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi, - China. -FAU - Xu, Juan-Ying -AU - Xu JY -AD - Department of Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical - University, Wuxi, China. -FAU - Xu, Ye-Hong -AU - Xu YH -AD - Department of Respiratory Medicine, Anhui Provincial Cancer Hospital, Hefei, - China. -FAU - Chen, Meng -AU - Chen M -AD - Department of Radiation Oncology, Xuzhou Central Hospital, Xuzhou, China. -FAU - Deng, Li-Chun -AU - Deng LC -AD - Department of Oncology, Jiangyin People's Hospital, Wuxi, China. -FAU - Wu, Jian-Ping -AU - Wu JP -AD - Department of Oncology, Changshu No. 1 People's Hospital, Suzhou, China. -FAU - Zhou, Tong -AU - Zhou T -AD - Department of Medical Oncology, Changzhou Tumor Hospital, Changzhou, China. -FAU - Zhang, Li-Qin -AU - Zhang LQ -AD - Department of Respiratory Medicine, Yijishan Hospital of Wannan Medical College, - Wuhu, China. -FAU - Tan, Jie -AU - Tan J -AD - Department of Oncology, Suzhou Municipal Hospital, Suzhou, China. -FAU - Pu, Xing-Xiang -AU - Pu XX -AD - Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China. -FAU - Shang, Yu-Long -AU - Shang YL -AD - Department of Respiratory Medicine, Xuzhou Cancer Hospital, Xuzhou, China. -FAU - Hua, Jun -AU - Hua J -AD - Cardio-Thoracic Surgery, The Second People's Hospital of Wuxi, Wuxi, China. -FAU - Li, Yuan-Qin -AU - Li YQ -AD - Department of Respiratory Medicine, The Affiliated Hospital of Xuzhou Medical - University, Xuzhou, China. -FAU - Cai, Wei -AU - Cai W -AD - Department of Oncology, The First People's Hospital of Wujiang, Suzhou, China. -FAU - Gu, Yu-Lan -AU - Gu YL -AD - Department of Oncology, Changshu No. 2 People's Hospital, Suzhou, China. -FAU - Peng, Xing-Chen -AU - Peng XC -AD - Department of Oncology, West China Hospital, Sichuan University, Chengdu, China. -FAU - Chan, Po-Chung -AU - Chan PC -AD - Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China. -FAU - Jabbour, Salma K -AU - Jabbour SK -AD - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers - Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ, USA. -FAU - Nam, Hae-Seong -AU - Nam HS -AD - Division of Pulmonology, Department of Internal Medicine, Inha University - Hospital, Inha University School of Medicine, Incheon, Korea. -FAU - Hua, Dong -AU - Hua D -AD - Department of Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical - University, Wuxi, China. -LA - eng -GR - R50 CA275877/CA/NCI NIH HHS/United States -PT - Journal Article -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -PMC - PMC9186180 -OTO - NOTNLM -OT - Second-line therapy -OT - anti-angiogenesis -OT - apatinib -OT - small cell lung cancer (SCLC) -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-313/coif). SKJ reports - that she receives institutional grant from Merck & Co., Inc. and consulting fees - form Merck & Co., Inc., Syntactx and IMX Medical. The other authors have no - conflicts of interest to declare. -EDAT- 2022/06/14 06:00 -MHDA- 2022/06/14 06:01 -PMCR- 2022/05/01 -CRDT- 2022/06/13 03:13 -PHST- 2022/02/24 00:00 [received] -PHST- 2022/05/18 00:00 [accepted] -PHST- 2022/06/13 03:13 [entrez] -PHST- 2022/06/14 06:00 [pubmed] -PHST- 2022/06/14 06:01 [medline] -PHST- 2022/05/01 00:00 [pmc-release] -AID - tlcr-11-05-832 [pii] -AID - 10.21037/tlcr-22-313 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2022 May;11(5):832-844. doi: 10.21037/tlcr-22-313. - -PMID- 33425746 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220419 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 10 -DP - 2020 -TI - Dyspnea in Patients Receiving Radical Radiotherapy for Non-Small Cell Lung - Cancer: A Prospective Study. -PG - 594590 -LID - 10.3389/fonc.2020.594590 [doi] -LID - 594590 -AB - BACKGROUND AND PURPOSE: Dyspnea is an important symptomatic endpoint for - assessment of radiation-induced lung injury (RILI) following radical radiotherapy - in locally advanced disease, which remains the mainstay of treatment at the time - of significant advances in therapy including combination treatments with - immunotherapy and chemotherapy and the use of local ablative radiotherapy - techniques. We investigated the relationship between dose-volume parameters and - subjective changes in dyspnea as a measure of RILI and the relationship to - spirometry. MATERIAL AND METHODS: Eighty patients receiving radical radiotherapy - for non-small cell lung cancer were prospectively assessed for dyspnea using two - patient-completed tools: EORTC QLQ-LC13 dyspnea quality of life assessment and - dyspnea visual analogue scale (VAS). Global quality of life, spirometry and - radiation pneumonitis grade were also assessed. Comparisons were made with lung - dose-volume parameters. RESULTS: The median survival of the cohort was 26 months. - In the evaluable group of 59 patients there were positive correlations between - lung dose-volume parameters and a change in dyspnea quality of life scale at 3 - months (V(30) p=0.017; V(40) p=0.026; V(50) p=0.049; mean lung dose p=0.05), and - a change in dyspnea VAS at 6 months (V(30) p=0.05; V(40) p=0.026; V(50) p=0.028) - after radiotherapy. Lung dose-volume parameters predicted a 10% increase in - dyspnea quality of life score at 3 months (V(40); p=0.041, V(50); p=0.037) and - dyspnea VAS score at 6 months (V(40); p=0.027) post-treatment. CONCLUSIONS: - Worsening of dyspnea is an important symptom of RILI. We demonstrate a - relationship between lung dose-volume parameters and a 10% worsening of - subjective dyspnea scores. Our findings support the use of subjective dyspnea - tools in future studies on radiation-induced lung toxicity, particularly at doses - below conventional lung radiation tolerance limits. -CI - Copyright © 2020 Sardaro, McDonald, Bardoscia, Lavrenkov, Singh, Ashley, Traish, - Ferrari, Meattini, Asabella and Brada. -FAU - Sardaro, Angela -AU - Sardaro A -AD - Lung Research Unit, The Royal Marsden NHS Foundation Trust, Sutton, United - Kingdom. -AD - Interdisciplinary Department of Medicine, Nuclear Medicine Unit and Section of - Radiology and Radiation Oncology, University of Bari Aldo Moro, Bari, Italy. -FAU - McDonald, Fiona -AU - McDonald F -AD - Lung Research Unit, The Royal Marsden NHS Foundation Trust, Sutton, United - Kingdom. -AD - Academic Radiotherapy Unit, The Institute of Cancer Research, Sutton, United - Kingdom. -FAU - Bardoscia, Lilia -AU - Bardoscia L -AD - Radiation Therapy Unit, Department of Oncology and Advanced Technology, Azienda - USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. -FAU - Lavrenkov, Konstantin -AU - Lavrenkov K -AD - Lung Research Unit, The Royal Marsden NHS Foundation Trust, Sutton, United - Kingdom. -AD - Department of Oncology, Soroka University Medical Center, Faculty of Health - Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. -FAU - Singh, Shalini -AU - Singh S -AD - Lung Research Unit, The Royal Marsden NHS Foundation Trust, Sutton, United - Kingdom. -AD - Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Department - of Radiotherapy, Lucknow, India. -FAU - Ashley, Sue -AU - Ashley S -AD - Lung Research Unit, The Royal Marsden NHS Foundation Trust, Sutton, United - Kingdom. -FAU - Traish, Daphne -AU - Traish D -AD - Lung Research Unit, The Royal Marsden NHS Foundation Trust, Sutton, United - Kingdom. -FAU - Ferrari, Cristina -AU - Ferrari C -AD - Interdisciplinary Department of Medicine, Nuclear Medicine Unit and Section of - Radiology and Radiation Oncology, University of Bari Aldo Moro, Bari, Italy. -FAU - Meattini, Icro -AU - Meattini I -AD - Lung Research Unit, The Royal Marsden NHS Foundation Trust, Sutton, United - Kingdom. -AD - Department of Biomedical, Experimental, and Clinical Sciences, University of - Florence, Radiation Oncology Unit - Oncology Department, Azienda - Ospedaliero-Universitaria Careggi, Florence, Italy. -FAU - Asabella, Artor Niccoli -AU - Asabella AN -AD - Interdisciplinary Department of Medicine, Nuclear Medicine Unit and Section of - Radiology and Radiation Oncology, University of Bari Aldo Moro, Bari, Italy. -FAU - Brada, Michael -AU - Brada M -AD - Lung Research Unit, The Royal Marsden NHS Foundation Trust, Sutton, United - Kingdom. -AD - Academic Radiotherapy Unit, The Institute of Cancer Research, Sutton, United - Kingdom. -AD - Department of Radiation Oncology, University of Liverpool and Clatterbridge - Cancer Centre NHS Foundation Trust, Wirral, United Kingdom. -LA - eng -PT - Journal Article -DEP - 20201223 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC7787051 -OTO - NOTNLM -OT - dose-volume parameters -OT - dyspnea -OT - non-small cell lung cancer -OT - radiation-induced lung injury -OT - radiotherapy -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2021/01/12 06:00 -MHDA- 2021/01/12 06:01 -PMCR- 2020/01/01 -CRDT- 2021/01/11 05:41 -PHST- 2020/08/20 00:00 [received] -PHST- 2020/11/18 00:00 [accepted] -PHST- 2021/01/11 05:41 [entrez] -PHST- 2021/01/12 06:00 [pubmed] -PHST- 2021/01/12 06:01 [medline] -PHST- 2020/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2020.594590 [doi] -PST - epublish -SO - Front Oncol. 2020 Dec 23;10:594590. doi: 10.3389/fonc.2020.594590. eCollection - 2020. - -PMID- 35978836 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20231105 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 12 -DP - 2022 -TI - State-of-the-art combination treatment strategies for advanced stage non-small - cell lung cancer. -PG - 958505 -LID - 10.3389/fonc.2022.958505 [doi] -LID - 958505 -AB - Non-small cell lung cancer (NSCLC) is the most abundant type of epithelial lung - cancer being diagnosed after 40% of invasions of excrescence in pulmonary - tissues. According to WHO, 30% of NSCLC patients can be cured if diagnosed and - treated early. Mutations play an important role in advanced stage NSCLC - treatment, which includes critical proteins necessary for cellular growth and - replication. Restricting such mutations may improve survival in lung cancer - patients. Newer technologies include endoscopic bronchial ultrasonography and - esophageal ultrasonography. Currently, policymaking or decision-making for - treatment regimens merely depends on the genomic alterations and mutations. DNA - sequencing, methylation, protein, and fragmented DNA analysis do NSCLC screening. - Achievement of these goals requires consideration of available therapeutics in - current anticancer approaches for improving quality of life and treatment - outcomes for NSCLC patient. The specific goals of this review are to discuss - first-line and second-line therapies for advanced-stage NSCLC and molecularly - targeted therapy including thoughtful discussion on precise role of treatment - strategies in specific tumors. Also, concerned diagnostics, new clinical trial - designs, and pursuing appropriate combinations of radiotherapy and/or - chemotherapy with biological therapy for exceptional cases considering resistance - mechanisms and palliative care will be discussed. -CI - Copyright © 2022 Yao, Fareed, Zafar, Saleem, Huang, Duan and Rehman. -FAU - Yao, Yongfang -AU - Yao Y -AD - Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, - Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, - Zhengzhou, China. -AD - Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, - School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China. -AD - State Key Laboratory of Esophageal Cancer Prevention and Treatment, School of - Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China. -FAU - Fareed, Rameesha -AU - Fareed R -AD - Riphah Institute of Pharmaceutical Sciences, Riphah International University, - Islamabad, Pakistan. -FAU - Zafar, Aliya -AU - Zafar A -AD - Riphah Institute of Pharmaceutical Sciences, Riphah International University, - Islamabad, Pakistan. -FAU - Saleem, Kalsoom -AU - Saleem K -AD - Riphah Institute of Pharmaceutical Sciences, Riphah International University, - Islamabad, Pakistan. -FAU - Huang, Tao -AU - Huang T -AD - Medical School, Huanghe Science and Technology University, Zhengzhou, China. -FAU - Duan, Yongtao -AU - Duan Y -AD - Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, - Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, - Zhengzhou, China. -FAU - Rehman, Masood Ur -AU - Rehman MU -AD - Riphah Institute of Pharmaceutical Sciences, Riphah International University, - Islamabad, Pakistan. -LA - eng -PT - Journal Article -PT - Review -DEP - 20220801 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC9376330 -OTO - NOTNLM -OT - advanced stage -OT - chemotherapy -OT - immunotherapy -OT - lung cancer -OT - small cell lung cancer -OT - targeted therapy -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/08/19 06:00 -MHDA- 2022/08/19 06:01 -PMCR- 2022/01/01 -CRDT- 2022/08/18 02:07 -PHST- 2022/05/31 00:00 [received] -PHST- 2022/06/27 00:00 [accepted] -PHST- 2022/08/18 02:07 [entrez] -PHST- 2022/08/19 06:00 [pubmed] -PHST- 2022/08/19 06:01 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2022.958505 [doi] -PST - epublish -SO - Front Oncol. 2022 Aug 1;12:958505. doi: 10.3389/fonc.2022.958505. eCollection - 2022. - -PMID- 36846007 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230228 -IS - 2305-5839 (Print) -IS - 2305-5847 (Electronic) -IS - 2305-5839 (Linking) -VI - 11 -IP - 3 -DP - 2023 Feb 15 -TI - The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung - cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort - study. -PG - 157 -LID - 10.21037/atm-22-6272 [doi] -LID - 157 -AB - BACKGROUND: Acquired drug resistance to various tyrosine kinase inhibitor (TKI) - inevitably develops in almost all epidermal growth factor receptor (EGFR)-mutant - non-small cell lung cancer (NSCLC). The present study aimed to evaluate the - efficacy and safety of programmed cell death protein 1 (PD-1) inhibitors for such - patients after TKI failure and further explore the subpopulation that exhibited - the most benefit. METHODS: A total of 102 EGFR-mutant NSCLC patients who received - PD-1 inhibitors after developing resistance to EGFR-TKIs were included in the - study. The primary endpoints were progression-free survival (PFS) and grade 3-5 - adverse events (AEs), while the secondary endpoints were overall survival (OS), - disease control rate (DCR) and subgroup analyses. RESULTS: All the 102 patients - received 2 or more lines of immunotherapy. The overall median PFS was 4.95 months - [95% confidence interval (CI): 3.91-5.89 months]. The EGFR(L858R) group showed a - significant PFS benefit compared with the EGFR(D19) group (6.4 vs. 3.5 months, - P=0.002), and likewise for the DCR between the 2 groups (EGFR(L858R) vs. - EGFR(D19) group: 84.3% vs. 66.7%, P=0.049). In addition, median PFS in the - EGFR(T790M)-negative group (6.47 months) was significantly longer than the - EGFR(T790M)-positive group (3.20 months) (P=0.003). The overall OS was 10.70 - months (95% CI: 8.92-12.48 months), without a prognostic factor. There was a - trend towards improved PFS and OS with combination therapy. The incidence of - grade 3-5 treatment-related AEs was 19.6%, while the incidence of grade 3-5 - immune-related AEs (irAEs) was 6.9%. Treatment-related AEs were similar in - different mutation subtypes. The incidence of grade 3-5 irAEs was higher in the - EGFR(D19) group (10.3%) compared with the EGFR(L858R) group (5.9%), and likewise - in the EGFR(T790M)-negative group (10%) compared with the EGFR(T790M)-positive - group (2.6%). CONCLUSIONS: After EGFR-TKI failure, PD-1 inhibitors provided - better survival in advanced NSCLC for the EGFR(L858R) subgroup and - EGFR(T790M)-negative subgroup, and there was a trend towards improved outcomes - with combination therapy. In addition, toxicity was well tolerated. Our - real-world study increased the population size and obtained a similar survival - outcome compared from clinical trials. -CI - 2023 Annals of Translational Medicine. All rights reserved. -FAU - Zhou, Chunyang -AU - Zhou C -AD - Department of Radiation Oncology, Qilu Hospital (Qingdao), Cheeloo College of - Medicine, Shandong University, Qingdao, China. -FAU - Wang, Zijian -AU - Wang Z -AD - College of Traditional Chinese Medicine, Shandong University of Traditional - Chinese Medicine, Jinan, China. -FAU - Fu, Chengrui -AU - Fu C -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - China. -FAU - Tao, Hengmin -AU - Tao H -AD - Department of Head and Neck Radiotherapy, Shandong Provincial ENT Hospital, - Shandong University, Jinan, China. -FAU - Liu, Chengxin -AU - Liu C -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - China. -AD - Cheeloo College of Medicine, Shandong University, Jinan, China. -LA - eng -PT - Journal Article -DEP - 20230210 -PL - China -TA - Ann Transl Med -JT - Annals of translational medicine -JID - 101617978 -PMC - PMC9951015 -OTO - NOTNLM -OT - Epidermal growth factor receptor (EGFR) -OT - immune checkpoint inhibitors (ICIs) -OT - immune combined therapy -OT - non-small cell lung cancer (NSCLC) -OT - programmed death-ligand 1 (PD-L1) -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://atm.amegroups.com/article/view/10.21037/atm-22-6272/coif). The authors - have no conflicts of interest to declare. -EDAT- 2023/02/28 06:00 -MHDA- 2023/02/28 06:01 -PMCR- 2023/02/15 -CRDT- 2023/02/27 05:30 -PHST- 2022/11/28 00:00 [received] -PHST- 2023/01/29 00:00 [accepted] -PHST- 2023/02/27 05:30 [entrez] -PHST- 2023/02/28 06:00 [pubmed] -PHST- 2023/02/28 06:01 [medline] -PHST- 2023/02/15 00:00 [pmc-release] -AID - atm-11-03-157 [pii] -AID - 10.21037/atm-22-6272 [doi] -PST - ppublish -SO - Ann Transl Med. 2023 Feb 15;11(3):157. doi: 10.21037/atm-22-6272. Epub 2023 Feb - 10. - -PMID- 34638296 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20211016 -IS - 2072-6694 (Print) -IS - 2072-6694 (Electronic) -IS - 2072-6694 (Linking) -VI - 13 -IP - 19 -DP - 2021 Sep 26 -TI - Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the - Age of Immunotherapy. -LID - 10.3390/cancers13194811 [doi] -LID - 4811 -AB - Stage III non-small-cell lung cancer (NSCLC) with N2 lymph node involvement is a - heterogeneous group with different potential therapeutic approaches. Patients - with potentially resectable III-N2 NSCLC are those who are considered to be able - to receive a multimodality treatment that includes tumour resection after - neoadjuvant therapy. Current treatment for these patients is based on neoadjuvant - chemotherapy +/- radiotherapy followed by surgery and subsequent assessment for - adjuvant chemotherapy and/or radiotherapy. In addition, some selected III-N2 - patients could receive upfront surgery or pathologic N2 incidental involvement - can be found a posteriori during analysis of the surgical specimen. The standard - treatment for these patients is adjuvant chemotherapy and evaluation for - complementary radiotherapy. Despite being a locally advanced stage, the cure rate - for these patients continues to be low, with a broad improvement margin. The most - immediate hope for improving survival data and curing these patients relies on - integrating immunotherapy into perioperative treatment. Immunotherapy based on - anti-PD1/PD-L1 immune checkpoint inhibitors is already a standard treatment in - stage III unresectable and advanced NSCLC. Data from the first phase II studies - in monotherapy neoadjuvant therapy and, in particular, in combination with - chemotherapy, are highly promising, with impressive improved and complete - pathological response rates. Despite the lack of confirmatory data from phase III - trials and long-term survival data, and in spite of various unresolved questions, - immunotherapy will soon be incorporated into the armamentarium for treating stage - III-N2 NSCLC. In this article, we review all therapeutic approaches to stage - III-N2 NSCLC, analysing both completed and ongoing studies that evaluate the - addition of immunotherapy with or without chemotherapy and/or radiotherapy. -FAU - Mielgo-Rubio, Xabier -AU - Mielgo-Rubio X -AUID- ORCID: 0000-0002-0985-6150 -AD - Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, 28922 - Madrid, Spain. -FAU - Montemuiño, Sara -AU - Montemuiño S -AD - Department of Radiation Oncology, Hospital Universitario Fuenlabrada, 28942 - Madrid, Spain. -FAU - Jiménez, Unai -AU - Jiménez U -AD - Department of Thoracic Surgery, Hospital Universitario Cruces, 48903 Barakaldo, - Bizkaia, Spain. -FAU - Luna, Javier -AU - Luna J -AD - Department of Radiation Oncology, Fundación Jiménez Díaz, 28040 Madrid, Spain. -FAU - Cardeña, Ana -AU - Cardeña A -AUID- ORCID: 0000-0001-5972-8651 -AD - Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, 28922 - Madrid, Spain. -FAU - Mezquita, Laura -AU - Mezquita L -AD - Department of Medical Oncology, Hospital Universitari Clínic Barcelona, 08036 - Barcelona, Spain. -FAU - Martín, Margarita -AU - Martín M -AD - Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, 28034 - Madrid, Spain. -FAU - Couñago, Felipe -AU - Couñago F -AUID- ORCID: 0000-0001-7233-0234 -AD - Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, - 28223 Madrid, Spain. -AD - Department of Radiation Oncology, Hospital La Luz, 28003 Madrid, Spain. -AD - Medicine Department, School of Biomedical Siciences, Universidad Europea, 28670 - Madrid, Spain. -LA - eng -PT - Journal Article -PT - Review -DEP - 20210926 -PL - Switzerland -TA - Cancers (Basel) -JT - Cancers -JID - 101526829 -PMC - PMC8507745 -OTO - NOTNLM -OT - N2 -OT - NSCLC -OT - immunotherapy -OT - non-small-cell lung cancer -OT - perioperative -OT - resectable -OT - stage III -COIS- Xabier Mielgo-Rubio declares the following conflicts of interest: advisory role; - Boehringer-Ingelheim, Astra Zeneca, Brystol Myers Squibb. Speakers’ bureau; - Roche, Astra Zeneca, Brystol Myers Squibb, MSD, Abbott, Kyowa Kirin. Research - funding; Brystol Myers Squibb. The rest of the authors declare that they have no - known conflict of interest or personal relationships that could have appeared to - influence the work reported in this paper. -EDAT- 2021/10/14 06:00 -MHDA- 2021/10/14 06:01 -PMCR- 2021/09/26 -CRDT- 2021/10/13 01:01 -PHST- 2021/08/20 00:00 [received] -PHST- 2021/09/21 00:00 [revised] -PHST- 2021/09/22 00:00 [accepted] -PHST- 2021/10/13 01:01 [entrez] -PHST- 2021/10/14 06:00 [pubmed] -PHST- 2021/10/14 06:01 [medline] -PHST- 2021/09/26 00:00 [pmc-release] -AID - cancers13194811 [pii] -AID - cancers-13-04811 [pii] -AID - 10.3390/cancers13194811 [doi] -PST - epublish -SO - Cancers (Basel). 2021 Sep 26;13(19):4811. doi: 10.3390/cancers13194811. - -PMID- 39147210 -OWN - NLM -STAT- Publisher -LR - 20241016 -IS - 1879-355X (Electronic) -IS - 0360-3016 (Linking) -DP - 2024 Aug 13 -TI - Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With - Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung - Cancer: Brief Report. -LID - S0360-3016(24)03177-8 [pii] -LID - 10.1016/j.ijrobp.2024.07.2333 [doi] -AB - PURPOSE: Consolidative durvalumab, an anti-programmed death ligand 1 (PDL1) - immune checkpoint inhibitor, administered after concurrent chemoradiation - improves outcomes of patients with locally advanced non-small cell lung cancer - (NSCLC) without substantially increasing toxicities. We studied a - chemotherapy-free regimen of thoracic radiation therapy (RT) with concurrent and - consolidative durvalumab. METHODS AND MATERIALS: This single-arm phase 2 trial - enrolled patients with stage III NSCLC (regardless of tumor PDL1 expression), - Eastern Cooperative Oncology Group (ECOG) performance status 0-1, adequate - pulmonary function, and RT fields meeting standard organ constraints. - Participants received 2 cycles of durvalumab (1500 mg every 4 weeks) concurrently - with thoracic RT (60 Gy in 30 fractions), followed by up to 13 cycles of - consolidative durvalumab. RESULTS: After 10 patients were enrolled, the trial was - closed because of poor clinical outcomes. With a median follow-up of 12 months, 5 - patients had disease progression and 8 patients died. Six patients experienced 15 - treatment-related, grade ≥3 events, including 1 grade 4 acute kidney injury - during consolidation and 2 fatal pulmonary events. One fatal pulmonary event - occurred during the concurrent phase in an active smoker; the other occurred - after the first cycle of consolidative durvalumab. The primary endpoint of - progression-free survival at 12 months was 20% (50% for PDL1≥1% vs 0% for PDL1 - unavailable or <1%). Median overall survival was not reached, 10.5 months, and 7 - months, for PDL1 ≥1%, <1%, and unavailable, respectively. CONCLUSIONS: In PDL1 - unselected stage III NSCLC, thoracic RT plus concurrent and consolidative - durvalumab is associated with high-grade toxicity and early disease progression. -CI - Copyright © 2024 Elsevier Inc. All rights reserved. -FAU - Zhang, Yuanyuan -AU - Zhang Y -AD - Departments of Radiation Oncology, Harold C. Simmons Comprehensive Cancer Center, - University of Texas Southwestern Medical Center, Dallas, Texas. Electronic - address: yuanyuan.zhang@utsouthwestern.edu. -FAU - Iyengar, Puneeth -AU - Iyengar P -AD - Departments of Radiation Oncology, Harold C. Simmons Comprehensive Cancer Center, - University of Texas Southwestern Medical Center, Dallas, Texas. -FAU - Montalvo, Steven -AU - Montalvo S -AD - Departments of Radiation Oncology, Harold C. Simmons Comprehensive Cancer Center, - University of Texas Southwestern Medical Center, Dallas, Texas. -FAU - Westover, Kenneth D -AU - Westover KD -AD - Departments of Radiation Oncology, Harold C. Simmons Comprehensive Cancer Center, - University of Texas Southwestern Medical Center, Dallas, Texas. -FAU - Rashdan, Sawsan -AU - Rashdan S -AD - Division of Hematology-Oncology, Internal Medicine, Harold C. Simmons - Comprehensive Cancer Center, University of Texas Southwestern Medical Center, - Dallas, Texas. -FAU - Donthireddy, Kavitha -AU - Donthireddy K -AD - Division of Hematology-Oncology, Internal Medicine, Harold C. Simmons - Comprehensive Cancer Center, University of Texas Southwestern Medical Center, - Dallas, Texas. -FAU - Kim, James -AU - Kim J -AD - Division of Hematology-Oncology, Internal Medicine, Harold C. Simmons - Comprehensive Cancer Center, University of Texas Southwestern Medical Center, - Dallas, Texas. -FAU - Dowell, Jonathan E -AU - Dowell JE -AD - Division of Hematology-Oncology, Internal Medicine, Harold C. Simmons - Comprehensive Cancer Center, University of Texas Southwestern Medical Center, - Dallas, Texas. -FAU - Drapkin, Benjamin -AU - Drapkin B -AD - Division of Hematology-Oncology, Internal Medicine, Harold C. Simmons - Comprehensive Cancer Center, University of Texas Southwestern Medical Center, - Dallas, Texas. -FAU - Bhalla, Sheena -AU - Bhalla S -AD - Division of Hematology-Oncology, Internal Medicine, Harold C. Simmons - Comprehensive Cancer Center, University of Texas Southwestern Medical Center, - Dallas, Texas. -FAU - Chukwuma, Christian -AU - Chukwuma C -AD - Departments of Radiation Oncology, Harold C. Simmons Comprehensive Cancer Center, - University of Texas Southwestern Medical Center, Dallas, Texas. -FAU - Nadeem, Urooba -AU - Nadeem U -AD - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, - Texas. -FAU - Ahn, Chul -AU - Ahn C -AD - Peter O'Donnell, Jr. School of Public Health, University of Texas Southwestern - Medical Center, Dallas, Texas. -FAU - Timmerman, Robert D -AU - Timmerman RD -AD - Departments of Radiation Oncology, Harold C. Simmons Comprehensive Cancer Center, - University of Texas Southwestern Medical Center, Dallas, Texas. -FAU - Gerber, David E -AU - Gerber DE -AD - Division of Hematology-Oncology, Internal Medicine, Harold C. Simmons - Comprehensive Cancer Center, University of Texas Southwestern Medical Center, - Dallas, Texas; Peter O'Donnell, Jr. School of Public Health, University of Texas - Southwestern Medical Center, Dallas, Texas. -LA - eng -GR - P30 CA142543/CA/NCI NIH HHS/United States -PT - Journal Article -DEP - 20240813 -PL - United States -TA - Int J Radiat Oncol Biol Phys -JT - International journal of radiation oncology, biology, physics -JID - 7603616 -SB - IM -EDAT- 2024/08/16 01:19 -MHDA- 2024/08/16 01:19 -CRDT- 2024/08/15 19:22 -PHST- 2024/03/12 00:00 [received] -PHST- 2024/07/10 00:00 [revised] -PHST- 2024/07/29 00:00 [accepted] -PHST- 2024/08/16 01:19 [pubmed] -PHST- 2024/08/16 01:19 [medline] -PHST- 2024/08/15 19:22 [entrez] -AID - S0360-3016(24)03177-8 [pii] -AID - 10.1016/j.ijrobp.2024.07.2333 [doi] -PST - aheadofprint -SO - Int J Radiat Oncol Biol Phys. 2024 Aug 13:S0360-3016(24)03177-8. doi: - 10.1016/j.ijrobp.2024.07.2333. - -PMID- 39199552 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240903 -IS - 2072-6694 (Print) -IS - 2072-6694 (Electronic) -IS - 2072-6694 (Linking) -VI - 16 -IP - 16 -DP - 2024 Aug 6 -TI - Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint - Blockers and Targeted Therapies. -LID - 10.3390/cancers16162779 [doi] -LID - 2779 -AB - The recent advent of tyrosine kinase inhibitors (TKIs) and immune checkpoint - blockers (ICBs) in early-stage non-small cell lung cancer (NSCLC) has - dramatically modified treatment strategies by improving the prognosis in this - setting. Osimertinib and alectinib, both TKIs, have shown significant - improvements in outcomes for patients with resected EGFR- and ALK-positive NSCLC, - respectively, changing the standard of care in these subgroups. More recently, - the LAURA trial showed the efficacy of osimertinib after chemoradiotherapy in - patients with unresectable stage III NSCLC harboring EGFR mutations. Numerous - trials are still ongoing to investigate neoadjuvant/perioperative TKIs in several - oncogene-driven NSCLC. In addition, several ICBs have been tested and approved as - adjuvant (atezolizumab and pembrolizumab), neoadjuvant (nivolumab), and - perioperative treatments (pembrolizumab) for patients with resectable early-stage - NSCLC. Despite these advances, many challenges remain regarding the use of TKIs - and ICBs in this setting, including the optimal duration of adjuvant TKI or - induction ICB therapy, the role of minimal residual disease to identify patients - at high-risk of disease relapse and to guide adjuvant treatment decisions, and - the role of adjuvant chemotherapy in resected oncogene-driven NSCLC. Furthermore, - potential predictive biomarkers for efficacy are needed to eventually intensify - the entire perioperative strategies. This review aims to summarize and discuss - the available evidence, the ongoing trials, and the challenges associated with - TKI- and ICB-based approaches in early-stage NSCLC. -FAU - Lavaud, Pernelle -AU - Lavaud P -AUID- ORCID: 0000-0002-1286-5955 -AD - Gustave Roussy, Department of Cancer Medicine, Paris-Saclay University, 114, rue - Edouard Vaillant, 94805 Villejuif, France. -FAU - Bortolot, Martina -AU - Bortolot M -AD - Department of Respiratory Medicine, Maastricht University Medical Centre, GROW - School for Oncology and Reproduction, 6229 ER Maastricht, The Netherlands. -AD - Department of Medicine (DMED), University of Udine, 33100 Udine, Italy. -FAU - Zullo, Lodovica -AU - Zullo L -AUID- ORCID: 0000-0002-1659-788X -AD - Gustave Roussy, Department of Cancer Medicine, Paris-Saclay University, 114, rue - Edouard Vaillant, 94805 Villejuif, France. -FAU - O'Reilly, David -AU - O'Reilly D -AD - Medical Oncology, Beaumont Hospital, RCSI University of Health Sciences, D02 YN77 - Dublin, Ireland. -FAU - Naidoo, Jarushka -AU - Naidoo J -AUID- ORCID: 0000-0002-3470-8686 -AD - Medical Oncology, Beaumont Hospital, RCSI University of Health Sciences, D02 YN77 - Dublin, Ireland. -FAU - Mountzios, Giannis -AU - Mountzios G -AD - Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant - Hospital Center, 11526 Athens, Greece. -FAU - Mercier, Olaf -AU - Mercier O -AUID- ORCID: 0000-0002-4760-6267 -AD - Department of Thoracic Surgery, Hôpital Marie Lannelongue, 92350 Le - Plessis-Robinson, France. -FAU - Hendriks, Lizza E L -AU - Hendriks LEL -AUID- ORCID: 0000-0002-3521-2535 -AD - Department of Respiratory Medicine, Maastricht University Medical Centre, GROW - School for Oncology and Reproduction, 6229 ER Maastricht, The Netherlands. -FAU - Remon, Jordi -AU - Remon J -AUID- ORCID: 0000-0002-9462-875X -AD - Gustave Roussy, Department of Cancer Medicine, Paris-Saclay University, 114, rue - Edouard Vaillant, 94805 Villejuif, France. -LA - eng -PT - Journal Article -PT - Review -DEP - 20240806 -PL - Switzerland -TA - Cancers (Basel) -JT - Cancers -JID - 101526829 -PMC - PMC11353229 -OTO - NOTNLM -OT - alectinib -OT - early-stage NSCLC -OT - induction -OT - lung cancer -OT - osimertinib -OT - perioperative -COIS- Jordi Remon reports investigator support from MSD, honoraria for advisory board - (paid to institution) from AstraZeneca, Edimark, Janssen, study support (paid to - institution) from Merck, travel support from OSE-Immunotherapeutics, and MSD. - Lizza Hendriks reports Grants/Research support (all to institution): Roche, - Boehringer Ingelheim, AstraZeneca, Takeda, Merck, Pfizer, Novartis, and Gilead. - Advisory boards (all to institution): Amgen, Boehringer Ingelheim, Lilly, - Novartis, Pfizer, Takeda, Merck, Janssen, MSD, Anheart, and Bayer. Speaker - educationals/webinars: AstraZeneca, Bayer, Lilly, MSD, high5oncology, Takeda, - Janssen, GSK, Sanofi, Pfizer (Inst), Medtalks, Benecke, VJOncology, and Medimix - (self). Local PI pharma studies (all to institution): AstraZeneca, GSK, Novartis, - Merck, Roche, Takeda, Blueprint, Mirati, Abbvie, Gilead, MSD, Pfizer, Boehringer, - and Ingelheim. Member guideline committees (self): Dutch guidelines on NSCLC, - brain metastases and leptomeningeal metastases. Other authors have not reported - competing interests. -EDAT- 2024/08/31 09:44 -MHDA- 2024/08/31 09:45 -PMCR- 2024/08/06 -CRDT- 2024/08/29 01:03 -PHST- 2024/07/19 00:00 [received] -PHST- 2024/08/01 00:00 [revised] -PHST- 2024/08/05 00:00 [accepted] -PHST- 2024/08/31 09:45 [medline] -PHST- 2024/08/31 09:44 [pubmed] -PHST- 2024/08/29 01:03 [entrez] -PHST- 2024/08/06 00:00 [pmc-release] -AID - cancers16162779 [pii] -AID - cancers-16-02779 [pii] -AID - 10.3390/cancers16162779 [doi] -PST - epublish -SO - Cancers (Basel). 2024 Aug 6;16(16):2779. doi: 10.3390/cancers16162779. - -PMID- 37142872 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230508 -IS - 2730-6011 (Electronic) -IS - 2730-6011 (Linking) -VI - 14 -IP - 1 -DP - 2023 May 4 -TI - Role of consolidative thoracic radiation in extensive-stage small-cell lung - cancer with first-line chemoimmunotherapy: a retrospective study from a single - cancer center. -PG - 55 -LID - 10.1007/s12672-023-00666-7 [doi] -LID - 55 -AB - OBJECTIVE: To investigate the role of consolidative thoracic radiation (TRT) in - extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line - chemo-immunotherapy followed by immunotherapy maintenance. PATIENTS AND METHODS: - Outcomes of patients without disease progression after first-line chemotherapy - were retrospectively reviewed (January 2020 to December 2021). Based on TRT or - not, patients were allocated to TRT group or non-TRT group. Progression-free - survival (PFS), overall survival (OS) and local-recurrence free survival (LRFS) - were calculated by the Kaplan-Meier method and compared by log-rank test. - RESULTS: Of 100 patients, 47 received TRT and 53 non-TRT. The median follow-up - was 20.3 months. The median PFS and OS in TRT were 9.1 months and 21.8 months, - versus 8.8 months (p = 0.93) and 24.3 months (p = 0.63), respectively, in - non-TRT. The median LRFS time in TRT was not reached, but significantly longer - than 10.8 months in non-TRT (HR = 0.27, p < 0.01). Second-line chemotherapy - significantly prolonged survival compared to that with chemo-free patients (mOS: - 24.5 vs. 21.4 months, p = 0.026). The subgroup analysis showed a trend of - patients with brain metastases benefit from TRT (21.8 versus 13.7 months, HR - 0.61, p = 0.38) while liver metastases did not. Of 47 patients with TRT, only - 10.6% of patients experienced grade 3 radiation-induced pneumonitis, while no - grade 4 or 5 adverse events occurred. CONCLUSION: Consolidative TRT in the period - of immunotherapy maintenance followed first-line chemo-immunotherapy did not - prolong OS and PFS but associated with improved LRFS in ES-SCLC. -CI - © 2023. The Author(s). -FAU - Li, Yuying -AU - Li Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan, - 250117, Shandong Province, China. -FAU - Jing, Wang -AU - Jing W -AD - Shandong First Medical University and Shandong Academy of Medical Science, Jinan, - 250021, Shandong Province, China. -FAU - Jing, Xuquan -AU - Jing X -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan, - 250117, Shandong Province, China. -FAU - Sun, Yulan -AU - Sun Y -AD - Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong - First Medical University and Shandong Academy of Medical Science, Jinan, 250117, - Shandong Province, China. -FAU - Tang, Xiaoyong -AU - Tang X -AD - Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong - First Medical University and Shandong Academy of Medical Science, Jinan, 250117, - Shandong Province, China. -FAU - Guo, Jun -AU - Guo J -AD - Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong - First Medical University and Shandong Academy of Medical Science, Jinan, 250117, - Shandong Province, China. -FAU - Zhang, Yan -AU - Zhang Y -AD - Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong - First Medical University and Shandong Academy of Medical Science, Jinan, 250117, - Shandong Province, China. -FAU - Zhu, Hui -AU - Zhu H -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Science, Jinan, - 250117, Shandong Province, China. drzhuh@126.com. -LA - eng -GR - 202209030456/Medical and Health Technology Development Program in Shandong/ -GR - 81972862/National Natural Science Foundation of China/ -GR - 320. 6750. 2022-22-13/Wu Jieping Medical Foundation/ -PT - Journal Article -DEP - 20230504 -PL - United States -TA - Discov Oncol -JT - Discover oncology -JID - 101775142 -PMC - PMC10160328 -OTO - NOTNLM -OT - Immunotherapy -OT - Small-cell lung cancer -OT - Survival -OT - Thoracic radiation -OT - Toxicity -COIS- The authors declare that they have no competing interests. -EDAT- 2023/05/05 00:42 -MHDA- 2023/05/05 00:43 -PMCR- 2023/05/04 -CRDT- 2023/05/04 23:33 -PHST- 2023/02/01 00:00 [received] -PHST- 2023/04/21 00:00 [accepted] -PHST- 2023/05/05 00:43 [medline] -PHST- 2023/05/05 00:42 [pubmed] -PHST- 2023/05/04 23:33 [entrez] -PHST- 2023/05/04 00:00 [pmc-release] -AID - 10.1007/s12672-023-00666-7 [pii] -AID - 666 [pii] -AID - 10.1007/s12672-023-00666-7 [doi] -PST - epublish -SO - Discov Oncol. 2023 May 4;14(1):55. doi: 10.1007/s12672-023-00666-7. - -PMID- 26862770 -OWN - NLM -STAT- MEDLINE -DCOM- 20161101 -LR - 20161230 -IS - 1543-0790 (Print) -IS - 1543-0790 (Linking) -VI - 13 -IP - 11 Suppl 11 -DP - 2015 Nov -TI - Technological Advances in the Treatment of Cancer: Combining Modalities to - Optimize Outcomes. -PG - 1-18 -AB - The anticancer treatment modality tumor treating fields (TTFields; Optune, - Novocure) use the lower frequency range of the electromagnetic spectrum to - destroy tumor cells during mitosis. This treatment has been evaluated in several - trials of patients with glioblastoma. In these patients, TTFields are delivered - through 4 transducer arrays applied to the scalp. In a phase 3 clinical trial of - patients with recurrent glioblastoma, TTFields were as effective as chemotherapy, - and were associated with fewer and milder systemic toxicities. Data from a phase - 3 trial in newly diagnosed glioblastoma suggested that the addition of TTFields - to postoperative radiation therapy and chemotherapy represents an important - advance in the management of newly diagnosed glioblastoma. Ongoing clinical - trials are investigating the efficacy and safety of TTFields in other tumor - types, including pancreatic cancer, mesothelioma, ovarian cancer, and non–small - cell lung cancer. Other recent advances in the management of cancer have been - seen with immunomodulatory therapy, including immune checkpoint inhibitors. - Further study will be necessary to evaluate whether TTFields will enhance or - impair other established and newly emerging therapies. -FAU - Wong, Eric T -AU - Wong ET -AD - Neuroscience Institute, Geisinger Health System, Danville, Pennsylvania. -FAU - Toms, Steven A -AU - Toms SA -FAU - Ahluwalia, Manmeet S -AU - Ahluwalia MS -LA - eng -PT - Journal Article -PL - United States -TA - Clin Adv Hematol Oncol -JT - Clinical advances in hematology & oncology : H&O -JID - 101167661 -SB - IM -MH - Clinical Trials as Topic/*standards -MH - Combined Modality Therapy -MH - Electric Stimulation Therapy/*methods -MH - Glioblastoma/*therapy -MH - Humans -MH - Practice Guidelines as Topic/*standards -MH - Treatment Outcome -EDAT- 2016/02/11 06:00 -MHDA- 2016/11/02 06:00 -CRDT- 2016/02/11 06:00 -PHST- 2016/02/11 06:00 [entrez] -PHST- 2016/02/11 06:00 [pubmed] -PHST- 2016/11/02 06:00 [medline] -PST - ppublish -SO - Clin Adv Hematol Oncol. 2015 Nov;13(11 Suppl 11):1-18. - -PMID- 38617775 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240425 -IS - 2072-1439 (Print) -IS - 2077-6624 (Electronic) -IS - 2072-1439 (Linking) -VI - 16 -IP - 3 -DP - 2024 Mar 29 -TI - Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy - in locally advanced and advanced non-small cell lung cancer: a retrospective - study. -PG - 1787-1803 -LID - 10.21037/jtd-23-1767 [doi] -AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) have dramatically changed the - first-line treatment pattern of non-small cell lung cancer (NSCLC) without driver - gene alterations. However, the optimal choice for second-line treatment after - initial treatment with ICIs is unclear. This study aimed to clarify the efficacy - and safety of ICI rechallenge therapy in locally advanced and advanced NSCLC. - METHODS: We retrospectively analyzed the histories of 224 patients with locally - advanced or advanced NSCLC treated with programmed death-1 (PD-1)/programmed - death-ligand 1 (PD-L1) inhibitors alone or in combination with chemotherapy - and/or antiangiogenic therapy in first-line treatment. Progression-free survival - 2 (PFS2) was the time from the first defined progress disease (PD) to the second - disease progression or death. Efficacy evaluation was performed directly in - accordance with RECIST v1.1 criteria. Adverse events (AEs) were graded following - the National Cancer Institute Common Terminology Criteria for Adverse Events - v5.0. Survival data were estimated using the Kaplan-Meier method or Cox survival - regression model and compared using the log-rank test in overall cohort and other - subgroups. RESULTS: There were no significant differences in objective response - rate (ORR) and median PFS2 (mPFS2) between the ICI rechallenge group and - non-rechallenge group (ORR: 10.3% vs. 15.3%, P=0.308; mPFS2: 5.33 vs. 4.40 - months, P=0.715). And the ICI rechallenge group showed no new safety signals - compared with non-rechallenge group. In ICI rechallenge group, patients resistant - to first-line immunotherapy had a lower ORR and shorter PFS2 compared with those - who responded to initial ICIs treatment (ORR: 7.0% vs. 17.6%, P=0.038; mPFS2: - 3.68 vs. 5.91 months, P=0.014). No significant difference in mPFS2 was observed - among different second-line treatment groups (P=0.362). Radiotherapy in - second-line treatment and ICI rechallenge therapy were not the main factors - affecting PFS2. CONCLUSIONS: ICI rechallenge therapy beyond disease progression - did not improve clinical outcomes in patients with NSCLC, but no new safety - signals emerged. However, patients with favorable response to initial ICIs - treatment still showed significant efficacy of subsequent ICI rechallenge - therapy. -CI - 2024 Journal of Thoracic Disease. All rights reserved. -FAU - Yan, Xiaoqi -AU - Yan X -AD - Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Zhao, Luqing -AU - Zhao L -AD - Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Wu, Fei -AU - Wu F -AD - Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Shen, Bo -AU - Shen B -AD - Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Zhou, Guoren -AU - Zhou G -AD - Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Feng, Jifeng -AU - Feng J -AD - Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Yue, Chao -AU - Yue C -AD - Department of General Surgery, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Zhu, Jingni -AU - Zhu J -AD - Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Yu, Shaorong -AU - Yu S -AD - Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical - University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, - Nanjing, China. -LA - eng -PT - Journal Article -DEP - 20240319 -PL - China -TA - J Thorac Dis -JT - Journal of thoracic disease -JID - 101533916 -PMC - PMC11009570 -OTO - NOTNLM -OT - ICI rechallenge therapy -OT - Immune checkpoint inhibitors (ICIs) -OT - disease progression -OT - non-small cell lung cancer (NSCLC) -OT - second-line treatment -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://jtd.amegroups.com/article/view/10.21037/jtd-23-1767/coif). The authors - have no conflicts of interest to declare. -EDAT- 2024/04/15 06:43 -MHDA- 2024/04/15 06:44 -PMCR- 2024/03/29 -CRDT- 2024/04/15 04:23 -PHST- 2023/11/16 00:00 [received] -PHST- 2024/01/26 00:00 [accepted] -PHST- 2024/04/15 06:44 [medline] -PHST- 2024/04/15 06:43 [pubmed] -PHST- 2024/04/15 04:23 [entrez] -PHST- 2024/03/29 00:00 [pmc-release] -AID - jtd-16-03-1787 [pii] -AID - 10.21037/jtd-23-1767 [doi] -PST - ppublish -SO - J Thorac Dis. 2024 Mar 29;16(3):1787-1803. doi: 10.21037/jtd-23-1767. Epub 2024 - Mar 19. - -PMID- 33717228 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220421 -IS - 1758-8340 (Print) -IS - 1758-8359 (Electronic) -IS - 1758-8340 (Linking) -VI - 13 -DP - 2021 -TI - A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy - followed by durvalumab for unresectable, locally advanced non-small-cell lung - cancer in Japan (SAMURAI study). -PG - 1758835921998588 -LID - 10.1177/1758835921998588 [doi] -LID - 1758835921998588 -AB - BACKGROUND: Based on the results of the PACIFIC study, chemoradiotherapy followed - by 1-year consolidation therapy with durvalumab was established as the standard - of care for unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC). - However, some topics not foreseen in that design can be explored, including - progression-free survival (PFS) and overall survival (OS) after the start of - chemoradiotherapy, the proportion of patients who proceeded to consolidation - therapy with durvalumab, and the optimal chemotherapeutic regimens. In Japan, the - combination regimen of S-1 + cisplatin (SP), for which the results of multiple - clinical studies have suggested a good balance of efficacy and tolerability, is - frequently selected in clinical settings. However, the efficacy and safety of - consolidation therapy with durvalumab following this SP regimen have not been - evaluated. We therefore planned a multicenter, prospective, single-arm, phase II - study. METHODS: In treatment-naïve LA-NSCLC, two cycles of combination - chemotherapy with S-1 (80-120 mg/body, Days 1-14) + cisplatin (60 mg/m(2), Day 1) - will be administered at an interval of 4 weeks, with concurrent thoracic - radiotherapy (60 Gy). Responders will then receive durvalumab every 2 weeks for - up to 1 year. The primary endpoint is 1-year PFS rate. DISCUSSION: Compared with - the conventional standard regimen in Japan, the SP regimen is expected to be - associated with lower incidences of pneumonitis, esophagitis, and febrile - neutropenia, which complicate the initiation of consolidation therapy with - durvalumab, and have higher antitumor efficacy during chemoradiotherapy. - Therefore, SP-based chemoradiotherapy is expected to be successfully followed by - consolidation therapy with durvalumab in more patients, resulting in prolonged - PFS and OS. Toxicity and efficacy results of the SP regimen in this study will - also provide information important to the future establishment of the concurrent - combination of chemoradiotherapy and durvalumab. TRIAL REGISTRATION: Japan - Registry of Clinical Trials, jRCTs031190127, registered 1 November 2019, - https://jrct.niph.go.jp/latest-detail/jRCTs031190127. -CI - © The Author(s), 2021. -FAU - Tanzawa, Shigeru -AU - Tanzawa S -AUID- ORCID: 0000-0001-5738-0313 -AD - Division of Medical Oncology, Department of Internal Medicine, Teikyo University - School of Medicine, Itabashi-City, Tokyo, Japan. -FAU - Ushijima, Sunao -AU - Ushijima S -AD - Department of Medical Oncology, Kumamoto Chuo Hospital, Kumamoto-City, Kumamoto, - Japan. -FAU - Shibata, Kazuhiko -AU - Shibata K -AD - Department of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka-City, Toyama, - Japan. -FAU - Shibayama, Takuo -AU - Shibayama T -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Okayama-City, Okayama, Japan. -FAU - Bessho, Akihiro -AU - Bessho A -AD - Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, - Okayama-City, Okayama, Japan. -FAU - Kaira, Kyoichi -AU - Kaira K -AD - Department of Respiratory Medicine, Saitama Medical University International - Medical Center, Hidaka-City, Saitama, Japan. -FAU - Misumi, Toshihiro -AU - Misumi T -AD - Department of Biostatistics, Yokohama City University School of Medicine, - Yokohama-City, Kanagawa, Japan. -FAU - Shiraishi, Kenshiro -AU - Shiraishi K -AUID- ORCID: 0000-0002-2295-517X -AD - Department of Radiology, Teikyo University School of Medicine, Itabashi-City, - Tokyo, Japan. -FAU - Matsutani, Noriyuki -AU - Matsutani N -AD - Department of Surgery, Teikyo University Mizonokuchi Hospital, Kawasaki-City, - Kanagawa, Japan. -FAU - Tanaka, Hisashi -AU - Tanaka H -AD - Department of Respiratory Medicine, Hirosaki University Graduate School of - Medicine, Hirosaki-City, Aomori, Japan. -FAU - Inaba, Megumi -AU - Inaba M -AD - Department of Respiratory Medicine, Kumamoto Chuo Hospital, Kumamoto-City, - Kumamoto, Japan. -FAU - Haruyama, Terunobu -AU - Haruyama T -AD - Division of Medical Oncology, Department of Internal Medicine, Teikyo University - School of Medicine, Itabashi-City, Tokyo, Japan. -FAU - Nakamura, Junya -AU - Nakamura J -AD - Department of Respiratory Medicine, Ehime Prefectural Central Hospital, - Matsuyama-City, Ehime, Japan. -FAU - Kishikawa, Takayuki -AU - Kishikawa T -AD - Division of Thoracic Oncology, Department of Medical Oncology, Tochigi Cancer - Center, Utsunomiya-City, Tochigi, Japan. -FAU - Nakashima, Masanao -AU - Nakashima M -AD - Department of Respiratory Medicine, Shin-Yurigaoka General Hospital, - Kawasaki-City, Kanagawa, Japan. -FAU - Iwasa, Keiichi -AU - Iwasa K -AD - Department of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka-City, Toyama, - Japan. -FAU - Fujiwara, Keiichi -AU - Fujiwara K -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Okayama-City, Okayama, Japan. -FAU - Kohyama, Tadashi -AU - Kohyama T -AD - Department of Internal medicine, Teikyo University Mizonokuchi Hospital, - Kawasaki-City, Kanagawa, Japan. -FAU - Kuyama, Shoichi -AU - Kuyama S -AD - Department of Respiratory Medicine, National Hospital Organization Iwakuni - Clinical Center, Iwakuni-City, Yamaguchi, Japan. -FAU - Miyazawa, Naoki -AU - Miyazawa N -AD - Department of Respiratory Medicine, Saiseikai Yokohamashi Nanbu Hospital, - Yokohama-City, Kanagawa, Japan. -FAU - Nakamura, Tomomi -AU - Nakamura T -AD - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal - Medicine, Faculty of Medicine, Saga University, Saga-City, Saga, Japan. -FAU - Miyawaki, Hiroshi -AU - Miyawaki H -AD - Department of Respiratory Medicine, Kagawa Prefectural Central Hospital, - Takamatsu-City, Kagawa, Japan. -FAU - Ishida, Hiroo -AU - Ishida H -AD - Department of Internal Medicine, Showa University Northern Yokohama Hospital, - Yokohama-City, Kanagawa, Japan. -FAU - Oda, Naohiro -AU - Oda N -AD - Department of Internal Medicine, Fukuyama City Hospital, Fukuyama-City, - Hiroshima, Japan. -FAU - Ishikawa, Nobuhisa -AU - Ishikawa N -AD - Department of Respiratory Medicine, Hiroshima Prefectural Hospital, - Hiroshima-City, Hiroshima, Japan. -FAU - Morinaga, Ryotaro -AU - Morinaga R -AD - Department of Thoracic Medical Oncology, Oita Prefectural Hospital, Oita-City, - Oita, Japan. -FAU - Kusaka, Kei -AU - Kusaka K -AD - The Center for Pulmonary Diseases, National Hospital Organization Tokyo National - Hospital, Kiyose-City, Tokyo, Japan. -FAU - Fujimoto, Nobukazu -AU - Fujimoto N -AD - Department of Medical Oncology, Okayama Rosai Hospital, Okayama-City, Okayama, - Japan. -FAU - Yokoyama, Toshihide -AU - Yokoyama T -AD - Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki-City, - Okayama, Japan. -FAU - Gemba, Kenichi -AU - Gemba K -AD - Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama-City, - Hiroshima, Japan. -FAU - Tsuda, Takeshi -AU - Tsuda T -AD - Department of Respiratory Medicine, Toyama Prefectural Central Hospital, - Toyama-City, Toyama, Japan. -FAU - Nakagawa, Hideyuki -AU - Nakagawa H -AD - Department of Respiratory Medicine, National Hospital Organization, Hirosaki - Hospital, Hirosaki-City, Aomori, Japan. -FAU - Ono, Hirotaka -AU - Ono H -AD - Department of Respiratory Medicine, Tsuboi Hospital, Koriyama-City, Fukushima, - Japan. -FAU - Shimizu, Tetsuo -AU - Shimizu T -AD - Division of Respiratory Medicine, Department of Internal Medicine, Nihon - University School of Medicine, Itabashi-City, Tokyo, Japan. -FAU - Nakamura, Morio -AU - Nakamura M -AD - Department of Pulmonary Medicine, Tokyo Saiseikai Central Hospital, Minato-City, - Tokyo, Japan. -FAU - Kusumoto, Sojiro -AU - Kusumoto S -AD - Division of Allergology and Respiratory Medicine, Showa University School of - Medicine, Shinagawa-City, Tokyo, Japan. -FAU - Hayashi, Ryuji -AU - Hayashi R -AD - Clinical Oncology, Toyama University Hospital, Toyama-City, Toyama, Japan. -FAU - Shirasaki, Hiroki -AU - Shirasaki H -AD - Department of Respiratory Medicine, Fukui-ken Saiseikai Hospital, Fukui-City, - Fukui, Japan. -FAU - Ochi, Nobuaki -AU - Ochi N -AD - General Internal Medicine 4, Kawasaki Medical School, Okayama-City, Okayama, - Japan. -FAU - Aoe, Keisuke -AU - Aoe K -AD - Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube - Medical Center, Ube-City, Yamaguchi, Japan. -FAU - Kanaji, Nobuhiro -AU - Kanaji N -AD - Department of Internal Medicine, Division of Hematology, Rheumatology and - Respiratory Medicine, Faculty of Medicine, Kagawa University, Kida-gun, Kagawa, - Japan. -FAU - Kashiwabara, Kosuke -AU - Kashiwabara K -AD - Department of Respiratory Medicine, Kumamoto Regional Medical Center, - Kumamoto-City, Kumamoto, Japan. -FAU - Inoue, Hiroshi -AU - Inoue H -AD - Department of Internal Medicine, Karatsu Red Cross Hospital, Karatsu-City, Saga, - Japan. -FAU - Seki, Nobuhiko -AU - Seki N -AD - Division of Medical Oncology, Department of Internal Medicine, Teikyo University - School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo 173-8606, Japan. -LA - eng -PT - Journal Article -DEP - 20210227 -PL - England -TA - Ther Adv Med Oncol -JT - Therapeutic advances in medical oncology -JID - 101510808 -PMC - PMC7917867 -OTO - NOTNLM -OT - S-1 -OT - chemoradiotherapy -OT - cisplatin -OT - durvalumab -OT - non-small-cell lung cancer -COIS- Conflict of interest statement: S.T. received research funding from AstraZeneca - K.K. N.S. received personal fees as honoraria from Lily Japan, AstraZeneca K.K., - MSD Oncology, Chugai Pharmaceutical, Taiho Pharmaceutical, Pfizer Japan Inc., Ono - Pharmaceutical, Nippon Boehringer Ingelheim Co., Ltd., and Bristol-Myers Squibb - Japan, and research funding from Nippon Boehringer Ingelheim Co., Ltd. -EDAT- 2021/03/16 06:00 -MHDA- 2021/03/16 06:01 -PMCR- 2021/02/27 -CRDT- 2021/03/15 06:59 -PHST- 2020/11/10 00:00 [received] -PHST- 2021/02/03 00:00 [accepted] -PHST- 2021/03/15 06:59 [entrez] -PHST- 2021/03/16 06:00 [pubmed] -PHST- 2021/03/16 06:01 [medline] -PHST- 2021/02/27 00:00 [pmc-release] -AID - 10.1177_1758835921998588 [pii] -AID - 10.1177/1758835921998588 [doi] -PST - epublish -SO - Ther Adv Med Oncol. 2021 Feb 27;13:1758835921998588. doi: - 10.1177/1758835921998588. eCollection 2021. - -PMID- 37476372 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230722 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 13 -DP - 2023 -TI - Factors associated with failure to start consolidation durvalumab after - definitive chemoradiation for locally advanced NSCLC. -PG - 1217424 -LID - 10.3389/fonc.2023.1217424 [doi] -LID - 1217424 -AB - INTRODUCTION: The introduction of consolidation immunotherapy after - chemoradiotherapy has improved outcome for patients with locally advanced - non-small cell lung cancer. However, not all patients receive this treatment. - This study identifies factors associated with failure to start durvalumab as - consolidation therapy with the aim of optimizing treatment, supportive care and - prehabilitation to ensure that more patients complete the planned treatment. - MATERIALS AND METHODS: Patients from two clinical trials and a named patient use - program, were included in this study. All patients received platinum-doublet - chemotherapy concomitant with radiotherapy to a total dose of 60-66 gray. Patient - characteristics, cancer treatment, toxicity, performance status and laboratory - data before and after chemoradiotherapy were recorded and patients who never - started durvalumab were compared with those who did. RESULTS: A total of 101 - patients were included, of which 83 started treatments with durvalumab after - chemoradiotherapy. The 18 patients who did not start durvalumab had significantly - higher lactate dehydrogenase at baseline and a worse performance status, - cumulative toxicity and higher c-reactive protein after completed - chemoradiotherapy. Data also suggest that pre-treatment diabetes and reduced - hemoglobin and/or diffusion capacity of the lungs for carbon monoxide contribute - to the risk of treatment abruption. CONCLUSION: Treatment plan disruption rate - was 18%. Systemic inflammation and performance status were associated with - failure to receive durvalumab after chemoradiation. Further studies are needed to - confirm findings and prospective trials should investigate whether - prehabilitation and supportive treatment could help more patients finishing the - planned treatment. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov, identifier - NCT03798535; NCT04392505. -CI - Copyright © 2023 Langberg, Horndalsveen, Helland and Haakensen. -FAU - Langberg, Christian Wilhelm -AU - Langberg CW -AD - Faculty of Medicine, University of Oslo, Oslo, Norway. -FAU - Horndalsveen, Henrik -AU - Horndalsveen H -AD - Department of Oncology, Oslo University Hospital, Oslo, Norway. -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, Oslo, Norway. -FAU - Helland, Åslaug -AU - Helland Å -AD - Department of Oncology, Oslo University Hospital, Oslo, Norway. -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, Oslo, Norway. -AD - Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, - Norway. -FAU - Haakensen, Vilde Drageset -AU - Haakensen VD -AD - Department of Oncology, Oslo University Hospital, Oslo, Norway. -AD - Department of Cancer Genetics, Institute for Cancer Research, Oslo University - Hospital, Oslo, Norway. -LA - eng -SI - ClinicalTrials.gov/NCT03798535 -SI - ClinicalTrials.gov/NCT04392505 -PT - Journal Article -DEP - 20230705 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC10354813 -OTO - NOTNLM -OT - chemoradiotherapy -OT - durvalumab -OT - non-small cell lung cancer -OT - personalized treatment -OT - prehabilitation -OT - toxicity -COIS- This study has not received funding, but is based on data from trials funded - completely or partially by Astra Zeneca. No funder has been involved in the study - design, collection, analysis, interpretation of data, the writing of this article - or the decision to submit it for publication. ÅH has received study funding and - honoraria from Astra Zeneca, but all payments have gone to the hospital and not - to personal accounts. HH and VDH have received honoraria from Astra Zeneca for - lectures and/or advisory boards, payments to personal accounts. The authors - declare no other competing interests. -EDAT- 2023/07/21 06:43 -MHDA- 2023/07/21 06:44 -PMCR- 2023/01/01 -CRDT- 2023/07/21 04:04 -PHST- 2023/05/05 00:00 [received] -PHST- 2023/06/19 00:00 [accepted] -PHST- 2023/07/21 06:44 [medline] -PHST- 2023/07/21 06:43 [pubmed] -PHST- 2023/07/21 04:04 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2023.1217424 [doi] -PST - epublish -SO - Front Oncol. 2023 Jul 5;13:1217424. doi: 10.3389/fonc.2023.1217424. eCollection - 2023. - -PMID- 34934361 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20211223 -IS - 1179-1322 (Print) -IS - 1179-1322 (Electronic) -IS - 1179-1322 (Linking) -VI - 13 -DP - 2021 -TI - Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus - Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The - DOLPHIN Study (WJOG11619L). -PG - 9167-9173 -LID - 10.2147/CMAR.S336262 [doi] -AB - Durvalumab (anti-programmed cell death ligand-1) administration after concurrent - chemoradiotherapy (cCRT) has improved the survival of patients with unresectable, - locally advanced (LA) stage III non-small cell lung cancer (NSCLC). Some patients - are unable to complete cCRT and cannot receive immunotherapy due to poor - performance status based on adverse events after cCRT. Immunotherapy plays an - important role in anti-programmed cell death ligand-1 (PD-L1)-positive advanced - NSCLC and is replacing chemotherapy. In addition, radiotherapy and immunotherapy - have been reported to have a synergistic effect. This Phase II, multicenter study - (DOLPHIN, WJOG11619L, JapicCTI-194840) is designed to assess the efficacy and - safety of durvalumab plus concurrent curative radiation therapy for - PD-L1-positive unresectable LA-NSCLC without chemotherapy. Unresectable LA stage - III NSCLC patients aged 20 years or older with a World Health - Organization/Eastern Cooperative Oncology Group (ECOG) performance status (PS) of - 0 or 1 and PD-L1 positivity are enrolled. The patients will receive curative - radiation therapy (60 Gy) plus durvalumab 10 mg/kg every 2 weeks (q2w) for up to - 12 months until there is evidence of disease progression (PD) or unacceptable - toxicity. The primary endpoint is the 12-month progression-free survival rate as - assessed by an independent central review. The secondary endpoints are - progression-free survival, overall survival, objective response rate, treatment - completion rate, and safety. Recruitment began in September 2019. -CI - © 2021 Tachihara et al. -FAU - Tachihara, Motoko -AU - Tachihara M -AUID- ORCID: 0000-0002-4598-220X -AD - Division of Respiratory Medicine, Department of Internal Medicine, Kobe - University Graduate School of Medicine, Kobe City, Japan. -FAU - Tsujino, Kayoko -AU - Tsujino K -AD - Department of Radiation Oncology, Hyogo Cancer Center, Akashi City, Japan. -FAU - Ishihara, Takeaki -AU - Ishihara T -AD - Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe - City, Japan. -FAU - Hayashi, Hidetoshi -AU - Hayashi H -AD - Department of Medical Oncology, Kindai University, Osakasayama City, Japan. -FAU - Sato, Yuki -AU - Sato Y -AD - Department of Respiratory Medicine, Kobe City Medical Center General Hospital, - Kobe City, Japan. -FAU - Kurata, Takayasu -AU - Kurata T -AUID- ORCID: 0000-0003-4123-3567 -AD - Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata - City, Japan. -FAU - Sugawara, Shunichi -AU - Sugawara S -AD - Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai City, Japan. -FAU - Okamoto, Isamu -AU - Okamoto I -AD - Research Institute for Diseases of the Chest, Graduate School of Medical - Sciences, Kyushu University, Fukuoka City, Japan. -FAU - Teraoka, Shunsuke -AU - Teraoka S -AD - Internal Medicine III, Wakayama Medical University, Wakayama, Japan. -FAU - Azuma, Koichi -AU - Azuma K -AD - Division of Respirology, Neurology, and Rheumatology, Department of Internal - Medicine, Kurume University School of Medicine, Fukuoka City, Japan. -FAU - Daga, Haruko -AU - Daga H -AD - Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan. -FAU - Yamaguchi, Masafumi -AU - Yamaguchi M -AUID- ORCID: 0000-0002-5601-4749 -AD - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer - Center, Fukuoka City, Japan. -FAU - Kodaira, Takeshi -AU - Kodaira T -AUID- ORCID: 0000-0002-7075-8488 -AD - Departments of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya City, - Aichi, Japan. -FAU - Satouchi, Miyako -AU - Satouchi M -AD - Department of Thoracic Oncology, Hyogo Cancer Center, Akashi City, Japan. -FAU - Shimokawa, Mototsugu -AU - Shimokawa M -AD - Department of Biostatistics, Yamaguchi University Graduate School of Medicine - Yamaguchi, Ube City, Japan. -FAU - Yamamoto, Nobuyuki -AU - Yamamoto N -AUID- ORCID: 0000-0002-7342-0853 -AD - Internal Medicine III, Wakayama Medical University, Wakayama, Japan. -FAU - Nakagawa, Kazuhiko -AU - Nakagawa K -AD - Department of Medical Oncology, Kindai University, Osakasayama City, Japan. -CN - members of the West Japan Oncology Group (WJOG) -LA - eng -PT - Journal Article -DEP - 20211214 -PL - New Zealand -TA - Cancer Manag Res -JT - Cancer management and research -JID - 101512700 -PMC - PMC8684372 -OTO - NOTNLM -OT - clinical study -OT - durvalumab -OT - immunotherapy -OT - locally advanced non-small cell lung cancer -OT - programmed cell death ligand-1 -OT - radiation -COIS- Dr. Tachihara reports grants and personal fees from AstraZeneca K.K., personal - fees from Eli Lilly Japan K.K., Taiho Pharmaceutical Co., Ltd., MSD K.K., Nippon - Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Ono - Pharmaceutical Co., Ltd. Dr. Tsujino reports personal fees from AstraZeneca K.K. - Dr. Hayashi reports grants and personal fees from AstraZeneca K.K., Boehringer - Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. - Ltd., personal fees or grants from Astellas Pharma Inc., SymBio Pharmaceuticals - Limited, AbbVie Inc, inVentiv Health Japan, ICON Japan K.K., GRITSONE - ONCOLOGY.INC, PAREXEL International Corp., Kissei Pharmaceutical Co., Ltd., EPS - Corporation., Syneos Health., Pfizer R&D Japan G.K., A2 Healthcare Corp., - Quintiles Inc./IQVIA Services JAPAN K.K., EP-CRSU CO., LTD., Linical Co., Ltd., - Eisai Co., Ltd., CMIC Shift Zero K.K., Kyowa Hakko Kirin Co., Ltd, Bayer Yakuhin, - Ltd, EPS International Co., Ltd., Otsuka Pharmaceutical Co., Ltd, Bristol-Myers - Squibb Co. Ltd., Eli Lilly Japan K.K., Kyorin pharmaceutical co. ltd, Merck - Biopharma Co., Ltd., MSD K.K., Novartis pharmaceuticals K.K, Shanghai Haihe - Biopharm, Taiho Pharmaceutical Co. Ltd, and Takeda Pharmaceutical Co., Ltd., - Pfizer Japan Inc., Shanghai Haihe Biopharm, Merck Biopharma Co., Ltd. Dr. Sato - reports honoraria from Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., - Ltd., MSD K.K., Novartis, Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., - Novartis, and Nippon Kayaku. Dr. Kurata reports grants and personal fees from - AstraZeneca K.K., Bristol-Myers Squibb, MSD K.K., grants from Novartis, Takeda - Pharmaceutical Co., Ltd., and persona fees from Ono Pharmaceutical Co., Ltd., - Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Boehringer Ingelheim Co., - Ltd. Dr. Sugawara reports personal fees from AstraZeneca K.K., Chugai - Pharmaceutical Co., Ltd., Boehringer Ingelheim Co., Ltd., Taiho Pharmaceutical - Co., Ltd., Pfizer, Eli Lilly Japan K.K., Novartis, Bristol-Myers Squibb, Ono - Pharmaceutical Co., Ltd., MSD Oncology, Yakult Honsha, Kyowa Hakko Kirin Co., - Ltd. Dr. Okamoto reports grants from AbbVie, Novartis, Astellas Pharma, grants - and personal fees from AstraZeneca K.K., Taiho Pharmaceutical Co., Ltd., - Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD Oncology, Eli - Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb, and - personal fees from Pfizer. Dr. Teraoka reports personal fees from Chugai - Pharmaceutical Co., Ltd., AstraZeneca K.K., Taiho Pharmaceutical Co., Ltd., - Novartis, Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd. Dr. Azuma - reports personal fees from AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., MSD - K.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd. Dr. Daga reports - personal fees from Chugai Pharmaceutical Co., Ltd., MSD K.K. Dr. Kodaira reports - personal fees from Merck Serono. Co., Hitachi Co., Bristol-Myers Squibb, Elekta - Co., Ono Pharmaceutical Co., Ltd., AstraZeneca K.K., Taiho Pharmaceutical Co., - Ltd., Canon Co., Ltd. Dr. Satouchi reports grants and personal fees from - AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Chugai Pharmaceutical Co. - Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., MSD K.K., Novartis pharmaceuticals - K.K., Bristol-Myers Squibb Co. Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi - Sankyo, EPS International, Janssen Pharmaceutical K.K., personal fees from Ono - Pharmaceutical Co. Ltd., Merck Biopharma Co., Ltd., Taiho Pharmaceutical Co. Ltd, - Eisai, Bayer, Nippon Kayaku, and grants from AbbVie Inc, Amgen. Dr.Yamamoto - reports grants and personal fees from Chugai Pharmaceutical Co., Ltd., - Boehringer-Ingelheim Co., Ltd., personal fees from AstraZeneca K.K., MSD K.K., - Ono Pharmaceutical Co., Ltd., TAIHO Pharmaceutical Co., Ltd., Takeda - Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Novartis, Bristol-Myers Squibb, - Nippon Kayaku, Life Technologies Japan Ltd., Thermo Fisher Scientific, Daiichi - Sankyo, GlaxoSmithKline K.K., Sanofi K.K., Hisamitsu Pharmaceutical Co.Inc., - Merck biopharma, Amgen Inc., Guardant Health Japan, Janssen Pharmaceutical K.K., - and grants from Tosoh Life Science Research Laboratory. Dr. Nakagawa reports - grants and personal fees from AstraZeneca K.K., Astellas Pharma Inc., MSD K.K., - Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Bristol Myers Squibb - Company, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Merck Serono - Co., Ltd./Merck Biopharma Co., Ltd., grants, personal fees and consulting fees - from Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Eli Lilly Japan K.K., - during the conduct of the study; personal fees from Clinical Trial Co., Ltd., - MEDICUS SHUPPAN, Publishers Co., Ltd., Care Net, Inc, Reno. Medical K.K., Medical - Review Co., Ltd., Roche Diagnostics K.K., Bayer Yakuhin, Ltd, Medical Mobile - Communications co., Ltd, 3H Clinical Trial Inc., Nichi-Iko Pharmaceutical Co., - Ltd., Hisamitsu Pharmaceutical Co., NANZANDO Co., Ltd., YODOSHA CO., LTD., Nikkei - Business Publications, Inc, Thermo Fisher Scientific K.K., YOMIURI TELECASTING - CORPORATION., Nippon Kayaku Co., Ltd., personal fees and consulting fees from - KYORIN Pharmaceutical Co., Ltd., grants, personal fees and consulting fees from - Takeda Pharmaceutical Co., Ltd., grants and personal fees from Taiho - Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Limited., AbbVie Inc, grants - from inVentiv Health Japan, ICON Japan K.K., GRITSONE ONCOLOGY.INC, PAREXEL - International Corp., Kissei Pharmaceutical Co., Ltd., EPS Corporation., Syneos - Health., Pfizer R&D Japan G.K., A2 Healthcare Corp., Quintiles Inc./IQVIA - Services JAPAN K.K., EP-CRSU CO., LTD., Linical Co., Ltd., Eisai Co., Ltd., CMIC - Shift Zero K.K., Kyowa Hakko Kirin Co., Ltd, Bayer Yakuhin, Ltd, EPS - International Co., Ltd., Otsuka Pharmaceutical Co., Ltd, PRA Health Sciences, - Covance Japan Inc., Medical Research Support, Sanofi K.K., PPD-SNBL K.K, Japan - Clinical Research Operations, Sysmex Corporation Mochida Pharmaceutical Co., Ltd. - GlaxoSmithKline K.K. Dr. Ishihara, Dr. Yamaguchi, and Dr. Shimokawa report no - conflicts of interest. -EDAT- 2021/12/23 06:00 -MHDA- 2021/12/23 06:01 -PMCR- 2021/12/14 -CRDT- 2021/12/22 06:47 -PHST- 2021/09/14 00:00 [received] -PHST- 2021/11/20 00:00 [accepted] -PHST- 2021/12/22 06:47 [entrez] -PHST- 2021/12/23 06:00 [pubmed] -PHST- 2021/12/23 06:01 [medline] -PHST- 2021/12/14 00:00 [pmc-release] -AID - 336262 [pii] -AID - 10.2147/CMAR.S336262 [doi] -PST - epublish -SO - Cancer Manag Res. 2021 Dec 14;13:9167-9173. doi: 10.2147/CMAR.S336262. - eCollection 2021. - -PMID- 32334337 -OWN - NLM -STAT- MEDLINE -DCOM- 20201109 -LR - 20201109 -IS - 1879-0852 (Electronic) -IS - 0959-8049 (Linking) -VI - 132 -DP - 2020 Jun -TI - Association between immune-related adverse events and long-term survival outcomes - in patients treated with immune checkpoint inhibitors. -PG - 61-70 -LID - S0959-8049(20)30158-1 [pii] -LID - 10.1016/j.ejca.2020.03.017 [doi] -AB - BACKGROUND: The impact of immune-related adverse events (irAE) on survival - outcomes after single-agent immune checkpoint inhibitors (ICIs) remains unclear. - We aimed to evaluate the association between irAEs and ICI efficacy in various - malignancies. METHODS: All patients treated with a single-agent ICI for any - advanced cancer were included in this retrospective multicentric series. The - primary objective was to assess the impact of all type grade ≥II irAEs on - progression-free survival (PFS) and overall survival (OS). IrAEs were first - considered as a fixed covariate and included in Cox-regression models. In - addition, as irAEs are time-related events and can occur at any point during - follow-up, we analysed the occurrence of irAEs as a time-varying covariate. - RESULTS: In this cohort of 410 patients, the majority of patients (70%) were - treated for non-small cell lung cancer. The ICI was an anti-PD(L)1 for 356 - patients (82%) and an anti-CTLA4 for 79 patients (18%). In total 126 (29%) of the - patients presented at least one grade ≥II irAEs. The first occurrence of a grade - ≥II irAE had a positive impact on PFS and OS when considered as a fixed or as a - time-varying covariate (hazard ratio [HR] for PFS = 0.63, 95% confidence interval - [CI] 0.50-0.81; P = 0.00022; HR for OS = 0.57, 95% CI 0.43-0.74, P < 0.0001). - This overall finding was confirmed in patients treated with an anti-PD(L)1 and - among patients with lung cancer. CONCLUSION: In this pooled multi-institutional - cohort, the incidence of irAEs was associated with better long-term survival - across different malignancies treated with ICI monotherapy. -CI - Copyright © 2020 Elsevier Ltd. All rights reserved. -FAU - Maillet, Denis -AU - Maillet D -AD - Hospices Civils de Lyon, Oncology Department, Pierre-Bénite, France; Université - de Lyon, F-69000 Lyon, France; Université Lyon 1, F-69100 Villeurbanne, France; - ImmuCare (Immunology Cancer Research) Institut de Cancérologie des Hospices - Civils de Lyon, Lyon, France. Electronic address: denis.maillet@chu-lyon.fr. -FAU - Corbaux, Pauline -AU - Corbaux P -AD - Hospices Civils de Lyon, Oncology Department, Pierre-Bénite, France; Université - de Lyon, F-69000 Lyon, France; Université Lyon 1, F-69100 Villeurbanne, France; - ImmuCare (Immunology Cancer Research) Institut de Cancérologie des Hospices - Civils de Lyon, Lyon, France. -FAU - Stelmes, Jean-Jacques -AU - Stelmes JJ -AD - Department of Radiation Oncology, University Hospital Zurich, Switzerland. -FAU - Dalle, Stéphane -AU - Dalle S -AD - Université de Lyon, F-69000 Lyon, France; Université Lyon 1, F-69100 - Villeurbanne, France; ImmuCare (Immunology Cancer Research) Institut de - Cancérologie des Hospices Civils de Lyon, Lyon, France; Hospices Civils de Lyon, - Cancer Research Center of Lyon, Dermatology Department, Pierre-Bénite, France. -FAU - Locatelli-Sanchez, Myriam -AU - Locatelli-Sanchez M -AD - Université de Lyon, F-69000 Lyon, France; Université Lyon 1, F-69100 - Villeurbanne, France; ImmuCare (Immunology Cancer Research) Institut de - Cancérologie des Hospices Civils de Lyon, Lyon, France; Hospices Civils de Lyon, - Cancer Research Center of Lyon, Department of Respiratory Medicine, - Pierre-Bénite, France. -FAU - Perier-Muzet, Marie -AU - Perier-Muzet M -AD - Université de Lyon, F-69000 Lyon, France; Université Lyon 1, F-69100 - Villeurbanne, France; ImmuCare (Immunology Cancer Research) Institut de - Cancérologie des Hospices Civils de Lyon, Lyon, France; Hospices Civils de Lyon, - Cancer Research Center of Lyon, Dermatology Department, Pierre-Bénite, France. -FAU - Duruisseaux, Michaël -AU - Duruisseaux M -AD - Université de Lyon, F-69000 Lyon, France; Université Lyon 1, F-69100 - Villeurbanne, France; ImmuCare (Immunology Cancer Research) Institut de - Cancérologie des Hospices Civils de Lyon, Lyon, France; Hospices Civils de Lyon, - Department of Respiratory Medicine, Groupement Hospitalier Est, Hôpital - Louis-Pradel, Lyon, France. -FAU - Kiakouama-Maleka, Lize -AU - Kiakouama-Maleka L -AD - Université de Lyon, F-69000 Lyon, France; Université Lyon 1, F-69100 - Villeurbanne, France; ImmuCare (Immunology Cancer Research) Institut de - Cancérologie des Hospices Civils de Lyon, Lyon, France; Hospices Civils de Lyon, - Department of Respiratory Medicine, Croix-rousse Hospital, Lyon, France. -FAU - Freyer, Gilles -AU - Freyer G -AD - Hospices Civils de Lyon, Oncology Department, Pierre-Bénite, France; Université - de Lyon, F-69000 Lyon, France; Université Lyon 1, F-69100 Villeurbanne, France. -FAU - Boespflug, Amélie -AU - Boespflug A -AD - Université de Lyon, F-69000 Lyon, France; Université Lyon 1, F-69100 - Villeurbanne, France; ImmuCare (Immunology Cancer Research) Institut de - Cancérologie des Hospices Civils de Lyon, Lyon, France; Hospices Civils de Lyon, - Cancer Research Center of Lyon, Dermatology Department, Pierre-Bénite, France. -FAU - Péron, Julien -AU - Péron J -AD - Hospices Civils de Lyon, Oncology Department, Pierre-Bénite, France; Université - de Lyon, F-69000 Lyon, France; Université Lyon 1, F-69100 Villeurbanne, France; - ImmuCare (Immunology Cancer Research) Institut de Cancérologie des Hospices - Civils de Lyon, Lyon, France; CNRS, UMR 5558, Laboratoire de Biométrie et - Biologie Evolutive, Equipe Biostatistique-Santé, F-69100 Villeurbanne, France. -LA - eng -PT - Journal Article -DEP - 20200422 -PL - England -TA - Eur J Cancer -JT - European journal of cancer (Oxford, England : 1990) -JID - 9005373 -RN - 0 (Antineoplastic Agents, Immunological) -RN - 0 (B7-H1 Antigen) -RN - 0 (CD274 protein, human) -RN - 0 (CTLA-4 Antigen) -RN - 0 (CTLA4 protein, human) -SB - IM -MH - Aged -MH - Antineoplastic Agents, Immunological/*adverse effects -MH - B7-H1 Antigen/*antagonists & inhibitors -MH - CTLA-4 Antigen/*antagonists & inhibitors -MH - Drug-Related Side Effects and Adverse Reactions/etiology/*mortality/pathology -MH - Female -MH - Follow-Up Studies -MH - Humans -MH - Male -MH - Middle Aged -MH - Neoplasms/drug therapy/*mortality/pathology -MH - Prognosis -MH - Retrospective Studies -MH - Survival Rate -OTO - NOTNLM -OT - CTLA4 inhibitors -OT - Immune checkpoint inhibitors -OT - Immune-related adverse events -OT - PD1 inhibitors -OT - PDL1 inhibitors -OT - Prognostic biomarkers -OT - Solid tumours -OT - Survival analysis -COIS- Conflict of interest statement The authors have declared no conflicts of - interest. -EDAT- 2020/04/26 06:00 -MHDA- 2020/11/11 06:00 -CRDT- 2020/04/26 06:00 -PHST- 2019/11/14 00:00 [received] -PHST- 2020/02/25 00:00 [revised] -PHST- 2020/03/04 00:00 [accepted] -PHST- 2020/04/26 06:00 [pubmed] -PHST- 2020/11/11 06:00 [medline] -PHST- 2020/04/26 06:00 [entrez] -AID - S0959-8049(20)30158-1 [pii] -AID - 10.1016/j.ejca.2020.03.017 [doi] -PST - ppublish -SO - Eur J Cancer. 2020 Jun;132:61-70. doi: 10.1016/j.ejca.2020.03.017. Epub 2020 Apr - 22. - -PMID- 35923924 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220805 -IS - 1758-8340 (Print) -IS - 1758-8359 (Electronic) -IS - 1758-8340 (Linking) -VI - 14 -DP - 2022 -TI - Prospective analysis of factors precluding the initiation of durvalumab from an - interim analysis of a phase II trial of S-1 and cisplatin with concurrent - thoracic radiotherapy followed by durvalumab for unresectable, locally advanced - non-small cell lung cancer in Japan (SAMURAI study). -PG - 17588359221116603 -LID - 10.1177/17588359221116603 [doi] -LID - 17588359221116603 -AB - BACKGROUND: The standard of care for unresectable, locally advanced non-small - cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, - based on the PACIFIC trial. Disease progression and pneumonitis were reported as - the main reasons to preclude the initiation of durvalumab in multiple - retrospective studies. However, the transition rate and the reasons for failure - to proceed to consolidation therapy with durvalumab after CRT were not evaluated - prospectively. Although phase II studies in Japan have shown high efficacy and - tolerability of CRT with cisplatin + S-1 (SP), no prospective study using - durvalumab after SP-based CRT has yet been reported. We therefore conducted a - phase II study to verify the efficacy and safety of durvalumab following SP-based - CRT. In this interim analysis, we report the transition rate and the reasons for - its failure. METHODS: In treatment-naïve LA-NSCLC, cisplatin (60 mg/m(2), day 1) - and S-1 (80-120 mg/body, days 1-14) were administered with two 4-week cycles with - concurrent thoracic radiotherapy (60 Gy) followed by durvalumab every 2 weeks for - up to 12 months. The primary endpoint was 12 month progression-free survival - rate. RESULTS: Fifty-nine patients were enrolled, of whom 86.4% (51/59) proceeded - to durvalumab. All of them initiated durvalumab within 42 days after CRT [median - 18 days (range: 3-38)], including 27.5% (14/51) in <14 days. Common reasons for - failure to proceed to durvalumab were disease progression (2/59, 3.4%) and - adverse events (6/59, 10.2%). Among the latter cases, four resumed treatment and - proceeded to durvalumab within 42 days on off-protocol. The objective response - rate and the disease control rate were 62.7% and 93.2%, respectively. The - incidences of ⩾grade 3 pneumonitis, febrile neutropenia, and esophagitis were 0%, - 8.5%, and 3.4%, respectively. CONCLUSION: Regarding durvalumab after CRT, this - interim analysis of the SAMURAI study clarified the high transition rate, early - introduction, and reasons for failure to proceed to consolidation therapy, which - were not determined in the PACIFIC trial. TRIAL REGISTRATION: Japan Registry of - Clinical Trials, jRCTs031190127, registered 1 November, 2019, - https://jrct.niph.go.jp/latest-detail/jRCTs031190127. -CI - © The Author(s), 2022. -FAU - Tanzawa, Shigeru -AU - Tanzawa S -AUID- ORCID: 0000-0001-5738-0313 -AD - Division of Medical Oncology, Department of Internal Medicine, Teikyo University - School of Medicine, Itabashi-ku, Tokyo, Japan. -FAU - Makiguchi, Tomonori -AU - Makiguchi T -AD - Department of Respiratory Medicine, Hirosaki University Graduate School of - Medicine, Hirosaki, Aomori, Japan. -FAU - Tasaka, Sadatomo -AU - Tasaka S -AD - Department of Respiratory Medicine, Hirosaki University Graduate School of - Medicine, Hirosaki, Aomori, Japan. -FAU - Inaba, Megumi -AU - Inaba M -AD - Department of Respiratory Medicine, Kumamoto Chuo Hospital, Kumamoto, Kumamoto, - Japan. -FAU - Ochiai, Ryosuke -AU - Ochiai R -AD - Division of Medical Oncology, Department of Internal Medicine, Teikyo University - School of Medicine, Itabashi-ku, Tokyo, Japan. -FAU - Nakamura, Junya -AU - Nakamura J -AD - Department of Respiratory Medicine, Ehime Prefectural Central Hospital, - Matsuyama, Ehime, Japan. -FAU - Inoue, Koji -AU - Inoue K -AD - Department of Respiratory Medicine, Ehime Prefectural Central Hospital, - Matsuyama, Ehime, Japan. -FAU - Kishikawa, Takayuki -AU - Kishikawa T -AD - Department of Respiratory Medicine, Tochigi Cancer Center, Utsunomiya, Tochigi, - Japan. -FAU - Nakashima, Masanao -AU - Nakashima M -AD - Department of Respiratory Medicine, Shin-Yurigaoka General Hospital, Kawasaki, - Kanagawa, Japan. -FAU - Fujiwara, Keiichi -AU - Fujiwara K -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Okayama, Okayama, Japan. -FAU - Kohyama, Tadashi -AU - Kohyama T -AD - Department of Internal medicine, Teikyo University Mizonokuchi Hospital, - Kawasaki, Kanagawa, Japan. -FAU - Ishida, Hiroo -AU - Ishida H -AD - Department of Internal Medicine, Showa University Northern Yokohama Hospital, - Yokohama, Kanagawa, Japan. -FAU - Kuyama, Shoichi -AU - Kuyama S -AD - Department of Respiratory Medicine, National Hospital Organization Iwakuni - Clinical Center, Iwakuni, Yamaguchi, Japan. -FAU - Miyazawa, Naoki -AU - Miyazawa N -AD - Department of Respiratory Medicine, Saiseikai Yokohamashi Nanbu Hospital, - Yokohama, Kanagawa, Japan. -FAU - Nakamura, Tomomi -AU - Nakamura T -AD - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal - Medicine, Faculty of Medicine, Saga University, Saga, Saga, Japan. -FAU - Miyawaki, Hiroshi -AU - Miyawaki H -AD - Department of Respiratory Medicine, Kagawa Prefectural Central Hospital, - Takamatsu, Kagawa, Japan. -FAU - Oda, Naohiro -AU - Oda N -AD - Department of Internal medicine, Fukuyama City Hospital, Fukuyama, Hiroshima, - Japan. -FAU - Ishikawa, Nobuhisa -AU - Ishikawa N -AD - Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, - Hiroshima, Japan. -FAU - Morinaga, Ryotaro -AU - Morinaga R -AD - Department of Thoracic Medical Oncology, Oita Prefectural Hospital, Oita, Oita, - Japan. -FAU - Kusaka, Kei -AU - Kusaka K -AD - The Center for Pulmonary Diseases, National Hospital Organization Tokyo National - Hospital, Kiyose, Tokyo, Japan. -FAU - Miyamoto, Yosuke -AU - Miyamoto Y -AD - Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Okayama, Japan. -FAU - Yokoyama, Toshihide -AU - Yokoyama T -AD - Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, - Okayama, Japan. -FAU - Matsumoto, Chiaki -AU - Matsumoto C -AD - Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, - Hiroshima, Japan. -FAU - Tsuda, Takeshi -AU - Tsuda T -AD - Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, - Toyama, Japan. -FAU - Ushijima, Sunao -AU - Ushijima S -AD - Department of Medical Oncology, Kumamoto Kenhoku Hospital, Tamana, Kumamoto, - Japan. -FAU - Shibata, Kazuhiko -AU - Shibata K -AD - Department of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka, Toyama, - Japan. -FAU - Shibayama, Takuo -AU - Shibayama T -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Okayama, Okayama, Japan. -FAU - Bessho, Akihiro -AU - Bessho A -AD - Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, - Okayama, Japan. -FAU - Kaira, Kyoichi -AU - Kaira K -AD - Department of Respiratory Medicine, Saitama Medical University International - Medical Center, Hidaka, Saitama, Japan. -FAU - Misumi, Toshihiro -AU - Misumi T -AD - Department of Biostatistics, Yokohama City University School of Medicine, - Yokohama, Kanagawa, Japan. -FAU - Shiraishi, Kenshiro -AU - Shiraishi K -AUID- ORCID: 0000-0002-2295-517X -AD - Department of Radiology, Teikyo University School of Medicine, Itabashi-ku, - Tokyo, Japan. -FAU - Matsutani, Noriyuki -AU - Matsutani N -AD - Department of Surgery, Teikyo University Mizonokuchi Hospital, Kawasaki, - Kanagawa, Japan. -FAU - Seki, Nobuhiko -AU - Seki N -AD - Division of Medical Oncology, Department of Internal Medicine, Teikyo University - School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo 173-8605, Japan. -LA - eng -PT - Journal Article -DEP - 20220729 -PL - England -TA - Ther Adv Med Oncol -JT - Therapeutic advances in medical oncology -JID - 101510808 -PMC - PMC9340896 -OTO - NOTNLM -OT - S-1 -OT - chemoradiotherapy -OT - cisplatin -OT - durvalumab -OT - non-small cell lung cancer -COIS- Competing Interests: ST received research funding from AstraZeneca and personal - fees as honoraria from AstraZeneca, Chugai Pharmaceutical, Taiho Pharmaceutical, - and Eli Lilly. SK received personal fees as honoraria from Chugai Pharmaceutical, - Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, Pfizer, Eli Lilly, MSD, - Taiho Pharmaceutical, Sanofi, Kyowa Kirin, Hisamitsu Pharmaceutical, DAIICHI - SANKYO, Nippon Kayaku, and Novartis. NI received personal fees as honoraria from - AstraZeneca. KK received personal fees as honoraria from AstraZeneca, Chugai - Pharmaceutical, Ono Pharmaceutical, and Nippon Kayaku. TY received research - funding from Bristol-Myers Squibb, MSD, Chugai Pharmaceutical, Takeda - Pharmaceutical, and Delta-Fly Pharma and personal fees as honoraria from - Bristol-Myers Squibb, Ono Pharmaceutical, Nippon Kayaku, Chugai Pharmaceutical, - Eli Lilly, AstraZeneca, Novartis, and Takeda Pharmaceutical. TT received personal - fees as honoraria from Chugai Pharmaceutical. KS received personal fees as - honoraria from AstraZeneca, Taiho Pharmaceutical, Chugai Pharmaceutical, - Bristol-Myers Squibb, and Ono Pharmaceutical. AB received research funding from - AstraZeneca and personal fees as honoraria from AstraZeneca and Taiho - Pharmaceutical. KK received research funding from AstraZeneca, and Nihon - Medi-Physics and personal fees as honoraria from Ono Pharmaceutical, Boehringer - Ingelheim, Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly, AstraZeneca, - and Pfizer. TM received personal fees as honoraria from Chugai Pharmaceutical and - AstraZeneca. NS received research funding from Ono Pharmaceutical, Boehringer - Ingelheim, Taiho Pharmaceutical, Chugai Pharmaceutical, Eisai, DAIICHI SANKYO, - Takeda Pharmaceutical, SHIONOGI, Nippon Kayaku, and Pfizer and personal fees as - honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, Chugai Pharmaceutical, - Eli Lilly, AstraZeneca, Boehringer Ingelheim, MSD, DAIICHI SANKYO, Novartis, - Bristol-Myers Squibb, Pfizer, Takeda Pharmaceutical, and Nippon Kayaku. No - potential conflicts of interest were disclosed by other authors. -EDAT- 2022/08/05 06:00 -MHDA- 2022/08/05 06:01 -PMCR- 2022/07/29 -CRDT- 2022/08/04 02:28 -PHST- 2022/04/07 00:00 [received] -PHST- 2022/07/12 00:00 [accepted] -PHST- 2022/08/04 02:28 [entrez] -PHST- 2022/08/05 06:00 [pubmed] -PHST- 2022/08/05 06:01 [medline] -PHST- 2022/07/29 00:00 [pmc-release] -AID - 10.1177_17588359221116603 [pii] -AID - 10.1177/17588359221116603 [doi] -PST - epublish -SO - Ther Adv Med Oncol. 2022 Jul 29;14:17588359221116603. doi: - 10.1177/17588359221116603. eCollection 2022. - -PMID- 33209620 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220418 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 9 -IP - 5 -DP - 2020 Oct -TI - GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in - patients with locally advanced/unresectable (stage III) non-small cell lung - cancer (NSCLC) who did not have disease progression after prior - concurrent/sequential chemoradiotherapy. -PG - 2008-2015 -LID - 10.21037/tlcr-20-608 [doi] -AB - BACKGROUND: In China, platinum-based doublet chemotherapy is the standard - treatment for patients who have unresectable stage III non-small cell lung cancer - (NSCLC), administered with radiotherapy on either a concurrent or sequential - basis. However, NSCLC patients who undergo this treatment can expect poor median - progression-free survival (PFS) of around 8-10 months and a dismal 5-year overall - survival (OS) rate of about 15%. In the recent PACIFIC trial, durvalumab was - demonstrated to hold significant clinical benefit for patients with locally - advanced/unresectable NSCLC who experienced no disease progression after - definitive concurrent chemoradiotherapy (cCRT). CS1001 is the first full-length, - fully human immunoglobin G4 (IgG4) monoclonal antibody (mAb) that targets - programmed death ligand-1 (PD-L1) created through the OMT transgenic rat - platform. The phase Ia/Ib study indicated CS1001 was well tolerated and exhibited - anti-tumor potential with a range of tumors. GEMSTONE-301 is a phase III - randomized, double-blind, study to explore the efficacy and safety of CS1001 - compared with a placebo as consolidation therapy for stage III unresectable NSCLC - patients. METHODS: In this trial, eligible patients will be randomized to receive - CS1001 1,200 mg or placebo, every 3 weeks (Q3W). The primary endpoint will be - investigator-assessed PFS, based on the Response Evaluation Criteria in Solid - Tumors (RECIST) v1.1. The secondary endpoints will include OS, PFS assessment - based on Blinded Independent Center Review (BICR), objective response rate (ORR), - other efficacy measurements, safety, and tolerability. DISCUSSION: This phase III - trial will determine the efficacy and safety of CS1001 as consolidation therapy - in patients with locally advanced/unresectable (stage III) NSCLC who did not have - disease progression after prior concurrent/sequential chemoradiotherapy (cCRT or - sCRT), and is the first phase III trial on an anti-PD-L1 mAb initiated in China - for this indication. PROTOCOL VERSION: Version 3.0/September 12, 2019. -CI - 2020 Translational Lung Cancer Research. All rights reserved. -FAU - Zhou, Qing -AU - Zhou Q -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and - Guangdong Academy of Medical Sciences, School of Medicine, South China University - of Technology, Guangzhou, China. -FAU - Chen, Ming -AU - Chen M -AD - Zhejiang Cancer Hospital, Hangzhou, China. -FAU - Wu, Gang -AU - Wu G -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, China. -FAU - Chang, Jian-Hua -AU - Chang JH -AD - Fudan University Shanghai Cancer Center, Shanghai, China. -FAU - Jiang, Ou -AU - Jiang O -AD - The Second People's Hospital of Neijiang, Sichuan Medical University, Neijiang, - China. -FAU - Cui, Jiu-Wei -AU - Cui JW -AD - The First Hospital of Jilin University, Jilin, China. -FAU - Han, Guang -AU - Han G -AD - Hubei Cancer Hospital, Wuhan, China. -FAU - Lin, Qin -AU - Lin Q -AD - Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, - China. -FAU - Fang, Jian -AU - Fang J -AD - Beijing Cancer Hospital, Beijing, China. -FAU - Chen, Gong-Yan -AU - Chen GY -AD - The Third Affiliated Hospital of Harbin Medical University, Harbin, China. -FAU - Wu, Yi-Long -AU - Wu YL -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and - Guangdong Academy of Medical Sciences, School of Medicine, South China University - of Technology, Guangzhou, China. -LA - eng -PT - Journal Article -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -PMC - PMC7653154 -OTO - NOTNLM -OT - Programmed death ligand-1 (PD-L1) -OT - clinical trial -OT - consolidation therapy -OT - non-small cell lung cancer (NSCLC) -OT - phase III -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at http://dx.doi.org/10.21037/tlcr-20-608). QZ reports honorary - from AstraZeneca and Roche, outside the submitted work; Dr. YLW reports personal - fees from AstraZeneca, grants and personal fees from BMS, personal fees from - Boehringer Ingelheim, personal fees from Eli Lilly, personal fees from MSD, - grants and personal fees from Pfizer, grants and personal fees from Roche, - outside the submitted work. The other authors have no conflicts of interest to - declare. -EDAT- 2020/11/20 06:00 -MHDA- 2020/11/20 06:01 -PMCR- 2020/10/01 -CRDT- 2020/11/19 05:46 -PHST- 2020/11/19 05:46 [entrez] -PHST- 2020/11/20 06:00 [pubmed] -PHST- 2020/11/20 06:01 [medline] -PHST- 2020/10/01 00:00 [pmc-release] -AID - tlcr-09-05-2008 [pii] -AID - 10.21037/tlcr-20-608 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015. doi: 10.21037/tlcr-20-608. - -PMID- 38192990 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240110 -IS - 2219-6803 (Electronic) -IS - 2218-676X (Print) -IS - 2218-676X (Linking) -VI - 12 -IP - 12 -DP - 2023 Dec 31 -TI - Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a - narrative review. -PG - 3764-3778 -LID - 10.21037/tcr-23-956 [doi] -AB - BACKGROUND AND OBJECTIVE: Mutations located in epidermal growth factor receptor - (EGFR) tyrosine kinase domains have been described as the 'Achilles heel' of - non-small cell lung cancer (NSCLC) and can be targeted by epidermal growth factor - receptor-tyrosine kinase inhibitors (EGFR-TKIs). However, the clinical benefits - of EGFR-TKIs are limited, and drug resistance inevitably occurs in NSCLC patients - after long-term exposure to certain drugs. EGFR-TKI combination therapies, - including combined targeted therapy, radiotherapy, chemotherapy, and - immunotherapy, have shown promise in addressing this issue. This literature - review analyzed the rationale and controversies of clinical research related to - various EGFR-TKI combination therapies. METHODS: The PubMed database was searched - to retrieve articles published from January 1, 2001 to April 15, 2023 using the - following Medical Subject Headings (MeSH) terms: "EGFR-mutated non-small cell - lung cancer" and "clinical trial". Google Scholar was also reviewed to retrieve - additional articles. The search was limited to articles published in English. KEY - CONTENT AND FINDINGS: In this review, we summarized EGFR-TKI combination - therapies, including combined targeted therapy, radiotherapy, chemotherapy, and - immunotherapy, most of which have shown efficacy and safety in patients with - EGFR-mutated NSCLC. A number of clinical studies with large sample sizes have - analyzed the activity and toxicity of combined therapies and explored potential - and well-tolerated treatment options. CONCLUSIONS: EGFR mutations have been - detected in many NSCLC patients and can be targeted by EGFR-TKIs. However, drug - resistance after long-term exposure remains a significant challenge for this type - of treatment. Most clinical trials have shown that the combination of EGFR-TKIs - and targeted therapy, chemotherapy, radiotherapy or immunotherapy is efficacious - and safe in the treatment of EGFR-mutated NSCLC. It should be noted that in some - instances, serious adverse events have led to the termination of trials. However, - EGFR-TKI combination therapy is indeed an effective approach for the treatment of - patients with EGFR-mutated NSCLC and deserves further development. -CI - 2023 Translational Cancer Research. All rights reserved. -FAU - Zhang, Qianru -AU - Zhang Q -AD - Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University - School of Medicine, Shanghai, China. -FAU - Wang, Ruo -AU - Wang R -AD - Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University - School of Medicine, Shanghai, China. -FAU - Xu, Lu -AU - Xu L -AD - Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University - School of Medicine, Shanghai, China. -LA - eng -PT - Journal Article -PT - Review -DEP - 20231124 -PL - China -TA - Transl Cancer Res -JT - Translational cancer research -JID - 101585958 -PMC - PMC10774042 -OTO - NOTNLM -OT - Combination therapy -OT - epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) -OT - non-small cell lung cancer (NSCLC) -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://tcr.amegroups.com/article/view/10.21037/tcr-23-956/coif). The authors - have no conflicts of interest to declare. -EDAT- 2024/01/09 06:41 -MHDA- 2024/01/09 06:42 -PMCR- 2023/12/31 -CRDT- 2024/01/09 03:58 -PHST- 2023/06/02 00:00 [received] -PHST- 2023/09/13 00:00 [accepted] -PHST- 2024/01/09 06:42 [medline] -PHST- 2024/01/09 06:41 [pubmed] -PHST- 2024/01/09 03:58 [entrez] -PHST- 2023/12/31 00:00 [pmc-release] -AID - tcr-12-12-3764 [pii] -AID - 10.21037/tcr-23-956 [doi] -PST - ppublish -SO - Transl Cancer Res. 2023 Dec 31;12(12):3764-3778. doi: 10.21037/tcr-23-956. Epub - 2023 Nov 24. - -PMID- 35785183 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220716 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 12 -DP - 2022 -TI - Treatment Patterns for Patients With Unresected Stage III NSCLC: Analysis of the - Surveillance, Epidemiology, and End Results (SEER) Database. -PG - 874022 -LID - 10.3389/fonc.2022.874022 [doi] -LID - 874022 -AB - BACKGROUND: Recently, immunotherapy (IO) has shown striking survival improvement - in unresectable stage III non-small cell lung cancer (NSCLC). However, the role - of chemo-radiotherapy (CRT) for improvement in outcomes should not be - disregarded. This study aimed to compare the treatment patterns and illustrate - the impact of radiotherapy on the cancer-specific survival (CSS) and overall - survival (OS) of patients with unresected locally advanced stage III NSCLC. - METHODS: We retrospectively analyzed the data of patients with stage III NSCLC - patients who did not undergo surgery from the National Cancer Institute - Surveillance, Epidemiology, and End Results (SEER) database between 2001 and - 2016, and three continuous years were regarded as one unit. Using the - Kaplan-Meier method, we identified the CSS and OS. Then, a linear regression - model was graphed to analyze the correlation between median survival of CSS or OS - and calendar years in the radiotherapy alone, chemotherapy alone, and CRT groups. - RESULTS: A total of 20986 patients were included in this study. In the overall - cohort, CSS and OS improved consistently. To explore the reason for the improved - survival, patients were divided into three different cohorts: radiotherapy alone, - chemotherapy alone, and CRT. From 2001 to 2015, the median CSS improved - persistently, 7, 8, 8, 9, and 11 months in the radiotherapy alone group and 12, - 13, 15, 17, 19 months in the CRT group, but improvement in outcomes was less - consistent in the chemotherapy alone group (10, 9, 11, 12, 12 months). To better - visualize the correlation between CSS and calendar year, linear regression was - performed, yielding r(2) = 0.8032, P = 0.0395 for the radiotherapy alone group; - r(2) = 0.7206, P = 0.0689 for the chemotherapy alone group; and r(2) = 0.9878, P - = 0.0006 for the CRT group. Similar findings were observed in the OS data. In - addition to this, we also analyzed different pathological types and also obtained - the same results. CONCLUSIONS: The survival of patients with unresectable stage - III NSCLC has improved substantially, and the most pronounced and consistent - improvements were observed in the CRT group. In addition to IO, radiotherapy - played an essential role in the treatment of unresectable stage III NSCLC in the - past years and should be considered in the design of clinical trials. -CI - Copyright © 2022 Shang, Wang, Wang, Wu, Chen and Yu. -FAU - Shang, Shijie -AU - Shang S -AD - Department of Radiation Oncology, Shandong University Cancer Center, Jinan, - China. -FAU - Wang, Ruiyang -AU - Wang R -AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of - Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, China. -FAU - Wang, Fei -AU - Wang F -AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of - Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, China. -FAU - Wu, Meng -AU - Wu M -AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of - Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, China. -FAU - Chen, Dawei -AU - Chen D -AD - Department of Radiation Oncology, Shandong University Cancer Center, Jinan, - China. -AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of - Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, China. -FAU - Yu, Jinming -AU - Yu J -AD - Department of Radiation Oncology, Shandong University Cancer Center, Jinan, - China. -AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of - Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First - Medical University and Shandong Academy of Medical Sciences, Jinan, China. -AD - Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, - China. -LA - eng -PT - Journal Article -DEP - 20220617 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC9248867 -OTO - NOTNLM -OT - SEER database -OT - non-small cell lung cancer (NSCLC) -OT - radiotherapy -OT - stage III -OT - unresected -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/07/06 06:00 -MHDA- 2022/07/06 06:01 -PMCR- 2022/01/01 -CRDT- 2022/07/05 10:36 -PHST- 2022/02/11 00:00 [received] -PHST- 2022/05/11 00:00 [accepted] -PHST- 2022/07/05 10:36 [entrez] -PHST- 2022/07/06 06:00 [pubmed] -PHST- 2022/07/06 06:01 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2022.874022 [doi] -PST - epublish -SO - Front Oncol. 2022 Jun 17;12:874022. doi: 10.3389/fonc.2022.874022. eCollection - 2022. - -PMID- 35832459 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220716 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 11 -IP - 6 -DP - 2022 Jun -TI - A cohort study of the efficacy and safety of immune checkpoint inhibitors plus - anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced - non-small cell lung cancer in the real world. -PG - 1051-1068 -LID - 10.21037/tlcr-22-350 [doi] -AB - BACKGROUND: Anlotinib is a new multi-target tyrosine kinase inhibitor (TKI) and - has been shown to have antitumor effects and synergistic antitumor effects with - immunotherapy only in animal studies and in the 2nd-line treatment in small - clinical trials. A real-world study with large sample to compare the efficacy and - safety of anlotinib plus immune checkpoint inhibitors (ICIs) with ICIs alone in - the multiline treatment of advanced non-small cell lung cancer (NSCLC) was - urgently needed. METHODS: The data of 535 advanced NSCLC patients were collected - from January 1, 2018, to December 31, 2021. The patients were divided into 2 - groups: (I) ICI monotherapy (230 patients); (II) ICI + anlotinib (305 patients). - After propensity-score matching (PSM) to reduce the effects of biases and - confounding variables, the progression-free survival time (PFS), occurrence of - adverse events, disease control rate (DCR), and objective response rate (ORR) of - the 2 groups were compared. The effects of clinical factors, including age, - gender, gene mutations, tumor proportion score, metastases, and combined - radiotherapy, were also analyzed. RESULTS: After PSM, the baseline clinical - characteristics were well balanced and the 2 group had a good comparability. - Patients in the ICI + anlotinib group had significantly longer median PFS in both - the 2nd-line treatment (7.73 vs. 4.70 months; P=0.003) and 3rd-line treatment - (5.90 vs. 3.37 months; P=0.020), but the difference lacked statistical - significance in the 1st-line treatment (8.40 vs. 5.20 months; P=0.229). The - overall median PFS of patients in the ICI + anlotinib group was also much longer - than that of patients in the ICI monotherapy group (6.37 vs. 3.90 months; - P<0.001). The ICI + anlotinib group also tended to have a higher DCR, a higher - ORR, and a higher probability of severe adverse drug reactions during the - treatment than the ICI monotherapy group, but the differences were not - statistically significant. Combining ICI + anlotinib could improve the outcomes - of patients with bone metastasis. CONCLUSIONS: Anlotinib + ICI therapy could have - greater efficacy in the treatment of advanced NSCLC patients than ICI - monotherapy. The probability of adverse events might increase in the combined - treatment, but could be controlled. -CI - 2022 Translational Lung Cancer Research. All rights reserved. -FAU - Shi, Yue -AU - Shi Y -AD - Department of Oncology, the Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Ji, Min -AU - Ji M -AD - Department of Oncology, the Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Jiang, Yingying -AU - Jiang Y -AD - Department of Radiotherapy, the Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Yin, Rong -AU - Yin R -AD - Department of Thoracic Surgery, the Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Wang, Zihan -AU - Wang Z -AD - School of Life Science, Nantong University, Nantong, China. -FAU - Li, Hang -AU - Li H -AD - Department of Chronic Disease Epidemiology, Yale School of Public Health, New - Haven, CT, USA. -FAU - Wang, Shuaiyu -AU - Wang S -AD - UCL School of Pharmacy, University College London, London, UK. -FAU - He, Kang -AU - He K -AD - Department of Oncology, the Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Ma, Yuxin -AU - Ma Y -AD - Department of Oncology, the Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Wang, Zhitong -AU - Wang Z -AD - Department of Radiotherapy, Nanjing Medical University, Nanjing, China. -FAU - Lu, Jianwei -AU - Lu J -AD - Department of Oncology, the Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Shi, Meiqi -AU - Shi M -AD - Department of Oncology, the Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Shen, Bo -AU - Shen B -AD - Department of Oncology, the Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Zhou, Guoren -AU - Zhou G -AD - Department of Oncology, the Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Leong, Tracy L -AU - Leong TL -AD - Department of Respiratory Medicine, Austin Hospital, Heidelberg, Victoria, - Australia. -FAU - Wang, Xiaohua -AU - Wang X -AD - Department of Oncology, the Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Chen, Cheng -AU - Chen C -AD - Department of Radiotherapy, the Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Nanjing, China. -FAU - Feng, Jifeng -AU - Feng J -AD - Department of Oncology, the Affiliated Cancer Hospital of Nanjing Medical - University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, - Nanjing, China. -LA - eng -PT - Journal Article -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -PMC - PMC9271442 -OTO - NOTNLM -OT - Non-small cell lung cancer (NSCLC) -OT - anlotinib -OT - combined therapy -OT - immunotherapy -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-350/coif). The authors - have no conflicts of interest to declare. -EDAT- 2022/07/15 06:00 -MHDA- 2022/07/15 06:01 -PMCR- 2022/06/01 -CRDT- 2022/07/14 02:23 -PHST- 2022/02/22 00:00 [received] -PHST- 2022/06/09 00:00 [accepted] -PHST- 2022/07/14 02:23 [entrez] -PHST- 2022/07/15 06:00 [pubmed] -PHST- 2022/07/15 06:01 [medline] -PHST- 2022/06/01 00:00 [pmc-release] -AID - tlcr-11-06-1051 [pii] -AID - 10.21037/tlcr-22-350 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2022 Jun;11(6):1051-1068. doi: 10.21037/tlcr-22-350. - -PMID- 36818454 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230224 -IS - 1179-5549 (Print) -IS - 1179-5549 (Electronic) -IS - 1179-5549 (Linking) -VI - 17 -DP - 2023 -TI - Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer. -PG - 11795549231152948 -LID - 10.1177/11795549231152948 [doi] -LID - 11795549231152948 -AB - Lung cancer remains the leading cause of cancer-related death with an incidence - that continues to increase in both sexes and all ages. However, 80% to 90% of - lung cancers are non-small cell lung cancer (NSCLC) and the remaining 10% to 20% - are small cell lung cancer. Adenocarcinoma is the most common histologic subtype - of lung cancer worldwide. More frequently, lung cancer diagnosis is made in - advanced stages. Stage III NSCLC refers to locoregionally advanced disease - without metastases and represents about 30% NSCLC cases. Despite the absence of - metastases at diagnosis, the outcome is generally poor. Stage III comprises a - heterogeneous group and optimal management requires the input of a - multidisciplinary team. All modalities of oncologic treatment are involved: - surgery, chemotherapy, radiotherapy, and more recently, immunotherapy and - targeted therapy. We will discuss the different therapeutic options in stage III - NSCLC, both in operable and inoperable scenarios, and the role of immunotherapy - and targeted therapy. -CI - © The Author(s) 2023. -FAU - Baudoux, Nathalie -AU - Baudoux N -AD - Oncology Department, Geneva University Hospitals, Geneva, Switzerland. -FAU - Friedlaender, Alex -AU - Friedlaender A -AD - Oncology Department, Geneva University Hospitals, Geneva, Switzerland. -AD - Oncology Service, Clinique Générale Beaulieu, Geneva, Switzerland. -FAU - Addeo, Alfredo -AU - Addeo A -AUID- ORCID: 0000-0003-0988-0828 -AD - Oncology Department, Geneva University Hospitals, Geneva, Switzerland. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230214 -PL - United States -TA - Clin Med Insights Oncol -JT - Clinical Medicine Insights. Oncology -JID - 101525771 -PMC - PMC9932776 -OTO - NOTNLM -OT - heterogeneity -OT - multidisciplinary team -OT - non-small cell lung cancer -COIS- The author(s) declared the following potential conflicts of interest with respect - to the research, authorship, and/or publication of this article: NB reports no - conflict of interest. AF received, outside of the present work, personal fees - from Bristol Myers Squibb, Roche Holdings AG, Pfizer, Astellas, and Merck Sharp & - Dohme. AA reports Consulting or advisory role from BMS, AstraZeneca, Boehringer - Ingelheim, Roche, MSD, Pfizer, Eli Lilly, and Astellas, and Speaker bureau from - Eli Lilly and AstraZeneca. -EDAT- 2023/02/24 06:00 -MHDA- 2023/02/24 06:01 -PMCR- 2023/02/14 -CRDT- 2023/02/23 09:50 -PHST- 2021/11/30 00:00 [received] -PHST- 2023/01/09 00:00 [accepted] -PHST- 2023/02/23 09:50 [entrez] -PHST- 2023/02/24 06:00 [pubmed] -PHST- 2023/02/24 06:01 [medline] -PHST- 2023/02/14 00:00 [pmc-release] -AID - 10.1177_11795549231152948 [pii] -AID - 10.1177/11795549231152948 [doi] -PST - epublish -SO - Clin Med Insights Oncol. 2023 Feb 14;17:11795549231152948. doi: - 10.1177/11795549231152948. eCollection 2023. - -PMID- 39233818 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240907 -IS - 1792-1082 (Electronic) -IS - 1792-1074 (Print) -IS - 1792-1074 (Linking) -VI - 28 -IP - 5 -DP - 2024 Nov -TI - Efficacy analysis of immunotherapy‑based combinations for patients with - EGFR‑mutant advanced non‑small cell lung cancer after TKI failure. -PG - 504 -LID - 10.3892/ol.2024.14637 [doi] -LID - 504 -AB - Treatment options for epidermal growth factor receptor (EGFR)-mutant advanced - non-small cell lung cancer (NSCLC) following tyrosine kinase inhibitor (TKI) - failure are limited, and platinum-based chemotherapy remains the main treatment. - The development of effective immunotherapy for this disease has been challenging. - In the present study, 37 patients with EGFR-mutant advanced NSCLC who were - treated with programmed cell death-1 (PD-1) inhibitor-based combinations after - TKI failure were reviewed. The total cohort had a median progression-free - survival (mPFS) of 5.2 months (95% CI, 4.077-6.323 months) and a median overall - survival (mOS) of 18.3 months (95% CI, 12.932-23.668 months). Patients with - Eastern Cooperative Oncology Group performance-status (ECOG-PS) scores of 0 or 1 - had longer mPFS than those with ECOG-PS scores of 2 (5.4 vs. 2.4 months; - P=0.006). In addition, a PFS benefit was observed in patients with EGFR - T790M-negative compared with EGFR T790M-positive tumors (mPFS 6.2 vs. 4.4 months; - P=0.041). Patients treated with immunotherapy-based combinations as a front-line - therapy had a longer mPFS than those in which the combinations were used as a - late-line therapy (6.2 vs. 2.4 months; P<0.001). PD-1 inhibitor combined with - chemotherapy and bevacizumab did not show a clear advantage over PD-1 inhibitor - combined with chemotherapy alone (mPFS, 6.2 vs. 4.4 months; P=0.681), although it - resulted in an improved overall response rate (ORR) and disease control rate. - Notably, the 7 patients with a programmed cell death ligand-1 (PD-L1) tumor - proportion score of ≥50% had an ORR of 100% and an mPFS of 8.3 months. Therefore, - it is suggested that PD-1 inhibitor-based combinations should be a priority - treatment option in selective populations, such as those with low ECOG-PS scores, - T790M-negative status or high PD-L1 expression in EGFR-mutant NSCLC after TKI - failure. The use of immunotherapy and chemotherapy in combination with - antiangiogenic agents appears to be a promising combination therapy for such - patients. -CI - Copyright: © 2024 Li et al. -FAU - Li, Meifang -AU - Li M -AD - Department of Thoracic Medical Oncology, Clinical Oncology School of Fujian - Medical University, Fujian Cancer Hospital, Fuzhou, Fujian 350014, P.R. China. -FAU - Lin, Cheng -AU - Lin C -AD - Department of Radiation Oncology, Clinical Oncology School of Fujian Medical - University, Fujian Cancer Hospital, Fuzhou, Fujian 350014, P.R. China. -FAU - Lin, Jinghui -AU - Lin J -AD - Department of Thoracic Medical Oncology, Clinical Oncology School of Fujian - Medical University, Fujian Cancer Hospital, Fuzhou, Fujian 350014, P.R. China. -FAU - Chen, Shijie -AU - Chen S -AD - Department of Thoracic Medical Oncology, Clinical Oncology School of Fujian - Medical University, Fujian Cancer Hospital, Fuzhou, Fujian 350014, P.R. China. -FAU - Weng, Lihong -AU - Weng L -AD - Department of Thoracic Medical Oncology, Clinical Oncology School of Fujian - Medical University, Fujian Cancer Hospital, Fuzhou, Fujian 350014, P.R. China. -FAU - He, Zhiyong -AU - He Z -AD - Department of Thoracic Medical Oncology, Clinical Oncology School of Fujian - Medical University, Fujian Cancer Hospital, Fuzhou, Fujian 350014, P.R. China. -LA - eng -PT - Journal Article -DEP - 20240820 -PL - Greece -TA - Oncol Lett -JT - Oncology letters -JID - 101531236 -PMC - PMC11369851 -OTO - NOTNLM -OT - EGFR mutation -OT - efficacy -OT - immunotherapy -OT - non-small cell lung cancer -COIS- The authors declare that they have no competing interests. -EDAT- 2024/09/05 06:41 -MHDA- 2024/09/05 06:42 -PMCR- 2024/08/20 -CRDT- 2024/09/05 04:15 -PHST- 2023/10/23 00:00 [received] -PHST- 2024/07/30 00:00 [accepted] -PHST- 2024/09/05 06:42 [medline] -PHST- 2024/09/05 06:41 [pubmed] -PHST- 2024/09/05 04:15 [entrez] -PHST- 2024/08/20 00:00 [pmc-release] -AID - OL-28-5-14637 [pii] -AID - 10.3892/ol.2024.14637 [doi] -PST - epublish -SO - Oncol Lett. 2024 Aug 20;28(5):504. doi: 10.3892/ol.2024.14637. eCollection 2024 - Nov. - -PMID- 39272970 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240916 -IS - 2072-6694 (Print) -IS - 2072-6694 (Electronic) -IS - 2072-6694 (Linking) -VI - 16 -IP - 17 -DP - 2024 Sep 9 -TI - Immunotherapy and Radiotherapy for Older Patients with Locally Advanced - Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline - Surgery and Chemotherapy: A Practical Proposal by the International Geriatric - Radiotherapy Group. -LID - 10.3390/cancers16173112 [doi] -LID - 3112 -AB - The standard of care for locally advanced non-small-cell lung cancer (NSCLC) is - either surgery combined with chemotherapy pre- or postoperatively or concurrent - chemotherapy and radiotherapy. However, older and frail patients may not be - candidates for surgery and chemotherapy due to the high mortality risk and are - frequently referred to radiotherapy alone, which is better tolerated but carries - a high risk of disease recurrence. Recently, immunotherapy with immune checkpoint - inhibitors (ICIs) may induce a high response rate among cancer patients with - positive programmed death ligand 1 (PD-L1) expression. Immunotherapy is also well - tolerated among older patients. Laboratory and clinical studies have reported - synergy between radiotherapy and ICI. The combination of ICI and radiotherapy may - improve local control and survival for NSCLC patients who are not candidates for - surgery and chemotherapy or decline these two modalities. The International - Geriatric Radiotherapy Group proposes a protocol combining radiotherapy and - immunotherapy based on the presence or absence of PD-L1 to optimize the survival - of those patients. -FAU - Nguyen, Nam P -AU - Nguyen NP -AUID- ORCID: 0000-0001-5106-6665 -AD - Department of Radiation Oncology, Howard University, Washington, DC 20059, USA. -FAU - Page, Brandi R -AU - Page BR -AD - Department of Radiation Oncology, Johns Hopkins University, Baltimore, MD 21218, - USA. -FAU - Giap, Huan -AU - Giap H -AD - Radiation Oncology Proton Therapy, OSF HeathCare Cancer Institute, University of - Illinois, Peoria, IL 61603, USA. -FAU - Dahbi, Zineb -AU - Dahbi Z -AUID- ORCID: 0000-0002-8290-7532 -AD - Department of Radiation Oncology, Mohammed VI University of Health Sciences, - Casablanca 82403, Morocco. -FAU - Vinh-Hung, Vincent -AU - Vinh-Hung V -AUID- ORCID: 0000-0002-6403-6120 -AD - Department of Radiation Oncology, Centre Hospitalier Public du Cotentin, 50100 - Cherbourg-en-Cotentin, France. -FAU - Gorobets, Olena -AU - Gorobets O -AD - Department of Oral Surgery, Cancer Tech Care Association, Perpignan 66000, - France. -FAU - Mohammadianpanah, Mohammad -AU - Mohammadianpanah M -AUID- ORCID: 0000-0001-9391-8977 -AD - Colorectal Research Center, Department of Radiation Oncology, Shiraz University - of Medical Sciences, Shiraz 71348-14336, Iran. -FAU - Motta, Micaela -AU - Motta M -AD - Department of Radiation Oncology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. -FAU - Portaluri, Maurizio -AU - Portaluri M -AUID- ORCID: 0000-0002-8777-5997 -AD - Department of Radiation Oncology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. -FAU - Arenas, Meritxell -AU - Arenas M -AUID- ORCID: 0000-0003-0815-2570 -AD - Department of Radiation Oncology, Sant Joan de Reus University Hospital, - University of Rovira I Virgili, 43007 Tarragona, Spain. -FAU - Bonet, Marta -AU - Bonet M -AUID- ORCID: 0000-0002-6417-0514 -AD - Department of Radiation Oncology, Arnau de Vilanova University Hospital, 25198 - Lleida, Spain. -FAU - Lara, Pedro Carlos -AU - Lara PC -AUID- ORCID: 0000-0003-1709-6232 -AD - Department of Radiation Oncology, Fernando Pessoria Canarias Las Palmas - University, 35002 Las Palmas, Spain. -FAU - Kim, Lyndon -AU - Kim L -AD - Division of Neuro-Oncology, Mount Sinai Hospital, New York, NY 10029, USA. -FAU - Dutheil, Fabien -AU - Dutheil F -AD - Department of Radiation Oncology, Clinique Sainte Clotilde, 97400 Saint Denis, - France. -FAU - Natoli, Elena -AU - Natoli E -AD - Department of Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di - Bologna, 40138 Bologna, Italy. -AD - Radiation Oncology, Department of Medical and Surgical Sciences (DIMEC), Alma - Mater Studorium, Bologna University, 40126 Bologna, Italy. -FAU - Loganadane, Gokoulakrichenane -AU - Loganadane G -AD - Department of Radiation Oncology, Institut Curie, 75005 Paris, France. -FAU - Lehrman, David -AU - Lehrman D -AD - Department of Radiation Oncology, International Geriatric Radiotherapy Group, - Washington, DC 20001, USA. -FAU - Bose, Satya -AU - Bose S -AD - Department of Radiation Oncology, Howard University, Washington, DC 20059, USA. -FAU - Kaur, Sarabjot -AU - Kaur S -AUID- ORCID: 0000-0001-6646-5562 -AD - Department of Radiation Oncology, Howard University, Washington, DC 20059, USA. -FAU - Blanco, Sergio Calleja -AU - Blanco SC -AD - Department of Oral Maxillofacial Surgery, Howard University, Washington, DC - 20059, USA. -FAU - Chi, Alexander -AU - Chi A -AD - Department of Radiation Oncology, Capital University Xuanwu Hospital, Beijing - 100053, China. -LA - eng -PT - Journal Article -DEP - 20240909 -PL - Switzerland -TA - Cancers (Basel) -JT - Cancers -JID - 101526829 -PMC - PMC11394154 -OTO - NOTNLM -OT - NSCLC -OT - frail -OT - immunotherapy -OT - locally advanced -OT - older -OT - radiotherapy -COIS- The authors have no conflicts of interest. -EDAT- 2024/09/14 10:46 -MHDA- 2024/09/14 10:47 -PMCR- 2024/09/09 -CRDT- 2024/09/14 01:05 -PHST- 2024/06/27 00:00 [received] -PHST- 2024/09/02 00:00 [revised] -PHST- 2024/09/05 00:00 [accepted] -PHST- 2024/09/14 10:47 [medline] -PHST- 2024/09/14 10:46 [pubmed] -PHST- 2024/09/14 01:05 [entrez] -PHST- 2024/09/09 00:00 [pmc-release] -AID - cancers16173112 [pii] -AID - cancers-16-03112 [pii] -AID - 10.3390/cancers16173112 [doi] -PST - epublish -SO - Cancers (Basel). 2024 Sep 9;16(17):3112. doi: 10.3390/cancers16173112. - -PMID- 35804997 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20231105 -IS - 2072-6694 (Print) -IS - 2072-6694 (Electronic) -IS - 2072-6694 (Linking) -VI - 14 -IP - 13 -DP - 2022 Jun 30 -TI - Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care - (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on - Pulmonary Toxicity. -LID - 10.3390/cancers14133226 [doi] -LID - 3226 -AB - Introduction: The standard of care (SoC) for unresectable stage III - non-small-cell lung cancer (NSCLC) is durvalumab maintenance therapy after - concurrent chemoradiation in patients with PD-L1 > 1%. However, the concurrent - approach is only amenable for about one-third of patients due to co-morbidities. - Although sequential regimens are usually not regarded as curative, these - schedules applied in a dose-escalated manner may be similarly radical as SoC. As - combining high-dose radiation and durvalumab remains a question of debate this - retrospective bi-center study aims to evaluate pulmonary toxicity after high-dose - chemoradiotherapy beyond 70 Gy compared to SoC. Patients and Methods: Patients - with NSCLC stage III received durvalumab after either sequential high-dose - chemoradiation or concomitant SoC. Chemotherapy consisted of platinum combined - with either pemetrexed, taxotere, vinorelbine, or gemcitabine. The primary - endpoint was short-term pulmonary toxicity occurring within six months after the - end of radiotherapy (RT). Results: A total of 78 patients were eligible for this - analysis. 18F-FDG-PET-CT, cranial MRT, and histological/cytological verification - were mandatory in the diagnostic work-up. The high-dose and SoC group included - 42/78 (53.8%) and 36/78 (46.2%) patients, respectively, which were matched - according to baseline clinical variables. While the interval between the end of - RT and the start of durvalumab was equal in both groups (p = 0.841), more courses - were administered in the high-dose cohort (p = 0.031). Pulmonary toxicity was - similar in both groups (p = 0.599), whereas intrathoracic disease control was - better in the high-dose group (local control p = 0.081, regional control p = - 0.184). Conclusion: The data of this hypothesis-generating study suggest that - sequential high-dose chemoradiation followed by durvalumab might be similar to - SoC in terms of pulmonary toxicity and potentially more effective with respect to - intra-thoracic disease control. Larger trials with a prospective design are - warranted to validate these results. -FAU - Wass, Romana -AU - Wass R -AD - Department of Pulmonology, Paracelsus Medical University, A-5020 Salzburg, - Austria. -AD - Department of Pulmonology, Kepler University Hospital, A-4020 Linz, Austria. -FAU - Hochmair, Maximilian -AU - Hochmair M -AUID- ORCID: 0000-0002-8673-2450 -AD - Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute - of Lung Cancer Research and Pulmonary Oncology, Klinik Floridsdorf, A-1210 - Vienna, Austria. -FAU - Kaiser, Bernhard -AU - Kaiser B -AD - Department of Pulmonology, Kepler University Hospital, A-4020 Linz, Austria. -FAU - Grambozov, Brane -AU - Grambozov B -AD - Department of Radiation Oncology, Paracelsus Medical University, A-5020 Salzburg, - Austria. -FAU - Feurstein, Petra -AU - Feurstein P -AD - Department of Radiation Oncology, Klinik Ottakring, A-1160 Vienna, Austria. -FAU - Weiß, Gertraud -AU - Weiß G -AD - Department of Pulmonology, Paracelsus Medical University, A-5020 Salzburg, - Austria. -FAU - Moosbrugger, Raphaela -AU - Moosbrugger R -AD - Department of Pulmonology, Paracelsus Medical University, A-5020 Salzburg, - Austria. -FAU - Sedlmayer, Felix -AU - Sedlmayer F -AD - Department of Radiation Oncology, Paracelsus Medical University, A-5020 Salzburg, - Austria. -AD - radART-Institute for Research and Development on Advanced Radiation Technologies, - Paracelsus Medical University, A-5020 Salzburg, Austria. -FAU - Lamprecht, Bernd -AU - Lamprecht B -AD - Department of Pulmonology, Kepler University Hospital, A-4020 Linz, Austria. -FAU - Studnicka, Michael -AU - Studnicka M -AD - Department of Pulmonology, Paracelsus Medical University, A-5020 Salzburg, - Austria. -FAU - Zehentmayr, Franz -AU - Zehentmayr F -AUID- ORCID: 0000-0001-5931-3907 -AD - Department of Radiation Oncology, Paracelsus Medical University, A-5020 Salzburg, - Austria. -AD - radART-Institute for Research and Development on Advanced Radiation Technologies, - Paracelsus Medical University, A-5020 Salzburg, Austria. -LA - eng -PT - Journal Article -DEP - 20220630 -PL - Switzerland -TA - Cancers (Basel) -JT - Cancers -JID - 101526829 -PMC - PMC9265119 -OTO - NOTNLM -OT - chemoradiotherapy -OT - durvalumab -OT - high dose radiation -OT - pneumonitis -OT - toxicity -COIS- The authors declare no conflict of interest. -EDAT- 2022/07/10 06:00 -MHDA- 2022/07/10 06:01 -PMCR- 2022/06/30 -CRDT- 2022/07/09 01:04 -PHST- 2022/05/25 00:00 [received] -PHST- 2022/06/27 00:00 [revised] -PHST- 2022/06/27 00:00 [accepted] -PHST- 2022/07/09 01:04 [entrez] -PHST- 2022/07/10 06:00 [pubmed] -PHST- 2022/07/10 06:01 [medline] -PHST- 2022/06/30 00:00 [pmc-release] -AID - cancers14133226 [pii] -AID - cancers-14-03226 [pii] -AID - 10.3390/cancers14133226 [doi] -PST - epublish -SO - Cancers (Basel). 2022 Jun 30;14(13):3226. doi: 10.3390/cancers14133226. - -PMID- 37915530 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20231103 -IS - 1179-5549 (Print) -IS - 1179-5549 (Electronic) -IS - 1179-5549 (Linking) -VI - 17 -DP - 2023 -TI - The Riddle of the Sphinx: Progress in Leptomeningeal Metastasis of Non-Small Cell - Lung Cancer. -PG - 11795549231205206 -LID - 10.1177/11795549231205206 [doi] -LID - 11795549231205206 -AB - Leptomeningeal metastasis (LM) is a serious complication of advanced non-small - cell lung cancer (NSCLC), and the incidence of LM has been increasing yearly in - recent times. There is no consensus on the best treatment modality for LM, which - underscores a difficult problem in the management of advanced NSCLC patients. The - existing treatments include molecular targeted therapy, systemic chemotherapy, - local radiotherapy, antivascular tumor therapy, intrathecal chemotherapy, and - immunotherapy, but their efficacy is not satisfactory. In this article, we - briefly describe the clinical manifestations, diagnosis, and treatment of - NSCLC-LM and discuss progress regarding evaluation of the efficacy of LM - treatment to better provide a necessary reference for clinical practice and - clinical trial evaluation. -CI - © The Author(s) 2023. -FAU - Zhao, Yuhua -AU - Zhao Y -AUID- ORCID: 0000-0002-3880-2223 -FAU - Yu, Limeng -AU - Yu L -FAU - Wang, Lili -AU - Wang L -FAU - Wu, Yingxi -AU - Wu Y -FAU - Chen, Haiyang -AU - Chen H -FAU - Wang, Qiming -AU - Wang Q -FAU - Wu, Yufeng -AU - Wu Y -LA - eng -PT - Journal Article -PT - Review -DEP - 20231030 -PL - United States -TA - Clin Med Insights Oncol -JT - Clinical Medicine Insights. Oncology -JID - 101525771 -PMC - PMC10617270 -OTO - NOTNLM -OT - Leptomeningeal metastasis -OT - efficacy evaluation -OT - liquid biopsy -OT - non–small cell lung cancer -OT - tyrosine kinase inhibitors -COIS- The author(s) declared no potential conflicts of interest with respect to the - research, authorship, and/or publication of this article. -EDAT- 2023/11/02 06:42 -MHDA- 2023/11/02 06:43 -PMCR- 2023/10/30 -CRDT- 2023/11/02 04:00 -PHST- 2023/06/02 00:00 [received] -PHST- 2023/09/15 00:00 [accepted] -PHST- 2023/11/02 06:43 [medline] -PHST- 2023/11/02 06:42 [pubmed] -PHST- 2023/11/02 04:00 [entrez] -PHST- 2023/10/30 00:00 [pmc-release] -AID - 10.1177_11795549231205206 [pii] -AID - 10.1177/11795549231205206 [doi] -PST - epublish -SO - Clin Med Insights Oncol. 2023 Oct 30;17:11795549231205206. doi: - 10.1177/11795549231205206. eCollection 2023. - -PMID- 27717798 -OWN - NLM -STAT- MEDLINE -DCOM- 20170905 -LR - 20210103 -IS - 1097-4180 (Electronic) -IS - 1074-7613 (Linking) -VI - 45 -IP - 4 -DP - 2016 Oct 18 -TI - Enterococcus hirae and Barnesiella intestinihominis Facilitate - Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. -PG - 931-943 -LID - S1074-7613(16)30378-8 [pii] -LID - 10.1016/j.immuni.2016.09.009 [doi] -AB - The efficacy of the anti-cancer immunomodulatory agent cyclophosphamide (CTX) - relies on intestinal bacteria. How and which relevant bacterial species are - involved in tumor immunosurveillance, and their mechanism of action are unclear. - Here, we identified two bacterial species, Enterococcus hirae and Barnesiella - intestinihominis that are involved during CTX therapy. Whereas E. hirae - translocated from the small intestine to secondary lymphoid organs and increased - the intratumoral CD8/Treg ratio, B. intestinihominis accumulated in the colon and - promoted the infiltration of IFN-γ-producing γδT cells in cancer lesions. The - immune sensor, NOD2, limited CTX-induced cancer immunosurveillance and the - bioactivity of these microbes. Finally, E. hirae and B. intestinihominis - specific-memory Th1 cell immune responses selectively predicted longer - progression-free survival in advanced lung and ovarian cancer patients treated - with chemo-immunotherapy. Altogether, E. hirae and B. intestinihominis represent - valuable "oncomicrobiotics" ameliorating the efficacy of the most common - alkylating immunomodulatory compound. -CI - Copyright © 2016 Elsevier Inc. All rights reserved. -FAU - Daillère, Romain -AU - Daillère R -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la - Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; University of - Paris-Saclay, Kremlin Bicêtre, 94270, France. -FAU - Vétizou, Marie -AU - Vétizou M -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la - Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; University of - Paris-Saclay, Kremlin Bicêtre, 94270, France. -FAU - Waldschmitt, Nadine -AU - Waldschmitt N -AD - University Lille, CNRS, Inserm, CHRU Lille, Institut Pasteur de Lille, U1019-UMR - 8204-CIIL, Centre d'Infection et d'Immunité de Lille, 59000 Lille, France. -FAU - Yamazaki, Takahiro -AU - Yamazaki T -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la - Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France. -FAU - Isnard, Christophe -AU - Isnard C -AD - Université de Caen Basse-Normandie, EA4655 U2RM (Équipe Antibio-Résistance), - Caen, 14033, France; CHU de Caen, Service de Microbiologie, Caen, 14033, France. -FAU - Poirier-Colame, Vichnou -AU - Poirier-Colame V -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la - Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; University of - Paris-Saclay, Kremlin Bicêtre, 94270, France. -FAU - Duong, Connie P M -AU - Duong CPM -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la - Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; Center of - Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, 94805, - France. -FAU - Flament, Caroline -AU - Flament C -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la - Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; Center of - Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, 94805, - France. -FAU - Lepage, Patricia -AU - Lepage P -AD - Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, 78350 - Jouy-en-Josas, France. -FAU - Roberti, Maria Paula -AU - Roberti MP -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la - Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; Center of - Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, 94805, - France. -FAU - Routy, Bertrand -AU - Routy B -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la - Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; University of - Paris-Saclay, Kremlin Bicêtre, 94270, France. -FAU - Jacquelot, Nicolas -AU - Jacquelot N -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la - Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; University of - Paris-Saclay, Kremlin Bicêtre, 94270, France. -FAU - Apetoh, Lionel -AU - Apetoh L -AD - Lipids, Nutrition, Cancer, INSERM, U866, Dijon, 21078, France; Department of - Medicine, Université de Bourgogne Franche-Comté, Dijon, 21078, France; Department - of Oncology, Centre Georges François Leclerc, Dijon, 21000, France. -FAU - Becharef, Sonia -AU - Becharef S -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la - Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; Center of - Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, 94805, - France. -FAU - Rusakiewicz, Sylvie -AU - Rusakiewicz S -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la - Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; Center of - Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, 94805, - France. -FAU - Langella, Philippe -AU - Langella P -AD - Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, 78350 - Jouy-en-Josas, France. -FAU - Sokol, Harry -AU - Sokol H -AD - Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, 78350 - Jouy-en-Josas, France; AVENIR Team Gut Microbiota and Immunity, ERL, INSERM U - 1157/UMR 7203, Faculté de Médecine, Saint-Antoine, Université Pierre et Marie - Curie (UPMC), Paris, 75012, France; Service de Gastroentérologie, Hôpital - Saint-Antoine, Assistance Publique-Hôpitaux de Paris (APHP), Paris, 75012, - France. -FAU - Kroemer, Guido -AU - Kroemer G -AD - INSERM U848, 94805 Villejuif, France; Metabolomics Platform, Institut Gustave - Roussy, Villejuif, 94805, France; Equipe 11 labellisée Ligue contre le Cancer, - Centre de Recherche des Cordeliers, INSERM U 1138, Paris, 75006, France; Pôle de - Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, 75015, France; - Université Paris Descartes, Sorbonne Paris Cité, Paris, 75006, France; Karolinska - Institute, Department of Women's and Children's Health, Karolinska University - Hospital, Stockholm, 17176, Sweden. -FAU - Enot, David -AU - Enot D -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Metabolomics Platform, Institut Gustave - Roussy, Villejuif, 94805, France. -FAU - Roux, Antoine -AU - Roux A -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la - Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; University of - Paris-Saclay, Kremlin Bicêtre, 94270, France; Université Paris Descartes, - Sorbonne Paris Cité, Paris, 75006, France. -FAU - Eggermont, Alexander -AU - Eggermont A -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; University of Paris-Saclay, Kremlin Bicêtre, - 94270, France. -FAU - Tartour, Eric -AU - Tartour E -AD - INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, - Sorbonne Paris Cité, Paris, 75015, France; Service d'immunologie biologique, - Hôpital Européen Georges Pompidou, Paris, 75015 France. -FAU - Johannes, Ludger -AU - Johannes L -AD - INSERM U1143, 75005 Paris, France; Institut Curie, PSL Research University, - Endocytic Trafficking and Therapeutic Delivery group, Paris, 75248, France; CNRS - UMR 3666, Paris, 75005, France. -FAU - Woerther, Paul-Louis -AU - Woerther PL -AD - Service de microbiologie, GRCC, Villejuif, 94805, France. -FAU - Chachaty, Elisabeth -AU - Chachaty E -AD - Service de microbiologie, GRCC, Villejuif, 94805, France. -FAU - Soria, Jean-Charles -AU - Soria JC -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; University of Paris-Saclay, Kremlin Bicêtre, - 94270, France. -FAU - Golden, Encouse -AU - Golden E -AD - Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA. -FAU - Formenti, Silvia -AU - Formenti S -AD - Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA. -FAU - Plebanski, Magdalena -AU - Plebanski M -AD - Department of Immunology and Pathology, Monash University, Alfred Hospital - Precinct, Melbourne, Prahran, Victoria 3181, Australia. -FAU - Madondo, Mutsa -AU - Madondo M -AD - Department of Immunology and Pathology, Monash University, Alfred Hospital - Precinct, Melbourne, Prahran, Victoria 3181, Australia. -FAU - Rosenstiel, Philip -AU - Rosenstiel P -AD - Institute of Clinical Molecular Biology, Christian-Albrechts-University and - University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany. -FAU - Raoult, Didier -AU - Raoult D -AD - AIX MARSEILLE UNIVERSITE, URMITE (Unité de Recherche sur les Maladies - Infectieuses et Tropicales Emergentes), UMR 7278, INSERM 1095, IRD 198, Faculté - de Médecine, Marseille 13005, France. -FAU - Cattoir, Vincent -AU - Cattoir V -AD - Université de Caen Basse-Normandie, EA4655 U2RM (Équipe Antibio-Résistance), - Caen, 14033, France; CHU de Caen, Service de Microbiologie, Caen, 14033, France; - CNR de la Résistance aux Antibiotiques, Laboratoire Associé Entérocoques, Caen, - 14033, France. -FAU - Boneca, Ivo Gomperts -AU - Boneca IG -AD - Institut Pasteur, Unit Biology and Genetics of the bacterial Cell Wall, Paris, - 75015, France. -FAU - Chamaillard, Mathias -AU - Chamaillard M -AD - University Lille, CNRS, Inserm, CHRU Lille, Institut Pasteur de Lille, U1019-UMR - 8204-CIIL, Centre d'Infection et d'Immunité de Lille, 59000 Lille, France. -FAU - Zitvogel, Laurence -AU - Zitvogel L -AD - Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard - Vaillant, Villejuif, 94805, France; Institut National de la Santé Et de la - Recherche Medicale (INSERM), U1015, GRCC, Villejuif, 94805, France; University of - Paris-Saclay, Kremlin Bicêtre, 94270, France; Center of Clinical Investigations - in Biotherapies of Cancer (CICBT) 1428, Villejuif, 94805, France. Electronic - address: laurence.zitvogel@gustaveroussy.fr. -LA - eng -GR - R01 CA161879/CA/NCI NIH HHS/United States -PT - Journal Article -PT - Research Support, N.I.H., Extramural -PT - Research Support, Non-U.S. Gov't -DEP - 20161004 -PL - United States -TA - Immunity -JT - Immunity -JID - 9432918 -RN - 0 (Immunologic Factors) -RN - 0 (Nod2 Signaling Adaptor Protein) -RN - 82115-62-6 (Interferon-gamma) -RN - 8N3DW7272P (Cyclophosphamide) -SB - IM -CIN - Immunity. 2016 Oct 18;45(4):714-716. doi: 10.1016/j.immuni.2016.10.007. PMID: - 27760335 -MH - Animals -MH - Colon/immunology/microbiology -MH - Cyclophosphamide/*pharmacology -MH - Enterococcus hirae/*immunology -MH - Immunologic Factors/*immunology -MH - Immunologic Memory/immunology -MH - Immunotherapy/methods -MH - Interferon-gamma/immunology -MH - Intestine, Small/immunology/microbiology -MH - Mice -MH - Mice, Inbred C57BL -MH - Monitoring, Immunologic -MH - Neoplasms/*drug therapy/*immunology -MH - Nod2 Signaling Adaptor Protein/immunology -MH - Th1 Cells/immunology -EDAT- 2016/10/21 06:00 -MHDA- 2017/09/07 06:00 -CRDT- 2016/10/09 06:00 -PHST- 2015/07/27 00:00 [received] -PHST- 2016/06/28 00:00 [revised] -PHST- 2016/07/22 00:00 [accepted] -PHST- 2016/10/21 06:00 [pubmed] -PHST- 2017/09/07 06:00 [medline] -PHST- 2016/10/09 06:00 [entrez] -AID - S1074-7613(16)30378-8 [pii] -AID - 10.1016/j.immuni.2016.09.009 [doi] -PST - ppublish -SO - Immunity. 2016 Oct 18;45(4):931-943. doi: 10.1016/j.immuni.2016.09.009. Epub 2016 - Oct 4. - -PMID- 27458526 -OWN - NLM -STAT- PubMed-not-MEDLINE -DCOM- 20160726 -LR - 20240325 -IS - 2095-3941 (Print) -IS - 2095-3941 (Linking) -VI - 13 -IP - 2 -DP - 2016 Jun -TI - Immuno-oncology combinations: raising the tail of the survival curve. -PG - 171-93 -LID - 10.20892/j.issn.2095-3941.2016.0015 [doi] -AB - There have been exponential gains in immuno-oncology in recent times through the - development of immune checkpoint inhibitors. Already approved by the U.S. Food - and Drug Administration for advanced melanoma and non-small cell lung cancer, - immune checkpoint inhibitors also appear to have significant antitumor activity - in multiple other tumor types. An exciting component of immunotherapy is the - durability of antitumor responses observed, with some patients achieving disease - control for many years. Nevertheless, not all patients benefit, and efforts - should thus now focus on improving the efficacy of immunotherapy through the use - of combination approaches and predictive biomarkers of response and resistance. - There are multiple potential rational combinations using an immunotherapy - backbone, including existing treatments such as radiotherapy, chemotherapy or - molecularly targeted agents, as well as other immunotherapeutics. The aim of such - antitumor strategies will be to raise the tail on the survival curve by - increasing the number of long term survivors, while managing any additive or - synergistic toxicities that may arise with immunotherapy combinations. Rational - trial designs based on a clear understanding of tumor biology and drug - pharmacology remain paramount. This article reviews the biology underpinning - immuno-oncology, discusses existing and novel immunotherapeutic combinations - currently in development, the challenges of predictive biomarkers of response and - resistance and the impact of immuno-oncology on early phase clinical trial - design. -FAU - Harris, Samuel J -AU - Harris SJ -AD - Drug Development Unit. -FAU - Brown, Jessica -AU - Brown J -AD - Drug Development Unit. -FAU - Lopez, Juanita -AU - Lopez J -AD - Drug Development Unit. -FAU - Yap, Timothy A -AU - Yap TA -AD - Drug Development Unit; Lung Unit, Royal Marsden Hospital and The Institute of - Cancer Research, London SM2 5PT, UK. -LA - eng -PT - Journal Article -PL - China -TA - Cancer Biol Med -JT - Cancer biology & medicine -JID - 101588850 -PMC - PMC4944548 -OTO - NOTNLM -OT - CTLA4 -OT - Combination drug therapy -OT - PD-1 -OT - PD-L1 -OT - biomarkers -OT - clinical trials -OT - immunotherapy -OT - oncology -EDAT- 2016/07/28 06:00 -MHDA- 2016/07/28 06:01 -PMCR- 2016/06/01 -CRDT- 2016/07/27 06:00 -PHST- 2016/07/27 06:00 [entrez] -PHST- 2016/07/28 06:00 [pubmed] -PHST- 2016/07/28 06:01 [medline] -PHST- 2016/06/01 00:00 [pmc-release] -AID - 10.20892/j.issn.2095-3941.2016.0015 [doi] -PST - ppublish -SO - Cancer Biol Med. 2016 Jun;13(2):171-93. doi: 10.20892/j.issn.2095-3941.2016.0015. - -PMID- 36570411 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240909 -IS - 1758-8340 (Print) -IS - 1758-8359 (Electronic) -IS - 1758-8340 (Linking) -VI - 14 -DP - 2022 -TI - A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy - followed by durvalumab for unresectable, locally advanced non-small-cell lung - cancer in Japan (SAMURAI study): primary analysis. -PG - 17588359221142786 -LID - 10.1177/17588359221142786 [doi] -LID - 17588359221142786 -AB - BACKGROUND: The standard of care for unresectable, locally advanced - non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by - durvalumab, based on the PACIFIC study. Although multiple Japanese phase II - studies have shown high efficacy and tolerability of CRT with cisplatin plus S-1 - (SP), no prospective study using durvalumab after SP-based CRT has been reported. - OBJECTIVES: We conducted a multicenter phase II study of this approach, the - interim analysis of which showed a high transition rate to durvalumab - consolidation therapy. Here, we report the primary analysis results. DESIGN: In - treatment-naïve LA-NSCLC, cisplatin (60 mg/m(2), day 1) and S-1 (80-120 mg/body, - days 1-14) were administered with two 4-week cycles with concurrent thoracic - radiotherapy (60 Gy) followed by durvalumab (10 mg/kg) every 2 weeks for up to - 1 year. METHODS: The primary endpoint was 1-year progression-free survival (PFS). - The expected 1-year PFS and its lower limit of the 80% confidence interval (CI) - were set as 63% and 47%, respectively, based on the results of TORG1018 study. - RESULTS: In all, 59 patients were enrolled, with 51 (86.4%) proceeding to - durvalumab. The objective response rate throughout the study was 72.9% (95% CI: - 59.7-83.6%). After median follow-up of 21.9 months, neither median PFS nor OS was - reached. The 1-year PFS was 72.5% (80% CI: 64.2-79.2%, 95% CI: 59.1-82.2%), while - the 1-year overall survival was 91.5% (95% CI: 80.8-96.4%). No grade 5 adverse - events were observed throughout the study. The most common adverse event during - the consolidation phase was pneumonitis (any grade, 78.4%; grade ⩾3, 2.0%). - Eventually, 52.5% of patients completed 1-year durvalumab consolidation therapy - from CRT initiation. CONCLUSION: This study of durvalumab after SP-based CRT met - its primary endpoint and found a 1-year PFS of 73% from CRT initiation. This - study provides the first prospective data on the prognosis and tolerability of - durvalumab consolidation from the initiation of CRT. TRIAL REGISTRATION: Japan - Registry of Clinical Trials, jRCTs031190127, registered 1 November, 2019, - https://jrct.niph.go.jp/latest-detail/jRCTs031190127. -CI - © The Author(s), 2022. -FAU - Tanaka, Hisashi -AU - Tanaka H -AD - Department of Respiratory Medicine, Hirosaki University Graduate School of - Medicine, Hirosaki, Aomori, Japan. -FAU - Tanzawa, Shigeru -AU - Tanzawa S -AUID- ORCID: 0000-0001-5738-0313 -AD - Division of Medical Oncology, Department of Internal Medicine, Teikyo University - School of Medicine, Itabashi-ku, Tokyo, Japan. -FAU - Misumi, Toshihiro -AU - Misumi T -AD - Department of Biostatistics, Yokohama City University School of Medicine, - Yokohama, Kanagawa, Japan. -FAU - Makiguchi, Tomonori -AU - Makiguchi T -AUID- ORCID: 0000-0001-9249-7904 -AD - Department of Respiratory Medicine, Hirosaki University Graduate School of - Medicine, Hirosaki, Aomori, Japan. -FAU - Inaba, Megumi -AU - Inaba M -AD - Department of Respiratory Medicine, Kumamoto Chuo Hospital, Kumamoto, Kumamoto, - Japan. -FAU - Honda, Takeshi -AU - Honda T -AD - Division of Medical Oncology, Department of Internal Medicine, Teikyo University - School of Medicine, Itabashi-ku, Tokyo, Japan. -FAU - Nakamura, Junya -AU - Nakamura J -AD - Department of Respiratory Medicine, Ehime Prefectural Central Hospital, - Matsuyama, Ehime, Japan. -FAU - Inoue, Koji -AU - Inoue K -AD - Department of Respiratory Medicine, Ehime Prefectural Central Hospital, - Matsuyama, Ehime, Japan. -FAU - Kishikawa, Takayuki -AU - Kishikawa T -AD - Department of Respiratory Medicine, Tochigi Cancer Center, Utsunomiya, Tochigi, - Japan. -FAU - Nakashima, Masanao -AU - Nakashima M -AD - Department of Respiratory Medicine, Shin-Yurigaoka General Hospital, Kawasaki, - Kanagawa, Japan. -FAU - Fujiwara, Keiichi -AU - Fujiwara K -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Okayama, Okayama, Japan. -FAU - Kohyama, Tadashi -AU - Kohyama T -AD - Department of Internal Medicine, Teikyo University Hospital, Mizonokuchi, - Kawasaki, Kanagawa, Japan. -FAU - Ishida, Hiroo -AU - Ishida H -AD - Department of Internal Medicine, Showa University Northern Yokohama Hospital, - Yokohama, Kanagawa, Japan. -FAU - Kuyama, Shoichi -AU - Kuyama S -AD - Department of Respiratory Medicine, National Hospital Organization Iwakuni - Clinical Center, Iwakuni, Yamaguchi, Japan. -FAU - Miyazawa, Naoki -AU - Miyazawa N -AD - Department of Respiratory Medicine, Saiseikai Yokohamashi Nanbu Hospital, - Yokohama, Kanagawa, Japan. -FAU - Nakamura, Tomomi -AU - Nakamura T -AD - Division of Hematology, Respiratory Medicine and Oncology, Department of Internal - Medicine, Faculty of Medicine, Saga University, Saga, Saga, Japan. -FAU - Miyawaki, Hiroshi -AU - Miyawaki H -AD - Department of Respiratory Medicine, Kagawa Prefectural Central Hospital, - Takamatsu, Kagawa, Japan. -FAU - Oda, Naohiro -AU - Oda N -AD - Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Hiroshima, - Japan. -FAU - Ishikawa, Nobuhisa -AU - Ishikawa N -AD - Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, - Hiroshima, Japan. -FAU - Morinaga, Ryotaro -AU - Morinaga R -AD - Department of Thoracic Medical Oncology, Oita Prefectural Hospital, Oita, Oita, - Japan. -FAU - Kusaka, Kei -AU - Kusaka K -AD - The Center for Pulmonary Diseases, National Hospital Organization Tokyo National - Hospital, Kiyose, Tokyo, Japan. -FAU - Fujimoto, Nobukazu -AU - Fujimoto N -AUID- ORCID: 0000-0002-4516-0433 -AD - Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Okayama, Japan. -FAU - Fukuda, Yasushi -AU - Fukuda Y -AD - Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, - Okayama, Japan. -FAU - Yasugi, Masayuki -AU - Yasugi M -AD - Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, - Hiroshima, Japan. -FAU - Tsuda, Takeshi -AU - Tsuda T -AD - Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, - Toyama, Japan. -FAU - Ushijima, Sunao -AU - Ushijima S -AD - Department of Medical Oncology, Kumamoto Kenhoku Hospital, Tamana, Kumamoto, - Japan. -FAU - Shibata, Kazuhiko -AU - Shibata K -AUID- ORCID: 0000-0002-4864-5970 -AD - Department of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka, Toyama, - Japan. -FAU - Shibayama, Takuo -AU - Shibayama T -AD - Department of Respiratory Medicine, National Hospital Organization Okayama - Medical Center, Okayama, Okayama, Japan. -FAU - Bessho, Akihiro -AU - Bessho A -AUID- ORCID: 0000-0002-0394-7377 -AD - Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, - Okayama, Japan. -FAU - Kaira, Kyoichi -AU - Kaira K -AD - Department of Respiratory Medicine, Saitama Medical University International - Medical Center, Hidaka, Saitama, Japan. -FAU - Shiraishi, Kenshiro -AU - Shiraishi K -AUID- ORCID: 0000-0002-2295-517X -AD - Department of Radiology, Teikyo University School of Medicine, Itabashi-ku, - Tokyo, Japan. -FAU - Matsutani, Noriyuki -AU - Matsutani N -AD - Department of Surgery, Teikyo University Hospital, Mizonokuchi, Kawasaki, - Kanagawa, Japan. -FAU - Seki, Nobuhiko -AU - Seki N -AD - Division of Medical Oncology, Department of Internal Medicine, Teikyo University - School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan. -LA - eng -PT - Journal Article -DEP - 20221218 -PL - England -TA - Ther Adv Med Oncol -JT - Therapeutic advances in medical oncology -JID - 101510808 -PMC - PMC9772940 -OTO - NOTNLM -OT - S-1 -OT - chemoradiotherapy -OT - cisplatin -OT - durvalumab -OT - non-small-cell lung cancer -COIS- H.T. received personal fees as honoraria from Boehringer Ingelheim, AstraZeneca, - Pfizer, Chugai Pharmaceutical, Bristol-Myers Squibb, and Ono Pharmaceutical. S.T. - received research funding from AstraZeneca, and personal fees as honoraria from - AstraZeneca, Chugai Pharmaceutical, Taiho Pharmaceutical, and Eli Lilly. T.Misu. - received personal fees as honoraria from Chugai Pharmaceutical and AstraZeneca. - S.K. received personal fees as honoraria from Chugai Pharmaceutical, - Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, Pfizer, Eli Lilly, MSD, - Taiho Pharmaceutical, Sanofi, Kyowa Kirin, Hisamitsu Pharmaceutical, Daiichi - Sankyo, Nippon Kayaku, and Novartis. N.I. received personal fees as honoraria - from AstraZeneca. K.Kusa. received personal fees as honoraria from AstraZeneca, - Chugai Pharmaceutical, Ono Pharmaceutical, and Nippon Kayaku. N.F. received - personal fees as honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, - Boehringer Ingelheim, and AstraZeneca. Y.F. received personal fees as honoraria - from Bristol-Myers Squibb, Ono Pharmaceutical, Chugai Pharmaceutical, - AstraZeneca, Novartis, Merck Biopharma, MSD, Boehringer Ingelheim, Taiho - Pharmaceutical, and Daiichi Sankyo. T.T. received personal fees as honoraria from - Chugai Pharmaceutical. K.Shib. received personal fees as honoraria from - AstraZeneca, Taiho Pharmaceutical, Chugai Pharmaceutical, Bristol-Myers Squibb, - and Ono Pharmaceutical. A.B. received research funding from AstraZeneca and - personal fees as honoraria from AstraZeneca and Taiho Pharmaceutical. K.Kair. - received research funding from AstraZeneca and Nihon Medi-Physics and personal - fees as honoraria from Ono Pharmaceutical, Boehringer Ingelheim, Chugai - Pharmaceutical, Taiho Pharmaceutical, Eli Lilly, AstraZeneca, and Pfizer. N.S. - received research funding from Ono Pharmaceutical, Boehringer Ingelheim, Taiho - Pharmaceutical, Chugai Pharmaceutical, Eisai, Daiichi Sankyo, Takeda - Pharmaceutical, Shionogi, Nippon Kayaku, and Pfizer, and personal fees as - honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, Chugai Pharmaceutical, - Eli Lilly, AstraZeneca, Boehringer Ingelheim, MSD, Daiichi Sankyo, Novartis, - Bristol-Myers Squibb, Pfizer, Takeda Pharmaceutical, and Nippon Kayaku. No - potential conflicts of interest were disclosed by the other authors. -EDAT- 2022/12/27 06:00 -MHDA- 2022/12/27 06:01 -PMCR- 2022/12/18 -CRDT- 2022/12/26 04:33 -PHST- 2022/08/10 00:00 [received] -PHST- 2022/11/16 00:00 [accepted] -PHST- 2022/12/26 04:33 [entrez] -PHST- 2022/12/27 06:00 [pubmed] -PHST- 2022/12/27 06:01 [medline] -PHST- 2022/12/18 00:00 [pmc-release] -AID - 10.1177_17588359221142786 [pii] -AID - 10.1177/17588359221142786 [doi] -PST - epublish -SO - Ther Adv Med Oncol. 2022 Dec 18;14:17588359221142786. doi: - 10.1177/17588359221142786. eCollection 2022. - -PMID- 29456881 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240313 -IS - 2167-4817 (Print) -IS - 2167-4817 (Electronic) -IS - 2167-4817 (Linking) -VI - 6 -IP - 2 -DP - 2018 -TI - Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with - the Evidence? -PG - 5 -LID - 10.1007/s40137-018-0202-0 [doi] -LID - 5 -AB - PURPOSE OF REVIEW: The majority of patients with non-small cell lung cancer - (NSCLC) present with advanced disease and overall survival rates are poor. This - article outlines the current and outstanding evidence for the use of - multimodality treatment in this group of patients, including in combination with - an increasing number of treatment options, such as immunotherapy and - genotype-targeted small molecule inhibitors. RECENT FINDINGS: Optimal therapy for - surgically resectable stage III disease remains debatable and currently the - choice of treatment reflects each individual patient's disease characteristics - and the expertise and opinion of the thoracic multi-disciplinary team. Evidence - for a distinct oligometastatic state in which improved outcomes can be achieved - remains minimal and there is as yet no consensus definition for oligometastatic - lung cancer. Whilst there is supporting evidence for the aggressive management of - isolated metastases, the use of consolidative therapy for multiple metastases - remains unproven. SUMMARY: Evolution of new RT technologies, improved surgical - technique and a plethora of interventional-radiology-guided ablative therapies - are widening the choice of available treatment modalities to patients with NSCLC. - In the setting of resectable locally advanced disease and the oligometastatic - state, there is a growing need for randomised comparison of the available - treatment modalities to guide both treatment and patient selection. -FAU - Jones, Christopher M -AU - Jones CM -AD - 1Leeds Institute of Cancer & Pathology, Faculty of Medicine & Health, University - of Leeds, Leeds, UK. ISNI: 0000 0004 1936 8403. GRID: grid.9909.9 -AD - 2Radiotherapy Research Group, Leeds Cancer Centre, The Leeds Teaching Hospitals - NHS Trust, Leeds, UK. ISNI: 0000 0000 9965 1030. GRID: grid.415967.8 -AD - 3School of Molecular & Cellular Biology, Faculty of Biological Sciences, - University of Leeds, Leeds, UK. ISNI: 0000 0004 1936 8403. GRID: grid.9909.9 -FAU - Brunelli, Alessandro -AU - Brunelli A -AD - 4Department of Thoracic Surgery, The Leeds Teaching Hospitals NHS Trust, Leeds, - UK. ISNI: 0000 0000 9965 1030. GRID: grid.415967.8 -FAU - Callister, Matthew E -AU - Callister ME -AD - 5Department of Respiratory Medicine, The Leeds Teaching Hospitals NHS Trust, - Leeds, UK. ISNI: 0000 0000 9965 1030. GRID: grid.415967.8 -FAU - Franks, Kevin N -AU - Franks KN -AD - 1Leeds Institute of Cancer & Pathology, Faculty of Medicine & Health, University - of Leeds, Leeds, UK. ISNI: 0000 0004 1936 8403. GRID: grid.9909.9 -AD - 2Radiotherapy Research Group, Leeds Cancer Centre, The Leeds Teaching Hospitals - NHS Trust, Leeds, UK. ISNI: 0000 0000 9965 1030. GRID: grid.415967.8 -LA - eng -GR - Wellcome Trust/United Kingdom -PT - Journal Article -PT - Review -DEP - 20180208 -PL - United States -TA - Curr Surg Rep -JT - Current surgery reports -JID - 101610691 -PMC - PMC5805813 -OTO - NOTNLM -OT - Chemotherapy -OT - Locally advanced -OT - Lung cancer -OT - Oligometastatic -OT - Radiotherapy -OT - Stereotactic ablative radiotherapy -OT - Surgery -OT - Treatment -COIS- Compliance with Ethics GuidelinesThe authors declare no conflicts of interest - relevant to this manuscript.This article does not contain any studies with human - or animal subjects performed by any of the authors. -EDAT- 2018/02/20 06:00 -MHDA- 2018/02/20 06:01 -PMCR- 2018/02/08 -CRDT- 2018/02/20 06:00 -PHST- 2018/02/20 06:00 [entrez] -PHST- 2018/02/20 06:00 [pubmed] -PHST- 2018/02/20 06:01 [medline] -PHST- 2018/02/08 00:00 [pmc-release] -AID - 202 [pii] -AID - 10.1007/s40137-018-0202-0 [doi] -PST - ppublish -SO - Curr Surg Rep. 2018;6(2):5. doi: 10.1007/s40137-018-0202-0. Epub 2018 Feb 8. - -PMID- 31887826 -OWN - NLM -STAT- MEDLINE -DCOM- 20200106 -LR - 20200108 -IS - 1673-0860 (Print) -IS - 1673-0860 (Linking) -VI - 54 -IP - 12 -DP - 2019 Dec 7 -TI - [Advances in immunotherapy of extranodal NK/T cell lymphoma]. -PG - 949-953 -LID - 10.3760/cma.j.issn.1673-0860.2019.12.015 [doi] -AB - Extranodal NK/T-cell lymphoma (ENKTCL) is a relatively rare group of highly - aggressive non-Hodgkin's lymphoma (NHL). The disease has rapid clinical progress, - high degree of malignancy and poor prognosis. Traditional chemoradiotherapy - regimens have not shown good efficacy. In recent years, the immunotherapy of - tumors has developed rapidly. At present, it has shown strong therapeutic - activity in the treatment of various solid tumors such as non-small cell lung - cancer, prostate cancer, melanoma and kidney cancer. Multiple tumor immunotherapy - drugs have been approved by the US Food and Drug Administration (FDA) for - clinical use. This article reviews recent novel immunotherapeutic regimens of - ENKTCL, hoping to change the treatment modality of this malignant disease. -FAU - Hao, D Q -AU - Hao DQ -AD - Shandong First Medical University (Shandong Academy of Medical Sciences), Taian - 271000, China. -FAU - Li, L Q -AU - Li LQ -AD - Liaocheng People's Hospital, Otorhinolaryngology Head and Neck Surgery, Liaocheng - 252000, China. -FAU - Li, M C -AU - Li MC -AD - Liaocheng People's Hospital, Otorhinolaryngology Head and Neck Surgery, Liaocheng - 252000, China. -FAU - Gong, L L -AU - Gong LL -AD - Liaocheng People's Hospital, Otorhinolaryngology Head and Neck Surgery, Liaocheng - 252000, China. -LA - chi -PT - Journal Article -PL - China -TA - Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi -JT - Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of - otorhinolaryngology head and neck surgery -JID - 101247574 -SB - IM -MH - Humans -MH - *Immunotherapy -MH - *Lymphoma, Extranodal NK-T-Cell/therapy -OTO - NOTNLM -OT - CD30 -OT - CD38 -OT - CTLA-4 -OT - EBV-associated antigen -OT - Immunotherapy -OT - Lymphoma, extranodal NK-T-cell -OT - PD1/PDL1 -EDAT- 2019/12/31 06:00 -MHDA- 2020/01/07 06:00 -CRDT- 2019/12/31 06:00 -PHST- 2019/12/31 06:00 [entrez] -PHST- 2019/12/31 06:00 [pubmed] -PHST- 2020/01/07 06:00 [medline] -AID - 10.3760/cma.j.issn.1673-0860.2019.12.015 [doi] -PST - ppublish -SO - Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019 Dec 7;54(12):949-953. doi: - 10.3760/cma.j.issn.1673-0860.2019.12.015. - -PMID- 39198089 -OWN - NLM -STAT- Publisher -LR - 20240828 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -DP - 2024 Jul 27 -TI - Single-drug Chemotherapy Plus Immunotherapy as First-line Treatment for Stage Ⅳ - Non-small Cell Lung Cancer Elderly Patients: A Phase II Clinical Trial UNICORN - Study. -LID - S1525-7304(24)00144-X [pii] -LID - 10.1016/j.cllc.2024.07.005 [doi] -AB - INTRODUCTION: Lung cancer remains the most common malignancy and the leading - cancer-related death among the elderly in China, which deserves more research - attention. Immunotherapy combined with platinum-based doublet chemotherapy has - been approved as the standard treatment for advanced non-small cell lung cancer - (NSCLC) patients who are devoid of specific gene mutations or fusions. Given that - patients with NSCLC over the age of 65 typically exhibit declining organ function - and physical condition, they often showed reduced tolerance for this rigorous - treatment regimen. However, the KEYNOTE-042 study illuminated a promising - pathway: in patients testing positive for programmed death-ligand 1 (PD-L1), - immunotherapy alone has demonstrated a superior overall survival (OS) compared to - platinum-based doublet chemotherapy. This suggests that moderating the intensity - of chemotherapy and prioritizing immunotherapy may be a gentler alternative in - elderly demographic. PATIENTS AND METHODS: This multicenter phase II clinical - trial named UNICORN aimed to enroll 49 patients aged 65 and older, utilizing - paclitaxel or nab-paclitaxel for those with squamous NSCLC, and pemetrexed for - those diagnosed with lung adenocarcinoma. The treatment protocol entails 4 cycles - of serplulimab plus chemotherapy followed by an extended regimen of serplulimab - maintenance, spanning a total of 35 cycles. Primary endpoints of this study are - progression-free survival (PFS), disease control rate (DCR) and the secondary - endpoints are OS, objective control rate (ORR) and safety metrics. CONCLUSION: - This is the first study to evaluate the efficacy and safety of serplulimab - combined with either paclitaxel or pemetrexed in elderly treatment-naïve patients - with stage IV NSCLC whose PD-L1 are positive. -CI - Copyright © 2024 Elsevier Inc. All rights reserved. -FAU - Ma, Jia -AU - Ma J -AD - Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, - Huazhong University of Science and Technology, Wuhan, China. -FAU - Peng, Min -AU - Peng M -AD - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China. -FAU - Bi, Jianping -AU - Bi J -AD - Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, - Huazhong University of Science and Technology, Wuhan, China. -FAU - Chen, Qian -AU - Chen Q -AD - Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, - Huazhong University of Science and Technology, Wuhan, China. -FAU - Pi, Guoliang -AU - Pi G -AD - Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, - Huazhong University of Science and Technology, Wuhan, China. -FAU - Li, Ying -AU - Li Y -AD - Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, - Huazhong University of Science and Technology, Wuhan, China. -FAU - Peng, Yi -AU - Peng Y -AD - Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, - Huazhong University of Science and Technology, Wuhan, China. -FAU - Zeng, Fanyu -AU - Zeng F -AD - Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, - Huazhong University of Science and Technology, Wuhan, China. -FAU - Xiao, Chuangying -AU - Xiao C -AD - Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, - Huazhong University of Science and Technology, Wuhan, China. -FAU - Han, Guang -AU - Han G -AD - Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, - Huazhong University of Science and Technology, Wuhan, China. Electronic address: - hg7913@hotmail.com. -LA - eng -PT - Journal Article -DEP - 20240727 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -SB - IM -OTO - NOTNLM -OT - Elderly cancer patients -OT - NSCLC -OT - Serplulimab -OT - Single-drug chemotherapy -OT - StageⅣ -COIS- Disclosure All authors declare that conflicts of interest do not exist. -EDAT- 2024/08/31 09:44 -MHDA- 2024/08/31 09:44 -CRDT- 2024/08/28 22:02 -PHST- 2024/05/04 00:00 [received] -PHST- 2024/07/08 00:00 [revised] -PHST- 2024/07/08 00:00 [accepted] -PHST- 2024/08/31 09:44 [medline] -PHST- 2024/08/31 09:44 [pubmed] -PHST- 2024/08/28 22:02 [entrez] -AID - S1525-7304(24)00144-X [pii] -AID - 10.1016/j.cllc.2024.07.005 [doi] -PST - aheadofprint -SO - Clin Lung Cancer. 2024 Jul 27:S1525-7304(24)00144-X. doi: - 10.1016/j.cllc.2024.07.005. - -PMID- 33747966 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220421 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 11 -DP - 2021 -TI - Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to - Immunotherapy in Advanced Non-Small Cell Lung Cancer. -PG - 642883 -LID - 10.3389/fonc.2021.642883 [doi] -LID - 642883 -AB - INTRODUCTION: Immune checkpoint inhibitors (ICIs) have changed the management of - non-small cell lung cancer (NSCLC). However, resistance is inevitable. The - disease progression patterns, sequential treatment, and prognosis beyond ICI - resistance are not completely understood. METHODS: We retrospectively analyzed - stage IV NSCLC patients who underwent ICI treatment at Zhejiang Cancer Hospital - between January 2016 and January 2020 and who suffered disease progression after - at least stable disease on immunotherapy for more than 3 months (at least two - cycles). Oligoprogression and systematic progression were defined as previous - reports. The main outcome measures were progression-free survival (PFS), second - PFS (PFS2), and overall survival (OS). Survival curves were plotted using the - Kaplan-Meier method. The Cox proportional hazards model was used for multivariate - analysis. RESULTS: Totally 1,014 NSCLC patients were administered immunotherapy. - Of them, 208 NSCLC patients were included in this retrospective study. The - estimated PFS, PFS2 and OS were 6.3 months (95% CI 5.6-7.0 months), 10.7 months - (95% CI 10.1-12.7 months), and 21.4 months (95% CI 20.6-26.4 months), - respectively. After resistance, 55.3% (N = 115) patients developed - oligoprogression, and 44.7% (N = 93) systemic progression. For patients with - systemic progression, chemotherapy (N = 35, 37.6%), best supportive care (N = 30, - 32.3%), and antiangiogenic therapy alone (N = 11, 11.8%) were the major - strategies. A combination of local radiotherapy (N = 38, 33.0%) with continued - ICIs was the most common treatment used in oligoprogression group, followed by - continued immunotherapy with antiangiogenic therapy (N = 19, 16.5%) and local - radiotherapy only (N = 17, 14.9%). For patients with oligoprogression, continued - immunotherapy plus local radiotherapy can lead to a significantly longer PFS2 - (12.9 vs. 10.0 months; p = 0.006) and OS (26.3 vs. 18.5 months, p = 0.001). The - PFS2 and OS of patients with oligoprogression were superior to those of patients - with systemic progression (PFS2: 13.1 vs. 10.0 months, p = 0.001; OS: 25.8 vs. - 19.1 months, p = 0.003). CONCLUSIONS: The major progression pattern after - acquired resistance from immunotherapy is oligoprogression. Local radiotherapy - with continued immunotherapy beyond oligoprogression in responders was feasible - and led to prolonged PFS2 and OS in advanced NSCLC patients. -CI - Copyright © 2021 Xu, Li and Fan. -FAU - Xu, Yanjun -AU - Xu Y -AD - Department of Medical Thoracic Oncology, Cancer Hospital of University of Chinese - Academy of Sciences, Zhejiang Cancer Hospital, Institute of Cancer Research and - Basic Medical Sciences of Chinese Academy of Sciences, Hangzhou, China. -FAU - Li, Hui -AU - Li H -AD - Department of Medical Thoracic Oncology, Cancer Hospital of University of Chinese - Academy of Sciences, Zhejiang Cancer Hospital, Institute of Cancer Research and - Basic Medical Sciences of Chinese Academy of Sciences, Hangzhou, China. -FAU - Fan, Yun -AU - Fan Y -AD - Department of Medical Thoracic Oncology, Cancer Hospital of University of Chinese - Academy of Sciences, Zhejiang Cancer Hospital, Institute of Cancer Research and - Basic Medical Sciences of Chinese Academy of Sciences, Hangzhou, China. -LA - eng -PT - Journal Article -DEP - 20210305 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC7973268 -OTO - NOTNLM -OT - immunotherapy -OT - local radiotherapy -OT - non-small cell lung cancer -OT - oligoprogression -OT - treatment beyond progression -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2021/03/23 06:00 -MHDA- 2021/03/23 06:01 -PMCR- 2021/01/01 -CRDT- 2021/03/22 08:20 -PHST- 2020/12/16 00:00 [received] -PHST- 2021/01/19 00:00 [accepted] -PHST- 2021/03/22 08:20 [entrez] -PHST- 2021/03/23 06:00 [pubmed] -PHST- 2021/03/23 06:01 [medline] -PHST- 2021/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2021.642883 [doi] -PST - epublish -SO - Front Oncol. 2021 Mar 5;11:642883. doi: 10.3389/fonc.2021.642883. eCollection - 2021. - -PMID- 35832447 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20221117 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 11 -IP - 6 -DP - 2022 Jun -TI - Efficacy and safety of camrelizumab plus apatinib in previously treated patients - with advanced non-small cell lung cancer harboring EGFR or ALK genetic - aberration. -PG - 964-974 -LID - 10.21037/tlcr-22-22 [doi] -AB - BACKGROUND: Camrelizumab plus apatinib shows encouraging antitumor activity and - acceptable toxicity in chemotherapy-pretreated patients with advanced non-small - cell lung cancer (NSCLC); however, clinical benefits from this combination - regimen in NSCLC patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) - have not been reported. We assessed the efficacy and safety of this combined - regimen in pretreated patients with advanced NSCLC and defined EGFR/ALK status - (EGFR+/ALK+) in a phase 1b/2 trial. METHODS: Previously treated patients with - advanced EGFR+/ALK+ NSCLC were enrolled and given camrelizumab 200 mg - intravenously every 2 weeks plus apatinib at the recommended dose of 250 mg - orally once daily. Patients harboring sensitive EGFR mutations or ALK fusion - genes had received at least one EGFR/ALK TKI and a platinum-based chemotherapy - regimen before the enrollment. The primary endpoint was objective response rate - (ORR). RESULTS: All 43 enrolled patients comprised the efficacy and safety - analysis population. The confirmed ORR was 18.6% (95% CI: 8.4-33.4%) and the - clinical benefit response rate was 27.9% (95% CI: 15.3-43.7%). Median - progression-free survival (PFS) was 2.8 months (95% CI: 1.9-5.5 months) and - median overall survival was not reached (95% CI: 7.3 months-not reached), with a - median follow-up period of 15.7 months (range, 0.5-24.4 months). The most common - grade ≥3 treatment-related adverse events (TRAEs) were hypertension (16.3%), - proteinuria (11.6%) and palmar-plantar erythrodysaesthesia syndrome (9.3%). No - unexpected adverse events were recorded. CONCLUSIONS: Camrelizumab plus apatinib - showed moderate antitumor activity and acceptable safety profile in previously - treated patients with advanced NSCLC and EGFR or ALK genetic aberrations, which - warranted further validation. TRIAL REGISTRATION: ClinicalTrials.gov identifier: - NCT03083041. Registered March 17, 2017. -CI - 2022 Translational Lung Cancer Research. All rights reserved. -FAU - Gao, Guanghui -AU - Gao G -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, - Shanghai, China. -FAU - Ni, Jian -AU - Ni J -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, - Shanghai, China. -FAU - Wang, Yina -AU - Wang Y -AD - Department of Oncology, The First Affiliated Hospital Zhejiang University, - Hangzhou, China. -FAU - Ren, Shengxiang -AU - Ren S -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, - Shanghai, China. -FAU - Liu, Zhihua -AU - Liu Z -AD - Thoracic Tumor Radiotherapy Department, Jiangxi Cancer Hospital, Nanchang, China. -FAU - Chen, Gongyan -AU - Chen G -AD - Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, China. -FAU - Gu, Kangsheng -AU - Gu K -AD - Department of Oncology, The First Affiliated Hospital of Anhui Medical - University, Hefei, China. -FAU - Zang, Aimin -AU - Zang A -AD - Department of Oncology, Affiliated Hospital of Hebei University, Hebei, China. -FAU - Zhao, Jun -AU - Zhao J -AD - Department of Oncology, Beijing Cancer Hospital, Beijing, China. -FAU - Guo, Renhua -AU - Guo R -AD - Department of Oncology, Jiangsu Province Hospital, Nanjing, China. -FAU - He, Jianxing -AU - He J -AD - Thoracic Surgery Department, The First Affiliated Hospital of Guangzhou Medical - University, Guangzhou, China. -FAU - Lin, Xiaoyan -AU - Lin X -AD - Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, China. -FAU - Pan, Yueyin -AU - Pan Y -AD - Department of Medical Oncology, The First Affiliated Hospital of USTC, Anhui - Provincial Hospital, Hefei, China. -FAU - Ma, Zhiyong -AU - Ma Z -AD - Department of Oncology, Henan Cancer Hospital, Zhengzhou, China. -FAU - Wang, Zhehai -AU - Wang Z -AD - Department of Oncology, Shandong Cancer Hospital, Jinan, China. -FAU - Fan, Min -AU - Fan M -AD - Radiation Oncology Center, Fudan University Shanghai Cancer Center, Shanghai, - China. -FAU - Liu, Yunpeng -AU - Liu Y -AD - Department of Medical Oncology, The First Hospital of China Medical University, - Shenyang, China. -FAU - Cang, Shundong -AU - Cang S -AD - Department of Oncology, Henan Provincial People's Hospital, Zhengzhou, China. -FAU - Yang, Xinfeng -AU - Yang X -AD - Department of Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals - Co., Ltd., Shanghai, China. -FAU - Li, Weixia -AU - Li W -AD - Department of Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals - Co., Ltd., Shanghai, China. -FAU - Wang, Quanren -AU - Wang Q -AD - Department of Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals - Co., Ltd., Shanghai, China. -FAU - Zhou, Caicun -AU - Zhou C -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, - Shanghai, China. -LA - eng -SI - ClinicalTrials.gov/NCT03083041 -PT - Journal Article -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -CIN - Transl Lung Cancer Res. 2022 Sep;11(9):1734-1738. doi: 10.21037/tlcr-22-492. - PMID: 36248330 -CIN - Transl Lung Cancer Res. 2022 Oct;11(10):2164-2166. doi: 10.21037/tlcr-22-522. - PMID: 36386458 -PMC - PMC9271438 -OTO - NOTNLM -OT - Apatinib -OT - Camrelizumab -OT - PD-L1 expression -OT - immunotherapy -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-22/coif). All authors - report that this study was funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd. - QW, WL, and XY were employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. CZ - serves as an unpaid editorial board member of Translational Lung Cancer Research - from August 2020 to July 2022. The authors have no other conflicts of interest to - declare. -EDAT- 2022/07/15 06:00 -MHDA- 2022/07/15 06:01 -PMCR- 2022/06/01 -CRDT- 2022/07/14 02:22 -PHST- 2022/01/10 00:00 [received] -PHST- 2022/05/18 00:00 [accepted] -PHST- 2022/07/14 02:22 [entrez] -PHST- 2022/07/15 06:00 [pubmed] -PHST- 2022/07/15 06:01 [medline] -PHST- 2022/06/01 00:00 [pmc-release] -AID - tlcr-11-06-964 [pii] -AID - 10.21037/tlcr-22-22 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2022 Jun;11(6):964-974. doi: 10.21037/tlcr-22-22. - -PMID- 32676337 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20200928 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 9 -IP - 3 -DP - 2020 Jun -TI - Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in - non-small cell lung cancer. -PG - 761-767 -LID - 10.21037/tlcr-20-539 [doi] -AB - Immunotherapy is one of the most effective treatments for patients with advanced - lung cancer. In many advanced non-small cell lung cancer (NSCLC) cases, the tumor - is centrally located. For such patients, sleeve lobectomy has been considered as - a more effective therapeutic option compared with pneumonectomy, achieving better - long-term survival and quality of life with no increase in morbidity or - mortality. Until now, there have been no studies regarding the efficacy and - safety of neo-adjuvant chemo-immunotherapy prior to sleeve lobectomy for lung - cancer. From January 2019 through October 2019, nine patients were diagnosed as - NSCLC and evaluated to undergo sleeve lobectomy surgery (SLS). Of these patients, - four received two cycles of pembrolizumab plus paclitaxel and cisplatin (PPC) - followed by sleeve lobectomy, while five patients underwent SLS alone. The - patients' clinical characteristics, perioperative parameters, and postoperative - outcomes were analyzed. Multiplex fluorescent immunohistochemistry was performed - to determine the number of macrophages, CD4+ and CD8 T cells, and Treg cells in - the bronchial mucosa. Three of the four patients achieved a complete pathological - response [0% viable tumor, pathologic complete response (pCR)]. All of the - patients in the PPC group achieved major pathological response (≤10% viable - tumor, MPR). No grade 3 or 4 treatment-related adverse events occurred in the PPC - group, nor did any of the patients in the group experience treatment-related - surgical delays. The mean surgical time and the number of lymph nodes dissected - were the same in the two groups. The PPC group had a higher number of CD8 + T - cells compared to the SLS group (P<0.01). No postoperative chylothorax, - pneumonia, or other postoperative complications occurred in either group. The - surgical difficulty and post-surgical complication rate of sleeve lobectomy with - neo-adjuvant chemo-immunotherapy were similar to those of SLS alone. Neo-adjuvant - chemo-immunotherapy is effective and safe with sleeve lobectomy for NSCLC - patients. Additional prospective multi-center randomized studies using larger - patient cohorts are necessary to validate our findings. -CI - 2020 Translational Lung Cancer Research. All rights reserved. -FAU - Chen, Yulong -AU - Chen Y -AD - Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University - Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key - Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center - for Cancer, Tianjin 300060, China. -FAU - Zhang, Lianmin -AU - Zhang L -AD - Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University - Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key - Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center - for Cancer, Tianjin 300060, China. -FAU - Yan, Bo -AU - Yan B -AD - Department of Radiotherapy, National Clinical Research Center of Cancer, Tianjin - Medical University Cancer Institute and Hospital, Tianjin 300060, China. -FAU - Zeng, Ziqing -AU - Zeng Z -AD - Immunology Lab, National Clinical Research Center of Cancer, National Clinical - Research Center of Cancer, Tianjin Medical University Cancer Institute and - Hospital, Tianjin 300060, China. -FAU - Hui, Zhenzhen -AU - Hui Z -AD - Immunology Lab, National Clinical Research Center of Cancer, National Clinical - Research Center of Cancer, Tianjin Medical University Cancer Institute and - Hospital, Tianjin 300060, China. -FAU - Zhang, Ran -AU - Zhang R -AD - Department of Minimally Invasive Surgery, Taishan Cancer Hospital, Tianjin - 300308, China. -FAU - Ren, Xiubao -AU - Ren X -AD - Immunology Lab, National Clinical Research Center of Cancer, National Clinical - Research Center of Cancer, Tianjin Medical University Cancer Institute and - Hospital, Tianjin 300060, China. -FAU - You, Jian -AU - You J -AD - Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University - Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key - Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center - for Cancer, Tianjin 300060, China. -LA - eng -PT - Journal Article -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -PMC - PMC7354158 -OTO - NOTNLM -OT - Neo-adjuvant chemo-immunotherapy -OT - non-small cell lung cancer (NSCLC) -OT - sleeve lobectomy -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at http://dx.doi.org/10.21037/tlcr-20-539). The authors have no - conflicts of interest to declare. -EDAT- 2020/07/18 06:00 -MHDA- 2020/07/18 06:01 -PMCR- 2020/06/01 -CRDT- 2020/07/18 06:00 -PHST- 2020/07/18 06:00 [entrez] -PHST- 2020/07/18 06:00 [pubmed] -PHST- 2020/07/18 06:01 [medline] -PHST- 2020/06/01 00:00 [pmc-release] -AID - tlcr-09-03-761 [pii] -AID - 10.21037/tlcr-20-539 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2020 Jun;9(3):761-767. doi: 10.21037/tlcr-20-539. - -PMID- 29124039 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20200930 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 7 -DP - 2017 -TI - Surgical Management of Stage IIIA Non-Small Cell Lung Cancer. -PG - 249 -LID - 10.3389/fonc.2017.00249 [doi] -LID - 249 -AB - According to the eighth edition of the tumor-node-metastasis classification, - stage III non-small cell lung cancer is subdivided into stages IIIA, IIIB, and - IIIC. They represent a heterogeneous group of bronchogenic carcinomas with - locoregional involvement by extension of the primary tumor and/or ipsilateral or - contralateral lymph node involvement. Surgical indications have not been - definitely established but, in general, long-term survival is only obtained in - those patients in whom a complete resection is obtained. This mini-review mainly - focusses on stage IIIA disease comprising patients with locoregionally advanced - lung cancers. Different subcategories of N2 involvement exist, which range from - unexpected N2 disease after thorough preoperative staging or "surprise" N2, to - bulky N2 involvement, mostly treated by chemoradiation, and finally, the - intermediate category of potentially resectable N2 disease treated with a - combined modality regimen. After induction therapy for preoperative N2 - involvement, best surgical results are obtained with proven mediastinal - downstaging when a lobectomy is feasible to obtain a microscopic complete - resection. However, no definite, universally accepted guidelines exist. A - relatively new entity is salvage surgery applied for recurrent disease after - full-dose chemoradiation when no other therapeutic options exist. Equally, only a - small subset of patients with T4N0-1 disease qualify for surgical resection after - thorough discussion within a multidisciplinary tumor board on the condition that - a complete resection is feasible. Targeted therapies and immunotherapy have - recently become part of our therapeutic armamentarium, and it might be expected - that they will be incorporated in current regimens after careful evaluation in - randomized clinical trials. -FAU - Van Schil, Paul E -AU - Van Schil PE -AD - Department of Thoracic and Vascular Surgery, Antwerp University Hospital and - Antwerp University, Antwerp, Belgium. -FAU - Berzenji, Lawek -AU - Berzenji L -AD - Department of Thoracic and Vascular Surgery, Antwerp University Hospital and - Antwerp University, Antwerp, Belgium. -FAU - Yogeswaran, Suresh K -AU - Yogeswaran SK -AD - Department of Thoracic and Vascular Surgery, Antwerp University Hospital and - Antwerp University, Antwerp, Belgium. -FAU - Hendriks, Jeroen M -AU - Hendriks JM -AD - Department of Thoracic and Vascular Surgery, Antwerp University Hospital and - Antwerp University, Antwerp, Belgium. -FAU - Lauwers, Patrick -AU - Lauwers P -AD - Department of Thoracic and Vascular Surgery, Antwerp University Hospital and - Antwerp University, Antwerp, Belgium. -LA - eng -PT - Journal Article -PT - Review -DEP - 20171026 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC5662551 -OTO - NOTNLM -OT - chemotherapy -OT - induction therapy -OT - lung cancer -OT - multimodality therapy -OT - radiotherapy -OT - stage III -OT - surgery -OT - treatment -EDAT- 2017/11/11 06:00 -MHDA- 2017/11/11 06:01 -PMCR- 2017/01/01 -CRDT- 2017/11/11 06:00 -PHST- 2017/07/27 00:00 [received] -PHST- 2017/10/06 00:00 [accepted] -PHST- 2017/11/11 06:00 [entrez] -PHST- 2017/11/11 06:00 [pubmed] -PHST- 2017/11/11 06:01 [medline] -PHST- 2017/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2017.00249 [doi] -PST - epublish -SO - Front Oncol. 2017 Oct 26;7:249. doi: 10.3389/fonc.2017.00249. eCollection 2017. - -PMID- 33569335 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240909 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 10 -IP - 1 -DP - 2021 Jan -TI - Induction treatment in patients with stage III non-small cell lung cancer. -PG - 539-554 -LID - 10.21037/tlcr-20-420 [doi] -AB - Stage III non-small cell lung cancer (NSCLC) comprises a highly heterogeneous - group of patients defined according to the extent and localization of disease. - Patients with discrete N2 involvement identified preoperatively with resectable - disease are candidates for multimodal therapy either with definitive - chemoradiation therapy, induction chemotherapy, or chemoradiotherapy (CTRT) - followed by surgery. Neoadjuvant chemotherapy has yielded comparable survival - benefit to adjuvant chemotherapy in patients with stage II-III disease and may - allow for downstaging the tumor or the lymph nodes, an earlier delivery of - systemic treatment, and better compliance to systemic therapy. The use of immune - checkpoint inhibitors (ICIs) as induction therapy shows encouraging activity and - a favorable safety profile in patients with resectable early stage or locally - advanced NSCLC. An unprecedented rate of pathological response and downstaging - has been reported in single-arm clinical trials, especially when immunotherapy is - combined with neoadjuvant chemotherapy. Ongoing randomized phase II/III clinical - trials assessing the efficacy and safety of induction with immunotherapy plus - chemotherapy have the potential to establish this therapeutic approach as a novel - standard of care. These trials aim to validate pathological response as a - surrogate marker of survival benefit and to demonstrate that this therapeutic - strategy can improve the cure rate in patients with stage II-III NSCLC. -CI - 2021 Translational Lung Cancer Research. All rights reserved. -FAU - Palmero, Ramón -AU - Palmero R -AD - Department of Medical Oncology, Catalan Institute of Oncology, Barcelona, Spain. -AD - Clinical Research in Solid Tumors (CReST) Group, Oncobell Program, Bellvitge - Biomedical Research Institute (IDIBELL), Barcelona, Spain. -FAU - Vilariño, Noelia -AU - Vilariño N -AD - Department of Medical Oncology, Catalan Institute of Oncology, Barcelona, Spain. -AD - Clinical Research in Solid Tumors (CReST) Group, Oncobell Program, Bellvitge - Biomedical Research Institute (IDIBELL), Barcelona, Spain. -FAU - Navarro-Martín, Arturo -AU - Navarro-Martín A -AD - Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, - Spain. -FAU - Nadal, Ernest -AU - Nadal E -AD - Department of Medical Oncology, Catalan Institute of Oncology, Barcelona, Spain. -AD - Clinical Research in Solid Tumors (CReST) Group, Oncobell Program, Bellvitge - Biomedical Research Institute (IDIBELL), Barcelona, Spain. -LA - eng -PT - Journal Article -PT - Review -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -PMC - PMC7867786 -OTO - NOTNLM -OT - Locally advanced non-small cell lung cancer (locally advanced NSCLC) -OT - induction therapy -OT - neoadjuvant treatment -OT - resectable disease -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at http://dx.doi.org/10.21037/tlcr-20-420). The series - “Multimodal management of locally advanced N2 non-small cell lung cancer” was - commissioned by the editorial office without any funding or sponsorship. EN - participated in advisory boards from Bristol Myers Squibb, Merck Sharpe & Dohme, - Lilly, Roche, Pfizer, Takeda, Boehringer Ingelheim, Amgen and AstraZeneca; EN has - participated as investigator of the NADIM, NADIM-II and Keynote-671 clinical - trials and has received research funding from Roche and Pfizer. RP participated - in advisory boards from Bristol Myers Squibb, Merck Sharpe & Dohme, Lilly, Roche, - Pfizer, Boehringer Ingelheim and AstraZeneca. NV reports personal fees and - non-financial support from Roche, personal fees and non-financial support from - Boehringer Ingelheim, personal fees from Bristol Mayers Squibb, personal fees and - non-financial support from Pfizer, personal fees and non-financial support from - Lilly, outside the submitted work. The authors have no other conflicts of - interest to declare. -EDAT- 2021/02/12 06:00 -MHDA- 2021/02/12 06:01 -PMCR- 2021/01/01 -CRDT- 2021/02/11 05:54 -PHST- 2021/02/11 05:54 [entrez] -PHST- 2021/02/12 06:00 [pubmed] -PHST- 2021/02/12 06:01 [medline] -PHST- 2021/01/01 00:00 [pmc-release] -AID - tlcr-10-01-539 [pii] -AID - 10.21037/tlcr-20-420 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2021 Jan;10(1):539-554. doi: 10.21037/tlcr-20-420. - -PMID- 37238201 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230530 -IS - 2075-4418 (Print) -IS - 2075-4418 (Electronic) -IS - 2075-4418 (Linking) -VI - 13 -IP - 10 -DP - 2023 May 12 -TI - CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT - Trial. -LID - 10.3390/diagnostics13101717 [doi] -LID - 1717 -AB - BACKGROUND: Non-small-cell lung cancer (NSCLC) is a common, steady growing lung - tumour that is often discovered when a surgical approach is forbidden. For - locally advanced inoperable NSCLC, the clinical approach consists of a - combination of chemotherapy and radiotherapy, eventually followed by adjuvant - immunotherapy, a treatment that is useful but may cause several mild and severe - adverse effect. Chest radiotherapy, specifically, may affect the heart and - coronary artery, impairing heart function and causing pathologic changes in - myocardial tissues. The aim of this study is to evaluate the damage coming from - these therapies with the aid of cardiac imaging. METHODS: This is a - single-centre, prospective clinical trial. Patients with NSCLC who are enrolled - will undergo computed tomography (CT) and magnetic resonance imaging (MRI) before - chemotherapy 3 months, 6 months, and 9-12 months after the treatment. We expect - to enrol 30 patients in 2 years. CONCLUSIONS: Our clinical trial will be an - opportunity not only to highlight the timing and the radiation dose needed for - pathological cardiac tissue changes to happen but will also provide useful data - to set new follow-up schedules and strategies, keeping in mind that, more often - than not, patients affected by NSCLC may present other heart- and lung-related - pathological conditions. -FAU - Nardone, Valerio -AU - Nardone V -AUID- ORCID: 0000-0002-7347-0965 -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - Belfiore, Maria Paola -AU - Belfiore MP -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - De Chiara, Marco -AU - De Chiara M -AUID- ORCID: 0000-0002-1927-9131 -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - De Marco, Giuseppina -AU - De Marco G -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - Patanè, Vittorio -AU - Patanè V -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - Balestrucci, Giovanni -AU - Balestrucci G -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - Buono, Mauro -AU - Buono M -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - Salvarezza, Maria -AU - Salvarezza M -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - Di Guida, Gaetano -AU - Di Guida G -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - D'Angiolella, Domenico -AU - D'Angiolella D -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - Grassi, Roberta -AU - Grassi R -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - D'Onofrio, Ida -AU - D'Onofrio I -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -AD - Radiotherapy Unit, Ospedale del Mare, ASL Napoli 1 Centro, 80138 Naples, Italy. -FAU - Cimmino, Giovanni -AU - Cimmino G -AUID- ORCID: 0000-0002-3802-7052 -AD - Department of Translational Medical Science, University of Campania "L. - Vanvitelli", 80138 Naples, Italy. -FAU - Della Corte, Carminia Maria -AU - Della Corte CM -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - Gambardella, Antonio -AU - Gambardella A -AUID- ORCID: 0000-0002-4125-0618 -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - Morgillo, Floriana -AU - Morgillo F -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - Ciardiello, Fortunato -AU - Ciardiello F -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - Reginelli, Alfonso -AU - Reginelli A -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -FAU - Cappabianca, Salvatore -AU - Cappabianca S -AD - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 - Naples, Italy. -LA - eng -PT - Journal Article -DEP - 20230512 -PL - Switzerland -TA - Diagnostics (Basel) -JT - Diagnostics (Basel, Switzerland) -JID - 101658402 -PMC - PMC10217672 -OTO - NOTNLM -OT - NSCLC -OT - cardiac CT -OT - cardiac MRI -OT - radiotherapy -OT - thoracic imaging -COIS- The authors declare no conflict of interest. The funders had no role in the - design of the study; in the collection, analyses, or interpretation of data; in - the writing of the manuscript; or in the decision to publish the results. -EDAT- 2023/05/27 09:42 -MHDA- 2023/05/27 09:43 -PMCR- 2023/05/12 -CRDT- 2023/05/27 01:04 -PHST- 2023/03/13 00:00 [received] -PHST- 2023/04/06 00:00 [revised] -PHST- 2023/04/12 00:00 [accepted] -PHST- 2023/05/27 09:43 [medline] -PHST- 2023/05/27 09:42 [pubmed] -PHST- 2023/05/27 01:04 [entrez] -PHST- 2023/05/12 00:00 [pmc-release] -AID - diagnostics13101717 [pii] -AID - diagnostics-13-01717 [pii] -AID - 10.3390/diagnostics13101717 [doi] -PST - epublish -SO - Diagnostics (Basel). 2023 May 12;13(10):1717. doi: 10.3390/diagnostics13101717. - -PMID- 37727216 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230921 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 13 -DP - 2023 -TI - Current status of clinical trial research and application of immune checkpoint - inhibitors for non-small cell lung cancer. -PG - 1213297 -LID - 10.3389/fonc.2023.1213297 [doi] -LID - 1213297 -AB - Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung - cancer (NSCLC) with remarkable success. Compared to chemotherapy patients, the - 5-year survival rate for immunotherapy patients is 3-fold higher, approximately - 4%-5% versus 15%-16%, respectively. Immunotherapies include chimeric antigen - receptor T-cell (CAR-T) therapy, tumor vaccines, immune checkpoint inhibitors, - and so forth. Among them, immune checkpoint inhibitors are in the spotlight. - Common immune checkpoint inhibitors (ICIs) currently in clinical use include - programmed death receptor-1(PD-1)/programmed death ligand-1(PD-L1) and cytotoxic - T lymphocyte-associated antigen 4(CTLA-4). This article focuses on monotherapy - and combination therapy of CTLA-4 and PD-1/PD-L1 immune checkpoint inhibitors. In - particular, the combination therapy of ICIs includes the combination of ICIs and - chemotherapy, the combination therapy of dual ICIs, the combination of ICIs and - anti-angiogenic drugs, the combination of ICIs and radiotherapy, and the - combination of ICIs inhibitors and tumor vaccines and so forth. This article - focuses on the combination therapy of ICIs with chemotherapy, the combination - therapy of dual ICIs, and the combination therapy of ICIs with anti-angiogenic - drugs. The efficacy and safety of ICIs as single agents in NSCLC have been - demonstrated in many trials. However, ICIs plus chemotherapy regimens offer - significant advantages in the treatment of NSCLC with little to no dramatic - increase in toxicity, while combined dual ICIs significantly reduce the adverse - effects (AEs) of chemotherapy. ICIs plus anti-angiogenic agents regimen improves - anti-tumor activity and safety and is expected to be the new paradigm for the - treatment of advanced NSCLC. Despite some limitations, these agents have achieved - better overall survival rates. In this article, we review the current status and - progress of research on ICIs in NSCLC in recent years, aiming to better guide the - individualized treatment of NSCLC patients. -CI - Copyright © 2023 Wang, Xia, Li, Gao and Fang. -FAU - Wang, Fuli -AU - Wang F -AD - Department of Oncology, Lianyungang Clinical College Affiliated to Bengbu Medical - College, Lianyungang, China. -AD - Department of Oncology, Gaochun Hospital Afliated to Jiangsu University, Nanjing, - China. -FAU - Xia, Teng -AU - Xia T -AD - Department of Oncology, Gaochun Hospital Afliated to Jiangsu University, Nanjing, - China. -FAU - Li, Zhiqiang -AU - Li Z -AD - Department of Oncology, Lianyungang Clinical College Affiliated to Bengbu Medical - College, Lianyungang, China. -FAU - Gao, Xuzhu -AU - Gao X -AD - Department of Oncology, Lianyungang Clinical College Affiliated to Bengbu Medical - College, Lianyungang, China. -AD - Department of Oncology, Gaochun Hospital Afliated to Jiangsu University, Nanjing, - China. -FAU - Fang, Xinjian -AU - Fang X -AD - Department of Oncology, Lianyungang Clinical College Affiliated to Bengbu Medical - College, Lianyungang, China. -AD - Department of Oncology, Gaochun Hospital Afliated to Jiangsu University, Nanjing, - China. -LA - eng -PT - Journal Article -PT - Review -DEP - 20230901 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC10505960 -OTO - NOTNLM -OT - CTLA-4 -OT - PD-1 -OT - PD-L1 -OT - immune checkpoint inhibitors -OT - non-small cell lung cancer -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2023/09/20 06:42 -MHDA- 2023/09/20 06:43 -PMCR- 2023/01/01 -CRDT- 2023/09/20 03:45 -PHST- 2023/04/27 00:00 [received] -PHST- 2023/08/17 00:00 [accepted] -PHST- 2023/09/20 06:43 [medline] -PHST- 2023/09/20 06:42 [pubmed] -PHST- 2023/09/20 03:45 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2023.1213297 [doi] -PST - epublish -SO - Front Oncol. 2023 Sep 1;13:1213297. doi: 10.3389/fonc.2023.1213297. eCollection - 2023. - -PMID- 38737682 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240514 -IS - 2219-6803 (Electronic) -IS - 2218-676X (Print) -IS - 2218-676X (Linking) -VI - 13 -IP - 4 -DP - 2024 Apr 30 -TI - Advances in monotherapy and combination therapy of S-1 for patients with advanced - non-small cell lung cancer: a narrative review. -PG - 2012-2025 -LID - 10.21037/tcr-23-2019 [doi] -AB - BACKGROUND AND OBJECTIVE: Both domestically and worldwide, non-small cell lung - cancer (NSCLC) remain the leading cause of cancer-related death. As a - fluorouracil derivative, S-1 which shows good efficacy and with few adverse - effects have been widely confirmed in many solid tumors that it can provide a - glimmer of hope for advanced NSCLC patients. We performed a review to explore the - results of previous clinical studies of S-1 monotherapy as well as combined - therapy involving S-1 in patients with advanced NSCLC. METHODS: A literature - search was conducted in Medline and PubMed databases using the keywords "S-1" AND - "Advanced lung cancer" OR "Pharmacological mechanism". KEY CONTENT AND FINDINGS: - A number of phase II clinical studies have reported on the favorable efficacy and - excellent safety profiles of S-1 monotherapy in first-line or in posterior-line - treatment for advanced NSCLC. In regard to S-1 in combination with chemotherapy, - a number of phase II/III clinical studies have found the objective response rate - (ORR), progression-free survival (PFS), and overall survival (OS) of these - regimens are similar to or better than immunological monotherapy with fewer - adverse effects. In the case of S-1 combined with anti-vascular therapy, a number - of phase II single-arm clinical studies have found that S-1 combined with - bevacizumab, anlotinib and apatinib in advanced NSCLC, exhibits higher antitumor - activity, less adverse effects for patients with advanced NSCLC. A phase II - single-arm clinical study of gefitinib combined with S-1 had the ORR of 85.7% in - the first-line treatment of advanced NSCLC. As for the combination of S-1 and - immunotherapy, preliminary results of a phase II retrospective clinical trial - demonstrated that the ORR was significantly better with S-1 sequential after - immune checkpoint inhibitors (ICIs) than with S-1 alone. CONCLUSIONS: The - findings indicate promising effectiveness and minimal toxicity with S-1 - monotherapy and S-1 containing combined therapy in patients with advanced NSCLC - to provide a potential treatment option for advanced NSCLC. -CI - 2024 Translational Cancer Research. All rights reserved. -FAU - Cao, Feiyi -AU - Cao F -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of - Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. -AD - Department of Medical Oncology, Postgraduate training base Alliance of Wenzhou - Medical University (Zhejiang Cancer Hospital), Hangzhou, China. -FAU - Gu, Cuiping -AU - Gu C -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of - Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. -FAU - Hong, Wei -AU - Hong W -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of - Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. -FAU - Jin, Ying -AU - Jin Y -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of - Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. -AD - Zhejiang Key Laboratory of Radiation Oncology, Hangzhou, China. -LA - eng -PT - Journal Article -PT - Review -DEP - 20240409 -PL - China -TA - Transl Cancer Res -JT - Translational cancer research -JID - 101585958 -PMC - PMC11082661 -OTO - NOTNLM -OT - Chemotherapy -OT - S-1 -OT - immune checkpoint inhibitors (ICIs) -OT - non-small cell lung cancer (NSCLC) -OT - platinum combination -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://tcr.amegroups.com/article/view/10.21037/tcr-23-2019/coif). The authors - have no conflicts of interest to declare. -EDAT- 2024/05/13 06:42 -MHDA- 2024/05/13 06:43 -PMCR- 2024/04/30 -CRDT- 2024/05/13 04:19 -PHST- 2023/10/31 00:00 [received] -PHST- 2024/02/29 00:00 [accepted] -PHST- 2024/05/13 06:43 [medline] -PHST- 2024/05/13 06:42 [pubmed] -PHST- 2024/05/13 04:19 [entrez] -PHST- 2024/04/30 00:00 [pmc-release] -AID - tcr-13-04-2012 [pii] -AID - 10.21037/tcr-23-2019 [doi] -PST - ppublish -SO - Transl Cancer Res. 2024 Apr 30;13(4):2012-2025. doi: 10.21037/tcr-23-2019. Epub - 2024 Apr 9. - -PMID- 37711815 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240924 -IS - 2223-4292 (Print) -IS - 2223-4306 (Electronic) -IS - 2223-4306 (Linking) -VI - 13 -IP - 9 -DP - 2023 Sep 1 -TI - Drug-eluting beads bronchial arterial chemoembolization/bronchial arterial - infusion chemotherapy with and without PD-1 blockade for advanced non-small cell - lung cancer: a comparative single-center cohort study. -PG - 6241-6256 -LID - 10.21037/qims-23-287 [doi] -AB - BACKGROUND: Drug-eluting beads bronchial arterial chemoembolization - (DEB-BACE)/bronchial artery infusion chemotherapy (BAI) have been investigated as - treatment options for advanced non-small cell lung cancer (NSCLC), especially for - those patients who develop refractoriness to or are intolerant to systemic - chemotherapy. This retrospective study aimed to compare the outcomes of - DEB-BACE/BAI with and without programmed cell death protein 1 (PD-1) blockade for - advanced NSCLC, and to investigate the effectiveness and safety of combination - regimens. METHODS: This retrospective cohort study included advanced NSCLC - patients who were intolerant to or were resistant to systemic chemotherapy, - radiotherapy, or molecular targeted therapy and underwent DEB-BACE/BAI between - October 2016 and October 2021 in Beijing Hospital, National Center of - Gerontology. A total of 84 advanced NSCLC patients (DEB-BACE/BAI + PD-1 blockade - group: group A, n=27; DEB-BACE/BAI: group B, n=57) were enrolled finally. The - embolic agent CalliSpheres (100-300, 300-500, or 500-700 µm) loaded with - gemcitabine (800 mg) was administered during the DEB-BACE procedure. The adverse - events (AEs) and outcomes were compared. Of these, the median progression-free - survival (PFS) and overall survival (OS) were compared via Kaplan-Meier (KM) - methods. Univariate and multivariate Cox regression analyses were used to - investigate the predictors of PFS and OS. RESULTS: KM methods showed that group A - had longer median PFS (12.0 vs. 3.0 months, P<0.001) and OS (27.0 vs. 8.0 months, - P<0.001) than group B. The predictors of PFS for DEB-BACE/BAI included tumor - diameter (P=0.013), immunotherapy (P<0.001), and DEB-BACE/BAI cycles (P=0.012), - whereas the predictors of OS included tumor diameter (P=0.021), extrapulmonary - metastases (P=0.041), immunotherapy (P<0.001), and DEB-BACE/BAI cycles (P=0.020). - The incidence rates of overall AEs in groups A and B were 40.7% (11/27) and 36.8% - (21/57), respectively, and no significant difference was found (P=0.731). Group A - had an incidence rate of 11.1% for grade 3 immunotherapy-related AEs (irAEs). - There were no incidences of ectopic embolization or spinal artery injury. - CONCLUSIONS: Compared with DEB-BACE/BAI, PD-1 blockade plus DEB-BACE/BAI could - improve the prognosis for advanced NSCLC despite the associated risk of grade 3 - irAEs. The combination regimens are promising and safe approaches for advanced - NSCLC. -CI - 2023 Quantitative Imaging in Medicine and Surgery. All rights reserved. -FAU - Xu, Sheng -AU - Xu S -AD - Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, - National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy - of Medical Sciences, Beijing, China. -FAU - Li, Yuan-Ming -AU - Li YM -AD - Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, - National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy - of Medical Sciences, Beijing, China. -FAU - Bie, Zhi-Xin -AU - Bie ZX -AD - Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, - National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy - of Medical Sciences, Beijing, China. -FAU - Li, Xiao-Guang -AU - Li XG -AD - Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, - National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy - of Medical Sciences, Beijing, China. -AD - Graduate School of Peking Union Medical College, Chinese Academy of Medical - Sciences, Beijing, China. -LA - eng -PT - Journal Article -DEP - 20230810 -PL - China -TA - Quant Imaging Med Surg -JT - Quantitative imaging in medicine and surgery -JID - 101577942 -PMC - PMC10498207 -OTO - NOTNLM -OT - Non-small cell lung cancer (NSCLC) -OT - chemoembolization -OT - drug-eluting beads -OT - immunotherapy -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://qims.amegroups.com/article/view/10.21037/qims-23-287/coif). The authors - have no conflicts of interest to declare. -EDAT- 2023/09/15 06:43 -MHDA- 2023/09/15 06:44 -PMCR- 2023/09/01 -CRDT- 2023/09/15 03:58 -PHST- 2023/03/08 00:00 [received] -PHST- 2023/07/28 00:00 [accepted] -PHST- 2023/09/15 06:44 [medline] -PHST- 2023/09/15 06:43 [pubmed] -PHST- 2023/09/15 03:58 [entrez] -PHST- 2023/09/01 00:00 [pmc-release] -AID - qims-13-09-6241 [pii] -AID - 10.21037/qims-23-287 [doi] -PST - ppublish -SO - Quant Imaging Med Surg. 2023 Sep 1;13(9):6241-6256. doi: 10.21037/qims-23-287. - Epub 2023 Aug 10. - -PMID- 38496691 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240319 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 13 -IP - 2 -DP - 2024 Feb 29 -TI - Immunotherapy for advanced non-small cell lung cancer with negative programmed - death-ligand 1 expression: a literature review. -PG - 398-422 -LID - 10.21037/tlcr-23-144 [doi] -AB - BACKGROUND AND OBJECTIVE: Lung cancer, mainly non-small cell lung cancer (NSCLC), - is a serious threat to human life. In particular, the prognosis for advanced - patients is poor, with the 5-year survival rate being exceedingly low. In recent - years, immune checkpoint inhibition has changed the pattern of the treatment of a - variety of cancers, including lung cancer; however, not all patients can benefit - from immunotherapy, and thus finding the right biomarkers is particularly - important for guiding precise treatment. Programmed death-ligand 1 (PD-L1) - expression is one of the most valuable biomarkers for predicting the efficacy of - lung cancer immunotherapy. Several studies have confirmed that patients with high - PD-L1 expression are more likely to benefit from immunotherapy, but there is a - high proportion of people with negative PD-L1 expression constituting a patient - population that cannot be ignored. This article reviews the distribution of PD-L1 - expression, the methods for evaluating PD-L1, and the effectiveness of - immunotherapy for advanced NSCLC with negative PD-L1 expression. METHODS: We - performed a literature review to identify relevant data published until September - 2022. In order to organize related information, we searched for literature in - PubMed; abstracts and reports published in the American Society of Clinical - Oncology (ASCO), the European Society for Medical Oncology (ESMO), the World - Conference on Lung Cancer (WCLC), and other congresses; and clinical trial - information registered on ClinicalTrials.gov. Information on the distribution of - PD-L1 expression, detection of PD-L1, and immunotherapy efficacy for NSCLC with - negative PD-L1 expression was collated and reviewed. KEY CONTENT AND FINDINGS: - The incidence of PD-L1 expression in patients with stage IIIB/IV NSCLC is similar - in all regions of the world, but PD-L1 expression level is associated with - certain clinicopathological features. The expression of PD-L1 can be evaluated by - various detecting methods. Some immunotherapy regimens have better efficacy than - traditional chemotherapy in patients with negative PD-L1 expression. CONCLUSIONS: - Patients with NSCLC and negative PD-L1 expression can receive better survival - benefits under some immunotherapy types, and these may represent a better - treatment option for this relatively small patient population. -CI - 2024 Translational Lung Cancer Research. All rights reserved. -FAU - Bai, Yibing -AU - Bai Y -AD - Medical School of Chinese PLA, Beijing, China. -AD - Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, - Beijing, China. -FAU - Yang, Wenyu -AU - Yang W -AD - Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, - Beijing, China. -AD - School of Medicine, Nankai University, Tianjin, China. -FAU - Käsmann, Lukas -AU - Käsmann L -AD - Department of Radiation Oncology, University Hospital, LMU Munich, Munich, - Germany. -AD - German Center for Lung Research (DZL), Partner Site Munich, Munich, Germany. -AD - German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. -FAU - Sorich, Michael J -AU - Sorich MJ -AD - College of Medicine and Public Health, Flinders University, Adelaide, Australia. -FAU - Tao, Haitao -AU - Tao H -AD - Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, - Beijing, China. -FAU - Hu, Yi -AU - Hu Y -AD - Medical School of Chinese PLA, Beijing, China. -AD - Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, - Beijing, China. -LA - eng -PT - Journal Article -PT - Review -DEP - 20240228 -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -PMC - PMC10938091 -OTO - NOTNLM -OT - Non-small cell lung cancer (NSCLC) -OT - biomarkers -OT - immune checkpoint inhibitor (ICI) -OT - immunotherapy -OT - negative programmed death-ligand 1 expression (negative PD-L1 expression) -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-144/coif). M.J.S. serves - as an unpaid editorial board member of Translational Lung Cancer Research from - October 2021 to September 2023. M.J.S. reports receiving grants from Pfizer - outside the submitted work. L.K. received honoraria from AMGEN outside of the - here mentioned review. The other authors have no conflicts of interest to - declare. -EDAT- 2024/03/18 06:42 -MHDA- 2024/03/18 06:43 -PMCR- 2024/02/29 -CRDT- 2024/03/18 04:41 -PHST- 2023/02/27 00:00 [received] -PHST- 2023/05/05 00:00 [accepted] -PHST- 2024/03/18 06:43 [medline] -PHST- 2024/03/18 06:42 [pubmed] -PHST- 2024/03/18 04:41 [entrez] -PHST- 2024/02/29 00:00 [pmc-release] -AID - tlcr-13-02-398 [pii] -AID - 10.21037/tlcr-23-144 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2024 Feb 29;13(2):398-422. doi: 10.21037/tlcr-23-144. - Epub 2024 Feb 28. - -PMID- 38249904 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240123 -IS - 2072-1439 (Print) -IS - 2077-6624 (Electronic) -IS - 2072-1439 (Linking) -VI - 15 -IP - 12 -DP - 2023 Dec 30 -TI - A real-world study of pneumonitis in non-small cell lung cancer patients - receiving durvalumab following concurrent chemoradiation. -PG - 6427-6435 -LID - 10.21037/jtd-22-1604 [doi] -AB - BACKGROUND: Locally advanced non-small cell lung cancer (LA-NSCLC) treated with - the programmed death-ligand 1 inhibitor durvalumab has been associated with - significant rates of pneumonitis, which has led to higher rates of - discontinuation of therapy in real-world populations. Thus far there has been no - consensus in the literature on the impact of pneumonitis on survival. METHODS: - This is a retrospective cohort study of veterans receiving durvalumab between - 12/5/2017 and 4/15/2020. Participants were identified using VINCI data services. - Patients were followed through 9/14/2021. Development of clinical pneumonitis was - assessed through review of documentation and graded using CTCAE 4.0 criteria. - Univariate logistic regression analysis evaluated for associations between body - mass index (BMI), age, race, co-morbidity index, chemotherapy regimen, chronic - obstructive pulmonary disease (COPD) severity, and development of clinical - pneumonitis. Progression-free survival (PFS) and overall survival (OS) were - evaluated using Kaplan-Meier methods. Cox proportional hazards models were - utilized to evaluate the association between risk of death at 1 and 2 years and - candidate predictor variables. RESULTS: A total of 284 patients were included in - this study. Sixty-one patients developed clinically significant pneumonitis, 7 - patients developed grade 5 pneumonitis (death from pneumonitis). The median OS in - patients that developed pneumonitis was 27.8 vs. 36.9 months in patients that did - not develop pneumonitis (P=0.22). BMI was found to be a clinical predictor of - pneumonitis (P=0.04). COPD severity, race, age at durvalumab start date, - chemotherapy regimen, and Romano comorbidity index were not significant - predictors of pneumonitis. Cox proportional hazards analysis failed to - demonstrate an association between the development of pneumonitis and risk of - death in this population. CONCLUSIONS: The incidence of clinically significant - pneumonitis is higher than noted in the PACIFIC trial in this cohort, however - this high rate of pneumonitis does not have an impact on OS or PFS. Obesity was - found to be a significant predictor of pneumonitis in this patient population. -CI - 2023 Journal of Thoracic Disease. All rights reserved. -FAU - Akkad, Neha -AU - Akkad N -AD - Washington University School of Medicine/Barnes Jewish Hospital, St. Louis, MO, - USA. -FAU - Thomas, Theodore S -AU - Thomas TS -AD - Washington University School of Medicine/Barnes Jewish Hospital, St. Louis, MO, - USA. -AD - St. Louis Veterans Health Administration Medical Center Research Service, St. - Louis, MO, USA. -FAU - Luo, Suhong -AU - Luo S -AD - Washington University School of Medicine/Barnes Jewish Hospital, St. Louis, MO, - USA. -FAU - Knoche, Eric -AU - Knoche E -AD - Washington University School of Medicine/Barnes Jewish Hospital, St. Louis, MO, - USA. -AD - St. Louis Veterans Health Administration Medical Center Research Service, St. - Louis, MO, USA. -FAU - Sanfilippo, Kristen M -AU - Sanfilippo KM -AD - Washington University School of Medicine/Barnes Jewish Hospital, St. Louis, MO, - USA. -AD - St. Louis Veterans Health Administration Medical Center Research Service, St. - Louis, MO, USA. -FAU - Keller, Jesse W -AU - Keller JW -AD - Washington University School of Medicine/Barnes Jewish Hospital, St. Louis, MO, - USA. -AD - St. Louis Veterans Health Administration Medical Center Research Service, St. - Louis, MO, USA. -LA - eng -PT - Journal Article -DEP - 20231123 -PL - China -TA - J Thorac Dis -JT - Journal of thoracic disease -JID - 101533916 -PMC - PMC10797388 -OTO - NOTNLM -OT - Checkpoint inhibitors -OT - chemoradiotherapy -OT - immunotherapy -OT - non-small cell lung cancer (NSCLC) -OT - toxicities -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://jtd.amegroups.com/article/view/10.21037/jtd-22-1604/coif). K.M.S. is an - Expert Case Review for Quinn Johnston, not related to the published work, - American Society of Hematology Junior Faculty Scholar Award, Research Funds Paid - to the institution, not related to the published work and a Consultant for Health - Services Advisory Group, not related to the published work. J.W.K.’s work is - supported by the Congressionally Directed Medical Research Program (Department of - Defense) Career Development Award #W81XWH-20-1-0785, CA191184 [2020–2023]. The - other authors have no conflicts of interest to declare. -EDAT- 2024/01/22 06:43 -MHDA- 2024/01/22 06:44 -PMCR- 2023/12/30 -CRDT- 2024/01/22 05:07 -PHST- 2023/01/31 00:00 [received] -PHST- 2023/10/11 00:00 [accepted] -PHST- 2024/01/22 06:44 [medline] -PHST- 2024/01/22 06:43 [pubmed] -PHST- 2024/01/22 05:07 [entrez] -PHST- 2023/12/30 00:00 [pmc-release] -AID - jtd-15-12-6427 [pii] -AID - 10.21037/jtd-22-1604 [doi] -PST - ppublish -SO - J Thorac Dis. 2023 Dec 30;15(12):6427-6435. doi: 10.21037/jtd-22-1604. Epub 2023 - Nov 23. - -PMID- 31737325 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220411 -IS - 2072-1439 (Print) -IS - 2077-6624 (Electronic) -IS - 2072-1439 (Linking) -VI - 11 -IP - 10 -DP - 2019 Oct -TI - Outcomes of patients with advanced non-small cell lung cancer and airway - obstruction treated with photodynamic therapy and non-photodynamic therapy - ablation modalities. -PG - 4389-4399 -LID - 10.21037/jtd.2019.04.60 [doi] -AB - BACKGROUND: Non-small cell lung cancer (NSCLC) patients with central airway - obstruction (CAO) may have better survival on systemic therapy if the airway - patency is successfully restored by bronchoscopic interventions. It remains - unclear which therapeutic bronchoscopic modality [laser, stenting, external beam - radiation, brachytherapy and photodynamic therapy (PDT)] used for restoring - airway patency positively affects outcomes in these patients. We analyzed the - effectiveness of PDT in terms of mortality, and time to subsequent treatments in - patients with stage III and IV NSCLC. METHODS: Study used Surveillance, - Epidemiology, and End Results (SEER) Medicare linked data. We categorized NSCLC - patients diagnosed between 2000 and 2011 and with stage III and IV, into three - treatment groups: PDT + radiation ± chemotherapy, non-PDT ablation therapy + - radiation ± chemotherapy, and radiation + chemotherapy. We analyzed all-cause and - cause-specific mortality using Cox proportional hazard models with an inverse - probability weighted propensity score adjustment. Time to subsequent treatment - was analyzed using GLM model. RESULTS: For the PDT group, hazard for all-cause - and cause-specific mortality was comparable to the radiation + chemotherapy group - (HR =1.03, 95% CI: 0.73-1.45; and HR =1.04, 95% CI: 0.71-1.51, respectively). The - non-PDT ablation group had higher hazard for all-cause (HR =1.22, 95% CI: - 1.13-1.33) and cause-specific mortality (HR =1.10, 95% CI: 1.01-1.20), compared - to the radiation + chemotherapy group. The PDT group had longer time to follow-up - treatment, compared to non-PDT ablation group. CONCLUSIONS: In our exploratory - study of stage III and IV NSCLC patients with CAO, addition of PDT demonstrated - hazard of mortality comparable to radiation + chemotherapy group. However, - addition of non-PDT ablation showed higher mortality compared to the radiation + - chemotherapy group. Future studies should investigate the efficacy and - effectiveness of multimodal therapy including radiation, chemo, immunotherapy and - bronchoscopic interventions. -CI - 2019 Journal of Thoracic Disease. All rights reserved. -FAU - Jayadevappa, Ravishankar -AU - Jayadevappa R -AD - Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. -AD - Leonard Davis Institute of Health Economics, University of Pennsylvania, - Philadelphia, PA, USA. -AD - Division of Urology, Department of Surgery, University of Pennsylvania School of - Medicine, Philadelphia, PA, USA. -AD - Abramson Cancer Center, University of Pennsylvania School of Medicine, - Philadelphia, PA, USA. -AD - Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA. -FAU - Chhatre, Sumedha -AU - Chhatre S -AD - Department of Psychiatry, University of Pennsylvania School of Medicine, - Philadelphia, PA, USA. -FAU - Soukiasian, Harmik J -AU - Soukiasian HJ -AD - Cedars-Sinai Medical Center, Los Angeles, CA, USA. -FAU - Murgu, Septimiu -AU - Murgu S -AD - University of Chicago Medicine, Chicago, IL, USA. -LA - eng -PT - Journal Article -PL - China -TA - J Thorac Dis -JT - Journal of thoracic disease -JID - 101533916 -PMC - PMC6837945 -OTO - NOTNLM -OT - Non-small cell lung cancer (NSCLC) -OT - advanced stage -OT - mortality -OT - photodynamic therapy (PDT) -COIS- Conflicts of Interest: Drs. Soukiasian and Murgu are Educational Consultants for - Pinnacle Biologics.There are no financial/nonfinancial conflicts of interest for - other authors. -EDAT- 2019/11/19 06:00 -MHDA- 2019/11/19 06:01 -PMCR- 2019/10/01 -CRDT- 2019/11/19 06:00 -PHST- 2019/11/19 06:00 [entrez] -PHST- 2019/11/19 06:00 [pubmed] -PHST- 2019/11/19 06:01 [medline] -PHST- 2019/10/01 00:00 [pmc-release] -AID - jtd-11-10-4389 [pii] -AID - 10.21037/jtd.2019.04.60 [doi] -PST - ppublish -SO - J Thorac Dis. 2019 Oct;11(10):4389-4399. doi: 10.21037/jtd.2019.04.60. - -PMID- 38736501 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240514 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 13 -IP - 4 -DP - 2024 Apr 29 -TI - Immunotherapy for patients with advanced non-small cell lung cancer harboring - oncogenic driver alterations other than EGFR: a multicenter real-world analysis. -PG - 861-874 -LID - 10.21037/tlcr-24-116 [doi] -AB - BACKGROUND: The administration of immune checkpoint inhibitors (ICIs) in advanced - non-small cell lung cancer (NSCLC) with oncogenic driver alterations other than - epidermal growth factor receptor (EGFR) aroused a heated discussion. We thus - aimed to evaluate ICI treatment in these patients in real-world routine clinical - practice. METHODS: A multicenter, retrospective study was conducted for NSCLC - patients with at least one gene alteration (KRAS, HER2, BRAF, MET, RET, ALK, - ROS1) receiving ICI monotherapy or combination treatment. The data regarding - clinicopathologic characteristics, clinical efficacy, and safety were - investigated. RESULTS: A total of 216 patients were included, the median age was - 60 years, 72.7% of patients were male, and 46.8% had a smoking history. The - molecular alterations involved KRAS (n=95), HER2 (n=42), BRAF (n=22), MET (n=21), - RET (n=14), ALK (n=14), and ROS1 (n=8); 56.5% of patients received immunotherapy - in the first-line, and the rest 43.5% were treated as a second-line and above. - For the entire cohort who received immunotherapy-based regimens in the - first-line, the median progression-free survival (PFS) was 7.5 months and the - median overall survival (OS) was 24.8 months. For the entire cohort who received - immunotherapy-based regimens in the second-line and above, the median PFS was 4.7 - months and median OS was 17.1 months. KRAS mutated NSCLC treated with - immunotherapy-based regimens in the first-line setting had a median PFS and OS - were 7.8 and 26.1 months, respectively. Moreover, the median PFS and OS of - immunotherapy-based regimens for KRAS-mutant NSCLC that progressed after - chemotherapy were 5.9 and 17.1 months. Programmed death ligand 1 (PD-L1) - expression level was not consistently associated with response to immunotherapy - across different gene alteration subsets. In the KRAS group, PD-L1 positivity - [tumor proportion score (TPS) ≥1%] was associated with better PFS and OS - according to the multivariate Cox analysis. No statistically significant - association was found for smoking status, age, or gender with clinical efficacy - in any gene group analyses. CONCLUSIONS: KRAS-mutant NSCLC could obtain clinical - benefits from ICIs either for treatment-naive patients or those who have - experienced progression after chemotherapy, and PD-L1 positive expression (TPS - >1%) may be a potential positive predictor. For NSCLC with ALK, RET and ROS1 - rearrangement, MET exon 14 skipping mutation, or BRAF V600E mutation, - effectiveness of single or combined ICI therapy remains limited, therefore, - targeted therapies should be considered prior to immunotherapy regimens. Future - studies should address the investigation of better predictive biomarkers for - immunotherapy response in oncogene-driven NSCLC. -CI - 2024 Translational Lung Cancer Research. All rights reserved. -FAU - Tian, Tian -AU - Tian T -AD - Division of Thoracic Tumor Multimodality Treatment and Department of Medical - Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Li, Yanying -AU - Li Y -AD - Division of Thoracic Tumor Multimodality Treatment and Department of Medical - Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Li, Juan -AU - Li J -AD - Department of Thoracic Cancer, Medical Oncology Center, Sichuan Cancer Hospital & - Institute, Sichuan Cancer Center, School of Medicine, University of Electronic - Science and Technology of China, Chengdu, China. -FAU - Xu, Hongyu -AU - Xu H -AD - Department of Oncology, 363 Hospital, Chengdu, China. -FAU - Fan, Hua -AU - Fan H -AD - Department of Oncology and Hematology, Leshan People's Hospital, Leshan, China. -FAU - Zhu, Jiang -AU - Zhu J -AD - Division of Thoracic Tumor Multimodality Treatment and Department of Medical - Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Wang, Yongsheng -AU - Wang Y -AD - Division of Thoracic Tumor Multimodality Treatment and Department of Medical - Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Peng, Feng -AU - Peng F -AD - Division of Thoracic Tumor Multimodality Treatment and Department of Medical - Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Gong, Youling -AU - Gong Y -AD - Division of Thoracic Tumor Multimodality Treatment and Department of Medical - Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Du, Yijia -AU - Du Y -AD - Division of Thoracic Tumor Multimodality Treatment and Department of Medical - Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Yan, Xiaoyan -AU - Yan X -AD - Division of Thoracic Tumor Multimodality Treatment and Department of Medical - Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - He, Xiulan -AU - He X -AD - Division of Thoracic Tumor Multimodality Treatment and Department of Medical - Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Cali Daylan, Ayse Ece -AU - Cali Daylan AE -AD - Department of Oncology, Montefiore Medical Center, Bronx, NY, USA. -FAU - Pircher, Andreas -AU - Pircher A -AD - Department of Hematology and Oncology, Internal Medicine V, Comprehensive Cancer - Center Innsbruck (CCCI), Medical University of Innsbruck (MUI), Innsbruck, - Austria. -FAU - Neibart, Shane S -AU - Neibart SS -AD - Harvard Radiation Oncology Program, Boston, MA, USA. -FAU - Okuma, Yusuke -AU - Okuma Y -AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. -FAU - Hong, Min Hee -AU - Hong MH -AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer - Center, Yonsei University College of Medicine, Seoul, Republic of Korea. -FAU - Huang, Meijuan -AU - Huang M -AD - Division of Thoracic Tumor Multimodality Treatment and Department of Medical - Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -FAU - Lu, You -AU - Lu Y -AD - Division of Thoracic Tumor Multimodality Treatment and Department of Medical - Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. -LA - eng -PT - Journal Article -DEP - 20240424 -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -PMC - PMC11082706 -OTO - NOTNLM -OT - Non-small cell lung cancer (NSCLC) -OT - immune checkpoint inhibitor (ICI) -OT - oncogenic alteration -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-116/coif). Y.O. serves - as an unpaid editorial board member of Translational Lung Cancer Research from - January 2024 to December 2025, and reports speakers bureaus from Astra Zeneca, - Boehringer Ingelheim, Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo, Eisai, - Ely-Lilly, MSD, Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., - Takeda Pharmaceutical Co. Ltd. A.E.C.D. reports support for attending meetings - and/or travel from MJH Life Sciences. A.P. reports speaker’s fee from MSD, - Daiichi Sankyo, Astra Zeneca, Sanofi, Merck, Takeda, Lilly, BMS, Roche; payment - or honoraria for lectures, presentations, speakers bureaus from Daiichi Sankyo - and BMS; support for attending meetings and/or travel from Merck and Sandoz. The - other authors have no conflicts of interest to declare. -EDAT- 2024/05/13 06:43 -MHDA- 2024/05/13 06:44 -PMCR- 2024/04/29 -CRDT- 2024/05/13 03:56 -PHST- 2024/02/01 00:00 [received] -PHST- 2024/03/25 00:00 [accepted] -PHST- 2024/05/13 06:44 [medline] -PHST- 2024/05/13 06:43 [pubmed] -PHST- 2024/05/13 03:56 [entrez] -PHST- 2024/04/29 00:00 [pmc-release] -AID - tlcr-13-04-861 [pii] -AID - 10.21037/tlcr-24-116 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2024 Apr 29;13(4):861-874. doi: 10.21037/tlcr-24-116. - Epub 2024 Apr 24. - -PMID- 38107371 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20231219 -IS - 1179-5549 (Print) -IS - 1179-5549 (Electronic) -IS - 1179-5549 (Linking) -VI - 17 -DP - 2023 -TI - Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with - Advanced NSCLC: A Systematic Review and Meta-Analysis. -PG - 11795549231215968 -LID - 10.1177/11795549231215968 [doi] -LID - 11795549231215968 -AB - BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors - (EGFR-TKIs) are considered as the first-line treatment for advanced EGFR - mutation-positive non-small cell lung cancer (NSCLC). We aimed to analyze the - efficacy of EGFR-TKIs treatment in patients with advanced NSCLC of different - smoking habits. METHODS: We conducted a search for meta-analyses and systematic - reviews on the PubMed, MEDLINE, Embase, and the Cochrane Library to address this - knowledge gap. Patients were divided into 2 groups: (1) experimental group: - treated with EGFR-TKIs or EGFR-TKIs combined with chemotherapy, immunotherapy, - antiangiogenesis, radiotherapy and (2) control group: treated with chemotherapy. - Progressive-free survival (PFS) and total survival (OS) were adopted for - evaluating the efficacy of EGFR-TKIs between experimental group and control - group. RESULTS: Eleven studies including 6760 patients were included in the - meta-analysis. The results showed that smoking (including previous and current - smoking) significantly reduces the PFS and OS in comparison to non-smoking group - in the treatment of NSCLC with EGFR-TKIs. In addition, EGFR-TKIs combined with - anti-vascular endothelial growth factor therapy can reduce the risk of disease - progression in smokers. CONCLUSIONS: Our study indicated that smoking - significantly reduced the PFS and OS in comparison to non-smoking group in the - treatment of NSCLC with EGFR-TKIs. -CI - © The Author(s) 2023. -FAU - Mo, Zexun -AU - Mo Z -AD - Department of Pulmonary and Critical Care Medicine, Guangzhou First People's - Hospital, School of Medicine, South China University of Technology, Guangzhou, - China. -FAU - Ye, Meifeng -AU - Ye M -AD - Department of Pulmonary and Critical Care Medicine, Guangzhou First People's - Hospital, School of Medicine, South China University of Technology, Guangzhou, - China. -FAU - He, Hua -AU - He H -AD - Department of Pulmonary and Critical Care Medicine, Guangzhou First People's - Hospital, School of Medicine, South China University of Technology, Guangzhou, - China. -FAU - Huang, Xiaomei -AU - Huang X -AD - Department of Pulmonary and Critical Care Medicine, Guangzhou First People's - Hospital, School of Medicine, South China University of Technology, Guangzhou, - China. -FAU - Guo, Weihong -AU - Guo W -AD - Department of Pulmonary and Critical Care Medicine, Guangzhou First People's - Hospital, School of Medicine, South China University of Technology, Guangzhou, - China. -FAU - Zhao, Ziwen -AU - Zhao Z -AD - Department of Pulmonary and Critical Care Medicine, Guangzhou First People's - Hospital, School of Medicine, South China University of Technology, Guangzhou, - China. -FAU - Li, Yujun -AU - Li Y -AD - Department of Pulmonary and Critical Care Medicine, Guangzhou First People's - Hospital, School of Medicine, South China University of Technology, Guangzhou, - China. -FAU - Wei, Shuquan -AU - Wei S -AUID- ORCID: 0000-0003-4044-2244 -AD - Department of Pulmonary and Critical Care Medicine, Guangzhou First People's - Hospital, School of Medicine, South China University of Technology, Guangzhou, - China. -LA - eng -PT - Journal Article -DEP - 20231212 -PL - United States -TA - Clin Med Insights Oncol -JT - Clinical Medicine Insights. Oncology -JID - 101525771 -PMC - PMC10722912 -OTO - NOTNLM -OT - Non-small cell lung cancer -OT - OS -OT - PFS -OT - epidermal growth factor receptor-tyrosine kinase inhibitors -OT - smoking -EDAT- 2023/12/18 06:42 -MHDA- 2023/12/18 06:43 -PMCR- 2023/12/12 -CRDT- 2023/12/18 04:56 -PHST- 2023/05/16 00:00 [received] -PHST- 2023/10/24 00:00 [accepted] -PHST- 2023/12/18 06:43 [medline] -PHST- 2023/12/18 06:42 [pubmed] -PHST- 2023/12/18 04:56 [entrez] -PHST- 2023/12/12 00:00 [pmc-release] -AID - 10.1177_11795549231215968 [pii] -AID - 10.1177/11795549231215968 [doi] -PST - epublish -SO - Clin Med Insights Oncol. 2023 Dec 12;17:11795549231215968. doi: - 10.1177/11795549231215968. eCollection 2023. - -PMID- 34532842 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220304 -IS - 2509-4254 (Electronic) -IS - 2509-4262 (Print) -IS - 2509-4262 (Linking) -VI - 6 -IP - 2 -DP - 2022 Mar -TI - Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival - Update and Model Validation from a UK Healthcare Perspective. -PG - 241-252 -LID - 10.1007/s41669-021-00301-7 [doi] -AB - BACKGROUND: In the phase III PACIFIC study, durvalumab improved survival versus - placebo in patients with unresectable stage III non-small-cell lung cancer - (NSCLC) whose disease had not progressed after platinum-based concurrent - chemoradiotherapy. The appraisal by the UK's National Institute for Health and - Care Excellence (NICE) included a cost-effectiveness analysis based on an early - data readout from PACIFIC [March 2018 data cut-off (DCO); median follow-up - duration 25.2 months; range 0.2-43.1]. Uncertainties regarding long-term survival - outcomes with durvalumab led to some challenges in estimating the cost - effectiveness of this therapy. OBJECTIVE: Here, we validate the survival - extrapolations used in the original company base-case analysis by benchmarking - them against updated survival data from the 4-year follow-up analysis of PACIFIC - (i.e. approximately 4 years after the last patient was randomised; March 2020 - DCO; median follow-up duration 34.2 months; range 0.2-64.9). Moreover, we update - the original analysis with these more mature survival data to examine the - consistency of key economic outputs with the original analysis. METHODS: The - original analysis used a semi-Markov (state-transition) approach and was based on - patients whose tumours expressed programmed cell death-ligand 1 on ≥ 1% of cells - (to reflect the European licence for durvalumab). We benchmarked the survival - extrapolations used in the original company base-case analysis against survival - data from the 4-year follow-up of PACIFIC and updated the cost-effectiveness - analysis with these more mature survival data. Early deaths avoided by the - adoption of durvalumab into the UK Cancer Drugs Fund (CDF) in March 2019 were - estimated using the 4-year follow-up survival data and an assumed uptake of 125 - patients/year (lower estimate) and 367 patients/year (higher estimate). RESULTS: - The original company base-case analysis had a good visual fit with the observed - overall survival (OS) distribution for the durvalumab arm and accurately - predicted the 48-month OS rate (predicted 55%; observed 55%); by comparison, the - fit was less precise for the placebo arm, for which the analysis underestimated - the 48-month OS rate (predicted 32%; observed 38%). In the updated company - base-case analysis, durvalumab yielded 2.51 incremental quality-adjusted - life-years (QALYs) (- 0.43 vs. the original company base-case analysis), - corresponding to an incremental cost-effectiveness ratio of £22,665/QALY (+£3298 - vs. the original analysis), which falls within the upper bound of NICE's - willingness-to-pay threshold (£30,000/QALY gained). We estimate that between 31 - and 91 early patient deaths may have been avoided by the adoption of durvalumab - into the CDF. CONCLUSIONS: These findings reinforce the patient benefit observed - with durvalumab in unresectable stage III NSCLC, support the routine use and cost - effectiveness of this therapy, and demonstrate how appropriate modelling can - inform the early adoption of therapies by payers to achieve patient benefit. -CI - © 2021. The Author(s). -FAU - Dunlop, Will -AU - Dunlop W -AUID- ORCID: 0000-0002-9794-8978 -AD - AstraZeneca Global Health Economics & Payer Evidence (Oncology), 1 Francis Crick - Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK. - william.dunlop@astrazeneca.com. -FAU - van Keep, Marjolijn -AU - van Keep M -AD - BresMed Netherlands, Utrecht, The Netherlands. -FAU - Elroy, Peter -AU - Elroy P -AD - BresMed Netherlands, Utrecht, The Netherlands. -FAU - Perez, Ignacio Diaz -AU - Perez ID -AD - AstraZeneca, Gaithersburg, MD, USA. -FAU - Ouwens, Mario J N M -AU - Ouwens MJNM -AD - AstraZeneca, Gothenburg, Sweden. -FAU - Sarbajna, Tina -AU - Sarbajna T -AD - AstraZeneca Global Health Economics & Payer Evidence (Oncology), 1 Francis Crick - Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK. -FAU - Zhang, Yiduo -AU - Zhang Y -AD - AstraZeneca, Gaithersburg, MD, USA. -FAU - Greystoke, Alastair -AU - Greystoke A -AD - Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation - Trust, Newcastle upon Tyne, UK. -LA - eng -PT - Journal Article -DEP - 20210916 -PL - Switzerland -TA - Pharmacoecon Open -JT - PharmacoEconomics - open -JID - 101700780 -PMC - PMC8864051 -OAB - Based on the results of a clinical trial, the European Medicines Agency approved - durvalumab for the treatment of adults with a specific type of advanced lung - cancer whose tumours cannot be removed surgically and whose disease has not - progressed after chemotherapy and radiotherapy. The UK’s National Institute for - Health and Care Excellence (NICE) invites companies to submit cost-effectiveness - analyses to help with decision making about adopting new therapies. The company - included an analysis based on early trial data that suggested durvalumab was cost - effective compared with other previous treatments. As patients in the study at - the time of the initial submission to NICE were only followed for approximately 2 - years, the long-term survival benefit that could be achieved with durvalumab was - uncertain. Therefore, NICE recommended durvalumab for use within the Cancer Drugs - Fund (CDF) to allow patients to access the drug while more data were being - collected. Here, we demonstrate that the original cost-effectiveness model - accurately predicted the rates of long-term survival for patients receiving - durvalumab and that durvalumab remains a cost-effective use of healthcare - resources based on recently published data from the trial (which added - approximately 2 further years of follow-up). Moreover, we estimate that adopting - durvalumab into the CDF may have avoided 31–91 early patient deaths from lung - cancer. These findings support NICE’s early decision to make durvalumab available - within the CDF and the adoption of durvalumab for routine use within the UK - national health service. -OABL- eng -COIS- Will Dunlop, Ignacio Diaz Perez, Mario JNM Ouwens, Tina Sarbajna, and Yiduo Zhang - report employment by AstraZeneca and stock ownership in AstraZeneca. Marjolijn - van Keep and Peter Elroy report employment by BresMed (under contract with - AstraZeneca). Alastair Greystoke has received honoraria, speaker’s fees, and - research funding from AstraZeneca. -EDAT- 2021/09/18 06:00 -MHDA- 2021/09/18 06:01 -PMCR- 2021/09/16 -CRDT- 2021/09/17 07:27 -PHST- 2021/08/22 00:00 [accepted] -PHST- 2021/09/18 06:00 [pubmed] -PHST- 2021/09/18 06:01 [medline] -PHST- 2021/09/17 07:27 [entrez] -PHST- 2021/09/16 00:00 [pmc-release] -AID - 10.1007/s41669-021-00301-7 [pii] -AID - 301 [pii] -AID - 10.1007/s41669-021-00301-7 [doi] -PST - ppublish -SO - Pharmacoecon Open. 2022 Mar;6(2):241-252. doi: 10.1007/s41669-021-00301-7. Epub - 2021 Sep 16. - -PMID- 36762057 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230211 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 12 -IP - 1 -DP - 2023 Jan 31 -TI - Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell - lung cancer patients: a multicenter real-world retrospective observational study - (CTONG2004-ADV). -PG - 127-140 -LID - 10.21037/tlcr-22-852 [doi] -AB - BACKGROUND: Camrelizumab plus chemotherapy have been approved as standards for - the treatment of advanced non-small cell lung cancer (NSCLC) patients based on - two phase III trials. However, clinical trial results may not be representative - of the general population, as clinical trials often have specific inclusion and - exclusion criteria. Our research aims to investigate the real-world effectiveness - and safety of camrelizumab in inoperable or advanced NSCLC patients. METHODS: - This multicenter retrospective observational study included inoperable or - advanced pathologically confirmed NSCLC patients who received at least one dose - of camrelizumab at 22 hospitals. Clinical and follow-up data of camrelizumab were - collected retrospectively from the medical records. The primary outcome was the - objective response rate (ORR) and secondary outcomes were disease control rate - (DCR), 6-month progression-free survival (PFS), overall survival (OS), and - treatment-related adverse events (TRAEs). Multivariate logistic and Cox - regression analyses were applied to identify potential predictive factors of ORR - and PFS, respectively. RESULTS: Between July 2019 and March 2021, 336 patients - were included. Adenocarcinoma was seen in 58.4% and stage IV disease in 69.3%. - Twenty-nine (8.6%) had liver metastasis at baseline. Most patients received - camrelizumab in the first-line setting (74.1%) and in combination with - chemotherapy (60.7%). The ORR was 40.2% [95% confidence interval (CI): - 34.9-45.6%] and DCR was 85.1% (95% CI: 81.3-88.9%), while the 6-month PFS and OS - rates were 73.0% (95% CI: 67.1-78.0%) and 93.1% (95% CI: 89.8-95.4%), - respectively. In multivariate analyses, liver metastasis [odds ratio (OR), 0.324; - 95% CI: 0.115-0.915; P=0.033] and increasing lines of camrelizumab treatment (vs. - first line, second line: OR, 0.347; 95% CI: 0.162-0.741; P=0.006; ≥ third line: - OR, 0.126; 95% CI: 0.043-0.367; P<0.001) were negatively associated, while a - longer duration of camrelizumab treatment was positively associated with ORR and - PFS. TRAEs were recorded in 164 (48.8%) patients, without new safety signal. - CONCLUSIONS: We conducted a comprehensive overview of the effectiveness and - safety profile of camrelizumab in a broader NSCLC population in real world NSCLC - patients, and subgroup analysis indicated the presence of liver metastasis was - associated with worse outcomes. -CI - 2023 Translational Lung Cancer Research. All rights reserved. -FAU - Xu, Chong-Rui -AU - Xu CR -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & - Guangdong Academy of Medical Sciences, Guangzhou, China. -FAU - Chen, Qixun -AU - Chen Q -AD - Department of Thoracic Oncological Surgery, Cancer Hospital of the University of - Chinese Academy of Sciences, Hangzhou, China. -FAU - Zhou, Chengzhi -AU - Zhou C -AD - State Key Laboratory of Respiratory Disease, National Clinical Research Centre - for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First - Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. -FAU - Wu, Lin -AU - Wu L -AD - Second Department of Thoracic Medicine, Hunan Cancer Hospital, The Affiliated - Cancer Hospital of Xiangya School of Medicine, Central South University, - Changsha, China. -FAU - Li, Wen -AU - Li W -AD - Department of Respiratory Medicine, The Second Affiliated Hospital, Zhejiang - University School Of Medicine, Hangzhou, China. -FAU - Zhang, Huizhong -AU - Zhang H -AD - Department of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen - University, Guangzhou, China. -FAU - Li, Yongsheng -AU - Li Y -AD - Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, - China. -FAU - Xu, Fei -AU - Xu F -AD - Department of Respiratory Medicine, The First Affiliated Hospital of Nanchang - University, Nanchang, China. -FAU - Xiong, Jianping -AU - Xiong J -AD - Department of Medical Oncology, The First Affiliated Hospital of Nanchang - University, Nanchang, China. -FAU - Wang, Qiming -AU - Wang Q -AD - Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou - University, Henan Cancer Hospital, Zhengzhou, China. -FAU - Zhang, Haibo -AU - Zhang H -AD - First Department of Internal Medicine, The Second Affiliated Hospital of - Guangzhou University of Chinese Medicine, Guangzhou, China. -FAU - Jiang, Yuequan -AU - Jiang Y -AD - Department of Thoracic Surgery, Chongqing University Cancer Hospital, Chongqing, - China. -FAU - Yin, Haitao -AU - Yin H -AD - Department of Radiotherapy, Xuzhou Central Hospital, Xuzhou, China. -FAU - Wu, Qingchen -AU - Wu Q -AD - Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing - Medical University, Chongqing, China. -FAU - Dai, Qiangsheng -AU - Dai Q -AD - Department of Medical Oncology, The First Affiliated Hospital, Sun Yat-sen - University, Guangzhou, China. -FAU - Hu, Jian -AU - Hu J -AD - Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang - University School of Medicine, Hangzhou, China. -FAU - Chen, Jianhua -AU - Chen J -AD - Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated - Cancer Hospital of Xiangya School of Medicine, Central South University, - Changsha, China. -FAU - Zhang, Jian -AU - Zhang J -AD - Department of Medical Oncology, Zhujiang Hospital of Southern Medical University, - Guangzhou, China. -FAU - Wu, Gang -AU - Wu G -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of - Science and Technology, Wuhan, China. -FAU - Yin, Jun -AU - Yin J -AD - Department of Respiratory Medicine, The Third People's Hospital of Chengdu, - Chengdu, China. -FAU - Zhao, Jianfu -AU - Zhao J -AD - Department of Oncology, The First Affiliated Hospital of Jinan University, - Guangzhou, China. -FAU - Liu, Baogang -AU - Liu B -AD - Department of Medical Oncology, Harbin Medical University Cancer Hospital, - Harbin, China. -FAU - Shan, Jianzhen -AU - Shan J -AD - Department of Medical Oncology, The First Affiliated Hospital, Zhejiang - University School Of Medicine, Hangzhou, China. -FAU - Sheng, Liming -AU - Sheng L -AD - Department of Thoracic Radiotherapy, Cancer Hospital of the University of Chinese - Academy of Sciences, Hangzhou, China. -FAU - Chen, Qunqing -AU - Chen Q -AD - Department of Thoracic Surgery, Zhujiang Hospital of Southern Medical University, - Guangzhou, China. -FAU - Han, Zhengxiang -AU - Han Z -AD - Department of Medical Oncology, The Affiliated Hospital of Xuzhou Medical - University, Xuzhou, China. -FAU - Shi, Huaqiu -AU - Shi H -AD - Department of Oncology, First Affiliated Hospital of Gannan Medical University, - Ganzhou, China. -FAU - Liu, Yimin -AU - Liu Y -AD - Department of Radiotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen - University, Guangzhou, China. -FAU - Chen, Jun -AU - Chen J -AD - Department of Medical Oncology, The Second Hospital of Dalian Medical University, - Dalian, China. -FAU - Wu, Yi-Long -AU - Wu YL -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & - Guangdong Academy of Medical Sciences, Guangzhou, China. -LA - eng -PT - Journal Article -DEP - 20230116 -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -PMC - PMC9903092 -OTO - NOTNLM -OT - Non-small cell lung cancer (NSCLC) -OT - observational study -OT - real-world -OT - samrelizumab -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-852/coif). All authors - report this research was supported and funded by Jiangsu Hengrui Pharmaceuticals - Co., Ltd. YW reports that he received grants or contracts from Boehringer - Ingelheim (Inst), Roche (Inst), Pfizer (Inst), and BMS (Inst), and consulting - fees from AstraZeneca, Roche, Boehringer Ingelheim, and Takeda, and payment or - honoraria for lectures, presentations, speakers bureaus, manuscript writing or - educational events from AstraZeneca, Lilly, Roche, Pfizer, Boehringer Ingelheim, - MSD Oncology, Bristol Myers Squibb/China, and Hengrui Pharmaceutical. The authors - have no other conflicts of interest to declare. -EDAT- 2023/02/11 06:00 -MHDA- 2023/02/11 06:01 -PMCR- 2023/01/31 -CRDT- 2023/02/10 03:19 -PHST- 2022/10/21 00:00 [received] -PHST- 2023/01/06 00:00 [accepted] -PHST- 2023/02/10 03:19 [entrez] -PHST- 2023/02/11 06:00 [pubmed] -PHST- 2023/02/11 06:01 [medline] -PHST- 2023/01/31 00:00 [pmc-release] -AID - tlcr-12-01-127 [pii] -AID - 10.21037/tlcr-22-852 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2023 Jan 31;12(1):127-140. doi: 10.21037/tlcr-22-852. - Epub 2023 Jan 16. - -PMID- 39272916 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240916 -IS - 2072-6694 (Print) -IS - 2072-6694 (Electronic) -IS - 2072-6694 (Linking) -VI - 16 -IP - 17 -DP - 2024 Sep 2 -TI - Real-World Analysis of Survival and Treatment Efficacy in Stage IIIA-N2 Non-Small - Cell Lung Cancer. -LID - 10.3390/cancers16173058 [doi] -LID - 3058 -AB - BACKGROUND: Stage IIIA-N2 non-small cell lung cancer (NSCLC) poses a significant - clinical challenge, with low survival rates despite advances in therapy. The lack - of a standardised treatment approach complicates patient management. This study - utilises real-world data from Guy's Thoracic Cancer Database to analyse patient - outcomes, identify key predictors of overall survival (OS) and disease-free - survival (DFS), and address the limitations of randomised controlled trials. - METHODS: This observational, single-centre, non-randomised study analysed 142 - patients diagnosed with clinical and pathological T1/2 N2 NSCLC who received - curative treatment from 2015 to 2021. Patients were categorised into three - groups: Group A (30 patients) underwent surgery for clinical N2 disease, Group B - (54 patients) had unsuspected N2 disease discovered during surgery, and Group C - (58 patients) received radical chemoradiation or radiotherapy alone (CRT/RT) for - clinical N2 disease. Data on demographics, treatment types, recurrence, and - survival rates were analysed. RESULTS: The median OS for the cohort was 31 - months, with 2-year and 5-year OS rates of 60% and 30%, respectively. Group A had - a median OS of 32 months, Group B 36 months, and Group C 25 months. The median - DFS was 18 months overall, with Group A at 16 months, Group B at 22 months, and - Group C at 17 months. Significant predictors of OS included ECOG performance - status, lymphovascular invasion, and histology. No significant differences in OS - were found between treatment groups (p = 0.99). CONCLUSIONS: This study - highlights the complexity and diversity of Stage IIIA-N2 NSCLC, with no single - superior treatment strategy identified. The findings underscore the necessity for - personalised treatment approaches and multidisciplinary decision-making. Future - research should focus on integrating newer therapeutic modalities and conducting - multi-centre trials to refine treatment strategies. Collaboration and ongoing - data collection are crucial for improving personalised treatment plans and - survival outcomes for Stage IIIA-N2 NSCLC patients. -FAU - Josephides, Eleni -AU - Josephides E -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -AD - Comprehensive Cancer Centre, King's College, London SE1 9RT, UK. -FAU - Dunn, Roberta -AU - Dunn R -AUID- ORCID: 0009-0003-7253-9128 -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -AD - Comprehensive Cancer Centre, King's College, London SE1 9RT, UK. -FAU - Henry, Annie-Rose -AU - Henry AR -AUID- ORCID: 0009-0005-8037-6546 -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -FAU - Pilling, John -AU - Pilling J -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -FAU - Harrison-Phipps, Karen -AU - Harrison-Phipps K -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -FAU - Patel, Akshay -AU - Patel A -AUID- ORCID: 0000-0001-9170-8618 -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -FAU - Ahmad, Shahreen -AU - Ahmad S -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -FAU - Skwarski, Michael -AU - Skwarski M -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -FAU - Spicer, James -AU - Spicer J -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -AD - Comprehensive Cancer Centre, King's College, London SE1 9RT, UK. -FAU - Georgiou, Alexandros -AU - Georgiou A -AUID- ORCID: 0000-0001-7500-9251 -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -FAU - Ghosh, Sharmistha -AU - Ghosh S -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -FAU - Van Hemelrijck, Mieke -AU - Van Hemelrijck M -AD - Comprehensive Cancer Centre, King's College, London SE1 9RT, UK. -FAU - Karapanagiotou, Eleni -AU - Karapanagiotou E -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -FAU - Smith, Daniel -AU - Smith D -AUID- ORCID: 0000-0002-6330-3936 -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -FAU - Bille, Andrea -AU - Bille A -AD - Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. -LA - eng -PT - Journal Article -DEP - 20240902 -PL - Switzerland -TA - Cancers (Basel) -JT - Cancers -JID - 101526829 -PMC - PMC11394025 -OTO - NOTNLM -OT - Stage IIIA-N2 -OT - chemoradiation -OT - chemotherapy -OT - immunotherapy -OT - multidisciplinary management -OT - non-small cell lung cancer (NSCLC) -OT - radiotherapy -OT - real-world data -OT - real-world evidence -OT - surgery -OT - survival outcomes -COIS- The authors declare no conflicts of interest, except for A.B. who serves as a - proctor for Intuitive. -EDAT- 2024/09/14 10:41 -MHDA- 2024/09/14 10:42 -PMCR- 2024/09/02 -CRDT- 2024/09/14 01:05 -PHST- 2024/07/14 00:00 [received] -PHST- 2024/08/20 00:00 [revised] -PHST- 2024/08/29 00:00 [accepted] -PHST- 2024/09/14 10:42 [medline] -PHST- 2024/09/14 10:41 [pubmed] -PHST- 2024/09/14 01:05 [entrez] -PHST- 2024/09/02 00:00 [pmc-release] -AID - cancers16173058 [pii] -AID - cancers-16-03058 [pii] -AID - 10.3390/cancers16173058 [doi] -PST - epublish -SO - Cancers (Basel). 2024 Sep 2;16(17):3058. doi: 10.3390/cancers16173058. - -PMID- 36523994 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20221222 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 12 -DP - 2022 -TI - Immune checkpoint inhibitors alone or in combination with chemotherapy for - treatment of advanced non-small cell lung cancer after first-line platinum-based - chemotherapy: A propensity score matching analysis. -PG - 974227 -LID - 10.3389/fonc.2022.974227 [doi] -LID - 974227 -AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) have changed the treatment - landscape of several cancer types. However, data are lacking with regard to the - clinical responsiveness of ICIs in patients with advanced non-small cell lung - cancer (NSCLC) after standard first-line chemotherapy. Therefore, we aimed to - evaluate the clinical efficacy of ICI alone or in combination with chemotherapy - for patients with advanced NSCLC after first-line platinum-based chemotherapy. - METHODS: We retrospectively collected patients with confirmed advanced NSCLC who - underwent ICI monotherapy or ICI plus chemotherapy after first-line - platinum-based chemotherapy between January 2018 and December 2020. A propensity - score matching analysis was used to balance baseline characteristics between the - two treatment groups. Kaplan-Meier methods and multivariable Cox regressions were - used for survival analyses. RESULTS: Among 832 eligible patients, 222 received - ICI monotherapy and 610 received ICI plus chemotherapy. The median overall - survival (OS) of patients who received ICI plus chemotherapy was 16.0 months - compared with 13.1 months in patients who received ICI monotherapy (HR: 0.64, 95% - CI: 0.49-0.85, P = 0.002). After 1:1 propensity score matching, all baseline - characteristics were well-balanced between the two treatment groups. Patients who - received ICI plus chemotherapy had significantly longer OS than those who - received ICI monotherapy (NR vs. 13.1 months, HR: 0.50, 95% CI: 0.34-0.71, P < - 0.001). Meanwhile, the median time to treatment discontinuation was 4.4 months in - the ICI-chemo group and 3.5 months in the ICI-mono group (HR: 0.72, 95% CI: - 0.58-0.89, P = 0.002). The multivariate analysis indicated that treatment regimen - was an independent prognostic factor for OS (HR: 0.488, 95% CI: 0.337-0.707, P < - 0.001). Moreover, a nomogram that integrated both treatment regimens and - clinicopathological factors was created for survival prediction. CONCLUSION: Our - study indicated that patients with advanced NSCLC who received ICI plus - chemotherapy after first-line platinum-based chemotherapy tended to have longer - OS than those who received ICI monotherapy. The multivariate analysis showed that - treatment regimen was an independent prognostic factor for OS. Future prospective - studies are needed to confirm these findings. -CI - Copyright © 2022 Qiu, Gao, Du, Sun, Liang, Sun, Li, Jia, Li, Sun, Jiao and Zhao. -FAU - Qiu, Lupeng -AU - Qiu L -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -AD - Department of Graduate Administration, Chinese People's Liberation Army (PLA) - General Hospital, Beijing, China. -FAU - Gao, Shan -AU - Gao S -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -AD - School of Medicine, Nankai University, Tianjin, China. -FAU - Du, Sicheng -AU - Du S -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -AD - Department of Graduate Administration, Chinese People's Liberation Army (PLA) - General Hospital, Beijing, China. -FAU - Sun, Shengjie -AU - Sun S -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Liang, Yanjie -AU - Liang Y -AD - Department of Radiotherapy, The First Medical Center of Chinese PLA General - Hospital, Beijing, China. -FAU - Sun, Zhuoya -AU - Sun Z -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Li, Tao -AU - Li T -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Jia, Guhe -AU - Jia G -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Li, Ke -AU - Li K -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Sun, Xiaohui -AU - Sun X -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Jiao, Shunchang -AU - Jiao S -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -FAU - Zhao, Xiao -AU - Zhao X -AD - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, - Beijing, China. -LA - eng -PT - Journal Article -DEP - 20221129 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC9745307 -OTO - NOTNLM -OT - chemotherapy -OT - immune checkpoint inhibitor -OT - non-small cell lung cancer -OT - overall survival -OT - propensity score matching -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2022/12/17 06:00 -MHDA- 2022/12/17 06:01 -PMCR- 2022/01/01 -CRDT- 2022/12/16 02:32 -PHST- 2022/06/21 00:00 [received] -PHST- 2022/11/14 00:00 [accepted] -PHST- 2022/12/16 02:32 [entrez] -PHST- 2022/12/17 06:00 [pubmed] -PHST- 2022/12/17 06:01 [medline] -PHST- 2022/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2022.974227 [doi] -PST - epublish -SO - Front Oncol. 2022 Nov 29;12:974227. doi: 10.3389/fonc.2022.974227. eCollection - 2022. - -PMID- 38706978 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240507 -IS - 2666-3643 (Electronic) -IS - 2666-3643 (Linking) -VI - 5 -IP - 4 -DP - 2024 Apr -TI - Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: - NEJ060. -PG - 100655 -LID - 10.1016/j.jtocrr.2024.100655 [doi] -LID - 100655 -AB - INTRODUCTION: Immune checkpoint inhibitor (ICI)-based treatment has become - standard treatment for patients with advanced NSCLC. We aimed to determine the - survival benefit of upfront radiotherapy for brain metastases (BMs) in patients - with NSCLC who received ICI alone (ICI-alone) or with chemotherapy (ICI-chemo). - METHODS: This study included consecutive patients with NSCLC having BMs who - received ICI alone or ICI-chemo at 50 institutes between February 2017 and - September 2021. The presence of BMs was confirmed by imaging before treatment. - Treatment outcomes were compared between patients who did and did not receive - upfront radiotherapy for BMs. Potential confounding factors were adjusted between - the groups through inverse probability treatment weighting (IPTW) analysis and - overlap weighting (OW) analysis with propensity scores. RESULTS: Patients were - grouped as ICI-alone cohort, 224 patients (upfront-radiotherapy group, 135 - patients; no-radiotherapy group, 89 patients) and ICI-chemo cohort, 367 patients - (upfront-radiotherapy group, 212 patients; no-radiotherapy group, 155 patients). - In the ICI-alone cohort, the overall survival of the upfront-radiotherapy group - was significantly longer than that of the no-radiotherapy group (IPTW-adjusted - hazards ratio [HR] = 0.45 [95% confidence interval [CI]: 0.29-0.72], OW-adjusted - HR = 0.52 [95% CI: 0.35-0.77]). In contrast, in the ICI-chemo cohort, the OS of - the upfront-radiotherapy group was not significantly different from that of the - no-radiotherapy group (IPTW-adjusted HR = 1.02 [95% CI: 0.70-1.48], OW-adjusted - HR = 0.93 [95% CI: 0.65-1.33]). CONCLUSIONS: Upfront radiotherapy for BMs was - associated with longer overall survival in patients with NSCLC who received ICI - alone; however, it did not exhibit survival benefits in the patients who received - ICI-chemo. -CI - © 2024 by the International Association for the Study of Lung Cancer. -FAU - Tozuka, Takehiro -AU - Tozuka T -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, Tokyo, Japan. -FAU - Minegishi, Yuji -AU - Minegishi Y -AD - Department of Respiratory Medicine, Mitsui. Memorial Hospital, Tokyo, Japan. -FAU - Yamaguchi, Ou -AU - Yamaguchi O -AD - Department of Respiratory Medicine, Saitama Medical University International - Medical Center, Hidaka, Saitama, Japan. -FAU - Watanabe, Kana -AU - Watanabe K -AD - Department of Respiratory Medicine, Miyagi Cancer Center, Miyagi, Japan. -FAU - Toi, Yukihiro -AU - Toi Y -AD - Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan. -FAU - Saito, Ryota -AU - Saito R -AD - Department of Respiratory Medicine, Tohoku University Graduate School of - Medicine, Sendai, Japan. -FAU - Nagai, Yoshiaki -AU - Nagai Y -AD - Department of Respiratory Medicine, Jichi Medical University, Saitama Medical - Center, Saitama, Japan. -FAU - Tamura, Yosuke -AU - Tamura Y -AD - Department of Respiratory Medicine and Thoracic Oncology, Osaka Medical and - Pharmaceutical University Hospital, Osaka, Japan. -FAU - Shoji, Tetsuaki -AU - Shoji T -AD - Department of Respiratory Medicine, Faculty of Medicine and Graduate School of - Medicine, Hokkaido University, Hokkaido, Japan. -FAU - Odagiri, Haruka -AU - Odagiri H -AD - Department of Respiratory Medicine, Hirosaki University Graduate School of - Medicine, Hirosaki, Japan. -FAU - Ebi, Noriyuki -AU - Ebi N -AD - Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan. -FAU - Sakai, Kosuke -AU - Sakai K -AD - Department of Pulmonary Medicine, Saitama Medical Center, Saitama Medical - University, Saitama, Japan. -FAU - Kanaji, Nobuhiro -AU - Kanaji N -AD - Department of Internal Medicine, Division of Hematology, Rheumatology, and - Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan. -FAU - Izumi, Makoto -AU - Izumi M -AD - Department of Chemotherapy, Yokosuka Kyosai Hospital, Kanagawa, Japan. -FAU - Soda, Sayo -AU - Soda S -AD - Department of Pulmonary and Clinical Immunology, Dokkyo Medical University School - of Medicine, Tochigi, Japan. -FAU - Watanabe, Satoshi -AU - Watanabe S -AD - Department of Respiratory Medicine and Infectious Diseases, Niigata University - Graduate School of Medical and Dental Sciences, Niigata, Japan. -FAU - Morita, Satoshi -AU - Morita S -AD - Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate - School of Medicine, Kyoto, Japan. -FAU - Kobayashi, Kunihiko -AU - Kobayashi K -AD - Department of Respiratory Medicine, Saitama Medical University International - Medical Center, Hidaka, Saitama, Japan. -FAU - Seike, Masahiro -AU - Seike M -AD - Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, - Nippon Medical School, Tokyo, Japan. -LA - eng -PT - Journal Article -DEP - 20240220 -PL - United States -TA - JTO Clin Res Rep -JT - JTO clinical and research reports -JID - 101769967 -PMC - PMC11069015 -OTO - NOTNLM -OT - Brain metastases -OT - Immunotherapy -OT - Non–small cell lung cancer -OT - Radiotherapy -COIS- Dr. Tozuka has received honoraria from Chugai Pharmaceutical and AstraZeneca. Dr. - Minegishi has received honoraria from AstraZeneca, Boehringer Ingelheim Japan, - Eli Lilly Japan, Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, - Eisai, Bristol-Myers Squibb, Daiichi-Sankyo, Nippon Kayaku, Takeda - Pharmaceutical, and GlaxoSmithKline. Dr. Yamaguchi has received honoraria from - Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., and Chugai - Pharmaceutical Co. Ltd. Dr. Toi has received honoraria from Bristol-Myers Squibb - Company, Ono Pharmaceutical Co., Ltd., Merck Sharp & Dohme K.K., AstraZeneca - Plc., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Pfizer - Inc., and Kyowa Kirin Co., Ltd. Dr. Tamura has received honoraria from Merck - Sharp & Dohme (Merck & Co., Inc.), Chugai Pharmaceutical Co., Ltd., AstraZeneca - K.K., and Ono Pharmaceutical Co., Ltd. Dr. Sakai has received grants from Eli - Lilly Japan K.K.; and has received honoraria from AstraZeneca K.K., Nippon - Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan - Inc., and ThermoFisher Scientific K.K. Dr. Watanabe has received funding from - Bristol-Myers Squibb K.K. and 10.13039/501100013170Ono Pharmaceutical Co., Ltd.; - has received grants from Boehringer Ingelheim and 10.13039/100018046Nippon - Kayaku; and has received honoraria from Eli Lilly, Novartis Pharma, Chugai - Pharma, Bristol-Myers, Ono Pharmaceutical, Daiichi-Sankyo, Taiho Pharmaceutical, - Nippon Kayaku, Kyowa Kirin, Merck, Takeda Pharmaceutical, Celltrion, and - AstraZeneca. Dr. Morita has received honoraria from AstraZeneca K.K, - Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan - K.K., Merck Sharp & Dohme K.K., Pfizer Japan Inc., and Taiho Pharmaceutical Co., - Ltd. Dr. Kobayashi has received honoraria from AstraZeneca, Daiichi-Sankyo - Pharmaceutical Co., and Takeda Pharmaceutical Co.; and is the Board Chairman in - NPO North East Japan Study Group. Dr. Seike has received honoraria from - AstraZeneca, Merck Sharp & Dohme K.K, Chugai Pharmaceutical, Taiho - Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Bristol-Myers Squibb, Nippon - Boehringer Ingelheim, Pfizer, Novartis, Takeda Pharmaceutical, Kyowa Hakko Kirin, - Nippon Kayaku, Daiichi-Sankyo Company, Merck Biopharma, and Amgen Inc.; and has - received research funding from 10.13039/100009954Taiho Pharmaceutical, - 10.13039/100010795Chugai Pharmaceutical, Eli Lilly, 10.13039/100017346Nippon - Boehringer Ingelheim, Nippon Kayaku and 10.13039/501100004095Kyowa Hakko Kirin. - The remaining authors declare no conflict of interest. -EDAT- 2024/05/06 06:43 -MHDA- 2024/05/06 06:44 -PMCR- 2024/02/20 -CRDT- 2024/05/06 04:07 -PHST- 2023/11/27 00:00 [received] -PHST- 2024/02/13 00:00 [revised] -PHST- 2024/02/18 00:00 [accepted] -PHST- 2024/05/06 06:44 [medline] -PHST- 2024/05/06 06:43 [pubmed] -PHST- 2024/05/06 04:07 [entrez] -PHST- 2024/02/20 00:00 [pmc-release] -AID - S2666-3643(24)00025-0 [pii] -AID - 100655 [pii] -AID - 10.1016/j.jtocrr.2024.100655 [doi] -PST - epublish -SO - JTO Clin Res Rep. 2024 Feb 20;5(4):100655. doi: 10.1016/j.jtocrr.2024.100655. - eCollection 2024 Apr. - -PMID- 33613698 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220420 -IS - 1758-8340 (Print) -IS - 1758-8359 (Electronic) -IS - 1758-8340 (Linking) -VI - 13 -DP - 2021 -TI - A phase II study of cisplatin plus vinorelbine combined with atezolizumab as - adjuvant therapy for completely resected non-small-cell lung cancer with EGFR - mutation (West Japan Oncology Group 11719L/ADJUST study). -PG - 1758835920987647 -LID - 10.1177/1758835920987647 [doi] -LID - 1758835920987647 -AB - BACKGROUND: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor - (TKI) is a standard treatment in EGFR-mutated advanced non-small-cell lung cancer - (NSCLC); however, previous data have suggested that EGFR-TKI has limited - potential as adjuvant therapy. On the contrary, based on subset analysis with the - immune checkpoint inhibitor (ICI) plus platinum-doublet chemotherapy in advanced - NSCLC with EGFR mutation, we hypothesized that this combination was worth testing - as adjuvant therapy in patients with EGFR-mutated NSCLC. METHODS: Herein, we - introduce our phase II study of cisplatin plus vinorelbine combined with - atezolizumab as adjuvant therapy for completely resected NSCLC with EGFR - mutation. Accrued patients will be pathological stage II-IIIA with completely - resected NSCLC and whose tumors have EGFR mutation. Treatment comprises four - cycles of cisplatin plus vinorelbine combined with atezolizumab followed by - maintenance with atezolizumab. The primary endpoint is the disease-free survival - (DFS) rate at 2 years. Secondary endpoints are DFS, overall survival, and safety. - In total, 18 patients will be enrolled in this study. DISCUSSION: Ongoing phase - III trials of adjuvant ICI allow the inclusion of patients with EGFR mutation, - but our current trial will provide the earliest clinical data on the efficacy of - platinum-doublet chemotherapy with atezolizumab. -CI - © The Author(s), 2021. -FAU - Shibaki, Ryota -AU - Shibaki R -AD - Internal Medicine III, Wakayama Medical University, Wakayama, Japan. -FAU - Akamatsu, Hiroaki -AU - Akamatsu H -AUID- ORCID: 0000-0001-5856-5512 -AD - Internal Medicine III, Wakayama Medical University, 811-1, Kimiidera, Wakayama - City, Wakayama 641-8509, Japan. -FAU - Kato, Terufumi -AU - Kato T -AD - Deparment of Thoracic Oncology Group, Kanagawa Cancer Center, Yokohama, Japan. -FAU - Nishino, Kazumi -AU - Nishino K -AD - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, - Japan. -FAU - Okada, Morihito -AU - Okada M -AD - Department of Surgical Oncology, Research Center for Radiation Casualty Medicine, - Hiroshima University, Hiroshima, Japan. -FAU - Mitsudomi, Tetsuya -AU - Mitsudomi T -AD - Department of Surgery, Kindai University Hospital, Osaka, Japan. -FAU - Wakuda, Kazushige -AU - Wakuda K -AD - Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. -FAU - Yoshimura, Kenichi -AU - Yoshimura K -AD - Medical Center for Translational and Clinical Research, Hiroshima University, - Hiroshima, Japan. -FAU - Yamamoto, Nobuyuki -AU - Yamamoto N -AD - Internal Medicine III, Wakayama Medical University, Wakayama, Japan. -FAU - Nakagawa, Kazuhiko -AU - Nakagawa K -AD - Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, - Japan. -LA - eng -PT - Journal Article -DEP - 20210121 -PL - England -TA - Ther Adv Med Oncol -JT - Therapeutic advances in medical oncology -JID - 101510808 -PMC - PMC7841658 -OTO - NOTNLM -OT - EGFR mutation -OT - adjuvant chemotherapy -OT - atezolizumab -OT - cisplatin -OT - vinorelbine -COIS- Conflict of interest statement: Dr. Shibaki has nothing to disclose. Dr. Akamatsu - reports personal fees from AstraZeneca K.K., personal fees from Boehringer - Ingelheim Japan Inc., personal fees from Bristol-Myers Squibb, grants and - personal fees from Chugai Pharmaceutical Co. Ltd., personal fees from Eli Lilly - Japan K.K., grants and personal fees from MSD K.K., personal fees from Novartis - Pharma K.K., personal fees from Ono Pharmaceutical Co. Ltd., personal fees from - Taiho Pharmaceutical Co. Ltd., from null, outside the submitted work. Dr. Kato - reports grants and personal fees from Abbvie, grants and personal fees from - Amgen, grants and personal fees from AstraZeneca, grants and personal fees from - Bristol Myers Squibb, grants and personal fees from Chugai, grants and personal - fees from Eli Lilly, grants and personal fees from Merck Biopharma, grants and - personal fees from MSD, grants and personal fees from Novartis, grants and - personal fees from Ono, grants and personal fees from Pfizer, grants and personal - fees from Taiho, personal fees from Boehringer Ingelheim, personal fees from - Daiichi-Sankyo, personal fees from Nippon Kayaku, personal fees from Takeda, - grants from Regeneron, outside the submitted work. Dr. Nishino reports personal - fees from AstraZeneca, personal fees from Chugai pharmaceutical, grants and - personal fees from Nippon Boehringer Ingelheim, personal fees from Eli Lilly - Japan, personal fees from Roche Diagnostics, personal fees from Novartis, - personal fees from Pfizer, personal fees from Ono Pharmaceutical, personal fees - from Merk, outside the submitted work. Dr. Okada reports grants and personal fees - from Chugai Pharmaceutical, during the conduct of the study. Dr. MItsudomi - reports grants and personal fees from CHugai, during the conduct of the study; - grants and personal fees from Boehringer Ingelheim, grants and personal fees from - AstraZeneca, grants and personal fees from Pfizer, personal fees from Novartis, - grants and personal fees from MSD, personal fees from BMS, personal fees from - Ono, grants and personal fees from Taiho, grants and personal fees from - Daiichi-Sankyo, personal fees from Janssen, personal fees from Eli-Lilly, outside - the submitted work. Dr. Wakuda reports grants and personal fees from Chugai - Pharmaceutical Co., Ltd., personal fees from Taiho Pharmaceutical, personal fees - from Boehringer Ingelheim, personal fees from Eli Lilly K.K., personal fees from - Ono Pharmaceutical, personal fees from MSD, grants and personal fees from - Astrazeneca, grants from Novartis, grants from Abbvie, outside the submitted - work. Dr. Yoshimura reports personal fees from Astra Zeneca, personal fees from - Chugai Pharma, personal fees from Eli lilly, personal fees from Eizai, personal - fees from Nihon-kayaku, personal fees from Taiho, personal fees from Takeda, - outside the submitted work. Dr. Yamamoto reports grants and personal fees from - MSD K.K., grants and personal fees from AstraZeneca, grants and personal fees - from ONO PHARMACEUTICAL CO., LTD., personal fees from Thermo Fisher Scientific, - grants and personal fees from DAIICHI SANKYO CO., LTD., grants and personal fees - from TAIHO PHARMACEUTICAL CO., LTD., grants and personal fees from Takeda - Pharmaceutical CO., LTD., grants and personal fees from Chugai Pharmaceutical - CO., LTD., grants and personal fees from Eli Lilly Japan K.K., grants and - personal fees from Boehringer-Ingelheim, grants and personal fees from Novartis, - grants and personal fees from Pfizer Inc., personal fees from Bristol-Myers - Squibb, personal fees from Life Technologies Japan Ltd., personal fees from - NIPPON KAYAKU, personal fees from Merk Biopharma, grants from Astellas Pharma - Inc., grants from TSUMURA & CO., grants from SHIONOGI Co., Ltd., grants from - AbbVie GK., grants from Amgen Inc., grants from KYORIN Pharmaceutical Co., Ltd., - grants from Eisai Co., Ltd., grants from TERUMO CORPORATION, grants from Toppan - Printing Co., Ltd., grants from TOSOH, outside the submitted work. Dr. Nakagawa - reports grants and personal fees from AstraZeneca K.K., grants and personal fees - from Astellas Pharma Inc., grants and personal fees from MSD K.K., grants, - personal fees and other from Ono Pharmaceutical Co.,Ltd., grants and personal - fees from Nippon Boehringer Ingelheim Co.,Ltd., grants and personal fees from - Novartis Pharma K.K., grants, personal fees and other from Pfizer Japan Inc., - grants and personal fees from Bristol Myers Squibb Company, grants, personal fees - and other from Eli Lilly Japan K.K., grants and personal fees from Chugai - Pharmaceutical Co.,Ltd., grants and personal fees from Daiichi Sankyo Co., Ltd., - grants and personal fees from Merck Serono Co., Ltd./ Merck Biopharma Co., Ltd., - during the conduct of the study; personal fees from Clinical Trial Co., Ltd., - personal fees from MEDICUS SHUPPAN,Publishers Co., Ltd., personal fees from Care - Net, Inc, personal fees from Reno. Medical K.K., personal fees and other from - KYORIN Pharmaceutical Co.,Ltd., personal fees from Medical Review Co., Ltd., - personal fees from Roche Diagnostics K.K., personal fees from Bayer Yakuhin, Ltd, - personal fees from Medical Mobile Communications co., Ltd, personal fees from 3H - Clinical Trial Inc., personal fees from Nichi-Iko Pharmaceutical Co., Ltd., - grants, personal fees and other from Takeda Pharmaceutical Co.,Ltd., grants and - personal fees from Taiho Pharmaceutical Co.,Ltd., grants and personal fees from - SymBio Pharmaceuticals Limited., personal fees from NANZANDO Co.,Ltd., personal - fees from YODOSHA CO., LTD., personal fees from Nikkei Business Publications, - Inc, personal fees from Thermo Fisher Scientific K.K., personal fees from YOMIURI - TELECASTING CORPORATION., personal fees from Nippon Kayaku Co.,Ltd., grants and - personal fees from AbbVie Inc, grants from inVentiv Health Japan, grants from - ICON Japan K.K., grants from GRITSONE ONCOLOGY.INC, grants from PAREXEL - International Corp., grants from Kissei Pharmaceutical Co.,Ltd., grants from EPS - Corporation., grants from Syneos Health., grants from Pfizer R&D Japan G.K., - grants from A2 Healthcare Corp., grants from Quintiles Inc. / IQVIA Services - JAPAN K.K., grants from EP-CRSU CO., LTD., grants from Linical Co.,Ltd., grants - from Eisai Co., Ltd., grants from CMIC Shift Zero K.K., grants from Kyowa Hakko - Kirin Co.,Ltd, grants from Bayer Yakuhin, Ltd, grants from EPS International - Co.,Ltd,., grants from Otsuka Pharmaceutical Co., Ltd., outside the submitted - work. -EDAT- 2021/02/23 06:00 -MHDA- 2021/02/23 06:01 -PMCR- 2021/01/21 -CRDT- 2021/02/22 05:54 -PHST- 2020/08/25 00:00 [received] -PHST- 2020/12/14 00:00 [accepted] -PHST- 2021/02/22 05:54 [entrez] -PHST- 2021/02/23 06:00 [pubmed] -PHST- 2021/02/23 06:01 [medline] -PHST- 2021/01/21 00:00 [pmc-release] -AID - 10.1177_1758835920987647 [pii] -AID - 10.1177/1758835920987647 [doi] -PST - epublish -SO - Ther Adv Med Oncol. 2021 Jan 21;13:1758835920987647. doi: - 10.1177/1758835920987647. eCollection 2021. - -PMID- 37035161 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230411 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 13 -DP - 2023 -TI - Immunotherapy combined with rh-endostatin improved clinical outcomes over - immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC. -PG - 1137224 -LID - 10.3389/fonc.2023.1137224 [doi] -LID - 1137224 -AB - BACKGROUND: Despite the fact that numerous clinical and preclinical studies have - demonstrated the synergistic effects of combining antiangiogenic or chemotherapy - with immunotherapy, no data have been found to indicate that combination therapy - is more effective and safer as second-line therapy. METHODS: We retrospectively - compared the effectiveness and safety of ICIs plus rh-endostatin to ICIs plus - chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). The - evaluation indicators of this study were progression-free survival (PFS), safety - profile, objective response rate (ORR), disease control rate (DCR), and 1-year - overall survival (OS). RESULTS: The median PFS with immunotherapy plus - rh-endostatin (IE) was 7.10 months (95% CI, 4.64 to 9.56) versus 5.13 months (95% - CI, 4.29 to 5.97) with immunotherapy plus chemotherapy (IC) (HR, 0.56; 95%CI, - 0.33 to 0.95). Treatment-related adverse events of grade 3 or 4 occurred in 7.5% - of the IE group versus 25.0% of the IC group. The ORR in the IE group was 35.0% - versus 20.8% in the IC group (P = 0.137), and the DCR in the IE group was 92.5% - versus 77.1% in the IC group (P = 0.049). The 1-year OS rate for the IE group was - 69.4%, which was higher than the 61.4% of the IC group. CONCLUSION: Our study - showed that ICI therapy combined with endostatin therapy exhibits high efficacy - and safety, suggesting that such a combination might be a viable treatment option - for patients with pre-treated NSCLC in the future. -CI - Copyright © 2023 Huang, Zhong, Zhu, Fu, Li, Peng, Liu, Lu and Chen. -FAU - Huang, Hongxiang -AU - Huang H -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, China. -FAU - Zhong, Peiyuan -AU - Zhong P -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, China. -FAU - Zhu, Xie -AU - Zhu X -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, China. -FAU - Fu, Silv -AU - Fu S -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, China. -AD - Department of Radiation Oncology, Jiangxi Provincial Cancer Hospital, Nanchang, - China. -FAU - Li, Siling -AU - Li S -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, China. -FAU - Peng, Sujuan -AU - Peng S -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, China. -FAU - Liu, Yangyang -AU - Liu Y -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, China. -FAU - Lu, Zhihui -AU - Lu Z -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, China. -FAU - Chen, Li -AU - Chen L -AD - Department of Oncology, The First Affiliated Hospital of Nanchang University, - Nanchang, China. -LA - eng -PT - Journal Article -DEP - 20230323 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC10076840 -OTO - NOTNLM -OT - angiogenesis inhibitors -OT - chemotherapy -OT - immune checkpoint inhibitors -OT - non-small cell lung cancer -OT - tumor microenvironments -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2023/04/11 06:00 -MHDA- 2023/04/11 06:01 -PMCR- 2023/01/01 -CRDT- 2023/04/10 04:17 -PHST- 2023/01/04 00:00 [received] -PHST- 2023/03/10 00:00 [accepted] -PHST- 2023/04/11 06:01 [medline] -PHST- 2023/04/10 04:17 [entrez] -PHST- 2023/04/11 06:00 [pubmed] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2023.1137224 [doi] -PST - epublish -SO - Front Oncol. 2023 Mar 23;13:1137224. doi: 10.3389/fonc.2023.1137224. eCollection - 2023. - -PMID- 34150659 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20220424 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 11 -DP - 2021 -TI - The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously - Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the - Lung Immune Prognostic Index. -PG - 690093 -LID - 10.3389/fonc.2021.690093 [doi] -LID - 690093 -AB - BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy remains the standard of - care for patients with previously treated non-small cell lung cancer. However, - few reports have compared the clinical benefits of second-line ICIs alone with - those of ICIs combined with other therapies, including anti-angiogenesis therapy - or chemotherapy. METHODS: Patients with previously treated advanced non-small - cell lung cancer who received ICIs were retrospectively reviewed. The - progression-free survival (PFS), overall survival, objective response rate, - disease control rate, and safety were assessed. Complete blood cell counts and - serum lactate dehydrogenase (LDH) levels were measured before and after ICI - treatment. RESULTS: Of 120 patients, 75 were treated with ICI monotherapy, 26 - with ICIs plus anti-angiogenic therapy (ICI+A), and 19 with ICIs plus - chemotherapy (ICI+C). The objective response rate was significantly higher in the - ICI+C group (57.9%) than ICI monotherapy (26.3%) and ICI+A (31.8%) groups. The - depth of response was significantly greater in the ICI+C (-35.1%) than ICI+A - (-2.04%) and ICI monotherapy (3.963%) groups. ICI+C afforded a better PFS - compared with the ICI monotherapy and ICI+A groups (8.5 vs. 4.6 and 4.1 months, - respectively). Notably, the pre- and post-treatment peripheral - neutrophil/lymphocyte ratios and serum LDH levels were negatively correlated with - the PFS of the entire cohort. More importantly, the pretreatment lung immune - prognostic index (neutrophil/lymphocyte ratio ≥ 4 and LDH level ≥ upper limit of - normal) satisfactorily predicted the responses to ICI-based strategies. Adverse - events (AEs) occurred in 65.3%, 92.3%, and 94.7% of patients in the ICI - monotherapy, ICI+A, and ICI+C groups, respectively. Grade 3-5 AEs were more - common in the combination therapy groups (ICI+A, 19.2%; ICI+C, 21%; ICI - monotherapy, 4%). CONCLUSION: In second-line settings and beyond, ICIs combined - with chemotherapy prolonged survival, with tolerable AEs. Addition of - anti-angiogenic agents to ICIs did not afford any additional benefits. Further - prospective studies are warranted. -CI - Copyright © 2021 Zhang, Yang, Zhao, Xia, Wang, Jin, Zhou, Zhang, Zhao, Li, Li and - Xia. -FAU - Zhang, Ting -AU - Zhang T -AD - Department of Radiation Oncology, Second Affiliated Hospital of Zhejiang - University School of Medicine, Hangzhou, China. -FAU - Yang, Xue -AU - Yang X -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education), Department of Thoracic Medical Oncology, Peking University Cancer - Hospital and Institute, Beijing, China. -FAU - Zhao, Jing -AU - Zhao J -AD - Department of Medical Oncology, Second Affiliated Hospital of Zhejiang University - School of Medicine, Hangzhou, China. -FAU - Xia, Lixia -AU - Xia L -AD - Key Laboratory of Respiratory Disease of Zhejiang Province, Department of - Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang - University School of Medicine, Hangzhou, China. -FAU - Wang, Qiyuan -AU - Wang Q -AD - Department of Radiology, Second Affiliated Hospital of Zhejiang University School - of Medicine, Hangzhou, China. -FAU - Jin, Rui -AU - Jin R -AD - Key Laboratory of Respiratory Disease of Zhejiang Province, Department of - Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang - University School of Medicine, Hangzhou, China. -FAU - Zhou, Lingxiao -AU - Zhou L -AD - Key Laboratory of Respiratory Disease of Zhejiang Province, Department of - Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang - University School of Medicine, Hangzhou, China. -FAU - Zhang, Bin -AU - Zhang B -AD - Key Laboratory of Respiratory Disease of Zhejiang Province, Department of - Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang - University School of Medicine, Hangzhou, China. -FAU - Zhao, Jun -AU - Zhao J -AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of - Education), Department of Thoracic Medical Oncology, Peking University Cancer - Hospital and Institute, Beijing, China. -FAU - Li, Huijie -AU - Li H -AD - Department of Medical Oncology, Affiliated Hospital of Shandong University of - Traditional Chinese Medicine, Jinan, China. -FAU - Li, Wen -AU - Li W -AD - Key Laboratory of Respiratory Disease of Zhejiang Province, Department of - Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang - University School of Medicine, Hangzhou, China. -FAU - Xia, Yang -AU - Xia Y -AD - Key Laboratory of Respiratory Disease of Zhejiang Province, Department of - Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang - University School of Medicine, Hangzhou, China. -LA - eng -PT - Journal Article -DEP - 20210604 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC8213016 -OTO - NOTNLM -OT - anti-angiogenic therapy -OT - chemotherapy -OT - immune checkpoint inhibitor (ICI) -OT - lung immune prognostic index (LIPI) -OT - non-small cell lung cancer (NSCLC) -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2021/06/22 06:00 -MHDA- 2021/06/22 06:01 -PMCR- 2021/01/01 -CRDT- 2021/06/21 06:00 -PHST- 2021/04/02 00:00 [received] -PHST- 2021/05/17 00:00 [accepted] -PHST- 2021/06/21 06:00 [entrez] -PHST- 2021/06/22 06:00 [pubmed] -PHST- 2021/06/22 06:01 [medline] -PHST- 2021/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2021.690093 [doi] -PST - epublish -SO - Front Oncol. 2021 Jun 4;11:690093. doi: 10.3389/fonc.2021.690093. eCollection - 2021. - -PMID- 39138106 -OWN - NLM -STAT- Publisher -LR - 20240813 -IS - 1938-0690 (Electronic) -IS - 1525-7304 (Linking) -DP - 2024 Jul 25 -TI - Real-World Outcomes of Subsequent Chemotherapy after Progression Following - Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small - Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005). -LID - S1525-7304(24)00152-9 [pii] -LID - 10.1016/j.cllc.2024.07.014 [doi] -AB - BACKGROUND: The optimal subsequent treatment strategy for locally advanced - non-small cell lung cancer (LA-NSCLC) after chemoradiotherapy (CRT) and - consolidative durvalumab therapy remains unknown. We aimed to determine the - optimal subsequent treatment strategy for this clinical population. MATERIALS AND - METHODS: We retrospectively enrolled 523 consecutive patients with LA-NSCLC - treated with CRT and analyzed the treatment outcomes of subsequent therapy after - progression following CRT and consolidative durvalumab therapy. Patients who - received tyrosine kinase inhibitors as subsequent therapy were excluded. RESULTS: - Out of 122 patients who received subsequent chemotherapy, 55% underwent - platinum-based, 25% non-platinum-based, and 20% immune checkpoint inhibitor - (ICI)-containing therapies. In the platinum-based group, patients with a - durvalumab-progression-free survival (Dur-PFS) ≥ 1 year had a significantly - longer median subsequent therapy-PFS (SubTx-PFS) than those with Dur-PFS < 1 year - (13.2 months vs. 4.7 months; hazard ratio, 0.45; 95% confidence interval, - 0.21-0.97; P = .04). Furthermore, among patients receiving non-platinum-based - chemotherapy, the median SubTx-PFS was longer in the combined with angiogenesis - inhibitor group than in the without group, although the difference was not - statistically significant. No significant difference of SubTx-PFS was observed - between the reason for durvalumab discontinuation and the outcomes of - ICI-containing therapy. CONCLUSION: In clinical practice, platinum-based - chemotherapy rechallenge is frequently employed following progression subsequent - to CRT and consolidative durvalumab therapy for LA-NSCLC. Optimal treatment - strategies may consider Dur-PFS and angiogenesis inhibitor feasibility. Further - research is warranted to identify clinical biomarkers that can help identify - patients who would benefit from ICI rechallenge. -CI - Copyright © 2024 Elsevier Inc. All rights reserved. -FAU - Kawachi, Hayato -AU - Kawachi H -AD - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, - Osaka, Japan; Department of Pulmonary Medicine, Graduate School of Medical - Science, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan. - Electronic address: kwhat@koto.kpu-m.ac.jp. -FAU - Tamiya, Motohiro -AU - Tamiya M -AD - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, - Osaka, Japan. -FAU - Oya, Yuko -AU - Oya Y -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, - Japan; Department of Respiratory Medicine, Fujita Health University, Toyoake, - Aichi, Japan. -FAU - Saito, Go -AU - Saito G -AD - Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, - Chiba, Japan. -FAU - Taniguchi, Yoshihiko -AU - Taniguchi Y -AD - Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Sakai, - Osaka, Japan. -FAU - Matsumoto, Hirotaka -AU - Matsumoto H -AD - Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical - Center, Amagasaki, Hyogo, Japan. -FAU - Sato, Yuki -AU - Sato Y -AD - Department of Respiratory Medicine, Kobe City Medical Center General Hospital, - Kobe, Hyogo, Japan. -FAU - Otsuki, Taiichiro -AU - Otsuki T -AD - Department of Respiratory Medicine and Hematology, School of Medicine, Hyogo - Medical University, Nishinomiya, Hyogo, Japan. -FAU - Suzuki, Hidekazu -AU - Suzuki H -AD - Department of Thoracic Oncology, Osaka Habikino Medical Center, Habikino, Osaka, - Japan. -FAU - Fukuda, Yasushi -AU - Fukuda Y -AD - Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, - Okayama, Japan. -FAU - Tanaka, Satoshi -AU - Tanaka S -AD - Department of Respiratory Medicine, Osaka General Medical Center, Osaka, Osaka, - Japan. -FAU - Tsukita, Yoko -AU - Tsukita Y -AD - Department of Respiratory Medicine, Tohoku University Hospital, Sendai, Miyagi, - Japan. -FAU - Uchida, Junji -AU - Uchida J -AD - Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama - Medical Center, Toyonaka, Osaka, Japan. -FAU - Sakata, Yoshihiko -AU - Sakata Y -AD - Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, - Kumamoto, Japan. -FAU - Nakatani, Yuki -AU - Nakatani Y -AD - Department of Medical Oncology, Osaka City General Hospital, Osaka, Osaka, Japan. -FAU - Shibaki, Ryota -AU - Shibaki R -AD - Internal Medicine III, Wakayama Medical University, Wakayama, Wakayama, Japan. -FAU - Arai, Daisuke -AU - Arai D -AD - Department of Internal Medicine, Saiseikai Utsunomiya Hospital, Utsunomiya, - Tochigi, Japan. -FAU - Okada, Asuka -AU - Okada A -AD - Department of Respiratory Medicine, Saiseikai Suita Hospital, Suita, Osaka, - Japan. -FAU - Hara, Satoshi -AU - Hara S -AD - Department of Respiratory Medicine, Itami City Hospital, Itami, Japan. -FAU - Takayama, Koichi -AU - Takayama K -AD - Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto - Prefectural University of Medicine, Kyoto, Kyoto, Japan. -FAU - Nishino, Kazumi -AU - Nishino K -AD - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, - Osaka, Japan. -LA - eng -PT - Journal Article -DEP - 20240725 -PL - United States -TA - Clin Lung Cancer -JT - Clinical lung cancer -JID - 100893225 -SB - IM -OTO - NOTNLM -OT - Durvalumab -OT - Immune checkpoint inhibitor -OT - Platinum-based chemotherapy -OT - Rechallenge -OT - Subsequent therapy -COIS- Disclosure Hayato Kawachi reported receiving personal fees from AstraZeneca, - Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, MSD, Ono Pharmaceutical, - and Taiho Pharmaceutical outside the submitted work. Motohiro Tamiya reported - receiving personal fees from Amgen, Asahi Kasei Pharmaceutical, AstraZeneca, - Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly, - MSD, Ono Pharmaceutical, Pfizer, and Taiho Pharmaceutical outside the submitted - work. Yuko Oya reported receiving personal fees from Amgen, AstraZeneca, Bristol - Myers Squibb, Chugai Pharmaceutical, Eli Lilly, MSD, Novartis Pharma KK, Pfizer, - Taiho Pharmaceutical, Daiichi Sankyo, and Takeda Pharmaceutical Company Limited - outside the submitted work. Go Saito reported receiving personal fees from - AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo Company, MSD, Novartis Pharma - KK, Ono Pharmaceutical, Pfizer, and Taiho Pharmaceutical outside the submitted - work. Yoshihiko Taniguchi reports receiving personal fees from AstraZeneca, - Bristol Myers Squibb, Chugai Pharmaceutical, MSD, and Ono Pharmaceutical outside - the submitted work. Hirotaka Matsumoto reported receiving personal fees from - AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, Kyowa Kirin, MSD, - Nippon Kayaku Co. Ltd., Ono Pharmaceutical, Taiho Pharmaceutical, and Takeda - Pharmaceutical Company Limited outside the submitted work. Yuki Sato reported - receiving personal fees from AstraZeneca, Bristol Myers Squibb, Chugai - Pharmaceutical, Eli Lilly, MSD, Novartis Pharma KK, Ono Pharmaceutical, Pfizer, - Taiho Pharmaceutical, Nippon Kayaku, Kyowa Kirin, and Takeda Pharmaceutical - Company Limited outside the submitted work. Taiichiro Otsuki reported receiving - personal fees from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, - Eisai Co. Ltd., MSD, Nippon Kayaku Co. Ltd., Ono Pharmaceutical, Takeda - Pharmaceutical Company Limited, and Tsumura & Co. outside the submitted work. - Hidekazu Suzuki reported receiving personal fees from AstraZeneca, Chugai - Pharmaceutical, MSD, and Takeda Pharmaceutical Company Limited outside the - submitted work. Yasushi Fukuda reported receiving personal fees from AstraZeneca, - Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi - Sankyo, Merck Biopharma, MSD, Novartis, Ono Pharmaceutical, and Taiho - Pharmaceutical outside the submitted work. Satoshi Tanaka declares that he has no - competing financial interests or personal relationships that would affect the - research reported in this paper. Yoko Tsukita reported receiving personal fees - from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai - Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly, MSD, and Taiho Pharmaceutical - outside the submitted work. Junji Uchida declares that he has no competing - financial interests or personal relationships that would affect the research - reported in this paper. Yoshihiko Sakata reported receiving personal fees from - AstraZeneca, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Chugai - Pharmaceutical Co Ltd, Eli Lilly, Kyowa KIRIN, MSD, Novartis Pharma KK, Taiho - Pharmaceutical, Takeda Pharmaceutical Company Limited outside the submitted work. - Yuki Nakatani declares that he has no competing financial interests or personal - relationships that would affect the research reported in this paper. Ryota - Shibaki reported receiving personal fees from AstraZeneca, Chugai Pharmaceutical, - MSD, and Taiho Pharmaceutical outside of the submitted work. Daisuke Arai - reported receiving personal fees from AstraZeneca, Chugai Pharmaceutical, Merck - Biopharma Co. Ltd., MSD, Nippon Kayaku Co. Ltd., Ono Pharmaceutical, Taiho - Pharmaceutical, and Takeda Pharmaceutical Company Limited outside the submitted - work. Asuka Okada reported receiving personal fees from AstraZeneca, Boehringer - Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Kyowa KIRIN, - MSD, and Nippon Kayaku Co. Ltd. outside the submitted work. Satoshi Hara declares - that he has no competing financial interests or personal relationships that would - affect the research reported in this paper. Koichi Takayama reported receiving - research grants from Chugai Pharmaceutical and Ono Pharmaceutical and personal - fees from AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, - Daiichi-Sankyo, Eli Lilly, MSD, and Merck outside the purview of the submitted - work. Kazumi Nishino reported receiving grants from Ono, TAIHO, MSD, AbbVie, - DAIICHI SANKYO, Amgen, Eisai, Sanofi, Janssen, Novartis, Pfizer, Eli Lilly, - Merck, Takeda, Chugai, and Merus; and personal fees from AstraZeneca, Bristol - Myers Squibb, Chugai, Eli Lilly, Janssen, Nippon Boehringer Ingerheim, Nippon - Kayaku, Merck, Novartis, Pfizer, and Roche outside the submitted work. -EDAT- 2024/08/14 00:42 -MHDA- 2024/08/14 00:42 -CRDT- 2024/08/13 21:55 -PHST- 2024/04/25 00:00 [received] -PHST- 2024/07/11 00:00 [revised] -PHST- 2024/07/21 00:00 [accepted] -PHST- 2024/08/14 00:42 [medline] -PHST- 2024/08/14 00:42 [pubmed] -PHST- 2024/08/13 21:55 [entrez] -AID - S1525-7304(24)00152-9 [pii] -AID - 10.1016/j.cllc.2024.07.014 [doi] -PST - aheadofprint -SO - Clin Lung Cancer. 2024 Jul 25:S1525-7304(24)00152-9. doi: - 10.1016/j.cllc.2024.07.014. - -PMID- 32411590 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20200928 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 10 -DP - 2020 -TI - Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy - in Advanced Non-Small Cell Lung Cancer. -PG - 480 -LID - 10.3389/fonc.2020.00480 [doi] -LID - 480 -AB - Objectives: Accumulating evidence has illustrated greater benefit of - immunotherapy in tumors with high tumor mutation burden (TMB), whereas its impact - on targeted therapy or chemotherapy is undefined. Herein, we evaluated TMB - outside of immuno-oncology in epidermal growth factor receptor (EGFR)-mutant - patients and EGFR/ALK wild-type cohorts. Methods: In this retrospective study, we - correlated TMB with response rate and progression-free survival (PFS) of patients - who received EGFR-tyrosine kinase inhibitors (TKIs) or pemetrexed/platinum as - first-line therapy. Tumor mutation burden was evaluated by targeted - next-generation sequencing. Patients were divided into low (L)/intermediate - (I)/high (H) TMB groups by tertiles. Results: In EGFR-mutant cohort, TMB-L - patients had a massively improved PFS compared to TMB-I and TMB-H patients (16.4 - vs. 9.0 vs. 7.4 months; log-rank p = 0.006) when treated with first-generation - EGFR-TKIs. In EGFR/ALK wild-type cohorts who received pemetrexed/platinum - regimen, the objective response rate (ORR) of TMB-L group was statistically - superior than that of TMB-I and TMB-H groups (53.8% vs. 23% vs. 8.3%; log-rank p - = 0.037), and patients with low TMB had a numerically but not significantly - prolonged PFS (6.9 vs. 4.3 vs. 4.6 m; log-rank p = 0.22). Conclusion: Our data - provide insights into the relevance between TMB and targeted/chemo therapy. - Higher non-synonymous TMB correlates with inferior PFS for first-generation - EGFR-TKIs in EGFR-driven patients and worse response to pemetrexed/platinum - regimen in EGFR/ALK wild-type patients, which has potential clinical implications - for cancer treatment but needs corroboration in larger studies. -CI - Copyright © 2020 Lin, Shi, Zhao, He, Fan, Xu, Shao, Yu and Jin. -FAU - Lin, Chen -AU - Lin C -AD - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, - Hangzhou, China. -AD - Department of Medical Oncology, Cancer Hospital of the University of Chinese - Academy of Sciences, Hangzhou, China. -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. -FAU - Shi, Xun -AU - Shi X -AD - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, - Hangzhou, China. -AD - Department of Medical Oncology, Cancer Hospital of the University of Chinese - Academy of Sciences, Hangzhou, China. -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. -FAU - Zhao, Jun -AU - Zhao J -AD - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, - Hangzhou, China. -AD - Department of Medical Oncology, Cancer Hospital of the University of Chinese - Academy of Sciences, Hangzhou, China. -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. -FAU - He, Qiong -AU - He Q -AD - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, - Hangzhou, China. -AD - Department of Medical Oncology, Cancer Hospital of the University of Chinese - Academy of Sciences, Hangzhou, China. -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. -FAU - Fan, Yun -AU - Fan Y -AD - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, - Hangzhou, China. -AD - Department of Medical Oncology, Cancer Hospital of the University of Chinese - Academy of Sciences, Hangzhou, China. -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. -FAU - Xu, Weizhen -AU - Xu W -AD - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, - Hangzhou, China. -AD - Clinical Trials Center, Zhejiang Cancer Hospital, Hangzhou, China. -FAU - Shao, Yang -AU - Shao Y -AD - Nanjing Geneseeq Technology Inc., Nangjing, China. -FAU - Yu, Xinmin -AU - Yu X -AD - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, - Hangzhou, China. -AD - Department of Medical Oncology, Cancer Hospital of the University of Chinese - Academy of Sciences, Hangzhou, China. -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. -AD - Zhejiang Key Laboratory of Diagnosis and Treatment Technology of Thoracic - Oncology, Hangzhou, China. -FAU - Jin, Ying -AU - Jin Y -AD - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, - Hangzhou, China. -AD - Department of Medical Oncology, Cancer Hospital of the University of Chinese - Academy of Sciences, Hangzhou, China. -AD - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. -AD - Zhejiang Key Laboratory of Radiation Oncology, Hangzhou, China. -LA - eng -PT - Journal Article -DEP - 20200429 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC7201001 -OTO - NOTNLM -OT - chemotherapy -OT - clinical benefit -OT - epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) -OT - non–small cell lung cancer (NSCLC) -OT - tumor mutation burden (TMB) -EDAT- 2020/05/16 06:00 -MHDA- 2020/05/16 06:01 -PMCR- 2020/01/01 -CRDT- 2020/05/16 06:00 -PHST- 2019/12/10 00:00 [received] -PHST- 2020/03/17 00:00 [accepted] -PHST- 2020/05/16 06:00 [entrez] -PHST- 2020/05/16 06:00 [pubmed] -PHST- 2020/05/16 06:01 [medline] -PHST- 2020/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2020.00480 [doi] -PST - epublish -SO - Front Oncol. 2020 Apr 29;10:480. doi: 10.3389/fonc.2020.00480. eCollection 2020. - -PMID- 27461275 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20191120 -IS - 1479-5876 (Electronic) -IS - 1479-5876 (Linking) -VI - 14 -IP - 1 -DP - 2016 Jul 25 -TI - Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. -PG - 65 -LID - 10.1186/s12967-016-0791-2 [doi] -LID - 65 -AB - MELANOMA BRIDGE 2015 KEYNOTE SPEAKER PRESENTATIONS Molecular and immuno-advances - K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma - Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies K2 - Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK - inhibitors help the establishment of drug resistance Gennaro Ciliberto, Luigi - Fattore, Debora Malpicci, Luigi Aurisicchio, Paolo Antonio Ascierto, Carlo M. - Croce, Rita Mancini K3 Tumor-intrinsic beta-catenin signaling mediates - tumor-immune avoidance Stefani Spranger, Thomas F. Gajewski K4 Intracellular - tumor antigens as a source of targets of antibody-based immunotherapy of melanoma - Yangyang Wang, Soldano Ferrone Combination therapies K5 Harnessing radiotherapy - to improve responses to immunotherapy in cancer Claire Vanpouille-Box, Erik - Wennerberg, Karsten A. Pilones, Silvia C. Formenti, Sandra Demaria K6 Creating a - T cell-inflamed tumor microenvironment overcomes resistance to checkpoint - blockade Haidong Tang, Yang Wang, Yang-Xin Fu K7 Biomarkers for treatment - decisions? Reinhard Dummer K8 Combining oncolytic therapies in the era of - checkpoint inhibitors Igor Puzanov K9 Immune checkpoint blockade for melanoma: - should we combine or sequence ipilimumab and PD-1 antibody therapy? Michael A. - Postow News in immunotherapy K10 An update on adjuvant and neoadjuvant therapy - for melanom Ahmad Tarhini K11 Targeting multiple inhibitory receptors in melanoma - Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, - Cindy Sanders, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. - Korman, Hassane M. Zarour K12 Improving adoptive immune therapy using genetically - engineered T cells David F. Stroncek Tumor microenvironment and biomarkers K13 - Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression? - Veronica Huber, Licia Rivoltini K14 Update on the SITC biomarker taskforce: - progress and challenges Magdalena Thurin World-wide immunoscore task force: an - update K15 The immunoscore in colorectal cancer highlights the importance of - digital scoring systems in surgical pathology Tilman Rau, Alessandro Lugli K16 - The immunoscore: toward an integrated immunomonitoring from the diagnosis to the - follow up of cancer’s patients Franck Pagès Economic sustainability of melanoma - treatments: regulatory, health technology assessment and market access issues K17 - Nivolumab, the regulatory experience in immunotherapy Jorge Camarero, Arantxa - Sancho K18 Evidence to optimize access for immunotherapies Claudio Jommi ORAL - PRESENTATIONS Molecular and immuno-advances O1 Ipilimumab treatment results in - CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCs - Yago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy Gentilcore, Isabel - Poschke, Giuseppe V. Masucci, Johan Hansson, Rolf Kiessling O2 Evaluation of - prognostic and therapeutic potential of COX-2 and PD-L1 in primary and metastatic - melanoma Giosuè Scognamiglio, Francesco Sabbatino, Federica Zito Marino, Anna - Maria Anniciello, Monica Cantile, Margherita Cerrone, Stefania Scala, Crescenzo - D’alterio, Angela Ianaro, Giuseppe Cirino, Paolo Antonio Ascierto, Giuseppina - Liguori, Gerardo Botti O3 Vemurafenib in patients with BRAFV600 mutation–positive - metastatic melanoma: final overall survival results of the BRIM-3 study Paul B. - Chapman, Caroline Robert, James Larkin, John B. Haanen, Antoni Ribas, David Hogg, - Omid Hamid, Paolo Antonio Ascierto, Alessandro Testori, Paul Lorigan, Reinhard - Dummer, Jeffrey A. Sosman, Keith T. Flaherty, Huibin Yue, Shelley Coleman, Ivor - Caro, Axel Hauschild, Grant A. McArthur O4 Updated survival, response and safety - data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) - and ipilimumab (IPI) in advanced melanoma Mario Sznol, Margaret K. Callahan, - Harriet Kluger, Michael A. Postow, RuthAnn Gordan, Neil H. Segal, Naiyer A. - Rizvi, Alexander Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, - Amanda Ralabate, Angel Rivera, Stephanie A. Kronenberg, Blessing Agunwamba, Mary - Ruisi, Christine Horak, Joel Jiang, Jedd Wolchok Combination therapies O5 - Efficacy and correlative biomarker analysis of the coBRIM study comparing - cobimetinib (COBI) + vemurafenib (VEM) vs placebo (PBO) + VEM in advanced - BRAF-mutated melanoma patients (pts) Paolo A. Ascierto, Grant A. McArthur, James - Larkin, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil - Stoyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline - Dutriaux, Claus Garbe, Matthew Wongchenko, Ilsung Chang, Daniel O. Koralek, - Isabelle Rooney, Yibing Yan, Antoni Ribas, Brigitte Dréno O6 Preliminary clinical - safety, tolerability and activity results from a Phase Ib study of atezolizumab - (anti-PDL1) combined with vemurafenib in BRAFV600-mutant metastatic melanoma Ryan - Sullivan, Omid Hamid, Manish Patel, Stephen Hodi, Rodabe Amaria, Peter Boasberg, - Jeffrey Wallin, Xian He, Edward Cha, Nicole Richie, Marcus Ballinger, Patrick Hwu - O7 Preliminary safety and efficacy data from a phase 1/2 study of epacadostat - (INCB024360) in combination with pembrolizumab in patients with - advanced/metastatic melanoma Thomas F. Gajewski, Omid Hamid, David C. Smith, Todd - M. Bauer, Jeffrey S. Wasser, Jason J. Luke, Ani S. Balmanoukian, David R. - Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Tara C. Gangadhar O8 Primary - analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and - pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma Reinhard Dummer, - Georgina V. Long, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, - Robert H.I. Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony - J. Olszanski, Thomas F. Gajewski, John M. Kirkwood, Christine Gause, Lisa Chen, - David R. Kaufman, Jeffrey Chou, F. Stephen Hodi News in immunotherapy O9 Two-year - survival and safety update in patients (pts) with treatment-naïve advanced - melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066 - Victoria Atkinson, Paolo A. Ascierto, Georgina V. Long, Benjamin Brady, Caroline - Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, - Catriona McNeil, Ewa Kalinka-Warzocha, Celeste Lebbé, Lars Ny, Matias Chacon, - Paola Queirolo, Carmen Loquai, Parneet Cheema, Alfonso Berrocal, Karmele Mujika - Eizmendi, Luis De La Cruz-Merino, Gil Bar-Sela, Christine Horak, Joel Jiang, - Helene Hardy, Caroline Robert O10 Efficacy and safety of nivolumab (NIVO) in - patients (pts) with advanced melanoma (MEL) who were treated beyond progression - in CheckMate 066/067 Georgina V. Long, Jeffrey S. Weber, James Larkin, Victoria - Atkinson, Jean-Jacques Grob, Reinhard Dummer, Caroline Robert, Ivan - Marquez-Rodas, Catriona McNeil, Henrik Schmidt, Karen Briscoe, Jean-François - Baurain, F. Stephen Hodi, Jedd D. Wolchok Tumor microenvironment and biomarkers - O11 New biomarkers for response/resistance to BRAF inhibitor therapy in - metastatic melanoma Rosamaria Pinto, Simona De Summa, Vito Michele Garrisi, - Sabino Strippoli, Amalia Azzariti, Gabriella Guida, Michele Guida, Stefania - Tommasi O12 Chemokine receptor patterns in lymphocytes mirror metastatic - spreading in melanoma and response to ipilimumab Nicolas Jacquelot, David Enot, - Caroline Flament, Jonathan M. Pitt, Nadège Vimond, Carolin Blattner, Takahiro - Yamazaki, Maria-Paula Roberti, Marie Vetizou, Romain Daillere, Vichnou - Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L Slingluff Jr, Federica - Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, - Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michaele - Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander - Eggermont, Laurence Zitvogel O13 Serum levels of PD1- and CD28-positive exosomes - before Ipilimumab correlate with therapeutic response in metastatic melanoma - patients Passarelli Anna, Tucci Marco, Stucci Stefania, Mannavola Francesco, - Capone Mariaelena, Madonna Gabriele, Ascierto Paolo Antonio, Silvestris Franco - O14 Immunological prognostic factors in stage III melanomas María Paula Roberti, - Nicolas Jacquelot, David P Enot, Sylvie Rusakiewicz, Michaela Semeraro, Sarah - Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Ana Carrizossa Anderson, - Caroline Robert, Christophe Borg, Benjamin Weide, François Aubin, Stéphane Dalle, - Michele Maio, Jedd D. Wolchok, Holbrook Kohrt, Maha Ayyoub, Guido Kroemer, - Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence Zitvogel - POSTER PRESENTATIONS Molecular and immuno-advances P1 Human melanoma cells - resistant to B-RAF and MEK inhibition exhibit mesenchymal-like features Anna Lisa - De Presbiteris, Fabiola Gilda Cordaro, Rosa Camerlingo, Federica Fratangelo, - Nicola Mozzillo, Giuseppe Pirozzi, Eduardo J. Patriarca, Paolo A. Ascierto, - Emilia Caputo P2 Anti-proliferative and pro-apoptotic effect of ABT888 on - melanoma cell lines and its potential role in the treatment of melanoma resistant - to B-RAF inhibitors Federica Fratangelo, Rosa Camerlingo, Emilia Caputo, Maria - Letizia Motti, Rosaria Falcone, Roberta Miceli, Mariaelena Capone, Gabriele - Madonna, Domenico Mallardo, Maria Vincenza Carriero, Giuseppe Pirozzi and Paolo - Antonio Ascierto P3 Involvement of the L-cysteine/CSE/H2S pathway in human - melanoma progression Elisabetta Panza, Paola De Cicco, Chiara Armogida, Giuseppe - Ercolano, Rosa Camerlingo, Giuseppe Pirozzi, Giosuè Scognamiglio, Gerardo Botti, - Giuseppe Cirino, Angela Ianaro P4 Cancer stem cell antigen revealing pattern of - antibody variable region genes were defined by immunoglobulin repertoire analysis - in patients with malignant melanoma Beatrix Kotlan, Gabriella Liszkay, Miri - Blank, Timea Balatoni, Judit Olasz, Emil Farkas, Andras Szollar, Akos Savolt, - Maria Godeny, Orsolya Csuka, Szabolcs Horvath, Klara Eles, Yehuda Shoenfeld and - Miklos Kasler P5 Upregulation of Neuregulin-1 expression is a hallmark of - adaptive response to BRAF/MEK inhibitors in melanoma Debora Malpicci, Luigi - Fattore, Susan Costantini, Francesca Capone, Paolo Antonio Ascierto, Rita - Mancini, Gennaro Ciliberto P6 HuR positively regulates migration of HTB63 - melanoma cells Farnaz Moradi, Pontus Berglund, Karin Leandersson, Rickard - Linnskog, Tommy Andersson, Chandra Prakash Prasad P7 Prolyl 4- (C-P4H) - hydroxylases have opposing effects in malignant melanoma: implication in - prognosis and therapy Cristiana Lo Nigro, Laura Lattanzio, Hexiao Wang, Charlotte - Proby, Nelofer Syed, Marcella Occelli, Carolina Cauchi, Marco Merlano, Catherine - Harwood, Alastair Thompson, Tim Crook P8 Urokinase receptor antagonists: novel - agents for the treatment of melanoma Maria Letizia Motti, Katia Bifulco, Vincenzo - Ingangi, Michele Minopoli, Concetta Ragone, Federica Fratangelo, Antonello Pessi, - Gennaro Ciliberto, Paolo Antonio Ascierto, Maria Vincenza Carriero P9 Exosomes - released by melanoma cell lines enhance chemotaxis of primary tumor cells - Francesco Mannavola, Stella D’Oronzo, Claudia Felici, Marco Tucci, Antonio - Doronzo, Franco Silvestris P10 New insights in mitochondrial metabolic - reprogramming in melanoma Anna Ferretta, Gabriella Guida, Stefania Guida, Imma - Maida, Tiziana Cocco, Sabino Strippoli, Stefania Tommasi, Amalia Azzariti, - Michele Guida P11 Lenalidomide restrains the proliferation in melanoma cells - through a negative regulation of their cell cycle Stella D’Oronzo, Anna - Passarelli, Claudia Felici, Marco Tucci, Davide Quaresmini, Franco Silvestris - Combination therapies P12 Chemoimmunotherapy elicits polyfunctional anti-tumor - CD8 + T cells depending on the activation of an AKT pathway sustained by ICOS - Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, MariaLaura - Foddai, Helena Stabile, Angela Gismondi, Angela Santoni, Paola Nisticò P13 - Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic - melanoma patients Andrea P. Sponghini, Francesca Platini, Elena Marra, David - Rondonotti, Oscar Alabiso, Maria T. Fierro, Paola Savoia, Florian Stratica, - Pietro Quaglino P14 Electrothermal bipolar vessel sealing system dissection - reduces seroma output or time to drain removal following axillary and - ilio-inguinal node dissection in melanoma patients: a pilot study Di Monta - Gianluca, Caracò Corrado, Di Marzo Massimiliano, Marone Ugo, Di Cecilia Maria - Luisa, Mozzillo Nicola News in immunotherapy P15 Clinical and immunological - response to ipilimumab in a metastatic melanoma patient with HIV infection - Francesco Sabbatino, Celeste Fusciello1, Antonio Marra, Rosario Guarrasi, Carlo - Baldi, Rosa Russo, Di Giulio Giovanni, Vincenzo Faiola, Pio Zeppa, Stefano Pepe - P16 Immunotherapy and hypophysitis: a case report Elisabetta Gambale, Consiglia - Carella, Alessandra Di Paolo, Michele De Tursi Tumor microenvironment and - biomarkers P17 New immuno- histochemical markers for the differential diagnosis - of atypical melanocytic lesions with uncertain malignant potential Laura Marra, - Giosuè Scognamiglio, Monica Cantile, Margherita Cerrone, Fara De Murtas, Valeria - Sorrentino, Anna Maria Anniciello, Gerardo Botti P18 Utility of simultaneous - measurement of three serum tumor markers in melanoma patients Angela Sandru, - Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca - P19 The significance of various cut-off levels of melanoma inhibitory activity in - evaluation of cutaneous melanoma patients Angela Sandru, Silviu Voinea, Eugenia - Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P20 The long noncoding - RNA HOTAIR is associated to metastatic progression of melanoma and it can be - identified in the blood of patients with advanced disease Chiara Botti, Giosuè - Scognamiglio, Laura Marra, Gabriella Aquino, Rosaria Falcone, Annamaria - Anniciello, Paolo Antonio Ascierto, Gerardo Botti, Monica Cantile Other P21 The - effect of Sentinel Lymph Node Biopsy in melanoma mortality: timing of dissection - Cristina Fortes, Simona Mastroeni, Alessio Caggiati, Francesca Passarelli, Alba - Zappalà, Maria Capuano, Riccardo Bono, Maurizio Nudo, Claudia Marino, Paola - Michelozzi P22 Epidemiological survey on related psychopathology in melanoma - Valeria De Biasio, Vincenzo C. Battarra IMMUNOTHERAPY BRIDGE KEYNOTE SPEAKER - PRESENTATIONS Immunotherapy beyond melanoma K19 Predictor of response to - radiation and immunotherapy Silvia Formenti K20 Response and resistance to PD-1 - pathway blockade: clues from the tumor microenvironment Maria Libera Ascierto, - Tracee L. McMiller, Alan E. Berger, Ludmila Danilova, Robert A. Anders, George J. - Netto, Haiying Xu, Theresa S. Pritchard, Jinshui Fan, Chris Cheadle, Leslie Cope, - Charles G. Drake, Drew M. Pardoll, Janis M. Taube and Suzanne L. Topalian K21 - Combination immunotherapy with autologous stem cell transplantation, protein - immunization, and PBMC reinfusion in myeloma patients Sacha Gnjatic, Sarah - Nataraj, Naoko Imai, Adeeb Rahman, Achim A. Jungbluth, Linda Pan, Ralph Venhaus, - Andrew Park, Frédéric F. Lehmann, Nikoletta Lendvai, Adam D. Cohen, and Hearn J. - Cho K22 Anti-cancer immunity despite T cell “exhaustion” Speiser Daniel - Immunotherapy in oncology (I-O): data from clinical trial K23 The Checkpoint - Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) - Vera Hirsh -FAU - Nanda, Vashisht G Y -AU - Nanda VGY -AD - Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer - Center, Houston, TX USA -FAU - Peng, Weiyi -AU - Peng W -AD - Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer - Center, Houston, TX USA -FAU - Hwu, Patrick -AU - Hwu P -AD - Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer - Center, Houston, TX USA -AD - The University of Texas MD Anderson Cancer Center, Houston, TX USA -FAU - Davies, Michael A -AU - Davies MA -AD - Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer - Center, Houston, TX USA -FAU - Ciliberto, Gennaro -AU - Ciliberto G -AD - Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, - Naples, Italy -AD - IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy -FAU - Fattore, Luigi -AU - Fattore L -AD - Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, - Naples, Italy -FAU - Malpicci, Debora -AU - Malpicci D -AD - Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di - Catanzaro “Magna Graecia”, Catanzaro, Italy -FAU - Aurisicchio, Luigi -AU - Aurisicchio L -AD - Takis s.r.l., Rome, Italy -FAU - Ascierto, Paolo Antonio -AU - Ascierto PA -AD - Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, - Naples, Italy -AD - Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio - e la Cura Tumori Fondazione “G. Pascale”, Napoli, Italy -AD - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale - Tumori Fondazione Pascale, Naples, Italy -AD - IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy -AD - IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy -AD - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale - Tumori Fondazione “G. Pascale”, Napoli, Italy -FAU - Croce, Carlo M -AU - Croce CM -AD - Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State - University Comprehensive Cancer Center, Columbus, OH USA -FAU - Mancini, Rita -AU - Mancini R -AD - Dipartimento di Chirurgia “P. Valdoni”, Sapienza Università di Roma, Rome, Italy -AD - Dipartimento di Medicina Clinica e Molecolare, Sapienza Università di Roma, Rome, - Italy -FAU - Spranger, Stefani -AU - Spranger S -AD - Department of Pathology, University of Chicago, Chicago, IL USA -FAU - Gajewski, Thomas F -AU - Gajewski TF -AD - Department of Pathology, University of Chicago, Chicago, IL USA -AD - Department of Medicine, University of Chicago, Chicago, IL USA -AD - Department of Pathology and Department of Medicine-Section of - Hematology/Oncology, University of Chicago, Chicago, IL USA -AD - The University of Chicago Medicine, Chicago, IL USA -FAU - Wang, Yangyang -AU - Wang Y -AD - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, - Boston, MA USA -FAU - Ferrone, Soldano -AU - Ferrone S -AD - Department of Surgery, Massachusetts General Hospital, Harvard Medical School, - Boston, MA USA -FAU - Vanpouille-Box, Claire -AU - Vanpouille-Box C -AD - Department of Pathology, NYU School of Medicine, New York, NY USA -FAU - Wennerberg, Erik -AU - Wennerberg E -AD - Department of Pathology, NYU School of Medicine, New York, NY USA -FAU - Pilones, Karsten A -AU - Pilones KA -AD - Department of Pathology, NYU School of Medicine, New York, NY USA -AD - Department of Radiation Oncology, NYU School of Medicine, New York, NY USA -FAU - Formenti, Silvia C -AU - Formenti SC -AD - Department of Radiation Oncology, Weill Cornell Medical College, New York, NY USA -FAU - Demaria, Sandra -AU - Demaria S -AD - Department of Pathology, NYU School of Medicine, New York, NY USA -AD - Department of Radiation Oncology, NYU School of Medicine, New York, NY USA -FAU - Tang, Haidong -AU - Tang H -AD - Department of Pathology, University of Texas Southwestern, Dallas, USA -FAU - Wang, Yang -AU - Wang Y -AD - Department of Pathology, University of Texas Southwestern, Dallas, USA -FAU - Fu, Yang-Xin -AU - Fu YX -AD - Department of Pathology, University of Texas Southwestern, Dallas, USA -FAU - Dummer, Reinhard -AU - Dummer R -AD - Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland -AD - Dermatologische Klinik, University of Zurich, Zurich, Switzerland -AD - University Hospital of Zurich, Zurich, Switzerland -AD - Universitaets Spital, Zurich, Switzerland -FAU - Puzanov, Igor -AU - Puzanov I -AD - Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN USA -AD - Vanderbilt University Medical Center, Nashville, TN USA -FAU - Tarhini, Ahmad -AU - Tarhini A -AD - Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, - Pittsburgh, Pennsylvania USA -FAU - Chauvin, Joe-Marc -AU - Chauvin JM -AD - Department of Medicine and Division of Hematology/Oncology, University of - Pittsburgh, School of Medicine, Pittsburgh, PA 15213 USA -AD - Department of Immunology, University of Pittsburgh, School of Medicine, - Pittsburgh, PA 15213 USA -FAU - Pagliano, Ornella -AU - Pagliano O -AD - Department of Medicine and Division of Hematology/Oncology, University of - Pittsburgh, School of Medicine, Pittsburgh, PA 15213 USA -AD - Department of Immunology, University of Pittsburgh, School of Medicine, - Pittsburgh, PA 15213 USA -FAU - Fourcade, Julien -AU - Fourcade J -AD - Department of Medicine and Division of Hematology/Oncology, University of - Pittsburgh, School of Medicine, Pittsburgh, PA 15213 USA -AD - Department of Immunology, University of Pittsburgh, School of Medicine, - Pittsburgh, PA 15213 USA -FAU - Sun, Zhaojun -AU - Sun Z -AD - Department of Medicine and Division of Hematology/Oncology, University of - Pittsburgh, School of Medicine, Pittsburgh, PA 15213 USA -AD - Department of Immunology, University of Pittsburgh, School of Medicine, - Pittsburgh, PA 15213 USA -FAU - Wang, Hong -AU - Wang H -AD - Department of Immunology, University of Pittsburgh, School of Medicine, - Pittsburgh, PA 15213 USA -AD - Department of Biostatistics, School of Medicine, University of Pittsburgh, - Pittsburgh, PA 15213 USA -FAU - Sanders, Cindy -AU - Sanders C -AD - Department of Medicine and Division of Hematology/Oncology, University of - Pittsburgh, School of Medicine, Pittsburgh, PA 15213 USA -AD - Department of Immunology, University of Pittsburgh, School of Medicine, - Pittsburgh, PA 15213 USA -FAU - Kirkwood, John M -AU - Kirkwood JM -AD - Department of Medicine and Division of Hematology/Oncology, University of - Pittsburgh, School of Medicine, Pittsburgh, PA 15213 USA -AD - Department of Immunology, University of Pittsburgh, School of Medicine, - Pittsburgh, PA 15213 USA -AD - University of Pittsburgh Medical Center, Pittsburgh, PA USA -AD - University of Pittsburgh Cancer Institute, Pittsburgh, PA USA -FAU - Chen, Tseng-hui Timothy -AU - Chen THT -AD - Department of Immunology, University of Pittsburgh, School of Medicine, - Pittsburgh, PA 15213 USA -AD - Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA 94063 USA -FAU - Maurer, Mark -AU - Maurer M -AD - Department of Immunology, University of Pittsburgh, School of Medicine, - Pittsburgh, PA 15213 USA -AD - Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA 94063 USA -FAU - Korman, Alan J -AU - Korman AJ -AD - Department of Immunology, University of Pittsburgh, School of Medicine, - Pittsburgh, PA 15213 USA -AD - Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA 94063 USA -FAU - Zarour, Hassane M -AU - Zarour HM -AD - Department of Medicine and Division of Hematology/Oncology, University of - Pittsburgh, School of Medicine, Pittsburgh, PA 15213 USA -AD - Department of Immunology, University of Pittsburgh, School of Medicine, - Pittsburgh, PA 15213 USA -AD - Department of Biostatistics, School of Medicine, University of Pittsburgh, - Pittsburgh, PA 15213 USA -AD - Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA 94063 USA -FAU - Stroncek, David F -AU - Stroncek DF -AD - Cell Processing Section, Department of Transfusion Medicine, Clinical Center, - National Institutes of Health, Bethesda, MD USA -FAU - Huber, Veronica -AU - Huber V -AD - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy -FAU - Rivoltini, Licia -AU - Rivoltini L -AD - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy -FAU - Thurin, Magdalena -AU - Thurin M -AD - Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, - Rockville, MD USA -FAU - Rau, Tilman -AU - Rau T -AD - Institute of Pathology, University of Bern, Bern, Switzerland -FAU - Lugli, Alessandro -AU - Lugli A -AD - Institute of Pathology, University of Bern, Bern, Switzerland -FAU - Pagès, Franck -AU - Pagès F -AD - Laboratory of Immunology, Hopital Européen Georges Pompidou, Paris, France -AD - INSERM team 15, Cordeliers Research Center, Paris, France -FAU - Camarero, Jorge -AU - Camarero J -AD - Oncology Area, Spanish Medicines Agency and Medical Devices (AEMPS), Madrid, - Spain -FAU - Sancho, Arantxa -AU - Sancho A -AD - Research Institute Hospital Puerta de Hierro Majadahonda, Madrid, Spain -FAU - Jommi, Claudio -AU - Jommi C -AD - Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Novara, - Italy -AD - Cergas (Centre for Research on Health and Social Care Management), Università - Bocconi, Milano, Italy -FAU - de Coaña, Yago Pico -AU - de Coaña YP -AD - Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska - Institutet, Stockholm, Sweden -FAU - Wolodarski, Maria -AU - Wolodarski M -AD - Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska - Institutet, Stockholm, Sweden -FAU - Yoshimoto, Yuya -AU - Yoshimoto Y -AD - Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska - Institutet, Stockholm, Sweden -FAU - Gentilcore, Giusy -AU - Gentilcore G -AD - Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska - Institutet, Stockholm, Sweden -AD - Division of Translational Medicine, Sidra Medical and Research Center, Doha, - Qatar -FAU - Poschke, Isabel -AU - Poschke I -AD - Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska - Institutet, Stockholm, Sweden -AD - Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research - Center, Heidelberg, Germany -FAU - Masucci, Giuseppe V -AU - Masucci GV -AD - Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska - Institutet, Stockholm, Sweden -FAU - Hansson, Johan -AU - Hansson J -AD - Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska - Institutet, Stockholm, Sweden -FAU - Kiessling, Rolf -AU - Kiessling R -AD - Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska - Institutet, Stockholm, Sweden -FAU - Scognamiglio, Giosuè -AU - Scognamiglio G -AD - Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione - “G. Pascale”, Napoli, Italy -AD - Unit of Pathology, Istituto Nazionale per lo Studio e la cura dei tumori - “Fondazione G. Pascale” IRCCS, Naples, Italy -AD - Cell Processing Section, Department of Transfusion Medicine, Clinical Center, - National Institutes of Health, Bethesda, MD USA -AD - Pathology Unit, Istituto Nazionale Tumori de Fondazione “G. Pascale”, Napoli, - Italy -FAU - Sabbatino, Francesco -AU - Sabbatino F -AD - Faculty of Pharmacy and Medicine, Department of Medicine, University of Salerno, - Baronissi, Salerno, Italy -AD - Department of Onco-Hematology, AOU S. Giovanni di Dio e Ruggi D’Aragona, - University of Salerno, Salerno, Italy -FAU - Marino, Federica Zito -AU - Marino FZ -AD - Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione - “G. Pascale”, Napoli, Italy -FAU - Anniciello, Anna Maria -AU - Anniciello AM -AD - Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione - “G. Pascale”, Napoli, Italy -AD - Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy -FAU - Cantile, Monica -AU - Cantile M -AD - Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione - “G. Pascale”, Napoli, Italy -AD - Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy -AD - Pathology Unit, Istituto Nazionale Tumori de Fondazione “G. Pascale”, Napoli, - Italy -FAU - Cerrone, Margherita -AU - Cerrone M -AD - Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione - “G. Pascale”, Napoli, Italy -AD - Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy -FAU - Scala, Stefania -AU - Scala S -AD - Molecular Immunology and Immuneregulation, Istituto Nazionale per lo Studio e la - Cura dei Tumori “Fondazione G. Pascale”, Napoli, Italy -FAU - D’alterio, Crescenzo -AU - D’alterio C -AD - Molecular Immunology and Immuneregulation, Istituto Nazionale per lo Studio e la - Cura dei Tumori “Fondazione G. Pascale”, Napoli, Italy -FAU - Ianaro, Angela -AU - Ianaro A -AD - Department of Pharmacy, University of Naples Federico II, Napoli, Italy -FAU - Cirin, Giuseppe -AU - Cirin G -AD - Department of Pharmacy, University of Naples Federico II, Napoli, Italy -FAU - Liguori, Giuseppina -AU - Liguori G -AD - Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione - “G. Pascale”, Napoli, Italy -FAU - Bott, Gerardo -AU - Bott G -AD - Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione - “G. Pascale”, Napoli, Italy -FAU - Chapman, Paul B -AU - Chapman PB -AD - Melanoma and Immunotherapies Service, Memorial Sloan Kettering Cancer Center, New - York, NY USA -FAU - Robert, Caroline -AU - Robert C -AD - Dermatology Unit, Institut Gustave Roussy, Paris, France -AD - Gustave Roussy, Paris-Sud University, Villejuif Paris-Sud, France -AD - Gustave Roussy and Paris-Sud University, Villejuif Paris-Sud, France -AD - CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -AD - Departments of Dermatology, Cancer Institute Gustave Roussy, Villejuif, France -AD - Clinical Oncology, Melanoma Branch, Gustave Roussy Cancer Institute, Villejuif, - France -FAU - Larkin, James -AU - Larkin J -AD - Department of Medical Oncology and Hematology, The Royal Marsden Hospital, - London, UK -FAU - Haanen, John B -AU - Haanen JB -AD - Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The - Netherlands -FAU - Ribas, Antoni -AU - Ribas A -AD - Department of Medicine, Jonsson Comprehensive Cancer Center at University of - California Los Angeles, Los Angeles, CA USA -AD - University of California at Los Angeles Medical Center, Los Angeles, CA USA -FAU - Hogg, David -AU - Hogg D -AD - Department of Medicine, Princess Margaret Hospital and University Health Network, - Toronto, Canada -FAU - Hamid, Omid -AU - Hamid O -AD - Melanoma Center, The Angeles Clinic and Research Institute, Los Angeles, CA USA -AD - The Angeles Clinic and Research Institute, Los Angeles, CA USA -AD - Research Department, The Angeles Clinic and Research Institute, Los Angeles, CA - USA -FAU - Testori, Alessandro -AU - Testori A -AD - Divisione chirurgia dermatoncologica, Europeo di Oncologia, Milan, Italy -FAU - Lorigan, Paul -AU - Lorigan P -AD - Institute of Cancer Sciences, University of Manchester, Manchester, UK -FAU - Sosman, Jeffrey A -AU - Sosman JA -AD - Division of Hematology and Oncology, Vanderbilt University School of Medicine, - Nashville, TN USA -FAU - Flaherty, Keith T -AU - Flaherty KT -AD - Department of Medicine, Massachusetts General Hospital, Boston, MA USA -FAU - Yue, Huibin -AU - Yue H -AD - Department of Biostatistics, Genentech Inc., San Francisco, CA USA -FAU - Coleman, Shelley -AU - Coleman S -AD - Product Development Oncology, Genentech Inc., San Francisco, CA USA -FAU - Caro, Ivor -AU - Caro I -AD - Dermatology Product Development, Genentech Inc., San Francisco, CA USA -FAU - Hauschild, Axel -AU - Hauschild A -AD - Department of Dermatology, University of Kiel, Kiel, Germany -FAU - McArthur, Grant A -AU - McArthur GA -AD - Skin and Melanoma Service, Peter MacCallum Cancer Centre, East Melbourne, - Australia -AD - Skin and Melanoma Service, Peter MacCallum Cancer Centre, Melbourne, VIC - Australia -FAU - Sznol, Mario -AU - Sznol M -AD - Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven - Hospital, New Haven, CT USA -FAU - Callahan, Margaret K -AU - Callahan MK -AD - Memorial Sloan Kettering Cancer Center, New York, USA -FAU - Kluger, Harriet -AU - Kluger H -AD - Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven - Hospital, New Haven, CT USA -FAU - Postow, Michael A -AU - Postow MA -AD - Memorial Sloan Kettering Cancer Center, New York, USA -AD - Weill Cornell Medical College, New York, NY USA -FAU - Gordan, RuthAnn -AU - Gordan R -AD - Memorial Sloan Kettering Cancer Center, New York, USA -FAU - Segal, Neil H -AU - Segal NH -AD - Memorial Sloan Kettering Cancer Center, New York, USA -FAU - Rizvi, Naiyer A -AU - Rizvi NA -AD - Memorial Sloan Kettering Cancer Center, New York, USA -FAU - Lesokhin, Alexander -AU - Lesokhin A -AD - Memorial Sloan Kettering Cancer Center, New York, USA -FAU - Atkins, Michael B -AU - Atkins MB -AD - Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC USA -FAU - Burke, Matthew M -AU - Burke MM -AD - Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven - Hospital, New Haven, CT USA -FAU - Ralabate, Amanda -AU - Ralabate A -AD - Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven - Hospital, New Haven, CT USA -FAU - Rivera, Angel -AU - Rivera A -AD - Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven - Hospital, New Haven, CT USA -FAU - Kronenberg, Stephanie A -AU - Kronenberg SA -AD - Memorial Sloan Kettering Cancer Center, New York, USA -FAU - Agunwamba, Blessing -AU - Agunwamba B -AD - Memorial Sloan Kettering Cancer Center, New York, USA -FAU - Ruisi, Mary -AU - Ruisi M -AD - Bristol-Myers Squibb, Princeton, NJ USA -FAU - Horak, Christine -AU - Horak C -AD - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale - Tumori Fondazione G. Pascale, Naples, Italy -FAU - Jiang, Joel -AU - Jiang J -AD - Bristol-Myers Squibb, Princeton, NJ USA -FAU - Wolchok, Jedd -AU - Wolchok J -AD - Memorial Sloan Kettering Cancer Center, New York, USA -AD - Ludwig Center for Cancer Immunotherapy, Department of Immunology and Department - of Medicine,, Memorial Sloan-Kettering Cancer Center, New York, NY USA -FAU - Ascierto, Paolo A -AU - Ascierto PA -AD - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale - Tumori Fondazione G. Pascale, Naples, Italy -AD - Melanoma Institute Australia, Sydney, NSW Australia -AD - Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy -FAU - Liszkay, Gabriella -AU - Liszkay G -AD - Division of Cancer Services National Institute of Oncology, Budapest, Hungary -AD - Oncodermatology, National Institute of Oncology, Budapest, Hungary -FAU - Maio, Michele -AU - Maio M -AD - Division of Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria - Senese, Siena, Italy -AD - University Hospital of Siena, Siena, Italy -AD - Medical Oncology and Immunotherapy, Department of Oncology, University Hospital - of Siena, Istituto Toscano Tumori, Siena, Italy -FAU - Mandalà, Mario -AU - Mandalà M -AD - Division of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy -FAU - Demidov, Lev -AU - Demidov L -AD - Department of Biotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow, - Russia -FAU - Stoyakovskiy, Daniil -AU - Stoyakovskiy D -AD - Department of Chemotherapy, Moscow City Oncology Hospital 62, Krasnogorsk, Russia -FAU - Thomas, Luc -AU - Thomas L -AD - Department of Dermatology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France -FAU - de la Cruz-Merino, Luis -AU - de la Cruz-Merino L -AD - Department of Clinical Oncology, Hospital Universitario Virgen Macarena, Seville, - Spain -FAU - Atkinson, Victoria -AU - Atkinson V -AD - Division of Cancer Services, Princess Alexandra Hospital, Woolloongabba, QLD - Australia -AD - Princess Alexandra Hospital, Gallipoli Medical Research Foundation, - Woolloongabba, Greenslopes, QLD Australia -AD - Gallipoli Medical Research Foundation and Princess Alexandra Hospital, - Greenslopes, QLD Australia -FAU - Dutriaux, Caroline -AU - Dutriaux C -AD - Department of Dermato-Oncology, Hôpital Saint André, Bordeaux, France -AD - Hôpital Saint André Centre Hospitalier Universitaire, Bordeaux, France -FAU - Garbe, Claus -AU - Garbe C -AD - Deptartment of Dermatology, University of Tübingen, Tübingen, Germany -FAU - Wongchenko, Matthew -AU - Wongchenko M -AD - Oncology Biomarker Development, Genentech Inc., South San Francisco, CA USA -FAU - Chang, Ilsung -AU - Chang I -AD - Product Development Oncology, Genentech, Inc., South San Francisco, CA USA -FAU - Koralek, Daniel O -AU - Koralek DO -AD - Product Development Oncology, Genentech, Inc., South San Francisco, CA USA -FAU - Rooney, Isabelle -AU - Rooney I -AD - Product Development Oncology, Genentech, Inc., South San Francisco, CA USA -FAU - Yan, Yibing -AU - Yan Y -AD - Oncology Biomarker Development, Genentech Inc., South San Francisco, CA USA -FAU - Dréno, Brigitte -AU - Dréno B -AD - Department of Dermato Cancerology, Nantes University, Nantes, France -FAU - Sullivan, Ryan -AU - Sullivan R -AD - Dana-Farber Cancer Institute, Boston, MD USA -FAU - Patel, Manish -AU - Patel M -AD - Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL USA -FAU - Hodi, Stephen -AU - Hodi S -AD - Dana-Farber Cancer Institute, Boston, MD USA -FAU - Amaria, Rodabe -AU - Amaria R -AD - The University of Texas MD Anderson Cancer Center, Houston, TX USA -FAU - Boasberg, Peter -AU - Boasberg P -AD - The Angeles Clinic and Research Institute, Los Angeles, CA USA -FAU - Wallin, Jeffrey -AU - Wallin J -AD - Genentech, Inc., South San Francisco, CA USA -FAU - He, Xian -AU - He X -AD - Genentech, Inc., South San Francisco, CA USA -FAU - Cha, Edward -AU - Cha E -AD - Genentech, Inc., South San Francisco, CA USA -FAU - Richie, Nicole -AU - Richie N -AD - Genentech, Inc., South San Francisco, CA USA -FAU - Ballinger, Marcus -AU - Ballinger M -AD - Genentech, Inc., South San Francisco, CA USA -FAU - Smith, David C -AU - Smith DC -AD - Department of Internal Medicine and Department of Urology, University of - Michigan, Ann Arbor, MI USA -FAU - Bauer, Todd M -AU - Bauer TM -AD - Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology PLLC, - Nashville, TN USA -FAU - Wasser, Jeffrey S -AU - Wasser JS -AD - Division of Hematology and Medical Oncology, University of Connecticut Health - Center, Farmington, CT USA -FAU - Luke, Jason J -AU - Luke JJ -AD - Department of Medicine-Section of Hematology/Oncology, University of Chicago, - Chicago, USA -FAU - Balmanoukian, Ani S -AU - Balmanoukian AS -AD - Department of Pathology and Department of Medicine-Section of - Hematology/Oncology, University of Chicago, Chicago, IL USA -FAU - Kaufman, David R -AU - Kaufman DR -AD - Merck Research Laboratories, Merck & Co. Inc., Kenilworth, NJ USA -AD - Merck & Co., Inc., Kenilworth, NJ USA -FAU - Zhao, Yufan -AU - Zhao Y -AD - Incyte Corporation, Drug Development, Wilmington, DE USA -FAU - Maleski, Janet -AU - Maleski J -AD - Incyte Corporation, Drug Development, Wilmington, DE USA -FAU - Leopold, Lance -AU - Leopold L -AD - Incyte Corporation, Drug Development, Wilmington, DE USA -FAU - Gangadhar, Tara C -AU - Gangadhar TC -AD - Hematology-Oncology Division, Abramson Cancer Center of the University of - Pennsylvania, Philadelphia, PA USA -FAU - Long, Georgina V -AU - Long GV -AD - Melanoma Institute Australia, The University of Sydney and The Mater Hospital, - Sydney, Australia -AD - Melanoma Institute Australia, Sydney, NSW Australia -AD - Melanoma Institute Australia, The University of Sydney, and Mater Hospital, - Sydney, NSW Australia -FAU - Michielin, Olivier -AU - Michielin O -AD - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland -FAU - VanderWalde, Ari -AU - VanderWalde A -AD - The West Clinic, Memphis, TN USA -FAU - Andtbacka, Robert H I -AU - Andtbacka RHI -AD - University of Utah Huntsman Cancer Institute, Salt Lake City, UT USA -FAU - Cebon, Jonathan -AU - Cebon J -AD - Olivia Newton-John Cancer Center, Heidelberg, Australia -FAU - Fernandez, Eugenio -AU - Fernandez E -AD - Hopitaux Universitaires de Geneve;, Geneva, Switzerland -FAU - Malvehy, Josep -AU - Malvehy J -AD - Hospital Clinic i Provincial de Barcelona, Barcelona, Spain -FAU - Olszanski, Anthony J -AU - Olszanski AJ -AD - Fox Chase Cancer Center, Philadelphia, PA USA -FAU - Gause, Christine -AU - Gause C -AD - Merck & Co., Inc., Kenilworth, NJ USA -FAU - Chen, Lisa -AU - Chen L -AD - Amgen Inc., Thousand Oaks, CA USA -FAU - Chou, Jeffrey -AU - Chou J -AD - Amgen Inc., Thousand Oaks, CA USA -FAU - Stephen Hodi, F -AU - Stephen Hodi F -AD - Dana-Farber Cancer Institute, Boston, MD USA -FAU - Brady, Benjamin -AU - Brady B -AD - Cabrini Health, Melbourne, VIC Australia -FAU - Mortier, Laurent -AU - Mortier L -AD - Hôpital Claude Huriez, Lille, France -FAU - Hassel, Jessica C -AU - Hassel JC -AD - University Hospital Heidelberg, Heidelberg, Germany -FAU - Rutkowski, Piotr -AU - Rutkowski P -AD - Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland -FAU - McNeil, Catriona -AU - McNeil C -AD - Chris O’Brien Lifehouse, Royal Prince Alfred Hospital and Melanoma Institute - Australia, Camperdown, NSW Australia -AD - Chris O’Brien Lifehouse, The Melanoma Institute Australia and Royal Prince Alfred - Hospital, Camperdown, Australia -FAU - Kalinka-Warzocha, Ewa -AU - Kalinka-Warzocha E -AD - Wojewódzki Szpital Specjalistyczny im. M., Lodz, Poland -FAU - Lebbé, Celeste -AU - Lebbé C -AD - Hôpital Saint-Louis University Paris Diderot, Paris, France -FAU - Ny, Lars -AU - Ny L -AD - University of Gothenburg, Gothenburg, Sweden -FAU - Chacon, Matias -AU - Chacon M -AD - Instituto Alexander Fleming, Buenos Aires, Argentina -FAU - Queirolo, Paola -AU - Queirolo P -AD - IRCCS San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, - Italy -FAU - Loquai, Carmen -AU - Loquai C -AD - University Hospital Mainz, 55122 Mainz, Germany -FAU - Cheema, Parneet -AU - Cheema P -AD - Sunnybrook Health Sciences Centre, Toronto, Canada -FAU - Berrocal, Alfonso -AU - Berrocal A -AD - Consorcio Hospital General Universitario de Valencia, Valencia, Spain -FAU - Eizmendi, Karmele Mujika -AU - Eizmendi KM -AD - Onkologikoa, Donosti, Gipuzkoa Spain -FAU - Bar-Sela, Gil -AU - Bar-Sela G -AD - Rambam Health Care Campus, Haifa, Israel -FAU - Horak, Christine -AU - Horak C -AD - Bristol-Myers Squibb, Hopewell, NJ USA -FAU - Hardy, Helene -AU - Hardy H -AD - Bristol-Myers Squibb, Hopewell, NJ USA -FAU - Weber, Jeffrey S -AU - Weber JS -AD - Moffitt Cancer Center, Tampa, FL USA -FAU - Grob, Jean-Jacques -AU - Grob JJ -AD - Hospital Timone APHM, Aix-Marseille University, Marseille, France -FAU - Marquez-Rodas, Ivan -AU - Marquez-Rodas I -AD - Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, - Madrid, Spain -FAU - Schmidt, Henrik -AU - Schmidt H -AD - Department of Oncology, Aarhus University Hospital, Aarhus, Denmark -FAU - Briscoe, Karen -AU - Briscoe K -AD - Department of Medical Oncology, Coffs Harbour Health Campus, Coffs Harbour, NSW - Australia -FAU - Baurain, Jean-François -AU - Baurain JF -AD - Cliniques Universitaires Saint-Luc, Bruxelles, Belgium -FAU - Wolchok, Jedd D -AU - Wolchok JD -AD - Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY USA -AD - Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research, - Weill Cornell Medical College, New York, NY USA -FAU - Pinto, Rosamaria -AU - Pinto R -AD - Istituto Tumori “Giovanni Paolo II, Bari, Italy -FAU - De Summa, Simona -AU - De Summa S -AD - Istituto Tumori “Giovanni Paolo II, Bari, Italy -FAU - Garrisi, Vito Michele -AU - Garrisi VM -AD - Istituto Tumori “Giovanni Paolo II, Bari, Italy -FAU - Strippoli, Sabino -AU - Strippoli S -AD - Istituto Tumori “Giovanni Paolo II, Bari, Italy -AD - Istituto Tumori “Giovanni Paolo II” I.R.R.C.S., Istituto di ricovero e cura a - carattere scientifico, Bari, Italy -FAU - Azzariti, Amalia -AU - Azzariti A -AD - Istituto Tumori “Giovanni Paolo II, Bari, Italy -AD - Istituto Tumori “Giovanni Paolo II” I.R.R.C.S., Istituto di ricovero e cura a - carattere scientifico, Bari, Italy -FAU - Guida, Gabriella -AU - Guida G -AD - Università di Bari, Bari, Italy -AD - Dipartimento di Scienze Mediche di Base, Neuroscienze e Organi di Senso, - Universita degli Studi di Bari, Bari, Italy -FAU - Guida, Michele -AU - Guida M -AD - Istituto Tumori “Giovanni Paolo II, Bari, Italy -AD - Istituto Tumori “Giovanni Paolo II” I.R.R.C.S., Istituto di ricovero e cura a - carattere scientifico, Bari, Italy -FAU - Tommasi, Stefania -AU - Tommasi S -AD - Istituto Tumori “Giovanni Paolo II, Bari, Italy -AD - Istituto Tumori “Giovanni Paolo II” I.R.R.C.S., Istituto di ricovero e cura a - carattere scientifico, Bari, Italy -FAU - Jacquelot, Nicolas -AU - Jacquelot N -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - University Paris Sud XI, Kremlin Bicêtre, France -AD - Gustave Roussy Cancer Institute, Villejuif, France -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - Gustave Roussy Cancer Campus, Villejuif, France -FAU - Enot, David -AU - Enot D -AD - Gustave Roussy Cancer Institute, Villejuif, France -AD - Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Institute, - Villejuif, France -FAU - Flament, Caroline -AU - Flament C -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - Gustave Roussy Cancer Institute, Villejuif, France -AD - CIC Biotherapie IGR Curie, CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -FAU - Pitt, Jonathan M -AU - Pitt JM -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - Gustave Roussy Cancer Institute, Villejuif, France -FAU - Vimond, Nadège -AU - Vimond N -AD - Gustave Roussy Cancer Institute, Villejuif, France -AD - CIC Biotherapie IGR Curie, CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -AD - Laboratory of Immunomonitoring in Oncology (L.I.O), UMS 3655 CNRS / US 23 INSERM, - Gustave Roussy Cancer Institute, Villejuif, France -FAU - Blattner, Carolin -AU - Blattner C -AD - Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany -AD - Department of Dermatology, Venereology and Allergology, University Medical Center - Mannheim Ruprecht-Karl University of Heidelberg, Mannheim, Germany -FAU - Yamazaki, Takahiro -AU - Yamazaki T -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - Gustave Roussy Cancer Institute, Villejuif, France -FAU - Roberti, Maria-Paula -AU - Roberti MP -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - Gustave Roussy Cancer Institute, Villejuif, France -FAU - Vetizou, Marie -AU - Vetizou M -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - Gustave Roussy Cancer Institute, Villejuif, France -FAU - Daillere, Romain -AU - Daillere R -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - University Paris Sud XI, Kremlin Bicêtre, France -AD - Gustave Roussy Cancer Institute, Villejuif, France -FAU - Poirier-Colame, Vichnou -AU - Poirier-Colame V -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - Gustave Roussy Cancer Institute, Villejuif, France -FAU - la Semeraro, Michaë -AU - la Semeraro M -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - Center of Clinical Investigation Hôpital Necker Enfants Malades, Paris, France -FAU - Caignard, Anne -AU - Caignard A -AD - INSERM U1016, CNRS UMR8104 Cochin Institute, Paris, France -FAU - Slingluff, Craig L Jr -AU - Slingluff CL Jr -AD - Division of Surgical Oncology, Department of Surgery, University of Virginia, - Charlottesville, VA USA -FAU - Sallusto, Federica -AU - Sallusto F -AD - Cellular Immunology Laboratory, Institute for Research in Biomedicine, Università - della Svizzera Italiana (USI), Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland -FAU - Rusakiewicz, Sylvie -AU - Rusakiewicz S -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - University Paris Sud XI, Kremlin Bicêtre, France -AD - Gustave Roussy Cancer Institute, Villejuif, France -AD - CIC Biotherapie IGR Curie, CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -FAU - Weide, Benjamin -AU - Weide B -AD - Department of Immunology, Eberhard Karls Universität Tübingen, Tübingen, Germany -AD - Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany -AD - Division of Dermatooncology, Department of Dermatology, University Medical - Center, Tübingen, Germany -FAU - Marabelle, Aurélien -AU - Marabelle A -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - Gustave Roussy Cancer Institute, Villejuif, France -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -AD - University Paris Sud XI, Kremlin Bicêtre, France -FAU - Kohrt, Holbrook -AU - Kohrt H -AD - Division of Oncology, Department of Medicine, Stanford University, Stanford, CA - USA -AD - Division of Oncology, Department of Medicine, Stanford University, Stanford, CA - USA -FAU - Dalle, Stéphane -AU - Dalle S -AD - Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, University Claude Bernard - Lyon 1, Lyon, France -AD - Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, University Claude Bernard - Lyon 1, Lyon, France -FAU - Cavalcanti, Andréa -AU - Cavalcanti A -AD - Gustave Roussy Cancer Institute, Villejuif, France -AD - CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -AD - Departments of Dermatology, Cancer Institute Gustave Roussy, Villejuif, France -AD - Department of Surgery, Gustave Roussy Cancer Campus, Villejuif, France -FAU - Kroemer, Guido -AU - Kroemer G -AD - Gustave Roussy Cancer Institute, Villejuif, France -AD - Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Institute, - Villejuif, France -AD - Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des - Cordeliers, Paris, France -AD - INSERM, U1138, Paris, France -AD - Université Paris Descartes, Sorbonne Paris Cité, Paris, France -AD - Université Pierre et Marie Curie, Paris, France -AD - Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France -AD - CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -AD - Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Institute, - Villejuif, France -AD - Department of Immunobiology, Yale School of Medicine, 10 Amistad Street, New - Haven, CT 06519 USA -AD - Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des - Cordeliers, Paris, France -AD - Université Paris Descartes, Sorbonne Paris Cité, Paris, France -AD - Université Pierre et Marie Curie, Paris, France -AD - Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France -FAU - Di Giacomo, Anna Maria -AU - Di Giacomo AM -AD - Medical Oncology and Immunotherapy Division, University Hospital of Siena, Viale - Bracci, 14, 53100 Siena, Italy -FAU - Maio, Michaele -AU - Maio M -AD - Medical Oncology and Immunotherapy, Department of Oncology,, University Hospital - of Siena, Istituto Toscano Tumori, Siena, Italy -FAU - Wong, Phillip -AU - Wong P -AD - Ludwig Center for Cancer Immunotherapy, Department of Immunology and Department - of Medicine,, Memorial Sloan-Kettering Cancer Center, New York, NY USA -FAU - Yuan, Jianda -AU - Yuan J -AD - Ludwig Center for Cancer Immunotherapy, Department of Immunology and Department - of Medicine,, Memorial Sloan-Kettering Cancer Center, New York, NY USA -FAU - Umansky, Viktor -AU - Umansky V -AD - Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany -AD - Department of Dermatology, Venereology and Allergology, University Medical Center - Mannheim Ruprecht-Karl University of Heidelberg, Mannheim, Germany -FAU - Eggermont, Alexander -AU - Eggermont A -AD - Gustave Roussy Cancer Institute, Villejuif, France -AD - CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -FAU - Zitvogel, Laurence -AU - Zitvogel L -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - University Paris Sud XI, Kremlin Bicêtre, France -AD - Gustave Roussy Cancer Institute, Villejuif, France -AD - CIC Biotherapie IGR Curie, CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - Gustave Roussy Cancer Campus, Villejuif, France -AD - CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -FAU - Anna, Passarelli -AU - Anna P -AD - Medical Oncology Unit, Department of Biomedical Sciences and Clinical Oncology, - University of Bari ‘Aldo Moro’, Bari, Italy -FAU - Marco, Tucci -AU - Marco T -AD - Medical Oncology Unit, Department of Biomedical Sciences and Clinical Oncology, - University of Bari ‘Aldo Moro’, Bari, Italy -FAU - Stefania, Stucci -AU - Stefania S -AD - Medical Oncology Unit, Department of Biomedical Sciences and Clinical Oncology, - University of Bari ‘Aldo Moro’, Bari, Italy -FAU - Francesco, Mannavola -AU - Francesco M -AD - Medical Oncology Unit, Department of Biomedical Sciences and Clinical Oncology, - University of Bari ‘Aldo Moro’, Bari, Italy -FAU - Mariaelena, Capone -AU - Mariaelena C -AD - Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, INT “G. Pascale”, - Napoli, Italy -FAU - Gabriele, Madonna -AU - Gabriele M -AD - Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, INT “G. Pascale”, - Napoli, Italy -FAU - Antonio, Ascierto Paolo -AU - Antonio AP -AD - Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, INT “G. Pascale”, - Napoli, Italy -FAU - Franco, Silvestris -AU - Franco S -AD - Medical Oncology Unit, Department of Biomedical Sciences and Clinical Oncology, - University of Bari ‘Aldo Moro’, Bari, Italy -FAU - Roberti, María Paula -AU - Roberti MP -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - Gustave Roussy Cancer Campus, Villejuif, France -AD - CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -FAU - Enot, David P -AU - Enot DP -AD - CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -AD - Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Institute, - Villejuif, France -FAU - Semeraro, Michaela -AU - Semeraro M -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -AD - Center of Clinical Investigation Hôpital Necker Enfants Malades, Paris, France -FAU - Jégou, Sarah -AU - Jégou S -AD - Saint Antoine Hospital, INSERM ERL 1157-CNRS UMR 7203, Paris, France -FAU - Flores, Camila -AU - Flores C -AD - CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -FAU - Chen, Tseng-hui Timothy -AU - Chen THT -AD - Department of Immunobiology, Yale School of Medicine, 10 Amistad Street, New - Haven, CT 06519 USA -FAU - Kwon, Byoung S -AU - Kwon BS -AD - Cancer Immunology Branch, Division of Cancer Biology, National Cancer Center, - Ilsan, Goyang, Gyeonggi Korea -AD - Section of Clinical Immunology, Allergy, and Rheumatology, Department of - Medicine, Tulane University Health Sciences Center, New Orleans, LA USA -FAU - Anderson, Ana Carrizossa -AU - Anderson AC -AD - Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic - Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA - 02115 USA -FAU - Borg, Christophe -AU - Borg C -AD - Department of Medical Oncology, University Hospital of Besancon, 3 Boulevard - Alexander Fleming, Besancon, 25030 France -AD - Clinical Investigational Centre, CIC-1431, University Hospital of Besançon, - Besançon, France -AD - INSERM U1098, University of Franche-Comté, Besançon, France -FAU - Aubin, François -AU - Aubin F -AD - EA3181, SFR4234, Service de Dermatologie, Université de Franche Comté, Centre - Hospitalier Universitaire (CHU), Besançon, France -FAU - Ayyoub, Maha -AU - Ayyoub M -AD - INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France -AD - Gustave Roussy Cancer Campus, Villejuif, France -AD - CIC Biothérapie IGR Curie CIC1428, Gustave Roussy Cancer Institute, Villejuif, - France -AD - University Paris Sud XI, Kremlin Bicêtre, France -FAU - De Presbiteris, Anna Lisa -AU - De Presbiteris AL -AD - Institute of Genetics and Biophysics –I.G.B., A. Buzzati-Traverso– CNR, Naples, - Italy -FAU - Cordaro, Fabiola Gilda -AU - Cordaro FG -AD - Institute of Genetics and Biophysics –I.G.B., A. Buzzati-Traverso– CNR, Naples, - Italy -FAU - Camerlingo, Rosa -AU - Camerlingo R -AD - Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy -AD - IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy -AD - Department of Experimental Oncology, Istituto Nazionale Tumori Fondazione “G. - Pascale”, Naples, Italy -FAU - Fratangelo, Federica -AU - Fratangelo F -AD - Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy -AD - IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy -AD - IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy -FAU - Mozzillo, Nicola -AU - Mozzillo N -AD - Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy -FAU - Pirozzi, Giuseppe -AU - Pirozzi G -AD - Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy -AD - IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy -AD - Department of Experimental Oncology, Istituto Nazionale Tumori Fondazione “G. - Pascale”, Naples, Italy -FAU - Patriarca, Eduardo J -AU - Patriarca EJ -AD - Institute of Genetics and Biophysics –I.G.B., A. Buzzati-Traverso– CNR, Naples, - Italy -FAU - Caputo, Emilia -AU - Caputo E -AD - Institute of Genetics and Biophysics –I.G.B., A. Buzzati-Traverso– CNR, Naples, - Italy -AD - Institute of Genetics and Biophysics –I.G.B.– CNR, Naples, Italy -FAU - Motti, Maria Letizia -AU - Motti ML -AD - IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy -AD - University Parthenope, Naples, Italy -AD - IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy -AD - University ‘Parthenope’, Naples, Italy -FAU - Falcon, Rosaria -AU - Falcon R -AD - IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy -AD - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale - Tumori Fondazione “G. Pascale”, Napoli, Italy -FAU - Miceli, Roberta -AU - Miceli R -AD - IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy -FAU - Capone, Mariaelena -AU - Capone M -AD - IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy -FAU - Madonna, Gabriele -AU - Madonna G -AD - IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy -FAU - Mallardo, Domenico -AU - Mallardo D -AD - IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy -FAU - Carrier, Maria Vincenza -AU - Carrier MV -AD - IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy -AD - IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy -FAU - Panza, Elisabetta -AU - Panza E -AD - Department of Pharmacy, University of Naples Federico II, Napoli, Italy -FAU - De Cicco, Paola -AU - De Cicco P -AD - Department of Pharmacy, University of Naples Federico II, Napoli, Italy -FAU - Armogida, Chiara -AU - Armogida C -AD - Department of Pharmacy, University of Naples Federico II, Napoli, Italy -FAU - Ercolano, Giuseppe -AU - Ercolano G -AD - Department of Pharmacy, University of Naples Federico II, Napoli, Italy -FAU - Botti, Gerardo -AU - Botti G -AD - Pathology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione - “G. Pascale”, Napoli, Italy -AD - Unit of Pathology, Istituto Nazionale per lo Studio e la cura dei tumori - “Fondazione G. Pascale” IRCCS, Naples, Italy -AD - Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy -AD - Pathology Unit, Istituto Nazionale Tumori de Fondazione “G. Pascale”, Napoli, - Italy -FAU - Cirino, Giuseppe -AU - Cirino G -AD - Department of Pharmacy, University of Naples Federico II, Napoli, Italy -FAU - Sandru, Angela -AU - Sandru A -AD - Molecular Immunology and Toxicology, National Institute of Oncology, Budapest, - Hungary -AD - Center of Surgical and Molecular Tumorpathology, National Institute of Oncology, - Budapest, Hungary -AD - Department of Surgical Oncology, Alexandru Trestioreanu” Oncologic Institute, - “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania -AD - Department of Surgical Oncology, “Carol Davila” University of Medicine and - Pharmacy, “Alexandru Trestioreanu” Oncologic Institute, Bucharest, Romania -FAU - Blank, Miri -AU - Blank M -AD - Zabludowitz Center for Autoimmune Diseases, Sheba Medical Center affiliated to - Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel -FAU - Balatoni, Timea -AU - Balatoni T -AD - Oncodermatology, National Institute of Oncology, Budapest, Hungary -FAU - Olasz, Judit -AU - Olasz J -AD - Pathogenetics, National Institute of Oncology, Budapest, Hungary -FAU - Farkas, Emil -AU - Farkas E -AD - Oncosurgery, National Institute of Oncology, Budapest, Hungary -FAU - Szollar, Andras -AU - Szollar A -AD - Oncosurgery, National Institute of Oncology, Budapest, Hungary -FAU - Savolt, Akos -AU - Savolt A -AD - Oncosurgery, National Institute of Oncology, Budapest, Hungary -FAU - Godeny, Maria -AU - Godeny M -AD - Department of Radiological Diagnostics, National Institute of Oncology, Budapest, - Hungary -FAU - Csuka, Orsolya -AU - Csuka O -AD - Pathogenetics, National Institute of Oncology, Budapest, Hungary -FAU - Horvath, Szabolcs -AU - Horvath S -AD - Center of Surgical and Molecular Tumorpathology, National Institute of Oncology, - Budapest, Hungary -FAU - Eles, Klara -AU - Eles K -AD - Center of Surgical and Molecular Tumorpathology, National Institute of Oncology, - Budapest, Hungary -FAU - Shoenfeld, Yehuda -AU - Shoenfeld Y -AD - Zabludowitz Center for Autoimmune Diseases, Sheba Medical Center affiliated to - Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel -FAU - Kasler, Miklos -AU - Kasler M -AD - Board of Directors, National Institute of Oncology, Budapest, Hungary -FAU - Costantini, Susan -AU - Costantini S -AD - Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, - Naples, Italy -FAU - Capone, Francesca -AU - Capone F -AD - Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, - Naples, Italy -FAU - Moradi, Farnaz -AU - Moradi F -AD - Dipartimento di Chirurgia “P. Valdoni”, Sapienza Università di Roma, Rome, Italy -FAU - Berglund, Pontus -AU - Berglund P -AD - Dipartimento di Chirurgia “P. Valdoni”, Sapienza Università di Roma, Rome, Italy -FAU - Leandersson, Karin -AU - Leandersson K -AD - Dipartimento di Medicina Clinica e Molecolare, Sapienza Università di Roma, Rome, - Italy -FAU - Linnskog, Rickard -AU - Linnskog R -AD - Dipartimento di Chirurgia “P. Valdoni”, Sapienza Università di Roma, Rome, Italy -FAU - Andersson, Tommy -AU - Andersson T -AD - Dipartimento di Chirurgia “P. Valdoni”, Sapienza Università di Roma, Rome, Italy -FAU - Prasad, Chandra Prakash -AU - Prasad CP -AD - Dipartimento di Chirurgia “P. Valdoni”, Sapienza Università di Roma, Rome, Italy -FAU - Nigro, Cristiana Lo -AU - Nigro CL -AD - Laboratory of Cancer Genetics and Translational Oncology, S. Croce & amp, Carle - Teaching Hospital, Cuneo, Italy -FAU - Lattanzio, Laura -AU - Lattanzio L -AD - Laboratory of Cancer Genetics and Translational Oncology, S. Croce & amp, Carle - Teaching Hospital, Cuneo, Italy -FAU - Wang, Hexiao -AU - Wang H -AD - Dundee Cancer Center, University of Dundee, Ninewells Hospital and Medical - School, Dundee, Scotland, UK -FAU - Proby, Charlotte -AU - Proby C -AD - Dundee Cancer Center, University of Dundee, Ninewells Hospital and Medical - School, Dundee, Scotland, UK -FAU - Syed, Nelofer -AU - Syed N -AD - Faculty of Medicine, Imperial College London, London, UK -FAU - Occelli, Marcella -AU - Occelli M -AD - Medical Oncology, Oncology Department, S. Croce & amp, Carle Teaching Hospital, - Cuneo, Italy -FAU - Cauchi, Carolina -AU - Cauchi C -AD - Medical Oncology, Oncology Department, S. Croce & amp, Carle Teaching Hospital, - Cuneo, Italy -FAU - Merlano, Marco -AU - Merlano M -AD - Medical Oncology, Oncology Department, S. Croce & amp, Carle Teaching Hospital, - Cuneo, Italy -FAU - Harwood, Catherine -AU - Harwood C -AD - Barts and the London School of Medicine and Dentistry, Queen Mary University of - London, London, UK -FAU - Thompson, Alastair -AU - Thompson A -AD - Dundee Cancer Center, University of Dundee, Ninewells Hospital and Medical - School, Dundee, Scotland, UK -FAU - Crook, Tim -AU - Crook T -AD - Dundee Cancer Center, University of Dundee, Ninewells Hospital and Medical - School, Dundee, Scotland, UK -FAU - Bifulco, Katia -AU - Bifulco K -AD - IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy -FAU - Ingangi, Vincenzo -AU - Ingangi V -AD - IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy -FAU - Minopoli, Michele -AU - Minopoli M -AD - IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy -FAU - Ragone, Concetta -AU - Ragone C -AD - IRCCS Istituto Nazionale Tumori de “Fondazione G. Pascale”, Naples, Italy -FAU - Pessi, Antonello -AU - Pessi A -AD - PeptiPharma, Viale Città D’Europa 679, 00144 Rome, Italy -FAU - Mannavola, Francesco -AU - Mannavola F -AD - Medical Oncology Unit, University of Bari ‘Aldo Moro’, Bari, Italy -FAU - D’Oronzo, Stella -AU - D’Oronzo S -AD - Medical Oncology Unit, University of Bari ‘Aldo Moro’, Bari, Italy -FAU - Felici, Claudia -AU - Felici C -AD - Medical Oncology Unit, University of Bari ‘Aldo Moro’, Bari, Italy -FAU - Tucci, Marco -AU - Tucci M -AD - Medical Oncology Unit, University of Bari ‘Aldo Moro’, Bari, Italy -FAU - Doronzo, Antonio -AU - Doronzo A -AD - Medical Oncology Unit, University of Bari ‘Aldo Moro’, Bari, Italy -FAU - Silvestris, Franco -AU - Silvestris F -AD - Medical Oncology Unit, University of Bari ‘Aldo Moro’, Bari, Italy -FAU - Ferretta, Anna -AU - Ferretta A -AD - Istituto Tumori “Giovanni Paolo II” I.R.R.C.S., Istituto di ricovero e cura a - carattere scientifico, Bari, Italy -AD - Dipartimento di Scienze Mediche di Base, Neuroscienze e Organi di Senso, - Universita degli Studi di Bari, Bari, Italy -FAU - Guida, Stefania -AU - Guida S -AD - Dipartimento di Scienze Mediche di Base, Neuroscienze e Organi di Senso, - Universita degli Studi di Bari, Bari, Italy -FAU - Maida, Imma -AU - Maida I -AD - Dipartimento di Scienze Mediche di Base, Neuroscienze e Organi di Senso, - Universita degli Studi di Bari, Bari, Italy -FAU - Cocco, Tiziana -AU - Cocco T -AD - Dipartimento di Scienze Mediche di Base, Neuroscienze e Organi di Senso, - Universita degli Studi di Bari, Bari, Italy -FAU - Passarelli, Anna -AU - Passarelli A -AD - Medical Oncology Unit, University of Bari ‘Aldo Moro’, Bari, Italy -FAU - Quaresmini, Davide -AU - Quaresmini D -AD - Medical Oncology Unit, University of Bari ‘Aldo Moro’, Bari, Italy -FAU - Franzese, Ornella -AU - Franzese O -AD - Department of Systems Medicine, University of Tor Vergata, Rome, Italy -FAU - Palermo, Belinda -AU - Palermo B -AD - Department of Research, Advanced Diagnostics and Technological Innovation, Regina - Elena National Cancer Institute, Rome, Italy -FAU - Di Donna, Cosmo -AU - Di Donna C -AD - Department of Research, Advanced Diagnostics and Technological Innovation, Regina - Elena National Cancer Institute, Rome, Italy -FAU - Sperduti, Isabella -AU - Sperduti I -AD - Biostatistics and Scientific Direction, Regina Elena National Cancer Institute, - Rome, Italy -FAU - Foddai, MariaLaura -AU - Foddai M -AD - Department of Research, Advanced Diagnostics and Technological Innovation, Regina - Elena National Cancer Institute, Rome, Italy -FAU - Stabile, Helena -AU - Stabile H -AD - Department of Molecular Medicine, University of Rome “La Sapienza”, Rome, Italy -FAU - Gismondi, Angela -AU - Gismondi A -AD - Department of Molecular Medicine, University of Rome “La Sapienza”, Rome, Italy -FAU - Santoni, Angela -AU - Santoni A -AD - Department of Molecular Medicine, University of Rome “La Sapienza”, Rome, Italy -FAU - Nisticò, Paola -AU - Nisticò P -AD - Department of Research, Advanced Diagnostics and Technological Innovation, Regina - Elena National Cancer Institute, Rome, Italy -FAU - Sponghini, Andrea P -AU - Sponghini AP -AD - A.O.U. Maggiore della Carità, S.C. di Oncologia, Novara, Italy -FAU - Platini, Francesca -AU - Platini F -AD - A.O.U. Maggiore della Carità, S.C. di Oncologia, Novara, Italy -FAU - Marra, Elena -AU - Marra E -AD - A.O.U. Città della Salute e della Scienza, S.C. di Dermatologia, Torino, Italy -FAU - Rondonotti, David -AU - Rondonotti D -AD - A.O.U. Maggiore della Carità, S.C. di Oncologia, Novara, Italy -FAU - Alabiso, Oscar -AU - Alabiso O -AD - A.O.U. Maggiore della Carità, S.C. di Oncologia, Novara, Italy -FAU - Fierro, Maria T -AU - Fierro MT -AD - A.O.U. Città della Salute e della Scienza, S.C. di Dermatologia, Torino, Italy -FAU - Savoia, Paola -AU - Savoia P -AD - A.O.U. Città della Salute e della Scienza, S.C. di Dermatologia, Torino, Italy -FAU - Stratica, Florian -AU - Stratica F -AD - A.O.U. Maggiore della Carità, S.C. di Oncologia, Novara, Italy -FAU - Quaglino, Pietro -AU - Quaglino P -AD - A.O.U. Città della Salute e della Scienza, S.C. di Dermatologia, Torino, Italy -FAU - Di Monta, Gianluca -AU - Di Monta G -AD - Department Melanoma, Division Surgery of Melanoma, National Cancer Institute - “Fondazione Pascale”, Naples, Italy -FAU - Corrado, Caracò -AU - Corrado C -AD - Department Melanoma, Division Surgery of Melanoma, National Cancer Institute - “Fondazione Pascale”, Naples, Italy -FAU - Di Marzo, Massimiliano -AU - Di Marzo M -AD - Department Melanoma, Division Surgery of Melanoma, National Cancer Institute - “Fondazione Pascale”, Naples, Italy -FAU - Ugo, Marone -AU - Ugo M -AD - Department Melanoma, Division Surgery of Melanoma, National Cancer Institute - “Fondazione Pascale”, Naples, Italy -FAU - Di Cecilia, Maria Luisa -AU - Di Cecilia ML -AD - Department Melanoma, Division Surgery of Melanoma, National Cancer Institute - “Fondazione Pascale”, Naples, Italy -FAU - Nicola, Mozzillo -AU - Nicola M -AD - Department Melanoma, Division Surgery of Melanoma, National Cancer Institute - “Fondazione Pascale”, Naples, Italy -FAU - Fusciello, Celeste -AU - Fusciello C -AD - Department of Onco-Hematology, AOU S. Giovanni di Dio e Ruggi D’Aragona, - University of Salerno, Salerno, Italy -FAU - Marra, Antonio -AU - Marra A -AD - Department of Onco-Hematology, AOU S. Giovanni di Dio e Ruggi D’Aragona, - University of Salerno, Salerno, Italy -FAU - Guarrasi, Rosario -AU - Guarrasi R -AD - Department of Onco-Hematology, AOU S. Giovanni di Dio e Ruggi D’Aragona, - University of Salerno, Salerno, Italy -FAU - Baldi, Carlo -AU - Baldi C -AD - Department of Onco-Hematology, AOU S. Giovanni di Dio e Ruggi D’Aragona, - University of Salerno, Salerno, Italy -FAU - Russo, Rosa -AU - Russo R -AD - Department of Onco-Hematology, AOU S. Giovanni di Dio e Ruggi D’Aragona, - University of Salerno, Salerno, Italy -FAU - Di Giulio, Giovanni -AU - Di Giulio G -AD - Department of Onco-Hematology, AOU S. Giovanni di Dio e Ruggi D’Aragona, - University of Salerno, Salerno, Italy -FAU - Faiola, Vincenzo -AU - Faiola V -AD - Department of Onco-Hematology, AOU S. Giovanni di Dio e Ruggi D’Aragona, - University of Salerno, Salerno, Italy -FAU - Zeppa, Pio -AU - Zeppa P -AD - Department of Onco-Hematology, AOU S. Giovanni di Dio e Ruggi D’Aragona, - University of Salerno, Salerno, Italy -FAU - Pepe, Stefano -AU - Pepe S -AD - Department of Onco-Hematology, AOU S. Giovanni di Dio e Ruggi D’Aragona, - University of Salerno, Salerno, Italy -FAU - Gambale, Elisabetta -AU - Gambale E -AD - Department of Medical, Oral and Biotechnological Sciences, University G. - D’Annunzio of Chieti-Pescara, Chieti, Italy -FAU - Carella, Consiglia -AU - Carella C -AD - Department of Medical, Oral and Biotechnological Sciences, University G. - D’Annunzio of Chieti-Pescara, Chieti, Italy -FAU - Di Paolo, Alessandra -AU - Di Paolo A -AD - Department of Medical, Oral and Biotechnological Sciences, University G. - D’Annunzio of Chieti-Pescara, Chieti, Italy -FAU - De Tursi, Michele -AU - De Tursi M -AD - Department of Medical, Oral and Biotechnological Sciences, University G. - D’Annunzio of Chieti-Pescara, Chieti, Italy -FAU - Marra, Laura -AU - Marra L -AD - Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy -AD - Pathology Unit, Istituto Nazionale Tumori de Fondazione “G. Pascale”, Napoli, - Italy -FAU - De Murtas, Fara -AU - De Murtas F -AD - Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy -FAU - Sorrentino, Valeria -AU - Sorrentino V -AD - Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy -FAU - Voinea, Silviu -AU - Voinea S -AD - Department of Surgical Oncology, Alexandru Trestioreanu” Oncologic Institute, - “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania -AD - Department of Surgical Oncology, “Carol Davila” University of Medicine and - Pharmacy, “Alexandru Trestioreanu” Oncologic Institute, Bucharest, Romania -FAU - Panaitescu, Eugenia -AU - Panaitescu E -AD - Department of Medical Informatics and Biostatistics, “Carol Davila” University of - Medicine and Pharmacy, Bucharest, Romania -FAU - Bolovan, Madalina -AU - Bolovan M -AD - Department of Carcinogenesis and Molecular Biology, “Alexandru Trestioreanu” - Oncologic Institute, Bucharest, Romania -FAU - Stanciu, Adina -AU - Stanciu A -AD - Department of Carcinogenesis and Molecular Biology, “Alexandru Trestioreanu” - Oncologic Institute, Bucharest, Romania -FAU - Cinca, Sabin -AU - Cinca S -AD - Department of Carcinogenesis and Molecular Biology, “Alexandru Trestioreanu” - Oncologic Institute, Bucharest, Romania -FAU - Botti, Chiara -AU - Botti C -AD - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale - Tumori Fondazione “G. Pascale”, Napoli, Italy -FAU - Aquino, Gabriella -AU - Aquino G -AD - Pathology Unit, Istituto Nazionale Tumori de Fondazione “G. Pascale”, Napoli, - Italy -FAU - Anniciello, Annamaria -AU - Anniciello A -AD - Pathology Unit, Istituto Nazionale Tumori de Fondazione “G. Pascale”, Napoli, - Italy -FAU - Fortes, Cristina -AU - Fortes C -AD - Epidemiology Unit, IDI-IRCCS, Rome, Italy -FAU - Mastroeni, Simona -AU - Mastroeni S -AD - Epidemiology Unit, IDI-IRCCS, Rome, Italy -FAU - Caggiati, Alessio -AU - Caggiati A -AD - Plastic Surgery Unit, IDI-IRCCS, Rome, Italy -FAU - Passarelli, Francesca -AU - Passarelli F -AD - Oncology Unit, IDI-IRCCS, Rome, Italy -FAU - Zappalà, Alba -AU - Zappalà A -AD - Oncology Unit, IDI-IRCCS, Rome, Italy -FAU - Capuano, Maria -AU - Capuano M -AD - Division Dermatology Villa Paola, Capranica, Italy -FAU - Bono, Riccardo -AU - Bono R -AD - Division Dermatology, IDI-IRCCS, Rome, Italy -FAU - Nudo, Maurizio -AU - Nudo M -AD - Division Dermatology, IDI-IRCCS, Rome, Italy -FAU - Marino, Claudia -AU - Marino C -AD - Division Dermatology, IDI-IRCCS, Rome, Italy -FAU - Michelozzi, Paola -AU - Michelozzi P -AD - Division Dermatology, IDI-IRCCS, Rome, Italy -FAU - De Biasio, Valeria -AU - De Biasio V -AD - Mental Health Department, Hospital of Lauria, Rome, Italy -FAU - Battarra, Vincenzo C -AU - Battarra VC -AD - Dermatology and Oncology surgery of skin growths Department, Hospital of Caserta, - Caserta, Italy -FAU - Formenti, Silvia -AU - Formenti S -AD - Department of Radiation Oncology, Weill Cornell Medical College, New York, NY USA -FAU - Ascierto, Maria Libera -AU - Ascierto ML -AD - Department of Oncology, The Johns Hopkins University School of Medicine and - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - McMiller, Tracee L -AU - McMiller TL -AD - Department of Surgery, The Johns Hopkins University School of Medicine and Sidney - Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - Berger, Alan E -AU - Berger AE -AD - The Lowe Family Genomics Core, The Johns Hopkins University School of Medicine - and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - Danilova, Ludmila -AU - Danilova L -AD - Department of Oncology, The Johns Hopkins University School of Medicine and - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -AD - Oncology Bioinformatics Core, The Johns Hopkins University School of Medicine and - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - Anders, Robert A -AU - Anders RA -AD - Department of Pathology, The Johns Hopkins University School of Medicine and - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - Netto, George J -AU - Netto GJ -AD - Department of Pathology, The Johns Hopkins University School of Medicine and - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - Xu, Haiying -AU - Xu H -AD - Department of Dermatology, The Johns Hopkins University School of Medicine and - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - Pritchard, Theresa S -AU - Pritchard TS -AD - Department of Surgery, The Johns Hopkins University School of Medicine and Sidney - Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - Fan, Jinshui -AU - Fan J -AD - The Lowe Family Genomics Core, The Johns Hopkins University School of Medicine - and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - Cheadle, Chris -AU - Cheadle C -AD - The Lowe Family Genomics Core, The Johns Hopkins University School of Medicine - and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - Cope, Leslie -AU - Cope L -AD - Department of Oncology, The Johns Hopkins University School of Medicine and - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -AD - Oncology Bioinformatics Core, The Johns Hopkins University School of Medicine and - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - Drake, Charles G -AU - Drake CG -AD - Department of Oncology, The Johns Hopkins University School of Medicine and - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -AD - The James Buchanan Brady Urological Institute, The Johns Hopkins University - School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD - 21287 USA -FAU - Pardoll, Drew M -AU - Pardoll DM -AD - Department of Oncology, The Johns Hopkins University School of Medicine and - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - Taube, Janis M -AU - Taube JM -AD - Department of Pathology, The Johns Hopkins University School of Medicine and - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -AD - Department of Dermatology, The Johns Hopkins University School of Medicine and - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - Topalian, Suzanne L -AU - Topalian SL -AD - Department of Surgery, The Johns Hopkins University School of Medicine and Sidney - Kimmel Comprehensive Cancer Center, Baltimore, MD 21287 USA -FAU - Gnjatic, Sacha -AU - Gnjatic S -AD - Icahn School of Medicine at Mount Sinai, New York city, USA -FAU - Nataraj, Sarah -AU - Nataraj S -AD - Icahn School of Medicine at Mount Sinai, New York city, USA -FAU - Imai, Naoko -AU - Imai N -AD - Icahn School of Medicine at Mount Sinai, New York city, USA -FAU - Rahman, Adeeb -AU - Rahman A -AD - Icahn School of Medicine at Mount Sinai, New York city, USA -FAU - Jungbluth, Achim A -AU - Jungbluth AA -AD - Ludwig Center for Cancer Immunotherapy, Department of Immunology and Department - of Medicine,, Memorial Sloan-Kettering Cancer Center, New York, NY USA -FAU - Pan, Linda -AU - Pan L -AD - Ludwig Institute for Cancer Research, New York, NY USA -FAU - Venhaus, Ralph -AU - Venhaus R -AD - Ludwig Institute for Cancer Research, New York, NY USA -FAU - Park, Andrew -AU - Park A -AD - Ludwig Institute for Cancer Research, New York, NY USA -FAU - Lehmann, Frédéric F -AU - Lehmann FF -AD - GSK Vaccines, Rixensart, Belgium -FAU - Lendvai, Nikoletta -AU - Lendvai N -AD - Ludwig Center for Cancer Immunotherapy, Department of Immunology and Department - of Medicine,, Memorial Sloan-Kettering Cancer Center, New York, NY USA -FAU - Cohen, Adam D -AU - Cohen AD -AD - University of Pennsylvania, Philadelphia, PA USA -FAU - Cho, Hearn J -AU - Cho HJ -AD - Icahn School of Medicine at Mount Sinai, New York city, USA -FAU - Daniel, Speiser -AU - Daniel S -AD - Department of Oncology and Ludwig Cancer Research Center, University of Lausanne, - Lausanne, Switzerland -AD - Campbell Family Institute, Princess Margaret Hospital, Toronto, Canada -FAU - Hirsh, Vera -AU - Hirsh V -AD - McGill University, MUHC Royal Victoria Hospital, Montreal, QC Canada -LA - eng -PT - Journal Article -DEP - 20160725 -PL - England -TA - J Transl Med -JT - Journal of translational medicine -JID - 101190741 -SB - IM -PMC - PMC4965835 -EDAT- 2016/07/28 06:00 -MHDA- 2016/07/28 06:01 -PMCR- 2016/07/25 -CRDT- 2016/07/28 06:00 -PHST- 2016/07/28 06:00 [entrez] -PHST- 2016/07/28 06:00 [pubmed] -PHST- 2016/07/28 06:01 [medline] -PHST- 2016/07/25 00:00 [pmc-release] -AID - 10.1186/s12967-016-0791-2 [pii] -AID - 791 [pii] -AID - 10.1186/s12967-016-0791-2 [doi] -PST - epublish -SO - J Transl Med. 2016 Jul 25;14(1):65. doi: 10.1186/s12967-016-0791-2. - -PMID- 38953934 -OWN - NLM -STAT- Publisher -LR - 20240702 -IS - 1619-7089 (Electronic) -IS - 1619-7070 (Linking) -DP - 2024 Jul 2 -TI - Repeated dynamic [(18)F]FDG PET/CT imaging using a high-sensitivity PET/CT - scanner for assessing non-small cell lung cancer patients undergoing induction - immuno-chemotherapy followed by hypo-fractionated chemoradiotherapy and - consolidative immunotherapy: report from a prospective observational study - (GASTO-1067). -LID - 10.1007/s00259-024-06819-2 [doi] -AB - OBJECTIVE: The study aims to investigate the role of dynamic [(18)F]FDG PET/CT - imaging by high-sensitivity PET/CT scanner for assessing patients with locally - advanced non-small cell lung cancer (LA-NSCLC) who undergo induction - immuno-chemotherapy, followed by concurrent hypo-fractionated chemoradiotherapy - (hypo-CCRT) and consolidative immunotherapy. METHODS: Patients with unresectable - LA-NSCLC are prospectively recruited. Dynamic [(18)F]FDG PET/CT scans are - conducted at four timepoints: before treatment (Baseline), after induction - immuno-chemotherapy (Post-IC), during hypo-CCRT (Mid-hypo-CCRT) and after - hypo-CCRT (Post-hypo-CCRT). The primary lung tumors (PTs) are manually - delineated, and the metabolic features, including the Patlak-Ki (Ki), maximum SUV - (SUV(max)), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) have - been evaluated. The expressions of CD3, CD8, CD68, CD163, CD34 and Ki67 in - primary lung tumors at baseline are assayed by immunohistochemistry. The levels - of blood lymphocytes at four timepoints are analyzed with flow cytometry. - RESULTS: Fifteen LA-NSCLC patients are enrolled between December 2020 and - December 2022. Baseline Ki of primary tumor yields the highest AUC values of - 0.722 and 0.796 for predicting disease progression and patient death, - respectively. Patients are classified into the High FDG Ki group (n = 8, - Ki > 2.779 ml/min/100 g) and the Low FDG Ki group (n = 7, - Ki ≤ 2.779 ml/min/100 g). The High FDG Ki group presents better progression-free - survival (P = 0.01) and overall survival (P = 0.025). The High FDG Ki group - exhibits more significant reductions in Ki after hypo-CCRT compared to the Low - FDG Ki group. Patients with a reduction in Ki > 73.1% exhibit better - progression-free survival than those with a reduction ≤ 73.1% in Ki (median: not - reached vs. 7.33 months, P = 0.12). The levels of CD3(+) T cells (P = 0.003), - CD8(+) T cells (P = 0.002), CD68(+) macrophages (P = 0.071) and CD163(+) - macrophages (P = 0.012) in primary tumor tissues are higher in the High FDG Ki - group. The High FDG Ki group has higher CD3(+)CD8(+) lymphocytes in blood at - baseline (P = 0.108), post-IC (P = 0.023) and post-hypo-CCRT (P = 0.041) than the - Low FDG Ki group. CONCLUSIONS: The metabolic features in the High FDG Ki group - significantly decrease during the treatment, particularly after induction - immuno-chemotherapy. The Ki value of primary tumor shows significant relationship - with the treatment response and survival in LA-NSCLC patients by the combined - immuno-chemoradiotherapy regimen. TRIAL REGISTRATION: ClinicalTrials.gov. - NCT04654234. Registered 4 December 2020. -CI - © 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, - part of Springer Nature. -FAU - Wang, DaQuan -AU - Wang D -AD - Department of Radiation Oncology, Guangdong Provincial Clinical Research Center - for Cancer, State Key Laboratory of Oncology in South China, Collaborative - Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 - Dongfeng Road East, Guangzhou, 510060, P. R. China. -FAU - Mo, YiWen -AU - Mo Y -AD - Department of Nuclear Medicine, Guangdong Provincial Clinical Research Center for - Cancer, State Key Laboratory of Oncology in South China, Collaborative Innovation - Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng - Road East, Guangzhou, Guangdong, 510060, P. R. China. -FAU - Liu, FangJie -AU - Liu F -AD - Department of Radiation Oncology, Guangdong Provincial Clinical Research Center - for Cancer, State Key Laboratory of Oncology in South China, Collaborative - Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 - Dongfeng Road East, Guangzhou, 510060, P. R. China. -FAU - Zheng, ShiYang -AU - Zheng S -AD - Department of Radiation Oncology, Guangdong Provincial Clinical Research Center - for Cancer, State Key Laboratory of Oncology in South China, Collaborative - Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 - Dongfeng Road East, Guangzhou, 510060, P. R. China. -FAU - Liu, Hui -AU - Liu H -AD - United Imaging Healthcare, Shanghai, China. -FAU - Li, HongDi -AU - Li H -AD - United Imaging Healthcare, Shanghai, China. -FAU - Guo, JinYu -AU - Guo J -AD - Department of Radiation Oncology, Guangdong Provincial Clinical Research Center - for Cancer, State Key Laboratory of Oncology in South China, Collaborative - Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 - Dongfeng Road East, Guangzhou, 510060, P. R. China. -FAU - Fan, Wei -AU - Fan W -AD - Department of Nuclear Medicine, Guangdong Provincial Clinical Research Center for - Cancer, State Key Laboratory of Oncology in South China, Collaborative Innovation - Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng - Road East, Guangzhou, Guangdong, 510060, P. R. China. -FAU - Qiu, Bo -AU - Qiu B -AD - Department of Radiation Oncology, Guangdong Provincial Clinical Research Center - for Cancer, State Key Laboratory of Oncology in South China, Collaborative - Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 - Dongfeng Road East, Guangzhou, 510060, P. R. China. qiubo@sysucc.org.cn. -FAU - Zhang, Xu -AU - Zhang X -AD - Department of Nuclear Medicine, Guangdong Provincial Clinical Research Center for - Cancer, State Key Laboratory of Oncology in South China, Collaborative Innovation - Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng - Road East, Guangzhou, Guangdong, 510060, P. R. China. zhangx2@sysucc.org.cn. -FAU - Liu, Hui -AU - Liu H -AD - Department of Radiation Oncology, Guangdong Provincial Clinical Research Center - for Cancer, State Key Laboratory of Oncology in South China, Collaborative - Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 - Dongfeng Road East, Guangzhou, 510060, P. R. China. liuhuisysucc@126.com. -LA - eng -SI - ClinicalTrials.gov/NCT04654234 -GR - 82073328/National Natural Science Foundation of China/ -PT - Journal Article -DEP - 20240702 -PL - Germany -TA - Eur J Nucl Med Mol Imaging -JT - European journal of nuclear medicine and molecular imaging -JID - 101140988 -SB - IM -OTO - NOTNLM -OT - High-sensitivity PET/CT scanner -OT - Immunotherapy -OT - Ki -OT - Lung cancer -EDAT- 2024/07/02 14:44 -MHDA- 2024/07/02 14:44 -CRDT- 2024/07/02 11:13 -PHST- 2024/03/17 00:00 [received] -PHST- 2024/06/07 00:00 [accepted] -PHST- 2024/07/02 14:44 [medline] -PHST- 2024/07/02 14:44 [pubmed] -PHST- 2024/07/02 11:13 [entrez] -AID - 10.1007/s00259-024-06819-2 [pii] -AID - 10.1007/s00259-024-06819-2 [doi] -PST - aheadofprint -SO - Eur J Nucl Med Mol Imaging. 2024 Jul 2. doi: 10.1007/s00259-024-06819-2. - -PMID- 26550444 -OWN - NLM -STAT- PubMed-not-MEDLINE -DCOM- 20151109 -LR - 20220408 -IS - 1940-5901 (Print) -IS - 1940-5901 (Electronic) -IS - 1940-5901 (Linking) -VI - 8 -IP - 8 -DP - 2015 -TI - Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer - cells in the treatment of non-small-cell lung cancer. -PG - 14527-37 -AB - BACKGROUND: Non-small-cell lung cancer (NSCLC) is one of the most fatal cancers, - which leads to large number of people dead. Followed by surgery, chemotherapy and - radiotherapy, chemotherapy combined dendritic cells with cytokine-induced killer - cells (DC-CIK) immunotherapy has been applied in NSCLC for some time, but little - consistent beneficial results are provided. So, it is essential to weigh the pros - and cons of the new therapeutic method. METHODS: We searched the randomized - controlled trials of NSCLC mainly by PubMed database. Terms combination of - "cytokine-induced killer cells", "tumor" and "cancer" were used. After evaluating - the heterogeneity of selected studies, then we performed the meta-analysis. - Pooled risk ratios (RRs) were estimated and 95% confidence intervals (CIs) were - calculated using a fixed-effect model. Sensitivity analysis was also performed. - RESULTS: Six eligible trials were enrolled. Efficiency and safety of chemotherapy - followed by DC-CIK immunotherapy (experimental group) and chemotherapy alone - (control group) were compared. 1-year overall survival (OS) (P=0.02) and - progression free survival (PFS) (P=0.005) in the experimental group were - significantly increased compared with the control. Disease control rate (DCR) - (P=0.006) rose significantly in experimental group. However, no significant - differences between the two groups were observed in 2-year OS (P=0.21), 2-year - PFS (P=0.10), overall response rate (ORR) (P=0.76) and partial response (PR) - (P=0.22). Temporary fever, anemia, leukopenia and nausea were the four major - adverse events (AEs) treated by chemotherapy. The incidence of anemia, leukopenia - and nausea in the experimental group was obviously lower than the control group. - Temporary fever rate was higher in experimental group than that in the control, - but could be alleviated by taking sufficient rest. CONCLUSIONS: Chemotherapy - combined with DC-CIK immunotherapy showed superiority in DCR, 1-year OS and PFS, - and no more AEs appeared, however, there was no significant improvement in ORR, - PR, 2-year OS and PFS. As a whole, the combination therapy is safer but modest in - efficacy for advanced NSCLC patients. -FAU - Zheng, Chenhong -AU - Zheng C -AD - Department of Comprehensive Surgery, South Building, Chinese PLA General Hospital - Beijing 100853, China ; Department of Chinese PLA General Logistics, No. 2 - Clinic, Management Support Bureau Beijing 100071, China. -FAU - Yu, Ganjun -AU - Yu G -AD - Institute of Immunology, National Key Laboratory of MedicalImmunology & Second - Military Medical University 800 Xiangyin Road, Shanghai 200433, China. -FAU - Wang, Hui -AU - Wang H -AD - Department of Plastic Surgery, Shanghai Changzheng Hospital, Second Military - Medical University Shanghai, China. -FAU - Tang, Airong -AU - Tang A -AD - Department of General Medicine, Beijing Tieying Hospital Beijing 100079, China. -FAU - Geng, Peiliang -AU - Geng P -AD - Department of Chinese PLA General Logistics, No. 2 Clinic, Management Support - Bureau Beijing 100071, China. -FAU - Zhang, Huiming -AU - Zhang H -AD - Department of Chinese PLA General Logistics, No. 2 Clinic, Management Support - Bureau Beijing 100071, China. -FAU - Zhu, Zhiquan -AU - Zhu Z -AD - Department of Chinese PLA General Logistics, No. 2 Clinic, Management Support - Bureau Beijing 100071, China. -FAU - Li, Fang -AU - Li F -AD - Department of Chinese PLA General Logistics, No. 2 Clinic, Management Support - Bureau Beijing 100071, China. -FAU - Xie, Xiaohua -AU - Xie X -AD - Department of Comprehensive Surgery, South Building, Chinese PLA General Hospital - Beijing 100853, China. -LA - eng -PT - Journal Article -DEP - 20150815 -PL - United States -TA - Int J Clin Exp Med -JT - International journal of clinical and experimental medicine -JID - 101471010 -PMC - PMC4613129 -OTO - NOTNLM -OT - DC-CIK -OT - Dendritic cells -OT - NSCLC -OT - chemotherapy -OT - cytokine-induced killer cells -OT - immunotherapy -EDAT- 2015/11/10 06:00 -MHDA- 2015/11/10 06:01 -PMCR- 2015/08/15 -CRDT- 2015/11/10 06:00 -PHST- 2015/04/26 00:00 [received] -PHST- 2015/07/10 00:00 [accepted] -PHST- 2015/11/10 06:00 [entrez] -PHST- 2015/11/10 06:00 [pubmed] -PHST- 2015/11/10 06:01 [medline] -PHST- 2015/08/15 00:00 [pmc-release] -PST - epublish -SO - Int J Clin Exp Med. 2015 Aug 15;8(8):14527-37. eCollection 2015. - -PMID- 36831618 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230228 -IS - 2072-6694 (Print) -IS - 2072-6694 (Electronic) -IS - 2072-6694 (Linking) -VI - 15 -IP - 4 -DP - 2023 Feb 17 -TI - Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with - Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung - Cancer after Chemoradiotherapy. -LID - 10.3390/cancers15041277 [doi] -LID - 1277 -AB - The study was conducted in the era when maintenance immunotherapy with durvalumab - was not available in clinical practice after chemoradiotherapy (CRT) in - unresectable non-small-cell lung cancer (NSCLC). The main aim of the study was to - check whether the presence of cardiovascular diseases (CVD) and their - pharmacotherapy affects the overall survival (OS) in such NSCLC patients - undergoing sequential CRT. The group of 196 patients were analyzed: 101 patients - with CVD (51.53%) and 95 patients with other reasons of qualification for - sequential CRT (decreased performance status, older age, and other - non-cardiovascular co-morbidities). Although patients with CVD were more often in - older age, and they more often experienced cardiac and nephrological - complications (p < 0.05 for all), there was a statistically nonsignificant trend - for lower all-cause mortality in patients with CVD. The lowest all-cause - mortality was observed in patients treated with beta-blockers and statins after - two (HR = 0.31; 95%CI: 0.1-0.98; p = 0.047), three (HR = 0.33; 95%CI: 0.13-0.81; - p = 0.015) and even four (HR = 0.45; 95%CI: 0.22-0.97; p = 0.027) years of - follow-up. The benefit in OS remained significant in 101 patients with CVD - treated with beta-blockers (HR = 0.65; 95%CI: 0.43-0.99; p = 0.045), and - eventually statin, throughout the whole follow-up (log-rank p < 0.05). Further - prospective studies are necessary to confirm the role of beta-blockers and - statins in reduction of mortality in NSCLC patients undergoing radical CRT. -FAU - Zaborowska-Szmit, Magdalena -AU - Zaborowska-Szmit M -AUID- ORCID: 0000-0002-8725-7698 -AD - Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National - Research Institute of Oncology, 02-781 Warsaw, Poland. -FAU - Szmit, Sebastian -AU - Szmit S -AUID- ORCID: 0000-0002-3075-1943 -AD - Department of Cardio-Oncology, Centre of Postgraduate Medical Education, - Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland. -AD - Clinic of Oncological Diagnostics and Cardio-Oncology, Maria Sklodowska-Curie - National Research Institute of Oncology, 02-781 Warsaw, Poland. -FAU - Olszyna-Serementa, Marta -AU - Olszyna-Serementa M -AD - Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National - Research Institute of Oncology, 02-781 Warsaw, Poland. -FAU - Badurak, Paweł -AU - Badurak P -AD - Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National - Research Institute of Oncology, 02-781 Warsaw, Poland. -FAU - Zajda, Katarzyna -AU - Zajda K -AD - Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National - Research Institute of Oncology, 02-781 Warsaw, Poland. -FAU - Janowicz-Żebrowska, Anna -AU - Janowicz-Żebrowska A -AD - Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National - Research Institute of Oncology, 02-781 Warsaw, Poland. -FAU - Piórek, Aleksandra -AU - Piórek A -AUID- ORCID: 0000-0002-3635-1772 -AD - Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National - Research Institute of Oncology, 02-781 Warsaw, Poland. -FAU - Knetki-Wróblewska, Magdalena -AU - Knetki-Wróblewska M -AUID- ORCID: 0000-0002-7603-099X -AD - Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National - Research Institute of Oncology, 02-781 Warsaw, Poland. -FAU - Jaśkiewicz, Piotr -AU - Jaśkiewicz P -AD - Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National - Research Institute of Oncology, 02-781 Warsaw, Poland. -FAU - Płużański, Adam -AU - Płużański A -AUID- ORCID: 0000-0002-3710-6445 -AD - Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National - Research Institute of Oncology, 02-781 Warsaw, Poland. -FAU - Krzakowski, Maciej -AU - Krzakowski M -AD - Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National - Research Institute of Oncology, 02-781 Warsaw, Poland. -FAU - Kowalski, Dariusz M -AU - Kowalski DM -AUID- ORCID: 0000-0002-9452-3229 -AD - Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National - Research Institute of Oncology, 02-781 Warsaw, Poland. -LA - eng -PT - Journal Article -DEP - 20230217 -PL - Switzerland -TA - Cancers (Basel) -JT - Cancers -JID - 101526829 -PMC - PMC9954027 -OTO - NOTNLM -OT - beta blocker -OT - cardio-oncology -OT - cardiovascular diseases -OT - lung cancer -OT - mortality -OT - statin -COIS- The authors declare no conflict of interest. -EDAT- 2023/02/26 06:00 -MHDA- 2023/02/26 06:01 -PMCR- 2023/02/17 -CRDT- 2023/02/25 01:41 -PHST- 2023/01/23 00:00 [received] -PHST- 2023/02/05 00:00 [revised] -PHST- 2023/02/14 00:00 [accepted] -PHST- 2023/02/25 01:41 [entrez] -PHST- 2023/02/26 06:00 [pubmed] -PHST- 2023/02/26 06:01 [medline] -PHST- 2023/02/17 00:00 [pmc-release] -AID - cancers15041277 [pii] -AID - cancers-15-01277 [pii] -AID - 10.3390/cancers15041277 [doi] -PST - epublish -SO - Cancers (Basel). 2023 Feb 17;15(4):1277. doi: 10.3390/cancers15041277. - -PMID- 36426286 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240907 -IS - 2666-3643 (Electronic) -IS - 2666-3643 (Linking) -VI - 3 -IP - 12 -DP - 2022 Dec -TI - The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven - NSCLC: A University of California Lung Cancer Consortium Retrospective Study. -PG - 100427 -LID - 10.1016/j.jtocrr.2022.100427 [doi] -LID - 100427 -AB - INTRODUCTION: There is a paucity of data on immune checkpoint inhibitors (ICIs) - plus doublet chemotherapy (C) in patients with advanced lung cancer whose tumor - harbors an actionable mutation. We sought to provide insight into the role of - this combination in relation to chemotherapy alone in this patient population. - METHODS: We conducted a retrospective study at the five University of California - National Cancer Institute-designated Comprehensive Cancer Centers. The primary - end point was progression-free survival (PFS). Secondary end points included - overall survival (OS) and significant adverse events. Adverse events in patients - who received a tyrosine kinase inhibitor (TKI) post-ICI were also captured. - RESULTS: A total of 246 patients were identified, 170 treated with C plus ICI and - 76 treated with C alone. Driver alterations included EGFR (54.9%), KRAS (32.9%), - ALK (5.3%), HER2/ERBB2 (2.9%), ROS1 (1.2%), MET (1.2%), RET (0.8%), and BRAF - non-V600 (0.8%). The overall PFS and OS hazard ratios were not significant at - 1.12 (95% confidence interval 0.83-1.51; p = 0.472) and 0.86 (95% confidence - interval: 0.60-1.24, p = 0.429), respectively. No significant differences in PFS - or OS were observed in the mutational subgroups. Grade 3 or greater adverse - events were lower in the C plus ICI group. The multivariate analysis for PFS and - OS revealed a performance status (Eastern Cooperative Oncology Group) score of 2, - and previous TKI treatment was associated with poorer outcomes with C plus ICI. - CONCLUSIONS: Our study suggests that patients with oncogenic-driven NSCLC, - primarily those with EGFR-driven tumors, treated with a TKI should not - subsequently receive C plus ICI. Analysis from prospective clinical trials will - provide additional information on the role of ICIs in this group of patients. -CI - © 2022 The Authors. -FAU - Benjamin, David J -AU - Benjamin DJ -AD - Divsion of Hematology/Oncology, Department of Medicine, University of California - Irvine, Irvine, California. -AD - Present Address: 1 Hoag Drive, Building 51, Newport Beach, California. -FAU - Chen, Shuai -AU - Chen S -AD - Division of Biostatistics, Department of Public Health Sciences, University of - California Davis, Davis, California. -FAU - Eldredge, Joanna B -AU - Eldredge JB -AD - Division of Hematology and Oncology, Department of Medicine, University of - California Davis School of Medicine, Sacramento, California. -FAU - Schokrpur, Shiruyeh -AU - Schokrpur S -AD - Division of Hematology-Oncology, Department of Medicine, University of - California, San Diego School of Medicine, La Jolla, California. -FAU - Li, Debory -AU - Li D -AD - David Geffen School of Medicine, University of California Los Angeles, Los - Angeles, California. -FAU - Quan, Zhikuan -AU - Quan Z -AD - Division of Biostatistics, Department of Public Health Sciences, University of - California Davis, Davis, California. -FAU - Chan, Jason W -AU - Chan JW -AD - Department of Radiation Oncology, University of California, San Francisco, San - Francisco, California. -FAU - Cummings, Amy L -AU - Cummings AL -AD - Division of Hematology Oncology, Department of Medicine, David Geffen School of - Medicine, University of California Los Angeles, Los Angeles, California. -FAU - Daly, Megan E -AU - Daly ME -AD - Department of Radiation Oncology, University of California Davis School of - Medicine, Sacramento, California. -FAU - Goldman, Jonathan W -AU - Goldman JW -AD - Division of Hematology Oncology, Department of Medicine, David Geffen School of - Medicine, University of California Los Angeles, Los Angeles, California. -FAU - Gubens, Matthew A -AU - Gubens MA -AD - Division of Hematology Oncology, Department of Medicine, University of California - San Francisco, San Francisco, California. -FAU - Harris, Jeremy P -AU - Harris JP -AD - Department of Radiation Oncology, University of California Irvine, Irvine, - California. -FAU - Onaitis, Mark W -AU - Onaitis MW -AD - Division of Hematology-Oncology, Department of Medicine, University of - California, San Diego School of Medicine, La Jolla, California. -AD - Division of Cardiothoracic Surgery, Department of Surgery, University of - California, San Diego, La Jolla, California. -FAU - Zhu, Viola W -AU - Zhu VW -AD - Divsion of Hematology/Oncology, Department of Medicine, University of California - Irvine, Irvine, California. -AD - Present Address: Nuvalent, 1 Broadway, 14th Floor, Cambridge, Massachusetts. -FAU - Patel, Sandip P -AU - Patel SP -AD - Division of Hematology-Oncology, Department of Medicine, University of - California, San Diego School of Medicine, La Jolla, California. -FAU - Kelly, Karen -AU - Kelly K -AD - Division of Hematology and Oncology, Department of Medicine, University of - California Davis School of Medicine, Sacramento, California. -AD - Present Address: 999, 17th Street, Suite 200, Denver, Colorado. -LA - eng -GR - P30 CA016042/CA/NCI NIH HHS/United States -GR - P30 CA093373/CA/NCI NIH HHS/United States -GR - UL1 TR001881/TR/NCATS NIH HHS/United States -PT - Journal Article -DEP - 20221029 -PL - United States -TA - JTO Clin Res Rep -JT - JTO clinical and research reports -JID - 101769967 -PMC - PMC9679033 -OTO - NOTNLM -OT - Actionable mutations -OT - Chemotherapy -OT - Driver mutations -OT - Immune checkpoint inhibitors -OT - Non–small cell lung cancer -OT - Oncogenic driven -EDAT- 2022/11/26 06:00 -MHDA- 2022/11/26 06:01 -PMCR- 2022/10/29 -CRDT- 2022/11/25 03:02 -PHST- 2022/07/27 00:00 [received] -PHST- 2022/10/08 00:00 [revised] -PHST- 2022/10/20 00:00 [accepted] -PHST- 2022/11/25 03:02 [entrez] -PHST- 2022/11/26 06:00 [pubmed] -PHST- 2022/11/26 06:01 [medline] -PHST- 2022/10/29 00:00 [pmc-release] -AID - S2666-3643(22)00151-5 [pii] -AID - 100427 [pii] -AID - 10.1016/j.jtocrr.2022.100427 [doi] -PST - epublish -SO - JTO Clin Res Rep. 2022 Oct 29;3(12):100427. doi: 10.1016/j.jtocrr.2022.100427. - eCollection 2022 Dec. - -PMID- 37325057 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20240927 -IS - 1837-9664 (Print) -IS - 1837-9664 (Electronic) -IS - 1837-9664 (Linking) -VI - 14 -IP - 9 -DP - 2023 -TI - Efficacy and Safety Analysis of Immune Checkpoint Inhibitors plus Angiogenesis - Inhibitors for the Treatment of Advanced Driver-negative NSCLC in Elderly - Patients: A Retrospective Study. -PG - 1623-1634 -LID - 10.7150/jca.83719 [doi] -AB - Background and Objective: Immune checkpoint inhibitors (ICIs) combined with - angiogenesis inhibitors may have synergistic effects in elderly patients with - advanced driver-negative NSCLC, but its true efficacy remains unclear. In - addition, chemotherapy tolerance in elderly NSCLC patients is poor, and the - precise identification of the population that may benefit from ICIs combined with - angiogenesis inhibitors is also the focus of current research. Methods: We - retrospectively compared the efficacy and safety of ICIs combined with or without - antiangiogenic agents in elderly patients with advanced driver-gene negative - NSCLC ≥65 years of age in the Cancer Center of Suzhou Hospital Affiliated to - Nanjing Medical University. The primary endpoint was PFS. Secondary endpoints - were OS, ORR, and immune-related adverse events (irAEs). Results: A total of 36 - patients in the IA group (immune checkpoint inhibitors plus angiogenesis - inhibitors group) and 43 patients in the NIA group (immune checkpoint inhibitors - without angiogenesis inhibitors group) were enrolled in the study between January - 1, 2019 and December 31, 2021. The median follow-up time for patients in the IA - group and NIA group was 18.2 months (95%CI: 14 - 22.5 months) and 21.4 months - (95%CI: 16.7 -26.1 months), respectively. The median PFS and median OS were - longer in the IA group compared to the NIA group (8.1 months vs 5.3 months; HR - for PFS: 0.778, 95%CI: 0.474-1.276, P=0.32; NA vs 30.9 months; HR for OS: 0.795, - 95%CI: 0.396-1.595, P=0.519). There were no significant differences in median PFS - and median OS between the two groups. Subgroup analysis showed that patients in - the IA group had significantly longer PFS in the subgroup with PD-L1 expression - ≥50% (P=0.017), and the association between different groups and disease - progression was still different in the two subgroups (P for interaction = 0.002). - There was no significant difference in ORR between the two groups (23.3% vs - 30.5%, P=0.465). The incidence of irAEs in the IA group was lower than that in - the NIA group (39.5% vs 19.4%, P=0.05), and the cumulative incidence of treatment - interruptions due to irAEs was significantly reduced (P=0.045). Conclusion: In - elderly patients with advanced driver-negative NSCLC, the addition of - antiangiogenic agents to ICIs therapy did not provide significant clinical - benefit, but the incidence of irAEs and treatment interruptions due to irAEs was - significantly reduced. In the subgroup analysis, we found that the clinical - benefit of this combination therapy was observed in patients with PD-L1 - expression ≥50%, which warrants further exploration. -CI - © The author(s). -FAU - Zhang, Jian -AU - Zhang J -AD - Department of Radiation Oncology, The Affiliated Suzhou Hospital of Nanjing - Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical - University, Suzhou 215001, China. -FAU - Zou, Zhonghua -AU - Zou Z -AD - Department of Radiation Oncology, The Affiliated Suzhou Hospital of Nanjing - Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical - University, Suzhou 215001, China. -FAU - Tan, Jie -AU - Tan J -AD - Department of Medical Oncology, The Affiliated Suzhou Hospital of Nanjing Medical - University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, - Suzhou 215001, China. -FAU - Shi, Jianping -AU - Shi J -AD - Department of Radiation Oncology, The Affiliated Suzhou Hospital of Nanjing - Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical - University, Suzhou 215001, China. -FAU - Yang, Hui -AU - Yang H -AD - Department of Medical Oncology, The Affiliated Suzhou Hospital of Nanjing Medical - University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, - Suzhou 215001, China. -FAU - Wang, Hao -AU - Wang H -AD - Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical - University, Hefei 230031, China. -FAU - Zhou, Jundong -AU - Zhou J -AD - Department of Radiation Oncology, The Affiliated Suzhou Hospital of Nanjing - Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical - University, Suzhou 215001, China. -FAU - Xue, Jing -AU - Xue J -AD - Department of Radiation Oncology, The Affiliated Suzhou Hospital of Nanjing - Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical - University, Suzhou 215001, China. -LA - eng -PT - Journal Article -DEP - 20230604 -PL - Australia -TA - J Cancer -JT - Journal of Cancer -JID - 101535920 -PMC - PMC10266243 -OTO - NOTNLM -OT - angiogenesis inhibitors -OT - elderly patient -OT - immune checkpoint inhibitors -OT - non-small cell lung cancer -OT - retrospective -COIS- Competing Interests: The authors have declared that no competing interest exists. -EDAT- 2023/06/16 06:42 -MHDA- 2023/06/16 06:43 -PMCR- 2023/01/01 -CRDT- 2023/06/16 04:18 -PHST- 2023/02/21 00:00 [received] -PHST- 2023/05/17 00:00 [accepted] -PHST- 2023/06/16 06:43 [medline] -PHST- 2023/06/16 06:42 [pubmed] -PHST- 2023/06/16 04:18 [entrez] -PHST- 2023/01/01 00:00 [pmc-release] -AID - jcav14p1623 [pii] -AID - 10.7150/jca.83719 [doi] -PST - epublish -SO - J Cancer. 2023 Jun 4;14(9):1623-1634. doi: 10.7150/jca.83719. eCollection 2023. - -PMID- 24954547 -OWN - NLM -STAT- MEDLINE -DCOM- 20150519 -LR - 20211021 -IS - 1523-6536 (Electronic) -IS - 1083-8791 (Print) -IS - 1083-8791 (Linking) -VI - 20 -IP - 10 -DP - 2014 Oct -TI - Parametric response mapping as an indicator of bronchiolitis obliterans syndrome - after hematopoietic stem cell transplantation. -PG - 1592-8 -LID - S1083-8791(14)00364-4 [pii] -LID - 10.1016/j.bbmt.2014.06.014 [doi] -AB - The management of bronchiolitis obliterans syndrome (BOS) after hematopoietic - cell transplantation presents many challenges, both diagnostically and - therapeutically. We developed a computed tomography (CT) voxel-wise methodology - termed parametric response mapping (PRM) that quantifies normal parenchyma, - functional small airway disease (PRM(fSAD)), emphysema, and parenchymal disease - as relative lung volumes. We now investigate the use of PRM as an imaging - biomarker in the diagnosis of BOS. PRM was applied to CT data from 4 patient - cohorts: acute infection (n = 11), BOS at onset (n = 34), BOS plus infection - (n = 9), and age-matched, nontransplant control subjects (n = 23). Pulmonary - function tests and bronchoalveolar lavage were used for group classification. - Mean values for PRM(fSAD) were significantly greater in patients with BOS - (38% ± 2%) when compared with those with infection alone (17% ± 4%, P < .0001) - and age-matched control subjects (8.4% ± 1%, P < .0001). Patients with BOS had - similar PRM(fSAD) profiles, whether a concurrent infection was present or not. An - optimal cut-point for PRM(fSAD) of 28% of the total lung volume was identified, - with values >28% highly indicative of BOS occurrence. PRM may provide a major - advance in our ability to identify the small airway obstruction that - characterizes BOS, even in the presence of concurrent infection. -CI - Copyright © 2014 American Society for Blood and Marrow Transplantation. Published - by Elsevier Inc. All rights reserved. -FAU - Galbán, Craig J -AU - Galbán CJ -AD - Department of Radiology, University of Michigan, Ann Arbor, Michigan. Electronic - address: cgalban@med.umich.edu. -FAU - Boes, Jennifer L -AU - Boes JL -AD - Department of Radiology, University of Michigan, Ann Arbor, Michigan. -FAU - Bule, Maria -AU - Bule M -AD - Department of Radiology, University of Michigan, Ann Arbor, Michigan. -FAU - Kitko, Carrie L -AU - Kitko CL -AD - Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, Michigan; - Department of Pediatrics and Communicable Diseases, University of Michigan, Ann - Arbor, Michigan. -FAU - Couriel, Daniel R -AU - Couriel DR -AD - Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, Michigan; - Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. -FAU - Johnson, Timothy D -AU - Johnson TD -AD - Department of Biostatistics, University of Michigan, Ann Arbor, Michigan. -FAU - Lama, Vihba -AU - Lama V -AD - Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. -FAU - Telenga, Eef D -AU - Telenga ED -AD - Department of Pulmonary Diseases, University of Groningen, University Medical - Center Groningen, Groningen, the Netherlands. -FAU - van den Berge, Maarten -AU - van den Berge M -AD - Department of Pulmonary Diseases, University of Groningen, University Medical - Center Groningen, Groningen, the Netherlands. -FAU - Rehemtulla, Alnawaz -AU - Rehemtulla A -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -FAU - Kazerooni, Ella A -AU - Kazerooni EA -AD - Department of Radiology, University of Michigan, Ann Arbor, Michigan. -FAU - Ponkowski, Michael J -AU - Ponkowski MJ -AD - Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, Michigan. -FAU - Ross, Brian D -AU - Ross BD -AD - Department of Radiology, University of Michigan, Ann Arbor, Michigan. -FAU - Yanik, Gregory A -AU - Yanik GA -AD - Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, Michigan; - Department of Pediatrics and Communicable Diseases, University of Michigan, Ann - Arbor, Michigan; Department of Internal Medicine, University of Michigan, Ann - Arbor, Michigan. -LA - eng -GR - T32EB005172/EB/NIBIB NIH HHS/United States -GR - P50CA93990/CA/NCI NIH HHS/United States -GR - R01 HL122438/HL/NHLBI NIH HHS/United States -GR - P01CA085878/CA/NCI NIH HHS/United States -GR - P01 CA085878/CA/NCI NIH HHS/United States -GR - T32 EB005172/EB/NIBIB NIH HHS/United States -GR - P50 CA093990/CA/NCI NIH HHS/United States -PT - Clinical Trial -PT - Journal Article -PT - Research Support, N.I.H., Extramural -DEP - 20140618 -PL - United States -TA - Biol Blood Marrow Transplant -JT - Biology of blood and marrow transplantation : journal of the American Society for - Blood and Marrow Transplantation -JID - 9600628 -RN - 0 (Myeloablative Agonists) -SB - IM -MH - Adolescent -MH - Adult -MH - Aged -MH - Bronchiolitis Obliterans/*diagnostic imaging/etiology/immunology/microbiology -MH - Bronchoalveolar Lavage Fluid/microbiology -MH - Case-Control Studies -MH - Child -MH - Female -MH - Hematologic Neoplasms/complications/*diagnostic imaging/immunology/microbiology -MH - *Hematopoietic Stem Cell Transplantation -MH - Humans -MH - Lung/*diagnostic imaging/immunology/microbiology -MH - Male -MH - Middle Aged -MH - Myeloablative Agonists/therapeutic use -MH - Prospective Studies -MH - Respiratory Function Tests -MH - Syndrome -MH - Tomography, X-Ray Computed/*methods -MH - Transplantation Conditioning/*methods -MH - Transplantation, Homologous -PMC - PMC4163140 -MID - NIHMS606721 -OTO - NOTNLM -OT - Bronchiolitis obliterans syndrome -OT - Pulmonary -OT - Transplantation -COIS- CONFLICTS OF INTEREST: BDR and CJG have a financial interest in the underlying - patented University of Michigan technology which was licensed to Imbio, LLC., a - company in which BDR and AR have a financial interest. There are no other author - conflicts of interest. -EDAT- 2014/06/24 06:00 -MHDA- 2015/05/20 06:00 -PMCR- 2015/10/01 -CRDT- 2014/06/24 06:00 -PHST- 2014/03/20 00:00 [received] -PHST- 2014/06/10 00:00 [accepted] -PHST- 2014/06/24 06:00 [entrez] -PHST- 2014/06/24 06:00 [pubmed] -PHST- 2015/05/20 06:00 [medline] -PHST- 2015/10/01 00:00 [pmc-release] -AID - S1083-8791(14)00364-4 [pii] -AID - 10.1016/j.bbmt.2014.06.014 [doi] -PST - ppublish -SO - Biol Blood Marrow Transplant. 2014 Oct;20(10):1592-8. doi: - 10.1016/j.bbmt.2014.06.014. Epub 2014 Jun 18. - -PMID- 35033834 -OWN - NLM -STAT- Publisher -LR - 20231016 -IS - 2468-2942 (Electronic) -IS - 2468-2942 (Linking) -VI - 30 -DP - 2022 -TI - Survival of clinical stage III NSCLC according to therapeutic strategy: Relevance - of the tumor board decision in the era of immunotherapy. -PG - 100508 -LID - S2468-2942(21)00204-5 [pii] -LID - 10.1016/j.ctarc.2021.100508 [doi] -AB - INTRODUCTION: Stage III NSCLC comprises a heterogeneous population. Different - treatment strategies are available, including surgery, radiotherapy, and - chemotherapy. The PACIFIC trial results represented a significant change and - improvement in the therapeutic strategy for these patients. We aimed to compare - the different treatment strategies employed in Stage III NSCLC patients within - our institution. METHODS: All Stage III NSCLC patients discussed during the - weekly thoracic oncology multidisciplinary team meetings at the University - hospital Grenoble Alpes (France) between January 2010 and January 2017 were - included. Patients' overall survival (OS) according to treatment strategies along - with their respective changes were compared. RESULTS: Overall, 476 patients were - identified. Among patients initially scheduled to receive neoadjuvant - chemotherapy followed by surgery (n = 60), only 37 (62%) actually underwent - surgery. Median OS of the cohort was 21.3 months [IQR 25%-75%: 9.6-48.3]. - Patients who received neoadjuvant chemotherapy followed by surgery displayed - better survival than those treated by CT-RT: 53.2 months [IQR 25%-75%: 16.1-87.3] - versus 23.9 [IQR 25%-75%, 13.3-48.1]. Survival was slightly superior for patients - treated by upfront CT-RT than for those planned for neoadjuvant chemotherapy - followed by surgery who eventually converted to CT-RT (concurrent or sequential): - 23.9 months [IQR 25%-75%: 13.3-48.1] versus 20.4 [IQR 25%-75%:10.8-36], - respectively. CONCLUSION: While patients who underwent neoadjuvant chemotherapy - followed by surgery displayed a better survival than those treated using CT-RT, - switch from surgery to CT-RT actually shortened survival. These results stress - the relevance of the tumor board in deciding which is the best therapeutic - strategy for Stage III disease patients. -CI - Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. -FAU - Benet, Justin -AU - Benet J -AD - Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, 38700 France. - Electronic address: jbenet@chu-grenoble.fr. -FAU - Toffart, Anne-Claire -AU - Toffart AC -AD - Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, 38700 France; - Institute for Advanced Biosciences INSERM U1209 CNRS UMR5309 Université Grenoble - Alpes, Grenoble, France. -FAU - Brichon, Pierre-Yves -AU - Brichon PY -AD - Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, 38700 France. -FAU - Chollier, Thibaut -AU - Chollier T -AD - Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, 38700 France. -FAU - Ruckly, Stéphane -AU - Ruckly S -AD - ICUREsearch, Paris, France. -FAU - Villa, Julie -AU - Villa J -AD - Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, 38700 France. -FAU - Emprou, Camille -AU - Emprou C -AD - Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, 38700 France; - Institute for Advanced Biosciences INSERM U1209 CNRS UMR5309 Université Grenoble - Alpes, Grenoble, France. -FAU - Pierret, Thomas -AU - Pierret T -AD - Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, 38700 France. -FAU - Dumas, Isabelle -AU - Dumas I -AD - Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, 38700 France. -FAU - Ferretti, Gilbert -AU - Ferretti G -AD - Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, 38700 France; - Institute for Advanced Biosciences INSERM U1209 CNRS UMR5309 Université Grenoble - Alpes, Grenoble, France. -FAU - Moro-Sibilot, Denis -AU - Moro-Sibilot D -AD - Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, 38700 France; - Institute for Advanced Biosciences INSERM U1209 CNRS UMR5309 Université Grenoble - Alpes, Grenoble, France. -FAU - Levra, Matteo Giaj -AU - Levra MG -AD - Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, 38700 France; - Institute for Advanced Biosciences INSERM U1209 CNRS UMR5309 Université Grenoble - Alpes, Grenoble, France. -LA - eng -PT - Journal Article -DEP - 20220104 -PL - England -TA - Cancer Treat Res Commun -JT - Cancer treatment and research communications -JID - 101694651 -SB - IM -OTO - NOTNLM -OT - Multidisciplinary tumor board -OT - Non-small-cell lung cancer -OT - Stage III disease -OT - Survival -EDAT- 2022/01/17 06:00 -MHDA- 2022/01/17 06:00 -CRDT- 2022/01/16 20:56 -PHST- 2021/11/09 00:00 [received] -PHST- 2021/12/29 00:00 [revised] -PHST- 2021/12/30 00:00 [accepted] -PHST- 2022/01/17 06:00 [pubmed] -PHST- 2022/01/17 06:00 [medline] -PHST- 2022/01/16 20:56 [entrez] -AID - S2468-2942(21)00204-5 [pii] -AID - 10.1016/j.ctarc.2021.100508 [doi] -PST - ppublish -SO - Cancer Treat Res Commun. 2022;30:100508. doi: 10.1016/j.ctarc.2021.100508. Epub - 2022 Jan 4. - -PMID- 36636408 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230115 -IS - 2218-6751 (Print) -IS - 2226-4477 (Electronic) -IS - 2218-6751 (Linking) -VI - 11 -IP - 12 -DP - 2022 Dec -TI - DNA damage repair gene mutations predict the efficacy of platinum-based - chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced - non-small cell lung cancer: a retrospective Chinese cohort study. -PG - 2539-2566 -LID - 10.21037/tlcr-22-746 [doi] -AB - BACKGROUND: Platinum-based chemotherapy (PC) and immunotherapy plus - platinum-based chemotherapy (IPC) remain the first-line treatment for advanced - NSCLC. But only a minority patients benefit from PC, and existing biomarkers, - such as PD-L1, have been shown to be defective in predicting the efficacy of IPC. - Highlighting the need to identify novel biomarkers for the efficacy of PC and - IPC. DNA damage repair (DDR) mutations are known to predict response to PC in - solid tumors. However, the predictive value of DDR in PC and IPC of NSCLC remains - unclear. METHODS: Patients diagnosed with advanced or metastatic NSCLC were - retrospectively included if they underwent next generation sequencing prior to - starting treatment. Primary endpoints were to explore whether DDR mutations - (DDRmut) are associated with clinical outcomes of PC and IPC. Secondary end point - were to explore the association between DDRmut and the choice to add - immunotherapy to chemotherapy, and the impact of different DDR pathways on - efficacy in PC and IPC. RESULTS: DDRmut showed a strong association with tumor - mutation burden-high (TMB-H) versus DDR wild-type (DDRwt) and higher rates of - PD-L1 TPS ≥50% positivity. In 63 patients treated with PC, ORRs were 15.38% and - 2.86% for DDRmut and DDRwt subgroup (P=0.1536), and DCRs were 88.46% and 45.72% - (P=0.00097) at 6 months after PC. The DDRmut patients had significantly improved - median PFS (mPFS) and median overall survival (mOS) than DDRwt group (mPFS: 7.6 - vs. 3.9 months, HR =1.93, 95% CI: 1.09 to 3.14, P=0.0220. mOS: 29.9 vs. 20.7 - months, HR =2.31, 95% CI: 1.09 to 4.9, P=0.0250). Moreover, among 37 patients - treated with IPC, ORRs were 45% and 11.76% for DDRmut and DDRwt patients - (P=0.0365), and the DCRs were 95% and 70.58% (P=0.0752), respectively at 6 months - after IPC. The DDRmut patients had significantly improved mPFS compared to the - DDRwt group (19.5 vs. 4.5 months, HR =3.28, 95% CI: 1.53 to 9.56, P=0.0022). In - DDRmut group, mPFS of IPC recipients was significantly better than that of PC - recipients (19.5 vs. 7.6 months, HR =2.09, 95% CI: 0.98 to 4.42, P=0.050). - CONCLUSIONS: There is potential for DDR to serve as a positive predictor of PC - and IPC in advanced NSCLC patients. -CI - 2022 Translational Lung Cancer Research. All rights reserved. -FAU - Xiao, Zhiwei -AU - Xiao Z -AD - Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese - Medicine, Guangzhou, China. -FAU - Sun, Lingling -AU - Sun L -AD - Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese - Medicine, Guangzhou, China. -FAU - Zheng, Yating -AU - Zheng Y -AD - The Medical Department, 3D Medicines Inc., Shanghai, China. -FAU - Chen, Hanrui -AU - Chen H -AD - Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese - Medicine, Guangzhou, China. -FAU - Zheng, Xinting -AU - Zheng X -AD - Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese - Medicine, Guangzhou, China. -FAU - Luo, Jiamin -AU - Luo J -AD - Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese - Medicine, Guangzhou, China. -FAU - Gu, Chuying -AU - Gu C -AD - Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese - Medicine, Guangzhou, China. -FAU - Lin, Ruiting -AU - Lin R -AD - The First Clinical Medical College of Guangzhou University of Chinese Medicine, - Guangzhou, China. -FAU - Huang, Mengli -AU - Huang M -AD - The Medical Department, 3D Medicines Inc., Shanghai, China. -FAU - Bai, Yuezong -AU - Bai Y -AD - The Medical Department, 3D Medicines Inc., Shanghai, China. -FAU - Chen, Zhe-Sheng -AU - Chen ZS -AD - Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, - St. John's University, Queens, NY, USA. -FAU - Kinslow, Connor J -AU - Kinslow CJ -AD - Department of Radiation Oncology, Vagelos College of Physicians and Surgeons, - Columbia University Irving Medical Center, New York, NY, USA. -FAU - Loh, Jerold -AU - Loh J -AD - Department of Haematology-Oncology, National University Cancer Institute, - Singapore (NCIS), National University Health System, Singapore, Singapore. -FAU - Lin, Lizhu -AU - Lin L -AD - Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese - Medicine, Guangzhou, China. -LA - eng -PT - Journal Article -PL - China -TA - Transl Lung Cancer Res -JT - Translational lung cancer research -JID - 101646875 -PMC - PMC9830265 -OTO - NOTNLM -OT - DNA damage repair (DDR) -OT - Non-small cell lung cancer (NSCLC) -OT - immunotherapy plus platinum-based chemotherapy (IPC) -OT - platinum-based chemotherapy (PC) -OT - prediction -COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure - form (available at - https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-746/coif). YZ, MH, and - YB are employed by the company 3D Medicines Inc. The other authors have no - conflicts of interest to declare. -EDAT- 2023/01/14 06:00 -MHDA- 2023/01/14 06:01 -PMCR- 2022/12/01 -CRDT- 2023/01/13 02:01 -PHST- 2022/08/04 00:00 [received] -PHST- 2022/12/19 00:00 [accepted] -PHST- 2023/01/13 02:01 [entrez] -PHST- 2023/01/14 06:00 [pubmed] -PHST- 2023/01/14 06:01 [medline] -PHST- 2022/12/01 00:00 [pmc-release] -AID - tlcr-11-12-2539 [pii] -AID - 10.21037/tlcr-22-746 [doi] -PST - ppublish -SO - Transl Lung Cancer Res. 2022 Dec;11(12):2539-2566. doi: 10.21037/tlcr-22-746. - -PMID- 36865790 -OWN - NLM -STAT- PubMed-not-MEDLINE -LR - 20230304 -IS - 2234-943X (Print) -IS - 2234-943X (Electronic) -IS - 2234-943X (Linking) -VI - 13 -DP - 2023 -TI - Integrated multi-dimensional deep neural network model improves prognosis - prediction of advanced NSCLC patients receiving bevacizumab. -PG - 1052147 -LID - 10.3389/fonc.2023.1052147 [doi] -LID - 1052147 -AB - BACKGROUND: The addition of bevacizumab was found to be associated with prolonged - survival whether in combination with chemotherapy, tyrosine kinase inhibitors or - immune checkpoint inhibitors in the treatment landscape of advanced non-small - cell lung cancer (NSCLC) patients. However, the biomarkers for efficacy of - bevacizumab were still largely unknown. This study aimed to develop a deep - learning model to provide individual assessment of survival in advanced NSCLC - patients receiving bevacizumab. METHODS: All data were retrospectively collected - from a cohort of 272 radiological and pathological proven advanced non-squamous - NSCLC patients. A novel multi-dimensional deep neural network (DNN) models were - trained based on clinicopathological, inflammatory and radiomics features using - DeepSurv and N-MTLR algorithm. And concordance index (C-index) and bier score was - used to demonstrate the discriminatory and predictive capacity of the model. - RESULTS: The integration of clinicopathologic, inflammatory and radiomics - features representation was performed using DeepSurv and N-MTLR with the C-index - of 0.712 and 0.701 in testing cohort. And Cox proportional hazard (CPH) and - random survival forest (RSF) models were also developed after data pre-processing - and feature selection with the C-index of 0.665 and 0.679 respectively. DeepSurv - prognostic model, indicated with best performance, was used for individual - prognosis prediction. And patients divided in high-risk group were significantly - associated with inferior PFS (median PFS: 5.4 vs 13.1 months, P<0.0001) and OS - (median OS: 16.4 vs 21.3 months, P<0.0001). CONCLUSIONS: The integration of - clinicopathologic, inflammatory and radiomics features representation based on - DeepSurv model exhibited superior predictive accuracy as non-invasive method to - assist in patients counseling and guidance of optimal treatment strategies. -CI - Copyright © 2023 Li, Yang, Jiang, Yao, Li, Cheng, Zou, Fan and Wang. -FAU - Li, Butuo -AU - Li B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Yang, Linlin -AU - Yang L -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Jiang, Chao -AU - Jiang C -AD - Department of Otorhinolaryngology Head and Neck Surgery, Shandong Provincial - Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. -AD - Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, - Jinan, Shandong, China. -FAU - Yao, Yueyuan -AU - Yao Y -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Li, Haoqian -AU - Li H -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Cheng, Shuping -AU - Cheng S -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Zou, Bing -AU - Zou B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Fan, Bingjie -AU - Fan B -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -FAU - Wang, Linlin -AU - Wang L -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, - Shandong First Medical University and Shandong Academy of Medical Sciences, - Jinan, Shandong, China. -LA - eng -PT - Journal Article -DEP - 20230214 -PL - Switzerland -TA - Front Oncol -JT - Frontiers in oncology -JID - 101568867 -PMC - PMC9972089 -OTO - NOTNLM -OT - bevacizumab -OT - deep learning -OT - non-squamous NSCLC -OT - prognosis prediction -OT - radiomics -COIS- The authors declare that the research was conducted in the absence of any - commercial or financial relationships that could be construed as a potential - conflict of interest. -EDAT- 2023/03/04 06:00 -MHDA- 2023/03/04 06:01 -PMCR- 2023/01/01 -CRDT- 2023/03/03 02:36 -PHST- 2022/09/23 00:00 [received] -PHST- 2023/01/31 00:00 [accepted] -PHST- 2023/03/03 02:36 [entrez] -PHST- 2023/03/04 06:00 [pubmed] -PHST- 2023/03/04 06:01 [medline] -PHST- 2023/01/01 00:00 [pmc-release] -AID - 10.3389/fonc.2023.1052147 [doi] -PST - epublish -SO - Front Oncol. 2023 Feb 14;13:1052147. doi: 10.3389/fonc.2023.1052147. eCollection - 2023. diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/scopus 438.bib" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/scopus 438.bib" deleted file mode 100644 index 82870da..0000000 --- "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/scopus 438.bib" +++ /dev/null @@ -1,7119 +0,0 @@ -Scopus -EXPORT DATE: 18 October 2024 - -@ARTICLE{Chen2024, - author = {Chen, Dawei and Zou, Bing and Li, Butuo and Gao, Aiqin and Huang, Wei and Shao, Qian and Meng, Xiangjiao and Zhang, Pinliang and Tang, Xiaoyong and Hu, Xudong and Zhang, Yan and Guo, Jun and Zhao, Changhong and Yuan, Jiajia and Li, Qian and Zhu, Changbin and Yu, Jinming and Wang, Linlin}, - title = {Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trial}, - year = {2024}, - journal = {eClinicalMedicine}, - volume = {75}, - doi = {10.1016/j.eclinm.2024.102795}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201460756&doi=10.1016%2fj.eclinm.2024.102795&partnerID=40&md5=3768bb8b7ae3502778c0fc02dbe18e2d}, - abstract = {Background: This phase II prospective trial aimed to investigate the efficacy and safety of adebrelimab (PD-L1 antibody) plus first-line chemotherapy followed by sequential thoracic radiotherapy (TRT) combined with adebrelimab in extensive-stage small–cell lung cancer (ES-SCLC). Biomarkers associated with potential therapeutic effects were also explored. Methods: Patients with previously untreated ES-SCLC were enrolled at Shandong Cancer Hospital and Institute (Jinan, China). Patients received 4–6 cycles of adebrelimab (20 mg/kg, D1, Q3W) combined with EP/EC (etoposide, 100 mg/m2, D1-3, Q3W and cisplatin, 75 mg/m2, D1, Q3W or carboplatin, AUC = 5, D1, Q3W). Then patients with response sequentially underwent consolidative TRT (≥30 Gy in 10 fractions or ≥50 Gy in 25 fractions, involved-field irradiation), and maintenance adebrelimab until disease progression or intolerable adverse events (AEs). The primary endpoint was overall survival (OS). Genomic and circulating tumour DNA (ctDNA) profiling were also analyzed with tumour tissues and peripheral blood. This trial was registered with ClinicalTrials.gov, NCT04562337. Findings: From October 2020 to April 2023, 67 patients diagnosed with ES-SCLC were enrolled and received at least one dose of study treatment. All patients were included in the efficacy and safety analyses. 45 patients received sequential TRT as planned. The median OS and progression-free survival (PFS) was 21.4 months (95% CI: 17.2–not reached months) and 10.1 months (95% CI: 6.9–15.5 months), respectively. The confirmed objective response rate was 71.6% (48/67, 95% CI: 59.3–82.0%) and disease control rate was 89.6% (60/67, 95% CI: 79.7–95.7%). There were no treatment-related deaths. The most common grade 3 or higher treatment-related adverse events (TRAEs) were hematological toxicities. The incidence of any grade and G3+ pneumonitis was 25% (17/67) and 6% (4/67), respectively. No unexpected adverse events were observed. Patients without co-mutations of TP53/RB1 in both tissue and peripheral blood displayed longer PFS (tissue, P = 0.071; ctDNA, P = 0.060) and OS (tissue, P = 0.032; ctDNA, P = 0.031). Interpretation: Adebrelimab plus chemotherapy and sequential TRT as first-line therapy for ES-SCLC showed promising efficacy and acceptable safety. Funding: This study was funded by the National Natural Science Foundation of China (82172865), Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Amoy Diagnostics Co., Ltd. © 2024 The Authors}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Wang2024, - author = {Wang, Jiaxin and Guo, Huaijuan and Yang, Jingjing and Mao, Jingxian and Wang, Ying and Yan, Xuebing and Guo, Hong}, - title = {Identification of C-PLAN index as a novel prognostic predictor for advanced lung cancer patients receiving immune checkpoint inhibitors}, - year = {2024}, - journal = {Frontiers in Oncology}, - volume = {14}, - doi = {10.3389/fonc.2024.1339729}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85185483549&doi=10.3389%2ffonc.2024.1339729&partnerID=40&md5=8d96f7d504b5d87c32b55612dcf5fd9e}, - abstract = {Objective: Increasing studies have highlighted the potential utility of non-invasive prognostic biomarkers in advanced lung cancer patients receiving immune checkpoint inhibitor (ICI) based anti-cancer therapies. Here, a novel prognostic predictor named as C-PLAN integrating C-reactive protein (CRP), Performance status (PS), Lactate dehydrogenase (LDH), Albumin (ALB), and derived Neutrophil-to-lymphocyte ratio (dNLR) was identified and validated in a single-center retrospective cohort. Methods: The clinical data of 192 ICI-treated lung cancer patients was retrospectively analyzed. The pretreatment levels of CRP, PS, LDH, ALB and dNLR were scored respectively and then their scores were added up to form C-PLAN index. The correlation of C-PLAN index with the progression-free survival (PFS) or overall survival (OS) was analyzed by a Kaplan–Meier model. The multivariate analysis was used to identify whether C-PLAN index was an independent prognostic predictor. Results: A total of 88 and 104 patients were included in the low and high C-PLAN index group respectively. High C-PLAN index was significantly correlated with worse PFS and OS in ICI-treated lung cancer patients (both p<0.001). The multivariate analysis revealed high C-PLAN index was an independent unfavorable factor affecting PFS (hazard ratio (HR)=1.821; 95%confidence interval (CI)=1.291-2.568) and OS (HR=2.058, 95%CI=1.431-2.959). The high C-PLAN index group had a significantly lower disease control rate than the low C-PLAN index group (p=0.024), while no significant difference was found for objective response rate (p=0.172). The subgroup analysis based on clinical features (pathological type, therapy strategy, TNM stage and age) confirmed the prognostic value of C-PLAN index, except for patients receiving ICI monotherapy or with age ranging from 18 to 65 years old. Finally, a nomogram was constructed based on C-PLAN index, age, gender, TNM stage and smoking status, which could predict well the 1-, 2- and 3-year survival of ICI-treated lung cancer patients. Conclusion: The C-PLAN index has great potential to be utilized as a non-invasive, inexpensive and reliable prognostic predictor for advanced lung cancer patients receiving ICI-based anti-cancer therapies. Copyright © 2024 Wang, Guo, Yang, Mao, Wang, Yan and Guo.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access} -} - -@ARTICLE{Mao2024, - author = {Mao, Yayun and Huang, Meiping and Liu, Jiafu}, - title = {Achieving long-term survival in extensive-stage SCLC: a case report and mini literature review}, - year = {2024}, - journal = {Lung Cancer Management}, - volume = {13}, - number = {1}, - doi = {10.2217/lmt-2023-0012}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85196896342&doi=10.2217%2flmt-2023-0012&partnerID=40&md5=4bc3e3cd8cf06b56afcaffdb2f00a6ad}, - abstract = {Managing extensive-stage SCLC (ES-SCLC) has long been challenging for clinicians and oncologists due to its aggressive nature and poor prognosis. We report a case of a 41-year-old female with ES-SCLC who survived for six years, defying the disease's typically poor prognosis. Through a heavy treatment strategy involving chemotherapy, targeted therapy, and immunotherapy, the patient experienced robust responses and avoided distant metastasis, including brain involvement. The long-term survival case in SCLC highlights the need for further research into personalized strategies and prognostic biomarkers. This case holds significant value for both clinicians and researchers as it challenges the conventional strategies for ES-SCLC and sets the stage for future evidence-based studies aimed at extending survival in SCLC. © 2024 The Authors.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Jeung2024139, - author = {Jeung, Ye Sul and Chun, June Young and Choi, Beom Kyu and Park, Seog Yun and Lim, Hyun-Ju and Park, Jong Woong and Han, Ji-Youn and Lee, Youngjoo}, - title = {Infection-related Hospitalizations during Immune Checkpoint Inhibitor Treatment Without Immunosuppressants}, - year = {2024}, - journal = {Journal of Immunotherapy}, - volume = {47}, - number = {4}, - pages = {139 – 147}, - doi = {10.1097/CJI.0000000000000504}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85189859429&doi=10.1097%2fCJI.0000000000000504&partnerID=40&md5=0d9cc0dc7482ab2ecb59ac505e0ea32e}, - abstract = {Immunosuppressants are increasingly being used in the clinic to manage immune-related adverse effects. Consequently, the incidence of secondary infections associated with immunosuppression is increasing. However, little is known about primary infections during immune checkpoint inhibitor (ICI) treatment without immunosuppressants. We aimed to evaluate primary infectious diseases during antiprogrammed death ligand-1 immunotherapy without immunosuppressants. We retrospectively screened medical records of 233 patients who underwent ICI treatment for advanced non-small cell lung cancer between January 2014 and May 2018 at National Cancer Center, Republic of Korea. Subsequently, we evaluated the clinical characteristics and treatment outcomes of selected patients hospitalized for potential infectious disease without immunosuppressive treatment (n=80). Eight cases (3.4%) were identified as bacterial pneumonia (n=5) and cellulitis, inflamed epidermoid cyst, and wound infection (n=1 each). The bacterial pathogens Streptococcus pneumoniae and Haemophilus influenzae were identified in 4 patients with pneumonia. The period between the start of ICI treatment and infection varied between 3 and 189 days (median, 24.5 days). Five (62.5%) patients were infected within a month after ICI treatment initiation. All patients were treated with empirical antibiotics and discharged without complications. The median progression-free and overall survival for ICI treatment was 11.5 and 25.5 months, respectively. Six patients experienced ICI-associated adverse effects postinfection: Herpes zoster infection (n=4) and pneumonitis (n=2). Infectious disease independent of immunosuppression is a rare, but possible event in patients with lung cancer receiving ICI treatment. Clinical awareness would enable prompt diagnosis of primary infection during immunotherapy. © 2024 Lippincott Williams and Wilkins. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Papavasileiou2024, - author = {Papavasileiou, Sotirios and Kouvela, Marousa and Charpidou, Andriani}, - title = {New therapies in small cell lung cancer: A narrative review}, - year = {2024}, - journal = {Pneumon}, - volume = {37}, - number = {1}, - doi = {10.18332/pne/183168}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186931794&doi=10.18332%2fpne%2f183168&partnerID=40&md5=fdec680c7fe8f2cf7d291aba28930dd8}, - abstract = {Lung cancer overall is the second most common malignancy in both men and women in the United States and remains the leading cause of cancer death. Small cell lung cancer (SCLC) accounts for approximately 10–15% of all cases. Chemotherapy with a platinum agent and etoposide remains the standard of care for limited-stage patients. In the past few years, several clinical trials have evaluated the efficacy of immunotherapy, when added to conventional chemotherapy, in extensive-stage patients, and two anti-PD-L1 monoclonal antibodies, atezolizumab and durvalumab, have already been approved by the USA Food and Drug Administration (FDA) for use in this setting. Moreover, numerous other new agents are currently being investigated while new molecular features of SCLC subtypes come to light. Further analysis of predictive biomarkers needs to be done as well as evaluation of immune checkpoint inhibitors in early-stage disease. © 2024, European Publishing. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Li2024, - author = {Li, Ran and Liang, Hongge and Li, Jun and Shao, Zhenyu and Yang, Donghong and Bao, Jing and Wang, Keqiang and Xi, Wen and Gao, Zhancheng and Guo, Renhua and Mu, Xinlin}, - title = {Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study}, - year = {2024}, - journal = {BMC Cancer}, - volume = {24}, - number = {1}, - doi = {10.1186/s12885-024-11860-3}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85182639682&doi=10.1186%2fs12885-024-11860-3&partnerID=40&md5=addd31ed15e0b864173d710616283440}, - abstract = {Background: Paclitaxel liposome (Lipusu) is known to be effective in non-small cell lung cancer (NSCLC) as first-line treatment. This study aimed to evaluate the effectiveness and safety of paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor in patients with advanced NSCLC. Methods: In this multicenter, retrospective, real-world study, patients with advanced NSCLC who were administered paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor in three centers (Peking University People’s Hospital as the lead center) in China between 2016 and 2022 were included. Progression-free survival (PFS), overall survival (OS), objective response rate, disease control rate, and adverse events (AEs) were evaluated. Results: A total of 49 patients were included, with 33 (67.3%) receiving paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor as first-line treatment. There were 34 patients (69.4%) diagnosed with squamous cell carcinoma and 15 (30.6%) with adenocarcinoma. The median follow-up was 20.5 (range: 3.1–41.1) months. The median PFS and OS of all patients were 9.7 months (95% confidence interval [CI], 7.0-12.4) and 30.5 months (95% CI, not evaluable-not evaluable), respectively. Patients with squamous cell carcinoma and adenocarcinoma had median PFS of 11 months (95%CI, 6.5–15.5) and 9.3 months (95%CI, 7.0-12.4), respectively. The median PFS was 9.9 months (95%CI, 7.1–12.7) in patients who received the combined regimen as first-line treatment. Treatment-related AEs of any grade were observed in 25 (51.0%) patients, and AEs of grade 3 or worse were observed in nine patients (18.4%). The most common treatment-related AEs were myelosuppression (14.3%) and fever (10.2%). Conclusions: Paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor prolonged the PFS in advanced NSCLC with acceptable safety, which was worthy of clinical application. © 2024, The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4; All Open Access, Gold Open Access} -} - -@ARTICLE{Hall2024, - author = {Hall, Madeleine L. and Ng, Sweet Ping and Hafeez, Umbreen and Tebbutt, Niall and Sinclair, Marie and Foroudi, Farshad and Chao, Michael and Khor, Richard}, - title = {Safety and tolerability of radiotherapy in combination with systemic targeted therapies for treatment of hepatocellular carcinoma: a narrative review}, - year = {2024}, - journal = {Chinese Clinical Oncology}, - volume = {13}, - number = {3}, - doi = {10.21037/cco-23-140}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85197649316&doi=10.21037%2fcco-23-140&partnerID=40&md5=cd11a05f524e4d064b96b53d328b1b7b}, - abstract = {Background and Objective: Palliative radiotherapy (RT) and systemic immuno- or targeted therapy both play significant roles in the treatment of advanced hepatocellular carcinoma (HCC). Concurrent application of these therapies is increasing, however, no guidelines exist regarding the combination of systemic therapy with RT. This narrative review summarises the existing literature reporting toxicity observed after concurrent treatment with RT and immuno- or targeted therapeutic agents commonly used in HCC. Methods: The PubMed database was searched for studies published between 2011 and 2023 reporting toxicity data on patients treated concurrently with RT and targeted agents used in HCC. Due to the paucity of relevant literature in HCC, the inclusion criteria were expanded to include non-HCC cohorts treated with targeted therapies commonly used in advanced HCC. Key Content and Findings: Sixty-seven articles were included in this review. Twenty-two articles reported combined RT with sorafenib, one with regorafenib, 22 with bevacizumab, three with lenvatinib and 19 with immune checkpoint inhibitors. Significant findings include a high rate severe hepatotoxicity with combination RT and sorafenib, ranging from 0–19% with liver stereotactic body radiotherapy (SBRT) and 3–18% with conventionally fractionated liver RT. Severe gastrointestinal (GI) toxicities including perforation and ulceration were seen with combination bevacizumab and RT, ranging from 0–27% in the acute setting and 0–23% in the late setting. The safety profile of combination immune checkpoint blockade agents and RT was similar to that seen in monotherapy. Conclusions: Existing data suggests that combination RT and targeted therapy given the risk of severe adverse events including hepatotoxicity and GI toxicity. There is an urgent need for future studies specifically examining the impact of combination therapy in HCC patients to guide clinical decision-making in the evolving landscape of immune- and targeted therapies. © Chinese Clinical Oncology. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Déborah2024, - author = {Déborah, Lamy and Pierre, Mouillot and Anne-Sophie, Mariet and Robby, Barnestein and Fleur-Marie, Quilot and Cléa, Fraisse and François, Ghiringhelli and Philippe, Bonniaud and Ayoube, Zouak and Pascal, Foucher}, - title = {Real-world comparison of chemo-immunotherapy and chemotherapy alone in the treatment of extensive-stage small-cell lung cancer}, - year = {2024}, - journal = {Respiratory Medicine and Research}, - volume = {86}, - doi = {10.1016/j.resmer.2024.101125}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85199020542&doi=10.1016%2fj.resmer.2024.101125&partnerID=40&md5=bec04d0c939ba1a209b399d46723aa39}, - abstract = {Introduction: Small cell lung cancer (SCLC) is a high-grade neuroendocrine carcinoma responsible for 200,000 deaths per year worldwide. Platinum-etoposide-based chemotherapy has been the standard of treatment for the past 40 years, with an overall survival of 10 months. Since 2019, the addition of immunotherapy (atezolizumab or durvalumab) to chemotherapy has become the standard of care for first-line treatment of extensive-stage SCLC following the demonstration of an improvement in overall survival in phase 3 studies. We aimed to evaluate the efficacy and safety of chemo-immunotherapy compared with chemotherapy alone in a “real-world” setting. Methods: Retrospective observational study including patients undergoing first-line treatment for extensive-stage SCLC between 2014 and 2022. We separated the study population into two arms (chemo-immunotherapy/chemotherapy). For each arm, progression-free survival (PFS), overall survival (OS) and serious side effects were collected. Associations between treatments and survival outcomes were adjusted for potential confounders. Consolidative palliative thoracic radiotherapy was introduced in the models as a time-dependent variable. Results: A total of 118 patients with a median age of 63 years were included. 65.2 % of patients were performance status 0 or 1. In univariate analysis, PFS and OS were not significantly different between the chemo-immunotherapy and chemotherapy alone groups (p = 0.70 and 0.24 respectively). In multivariate analysis, the addition of immunotherapy to chemotherapy was not significantly associated with better PFS (HR 0.76, IC (0.49 – 1.19), p = 0.23), but it was significantly associated with better OS (HR 0.61, IC (0.38 – 0.98), p = 0.04). Consolidative palliative thoracic radiotherapy (time-dependent variable), when applied (almost only in the chemotherapy alone group), was significantly associated with better PFS and OS. Discussion: In this real-world study, chemo-immunotherapy was associated with slightly better OS compared to chemotherapy alone as a first-line treatment in ES-SCLC patients in multivariate analysis, which is not explained by a benefit in PFS. However, consolidative palliative thoracic radiotherapy seems to be significantly associated with better OS and PFS, suggesting that we should also consider using it in patients receiving chemo-immunotherapy. © 2024 The Author(s)}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Qin2024, - author = {Qin, Boyu and Xin, Lingli and Liang, Chen and Li, Lingling and Song, Qi and Long, Yaping and Zhang, Xiaoling and Wang, Dan and Shi, Weiwei and Zhang, Jing and Hu, Yi and Yang, Bo and Xiong, Qi}, - title = {Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study}, - year = {2024}, - journal = {BMC Cancer}, - volume = {24}, - number = {1}, - doi = {10.1186/s12885-024-11833-6}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85182650513&doi=10.1186%2fs12885-024-11833-6&partnerID=40&md5=143a32348c3129b8668f94c3bd9d5d2c}, - abstract = {Background: Immunotherapy targeting PD-1/PD-L1 has revolutionized the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, clinical trials suggest differential efficacy of anti-PD-1 agents and anti-PD-L1 agents in first-line treatment of ES-SCLC. This retrospective multicenter study aimed to compare the efficacy and safety of anti-PD-1 agents versus anti-PD-L1 agents in first-line treatment of ES-SCLC in real-world practice. Methods: Patients with pathologically or cytologically confirmed ES-SCLC treated with platinum plus etoposide combined with anti-PD-1 or PD-L1 agents as first-line treatment in different centers of PLA General Hospital between January 2017 and October 2021 were included for this study. Survival outcomes and safety were compared between patients receiving anti-PD-1 and PD-L1 agents. Results: Of the total 154 included patients, 68 received anti-PD-1 agents plus chemotherapy (PD-1 group), and 86 received anti-PD-L1 agents plus chemotherapy (PD-L1 group). Progression-free survival (PFS) and overall survival (OS) in the entire cohort were 7.6 months (95% confidence interval [CI]: 6.5–8.2 months) and 17.4 months (95% CI: 15.3–19.3 months), respectively. Median PFS and OS were comparable between the PD-1 group and PD-L1 group (PFS: 7.6 months vs. 8.3 months, HR = 1.13, 95% CI: 0.79–1.62, p = 0.415; OS: 26.9 months vs. 25.6 months, HR = 0.96, 95% CI: 0.63–1.47, p = 0.859. The objective response rate and disease control rate were comparable between the two groups: 79.4% vs. 79.1% and 92.6% vs. 94.2%, respectively. The 6-month, 12-month, and 18-month PFS and OS rates were slightly higher in the PD-L1 group than in the PD-1 group, while the 24-month PFS rate was slightly higher in the PD-1 group than in the PD-L1 group. Stratified analysis showed that locoregional thoracic radiotherapy and normal lactate dehydrogenase level were independent predictors of better OS in ES-SCLC patients treated with first-line chemotherapy plus ICI. Adverse events were not significantly different between the two groups. Conclusions: Anti-PD-1 agents and anti-PD-L1 agents combined with chemotherapy as first-line treatment for ES-SCLC are comparably effective and well tolerated. © 2024, The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access} -} - -@ARTICLE{Huang2024, - author = {Huang, Litang and Chen, Shen and Liu, Hui and Meng, Lu and Liu, Chengxing and Wu, Xiaoting and Wang, Yingying and Luo, Shilan and Tu, Hongbin and Wang, Chunlei and Zhang, Ming and Gong, Xiaomei}, - title = {PD-L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence}, - year = {2024}, - journal = {Cancer Medicine}, - volume = {13}, - number = {7}, - doi = {10.1002/cam4.7125}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190298606&doi=10.1002%2fcam4.7125&partnerID=40&md5=f1bebc83744d0dd06b75627de2f41596}, - abstract = {Background: Numerous studies have demonstrated that brain metastases patients may benefit from intracranial radiotherapy combined with immune checkpoint inhibitors (ICIs). However, it is unclear whether this treatment is effective for patients with small cell lung cancer brain metastases (SCLC-BMs). Methods: We conducted a retrospective study by analyzing medical records of patients with SCLC-BMs from January 1, 2017 to June 1, 2022. Data related to median overall survival (mOS), median progression-free survival (mPFS), and intracranial progression-free survival (iPFS) were analyzed. Results: A total of 109 patients were enrolled, of which 60 received WBRT and 49 received WBRT-ICI. Compared to the WBRT alone cohort, the WBRT-ICI cohort showed longer mOS (20.4 months vs. 29.3 months, p = 0.021), mPFS (7.9 months vs. 15.1 months, p < 0.001), and iPFS (8.3 months vs. 16.5 months, p < 0.001). Furthermore, WBRT-ICI cohort had a better response rate for both BMs. (p = 0.035) and extracranial diseases (p < 0.001) compared to those receiving WBRT alone. Notably, the use of WBRT before ICI was associated with longer mOS compared to the use of WBRT after ICI (23.3 months for the ICI-WBRT group vs. 34.8 months for the WBRT-ICI group, p = 0.020). Conclusion: Our results indicated that WBRT combined with immunotherapy improved survival in SCLC-BMs patients compared to WBRT monotherapy. Administering WBRT prior to ICI treatment is associated with improved survival outcomes compared to WBRT following ICI treatment, for patients with SCLC-BMs. These findings highlight the significance of conducting further prospective researches on combination strategies of intracranial radiotherapy and ICI in SCLC-BMs patients. © 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Mu2024, - author = {Mu, Xiaoli and Zhou, Yixin and Liu, Qing and Wang, Jiantao and Xu, Feng and Luo, Feng and Wang, Ke and Li, Lu and Tian, Panwen and Li, Yalun and Liu, Jiewei and Zhang, Yan and Liu, Jiyan and Li, Yan}, - title = {Impact of thoracic radiotherapy on first-line treatment outcomes in ES-SCLC patients}, - year = {2024}, - journal = {Cancer Medicine}, - volume = {13}, - number = {17}, - doi = {10.1002/cam4.70175}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85203355571&doi=10.1002%2fcam4.70175&partnerID=40&md5=bf98041009cfa958f22d13597961acfb}, - abstract = {Background: The therapeutic advantage of thoracic radiotherapy (tRT) as an adjunct to first-line immunotherapy and chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) remains unclear. We sought to elucidate this in a retrospective cohort study comparing the effectiveness and safety of tRT in combination with first-line immunotherapy and chemotherapy. Methods: Our retrospective study included patients with ES-SCLC, treated at the West China Hospital between January 2019 and December 2022. They received first-line immunotherapy and chemotherapy and were categorized into two cohorts based on the administration of tRT. The primary outcomes were overall survival (OS) and progression-free survival (PFS). Cox regression analysis was utilized to identify potential independent predictors of prognosis and to compare the treatment outcomes across various patient subgroups. Treatment-related toxicities across both cohorts were compared using the Chi-squared test. Results: A total of 99patients were eligible for the study, out of which 55 received tRT. The medianduration of follow-up was 39 months. Remarkably, patients who received tRTdemonstrated superior OS and PFS in comparison to those who did not (P < 0.05). Subgroup analysis further confirmed these findings. Multivariate analysisidentified treatment group and liver metastasis as independent prognosticfactors (P < 0.05). The incidence of grade 3-4 adverse events showed nostatistically significant difference between the two cohorts. Conclusions: Thus, weconfirmed that the addition of tRT to the conventional regimen of first-linechemotherapy and immunotherapy yields better survival outcomes without asignificant increase in toxicity. © 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Corrigan2024, - author = {Corrigan, Kelsey L. and Xu, Ting and Sasaki, Yuki and Lin, Ruitao and Chen, Aileen B. and Welsh, James W. and Lin, Steven H. and Chang, Joe Y. and Ning, Matthew S. and Gandhi, Saumil and O'Reilly, Michael S. and Gay, Carl M. and Altan, Mehmet and Lu, Charles and Cascone, Tina and Koutroumpakis, Efstratios and Sheshadri, Ajay and Zhang, Xiaodong and Liao, Li and Zhu, X. Ronald and Heymach, John V. and Nguyen, Quynh-Nhu and Liao, Zhongxing}, - title = {Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma}, - year = {2024}, - journal = {Radiotherapy and Oncology}, - volume = {193}, - doi = {10.1016/j.radonc.2024.110121}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184751873&doi=10.1016%2fj.radonc.2024.110121&partnerID=40&md5=264f5019f49bf5001da0aecc91f6ff2a}, - abstract = {Introduction: Adjuvant immunotherapy (IO) following concurrent chemotherapy and photon radiation therapy confers an overall survival (OS) benefit for patients with inoperable locally advanced non-small cell lung carcinoma (LA-NSCLC); however, outcomes of adjuvant IO after concurrent chemotherapy with proton beam therapy (CPBT) are unknown. We investigated OS and toxicity after CPBT with adjuvant IO versus CPBT alone for inoperable LA-NSCLC. Materials and methods: We analyzed 354 patients with LA-NSCLC who were prospectively treated with CPBT with or without adjuvant IO from 2009 to 2021. Optimal variable ratio propensity score matching (PSM) matched CPBT with CPBT + IO patients. Survival was estimated with the Kaplan-Meier method and compared with log-rank tests. Multivariable Cox proportional hazards regression evaluated the effect of IO on disease outcomes. Results: Median age was 70 years; 71 (20%) received CPBT + IO and 283 (80%) received CPBT only. After PSM, 71 CPBT patients were matched with 71 CPBT + IO patients. Three-year survival rates for CPBT + IO vs CPBT were: OS 67% vs 30% (P < 0.001) and PFS 59% vs 35% (P = 0.017). Three-year LRFS (P = 0.137) and DMFS (P = 0.086) did not differ. Receipt of adjuvant IO was a strong predictor of OS (HR 0.40, P = 0.001) and PFS (HR 0.56, P = 0.030), but not LRFS (HR 0.61, P = 0.121) or DMFS (HR 0.61, P = 0.136). There was an increased incidence of grade ≥3 esophagitis in the CPBT-only group (6% CPBT + IO vs 17% CPBT, P = 0.037). Conclusion: This study, one of the first to investigate CPBT followed by IO for inoperable LA-NSCLC, showed that IO conferred survival benefits with no increased rates of toxicity. © 2024 Elsevier B.V.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1} -} - -@ARTICLE{Yamani2024, - author = {Yamani, Naser and Ahmed, Aymen and Ruiz, Gabriel and Zubair, Amraha and Arif, Fariha and Mookadam, Farouk}, - title = {Immune checkpoint inhibitor-induced cardiotoxicity in patients with lung cancer: a systematic review and meta-analysis}, - year = {2024}, - journal = {Cardio-Oncology}, - volume = {10}, - number = {1}, - doi = {10.1186/s40959-024-00229-x}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85196072796&doi=10.1186%2fs40959-024-00229-x&partnerID=40&md5=81a18aa959e3ecd2a30ac61527cb2aeb}, - abstract = {Background: The use of immune checkpoint inhibitors (ICIs) for the treatment of lung cancer may precipitate cardiotoxic events. We aimed to perform a meta-analysis to evaluate the cardiotoxicity associated with ICIs in patients with lung cancer. Methods: A literature search was conducted across four electronic databases (Cochrane CENTRAL, MEDLINE, OVID EMBASE and Google Scholar) from inception through 31st May 2023. Randomized controlled trials (RCTs) assessing the impact of ICIs on cardiac outcomes in lung cancer patients were considered for inclusion. Risk ratios (RR) with 95% confidence intervals (CIs) were pooled and analysis was performed using a random-effects model. The Grading of Recommendations Assessment, Development and Evaluation approach was followed to assess confidence in the estimates of effect (i.e., the quality of evidence). Results: A total of 30 studies including 16,331 patients, were included in the analysis. Pooled results showed that single ICI (RR: 2.15; 95% CI: 1.13–4.12; p = 0.02; I2 = 0%) or a combination of single ICI plus chemotherapy (RR: 1.38 [1.05–1.82]; p = 0.02) significantly increased the risk of cardiac adverse events when compared with chemotherapy alone. No significant difference was noted when a dual ICI (RR: 0.48 [0.13–1.80]; p = 0.27) was compared with single ICI. In addition, there was no significant association between the use of ICIs and incidence of cardiac failure (RR: 1.11 [0.48–2.58]; p = 0.80), or arrhythmia (RR: 1.87; [0.69–5.08]; p = 0.22). Conclusion: Compared with chemotherapy alone, use of a single ICI or a combination of single ICI plus chemotherapy significantly increased the risk of cardiotoxicity. However, employing dual immunotherapy did not result in a significant increase in the risk of cardiotoxicity when compared to the use of a single ICI. © The Author(s) 2024.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Ding2024, - author = {Ding, Kaibo and Peng, Zhongsheng}, - title = {Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers}, - year = {2024}, - journal = {Therapeutic Advances in Medical Oncology}, - volume = {16}, - doi = {10.1177/17588359241249041}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85192394836&doi=10.1177%2f17588359241249041&partnerID=40&md5=147fa7de625ca29529213636c7406999}, - abstract = {Pulmonary sarcomatoid carcinoma (PSC), a rare subtype of non-small cell lung cancer, is highly malignant and has a poor prognosis. Treatments for PSC are presently limited. Traditional treatments provide fewer benefits to PSC patients and are associated with early recurrence and metastasis. Surgical intervention is the preferred option for early-stage PSC patients, whereas chemotherapy, radiotherapy, immunotherapy, and other targeted therapies are recommended for advanced PSC patients. Targeted therapy is only effective in a small number of PSC patients. The initial efficacy of immune checkpoint inhibitors has been acceptable in patients with advanced PSC; therefore, much attention on related biomarkers has been sought. This article aimed to review the research progress of PSC immunotherapy and related diagnostic and prognostic biomarkers in recent years. © The Author(s), 2024.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Badin2024, - author = {Badin, Firas}, - title = {Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting}, - year = {2024}, - journal = {Cancer Treatment and Research Communications}, - volume = {39}, - doi = {10.1016/j.ctarc.2024.100803}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85187934629&doi=10.1016%2fj.ctarc.2024.100803&partnerID=40&md5=692f0d7cfae64f5d6700187ae00c9299}, - abstract = {Small cell lung cancer (SCLC) is characterized by high initial responses to platinum-based chemotherapy plus immune checkpoint inhibitors; however, most patients quickly relapse and require subsequent treatment. Second-line treatment options in SCLC remain limited, and treatment algorithms are not completely consistent across the available guidelines in this setting. This review highlights key considerations regarding selection of second-line treatment for patients with relapsed SCLC. In particular, the role of lurbinectedin, which was first approved in 2020, representing the first significant addition to treatment algorithms in this setting for decades, is summarized. Future directions, including the identification of SCLC subtypes and the need for predictive biomarkers to guide patient selection and targeted therapy, are also discussed. © 2024 The Author}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access} -} - -@ARTICLE{Agarwal20233546, - author = {Agarwal, Muskan and Liu, Alex and Almquist, Daniel and Langlais, Blake T. and Leventakos, Konstantinos and Yu, Nathan Y. and Manochakian, Rami and Ernani, Vinicius}, - title = {Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status}, - year = {2023}, - journal = {Cancer}, - volume = {129}, - number = {22}, - pages = {3546 – 3553}, - doi = {10.1002/cncr.34966}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85166941065&doi=10.1002%2fcncr.34966&partnerID=40&md5=f2d6fa6fb1b980370ffec3fc468c3083}, - abstract = {Background: Immune checkpoint inhibitor combined with platinum-etoposide is the standard first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). The phase 3 clinical trials that led to the approval of chemoimmunotherapy in ES-SCLC excluded patients who had an Eastern Cooperative Group (ECOG) performance status (PS) of 2–3. Therefore, data on the efficacy of chemoimmunotherapy in patients with an ECOG PS of 2–3 are limited. Methods: A retrospective analysis was performed on patients diagnosed with ES-SCLC who received chemoimmunotherapy (atezolizumab or durvalumab) within the Mayo Clinic Health System between January 2016 and January 2021. The objective of this study was to compare the overall survival (OS), progression-free survival (PFS), and best clinical response to therapy in patients with an ECOG PS of 0–1 vs. patients with an ECOG PS of 2–3 who received chemoimmunotherapy for newly diagnosed ES-SCLC. Results: In total, 82 patients were included in the study. The mean ± standard deviation age was 68.1 ± 8.3 years. Of these, 56 patients were identified with an ECOG PS of 0–1, and 26 patients were identified with an ECOG PS of 2–3. The median PFS was similar regardless of ECOG PS (5.8 months [95% CI, 4.3–6.0 months] in the ECOG PS 0–1 group vs. 4.1 months [95% CI, 3.8–6.9 months] in the ECOG PS 2–3; p =.2994). The median OS was also similar regardless of ECOG PS (10.6 months [95% CI, 8.4–13.4 months] in the ECOG PS 0–1 group vs. 9.3 months [95% CI, 4.9–12.8 months]; p =.2718) in the ECOG PS 2-3 group. Conclusions: The study results demonstrated no significant difference in PFS or OS among the ECOG PS 2–3 and ECOG PS 0–1 groups. Therefore, chemoimmunotherapy should be considered for patients who have ES-SCLC with an ECOG PS of 2–3. © 2023 American Cancer Society.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1} -} - -@ARTICLE{Ji20241695, - author = {Ji, Xiaoyu and Jiang, Rongrong and Liu, Tao and Provencio, Mariano and Lee, Sang Chul and Zhan, Qiong and Zhou, Xinli}, - title = {Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with leptomeningeal metastases harboring targetable mutations}, - year = {2024}, - journal = {Translational Lung Cancer Research}, - volume = {13}, - number = {7}, - pages = {1695 – 1707}, - doi = {10.21037/tlcr-24-477}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85199863001&doi=10.21037%2ftlcr-24-477&partnerID=40&md5=507d4f0165b2d901e96f7ef3df3235f5}, - abstract = {Background: Driver gene-positive non-small cell lung cancer (NSCLC) patients are prone to develop leptomeningeal metastasis (LM), leading to an extremely high mortality. The objective of this study was to assess the efficacy and safety of immune checkpoint inhibitors (ICIs) treatments for patients with NSCLC and LM harboring targetable mutations. Methods: We retrospectively collected records of patients with NSCLC harboring targetable mutations and prescribed ICIs following the diagnosis of LM at Huashan Hospital, Fudan University. In addition, we reviewed relevant literature and enrolled patients who met the inclusion criteria. Clinical characteristics were statistically analyzed, and the Kaplan-Meier method and log-rank test were employed to assess the median progression-free survival (mPFS) and median overall survival (mOS). Results: A total of 37 patients with NSCLC harboring targetable mutations who received ICIs after LM diagnosis were included. The median age of the enrolled patients was 54 years (range, 33–70 years), and 62.2% were female. Following ICI administration, the intracranial objective response rate (iORR) and intracranial disease control rate (iDCR) for all enrolled patients were 18.9% and 62.2%, respectively. The mPFS of all patients was 2.5 months [95% confidence interval (CI): 2.166–2.834 months] and the mOS was 5.8 months (95% CI: 5.087–6.513 months). Both univariate and multivariate analyses revealed a significant increase in mOS or individuals who had previously undergone cranial radiation therapy compared to those who had not. Furthermore, different histology molecular types were found to be potentially associated with survival time. Conclusions: Some patients with NSCLC harboring targetable gene mutations following LM diagnosis may benefit from ICI treatment with relatively good tolerance. However, further screening of the most suitable patient populations for ICIs is required. © Translational Lung Cancer Research. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Li2023, - author = {Li, Lijuan and Yang, Dan and Min, Yanmei and Liao, Anyan and Zhao, Jing and Jiang, Leilei and Dong, Xin and Deng, Wei and Yu, Huiming and Yu, Rong and Zhao, Jun and Shi, Anhui}, - title = {First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer}, - year = {2023}, - journal = {BMC Cancer}, - volume = {23}, - number = {1}, - doi = {10.1186/s12885-023-10784-8}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85151830048&doi=10.1186%2fs12885-023-10784-8&partnerID=40&md5=3e008dcc20b87f6555fbd761cf3618b4}, - abstract = {Background: Immunotherapy has made significant advances in the treatment of extensive-stage small-cell lung cancer (ES-SCLC), but data in combination with radiotherapy are scarce. This study aims to assess the safety and efficacy of chemoimmunotherapy combined with thoracic radiotherapy in patients with ES-SCLC. Methods: This single-center retrospective study analyzed patients with ES-SCLC who received standard platinum–etoposide chemotherapy combined with atezolizumab or durvalumab immunotherapy as induction treatment, followed by consolidative thoracic radiotherapy (CTRT) before disease progression in the first-line setting. Adverse events during radiotherapy with or without maintenance immunotherapy and survival outcomes were assessed. Results: Between December 2019 and November 2021, 36 patients with ES-SCLC were identified to have received such treatment modality at one hospital. The number of metastatic sites at diagnosis was 1–4. The biological effective dose of CTRT ranged from 52 to 113 Gy. Only two patients (6%) developed grade 3 toxic effect of thrombocytopenia, but none experienced grade 4 or 5 toxicity. Four patients developed immune-related pneumonitis during the induction treatment period but successfully completed later CTRT. The rate of radiation-related pneumonitis was 8% with grades 1–2 and well tolerated. The median progression-free survival (PFS) was 12.8 months, but the median overall survival (OS) was not determined. The estimated 1-year OS was 80.2% and 1-year PFS was 53.4%. Conclusions: Immunotherapy combined with CTRT for ES-SCLC is safe and has ample survival benefit. © 2023, The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 11; All Open Access, Gold Open Access} -} - -@ARTICLE{Sun2024, - author = {Sun, Meiling and Ji, Huaijun and Deng, Fang and Li, Jingyi and Xu, Ning and Li, Yu}, - title = {Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: a real-world study}, - year = {2024}, - journal = {BMC Cancer}, - volume = {24}, - number = {1}, - doi = {10.1186/s12885-024-12942-y}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85205446267&doi=10.1186%2fs12885-024-12942-y&partnerID=40&md5=e47ef2aead349b9fe9965f968cc36025}, - abstract = {Background: Patients with extensive-stage small cell lung cancer (ES-SCLC) experience significant therapeutic challenges and limited survival rates. This study aimed to investigate the efficacy of combining immunotherapy (IT) with chemotherapy (CT) for treating ES-SCLC and to explore the synergistic effect between radiotherapy (RT) and IT. Methods: This retrospective analysis examined patients with ES-SCLC who received treatment at three centers. Furthermore, propensity score-matched (PSM) analysis was conducted. The Kaplan‒Meier method and Cox proportional hazards regression were used to compare the survival outcomes. Results: A total of 257 eligible patients with ES-SCLC were included in the analysis. Among all patients, the median overall survival (mOS) was 18.0 m in the chemoimmunotherapy (CT + IT) group and 15.7 m in the CT group (p = 0.208). The median real-world progression-free survival (mrwPFS) was 7.7 m and 6.8 m (p = 0.043) in the CT + IT and CT group, respectively. Moreover, the mOS was 22.0 m in the chemoradiotherapy (CT + RT) group and 13.6 m in the CT group (p < 0.001). The mrwPFS was 7.4 m and 6.0 m (p = 0.175) in the CT + RT group and CT group, respectively. The multivariate analyses revealed that sex, liver metastasis and RT were independent prognostic factors for OS (p < 0.05), while liver metastasis and IT were found to be independent predictive factors of real-world progression-free survival (rwPFS) (p < 0.05). After PSM, the mOS was 23.2 m in the CT + IT group and 13.0 m in the CT group (p = 0.008). The mrwPFS was 7.3 m and 6.2 m (p = 0.096) in the CT + IT group and the CT group, respectively. Moreover, the mOS was 21.4 m in the CT + RT group and 12.5 m in the CT group (p < 0.001). The mrwPFS was 7.3 m and 5.2 m (p = 0.220) in the CT + RT group and the CT group, respectively. Additionally, our study revealed that in the PD-1 group, RT significantly improved patient survival (36.0 m vs. 15.8 m, p = 0.041). Conclusion: An increasing number of treatment options are being explored for ES-SCLC, and CT is the cornerstone of treatment for this disease. Combining CT with IT and RT has demonstrated remarkable efficacy and excellent safety profiles, and such treatments are worthy of further exploration. © The Author(s) 2024.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Porte2024e101, - author = {Porte, Marie and Vaudron, Adrien and Crequit, Perrine and Vaugier, Loig and Chatellier, Thierry and Fronteau, Clémentine and Raimbourg, Judith and Goronflot, Thomas and Bennouna, Jaafar and Pons-Tostivint, Elvire}, - title = {A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients}, - year = {2024}, - journal = {Clinical Lung Cancer}, - volume = {25}, - number = {2}, - pages = {e101 – e111.e2}, - doi = {10.1016/j.cllc.2023.11.009}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85179614510&doi=10.1016%2fj.cllc.2023.11.009&partnerID=40&md5=d447d4659e61544d83dd7a24ce494708}, - abstract = {Background: First-line chemotherapy plus immunotherapy (CT-IO) has recently demonstrated survival benefits over CT alone in extensive-stage small-cell lung cancer (ES-SCLC), based on randomized phase III studies. This retrospective multicenter study assessed the real-world use and effectiveness of CT-IO in ES-SCLC patients. Patients and Methods: All newly diagnosed ES-SCLC patients from 4 French hospitals treated with CT alone or CT-IO between May 2020 and December 2021 were included. Overall survival (OS) and real-world progression-free survival (rwPFS) were estimated using the Kaplan-Meier method. Cox proportional hazard models were performed to estimate hazard ratios (HRs) with 95 % confidence intervals (CIs) in univariate and multivariate models. The aim was not to compare efficacy between groups. Results: Among 104 patients, 75 (72.1%) received CT-IO. Brain metastases were diagnosed in 28.3% of patients, and 29.8% were performance status (PS) ≥ 2. At a median follow-up of 16.8 months (95%CI, 14.9-23.4), the median OS was 11.4 months (95%CI, 7.7-14.7) in the CT-IO group, and the 12-month OS rate was 43.6% (95%CI, 33.3-57.2). In the CT group, the median OS was 7.8 months (95%CI, 5.4-11.8) and the 12-month OS rate was 15.3% (95%CI, 5.7-41.0). In multivariate analyses, baseline brain and liver metastases were associated with a shorter OS for patients treated in the CT-IO group (HR, 3.80 [95%CI, 1.90-7.60] and 3.12 [95%CI, 1.60-6.08] respectively; P < 0.001 for both). Conclusion: We showed that clinicians have chosen to use IO beyond the specific criteria defined in guidelines. Survival data appeared promising with a median OS comparable to the one previously demonstrated in clinical trials. © 2023 Elsevier Inc.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Bronze Open Access} -} - -@ARTICLE{Naratornsirakul2024, - author = {Naratornsirakul, Danainut and Chewaskulyong, Busyamas and Kongkarnka, Sarawut and Oranratnachai, Songporn}, - title = {Comparison of treatment outcome between first-line combination immunotherapy (anti-PD-L1 or anti-PD1) with or without chemotherapy and chemotherapy alone in advanced non-small cell lung cancer patients in tertiary care hospital}, - year = {2024}, - journal = {Cancer Medicine}, - volume = {13}, - number = {14}, - doi = {10.1002/cam4.70007}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85199092543&doi=10.1002%2fcam4.70007&partnerID=40&md5=49a2e2bb1eecba73077634cf614580e6}, - abstract = {Background: Despite promising outcomes of first-line immunotherapy with or without chemotherapy in advanced non-small cell lung cancer (NSCLC), limited accessibility due to reimbursement was remain the problem in low to middle income countries. This study aimed to evaluate real-world effectiveness of immunotherapy in patients with advanced NSCLC in Northern Thailand. Method: A retrospective, single-centered cohort, was conducted. Patients with advanced NSCLC who underwent PD-L1 testing (excluding EGFR and ALK mutations) and were treated with immunotherapy or without chemotherapy or chemotherapy alone were included. The primary end point was progression-free survival (PFS). The secondary endpoints were overall survival (OS), objective response rate (ORR), and adverse events. Results: A total of 123 patients, of which 21 patients received immunotherapy-based regimen and 102 patients received chemotherapy alone. The median PFS was 11.9 months in immunotherapy-based group compared to 5.93 months in the chemotherapy group, with a. hazard ratio (HR) of 0.4 (95% confidence interval [CI], 0.23 to 0.68; p = 0.001). Similarly, the median OS was 26.68 months in the immunotherapy-based group and 11.21 months in the chemotherapy group, with HR of 0.42 (95% CI 0.22–0.8; p = 0.009). ORRs were significantly higher in the immunotherapy-based group, with 65% of patients showing a response compared to 32% in the chemotherapy group (p = 0.006). Conclusion: The result of this real-world study in patients with advanced stage NSCLC indicate that first-line immunotherapy-based regimen was associated with significantly greater PFS, OS, and ORR with a safety profile consistent with pivotal studies. © 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access} -} - -@ARTICLE{Mohanty2023174, - author = {Mohanty, Sambit K. and Mishra, Sourav K. and Amin, Mahul B. and Agaimy, Abbas and Fuchs, Florian}, - title = {Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers}, - year = {2023}, - journal = {Advances in Anatomic Pathology}, - volume = {30}, - number = {3}, - pages = {174 – 194}, - doi = {10.1097/PAP.0000000000000395}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152099014&doi=10.1097%2fPAP.0000000000000395&partnerID=40&md5=85794287f170e05dbe653f9dbe2290ba}, - abstract = {Until very recently, surgery, chemotherapy, and radiation therapy have been the mainstay of treatment in non-small cell carcinomas (NSCLCs). However, recent advances in molecular immunology have unveiled some of the complexity of the mechanisms regulating cellular immune responses and led to the successful targeting of immune checkpoints in attempts to enhance antitumor T-cell responses. Immune checkpoint molecules such as cytotoxic T-lymphocyte associated protein-4, programmed cell death protein-1, and programmed death ligand (PD-L) 1 have been shown to play central roles in evading cancer immunity. Thus, these molecules have been targeted by inhibitors for the management of cancers forming the basis of immunotherapy. Advanced NSCLC has been the paradigm for the benefits of immunotherapy in any cancer. Treatment decisions are made based on the expression of PD-L1 on the tumor cells and the presence or absence of driver mutations. Patients with high PD-L1 expression (≥50%) and no driver mutations are treated with single-agent immunotherapy whereas, for all other patients with a lower level of PD-L1 expression, a combination of chemotherapy and immunotherapy is preferred. Thus, PD-L1 blockers are the only immunotherapeutic agents approved in advanced NSCLC without any oncogenic driver mutations. PD-L1 immunohistochemistry, however, may not be the best biomarker in view of its dynamic nature in time and space, and the benefits may be seen regardless of PD -L1 expression. Each immunotherapy molecule is prescribed based on the levels of PD-L1 expression as assessed by a Food and Drug Administration-approved companion diagnostic assay. Other biomarkers that have been studied include tumor mutational burden, the T-effector signature, tumor-infiltrating lymphocytes, radiomic assays, inflammation index, presence or absence of immune-related adverse events and specific driver mutations, and gut as well as local microbiome. At the current time, none of these biomarkers are routinely used in the clinical decision-making process for immunotherapy in NSCLC. However, in individual cases, they can be useful adjuncts to conventional therapy. This review describes our current understanding of the role of biomarkers as predictors of response to immune checkpoint molecules. To begin with a brief on cancer immunology in general and in NSCLC, in particular, is discussed. In the end, recent advancements in laboratory techniques for refining biomarker assays are described. © 2023 Lippincott Williams and Wilkins. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Kang2023, - author = {Kang, Kai and Wu, Yijun and Yao, Zhuoran and Lu, You}, - title = {Tackling the current dilemma of immunotherapy in extensive-stage small cell lung cancer: A promising strategy of combining with radiotherapy}, - year = {2023}, - journal = {Cancer Letters}, - volume = {565}, - doi = {10.1016/j.canlet.2023.216239}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160248620&doi=10.1016%2fj.canlet.2023.216239&partnerID=40&md5=c6129bad574d94677f16e8a2cf83ed1b}, - abstract = {Progress in the treatment of small cell lung cancer (SCLC) has been modest over the past decades until the advent of immune checkpoint inhibitors, which have redefined the standard first-line treatment for extensive-stage SCLC (ES-SCLC). However, despite the positive results of several clinical trials, the limited survival benefit achieved suggests that the priming and sustaining of immunotherapeutic efficacy are poor and further investigation is urgently needed. In this review, we aim to summarize the potential mechanisms underlying the limited efficacy of immunotherapy and intrinsic resistance in ES-SCLC, including impaired antigen presentation and limited T cell infiltration. Moreover, to tackle the current dilemma, given the synergistic effects of radiotherapy on immunotherapy, especially the unique advantages of low-dose radiotherapy (LDRT), such as less immunosuppression and lower radiation toxicity, we propose radiotherapy as a booster to enhance the immunotherapeutic efficacy by overcoming the poor priming effect. Recent clinical trials, including ours, have also focused on adding radiotherapy, including LDRT, to first-line treatment of ES-SCLC. Additionally, we also suggest combination strategies to sustain the immunostimulatory effect of radiotherapy, as well as the cancer-immunity cycle, and further improve survival outcomes. © 2023 The Authors}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 13; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Zhang2023, - author = {Zhang, Chenyue and Zhang, Chenxing and Wang, Haiyong}, - title = {Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions}, - year = {2023}, - journal = {Cancer Letters}, - volume = {562}, - doi = {10.1016/j.canlet.2023.216182}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152674612&doi=10.1016%2fj.canlet.2023.216182&partnerID=40&md5=188f4afb469ad723b4c5eb8033b6f54a}, - abstract = {Cancer treatment has been advanced with the advent of immune checkpoint inhibitors (ICIs) exemplified by anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) drugs. Patients have reaped substantial benefit from ICIs in many cancer types. However, few patients benefit from ICIs whereas the vast majority undergoing these treatments do not obtain survival benefit. Even for patients with initial responses, they may encounter drug resistance in their subsequent treatments, which limits the efficacy of ICIs. Therefore, a deepening understanding of drug resistance is critically important for the explorations of approaches to reverse drug resistance and to boost ICI efficacy. In the present review, different mechanisms of ICI resistance have been summarized according to the tumor intrinsic, tumor microenvironment (TME) and host classifications. We further elaborated corresponding strategies to battle against such resistance accordingly, which include targeting defects in antigen presentation, dysregulated interferon-γ (IFN-γ) signaling, neoantigen depletion, upregulation of other T cell checkpoints as well as immunosuppression and exclusion mediated by TME. Moreover, regarding the host, several additional approaches that interfere with diet and gut microbiome have also been described in reversing ICI resistance. Additionally, we provide an overall glimpse into the ongoing clinical trials that utilize these mechanisms to overcome ICI resistance. Finally, we summarize the challenges and opportunities that needs to be addressed in the investigation of ICI resistance mechanisms, with the aim to benefit more patients with cancer. © 2023 Elsevier B.V.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 31} -} - -@ARTICLE{Haugaard2024, - author = {Haugaard, Anna Karen and Saude Conde, Rita and J Maria, Ana Rita and Vithal Yergolkar, Abhijna and Jørgensen, Karsten Juhl and Heleno, Bruno}, - title = {Immunotherapy for advanced and recurrent malignant pleural mesothelioma}, - year = {2024}, - journal = {Cochrane Database of Systematic Reviews}, - volume = {2024}, - number = {9}, - doi = {10.1002/14651858.CD014720}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85204475296&doi=10.1002%2f14651858.CD014720&partnerID=40&md5=c60629f7e9cbbb38a58300bbab211017}, - abstract = {Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effects of immune checkpoint inhibitors (single-agent or combination therapy) in people with advanced malignant pleural mesothelioma in a first-line or salvage setting. Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Rao2024, - author = {Rao, Sunyin and Min, Li and Zhao, Jie and Su, Juan and Ye, Lianhua}, - title = {Efficacy of consolidation of immune checkpoint inhibitor after chemoradiation for unresectable, locally advanced PD‑L1 negative non‑small cell lung cancer: A systematic review and meta‑analysis}, - year = {2024}, - journal = {Oncology Letters}, - volume = {27}, - number = {6}, - doi = {10.3892/ol.2024.14375}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190850374&doi=10.3892%2fol.2024.14375&partnerID=40&md5=e2d1ce8a5b367ec3ed3b4fa68bf9692b}, - abstract = {Chemoradiotherapy (CRT) followed by consoli‑ dation of immune checkpoint inhibitors (ICIs), such as durvalumab or pembrolizumab, for patients with unresectable, locally advanced non‑small cell lung cancer (NSCLC) with tumor PD‑L1 expression <1% remains a topic of controversy. Previous studies from PubMed, Cochrane Library and Embase databases were searched for a meta‑analysis. A total of 16 studies were included in part one of the meta‑analysis and it was observed that consolidation of ICIs after CRT improved overall survival (OS) [hazard ratio (HR) 1.46; P=0.005] and progression‑free survival (PFS) (HR 1.26; P=0.023) for the patients with PD‑L1 expression ≥1% compared with those with PD‑L1 expression <1%. Then, 15 studies were included in part two of the meta‑analysis and the results indicated that the pooled 1, 2 and 3‑year OS were 77% vs. 83% (P=0.07), 55% vs. 59% (P=0.327) and 38% vs. 51% (P=0.006) for CRT alone compared with CRT followed by consolidation of ICIs, respectively. The pooled 1, 2 and 3‑year PFS were 51% vs. 53% (P=0.632), 29% vs. 40% (P=0.015) and 20% vs. 28% (P=0.153) for CRT alone compared with CRT followed by consolidation of ICIs, respectively. The findings of the present study highlighted that the benefits of CRT followed by consolidation of ICIs were higher compared with CRT alone in patients with unresectable, locally advanced NSCLC and PD‑L1 expression <1%. Consolidation of ICIs after CRT would provide greater benefits for locally advanced NSCLC patients with PD‑L1 expression ≥1% compared with those with PD‑L1 expression <1%. © 2024 Spandidos Publications. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Zou20233339, - author = {Zou, Yuxia and Ren, Xueru and Zhang, Huanhuan and Wang, Yuenan and Wang, Hanqi and Bai, Rubing and Zhang, Zhihong and Sun, Gengyun and Xu, Ling}, - title = {Efficacy and safety of durvalumab + chemotherapy vs. atezolizumab + chemotherapy in the treatment of small‑cell lung cancer: a retrospective comparative cohort study}, - year = {2023}, - journal = {Journal of Thoracic Disease}, - volume = {15}, - number = {6}, - pages = {3339 – 3349}, - doi = {10.21037/jtd-23-588}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85166173550&doi=10.21037%2fjtd-23-588&partnerID=40&md5=72de334328ff8f5e4d298126f4a24ac8}, - abstract = {Background: Durvalumab and atezolizumab have recently been approved in extensive small cell lung cancer (SCLC) with moderate median overall survival (OS) improvements. However, only limited data exist regarding the impact of immunotherapy in real-world SCLC patients. This study sought to assess the efficacy and safety of atezolizumab plus chemotherapy and durvalumab plus chemotherapy in the treatment of SCLC in a real-world setting. Methods: A retrospective cohort study of all patients treated for SCLC with chemotherapy with PD-L1 inhibitor, at 3 centers in China between February 1, 2020 and April 30, 2022. Patient characteristics, adverse-events and survival analyses were conducted. Results: A total of 143 patients were enrolled in this study, 100 were treated with durvalumab and the remainder with atezolizumab. The baseline characteristics of the two groups were fundamentally balanced before using PD-L1 inhibitors (P>0.05). The median OS (mOS) of the patients who received durvalumab or atezolizumab as the first-line treatment were 22.0 and 10.0 months, respectively (P=0.03). Survival analysis of patients with brain metastasis (BM) revealed that the median progression-free survival (mPFS) of patients without BM treated with durvalumab plus chemotherapy (5.5 months) was longer than that of those with BM (4.0 months) (P=0.03). In contrast, in the atezolizumab plus chemotherapy regimen, BM did not affect survival. In addition, the addition of radiotherapy to treatment with PD-L1 inhibitors in combination with chemotherapy has a tendency to improve long-term survival. As for safety analysis, there was no significant difference in the incidence of immune-related adverse events (IRAEs) during PD-L1 inhibitor therapy between the 2 groups (P>0.05). And during treatment with immunochemotherapy, radiotherapy was not associated with the development of IRAE (P=0.42) but increased the risk of immune-related pneumonitis (P=0.026). Conclusions: The implication of this study for clinical practice is a preference for durvalumab in first-line immunotherapy for SCLC. In addition, appropriate radiotherapy during treatment with PD-L1 inhibitors in combination with chemotherapy may prolong long-term survival, but the occurrence of immune-related pneumonitis should be vigilant. Data from this study are limited and the baseline characteristics of the two populations still need to be more finely classified. © 2023 AME Publishing Company. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Ma20231035, - author = {Ma, Lin and Deng, Liufu and Peng, Jianfeng and Yu, Jinming and Meng, Xiangjiao}, - title = {Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?}, - year = {2023}, - journal = {Cancer Biology and Medicine}, - volume = {20}, - number = {12}, - pages = {1035 – 1046}, - doi = {10.20892/j.issn.2095-3941.2023.0402}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184429233&doi=10.20892%2fj.issn.2095-3941.2023.0402&partnerID=40&md5=488a43419c69e5b15e204e943f62a0ef}, - abstract = {Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches for LA-NSCLC. Several recent investigations involving the synergistic potential of immunotherapy combined with radiotherapy (iRT) have generated encouraging results. This review discusses the existing studies and prospective directions of chemotherapy-free iRT strategies in unresectable LA-NSCLC. Although the initial findings of chemotherapy-free iRT strategies have shown promising efficacy, we must consider the methodologic limitations of current studies and the myriad of challenges that accompany the implementation of chemotherapy-free iRT. These challenges include determining the optimal dose and fractionation, precise target volume delineation, and identification of additional suitable patient cohorts. Furthermore, the feasibility of chemotherapy-free iRT as a novel treatment modality for select patients with LA-NSCLC is contingent upon validation through randomized phase III trials. ©2023 Cancer Biology & Medicine.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Gold Open Access} -} - -@ARTICLE{Bavaro2023, - author = {Bavaro, Davide Fiore and Diella, Lucia and Pizzutilo, Pamela and Catino, Annamaria and Signorile, Fabio and Pesola, Francesco and Belati, Alessandra and Marech, Ilaria and Garrisi, Vito and Lamorgese, Nino and Di Gennaro, Francesco and Saracino, Annalisa and Galetta, Domenico}, - title = {Incidence and predictors of infections in patients with advanced non-small cell lung cancer treated with checkpoint inhibitor immunotherapies: A monocentric retrospective cohort study}, - year = {2023}, - journal = {Scandinavian Journal of Immunology}, - volume = {98}, - number = {3}, - doi = {10.1111/sji.13303}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85162209863&doi=10.1111%2fsji.13303&partnerID=40&md5=ce3ac55edc317ffeeb35e75b1335f4f3}, - abstract = {Immune checkpoint inhibitors (ICIs) represent the cornerstone of the current treatment of non-small cell lung cancer (NSCLC). However, the occurrence of concomitant infections might hamper success. All consecutive patients with advanced NSCLC who started ICIs as a first- or second-line therapy from January 1, 2017 to June 30, 2020 were retrospectively evaluated. The occurrence of infectious events during ICIs was correlated with clinical characteristics, including previous Cytotoxic Chemotherapy (CC), occurrence of immune-related-adverse-events (irAEs). A total of 211 patients were included, 46 (22%) females, with a median (q1-q3) age of 69 (62-76) years. Overall, 85 patients (40%) received ICIs as a first treatment line and 126 (60%) as a second line; 40 patients (19%) had at least one infection during ICIs, and 17 (8%) more than one. Notably, autoimmune diseases (P <.005), neutropenia (P =.001) or infections during previous CC (P =.001), irAEs (P =.006), or steroid therapy for irAEs (P <.001) were associated with infection development. By multivariate Cox-regression, autoimmune diseases (aHR = 6.27; 95%CI = 2.38-16.48; P <.001) and steroid therapy for irAEs (aHR = 2.65; 95%CI = 1.27-5.52; P <.009) were associated with a higher risk of infection during ICIs. Interestingly, autoimmune diseases were confirmed as risk factors in patients treated with ICIs as a first line, while previous infections were the only independent predictor of infections in patients treated with ICIs as a second line. Patients with NSCLC treated with ICIs with concurrent autoimmune disease, receiving steroid therapy for management of irAEs, or having a history of previous infections during CC should be actively monitored for the risk of developing infectious complications. © 2023 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Song2023, - author = {Song, Xin-Yun and Liu, Jun and Li, Hong-Xuan and Cai, Xu-Wei and Li, Zhi-Gang and Su, Yu-Chen and Li, Yue and Dong, Xiao-Huan and Yu, Wen and Fu, Xiao-Long}, - title = {Enhancing Prediction for Tumor Pathologic Response to Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Cancer by Dynamic Parameters from Clinical Assessments}, - year = {2023}, - journal = {Cancers}, - volume = {15}, - number = {17}, - doi = {10.3390/cancers15174377}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85170272083&doi=10.3390%2fcancers15174377&partnerID=40&md5=8f18993837ac7feaa9bc6efac7bd19a2}, - abstract = {To develop accurate and accessible prediction methods for assessing pathologic response following NICT prior to surgery, we conducted a retrospective study including 137 patients with esophageal squamous cell carcinoma (ESCC) who underwent surgery after two cycles of NICT between January 2019 and March 2022 at our center. We collected clinical parameters to evaluate the dynamic changes in the primary tumor. Univariate and multivariate analyses were performed to determine the correlations between these parameters and the pathologic response of the primary tumor. Subsequently, we constructed prediction models for pCR and MPR using multivariate logistic regression. The MPR prediction Model 2 was internally validated using bootstrapping and externally validated using an independent cohort from our center. The univariate logistic analysis revealed significant differences in clinical parameters reflecting tumor regression among patients with varying pathologic responses. The clinical models based on these assessments demonstrated excellent predictive performance, with the training cohort achieving a C-index of 0.879 for pCR and 0.912 for MPR, while the testing cohort also achieved a C-index of 0.912 for MPR. Notably, the MPR prediction Model 2, with a threshold cut-off of 0.74, exhibited 92.7% specificity and greater than 70% sensitivity, indicating a low rate of underestimating residual tumors. In conclusion, our study demonstrated the high accuracy of clinical assessment-based models in pathologic response prediction, aiding in decision-making regarding organ preservation and radiotherapy adjustments after induction immunochemotherapy. © 2023 by the authors.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Oh2024694, - author = {Oh, Do-Youn and He, Aiwu Ruth and Bouattour, Mohamed and Okusaka, Takuji and Qin, Shukui and Chen, Li-Tzong and Kitano, Masayuki and Lee, Choong-kun and Kim, Jin Won and Chen, Ming-Huang and Suksombooncharoen, Thatthan and Ikeda, Masafumi and Lee, Myung Ah and Chen, Jen-Shi and Potemski, Piotr and Burris, Howard A and Ostwal, Vikas and Tanasanvimon, Suebpong and Morizane, Chigusa and Zaucha, Renata E and McNamara, Mairéad G and Avallone, Antonio and Cundom, Juan E and Breder, Valeriy and Tan, Benjamin and Shimizu, Satoshi and Tougeron, David and Evesque, Ludovic and Petrova, Mila and Zhen, David B and Gillmore, Roopinder and Gupta, Vineet Govinda and Dayyani, Farshid and Park, Joon Oh and Buchschacher, Gary L and Rey, Felipe and Kim, Hyosung and Wang, Julie and Morgan, Claire and Rokutanda, Nana and Żotkiewicz, Magdalena and Vogel, Arndt and Valle, Juan W}, - title = {Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study}, - year = {2024}, - journal = {The Lancet Gastroenterology and Hepatology}, - volume = {9}, - number = {8}, - pages = {694 – 704}, - doi = {10.1016/S2468-1253(24)00095-5}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85195637201&doi=10.1016%2fS2468-1253%2824%2900095-5&partnerID=40&md5=09e1c7f4ac9f4ad20d196fbec64fddf7}, - abstract = {Background: In the preplanned interim analysis of the TOPAZ-1 study, durvalumab plus gemcitabine–cisplatin significantly improved overall survival versus placebo plus gemcitabine–cisplatin in participants with advanced biliary tract cancer. We aimed to report updated overall survival and safety data from TOPAZ-1 with additional follow-up and data maturity beyond the interim analysis. Methods: TOPAZ-1 was a phase 3, randomised, double-masked, placebo-controlled, global study done at 105 sites in 17 countries. Participants aged 18 years or older with unresectable, locally advanced, or metastatic biliary tract cancer were randomly assigned (1:1) to durvalumab plus gemcitabine–cisplatin or placebo plus gemcitabine–cisplatin using a computer-generated randomisation scheme, stratified by disease status and primary tumour location. Participants received durvalumab (1500 mg) or placebo on day 1 of each cycle every 3 weeks for up to eight cycles, plus gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) intravenously on days 1 and 8 of each cycle every 3 weeks for up to eight cycles, followed by durvalumab (1500 mg) or placebo monotherapy every 4 weeks until disease progression or other discontinuation criteria were met. Investigators and participants were masked to study treatment. The primary endpoint was overall survival. TOPAZ-1 met its primary endpoint at the preplanned interim analysis, and the study is active but no longer recruiting participants. Updated overall survival and safety data from TOPAZ-1, with additional follow-up (data cutoff Feb 25, 2022) and data maturity beyond the interim analysis, are reported here. Efficacy was assessed in the full analysis set (all randomly assigned participants). Safety was assessed in the safety analysis set (all participants who received at least one dose of study treatment). The TOPAZ-1 study is registered with ClinicalTrials.gov, NCT03875235. Findings: From April 16, 2019, to Dec 11, 2020, 914 participants were enrolled, 685 of whom were randomly assigned (341 to the durvalumab plus gemcitabine–cisplatin group and 344 to the placebo plus gemcitabine–cisplatin group). 345 (50%) participants were male and 340 (50%) were female. Median follow-up at the updated data cutoff was 23·4 months (95% CI 20·6–25·2) in the durvalumab plus gemcitabine–cisplatin group and 22·4 months (21·4–23·8) in the placebo plus gemcitabine–cisplatin group. At the updated data cutoff, 248 (73%) participants in the durvalumab plus gemcitabine–cisplatin group and 279 (81%) participants in the placebo plus gemcitabine–cisplatin group had died (median overall survival 12·9 months [95% CI 11·6–14·1] vs 11·3 months [10·1–12·5]; hazard ratio 0·76 [95% CI 0·64–0·91]). Kaplan–Meier-estimated 24-month overall survival rates were 23·6% (95% CI 18·7–28·9) in the durvalumab plus gemcitabine–cisplatin group and 11·5% (7·6–16·2) in the placebo plus gemcitabine–cisplatin group. Maximum grade 3 or 4 adverse events occurred in 250 (74%) of 338 participants in the durvalumab plus gemcitabine–cisplatin group and 257 (75%) of 342 in the placebo plus gemcitabine–cisplatin group. The most common maximum grade 3 or 4 treatment-related adverse events were decreased neutrophil count (70 [21%] vs 86 [25%]), anaemia (64 [19%] vs 64 [19%]), and neutropenia (63 [19%] vs 68 [20%]). Interpretation: Durvalumab plus gemcitabine–cisplatin showed robust and sustained overall survival benefit with no new safety signals. Findings continue to support the regimen as a standard of care for people with untreated, advanced biliary tract cancer. Funding: AstraZeneca. © 2024 Elsevier Ltd}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 9} -} - -@ARTICLE{Miao20241264, - author = {Miao, Chuanwang and Chen, Yuanji and Zhang, Hao and Zhao, Wei and Wang, Cunliang and Ma, Zeliang and Zhu, Shan and Hu, Xudong}, - title = {Heterogeneity of lymphocyte subsets in predicting immune checkpoint inhibitor treatment response in advanced lung cancer: an analysis across different pathological types, therapeutic drugs, and age groups}, - year = {2024}, - journal = {Translational Lung Cancer Research}, - volume = {13}, - number = {6}, - pages = {1264 – 1276}, - doi = {10.21037/tlcr-24-109}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85197641128&doi=10.21037%2ftlcr-24-109&partnerID=40&md5=287cb95d8e623c07167c2651b34c5232}, - abstract = {Background: Immune checkpoint inhibitor (ICI) has become pivotal in the treatment of advanced lung cancer, yet the absence of reliable biomarkers for assessing treatment response poses a significant challenge. This study aims to explore the predictive value of various lymphocyte subsets in different lung cancer subtypes, thus potentially identifying novel biomarkers to improve ICI treatment stratification and outcomes. Methods: We conducted a retrospective analysis of 146 stage III or IV lung cancer patients undergoing ICI treatment. The study focused on exploring the relationship between various lymphocyte subsets and the efficacy of ICIs, aiming to determine their predictive value for post-treatment outcomes. Results: Subgroup analysis revealed a positive correlation (P=0.01) between lower CD3+CD8+ T lymphocyte levels and treatment response in squamous cell carcinoma patients. However, no significance was observed in lung adenocarcinoma patients. Additionally, the predictive ability of lymphocyte subsets for different immunotherapy drugs varies. In individuals receiving anti-programmed cell death ligand 1 (PDL1) treatment, a lower CD3+CD8+ T lymphocyte levels is significantly associated with a positive treatment outcome (P=0.002), while there is no difference for programmed death 1 (PD-1) drugs. Among patients under 60, higher expression of CD3+CD4+ T lymphocytes (P=0.03) combined with lower CD3+CD8+ T lymphocyte levels (P=0.006) showed a statistically significant association with improved treatment response. However, in patients aged over 60, no discernible correlation was ascertained between lymphocyte subsets and therapeutic response. Through prognostic analysis, two distinct lymphocyte subsets were identified, both exerting considerable impact on progression-free survival subsequent to ICIs treatment: CD3+CD4+ T lymphocytes [hazard ratio (HR) =0.50, P=0.006] and CD3+CD8+ T lymphocytes (HR =1.78, P=0.02). Conclusions: Our findings underscore the significant heterogeneity in the predictive value of distinct lymphocyte subsets for lung cancer patients undergoing ICI treatment. These findings are particularly salient when considering various pathological types, immunotherapeutic agents, and patient age groups. © Translational Lung Cancer Research. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Feng2024, - author = {Feng, Baijie and Zheng, Yue and Zhang, Jiayuan and Tang, Min and Na, Feifei}, - title = {Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: A systematic review and meta-analysis}, - year = {2024}, - journal = {Radiotherapy and Oncology}, - volume = {190}, - doi = {10.1016/j.radonc.2023.110014}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85182210064&doi=10.1016%2fj.radonc.2023.110014&partnerID=40&md5=e67538504ce82e866e8e92c2f0d5bf6e}, - abstract = {Introduction: This study aimed to evaluate the efficacy and safety of chemoimmunotherapy combined with consolidative thoracic radiation therapy (cTRT) in patients with extensive-stage small cell lung cancer (ES-SCLC). Methods: A meta-analysis was conducted. PubMed, Embase, Web of Science, and the Cochrane Library were searched. The study was registered in PROSPERO (registration no. CRD42023410344). Results: A total of 4677 studies were initially screened and 15 studies encompassing a total of 1033 patients were included. Chemoimmunotherapy combined with cTRT significantly improved survival (HR = 0.52, 95 % CI: 0.39, 0.68) with favorable 6-month (0.89, 95 % CI: 0.77, 1.00) and 1-year (0.77, 95 % CI: 0.72, 0.82) OS, without affecting ≥3 grade TRAEs (RR = 1.29, 95 % CI: 0.85, 1.98). Pooled 6-month and 1-year PFS were 0.67 (95 % CI: 0.47, 0.86) and 0.38 (95 % CI: 0.22, 0.55), respectively. Incidence of ≥3 grade TRAEs was 0.24 (95 % CI: 0.08, 0.39) and radiation pneumonitis was 0.03 (95 % CI: 0.01, 0.06). Conclusions: Chemoimmunotherapy combined with cTRT improves survival and shows favorable outcomes in ES-SCLC patients, with manageable adverse events. Further research with larger samples is needed to confirm these findings. © 2023 Elsevier B.V.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2} -} - -@ARTICLE{Que20245539, - author = {Que, Shuhao and Wang, Huaiyu and Xu, Huan and Dai, Enhui and Liang, Xu and Zhai, Shuwei and Li, Yuetong and Wang, Jingjing and Mo, Qi and Xu, Yujin and Feng, Wei}, - title = {Enhancing outcomes in extensive-stage small cell lung cancer brain metastases: a retrospective study on the synergistic effects of immune checkpoint inhibitor, brain radiotherapy, and chemotherapy}, - year = {2024}, - journal = {Journal of Thoracic Disease}, - volume = {16}, - number = {9}, - pages = {5539 – 5558}, - doi = {10.21037/jtd-24-654}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85205349211&doi=10.21037%2fjtd-24-654&partnerID=40&md5=3fdd0900b3f1cb0edb163e60c94e11da}, - abstract = {Background: Brain metastasis is a frequent complication in small cell lung cancer (SCLC), and there is an urgent need for new treatment modalities, given the limited success of traditional approaches. This study evaluates the combined efficacy and safety of brain radiotherapy (BRT), chemotherapy, and immune checkpoint inhibitors (ICIs) in the treatment of brain metastases in patients with extensive-stage SCLC (ES-SCLC). Additionally, it seeks to identify prognostic factors in these cases. Methods: A retrospective analysis was performed on 187 patients with ES-SCLC and brain metastases treated at Zhejiang Cancer Hospital from January 2017 to October 2023. Patients were divided into three groups based on their initial treatment: BRT alone, ICI alone, and a combined ICI + BRT approach, with chemotherapy included in all regimens. Variables such as age, number of brain metastases, symptoms, comorbidities, Karnofsky Performance Status (KPS) scores, smoking history, Graded Prognostic Assessment (GPA) scores, survival time, and treatment-related adverse events (TRAEs), including hematologic and hepatic toxicities were evaluated. Prognostic factors were assessed using univariate and multivariate analyses via Cox’s proportional hazards model. The study also compared outcomes and TRAEs between patients undergoing synchronous treatment (ICI and BRT within four weeks) versus those with asynchronous therapy (more than four weeks apart). Results: Median overall survival (OS) times differed significantly across the groups: 11.6 months for BRT, 11.6 months for ICI, and 20.9 months for ICI + BRT (P<0.001). The ICI + BRT group also exhibited notably better progression-free survival (PFS) and intracranial PFS (iPFS), with medians of 12.6 and 14.9 months, respectively (P<0.001). This group demonstrated significantly improved systemic and intracranial objective response rates (ORR) and disease control rates (DCR). No significant differences in acute radiation injury rates were observed between the BRT and ICI + BRT groups. Multivariate analysis identified several factors influencing OS, including treatment regimen, number of chemotherapy and ICI cycles, presence of bone and multiple brain metastases, and antiangiogenesis therapies and extracranial radiotherapy. Both atezolizumab and serplulimab ICIs, in combination with various radiotherapy regimens [whole BRT (WBRT), WBRT with boost], were effective. Notably, asynchronous ICI and BRT treatment demonstrated advantages in PFS and iPFS over concurrent therapy, with no significant differences in other therapeutic indices or TRAE incidence rates. Conclusions: For ES-SCLC patients with synchronous brain metastases, combined ICI and BRT, alongside chemotherapy, surpasses the efficacy of either treatment alone with manageable TRAEs. Importantly, asynchronous ICI and BRT therapy showed superior outcomes compared to synchronous treatment modalities. © AME Publishing Company.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Chen2024497, - author = {Chen, Mengting and He, Zhichao and Zhu, Jianhong and Yang, Shan and Gao, Siyuan and Wu, Jie and Ren, Huaying and Liang, Dan and Jiang, Wei and Zou, Ying and Yu, Xiaoxia and Wu, Junyan}, - title = {Hemorrhage profile associated with immune checkpoint inhibitors: a systematic review and a real-world study based on the FAERS database}, - year = {2024}, - journal = {Expert Opinion on Drug Safety}, - volume = {23}, - number = {4}, - pages = {497 – 511}, - doi = {10.1080/14740338.2024.2327504}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85189295825&doi=10.1080%2f14740338.2024.2327504&partnerID=40&md5=489d0d0b2020a9792cbcf82bf24bcd96}, - abstract = {Objectives: To investigate the risk of hemorrhage associated with Immune Checkpoint Inhibitors (ICIs) and characterize its clinical features. Methods: We systematically reviewed randomized clinical trials (RCTs) of hemorrhage related to ICIs and calculated odds ratios (ORs) with 95% confidence intervals (CIs). Pharmacovigilance studies were conducted by collecting ICIs-related hemorrhage cases from the FAERS database and assessing disproportionalities by reporting odds ratios (RORs) and information components (ICs). Results: A total of 79 RCTs involving 45,100 patients were finally included in the systematic review, with four published RCTs (n = 1965) and 75 unpublished RCTs (n = 43135). The primary analysis showed no significant difference in ICIs compared to the control group (OR 1.18 [95% CI 1.00–1.38], p = 0.05). In subgroup analyses, anti-PD-L1 combined with anti-CTLA-4 increased the risk of hemorrhage (OR 1.95, p = 0.03), and anti-CTLA-4 increased the risk of hemorrhage in the gastrointestinal system (OR 2.23, p = 0.04). 3555 cases of hemorrhage from the FAERS database were included in the disproportionate analysis, and the result suggested that ICIs increased the risk of hemorrhage (IC025 = 0.23). Conclusion: Our study suggests that ICIs increase the risk of hemorrhage, and in particular, anti-CTLA-4 significantly increases the risk of hemorrhage in the gastrointestinal system. © 2024 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Green Open Access} -} - -@ARTICLE{Adachi2024229, - author = {Adachi, Hiroyuki and Ito, Hiroyuki and Nagashima, Takuya and Isaka, Tetsuya and Saito, Aya}, - title = {Dual immuno-oncology agents as neoadjuvant therapy for patients with resectable non-small cell lung cancer}, - year = {2024}, - journal = {Translational Lung Cancer Research}, - volume = {13}, - number = {2}, - pages = {229 – 235}, - doi = {10.21037/tlcr-23-738}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85187497284&doi=10.21037%2ftlcr-23-738&partnerID=40&md5=1f8659df2d05b4e4e9ea7b10e825ed1e}, - type = {Editorial}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Kim2024430, - author = {Kim, Dowook and Kim, Hak Jae and Wu, Hong-Gyun and Lee, Joo Ho and Kim, Suzy and Kim, Tae Min and Kim, Jin-Soo and Kim, Byoung Hyuck}, - title = {Intrathoracic Progression Is Still the Most Dominant Failure Pattern after First-Line Chemo-immunotherapy in Extensive-Stage Small-Cell Lung Cancer: Implications for Thoracic Radiotherapy}, - year = {2024}, - journal = {Cancer Research and Treatment}, - volume = {56}, - number = {2}, - pages = {430 – 441}, - doi = {10.4143/crt.2023.931}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190340328&doi=10.4143%2fcrt.2023.931&partnerID=40&md5=bf8070749c041698295342db48ff97b2}, - abstract = {Purpose This study aimed to compare the failure patterns before and after the introduction of immunotherapy and to determine the role of thoracic radiotherapy (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) treatment. Materials and Methods We retrospectively reviewed 294 patients with ES-SCLC, of which 62.2% underwent chemotherapy alone, 13.3% underwent chemotherapy followed by consolidative TRT (TRT group), and 24.5% underwent chemotherapy with immune checkpoint inhibitor (ICI group). We performed propensity-score matching (PSM) to compare each treatment group. Results The median follow-up duration was 10.4 months. At the first relapse, in the cohort showing objective response, the proportion of cases showing intrathoracic progression was significantly lower in the TRT group (37.8%) than in the chemotherapy-alone (77.2%, p < 0.001) and the ICI (60.3%, p=0.03) groups. Furthermore, in the subgroup analysis, TRT showed benefits related to intrathoracic progression-free survival (PFS) in comparison with ICI in patients with less than two involved extrathoracic sites (p=0.008) or without liver metastasis (p=0.02) or pleural metastasis (p=0.005) at diagnosis. After PSM, the TRT group showed significantly better intrathoracic PFS than both chemotherapy-alone and ICI groups (p < 0.001 and p=0.04, respectively), but showed no significant benefit in terms of PFS and overall survival in comparison with the ICI group (p=0.17 and p=0.31, respectively). Conclusion In ES-SCLC, intrathoracic progression was the most dominant failure pattern after immunotherapy. In the era of chemoimmunotherapy, consolidative TRT can still be considered a useful treatment strategy for locoregional control. © 2024 Korean Cancer Association. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access} -} - -@ARTICLE{Melosky20236289, - author = {Melosky, Barbara L. and Leighl, Natasha B. and Dawe, David and Blais, Normand and Wheatley-Price, Paul F. and Chu, Quincy S.-C. and Juergens, Rosalyn A. and Ellis, Peter M. and Sun, Alexander and Schellenberg, Devin and Ionescu, Diana N. and Cheema, Parneet K.}, - title = {Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer}, - year = {2023}, - journal = {Current Oncology}, - volume = {30}, - number = {7}, - pages = {6289 – 6315}, - doi = {10.3390/curroncol30070465}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165922838&doi=10.3390%2fcurroncol30070465&partnerID=40&md5=0322fa582aa137919882f79630d984a3}, - abstract = {Small-cell lung cancer (SCLC) is an aggressive, neuroendocrine tumour with high relapse rates, and significant morbidity and mortality. Apart from advances in radiation therapy, progress in the systemic treatment of SCLC had been stagnant for over three decades despite multiple attempts to develop alternative therapeutic options that could improve responses and survival. Recent promising developments in first-line and subsequent therapeutic approaches prompted a Canadian Expert Panel to convene to review evidence, discuss practice patterns, and reach a consensus on the treatment of extensive-stage SCLC (ES-SCLC). The literature search included guidelines, systematic reviews, and randomized controlled trials. Regular meetings were held from September 2022 to March 2023 to discuss the available evidence to propose and agree upon specific recommendations. The panel addressed biomarkers and histological features that distinguish SCLC from non-SCLC and other neuroendocrine tumours. Evidence for initial and subsequent systemic therapies was reviewed with consideration for patient performance status, comorbidities, and the involvement and function of other organs. The resulting consensus recommendations herein will help clarify evidence-based management of ES-SCLC in routine practice, help clinician decision-making, and facilitate the best patient outcomes. © 2023 by the authors.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Gold Open Access} -} - -@ARTICLE{Park2024, - author = {Park, Daniel and Jeon, Won Jin and Yang, Chieh and Castillo, Dani Ran}, - title = {Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings}, - year = {2024}, - journal = {Cancers}, - volume = {16}, - number = {2}, - doi = {10.3390/cancers16020318}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85183370015&doi=10.3390%2fcancers16020318&partnerID=40&md5=cb4a72fbca2aeada0d4c017da8e0c148}, - abstract = {Locally advanced esophageal cancer (LAEC) poses a significant and persistent challenge in terms of effective treatment. Traditionally, the primary strategy for managing LAEC has involved concurrent neoadjuvant chemoradiation followed by surgery. However, achieving a pathologic complete response (pCR) has proven to be inconsistent, and despite treatment, roughly half of patients experience locoregional recurrence or metastasis. Consequently, there has been a paradigm shift towards exploring the potential of immunotherapy in reshaping the landscape of LAEC management. Recent research has particularly focused on immune checkpoint inhibitors, investigating their application in both neoadjuvant and adjuvant settings. These inhibitors, designed to block specific proteins in immune cells, are meant to enhance the immune system’s ability to target and combat cancer cells. Emerging evidence from these studies suggests the possibility of a mortality benefit, indicating that immunotherapy may contribute to improved overall survival rates for individuals grappling with esophageal cancer. This manuscript aims to meticulously review the existing literature surrounding neoadjuvant and adjuvant immunotherapy in the context of LAEC management. The intention is to thoroughly examine the methodologies and findings of relevant studies, providing a comprehensive synthesis of the current understanding of the impact of immunotherapy on esophageal cancer. © 2024 by the authors.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Gold Open Access} -} - -@ARTICLE{Tsakonas20231556, - author = {Tsakonas, Georgios and Ekman, Simon and Koulouris, Andreas and Adderley, Helen and Ackermann, Christoph Jakob and Califano, Raffaele}, - title = {Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis}, - year = {2023}, - journal = {International Journal of Cancer}, - volume = {153}, - number = {9}, - pages = {1556 – 1567}, - doi = {10.1002/ijc.34628}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85161963939&doi=10.1002%2fijc.34628&partnerID=40&md5=078aab0432bdcb7eba2ea5ff3898eb04}, - abstract = {The presence of brain metastases (BM) is a negative prognostic factor for patients with advanced nonsmall cell lung cancer (NSCLC). Their incidence seems to be higher in patients with oncogene-driven tumours, especially those with EGFR-mutated or ALK-rearranged tumours. Although targeted treatments demonstrate significant efficacy regarding BM, they only apply to a minority of NSCLC patients. On the other hand, systemic therapies for nononcogenic-driven NSCLC with BM have shown limited clinical benefit. In recent years, immunotherapy alone or combined with chemotherapy has been adopted as a new standard of care in first-line therapy. This approach seems to be beneficial to patients with BM in terms of efficacy and toxicity. Combined immune checkpoint inhibition as well as the combination of immunotherapy and radiation therapy show promising results with significant, but overall acceptable toxicity. A pragmatic approach of allowing enrolment of patients with untreated or symptomatic BM in randomised trials evaluating immune checkpoint inhibitors strategies, possibly coupled with central nervous system-related endpoints may be needed to generate data to refine treatment for this patient population. © 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 5; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Yan20241787, - author = {Yan, Xiaoqi and Zhao, Luqing and Wu, Fei and Shen, Bo and Zhou, Guoren and Feng, Jifeng and Yue, Chao and Zhu, Jingni and Yu, Shaorong}, - title = {Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study}, - year = {2024}, - journal = {Journal of Thoracic Disease}, - volume = {16}, - number = {3}, - pages = {1787 – 1803}, - doi = {10.21037/jtd-23-1767}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85188801249&doi=10.21037%2fjtd-23-1767&partnerID=40&md5=2ab89b1726311c7f63862c6d150fdb99}, - abstract = {Background: Immune checkpoint inhibitors (ICIs) have dramatically changed the first-line treatment pattern of non-small cell lung cancer (NSCLC) without driver gene alterations. However, the optimal choice for second-line treatment after initial treatment with ICIs is unclear. This study aimed to clarify the efficacy and safety of ICI rechallenge therapy in locally advanced and advanced NSCLC. Methods: We retrospectively analyzed the histories of 224 patients with locally advanced or advanced NSCLC treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors alone or in combination with chemotherapy and/or antiangiogenic therapy in first-line treatment. Progression-free survival 2 (PFS2) was the time from the first defined progress disease (PD) to the second disease progression or death. Efficacy evaluation was performed directly in accordance with RECIST v1.1 criteria. Adverse events (AEs) were graded following the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Survival data were estimated using the Kaplan-Meier method or Cox survival regression model and compared using the log-rank test in overall cohort and other subgroups. Results: There were no significant differences in objective response rate (ORR) and median PFS2 (mPFS2) between the ICI rechallenge group and non-rechallenge group (ORR: 10.3% vs. 15.3%, P=0.308; mPFS2: 5.33 vs. 4.40 months, P=0.715). And the ICI rechallenge group showed no new safety signals compared with non-rechallenge group. In ICI rechallenge group, patients resistant to first-line immunotherapy had a lower ORR and shorter PFS2 compared with those who responded to initial ICIs treatment (ORR: 7.0% vs. 17.6%, P=0.038; mPFS2: 3.68 vs. 5.91 months, P=0.014). No significant difference in mPFS2 was observed among different second-line treatment groups (P=0.362). Radiotherapy in second-line treatment and ICI rechallenge therapy were not the main factors affecting PFS2. Conclusions: ICI rechallenge therapy beyond disease progression did not improve clinical outcomes in patients with NSCLC, but no new safety signals emerged. However, patients with favorable response to initial ICIs treatment still showed significant efficacy of subsequent ICI rechallenge therapy. © Journal of Thoracic Disease. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Cui2024, - author = {Cui, Ran and Li, Yun and Yu, Xinlin and Wei, Chun and Jiang, Ou}, - title = {Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm metaanalysis}, - year = {2024}, - journal = {PLoS ONE}, - volume = {19}, - number = {6 June}, - doi = {10.1371/journal.pone.0304941}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85195808386&doi=10.1371%2fjournal.pone.0304941&partnerID=40&md5=698592652b570c0342fae1a2c3775d40}, - abstract = {Background The recent usage of immunotherapy combined with chemoradiotherapy has improved survival in advanced non-small cell lung cancer (NSCLC) patients. However, determining the most effective therapy combination remains a topic of debate. Research suggests immune checkpoint inhibitors (ICIs) post-chemoradiotherapy enhance survival, but the impact of concurrent ICIs during chemoradiotherapy on rapid disease progression is unclear. This meta-analysis aims to assess the effectiveness and safety of concurrent ICIs with radiotherapy or chemoradiotherapy in advanced non-small cell lung cancer. Methods We searched PubMed, Embase, the Cochrane Library, and Web of Science for relevant studies, extracting data on overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs). Results The analysis included ten studies with 490 participants. Stage III NSCLC ORR was 81.8%, while Stage IV ORR was 39.9%. One-year PFS and OS for Stage III were 68.2% and 82.6%, compared to 27.9% and 72.2% for Stage IV. Common adverse events included anemia (46.6%), nausea (47.6%), rash (36.4%), and radiation pneumonitis (36.3%). Conclusions Our meta-analysis shows concurrent ICIs with chemoradiotherapy are effective and safe in advanced NSCLC, particularly in stage III patients at risk of progression before starting ICIs after chemoradiotherapy. The findings support further phase III trials. The review protocol was registered on PROSPERO (CRD42023493685) and is detailed on the NIHR HTA programme website. © 2024 Cui et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access} -} - -@ARTICLE{Paczkowski20243682, - author = {Paczkowski, Freeman and Raphael, Jacques and Browne, Claire}, - title = {Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report}, - year = {2024}, - journal = {Current Oncology}, - volume = {31}, - number = {7}, - pages = {3682 – 3689}, - doi = {10.3390/curroncol31070271}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85199604475&doi=10.3390%2fcurroncol31070271&partnerID=40&md5=d8b0ccde513ea750dca21b0b0fc4dd9b}, - abstract = {Small-cell lung cancer (SCLC) remains a disease with poor prognosis, particularly in extensive-stage SCLC (ES-SCLC). Current standard-of-care treatment includes chemotherapy with platinum agents and etoposide plus immunotherapy with atezolizumab or durvalumab, which has achieved a mean overall survival of 12–13 months in clinical trials. However, long-term survival in ES-SCLC, even with the addition of immunotherapy, continues to be rare. We present the case of a middle-aged male patient diagnosed with ES-SCLC who was treated with four cycles of induction chemotherapy (carboplatin and etoposide) and atezolizumab, starting maintenance atezolizumab every 21 days thereafter, and thoracic radiotherapy. After 9 months, he experienced mild disease progression and was rechallenged with six cycles of carboplatin and etoposide with continued atezolizumab. Subsequent imaging showed near-complete disease resolution which has been sustained since. He has continued on maintenance atezolizumab since diagnosis and has achieved 60 months overall survival and 44 months progression-free survival. Throughout treatment, he has maintained a high functional capacity and only experienced one immune-related adverse event. Our patient is representative of a small subset who are capable of achieving durable responses to immunotherapy and his case highlights the need for further research to elucidate the clinical and biological factors driving this response. © 2024 by the authors.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Preda2024, - author = {Preda, Alexandra-Cristina and Ciuleanu, Tudor-Eliade and Todor, Nicolae and Vlad, Cătălin and Iancu, Dana Ioana and Mocan, Cristina and Bandi-Vasilica, Mariana and Albu, Florina and Todor-Bondei, Irina Mihaela and Hapca, Mădălina Claudia and Kubelac, Milan-Paul and Kubelac-Varro, Adelina Dadiana}, - title = {Use of Different Anti-PD-1 Checkpoint Combination Strategies for First-Line Advanced NSCLC Treatment—The Experience of Ion Chiricuță Oncology Institute}, - year = {2024}, - journal = {Cancers}, - volume = {16}, - number = {11}, - doi = {10.3390/cancers16112022}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85195779035&doi=10.3390%2fcancers16112022&partnerID=40&md5=187231115456f98cb15b29db762c8c86}, - abstract = {Purpose. Different combination modalities between an anti-PD-1/PD-L1 agent and a platinum-based chemotherapy or another checkpoint inhibitor (with or without a short course or full course of a platinum doublet) proved superior to chemotherapy alone in multiple clinical trials, but these strategies were not directly compared. The aim of this study is to report the real-world data results with different immunotherapy combinations in a series of patients treated in consecutive cohorts at the Ion Chiricuță Oncology Institute. Methods. A total of 122 patients were successively enrolled in three cohorts: (1A) nivolumab + ipilimumab (18 patients), (1B) nivolumab + ipilimumab + short-course chemotherapy (33 patients), and (2) pembrolizumab plus full-course chemotherapy (71 patients). Endpoints included overall survival (OS), progression-free survival (PFS), objective response (ORR), and univariate and multivariate exploratory analysis of prognostic factors. RESULTS. Median follow-up in the consecutive cohorts 1A, 1B, and 2 was 83 versus 59 versus 14.2 months. Median OS and PFS for all patients were 22.2 and 11.5 months, respectively, and 2-year actuarial OS and PFS were 49% and 35%, respectively. For the nivolumab + ipilimumab (cohorts 1A and 1B) versus pembrolizumab combinations (cohort 2), median OS was 14 vs. 24.8 months (p = 0.18) and 2-year actuarial survival 42% vs. 53%; median PFS was 8.6 vs. 12.7 months (p = 0.41) and 2-year actuarial PFS 34% vs. 35%; response rates were 33.3% vs. 47.9% (p = 0.22). Older age, impaired PS (2 versus 0–1), corticotherapy in the first month of immunotherapy, and >3.81 neutrophils to lymphocytes ratio were independent unfavorable prognostic factors in the multivariate analysis of survival (limited to 2 years follow-up). The 5-year long-term survival was 30.5% and 18.8% for cohorts 1A and 1B, respectively (not enough follow-up for cohort 2). Conclusions. Efficacy results using different immunotherapy combination strategies were promising and not significantly different between protocols at 2 years. Real-world efficacy and long-term results in our series were in line with those reported in the corresponding registration trials. © 2024 by the authors.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Mao2024, - author = {Mao, Zhirong and Pang, Guanchao and Huang, Xiaojie and Chen, Xiuxiu and Wu, Jiaji and Xu, Xia and Teng, Zhihua and Tan, Yanbin and Wang, Pingli}, - title = {Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC}, - year = {2024}, - journal = {BMC Pulmonary Medicine}, - volume = {24}, - number = {1}, - doi = {10.1186/s12890-024-03041-6}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85194105755&doi=10.1186%2fs12890-024-03041-6&partnerID=40&md5=847970286df8faf68c6418edeaf4d4a9}, - abstract = {Background: The incidence of checkpoint inhibitor-associated pneumonitis (CIP) in advanced non-small cell lung cancer (NSCLC) has been substantiated through large-scale clinical trials or real-world studies. However, reports on CIP incidence within the context of neoadjuvant immunotherapy for resectable NSCLC remain scarce. This study endeavors to investigate the incidence, risk factors, and outcomes of CIP in patients with resectable NSCLC receiving neoadjuvant immunochemotherapy. Methods: A retrospective, case-control study was conducted on patients diagnosed with NSCLC stages IIA–IIIB who received neoadjuvant immunochemotherapy between January 2018 and September 2022. Patients were stratified into two groups based on the presence or absence of CIP, facilitating a comparative analysis of clinical characteristics, treatment modalities, physiological indicators, and prognostic outcomes. Results: The study cohort comprised 245 patients, with 11.4% (28/245) experiencing CIP. The median period of CIP onset was 70 (range, 40–221) days. The incidence of severe CIP (grade 3–4) was 3.7% (9/245). Patients with CIP showed a higher all-cause mortality rate of 21.4% (6/28) compared to that of patients without CIP. Those who developed CIP exhibited elevated body mass index (BMI) values (p = 0.028) and increased fibrinogen (FIB) levels (p < 0.001), alongside a significant decrease in both diffusing capacity for carbon monoxide (DLCO)% pred (p = 0.001) and DLCO/VA% pred (p = 0.021) after neoadjuvant therapy compared to pre-indicators. Receiver operating characteristic curve (ROC) analysis showed that the area under the ROC curve of three assessed variables (FIB levels, BMI, DLCO) reached 0.806 in predicting CIP occurrence at an early stage. Conclusions: This cohort demonstrated that elevated BMI, increased FIB levels, and decreased pulmonary diffusion function after neoadjuvant therapy are risk factors of CIP occurrence. Early assessment and continuous monitoring of these indicators are imperative for the predictive identification of CIP, enhancing patient management and outcomes. © The Author(s) 2024.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Li2024, - author = {Li, Chengye and Zhou, Zhifeng and Hou, Lingxian and Hu, Keli and Wu, Zongda and Xie, Yupeng and Ouyang, Jinsheng and Cai, Xueding}, - title = {A novel machine learning model for efficacy prediction of immunotherapy-chemotherapy in NSCLC based on CT radiomics}, - year = {2024}, - journal = {Computers in Biology and Medicine}, - volume = {178}, - doi = {10.1016/j.compbiomed.2024.108638}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85196511928&doi=10.1016%2fj.compbiomed.2024.108638&partnerID=40&md5=f4383572e294aa39f95b0ac84f8bce9b}, - abstract = {Lung cancer is categorized into two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer. Of these, NSCLC accounts for approximately 85% of all cases and encompasses varieties such as squamous cell carcinoma and adenocarcinoma. For patients with advanced NSCLC that do not have oncogene addiction, the preferred treatment approach is a combination of immunotherapy and chemotherapy. However, the progression-free survival (PFS) typically ranges only from about 6 to 8 months, accompanied by certain adverse events. In order to carry out individualized treatment more effectively, it is urgent to accurately screen patients with PFS for more than 12 months under this treatment regimen. Therefore, this study undertook a retrospective collection of pulmonary CT images from 60 patients diagnosed with NSCLC treated at the First Affiliated Hospital of Wenzhou Medical University. It developed a machine learning model, designated as bSGSRIME-SVM, which integrates the rime optimization algorithm with self-adaptive Gaussian kernel probability search (SGSRIME) and support vector machine (SVM) classifier. Specifically, the model initiates its process by employing the SGSRIME algorithm to identify pivotal image features. Subsequently, it utilizes an SVM classifier to assess these features, aiming to enhance the model's predictive accuracy. Initially, the superior optimization capability and robustness of SGSRIME in IEEE CEC 2017 benchmark functions were validated. Subsequently, employing color moments and gray-level co-occurrence matrix methods, image features were extracted from images of 60 NSCLC patients undergoing immunotherapy combined with chemotherapy. The developed model was then utilized for analysis. The results indicate a significant advantage of the model in predicting the efficacy of immunotherapy combined with chemotherapy for NSCLC, with an accuracy of 92.381% and a specificity of 96.667%. This lays the foundation for more accurate PFS predictions and personalized treatment plans. © 2024}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Zhao2024, - author = {Zhao, Luqing and Zhao, Zhiting and Yan, Xiaoqi and Hu, Xiao and Feng, Jifeng and Yu, Shaorong}, - title = {Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis}, - year = {2024}, - journal = {Technology in Cancer Research and Treatment}, - volume = {23}, - doi = {10.1177/15330338241227055}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85182814828&doi=10.1177%2f15330338241227055&partnerID=40&md5=6409f26f41f337a0089b9abaf24b30b8}, - abstract = {Objective: As monotherapy such as topotecan has reached a plateau of effectiveness, new second-line treatments based on experience have been used in clinical application. This study compared the efficacy and safety of different second-line treatments for advanced small-cell lung cancer (SCLC). Methods: A total of 380 patients with advanced SCLC were screened selectively in the retrospective study. Adverse events and patient responses were assessed using Common Terminology Criteria for Adverse Events v5.0 and Response Evaluation Criteria for Solid Tumors v1.1. The progression-free survival (PFS) was estimated using the Kaplan-Meier method or Cox survival regression model and compared using the log-rank test. Results: In the platinum-resistant group, disease control rate (DCR) and median PFS (mPFS) were prolonged in the combination group versus single-agent group (DCR: 49.24% vs 24.39%, P =.004; mPFS: 3.73 vs 1.90 months, P <.001). Grade 3/4 toxicity was similar between the 2 groups (P =.683). The mPFS did not differ among single-agent groups (P =.380). No significant difference was observed in mPFS of different combination therapy groups (P =.170). In terms of platinum-based chemotherapy, the DCR and mPFS were prolonged in irinotecan-platinum group versus taxol-platinum group (DCR: 56.14% vs 9.09%, P =.004; mPFS: 3.87 vs 1.93 months, P =.012). Grade 3/4 toxicity was similar between the 2 groups (P =.614). The mPFS was prolonged in the chemotherapy plus immunotherapy group versus single-agent chemotherapy group (P =.003). In the platinum-sensitive group, the mPFS did not differ between the combination group and single-agent group (P =.200). The mPFS did not differ among different single-agent groups (P =.260) or combination groups (P =.150). There was no difference in mPFS among different platinum-based chemotherapy groups (P =.830). Conclusions: For patients with platinum-resistant SCLC, combination therapy has shown better efficacy and acceptable toxicity profile than monotherapy. Among combination therapies, irinotecan–platinum has shown better efficacy than taxol–platinum. For patients with platinum-sensitive SCLC, the efficacy of different single-agent or combination therapies was similar. © The Author(s) 2024.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Wei2024:635, - author = {Wei, Yuxuan and Wang, Lei and Jin, Zheng and Jia, Qingzhu and Brcic, Luka and Akaba, Tomohiro and Chu, Qian}, - title = {Biological characteristics and clinical treatment of pulmonary sarcomatoid carcinoma: a narrative review}, - year = {2024}, - journal = {Translational Lung Cancer Research}, - volume = {13}, - number = {3}, - pages = {:635 – 653}, - doi = {10.21037/tlcr-24-127}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85191871694&doi=10.21037%2ftlcr-24-127&partnerID=40&md5=359c05709bab60a6b561a013a6c11ab5}, - abstract = {Background and Objective: Pulmonary sarcomatoid carcinoma (PSC) is a subset of non-small cell lung cancer (NSCLC) with highly malignant, aggressive, and heterogeneous features. Patients with this disease account for approximately 0.1–0.4% of lung cancer cases. The absence of comprehensive summaries on the basic biology and clinical treatments for PSC means there is limited systematic awareness and understanding of this rare disease. This paper provides an overview of the biological characteristics of PSC and systematically summarizes various treatment strategies available for patients with this disease. Methods: For this narrative review, we have searched literature related to the basic biology and clinical treatment approaches of PSC by searching the PubMed database for articles published from July 16, 1990 to August 29, 2023. The following keywords were used: “pulmonary sarcomatoid carcinoma”, “genetic mutations”, “immune microenvironment”, “hypoxia”, “angiogenesis”, “overall survival”, “surgery”, “radiotherapy”, “chemotherapy”, and “immune checkpoint inhibitors”. Key Content and Findings: Classical PSC comprises epithelial and sarcomatoid components, with most studies suggesting a common origin. PSC exhibits a higher tumor mutational burden (TMB) and mutation frequency than other types of NSCLC. The tumor microenvironment (TME) of PSC is characterized by hypoxia, hypermetabolism, elevated programmed cell death protein 1/programmed cell death-ligand 1 expression, and high immune cell infiltration. Treatment strategies for advanced PSC are mainly based on traditional NSCLC treatments, but PSC exhibits resistance to chemotherapy and radiotherapy. The advancement of genome sequencing has introduced targeted therapies as an option for mutation-positive PSC cases. Moreover, due to the characteristics of the immune microenvironment of PSC, many patients positively respond to immunotherapy, demonstrating its potential for the management of PSC. Conclusions: Although several studies have examined and assessed the TME of PSC, these are limited in quantity and quality, presenting challenges for research into the clinical treatment strategies for PSC. With the emergence of new technologies and the advancement of clinical research, for example, savolitinib’s clinical study for MET exon 14 skipping mutations positive PSC patients have shown promising outcomes, more in-depth studies on PSC are eagerly anticipated. © Translational Lung Cancer Research. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access} -} - -@ARTICLE{Liu2023, - author = {Liu, Tingting and Li, Sihan and Ding, Silu and Qiu, Jingping and Ren, Chengbo and Chen, Jun and Wang, He and Wang, Xiaoling and Li, Guang and He, Zheng and Dang, Jun}, - title = {Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis}, - year = {2023}, - journal = {eClinicalMedicine}, - volume = {64}, - doi = {10.1016/j.eclinm.2023.102246}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85171866461&doi=10.1016%2fj.eclinm.2023.102246&partnerID=40&md5=1fd4e596f335580ae799ea05405dfcf7}, - abstract = {Background: Pneumonitis is a common complication for patients with locally advanced non-small cell lung cancer undergoing definitive chemoradiotherapy (CRT). It remains unclear whether there is ethnic difference in the incidence of post-CRT pneumonitis. Methods: PubMed, Embase, Cochrane Library, and Web of Science were searched for eligible studies from January 1, 2000 to April 30, 2023. The outcomes of interest were incidence rates of pneumonitis. The random-effect model was used for statistical analysis. This meta-analysis was registered with PROSPERO (CRD42023416490). Findings: A total of 248 studies involving 28,267 patients were included. Among studies of CRT without immunotherapy, the pooled rates of pneumonitis for Asian patients were significantly higher than that for non-Asian patients (all grade: 66.8%, 95% CI: 59.2%–73.9% vs. 28.1%, 95% CI: 20.4%–36.4%; P < 0.0001; grade ≥2: 25.1%, 95% CI: 22.9%–27.3% vs. 14.9%, 95% CI: 12.0%–18.0%; P < 0.0001; grade ≥3: 6.5%, 95% CI: 5.6%–7.3% vs. 4.6%, 95% CI: 3.4%–5.9%; P = 0.015; grade 5: 0.6%, 95% CI: 0.3%–0.9% vs. 0.1%, 95% CI: 0.0%–0.2%; P < 0.0001). Regarding studies of CRT plus immunotherapy, Asian patients had higher rates of all-grade (74.8%, 95% CI: 63.7%–84.5% vs. 34.3%, 95% CI: 28.7%–40.2%; P < 0.0001) and grade ≥2 (34.0%, 95% CI: 30.7%–37.3% vs. 24.6%, 95% CI: 19.9%–29.3%; P = 0.001) pneumonitis than non-Asian patients, but with no significant differences in the rates of grade ≥3 and grade 5 pneumonitis. Results from subgroup analyses were generally similar to that from the all studies. In addition, the pooled median/mean of lung volume receiving ≥20 Gy and mean lung dose were relatively low in Asian studies compared to that in non-Asian studies. Interpretation: Asian patients are likely to have a higher incidence of pneumonitis than non-Asian patients, which appears to be due to the poor tolerance of lung to radiation. Nevertheless, these findings are based on observational studies and with significant heterogeneity, and need to be validated in future large prospective studies focusing on the subject. Funding: None. © 2023 The Author(s)}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Gold Open Access} -} - -@ARTICLE{Chen2024, - author = {Chen, Xiang and Chen, Ling-Juan and Peng, Xiao-Fei and Deng, Ling and Wang, Yan and Li, Jiu-Jiang and Guo, Dong-Li and Niu, Xiao-Hua}, - title = {Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations}, - year = {2024}, - journal = {Translational Oncology}, - volume = {40}, - doi = {10.1016/j.tranon.2023.101851}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85179010420&doi=10.1016%2fj.tranon.2023.101851&partnerID=40&md5=b36958125bbea0d296b6aa0a16013192}, - abstract = {Colorectal cancer (CRC) is the third most prevalent cancer in the world. The PD-1/PD-L1 pathway plays a crucial role in modulating immune response to cancer, and PD-L1 expression has been observed in tumor and immune cells within the tumor microenvironment of CRC. Thus, immunotherapy drugs, specifically checkpoint inhibitors, have been developed to target the PD-1/PD-L1 signaling pathway, thereby inhibiting the interaction between PD-1 and PD-L1 and restoring T-cell function in cancer cells. However, the emergence of resistance mechanisms can reduce the efficacy of these treatments. To counter this, monoclonal antibodies (mAbs) have been used to improve the efficacy of CRC treatments. mAbs such as nivolumab and pembrolizumab are currently approved for CRC treatment. These antibodies impede immune checkpoint receptors, including PD-1/PD-L1, and their combination therapy shows promise in the treatment of advanced CRC. This review presents a concise overview of the use of the PD-1/PD-L1 blockade as a therapeutic strategy for CRC using monoclonal antibodies and combination therapies. Additionally, this article outlines the function of PD-1/PD-L1 as an immune response suppressor in the CRC microenvironment as well as the potential advantages of administering inflammatory agents for CRC treatment. Finally, this review analyzes the outcomes of clinical trials to examine the challenges of anti-PD-1/PD-L1 therapeutic resistance. © 2023}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 6; All Open Access, Gold Open Access} -} - -@ARTICLE{Yao2024, - author = {Yao, Yueyuan and Li, Butuo and Song, Ruiting and Yang, Linlin and Zou, Bing and Wang, Linlin}, - title = {Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis}, - year = {2024}, - journal = {Radiation Oncology}, - volume = {19}, - number = {1}, - doi = {10.1186/s13014-024-02420-x}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186258582&doi=10.1186%2fs13014-024-02420-x&partnerID=40&md5=fa20e731a8d39b76e8d31116808c9015}, - abstract = {Background: Platinum-etoposide chemotherapy combined with immune checkpoint inhibitors (ICIs) has been recommended as the first-line standard treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, the effect of thoracic radiotherapy (TRT) on these patients is still unknown. This study aimed to evaluate the efficacy and safety of TRT for ES-SCLC patients who responded to first-line ICIs and chemotherapy (CHT). Methods: Patients who received 4 to 6 cycles of ICIs and CHT as first-line therapy at three hospitals between 2018 and 2022 were included in the analysis. All patients were divided into two groups based on whether they received TRT as first-line treatment, and propensity score matching (PSM) was performed to ensure that the characteristics of two groups were well-balanced. The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoint was toxic effects. Results: A total of 276 patients were included, and the median follow-up time was 22.3 (range, 4.0-53.73) months. After PSM, 197 patients were further analysed, and 99 of whom received TRT. The baseline characteristics were well-balanced between patients in the TRT and non-TRT groups. There were significant differences in PFS between the TRT and non-TRT groups, with the median PFS of 10.76 and 7.63 months, respectively (P = 0.014). Significantly improved OS was observed in the TRT group (21.67 vs. 16.6 months, P = 0.009). In addition, the use of TRT was an independent prognostic factor for PFS and OS of ES-SCLC patients receiving ICIs plus CHT. In terms of safety, no significant increase of any grades adverse event (AE) (P = 0.874) and G3-4 AE (P = 0.909) was observed for patients receiving TRT. Radiation esophagitis, gastrointestinal and hematologic toxicities were the most common AEs in TRT group, which were tolerable. And high-dose radiotherapy was associated with higher incidence of pneumonitis. Conclusion: Addition of TRT showed significant survival benefits and well tolerability in ES-SCLC patients receiving platinum-etoposide CHT and ICIs, which could be a feasible first-line treatment strategy for ES-SCLC patients. © The Author(s) 2024.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access} -} - -@ARTICLE{Dehghani2023, - author = {Dehghani, Tannaz and Shahrjerdi, Alireza and Kahrizi, Mohammad Saeed and Soleimani, Elnaz and Ravandeh, Saeideh and Merza, Muna S. and Rahnama, Negin and Ebrahimzadeh, Farnoosh and Bakhshesh, Morteza}, - title = {Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances}, - year = {2023}, - journal = {Pathology Research and Practice}, - volume = {246}, - doi = {10.1016/j.prp.2023.154470}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85156272648&doi=10.1016%2fj.prp.2023.154470&partnerID=40&md5=74ff27c7e7645ccc1821c1b95005df20}, - abstract = {The immune system uses various immune checkpoint axes to adjust responses, support homeostasis, and deter self-reactivity and autoimmunity. Nevertheless, non-small-cell lung carcinoma (NSCLC) can use protective mechanisms to facilitate immune evasion, which leads to potentiated cancer survival and proliferation. In this light, many blocking anti-bodies have been developed to negatively regulate checkpoint molecules, in particular, programmed cell death protein 1 (PD-1) / PD-ligand 1 (L1), and bypass these immune suppressive mechanisms. Meanwhile, anti-PD-1 anti-bodies such as nivolumab, pembrolizumab, cemiplimab, and sintilimab have shown excellent competence in successfully inspiring immune responses versus NSCLC. Accordingly, the United States Food and Drug Administration (FDA) has recently approved nivolumab (alone or in combination with ipilimumab) and pembrolizumab (alone or in combination with chemotherapy) as first-line treatment for advanced NSCLC patients. However, PD-1 blockade monotherapy remains inefficient in more than 60% of NSCLC patients, and many patients don't respond or acquire resistance to this modality. Also, toxicities related to anti-PD-1 anti-body have been progressively identified in clinical trials and oncology practice. Herein, we will outline the clinical benefits of PD-1 blockade therapy alone or in combination with other treatments (e.g., chemotherapy, radiotherapy, anti-angiogenic therapy) in NSCLC patients. Moreover, we will take a glimpse into the recently identified predictive biomarkers to determine patients most likely to suffer serious adverse events to decrease untoward toxicity risk and diminish treatment costs. © 2023 Elsevier GmbH}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4} -} - -@ARTICLE{Li2024, - author = {Li, Ying and Zhao, Junfeng and Li, Ruyue and Yao, Xiujing and Dong, Xue and Zhang, Ruidan and Li, Yintao}, - title = {Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study}, - year = {2024}, - journal = {Neoplasia (United States)}, - volume = {57}, - doi = {10.1016/j.neo.2024.101043}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85202835912&doi=10.1016%2fj.neo.2024.101043&partnerID=40&md5=36ce54d63c4b1ef77fca4fb0357cef77}, - abstract = {Objective: Whether to continue administering immunotherapy to patients with advanced non-small cell lung cancer (NSCLC) who have experienced tumor progression remains controversial after immunotherapy. The aims were to explore survival outcomes after further immunotherapy post-progression and to determine the optimal combination therapy in such cases. Methods: Overall, 507 patients with NSCLC who underwent immunotherapy and experienced tumor progression were retrospectively divided into Immuno-combination and No-immuno groups according to whether additional combination therapy involving immunotherapy was administered post-progression. Progression-free survival (PFS) and overall survival (OS) were evaluated. Subgroup analyses were performed according to the different treatment regimens for patients in the Immuno-combination group. Results: After propensity score matching, there were 150 patients in the No-immuno group and 300 patients in the Immuno combination group. Superior PFS was observed in the Immuno-combination group compared with those in the No-immuno group (6-month PFS: 25.3 % vs. 60.6 %; 12-month PFS: 6.7 % vs. 24.4 %; P < 0.001). Similar intergroup differences were observed for OS (12-month OS: 22.3 % vs. 69.4 %; 18-month OS: 6.4 % vs. 40.4 %; P < 0.001). Superior PFS outcomes were observed in the Immuno+Antiangiogenic group compared with the Immuno+Chemo group (6-month PFS: 51.3 % vs. 71.5 %; 12-month PFS: 23.1 % vs. 25.7 %; P = 0.017). Similar differences in OS were observed between those same subgroups (12-month OS: 62.1 % vs. 77.9 %; 18-month OS: 33.3 % vs. 48.7 %; P = 0.006). Conclusion: Patients with NSCLC experiencing tumor progression post-immunotherapy can still benefit from further treatment, with immunotherapy combined with antiangiogenic therapy the most efficacious option. © 2024}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Carlisle20233525, - author = {Carlisle, Jennifer W. and Leal, Ticiana}, - title = {Advancing immunotherapy in small cell lung cancer}, - year = {2023}, - journal = {Cancer}, - volume = {129}, - number = {22}, - pages = {3525 – 3534}, - doi = {10.1002/cncr.34977}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85168363283&doi=10.1002%2fcncr.34977&partnerID=40&md5=a1626934e99f5de313d9d356fe94d80e}, - abstract = {Small cell lung cancer (SCLC) is a rapidly progressive neuroendocrine carcinoma that, until recently, had a very small armamentarium of effective treatments. Advances in DNA sequencing and whole transcriptomics have delineated key subtypes; therefore, SCLC is no longer viewed as a homogeneous cancer. Chemoimmunotherapy with PD1 blockade is now the standard of care for advanced disease, and ongoing research efforts are moving this strategy into the limited stage setting. Combination strategies of immunotherapy with radiation are also under active clinical trial in both limited and extensive stage disease. Plain Language Summary: Small cell lung cancer (SCLC) is a rapidly progressive neuroendocrine carcinoma that, until recently, had a very small armamentarium of effective treatments. Chemoimmunotherapy with immune check point inhibitors is now the standard of care for advanced disease. This comprehensive review provides an overview of current treatment strategies for SCLC, unmet needs in this patient population, and emerging treatment strategies incorporating immunotherapy that will hopefully further improve outcomes for patients. © 2023 American Cancer Society.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3} -} - -@ARTICLE{Yang20244391, - author = {Yang, Pan and Luo, Hu and Zhao, Lintao and Xiong, Fu and Tang, Chunlan}, - title = {Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/ PD-L1 antibodies in extensive-stage small cell lung cancer: a real-world study}, - year = {2024}, - journal = {Journal of Thoracic Disease}, - volume = {16}, - number = {7}, - pages = {4391 – 4399}, - doi = {10.21037/jtd-24-394}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85199985126&doi=10.21037%2fjtd-24-394&partnerID=40&md5=01e78008fd0a85b1f0fe244f1d7bdade}, - abstract = {Background: Currently, chemotherapy plus immunotherapy followed by maintenance therapy with immune monotherapy is the preferred first-line treatment option for extensive-stage small cell lung cancer (ES-SCLC), but with limited overall survival (OS) and progression-free survival (PFS) benefits. The combination of antiangiogenic drugs with immunotherapy has shown encouraging anti-tumor activity and tolerability, with some degree of overcoming immune resistance. This study aimed to evaluate the effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with immunotherapy in ES-SCLC. Methods: Between June 2020 and December 2021, 12 patients with newly diagnosed ES-SCLC in the First Affiliated Hospital of Army Medical University were retrospectively analyzed. All patients without disease progression after 4–6 cycles of first-line platinum-containing chemotherapy plus anti-PD-1/PD-L1 antibodies received anlotinib (12 mg oral/day, days 1–14, followed by 1 week off, every 3 weeks per cycle) plus anti-PD-1/PD-L1 antibodies as maintenance therapy. Several patients underwent chest radiotherapy (intensity-modulated radiotherapy using a 6 MV X-ray) without disease progression before maintenance therapy. The effectiveness and safety of anlotinib plus anti-PD-1/PD-L1 antibodies as maintenance therapy after first-line chemotherapy combined with immunotherapy in ES-SCLC were evaluated. Results: The median follow-up time was 31.1 months. During first-line treatment (including maintenance therapy), one patient achieved a complete response, eight patients achieved a partial response (PR), and three patients had stable disease, with an objective response rate of 75.0% and a disease control rate of 100.0%. During maintenance therapy with anlotinib plus anti-PD-1/PD-L1 antibodies, 50.0% of patients achieved further lesion remission on the basis of the prior initial treatment, of which one patient achieved a PR. The median PFS was 13.6 [95% confidence interval (CI): 11.2–15.6] months, and the median OS was 19.5 (95% CI: 14.5–24.5) months. Treatment-related any grade and grade 3–4 adverse events (AEs) were reported in 100.0% and 58.3% of patients, respectively. No life-threatening AEs were observed. Grade 3–4 AEs included leukocytopenia (58.3%, 7/12), thrombocytopenia (33.3%, 4/12), nausea (33.3%, 4/12), anemia (16.7%, 2/12), and fatigue (8.3%, 1/12). All AEs during maintenance therapy were tolerated and were regarded as grade 1–2, with the majority being fatigue, nausea, rash, and hemoptysis. Conclusions: The combination of anlotinib with anti-PD-1/PD-L1 antibodies demonstrated encouraging effectiveness and safety in treating patients with ES-SCLC, suggesting that it may be a preferred option for maintenance therapy after first-line chemotherapy combined with immunotherapy. © Journal of Thoracic Disease. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{García-Campelo20232760, - author = {García-Campelo, Rosario and Sullivan, Ivana and Arriola, Edurne and Insa, Amelia and Juan Vidal, Oscar and Cruz-Castellanos, Patricia and Morán, Teresa and Reguart, Noemí and Zugazagoitia, Jon and Dómine, Manuel}, - title = {Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2679-2691), 10.1007/s12094-023-03216-3)}, - year = {2023}, - journal = {Clinical and Translational Oncology}, - volume = {25}, - number = {9}, - pages = {2760 – 2762}, - doi = {10.1007/s12094-023-03290-7}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85167349845&doi=10.1007%2fs12094-023-03290-7&partnerID=40&md5=1809dd855af9911bd157bb5bee8a4d3e}, - abstract = {In Table 3 of this article, for the point "Second-line treatment in ES-SCLC", the statement "At the time of writing guideline document, lurbinectedin is FDA and EMA approved but not authorized in Spain" was incorrect but it should have been "At the time of writing guideline document, lurbinectedin is FDA approved, has granted orphan drug designation by the EMA, but not authorized in Spain." The corrected Table 3 is provided below. (Table presented.) Summary of recommendations Pathological diagnosis and staging Pathological diagnosis of SCLC should be made using the World Health Organization classification Initial evaluation must include adequate anamnesis, medical/smoking histories, physical examination, complete blood count, and biochemistry, including liver enzymes, sodium, potassium, calcium, glucose, lactate dehydrogenase levels, and renal function test (V, A) Lung function tests in patients candidate to TRT (V, B) The presence of neurologic paraneoplastic syndromes that can be aggravated by immunotherapy must be ruled out (V, C) Full staging includes: CT scan with intravenous contrast of the chest/abdomen, MRI (preferred), or CT scan (with intravenous contrast) for brain imaging (III, A) 18F-FDG-PET/TC scan is recommended in localized disease to assist to thoracic radiotherapy (III, A). In patients with a solitary metastasis, its pathological confirmation is recommended (III, C) Bone marrow aspiration or biopsy is recommended if direct or indirect data of bone marrow infiltration (III, B) 8th edition of the TNM staging system according to the AJCC should be used (Table 1) (I, A). Combined use of TNM and VA classification is appropriate Management of limited Stage I–IIA (T1–T2, N0, M0) Surgery should be recommended in patients with clinical stages I and II (cT1-2N0) (III, B) Lobectomy with a systematic lymph-node dissection is the preferred surgical procedure after mediastinal staging (II, A) ChT and TRT (IV, A) concurrent (preferred) or sequentially (IV, A) should be recommended in patients with R0 pN1–pN2 or R1–R2 after surgery Patients with N0 disease should be recommended adjuvant chemotherapy (IV, A) SBRT (≥ 50 Gy) represents an alternative for patients with stage I–IIA SCLC with surgical contraindication or refusing surgery. After completion of SBRT patients should receive four cycles of adjuvant chemotherapy (III, A) PCI is not recommended in this subgroup of patients (II, E) Management of limited-stage IIB–IIIC (T3–4, N0 M0; T1–4, N1–3, M0) Patients should be treated with concurrent ChT and TRT (I, A) The recommended ChT is the combination of 4 cycles of cisplatin–etoposide (I, A). Carboplatin could replace cisplatin when contraindication (II, A) ChT dose reductions should be avoided, especially during the first two cycles of treatment (II, B) The use of G/GM-CSF is safe, when clinically indicated (II, B) 45 Gy with twice-daily fraction (I, A) or 60–70 Gy (II, A); with once-daily fraction are accepted treatments. Either of them should be administered concomitantly to systemic therapy (II, A) RT should be started as early as with the 1st or 2nd course of ChT (II, A) PCI (25 Gy in ten daily fractions) should be administered after CRT in patients without progression (I, A) Hippocampal avoidance PCI is an alternative option to PCI (II, B) Management of extensive-stage (any T, any N, M1a, b, c): first-line treatment The recommended first-line treatment is the use of platinum–etoposide + IO (I, A) Atezolizumab–carboplatin–etoposide 4 cycles followed by maintenance atezolizumab Durvalumab + carboplatin or cisplatin–etoposide 4 cycles followed by maintenance durvalumab If no candidate to receive IO, the recommended treatment is chemotherapy 4 cycles of cisplatin–etoposide (I, A). Carboplatin could replace cisplatin when contraindicated (I, B) Alternative regimens are cisplatin–irinotecan, carboplatin– irinotecan (II, B) Management of extensive-stage (any T, any N, M1a, b, c): radiotherapy Consolidative thoracic radiation to the residual tumor and lymph nodes (30 Gy/10 fractions) in selected patients who achieved a response to ChT is a treatment option (II, B) PCI (25 Gy) should be evaluated in patients with good PS who achieve a response (II, B) An alternative to PCI in patients without brain metastases on brain MRI after ChT is follow up with regular brain MRI omitting PCI (II, B) The benefit of adding PCI in patients receiving ChT–IO has yet to be determined (V, C) Second-line treatment in ES-SCLC Retreatment with platinum–etoposide is recommended for patients with sensitive relapse (platinum-free interval ≥ 3 months) (I, A) Single-agent topotecan is recommended for patients with refractory disease, resistant relapse, or in patients with sensitive relapse that are not candidates for platinum rechallenge (e.g., ECOG PS > 1, prior significant toxicity with doublet platinum-based ChT, or any other contraindication to receive platinum) (I, B) In this same situation, CAV (II, B), irinotecan (III, B) or weekly paclitaxel (III, C) are also reasonable treatment options Single-agent lurbinectedin is clinically active in relapsed SCLC, and it can be considered and recommended in patients with relapsed SCLC regardless of platinum-free interval (III, A). At the time of writing guideline document, lurbinectedin is FDA approved, has granted orphan drug designation by the EMA, but not authorized in Spain Single-agent PD-1 axis blockade is not generally recommended in unselected patients with relapsed SCLC (I, D) Elderly and frail patients In LS-SCLC, concurrent cCRT with modern technics could be a treatment option for fit and elderly patients (IV, B) Unfit patients ineligible for cCRT may be considered for sequential (II, C) For elderly ES-SCLC patients, carboplatin/etoposide is preferred than cisplatin/etoposide (I, B) In ES-SCLC, ChT–IO combination are recommended as first-line treatment (I, B) Shared decision process to indicate PCI over close surveillance is recommended in older patients with LS-SCLC Active CNS surveillance than PCI is preferred in older patients with ES-SCLC (I, A) Follow-up LS-SCLC: CT scan every 3 months the first year, every 6 months year 2–3 and after annually (V, C) ES-SCLC: CT scan every 2–3 months the first year, every 3 months year 2 and 3, every 6 months year 4–5 and then annually (V, C) MRI (preferred) or CT brain with contrast every 3 months during the first year, then every 6 months thereafter are recommended in patients who did not undergo PCI The Acknowledgments and Conflict of interest sections were missing from this article and should have read as follows. The authors thank Enriqueta Felip y Javier de Castro for their review and validation of the levels of evidence and grades of recommendation in this guideline. RGC reports Advisory boards, Consultancy and Speaker honoraria from MSD, BMS, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takea and Amgen. IS reports Advisory Board from Roche, Novartis, Boehringer Ingelheim, Takeda and Sanofi; Speaker from Roche, MSD, Pfizer, BMS and AstraZeneca; Grant from Roche, Takeda, Pfizer, BMS and AstraZeneca; Non-financial Support from Member of GECP. EA reports Advisory Board, Speakerand Grant from Roche; Advisory Board and Speaker from Astra Zeneca and BMS; Advisory Board, Speaker and Non-financial Support from Takeda; Advisory Board from Lilly and Boehringer-Ingelheim; Speaker from MSD, Merck, Thermo Fisher Scientific and Guardant Health; Speaker and- Non-financial Support from Pfizer. AI reports Advisory Board and Speaker from Roche, AstraZeneca and Sanofi; Speaker from Takeda and BMS. OJJV reports Advisory Board and Speaker from BMS and Janssen; Speker from Roche; Advisory Board, Speaker and Other from AstraZeneca, Takeda and Janssen; Advisory Board from Lilly. NR reports Advisory Board, Speaker and- Other from MSD; Advisory Board and Speaker from AstraZeneca, Takeda, Amgen, Lilly, Sanofi, Roche and Janssen. JZ reports Speaker, Grant and Personal Feels from BMS and AstraZencea; Advisory Board and Personal Feels from Sanofi; Speaker from MSD; Grant and Personal Feels from Roche; Speaker and Personal Feels from Pfizer; Advisory Board from Novartis and Speaker from NanoString. MD reports Advisory Board and Speaker from AatraZeneca, Pfizer and Takeda; Speaker from BMS, MSD and Roche; Advisory Board from Janssen and Sanofi. TM and PCC have nothing to disclose. The original article has been corrected. © 2023, The Author(s).}, - type = {Erratum}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Green Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Saalfeld2024801, - author = {Saalfeld, Felix Carl and Wermke, Martin}, - title = {Checkpoint inhibitors in metastatic and localized small cell lung cancer—current use and recent developments; [Gegenwärtiger Einsatz und aktuelle Entwicklungen der Immuncheckpointinhibition beim metastasierten und lokalisierten kleinzelligen Lungenkarzinom]}, - year = {2024}, - journal = {Onkologie}, - volume = {30}, - number = {9}, - pages = {801 – 808}, - doi = {10.1007/s00761-024-01566-3}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85199092511&doi=10.1007%2fs00761-024-01566-3&partnerID=40&md5=34e40f036920c96377c967f6188f1c55}, - abstract = {Small cell lung cancer (SCLC) is characterized by aggressive proliferation kinetics, early development of distant metastasis, and an overall dismal prognosis. Addition of the PD-L1 antibodies atezolizumab and durvalumab to platinum-/etoposide-based chemotherapy improves overall survival and represents the first change in therapeutic standards for almost 30 years in metastasized SCLC (stage IV or extensive disease [ED] according to the Veterans Administration Lung Study Group [VALG]). Although the numeric gains in median overall survival are limited (approximately 3 months), the addition of a PD-L1 antibody led to a clinically relevant increase in 3‑year overall survival from 5.8 to 17.6%. Therefore, anti-PD-L1-based immunochemotherapy represents the current standard for ED-SCLC and should be applied irrespective of PD-L1 expression and other biomarkers. Standard of care in curatively treatable SCLC limited to the hemithorax (limited stage [LD] according to VALG) remains is accelerated concurrent chemoradiotherapy. The recently presented findings of the ADRIATIC study demonstrate a benefit from consolidation therapy with the PD-L1 antibody durvalumab. A corresponding expansion of the drugʼs approval can be expected. In conclusion, treatment of SCLC remains a challenge and improvements in therapeutic standards are much slower than those seen in NSCLC. © The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2024.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Falchero2023, - author = {Falchero, Lionel and Guisier, Florian and Darrason, Marie and Boyer, Arnaud and Dayen, Charles and Cousin, Sophie and Merle, Patrick and Lamy, Régine and Madroszyk, Anne and Otto, Josiane and Tomasini, Pascale and Assoun, Sandra and Canellas, Anthony and Gervais, Radj and Hureaux, José and Le Treut, Jacques and Leleu, Olivier and Naltet, Charles and Tiercin, Marie and Van Hulst, Sylvie and Missy, Pascale and Morin, Franck and Westeel, Virginie and Girard, Nicolas}, - title = {Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study}, - year = {2023}, - journal = {Lung Cancer}, - volume = {185}, - doi = {10.1016/j.lungcan.2023.107379}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85172323322&doi=10.1016%2fj.lungcan.2023.107379&partnerID=40&md5=35f305302158b285b53ae75c8abf7696}, - abstract = {Background: Small cell lung cancer (SCLC) has a tendency towards recurrence and limited survival. Standard-of-care in 1st-line is platinum-etoposide chemotherapy plus atezolizumab or durvalumab, based on landmark clinical trials. Methods: IFCT-1905 CLINATEZO is a nationwide, non-interventional, retrospective study of patients with extensive-SCLC receiving atezolizumab plus chemotherapy as part of French Early Access Program. Objectives were to analyse effectiveness, safety and subsequent treatments. Results: The population analyzed included 518 patients who received atezolizumab in 65 participating centers. There were 66.2% male, mean age was 65.7 years; 89.1% had a performance status (PS) 0/1 and 26.6% brain metastases. Almost all (95.9%) were smokers. Fifty-five (10.6%) received at least 1 previous treatment. Median number of atezolizumab injections was 7.0 (range [1.0–48.0]) for a median duration of 4.9 months (95% CI 4.5–5.1). Atezolizumab was continued beyond progression in 122 patients (23.6%) for a median duration of 1.9 months (95% CI: [1.4–2.3]). Best objective response was complete and partial in 19 (3.9%) and 378 (77.1%) patients. Stable disease was observed in 50 patients (10.2%). Median follow-up was 30.8 months (95% CI: [29.9–31.5]). Median overall survival (OS), 12-, 24-month OS rates were 11.3 months (95% CI: [10.1–12.4]), 46.7% (95% CI [42.3–50.9]) and 21.2% (95% CI [17.7–24.8]). Median real-world progression-free survival, 6-, 12-month rates were 5.2 months (95% CI [5.0–5.4]), 37.5% (95% CI [33.3–41.7]) and 15.2% (95% CI [12.2–18.6]). For patients with PS 0/1, median OS was 12.2 months (95% CI [11.0–13.5]). For patients with previous treatment, median OS was 14.9 months (95% CI [10.1–21.5]). Three-hundred-and-twenty-six patients (66.4%) received subsequent treatment and 27 (5.2%) were still under atezolizumab at date of last news. Conclusions: IFCT-1905 CLINATEZO shows reproductibility, in real-life, of IMpower-133 survival outcomes, possibly attributed to selection of patients fit for this regimen, adoption of pragmatic approaches, including concurrent radiotherapy and treatment beyond progression. © 2023 The Author(s)}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Minuti2023414, - author = {Minuti, Gabriele and Stefani, Alessio and Trodella, Luca and Cappellini, Giancarlo Antonini and Cecere, Fabiana and Dionisi, Francesco and Di Salvatore, Mariantonietta and Mariotti, Sabrina and Mazzarella, Ciro and Nelli, Fabrizio and Pisegna, Simona and Ricciardi, Serena and Russano, Marco and Ramella, Sara and Bria, Emilio and Cappuzzo, Federico}, - title = {Management of the patient with extensive stage microcytoma. The importance of collaboration between oncology and radiotherapy; [Gestione del paziente con microcitoma a stadio esteso. L’importanza della collaborazione tra oncologia e radioterapia]}, - year = {2023}, - journal = {Recenti Progressi in Medicina}, - volume = {114}, - number = {7}, - pages = {414 – 425}, - doi = {10.1701/4062.40460}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164234349&doi=10.1701%2f4062.40460&partnerID=40&md5=1ee8e6ca6a774e3307badb69a38997ec}, - abstract = {Small cell lung cancer (SCLC) represents one of the most complex challenges in the oncological field, with a very slow advancement in research, contrary to the rapid evolutionary of the disease. For nearly two years, the mainstay of treatment for extensive-stage disease (ES-SCLC) has been the combination of platinum-based chemotherapy and immunotherapy, following the approval of atezolizumab and subsequently durvalumab, based on a modest, but significant improvement in overall survival compared to chemotherapy alone. The poor prognosis after the failure of first-line treatment explains the need to maximize the duration and efficacy of up-front systemic therapies, in particular, the emerging role of radiotherapy, also in ES-SCLC. On 10 November 2022, a meeting concerning the integrated treatment of patients with ES-SCLC was held in Rome and was attended by 12 specialists in oncology and radiotherapy from various centers in Lazio, under the direction of Federico Cappuzzo, Emilio Bria and Sara Ramella. The aim of the meeting was to share their clinical experience and to provide a series of practical indications in order to support physicians in the correct integration between first-line chemo-immunotherapy and radiotherapy treatments in ES-SCLC. © 2023 Il Pensiero Scientifico Editore s.r.l.. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Portal2024, - author = {Portal, Daniella and Lu, Shou-En and Piperdi, Huzaifa and Jabbour, Salma K. and Reyhan, Meral}, - title = {Adaptive Lung Radiation Therapy in the Era of Immunotherapy: A Single-Center Retrospective Study}, - year = {2024}, - journal = {Advances in Radiation Oncology}, - volume = {9}, - number = {1}, - doi = {10.1016/j.adro.2023.101315}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85171536564&doi=10.1016%2fj.adro.2023.101315&partnerID=40&md5=792ba806e54e202e7cbfb1e015b45c8b}, - abstract = {Purpose: Treatment for locally advanced non-small cell lung cancer consists of concurrent chemoradiation followed by immunotherapy. Though this combination has been shown to have a benefit in both progression-free survival and overall survival, treatment is often limited by the development of pneumonitis. One way to mitigate toxicity is through adaptive radiation therapy, which does not currently have a standardized implementation in clinical practice. Methods and Materials: A single-center retrospective review of patients with locally advanced stage III or oligometastatic stage IV non-small cell lung cancer who were treated with chemoradiation with concurrent or subsequent immunotherapy from 2015 to 2020 was performed. Patients were stratified based on having 1 or more offline adapted plan. The aim of this study was to evaluate the association between dose-volume histogram values and common toxicities experienced during this treatment, including pneumonitis and esophagitis. Results: Twenty-five patients were included in the final analysis: 10 with adapted plans (AP), and 15 with nonadapted plans (NAP). Mean age at onset was 74 years. The most common histology was adenocarcinoma (N = 13). Five patients experienced pneumonitis: 2 in AP and 3 in NAP. Mann-Whitney U test of gross tumor volume sizes between AP (346.2 ± 269.7 cm3) and NAP (153.1 ± 99.6 cm3) was significant (P = .019). Multiple linear regression analysis with adjustment for covariates of pneumonitis versus plan adaptation (P = .106) and esophagitis versus plan adaptation (P = .59) did not demonstrate a significant difference in toxicity between the adapted and nonadaptive patients. Conclusions: Despite similar toxicities in both groups, the gross tumor volume size in the AP was more than double compared with NAP, suggesting that adaptive techniques provide a method for patients with larger target volumes to be treated without an observed difference in pneumonitis rates. These results suggest adaptive radiation therapy may have a role in mitigating toxicity experience from chemoradiation and immunotherapy and warrants further investigation. © 2023 The Authors}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Ye2023, - author = {Ye, Wei and Li, Meiye and Luo, Kewang}, - title = {Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer}, - year = {2023}, - journal = {Pharmaceutics}, - volume = {15}, - number = {7}, - doi = {10.3390/pharmaceutics15071788}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85166292773&doi=10.3390%2fpharmaceutics15071788&partnerID=40&md5=e31d5f03261053d838fdf98aa2528eb4}, - abstract = {The tumor microenvironment (TME) plays critical roles in immune modulation and tumor malignancies in the process of cancer development. Immune cells constitute a significant component of the TME and influence the migration and metastasis of tumor cells. Recently, a number of therapeutic approaches targeting immune cells have proven promising and have already been used to treat different types of cancer. In particular, PD-1 and PD-L1 inhibitors have been used in the first-line setting in non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%, as approved by the FDA. In this review, we provide an introduction to the immune cells in the TME and their efficacies, and then we discuss current immunotherapies in NSCLC and scientific research progress in this field. © 2023 by the authors.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Li2023, - author = {Li, Yuying and Jing, Wang and Jing, Xuquan and Sun, Yulan and Tang, Xiaoyong and Guo, Jun and Zhang, Yan and Zhu, Hui}, - title = {Role of consolidative thoracic radiation in extensive-stage small-cell lung cancer with first-line chemoimmunotherapy: a retrospective study from a single cancer center}, - year = {2023}, - journal = {Discover Oncology}, - volume = {14}, - number = {1}, - doi = {10.1007/s12672-023-00666-7}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85158842938&doi=10.1007%2fs12672-023-00666-7&partnerID=40&md5=1b69bb6f5724bfdb5517eea30a9a397c}, - abstract = {Objective: To investigate the role of consolidative thoracic radiation (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line chemo-immunotherapy followed by immunotherapy maintenance. Patients and methods: Outcomes of patients without disease progression after first-line chemotherapy were retrospectively reviewed (January 2020 to December 2021). Based on TRT or not, patients were allocated to TRT group or non-TRT group. Progression-free survival (PFS), overall survival (OS) and local-recurrence free survival (LRFS) were calculated by the Kaplan–Meier method and compared by log-rank test. Results: Of 100 patients, 47 received TRT and 53 non-TRT. The median follow-up was 20.3 months. The median PFS and OS in TRT were 9.1 months and 21.8 months, versus 8.8 months (p = 0.93) and 24.3 months (p = 0.63), respectively, in non-TRT. The median LRFS time in TRT was not reached, but significantly longer than 10.8 months in non-TRT (HR = 0.27, p < 0.01). Second-line chemotherapy significantly prolonged survival compared to that with chemo-free patients (mOS: 24.5 vs. 21.4 months, p = 0.026). The subgroup analysis showed a trend of patients with brain metastases benefit from TRT (21.8 versus 13.7 months, HR 0.61, p = 0.38) while liver metastases did not. Of 47 patients with TRT, only 10.6% of patients experienced grade 3 radiation-induced pneumonitis, while no grade 4 or 5 adverse events occurred. Conclusion: Consolidative TRT in the period of immunotherapy maintenance followed first-line chemo-immunotherapy did not prolong OS and PFS but associated with improved LRFS in ES-SCLC. © 2023, The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 5; All Open Access, Gold Open Access} -} - -@ARTICLE{Yang2023207, - author = {Yang, Fujun and Zhao, Huan}, - title = {Progress in radiotherapy for small-cell lung cancer}, - year = {2023}, - journal = {Precision Radiation Oncology}, - volume = {7}, - number = {3}, - pages = {207 – 217}, - doi = {10.1002/pro6.1205}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85166408423&doi=10.1002%2fpro6.1205&partnerID=40&md5=c2e848d8f7a3ba8dbd650b535867e95f}, - abstract = {Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor that is prone to spread extensively. Compared to non-small-cell lung cancer (NSCLC), SCLC treatment progresses slowly. Although SCLC is highly sensitive to chemotherapy during the initial treatment, most patients still experience resistance and recurrence after receiving chemotherapy. A meta-analysis demonstrated that thoracic radiotherapy (TRT) improves overall survival in SCLC. The results of the CALGB and CONVERT trials provide evidence for the efficacy of once-daily high-dose TRT. TRT at 60 Gy administered twice daily significantly improved survival without increasing toxicity. The long-standing debate over the optimal timing of radiotherapy has not been fully resolved. SBRT has excellent local control rates and is a safe and effective treatment option for patients with stage I or II SCLC. Prophylactic cranial irradiation (PCI) is used to reduce treatment-related neurotoxicity to the extent that there has been a recent discussion on whether magnetic resonance imaging (MRI) monitoring can replace PCI. Radiotherapy combined with immunotherapy significantly improves the survival rate of patients with NSCLC; however, its clinical effectiveness has not been systematically explored in patients with SCLC. Therefore, we summarize the evolving therapeutic strategies, (TRT for limited stage-SCLC and consolidative TRT for extensive stage-SCLC) and improved radiotherapy techniques (role of SBRT in stage I or II node-negative SCLC, progress of PCI, and stereotactic radiosurgery), and discuss the possibilities and prospects of radiotherapy combined with immunotherapy for SCLC. © 2023 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Gold Open Access} -} - -@ARTICLE{Stella2023, - author = {Stella, Giulia Maria and Lettieri, Sara and Piloni, Davide and Ferrarotti, Ilaria and Perrotta, Fabio and Corsico, Angelo Guido and Bortolotto, Chandra}, - title = {Smart Sensors and Microtechnologies in the Precision Medicine Approach against Lung Cancer}, - year = {2023}, - journal = {Pharmaceuticals}, - volume = {16}, - number = {7}, - doi = {10.3390/ph16071042}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85166290874&doi=10.3390%2fph16071042&partnerID=40&md5=4137f883e45d7fe9b299c6ca31e0fd55}, - abstract = {Background and rationale. The therapeutic interventions against lung cancer are currently based on a fully personalized approach to the disease with considerable improvement of patients’ outcome. Alongside continuous scientific progresses and research investments, massive technologic efforts, innovative challenges, and consolidated achievements together with research investments are at the bases of the engineering and manufacturing revolution that allows a significant gain in clinical setting. Aim and methods. The scope of this review is thus to focus, rather than on the biologic traits, on the analysis of the precision sensors and novel generation materials, as semiconductors, which are below the clinical development of personalized diagnosis and treatment. In this perspective, a careful revision and analysis of the state of the art of the literature and experimental knowledge is presented. Results. Novel materials are being used in the development of personalized diagnosis and treatment for lung cancer. Among them, semiconductors are used to analyze volatile cancer compounds and allow early disease diagnosis. Moreover, they can be used to generate MEMS which have found an application in advanced imaging techniques as well as in drug delivery devices. Conclusions. Overall, these issues represent critical issues only partially known and generally underestimated by the clinical community. These novel micro-technology-based biosensing devices, based on the use of molecules at atomic concentrations, are crucial for clinical innovation since they have allowed the recent significant advances in cancer biology deciphering as well as in disease detection and therapy. There is an urgent need to create a stronger dialogue between technologists, basic researchers, and clinicians to address all scientific and manufacturing efforts towards a real improvement in patients’ outcome. Here, great attention is focused on their application against lung cancer, from their exploitations in translational research to their application in diagnosis and treatment development, to ensure early diagnosis and better clinical outcomes. © 2023 by the authors.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Gold Open Access} -} - -@ARTICLE{Petrella20233160, - author = {Petrella, Francesco and Rizzo, Stefania and Attili, Ilaria and Passaro, Antonio and Zilli, Thomas and Martucci, Francesco and Bonomo, Luca and Del Grande, Filippo and Casiraghi, Monica and De Marinis, Filippo and Spaggiari, Lorenzo}, - title = {Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options}, - year = {2023}, - journal = {Current Oncology}, - volume = {30}, - number = {3}, - pages = {3160 – 3175}, - doi = {10.3390/curroncol30030239}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85151137181&doi=10.3390%2fcurroncol30030239&partnerID=40&md5=98bf5efa334b5e3cdc92af5f0ab57aa6}, - abstract = {Lung cancer is the second-most commonly diagnosed cancer and the leading cause of cancer death worldwide. The most common histological type is non-small-cell lung cancer, accounting for 85% of all lung cancer cases. About one out of three new cases of non-small-cell lung cancer are diagnosed at a locally advanced stage—mainly stage III—consisting of a widely heterogeneous group of patients presenting significant differences in terms of tumor volume, local diffusion, and lymph nodal involvement. Stage III NSCLC therapy is based on the pivotal role of multimodal treatment, including surgery, radiotherapy, and a wide-ranging option of systemic treatments. Radical surgery is indicated in the case of hilar lymphnodal involvement or single station mediastinal ipsilateral involvement, possibly after neoadjuvant chemotherapy; the best appropriate treatment for multistation mediastinal lymph node involvement still represents a matter of debate. Although the main scope of treatments in this setting is potentially curative, the overall survival rates are still poor, ranging from 36% to 26% and 13% in stages IIIA, IIIB, and IIIC, respectively. The aim of this article is to provide an up-to-date, comprehensive overview of the state-of-the-art treatments for stage III non-small-cell lung cancer. © 2023 by the authors.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 20; All Open Access, Gold Open Access} -} - -@ARTICLE{Zhou20242719, - author = {Zhou, Rui and Liu, FangJie and Zhang, HongMei and Wang, DaQuan and Zhang, PengXin and Zheng, ShiYang and Liu, YiMei and Chen, Li and Guo, JinYu and Zou, YingYi and Rong, Yu-Ming and Liu, Hui and Qiu, Bo}, - title = {Fraction Dose Escalation of Hypofractionated Radiotherapy with Concurrent Chemotherapy and Subsequent Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer: A Phase I Study}, - year = {2024}, - journal = {Clinical Cancer Research}, - volume = {30}, - number = {13}, - pages = {2719 – 2728}, - doi = {10.1158/1078-0432.CCR-23-3600}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85197962338&doi=10.1158%2f1078-0432.CCR-23-3600&partnerID=40&md5=f7e3504a4eee1b917269a5ed3cf266b9}, - abstract = {Purpose: This phase I trial aimed to determine the maximum tolerated fraction dose (MTFD) of hypofractionated radiotherapy (hypo-RT) combined with concurrent chemotherapy and subsequent consolidation immune checkpoint inhibitors (cICI) for patients with locally advanced non-small cell lung cancer. Patients and Methods: Split-course hypo-RT and hypoboost combined with concurrent chemotherapy was administered at three dose levels (DL), using a stepwise dose-escalation protocol. The sophisticated esophagus-sparing technique was implemented to restrict the dose to the esophagus. Patients who did not experience disease progression or unresolved ≥grade 2 (G2+) toxicities after RT received cICI. Each DL aimed to treat six patients. The MTFD was defined as the highest DL at which ≤2 patients of the six who were treated experienced treatment-related G3+ toxicity and ≤1 patient experienced G4+ toxicity within 12 months post-RT. Results: Eighteen patients were enrolled, with six patients in each DL. All patients completed hypo-RT and concurrent chemotherapy, and 16 (88.9%) received at least one infusion of cICI, with a median of 10 infusions. Within the 12-month assessment period, one patient in DL1 experienced G3 pneumonitis, and one patient in DL3 developed G3 tracheobronchitis. The MTFD was not reached. The objective response rate was 100%. With a median follow-up of 20.9 months, the 1-year overall survival and progression-free survival rates were 94.4% and 83.3%, respectively. Conclusions: Utilizing the split-course hypo-RT and hypoboost approach, a fraction dose of 5 Gy to a total dose of 60 Gy, combined with concurrent chemotherapy and subsequent cICI, was well tolerated and yielded a promising objective response rate and survival outcomes. © 2024 American Association for Cancer Research.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Yu20232243, - author = {Yu, Ying and Chen, Kaiyan and Fan, Yun}, - title = {Extensive-stage small-cell lung cancer: Current management and future directions}, - year = {2023}, - journal = {International Journal of Cancer}, - volume = {152}, - number = {11}, - pages = {2243 – 2256}, - doi = {10.1002/ijc.34346}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142936683&doi=10.1002%2fijc.34346&partnerID=40&md5=3ef72f9520818700133ee63eb64e9713}, - abstract = {Extensive-stage small-cell lung cancer (ES-SCLC) is regarded as a refractory carcinoma associated with extremely rapid disease progression. After more than three decades without clinical advances, research on immune checkpoint inhibitors (ICIs) combined with platinum-based chemotherapy has led to the first treatment breakthrough, establishing a new standard for the first-line treatment of ES-SCLC. Further studies have extensively evaluated small-molecule antiangiogenic drugs, PARP inhibitors, as well as lurbinectedin in SCLC and have demonstrated some benefit, although no breakthroughs have been made. In addition, newer therapeutic strategies with targeted agents, novel chemotherapeutics and immunotherapies are evolving as they are being actively explored and hold promise for patients with this disease. Notably, the preliminary identification of SCLC molecular subtypes driven by the expression of dominant transcription factors with RNA sequencing profiles has made it possible to identify molecularly tailored therapeutic approaches, which increases the potential for individualized precision treatment of SCLC. In this review, we summarize recent research advances in ES-SCLC, outline the current management of this disease and reflect on directions for future development. © 2022 UICC.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 11} -} - -@ARTICLE{Aldea2023576, - author = {Aldea, Mihaela and Marinello, Arianna and Duruisseaux, Michael and Zrafi, Wael and Conci, Nicole and Massa, Giacomo and Metro, Giulio and Monnet, Isabelle and Gomez Iranzo, Patricia and Tabbo, Fabrizio and Bria, Emilio and Guisier, Florian and Vasseur, Damien and Lindsay, Colin R. and Ponce-Aix, Santiago and Cousin, Sophie and Citarella, Fabrizio and Fallet, Vincent and Minatta, Jose Nicolas and Eisert, Anna and de Saint Basile, Hortense and Audigier-Valette, Clarisse and Mezquita, Laura and Calles, Antonio and Mountzios, Giannis and Tagliamento, Marco and Remon Masip, Jordi and Raimbourg, Judith and Terrisse, Safae and Russo, Alessandro and Cortinovis, Diego and Rochigneux, Philippe and Pinato, David James and Cortellini, Alessio and Leonce, Camille and Gazzah, Anas and Ghigna, Maria-Rosa and Ferrara, Roberto and Dall'Olio, Filippo Gustavo and Passiglia, Francesco and Ludovini, Vienna and Barlesi, Fabrice and Felip, Enriqueta and Planchard, David and Besse, Benjamin}, - title = {RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion}, - year = {2023}, - journal = {Journal of Thoracic Oncology}, - volume = {18}, - number = {5}, - pages = {576 – 586}, - doi = {10.1016/j.jtho.2022.12.018}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149658996&doi=10.1016%2fj.jtho.2022.12.018&partnerID=40&md5=db8856b54cadba7618cbc697e432081c}, - abstract = {Introduction: Nearly 1% to 2% of NSCLCs harbor RET fusions. Characterization of this rare population is still incomplete. Methods: This retrospective multicenter study included patients with any-stage RET positive (RET+) NSCLC from 31 cancer centers. Molecular profiling included DNA/RNA sequencing or fluorescence in situ hybridization analyses. Clinicobiological features and treatment outcomes (per investigator) with surgery, chemotherapy (CT), immune checkpoint blockers (ICBs), CT-ICB, multityrosine kinase inhibitors, and RET inhibitors (RETis) were evaluated. Results: For 218 patients included between February 2012 and April 2022, median age was 63 years, 56% were females, 93% had adenocarcinoma, and 41% were smokers. The most frequent fusion partner was KIF5B (72%). Median tumor mutational burden was 2.5 (range: 1–4) mutations per megabase, and median programmed death-ligand 1 expression was 10% (range: 0%–55%). The most common metastatic sites were the lung (50%), bone (43%), and pleura (40%). Central nervous system metastases were found at diagnosis of advanced NSCLC in 21% of the patients and at last follow-up or death in 31%. Overall response rate and median progression-free survival were 55% and 8.7 months with platinum doublet, 26% and 3.6 months with single-agent CT, 46% and 9.6 months with CT-ICB, 23% and 3.1 months with ICB, 37% and 3 months with multityrosine kinase inhibitor, and 76% and 16.2 months with RETi, respectively. Median overall survival was longer in patients treated with RETi versus no RETi (50.6 mo [37.7–72.1] versus 16.3 mo [12.7–28.8], p < 0.0001). Conclusions: Patients with RET+ NSCLC have mainly thoracic and bone disease and low tumor mutational burden and programmed death-ligand 1 expression. RETi markedly improved survival, whereas ICB may be active in selected patients. © 2023 International Association for the Study of Lung Cancer}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 23; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Ouyang2024, - author = {Ouyang, Peng and Wang, Lijuan and Wu, Jianlong and Tian, Yao and Chen, Caiyun and Li, Dengsheng and Yao, Zengxi and Chen, Ruichang and Xiang, Guoan and Gong, Jin and Bao, Zhen}, - title = {Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors}, - year = {2024}, - journal = {Frontiers in Immunology}, - volume = {15}, - doi = {10.3389/fimmu.2024.1344272}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85188601134&doi=10.3389%2ffimmu.2024.1344272&partnerID=40&md5=3a971195a0b9de94be89783786dcf45a}, - abstract = {Immune Checkpoint Inhibitors (ICIs) therapy has advanced significantly in treating malignant tumors, though most ‘cold’ tumors show no response. This resistance mainly arises from the varied immune evasion mechanisms. Hence, understanding the transformation from ‘cold’ to ‘hot’ tumors is essential in developing effective cancer treatments. Furthermore, tumor immune profiling is critical, requiring a range of diagnostic techniques and biomarkers for evaluation. The success of immunotherapy relies on T cells’ ability to recognize and eliminate tumor cells. In ‘cold’ tumors, the absence of T cell infiltration leads to the ineffectiveness of ICI therapy. Addressing these challenges, especially the impairment in T cell activation and homing, is crucial to enhance ICI therapy’s efficacy. Concurrently, strategies to convert ‘cold’ tumors into ‘hot’ ones, including boosting T cell infiltration and adoptive therapies such as T cell-recruiting bispecific antibodies and Chimeric Antigen Receptor (CAR) T cells, are under extensive exploration. Thus, identifying key factors that impact tumor T cell infiltration is vital for creating effective treatments targeting ‘cold’ tumors. Copyright © 2024 Ouyang, Wang, Wu, Tian, Chen, Li, Yao, Chen, Xiang, Gong and Bao.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Fang2023423, - author = {Fang, Min and Wang, Le and Gu, Qing and Wu, Huiwen and Du, Xianghui and Lai, Xiaojing}, - title = {Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world}, - year = {2023}, - journal = {Clinical and Experimental Metastasis}, - volume = {40}, - number = {5}, - pages = {423 – 429}, - doi = {10.1007/s10585-023-10227-5}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85168120278&doi=10.1007%2fs10585-023-10227-5&partnerID=40&md5=9651d57edb098be9c2839d16fb7985dd}, - abstract = {The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive-stage small lung cancer (ES-SCLC). The CREST trial reported consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for ES-SCLC with intrathoracic residual after chemotherapy. In this study, patients with ES-SCLC who received immunotherapy were assigned to receive either TRT or no TRT. TRT significantly improved progression-free survival (PFS), local recurrence-free survival (LRFS) and OS with well tolerated toxicity. Further sub-cohort analysis, TRT significantly improved LRFS in patients with oligo-metastasis and without liver metastasis. © 2023, The Author(s), under exclusive licence to Springer Nature B.V.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Green Open Access} -} - -@ARTICLE{Wang2023590, - author = {Wang, Yu and Zhang, Tao and Wang, Jianyang and Zhou, Zongmei and Liu, Wenyang and Xiao, Zefen and Deng, Lei and Feng, Qinfu and Wang, Xin and Lv, Jima and Ma, Xiangyu and Xue, Qi and Wang, Jie and Wang, Zhijie and Bi, Nan}, - title = {Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer}, - year = {2023}, - journal = {International Journal of Radiation Oncology Biology Physics}, - volume = {116}, - number = {3}, - pages = {590 – 600}, - doi = {10.1016/j.ijrobp.2022.12.042}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85147388925&doi=10.1016%2fj.ijrobp.2022.12.042&partnerID=40&md5=d8de0c3ab00986a62fb381d8f0858f83}, - abstract = {Purpose: In the era of immunotherapy, the treatment for bulky, locally advanced non-small cell lung cancer (LA-NSCLC) remains challenging. This study explored the feasibility of induction immune checkpoint inhibitors (ICIs) plus chemotherapy before definitive chemoradiation therapy (CRT) for bulky LA-NSCLC. Methods and Materials: Patients with bulky, unresectable stage III NSCLC (primary tumor ≥5 cm in greatest dimension or metastatic lymph nodes ≥2 cm in shortest diameter) receiving ICIs and chemotherapy before CRT from 2018 to 2022 were identified. Survival outcomes and toxic effects were analyzed. Radiation therapy plans on computed tomography images before and after 2 cycles of induction chemoimmunotherapy were simulated to evaluate dosimetric outcomes. Results: Seventy-five patients were included. One- and 2-year overall-survival (OS) rates were 91.5% (95% CI, 85.2%-98.3%) and 75.1% (95% CI, 64.1%-88.0%), respectively. One- and 2-year progression-free-survival (PFS) rates were 85.8% (95% CI, 78.0%-94.4%) and 64.2% (95% CI, 52.5%-78.6%), respectively. Median OS was not reached (NR). Median PFS was 30.6 months (95% CI, 25.9 months to NR). Grade 2 and ≥3 pneumonitis occurred in 26.7% and 9.3% of patients, respectively. Grade ≥3 pneumonitis was significantly associated with poorer OS (P = .003) and PFS (P = .018). Treatment discontinuation was significantly associated with shorter OS (P = .023) and PFS (P = .047). Patients with consolidation ICIs exhibited numerically better OS than those without consolidation ICIs (2-year OS, 85.8% vs 64.2%; P = .170). The objective response rate was 76.1% for induction treatment and 86.7% for induction treatment plus CRT. The disease control rate after 2 cycles of induction therapy was significantly greater than after 4 (P = .046) or more cycles (P = .025). Simulated radiation plans indicated that all target volumes, mean lung dose, and volume of lung parenchyma receiving ≥5 Gy, ≥20 Gy, and ≥30 Gy significantly decreased after 2 cycles (all P < .005). Conclusions: Two cycles of induction ICIs plus chemotherapy before definitive CRT were feasible for bulky LA-NSCLC, with significant tumor reduction and normal lung protection. Further investigations on CRT combined with induction and consolidation ICIs are warranted. © 2023 Elsevier Inc.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 14} -} - -@ARTICLE{Lim202310396, - author = {Lim, Chloe Ahryung and Ghosh, Sunita and Morrison, Hali and Meyers, Daniel and Stukalin, Igor and Kerba, Marc and Hao, Desiree and Pabani, Aliyah}, - title = {Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study}, - year = {2023}, - journal = {Current Oncology}, - volume = {30}, - number = {12}, - pages = {10396 – 10407}, - doi = {10.3390/curroncol30120757}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85180654079&doi=10.3390%2fcurroncol30120757&partnerID=40&md5=8a37b35dabb77e7c86aa0c8aa19af295}, - abstract = {The PACIFIC trial led to a new standard of care for patients with locally advanced lung cancer, but real-world practice has demonstrated that immune checkpoint inhibitor (ICI) pneumonitis can lead to significant clinical complications. This study aimed to examine the clinical predictors, outcomes, and healthcare utilization data in patients who received consolidation durvalumab. Using the Alberta Immunotherapy Database, NSCLC patients who received durvalumab in Alberta, Canada, from January 2018 to December 2021 were retrospectively evaluated. We examined incidence and predictive values of severe pneumonitis, with overall survival (OS) and time-to-treatment failure (TTF) using exploratory multivariate analyses. Of 189 patients, 91% were ECOG 0–1 and 85% had a partial response from chemoradiation prior to durvalumab. Median TTF and OS were not reached; 1-year OS was 82%. An amount of 26% developed any grade of pneumonitis; 9% had ≥grade 3 pneumonitis. Male gender and a pre-existing autoimmune condition were associated with severe pneumonitis. V20 was associated with any grade of pneumonitis. Pneumonitis development was found to be an independent risk factor for worse OS (p = 0.038) and TTF (p = 0.007). Our results suggest clinical and dosimetric predictive factors of durvalumab-associated pneumonitis. These results affirm the importance of careful patient selection for safe completion of consolidation durvalumab in real-world LA-NSCLC population. © 2023 by the authors.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Yang20231910, - author = {Yang, Haiou and Li, Xuewei and Yang, Wenhui}, - title = {Advances in targeted therapy and immunotherapy for esophageal cancer}, - year = {2023}, - journal = {Chinese Medical Journal}, - volume = {136}, - number = {16}, - pages = {1910 – 1922}, - doi = {10.1097/CM9.0000000000002768}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85168428048&doi=10.1097%2fCM9.0000000000002768&partnerID=40&md5=ce4fca7573657345c3a364720aa76ec5}, - abstract = {Esophageal cancer (EC) is one of the most common aggressive malignant tumors in the digestive system with a severe epidemiological situation and poor prognosis. The early diagnostic rate of EC is low, and most EC patients are diagnosed at an advanced stage. Multiple multimodality treatments have gradually evolved into the main treatment for advanced EC, including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. And the emergence of targeted therapy and immunotherapy has greatly improved the survival of EC patients. This review highlights the latest advances in targeted therapy and immunotherapy for EC, discusses the efficacy and safety of relevant drugs, summarizes related important clinical trials, and tries to provide references for therapeutic strategy of EC. © 2023 Lippincott Williams and Wilkins. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 6; All Open Access, Gold Open Access} -} - -@ARTICLE{Hashimoto20241541, - author = {Hashimoto, Kosuke and Kaira, Kyoichi and Imai, Hisao and Miura, Yu and Shiono, Ayako and Mouri, Atsuto and Yamaguchi, Ou and Kobayashi, Kunihiko and Kagamu, Hiroshi and Kuji, Ichiei}, - title = {Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer}, - year = {2024}, - journal = {Anticancer Research}, - volume = {44}, - number = {4}, - pages = {1541 – 1551}, - doi = {10.21873/anticanres.16951}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85189179131&doi=10.21873%2fanticanres.16951&partnerID=40&md5=82b2eef695d057056a9e39dc682e1be5}, - abstract = {Background/Aim: Chemo-immunotherapy, including the programmed death ligand 1 (PD-L1) antibody, is an effective treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC). However, no biomarker has been established for the prediction of chemo-immunotherapy. Therefore, we investigated the potential of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) as a predictive marker. Patients and Methods: Forty-six patients with ES-SCLC who received 18F-FDG-PET immediately before combined platinum-based chemotherapy with PD-L1 blockade as a first-line treatment were eligible, and the maximum standard uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) on 18F-FDG uptake were evaluated. Results: PD-L1 and tumor infiltrative lymphocytes (TILs) were immunohistochemically analyzed in 36 of the 46 patients. A high MTV was significantly associated with poor performance status and low albumin levels, and there was a significant association between low albumin and high TLG. Univariate analysis identified sex, Brinkman index, and MTV as significant predictors of progression-free survival (PFS), and sex, SUVmax, MTV, and TLG as significant factors of overall survival (OS). Multivariate analysis revealed that sex, Brinkman index, and MTV were independent prognostic factors for PFS, and sex, SUVmax, MTV, and TLG were significant predictors of OS. SUVmax was significantly higher in patients with positive PD-L1 expression than in those with negative expression but was not significantly different between positive and negative TILs. Moreover, the levels of MTV and TLG were not closely associated with the levels of PD-L1 and TILs. Conclusion: MTV or TLG metabolic tumor activity is suitable for the prediction of chemo-immunotherapy outcomes in patients with ES-SCLC. © 2024 International Institute of Anticancer Research. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Green Open Access} -} - -@ARTICLE{Girigoswami2023, - author = {Girigoswami, Agnishwar and Girigoswami, Koyeli}, - title = {Potential Applications of Nanoparticles in Improving the Outcome of Lung Cancer Treatment}, - year = {2023}, - journal = {Genes}, - volume = {14}, - number = {7}, - doi = {10.3390/genes14071370}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165943800&doi=10.3390%2fgenes14071370&partnerID=40&md5=0ff2a482ec6d79b01de9c4bbbfa548fe}, - abstract = {Lung cancer is managed using conventional therapies, including chemotherapy, radiation therapy, or a combination of both. Each of these therapies has its own limitations, such as the indiscriminate killing of normal as well as cancer cells, the solubility of the chemotherapeutic drugs, rapid clearance of the drugs from circulation before reaching the tumor site, the resistance of cancer cells to radiation, and over-sensitization of normal cells to radiation. Other treatment modalities include gene therapy, immunological checkpoint inhibitors, drug repurposing, and in situ cryo-immune engineering (ICIE) strategy. Nanotechnology has come to the rescue to overcome many shortfalls of conventional therapies. Some of the nano-formulated chemotherapeutic drugs, as well as nanoparticles and nanostructures with surface modifications, have been used for effective cancer cell killing and radio sensitization, respectively. Nano-enabled drug delivery systems act as cargo to deliver the sensitizer molecules specifically to the tumor cells, thereby enabling the radiation therapy to be more effective. In this review, we have discussed the different conventional chemotherapies and radiation therapies used for inhibiting lung cancer. We have also discussed the improvement in chemotherapy and radiation sensitization using nanoparticles. © 2023 by the authors.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Murphy2023409, - author = {Murphy, David J. and Mayoral, Maria and Larici, Anna R. and Ginsberg, Michelle S. and Cicchetti, Giuseppe and Fintelmann, Florian J. and Marom, Edith M. and Truong, Mylene T. and Gill, Ritu R.}, - title = {Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer: AJR Expert Panel Narrative Review}, - year = {2023}, - journal = {American Journal of Roentgenology}, - volume = {221}, - number = {4}, - pages = {409 – 424}, - doi = {10.2214/AJR.23.29104}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165232783&doi=10.2214%2fAJR.23.29104&partnerID=40&md5=94243db89430367daf371bbb5605a0e8}, - abstract = {Lung cancer continues to be the most common cause of cancer-related death worldwide. In the past decade, with the implementation of lung cancer screening programs and advances in surgical and nonsurgical therapies, the survival of patients with lung cancer has increased, as has the number of imaging studies that these patients undergo. However, most patients with lung cancer do not undergo surgical resection, because they have comorbid disease or lung cancer in an advanced stage at diagnosis. Nonsurgical therapies have continued to evolve with a growing range of systemic and targeted therapies, and there has been an associated evolution in the imaging findings encountered at follow-up examinations after such therapies (e.g., with respect to posttreatment changes, treatment complications, and recurrent tumor). This AJR Expert Panel Narrative Review describes the current status of nonsurgical therapies for lung cancer and their expected and unexpected imaging manifestations. The goal is to provide guidance to radiologists regarding imaging assessment after such therapies, focusing mainly on non-small cell lung cancer. Covered therapies include systemic therapy (conventional chemotherapy, targeted therapy, and immunotherapy), radiotherapy, and thermal ablation. © 2023 American Roentgen Ray Society. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4; All Open Access, Green Open Access} -} - -@ARTICLE{Peng2023, - author = {Peng, Jianfeng and Zhang, Lemeng and Wang, Liping and Feng, Hui and Yao, Dongmei and Meng, Rui and Liu, Xiaomei and Li, Xiaohua and Liu, Ningbo and Tan, Bingxu and Huang, Zhaoqin and Li, Shanshan and Meng, Xiangjiao}, - title = {Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer}, - year = {2023}, - journal = {Radiation Oncology}, - volume = {18}, - number = {1}, - doi = {10.1186/s13014-023-02308-2}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164117322&doi=10.1186%2fs13014-023-02308-2&partnerID=40&md5=6919f276409f282d9217b7128800c59f}, - abstract = {Background: The CREST study showed that the addition of thoracic radiotherapy (TRT) could improve the survival rate in patients with extensive stage small cell lung cancer (ES-SCLC), but whether TRT can bring survival benefit in the era of immunotherapy remains controversial. This study aimed to explore the efficacy and safety of adding TRT to the combination of PD-L1 inhibitors and chemotherapy. Methods: The patients who received durvalumab or atezolizumab combined with chemotherapy as the first-line treatment of ES-SCLC from January 2019 to December 2021 were enrolled. They were divided into two groups, based on whether they received TRT or not. Propensity score matching (PSM) with a 1:1 ratio was performed. The primary endpoints were progression-free survival (PFS), overall survival (OS) and safety. Results: A total of 211 patients with ES-SCLC were enrolled, of whom 70 (33.2%) patients received standard therapy plus TRT as first-line treatment, and 141 (66.8%) patients in the control group received PD-L1 inhibitors plus chemotherapy. After PSM, a total of 57 pairs of patients were enrolled in the analysis. In all patients, the median PFS (mPFS) in the TRT and non-TRT group was 9.5 and 7.2 months, respectively, with HR = 0.59 (95%CI 0.39–0.88, p = 0.009). The median OS (mOS) in the TRT group was also significantly longer than that in the non-TRT group (24.1 months vs. 18.5 months, HR = 0.53, 95%CI 0.31–0.89, p = 0.016). Multivariable analysis showed that baseline liver metastasis and the number of metastases ≥ 3 were independent prognostic factors for OS. Addition of TRT increased the incidence of treatment-related pneumonia (p = 0.018), most of which were grade 1–2. Conclusions: Addition of TRT to durvalumab or atezolizumab plus chemotherapy significantly improves survival in ES-SCLC. Although it may leads to increased incidence of treatment-related pneumonia, a majority of the cases can be relieved after symptomatic treatment. © 2023, The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 8; All Open Access, Gold Open Access} -} - -@ARTICLE{Yao2023111, - author = {Yao, Yuanhu and Yao, Nan and Qin, Zhaohui and Ma, Ji and Lu, Jiaying and Cui, Li and Qu, Wanxi and Yuan, Shiwang and Tong, Shaodong and Li, Na and Li, Hao}, - title = {Extensive-stage small cell lung cancer: Is prophylactic cranial irradiation necessary in the era of immunotherapy with MRI surveillance?}, - year = {2023}, - journal = {Precision Radiation Oncology}, - volume = {7}, - number = {2}, - pages = {111 – 117}, - doi = {10.1002/pro6.1200}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85162720330&doi=10.1002%2fpro6.1200&partnerID=40&md5=dd528876fda96ae8bd0818b3da47125e}, - abstract = {Objective: The role of prophylactic cranial irradiation (PCI) in treating extensive-stage small-cell lung cancer (ES-SCLC) has been controversial. This study aimed to comprehensively analyze the efficacy of PCI for the treatment of ES-SCLC under active brain magnetic resonance imaging (MRI) surveillance. Methods: Patients with ES-SCLC with no brain metastases (BM) confirmed by MRI at the time of diagnosis who responded well to first-line chemoimmunotherapy at three general hospitals were retrospectively included. Overall survival (OS), progression-free survival (PFS), and cumulative incidence of BM were compared between patients who underwent PCI and those who did not. Results: In total, 66 consecutive patients treated between March 2019 and December 2021 were included in our dataset. Seventeen patients underwent PCI (PCI group) and 49 patients did not (non-PCI group). In comparison with the non-PCI group, PCI did not provide OS (median OS: 18.53 vs. 17.35 months, p = 0.28) or PFS (median PFS: 8.61 vs. 7.56 months, p = 0.41) benefits. When death was counted as a competing risk, the difference in the cumulative incidence rate of BM was not statistically significant (1-year: 12.79% vs. 38.09%; p = 0.14). Conclusion: Compared to active MRI surveillance, first-line chemoimmunotherapy followed by PCI did not improve the prognosis of patients with ES-SCLC. Further studies are warranted to evaluate the therapeutic effects of PCI following chemoimmunotherapy. © 2023 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access} -} - -@ARTICLE{Borgeaud2023, - author = {Borgeaud, Maxime and Sandoval, Jose and Obeid, Michel and Banna, Giuseppe and Michielin, Olivier and Addeo, Alfredo and Friedlaender, Alex}, - title = {Novel targets for immune-checkpoint inhibition in cancer}, - year = {2023}, - journal = {Cancer Treatment Reviews}, - volume = {120}, - doi = {10.1016/j.ctrv.2023.102614}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85168496031&doi=10.1016%2fj.ctrv.2023.102614&partnerID=40&md5=7a59cc9058db2fed6bc882dd9c5dca1c}, - abstract = {Immune-checkpoint inhibitors have revolutionized cancer therapy, yet many patients either do not derive any benefit from treatment or develop a resistance to checkpoint inhibitors. Intrinsic resistance can result from neoantigen depletion, defective antigen presentation, PD-L1 downregulation, immune-checkpoint ligand upregulation, immunosuppression, and tumor cell phenotypic changes. On the other hand, extrinsic resistance involves acquired upregulation of inhibitory immune-checkpoints, leading to T-cell exhaustion. Current data suggest that PD-1, CTLA-4, and LAG-3 upregulation limits the efficacy of single-agent immune-checkpoint inhibitors. Ongoing clinical trials are investigating novel immune-checkpoint targets to avoid or overcome resistance. This review provides an in-depth analysis of the evolving landscape of potentially targetable immune-checkpoints in cancer. We highlight their biology, emphasizing the current understanding of resistance mechanisms and focusing on promising strategies that are under investigation. We also summarize current results and ongoing clinical trials in this crucial field that could once again revolutionize outcomes for cancer patients. © 2023 The Author(s)}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 22; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Han20241179, - author = {Han, Chong and Qiu, Jingping and Bai, Lu and Liu, Tingting and Chen, Jun and Wang, He and Dang, Jun}, - title = {Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis}, - year = {2024}, - journal = {International Journal of Radiation Oncology Biology Physics}, - volume = {119}, - number = {4}, - pages = {1179 – 1207}, - doi = {10.1016/j.ijrobp.2024.01.217}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85187351741&doi=10.1016%2fj.ijrobp.2024.01.217&partnerID=40&md5=f67202861f32868bed2f6cac8f705ab3}, - abstract = {Purpose: Chemoradiotherapy (CRT) combined with immune checkpoint inhibitors (ICIs) is the standard of care for patients with unresectable and locally advanced non-small cell lung cancer. This study aimed to determine whether the addition of ICIs to CRT is associated with an increased risk of pneumonitis. Methods and Materials: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published between January 1, 2015, and July 31, 2023. The outcome of interest was the incidence rate of pneumonitis. A random-effects model was used for statistical analysis. Results: A total of 185 studies with 24,527 patients were included. The pooled rate of grade ≥2 pneumonitis for CRT plus ICIs was significantly higher than that for CRT alone (29.6%; 95% CI, 25.7%-33.6% vs 20.2%; 95% CI, 17.7%-22.8%; P <.0001) but not that of grade ≥3 (5.7%; 95% CI, 4.8%-6.6% vs 5.6%; 95% CI, 4.7%-6.5%; P =.64) or grade 5 (0.1%; 95% CI, 0.0%-0.2% vs 0.3%; 95% CI, 0.1%-0.4%; P =.68). The results from the subgroup analyses of prospective studies, retrospective studies, Asian and non-Asian studies, concurrent CRT (cCRT), and durvalumab consolidation were comparable to the overall results. However, CRT or cCRT plus PD-1 inhibitors not only significantly increased the incidence of grade ≥2 but also that of grade ≥3 pneumonitis compared to CRT alone or cCRT plus PD-L1 inhibitors. Conclusions: Compared with CRT alone, durvalumab consolidation after CRT appears to be associated with a higher incidence of moderate pneumonitis and CRT plus PD-1 inhibitors with an increased risk of severe pneumonitis. Nevertheless, these findings are based on observational studies and need to be validated in future large head-to-head studies. © 2024 Elsevier Inc.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4} -} - -@ARTICLE{Goto2024917, - author = {Goto, Eisuke and Hattori, Aritoshi and Fukui, Mariko and Matsunaga, Takeshi and Takamochi, Kazuya and Suzuki, Kenji}, - title = {Salvage extended surgery after immune-checkpoint inhibitor treatment for advanced non-small cell lung cancer}, - year = {2024}, - journal = {Surgery Today}, - volume = {54}, - number = {8}, - pages = {917 – 926}, - doi = {10.1007/s00595-024-02812-2}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85188351679&doi=10.1007%2fs00595-024-02812-2&partnerID=40&md5=3b8ade7747472c29a7d3e4286f00cb36}, - abstract = {Purpose: We evaluated the surgical outcomes of salvage extended surgery after definitive medical treatment with an immune-checkpoint inhibitor (ICI) for locally advanced or unresectable non-small-cell lung cancer (NSCLC). Methods: The subjects of this single-center retrospective analysis were 14 patients who underwent salvage surgery after ICI treatment between May, 2017 and April, 2023 at our institute. We reviewed the comprehensive surgical outcomes, including operative procedures, intraoperative findings, and postoperative morbidities. Overall survival (OS) was calculated using a Kaplan–Meier estimation. Results: The initial clinical stage before medical treatment (c-stage) was stage III in eight patients, stage IV in five patients, and one patient had postoperative lung cancer recurrence. The indications for surgery were as follows: local control for relapse or residual tumor in ten patients and discontinuation of systemic therapy because of treatment-related complications in four patients. The surgical modes were segmentectomy (n = 1), lobectomy (n = 4), bilobectomy (n = 3), pneumonectomy (n = 6), and bronchoplasty (n = 7). Grade 3 or higher postoperative morbidities were observed in six patients, including only one case of 90-day mortality. Conclusions: Our series demonstrated that the surgical outcome of salvage extended surgery after ICI therapy may be positive with careful selection of the procedure and indication. © The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd. 2024.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1} -} - -@ARTICLE{Delasos2023e205, - author = {Delasos, Lukas and Wei, Wei and Hassan, Khaled A. and Pennell, Nathan A. and Patil, Pradnya and Stevenson, James}, - title = {Clinical Outcomes With Pembrolizumab-Based Therapies in Recurrent/Refractory NSCLC After Chemoradiation and Consolidative Durvalumab}, - year = {2023}, - journal = {Clinical Lung Cancer}, - volume = {24}, - number = {6}, - pages = {e205 – e213}, - doi = {10.1016/j.cllc.2023.04.008}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85159157653&doi=10.1016%2fj.cllc.2023.04.008&partnerID=40&md5=24c0d4005382994b18ad6545fdbb1d1c}, - abstract = {Background: Often, patients with NSCLC experience recurrent/refractory (R/R) disease within 2 years of chemoradiation (CRT) and consolidative durvalumab. Despite prior immune checkpoint inhibitor exposure, immunotherapy with or without chemotherapy is typically initiated if a driver-oncogene is absent. However, there remains a paucity of data regarding the efficacy of immunotherapy in this patient population. Here, we present survival outcomes associated with pembrolizumab for R/R NSCLC. Materials and Methods: We retrospectively assessed adults with NSCLC who received pembrolizumab for R/R disease between January 2016 to January 2023. Primary objective was to estimate OS and PFS in this cohort compared to historical outcomes. Secondary objective was to compare OS and PFS among subgroups. Results: Fifty patients were evaluated. Median follow-up time was 11.3 months (2.9-38.2). OS was 10.6 months (95% CI, 8.8-19.2); 1-year OS rate 49% (95% CI, 36 - 67%). PFS was 6.1 months (95% CI, 4.7-9.0); 1-year PFS rate 25% (95% CI, 15%-42%). Current smokers had significantly better median OS/PFS as compared to former smokers (NA vs. 10.5 and 9.9 vs. 6.0 months, respectively). The addition of chemotherapy demonstrated an OS benefit (median OS 12.9 vs. 6.0 months) but was not statistically significant. Conclusion: Patients with R/R NSCLC represent a distinct cohort with inferior survival outcomes when compared to those with de novo stage IV disease treated with pembrolizumab-based regimens. Based on our findings, we recommend oncologists exercise caution when considering checkpoint inhibitor monotherapy in the front-line setting for R/R NSCLC, regardless of PD-L1 expression. © 2023 Elsevier Inc.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 6; All Open Access, Bronze Open Access} -} - -@ARTICLE{Hoffmann2023668, - author = {Hoffmann, Elgin and De-Colle, Chiara and Potkrajcic, Vlatko and Baumann, David and Spengler, Werner and Gani, Cihan and Utz, David}, - title = {Is consolidative thoracic radiotherapy of extensive-stage small cell lung cancer still beneficial in the era of immunotherapy? A retrospective analysis}, - year = {2023}, - journal = {Strahlentherapie und Onkologie}, - volume = {199}, - number = {7}, - pages = {668 – 675}, - doi = {10.1007/s00066-023-02075-9}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152375535&doi=10.1007%2fs00066-023-02075-9&partnerID=40&md5=dcc8124798267acb806aadb01ea494ef}, - abstract = {Purpose: Extensive-stage small cell lung cancer (ES-SCLC) carries a dismal prognosis. The benefit of consolidative thoracic radiotherapy (TR) after first-line chemoimmunotherapy with PD-L1 inhibitors in this setting remains unclear. As TR can improve overall survival (OS) after conventional chemotherapy, we retrospectively analyzed OS of an inhouse cohort treated either with TR or with chemoimmunotherapy alone. Methods: A total of 41 patients treated with chemoimmunotherapy with PD-L1 inhibitors (atezolizumab or durvalumab) for ES-SCLC at our hospital since 2019 were analyzed. TR was administered in 10 fractions of 3 Gy. Patient characteristics, number of immunotherapy cycles received, brain irradiation, and presence of hepatic and cerebral metastasis at diagnosis were assessed. Primary endpoint was OS after first diagnosis. Results: Consolidative TR was associated with a significantly longer OS than systemic therapy alone (1-year OS 78.6% and 2‑year OS 37.1% vs. 1‑year OS 39.7% and 2 years not reached, p = 0.019). With regard to radiotherapy indication, survival at 1 year was 88.9% (log-rank p = 0.016) for patients receiving consolidative TR. For patients receiving TR in case of progression, 1‑year survival was 66.7%. Hepatic and cerebral metastasis at first diagnosis had no significant effect on OS. Conclusion: TR was significantly associated with longer OS. The survival benefit of TR was most pronounced for consolidative radiotherapy after initial chemoimmunotherapy compared to TR in case of progression. Although retrospective findings need to be interpreted with caution, in the absence of prospective data, our findings provide a basis for offering consolidative TR in the era of chemoimmunotherapy. © 2023, The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 5; All Open Access, Green Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Friedes20241435, - author = {Friedes, Cole and Iocolano, Michelle and Lee, Sang Ho and Li, Bolin and Duan, Lian and Levin, William P. and Cengel, Keith A. and Sun, Lova L. and Aggarwal, Charu and Marmarelis, Melina E. and Doucette, Abigail and Cohen, Roger B. and Xiao, Ying and Langer, Corey J. and Bradley, Jeffrey and Feigenberg, Steven J. and Yegya-Raman, Nikhil}, - title = {Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors}, - year = {2024}, - journal = {International Journal of Radiation Oncology Biology Physics}, - volume = {118}, - number = {5}, - pages = {1435 – 1444}, - doi = {10.1016/j.ijrobp.2023.10.005}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85176229954&doi=10.1016%2fj.ijrobp.2023.10.005&partnerID=40&md5=fa6596fae62a2d096d1f4f12b4751715}, - abstract = {Purpose: The objective of this study was to describe the patterns of failure, frequency of low-volume relapse (LVR), and candidacy for ablative therapy at time of disease progression (PD) after chemoradiation and consolidative immunotherapy (CRT + ICI) in patients with stage III non-small cell lung cancer. Methods and Materials: We identified 229 consecutive patients with stage III non-small cell lung cancer treated with CRT + ICI between October 2017 and December 2021 at a single institution. PD was classified as isolated locoregional failure (LRF), isolated distant failure (DF), or synchronous LRF + DF. Any LRF was subclassified as in-field failure, marginal failure, or out-of-field failure. LVR was defined as 3 or fewer sites of PD in any number of organs. Ablative candidates were defined as having 5 or fewer sites of PD radiographically amenable to high-dose radiation or surgery. Time-to-event data were calculated using cumulative incidence analysis and Kaplan-Meier methods. Multivariable Cox modeling was used to examine the correlations between characteristics of relapse and postprogression survival. Results: Of the 229 patients, 119 (52%) had PD. Of these 119 patients, 20 (21%) had isolated LRF, 28 (24%) had synchronous LRF + DF, and 71 (60%) had isolated DF. Of the 48 patients with any LRF, 28 (58%) had in-field failure, 10 (21%) marginal failure, and 10 (21%) out-of-field failure. The cumulative incidence of LRF and DF was 13% (95% CI, 9.2%-18%) and 32% (95% CI, 26%-38%) at 1 year and 19% (95% CI, 14%-24%) and 39% (95% CI, 33%-46%) at 2 years, respectively. Overall, 64 patients (54%) were considered to have LVR. At time of PD, 60 patients (50%) were eligible for ablative therapy. Patients with LVR had longer median survival versus with high-volume relapse (37.4 vs 15.2 months, P < .001). On multivariable analysis, LVR (hazard ratio, 0.32; 95% CI, 0.18-0.56; P < .001) was associated with improved postprogression survival. Conclusions: After CRT + ICI, approximately half of patients experience LVR at time of PD and are candidates for ablative therapies. Prospective trials are needed to validate the optimal treatment strategy for LVR. © 2023 Elsevier Inc.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3} -} - -@ARTICLE{Wu2023, - author = {Wu, Leilei and Zhang, Zhenshan and Bai, Menglin and Yan, Yujie and Yu, Jinming and Xu, Yaping}, - title = {Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations}, - year = {2023}, - journal = {Cell Communication and Signaling}, - volume = {21}, - number = {1}, - doi = {10.1186/s12964-023-01139-8}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85159966390&doi=10.1186%2fs12964-023-01139-8&partnerID=40&md5=a03f91e55981b3afd062282d2bcd1cc0}, - abstract = {Until the advent of immune checkpoint inhibitors (ICIs), definitive radiotherapy (RT) concurrently with chemotherapy was recommended for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC). The trimodality paradigm with consolidation ICIs following definitive concurrent chemoradiotherapy has been the standard of care since the PACIFIC trial. Preclinical evidence has demonstrated the role of RT in the cancer-immune cycle and the synergistic effect of RT combined with ICIs (iRT). However, RT exerts a double-edged effect on immunity and the combination strategy still could be optimized in many areas. In the context of LA-NSCLC, optimized RT modality, choice, timing, and duration of ICIs, care for oncogenic addicted tumors, patient selection, and novel combination strategies require further investigation. Targeting these blind spots, novel approaches are being investigated to cross the borders of PACIFIC. We discussed the development history of iRT and summarized the updated rationale for the synergistic effect. We then summarized the available research data on the efficacy and toxicity of iRT in LA-NSCLC for cross-trial comparisons to eliminate barriers. Progression during and after ICIs consolidation therapy has been regarded as a distinct resistance scenario from primary or secondary resistance to ICIs, the subsequent management of which has also been discussed. Finally, based on unmet needs, we probed into the challenges, strategies, and auspicious orientations to optimize iRT in LA-NSCLC. In this review, we focus on the underlying mechanisms and recent advances of iRT with an emphasis on future challenges and directions that warrant further investigation. Taken together, iRT is a proven and potential strategy in LA-NSCLC, with multiple promising approaches to further improve the efficacy. [MediaObject not available: see fulltext.]. © 2023, The Author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12; All Open Access, Gold Open Access} -} - -@ARTICLE{Kagamu2024307, - author = {Kagamu, Hiroshi}, - title = {Immunotherapy for non-small cell lung cancer}, - year = {2024}, - journal = {Respiratory Investigation}, - volume = {62}, - number = {2}, - pages = {307 – 312}, - doi = {10.1016/j.resinv.2024.01.011}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85183963379&doi=10.1016%2fj.resinv.2024.01.011&partnerID=40&md5=161de352ff52ed3ebd5da6195a7bc07d}, - abstract = {Immune checkpoint inhibitors (ICI) bind to programmed cell death-1 (PD-1)/PD-1 ligand-1 (PD-L1) and Cytotoxic T-lymphocyte antigen-4 (CTLA-4), which suppress T-cell function and inhibit their inhibitory function, resulting in T-cell activation. ICI have been approved for a wide range of cancers, including malignant melanoma, renal cell carcinoma, non-small cell lung cancer, head and neck cancer, Hodgkin's disease, small-cell lung cancer, malignant pleural mesothelioma, gastric cancer, esophageal cancer, breast cancer, uterine cancer, and hepatocellular carcinoma, and the number of indications continues to grow. In addition to the treatment of advanced disease, the anti-tumor effect has been demonstrated across disease stages, from locally advanced disease to early-stage operative disease. The treatment of lung cancer is at the forefront of this trend and long-term durable responses and survival benefits in lung cancer have been exhibited that were unimaginable when cytotoxic anticancer agents were the only treatment options. However, treatment efficacy varies greatly from case to case, and no biomarkers have been developed to accurately predict efficacy. In this article, we discuss the past and future of ICI therapy for lung cancer, based on clinical and basic evidence accumulated to-date. © 2024 The Japanese Respiratory Society}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3} -} - -@ARTICLE{Oh2023533, - author = {Oh, Sarah and Botros, George N. and Patel, Milan and Haigentz, Missak and Patel, Eshan and Kontopidis, Iaonnis and Langenfeld, John and Deek, Matthew P. and Jabbour, Salma K.}, - title = {Locally Advanced Lung Cancer}, - year = {2023}, - journal = {Hematology/Oncology Clinics of North America}, - volume = {37}, - number = {3}, - pages = {533 – 555}, - doi = {10.1016/j.hoc.2023.02.007}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85151554997&doi=10.1016%2fj.hoc.2023.02.007&partnerID=40&md5=103f4af537c6ab172687abfb6a919fc6}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Stanley2023, - author = {Stanley, Robyn and Flanagan, Saoirse and Reilly, David O’ and Kearney, Ella and Naidoo, Jarushka and Dowling, Catríona M.}, - title = {Immunotherapy through the Lens of Non-Small Cell Lung Cancer}, - year = {2023}, - journal = {Cancers}, - volume = {15}, - number = {11}, - doi = {10.3390/cancers15112996}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85161456067&doi=10.3390%2fcancers15112996&partnerID=40&md5=dd86111243dc754db69db34254508bdd}, - abstract = {Immunotherapy has revolutionised anti-cancer treatment in solid organ malignancies. Specifically, the discovery of CTLA-4 followed by PD-1 in the early 2000s led to the practice-changing clinical development of immune checkpoint inhibitors (ICI). Patients with lung cancer, including both small cell (SCLC) and non-small cell lung cancer (NSCLC), benefit from the most commonly used form of immunotherapy in immune checkpoint inhibitors (ICI), resulting in increased survival and quality of life. In NSCLC, the benefit of ICIs has now extended from advanced NSCLC to earlier stages of disease, resulting in durable benefits and the even the emergence of the word ‘cure’ in long term responders. However, not all patients respond to immunotherapy, and few patients achieve long-term survival. Patients may also develop immune-related toxicity, a small percentage of which is associated with significant mortality and morbidity. This review article highlights the various types of immunotherapeutic strategies, their modes of action, and the practice-changing clinical trials that have led to the widespread use of immunotherapy, with a focus on ICIs in NSCLC and the current challenges associated with advancing the field of immunotherapy. © 2023 by the authors.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Gold Open Access} -} - -@ARTICLE{Zeng20231978, - author = {Zeng, Qingyu and Chen, Chengqian and Chen, Diyan and Zhang, Guolong and Wang, Xiuli}, - title = {Non-Surgical Therapeutic Strategies for Non-Melanoma Skin Cancers}, - year = {2023}, - journal = {Current Treatment Options in Oncology}, - volume = {24}, - number = {12}, - pages = {1978 – 1993}, - doi = {10.1007/s11864-023-01154-4}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85179653662&doi=10.1007%2fs11864-023-01154-4&partnerID=40&md5=fbfdc0481a14bcef8fb94a572899a661}, - abstract = {Non-melanoma skin cancer (NMSC) is a globally prevalent skin disease, with basal cell carcinoma and squamous cell carcinoma accounting for 99% of NMSC cases. While surgical excision is the most common approach, numerous non-surgical therapies have rapidly advanced in recent years. In cases of low-risk NMSC, alongside surgical excision, priority should be given to physical therapy and photodynamic therapy. Physical therapy modalities, exemplified by electrodessication and curettage, emerge as safe and efficacious alternatives. In juxtaposition, photodynamic therapy, albeit relatively more costly, assumes preference for patients exhibiting heightened cosmetic concerns owing to the scarring risks inherent to physical therapy and surgical excision. Notably, the combination of curettage and photodynamic therapy has exhibited remarkable efficacy in the treatment of nodular basal cell carcinoma. Additionally, for elderly patients who may be intolerant to stimulation, modified photodynamic therapy offers an almost painless option. When surgery is unavoidable, photodynamic therapy can be a valuable adjunct, allowing for a more conservative surgical approach, either before or after the procedure. Radiotherapy holds a prominent role in comprehensive treatment strategies, especially for patients ineligible for surgical intervention or those with lesions precluding further surgical measures. In cases of NMSC exhibiting perineural invasion or lymphovascular involvement, adjunctive radiotherapy is advised; however, potential adverse effects necessitate careful consideration. For advanced NMSC cases where surgery and physical therapy fall short, immunotherapy provide viable solutions. Systemic therapy employing Hedgehog pathway inhibitors can be considered for patients with distant metastatic basal cell carcinoma, despite its low incidence, or individuals with locally advanced lesions who are not surgical candidates, or those encountering recurrences after resection and radiotherapy. However, close monitoring of disease progression and adverse reactions is crucial. In this evolving landscape of NMSC treatment, personalized and multidisciplinary approaches are key, ensuring optimal outcomes while prioritizing patient safety and satisfaction. © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 5} -} - -@ARTICLE{Xu2024, - author = {Xu, Zihan and Zhang, Huien and Ma, Guikai and Meng, Wenjuan and Du, Junliang and Wu, Xin and Yang, Baohong and Wang, Ningning and Ding, Yanhong and Zhang, Qingyun and Li, Na and Zhang, Xuede and Yu, Guohua and Liu, Shuzhen and Li, Zhenhua}, - title = {Real‑world evidence of advanced non‑small cell lung carcinoma treated with an immune checkpoint inhibitor plus chemotherapy}, - year = {2024}, - journal = {Oncology Letters}, - volume = {28}, - number = {3}, - doi = {10.3892/ol.2024.14538}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85198314865&doi=10.3892%2fol.2024.14538&partnerID=40&md5=5cb8095235c67b918f91d86ca5a5b77f}, - abstract = {Immunotherapy is an effective treatment strategy for patients with advanced non‑small cell lung cancer (NSCLC). Although clinical trials on immunotherapy have provided promising results, real‑world research in clinical practice is needed to assess the effectiveness and safety of immunotherapy. The present study aimed to characterize real‑world outcomes in patients with advanced NSCLC treated with immune checkpoint inhibitor (ICI)‑based regimens. The medical records of patients with advanced NSCLC, who were treated with programmed cell death protein‑1 (PD‑1)/programmed cell death 1 ligand 1 (PD‑L1) inhibitors, were reviewed for data collection. The primary objectives were to evaluate progression‑free survival (PFS) and overall survival (OS). Therefore, multiple Cox regression models were used to investigate the predictive factors for survival outcomes. Furthermore, survival curves for PFS and OS were created using Kaplan‑Meier estimates and compared using the log‑rank test. The present study included a total of 133 patients with advanced NSCLC who received therapy with ICIs between January 1, 2019 and December 31, 2022. The final follow‑up date was August 24, 2023. The median PFS and OS times were 9.8 and 27.2 months, respectively. Univariate Cox regression analysis demonstrated that sex, clinical stage, PD‑L1 status, previous systemic therapy, and brain and liver metastases were associated with PFS, while Eastern Cooperative Oncology Group (ECOG) status, clinical stage, PD‑L1 status and brain metastasis were associated with OS. Furthermore, multi‑ variate Cox regression analysis demonstrated that a PD‑L1 tumor proportion score (TPS) of ≥50% was an indicator of favorable PFS and OS. An ECOG performance status score of ≥1 was also associated with poor OS but not with PFS. Furthermore, brain metastasis was an indicator for poor PFS and OS, while liver metastasis was only associated with a poor PFS. Finally, the results of the present study demonstrated that PD‑L1 status was an independent predictor for PFS and OS in patients with advanced NSCLC, especially adenocarcinoma, who were treated with ICIs plus chemotherapy. The results also suggested that patients with a PD‑L1 TPS of ≥50% could benefit when the aforementioned regimens were administrated as a first‑line or later‑line therapy. © 2024 Xu et al.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Lu202418, - author = {Lu, Shuangqing and Guo, Xiaokang and Li, Yuying and Liu, Haoyu and Zhang, Yan and Zhu, Hui}, - title = {Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive-stage small cell lung cancer: A retrospective analysis}, - year = {2024}, - journal = {Cancer}, - volume = {130}, - number = {1}, - pages = {18 – 30}, - doi = {10.1002/cncr.35003}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85170549270&doi=10.1002%2fcncr.35003&partnerID=40&md5=398f340a2c15c0ea727cb8473e32583f}, - abstract = {Background: Immunotherapy (IO) has demonstrated promising results in treating extensive-stage small cell lung cancer (ES-SCLC), and the management of ES-SCLC brain metastases (BMs) is now receiving significant clinical attention. The objective of this study was to evaluate the role of IO in the clinical management of BMs. Methods: Between January 2020 and December 2021, the study included the records of 250 patients who were diagnosed with ES-SCLC. Overall survival (OS), progression-free survival, intracranial progression-free survival, and the cumulative incidence of BMs were calculated using the Kaplan–Meier method and were compared using the log-rank test. In addition, the Cox regression model was used to analyze prognostic factors. Results: In the entire group, 85 patients had baseline BMs (IO plus chemotherapy [IO + ChT], n = 38; ChT alone, n = 47), and 165 patients (IO + ChT, n = 86; ChT alone, n = 79) did not have BMs at the time of initial diagnosis. The median follow-up was 22.4 months. The OS benefit with first-line antiprogrammed death ligand 1 therapy was maintained regardless of whether patients had BMs (with BMs, 17.97 vs. 13.14 months [p =.03]; without BMs, 18.46 vs. 15.05 months [p =.047]). However, in patients without BMs, IO did not delay the median time to developing brain progression (10.84 vs. 10.74 months; p =.84), and it did not significantly reduce the risk of developing intracranial metastases (the 2-year actuarial risk of developing BMs was 57.0% vs. 50.6%, respectively). Conclusions: Antiprogrammed death ligand 1 therapy improved OS regardless of the presence of BMs. However, IO did not delay the median time to brain progression or reduce the risk of intracranial metastasis in patients without baseline BMs. The findings of this study have important clinical implications for the future management of BMs from ES-SCLC. © 2023 American Cancer Society.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2} -} - -@ARTICLE{Megyesfalvi2023620, - author = {Megyesfalvi, Zsolt and Gay, Carl M. and Popper, Helmut and Pirker, Robert and Ostoros, Gyula and Heeke, Simon and Lang, Christian and Hoetzenecker, Konrad and Schwendenwein, Anna and Boettiger, Kristiina and Bunn, Paul A. and Renyi-Vamos, Ferenc and Schelch, Karin and Prosch, Helmut and Byers, Lauren A. and Hirsch, Fred R. and Dome, Balazs}, - title = {Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions}, - year = {2023}, - journal = {CA Cancer Journal for Clinicians}, - volume = {73}, - number = {6}, - pages = {620 – 652}, - doi = {10.3322/caac.21785}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85161960246&doi=10.3322%2fcaac.21785&partnerID=40&md5=c9bdf4e806381a586d0029400f23d021}, - abstract = {Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity. It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority of SCLCs exhibit neuroendocrine features, an important subset of tumors lacks these properties. Genomic profiling of SCLC reveals genetic instability, almost universal inactivation of the tumor suppressor genes TP53 and RB1, and a high mutation burden. Because of early metastasis, only a small fraction of patients are amenable to curative-intent lung resection, and these individuals require adjuvant platinum-etoposide chemotherapy. Therefore, the vast majority of patients are currently being treated with chemoradiation with or without immunotherapy. In patients with disease confined to the chest, standard therapy includes thoracic radiotherapy and concurrent platinum-etoposide chemotherapy. Patients with metastatic (extensive-stage) disease are treated with a combination of platinum-etoposide chemotherapy plus immunotherapy with an anti-programmed death-ligand 1 monoclonal antibody. Although SCLC is initially very responsive to platinum-based chemotherapy, these responses are transient because of the development of drug resistance. In recent years, the authors have witnessed an accelerating pace of biologic insights into the disease, leading to the redefinition of the SCLC classification scheme. This emerging knowledge of SCLC molecular subtypes has the potential to define unique therapeutic vulnerabilities. Synthesizing these new discoveries with the current knowledge of SCLC biology and clinical management may lead to unprecedented advances in SCLC patient care. Here, the authors present an overview of multimodal clinical approaches in SCLC, with a special focus on illuminating how recent advancements in SCLC research could accelerate clinical development. © 2023 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 78; All Open Access, Gold Open Access} -} - -@ARTICLE{Kroemer2024187, - author = {Kroemer, Guido and Chan, Timothy A. and Eggermont, Alexander M. M. and Galluzzi, Lorenzo}, - title = {Immunosurveillance in clinical cancer management}, - year = {2024}, - journal = {CA Cancer Journal for Clinicians}, - volume = {74}, - number = {2}, - pages = {187 – 202}, - doi = {10.3322/caac.21818}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85174624601&doi=10.3322%2fcaac.21818&partnerID=40&md5=11b687668730385ad4cc5f4b82940d51}, - abstract = {The progression of cancer involves a critical step in which malignant cells escape from control by the immune system. Antineoplastic agents are particularly efficient when they succeed in restoring such control (immunosurveillance) or at least establish an equilibrium state that slows down disease progression. This is true not only for immunotherapies, such as immune checkpoint inhibitors (ICIs), but also for conventional chemotherapy, targeted anticancer agents, and radiation therapy. Thus, therapeutics that stress and kill cancer cells while provoking a tumor-targeting immune response, referred to as immunogenic cell death, are particularly useful in combination with ICIs. Modern oncology regimens are increasingly using such combinations, which are referred to as chemoimmunotherapy, as well as combinations of multiple ICIs. However, the latter are generally associated with severe side effects compared with single-agent ICIs. Of note, the success of these combinatorial strategies against locally advanced or metastatic cancers is now spurring successful attempts to move them past the postoperative (adjuvant) setting to the preoperative (neoadjuvant) setting, even for patients with operable cancers. Here, the authors critically discuss the importance of immunosurveillance in modern clinical cancer management. © 2023 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 27; All Open Access, Gold Open Access} -} - -@ARTICLE{Molife20233135, - author = {Molife, Cliff and Winfree, Katherine B. and Bailey, Hollie and D’yachkova, Yulia and Forshaw, Cameron and Kim, Sangmi and Taipale, Kaisa-Leena and Puri, Tarun}, - title = {Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study}, - year = {2023}, - journal = {Advances in Therapy}, - volume = {40}, - number = {7}, - pages = {3135 – 3168}, - doi = {10.1007/s12325-023-02530-0}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160222467&doi=10.1007%2fs12325-023-02530-0&partnerID=40&md5=97dc595d9406fb01cad68d71a1ef35db}, - abstract = {Introduction: Treatment landscape for advanced/metastatic NSCLC (aNSCLC) has evolved considerably over the past few decades with the advent of targeted therapies for epidermal growth factor receptor-mutated (EGFRm+) aNSCLC treatment. This study described real-world patient and disease characteristics, treatment and practice patterns, and clinical, economic, and patient-reported outcomes (PROs) in patients with EGFRm+ aNSCLC. Methods: Data were derived from the Adelphi NSCLC Disease Specific Programme™ (DSP™), a point-in-time survey conducted between July and December 2020. The survey included oncologists and pulmonologists, and their consulting patients (with physician-confirmed EGFRm+ aNSCLC) from nine countries: the US, Brazil, the UK, Italy, France, Spain, Germany, Japan, and Taiwan. All analyses were descriptive. Results: Overall, 542 physicians reported data for 2857 patients (mean age 65.6 years), and most patients were female (56.0%), white (61.0%), and had stage IV disease at initial diagnosis (76.0%), and adenocarcinoma histology (89.0%). Most patients received EGFR-tyrosine kinase inhibitors (TKI) therapy in first- (91.0%), second- (74.0%), and third-line (67.0%). The most common tumor samples and methods for EGFR detection were EGFR-specific mutation detection tests (44.0%) and core needle biopsy (56.0%). Median time to next treatment was 14.0 (IQR 8.0–22.0) months and disease progression was the main physician-reported reason for early discontinuation. The most common physician-reported disease symptoms were cough (51.0%), fatigue (37.0%), and dyspnea (33.0%). In patients assessed for PROs, mean EQ-5D-5L index and FACT-L health utility scores were 0.71 and 83.5, respectively. On average, patients lost 10.6 h of work/week for approximately 29.2 weeks due to EGFRm+ aNSCLC. Conclusion: This real-world multinational data set showed that most patients with EGFRm+ aNSCLC were treated per the country relevant clinical guidelines, with progression as the main reason for early treatment discontinuation. For the included countries, these findings may offer a useful benchmark for decision makers to determine future allocation of healthcare resources for patients with EGFRm+ aNSCLC. © 2023, The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Xie2023, - author = {Xie, Zhaoliang and Liu, Jingru and Wu, Min and Wang, Xiaohan and Lu, Yuhan and Han, Chunyan and Cong, Lei and Li, Jisheng and Meng, Xue}, - title = {Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer}, - year = {2023}, - journal = {Journal of Clinical Medicine}, - volume = {12}, - number = {11}, - doi = {10.3390/jcm12113828}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85161441945&doi=10.3390%2fjcm12113828&partnerID=40&md5=62ef2b7a16243a95dfcd6eba1b993204}, - abstract = {(1) Background: At present, the efficacy and safety of thoracic radiotherapy (TRT) after chemo-immunotherapy (CT-IT) in patients with extensive-stage small-cell lung cancer (ES-SCLC) still remain unclear. The purpose of this study was to evaluate the role of TRT after CT-IT in patients with ES-SCLC. (2) Methods: From January 2020 to October 2021, patients with ES-SCLC treated with first-line anti-PD-L1 antibody plus platinum-etoposide chemotherapy were enrolled retrospectively. The survival data and adverse events data of patients treated with or without TRT after CT-IT were collected for analysis. (3) Results: A total of 118 patients with ES-SCLC treated with first-line CT-IT were retrospectively enrolled, with 45 patients with TRT and 73 patients without TRT after CT-IT. The median PFS and OS in the CT-IT + TRT group and CT-IT only group were 8.0 months versus 5.9 months (HR = 0.64, p = 0.025) and 22.7 months versus 14.7 months (HR = 0.52, p = 0.015), respectively. The median PFS and OS in all 118 patients treated with first-line CT-IT were 7.2 and 19.8 months with an ORR of 72.0%. In multivariate analyses, liver metastasis and response to CT-IT were shown to be independent prognostic factors of PFS (p < 0.05), while liver metastasis and bone metastasis were independent predictive factors of OS (p < 0.05). Although TRT was significantly associated with better PFS and OS in univariate analysis, the association of TRT and OS failed to reach statistical significance (HR = 0.564, p = 0.052) in multivariate analysis. There was no significant difference in adverse events (AEs) between two treatment groups (p = 0.58). (4) Conclusions: ES-SCLC patients treated with TRT after first-line CT-IT had prolonged PFS and OS with an acceptable safety profile. Further prospective randomized studies are necessary to explore the efficacy and safety of this treatment modality for ES-SCLC in future. © 2023 by the authors.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 7; All Open Access, Gold Open Access} -} - -@ARTICLE{Jachowski2023695, - author = {Jachowski, Andrzej and Marcinkowski, Mikołaj and Szydłowski, Jakub and Grabarczyk, Oskar and Nogaj, Zuzanna and Marcin, Łaz and Pławski, Andrzej and Jagodziński, Paweł Piotr and Słowikowski, Bartosz Kazimierz}, - title = {Modern therapies of nonsmall cell lung cancer}, - year = {2023}, - journal = {Journal of Applied Genetics}, - volume = {64}, - number = {4}, - pages = {695 – 711}, - doi = {10.1007/s13353-023-00786-4}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85171164941&doi=10.1007%2fs13353-023-00786-4&partnerID=40&md5=100abd6e7df7ad49e39d977d8b8bdd11}, - abstract = {Lung cancer (LC), particularly nonsmall cell lung cancer (NSCLC), is one of the most prevalent types of neoplasia worldwide, regardless of gender, with the highest mortality rates in oncology. Over the years, treatment for NSCLC has evolved from conventional surgery, chemotherapy, and radiotherapy to more tailored and minimally invasive approaches. The use of personalised therapies has increased the expected efficacy of treatment while simultaneously reducing the frequency of severe adverse effects (AEs). In this review, we discuss established modern approaches, including immunotherapy and targeted therapy, as well as experimental molecular methods like clustered regularly interspaced short palindromic repeat (CRISPR) and nanoparticles. These emerging methods offer promising outcomes and shorten the recovery time for various patients. Recent advances in the diagnostic field, including imaging and genetic profiling, have enabled the implementation of these methods. The versatility of these modern therapies allows for multiple treatment options, such as single-agent use, combination with existing conventional treatments, or incorporation into new regimens. As a result, patients can survive even in the advanced stages of NSCLC, leading to increased survival indicators such as overall survival (OS) and progression-free survival (PFS). © 2023, The Author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4; All Open Access, Green Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Cai2023, - author = {Cai, Letong and Li, Yuchen and Tan, Jiaxiong and Xu, Ling and Li, Yangqiu}, - title = {Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy}, - year = {2023}, - journal = {Journal of Hematology and Oncology}, - volume = {16}, - number = {1}, - doi = {10.1186/s13045-023-01499-1}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85169675668&doi=10.1186%2fs13045-023-01499-1&partnerID=40&md5=ab086c5da9f967bc371bd9603636d8a3}, - abstract = {In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies. However, not all cancer patients benefit from single or combination therapy with anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies. Thus, an increasing number of immune checkpoint proteins (ICPs) have been screened and their effectiveness evaluated in preclinical and clinical trials. Lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain-containing-3 (TIM-3), and T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) constitute the second wave of immunotherapy targets that show great promise for use in the treatment of solid tumors and leukemia. To promote the research and clinical application of ICBs directed at these targets, we summarize their discovery, immunotherapy mechanism, preclinical efficiency, and clinical trial results in this review. © 2023, BioMed Central Ltd., part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 57; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Orosz2024, - author = {Orosz, Zsuzsanna and Kovács, Árpád}, - title = {The role of chemoradiotherapy and immunotherapy in stage III NSCLC}, - year = {2024}, - journal = {Pathology and Oncology Research}, - volume = {30}, - doi = {10.3389/pore.2024.1611716}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85192109379&doi=10.3389%2fpore.2024.1611716&partnerID=40&md5=01dd5332e5ed3372bb9a5a8efd177eb4}, - abstract = {Locally advanced non-small lung cancer encompasses a diverse range of tumors. In the last few years, the treatment of stage III unresectable non-small lung cancer has evolved significantly. The PACIFIC trial opened a new therapeutic era in the treatment of locally advanced NSCLC, establishing durvalumab consolidation therapy as the new standard of care worldwide. A careful evaluation of this type of lung cancer and a discussion of the management of these patients within a multidisciplinary team represents a crucial step in defining the best treatment strategy for each patient. For unresectable stage III NSCLC, definitive concurrent chemoradiotherapy (CCRT) was historically recommended as a treatment with a 5-year survival rate ranging from 20% to 30%. The PACIFIC study conducted in 2017 compared the use of chemoradiotherapy and maintenance therapy with the anti-PD-L1 monoclonal antibody durvalumab to a placebo in patients with locally advanced NSCLC who had not experienced disease progression. The study was prospective, randomized, and phase III. The administration of this medication in patients with locally advanced non-small cell lung cancer (NSCLC) has demonstrated a notable improvement in overall survival. Multiple clinical trials are currently exploring various immune checkpoint inhibition regimens to enhance the treatment efficacy in patients with stage III cancer. Our goal is to offer an up-to-date summary of the planned clinical trials for treatment options, focusing on the significant obstacles and prospects in the post-PACIFIC era. Copyright © 2024 Orosz and Kovács.}, - type = {Short survey}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Wu2023, - author = {Wu, Min and Wu, Shihao and Chen, Yuetong and Sun, Liangchao and Zhou, Jundong}, - title = {Immune Activation Effects at Different Irradiated Sites and Optimal Timing of Radioimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer: a Real-World Analysis}, - year = {2023}, - journal = {Biological Procedures Online}, - volume = {25}, - number = {1}, - doi = {10.1186/s12575-023-00217-y}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85171381055&doi=10.1186%2fs12575-023-00217-y&partnerID=40&md5=a94c7a7ddf5fc1f0b137e1e8a5ef4451}, - abstract = {Background: In view of the limited data on radiotherapy (RT) combined with immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC), this study aimed to identify the immune activation effect on different sites and the survival outcomes of radioimmunotherapy at different treatment stages. Methods: Forty-five patients diagnosed with ES-SCLC were included in this retrospective analysis. We collected the overall survival (OS) of the patients, recorded the blood cell counts before, during, and after RT, and derived blood index ratios such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). The datasets were analyzed using the Spearman rank correlation test, Kruskal–Wallis rank sum test and logistic regression. Results: Among the selected blood indices, the delta-NLR/PLR/Sll correlated with different irradiated organs, and the mean ranks of these three indices were the lowest in the brain-irradiated group during immunotherapy. Additionally, adjunct first-line immunotherapy with RT demonstrated a significant improvement compared to second- or third-line therapy and subsequent therapies. Conclusion: Our findings suggest that compared to other organs, the strongest immune activation effect occurs with brain RT, and ES-SCLC patients who received radioimmunotherapy (RIT) earlier achieved higher OS rates. © 2023, BioMed Central Ltd., part of Springer Nature.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Jovanoski2023, - author = {Jovanoski, Nick and Bowes, Kathleen and Brown, Audrey and Belleli, Rossella and Di Maio, Danilo and Chadda, Shkun and Abogunrin, Seye}, - title = {Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence}, - year = {2023}, - journal = {Lung Cancer Management}, - volume = {12}, - number = {3}, - doi = {10.2217/lmt-2023-0003}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186409664&doi=10.2217%2flmt-2023-0003&partnerID=40&md5=73291ff2dce8cc7639e6725d3f9b010a}, - abstract = {Aim: Assess the long-term survival and quality-of-life outcomes in early-stage NSCLC (eNSCLC) patients. Methods: Review of long-term survival and quality-of-life after curative treatment in eNSCLC patients in observational studies. Results: Disease-free proportion decreased in stage III vs stage I patients. Recurrence-free proportion decreased with age and disease stage. Advanced stage and vascular invasion increased risk of late recurrence. Conditional 5-year relative survival rates did not exceed 87%, indicating higher mortality in eNSCLC survivors. Lower conditional survival rates and relative survival rates were associated with older age and advanced disease. Survivors of eNSCLC had poorer physical quality-of-life. Conclusion: Despite curative-intent therapy, survivors of eNSCLC still face significant risks of recurrence, excess mortality, and diminished quality-of-life.Plain language summary Early-stage NSCLC (eNSCLC) encompassing stage I and II, and resectable stage III disease is initially managed with curative-intent surgery and adjuvant chemotherapy to reduce the risk of recurrence. However, understanding the true curative potential and long-term outcomes is crucial for optimal clinical management. A literature review was conducted to identify observational studies describing long-term survival and quality-of-life outcomes following curative intent therapy in patients with eNSCLC. The proportion of patients who remained disease-free over time (without recurrence or death) statistically significantly decreased in patients with stage III disease compared with stage I disease. Similarly, the proportion of patients who remained recurrence-free over time decreased with increasing age and disease stage. A considerable risk of late recurrence (recurrence five or more years following resection) remained, increasing with advanced stage and tumor characteristics such as vascular invasion. Conditional 5-year relative survival rates did not exceed 87% in any study, indicating higher rates of all-cause mortality in long-term survivors of eNSCLC compared with members of the general population of the same age. Lower conditional 5-year relative survival rates, and 5 and 10-year relative survival rates were associated with older age and higher pathologic stage. Compared with the general population, survivors of eNSCLC reported significantly poorer physical quality-of-life, suggesting that symptoms persist after treatment. Overall, real-world evidence suggests that after standard curative-intent therapy, survivors of eNSCLC may not be considered fully cured, indicating a need for more effective adjuvant treatment in addition to the current standard of care. © 2023 Nick Jovanoski, Kathleen Bowes, Audrey Brown, Rossella Belleli, Danilo Di Maio, Shkun Chadda, Seye Abogunrin.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Gold Open Access} -}@ARTICLE{Merle2023143, - author = {Merle, Geoffrey and Addeo, Alfredo}, - title = {Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC); [Immuntherapie bei nicht-kleinzelligem Lungenkarzinom (NSCLC)]}, - year = {2023}, - journal = {Praxis}, - volume = {112}, - number = {3}, - pages = {143 – 147}, - doi = {10.1024/1661-8157/a003973}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149153634&doi=10.1024%2f1661-8157%2fa003973&partnerID=40&md5=b37af09d4e944d662fd8be093ccccc15}, - abstract = {Treatment of non-small-cell lung cancer depends heavily on the cancer stage, and immunotherapy can play a major role at any stage. For locally advanced stages, the addition of an immune checkpoint inhibitor (ICI) to neoadjuvant chemotherapy improves pathological response and event-free survival. In the adjuvant setting, adding ICI, after adjuvant chemotherapy for resectable cancer, increases the disease-free survival. In unresectable stage III treated with concomitant chemotherapy and radiotherapy, adding ICI as a maintenance therapy increases progression-free survival and overall survival. In the metastatic setting, the addition of ICI to chemotherapy improves overall survival, progression-free survival, and response rates irrespective of the PD-L1 expression. ICI on its own may be considered in cases of PD-L1 expression equal or greater than at least 50 %. © 2023 Hogrefe.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1} -} - -@ARTICLE{Riano2023, - author = {Riano, Ivy and Abuali, Inas and Sharma, Aditya and Durant, Jewelia and Dragnev, Konstantin H.}, - title = {Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer}, - year = {2023}, - journal = {Pharmaceuticals}, - volume = {16}, - number = {2}, - doi = {10.3390/ph16020233}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148944641&doi=10.3390%2fph16020233&partnerID=40&md5=1c582b1e75b8dc98b7cb88c8ea234266}, - abstract = {The neoadjuvant use of immune checkpoint inhibitors (ICI) in resectable non-small cell lung cancer (NSCLC) is being increasingly adopted, but questions about the most appropriate applications remain. Although patients with resectable NSCLC are often treated with surgery and adjuvant chemotherapy or targeted therapies +/− radiotherapy, they still have a high risk of recurrence and death. In recent years, immune checkpoint inhibitors (ICI) (anti-PD-1/PD-L1 and anti-CTLA-4) have provided a new and effective therapeutic strategy for the treatment of advanced NSCLC. Therefore, it is possible that ICIs for early-stage NSCLC may follow the pattern established in metastatic disease. Currently, there are several ongoing trials to determine the efficacy in the neoadjuvant setting for patients with local or regional disease. To date, only nivolumab in combination with chemotherapy has been approved by the U.S. FDA in the preoperative setting, but data continue to evolve rapidly, and treatment guidelines need to be determined. In this article, we review the current preclinical and clinical evidence on neoadjuvant ICIs alone and combination in the treatment of early-stage NSCLC. © 2023 by the authors.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Ma2022685, - author = {Ma, Ji and Tian, Yaru and Hao, Shaoyu and Zheng, Liangjie and Hu, Weibo and Zhai, Xiaoyang and Meng, Dongfang and Zhu, Hui}, - title = {Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis}, - year = {2022}, - journal = {Journal of Neuro-Oncology}, - volume = {159}, - number = {3}, - pages = {685 – 693}, - doi = {10.1007/s11060-022-04111-7}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136153489&doi=10.1007%2fs11060-022-04111-7&partnerID=40&md5=5ac4b37d9a905287520dae1dccdf621b}, - abstract = {Introduction: Anti-programmed cell death-ligand 1 (Anti-PD-L1) blockades have become the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) from CASPIAN and IMpower133 trials. SCLC has a high incidence of brain metastasis (BM) and brain radiotherapy (BRT) is the main local treatment method, but there is limited data on the BRT-immunotherapy scheme. The aim of the retrospective study is to investigate the clinical efficacy and safety of the first-line anti-PD-L1 blockades combined with BRT in ES-SCLC with BM. Methods: Patients with newly diagnosed ES-SCLC with baseline BMs at Shandong Cancer Hospital and Research Institute between 2017 and 2021 were selected. Patients were divided into the anti-PD-L1+BRT group and BRT group. We also assessed the leukoencephalopathy in both groups. Results: A total of 46 patients were selected. Fifteen were divided into anti-PD-L1+BRT group and 31 to BRT group. The median overall survival (OS) was not reached (NR) vs 15.9 m (P = 0.172). Progression-free survival (PFS) was numerically prolonged with anti-PD-L1 blockades, but the significance was not reached (median: 9.4 m vs 7.4 m, P = 0.362). The median intracranial PFS was not improved, neither (median: 8.2 m vs 8.9 m, P = 0.620). Objective response rate (ORR) in the two groups was 73.33% vs 77.42% (P = 0.949) and disease control rate (DCR) was both 100%. Intracranial ORR and DCR were 53.33% vs 70.97% (P = 0.239) and 73.33% vs 80.65% (P = 0.855), respectively. There was no significant difference in leukoencephalopathy incidence between the two groups. Conclusion: The combination of first-line anti-PD-L1 blockades with BRT did not confer a significant survival benefit in ES-SCLC with BM, without enhancing cranial neurotoxicity. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 5} -} - -@ARTICLE{Tanchuco2022219, - author = {Tanchuco, Joven Q.}, - title = {Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small Cell Lung Carcinoma with Focus on the Philippines}, - year = {2022}, - journal = {Phillippine Journal of Internal Medicine}, - volume = {60}, - number = {3}, - pages = {219 – 237}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143348110&partnerID=40&md5=235ff206b20bf63df3937bc01fbb3c3f}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Zeng2023, - author = {Zeng, Jiao and Ding, Xinjing and Ding, Jianghua and Wang, Xin}, - title = {Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy}, - year = {2023}, - journal = {Frontiers in Immunology}, - volume = {14}, - doi = {10.3389/fimmu.2023.1275957}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85176594894&doi=10.3389%2ffimmu.2023.1275957&partnerID=40&md5=b83026e2214b68f7ae5e1a7585416e89}, - abstract = {The phenomenon of histological transformation has been widely reported in advanced non-small cell lung cancer (NSCLC) with EGFR mutations following the failure of EGFR-TKI treatment. Recent evidence suggests that similar histological changes can also occur in advanced NSCLC without driver gene mutations after developing resistance to immunotherapy. In this review, it was found that 66.7% of cases with immunotherapy-induced histological transformation were classified as lung squamous cell carcinoma (LSCC), while histological conversion into lung adenocarcinoma (LUAD) without EGFR or ALK gene mutations has rarely been reported. There have been sporadic reports on the occurrence of mutual transformation between LUAD and LSCC. The histological conversion from NSCLC into small cell lung cancer (SCLC) appears to be significantly underestimated, likely due to the infrequency of re-biopsy following the development of immunotherapy resistance. Several studies have reported a close association between the transformation and mutations at TP53 and the RB1 splice site, as well as the loss of an FBXW7 mutation. However, the exact mechanisms underlying this conversion remain unclear. Currently, there is a lack of guidelines for the management of transformed SCLC from NSCLC following immunotherapy, with chemotherapy being the most commonly employed treatment approach. Copyright © 2023 Zeng, Ding, Ding and Wang.}, - type = {Short survey}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Lee2022288, - author = {Lee, Percy}, - title = {Radiation Therapy and Immunotherapy in Locally Advanced NSCLC}, - year = {2022}, - journal = {Clinical Advances in Hematology and Oncology}, - volume = {20}, - number = {5}, - pages = {288 – 290}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130179998&partnerID=40&md5=ec324959c5bbeef1427fa5b162ffff0a}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Ni2023, - author = {Ni, Jun and Si, Xiaoyan and Wang, Hanping and Zhang, Xiaotong and Zhang, Li}, - title = {Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial}, - year = {2023}, - journal = {Frontiers in Immunology}, - volume = {14}, - doi = {10.3389/fimmu.2023.1168879}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85153485375&doi=10.3389%2ffimmu.2023.1168879&partnerID=40&md5=83d437c5a941c601851389197a03c853}, - abstract = {Background: Programmed cell death-ligand 1 (PD-L1) inhibitors plus chemotherapy have made substantial progress in extensive-stage small-cell lung cancer (ES-SCLC), but the survival benefit is still limited. This study aimed to evaluate the preliminary efficacy and safety of camrelizumab plus platinum-irinotecan (IP/IC) followed by maintenance camrelizumab plus apatinib in patients with untreated ES-SCLC. Methods: In this non-randomized clinical trial (NCT04453930), eligible patients with untreated ES-SCLC received 4-6 cycles of camrelizumab plus IP/IC, followed by maintenance with camrelizumab plus apatinib until disease progression or unmanageable toxicity. The primary endpoint was progression-free survival (PFS). Patients who received PD-L1 inhibitors (atezolizumab or durvalumab) plus platinum-etoposide (EP/EC) were selected as the historical control. Results: Nineteen patients received IP/IC plus camrelizumab and 34 patients received EP/EC plus PD-L1 inhibitor. At a median follow-up time of 12.1 months, the median PFS was 10.25 months (95% CI: 9.40-NA) in the IP/IC plus camrelizumab group and 7.10 months (95% CI 5.79-8.40) in the EP/EC plus PD-L1 inhibitor group, respectively (HR=0.58, 95% CI 0.42-0.81). The objective response rate of IP/IC plus camrelizumab and EP/EC plus PD-L1 inhibitor was 89.6% and 82.4%, respectively. The most common treatment-related adverse events in the IP/IC plus camrelizumab group was neutropenia, followed by reactive cutaneous capillary endothelial proliferation (RCCEP) and diarrhea. The occurrence of immune-related adverse event was found to be associated with a prolonged PFS (HR=4.64, 95% CI 1.92-11.18). Conclusions: IP/IC plus camrelizumab followed by maintenance camrelizumab plus apatinib showed preliminary efficacy and acceptable safety profile in patients with untreated ES-SCLC. Copyright © 2023 Ni, Si, Wang, Zhang and Zhang.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 8; All Open Access, Gold Open Access} -} - -@ARTICLE{Tian20221027, - author = {Tian, Tian and Yu, Min and Yu, Yang and Wang, Ke and Tian, Panwen and Luo, Ziyue and Ding, Zhenyu and Wang, Ye and Gong, Youling and Zhu, Jiang and Zou, Bingwen and Sio, Terence T. and Alves, Adelaide and Liu, Yongmei and Huang, Meijuan and Lu, You}, - title = {Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study}, - year = {2022}, - journal = {Translational Lung Cancer Research}, - volume = {11}, - number = {6}, - pages = {1027 – 1037}, - doi = {10.21037/tlcr-22-376}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85133256410&doi=10.21037%2ftlcr-22-376&partnerID=40&md5=b8eac96443adbf32664ab38ebd10b1e9}, - abstract = {Background: Although immune checkpoint inhibitors (ICIs) provide unprecedented survival improvement for patients with advanced non-small cell lung cancer (NSCLC), disease progression inevitably occurs. After ICIs failure, limited data exist on whether ICI-based treatment beyond progression (TBP) may be beneficial to advanced NSCLC. This retrospective study aimed to evaluate the efficacy of this treatment approach in advanced NSCLC and identify potential beneficial factors. Methods: Patients with stage IV NSCLC who received ICI-based treatment after the failure of prior PD-1/PD-L1 inhibitor treatments (monotherapy or combination therapy) between January 2016 and July 2020 were enrolled. Their clinical characteristics and treatment procedures were collected, and the follow-up would be performed. Results: A total of 204 patients were included. All patients had disease progression after prior immunotherapy, with 49.5% (101/204) of patients presenting with new metastasis lesions and the rest 50.5% (103/204) of patients' progression on originate lesions. Within the entire cohort, the median progression-free survival (PFS) and median overall survival (OS) of ICI-based TBP with prior immunotherapy were 5.0 months (95% CI: 4.5-5.5 months) and 15.7 months (95% CI: 14.7-16.8 months), respectively. The objective response rate (ORR) and disease control rate (DCR) were 9.3% and 74.0%, respectively. According to the multivariate analysis, ICI-based combination therapy [PFS: hazard ratio (HR), 0.48, 95% confidence interval (CI): 0.28-0.84, P=0.011] (OS: HR, 0.44, 95% CI: 0.23-0.85, P=0.014), not having targetable gene alterations (PFS: HR, 0.56, 95% CI: 0.40-0.79, P=0.001) (OS: HR, 0.57, 95% CI: 0.37-0.87, P=0.009), and good response to prior immunotherapy (PFS: HR, 0.36, 95% CI: 0.24-0.53, P<0.0001) (OS: HR, 0.31, 95% CI: 0.19-0.52, P<0.0001) were independently associated with improved PFS and OS. Moreover, disease progression due to appearances of new metastasis (OS: HR, 0.56, 95% CI: 0.37-0.84, P=0.005) was only associated with better OS. Conclusions: While the ORR in patients with advanced NSCLC receiving ICI-based TBP with prior immunotherapy was limited, the DCR was relatively high in our study which is encouraging. ICI-based treatment strategy may be a reasonable option for patients who progressed from prior immunotherapy. Further prospective studies on larger sample size are warranted. © 2022 AME Publishing Company. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 11; All Open Access, Gold Open Access} -} - -@ARTICLE{Yang2023, - author = {Yang, Hongjian and Miao, Yuxi and Yu, Zhaojin and Wei, Minjie and Jiao, Xue}, - title = {Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application}, - year = {2023}, - journal = {Frontiers in Oncology}, - volume = {13}, - doi = {10.3389/fonc.2023.1107631}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149681511&doi=10.3389%2ffonc.2023.1107631&partnerID=40&md5=a55e5a7b849baaf3511be37515f7c65b}, - abstract = {Advanced non-small cell lung cancer (NSCLC) is a severe disease and still has high mortality rate after conventional treatment (e.g., surgical resection, chemotherapy, radiotherapy and targeted therapy). In NSCLC patients, cancer cells can induce immunosuppression, growth and metastasis by modulating cell adhesion molecules of both cancer cells and immune cells. Therefore, immunotherapy is increasingly concerned due to its promising anti-tumor effect and broader indication, which targets cell adhesion molecules to reverse the process. Among these therapies, immune checkpoint inhibitors (mainly anti-PD-(L)1 and anti-CTLA-4) are most successful and have been adapted as first or second line therapy in advanced NSCLC. However, drug resistance and immune-related adverse reactions restrict its further application. Further understanding of mechanism, adequate biomarkers and novel therapies are necessary to improve therapeutic effect and alleviate adverse effect. Copyright © 2023 Yang, Miao, Yu, Wei and Jiao.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Kim2022415, - author = {Kim, Kyung Hwan and Pyo, Hongryull and Lee, Hoyoung and Oh, Dongryul and Noh, Jae Myoung and Ahn, Yong Chan and Yoon, Hong In and Moon, Hyowon and Lee, Jiyun and Park, Sehhoon and Jung, Hyun-Ae and Sun, Jong-Mu and Lee, Se-Hoon and Ahn, Jin Seok and Park, Keunchil and Ku, Bo Mi and Ahn, Myung-Ju and Shin, Eui-Cheol}, - title = {Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy}, - year = {2022}, - journal = {International Journal of Radiation Oncology Biology Physics}, - volume = {113}, - number = {2}, - pages = {415 – 425}, - doi = {10.1016/j.ijrobp.2022.02.003}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85126354910&doi=10.1016%2fj.ijrobp.2022.02.003&partnerID=40&md5=cce9bdbe744693f25d8f142c64cbbc41}, - abstract = {Purpose: Chemoradiotherapy (CRT) followed by consolidation immune checkpoint inhibitors significantly improves survival in unresectable locally advanced non-small cell lung cancer. However, the optimal sequence for CRT and immune checkpoint inhibitors has not yet been established. We investigated the dynamics of peripheral blood immune cells during CRT to determine the best sequence for treatment. Methods and Materials: Peripheral blood samples were prospectively collected pretreatment, weekly during CRT for 6 weeks, and 1 month posttreatment in 24 patients with locally advanced non-small cell lung cancer who received definitive CRT. Immune cell analysis was performed by flow cytometry. Ex vivo PD-1 blockade assays were performed by IFN-γ intracellular cytokine staining. Results: Lymphopenia was prominently observed during CRT and mostly recovered 1 month post-CRT. Robust proliferation of CD8+ T cells was induced, peaking in the last week during CRT and decreasing post-CRT. The robust proliferation of CD8+ T cells led to an increase in the frequency of CD28–CD57+ replicative senescent and terminally differentiated cells post-CRT. Tumor-reactive CD8+ T cells increased during CRT and peaked in the last week. One month post-CRT, the frequency of tumor-reactive CD8+ T cells decreased and TOXhiTCF1lo terminally exhausted CD8+ T cells significantly increased. Anti-PD-1-induced functional restoration of PD-1+CD8+ T cells was maximized in the last week of CRT and significantly decreased post-CRT. Conclusions: The findings suggest that earlier administration of PD-1 blockade may be associated with superior efficacy compared with delayed administration after completion of CRT. These findings provide an immunologic rationale for optimal timing of combining immune checkpoint inhibitors with CRT in clinical trials. © 2022 Elsevier Inc.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 10} -} - -@ARTICLE{Sathiyapalan20229046, - author = {Sathiyapalan, Arani and Febbraro, Michela and Pond, Gregory R. and Ellis, Peter M.}, - title = {Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis}, - year = {2022}, - journal = {Current Oncology}, - volume = {29}, - number = {12}, - pages = {9046 – 9065}, - doi = {10.3390/curroncol29120709}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144499070&doi=10.3390%2fcurroncol29120709&partnerID=40&md5=40832ddcf2bc86a63601a959b91d1bd2}, - abstract = {Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with early metastatic potential. The standard-of-care treatment has not changed in years. Recent studies report improved progression-free survival (PFS) and overall survival (OS) with combined ICI and chemotherapy in ES-SCLC. We conducted a systematic review and meta-analysis to assess the magnitude of survival benefits. We searched MEDLINE, EMBASE, and Cochrane between 1 January 2010 and 15 July 2022 and conference proceedings from 2018 to 2022, for randomised controlled trials, evaluating chemo-ICI compared with platinum-doublet chemotherapy in untreated ES-SCLC. Outcomes assessed were PFS, OS, objective response rate (ORR), duration of response (DoR), toxicity, and health-related quality of life (HRQoL). The search identified 8061 studies, with 8 (56 publications) included in the final analysis. PFS and OS were significantly improved for patients randomised to chemo-ICI (PFS hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.70–0.80) and (OS HR 0.79, 95% CI 0.73–0.85). Subgroup analysis demonstrated a differential effect between PD-1/PD-L1 and CTLA-4 inhibitors. There was no difference in ORR and DoR. All-grade adverse events (RR 1.06, 95% CI 1.00–1.12) were similar. The addition of ICI to chemotherapy in untreated ES-SCLC results in a 22% risk reduction in death, and a 25% risk reduction in disease progression with a minimal increase in toxicity. These improvements are modest but represent progress beyond the standard of care. © 2022 by the authors.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 13; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Jiang2022, - author = {Jiang, Xiaotong and Chen, Jinyu and Zheng, Min and Jia, Hanxue}, - title = {Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china}, - year = {2022}, - journal = {PLoS ONE}, - volume = {17}, - number = {6 June}, - doi = {10.1371/journal.pone.0270118}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132818194&doi=10.1371%2fjournal.pone.0270118&partnerID=40&md5=10ede143b8525f28982242e23cf05a16}, - abstract = {Objective The aim of this study was to evaluate the cost-effectiveness of durvalumab compared with Best supportive care (BSC) after chemoradiotherapy in patients with stage III non-small cell lung cancer from healthcare system perspective in China. Methods A dynamic state transition model was adopted to simulate life time, direct medical costs and QALYs. In the base case scenario, for patients with unresectable, stage Ⅲ non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiation therapy, the treatment group would use durvalumab whereas the control group would use BSC. Clinical data and health utility were derived from the patient-level data of Asian ethnicity in the PACIFIC trial. Cost of drug acquisition, follow-up, medical service, inspection, terminal care and adverse event treatment were considered in this model. The cost of durvalumab was calculated based on retail prices and Patient Assistance Program. Results In the base case, the durvalumab group yielded an additional 2.60 LYs and 2.37QALYs (discounted), causing an additional cost of 0.459 million RMB and 0.109 million RMB without and with PAP, so the ICER was 193,898 RMB/QALY and 46,093.12 RMB/QALY respectively. Conclusions This study demonstrated that durvalumab can improve the survival of patients with unresectable, stage Ⅲ non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiation therapy and would be a cost-effective option compared with BSC at a willingness to pay (WTP) threshold of 212676 RMB (three times GDP per capita of China in 2019). © 2022 Jiang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Vafaei2022, - author = {Vafaei, Somayeh and Zekiy, Angelina O. and Khanamir, Ramadhan Ado and Zaman, Burhan Abdullah and Ghayourvahdat, Arman and Azimizonuzi, Hannaneh and Zamani, Majid}, - title = {Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier}, - year = {2022}, - journal = {Cancer Cell International}, - volume = {22}, - number = {1}, - doi = {10.1186/s12935-021-02407-8}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122295584&doi=10.1186%2fs12935-021-02407-8&partnerID=40&md5=b1ad469ec9070b4e2b10d45181b56231}, - abstract = {Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects. Though, tumor inherent or acquired resistance to ICIs accompanied with treatment-related toxicities hamper their clinical utility. Overall, about 60–70% of patients (e.g., melanoma and lung cancer) who received ICIs show no objective response to intervention. The resistance to ICIs mainly caused by alterations in the tumor microenvironment (TME), which in turn, supports angiogenesis and also blocks immune cell antitumor activities, facilitating tumor cells' evasion from host immunosurveillance. Thereby, it has been supposed and also validated that combination therapy with ICIs and other therapeutic means, ranging from chemoradiotherapy to targeted therapies as well as cancer vaccines, can capably compromise tumor resistance to immune checkpoint blocked therapy. Herein, we have focused on the therapeutic benefits of ICIs as a groundbreaking approach in the context of tumor immunotherapy and also deliver an overview concerning the therapeutic influences of the addition of ICIs to other modalities to circumvent tumor resistance to ICIs. © 2021, The Author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 107; All Open Access, Gold Open Access} -} - -@ARTICLE{Shukla2022, - author = {Shukla, Utkarsh and Chhabra, Arpit and Wazer, David and Chowdhary, Mudit}, - title = {American Society of Clinical Oncology 2021 Annual Meeting Highlights for Radiation Oncologists}, - year = {2022}, - journal = {Advances in Radiation Oncology}, - volume = {7}, - number = {1}, - doi = {10.1016/j.adro.2021.100779}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119601131&doi=10.1016%2fj.adro.2021.100779&partnerID=40&md5=b5644a4b9996ae8fe152c00df274d90a}, - abstract = {The annual meeting of the American Society of Clinical Oncology is the largest multidisciplinary oncology-focused conference in the world. With more than 4900 total abstracts in 2021 alone, it is difficult for individuals to evaluate all the results. This article presents a review of 32 selected abstracts across all disease sites, focusing on those of greatest relevance to radiation oncologists. © 2021 The Authors}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access} -} - -@ARTICLE{Rekulapelli2023, - author = {Rekulapelli, Akhil and E. Flausino, Lucas and Iyer, Gayatri and Balkrishnan, Rajesh}, - title = {Effectiveness of immunological agents in non-small cell lung cancer}, - year = {2023}, - journal = {Cancer Reports}, - volume = {6}, - number = {1}, - doi = {10.1002/cnr2.1739}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85141380040&doi=10.1002%2fcnr2.1739&partnerID=40&md5=56dc6794b7a95456998f426b1bce482a}, - abstract = {Background and aim: Non-small cell lung cancer (NSCLC) continues to claim millions of lives worldwide. Although its poor prognosis is largely attributed to the lack of adequate and precise detection technologies, cancer cells’ suppression of the immune system adds on to the difficulty of identifying abnormal NSCLC tumors in their early stages. Therefore, cancer immunotherapy, which activates the immune system and helps it fight tumors, has recently become the most sought-after technique, especially in the advanced stages of NSCLC, where surgery or chemotherapy may or may not bring about the desired survival benefits in patients. Methods: This review focuses on the various immunotherapeutic interventions and their efficacy in advanced NSCLC clinical trials. Monoclonal antibodies like anti-PD-1/PD-L1 agents and anti-CTLA-4 antibodies, cancer vaccines, oncolytic viruses and adoptive T cell therapy have been discussed in brief. Furthermore, the effects of gender, age, and race on the efficacy of immune checkpoint inhibitors and suggest plausible future approaches in the realm of immuno-oncology. Results: Immunotherapy is used alone or in combination either with other immunological agents or with chemotherapy. However, the efficacy of these strategies depends extensively on various demographic variables, as some patients respond perfectly well to immunotherapy, while others do not benefit at all or experience disease progression. By targeting a “hallmark” of cancer (immune evasion), immunotherapy has transformed NSCLC management, though several barriers prevent its complete effectiveness. Conclusions: All these immunological strategies should be interpreted in the current setting of synergistic treatment, in which these agents can be combined with chemotherapy, radiotherapy, and, or surgery following patient and tumor characteristics to proportionate the best-individualized treatment and achieve superior results. To better pursue this goal, further investigations on cost-effectiveness and sex-gender, race, and age differences in immunotherapy are needed. © 2022 The Authors. Cancer Reports published by Wiley Periodicals LLC.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Ascierto2022, - author = {Ascierto, Paolo A. and Avallone, Antonio and Bhardwaj, Nina and Bifulco, Carlo and Bracarda, Sergio and Brody, Joshua D. and Buonaguro, Luigi and Demaria, Sandra and Emens, Leisha A. and Ferris, Robert L. and Galon, Jérôme and Khleif, Samir N. and Klebanoff, Christopher A. and Laskowski, Tamara and Melero, Ignacio and Paulos, Chrystal M. and Pignata, Sandro and Ruella, Marco and Svane, Inge Marie and Taube, Janis M. and Fox, Bernard A. and Hwu, Patrick and Puzanov, Igor}, - title = {Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021}, - year = {2022}, - journal = {Journal of Translational Medicine}, - volume = {20}, - number = {1}, - doi = {10.1186/s12967-022-03471-y}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131465855&doi=10.1186%2fs12967-022-03471-y&partnerID=40&md5=f8b9f262042b5d46aebdd55a2b5ad501}, - abstract = {Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients with different cancers has focused attention on the potential for other immunotherapeutic approaches. These include inhibitors of additional immune checkpoints, adoptive cell transfer (ACT), and therapeutic vaccines. Patients with advanced cancers who previously had limited treatment options available may now benefit from immunotherapies that can offer durable responses and improved survival outcomes. However, despite this, a significant proportion of patients fail to respond to immunotherapy, especially those with less immunoresponsive cancer types, and there remains a need for new treatment strategies. The virtual Immunotherapy Bridge (December 1st–2nd, 2021), organized by the Fondazione Melanoma Onlus, Naples, Italy in collaboration with the Society for Immunotherapy of Cancer addressed several areas of current research in immunotherapy, including lessons learned from cell therapies, drivers of immune response, and trends in immunotherapy across different cancers, and these are summarised here. © 2022, The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Gold Open Access} -} - -@ARTICLE{Gowd2022624, - author = {Gowd, Vemana and Ahmad, Anas and Tarique, Mohammad and Suhail, Mohd and Zughaibi, Torki A. and Tabrez, Shams and Khan, Rehan}, - title = {Advancement of cancer immunotherapy using nanoparticles-based nanomedicine}, - year = {2022}, - journal = {Seminars in Cancer Biology}, - volume = {86}, - pages = {624 – 644}, - doi = {10.1016/j.semcancer.2022.03.026}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128185421&doi=10.1016%2fj.semcancer.2022.03.026&partnerID=40&md5=36885446f3066f1643a86205780c63ab}, - abstract = {Cancer has complex pathophysiology and is one of the primary causes of death and morbidity across the world. Chemotherapy, targeted therapy, radiation therapy, and immunotherapy are examples of traditional cancer treatments. However, these conventional treatment regimens have many drawbacks, such as lack of selectivity, non-targeted cytotoxicity, insufficient drug delivery at tumor sites, and multi-drug resistance, leading to less potent/ineffective cancer treatment. Due to its immanent biophysical property and ability to change in numerous ways, nano-technology has completely transformed how cancer is identified and treated in recent years. Furthermore, nanotechnology providing solutions to these restrictions and boosting cancer therapy. Nanoparticles are widely used nanomedicine platform in cancer immunotherapy due to their excellent physicochemical properties that include size, shape, and surface features, resulting into desirable biological interactions and have been categorized into several types. Nanoparticles can also be potentially be up taken by antigen-presenting cells that promote the cytosolic delivery of encapsulated antigens and adjuvants. Furthermore, nanoparticles can be fine-tuned and functionalized with specific moieties to promote their efficacy in targeting and delivering cargo materials to specific locations. In this review, we summarized and discussed nanoparticles and potential features to be used as carriers in cancer immunotherapy, the current status of different types of nanoparticles, and the importance of their functionalization. Furthermore, we have also discussed nanoparticles-based nanomedicine in targeted delivery of encapsulated cancer immunotherapeutic and their involvement in the modulation of the tumor microenvironment, promoting cancer immunotherapy. © 2022 Elsevier Ltd}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 67} -} - -@ARTICLE{Tian2022, - author = {Tian, Zhichao and Yao, Weitao}, - title = {Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas}, - year = {2022}, - journal = {Frontiers in Oncology}, - volume = {12}, - doi = {10.3389/fonc.2022.815900}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125282202&doi=10.3389%2ffonc.2022.815900&partnerID=40&md5=0d07d55f873a6c9fb3b33b68fbb373c3}, - abstract = {Taxanes (paclitaxel and docetaxel) play an important role in the treatment of advanced sarcomas. Albumin-bound paclitaxel (nab-paclitaxel) is a new kind of taxane and has many advantages compared with paclitaxel and docetaxel. Nab-paclitaxel is currently approved for the treatment of advanced breast, non-small cell lung, and pancreatic cancers. However, the efficacy of nab-paclitaxel in sarcomas has not been reviewed. In this review, we first compare the similarities and differences among nab-paclitaxel, paclitaxel, and docetaxel and then summarize the efficacy of nab-paclitaxel against various non-sarcoma malignancies based on clinical trials with reported results. The efficacy and clinical research progress on nab-paclitaxel in sarcomas are also summarized. This review will serve as a good reference for the application of nab-paclitaxel in clinical sarcoma treatment studies and the design of clinical trials. Copyright © 2022 Tian and Yao.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 21; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Baudoux2023, - author = {Baudoux, Nathalie and Friedlaender, Alex and Addeo, Alfredo}, - title = {Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer}, - year = {2023}, - journal = {Clinical Medicine Insights: Oncology}, - volume = {17}, - doi = {10.1177/11795549231152948}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148433700&doi=10.1177%2f11795549231152948&partnerID=40&md5=72ff147881038b641b35d3eb58986708}, - abstract = {Lung cancer remains the leading cause of cancer-related death with an incidence that continues to increase in both sexes and all ages. However, 80% to 90% of lung cancers are non-small cell lung cancer (NSCLC) and the remaining 10% to 20% are small cell lung cancer. Adenocarcinoma is the most common histologic subtype of lung cancer worldwide. More frequently, lung cancer diagnosis is made in advanced stages. Stage III NSCLC refers to locoregionally advanced disease without metastases and represents about 30% NSCLC cases. Despite the absence of metastases at diagnosis, the outcome is generally poor. Stage III comprises a heterogeneous group and optimal management requires the input of a multidisciplinary team. All modalities of oncologic treatment are involved: surgery, chemotherapy, radiotherapy, and more recently, immunotherapy and targeted therapy. We will discuss the different therapeutic options in stage III NSCLC, both in operable and inoperable scenarios, and the role of immunotherapy and targeted therapy. © The Author(s) 2023.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access} -} - -@ARTICLE{Mantovani2022799, - author = {Mantovani, Alberto and Allavena, Paola and Marchesi, Federica and Garlanda, Cecilia}, - title = {Macrophages as tools and targets in cancer therapy}, - year = {2022}, - journal = {Nature Reviews Drug Discovery}, - volume = {21}, - number = {11}, - pages = {799 – 820}, - doi = {10.1038/s41573-022-00520-5}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136204988&doi=10.1038%2fs41573-022-00520-5&partnerID=40&md5=64a130093ef772cc25fa9fe2a91895f8}, - abstract = {Tumour-associated macrophages are an essential component of the tumour microenvironment and have a role in the orchestration of angiogenesis, extracellular matrix remodelling, cancer cell proliferation, metastasis and immunosuppression, as well as in resistance to chemotherapeutic agents and checkpoint blockade immunotherapy. Conversely, when appropriately activated, macrophages can mediate phagocytosis of cancer cells and cytotoxic tumour killing, and engage in effective bidirectional interactions with components of the innate and adaptive immune system. Therefore, they have emerged as therapeutic targets in cancer therapy. Macrophage-targeting strategies include inhibitors of cytokines and chemokines involved in the recruitment and polarization of tumour-promoting myeloid cells as well as activators of their antitumorigenic and immunostimulating functions. Early clinical trials suggest that targeting negative regulators (checkpoints) of myeloid cell function indeed has antitumor potential. Finally, given the continuous recruitment of myelomonocytic cells into tumour tissues, macrophages are candidates for cell therapy with the development of chimeric antigen receptor effector cells. Macrophage-centred therapeutic strategies have the potential to complement, and synergize with, currently available tools in the oncology armamentarium. © 2022, Springer Nature Limited.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 686; All Open Access, Bronze Open Access, Green Open Access} -} - -@ARTICLE{Jabbour2022168, - author = {Jabbour, Salma K. and Keller, Steven M. and Reck, Martin}, - title = {Analysis of Outcomes with Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer - Reply}, - year = {2022}, - journal = {JAMA Oncology}, - volume = {8}, - number = {1}, - pages = {168 – 169}, - doi = {10.1001/jamaoncol.2021.5611}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118985079&doi=10.1001%2fjamaoncol.2021.5611&partnerID=40&md5=95788e5cc1c562098643a0c4bf81029b}, - type = {Letter}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2} -} - -@ARTICLE{Aghanejad2022592, - author = {Aghanejad, Ayuob and Bonab, Samad Farashi and Sepehri, Maryam and Haghighi, Fatemeh Sadat and Tarighatnia, Ali and Kreiter, Christopher and Nader, Nader D. and Tohidkia, Mohammad Reza}, - title = {A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors}, - year = {2022}, - journal = {International Journal of Biological Macromolecules}, - volume = {207}, - pages = {592 – 610}, - doi = {10.1016/j.ijbiomac.2022.03.057}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85126276751&doi=10.1016%2fj.ijbiomac.2022.03.057&partnerID=40&md5=2c54ac452abaf993061db9c6d8a93b3f}, - abstract = {Monoclonal antibodies (mAbs) as biological macromolecules have been remarked the large and growing pipline of the pharmaceutical market and also the most promising tool in modern medicine for cancer therapy. These therapeutic entities, which consist of whole mAbs, armed mAbs (i.e., antibody-toxin conjugates, antibody-drug conjugates, and antibody-radionuclide conjugates), and antibody fragments, mostly target tumor cells. However, due to intrinsic heterogeneity of cancer diseases, tumor cells targeting mAb have been encountered with difficulties in their unpredictable efficacy as well as variability in remission and durable clinical benefits among cancer patients. To address these pitfalls, the area has undergone two major evolutions with the intent of minimizing anti-drug responses and addressing limitations experienced with tumor cell-targeted therapies. As a novel hallmark of cancer, the tumor microenvironment (TME) is becoming the great importance of attention to develop innovative strategies based on therapeutic mAbs. Here, we underscore innovative strategies targeting TME by mAbs which destroy tumor cells indirectly through targeting vasculature system (e.g., anti-angiogenesis), immune system modulation (i.e., stimulation, suppression, and depletion), the targeting and blocking of stroma-based growth signals (e.g., cancer-associated fibroblasts), and targeting cancer stem cells, as well as, their effector mechanisms, clinical uses, and relevant mechanisms of resistance. © 2022 Elsevier B.V.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 53} -} - -@ARTICLE{De Mello2022, - author = {De Mello, Ramon Andrade Bezerra and Voscaboinik, Rafael and Luciano, João Vittor Pires and Cremonese, Rafaela Vilela and Amaral, Giovanna Araujo and Castelo-Branco, Pedro and Antoniou, Georgios}, - title = {Immunotherapy in patients with advanced non-small cell lung cancer lacking driver mutations and future perspectives}, - year = {2022}, - journal = {Cancers}, - volume = {14}, - number = {1}, - doi = {10.3390/cancers14010122}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121752579&doi=10.3390%2fcancers14010122&partnerID=40&md5=344c45646a6c0091ed5e30f6dd7934ac}, - abstract = {From a complete literature review, we were able to present in this paper what is most current in the treatment with immunotherapy for advanced non-small cell lung cancer (NSCLC). Especially the use of immunotherapy, particularly inhibitors of PD-1 (programmed cell death protein 1), PDL-1 (programmed cell death protein ligand 1), and CTLA-4 (cytotoxic T-lymphocyte antigen 4). Since 2015, these drugs have transformed the treatment of advanced NSCLC lacking driver mutations, evolving from second-line therapy to first-line, with excellent results. The arrival of new checkpoint inhibitors such as cemiplimab and the use of checkpoint inhibitors earlier in the therapy of advanced and metastatic cancers has been making the future prospects for treating NSCLC lacking driver mutations more favorable and optimistic. In addition, for those patients who have low PDL-1 positivity tumors, the combination of cytotoxic chemotherapy, VEGF inhibitor, and immunotherapy have shown an important improvement in global survival and progression free survival regardless the PDL-1 status. We also explored the effectiveness of adding radiotherapy to immunotherapy and the most current results about this combination. One concern that cannot be overlooked is the safety profile of immune checkpoint inhibitors (ICI) and the most common toxicities are described throughout this paper as well as tumor resistance to ICI. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 17; All Open Access, Gold Open Access} -} - -@ARTICLE{Arora2022577, - author = {Arora, Sankalp and Asawa, Palash and Kataria, Nilansh and Hendriks, Lizza E.L. and Desai, Aakash P.}, - title = {Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022}, - year = {2022}, - journal = {Cancer Investigation}, - volume = {40}, - number = {7}, - pages = {577 – 589}, - doi = {10.1080/07357907.2022.2077566}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85133228335&doi=10.1080%2f07357907.2022.2077566&partnerID=40&md5=12ad0b6cdce6c5b9af3e7a5ad1881fab}, - abstract = {The recently concluded European Lung Cancer Congress 2022 (ELCC22) showcased some very exciting data, with more than 200 abstracts presented during the meeting. Through this review, we focus on selected clinically relevant abstracts that in our opinion represent significant updates in the current management of non-small cell lung cancer (NSCLC). Here, we summarize the updates in surgical management, adjuvant therapy and therapy for advanced stage NSCLC and put these advances in the context of the current clinical standard of care. © 2022 Taylor & Francis Group, LLC.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Green Open Access} -} - -@ARTICLE{Pham2023, - author = {Pham, Timothy T. and Gordon, Aliza S. and Chen, Xiaoxue and Debono, David and Fisch, Michael J.}, - title = {Immunotherapy in combination with chemotherapy vs. immunotherapy alone for advanced non-small cell lung cancer and programmed death ligand 1 score <50%}, - year = {2023}, - journal = {Cancer Treatment and Research Communications}, - volume = {37}, - doi = {10.1016/j.ctarc.2023.100769}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85173989254&doi=10.1016%2fj.ctarc.2023.100769&partnerID=40&md5=afcb53ab69acc812583117bcf900b675}, - abstract = {Introduction: Little is known about the effectiveness of immunotherapy alone or with chemotherapy for patients with non-small cell lung cancer (NSCLC) and programmed death ligand 1 (PD-L1) expression <50 %. We examined the outcomes of PD-L1 therapy vs. PD-L1 therapy in combination with chemotherapy as first-line treatment among NSCLC patients with PD-L1 score <50 %. Methods: We used administrative claims and prior authorization data of a national insurer from November 2015 to July 2021. We selected patients with Stage IIIb/IV NSCLC and PD-L1 expression <50 %. Each patient was required to have ≥1 claim of a PD-L1 or PD-1 inhibitor. Treatment groups were propensity-score matched 1:1 on baseline characteristics. We measured PD-L1 therapy duration, incident immune-related adverse events (irAEs), healthcare utilization, costs, and overall survival (OS). Results: In the matched sample totaling 176 patients, mean duration of PD-L1 therapy was similar (4.1 [SD 3.3] months combination vs. 4.0 [SD 4.9] months monotherapy, p = 0.800). IrAEs were similar, both for FDA-recognized irAEs (48.9 % combination, 48.9 % monotherapy, p = 0.710) and other types (34.1 % combination, 39.8 % monotherapy, p = 0.473). The combination group had more all-cause inpatient stays, ER visits, and outpatient visits (all p < 0.001). Total adjusted all-cause medical cost was $112,833 (95 % CI $5,548-$251,973) higher for combination therapy. We saw no difference in OS (adjusted hazard ratio 1.09 [95 % CI 0.72–1.65]). Conclusion: This study found no difference in adverse drug effects or survival between PD-L1 monotherapy compared to combination therapy for patients with Stage IIIb/IV NSCLC and PD-L1 expression <50 %, though the combination therapy cohort had higher healthcare utilization and costs. Use of immunotherapy alone or combined with chemotherapy for patients with non-small cell lung cancer and programmed death ligand 1 expression <50 % is understudied. Our observational study using claims and authorization data from a matched sample of 176 patients found no difference in survival or the rate of adverse drug effects between groups, although the chemo-immunotherapy cohort generated higher overall healthcare costs. © 2023}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Shinada202399, - author = {Shinada, Kanako and Murakami, Shuji}, - title = {Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward}, - year = {2023}, - journal = {OncoTargets and Therapy}, - volume = {16}, - pages = {99 – 108}, - doi = {10.2147/OTT.S399657}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148443382&doi=10.2147%2fOTT.S399657&partnerID=40&md5=c7d2c14c97bdf9efd2ea80bff681cbd9}, - abstract = {Perioperative therapy for non-small cell lung cancer has been studied extensively in a bid to improve overall survival, as approximately half of the patients with surgically resectable tumors at the time of diagnosis relapse. In recent years, immune checkpoint inhibitor therapies, such as the anti-programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) blockade, have contributed to achieving an improved overall survival of patients with advanced stage lung cancer. Thus, the development of this treatment strategy has considerable potential to precipitate a breakthrough in cancer immunotherapy. PD-1/PD-L1 blockade has several potential immunological benefits when used as a neoadjuvant therapy. However, there are concerns associated with this neoadjuvant therapy. Many studies have reported its efficacy, but there is limited evidence regarding the long-term survival of patients. Similarly, it is unclear whether existing biomarkers are adequate for monitoring the prognosis of patients, or if new biomarkers are required. In this article, we present recent reports on neoadjuvant PD-1/PD-L1 blockade therapy and discuss its future challenges. © 2023 Shinada and Murakamicom/terms.php and incorporate.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Mahmood2022136, - author = {Mahmood, Umair}, - title = {Radiotherapy driven immunomodulation of the tumor microenvironment and its impact on clinical outcomes: a promising new treatment paradigm}, - year = {2022}, - journal = {Immunological Medicine}, - volume = {45}, - number = {3}, - pages = {136 – 145}, - doi = {10.1080/25785826.2021.1997268}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118303719&doi=10.1080%2f25785826.2021.1997268&partnerID=40&md5=906990dda8da2914aef30808fe24ab0d}, - abstract = {Traditional treatment approaches for advanced malignancies have been associated with limited clinical outcomes necessitating the development of novel therapies. However, the ability of radiotherapy to induce pro-immunogenic changes in tumor immune microenvironment can be leveraged when combined with systemic agents. Radio-immunotherapeutic initiatives employing the use of monoclonal antibodies, genetically engineered T cells, cytokines and virus-vector mediated gene therapies have demonstrated promising potential for the management of various solid malignancies. Future studies incorporating biomarker enrichment strategies and radiobiological variables could pave the way for immune-oncology based personalized medicine approaches to be integrated in standard of care practices for the treatment of challenging clinical populations. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of the Japanese Society of Clinical Immunology.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Wu2022E842, - author = {Wu, Jia-Jun and Huang, Jing-Wen and Hsu, Kuo-Hsuan and Huang, Yen-Hsiang and Chen, Kun-Chieh and Tseng, Jeng-Sen and Yang, Tsung-Ying and Chang, Gee-Chen}, - title = {Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy}, - year = {2022}, - journal = {Anti-Cancer Drugs}, - volume = {33}, - number = {10}, - pages = {E842 – E849}, - doi = {10.1097/CAD.0000000000001374}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85140274659&doi=10.1097%2fCAD.0000000000001374&partnerID=40&md5=4668c9194e4cc611ef77d0687731fdec}, - abstract = {Objective Immunotherapy plus etoposide and platinum (EP)-based chemotherapy is the standard of care for patients with extensive stage-small cell lung carcinoma (ES-SCLC). In the era of immunotherapy, the role of thoracic radiotherapy for ES-SCLC remains unclear. Methods We retrospectively included ES-SCLC patients treated with first-line EP-based chemotherapy plus atezolizumab or durvalumab at Taichung Veterans General Hospital to evaluate the prognostic role and safety of thoracic radiotherapy. Results A total of 22 patients were included. The median age was 64 years and most of them were male and smokers. Sixteen patients (72.7%) received durvalumab, while the other 6 patients (27.3%) underwent atezolizumab treatment. Among these patients, 11 (50.0%) had a history of thoracic radiotherapy. There was no significant difference in baseline characteristics between patients with and without thoracic radiotherapy. In the overall population, the objective response rate to immunotherapy plus chemotherapy was 73.7%. The progression-free survival and overall survival were 6.0 months (95% CI: 4.0-7.9) and 13.8 months (95% CI: 8.0-19.6), respectively. The overall survival was significantly longer in patients with thoracic radiotherapy (not-reached [NR] [95% CI NR-NR] vs. 9.6 months [95% CI 2.5-16.6]), respectively (P value by log-rank test <0.001). Both multivariate analysis and subgroup analysis specifically comparing patients with consolidative thoracic radiotherapy and patients with clinical benefits to systemic therapy who did not undergo thoracic radiotherapy indicated that thoracic radiotherapy improved survival. Conclusion The real-world efficacy of EP-based chemotherapy plus atezolizumab or durvalumab was comparable with that of clinical trials. Thoracic radiotherapy may improve the outcome of ES-SCLC. © 2022 Lippincott Williams and Wilkins. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 9} -} - -@ARTICLE{Wang2022, - author = {Wang, Lina and Xu, Xiaolong and Shang, Bin and Sun, Jian and Liang, Bin and Wang, Xingguang and You, Wenjie and Jiang, Shujuan}, - title = {High farnesoid X receptor expression predicts favorable clinical outcomes in PD-L1low/negative non-small cell lung cancer patients receiving anti-PD-1-based chemo-immunotherapy}, - year = {2022}, - journal = {International Journal of Oncology}, - volume = {60}, - number = {4}, - doi = {10.3892/ijo.2022.5330}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125299375&doi=10.3892%2fijo.2022.5330&partnerID=40&md5=e37e66b3b6b64e7f99916de03186c30b}, - abstract = {Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)-directed immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). However, predictive biomarkers are still lacking, particularly in identifying PD-L1low/negative patients who will benefit from immunotherapy. It was previously reported that farnesoid X receptor (FXR) downregulated PD-L1 expression in NSCLC, and that FXRhighPD-L1low mouse Lewis lung carcinoma tumors showed an increased susceptibility to PD-1 blockade compared with mock tumors. At present, whether the FXRhighPD-L1low phenotype predicts clinical response to immunotherapy in patients with NSCLC remains unclear. Herein, a retrospective study was conducted to examine the expression levels of FXR, PD-L1 and CD8+ T cells by immunohistochemistry in a cohort of 149 patients with NSCLC receiving anti-PD-1-based chemo-immunotherapy. The results revealed that high FXR and PD-L1 expression levels were associated with higher objective response rates (ORR) in all patients. High PD-L1 expression also indicated superior progression-free survival (PFS). Interestingly, an inverse correlation was identified between FXR and PD-L1 expression in specimens with NSCLC. Subgroup analysis revealed that high FXR expression was associated with a higher ORR, as well as longer PFS and overall survival (OS) in PD-L1low patients. Cox multivariate analysis revealed that high FXR expression was an independent predictor for PFS and OS in PD-L1low patients. Tumor microenvironment evaluation revealed a statistically significant decrease of infiltrating CD8+ T cells in FXRhigh specimens with NSCLC. Overall, the present study proposed an FXRhighPD-L1low signature as a candidate predictor of response to anti-PD-1-based chemo-immunotherapy in PD-L1low/negative patients with NSCLC, providing evidence that could be used to broaden the patients benefitting from immunotherapy. © 2022 Spandidos Publications. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Qu2023317, - author = {Qu, Fanjie and Yan, Xin and Yu, Weiwei}, - title = {Combination toripalimab and bevacizumab for an elderly urothelial carcinoma patient with brain metastasis who failed rapidly after radiotherapy: a case report and literature review}, - year = {2023}, - journal = {Anti-Cancer Drugs}, - volume = {34}, - number = {2}, - pages = {317 – 324}, - doi = {10.1097/CAD.0000000000001407}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85147720626&doi=10.1097%2fCAD.0000000000001407&partnerID=40&md5=dc527aa2258cee9f42cb7272c69cb400}, - abstract = {Brain metastasis is a rare refractory event in patients with urothelial carcinoma. Platinum-based chemotherapy is the recommended first-line standard therapy for all metastasis urothelial carcinoma patients eligible for cisplatin or carboplatin. Patients ineligible for platinum may receive immunotherapy. No clear evidence exists that UC with brain metastasis is sensitive to immunotherapy, and the optimal treatment for patients with BM is uncertain. We evaluated the safety and efficacy of combined immunotherapy and antivascular therapy in an elderly patient with urothelial carcinoma with brain metastasis, and summarize the currently available evidence. First, she underwent a left nephrectomy and left ureterectomy and recovered well postoperatively. The postoperative pathologic findings were consistent with urothelial carcinoma. Approximately 2 years later, the patient developed impaired limb movement on the right side and underwent MRI, which revealed lesions in the left frontal lobe and suggested brain metastasis. The brain metastasis responded to local radiotherapy but progressed again in a short time. Then, the patient was administered toripalimab at 240 mg combined with bevacizumab at 300 mg every 3 weeks. After 1cycle of treatment, the patient achieved a quick response, and symptoms improved significantly. Repeat evaluation imaging demonstrated that the lesions in the brain and lung were significantly smaller and evaluation showed partial response. The treatment was well tolerated and the patient remained in partial response until the last follow-up by July 2022, 6 months after the initiation of treatment. This case suggests that immune checkpoint blockade combined with antivascular therapy might be a new possibility for patients with metastatic urothelial carcinoma, including brain metastases. © 2023 Lippincott Williams and Wilkins. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Green Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Liu2022112, - author = {Liu, Yufei and Yao, Luyang and Kalhor, Neda and Carter, Brett W. and Altan, Mehmet and Blumenschein, George and Byers, Lauren A. and Fossella, Frank and Gibbons, Don L. and Kurie, Jonathan M. and Lu, Charles and Skoulidis, Ferdinandos and Chang, Joe Y. and Liao, Zhongxing and Gomez, Daniel R. and O'Reilly, Michael and Heymach, John V. and Tsao, Anne S. and Lin, Steven H.}, - title = {Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial}, - year = {2022}, - journal = {Lung Cancer}, - volume = {174}, - pages = {112 – 117}, - doi = {10.1016/j.lungcan.2022.10.006}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85141526535&doi=10.1016%2fj.lungcan.2022.10.006&partnerID=40&md5=d950c9609a5632713b2165cce801a6f3}, - abstract = {Introduction: The phase II DETERRED trial assessed the safety and efficacy of consolidation and concurrent immunotherapy with chemoradiation in unresectable locally advanced non-small cell lung cancer. We present updated efficacy analysis of this trial. Methods: The trial was conducted in 2 parts with patients in part 1 (n = 10) receiving chemoradiation with consolidation atezolizumab, while patients in part 2 (n = 30) received concurrent and consolidation atezolizumab. Progression-free survival (PFS), time to second progression (PFS2), and overall survival (OS) were assessed using Kaplan-Meier analysis. Subset analyses were performed by programmed cell death ligand-1 (PD-L1) status and targetable driver oncogene mutation status. Results: At a median follow-up of 39.2 months, the median PFS for part 1 was 18.9 months and 15.1 months for part 2. Median OS for part 1 was 26.5 months and was not reached for part 2. For the cohort, 3-year OS was 53.8%, while 4-year OS was 47.4%. Patients with targetable driver oncogene mutations had a median PFS of 9.4 months and OS of not reached compared to 16.6 months (HR: 3.49, p = 0.02) and 26.9 months (HR: 0.40, p = 0.12) respectively compared to those without targetable driver oncogene mutations. Patients with PD-L1 < 1% had median PFS of 11.0 months and OS of 26.5 months compared to 27.4 months (HR: 2.01, p = 0.10) and not reached (HR: 1.49, p = 0.41) respectively for those with PD-L1 ≥ 1%. Conclusions: In the DETERRED trial, chemoradiation with concurrent and/or consolidative atezolizumab led to comparable efficacy as consolidative durvalumab in the PACIFIC trial. The presence of targetable driver oncogene mutations led to worse PFS, while PD-L1 < 1% trended to worse PFS. © 2022 Elsevier B.V.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 13} -} - -@ARTICLE{All2023533, - author = {All, Sean and Sher, David J.}, - title = {Multimodality Treatment of Stage IIIA/N2 Non-Small Cell Lung Cancer: When YES to Surgery}, - year = {2023}, - journal = {Medical Radiology}, - volume = {Part F1269}, - pages = {533 – 545}, - doi = {10.1007/174_2021_276}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85171155872&doi=10.1007%2f174_2021_276&partnerID=40&md5=e4fc7d8f4a8cdd8d3c31eac5ccf5a247}, - abstract = {Stage III non-small cell lung cancer (NSCLC) is comprised of a heterogeneous cohort of patient presentations that are broadly considered as “locally advanced disease,” but stage IIIA/N2 further selects a subset of this category with a potentially improved prognosis. These individuals may have ipsilateral mediastinal and/or subcarinal lymph node involvement, varying tumor size (up to 7 cm), and possible invasion of surrounding mediastinal structures. Multimodality treatment is universally accepted as the standard-of-care for their management, and historically, definitive concurrent chemoradiotherapy (CRT) has been the preferred paradigm. However, because it has been long recognized that long-term survival is feasible in a small but non-trivial and growing group of these patients, there has been considerable controversy about intensifying their local therapy by using surgical resection. In fact, there are some data that support improved locoregional control and hence progression-free and even overall survival with trimodality therapy potentially warranting the increase in morbidity. This chapter will focus on reviewing the published evidence supporting the incorporation of surgery into the multimodality treatment of stage IIIA/N2 NSCLC patients. © 2021, The Author(s), under exclusive license to Springer Nature Switzerland AG.}, - type = {Book chapter}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Wang2022425, - author = {Wang, Wei Wei and Zhang, Jia Qi and Li, Shan Qing}, - title = {Clinical Progress in the Immunotherapy of Small Cell Lung Cancer}, - year = {2022}, - journal = {Chinese Journal of Lung Cancer}, - volume = {25}, - number = {6}, - pages = {425 – 433}, - doi = {10.3779/j.issn.1009-3419.2022.102.15}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132848355&doi=10.3779%2fj.issn.1009-3419.2022.102.15&partnerID=40&md5=3eaac030de8904badfb15366725858b9}, - abstract = {Small cell lung cancer is a kind of malignant tumor with strong invasiveness and poor prognosis, and the classic therapeutic modality of the disease remains multidisciplinary and comprehensive treatment. Treatment options for small cell lung cancer have been stalled for a long time, and new opportunities have emerged in recent years due to the development and initial experience of immunotherapeutic drugs. Clinical trials of some selected immune checkpoint inhibitors have confirmed the efficacy and safety in small cell lung cancer. Based on the results of phase III clinical trials (Impower133 and CASPIAN), Atezolizumab or Durvalumab in combination with chemotherapy has been approved by the U.S. Food and Drug Administration for the first-line treatment of extensive-stage small cell lung cancer. Clinical trials involving immune checkpoint inhibitors are being actively carried out and provide different perspectives for the management of small cell lung cancer. This article aimed to review the clinical progress in immunotherapy of small cell lung cancer. © 2022, Chinese Journal of Lung Cancer. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Belluomini2022, - author = {Belluomini, Lorenzo and Calvetti, Lorenzo and Inno, Alessandro and Pasello, Giulia and Roca, Elisa and Vattemi, Emanuela and Veccia, Antonello and Menis, Jessica and Pilotto, Sara}, - title = {SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs}, - year = {2022}, - journal = {Frontiers in Oncology}, - volume = {12}, - doi = {10.3389/fonc.2022.840783}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139067450&doi=10.3389%2ffonc.2022.840783&partnerID=40&md5=93c18bd3c23fc4846207a64bcab55051}, - abstract = {Small cell lung cancer (SCLC) represents about 13%–15% of all lung cancers. It has a particularly unfavorable prognosis and in about 70% of cases occurs in the advanced stage (extended disease). Three phase III studies tested the combination of immunotherapy (atezolizumab, durvalumab with or without tremelimumab, and pembrolizumab) with double platinum chemotherapy, with practice-changing results. However, despite the high tumor mutational load and the chronic pro-inflammatory state induced by prolonged exposure to cigarette smoke, the benefit observed with immunotherapy is very modest and most patients experience disease recurrence. Unfortunately, biological, clinical, or molecular factors that can predict this risk have not yet been identified. Thanks to these clinically meaningful steps forward, SCLC is no longer considered an “orphan” disease. Innovative treatment strategies and combinations are currently under investigation to further improve the expected prognosis of patients with SCLC. Following the recent therapeutic innovations, we have reviewed the available literature data about SCLC management, with a focus on current unmet needs and potential predictive factors. In detail, the role of radiotherapy; fragile populations, such as elderly or low-performance status patients (ECOG PS 2), usually excluded from randomized studies; predictive factors of response useful to optimize and guide therapeutic choices; and new molecular targets and future combinations have been explored and revised. Copyright © 2022 Belluomini, Calvetti, Inno, Pasello, Roca, Vattemi, Veccia, Menis and Pilotto.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 20; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Barrows2022868, - author = {Barrows, Elizabeth D. and Blackburn, Matthew J. and Liu, Stephen V.}, - title = {Evolving role of immunotherapy in small cell lung cancer}, - year = {2022}, - journal = {Seminars in Cancer Biology}, - volume = {86}, - pages = {868 – 874}, - doi = {10.1016/j.semcancer.2022.02.021}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125624313&doi=10.1016%2fj.semcancer.2022.02.021&partnerID=40&md5=700b459b27d1a2e8b5a0eac0d7ca941a}, - abstract = {Small cell lung cancer (SCLC) is a highly lethal subtype of lung cancer with a particularly poor prognosis. For decades, the best available systemic therapy was platinum plus etoposide chemotherapy, which offered frequent but transient responses. Survival gains were finally realized with the addition of immune checkpoint inhibitors to first-line chemotherapy. The phase III IMpower 133 trial showed that the addition of atezolizumab to chemotherapy improved survival. The subsequent CASPIAN trial demonstrated a similar benefit with durvalumab. These results quickly established chemo-immunotherapy as the preferred initial treatment for advanced SCLC, but outcomes remain poor for most patients. Here, we review the current and evolving role of immunotherapy in SCLC and outline emerging strategies poised to further elevate the standard of care. © 2022 Elsevier Ltd}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 19} -} - -@ARTICLE{Rittberg2022, - author = {Rittberg, Rebekah and Leung, Bonnie and Al-Hashami, Zamzam and Ho, Cheryl}, - title = {Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer}, - year = {2022}, - journal = {Frontiers in Oncology}, - volume = {12}, - doi = {10.3389/fonc.2022.1002385}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139044098&doi=10.3389%2ffonc.2022.1002385&partnerID=40&md5=cf253a182b75045eb7bb4c55f1cc92eb}, - abstract = {Introduction: Small cell lung cancer (SCLC) is a rapidly progressing aggressive malignancy. Durvalumab in CASPIAN and atezolizumab in IMPower133 were found to improve overall survival (OS) for extensive-stage SCLC. Here we evaluate the proportion of real-world ES SCLC patients who may be eligible for first-line immune checkpoint inhibitor (ICI) with platinum doublet. Methods: A retrospective cohort analysis was conducted of referred ES SCLC between 2015 and 2017 in British Columbia, Canada. Patient demographics, staging, treatment, and survival data were collected through the Cancer Registry. Retrospective chart review was completed to extract past medical history and missing variables. CASPIAN/IMPower133 excluded patients with autoimmune diseases, active infection, and performance status (PS) ≥2. Results: Between 2015 and 2017, 349 patients were diagnosed with ES SCLC. In patients who received platinum-doublet chemotherapy (n=227), 15 had medical contraindication to ICI: inflammatory bowel disease (n=4), rheumatoid arthritis (n=4), idiopathic pulmonary fibrosis (n=3), lupus (n=1), Sjogren’s (n=1), Takayasu arteritis (n=1), and active tuberculosis (n=1). ECOG PS was 0–1 in 96 (45%), PS was 2 in 61 (29%), and ≥3 in 51 (10%). Prior to cycle 1, 82 (36%) patients were eligible for ICI in addition to platinum doublet, 23% of the entire ES population. After cycles 1 and 2, additional 15 (7%) and 8 (4%) patients became PS 0–1, respectively. mOS for ES SCLC who received first-line platinum doublet, non-platinum chemotherapy, and best supportive care was 8.4 1.9 and 1.5 months (p<0.001). Discussion: By CASPIAN/IMpower133 trial eligibility, only 36% of our real-world platinum-treated patients would have been eligible for the addition of ICI, which is 23% of the entire ES population in one Canadian province. After one or two cycles of chemotherapy, an additional 11% of patients showed PS improvement to 0–1. While the results of CASPIAN/IMpower133 are practice-changing, the majority of the patients will not meet clinical trial eligibility and clinical trials including patients with poor PS are necessary. Copyright © 2022 Rittberg, Leung, Al-Hashami and Ho.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 5; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Yang20226203, - author = {Yang, Rui-Xia and Hei, Yue and Zhu, Wen-Ting and Wang, Qian-Rong and Zhang, Hong-Mei and Chen, Yan}, - title = {Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report}, - year = {2022}, - journal = {Current Oncology}, - volume = {29}, - number = {9}, - pages = {6203 – 6210}, - doi = {10.3390/curroncol29090487}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85138243524&doi=10.3390%2fcurroncol29090487&partnerID=40&md5=13d8d508c4aad5e2878facf8f315d090}, - abstract = {Durvalumab consolidation therapy is the standard treatment after concurrent chemoradiotherapy for patients with surgically unresectable stage IIIA (N2) non-small-cell lung cancer (NSCLC). Neoadjuvant therapy followed by surgery could reduce locoregional and distant recurrence and improve the survival rate for surgically resectable NSCLC. However, the value of neoadjuvant therapy in locally advanced potentially resectable NSCLC remains controversial. Herein, we report a locally advanced potentially resectable NSCLC case with a history of breast cancer who achieved a pathologic complete response (pCR) after preoperative treatment with pembrolizumab and chemotherapy. A 50-year-old woman developed squamous cell carcinoma (SCC) (left lower lobe of the lung, stage IIIA-N2) after two years of chemotherapy and anti-HER2 therapy following a diagnosis of HER2-overexpressing breast cancer. Surgical resection was attempted despite an MDT classification as unamenable to curative surgical resection. After two cycles of neoadjuvant chemotherapy combined with anti-PD1 immunotherapy, the tumor significantly shrank, then the patient underwent a left lower lobectomy. Complete resection with negative margins (R0 resection) was achieved in the patient. The patient experienced grade 1–2 adverse effects and no grade 3 or worse adverse effects occurred. Cardiotoxicity did not occur in the patient despite prior anti-HER2 treatment for breast cancer. Our case study contributes to the existing evidence on the feasibility, efficacy, and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced unresectable NSCLC. Furthermore, future studies are needed to determine which patients can benefit from immunoadjuvant therapy and the duration and course of preoperative and postoperative immunotherapy. © 2022 by the authors.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Yang2022, - author = {Yang, Guanqun and Xing, Ligang and Sun, Xiaorong}, - title = {Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases}, - year = {2022}, - journal = {Frontiers in Immunology}, - volume = {13}, - doi = {10.3389/fimmu.2022.852811}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128339066&doi=10.3389%2ffimmu.2022.852811&partnerID=40&md5=cd61810a03c8ab51ebb0e0f57cc00faf}, - abstract = {Brain metastases (BMs) in non-small-cell lung cancer (NSCLC) patients are associated with significant morbidity and poor prognosis. Immune checkpoint inhibitors (ICIs) have resulted in a paradigm shift in the management of advanced NSCLC. However, the value of ICIs in NSCLC patients with BMs remains unclear because patients with BMs are routinely excluded in numerous prospective trials on ICIs. Here, starting from the mechanisms of ICIs for BMs, we will reveal the value of ICIs by reviewing the efficacy and adverse effects of ICIs monotherapy as well as promising combination strategies, such as combinations with chemotherapy, radiotherapy, and anti-angiogenic drugs, etc. In addition, the methods of patient selection and response assessment will be summarized to assist clinical practice and further studies. Copyright © 2022 Yang, Xing and Sun.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 9; All Open Access, Gold Open Access} -} - -@ARTICLE{Werner2021, - author = {Werner, Raphael S. and Opitz, Isabelle}, - title = {Patient selection for local aggressive treatment in oligometastatic non-small cell lung cancer}, - year = {2021}, - journal = {Cancers}, - volume = {13}, - number = {24}, - doi = {10.3390/cancers13246374}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121295923&doi=10.3390%2fcancers13246374&partnerID=40&md5=d7ed790fde2b223352fa11172fe05876}, - abstract = {One-fourth of all patients with metastatic non-small cell lung cancer presents with a limited number of metastases and relatively low systemic tumor burden. This oligometastatic state with limited systemic tumor burden may be associated with remarkably improved overall and progression-free survival if both primary tumor and metastases are treated radically combined with systemic therapy. This local aggressive therapy (LAT) requires a multidisciplinary approach including medical oncologists, radiation therapists, and thoracic surgeons. A surgical resection of the often advanced primary tumor should be part of the radical treatment whenever feasible. However, patient selection, timing, and a correct treatment allocation for LAT appear to be essential. In this review, we aimed to summarize and discuss the current evidence on patient selection criteria such as characteristics of the primary tumor and metastases, response to neoadjuvant or first-line treatment, molecular characteristics, mediastinal lymph node involvement, and other factors for LAT in oligometastatic NSCLC. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4; All Open Access, Gold Open Access} -} - -@ARTICLE{Schlam2022538, - author = {Schlam, Ilana and Gatti-Mays, Margaret E.}, - title = {Immune Checkpoint Inhibitors in theTreatment of Breast Cancer Brain Metastases}, - year = {2022}, - journal = {Oncologist}, - volume = {27}, - number = {7}, - pages = {538 – 547}, - doi = {10.1093/oncolo/oyac064}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85134083596&doi=10.1093%2foncolo%2foyac064&partnerID=40&md5=7f05a3bae4bed86e1aee690b8fd346df}, - abstract = {The management of breast cancer brain metastases (BCBM) has historically involved local therapies. However, as novel systemic treatments have become more effective in controlling visceral disease, BCBM have also been better controlled. Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in brain metastases in patients with lung cancer and melanoma and represent a promising option for patients with triple-negative BCBM, a group with limited systemic therapy options. In this review we summarize current data about the role of ICIs in the treatment BCBM. We identified 15 clinical trials that evaluated ICIs ± chemotherapy in patients with breast cancer. The studies were mostly focused on triple-negative breast cancer (TNBC). Of these trials, 4 excluded patients with BCBM, while 11 allowed patients with stable, treated or asymptomatic BCBM. In total, 2692 patients were enrolled in the identified clinical trials, but only 91 trial patients (3.3%) had BCBM. Furthermore, only 2 of these clinical trials reported BCBM-specific outcomes and none of the clinical trials reported BCBM-specific adverse events. Up to 45% of patients with TNBC will develop BCBM; however, only 3.3% of the patients included in the clinical trials that led to the U.S. Food and Drug Administration approvals for ICIs in advanced breast cancer had brain metastases. This review reinforces that efficacy data are greatly needed for patients with BCBM—this is an area of unmet need in oncology. More inclusive clinical trials and real-world data that evaluate the safety and efficacy of ICIs in patients with BCBM are greatly needed. © The Author(s) 2022. Published by Oxford University Press.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 6; All Open Access, Gold Open Access} -} - -@ARTICLE{Roch20221S23, - author = {Roch, B. and Pujol, J.-L.}, - title = {Apport de l'immunothérapie dans les tumeurs pulmonaires neuroendocrines à petites cellules}, - year = {2022}, - journal = {Revue des Maladies Respiratoires Actualites}, - volume = {14}, - number = {1}, - pages = {1S23 – 1S31}, - doi = {10.1016/S1877-1203(22)00010-6}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131241699&doi=10.1016%2fS1877-1203%2822%2900010-6&partnerID=40&md5=9d821338f8d054ff9bca90761013265e}, - abstract = {This article focuses on development and use of immunotherapy, namely immune checkpoint inhibitors (ICI), as the treatment of neuroendocrine small-cell lung cancer (SCLC). Considering both remaining quite-high incidence and poor prognosis, these ICI have successfully enriched the existing therapeutic armamentarium against SCLC. If ICI were initially evaluated as maintenance therapy of limited-stage SCLC after concomitant chemoradiotherapy, and as mono/bitherapies for second-line treatment of extensive-stage SCLC, first attempts were not really conclusive. PD-(L)1 inhibitors really proved to be relevant as first-line treatment of extensive-stage SCLC through combination with platine-etoposide chemotherapy. Thus, IMpower133 and CASPIAN studies granted a European marketing approval in this indication for atezolizumab and durvalumab, respectively. However, if the provided benefit might not be denied, an unequivocal predictive biomarker of ICI is still missing while the improvement of SCLC molecular phenotyping is going on. This may confirm that some SCLC subtypes are more likely to respond to ICI, either as combinations or with chemotherapy, and consequently push forward care individualisation of patients suffering from SCLC. © 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved. © 2022 SPLF. Publié par Elsevier Masson SAS. Tous droits réservés.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Bronze Open Access} -} - -@ARTICLE{Wang20223062, - author = {Wang, Q. and Liu, A.-H. and Fan, H.-J. and He, A.-B. and Cao, D.-D. and Hu, Wei and Xu, Huilin}, - title = {The incidences of adverse events in small-cell lung cancer patients after radiotherapy and immunotherapy treatment: a systematic review and meta-analysis}, - year = {2022}, - journal = {European Review for Medical and Pharmacological Sciences}, - volume = {26}, - number = {9}, - pages = {3062 – 3073}, - doi = {10.26355/eurrev_202205_28723}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130288771&doi=10.26355%2feurrev_202205_28723&partnerID=40&md5=cc60239160d46c128238a8e78507ce25}, - abstract = {Immunotherapy is important in treating small-cell lung cancer (SCLC), and its anti-tumor effects are better when combined with radiotherapy. However, the toxicity of this combination is little known. This study assessed the incidences of adverse events when adding radiotherapy to ICIs in patients with SCLC. We searched the online databases to identify eligible studies and included nine references. For extensive-stage SCLC patients, the median PFS ranged from 4.5 to 12.5 months, and median OS ranged from 8.4 to NR months, respectively. The incidences of grade 3 or higher pneumonitis, lung infection, diarrhea, and fatal adverse events were 8.7% (95% CI: 5%-14.7%), 6.7% (95% CI: 2.5%-16.5%), 12.6% (95% CI: 7.6%-20%), and 5.1% (95% CI: 2.1%-11.6%), respectively. Our findings suggest that radiotherapy plus ICIs may provide acceptable safety and favorable efficacy for SCLC patients. © 2022 Verduci Editore s.r.l. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2} -} - -@ARTICLE{Zhang2023, - author = {Zhang, Xiaofei and Zhang, Jianguo and Liu, Peiyi and Wang, Juan and Zhao, Kuaile and Zhu, Zhengfei and Gu, Kangsheng and Zhao, Weixin}, - title = {Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer}, - year = {2023}, - journal = {Frontiers in Oncology}, - volume = {13}, - doi = {10.3389/fonc.2023.1022042}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148655172&doi=10.3389%2ffonc.2023.1022042&partnerID=40&md5=fd261fae58d075b080d6c2db60bc10f9}, - abstract = {Non-small cell lung cancer negative for actionable molecular markers entered the splendid era of immunotherapy. This review aims to provide an evidence-based summary for immunotherapy for unresectable locally advanced non-small cell lung cancer, and references for clinical strategies of immunotherapy. Through literature review, the standard treatment for unresectable locally advanced non-small cell lung cancer should be radical concurrent radiotherapy and chemotherapy followed by consolidation immunotherapy. However, the efficacy of concurrent radiotherapy, chemotherapy combined with immunotherapy has not been improved, and its safety should be further validated. It is believed that induction immunotherapy plus concurrent radiotherapy and chemotherapy plus consolidation immunotherapy is promising. In clinical practice, the delineation of radiotherapy target should be relatively small. Pemetrexed combined with PD-1 inhibitor induces the strongest immunogenicity in chemotherapy, which is suggested by preclinical pathway study. Although there is no significant difference between PD1 and PD1 for effect, PD-L1 inhibitor is better in the combination treatment of radiotherapy which presents significantly less adverse events. Copyright © 2023 Zhang, Zhang, Liu, Wang, Zhao, Zhu, Gu and Zhao.}, - type = {Short survey}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Verma2023, - author = {Verma, Saurav and Young, Sympascho and Louie, Alexander V. and Palma, David and Breadner, Daniel}, - title = {The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer}, - year = {2023}, - journal = {Therapeutic Advances in Medical Oncology}, - volume = {15}, - doi = {10.1177/17588359231192399}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85169314673&doi=10.1177%2f17588359231192399&partnerID=40&md5=552c3c72785c6f9cd314f689f3523862}, - abstract = {The improvement in treatment strategies and outcomes in small cell lung cancer (SCLC) has lagged behind other cancers. The addition of immune checkpoint inhibitors (ICIs), durvalumab and atezolizumab, to the platinum-based chemotherapy in frontline setting has improved the survival in extensive stage SCLC, (ES-SCLC), albeit modestly, and is now the new standard of care. Prior to advent of immunotherapy into the therapeutic armamentarium in ES-SCLC, consolidative thoracic radiotherapy (TRT) was associated with improved thoracic control and survival outcomes. In the era of ICIs, the role of TRT is not well defined, chiefly because TRT was not incorporated in any immunotherapy trials, secondly due to concerns regarding the increased risks of pneumonitis, and finally uncertain magnitude of benefit with this combined approach. In principle, radiation can increase in the immunogenicity of tumor and hence the activity of immune checkpoint blockade, thereby increasing efficacy both locally and distantly. Such an approach has been promising in non-small cell lung cancer with ICIs improving outcomes after concurrent chemoradiation, but remains unanswered in ES-SCLC. It is, thus, possible that the modest improvement in survival by addition of ICIs to chemotherapy in ES-SCLC can be further improved by the incorporation of consolidative TRT in selected patients. Several early phase trials and retrospective studies have suggested that such an approach may be feasible and safe. Prospective trials are ongoing to answer whether adding radiation therapy to chemoimmunotherapy will improve outcomes in ES-SCLC. © The Author(s), 2023.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Cheng2022, - author = {Cheng, Xi and Wang, Jiawei and Gong, Liu and Dong, Yong and Shou, Jiawei and Pan, Hongming and Yu, Zhaonan and Fang, Yong}, - title = {Composition of the Gut Microbiota Associated with the Response to Immunotherapy in Advanced Cancer Patients: A Chinese Real-World Pilot Study}, - year = {2022}, - journal = {Journal of Clinical Medicine}, - volume = {11}, - number = {18}, - doi = {10.3390/jcm11185479}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85138755237&doi=10.3390%2fjcm11185479&partnerID=40&md5=1e50114bb861f9f1583b00ac584c926a}, - abstract = {Background: The composition of the gut microbiota is associated with the response to immunotherapy for different cancers. However, the majority of previous studies have focused on a single cancer and a single immune checkpoint inhibitor. Here, we investigated the relationship between the gut microbiota and the clinical response to anti-programmed cell death protein 1 (PD-1) immunotherapy in patients with advanced cancers. Method: In this comprehensive study, 16S rRNA sequencing was performed on the gut microbiota of pre-immunotherapy and post-immunotherapy, of 72 advanced cancer patients in China. Results: At the phylum level, Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria were the main components of the microbiota in the 72 advanced cancer patients. At the genus level, Bacteroides and Prevotella were the dominant microbiota among these 72 patients. The PD_whole_tree, Chao1, Observed_species and Shannon indices of R.0 and R.T were higher than those of NR.0 and NR.T. The results of LEfSe showed that Archaea, Lentisphaerae, Victivallaceae, Victivallales, Lentisphaeria, Methanobacteriaceae, Methanobacteria, Euryarchaeota, Methanobrevibacter, and Methanobacteriales were significantly enriched in the response group before immunotherapy (R.0), and the Clostridiaceae was significantly enriched in the non-response group before immunotherapy (NR.0) (p < 0.05). Lachnospiraceae and Thermus were significantly enriched in the response group after immunotherapy (R.T), and Leuconostoc was significantly enriched in R.0 (p < 0.05). ROC analysis showed that the microbiota of R.T (AUC = 0.70) had obvious diagnostic value in differentiating Chinese cancer patients based on their response to immunotherapy. Conclusions: We demonstrated that the gut microbiota was associated with the clinical response to anti-PD-1 immunotherapy in cancer patients. Taxonomic signatures enriched in responders were effective biomarkers to predict the clinical response. Our findings provide a new strategy to improve the efficiency of responses to immunotherapy among cancer patients. © 2022 by the authors.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 11; All Open Access, Gold Open Access} -} - -@ARTICLE{Sham20223275, - author = {Sham, Nelson O.W. and Zhao, Lei and Zhu, Ziwen and Roy, Tanner M. and Xiao, Huaping and Bai, Qian and Wakefield, Mark R. and Fang, Yujiang}, - title = {Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets}, - year = {2022}, - journal = {Anticancer Research}, - volume = {42}, - number = {7}, - pages = {3275 – 3284}, - doi = {10.21873/anticanres.15816}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85133246846&doi=10.21873%2fanticanres.15816&partnerID=40&md5=12d9c99c330da8b41a8b1dcca8b208ce}, - abstract = {From radiation therapy and surgery to chemotherapy and targeted therapy, the treatment of non-small cell lung cancer (NSCLC) has remarkably evolved over the past few decades. In recent years, immunotherapy has become an increasingly attractive area of interest in the treatment of NSCLC, especially those in advanced stages. Cytokine and immune checkpoint inhibitors are among the most studied immunotherapies for many cancer types. Herein, we provide an overview of current popular cytokine and checkpoint inhibitor treatment regimens available for patients with NSCLC. Ongoing clinic trials and novel molecular targets that are discussed here could lead to promising new treatment options for NSCLC. The evidence summarized in this review might be helpful for clinicians to better manage patients with NSCLC. © 2022 International Institute of Anticancer Research. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 8; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Farris2023385, - author = {Farris, Michael K. and Steber, Cole and Helis, Corbin and Blackstock, William}, - title = {Combined Radiotherapy and Chemotherapy: Theoretical Considerations and Biological Premises}, - year = {2023}, - journal = {Medical Radiology}, - volume = {Part F1269}, - pages = {385 – 397}, - doi = {10.1007/174_2022_314}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85171176944&doi=10.1007%2f174_2022_314&partnerID=40&md5=8e294f1285e705766efa15f28511f604}, - abstract = {Understanding the general radiobiological principles at play in the setting of combined radiation and chemotherapy is essential to appreciate how this approach has evolved over time into the standard of care for locally advanced non-small cell lung cancer (NSCLC). The basic biological pathways through which these modalities interact with each other as well as cancerous and noncancerous cells have been described over the last several decades. Key mechanisms reviewed below include spatial cooperation, independent cell kill, protection of normal tissues, and finally enhancement of tumor response (i.e., radiosensitization or radio-enhancement). Translation of these principles into clinical trials has slowly enhanced our understanding of each, and revealed potential exploits that can guide us toward further improving the therapeutic ratio in lung cancer treatment. Modern radiation therapy techniques as well as newly identified targeted drugs and immunotherapies will continue to evolve our understanding in this setting. © 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.}, - type = {Book chapter}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1} -} - -@ARTICLE{Césaire2022, - author = {Césaire, Mathieu and Montanari, Juliette and Curcio, Hubert and Lerouge, Delphine and Gervais, Radj and Demontrond, Pierre and Balosso, Jacques and Chevalier, François}, - title = {Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives}, - year = {2022}, - journal = {Cancers}, - volume = {14}, - number = {12}, - doi = {10.3390/cancers14122829}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131559675&doi=10.3390%2fcancers14122829&partnerID=40&md5=6146281343b403f47b76703e3e0119b1}, - abstract = {Survival in unresectable locally advanced stage non-small cell lung cancer (NSCLC) patients remains poor despite chemoradiotherapy. Recently, adjuvant immunotherapy improved survival for these patients but we are still far from curing most of the patients with only a 57% survival remaining at 3 years. This poor survival is due to the resistance to chemoradiotherapy, local relapses, and distant relapses. Several biological mechanisms have been found to be involved in the chemoradioresistance such as cancer stem cells, cancer mutation status, or the immune system. New drugs to overcome this radioresistance in NSCLCs have been investigated such as radiosensitizer treatments or immunotherapies. Different modalities of radiotherapy have also been investigated to improve efficacity such as dose escalation or proton irradiations. In this review, we focused on biological mechanisms such as the cancer stem cells, the cancer mutations, the antitumor immune response in the first part, then we explored some strategies to overcome this radioresistance in stage III NSCLCs with new drugs or radiotherapy modalities. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 25; All Open Access, Gold Open Access} -} - -@ARTICLE{Criscitiello2022787, - author = {Criscitiello, Carmen and Guerini-Rocco, Elena and Viale, Giulia and Fumagalli, Caterina and Sajjadi, Elham and Venetis, Konstantinos and Piciotti, Roberto and Invernizzi, Marco and Malapelle, Umberto and Fusco, Nicola}, - title = {Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology}, - year = {2022}, - journal = {Anti-Cancer Agents in Medicinal Chemistry}, - volume = {22}, - number = {4}, - pages = {787 – 800}, - doi = {10.2174/1871520621666210706144112}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125576376&doi=10.2174%2f1871520621666210706144112&partnerID=40&md5=cf6b3a7a4549e50e92de93a59be362b3}, - abstract = {Immune Checkpoint Inhibitors (ICIs) have remarkably modified the way solid tumors are managed, including breast cancer. Unfortunately, only a relatively small number of breast cancer patients significantly respond to these treatments. To maximize the immunotherapy benefit in breast cancer, several efforts are currently being put forward for the identification of i) the best therapeutic strategy (i.e. ICI monotherapy or in association with chemotherapy, radiotherapy, or other drugs); ii) optimal timing for administration (e.g. early/advanced stage of disease; adjuvant/neoadjuvant setting); iii) most effective and reliable predictive biomarkers of response (e.g. tumor-infiltrating lymphocytes, programmed death-ligand 1, microsatellite instability associated with mismatch repair deficiency, and tumor mutational burden). In this article, we review the impacts and gaps in the characterization of immune-related biomarkers raised by clinical and translational research studies with immunotherapy treatments. Particular emphasis has been put on the documented evidence of significant clinical benefits of ICI in different randomized clinical trials, along with preanalytical and analytical issues in predictive biomarkers pathological assessment. © 2022 Bentham Science Publishers.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 25; All Open Access, Green Open Access} -} - -@ARTICLE{Tian2022, - author = {Tian, Yaru and Ma, Ji and Jing, Xuquan and Zhai, Xiaoyang and Li, Yuying and Guo, Zhijun and Yu, Jinming and Zhu, Hui}, - title = {Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy}, - year = {2022}, - journal = {Cancer Letters}, - volume = {541}, - doi = {10.1016/j.canlet.2022.215719}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130552550&doi=10.1016%2fj.canlet.2022.215719&partnerID=40&md5=e175f43d53bb392cc40d515470a73144}, - abstract = {Unlike non-small-cell lung cancer (NSCLC), the progression of small-cell lung cancer (SCLC) is slow. Extensive-stage SCLC (ES-SCLC) is a serious threat to human health, with a 5-year survival rate of <7%. Chemotherapy has been the first-line treatment for the past 30 years. The anti-PD-L1 checkpoint blockades durvalumab and atezolizumab have greatly prolonged overall survival and have become the standard first-line therapy for ES-SCLC since the CASPIAN and IMpower133 trials. In the era of chemotherapy, radiation therapy (RT), including thoracic radiation therapy (TRT) and brain radiation therapy (BRT), has shown clinical effects in randomized and retrospective studies on ES-SCLC. RT-immunotherapy has shown exciting synergistic effects in NSCLC. For ES-SCLC, the clinical effects of combining TRT/BRT with immunotherapy have not yet been systematically explored. In this review, we found that studies on RT-immunotherapy in ES-SCLC are relatively few and limited to early phase studies focusing on toxicity. The efficacy and safety profiles of early phase studies encourage prospective clinical trials. In this review, we discuss the best population, optimum TRT dose, proper TRT time, and strategies for reducing radiation-induced neurotoxicity. Furthermore, we suggest that biomarkers and patient performance status should be fully assessed before RT-immunotherapy treatment. Prospective trials are needed to provide more evidence for RT-immunotherapy applications in ES-SCLC. © 2022 Elsevier B.V.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 22} -} - -@ARTICLE{Zheng2022, - author = {Zheng, Jiaxi and Shao, Minghai and Yang, Weifang and Ren, Justin and Chen, Xiaofeng and Yang, Haihua}, - title = {Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis}, - year = {2022}, - journal = {International Immunopharmacology}, - volume = {112}, - doi = {10.1016/j.intimp.2022.109244}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85138030855&doi=10.1016%2fj.intimp.2022.109244&partnerID=40&md5=50f177d6dca63f4837761071d0c31874}, - abstract = {Objectives: To investigate the clinical benefits of combination therapy with immune checkpoint inhibitors (ICIs) and best combination regimen for people with advanced hepatocellular carcinoma (HCC) and to explore the predictive performance of tumour mutation burden (TMB). Methods: We conducted a systematic literature search to identify clinical trials. Meta-analysis and subgroup analyses were performed to estimate the benefits of combination regimens with PD-1/PD-L1 inhibitors for patients with advanced HCC and compare the effectiveness of PD-1/PD-L1 inhibitors and sorafenib as first-line therapy. Individualized analysis and Kaplan-Meier were used to assess the prognostic value of TMB. Results: A total of 29 studies with 5396 patients were included. ICIs’ combination therapy had higher ORR (26 % vs 15 %) and DCR (73 % vs 55 %), longer PFS (5.5 vs 3.1 months) and OS (15.9 vs 12.6 months) compared to monotherapy. Anti-PD-1/PD-L1 agents provided improved ORR, DCR, PFS and OS compared to sorafenib. The overall ORs of ORR and DCR in subgroup analysis were 3.49 (95 % CI 2.36–5.17, p < 0.01) and 1.60 (95 % CI 1.15–2.21, p < 0.01). The overall HRs of PFS and OS were 0.68 (95 % CI 0.48–0.96, p = 0.03) and 0.73 (95 % CI 0.62–0.85, p < 0.01). PD-1/PD-L1 inhibitors plus anti-VEGF agents had an advantage in DCR (0.80 vs 0.48, meta-regression = − 0.32, P < 0.001), but an equal ORR (0.29 vs 0.26) compared to dual immune checkpoint inhibitors. The total OS in Dua-ICIs were 16.5 months (95 % CI 14.2–18.7), yet not reached in the major studies of ICI plus anti-VEGF regimen. In individualized analysis, the 1-year OS was superior for patients who had high-TMB (>10, mutations/Mb) than moderate-TMB (1–10, mutations/Mb; 28 % vs 15 %, P = 0.025). Conclusion: Immune checkpoint inhibitors’ combination therapy improved clinical outcomes in the management of advanced hepatocellular carcinoma. However, the overall objective response rate still did not exceed 30%. PD-1/PD-L1 inhibitors plus anti-angiogenic agents and dual immunotherapy provided significantly increased survival over sorafenib, which also pose new challenges for future research, and more appropriate and guided control regimens are required. Also, TMB may be a promising prognostic biomarker for immunotherapy in HCC. However, the validation of prospective and large sample studies is needed. © 2022 The Author(s)}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 13; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Amaoui2021160, - author = {Amaoui, Bouchra and Lalya, Issam and Safini, Fatima and Semghouli, Slimane}, - title = {Combination of immunotherapy-radiotherapy in non-small cell lung cancer: Reality and perspective}, - year = {2021}, - journal = {Radiation Medicine and Protection}, - volume = {2}, - number = {4}, - pages = {160 – 164}, - doi = {10.1016/j.radmp.2021.09.002}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120686289&doi=10.1016%2fj.radmp.2021.09.002&partnerID=40&md5=249aa017a6943b8bc1b0d570a65caae5}, - abstract = {The aim of this review was to examine the theoretical, preclinical and clinical bases of the combination radiotherapy immunotherapy in the management of non-small cell lung cancer (NSCLC). Preclinical studies have shown that in addition to its well-established tumoricidal effects, radiotherapy can activate the host immune system and modify the tumor microenvironment. Immunotherapy is currently part of the therapeutic arsenal of the NSCLC given its capacity to restore the host's immune system's ability to recognize and destroy tumor cells. The combination of radiotherapy and immunotherapy seems to be synergistic, particularly with inhibitors of immune checkpoints. This association has become standard in the metastatic stages and especially in consolidation after radiochemotherapy in the locally advanced, unresectable and stable stages. Several questions remain unanswered including the optimal sequence of this combination, the type of radiotherapy (hypo-fractionated or normofractionated), the association of several immunotherapies and the cross-toxicity of the combination. The association of radiotherapy and immunotherapy is a promising treatment. © 2021 The Authors}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Gold Open Access} -} - -@ARTICLE{Takeda2023, - author = {Takeda, Takayuki and Yamada, Tadaaki and Kunimatsu, Yusuke and Tanimura, Keiko and Morimoto, Kenji and Shiotsu, Shinsuke and Chihara, Yusuke and Okada, Asuka and Horiuchi, Shigeto and Hibino, Makoto and Uryu, Kiyoaki and Honda, Ryoichi and Yamanaka, Yuta and Yoshioka, Hiroshige and Kurata, Takayasu and Takayama, Koichi}, - title = {Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study}, - year = {2023}, - journal = {Cancers}, - volume = {15}, - number = {5}, - doi = {10.3390/cancers15051543}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149839223&doi=10.3390%2fcancers15051543&partnerID=40&md5=4c24c199c4143747f707a48ad46390c5}, - abstract = {Chemoimmunotherapy improved overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC) in two phase III trials. They set the age-stratified subgroup analyses at 65 years; however, over half of the patients with lung cancer were newly diagnosed at ≥75 years in Japan. Therefore, treatment efficacy and safety in elderly patients ≥ 75 years with ES-SCLC should be evaluated through real-world Japanese evidence. Consecutive Japanese patients with untreated ES-SCLC or limited-stage SCLC unfit for chemoradiotherapy between 5 August 2019 and 28 February 2022 were evaluated. Patients treated with chemoimmunotherapy were divided into the non-elderly (<75 years) and elderly (≥75 years) groups, and efficacy, including PFS, OS, and post-progression survival (PPS) were evaluated. In total, 225 patients were treated with first-line therapy, and 155 received chemoimmunotherapy (98 non-elderly and 57 elderly patients). The median PFS and OS in non-elderly and elderly were 5.1 and 14.1 months and 5.5 and 12.0 months, respectively, without significant differences. Multivariate analyses revealed that age and dose reduction at the initiation of the first chemoimmunotherapy cycle were not correlated with PFS or OS. In addition, patients with an Eastern Cooperative Oncology Group performance status (ECOG-PS) = 0 who underwent second-line therapy had significantly longer PPS than those with ECOG-PS = 1 at second-line therapy initiation (p < 0.001). First-line chemoimmunotherapy had similar efficacy in elderly and non-elderly patients. Individual ECOG-PS maintenance during first-line chemoimmunotherapy is crucial for improving the PPS of patients proceeding to second-line therapy. © 2023 by the authors.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Gold Open Access} -} - -@ARTICLE{Tang2022, - author = {Tang, Shengjie and Qin, Chao and Hu, Haiyang and Liu, Tao and He, Yiwei and Guo, Haiyang and Yan, Hang and Zhang, Jun and Tang, Shoujun and Zhou, Haining}, - title = {Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects}, - year = {2022}, - journal = {Cells}, - volume = {11}, - number = {3}, - doi = {10.3390/cells11030320}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122895876&doi=10.3390%2fcells11030320&partnerID=40&md5=849acdcdba22fd466210a12d0d8f9481}, - abstract = {Non-small cell lung cancer is one of the most common types of malignances worldwide and the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical resection, chemotherapy, radiotherapy, and targeted therapy, with poor therapeutic effectiveness. In recent years, immune checkpoint inhibitors have applied in NSCLC treatment. A large number of experimental studies have shown that immune checkpoint inhibitors are safer and more effective than traditional therapeutic modalities and have allowed for the development of better guidance in the clinical treatment of advanced NSCLC patients. In this review, we describe clinical trials using ICI immunotherapies for NSCLC treatment, the available data on clinical efficacy, and the emerging evidence regarding biomarkers. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 63; All Open Access, Gold Open Access} -} - -@ARTICLE{Cicala2023, - author = {Cicala, Carlo Maria and Musacchio, Lucia and Scambia, Giovanni and Lorusso, Domenica}, - title = {Dostarlimab: From preclinical investigation to drug approval and future directions}, - year = {2023}, - journal = {Human Vaccines and Immunotherapeutics}, - volume = {19}, - number = {1}, - doi = {10.1080/21645515.2023.2178220}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148301596&doi=10.1080%2f21645515.2023.2178220&partnerID=40&md5=80aa493e009b56d79ea061e72b7ccb37}, - abstract = {Immune checkpoint blockers (ICB) act by reverting the immunosuppressive phenotype of cancer cells, thus allowing host immune system to generate an immune response to the tumor. One of the key mechanisms targeted by ICB is the PD-1/PD-L1 axis, which lies onto the interaction between the programmed-cell death protein 1 and its ligand, overexpressed in several tumor types. This interaction leads to the inhibition of T-cell proliferation and their apoptosis and exhaustion. Anti-PD-1/PD-L1 monoclonal antibodies are now the mainstay of treatment for several advanced stage tumors. Dostarlimab is a novel IgG4 anti-PD-1 antibody which has yielded remarkable results in mismatch-repair deficient endometrial cancer and locally advanced rectal cancer. This product review will illustrate the preclinical development of dostarlimab and its pharmacological characteristics, the clinical trials published so far and the ongoing clinical investigations. © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 6; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Mamdani2022, - author = {Mamdani, Hirva and Matosevic, Sandro and Khalid, Ahmed Bilal and Durm, Gregory and Jalal, Shadia I.}, - title = {Immunotherapy in Lung Cancer: Current Landscape and Future Directions}, - year = {2022}, - journal = {Frontiers in Immunology}, - volume = {13}, - doi = {10.3389/fimmu.2022.823618}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125141928&doi=10.3389%2ffimmu.2022.823618&partnerID=40&md5=029cec66409a90283e5ae5c2be5e2f94}, - abstract = {Over the past decade, lung cancer treatment has undergone a major paradigm shift. A greater understanding of lung cancer biology has led to the development of many effective targeted therapies as well as of immunotherapy. Immune checkpoint inhibitors (ICIs) have shown tremendous benefit in the treatment of non-small cell lung cancer (NSCLC) and are now being used as first-line therapies in metastatic disease, consolidation therapy following chemoradiation in unresectable locally advanced disease, and adjuvant therapy following surgical resection and chemotherapy in resectable disease. Despite these benefits, predicting who will respond to ICIs has proven to be difficult and there remains a need to discover new predictive immunotherapy biomarkers. Furthermore, resistance to ICIs in lung cancer is frequent either because of a lack of response or disease progression after an initial response. The utility of ICIs in the treatment of small cell lung cancer (SCLC) remains limited to first-line treatment of extensive stage disease in combination with chemotherapy with modest impact on overall survival. It is thus important to explore and exploit additional targets to reap the full benefits of immunotherapy in the treatment of lung cancer. Here, we will summarize the current state of immunotherapy in lung cancer, discuss novel targets, and explore the intersection between DNA repair defects and immunotherapy. Copyright © 2022 Mamdani, Matosevic, Khalid, Durm and Jalal.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 146; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Wang2023, - author = {Wang, Jun and Zhang, Bicheng and Peng, Ling and Liu, Xiufeng and Sun, Jianguo and Su, Chunxia and Wang, Huijuan and Zhao, Zheng and Si, Lu and Duan, Jianchun and Zhang, Hongmei and Li, Mengxia and Zhu, Bo and Zhang, Li and Li, Jin and Guo, Jun and Luo, Rongcheng and Qiu, Wensheng and Ye, Dingwei and Chu, Qian and Cui, Jiuwei and Dong, Xiaorong and Fan, Yun and Gao, Quanli and Guo, Ye and He, Zhiyong and Li, Wenfeng and Lin, Gen and Liu, Lian and Liu, Yutao and Qin, Haifeng and Ren, Shengxiang and Ren, Xiubao and Wang, Yongsheng and Xue, Junli and Yang, Yunpeng and Yang, Zhenzhou and Yue, Lu and Zhan, Xianbao and Zhang, Junping and Ma, Jun and Qin, Shukui and Wang, Baocheng}, - title = {Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations}, - year = {2023}, - journal = {Therapeutic Advances in Medical Oncology}, - volume = {15}, - doi = {10.1177/17588359231187205}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165138866&doi=10.1177%2f17588359231187205&partnerID=40&md5=2089d1a96d4cf449adeeb6c62ec20ecd}, - abstract = {Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown significantly durable clinical benefits and tolerable toxicities and have improved the survival of patients with various types of cancer. Since 2018, the National Medical Products Administration of China has approved 17 ICIs as the standard treatment for certain advanced or metastatic solid tumors. As ICIs represent a broad-spectrum antitumor strategy, the populations eligible for cancer immunotherapy are rapidly expanding. However, the clinical applications of ICIs in cancer patient populations with special issues, a term that refers to complex subgroups of patients with comorbidities, special clinical conditions, or concomitant medications who are routinely excluded from prospective clinical trials of ICIs or are underrepresented in these trials, represent a great real-world challenge. Although the Chinese Society of Clinical Oncology (CSCO) has provided recommendations for screening before the use of ICIs in special populations, the recommendations for full-course management remain insufficient. The CSCO Expert Committee on Immunotherapy organized leading medical oncology and multidisciplinary experts to develop a consensus that will serve as an important reference for clinicians to guide the proper application of ICIs in special patient populations. This article is a translation of a study first published in Chinese in The Chinese Clinical Oncology (ISSN 1009-0460, CN 32-1577/R) in May 2022 (27(5):442–454). The publisher of the original paper has provided written confirmation of permission to publish this translation in Therapeutic Advances in Medical Oncology. © The Author(s), 2023.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Gold Open Access} -} - -@ARTICLE{Wang2022, - author = {Wang, Bi-Cheng and Kuang, Bo-Hua and Lin, Guo-He}, - title = {Immunotherapy Alone or in Combination with Stereotactic Body Radiotherapy in Advanced Lung Cancer: A Pooled Analysis of Randomized Clinical Trials}, - year = {2022}, - journal = {Journal of Oncology}, - volume = {2022}, - doi = {10.1155/2022/7506300}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139424605&doi=10.1155%2f2022%2f7506300&partnerID=40&md5=d8116cbb5edea05c8697ec8f3148244a}, - abstract = {Background. Immunotherapy has revolutionized the treatment of advanced lung cancer. Nevertheless, it remains unclear whether adding stereotactic body radiotherapy (SBRT) to immunotherapy (IT) further improves responses and survival outcomes. Therefore, in this pooled analysis, we comprehensively compared IT plus SBRT with IT alone in patients with advanced lung cancer. Methods. Online databases, including PubMed, Web of Science, Embase, and Cochrane CENTRAL, were systematically searched on April 24, 2022. Eligible studies were randomized clinical trials comparing IT plus SBRT to IT. The primary outcomes were the objective response rate (ORR) and disease control rate (DCR). Progression-free survival (PFS) and overall survival (OS) were explored as secondary outcomes. Results. Overall, three phase 2 randomized clinical trials with a total of 146 previously treated lung cancer patients were enrolled. The median PFS and OS were 3.8 months and 9.5 months for IT plus SBRT versus 2.4 months and 6.1 months for IT. Comparing IT plus SBRT with IT alone, pooled risk ratios for ORR and DCR were 1.95 (95% confidence interval 1.07-3.53, p = 0.03) and 1.28 (0.94-1.73, p = 0.12). While pooled hazard ratios were 0.77 (0.25-2.42, p = 0.66) for PFS and 0.71 (0.16-3.21, p = 0.65) for OS, respectively. No publication bias was found across the trials. Conclusion. Compared to IT alone, the addition of SBRT improved the best response but failed to prolong the survival outcomes in treating advanced lung cancer patients. Future studies are necessary to explore new modalities of the combination of IT and SBRT. © 2022 Bi-Cheng Wang et al.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access} -} - -@ARTICLE{Roller2022, - author = {Roller, John F. and Veeramachaneni, Nirmal K. and Zhang, Jun}, - title = {Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC}, - year = {2022}, - journal = {Cancers}, - volume = {14}, - number = {3}, - doi = {10.3390/cancers14030741}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85124029011&doi=10.3390%2fcancers14030741&partnerID=40&md5=02559b0b22b58521d1d9188622a67e89}, - abstract = {While lung cancer remains the leading cause of cancer death worldwide, lung cancer mortality has notably decreased in the past decade. Immunotherapy with immune checkpoint inhibitors have played a noteworthy role in contributing to this improved survival, particularly for patients with non-small cell lung cancer (NSCLC). However, until now the benefits have primarily been seen in patients with advanced or metastatic disease. Several recent early phase and ongoing phase III trials have been assessing whether the treatment benefit of immunotherapy in NSCLC can extend to the neoadjuvant setting for resectable diseases. In this comprehensive narrative review, we evaluate the most recent efficacy and safety data from these studies. We also outline questions that will need to be further examined to legitimate neoadjuvant immunotherapy’s role in NSCLC treatment, including the best surrogate marker of response, the incorporation of liquid biopsy for disease monitoring, the ability to be combined with other treatment modalities, the need for further adjuvant therapy, and potential future treatment combinations. © 2022 by the authors. LicenseeMDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12; All Open Access, Gold Open Access} -} - -@ARTICLE{Chen2022, - author = {Chen, Jia and Wei, Sheng and Zhao, Tianye and Zhang, Xunlei and Wang, Yilang and Zhang, Xiaodong}, - title = {Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB}, - year = {2022}, - journal = {Disease Markers}, - volume = {2022}, - doi = {10.1155/2022/7137357}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85135684972&doi=10.1155%2f2022%2f7137357&partnerID=40&md5=66baba303913a56639559c6d4dd57906}, - abstract = {Background. To assess the prognostic value of pretreatment serum biomarkers in stage IV non-small-cell lung cancer (NSCLC) patients treated with PD-1 (programmed cell death protein 1) inhibitors and their value as a predictor of benefit. Methods. We performed a retrospective study including patients with stage IV NSCLC who were treated with anti-PD-1 drugs in first or advanced lines of therapy in the Affiliated Tumor Hospital of Nantong University. Serum biomarkers such as NLR, dNLR, LMR, PAB, ALB, and LIPI scores were calculated and analyzed in detail. Results. A total of 85 patients with stage IV NSCLC treated with PD-1 inhibitors in the first or advanced lines of therapy were included in this subject. According to the tumor response of PD-1-based treatment, ORR was 42.4% (36/85) and DCR was 68.2% (58/85). The median OS and PFS were 20.0 months and 7.0 months, respectively. The ROC curves showed that the serum biomarkers of NLR, dNLR, LDH, LMR, PAB, and ALB were significantly associated with overall survival and helped to determine the cut-off value. The multivariate Cox proportional hazard analyses for stage IV NSCLC patients treated with PD-1 inhibitors indicated that dNLR (P<0.001) and ALB (P=0.033) were independent prognostic indicators of PFS, while liver metastasis (P=0.01), NLR (P=0.01), dNLR (P=0.001), and LMR (P=0.006) were independent prognostic indicators of OS. Moreover, patients of the good LIPI group showed prolonged PFS and OS than those with intermediate/poor LIPI score (P<0.001 and P=0.006, respectively). Conclusions. Pretreatment dNLR is an independent prognostic indicator of both PFS and OS in stage IV NSCLC patients treated with PD-1 inhibitors. Pretreatment LIPI, combining dNLR>3 and LDH>ULN, was correlated with worse outcome for stage IV NSCLC patients treated with ICI. High NLR, high dNLR, low LMR, and low ALB at baseline might be useful as an early predictive biomarker of benefit. © 2022 Jia Chen et al.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 14; All Open Access, Gold Open Access} -} - -@ARTICLE{Yu2022, - author = {Yu, Renren and Zhu, Bo and Chen, Degao}, - title = {Type I interferon-mediated tumor immunity and its role in immunotherapy}, - year = {2022}, - journal = {Cellular and Molecular Life Sciences}, - volume = {79}, - number = {3}, - doi = {10.1007/s00018-022-04219-z}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85126323237&doi=10.1007%2fs00018-022-04219-z&partnerID=40&md5=18ff3ffe451b91f3d4209a1f562da952}, - abstract = {Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cancer; however, most patients who receive ICB monotherapy fail to achieve long-term responses, and some tumors become immunotherapy-resistant and even hyperprogressive. Type I interferons (IFNs) have been demonstrated to inhibit tumor growth directly and indirectly by acting upon tumor and immune cells, respectively. Furthermore, accumulating evidence indicates that endo- and exogenously enhancing type I IFNs have a synergistic effect on anti-tumor immunity. Therefore, clinical trials studying new treatment strategies that combine type I IFN inducers with ICB are currently in progress. Here, we review the cellular sources of type I IFNs and their roles in the immune regulation of the tumor microenvironment. In addition, we highlight immunotherapies based on type I IFNs and combination therapy between type I IFN inducers and ICBs. © 2022, The Author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 120; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Schlick20221104, - author = {Schlick, Brian and Shields, Misty Dawn and Marin-Acevedo, Julian A. and Patel, Ishika and Pellini, Bruna}, - title = {Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer}, - year = {2022}, - journal = {Current Treatment Options in Oncology}, - volume = {23}, - number = {8}, - pages = {1104 – 1120}, - doi = {10.1007/s11864-022-00989-7}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132275817&doi=10.1007%2fs11864-022-00989-7&partnerID=40&md5=916693b0bd895ca4196a275bd27e1961}, - abstract = {Limited-stage small cell lung cancer (LS-SCLC) is a potentially curable disease. However, most patients develop disease relapse shortly after definitive treatment. The landmark trials IMpower133 and CASPIAN demonstrated a survival benefit with the addition of immunotherapy to first-line platinum/etoposide for extensive-stage small cell lung cancer. Therefore, it is critical to determine whether advancements in overall survival with immunotherapy can be translated earlier into the treatment paradigm for LS-SCLC. Decades of robust preclinical research into the synergism of radiation therapy and immunotherapy set the stage for the combination of these treatment modalities. Recently published data suggests tolerability of single agent immunotherapy concurrent with chemoradiation in LS-SCLC, along with promising efficacy. However, combination immunotherapy in the consolidation setting appears too toxic, although this may be reflective of the dosing schedule rather than inherent to any combination immune checkpoint blockade. Here, we review underlying mechanisms of synergy with the combination of radiation and immunotherapy, the safety and efficacy of respective treatment modalities, and the ongoing trials that are exploring novel therapeutic approaches for LS-SCLC. Pivotal trials in LS-SCLC are ongoing and anticipated to aid in understanding efficacy and safety of immunotherapy with concurrent platinum-based chemoradiotherapy. © 2022, The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 9; All Open Access, Green Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Sands2023, - author = {Sands, Jacob and Subramanian, Janakiraman}, - title = {Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting}, - year = {2023}, - journal = {Frontiers in Oncology}, - volume = {13}, - doi = {10.3389/fonc.2023.1161931}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85182179218&doi=10.3389%2ffonc.2023.1161931&partnerID=40&md5=cf080b8bd405b203bc422c7b9e5e7ee3}, - abstract = {Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive disease with poor 5-year survival. The first-line standard-of-care for ES-SCLC is platinum plus etoposide, along with 1 of the immune checkpoint inhibitors atezolizumab or durvalumab. Although SCLC first-line therapy often leads to rapid responses, treatment becomes more challenging at progression, particularly for those with a chemotherapy-free interval (CTFI) of ≤6 months. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for SCLC no longer specify treatment recommendations in this setting, but options approved by the US Food and Drug Administration include topotecan and lurbinectedin. Participation in a clinical trial is recommended as an option regardless of CTFI. Other NCCN-recommended regimens are paclitaxel, irinotecan, temozolomide, and cyclophosphamide/doxorubicin/vincristine, among others. Nivolumab and pembrolizumab are options in those not previously treated with a checkpoint inhibitor. For patients with platinum-sensitive SCLC (CTFI >6 months), preferred treatment per the NCCN Guidelines® for SCLC is retreatment with platinum and etoposide, although the use of immune checkpoint inhibitors is discouraged if there is progression on a drug in this class. Further research on immunotherapies and combination regimens is ongoing, and continuing work on the subcharacterization of SCLC may lead to better precision of therapies that promote more durable responses in individual patients with ES-SCLC. Copyright © 2023 Sands and Subramanian.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Xu2022149, - author = {Xu, Ting and Wu, Lirong and Gandhi, Saumil and Jing, Wang and Nguyen, Quyhn-Nhu and Chen, Aileen and Chang, Joe Y. and Nurieva, Roza and Sheshadri, Ajay and Altan, Mehmet and Lee, Percy P. and Lin, Steven H. and Liao, Zhongxing}, - title = {Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer}, - year = {2022}, - journal = {Radiotherapy and Oncology}, - volume = {176}, - pages = {149 – 156}, - doi = {10.1016/j.radonc.2022.10.002}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85140274441&doi=10.1016%2fj.radonc.2022.10.002&partnerID=40&md5=ac901c0a1bb1450402a74ce77c11fa97}, - abstract = {Purpose: We compared treatment-related pulmonary adverse events (TRPAE), progression-free survival (PFS), and overall survival (OS) among locally advanced non-small cell lung cancer (NSCLC) patients who received concurrent chemoradiotherapy (CRT) versus CRT followed by immune check point inhibitor (ICI) immunotherapy (CRTI). Materials and methods: TRPAE was defined as any pulmonary events as defined in CTCAE v.5 occurring within 12 months after completion of radiotherapy. Outcomes were compared between CRT and CTRI by Cox proportional hazard regression and Kaplan-Meier analyses. We also assessed if TRPAE-induced discontinuation of ICI affected survival. Results: We analyzed 326 patients treated between July 2010 and November 2019; 195 patients received CRT and 131 received CRTI. The incidences of severe grade ≥ 3 TRPAE were similar between the two groups, however, symptomatic TRPAE was almost doubled in CRTI group (65.7 % CTRI vs 35.9 % CRT, P < 0.0001). The rates of 4-year OS and PFS were 54.5 % vs 36.7 % (P = 0.0003) and 43.8 % vs 35.8 % (P = 0.038) in CRT + Durvalumab and CRT group, respectively. Receipt of ICI Durvalumab was associated with better 4-year OS (HR 0.53, 95 % CI 0.36–0.78, P = 0.001) and PFS (HR 0.55, 95 % CI 0.38–0.80, P = 0.002). Patients who discontinued ICI because of TRPAE had worse 4-year OS (P = 0.001) and higher rates of distant metastasis (P = 0.003) than those who completed planned ICI after developing TRPAE. Conclusion: CRT followed by adjuvant ICI led to improved 4-year OS and PFS consistent with published data. CRTI was associated with higher incidence of grade ≥ 2 TRPAE in both high and low mean lung dose groups without significant difference in grade ≥ 3 TRPAE. Discontinuation of ICI due to TRPAE was associated with poorer OS and distant disease control than completing ICI as planned after developing TRPAE. © 2022 The Authors}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 11; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Qin2023, - author = {Qin, Jian and Yi, Shouhui and Zhou, Hanjing and Zeng, Chuan and Zou, Minghua and Zeng, Xuan and Yang, Zhenzhou and Huang, Yusheng}, - title = {Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis}, - year = {2023}, - journal = {Frontiers in Immunology}, - volume = {14}, - doi = {10.3389/fimmu.2023.1138025}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160969325&doi=10.3389%2ffimmu.2023.1138025&partnerID=40&md5=74ea7f5ba8f55561ee84b8d72933521b}, - abstract = {Aim: To compare the efficacy and safety of radiotherapy in combination with immunotherapy after achieving disease control from the first-line combination therapy of platinum-based chemotherapy and immunotherapy for advanced lung squamous cell carcinoma (LUSC). Methods: This study retrospectively evaluated the patients with advanced LUSC treated with the combination of radiotherapy with immunotherapy and chemotherapy (ICRT group, n = 52) or immunotherapy and chemotherapy (ICT group, n = 63) as the first-line treatment from April 2018 to April 2022. Using propensity score matching (PSM), 50 pairs were created, while the confounders and bias were controlled. The objective response rate (ORR), duration of overall response (DOR), progression-free survival (PFS), overall survival (OS), and adverse events were analyzed in the two groups. The PFS and OS were re-analyzed separately for patients treated with thoracic radiotherapy. Results: After PSM, the median PFS (12.23 vs. 7.43 months; P <0.001) and median OS (19.7 vs. 12.9 months; P <0.001) were significantly longer in the ICRT group than those in the ICT group. Both the PFS and OS rates were also significantly higher in the ICRT group than those in the ICT group, except for the OS rates in the 6th and 12th months. The mDOR of the ICRT group patients (17.10 vs. 8.27 months; P <0.001) was significantly higher than that of the ICT group patients. The median PFS, median OS, and local control rate were significantly longer in the thoracic radiotherapy group than in the control group. Radiation pneumonia was the most common adverse effect after radiotherapy; however, no treatment-related deaths occurred. The Cox regression analysis showed that ECOG scores 0-1, presence of necrosis in the tumor, radiotherapy, and optimal efficacy better than the stable disease (SD) were independent factors, affecting the PFS, while the patients with recurrent post-operative, pre-treatment NLR, radiotherapy, and optimal efficacy better than SD were the independent factors, affecting the OS. Conclusions: The combination of radiotherapy with systematic immunotherapy and chemotherapy for the advanced LUSC was effective with tolerable adverse effects. Copyright © 2023 Qin, Yi, Zhou, Zeng, Zou, Zeng, Yang and Huang.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Wu202340, - author = {Wu, Yuan-Hua and Chen, Rong-Jane and Chiu, Hui-Wen and Yang, Li-Xing and Wang, Yung-Li and Chen, Yu-Ying and Yeh, Ya-Ling and Liao, Mei-Yi and Wang, Ying-Jan}, - title = {Nanoparticles augment the therapeutic window of RT and immunotherapy for treating cancers: pivotal role of autophagy}, - year = {2023}, - journal = {Theranostics}, - volume = {13}, - number = {1}, - pages = {40 – 58}, - doi = {10.7150/thno.77233}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143868862&doi=10.7150%2fthno.77233&partnerID=40&md5=fff007e678c286beec73a599cee602da}, - abstract = {Immunotherapies are now emerging as an efficient anticancer therapeutic strategy. Cancer immunotherapy utilizes the host’s immune system to fight against cancer cells and has gained increasing interest due to its durable efficacy and low toxicity compared to traditional antitumor treatments, such as chemotherapy and radiotherapy (RT). Although the combination of RT and immunotherapy has drawn extensive attention in the clinical setting, the overall response rates are still low. Therefore, strategies for further improvement are urgently needed. Nanotechnology has been used in cancer immunotherapy and RT to target not only cancer cells but also the tumor microenvironment (TME), thereby helping to generate a long-term immune response. Nanomaterials can be an effective delivery system and a strong autophagy inducer, with the ability to elevate autophagy to very high levels. Interestingly, autophagy could play a critical role in optimal immune function, mediating cell-extrinsic homeostatic effects through the regulation of danger signaling in neoplastic cells under immunogenic chemotherapy and/or RT. In this review, we summarize the preclinical and clinical development of the combination of immunotherapy and RT in cancer therapy and highlight the latest progress in nanotechnology for augmenting the anticancer effects of immunotherapy and RT. The underlying mechanisms of nanomaterial-triggered autophagy in tumor cells and the TME are discussed in depth. Finally, we suggest the implications of these three strategies combined together to achieve the goal of maximizing the therapeutic advantages of cancer therapy and show recent advances in biomarkers for tumor response in the evaluation of those therapies. © The author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 8; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Varlotto2022547, - author = {Varlotto, John Michael and Sun, Zhuoxin and Ky, Bonnie and Upshaw, Jenica and Fitzgerald, Thomas J. and Diehn, Max and Lovly, Christine and Belani, Chandra and Oettel, Kurt and Masters, Gregory and Harkenrider, Matthew and Ross, Helen and Ramalingam, Suresh and Pennell, Nathan A.}, - title = {A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181}, - year = {2022}, - journal = {Clinical Lung Cancer}, - volume = {23}, - number = {7}, - pages = {547 – 560}, - doi = {10.1016/j.cllc.2022.06.005}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85134751386&doi=10.1016%2fj.cllc.2022.06.005&partnerID=40&md5=8324bf43a10d146b4d349eb8603dc54a}, - abstract = {ECOG-ACRIN EA5181 is a current prospective, randomized trial that is investigating whether the addition of concomitant durvalumab to standard chemo/radiation followed by 1 year of consolidative durvalumab results in an overall survival benefit over standard chemo/radiation alone followed by 1 year of consolidative durvalumab in patients with locally advanced, unresectable non-small cell lung cancer (NSCLC). Because multiple phase I/II trials have shown the relative safety of adding immunotherapy to chemo/radiation and due to the known synergism between chemotherapy and immunotherapy, it is hoped that concomitant durvalumab can reduce the relatively high incidence of local failure (38%-46%) as seen in recent prospective, randomized trials of standard chemo/radiation in this patient population. We will review the history of radiation for LA-NSCLC and discuss the role of induction, concurrent and consolidative chemotherapy as well as the concerns for late cardiac and pulmonary toxicities associated with treatment. Furthermore, we will review the potential role of next generation sequencing, PD-L1, ctDNA and tumor mutation burden and their possible impact on this trial. © 2022 Elsevier Inc.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3} -} - -@ARTICLE{Berta202354, - author = {Berta, Judit and Rózsás, Anita and Megyesfalvi, Zsolt and Ostoros, Gyula and Döme, Balázs}, - title = {Thoracic irradiation as consolidation therapy in patients with extensive-stage small cell lung cancer}, - year = {2023}, - journal = {Current Opinion in Oncology}, - volume = {35}, - number = {1}, - pages = {54 – 60}, - doi = {10.1097/CCO.0000000000000911}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143645053&doi=10.1097%2fCCO.0000000000000911&partnerID=40&md5=4a2e680fa6af7ea4714a7ca80ce1f41e}, - abstract = {Purpose of reviewSmall cell lung cancer (SCLC) is marked by an exceptionally high proliferative rate and poor prognosis. Given its high propensity to metastasize, nearly two-thirds of SCLC patients are diagnosed with extensive-stage (ES) disease when surgery is not a treatment option anymore. Over several decades, only minimal changes have been made in the therapeutic armamentarium of ES-SCLC. Recently, however, several new therapeutic avenues were defined, thus renewing the hope for patients with this recalcitrant cancer. Here, we present an overview of the most current therapeutic advances in ES-SCLC focusing in particular on consolidative thoracic radiation therapy (cTRT) and chemo-immunotherapy.Recent findingsThe incorporation of immunotherapy in the standard-of-care of ES-SCLC patients and the resulting outcomes are both a remarkable hallmark of progress and a disappointment. Indeed, chemo-immunotherapy with or without cTRT and prophylactic cranial irradiation contributes to longer survival outcomes with minimal toxicity rates in well selected and properly monitored patients. Nevertheless, the gain in overall survival is still modest relative to that seen in many other solid tumors.SummaryDespite the encouraging results, further clinical trials are needed to determine the efficacy and safety of these therapeutic approaches, and moreover, to identify new predictive biomarkers of response. © 2023 Lippincott Williams and Wilkins. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3} -} - -@ARTICLE{Tang2023, - author = {Tang, Wen-Fang and Ye, Hong-Yu and Tang, Xuan and Su, Jian-Wei and Xu, Kang-Mei and Zhong, Wen-Zhao and Liang, Yi}, - title = {Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone}, - year = {2023}, - journal = {Frontiers in Oncology}, - volume = {13}, - doi = {10.3389/fonc.2023.1063183}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85147677402&doi=10.3389%2ffonc.2023.1063183&partnerID=40&md5=ee48a2ca3ae1b9b8455ef11144fb878d}, - abstract = {Currently, chemotherapy is the standard adjuvant treatment for early-stage non-small cell lung cancer (NSCLC). However, adjuvant cisplatin-based chemotherapy after surgery has been shown to improve 5-year survival rates by only 4−5%. Immunotherapy using immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced NSCLC, there is a growing interest in the role of immunotherapy in early-stage NSCLC. Here, we summarize the rationale for adjuvant immunotherapy, including the postoperative immunosuppressive environment and immunological effects of platinum chemotherapy. Many ongoing clinical trials and the related progress in adjuvant immunotherapy in early-stage resectable NSCLC are discussed. Furthermore, we highlight several unresolved challenges, including markers predictive of treatment benefit, the efficacy of treatment for some oncogene-addicted tumors, the optimal combination therapy, the duration of adjuvant immunotherapy, and optimal selection between neoadjuvant and adjuvant immunotherapy. Early findings in some clinical trials are promising, and updated overall survival results will be useful for validating the current role of adjuvant immunotherapy, particularly in the context of perioperative strategy. Copyright © 2023 Tang, Ye, Tang, Su, Xu, Zhong and Liang.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Vokes2023, - author = {Vokes, Natalie I. and Pan, Kelsey and Le, Xiuning}, - title = {Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer}, - year = {2023}, - journal = {Therapeutic Advances in Medical Oncology}, - volume = {15}, - doi = {10.1177/17588359231161409}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85150422616&doi=10.1177%2f17588359231161409&partnerID=40&md5=9f640006eceab76757dfd57ef92e3165}, - abstract = {For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven approvals within the last 5 years. This accelerated drug development has expanded the reach of targeted therapies, and it may soon be that a majority of patients with lung adenocarcinoma will be eligible for a targeted therapy during their treatment course. With these emerging therapeutic options, it is important to understand the existing data on immune checkpoint inhibitors (ICIs), along with their efficacy and safety for each oncogene-driven lung cancer, to best guide the selection and sequencing of various therapeutic options. This article reviews the clinical data on ICIs for each of the driver oncogene defined lung cancer subtypes, including efficacy, both for ICI as monotherapy or in combination with chemotherapy or radiation; toxicities from ICI/targeted therapy in combination or in sequence; and potential strategies to enhance ICI efficacy in oncogene-driven non-small-cell lung cancers. © The Author(s), 2023.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 16; All Open Access, Green Open Access} -} - -@ARTICLE{Knapp2022, - author = {Knapp, Brendan and Mezquita, Laura and Devarakonda, Siddhartha and Aldea, Mihaela and Waqar, Saiama N. and Pepin, Kym and Ward, Jeffrey P. and Botticella, Angela and Howarth, Karen and Knape, Charlene and Morris, Clive and Govindan, Ramaswamy and Besse, Benjamin and Morgensztern, Daniel}, - title = {Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer}, - year = {2022}, - journal = {Frontiers in Oncology}, - volume = {12}, - doi = {10.3389/fonc.2022.856132}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128382538&doi=10.3389%2ffonc.2022.856132&partnerID=40&md5=3c220b8f11b6431e2a9480cf00e70452}, - abstract = {Introduction: Circulating tumor DNA (ctDNA) testing may identify patients at high risk for recurrence following chemoradiation (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC). We evaluated the feasibility of ctDNA testing on a readily available commercial fixed-gene panel to predict outcomes in patients with LA-NSCLC. Methods: Plasma of 43 patients was collected at CRT initiation (pre-CRT), completion (post-CRT1), quarterly follow up for 12 months (post-CRT2, 3, 4, 5 respectively) after CRT, and at disease progression. ctDNA analysis was performed using InVisionFirst®-Lung to detect mutations in 36 cancer-related genes. ctDNA clearance was defined as absence of pre-CRT variants at post-CRT1. Patients without detectable pre-CRT variants or no post-CRT1 samples were excluded. Results: Twenty eight of 43 patients (65%) had detectable variants pre-CRT. Nineteen of 43 patients (44%) had detectable pre-CRT variants and post-CRT1 samples and were included in analysis. Median age at diagnosis was 65 years (43-82), and most patients had stage IIIB disease (10/19, 53%). Two patients died from non-cancer related causes before post-CRT2 and were excluded from further analysis. All three patients who did not clear ctDNA had tumor relapse with a median time to relapse of 74 days (30-238), while 50% (7/14) of those who cleared ctDNA have remained disease free. Progression free survival was longer in patients who cleared ctDNA compared to those who did not (median 567 vs 74 d, p = 0.01). Conclusions: Although it is feasible to use ctDNA testing on a limited gene panel to identify patients with LA-NSCLC who are at high risk for disease recurrence following CRT, further studies will be necessary to optimize these assays before they can be used to inform clinical care in patients with lung cancer. Copyright © 2022 Knapp, Mezquita, Devarakonda, Aldea, Waqar, Pepin, Ward, Botticella, Howarth, Knape, Morris, Govindan, Besse and Morgensztern.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Gold Open Access} -} - -@ARTICLE{Bogart2022661, - author = {Bogart, Jeffrey A. and Waqar, Saiama N. and Mix, Michael D.}, - title = {Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer}, - year = {2022}, - journal = {Journal of Clinical Oncology}, - volume = {40}, - number = {6}, - pages = {661 – 670}, - doi = {10.1200/JCO.21.01639}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85124808556&doi=10.1200%2fJCO.21.01639&partnerID=40&md5=c7105363cf5125585a26f26bda530f1b}, - abstract = {Progress in the overall treatment of small-cell lung cancer (SCLC) has moved at a slower pace than non–small-cell lung cancer. In fact, the standard treatment regimen for limited stage SCLC has not appreciably shifted in more than 20 years, consisting of four to six cycles of cisplatin and etoposide chemotherapy concurrent with thoracic radiotherapy (TRT) followed by prophylactic cranial irradiation (PCI) for responsive disease. Nevertheless, long-term outcomes have improved with median survival approaching 25-30 months, and approximately one third of patients now survive 5 years. This is likely attributable in part to improvements in staging, including use of brain magnetic resonance imaging and fluorodeoxyglucose–positron emission tomography imaging, advances in radiation treatment planning, and supportive care. The CONVERT and CALGB 30610 phase III trials failed to demonstrate a survival advantage for high-dose, once-daily TRT compared with standard 45 Gy twice-daily TRT, although high-dose, once-daily TRT remains common in practice. A phase III comparison of high-dose 60 Gy twice-daily TRT versus 45 Gy twice-daily TRT aims to confirm the provocative outcomes reported with 60 Gy twice daily in the phase II setting. Efforts over time have shifted from intensifying PCI, to attempting to reduce treatment-related neurotoxicity, to more recently questioning whether careful magnetic resonance imaging surveillance may obviate the routine need for PCI. The addition of immunotherapy has resulted in mixed success in extensive-stage SCLC with modest benefit observed with programmed death-ligand 1 inhibitors, and several ongoing trials assess programmed death-ligand 1 inhibition concurrent or adjuvant to chemoradiotherapy in limited-stage SCLC. Major advances in future treatment will likely depend on a better understanding and exploiting of molecular characteristics of SCLC with increasing personalization of therapy. © 2022 by American Society of Clinical Oncology}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 55; All Open Access, Green Open Access} -} - -@ARTICLE{Chen2023689, - author = {Chen, Mo and Wei, Lingyun and Wang, Qin and Xie, Jingyuan and Xu, Ke and Lv, Tangfeng and Song, Yong and Zhan, Ping}, - title = {Efficacy of different therapies for brain metastases of non-small cell lung cancer: a systematic review and meta-analysis}, - year = {2023}, - journal = {Translational Lung Cancer Research}, - volume = {12}, - number = {4}, - pages = {689 – 706}, - doi = {10.21037/tlcr-22-515}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160300251&doi=10.21037%2ftlcr-22-515&partnerID=40&md5=fb3b300ec39d3f7de2a0ce61ca8b6de5}, - abstract = {Background: As one of the most common causes of death in advanced non-small cell lung cancer (NSCLC), brain metastases (BM) have attracted attention and debate about treatment options, especially for patients with negative driver genes or resistance to targeted agents. Therefore, we conducted a meta-analysis to investigate the potential benefit of different therapeutic regimens for intracranial lesions in non-targeted therapy NSCLC patients. Methods: A comprehensive search was conducted in databases including PubMed, Embase, and the Cochrane Library. The primary endpoints included the intracerebral objective response rate (icORR) and intracerebral progression-free survival (iPFS) in patients with BM. Results: Thirty-six studies involving 1,774 NSCLC patients with baseline BM were included in this meta-analysis. Antitumor agents plus radiotherapy (RT) showed the most significant synergistic effects; the highest pooled icORR that appeared in the combination of immune checkpoint inhibitor (ICI) and RT was 81% [95% confidence interval (CI): 16–100%], and the median iPFS was 7.04 months (95% CI: 2.54–11.55 months). The pooled icORR and median iPFS of RT plus chemotherapy were 46% (95% CI: 34–57%) and 5.7 months (95% CI: 3.90–7.50 months), respectively. The highest median iPFS in nivolumab plus ipilimumab plus chemotherapy was 13.5 months (95% CI: 8.35–18.65 months). ICI plus chemotherapy also showed potent antitumor activity in BM, with a pooled icORR of 56% (95% CI: 29–82%) and a median iPFS of 6.9 months (95% CI: 3.20–10.60 months). Notably, the subgroup analysis indicated that the pooled icORR of patients in programmed cell death-ligand 1 (PD-L1) (≥50%) who received ICI was 54% (95% CI: 30–77%), and that of patients who received first-line ICI was 69.0% (95% CI: 51–85%). Conclusions: ICI-based combination treatment provides a long-term survival benefit for non-targeted therapy patients, with the most significant benefits observed in improving icORR and prolonging overall survival (OS) and iPFS. In particular, patients who received first-line treatment or who were PD-L1-positive had a more significant survival benefit from aggressive ICI-based therapies. For patients with a PD-L1-negative status, chemotherapy plus RT led to better clinical outcomes than other treatment regimens. These innovative findings could help clinicians to better select therapeutic strategies for NSCLC patients with BM. © Translational Lung Cancer Research. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Gold Open Access} -} - -@ARTICLE{Grau-Bejar2023, - author = {Grau-Bejar, Juan Francisco and Garcia-Duran, Carmen and Garcia-Illescas, David and Mirallas, Oriol and Oaknin, Ana}, - title = {Advances in immunotherapy for cervical cancer}, - year = {2023}, - journal = {Therapeutic Advances in Medical Oncology}, - volume = {15}, - doi = {10.1177/17588359231163836}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85151414075&doi=10.1177%2f17588359231163836&partnerID=40&md5=78c52cd28e8982eb4cff630aaaee40b6}, - abstract = {Cervical cancer still represents a major public health problem, being the fourth most common cancer in incidence and mortality in women worldwide. These figures are unacceptable since cervical cancer, an human papillomavirus-related malignancy, is a largely preventable disease by means of well-established screening and vaccination programs. Patients with recurrent, persistent, or metastatic disease unsuitable for curative therapeutic approaches represent a dismal prognosis population. Until recently, these patients were only candidates for cisplatin-based chemotherapy plus bevacizumab. However, the introduction of immune checkpoint inhibitors has revolutionized the treatment landscape of this disease achieving historical overall survival improvements in both the post-platinum and frontline settings. Interestingly, the clinical development of immunotherapy in cervical cancer is currently advancing to earlier stages of the disease, as the locally advanced setting, whose standard of care has not changed in the last decades with still modest outcomes. As more innovative immunotherapy approaches are in clinical early development in advanced cervical cancer, promising efficacy data are emerging that may shape the future of this disease. This review summarizes the main treatment advances carried out in the field of immunotherapy throughout the past years. © The Author(s), 2023.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 13; All Open Access, Gold Open Access} -} - -@ARTICLE{Król2023, - author = {Król, Katarzyna and Mazur, Anna and Stachyra-Strawa, Paulina and Grzybowska-Szatkowska, Ludmiła}, - title = {Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy—A Review}, - year = {2023}, - journal = {International Journal of Molecular Sciences}, - volume = {24}, - number = {6}, - doi = {10.3390/ijms24065858}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85151107666&doi=10.3390%2fijms24065858&partnerID=40&md5=5d3d9813c8cd0e9d67832c86a451f56a}, - abstract = {Lung cancer is the leading cause of death worldwide for both men and women. Surgery can be offered as a radical treatment at stages I and II and selected cases of stage III (III A). Whereas at more advanced stages, combined modalities of treatment are applied: radiochemotherapy (IIIB) and molecularly targeted treatment (small molecule tyrosine kinase inhibitors, VEGF receptor inhibitors, monoclonal antibodies, and immunological treatment with monoclonal antibodies). Combination treatment, composed of radiotherapy and molecular therapy, is increasingly employed in locally advanced and metastatic lung cancer management. Recent studies have indicated a synergistic effect of such treatment and modification of immune response. The combination of immunotherapy and radiotherapy may result in the enhancement of the abscopal effect. Anti-angiogenic therapy, in combination with RT, is associated with high toxicity and should be not recommended. In this paper, the authors discuss the role of molecular treatment and the possibility of its concurrent use with radiotherapy in non-small cell lung cancer (NSCLC). © 2023 by the authors.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 10; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Meijer2022376, - author = {Meijer, Job-Joris and Leonetti, Alessandro and Airò, Giulia and Tiseo, Marcello and Rolfo, Christian and Giovannetti, Elisa and Vahabi, Mahrou}, - title = {Small cell lung cancer: Novel treatments beyond immunotherapy}, - year = {2022}, - journal = {Seminars in Cancer Biology}, - volume = {86}, - pages = {376 – 385}, - doi = {10.1016/j.semcancer.2022.05.004}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130951386&doi=10.1016%2fj.semcancer.2022.05.004&partnerID=40&md5=0004675a6c7b05b226bae4a52cfe2d39}, - abstract = {Small cell lung cancer (SCLC) arises in peribronchial locations and infiltrates the bronchial submucosa, including about 15% of lung cancer cases. Despite decades of research, the prognosis for SCLC patients remains poor because this tumor is characterized by an exceptionally high proliferative rate, strong tendency for early widespread metastasis and acquired chemoresistance. Omics profiling revealed that SCLC harbor extensive chromosomal rearrangements and a very high mutation burden. This led to the development of immune-checkpoint inhibitors as single agents or in combination with chemotherapy, which however resulted in a prolonged benefit only for a small subset of patients. Thus, the present review discusses the rationale and limitations of immunotherapeutic approaches, presenting the current biological understanding of aberrant signaling pathways that might be exploited with new potential treatments. In particular, new agents targeting DNA damage repair, cell cycle checkpoint, and apoptosis pathways showed several promising results in different preclinical models. Epigenetic alterations, gene amplifications and mutations can act as biomarkers in this context. Future research and improved clinical outcome for SCLC patients will depend on the integration between these omics and pharmacological studies with clinical translational research, in order to identify specific predictive biomarkers that will be hopefully validated using clinical trials with biomarker-selected targeted treatments. © 2022 The Authors}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 39; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Merie2022741, - author = {Merie, R. and Gee, H. and Hau, E. and Vinod, S.}, - title = {An Overview of the Role of Radiotherapy in the Treatment of Small Cell Lung Cancer – A Mainstay of Treatment or a Modality in Decline?}, - year = {2022}, - journal = {Clinical Oncology}, - volume = {34}, - number = {11}, - pages = {741 – 752}, - doi = {10.1016/j.clon.2022.08.024}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137619199&doi=10.1016%2fj.clon.2022.08.024&partnerID=40&md5=37616927c34bc68ce3ccbb8c2b51c6d8}, - abstract = {Aims: Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers. Chemotherapy, immunotherapy and radiotherapy all play important roles in the management of SCLC. The aim of this study was to provide a comprehensive overview of the role and evidence of radiotherapy in the cure and palliation of SCLC. Materials and methods: The search strategy included a search of the PubMed database, hand searches, reference lists of relevant review articles and relevant published abstracts. ClinicalTrials.gov was also queried for relevant trials. Results: Thoracic radiotherapy improves overall survival in limited stage SCLC, but the timing and dose remain controversial. The role of thoracic radiotherapy in extensive stage SCLC with immunotherapy is the subject of several ongoing trials. Current evidence supports the use of prophylactic cranial irradiation (PCI) for limited stage SCLC but the evidence is equivocal in extensive stage SCLC. Whole brain radiotherapy is well established for the treatment of brain metastases but evidence is rapidly accumulating for the use of stereotactic radiosurgery. Further studies will define the role of PCI, whole brain radiotherapy and hippocampal avoidant PCI in the immunotherapy era. Conclusion: Radiotherapy is an essential component in the multimodality management of SCLC. Technological advances have allowed safer delivery of radiotherapy with reduced toxicities. Discussion at multidisciplinary team meetings is important to ensure radiotherapy is considered and offered in appropriate patients. © 2022}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3} -} - -@ARTICLE{Heynemann20212012, - author = {Heynemann, Sarah and Mitchell, Paul}, - title = {Developments in systemic therapies for the management of lung cancer}, - year = {2021}, - journal = {Internal Medicine Journal}, - volume = {51}, - number = {12}, - pages = {2012 – 2020}, - doi = {10.1111/imj.15609}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121619045&doi=10.1111%2fimj.15609&partnerID=40&md5=03d7b409c538aeb7bcdc80a7b52e6648}, - abstract = {Lung cancer accounts for approximately 1 in 10 new cancer diagnoses annually and is responsible for the most cancer-associated deaths in Australia. Despite such figures, there is reason for optimism with many practice-changing developments to report for the management of patients with thoracic malignancies over the last few years. We outline such changes, including the emerging role of immunotherapy in the neoadjuvant and adjuvant setting for patients with localised non-small-cell lung cancer, as well as the established standard of consolidation immunotherapy following definitive chemoradiotherapy for those with locally advanced disease. In the metastatic setting, combination chemotherapy–immunotherapy approaches have become the new paradigm for most patients in the absence of a recognised driver mutation. A range of novel targeted therapies now exist and are Pharmaceutical Benefits Scheme (PBS)-subsidised for targets such as EGFR, ALK and ROS1, with many others, such as KRAS G12C, NTRK, MET, RET and HER2, also with therapies rapidly being developed. Even among patients with small-cell lung cancer, who account for the worst prognoses and until recently have received a chemotherapy regimen that has remained unchanged in over 20 years, there is a new standard-of-care in combination chemotherapy–immunotherapy. Furthermore, immunotherapy and potentially anti-vascular endothelial growth factor agents now also play a role in mesothelioma treatment. Last, given recent developments in immunotherapy, targeted therapy and combination approaches in the non-small-cell lung cancer space, there is an increasing recognition of the diversity of lived experience for such patients and need for survivorship programmes to acknowledge such nuances. © 2021 Royal Australasian College of Physicians.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 5; All Open Access, Bronze Open Access} -} - -@ARTICLE{Wang2023, - author = {Wang, Fuli and Xia, Teng and Li, Zhiqiang and Gao, Xuzhu and Fang, Xinjian}, - title = {Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer}, - year = {2023}, - journal = {Frontiers in Oncology}, - volume = {13}, - doi = {10.3389/fonc.2023.1213297}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85171363986&doi=10.3389%2ffonc.2023.1213297&partnerID=40&md5=a0e6831b835fe57cffc90b6df60a889c}, - abstract = {Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung cancer (NSCLC) with remarkable success. Compared to chemotherapy patients, the 5-year survival rate for immunotherapy patients is 3-fold higher, approximately 4%–5% versus 15%–16%, respectively. Immunotherapies include chimeric antigen receptor T-cell (CAR-T) therapy, tumor vaccines, immune checkpoint inhibitors, and so forth. Among them, immune checkpoint inhibitors are in the spotlight. Common immune checkpoint inhibitors (ICIs) currently in clinical use include programmed death receptor-1(PD-1)/programmed death ligand-1(PD-L1) and cytotoxic T lymphocyte-associated antigen 4(CTLA-4). This article focuses on monotherapy and combination therapy of CTLA-4 and PD-1/PD-L1 immune checkpoint inhibitors. In particular, the combination therapy of ICIs includes the combination of ICIs and chemotherapy, the combination therapy of dual ICIs, the combination of ICIs and anti-angiogenic drugs, the combination of ICIs and radiotherapy, and the combination of ICIs inhibitors and tumor vaccines and so forth. This article focuses on the combination therapy of ICIs with chemotherapy, the combination therapy of dual ICIs, and the combination therapy of ICIs with anti-angiogenic drugs. The efficacy and safety of ICIs as single agents in NSCLC have been demonstrated in many trials. However, ICIs plus chemotherapy regimens offer significant advantages in the treatment of NSCLC with little to no dramatic increase in toxicity, while combined dual ICIs significantly reduce the adverse effects (AEs) of chemotherapy. ICIs plus anti-angiogenic agents regimen improves anti-tumor activity and safety and is expected to be the new paradigm for the treatment of advanced NSCLC. Despite some limitations, these agents have achieved better overall survival rates. In this article, we review the current status and progress of research on ICIs in NSCLC in recent years, aiming to better guide the individualized treatment of NSCLC patients. Copyright © 2023 Wang, Xia, Li, Gao and Fang.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 6; All Open Access, Gold Open Access} -} - -@ARTICLE{Chen2022937, - author = {Chen, Peixin and Liu, Yunhuan and Wen, Yaokai and Zhou, Caicun}, - title = {Non-small cell lung cancer in China}, - year = {2022}, - journal = {Cancer Communications}, - volume = {42}, - number = {10}, - pages = {937 – 970}, - doi = {10.1002/cac2.12359}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137666863&doi=10.1002%2fcac2.12359&partnerID=40&md5=3e1e8045df77fa9f1c85857ef6273abc}, - abstract = {In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early-stage non-small cell lung cancer (NSCLC) patients miss the optimal timing for treatment due to the lack of clinical presentations. Population-based nationwide screening programs are of significant help in increasing the early detection and survival rates of NSCLC in China. The understanding of molecular carcinogenesis and the identification of oncogenic drivers dramatically facilitate the development of targeted therapy for NSCLC, thus prolonging survival in patients with positive drivers. In the exploration of immune escape mechanisms, programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor monotherapy and PD-1/PD-L1 inhibitor plus chemotherapy have become a standard of care for advanced NSCLC in China. In the Chinese Society of Clinical Oncology's guidelines for NSCLC, maintenance immunotherapy is recommended for locally advanced NSCLC after chemoradiotherapy. Adjuvant immunotherapy and neoadjuvant chemoimmunotherapy will be approved for resectable NSCLC. In this review, we summarized recent advances in NSCLC in China in terms of epidemiology, biology, molecular pathology, pathogenesis, screening, diagnosis, targeted therapy, and immunotherapy. © 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 231; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Colciago2023135, - author = {Colciago, Riccardo Ray and Fischetti, Irene and Giandini, Carlotta and La Rocca, Eliana and Rancati T, Tiziana and Rejas Mateo, Alicia and Colombo, Mario Paolo and Lozza, Laura and Chiodoni, Claudia and Jachetti, Elena and De Santis, Maria Carmen}, - title = {Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement}, - year = {2023}, - journal = {Expert Review of Anticancer Therapy}, - volume = {23}, - number = {2}, - pages = {135 – 145}, - doi = {10.1080/14737140.2023.2173175}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148529561&doi=10.1080%2f14737140.2023.2173175&partnerID=40&md5=bc5a7ef318dd26df35d1c7f534453ddf}, - abstract = {Introduction: Oncological treatments are changing rapidly due to the advent of several targeted anticancer drugs and regimens. The primary new area of research in oncological medicine is the implementation of a combination of novel therapies and standard care. In this scenario, radioimmunotherapy is one of the most promising fields, as proven by the exponential growth of publications in this context during the last decade. Areas covered: This review provides an overview of the synergistic use of radiotherapy and immunotherapy and addresses questions like the importance of this subject, aspects clinicians look for in patients to administer this combined therapy, individuals who would benefit the most from this treatment, how to achieve abscopal effect and when does radio-immunotherapy become standard clinical practice. Expert opinion: Answers to these queries generate further issues that need to be addressed and solved. The abscopal and bystander effects are not utopia, rather physiological phenomena that occur in our bodies. Nevertheless, substantial evidence regarding the combination of radioimmunotherapy is lacking. In conclusion, joining forces and finding answers to all these open questions is of paramount importance. © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 8; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Panagi20226106, - author = {Panagi, Myrofora and Pilavaki, Pampina and Constantinidou, Anastasia and Stylianopoulos, Triantafyllos}, - title = {Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness}, - year = {2022}, - journal = {Theranostics}, - volume = {12}, - number = {15}, - pages = {6106 – 6129}, - doi = {10.7150/thno.72800}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85138072994&doi=10.7150%2fthno.72800&partnerID=40&md5=b251ffa97e2e0cb9dbb582ba8bb37cc6}, - abstract = {Sarcomas are uncommon malignancies of mesenchymal origin that can arise throughout the human lifespan, at any part of the body. Surgery remains the optimal treatment modality whilst response to conventional treatments, such as chemotherapy and radiation, is minimal. Immunotherapy has emerged as a novel approach to treat different cancer types but efficacy in soft tissue sarcoma and bone sarcoma is limited to distinct subtypes. Growing evidence shows that cancer-stroma cell interactions and their microenvironment play a key role in the effectiveness of immunotherapy. However, the pathophysiological and immunological properties of the sarcoma tumor microenvironment in relation to immunotherapy advances, has not been broadly reviewed. Here, we provide an up-to-date overview of the different immunotherapy modalities as potential treatments for sarcoma, identify barriers posed by the sarcoma microenvironment to immunotherapy, highlight their relevance for impeding effectiveness, and suggest mechanisms to overcome these barriers. © 2022 Ivyspring International Publisher. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 19; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Bogart20221330, - author = {Bogart, Jeffrey A.}, - title = {Immune Checkpoint Inhibition for Locally Advanced NSCLC: Time to Ask New Questions?}, - year = {2022}, - journal = {Journal of Thoracic Oncology}, - volume = {17}, - number = {12}, - pages = {1330 – 1332}, - doi = {10.1016/j.jtho.2022.08.019}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142132874&doi=10.1016%2fj.jtho.2022.08.019&partnerID=40&md5=600ffb95490936d8c60371ce7b8e12ef}, - type = {Editorial}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Bronze Open Access} -} - -@ARTICLE{Silva2022617, - author = {Silva, Virgilio S. and Riechelmann, Rachel P. and Mello, Celso A. and Felismino, Tiago and Taboada, Rodrigo}, - title = {The Current and Evolving Role of Immunotherapy in Metastatic Colorec-tal Cancer}, - year = {2022}, - journal = {Current Cancer Drug Targets}, - volume = {22}, - number = {8}, - pages = {617 – 628}, - doi = {10.2174/1568009622666220224110912}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136215679&doi=10.2174%2f1568009622666220224110912&partnerID=40&md5=7a674b7151bccc66cb25495e1344432c}, - abstract = {Immunotherapy can be considered a therapeutic revolution in oncology, with great impact on many tumor types, such as melanoma and non-small cell lung cancer. However, in metastatic colo-rectal cancer, the benefits in terms of prolonged tumor control and high response rate are limited to the rare subgroup of tumors with high mutation burden-mostly tumors that harbor microsatellite instability (MSI) or a deficient mismatch repair system (dMMR), or tumor microsatellite stability and damag-ing mutations in the exonuclease domains of POLE or POLD. The KEYNOTE-028 uncontrolled phase II trial demonstrated an impressive antitumor activity of pembrolizumab in patients with treatment-refractory Lynch-associated tumors, including colorectal cancer. Nivolumab with or without ipili-mumab confirmed the efficacy of immune checkpoint inhibitors in patients with previously treated dMMR / MSI metastatic colorectal cancer. The recent KEYNOTE-177 phase III trial demonstrated that pembrolizumab significantly reduced the relative risk of disease progression or death and improved progression-free survival in patients with treatment-naive dMMR / MSI metastatic colorectal cancer in comparison with first-line chemotherapy with or without biologics. Unfortunately, current pharmacological strategies with immunotherapy have not been successful for most patients with mi-crosatellite stable metastatic colorectal cancer. In this review, we critically appraise the applicability of immune checkpoint inhibitors in dMMR/MSI metastatic colorectal cancer. We also discuss the recent negative trials of immunotherapy combinations in microsatellite stable tumors and more mature immu-notherapy ongoing studies in the field of advanced colorectal cancer. © 2022 Bentham Science Publishers.}, - type = {Short survey}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4} -} - -@ARTICLE{Kashihara2023, - author = {Kashihara, Tairo and Nakayama, Yuko and Okuma, Kae and Takahashi, Ayaka and Kaneda, Tomoya and Katagiri, Mika and Nakayama, Hiroki and Kubo, Yuko and Ito, Kimiteru and Nakamura, Satoshi and Takahashi, Kana and Inaba, Koji and Murakami, Naoya and Saito, Tetsuo and Okamoto, Hiroyuki and Itami, Jun and Kusumoto, Masahiko and Ohe, Yuichiro and Igaki, Hiroshi}, - title = {Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer}, - year = {2023}, - journal = {Radiotherapy and Oncology}, - volume = {180}, - doi = {10.1016/j.radonc.2022.109454}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149765402&doi=10.1016%2fj.radonc.2022.109454&partnerID=40&md5=57ad615ca8120675d6af9e857155630e}, - abstract = {Introduction: Concurrent chemoradiotherapy (CCRT) has been the standard of care for patients with locally advanced non-small cell lung cancer (LA-NSCLC). Background and Purpose: The results of the PACIFIC trial established the use of consolidative durvalumab after concurrent chemoradiotherapy (CCRT) as the standard of care for patients with locally advanced non-small cell lung cancer (LA-NSCLC). A subgroup analysis of the PACIFIC trial reported a better progression-free survival (PFS) in Asians. Although real-world data on LA-NSCLC patients who received CCRT plus durvalumab have been reported, there have been few large-scale reports on Asians. In this study, we investigated prognostic factors in the largest real-world data set in Asia of only Japanese LA-NSCLC patients treated with CCRT plus durvalumab. Materials and Methods: One hundred and thirteen LA-NSCLC patients who received definitive CCRT and consolidative durvalumab at our institution between May 2018 and April 2021 were analyzed. Overall survival (OS), cause-specific survival (CSS), PFS, distant metastasis-free survival (DMFS), and in-field progression-free survival (IFPFS) were investigated as treatment outcomes using competing risk analyses. Results: During a median follow-up of 24 months (range, 5–47) after the initiation of durvalumab therapy, 31 patients died, of whom 23 died of lung cancer. In the multivariate analysis, the pretreatment factors that correlated with OS were ILA scores, adenocarcinoma, and performance status at the initiation of durvalumab. Furthermore, ILA score and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 1 % were significantly correlated with CSS, and PD-L1 TPS ≥ 1 % was significantly correlated with PFS and IFPFS. Conclusion: Pretreatment ILA, adenocarcinoma, and performance status may have an impact on OS of LA-NSCLC patients receiving CCRT plus durvalumab. © 2022 The Author(s)}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 5} -} - -@ARTICLE{Kerrigan2022113, - author = {Kerrigan, Kathleen and Puri, Sonam}, - title = {Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer}, - year = {2022}, - journal = {Current Oncology Reports}, - volume = {24}, - number = {1}, - pages = {113 – 123}, - doi = {10.1007/s11912-021-01164-1}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123235046&doi=10.1007%2fs11912-021-01164-1&partnerID=40&md5=725e997bfd5672150b5e06dffe0e9b30}, - abstract = {Purpose of Review: The use of single-agent or combination immunotherapy strategies has revolutionized the management of patients with non-small cell lung cancer (NSCLC). Here, we review the current role for CTLA-4 inhibitors in early-stage resectable NSCLC, unresectable stage III NSCLC, and in metastatic NSCLC. Recent Findings: Immunotherapy agents alone, or in combination with chemotherapy, represent the new standard of care for the management of metastatic squamous and non-squamous NSCLC without driver mutations. Combination CTLA-4 and PD-1/L1 inhibitors can be efficacious, particularly in tumor mutation burden (TMB) high tumors, providing a chemotherapy-free strategy for metastatic patients. Early signals from neoadjuvant trials suggest a benefit for combination CTLA-4 and PD-1 inhibitions prior to surgery, with improved rates of major pathologic response (MPR). The role for CTLA4 inhibitors is currently unknown in the adjuvant and unresectable stage III setting, although clinical trials are ongoing to evaluate this approach. Summary: There is a growing role for CTLA-4 inhibition in the neoadjuvant and metastatic settings for patients with NSCLC. Biomarker selection in ongoing clinical trials will be crucial to guide patient selection for CTLA4 inhibitor therapy. Combination strategies with PD-1/L1 inhibition have demonstrated the greatest efficacy to date. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 5} -} - -@ARTICLE{Zhou2022656, - author = {Zhou, Juan and Wu, Yinfei and Xie, Mengqing and Fang, Yujia and Zhao, Jing and Lee, Sung Yong and Im, Yunjoo and Ye, Lingyun and Su, Chunxia}, - title = {The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases}, - year = {2022}, - journal = {Translational Lung Cancer Research}, - volume = {11}, - number = {4}, - pages = {656 – 669}, - doi = {10.21037/tlcr-22-260}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129405115&doi=10.21037%2ftlcr-22-260&partnerID=40&md5=6c1fdacb3f8ebd7039f8b2d6df01ed1c}, - abstract = {Background: The data about efficacy of immunotherapy for non-small cell lung cancer with brain metastases (BMs) from real-word settings are controversial. This real-word study is aimed to evaluate the clinical outcome of immune checkpoint inhibitor (ICI)-based treatment in lung adenocarcinoma patients with brain metastases (BMs) and explore potential risk factors, with a focus on the spatial distribution of BMs as previous studies suggested spatial heterogeneity on the brain immune microenvironment. Methods: Advanced lung adenocarcinoma patients with non-oncogene-addicted, who received ICI monotherapy or plus chemotherapy, were enrolled. Efficacy was assessed by Response Evaluation Criteria in Solid Tumors version 1.1. Intergroup comparisons were performed using Pearson's x2 or Fisher's exact tests for categorical variables. The progression-free survival (PFS) was estimated using Kaplan-Meier method and compared using log-rank test. Cox proportional hazards model was used for multivariate analyses. Peripheral blood was collected from 15 patients with BMs. Tumor-derived exosomes in plasma were isolated by size exclusion chromatography and the cDNA library preparations for miRNA were sequenced on an Illumina Hiseq platform. Differentially expressed genes in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were analyzed. Results: A total of 198 patients were enrolled and brain metastasis occurred in 20.7% patients (N=41). Compared with patients without BMs, those with BMs had a comparable objective response rate (ORR; 29.3% vs. 43.9%; P=0.089), a lower disease control rate (DCR; 58.5% vs. 78.3%; P=0.01), and a shorter PFS (3.6 vs. 8.6 months; P=0.069). For patients with BMs, factors, including the presence of neurological symptoms, the treatment of intracranial radiotherapy, and the combination of ICI with chemotherapy, had no impact on PFS, whereas cerebellum metastasis was significantly associated with shorter PFS (2.8 vs. 13.8 months, P=0.007). Six upregulated miRNAs were identified in patients with cerebellum metastases (N=8) compared with those without (N=7). The enrichment of differentially expression genes in the KEGG pathways indicated upregulated sulfur metabolism pathway in patients with cerebellum metastases. Conclusions: For lung adenocarcinoma patients, those with BMs have inferior response to ICI-based treatment, but not significantly, and cerebellum metastasis is an independent risk factor with poor outcome for such patients, might attributing to the upregulated sulfur metabolism. © 2022 AME Publishing Company. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Gold Open Access} -} - -@ARTICLE{Zugazagoitia2022671, - author = {Zugazagoitia, Jon and Paz-Ares, Luis}, - title = {Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options}, - year = {2022}, - journal = {Journal of Clinical Oncology}, - volume = {40}, - number = {6}, - pages = {671 – 680}, - doi = {10.1200/JCO.21.01881}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85124809057&doi=10.1200%2fJCO.21.01881&partnerID=40&md5=075f305bdaed5142375c8ad139996fc6}, - abstract = {Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more than two decades without clinical progress, the addition of programmed cell death protein 1 axis blockade to platinum-based chemotherapy has demonstrated sustained overall survival benefit and represents the current standard of care in the first-line setting. Despite this benefit, resistance emerges relatively rapidly in virtually all patients. Although newer treatments are being incorporated in the relapse setting, marked therapeutic resistance is typically observed in patients with relapsed small-cell lung cancer (SCLC), underscoring the need of developing more effective therapies in this setting. Notably, recent progress in the understanding of the molecular biology of SCLC might bring possibilities toward molecularly informed therapeutic strategies for patients with SCLC, which could have a significant impact for improving outcomes in this disease. Here, we review current treatment options and recent progress made in the first-line and relapsed SCLC, including the role of biomarkers and new evolving therapeutic strategies. Copyright © 2022 American Society of Clinical Oncology. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 100} -} - -@ARTICLE{Li2023, - author = {Li, Rongyang and Huang, Bing and Tian, Hui and Sun, Zhenguo}, - title = {Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment}, - year = {2023}, - journal = {Frontiers in Oncology}, - volume = {12}, - doi = {10.3389/fonc.2022.1096717}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85146888460&doi=10.3389%2ffonc.2022.1096717&partnerID=40&md5=49b3c232c45abbeb8bde7d57ab30b80f}, - abstract = {Esophageal cancer (EC) is one of the most life-threatening malignancies worldwide. Esophageal squamous cell carcinoma (ESCC) is the dominant subtype, accounting for approximately 90% of new incident EC each year. Although multidisciplinary treatment strategies have advanced rapidly, patients with ESCC are often diagnosed at advanced stage and the long-term prognosis remains unsatisfactory. In recent decades, immunotherapy, such as immune checkpoint inhibitors (ICIs), tumor vaccines, and chimeric antigen receptor T-cell (CAR-T) therapy, has been successfully used in clinical practice as a novel therapy for treating tumors, bringing new hope to ESCC patients. However, only a small fraction of patients achieved clinical benefits due to primary or acquired resistance. Immune evasion plays a pivotal role in the initiation and progression of ESCC. Therefore, a thorough understanding of the mechanisms by which ESCC cells escape from anti-tumor immunity is necessary for a more effective multidisciplinary treatment strategy. It has been widely recognized that immune evasion is closely associated with the crosstalk between tumor cells and the tumor microenvironment (TME). TME is a dynamic complex and comprehensive system including not only cellular components but also non-cellular components, which influence hallmarks and fates of tumor cells from the outside. Novel immunotherapy targeting tumor-favorable TME represents a promising strategy to achieve better therapeutic responses for patients with ESCC. In this review, we provide an overview of immune evasion in ESCC, mainly focusing on the molecular mechanisms that underlie the role of TME in immune evasion of ESCC. In addition, we also discuss the challenges and opportunities of precision therapy for ESCC by targeting TME. Copyright © 2023 Li, Huang, Tian and Sun.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12; All Open Access, Gold Open Access} -} - -@ARTICLE{Dora2023, - author = {Dora, David and Ligeti, Balazs and Kovacs, Tamas and Revisnyei, Peter and Galffy, Gabriella and Dulka, Edit and Krizsán, Dániel and Kalcsevszki, Regina and Megyesfalvi, Zsolt and Dome, Balazs and Weiss, Glen J. and Lohinai, Zoltan}, - title = {Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status}, - year = {2023}, - journal = {OncoImmunology}, - volume = {12}, - number = {1}, - doi = {10.1080/2162402X.2023.2204746}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85159176139&doi=10.1080%2f2162402X.2023.2204746&partnerID=40&md5=4a20a3d840a9997df651b846c09e91c2}, - abstract = {Due to the high variance in response rates concerning anti-PD1 immunotherapy (IT), there is an unmet need to discover innovative biomarkers to predict immune checkpoint inhibitor (ICI)-efficacy. Our study included 62 Caucasian advanced-stage non-small cell lung cancer (NSCLC) patients treated with anti-PD1 ICI. Gut bacterial signatures were evaluated by metagenomic sequencing and correlated with progression-free survival (PFS), PD-L1 expression and other clinicopathological parameters. We confirmed the predictive role of PFS-related key bacteria with multivariate statistical models (Lasso- and Cox-regression) and validated on an additional patient cohort (n = 60). We find that alpha-diversity showed no significant difference in any comparison. However, there was a significant difference in beta-diversity between patients with long- (>6 months) vs. short (≤6 months) PFS and between chemotherapy (CHT)-treated vs. CHT-naive cases. Short PFS was associated with increased abundance of Firmicutes (F) and Actinobacteria phyla, whereas elevated abundance of Euryarchaeota was specific for low PD-L1 expression. F/Bacteroides (F/B) ratio was significantly increased in patients with short PFS. Multivariate analysis revealed an association between Alistipes shahii, Alistipes finegoldii, Barnesiella visceriola, and long PFS. In contrast, Streptococcus salivarius, Streptococcus vestibularis, and Bifidobacterium breve were associated with short PFS. Using Random Forest machine learning approach, we find that taxonomic profiles performed superiorly in predicting PFS (AUC = 0.74), while metabolic pathways including Amino Acid Synthesis and Fermentation were better predictors of PD-L1 expression (AUC = 0.87). We conclude that specific metagenomic features of the gut microbiome, including bacterial taxonomy and metabolic pathways might be suggestive of ICI efficacy and PD-L1 expression in NSCLC patients. © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 10; All Open Access, Gold Open Access} -} - -@ARTICLE{Yao2022, - author = {Yao, Yongfang and Fareed, Rameesha and Zafar, Aliya and Saleem, Kalsoom and Huang, Tao and Duan, Yongtao and Rehman, Masood Ur}, - title = {State-of-the-art combination treatment strategies for advanced stage non–small cell lung cancer}, - year = {2022}, - journal = {Frontiers in Oncology}, - volume = {12}, - doi = {10.3389/fonc.2022.958505}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136186213&doi=10.3389%2ffonc.2022.958505&partnerID=40&md5=28303b4f2b2324d5dfc043d6f60d46b9}, - abstract = {Non–small cell lung cancer (NSCLC) is the most abundant type of epithelial lung cancer being diagnosed after 40% of invasions of excrescence in pulmonary tissues. According to WHO, 30% of NSCLC patients can be cured if diagnosed and treated early. Mutations play an important role in advanced stage NSCLC treatment, which includes critical proteins necessary for cellular growth and replication. Restricting such mutations may improve survival in lung cancer patients. Newer technologies include endoscopic bronchial ultrasonography and esophageal ultrasonography. Currently, policymaking or decision-making for treatment regimens merely depends on the genomic alterations and mutations. DNA sequencing, methylation, protein, and fragmented DNA analysis do NSCLC screening. Achievement of these goals requires consideration of available therapeutics in current anticancer approaches for improving quality of life and treatment outcomes for NSCLC patient. The specific goals of this review are to discuss first-line and second-line therapies for advanced-stage NSCLC and molecularly targeted therapy including thoughtful discussion on precise role of treatment strategies in specific tumors. Also, concerned diagnostics, new clinical trial designs, and pursuing appropriate combinations of radiotherapy and/or chemotherapy with biological therapy for exceptional cases considering resistance mechanisms and palliative care will be discussed. Copyright © 2022 Yao, Fareed, Zafar, Saleem, Huang, Duan and Rehman.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 11; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Karampitsakos2022253, - author = {Karampitsakos, Theodoros and Sampsonas, Fotios and Spagnolo, Paolo and Tzouvelekis, Argyris}, - title = {Pulmonary effects of cancer treatments}, - year = {2022}, - journal = {ERS Monograph}, - volume = {2022}, - number = {98}, - pages = {253 – 264}, - doi = {10.1183/2312508X.10020421}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85159631213&doi=10.1183%2f2312508X.10020421&partnerID=40&md5=8201562c8e24ff01dd6b7993c8ae1ac7}, - abstract = {A revolution in cancer management has been brewing in the past 10 years with the implementation of novel chemotherapeutic compounds and techniques of radiation therapy. A minority of patients receiving ICIs, TKIs and radiotherapy techniques present with pulmonary toxicity. Lung toxicity secondary to cancer treatments is an infrequent but potentially severe complication, usually occurring during the first months of treatment. Timely diagnosis and management are crucial to achieving recovery or substantial improvement. This chapter aims to summarise the pulmonary effects of cancer treatment and highlight future perspectives in the field. © ERS 2021.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1} -} - -@ARTICLE{Yin20231520, - author = {Yin, Shuangneng and Chen, Zhaojun and Chen, Dugang and Yan, Dan}, - title = {Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy}, - year = {2023}, - journal = {Theranostics}, - volume = {13}, - number = {5}, - pages = {1520 – 1544}, - doi = {10.7150/thno.80091}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152409805&doi=10.7150%2fthno.80091&partnerID=40&md5=e392858719022f16c017680e9f02a24e}, - abstract = {Immunotherapy has achieved great success recently and opened a new avenue for anti-tumor treatment. Programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) are typical immune checkpoints that transmit coinhibitory signals, muting the host immunity. Monoclonal antibodies that block PD-1/PD-L1 axis have benefited many patients with different tumor diseases. However, the objective response rate is still unsatisfactory. In this review, we summarize three strategies targeting PD-L1 based on different forms of PD-L1 and various regulating mechanisms to enhance the therapeutic effect, including blockade of the interaction between PD-L1 and PD-1, downregulation of PD-L1 expression and degradation of mature PD-L1. Thereinto, we describe a variety of materials have been designed to target PD-L1, including antibodies, nanoparticle, peptide, aptamer, RNA, and small molecule. Additionally, we list the drugs with PD-L1 regulation capacity used in clinical and ongoing studies to explore other alternatives for targeting PD-L1 besides anti-PD-L1 monoclonal antibodies. Moreover, we discuss associated opportunities for cancer combination therapy with other modalities such as chemotherapy, radiotherapy, photodynamic therapy (PDT) and photothermal therapy (PTT), as these conventional or emerging modalities are capable of increasing the immune response of tumor cells by altering the tumor microenvironment (TME), and would display synergistic effect. At last, we give a brief summary and outlook regarding the research status and future prospect of immunotherapy. © The author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 40; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Zhou2022536, - author = {Zhou, Xin and Jiang, Jinquan and Yang, Xue and Liu, Teli and Ding, Jin and Nimmagadda, Sridhar and Pomper, Martin G. and Zhu, Hua and Zhao, Jun and Yang, Zhi and Li, Nan}, - title = {First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients}, - year = {2022}, - journal = {Journal of Nuclear Medicine}, - volume = {63}, - number = {4}, - pages = {536 – 542}, - doi = {10.2967/jnumed.121.262045}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118996854&doi=10.2967%2fjnumed.121.262045&partnerID=40&md5=c57f672cb38976a6ebb2280450cd8aab}, - abstract = {68Ga-NOTA-WL12 is a peptide-based PET imaging agent. We conducted a first-in-human study of 68Ga-NOTA-WL12 for PET to study the in vivo biodistribution, metabolism, radiation dosimetry, safety, and potential for quantifying programmed death ligand-1 (PD-L1) expression levels in patients with advanced non–small cell lung cancer (NSCLC). Methods: In vitro assessment of the PD-L1 expression and cellular uptake of 68Ga-NOTA-WL12 was performed, followed by in vivo evaluation of 68Ga-NOTA-WL12 uptake in mouse models with tumors. Nine patients with NSCLC with lesions expressing PD-L1 were enrolled and monitored for adverse events during the study. 68Ga-NOTA-WL12 and paired 18F-FDG PET/CT imaging were performed. Uptake (SUV, SUL [SUVlean], and kBq/mL) values of tumors and normal organs were obtained. Radiopharmaceutical biodistribution, radiation dosimetry, and the relationship of tumor uptake to PD-L1 expression were evaluated. Follow-up 18F-FDG PET/CT was performed in patients who had undergone treatment with a combination of pembrolizumab with chemotherapy. Results: 68Ga-NOTA-WL12 exhibited PD-L1– specific uptake in vitro and in PD-L1–positive tumors in vivo. 68Ga-NOTA-WL12 PET imaging proved safe with acceptable radiation dosimetry. Physiologic tracer uptake was mainly visible in the liver, spleen, small intestine, and kidney. Tumors were clearly visible, particularly in the lungs, with a tumor-to-lung ratio of 4.45 6 1.89 at 1 h. One hour was a suitable time point for image acquisition because no significant differences were noted in tumor-to-background ratios between 1 and 2 h. A strong, positive correlation was found between tumor uptake (SUVpeak) and PD-L1 immunohistochemistry results (r 5 0.9349; P 5 0.002). 68Ga-NOTA-WL12 and 18F-FDG PET studies suggest that PD-L1 PET before therapy may indicate the therapeutic efficacy of pembrolizumab plus chemotherapy combination treatment. Conclusion: Our first-in-human findings demonstrate the safety and feasibility of 68Ga-NOTA-WL12 for noninvasive, in vivo detection of tumor PD-L1 expression levels, indicating potential benefits for clinical PD-L1 therapy. COPYRIGHT © 2022 by the Society of Nuclear Medicine and Molecular Imaging.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 75; All Open Access, Bronze Open Access, Green Open Access} -} - -@ARTICLE{Wang2023, - author = {Wang, Chunyu and Mu, Shuai and Yang, Xuhui and Li, Lingling and Tao, Haitao and Zhang, Fan and Li, Ruixin and Hu, Yi and Wang, Lijie}, - title = {Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases}, - year = {2023}, - journal = {Frontiers in Oncology}, - volume = {13}, - doi = {10.3389/fonc.2023.1110949}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85159908991&doi=10.3389%2ffonc.2023.1110949&partnerID=40&md5=89c7e7f4e73f22795026f9bb3f2ad7c4}, - abstract = {Objectives: Brain metastases (BMs) are common in extensive-stage small-cell lung cancer (SCLC) and are underrepresented in pivotal clinical trials that demonstrate the efficacy of immune checkpoint inhibitors (ICIs). We conducted a retrospective analysis to assess the role of ICIs in BM lesions in less selected patients. Materials and methods: Patients with histologically confirmed extensive-stage SCLC who were treated with ICIs were included in this study. Objective response rates (ORRs) were compared between the with-BM and without-BM groups. Kaplan−Meier analysis and the log-rank test were used to evaluate and compare progression-free survival (PFS). The intracranial progression rate was estimated using the Fine-Gray competing risks model. Results: A total of 133 patients were included, 45 of whom started ICI treatment with BMs. In the whole cohort, the overall ORR was not significantly different for patients with and without BMs (p = 0.856). The median progression-free survival for patients with and without BMs was 6.43 months (95% CI: 4.70-8.17) and 4.37 months (95% CI: 3.71-5.04), respectively (p =0.054). In multivariate analysis, BM status was not associated with poorer PFS (p = 0.101). Our data showed that different failure patterns occurred between groups, with 7 patients (8.0%) without BM and 7 patients (15.6%) with BM having intracranial-only failure as the first site progression. The cumulative incidences of brain metastases at 6 and 12 months were 15.0% and 32.9% in the without-BM group and 46.2% and 59.0% in the BM group, respectively (Gray’s p<0.0001). Conclusions: Although patients with BMs had a higher intracranial progression rate than patients without BMs, the presence of BMs was not significantly associated with a poorer ORR and PFS with ICI treatment in multivariate analysis. Copyright © 2023 Wang, Mu, Yang, Li, Tao, Zhang, Li, Hu and Wang.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Allaeys2022, - author = {Allaeys, Toon and Berzenji, Lawek and Lauwers, Patrick and Yogeswaran, Suresh Krishan and Hendriks, Jeroen M. H. and Billiet, Charlotte and De Bondt, Charlotte and Van Schil, Paul E.}, - title = {Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer}, - year = {2022}, - journal = {Cancers}, - volume = {14}, - number = {7}, - doi = {10.3390/cancers14071656}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127042307&doi=10.3390%2fcancers14071656&partnerID=40&md5=1f965541b660bd1fd9ad6b20134f8d72}, - abstract = {For patients with locally advanced non-small cell lung cancer (NSCLC) or positive N1 nodes, multimodality treatment is indicated. However, the optimal management of patients presenting with ipsilateral positive mediastinal nodes (N2 disease) has not been determined yet. Different treatment regimens consisting of chemotherapy, radiation therapy, and surgery have been proposed and implemented previously. In more recent years, immunotherapy and targeted therapies have been added as therapeutic options. The role of surgery is currently redefined. Recent studies have shown that surgical resection after induction immunotherapy or targeted therapy is feasible and yields good short-term results. In this review, we summarize the latest data on multimodality treatment options for stage IIIA-N2 locally advanced NSCLC, depending on the extent of nodal involvement. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 6; All Open Access, Gold Open Access} -} - -@ARTICLE{Ganti20211441, - author = {Ganti, Apar Kishor P. and Loo, Billy W. and Bassetti, Michael and Blakely, Collin and Chiang, Anne and D'Amico, Thomas A. and D'Avella, Christopher and Dowlati, Afshin and Downey, Robert J. and Edelman, Martin and Florsheim, Charles and Gold, Kathryn A. and Goldman, Jonathan W. and Grecula, John C. and Hann, Christine and Iams, Wade and Iyengar, Puneeth and Kelly, Karen and Khalil, Maya and Koczywas, Marianna and Merritt, Robert E. and Mohindra, Nisha and Molina, Julian and Moran, Cesar and Pokharel, Saraswati and Puri, Sonam and Qin, Angel and Rusthoven, Chad and Sands, Jacob and Santana-Davila, Rafael and Shafique, Michael and Waqar, Saiama N. and Gregory, Kristina M. and Hughes, Miranda}, - title = {Small Cell Lung Cancer, Version 2.2022}, - year = {2021}, - journal = {JNCCN Journal of the National Comprehensive Cancer Network}, - volume = {19}, - number = {12}, - pages = {1441 – 1464}, - doi = {10.6004/JNCCN.2021.0058}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122359913&doi=10.6004%2fJNCCN.2021.0058&partnerID=40&md5=79dd51dcea49b3ec0699a6e4ac98ba78}, - abstract = {The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The “Summary of the Guidelines Updates” section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text. © National Comprehensive Cancer Network, Inc. 2021.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 197; All Open Access, Bronze Open Access} -} - -@ARTICLE{Ueno2022812, - author = {Ueno, Tsuyoshi and Yamashita, Motohiro and Yamashita, Natsumi and Uomoto, Masashi and Kawamata, Osamu and Sano, Yoshifumi and Inokawa, Hidetoshi and Hirayama, Shin and Okazaki, Mikio and Toyooka, Shinichi}, - title = {Safety of salvage lung resection after immunotherapy for unresectable non-small cell lung cancer}, - year = {2022}, - journal = {General Thoracic and Cardiovascular Surgery}, - volume = {70}, - number = {9}, - pages = {812 – 817}, - doi = {10.1007/s11748-022-01798-3}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85126441283&doi=10.1007%2fs11748-022-01798-3&partnerID=40&md5=25108cb3291e796159d47c8b2d8beed6}, - abstract = {Background: The safety of salvage lung resection after immune checkpoint inhibitor (ICI) therapy in patients with advanced non-small cell lung cancer (NSCLC) is not well understood. Methods: In this retrospective multicenter study, we reviewed perioperative morbidity and mortality rates in 11 patients (8 men, 3 women; median age 70 years) who underwent salvage lung resection for unresectable NSCLC after ICI therapy in the 4 years since 2017. Operative factors were also compared according to operating time (> 6 h, n = 7; < 6 h, n = 4). Results: The clinical stage at the time of diagnosis was IIIA in 2 patients, IIIB in 4, IVA in 2, and IVB in 3. Eight patients received pembrolizumab and 3 received durvalumab. Two patients received an ICI agent alone, 3 underwent chemoradiotherapy, and 6 received chemotherapy. Lobectomy was performed in 10 cases and bilobectomy in 1 case. All patients underwent complete resection. Median operating time was 429 (range 169–570) min with a median blood loss of 199 (range 10–5, 140) mL. The only intraoperative complication was damage to the pulmonary artery. The perioperative morbidity and mortality rates were 27% and 0%, respectively. The 90-day mortality rate was 9% (1 patient died of acute exacerbation of interstitial pneumonia). Patients in whom the operating time was > 6 h more frequently had lymph node metastasis at the time of initial diagnosis (100% vs 25%, p = 0.02). Conclusions: Salvage lung resection was tolerated after ICI therapy in these patients. Lymph node metastasis at the time of initial diagnosis might make salvage surgery difficult. © 2022, The Author(s), under exclusive licence to The Japanese Association for Thoracic Surgery.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12} -} - -@BOOK{Jonna2023305, - author = {Jonna, Sushma and Montenegro, Gabriella B. and Liu, Stephen V.}, - title = {Small cell lung cancer}, - year = {2023}, - journal = {Lung Cancer: an Evidence-Based Approach to Multidisciplinary Management}, - pages = {305 – 324}, - doi = {10.1016/B978-0-323-69573-2.00023-1}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85189405786&doi=10.1016%2fB978-0-323-69573-2.00023-1&partnerID=40&md5=8b7d6337be7560351da22349920d5371}, - abstract = {Small cell lung cancer is a highly lethal subtype of lung cancer, characterized by early dissemination and poor survival. Classically, it arises centrally and often presents with symptoms related to local obstruction of airways or blood vessels. When detected at a relatively early stage, definitive thoracic radiation coupled with platinum-based chemotherapy offers high response rates, but long-term survival will be achieved only by a small minority of patients. Most patients present with advanced disease at diagnosis. In the advanced or relapsed setting, systemic chemotherapy has been the standard of care for decades. Response rates are high but progression free, and overall survival are limited. The standard of care was stagnant for many years, but recent advances in immunotherapy have led to better outcomes. The addition of the checkpoint inhibitor atezolizumab to standard chemotherapy led to a significant improvement in overall survival, the first intervention to do so in decades. A subsequent trial demonstrated similar improvement with the addition of durvalumab to chemotherapy. While combination chemotherapy plus immunotherapy has established a new standard of care, survival is poor for most patients and more effective treatment strategies remain an unmet need. © 2024 Elsevier Inc. All rights reserved.}, - type = {Book chapter}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Basnet20221607, - author = {Basnet, Alina and Alahmadi, Asrar and Gajra, Ajeet}, - title = {Older Patients with Lung Cancer: a Summary of Seminal Contributions to Optimal Patient Care}, - year = {2022}, - journal = {Current Oncology Reports}, - volume = {24}, - number = {11}, - pages = {1607 – 1618}, - doi = {10.1007/s11912-022-01307-y}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85135252977&doi=10.1007%2fs11912-022-01307-y&partnerID=40&md5=ec892fa1c3664b0f054b1f4d2e723fc7}, - abstract = {Purpose of Review: This review aspires to summarize the landmark advancements in the management of the non-small cell lung cancer (NSCLC), both historically and contemporarily with special focus in older adults. Recent Findings: The past two decades have witnessed remarkable improvements in the diagnosis and management of lung cancer. Screening recommendations now facilitate earlier diagnosis in high-risk individuals, PET/CT scans have improved radiologic accuracy in identifying sites of disease, and surgical management with minimally invasive techniques has rendered surgery safer in those with limited physiologic reserve. Radiation enhancements, especially radiosurgery, have extended the reach and safety of radiation among high-risk populations. Finally, the revolution in precision medicine with identification of numerous actionable mutations, the advent of immunotherapy, and enhanced supportive care have revolutionized the outcomes in patients with advanced lung cancer. Summary: Older adults who represent a majority of patients battling lung cancer have not benefitted to the same extent as their younger counterparts. This special population is only expected to grow in coming days. Hence, addressing major gaps in the management of older adults with NSCLC and optimizing the care are much needed. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2} -}@ARTICLE{Azghadi2021, - author = {Azghadi, Soheila and Daly, Megan E.}, - title = {Radiation and immunotherapy combinations in non-small cell lung cancer}, - year = {2021}, - journal = {Cancer Treatment and Research Communications}, - volume = {26}, - doi = {10.1016/j.ctarc.2020.100298}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098492994&doi=10.1016%2fj.ctarc.2020.100298&partnerID=40&md5=609ae61eb68c879942e9ae5436f0a62f}, - abstract = {Non-small cell lung cancer (NSCLC) is a common and lethal malignancy. The recent development of immune checkpoint inhibitors has afforded a durable, dramatic treatment response for a subset of patients, but strategies to expand these benefits to a broader swath of patients are needed. Preliminary evidence suggests radiotherapy may modulate a patient's immune system, particularly when delivered in high doses over few fractions with conformal techniques, as with stereotactic ablative radiotherapy (SABR). Radiotherapy for advanced stage NSCLC has traditionally been administered with palliative intent. However, an emergence of data from retrospective studies and, more recently, prospective trials has indicated the potential of using stereotactic ablative radiotherapy (SABR), in combination with systemic immunotherapy agents have synergistic effect and may enhance survival. We review current evidence for synergy between radiation and immunotherapy in metastatic, locally advanced, and localized NSCLC and discuss ongoing studies. © 2020}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 14; All Open Access, Gold Open Access} -} - -@ARTICLE{Zhou2021166, - author = {Zhou, Shujie and Xie, Jingjing and Huang, Zhaoqin and Deng, Liufu and Wu, Leilei and Yu, Jinming and Meng, Xiangjiao}, - title = {Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges}, - year = {2021}, - journal = {Cancer Letters}, - volume = {502}, - pages = {166 – 179}, - doi = {10.1016/j.canlet.2020.12.043}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100210807&doi=10.1016%2fj.canlet.2020.12.043&partnerID=40&md5=d1aeeeb1203edd3002bc2d65f1b05b32}, - abstract = {The brain is one of the most common metastatic sites in non-small cell lung cancer (NSCLC), which is associated with an extremely poor prognosis. Despite the availability of several therapeutic options, the treatment efficacy remains unsatisfactory for NSCLC brain metastases. Anti-programmed cell death-1 (PD-1) and its ligand (PD-L1) monoclonal antibodies have reshaped therapeutic strategies in advanced NSCLC. Preliminary evidence has shown that anti-PD-(L)1 monotherapy is also effective in NSCLC patients with brain metastases. However, the traditional view asserted that these therapeutic antibodies were incapable of crossing the blood-brain barrier (BBB) with large molecular size, thus most patients with brain metastases were excluded from most studies on anti-PD-(L)1 immunotherapy. Therefore, the efficacy and its mechanisms of action of anti-PD-(L)1 immunotherapy against brain metastases in NSCLC have not been clarified. In this review, we will survey the underlying mechanisms and current clinical advances of anti-PD-(L)1 immunotherapy in the treatment of brain metastases in NSCLC. The trafficking of activated cytotoxic T cells that are mainly derived from the primary tumor and deep cervical lymph nodes is critical for the intracranial response to anti-PD-(L)1 immunotherapy, which is driven by interferon-γ (IFN-γ). Additionally, promising combined strategies with the rationale in the treatment of brain metastases will be presented to provide future directions for clinical study design. Several significant challenges in the preclinical and clinical studies of brain metastases, as well as potential solutions, will also be discussed. © 2021}, - type = {Short survey}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 19} -} - -@ARTICLE{Tjong2020, - author = {Tjong, Michael C. and Mak, David Y. and Shahi, Jeevin and Li, George J. and Chen, Hanbo and Louie, Alexander V.}, - title = {Current Management and Progress in Radiotherapy for Small Cell Lung Cancer}, - year = {2020}, - journal = {Frontiers in Oncology}, - volume = {10}, - doi = {10.3389/fonc.2020.01146}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088787465&doi=10.3389%2ffonc.2020.01146&partnerID=40&md5=22ca9e8f393fbf607e9b012abf4df633}, - abstract = {Radiotherapy (RT) and chemotherapy continue to be widely utilized in small cell lung cancer (SCLC) management. In most limited stage (LS)-SCLC cases, the standard initial therapy remains concurrent chemoradiotherapy (CRT), typically with an etoposide and platinum-based regimen. Hyperfractionated twice daily (BID) RT remains the standard of care, though conventional daily (QD) RT is now a viable alternative supported by randomized evidence. In LS-SCLC patients who experienced good response to CRT, prophylactic cranial irradiation (PCI) remains the standard of care. Brain imaging, ideally with MRI, should be performed prior to PCI to screen for clinically apparent brain metastases that may require a higher dose of cranial irradiation. Platinum doublet chemotherapy alone is the historic standard initial therapy in extensive stage (ES)-SCLC. Addition of immunotherapy such as atezolizumab and durvalumab to chemotherapy is now recommended after their benefits were demonstrated in recent trials. In patients with response to chemotherapy, consolidation thoracic RT and PCI could be considered, though with caveats. Emergence of hippocampal avoidance cranial irradiation and SRS in SCLC patients may supplant whole cranial irradiation as future standards of care. Incorporation of novel systemic therapies such as immunotherapies has changed the treatment paradigm and overall outlook of patients with SCLC. This narrative review summarizes the current state, ongoing trials, and future directions of radiotherapy in management of SCLC. © Copyright © 2020 Tjong, Mak, Shahi, Li, Chen and Louie.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 24; All Open Access, Gold Open Access} -} - -@ARTICLE{Zhang20204081, - author = {Zhang, Shanshan and Bi, Minghong}, - title = {The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: A meta-analysis}, - year = {2020}, - journal = {Annals of Palliative Medicine}, - volume = {9}, - number = {6}, - pages = {4081 – 4088}, - doi = {10.21037/apm-20-2011}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096897771&doi=10.21037%2fapm-20-2011&partnerID=40&md5=a828fbf15dd6af40aaad0e3d634f6ffc}, - abstract = {Background: Small cell lung cancer (SCLC) is highly invasive and fatal, sensitive to chemotherapy and radiotherapy but prone to relapse, with a poor overall survival rate. It is particularly urgent for SCLC patients to receive effective follow-up treatment. In the past 20 years, there has been no breakthrough in clinical treatment of SCLC. Currently, clinical studies on immunotherapy for SCLC with extensive stage disease (ED) have achieved good efficacy, bringing new hope for the treatment of small-cell lung cancer. PD-1 inhibitors used to treat small cell lung cancer include Pembrolizumab and Nivolumab. PD-L1 inhibitors mainly include Atezolizumab and Durvalumab. Other PD-1/PD-L1 inhibitors, such as Avelumab, are currently being tried for SCLC and the results have not yet been published. This study is to evaluate the efficacy and safety of immunotherapy in patients with ED SCLC. Methods: A literature search of the PubMed, Embase, and Cochrane Library databases were performed. Two reviewers independently screened the literature, extracted the data, and evaluated the risk of bias of the included studies. RevMan 5.3 software was used for meta-analysis. Results: Four studies involving 1,981 patients with ED SCLC were included. Both overall survival (OS) [hazard ratio (HR) =0.80, 95% confidence interval (CI) (0.68, 0.95), P=0.009] and progression-free survival (PFS) [HR =0.82, 95% CI (0.75, 0.90), P <0.00001] were longer in the immunotherapy group than in the chemotherapy group. The incidence of total treatment-related adverse events in the immunotherapy group were lower than those in the chemotherapy group [relative risk (RR) =1.050, 95% CI (1.010, 1.080), P=0.007], and the differences were statistically significant. Conclusions: Immunotherapy has better efficacy and safety than chemotherapy for the treatment of ED SCLC. © Annals of Palliative Medicine. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 9; All Open Access, Gold Open Access} -} - -@ARTICLE{Choi2020, - author = {Choi, Yeonjoo and Shi, Yaoyao and Haymaker, Cara L. and Naing, Aung and Ciliberto, Gennaro and Hajjar, Joud}, - title = {T-cell agonists in cancer immunotherapy}, - year = {2020}, - journal = {Journal for ImmunoTherapy of Cancer}, - volume = {8}, - number = {2}, - doi = {10.1136/jitc-2020-000966}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092654268&doi=10.1136%2fjitc-2020-000966&partnerID=40&md5=352d45fb20d58946857f2a2d5004b7fa}, - abstract = {Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T cells, such as 4-1BB, OX40, inducible T-cell costimulator and glucocorticoid-induced tumor necrosis factor receptor. In addition, CD40 targets the modulation of the activation of antigen-presenting cells, which ultimately leads to T-cell activation. Agonists of these costimulatory molecules have demonstrated promising results in preclinical and early-phase trials and are now being tested in ongoing clinical trials. In addition, researchers are conducting trials of combinations of such immune modulators with checkpoint blockade, radiotherapy and cytotoxic chemotherapeutic drugs in patients with advanced tumors. This review gives a comprehensive picture of the current knowledge of T-cell agonists based on their use in recent and ongoing clinical trials. © Author(s) 2020.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 83; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Faehling2021175, - author = {Faehling, Martin and Fallscheer, Sabine and Kramberg, Sebastian and Sträter, Jörn and Eschmann, Susanne and Sätzler, Rainer and Heinzelmann, Frank}, - title = {Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option}, - year = {2021}, - journal = {European Journal of Cancer}, - volume = {156}, - pages = {175 – 186}, - doi = {10.1016/j.ejca.2021.07.035}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85113455172&doi=10.1016%2fj.ejca.2021.07.035&partnerID=40&md5=a035eafdab63f99d2b2273f020c9004e}, - abstract = {Background: Recent phase II–III trials of immuno(chemo)therapy before resection in locally advanced resectable non-small cell lung cancer (NSCLC) report high rates of pathological response and promising survival. However, primarily, patients who did not undergo resection were excluded from these studies. Moreover, there are no data on chemoradiotherapy (CRT) after immuno(chemo)therapy in patients who are primarily not amenable to CRT. We hypothesised that induction immuno(chemo)therapy may enable patients with NSCLC with a potentially curative stage (III–IVA), for whom primary curative treatment (either resection or CRT) is not possible for anatomical or functional reasons, to receive curative treatment. Patients and methods: We enrolled 35 patients with NSCLC with aforementioned characteristics into a prospective real-world trial of induction immuno(chemo)therapy followed by morphologic and metabolic reassessment and multidisciplinary board-guided curative treatment (resection [preferred] or CRT) or palliative therapy. The primary end-point was the proportion of patients receiving curative treatment. Results: Thirty-two patients (91%) received curative treatment (11 resections and 21 CRT). 73% and 64% of patients who underwent resection had a major or complete pathological response, respectively. There were 14 recurrences: 2 (18%) in patients who underwent resection, 9 (43%) in patients who received CRT and 3 (100%) in patients who received palliative therapy (median follow-up 17 months). Eight tumour-related deaths occurred: 5 (24%) in patients who received CRT; and 3 (100%) in patients who received palliative therapy. There were no treatment-related deaths. Conclusions: In locally advanced or oligometastatic NSCLC without a primary curative option, induction immuno(chemo)therapy results in a high rate of curative treatment with promising early survival data. patients who underwent resection achieved a high rate of prognostically favourable pathological response. © 2021 Elsevier Ltd}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3} -} - -@ARTICLE{Cortinovis20211, - author = {Cortinovis, Diego and Bidoli, Paolo and Canova, Stefania and Colonese, Francesca and Gemelli, Maria and Lavitrano, Maria Luisa and Banna, Giuseppe Luigi and Liu, Stephen V. and Morabito, Alessandro}, - title = {Novel cytotoxic chemotherapies in small cell lung carcinoma}, - year = {2021}, - journal = {Cancers}, - volume = {13}, - number = {5}, - pages = {1 – 17}, - doi = {10.3390/cancers13051152}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102037730&doi=10.3390%2fcancers13051152&partnerID=40&md5=a75d5e98dc1c8f0a0c478e9f5a1e65f5}, - abstract = {Small cell lung cancer (SCLC) is one of the deadliest thoracic neoplasms, in part due to its fast doubling time and early metastatic spread. Historically, cytotoxic chemotherapy consisting of platinum–etoposide or anthracycline-based regimens has demonstrated a high response rate, but early chemoresistance leads to a poor prognosis in advanced SCLC. Only a fraction of patients with limited-disease can be cured by chemo-radiotherapy. Given the disappointing survival rates in advanced SCLC, new cytotoxic agents are eagerly awaited. Unfortunately, few novel chemotherapy drugs have been developed in the latest decades. This review describes the results and potential application in the clinical practice of novel chemotherapy agents for SCLC. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 10; All Open Access, Gold Open Access} -} - -@ARTICLE{Ogawa20201901, - author = {Ogawa, Koichi and Kaneda, Hiroyasu and Kawamoto, Tamaki and Tani, Yoko and Izumi, Motohiro and Matsumoto, Yoshiya and Sawa, Kenji and Suzumura, Tomohiro and Watanabe, Tetsuya and Mitsuoka, Shigeki and Asai, Kazuhisa and Kawaguchi, Tomoya}, - title = {Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review}, - year = {2020}, - journal = {Investigational New Drugs}, - volume = {38}, - number = {6}, - pages = {1901 – 1905}, - doi = {10.1007/s10637-020-00947-w}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084665344&doi=10.1007%2fs10637-020-00947-w&partnerID=40&md5=2e6d0857150f0da545987192500317bc}, - abstract = {Immune checkpoint inhibitors (ICIs) have improved the overall survival of many patients with advanced cancers. However, unlike cytotoxic and targeted drugs, ICIs may cause various immune-related adverse events (irAEs). Among these irAEs, autoimmune meningitis is very rare. Here, we report a case of early-onset, atezolizumab-induced meningitis after administration of one dose of atezolizumab. A 56-year-old man with lung adenocarcinoma had received seventh-line treatment with atezolizumab when he experienced dysarthria. Blood examinations, including the measurement of electrolytes, glucose, and organ functions, were unremarkable, but enhanced head magnetic resonance imaging T1-weighted images showed meningeal enhancement. Although cerebral spinal fluid (CSF) examinations revealed elevated lymphocyte and protein levels, no cancer cells were detected in the CSF. CSF cultures and serological tests, including polymerase chain reaction for herpes simplex virus, were negative. The patient was therefore diagnosed with atezolizumab-triggered autoimmune meningitis. With steroid treatment, the patient’s clinical and neurological state improved immediately and he recovered to baseline conditions. Prompt diagnosis and therapeutic intervention are essential for the effective treatment of autoimmune meningitis. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 5} -} - -@ARTICLE{Ahern2021, - author = {Ahern, Elizabeth and Solomon, Ben J and Hui, Rina and Pavlakis, Nick and O'Byrne, Ken and Hughes, Brett G M}, - title = {Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time?}, - year = {2021}, - journal = {Journal for ImmunoTherapy of Cancer}, - volume = {9}, - number = {6}, - doi = {10.1136/jitc-2020-002248}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107671919&doi=10.1136%2fjitc-2020-002248&partnerID=40&md5=d5d4b18af1173f870cc7c6e2a388cafc}, - abstract = {Standard curative treatment of early-stage non-small cell lung cancer (NSCLC) involves surgery in combination with postoperative (adjuvant) platinum-based chemotherapy where indicated. Preoperative (neoadjuvant) therapies offer certain theoretical benefits compared with adjuvant approaches, including the ability to assess on-treatment response, reduce the tumor bulk prior to surgery, and enhance tolerability in the preoperative setting. Indeed, the use of neoadjuvant therapies are well established in other cancers such as breast and rectal cancers to debulk the tumor and guide ongoing therapy, and neoadjuvant chemotherapy has similar efficacy but less toxicity in NSCLC. More recently, immune checkpoint inhibitors (ICI) targeting programmed death-1 (PD1)/PD1-ligand 1 (PD-L1) have transformed the treatment of advanced NSCLC; the unique mechanisms of action of ICI offer additional rationale for assessment in the neoadjuvant setting. Preclinical studies in mouse cancer models support the proof of concept of neoadjuvant ICI (NAICI) through improvement of T-cell effector function and long-term memory induction. Preliminary early-phase human trial data support the proposition that NAICI in NSCLC may provide an feasible and potentially efficacious future treatment strategy and large, randomized phase III trials are currently recruiting to assess this approach. However, outstanding issues include defining optimal treatment combinations which balance high efficacy with acceptable toxicity, validating biomarkers to aid in patient selection, and avoiding potential pitfalls such as missing a window for successful surgery, that is, choosing the right drugs, for the right patient, at the right time. Predictive biomarkers to direct selection of therapy are required, and the validation of major pathological response (MPR) as a surrogate for survival will be important in the uptake of the neoadjuvant approach. © 2021 BMJ Publishing Group. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 39; All Open Access, Gold Open Access} -} - -@ARTICLE{Rijavec20211427, - author = {Rijavec, Erika and Genova, Carlo and Biello, Federica and Rossi, Giovanni and Indini, Alice and Grossi, Francesco}, - title = {Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer}, - year = {2021}, - journal = {Expert Review of Respiratory Medicine}, - volume = {15}, - number = {11}, - pages = {1427 – 1435}, - doi = {10.1080/17476348.2021.1987887}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85117224451&doi=10.1080%2f17476348.2021.1987887&partnerID=40&md5=2f01e1a6abe1c0c433854c3f7a848b39}, - abstract = {Introduction: Small cell lung cancer (SCLC) is an aggressive tumor with a severe prognosis. At the time of diagnosis, most patients present with extensive-stage (ES) disease. For decades, platinum-based chemotherapy has been the only pillar of SCLC treatment, but now, the clinical management of this disease is rapidly evolving thanks to the introduction of immune checkpoint inhibitors (ICIs). Areas covered: In this review, we describe the most recent advances in the treatment of SCLC and discuss the emerging challenges associated with ICI treatments. Meaningful data were collected from the currently available literature on PubMed and in international oncology meetings. Expert opinion: Recently, meaningful improvements in outcomes of SCLC patients have been achieved with anti-PD-L1 atezolizumab or durvalumab combined with chemotherapy in first line. Results of studies evaluating the role of ICIs in limited-stage (LS) SCLC patients are awaited. Further efforts are required to better understand the role of immunotherapy in the treatment of SCLC and to identify patients most likely to benefit from this treatment strategy. © 2021 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 15} -} - -@ARTICLE{Naito202195, - author = {Naito, Tomoyuki and Shiraishi, Hideaki and Fujiwara, Yutaka}, - title = {Durvalumab for the treatment of PD-L1 non-small cell lung cancer}, - year = {2021}, - journal = {Expert Review of Precision Medicine and Drug Development}, - volume = {6}, - number = {2}, - pages = {95 – 105}, - doi = {10.1080/23808993.2021.1855075}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097632126&doi=10.1080%2f23808993.2021.1855075&partnerID=40&md5=b0f06da2676d14bdf04f9c4e502f1cb6}, - abstract = {Introduction: Immune checkpoint inhibitors, monoclonal antibodies directed against programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1), have broadened treatment options for patients with non-small cell lung cancer (NSCLC). Durvalumab is a selective, high-affinity, human IgG1 monoclonal anti-PD-L1 antibody that blocks interactions of PD-L1 with PD-1 and CD80. Areas covered: We reviewed clinical data supporting the use of durvalumab as a monotherapy and combination therapy for the treatment of locally advanced and advanced NSCLC. Expert commentary: Durvalumab as a monotherapy or combination therapy has shown well-tolerated safety profiles for NSCLC in several trials. Durvalumab monotherapy in advanced NSCLC patients with PD-L1 ≥ 25% as later line (ATLANTIC study) therapy led to clinically meaningful improvements compared to standard of care. Combination therapy comprising durvalumab plus tremelimumab for advanced NSCLC did not show clinical efficacy in three phase III trials. Durvalumab administered after chemoradiotherapy in stage III NSCLC (PACIFIC study) significantly improved progression-free survival and overall survival. This result has led to approval of durvalumab for patients with locally advanced NSCLC as the standard of care. Ongoing trials provide insight into how durvalumab fits into the rapidly evolving therapeutic landscape for locally advanced or advanced NSCLC. © 2020 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1} -} - -@ARTICLE{Singh2020579, - author = {Singh, Aditi P. and Berman, Abigail T. and Marmarelis, Melina E. and Haas, Andrew R. and Feigenberg, Steven J. and Braun, Jennifer and Ciunci, Christine A. and Bauml, Joshua M. and Cohen, Roger B. and Kucharczuk, John C. and Shulman, Lawrence N. and Langer, Corey J. and Aggarwal, Charu}, - title = {Management of lung cancer during the COVID-19 pandemic}, - year = {2020}, - journal = {JCO Oncology Practice}, - volume = {16}, - number = {9}, - pages = {579 – 586}, - doi = {10.1200/OP.20.00286}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087017329&doi=10.1200%2fOP.20.00286&partnerID=40&md5=47f0b25aea5f00393f30d21e29f65983}, - abstract = {Coronavirus disease 2019 (COVID-19) has had a devastating impact around the world. With high rates of transmission and no curative therapies or vaccine yet available, the current cornerstone of management focuses on prevention by social distancing. This includes decreased health care contact for patients. Patients with lung cancer are a particularly vulnerable population, where the risk of mortality from cancer must now be balanced by the potential risk of a life-threatening infection. In these unprecedented times, a collaborative and multidisciplinary approach is required to streamline but not compromise care. We have developed guidelines at our academic cancer center to standardize management of patients with lung cancer across our health care system and provide guidance to the larger oncology community. We recommend that general principles of lung cancer treatment continue to be followed in most cases where delays could result in rapid cancer progression. We recognize that our recommendations may change over time based on clinical resources and the evolving nature of the COVID-19 pandemic. In principle, however, treatment paradigms must continue to be individualized, with careful consideration of risks and benefits of continuing or altering lung cancer-directed therapy. © 2020 by American Society of Clinical Oncology}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 53} -} - -@ARTICLE{French2020629, - author = {French, Jena D.}, - title = {Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies}, - year = {2020}, - journal = {Nature Reviews Endocrinology}, - volume = {16}, - number = {11}, - pages = {629 – 641}, - doi = {10.1038/s41574-020-0398-9}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089782098&doi=10.1038%2fs41574-020-0398-9&partnerID=40&md5=464807ab13f653534d42ebadd5096953}, - abstract = {In the past decade, the field of cancer immunotherapy has been revolutionized by immune checkpoint blockade (ICB) technologies. Success across a broad spectrum of cancers has led to a paradigm shift in therapy for patients with advanced cancer. Early data are now accumulating in progressive thyroid cancers treated with single-agent ICB therapies and combination approaches that incorporate ICB technologies. This Review discusses our current knowledge of the immune response in thyroid cancers, the latest and ongoing immune-based approaches, and the future of immunotherapies in thyroid cancer. Physiologically relevant preclinical mouse models and human correlative research studies will inform development of the next stage of immune-based therapies for patients with advanced thyroid cancer. © 2020, Springer Nature Limited.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 48} -} - -@ARTICLE{Matsubara20213286, - author = {Matsubara, Taichi and Takamori, Shinkichi and Fujishita, Takatoshi and Toyozawa, Ryo and Ito, Kensaku and Yamaguchi, Masafumi and Seto, Takashi and Okamoto, Tatsuro}, - title = {Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy}, - year = {2021}, - journal = {Thoracic Cancer}, - volume = {12}, - number = {23}, - pages = {3286 – 3289}, - doi = {10.1111/1759-7714.14200}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85117714837&doi=10.1111%2f1759-7714.14200&partnerID=40&md5=82e4acb43ff1b6a80c3e2c4f164fb1e1}, - abstract = {Concurrent chemoradiation therapy (CRT) is the standard of care for patients with unresectable stage II/III lung cancer. However, systemic chemotherapy is required for patients who are ineligible for radical radiation therapy. There is little evidence to date for the safety and efficacy of CRT administered after treatment with immune checkpoint inhibitors (ICIs). The cases reported here had inoperable stage III lung cancer (non-small cell lung cancer and small cell lung cancer) and were ineligible for radical radiation therapy. They were administered ICIs plus chemotherapy and subsequently underwent late concurrent CRT. Because of the remarkable tumor shrinkage achieved by the ICIs plus chemotherapy, adverse events of CRT were tolerable. They were alive without tumor progression as of this report, over 1 year after CRT was terminated. CRT is administered with curative intent, while the intent of immunochemotherapy is palliative. Late concurrent CRT after immunochemotherapy is probably effective and tolerable. After treatment with systemic chemotherapy in patients judged ineligible for radical radiation therapy, radiation therapy should be reconsidered because of its importance once tumor shrinkage has been achieved. © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Green Open Access} -} - -@ARTICLE{Higgins202154, - author = {Higgins, Kristin A. and Simone, Charles B. and Amini, Arya and Chetty, Indrin J. and Donington, Jessica and Edelman, Martin J. and Chun, Stephen G. and Kestin, Larry L. and Movsas, Benjamin and Rodrigues, George B. and Rosenzweig, Kenneth E. and Slotman, Ben J. and Rybkin, Igor I. and Wolf, Andrea and Chang, Joe Y.}, - title = {American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC}, - year = {2021}, - journal = {Journal of Thoracic Oncology}, - volume = {16}, - number = {1}, - pages = {54 – 65}, - doi = {10.1016/j.jtho.2020.09.013}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094621493&doi=10.1016%2fj.jtho.2020.09.013&partnerID=40&md5=c538b93912158ae5656f6756a80bb1d7}, - abstract = {Introduction: The standard-of-care therapy for extensive-stage SCLC has recently changed with the results of two large randomized trials revealing improved survival with the addition of immunotherapy to first-line platinum or etoposide chemotherapy. This has led to a lack of clarity around the role of consolidative thoracic radiation and prophylactic cranial irradiation in the setting of chemoimmunotherapy. Methods: The American Radium Society Appropriate Use Criteria are evidence-based guidelines for specific clinical conditions that are reviewed by a multidisciplinary expert panel. The guidelines include a review and analysis of current evidence with the application of consensus methodology (modified Delphi) to rate the appropriateness of treatments recommended by the panel for extensive-stage SCLC. Results: Current evidence supports either prophylactic cranial irradiation or surveillance with magnetic resonance imaging every 3 months for patients without evidence of brain metastases. Patients with brain metastases should receive whole-brain radiation with a recommended dose of 30 Gy in 10 fractions. Consolidative thoracic radiation can be considered in selected cases with the recommended dose ranging from 30 to 54 Gy; this recommendation was driven by expert opinion owing to the limited strength of evidence, as clinical trials addressing this question remain ongoing. Conclusions: Radiation therapy remains an integral component in the treatment paradigm for ES-SCLC. © 2020}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 16; All Open Access, Bronze Open Access} -} - -@ARTICLE{Chicas-Sett20201, - author = {Chicas-Sett, Rodolfo and Zafra-Martin, Juan and Morales-Orue, Ignacio and Castilla-Martinez, Juan and Berenguer-Frances, Miguel A. and Gonzalez-Rodriguez, Elisa and Rodriguez-Abreu, Delvys and Couñago, Felipe}, - title = {Immunoradiotherapy as an effective therapeutic strategy in lung cancer: From palliative care to curative intent}, - year = {2020}, - journal = {Cancers}, - volume = {12}, - number = {8}, - pages = {1 – 20}, - doi = {10.3390/cancers12082178}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090428468&doi=10.3390%2fcancers12082178&partnerID=40&md5=68c244bab83428f7fad9bb1b8f5ec13f}, - abstract = {Lung cancer is one of the main causes of cancer-related mortality worldwide. Over the years, different therapeutic modalities have been adopted depending on tumor stage and patient characteristics, such as surgery, radiotherapy (RT), and chemotherapy. Recently, with the development of immune-checkpoint inhibitors (ICI), the treatment of metastatic and locally advanced non-small cell lung cancer (NSCLC) has experienced a revolution that has resulted in a significant improvement in overall survival with an enhanced toxicity profile. Despite this paradigm shift, most patients present some kind of resistance to ICI. In this setting, current research is shifting towards the integration of multiple therapies, with RT and ICI being one of the most promising based on the potential immunostimulatory synergy of this combination. This review gives an overview of the evolution and current state of the combination of RT and ICI and provides evidence-based data that can improve patient selection. The combination in lung cancer is a safe therapeutic approach that improves local control and progression-free survival, and it has the potential to unleash abscopal responses. Additionally, this treatment strategy seems to be able to re-sensitize select patients that have reached a state of resistance to ICI, further enabling the continuation of systemic therapy. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 20; All Open Access, Gold Open Access} -} - -@ARTICLE{Donlon202184, - author = {Donlon, N.E. and Power, R. and Hayes, C. and Reynolds, J.V. and Lysaght, J.}, - title = {Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity}, - year = {2021}, - journal = {Cancer Letters}, - volume = {502}, - pages = {84 – 96}, - doi = {10.1016/j.canlet.2020.12.045}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099345462&doi=10.1016%2fj.canlet.2020.12.045&partnerID=40&md5=f9f726494fab595df6f178d7321bfdc8}, - abstract = {Immune checkpoint blockade (ICB) has revolutionised the treatment of solid tumours, yet most patients do not derive a clinical benefit. Resistance to ICB is often contingent on the tumour microenvironment (TME) and modulating aspects of this immunosuppressive milieu is a goal of combination treatment approaches. Radiation has been used for over a century in the management of cancer with more than half of all cancer patients receiving radiotherapy. Here, we outline the rationale behind combining radiotherapy with ICB, a potential synergy through mutually beneficial remodelling of the TME. We discuss the pleiotropic effects radiation has on the TME including immunogenic cell death, activation of cytosolic DNA sensors, remodelling the stroma and vasculature, and paradoxical infiltration of both anti-tumour and suppressive immune cell populations. These events depend on the radiation dose and fractionation and optimising these parameters will be key to develop safe and effective combination regimens. Finally, we highlight ongoing efforts that combine radiation, immunotherapy and inhibitors of DNA damage response, which can help achieve a favourable equilibrium between the immunogenic and tolerogenic effects of radiation on the immune microenvironment. © 2021 The Authors}, - type = {Short survey}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 106; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Kumar2021, - author = {Kumar, Sunil and Sarthi, Parth and Mani, Indra and Ashraf, Muhammad Umer and Kang, Myeong-Ho and Kumar, Vishal and Bae, Yong-Soo}, - title = {Epitranscriptomic approach: To improve the efficacy of icb therapy by co‐targeting intracellular checkpoint cish}, - year = {2021}, - journal = {Cells}, - volume = {10}, - number = {9}, - doi = {10.3390/cells10092250}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115887635&doi=10.3390%2fcells10092250&partnerID=40&md5=cbfd3a38eae6fc216ce7b756c2b9205e}, - abstract = {Cellular immunotherapy has recently emerged as a fourth pillar in cancer treatment co-joining surgery, chemotherapy and radiotherapy. Where, the discovery of immune checkpoint blockage or inhibition (ICB/ICI), anti‐PD‐1/PD‐L1 and anti‐CTLA4‐based, therapy has revolution-ized the class of cancer treatment at a different level. However, some cancer patients escape this immune surveillance mechanism and become resistant to ICB‐therapy. Therefore, a more advanced or an alternative treatment is required urgently. Despite the functional importance of epitran-scriptomics in diverse clinico‐biological practices, its role in improving the efficacy of ICB therapeutics has been limited. Consequently, our study encapsulates the evidence, as a possible strategy, to improve the efficacy of ICB‐therapy by co‐targeting molecular checkpoints especially N6A‐modifi-cation machineries which can be reformed into RNA modifying drugs (RMD). Here, we have ex-plained the mechanism of individual RNA‐modifiers (editor/writer, eraser/remover, and effec-tor/reader) in overcoming the issues associated with high‐dose antibody toxicities and drug‐re-sistance. Moreover, we have shed light on the importance of suppressor of cytokine signaling (SOCS/CISH) and microRNAs in improving the efficacy of ICB‐therapy, with brief insight on the current monoclonal antibodies undergoing clinical trials or already approved against several solid tumor and metastatic cancers. We anticipate our investigation will encourage researchers and clini-cians to further strengthen the efficacy of ICB‐therapeutics by considering the importance of epi-transcriptomics as a personalized medicine. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 6; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Zeng2021105, - author = {Zeng, Jing and Bowen, Stephen R.}, - title = {Treatment Intensification in Locally Advanced/Unresectable NSCLC Through Combined Modality Treatment and Precision Dose Escalation}, - year = {2021}, - journal = {Seminars in Radiation Oncology}, - volume = {31}, - number = {2}, - pages = {105 – 111}, - doi = {10.1016/j.semradonc.2020.11.007}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099502070&doi=10.1016%2fj.semradonc.2020.11.007&partnerID=40&md5=6d9594c0a950b3ee716cb82497a97453}, - abstract = {The best survival for patients with unresectable, locally advanced NSCLC is currently achieved through concurrent chemoradiation followed by durvalumab for a year. Despite the best standard of care treatment, the majority of patients still develop disease recurrence, which could be distant and/or local. Trials continue to try and improve outcomes for patients with unresectable NSCLC, typically through treatment intensification, with the addition of more systemic agents, or more radiation dose to the tumor. Although RTOG 0617 showed that uniform dose escalation across an unselected population of patients undergoing chemoradiation is not beneficial, efforts continue to select patients and tumor subsets that are likely to benefit from dose escalation. This review describes some of the ongoing therapeutic trials in unresectable NSCLC, with an emphasis on quantitative imaging and precision radiation dose escalation. © 2020 Elsevier Inc.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 5; All Open Access, Green Open Access} -} - -@ARTICLE{Sørup2021871, - author = {Sørup, Signe and Darvalics, Bianka and Khalil, Azza Ahmed and Nordsmark, Marianne and Hæe, Mette and Donskov, Frede and Agerbæk, Mads and Russo, Leo and Oksen, Dina and Boutmy, Emmanuelle and Verpillat, Patrice and Cronin-Fenton, Deirdre}, - title = {Treatment and survival in advanced non-small cell lung cancer, urothelial, ovarian, gastric and kidney cancer: A nationwide comprehensive evaluation}, - year = {2021}, - journal = {Clinical Epidemiology}, - volume = {13}, - pages = {871 – 882}, - doi = {10.2147/CLEP.S326470}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115864813&doi=10.2147%2fCLEP.S326470&partnerID=40&md5=d13679f43d0ae7cb34e14627de86cb10}, - abstract = {Purpose: Few studies have described real-world treatment patterns and survival before the widespread use of immune checkpoint inhibitors (ICIs). We aimed to describe anti-cancer treatment including the use of programmed cell death-1 and ligand-1 (PD-1/PD-L1) ICIs and overall survival (OS) in advanced cancer patients as a benchmarking real-world standard before widespread use of ICIs. Patients and Methods: Using nationwide Danish medical registries, we assembled cohorts of Danish patients with advanced non-small cell lung cancer (NSCLC) (n=12,283), urothelial carcinoma (n=2504), epithelial ovarian cancer (n=1466), gastric adenocarcinoma (n=1457), and renal cell carcinoma (RCC) (n=1261) diagnosed between 1/1/2013 and 31/12/2017. We describe anti-cancer treatment and OS using proportions, medians, and Kaplan–Meier methods. Results: Between 9% (ovarian cancer) and 25% (gastric adenocarcinoma) of patients did not receive anti-cancer treatment. The remaining patients received surgery, radiation therapy, and/or medical therapy. Chemotherapy was the most frequent medical therapy in all cohorts except for RCC (tyrosine kinase inhibitors). PD-L1/PD-1 ICIs were used in 7–8% of the NSCLC and RCC cohorts—mainly as second or higher line treatments. OS was longest in patients starting treatment with surgery (eg 25.6 months [95%-confidence interval (CI) =21.9–29.4] for NSCLC and 21.4 months [95%-CI=19.8–23.5] for urothelial carcinoma) and shortest for radiation therapy (eg 3.9 months [95%-CI=3.6–4.2] for NSCLC and 12.6 months [95%-CI=9.2–17.5] for urothelial carcinoma). NSCLC patients starting with medical therapy had OS between these limits. Median OS for NSCLC patients starting treatment with PD-L1/PD-1 ICIs was 21.4 months (95%-CI=13.9-not estimable). Conclusion: Most patients with advanced NSCLC, urothelial carcinoma, epithelial ovarian cancer, gastric adenocarcinoma and RCC had poor OS in an era where only a minority received PD-L1/PD-1 ICIs. This information on treatment patterns and survival is important as a benchmarking real-world standard before widespread use of ICIs. © 2021 Sørup et al.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Gold Open Access} -} - -@ARTICLE{Genta2021, - author = {Genta, Sofia and Martorana, Federica and Stathis, Anastasios and Colombo, Ilaria}, - title = {Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment}, - year = {2021}, - journal = {Critical Reviews in Oncology/Hematology}, - volume = {168}, - doi = {10.1016/j.critrevonc.2021.103539}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119699373&doi=10.1016%2fj.critrevonc.2021.103539&partnerID=40&md5=fa820333274d45c62ebbfae69f90ca40}, - abstract = {Cancer derives from alterations of pathways responsible for cell survival, differentiation and proliferation. Dysfunctions of mechanisms protecting genome integrity can promote oncogenesis but can also be exploited as therapeutic target. Poly-ADP-Ribose-Polymerase (PARP)-inhibitors, the first approved targeted agents able to tackle DNA damage response (DDR), have demonstrated antitumor activity, particularly when homologous recombination impairment is present. Despite the relevant results achieved, a large proportion of patients fail to obtain durable responses. The development of innovative treatments, able to overcome resistance and ensure long-lasting benefit for a wider population is still an unmet need. Moreover, improvement in biomarker assays is necessary to properly identify patients who can benefit from DDR targeting agents. Here we summarize the main DDR pathways, explain the current role of PARP inhibitors in cancer therapy and illustrate new therapeutic strategies targeting the DDR, focusing on the combinations of PARP inhibitors with other agents and on cell-cycle checkpoint inhibitors. © 2021 Elsevier B.V.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 11} -} - -@ARTICLE{Zhou20204498, - author = {Zhou, Jieling and Huang, Qian and Huang, Zijian and Li, Jiqiang}, - title = {Combining immunotherapy and radiotherapy in lung cancer: A promising future?}, - year = {2020}, - journal = {Journal of Thoracic Disease}, - volume = {12}, - number = {8}, - pages = {4498 – 4503}, - doi = {10.21037/JTD-2019-ITM-001}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091820989&doi=10.21037%2fJTD-2019-ITM-001&partnerID=40&md5=ea180d2cd9b0b5b610d6e3ddf2874e49}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 7; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Pacheco20206212, - author = {Pacheco, Jose M.}, - title = {Immunotherapy for extensive stage small cell lung cancer}, - year = {2020}, - journal = {Journal of Thoracic Disease}, - volume = {12}, - number = {10}, - pages = {6212 – 6224}, - doi = {10.21037/jtd.2020.01.37}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096109120&doi=10.21037%2fjtd.2020.01.37&partnerID=40&md5=428f1ec1e96a5135c21301218902a4ff}, - abstract = {Small cell lung cancer (SCLC) is an aggressive malignancy. Until recently the standard of care for newly diagnosed patients with extensive-stage disease was chemotherapy consisting of etoposide plus a platinum (EP). The median overall survival (OS) was only about 10 months with this systemic therapy. Immune checkpoint inhibitors were first evaluated as second or subsequent line treatments in extensive stage disease and later in combination with EP in the first-line setting. Recently two randomized phase III trials have demonstrated statistically improved OS with addition of a programmed death ligand-1 (PD-L1) inhibitor to EP. As a result, the standard of care for newly diagnosed patients with extensive-stage SCLC has changed for the first time in decades. However, many patients do not derive benefit from the addition of a PD-L1 inhibitor to EP. In this review we discuss first-line trials of chemoimmunotherapy in extensive stage SCLC and summarize data on second and subsequent line treatment with immune checkpoint inhibitors in immunotherapy-naïve patients. Additionally, we discuss potential biomarkers that could be utilized to select for which patients derive benefit from addition of a PD-L1 inhibitor to EP and propose ways to improve on first-line chemoimmunotherapy. © 2020 AME Publishing Company. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Varlotto2021523, - author = {Varlotto, John M. and Sun, Zhuoxin and Ky, Bonnie and Upshaw, Jenica and Katz, Sharyn I. and Fitzgerald, Thomas J. and Wakelee, Heather and Diehn, Maximilian and Mankoff, David A. and Lovely, Christine and Belani, Chandra and Oettel, Kurt and Masters, Gregory and Ramalingam, Suresh and Pennell, Nathan A.}, - title = {A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study}, - year = {2021}, - journal = {Oncologist}, - volume = {26}, - number = {6}, - pages = {523 – 532}, - doi = {10.1002/onco.13725}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102646271&doi=10.1002%2fonco.13725&partnerID=40&md5=971acb88568ebd08a2177553e5f61f0d}, - abstract = {ECOG-ACRIN EA5181 is a phase III prospective, randomized trial that randomizes patients undergoing chemo/radiation for locally advanced non-small cell lung cancer (LA-NSCLC) to concomitant durvalumab or no additional therapy, with both arms receiving 1 year of consolidative durvalumab. Radiation dose escalation failed to improve overall survival in RTOG 0617. However, conventionally fractionated radiation to 60 Gy with concomitant chemotherapy is associated with a high risk of local failure (38%–46%). It is hoped that concomitant immunotherapy during chemo/radiation can help decrease the risk of local failure, thereby improving overall survival and progression-free survival with acceptable toxicity. In this article, we review conventional chemo/radiation therapy for LA-NSCLC, as well as the quickly evolving world of immunotherapy in the treatment of non-small cell lung cancer and discuss the rationale and study design of EA5181. Implications for Practice: This article provides an up-to-date assessment of how immunotherapy is reshaping the landscape of metastatic non-small cell lung cancer (NSCLC) and how the impact of this therapy is now rapidly moving into the treatment of patients with locally advanced NSCLC who are presenting for curative treatment. This article reviews the recent publications of chemo/radiation as well as those combining immunotherapy with chemotherapy and chemo/radiation, and provides a strategy for improving overall survival of patients with locally advanced NSCLC by using concomitant immunotherapy with standard concurrent chemo/radiation. © 2021 AlphaMed Press.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4; All Open Access, Bronze Open Access, Green Open Access} -} - -@ARTICLE{Chen2020, - author = {Chen, Yu and Gao, Min and Huang, Zhaoqin and Yu, Jinming and Meng, Xiangjiao}, - title = {SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: A focus on the mechanisms, advances, and future challenges}, - year = {2020}, - journal = {Journal of Hematology and Oncology}, - volume = {13}, - number = {1}, - doi = {10.1186/s13045-020-00940-z}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088879865&doi=10.1186%2fs13045-020-00940-z&partnerID=40&md5=27e617cff451a99da68cdacb4e76c9a5}, - abstract = {Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have revolutionized the treatment protocols of a broad spectrum of tumor types, especially non-small-cell lung cancer (NSCLC). Despite the substantial optimism of treatment with PD-1/PD-L1 inhibitors, there is still a large proportion of patients with advanced NSCLC who are resistant to the inhibitors. Preclinical and clinical trials have demonstrated that radiotherapy can induce a systemic antitumor immune response and have a great potential to sensitize refractory "cold"tumors to immunotherapy. Stereotactic body radiation therapy (SBRT), as a novel radiotherapy modality that delivers higher doses to smaller target lesions, has shown favorable antitumor effects with significantly improved local and distant control as well as better survival benefits in various solid tumors. Notably, research has revealed that SBRT is superior to conventional radiotherapy, possibly because of its more powerful immune activation effects. Thus, PD-1/PD-L1 inhibitors combined with SBRT instead of conventional radiotherapy might be more promising to fight against NSCLC, further achieving more favorable survival outcomes. In this review, we focus on the underlying mechanisms and recent advances of SBRT combined with PD-1/PD-L1 inhibitors with an emphasis on some future challenges and directions that warrant further investigation. © 2020 The Author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 96; All Open Access, Gold Open Access} -} - -@ARTICLE{Shukla202151, - author = {Shukla, Nikhil and Hanna, Nasser}, - title = {Neoadjuvant and adjuvant immunotherapy in early-stage non-small cell lung cancer}, - year = {2021}, - journal = {Lung Cancer: Targets and Therapy}, - volume = {12}, - pages = {51 – 60}, - doi = {10.2147/LCTT.S277717}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109377063&doi=10.2147%2fLCTT.S277717&partnerID=40&md5=63547b14b7f1bb3be58c4da8af4f32a8}, - abstract = {Surgery or concurrent chemoradiation are standard of care treatments for patients with localized and locally advanced non-small cell lung cancer (NSCLC). While resection and chemoradiation are potentially curative therapies for early-stage disease, relapse rates remain high. Adjuvant or neoadjuvant chemotherapy improves cure rates 5–15% compared with surgery alone for patients with resectable disease. Immune checkpoint inhibitors (ICI) have heralded a new era for the treatment of advanced NSCLC with one-third of patients experiencing long-term survival. There is increasing interest in examining the role of ICI therapy in patients with early-stage NSCLC. Consolidation durvalumab after chemoradiation has become a part of standard of care for patients with inoperable, locally advanced disease. More recently, there is emerging evidence that neoadjuvant treatment with ICIs results in substantial rates of major pathologic response and pathologic complete response, and high rates of R0 resection with no significant delay in time to surgery. Furthermore, preliminary data show that adjuvant treatment with ICIs after adjuvant chemotherapy improves disease-free survival and may play a critical role in reducing disease recurrence in patients with resectable disease. In this review, we discuss recently reported and ongoing studies that are designed to define the role of immunotherapy in patients with non-metastatic NSCLC. © 2021 Shukla and Hanna.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 19; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Pellerino2021, - author = {Pellerino, Alessia and Bruno, Francesco and Rudà, Roberta and Soffietti, Riccardo}, - title = {Systemic Therapy for Lung Cancer Brain Metastases}, - year = {2021}, - journal = {Current Treatment Options in Oncology}, - volume = {22}, - number = {12}, - doi = {10.1007/s11864-021-00911-7}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85117774571&doi=10.1007%2fs11864-021-00911-7&partnerID=40&md5=da2ad881e15da371e5797b3397ab43b5}, - abstract = {Systemic therapy for brain metastases (BM) is quickly moving from conventional cytotoxic chemotherapy toward targeted therapies, that allow a disruption of driver molecular pathways. The discovery of actionable driver mutations has led to the development of an impressive number of tyrosine kinase inhibitors (TKIs), that target the epidermal growth factor receptor (EGFR) mutations, anaplastic-lymphoma-kinase (ALK) rearrangements, and other rare molecular alterations in patients bearing metastatic non-small cell lung cancer (NSCLC) in the brain, with remarkable results in terms of intracranial disease control and overall survival. Moreover, these drugs may delay the use of local therapies, such as stereotactic radiosurgery (SRS) or whole-brain radiotherapy (WBRT). New drugs with higher molecular specificity and ability to cross the CNS barriers (BBB, BTB and blood-CSF) are being developed. Two major issues are related to targeted therapies. First, the emergence of a resistance is a common event, and a deeper understanding of molecular pathways that are involved is critical for the successful development of effective new targeted agents. Second, an early detection of tumor progression is of utmost importance to avoid the prolongation of an ineffective therapy while changing to another drug. In order to monitor over time the treatment to targeted therapies, liquid biopsy, that allows the detection in biofluids of either circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) or exosomes, is increasingly employed in clinical trials: with respect to BM the monitoring of both blood and CSF is necessary. Also, radiomics is being developed to predict the mutational status of the BM on MRI. For patients without druggable mutations or who do not respond to targeted agents, immunotherapy with checkpoint inhibitors is increasingly employed, alone or in combination with radiotherapy. Pseudoprogression after immunotherapy alone maybe a challenge for several months after the start of treatment, and the same is true for radionecrosis after the combination of immunotherapy and SRS. In this regard, the value of advanced MRI techniques and PET imaging for a better distinction of pseudoprogression/radionecrosis and true tumor progression is promising, but needs validation in large prospective datasets. Last, a new frontier in the near future will be chemoprevention (primary and secondary), but we need to identify among solid tumors those subgroups of patients with a higher risk of relapsing into the brain and novel drugs, active on either neoplastic or normal cells of the microenvironment, that are cooperating in the invasion of brain tissue. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12} -} - -@ARTICLE{Xing2021, - author = {Xing, Rui and Gao, Jinping and Cui, Qi and Wang, Qian}, - title = {Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma}, - year = {2021}, - journal = {Frontiers in Immunology}, - volume = {12}, - doi = {10.3389/fimmu.2021.783236}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120969558&doi=10.3389%2ffimmu.2021.783236&partnerID=40&md5=fd53cf7dd85b6247e7badafddf1e1be9}, - abstract = {Hepatocellular carcinoma (HCC), one of the most fatal malignancies in the world, is usually diagnosed in advanced stages due to late symptom manifestation with very limited therapeutic options, which leads to ineffective intervention and dismal prognosis. For a decade, tyrosine kinase inhibitors (TKIs) have offered an overall survival (OS) benefit when used in a first-line (sorafenib and lenvatinib) and second-line setting (regorafenib and cabozantinib) in advanced HCC, while long-term response remains unsatisfactory due to the onset of primary or acquired resistance. Recently, immunotherapy has emerged as a promising therapy in the treatment of several solid tumors, such as melanoma and non-small cell lung cancer. Moreover, as the occurrence of HCC is associated with immune tolerance and immunosurveillance escape, there is a potent rationale for employing immunotherapy in HCC. However, immunotherapy monotherapy, mainly including immune checkpoint inhibitors (ICIs) that target checkpoints programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and the cytotoxic T lymphocyte antigen-4 (CTLA-4), has a relatively low response rate. Thus, the multi-ICIs or the combination of immunotherapy with other therapies, like antiangiogenic drugs and locoregional therapies, has become a novel strategy to treat HCC. Combining different ICIs may have a synergistical effect attributed to the complementary effects of the two immune checkpoint pathways (CTLA-4 and PD-1/PD-L1 pathways). The incorporation of antiangiogenic drugs in ICIs can enhance antitumor immune responses via synergistically regulating the vasculature and the immune microenvironment of tumor. In addition, locoregional treatments can improve antitumor immunity by releasing the neoplasm antigens from killed tumor cells; in turn, this antitumor immune response can be intensified by immunotherapy. Therefore, the combination of locoregional treatments and immunotherapy may achieve greater efficacy through further synergistic effects for advanced HCC. This review aims to summarize the currently reported results and ongoing trials of the ICIs-based combination therapies for HCC to explore the rational combination strategies and further improve the survival of patients with HCC. Copyright © 2021 Xing, Gao, Cui and Wang.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 83; All Open Access, Gold Open Access} -} - -@ARTICLE{Naidoo2020e435, - author = {Naidoo, Jarushka and Nishino, Mizuki and Patel, Sandip Pravin and Shankar, Bairavi and Rekhtman, Natasha and Illei, Peter and Camus, Phillipe}, - title = {Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non–Small-Cell Lung Cancer}, - year = {2020}, - journal = {Clinical Lung Cancer}, - volume = {21}, - number = {5}, - pages = {e435 – e444}, - doi = {10.1016/j.cllc.2020.02.025}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086870395&doi=10.1016%2fj.cllc.2020.02.025&partnerID=40&md5=9023cb4752e4f1e7b92ba7d71964f4f3}, - abstract = {Approximately one third of patients with non–small-cell lung cancer (NSCLC) present with stage III or locally advanced NSCLC. These patients have historically been managed with chemoradiotherapy. However, outcomes for these patients remain poor, with a 5-year survival rate between 15% and 32%. Immune checkpoint inhibitors have revolutionized the treatment of patients with NSCLC. One such agent, durvalumab, a selective high-affinity human immunoglobulin G1 monoclonal antibody that blocks programmed cell death ligand 1 binding to programmed cell death protein 1 and cluster of differentiation 80, was recently approved in the consolidation setting after completion of definitive platinum-based chemoradiotherapy and has become the current standard of care for patients with stage III locally advanced NSCLC. Immune checkpoint blockade is associated with increased risk of immunotherapy-related adverse events, which can be managed most effectively when detected early, ideally in the context of a multidisciplinary approach. Pneumonitis represents the potentially most severe and life-threatening of all reported immunotherapy-related adverse events, but it is further complicated in the context of recent prior therapies also known to cause pulmonary toxicity, such as radiotherapy. However, there are major gaps in our ability to identify immunotherapy-related pneumonitis and distinguish it from radiation pneumonitis. This review aims to define the key steps in the detection, diagnosis, and treatment of immunotherapy-related pneumonitis. © 2020 The Author(s)}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 48; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Tariq2021579, - author = {Tariq, Sara and Kim, So Yeon and Monteiro de Oliveira Novaes, Jose and Cheng, Haiying}, - title = {Update 2021: Management of Small Cell Lung Cancer}, - year = {2021}, - journal = {Lung}, - volume = {199}, - number = {6}, - pages = {579 – 587}, - doi = {10.1007/s00408-021-00486-y}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119138653&doi=10.1007%2fs00408-021-00486-y&partnerID=40&md5=9792d6921a9e5b418fefe000de04b1f4}, - abstract = {Background: Accounting for 14% of lung cancer, small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy with rapid proliferation, early spread, and poor survival. Aim and Methods: We provide an overview of recent advances regarding SCLC pathogenesis, subtypes, and treatment development through literature review of key trials. Results: There are no validated biomarkers or approved targeted treatments for this overly heterogeneous disease, but recent analyses have identified some promising targets and four major subtypes which may carry unique therapeutic vulnerabilities in SCLC. Treatment wise, only a third of patients present with limited stage SCLC, which can be managed with a combined modality approach with curative intent (usually chemo-radiotherapy, but in some eligible patients, surgery followed by systemic treatment). For advanced or extensive stage SCLC, combined chemotherapy (platinum–etoposide) and immunotherapy (atezolizumab or durvalumab during and after chemotherapy) has become the new standard front-line treatment, with modest improvement in overall survival. In the second-line setting, for disease relapse ≤ 6 months, topotecan, lurbinectedin, and clinical trials are reasonable treatment options; for disease relapse > 6 months, original regimen, topotecan or lurbinectedin can be considered. Moreover, Trilaciclib, a CD4/CD6 inhibitor, was recently FDA-approved to decrease the incidence of chemotherapy-related myelosuppression in SCLC patients. Conclusions: While modest improvements in survival have been made especially in the metastatic setting with chemo-immunotherapy, further research in understanding the biology of SCLC is warranted to develop biomarker-driven therapeutic strategies and combinational approaches for this aggressive disease. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 44} -} - -@ARTICLE{Debele20201, - author = {Debele, Tilahun Ayane and Yeh, Cheng-Fa and Su, Wen-Pin}, - title = {Cancer immunotherapy and application of nanoparticles in cancers immunotherapy as the delivery of immunotherapeutic agents and as the immunomodulators}, - year = {2020}, - journal = {Cancers}, - volume = {12}, - number = {12}, - pages = {1 – 24}, - doi = {10.3390/cancers12123773}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097819310&doi=10.3390%2fcancers12123773&partnerID=40&md5=c52548811da33695db8b8c36d11516f0}, - abstract = {In the last few decades, cancer immunotherapy becomes an important tactic for cancer treatment. However, some immunotherapy shows certain limitations including poor therapeutic targeting and unwanted side effects that hinder its use in clinics. Recently, several researchers are exploring an alternative methodology to overcome the above limitations. One of the emerging tracks in this field area is nano-immunotherapy which has gone through rapid progress and revealed considerable potentials to solve limitations related to immunotherapy. Targeted and stimuli-sensitive biocompatible nanoparticles (NPs) can be synthesized to deliver immunotherapeutic agents in their native conformations to the site of interest to enhance their antitumor activity and to enhance the survival rate of cancer patients. In this review, we have discussed cancer immunotherapy and the application of NPs in cancer immunotherapy, as a carrier of immunotherapeutic agents and as a direct immunomodulator. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 40; All Open Access, Gold Open Access} -} - -@ARTICLE{Li2021, - author = {Li, Kexin and Zhang, Ashley and Li, Xiaoya and Zhang, Hongtao and Zhao, Lianmei}, - title = {Advances in clinical immunotherapy for gastric cancer}, - year = {2021}, - journal = {Biochimica et Biophysica Acta - Reviews on Cancer}, - volume = {1876}, - number = {2}, - doi = {10.1016/j.bbcan.2021.188615}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112780836&doi=10.1016%2fj.bbcan.2021.188615&partnerID=40&md5=6d4d13176a87e81a112b7f02f65f03f0}, - abstract = {Gastric cancer (GC) is one of the most malignant human cancers with increasing incidence worldwide, ranking among the top five malignant tumors worldwide in terms of incidence and mortality. The clinical efficacy of conventional therapies is limited, and the median overall survival (mOS) for advanced-stage gastric cancer is only about 8 months. Emerging as one of breakthroughs for cancer therapy, immunotherapy has become an effective treatment modality after surgery, chemotherapy, radiotherapy, and targeted therapy. In this review, we have summarized the progresses of clinical development of immunotherapies for gastric cancer. Major advances with immune checkpoint inhibitors (ICIs) have started to change the clinical practice for gastric cancer treatment and prognosis. Additionally, combination therapies with other modalities, such as targeted therapies, are expected to push immunotherapies to front-line. In this review, the efficacy of ICIs and targeted therapy alone or combination with existing therapies gastric cancer treatment was described and the predictive value of biomarkers for immunotherapies in gastric cancer treatment is also discussed. © 2021}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 219} -} - -@ARTICLE{Zhang2020, - author = {Zhang, Zhibo and Yuan, Fang and Chen, Runzhe and Li, Ye and Ma, Junxun and Yan, Xiang and Wang, Lijie and Zhang, Fan and Tao, Haitao and Guo, Dong and Huang, Zhiyue and Zhang, Sujie and Li, Xiaoyan and Zhi, Xiaoyu and Ge, Xiangwei and Hu, Yi and Wang, Jinliang}, - title = {Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors}, - year = {2020}, - journal = {Frontiers in Immunology}, - volume = {11}, - doi = {10.3389/fimmu.2020.01173}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087010476&doi=10.3389%2ffimmu.2020.01173&partnerID=40&md5=582c7987cb67d6c9b803501da920f13f}, - abstract = {Background: Serum tumor markers carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cytokeratin 19 fragment (CYFRA21-1) and squamous-cell carcinoma-related antigen (SCC-Ag) are routinely used for monitoring the response to chemotherapy or targeted therapy in advanced-stage non-small cell lung cancer (NSCLC), however their role in immunotherapy remains unclear. The aim of this study was to investigate whether dynamics of these serum markers were associated with the efficacy and prognosis of Chinese late-stage NSCLC patients treated with programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors. Methods: We initiated a longitudinal prospective study on advanced NSCLC patients treated with PD-1/PD-L1 inhibitors in Chinese PLA general hospital (Beijing, China). Blood samples of baseline and after 6 weeks' treatment were collected. CT scan were used by all patients to evaluate treatment efficacy according to RECIST 1.1. Serum tumor markers levels were measured with an electrochemical luminescence for SCC-Ag and with a chemiluminescent microparticle immunoassay for serum CEA, CA125, and CYFRA21-1. At least 20% decreases of the biomarkers from baseline were considered as meaningful improvements after 6 weeks of treatment with immune checkpoint inhibitors (ICIs). Optimization-based method was used to balance baseline covariates between different groups. Associations between serum tumor biomarker improvements and objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were analyzed. Results: A total of 308 Chinese patients with advanced NSCLC were enrolled in the study. After balancing baseline covariates, patients with meaningful improvements in <2 out of 4 biomarkers (CEA, CA125, CYFRA21-1, and SCC-Ag) was ended up with lower ORR (0.08 vs. 0.35, p < 0.001), shorten PFS (median: 5.4 vs. 12.5 months, p < 0.001), and OS (median: 11.7 vs. 25.6 months, p < 0.001) in the total population. Subgroup analysis of patients with adenocarcinoma revealed that patients with meaningful improvements in <2 out of 4 biomarkers had significant lower ORR (0.06 vs. 0.36, p < 0.001), shorten PFS (median: 4.1 vs. 11.9 months, p < 0.001), and OS (median: 11.9 vs. 24.2 months, p < 0.001). So as in patients with squamous cell carcinoma, meaningful improvements in at least 2 out of 4 biomarkers were linked to better ORR (0.42 vs. 0.08, p = 0.014), longer PFS (median: 13.1 vs. 5.6 months, p = 0.001), and OS (median: 25.6 vs. 10.9 months, p = 0.06). Conclusions: The dynamic change of CEA, CA125, CYFRA21-1, and SCC-Ag from baseline have prognostic value for late-stage NSCLC patients treated with PD-1/PD-L1 inhibitors. Decrease of associated biomarkers serum levels were associated with favorable clinical outcomes. © Copyright © 2020 Zhang, Yuan, Chen, Li, Ma, Yan, Wang, Zhang, Tao, Guo, Huang, Zhang, Li, Zhi, Ge, Hu and Wang.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 33; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Passaro2021, - author = {Passaro, Antonio and Bestvina, Christine and Velez Velez, Maria and Garassino, Marina Chiara and Garon, Edward and Peters, Solange}, - title = {Severity of COVID-19 in patients with lung cancer: Evidence and challenges}, - year = {2021}, - journal = {Journal for ImmunoTherapy of Cancer}, - volume = {9}, - number = {3}, - doi = {10.1136/jitc-2020-002266}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103034628&doi=10.1136%2fjitc-2020-002266&partnerID=40&md5=fb51836bc7bd3f17a637d53db6964e4d}, - abstract = {Cancer patients are highly vulnerable to SARS-CoV-2 infections due to frequent contacts with the healthcare system, immunocompromised state from cancer or its therapies, supportive medications such as steroids and most importantly their advanced age and comorbidities. Patients with lung cancer have consistently been reported to suffer from an increased risk of death compared with other cancers. This is possibly due to the combination of specific pathophysiological aspects, including underlying pulmonary compromise due to smoking history and the increased specific pressures on respiratory healthcare services caused by the related pandemic. Rationally and safely treating patients with lung cancer during the pandemic has become a continuous challenge over the last year. Deciding whether to offer, modify, postpone or even cancel treatments for this particular patient's population has become the crucial recurrent dilemma for lung cancer professionals. Chemotherapy, immunotherapy and targeted agents represent distinct risks factors in the context of COVID-19 that should be balanced with the short-term and long-term consequences of delaying cancer care. Despite the rapid and persistent trend of the pandemic, declared by WHO on March 11, 2020, and still ongoing at the time of writing (January 2021), various efforts were made by oncologists worldwide to understand the impact of COVID-19 on patients with cancer. Adapted recommendations of our evidence-based practice guidelines have been developed for all stakeholders. Different small and large-scale registries, such as the COVID-19 and Cancer Consortium (CCC19) and Thoracic Cancers International COVID-19 Collaboration quickly collected data, supporting cancer care decisions under the challenging circumstance created by the COVID-19 pandemic. Several recommendations were developed as guidance for prioritizing the various aspects of lung cancer care in order to mitigate the adverse effects of the COVID-19 healthcare crisis, potentially reducing the morbidity and mortality of our patients from COVID-19 and from cancer. These recommendations helped inform decisions about treatment of established disease, continuation of clinical research and lung cancer screening. In this review, we summarize available evidence regarding the direct and indirect impact of the COVID-19 pandemic on lung cancer care and patients. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 90; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Johal20213692, - author = {Johal, Sukhvinder and Hettle, Robert and Carroll, Joe and Maguire, Peter and Wynne, Tammy}, - title = {Real-world treatment patterns and outcomes in small-cell lung cancer: A systematic literature review}, - year = {2021}, - journal = {Journal of Thoracic Disease}, - volume = {13}, - number = {6}, - pages = {3692 – 3707}, - doi = {10.21037/jtd-20-3034}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108835635&doi=10.21037%2fjtd-20-3034&partnerID=40&md5=a705d44a46690e72e0aba0f3688aff76}, - abstract = {Background: Small-cell lung cancer (SCLC) accounts for 12-15% of lung cancers and is associated with poor survival outcomes and high symptom burden. This study employed a broad, systematic search strategy and timeframe to identify evidence on real-world treatment patterns and outcomes for SCLC outside the USA, including understanding sub-populations such as extensive-stage (ES) or limited-stage (LS) disease. Methods: Databases (MEDLINE, Embase, and EBM reviews) were searched for journal articles published in the English language between 1 January 2000-1 March 2020 and supplemented by hand searching of conference abstracts and posters presented at conferences between 1 January 2016-1 March 2020 reporting real-world treatment outcomes in patients with SCLC. A targeted clinical guideline review was also completed. Results: One-hundred studies provided quantitative data; 57 were available as full-text articles, whilst the remaining 43 were presented as abstracts or posters. The majority (80 studies, 80%) of included studies reported treatment in the first-line setting, where platinum-based chemotherapy and chemoradiotherapy was the most commonly used treatment strategy, in line with current treatment guidelines in SCLC. First-line treatments were found to have a high response rate; however, most patients relapsed early. No studies reported treatment or outcomes with immune-oncology therapies. Second-line treatment options were very limited, and primarily consisted of either re-treatment with first-line regimen or topotecan, but the prognosis for these patients remained poor. Outcomes were particularly poor amongst those with ES or relapsed disease vs. LS disease. Conclusions: SCLC treatment patterns and short survival outcomes have remained constant over the previous 20 years. Due to the search timeframe, none of the studies identified reported on the impact of recently approved immune-oncology therapies in SCLC. Further data is needed on the impact of immunotherapies on treatment patterns and real-world outcomes in SCLC. © Journal of Thoracic Disease. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Ortega-Franco20202656, - author = {Ortega-Franco, Ana and Calvo, Virginia and Franco, Fabio and Provencio, Mariano and Califano, Raffaele}, - title = {Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: A narrative review}, - year = {2020}, - journal = {Translational Lung Cancer Research}, - volume = {9}, - number = {6}, - pages = {2656 – 2673}, - doi = {10.21037/tlcr-20-546}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100165101&doi=10.21037%2ftlcr-20-546&partnerID=40&md5=f9fe2516f285e60825c0d8c2b97e69ae}, - abstract = {Prognosis of early stage non-small cell lung cancer (eNSCLC) is poor even when treated radically with surgery and (neo)adjuvant chemotherapy (Cht). The discovery of tyrosine kinase inhibitors (TKIs) for oncogene addicted NSCLC and immune checkpoint inhibitors (ICIs) have revolutionised the therapeutic paradigm and improved survival of advanced NSCLC. The unprecedented impact of these drugs has shifted the focus of investigation to early stage disease aiming at improving cure. In this context, several single arm phase II studies evaluating neoadjuvant ICI alone or in combination with platinum-based Cht have shown encouraging rates of pathological response which have spurred several ongoing randomized trials with (neo)adjuvant ICI. More recently, ADAURA study evaluating adjuvant osimertinib demonstrated a profound reduction of the risk of recurrence in patients with stage I (>4 cm)-IIIA eNSCLC harbouring EGFR sensitizing mutations. ICIs and TKIs represent a true revolution in the treatment of eNSCLC call to challenge the current standard of care. However, questions regarding drug resistance, recurrence patterns, biomarker identification, optimal treatment duration and sequencing need be answered to effectively integrate new drugs in the rapidly evolving therapeutic landscape of NSCLC. In this review we critically review new developments and future perspectives of TKIs and ICI as (neo)adjuvant strategies for eNSCLC. © Translational Lung Cancer Research. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 14; All Open Access, Gold Open Access} -} - -@ARTICLE{Delmas2021, - author = {Delmas, Dominique and Hermetet, François and Aires, Virginie}, - title = {PD-1/PD-l1 checkpoints and resveratrol: A controversial new way for a therapeutic strategy}, - year = {2021}, - journal = {Cancers}, - volume = {13}, - number = {18}, - doi = {10.3390/cancers13184509}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114291751&doi=10.3390%2fcancers13184509&partnerID=40&md5=e3759a7220dfc9e8d290cd59925204dc}, - abstract = {Immune checkpoints refer to a range of immunoregulatory molecules that modulate the immune response. For example, proteins expressed at the surface of T-cells (including PD-1 and CTLA-4) and their ligands (PD-L1 and B7-1/B7-2, respectively), expressed by cancer cells and anti-gen-presenting cells, are needed to prevent excessive immune responses. However, they dampen anti-tumor immunity by limiting T-cell activity, making them promising therapeutic targets in cancer. Although immunotherapies using checkpoint blocking/neutralizing antibodies targeting PD- L1 or PD-1 have proven their superiority over conventional chemotherapies or targeted therapies by enhancing T-cell-mediated anti-tumor immunity, some limitations have emerged. These include a relatively low rate of “responders” (<50%; irrespective of cancer type), the high cost of injections, and a rare risk of hyper-progression. For clinicians, the current challenge is thus to improve the existing therapies, potentially through combinatory approaches. Polyphenols such as resveratrol (RSV), a trihydroxystilbene found in various plants and an adjuvant in numerous nutraceuticals, have been proposed as potential therapeutic targets. Beyond its well-known pleiotropic effects, RSV affects PD-L1 and PD-1 expression as well as PD-L1 subcellular localization and post-translational modifications, which we review here. We also summarize the consequences of PD-1/PD-L1 signaling, the modalities of their blockade in the context of cancer, and the current status and limitations of these immunotherapies. Finally, we discuss their potential use in combination with chemotherapies, and, using RSV as a model, we propose polyphenols as adjuvants to enhance the efficacy of anti-PD-1/anti-PD-L1 immunotherapies. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12; All Open Access, Gold Open Access} -} - -@ARTICLE{Qu2021, - author = {Qu, Jingjing and Mei, Quanhui and Liu, Li and Cheng, Tianli and Wang, Peng and Chen, Lijun and Zhou, Jianying}, - title = {The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer}, - year = {2021}, - journal = {Therapeutic Advances in Medical Oncology}, - volume = {13}, - doi = {10.1177/1758835921992968}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100965258&doi=10.1177%2f1758835921992968&partnerID=40&md5=3afc2b5ee852b6403986c9aaae40b00d}, - abstract = {The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1) inhibitors is the standard therapy for the first-line or second-line treatment of patients with non-small-cell lung cancer (NSCLC). In contrast to current traditional treatments such as chemotherapy or radiotherapy, anti-PD-1 and anti-PD-L1 treatments can directly attenuate tumour-mediated exhaustion and effectively modulate the host anti-tumour immune response in vivo. In addition, compared with traditional therapy, PD-1/PD-L1 inhibitor monotherapy can significantly prolong survival without obvious side effects in the treatment of advanced NSCLC. Ideally, several biomarkers could be used to monitor the safety and effectiveness of anti-PD-1 and anti-PD-L1 treatments; however, the current lack of optimal prognostic markers remains a widespread limitation and challenge for further clinical applications, as does the possibility of immune-related adverse events and drug resistance. In this review, we aimed to summarise the latest progress in anti-PD-1/anti-PD-L1 treatment of advanced NSCLC, worldwide, including in China. An exploration of underlying biomarker identification and future challenges will be discussed in this article to facilitate translational studies in cancer immunotherapy. © The Author(s), 2021.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 50; All Open Access, Gold Open Access} -} - -@ARTICLE{Zhou2021279, - author = {Zhou, Fei and Qiao, Meng and Zhou, Caicun}, - title = {The cutting-edge progress of immune-checkpoint blockade in lung cancer}, - year = {2021}, - journal = {Cellular and Molecular Immunology}, - volume = {18}, - number = {2}, - pages = {279 – 293}, - doi = {10.1038/s41423-020-00577-5}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85095849234&doi=10.1038%2fs41423-020-00577-5&partnerID=40&md5=6bf784dcd310c41871216efe2165e8ef}, - abstract = {Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or combination therapy, has been established as the standard of care for patients with locally advanced/metastatic non-small cell lung cancer without EGFR/ALK alterations or extensive-stage small cell lung cancer. An increasing number of clinical trials are also ongoing to further investigate the role of ICIs in patients with early-stage lung cancer as neoadjuvant or adjuvant therapy. Although PD-L1 expression and tumor mutational burden have been widely studied for patient selection, both of these biomarkers are imperfect. Due to the complex cancer-immune interactions among tumor cells, the tumor microenvironment and host immunity, collaborative efforts are needed to establish a multidimensional immunogram to integrate complementary predictive biomarkers for personalized immunotherapy. Furthermore, as a result of the wide use of ICIs, managing acquired resistance to ICI treatment remains an inevitable challenge. A deeper understanding of the underlying biological mechanisms of acquired resistance to ICIs is helpful to overcome these obstacles. In this review, we describe the cutting-edge progress made in patients with lung cancer, the optimal duration of ICI treatment, ICIs in some special populations, the unique response patterns during ICI treatment, the emerging predictive biomarkers, and our understanding of primary and acquired resistance mechanisms to ICI treatment. © 2020, CSI and USTC.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 117; All Open Access, Bronze Open Access} -} - -@ARTICLE{Yotsukura202128, - author = {Yotsukura, Masaya and Nakagawa, Kazuo and Suzuki, Kenji and Takamochi, Kazuya and Ito, Hiroyuki and Okami, Jiro and Aokage, Keiju and Shiono, Satoshi and Yoshioka, Hiroshige and Aoki, Tadashi and Tsutani, Yasuhiro and Okada, Morihito and Watanabe, Shun-Ichi}, - title = {Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer}, - year = {2021}, - journal = {Japanese Journal of Clinical Oncology}, - volume = {51}, - number = {1}, - pages = {28 – 36}, - doi = {10.1093/jjco/hyaa187}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099073325&doi=10.1093%2fjjco%2fhyaa187&partnerID=40&md5=182dbdacae5773bb5ceaac79b3333183}, - abstract = {The superior efficacy of immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancer has inspired many clinical trials to use immune checkpoint inhibitors in earlier stages of lung cancer worldwide. Based on the theoretical feasibility that neoantigens derived from a tumor tissue are present in vivo, some clinical trials have recently evaluated the neoadjuvant, rather than the adjuvant, use of immune checkpoint inhibitors. Some of these trials have already produced evidence on the safety and efficacy of immune checkpoint inhibitors in a neoadjuvant setting, with a favorable major pathologic response and few adverse events. In the most impactful report from Johns Hopkins University and the Memorial Sloan Kettering Cancer Center, the programed death-1 inhibitor nivolumab was administered to 21 patients in a neoadjuvant setting. The authors reported a major pathologic response rate of 45%, with no unexpected delay of surgery related to the adverse effects of nivolumab. The adjuvant as well as the neoadjuvant administration of immune checkpoint inhibitors has also been considered in various clinical trials, with or without the combined use of chemotherapy or radiotherapy. The development of appropriate biomarkers to predict the efficacy of immune checkpoint inhibitors is also underway. The expression of programed death ligand-1 and the tumor mutation burden are promising biomarkers that have been evaluated in many settings. To establish an appropriate method for using immune checkpoint inhibitors in combination with surgery, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group will manage clinical trials using a multimodality treatment, including immune checkpoint inhibitors and surgery. © The Author(s) 2020. Published by Oxford University Press. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 6; All Open Access, Bronze Open Access} -} - -@ARTICLE{Chaft2021547, - author = {Chaft, Jamie E. and Rimner, Andreas and Weder, Walter and Azzoli, Christopher G. and Kris, Mark G. and Cascone, Tina}, - title = {Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer}, - year = {2021}, - journal = {Nature Reviews Clinical Oncology}, - volume = {18}, - number = {9}, - pages = {547 – 557}, - doi = {10.1038/s41571-021-00501-4}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105225915&doi=10.1038%2fs41571-021-00501-4&partnerID=40&md5=937b7eb4475fcf045cff4d44880a99c6}, - abstract = {The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary discussions of surgical resectability and medical operability determine the modality of definitive local treatment (surgery or radiotherapy) and the associated systemic therapies to further improve the likelihood of cure. Trial evidence supports cisplatin-based adjuvant therapy either after surgical resection or concurrently with radiotherapy. Consensus guidelines support neoadjuvant chemotherapy in lieu of adjuvant chemotherapy and carboplatin-based regimens for patients who are ineligible for cisplatin. The incorporation of newer agents, now standard for patients with stage IV lung cancer, into the curative therapy paradigm has lagged owing to inefficient trial designs, the lengthy follow-up needed to assess survival end points and a developmental focus on the advanced-stage disease setting. Surrogate end points, such as pathological response, are being studied and might shorten trial durations. In 2018, the anti-PD-L1 antibody durvalumab was approved for patients with stage III lung cancer after concurrent chemoradiotherapy. Since then, the study of targeted therapies and immunotherapies in patients with early-stage lung cancer has rapidly expanded. In this Review, we present the current considerations in the treatment of patients with early-stage lung cancer and explore the current and future state of clinical research to develop systemic therapies for non-metastatic lung cancer. © 2021, Springer Nature Limited.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 193; All Open Access, Green Open Access} -} - -@ARTICLE{Wong20211, - author = {Wong, Selina K. and Iams, Wade T.}, - title = {Front line applications and future directions of immunotherapy in small-cell lung cancer}, - year = {2021}, - journal = {Cancers}, - volume = {13}, - number = {3}, - pages = {1 – 15}, - doi = {10.3390/cancers13030506}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099989469&doi=10.3390%2fcancers13030506&partnerID=40&md5=701229a860e014bb8ea23874b99e7f63}, - abstract = {After being stagnant for decades, there has finally been a paradigm shift in the treatment of small-cell lung cancer (SCLC) with the emergence and application of immune checkpoint inhibitors (ICIs). Multiple trials of first-line ICI-chemotherapy combinations have demonstrated survival benefit compared to chemotherapy alone in patients with extensive-stage SCLC, establishing this as the new standard of care. ICIs are now being applied in the potentially curative limited-stage setting, actively being investigated as concurrent treatment with chemoradiation and as adjuvant treatment following completion of chemoradiation. This review highlights the evidence behind the practice-changing addition of ICIs in the first-line setting of extensive-stage SCLC, the potentially practice-changing immunotherapy trials that are currently underway in the limited-stage setting, and alternate immunotherapeutic strategies being studied in the treatment of SCLC. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12; All Open Access, Gold Open Access} -} - -@ARTICLE{Xia20202120, - author = {Xia, Wu-Yan and Feng, Wen and Zhang, Chen-Chen and Shen, Yu-Jia and Zhang, Qin and Yu, Wen and Cai, Xu-Wei and Fu, Xiao-Long}, - title = {Radiotherapy for non-small cell lung cancer in the immunotherapy era: The opportunity and challenge-a narrative review}, - year = {2020}, - journal = {Translational Lung Cancer Research}, - volume = {9}, - number = {5}, - pages = {2120 – 2136}, - doi = {10.21037/tlcr-20-827}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096088329&doi=10.21037%2ftlcr-20-827&partnerID=40&md5=1663144217fdc68083f44117e41b2b87}, - abstract = {Immunotherapy has radically changed the clinical management of patients with cancer in recent years. Immune checkpoint inhibitors (ICIs) reversing the immunosuppressive effects of the tumor microenvironment are one type of immunotherapy, several of which are approved by the US Food and Drug Administration (FDA) as first-line treatments for patients with non-small cell lung cancer (NSCLC). However, response rates to ICIs are around 19-47% among patients with advanced NSCLC. As a result, the development of combined ICI and radiotherapy has begun with the aim of strengthening patients' antitumor immunity. Radiotherapy with substantial technological improvements not only achieves local tumor control through the induction of deoxyribonucleic acid (DNA) damage in irradiated regions, but also has the potential to mediate immunostimulatory effects that could result in tumor regression beyond irradiated regions. At present, numerous preclinical and clinical research are investigating the efficiency and safety of combining ICI with radiotherapy. The PACIFIC trial showed that combining chemoradiotherapy with ICI could improve clinical outcomes. In this review, we summarize the rationale for combining radiotherapy with immunotherapy. We also discuss the opportunities and challenges of combination therapy, including the timing of radiotherapy, optimal dose and fractionations, radiotherapy target and target volume, acquired resistance, patient selection, and radioimmunotherapy toxicity. © Translational Lung Cancer Research. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 17; All Open Access, Gold Open Access} -} - -@ARTICLE{Qian2021, - author = {Qian, Jack M. and Schoenfeld, Jonathan D.}, - title = {Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges}, - year = {2021}, - journal = {Frontiers in Oncology}, - volume = {10}, - doi = {10.3389/fonc.2020.608772}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100925956&doi=10.3389%2ffonc.2020.608772&partnerID=40&md5=3afbd73e85e553f3f44bd2bf730d8bcb}, - abstract = {Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment over the past decade. However, although the immune landscape suggests a strong rationale for the use of these agents in patients with head and neck squamous cell carcinoma, the available clinical evidence indicates that most patients currently do not respond to ICI monotherapy. Radiotherapy is a primary treatment modality for many patients with locally advanced head and neck cancer. While ionizing radiation traditionally has been thought to act in a purely cytotoxic fashion, a growing body of preclinical studies have demonstrated additional profound immunomodulatory effects. Consequently, there has been a surge of interest in the potential synergy between radiotherapy and immunotherapy, both the potential for radiotherapy to augment the systemic anti-tumor immune response and the potential for immunotherapy to improve in-field tumor response to radiation. In this review, we summarize the current preclinical and clinical evidence for radioimmunotherapy, with a particular focus on studies directly relevant to head and neck squamous cell carcinoma, as well as existing challenges and future directions for this emerging field. © Copyright © 2021 Qian and Schoenfeld.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 41; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Chung20212430, - author = {Chung, Seung Woo and Xie, Yunxuan and Suk, Jung Soo}, - title = {Overcoming physical stromal barriers to cancer immunotherapy}, - year = {2021}, - journal = {Drug Delivery and Translational Research}, - volume = {11}, - number = {6}, - pages = {2430 – 2447}, - doi = {10.1007/s13346-021-01036-y}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111921768&doi=10.1007%2fs13346-021-01036-y&partnerID=40&md5=a9ac5201936223e0e6c5a35d3a2e4ea7}, - abstract = {Immunotherapy has emerged as an unprecedented hope for the treatment of notoriously refractory cancers. Numerous investigational drugs and immunotherapy-including combination regimens are under preclinical and clinical investigation. However, only a small patient subpopulation across different types of cancer responds to the therapy due to the presence of several mechanisms of resistance. There have been extensive efforts to overcome this limitation and to expand the patient population that could be benefited by this state-of-the-art therapeutic modality. Among various causes of the resistance, we here focus on physical stromal barriers that impede the access of immunotherapeutic drug molecules and/or native and engineered immune cells to cancer tissues and cells. Two primary stromal barriers that contribute to the resistance include aberrant tumor vasculatures and excessive extracellular matrix build-ups that restrict extravasation and infiltration, respectively, of molecular and cellular immunotherapeutic agents into tumor tissues. Here, we review the features of these barriers that limit the efficacy of immunotherapy and discuss recent advances that could potentially help immunotherapy overcome the barriers and improve therapeutic outcomes. Graphical abstract: [Figure not available: see fulltext.] © 2021, Controlled Release Society.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 6; All Open Access, Green Open Access} -} - -@ARTICLE{Palmero2021539, - author = {Palmero, Ramón and Vilariño, Noelia and Navarro-Martín, Arturo and Nadal, Ernest}, - title = {Induction treatment in patients with stage III non-small cell lung cancer}, - year = {2021}, - journal = {Translational Lung Cancer Research}, - volume = {10}, - number = {1}, - pages = {539 – 554}, - doi = {10.21037/tlcr-20-420}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101019826&doi=10.21037%2ftlcr-20-420&partnerID=40&md5=ae03178b48351ce02731e6f8e1249498}, - abstract = {Stage III non-small cell lung cancer (NSCLC) comprises a highly heterogeneous group of patients defined according to the extent and localization of disease. Patients with discrete N2 involvement identified preoperatively with resectable disease are candidates for multimodal therapy either with definitive chemoradiation therapy, induction chemotherapy, or chemoradiotherapy (CTRT) followed by surgery. Neoadjuvant chemotherapy has yielded comparable survival benefit to adjuvant chemotherapy in patients with stage II–III disease and may allow for downstaging the tumor or the lymph nodes, an earlier delivery of systemic treatment, and better compliance to systemic therapy. The use of immune checkpoint inhibitors (ICIs) as induction therapy shows encouraging activity and a favorable safety profile in patients with resectable early stage or locally advanced NSCLC. An unprecedented rate of pathological response and downstaging has been reported in single-arm clinical trials, especially when immunotherapy is combined with neoadjuvant chemotherapy. Ongoing randomized phase II/III clinical trials assessing the efficacy and safety of induction with immunotherapy plus chemotherapy have the potential to establish this therapeutic approach as a novel standard of care. These trials aim to validate pathological response as a surrogate marker of survival benefit and to demonstrate that this therapeutic strategy can improve the cure rate in patients with stage II–III NSCLC. © Translational Lung Cancer Research. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 10; All Open Access, Gold Open Access} -} - -@ARTICLE{Bade2020295, - author = {Bade, Brett C. and Possick, Jennifer D.}, - title = {Pulmonary Complications of Immunotherapy}, - year = {2020}, - journal = {Clinics in Chest Medicine}, - volume = {41}, - number = {2}, - pages = {295 – 305}, - doi = {10.1016/j.ccm.2020.02.012}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084263291&doi=10.1016%2fj.ccm.2020.02.012&partnerID=40&md5=0da1d64686fbe59d45dde24bfb74d2c2}, - abstract = {Immune checkpoint inhibitor (ICI) therapy represents a paradigm shift in the treatment of patients with locally advanced and metastatic lung cancer. Although immunotherapy generally has a more favorable safety profile when compared with chemotherapy, immune-related adverse events represent important, but incompletely understood, treatment-limiting complications associated with significant morbidity and mortality risk. Current guidelines for diagnosis and management are derived from consensus experience, highlighting that further prospective investigation in this area is needed. As ICI-related pneumonitis is a clinically and radiographically diverse toxidrome, clinical vigilance is important while treating patients with lung cancer. © 2020 Elsevier Inc.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2} -} - -@ARTICLE{Gomes2020874, - author = {Gomes, Fabio and Wong, Melisa and Battisti, Nicolò Matteo Luca and Kordbacheh, Tiana and Kiderlen, Mandy and Greystoke, Alastair and Luciani, Andrea}, - title = {Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper}, - year = {2020}, - journal = {British Journal of Cancer}, - volume = {123}, - number = {6}, - pages = {874 – 884}, - doi = {10.1038/s41416-020-0986-4}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088298641&doi=10.1038%2fs41416-020-0986-4&partnerID=40&md5=645f6ab322623379a63a0055a754b4d9}, - abstract = {Immunotherapy with checkpoint inhibitors against programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1) has been implemented in the treatment pathway of patients with non-small cell lung cancer (NSCLC) from locally advanced disease to the metastatic setting. This approach has resulted in improved survival and a more favourable toxicity profile when compared with chemotherapy. Following the successful introduction of single-agent immunotherapy, current clinical trials are focusing on combination treatments with chemotherapy or radiotherapy or even other immunotherapeutic agents. However, most of the data available from these trials are derived from, and therefore might be more applicable to younger and fitter patients rather than older and often frail lung cancer real-world patients. This article provides a detailed review of these immunotherapy agents with a focus on the data available regarding older NSCLC patients and makes recommendations to fill evidence gaps in this patient population. © 2020, The Author(s), under exclusive licence to Cancer Research UK.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 20; All Open Access, Green Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Guaitoli20212890, - author = {Guaitoli, Giorgia and Tiseo, Marcello and Di Maio, Massimo and Friboulet, Luc and Facchinetti, Francesco}, - title = {Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: A systematic review and meta-analysis}, - year = {2021}, - journal = {Translational Lung Cancer Research}, - volume = {10}, - number = {6}, - pages = {2890 – 2916}, - doi = {10.21037/tlcr-20-941}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108973566&doi=10.21037%2ftlcr-20-941&partnerID=40&md5=9809cc031ad4ecfd0d246863d97f9ca8}, - abstract = {Background: Treatment of oncogene-addicted non-small cell lung cancer (NSCLC) has been changed by the advent of tyrosine kinase inhibitors (TKIs). Albeit great benefits are achieved with target therapies, resistance invariably occurs and recourse to alternative treatments is unavoidable. Immune checkpoint inhibitors (ICIs) role and the best setting of immunotherapy administration in oncogene-driven NSCLC are matter of debate. Methods: We performed a systematic literature review through PubMed, in order to gather all the available information regarding ICI activity and efficacy in oncogene-addicted NSCLC, from both prospective trials and retrospective series. A meta-analysis of objective response rate in different molecular subgroups was provided. Combinatorial strategies including ICIs and related toxicities were also recorded. Results: Eighty-seven studies were included in the qualitative analysis. EGFR mutation may be a biomarker of poor response to single-agent ICIs (7% of EGFR-mutant NSCLC patients achieved disease response in prospective trials), while encouraging results have been shown with combination strategies. KRASmutated disease (response rate, RR, 22%) has different clinical and pathological characteristics, and the coexistence of additional mutations (e.g., STK11 or TP53) influence tumor microenvironment and response to immunotherapy. Other molecular alterations have been marginally considered prospectively, and data from clinical practice are variegated, given poor effectiveness of ICIs in ALK-rearranged disease (RR 9.5%, pooling the data of retrospective studies) or some encouraging results in BRAF-(RR 25%, retrospective data) or MET-driven one (with estimations conditioned by the presence of both exon 14 skipping mutations and gene amplification in reported series). Conclusions: In oncogene-addicted NSCLC (with the exception of KRAS-mutated), ICIs are usually administered at the failure of other treatment options, but administering single-agent immunotherapy in later disease phases may limit its efficacy. With the progressive administration of TKIs and ICIs in early-stage disease, molecular characterization will become fundamental in this setting. © 2021 AME Publishing Company. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 25; All Open Access, Gold Open Access} -} - -@ARTICLE{Baldini20201681, - author = {Baldini, E. and Tibaldi, C. and Delli Paoli, C.}, - title = {Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: a review}, - year = {2020}, - journal = {Clinical and Translational Oncology}, - volume = {22}, - number = {10}, - pages = {1681 – 1686}, - doi = {10.1007/s12094-020-02326-6}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081555735&doi=10.1007%2fs12094-020-02326-6&partnerID=40&md5=960a79342f13ab569b9a735b30871178}, - abstract = {Approximately one-third of all non-small-cell lung cancer (NSCLC) are locally-advanced at diagnosis, and 15–17% of these tumors are unresectable at presentation. Definitive chemo-radiotherapy (CRT) represents the standard therapeutic approach. However, the literature has shown that only 15% of patients are alive at 5 years and this percentage has remained unchanged despite various attempts of improvement. The recent introduction of immunotherapy has not only strongly changed the clinical scenario but has also drawn attention to a stage of disease apparently forgotten for decades. Stage III NSCLC can represent an interesting setting for the combined use of chemo-radiation and immunotherapy, due to the potential synergistic effect between radiation and immune checkpoint inhibitors. We reviewed the available literature in order to report the state of art of stage III NSCLC, by focusing on trials that evaluate different combinations of CRT and new drugs of PD-1/PD-L1 axis, and anti-CTLA-4. The future goal in the management of unresectable stage III NSCLC will be the optimal patients’ selection combined with the use of individualized immuno/chemotherapies that could potentially improve clinical outcomes. © 2020, Federación de Sociedades Españolas de Oncología (FESEO).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 13} -} - -@ARTICLE{Kaen2021113, - author = {Kaen, Diego L. and Minatta, Nicolas and Russo, Alessandro and Malapelle, Umberto and de Miguel-Pérez, Diego and Rolfo, Christian}, - title = {Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?}, - year = {2021}, - journal = {Advances in Experimental Medicine and Biology}, - volume = {1342}, - pages = {113 – 142}, - doi = {10.1007/978-3-030-79308-1_4}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122459754&doi=10.1007%2f978-3-030-79308-1_4&partnerID=40&md5=7dac3879013f99bcde2dcca7d0bb1afa}, - abstract = {Over the last few years, agents targeting immune checkpoints have shown potential to improve therapeutic outcomes in patients with lung cancer in multiple clinical settings. Inhibitors of PD-1/PD-L1 have been approved for the treatment of different types of lung cancer by the FDA either alone or in combination with chemotherapy or other immune checkpoint inhibitors, such as anti-CTLA-4 agents. The introduction of these agents in clinical practice has revolutionized the therapeutic approach to lung cancer, keeping the promises of long-term benefit in selected patient populations. The therapeutic indications of immunotherapy in lung cancer are rapidly growing, and multiple combinations entered clinical practice or are under active development. Furthermore, the quest for a reliable predictive biomarker is still ongoing to overcome the limits of currently approved tests for patients’ selection. In this review, we summarized the current status and progress of anti-PD-1/PD-L1 agents in lung cancer treatment. © 2021, The Author(s), under exclusive license to Springer Nature Switzerland AG.}, - type = {Book chapter}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4} -} - -@ARTICLE{Shaverdian20201719, - author = {Shaverdian, N. and Beattie, J. and Thor, M. and Offin, M. and Shepherd, A.F. and Gelblum, D.Y. and Wu, A.J. and Simone, C.B. and Hellmann, M.D. and Chaft, J.E. and Rimner, A. and Gomez, D.R.}, - title = {Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors}, - year = {2020}, - journal = {Annals of Oncology}, - volume = {31}, - number = {12}, - pages = {1719 – 1724}, - doi = {10.1016/j.annonc.2020.09.016}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85093934442&doi=10.1016%2fj.annonc.2020.09.016&partnerID=40&md5=bf0eeef82bfe77be3819fe0bfc014e07}, - abstract = {Background: Immune checkpoint inhibitors (ICIs) and thoracic radiotherapy are increasingly used to treat advanced cancers. Despite data indicating exaggerated radiation toxicities in patients with autoimmune disease, the safety of thoracic radiotherapy in patients with prior ICI-associated immune-related adverse events (irAEs) is undefined. Patients and methods: Patients treated from 2014 to 2020 with ICIs were queried for receipt of corticosteroids and radiotherapy. Patients who received thoracic radiation after symptomatic irAEs were assessed for ≥grade 2 radiation pneumonitis (RP). Characteristics predictive of RP were assessed using logistic regression and response relationships were modeled. Results: Among 496 assessed patients, 41 with irAE history subsequently treated with thoracic radiotherapy were analyzed. Most irAEs were grade 2 (n = 21) and 3 (n = 19). Median time from irAE onset to radiotherapy was 8.1 months. Most patients received stereotactic body radiation therapy (n = 20) or hypofractionated radiotherapy (n = 18). In total, 25 patients (61%) developed ≥grade 2 RP at a median of 4 months from radiotherapy and 11 months from onset of irAEs. Three months from RP onset, 16 of 24 (67%) assessable patients had persistent symptoms. Among patients with prior ICI pneumonitis (n = 6), five patients (83%) developed ≥grade 2 RP (grade 2, n = 3; grade ≥3, n = 2). The mean lung radiation dose (MLD) predicted for RP (odds ratio: 1.60, P = 0.00002). The relationship between MLD and RP was strong (area under the receiver-operating characteristic curve: 0.85) and showed an exaggerated dose-response. Among patients with an MLD >5 Gy (n = 26), 21 patients (81%) developed ≥grade 2 RP. Conclusion: This is the first study assessing the toxicity of radiotherapy among patients with prior irAEs from ICIs. Patients with prior irAEs were found to be at very high risk for clinically significant and persistent RP from thoracic radiotherapy. Careful consideration should be given to the possibility of an increased risk of RP, and close monitoring is recommended in these patients. © 2020 European Society for Medical Oncology}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 25; All Open Access, Bronze Open Access} -} - -@ARTICLE{Crombet Ramos2021, - author = {Crombet Ramos, Tania and Santos Morales, Orestes and Dy, Grace K. and León Monzón, Kalet and Lage Dávila, Agustín}, - title = {The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer}, - year = {2021}, - journal = {Frontiers in Oncology}, - volume = {11}, - doi = {10.3389/fonc.2021.639745}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118904945&doi=10.3389%2ffonc.2021.639745&partnerID=40&md5=0f286d61183ca6051cc52ecc42566761}, - abstract = {Advanced non-small cell lung cancer (NSCLC) has faced a therapeutic revolution with the advent of tyrosine kinase inhibitors (TKIs) and immune checkpoints inhibitors (ICIs) approved for first and subsequent therapies. CIMAvax-EGF is a chemical conjugate between human-recombinant EGF and P64, a recombinant protein from Neisseria meningitides, which induces neutralizing antibodies against EGF. In the last 15 years, it has been extensively evaluated in advanced NSCLC patients. CIMAvax-EGF is safe, even after extended use, and able to keep EGF serum concentration below detectable levels. In a randomized phase III study, CIMAvax-EGF increased median overall survival of advanced NSCLC patients with at least stable disease after front-line chemotherapy. Patients bearing squamous-cell or adenocarcinomas and serum EGF concentration above 870 pg/ml had better survival compared to control patients treated with best supportive care as maintenance, confirming tumors’ sensitivity to the EGF depletion. This manuscript reviews the state-of-the-art NSCLC therapy and proposes the most promising scenarios for evaluating CIMAvax-EGF, particularly in combination with TKIs or ICIs. We hypothesize that the optimal combination of CIMAvax-EGF with established therapies can further contribute to transform advanced cancer into a manageable chronic disease, compatible with years of good quality of life. © Copyright © 2021 Crombet Ramos, Santos Morales, Dy, León Monzón and Lage Dávila.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 7; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Larribère2021, - author = {Larribère, Lionel and Martens, Uwe M.}, - title = {Advantages and challenges of using ctdna ngs to assess the presence of minimal residual disease (Mrd) in solid tumors}, - year = {2021}, - journal = {Cancers}, - volume = {13}, - number = {22}, - doi = {10.3390/cancers13225698}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118859419&doi=10.3390%2fcancers13225698&partnerID=40&md5=ff501e2424e55c052295ca24fe3f5de0}, - abstract = {The ability to detect minimal residual disease (MRD) after a curative-intent surgery or treatment is of paramount importance, because it offers the possibility to help guide the clinical decisions related adjuvant therapy. Thus, the earlier MRD is detected, the earlier potentially beneficial treatment can be proposed to patients who might need it. Liquid biopsies, and in particular the next-generation sequencing of circulating tumor DNA (ctDNA) in the blood, have been the focus of an increasing amount of research in the past years. The ctDNA detection at advanced cancer stages is practicable for several solid tumors, and complements molecular information on acquired therapy resistance. In the context of MRD, it is by definition more challenging to detect ctDNA, but it is technically achievable and provides information on treatment response and probability of relapse significantly earlier than standard imaging methods. The clinical benefit of implementing this new technique in the routine is being tested in interventional clinical trials at the moment. We propose here an update of the current use of ctDNA detection by NGS as a tool to assess the presence of MRD and improve adjuvant treatment of solid tumors. We also discuss the main limitations and medium-term perspectives of this process in the clinic. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 30; All Open Access, Gold Open Access} -} - -@ARTICLE{Ready2021302, - author = {Ready, Neal Edward}, - title = {What’s next for immunotherapy in locally advanced nsclc?}, - year = {2021}, - journal = {Clinical Advances in Hematology and Oncology}, - volume = {19}, - number = {5}, - pages = {302 – 304}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106503402&partnerID=40&md5=25b9ff50255ce02c4ce87114037ea724}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Grant202175, - author = {Grant, Michael J. and Politi, Katerina and Gettinger, Scott}, - title = {Immune Therapy: What Can We Learn From Acquired Resistance?}, - year = {2021}, - journal = {Current Cancer Research}, - pages = {75 – 114}, - doi = {10.1007/978-3-030-74028-3_5}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116897581&doi=10.1007%2f978-3-030-74028-3_5&partnerID=40&md5=ad61fd1903f02ef3acdd97772acc55e8}, - abstract = {Programmed death-1 (PD-1) pathway inhibitors have revolutionized the treatment of locally advanced and advanced non-small cell lung cancer (NSCLC). Response to these agents can be durable, but most patients will go on to develop resistance after initial tumor regression or prolonged disease stability. In patients with ‘acquired oligo-resistance,’ in whom progression is limited to two or less disease sites, local therapy may be an effective management strategy. For those experiencing systemic progression, immunotherapy based combinations are currently under investigation. Translational work has uncovered neoantigen loss and antigen processing/presentation defects as mediators of resistance to PD-1 axis inhibitors NSCLC. In other tumor types, defects in IFN- γ signaling, upregulation of alternative immune checkpoint pathways, and various tumor genomic or epigenetic changes have been implicated. In this review, we propose clinical criteria, highlight emerging management strategies, and discuss mechanistic insights into acquired resistance to PD-1 axis inhibitors in NSCLC. © 2021, Springer Nature Switzerland AG.}, - type = {Book chapter}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Remon2020914, - author = {Remon, Jordi and Passiglia, Francesco and Ahn, Myung-Ju and Barlesi, Fabrice and Forde, Patrick M. and Garon, Edward B. and Gettinger, Scott and Goldberg, Sarah B. and Herbst, Roy S. and Horn, Leora and Kubota, Kaoru and Lu, Shun and Mezquita, Laura and Paz-Ares, Luis and Popat, Sanjay and Schalper, Kurt A. and Skoulidis, Ferdinandos and Reck, Martin and Adjei, Alex A. and Scagliotti, Giorgio V.}, - title = {Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations}, - year = {2020}, - journal = {Journal of Thoracic Oncology}, - volume = {15}, - number = {6}, - pages = {914 – 947}, - doi = {10.1016/j.jtho.2020.03.006}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083154483&doi=10.1016%2fj.jtho.2020.03.006&partnerID=40&md5=a9616360990ef9c3653789c2f50ea838}, - abstract = {In the past 10 years, a deeper understanding of the immune landscape of cancers, including immune evasion processes, has allowed the development of a new class of agents. The reactivation of host antitumor immune response offers the potential for long-term survival benefit in a portion of patients with thoracic malignancies. The advent of programmed cell death protein 1/programmed death ligand-1 immune checkpoint inhibitors (ICIs), both as single agents and in combination with chemotherapy, and more recently, the combination of ICI, anti–programmed cell death protein 1, and anticytotoxic T-lymphocyte antigen 4 antibody, have led to breakthrough therapeutic advances for patients with advanced NSCLC, and to a lesser extent, patients with SCLC. Encouraging activity has recently emerged in pretreated patients with thymic carcinoma (TC). Conversely, in malignant pleural mesothelioma, pivotal positive signs of activity have not been fully confirmed in randomized trials. The additive effects of chemoradiation and immunotherapy suggested intriguing potential for therapeutic synergy with combination strategies. This has led to the introduction of ICI consolidation therapy in stage III NSCLC, creating a platform for future therapeutic developments in earlier-stage disease. Despite the definitive clinical benefit observed with ICI, primary and acquired resistance represent well-known biological phenomena, which may affect the therapeutic efficacy of these agents. The development of innovative strategies to overcome ICI resistance, standardization of new patterns of ICI progression, identification of predictive biomarkers of response, optimal treatment duration, and characterization of ICI efficacy in special populations, represent crucial issues to be adequately addressed, with the aim of improving the therapeutic benefit of ICI in patients with thoracic malignancies. In this article, an international panel of experts in the field of thoracic malignancies discussed these topics, evaluating currently available scientific evidence, with the final aim of providing clinical recommendations, which may guide oncologists in their current practice and elucidate future treatment strategies and research priorities. © 2020 International Association for the Study of Lung Cancer}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 129; All Open Access, Bronze Open Access} -} - -@ARTICLE{Wojas-Krawczyk2021, - author = {Wojas-Krawczyk, Kamila and Krawczyk, Paweł and Gil, Michał and Strzemski, Maciej}, - title = {Two complementarity immunotherapeutics in non-small-cell lung cancer patients—mechanism of action and future concepts}, - year = {2021}, - journal = {Cancers}, - volume = {13}, - number = {11}, - doi = {10.3390/cancers13112836}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107316359&doi=10.3390%2fcancers13112836&partnerID=40&md5=cd78b3eaa94cc392c8251b50ef57ae8e}, - abstract = {Due to the limited effectiveness of immunotherapy used as first-line monotherapy in patients with non-small-cell lung cancer (NSCLC), the concepts of combining classical immunotherapy based on immune checkpoint antibodies with other treatment methods have been developed. Pembrolizumab and atezolizumab were registered in combination with chemotherapy for the treatment of metastatic NSCLC, while durvalumab found its application in consolidation therapy after successful chemoradiotherapy in patients with locally advanced NSCLC. Exceptionally attractive, due to their relatively low toxicity and high effectiveness, are treatment approaches in which a combination of two different immunotherapy methods is applied. This method is based on observations from clinical trials in which nivolumab and ipilimumab were used as first-line therapy for advanced NSCLC. It turned out that the dual blockade of immune checkpoints activated T lymphocytes in different compartments of the immune response, at the same time affecting the downregulation of immune suppressor cells (regulatory T cells). These experiments not only resulted in the registration of combination therapy with nivolumab and ipilimumab, but also initiated other clinical trials using immune checkpoint inhibitors (ICIs) in combination with other ICIs or activators of costimulatory molecules found on immune cells. There are also studies in which ICIs are associated with molecules that modify the tumour environment. This paper describes the mechanism of the synergistic effect of a combination of different immunotherapy methods in NSCLC patients. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Gold Open Access} -} - -@ARTICLE{Di Cintio2020, - author = {Di Cintio, Federica and Dal Bo, Michele and Baboci, Lorena and De Mattia, Elena and Polano, Maurizio and Toffoli, Giuseppe}, - title = {The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices}, - year = {2020}, - journal = {Frontiers in Neuroscience}, - volume = {14}, - doi = {10.3389/fnins.2020.603647}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097430262&doi=10.3389%2ffnins.2020.603647&partnerID=40&md5=917c39f80aeeda9ebacaaa3fc616bc29}, - abstract = {Glioblastoma (GBM) is the most frequent and aggressive primary central nervous system tumor. Surgery followed by radiotherapy and chemotherapy with alkylating agents constitutes standard first-line treatment of GBM. Complete resection of the GBM tumors is generally not possible given its high invasive features. Although this combination therapy can prolong survival, the prognosis is still poor due to several factors including chemoresistance. In recent years, a comprehensive characterization of the GBM-associated molecular signature has been performed. This has allowed the possibility to introduce a more personalized therapeutic approach for GBM, in which novel targeted therapies, including those employing tyrosine kinase inhibitors (TKIs), could be employed. The GBM tumor microenvironment (TME) exerts a key role in GBM tumor progression, in particular by providing an immunosuppressive state with low numbers of tumor-infiltrating lymphocytes (TILs) and other immune effector cell types that contributes to tumor proliferation and growth. The use of immune checkpoint inhibitors (ICIs) has been successfully introduced in numerous advanced cancers as well as promising results have been shown for the use of these antibodies in untreated brain metastases from melanoma and from non-small cell lung carcinoma (NSCLC). Consequently, the use of PD-1/PD-L1 inhibitors has also been proposed in several clinical trials for the treatment of GBM. In the present review, we will outline the main GBM molecular and TME aspects providing also the grounds for novel targeted therapies and immunotherapies using ICIs for GBM. © Copyright © 2020 Di Cintio, Dal Bo, Baboci, De Mattia, Polano and Toffoli.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 30; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Konala2020749, - author = {Konala, Venu Madhav and Madhira, Bhaskar Reddy and Ashraf, Sara and Graziano, Stephen}, - title = {Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer}, - year = {2020}, - journal = {Oncology (Switzerland)}, - volume = {98}, - number = {11}, - pages = {749 – 754}, - doi = {10.1159/000508516}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088367074&doi=10.1159%2f000508516&partnerID=40&md5=0a6da327b1befa2490159838ad1c0005}, - abstract = {Lung cancer is a leading cause of cancer death in the United States and around the world. Approximately 13% of lung cancers are small cell lung cancer (SCLC). SCLC is generally classified as a limited-stage and extensive-stage disease depending on the extent of involvement. For patients with the extensive-stage disease, until recently, chemotherapy alone has been the recommended treatment, although radiotherapy could be used in select patients for palliation of symptoms. The standard of care for extensive-stage SCLC is platinum doublet chemotherapy with either cisplatin or carboplatin in combination with etoposide. Even though first-line therapy has an initial response rate of 60-80%, the prognosis is poor, with overall survival of 10-12 months. The only FDA-approved second line of therapy is topotecan, approved both as an intravenous formulation as well as an oral formulation, with response rates of 6-12% in chemorefractory disease and 15-37% in chemosensitive disease. Immunotherapy has recently been approved as a first-line agent in metastatic SCLC in combination with chemotherapy. It is also approved as a third-line agent in metastatic SCLC after the failure of two chemotherapy regimens. The FDA approved four drugs, two of them being PD-1 inhibitors (pembrolizumab, nivolumab), and two of them being PD-L1 inhibitors (atezolizumab and durvalumab) in SCLC. This review article summarizes the significance of immunotherapy in the treatment of extensive-stage SCLC, its side effects, and limitations. © 2020 S. Karger AG, Basel.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 21} -} - -@ARTICLE{Frak20211, - author = {Frak, Małgorzata and Krawczyk, Paweł and Kalinka, Ewa and Milanowski, Janusz}, - title = {Molecular and clinical premises for the combination therapy consisting of radiochemotherapy and immunotherapy in non-small cell lung cancer patients}, - year = {2021}, - journal = {Cancers}, - volume = {13}, - number = {6}, - pages = {1 – 15}, - doi = {10.3390/cancers13061222}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102964851&doi=10.3390%2fcancers13061222&partnerID=40&md5=7b022a93e564e0e9b2f2b8e3cf9e9c9b}, - abstract = {Non-small cell lung cancer (NSCLC) is one of the most common malignancies around the world. Due to the advanced stage of the disease at the time of diagnosis, most patients require systemic treatment. Immunotherapy with immune checkpoints inhibitors is becoming the main treatment method for many cancers, including NSCLC. Numerous studies have shown greater efficacy of immunotherapy used monoclonal antibodies anti-PD-1 (pembrolizumab and nivolumab) or anti-PD-L1 (atezolizumab and durvalumab) compared to chemotherapy. Unfortunately, cancer cells can develop a number of mechanisms to escape from immune surveillance, including avoid-ance of cancer cells by the immune system (immune desert), production of immunosuppressive compounds (prostaglandins, IDO, TGF-beta), or direct immune checkpoints interactions. Therapy based on the use of radiochemotherapy with subsequent immunotherapy is becoming the main focus of research in the field of new NSCLC therapies. Radiation therapy stimulates the immune response multidirectionally, affects production of neoantigens and proinflammatory compounds, which transform non-immunogenic (“cold”) tumors into highly immunogenic (“hot”) tumors. As a result, the mechanisms of escape of cancer cells from immune surveillance break down and the effectiveness of immunotherapy increases significantly. The results of clinical trials in this area bring new hope and indicate greater effectiveness of such treatment in terms of prolongation of progression-free survival and overall survival. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 10; All Open Access, Gold Open Access} -} - -@ARTICLE{Remon20211637, - author = {Remon, J. and Soria, J.-C. and Peters, S.}, - title = {Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy}, - year = {2021}, - journal = {Annals of Oncology}, - volume = {32}, - number = {12}, - pages = {1637 – 1642}, - doi = {10.1016/j.annonc.2021.08.1994}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116904774&doi=10.1016%2fj.annonc.2021.08.1994&partnerID=40&md5=74af21edcc502df0c72696e5195c174c}, - type = {Letter}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 195; All Open Access, Bronze Open Access} -} - -@ARTICLE{Agrawal2021, - author = {Agrawal, Vishesh and Benjamin, Kimberly Thomas and Ko, Eric C.}, - title = {Radiotherapy and Immunotherapy Combinations for Lung Cancer}, - year = {2021}, - journal = {Current Oncology Reports}, - volume = {23}, - number = {1}, - doi = {10.1007/s11912-020-00993-w}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096289591&doi=10.1007%2fs11912-020-00993-w&partnerID=40&md5=7ba37cd8ff6bff3e0594616475952fc1}, - abstract = {Purpose of Review: Positive results from recent immunotherapy trials of non-small cell lung cancer (NSCLC) have coincided with a greater appreciation for the impact of radiation therapy (RT) on tumor immunity. Here, we summarize key clinical findings and ongoing efforts to combine immunotherapy and RT for the treatment of NSCLC. Recent Findings: The role of immunotherapy for NSCLC has expanded significantly following the pivotal approvals of nivolumab and pembrolizumab for metastatic NSCLC, maintenance durvalumab in unresectable stage III NSCLC, and atezolizumab for metastatic NSCLC. Several small early-phase trials have demonstrated the ability of RT to elicit clinically significant tumor immunity. These positive findings support current trial efforts combining RT with immunotherapy for NSCLC. Summary: Recently initiated trials of RT and immunotherapy hold significant promise in expanding the therapeutic options for NSCLC. Optimization of therapy will require careful patient selection to yield meaningful improvements in clinical outcomes. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12} -} - -@ARTICLE{Mielgo-Rubio2021, - author = {Mielgo-Rubio, Xabier and Montemuiño, Sara and Jiménez, Unai and Luna, Javier and Cardeña, Ana and Mezquita, Laura and Martín, Margarita and Couñago, Felipe}, - title = {Management of resectable stage iii-n2 non-small-cell lung cancer (Nsclc) in the age of immunotherapy}, - year = {2021}, - journal = {Cancers}, - volume = {13}, - number = {19}, - doi = {10.3390/cancers13194811}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115774009&doi=10.3390%2fcancers13194811&partnerID=40&md5=c44f0e639fff3f1ce3729ffe24720b35}, - abstract = {Stage III non-small-cell lung cancer (NSCLC) with N2 lymph node involvement is a heterogeneous group with different potential therapeutic approaches. Patients with potentially resectable III-N2 NSCLC are those who are considered to be able to receive a multimodality treatment that includes tumour resection after neoadjuvant therapy. Current treatment for these patients is based on neoadjuvant chemotherapy +/− radiotherapy followed by surgery and subsequent assessment for adjuvant chemotherapy and/or radiotherapy. In addition, some selected III-N2 patients could receive upfront surgery or pathologic N2 incidental involvement can be found a posteriori during analysis of the surgical specimen. The standard treatment for these patients is adjuvant chemotherapy and evaluation for complementary radiotherapy. Despite being a locally advanced stage, the cure rate for these patients continues to be low, with a broad improvement margin. The most immediate hope for improving survival data and curing these patients relies on integrating immunotherapy into perioperative treatment. Immunotherapy based on anti-PD1/PD-L1 immune checkpoint inhibitors is already a standard treatment in stage III unresectable and advanced NSCLC. Data from the first phase II studies in monotherapy neoadjuvant therapy and, in particular, in combination with chemotherapy, are highly promising, with impressive improved and complete pathological response rates. Despite the lack of confirmatory data from phase III trials and longterm survival data, and in spite of various unresolved questions, immunotherapy will soon be incorporated into the armamentarium for treating stage III-N2 NSCLC. In this article, we review all therapeutic approaches to stage III-N2 NSCLC, analysing both completed and ongoing studies that evaluate the addition of immunotherapy with or without chemotherapy and/or radiotherapy. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 18; All Open Access, Gold Open Access} -} - -@ARTICLE{Mielgo-Rubio20201, - author = {Mielgo-Rubio, Xabier and Calvo, Virginia and Luna, Javier and Remon, Jordi and Martín, Margarita and Berraondo, Pedro and Jarabo, José Ramón and Higuera, Oliver and Conde, Esther and De Castro, Javier and Provencio, Mariano and Trancho, Florentino Hernando and López-Ríos, Fernando and Couñago, Felipe}, - title = {Immunotherapy moves to the early-stage setting in non-small cell lung cancer: Emerging evidence and the role of biomarkers}, - year = {2020}, - journal = {Cancers}, - volume = {12}, - number = {11}, - pages = {1 – 21}, - doi = {10.3390/cancers12113459}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096455198&doi=10.3390%2fcancers12113459&partnerID=40&md5=414755b64ed3e0d0d7bf66955860571c}, - abstract = {Despite numerous advances in targeted therapy and immunotherapy in the last decade, lung cancer continues to present the highest mortality rate of all cancers. Targeted therapy based on specific genomic alterations, together with PD-1 and CTLA-4 axis blocking-based immunotherapy, have significantly improved survival in advanced non-small cell lung cancer (NSCLC) and both therapies are now well-established in this clinical setting. However, it is time for immunotherapy to be applied in patients with early-stage disease, which would be an important qualitative leap in the treatment of lung cancer patients with curative intent. Preliminary data from a multitude of studies are highly promising, but therapeutic decision-making should be guided by an understanding of the molecular features of the tumour and host. In the present review, we discuss the most recently published studies and ongoing clinical trials, controversies, future challenges and the role of biomarkers in the selection of best therapeutic options. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 13; All Open Access, Gold Open Access} -} - -@ARTICLE{Manzo2020775, - author = {Manzo, Anna and Carillio, Guido and Montanino, Agnese and Sforza, Vincenzo and Palumbo, Giuliano and Esposito, Giovanna and Costanzo, Raffaele and Sandomenico, Claudia and La Manna, Carmine and Martucci, Nicola and La Rocca, Antonello and De Luca, Giuseppe and Piccirillo, Maria Carmela and De Cecio, Rossella and Botti, Gerardo and Totaro, Giuseppe and Muto, Paolo and Picone, Carmine and Normanno, Nicola and Morabito, Alessandro}, - title = {The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer}, - year = {2020}, - journal = {Expert Opinion on Drug Safety}, - volume = {19}, - number = {7}, - pages = {775 – 783}, - doi = {10.1080/14740338.2020.1767584}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085990962&doi=10.1080%2f14740338.2020.1767584&partnerID=40&md5=e5530fedff01d8fcd0ebb2fceb4fc1ac}, - abstract = {Introduction: Atezolizumab is a humanized monoclonal antibody against PD-L1 capable of enhancing antitumor immune activity, with a demonstrated activity as single agent in patients with advanced non-small-cell lung cancer (NSCLC). Areas covered: This review summarizes the clinical data emerging from randomized clinical studies with atezolizumab in NSCLC and small-cell lung cancer (SCLC), focusing in particular on the efficacy and safety data regarding the combinations of atezolizumab plus chemotherapy in the IMpower studies. Expert opinion: A significant improvement in progression-free survival and in overall survival was observed in IMpower 130 and 150 (NSCLC non-squamous) and 133 (SCLC), with an acceptable safety profile. In particular, the most common immune-related adverse events were rash (18–28% of patients), hypothyroidism (8–15%), hepatitis (5–17%), pneumonitis (2–7%), and colitis (1.5–2.3%). The safety profile of atezolizumab in combination with chemotherapy was consistent with the known adverse events related to single-agent atezolizumab and no new adverse events were observed. Ongoing studies will evaluate the role of atezolizumab in other settings (adjuvant and neoadjuvant) and in combination with chemotherapy and radiotherapy for patients with locally advanced NSCLC and the role of predictive factors (B-FAST study). © 2020 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3} -} - -@ARTICLE{Zichi202149, - author = {Zichi, Clizia and Paratore, Chiara and Gargiulo, Piera and Mariniello, Annapaola and Reale, Maria Lucia and Audisio, Marco and Bungaro, Maristella and Caglio, Andrea and Gamba, Teresa and Perrone, Francesco and Di Maio, Massimo}, - title = {Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review}, - year = {2021}, - journal = {European Journal of Cancer}, - volume = {149}, - pages = {49 – 60}, - doi = {10.1016/j.ejca.2021.03.007}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103559501&doi=10.1016%2fj.ejca.2021.03.007&partnerID=40&md5=64fa6a7784f71cfb72387523b2beba58}, - abstract = {Background and aim: Trial designs using multiple primary endpoints (MPEs) are increasing in phase III cancer trials. Our objectives were to describe the incidence of MPEs in recently published phase III trials testing systemic treatments in patients with advanced cancer; the main characteristics of trials adopting MPEs; the presence of mature results for all endpoints in the primary publication; consistency between results of each endpoint and authors’ conclusions. Methods: Articles of randomised phase III trials conducted in patients with advanced cancer, published between 2017 and 2020, were retrieved from PubMed. The main outcome was the proportion of trials with MPEs. In principle, according to regulatory agencies, we considered two distinct cases: (i) MPEs correspond to ‘multiple chances’ for the success of experimental treatment, needing adjustment for multiplicity, and (ii) a positive result depends on the success in all MPEs (‘co-primary’ endpoints). Results: Out of 235 eligible trials, 27 trials (12%) adopted MPE, mostly overall survival (OS) and progression-free survival (PFS). The proportion of trials with MPEs increased over time, from 6% in 2017 to 20% in 2020 (p = 0.025). MPEs were adopted in 16% of for-profit trials versus 4% of non-profit trials (p = 0.006). The proportion of trials adopting MPEs was particularly high with immunotherapy (53%, p < 0.00001). Out of 27 trials with MPEs, 10 (37%) adopted an explicit definition of ‘co-primary’ endpoints, but only 1/10 declared the positivity of both endpoints critical for interpretation. Most trials (23, 85%) planned correction for multiplicity. Of 21 publications with positive conclusions, only 12 had a statistically significant positive result in both primary endpoints. In four cases (15%), positive conclusions were based on PFS results alone. Conclusions: Adoption of MPEs in randomised trials in oncology is quite common. Only a minority of trials respect recommendations by regulatory agencies about the adoption of MPEs, definition of ‘co-primary’ endpoints and correction for multiplicity. © 2021 Elsevier Ltd}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 2; All Open Access, Green Open Access} -} - -@ARTICLE{Esposito20201, - author = {Esposito, Giovanna and Palumbo, Giuliano and Carillio, Guido and Manzo, Anna and Montanino, Agnese and Sforza, Vincenzo and Costanzo, Raffaele and Sandomenico, Claudia and La Manna, Carmine and Martucci, Nicola and La Rocca, Antonello and De Luca, Giuseppe and Piccirillo, Maria Carmela and De Cecio, Rossella and Botti, Gerardo and Totaro, Giuseppe and Muto, Paolo and Picone, Carmine and Normanno, Nicola and Morabito, Alessandro}, - title = {Immunotherapy in small cell lung cancer}, - year = {2020}, - journal = {Cancers}, - volume = {12}, - number = {9}, - pages = {1 – 17}, - doi = {10.3390/cancers12092522}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85093910505&doi=10.3390%2fcancers12092522&partnerID=40&md5=a0889786fadce8f6e50dd25d27758878}, - abstract = {Small-cell lung cancer (SCLC) is an aggressive tumor type with limited therapeutic options and poor prognosis. Chemotherapy regimens containing platinum represent the cornerstone of treatment for patients with extensive disease, but there has been no real progress for 30 years. The evidence that SCLC is characterized by a high mutational burden led to the development of immune-checkpoint inhibitors as single agents or in combination with chemotherapy. Randomized phase III trials demonstrated that the combination of atezolizumab (IMpower-133) or durvalumab (CASPIAN) with platinum-etoposide chemotherapy improved overall survival of patients with extensive disease. Instead, the KEYNOTE-604 study demonstrated that the addition of pembrolizumab to chemotherapy failed to significantly improve overall survival, but it prolonged progression-free survival. The safety profile of these combinations was similar with the known safety profiles of all single agents and no new adverse events were observed. Nivolumab and pembrolizumab single agents showed anti-tumor activity and acceptable safety profile in Checkmate 032 and KEYNOTE 028/158 trials, respectively, in patients with SCLC after platinum-based therapy and at least one prior line of therapy. Future challenges are the identification predictive biomarkers of response to immunotherapy in SCLC and the definition of the role of immunotherapy in patients with limited stage SCLC, in combination with radiotherapy or with other biological agents. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 67; All Open Access, Gold Open Access} -} - -@ARTICLE{Williams2021439, - author = {Williams, Terence M.}, - title = {Stereotactic body radiation therapy in advanced nsclc}, - year = {2021}, - journal = {Clinical Advances in Hematology and Oncology}, - volume = {19}, - number = {7}, - pages = {439 – 441}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85110972198&partnerID=40&md5=a22e473995921b7093db68dedbe611b6}, - type = {Note}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Kang2021287, - author = {Kang, Jin and Zhang, Chao and Zhong, Wen-Zhao}, - title = {Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art}, - year = {2021}, - journal = {Cancer Communications}, - volume = {41}, - number = {4}, - pages = {287 – 302}, - doi = {10.1002/cac2.12153}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102241762&doi=10.1002%2fcac2.12153&partnerID=40&md5=71a122f1ffa808b19e0c857429e6474c}, - abstract = {Lung cancer mortality has decreased over the past decade and can be partly attributed to advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have rapidly evolved from investigational drugs to standard of care for the treatment of metastatic non-small cell lung cancer (NSCLC). In particular, antibodies that block inhibitory immune checkpoints, such as programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1), have revolutionized the treatment of advanced NSCLC, when administered alone or in combination with chemotherapy. Immunotherapy is associated with higher response rates, improved overall survival (OS), and increased tolerability compared with conventional cytotoxic chemotherapy. These benefits may increase the utility of immunotherapy and its combinational use with chemotherapy in the neoadjuvant treatment of patients with NSCLC. Early findings from various ongoing clinical trials suggest that neoadjuvant ICIs alone or combined with chemotherapy may significantly reduce systemic recurrence and improve long-term OS or cure rates in resectable NSCLC. Here we further summarize the safety and efficacy of various neoadjuvant treatment regimens including immunotherapy from ongoing clinical trials and elaborate the role of neoadjuvant immunotherapy in patients with resectable NSCLC. In addition, we discuss several unresolved challenges, including the evaluations to assess neoadjuvant immunotherapy response, the role of adjuvant treatment after neoadjuvant immunotherapy, the efficacy of treatment for oncogenic-addicted tumors, and predictive biomarkers. We also provide our perspective on ways to overcome current obstacles and establish neoadjuvant immunotherapy as a standard of care. © 2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 92; All Open Access, Green Open Access} -} - -@ARTICLE{Riano2021441, - author = {Riano, Ivy and Patel, Shruti R. and Liu, Stephen V. and Duma, Narjust}, - title = {Evidence to date: Evaluating Pembrolizumab in the treatment of extensive-stage small-cell lung cancer}, - year = {2021}, - journal = {Clinics and Practice}, - volume = {11}, - number = {3}, - pages = {441 – 454}, - doi = {10.3390/clinpract11030059}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136675010&doi=10.3390%2fclinpract11030059&partnerID=40&md5=efb2c9c316c40ff288e3f0a48b873e33}, - abstract = {Small-cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by a rapid initial response and early development of resistance to systemic therapy and radiation. The management of SCLC significantly changed for the first time in decades with the introduction of immune checkpoint inhibitors. Pembrolizumab, a humanized IgG4 isotype antibody, targets the programmed cell death protein 1 (PD-1) pathway to restore anti-tumor immunity. Prospective trials of pembrolizumab in patients with previously treated SCLC showed significant durability of responses. These results led to the U.S. Food and Drug Administration (FDA) granting pembrolizumab accelerated approval as second- or third-line monotherapy for patients with extensive-stage (ES) SCLC. In a recent clinical trial that included patients with previously untreated ES-SCLC, pembrolizumab in combination with platinum/etoposide met its progression-free survival endpoint, but overall survival (OS) did not cross the threshold for superiority. With the therapeutic landscape for SCLC rapidly evolving, we review prior experience and future directions of pembrolizumab in ES-SCLC. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Gold Open Access} -} - -@ARTICLE{Yang20201, - author = {Yang, Minfeng and Oh, In Young and Mahanty, Arpan and Jin, Wei-Lin and Yoo, Jung Sun}, - title = {Immunotherapy for glioblastoma: Current state, challenges, and future perspectives}, - year = {2020}, - journal = {Cancers}, - volume = {12}, - number = {9}, - pages = {1 – 23}, - doi = {10.3390/cancers12092334}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089667601&doi=10.3390%2fcancers12092334&partnerID=40&md5=c20024ee609e52ef83138684334a2418}, - abstract = {Glioblastoma is the most lethal intracranial primary malignancy by no optimal treatment option. Cancer immunotherapy has achieved remarkable survival benefits against various advanced tumors, such as melanoma and non-small-cell lung cancer, thus triggering great interest as a new therapeutic strategy for glioblastoma. Moreover, the central nervous system has been rediscovered recently as a region for active immunosurveillance. There are vibrant investigations for successful glioblastoma immunotherapy despite the fact that initial clinical trial results are somewhat disappointing with unique challenges including T-cell dysfunction in the patients. This review will explore the potential of current immunotherapy modalities for glioblastoma treatment, especially focusing on major immune checkpoint inhibitors and the future strategies with novel targets and combo therapies. Immune-related adverse events and clinical challenges in glioblastoma immunotherapy are also summarized. Glioblastoma provides persistent difficulties for immunotherapy with a complex state of patients’ immune dysfunction and a variety of constraints in drug delivery to the central nervous system. However, rational design of combinational regimens and new focuses on myeloid cells and novel targets to circumvent current limitations hold promise to advent truly viable immunotherapy for glioblastoma. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 20; All Open Access, Gold Open Access} -} - -@ARTICLE{Paz-Ares2020, - author = {Paz-Ares, Luis}, - title = {Foreword to ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’}, - year = {2020}, - journal = {British Journal of Cancer}, - volume = {123}, - doi = {10.1038/s41416-020-01068-0}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097287146&doi=10.1038%2fs41416-020-01068-0&partnerID=40&md5=897bb60b3a33de47c09f5b5fbd4c749d}, - type = {Editorial}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Green Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Ackermann20201783, - author = {Ackermann, Christoph Jakob and Adderley, Helen and Ortega-Franco, Ana and Khan, Adeel and Reck, Martin and Califano, Raffaele}, - title = {First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions}, - year = {2020}, - journal = {Drugs}, - volume = {80}, - number = {17}, - pages = {1783 – 1797}, - doi = {10.1007/s40265-020-01409-6}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091680492&doi=10.1007%2fs40265-020-01409-6&partnerID=40&md5=744147dd4fd25c039a2f656338b6db92}, - abstract = {The advent of PD-(L)1 and CTLA-4 immune check point inhibitors (CPIs) has dramatically changed the treatment landscape of advanced non-small-cell lung cancer (NSCLC). For up to a quarter of patients with advanced NSCLC, CPIs have the potential to induce durable responses with long-term survival outcomes. Since the approval of first-line pembrolizumab for patients whose tumors express a PD-L1 ≥ 50%, several pivotal first-line CPI-based phase 3 studies have been conducted investigating combination treatments combining CPIs with chemotherapy (ChT) or combining different CPIs with or without ChT. As a result, there has been an increase in front-line treatment options for advanced NSCLC, and treatment algorithms are changing very quickly. In fit patients with advanced NSCLC, combination treatments including CPI and ChT are considered the new standard of care with improved clinical outcomes. CPI combination treatments are well tolerated and quality of life also seems to be better when CPIs are implemented in the first-line setting. The aim of this review is to provide a summary of the recently published first-line phase 3 studies investigating CPIs as monotherapy or in combination with other CPIs or ChT in advanced NSCLC, and to suggest possible treatment algorithms. © 2020, Springer Nature Switzerland AG.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12} -} - -@ARTICLE{Yang20202059, - author = {Yang, Zhang-Ru and Liu, Mi-Na and Yu, Jia-Hua and Yang, Yun-Hai and Chen, Tian-Xiang and Han, Yu-Chen and Zhu, Lei and Zhao, Ji-Kai and Fu, Xiao-Long and Cai, Xu-Wei}, - title = {Treatment of stage III non-small cell lung cancer in the era of immunotherapy: Pathological complete response to neoadjuvant pembrolizumab and chemotherapy}, - year = {2020}, - journal = {Translational Lung Cancer Research}, - volume = {9}, - number = {5}, - pages = {2059 – 2073}, - doi = {10.21037/tlcr-20-896}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096133800&doi=10.21037%2ftlcr-20-896&partnerID=40&md5=343d33e1d026dc21a987eb7c9f916f17}, - abstract = {Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. The expected 5-year survival of stage III NSCLC ranges from 13% to 36% for stage III. Due to the heterogeneity and poor efficacy of stage III patients, there is great controversy on how to optimize the therapy strategy. Immunotherapy is providing better clinical efficacy to more NSCLC patients, and is rapidly extending its range of care from advanced stage to locally advanced stage and early stage NSCLC. Due to the patient's strong treatment intention, drug availability, and a few encouraging results from clinical trials (NADIM, NCT02716038, etc.), the authors observed a case of stage III NSCLC that achieved complete remission after receiving neoadjuvant chemotherapy combined with immunotherapy. In view of such a satisfactory result in neoadjuvant therapy, this article discusses how comprehensive treatment for stage III NSCLC patients may be conducted and the manner in which various therapeutic techniques can be mastered in the era of immunotherapy. Immunotherapy has opened the exploratory space for finding resolutions to numerous challenges of treating stage III NSCLC. Further clinical studies and exploration of personalized treatment, guided by imaging data, and clinical and pathological biomarkers are imperative for the benefit of these patients. © Translational Lung Cancer Research. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 11; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Lucarini20211, - author = {Lucarini, Valeria and Melaiu, Ombretta and Tempora, Patrizia and D’amico, Silvia and Locatelli, Franco and Fruci, Doriana}, - title = {Dendritic cells: Behind the scenes of t-cell infiltration into the tumor microenvironment}, - year = {2021}, - journal = {Cancers}, - volume = {13}, - number = {3}, - pages = {1 – 22}, - doi = {10.3390/cancers13030433}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099818171&doi=10.3390%2fcancers13030433&partnerID=40&md5=5ed76f4f7a5a6a04c30f34a5a33a4a53}, - abstract = {Tumor-infiltrating CD8+ T cells have been shown to play a crucial role in controlling tumor progression. However, the recruitment and activation of these immune cells at the tumor site are strictly dependent on several factors, including the presence of dendritic cells (DCs), the main orchestrators of the antitumor immune responses. Among the various DC subsets, the role of cDC1s has been demonstrated in several preclinical experimental mouse models. In addition, the high density of tumor-infiltrating cDC1s has been associated with improved survival in many cancer patients. The ability of cDC1s to modulate antitumor activity depends on their interaction with other immune populations, such as NK cells. This evidence has led to the development of new strategies aimed at increasing the abundance and activity of cDC1s in tumors, thus providing attractive new avenues to enhance antitumor immunity for both established and novel anticancer immunotherapies. In this review, we provide an overview of the various subsets of DCs, focusing in particular on the role of cDC1s, their ability to interact with other intratumoral immune cells, and their prognostic significance on solid tumors. Finally, we outline key therapeutic strategies that promote the immunogenic functions of DCs in cancer immunotherapy. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 27; All Open Access, Gold Open Access} -} - -@ARTICLE{Huang2020272, - author = {Huang, Joy and Reckamp, Karen L.}, - title = {Immunotherapy in advanced lung cancer}, - year = {2020}, - journal = {ONCOLOGY (United States)}, - volume = {34}, - number = {7}, - pages = {272 – 279}, - doi = {10.46883/ONC.2020.3407.0272}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088154925&doi=10.46883%2fONC.2020.3407.0272&partnerID=40&md5=db0cae007270653b0e317d87f4004f84}, - abstract = {Historically, platinum-based chemotherapy was the standard of care for metastatic lung cancer. However, since the success of immune checkpoint inhibitors (ICIs) in melanoma, PD-1/PD-L1 and CTLA-4 immune checkpoint pathways have been established as effective therapies to manage advanced non-small cell lung cancer (NSCLC) and extensive-stage (ES) small cell lung cancer (SCLC). Multiple large-scale randomized clinical trials have analyzed the effects of ICIs in NSCLC, and results of these trials have since translated to the approval of single-agent PD-1/PD-L1 inhibitors, and the combination of PD-1 inhibitors with platinum-based chemotherapy has become the new standard of care for patients with advanced NSCLC. Furthermore, in ES SCLC, in which chemotherapy or chemoradiation has been the standard of care for decades, 2 anti-PD-1/PD-L1 agents have been approved for use in the frontline setting for ES SCLC, in combination with chemotherapy. Despite progressive integration of immunotherapy into treatment regimens, there remains a need for reliable biomarkers to precisely determine therapy candidates. © 2020 UBM Medica Healthcare Publications. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Bronze Open Access} -} - -@ARTICLE{Ceci20201, - author = {Ceci, Claudia and Atzori, Maria Grazia and Lacal, Pedro Miguel and Graziani, Grazia}, - title = {Targeting tumor-associated macrophages to increase the efficacy of immune checkpoint inhibitors: A glimpse into novel therapeutic approaches for metastatic melanoma}, - year = {2020}, - journal = {Cancers}, - volume = {12}, - number = {11}, - pages = {1 – 32}, - doi = {10.3390/cancers12113401}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096315020&doi=10.3390%2fcancers12113401&partnerID=40&md5=5dc7c13a3551bd7a4a86dd790d4e2919}, - abstract = {Immune checkpoint inhibitors (ICIs) represent a promising therapeutic intervention for a variety of advanced/metastatic solid tumors, including melanoma, but in a large number of cases, patients fail to establish a sustained anti-tumor immunity and to achieve a long-lasting clinical benefit. Cells of the tumor micro-environment such as tumor-associated M2 macrophages (M2-TAMs) have been reported to limit the efficacy of immunotherapy, promoting tumor immune evasion and progression. Thus, strategies targeting M2-TAMs have been suggested to synergize with immune checkpoint blockade. This review recapitulates the molecular mechanisms by which M2-TAMs promote cancer immune evasion, with focus on the potential cross-talk between pharmacological interventions targeting M2-TAMs and ICIs for melanoma treatment. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 46; All Open Access, Gold Open Access} -} - -@ARTICLE{Mehra2021153, - author = {Mehra, Ranee and Yong, Candice and Seal, Brian and Van Keep, Marjolijn and Raad, Angie and Zhang, Yiduo}, - title = {Cost-effectiveness of durvalumab after chemoradiotherapy in unresectable Stage III nsclc: A us healthcare perspective}, - year = {2021}, - journal = {JNCCN Journal of the National Comprehensive Cancer Network}, - volume = {19}, - number = {2}, - pages = {153 – 162}, - doi = {10.6004/jnccn.2020.7621}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101027222&doi=10.6004%2fjnccn.2020.7621&partnerID=40&md5=c522eda14595b32530ec071c5f04a158}, - abstract = {Background: Durvalumab was approved by the FDA in February 2018 for patients with unresectable stage III NSCLC that has not progressed after platinum-based concurrent chemoradiotherapy (cCRT), and this regimen is the current standard of care. The objective of this study was to examine the cost-effectiveness of durvalumab following cCRT versus cCRT alone in patients with locally advanced, unresectable stage III NSCLC. Methods: A 3-state semi-Markov model was used. Modeling was performed in a US healthcare setting from Medicare and commercial payer perspectives over a 30-year time horizon. Clinical efficacy (progression-free and post progression survival) and utility inputs were based on PACIFIC study data (ClinicalTrials. gov identifier: NCT02125461; data cutoff March 22, 2018). Overall survival extrapolation was validated using overall survival data from a later data cutoff (January 31, 2019). The main outcome was the incremental cost-effectiveness ratio (ICER) of durvalumab following cCRT versus cCRT alone, calculated as the difference in total costs between treatment strategies per quality-adjusted life-year (QALY) gained. Results: In the base-case analysis, durvalumab following cCRT was cost-effective versus cCRT alone from Medicare and commercial insurance perspectives, with ICERs of $55,285 and $61,111, respectively, per QALY gained. Durvalumab was thus considered cost-effective at the $100,000 willingness-to-pay (WTP) threshold. Sensitivity analyses revealed the model was particularly affected by variables associated with subsequent treatment, although no tested variable increased the ICER above the WTP threshold. Scenario analyses showed the model was most sensitive to assumptions regarding time horizon, treatment effect duration, choice of fitted progression-free survival curve, subsequent immunotherapy treatment duration, and use of a partitioned survival model structure. Conclusions: In a US healthcare setting, durvalumab was costeffective compared with cCRT alone, further supporting the adoption of durvalumab following cCRT as the new standard of care in patients with unresectable stage III NSCLC. © 2021 Harborside Press. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 14; All Open Access, Bronze Open Access} -} - -@ARTICLE{Gutiérrez Calderón2021, - author = {Gutiérrez Calderón, Vanesa and Cantero González, Alexandra and Gálvez Carvajal, Laura and Aguilar Lizarralde, Yolanda and Rueda Domínguez, Antonio}, - title = {Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model}, - year = {2021}, - journal = {Therapeutic Advances in Medical Oncology}, - volume = {13}, - doi = {10.1177/1758835920984061}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101574322&doi=10.1177%2f1758835920984061&partnerID=40&md5=997fcaaaca278bf5374dad8995a8975b}, - abstract = {Squamous cell carcinoma of oral cavity (OCSCC) accounts for approximately 25% of cases of head and neck squamous cell carcinoma (HNSCC). Tobacco and alcohol consumption are the main risk factors for both cancers. Surgical resection, combined with adjuvant radiotherapy or radiochemotherapy in patients with high risk of relapse, is the key element in management in the initial stages. However, despite the availability of aggressive multidisciplinary treatments, advanced resectable OCSCC carries poor prognosis; only half of the patients are disease-free 5 years after the surgery. Immunotherapy based on the use of immune checkpoint inhibitors has been proven to be effective in a wide variety of tumours, including recurrent and metastatic HNSCC. These positive results resulted in investigations into its effectiveness in earlier stages of the disease with OCSCC emerging as an interesting research model because of the accessible location of the tumours. This article reviews the potential advantages of emerging immunotherapeutic agents [mainly monoclonal antibodies against programmed cell death-1 (PD-1) immune checkpoint inhibitors] as neoadjuvant treatment for OCSCC at locoregional stages as well as the ongoing clinical trials, challenges in evaluating tumour response, and possible predictive biomarkers of response with highlights regarding the role of oral microbiota as modulators of immune response. The efficacy and safety of anti-PD-1 drugs in these patients have been proven in preliminary trials. If there is a decrease in the relapse rate and an improvement in the overall survival after surgical resection in ongoing trials, preoperative immunotherapy may be established as a treatment option for patients with early stages of the disease. © The Author(s), 2021.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 11; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Melosky2020981, - author = {Melosky, Barbara and Cheema, Parneet K. and Brade, Anthony and McLeod, Deanna and Liu, Geoffrey and Price, Paul Wheatley and Jao, Kevin and Schellenberg, Devin D. and Juergens, Rosalyn and Leighl, Natasha and Chu, Quincy}, - title = {Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer}, - year = {2020}, - journal = {Oncologist}, - volume = {25}, - number = {11}, - pages = {981 – 992}, - doi = {10.1634/theoncologist.2020-0193}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091272072&doi=10.1634%2ftheoncologist.2020-0193&partnerID=40&md5=3d3d1bd4f06bcd58351c00a3872e921e}, - abstract = {Background: Small cell lung cancer (SCLC) represents approximately 15% of lung cancers, and approximately 70% are diagnosed as extensive-stage SCLC (ES-SCLC). Although ES-SCLC is highly responsive to chemotherapy, patients typically progress rapidly, and there is an urgent need for new therapies. Immune checkpoint inhibitors (ICIs) have recently been investigated in SCLC, and this review provides guidance on the use of these agents in ES-SCLC based on phase III evidence. Methods: Published and presented literature on phase III data addressing use of ICIs in ES-SCLC was identified using the key search terms “small cell lung cancer” AND “checkpoint inhibitors” (OR respective aliases). Directed searches of eligible studies were periodically performed to ensure capture of the most recent data. Results: Six phase III trials were identified, with four assessing the benefits of ICIs plus chemotherapy first-line, one evaluating ICIs as first-line therapy maintenance, and one assessing ICI monotherapy after progression on platinum-based chemotherapy. The addition of ipilimumab or tremelimumab to first-line treatment or as first-line maintenance did not improve survival. Two out of three studies combining PD-1/PD-L1 inhibitors with first-line platinum-based chemotherapy demonstrated significant long-lasting survival benefits and improved quality of life with no unexpected safety concerns. PD-1/PD-L1 inhibitors as first-line maintenance or in later lines of therapy did not improve survival. Biomarker research is ongoing as well as research into the role of ICIs in combination with radiation therapy in limited-stage SCLC. Conclusion: The addition of atezolizumab or durvalumab to first-line platinum-based chemotherapy for ES-SCLC prolongs survival and improves quality of life. Implications for Practice: Platinum-based chemotherapy has been standard of care for extensive-stage small cell lung cancer (ES-SCLC) for more than a decade. Six recent phase III trials investigating immune checkpoint inhibitors (ICIs) have clarified the role of these agents in this setting. Although ICIs were assessed first-line, as first-line maintenance, and in later lines of therapy, the additions of atezolizumab or durvalumab to first-line platinum-based chemotherapy were the only interventions that significantly improved overall survival and increased quality of life. These combinations should therefore be considered standard therapy for first-line ES-SCLC. Biomarker research and investigations into the role of ICIs for limited-stage disease are ongoing. © AlphaMed Press 2020}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 25; All Open Access, Bronze Open Access} -} - -@ARTICLE{Lim20202423, - author = {Lim, Raymond J. and Liu, Bin and Krysan, Kostyantyn and Dubinett, Steven M.}, - title = {Lung cancer and immunity markers}, - year = {2020}, - journal = {Cancer Epidemiology Biomarkers and Prevention}, - volume = {29}, - number = {12}, - pages = {2423 – 2430}, - doi = {10.1158/1055-9965.EPI-20-0716}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100967525&doi=10.1158%2f1055-9965.EPI-20-0716&partnerID=40&md5=f305a9710bab505ba6bde701e6b4325d}, - abstract = {An in-depth understanding of lung cancer biology and mechanisms of tumor progression has facilitated significant advances in the treatment of lung cancer. There remains a pressing need for the development of innovative approaches to detect and intercept lung cancer at its earliest stage of development. Recent advances in genomics, computational biology, and innovative technologies offer unique opportunities to identify the immune landscape in the tumor microenvironment associated with early-stage lung carcinogenesis, and provide further insight in the mechanism of lung cancer evolution. This review will highlight the concept of immunoediting and focus on recent studies assessing immune changes and biomarkers in pulmonary premalignancy and early-stage non-small cell lung cancer. A protumor immune response hallmarked by an increase in checkpoint inhibition and inhibitory immune cells and a simultaneous reduction in antitumor immune response have been correlated with tumor progression. The potential systemic biomarkers associated with early lung cancer will be highlighted along with current clinical efforts for lung cancer interception. Research focusing on the development of novel strategies for cancer interception prior to the progression to advanced stages will potentially lead to a paradigm shift in the treatment of lung cancer and have a major impact on clinical outcomes. © 2020 American Association for Cancer Research.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 11; All Open Access, Bronze Open Access} -} - -@ARTICLE{Beer2020467, - author = {Beer, Lucian and Hochmair, Maximilian and Kifjak, Daria and Haug, Alexander R. and Prayer, Florian and Mayerhoefer, Marius E. and Herold, Christian and Prosch, Helmut}, - title = {Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma}, - year = {2020}, - journal = {Wiener Klinische Wochenschrift}, - volume = {132}, - number = {15-16}, - pages = {467 – 474}, - doi = {10.1007/s00508-020-01667-0}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085492014&doi=10.1007%2fs00508-020-01667-0&partnerID=40&md5=6018436c1ad1ffa092c0b1e840cecd73}, - abstract = {Background: Immune checkpoint inhibitors have become a valuable tool in the therapeutic strategy against metastasized non-small cell lung cancer (NSCLC) as they represent an effective and safe treatment option for many patients; however, the treatment response and side effects of this class of drugs can considerably differ compared to classical chemotherapeutics. The aim of this study was to highlight specific radiological pulmonary findings of NSCLC patients treated with immune checkpoint inhibitors. Methods and results: Medical records and images of prospectively collected data from 70 patients with advanced NSCLC, treated with immune checkpoint inhibitors, were reviewed. Of the patients two experienced an initial increase in tumor size, followed by a decrease in tumor size that was described as pseudoprogression. Another patient developed a sarcoid-like reaction accompanied by clinical improvements and radiological treatment response. A further two patients developed immune checkpoint-associated pulmonary injury that was clinically and radiologically classified as pneumonitis, which responded well to anti-inflammatory treatment. Conclusion: Management of patients with NSCLC using immune checkpoint inhibitors requires a knowledge of specific clinical and radiological findings. Both oncologists and radiologists have to be aware of the most common types, including atypical response patterns, such as a sarcoid-like reaction and pseudoprogression as well as of the pulmonary side effects that can encompass pneumonitis. © 2020, The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 6; All Open Access, Green Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Zhang202135, - author = {Zhang, Lili and Reynolds, Kerry L. and Lyon, Alexander R. and Palaskas, Nicolas and Neilan, Tomas G.}, - title = {The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer}, - year = {2021}, - journal = {JACC: CardioOncology}, - volume = {3}, - number = {1}, - pages = {35 – 47}, - doi = {10.1016/j.jaccao.2020.11.012}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100064112&doi=10.1016%2fj.jaccao.2020.11.012&partnerID=40&md5=6d0cd199d796f236057504accbf43692}, - abstract = {Immune checkpoint inhibitors (ICIs) are newer therapies being applied to an increasing number of patients with cancer. Data suggest that up to 36% of cancer patients may be eligible for immunotherapy and, in late 2019, there were more than 3,362 clinical trials initiated to evaluate the effectiveness of immunotherapy, either as single agents or in combination with other immunotherapy, targeted therapies, or traditional cytotoxic or radiation therapy. With the combination of both immune and non-immune treatment approaches, the complexity in making the diagnosis of cardiotoxicity related to an ICI will increase substantially. Here, we summarize the published data on the epidemiology, diagnosis, and management of cardiotoxicity of ICIs. This is a rapidly evolving field, and as our understanding continues to evolve, previously considered hypotheses may not prove to be entirely correct. Research and continued collaborations are urgently needed to provide evidence-based cardiovascular care for this rapidly expanding and vulnerable cohort of patients. © 2021 The Authors}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 96; All Open Access, Gold Open Access} -} - -@ARTICLE{Chitsike2021, - author = {Chitsike, Lennox and Duerksen-Hughes, Penelope J.}, - title = {Targeted Therapy as a Potential De-Escalation Strategy in Locally Advanced HPV-Associated Oropharyngeal Cancer: A Literature Review}, - year = {2021}, - journal = {Frontiers in Oncology}, - volume = {11}, - doi = {10.3389/fonc.2021.730412}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114225009&doi=10.3389%2ffonc.2021.730412&partnerID=40&md5=a206207df22b63d27b5ea00d64015cf4}, - abstract = {The treatment landscape of locally advanced HPV-oropharyngeal squamous cell carcinoma (OPSCC) is undergoing transformation. This is because the high cures rates observed in OPSCC are paired with severe treatment-related, long-term toxicities. These significant adverse effects have led some to conclude that the current standard of care is over-treating patients, and that de-intensifying the regimens may achieve comparable survival outcomes with lower toxicities. Consequently, several de-escalation approaches involving locally advanced OPSCC are underway. These include the reduction of dosage and volume of intensive cytotoxic regimens, as well as elimination of invasive surgical procedures. Such de-intensifying treatments have the potential to achieve efficacy and concurrently alleviate morbidity. Targeted therapies, given their overall safer toxicity profiles, also make excellent candidates for de-escalation, either alone or alongside standard treatments. However, their role in these endeavors is currently limited, because few targeted therapies are currently in clinical use for head and neck cancers. Unfortunately, cetuximab, the only FDA-approved targeted therapy, has shown inferior outcomes when paired with radiation as compared to cisplatin, the standard radio-sensitizer, in recent de-escalation trials. These findings indicate the need for a better understanding of OPSCC biology in the design of rational therapeutic strategies and the development of novel, OPSCC-targeted therapies that are safe and can improve the therapeutic index of standard therapies. In this review, we summarize ongoing research on mechanism-based inhibitors in OPSCC, beginning with the salient molecular features that modulate tumorigenic processes and response, then exploring pharmacological inhibition and pre-clinical validation studies of candidate targeted agents, and finally, summarizing the progression of those candidates in the clinic. © Copyright © 2021 Chitsike and Duerksen-Hughes.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 7; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Saltos2020, - author = {Saltos, Andreas and Shafique, Michael and Chiappori, Alberto}, - title = {Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)}, - year = {2020}, - journal = {Frontiers in Oncology}, - volume = {10}, - doi = {10.3389/fonc.2020.01074}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088816977&doi=10.3389%2ffonc.2020.01074&partnerID=40&md5=28e3bb18e06d5e3ebc6bea271308124a}, - abstract = {Small-cell lung cancer (SCLC) accounts for 13–15% of all new lung cancer cases in the US. The tumor has a tendency to disseminate early resulting in 80–85% of patients being diagnosed with extensive disease (ES-SCLC). Chemotherapy has provided SCLC patients considerable survival benefits over the past three decades. Nonetheless, most patients relapse and rarely survive beyond 2 years. Despite consistent overall response rates of ≥50%, until recently, median survival times and 2-year survivals only ranged between 7–10 months and 10–20%, respectively. Several chemotherapy agents possess activity against SCLC, both, as single agents and in combinations but etoposide-platinum emerged as the preferred first line regimen. Upon relapse, many patients remain candidates for additional therapy. However, the sensitivity of relapsed SCLC to further therapies is markedly reduced and dependent upon the level and duration of response to the initial treatment (platinum-sensitive vs. resistant relapse). Multiple factors suggest a therapeutic role for immunotherapy in SCLC: SCLC has been associated with immune-mediated paraneoplastic processes (cerebellar degeneration, limbic encephalitis, and Lambert–Eaton syndrome) and patients presenting with these paraneoplastic syndromes have shown more favorable outcomes, suggesting an underlying immune response mechanism. Comprehensive genomic profiling of SCLC indicates that the majority lack functional p53 (90%) and Rb1 (65%). These universal genetic aberrations facilitate poor genomic stability, thus perpetuating the generation of tumor associated antigens, amenable to targeting with immunotherapy. SCLC has one of the highest mutational loads, likely a reflection of the myriad of insults inflicted by smoking-related carcinogens. The relationship between tumor mutational load and response to immune checkpoint inhibitors has been established in multiple solid tumors, including preliminary results in relapsed SCLC. In this manuscript, we review the early (some failed and discontinued, some partly successful, and still ongoing) attempts to incorporate immunotherapy (particularly vaccine based approaches) to the treatment of SCLC, and the latest attempts (mostly incorporating the use of checkpoint inhibitors), including those with favorable but preliminary results (CheckMate 032, Keynote 028 and 158), and those with more definitive positive (iMpower 133 and CASPIAN) and negative (CheckMate 331 and 451) results. © Copyright © 2020 Saltos, Shafique and Chiappori.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 85; All Open Access, Green Open Access} -} - -@ARTICLE{Pecci2021, - author = {Pecci, Federica and Cantini, Luca and Bittoni, Alessandro and Lenci, Edoardo and Lupi, Alessio and Crocetti, Sonia and Giglio, Enrica and Giampieri, Riccardo and Berardi, Rossana}, - title = {Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer}, - year = {2021}, - journal = {Current Treatment Options in Oncology}, - volume = {22}, - number = {8}, - doi = {10.1007/s11864-021-00870-z}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107540349&doi=10.1007%2fs11864-021-00870-z&partnerID=40&md5=4c69158ad30cdbb4a442927a5070ba7a}, - abstract = {Advanced colorectal cancer (CRC) is a heterogeneous disease, characterized by several subtypes with distinctive genetic and epigenetic patterns. During the last years, immune checkpoint inhibitors (ICIs) have revamped the standard of care of several tumors such as non-small cell lung cancer and melanoma, highlighting the role of immune cells in tumor microenvironment (TME) and their impact on cancer progression and treatment efficacy. An “immunoscore,” based on the percentage of two lymphocyte populations both at tumor core and invasive margin, has been shown to improve prediction of treatment outcome when added to UICC-TNM classification. To date, pembrolizumab, an anti-programmed death protein 1 (PD1) inhibitor, has gained approval as first-line therapy for mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) advanced CRC. On the other hand, no reports of efficacy have been presented in mismatch-repair-proficient (pMMR) and microsatellite instability-low (MSI-L) or microsatellite stable (MSS) CRC. This group includes roughly 95% of all advanced CRC, and standard chemotherapy, in addition to anti-EGFR or anti-angiogenesis drugs, still represents first treatment choice. Hopefully, deeper understanding of CRC immune landscape and of the impact of specific genetic and epigenetic alterations on tumor immunogenicity might lead to the development of new drug combination strategies to overcome ICIs resistance in pMMR CRC, thus paving the way for immunotherapy even in this subgroup. © 2021, The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 19; All Open Access, Green Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Sepesi2020555, - author = {Sepesi, Boris and Cascone, Tina and Chun, Stephen G. and Altan, Mehmet and Le, Xiuning}, - title = {Emerging Therapies in Thoracic Malignancies—Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non–Small Cell Lung Cancer}, - year = {2020}, - journal = {Surgical Oncology Clinics of North America}, - volume = {29}, - number = {4}, - pages = {555 – 569}, - doi = {10.1016/j.soc.2020.06.009}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088933546&doi=10.1016%2fj.soc.2020.06.009&partnerID=40&md5=c7d210855c0e134fa3eba4358a92d13c}, - abstract = {Immunotherapy, targeted therapy, and adoptive T-cell therapy have been revolutionary advancements in cancer research. Some of these therapies have become the standard of care for lung cancer and replaced older treatment algorithms; some continue to be studied in clinical trials. This article discusses the current state of novel treatment options for non–small cell lung cancer patients with metastatic and locoregional disease, with focus on immunotherapy, targeted therapy, and adoptive T-cell therapy. © 2020 Elsevier Inc.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 8; All Open Access, Green Open Access} -} - -@ARTICLE{Chitsike2020, - author = {Chitsike, Lennox and Duerksen-Hughes, Penelope}, - title = {The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature}, - year = {2020}, - journal = {Current Treatment Options in Oncology}, - volume = {21}, - number = {12}, - doi = {10.1007/s11864-020-00790-4}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092061302&doi=10.1007%2fs11864-020-00790-4&partnerID=40&md5=7680a66192941779a9f821cbfc2726a3}, - abstract = {Cervical cancer (CC) is most often caused by the human papillomavirus (HPV). In principle, these ties to the virus should make HPV tumors a relatively easy target for clearance by the immune system. However, these HPV-associated tumors have evolved strategies to escape immune attack. Checkpoint inhibition immunotherapy, which has had remarkable success in cancer treatment, has the potential to overcome the immune escape in CC by harnessing the patient’s own immune system and priming it to recognize and kill tumors. Recent work involving PD-1/PD-L1 inhibitors in CC lends credence to this belief, as pembrolizumab has shown evidence of clinical efficacy and consequently been granted accelerated approval by the FDA. That being said, the oncologic outcomes following monotherapy with these biologics have mostly been modest and variable, and this can be attributed to alternative resistance mechanisms to tumor response. The use of therapies that stimulate immune responses via checkpoint-independent activation will therefore augment release of T cell inhibition by checkpoint inhibitors for stronger and more sustained clinical responses. Such a combinatorial approach holds promise for weak- or non-responders to checkpoint therapies as supported by evidence from various, recent pre-clinical, and preliminary clinical studies. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 17} -} - -@ARTICLE{Reckamp2020, - author = {Reckamp, Karen L. and Huang, Joy}, - title = {Immunotherapy in Advanced Lung Cancer}, - year = {2020}, - journal = {ONCOLOGY (United States)}, - volume = {34}, - number = {7}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091596390&partnerID=40&md5=b0c09b6cd8c2cdf7a11fcd27da0d0212}, - abstract = {Historically, platinum-based chemotherapy was the standard of care for metastatic lung cancer. However, since the success of immune checkpoint inhibitors (ICIs) in melanoma, PD-1/PD-L1 and CTLA-4 immune checkpoint pathways have been established as effective therapies to manage advanced non–small cell lung cancer (NSCLC) and extensive-stage (ES) small cell lung cancer (SCLC). Multiple large-scale randomized clinical trials have analyzed the effects of ICIs in NSCLC, and results of these trials have since translated to the approval of single-agent PD-1/PD-L1 inhibitors, and the combination of PD-1 inhibitors with platinum-based chemotherapy has become the new standard of care for patients with advanced NSCLC. Furthermore, in ES SCLC, in which chemotherapy or chemoradiation has been the standard of care for decades, 2 anti–PD-1/PD-L1 agents have been approved for use in the frontline setting for ES SCLC, in combination with chemotherapy. Despite progressive integration of immunotherapy into treatment regimens, there remains a need for reliable biomarkers to precisely determine therapy candidates. © 2020 UBM Medica Healthcare Publications. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Huang2020, - author = {Huang, Chengliang and Gan, Gregory N. and Zhang, Jun}, - title = {IMpower, CASPIAN, and more: Exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer}, - year = {2020}, - journal = {Journal of Hematology and Oncology}, - volume = {13}, - number = {1}, - doi = {10.1186/s13045-020-00898-y}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086052612&doi=10.1186%2fs13045-020-00898-y&partnerID=40&md5=8aafbd57e30b0c9b40946e5ce3841dcd}, - abstract = {The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2-3 decades until two recent trials (CASPIAN and IMpower133) showing the addition of anti-programmed death ligand (PD-L1) therapy to chemotherapy has survival benefit over chemotherapy alone. However, such benefit is relatively small and was not even observed in some other trials using immunotherapy, raising the question of optimal chemoimmunotherapy combination in the 1st-line setting for ES-SCLC. Here, we discussed several thought-provoking questions with the focus on IMpower133 and CASPIAN trials. © 2020 The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 7; All Open Access, Gold Open Access} -} - -@ARTICLE{De Giglio2021, - author = {De Giglio, Andrea and Di Federico, Alessandro and Nuvola, Giacomo and Deiana, Chiara and Gelsomino, Francesco}, - title = {The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)}, - year = {2021}, - journal = {Current Oncology Reports}, - volume = {23}, - number = {11}, - doi = {10.1007/s11912-021-01124-9}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85113618144&doi=10.1007%2fs11912-021-01124-9&partnerID=40&md5=222ea13f7d1dd331dd98c84d2feee8c7}, - abstract = {Purpose of Review: In this review, we analyzed the current landscape of non-PD-(L)1 targeting immunotherapy. Recent Findings: The advent of immunotherapy has completely changed the standard approach toward advanced NSCLC. Inhibitors of the PD-1/PD-L1 axis have quickly taken place as first-line treatment for NSCLC patients without targetable “driver” mutations. However, a non-negligible portion of patients derive modest benefit from immune-checkpoint inhibitors, and valid second-line alternatives are lacking, pushing researchers to analyze other molecules and pathways as potentially viable targets in the struggle against NSCLC. Summary: Starting from the better characterized CTLA-4 inhibitors, we then critically collected the actual knowledge on NSCLC vaccines as well as on other emerging molecules, many of them in their early phase of testing, to provide to the reader a comprehensive overview of the state of the art of immunotherapy in NSCLC beyond PD-1/PD-L1 inhibitors. © 2021, The Author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 39; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Solinas2020444, - author = {Solinas, Cinzia and Saba, Luca and Sganzerla, Paolo and Petrelli, Fausto}, - title = {Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review}, - year = {2020}, - journal = {Thrombosis Research}, - volume = {196}, - pages = {444 – 453}, - doi = {10.1016/j.thromres.2020.09.038}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092526934&doi=10.1016%2fj.thromres.2020.09.038&partnerID=40&md5=c3ec85679ec414aa82231a7917530add}, - abstract = {Background: Venous (VTEs) and arterial thromboembolic events (ATEs) are causes of morbidity, disability, mortality, and increase in treatment costs in cancer patients. The risk associated with immune checkpoint inhibitors (ICIs) has not yet been clarified. The primary objective of this systematic review was to evaluate the incidence of VTEs and ATEs in patients treated with ICIs as single agents or in combination with other treatments. Material and methods: Data from retrospective and prospective studies were selected from PubMed, EMBASE, SCOPUS, and The Cochrane Library from inception up to May up to 21st May 2020. All studies had to be in English and use human study participants. The studies were eligible if they provided a number (or rate) of VTEs and ATEs and the size of the population included. The PRISMA guidelines were followed. The data on the incidence of VTEs and ATEs were extracted for each arm, analyzed using random-effects models, and reported as weighted measures. Results: A total of 20,273 patients from 68 studies were included (median follow-up ranged from a few months up to three years). Overall, there were 390 VTEs and 59 ATEs, with incidence rates of 2.7% (95%CI 1.8%–4%) and 1.1% (95%CI 0.5%–2.1%), respectively. The rate of pulmonary embolism was 1.6% (95%CI 0.7%–3.2%) and deep venous thrombosis was 2.7% (95%CI 1.4%–5.4%). In studies where ICIs were administered with chemotherapy, rates of VTEs were similar to ICI alone arms (2.8% vs 2.5%). The rate of stroke and myocardial infarction were 1.1% (95%CI 0.65%–1.45%) and 0.7% (95%CI 0.15%–1.15%), respectively. In randomized trials, compared with non-ICIs containing arms (e.g. chemotherapy), the relative risk (RR) of VTEs due to ICIs was similar (RR 1.08, 95%CI 0.6–1.9; P =.79). Conclusions: Thromboembolic events associated with ICIs are relatively rare in cancer patients with an advanced stage of the disease. However, in randomized studies, their incidence is similar to control arms, suggesting that the contributory role of ICIs to the thromboembolic risk in many cancer settings is small. © 2020 Elsevier Ltd}, - type = {Short survey}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 62} -} - -@ARTICLE{Xiong2021, - author = {Xiong, Wei and Zhao, Yunfeng and Du, He and Guo, Xuejun}, - title = {Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer}, - year = {2021}, - journal = {Frontiers in Oncology}, - volume = {11}, - doi = {10.3389/fonc.2021.704336}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114342283&doi=10.3389%2ffonc.2021.704336&partnerID=40&md5=1051c66af1d193cc76a5504b8c977745}, - abstract = {Immunotherapy is a major breakthrough in the treatment of cancer in recent years. Immune checkpoint inhibitors (ICIs) including programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have been used for different histologic types of cancer including primary lung cancer that represents the most common and fatal cancer globally. Among ICI immunotherapy agents, atezolizumab, durvalumab, ipilimumab, nivolumab, and pembrolizumab are currently used as standard-of-care (SOC) treatment for metastatic or earlier stages of lung cancer. Major issues of ICI immunotherapy in lung cancer comprise the use of immune biomarkers prior to ICI therapy, selection of ICI agents, combination of ICIs/chemotherapy, combination of ICIs/radiotherapy, sequence of tyrosine kinase inhibitor (TKI) targeted therapy and ICI immunotherapy, sequence of chemotherapy and ICI immunotherapy, treatment duration of ICI regimen and ICI therapy for different histopathology, stage, PD-L1, and performance status. Based on the contemporary major clinical trials and authoritative guidelines, the objective of this review is to present an overview of the current status of ICI immunotherapy in lung cancer. © Copyright © 2021 Xiong, Zhao, Du and Guo.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 27; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Wang2021709, - author = {Wang, Jie and Lu, Shun and Yu, Xinmin and Hu, Yanping and Sun, Yuping and Wang, Zhijie and Zhao, Jun and Yu, Yan and Hu, Chunhong and Yang, Kunyu and Feng, Guosheng and Ying, Kejing and Zhuang, Wu and Zhou, Jianying and Wu, Jingxun and Leaw, Shiang Jiin and Zhang, Jing and Lin, Xiao and Liang, Liang and Yang, Nong}, - title = {Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer a phase 3 randomized clinical trial}, - year = {2021}, - journal = {JAMA Oncology}, - volume = {7}, - number = {5}, - pages = {709 – 717}, - doi = {10.1001/jamaoncol.2021.0366}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103598623&doi=10.1001%2fjamaoncol.2021.0366&partnerID=40&md5=bf613576e4f2b3d62b4288680ae9ee30}, - abstract = {IMPORTANCE This study demonstrates that tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS) in patients with advanced squamous non-small-cell lung cancer (sq-NSCLC). OBJECTIVE To assess the efficacy and safety/tolerability of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for patients with advanced sq-NSCLC. DESIGN, SETTING, AND PARTICIPANTS This open-label, randomized phase 3 clinical trial was conducted at 46 sites in China between July 2018 and June 2019 and included patients with treatment-naive, histologically confirmed stage IIIB/IV sq-NSCLC. The data cutoff for these analyses was December 6, 2019; data extraction occurred on January 7, 2020. INTERVENTIONS Patients were randomized (1:1:1) to receive 1 of the following regimens intravenously on a 21-day cycle: tislelizumab (200 mg, day 1) plus paclitaxel (175 mg/m2, day 1) and carboplatin (area under the concentration of 5, day 1) (arm A); tislelizumab plus nab-paclitaxel (100 mg/m2, days 1, 8, and 15) and carboplatin (arm B); and paclitaxel and carboplatin (arm C). Patients were stratified by disease stage and tumor programmed cell death 1 ligand 1 (PD-L1) expression (<1% vs 1%-49% vs >50%). MAIN OUTCOMES AND MEASURES The primary end point was progression-free survival (PFS) assessed by an independent review committee (IRC). Secondary end points included overall survival, investigator-assessed (INV) PFS, IRC-assessed objective response rate (ORR), and IRC-assessed duration of response, as well as the incidence and severity of adverse events (AEs). RESULTS Overall, 355 patients (median [range] age, 62 [34-74] years; 330 men [91.7%]) with sq-NSCLC received treatment. After a median study follow-up of 8.6 months (95% CI, 8.1-9.0 months), IRC-assessed PFS was significantly improved with tislelizumab plus chemotherapy (arm A, 7.6 months; arm B, 7.6 months) vs chemotherapy alone (arm C, 5.5 months; hazard ratios were 0.524 (95% CI, 0.370-0.742; P <.001 [A vs C]) and 0.478 (95% CI, 0.336-0.679; P <.001 [B vs C]). Higher IRC-assessed ORR and longer IRC-assessed duration of response were observed in arms A (72.5%; 8.2 months) and B (74.8%; 8.6 months) vs C (49.6%; 4.2 months). No association was observed between PD-L1 expression and IRC-assessed PFS or ORR. Discontinuation of any treatment because of AEs was reported in 15 (12.5%; arm A), 35 (29.7%; arm B), and 18 (15.4%; arm C) patients. In each arm, the most common grade of 3 or greater AE was decreased neutrophil levels, which aligned with known chemotherapy toxic effects. Six treatment-related AEs leading to death occurred; however, no deaths were solely attributed to tislelizumab. CONCLUSIONS AND RELEVANCE In this phase 3 randomized clinical trial, adding tislelizumab to chemotherapy was associated with significantly prolonged IRC-assessed PFS, higher IRC-assessed ORRs, and a manageable safety/tolerability profile in patients with advanced sq-NSCLC, regardless of PD-L1 expression. © 2021 American Medical Association.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 247; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Girard2020, - author = {Girard, N. and Greillier, L. and Zalcman, G. and Cadranel, J. and Moro-Sibilot, D. and Mazières, J. and Audigier-Valette, C. and Bennouna, J. and Besse, B. and Cortot, A. and Couraud, S. and Duruisseaux, M. and Giroux-Leprieur, E. and Toffart, A.-C. and Westeel, V. and Wislez, M.}, - title = {Proposals for managing patients with thoracic malignancies during COVID-19 pandemic}, - year = {2020}, - journal = {Respiratory Medicine and Research}, - volume = {78}, - doi = {10.1016/j.resmer.2020.100769}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086571781&doi=10.1016%2fj.resmer.2020.100769&partnerID=40&md5=29ff4f2414bc3faf4ad04191ec66e170}, - abstract = {The objective of this document is to formalize a degraded mode management for patients with thoracic cancers in the context of the COVID-19 pandemic. The proposals are based on those of the French High Council for Public Health, on published data outside the context of COVID-19, and on a concerted analysis of the risk-benefit ratio for our patients by a panel of experts specialized on thoracic oncology under the aegis of the French-Language Society of Pulmonology (SPLF)/French-language oncology group. These proposals are evolving (10 April 2020) according to the situations encountered, which will enrich it, and are to be adapted to our institutional organisations and to the evolution of resources during the COVID-19 epidemic. Patients with symptoms and/or COVID-19+ are not discussed in this document and are managed within the framework of specific channels. © 2020}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 14; All Open Access, Bronze Open Access} -} - -@ARTICLE{Ding2020, - author = {Ding, Haiying and Xin, Wenxiu and Tong, Yinghui and Sun, Jiao and Xu, Gaoqi and Ye, Ziqi and Rao, Yuefeng}, - title = {Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review}, - year = {2020}, - journal = {PLoS ONE}, - volume = {15}, - number = {9 September}, - doi = {10.1371/journal.pone.0238536}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090261360&doi=10.1371%2fjournal.pone.0238536&partnerID=40&md5=008c8af98d5d81dcb89933a30901e504}, - abstract = {Background Immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC) have been rapidly evolving. ICIs are likely to be more effective but also lead to escalating healthcare costs. Objectives The aim of this study was to evaluate the cost effectiveness of immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC). Methods We searched the PubMed, Web of Science, and Cochrane Library for studies comparing the cost effectiveness of ICIs for NSCLC. Potential studies identified were independently checked for eligibility by two authors, with disagreement resolved by a third reviewer. Quality of the included studies was evaluated using Consolidated Health Economic Evaluation Reporting Standards checklists. Results A total of 22 economic studies were included. Overall reporting of the identified studies largely met CHEERS recommendations. In the first-line setting, for advanced or metastatic NSCLC patients with PD-L1 ≥ 50%, pembrolizumab appeared cost-effective compared with platinum-based chemotherapy in the US and Hong Kong (China), but not in the UK and China. The cost-effectiveness of pembrolizumab versus chemotherapy for first-line treatment of NSCLC in PD-L1 ≥ 1% patients remained obscure. Regardless of PD-L1 expression status, pembrolizumab in combination with chemotherapy could be a cost-effective first-line therapy in the US. On the contrary, addition of atezolizumab to the combination of bevacizumab and chemotherapy was not cost-effective for patients with metastatic nonsquamous NSCLC from the US payer perspective. In the second-line setting compared with docetaxel, pembrolizumab was cost-effective; though nivolumab was not cost-effective in the base case, it could be by increased PD-L1 threshold. Results of the cost-effectiveness of atezolizumab second-line treatment remained inconsistent. In addition, the adoption of durvalumab consolidation therapy after chemoradiotherapy could be cost-effective versus no consolidation therapy for patients with stage III NSCLC. Conclusions Immunotherapy can be a cost-effective option for treatment of NSCLC in several scenarios. A discount of the agents or the use of PD-L1 expression as a biomarker improves the cost-effectiveness of immunotherapy. © 2020 Ding et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 36; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Piña-Sánchez2021, - author = {Piña-Sánchez, Patricia and Chávez-González, Antonieta and Ruiz-Tachiquín, Martha and Vadillo, Eduardo and Monroy-García, Alberto and Montesinos, Juan José and Grajales, Rocío and Gutiérrez de la Barrera, Marcos and Mayani, Hector}, - title = {Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective}, - year = {2021}, - journal = {Cancer Control}, - volume = {28}, - doi = {10.1177/10732748211038735}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116045132&doi=10.1177%2f10732748211038735&partnerID=40&md5=ea36e67b792b36d0822f4709e700b754}, - abstract = {Since the second half of the 20th century, our knowledge about the biology of cancer has made extraordinary progress. Today, we understand cancer at the genomic and epigenomic levels, and we have identified the cell that starts neoplastic transformation and characterized the mechanisms for the invasion of other tissues. This knowledge has allowed novel drugs to be designed that act on specific molecular targets, the immune system to be trained and manipulated to increase its efficiency, and ever more effective therapeutic strategies to be developed. Nevertheless, we are still far from winning the war against cancer, and thus biomedical research in oncology must continue to be a global priority. Likewise, there is a need to reduce unequal access to medical services and improve prevention programs, especially in countries with a low human development index. © The Author(s) 2021.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 23; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Chai2021, - author = {Chai, Rong and Yin, Yipengchen and Cai, Xuwei and Fu, Xiaolong and Zhang, Qin}, - title = {Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors}, - year = {2021}, - journal = {Frontiers in Oncology}, - volume = {11}, - doi = {10.3389/fonc.2021.724722}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115361696&doi=10.3389%2ffonc.2021.724722&partnerID=40&md5=99d44caa34cef755832f171772421dbc}, - abstract = {Objective: The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment paradigm of non-small cell lung cancer (NSCLC). Despite the durability of response to ICIs, the vast majority of patients will later develop progression. However, the failure patterns of ICI treatment are unknown. Here, our study explored the failure patterns in advanced NSCLC patients treated with ICIs. Methods: A cohort of 156 IIIB or IV NSCLC patients treated with first-/second-line ICIs were retrospectively analyzed. Patients who experienced clinical benefit and then developed progression were identified. The disease progression patterns were divided into three categories: progression in new sites, progression in existing sites, and combined progression. The number of progression sites was also recorded. Results: Before the cutoff date, 91 (77.1%) patients had experienced disease progression; 34% of patients had progressed in the last 9 months of the first year. Fifty-three (58.2%) patients had developed progression at existing lesions, and 56 (61.5%) patients had shown ≤2 progression sites (oligo-progression). In patients with oligo-progression, the median time of disease progression was 8.23 months and the counterpart (systemic progression) was 5.97 months. The oligo-progression patients showed prolonged median overall survival (27.23 months) compared with patients with systemic progression (18.87 months). Conclusions: Failure patterns of ICI therapy were predominantly “existing” sites, and the most common lesions of progression were the lung and lymph nodes. Most patients experienced oligo-progression which occurred later than systemic progression and showed prolonged overall survival. The control of the local lesions might be beneficial to improve ICI treatment efficacy. © Copyright © 2021 Chai, Yin, Cai, Fu and Zhang.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 5; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Tian20213, - author = {Tian, Yaru and Zhai, Xiaoyang and Yan, Weiwei and Zhu, Hui and Yu, Jinming}, - title = {Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC}, - year = {2021}, - journal = {Cancer Medicine}, - volume = {10}, - number = {1}, - pages = {3 – 14}, - doi = {10.1002/cam4.3590}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096792434&doi=10.1002%2fcam4.3590&partnerID=40&md5=c38f5e88bc9a0f427ad1ee23e211fc96}, - abstract = {Immune checkpoint blockades (ICBs) have changed the standard of care of squamous and adenocarcinoma non-small cell lung cancer (NSCLC). Whereas detailed researches regarding ICBs in the two major histological subtypes are rare. In order to uncover the clinical efficacy differences between squamous and adenocarcinoma NSCLC and better understand the underlying immune-regulatory mechanisms, we compared the survival benefits of ICBs between the two subtypes by revealing phase 3 randomized trials and attempted to uncover the immune-regulatory discrepancy. Generally, compared with nonsquamous NSCLC, squamous NSCLC benefited more from ICBs in Keynote 024, CheckMate 026, CheckMate 227 and CheckMate 017 and similar in OAK, but less in Keynote 010 and PACIFIC. We revealed that the tumor mutation burden (TMB) level, the programmed cell death ligand 1 (PD-L1) expression, tumor infiltrating lymphocytes (TILs) in the tumor microenvironment (TME), chemokines, and oncogenic driver alterations within the two subtypes may contributed to the clinical outcomes of ICBs. We prospected that the combinations of ICBs with chemotherapy, radiation therapy, and antiangiogenic therapy could be promising strategies to re-immunize the less immunogenic tumors and further enhance the efficacy of ICBs. © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 29; All Open Access, Gold Open Access, Green Open Access} -}@ARTICLE{Chen2020, - author = {Chen, Hao and Horita, Nobuyuki and Ito, Kentaro and Nagakura, Hideyuki and Hara, Yu and Kobayash, Nobuaki and Yamamoto, Masaki and Kudo, Makoto and Kaneko, Takeshi}, - title = {Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis}, - year = {2020}, - journal = {Therapeutic Advances in Medical Oncology}, - volume = {12}, - doi = {10.1177/1758835920965841}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092768556&doi=10.1177%2f1758835920965841&partnerID=40&md5=3a30378ea1fc3d840fc07e5308cff0a4}, - abstract = {Background: Our goal was to organize the data from randomized controlled trials that evaluated first-line chemotherapy for chemo-naïve extensive disease small-cell lung cancer (ED-SCLC). Methods: The protocol following PRISMA methodology was submitted as PROSPERO 154049. We included individually randomized trials comparing two or more chemotherapy regimens as the first-line treatment for chemo-naïve ED-SCLC regardless of the age, sex, performance status, co-morbidities, and organ functions written in the English language since 2000. Molecular targeted agents and immune checkpoint inhibitors were considered chemotherapy along with cytotoxic medications. We pooled the logarithm of hazard ratio (HR) and its standard error using the frequentist weighted least squares approach random-model network meta-analysis. Results: A total of 46 eligible trials that involved 11,987 patients were included. The primary endpoint, HR of overall survival (OS, HRos) of the selected comparisons was as follows: carboplatin+amrubicin (HRos 0.56, 95% confidence interval (CI) 0.33–0.96), carboplatin+etoposide+atezolizumab (HRos 0.70, 95% CI 0.53–0.92), and carboplatin+irinotecan (HRos 0.73, 95% CI 0.58–0.91) were compared with carboplatin+etoposide. The carboplatin+etoposide+atezolizumab regimen was compared with carboplatin+irinotecan (HRos 0.97, 95% CI 0.68–1.37) and cisplatin+irinotecan regimen (HRos 0.87, 95% CI 0.58–1.31). “Selective carboplatin or cisplatin (CBDCA/CDDP)”+etoposide+durvalumab was compared with CBDCA/CDDP+etoposide (HRos 0.73, 95% CI 0.59–0.91). Platinum+etoposide+durvalumab was compared with platinum+irinotecan (HRos 0.88, 95% CI 0.67–1.15). Cumulative meta-analysis suggested that platinum+irinotecan was associated with better OS than platinum+etoposide as of 2010 through 40 out of 46 trials in our review that used platinum+etoposide as a reference regimen. Conclusion: Patients treated with carboplatin+amrubicin, carboplatin+etoposide+atezolizumab, CBDCA/CDDP+etoposide+durvalumab, and platinum+irinotecan showed better HRos than those treated with platinum+etoposide, one of the standard regimens. © The Author(s), 2020.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 9; All Open Access, Gold Open Access} -} - -@ARTICLE{Qi20175745, - author = {Qi, Xinmeng and Jia, Bo and Zhao, Xue and Yu, Dan}, - title = {Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma}, - year = {2017}, - journal = {OncoTargets and Therapy}, - volume = {10}, - pages = {5745 – 5754}, - doi = {10.2147/OTT.S148182}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85037725165&doi=10.2147%2fOTT.S148182&partnerID=40&md5=61d0ee59566d0039f72890b12634baf5}, - abstract = {Head and neck squamous cell carcinoma (HNSCC) has been found to be a complex group of malignancies characterized by their profound immunosuppression and high aggressiveness. In most cases of advanced HNSCC, treatment fails to obtain total cancer cure. Efforts are needed to develop new therapeutic approaches to improve HNSCC outcomes. In this light, T-cells “immune checkpoint” has attracted much attention in cancer immunotherapy. It has been broadly accepted that inhibitory T-cell immune checkpoints contribute to tumor immune escape through negative immune regulatory signals (cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4], programmed cell death 1 [PD-1], B7-H3, and B7-H4, etc). Current data suggest that PD-1 and CTLA-4 receptors can inhibit T-cell receptors and T-cell proliferation. Blockade of PD-1/PD-L1 and/or CTLA-4/CD28 pathways has shown promising tumor outcomes in clinical trials for advanced solid tumors like melanoma, renal cell cancer, and non-small cell lung cancer. The present review attempts to explore what is known about PD-1/PD-L1 and CTLA-4/CD28 pathways with a focus on HNSCC. We further discuss how these pathways can be manipulated with therapeutic intent. © 2017 Qi et al.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 21; All Open Access, Gold Open Access} -} - -@ARTICLE{Rocco202011, - author = {Rocco, Danilo and Gravara, Luigi D. and Gridelli, Cesare}, - title = {The new immunotherapy combinations in the treatment of advanced non-small cell lung cancer: Reality and perspectives}, - year = {2020}, - journal = {Current Clinical Pharmacology}, - volume = {15}, - number = {1}, - pages = {11 – 19}, - doi = {10.2174/1574884714666190809124555}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079195376&doi=10.2174%2f1574884714666190809124555&partnerID=40&md5=32f972be283cb6c74f6a946b044e909a}, - abstract = {Background: In the recent years, immunotherapeutics and specifically immune-checkpoints inhibitors have marked a significant shift in the diagnostic and therapeutic algorithm of Non-Small Cell Lung Cancer (NSCLC), allowing us to use immunotherapeutics alone or combined with chemotherapy for a great subset of patients. However, new interesting approaches are being presently investigated, markedly immunotherapy combinations, that is, the use of two or more im-munotherapeutics combined. Methods: In particular, the combination of anti-PD-1 nivolumab and anti-CTLA-4 ipilimumab has already provided groundbreaking positive results in the advanced NSCLC and other combinations are currently under investigation. Results: Therefore, this paper aims to provide a comprehensive state-of-the-art review about immu-notherapy combination, along with suggestions about future directions. A comprehensive literature search was carried out to identify eligible studies from MEDLINE/PubMed and ClinicalTrials.gov. Conclusion: Nivolumab plus ipilimumab represent the most promising immunotherapy combination for the treatment of advanced NSCLC patients; safety, tolerability and efficacy of new immu-notherapeutics (in monotherapy and in immunotherapy combinations) must be further assessed in future studies. © 2020 Bentham Science Publishers.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 14; All Open Access, Green Open Access} -} - -@ARTICLE{Vivaldi2020, - author = {Vivaldi, Caterina and Catanese, Silvia and Massa, Valentina and Pecora, Irene and Salani, Francesca and Santi, Stefano and Lencioni, Monica and Vasile, Enrico and Falcone, Alfredo and Fornaro, Lorenzo}, - title = {Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist?}, - year = {2020}, - journal = {International Journal of Molecular Sciences}, - volume = {21}, - number = {5}, - doi = {10.3390/ijms21051658}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85080987227&doi=10.3390%2fijms21051658&partnerID=40&md5=df68e351eb3a62dd48f475199322efe3}, - abstract = {Esophageal cancer remains a challenging disease due to limited treatment options and poor prognosis. In recent years, immune checkpoint inhibitors (ICI) have been proven to be safe and effective in the treatment of highly lethal malignancies, such as non‐small cell lung cancer and melanoma. Recent clinical trials also showed promising activity in immune checkpoint inhibitors in pretreated advanced esophageal carcinoma and a potentially significant impact on the outcome of selected patients, independently of histology. Combination studies evaluating immunotherapy and chemotherapy and, in localized disease, radiotherapy are in progress and will hopefully confirm their promises in the near future. However, reliable predictive biomarkers are still lacking. Indeed, at present, the role of programmed cell death ligand 1 expression and other factors (such as microsatellite instability and tumor mutational burden) as predictive biomarkers of benefit to immune checkpoint inhibitors is still controversial. Our aim was to explore the rationale of ICIs in esophageal cancer, review the results already available in multiple settings, and investigate future perspectives with single‐agent and combination strategies. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 21; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Beer2019535, - author = {Beer, Lucian and Hochmair, Maximilian and Haug, Alexander R. and Schwabel, Bernhard and Kifjak, Daria and Wadsak, Wolfgang and Fuereder, Thorsten and Fabikan, Hannah and Fazekas, Andreas and Schwab, Sophia and Mayerhoefer, Marius E. and Herold, Christian and Prosch, Helmut}, - title = {Comparison of RECIST, iRECIST, and PERCIST for the evaluation of response to PD-1/PD-L1 blockade therapy in patients with non-small cell lung cancer}, - year = {2019}, - journal = {Clinical Nuclear Medicine}, - volume = {44}, - number = {7}, - pages = {535 – 543}, - doi = {10.1097/RLU.0000000000002603}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067089744&doi=10.1097%2fRLU.0000000000002603&partnerID=40&md5=887e59e08d9d3faf0969126edec595e2}, - abstract = {Purpose The aim of this study was to compare the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, the immune RECIST (iRECIST) criteria, and the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) 1.0 in patients with advanced non-small cell lung cancer treated with programmed cell death protein 1 (PD-1)/programmed cell death protein 1 ligand (PD-L1) inhibitors. Methods This prospective study of 42 patients treated with a PD-1/PD-L1 inhibitor was approved by our institutional review board, and all patients gave written, informed consent. Tumor burden dynamics were assessed on 18F-FDG PET/CT before and after treatment initiation. Immunotherapeutic responses were evaluated according to RECIST 1.1, iRECIST, and PERCIST 1.0 for the dichotomous groups, responders versus nonresponders. Cohen κ and Wilcoxon signed rank tests were used to evaluate concordance among these criteria. We assessed progression-free survival and overall survival using the Kaplan-Meier estimator. Results The RECIST 1.1 and PERCIST 1.0 response classifications were discordant in 6 patients (14.2%; κ = 0.581). RECIST 1.1 and iRECIST were discordant in 2 patients, who evidenced pseudoprogression after treatment initiation. Median progression-free survival, as well as overall survival, was significantly longer for responders compared with nonresponders for all criteria (P < 0.001), with no significant difference between the 3 criteria (P > 0.05). Conclusions RECIST 1.1 and PERCIST 1.0 show only moderate agreement, but both can predict treatment response to PD-1/PD-L1 inhibitor therapy. In case of pseudoprogression, metabolic tumor activity may help to correctly classify treatment response. © 2019 Wolters Kluwer Health, Inc. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 46} -} - -@ARTICLE{Mezquita2018205, - author = {Mezquita, Laura and Planchard, David}, - title = {Durvalumab in non-small-cell lung cancer patients: Current developments}, - year = {2018}, - journal = {Future Oncology}, - volume = {14}, - number = {3}, - pages = {205 – 222}, - doi = {10.2217/fon-2017-0373}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041558247&doi=10.2217%2ffon-2017-0373&partnerID=40&md5=3f2a8a6c504c44778044a0e3c26b04cc}, - abstract = {Immune checkpoint inhibitors (ICIs) are a key component of treating advanced cancer patients, principally antibodies against CTLA-4 and PD-1 or PD-L1. Durvalumab (MEDI4736) is a selective, high-affinity, human IgG1 monoclonal antibody that blocks PD-L1, which binds to PD-1 and CD80, but not to PD-L2. Single-agent durvalumab showed clinical efficacy and a manageable safety profile in advanced non-small-cell lung cancer, particularly the ≥25% PD-L1+ population. Durvalumab is under evaluation in early, locally advanced and advanced disease as monotherapy and combined with ICIs, targeted therapies, chemotherapy and radiotherapy. Impressive activity has been recently reported after chemoradiation in locally advanced patients; promising activity was observed with other ICI combinations, and potentially with other drugs including platinum-based chemotherapy. In contrast, early data reveal lower response rates in EGFR and ALK-positive patients. © 2018 2018 Future Medicine Ltd.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 13} -} - -@ARTICLE{Brahmer2018, - author = {Brahmer, Julie R. and Govindan, Ramaswamy and Anders, Robert A. and Antonia, Scott J. and Sagorsky, Sarah and Davies, Marianne J. and Dubinett, Steven M. and Ferris, Andrea and Gandhi, Leena and Garon, Edward B. and Hellmann, Matthew D. and Hirsch, Fred R. and Malik, Shakuntala and Neal, Joel W. and Papadimitrakopoulou, Vassiliki A. and Rimm, David L. and Schwartz, Lawrence H. and Sepesi, Boris and Yeap, Beow Yong and Rizvi, Naiyer A. and Herbst, Roy S.}, - title = {The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)}, - year = {2018}, - journal = {Journal for ImmunoTherapy of Cancer}, - volume = {6}, - number = {1}, - doi = {10.1186/s40425-018-0382-2}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050106401&doi=10.1186%2fs40425-018-0382-2&partnerID=40&md5=30af6b1ab34d7a3a88b2fcb77b9883db}, - abstract = {Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy - characterized by some benefit but only rare durable responses - was the only treatment option for patients with NSCLC whose tumors lacked targetable mutations. By contrast, immune checkpoint inhibitors have demonstrated distinctly durable responses and represent the advent of a new treatment approach for patients with NSCLC. Three immune checkpoint inhibitors, pembrolizumab, nivolumab and atezolizumab, are now approved for use in first- and/or second-line settings for selected patients with advanced NSCLC, with promising benefit also seen in patients with stage III NSCLC. Additionally, durvalumab following chemoradiation has been approved for use in patients with locally advanced disease. Due to the distinct features of cancer immunotherapy, and rapid progress in the field, clinical guidance is needed on the use of these agents, including appropriate patient selection, sequencing of therapies, response monitoring, adverse event management, and biomarker testing. The Society for Immunotherapy of Cancer (SITC) convened an expert Task Force charged with developing consensus recommendations on these key issues. Following a systematic process as outlined by the National Academy of Medicine, a literature search and panel voting were used to rate the strength of evidence for each recommendation. This consensus statement provides evidence-based recommendations to help clinicians integrate immune checkpoint inhibitors into the treatment plan for patients with NSCLC. This guidance will be updated following relevant advances in the field. © 2018 The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 185; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Bryan2019, - author = {Bryan, Darren S. and Donington, Jessica S.}, - title = {The Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer}, - year = {2019}, - journal = {Current Treatment Options in Oncology}, - volume = {20}, - number = {4}, - doi = {10.1007/s11864-019-0624-7}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062988173&doi=10.1007%2fs11864-019-0624-7&partnerID=40&md5=09f66b0fe878cbc23a40fa089ee0ccde}, - abstract = {Patients with locally advanced non-small cell lung cancer (NSCLC) are treated for cure, but treatment decisions are not straightforward. Chemotherapy is essential due to the high risk of systemic relapse, but local therapy is also required for cure. In the small subset of stage III patients with N0 or N1 disease, surgery is typically the initial therapy and extended resections are frequent. The majority of IIIA patients present with N2 disease and treatment paradigms for these patients are controversial, particularly concerning the role of resection. Surgery has a limited role in bulky IIIA, IIIB, and IIIC disease, which is typically treated with combined systemic therapy and radiation. The authors believe that in resectable IIIA disease, the addition of surgery to multimodality treatment appears to improve local control and overall survival. Induction therapy is essential, and the use of chemotherapy alone or chemoradiotherapy remains an area of debate. Pneumonectomy should be used with caution in IIIA disease, as numerous prospective trials have noted excessive perioperative mortality. The introduction of immunotherapies in this stage may quickly transform treatment decisions. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 38} -} - -@ARTICLE{Assi2018248, - author = {Assi, Hazem I. and Kamphorst, Alice O. and Moukalled, Nour M. and Ramalingam, Suresh S.}, - title = {Immune checkpoint inhibitors in advanced non–small cell lung cancer}, - year = {2018}, - journal = {Cancer}, - volume = {124}, - number = {2}, - pages = {248 – 261}, - doi = {10.1002/cncr.31105}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040255379&doi=10.1002%2fcncr.31105&partnerID=40&md5=fe5f36b495181f7ad84d92696657e3d5}, - abstract = {The emergence of immune checkpoint inhibitors for the treatment of cancer has led to major changes to the therapeutic landscape of lung cancer. Improvements in overall survival relative to standard chemotherapy have been observed in the first-line and second-line therapy settings for patients with advanced non–small cell lung cancer (NSCLC) who are treated with immune checkpoint inhibitors. Consequently, every patient with advanced-stage NSCLC is now a candidate for immune checkpoint inhibitor therapy. However, it is clear that the benefit from therapy is not universal, and identification of biomarkers to select therapy has assumed importance. In addition to programmed cell death receptor ligand 1 expression, both tissue-based and blood-based markers are under evaluation to select patients. In an era of increasing costs of care and potential for toxicities related to immune checkpoint inhibition, proper patient selection is critical to the optimal use of this new class of agents. In addition, development of novel combination approaches has also emerged as an important way to improve the efficacy of immune checkpoint inhibition. Studies in earlier stages of NSCLC are already underway with the hope of improving the cure rate. In this article, the authors review the current landscape of immune checkpoint inhibitors in the treatment of advanced NSCLC. Cancer 2018;124:248-61. © 2017 American Cancer Society. © 2017 American Cancer Society}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 93; All Open Access, Bronze Open Access} -} - -@ARTICLE{Marino2019, - author = {Marino, Donatella and Zichi, Clizia and Audisio, Marco and Sperti, Elisa and Di Maio, Massimo}, - title = {Second-line treatment options in hepatocellular carcinoma}, - year = {2019}, - journal = {Drugs in Context}, - volume = {8}, - doi = {10.7573/dic.212577}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070207227&doi=10.7573%2fdic.212577&partnerID=40&md5=0e4c2d346bb17fccf8fed94936d606e7}, - abstract = {For many years, sorafenib has been the only approved systemic treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-line treatment have failed to prove any survival benefit. However, in the past few years, several advances have been made especially in pretreated patients; phase III trials of regorafenib, cabozantinib, and ramucirumab in patients with elevated α-fetoprotein have demonstrated efficacy in patients progressing after or intolerant to sorafenib. In addition, early phase I and II trials have shown promising results of immunotherapy alone or in combination with tyrosine-kinase inhibitors or monoclonal antibodies in the same setting of patients. In this review, we will discuss the evidence on second-line options for HCC, focusing on the latest results that are currently refining the treatment scenario. Copyright © 2019 Marino D, Zichi C, Audisio M, Sperti E, Di Maio M.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 27; All Open Access, Gold Open Access} -} - -@ARTICLE{Chae2018, - author = {Chae, Young Kwang and Arya, Ayush and Iams, Wade and Cruz, Marcelo R. and Chandra, Sunandana and Choi, Jaehyuk and Giles, Francis}, - title = {Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)}, - year = {2018}, - journal = {Journal for ImmunoTherapy of Cancer}, - volume = {6}, - number = {1}, - doi = {10.1186/s40425-018-0349-3}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047100576&doi=10.1186%2fs40425-018-0349-3&partnerID=40&md5=e061e43034aa0a41818c9a9eb405d8eb}, - abstract = {Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens. Preliminary trials assessing combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 immune-checkpoint inhibitors have documented considerable advantages in survival indices over single-agent immunotherapy. The therapeutic potential of combinatorial approaches is highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients with advanced melanoma. Presently, dual-immune checkpoint inhibition with anti-programmed death receptor-1/programmed cell death receptor- ligand-1 (anti-PD-1/PD-L1) plus anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) monoclonal antibodies (MoAbs) is being evaluated for a wide range of tumor histologies. Furthermore, several ongoing clinical trials are investigating combination checkpoint inhibition in association with traditional treatment modalities such as chemotherapy, surgery, and radiation. In this review, we summarize the current landscape of combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 MoAbs for patients with melanoma and non-small cell lung cancer (NSCLC). We present a synopsis of the prospects for expanding the indications of dual immune-checkpoint inhibition therapy to a more diverse set of tumor histologies. © 2018 The Author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 310; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Falzone2018, - author = {Falzone, Luca and Salomone, Salvatore and Libra, Massimo}, - title = {Evolution of cancer pharmacological treatments at the turn of the third millennium}, - year = {2018}, - journal = {Frontiers in Pharmacology}, - volume = {9}, - number = {NOV}, - doi = {10.3389/fphar.2018.01300}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056833259&doi=10.3389%2ffphar.2018.01300&partnerID=40&md5=fe7eb64a6ab8171ba1038e5624c26613}, - abstract = {The medical history of cancer began millennia ago. Historical findings of patients with cancer date back to ancient Egyptian and Greek civilizations, where this disease was predominantly treated with radical surgery and cautery that were often ineffective, leading to the death of patients. Over the centuries, important discoveries allowed to identify the biological and pathological features of tumors, without however contributing to the development of effective therapeutic approaches until the end of the 1800s, when the discovery of X-rays and their use for the treatment of tumors provided the first modern therapeutic approach in medical oncology. However, a real breakthrough took place after the Second World War, with the discovery of cytotoxic antitumor drugs and the birth of chemotherapy for the treatment of various hematological and solid tumors. Starting from this epochal turning point, there has been an exponential growth of studies concerning the use of new drugs for cancer treatment. The second fundamental breakthrough in the field of oncology and pharmacology took place at the beginning of the '80s, thanks to molecular and cellular biology studies that allowed the development of specific drugs for some molecular targets involved in neoplastic processes, giving rise to targeted therapy. Both chemotherapy and target therapy have significantly improved the survival and quality of life of cancer patients inducing sometimes complete tumor remission. Subsequently, at the turn of the third millennium, thanks to genetic engineering studies, there was a further advancement of clinical oncology and pharmacology with the introduction of monoclonal antibodies and immune checkpoint inhibitors for the treatment of advanced or metastatic tumors, for which no effective treatment was available before. Today, cancer research is always aimed at the study and development of new therapeutic approaches for cancer treatment. Currently, several researchers are focused on the development of cell therapies, anti-tumor vaccines, and new biotechnological drugs that have already shown promising results in preclinical studies, therefore, in the near future, we will certainly assist to a new revolution in the field of medical oncology. Copyright © 2018 Falzone, Salomone and Libra.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 636; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Remon201821, - author = {Remon, J. and Vilariño, N. and Reguart, N.}, - title = {Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions}, - year = {2018}, - journal = {Cancer Treatment Reviews}, - volume = {64}, - pages = {21 – 29}, - doi = {10.1016/j.ctrv.2018.02.002}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042196270&doi=10.1016%2fj.ctrv.2018.02.002&partnerID=40&md5=2d3e02b2fa237fc2c7471177b0311877}, - abstract = {Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment strategy of advanced non-small cell lung cancer (NSCLC). Beyond the already approved indications in first- and second-line setting of advanced NSCLC, new data has recently emerged demonstrating its efficacy in locally advanced disease as maintenance after chemo-radiotherapy and currently several trials are also exploring its efficacy in earlier stages of the disease to evaluate whether these results could be extrapolated to the adjuvant setting. With the advent of all these new therapies, their potential in other thoracic malignancies such as mesothelioma and small-cell lung cancer are also being evaluated with encouraging preliminary data that endorses their short-term incorporation as new therapeutic options in these thoracic malignancies. However, despite all these new evidence, there are still several open questions that remain to be solved like the use of immune agents in special subpopulations such as elderly or fragile patients or the case of patients with brain metastases or autoimmune disorders. In addition some other open questions remain with regards ICIs activity in patients receiving corticosteroid or antibiotics, the potential use in oncogenic addicted tumours, as well as the safety of retreatment after the onset of immune-related adverse events (ir-AE) or the optimal dose schedule or time on treatment for ICIs administration. Herein, we propose to address all these questions, reviewing most recent evidence available in order to give readers some practical advises and guidance on how to deal with these challenges when treating NSCLC patients with immunotherapy. © 2018 Elsevier Ltd}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 38} -} - -@ARTICLE{Wang2020667, - author = {Wang, Shiqiang and Hu, Chongling and Xie, Fei and Liu, Yanhui}, - title = {Use of programmed death receptor-1 and/or programmed death ligand 1 inhibitors for the treatment of brain metastasis of lung cancer}, - year = {2020}, - journal = {OncoTargets and Therapy}, - volume = {13}, - pages = {667 – 683}, - doi = {10.2147/OTT.S235714}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078803465&doi=10.2147%2fOTT.S235714&partnerID=40&md5=513356fd3485e963714631413a658eff}, - abstract = {The central nervous system (CNS) is regarded as an immune privileged environment; however, changes in the neuroimmunology paradigm have led to an increased interest in systematic immunotherapy in lung cancer therapy. The presence of the lymphatic system in the CNS as well as the physiological and biochemical changes in the blood–brain barrier in the tumor microenvironment suggests that immunocytes are fully capable of entering and exiting the CNS. Emerging clinical data suggest that inhibitors of programmed death receptor-1/programmed death ligand 1 (PD-1/PD-L1) can stimulate surrounding T cells and thus have antitumor effects in the CNS. For example, PD-1 antibody (pembrolizumab) monotherapy has displayed a 20–30% encephalic response rate in patients with brain metastases from malignant melanoma or non-small cell lung cancer. Combined application of nivolumab and ipilimumab anti-PD-1 and anti-cytotoxic T-lymphocyte-associated protein 4 showed an encephalic response rate of 55% in patients with brain metastases of melanoma. Further evidence is required to verify these response rates and identify the mechanisms of curative effects and drug tolerance. While regional treatments such as whole-brain radiosurgery, stereotactic radiosurgery, and brain surgery remain the mainstream, PD-1/PD-L1 inhibitors display potential decreased neurotoxic effects. To date, five drugs have been approved for use in patients with encephalic metastases of lung carcinoma: the anti-PD-1 drugs, pembrolizumab and nivolumab, and the anti-PD-L1 agents, atezolizumab, durvalumab, and avelu-mab. In recent years, clinical trials of inhibitors in combination with other drugs to treat brain metastasis have also emerged. This review summarizes the biological principles of PD-1/PD-L1 immunotherapy for brain metastasis of lung cancer, as well as ongoing clinical trials to explore unmet needs. © 2020 Wang et al.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 26; All Open Access, Gold Open Access} -} - -@ARTICLE{Agustoni2018S19, - author = {Agustoni, Francesco and Hirsch, Fred R.}, - title = {PACIFIC trial: New perspectives for immunotherapy in lung cancer}, - year = {2018}, - journal = {Translational Lung Cancer Research}, - volume = {7}, - pages = {S19 – S24}, - doi = {10.21037/tlcr.2017.12.12}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041861563&doi=10.21037%2ftlcr.2017.12.12&partnerID=40&md5=9740176a8e8182d71ce1a9e959b414be}, - type = {Editorial}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1; All Open Access, Green Open Access} -} - -@ARTICLE{Rusch20181777, - author = {Rusch, Valerie W. and Chaft, Jamie and Hellmann, Matthew}, - title = {KEYNOTE-024: Unlocking a pathway to lung cancer cure?}, - year = {2018}, - journal = {Journal of Thoracic and Cardiovascular Surgery}, - volume = {155}, - number = {4}, - pages = {1777 – 1780}, - doi = {10.1016/j.jtcvs.2017.10.155}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041054877&doi=10.1016%2fj.jtcvs.2017.10.155&partnerID=40&md5=133620f93e79f498f2eb7e4a7fedb377}, - type = {Editorial}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 8; All Open Access, Bronze Open Access} -} - -@ARTICLE{Murakami20191009, - author = {Murakami, Shuji}, - title = {Durvalumab for the treatment of non-small cell lung cancer}, - year = {2019}, - journal = {Expert Review of Anticancer Therapy}, - volume = {19}, - number = {12}, - pages = {1009 – 1016}, - doi = {10.1080/14737140.2019.1699407}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076051961&doi=10.1080%2f14737140.2019.1699407&partnerID=40&md5=06a91f17188815451501cc09768dbd2f}, - abstract = {Introduction: The prognosis of patients with advanced non-small cell lung cancer (NSCLC) remains poor, with a 5-year overall survival rate of around 15%. Immune checkpoint inhibitors, such as programmed cell death protein 1 and programmed death-ligand 1 (PD-L1) inhibitors, have opened a new era in the management of NSCLC. Three checkpoint inhibitors (nivolumab, pembrolizumab, and atezolizumab) are currently approved by the US Food and Drug Administration (FDA) for advanced NSCLC. Durvalumab, an anti-PD-L1 antibody, is under investigation in several trials. Areas covered: This article reviews the pharmacological properties, clinical efficacy, and safety of durvalumab as monotherapy and in combination with other drugs for the treatment of locally advanced and advanced NSCLC. Expert opinion: Durvalumab as monotherapy or in combination with tremelimumab was effective with well-tolerated safety profiles for advanced NSCLC in several phase I or II studies. The PACIFIC study assessed the effectiveness of durvalumab as maintenance therapy following definitive chemoradiotherapy for unresectable stage III NSCLC, and met its primary endpoints of progression-free survival and overall survival. These results led to FDA approval for this NSCLC population. It will be exciting to follow ongoing phase III studies assessing how durvalumab fits into the rapidly evolving therapeutic landscape for advanced NSCLC. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 20} -} - -@ARTICLE{Meng201729, - author = {Meng, Xiangjiao and Liu, Yanli and Zhang, Jianjun and Teng, Feifei and Xing, Ligang and Yu, Jinming}, - title = {PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges}, - year = {2017}, - journal = {Cancer Letters}, - volume = {405}, - pages = {29 – 37}, - doi = {10.1016/j.canlet.2017.06.033}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85026522198&doi=10.1016%2fj.canlet.2017.06.033&partnerID=40&md5=09d0c1b6dadc8c4c7ea242835a07b904}, - abstract = {PD-1/PD-L1 checkpoint blockades have dramatically changed the landscape for second-line treatment of non-small cell lung cancer (NSCLC). Based on the promising results of Keynote-024 presented so far, pembrolizumab has been approved as first-line treatment for advanced PD-L1 positive NSCLC patients. However, overall response rate (ORR) is limited to PD-1/PD-L1 checkpoint blockades when used as single agent. Combining with chemotherapy, anti-CTLA-4 antibodies, targeted therapy, radiotherapy or other treatment options is perceived as an appealing method aimed at achieving higher efficacy. There are many clinical trials on going or finished assessing the efficacy and safety of the PD-1/PD-L1 blockades alone or combining with other approaches in first-line or second-line treatments. A lot of challenges need to be overcome before PD-1/PD-L1 checkpoint blockades are widely used in the patients with NSCLC including the identification of optimal combination, treatment-related adverse effects, the high cost and lack of effective predictive markers. In this review, we focus on outlining current clinical trials and challenges for future research of PD-1/PD-L1 pathway checkpoint blockades in NSCLC. © 2017 Elsevier B.V.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 78} -} - -@ARTICLE{Qin2017709, - author = {Qin, Angel and Gadgeel, Shirish}, - title = {The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions}, - year = {2017}, - journal = {Targeted Oncology}, - volume = {12}, - number = {6}, - pages = {709 – 718}, - doi = {10.1007/s11523-017-0526-1}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028605348&doi=10.1007%2fs11523-017-0526-1&partnerID=40&md5=40bdaba01435796bda579c49db208d31}, - abstract = {Tumorigenic rearrangements in anaplastic lymphoma kinase (ALK) account for 3–7% of all non-small cell lung cancers (NSCLC). Treatment with targeted tyrosine kinase inhibitors (TKIs) has shown impressive clinical responses. Crizotinib was the first agent approved for front-line therapy of ALK-rearranged NSCLC after it demonstrated superiority to chemotherapy in response rate, duration of response, and progression-free survival. However, eventually all patients progress on crizotinib therapy, with the central nervous system (CNS) being the most common site, which served as the impetus for the development of more potent next-generation ALK inhibitors. Currently, ceritinib, alectinib, and brigatinib are all approved for second-line therapy after progression on or intolerance to crizotinib. Investigations into whether the initiation of a second-generation ALK inhibitor as first-line therapy is the superior treatment paradigm has resulted in the approval of ceritinib as initial therapy. Alectinib has also shown impressive results as front-line therapy, as recently reported in two large randomized studies that compared it to crizotinib. There is a significant need to better understand the drivers of and mechanisms underlying resistance to ALK inhibitors. While specific mutations have been identified, there is currently only limited evidence that the identification of specific mutations should impact selection of the next ALK inhibitor. The best treatment option for patients who become TKI refractory is also unclear, though there is some evidence to suggests that these patients are not responsive to checkpoint inhibitors and may respond better to chemotherapy. Combination therapy with other classes of agents may help to overcome resistance mechanisms and should be investigated further. © 2017, Springer International Publishing AG.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 16; All Open Access, Green Open Access} -} - -@ARTICLE{Samimi2019391, - author = {Samimi, Mahtab}, - title = {Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma}, - year = {2019}, - journal = {American Journal of Clinical Dermatology}, - volume = {20}, - number = {3}, - pages = {391 – 407}, - doi = {10.1007/s40257-019-00427-9}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066115730&doi=10.1007%2fs40257-019-00427-9&partnerID=40&md5=fa4d4f471323bcf41b3d997738ee8e78}, - abstract = {Merkel cell carcinoma (MCC) is an aggressive skin cancer. Until 2017, patients with advanced disease were typically treated with conventional chemotherapies, with a median response duration of 3 months. Increased evidence of the role of the immune system in controlling this cancer has paved the way for immune-based therapies, with programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitors at the frontline. Avelumab, an anti-PD-L1 antibody, was the first-ever drug approved in advanced MCC after showing meaningful efficacy in a second-line setting. Objective responses were observed in one-third of patients and, most importantly, were durable with half of patients and one-third of patients still alive at 1 and 2 years, respectively. When used in a first-line setting, PD-1/PD-L1 inhibitors (avelumab, pembrolizumab, nivolumab) are even more promising as objective responses are observed in approximately 50–70% of patients within the first 4–8 weeks of treatment. Safety profiles are acceptable with 10–20% of patients experiencing adverse events grade ≥ 3. PD-1/PD-L1 inhibitors are considered the standard of care in advanced MCC and are currently being investigated in the adjuvant and neoadjuvant settings. However, innovative treatments are still needed in the metastatic setting, as approximately 50% of these patients will not persistently respond to currently available immunotherapies, and no predictors of response are available yet. Therefore, other immunotherapeutic strategies are now being investigated—ideally in combinations—to enhance the various aspects of the immune response against tumoral cells. © 2019, Springer Nature Switzerland AG.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 33} -} - -@ARTICLE{Botticella2019, - author = {Botticella, Angela and Mezquita, Laura and Le Pechoux, Cecile and Planchard, David}, - title = {Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience}, - year = {2019}, - journal = {Therapeutic Advances in Respiratory Disease}, - volume = {13}, - doi = {10.1177/1753466619885530}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074545394&doi=10.1177%2f1753466619885530&partnerID=40&md5=4137fcc5d8c7b3c503b8d817adbedad2}, - abstract = {Stage III non-small cell lung cancer (NSCLC) has a dismal prognosis, with only 15–20% of patients alive at 5 years after concomitant chemo–radiotherapy, which represents the standard treatment. Targeting immune-checkpoint inhibitors represents a standard option for advanced NSCLC. Improvements in understanding of the immune profile of NSCLC has led to the development of immunotherapeutic strategies, including inhibitory molecules responsible for abrogating an anticancer immune response such as programmed cell-death 1 and programmed cell-death ligand 1. A recently published phase III trial (PACIFIC) showed for the first time an improved overall survival in stage III NSCLC patients with consolidative durvalumab. The aim of this review is to summarize and discuss the clinical evidence for the use of durvalumab in stage III NSCLC, with a brief overview on future perspectives in this setting. © The Author(s), 2019.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 20; All Open Access, Gold Open Access} -} - -@ARTICLE{Kim2018172, - author = {Kim, Jae Ho and Jenrow, Kenneth A. and Brown, Stephen L.}, - title = {Novel biological strategies to enhance the radiation therapeutic ratio}, - year = {2018}, - journal = {Radiation Oncology Journal}, - volume = {36}, - number = {3}, - pages = {172 – 181}, - doi = {10.3857/roj.2018.00332}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056571187&doi=10.3857%2froj.2018.00332&partnerID=40&md5=78add682019a614d71f77182e1816579}, - abstract = {Successful anticancer strategies require a differential response between tumor and normal tissue (i.e., a therapeutic ratio). In fact, improving the effectiveness of a cancer therapeutic is of no clinical value in the absence of a significant increase in the differential response between tumor and normal tissue. Although radiation dose escalation with the use of intensity modulated radiation therapy has permitted the maximum tolerable dose for most locally advanced cancers, improvements in tumor control without damaging normal adjacent tissues are needed. As a means of increasing the therapeutic ratio, several new approaches are under development. Drugs targeting signal transduction pathways in cancer progression and more recently, immunotherapeutics targeting specific immune cell subsets have entered the clinic with promising early results. Radiobiological research is underway to address pressing questions as to the dose per fraction, irradiated tumor volume and time sequence of the drug administration. To exploit these exciting novel strategies, a better understanding is needed of the cellular and molecular pathways responsible for both cancer and normal tissue and organ response, including the role of radiation-induced accelerated senescence. This review will highlight the current understanding of promising biologically targeted therapies to enhance the radiation therapeutic ratio. © 2018. The Korean Society for Radiation Oncology.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 14; All Open Access, Gold Open Access} -} - -@ARTICLE{Huber2019, - author = {Huber, Rudolf M. and De Ruysscher, Dirk and Hoffmann, Hans and Reu, Simone and Tufman, Amanda}, - title = {Interdisciplinary multimodality management of stage III nonsmall cell lung cancer}, - year = {2019}, - journal = {European Respiratory Review}, - volume = {28}, - number = {152}, - doi = {10.1183/16000617.0024-2019}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069311446&doi=10.1183%2f16000617.0024-2019&partnerID=40&md5=dd4372e307f508e89ea356888a43f04c}, - abstract = {Stage III nonsmall cell lung cancer (NSCLC) comprises about one-third of NSCLC patients and is very heterogeneous with varying and mostly poor prognosis. It is also called “locoregionally or locally advanced disease”. Due to its heterogeneity a general schematic management approach is not appropriate. Usually a combination of local therapy (surgery or radiotherapy, depending on functional, technical and oncological operability) with systemic platinum-based doublet chemotherapy and, recently, followed by immune therapy is used. A more aggressive approach of triple agent chemotherapy or two local therapies (surgery and radiotherapy, except for specific indications) has no benefit for overall survival. Until now tumour stage and the general condition of the patient are the most relevant prognostic factors. Characterising the tumour molecularly and immunologically may lead to a more personalised and effective approach. At the moment, after an exact staging and functional evaluation, an interdisciplinary discussion amongst the tumour board is warranted and offers the best management strategy. © ERS 2019.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 57; All Open Access, Gold Open Access} -} - -@ARTICLE{Huber2019, - author = {Huber, Rudolf M.}, - title = {Disease progression in non-small cell lung cancer on immune-checkpoint inhibition, what are the options?}, - year = {2019}, - journal = {Precision Cancer Medicine}, - volume = {2}, - doi = {10.21037/pcm.2019.03.01}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85110645031&doi=10.21037%2fpcm.2019.03.01&partnerID=40&md5=ce4af27eaf80dec6ea2da9d272dc1e5d}, - abstract = {Most patients with advanced non-small cell lung cancer (NSCLC) and without driver mutations get or will get in the near future pembrolizumab (high expressers of PD-L1) or a combination of PD-1-/PD-L1- with chemotherapy or perhaps a combination of PD-1- and CTLA4-inhibition. In stage III after chemoradiotherapy consolidation with durvalumab is in use. If there is a response to first-line therapy, most patients will still get a recurrence or progress. The question is what kind of therapy we can offer to these patients. With the introduction of PD-1- and PD-L1-inhibition in the recurrent disease situation we got a good treatment option with solid evidence from randomized trials. As these immune-checkpoint-inhibitors are moving in first-line we have to find alternatives for recurrent or refractory tumours. Until now almost no relevant data exist what the best options are. Extrapolating from the knowledge we have from earlier situations we can suggest the following scenarios, but they have to be confirmed by prospective clinical trials: (I) if in first-line pembrolizumab alone was given, probably a classical chemotherapy doublet should be given. In the case of mono/oligo-progression local therapies can be added. Alternatively the addition of a further immune modulating drug can be examined in clinical trials; (II) if in first-line a combination of immune-checkpoint-inhibition and chemotherapy was applied, probably classical second-line chemotherapy is reasonable. If in first-line pemetrexed was not given, it could be applied in non-squamous NSCLC for second-line. Else usually docetaxel will be chosen. The question of rapid recurrence/progression leads to the option of adding antiangiogenetic drugs in early progression/recurrence. Of course a further immune modulating drug can be tested in prospective clinical trials and in mono/oligo-progression local treatment can be discussed; (III) if in first-line a combination of PD-1- and CTLA4-inhibition was used, classical doublet chemotherapy is probably the preferred option. Alternatively prospective clinical trials can examine further immune modulating agents. In case of mono/ oligo-progression local treatments can be evaluated. For the situation of 2nd recurrence at the moment only individualized treatment decisions can be offered. Overall there is unfortunately no good evidence until now how to proceed after disease progression after treatment with immune-checkpoint-inhibitors. Prospective clinical trials in order to select good sequence options for the treatment of advance NSCLC without driver mutations are urgently needed. © Precision Cancer Medicine. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1} -} - -@ARTICLE{Gullapalli20206885, - author = {Gullapalli, Sneha and Remon, Jordi and Hendriks, Lizza E. L. and Lopes, Gilberto}, - title = {Update on targeted therapies for advanced non-small cell lung cancer: Durvalumab in context}, - year = {2020}, - journal = {OncoTargets and Therapy}, - volume = {13}, - pages = {6885 – 6896}, - doi = {10.2147/OTT.S259308}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087930145&doi=10.2147%2fOTT.S259308&partnerID=40&md5=7717badcae9cd384394d0067bcd63b20}, - abstract = {Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as mono-therapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients. © 2020 Gullapalli et al.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Gold Open Access} -} - -@ARTICLE{Kagamu202010, - author = {Kagamu, Hiroshi and Kaira, Kyoichi}, - title = {Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients}, - year = {2020}, - journal = {Immunological Medicine}, - volume = {43}, - number = {1}, - pages = {10 – 15}, - doi = {10.1080/25785826.2019.1710427}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078589365&doi=10.1080%2f25785826.2019.1710427&partnerID=40&md5=827965d111f5e4ba0c5436d4423ee990}, - abstract = {Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) or PD-1 ligand-1 (PD-L1) have brought paradigm shift in lung cancer treatment. The median overall survival of patients with advanced non-small cell lung cancer treated with former standard platinum doublet cytocidal therapy is less than 1 year; however, patients responding to ICIs have durable antitumor efficacy resulting in survival longer than 5 years. Lung cancer has much gene mutations, which is a characteristic of cancer caused by extrinsic factors, such as cigarette smoking. The heterogeneity underlined by genetic mutations results in the generation of resistant clones against chemotherapy and molecular targeted therapy. On the other hand, gene mutation products generate neoepitopes that are recognized as ‘non-self’ by T cell immune system. This is one of the reasons lung cancer is a good target for ICIs. However, drastic antitumor response is observed in relatively small percentage of patients. The pre-existing T cell immunity required for PD-1 inhibitor to exhibit antitumor efficacy has been elucidated. © 2020, © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of the Japanese Society of Clinical Immunology.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4; All Open Access, Gold Open Access} -} - -@ARTICLE{Jeanson20171317, - author = {Jeanson, Arnaud and Barlesi, Fabrice}, - title = {MEDI 4736 (durvalumab) in non-small cell lung cancer}, - year = {2017}, - journal = {Expert Opinion on Biological Therapy}, - volume = {17}, - number = {10}, - pages = {1317 – 1323}, - doi = {10.1080/14712598.2017.1351939}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023739534&doi=10.1080%2f14712598.2017.1351939&partnerID=40&md5=3664876a202ac75d984957eafd3d0984}, - abstract = {Introduction: Immune checkpoint inhibitors (ICI) are now a therapeutic option for advanced non-small cell lung cancer (NSCLC) patients. ICI, such as the PD-1 inhibitors nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab, have already been marketed for the treatment of pretreated patients with advanced NSCLC. Other notable PD-L1 inhibitors under development include avelumab and durvalumab. Areas covered: This article reviews literature on durvalumab development, from the preclinical data to the results of phase III clinical trials, whether published or presented at international scientific conferences. Ongoing clinical trials were also reviewed. Expert opinion: Early phase trials of durvalumab monotherapy (and in combination) have demonstrated activity in advanced NSCLC patients and it has demonstrated a good safety profile. The authors believe that durvalumab will likely play an important role in future treatment strategies for NSCLC. The PACIFIC trial assessing durvalumab after standard chemoradiotherapy for locally advanced NSCLC has already met its primary endpoint and the potential of durvalumab will be reinforced if phase III randomized studies of first-line (MYSTIC trial) and second or subsequent (ARCTIC trial) lines of therapy demonstrate superiority over the current standard of care. © 2017 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 11} -} - -@ARTICLE{Voong2019e470, - author = {Voong, Khinh Ranh and Hazell, Sarah Z. and Fu, Wei and Hu, Chen and Lin, Cheng Ting and Ding, Kai and Suresh, Karthik and Hayman, Jonathan and Hales, Russell K. and Alfaifi, S. and Marrone, Kristen A. and Levy, Benjamin and Hann, Christine L. and Ettinger, David S. and Feliciano, Josephine L. and Peterson, Valerie and Kelly, Ronan J. and Brahmer, Julie R. and Forde, Patrick M. and Naidoo, Jarushka}, - title = {Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non–Small-Cell Lung Cancer}, - year = {2019}, - journal = {Clinical Lung Cancer}, - volume = {20}, - number = {4}, - pages = {e470 – e479}, - doi = {10.1016/j.cllc.2019.02.018}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064644650&doi=10.1016%2fj.cllc.2019.02.018&partnerID=40&md5=38ec85eed5b00211f06846c2800470a0}, - abstract = {Purpose: To investigate the relationship between radiotherapy (RT), in particular chest RT, and development of immune-related (IR) pneumonitis in non–small-cell lung cancer (NSCLC) patients treated with anti–programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1). Patients and Methods: Between June 2011 and July 2017, NSCLC patients treated with anti–PD-1/PD-L1 at a tertiary-care academic cancer center were identified. Patient, treatment, prior RT (intent, technique, timing, courses), and IR pneumonitis details were collected. Treating investigators diagnosed IR pneumonitis clinically. Diagnostic IR pneumonitis scans were overlaid with available chest RT plans to describe IR pneumonitis in relation to prior chest RT. We evaluated associations between patient, treatment, RT details, and development of IR pneumonitis by Fisher exact and Wilcoxon rank-sum tests. Results: Of the 188 NSCLC patients we identified, median follow-up was 6.78 (range, 0.30-79.3) months and median age 66 (range, 39-91) years; 54% (n = 102) were male; and 42% (n = 79) had stage I-III NSCLC at initial diagnosis. Patients received anti–PD-1/PD-L1 monotherapy (n = 127, 68%) or PD-1/PD-L1-based combinations (n = 61, 32%). In the entire cohort, 70% (132/188) received any RT, 53% (100/188) chest RT, and 37% (70/188) curative-intent chest RT. Any grade IR pneumonitis occurred in 19% (36/188; 95% confidence interval, 13.8-25.6). Of those who developed IR pneumonitis and received chest RT (n = 19), patients were more likely to have received curative-intent versus palliative-intent chest RT (17/19, 89%, vs. 2/19, 11%; P = .051). Predominant IR pneumonitis appearances were ground-glass opacities outside high-dose chest RT regions. Conclusion: No RT parameter was significantly associated with IR pneumonitis. On subset analysis of patients who developed IR pneumonitis and who had received prior chest RT, IR pneumonitis was more common in patients who received curative-intent chest RT. Attention should be paid to NSCLC patients receiving curative-intent RT followed by anti–PD-1/PD-L1 agents. In patients with non–small-cell lung cancer treated with anti–PD-1/PD-L1 agents, no specific radiation parameter was significantly associated with immune-related (IR) pneumonitis. We identify on subset analysis of patients who developed IR pneumonitis and received chest radiation, patients were numerically more likely to have received chest radiation with curative intent than with palliative intent (89% vs. 11%), that approached statistical significance. © 2019 Elsevier Inc.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 72; All Open Access, Green Open Access} -} - -@ARTICLE{Tolba2018202, - author = {Tolba, Mai F. and Omar, Hany A.}, - title = {Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders}, - year = {2018}, - journal = {Critical Reviews in Oncology/Hematology}, - volume = {122}, - pages = {202 – 207}, - doi = {10.1016/j.critrevonc.2018.01.005}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040572450&doi=10.1016%2fj.critrevonc.2018.01.005&partnerID=40&md5=49a096e9c58e05e213163b8fd8e4e6f1}, - abstract = {Immunotherapy comprises a promising new era in cancer therapy. Immune checkpoint inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were first approved by the Food and Drug Administration (FDA) for the management of metastatic melanoma in 2011. The approval of this class is being extended to include other types of immunogenic tumors. Although breast cancer (BC) was first categorized as non-immunogenic tumor type, there are certain subsets of BC that showed a high level of tumor infiltrating lymphocytes (TILs). Those subsets include the triple negative breast cancer (TNBC) and HER-2 positive breast tumors. Preliminary data from clinical trials presented promising outcomes for patients with advanced stage/metastatic TNBC. While the objective response rate (ORR) was relatively low, it is still promising because of the observation that the patients who respond to the treatment with immune checkpoint blockade have favorable prognosis and often show a significant increase in the overall survival. Therefore, the main challenge is to find ways to enhance the tumor response to such therapy and to convert the non-responders to responders. This will consequently bring new hopes for patients with advanced stage metastatic TNBC and help to decrease death tolls from this devastating disease. In the current review, we are highlighting and discussing the up-to-date strategies adopted at either the preclinical or the clinical settings to enhance tumor responsiveness to immunotherapy. © 2018 Elsevier B.V.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 45} -} - -@ARTICLE{Low2019, - author = {Low, Jia Li and Walsh, Robert J. and Ang, Yvonne and Chan, Gloria and Soo, Ross A.}, - title = {The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer}, - year = {2019}, - journal = {Therapeutic Advances in Medical Oncology}, - volume = {11}, - doi = {10.1177/1758835919870360}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071934352&doi=10.1177%2f1758835919870360&partnerID=40&md5=3f9211206fc26dbe160e902a02cc54a6}, - abstract = {Lung cancer is the most common cancer and leading cause of cancer death. While targeted therapies have redefined treatment options for non-small cell lung carcinoma (NSCLC) with genetic aberrations such as epidermal growth factor and anaplastic lymphoma kinase, many patients do not harbour these oncogenic drivers. Cancer immunology has enabled the development of immune modulators that has dramatically altered the therapeutic landscape of advanced NSCLC. The success of immune-checkpoint inhibitors in pretreated NSCLC has led to the conduct of multiple studies exploring their role in the first-line setting. This article provides an overview of the evolving landscape of immune-checkpoint inhibitors with a focus on the programmed cell-death 1 (PD-1; pembrolizumab, nivolumab) and programmed cell-death ligand 1 (PD-L1; atezolizumab, durvalumab, avelumab) immune-checkpoint inhibitors as single agent or in combination with either chemotherapy or with another immune-checkpoint inhibitor in the treatment of NSCLC, the challenges faced, as well as future perspectives. © The Author(s), 2019.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 50; All Open Access, Gold Open Access} -} - -@ARTICLE{Mignard2018498, - author = {Mignard, X. and Chaabane, N. and Chapron, J. and Giraud, F. and Arrondeau, J. and Fabre, E. and Damotte, D. and Alifano, M. and Goldwasser, F. and Wislez, M.}, - title = {Immunotherapy in NSCLC: state of the art and perspectives; [Actualités et perspectives concernant l'immunothérapie au cours des CBNPC]}, - year = {2018}, - journal = {Revue des Maladies Respiratoires Actualites}, - volume = {10}, - number = {4}, - pages = {498 – 504}, - doi = {10.1016/S1877-1203(18)30006-5}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057607440&doi=10.1016%2fS1877-1203%2818%2930006-5&partnerID=40&md5=8a6e0b979c2798f20a96cf6080e6e4b6}, - abstract = {Immune checkpoint inhibitors (ICI) are monoclonal antibodies that inhibit molecular interaction between an immune checkpoint and its ligand, which leads to increased anti-tumoral immune response. Programmed Death-1 (PD-1) and Cytotoxic T-lymphocyte Associated 4 (CTLA-4) are the most commonly known immune checkpoints. ICI now have their place in the management of non-small cell lung cancer (NSCLC), with FDA approvals after chemotherapy for nivolumab, pembrolizumab (anti-PD-1 antibodies) and atezolizumab (anti-PD-LI antibody), and as 1st line treatment for advanced NSCLC without EGFR mutation or ALK rearrangement, with strong (≥50%) PD-L1 (Programmed Death Ligand 1) expression for pembrolizumab. More recently, durvalumab (anti-PD-LI antibody) was approved as consolidation after chemo-radiotherapy for locally advanced NSCLC. In this chapter, we will develop the prospects for ICI in localized perioperative stages and recent results regarding combinations of ICI with chemotherapy or other ICIs in 1st line treatment for advanced NSCLC. © 2018 Elsevier Masson SAS.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Mulherkar2020212, - author = {Mulherkar, Ria and Grewal, Amardeep S. and Berman, Abigail T.}, - title = {Emerging role of immunotherapy in locally advanced non-small cell lung cancer}, - year = {2020}, - journal = {Clinical Advances in Hematology and Oncology}, - volume = {18}, - number = {4}, - pages = {212 – 217}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083674063&partnerID=40&md5=66b628ab31fef860b6b57f10bc2abbf4}, - abstract = {Non-small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC have locally advanced or metastatic disease at the time of diagnosis. The 5-year overall survival rate for patients with locally advanced NSCLC is 15% to 20%. The traditional treatment paradigm for unresectable locally advanced NSCLC consists of platinum-based chemotherapy with concurrent radiation. Evidence from phase 3 clinical trials has established a role for immunotherapy after chemoradiation, and emerging data continue to elucidate the expanding role of immunotherapy. © 2020, Millennium Medical Publishing, Inc. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 8} -} - -@ARTICLE{Ernani2018607, - author = {Ernani, Vinicius}, - title = {Nasopharyngeal carcinoma: Chemotherapy or no chemotherapy?}, - year = {2018}, - journal = {Journal of Oncology Practice}, - volume = {14}, - number = {10}, - pages = {607 – 608}, - doi = {10.1200/JOP.18.00532}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054898458&doi=10.1200%2fJOP.18.00532&partnerID=40&md5=7680d1733a6716ca73fa8a7603844ba4}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Bronze Open Access} -} - -@ARTICLE{Lauko2018, - author = {Lauko, Adam and Thapa, Bicky and Venur, Vyshak Alva and Ahluwalia, Manmeet S.}, - title = {Management of Brain Metastases in the New Era of Checkpoint Inhibition}, - year = {2018}, - journal = {Current Neurology and Neuroscience Reports}, - volume = {18}, - number = {10}, - doi = {10.1007/s11910-018-0877-8}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85051781975&doi=10.1007%2fs11910-018-0877-8&partnerID=40&md5=5481ef06affb05e767faa634f5b79df5}, - abstract = {Purpose of the Review: Brain metastasis is a common complication of advanced malignancies, especially, lung cancer, breast cancer, renal cell carcinoma, and melanoma. Traditionally surgery, when indicated, and radiation therapy, either as whole-brain radiation therapy or stereotactic radiosurgery, constituted the major treatment options for brain metastases. Until recently, most of the systemic chemotherapy agents had limited activity for brain metastases. However, with the advent of small molecule tyrosine kinase inhibitors and immunotherapy agents, there has been renewed interest in using these agents in the management of brain metastases. Recent Findings: Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, lung cancer, kidney cancer, and bladder cancer among others. They modulate the immune system to recognize tumor antigens as “non-self” antigens and mount an immune response against them. Summary: Initial studies of using immune checkpoint inhibitors in brain metastases have shown promising activity, and several clinical trials are currently underway. Studies are also assessing the combination of radiation therapy and immunotherapy in brain metastases. The results of these ongoing clinical trials have the potential to change the therapeutic paradigm in patients with brain metastases. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 28} -} - -@ARTICLE{Nie2020, - author = {Nie, Run-Cong and Zhao, Chong-Bang and Xia, Xiao-Wei and Luo, Ying-Shan and Wu, Ting and Zhou, Zhi-Wei and Yuan, Shu-Qiang and Wang, Yun and Li, Yuan-Fang}, - title = {The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis}, - year = {2020}, - journal = {BioMed Research International}, - volume = {2020}, - doi = {10.1155/2020/5059079}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085330125&doi=10.1155%2f2020%2f5059079&partnerID=40&md5=74080b88141c5ff46a750931192bb9fa}, - abstract = {Objectives. To evaluate the efficacy of immuno-oncology combinational therapy (IOCT) versus monotherapy with programmed cell death 1 (PD-1) or PD-ligand 1 (PD-L1) inhibitors or conventional therapies, i.e., non-IOCT, in patients with advanced solid tumors. Methods. We systematically searched the PubMed, Embase, and Cochrane Library databases from January 2015 to October 2018 for eligible studies. We included randomized trials of IOCT with available hazard ratios (HR) for death. The random effects model was used to calculate pooled HR for death; heterogeneity was assessed using I2 statistics. The main outcome measure was overall survival (OS). Results. After screening 483 relevant articles, we identified twelve trials comprising 5388 patients for quantitative analysis. IOCT-treated patients had significantly higher tumor response rate (relative risk (RR): 2.51, 95% confidence interval (CI): 1.82-3.47), prolonged progression-free survival (HR 0.62, 95% CI: 0.53-0.74), and OS (HR 0.69, 95% CI: 0.61-0.78), compared with non-IOCT-treated patients. Sensitivity analyses also demonstrated the OS advantage of IOCT across different combination modalities, intervention agents, malignancy types, and PD-L1 expression (all P<0.05). Notably, there were higher odds of high-grade (grade≥3) adverse events with IOCT (RR: 1.81, 95% CI: 1.13-2.90), but the risk of treatment-related death (RR: 1.16, 95% CI: 0.84-1.60) was not increased compared with non-IOCT. Conclusions. IOCT is a preferable treatment option over PD-1/PD-L1 inhibitor monotherapy and conventional therapy for patients with advanced solid tumors. However, we should note the increased incidence rate of high-grade AEs in IOCT. © 2020 Run-Cong Nie et al.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 10; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Faehling2019228, - author = {Faehling, Martin and Kopp, Marcel and Schwenk, Birgit and Fallscheer, Sabine and Kramberg, Sebastian and Eckert, Robert}, - title = {Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice}, - year = {2019}, - journal = {Oncology (Switzerland)}, - volume = {97}, - number = {4}, - pages = {228 – 235}, - doi = {10.1159/000500885}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067604717&doi=10.1159%2f000500885&partnerID=40&md5=d19963fceb7758e2bfe6f8d69a6ba6cf}, - abstract = {Background: Immuno-oncological (IO) therapies such as PD-1 and PD-L1 antibodies have been introduced in the treatment of advanced non-small cell lung cancer (NSCLC) since 2015 based on randomized trials showing unprecedented advantages in overall survival (OS) with hazard ratios (HRs) between 0.5 and 0.7. The impact of these treatments on OS in routine clinical practice and the role of tumor mass have not been studied. Methods: 557 consecutive patients with inoperable stage III or stage IV NSCLC diagnosed in our certified lung cancer center from 2006 to 2018 were included if they had received at least one line of systemic treatment. OS of immuno-oncologically treated patients (IO patients, n = 144) who received treatment with a PD-1 antibody (nivolumab [n = 77] or pembrolizumab [n = 51]) or a PD-L1 antibody (atezolizumab [n = 4] or durvalumab [n = 12]) was compared to historic controls treated before availability of IO treatment (n = 413) using case-control analysis. IO patients and historic controls were individually matched for stage, performance state, histology, smoking status, gender, age, and initial treatment mode (palliative vs. definitive radio-chemotherapy). Results: Case-control analysis of 91 matched pairs showed significantly longer OS in IO patients compared to historic controls (21.2 vs. 10.9 months, HR 0.526, CI 0.373-0.723). The benefit was more pronounced in patients with lower tumor stage (HR 0.48 [stage III], 0.40 [IVA], 0.63 [IVB]) or smaller tumor size (HR 0.38 [RECIST ≤57 mm], 0.40 [RECIST 58-94 mm], 0.59 [RECIST 95-141 mm], 0.75 [RECIST ≥142 mm]). Conclusions: IO patients showed significant benefit in OS with HRs comparable to those reported in phase III trials. The benefit tended to be greater in patients with lower tumor mass. © 2019 S. Karger AG, Basel.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12} -} - -@ARTICLE{Costantini2018, - author = {Costantini, Adrien and Grynovska, Marta and Lucibello, Francesca and Moisés, Jorge and Pagès, Franck and Tsao, Ming S. and Shepherd, Frances A. and Bouchaab, Hasna and Garassino, Marina and Aerts, Joachim G.J.V. and Mazières, Julien and Mondini, Michele and Berghmans, Thierry and Meert, Anne-Pascale and Cadranel, Jacques}, - title = {Immunotherapy: A new standard of care in thoracic malignancies?}, - year = {2018}, - journal = {European Respiratory Journal}, - volume = {51}, - number = {2}, - doi = {10.1183/13993003.02072-2017}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050941688&doi=10.1183%2f13993003.02072-2017&partnerID=40&md5=b3f3f915e1325c2350356f7aef325876}, - abstract = {In May 2017, the second European Respiratory Society research seminar of the Thoracic Oncology Assembly entitled “Immunotherapy, a new standard of care in thoracic malignancies?” was held in Paris, France. This seminar provided an opportunity to review the basis of antitumour immunity and to explain how immune checkpoint inhibitors (ICIs) work. The main therapeutic trials that have resulted in marketing authorisations for use of ICIs in lung cancer were reported. A particular focus was on the toxicity of these new molecules in relation to their immune-related adverse events. The need for biological selection, currently based on immunohistochemistry testing to identify the tumour expression of programmed death ligand (PD-L)1, was stressed, as well as the need to harmonise PD-L1 testing and techniques. Finally, sessions were dedicated to the combination of ICIs and radiotherapy and the place of ICIs in nonsmall cell lung cancer with oncogenic addictions. Finally, an important presentation was dedicated to the future of antitumour vaccination and of all ongoing trials in thoracic oncology. Copyright ©ERS 2018}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12; All Open Access, Bronze Open Access} -} - -@ARTICLE{Qiao2018S1534, - author = {Qiao, Meng and Jiang, Tao and Zhou, Caicun}, - title = {Shining light on advanced NSCLC in 2017: Combining immune checkpoint inhibitors}, - year = {2018}, - journal = {Journal of Thoracic Disease}, - volume = {10}, - pages = {S1534 – S1546}, - doi = {10.21037/jtd.2018.04.99}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047771114&doi=10.21037%2fjtd.2018.04.99&partnerID=40&md5=c88b794c03b4784b9257fe523996c422}, - abstract = {The treatment landscape has changed since the immune checkpoint inhibitors were approved in the treatment of non-small cell lung cancer (NSCLC). Although the promising clinical benefit from programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitors was observed in the second or subsequent line treatment of patients who progressed on chemotherapy, it has a long way for single PD-1/ PD-L1 inhibitor to move forward to the frontline without a predictive biomarker. Tumor response is far from satisfactory without selection and primary or acquired resistance to PD-1/PD-L1 inhibitors hampered their utility. Therefore, it is crucial to determine a strategy that can optimize the application of immune checkpoint inhibitors and increase the numbers of the responders. Multiple combination approaches based on PD-1/PD-L1 inhibitors are designed and aimed to boost anti-tumor response and benefit a broader population. In this review, we will integrate the updated clinical data to highlight the four most promising combination strategies in advance NSCLC: combination of checkpoint inhibition with chemotherapy, antiangiogenesis, immunotherapy and radiotherapy. We further discuss the issues needed to be addressed and perspectives in the context of "combination era". © Journal of Thoracic Diseasel.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 7; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Houssaini2020, - author = {Houssaini, Mohammed Sqalli and Damou, Meriem and Ismaili, Nabil}, - title = {Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting}, - year = {2020}, - journal = {Cancer Treatment and Research Communications}, - volume = {25}, - doi = {10.1016/j.ctarc.2020.100239}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096972388&doi=10.1016%2fj.ctarc.2020.100239&partnerID=40&md5=9705bbc719e2bd8ffeafaaf53e47e1da}, - abstract = {At the meeting of the American Society of Clinical Oncology (ASCO 2020), held this year virtually on May 29–31, investigators presented important practice changing findings in non-small cell lung cancer (NSCLC). In the early-stage resectable NSCLC, the key presentation was ADAURA study. This phase III clinical trial showed that the use of adjuvant osimertinib in stage IB–IIIA NSCLC patients harboring EGFR mutations had a clinically meaningful benefit. In locally advanced NSCLC, the recent studies investigated the role of immune checkpoint inhibitors (ICIs) administred early with or before concurrent chemoradiotherapy. In advanced-stage NSCLC with driver mutations, new targets and drugs were explored. The major step forward was the approval of personalized treatment in very uncommon genomic alterations, as RET fusions or MET mutations. In advanced NSCLC without targetable mutations, some new immunotherapy combination strategies have been presented. One of such combination was tiragolumab, an immune checkpoint inhibitor binding to TIGIT, evaluated with atezolizumab. There were also data from the Checkmate 227 and Checkmate 9LA trials that led to recent approvals. © 2020}, - type = {Letter}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 18; All Open Access, Gold Open Access} -} - -@ARTICLE{Zhu2019, - author = {Zhu, Mayanne M. T. and Dancsok, Amanda R. and Nielsen, Torsten O.}, - title = {Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development}, - year = {2019}, - journal = {Current Oncology Reports}, - volume = {21}, - number = {1}, - doi = {10.1007/s11912-019-0750-1}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060154614&doi=10.1007%2fs11912-019-0750-1&partnerID=40&md5=b4360367964af3b56bded40889f2e933}, - abstract = {Purpose of Review: This review focuses on the recent clinical development of indolamine-2,3-dioxygenase-1 (IDO-1) inhibitors. Recent Findings: IDO-1 alters tryptophan metabolism in a manner enhancing T-regulatory cell activity, but pre-clinical data show that its role in tumorigenesis is context-dependent on host and tumor interaction, highlighting some challenges in understanding the molecular oncology of this enzymatic drug target. Because results from phase I/II trials of IDO-1 inhibitor monotherapy have been disappointing, current clinical trials employ IDO-1 inhibitors in combination strategies with other immunotherapy agents or with chemotherapy ± radiation. Combinations with anti-PD-1/PD-L1 antibodies are already showing promise, and related strategies are under active evaluation. Summary: While further research is needed to elucidate the precise role of IDO-1 in tumor development, its mechanisms of action appear sufficiently distinct from other immunotherapy targets to warrant inclusion in combination immunotherapy regimens, an approach where multiple clinical trials are currently underway. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 39} -} - -@ARTICLE{Lin2020248, - author = {Lin, Steven H. and Lin, Yan and Yao, Luyang and Kalhor, Neda and Carter, Brett W. and Altan, Mehmet and Blumenschein, George and Byers, Lauren A. and Fossella, Frank and Gibbons, Don L. and Kurie, Jonathan M. and Lu, Charles and Simon, George and Skoulidis, Ferdinandos and Chang, Joe Y. and Jeter, Melenda D. and Liao, Zhongxing and Gomez, Daniel R. and O'Reilly, Michael and Papadimitrakopoulou, Vali and Thall, Peter and Heymach, John V. and Tsao, Anne S.}, - title = {Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC}, - year = {2020}, - journal = {Journal of Thoracic Oncology}, - volume = {15}, - number = {2}, - pages = {248 – 257}, - doi = {10.1016/j.jtho.2019.10.024}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077167654&doi=10.1016%2fj.jtho.2019.10.024&partnerID=40&md5=fff96284bac2b3a96726001b8edceaea}, - abstract = {Introduction: Consolidation durvalumab after chemoradiation (CRT) is the current standard of care for locally advanced NSCLC. We hypothesized that adding immunotherapy concurrently with CRT (cCRT) would increase efficacy without additive toxicity. Methods: This phase II study was conducted in two parts. Part 1 (n = 10) involved administration of conventionally fractionated CRT followed by consolidation chemotherapy (atezolizumab [two cycles] and maintenance atezolizumab up to 1 y). Part 2 (n = 30) involved administration of cCRT with atezolizumab followed by the same consolidation and maintenance therapies as in part 1. Programmed cell death ligand-1 staining cutoffs (1% or 50%) using Dako 22C3 immunohistochemistry were correlated with clinical outcomes. Results: The overall toxicities for part 1/2 were overall adverse events of grade 3 and above of 80%/80%; immune-related adverse events of grade 3 and above of 30%/20%; and pneumonitis of grade 2 and above of 10%/16%, respectively. In part 1, for preliminary efficacy results, with a median follow-up of 22.5 months, the median progression-free survival was 18.6 months, and the overall survival was 22.8 months. In part 2, with a median follow-up time of 15.1 months, the median progression-free survival was 13.2 months, and the overall survival was not reached. There was no difference in cancer recurrence regardless of programmed cell death ligand-1 status. Conclusions: Atezolizumab with cCRT is safe and feasible and has no added toxicities compared with historical rates. © 2019 International Association for the Study of Lung Cancer}, - type = {Conference paper}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 103; All Open Access, Bronze Open Access} -} - -@ARTICLE{Kloten2019, - author = {Kloten, Vera and Lampignano, Rita and Krahn, Thomas and Schlange, Thomas}, - title = {Circulating tumor cell PD-L1 expression as biomarker for therapeutic efficacy of immune checkpoint inhibition in NSCLC}, - year = {2019}, - journal = {Cells}, - volume = {8}, - number = {8}, - doi = {10.3390/cells8080809}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073958821&doi=10.3390%2fcells8080809&partnerID=40&md5=cd897a1041a125ea76042d70eebff161}, - abstract = {Over the last decade, the immune checkpoint blockade targeting the programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis has improved progression-free and overall survival of advanced non-small cell lung cancer (NSCLC) patients. PD-L1 tumor expression, along with tumor mutational burden, is currently being explored as a predictive biomarker for responses to immune checkpoint inhibitors (ICIs). However, lung cancer patients may have insufficient tumor tissue samples and the high bleeding risk often prevents additional biopsies and, as a consequence, immunohistological evaluation of PD-L1 expression. In addition, PD-L1 shows a dynamic expression profile and can be influenced by intratumoral heterogeneity as well as the immune cell infiltrate in the tumor and its microenvironment, influencing the response rate to PD-1/PD-L1 axis ICIs. Therefore, to identify subgroups of patients with advanced NSCLC that will most likely benefit from ICI therapies, molecular characterization of PD-L1 expression in circulating tumor cells (CTCs) might be supportive. In this review, we highlight the use of CTCs as a complementary diagnostic tool for PD-L1 expression analysis in advanced NSCLC patients. In addition, we examine technical issues of PD-L1 measurement in tissue as well as in CTCs. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 81; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Cheema201937, - author = {Cheema, Parneet K. and Rothenstein, J. and Melosky, B. and Brade, A. and Hirsh, V.}, - title = {Perspectives on treatment advances for stage iii locally advanced unresectable non-small-cell lung cancer}, - year = {2019}, - journal = {Current Oncology}, - volume = {26}, - number = {1}, - pages = {37 – 42}, - doi = {10.3747/co.26.4096}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062700733&doi=10.3747%2fco.26.4096&partnerID=40&md5=7f664f098b7f01a9a3b949013109f0a0}, - abstract = {For more than a decade, there has been no improvement in outcomes for patients with unresectable locally advanced (la) non-small-cell lung cancer (nsclc). The standard treatment in that setting is definitive concurrent chemotherapy and radiation (ccrt). Although the intent of treatment is curative, most patients rapidly progress, and their prognosis is poor, with a 5-year overall survival (os) rate in the 15%–25% range. Those patients therefore represent a critical unmet need, warranting expedited approval of, and access to, new treatments that can improve outcomes. The pacific trial, which evaluated durvalumab consolidation therapy after ccrt in unresectable la nsclc, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (pfs) and a significant improvement in os. Durvalumab thus fills a critical unmet need in the setting of unresectable la nsclc and provides a new option for patients treated with curative intent. Here, we review the treatment of unresectable la nsclc, with a focus on the effect of the clinical data for durvalumab. © 2019 Multimed Inc.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 55; All Open Access, Gold Open Access} -} - -@ARTICLE{Xia2019S31, - author = {Xia, Liliang and Liu, Yuanyong and Wang, Ying}, - title = {PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions}, - year = {2019}, - journal = {Oncologist}, - volume = {24}, - pages = {S31 – S41}, - doi = {10.1634/theoncologist.2019-IO-S1-s05}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062229860&doi=10.1634%2ftheoncologist.2019-IO-S1-s05&partnerID=40&md5=f4ca152b431e19f91539abbda80eab36}, - abstract = {The use of immune checkpoint inhibitors (ICIs) has become one of the most promising approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells, such as chemotherapy, radiotherapy, or targeted therapy, ICIs directly restore the exhausted host antitumor immune responses mediated by the tumors. Among multiple immune modulators identified, the programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis leading to the exhaustion of T-cell immunity in chronic infections and tumors has been widely investigated. Therefore, blocking antibodies targeting PD-1 or PD-L1 have been developed and approved for the treatment of various advanced cancers, including non-small-cell lung cancer (NSCLC), making them the most successful ICIs. Compared with chemotherapy or radiotherapy, PD-1/PD-L1 blockade therapy significantly improves the durable response rate and prolongs long-term survival with limited adverse effects in both monotherapy and combination therapy for advanced NSCLC. However, extensive challenges exist for further clinical applications, such as a small fraction of benefit population, primary and acquired resistance, the lack of predictive and prognostic biomarkers, and treatment-related adverse effects. In this article, we summarize the latest clinical applications of PD-1/PD-L1 blockade therapy in advanced NSCLC worldwide, as well as in China, and discuss the bottlenecks related to the use of this therapy in clinical practice. An exploration of the underlying mechanism of PD-1/PD-L1 blockade therapy and biomarker identification will maximize the application of ICIs in advanced NSCLC and facilitate bedside-to-bench studies in cancer immunotherapy as well. Implications for Practice: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) display apparent benefits for the treatment of advanced non-small-cell lung cancer (NSCLC). However, the clinical applications of these therapies are challenged by the limited benefit population with additional high economic burden and adverse events. This review discusses the bottlenecks of ICI therapy in clinical practice and provides appropriate guidance in the development of predictive biomarkers, the establishment of the criteria for combining PD-1/PD-L1 blockade therapy with the existing therapies, and the management of adverse events observed both in monotherapy and combination therapy, which will help maximize the applications of ICIs in advanced NSCLC. © AlphaMed Press 2019}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 269; All Open Access, Bronze Open Access, Green Open Access} -} - -@ARTICLE{Fucà2018345, - author = {Fucà, Giovanni and De Braud, Filippo and Di Nicola, Massimo}, - title = {Immunotherapy-based combinations: An update}, - year = {2018}, - journal = {Current Opinion in Oncology}, - volume = {30}, - number = {5}, - pages = {345 – 351}, - doi = {10.1097/CCO.0000000000000466}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055137690&doi=10.1097%2fCCO.0000000000000466&partnerID=40&md5=8ea330e88d97875b309755d10aca3c5d}, - abstract = {Purpose of reviewThe advent of immunotherapy significantly improved clinical outcomes in cancer patients, although immune checkpoint blockade (ICB) still lack of efficacy in a consistent proportion of treated patients. The purpose of this article is to review the most innovative and clinically promising ICB-based combinations designed to improve the efficacy of cancer immunotherapy.Recent findingsFirst-line combinatorial treatment with ipilimumab and nivolumab has recently shown to be superior to the standard of care in a subset of metastatic nonsmall cell lung cancer (NSCLC) and renal cell carcinoma (RCC). The combination of programmed cell death protein 1 (PD-1)/PD-L1 blockade with antiangiogenics has demonstrated a consistent clinical efficacy, especially for the combination of bevacizumab and atezolizumab as first-line therapy in metastatic RCC. The sequential combination of definitive chemoradiotherapy followed by durvalumab maintenance in advanced, unresectable NSCLC became the new standard of care, while the addition of pembrolizumab to first-line chemotherapy in metastatic NSCLC significantly improves overall survival. Despite promising results for the combination of ICBs with v-raf murine sarcoma viral oncogene homolog B/MAPK/ERK kinase inhibitors or epidermal growth factor receptor inhibitors, especially in melanoma and NSCLC, safety concerns slowed down the development of such strategies.SummaryImmunotherapy-based combinations are becoming the standard of care for cancer treatment, in particularly for advanced melanoma, NSCLC and RCC. © 2018 Lippincott Williams and Wilkins. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 23} -} - -@ARTICLE{Looi2019, - author = {Looi, Chin-King and Chung, Felicia Fei-Lei and Leong, Chee-Onn and Wong, Shew-Fung and Rosli, Rozita and Mai, Chun-Wai}, - title = {Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment}, - year = {2019}, - journal = {Journal of Experimental and Clinical Cancer Research}, - volume = {38}, - number = {1}, - doi = {10.1186/s13046-019-1153-8}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064409631&doi=10.1186%2fs13046-019-1153-8&partnerID=40&md5=d68a27bf489631d9716b731488f88cd5}, - abstract = {Background: Pancreatic cancer is one of the most lethal type of cancers, with an overall five-year survival rate of less than 5%. It is usually diagnosed at an advanced stage with limited therapeutic options. To date, no effective treatment options have demonstrated long-term benefits in advanced pancreatic cancer patients. Compared with other cancers, pancreatic cancer exhibits remarkable resistance to conventional therapy and possesses a highly immunosuppressive tumor microenvironment (TME). Main body: In this review, we summarized the evidence and unique properties of TME in pancreatic cancer that may contribute to its resistance towards immunotherapies as well as strategies to overcome those barriers. We reviewed the current strategies and future perspectives of combination therapies that (1) promote T cell priming through tumor associated antigen presentation; (2) inhibit tumor immunosuppressive environment; and (3) break-down the desmoplastic barrier which improves tumor infiltrating lymphocytes entry into the TME. Conclusions: It is imperative for clinicians and scientists to understand tumor immunology, identify novel biomarkers, and optimize the position of immunotherapy in therapeutic sequence, in order to improve pancreatic cancer clinical trial outcomes. Our collaborative efforts in targeting pancreatic TME will be the mainstay of achieving better clinical prognosis among pancreatic cancer patients. Ultimately, pancreatic cancer will be a treatable medical condition instead of a death sentence for a patient. © 2019 The Author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 123; All Open Access, Gold Open Access} -} - -@ARTICLE{Maymani2018137, - author = {Maymani, Hossein and Hess, Kenneth and Groisberg, Roman and Hong, David S. and Naing, Aung and Piha-Paul, Sarina and Janku, Filip and Fu, Siqing and Tsimberidou, Apostolia M. and Pant, Shubham and Karp, Daniel and Liu, Shuang and Sun, Ming and Heymach, John and Simon, George and Meric-Bernstam, Funda and Subbiah, Vivek}, - title = {Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials}, - year = {2018}, - journal = {Lung Cancer}, - volume = {120}, - pages = {137 – 141}, - doi = {10.1016/j.lungcan.2018.03.020}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046024643&doi=10.1016%2fj.lungcan.2018.03.020&partnerID=40&md5=ebfd33b84d577fca2f957aaa81166e44}, - abstract = {Objectives: Immunotherapy (IO) has altered the non-small cell lung cancer (NSCLC) therapeutic landscape. However, the majority of patients do not respond to immune-checkpoint blockade, and subsequently either receive further chemotherapy or are referred for clinical trials. Here we examined the outcomes and predictors of response to IO in early phase clinical trials. Materials and methods: We analyzed the records of 74 patients with metastatic NSCLC that were enrolled on phase 1 IO trials within MD Anderson Cancer Center from 1/2010 to 7/2017. Results: The median age was 68, with a median follow-up of 12.3 months. The median lines of prior therapy was three. There were 53 patients who did not receive any IO as a prior line of treatment with a mOS of 8.2 months and mPFS of 3.4 months. There were 21 patients who progressed on a prior IO agent and subsequently went on an IO study with a mOS of 10.5 months and mPFS of 4.3 months, which was similar to patients who did not receive IO OS HR 0.81 (P =.51) and PFS HR 0.85 (P =.59). Royal Marsden Hospital (RMH) prognostic score >1 was predictive of decreased OS HR 3.59 (P =.014) although PFS was not statistically different. MDACC prognostic score was predictive of both OS HR 3.39 (P =.0002) and PFS HR 1.9 (P =.030). ANC/ALC ratio (NLR) of >6 was predictive of decreased survival mOS 3.2 months compared to NLR <6 mOS 11 months; HR 3.0 (P =.0023). Conclusions: In our heavily pretreated patient population with NSCLC, early phase clinical trials with IO demonstrated similar outcomes to those seen in larger clinical studies that also used immune checkpoint inhibitors. The addition of NLR to RMH and MDACC prognostic scores can identify patients with poor overall outcomes treated with early phase IO studies. © 2018 Elsevier B.V.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 25; All Open Access, Green Open Access} -} - -@ARTICLE{Nagano2019595, - author = {Nagano, Tatsuya and Tachihara, Motoko and Nishimura, Yoshihiro}, - title = {Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer}, - year = {2019}, - journal = {Current Cancer Drug Targets}, - volume = {19}, - number = {8}, - pages = {595 – 630}, - doi = {10.2174/1568009619666181210114559}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069271345&doi=10.2174%2f1568009619666181210114559&partnerID=40&md5=f98390f8621746a8978ce2be80c7df2c}, - abstract = {Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancers. Indeed, gefitinib, which was the first molecular targeted therapeutic agent, has actually doubled the survival time of NSCLC patients. Vigorous efforts of clinicians and researchers have revealed that lung cancer develops through the activating mutations of many driver genes including the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), v-Raf murine sarcoma viral oncogene homolog B (BRAF), and rearranged during transfection (RET) genes. Although ALK, ROS1, and RET are rare genetic abnormalities, corresponding tyrosine kinase inhibitors (TKIs) can exert dramatic therapeutic effects. In addition to anticancer drugs targeting driver genes, bevacizumab specifically binds to human vascular endothelial growth factor (VEGF) and blocks the VEGF signaling pathway. The VEGF signal blockade suppresses angiogenesis in tumor tissues and inhibits tumor growth. In this review, we also explore immunotherapy, which is a promising new NSCLC treatment approach. In general, antitumor immune responses are suppressed in cancer patients, and cancer cells escape from the immune surveillance mechanism. Immune checkpoint inhibitors (ICIs) are antibodies that target the primary escape mechanisms, immune checkpoints. Patients who respond to ICIs are reported to experience long-lasting therapeutic effects. A wide range of clinical approaches, including combination therapy involving chemotherapy or radiation plus adjuvant therapy, are being developed. © 2019 Bentham Science Publishers.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 77; All Open Access, Green Open Access} -} - -@ARTICLE{Ling201812, - author = {Ling, Diane C. and Bakkenist, Chris J. and Ferris, Robert L. and Clump, David A.}, - title = {Role of Immunotherapy in Head and Neck Cancer}, - year = {2018}, - journal = {Seminars in Radiation Oncology}, - volume = {28}, - number = {1}, - pages = {12 – 16}, - doi = {10.1016/j.semradonc.2017.08.009}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85031703999&doi=10.1016%2fj.semradonc.2017.08.009&partnerID=40&md5=a417def8395dde3725accd5a5ba40433}, - abstract = {Immune system dysfunction plays a role in both the development and progression of head and neck squamous cell carcinoma (HNSCC), highlighting the potential role for immunotherapy to improve outcomes in this disease. The application of anti-PD-1 therapies for recurrent or metastatic HNSCC has found promising results. This has led to interest in combining immunotherapy with radiation therapy (RT) for the primary treatment of locally advanced HNSCC. RT with concurrent cetuximab is an option for patients who are medically unfit to receive cisplatin, and ongoing trials seek to determine to role of cetuximab-RT in treatment de-intensification for HPV+ oropharyngeal HNSCC. Other ongoing trials are evaluating the use of anti-PD-1 and anti-PD-L1 therapies in the upfront setting for newly diagnosed high-risk, locally advanced HNSCC, in an effort to improve disease control. Finally, early phase I studies are now investigating the use of anti-PD-1 therapy in conjunction with RT for refractory recurrent or metastatic HNSCC. © 2017}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 62} -} - -@ARTICLE{Wills2018, - author = {Wills, Beatriz and Brahmer, Julie R. and Naidoo, Jarushka}, - title = {Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer}, - year = {2018}, - journal = {Current Treatment Options in Oncology}, - volume = {19}, - number = {9}, - doi = {10.1007/s11864-018-0562-9}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85051469984&doi=10.1007%2fs11864-018-0562-9&partnerID=40&md5=0417a03805a7c0cba364d441a2faaf25}, - abstract = {Immune checkpoint inhibitors have revolutionized the management of advanced NSCLC. With the intention of generating an anti-tumor immune response, ICIs can also lead to inflammatory side effects involving a wide variety of organs in the body, termed immune-related adverse events. Although no prospective clinical trial exists to guide recommendations for optimal and more specific immunosuppressive treatments rather than corticosteroids, further studies may lead to a more mechanistic-based approach towards these toxicities in the future. In relation to current practice, we recommend adherence to the recent published guidelines which emphasize the importance of early recognition and administration of temporary immunosuppressive therapy with corticosteroids in most cases, depending on the organ system involved, and the severity of toxicity. Recognition of these toxicities is increasingly important as the use of these agents expand within different indications for patients with lung cancers, and to other tumor types. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 14; All Open Access, Green Open Access} -} - -@ARTICLE{Iwama2018267, - author = {Iwama, Eiji and Nakanishi, Yoichi and Okamoto, Isamu}, - title = {Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer}, - year = {2018}, - journal = {Expert Review of Anticancer Therapy}, - volume = {18}, - number = {3}, - pages = {267 – 276}, - doi = {10.1080/14737140.2018.1432356}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042351253&doi=10.1080%2f14737140.2018.1432356&partnerID=40&md5=a938f342fdd2d247d4fe8181018449b1}, - abstract = {Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have a pronounced clinical benefit for patients with advanced non–small cell lung cancer (NSCLC) positive for EGFR activating mutations. Such individuals inevitably develop resistance to these drugs, however, new treatment strategies to overcome such resistance are being actively pursued. The clinical benefit of EGFR-TKIs for patients with locally advanced NSCLC remains to be clarified. Areas covered: This review summarizes the recent progress in combination treatment with EGFR-TKIs and either chemotherapy or radiotherapy for patients with NSCLC positive for EGFR activating mutations. Expert commentary: Combination therapy with EGFR-TKIs and various other treatment options are under investigation in clinical studies. Although early studies failed to show a clinical benefit for such combination therapy because of a lack of patient selection, clinical studies with patient selection based on EGFR mutation status have shown promising results. Such combination therapy might eventually replace the current standard treatment for patients with NSCLC positive for EGFR activating mutations. © 2018 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 15} -} - -@ARTICLE{Yoon20173525, - author = {Yoon, Shinkyo and Lee, Dae Ho and Kim, Sang-We}, - title = {Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505)}, - year = {2017}, - journal = {Journal of Thoracic Disease}, - volume = {9}, - number = {10}, - pages = {3525 – 3528}, - doi = {10.21037/jtd.2017.09.12}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85036574282&doi=10.21037%2fjtd.2017.09.12&partnerID=40&md5=359f58621490804605349838e3093774}, - type = {Editorial}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Green Open Access} -} - -@ARTICLE{Ardolino201962, - author = {Ardolino, Luke and Joshua, Anthony}, - title = {Immune checkpoint inhibitors in malignancy}, - year = {2019}, - journal = {Australian Prescriber}, - volume = {42}, - number = {2}, - pages = {62 – 67}, - doi = {10.18773/austprescr.2019.012}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065228575&doi=10.18773%2faustprescr.2019.012&partnerID=40&md5=dbda2048997957168874a985ce0673c1}, - abstract = {Immune checkpoints normally stop the body from mounting an immune response against healthy cells. Some cancers can acquire these checkpoints so that the tumour cells are not recognised by the immune system. Inhibiting the checkpoints therefore enables the tumour cells to be recognised and allows an immune response to be activated against them. Immune checkpoint inhibitors can improve the survival of some patients with advanced malignancies. These include malignant melanoma, renal cell carcinoma, urothelial bladder cancer and non-small cell lung cancer. Trials have shown that immune checkpoint inhibitors have significant benefits over conventional therapies so they are increasingly being used in routine clinical practice. However, a significant proportion of patients will not respond to immune checkpoint inhibitors and retain a poor prognosis. The optimal use of these drugs requires further study. Immune-related adverse events commonly include pneumonitis, hepatitis, nephritis, colitis and endocrinopathies. However, nearly any organ system can be affected. These toxicities present clinicians with a new challenge of recognising them early and acting promptly. © 2019 NPS MedicineWise.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 22; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Magalhães2018, - author = {Magalhães, Helena and Fontes-Sousa, Mário and MacHado, Manuela}, - title = {Immunotherapy in Advanced Gastric Cancer: An Overview of the Emerging Strategies}, - year = {2018}, - journal = {Canadian Journal of Gastroenterology and Hepatology}, - volume = {2018}, - doi = {10.1155/2018/2732408}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052879979&doi=10.1155%2f2018%2f2732408&partnerID=40&md5=81f4cf89899fb0613e07f2cc9067d99b}, - abstract = {Gastric cancer (GC) remains a public health problem, being the fifth most common cancer worldwide. In the western countries, the majority of patients present with advanced disease. Additionally, 65 to 75% of patients treated with curative intent will relapse and develop systemic disease. In metastatic disease, systemic treatment still represents the state of the art, with less than a year of median overall survival. The new molecular classification of GC was published in 2014, identifying four distinct major subtypes of gastric cancer, and has encouraged the investigation of new and more personalized treatment strategies. This paper will review the current evidence of immunotherapy in advanced gastric cancer. © 2018 Helena Magalhães et al.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 17; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Iams2020300, - author = {Iams, Wade T. and Porter, Jason and Horn, Leora}, - title = {Immunotherapeutic approaches for small-cell lung cancer}, - year = {2020}, - journal = {Nature Reviews Clinical Oncology}, - volume = {17}, - number = {5}, - pages = {300 – 312}, - doi = {10.1038/s41571-019-0316-z}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079520021&doi=10.1038%2fs41571-019-0316-z&partnerID=40&md5=d07049ec834241b946570b181fe97665}, - abstract = {Immune-checkpoint inhibitors (ICIs) are approved in the first-line and third-line settings for patients with extensive-stage or relapsed small-cell lung cancer (SCLC), respectively. In the first-line setting, the addition of the anti-programmed cell death 1 ligand 1 (PD-L1) antibody atezolizumab to chemotherapy improves overall survival (OS). In patients with relapsed disease, data from nonrandomized trials have revealed promising responses, although a significant improvement in OS over that obtained with conventional chemotherapy was not achieved in a randomized trial in this setting. Substantial research interest exists in identifying predictive biomarkers that could guide the use of ICIs in patients with SCLC. PD-L1 expression is typically low or absent in SCLC, which has precluded its use as a predictive biomarker. Tumour mutational burden might have some predictive value, although blood-based measures of tumour mutational burden did not have predictive value in patients receiving atezolizumab plus chemotherapy in the first-line setting. After three decades, ICIs have finally enabled an improvement in OS for patients with SCLC; however, a substantial amount of research remains to be done, including identifying the optimal therapeutic strategy and predictive biomarkers. In this Review, we describe the available data on clinical efficacy, the emerging evidence regarding biomarkers and ongoing clinical trials using ICIs and other immunotherapies in patients with SCLC. © 2020, Springer Nature Limited.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 219; All Open Access, Bronze Open Access} -} - -@ARTICLE{Park2020191, - author = {Park, K. and Vansteenkiste, J. and Lee, K.H. and Pentheroudakis, G. and Zhou, C. and Prabhash, K. and Seto, T. and Voon, P.J. and Tan, D.S.W. and Yang, J.C.H. and Wang, J. and Babu, K. Govind and Nakayama, Y. and Alip, A. and Chua, K.L.M. and Cheng, J.C.-H. and Senan, S. and Ahn, Y.C. and Kim, T.-Y. and Ahn, H.K. and Peters, S. and Yoshino, T. and Douillard, J.-Y.}, - title = {Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS}, - year = {2020}, - journal = {Annals of Oncology}, - volume = {31}, - number = {2}, - pages = {191 – 201}, - doi = {10.1016/j.annonc.2019.10.026}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078563925&doi=10.1016%2fj.annonc.2019.10.026&partnerID=40&md5=1966041a09b62831696863ce8cca4030}, - abstract = {The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of early and locally-advanced non-small-cell lung cancer (NSCLC) was published in 2017, and covered the diagnosis, staging, management and treatment of both early stage I and II disease and locally-advanced stage III disease. At the ESMO Asia Meeting in November 2018, it was decided by both the ESMO and the Korean Society of Medical Oncology (KSMO) to convene a special face-to-face guidelines meeting in 2019 in Seoul. The aim was to adapt the ESMO 2017 guidelines to take into account potential differences related to ethnicity, cancer biology and standard practices associated with the treatment of locally-advanced, unresectable NSCLC in Asian patients. These guidelines represent the consensus opinions reached by those experts in the treatment of patients with lung cancer who represented the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and it was independent of both local current treatment practices and the treatment availability and reimbursement situations in the individual participating Asian countries. © 2019 European Society for Medical Oncology}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 73; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Calles2019961, - author = {Calles, A. and Aguado, G. and Sandoval, C. and Álvarez, R.}, - title = {The role of immunotherapy in small cell lung cancer}, - year = {2019}, - journal = {Clinical and Translational Oncology}, - volume = {21}, - number = {8}, - pages = {961 – 976}, - doi = {10.1007/s12094-018-02011-9}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060027898&doi=10.1007%2fs12094-018-02011-9&partnerID=40&md5=ebc0f835003aac043af1cd600efcb4e1}, - abstract = {Despite decades of research, prognosis for SCLC patients remains poor, and treatment options limited. SCLC is an immunogenic tumor with high somatic mutation rates due to tobacco exposure resulting in potential neo-antigens, the presence of suppressed immune responses, and occurrence of paraneoplastic disorders. The use of T cell immune-checkpoint inhibitors (anti-PD1: nivolumab, pembrolizumab; anti-PD-L1: atezolizumab, durvalumab; anti-CTLA-4: ipilimumab, tremelimumab) have shown promising antitumor activity with the potential to prolong survival in SCLC patients. In fact, atezolizumab when combined with chemotherapy has achieved the milestone of being the first drug to improve survival in patients with newly diagnosed extensive-stage SCLC. Other immunotherapeutic approaches evaluated in clinical trials for SCLC include the use of cytokines, cancer vaccines, antiganglioside therapies, TLR9 inhibition, anti-Notch signaling, and anti-CD47. This review discusses the rationale and clinical evidence of immunotherapy in SCLC, the conflictive clinical results of novel immunotherapeutic agents and combinatorial therapies under evaluation in SCLC patients. © 2019, Federación de Sociedades Españolas de Oncología (FESEO).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 85} -} - -@ARTICLE{Teixidó2018, - author = {Teixidó, Cristina and Vilariño, Noelia and Reyes, Roxana and Reguart, Noemí}, - title = {PD-L1 expression testing in non-small cell lung cancer}, - year = {2018}, - journal = {Therapeutic Advances in Medical Oncology}, - volume = {10}, - doi = {10.1177/1758835918763493}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048835703&doi=10.1177%2f1758835918763493&partnerID=40&md5=bdaaee649d248852654c195ea0bc57f5}, - abstract = {In recent years, immunotherapy has revolutionized and changed the standard of care in patients with advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors, fundamentally those that act by blocking the programmed cell death receptor-1 (PD-1) and its ligand the programmed cell death ligand-1 (PD-L1) have emerged as novel treatment strategies in NSCLC, demonstrating undoubted superiority over chemotherapy in terms of efficacy. Several of these immune checkpoint modulators have recently gained regulatory approval for the treatment of advanced NSCLC, such as nivolumab, atezolizumab and pembrolizumab in first-line (only the latter) and second-line settings, and more recently, durvalumab as maintenance after chemoradiotherapy in locally advanced disease. There is consensus that PD-L1 expression on tumor cells predicts responsiveness to PD-1 inhibitors in several tumor types. Hence PD-L1 expression evaluated by immunohistochemistry (IHC) is currently used as a clinical decision-making tool to support the use of checkpoint inhibitors in NSCLC patients. However, the value of PD-L1 as the ‘definitive’ biomarker is controversial as its testing is puzzled by multiple unsolved issues such as the use of different staining platforms and antibodies, the type of cells in which PD-L1 is assessed (tumor versus immune cells), thresholds used for PD-L1-positivity, or the source and timing for sample collection. Therefore, newer biomarkers such as tumor mutation burden and neoantigens as well as biomarkers reflecting host environment (microbiome) or tumor inflamed microenvironment (gene expression signatures) are being explored as more reliable and accurate alternatives to IHC for guiding treatment selection with checkpoint inhibitors in NSCLC. © The Author(s), 2018.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 116; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Suresh20181416, - author = {Suresh, Karthik and Naidoo, Jarushka and Lin, Cheng Ting and Danoff, Sonye}, - title = {Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities}, - year = {2018}, - journal = {Chest}, - volume = {154}, - number = {6}, - pages = {1416 – 1423}, - doi = {10.1016/j.chest.2018.08.1048}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055756124&doi=10.1016%2fj.chest.2018.08.1048&partnerID=40&md5=24ae4ac76cd34b83a5d427707dc4d1f2}, - abstract = {Immune checkpoint inhibitors (ICIs) are newer, immunotherapy-based drugs that have been shown to improve survival in advanced non-small cell lung cancer (NSCLC). Unlike traditional chemotherapeutic agents, ICIs work by boosting the body's natural tumor killing response. However, this unique mechanism of action has also led to the recognition of class-specific side effects. Labeled immune-related adverse events, these toxicities can affect multiple organ systems including the lungs. Immune-mediated lung injury because of ICI use, termed checkpoint inhibitor pneumonitis (CIP), occurs in about 3% to 5% of patients receiving ICIs; however, the real-world incidence of this entity may be higher, especially now that ICIs are being used in nonclinical trial settings. In this review, we briefly introduce the biology of ICIs and the indications for ICI use in NSCLC and then discuss the epidemiology and clinical and radiologic manifestations of CIP. Next, we discuss management strategies for CIP, including the current consensus on management of steroid-refractory CIP. Given the nascent nature of this field, we highlight areas of uncertainty and emerging research questions in the burgeoning field of checkpoint inhibitor pulmonary toxicity. © 2018 American College of Chest Physicians}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 264; All Open Access, Green Open Access} -} - -@ARTICLE{Lee2020109, - author = {Lee, Victor Ho-Fun and Yang, Li and Jiang, Yong and Kong, Feng-Ming (Spring)}, - title = {Radiation Therapy for Thoracic Malignancies}, - year = {2020}, - journal = {Hematology/Oncology Clinics of North America}, - volume = {34}, - number = {1}, - pages = {109 – 125}, - doi = {10.1016/j.hoc.2019.09.007}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074498607&doi=10.1016%2fj.hoc.2019.09.007&partnerID=40&md5=91b5d4b92b8bcc607f7af04d7eff7628}, - abstract = {Radiotherapy is the most commonly used nonsurgical modality in treatment of lung cancers, non–small cell lung cancer (NSCLC) in particular. Radiation therapy has been increasingly used as definitive radical treatment, either alone or in combination with concurrent chemoradiation for locally advanced disease. More recently with the advent of novel radiation techniques and modalities such as stereotactic radiotherapy and proton therapy, radiotherapy can now be used as sole radical treatment of small solitary tumors. This article reviews the current indications and future directions of radiotherapy in lung cancer management. © 2019 Elsevier Inc.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 8} -} - -@ARTICLE{Rossi2018473, - author = {Rossi, Antonio and Tay, Rebecca and Chiramel, Jaseela and Prelaj, Arsela and Califano, Raffaele}, - title = {Current and future therapeutic approaches for the treatment of small cell lung cancer}, - year = {2018}, - journal = {Expert Review of Anticancer Therapy}, - volume = {18}, - number = {5}, - pages = {473 – 486}, - doi = {10.1080/14737140.2018.1453361}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045296183&doi=10.1080%2f14737140.2018.1453361&partnerID=40&md5=82aebedf038b2d7beaa12d46539050e2}, - abstract = {Introduction: Small-cell lung cancer (SCLC) is a very aggressive disease characterized by a high response rate to first-line chemotherapy, but most patients relapse within 1 year with disappointing results to second-line treatments. Chemotherapy has reached a plateau of effectiveness and new therapeutic strategies are needed to change the natural history of SCLC. Areas covered: This review will focus on the current results and the future development of the therapeutic approaches for the treatment of SCLC. Expert commentary: Immunotherapy is becoming a new frontier for the management of SCLC with preliminary interesting results. To date, no targeted drugs have been approved for clinical practice but several novel agents are in an advanced stage of clinical development in SCLC. © 2018 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 32} -} - -@ARTICLE{Rocco2019120, - author = {Rocco, Danilo and Battiloro, Ciro and Della Gravara, Luigi and Gridelli, Cesare}, - title = {Advanced non-small cell lung cancer with activating epidermal growth factor receptor mutation: First line treatment and beyond}, - year = {2019}, - journal = {Reviews on Recent Clinical Trials}, - volume = {14}, - number = {2}, - pages = {120 – 128}, - doi = {10.2174/1574887114666181205155211}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068415104&doi=10.2174%2f1574887114666181205155211&partnerID=40&md5=af79cd3d29720745d03ea79ea8b51ee5}, - abstract = {Background: Lung cancer is the leading cause of cancer mortality, being responsible for more than 1.6 million deaths each year worldwide and non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers; moreover, 10 to 15% of all NSCLCs harbor EGFR (epidermal growth factor receptor) activating mutations, being suitable for EGFR-Tyrosine Kinase Inhibitors (TKI) molecular targeted therapy. However, EGFR+ NSCLCs gain acquired resistance to these agents, representing one of the key challenges for modern precision oncology. Objective: Therefore, this paper aims to provide an extensive state of the art review, alongside with hints about future perspectives. Conclusion: To date, in the light of the data from the FLAURA study, osimertinib represents the best first-line option in NSCLC patients with EGFR activating mutations; EGFR-TKI plus chemotherapy combination therapies, even though interesting, must still be considered investigational. © 2019 Bentham Science Publishers.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 15} -} - -@ARTICLE{Jung201829, - author = {Jung, Chi Young and Antonia, Scott J.}, - title = {Tumor immunology and immune checkpoint inhibitors in non-small cell lung cancer}, - year = {2018}, - journal = {Tuberculosis and Respiratory Diseases}, - volume = {81}, - number = {1}, - pages = {29 – 41}, - doi = {10.4046/trd.2017.0120}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041524037&doi=10.4046%2ftrd.2017.0120&partnerID=40&md5=097c70d4919fdc9f5d456d9cd41177eb}, - abstract = {Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths worldwide. Although progress in the treatment of advanced non-small cell lung cancer (NSCLC) has been made over the past decade, the 5-year survival rate in patients with lung cancer remains only 10%–20%. Obviously, new therapeutic options are required for patients with advanced NSCLC and unmet medical needs. Cancer immunotherapy is an evolving treatment modality that uses a patient’s own immune systems to fight cancer. Theoretically, cancer immunotherapy can result in long-term cancer remission and may not cause the same side effects as chemotherapy and radiation. Immuno-oncology has become an important focus of basic research as well as clinical trials for the treatment of NSCLC. Immune checkpoint inhibitors are the most promising approach for cancer immunotherapy and they have become the standard of care for patients with advanced NSCLC. This review summarizes basic tumor immunology and the relevant clinical data on immunotherapeutic approaches, especially immune checkpoint inhibitors in NSCLC. Copyright © 2018 The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 26; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Biswas2020, - author = {Biswas, Tithi and Patel, Monaliben and Bruno, Debora and Grubb, William}, - title = {The changing landscape of stage III lung cancer: a literature review}, - year = {2020}, - journal = {Expert Review of Anticancer Therapy}, - doi = {10.1080/14737140.2020.1796645}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088112056&doi=10.1080%2f14737140.2020.1796645&partnerID=40&md5=ff04404197fc5a492f52d72951ade793}, - abstract = {Introduction: The treatment of stage III non-small cell lung cancer (NSCLC) remains challenging and associated with overall poor outcomes. Since seminal studies in the early 90’s introduced concurrent chemo-radiotherapy as standard of care for treatment of this disease, no major advances have been introduced in this landscape. Both radiation dose escalation and neoadjuvant/adjuvant chemotherapy strategies were unsuccessful to improve the survival over standard of care radiation dose and chemotherapy schedule: five-year overall survival (OS) ranging from 15-20%. However, in 2017 the PACIFIC Trial demonstrated that the addition of consolidative immune checkpoint inhibitor durvalumab for one year led to superior progression free survival (PFS) and 3-year overall survival with no significant increase in toxicity compared to placebo in patients who achieved disease control with concurrent chemo-RT. Areas covered: This article reviews the treatment evolution of stage III NSCLC over the past decades, discusses current standard of care strategies and highlights potential future directions for the management of this condition. Expert opinion: Ongoing trials incorporating upfront checkpoint inhibitors with radiotherapy will answer whether adding checkpoint inhibitors to chemotherapy or substituting them for chemotherapy altogether will improve long-term outcome. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3} -} - -@ARTICLE{Mollica2019132, - author = {Mollica, M. and Salvi, R. and Paoli, G. and Graziani, V. and Cerqua, F.S. and Iadevaia, C. and Lavoretano, S. and D’agnano, V. and Rocco, D. and Fiorelli, A. and Tranfa, C.M. and Bianco, A. and Perrotta, Fabio}, - title = {Lung cancer management: Challenges in elderly patients}, - year = {2019}, - journal = {Journal of Gerontology and Geriatrics}, - volume = {2019}, - number = {2}, - pages = {132 – 140}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071830966&partnerID=40&md5=876704539ced2eea890ba715d7810cb2}, - abstract = {Elderly patients represent the majority of lung cancer cases, but they are often under-represented in clinical cancer treatment trials or excluded from studies because of comorbidities. Due to lack of data, treatment options for this population must be carefully evaluated and preliminary assessment should aim to stratify patients into different risk subgroups. In early NSCLC stages, surgery remains the best therapeutic option in low-mod-erate risk patients. Conversely, in patients unfit for surgery or in advanced stages, chemotherapy and radiotherapy should be considered as they may offer benefits in terms of clinical outcomes. Recent developments in targeting driver genes mutations as well as immune checkpoints have opened novel horizon in lung cancer management and systematic investigation in elderly population is required. In this review, we examined the more recent results of the literature about the therapeutic scenario in limited and advanced lung cancer stages in elderly and very elderly population. © by Società Italiana di Gerontologia e Geriatria (SIGG).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 9} -} - -@ARTICLE{Götschke201969, - author = {Götschke, J. and Kahnert, K. and Tufman, A.}, - title = {Personalized treatment of lung cancer; [Die personalisierte Therapie des Lungenkarzinoms]}, - year = {2019}, - journal = {Pneumologe}, - volume = {16}, - number = {2}, - pages = {69 – 75}, - doi = {10.1007/s10405-019-0232-z}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061755633&doi=10.1007%2fs10405-019-0232-z&partnerID=40&md5=f1362ce6dc435fb1a56dd96888f966f4}, - abstract = {There have been fundamental changes in the treatment of lung cancer in recent years with advances in molecular biology leading to the approval of new medications. For patients with stage IV non-small cell lung cancer (NSCLC) targeted therapies are available for genetic driver mutations or fusions. Tumors with an epidermal growth factor receptor (EGFR) gene mutation or a translocation in the anaplastic lymphoma kinase (ALK) gene should receive specific treatment with a tyrosine kinase inhibitor. For less common mutations, treatment is offered within the framework of clinical trials. In stage IV NSCLC without a driver mutation, the immunotherapeutic checkpoint inhibitor pembrolizumab can be administered in combination with a platinum-containing cytostatic agent (cisplatin or carboplatin) and pemetrexed for non-squamous epithelium histology. In stage III NSCLC, patients with a positive programmed cell death ligand 1 (PD-L1) status can be offered consolidation therapy with the checkpoint inhibitor durvalumab after radiochemotherapy. In advanced small cell lung cancer (SCLC) chemotherapy is still the most important pillar of treatment. There is also growing evidence for the use of immunotherapy in SCLC. © 2019, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1} -} - -@ARTICLE{Ko20185792, - author = {Ko, Eric C. and Raben, David and Formenti, Silvia C.}, - title = {The integration of radiotherapy with immunotherapy for the treatment of non–small cell lung cancer}, - year = {2018}, - journal = {Clinical Cancer Research}, - volume = {24}, - number = {23}, - pages = {5792 – 5806}, - doi = {10.1158/1078-0432.CCR-17-3620}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056147537&doi=10.1158%2f1078-0432.CCR-17-3620&partnerID=40&md5=9ef4d867b4d1b6d135e1f1c4a5229fea}, - abstract = {Five-year survival rates for non–small cell lung cancer (NSCLC) range from 14% to 49% for stage I to stage IIIA disease, and are <5% for stage IIIB/IV disease. Improvements have been made in the outcomes of patients with NSCLC due to advancements in radiotherapy (RT) techniques, the use of concurrent chemotherapy with RT, and the emergence of immunotherapy as first- and second-line treatment in the metastatic setting. RT remains the mainstay treatment in patients with inoperable early-stage NSCLC and is given concurrently or sequentially with chemotherapy in patients with locally advanced unresectable disease. There is emerging evidence that RT not only provides local tumor control but also may influence systemic control. Multiple preclinical studies have demonstrated that RT induces immunomodulatory effects in the local tumor microenvironment, supporting a synergistic combination approach with immunotherapy to improve systemic control. Immunotherapy options that could be combined with RT include programmed cell death-1/programmed cell death ligand-1 blockers, as well as investigational agents such as OX-40 agonists, toll-like receptor agonists, indolea-mine 2,3-dioxygenase-1 inhibitors, and cytokines. Here, we describe the rationale for the integration of RT and immunotherapy in patients with NSCLC, present safety and efficacy data that support this combination strategy, review planned and ongoing studies, and highlight unanswered questions and future research needs. ©2018 American Association for Cancer Research.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 198} -} - -@ARTICLE{Inoue2019161, - author = {Inoue, Hiroyuki and Okamoto, Isamu}, - title = {Immune checkpoint inhibitors for the treatment of unresectable stage iii non–small cell lung cancer: Emerging mechanisms and perspectives}, - year = {2019}, - journal = {Lung Cancer: Targets and Therapy}, - volume = {10}, - pages = {161 – 170}, - doi = {10.2147/LCTT.S184380}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077864060&doi=10.2147%2fLCTT.S184380&partnerID=40&md5=79a3086a8cd29325aa295c38c747a42f}, - abstract = {There has been no improvement in outcome for patients with unresectable locally advanced (stage III) non–small cell lung cancer (NSCLC) for more than 10 years. The standard treatment for these patients is definitive concurrent chemotherapy and radiation (CCRT). Although the goal of treatment in this setting is to achieve a cure, most patients progress and their prognosis is poor, with a 5-year survival rate of 15–30%. There is thus an urgent need for the development of novel anticancer treatments in this patient population. Recent advances in cancer immunotherapy have led to a marked improvement in clinical outcome for advanced NSCLC. Such immunotherapy mainly consists of the administration of immune checkpoint inhibitors (ICIs) such as antibodies to cytotoxic T lymphocyte–associated protein–4 (CTLA-4) or to either programmed cell death–1 (PD-1) or its ligand PD-L1. Durvalumab (MEDI4736) is a high-affinity human immunoglobulin G1 monoclonal antibody that blocks the binding of PD-L1 on tumor cells or antigen-presenting cells to PD-1 on T cells. The PACIFIC study recently evaluated consolidation immunotherapy with durvalumab versus placebo administered after concurrent chemoradiotherapy (CCRT) in patients with unresectable stage III NSCLC. It revealed a significant improvement in both progression-free and overall survival with durvalumab, and this improvement was associated with a favorable safety profile. This achievement has made durvalumab a standard of care for consolidation after CCRT in patients with unresectable stage III NSCLC, and it has now been approved in this setting by regulatory agencies in the United States, Canada, Japan, Australia, Switzerland, Malaysia, Singapore, India, and the United Arab Emirates. In this review, we briefly summarize the results of the PACIFIC trial, including those of post hoc analysis, and we address possible molecular mechanisms, perspectives, and remaining questions related to combined treatment with CCRT and ICIs in this patient population. © 2019 Inoue and Okamoto.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 8; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Li2019323, - author = {Li, Mengqian and Gan, Lu and Song, Andrew and Xue, Jianxin and Lu, You}, - title = {Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy}, - year = {2019}, - journal = {Biochimica et Biophysica Acta - Reviews on Cancer}, - volume = {1871}, - number = {2}, - pages = {323 – 330}, - doi = {10.1016/j.bbcan.2019.02.004}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062470786&doi=10.1016%2fj.bbcan.2019.02.004&partnerID=40&md5=30192dafb4932a4e685eda42826ec675}, - abstract = {The combination of programmed cell death 1/programmed cell death ligand 1 blockade and thoracic radiotherapy has become the new standard of care in the treatment of locally advanced non-small-cell lung cancer. The information regarding the pulmonary safety of such therapy remains limited to mostly retrospective studies and case reports with a small portion of data from prospective clinical trials. By analyzing the underlying mechanisms of interactions between radiation and immunotherapy from preclinical data and summarizing safety data from relevant clinical studies with pulmonary toxicity, we believe that longer and rigorous follow-up is warranted, to determine if the combination of such modalities is appropriate for patients without risking undue toxicity. © 2019 Elsevier B.V.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 20} -} - -@ARTICLE{Jin2020, - author = {Jin, Rui and Zhao, Jing and Xia, Lexin and Li, Qin and Li, Wen and Peng, Ling and Xia, Yang}, - title = {Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench}, - year = {2020}, - journal = {Therapeutic Advances in Medical Oncology}, - volume = {12}, - doi = {10.1177/1758835920930333}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086260998&doi=10.1177%2f1758835920930333&partnerID=40&md5=4cd76dd8b208975a6f9d04775b40abbf}, - abstract = {Targeted therapies are efficient in the context of oncogenic driver mutations. Epidermal growth factor receptor (EGFR)-mutant lung cancers represent a distinct subset of non-small-cell lung cancer (NSCLC) with marked sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Despite the high response rate to EGFR TKIs in EGFR-mutant lung cancer, resistance and tumor recurrence are unavoidable. Therapeutic options are restricted in patients after exhaustion of targeted therapies. Immune checkpoint inhibitors (ICIs) represent a novel therapeutic option for advanced NSCLC with significant overall survival benefit in registration trials. No superiority in terms of long-term survival was observed in the EGFR mutation subgroup when ICIs were given as monotherapy in second-line treatment in earlier studies. Thus, the appropriate application of ICIs to patients harboring EGFR mutations remains an important field of ongoing research. Here, we discuss different immune checkpoint blockade strategies, including ICIs alone and in combination with TKIs, chemotherapy, radiation, and antiangiogenic agents in EGFR-mutant NSCLC as first-line and subsequent treatments. We also summarize the evidence concerning the heterogeneous molecular features and immune signatures of EGFR mutations and their associations with ICI therapy outcomes. This study was performed to improve our understanding of the optimal mode of immune-based treatment approaches in EGFR-mutant NSCLC. © The Author(s), 2020.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 28; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Kazaz2017101, - author = {Kazaz, Seher Nazlı and Öztop, İlhan}, - title = {Immune checkpoint inhibitors in advanced-stage non-small cell lung cancer}, - year = {2017}, - journal = {Turkish Thoracic Journal}, - volume = {18}, - number = {4}, - pages = {101 – 107}, - doi = {10.5152/TurkThoracJ.2017.17006}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042935058&doi=10.5152%2fTurkThoracJ.2017.17006&partnerID=40&md5=7ad9957d752a9c0b4b52e451c20f1398}, - abstract = {More than half of non-small cell lung cancer (NSCLC) patients are at an advanced stage at the time of diagnosis, and they have a poor prognosis. Systemic treatment is the basic treatment approach for advanced-stage NSCLC, and chemotherapy and targeted treatments are commonly used based on the molecular characteristics. Although targeted therapies have led to a significant level of improvement in terms of survival, the results are still unsatisfactory. However, considerable attention has been focused to the immunotherapy with recent positive results reported by studies on this field. In this context, a certain portion of clinical studies have shown dramatic results, and these have involved inhibitors developed particularly against the immune checkpoint protein programmed death receptor-1 and its ligand (programmed death ligand-1). This review aims to present the significance of immune checkpoint inhibitors in NSCLC and to summarize the findings of relevant contemporary clinical studies. © 2017 by Turkish Thoracic Society.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Green Open Access} -} - -@ARTICLE{Jain2019, - author = {Jain, Natasha A. and Otterson, Gregory A.}, - title = {Immunotherapy in inoperable stage III non-small cell lung cancer: A review}, - year = {2019}, - journal = {Drugs in Context}, - volume = {8}, - doi = {10.7573/dic.212578}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070185559&doi=10.7573%2fdic.212578&partnerID=40&md5=89e90f4c47d22bf3acae4ac76f2d4d0b}, - abstract = {The leading cause of cancer-related deaths in the United States continues to be lung cancer. Approximately 25–30% of patients are diagnosed with locally advanced non-small cell lung cancer (NSCLC). Concurrent chemoradiation with a platinum-based doublet is the current standard of care for patients with inoperable stage III NSCLC. Unfortunately, only 15–20% of patients treated with definitive chemoradiation are alive at 5 years. Thus, there has been a major unmet need in this area. In this article, we summarize the current status and ongoing clinical trials incorporating immunotherapy into the management of inoperable stage III NSCLC, and we also present our perspective on the future directions. Copyright © 2019 Jain NA, Otterson GA.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 8; All Open Access, Gold Open Access} -} - -@ARTICLE{Hendriks2019151, - author = {Hendriks, Lizza E. L. and Menis, Jessica and Reck, Martin}, - title = {Prospects of targeted and immune therapies in SCLC}, - year = {2019}, - journal = {Expert Review of Anticancer Therapy}, - volume = {19}, - number = {2}, - pages = {151 – 167}, - doi = {10.1080/14737140.2019.1559057}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060190284&doi=10.1080%2f14737140.2019.1559057&partnerID=40&md5=fa20f6f252ee3a11e6139ed45b33211e}, - abstract = {Introduction: Small cell lung cancer (SCLC) is a tumor with a poor prognosis, often diagnosed in an advanced stage. Despite aggressive treatment of early and locally advanced disease, SCLC often relapses. First line chemotherapy provides good response rates in advanced disease, but progression free and overall survival are limited. New drugs such as some targeted therapies and immune therapies are promising in SCLC. Areas covered: In this review, we discuss the preclinical rationale and trial data for targeted therapies and immune therapies in SCLC, with a specific focus on clinical trials. Expert commentary: Lack of identification of clear prognostic and predictive biomarkers has limited the advances in treatment efficacy. This has most likely been the main cause of failure for compounds tested so far. Due to the highly mutational profile and the rapid growth pattern of SCLC, immunotherapy combined with chemotherapy seems the most promising treatment option. Concerning targeted agents, achievements made so far are small, but DLL3-antibodies or combinations of PARPi and immunotherapy could be very promising. These promising strategies also need testing in limited disease. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 16; All Open Access, Green Open Access} -} - -@ARTICLE{Cadranel2019, - author = {Cadranel, Jacques and Canellas, Anthony and Matton, Lise and Darrason, Marie and Parrot, Antoine and Naccache, Jean-Marc and Lavolé, Armelle and Ruppert, Anne-Marie and Fallet, Vincent}, - title = {Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer}, - year = {2019}, - journal = {European Respiratory Review}, - volume = {28}, - number = {153}, - doi = {10.1183/16000617.0058-2019}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073108994&doi=10.1183%2f16000617.0058-2019&partnerID=40&md5=a2828572fe42d8e54f3b03f4bd7b17c9}, - abstract = {Immune checkpoint inhibitor-related pneumonitis (ICI-P) during cancer treatment is rarely observed (<5%). ICI-P is more often observed in patients with nonsmall cell lung cancer (NSCLC) than in those with other cancers. Likewise, it is more common in those receiving programmed cell death (PD)-1/ PD-1 ligand inhibitors rather than cytotoxic T-lymphocyte antigen (CTLA)-4 inhibitors alone. The frequency of ICI-P is higher when anti-PD-1 and anti-CTLA-4 are administered concomitantly. Despite the low fatality rate (≈13%), ICI-P is the leading cause of ICI-related deaths. This narrative review focuses on the epidemiology, clinical and radiological presentation and prognosis of ICI-P occurring in patients, especially those with advanced NSCLC. Emphasis is placed on the differences in terms of frequency or clinical picture observed depending on whether the ICI is used as monotherapy or in combination with another ICI or chemotherapy. Other pulmonary complications observed in cancer patients, yet not necessarily immune-related, are reviewed, such as sarcoid-like granulomatosis, tuberculosis or other infections. A proposal for pragmatic management, including differential diagnosis and therapeutic strategies, is presented, based on the ICI-P series reported in the literature and published guidelines. © ERS 2019.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 76; All Open Access, Gold Open Access} -} - -@ARTICLE{Wang2019, - author = {Wang, Dongxu and Lin, Jianzhen and Yang, Xu and Long, Junyu and Bai, Yi and Yang, Xiaobo and Mao, Yilei and Sang, Xinting and Seery, Samuel and Zhao, Haitao}, - title = {Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies}, - year = {2019}, - journal = {Journal of Hematology and Oncology}, - volume = {12}, - number = {1}, - doi = {10.1186/s13045-019-0730-9}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064805268&doi=10.1186%2fs13045-019-0730-9&partnerID=40&md5=bbaa328b7fba0c8d6867292f3d86c18b}, - abstract = {Gastrointestinal (GI) malignant neoplasms have a high global incidence and treatment prospects for patients with advanced GI tumors are dismal. PD-1/PD-L1 inhibitors emerged as a frontline treatment for several types of cancer. However, the shortcomings of PD-1/PD-L1 inhibitors have been observed, including low objective response rates and acquired tumor resistance, especially in patients receiving PD-1/PD-L1 inhibitors as a single treatment. Accumulating evidence from clinical trials increasingly suggests that combined immunotherapies enhance therapeutic responses in patients with malignances, especially for GI tumors which have a complex matrix, and significant molecular and immunological differences. Preclinical and clinical studies suggest there are advantages to combined immunological regimens, which represents the next logical step in this field, although further research is necessary. This literature review explores the current limitations of monotherapies, before critically discussing the rationale behind combination regimens. Then, we provide a summary of the clinical applications for gastrointestinal cancers. © 2019 The Author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 65; All Open Access, Gold Open Access} -} - -@ARTICLE{Shah202015, - author = {Shah, Dhaval R. and Masters, Gregory A.}, - title = {Precision Medicine in Lung Cancer Treatment}, - year = {2020}, - journal = {Surgical Oncology Clinics of North America}, - volume = {29}, - number = {1}, - pages = {15 – 21}, - doi = {10.1016/j.soc.2019.08.002}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073919625&doi=10.1016%2fj.soc.2019.08.002&partnerID=40&md5=8c38e8e88c1a2ed26facde1b1b2ceec0}, - abstract = {Lung cancer remains second most common cancer in men and women in the United States. More than 50% of patients are diagnosed in the advanced stage. Traditionally, chemotherapy has been the backbone of management of stage IV lung cancer. A better understanding of the molecular pathogenesis has led to rapid development of targeted therapy and immunotherapy. This has led to significant improvement in survival of patients with lung cancer stages III to IV. These drugs are being studied in early stage lung cancer. Several trials are ongoing to improve the survival and quality of life of our patients. © 2019 Elsevier Inc.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 28} -} - -@ARTICLE{Zhang2020, - author = {Zhang, Shuling and Bai, Xueli and Shan, Fengping}, - title = {The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer}, - year = {2020}, - journal = {International Immunopharmacology}, - volume = {80}, - doi = {10.1016/j.intimp.2020.106247}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078668455&doi=10.1016%2fj.intimp.2020.106247&partnerID=40&md5=6ba2353a0a9655470bf9c8efde578833}, - abstract = {Recently, immunotherapy has evolved into a true treatment modality with the approval of PD-1 and PD-L1 inhibitors as the standard care for first-line treatment in patients with non-small cell lung cancer (NSCLC). Until now, for patients with advanced NSCLC, treatment of targeting immune checkpoints reveals a promising survival benefit, and some patients even get long term survive, which creates a paradigm shift in NSCLC treatment. However, many issues or problems are also appearing in clinical practice, such as the lower overall efficacy rate (20–40%), treatment modes, populations choice of immunotherapy, drug resistance, and safety, etc. Thus, in this review, we will mainly summarize and discuss the recent development and confusion of PD-1/PD-L1 inhibitors for advanced NSCLC patients based on current clinical studies. © 2020 Elsevier B.V.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 31} -} - -@ARTICLE{Remon20191134, - author = {Remon, Jordi and Ahn, Myung-Ju and Girard, Nicolas and Johnson, Melissa and Kim, Dong-Wan and Lopes, Gilberto and Pillai, Rathi N. and Solomon, Benjamin and Villacampa, Guillermo and Zhou, Qing}, - title = {Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018}, - year = {2019}, - journal = {Journal of Thoracic Oncology}, - volume = {14}, - number = {7}, - pages = {1134 – 1155}, - doi = {10.1016/j.jtho.2019.03.022}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065977894&doi=10.1016%2fj.jtho.2019.03.022&partnerID=40&md5=a0eb12459cf066f715e165a4a09ffe58}, - abstract = {In 2018 research in the field of advanced NSCLCs led to an expanded reach and impact of immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of histologic subtype, with ICI use extended to include stage III disease, shifting the prognosis of all these patients. This new standard first-line approach opens a gap in standard second-line treatment, and older combinations may again become standard of care after progression during treatment with an ICI. The characterization of predictive biomarkers, patient selection, the definition of strategies with ICI combinations upon progression during treatment with ICIs, as well as prospective evaluation of the efficacy of ICIs in subpopulations (such as patients with poor performance status or brain metastases) represent upcoming challenges in advanced thoracic malignancies. In oncogene-addicted NSCLC three major steps were taken during 2018: next-generation tyrosine kinase inhibitors have overtaken more established agents as the new standard of care in EGFR and ALK receptor tyrosine kinase gene (ALK)-positive tumors. Mechanisms of acquired resistance have been reported among patients treated with next-generation EGFR tyrosine kinase inhibitors, reflecting the diversity of the landscape. One major step forward was the approval of personalized treatment in very uncommon genomic alterations, mainly fusions. This raises a new question about the challenge of implementation of next-generation sequencing in daily clinical practice to detect new and uncommon genomic alterations and to capture the heterogeneity of the mechanisms of acquired resistance during treatment, as well as the need to extend research into new therapeutic strategies to overcome them. © 2019 International Association for the Study of Lung Cancer}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 63; All Open Access, Bronze Open Access} -} - -@ARTICLE{Badiyan2018S2492, - author = {Badiyan, Shahed N. and Roach, Michael C. and Chuong, Michael D. and Rice, Stephanie R. and Onyeuku, Nasarachi E. and Remick, Jill and Chilukuri, Srinivas and Glass, Erica and Mohindra, Pranshu and Simone, Charles B.}, - title = {Combining immunotherapy with radiation therapy in thoracic oncology}, - year = {2018}, - journal = {Journal of Thoracic Disease}, - volume = {10}, - pages = {S2492 – S2507}, - doi = {10.21037/jtd.2018.05.73}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85051252947&doi=10.21037%2fjtd.2018.05.73&partnerID=40&md5=1181fe5b3fee56bf1d8fb3c0734676aa}, - abstract = {Thoracic malignancies comprise some of the most common and deadly cancers. Immunotherapies have been proven to improve survival outcomes for patients with advanced nonsmall cell lung cancer (NSCLC) and show great potential for patients with other thoracic malignancies. Radiation therapy (RT), an established and effective treatment for thoracic cancers, has acted synergistically with immunotherapies in preclinical studies. Ongoing clinical trials are exploring the clinical benefits of combining RT with immunotherapies and the optimal manner in which to deliver these complementary treatments. © Journal of Thoracic Disease.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 14; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Puri2020, - author = {Puri, Sonam and Saltos, Andreas and Perez, Bradford and Le, Xiuning and Gray, Jhanelle E.}, - title = {Locally Advanced, Unresectable Non-Small Cell Lung Cancer}, - year = {2020}, - journal = {Current Oncology Reports}, - volume = {22}, - number = {4}, - doi = {10.1007/s11912-020-0882-3}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081262668&doi=10.1007%2fs11912-020-0882-3&partnerID=40&md5=475139d2d725bef146bae7aeece59143}, - abstract = {Purpose of Review: Treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) has recently been revolutionized by the incorporation of immunotherapy to standard platinum-based concurrent chemoradiation. This review examines the current standard practices and ongoing studies on the management of locally advanced, unresectable NSCLC. Recent Findings: Concurrent chemoradiation is the cornerstone of treatment of unresectable, locally advanced NSCLC. However, chemoradiation can be associated with high therapy-related toxicities, and risk of disease relapse remains significantly elevated despite treatment with curative intent. Durvalumab, a PD-L1 inhibitor, was recently approved as consolidation therapy following concurrent chemoradiation; this agent represents a major advancement in treatment of unresectable stage III NSCLC. Several clinical trials are currently underway to evaluate the benefit of different immunotherapy sequencing and other biomarker-driven strategies in this disease setting. Summary: Multiple trials are presently ongoing to assess novel immunotherapy and targeted therapy strategies to improve outcomes and decrease treatment-associated toxicities in patients with locally advanced NSCLC. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 21} -} - -@ARTICLE{Hwang2018477, - author = {Hwang, William L. and Pike, Luke R. G. and Royce, Trevor J. and Mahal, Brandon A. and Loeffler, Jay S.}, - title = {Safety of combining radiotherapy with immune-checkpoint inhibition}, - year = {2018}, - journal = {Nature Reviews Clinical Oncology}, - volume = {15}, - number = {8}, - pages = {477 – 494}, - doi = {10.1038/s41571-018-0046-7}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048036084&doi=10.1038%2fs41571-018-0046-7&partnerID=40&md5=89932e6a661d625c146cff06f5e79c6b}, - abstract = {Immune-checkpoint inhibitors targeting cytotoxic T- lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death 1 ligand 1 (PD-L1) have transformed the care of patients with a wide range of advanced-stage malignancies. More than half of these patients will also have an indication for treatment with radiotherapy. The effects of both radiotherapy and immune-checkpoint inhibition (ICI) involve a complex interplay with the innate and adaptive immune systems, and accumulating evidence suggests that, under certain circumstances, the effects of radiotherapy synergize with those of ICI to augment the antitumour responses typically observed with either modality alone and thus improve clinical outcomes. However, the mechanisms by which radiotherapy and immune-checkpoint inhibitors synergistically modulate the immune response might also affect both the type and severity of treatment-related toxicities. Moreover, in patients receiving immune-checkpoint inhibitors, the development of immune-related adverse events has been linked with superior treatment responses and patient survival durations, suggesting a relationship between the antitumour and adverse autoimmune effects of these agents. In this Review, we discuss the emerging data on toxicity profiles related to immune-checkpoint inhibitors and radiotherapy, both separately and in combination, their potential mechanisms, and the approaches to managing these toxicities. © 2018, Macmillan Publishers Ltd., part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 219} -} - -@ARTICLE{Galldiks202017, - author = {Galldiks, Norbert and Kocher, Martin and Ceccon, Garry and Werner, Jan-Michael and Brunn, Anna and Deckert, Martina and Pope, Whitney B and Soffietti, Riccardo and Le Rhun, Emilie and Weller, Michael and Tonn, Jörg C and Fink, Gereon R and Langen, Karl-Josef}, - title = {Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: Response, progression, and pseudoprogression}, - year = {2020}, - journal = {Neuro-Oncology}, - volume = {22}, - number = {1}, - pages = {17 – 20}, - doi = {10.1093/neuonc/noz147}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077781207&doi=10.1093%2fneuonc%2fnoz147&partnerID=40&md5=9b808ca3232769f7cfaff79e75f75ddd}, - abstract = {The advent of immunotherapy using immune checkpoint inhibitors (ICIs) and targeted therapy (TT) has dramatically improved the prognosis of various cancer types. However, following ICI therapy or TT - either alone (especially ICI) or in combination with radiotherapy - imaging findings on anatomical contrast-enhanced MRI can be unpredictable and highly variable, and are often difficult to interpret regarding treatment response and outcome. This review aims at summarizing the imaging challenges related to TT and ICI monotherapy as well as combined with radiotherapy in patients with brain metastases, and to give an overview on advanced imaging techniques which potentially overcome some of these imaging challenges. Currently, major evidence suggests that imaging parameters especially derived from amino acid PET, perfusion-/diffusion-weighted MRI, or MR spectroscopy may provide valuable additional information for the differentiation of treatment-induced changes from brain metastases recurrence and the evaluation of treatment response. © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 95; All Open Access, Bronze Open Access} -} - -@ARTICLE{Chang201949, - author = {Chang, Xiaofeng and Lu, Xiaofeng and Guo, Jinhe and Teng, Gao-Jun}, - title = {Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy}, - year = {2019}, - journal = {Cancer Treatment Reviews}, - volume = {74}, - pages = {49 – 60}, - doi = {10.1016/j.ctrv.2018.08.006}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062274261&doi=10.1016%2fj.ctrv.2018.08.006&partnerID=40&md5=a1488b0eee993b5888481f7e91b38ff1}, - abstract = {Immune checkpoint inhibitors-based immunotherapy offers a new effective modality in the treatment of advanced malignancies. Considering the remarkable efficacy of immune checkpoint inhibitors in clinical trials, the FDA has approved a variety of immune checkpoint inhibitors for the treatment of advanced tumors. However, only limited patients with certain cancers can benefit from monotherapy of immune checkpoint inhibitors. Interventional therapy for cancer can not only destroy the primary tumors, but also regulate the immune system through different mechanisms, which provides a potential possibility for the combination of immune checkpoint inhibitors and interventional modalities in cancer treatment. This article reviews the possible synergistic mechanisms of interventional therapy combined with immune checkpoint inhibitors and summarizes the research progress of the combined therapy in cancer treatment. © 2018}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 39} -} - -@ARTICLE{Vafadar201937, - author = {Vafadar, Sam}, - title = {Immunotherapy for non-small cell lung cancer}, - year = {2019}, - journal = {Journal of the American Academy of Physician Assistants}, - volume = {32}, - number = {9}, - pages = {37 – 42}, - doi = {10.1097/01.JAA.0000569792.99069.e6}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071767036&doi=10.1097%2f01.JAA.0000569792.99069.e6&partnerID=40&md5=5144bef8116e11330ae3c992ceef7d6b}, - abstract = {Immunotherapy is a new genre of treatment for patients with advanced cancer. Initially approved for use in metastatic melanoma, immunotherapy has found a significant place in treating non-small cell lung cancer (NSCLC). Clinical trials using several combinations of immunotherapy are underway to help to determine the best treatment for specific patient groups. This article reviews approved uses of immunotherapy for NSCLC, immune-related toxicities, and explores the future direction of this treatment. © 2019 American Academy of Physician Assistants.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 10} -} - -@ARTICLE{Liu2017, - author = {Liu, Bingshan and Song, Yongping and Liu, Delong}, - title = {Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy}, - year = {2017}, - journal = {Journal of Hematology and Oncology}, - volume = {10}, - number = {1}, - doi = {10.1186/s13045-017-0541-9}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85036569976&doi=10.1186%2fs13045-017-0541-9&partnerID=40&md5=114bdbbaee4f900505c0ea1b3f46c19a}, - abstract = {Antibodies against programmed death (PD) pathway are revolutionizing cancer immunotherapy. Currently five antibodies against PD-1/PD-L1 have been approved. The clinical use of these antibodies is rapidly expanding. Incorporation of PD antibodies into chemotherapy regimens is in active clinical investigations. The combination of pembrolizumab with carboplatin and pemetrexed has been approved for the first line therapy of metastatic non-squamous non-small cell lung cancer. Combination of PD-1/PD-L1 antibodies with small molecule inhibitors such as tyrosine kinase inhibitors and IDO inhibitors are in active clinical trials. This review summarized recent development in clinical trials of PD-1 and PD-L1 antibodies for cancer immunotherapy. © 2017 The Author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 98; All Open Access, Gold Open Access} -} - -@ARTICLE{Petrella2018813, - author = {Petrella, Francesco and Rimoldi, Isabella and Facchetti, Giorgio and Spaggiari, Lorenzo}, - title = {Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives}, - year = {2018}, - journal = {Expert Opinion on Therapeutic Patents}, - volume = {28}, - number = {11}, - pages = {813 – 821}, - doi = {10.1080/13543776.2018.1528234}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055421184&doi=10.1080%2f13543776.2018.1528234&partnerID=40&md5=7e660c23a12e401c44910f1e51422cc0}, - abstract = {Introduction: Non-small cell lung cancer and malignant pleural mesothelioma represent two of the most intriguing and scrutinized thoracic malignancies, presenting interesting perspectives of experimental development and clinical applications. Areas covered: In advanced non-small cell lung cancer, molecular targeted therapy is the standard first-line treatment for patients with identified driver mutations; on the other hand, chemotherapy is the standard treatment for patients without EGFR mutations or ALK rearrangement or those with unknown mutation status. Once considered an ineffective therapy in pulmonary neoplasms, immunotherapy has been now established as one of the most promising therapeutic options. Mesenchymal stromal cells are able to migrate specifically toward solid neoplasms and their metastatic localizations when injected intravenously. This peculiar cancer tropism has opened up an emerging field to use them as vectors to deliver antineoplastic drugs for targeted therapies. Expert opinion: Molecular targeted therapy and immunotherapy are the new alternatives to standard chemotherapy. Mesenchymal stromal cells are a new promising tool in oncology and—although not yet utilized in the clinical practice, we think they will represent another main tool for cancer therapy and will probably play a leading role in the field of nanovectors and molecular medicine. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 7; All Open Access, Green Open Access} -} - -@ARTICLE{Romano2019117, - author = {Romano, G. and Marino, I.R.}, - title = {Abscopal effects observed in cancer radiation therapy and oncolytic virotherapy: An overview}, - year = {2019}, - journal = {Drugs of Today}, - volume = {55}, - number = {2}, - pages = {117 – 130}, - doi = {10.1358/dot.2019.55.2.2903217}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062411145&doi=10.1358%2fdot.2019.55.2.2903217&partnerID=40&md5=abb804ce23acb536faec0b13243c41d6}, - abstract = {Immunoglobulin-mediated suppression of immune checkpoint pathways may lead to a considerable activation of host immune responses against malignancies. Substantial therapeutic benefits were reported among patients who participated in cancer immunotherapy clinical trials which utilized monoclonal antibodies against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1). In a subsequent stage, immune checkpoint inhibitors were used in various clinical trials in combination with other therapeutic agents, such as immunomodulatory factors, chemotherapeutics, oncolytic viruses and radiation therapy. Interestingly, local antitumor interventions based either on radiation therapy or oncolytic viruses resulted in systemic immune responses in a number of oncological patients. The elimination of untreated cancer tissues that may follow a localized therapeutic intervention was termed abscopal effect, which represents a major achievement in the field of cancer therapy. Copyright © 2019 Clarivate Analytics.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 4} -} - -@ARTICLE{Wagner2020, - author = {Wagner, Gernot and Stollenwerk, Hannah Karolina and Klerings, Irma and Pecherstorfer, Martin and Gartlehner, Gerald and Singer, Josef}, - title = {Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review}, - year = {2020}, - journal = {OncoImmunology}, - volume = {9}, - number = {1}, - doi = {10.1080/2162402X.2020.1774314}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087385737&doi=10.1080%2f2162402X.2020.1774314&partnerID=40&md5=7ab32f91969dbf381dec40106bc4a456}, - abstract = {Background: Therapeutic strategies with immune checkpoint inhibitors (ICIs) counteract the immunosuppressive effects of programmed cell death protein-1 (PD-1) and ligand-1 (PD-L1). ICI treatment has emerged in first- and second-line therapy of non–small cell lung cancer (NSCLC). As immunotherapeutic treatment with ICIs is a dynamic field where new drugs and combinations are constantly evaluated, we conducted an up-to-date systematic review on comparative efficacy and safety in patients with advanced NSCLC. Methods: We searched PubMed up to February 2020 and Embase, CENTRAL, and clinical trial registries up to August 2018. Additionally, we checked reference lists. We dually screened titles, abstracts and, subsequently, full-texts for eligibility. Two reviewers assessed the risk of bias and graded the certainty of evidence following GRADE (Grading of Recommendations Assessment, Development and Evaluation). For second-line therapy, we performed random-effects meta-analyses. Due to considerable clinical heterogeneity, we reported first-line results narratively. Results: Of 1497 references, we identified 22 relevant publications of 16 studies. For first-line therapy, a combination of an ICI with chemotherapy improved progression-free survival and overall survival compared to chemotherapy but increased the risk of serious adverse events. Single-agent pembrolizumab increased overall and progression-free survival in patients with PD-L1 expression of ≥50% and resulted in less TRAE than chemotherapy. Compared to placebo, maintenance therapy with durvalumab increased overall and progression-free survival at the downside of higher risk of TRAE. For second-line therapy, a random-effects meta-analysis yielded a statistically significantly improved overall survival (OS) and progression-free survival (PFS) for ICIs compared to docetaxel (HR 0.69; 95% CI: 0.63–0.75 for OS; HR 0.85; 95% CI: 0.77 − 0.93 for PFS; 6 studies, 3478 patients; median OS benefit in months: 2.4 to 4.2). In meta-analysis, risk of any treatment-related adverse events of any grade was lower for ICI than docetaxel as second-line therapy (RR 0.76, 95% CI: 0.73–0.79; 6 studies, 3763 patients). Conclusion: In first-line therapy of patients with advanced NSCLC, ICI is effective when combined with chemotherapy not depending on PD-L1 expression, or as monotherapy in high PD-L1 expressing tumors. For second-line therapy, single-agent ICI improves efficacy and safety compared to docetaxel. © 2020, © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 37; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Pérol2018469, - author = {Pérol, M.}, - title = {Pivotal immuno-oncology trials in lung cancer; [Les essais cliniques princeps en immuno-oncologie dans les cancers broncho-pulmonaires]}, - year = {2018}, - journal = {Revue des Maladies Respiratoires Actualites}, - volume = {10}, - number = {4}, - pages = {469 – 480}, - doi = {10.1016/S1877-1203(18)30002-8}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057630327&doi=10.1016%2fS1877-1203%2818%2930002-8&partnerID=40&md5=ef271b164b3a876c0ba90923d525d9c0}, - abstract = {The development of immunotherapy with checkpoints inhibitors in non-small cell lung cancer has been conducted at an unprecedented scale, leading to a vast number of pivotal phase III trials which results have overturned the treatment algorithms for metastatic and locally advanced diseases. After establishing a new standard of care with anti-PD(L)-1 as single agents in second-line setting, the results of phase III trials are favouring their use in frontline setting, either as single agent for pembrolizumab when there is a high level of PD-L1 expression in tumour cells, or in combination with cytotoxic chemotherapy. The room for combination of anti-CTLA-4 with anti-PD(L)-1 still remains difficult to assess but might be especially active in case of a high tumour mutational burden. The addition of durvalumab after concurrent chemoradiation therapy in locally advanced disease has also improved progression-free survival, translating into a survival benefit with an actually unknown magnitude. Anti-PD(L)-1 have been also developed in small-cell lung cancer, leading to a possible change in the treatment algorithm for extensive stage with the addition of atezolizumab to first-line chemotherapy. The next step will need to better know the mechanisms of primary and acquired resistance to immunotherapy and to identify additional biomarkers as tumour mutational burden in order to more tailor the treatment sequences to each given patient. © 2018 Elsevier Masson SAS.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0} -} - -@ARTICLE{Johnson2018, - author = {Johnson, C. Bryce and Win, Shwe Y.}, - title = {Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials}, - year = {2018}, - journal = {OncoImmunology}, - volume = {7}, - number = {4}, - doi = {10.1080/2162402X.2017.1408744}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043688277&doi=10.1080%2f2162402X.2017.1408744&partnerID=40&md5=e051e48fdb51a73cf5d6e39c42f6ec2d}, - abstract = {Monoclonal antibodies (mAbs) that block the programmed death 1 (PD-1) or programmed death-ligand 1 (PD-L1) receptors are the most clinically advanced tumor immunotherapies. Given the broad antitumor efficacy and novel mechanism of action, numerous combinatorial approaches incorporating PD-1/PD-L1 blockade have been suggested; herein we present a comprehensive analysis of these clinical trials. We queried clinicaltrials.gov for all PD-1/PD-L1 mAbs administered for cancer therapy with an end date of 4/30/2017. A total of 1,218 clinical trials met our search criteria. These trials have a planned enrollment of 227,190 patients, and approximately half (493) were initiated in 2016 alone. Of these over 1,200 trials, 916 combine PD-1/PD-L1 blockade with at least one additional therapy, ranging from traditional treatment modalities like surgery and chemoradiation to newer therapies like small molecule inhibitors and other immunotherapies. The staggering proliferation of clinical trials combining PD-1/PD-L1 blockade with disparate treatments necessitates careful accounting to maximize efficiency and highlight areas of unmet needs. We believe our analysis provides this data and expect it will facilitate the design of future clinical trials in this burgeoning area of oncology research. © 2018 Taylor & Francis Group, LLC.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 25; All Open Access, Bronze Open Access, Green Open Access} -} - -@ARTICLE{Arbour2019764, - author = {Arbour, Kathryn C. and Riely, Gregory J.}, - title = {Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review}, - year = {2019}, - journal = {JAMA - Journal of the American Medical Association}, - volume = {322}, - number = {8}, - pages = {764 – 774}, - doi = {10.1001/jama.2019.11058}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071285353&doi=10.1001%2fjama.2019.11058&partnerID=40&md5=d38be7d0407f4db057618ee2f6d0eea9}, - abstract = {Importance: Non-small cell lung cancer remains the leading cause of cancer death in the United States. Until the last decade, the 5-year overall survival rate for patients with metastatic non-small cell lung cancer was less than 5%. Improved understanding of the biology of lung cancer has resulted in the development of new biomarker-targeted therapies and led to improvements in overall survival for patients with advanced or metastatic disease. Observations: Systemic therapy for metastatic non-small cell lung cancer is selected according to the presence of specific biomarkers. Therefore, all patients with metastatic non-small cell lung cancer should undergo molecular testing for relevant mutations and expression of the protein PD-L1 (programmed death ligand 1). Molecular alterations that predict response to treatment (eg, EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF V600E mutations) are present in approximately 30% of patients with non-small cell lung cancer. Targeted therapy for these alterations improves progression-free survival compared with cytotoxic chemotherapy. For example, somatic activating mutations in the EGFR gene are present in approximately 20% of patients with advanced non-small cell lung cancer. Tyrosine kinase inhibitors such as gefitinib, erlotinib, and afatinib improve progression-free survival in patients with susceptible EGFR mutations. In patients with overexpression of ALK protein, the response rate was significantly better with crizotinib (a tyrosine kinase inhibitor) than with the combination of pemetrexed and either cisplatin or carboplatin (platinum-based chemotherapy) (74% vs 45%, respectively; P <.001) and progression-free survival (median, 10.9 months vs 7.0 months; P <.001). Subsequent generations of tyrosine kinase inhibitors have improved these agents. For patients without biomarkers indicating susceptibility to specific targeted treatments, immune checkpoint inhibitor-containing regimens either as monotherapy or in combination with chemotherapy are superior vs chemotherapy alone. These advances in biomarker-directed therapy have led to improvements in overall survival. For example, the 5-year overall survival rate currently exceeds 25% among patients whose tumors have high PD-L1 expression (tumor proportion score of ≥50%) and 40% among patients with ALK-positive tumors. Conclusions and Relevance: Improved understanding of the biology and molecular subtypes of non-small cell lung cancer have led to more biomarker-directed therapies for patients with metastatic disease. These biomarker-directed therapies and newer empirical treatment regimens have improved overall survival for patients with metastatic non-small cell lung cancer.. © 2019 American Medical Association. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 763} -} - -@ARTICLE{Song2018657, - author = {Song, Andrew and Lu, Bo}, - title = {Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer}, - year = {2018}, - journal = {Journal of Thoracic Disease}, - volume = {10}, - number = {2}, - pages = {657 – 660}, - doi = {10.21037/jtd.2018.01.22}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042128204&doi=10.21037%2fjtd.2018.01.22&partnerID=40&md5=eb02051c8242eab1156d00c8a2e9e084}, - type = {Editorial}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 3; All Open Access, Green Open Access} -} - -@ARTICLE{Puri2018, - author = {Puri, Sonam and Shafique, Michael and Gray, Jhanelle E.}, - title = {Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer}, - year = {2018}, - journal = {Current Treatment Options in Oncology}, - volume = {19}, - number = {8}, - doi = {10.1007/s11864-018-0556-7}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048899084&doi=10.1007%2fs11864-018-0556-7&partnerID=40&md5=ec03c019b19462ddce73386a18d96507}, - abstract = {Surgical resection ± chemotherapy ± radiation or stereotactic body radiation therapy (SBRT) are established treatment modalities for resectable stage non-small cell lung cancer (NSCLC), and concurrent chemotherapy with radiation is the therapy of choice for unresectable locally advanced disease. Despite treatment with curative intent, most patients subsequently relapse and develop distant disease. Treatment with checkpoint inhibitors represents a major advancement in the treatment of metastatic NSCLC. Therapy against programed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1) is associated with a significant improvement in overall survival in stage IV disease, and these results have led to a great interest in evaluating these agents in earlier-stage NSCLC. The preliminary data from ongoing trials suggest that the integration of checkpoint blockage into the treatment of early-stage and locally advanced NSCLC is safe, tolerable, and has the potential to improve outcomes without adding substantial toxicity. In the current review, we provide an overview of the emerging data on the role of PD-1/PD-L1 and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitors in the treatment of early-stage and locally advanced NSCLC, with a focus on ongoing clinical trials and combination strategies. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 20} -} - -@ARTICLE{Perrotta2019, - author = {Perrotta, Fabio and Rocco, Danilo and Vitiello, Fabiana and De Palma, Raffaele and Guerra, Germano and De Luca, Antonio and Navani, Neal and Bianco, Andrea}, - title = {Immune checkpoint blockade for advanced NSCLC: A new landscape for elderly patients}, - year = {2019}, - journal = {International Journal of Molecular Sciences}, - volume = {20}, - number = {9}, - doi = {10.3390/ijms20092258}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065778586&doi=10.3390%2fijms20092258&partnerID=40&md5=7ac368cf921e4c29563b31f7bce462bb}, - abstract = {The therapeutic scenario for elderly patients with advanced NSCLC has been limited to radiotherapy and chemotherapy. Recently, a novel therapeutic approach based on targeting the immune-checkpoints has showed noteworthy results in advanced NSCLC. PD1/PD-L1 pathway is co-opted by tumor cells through the expression of PD-L1 on the tumor cell surface and on cells within the microenvironment, leading to suppression of anti-tumor cytolytic T-cell activity by the tumor. The success of immune-checkpoints inhibitors in clinical trials led to rapid approval by the FDA and EMA. Currently, data regarding efficacy and safety of ICIs in older subjects is limited by the poor number of elderly recruited in clinical trials. Careful assessment and management of comorbidities is essential to achieve better outcomes and limit the immune related adverse events in elderly NSCLC patients. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 32; All Open Access, Gold Open Access} -} - -@ARTICLE{Longo2019, - author = {Longo, Vito and Brunetti, Oronzo and Azzariti, Amalia and Galetta, Domenico and Nardulli, Patrizia and Leonetti, Francesco and Silvestris, Nicola}, - title = {Strategies to improve cancer immune checkpoint inhibitors efficacy, other than abscopal effect: A systematic review}, - year = {2019}, - journal = {Cancers}, - volume = {11}, - number = {4}, - doi = {10.3390/cancers11040539}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065421883&doi=10.3390%2fcancers11040539&partnerID=40&md5=443b77633a69317b801ea5f88e01a529}, - abstract = {Despite that the impact of immune checkpoint inhibitors on malignancies treatment is unprecedented, a lack of response to these molecules is observed in several cases. Differently from melanoma and non-small cell lung cancer, where the use of immune checkpoint inhibitors results in a high efficacy, the response rate in other tumors, such as gastrointestinal cancers, breast cancer, sarcomas, and part of genitourinary cancers remains low. The first strategy evaluated to improve the response rate to immune checkpoint inhibitors is the use of predictive factors for the response such as PD-L1 expression, tumor mutational burden, and clinical features. In addition to the identification of the patients with a higher expression of immune checkpoint molecules, another approach currently under intensive investigation is the use of therapeutics in a combinatory manner with immune checkpoint inhibitors in order to obtain an enhancement of efficacy through the modification of the tumor immune microenvironment. In addition to the abscopal effect induced by radiotherapy, a lot of studies are evaluating several drugs able to improve the response rate to immune checkpoint inhibitors, including microbiota modifiers, drugs targeting co-inhibitory receptors, anti-angiogenic therapeutics, small molecules, and oncolytic viruses. In view of the rapid and extensive development of this research field, we conducted a systematic review of the literature identifying which of these drugs are closer to achieving validation in the clinical practice. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 49; All Open Access, Gold Open Access} -} - -@ARTICLE{Lantuejoul2019S89, - author = {Lantuejoul, Sylvie and Damotte, Diane and Hofman, Véronique and Adam, Julien}, - title = {Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma}, - year = {2019}, - journal = {Journal of Thoracic Disease}, - volume = {11}, - pages = {S89 – S101}, - doi = {10.21037/jtd.2018.12.103}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061138046&doi=10.21037%2fjtd.2018.12.103&partnerID=40&md5=05bdcdb5faee652c6d38d18645221d17}, - abstract = {Lung cancer is the leading cause of cancer death worldwide with low response rates to conventional chemotherapy. New promising therapies have emerged based on programmed cell death protein 1 (PD-1) immunity checkpoint inhibitors (ICI), including anti-PD-1, such as nivolumab and pembrolizumab, or programmed death ligand 1 (PD-L1) inhibitors, such as atezolizumab, durvalumab, and avelumab. The prescription of pembrolizumab has been approved by FDA and EMA for advanced stages non-small cell lung carcinoma (NSCLC), restricted for first-line setting to patients whose tumor presents ≥50% of PD-L1 positive tumor cells (TC), and ≥1% for second-line and beyond, leading to consider PD-L1 assay as a companion diagnostic tool for pembrolizumab. Very recently, the EMA has approved durvalumab for the treatment of patients with unresectable stage III NSCLC not progressing after chemoradiotherapy and whose tumors express PD-L1 on ≥1% of TC. Four standardized PD-L1 immunohistochemistry assays have been used in clinical trials; 22C3 and 28-8 PharmDx assays on Dako/Agilent platforms, and SP142 and SP263 assays on Ventana platforms, each test having been developed initially for a specific ICI. They differ in terms of primary monoclonal antibody, platform, detection system and scoring methods with different thresholds of positivity validated in clinical trials. Several studies have shown a close analytical performance of the 22C3, 28-8 and SP263 assays regarding TC staining in NSCLC, with poor concordance with SP142 assay and for immune cells. However, as dedicated platforms are not available in all pathology laboratories and because of the high cost of these assays, laboratory developed tests are widely used in many countries. Their validation must guarantee the same sensitivities and specificities as compared to standardized assays. Overall, PD-L1 test is of great help to select patients who could benefit for ICI and most pathologists have included this test in their daily practice for advanced stages NSCLC, besides ALK and ROS1 IHC. © Journal of Thoracic Disease. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 56; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Tapia Rico2020, - author = {Tapia Rico, G. and Chan, M.M. and Loo, K.F.}, - title = {The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence}, - year = {2020}, - journal = {Cancer Treatment Reviews}, - volume = {86}, - doi = {10.1016/j.ctrv.2020.102011}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082179149&doi=10.1016%2fj.ctrv.2020.102011&partnerID=40&md5=05220f0de3f173c902e0c0575cc0a048}, - abstract = {The treatment paradigm of several cancers has dramatically changed in recent years with the introduction of immunotherapy. Most oncology trials involving immune checkpoint inhibitors (ICIPs) have routinely excluded patients with HIV infection and chronic viral hepatitis B (HBV) and C (HCV) due to concerns about viral reactivation, fears of increased toxicity, and the potential lack of efficacy in these patient subgroups. However, with current antiviral therapies, HIV and HBV infections have become chronic diseases and HCV infections can even be cured. Broadening cancer trial eligibility criteria in order to include cancer patients with chronic viral infections can maximize the ecological validity of study results and the ability to understand the ICPIs’ benefit-risk profile in patients with these comorbidities. In this review, we examined the evidence on the efficacy and safety of using ICPIs in cancer patients with concurrent chronic viral infections. © 2020 Elsevier Ltd}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 27} -} - -@ARTICLE{Wang20191599, - author = {Wang, Shuhang and Zimmermann, Stefan and Parikh, Kaushal and Mansfield, Aaron S. and Adjei, Alex A.}, - title = {Current Diagnosis and Management of Small-Cell Lung Cancer}, - year = {2019}, - journal = {Mayo Clinic Proceedings}, - volume = {94}, - number = {8}, - pages = {1599 – 1622}, - doi = {10.1016/j.mayocp.2019.01.034}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069804491&doi=10.1016%2fj.mayocp.2019.01.034&partnerID=40&md5=43e18cc4699accaf99d24b9b551e126a}, - abstract = {Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical, and molecular characteristics from non–small-cell lung cancer. SCLC has high metastatic potential, resulting in a clinically poor prognosis. Early concurrent chemo-radiation is the standard of care for limited-stage SCLC (LS-SCLC). Prophylactic cranial irradiation (PCI) is recommended for patients with LS-SCLC without progression of disease after initial therapy. A combination of etoposide and cisplatin or carboplatin remains the mainstay of first-line treatment for ES-SCLC, with the addition of atezolizumab, now becoming standard. Most SCLCs initially respond to therapy but almost invariably recur. Topotecan and amrubicin (in Japan) remain the primary chemotherapy options for relapsed SCLC. Immunotherapy, including nivolumab with or without ipilimumab, is now available for refractory disease. In general, the poor prognosis of SCLC has not improved significantly for more than 3 decades. Recently, next-generation molecular profiling studies have identified new therapeutic targets for SCLC. A variety of proapoptotic agents, compounds capitalizing on DNA-repair defects, immunotherapy agents, and antibody–drug conjugates are being evaluated in SCLC, with a number of them showing early promise. © 2019 Mayo Foundation for Medical Education and Research}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 201; All Open Access, Bronze Open Access} -} - -@ARTICLE{O’Leary20202185, - author = {O’Leary, Connor and McSorley, Lynda and Hennessy, Bryan and Grogan, Liam and Breathnach, Oscar and Morris, Patrick}, - title = {Challenges associated with systemic therapy for older patients with inoperable non-small cell lung cancer}, - year = {2020}, - journal = {Expert Opinion on Pharmacotherapy}, - volume = {21}, - number = {17}, - pages = {2185 – 2194}, - doi = {10.1080/14656566.2020.1801639}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090008717&doi=10.1080%2f14656566.2020.1801639&partnerID=40&md5=e9b9ee6ab5680212132bdf3575cb1a2a}, - abstract = {Introduction: Lung cancer is the most common cancer diagnosed worldwide. Data from several studies fall short to make appropriate conclusions on the management for elderly patients. The discovery of targeted therapy and immunotherapy has allowed these patients access to a wider array of options. Areas covered: The authors review research for treating older patients with lung cancer focusing on research performed in this patient population. Data are presented relating to chemotherapy, immunotherapy, and targeted therapy in the advanced setting. Expert opinion: Elderly patients particularly benefit from advances in systemic therapy. Based on the tumor profile, treatment with targeted therapy or immunotherapy should be favored over chemotherapy where possible in the elderly population. Elderly patients benefit from EGFR, ALK, and ROS-1 inhibition in the setting of these tumor alterations. These agents should be utilized early in the treatment course. Across many studies, the benefit from immunotherapy is seen irrespective of age. Favorable outcomes and toxicity profiles from immunotherapy compared to chemotherapy are well described. Chemotherapy should be offered with caution after a detailed assessment. Options include combination or single-agent chemotherapy regimens. Best supportive care alone is a reasonable option in the frailer, highly co-morbid patient. © 2020 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1} -} - -@ARTICLE{Fukui20201005, - author = {Fukui, Tomoya and Hosotani, Shinji and Soda, Itaru and Ozawa, Takahiro and Kusuhara, Seiichiro and Kakegawa, Mikiko I. and Kasajima, Masashi and Hiyoshi, Yasuhiro and Igawa, Satoshi and Yokoba, Masanori and Mitsufuji, Hisashi and Kubota, Masaru and Katagiri, Masato and Sasaki, Jiichiro and Ishiyama, Hiromichi and Naoki, Katsuhiko}, - title = {Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab}, - year = {2020}, - journal = {Thoracic Cancer}, - volume = {11}, - number = {4}, - pages = {1005 – 1014}, - doi = {10.1111/1759-7714.13357}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079438966&doi=10.1111%2f1759-7714.13357&partnerID=40&md5=5f025b18f3f926e3654c4fe1ca49ba6d}, - abstract = {Background: The standard treatment for patients with unresectable locally advanced (LA) non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT). Consolidation therapy with durvalumab after CRT demonstrated survival benefits and was approved in Japan in July 2018. The use of immune checkpoint inhibitors (ICIs) is entering routine oncological practice, and here we investigate the feasibility of concurrent CRT for LA-NSCLC patients based on the PACIFIC criteria. Methods: We performed a retrospective study to evaluate the feasibility and efficacy of concurrent CRT prior to the approval of durvalumab. We assessed consecutive patients with LA-NSCLC treated with CRT between January 2012 and June 2018. Results: We analyzed a total of 108 consecutive patients who received radical thoracic radiotherapy and concurrent platinum-based chemotherapy. Of those patients, 105 (97%) completed the planned radiotherapy. Radiation pneumonitis was observed in 93 patients (85%), with a median of 130 days (range: 41–317 days) from the initiation of radiation to the onset of the complication. Among the patients, 74 (69%) were considered eligible for consolidation therapy with durvalumab. The overall response rate was 64%, and the two-year survival rate was 63%. Patients who received an ICI after relapse were associated with significantly better survival than those who did not receive an ICI (two-year survival rate: 87% vs. 41%, respectively; P = 0.001). Conclusions: Prior to the approval of durvalumab, the clinical application of ICIs improved the outcome of patients with relapsed NSCLC after CRT for LA-NSCLC. The management of radiation pneumonitis remains a challenge following the approval of durvalumab. © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 12; All Open Access, Gold Open Access, Green Open Access} -}@ARTICLE{Sullivan2016945, - author = {Sullivan, Ivana and Planchard, David}, - title = {Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer}, - year = {2016}, - journal = {Future Oncology}, - volume = {12}, - number = {7}, - pages = {945 – 961}, - doi = {10.2217/fon.16.15}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84962235794&doi=10.2217%2ffon.16.15&partnerID=40&md5=621641da3f63e16d20bb1d9098b027c3}, - abstract = {The ALK gene plays a key role in the pathogenesis of non-small-cell lung cancer (NSCLC). Patients with NSCLC harboring an ALK-rearrangement represent the second oncogene addiction to be identified in this disease. Crizotinib was the first ALK inhibitor showing pronounced clinical activity, and is now a reference treatment for ALK-positive NSCLC disease. However, despite initial impressive responses to crizotinib, acquired resistance almost invariably develops within 12 months. The pressing need for effective second-line agents has prompted the rapid development of next-generation ALK inhibitors. These agents, notably ceritinib and alectinib as the most developed, have a higher potency against ALK than crizotinib, along with activity against tumors harboring crizotinib-resistant mutations and potentially improved CNS penetration. © 2016 Future Medicine Ltd.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 16} -} - -@ARTICLE{Hellmann2016251, - author = {Hellmann, Matthew D. and Friedman, Claire F. and Wolchok, Jedd D.}, - title = {Combinatorial Cancer Immunotherapies}, - year = {2016}, - journal = {Advances in Immunology}, - volume = {130}, - pages = {251 – 277}, - doi = {10.1016/bs.ai.2015.12.005}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84954285734&doi=10.1016%2fbs.ai.2015.12.005&partnerID=40&md5=28fd6c9302d1e9de6079ccb2d679aae9}, - abstract = {T cell checkpoint blockade therapies are revolutionizing the treatment of patients with cancer. Highlighted by the recent success of PD-1 plus CTLA-4 blockade in patients with melanomas, synergistic immunotherapy combinations of modalities represent an important opportunity to improve responses and outcomes for patients. We review the rationale and experience with T cell checkpoint blockade in combination with targeting of other coinhibitory or costimulatory checkpoints, immunomodulatory molecules in the tumor microenvironment, and other anticancer modalities such as vaccines, chemotherapy, and radiation. © 2016 Elsevier Inc.}, - type = {Book chapter}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 93} -} - -@ARTICLE{Iwai2017, - author = {Iwai, Yoshiko and Hamanishi, Junzo and Chamoto, Kenji and Honjo, Tasuku}, - title = {Cancer immunotherapies targeting the PD-1 signaling pathway}, - year = {2017}, - journal = {Journal of Biomedical Science}, - volume = {24}, - number = {1}, - doi = {10.1186/s12929-017-0329-9}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85016724516&doi=10.1186%2fs12929-017-0329-9&partnerID=40&md5=7e1efe23b98dc565ccec5195ce7b046a}, - abstract = {Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However, the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified research on combination therapies and predictive biomarkers. Here we summarize the development of PD-1-blockade immunotherapy and current issues in its clinical use. © 2017 The Author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 485; All Open Access, Gold Open Access} -} - -@ARTICLE{Guibert2015105, - author = {Guibert, Nicolas and Delaunay, Myriam and Mazières, Julien}, - title = {Targeting the immune system to treat lung cancer: Rationale and clinical experience}, - year = {2015}, - journal = {Therapeutic Advances in Respiratory Disease}, - volume = {9}, - number = {3}, - pages = {105 – 120}, - doi = {10.1177/1753465815578349}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84930719096&doi=10.1177%2f1753465815578349&partnerID=40&md5=d16c156b8ae3a79ece23a608fd73e4f1}, - abstract = {The use of immunotherapy that harnesses and enhances the innate powers of the immune system to fight cancer cells represents the most promising new cancer treatment approach since the development of the first chemotherapies and, more recently, targeted therapies. Unexpectedly, lung cancer has recently emerged as an exciting new target for immune-based therapies. Several approaches to immunotherapy for lung cancer have shown promise in early clinical trials and in late-phase development. The most advanced strategies can be split into two main categories: therapeutic vaccines and checkpoint inhibitors. At this time of great expectations, this review provides the reader with an update on the immunotherapies used to treat lung cancer with a focus on the rationale of targeting the immune system. It reports the results from recent major clinical trials, describes new toxicity profiles associated with such drugs, and particularly the role of the pulmonologists in their management. This review provides an overview of the main perspectives within this field. © 2015, SAGE Publications. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 15} -} - -@ARTICLE{Preusser2015504, - author = {Preusser, Matthias and Lim, Michael and Hafler, David A. and Reardon, David A. and Sampson, John H.}, - title = {Prospects of immune checkpoint modulators in the treatment of glioblastoma}, - year = {2015}, - journal = {Nature Reviews Neurology}, - volume = {11}, - number = {9}, - pages = {504 – 514}, - doi = {10.1038/nrneurol.2015.139}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941025149&doi=10.1038%2fnrneurol.2015.139&partnerID=40&md5=4d50661d7152b52c80b43e0dc87b7805}, - abstract = {Glioblastoma is the most common primary brain tumour in adults. Prognosis is poor: even with the current gold-standard first-line treatment - maximal safe resection and combination of radiotherapy with temozolomide chemotherapy - the median overall survival time is only approximately 15-17 months, because the tumour recurs in virtually all patients, and no commonly accepted standard treatment for recurrent disease exists. Several targeted agents have failed to improve patient outcomes in glioblastoma. Immunotherapy with immune checkpoint inhibitors such as ipilimumab, nivolumab, and pembrolizumab has provided relevant clinical improvements in other advanced tumours for which conventional therapies have had limited success, making immunotherapy an appealing strategy in glioblastoma. This Review summarizes current knowledge on immune checkpoint modulators and evaluates their potential role in glioblastoma on the basis of preclinical studies and emerging clinical data. Furthermore, we discuss challenges that need to be considered in the clinical development of drugs that target immune checkpoint pathways in glioblastoma, such as specific properties of the immune system in the CNS, issues with radiological response assessment, and potential interactions with established and emerging treatment strategies. © 2015 Macmillan Publishers Limited.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 315; All Open Access, Green Open Access} -} - -@ARTICLE{Yang20161209, - author = {Yang, Jiali and Chen, Juan and Wei, Jun and Liu, Xiaoming and Cho, William C.}, - title = {Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer}, - year = {2016}, - journal = {Expert Opinion on Biological Therapy}, - volume = {16}, - number = {10}, - pages = {1209 – 1223}, - doi = {10.1080/14712598.2016.1214265}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84985997817&doi=10.1080%2f14712598.2016.1214265&partnerID=40&md5=7e364d654dc3dd08ca7cdbcc8501a6eb}, - abstract = {Introduction: The recent emergence of immune checkpoint blockade therapy and the progression of immunobiology in cancer have spurred an increasing interest in the immunotherapy for advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs), designed to directly target immune inhibitory molecules, have demonstrated efficacy in the treatment of patients with advanced NSCLC. Areas covered: In the present article, the authors summarize the mechanism, efficacy and safety of major ICIs for the treatment of advanced or metastatic NSCLC. Combinations of different ICIs or conventional therapy and/or targeted agents for NSCLC treatment in clinical trials are also updated. In addition, immune-related adverse events and the roles of inhibitory immune checkpoint molecules as potential biomarkers in the immune checkpoint blockade therapy for NSCLC are emphatically elucidated. Expert opinion: Immunotherapies targeting the immune checkpoint pathways have shown potential to generate durable responses and improve survival for NSCLC patients. Although the toxicity profile of this immunotherapy is manageable, immune-related adverse events and drug resistance may cause therapeutic failure. Therefore, a better understanding of the mechanisms underpinning its function and the potential side effects of ICIs, as well as the identification of predictive biomarkers for patient selection are essential. © 2016 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 15} -} - -@ARTICLE{Jing2016489, - author = {Jing, Wang and Li, Miaomiao and Zhang, Yan and Teng, Feifei and Han, Anqin and Kong, Li and Zhu, Hui}, - title = {PD-1/PD-l1 blockades in non-small-cell lung cancer therapy}, - year = {2016}, - journal = {OncoTargets and Therapy}, - volume = {9}, - pages = {489 – 502}, - doi = {10.2147/OTT.S94993}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84957536816&doi=10.2147%2fOTT.S94993&partnerID=40&md5=2490650877c84f4c661c028ba8df44eb}, - abstract = {Lung cancer is the leading cause of cancer death in males and the second leading cause of death in females worldwide. Non-small-cell lung cancer (NSCLC) is the main pathological type of lung cancer, and most newly diagnosed NSCLC patients cannot undergo surgery because the disease is already locally advanced or metastatic. Despite chemoradiotherapy and targeted therapy improving clinical outcomes, overall survival remains poor. Immune checkpoint blockade, especially blockade of programmed death-1 (PD-1) receptor and its ligand PD-L1, achieved robust responses and improved survival for patients with locally advanced/metastatic NSCLC in preclinical and clinical studies. However, with regard to PD-1/PD-L1 checkpoint blockade as monotherapy or in combination with other antitumor therapies, such as chemotherapy, radiotherapy (including conventional irradiation and stereotactic body radiotherapy), and target therapy, there are still many unknowns in treating patients with NSCLC. Despite this limited understanding, checkpoint blockade as a novel therapeutic approach may change the treatment paradigm of NSCLC in the future. Here we review the main results from completed and ongoing studies to investigate the feasibility of PD-1/PD-L1 inhibitors, as monotherapy or combinatorial agents in patients with locally advanced and metastatic NSCLC, and explore optimal strategy in such patients. © 2016 Jing et al.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 51; All Open Access, Gold Open Access} -} - -@ARTICLE{Kim2017591, - author = {Kim, Hee Kyung and Heo, Mi Hwa and Lee, Han Sang and Sun, Jong-Mu and Lee, Se-Hoon and Ahn, Jin Seok and Park, Keunchil and Ahn, Myung-Ju}, - title = {Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors}, - year = {2017}, - journal = {Cancer Chemotherapy and Pharmacology}, - volume = {80}, - number = {3}, - pages = {591 – 598}, - doi = {10.1007/s00280-017-3396-4}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85025480789&doi=10.1007%2fs00280-017-3396-4&partnerID=40&md5=ff987cfd70b948b194f1a7f2595b5116}, - abstract = {Purpose: Given that immune-related response in non-small cell lung cancer (NSCLC) has not been well evaluated, we assessed tumor response using the response evaluation criteria in solid tumors, version 1.1 (RECIST v1.1) and immune-related response criteria (irRC) to identify atypical responses in patients with advanced NSCLC treated with immunotherapeutic agents. Methods: Patients received immune-checkpoint inhibitors (pembrolizumab, atezolizumab, nivolumab, and durvalumab plus tremelimumab) to treat metastatic or recurrent NSCLC after failed platinum-based chemotherapy. Tumor response was assessed according to both RECIST v1.1 and irRC. Results: Responses by 41 patients were analyzed. The overall response rate (ORR) was 29.2% (95% CI 17.6–44.5) assessed by RECIST v1.1 and 34.1% (95% CI 21.6–49.4) by irRC, showing similar results from the two methods (p = 0.923). Two patients (4.9%) were defined as having progressive disease as assessed by RECIST but not by irRC. The patients eventually experienced tumor regression, suggesting delayed pseudoprogression. For all patients, the median PFS was 5.1 months (95% CI 3.4–6.7) and OS was 18.3 months (95% CI 6.7–29.8). In multivariate analysis, ex- or current smokers (HR 0.34, p = 0.14) and EGFR mutation negativity (HR 0.16, p = 0.05) were associated with significantly longer PFS. Conclusion: Our study found that pseudoprogression was not frequently observed in NSCLC. Conventional RECIST v1.1 might underestimate the benefit of immune-checkpoint inhibitors. Given the small number of patients studied, further study is warranted on whether treatment with immune-checkpoint inhibitors beyond RECIST progression benefits patients with advanced NSCLC. © 2017, Springer-Verlag GmbH Germany.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 52} -} - -@ARTICLE{Roth2016326, - author = {Roth, Patrick and Preusser, Matthias and Weller, Michael}, - title = {Immunotherapy of Brain Cancer}, - year = {2016}, - journal = {Oncology Research and Treatment}, - volume = {39}, - number = {6}, - pages = {326 – 334}, - doi = {10.1159/000446338}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84970028919&doi=10.1159%2f000446338&partnerID=40&md5=1145c7720097a2ede826cfb21c9bda50}, - abstract = {The brain has long been considered an immune-privileged site precluding potent immune responses. Nevertheless, because of the failure of conventional anti-cancer treatments to achieve sustained control of intracranial neoplasms, immunotherapy has been considered as a promising strategy for decades. However, several efforts aimed at exploiting the immune system as a therapeutic weapon were largely unsuccessful. The situation only changed with the introduction of the checkpoint inhibitors, which target immune cell receptors that interfere with the activation of immune effector cells. Following the observation of striking effects of drugs that target CTLA-4 or PD-1 against melanoma and other tumor entities, it was recognized that these drugs may also be active against metastatic tumor lesions in the brain. Their therapeutic activity against primary brain tumors is currently being investigated within clinical trials. In parallel, other immunotherapeutics such as peptide vaccines are at an advanced stage of clinical development. Further immunotherapeutic strategies currently under investigation comprise adoptive immune cell transfer as well as inhibitors of metabolic pathways involved in the local immunosuppression frequently found in brain tumors. Thus, the ongoing implementation of immunotherapeutic concepts into clinical routine may represent a powerful addition to the therapeutic arsenal against various brain tumors. © 2016 S. Karger GmbH, Freiburg.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 14; All Open Access, Green Open Access} -} - -@ARTICLE{Bellmunt201758, - author = {Bellmunt, Joaquin and Powles, Thomas and Vogelzang, Nicholas J.}, - title = {A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now}, - year = {2017}, - journal = {Cancer Treatment Reviews}, - volume = {54}, - pages = {58 – 67}, - doi = {10.1016/j.ctrv.2017.01.007}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013167787&doi=10.1016%2fj.ctrv.2017.01.007&partnerID=40&md5=33670a741cbbd477fc6c699c91cb42f7}, - abstract = {The treatment of bladder cancer has evolved over time to encompass not only the traditional modalities of chemotherapy and surgery, but has been particularly impacted by the use of immunotherapy. The first immunotherapy was the live, attenuated bacterial Bacillus Calmette–Guérin vaccine, which has been the standard of care non-muscle-invasive bladder cancer since 1990. Modern immunotherapy has focused on inhibitors of checkpoint proteins, which are molecules that impede immune function, thereby allowing tumor cells to grow and proliferate unregulated. Several checkpoint targets (programmed death ligand-1 [PD-L1] programmed cell death protien-1 [PD-1], and cytotoxic T-lymphocyte associated protein 4 [CTLA4]) have received the most attention in the treatment of bladder cancer, and have inhibitor agents either approved or in late-stage development. This review describes the most recent data on agents that inhibit PD-L1, found on the surface of tumor cells, and PD-1 found on activated T and B cells and macrophages. Atezolizumab is the only member of this class currently approved for the treatment of bladder cancer, but nivolumab, pembrolizumab, durvalumab, and avelumab all have positive results for this indication, and approvals are anticipated in the near future. The checkpoint inhibitors offer an effective alternative for patients for whom previously there were few options for durable responses, including those who are ineligible for cisplatin-based regimens or who are at risk of significant toxicity. Research is ongoing to further categorize responses, define ideal patient populations, and investigate combinations of checkpoint inhibitors to address multiple pathways in immune system functioning. © 2017 Elsevier Ltd}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 303; All Open Access, Green Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Montella20166114, - author = {Montella, Liliana and Palmieri, Giovannella and Addeo, Raffaele and Del Prete, Salvatore}, - title = {Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?}, - year = {2016}, - journal = {World Journal of Gastroenterology}, - volume = {22}, - number = {27}, - pages = {6114 – 6126}, - doi = {10.3748/wjg.v22.i27.6114}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84978499766&doi=10.3748%2fwjg.v22.i27.6114&partnerID=40&md5=daaa554df6c458da76b48b62f9ae1315}, - abstract = {Cancer treatment has been revolutionized by the advent of new molecular targeted and immunotherapeutic agents. Identification of the role of tumor angiogenesis changed the understanding of many tumors. After the unsuccessful results with chemotherapy, sorafenib, by interfering with angiogenic pathways, has become pivotal in the treatment of hepatocellular carcinoma. Sorafenib is the only systemic treatment to show a modest but statistically significant survival benefit. All novel drugs and strategies for treatment of advanced hepatocellular carcinoma must be compared with the results obtained with sorafenib, but no new drug or drug combination has yet achieved better results. In our opinion, the efforts to impact the natural history of the disease will be directed not only to drug development but also to understanding the underlying liver disease (usually hepatitis B virus- or hepatitis C virus-related) and to interrupting the progression of cirrhosis. It will be important to define the role and amount of mutations in the complex pathogenesis of hepatocellular carcinoma and to better integrate locoregional and systemic therapies. It will be important also to optimize the therapeutic strategies with existing chemotherapeutic drugs and new targeted agents. © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 25; All Open Access, Green Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Califano2016, - author = {Califano, Raffaele and Kerr, Keith and Morgan, Robert David and Russo, Giuseppe Lo and Garassino, Marina and Morgillo, Floriana and Rossi, Antonio}, - title = {Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer}, - year = {2016}, - journal = {Current Oncology Reports}, - volume = {18}, - number = {9}, - doi = {10.1007/s11912-016-0544-7}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84982701921&doi=10.1007%2fs11912-016-0544-7&partnerID=40&md5=ecc255b1bb14e7addae4b16a5d93f597}, - abstract = {Despite better understanding of it’s molecular biology, non-small cell lung cancer (NSCLC) remains a challenging disease to treat. Unfortunately, treatment options are still very limited and prognosis for advanced disease is poor. Immune surveillance plays a crucial role in a host’s defence against tumour cells, and this is particular relevant for lung cancer due to it’s high somatic mutational load, which increases the chances for the immune system to recognize cancer cells as ‘non-self’. Novel immunotherapies are emerging as an effective treatment for this disease. In this review, we present the data on immune checkpoint inhibitors for NSCLC, describing their mechanism of action, data efficacy from recent clinical trials, and strategies to select patients more likely to benefit from these agents. © 2016, Springer Science+Business Media New York.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 39} -} - -@ARTICLE{Somasundaram2017, - author = {Somasundaram, Ashwin and Burns, Timothy F.}, - title = {The next generation of immunotherapy: Keeping lung cancer in check Ahmed Tarhini; Timothy Burns; Rahul Parikh; Guarvel Goel; Annie im}, - year = {2017}, - journal = {Journal of Hematology and Oncology}, - volume = {10}, - number = {1}, - doi = {10.1186/s13045-017-0456-5}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018797196&doi=10.1186%2fs13045-017-0456-5&partnerID=40&md5=ea2f5a253438f9142077fcab5b8cfc61}, - abstract = {Lung cancer is the deadliest malignancy with more cancer deaths per year than the next three cancers combined. Despite remarkable advances in targeted therapy, advanced lung cancer patients have not experienced a significant improvement in mortality. Lung cancer has been shown to be immunogenic and responsive to checkpoint blockade therapy. Checkpoint signals such as CTLA-4 and PD-1/PD-L1 dampen T cell activation and allow tumors to escape the adaptive immune response. Response rates in patients with pretreated, advanced NSCLC were much higher and more durable with PD-1 blockade therapy compared to standard-of-care, cytotoxic chemotherapy. Therefore, PD-1 inhibitors such as nivolumab and pembrolizumab were rapidly approved for both squamous and nonsquamous lung cancer in the pretreated population. The advent of these new therapies have revolutionized the treatment of lung cancer; however, the majority of NSCLC patients still do not respond to PD-1/PD-L1 inhibition leaving an unmet need for a large and growing population. Immunotherapy combinations with chemotherapy, radiation therapy, or novel immunomodulatory agents are currently being examined with the hope of achieving higher response rates and improving overall survival rate. Chemotherapy and radiation therapy has been theorized to increase the release of tumor antigen leading to increased responses with immunotherapy. However, cytotoxic chemotherapy and radiation therapy may also destroy actively proliferating T cells. The correct combination and order of therapy is under investigation. The majority of patients who do respond to immunotherapy have a durable response attributed to the effect of adaptive immune system's memory. Unfortunately, some patients' tumors do progress afterward and investigation of checkpoint blockade resistance is still nascent. This review will summarize the latest efficacy and safety data for early and advanced NSCLC in both the treatment-naïve and pretreated settings. The emerging role of immunotherapy for the treatment of small cell lung cancer and malignant mesothelioma will also be discussed. © 2017 The Author(s).}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 83; All Open Access, Gold Open Access} -} - -@ARTICLE{La-Beck2015963, - author = {La-Beck, Ninh M. and Jean, Gary W. and Huynh, Cindy and Alzghari, Saeed K. and Lowe, Devin B.}, - title = {Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy}, - year = {2015}, - journal = {Pharmacotherapy}, - volume = {35}, - number = {10}, - pages = {963 – 976}, - doi = {10.1002/phar.1643}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84945122687&doi=10.1002%2fphar.1643&partnerID=40&md5=5ced010c90d31122441d2f8d3d9fd695}, - abstract = {The treatment of cancer has largely relied on killing tumor cells with nonspecific cytotoxic therapies and radiotherapy. This approach, however, has limitations including severe systemic toxicities, bystander effects on normal cells, recurrence of drug-resistant tumor cells, and the inability to target micrometastases or subclinical disease. An increased understanding of the critical role of the immune system in cancer development and progression has led to new treatment strategies using various immunotherapies. It is now recognized that established tumors have numerous mechanisms of suppressing the antitumor immune response including production of inhibitory cytokines, recruitment of immunosuppressive immune cells, and upregulation of coinhibitory receptors known as immune checkpoints. This review focuses on the immune checkpoint inhibitors, a novel class of immunotherapy first approved in 2011. Our objective is to highlight similarities and differences among the three immune checkpoint inhibitors approved by the U.S. Food and Drug Administration - ipilimumab, pembrolizumab, and nivolumab - to facilitate therapeutic decision making. We conducted a review of the published literature and conference proceedings and present a critical appraisal of the clinical evidence supporting their use in the treatment of metastatic melanoma and advanced squamous non-small cell lung cancer (NSCLC). We also compare and contrast their current place in cancer therapy and patterns of immune-related toxicities, and discuss the role of dual immune checkpoint inhibition and strategies for the management of immune-related adverse events. The immune checkpoint inhibitors have demonstrated a dramatic improvement in overall survival in patients with advanced melanoma and squamous NSCLC, along with acceptable toxicity profiles. These agents have a clear role in the first-line treatment of advanced melanoma and in the second-line treatment of advanced squamous NSCLC. © 2015 Pharmacotherapy Publications, Inc.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 195} -} - -@ARTICLE{Chen20177, - author = {Chen, Yuh-Min}, - title = {Immune checkpoint inhibitors for nonsmall cell lung cancer treatment}, - year = {2017}, - journal = {Journal of the Chinese Medical Association}, - volume = {80}, - number = {1}, - pages = {7 – 14}, - doi = {10.1016/j.jcma.2016.08.005}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84999791810&doi=10.1016%2fj.jcma.2016.08.005&partnerID=40&md5=903c1fa74fd981e6e2b9bbac755147e0}, - abstract = {Immune checkpoint inhibition with blocking antibodies that target cytotoxic T-lymphocyte antigen-4 (CTLA-4) and the programmed cell death protein 1 (PD-1) pathway [PD-1/programmed death-ligand 1 (PD-L1)] have demonstrated promise in a variety of malignancies. While ipilimumab has been approved as a CTLA-4 blocking antibody by the US Food and Drug Administration for the treatment of advanced melanoma, it is still not approved for lung cancer treatment. In contrast, nivolumab and pembrolizumab, both PD-1 blocking antibodies, have been approved for second-line treatment of nonsmall cell lung cancer in 2015 because of their high potency and long-lasting effects in some patient subgroups. Other PD-1 and PD-L1 monoclonal antibodies are also in active development phase. Treatment with such immune checkpoint inhibitors is associated with a unique pattern of immune-related adverse events or side effects. Combination approaches involving CTLA-4 and PD-1/PD-L1 blockade or checkpoint inhibitors with chemotherapy or radiotherapy are being investigated to determine whether they may enhance the efficacy of treatment. Despite many challenges ahead, immunotherapy with checkpoint inhibitors has already become a new and important treatment modality for lung cancer in the last decade following the discovery of targeted therapy. © 2016}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 37; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Koo2016250, - author = {Koo, Taeryool and Kim, In Ah}, - title = {Radiotherapy and immune checkpoint blockades: A snapshot in 2016}, - year = {2016}, - journal = {Radiation Oncology Journal}, - volume = {34}, - number = {4}, - pages = {250 – 259}, - doi = {10.3857/roj.2016.02033}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85007552688&doi=10.3857%2froj.2016.02033&partnerID=40&md5=bd3ac09cffaf58ea4a21db6aef557ec4}, - abstract = {Immune checkpoint blockades including monoclonal antibodies (mAbs) of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) have been emerged as a promising anticancer therapy. Several immune checkpoint blockades have been approved by US Food and Drug Administration (FDA), and have shown notable success in clinical trials for patients with advanced melanoma and non-small cell lung cancer. Radiotherapy is a promising combination partner of immune checkpoint blockades due to its potent pro-immune effect. This review will cover the current issue and the future perspectives for combined with radiotherapy and immune checkpoint blockades based upon the available preclinical and clinical data. © 2016. The Korean Society for Radiation Oncology.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 25; All Open Access, Gold Open Access} -} - -@ARTICLE{Anagnostou2015976, - author = {Anagnostou, Valsamo K. and Brahmer, Julie R.}, - title = {Cancer immunotherapy: A future paradigm shift in the treatment of non-small cell lung cancer}, - year = {2015}, - journal = {Clinical Cancer Research}, - volume = {21}, - number = {5}, - pages = {976 – 984}, - doi = {10.1158/1078-0432.CCR-14-1187}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929456860&doi=10.1158%2f1078-0432.CCR-14-1187&partnerID=40&md5=1dde9a2b760b963ccaa7bb37b33a2ad4}, - abstract = {Emerging evidence on the role of the antitumor activity of the immune system has generated great interest in immunotherapy even for tumors that were historically considered as nonimmunogenic. Immunotherapy is emerging as a major modality in non-small cell lung cancer (NSCLC) treatment focusing on vaccine approaches to elicit specific immune responses and development of inhibitors of the molecular mediators of cancer-induced immunosuppression (immune checkpoints) to boost antitumor immune responses. Amplification of the host response against evolving tumors through vaccination is being investigated in ongoing clinical trials with tumor cell vaccines; however, the clinical efficacy of these agents has been limited. Blocking inhibitory pathways such as the CTL antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) checkpoint pathways with mAbs has generated antitumor immune responses that are transforming cancer therapeutics. PD-1 and programmed cell death ligand 1 (PD-L1) antibodies have shown durable responses in NSCLC, with a favorable safety profile and manageable side effects. The activity of immune checkpoint inhibitors is currently been assessed in treatment-naive patients with PD-L1-positive advanced NSCLC. Combinatorial approaches with other immune checkpoint inhibitors, chemotherapy, or targeted agents are being explored in ongoing clinical trials, and may improve outcome in NSCLC. © 2015 American Association for Cancer Research.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 200} -} - -@ARTICLE{Hellmann20161829, - author = {Hellmann, M.D. and Li, B.T. and Chaft, J.E. and Kris, Mark G.}, - title = {Chemotherapy remains an essential element of personalized care for persons with lung cancers}, - year = {2016}, - journal = {Annals of Oncology}, - volume = {27}, - number = {10}, - pages = {1829 – 1835}, - doi = {10.1093/ANNONC/MDW271}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017303190&doi=10.1093%2fANNONC%2fMDW271&partnerID=40&md5=c2d8e9f81a7fe3cc266f64b6106e56be}, - abstract = {Molecularly targeted and immunotherapies have improved the care of patients with lung cancers. These successes have rallied calls to replace or avoid chemotherapy. Yet, even in this era of precision medicine and exciting advances, cytotoxic chemotherapies remain an essential component of lung cancer treatment. In the setting of locoregional disease, chemotherapy is the only systemic therapy thus far proven to enhance curability when combined with surgery or radiation. In the metastatic setting, chemotherapy can improve the length and quality of life in many patients. Chemotherapy remains the mainstay of care for individuals whose cancers with oncogenic drivers have acquired resistance to targeted agents. Chemotherapy also has the potential to modulate the immune system to enhance the effectiveness of immune checkpoint inhibitors. In this context, chemotherapy should be framed as a critical component of the armamentarium available for optimizing cancer care rather than an unfortunate anachronism. We examine the role of chemotherapy with precision medicine in the current care of patients with lung cancers, as well as opportunities for future integration in combinations with targeted agents, angiogenesis inhibitors, immunotherapies, and antibody drug conjugates. © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 90; All Open Access, Hybrid Gold Open Access} -} - -@ARTICLE{Lote2015893, - author = {Lote, Hazel and Cafferkey, Catherine and Chau, Ian}, - title = {PD-1 and PD-L1 blockade in gastrointestinal malignancies}, - year = {2015}, - journal = {Cancer Treatment Reviews}, - volume = {41}, - number = {10}, - pages = {893 – 903}, - doi = {10.1016/j.ctrv.2015.09.004}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84958836241&doi=10.1016%2fj.ctrv.2015.09.004&partnerID=40&md5=0cd3ea693cf8bbea43568107d7d8011e}, - abstract = {Immunotherapy represents a major breakthrough in cancer therapy in recent years. Immune-checkpoint blockade using PD-1 and PD-L1 antibodies appears to be one of the most promising immunotherapy approaches. Immunotherapy differs from conventional cancer treatment because of its ability to produce durable responses in some patients. In this review article, we explore the available evidence and summarise current clinical trials for PD-1 and PD-L1 blockade in gastrointestinal malignancies. The challenge now is to develop strategies to increase the efficacy of PD-1 and PD-L1 blockade in gastrointestinal cancer patients, such as combination therapy with chemotherapy, radiotherapy or other immunotherapy, along with validating biomarkers to select patients and personalise treatment. © 2015 Elsevier Ltd.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 61} -} - -@ARTICLE{Gridelli20161479, - author = {Gridelli, Cesare and Ascierto, Paolo A. and Barberis, Massimo C.P. and Felip, Enriqueta and Garon, Edward B and O’brien, Mary and Senan, Suresh and Casaluce, Francesca and Sgambato, Assunta and Papadimitrakopoulou, Vali and De Marinis, Filippo}, - title = {Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology}, - year = {2016}, - journal = {Expert Opinion on Biological Therapy}, - volume = {16}, - number = {12}, - pages = {1479 – 1489}, - doi = {10.1080/14712598.2016.1234602}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994388924&doi=10.1080%2f14712598.2016.1234602&partnerID=40&md5=bfdb72b15609f988c8ad1cc0b3ea5dc4}, - abstract = {Introduction: The potential long term survival gain, related to immune adaptability and memory, the potential activity across multiple tumour types through targeting the immune system, and the opportunity for combinations offered by the unique mechanism of actions and safety profile of these new agents, all support the role of immunotherapy in the cancer treatment pathway or paradigm. Areas covered: The authors discuss the recent advances in the understanding of immunology and antitumor immune responses that have led to the development of new immunotherapies, including monoclonal antibodies that inhibit immune checkpoint pathways, such as Programmed Death-1 (PD-1) and Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4). Currently, two PD-1 inhibitors are available in clinical practice for treatment of advanced non-small cell lung cancer (NSCLC): nivolumab and pembrolizumab. Expert opinion: Ongoing research will dictate future strategies, including the potential incorporation of immunotherapy in stage dependent treatment settings (early stage locally advanced disease and first line therapy for metastatic disease). Immunotherapy combinations are promising avenues, and careful selection of patients, doses of each agent and information supporting strategies (i.e. concomitant or sequential) is still needed. © 2016 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 11} -} - -@ARTICLE{Santarpia2016781, - author = {Santarpia, Mariacarmela and Giovannetti, Elisa and Rolfo, Christian and Karachaliou, Niki and González-Cao, Maria and Altavilla, Giuseppe and Rosell, Rafael}, - title = {Recent developments in the use of immunotherapy in non-small cell lung cancer}, - year = {2016}, - journal = {Expert Review of Respiratory Medicine}, - volume = {10}, - number = {7}, - pages = {781 – 798}, - doi = {10.1080/17476348.2016.1182866}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84975475669&doi=10.1080%2f17476348.2016.1182866&partnerID=40&md5=2703231cea41938840d43562741e5e6a}, - abstract = {Introduction: Targeted therapies have significantly improved the prognosis of subsets of patients with advanced non-small-cell lung cancer (NSCLC) harboring somatically activated oncogenes, such as mutant EGFR and rearranged ALK. However, the efficacy of these agents is limited by the development of acquired resistance which occurs after variable periods of time. Therefore, there is an urgent need for novel therapeutic strategies to achieve long lasting disease control, as well as new therapies for those patients without targetable driver mutations. A deeper understanding of interactions between the immune system and tumor cells has led to the development of a number of immunotherapeutic agents. Areas covered: We review current data on immunotherapy for lung cancer treatment, with a focus on checkpoint inhibitors and therapeutic vaccines. References for this review were identified through searches of PubMed, congress proceedings and reference lists from key original and review papers. Expert commentary: While most vaccines have been unsuccessful, inhibitors of specific immune checkpoints, including CTLA-4 and PD-1/PD-L1 pathway, have shown significant clinical activity and manageable toxicities and recently, two anti-PD-1 monoclonal antibodies have been approved by the FDA for treatment of patients with advanced NSCLC. Identification of reliable predictive biomarkers for patient selection and novel rational combinations are currently active areas of research to further improve the efficacy of immunotherapy. © 2016 Informa UK Limited, trading as Taylor & Francis Group.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 29} -} - -@ARTICLE{Economopoulou2014, - author = {Economopoulou, Panagiota and Kotsantis, Giannis and Kavourakis, George and Psyrri, Amanda}, - title = {Head and neck cancer highlights of ESMO congress 2014}, - year = {2014}, - journal = {European Oncology and Haematology}, - volume = {10}, - number = {2}, - doi = {10.17925/eoh.2014.10.2.96}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84920972869&doi=10.17925%2feoh.2014.10.2.96&partnerID=40&md5=5326f97b3141b55b772dd9f209d78553}, - abstract = {Head and neck squamous cell carcinoma (HNSCC) is a challenging cancer to treat and cure. A great proportion of patients present with advanced disease and appropriate treatment options include surgical resection with adjuvant radiotherapy (RT) or chemoradiotherapy (CRT), radical concurrent CRT or RT with monoclonal antibody cetuximab. Despite improved outcomes with CRT, overall prognosis is still unsatisfactory and treatment-related toxicity is a matter of major importance. To obtain improved outcomes and mitigate disease recurrence, current research is focused on novel molecular targeted agents, immunotherapy and discovery of predictive markers. Herein, we summarise recent advances in treatment of head and neck cancer, as presented in European Society for Medical Oncology (ESMO) Congress 2014. © Touch medical media 2014.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 1} -} - -@ARTICLE{Wagner20172097, - author = {Wagner, Lars M and Adams, Val R}, - title = {Targeting the PD-1 pathway in pediatric solid tumors and brain tumors}, - year = {2017}, - journal = {OncoTargets and Therapy}, - volume = {10}, - pages = {2097 – 2106}, - doi = {10.2147/OTT.S124008}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017502113&doi=10.2147%2fOTT.S124008&partnerID=40&md5=16f21a04e7bf8e3a5e76abec4dd09833}, - abstract = {While remarkable advances have been made in the treatment of pediatric leukemia over the past decades, new therapies are needed for children with advanced solid tumors and high-grade brain tumors who fail standard chemotherapy regimens. Immunotherapy with immune checkpoint inhibitors acting through the programmed cell death-1 (PD-1) pathway has shown efficacy in some chemotherapy-resistant adult cancers, generating interest that these agents may also be helpful to treat certain refractory pediatric malignancies. In this manuscript we review current strategies for targeting the PD-1 pathway, highlighting putative biomarkers and the rationale for investigation of these drugs to treat common pediatric tumors such as sarcoma, neuroblastoma, and high-grade glioma. We summarize the completed and ongoing clinical trial data available, and suggest potential applications for further study. © 2017 Wagner and Adams.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 45; All Open Access, Gold Open Access} -} - -@ARTICLE{Matikas201617, - author = {Matikas, Alexios and Aggelaki, Sofia}, - title = {Targeting the PD-1/PD-L1 axis in the treatment of lung cancer}, - year = {2016}, - journal = {Forum of Clinical Oncology}, - volume = {7}, - number = {1}, - pages = {17 – 27}, - doi = {10.1515/fco-2015-0021}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84989169795&doi=10.1515%2ffco-2015-0021&partnerID=40&md5=21bbae7abef629c6f2c84a784c605237}, - abstract = {In recent years major advances in the field of molecular profiling of non-small cell lung cancer led to the identification of targetable driver mutations and revolutionized the treatment of specific patient subsets. However, the majority of NSCLC tumors do not harbor these genomic events. On the other hand, current studies have confirmed an expanding role for immunotherapy in lung cancer and new agents, such as inhibitors of the programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis have been introduced in the treatment armamentarium. The monoclonal antibodies nivolumab and pembrolizumab targeting PD-1 resulted in superior survival when compared to standard second line chemotherapy within the context of randomized trials and received regulatory approval. Moreover, several other anti-PD-L1 antibodies have demonstrated encouraging preliminary efficacy and multiple clinical trials in various settings during the disease trajectory are currently underway. Early immunotherapy trials have also illustrated the potential of PD-1 blockade in small cell lung cancer treatment, a disease for which major advances in systemic therapy are lacking. The currently available clinical data on PD-1/PD-L1 inhibition in lung cancer are summarized in this review. © De Gruyter Open.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 0; All Open Access, Gold Open Access} -} - -@ARTICLE{Zandberg2014627, - author = {Zandberg, Dan P. and Strome, Scott E.}, - title = {The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck}, - year = {2014}, - journal = {Oral Oncology}, - volume = {50}, - number = {7}, - pages = {627 – 632}, - doi = {10.1016/j.oraloncology.2014.04.003}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901770708&doi=10.1016%2fj.oraloncology.2014.04.003&partnerID=40&md5=d555d009966b11267e547042fa81a33e}, - abstract = {Antigen specific stimulation of immune cells, triggers expression of a diverse array of co-signaling molecules that help define the fate of the resultant immune response. Antibodies and fusion proteins, capable of blocking and/or activating these co-signaling pathways, are emerging as potent therapeutic options for the treatment of cancer and autoimmune disease. Blockade of one such pair of co signaling interactions, termed PD-L1:PD-1, has shown tremendous promise in phase I treatment trials for advanced solid tumors like non-small cell lung cancer and melanoma, with long term disease remission in select patients. Based on intriguing preclinical data from our group and others, several trials are actively evaluating the utility of PD-L1:PD-1 blockade for the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). In this review we will explore what is known about the interactions between PD-1 and PD-L1, with a focus on SCCHN, and specifically discuss how this pathway can be manipulated with therapeutic intent. © 2014 Elsevier Ltd. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 195} -} - -@ARTICLE{Schild2016590, - author = {Schild, S.E. and Vokes, E.E.}, - title = {Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer}, - year = {2016}, - journal = {Annals of Oncology}, - volume = {27}, - number = {4}, - pages = {590 – 599}, - doi = {10.1093/annonc/mdv621}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964670270&doi=10.1093%2fannonc%2fmdv621&partnerID=40&md5=6ca632f2148699e31b1fef5e6e0969ca}, - abstract = {Background: Lung cancer is the leading cause of cancer deaths, having caused an estimated 1.6 million deaths worldwide in 2012 [Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386]. Materials and methods: Although the majority of patients are not cured with currently available therapies, there have been significant improvements in stage-specific outcomes over time [Videtic G, Vokes E, Turrisi A et al. The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years. In The 39th Annual Meeting of the American Society of Clinical Oncology, ASCO 2003, Chicago, IL. Abstract 2557. p. 291]. This review focuses on past progress and ongoing research in the treatment of locally advanced, inoperable nonsmall-cell lung cancer (NSCLC). Results: In the past, randomized trials revealed advantages to the use of thoracic radiotherapy (TRT) and then, the addition of induction chemotherapy. This was followed by studies that determined concurrent chemoradiotherapy to be superior to sequential therapy. A recent large phase III trial found that the administration of 74 Gy of conventionally fractionated photon-based TRT provided poorer survival than did the standard 60 Gy. However, further research on other methods of applying radiotherapy (hypofractionation, adaptive TRT, proton therapy, and stereotactic TRT boosting) is proceeding and may improve outcomes. The molecular characterization of tumors has provided more effective and less toxic targeted treatments in the stage IV setting and these agents are currently under investigation for earlier stage disease. Similarly, immune-enhancing therapies have shown promise in stage IV disease and are also being tested in the locally advanced setting. Conclusion: For locally advanced, inoperable NSCLC, standard therapy has evolved from TRT alone to combined modality therapy. We summarize the recent clinical trial experience and outline promising areas of investigation in an era of greater molecular and immunologic understanding of cancer care. © The Author 2015.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 30; All Open Access, Bronze Open Access} -} - -@ARTICLE{Decatris20161805, - author = {Decatris, Marios P. and O'Byrne, Kenneth J.}, - title = {Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer}, - year = {2016}, - journal = {Future Oncology}, - volume = {12}, - number = {15}, - pages = {1805 – 1822}, - doi = {10.2217/fon-2016-0086}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979747908&doi=10.2217%2ffon-2016-0086&partnerID=40&md5=489a9302fe2ed47a1345e766b989f4e5}, - abstract = {Advanced non-small-cell lung cancer (NSCLC) has a poor prognosis with few treatment options available for patients after failure of first-line therapy. Nivolumab is the first immune checkpoint inhibitor targeting the PD-1 to be approved in recurrent NSCLC with squamous and nonsquamous histology. More recently, pembrolizumab has also been approved as salvage therapy in PD-L1-positive recurrent NSCLC. The success of immunotherapy in malignant melanoma, previously a disease with no effective treatment, has generated optimism and expectation that some of the checkpoint inhibitors currently in clinical development will soon become available as first-line therapy and hence improve outcomes for the vast majority of patients with advanced NSCLC. This article summarizes the progress accomplished in the field and discusses controversies surrounding the use of immune checkpoint inhibitors. © 2016 Future Medicine Ltd.}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 7} -} - -@ARTICLE{Park201722, - author = {Park, Jeong A. and Cheung, Nai-Kong V.}, - title = {Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies}, - year = {2017}, - journal = {Cancer Treatment Reviews}, - volume = {58}, - pages = {22 – 33}, - doi = {10.1016/j.ctrv.2017.05.006}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020725218&doi=10.1016%2fj.ctrv.2017.05.006&partnerID=40&md5=512ddf6f2b5377ddb679ec709654ca8c}, - abstract = {Immune checkpoint inhibitors (ICI) have shown great promise in a wide spectrum of adult solid and hematological malignancies, achieving objective tumor responses and prolonging survival. However, there is limited clinical success amongst pediatric patients. In this review, we summarize the current understanding of ICI and present an up-to-date overview of recent and ongoing clinical trials of ICI in pediatric malignancies. In addition, we will discuss immunologic and clinical difficulties in this young population, as well as future prospects for combination of ICI with other immune-based and conventional treatments. © 2017 Elsevier Ltd}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 78; All Open Access, Green Open Access} -} - -@ARTICLE{Seetharamu201767, - author = {Seetharamu, Nagashree and Preeshagul, Isabel R. and Sullivan, Kevin M.}, - title = {New PD-L1 inhibitors in non-small cell lung cancer – Impact of atezolizumab}, - year = {2017}, - journal = {Lung Cancer: Targets and Therapy}, - volume = {8}, - pages = {67 – 78}, - doi = {10.2147/LCTT.S113177}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85026813378&doi=10.2147%2fLCTT.S113177&partnerID=40&md5=0f9262816e31062cc795bf558b68bc01}, - abstract = {The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies. Lung cancer has been in the forefront of checkpoint inhibition for the past 2 years and has paved the path for other subspecialties. While PD-1 inhibitors nivolumab and pembrolizumab have been approved for non-small cell lung cancer (NSCLC), this review focuses on atezolizumab, its landmark studies, and ongoing trials. Atezolizumab is the first programmed death ligand 1 (PD-L1) inhibitor to receive US Food and Drug Administration (FDA) approval for metastatic NSCLC patients who have progressed on frontline chemotherapy. This approval was based on two open-label Phase II multicenter trials, POPLAR (NCT01903993) and BIRCH (NCT02031458). Both studies revealed a benefit in overall survival (OS), progression-free survival, and response rate in the atezolizumab arm when compared to single-agent docetaxol. There were also fewest Grade 3–5 treatment-related adverse events (TRAEs) in the atezolizumab cohort. The open-label randomized Phase III OAK trial (NCT02008227) further established the role of atezolizumab in previously treated NSCLC. This study compared atezolizumab with docetaxel in patients with advanced NSCLC (squamous or nonsquamous histologies) who had progressed on one to two prior chemotherapy regimens. OS in the PD-L1-enriched population was superior in the atezolizumab arm (n=241) at 15.7 months compared with docetaxel (n=222) at 10.3 months (hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.58–0.93; p=0.0102). Patients lacking PD-L1 also had survival benefit with atezolizumab with a median OS (mOS) of 12.6 months versus 8.9 months with chemotherapy (HR 0.75, 95% CI 0.59–0.96). Benefit was noted in both squamous and nonsquamous NSCLC subsets and regardless of PD-L1 expressivity. As seen in the POPLAR and BIRCH studies, the toxicity profile was significantly better with immunotherapy. The future is unfolding rapidly as new checkpoint inhibitors are gaining FDA approval. It is still not known if these agents will be used in combination with chemotherapy, with other immune-modulating agents, radiation therapy, or all of the above. The results of these studies investigating their use in combination with chemotherapy agents, with other immunotherapy agents such as CTLA-4 inhibitors, and with radiation therapy, are eagerly awaited. © 2017 Seetharamu et al.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 33; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{El-Osta20165010, - author = {El-Osta, Hazem and Shahid, Kamran and Mills, Glenn M. and Peddi, Prakash}, - title = {Immune checkpoint inhibitors: The new frontier in non-small-cell lung cancer treatment}, - year = {2016}, - journal = {OncoTargets and Therapy}, - volume = {9}, - pages = {5010 – 5116}, - doi = {10.2147/OTT.S111209}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84988810639&doi=10.2147%2fOTT.S111209&partnerID=40&md5=d8cbd9be8e48802d69749e8519a9f719}, - abstract = {Lung cancer is the major cause for cancer-related death in the US. Although advances in chemotherapy and targeted therapy have improved the outcome of metastatic non-small-cell lung cancer, its prognosis remains dismal. A deeper understanding of the complex interaction between the immune system and tumor microenvironment has identified immune checkpoint inhibitors as new avenue of immunotherapy. Rather than acting directly on the tumor, these therapies work by removing the inhibition exerted by tumor cell or other immune cells on the immune system, promoting antitumoral immune response. To date, two programmed death-1 inhibitors, namely nivolumab and pembrolizumab, have received the US Food and Drug Administration approval for the treatment of advanced non-small-cell lung cancer that failed platinum-based chemotherapy. This manuscript provides a brief overview of the pathophysiology of cancer immune evasion, summarizes pertinent data on completed and ongoing clinical trials involving checkpoint inhibitors, discusses the different strategies to optimize their function, and outlines various challenges that are faced in this promising yet evolving field. © 2016 El-Osta et al.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 27; All Open Access, Gold Open Access} -} - -@ARTICLE{Schoenhals201753, - author = {Schoenhals, Jonathan E. and Skrepnik, Tijana and Selek, Ugur and Cortez, Maria A. and Li, Ailin and Welsh, James W.}, - title = {Optimizing radiotherapy with immunotherapeutic approaches}, - year = {2017}, - journal = {Advances in Experimental Medicine and Biology}, - volume = {995}, - pages = {53 – 71}, - doi = {10.1007/978-3-319-53156-4_3}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015877142&doi=10.1007%2f978-3-319-53156-4_3&partnerID=40&md5=5924f27d5a6cacd0e1d3019374a9a99f}, - abstract = {Several factors must be considered to successfully integrate immunotherapy with radiation into clinical practice. One such factor is that concepts arising from preclinical work must be tested in combination with radiation in preclinical models to better understand how combination therapy will work in patients; examples include checkpoint inhibitors, tumor growth factor-beta (TGF-β) inhibitors, and natural killer (NK) cell therapy. Also, many radiation fields and fractionation schedules typically used in radiation therapy had been standardized before the introduction of advanced techniques for radiation planning and delivery that account for changes in tumor size, location, and motion during treatment, as well as uncertainties introduced by variations in patient setup between treatment fractions. As a result, radiation therapy may involve the use of large treatment volumes, often encompassing nodal regions that may not be irradiated with more conformal techniques. Traditional forms of radiation in particular pose challenges for combination trials with immunotherapy. This chapter explores these issues in more detail and provides insights as to how radiation therapy can be optimized to combine with immunotherapy. © Springer International Publishing AG 2017.}, - type = {Book chapter}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 10} -} - -@ARTICLE{Dragani2016, - author = {Dragani, Tommaso A. and Castells, Antoni and Kulasingam, Vathany and Diamandis, Eleftherios P. and Earl, Helena and Iams, Wade T. and Lovly, Christine M. and Sedelaar, J.P.Michiel and Schalken, Jack A.}, - title = {Major milestones in translational oncology}, - year = {2016}, - journal = {BMC Medicine}, - volume = {14}, - number = {1}, - doi = {10.1186/s12916-016-0654-y}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979517755&doi=10.1186%2fs12916-016-0654-y&partnerID=40&md5=1882399f2d00d276f12ca2fffef91e22}, - abstract = {Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. Today, translational research in oncology benefits from an abundance of knowledge resulting from genome-scale studies regarding the molecular pathways involved in tumorigenesis. In this Forum article, we highlight the state of the art of translational oncology in five major cancer types. We illustrate the use of molecular profiling to subtype colorectal cancer for both diagnosis and treatment, and summarize the results of a nationwide screening program for ovarian cancer based on detection of a tumor biomarker in serum. Additionally, we discuss how circulating tumor DNA can be assayed to safely monitor breast cancer over the course of treatment, and report on how therapy with immune checkpoint inhibitors is proving effective in advanced lung cancer. Finally, we summarize efforts to use molecular profiling of prostate cancer biopsy specimens to support treatment decisions. Despite encouraging early successes, we cannot disregard the complex genetics of individual susceptibility to cancer nor the enormous complexity of the somatic changes observed in tumors, which urge particular attention to the development of personalized therapies. © 2016 The Author(s).}, - type = {Article}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 11; All Open Access, Gold Open Access} -} - -@ARTICLE{Kumar2017111, - author = {Kumar, Rajiv and Collins, Dearbhaile and Dolly, Saoirse and McDonald, Fiona and O'Brien, Mary E.R. and Yap, Timothy A.}, - title = {Targeting the PD-1/PD-L1 axis in non–small cell lung cancer}, - year = {2017}, - journal = {Current Problems in Cancer}, - volume = {41}, - number = {2}, - pages = {111 – 124}, - doi = {10.1016/j.currproblcancer.2016.12.002}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85012927932&doi=10.1016%2fj.currproblcancer.2016.12.002&partnerID=40&md5=b8275acff8bb62aa095015b6d19f06bc}, - abstract = {The last decade has witnessed rapid advances in the discovery and development of immune checkpoint inhibitors in cancer medicine, particularly drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in non–small cell lung cancer (NSCLC). The proven antitumor efficacy coupled with low rates of drug-related toxicities observed, albeit idiosyncratic, with these novel immunotherapeutics have led to the registration of multiple PD-1 and PD-L1 inhibitors, such as nivolumab, pembrolizumab, and atezolizumab, in second-line advanced NSCLC, whereas durvalumab and avelumab are in late-phase clinical testing. Moreover, pembrolizumab has shown a survival advantage in the first-line setting; however, nivolumab failed to show a survival benefit possibly relating to patient selection based on PD-L1 expression. Current patient selection is based on PD-L1 expression, using the relevant companion diagnostic test, where patients with strong PD-L1 expression being more likely to respond to these novel agents. Ongoing clinical research focuses on the development of PD-1 and PD-L1 inhibitor monotherapy in neoadjuvant and adjuvant NSCLC. There is also much interest in using these drugs as a therapeutic backbone for rational combinations with other treatment modalities including cytotoxic chemotherapies in the first-line NSCLC, other immunotherapies such as cytotoxic T-lymphocyte–associated protein 4 antagonists, molecularly targeted agents including EGFR and ALK inhibitors, and radiotherapy. Concurrent treatment with radiotherapy is of particular interest owing to the potential for the abscopal effect, using radiotherapy to facilitate systemic treatment. © 2017 Elsevier Inc.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 35} -} - -@ARTICLE{Malhotra2017196, - author = {Malhotra, Jyoti and Jabbour, Salma K. and Aisner, Joseph}, - title = {Current state of immunotherapy for non-small cell lung cancer}, - year = {2017}, - journal = {Translational Lung Cancer Research}, - volume = {6}, - number = {2}, - pages = {196 – 211}, - doi = {10.21037/tlcr.2017.03.01}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018243538&doi=10.21037%2ftlcr.2017.03.01&partnerID=40&md5=fa3b69fdab86980c39681711fe95120f}, - abstract = {Lung cancer is the leading cause of cancer mortality and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers. Platinum-based doublet chemotherapy is the standard first-line treatment for metastatic NSCLC when genomic testing reveals no targetable alteration such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) or ROS1 translocation/re-arrangements. But, chemotherapy produces response rates ranging only between 15-30%. For patients whose disease progresses on first-line chemotherapy, second-line therapy historically consists of taxane-based salvage chemotherapy with a response rate of less than 25%. Recently, immunotherapy with checkpoint inhibitor agents have demonstrated responses in advanced NSCLC, with some patients exhibiting durable responses after discontinuing therapy. In 2015, two immune checkpoint inhibitors targeting programmed cell death-1 (PD-1), nivolumab and pembrolizumab were approved for second-line therapy of NSCLC. In 2016, another checkpoint inhibitor targeting program death-ligand 1 (PD-L1), atezolizumab was approved for the same indication. Moreover, pembrolizumab also received approval in 2016 for first-line NSCLC treatment in patients with high PD-L1 expressing tumors. Immunotherapy for NSCLC has therefore, recently evolved into a true treatment modality with the acceptance of PD-1 and PD-L1 inhibitors as the new standard of care for second-line treatment. However, it is still at the discretion of the treating physician whether to use PD-1 or PD-L1 inhibitor as data to compare these two pathways is lacking. Focus is now also on exploring their role in the adjuvant and consolidation settings for NSCLC as well as on exploring novel combinations combining these agents with chemotherapy or radiation. Research is also needed in the development of predictive and prognostic biomarkers for these agents. While vaccine therapy trials in NSCLC have so far failed to show significant clinical benefit, the demonstration of enhanced immune response in these trials suggest the vaccine therapy needs additional evaluation in combination with other therapeutic modalities especially checkpoint inhibition. © Translational lung cancer research. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 145; All Open Access, Green Open Access} -} - -@ARTICLE{Sacco20174, - author = {Sacco, Paola C. and Maione, Paolo and Guida, Cesare and Gridelli, Cesare}, - title = {The combination of new immunotherapy and radiotherapy: A new potential treatment for locally advanced non-small cell lung cancer}, - year = {2017}, - journal = {Current Clinical Pharmacology}, - volume = {12}, - number = {1}, - pages = {4 – 10}, - doi = {10.2174/1574884711666161201123439}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85022219644&doi=10.2174%2f1574884711666161201123439&partnerID=40&md5=fbe21564656b979538e4fc9624fa3002}, - abstract = {Lung cancer is the main reason of cancer death worldwide. About 30% of non-small-cell lung cancer (NSCLC) cases are diagnosed with locally advanced disease (stage III). This is a mixed population including patients who have far more extensive and bulky disease than others. Management of these patients continue to be a challenge; frequently, patients have both local recurrence and distant metastases in this stage and the prognosis is very poor with a 5-year overall survival estimated between 3% and 7% for inoperable disease. The standard treatment for these patients is concurrent chemo-radiotherapy (CRT) improving survival when compared to sequential combination as shown in several metanalysis. Recently, immune-therapies, including checkpoint inhibitor, such as monoclonal antibodies against programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1), have shown to enhance survival compared to chemotherapy in patients with advanced NSCLC. The integration of radiotherapy with immunotherapy is a conceptually promising strategy and several preclinical experiments have further developed the rationale for combining them. Radiotherapy has the capacity to overcome a lot of tumor immune escape mechanisms through the liberation of immunogenic private antigens showing a better local control and augmenting the immune response of systemic agents. This manuscript discusses the potential clinical interest for the combination of radiation and immunotherapy in locally advanced NSCLC. © 2017 Bentham Science Publishers.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 6} -} - -@ARTICLE{Shen2017, - author = {Shen, Meng and Ren, Xiubao}, - title = {Highlights on immune checkpoint inhibitors in non–small cell lung cancer}, - year = {2017}, - journal = {Tumor Biology}, - volume = {39}, - number = {3}, - doi = {10.1177/1010428317695013}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85016923647&doi=10.1177%2f1010428317695013&partnerID=40&md5=1bf0536c1ddad4f0b6d3f5a0e5b0010c}, - abstract = {The treatment of advanced or refractory non–small cell lung cancer has been historically difficult owing to the lack of studies on effective systemic cure. The progress in lung cancer treatment has plateaued, necessitating new options for additional benefits. Immune checkpoint proteins are co-inhibitory factors that can diminish the antigen-specific immune responses by attenuating the regulatory role of cytotoxic T-lymphocyte-associated protein 4, programmed cell death-1, lymphocyte-activation gene 3, and T-cell immunoglobulin mucin-3. The therapeutic strategies targeting immune checkpoints mainly focus on the monoclonal antibody of these regulatory factors, which may facilitate clinical decision making. An enhanced understanding of the drug-resistance mechanisms and the therapeutic efficacy regulation will provide opportunities to improve the clinical outcomes of non–small cell lung cancer patients. Preclinical and clinical trials on these key immune-regulatory agents, which has heralded a new era in immuno-oncology in non–small cell lung cancer treatment, are currently in development. © 2017, © The Author(s) 2017.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 18; All Open Access, Gold Open Access} -} - -@ARTICLE{Remon2017, - author = {Remon, Jordi and Besse, Benjamin and Soria, Jean-Charles}, - title = {Successes and failures: What did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?}, - year = {2017}, - journal = {BMC Medicine}, - volume = {15}, - number = {1}, - doi = {10.1186/s12916-017-0819-3}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014878389&doi=10.1186%2fs12916-017-0819-3&partnerID=40&md5=dc52edf94afb3001d929c5531e5a986e}, - abstract = {The immune checkpoint inhibitors have significantly modified the therapeutic landscape of advanced non-small cell lung cancer in second-line and, more recently, first-line settings. Because of the superior outcome with pembrolizumab as an upfront strategy, PD-L1 status should now be considered a new reflex biomarker for guiding first-line treatment in patients with advanced non-small cell lung cancer. Improved responses have also been reported with the combination of immune checkpoint inhibitors and chemotherapy as the first-line treatment; however, this strategy has not yet been validated by phase III trial data and its interplay with PD-L1 status still requires clarification. In this manuscript we review the contradictory results of recent phase III trials with immune checkpoint inhibitors in the first-line setting, the potential reasons for discrepancies, and some of the remaining open questions related to the positioning of immune checkpoint inhibitors in the first-line setting of non-small cell lung cancer. © 2017 The Author(s).}, - type = {Short survey}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 62; All Open Access, Gold Open Access, Green Open Access} -} - -@ARTICLE{Jin2016771, - author = {Jin, Zhaohui and Yoon, Harry H.}, - title = {The promise of PD-1 inhibitors in gastro-esophageal cancers: Microsatellite instability vs. PD-L1}, - year = {2016}, - journal = {Journal of Gastrointestinal Oncology}, - volume = {7}, - number = {5}, - pages = {771 – 788}, - doi = {10.21037/jgo.2016.08.06}, - url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009976759&doi=10.21037%2fjgo.2016.08.06&partnerID=40&md5=21899eaa2c408806d165110971d45a22}, - abstract = {Preliminary clinical studies of anti-programmed cell death-1 (anti-PD-1) therapy in gastroesophageal cancers have suggested promising single-agent activity. In patients who received prior treatment for advanced disease, pembrolizumab has been associated with a response rate of 20% in programmed cell death-1 ligand 1 (PD-L1)-positive tumors, and nivolumab with a response rate of 12% in unselected tumors. Both agents yielded a median duration of response lasting ~6-7 months. PD-L1 expression and microsatellite instability (MSI) have emerged as potential predictive markers for PD-1/PD-L1 blockade. PD-L1 expression in tumor cells and in immune cells within the tumor microenvironment has been detected in 14-24% and ~35% of patients with gastro-esophageal cancer, respectively. PD-L1 tumor cell expression appears to be more common in Epstein-Barr virus (EBV)-positive gastric cancers (GCs) and has been associated with an increased density of tumor-infiltrating lymphocytes (TIL). To date, data are too sparse to determine whether PD-L1 expression predicts efficacy of anti-PD-1 therapy in gastro-esophageal cancer, but data from other tumor types have not been consistent regarding its predictive value. MSI occurs in 10-20% of gastro-esophageal cancers and arises from deficient mismatch repair (MMR). MSI is highly correlated with non-synonymous mutation burden, as well as a dense accumulation of TILs. MSI has been associated with improved response to anti-PD-1 therapy in gastrointestinal cancers. Multiple studies are ongoing which examine therapeutic blockade of the PD-1/PD-L1 axis in unselected patients with gastro-esophageal cancer, as well as patients whose tumors express PD-L1 or exhibit MSI. These studies will clarify their activity in this disease and potentially can determine whether identify a strong predictive biomarker can be identified. Checkpoint inhibition is also being studied in combination with curative-intent chemo (radio) therapy and surgery. © Journal of Gastrointestinal Oncology. All rights reserved.}, - type = {Review}, - publication_stage = {Final}, - source = {Scopus}, - note = {Cited by: 80; All Open Access, Green Open Access} -} \ No newline at end of file diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/web of science 1-500.ris" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/web of science 1-500.ris" deleted file mode 100644 index b656d03..0000000 --- "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/web of science 1-500.ris" +++ /dev/null @@ -1,17405 +0,0 @@ -TY - JOUR -AU - Bortolot, Martina -AU - Cortiula, Francesco -AU - Fasola, Gianpiero -AU - De Ruysscher, Dirk -AU - Naidoo, Jarushka -AU - Hendriks, Lizza E. L. -TI - Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials -T2 - CANCER TREATMENT REVIEWS -M3 - Review -AB - Concurrent chemoradiotherapy (cCRT) followed by one year of consolidation durvalumab is the current standard-of-care for patients with unresectable stage III non-small cell lung cancer (NSCLC), of good functional status. However, cCRT and consolidation durvalumab may be challenging to administer for selected patient populations underrepresented or even excluded in clinical trials: older and/or frail patients; those with cardiovascular or respiratory comorbidities in which treatment-related adverse events may be higher, and patients with pre-existing autoimmune disorders for whom immunotherapy use is controversial. In this narrative review, we discuss the current evidence, challenges, ongoing clinical trials and potential future treatment scenarios in relevant subgroups of patients with locally advanced NSCLC, who are underrepresented in clinical trials. -PU - ELSEVIER SCI LTD -PI - London -PA - 125 London Wall, London, ENGLAND -SN - 0305-7372 -SN - 1532-1967 -DA - 2024 SEP -PY - 2024 -VL - 129 -C7 - 102797 -DO - 10.1016/j.ctrv.2024.102797 -AN - WOS:001267064900001 -C6 - JUL 2024 -AD - Univ Udine, Dept Med DAME, Udine, Italy -AD - Univ Hosp Udine, Dept Oncol, Piazzale Santa Maria Misericordia, I-33100 Udine, Italy -AD - Maastricht Univ, GROW Sch Oncol & Reprod, Dept Radiat Oncol Maastro, Med Ctr, Maastricht, Netherlands -AD - Beaumont Hosp, Dublin, Ireland -AD - RCSI Univ Hlth Sci, Dublin, Ireland -AD - Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA -AD - Maastricht Univ, GROW Sch Oncol & Reprod, Dept Pulm Dis, Med Ctr, Maastricht, Netherlands -M2 - Beaumont Hosp -M2 - RCSI Univ Hlth Sci -Y2 - 2024-07-18 -ER - - -TY - JOUR -AU - Pujol, Jean-Louis -AU - Roch, Benoit -AU - Pujol, Camille N. -AU - Goze, Catherine -TI - Medical treatment of small cell lung cancer: Can we leave the area of cisplatinetoposide? -T2 - BULLETIN DU CANCER -M3 - Review -AB - Small cell lung cancer accounts for 14% of all lung cancers. It remains a major challenge for oncology as the progresses made in the past three decades are modest. After a rapid overview of current knowledge regarding somatic genomic alterations, this state-of-art addresses pathways to improve small-cell lung cancer outcome such as the targeting of DNA damage repair mechanisms firstly anti-PARPs, inhibitory molecules of EZH2, derepression of the NOTCH pathway, rovalbituzumab-tesirine, inhibition of serine/threonine Aurora A kinase, temozolomide and its dependence on methylation of the MGMT promoter. This first chapter suggests the beginning of precision medicine in small cell lung cancer. The last section focuses on the development of immuno-oncological agents and the information collected from phase 1 and 2 studies: the low intensity of PD-L1 tissue expression and the possible relationship of the activity of these agents as a function of tumor mutational burden are pointed out. -PU - JOHN LIBBEY EUROTEXT LTD -PI - MONTROUGE -PA - 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE -SN - 0007-4551 -SN - 1769-6917 -DA - 2018 OCT -PY - 2018 -VL - 105 -IS - 10 -SP - 955 -EP - 966 -DO - 10.1016/j.bulcan.2018.05.014 -AN - WOS:000447782000015 -AD - Hop Arnaud de Villeneuve, Serv Malad Resp, Unite Oncol Thorac, Ave Doyen Giraud, F-34295 Montpellier, France -AD - CNRS UMR 5203, Inst Genom Fonct, INSERM, U661, F-34094 Montpellier, France -AD - Hop Arnaud de Villeneuve, Lab Biol Cellulaire, Unite Oncol Thorac, Ave Doyen Giraud, F-34295 Montpellier, France -Y2 - 2018-10-30 -ER - - -TY - JOUR -AU - Mansfield, Aaron S. -AU - Liu, Stephen V. -AU - Szczesna, Aleksandra -AU - Havel, Libor -AU - Kzrakowski, Maciej -AU - Hochmair, Maximilian J. -AU - Huemer, Florian -AU - Losonczy, Gyorgy -AU - Johnson, Melissa L. -AU - Nishio, Makoto -AU - Reck, Martin -AU - Mok, Tony S. -AU - Lam, Sivuonthanh -AU - Shames, David S. -AU - Liu, Juan -AU - Kabbinavar, Fairooz -AU - Sandler, Alan -AU - Horn, Leora -TI - IMpower133: Primary efficacy and safety plus CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC) -T2 - CANCER RESEARCH -M3 - Meeting Abstract -CP - Annual Meeting of the American-Association-for-Cancer-Research (AACR) -CL - Atlanta, GA -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 0008-5472 -SN - 1538-7445 -DA - 2019 JUL -PY - 2019 -VL - 79 -IS - 13 -MA - CT199 -DO - 10.1158/1538-7445.AM2019-CT199 -AN - WOS:000488129900176 -AD - Mayo Clin, Rochester, MN USA -AD - Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA -AD - Mazowieckie Ctr Leczenia Chorob Pluc & Gruzlicy, Otwock, Poland -AD - Pneumol Klin 1 LF UK, Thomayerova Neomicnice, Prague, Czech Republic -AD - Inst M Sklodowskiej Curie Warszawie, Ctr Onkol, Warsaw, Poland -AD - Otto Wagner Spital, Dept Resp & Crit Care Med, Vienna, Austria -AD - Otto Wagner Spital, Ludwig Boltzmann Inst COPD & Resp Epidemiol Baumg, Vienna, Austria -AD - Otto Wagner Spital, Dept Resp & Crit Care Med 2, Vienna, Austria -AD - Pulmonol Klin, Semmelweis Egyet AOK, Budapest, Hungary -AD - Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA -AD - Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan -AD - German Ctr Lung Res, LungClin Grosshansdorf, Grosshansdorf, Germany -AD - Chinese Univ Hong Kong, State Key Lab South China, Hong Kong, Peoples R China -AD - Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA -AD - F Hoffmann La Roche Ltd, Shanghai, Peoples R China -AD - Genentech Inc, San Francisco, CA 94080 USA -AD - Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA -M2 - Mazowieckie Ctr Leczenia Chorob Pluc & Gruzlicy -M2 - Pneumol Klin 1 LF UK -M2 - Inst M Sklodowskiej Curie Warszawie -M2 - Otto Wagner Spital -M2 - Otto Wagner Spital -M2 - Otto Wagner Spital -M2 - German Ctr Lung Res -M2 - F Hoffmann La Roche Ltd -Y2 - 2019-10-14 -ER - - -TY - JOUR -AU - Liveringhouse, Casey -AU - Latifi, Kujtim -AU - Asous, Amalin -AU - Cruz-Chamorro, Ruben -AU - Mills, Matthew -AU - Li, Jiannong -AU - Schell, Michael -AU - Rosenberg, Stephen -AU - Dilling, Thomas -AU - Perez, Bradford -TI - Early Post-treatment Imaging Changes May Predict Pulmonary Toxicity in Patients with Locally Advanced Non-small Cell Lung Cancer Receiving Definitive Chemoradiation and Immunotherapy -T2 - AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS -M3 - Meeting Abstract -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0277-3732 -SN - 1537-453X -DA - 2022 SEP -PY - 2022 -VL - 45 -IS - 9 -MA - OA31 -SP - S17 -EP - S18 -AN - WOS:000847787800038 -AD - H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA -AD - H Lee Moffitt Canc Ctr Res Inst, Dept Radiat Oncol, Tampa, FL USA -Y2 - 2022-09-09 -ER - - -TY - JOUR -AU - Zhou, Lin -AU - Sun, Jianguo -AU - Xie, Conghua -AU - Gong, Youling -AU - Huang, Meijuan -AU - Yuan, Zhiyong -AU - Wu, Lin -AU - Wang, Hui -AU - Bi, Nan -AU - Xu, Yaping -AU - Zhu, Jiang -AU - Liu, Yongmei -AU - Zhang, Yan -AU - Fan, Min -AU - Zou, Bingwen -AU - Yu, Min -AU - Li, Yanying -AU - Na, Feifei -AU - Xiu, Weigang -AU - Xu, Yong -AU - Wang, Jin -AU - Zhang, Xuanwei -AU - Xue, Jianxin -AU - Lu, You -TI - Efficacy and safety of Low dose radiotherapy (LDRT) concurrent Atezolizumab (Atezo) plus chemotherapy as first line (1L) therapy for ES-SCLC: Primary analysis of Phase II MATCH study -T2 - CANCER RESEARCH -M3 - Meeting Abstract -CP - 114th Annual Meeting of the American Association for Cancer Research (AACR) -CL - Orlando, FL -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 0008-5472 -SN - 1538-7445 -DA - 2023 APR 15 -PY - 2023 -VL - 83 -IS - 8 -MA - CT219 -DO - 10.1158/1538-7445.AM2023-CT219 -AN - WOS:001018089900189 -Y2 - 2023-08-30 -ER - - -TY - JOUR -AU - Gomes, Fabio -AU - Wong, Melisa -AU - Battisti, Nicolo Matteo Luca -AU - Kordbacheh, Tiana -AU - Kiderlen, Mandy -AU - Greystoke, Alastair -AU - Luciani, Andrea -TI - Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper -T2 - BRITISH JOURNAL OF CANCER -M3 - Review -AB - Immunotherapy with checkpoint inhibitors against programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1) has been implemented in the treatment pathway of patients with non-small cell lung cancer (NSCLC) from locally advanced disease to the metastatic setting. This approach has resulted in improved survival and a more favourable toxicity profile when compared with chemotherapy. Following the successful introduction of single-agent immunotherapy, current clinical trials are focusing on combination treatments with chemotherapy or radiotherapy or even other immunotherapeutic agents. However, most of the data available from these trials are derived from, and therefore might be more applicable to younger and fitter patients rather than older and often frail lung cancer real-world patients. This article provides a detailed review of these immunotherapy agents with a focus on the data available regarding older NSCLC patients and makes recommendations to fill evidence gaps in this patient population. -PU - SPRINGERNATURE -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND -SN - 0007-0920 -SN - 1532-1827 -DA - 2020 SEP 15 -PY - 2020 -VL - 123 -IS - 6 -SP - 874 -EP - 884 -DO - 10.1038/s41416-020-0986-4 -AN - WOS:000551056900001 -C6 - JUL 2020 -AD - Christie NHS Fdn Trust, Med Oncol, Manchester, Lancs, England -AD - Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA -AD - Royal Marsden NHS Fdn Trust, Dept Med, London, England -AD - Univ Manchester, Div Canc Sci, Manchester, Lancs, England -AD - Erasmus MC, Radiat Oncol, Canc Inst, Rotterdam, Netherlands -AD - Newcastle Upon Tyne NHS Fdn Trust, Med Oncol, Newcastle, England -AD - Osped S Paolo Univ Hosp, Med Oncol, Milan, Italy -M2 - Osped S Paolo Univ Hosp -Y2 - 2020-08-04 -ER - - -TY - JOUR -AU - Orosz, Zsuzsanna -AU - Kovacs, Arpad -TI - The role of chemoradiotherapy and immunotherapy in stage III NSCLC -T2 - PATHOLOGY & ONCOLOGY RESEARCH -M3 - Review -AB - Locally advanced non-small lung cancer encompasses a diverse range of tumors. In the last few years, the treatment of stage III unresectable non-small lung cancer has evolved significantly. The PACIFIC trial opened a new therapeutic era in the treatment of locally advanced NSCLC, establishing durvalumab consolidation therapy as the new standard of care worldwide. A careful evaluation of this type of lung cancer and a discussion of the management of these patients within a multidisciplinary team represents a crucial step in defining the best treatment strategy for each patient. For unresectable stage III NSCLC, definitive concurrent chemoradiotherapy (CCRT) was historically recommended as a treatment with a 5-year survival rate ranging from 20% to 30%. The PACIFIC study conducted in 2017 compared the use of chemoradiotherapy and maintenance therapy with the anti-PD-L1 monoclonal antibody durvalumab to a placebo in patients with locally advanced NSCLC who had not experienced disease progression. The study was prospective, randomized, and phase III. The administration of this medication in patients with locally advanced non-small cell lung cancer (NSCLC) has demonstrated a notable improvement in overall survival. Multiple clinical trials are currently exploring various immune checkpoint inhibition regimens to enhance the treatment efficacy in patients with stage III cancer. Our goal is to offer an up-to-date summary of the planned clinical trials for treatment options, focusing on the significant obstacles and prospects in the post-PACIFIC era. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1219-4956 -SN - 1532-2807 -DA - 2024 APR 19 -PY - 2024 -VL - 30 -C7 - 1611716 -DO - 10.3389/pore.2024.1611716 -AN - WOS:001220818000001 -AD - Univ Debrecen, Fac Med, Dept Pulmonol, Debrecen, Hungary -AD - Univ Debrecen, Fac Med, Dept Oncoradiol, Debrecen, Hungary -Y2 - 2024-05-18 -ER - - -TY - JOUR -AU - Chaithra, N. -AU - Jain, Anisha -AU - Sahana, C. -AU - Shreevatsa, Bhargav -AU - Rajendrasozhan, Saravanan -AU - Dharmashekar, Chandan -AU - Suresh, Kuralayanapalya Puttahonnappa -AU - Patil, Sharanagouda S. -AU - Singh, Pranav -AU - Vishwanath, Prashant -AU - Srinivasa, Chandrashekar -AU - Kollur, Shiva Prasad -AU - Shivamallu, Chandan -TI - Progression-free survival estimation of docetaxel-based second-line treatment for advanced non-small cell lung cancer: a pooled analysis from 18 randomized control trials -T2 - FRONTIERS IN ONCOLOGY -M3 - Article -AB - Background: Lung cancer is the foremost cause of cancer-related death globally, with non-small cell lung cancer (NSCLC) accounting for 85-90% of cases. Targeted therapy is the most essential therapeutic option for NSCLC, other common treatments include radiation therapy, surgery, chemotherapy, and immunotherapy. Objective: Our study objective was to estimate whether progression-free survival (PFS) is an outcome of NSCLC extracted from 18 randomized control trials (RCTs) with docetaxel as experimental group and antineoplastic agent, kinase inhibitor, and monoclonal antibodies as a control group. Methods: We selected relevant studies published between 2011 and 2022 using Google Scholar, PubMed, Scopus, Science Direct, and Cochrane Library. Advanced NSCLC, chemotherapy, RCT, docetaxel, and second-line treatment were the terms included in the search. A total of 9738 patients were evaluated from the 18 identified studies. We used the meta package of R Studio to perform the meta-analysis. Graphical funnel plots were used to evaluate publication bias visually. Results: Patients who underwent docetaxel-based therapy had a considerably longer PFS than those who got antineoplastic agents, kinase inhibitors, or monoclonal antibodies-based treatment. Patients in the standard treatment arm had a slightly longer PFS than those in the experimental therapy arm in the overall meta-analysis. Conclusion: Docetaxel outperformed monoclonal antibodies, antineoplastic agents, and kinase inhibitors in the second-line therapy of advanced NSCLC since PFS was extensively utilized. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2024 MAY 14 -PY - 2024 -VL - 14 -C7 - 1298786 -DO - 10.3389/fonc.2024.1298786 -AN - WOS:001232783200001 -AD - JSS Acad Higher Educ & Res, Life Sci Dept, Div Med Stat, Mysuru, Karnataka, India -AD - JSS Acad Higher Educ & Res, Nat Sci Dept, Div Med Stat, Mysuru, Karnataka, India -AD - JSS Acad Higher Educ & Res, Dept Microbiol, Mysuru, Karnataka, India -AD - JSS Acad Higher Educ & Res, Dept Biotechnol & Bioinformat, Mysuru, Karnataka, India -AD - Univ South Carolina, Sch Med, Pathol Microbiol & Immunol Dept, Columbia, SC USA -AD - Univ Hail, Fac Sci, Dept Chem, Hail, Saudi Arabia -AD - ICAR Natl Inst Vet Epidemiol & Dis Informat, Dept Spatial Epidemiol, Bengaluru, Karnataka, India -AD - ICAR Natl Inst Vet Epidemiol & Dis Informat, Bengaluru, Karnataka, India -AD - Manipal Acad Higher Educ, Kasturba Med Coll, Dept Med, Udupi, Karnataka, India -AD - JSS Acad Higher Educ & Res, JSS Med Coll, Ctr Excellence Mol Biol & Regenerat Med, Dept Biochem, Mysore, Karnataka, India -AD - Davangere Univ, Dept Studies Biotechnol, Davangere, Karnataka, India -AD - Amrita Vishwa Vidyapeetham, Sch Phys Sci, Mysuru, Karnataka, India -Y2 - 2024-06-09 -ER - - -TY - JOUR -AU - Konala, Venu Madhav -AU - Madhira, Bhaskar Reddy -AU - Ashraf, Sara -AU - Graziano, Stephen -TI - Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer -T2 - ONCOLOGY -M3 - Review -AB - Lung cancer is a leading cause of cancer death in the United States and around the world. Approximately 13% of lung cancers are small cell lung cancer (SCLC). SCLC is generally classified as a limited-stage and extensive-stage disease depending on the extent of involvement. For patients with the extensive-stage disease, until recently, chemotherapy alone has been the recommended treatment, although radiotherapy could be used in select patients for palliation of symptoms. The standard of care for extensive-stage SCLC is platinum doublet chemotherapy with either cisplatin or carboplatin in combination with etoposide. Even though first-line therapy has an initial response rate of 60-80%, the prognosis is poor, with overall survival of 10-12 months. The only FDA-approved second line of therapy is topotecan, approved both as an intravenous formulation as well as an oral formulation, with response rates of 6-12% in chemorefractory disease and 15-37% in chemosensitive disease. Immunotherapy has recently been approved as a first-line agent in metastatic SCLC in combination with chemotherapy. It is also approved as a third-line agent in metastatic SCLC after the failure of two chemotherapy regimens. The FDA approved four drugs, two of them being PD-1 inhibitors (pembrolizumab, nivolumab), and two of them being PD-L1 inhibitors (atezolizumab and durvalumab) in SCLC. This review article summarizes the significance of immunotherapy in the treatment of extensive-stage SCLC, its side effects, and limitations. -PU - KARGER -PI - BASEL -PA - ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND -SN - 0030-2414 -SN - 1423-0232 -DA - 2020 NOV -PY - 2020 -VL - 98 -IS - 11 -SP - 749 -EP - 754 -DO - 10.1159/000508516 -AN - WOS:000587575500001 -AD - Ashland Bellefonte Canc Ctr, 122 St Christopher Dr, Ashland, KY 41101 USA -AD - SUNY Upstate Med Univ, Syracuse, NY 13210 USA -AD - Marshall Univ, Joan C Edwards Sch Med, Huntington, WV USA -M2 - Ashland Bellefonte Canc Ctr -Y2 - 2020-11-23 -ER - - -TY - JOUR -AU - Trommer, Maike -TI - Radiotherapy plus durvalumab in locally advanced NSCLC: the DOLPHIN study -T2 - STRAHLENTHERAPIE UND ONKOLOGIE -M3 - Book Review -PU - SPRINGER HEIDELBERG -PI - HEIDELBERG -PA - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY -SN - 0179-7158 -SN - 1439-099X -DA - 2024 JUL -PY - 2024 -VL - 200 -IS - 7 -SP - 646 -EP - 648 -DO - 10.1007/s00066-024-02231-9 -AN - WOS:001205832800001 -C6 - APR 2024 -AD - Med Fak, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Klin & Poliklin Radioonkol Cyberknife & Strahlenth, Cologne, Germany -AD - Univ Klinikum Koln, Cologne, Germany -AD - Austin Hlth, Olivia Newton John Canc Wellness & Res Ctr, Dept Radiat Oncol, Melbourne, Australia -AD - Univ Klinikum Koln, Ctr Mol Med Cologne CMMC, Cologne, Germany -M2 - Med Fak -Y2 - 2024-04-25 -ER - - -TY - JOUR -AU - Tang, Chunyin -AU - Liu, Jieting -AU - Yang, Chunsong -AU - Ma, Jun -AU - Chen, Xuejiao -AU - Liu, Dongwen -AU - Zhou, Yao -AU - Zhou, Wei -AU - Lin, Yunzhu -AU - Yuan, Xiaohuan -TI - Curcumin and Its Analogs in Non-Small Cell Lung Cancer Treatment: Challenges and Expectations -T2 - BIOMOLECULES -M3 - Review -AB - Researchers have made crucial advances in understanding the pathogenesis and therapeutics of non-small cell lung cancer (NSCLC), improving our understanding of lung tumor biology and progression. Although the survival of NSCLC patients has improved due to chemoradiotherapy, targeted therapy, and immunotherapy, overall NSCLC recovery and survival rates remain low. Thus, there is an urgent need for the continued development of novel NSCLC drugs or combination therapies with less toxicity. Although the anticancer effectiveness of curcumin (Cur) and some Cur analogs has been reported in many studies, the results of clinical trials have been inconsistent. Therefore, in this review, we collected the latest related reports about the anti-NSCLC mechanisms of Cur, its analogs, and Cur in combination with other chemotherapeutic agents via the Pubmed database (accessed on 18 June 2022). Furthermore, we speculated on the interplay of Cur and various molecular targets relevant to NSCLC with discovery studio and collected clinical trials of Cur against NSCLC to clarify the role of Cur and its analogs in NSCLC treatment. Despite their challenges, Cur/Cur analogs may serve as promising therapeutic agents or adjuvants for lung carcinoma treatment. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2218-273X -DA - 2022 NOV -PY - 2022 -VL - 12 -IS - 11 -C7 - 1636 -DO - 10.3390/biom12111636 -AN - WOS:000881053000001 -AD - Sichuan Univ, Evidence Based Pharm Ctr, Key Lab Birth Defects & Related Dis Women & Child, Dept Pharm,West China Univ Hosp 2, Chengdu 610000, Sichuan, Peoples R China -AD - Mudanjiang Med Univ, Heilongjiang Key Lab Antifibrosis Biotherapy, Mudanjiang 157000, Peoples R China -AD - Banan Second Peoples Hosp, Dept Pharm, Chongqing 401320, Peoples R China -M2 - Banan Second Peoples Hosp -Y2 - 2022-11-22 -ER - - -TY - CHAP -AU - Schneider, Bryan J. -AU - Kalemkerian, Gregory P. -ED - Ahmad, A -ED - Gadgeel, SM -TI - Personalized Therapy of Small Cell Lung Cancer -T2 - LUNG CANCER AND PERSONALIZED MEDICINE: NOVEL THERAPIES AND CLINICAL MANAGEMENT -M3 - Article -M3 - Book Chapter -AB - Small cell lung cancer (SCLC) is an aggressive, poorly differentiated neuroendocrine carcinoma with distinct clinical, pathological and molecular characteristics. Despite robust responses to initial chemotherapy and radiation, the prognosis of patients with SCLC remains poor with an overall 5-year survival rate of less than 10 %. Despite the fact that numerous molecularly targeted approaches have thus far failed to demonstrate clinical utility in SCLC, further advances will rely on better definition of the biological pathways that drive survival, proliferation and metastasis. Recent next-generation, molecular profiling studies have identified many new therapeutic targets in SCLC, as well as extreme genomic instability which explains the high degree of resistance. A wide variety of anti-angiogenic agents, growth factor inhibitors, pro-apoptotic agents, and epigenetic modulators have been evaluated in SCLC and many studies of these strategies are on-going. Perhaps the most promising approaches involve agents targeting cancer stem cell pathways and immunomodulatory drugs that interfere with the PD1 and CTLA-4 pathways. SCLC offers many barriers to the development of successful therapy, including limited tumor samples, inadequate preclinical models, high mutational burden, and aggressive tumor growth which impairs functional status and hampers enrollment on clinical trials. -PU - SPRINGER-VERLAG BERLIN -PI - BERLIN -PA - HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY -SN - 0065-2598 -SN - 2214-8019 -SN - 978-3-319-24932-2 -SN - 978-3-319-24931-5 -DA - 2016 -PY - 2016 -VL - 890 -SP - 149 -EP - 174 -DO - 10.1007/978-3-319-24932-2_9 -DO - 10.1007/978-3-319-24932-2 -AN - WOS:000369068700010 -AD - Univ Michigan, Div Hematol Oncol, C411 Med Inn,SPC 5848,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA -AD - Univ Michigan, Div Hematol Oncol, C350 Med Inn,SPC 5848,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA -Y2 - 2016-02-17 -ER - - -TY - JOUR -AU - Polivka, Jiri, Jr. -AU - Polivka, Jiri -AU - Holubec, Lubos -AU - Kubikova, Tereza -AU - Priban, Vladimir -AU - Hes, Ondrej -AU - Pivovarcikova, Kristyna -AU - Treskova, Inka -TI - Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme -T2 - ANTICANCER RESEARCH -M3 - Review -AB - Glioblastoma multiforme (GBM) represents the most malignant primary brain tumor in adults with generally dismal prognosis, early clinical deterioration and high mortality. GBM is extremely invasive, characterized by intense and aberrant vascularization and high resistance to multimodal treatment. Standard therapy (surgery, radiotherapy and chemotherapy with temozolomide) has very limited effectiveness, with median overall survival of patients no longer than 15 months. Progress in genetics and epigenetics of GBM over the past decade has revealed various aberrations in cellular signaling pathways, the tumor microenvironment, and pathological angiogenesis. A number of targeted anticancer drugs, such as small-molecule kinase inhibitors and monoclonal antibodies, have been evaluated in clinical trials with newly-diagnosed, as well as recurrent GBM. Unfortunately, to date, only a single anti-angiogenic agent, bevacizumab, has been approved for the treatment of recurrent GBM in the USA and Canada. The novel possibilities of cancer immunotherapy, especially immune checkpoint inhibitors, are being evaluated in clinical trials of patients with GBM. The most recent clinical experiences with targeted therapy as well as immunotherapy of GBM are given in this review. The relative lack of success of some of these approaches recently revealed in well-designed randomized clinical trials is also discussed. -PU - INT INST ANTICANCER RESEARCH -PI - ATHENS -PA - EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE -SN - 0250-7005 -SN - 1791-7530 -DA - 2017 JAN -PY - 2017 -VL - 37 -IS - 1 -SP - 21 -EP - 33 -DO - 10.21873/anticanres.11285 -AN - WOS:000391958800004 -AD - Charles Univ Prague, Fac Med Plzen, Biomed Ctr, Plzen, Czech Republic -AD - Charles Univ Prague, Fac Med Plzen, Dept Histol & Embryol, Plzen, Czech Republic -AD - Charles Univ Prague, Fac Hosp Plzen, Fac Med Plzen, Dept Neurol, Plzen, Czech Republic -AD - Charles Univ Prague, Fac Med Plzen, Dept Neurosurg, Plzen, Czech Republic -AD - Fac Hosp Plzen, Plzen, Czech Republic -AD - Charles Univ Prague, Dept Pathol, Fac Med Plzen, Plzen, Czech Republic -AD - Charles Univ Prague, Fac Med Plzen, Dept Surg, Plzen, Czech Republic -M2 - Fac Hosp Plzen -Y2 - 2017-02-08 -ER - - -TY - JOUR -AU - Karp, DD -AU - Atkins, MB -TI - Adoptive immunotherapy for nonsmall cell lung carcinoma - A fourth treatment modality, complicated radiation sensitizer, or none of the above -T2 - CANCER -M3 - Editorial Material -PU - WILEY-LISS -PI - NEW YORK -PA - DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 -SN - 0008-543X -DA - 1996 JUL 15 -PY - 1996 -VL - 78 -IS - 2 -SP - 195 -EP - 198 -DO - 10.1002/(SICI)1097-0142(19960715)78:2<195::AID-CNCR1>3.0.CO;2-L -AN - WOS:A1996UV02200001 -AD - TUFTS UNIV NEW ENGLAND MED CTR,TUPPER RES INST,DIV HEMATOL ONCOL,BOSTON,MA 02111 -Y2 - 1996-07-15 -ER - - -TY - JOUR -AU - Waqar, Saiama N. -AU - Morgensztern, Daniel -TI - Treatment advances in small cell lung cancer (SCLC) -T2 - PHARMACOLOGY & THERAPEUTICS -M3 - Review -AB - Small cell lung cancer (SCLC) is an aggressive tumor characterized by rapid doubling time and high propensity for early development of disseminated disease. Although most patients respond to initial therapy with a platinum doublet, the majority of those with limited stage and virtually all patients with metastatic disease eventually develop tumor progression for which there are limited treatment options. There have been no recent changes in the treatment of SCLC, with platinum plus etoposide and topotecan as the standard first-line and second-line respectively, neither showing survival benefit over the combination of cyclophosphamide, doxorubicin and vincristine, which was developed in the 1970s. More recently, a new understanding of the biology of SCLC has led to the development of novel drugs, of which the most promising are the immune checkpoint inhibitors and the antibody drug conjugate rovalpituzumab tesirine. (C) 2017 Elsevier Inc.All rights reserved. -PU - PERGAMON-ELSEVIER SCIENCE LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND -SN - 0163-7258 -SN - 1879-016X -DA - 2017 DEC -PY - 2017 -VL - 180 -SP - 16 -EP - 23 -DO - 10.1016/j.pharmthera.2017.06.002 -AN - WOS:000416394600002 -AD - Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA -Y2 - 2017-12-06 -ER - - -TY - JOUR -AU - Shin, Daniel Sanghoon -AU - Ribas, Antoni -TI - The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? -T2 - CURRENT OPINION IN IMMUNOLOGY -M3 - Review -AB - Unleashing the immune system to fight cancer has become one of the main treatment modalities since the anti-CTLA-4 antibody, ipilimumab was approved for patients with advanced melanoma in 2011. Pembrolizumab and nivolumab, two anti-PD-1 antibodies recently approved for the treatment of patients with metastatic melanoma, are being actively investigated for the treatment of multiple caners including lung, breast, bladder and renal cancers along with other anti-PD-1/L1 antibodies. Early results of combining of anti-CTLA-4 antibody and anti-PD-1 antibody treatment for advanced melanoma patients are showing impressive response rates with manageable toxicity profiles. There are several other checkpoint molecules that are likely potential inhibitory targets. The outcome of blocking some of these negative immune regulators, such as LAG-3 or TIM-3, is being pursued in the clinic or about to enter clinical development. Blockade of these molecules is demonstrating promising preclinical activity alone or when combined with anti-PD-1/L1. Future studies will define bio-markers of these therapies and how to target them alone or in combination with other immunotherapies, chemotherapy, radiotherapy and small molecule inhibitors. -PU - CURRENT BIOLOGY LTD -PI - LONDON -PA - 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND -SN - 0952-7915 -SN - 1879-0372 -DA - 2015 APR -PY - 2015 -VL - 33 -SP - 23 -EP - 35 -DO - 10.1016/j.coi.2015.01.006 -AN - WOS:000353754200006 -AD - Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA -AD - Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA -AD - Univ Calif Los Angeles, Dept Surg, Div Surg Oncol, Los Angeles, CA 90024 USA -AD - Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA -AD - Univ Calif Los Angeles, Dept Mol Cellular & Integrat Physiol, Los Angeles, CA 90024 USA -Y2 - 2015-04-01 -ER - - -TY - JOUR -AU - Zeng, J. -AU - Thomas, H. M. T. -AU - Rengan, R. -AU - Hippe, D. S. -AU - Vesselle, H. J. -AU - Kinahan, P. E. -AU - Bowen, S. R. -TI - Predicting Survival in Patients Undergoing Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Using Mid-Treatment Imaging Response and Radiation Parameters -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 62nd Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - ELECTR NETWORK -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2020 NOV 1 -PY - 2020 -VL - 108 -IS - 3 -MA - 2290 -SP - E131 -EP - E131 -AN - WOS:000582521500291 -AD - Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA -AD - Univ Washington, Dept Radiol, Seattle, WA 98195 USA -AD - Univ Washington, Dept Radiat Oncol & Radiol, Seattle, WA 98195 USA -Y2 - 2020-11-27 -ER - - -TY - JOUR -AU - Carlisle, Jennifer W. -AU - Ramalingam, Suresh S. -TI - A banner year for immunotherapy and targeted therapy -T2 - NATURE REVIEWS CLINICAL ONCOLOGY -M3 - Editorial Material -AB - In 2018, advances in the treatment of non-small-cell lung cancer (NSCLC) have been observed both in trials of immunotherapies and targeted agents, leading to dramatically improved options for patients with metastatic and stage III NSCLC. -PU - NATURE PUBLISHING GROUP -PI - NEW YORK -PA - 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA -SN - 1759-4774 -SN - 1759-4782 -DA - 2019 FEB -PY - 2019 -VL - 16 -IS - 2 -SP - 79 -EP - 80 -DO - 10.1038/s41571-018-0138-4 -AN - WOS:000456502600013 -AD - Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA -Y2 - 2019-02-01 -ER - - -TY - JOUR -AU - Wu, Yi-Long -AU - Johnson, Melissa -AU - Soo, Ross -AU - Baktash, Navid -AU - Maier, Daniela -AU - Eigenbrod-Giese, Sabina -AU - Yoshida, Tatsuya -TI - A phase 3 randomized controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations: Beamion LUNG-2 -T2 - CANCER RESEARCH -M3 - Meeting Abstract -CP - Annual Meeting of the American-Association-for-Cancer-Research (AACR) -CL - San Diego, CA -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 0008-5472 -SN - 1538-7445 -DA - 2024 APR 1 -PY - 2024 -VL - 84 -IS - 7 -MA - CT284 -DO - 10.1158/1538-7445.AM2024-CT284 -AN - WOS:001203184200230 -Y2 - 2024-05-19 -ER - - -TY - JOUR -AU - Cooper, Benjamin -AU - Chmura, Steven J. -AU - Luke, Jason J. -AU - Shiao, Stephen L. -AU - Basho, Reva K. -AU - Iams, Wade T. -AU - Page, David B. -AU - Li, Cong -AU - Gregory, Richard C. -AU - Shaw, Michael H. -AU - Horn, Kristin H. -AU - Gibbs, John P. -AU - Appleman, Vicky A. -AU - Berger, Allison J. -AU - Abu-Yousif, Adnan O. -AU - Lineberry, Neil B. -AU - Stumpo, Kate F. -AU - Elfiky, Aymen -AU - Gerber, Naamit K. -TI - Phase 1 study of TAK-676+pembrolizumab following radiation therapy in patients with advanced non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN). -T2 - CANCER RESEARCH -M3 - Meeting Abstract -CP - Annual Meeting of the American-Association-for-Cancer-Research (AACR) -CL - New Orleans, LA -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 0008-5472 -SN - 1538-7445 -DA - 2022 JUN 15 -PY - 2022 -VL - 82 -IS - 12 -MA - CT243 -AN - WOS:000892509502182 -AD - NYU, Sch Med, Perlmutter Canc Ctr, Dept Radiat Oncol, New York, NY USA -AD - Univ Chicago, Chicago, IL 60637 USA -AD - Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA -AD - Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA -AD - Vanderbilt Univ, Med Ctr, Nashville, TN USA -AD - Providence Canc Inst, Portland, OR USA -AD - Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA -M2 - Providence Canc Inst -M2 - Takeda Dev Ctr Amer Inc TDCA -Y2 - 2023-04-04 -ER - - -TY - JOUR -AU - Silva, Ana P. S. -AU - Coelho, Priscila V. -AU - Anazetti, Maristella -AU - Simioni, Patricia U. -TI - Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors -T2 - HUMAN VACCINES & IMMUNOTHERAPEUTICS -M3 - Review -AB - The usual treatments for patients with non-small-cell lung cancer (NSCLC), such as advanced lung adenocarcinoma, are unspecific and aggressive, and include lung resection, radiotherapy and chemotherapy. Recently, treatment with monoclonal antibodies and biological inhibitors has emerged as an effective alternative, generating effective results with few side effects. In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and 4 of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. Also, biological inhibitors are attractive tolls for biological applications. Among the approved inhibitors are crizotinib, erlotinib, afatinib and gefitinib, and side effects are usually mild to intense. Nevertheless, biological molecule treatments are under development, and several new monoclonal antibodies and biological inhibitors are in trial to treat NSCLC. Also under trial study are as follows: anti-epidermal growth factor receptor (EGFR) antibodies (nimotuzumab and ficlatuzumab), anti-IGF 1 receptor (IGF-1R) monoclonal antibody (figitumumab), anti-NR-LU-10 monoclonal antibody (nofetumomab) as well as antibodies directly affecting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) molecule (ipilimumab and tremelimumab), to receptor activator of nuclear factor-kappa B ligand (RANKL) (denosumab) or to polymerase enzyme (veliparib and olaparib). Among new inhibitors under investigation are poly-ADP ribose polymerase (PARP) inhibitors (veliparib and olaparib) and phosphatidylinositol 3-kinase (PI3K) inhibitor (buparlisib). However, the success of immunotherapies still requires extensive research and additional controlled trials to evaluate the long-term benefits and side effects. -PU - TAYLOR & FRANCIS INC -PI - PHILADELPHIA -PA - 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA -SN - 2164-5515 -SN - 2164-554X -DA - 2017 -PY - 2017 -VL - 13 -IS - 4 -SP - 843 -EP - 853 -DO - 10.1080/21645515.2016.1249551 -AN - WOS:000399658300020 -AD - Fac Americana, Dept Biomed Sci, Americana, SP, Brazil -AD - Fac DeVry Metrocamp, Dept Hlth Sci, Campinas, SP, Brazil -AD - Univ Campinas UNICAMP, Inst Biol, Dept Genet Evolut & Bioagents, POB 6109, BR-13083970 Campinas, SP, Brazil -AD - Univ Estadual Paulista, Inst Biosci, Dept Biochem & Microbiol, UNESP, Rio Claro, SP, Brazil -M2 - Fac Americana -M2 - Fac DeVry Metrocamp -Y2 - 2017-05-17 -ER - - -TY - JOUR -AU - Liu, Yufei -AU - Rinsurongkawong, Waree -AU - Gay, Carl -AU - Lewis, Jeff -AU - Rinsurongkawong, Vadeerat -AU - Lee, Jack -AU - Lee, Percy -AU - Zhang, Jianjun -AU - Gibbons, Don -AU - Vaporciyan, Ara -AU - Heymach, John -AU - Lin, Steven -TI - Timing of Salvage Tyrosine Kinase Inhibitors for Patients with Progressive Locally Advanced Non-Small Cell Lung Cancer Initially Treated with Chemoradiation and Consolidative Durvalumab -T2 - AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS -M3 - Meeting Abstract -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0277-3732 -SN - 1537-453X -DA - 2022 SEP -PY - 2022 -VL - 45 -IS - 9 -MA - OA26 -SP - S15 -EP - S16 -AN - WOS:000847787800033 -AD - Univ Texas MD Anderson Canc Ctr, Houston, TX USA -Y2 - 2022-09-09 -ER - - -TY - JOUR -AU - Antoni, Delphine -AU - Mornex, Francoise -TI - Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives -T2 - CURRENT OPINION IN ONCOLOGY -M3 - Review -AB - Purpose of reviewThe treatment of locally advanced nonsmall cell lung cancer (NSCLC) is becoming a significant challenge because of a growing proportion of patients with unresectable or potentially eligible for surgery after a multimodality treatment, stage II to III disease. Despite a multimodality approach consisting in concurrent chemoradiotherapy, the prognosis remains poor.Recent findingsDifferent strategies, including induction and consolidation chemotherapy, chemotherapy regimens, fractionation and radiation doses have been evaluated in phase II and III trials, as well as new therapeutic approaches such as immunotherapy. For patients with resectable stage III disease the optimal strategy remains unclear. The American Society for Radiation and Clinical Oncology and the European Society for Medical Oncology published recent guidelines in 2015.SummaryConcurrent chemoradiotherapy improves overall survival compared with sequential chemotherapy followed by radiation. Adding induction or consolidation chemotherapy to chemoradiotherapy does not appear to improve the outcome. Chemotherapy based on cisplatin combined with radiation is recommended in stage III NSCLC. The standard dose and fractionation of radiotherapy are 60Gy, one daily fraction of 2Gy over 6 weeks. Targeted therapies and immunotherapy may improve the management of locally advanced NSCLC in the future. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1040-8746 -SN - 1531-703X -DA - 2016 MAR -PY - 2016 -VL - 28 -IS - 2 -SP - 104 -EP - 109 -DO - 10.1097/CCO.0000000000000265 -AN - WOS:000369538700002 -AD - UNICANC, Ctr Paul Strauss, Dept Univ Radiotherapie, 3 Rue Porte Hop, Strasbourg, France -AD - Univ Strasbourg, FMTS, EA 3430, Strasbourg, France -AD - Ctr Hosp Lyon Sud, Dept Radiotherapie Oncol, 165 Chemin Grand Revoyet, Pierre Benite, France -AD - Univ Lyon 1, EA 3738, Domaine Rockefeller 8, F-69365 Lyon, France -Y2 - 2016-02-24 -ER - - -TY - JOUR -AU - Spieler, B. -AU - Azzam, G. -AU - Asher, D. -AU - Lopes, G. -AU - Saravia, D. -AU - Kwon, D. -AU - Yechieli, R. -AU - Dal Pra, A. -AU - Diwanji, T., Jr. -AU - Mihaylov, I. B. -TI - Overall Survival of Patients with Advanced NSCLC Treated with Nivolumab Correlates with Texture Features on Pre-Immunotherapy CT Imaging and Radiotherapy History -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 61st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - Chicago, IL -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2019 SEP 1 -PY - 2019 -VL - 105 -IS - 1 -MA - 3221 -SP - E531 -EP - E532 -DO - 10.1016/j.ijrobp.2019.06.2438 -AN - WOS:000485671501506 -AD - Sylvester Comprehens Canc Ctr, Dept Radiat Oncol, Miami, FL USA -AD - Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA -AD - Riverside Reg Med Ctr, Newport News, VA USA -AD - Univ Miami, Miller Sch Med, Miami, FL 33136 USA -AD - Univ Miami, Miami, FL USA -M2 - Sylvester Comprehens Canc Ctr -M2 - Riverside Reg Med Ctr -Y2 - 2019-09-30 -ER - - -TY - JOUR -AU - McCall, Neal S. -AU - Dicker, Adam P. -AU - Lu, Bo -TI - Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer -T2 - CLINICAL CANCER RESEARCH -M3 - Article -AB - Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard-of-care therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC). Although cCRT is potentially curative, 5-year overall survival has hovered around 20%, despite extensive efforts to improve outcomes with increasing doses of conformal radiation and intensification of systemic therapy with either induction or consolidation chemotherapy. PD-1/PD-L1 immune checkpoint inhibitors have demonstrated unprecedented efficacy in patients with stage IV NSCLC, In addition, predinical and early clinical evidence suggests that chemotherapy and radiation may work synergistically with anti-PD-1/PD-L1 therapy to promote antitumor immunity, which has led to the initiation of clinical trials testing these drugs in patients with stage Ill NSCLC. A preliminary report of a randomized phase III trial, the PACIFIC trial, demonstrated an impressive increase in median progression-free survival with consolidative durvalumab, a PD-L1 inhibitor, compared with observation after cCRT. Here, we discuss the clinical and translational implications of integrating PD-1/PD-L1 inhibitors in the management of patients with unresectable stage III NSCLC. (C) 2018 AACR. -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 1078-0432 -SN - 1557-3265 -DA - 2018 MAR 15 -PY - 2018 -VL - 24 -IS - 6 -SP - 1271 -EP - 1276 -DO - 10.1158/1078-0432.CCR-17-3269 -AN - WOS:000427627400005 -AD - Thomas Jefferson Univ Hosp, Dept Radiat Oncol, Philadelphia, PA 19107 USA -Y2 - 2018-12-28 -ER - - -TY - JOUR -AU - Lee, P. -AU - Luterstein, E. -AU - Goldman, J. -AU - Garon, E. -AU - Lee, J. M. -AU - Felix, C. -AU - Cao, M. -AU - Tenn, S. E. -AU - Low, D. -AU - Kupelian, P. A. -AU - Steinberg, M. L. -TI - Accelerated Hypofractionated CRT Followed by SABR Boost (HyCRT-SABR) for Locally Advanced Unresectable NSCLC: A Prospective Phase II Radiation Dose-Escalation Study -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 61st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - Chicago, IL -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2019 SEP 1 -PY - 2019 -VL - 105 -IS - 1 -MA - 90 -SP - S44 -EP - S44 -DO - 10.1016/j.ijrobp.2019.06.469 -AN - WOS:000485671502501 -AD - Univ Calif Los Angeles, Los Angeles, CA USA -AD - Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90024 USA -AD - Univ Calif Los Angeles, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90024 USA -AD - Univ Calif Los Angeles, Dept Surg, Div Thorac Surg, Los Angeles, CA 90024 USA -Y2 - 2019-09-30 -ER - - -TY - JOUR -AU - Ohri, Nitin -AU - Halmos, Balazs -AU - Cheng, Haiying -AU - Abraham, Tony -AU - Yahya, Tahir -AU - Garg, Madhur -AU - Bodner, William -AU - Kabarriti, Rafi -AU - Kalnicki, Shalom -AU - Yellin, Michael J. -AU - Keler, Tibor -AU - Guha, Chandan -TI - FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced non-small cell lung cancer -T2 - CANCER RESEARCH -M3 - Meeting Abstract -CP - Annual Meeting of the American-Association-for-Cancer-Research (AACR) -CL - Chicago, IL -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 0008-5472 -SN - 1538-7445 -DA - 2018 JUL -PY - 2018 -VL - 78 -IS - 13 -MA - CT005 -DO - 10.1158/1538-7445.AM2018-CT005 -AN - WOS:000468818900005 -AD - Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA -AD - Celldex Therapeut Inc, Hampton, NJ USA -Y2 - 2019-06-14 -ER - - -TY - JOUR -AU - Le Rhun, Emilie -AU - Galanis, Evanthia -TI - Leptomeningeal metastases of solid cancer -T2 - CURRENT OPINION IN NEUROLOGY -M3 - Review -AB - Purpose of reviewTo review recent original data on leptomeningeal metastases in patients with solid cancer.Recent findingsLung and breast cancer as well as melanoma remain the most common primaries. Advanced cytological methods and targeted sequencing for candidate tumor-specific mutations may improve the sensitivity of cerebrospinal fluid diagnostics in leptomeningeal metastases. Targeted treatments like epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer, anti-human epidermal growth factor receptor-2 treatments for breast cancer or B-rapidly accelerated fibrosarcoma-targeted or immunotherapy for melanoma have an emerging role in the management of this condition.SummaryNovel diagnostic approaches and the introduction of targeted agents may improve the clinical management of patients with leptomeningeal metastases from solid cancers. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1350-7540 -SN - 1473-6551 -DA - 2016 DEC -PY - 2016 -VL - 29 -IS - 6 -SP - 797 -EP - 805 -DO - 10.1097/WCO.0000000000000393 -AN - WOS:000387353900019 -AD - Ctr Oscar Lambret, Dept Med Oncol, Breast Unit, Lille, France -AD - Univ Hosp, Dept Neurosurg, Neurooncol, Lille, France -AD - Univ Lille, INSERM, U 1192, Lab Prote Reponse Inflammatoire Spectrometrie Mas, Lille, France -AD - Mayo Clin, Dept Oncol, Rochester, MN USA -Y2 - 2016-11-30 -ER - - -TY - JOUR -AU - Altan, Mehmet -AU - Chiang, Anne C. -TI - Management of Small Cell Lung Cancer Progress and Updates -T2 - CANCER JOURNAL -M3 - Review -AB - Small cell lung cancer (SCLC) remains a major public health problem and accounts for 10% to 15% of all lung cancers. It has unique clinical features such as rapid growth, early metastatic spread, and widespread dissemination. A platinum-etoposide combination is the backbone treatment of SCLC; addition of thoracic and prophylactic cranial irradiation has been shown to improve outcome in limited-stage SCLC and in subgroups of extensive-stage SCLC. Over the last decade, significant progress has been made in characterizing the SCLC tumor biology and its developmental pathways. Most recently, efforts have focused not only on molecular targets, but also on the development of novel drugs targeting tumor evolution and immune escape mechanisms; these approaches are promising and offer opportunities that may finally improve the outcomes of SCLC. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1528-9117 -SN - 1540-336X -DA - 2015 SEP-OCT -PY - 2015 -VL - 21 -IS - 5 -SP - 425 -EP - 433 -DO - 10.1097/PPO.0000000000000148 -AN - WOS:000362178300011 -AD - Smilow Canc Hosp, Yale Canc Ctr, Thorac Oncol, New Haven, CT USA -Y2 - 2015-10-22 -ER - - -TY - JOUR -AU - Rimner, A. -AU - Offin, M. -AU - Shaverdian, N. -AU - McKnight, D. -AU - Li, H. -AU - Mccune, M. -AU - Patson, B. -AU - Kotecha, R. -AU - Gomez, D. R. -AU - Chaft, J. -TI - Durvalumab with Concurrent Definitive Radiation Therapy (DART) for Locally-Advanced Non-Small Cell Lung Cancer - A Phase II Study -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 62nd Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - ELECTR NETWORK -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2020 NOV 1 -PY - 2020 -VL - 108 -IS - 3 -MA - 4162 -SP - E929 -EP - E929 -AN - WOS:000582521503199 -AD - Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA -AD - Lehigh Valley Hlth Network, Allentown, PA USA -AD - Miami Canc Inst, Miami, FL USA -M2 - Miami Canc Inst -Y2 - 2020-11-27 -ER - - -TY - JOUR -AU - Jeanson, Arnaud -AU - Barlesi, Fabrice -TI - MEDI 4736 (durvalumab) in non-small cell lung cancer -T2 - EXPERT OPINION ON BIOLOGICAL THERAPY -M3 - Article -AB - Introduction: Immune checkpoint inhibitors (ICI) are now a therapeutic option for advanced non-small cell lung cancer (NSCLC) patients. ICI, such as the PD-1 inhibitors nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab, have already been marketed for the treatment of pretreated patients with advanced NSCLC. Other notable PD-L1 inhibitors under development include avelumab and durvalumab.Areas covered: This article reviews literature on durvalumab development, from the preclinical data to the results of phase III clinical trials, whether published or presented at international scientific conferences. Ongoing clinical trials were also reviewed.Expert opinion: Early phase trials of durvalumab monotherapy (and in combination) have demonstrated activity in advanced NSCLC patients and it has demonstrated a good safety profile. The authors believe that durvalumab will likely play an important role in future treatment strategies for NSCLC. The PACIFIC trial assessing durvalumab after standard chemoradiotherapy for locally advanced NSCLC has already met its primary endpoint and the potential of durvalumab will be reinforced if phase III randomized studies of first-line (MYSTIC trial) and second or subsequent (ARCTIC trial) lines of therapy demonstrate superiority over the current standard of care. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1471-2598 -SN - 1744-7682 -DA - 2017 -PY - 2017 -VL - 17 -IS - 10 -SP - 1317 -EP - 1323 -DO - 10.1080/14712598.2017.1351939 -AN - WOS:000409205800012 -AD - Aix Marseille Univ, AP HM, Early Phase Canc Ctr CLIP2, Marseille, France -Y2 - 2017-09-14 -ER - - -TY - JOUR -AU - Olin, Michael R. -AU - Neil, Elizabeth C. -AU - Eaton, Anne -AU - Lunn, Shannon -AU - Moertel, Christopher L. -TI - First in human CD200 activation receptor ligand and tumor lysate vaccine immunotherapy for recurrent glioblastoma in adults -T2 - CANCER RESEARCH -M3 - Meeting Abstract -CP - Annual Meeting of the American-Association-for-Cancer-Research (AACR) -CL - New Orleans, LA -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 0008-5472 -SN - 1538-7445 -DA - 2022 JUN 15 -PY - 2022 -VL - 82 -IS - 12 -MA - CT245 -AN - WOS:000892509502184 -AD - Univ Minnesota, Minneapolis, MN USA -Y2 - 2023-04-04 -ER - - -TY - JOUR -AU - Soffietti, Riccardo -AU - Ahluwalia, Manmeet -AU - Lin, Nancy -AU - Ruda, Roberta -TI - Management of brain metastases according to molecular subtypes -T2 - NATURE REVIEWS NEUROLOGY -M3 - Review -AB - This Review outlines the advances of molecular treatment of brain metastases from non-small-cell lung cancer, breast cancer and melanoma. Substantial improvements in survival have been achieved in patients with molecular subgroups whose alterations can be targeted with specific molecular compounds.The incidence of brain metastases has markedly increased in the past 20 years owing to progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an ageing population. Although local therapies remain the mainstay of treatment for many patients with brain metastases, a growing number of systemic options are now available and/or are under active investigation. HER2-targeted therapies (lapatinib, neratinib, tucatinib and trastuzumab emtansine), alone or in combination, yield a number of intracranial responses in patients with HER2-positive breast cancer brain metastases. New inhibitors are being investigated in brain metastases from ER-positive or triple-negative breast cancer. Several generations of EGFR and ALK inhibitors have shown activity on brain metastases from EGFR and ALK mutant non-small-cell lung cancer. Immune-checkpoint inhibitors (ICIs) hold promise in patients with non-small-cell lung cancer without druggable mutations and in patients with triple-negative breast cancer. The survival of patients with brain metastases from melanoma has substantially improved after the advent of BRAF inhibitors and ICIs (ipilimumab, nivolumab and pembrolizumab). The combination of targeted agents or ICIs with stereotactic radiosurgery could further improve the response rates and survival but the risk of radiation necrosis should be monitored. Advanced neuroimaging and liquid biopsy will hopefully improve response evaluation. -PU - NATURE PORTFOLIO -PI - BERLIN -PA - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY -SN - 1759-4758 -SN - 1759-4766 -DA - 2020 OCT -PY - 2020 -VL - 16 -IS - 10 -SP - 557 -EP - 574 -DO - 10.1038/s41582-020-0391-x -AN - WOS:000565153500001 -C6 - SEP 2020 -AD - Univ & City Hlth & Sci Hosp, Dept Neurooncol, Turin, Italy -AD - Cleveland Clin, Taussig Ctr Inst, Burkhardt Brain Tumor & Neurooncol Ctr, Cleveland, OH 44106 USA -AD - Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA -Y2 - 2020-09-01 -ER - - -TY - JOUR -AU - Esposito, Giovanna -AU - Palumbo, Giuliano -AU - Carillio, Guido -AU - Manzo, Anna -AU - Montanino, Agnese -AU - Sforza, Vincenzo -AU - Costanzo, Raffaele -AU - Sandomenico, Claudia -AU - La Manna, Carmine -AU - Martucci, Nicola -AU - La Rocca, Antonello -AU - De Luca, Giuseppe -AU - Piccirillo, Maria Carmela -AU - De Cecio, Rossella -AU - Botti, Gerardo -AU - Totaro, Giuseppe -AU - Muto, Paolo -AU - Picone, Carmine -AU - Normanno, Nicola -AU - Morabito, Alessandro -TI - Immunotherapy in Small Cell Lung Cancer -T2 - CANCERS -M3 - Review -AB - Simple Summary Small cell lung cancer (SCLC) accounts for about 15% of lung cancers and it has limited therapeutic options and poor prognosis. There has been no real progress for over 30 years in the treatment of this aggressive tumor type and platinum based chemotherapy represented the cornerstone of therapy. Immune checkpoint inhibitors are the first agents in the last decades to determine an improvement in outcomes of patients with extensive stage (ES) SCLC patients. In the IMpower 133 and CASPIAN studies, the addition of atezolizumab or durvalumab, respectively, to first-line chemotherapy produced a significant improvement in overall survival with an acceptable safety profile in previously untreated patients with ES-SCLC, leading to a new standard of care. This review summarizes the main results observed with checkpoint inhibitors in SCLC, discussing the critical issues related to the use of novel checkpoint inhibitors and the future research with immunotherapy agents in SCLC. Small-cell lung cancer (SCLC) is an aggressive tumor type with limited therapeutic options and poor prognosis. Chemotherapy regimens containing platinum represent the cornerstone of treatment for patients with extensive disease, but there has been no real progress for 30 years. The evidence that SCLC is characterized by a high mutational burden led to the development of immune-checkpoint inhibitors as single agents or in combination with chemotherapy. Randomized phase III trials demonstrated that the combination of atezolizumab (IMpower-133) or durvalumab (CASPIAN) with platinum-etoposide chemotherapy improved overall survival of patients with extensive disease. Instead, the KEYNOTE-604 study demonstrated that the addition of pembrolizumab to chemotherapy failed to significantly improve overall survival, but it prolonged progression-free survival. The safety profile of these combinations was similar with the known safety profiles of all single agents and no new adverse events were observed. Nivolumab and pembrolizumab single agents showed anti-tumor activity and acceptable safety profile in Checkmate 032 and KEYNOTE 028/158 trials, respectively, in patients with SCLC after platinum-based therapy and at least one prior line of therapy. Future challenges are the identification predictive biomarkers of response to immunotherapy in SCLC and the definition of the role of immunotherapy in patients with limited stage SCLC, in combination with radiotherapy or with other biological agents. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2020 SEP -PY - 2020 -VL - 12 -IS - 9 -C7 - 2522 -DO - 10.3390/cancers12092522 -AN - WOS:000580097300001 -AD - IRCCS Fdn G Pascale, Ist Nazl Tumori, Thorac Med Oncol, I-80131 Naples, Italy -AD - Azienda Osped Pugliese Ciaccio, Dept Hematol & Oncol, I-88100 Catanzaro, Italy -AD - Fdn G Pascale IRCCS, Ist Nazl Tumori, Thorac Surg, I-80131 Naples, Italy -AD - Fdn G Pascale IRCCS, Ist Nazl Tumori, Clin Trials Unit, I-80131 Naples, Italy -AD - Fdn G Pascale IRCCS, Ist Nazl Tumori, Pathol, I-80131 Naples, Italy -AD - Fdn G Pascale IRCCS, Ist Nazl Tumori, Sci Directorate, I-80131 Naples, Italy -AD - Fdn G Pascale IRCCS, Ist Nazl Tumori, Radiotherapy, I-80131 Naples, Italy -AD - Fdn G Pascale IRCCS, Ist Nazl Tumori, Radiol, I-80131 Naples, Italy -AD - Fdn G Pascale IRCCS, Ist Nazl Tumori, Cellular Biol & Biotherapy, I-80131 Naples, Italy -M2 - Azienda Osped Pugliese Ciaccio -Y2 - 2020-09-01 -ER - - -TY - JOUR -AU - Kelly, Ronan J. -AU - Lopez-Chavez, Ariel -AU - Citrin, Deborah -AU - Janik, John E. -AU - Morris, John C. -TI - Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin -T2 - MOLECULAR CANCER -M3 - Review -AB - Survivin (BIRC5), a member of the inhibitor of apoptosis protein (IAP) family that inhibits caspases and blocks cell death is highly expressed in cancer and is associated with a poorer clinical outcome. Functioning simultaneously during cell division and apoptosis inhibition, survivin plays a pivotal role in determining cell survival. Survivin has consistently been identified by molecular profiling analysis to be associated with higher tumor grade, more advanced disease, abbreviated survival, accelerated rates of recurrence, and chemotherapy and radiation resistance. Survivin's differential expression in cancer compared to normal tissue and its role as a nodal protein in a number of cellular pathways make it a highly flexible therapeutic target, suitable for small-molecule inhibitiors, molecular antagonists, and vaccination-based therapies. By targeting survivin it is hoped that multiple tumor signaling circuitries may be simultaneously disabled. This effect may be applicable to many tumor histologies irrespective of specific genetic makeup. To date, survivin inhibitors have shown modest activity as single agents, but it is anticipated that when given in combination with cytotoxic chemotherapy or monoclonal antibodies they may exhibit enhanced efficacy. This review discusses the complex circuitry of survivin in human cancers and highlights clinical trials involving novel agents that target this important protein. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1476-4598 -DA - 2011 APR 6 -PY - 2011 -VL - 10 -C7 - 35 -DO - 10.1186/1476-4598-10-35 -AN - WOS:000289941600001 -AD - Univ Cincinnati, Dept Med, Div Hematol Oncol, Cincinnati, OH 45267 USA -AD - NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA -AD - NCI, Radiat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA -AD - NCI, Metab Branch, Ctr Canc Res, Bethesda, MD 20892 USA -Y2 - 2011-05-13 -ER - - -TY - JOUR -AU - Lillie, Tom -AU - Parkes, Eileen -AU - Ottensmeier, Christian -AU - Krige, David -AU - Ravanfar, Behnaz -AU - Evilevitch, Vladimir -AU - Thomas, Matthew -AU - Rosen, Lee -TI - A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA). -T2 - CANCER RESEARCH -M3 - Meeting Abstract -CP - Annual Meeting of the American-Association-for-Cancer-Research (AACR) -CL - New Orleans, LA -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 0008-5472 -SN - 1538-7445 -DA - 2022 JUN 15 -PY - 2022 -VL - 82 -IS - 12 -MA - CT214 -AN - WOS:000892509502126 -AD - PsiOxus Therapeut Ltd, Abingdon, Oxon, England -AD - Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England -AD - Univ Liverpool, Inst Syst Mol & Integrat Biol, Liverpool Head & Neck Ctr, Liverpool, Merseyside, England -AD - Clatterbridge Canc Ctr NHS Fdn Trust, Liverpool, Merseyside, England -AD - UCLA Div Hematol Oncol, Santa Monica, CA USA -M2 - PsiOxus Therapeut Ltd -M2 - Clatterbridge Canc Ctr NHS Fdn Trust -M2 - UCLA Div Hematol Oncol -Y2 - 2023-04-04 -ER - - -TY - JOUR -AU - Herrera, Zaima Mazorra -AU - Ramos, Tania Crombet -TI - Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients -T2 - CANCER IMMUNOLOGY IMMUNOTHERAPY -M3 - Review -AB - Cancer vaccines contain tumor antigens in a pro-inflammatory context with the purpose to generate potent antitumor immune responses. However, tumor cells develop different immunosuppressive mechanisms that limit the effectiveness of an anticancer immune response. Therefore, therapeutic vaccine treatment alone is usually not sufficient to generate tumor regression or survival improvement, especially in the advanced disease scenario in which most clinical studies have been conducted. Combining cancer vaccines with different anticancer therapies such as chemotherapy, radiotherapy and other immunotherapeutic agents has had different levels of success. However, the combination of cancer vaccines with different mechanisms of action has not been explored in clinical trials. To address this issue, the current review summarizes the main clinical and immunological results obtained with two different therapeutic vaccines used in advanced non-small-cell lung cancer patients, inducing an immune response against epidermal growth factor (CIMAvax-EGF) and NGcGM3 ganglioside (racotumomab). We also discuss preliminary findings obtained in a trial of combination of these two vaccines and future challenges with these therapies. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 0340-7004 -SN - 1432-0851 -DA - 2014 JUL -PY - 2014 -VL - 63 -IS - 7 -SP - 737 -EP - 747 -DO - 10.1007/s00262-014-1552-9 -AN - WOS:000339873300008 -AD - Ctr Mol Immunol, Clin Immunol Dept Clin Direct, Havana, Cuba -M2 - Ctr Mol Immunol -Y2 - 2014-08-27 -ER - - -TY - JOUR -AU - JACKSON, DV -AU - CASE, LD -TI - SMALL-CELL LUNG-CANCER - A 10-YEAR PERSPECTIVE -T2 - SEMINARS IN ONCOLOGY -M3 - Article -PU - W B SAUNDERS CO -PI - PHILADELPHIA -PA - INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 -SN - 0093-7754 -DA - 1986 SEP -PY - 1986 -VL - 13 -IS - 3 -SP - 63 -EP - 74 -AN - WOS:A1986E248800011 -AD - WAKE FOREST UNIV,BOWMAN GRAY SCH MED,PIEDMONT ONCOL ASSOC,WINSTON SALEM,NC 27103 -Y2 - 1986-09-01 -ER - - -TY - JOUR -AU - Reckamp, Karen L. -AU - Akerley, Wallace -AU - Edelman, Martin J. -AU - Halmos, Balazs -AU - He, Kai -AU - Johnson, Melissa -AU - Mudad, Raja -AU - Neal, Joel W. -AU - Owonikoko, Taofeek K. -AU - Patel, Jyoti D. -AU - Patel, Sandip P. -AU - Riess, Jonathan W. -AU - Sacher, Adrian G. -AU - Turcotte, Simon -AU - Villaruz, Liza C. -AU - Zauderer, Marjorie G. -AU - Farsaci, Benedetto -AU - Hasan, Aisha -AU - Patel, Roma -AU - Wu, Yuehui -AU - Chisamore, Michael -AU - Lam, Vincent -TI - A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer -T2 - CANCER RESEARCH -M3 - Meeting Abstract -CP - Annual Meeting of the American-Association-for-Cancer-Research (AACR) -CL - Atlanta, GA -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 0008-5472 -SN - 1538-7445 -DA - 2019 JUL -PY - 2019 -VL - 79 -IS - 13 -MA - CT225 -DO - 10.1158/1538-7445.AM2019-CT225 -AN - WOS:000488129900201 -AD - City Hope Comprehens Canc Ctr, Duarte, CA USA -AD - Huntsman Canc Inst, Salt Lake City, UT USA -AD - Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA -AD - Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA -AD - Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA -AD - James Canc Hosp, Columbus, OH USA -AD - Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA -AD - Univ Miami, Miller Sch Med, Dept Med, Div Oncol, Miami, FL 33136 USA -AD - Sylvester Comprehens Canc Ctr, Miami, FL USA -AD - Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA -AD - Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA -AD - Univ Chicago, Chicago, IL 60637 USA -AD - UC San Diego Moores Canc Ctr, San Diego, CA USA -AD - UC Davis Comprehens Canc Ctr, Div Hematol Oncol, Sacramento, CA USA -AD - Princess Margaret Canc Ctr, Toronto, ON, Canada -AD - Ctr Hosp Univ Montreal, Montreal, PQ, Canada -AD - UPMC Hillman Canc Ctr, Pittsburgh, PA USA -AD - Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA -AD - GSK, Philadelphia, PA USA -AD - GSK, Uxbridge, Middx, England -AD - Merck & Co Inc, N Wales, PA USA -AD - Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA -M2 - Sylvester Comprehens Canc Ctr -M2 - UC San Diego Moores Canc Ctr -M2 - UC Davis Comprehens Canc Ctr -M2 - UPMC Hillman Canc Ctr -Y2 - 2019-10-14 -ER - - -TY - JOUR -AU - Wong, Selina K. -AU - Horn, Leora -TI - How I Treat Non-Small Cell Lung Cancer Refractory to Immunotherapy -T2 - CANCER JOURNAL -M3 - Review -AB - Lung cancer is a leading cause of cancer-related mortality despite continued advances in diagnostic and therapeutic strategies. Although the development of immune checkpoint inhibitors has revolutionized the treatment landscape for advanced non-small cell lung cancer, many patients either have primary resistance to these agents or eventually develop secondary resistance necessitating a change to an alternate therapy. Understanding novel patterns of response to immunotherapy is crucial in determining appropriate selection and sequencing of treatment. Chemotherapy remains the standard of care in immunotherapy-refractory disease, but multiple trials are ongoing to explore the role of combination radioimmunotherapy and rechallenging with immunotherapy either alone or in combination with other antineoplastic agents. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1528-9117 -SN - 1540-336X -DA - 2020 NOV-DEC -PY - 2020 -VL - 26 -IS - 6 -SP - 496 -EP - 501 -DO - 10.1097/PPO.0000000000000482 -AN - WOS:000596657500004 -AD - Vanderbilt Ingram Canc Ctr, Nashville, TN USA -Y2 - 2021-01-22 -ER - - -TY - JOUR -AU - Rijavec, Erika -AU - Genova, Carlo -AU - Barletta, Giulia -AU - Burrafato, Giovanni -AU - Biello, Federica -AU - Dal Bello, Maria Giovanna -AU - Coco, Simona -AU - Truini, Anna -AU - Alama, Angela -AU - Boccardo, Francesco -AU - Grossi, Francesco -TI - Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy -T2 - EXPERT OPINION ON BIOLOGICAL THERAPY -M3 - Article -AB - Introduction: Despite recent advances with new chemotherapeutic agents and target therapies, the prognosis of NSCLC remains poor. Recent results from clinical trials of immunotherapeutic agents, especially with immune checkpoint inhibitors, make this approach very exciting in NSCLC. Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen 4 that is able to stimulate the antitumour immune response by promoting T-cell activation.Areas covered: We have reviewed the literature and have described the most important results obtained with ipilimumab in NSCLC in recent trials with a specific focus on its peculiar toxicity profile and pattern of response. Trials ongoing with ipilimumab are also reported.Expert opinion: The results from clinical trials with ipilimumab are promising. Some important issues in the near future will be to identify prognostic and predictive biomarkers to select patients who could benefit from this drug. Further studies are warranted to understand how to combine ipilimumab with other anticancer strategies. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1471-2598 -SN - 1744-7682 -DA - 2014 JUL -PY - 2014 -VL - 14 -IS - 7 -SP - 1007 -EP - 1017 -DO - 10.1517/14712598.2014.907786 -AN - WOS:000337023000012 -AD - IST Ist Nazl Ric Cancro, UOS Tumori Polmonari, IRCCS San Martino, Genoa, Italy -AD - IST Ist Nazl Ric Cancro, UO Clin Oncol Med, IRCCS San Martino, Genoa, Italy -AD - Univ Genoa, Dipartimento Med Interna & Specialita Med DIMI, Genoa, Italy -Y2 - 2014-07-09 -ER - - -TY - JOUR -AU - Patel, Priyanka -AU - Alrifai, Doraid -AU - McDonald, Fiona -AU - Forster, Martin -A1 - AstraZeneca UK Ltd -TI - Beyond chemoradiotherapy: improving treatment outcomes or patients with stage III nresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®Down-pointingTriangle, AstraZeneca UK Limited) -T2 - BRITISH JOURNAL OF CANCER -M3 - Review -AB - The treatment paradigm of non-small-cell lung cancer (NSCLC) has rapidly changed in recent years following the introduction of immune-checkpoint inhibition (ICI). Pre-clinically, both chemotherapy and radiotherapy modulate the tumour microenvironment, providing the rationale for clinical trials evaluating their role in combination with immunotherapy. Standard-of-care treatment for patients with unresectable stage III disease is concurrent chemoradiotherapy (cCRT); however, only recently, the combination with ICI has been explored. The Phase 3 PACIFIC study randomised 713 patients with confirmed locally advanced, unresectable, stage III NSCLC, whose disease has not progressed following cCRT, to either the anti-programmed death-ligand 1 (PD-L1) agent durvalumab (Imfinzi(R)Down-pointing Triangle, AstraZeneca UK Limited) or placebo. Patients with a PD-L1 status >= 1% treated with durvalumab had a significantly longer median progression-free survival compared with placebo (17.2 vs. 5.6 months, respectively; HR: 0.51; 95% CI: 0.41-0.63), prolonged median overall survival (OS) (NR vs. 28.7 months, respectively; HR: 0.68; 99.73% CI: 0.47-0.997; P = 0.0025) and long-term clinical benefit (3-year OS HR: 0.69; 95% CI: 0.55-0.86). Grade 3 or 4 toxicity was marginally greater in the durvalumab cohort versus placebo (30.5% vs. 26.1%). Based on these results, durvalumab has been licensed in this setting, and further clinical trials are exploring the use of ICI in unresectable stage III NSCLC. -PU - SPRINGERNATURE -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND -SN - 0007-0920 -SN - 1532-1827 -DA - 2020 DEC 1 -PY - 2020 -VL - 123 -IS - SUPPL 1 -SP - 18 -EP - 27 -DO - 10.1038/s41416-020-01071-5 -AN - WOS:000600554700003 -AD - Royal Marsden NHS Fdn Trust, Dept Radiotherapy, London, England -AD - UCL, Rayne Inst, Lungs Living Res Ctr, UCL Resp, London, England -AD - Univ Coll Hosp, London, England -AD - UCL, UCL Canc Inst, London, England -Y2 - 2021-01-11 -ER - - -TY - JOUR -AU - Sun, Lova -AU - Aggarwal, Charu -TI - Immunotherapy for Lung Cancer-Improving Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer With Immunotherapy -T2 - CANCER JOURNAL -M3 - Review -AB - Patients with locally advanced non-small cell lung cancer (NSCLC), a heterogenous group encompassing stage IIIA-IIIC disease, often have surgically unresectable cancer and are managed with concurrent chemoradiation. Since the establishment of platinum-based chemoradiation as standard of care for unresectable locally advanced NSCLC, various strategies including escalating radiation dose, targeted therapies, antiangiogenic agents, and induction or consolidation chemotherapy have failed to show improvement in outcomes. However, recently, use of consolidation immunotherapy with durvalumab following concurrent chemoradiation therapy has been associated with improvement in survival and has led to a paradigm shift. In this review, we will summarize results from trials of immunotherapy in locally advanced NSCLC and comment on ongoing trials and potential future investigations. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1528-9117 -SN - 1540-336X -DA - 2020 NOV-DEC -PY - 2020 -VL - 26 -IS - 6 -SP - 548 -EP - 554 -DO - 10.1097/PPO.0000000000000485 -AN - WOS:000596657500011 -AD - Univ Penn, Dept Med, Div Hematol Oncol, 10-137 South Pavil,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA -Y2 - 2021-01-22 -ER - - -TY - JOUR -AU - Criscitiello, Carmen -AU - Guerini-Rocco, Elena -AU - Viale, Giulia -AU - Fumagalli, Caterina -AU - Sajjadi, Elham -AU - Venetis, Konstantinos -AU - Piciotti, Roberto -AU - Invernizzi, Marco -AU - Malapelle, Umberto -AU - Fusco, Nicola -TI - Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology -T2 - ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY -M3 - Review -AB - Immune Checkpoint Inhibitors (ICIs) have remarkably modified the way solid tumors are managed, including breast cancer. Unfortunately, only a relatively small number of breast cancer patients significantly respond to these treatments. To maximize the immunotherapy benefit in breast cancer, several efforts are currently being put forward for the identification of i) the best therapeutic strategy (i.e. ICI monotherapy or in association with chemotherapy, radiotherapy, or other drugs); ii) optimal timing for administration (e.g. early/advanced stage of disease; adjuvant/neoadjuvant setting); iii) most effective and reliable predictive biomarkers of response (e.g. tumor-infiltrating lymphocytes, programmed death-ligand 1, microsatellite instability associated with mismatch repair deficiency, and tumor mutational burden). In this article, we review the impacts and gaps in the characterization of immune-related biomarkers raised by clinical and translational research studies with immunotherapy treatments. Particular emphasis has been put on the documented evidence of significant clinical benefits of ICI in different randomized clinical trials, along with preanalytical and analytical issues in predictive biomarkers pathological assessment. -PU - BENTHAM SCIENCE PUBL LTD -PI - SHARJAH -PA - EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES -SN - 1871-5206 -SN - 1875-5992 -DA - 2022 FEB -PY - 2022 -VL - 22 -IS - 4 -SP - 787 -EP - 800 -DO - 10.2174/1871520621666210706144112 -AN - WOS:000823112700016 -AD - Univ Milan, Dept Oncol & Hematooncol, Milan, Italy -AD - European Inst Oncol IRCCS, Div Early Drug Dev Innovat Therapies, IEO, Milan, Italy -AD - European Inst Oncol IRCCS, Div Pathol, IEO, Milan, Italy -AD - IRCCS San Raffaele Hosp, Dept Med Oncol, Milan, Italy -AD - Univ Piemonte Orientale, Dept Hlth Sci, Phys & Rehabil Med, Viale Piazza DArmi 1, Novara, Italy -AD - Univ Naples Federico II, Dept Publ Hlth, Naples, Italy -Y2 - 2022-07-22 -ER - - -TY - JOUR -AU - Tang, Shengjie -AU - Qin, Chao -AU - Hu, Haiyang -AU - Liu, Tao -AU - He, Yiwei -AU - Guo, Haiyang -AU - Yan, Hang -AU - Zhang, Jun -AU - Tang, Shoujun -AU - Zhou, Haining -TI - Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects -T2 - CELLS -M3 - Review -AB - Non-small cell lung cancer is one of the most common types of malignances worldwide and the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical resection, chemotherapy, radiotherapy, and targeted therapy, with poor therapeutic effectiveness. In recent years, immune checkpoint inhibitors have applied in NSCLC treatment. A large number of experimental studies have shown that immune checkpoint inhibitors are safer and more effective than traditional therapeutic modalities and have allowed for the development of better guidance in the clinical treatment of advanced NSCLC patients. In this review, we describe clinical trials using ICI immunotherapies for NSCLC treatment, the available data on clinical efficacy, and the emerging evidence regarding biomarkers. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2073-4409 -DA - 2022 FEB -PY - 2022 -VL - 11 -IS - 3 -C7 - 320 -DO - 10.3390/cells11030320 -AN - WOS:000760562100001 -AD - Chongqing Med Univ, Affiliated Hosp, Suining Cent Hosp, Dept Thorac Surg, Suining 629099, Peoples R China -AD - Zunyi Med Univ, Inst Surg, Grad Sch, Zunyi 563002, Guizhou, Peoples R China -AD - Chengdu Univ TCM, Inst Surg, Grad Sch, Chengdu 610075, Peoples R China -Y2 - 2022-03-03 -ER - - -TY - JOUR -AU - Parikh, Mamta -AU - Riess, Jonathan -AU - Lara, Primo N., Jr. -TI - New and emerging developments in extensive-stage small cell lung cancer therapeutics -T2 - CURRENT OPINION IN ONCOLOGY -M3 - Review -AB - Purpose of reviewExtensive-stage small cell lung cancer (ES-SCLC) remains a disease with a dismal prognosis, with median survival of approximately 8-10 months. Despite many attempts to develop effective systemic therapies, very little progress has been made in the last several decades. Platinum-based combination chemotherapy remains the standard of care in the first-line setting and is associated with high response rates albeit short-lived. However, there have been recent advances in the use of radiation therapy, as well as new insights into the biology of SCLC.Recent findingsSome of the most appreciable advances in the last decade have involved the use of local radiation therapy. With the use of new laboratory techniques such as genomic sequencing, there remains promise of rationally targeted drug development. Circulating tumor cell research may also provide insights to SCLC biology and further refine treatment.SummarySystemic therapy for SCLC has changed little over the past 30 years with the most significant advances in ES-SCLC relating to radiotherapy rather than systemic therapy. The effectiveness of prophylactic cranial irradiation and thoracic radiotherapy has renewed interest in therapeutics focused on the modulation of DNA damage or repair. Recent developments in genomic sequencing and immunotherapy may translate to new treatment paradigms for SCLC. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1040-8746 -SN - 1531-703X -DA - 2016 MAR -PY - 2016 -VL - 28 -IS - 2 -SP - 97 -EP - 103 -DO - 10.1097/CCO.0000000000000264 -AN - WOS:000369538700001 -AD - Univ Calif Davis, Sch Med, Dept Internal Med, Div Hematol Oncol, Sacramento, CA 95817 USA -AD - Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA -Y2 - 2016-02-24 -ER - - -TY - JOUR -AU - Shimoyama, Ryo -AU - Omori, Shota -AU - Nomura, Shogo -AU - Kenmotsu, Hirotsugu -AU - Takahashi, Toshiaki -AU - Harada, Hideyuki -AU - Ishikura, Satoshi -AU - Mizutani, Tomonori -AU - Ando, Masahiko -AU - Kataoka, Tomoko -AU - Fukuda, Haruhiko -AU - Ohe, Yuichiro -A1 - Japan Clinical Oncology Grp -TI - A multi-institutional randomized phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin as regimens for concurrent chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG1914 -T2 - JAPANESE JOURNAL OF CLINICAL ONCOLOGY -M3 - Article -AB - Daily low-dose carboplatin plus concurrent thoracic radiotherapy is the standard treatment for elderly patients with unresectable clinical stage (c-Stage) III non-small cell lung cancer (NSCLC) in Japan. However, a phase I study by Omori et al. suggests that weekly carboplatin and nab-paclitaxel plus concurrent thoracic radiotherapy have comparable efficacy outcomes with more manageable adverse events. In December 2020, we initiated a randomized controlled trial in Japan to confirm whether the weekly carboplatin plus nab-paclitaxel regimen is noninferior to the daily low-dose carboplatin regimen for concurrent chemoradiotherapy in elderly patients with unresectable c-Stage III NSCLC. We plan to enroll 166 patients from 50 institutions in 3.5 years. The primary endpoint is overall survival. The secondary endpoints are progression-free survival, response rate, proportion of patients starting maintenance durvalumab therapy, adverse events, site of progression, Functional Assessment of Cancer Therapy-Trial Outcome Index deterioration and Instrumental Activities of Daily Living deterioration. -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 0368-2811 -SN - 1465-3621 -DA - 2021 MAY -PY - 2021 -VL - 51 -IS - 5 -SP - 836 -EP - 841 -DO - 10.1093/jjco/hyab025 -AN - WOS:000649258300022 -C6 - MAR 2021 -AD - Natl Canc Ctr, JCOG Data Ctr, Operat Off, Tokyo, Japan -AD - Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan -AD - Shizuoka Canc Ctr, Radiat & Proton Therapy Ctr, Shizuoka, Japan -AD - Nagoya City Univ, Dept Radiol, Grad Sch Med Sci, Nagoya, Aichi, Japan -AD - Kyorin Univ, Dept Med Oncol, Fac Med, Tokyo, Japan -AD - Nagoya Univ Hosp, Dept Adv Med, Nagoya, Aichi, Japan -AD - Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan -Y2 - 2021-06-01 -ER - - -TY - JOUR -AU - Lo Russo, Giuseppe -AU - Macerelli, Marianna -AU - Platania, Marco -AU - Zilembo, Nicoletta -AU - Vitali, Milena -AU - Signorelli, Diego -AU - Proto, Claudia -AU - Ganzinelli, Monica -AU - Gallucci, Rosaria -AU - Agustoni, Francesco -AU - Fasola, Gianpiero -AU - de Braud, Filippo -AU - Garassino, Marina Chiara -TI - Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem -T2 - CURRENT DRUG TARGETS -M3 - Review -AB - Small cell lung cancer is a highly aggressive, difficult to treat neoplasm. Among all lung tumors, small cell lung cancers account for about 20%. Patients typically include heavy smokers in 70s age group, presenting with symptoms such as intrathoracic tumors growth, distant spread or paraneoplastic syndromes at the time of diagnosis. A useful and functional classification divides small cell lung cancers into limited disease and extensive disease. Concurrent chemo-radiotherapy is the standard treatment for limited disease, with improved survival when combined with prophylactic cranial irradiation. Platinum compounds (cisplatin/carboplatin) plus etoposide remain the cornerstone for extensive disease. Nevertheless, despite high chemo-and radio-sensitivity of this cancer, nearly all patients relapse within the first two years and the prognosis is extremely poor. A deeper understanding about small cell lung cancer carcinogenesis led to develop and test a considerable number of new and targeted agents but the results are currently weak or insufficient. To date, small cell lung cancer is still a challenge for researchers. In this review, key aspects of small cell lung cancer management and controversial points of standard and new treatments will be discussed. -PU - BENTHAM SCIENCE PUBL LTD -PI - SHARJAH -PA - EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES -SN - 1389-4501 -SN - 1873-5592 -DA - 2017 -PY - 2017 -VL - 18 -IS - 3 -SP - 341 -EP - 362 -DO - 10.2174/1389450117666160502152331 -AN - WOS:000394387900009 -AD - Ist Nazl Tumori, Fdn IRCCS, Dept Med Oncol, Milan, Italy -AD - Univ Hosp Santa Maria Grazie, Dept Med Oncol, Udine, Italy -M2 - Univ Hosp Santa Maria Grazie -Y2 - 2017-03-29 -ER - - -TY - JOUR -AU - Vafadar, Sam -TI - Immunotherapy for non-small cell lung cancer -T2 - JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS -M3 - Review -AB - Immunotherapy is a new genre of treatment for patients with advanced cancer. Initially approved for use in metastatic melanoma, immunotherapy has found a significant place in treating non-small cell lung cancer (NSCLC). Clinical trials using several combinations of immunotherapy are underway to help to determine the best treatment for specific patient groups. This article reviews approved uses of immunotherapy for NSCLC, immune-related toxicities, and explores the future direction of this treatment. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1547-1896 -SN - 0893-7400 -DA - 2019 SEP -PY - 2019 -VL - 32 -IS - 9 -SP - 37 -EP - 42 -DO - 10.1097/01.JAA.0000569792.99069.e6 -AN - WOS:000506397200008 -AD - H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol, Tampa, FL 33612 USA -Y2 - 2020-01-17 -ER - - -TY - JOUR -AU - Dohopolski, Michael -AU - Gottumukkala, Sujana -AU - Gomez, Daniel -AU - Iyengar, Puneeth -TI - Radiation Therapy in Non-Small-Cell Lung Cancer -T2 - COLD SPRING HARBOR PERSPECTIVES IN MEDICINE -M3 - Article -AB - The management of non-small-cell lung cancer (NSCLC) varies according to stage. Surgical resection is reserved for operable patients with early-stage NSCLC, while high-dose target radiation-stereotactic body radiation therapy (SBRT)-is reserved for patients whose comorbidities prohibit them from a major surgical procedure. The treatment of locally advanced NSCLC (LA-NSCLC) is stratified according to resectability. Those with resectable disease may require additional treatments such as chemotherapy and radiation, while patients with unresectable disease will require definitive chemoradiation therapy with adjuvant durvalumab. Patients with limited metastatic disease benefit from the combination of SBRT and systemic therapy. -PU - COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT -PI - COLD SPRING HARBOR -PA - 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA -SN - 2157-1422 -DA - 2021 OCT -PY - 2021 -VL - 11 -IS - 10 -C7 - a037713 -DO - 10.1101/cshperspect.a037713 -AN - WOS:000703311200002 -AD - UT Southwestern Med Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA -AD - Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA -Y2 - 2021-10-10 -ER - - -TY - JOUR -AU - Chen, Yu -AU - Gao, Min -AU - Huang, Zhaoqin -AU - Yu, Jinming -AU - Meng, Xiangjiao -TI - SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges -T2 - JOURNAL OF HEMATOLOGY & ONCOLOGY -M3 - Review -AB - Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have revolutionized the treatment protocols of a broad spectrum of tumor types, especially non-small-cell lung cancer (NSCLC). Despite the substantial optimism of treatment with PD-1/PD-L1 inhibitors, there is still a large proportion of patients with advanced NSCLC who are resistant to the inhibitors. Preclinical and clinical trials have demonstrated that radiotherapy can induce a systemic antitumor immune response and have a great potential to sensitize refractory "cold" tumors to immunotherapy. Stereotactic body radiation therapy (SBRT), as a novel radiotherapy modality that delivers higher doses to smaller target lesions, has shown favorable antitumor effects with significantly improved local and distant control as well as better survival benefits in various solid tumors. Notably, research has revealed that SBRT is superior to conventional radiotherapy, possibly because of its more powerful immune activation effects. Thus, PD-1/PD-L1 inhibitors combined with SBRT instead of conventional radiotherapy might be more promising to fight against NSCLC, further achieving more favorable survival outcomes. In this review, we focus on the underlying mechanisms and recent advances of SBRT combined with PD-1/PD-L1 inhibitors with an emphasis on some future challenges and directions that warrant further investigation. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1756-8722 -DA - 2020 JUL 28 -PY - 2020 -VL - 13 -IS - 1 -C7 - 105 -DO - 10.1186/s13045-020-00940-z -AN - WOS:000556795800002 -AD - Shandong Univ, Cheeloo Coll Med, Jinan, Shandong, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China -AD - Shandong First Med Univ, Shandong Prov Hosp, Dept Radiol, Jinan, Shandong, Peoples R China -Y2 - 2020-08-19 -ER - - -TY - JOUR -AU - Agustoni, Francesco -AU - Suda, Kenichi -AU - Yu, Hui -AU - Ren, Shengxiang -AU - Rivard, Christopher J. -AU - Ellison, Kim -AU - Caldwell, Charles, Jr. -AU - Rozeboom, Leslie -AU - Brovsky, Kristine -AU - Hirsch, Fred R. -TI - EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis -T2 - CANCER TREATMENT REVIEWS -M3 - Review -AB - Lung cancer still represents one of the most common and fatal neoplasm, accounting for nearly 30% of all cancer-related deaths. Targeted therapies based on molecular tumor features and programmed death-1 (PD-1)/programmed death ligand-1 (PDL-1) blockade immunotherapy have offered new therapeutic options for patients with advanced non-small-cell lung cancer (NSCLC). Activation of the epidermal growth factor receptor (EGFR)pathway promotes tumor growth and progression, including angiogenesis, invasion, metastasis and inhibition of apoptosis, providing a strong rationale for targeting this pathway. EGFR expression is detected in up to 85% of NSCLC and has been demonstrated to be associated with poor prognosis. Two approaches for blocking EGFR signaling are available: prevention of ligand binding to the extracellular domain with monoclonal antibodies (mAbs) and inhibition of the intracellular tyrosine kinase activity with small molecules. There is a strong rationale to consider the tumor's level of EGFR expression as one of the most significant predictive biomarkers in this setting. In this paper we provide an update focusing on the current status of EGFR-directed mAbs use for the treatment of patients with advanced NSCLC, through a review of all clinical trials involving anti-EGFR mAbs in combination with chemotherapy (CT) for advanced disease and with chemo-radiotherapy for stage III disease. Here we also discuss the current status of predictive biomarkers for anti-EGFR mAbs when added to first-line CT in patients with advanced NSCLC. Finally, we focused on the relevance of EGFR fluorescence in situ hybridization (FISH) + and immunohistochemistry (IHC)-Score >= 200 as predictive biomarkers for the selection of patients who would be most likely to derive a clinical benefit from treatment with CT in combination with anti-EGFR mAbs, with particular reference also to histology. -PU - ELSEVIER SCI LTD -PI - London -PA - 125 London Wall, London, ENGLAND -SN - 0305-7372 -SN - 1532-1967 -DA - 2019 JAN -PY - 2019 -VL - 72 -SP - 15 -EP - 27 -DO - 10.1016/j.ctrv.2018.08.002 -AN - WOS:000456221400003 -AD - Univ Colorado, Div Med Oncol, Anschutz Med Campus, Aurora, CO 80045 USA -AD - Kindai Univ, Fac Med, Dept Surg, Div Thorac Surg, Osaka, Japan -AD - Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China -AD - Tongji Univ, Sch Med, Thorac Canc Inst, Shanghai, Peoples R China -Y2 - 2019-01-01 -ER - - -TY - JOUR -AU - Wang, Shuhang -AU - Zimmermann, Stefan -AU - Parikh, Kaushal -AU - Mansfield, Aaron S. -AU - Adjei, Alex A. -TI - Current Diagnosis and Management of Small-Cell Lung Cancer -T2 - MAYO CLINIC PROCEEDINGS -M3 - Review -AB - Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical, and molecular characteristics from non-small-cell lung cancer. SCLC has high metastatic potential, resulting in a clinically poor prognosis. Early concurrent chemo-radiation is the standard of care for limited-stage SCLC (LS-SCLC). Prophylactic cranial irradiation (PCI) is recommended for patients with LS-SCLC without progression of disease after initial therapy. A combination of etoposide and cisplatin or carboplatin remains the mainstay of first-line treatment for ES-SCLC, with the addition of atezolizumab, now becoming standard. Most SCLCs initially respond to therapy but almost invariably recur. Topotecan and amrubicin (in Japan) remain the primary chemotherapy options for relapsed SCLC. Immunotherapy, including nivolumab with or without ipilimumab, is now available for refractory disease. In general, the poor prognosis of SCLC has not improved significantly for more than 3 decades. Recently, next-generation molecular profiling studies have identified new therapeutic targets for SCLC. A variety of proapoptotic agents, compounds capitalizing on DNA-repair defects, immunotherapy agents, and antibody-drug conjugates are being evaluated in SCLC, with a number of them showing early promise. (C) 2019 Mayo Foundation for Medical Education and Research -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0025-6196 -SN - 1942-5546 -DA - 2019 AUG -PY - 2019 -VL - 94 -IS - 8 -SP - 1599 -EP - 1622 -DO - 10.1016/j.mayocp.2019.01.034 -AN - WOS:000478016900030 -AD - Peking Univ, Canc Hosp, Beijing, Peoples R China -AD - CHU Vaudois, Serv Immunooncol, Dept Oncol, Lausanne, Switzerland -AD - Mayo Clin, 200 First St SW, Rochester, MN 55905 USA -Y2 - 2019-08-01 -ER - - -TY - JOUR -AU - Hopstaken, J S -AU - de Ruiter, J C -AU - van Diessen, J N A -AU - Theelen, W S M E -AU - Monkhorst, K -AU - Hartemink, K J -TI - [Treatment of non-small cell lung cancer]. -T2 - Nederlands tijdschrift voor geneeskunde -M3 - Journal Article -M3 - Review -AB - In this review article we discuss the diagnostic workup and current treatment strategies for non-small cell lung cancer (NSCLC). Anatomical resection and systematic lymph node dissection is the recommended treatment for early-stage NSCLC. Stereotactic body radiotherapy (SBRT) is an alternative for non-operable patients. Locally advanced NSCLC could be treated with a combination of chemotherapy, radiotherapy and immunotherapy, and in select cases followed by surgical resection. Treatment for patients with metastasized NSCLC depends on molecular tumor characteristics, PD-L1 expression and could consist of chemotherapy, immunotherapy, targeted therapy or a combination of these modalities. In all stages, best supportive care is an option to consider. Because of the success of immunotherapy and targeted therapy for stage IV NSCLC, numerous trials have started to investigate the efficacy of these modalities in early-stage NSCLC as well, further optimizing treatment strategies for this patient group. -SN - 1876-8784 -DA - 2021 02 04 -PY - 2021 -VL - 165 -AN - MEDLINE:33651512 -AD - Nederlands Kankerinstituut-Antoni van Leeuwenhoek, afd. Chirurgie, Amsterdam (thans: Radboudumc, afd. Chirurgie, Nijmegen). -AD - Nederlands Kankerinstituut-Antoni van Leeuwenhoek, afd. Chirurgie, Amsterdam. -AD - Nederlands Kankerinstituut-Antoni van Leeuwenhoek, afd. Radiotherapie, Amsterdam. -AD - Nederlands Kankerinstituut-Antoni van Leeuwenhoek, afd. Thoracale Oncologie, Amsterdam. -AD - Nederlands Kankerinstituut-Antoni van Leeuwenhoek, afd. Pathologie, Amsterdam. -AD - Contact: K.J. Hartemink (k.hartemink@nki.nl). -Y2 - 2021-03-03 -ER - - -TY - JOUR -AU - Chen, Mo -AU - Wei, Lingyun -AU - Wang, Qin -AU - Xie, Jingyuan -AU - Xu, Ke -AU - Lv, Tangfeng -AU - Song, Yong -AU - Zhan, Ping -TI - Efficacy of different therapies for brain metastases of non-small cell lung cancer: a systematic review and meta-analysis -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Background: As one of the most common causes of death in advanced non-small cell lung cancer (NSCLC), brain metastases (BM) have attracted attention and debate about treatment options, especially for patients with negative driver genes or resistance to targeted agents. Therefore, we conducted a meta-analysis to investigate the potential benefit of different therapeutic regimens for intracranial lesions in non-targeted therapy NSCLC patients. Methods: A comprehensive search was conducted in databases including PubMed, Embase, and the Cochrane Library. The primary endpoints included the intracerebral objective response rate (icORR) and intracerebral progression-free survival (iPFS) in patients with BM. Results: Thirty-six studies involving 1,774 NSCLC patients with baseline BM were included in this meta-analysis. Antitumor agents plus radiotherapy (RT) showed the most significant synergistic effects; the highest pooled icORR that appeared in the combination of immune checkpoint inhibitor (ICI) and RT was 81% [95% confidence interval (CI): 16-100%], and the median iPFS was 7.04 months (95% CI: 2.54-11.55 months). The pooled icORR and median iPFS of RT plus chemotherapy were 46% (95% CI: 34-57%) and 5.7 months (95% CI: 3.90-7.50 months), respectively. The highest median iPFS in nivolumab plus ipilimumab plus chemotherapy was 13.5 months (95% CI: 8.35-18.65 months). ICI plus chemotherapy also showed potent antitumor activity in BM, with a pooled icORR of 56% (95% CI: 29-82%) and a median iPFS of 6.9 months (95% CI: 3.20-10.60 months). Notably, the subgroup analysis indicated that the pooled icORR of patients in programmed cell death-ligand 1 (PD-L1) (>= 50%) who received ICI was 54% (95% CI: 30-77%), and that of patients who received first-line ICI was 69.0% (95% CI: 51-85%). Conclusions: ICI-based combination treatment provides a long-term survival benefit for non-targeted therapy patients, with the most significant benefits observed in improving icORR and prolonging overall survival (OS) and iPFS. In particular, patients who received first-line treatment or who were PD-L1-positive had a more significant survival benefit from aggressive ICI-based therapies. For patients with a PD-L1-negative status, chemotherapy plus RT led to better clinical outcomes than other treatment regimens. These innovative findings could help clinicians to better select therapeutic strategies for NSCLC patients with BM. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2023 APR -PY - 2023 -VL - 12 -IS - 4 -SP - 689 -EP - 706 -DO - 10.21037/tlcr-22-515 -AN - WOS:000971286200001 -C6 - MAR 2023 -AD - Nanjing Med Univ, Jinling Hosp, Dept Resp & Crit Care Med, Nanjing, Peoples R China -AD - Nanjing Univ, Jinling Hosp, Sch Med, Dept Cardiothorac Surg, Nanjing, Peoples R China -AD - Nanjing Univ, Jinling Hosp, Sch Med, Dept Resp & Crit Care Med, Nanjing, Peoples R China -AD - Southeast Univ, Jinling Hosp, Dept Resp & Crit Care Med, Med Sch, Nanjing, Peoples R China -AD - Nanjing Med Univ, Jinling Hosp, Dept Resp & Crit Care Med, Nanjing, Peoples R China -Y2 - 2024-03-02 -ER - - -TY - JOUR -AU - Sugimoto, Akira -AU - Kaneda, Hiroyasu -AU - Yoshimoto, Naoki -AU - Nagata, Kenji -AU - Fujii, Tatsuo -AU - Michimoto, Koichi -AU - Ueno, Shunsuke -AU - Kamimori, Takao -AU - Ishii, Yoshie -AU - Sakagami, Mai -AU - Inokuchi, Haruo -AU - Shibuya, Keiko -AU - Mizutani, Megumi -AU - Nagamine, Hiroaki -AU - Nakahama, Kenji -AU - Matsumoto, Yoshiya -AU - Tani, Yoko -AU - Sawa, Kenji -AU - Kawaguchi, Tomoya -TI - Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer -T2 - SCIENTIFIC REPORTS -M3 - Article -AB - The usefulness of the derived neutrophil-to-lymphocyte ratio (dNLR) and its dynamics before/after durvalumab consolidation therapy to predict safety or efficacy remains unclear. We retrospectively reviewed patients with locally advanced non-small cell lung cancer treated with durvalumab consolidation therapy after chemoradiotherapy (D group) or chemoradiotherapy alone (non-D group) at multiple institutions. We investigated the association between dNLR, or its dynamics, and pneumonitis, checkpoint inhibitor-related pneumonitis (CIP), irAEs, and efficacy. Ninety-eight and fifty-six patients were enrolled in the D and non-D groups, respectively. The dNLR at baseline was significantly lower in patients who experienced irAEs or CIP than in those who did not. The low dNLR group, 28 days following durvalumab consolidation therapy (dNLR28 <= 3), demonstrated longer progression-free survival (PFS) and overall survival (OS) than the high dNLR group (dNLR28 > 3) (PFS, hazard ratio [HR] 0.44, 95% confidence interval [CI] 0.22-0.88, p = 0.020; OS, HR 0.39, 95% CI 0.16-0.94, p = 0.037). Among patients with high dNLR at baseline (dNLR > 3), the dNLR28 <= 3 group showed longer PFS than the dNLR28 > 3 group (p = 0.010). The dNLR is a predictive factor for irAEs and CIP in patients receiving durvalumab consolidation therapy. The dNLR at 28 days after durvalumab consolidation therapy and its dynamics predict favorable outcomes. -PU - NATURE PORTFOLIO -PI - BERLIN -PA - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY -SN - 2045-2322 -DA - 2024 AUG 23 -PY - 2024 -VL - 14 -IS - 1 -C7 - 19596 -DO - 10.1038/s41598-024-70214-y -AN - WOS:001297470500010 -AD - Osaka Metropolitan Univ, Grad Sch Med, Dept Resp Med, 1-4-3 Asahi Machi,Abeno Ku, Osaka 5458585, Japan -AD - Osaka Metropolitan Univ, Grad Sch Med, Dept Resp Med, 1-4-3 Asahi Machi,Abeno Ku, Osaka 5458585, Japan -AD - Osaka Metropolitan Univ, Grad Sch Med, Dept Clin Oncol, 1-4-3 Asahi Machi,Abeno ku, Osaka 5458585, Japan -AD - Ishikiriseiki Hosp, Dept Resp Med, 18-28 Yayoi Cho, Higashiosaka, Osaka 5798026, Japan -AD - Ishikiriseiki Hosp, Dept Radiat Oncol, 18-28 Yayoi Cho, Higashiosaka, Osaka 5798026, Japan -AD - West Japan Railway Co, Osaka Gen Hosp, Dept Resp Med, 1-2-22 Matsuzaki Cho,Abeno Ku, Osaka 5450053, Japan -AD - Osaka Gen Hosp, Dept Radiat Therapy, West Japan Railway Co, 1-2-22 Matsuzaki Cho,Abeno Ku, Osaka 5450053, Japan -AD - Yodogawa Christians Hosp, Dept Resp Med, 1-7-50 Kunijima,Higashiyodogawa Ku, Osaka 5330024, Japan -AD - Yodogawa Christians Hosp, Dept Radiat Therapy, 1-7-50 Kunijima,Higashiyodogawa Ku, Osaka 5330024, Japan -AD - Osaka Metropolitan Univ, Grad Sch Med, Dept Radiat Oncol, 1-4-3 Asahi Machi,Abeno Ku, Osaka 5458585, Japan -M2 - Osaka Metropolitan Univ -M2 - Osaka Metropolitan Univ -M2 - Osaka Metropolitan Univ -M2 - Ishikiriseiki Hosp -M2 - Ishikiriseiki Hosp -M2 - Yodogawa Christians Hosp -M2 - Yodogawa Christians Hosp -M2 - Osaka Metropolitan Univ -Y2 - 2024-09-06 -ER - - -TY - JOUR -AU - Perez, B. A. -AU - Kim, S. -AU - Dilling, T. J. -AU - Latifi, K. -AU - Rose, T. -AU - Lannon, A. -AU - Macmillan, G. -AU - Grass, G. D. -AU - Chiappori, A. -AU - Haura, E. B. -AU - Creelan, B. -AU - Gray, J. -AU - Tanvetyanon, T. -AU - Shafique, M. -AU - Saltos, A. N. -AU - Rosenberg, S. A. -AU - Schell, M. -AU - Antonia, S. J. -TI - A Prospective Single Arm Phase I/II Study: Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 61st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - Chicago, IL -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2019 SEP 1 -PY - 2019 -VL - 105 -IS - 1 -MA - 73 -SP - S36 -EP - S36 -DO - 10.1016/j.ijrobp.2019.06.452 -AN - WOS:000485671502484 -AD - H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL USA -Y2 - 2019-09-30 -ER - - -TY - JOUR -AU - Lechpammer, Mirna -AU - Rao, Rohan -AU - Shah, Sanjit -AU - Mirheydari, Mona -AU - Bhattacharya, Debanjan -AU - Koehler, Abigail -AU - Toukam, Donatien Kamdem -AU - Haworth, Kevin J. -AU - Pomeranz Krummel, Daniel -AU - Sengupta, Soma -TI - Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers -T2 - CANCERS -M3 - Review -AB - Simple Summary The poor prognosis for glioblastoma (GBM) despite the existence of a standard-of-care treatment of resection, radiotherapy, and adjuvant chemotherapy has necessitated the exploration of other therapeutic avenues. One particularly promising avenue is an immunotherapeutic approach in which the body ' s immune system is artificially stimulated to directly identify and attack the tumor cells. A variety of methods including immune checkpoint inhibition, T-cell transfer, vaccination, and a viral approach are being developed for GBM. Barriers such as tumor heterogeneity, the physical blood-brain barrier, the immunosuppressive nature of GBM, and the limited number of identifiable GBM-specific targets have reduced the efficacy of the aforementioned approaches. In the following review, we document the advances in immunotherapy, the barriers to implementation, and the development of a new technology (microbubble-enhanced focused ultrasound) to overcome the physical barriers to immunotherapy. Glioblastoma, or glioblastoma multiforme (GBM, WHO Grade IV), is a highly aggressive adult glioma. Despite extensive efforts to improve treatment, the current standard-of-care (SOC) regimen, which consists of maximal resection, radiotherapy, and temozolomide (TMZ), achieves only a 12-15 month survival. The clinical improvements achieved through immunotherapy in several extracranial solid tumors, including non-small-cell lung cancer, melanoma, and non-Hodgkin lymphoma, inspired investigations to pursue various immunotherapeutic interventions in adult glioblastoma patients. Despite some encouraging reports from preclinical and early-stage clinical trials, none of the tested agents have been convincing in Phase III clinical trials. One, but not the only, factor that is accountable for the slow progress is the blood-brain barrier, which prevents most antitumor drugs from reaching the target in appreciable amounts. Herein, we review the current state of immunotherapy in glioblastoma and discuss the significant challenges that prevent advancement. We also provide thoughts on steps that may be taken to remediate these challenges, including the application of ultrasound technologies. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2022 APR -PY - 2022 -VL - 14 -IS - 7 -C7 - 1627 -DO - 10.3390/cancers14071627 -AN - WOS:000782031700001 -AD - Fdn Med Inc, Cambridge, MA 02141 USA -AD - NYU, Dept Biochem & Mol Pharmacol, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA -AD - Univ Cincinnati, Coll Med, Dept Neurol & Rehabil Med, Cincinnati, OH 45267 USA -AD - Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA -AD - Univ Cincinnati, Coll Med, Dept Internal Med, Div Cardiovasc Hlth & Dis, Cincinnati, OH 45267 USA -Y2 - 2022-04-24 -ER - - -TY - JOUR -AU - Nagano, Tatsuya -AU - Tachihara, Motoko -AU - Nishimura, Yoshihiro -TI - Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer -T2 - CURRENT CANCER DRUG TARGETS -M3 - Review -AB - Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancers. Indeed, gefitinib, which was the first molecular targeted therapeutic agent, has actually doubled the survival time of NSCLC patients. Vigorous efforts of clinicians and researchers have revealed that lung cancer develops through the activating mutations of many driver genes including the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROSI), v-Raf murine sarcoma viral oncogene homolog B (BRAF), and rearranged during transfection (RET) genes. Although ALK, ROS1, and RET are rare genetic abnormalities, corresponding tyrosine kinase inhibitors (TKIs) can exert dramatic therapeutic effects. In addition to anticancer drugs targeting driver genes, bevacizumab specifically binds to human vascular endothelial growth factor (VEGF) and blocks the VEGF signaling pathway. The VEGF signal blockade suppresses angiogenesis in tumor tissues and inhibits tumor growth. In this review, we also explore immunotherapy, which is a promising new NSCLC treatment approach. In general, antitumor immune responses are suppressed in cancer patients, and cancer cells escape from the immune surveillance mechanism. Immune checkpoint inhibitors (ICIs) are antibodies that target the primary escape mechanisms, immune checkpoints. Patients who respond to ICIs are reported to experience long-lasting therapeutic effects. A wide range of clinical approaches, including combination therapy involving chemotherapy or radiation plus adjuvant therapy, are being developed. -PU - BENTHAM SCIENCE PUBL LTD -PI - SHARJAH -PA - EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES -SN - 1568-0096 -SN - 1873-5576 -DA - 2019 -PY - 2019 -VL - 19 -IS - 8 -SP - 595 -EP - 630 -DO - 10.2174/1568009619666181210114559 -AN - WOS:000484772200001 -AD - Kobe Univ, Dept Internal Med, Div Resp Med, Grad Sch Med, Kobe, Hyogo, Japan -Y2 - 2019-09-23 -ER - - -TY - JOUR -AU - Sekine, Ikuo -TI - Clinical development of immune checkpoint inhibitors in Japan-the same goal, different paths -T2 - JAPANESE JOURNAL OF CLINICAL ONCOLOGY -M3 - Editorial Material -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 0368-2811 -SN - 1465-3621 -DA - 2023 OCT 4 -PY - 2023 -VL - 53 -IS - 10 -SP - 873 -EP - 874 -DO - 10.1093/jjco/hyad085 -AN - WOS:001093269300001 -C6 - AUG 2023 -AD - Univ Tsukuba, Inst Med, Dept Med Oncol, Tennodai 1-1-1, Tsukuba, Ibaraki 3058575, Japan -Y2 - 2023-11-11 -ER - - -TY - JOUR -AU - Seo, Bo Mi -AU - Choi, Jiin -AU - Chang, Boksoon -AU - Kim, Bo-Guen -AU - Park, Tai Sun -AU - Lee, Hyun -AU - Moon, Ji-Yong -AU - Kim, Sang-Heon -AU - Kim, Tae-Hyung -AU - Yoo, Seung-Jin -AU - Park, Hae Jin -AU - Yoon, Ho Joo -AU - Sohn, Jang Won -AU - Lee, Seung Hyeun -AU - Park, Dong Won -TI - Clinical significance of the advanced lung cancer inflammation index in patients with limited-stage small cell lung cancer treated with chemoradiotherapy -T2 - SCIENTIFIC REPORTS -M3 - Article -AB - The aim of the study was to investigate the prognostic significance of the advanced lung cancer inflammation index (ALI) in patients with limited-stage small-cell lung cancer (LS-SCLC) undergoing definite chemo-radiotherapy (CRT). We included 87 patients with LS-SCLC from South Korea, treated between 2005 and 2019 with definite CRT. ALI was calculated using body mass index, serum albumin, and neutrophil-lymphocyte ratio. We categorized 38 patients into the high ALI group (ALI >= 44.3) and 48 into the low ALI group (ALI<44.3). Patients in the high ALI group exhibited longer overall survival (OS) than patients in the low ALI group. In multivariate analysis, prophylactic cranial irradiation (hazard ratio [HR]=0.366, 95% confidence interval [CI] 0.20-0.66, P=0.0008), and high ALI (HR=0.475, 95% CI 0.27-0.84, P=0.0103) were identified as independent prognostic factors for predicting better OS. Notably, a high ALI score was particularly indicative of longer survival in patients treated with the combination of etoposide and cisplatin. In conclusion, this study demonstrated that a high pretreatment ALI was significantly associated with better OS in patients with LS-SCLC undergoing definite CRT. This suggests that ALI could be a useful tool for predicting prognosis and guiding chemotherapy regimen selections in clinical practice for LS-SCLC. -PU - NATURE PORTFOLIO -PI - BERLIN -PA - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY -SN - 2045-2322 -DA - 2024 MAY 6 -PY - 2024 -VL - 14 -IS - 1 -C7 - 10347 -DO - 10.1038/s41598-024-61145-9 -AN - WOS:001253949600091 -AD - Hanyang Univ, Dept Internal Med, Coll Med, 222-1 Wangsimni Ro, Seoul 04763, South Korea -AD - Seoul Natl Univ Hosp, Off Hosp Informat, Seoul, South Korea -AD - Kyung Hee Univ, Div Pulm Allergy & Crit Care Med, Dept Internal Med, Coll Med, Kyungheedae Ro 23, Seoul 02447, South Korea -AD - Hanyang Univ, Dept Radiol, Coll Med, Seoul, South Korea -AD - Hanyang Univ, Dept Radiat Oncol, Coll Med, Seoul, South Korea -Y2 - 2024-07-10 -ER - - -TY - JOUR -AU - Soffietti, Riccardo -AU - Trevisan, Elisa -AU - Ruda, Roberta -TI - Targeted therapy in brain metastasis -T2 - CURRENT OPINION IN ONCOLOGY -M3 - Review -AB - Purpose of reviewTo review the state of the art and new developments in the field of targeted agents for brain metastases.Recent findingsThe huge amount of information on new molecular compounds and the advances in understanding the molecular pathways that mediate brain colonization have led to an increase of interest in preclinical and clinical investigations in the field of brain metastases. Targeted therapies can be employed either on established brain metastases or in a prevention setting. Targeting angiogenesis is an attractive approach. Up to date, large clinical trial datasets have shown that antiangiogenic agents do not increase the risk of bleeding into the brain. Bevacizumab (an anti-VEGF agent) is undergoing investigation in clinical trials on brain metastases from non-small cell lung cancer (NSCLC), breast cancer and melanoma. Sunitinib, a multitarget small molecule tyrosine kinase inhibitor (TKI), is a promising agent in brain metastases from renal cell cancer. The EGFR inhibitors gefitinib and erlotinib have a definite activity in brain metastases from NSCLC with activating EGFR mutations. Regarding HER2-positive breast cancer patients with established brain metastases, lapatinib (small molecule TKI) seems particularly active in association with capecitabine. Lapatinib alone is attractive in the prevention setting. Brain metastases from melanoma with BRAF V600E mutations respond to a specific inhibitor, such as vemurafenib. The immunomodulator ipilimumab is also active on brain metastases from melanoma.SummaryThe use of targeted agents in brain metastases from solid tumors is promising. The setting of prevention will be probably expanded in the next years. Well designed clinical trials with proper endpoints are needed. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1040-8746 -SN - 1531-703X -DA - 2012 NOV -PY - 2012 -VL - 24 -IS - 6 -SP - 679 -EP - 686 -DO - 10.1097/CCO.0b013e3283571a1c -AN - WOS:000310361500012 -AD - Univ & San Giovanni Battista Hosp, Div Neurooncol, Dept Neurosci, I-10126 Turin, Italy -Y2 - 2012-11-28 -ER - - -TY - JOUR -AU - Reck, Martin -AU - Rabe, Klaus F. -TI - Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer -T2 - NEW ENGLAND JOURNAL OF MEDICINE -M3 - Review -PU - MASSACHUSETTS MEDICAL SOC -PI - WALTHAM -PA - WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA -SN - 0028-4793 -SN - 1533-4406 -DA - 2017 AUG 31 -PY - 2017 -VL - 377 -IS - 9 -SP - 849 -EP - 861 -DO - 10.1056/NEJMra1703413 -AN - WOS:000408626400008 -AD - LungenClin Grosshansdorf, Grosshansdorf, Germany -AD - Airway Res Ctr North, Grosshansdorf, Germany -AD - German Ctr Lung Res, Giessen, Germany -AD - Univ Lubeck, Lubeck, Germany -AD - Christian Albrechts Univ Kiel, Kiel, Germany -M2 - Airway Res Ctr North -M2 - German Ctr Lung Res -Y2 - 2017-08-31 -ER - - -TY - JOUR -AU - Wang, Yimeng -AU - Wang, Yao -AU - Yu, Jinming -AU - Meng, Xiangjiao -TI - The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues -T2 - CANCER LETTERS -M3 - Article -AB - The treatment efficacy for patients with unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC) stagnated for a long time until the advent of immunotherapy. Immune checkpoint inhibitors, particularly programmed cell death protein 1/programmed death-ligand 1 inhibitors, have thrived, reshaping the treatment landscape for patients with lung cancer. Based on the results of the PACIFIC trial, concurrent chemoradiotherapy followed by durvalumab has become the standard of care for patients with unresectable LA-NSCLC; however, numerous issues are yet to be resolved. Currently, several clinical trials are exploring an optimal treatment paradigm, and we have summarized them for comparison to eliminate barriers. In addition, we discuss better predictive biomarkers, therapeutic options for specific populations, and other challenges to identify directions for future research design. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0304-3835 -SN - 1872-7980 -DA - 2022 NOV 28 -PY - 2022 -VL - 551 -C7 - 215947 -DO - 10.1016/j.canlet.2022.215947 -AN - WOS:000877713800005 -C6 - OCT 2022 -AD - Shandong First Med Univ, Dept Radiat Oncol, Shandong Canc Hosp, Jinan, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Shandong Prov Key Lab Radiat Oncol, Jinan, Shandong, Peoples R China -AD - Chinese Acad Med Sci, Res Unit Radiat Oncol, Jinan, Shandong, Peoples R China -Y2 - 2022-11-13 -ER - - -TY - JOUR -AU - Hasegawa, Tsukasa -AU - Ariyasu, Ryo -AU - Tanaka, Hisashi -AU - Saito, Ryota -AU - Kawashima, Yosuke -AU - Horiike, Atsushi -AU - Sakatani, Toshio -AU - Tozuka, Takehiro -AU - Shiihara, Jun -AU - Saiki, Masafumi -AU - Tambo, Yuichi -AU - Sonoda, Tomoaki -AU - Miyazaki, Akito -AU - Uematsu, Shinya -AU - Tsuchiya-Kawano, Yuko -AU - Yanagitani, Noriko -AU - Nishino, Makoto -TI - Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02) -T2 - CANCER CHEMOTHERAPY AND PHARMACOLOGY -M3 - Article -AB - PurposeFor patients with locally advanced non-small-cell lung cancer (LA-NSCLC) that progressed after definitive chemoradiotherapy (CRT) and durvalumab consolidation therapy, no subsequent standard treatment exists. The type of treatment selected for each timing of disease progression and its efficacy have not been investigated.MethodsWe retrospectively enrolled patients with LA-NSCLC or inoperable NSCLC that progressed after definitive CRT and durvalumab consolidation therapy at 15 Japanese institutions. Patients were classified into the following: Early Discontinuation group (disease progression within 6 months after durvalumab initiation), Late Discontinuation group (disease progression from 7 to 12 months after durvalumab initiation), and Accomplishment group (disease progression from 12 months after durvalumab initiation).ResultsAltogether, 127 patients were analyzed, including 50 (39.4%), 42 (33.1%) and 35 (27.5%) patients from the Early Discontinuation, Late Discontinuation, and Accomplishment groups, respectively. Subsequent treatments were Platinum plus immune checkpoint inhibitors (ICI) in 18 (14.2%), ICI in 7 (5.5%), Platinum in 59 (46.4%), Non-Platinum in 35 (27.6%), and tyrosine kinase inhibitor in 8 (6.3%) patients. In the Early Discontinuation, Late Discontinuation, and Accomplishment groups, 4 (8.0%), 7 (16.7%), and 7 (20.0%) patients were receiving Platinum plus ICI; 21 (42.0%), 22 (52.4%), and 16 (45.7%) were receiving Platinum, and 20 (40.0%), 8 (19.0%), and 7 (20.0%) were receiving Non-Platinum, respectively. No significant difference in progression-free survival was observed in the timing of disease progression.ConclusionIn patients with LA-NSCLC hat progressed after definitive CRT and durvalumab consolidation therapy, subsequent treatment may change depending on the timing of disease progression. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 0344-5704 -SN - 1432-0843 -DA - 2023 JUL -PY - 2023 -VL - 92 -IS - 1 -SP - 29 -EP - 37 -DO - 10.1007/s00280-023-04547-2 -AN - WOS:000994560000001 -C6 - MAY 2023 -AD - Jikei Univ, Dept Internal Med, Div Resp Dis, Daisan Hosp, Tokyo, Japan -AD - Canc Inst Hosp Japanese Fdn Canc Res, Dept Thorac Med Oncol, Tokyo, Japan -AD - Hirosaki Univ, Dept Resp Med, Grad Sch Med, Hirosaki, Japan -AD - Tohoku Univ Hosp, Dept Resp Med, Sendai, Japan -AD - Sendai Kousei Hosp, Dept Pulm Med, Sendai, Japan -AD - Showa Univ, Dept Med, Div Med Oncol, Sch Med, Tokyo, Japan -AD - NTT Med Ctr, Div Resp, Tokyo, Japan -AD - Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan -AD - Jichi Med Univ, Saitama Med Ctr, Dept Pulm Med, Saitama, Japan -AD - Univ Yamanashi, Grad Sch Med, Dept Resp Med, Yamanashi, Japan -AD - Kanazawa Univ, Dept Resp Med, Kanazawa, Japan -AD - Univ Fukui, Fac Med Sci, Dept Internal Med 3, Fukui, Japan -AD - Natl Hosp Org Osaka Toneyama Med Ctr, Dept Thorac Oncol, Osaka, Japan -AD - Osaka Red Cross Hosp, Dept Resp Med, Osaka, Japan -AD - Kitakyushu Municipal Med Ctr, Dept Resp Med, Kitakyushu, Japan -M2 - Natl Hosp Org Osaka Toneyama Med Ctr -M2 - Kitakyushu Municipal Med Ctr -Y2 - 2023-06-03 -ER - - -TY - JOUR -AU - Joy, Anil A. -AU - Butts, Charles A. -TI - Extending Outcomes: Epidermal Growth Factor Receptor-Targeted Monoclonal Antibodies in Non-Small-Cell Lung Cancer -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - The epidermal growth factor receptor (EGFR) pathway plays an important part in the formation of many epithelial malignancies and has been the target of intensive drug development. Although the small-molecule EGFR tyrosine kinase inhibitors (TKIs) have an established role as single-agent therapy in the second- or third-line treatment of patients with advanced non-small-cell lung cancer (NSCLC), they have failed to demonstrate any additive benefit when combined with standard cytotoxic chemotherapy. Monoclonal antibodies (MoAbs) to EGFR are a distinct class of agents that differ significantly from the TKIs in their interaction with the EGFR pathway. A number of MoAbs targeting EGFR are currently in development and their clinical usefulness in the treatment of NSCLC is discussed, with particular attention given to cetuximab. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2009 MAR -PY - 2009 -VL - 10 -SP - S24 -EP - S29 -DO - 10.3816/CLC.2009.s.004 -AN - WOS:000264789000004 -AD - Univ Alberta, Dept Oncol, Edmonton, AB, Canada -Y2 - 2009-03-01 -ER - - -TY - JOUR -AU - Jabbour, S. K. -AU - Cho, B. C. -AU - Bria, E. -AU - Kato, T. -AU - Bhosle, J. -AU - Gainor, J. F. -AU - Reguart, N. -AU - Wang, L. -AU - Morgensztern, D. -AU - Gurary, E. B. -AU - Ashraf, T. B. -AU - Lara-Guerra, H. -AU - Reck, M. -TI - KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Durvalumab in Unresectable, Locally Advanced, Stage III Non-Small-Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 2909 -SP - E440 -EP - E441 -AN - WOS:000715803800905 -AD - Rutgers State Univ, Robert Wood Johnson Med Sch, Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA -AD - Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea -AD - Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy -AD - Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan -AD - Royal Marsden Hosp, Lung Unit, Sutton, Surrey, England -AD - Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02115 USA -AD - Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain -AD - Chinese Acad Med Sci, Shenzhen Hosp, Canc Hosp, Shenzhen, Peoples R China -AD - Washington Univ, Siteman Canc Ctr, St Louis, MO 63110 USA -AD - Merck & Co Inc, Kenilworth, NJ USA -AD - German Ctr Lung Res DZL, Airway Res Ctr North ARCN, LungenClin Grosshansdorf, Grosshansdorf, Germany -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - van den Bulk, Jitske -AU - Verdegaal, Els Me -AU - de Miranda, Noel Fcc -TI - Cancer immunotherapy: broadening the scope of targetable tumours. -T2 - Open biology -M3 - Journal Article -M3 - Research Support, Non-U.S. Gov't -M3 - Review -AB - Cancer immunotherapy has experienced remarkable advances in recent years. Striking clinical responses have been achieved for several types of solid cancers (e.g. melanoma, non-small cell lung cancer, bladder cancer and mismatch repair-deficient cancers) after treatment of patients with T-cell checkpoint blockade therapies. These have been shown to be particularly effective in the treatment of cancers with high mutation burden, which places tumour-mutated antigens (neo-antigens) centre stage as targets of tumour immunity and cancer immunotherapy. With current technologies, neo-antigens can be identified in a short period of time, which may support the development of complementary, personalized approaches that increase the number of tumours amenable to immunotherapeutic intervention. In addition to reviewing the state of the art in cancer immunotherapy, we discuss potential avenues that can bring the immunotherapy revolution to a broader patient group including cancers with low mutation burden. -SN - 2046-2441 -DA - 2018 06 -PY - 2018 -VL - 8 -IS - 6 -DO - 10.1098/rsob.180037 -AN - MEDLINE:29875199 -AD - Department of Pathology, LUMC, Leiden, The Netherlands. -AD - Department of Clinical Oncology, LUMC, Leiden, The Netherlands. -AD - Department of Pathology, LUMC, Leiden, The Netherlands n.f.de_miranda@lumc.nl. -Y2 - 2018-01-01 -ER - - -TY - JOUR -AU - Heigener, David F. -AU - Reck, Martin -TI - Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure? -T2 - DRUGS -M3 - Review -AB - Immune checkpoint inhibition of programmed-death receptor 1 (PD-1) or its ligand (PD-L1) has become a standard in the treatment of metastatic non-small cell lung cancer, either as monotherapy or in combination. Recently, it could be shown that immunotherapy works as consolidation after chemoradiotherapy in locally advanced disease if the tumours express PD-L1. A significant and meaningful survival benefit for consolidation with durvalumab after chemoradiotherapy compared to chemoradiotherapy alone was observed in the PACIFIC trial. In addition, there is a growing body of evidence that this treatment modality is also effective in a neoadjuvant setting in early stages, whereas the role as adjuvant treatment after surgery needs to be determined. The impact of combination therapies in non-metastatic stages-either neoadjuvant or adjuvant-needs to be evaluated in future trials. It is yet unclear whether PD-L1 and tumour mutational burden are predictive biomarkers as randomised trials are missing. -PU - ADIS INT LTD -PI - NORTHCOTE -PA - 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND -SN - 0012-6667 -SN - 1179-1950 -DA - 2019 DEC -PY - 2019 -VL - 79 -IS - 18 -SP - 1937 -EP - 1945 -DO - 10.1007/s40265-019-01222-w -AN - WOS:000500830300002 -AD - Helios Klin Schleswig, Dept Pulm Med, Schleswig, Germany -AD - Univ Kiel, Sch Med, Kiel, Germany -AD - LungenClin Grosshansdorf, Dept Oncol, Woehrendamm 80, Grosshansdorf, Germany -AD - German Ctr Lung Res DZL, Airway Res Ctr North, Grosshansdorf, Germany -M2 - German Ctr Lung Res DZL -Y2 - 2019-12-18 -ER - - -TY - JOUR -AU - Gridelli, Cesare -AU - Ascierto, Paolo A. -AU - Barberis, Massimo C. P. -AU - Felip, Enriqueta -AU - Garon, Edward B. -AU - O'brien, Mary -AU - Senan, Suresh -AU - Casaluce, Francesca -AU - Sgambato, Assunta -AU - Papadimitrakopoulou, Vali -AU - De Marinis, Filippo -TI - Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology -T2 - EXPERT OPINION ON BIOLOGICAL THERAPY -M3 - Review -AB - Introduction: The potential long term survival gain, related to immune adaptability and memory, the potential activity across multiple tumour types through targeting the immune system, and the opportunity for combinations offered by the unique mechanism of actions and safety profile of these new agents, all support the role of immunotherapy in the cancer treatment pathway or paradigm.Areas covered: The authors discuss the recent advances in the understanding of immunology and antitumor immune responses that have led to the development of new immunotherapies, including monoclonal antibodies that inhibit immune checkpoint pathways, such as Programmed Death-1 (PD-1) and Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4). Currently, two PD-1 inhibitors are available in clinical practice for treatment of advanced non-small cell lung cancer (NSCLC): nivolumab and pembrolizumab.Expert opinion: Ongoing research will dictate future strategies, including the potential incorporation of immunotherapy in stage dependent treatment settings (early stage locally advanced disease and first line therapy for metastatic disease). Immunotherapy combinations are promising avenues, and careful selection of patients, doses of each agent and information supporting strategies (i.e. concomitant or sequential) is still needed. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1471-2598 -SN - 1744-7682 -DA - 2016 -PY - 2016 -VL - 16 -IS - 12 -SP - 1479 -EP - 1489 -DO - 10.1080/14712598.2016.1234602 -AN - WOS:000387445600004 -AD - SG Moscati Hosp, Div Med Oncol, Avellino, Italy -AD - Fdn G Pascale, Canc Immunotherapy & Innovat Therapy, Ist Nazl Tumori, Melanoma Unit, Naples, Italy -AD - European Inst Oncol, Pathol, Milan, Italy -AD - Vall dHebron Univ Hosp, Dept Oncol, Lung Canc Unit, Barcelona, Spain -AD - Univ Calif Los Angeles, David Geffen Sch Med, Dept Hematol Oncol, Los Angeles, CA 90095 USA -AD - Royal Marsden NHS Fdn Trust, Dept Med, London, England -AD - Vrije Univ Amsterdam, Med Ctr, Dept Radiat Oncol, Amsterdam, Netherlands -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA -AD - European Inst Oncol, Thorac Div, Dept Med Oncol, Milan, Italy -Y2 - 2016-11-30 -ER - - -TY - JOUR -AU - Sa, Huanlan -AU - Song, Peng -AU - Ma, Kewei -AU - Gao, Yong -AU - Zhang, Li -AU - Wang, Deqiang -TI - Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer -T2 - ONCOTARGETS AND THERAPY -M3 - Review -AB - Targeted therapy and immunotherapy have changed the treatment modes for advanced non-small cell lung cancer (NSCLC), moving from second-line to first-line treatment and significantly extending patients' survival. Surgery and chemoradiotherapy remain the main treatment options for patients with locally advanced lung cancer, but recurrence and metastasis still occur in some patients. The survival rates of conventional perioperative chemotherapy among NSCLC patients have increased by only 5%. Therefore, more studies have begun to explore targeted and immune neoadjuvant/adjuvant therapies in early-stage and locally advanced NSCLC, and the relevant clinical research data have shown good efficacy and safety profiles. This article summarizes several clinical studies of critical importance. -PU - DOVE MEDICAL PRESS LTD -PI - ALBANY -PA - PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND -SN - 1178-6930 -DA - 2019 -PY - 2019 -VL - 12 -SP - 8151 -EP - 8159 -DO - 10.2147/OTT.S222412 -AN - WOS:000489295400004 -AD - Binzhou Med Univ, Affiliated Hosp, Dept Pain Management, Binzhou 256603, Peoples R China -AD - Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Resp Med, Beijing 100010, Peoples R China -AD - Peking Union Med Coll, Beijing 100010, Peoples R China -AD - Jilin Univ, Hosp 1, Dept Oncol Canc, Canc Ctr, Changchun 130021, Jilin, Peoples R China -Y2 - 2019-01-01 -ER - - -TY - JOUR -AU - Li, Feng -AU - Liao, Binchi -AU - Wang, Ting -AU - Qi, Tingting -AU - Wang, Yixin -TI - Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment -T2 - FRONTIERS IN PHARMACOLOGY -M3 - Review -AB - PD-1/PD-L1 play key roles in tumor immune escape and the formation of the tumor microenvironment, and are closely related to the generation and development of tumors. Blocking the PD-1/PD-L1 pathway can reshape the tumor microenvironment or block the formation of the tumor microenvironment and enhance endogenous antitumor immune response. Clinical trials show that the treatment of non-small cell lung cancer (NSCLC) with PD-1/PD-L1 inhibitors has significant advantages. The review briefly describes these basic principles of the PD-1/PD-L1 pathway and action mechanism in the treatment of NSCLC. A summary of global PD-1/PD-L1 clinical trials and five PD-1/PD-L1 inhibitors approved by FDA, EMA and NMPA for advanced NSCLC were analyzed. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1663-9812 -DA - 2022 JUN 16 -PY - 2022 -VL - 13 -C7 - 918709 -DO - 10.3389/fphar.2022.918709 -AN - WOS:000819183300001 -AD - Univ Elect Sci & Technol China, Sichuan Canc Hosp, Sch Med, Canc Hosp, Chengdu, Peoples R China -AD - Univ Elect Sci & Technol China, Sch Med, Chengdu, Peoples R China -AD - Natl Med Prod Adm, Inst Execut Dev, Beijing, Peoples R China -M2 - Natl Med Prod Adm -Y2 - 2022-07-10 -ER - - -TY - JOUR -AU - Oh, Sarah -AU - Botros, George N. -AU - Patel, Milan -AU - Haigentz, Missak -AU - Patel, Eshan -AU - Kontopidis, Iaonnis -AU - Langenfeld, John -AU - Deek, Matthew P. -AU - Jabbour, Salma K. -TI - Locally Advanced Lung Cancer -T2 - HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA -M3 - Article -PU - W B SAUNDERS CO-ELSEVIER INC -PI - PHILADELPHIA -PA - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA -SN - 0889-8588 -SN - 1558-1977 -DA - 2023 JUN -PY - 2023 -VL - 37 -IS - 3 -SP - 533 -EP - 555 -DO - 10.1016/j.hoc.2023.02.007 -AN - WOS:001041336300001 -C6 - MAY 2023 -AD - Rutgers State Univ, Rutgers Canc Inst New Jersey, Rutgers Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ USA -AD - Rutgers State Univ, Rutgers Canc Inst New Jersey, Rutgers Robert Wood Johnson Med Sch, Div Thorac Oncol, New Brunswick, NJ USA -AD - Rutgers Canc Inst New Jersey, Div Med Oncol, New Brunswick, NJ USA -AD - Robert Wood Johnson Univ Hosp, Rutgers Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ USA -AD - Rutgers Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08901 USA -Y2 - 2023-08-18 -ER - - -TY - JOUR -AU - Fabian, Alexander -AU - Domschikowski, Justus -AU - Dunst, Juergen -AU - Krug, David -TI - Locally advanced non-small cell lung cancer: radioimmunotherapy as new standard of care? -T2 - PNEUMOLOGE -M3 - Article -AB - Background. Concurrent radiochemotherapy has been established as a treatment standard for patients with inoperable non-small cell lung cancer (NSCLC) since the 1990s. There are potential synergistic effects between radiochemotherapy and immunotherapy. Thus, immune checkpoint inhibitors are increasingly used in patients with metastatic tumors.Objectives. What is the role of radioim-muntherapy in patients with stage III NSCLC?Materials and methods. A semistructured literature search was performed.Results. In this review, the established radiochemotherapy and the current data regarding potential synergisms between radiotherapy and immunotherapy are summarized. In this context, consolidation immunotherapy with durvalumab after chemoradiation offers a significant overall survival benefit as shown by the PACIFIC trial.Conclusion. Immunotherapy with durvalumab as consolidation therapy after concurrent radiochemotherapy represents a new paradigm for patients with stage III NSCLC. This could lead to a rearrangement of the current treatment algorithms for patients with stage III NSCLC, also with respect to surgery. While long-term data are still pending, further clinical studies are currently testing the role of immunotherapy in patients with stage III NSCLC. -PU - SPRINGER HEIDELBERG -PI - HEIDELBERG -PA - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY -SN - 1613-5636 -SN - 1613-6055 -DA - 2019 NOV -PY - 2019 -VL - 16 -IS - 6 -SP - 366 -EP - 372 -DO - 10.1007/s10405-019-0265-3 -AN - WOS:000502007400005 -AD - UKSH, Klin Strahlentherapie, Campus Kiel,Arnold Heller Str 3, D-24105 Kiel, Germany -Y2 - 2019-12-24 -ER - - -TY - JOUR -AU - Marrone, Kristen A. -AU - Brahmer, Julie R. -TI - Using Immune Checkpoint Inhibitors in Lung Cancer -T2 - ONCOLOGY-NEW YORK -M3 - Review -AB - Immune checkpoint inhibition using targeted monoclonal antibodies is changing the treatment paradigm for lung cancer. Approval by the US Food and Drug Administration of two anti-programmed death 1 immune checkpoint inhibitors for second-line treatment of advanced or metastatic non-small-cell lung cancer (NSCLC) has led to increased use of these agents in the clinic. Ongoing clinical trials are evaluating the administration of immune checkpoint inhibitors alone or in combination with each other, and in combination with targeted therapy, radiation therapy, and chemotherapy regimens. Other trials are evaluating these monoclonal antibodies in small-cell lung cancer and across a variety of treatment regimens and disease stages in NSCLC. Ongoing translational work to identify relevant biomarkers will deepen our understanding of when and how to use immune checkpoint agents in our patients with lung cancer. We must continue to improve the cost-benefit ratios for efficacy, safety, and outcomes associated with the use of these medications. This is an exciting time in the field of lung cancer research as we work to understand how best to use this novel class of agents. -PU - UBM MEDICA -PI - NORWALK -PA - 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA -SN - 0890-9091 -DA - 2016 AUG -PY - 2016 -VL - 30 -IS - 8 -SP - 713 -EP - 721 -AN - WOS:000381452700005 -AD - Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Bunting Blaustein Canc Res Bldg,Rm 186, Baltimore, MD 21231 USA -Y2 - 2016-09-28 -ER - - -TY - JOUR -AU - Tariq, Sara -AU - Kim, So Yeon -AU - Novaes, Jose Monteiro de Oliveira -AU - Cheng, Haiying -TI - Update 2021: Management of Small Cell Lung Cancer -T2 - LUNG -M3 - Review -AB - Background Accounting for 14% of lung cancer, small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy with rapid proliferation, early spread, and poor survival. Aim and Methods We provide an overview of recent advances regarding SCLC pathogenesis, subtypes, and treatment development through literature review of key trials. Results There are no validated biomarkers or approved targeted treatments for this overly heterogeneous disease, but recent analyses have identified some promising targets and four major subtypes which may carry unique therapeutic vulnerabilities in SCLC. Treatment wise, only a third of patients present with limited stage SCLC, which can be managed with a combined modality approach with curative intent (usually chemo-radiotherapy, but in some eligible patients, surgery followed by systemic treatment). For advanced or extensive stage SCLC, combined chemotherapy (platinum-etoposide) and immunotherapy (atezolizumab or durvalumab during and after chemotherapy) has become the new standard front-line treatment, with modest improvement in overall survival. In the second-line setting, for disease relapse <= 6 months, topotecan, lurbinectedin, and clinical trials are reasonable treatment options; for disease relapse > 6 months, original regimen, topotecan or lurbinectedin can be considered. Moreover, Trilaciclib, a CD4/CD6 inhibitor, was recently FDA-approved to decrease the incidence of chemotherapy-related myelosuppression in SCLC patients. Conclusions While modest improvements in survival have been made especially in the metastatic setting with chemo-immunotherapy, further research in understanding the biology of SCLC is warranted to develop biomarker-driven therapeutic strategies and combinational approaches for this aggressive disease. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 0341-2040 -SN - 1432-1750 -DA - 2021 DEC -PY - 2021 -VL - 199 -IS - 6 -SP - 579 -EP - 587 -DO - 10.1007/s00408-021-00486-y -AN - WOS:000716896500001 -C6 - NOV 2021 -AD - Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med Oncol, Bronx, NY 10461 USA -AD - Montefiore Med Ctr, Bronx, NY 10461 USA -Y2 - 2021-11-10 -ER - - -TY - JOUR -AU - MCCRACKEN, JD -AU - HEILBRUN, L -AU - WHITE, J -AU - REED, R -AU - SAMSON, M -AU - SAIERS, JH -AU - STEPHENS, R -AU - STUCKEY, WJ -AU - BICKERS, J -AU - LIVINGSTON, R -TI - COMBINATION CHEMOTHERAPY, RADIOTHERAPY, AND BCG IMMUNOTHERAPY IN EXTENSIVE (METASTATIC) SMALL CELL-CARCINOMA OF THE LUNG - A SOUTHWEST ONCOLOGY GROUP-STUDY -T2 - CANCER -M3 - Article -AB - From Nov. 1976 to Nov. 1978, the Southwest Oncology Group [USA] treated 254 patients with extensive (metastatic) small cell carcinoma of the lung with combination chemotherapy [cytoxan, vincristine, methotrexate, 5-fluorouracil, doxorubicin, cyclophosphamide] and radiotherapy with and without BCG immunotherapy. Patients receiving BCG achieved a response rate of 50% vs. those patients not receiving BCG of 46% (P = 0.704). Response duration was 20 wk for the BCG arms and 23 wk for the no-BCG arms; survival was 28 wk for the BCG arms vs. 29 wk for the no-BCG arms. An adverse effect in patients surviving more than 1 yr was detected; those continuing to receive BCG had significantly shorter survival, 60 wk vs. 85 wk (P = 0.019). Toxicities of the programs were not affected by the addition of BCG immunotherapy. BCG immunotherapy probably has no beneficial effect on response rate or duration of response in programs using chemotherapy and radiotherapy for control of metastatic small cell carcinoma of the lung. Because of the adverse effect on long-term survival, the addition of BCG immunotherapy as a treatment modality in this tumor type is not recommended. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0008-543X -SN - 1097-0142 -DA - 1980 -PY - 1980 -VL - 46 -IS - 11 -SP - 2335 -EP - 2340 -AN - WOS:A1980KR85700001 -AD - WAYNE STATE UNIV, DEPT ONCOL, DETROIT, MI 48202 USA -AD - LOUISIANA STATE UNIV, MED CTR, SCH MED, ONCOL SECT, NEW ORLEANS, LA 70112 USA -AD - VET ADM HOSP, DEPT MED ONCOL, ALBUQUERQUE, NM 87108 USA -AD - UNIV KANSAS, MED CTR, DEPT MED, DIV ONCOL, KANSAS CITY, KS 66103 USA -AD - TULANE UNIV, SCH MED, HEMATOL ONCOL SECT, NEW ORLEANS, LA 70118 USA -AD - BROOKE ARMY MED CTR, ONCOL SERV, FT SAM HOUSTON, TX 78234 USA -AD - HENRY FORD HOSP, DEPT THERAPEUT RADIOL, DETROIT, MI 48202 USA -AD - UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA -AD - UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST, SW ONCOL STAT OFF, HOUSTON, TX 77030 USA -AD - CLEVELAND CLIN EDUC FDN, DEPT HEMATOL ONCOL, CLEVELAND, OH 44106 USA -AD - VET ADM HOSP, SAN ANTONIO, TX USA -M2 - WAYNE STATE UNIV -M2 - LOUISIANA STATE UNIV -M2 - VET ADM HOSP -M2 - UNIV KANSAS -M2 - TULANE UNIV -M2 - BROOKE ARMY MED CTR -M2 - HENRY FORD HOSP -M2 - UNIV TEXAS -M2 - UNIV TEXAS -M2 - CLEVELAND CLIN EDUC FDN -M2 - VET ADM HOSP -Y2 - 1980-01-01 -ER - - -TY - JOUR -AU - Yamada, Tadaaki -AU - Uchino, Junji -AU - Chihara, Yusuke -AU - Shimamoto, Takayuki -AU - Iwasaku, Masahiro -AU - Tamiya, Nobuyo -AU - Kaneko, Yoshiko -AU - Kiyomi, Fumiaki -AU - Takayama, Koichi -TI - Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study) -T2 - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY -M3 - Article -AB - Background:In the PACIFIC study, progression-free survival (PFS) and overall survival (OS) of patients with unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC) were prolonged by durvalumab as maintenance therapy after radical concurrent chemoradiotherapy using platinum-based antitumor agents. However, no data were obtained to reveal the efficacy of durvalumab after radiation monotherapy in patients unsuitable for chemoradiotherapy. Here, we describe an ongoing single-arm, prospective, open-label, multicenter phase II trial of durvalumab in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study).Methods:Durvalumab at 10 mg/kg body weight is administered every 2 weeks after radiation therapy until individual patients meet the discontinuation criteria. The treatment duration is up to 12 months. The primary endpoint is the 1-year PFS rate. Secondary endpoints are response rate, PFS, OS, and safety. Durvalumab treatment after radiation monotherapy is expected to prolong 1-year PFS rate and have acceptable adverse events.Discussion:We are conducting an intervention study to investigate the safety and efficacy of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1758-8340 -SN - 1758-8359 -DA - 2020 MAY -PY - 2020 -VL - 12 -C7 - 1758835920927841 -DO - 10.1177/1758835920927841 -AN - WOS:000538872200001 -AD - Kyoto Prefectural Univ Med, Dept Pulm Med, Kamigyo Ku, 465 Kajii Cho, Kyoto 6020857, Japan -AD - Kyoto Prefectural Univ Med, Dept Pulm Med, Kyoto, Japan -AD - Clin Res Support Ctr Kyushu, Stat & Data Ctr, Fukuoka, Japan -M2 - Clin Res Support Ctr Kyushu -Y2 - 2020-06-19 -ER - - -TY - JOUR -AU - Bi, N. -AU - Deng, L. -AU - Hu, X. -AU - Shayan, G. -AU - Zhao, L. -AU - Zhang, L. -AU - Jiang, W. -AU - Zhang, J. -AU - Zhu, X. -AU - Wang, Y. -AU - Ge, H. -AU - Cao, J. -AU - Lin, Q. -AU - Chen, M. -AU - Wang, L. -TI - 30 Gy vs. 45 Gy Consolidative Thoracic Radiation (cTRT) for Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Multicenter, Randomized, Phase 3 Trial -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 208 -SP - S56 -EP - S57 -AN - WOS:001079706803110 -AD - Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Radiat Oncol,Natl Canc Ctr, Beijing, Peoples R China -AD - Chinese Acad Sci, Zhejiang Prov Key Lab Radiat Oncol, Inst Basic Med Sci & Canc Res, Dept Radiat Oncol,Zhejiang Canc Hosp, Hangzhou, Peoples R China -AD - Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Tianjins Clin Res, Tianjin, Peoples R China -AD - Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China -AD - Chinese Acad Med Sci & Peking Union Med Coll, Dept Radiat Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Shenzhen, Peoples R China -AD - Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China -AD - Fudan Univ, Shanghai Med Coll, Shanghai, Peoples R China -AD - Jiangsu Canc Hosp, Nanjing, Peoples R China -AD - Jiangsu Inst Canc Res, Nanjing, Peoples R China -AD - Nanjing Med Univ, Affiliated Canc Hosp, Nanjing, Peoples R China -AD - Air Force Med Ctr, Dept Radiotherapy, Beijing, Peoples R China -AD - Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China -AD - Shanxi Med Univ, Canc Hosp, Chinese Acad Med Sci, Shanxi Prov Canc Hosp,Shanxi Hosp, Taiyuan, Peoples R China -AD - Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China -AD - Zhejiang Canc Hosp, Hangzhou, Peoples R China -AD - Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, Guangzhou, Peoples R China -AD - Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Radiat Oncol,Natl Canc Ctr, Beijing, Peoples R China -AD - Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Radiat Oncol, Natl Canc Ctr, Shenzhen, Peoples R China -AD - Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China -M2 - Air Force Med Ctr -Y2 - 2024-03-02 -ER - - -TY - JOUR -AU - Chaudhary, K. R. -AU - Halmos, B. -AU - Cheng, H. -AU - Cheng, S. K. -TI - Bmi1 Resistance Pathway and Immune Checkpoint Blockade in Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 2893 -SP - E432 -EP - E433 -AN - WOS:000715803800889 -AD - Columbia Univ, Irving Med Ctr, Dept Radiat Oncol, New York, NY USA -AD - Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA -AD - Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA -AD - Columbia Univ, Irving Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Qiu, Guihuan -AU - Wang, Fei -AU - Xie, Xiaohong -AU - Liu, Ting -AU - Zeng, Chen -AU - Chen, Ziyao -AU - Zhou, Maolin -AU - Deng, Haiyi -AU - Yang, Yilin -AU - Lin, Xinqing -AU - Xie, Zhanhong -AU - Sun, Gengyun -AU - Zhou, Chengzhi -AU - Liu, Ming -TI - A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer -T2 - CANCER MEDICINE -M3 - Article -AB - Background: The treatment of extensive stage small-cell lung cancer (ES-SCLC) has only made modest progress in the past decade, with two immune checkpoint inhibitors (ICIs), atezolizumab and durvalumab, approved for the treatment of SCLC by January 2022. However, currently, there is limited real-world data on ES-SCLC patients received immunotherapy.Methods: We retrospectively collected and analyzed the demographic and treatment data of ES-SCLC patients at the First Affiliated Hospital of Guangzhou Medical University from January 2017 to January 2022. Survival and prognosis information was obtained through follow-up.Results: A total of 353 ES-SCLC patients were included, of which 165 received immunotherapy combined with chemotherapy as the first-line (FL) treatment (chemo-immune group), and 188 received chemotherapy (chemotherapy group). The objective response rate (ORR) and disease control rate (DCR) of patients receiving immunotherapy as the FL treatment were better than the chemotherapy group (76.97% vs. 48.40%, p < 0.001, and 83.03% vs. 68.09%, p < 0.001). Moreover, the progression-free survival (PFS) and overall survival (OS) of ES-SCLC patients receiving immunotherapy as the FL treatment were better than the chemotherapy group (6.7 months vs. 5.1 months, p < 0.001, and 12.5 months vs. 11.2 months, p < 0.001). Furthermore, the OS of ES-SCLC patients who received immunotherapy as second-line treatment was better than that in the chemotherapy group (15.9 months vs. 12.9 months, p = 0.036).Conclusion: ICIs combined with chemotherapy as the FL treatment could be beneficial to the ORR, DCR, PFS, and OS of ES-SCLC patients. Furthermore, ES-SCLC patients can benefit from ICIs in the second-line treatment, even if they had not received ICIs in the FL treatment. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2045-7634 -DA - 2023 JUL -PY - 2023 -VL - 12 -IS - 14 -SP - 14881 -EP - 14891 -DO - 10.1002/cam4.5843 -AN - WOS:001031462000001 -C6 - JUL 2023 -AD - Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, Natl Clin Res Ctr Resp Dis,State Key Lab Resp Dis,, Guangzhou, Peoples R China -AD - Anhui Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Hefei, Peoples R China -Y2 - 2023-08-05 -ER - - -TY - JOUR -AU - Li, Mengqian -AU - Gan, Lu -AU - Song, Andrew -AU - Xue, Jianxin -AU - Lu, You -TI - Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy -T2 - BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER -M3 - Review -AB - The combination of programmed cell death 1/programmed cell death ligand 1 blockade and thoracic radiotherapy has become the new standard of care in the treatment of locally advanced non-small-cell lung cancer. The information regarding the pulmonary safety of such therapy remains limited to mostly retrospective studies and case reports with a small portion of data from prospective clinical trials. By analyzing the underlying mechanisms of interactions between radiation and immunotherapy from preclinical data and summarizing safety data from relevant clinical studies with pulmonary toxicity, we believe that longer and rigorous follow-up is warranted, to determine if the combination of such modalities is appropriate for patients without risking undue toxicity. -PU - ELSEVIER SCIENCE BV -PI - AMSTERDAM -PA - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS -SN - 0304-419X -SN - 1879-2561 -DA - 2019 APR -PY - 2019 -VL - 1871 -IS - 2 -SP - 323 -EP - 330 -DO - 10.1016/j.bbcan.2019.02.004 -AN - WOS:000469889900011 -AD - Sichuan Univ, West China Hosp, Ctr Canc, Dept Thorac Oncol, Chengdu, Sichuan, Peoples R China -AD - Sichuan Univ, West China Hosp, Translat Neurosci Ctr, Lab Anesthesia & Crit Care Med, Chengdu, Sichuan, Peoples R China -AD - Thomas Jefferson Univ, Dept Radiat Oncol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA -Y2 - 2019-04-01 -ER - - -TY - JOUR -AU - HOLMES, EC -TI - POSTOPERATIVE CHEMOTHERAPY FOR NON-SMALL-CELL LUNG-CANCER -T2 - CHEST -M3 - Article -AB - The Lung Cancer Study Group has performed a number of postoperative adjuvant trials in patients with resectable non-small-cell lung cancer (NSCLC). Adjuvant cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy was compared with immunotherapy in the treatment of 130 patients with stage II or III adenocarcinoma or large cell undifferentiated carcinoma. Careful intraoperative staging was performed in all patients. Disease-free interval was significantly prolonged in the chemotherapy group (p = 0.032). After 7.5 years of follow-up, the difference in time to recurrence and cancer deaths remains statistically significant. Another study compared CAP chemotherapy plus radiotherapy with radiotherapy alone in advanced stages II and III resected NSCLC. Again, the chemotherapy arm had significantly increased disease-free survival. In a third study, patients with high-risk stage I NSCLC were randomized after surgery to CAP chemotherapy or observation. In this study there was no difference in recurrence-free survival or overall survival. -PU - AMER COLL CHEST PHYSICIANS -PI - NORTHBROOK -PA - 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA -SN - 0012-3692 -DA - 1993 JAN -PY - 1993 -VL - 103 -IS - 1 -SP - S30 -EP - S34 -AN - WOS:A1993KG37700007 -Y2 - 1993-01-01 -ER - - -TY - JOUR -AU - Domingues, Duarte -AU - Turner, Alice -AU - Silva, Maria Dilia -AU - Marques, Dania Sofia -AU - Mellidez, Juan Carlos -AU - Wannesson, Luciano -AU - Mountzios, Giannis -AU - de Mello, Ramon Andrade -TI - Immunotherapy and lung cancer: current developments and novel targeted therapies -T2 - IMMUNOTHERAPY -M3 - Review -AB - Non-small-cell lung cancer (NSCLC) is a highly prevalent and aggressive disease. In the metastatic setting, major advances include the incorporation of immunotherapy and targeted therapies into the clinician's therapeutic armamentarium. Standard chemotherapeutic regimens have long been reported to interfere with the immune response to the tumor; conversely, antitumor immunity may add to the effects of those therapies. The aim of immunotherapy is to specifically enhance the immune response directed to the tumor. Recently, many trials addressed the role of such therapies for metastatic NSCLC treatment: ipilimumab, tremelimumab, nivolumab and lambrolizumab are immunotherapeutic agents of main interest in this field. In addition, anti-tumor vaccines, such as MAGE-A3, Tecetomide, TG4010, CIMAvax, ganglioside vaccines, tumor cell vaccines and dendritic cell vaccines, emerged as potent inducers of immune response against the tumor. The current work aims to address the most recent developments regarding these innovative immunotherapies and their implementation in the treatment of metastatic NSCLC. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1750-743X -SN - 1750-7448 -DA - 2014 -PY - 2014 -VL - 6 -IS - 11 -SP - 1221 -EP - 1235 -DO - 10.2217/imt.14.82 -AN - WOS:000346263600006 -AD - Portuguese Oncol Inst IPO PORTO, Dept Med Oncol, P-4200072 Oporto, Portugal -AD - Hosp Infante Dom Pedro, Dept Med Oncol, Aveiro, Portugal -AD - Univ Otago, Sch Med, Christchurch 8011, New Zealand -AD - Oncol Inst Southern Switzerland IOSI, CH-6500 Bellinzona, Switzerland -AD - Univ Athens, Sch Med, Dept Med Oncol, GR-11527 Athens, Greece -AD - Univ Algarve, Sch Med, Dept Biomed Sci & Med, P-8005139 Faro, Portugal -M2 - Hosp Infante Dom Pedro -Y2 - 2015-01-14 -ER - - -TY - JOUR -AU - Williams, T. M. -AU - Welliver, M. X. -AU - Brownstein, J. M. -AU - Otterson, G. -AU - Owen, D. -AU - Pan, J. -AU - Haglund, K. E. -AU - Shields, P. G. -AU - Bertino, E. M. -AU - Presley, C. -AU - He, K. -AU - Miller, E. D. -AU - Yang, X. -AU - Knopp, M. -AU - Essan, J. Kousou -AU - McElroy, S. -AU - Carbone, D. P. -AU - Bazan, J. G., Jr. -TI - A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC) -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 175 -SP - S90 -EP - S90 -AN - WOS:000715803801516 -AD - City Hope Natl Med Ctr, Dept Radiat Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA -AD - Ohio State Univ, Dept Radiat Oncol, Wexner Med Ctr, Columbus, OH 43210 USA -AD - Ohio State Univ, Columbus, OH 43210 USA -AD - Ohio State Univ, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA -AD - Ohio State Univ, Ctr Biostat, Wexner Med Ctr, Columbus, OH 43210 USA -AD - Ohio State Univ, James Canc Ctr, Columbus, OH 43210 USA -AD - Ohio State Univ, Dept Radiol, Wexner Med Ctr, Columbus, OH 43210 USA -AD - Ohio State Univ, Dept Radiat Oncol, Columbus, OH 43210 USA -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Wakelee, H -AU - Kelly, K -TI - Novel approaches for the treatment of small cell lung cancer -T2 - HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA -M3 - Article -AB - Small cell lung cancer (SCLC) is characterized by its exquisite sensitivity to chemotherapy and radiotherapy. Despite dramatic tumor shrinkage, however, patients are rarely cured and median survival is less than I year for most patients who present with extensive-stage disease (ED) and 18 months for patients with limited-stage disease (LD). Other articles in this issue have detailed current strategies to improve survival by evaluating new cytotoxic agents and radiotherapy techniques. Meanwhile, our growing understanding of the biology of SCLC provides additional targets to exploit for therapeutic benefit [1]. Table I lists molecular abnormalities and their frequency in SCLC [2-24]. In this article, the authors review the current status of biologically targeted agents directed toward several of these abnormalities. -PU - W B SAUNDERS CO-ELSEVIER INC -PI - PHILADELPHIA -PA - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA -SN - 0889-8588 -SN - 1558-1977 -DA - 2004 APR -PY - 2004 -VL - 18 -IS - 2 -SP - 499 -EP - + -DO - 10.1016/j.hoc.2004.01.001 -AN - WOS:000221346600014 -AD - Stanford Univ, Sch Med, Div Oncol, Dept Med, Stanford, CA 94305 USA -AD - Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Dept Med, Denver, CO 80262 USA -Y2 - 2004-04-01 -ER - - -TY - JOUR -AU - Inoue, Hiroto -AU - Ono, Akira -AU - Kawabata, Takanori -AU - Mamesaya, Nobuaki -AU - Kawamura, Takahisa -AU - Kobayashi, Haruki -AU - Omori, Shota -AU - Wakuda, Kazushige -AU - Kenmotsu, Hirotsugu -AU - Naito, Tateaki -AU - Murakami, Haruyasu -AU - Yasui, Kazuaki -AU - Ogawa, Hirofumi -AU - Onoe, Tsuyoshi -AU - Endo, Masahiro -AU - Harada, Hideyuki -AU - Takahashi, Toshiaki -TI - Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer -T2 - INVESTIGATIONAL NEW DRUGS -M3 - Article -AB - Introduction Durvalumab has been shown to confer a survival benefit after definitive chemoradiotherapy in the patients with locally advanced non-small cell lung cancer, but no studies have attempted to identify risk factors for pneumonitis after durvalumab therapy. The purpose of this study was to investigate associations between clinical and radiation dose-volume factors, and the severity of pneumonitis. Methods We retrospectively assessed the cases of 30 patients who had been started on durvalumab therapy between July 2018 and February 2019. In this study we evaluated the percentage of lung volume receiving radiation dose in excess of 20 Gy (V20) as radiation dose-volume factor. We compared V20 and some baseline factors between a grade 0 or 1 (Gr 0/1) pneumonitis group and a grade 2 or more (>= Gr 2) pneumonitis group, and we performed a logistic regression analysis to establish the associations between variables and >= Gr 2 pneumonitis. Results Pneumonitis had developed in 22 patients (73.3%): Gr 1/2/3-5 in 8 (26.7%)/14 (46.7%) /0 (0%), respectively. The difference in V20 between the Gr 0/1 group and Gr 2 group (median: 20.5% vs. 23.5%, p = 0.505) was not statistically significant, and thus V20 was not a risk factor for Gr 2 pneumonitis (odds ratio: 1.047, p = 0.303). None of the clinical factors, including sex, age, smoking history, presence of baseline pneumonitis, type of radiation therapy, location of lesion and facility, were risk factors. Conclusions Our study suggest that the severity of pneumonitis after durvalumab is unrelated to V20 or any of the clinical factors assessed in this study. -PU - SPRINGER -PI - DORDRECHT -PA - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS -SN - 0167-6997 -SN - 1573-0646 -DA - 2020 OCT -PY - 2020 -VL - 38 -IS - 5 -SP - 1612 -EP - 1617 -DO - 10.1007/s10637-020-00917-2 -AN - WOS:000518082000002 -C6 - MAR 2020 -AD - Shizuoka Canc Ctr, Div Thorac Oncol, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan -AD - Shizuoka Canc Ctr, Clin Res Ctr, Shizuoka, Japan -AD - Shizuoka Canc Ctr, Div Radiat Oncol, Shizuoka, Japan -AD - Shizuoka Canc Ctr, Div Diagnost Radiol, Shizuoka, Japan -Y2 - 2020-03-03 -ER - - -TY - JOUR -AU - Bethge, WA -AU - Sandmaier, BM -TI - Targeted cancer therapy using radiolabeled monoclonal antibodies -T2 - TECHNOLOGY IN CANCER RESEARCH & TREATMENT -M3 - Review -AB - Radioimmunotherapy (RIT) combines the advantages of targeted radiation therapy and specific immunotherapy using monoclonal antibodies. RIT can be used either to target tumor cells or to specifically suppress immunocompetent host cells in the setting of allogeneic transplantation. The choice of radionuclide used for RIT depends on its distinct radiation characteristics and the type of malignancy or cells targeted. Beta-emitters with their lower, energy and longer path length are more suitable to target bulky, solid tumors whereas alpha-emitters with their high linear energy transfer and short path length are better suited to target hematopoietic cells (normal or malignant). Different approaches of RIT such as the use of stable radioimmunoconjugates or of pretargeting strategies are available. Encouraging results have been obtained with RIT in patients with hematologic malignancies. The results in solid tumors are somewhat less favorable but new strategies for patients with minimal residual disease using adjuvant and locoregional treatment are evolving. This report outlines basic principles of RIT, gives an overview of available radionuclides and radioimmunoconjugates, and discusses clinical results with special emphasis on their use in hematologic malignancies including use in conditioning regimens for bone marrow transplantation. -PU - SAGE PUBLICATIONS INC -PI - THOUSAND OAKS -PA - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA -SN - 1533-0346 -SN - 1533-0338 -DA - 2005 AUG -PY - 2005 -VL - 4 -IS - 4 -SP - 393 -EP - 405 -DO - 10.1177/153303460500400407 -AN - WOS:000231567400007 -AD - Univ Tubingen, Ctr Med, Dept Hematol & Oncol, D-72076 Tubingen, Germany -AD - Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA -AD - Univ Washington, Dept Med, Seattle, WA 98195 USA -Y2 - 2005-08-01 -ER - - -TY - JOUR -AU - Lu, Shun -AU - Kato, Terufumi -AU - Dong, Xiaorong -AU - Ahn, Myung-Ju -AU - Quang, Le-Van -AU - Soparattanapaisarn, Nopadol -AU - Inoue, Takako -AU - Wang, Chih-Liang -AU - Huang, Meijuan -AU - Yang, James Chih-Hsin -AU - Cobo, Manuel -AU - Ozguroglu, Mustafa -AU - Casarini, Ignacio -AU - Khiem, Dang-Van -AU - Sriuranpong, Virote -AU - Cronemberger, Eduardo -AU - Takahashi, Toshiaki -AU - Runglodvatana, Yotsawaj -AU - Chen, Ming -AU - Huang, Xiangning -AU - Grainger, Ellie -AU - Ghiorghiu, Dana -AU - van der Gronde, Toon -AU - Ramalingam, Suresh S. -TI - Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC -T2 - NEW ENGLAND JOURNAL OF MEDICINE -M3 - Article -AB - Background Osimertinib is a recommended treatment for advanced non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant treatment for resected EGFR-mutated NSCLC. EGFR-tyrosine kinase inhibitors have shown preliminary efficacy in unresectable stage III EGFR-mutated NSCLC. Methods In this phase 3, double-blind, placebo-controlled trial, we randomly assigned patients with unresectable EGFR-mutated stage III NSCLC without progression during or after chemoradiotherapy to receive osimertinib or placebo until disease progression occurred (as assessed by blinded independent central review) or the regimen was discontinued. The primary end point was progression-free survival as assessed by blinded independent central review. Results A total of 216 patients who had undergone chemoradiotherapy were randomly assigned to receive osimertinib (143 patients) or placebo (73 patients). Osimertinib resulted in a significant progression-free survival benefit as compared with placebo: the median progression-free survival was 39.1 months with osimertinib versus 5.6 months with placebo, with a hazard ratio for disease progression or death of 0.16 (95% confidence interval [CI], 0.10 to 0.24; P<0.001). The percentage of patients who were alive and progression free at 12 months was 74% (95% CI, 65 to 80) with osimertinib and 22% (95% CI, 13 to 32) with placebo. Interim overall survival data (maturity, 20%) showed 36-month overall survival among 84% of patients with osimertinib (95% CI, 75 to 89) and 74% with placebo (95% CI, 57 to 85), with a hazard ratio for death of 0.81 (95% CI, 0.42 to 1.56; P=0.53). The incidence of adverse events of grade 3 or higher was 35% in the osimertinib group and 12% in the placebo group; radiation pneumonitis (majority grade, 1 to 2) was reported in 48% and 38%, respectively. No new safety concerns emerged. Conclusions Treatment with osimertinib resulted in significantly longer progression-free survival than placebo in patients with unresectable stage III EGFR-mutated NSCLC. (Funded by AstraZeneca; LAURA ClinicalTrials.gov number, NCT03521154.) -PU - MASSACHUSETTS MEDICAL SOC -PI - WALTHAM -PA - WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA -SN - 0028-4793 -SN - 1533-4406 -DA - 2024 JUN 2 -PY - 2024 -DO - 10.1056/NEJMoa2402614 -AN - WOS:001236894000001 -AD - Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Med Oncol, 241 Huai Hai Rd West, Shanghai, Peoples R China -AD - Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China -AD - Sichuan Univ, West China Hosp, Canc Ctr, Div Thorac Tumor Multimodal Treatment, Chengdu, Peoples R China -AD - Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu, Peoples R China -AD - Univ Chinese Acad Sci, Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc,Canc Hosp,Dept Radiotherapy, Hangzhou, Peoples R China -AD - Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Japan -AD - Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan -AD - Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan -AD - Sungkyunkwan Univ, Samsung Med Ctr, Dept Hematol Oncol, Sch Med, Seoul, South Korea -AD - Hanoi Med Univ, Dept Oncol, Hanoi, Vietnam -AD - Vietnam Natl Lung Hosp, Dept Oncol, Hanoi, Vietnam -AD - Mahidol Univ, Siriraj Hosp, Fac Med, Bangkok, Thailand -AD - Chulalongkorn Univ, Fac Med, Div Med Oncol, Bangkok, Thailand -AD - King Chulalongkorn Mem Hosp, Bangkok, Thailand -AD - Navamindradhiraj Univ, Vajira Hosp, Fac Med, Bangkok, Thailand -AD - Med Coll Chang Gung Univ, Linkou Chang Gung Mem Hosp, Dept Thorac Med, Div Pulm Oncol & Intervent Bronchoscopy, Taoyuan, Taiwan -AD - Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan -AD - Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan -AD - Hosp Univ Reg & Virgen Victoria, Unidad Gest Clin Interctr Oncol Med, Inst Invest Biomed Malaga, Malaga, Spain -AD - Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Internal Med, Div Med Oncol,Clin Trial Unit, Istanbul, Turkiye -AD - Hosp Bernardo Houssay, Serv Oncol, Mar Del Plata, Buenos Aires, Argentina -AD - Ctr Reg Integrado Oncol, Ctr Pesquisa Clin, Fortaleza, Brazil -AD - AstraZeneca, Biometrics, Late Stage Dev, Oncol Res & Dev, Cambridge, England -AD - AstraZeneca, Late Stage Dev, Oncol Res & Dev, Baar, Switzerland -AD - AstraZeneca, Late Stage Dev, Oncol Res & Dev, New York, NY USA -AD - Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Sch Med, 1365 Clifton Rd NE,C-4014E, Atlanta, GA 30322 USA -M2 - Osaka Int Canc Inst -M2 - Vietnam Natl Lung Hosp -M2 - Navamindradhiraj Univ -M2 - Hosp Univ Reg & Virgen Victoria -M2 - Hosp Bernardo Houssay -M2 - Ctr Reg Integrado Oncol -Y2 - 2024-06-07 -ER - - -TY - JOUR -AU - Yamada, Tadaaki -AU - Uchino, Junji -AU - Chihara, Yusuke -AU - Shimamoto, Takayuki -AU - Iwasaku, Masahiro -AU - Tamiya, Nobuyo -AU - Kaneko, Yoshiko -AU - Kiyomi, Fumiaki -AU - Takayama, Koichi -TI - Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). -T2 - Therapeutic advances in medical oncology -M3 - Journal Article -AB - BACKGROUND: In the PACIFIC study, progression-free survival (PFS) and overall survival (OS) of patients with unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC) were prolonged by durvalumab as maintenance therapy after radical concurrent chemoradiotherapy using platinum-based antitumor agents. However, no data were obtained to reveal the efficacy of durvalumab after radiation monotherapy in patients unsuitable for chemoradiotherapy. Here, we describe an ongoing single-arm, prospective, open-label, multicenter phase II trial of durvalumab in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study).METHODS: Durvalumab at 10mg/kg body weight is administered every 2weeks after radiation therapy until individual patients meet the discontinuation criteria. The treatment duration is up to 12months. The primary endpoint is the 1-year PFS rate. Secondary endpoints are response rate, PFS, OS, and safety. Durvalumab treatment after radiation monotherapy is expected to prolong 1-year PFS rate and have acceptable adverse events.DISCUSSION: We are conducting an intervention study to investigate the safety and efficacy of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy. -SN - 1758-8340 -DA - 2020 -PY - 2020 -VL - 12 -SP - 1758835920927841 -EP - 1758835920927841 -DO - 10.1177/1758835920927841 -AN - MEDLINE:32536981 -AD - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. -AD - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto 602-0857, Japan. -AD - Statistics and Data Center, Clinical Research Support Center Kyushu, Fukuoka, Japan. -Y2 - 2020-01-01 -ER - - -TY - JOUR -AU - Melillo, Giovanni -AU - Chand, Vikram -AU - Yovine, Alejandro -AU - Gupta, Ashok -AU - Massacesi, Cristian -TI - Curative-Intent Treatment with Durvalumab in Early-Stage Cancers -T2 - ADVANCES IN THERAPY -M3 - Review -AB - The introduction of immunotherapy has fundamentally transformed the treatment landscape in cancer, providing long-term survival benefit for patients with advanced disease across multiple tumor types, including non-small cell lung cancer (NSCLC). In the placebo-controlled phase 3 PACIFIC trial, the PD-L1 inhibitor durvalumab demonstrated significant improvements in progression-free survival and overall survival in patients with unresectable, stage III NSCLC who had not progressed after platinum-based chemoradiotherapy (CRT). These findings have led to the widespread acceptance of the 'PACIFIC regimen' (durvalumab after CRT) as the standard of care in this setting. Moreover, the PACIFIC trial is the first study to demonstrate a proven survival advantage with an immunotherapy in a curative-intent setting, thereby providing a strong rationale for further investigation of durvalumab in early-stage cancers. Herein, we describe the extensive clinical development program for durvalumab across multiple tumor types in curative-intent settings, outlining the scientific rationale(s) for its use and highlighting the innovative research (e.g., personalized cancer monitoring) advanced by these trials. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 0741-238X -SN - 1865-8652 -DA - 2021 JUN -PY - 2021 -VL - 38 -IS - 6 -SP - 2759 -EP - 2778 -DO - 10.1007/s12325-021-01675-0 -AN - WOS:000642024000001 -C6 - APR 2021 -AD - AstraZeneca, Gaithersburg, MD 20878 USA -AD - AstraZeneca, Cambridge, England -M2 - AstraZeneca -Y2 - 2021-05-10 -ER - - -TY - JOUR -AU - Rallis, Kathrine S. -AU - Yau, Thomas Ho Lai -AU - Sideris, Michail -TI - Chemoradiotherapy in Cancer Treatment: Rationale and Clinical Applications -T2 - ANTICANCER RESEARCH -M3 - Review -AB - Chemoradiotherapy (CRT) refers to the combined administration of both chemotherapy and radiotherapy as an anticancer treatment. Over the years, CRT has become an established treatment for a diverse range of locally advanced solid tumours. The rationale for CRT is based on the two concepts of spatial cooperation and in-field cooperation, whereby the end goal is to achieve synergistic antitumour effects from the combination of both treatment modalities. CRT offers notable patient survival benefits and local disease control without significant long-term toxicities. Although the enhancement of cytotoxic effects inevitably increases damage to normal tissues as well as tumour cells, if the damage to normal tissue is lesser than that to tumour cells, CRT is still deemed beneficial. Thus, the search to optimise dose, timings and fractionation of CRT is of particular interest. Considering the recent success achieved with anticancer immunotherapies including immune checkpoint inhibitors, the combination of CRT and immunotherapy has emerged as an exciting field of research with the potential for significant clinical benefit. This report outlines the rationale underlying CRT and discusses its advantages through clinical examples focusing on anal, cervical, non-small-cell lung cancer and bladder cancer. -PU - INT INST ANTICANCER RESEARCH -PI - ATHENS -PA - EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE -SN - 0250-7005 -SN - 1791-7530 -DA - 2021 JAN -PY - 2021 -VL - 41 -IS - 1 -SP - 1 -EP - 7 -DO - 10.21873/anticanres.14746 -AN - WOS:000608682400001 -AD - Queen Mary Univ London, Barts Canc Inst, London, England -AD - Queen Mary Univ London, Barts & London Sch Med & Dent, London, England -AD - Queen Mary Univ London, Womens Hlth Res Unit, London, England -Y2 - 2021-02-09 -ER - - -TY - JOUR -AU - Puri, Sonam -AU - Chatwal, Monica -AU - Gray, Jhanelle E. -TI - Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents -T2 - EXPERT REVIEW OF RESPIRATORY MEDICINE -M3 - Article -AB - Introduction: Lung cancer is the most common cause of cancer-related deaths in the world. Despite recent advances, the estimated 5-year overall survival is only around 17%. There is an urgent need for development of new effective drug strategies for the treatment of advanced-stage lung cancer.Areas covered: This review focuses on ongoing research in immune and non-immune oncology combinations for the treatment of non-small cell lung cancer (NSCLC). Here, we will focus on the combination of PD-L1 inhibitors (immunotherapy) with chemotherapy, vascular endothelial growth factor inhibitors, targeted therapies, and radiation.Expert commentary: Immunotherapy is a major advancement in the treatment of NSCLC due to its durable responses and overall favorable toxicity profile. However, these responses are seen in only a subset of patients. Mechanisms of resistance to this therapy continue to emerge. Studies on combination therapies are underway as the therapeutic mechanisms of these established agents are not only distinctly different but also synergistic with immunotherapy. Overall, some benefits have been noted, although associated toxicities have also been shown, and the long-term benefits including overall survival have yet to be determined. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1747-6348 -SN - 1747-6356 -DA - 2017 -PY - 2017 -VL - 11 -IS - 10 -SP - 791 -EP - 805 -DO - 10.1080/17476348.2017.1361323 -AN - WOS:000410861400003 -AD - Univ S Florida, Dept Hematol & Oncol, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, 12902 Magnolia Dr,FOB1, Tampa, FL 33612 USA -Y2 - 2017-10-16 -ER - - -TY - JOUR -AU - Xiong, Anwen -AU - Li, Wei -AU - Li, Xingya -AU - Fan, Yun -AU - Ma, Zhiyong -AU - Fang, Jian -AU - Xie, Qiang -AU - Zhuang, Wu -AU - Kang, Mafei -AU - Wang, Jing -AU - Xu, Ting -AU - Xu, Mo -AU - Zhi, Lihua -AU - Liu, Qing -AU - Wang, Ni -AU - Zhou, Caicun -TI - Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study -T2 - EUROPEAN JOURNAL OF CANCER -M3 - Article -AB - Background: This study aimed to evaluate the efficacy and safety of KN046, a novel recombinant humanised antibody targeting PD-L1 and CTLA-4 in advanced non-small cell lung cancer (NSCLC) patients after failure or intolerance to platinum-based che-motherapy.Methods: In this multi-centre, open-label phase II clinical trial, patients were enroled after failure or intolerance to platinum-based chemotherapy. KN046 at 3 mg/kg or 5 mg/kg was administered intravenously every 2 weeks. The primary end-point was objective response rate (ORR) evaluated by a blinded independent review committee (BIRC).Results: A total of 30 and 34 patients were included in the 3 mg/kg (cohort A) and 5 mg/kg (cohort B) cohorts. On 31st August 2021, the median follow-up duration was 24.08 months (interquartile [IQR], 22.28, 24.84) and 19.35 months (IQR, 17.25, 20.90) in the 3 mg/kg and 5 mg/kg cohorts, respectively. BIRC-assessed ORRs were 13.3% and 14.7% in the 3 mg/kg and 5 mg/kg cohorts, respectively. Median progression-free survival was 3.68 (95% confidence interval [CI] 3.22-7.29) and 3.68 (95%CI 1.81-7.39) months, while overall survival was 19.70 (95.5%CI 15.44-not estimated [NE]) and 13.04 (95.5%CI 9.86-NE) months, respectively. The most common treatment-related adverse events (TRAEs) were anaemia (28.1%), hypergly-caemia (26.7%), and infusion-related reactions (26.7%). The incidence rates of grade & GE; 3 TRAEs and TRAEs leading to treatment discontinuation were 42.2% and 14.1%, respectively.Conclusions: Both 3 mg/kg and 5 mg/kg KN046 showed promising efficacy and favourable safety profile for advanced NSCLC after failure or intolerance to previous platinum-based chemotherapy.Trial registration number: NCT03838848 & COPY; 2023 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCI LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND -SN - 0959-8049 -SN - 1879-0852 -DA - 2023 SEP -PY - 2023 -VL - 190 -C7 - 112936 -DO - 10.1016/j.ejca.2023.05.024 -AN - WOS:001032525200001 -C6 - JUN 2023 -AD - Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China -AD - First Affiliated Hosp Zhengzhou Univ, Dept Med Oncol, Zhengzhou, Peoples R China -AD - Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China -AD - Henan Canc Hosp, Dept Resp Med, Zhengzhou, Peoples R China -AD - Beijing Canc Hosp, Dept Thorac Oncol 2, Beijing, Peoples R China -AD - Fuzhou Pulm Hosp Fujian, Area Three Dept Med Oncol, Fuzhou, Peoples R China -AD - Fujian Canc Hosp, Dept Thorac Oncol, Fuzhou, Peoples R China -AD - Affiliated Hosp Guilin Med Univ, Dept Med Oncol, Guilin, Peoples R China -AD - Med Jiangsu Alphamab Biopharmaceut Co Ltd, Suzhou, Peoples R China -AD - Biostat Jiangsu Alphamab Biopharmaceut Co Ltd, Suzhou, Peoples R China -M2 - Shanghai Pulm Hosp -M2 - Beijing Canc Hosp -M2 - Fuzhou Pulm Hosp Fujian -M2 - Fujian Canc Hosp -M2 - Med Jiangsu Alphamab Biopharmaceut Co Ltd -M2 - Biostat Jiangsu Alphamab Biopharmaceut Co Ltd -Y2 - 2023-07-30 -ER - - -TY - JOUR -AU - Chang, Myung Hee -AU - Kim, Kyoung Ha -AU - Jun, Hyun Jung -AU - Kim, Hyo Song -AU - Yi, Seong Yoon -AU - Uhm, Ji Eun -AU - Park, Min Jae -AU - Lim, Do Hyoung -AU - Ji, Sang Hoon -AU - Hwang, In Gyu -AU - Lee, Jeeyun -AU - Park, Yeon Hee -AU - Ahn, Jin Seok -AU - Ahn, Myung-ju -AU - Park, Keunchil -TI - Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer -T2 - CANCER CHEMOTHERAPY AND PHARMACOLOGY -M3 - Article -AB - We conducted a prospective phase II trial of IrOx in patients with advanced non-small cell lung cancer to evaluate the efficacy and toxicity.Patients with histologically or cytologically proven non-small cell lung cancer (NSCLC), aged a parts per thousand yen18 years, Eastern Cooperative Oncology Group performance status 0-1, at stage IIIB (pleural effusion)/IV or with recurrent disease not suitable for primary surgical treatment, with no palliative chemotherapy or radiotherapy to the chest or immunotherapy or biologic therapy, the presence of measurable disease by RECIST, and who had given signed written informed consent, were eligible. Treatment consisted of irinotecan 65 mg/m(2) on days 1 and 8 and oxaliplatin 130 mg/m(2) on day 1, repeated every 3 weeks.A total of 18 patients were enrolled in June and August 2007, the median age was 59 years (47-73). In total, 71 cycles were administered with a median of 4 cycles per patient (range, 1-6 cycles) and 18 patients were evaluable for treatment response. An independent review of tumor responses gave an overall response rate of 27.7% (CR: 0, PR: 5/18; 95% CI, 7-48.4%) by intent-to-treat analysis. The median overall survival of all patients was 14 months and the median time-to-progression was 4.2 months (95% CI, 1.959-6.441). The most common grade 3/4 toxicities were diarrhea (7% of all cycles) and neutropenia (5.6% of all cycles). Grade 3 peripheral neuropathy occurred in one patient and one patient died due to sepsis.This study suggests that IrOx combination therapy has moderate activity with a tolerable toxicity profile. However, it was not warranted to evaluate further this regimen as first-line treatment for patients with advanced or metastatic NSCLC using the current dosages and schedule. -PU - SPRINGER -PI - NEW YORK -PA - 233 SPRING ST, NEW YORK, NY 10013 USA -SN - 0344-5704 -SN - 1432-0843 -DA - 2009 OCT -PY - 2009 -VL - 64 -IS - 5 -SP - 917 -EP - 924 -DO - 10.1007/s00280-009-0943-7 -AN - WOS:000269076700008 -AD - Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea -AD - Chung Ang Univ, Young San Hosp, Dept Med, Div Hematol Oncol, Seoul 156756, South Korea -Y2 - 2009-10-01 -ER - - -TY - JOUR -AU - Yang, Gowoon -AU - Yoon, Hong In -AU - Lee, Joongyo -AU - Kim, Jihun -AU - Kim, Hojin -AU - Cho, Jaeho -AU - Lee, Chang Geol -AU - Chang, Jee Suk -AU - Cho, Yeona -AU - Kim, Jin Sung -AU - Kim, Kyung Hwan -TI - Risk of on-treatment lymphopenia is associated with treatment outcome and efficacy of consolidation immunotherapy in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy -T2 - RADIOTHERAPY AND ONCOLOGY -M3 - Article -AB - Background and purpose: The ability of the effective dose to immune cells (EDIC) and the pre-radiotherapy (RT) absolute lymphocyte count (ALC) to predict lymphopenia during RT, treatment outcomes, and efficacy of consolidation immunotherapy in patients with locally advanced non-small cell lung cancer was investigated.Methods and materials: Among 517 patients treated with concurrent chemoradiotherapy, EDIC was calculated using the mean doses to the lungs, heart, and total body. The patients were grouped according to high and low EDIC and pre-RT ALC, and the correlations with radiation-induced lymphopenia and survival outcomes were determined.Results: Altogether, 195 patients (37.7%) received consolidation immunotherapy. The cutoff values of EDIC and pre-RT ALC for predicting severe lymphopenia were 2.89 Gy and 2.03 x 10(9) cells/L, respectively. The high-risk group was defined as EDIC >= 2.89 Gy and pre-RT ALC < 2.03 x 10(9) cells/L, while the low-risk group as EDIC < 2.89 Gy and pre-RT ALC >= 2.03 x 10(9) cells/L, and the rest of the patients as the intermediate-risk group. The incidences of severe lymphopenia during RT in the high-, intermediate-, and low-risk groups were 90.1%, 77.1%, and 52.3%, respectively (P < 0.001). The risk groups could independently predict both progression-free (P < 0.001) and overall survival (P < 0.001). The high-risk group showed a higher incidence of locoregional and distant recurrence (P < 0.001). Consolidation immunotherapy showed significant survival benefit in the low- and intermediate-risk groups but not in the high-risk group.Conclusions: The combination of EDIC and pre-RT ALC predicted severe lymphopenia, recurrence, and survival. It may potentially serve as a biomarker for consolidation immunotherapy. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0167-8140 -SN - 1879-0887 -DA - 2023 DEC -PY - 2023 -VL - 189 -C7 - 109934 -DO - 10.1016/j.radonc.2023.109934 -AN - WOS:001096408200001 -C6 - OCT 2023 -AD - Yonsei Univ, Coll Med, Heavy Ion Therapy Res Inst, Dept Radiat Oncol,Yonsei Canc Ctr, 50-1 Yonsei Ro, Seoul 03722, South Korea -AD - Yonsei Univ, Coll Med, Dept Radiat Oncol, Gangnam Severance Hosp, 211 Eonjuro, Seoul 06273, South Korea -Y2 - 2023-11-16 -ER - - -TY - JOUR -AU - VALDIVIESO, M -AU - TENCZYNSKI, TF -AU - RODRIGUEZ, V -AU - BURGESS, MA -AU - MOUNTAIN, CF -AU - BARKLEY, HT -AU - HERSH, EM -AU - BODEY, GP -TI - CHEMO-IMMUNOTHERAPY OF SMALL CELL BRONCHOGENIC-CARCINOMA WITH VP-16-213, IFOSFAMIDE, VINCRISTINE, ADRIAMYCIN, AND CORYNEBACTERIUM-PARVUM -T2 - CANCER -M3 - Article -AB - Patients (35) with small cell bronchogenic carcinoma (SCBC) received chemoimmunotherapy with VP-16-213, ifosfamide, vincristine, Adriamycin and C. parvum. Of 33 evaluable patients, 26 (79%) responded with complete (55%) or partial (24%) remissions. Complete remissions were more common among patients with limited disease (11/14 patients, 79%) compared with those with extensive disease (7/19 patients, 37%) and among patients who were ambulatory prior to therapy (16/25 patients, 64%) compared with those who were nonambulatory (2/8 patients, 25%). Myelosuppression consisted primarily of neutropenia. Eight percent of the treatment courses in 29% of the patients were associated with hematuria and/or documented episodes of infection during neutropenia. There were 3 deaths possibly related to treatment, in 2 of which there was no evidence of disease at post-mortem examination. Six patients relapsed in the CNS. In 4 instances, CNS relapse was the only site of tumor progression. CNS relapse was more common among evaluable patients who did not receive prophylactic brain irradiation (5/17 patients, 29%, vs. 1/15 patients, 7%; P = 0.23). The median survival duration for all patients was 63 wk, being slightly longer for patients with limited disease than for those with extensive disease (70.9 wk vs. 56 wk; P = 0.18). This was also true for patients who achieved complete rather than partial remissions (71 wk vs. 50 wk; P = 0.09). Patients receiving prophylactic brain irradiation experienced longer survival (100.8 wk vs. 48 wk; P = 0.01). -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0008-543X -SN - 1097-0142 -DA - 1981 -PY - 1981 -VL - 48 -IS - 2 -SP - 238 -EP - 244 -DO - 10.1002/1097-0142(19810715)48:2<238::AID-CNCR2820480205>3.0.CO;2-C -AN - WOS:A1981LW16900004 -AD - UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST, CTR CANC, DEPT RADIOTHERAPY, HOUSTON, TX 77025 USA -AD - UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST, CTR CANC, DEPT SURG, HOUSTON, TX USA -Y2 - 1981-01-01 -ER - - -TY - JOUR -AU - Tsakonas, Georgios -AU - Ekman, Simon -AU - Koulouris, Andreas -AU - Adderley, Helen -AU - Ackermann, Christoph Jakob -AU - Califano, Raffaele -TI - Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis -T2 - INTERNATIONAL JOURNAL OF CANCER -M3 - Review -AB - The presence of brain metastases (BM) is a negative prognostic factor for patients with advanced nonsmall cell lung cancer (NSCLC). Their incidence seems to be higher in patients with oncogene-driven tumours, especially those with EGFR-mutated or ALK-rearranged tumours. Although targeted treatments demonstrate significant efficacy regarding BM, they only apply to a minority of NSCLC patients. On the other hand, systemic therapies for nononcogenic-driven NSCLC with BM have shown limited clinical benefit. In recent years, immunotherapy alone or combined with chemotherapy has been adopted as a new standard of care in first-line therapy. This approach seems to be beneficial to patients with BM in terms of efficacy and toxicity. Combined immune checkpoint inhibition as well as the combination of immunotherapy and radiation therapy show promising results with significant, but overall acceptable toxicity. A pragmatic approach of allowing enrolment of patients with untreated or symptomatic BM in randomised trials evaluating immune checkpoint inhibitors strategies, possibly coupled with central nervous system-related endpoints may be needed to generate data to refine treatment for this patient population. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0020-7136 -SN - 1097-0215 -DA - 2023 NOV 1 -PY - 2023 -VL - 153 -IS - 9 -SP - 1556 -EP - 1567 -DO - 10.1002/ijc.34628 -AN - WOS:001010086500001 -C6 - JUN 2023 -AD - Karolinska Univ Hosp, Karolinska Inst, Thorac Oncol Ctr, Dept Oncol Pathol, Stockholm, Sweden -AD - Univ Crete, Fac Med, Iraklion, Greece -AD - Christie NHS Fdn Trust, Dept Med Oncol, Manchester, England -AD - Manchester Univ NHS Fdn Trust, Dept Med Oncol, Manchester, England -AD - Univ Manchester, Div Canc Sci, Manchester, England -M2 - Manchester Univ NHS Fdn Trust -Y2 - 2023-06-29 -ER - - -TY - JOUR -AU - Fan, Yun -AU - Mao, Weimin -TI - Immune checkpoint inhibitors in lung cancer: current status and future directions. -T2 - Chinese clinical oncology -M3 - Journal Article -M3 - Review -AB - Recently, the immune checkpoint inhibitors that target programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) have made a breakthrough in treating advanced non-small cell lung cancer (NSCLC) with the efficacy of approximately 20%; among which, nivolumab has acquired treatment indications in lung squamous cell carcinoma. The inhibitors targeting cytotoxic T lymphocyte associated antigen 4 (CTLA-4) are also undergoing clinical trials. Researches on immune checkpoint inhibitors have been rapidly implemented in a variety of different types of lung cancer, such as small cell lung cancer (SCLC) and locally advanced NSCLC, and these inhibitors began to be applied in combination with some established treatments, including chemotherapy, targeting therapy and radiotherapy. Undoubtedly, the immune checkpoint inhibitors have become a hot spot in the research and treatment of lung cancer. However, many problems wait to be solved, such as searching for ideal biomarkers, constituting the best criteria for curative effect evaluation, exploring different combination treatment models, and clearly understanding the mechanisms of primary or secondary drug resistance. Along with these problems to be successfully solved, the immune checkpoint inhibitors will have more broad applications in lung cancer therapy. -SN - 2304-3873 -DA - 2017 Apr -PY - 2017 -VL - 6 -IS - 2 -SP - 17 -EP - 17 -DO - 10.21037/cco.2017.02.05 -AN - MEDLINE:28482670 -AD - Department of Cancer Medicine (Thoracic), Zhejiang Cancer Hospital, Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology (Esophagus, Lung), Hangzhou 310022, China. fanyun@zjcc.org.cn. -AD - Department of Cancer Medicine (Thoracic), Zhejiang Cancer Hospital, Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology (Esophagus, Lung), Hangzhou 310022, China. -Y2 - 2017-05-11 -ER - - -TY - JOUR -AU - Chiu, Li-Chung -AU - Lin, Shu-Min -AU - Lo, Yu-Lun -AU - Kuo, Scott Chih-Hsi -AU - Yang, Cheng-Ta -AU - Hsu, Ping-Chih -TI - Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC) -T2 - VACCINES -M3 - Review -AB - Early-stage NSCLC (stages I and II, and some IIIA diseases) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases, with surgery being its main treatment modality. The risk of disease recurrence and cancer-related death, however, remains high among NSCLC patients after complete surgical resection. In previous studies on the long-term follow-up of post-operative NSCLC, the results showed that the five-year survival rate was about 65% for stage IB and about 35% for stage IIIA diseases. Platinum-based chemotherapy with or without radiation therapy has been used as a neoadjuvant therapy or post-operative adjuvant therapy in NSCLC, but the improvement of survival is limited. Immune checkpoint inhibitors (ICIs) have effectively improved the 5-year survival of advanced NSCLC patients. Cancer vaccination has also been explored and used in the prevention of cancer or reducing disease recurrence in resected NSCLC. Here, we review studies that have focused on the use of immunotherapies (i.e., ICIs and vaccination) in surgically resectable NSCLC. We present the results of completed clinical trials that have used ICIs as neoadjuvant therapies in pre-operative NSCLC. Ongoing clinical trials investigating ICIs as neoadjuvant and adjuvant therapies are also summarized. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2076-393X -DA - 2021 JUL -PY - 2021 -VL - 9 -IS - 7 -C7 - 689 -DO - 10.3390/vaccines9070689 -AN - WOS:000676941000001 -AD - Chang Gung Mem Hosp Linkou, Coll Med, Dept Internal Med, Div Thorac Med, Taoyuan 33305, Taiwan -AD - New Taipei Municipal Tu Cheng Hosp, Dept Thorac Med, New Taipei 23652, Taiwan -AD - Chang Gung Univ, Coll Med, Dept Med, Taoyuan 33302, Taiwan -AD - Taoyuan Chang Gung Mem Hosp, Dept Internal Med, Taoyuan 33378, Taiwan -AD - Chang Gung Univ, Coll Med, Dept Resp Therapy, Taoyuan 33302, Taiwan -M2 - New Taipei Municipal Tu Cheng Hosp -Y2 - 2021-07-30 -ER - - -TY - JOUR -AU - Mignard, Xavier -AU - Chaabane, Nouha -AU - Fallet, Vincent -AU - Wislez, Marie -TI - Immunotherapy in thoracic oncology: state of the art and perspectives -T2 - BULLETIN DU CANCER -M3 - Article -AB - Immune checkpoint inhibitors (ICI) are monoclonal antibodies that inhibit molecular interaction between an immune checkpoint and its ligand, which leads to increased anti-tumoral immune response, Programmed Death 1 (PD-1) and Cytotoxic T-Lymphocyte Associated-4 (CTLA-4) are the most commonly known immune checkpoints.ICIs are currently placed early in the course of the treatment of patients with non-small cell lung cancer (NSCLC). In France, approvals have been pronounced for nivolumab and pembrolizumab anti-PD-1 antibodies) as second-line treatments after chemotherapy in patients with advanced NSCLC, and pembrolizumab has been approved as a first-line treatment in patients with advanced NSCLC, without EGFR mutation or ALK rearrangement, with strong (>= 50%) PD-L1 (Programmed Death Ligand 1) expression. Atezolizumab is currently soon to be approved as a second-line treatment.Numerous studies are currently evaluating ICIs in thoracic oncology. In this article, we will develop perspectives regarding ICIs for early stage or locally advanced NSCLCs, ICIs used in other thoracic cancers (small cell lung cancer, malignant pleural mesothelioma, thymic epithelial tumors), and trials with combinations involving ICIs: two ICIs combined, or 10s combined with chemotherapy, radiotherapy or other anti-cancer treatments. -PU - ELSEVIER MASSON, CORP OFF -PI - PARIS -PA - 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE -SN - 0007-4551 -SN - 1769-6917 -DA - 2018 DEC -PY - 2018 -VL - 105 -SP - S16 -EP - S23 -AN - WOS:000458162900003 -AD - Sorbonne Univ, GRC 04, Theranoscan, Hop Tenon,AP HP, F-75020 Paris, France -AD - Hop Tenon, AP HP, Serv Pneumol, F-75020 Paris, France -Y2 - 2019-02-19 -ER - - -TY - JOUR -AU - Pellerino, Alessia -AU - Interno, Valeria -AU - Muscolino, Erminia -AU - Mo, Francesca -AU - Bruno, Francesco -AU - Pronello, Edoardo -AU - Franchino, Federica -AU - Soffietti, Riccardo -AU - Ruda, Roberta -TI - Leptomeningeal metastases from non- small cell lung cancer: state of the art and recent advances -T2 - JOURNAL OF CANCER METASTASIS AND TREATMENT -M3 - Review -AB - Patients with leptomeningeal metastases (LM) from non-small cell lung cancer (NSCLC) have a poor outcome with survival of less than 1 year regardless of advancements in treatment strategy. In the past, some randomized clinical trials have been conducted with heterogeneous inclusion criteria, diagnostic parameters, response evaluation and primary endpoints. Efforts to develop a standardized magnetic resonance imaging (MRI) assessment and liquid biopsy techniques to monitor disease evolution in plasma or cerebrospinal fluid (CSF) are underway. This review aims to cover the main clinical and diagnostic challenges of LM from NSCLC, in particular the role of MRI, CSF cytology and liquid biopsy for the diagnosis and monitoring of the disease, as well as the most recent clinical trials on targeted therapies. Targeted therapy, such as epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase rearranged inhibitors, represent a feasible treatment with encouraging results in terms of disease control and survival. For ineligible patients, immune checkpoint inhibitors could represent a therapeutic option with acceptable tolerance, although clinical trials focused on LM from NSCLC are lacking and represent a research focus for the future. -PU - OAE PUBLISHING INC -PI - ALHAMBRA -PA - 245 E MAIN ST, ST122, ALHAMBRA, CA 91801 USA -SN - 2394-4722 -SN - 2454-2857 -DA - 2020 -PY - 2020 -VL - 6 -C7 - 41 -DO - 10.20517/2394-4722.2020.80 -AN - WOS:000911185200041 -AD - Univ Turin, Dept Neurooncol, Via Cherasco 15, I-10126 Turin, Italy -AD - City Hlth & Sci Hosp, Via Cherasco 15, I-10126 Turin, Italy -AD - Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, I-70121 Bari, Italy -Y2 - 2020-01-01 -ER - - -TY - JOUR -AU - Harris, Sarnuel J. -AU - Brown, Jessica -AU - Lopez, Juanita -AU - Yap, Timothy A. -TI - Immuno-oncology combinations: raising the tail of the survival curve -T2 - CANCER BIOLOGY & MEDICINE -M3 - Review -AB - There have been exponential gains in immuno-oncology in recent times through the development of immune checkpoint inhibitors. Already approved by the U.S. Food and Drug Administration for advanced melanoma and non-small cell lung cancer, immune checkpoint inhibitors also appears to have significant antitumor activity in multiple other tumor types. An exciting component of immunotherapy is the durability of antitumor responses observed, with some patients achieving disease control for many years. Nevertheless, not all patients benefit, and efforts should thus now focus on improving the efficacy of immunotherapy through the use of combination approaches and predictive biomarkers of response and resistance. There are multiple potential rational combinations using an immunotherapy backbone, including existing treatments such as radiotherapy, chemotherapy or molecularly targeted agents, as well as other immunotherapeutics. The aim of such antitumor strategies will be to raise the tail on the survival curve by increasing the number of long term survivors, while managing any additive or synergistic toxicities that may arise with immunotherapy combinations. Rational trial designs based on a clear understanding of tumor biology and drug pharmacology remain paramount. This article reviews the biology underpinning immuno-oncology, discusses existing and novel immunotherapeutic combinations currently in development, the challenges of predictive biomarkers of response and resistance and the impact of immuno-oncology on early phase clinical trial design. -PU - CHINA ANTI-CANCER ASSOC -PI - TIANJIN -PA - TIANJIN MEDICAL UNIV, CANCER INST & HOSPITAL TI-YUAN-BEI, HUANHU XI LU, HEXIQU, TIANJIN, 300060, PEOPLES R CHINA -SN - 2095-3941 -DA - 2016 JUN -PY - 2016 -VL - 13 -IS - 2 -SP - 171 -EP - 193 -DO - 10.20892/j.issn.2095-3941.2016.0015 -AN - WOS:000379196800002 -AD - Royal Marsden Hosp, Drug Dev Unit, London SM2 5PT, Surrey, England -AD - Royal Marsden Hosp, Lung Unit, London SM2 5PT, Surrey, England -AD - Inst Canc Res, London SM2 5PT, Surrey, England -Y2 - 2016-06-01 -ER - - -TY - JOUR -AU - Kim, Soo Han -AU - Jo, Eun Jung -AU - Mok, Jeongha -AU - Lee, Kwangha -AU - Kim, Ki Uk -AU - Park, Hye-Kyung -AU - Lee, Min Ki -AU - Eom, Jung Seop -AU - Kim, Mi-Hyun -TI - Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer -T2 - KOREAN JOURNAL OF INTERNAL MEDICINE -M3 - Article -AB - Background/Aims: Despite the obvious benefits of adding immune checkpoint inhibitors to platinum-etoposide chemotherapy in patients with extensive-stage small- cell lung cancer (ES-SCLC), real-world data remain scarce.Methods: This retrospective study included 89 patients with ES-SCLC treated with platinum-etoposide chemotherapy alone (chemo- only group; n = 48) or in combination with atezolizumab (atezolizumab group; n = 41) and compared the survival outcomes between these two groups.Results: Overall survival (OS) was significantly longer in the atezolizumab group than in the chemo- only group (15.2 months vs. 8.5 months; p = 0.047), whereas the median progression-free survival was almost the same (5.1 months vs. 5.0 months) in both groups (p = 0.754). Subsequent multivariate analysis revealed that thoracic radiation ( hazard ratio [HR], 0.223; 95% confidence interval [CI], 0.092- 0.537; p = 0.001) and atezolizumab administration (HR, 0.350; 95% CI, 0.184-0.668; p = 0.001) were favorable prognostic factors for OS. In the thoracic radiation subgroup, patients who received atezolizumab demonstrated favorable survival outcomes and no grade 3-4 adverse events (AEs).Conclusions: The addition of atezolizumab to platinum-etoposide resulted in favorable outcomes in this real-world study. Thoracic radiation was associated with improved OS and acceptable AE risk in combination with immunotherapy in patients with ES-SCLC. -PU - KOREAN ASSOC INTERNAL MEDICINE -PI - SEOUL -PA - 101-2501 LOTTE CASTLE PRESIDENT, 109 MAPO-DAERO, MAPO-GU, SEOUL, SOUTH KOREA -SN - 1226-3303 -SN - 2005-6648 -DA - 2023 MAR -PY - 2023 -VL - 38 -IS - 2 -SP - 218 -EP - 225 -DO - 10.3904/kjim.2022.361 -AN - WOS:000935510300001 -C6 - FEB 2023 -AD - Pusan Natl Univ, Sch Med, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea -AD - Pusan Natl Univ Hosp, Biomed Res Inst, 179 Gudeok Ro, Busan 49241, South Korea -Y2 - 2023-03-17 -ER - - -TY - JOUR -AU - Yotsukura, Masaya -AU - Nakagawa, Kazuo -AU - Suzuki, Kenji -AU - Takamochi, Kazuya -AU - Ito, Hiroyuki -AU - Okami, Jiro -AU - Aokage, Keiju -AU - Shiono, Satoshi -AU - Yoshioka, Hiroshige -AU - Aoki, Tadashi -AU - Tsutani, Yasuhiro -AU - Okada, Morihito -AU - Watanabe, Shun-ichi -A1 - Japan Clinical Oncology Grp JCOG -TI - Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer -T2 - JAPANESE JOURNAL OF CLINICAL ONCOLOGY -M3 - Review -AB - The superior efficacy of immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancer has inspired many clinical trials to use immune checkpoint inhibitors in earlier stages of lung cancer worldwide. Based on the theoretical feasibility that neoantigens derived from a tumor tissue are present in vivo, some clinical trials have recently evaluated the neoadjuvant, rather than the adjuvant, use of immune checkpoint inhibitors. Some of these trials have already produced evidence on the safety and efficacy of immune checkpoint inhibitors in a neoadjuvant setting, with a favorable major pathologic response and few adverse events. In the most impactful report from Johns Hopkins University and the Memorial Sloan Kettering Cancer Center, the programed death-1 inhibitor nivolumab was administered to 21 patients in a neoadjuvant setting. The authors reported a major pathologic response rate of 45%, with no unexpected delay of surgery related to the adverse effects of nivolumab. The adjuvant as well as the neoadjuvant administration of immune checkpoint inhibitors has also been considered in various clinical trials, with or without the combined use of chemotherapy or radiotherapy. The development of appropriate biomarkers to predict the efficacy of immune checkpoint inhibitors is also underway. The expression of programed death ligand-1 and the tumor mutation burden are promising biomarkers that have been evaluated in many settings. To establish an appropriate method for using immune checkpoint inhibitors in combination with surgery, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group will manage clinical trials using a multimodality treatment, including immune checkpoint inhibitors and surgery. -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 0368-2811 -SN - 1465-3621 -DA - 2021 JAN -PY - 2021 -VL - 51 -IS - 1 -SP - 28 -EP - 36 -DO - 10.1093/jjco/hyaa187 -AN - WOS:000608420900005 -AD - Natl Canc Ctr, Dept Thorac Surg, Tokyo, Japan -AD - Juntendo Univ Hosp, Div Gen Thorac Surg, Tokyo, Japan -AD - Kanagawa Canc Ctr, Dept Thorac Surg, Yokohama, Kanagawa, Japan -AD - Osaka Int Canc Inst, Dept Thorac Surg, Osaka, Japan -AD - Natl Canc Ctr Hosp East, Div Thorac Surg, Chiba, Japan -AD - Yamagata Prefectural Cent Hosp, Dept Thorac Surg, Yamagata, Japan -AD - Kansai Med Univ Hosp, Dept Thorac Oncol, Osaka, Japan -AD - Niigata Canc Ctr Hosp, Dept Thorac Surg, Niigata, Japan -AD - Hiroshima Univ, Dept Surg Oncol, Hiroshima, Japan -M2 - Osaka Int Canc Inst -M2 - Niigata Canc Ctr Hosp -Y2 - 2021-02-09 -ER - - -TY - JOUR -AU - Iyengar, Puneeth -AU - Gerber, David E. -TI - Locally Advanced Lung Cancer An Optimal Setting for Vaccines and Other Immunotherapies -T2 - CANCER JOURNAL -M3 - Review -AB - Lung cancer has traditionally been considered relatively resistant to immunotherapies. However, recent advances in the understanding of tumor-associated antigens, anti-tumor immune responses, and tumor immunosuppression mechanisms have resulted in a number of promising immunomodulatory therapies such as vaccines and checkpoint inhibitors. Locally advanced non-small cell lung cancer is an optimal setting for these treatments because standard therapies such as surgery, radiation, and chemotherapy may enhance anti-tumor immune effects by debulking the tumor, increasing tumor antigen presentation, and promoting T-cell response and trafficking. Clinical trials incorporating immunomodulatory agents into combined modality therapy of locally advanced non-small cell lung cancer have shown promising results. Future challenges include identifying biomarkers to predict those patients most likely to benefit from this approach, radiographic assessment of treatment effects, the timing and dosing of combined modality treatment including immunotherapies, and avoidance of potentially overlapping toxicities. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1528-9117 -SN - 1540-336X -DA - 2013 MAY-JUN -PY - 2013 -VL - 19 -IS - 3 -SP - 247 -EP - 262 -DO - 10.1097/PPO.0b013e318292e51a -AN - WOS:000319557700010 -AD - Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA -AD - Univ Texas SW Med Ctr Dallas, Dept Internal Med Hematol Oncol, Dallas, TX 75390 USA -AD - Univ Texas SW Med Ctr Dallas, Harold C Simmons Canc Ctr, Dallas, TX 75390 USA -Y2 - 2013-07-03 -ER - - -TY - JOUR -AU - An, Ning -AU - Jin, Xiangfeng -AU - Yang, Xue -TI - Endostar (rh-endostatin) consolidation therapy after sequential chemoradiotherapy in stage III, unresectable lung adenocarcinoma with novel STK11, TP53 and ATM mutations: a case report -T2 - AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH -M3 - Article -AB - Concurrent chemoradiotherapy (cCRT) has been predominantly used as the standard therapy for locally advanced or unresectable non-small cell lung cancer (NSCLC) patients with stage III disease. Based on the outstanding results of Phase III Pacific study, Programmed Death-Ligand 1 (PD-L1) inhibitor consolidation therapy after cCRT without progression disease (PD) has been recommended by National Comprehensive Cancer Network (NCCN) guideline as standard therapy for these patients. However, not all patients can tolerate a full course of cCRT due to the poor performance status, concurrent complications, or poor pulmonary function. Therefore, sequential chemoradiotherapy (sCRT) is often conducted for these selected patients who have been assessed as not suitable for cCRT. Moreover, not all patients are suitable for immunotherapy, especially for those with auto-immune disease or certain gene mutations associated with non-response of immunotherapy. Hence, we presented a case with both autoimmune disease and serine/threonine kinase 11 (STK11) mutation, who underwent angiogenesis inhibitor Endostar consolidation therapy after sCRT, and achieved a progression-free survival (PFS) more than 17 months and still in the process of follow-up. This case may offer an effective consolidation treatment for these patients with stage III disease unsuitable for immunotherapy. Further clinical trials are required to confirm this treatment option. -PU - E-CENTURY PUBLISHING CORP -PI - MADISON -PA - 40 WHITE OAKS LN, MADISON, WI 53711 USA -SN - 1943-8141 -DA - 2023 -PY - 2023 -VL - 15 -IS - 6 -SP - 4262 -EP - 4269 -AN - WOS:001032073000026 -AD - Qingdao Univ, Affiliated Hosp, Dept Radiat Oncol, 16 Jiangsu Rd, Qingdao 266003, Shandong, Peoples R China -AD - Qingdao Univ, Affiliated Hosp, Dept Thorac Surg, Qingdao 266003, Shandong, Peoples R China -AD - Qingdao Univ, Affiliated Hosp, Dept Med Oncol, Qingdao 266003, Shandong, Peoples R China -Y2 - 2023-08-17 -ER - - -TY - JOUR -AU - Kang, Jin -AU - Zhang, Chao -AU - Zhong, Wen-Zhao -TI - Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art -T2 - CANCER COMMUNICATIONS -M3 - Review -AB - Lung cancer mortality has decreased over the past decade and can be partly attributed to advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have rapidly evolved from investigational drugs to standard of care for the treatment of metastatic non-small cell lung cancer (NSCLC). In particular, antibodies that block inhibitory immune checkpoints, such as programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1), have revolutionized the treatment of advanced NSCLC, when administered alone or in combination with chemotherapy. Immunotherapy is associated with higher response rates, improved overall survival (OS), and increased tolerability compared with conventional cytotoxic chemotherapy. These benefits may increase the utility of immunotherapy and its combinational use with chemotherapy in the neoadjuvant treatment of patients with NSCLC. Early findings from various ongoing clinical trials suggest that neoadjuvant ICIs alone or combined with chemotherapy may significantly reduce systemic recurrence and improve long-term OS or cure rates in resectable NSCLC. Here we further summarize the safety and efficacy of various neoadjuvant treatment regimens including immunotherapy from ongoing clinical trials and elaborate the role of neoadjuvant immunotherapy in patients with resectable NSCLC. In addition, we discuss several unresolved challenges, including the evaluations to assess neoadjuvant immunotherapy response, the role of adjuvant treatment after neoadjuvant immunotherapy, the efficacy of treatment for oncogenic-addicted tumors, and predictive biomarkers. We also provide our perspective on ways to overcome current obstacles and establish neoadjuvant immunotherapy as a standard of care. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2523-3548 -DA - 2021 APR -PY - 2021 -VL - 41 -IS - 4 -SP - 287 -EP - 302 -DO - 10.1002/cac2.12153 -AN - WOS:000639979700001 -AD - Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangdong Prov Key Lab Translat Med Lung Canc, Guangdong Prov Peoples Hosp,Sch Med, Guangzhou 510080, Guangdong, Peoples R China -AD - Southern Med Univ, Guangzhou 510515, Guangdong, Peoples R China -Y2 - 2021-04-01 -ER - - -TY - JOUR -AU - RICHARDS, F -AU - HOWARD, V -AU - SHORE, A -AU - MUSS, HB -AU - WHITE, DR -AU - JACKSON, DV -AU - COOPER, MR -AU - BEARDEN, J -AU - STUART, JJ -AU - SARTIANO, G -AU - RHYNE, AL -AU - SPURR, CL -TI - COMBINATION CHEMOTHERAPY WITH AND WITHOUT THE METHANOL-EXTRACTED RESIDUE OF BACILLUS CALMETTE-GUERIN (MER) IN EXTENSIVE NON-SMALL-CELL LUNG-CANCER - A PROSPECTIVE RANDOMIZED STUDY FOR THE PIEDMONT ONCOLOGY ASSOCIATION -T2 - CANCER -M3 - Article -PU - WILEY-LISS -PI - NEW YORK -PA - DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 -SN - 0008-543X -DA - 1981 -PY - 1981 -VL - 47 -IS - 12 -SP - 2827 -EP - 2832 -DO - 10.1002/1097-0142(19810615)47:12<2827::AID-CNCR2820471212>3.0.CO;2-D -AN - WOS:A1981LU30100010 -Y2 - 1981-01-01 -ER - - -TY - JOUR -AU - Subramaniyan, Vetriselvan -AU - Fuloria, Shivkanya -AU - Gupta, Gaurav -AU - Kumar, Darnal Hari -AU - Sekar, Mahendran -AU - Sathasivam, Kathiresan, V -AU - Sudhakar, Kalvatala -AU - Alharbi, Khalid Saad -AU - Al-Malki, Waleed Hassan -AU - Afzal, Obaid -AU - Kazmi, Imran -AU - Al-Abbasi, Fahad A. -AU - Altamimi, Abdulmalik Saleh Alfawaz -AU - Fuloria, Neeraj Kumar -TI - A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer -T2 - CHEMICO-BIOLOGICAL INTERACTIONS -M3 - Review -AB - Epithelial growth factor receptor (EGFR) is a cell surface transmembrane receptor that mediates the tyrosine signaling pathway to carry the extracellular messages inside the cell and thereby alter the function of nucleus. This leads to the generation of various protein products to up or downregulate the cellular function. It is encoded by cell erythroblastosis virus oncogene B1, so called C-erb B1/ERBB2/HER-2 gene that acts as a proto-oncogene. It belongs to the HER-2 receptor-family in breast cancer and responds best with anti-Herceptin therapy (anti-tyrosine kinase monoclonal antibody). HER-2 positive breast cancer patient exhibits worse prognosis without Herceptin therapy. Similar incidence and prognosis are reported in other epithelial neoplasms like EGFR + lung non-small cell carcinoma and glioblastoma (grade IV brain glial tumor). Present study highlights the role and connectivity of EGF with various cancers via signaling pathways, cell surface receptors mechanism, macromolecules, mitochondrial genes and neoplasm. Present study describes the EGFR associated gene expression profiling (in breast cancer and NSCLC), relation between mitrochondrial genes and carcinoma, and several in vitro and in vivo models to screen the synergistic effect of various combination treatments. According to this study, although clinical studies including targeted treatments, immunotherapies, radiotherapy, TKi-EGFR combined targeted therapy have been carried out to investigate the synergism of combination therapy; however still there is a gap to apply the scenarios of experimental and clinical studies for further developments. This review will give an idea about the transition from experimental to most advanced clinical studies with different combination drug strategies to treat cancer. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0009-2797 -SN - 1872-7786 -DA - 2022 JAN 5 -PY - 2022 -VL - 351 -C7 - 109735 -DO - 10.1016/j.cbi.2021.109735 -AN - WOS:000721105700005 -C6 - NOV 2021 -AD - MAHSA Univ, Fac Med Biosci & Nursing, Jalan SP 2, Jenjarom 42610, Selangor, Malaysia -AD - AIMST Univ, Fac Pharm, Bedong 08100, Kedah, Malaysia -AD - AIMST Univ, Ctr Excellence Biomat Engn, Bedong 08100, Kedah, Malaysia -AD - Suresh Gyan Vihar Univ, Dept Pharmacol, Mahal Rd, Jaipur, Rajasthan, India -AD - Saveetha Univ, Saveetha Dent Coll & Hosp, Saveetha Inst Med Sci, Dept Pharmacol, Chennai, Tamil Nadu, India -AD - Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Selngor 47500, Malaysia -AD - Univ Kuala Lumpur, Fac Pharm & Hlth Sci, Dept Pharmaceut Chem, Royal Coll Med Perak, Ipoh 30450, Malaysia -AD - AIMST Univ, Fac Appl Sci, Bedong 08100, Kedah, Malaysia -AD - Lovely Profess Univ, Sch Pharmaceut Sci LIT Pharm, Jalandhar 144411, Punjab, India -AD - Jouf Univ, Coll Pharm, Dept Pharmacol, Sakaka, Al Jouf, Saudi Arabia -AD - Umm Al Qura Univ, Coll Pharm, Dept Pharmacol, Mecca, Saudi Arabia -AD - Prince Sattam BinAbdulaziz Univ, Coll Pharm, Dept Pharmaceut Chem, Alkharj 11942, Saudi Arabia -AD - King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah 21589, Saudi Arabia -M2 - Suresh Gyan Vihar Univ -M2 - Monash Univ Malaysia -Y2 - 2021-11-06 -ER - - -TY - JOUR -AU - Turriziani, Mario -AU - Fantini, Massimo -AU - Benvenuto, Monica -AU - Izzi, Valerio -AU - Masuelli, Laura -AU - Sacchetti, Pamela -AU - Modesti, Andrea -AU - Bei, Roberto -TI - Carcinoembryonic Antigen (CEA)-Based Cancer Vaccines: Recent Patents and Antitumor Effects from Experimental Models to Clinical Trials -T2 - RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY -M3 - Review -AB - Carcinoembryonic antigen (CEA), a glycosylated protein of MW 180 kDa, is overexpressed in a wide range of human carcinomas, including colorectal, gastric, pancreatic, non-small cell lung and breast carcinomas. Accordingly, CEA is one of several oncofetal antigens that may serve as a target for active anti-cancer specific immunotherapy. Experimental results obtained by employing animal models have supported the design of clinical trials using a CEA-based vaccine for the treatment of different types of human cancers. This review reports findings from experimental models and clinical evidence on the use of a CEA-based vaccine for the treatment of cancer patients. Among the diverse CEA-based cancer vaccines, DCs- and recombinant viruses-based vaccines seem the most valid. However, although vaccination was shown to induce a strong immune response to CEA, resulting in a delay in tumor progression and prolonged survival in some cancer patients, it failed to eradicate the tumor in most cases, owing partly to the negative effect exerted by the tumor microenvironment on immune response. Thus, in order to develop more efficient and effective cancer vaccines, it is necessary to design new clinical trials combining cancer vaccines with chemotherapy, radiotherapy and drugs which target those factors responsible for immunosuppression of immune cells. This review also discusses relevant patents relating to the use of CEA as a cancer vaccine. -PU - BENTHAM SCIENCE PUBL LTD -PI - SHARJAH -PA - EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES -SN - 1574-8928 -DA - 2012 SEP -PY - 2012 -VL - 7 -IS - 3 -SP - 265 -EP - 296 -DO - 10.2174/157489212801820020 -AN - WOS:000307943700002 -AD - Univ Roma Tor Vergata, Dept Internal Med, I-00133 Rome, Italy -AD - Univ Roma Tor Vergata, Dept Clin Sci & Translat Med, I-00133 Rome, Italy -AD - Univ Roma La Sapienza, Dept Expt Med, I-00161 Rome, Italy -Y2 - 2012-09-19 -ER - - -TY - JOUR -AU - Botticella, Angela -AU - Mezquita, Laura -AU - Le Pechoux, Cecile -AU - Planchard, David -TI - Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience -T2 - THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE -M3 - Review -AB - Stage III non-small cell lung cancer (NSCLC) has a dismal prognosis, with only 15-20% of patients alive at 5 years after concomitant chemo-radiotherapy, which represents the standard treatment. Targeting immune-checkpoint inhibitors represents a standard option for advanced NSCLC. Improvements in understanding of the immune profile of NSCLC has led to the development of immunotherapeutic strategies, including inhibitory molecules responsible for abrogating an anticancer immune response such as programmed cell-death 1 and programmed cell-death ligand 1. A recently published phase III trial (PACIFIC) showed for the first time an improved overall survival in stage III NSCLC patients with consolidative durvalumab. The aim of this review is to summarize and discuss the clinical evidence for the use of durvalumab in stage III NSCLC, with a brief overview on future perspectives in this setting. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1753-4658 -SN - 1753-4666 -DA - 2019 NOV -PY - 2019 -VL - 13 -C7 - 1753466619885530 -DO - 10.1177/1753466619885530 -AN - WOS:000494802800001 -AD - Gustave Roussy, Med Oncol Dept, Thorac Oncol Grp, 114 Rue Edouard Vaillant, F-94805 Villejuif, France -AD - Gustave Roussy, Dept Radiat Oncol, Villejuif, France -AD - Gustave Roussy, Med Oncol Dept, Villejuif, France -Y2 - 2019-11-19 -ER - - -TY - JOUR -AU - Neise, Svenja -AU - Reck, Martin -TI - State of the art: nononcogene-driven stage IV non-small-cell lung cancer -T2 - ONKOLOGIE -M3 - Article -AB - Background In Germany, lung cancer is the third most common malignant tumor in women and ranks second in number of cancer-related deaths, while in men it is the second most common cancer and ranks highest in number of cancer-related deaths. In the majority of cases, it is diagnosed at an advanced stage, so that curative therapy is not an option. New therapy options with checkpoint inhibitors can significantly improve the overall very poor prognosis of these patients. Objectives Based on the relevant clinical trials of the last few years, the following article is intended to provide an overview of the current possibilities in immuno-oncological therapy for the treatment of metastatic non-small-cell lung carcinoma without therapy-relevant molecular alterations. In addition, the pathophysiological principles of checkpoint inhibition are briefly explained. Conclusions In first-line therapy, immunochemotherapy, regardless of programmed death ligand 1 (PD-L1) expression, and immunomonotherapy for PD-L1 high-expressing tumors represent the standard of care for metastatic non-small-cell lung cancer of any histology. Dual checkpoint inhibition using PD-1/CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) inhibitors also offers a chemotherapy-sparing treatment option. In addition to docetaxel + ramucirumab/bevacizumab, checkpoint inhibitors are also used successfully in postprogression therapy. Since biomarker-based criteria for selecting the optimal therapy regimen and sequence for the individual patient are the subject of current research, these decisions can currently only be made clinically. -PU - SPRINGER HEIDELBERG -PI - HEIDELBERG -PA - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY -SN - 2731-7226 -SN - 2731-7234 -DA - 2022 DEC -PY - 2022 -VL - 28 -IS - 12 -SP - 1095 -EP - 1104 -DO - 10.1007/s00761-022-01247-z -AN - WOS:000873363300005 -C6 - OCT 2022 -AD - DRK Klinken Berlin Mitte, Klin Innere Med Pneumol & Schlafmed, Drontheimer Str 39-40, D-13359 Berlin, Germany -AD - LungenClin Grosshansdorf, Grosshansdorf, Germany -M2 - DRK Klinken Berlin Mitte -Y2 - 2022-11-04 -ER - - -TY - JOUR -AU - HOLMES, EC -TI - SURGICAL ADJUVANT THERAPY OF NON-SMALL-CELL LUNG-CANCER -T2 - JOURNAL OF SURGICAL ONCOLOGY -M3 - Article -AB - Results of several studies by the Lung Cancer Study Group have shown that postoperative adjuvant chemotherapy enhances survival following surgery for lung cancer. The 18-month disease-free survival almost doubled in one study using cyclophosphamide, doxorubicin, cisplatin (CAP) chemotherapy postoperatively. The recurrence rate remained significant, however. Patients with more advanced resectable disease seem to benefit most from postoperative chemotherapy. Results also suggest that CAP delays recurrences more effectively in patients with nonsquamous vs. squamous lung carcinoma. There has been considerable interest in the use of preoperative adjuvant therapy as well. Findings from studies of preoperative or induction therapy.sbd.either chemotherapy alone or in combination with radiation therapy.sbd.have shown high response rates and that patients with unresectable disease can be converted to technically resectable. Although preoperative therapy can cause difficulties with surgical dissection, surgical morbidity is acceptable. Preoperative chemotherapy and radiotherapy followed by surgical resection clearly eliminates local recurrence. Systemic recurrences remain a significant problem. The evidence, as yet, does not indicate that preoperative adjuvant therapy prolongs survival. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0022-4790 -SN - 1096-9098 -DA - 1989 -PY - 1989 -SP - 26 -EP - 33 -AN - WOS:A1989U678800006 -AD - UNIV CALIF LOS ANGELES, SCH MED, DEPT SURG ONCOL, LUNG CANC STUD GRP, LOS ANGELES, CA 90024 USA -Y2 - 1989-01-01 -ER - - -TY - JOUR -AU - Liang, Shuzhen -AU - Lin, Mao -AU - Niu, Lizhi -AU - Xu, Kecheng -AU - Wang, Xiaohua -AU - Liang, Yingqing -AU - Zhang, Mingjie -AU - Du, Duanming -AU - Chen, Jibing -TI - Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC) -T2 - AMERICAN JOURNAL OF CANCER RESEARCH -M3 - Article -AB - Natural killer (NK) cells therapy has the potential to prolong survival in patients with advanced non-small cell lung cancer (NSCLC). We conducted a clinical trial to investigate the safety and efficacy of cetuximab plus NK cells therapy in patients with advanced NSCLC. Between June 2015 and August 2016, 54 patients with advanced EGFR-expressing NSCLC were assigned randomly to the cetuximab plus NK cells therapy group (A; n = 27) or cetuximab alone group (B; n = 27). Patients in group A received two courses of NK cells therapy continuously. Cetuximab was administered intravenously and the weekly maintenance dose was continued until tumor progression. All adverse effects were manageable and no significant difference was noted between the two groups (P > 0.05). Levels of CEA, NSE and circulating tumor cells (CTCs) in group A were significantly lower than those before treatment (P < 0.05). Patients in group A had a significant improvement in immune function and quality of life (QOL) (P < 0.05). Patients in group A survived longer than those in group B (median PFS: 6 months vs 4.5 months; median OS: 9.5 months vs 7.5 months; P < 0.05). Combination therapy could be an alternative to chemoradiotherapy for patients with advanced NSCLC. -PU - E-CENTURY PUBLISHING CORP -PI - MADISON -PA - 40 WHITE OAKS LN, MADISON, WI 53711 USA -SN - 2156-6976 -DA - 2018 -PY - 2018 -VL - 8 -IS - 5 -SP - 879 -EP - 891 -AN - WOS:000433361200009 -AD - Jinan Univ, Fuda Canc Hosp, Dept Cent Lab, 2 Tangde West Rd, Guangzhou, Guangdong, Peoples R China -AD - Fuda Canc Inst, Guangzhou, Guangdong, Peoples R China -AD - Hank Bioengn Co Ltd, Shenzhen, Peoples R China -AD - Shenzhen Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp 2, 3002 Shungang Rd, Shenzhen, Peoples R China -M2 - Fuda Canc Inst -M2 - Hank Bioengn Co Ltd -Y2 - 2018-06-12 -ER - - -TY - JOUR -AU - Li, Dongqi -AU - He, Chuanchun -AU - Xia, Yaoxiong -AU - Du, Yaxi -AU - Zhang, Jing -TI - Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report. -T2 - Journal of medical case reports -M3 - Case Reports -M3 - Journal Article -AB - BACKGROUND: Pembrolizumab has significantly improved outcomes in patients with advanced non-small cell lung cancer. Combining programmed death-1 inhibitor with stereotactic body radiotherapy showed a slight toxicity and good benefits in recent clinical trials. However, patients infected with human immunodeficiency virus were excluded from most trials because it was assumed that their anti-tumor immunity was compromised compared with immunocompetent patients.CASE PRESENTATION: In June 2016, a 52-year-old Chineseman presented with human immunodeficiency virus and lung adenocarcinoma (T1bN3M1b). From November 2016 to December 2016, systemic chemotherapy and palliative radiotherapy for bone metastasis of femoral neck were carried out, but the tumor progressed. In January 2017, after immunochemistry detection of programmed death-1 and programmed death-ligand 1 expression (both >50%), pembrolizumab was started. Three weeks after pembrolizumab, we combined stereotactic body radiotherapy for the primary lung tumor. He received no comfort and his CD4 lymphocyte count was stable. Human immunodeficiency virus-ribonucleic acid remained below the limits of detection. In March 2017, after threecycles of pembrolizumab and 5weeks of stereotactic body radiotherapy therapy, he suddenly presented with palpitations. Emergency computed tomography scanning showed massive pericardial effusion and interstitial pneumonia. So we interrupted the pembrolizumab use and initiated treatment with prednisolone 1mg/kg; however, the tumor progressed. Then, his CD4 lymphocyte count declined. Finally he died in June 2017 due to dyscrasia.CONCLUSIONS: Pembrolizumab combined with SBRT therapy for patients with human immunodeficiency virus infection and non-small cell lung cancer may lead to serious immune-related adverse events and more clinical trials are needed. -SN - 1752-1947 -DA - 2018 Apr 23 -PY - 2018 -VL - 12 -IS - 1 -SP - 104 -EP - 104 -DO - 10.1186/s13256-018-1667-2 -AN - MEDLINE:29681240 -AD - Bone and Soft Tissue Tumors Research Center of Yunnan Province, Department of Orthopaedics, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, 650118, People's Republic of China. -AD - Department of Radiotherapy, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, 650118, People's Republic of China. -AD - Lung Cancer Research Center, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, 650118, People's Republic of China. -AD - Bone and Soft Tissue Tumors Research Center of Yunnan Province, Department of Orthopaedics, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, 650118, People's Republic of China. zhangjingnmlimit@tom.com. -Y2 - 2018-04-27 -ER - - -TY - JOUR -AU - Taugner, Julian -AU - Kaesmann, Lukas -AU - Eze, Chukwuka -AU - Ruehle, Alexander -AU - Tufman, Amanda -AU - Reinmuth, Niels -AU - Duell, Thomas -AU - Belka, Claus -AU - Manapov, Farkhad -TI - Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients -T2 - INVESTIGATIONAL NEW DRUGS -M3 - Article -AB - The aim of this prospective study is to evaluate the clinical use and real-world efficacy of durvalumab maintenance treatment after chemoradiotherapy (CRT) in unresectable stage, locally advanced non-small cell lung cancer (NSCLC). All consecutive patients with unresectable, locally advanced NSCLC and PD-L1 expression (>= 1%) treated after October 2018 were included. Regular follow up, including physical examination, PET/CT and/or contrast-enhanced CT-Thorax/Abdomen were performed every three months after CRT. Descriptive treatment pattern analyses, including reasons of discontinuation and salvage treatment, were undertaken. Statistics were calculated from the last day of thoracic irradiation (TRT). Twenty-six patients were included. Median follow up achieved 20.6 months (range: 1.9-30.6). Durvalumab was initiated after a median of 25 (range: 13-103) days after completion of CRT. In median 14 (range: 2-24) cycles of durvalumab were applied within 6.4 (range 1-12.7) months. Six patients (23%) are still in treatment and seven (27%) have completed treatment with 24 cycles. Maintenance treatment was discontinued in 13 (50%) patients: 4 (15%) patients developed grade 3 pneumonitis according to CTCAE v5 after a median of 3.9 (range: 0.5-11.6) months and 7 (range: 2-17) cycles of durvalumab. Four (15%) patients developed grade 2 skin toxicity. One (4%) patient has discontinued treatment due to incompliance. Six and 12- month progression-free survival (PFS) rates were 82% and 62%, median PFS was not reached. No case of hyperprogression was documented. Eight (31%) patients have relapsed during maintenance treatment after a median of 4.8 (range: 2.2-11.3) months and 11 (range: 6-17) durvalumab cycles. Two patients (9%) developed a local-regional recurrence after 14 and 17 cycles of durvalumab. Extracranial distant metastases and brain metastases as first site of failure were detected in 4 (15%) and 2 (8%) patients, respectively. Three (13%) patients presented with symptomatic relapse. Our prospective study confirmed a favourable safety profile of durvalumab maintenance treatment after completion of CRT in unresectable stage, locally advanced NSCLC in a real-world setting. In a median follow-up time of 20.6 months, durvalumab was discontinued in 27% of all patients due to progressive disease. All patients with progressive disease were eligible for second-line treatment. -PU - SPRINGER -PI - DORDRECHT -PA - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS -SN - 0167-6997 -SN - 1573-0646 -DA - 2021 AUG -PY - 2021 -VL - 39 -IS - 4 -SP - 1189 -EP - 1196 -DO - 10.1007/s10637-021-01091-9 -AN - WOS:000627662400002 -C6 - MAR 2021 -AD - Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiat Oncol, Marchioninistr 15, D-81377 Munich, Germany -AD - German Ctr Lung Res DZL, Comprehens Pneumol Ctr Munich CPC M, Munich, Germany -AD - German Canc Consortium DKTK, Munich, Germany -AD - Freiburg Univ, Dept Radiat Oncol, Med Ctr, Freiburg, Germany -AD - German Canc Res Ctr, German Canc Consortium DKTK Partner Site Freiburg, Heidelberg, Germany -AD - Ludwig Maximilians Univ Munchen, Dept Internal Med 5, Div Resp Med & Thorac Oncol, Thorac Oncol Ctr Munich, Munich, Germany -AD - Asklepios Kliniken GmbH, Asklepios Fachkliniken Muenchen, Gauting, Germany -M2 - German Ctr Lung Res DZL -M2 - Asklepios Kliniken GmbH -Y2 - 2021-03-30 -ER - - -TY - JOUR -AU - Leary, Robyn -AU - Gardner, Robert B. -AU - Mockbee, Colleen -AU - Roychowdhury, Debasish F. -TI - Boosting Abscopal Response to Radiotherapy with Sargramostim: A Review of Data and Ongoing Studies -T2 - CUREUS JOURNAL OF MEDICAL SCIENCE -M3 - Review -AB - Drug development in oncology today routinely focuses on approaches that utilize the patients' immune system to destroy the malignancy. Combinatorial approaches of antineoplastic agents, both new and old, are being incorporated in the armamentarium of cancer treatments. The overarching goal of therapy remains the achievement of a complete and durable response with long term remission or cure. One approach in advancing treatment is aimed at strategies that improve immunological memory to induce long lasting immunity against the tumor. Although radiation therapy has not traditionally been thought to elicit an immunological effect, an increasing number of reports document the induction of an immune response against a tumor that kills cancer cells distant to the original site of treatment after local irradiation to a tumor. This phenomenon is called an abscopal effect. Since radiation alone is rarely associated with such a response, it is being combined with immuno-oncology drugs in an attempt to enhance response. One such strategy combines sargramostim, a recombinant human granulocyte macrophage colony stimulating factor (rhu GM-CSF), with radiotherapy. GM-CSF is a cytokine secreted by multiple cells types that promotes maturation of dendritic cells and enables the presentation of tumor-associated antigens to generate a T-cell response. This review article discusses the outcomes of clinical trials and case reports examining the efficacy and safety of combining radiation therapy with this immunomodulatory agent. We will also examine future studies and challenges facing the translation of this therapeutic approach. -PU - SPRINGERNATURE -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND -SN - 2168-8184 -DA - 2019 MAR 19 -PY - 2019 -VL - 11 -IS - 3 -C7 - e4276 -DO - 10.7759/cureus.4276 -AN - WOS:000462083400010 -AD - Partner Therapeut, Oncol, Lexington, MA 02421 USA -AD - Partner Therapeut, Clin Dev, Lexington, MA 02421 USA -M2 - Partner Therapeut -M2 - Partner Therapeut -Y2 - 2019-04-02 -ER - - -TY - JOUR -AU - O'Donnell, Jake S. -AU - Hoefsmit, Esmee P. -AU - Smyth, Mark J. -AU - Blank, Christian U. -AU - Teng, Michele W. L. -TI - The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment -T2 - CLINICAL CANCER RESEARCH -M3 - Review -AB - Cancer immunotherapies utilizing immune checkpoint inhibitors (ICI) have demonstrated durable efficacy in a proportion of patients with advanced/metastatic cancers. More recently, the use of ICIs for the adjuvant treatment of patients with surgically resectable melanoma has also demonstrated efficacy by improving relapse-free survival and in the case of ipilimumab (anti-CTLA-4) also improving overall survival. Although promising, the effective scheduling of surgery and immunotherapy and its duration is not well elucidated. Recent preclinical studies suggest that surgery followed by adjuvant therapy might be suboptimal as compared with an approach in which immunotherapy is applied before surgery (neoadjuvant immunotherapy). Encouraging findings from early-phase clinical trials in melanoma, non-small cell lung carcinoma, and glioblastoma support the idea that neoadjuvant immunotherapy might have improved clinical efficacy over an adjuvant application. In this review, we discuss the existing rationale for the use of neoadjuvant immunotherapy, its apparent strengths and weaknesses, and implications for the design of future clinical trials. -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 1078-0432 -SN - 1557-3265 -DA - 2019 OCT 1 -PY - 2019 -VL - 25 -IS - 19 -SP - 5743 -EP - 5751 -DO - 10.1158/1078-0432.CCR-18-2641 -AN - WOS:000489644500004 -AD - QIMR Berghofer Med Res Inst, Canc Immunoregulat & Immunotherapy Lab, Herston, Qld, Australia -AD - QIMR Berghofer Med Res Inst, Immunol Canc & Infect Lab, Herston, Qld, Australia -AD - Univ Queensland, Sch Med, Herston, Qld, Australia -AD - Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands -AD - Netherlands Canc Inst, Med Oncol Dept, Amsterdam, Netherlands -Y2 - 2019-10-22 -ER - - -TY - JOUR -AU - West, Howard -TI - The Evolving Role of Targeted Therapy in Early-Stage and Locally Advanced Non-small Cell Lung Cancer -T2 - CURRENT ONCOLOGY REPORTS -M3 - Article -AB - Many of the leading developments in management of non-small cell lung cancer (NSCLC) have been provided by the integration of specific targeted therapies either in combination with a backbone of standard chemotherapy or as a single agent. Agents that inhibit a specific pathway, such as that triggered by the activity of the epidermal growth factor receptor, or a regulatory process like angiogenesis, have made it possible to markedly increase response rates and extend survival, sometimes dramatically, along with a favorable therapeutic index. However, these novel therapies have established clinical benefit thus for only in the setting of incurable, advanced NSCLC. The value of these strategies in not only extending survival but potentially improving the cure rate when added to, or substituting for, conventional chemotherapy in the setting of early-stage resectable NSCLC or locally advanced NSCLC remains to be determined. A wide range of clinical trials for these settings have been pursued, with several pivotal studies still ongoing, and will be reviewed for their potential to redefine our current standards of care for potentially curable NSCLC through the integration of targeted therapies. -PU - SPRINGER -PI - NEW YORK -PA - 233 SPRING ST, NEW YORK, NY 10013 USA -SN - 1523-3790 -DA - 2011 AUG -PY - 2011 -VL - 13 -IS - 4 -SP - 280 -EP - 289 -DO - 10.1007/s11912-011-0181-0 -AN - WOS:000292469500007 -AD - Swedish Canc Inst, Thorac Oncol Program, Seattle, WA 98104 USA -Y2 - 2011-07-29 -ER - - -TY - JOUR -AU - Herbst, RS -AU - Langer, CJ -TI - Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers -T2 - SEMINARS IN ONCOLOGY -M3 - Review -PU - W B SAUNDERS CO -PI - PHILADELPHIA -PA - INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA -SN - 0093-7754 -DA - 2002 FEB -PY - 2002 -VL - 29 -IS - 1 -SP - 27 -EP - 36 -DO - 10.1053/sonc.2002.31525 -AN - WOS:000174419200004 -AD - Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA -AD - Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA -AD - Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA -Y2 - 2002-02-01 -ER - - -TY - JOUR -AU - Huber, Rudolf M. -AU - Reck, Martin -AU - Thomas, Michael -TI - Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer -T2 - EUROPEAN RESPIRATORY JOURNAL -M3 - Article -AB - Stage III nonsmall cell lung cancer (NSCLC) encompasses a heterogeneous group of patients, some of whom may be candidates for potentially curative surgery, although for the majority surgery is not an option. Recommended therapy for patients with unresectable stage III disease is concurrent treatment with chemotherapy and thoracic radiotherapy, although even with this dual modality therapy survival remains disappointing. Novel classes of agents including targeted therapies have been shown to improve survival in advanced stage NSCLC, raising the possibility that these agents may have benefits in multimodal therapy when combined with chemoradiotherapy. Here we consider the rationale for combining new agents with chemoradiotherapy and the evidence from clinical studies assessing multimodal strategies for the management of patients with unresectable stage III NSCLC. -PU - EUROPEAN RESPIRATORY SOC JOURNALS LTD -PI - SHEFFIELD -PA - 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND -SN - 0903-1936 -SN - 1399-3003 -DA - 2013 OCT -PY - 2013 -VL - 42 -IS - 4 -SP - 1119 -EP - 1133 -DO - 10.1183/09031936.00143112 -AN - WOS:000325383100033 -AD - Univ Munich, Dept Med, Div Resp Med & Thorac Oncol, Munich, Germany -AD - Thorac Oncol Ctr Munich, Munich, Germany -AD - Hosp Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany -AD - Univ Klinikum Heidelberg, Thoraxklin, Heidelberg, Germany -M2 - Thorac Oncol Ctr Munich -Y2 - 2013-11-07 -ER - - -TY - JOUR -AU - Ratto, GB -AU - Zino, P -AU - Mirabelli, S -AU - Minuti, P -AU - Aquilina, R -AU - Fantino, G -AU - Spessa, E -AU - Ponte, M -AU - Bruzzi, P -AU - Melioli, G -TI - A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma -T2 - CANCER -M3 - Article -AB - BAGKGROUND. A previous pilot study from our group suggested that: (1) adoptive immunotherapy (Al) with tumor-infiltrating lymphocytes (TIL) and recombinant interleukin-2 (rIL-2) may be applied with safety to more than 80% of the patients who had surgery for Stage TIT nonsmall cell lung carcinoma (NSCLC); and (2) AI could be useful in patients with locally advanced disease. The present randomized study was planned to assess the efficacy of AI in the postoperative treatment of Stage II, IIIa, or mb NSCLC.METHODS. TIL were expanded in vitro from tissue samples obtained from the surgically removed specimens of 131 patients. Eighteen cultures yielded no growth of TIL. The remaining 113 patients were stratified according to disease stage and randomized to receive Al or standard chemoradiotherapy. TIL were infused intravenously 6 to 8 weeks after surgery. rIL-2 was administered subcutaneously at escalating doses for 2 weeks, and then at reduced doses for 2 weeks and then for 2 to 3 months.RESULTS. Three-year survival was significantly better (P < 0.05) for patients who underwent AI than for controls. Al was of no benefit to patients with Stage II NSCLC, potentially useful to patients with Stage IIIa NSCLC (P = 0.06), and significantly advantageous to patients with Stage mb (T4) NSCLC (P < 0.01). For patients with Stage III NSCLC, local relapse (but not distant relapse) was significantly reduced following Al (P < 0.05).CONCLUSIONS. AI should be considered when designing future adjuvant therapy protocols for the treatment of NSCLC. (C) 1996 American Cancer Society. -PU - WILEY-LISS -PI - NEW YORK -PA - DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 -SN - 0008-543X -DA - 1996 JUL 15 -PY - 1996 -VL - 78 -IS - 2 -SP - 244 -EP - 251 -DO - 10.1002/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L -AN - WOS:A1996UV02200009 -AD - OSPED SANTA CORONA,PIETRA LIGURE,SAVONA,ITALY -AD - OSPED COSTA RAINERA,IMPERIA,ITALY -AD - IST NAZL RIC CANC,I-16132 GENOA,ITALY -M2 - OSPED SANTA CORONA -M2 - OSPED COSTA RAINERA -Y2 - 1996-07-15 -ER - - -TY - JOUR -AU - Horndalsveen, Henrik -AU - Alver, Tine Norman -AU - Dalsgaard, Astrid Marie -AU - Rogg, Lotte Victoria -AU - Helbekkmo, Nina -AU - Gronberg, Bjorn Henning -AU - Halvorsen, Tarje Onsoien -AU - Ramberg, Christina -AU - Haakensen, Vilde Drageset -AU - Ooejlert, Asa Kristina -AU - Bjaanaes, Maria Moksnes -AU - Helland, Aslaug -TI - Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial -T2 - MOLECULAR ONCOLOGY -M3 - Article -AB - The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non-small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this phase II trial, we investigated the toxicity, systemic responses and circulating tumour DNA responses in patients (n = 21) with advanced non-small-cell lung cancer treated with atezolizumab and stereotactic body radiotherapy in the second or later line. We found the combined treatment to be safe with grade 3 toxicity reported in three patients. As the best overall response, four patients had a partial response, eight had stable disease and five had progressive disease. Median overall survival time was still not reached after a median follow-up of 26.5 months and 10/15 patients with programmed death-ligand 1 negative tumours were alive >18 months after the start of the study treatment. ctDNA was detectable at baseline in 11 patients. A rapid decline in ctDNA to <30% of baseline levels was seen in three patients, two of which were radiographic responders and one was considered clinically benefiting from therapy for almost 1 year. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1574-7891 -SN - 1878-0261 -DA - 2023 MAR -PY - 2023 -VL - 17 -IS - 3 -SP - 487 -EP - 498 -DO - 10.1002/1878-0261.13330 -AN - WOS:000888099100001 -C6 - NOV 2022 -AD - Oslo Univ Hosp, Dept Oncol, Oslo, Norway -AD - Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo N-0424, Norway -AD - Univ Oslo, Dept Clin Med, Oslo, Norway -AD - Univ Hosp North Norway, Dept Pulmonol, Tromso, Norway -AD - Norwegian Univ Sci & Technol, NTNU, Dept Clin & Mol Med, Trondheim, Norway -AD - Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Oncol, Oslo, Norway -AD - Oslo Univ Hosp, Dept Med Phys, Oslo, Norway -Y2 - 2022-11-30 -ER - - -TY - JOUR -AU - Rossi, Antonio -AU - Tay, Rebecca -AU - Chiramel, Jaseela -AU - Prelaj, Arsela -AU - Califano, Raffaele -TI - Current and future therapeutic approaches for the treatment of small cell lung cancer -T2 - EXPERT REVIEW OF ANTICANCER THERAPY -M3 - Review -AB - Introduction: Small-cell lung cancer (SCLC) is a very aggressive disease characterized by a high response rate to first-line chemotherapy, but most patients relapse within 1year with disappointing results to second-line treatments. Chemotherapy has reached a plateau of effectiveness and new therapeutic strategies are needed to change the natural history of SCLC.Areas covered: This review will focus on the current results and the future development of the therapeutic approaches for the treatment of SCLC.Expert commentary: Immunotherapy is becoming a new frontier for the management of SCLC with preliminary interesting results. To date, no targeted drugs have been approved for clinical practice but several novel agents are in an advanced stage of clinical development in SCLC. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1473-7140 -SN - 1744-8328 -DA - 2018 -PY - 2018 -VL - 18 -IS - 5 -SP - 473 -EP - 486 -DO - 10.1080/14737140.2018.1453361 -AN - WOS:000429352500008 -AD - Sci Inst Res & Hlth Care IRCCS Casa Sollievo dell, Div Med Oncol, San Giovanni Rotondo, Italy -AD - Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England -AD - Sapienza Univ Rome, Dept Radiol Pathol & Oncol Sci, Rome, Italy -AD - Manchester Univ NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England -AD - Univ Manchester, Div Canc Sci, Manchester, Lancs, England -M2 - Manchester Univ NHS Fdn Trust -Y2 - 2018-12-28 -ER - - -TY - JOUR -AU - Qu, Fan-jie -AU - Zhou, Yi -AU - Wu, Shuang -TI - Progress of immune checkpoint inhibitors therapy fornon-small cell lung cancer with liver metastases -T2 - BRITISH JOURNAL OF CANCER -M3 - Review -AB - Nearly one-fifth of patients with non-small cell Lung Cancer (NSCLC) will develop liver metastases (LMs), and the overall treatment strategy of LMs will directly affect the survival of patients. However, some retrospective studies have found that patients receiving chemotherapy or targeted therapy have a poorer prognosis once LMs develop. In recent years, multiple randomised controlled trials (RCTS) have shown significant improvements in outcomes for patients with advanced lung cancer following the introduction of immune checkpoint inhibitors (ICIs) compared to conventional chemotherapy. ICIs is safe and effective in patients with LMs, although patients with LMs are mostly underrepresented in randomised clinical trials. However, NSCLC patients with LMs have a significantly worse prognosis than those without LMs when treated with ICIs, and the mechanism by which LMs induce systemic anti-tumour immunity reduction is unknown, so the management of LMs in patients with NSCLC is a clinical challenge that requires more optimised therapies to achieve effective disease control. In this review, we summarised the mechanism of ICIs in the treatment of LMs, the clinical research and treatment progress of ICIs and their combination with other therapies in patients with LMs from NSCLC. -PU - SPRINGERNATURE -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND -SN - 0007-0920 -SN - 1532-1827 -DA - 2024 FEB 10 -PY - 2024 -VL - 130 -IS - 2 -SP - 165 -EP - 175 -DO - 10.1038/s41416-023-02482-w -AN - WOS:001156905000004 -AD - Dalian Med Univ, Dept Oncol, Affiliated Dalian Peoples Hosp 3, Dalian 116033, Peoples R China -Y2 - 2024-02-28 -ER - - -TY - JOUR -AU - Zhang, Shuling -AU - Bai, Xueli -AU - Shan, Fengping -TI - The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer -T2 - INTERNATIONAL IMMUNOPHARMACOLOGY -M3 - Article -AB - Recently, immunotherapy has evolved into a true treatment modality with the approval of PD-1 and PD-L1 inhibitors as the standard care for first-line treatment in patients with non-small cell lung cancer (NSCLC). Until now, for patients with advanced NSCLC, treatment of targeting immune checkpoints reveals a promising survival benefit, and some patients even get long term survive, which creates a paradigm shift in NSCLC treatment. However, many issues or problems are also appearing in clinical practice, such as the lower overall efficacy rate (20-40%), treatment modes, populations choice of immunotherapy, drug resistance, and safety, etc. Thus, in this review, we will mainly summarize and discuss the recent development and confusion of PD-1/PD-L1 inhibitors for advanced NSCLC patients based on current clinical studies. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 1567-5769 -SN - 1878-1705 -DA - 2020 MAR -PY - 2020 -VL - 80 -C7 - 106247 -DO - 10.1016/j.intimp.2020.106247 -AN - WOS:000518708400072 -AD - China Med Univ, Shengjing Hosp, Dept Clin Oncol, Shenyang 110022, Peoples R China -AD - China Med Univ, Affiliated Hosp 4, Dept Gynecol, Shenyang 110004, Peoples R China -AD - China Med Univ, Sch Basic Med Sci, Dept Immunol, Shenyang 110122, Peoples R China -Y2 - 2020-03-26 -ER - - -TY - JOUR -AU - Freitas, Claudia -AU - Jacob, Maria -AU - Tavares, Nuno -AU - Cruz-Martins, Natalia -AU - Souto-Moura, Conceicao -AU - Araujo, David -AU - Novais-Bastos, Helder -AU - Santos, Vanessa -AU - Fernandes, Gabriela -AU - Magalhaes, Adriana -AU - Hespanhol, Venceslau -AU - Queiroga, Henrique -TI - Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents -T2 - ANTI-CANCER DRUGS -M3 - Article -AB - Immune checkpoint inhibitors were approved for advanced nonsmall cell lung cancer (NSCLC) treatment. Despite improved survival, not all patients benefit from these agents. Here, the prognostic impact of pretreatment modified Glasgow Prognostic Score (mGPS) and neutrophil-to-lymphocyte ratio (NLR) was assessed. From 77 patients included, 83.2% received at least one prior systemic therapy. Immune-related adverse events (irAE) occurred in 20 patients. A lower mGPS was associated with higher median overall survival (OS), and a lower Eastern Cooperative Oncology Group (ECOG), irAE and fewer metastatic sites with better survival. A trend towards greater OS and progression-free survival (PFS) was stated among patients with NLR 2 with worse OS and irAE with better survival. Pretreatment mGPS seems to be useful for predicting survival among advanced NSCLC patients treated with anti-programmed cell death 1 drugs, with ECOG performance status, irAE occurrence, and number of metastatic sites acting as survival predictors. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0959-4973 -SN - 1473-5741 -DA - 2021 JUN -PY - 2021 -VL - 32 -IS - 5 -SP - 567 -EP - 574 -DO - 10.1097/CAD.0000000000001060 -AN - WOS:000639592000010 -AD - Ctr Hosp & Univ Sao Joao, Dept Pulmonol, Porto, Portugal -AD - Univ Porto, Fac Med, Dept Med, Alameda Prof Hernani Monteiro, Porto, Portugal -AD - Ctr Hosp & Univ Sao Joao, Dept Oncol, Porto, Portugal -AD - Univ Porto, Inst Res & Innovat Hlth, Metab Nutr & Endocrinol, Rua Alfredo Allen, Porto, Portugal -AD - Univ Porto, Fac Psychol & Educ Sci, Lab Neuropsychophysiol, Porto, Portugal -AD - Ctr Hosp & Univ Sao Joao, Dept Pathol, Porto, Portugal -M2 - Ctr Hosp & Univ Sao Joao -M2 - Ctr Hosp & Univ Sao Joao -M2 - Ctr Hosp & Univ Sao Joao -Y2 - 2021-05-20 -ER - - -TY - JOUR -AU - Cortinovis, Diego -AU - Bidoli, Paolo -AU - Canova, Stefania -AU - Colonese, Francesca -AU - Gemelli, Maria -AU - Lavitrano, Maria Luisa -AU - Banna, Giuseppe Luigi -AU - Liu, Stephen V. -AU - Morabito, Alessandro -TI - Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma -T2 - CANCERS -M3 - Review -AB - Simple SummarySmall cell lung cancer is a subtype of lung cancer and one of the deadliest thoracic tumours. Historically, chemotherapy consisting of either platinum plus etoposide or anthracycline-based regimens have been associated with a high response rate and rapid development of acquired resistance, contributing to the poor overall prognosis. Only a fraction of patients with local or early disease can be cured, whilst the treatment is palliative in those with extensive disease. In recent decades, few novel drugs have been developed, which are herein described.Small cell lung cancer (SCLC) is one of the deadliest thoracic neoplasms, in part due to its fast doubling time and early metastatic spread. Historically, cytotoxic chemotherapy consisting of platinum-etoposide or anthracycline-based regimens has demonstrated a high response rate, but early chemoresistance leads to a poor prognosis in advanced SCLC. Only a fraction of patients with limited-disease can be cured by chemo-radiotherapy. Given the disappointing survival rates in advanced SCLC, new cytotoxic agents are eagerly awaited. Unfortunately, few novel chemotherapy drugs have been developed in the latest decades. This review describes the results and potential application in the clinical practice of novel chemotherapy agents for SCLC. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2021 MAR -PY - 2021 -VL - 13 -IS - 5 -C7 - 1152 -DO - 10.3390/cancers13051152 -AN - WOS:000627950800001 -AD - ASST Monza Osped San Gerardo, Dept Med Oncol, Via Pergolesi 33, I-20090 Monza, Italy -AD - Univ Milano Bicocca, Sch Med & Surg, I-20900 Monza, Italy -AD - Portsmouth Hosp Univ NHS Trust, Dept Oncol, Portsmouth PO6 3LY, Hants, England -AD - Georgetown Univ, Lombardi Comprehens Canc Ctr, 3800 Reservoir Rd NW, Washington, DC 20007 USA -AD - IRCCS Ist Nazl Tumori, Fdn Pascale, SC Oncol Med Toraco Polmonare, I-80100 Naples, Italy -M2 - ASST Monza Osped San Gerardo -M2 - Portsmouth Hosp Univ NHS Trust -Y2 - 2021-03-01 -ER - - -TY - JOUR -AU - FELD, R -TI - LUNG-CANCER - 1983 -T2 - CANADIAN JOURNAL OF SURGERY -M3 - Article -PU - CMA-CANADIAN MEDICAL ASSOC -PI - OTTAWA -PA - 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA -SN - 0008-428X -SN - 1488-2310 -DA - 1983 -PY - 1983 -VL - 26 -IS - 3 -SP - 266 -EP - 268 -AN - WOS:A1983QQ97800024 -AD - UNIV TORONTO, DEPT MED, TORONTO M5S 1A1, ONTARIO, CANADA -Y2 - 1983-01-01 -ER - - -TY - JOUR -AU - Geraci, Emily -AU - Chablani, Lipika -TI - Immunotherapy as a second-line or later treatment modality for advanced non-small cell lung cancer: A review of safety and efficacy -T2 - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY -M3 - Review -AB - Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for 80-85% of these cases. Surgical resection is the most common conventional treatment of lung cancer. For patients with advanced NSCLC, platinum-based chemotherapy remains the cornerstone of treatment. Although platinum-based chemotherapy demonstrated improved outcomes, the need for the second-line/later therapies is evident. A review was conducted to assess the safety and efficacy of immunotherapies as the second-line/later therapy of advanced NSCLC. Clinical trial data was collected via PubMed and Clinicaltrials.gov. Recent studies were selected based on prespecified inclusion/exclusion criteria. Data on the safety and efficacy of the immunotherapy was subsequently compiled from relevant trials. Monoclonal antibodies targeting PD-1/PD-L1 showed the most promising results as the second-line/later treatment modalities. Immunizations did not produce as robust of an immune response in participants; however, they warrant further research to determine their place in therapy. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1040-8428 -SN - 1879-0461 -DA - 2020 AUG -PY - 2020 -VL - 152 -C7 - 103009 -DO - 10.1016/j.critrevonc.2020.103009 -AN - WOS:000549168700016 -AD - St John Fisher Coll, Wegmans Sch Pharm, Rochester, NY 14618 USA -Y2 - 2020-07-28 -ER - - -TY - JOUR -AU - Cheema, P. K. -AU - Rothenstein, J. -AU - Melosky, B. -AU - Brade, A. -AU - Hirsh, V. -TI - Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer -T2 - CURRENT ONCOLOGY -M3 - Review -AB - For more than a decade, there has been no improvement in outcomes for patients with unresectable locally advanced (LA) non-small-cell lung cancer (NSCLC). The standard treatment in that setting is definitive concurrent chemotherapy and radiation (CCRT). Although the intent of treatment is curative, most patients rapidly progress, and their prognosis is poor, with a 5-year overall survival (OS) rate in the 15%-25% range. Those patients therefore represent a critical unmet need, warranting expedited approval of, and access to, new treatments that can improve outcomes. The pacific trial, which evaluated durvalumab consolidation therapy after CCRT in unresectable la NSCLC, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and a significant improvement in OS. Durvalumab thus fills a critical unmet need in the setting of unresectable la NSCLC and provides a new option for patients treated with curative intent. Here, we review the treatment of unresectable la NSCLC, with a focus on the effect of the clinical data for durvalumab. -PU - MULTIMED INC -PI - TORONTO -PA - 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA -SN - 1198-0052 -DA - 2019 FEB -PY - 2019 -VL - 26 -IS - 1 -SP - 37 -EP - 42 -DO - 10.3747/co.25.4096 -AN - WOS:000459451200025 -AD - William Osler Hlth Syst, Brampton Toronto, ON, Canada -AD - Univ Toronto, Toronto, ON, Canada -AD - RS McLaughlin Durham Reg Canc Ctr, Oshawa, ON, Canada -AD - Queens Univ, Kingston, ON, Canada -AD - BC Canc Vancouver, Vancouver, BC, Canada -AD - Univ British Columbia, Vancouver, BC, Canada -AD - Peel Reg Canc Ctr, Mississauga, ON, Canada -AD - Royal Victoria Hosp, Montreal, PQ, Canada -AD - McGill Univ, Montreal, PQ, Canada -M2 - William Osler Hlth Syst -M2 - RS McLaughlin Durham Reg Canc Ctr -M2 - BC Canc Vancouver -M2 - Peel Reg Canc Ctr -Y2 - 2019-03-07 -ER - - -TY - JOUR -AU - Suzuki, Shinsuke -AU - Toyoma, Satoshi -AU - Tomizawa, Hiroki -AU - Yamada, Toshiki -AU - Iikawa, Nobuko -AU - Shiina, Kazuhiro -AU - Saito, Hidekazu -AU - Koizumi, Koh -AU - Kawasaki, Yohei -AU - Yamada, Takechiyo -TI - Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck -T2 - AURIS NASUS LARYNX -M3 - Article -AB - Nivolumab, a programmed death-1 (PD-1) inhibitor, has shown promising results against squamous cell carcinoma of the head and neck (SCCHN) in cases of recurrence or in a metastatic setting after platinum-based therapy. However, treatment alternatives for patients with nivolumab-refractory are limited, and a constant opinion is not provided.Recently, accumulating studies have demonstrated that chemotherapy after immune checkpoint inhibitor treatment may induce better objective responses in patients with advanced non-small cell lung cancer. However, there are few reports on the increased effect of chemotherapy after nivolumab treatment in SCCHN. Therefore, cases must be accumulated to identify patients with nivolumab-refractory SCCHN who may benefit from chemotherapy.Here, we present patients with SCCHN who exhibited a significant response to chemotherapy after nivolumab treatment. (C) 2019 Elsevier B.V. All rights reserved. -PU - ELSEVIER SCI LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND -SN - 0385-8146 -SN - 1879-1476 -DA - 2020 JUN -PY - 2020 -VL - 47 -IS - 3 -SP - 485 -EP - 488 -DO - 10.1016/j.anl.2019.06.004 -AN - WOS:000568859600023 -AD - Akita Univ, Dept Otorhinolaryngol & Head & Neck Surg, Grad Sch Med, Akita 0108543, Japan -Y2 - 2020-09-25 -ER - - -TY - JOUR -AU - Nguyen, Nam P. -AU - Page, Brandi R. -AU - Giap, Huan -AU - Dahbi, Zineb -AU - Vinh-Hung, Vincent -AU - Gorobets, Olena -AU - Mohammadianpanah, Mohammad -AU - Motta, Micaela -AU - Portaluri, Maurizio -AU - Arenas, Meritxell -AU - Bonet, Marta -AU - Lara, Pedro Carlos -AU - Kim, Lyndon -AU - Dutheil, Fabien -AU - Natoli, Elena -AU - Loganadane, Gokoulakrichenane -AU - Lehrman, David -AU - Bose, Satya -AU - Kaur, Sarabjot -AU - Blanco, Sergio Calleja -AU - Chi, Alexander -TI - Immunotherapy and Radiotherapy for Older Patients with Locally Advanced Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline Surgery and Chemotherapy: A Practical Proposal by the International Geriatric Radiotherapy Group -T2 - CANCERS -M3 - Article -AB - Simple Summary Older patients with locally advanced non-small cell lung cancer may not be candidates for standard treatment due to their poor performance status. Immunotherapy and radiotherapy are well tolerated and may become the treatment of choice for those patients. This hypothesis should be confirmed in future clinical trials. Abstract The standard of care for locally advanced non-small-cell lung cancer (NSCLC) is either surgery combined with chemotherapy pre- or postoperatively or concurrent chemotherapy and radiotherapy. However, older and frail patients may not be candidates for surgery and chemotherapy due to the high mortality risk and are frequently referred to radiotherapy alone, which is better tolerated but carries a high risk of disease recurrence. Recently, immunotherapy with immune checkpoint inhibitors (ICIs) may induce a high response rate among cancer patients with positive programmed death ligand 1 (PD-L1) expression. Immunotherapy is also well tolerated among older patients. Laboratory and clinical studies have reported synergy between radiotherapy and ICI. The combination of ICI and radiotherapy may improve local control and survival for NSCLC patients who are not candidates for surgery and chemotherapy or decline these two modalities. The International Geriatric Radiotherapy Group proposes a protocol combining radiotherapy and immunotherapy based on the presence or absence of PD-L1 to optimize the survival of those patients. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2024 SEP -PY - 2024 -VL - 16 -IS - 17 -C7 - 3112 -DO - 10.3390/cancers16173112 -AN - WOS:001311327700001 -AD - Howard Univ, Dept Radiat Oncol, Washington, DC 20059 USA -AD - Johns Hopkins Univ, Dept Radiat Oncol, Baltimore, MD 21218 USA -AD - Univ Illinois, OSF HeathCare Canc Inst, Radiat Oncol Proton Therapy, Peoria, IL 61603 USA -AD - Mohammed VI Univ Hlth Sci, Dept Radiat Oncol, Casablanca 82403, Morocco -AD - Ctr Hosp Publ Cotentin, Dept Radiat Oncol, F-50100 Cherbourg En Cotentin, France -AD - Canc Tech Care Assoc, Dept Oral Surg, F-66000 Perpignan, France -AD - Shiraz Univ Med Sci, Colorectal Res Ctr, Dept Radiat Oncol, Shiraz 7134814336, Iran -AD - ASST Papa Giovanni XXIII, Dept Radiat Oncol, I-24127 Bergamo, Italy -AD - Univ Rovira I Virgili, St Joan de Reus Univ Hosp, Dept Radiat Oncol, Tarragona 43007, Spain -AD - Arnau de Vilanova Univ Hosp, Dept Radiat Oncol, Lleida 25198, Spain -AD - Fernando Pessoria Canarias Las Palmas Univ, Dept Radiat Oncol, Las Palmas Gran Canaria 35002, Spain -AD - Mt Sinai Hosp, Div Neurooncol, New York, NY 10029 USA -AD - Clin St Clotilde, Dept Radiat Oncol, F-97400 St Denis, France -AD - IRCCS Azienda Osped Univ Bologna, Dept Radiat Oncol, I-40138 Bologna, Italy -AD - Bologna Univ, Dept Med & Surg Sci DIMEC, Radiat Oncol, Alma Mater Studorium, I-40126 Bologna, Italy -AD - Inst Curie, Dept Radiat Oncol, F-75005 Paris, France -AD - Int Geriatr Radiotherapy Grp, Dept Radiat Oncol, Washington, DC 20001 USA -AD - Howard Univ, Dept Oral Maxillofacial Surg, Washington, DC 20059 USA -AD - Capital Univ, Xuanwu Hosp, Dept Radiat Oncol, Beijing 100053, Peoples R China -M2 - Ctr Hosp Publ Cotentin -M2 - Canc Tech Care Assoc -M2 - Arnau de Vilanova Univ Hosp -M2 - Fernando Pessoria Canarias Las Palmas Univ -M2 - Clin St Clotilde -M2 - Int Geriatr Radiotherapy Grp -Y2 - 2024-09-18 -ER - - -TY - JOUR -AU - Rajan, Arun -AU - Kim, Chul -AU - Heery, Christopher R. -AU - Guha, Udayan -AU - Gulley, James L. -TI - Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers -T2 - HUMAN VACCINES & IMMUNOTHERAPEUTICS -M3 - Review -AB - The development of immune checkpoint inhibitors has altered the landscape of treatment of advanced cancers. These drugs are well tolerated and have shown clinical activity against a wide variety of solid tumors and hematological malignancies. The durability of response is particularly impressive when compared to other forms of systemic therapy. Nivolumab (Opdivo) is an IgG4 antibody that causes immune checkpoint blockade by diminishing inhibitory signaling through the programmed death receptor-1 pathway. It is approved for treatment of recurrent non-small cell lung cancer, melanoma, and renal cell carcinoma. Efforts to identify biomarkers of response to nivolumab are ongoing. Clinical trials are also being conducted to determine the benefits of combining nivolumab with other forms of treatment including chemotherapy, molecular-targeted therapy, radiation therapy, and other forms of immune therapy. This review outlines the clinical trials that have led to the emergence of nivolumab as a treatment option for patients with advanced cancers. -PU - TAYLOR & FRANCIS INC -PI - PHILADELPHIA -PA - 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA -SN - 2164-5515 -SN - 2164-554X -DA - 2016 -PY - 2016 -VL - 12 -IS - 9 -SP - 2219 -EP - 2231 -DO - 10.1080/21645515.2016.1175694 -AN - WOS:000384217200014 -AD - NCI, Thorac & Gastrointestinal Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA -AD - NCI, Tumor Immunol & Biol Lab, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA -AD - NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA -Y2 - 2016-01-01 -ER - - -TY - JOUR -AU - Mielgo-Rubio, Xabier -AU - Montemuino, Sara -AU - Jimenez, Unai -AU - Luna, Javier -AU - Cardena, Ana -AU - Mezquita, Laura -AU - Martin, Margarita -AU - Counago, Felipe -TI - Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy -T2 - CANCERS -M3 - Review -AB - Simple SummaryThe treatment of resectable stage III non-small-cell lung cancer with N2 lymph node involvement is usually multimodal and is generally based on neoadjuvant chemotherapy +/- radiotherapy followed by surgery, but the cure rate is still low. Immunotherapy based on anti-PD1/PD-L1 immune checkpoint inhibitors has improved survival in advanced and stage III non-resectable NSCLC patients and is being studied in earlier stages to improve the cure rate of lung cancer. In this article, we review all therapeutic approaches to stage III-N2 NSCLC, analysing both completed and ongoing studies that evaluate the addition of immunotherapy with or without chemotherapy and/or radiotherapy.Stage III non-small-cell lung cancer (NSCLC) with N2 lymph node involvement is a heterogeneous group with different potential therapeutic approaches. Patients with potentially resectable III-N2 NSCLC are those who are considered to be able to receive a multimodality treatment that includes tumour resection after neoadjuvant therapy. Current treatment for these patients is based on neoadjuvant chemotherapy +/- radiotherapy followed by surgery and subsequent assessment for adjuvant chemotherapy and/or radiotherapy. In addition, some selected III-N2 patients could receive upfront surgery or pathologic N2 incidental involvement can be found a posteriori during analysis of the surgical specimen. The standard treatment for these patients is adjuvant chemotherapy and evaluation for complementary radiotherapy. Despite being a locally advanced stage, the cure rate for these patients continues to be low, with a broad improvement margin. The most immediate hope for improving survival data and curing these patients relies on integrating immunotherapy into perioperative treatment. Immunotherapy based on anti-PD1/PD-L1 immune checkpoint inhibitors is already a standard treatment in stage III unresectable and advanced NSCLC. Data from the first phase II studies in monotherapy neoadjuvant therapy and, in particular, in combination with chemotherapy, are highly promising, with impressive improved and complete pathological response rates. Despite the lack of confirmatory data from phase III trials and long-term survival data, and in spite of various unresolved questions, immunotherapy will soon be incorporated into the armamentarium for treating stage III-N2 NSCLC. In this article, we review all therapeutic approaches to stage III-N2 NSCLC, analysing both completed and ongoing studies that evaluate the addition of immunotherapy with or without chemotherapy and/or radiotherapy. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2021 OCT -PY - 2021 -VL - 13 -IS - 19 -C7 - 4811 -DO - 10.3390/cancers13194811 -AN - WOS:000707213400001 -AD - Hosp Univ Fdn Alcorcon, Dept Med Oncol, Madrid 28922, Spain -AD - Hosp Univ Fuenlabrada, Dept Radiat Oncol, Madrid 28942, Spain -AD - Hosp Univ Cruces, Dept Thorac Surg, Baracaldo 48903, Bizkaia, Spain -AD - Fdn Jimenez Diaz, Dept Radiat Oncol, Madrid 28040, Spain -AD - Hosp Univ Clin Barcelona, Dept Med Oncol, Barcelona 08036, Spain -AD - Hosp Univ Ramon y Cajal, Dept Radiat Oncol, Madrid 28034, Spain -AD - Hosp Univ Quironsalud Madrid, Dept Radiat Oncol, Madrid 28223, Spain -AD - Hosp La Luz, Dept Radiat Oncol, Madrid 28003, Spain -AD - Univ Europea, Sch Biomed Siciences, Med Dept, Madrid 28670, Spain -M2 - Fdn Jimenez Diaz -M2 - Hosp Univ Clin Barcelona -M2 - Hosp La Luz -Y2 - 2021-10-01 -ER - - -TY - JOUR -AU - Luke, Jason J. -AU - Onderdonk, Benjamin E. -AU - Bhave, Sandeep R. -AU - Karrison, Theodore -AU - Lemons, Jeffrey M. -AU - Chang, Paul -AU - Zha, Yuanyuan -AU - Carll, Tim -AU - Krausz, Thomas -AU - Huang, Lei -AU - Martinez, Carlos -AU - Janisch, Linda A. -AU - Hseu, Robyn D. -AU - Moroney, John W. -AU - Patel, Jyoti D. -AU - Khodarev, Nikolai N. -AU - Salama, Joseph K. -AU - Ott, Patrick A. -AU - Fleming, Gini F. -AU - Gajewski, Thomas F. -AU - Weichselbaum, Ralph R. -AU - Pitroda, Sean P. -AU - Chmura, Steven J. -TI - Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial -T2 - CLINICAL CANCER RESEARCH -M3 - Article -M3 - Proceedings Paper -CP - ASTRO-RSNA Research Workshop on Treatment of Oligometastatic Disease -CL - Washington, DC -AB - Purpose: Multisite stereotactic body radiotherapy followed by pembrolizumab (SBRT+P) has demonstrated safety in advanced solid tumors (ASTs). However, no studies have examined the relationships between irradiated tumor response, SBRT-induced tumor gene expression, and overall survival (OS).Patients and Methods: Patients with AST received SBRT (30-50 Gy in 3-5 fractions) to two to four metastases followed by pembrolizumab (200 mg i.v. every 3 weeks). SBRT was prescribed to a maximum tumor volume of 65 mL. Small metastases received the complete prescribed coverage (cornplete-Rx), while larger metastases received partial coverage (partial-Rx). Treated metastasis control (TMC) was defined as a lack of progression for an irradiated metastasis. Landmark analysis was used to assess the relationship between TMC and OS. Thirty-five biopsies were obtained from 24 patients: 19 pre-SBRT and 16 post-SBRT (11 matched) prior to pembrolizumab and were analyzed via RNA microarray.Results: Sixty-eight patients (139 metastases) were enrolled with a median follow-up of 10.4 months. One-year TMC was 895% with no difference between complete-Rx or partial-Rx. On multivariable analysis, TMC was independently associated with a reduced risk for death (HR, 0.36; 95% confidence interval, 0.17 0.75; P = 0.006). SBRT increased expression of innate and adaptive immune genes and concomitantly decreased expression of cell cycle and DNA repair genes in the irradiated tumors. Elevated post-SBRT expression of DNASE1 correlated with increased expression of cytolytic T-cell genes and irradiated tumor response.Conclusions: In the context of SBRT-FP, TMC independently correlates with OS. SBRT impacts intratumoral immune gene expression associated with TMC. Randomized trials are needed to validate these findings. -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 1078-0432 -SN - 1557-3265 -DA - 2020 DEC 15 -PY - 2020 -VL - 26 -IS - 24 -SP - 6437 -EP - 6444 -DO - 10.1158/1078-0432.CCR-20-1790 -AN - WOS:000606533000007 -AD - Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA -AD - Univ Chicago Med, Chicago, IL USA -AD - Canc Care Grp PC, Indianapolis, IN USA -AD - Radiat Oncol Associates, Dover, NH USA -AD - Northwestern Med, Chicago, IL USA -AD - Duke Hlth, Durham, NC USA -AD - Dana Farber Canc Inst, Boston, MA 02115 USA -M2 - Univ Chicago Med -M2 - Canc Care Grp PC -M2 - Radiat Oncol Associates -M2 - Duke Hlth -Y2 - 2021-02-03 -ER - - -TY - JOUR -AU - Nagai, Yoshiaki -AU - Sata, Masafumi -AU - Ohta, Hiromitsu -AU - Onuki, Tsugitoshi -AU - Saito, Tatsuya -AU - Uchiyama, Ayumi -AU - Kurosaki, Ayako -AU - Yoshizumi, Naoko -AU - Takigami, Ayako -AU - Nakazawa, Shoko -AU - Nakayama, Masayuki -AU - Yamaguchi, Hironori -AU - Hagiwara, Koichi -TI - Herpes zoster in patients with lung cancer treated with PD-1/PD-L1 antibodies -T2 - IMMUNOTHERAPY -M3 - Article -AB - Background: There are no available clinical data on immunotherapy and the risk of herpes zoster. Materials & methods: This retrospective study included patients with recurrent or advanced lung cancer who were inoperable and ineligible for radiotherapy and were treated with either a PD-1/PD-L1 antibody (136 patients) or an EGFR tyrosine kinase inhibitor (149 patients) at Jichi Medical University Hospital between January 2016 and December 2018. Results: Herpes zoster-free survival was significantly shorter in the PD-1/PD-L1 antibody-treated group compared with the EGFR tyrosine kinase inhibitor-treated group (hazard ratio: 0.20; 95% CI: 0.048-0.84; p = 0.016). PD-1/PD-L1 antibody administration was independently and significantly associated with herpes zoster occurrence. Conclusion: Clinicians should anticipate herpes zoster in patients with lung cancer during treatment with PD-1/PD-L1 antibodies.Tweetable abstract Herpes zoster occurs more frequently in patients on immune checkpoint inhibitors for lung cancer than in those on EGFR tyrosine kinase inhibitors. Clinicians should be cautious of this during treatment with immune checkpoint inhibitors.Plain language summary There are no available clinical data on immunotherapy and the risk of herpes zoster. This retrospective study included patients with recurrent or advanced lung cancer who were inoperable and ineligible for radiotherapy and were treated with either an immune checkpoint inhibitor (136 patients) or an EGFR tyrosine kinase inhibitor (149 patients) through the authors' university between January 2016 and December 2018. The herpes zoster-free period was significantly shorter in the immune checkpoint inhibitor-treated group compared with the EGFR tyrosine kinase inhibitor-treated group (hazard ratio: 0.20; 95% CI: 0.048-0.84; p = 0.016). Immune checkpoint inhibitor antibody administration was independently and significantly associated with herpes zoster occurrence. Clinicians should be cautious of herpes zoster in patients with lung cancer during treatment with immune checkpoint inhibitors. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1750-743X -SN - 1750-7448 -DA - 2022 OCT -PY - 2022 -VL - 14 -IS - 15 -SP - 1211 -EP - 1217 -DO - 10.2217/imt-2021-0318 -AN - WOS:000847382900001 -C6 - AUG 2022 -AD - Jichi Med Univ Hosp, Dept Internal Med, Div Resp Med, 3311-1 Yakushi Ji, Shimotsuke, Tochigi 3290431, Japan -AD - Jichi Med Univ, Dept Resp Med, Saitama Med Ctr, Saitama, Japan -AD - Jichi Med Univ Hosp, Dept Clin Oncol, 3311-1 Yakushi Ji, Shimotsuke, Tochigi 3290431, Japan -Y2 - 2022-09-04 -ER - - -TY - JOUR -AU - Pastina, Pierpaolo -AU - Nardone, Valerio -AU - Botta, Cirino -AU - Croci, Stefania -AU - Tini, Paolo -AU - Battaglia, Giuseppe -AU - Ricci, Veronica -AU - Cusi, Maria Grazia -AU - Gandolfo, Claudia -AU - Misso, Gabriella -AU - Zappavigna, Silvia -AU - Caraglia, Michele -AU - Giordano, Antonio -AU - Aldinucci, Donatella -AU - Tassone, Pierfrancesco -AU - Tagliaferri, Pierosandro -AU - Pirtoli, Luigi -AU - Correale, Pierpaolo -TI - Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev) -T2 - ONCOTARGET -M3 - Article -AB - Radiotherapy (RT), together with a direct cytolytic effect on tumor tissue, also elicits systemic immunological events, which sometimes result in the regression of distant metastases (abscopal effect). We have shown the safety and anti-tumor activity of a novel metronomic chemotherapy (mCH) regimen with dose-fractioned cisplatin, oral etoposide and bevacizumab, a mAb against the vasculo-endothelial-growth-factor (mPEBev regimen), in metastatic non-small-cell-lung cancer (mNSCLC). This regimen, designed on the results of translational studies, showed immune-modulating effects that could trigger and empower the immunological effects associated with tumor irradiation. In order to assess this, we carried out a retrospective analysis in a subset of 69 consecutive patients who received the mPEBev regimen within the BEVA2007 trial. Forty-five of these patients, also received palliative RT of one or more metastatic sites. Statistical analysis (a Log-rank test) revealed a much longer median survival in the group of patients who received RT [mCH vs mCH + RT: 12.1+/-2.5 (95% CI 3.35-8.6) vs 22.12+/- 4.3 (95% CI 11.9-26.087) months; P=0.015] with no difference in progression-free survival. In particular, their survival correlated with the mPEBev regimen ability to induce the percentage of activated dendritic cells (DCs) (CD3-CD11b+CD15-CD83+CD80+) [Fold to baseline value (FBV) <= 1 vs > 1: 4+/-5.389 (95% CI, 0-14.56) vs 56+/-23.05 (95% CI, 10.8-101.2) months; P:0.049)] and central-memory-T-cells (CD3+CD8+CD45RA-CCR7+) [FBV <= 1 vs > 1: 8+/-5.96 (95% CI, 0-19.68) vs 31+/-12.3 (95% CI, 6.94-55.1) months; P: 0.045].These results suggest that tumor irradiation may prolong the survival of NSCLC patients undergone mPEBev regimen presumably by eliciting an immune-mediated effect and provide the rationale for further perspective clinical studies. -PU - IMPACT JOURNALS LLC -PI - ORCHARD PARK -PA - 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA -SN - 1949-2553 -DA - 2017 SEP 29 -PY - 2017 -VL - 8 -IS - 44 -SP - 75904 -EP - 75913 -DO - 10.18632/oncotarget.20411 -AN - WOS:000412066700012 -AD - Siena Univ Hosp, Radiotherapy Unit, Dept Med Surg & Neurosci, Siena, Italy -AD - Magna Graecia Univ Catanzaro, AUO Mater Domini, Med Oncol Unit, Catanzaro, Italy -AD - Siena Univ Hosp, Radiol Unit, Dept Med Surg & Neurosci, Siena, Italy -AD - Univ Siena, Dept Med Biotechnol, Microbiol & Virol Unit, Siena, Italy -AD - Univ Campania L Vanvitelli, Dept Biochem Biophys & Gen Pathol, Naples, Italy -AD - Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA -AD - Univ Siena, Dept Med Surg & Neurosci, Siena, Italy -AD - ITT, Siena, Italy -AD - CRO Aviano Natl Canc Inst, Dept Expt Oncol 2, Aviano, Italy -AD - Metropolitan Hosp Bianchi Melacrino Morelli, Med Oncol Unit, Reggio Di Calabria, Italy -M2 - Metropolitan Hosp Bianchi Melacrino Morelli -Y2 - 2017-09-29 -ER - - -TY - JOUR -AU - La-Beck, Ninh M. -AU - Jean, Gary W. -AU - Huynh, Cindy -AU - Alzghari, Saeed K. -AU - Lowe, Devin B. -TI - Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy -T2 - PHARMACOTHERAPY -M3 - Review -AB - The treatment of cancer has largely relied on killing tumor cells with nonspecific cytotoxic therapies and radiotherapy. This approach, however, has limitations including severe systemic toxicities, bystander effects on normal cells, recurrence of drug-resistant tumor cells, and the inability to target micrometastases or subclinical disease. An increased understanding of the critical role of the immune system in cancer development and progression has led to new treatment strategies using various immunotherapies. It is now recognized that established tumors have numerous mechanisms of suppressing the antitumor immune response including production of inhibitory cytokines, recruitment of immunosuppressive immune cells, and upregulation of coinhibitory receptors known as immune checkpoints. This review focuses on the immune checkpoint inhibitors, a novel class of immunotherapy first approved in 2011. Our objective is to highlight similarities and differences among the three immune checkpoint inhibitors approved by the U.S. Food and Drug Administration-ipilimumab, pembrolizumab, and nivolumab-to facilitate therapeutic decision making. We conducted a review of the published literature and conference proceedings and present a critical appraisal of the clinical evidence supporting their use in the treatment of metastatic melanoma and advanced squamous non-small cell lung cancer (NSCLC). We also compare and contrast their current place in cancer therapy and patterns of immune-related toxicities, and discuss the role of dual immune checkpoint inhibition and strategies for the management of immune-related adverse events. The immune checkpoint inhibitors have demonstrated a dramatic improvement in overall survival in patients with advanced melanoma and squamous NSCLC, along with acceptable toxicity profiles. These agents have a clear role in the first-line treatment of advanced melanoma and in the second-line treatment of advanced squamous NSCLC. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0277-0008 -SN - 1875-9114 -DA - 2015 OCT -PY - 2015 -VL - 35 -IS - 10 -SP - 963 -EP - 976 -DO - 10.1002/phar.1643 -AN - WOS:000364240300010 -AD - Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Immunotherapeut & Biotechnol, Abilene, TX 79601 USA -AD - Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharm Practice, Abilene, TX 79601 USA -AD - Texas Tech Univ, Hlth Sci Ctr, Experimmune, Abilene, TX 79601 USA -Y2 - 2015-10-01 -ER - - -TY - JOUR -AU - Chu, Xiangling -AU - Han, Chaonan -AU - Su, Chunxia -TI - Treatment of small cell lung cancer: recent advances -T2 - CURRENT OPINION IN ONCOLOGY -M3 - Review -AB - Purpose of review In this article, we aimed to summarize the recent progress being made in treatment of small cell lung cancer (SCLC). Recent findings SCLC is characterized by strong invasiveness, easy recurrence and early metastasis. In recent years, the emergence of immune checkpoint inhibitors (ICIs) therapy has broken the deadlock in the treatment field of SCLC. Combination strategies, such as the addition of ICIs to chemotherapy and radiotherapy, are actively underway. Some of these strategies have yielded significant survival benefits and tolerable adverse events, whereas several of them have failed with no significant improvement. In addition, the new classification of SCLC based on genomic analysis has deepened the understanding of SCLC and suggested new therapeutic directions. Similarly, the discovery of some new therapeutic targets, such as DDL3, CDK7 and PARP, also brings new hope for improving the survival of patients with SCLC. In this article, we will review the recent advances of therapeutic regimen for patients with SCLC. Following the revolutionary success of adding ICIs to chemotherapy, more varieties of combination strategies have been explored in recent trials. In addition, therapeutic drug research and efficacy evaluation against for new targets are under investigation. Altogether, progress on genomic analysis, investigation of biological pathways and treatment regimen combination are providing renewed hope for patients with SCLC. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1040-8746 -SN - 1531-703X -DA - 2022 JAN -PY - 2022 -VL - 34 -IS - 1 -SP - 83 -EP - 88 -DO - 10.1097/CCO.0000000000000804 -AN - WOS:000725148000012 -AD - Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China -AD - Tongji Univ, Sch Med, Thorac Canc Inst, Shanghai, Peoples R China -Y2 - 2021-12-10 -ER - - -TY - JOUR -AU - Zaborowska-Szmit, Magdalena -AU - Szmit, Sebastian -AU - Olszyna-Serementa, Marta -AU - Badurak, Pawel -AU - Zajda, Katarzyna -AU - Janowicz-Zebrowska, Anna -AU - Piorek, Aleksandra -AU - Knetki-Wroblewska, Magdalena -AU - Jaskiewicz, Piotr -AU - Pluzanski, Adam -AU - Krzakowski, Maciej -AU - Kowalski, Dariusz M. -TI - Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy -T2 - CANCERS -M3 - Article -AB - Simple Summary Concurrent platinum-based chemoradiotherapy (CRT) followed by maintenance treatment with the PD-L1 inhibitor durvalumab is the most effective therapy in unresectable stage III non-small-cell lung cancer (NSCLC). However, severe toxicity of this approach may lead to an unsatisfactory outcome. Cardiovascular diseases (CVD) may justify the use of sequential CRT to avoid severe adverse events and maintain satisfactory effectiveness. Ensuring that patients with CVD do not have a worse prognosis than patients without CVD is one of the goals of cardio-oncology. It is important that, after sequential CRT as personalized for patients with CVD, there is no increased mortality, and this is the first achievement of this study. Patients receiving beta-blockers and statins had lower all-cause mortality over 2, 3, and 4 years. The clear benefit of treatment with beta-blockers (in possible combination with statin) was confirmed in a subgroup of patients with CVD. The patients with CVD and indications for different cardiac therapy could live significantly longer if they received beta-blockers with or without statins during long-term follow-up. It may be a time to consider beta-blockers and statins as prevention strategy in patients undergoing CRT for NSCLC. The study was conducted in the era when maintenance immunotherapy with durvalumab was not available in clinical practice after chemoradiotherapy (CRT) in unresectable non-small-cell lung cancer (NSCLC). The main aim of the study was to check whether the presence of cardiovascular diseases (CVD) and their pharmacotherapy affects the overall survival (OS) in such NSCLC patients undergoing sequential CRT. The group of 196 patients were analyzed: 101 patients with CVD (51.53%) and 95 patients with other reasons of qualification for sequential CRT (decreased performance status, older age, and other non-cardiovascular co-morbidities). Although patients with CVD were more often in older age, and they more often experienced cardiac and nephrological complications (p < 0.05 for all), there was a statistically nonsignificant trend for lower all-cause mortality in patients with CVD. The lowest all-cause mortality was observed in patients treated with beta-blockers and statins after two (HR = 0.31; 95%CI: 0.1-0.98; p = 0.047), three (HR = 0.33; 95%CI: 0.13-0.81; p = 0.015) and even four (HR = 0.45; 95%CI: 0.22-0.97; p = 0.027) years of follow-up. The benefit in OS remained significant in 101 patients with CVD treated with beta-blockers (HR = 0.65; 95%CI: 0.43-0.99; p = 0.045), and eventually statin, throughout the whole follow-up (log-rank p < 0.05). Further prospective studies are necessary to confirm the role of beta-blockers and statins in reduction of mortality in NSCLC patients undergoing radical CRT. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2023 FEB -PY - 2023 -VL - 15 -IS - 4 -C7 - 1277 -DO - 10.3390/cancers15041277 -AN - WOS:000944850200001 -AD - Mar Sklodowska Curie Natl Res Inst Oncol, Dept Lung Canc & Thorac Tumors, PL-02781 Warsaw, Poland -AD - Inst Hematol & Transfus Med, Ctr Postgrad Med Educ, Dept Cardio Oncol, PL-02776 Warsaw, Poland -AD - Mar Sklodowska Curie Natl Res Inst Oncol, Clin Oncol Diagnost & Cardio Oncol, PL-02781 Warsaw, Poland -M2 - Mar Sklodowska Curie Natl Res Inst Oncol -M2 - Mar Sklodowska Curie Natl Res Inst Oncol -Y2 - 2023-03-22 -ER - - -TY - JOUR -AU - Li, Fenge -AU - Wu, Huancheng -AU - Du, Xueming -AU - Sun, Yimo -AU - Rausseo, Barbara Nassif -AU - Talukder, Amjad -AU - Katailiha, Arjun -AU - Elzohary, Lama -AU - Wang, Yupeng -AU - Wang, Zhiyu -AU - Lizee, Gregory -TI - Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma -T2 - VACCINES -M3 - Review -AB - The epidermal growth factor receptor (EGFR) plays crucial roles in several important biological functions such as embryogenesis, epithelial tissue development, and cellular regeneration. However, in multiple solid tumor types overexpression and/or activating mutations of the EGFR gene frequently occur, thus hijacking the EGFR signaling pathway to promote tumorigenesis. Non-small cell lung cancer (NSCLC) tumors in particular often contain prevalent and shared EGFR mutations that provide an ideal source for public neoantigens (NeoAg). Studies in both humans and animal models have confirmed the immunogenicity of some of these NeoAg peptides, suggesting that they may constitute viable targets for cancer immunotherapies. Peptide vaccines targeting mutated EGFR have been tested in multiple clinical trials, demonstrating an excellent safety profile and encouraging clinical efficacy. For example, the CDX-110 (rindopepimut) NeoAg peptide vaccine derived from the EGFRvIII deletion mutant in combination with temozolomide and radiotherapy has shown efficacy in treating EGFRvIII-harboring glioblastoma multiforme (GBM) patients undergone surgery in multiple Phase I and II clinical trials. Furthermore, pilot clinical trials that have administered personalized NeoAg peptides for treating advanced-stage NSCLC patients have shown this approach to be a feasible and safe method to increase antitumor immune responses. Amongst the vaccine peptides administered, EGFR mutation-targeting NeoAgs induced the strongest T cell-mediated immune responses in patients and were also associated with objective clinical responses, implying a promising future for NeoAg peptide vaccines for treating NSCLC patients with selected EGFR mutations. The efficacy of NeoAg-targeting peptide vaccines may be further improved by combining with other modalities such as tyrosine kinase or immune checkpoint inhibitor (ICI) therapy, which are currently being tested in animal models and clinical trials. Herein, we review the most current basic and clinical research progress on EGFR-targeted peptide vaccination for the treatment of NSCLC and other solid tumor types. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2076-393X -DA - 2023 SEP -PY - 2023 -VL - 11 -IS - 9 -C7 - 1460 -DO - 10.3390/vaccines11091460 -AN - WOS:001072204100001 -AD - Tianjin BeiChen Hosp, Core Lab, Beiyi Rd, Tianjin 300400, Peoples R China -AD - Tianjin Beichen Hosp, Dept Pathol, Tianjin, Peoples R China -AD - Tianjin Beichen Hosp, Dept Neurosurg, Tianjin 300400, Peoples R China -AD - Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77054 USA -AD - Hebei Med Univ, Dept Immunooncol, Hosp 4, Shijiazhuang 050011, Peoples R China -AD - Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77054 USA -M2 - Tianjin BeiChen Hosp -M2 - Tianjin Beichen Hosp -M2 - Tianjin Beichen Hosp -Y2 - 2023-10-08 -ER - - -TY - JOUR -AU - Chen, Can -AU - Chen, Minjun -AU - Bai, Yuju -AU - Li, Yajun -AU - Peng, Jie -AU - Yao, Biao -AU - Feng, Jiangping -AU - Zhou, Jian-Guo -AU - Ma, Hu -TI - A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer -T2 - TECHNOLOGY IN CANCER RESEARCH & TREATMENT -M3 - Article -AB - Background Cadonilimab (AK104) is a bispecific IgG-single-chain Fv fragment (ScFv) antibody that binds to PD-1 and CTLA-4. Cadonilimab has shown encouraging anti-tumour activity and a favourable safety profile in several tumour types. In second-line treatment, there is no defined standard of care for patients with extensive-stage small-cell lung cancer (ES-SCLC). Cadonilimab is expected to show substantial clinical efficacy.Objective To assess the antitumor activity and safety of cadonilimab monotherapy or combination with conventional therapy in ES-SCLC patients who failed first-line treatment.Methods In this multicenter, open-label, phase II study, ES-SCLC patients who had failed first-line treatment, also aged 18 years to 70 years with histologically or cytologically confirmed ES-SCLC, and an Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0-2 were eligible. Patients will receive cadonilimab 10 mg/kg every three weeks (Q3 W) among 24 months until progressive disease (PD) or adverse events (AE) discovery. The primary endpoint is progression-free survival (PFS).Trial registration NCT05901584. -PU - SAGE PUBLICATIONS INC -PI - THOUSAND OAKS -PA - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA -SN - 1533-0346 -SN - 1533-0338 -DA - 2024 -PY - 2024 -VL - 23 -C7 - 15330338241249690 -DO - 10.1177/15330338241249690 -AN - WOS:001216092800001 -AD - Zunyi Med Univ, Affiliated Hosp 2, Dept Oncol, Intersect Xinlong & Xinpu Ave, Zunyi 563000, Peoples R China -AD - First Peoples Hosp Zunyi, Dept Oncol, Zunyi, Guizhou, Peoples R China -AD - Guizhou Med Univ, Affiliated Hosp 2, Dept Oncol, Kaili, Guizhou, Peoples R China -AD - Tongren Peoples Hosp, Dept Oncol, Tongren, Guizhou, Peoples R China -AD - Xingyi Peoples Hosp, Dept Oncol, Xingyi, Guizhou, Peoples R China -M2 - First Peoples Hosp Zunyi -M2 - Tongren Peoples Hosp -M2 - Xingyi Peoples Hosp -Y2 - 2024-05-13 -ER - - -TY - JOUR -AU - Watanabe, Shigenobu -AU - Ogino, Ichiro -AU - Shigenaga, Daisuke -AU - Hata, Masaharu -TI - Relationship Between Radiation Pneumonitis Following Definitive Radiotherapy for Non-small Cell Lung Cancer and Isodose Line -T2 - IN VIVO -M3 - Article -AB - Background/Aim: It is important to identify radiation pneumonitis above Common Terminology Criteria for Adverse Events Grade 2 (G2) in order to safely continue durvalumab maintenance after chemoradiotherapy for advanced lung cancer. The aim of this study was to discover factors that predict pneumonitis above G2. Patients and Methods: A follow-up computed tomography (CT) image was superimposed on the planning CT image using deformable image registration (DIR). The pneumonitis area was contoured on follow-up CT after DIR and the dose-volume histogram parameters of the contoured pneumonitis area were calculated. Results: V5 (Percentage of total volume receiving >= 5 Gy) to V50 of pneumonitis were significantly lower in patients with G2 pneumonitis than in those with G1 pneumonitis. The pneumonitis V15 was the most significant. The group with pneumonitis V15 <87.10% had significantly more G2 pneumonitis than the group with pneumonitis V15 >= 87.10%. Conclusion: Pneumonitis V15 <87.10% was a risk factor for G2 pneumonitis. -PU - INT INST ANTICANCER RESEARCH -PI - ATHENS -PA - EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE -SN - 0258-851X -SN - 1791-7549 -DA - 2021 NOV-DEC -PY - 2021 -VL - 35 -IS - 6 -SP - 3441 -EP - 3448 -DO - 10.21873/invivo.12644 -AN - WOS:000711693300029 -AD - Yokohama City Univ, Med Ctr, Dept Radiat Oncol, Yokohama, Kanagawa, Japan -AD - Yokohama City Univ, Grad Sch Med, Dept Radiat Oncol, Yokohama, Kanagawa, Japan -Y2 - 2021-11-11 -ER - - -TY - JOUR -AU - Puri, Sonam -AU - Saltos, Andreas -AU - Perez, Bradford -AU - Le, Xiuning -AU - Gray, Jhanelle E. -TI - Locally Advanced, Unresectable Non-Small Cell Lung Cancer -T2 - CURRENT ONCOLOGY REPORTS -M3 - Review -AB - Purpose of Review Treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) has recently been revolutionized by the incorporation of immunotherapy to standard platinum-based concurrent chemoradiation. This review examines the current standard practices and ongoing studies on the management of locally advanced, unresectable NSCLC. Recent Findings Concurrent chemoradiation is the cornerstone of treatment of unresectable, locally advanced NSCLC. However, chemoradiation can be associated with high therapy-related toxicities, and risk of disease relapse remains significantly elevated despite treatment with curative intent. Durvalumab, a PD-L1 inhibitor, was recently approved as consolidation therapy following concurrent chemoradiation; this agent represents a major advancement in treatment of unresectable stage III NSCLC. Several clinical trials are currently underway to evaluate the benefit of different immunotherapy sequencing and other biomarker-driven strategies in this disease setting. Multiple trials are presently ongoing to assess novel immunotherapy and targeted therapy strategies to improve outcomes and decrease treatment-associated toxicities in patients with locally advanced NSCLC. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1523-3790 -SN - 1534-6269 -DA - 2020 MAR 5 -PY - 2020 -VL - 22 -IS - 4 -C7 - 31 -DO - 10.1007/s11912-020-0882-3 -AN - WOS:000518548600001 -AD - Univ Utah, Huntsman Canc Inst, Div Med Oncol, Salt Lake City, UT USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL 33612 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac & Head & Neck Med Oncol, Houston, TX 77030 USA -Y2 - 2020-03-19 -ER - - -TY - JOUR -AU - BUNN, PA -TI - THE TREATMENT OF NONSMALL CELL LUNG-CANCER - CURRENT PERSPECTIVES AND CONTROVERSIES, FUTURE-DIRECTIONS -T2 - SEMINARS IN ONCOLOGY -M3 - Article -M3 - Proceedings Paper -CP - Fox-Chase-Cancer-Center Workshop on the Role of Platinum Compounds in Cancer Treatment - Chemotherapy with Platinum compounds: Current Status and Future Directions -CL - KONA, HI -PU - W B SAUNDERS CO -PI - PHILADELPHIA -PA - INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 -SN - 0093-7754 -DA - 1994 JUN -PY - 1994 -VL - 21 -IS - 3 -SP - 49 -EP - 59 -AN - WOS:A1994PC97100007 -Y2 - 1994-06-01 -ER - - -TY - JOUR -AU - Ceresoli, Giovanni Luca -AU - Rossi, Giulio -AU - Agustoni, Francesco -AU - Bonomi, Lucia -AU - Borghetti, Paolo -AU - Bulotta, Alessandra -AU - Casartelli, Clelia -AU - Cerea, Giulio -AU - Colonese, Francesca -AU - del Signore, Ester -AU - Finocchiaro, Giovanna -AU - Gianoncelli, Letizia -AU - Grisanti, Salvatore -AU - Maiolani, Martina -AU - Pagni, Fabio -AU - Proto, Claudia -AU - Rijavec, Erika -AU - Vittimberga, Isabella -AU - Arcangeli, Stefano -AU - Filippi, Andrea Riccardo -TI - Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach -T2 - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY -M3 - Review -AB - Background: Immunotherapy represented a turning point for treating extensive small-cell lung cancer (ES-SCLC). Although, many issues remain debated. Methods: A group of Italian medical and radiation oncologists with expertise in managing patients with ES-SCLC developed a list of statements divided in six areas of interest. The Delphi method was used to assess the consensus on the defined list of statements. Results: 32 statements were included in the final list to be voted by the Delphi panel, and 26 reached a consensus on the agreement. A prompt involvement of a multidisciplinary team is a priority to provide an integrated treatment strategy. First-line recommended treatment is immunotherapy in combination with platinum-based chemotherapy and etoposide for four cycles followed by maintenance immunotherapy. Conclusions: While awaiting new data from clinical trials and real-world studies, these recommendations can represent a useful tool to guide the management of ES-SCLC patients in daily practice. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1040-8428 -SN - 1879-0461 -DA - 2024 JUL -PY - 2024 -VL - 199 -C7 - 104247 -DO - 10.1016/j.critrevonc.2023.104247 -AN - WOS:001300475600001 -AD - Human Gavazzeni Hosp, Dept Med Oncol, Bergamo, Italy -AD - Hosp Inst Fdn Poliambulanza, Pathol Unit, Via Bissolati 57, I-25124 Brescia, Italy -AD - Univ Pavia, Dept Internal Med & Med Therapy, Pavia, Italy -AD - Fdn IRCCS Policlin San Matteo, Med Oncol Unit, Pavia, Italy -AD - ASST Papa Giovanni XXIII Hosp, Unit Oncol, Bergamo, Italy -AD - ASST Spedali Civili & Univ Brescia, Radiat Oncol Dept, Brescia, Italy -AD - IRCCS San Raffaele, Dept Oncol, via Olgettina 60, Milan, Italy -AD - Valduce Hosp, Unit Oncol, Como, Italy -AD - ASST Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy -AD - ASST San Gerardo Monza, Med Oncol Unit, Monza, Italy -AD - European Inst Oncol, Div Thorac Oncol, IEO, Milan, Italy -AD - IRCCS, Ist Clin Human, Human Canc Ctr, Med Oncol & Hematol Unit, Rozzano, Italy -AD - San Paolo Hosp, Med Oncol Unit, ASST Santi Paolo & Carlo, Milan, Italy -AD - Univ Brescia, ASST Spedali Civili Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlth, Med Oncol Unit, Brescia, Italy -AD - UOC Oncol Med ASST Valtellina & Alto Lario, Sondrio, Italy -AD - Univ Milano Bicocca, Dept Med & Surg, Pathol, Via Cadore 48, I-20900 Monza, Italy -AD - Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy -AD - ASST Sette Laghi, Osped Circolo & Fdn Macchi, Unit Med Oncol, Varese, Italy -AD - Osped A Manzoni, Oncol Dept, Lecce, Italy -AD - Univ Milano Bicocca, Dept Radiat Oncol, Milan, Italy -AD - Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy -AD - Fdn IRCCS Policlin San Matteo, Radiat Oncol, Pavia, Italy -M2 - Human Gavazzeni Hosp -M2 - Hosp Inst Fdn Poliambulanza -M2 - ASST Spedali Civili & Univ Brescia -M2 - Valduce Hosp -M2 - ASST Grande Osped Metropolitano Niguarda -M2 - ASST San Gerardo Monza -M2 - IRCCS -M2 - UOC Oncol Med ASST Valtellina & Alto Lario -M2 - Osped A Manzoni -Y2 - 2024-09-02 -ER - - -TY - JOUR -AU - Hanna, Gerard G. -AU - Coyle, Victoria M. -AU - Prise, Kevin M. -TI - Immune modulation in advanced radiotherapies: Targeting out-of-field effects -T2 - CANCER LETTERS -M3 - Review -AB - By virtue of being a localized treatment modality, radiotherapy is unable to deliver a tumoricidal radiation dose to tissues outside of the irradiated field. Nevertheless, ionizing radiation may result in radiation damage mediated by a bystander like effect away from the irradiated field, but this response is likely to be modest when radiotherapy is the sole treatment modality. Over the last decade there has been a reemergence of immune modulating therapies as anti-cancer treatment modalities. Clinical trials on vaccines have on the whole been largely disappointing, but greater response rates have been observed from the immune checkpoint modulators. A clinical benefit of using such agents has been shown in disease sites such as melanoma and non-small cell lung cancer. There is growing pre-clinical data and a number of case reports which suggest the presence of abscopal effects when radiotherapy is co-administered with immune checkpoint inhibitors, suggesting that this combination may lead to an enhanced tumour response outside of the primary treatment field. In this review, the mechanisms of such an enhanced out-of-field tumour response, the potential clinical utilities, the optimal radiotherapy delivery and considerations for clinical follow-up following treatment are discussed. (C) 2015 Elsevier Ireland Ltd. All rights reserved. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0304-3835 -SN - 1872-7980 -DA - 2015 NOV 28 -PY - 2015 -VL - 368 -IS - 2 -SP - 246 -EP - 251 -DO - 10.1016/j.canlet.2015.04.007 -AN - WOS:000361864200013 -AD - Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7AE, Antrim, North Ireland -Y2 - 2015-11-28 -ER - - -TY - JOUR -AU - Raben, D -AU - Helfrich, B -AU - Bunn, PA -TI - Targeted therapies for non-small-cell lung cancer: Biology, rationale, and preclinical results from a radiation oncology perspective -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Article -AB - The epidermal growth factor receptor (EGFR) is overexpressed in the majority of non-small-cell lung cancers (NSCLCs). This presents an opportune target for new treatment strategies designed to selectively interfere with the cancer cell growth cycle. Recent investigations into the biology of the EGFR and its downstream signaling pathways have reminded us of the complexity of cancer cell communications from the cytoplasm to the nucleus. Multiple pathways are activated with stimulation of the autocrine and paracrine EGFR loop, from the ras-raf-MEK activation of ERK 1/2 to the PI3K-Akt pathway, each playing an important role in cancer cell survival, invasion, and angiogenesis. Preclinical studies have demonstrated that molecules targeting the EGFR, either through extracellular blockade or intracellular interference with the EGFR-associated tyrosine kinase, reversibly or irreversibly, inhibit cancer cell growth. Potent antitumor effects have been observed in human tumor xenograft models. Preclinical studies have also demonstrated cooperative effects when anti-EGFR agents are combined with radiation or chemotherapy. Many of these agents have now entered into advanced human clinical trials with modest dose-related toxicity despite chronic administration. Encouraging response rates with single-agent targeted therapy have been reported in heavily pretreated patients with advanced NSCLC. In addition, agents targeting the angiogenic pathway, which plays a key role in the regulation of angiogenesis, may play an important role in enhancing the efficacy of anti-EGFR agents. This article will focus on the biology, rationale, and preclinical studies with targeted anti-EGFR and antiangiogenic therapies for the management of NSCLC. (C) 2004 Elsevier Inc. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2004 -PY - 2004 -VL - 59 -IS - 2 -SP - 27 -EP - 38 -DO - 10.1016/j.ijrobp.2004.01.054 -AN - WOS:000221597800005 -AD - Univ Colorado, Hlth Sci Ctr, Dept Radiat Oncol, Aurora, CO 80010 USA -AD - Univ Colorado, Hlth Sci Ctr, Dept Med Oncol, Aurora, CO 80010 USA -Y2 - 2004-01-01 -ER - - -TY - JOUR -AU - Chae, Young Kwang -AU - Pan, Alan -AU - Davis, Andrew A. -AU - Mohindra, Nisha -AU - Matsangou, Maria -AU - Villaflor, Victoria -AU - Giles, Francis -TI - Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer -T2 - CLINICAL LUNG CANCER -M3 - Review -AB - Small-cell lung cancer (SCLC) is distinguished from nonesmall-cell lung cancer by its rapid growth and more frequent metastases. Although patients with SCLC are highly responsive to chemotherapy and radiation therapy, long-term prognosis remains poor, with relapse and disease recurrence occurring in almost all cases. Whereas combination chemotherapies continue to be the standard of care in extensive-stage SCLC, there is value in exploring whether immune-checkpoint inhibition is an effective treatment strategy, given the durable responses in nonesmall-cell lung cancer. Data from SCLC trials have shown clinical activity and response to cytotoxic T-lymphocyte antigen-4 protein and programmed cell death-1 blockade, suggesting that antibodies targeting these pathways may be effective in improving survival outcome. However, data on clinical activity by programmed cell death-1 ligand expression in SCLC are not widely available. Limited data indicate that programmed cell death-1 ligand expression may not be an ideal biomarker for patient selection. Continued research is necessary to better optimize patient selection and response to therapy. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2017 MAR -PY - 2017 -VL - 18 -IS - 2 -SP - 132 -EP - 140 -DO - 10.1016/j.cllc.2016.07.004 -AN - WOS:000397933900011 -AD - Northwestern Univ, Div Hematol Oncol, Dev Therapeut Program, 645 N Michigan Ave,Suite 1006, Chicago, IL 60611 USA -AD - Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, 645 N Michigan Ave,Suite 1006, Chicago, IL 60611 USA -AD - Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, 645 N Michigan Ave,Suite 1006, Chicago, IL 60611 USA -Y2 - 2017-03-01 -ER - - -TY - JOUR -AU - Pennock, M. M. -AU - Halmos, B. -AU - Bodner, W. R., III -AU - Cheng, H. -AU - Gucalp, R. -AU - Ohri, N. -TI - Predictors of Early Durvalumab Discontinuation After Chemoradiotherapy for Non-Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 2928 -SP - E448 -EP - E449 -AN - WOS:000715803800923 -AD - Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10467 USA -AD - Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA -AD - Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA -AD - Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA -AD - Montefiore Med Ctr, New York, NY USA -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Mezquita, Laura -AU - Planchard, David -TI - Durvalumab in non-small-cell lung cancer patients: current developments -T2 - FUTURE ONCOLOGY -M3 - Article -AB - Immune checkpoint inhibitors (ICIs) are a key component of treating advanced cancer patients, principally antibodies against CTLA-4 and PD-1 or PD-L1. Durvalumab (MEDI4736) is a selective, high-affinity, human IgG1 monoclonal antibody that blocks PD-L1, which binds to PD-1 and CD80, but not to PD-L2. Single-agent durvalumab showed clinical efficacy and a manageable safety profile in advanced non-small-cell lung cancer, particularly the >= 25% PD-L1+ population. Durvalumab is under evaluation in early, locally advanced and advanced disease as monotherapy and combined with ICIs, targeted therapies, chemotherapy and radiotherapy. Impressive activity has been recently reported after chemoradiation in locally advanced patients; promising activity was observed with other ICI combinations, and potentially with other drugs including platinum-based chemotherapy. In contrast, early data reveal lower response rates in EGFR and ALK-positive patients. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1479-6694 -SN - 1744-8301 -DA - 2018 FEB -PY - 2018 -VL - 14 -IS - 3 -SP - 205 -EP - 222 -DO - 10.2217/fon-2017-0373 -AN - WOS:000427262500004 -AD - Gustave Roussy, Med Oncol Dept, Villejuif, France -Y2 - 2018-03-28 -ER - - -TY - JOUR -AU - Cui, Ran -AU - Li, Yun -AU - Yu, Xinlin -AU - Wei, Chun -AU - Jiang, Ou -TI - Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis -T2 - PLOS ONE -M3 - Article -AB - Background The recent usage of immunotherapy combined with chemoradiotherapy has improved survival in advanced non-small cell lung cancer (NSCLC) patients. However, determining the most effective therapy combination remains a topic of debate. Research suggests immune checkpoint inhibitors (ICIs) post-chemoradiotherapy enhance survival, but the impact of concurrent ICIs during chemoradiotherapy on rapid disease progression is unclear. This meta-analysis aims to assess the effectiveness and safety of concurrent ICIs with radiotherapy or chemoradiotherapy in advanced non-small cell lung cancer.Methods We searched PubMed, Embase, the Cochrane Library, and Web of Science for relevant studies, extracting data on overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs).Results The analysis included ten studies with 490 participants. Stage III NSCLC ORR was 81.8%, while Stage IV ORR was 39.9%. One-year PFS and OS for Stage III were 68.2% and 82.6%, compared to 27.9% and 72.2% for Stage IV. Common adverse events included anemia (46.6%), nausea (47.6%), rash (36.4%), and radiation pneumonitis (36.3%).Conclusions Our meta-analysis shows concurrent ICIs with chemoradiotherapy are effective and safe in advanced NSCLC, particularly in stage III patients at risk of progression before starting ICIs after chemoradiotherapy. The findings support further phase III trials. The review protocol was registered on PROSPERO (CRD42023493685) and is detailed on the NIHR HTA programme website. -PU - PUBLIC LIBRARY SCIENCE -PI - SAN FRANCISCO -PA - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA -SN - 1932-6203 -DA - 2024 JUN 12 -PY - 2024 -VL - 19 -IS - 6 -C7 - e0304941 -DO - 10.1371/journal.pone.0304941 -AN - WOS:001248347100035 -AD - First Peoples Hosp Neijiang, Dept Oncol, Neijiang, Sichuan, Peoples R China -AD - Second Peoples Hosp Neijiang, Dept Oncol, Neijiang, Sichuan, Peoples R China -M2 - First Peoples Hosp Neijiang -M2 - Second Peoples Hosp Neijiang -Y2 - 2024-06-30 -ER - - -TY - JOUR -AU - Oliver, Timothee -AU - Prasad, Vinay -TI - Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later? -T2 - TRANSLATIONAL ONCOLOGY -M3 - Article -AB - On March 4th 2022, nivolumab received regular US Food and Drug Administration approval, based on the CheckMate 816 trial results, for use "with platinum -doublet chemotherapy for adult patients with resectable NSCLC in the neoadjuvant setting ". This is the first neoadjuvant approval of a checkpoint inhibitor, a unique event in the history of lung cancer treatment. However, open questions remains. First, the co-primary endpoints of the CheckMate 816 trial (event-free survival and pathological complete response) are not yet validated surrogate endpoints in this setting. Second, the control arm was not reflecting the most common approach, being upfront surgery followed by adjuvant chemotherapy. Third, protocol changes were not plainly justified, questioning the analytic plan of the trial. Fourth and last, a subpar access to checkpoint inhibitor for patients upon progression may weaken overall survival results. Neoadjuvant strategies allow to study initial response under treatment, and constitute an encouraging therapeutic avenue. However, the best sequence of treatment is the key question in the neoadjuvant or adjuvant settings: is treating everyone upfront better than treating only patients that will eventually recur?Investigating optimal sequence strategy is even more critical within the checkpoint-inhibitor era, where patients with advanced or metastatic disease may present long-term advantage. Trials with optimal post -progression treatment are needed to help optimize our treatment algorithm, and spare toxicity for patients who don't derive benefit. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1936-5233 -DA - 2022 OCT -PY - 2022 -VL - 24 -C7 - 101505 -DO - 10.1016/j.tranon.2022.101505 -AN - WOS:000864875900001 -C6 - AUG 2022 -AD - Geneva Univ Hosp, Dept Oncol, 4 Gabrielle Perret Gentil St, CH-1205 Geneva, Switzerland -AD - Univ Calif San Francisco, Dept Epidemiol & Biostat, 550 16th St, 2nd Fl, San Francisco, CA 94158 USA -Y2 - 2022-10-21 -ER - - -TY - JOUR -AU - Huo, L. -AU - Chu, C. -AU - Jiang, X. -AU - Zheng, S. -AU - Zhang, P. -AU - Zhou, R. -AU - Chen, N. -AU - Guo, J. -AU - Qiu, B. -AU - Liu, H. -TI - A Pilot Trial of Consolidation Bevacizumab after HypoFractionated Concurrent Chemoradiotherapy in Patients with Unresectable Locally Advanced Non-Squamous Non Small -Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2082 -SP - E38 -EP - E38 -AN - WOS:001079706800078 -AD - SunYat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China -AD - SunYat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China -AD - Sun Yat Sen Univ Canc Ctr, Guangzhou, Peoples R China -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Manglaviti, Sara -AU - Bini, Marta -AU - Apollonio, Giulia -AU - Zecca, Ernesto -AU - Galli, Giulia -AU - Sangaletti, Sabina -AU - Labianca, Alice -AU - Sottotetti, Elisa -AU - Brambilla, Marta -AU - Occhipinti, Mario -AU - Proto, Claudia -AU - Prelaj, Arsela -AU - Signorelli, Diego -AU - De Toma, Alessandro -AU - Viscardi, Giuseppe -AU - Beninato, Teresa -AU - Mazzeo, Laura -AU - Bottiglieri, Achille -AU - Leporati, Rita -AU - Fotia, Giuseppe -AU - Ganzinelli, Monica -AU - Portararo, Paola -AU - Garassino, Marina Chiara -AU - de Braud, Filippo G. M. -AU - Lo Russo, Giuseppe -AU - Torri, Valter -AU - Ferrara, Roberto -TI - High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors -T2 - LUNG CANCER -M3 - Article -AB - Background: Bone-targeted agents (BTA), such as denosumab (DN) and zoledronic acid (ZA), have historically reduced the risk of skeletal related events in cancer patients with bone metastases (BM), with no improvement in survival outcomes. In the immunotherapy era, BM have been associated with poor prognosis upon immune -checkpoint inhibitors (ICI). Currently, the impact of bone tumor burden on survival upon BTAs in advanced non-small cell lung cancer (aNSCLC) patients treated with ICI remains unknown. Methods: Data from ICI-treated aNSCLC patients with BM (4/2013-5/2022) in one institution were retrospec-tively collected. BTA-ICI concurrent treatment was defined as BTA administration at any time before or within 90 days from ICI start. High bone tumor burden (HBTB) was defined as >= 3 sites of BM. Median OS (mOS) was estimated with Kaplan-Meier. Aikaike's information criterion (AIC) was used to select the best model for data analysis adjusted for clinical variables. Results: Of 134 patients included, 51 (38 %) received BTA. At a mFU of 39.6 months (m), BTA-ICIs concurrent treatment did not significantly impact on mOS [8.3 m (95% CI 3.9-12.8) versus (vs) 6.8 m (95% CI 4.0-9.6) p = 0.36]; these results were confirmed after adjustment for clinical variables selected by AIC. A multivariate model showed a significant interaction between BTA use and HBTB or radiation therapy to BM. In subgroup analyses, only HBTB confirmed to be associated with significantly longer mOS [8.3 m (95% CI 2.4-14.2) vs 3.5 m (95% CI 2.9-4.1), p = 0.003] and mPFS [3.0 m (95% CI 1.6-4.4) vs 1.8 m (95% CI 1.6-2.0) p = 0.001] upon BTA-ICI concurrent treatment, with the most pronounced OS benefit observed for DN-ICI concurrent regimen [15.2 m (95% CI 0.1-30.7) vs 3.5 m (95% CI 2.9-4.1) p = 0.002]. Conclusions: In the immunotherapy era, HBTB can identify patients experiencing survival benefit with BTA, especially with DN-ICI combination. HBTB should be included as a stratification factor in the upcoming trials assessing BTA and ICI combinations in patients with aNSCLC and BM. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2023 DEC -PY - 2023 -VL - 186 -C7 - 107417 -DO - 10.1016/j.lungcan.2023.107417 -AN - WOS:001105605200001 -C6 - OCT 2023 -AD - Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Milan, Italy -AD - Fdn IRCCS Ist Nazl Tumori, Palliat Care Pain Therapy & Rehabil Unit, Milan, Italy -AD - Fdn IRCCS Ist Nazl Tumori, Dept Res, Mol Immunol Unit, Milan, Italy -AD - Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy -AD - Univ Campania Luigi Vanvitelli, Precis Med Dept, Naples, Italy -AD - Univ Chicago, Div Biol Sci, Chicago, IL USA -AD - Univ Milan, Oncol & Hematooncol Dept, Milan, Italy -AD - Ist Ricovero & Cura Carattere Sci IRCCS, Ist Ric Farmacol Mario Negri, Methodol Clin Res Lab, Milan, Italy -AD - Univ Vita Salute San Raffaele, Milan, Italy -AD - IRCCS Osped San Raffaele, Med Oncol, Milan, Italy -M2 - Grande Osped Metropolitano Niguarda -Y2 - 2023-12-01 -ER - - -TY - JOUR -AU - Paz-Ares, Luis -AU - Dvorkin, Mikhail -AU - Chen, Yuanbin -AU - Reinmuth, Niels -AU - Hotta, Katsuyuki -AU - Trukhin, Dmytro -AU - Statsenko, Galina -AU - Hochmair, Maximilian J. -AU - Ozguroglu, Mustafa -AU - Ji, Jun Ho -AU - Voitko, Oleksandr -AU - Poltoratskiy, Artem -AU - Ponce, Santiago -AU - Verderame, Francesco -AU - Havel, Libor -AU - Bondarenko, Igor -AU - Kazarnowicz, Andrzej -AU - Losonczy, Gyorgy -AU - Conev, Nikolay V. -AU - Armstrong, Jon -AU - Byrne, Natalie -AU - Shire, Norah -AU - Jiang, Haiyi -AU - Goldman, Jonathan W. -AU - Batagelj, Emilio -AU - Casarini, Ignacio -AU - Pastor, Anea Viviana -AU - Sena, Susana Noemi -AU - Zarba, Juan Jose -AU - Burghuber, Otto -AU - Hartl, Sylvia -AU - Hochmair, Maximilian J. -AU - Lamprecht, Bernd -AU - Studnicka, Michael -AU - Schlittler, Luis Alberto -AU - de Oliveira, Fabricio Augusto Martinelli -AU - Calabrich, Aknar -AU - Girotto, Gustavo Colagiovanni -AU - Dos Reis, Peo -AU - Gorini, Carlos Fausto Nino -AU - De Marchi, Peo Rafael Martins -AU - Baldotto, Clarissa Serodio da Rocha -AU - Sette, Claudia -AU - Zukin, Mauro -AU - Conev, Nikolay V. -AU - Dudov, Assen -AU - Ilieva, Rumyana -AU - Koynov, Krassimir -AU - Krasteva, Rositsa -AU - Tonev, Ivan -AU - Valev, Spartak -AU - Venkova, Violetka -AU - Bi, Minghong -AU - Chen, Chengshui -AU - Chen, Yuan -AU - Chen, Zhendong -AU - Fang, Jian -AU - Feng, Jifeng -AU - Han, Zhigang -AU - Hu, Jie -AU - Hu, Yi -AU - Li, Wei -AU - Liang, Zongan -AU - Lin, Zhong -AU - Ma, Rui -AU - Ma, Shenglin -AU - Nan, Kejun -AU - Shu, Yongqian -AU - Wang, Kai -AU - Wang, Mengzhao -AU - Wu, Gang -AU - Yang, Nong -AU - Yang, Zhixiong -AU - Zhang, Helong -AU - Zhang, Wei -AU - Zhao, Jun -AU - Zhao, Yanqiu -AU - Zhou, Caicun -AU - Zhou, Jianying -AU - Zhou, Xiangdong -AU - Havel, Libor -AU - Kolek, Vitezslav -AU - Koubkova, Leona -AU - Roubec, Jaromir -AU - Skrickova, Jana -AU - Zemanova, Milada -AU - Chouaid, Christos -AU - Hilgers, Werner -AU - Lena, Herve -AU - Moro-Sibilot, Denis -AU - Robinet, Gilles -AU - Souquet, Pierre-Jean -AU - Alt, Jurgen -AU - Bischoff, Helge -AU - Grohe, Christian -AU - Laack, Eckart -AU - Lang, Susanne -AU - Panse, Jens -AU - Reinmuth, Niels -AU - Schulz, Christian -AU - Bogos, Krisztina -AU - Csanky, Eszter -AU - Fulop, Anea -AU - Horvath, Zsolt -AU - Kosa, Judit -AU - Laczo, Ibolya -AU - Losonczy, Gyorgy -AU - Pajkos, Gabor -AU - Papai, Zsuzsanna -AU - Szekely, Zsolt Papai -AU - Sarosi, Veronika -AU - Somfay, Attila -AU - Ezer, Eva Somogyine -AU - Telekes, Anas -AU - Bar, Jair -AU - Gottfried, Maya -AU - Heching, Norman Isaac -AU - Kuch, Alona Zer -AU - Bartolucci, Roberta -AU - Bettini, Anna Cecilia -AU - Delmonte, Angelo -AU - Garassino, Marina Chiara -AU - Minelli, Mauro -AU - Roila, Fausto -AU - Verderame, Francesco -AU - Atagi, Shinji -AU - Azuma, Koichi -AU - Goto, Hisatsugu -AU - Goto, Koichi -AU - Hara, Yu -AU - Hayashi, Hidetoshi -AU - Hida, Toyoaki -AU - Hotta, Katsuyuki -AU - Kanazawa, Kenya -AU - Kanda, Shintaro -AU - Kim, Young Hak -AU - Kuyama, Shoichi -AU - Maeda, Tadashi -AU - Morise, Masahiro -AU - Nakahara, Yasuharu -AU - Nishio, Makoto -AU - Nogami, Naoyuki -AU - Okamoto, Isamu -AU - Saito, Haruhiro -AU - Shinoda, Masahiro -AU - Umemura, Shigeki -AU - Yoshida, Tatsuya -AU - Claessens, Niels -AU - Cornelissen, Robin -AU - Heniks, Lizza -AU - Hiltermann, Jeroen -AU - Smit, Egbert -AU - van den Brekel, Agnes Staal -AU - Kazarnowicz, Andrzej -AU - Kowalski, Dariusz -AU - Mandziuk, Slawomir -AU - Mroz, Robert -AU - Wojtukiewicz, Marek -AU - Ciuleanu, Tudor -AU - Ganea, Doina -AU - Ungureanu, Anei -AU - Dvorkin, Mikhail -AU - Luft, Alexander -AU - Moiseenko, Vladimir -AU - Poltoratskiy, Artem -AU - Sakaeva, Dina -AU - Smolin, Alexey -AU - Statsenko, Galina -AU - Vasilyev, Alexander -AU - Vladimirova, Lyubov -AU - Anasina, Igor -AU - Chovanec, Jozef -AU - Demo, Pavol -AU - Godal, Robert -AU - Kasan, Peter -AU - Stresko, Marian -AU - Urda, Michal -AU - Cho, Eun Kyung -AU - Ji, Jun Ho -AU - Kim, Joo-Hang -AU - Kim, Sang-We -AU - Lee, Gyeong-Won -AU - Lee, Jong-Seok -AU - Lee, Ki Hyeong -AU - Lee, Kyung Hee -AU - Lee, Yun Gyoo -AU - Molla, Maria Amelia Insa -AU - Gomez, Manuel Domine -AU - Mingorance, Juan Ignacio Delgado -AU - Casado, Dolores Isla -AU - Brea, Marta Lopez -AU - Tarruella, Margarita Majem -AU - Bueno, Teresa Moran -AU - Mendivil, Alejano Navarro -AU - Rodriguez, Luis Paz-Ares -AU - Aix, Santiago Ponce -AU - Campelo, Maria Rosario Garcia -AU - Chang, Gee-Chen -AU - Chen, Yen-Hsun -AU - Chiu, Chao-Hua -AU - Hsia, Te-Chun -AU - Lee, Kang-Yun -AU - Li, Chien-Te -AU - Wang, Chin-Chou -AU - Wei, Yu-Feng -AU - Wu, Shang-Yin -AU - Alacacioglu, Ahmet -AU - Cicin, Irfan -AU - Demirkazik, Ahmet -AU - Erman, Mustafa -AU - Goksel, Tuncay -AU - Ozguroglu, Mustafa -AU - Adamchuk, Hryhoriy -AU - Bondarenko, Igor -AU - Kolesnik, Oleksii -AU - Kryzhanivska, Anna -AU - Ostapenko, Yuriv -AU - Shevnia, Serhii -AU - Shparyk, Yaroslav -AU - Trukhin, Dmytro -AU - Ursol, Grygorii -AU - Voitko, Nataliia -AU - Voitko, Oleksandr -AU - Vynnychenko, Ihor -AU - Babu, Sunil -AU - Chen, Yuanbin -AU - Chiang, Anne -AU - Chua, Winston -AU - Dakhil, Shaker -AU - Dowlati, Afshin -AU - Goldman, Jonathan W. -AU - Haque, Basir -AU - Jamil, Rodney -AU - Knoble, Jeanna -AU - Lakhanpal, Shailena -AU - Mi, Kailhong -AU - Nikolinakos, Petros -AU - Powell, Steven -AU - Ross, Helen -AU - Schaefer, Eric -AU - Schneider, Jeffrey -AU - Spahr, Joseph -AU - Spigel, David -AU - Stilwill, Joseph -AU - Sumey, Christopher -AU - Williamson, Michael -A1 - CASPIAN Investigators -TI - Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial -T2 - LANCET -M3 - Article -AB - Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum-etoposide) in treatment-naive patients with ES-SCLC.Methods This randomised, open-label, phase 3 trial was done at 209 sites across 23 countries. Eligible patients were adults with untreated ES-SCLC, with WHO performance status 0 or 1 and measurable disease as per Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were randomly assigned (in a 1:1:1 ratio) to durvalumab plus platinum-etoposide; durvalumab plus tremelimumab plus platinum-etoposide; or platinum-etoposide alone. All drugs were administered intravenously. Platinum-etoposide consisted of etoposide 80-100 mg/m(2) on days 1-3 of each cycle with investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m(2) (administered on day 1 of each cycle). Patients received up to four cycles of platinum-etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks in the immunotherapy groups and up to six cycles of platinum-etoposide every 3 weeks plus prophylactic cranial irradiation (investigator's discretion) in the platinum-etoposide group. The primary endpoint was overall survival in the intention-to-treat population. We report results for the durvalumab plus platinumetoposide group versus the platinum-etoposide group from a planned interim analysis. Safety was assessed in all patients who received at least one dose of their assigned study treatment. This study is registered at ClinicalTrials.gov, NCT03043872, and is ongoing.Findings Patients were enrolled between March 27, 2017, and May 29, 2018. 268 patients were allocated to the durvalumab plus platinum-etoposide group and 269 to the platinum-etoposide group. Durvalumab plus platinumetoposide was associated with a significant improvement in overall survival, with a hazard ratio of 0.73 (95% CI 0.59-0.91; p=0.0047]); median overall survival was 13.0 months (95% CI 11.5-14.8) in the durvalumab plus platinum-etoposide group versus 10.3 months (9.3-11.2) in the platinum-etoposide group, with 34% (26.9-41.0) versus 25% (18.4-31.6) of patients alive at 18 months. Any-cause adverse events of grade 3 or 4 occurred in 163 (62%) of 265 treated patients in the durvalumab plus platinum-etoposide group and 166 (62%) of 266 in the platinumetoposide group; adverse events leading to death occurred in 13 (5%) and 15 (6%) patients.Interpretation First-line durvalumab plus platinum-etoposide significantly improved overall survival in patients with ES-SCLC versus a clinically relevant control group. Safety findings were consistent with the known safety profiles of all drugs received. Copyright (C) 2019 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0140-6736 -SN - 1474-547X -DA - 2019 NOV 23 -PY - 2019 -VL - 394 -IS - 10212 -SP - 1929 -EP - 1939 -DO - 10.1016/S0140-6736(19)32222-6 -AN - WOS:000498868500027 -AD - Univ Complutense, Dept Med Oncol, Hosp Univ 12 Octubre, H120 CNIO Lung Canc Unit, Madrid, Spain -AD - Ciberonc, Madrid, Spain -AD - BHI Omsk Reg Clin Oncol Dispensary, Omsk, Russia -AD - Canc & Hematol Ctr Western Michigan, Grand Rapids, MI USA -AD - Asklepios Lung Clin, Munich, Germany -AD - Okayama Univ Hosp, Okayama, Japan -AD - Odessa Natl Med Univ, Odessa, Ukraine -AD - Omsk Reg Canc Ctr, Omsk, Russia -AD - Krankenhaus Nord, Karl Landsteiner Inst Lung Res & Pulm Oncol, Vienna, Austria -AD - Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Istanbul, Turkey -AD - Sungkyunkwan Univ, Samsung Changwon Hosp, Sch Med, Chang Won, South Korea -AD - Kyiv City Clin Oncol Ctr, Kiev, Ukraine -AD - Petrov Res Inst Oncol, St Petersburg, Russia -AD - AO Osped Riuniti PO Vincenzo Cervello, Palermo, Italy -AD - Charles Univ Prague, Thomayer Hosp, Fac Med 1, Prague, Czech Republic -AD - Dnipropetrovsk Med Acad, Dnipro, Ukraine -AD - TB & Lung Dis Hosp, Olsztyn, Poland -AD - Semmelweis Univ, Budapest, Hungary -AD - UMHAT St Marina, Clin Med Oncol, Varna, Bulgaria -AD - AstraZeneca, Cambridge, England -AD - AstraZeneca, Gaithersburg, MD USA -AD - Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA -AD - Sumy State Univ, Dept Surg & Oncol, Sumy, Ukraine -M2 - BHI Omsk Reg Clin Oncol Dispensary -M2 - Canc & Hematol Ctr Western Michigan -M2 - Asklepios Lung Clin -M2 - Omsk Reg Canc Ctr -M2 - Krankenhaus Nord -M2 - Kyiv City Clin Oncol Ctr -M2 - AO Osped Riuniti PO Vincenzo Cervello -M2 - TB & Lung Dis Hosp -M2 - AstraZeneca -Y2 - 2019-11-23 -ER - - -TY - JOUR -AU - Liang, Hongge -AU - Wang, Mengzhao -TI - MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis -T2 - ONCOTARGETS AND THERAPY -M3 - Review -AB - Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide and has a poor prognosis. Current treatments for advanced NSCLC included traditional chemotherapy, radiotherapy, targeted therapy, and immunotherapy. The efficacy of targeted therapy relies on oncogene addiction. Mesenchymal-epithelial transition factor (MET) gene can encode unconventional receptor tyrosine kinases with pleiotropic functions, when signals are abnormally activated, it can initiate and maintain tumor transformation, promote cell proliferation, survival, tumor invasion and angiogenesis. Thus, it is a promising therapeutic target. Previous studies have shown that elevated levels of HGF and/or overexpression of c-Met are associated with poor prognosis in lung cancer. In preclinical and clinical trials, c-MET inhibitors have shown some antitumor activity in NSCLC. Although the efficacy results of MET inhibitors in Phase III clinical trials are disappointing, given the molecular heterogeneity of NSCLC, only subgroups of patients with MET gene alterations may benefit from c-MET inhibitors. The challenge for the future is to screen out the potential beneficiaries. To solve this problem, there is need for large data analysis for the detection methods and treatment effects, to establish standards that meet the MET activation status, and determine reliable thresholds to achieve effective patient stratification and clinical decision making. This article summarized the structure of the hepatocyte growth factor (HGF)/c-Met axis, the different mechanisms of MET addiction, as well as MET amplification as acquired resistance mechanism to epidermal growth factor receptor-tyrosine kinase inhibitors, the latest advances of MET inhibitors, and immuotherapy in the treatment of NSCLC with MET alterations. -PU - DOVE MEDICAL PRESS LTD -PI - ALBANY -PA - PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND -SN - 1178-6930 -DA - 2020 -PY - 2020 -VL - 13 -SP - 2491 -EP - 2510 -DO - 10.2147/OTT.S231257 -AN - WOS:000521615400001 -AD - Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, 1 Shuaifuyuan, Beijing 100730, Peoples R China -Y2 - 2020-04-06 -ER - - -TY - JOUR -AU - Boyer, Matthew J. -AU - Gu, Lin -AU - Wang, Xiaofei -AU - Kelsey, Chris R. -AU - Yoo, David S. -AU - Onaitis, Mark W. -AU - Dunphy, Frank R. -AU - Crawford, Jeffrey -AU - Ready, Neal E. -AU - Salama, Joseph K. -TI - Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer -T2 - LUNG CANCER -M3 - Article -AB - To determine the feasibility and toxicity of radiation therapy, delivered either as definitive treatment or following surgery, following neo-adjuvant immune checkpoint inhibition for locally advanced NSCLC sixteen patients who received neo-adjuvant chemotherapy including ipilimumab as part of a phase II study were identified. Patients were analyzed by intent of radiation and toxicity graded based on CTCAE 4.0. There were seven patients identified who received definitive radiation and nine who received postoperative radiation. There was no grade 3 or greater toxicity in the definitive treatment group although one patient stopped treatment early due to back pain secondary to progression outside of the treatment field. In the post-operative treatment group, one patient required a one week break due to grade 2 odynophagia and no grade 3 or greater toxicity was observed. In this study of radiation as definitive or post-operative treatment following neo-adjuvant chemotherapy including ipilimumab for locally advanced NSCLC was feasible and well tolerated with limited toxicity. (C) 2016 Elsevier Ireland Ltd. All rights reserved. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2016 AUG -PY - 2016 -VL - 98 -SP - 76 -EP - 78 -DO - 10.1016/j.lungcan.2016.05.014 -AN - WOS:000380596400012 -AD - Duke Univ, Dept Radiat Oncol, Durham, NC 27710 USA -AD - Duke Univ, Duke Canc Inst, Dept Biostat, Durham, NC 27710 USA -AD - Duke Univ, Dept Surg, Div Cardiothorac Surg, Durham, NC 27710 USA -AD - Duke Univ, Dept Med, Div Med Oncol, Durham, NC 27710 USA -Y2 - 2016-09-13 -ER - - -TY - JOUR -AU - Klinakis, Apostolos -AU - Karagiannis, Dimitris -AU - Rampias, Theodoros -TI - Targeting DNA repair in cancer: current state and novel approaches -T2 - CELLULAR AND MOLECULAR LIFE SCIENCES -M3 - Review -AB - DNA damage response, DNA repair and genomic instability have been under study for their role in tumor initiation and progression for many years now. More recently, next-generation sequencing on cancer tissue from various patient cohorts have revealed mutations and epigenetic silencing of various genes encoding proteins with roles in these processes. These findings, together with the unequivocal role of DNA repair in therapeutic response, have fueled efforts toward the clinical exploitation of research findings. The successful example of PARP1/2 inhibitors has also supported these efforts and led to numerous preclinical and clinical trials with a large number of small molecules targeting various components involved in DNA repair singularly or in combination with other therapies. In this review, we focus on recent considerations related to DNA damage response and new DNA repair inhibition agents. We then discuss how immunotherapy can collaborate with these new drugs and how epigenetic drugs can rewire the activity of repair pathways and sensitize cancer cells to DNA repair inhibition therapies. -PU - SPRINGER BASEL AG -PI - BASEL -PA - PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND -SN - 1420-682X -SN - 1420-9071 -DA - 2020 FEB -PY - 2020 -VL - 77 -IS - 4 -SP - 677 -EP - 703 -DO - 10.1007/s00018-019-03299-8 -AN - WOS:000489938000001 -C6 - OCT 2019 -AD - Acad Athens, Biomed Res Fdn, Athens 11527, Greece -AD - Columbia Univ, Med Ctr, Dept Genet & Dev, New York, NY 10032 USA -Y2 - 2019-10-23 -ER - - -TY - JOUR -AU - Kim, Y. -AU - Saraf, A. -AU - McClatchy, D. M., III -AU - Gainor, J. -AU - Paganetti, H. -AU - Sung, W. -AU - Khandekar, M. J. -AU - Cho, Y., II -AU - Cho, S. -AU - Kim, J. -AU - Keane, F. K. -AU - Yoon, H. I. -AU - Grassberger, C. -TI - Quantitative Evaluation of Normal Lung Density Changes in Non-Small Cell Lung Cancer Patients Treated With Radiotherapy and PD-1 Immune Checkpoint Inhibitors -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 2230 -SP - E131 -EP - E131 -AN - WOS:000715803800231 -AD - Korea Adv Inst Sci & Technol, Daejeon, South Korea -AD - Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA -AD - Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA -AD - Harvard Med Sch, Dept Radiat Oncol, Massachusetts Gen Hosp, Boston, MA 02115 USA -AD - Yonsei Univ, Dept Radiat Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea -AD - Harvard Med Sch, Boston, MA 02115 USA -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Eguren-Santamaria, Inaki -AU - Sanmamed, Miguel F. -AU - Goldberg, Sarah B. -AU - Kluger, Harriet M. -AU - Idoate, Miguel A. -AU - Lu, Benjamin Y. -AU - Corral, Jesus -AU - Schalper, Kurt A. -AU - Herbst, Roy S. -AU - Gil-Bazo, Ignacio -TI - PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice -T2 - CLINICAL CANCER RESEARCH -M3 - Review -AB - Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced non-small cell lung cancer (NSCLC). However, most pivotal phase III trials systematically excluded patients with active brain metastases, precluding the generalization of the results. Although theoretically restricted from crossing the blood-brain barrier, the novel pharmacokinetic/pharmacodynamic profiles of anti-PD-1/PD-L1 drugs have prompted studies to evaluate their activity in patients with NSCLC with active central nervous system (CNS) involvement. Encouraging results have suggested that ICI could be active in the CNS in selected patients with driver-negative advanced NSCLC with high PD-L1 expression and low CNS disease burden. Single-agent CNS response rates around 30% have been reported. Beyond this particular setting, anti-PD-1/PD-L1 antibodies have been evaluated in patients receiving local therapy for brain metastases (BM), addressing concerns about potential neurologic toxicity risks associated with radiotherapy, more specifically, radionecrosis (RN). Accordingly, a variety of clinical and imaging strategies are being appropriately developed to evaluate tumor response and to rule out pseudoprogression or radionecrosis. Our purpose is to critically summarize the advances regarding the role of systemic anti-PD-1/PD-L1 antibodies for the treatment of NSCLC BM. Data were collected from the PubMed database, reference lists, and abstracts from the latest scientific meetings. Recent reports suggest anti-PD-1/PD-L1 agents are active in a subset of patients with NSCLC with BM showing acceptable toxicity. These advances are expected to change soon the management of these patients but additional research is required to address concerns regarding radionecrosis and the appropriate sequencing of local and systemic therapy combinations. -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 1078-0432 -SN - 1557-3265 -DA - 2020 AUG 15 -PY - 2020 -VL - 26 -IS - 16 -SP - 4186 -EP - 4197 -DO - 10.1158/1078-0432.CCR-20-0798 -AN - WOS:000558688100005 -AD - Clin Univ Navarra, Dept Oncol, Pamplona, Spain -AD - Univ Navarra, Ctr Appl Med Res, Program Immunol & Immunotherapy, Pamplona, Spain -AD - Navarra Inst Hlth Res, IdiSNA, Pamplona, Spain -AD - Ctr Invest Biomed Red Canc CIBERON, Madrid, Spain -AD - Yale Univ, Sch Med, New Haven, CT USA -AD - Yale Canc Ctr, New Haven, CT USA -AD - Clin Univ Navarra, Dept Pathol, Pamplona, Spain -AD - Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA -AD - Univ Navarra, Ctr Appl Med Res, Program Solid Tumors, Pamplona, Spain -M2 - Navarra Inst Hlth Res -M2 - Ctr Invest Biomed Red Canc CIBERON -Y2 - 2020-08-26 -ER - - -TY - JOUR -AU - Wang, Pascal -AU - Duchemann, Boris -AU - Chouahnia, Kader -AU - Matton, Lise -AU - Benabadji, Ambre -AU - Zelek, Laurent -AU - Popotte, Hosni -AU - Paix, Adrien -TI - Postoperative radiotherapy in non-small cell lung cancer stage IIIA-N2: Focus and perspectives -T2 - BULLETIN DU CANCER -M3 - Article -AB - Patients with resectable stage IIIA - N2 lung cancer represent a very heterogeneous population with variable risks of postoperative recurrence depending on the type of N2 involvement (unisite N2, multisite N2, bulky N2, extra-capsular rupture, incomplete resection. . .). This heterogeneity associated with the difficulty of carrying out prospective randomized studies with sufficient power in stages IIIA - 2, results in the absence of clear and consensual recommendations (except for stages IIIA- N2 resectable R0, since LungART and PORT-C studies). The objective of this article is to make an update on the place of postoperative radiotherapy in the management of stages IIIA - N2 following the publication of two recent randomized trials (PORT-C and LungART) but also compare them fort a better understanding of the current issues raised by these first published results. Indeed, these two trials do not find any benefit in terms of progression free survival and overall survival of postoperative radiotherapy but exploratory analyzes from these two studies seem to show a potential benefit of postoperative in some pN2 populations at high risk of locoregional recurrence (N2 multisite, N2 bulky. . .). In addition, the advent of immunotherapy (atezolizumab or pembrolizumab) and targeted therapies (osimertinib) in the adjuvant situation are redebating the place of a possible indication for postoperative radiotherapy in stage IIIA - 2. -PU - ELSEVIER MASSON, CORP OFF -PI - PARIS -PA - 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE -SN - 0007-4551 -SN - 1769-6917 -DA - 2023 JAN -PY - 2023 -VL - 110 -IS - 1 -SP - 101 -EP - 112 -DO - 10.1016/j.bulcan.2022.08.010 -AN - WOS:000992049500001 -C6 - JAN 2023 -AD - Avicenne Hosp, AP HP, Serv Oncol Med & Thorac, Bobigny, France -AD - Inst Radiotherapie Bobigny Ramsay Sante, Rue Lautreamont, F-93000 Bobigny, France -AD - Gustave Roussy Canc Campus, Lab Immunomonitoring Oncol, Inserm US23, CNRS,UMS 3655, F-94805 Villejuif, France -AD - Hop Tenon, AP HP, Serv Oncol Radiotherapie, Paris, France -M2 - Inst Radiotherapie Bobigny Ramsay Sante -Y2 - 2023-05-28 -ER - - -TY - JOUR -AU - Murakami, Shuji -TI - Durvalumab for the treatment of non-small cell lung cancer -T2 - EXPERT REVIEW OF ANTICANCER THERAPY -M3 - Article -AB - Introduction: The prognosis of patients with advanced non-small cell lung cancer (NSCLC) remains poor, with a 5-year overall survival rate of around 15%. Immune checkpoint inhibitors, such as programmed cell death protein 1 and programmed death-ligand 1 (PD-L1) inhibitors, have opened a new era in the management of NSCLC. Three checkpoint inhibitors (nivolumab, pembrolizumab, and atezolizumab) are currently approved by the US Food and Drug Administration (FDA) for advanced NSCLC. Durvalumab, an anti-PD-L1 antibody, is under investigation in several trials. Areas covered: This article reviews the pharmacological properties, clinical efficacy, and safety of durvalumab as monotherapy and in combination with other drugs for the treatment of locally advanced and advanced NSCLC. Expert opinion: Durvalumab as monotherapy or in combination with tremelimumab was effective with well-tolerated safety profiles for advanced NSCLC in several phase I or II studies. The PACIFIC study assessed the effectiveness of durvalumab as maintenance therapy following definitive chemoradiotherapy for unresectable stage III NSCLC, and met its primary endpoints of progression-free survival and overall survival. These results led to FDA approval for this NSCLC population. It will be exciting to follow ongoing phase III studies assessing how durvalumab fits into the rapidly evolving therapeutic landscape for advanced NSCLC. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1473-7140 -SN - 1744-8328 -DA - 2019 DEC 2 -PY - 2019 -VL - 19 -IS - 12 -SP - 1009 -EP - 1016 -DO - 10.1080/14737140.2019.1699407 -AN - WOS:000500417700001 -C6 - DEC 2019 -AD - Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan -Y2 - 2019-12-11 -ER - - -TY - JOUR -AU - Lavaud, Pernelle -AU - Bortolot, Martina -AU - Zullo, Lodovica -AU - O'Reilly, David -AU - Naidoo, Jarushka -AU - Mountzios, Giannis -AU - Mercier, Olaf -AU - Hendriks, Lizza E. L. -AU - Remon, Jordi -TI - Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies -T2 - CANCERS -M3 - Review -AB - Simple Summary The current review summarizes the new potential treatment strategies for patients with early-stage non-small cell lung cancer with immunotherapy and targeted therapies and defines the current challenges for making treatment decisions with these approaches in daily practice.Abstract The recent advent of tyrosine kinase inhibitors (TKIs) and immune checkpoint blockers (ICBs) in early-stage non-small cell lung cancer (NSCLC) has dramatically modified treatment strategies by improving the prognosis in this setting. Osimertinib and alectinib, both TKIs, have shown significant improvements in outcomes for patients with resected EGFR- and ALK-positive NSCLC, respectively, changing the standard of care in these subgroups. More recently, the LAURA trial showed the efficacy of osimertinib after chemoradiotherapy in patients with unresectable stage III NSCLC harboring EGFR mutations. Numerous trials are still ongoing to investigate neoadjuvant/perioperative TKIs in several oncogene-driven NSCLC. In addition, several ICBs have been tested and approved as adjuvant (atezolizumab and pembrolizumab), neoadjuvant (nivolumab), and perioperative treatments (pembrolizumab) for patients with resectable early-stage NSCLC. Despite these advances, many challenges remain regarding the use of TKIs and ICBs in this setting, including the optimal duration of adjuvant TKI or induction ICB therapy, the role of minimal residual disease to identify patients at high-risk of disease relapse and to guide adjuvant treatment decisions, and the role of adjuvant chemotherapy in resected oncogene-driven NSCLC. Furthermore, potential predictive biomarkers for efficacy are needed to eventually intensify the entire perioperative strategies. This review aims to summarize and discuss the available evidence, the ongoing trials, and the challenges associated with TKI- and ICB-based approaches in early-stage NSCLC. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2024 AUG -PY - 2024 -VL - 16 -IS - 16 -C7 - 2779 -DO - 10.3390/cancers16162779 -AN - WOS:001305198200001 -AD - Paris Saclay Univ, Dept Canc Med, Gustave Roussy, 114 Rue Edouard Vaillant, F-94805 Villejuif, France -AD - Maastricht Univ, GROW Sch Oncol & Reprod, Dept Resp Med, Med Ctr, NL-6229 ER Maastricht, Netherlands -AD - Univ Udine, Dept Med DMED, I-33100 Udine, Italy -AD - RCSI Univ Hlth Sci, Beaumont Hosp, Med Oncol, Dublin D02YN77, Ireland -AD - Henry Dunant Hosp Ctr, Dept Med Oncol 4, Athens 11526, Greece -AD - Henry Dunant Hosp Ctr, Clin Trials Unit, Athens 11526, Greece -AD - Hop Marie Lannelongue, Dept Thorac Surg, F-92350 Le Plessis Robinson, France -M2 - RCSI Univ Hlth Sci -Y2 - 2024-09-15 -ER - - -TY - JOUR -AU - Murray, David -AU - McBride, William H. -AU - Schwartz, Jeffrey L. -TI - Radiation Biology in the Context of Changing Patterns of Radiotherapy -T2 - RADIATION RESEARCH -M3 - Review -AB - The last decade has witnessed a revolution in the clinical application of high-dose "ablative" radiation therapy. Initially this approach was limited to the treatment of brain tumors, but more recently we have seen its successful extension to tumors outside the brain, e.g., for small lung nodules. These advances have been driven largely by improvements in image-guided inverse treatment planning that allow the dose per fraction to the tumor to be increased over the conventional 2 Gy dose while keeping the late normal tissue complications at an acceptable level by dose limitation. Despite initial concerns about excessive late complications, as might be expected based on dose extrapolations using the linear-quadratic equation, these approaches have shown considerable clinical promise. Our knowledge of the biological consequences of high-doses of ionizing radiation in normal and cancerous tissues has lagged behind these clinical advances. Our intent here is to survey recent experimental findings from the perspective of better understanding the biological effects of high-dose therapy and whether they are truly different from conventional doses. We will also consider the implications of this knowledge for further refining and improving these approaches on the basis of underlying mechanisms. (C) 2014 by Radiation Research Society -PU - RADIATION RESEARCH SOC -PI - LAWRENCE -PA - 810 E TENTH STREET, LAWRENCE, KS 66044 USA -SN - 0033-7587 -SN - 1938-5404 -DA - 2014 SEP -PY - 2014 -VL - 182 -IS - 3 -SP - 259 -EP - 272 -DO - 10.1667/RR13740.1 -AN - WOS:000341309000002 -AD - Univ Alberta, Dept Oncol, Div Expt Oncol, Edmonton, AB, Canada -AD - Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90095 USA -AD - Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA -Y2 - 2014-10-01 -ER - - -TY - JOUR -AU - Kobayashi, Haruki -AU - Omori, Shota -AU - Nakashima, Kazuhisa -AU - Wakuda, Kazushige -AU - Ono, Akira -AU - Kenmotsu, Hirotsugu -AU - Naito, Tateaki -AU - Murakami, Haruyasu -AU - Endo, Masahiro -AU - Takahashi, Toshiaki -TI - Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer -T2 - INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY -M3 - Article -AB - Background Currently, no markers predictive of response to nivolumab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) are currently recognized in Japan. The present study was undertaken to identify such markers.Materials and methods Medical records of 50 patients with advanced NSCLC and treated with nivolumab monotherapy at Shizuoka Cancer Center between December 2015 and April 2016 were retrospectively reviewed. The parameters studied were age, sex, Eastern Cooperative Oncology Group performance status, smoking history, histological diagnosis, epidermal growth factor receptor or anaplastic lymphoma kinase status, therapeutic line of nivolumab, efficacy of treatment immediately before nivolumab monotherapy, and time since previous therapy.Results The objective response rate to nivolumab monotherapy was 18% [95% confidence interval (CI) 10-31]. Multivariate logistic regression identified "squamous histology" [odds ratio (OR) 0.00054; 95% CI 0-0.27] and "response to the treatment immediately before nivolumab monotherapy" (OR 0.0011; 95% CI 0-0.092) as independently associated with response to nivolumab monotherapy.Conclusion "Response to the treatment immediately before nivolumab monotherapy" might be a predictive marker of response to nivolumab in patients with advanced NSCLC. -PU - SPRINGER JAPAN KK -PI - TOKYO -PA - CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN -SN - 1341-9625 -SN - 1437-7772 -DA - 2017 AUG -PY - 2017 -VL - 22 -IS - 4 -SP - 690 -EP - 697 -DO - 10.1007/s10147-017-1118-x -AN - WOS:000406689300011 -AD - Shizuoka Canc Ctr, Div Thorac Oncol, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan -AD - Shizuoka Canc Ctr, Div Diagnost Radiol, Nagaizumi, Shizuoka, Japan -Y2 - 2017-08-22 -ER - - -TY - JOUR -AU - Ackermann, Christoph Jakob -AU - Adderley, Helen -AU - Ortega-Franco, Ana -AU - Khan, Adeel -AU - Reck, Martin -AU - Califano, Raffaele -TI - First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions -T2 - DRUGS -M3 - Review -AB - The advent of PD-(L)1 and CTLA-4 immune check point inhibitors (CPIs) has dramatically changed the treatment landscape of advanced non-small-cell lung cancer (NSCLC). For up to a quarter of patients with advanced NSCLC, CPIs have the potential to induce durable responses with long-term survival outcomes. Since the approval of first-line pembrolizumab for patients whose tumors express a PD-L1 >= 50%, several pivotal first-line CPI-based phase 3 studies have been conducted investigating combination treatments combining CPIs with chemotherapy (ChT) or combining different CPIs with or without ChT. As a result, there has been an increase in front-line treatment options for advanced NSCLC, and treatment algorithms are changing very quickly. In fit patients with advanced NSCLC, combination treatments including CPI and ChT are considered the new standard of care with improved clinical outcomes. CPI combination treatments are well tolerated and quality of life also seems to be better when CPIs are implemented in the first-line setting. The aim of this review is to provide a summary of the recently published first-line phase 3 studies investigating CPIs as monotherapy or in combination with other CPIs or ChT in advanced NSCLC, and to suggest possible treatment algorithms. -PU - ADIS INT LTD -PI - NORTHCOTE -PA - 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND -SN - 0012-6667 -SN - 1179-1950 -DA - 2020 NOV -PY - 2020 -VL - 80 -IS - 17 -SP - 1783 -EP - 1797 -DO - 10.1007/s40265-020-01409-6 -AN - WOS:000573451100001 -C6 - SEP 2020 -AD - Spital STS AG, Dept Med Oncol, Thun, Switzerland -AD - Christie NHS Fdn Trust, Dept Med Oncol, Wilmslow Rd, Manchester, Lancs, England -AD - LungenClin Grosshansdorf, German Ctr Lung Res, Airway Res Ctr North ARCN, Dept Thorac Oncol, Grosshansdorf, Germany -AD - Manchester Univ NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England -AD - Univ Manchester, Div Canc Sci, Manchester, Lancs, England -M2 - Spital STS AG -M2 - Manchester Univ NHS Fdn Trust -Y2 - 2020-10-13 -ER - - -TY - JOUR -AU - Singh, Apurva -AU - Horng, Hannah -AU - Chitalia, Rhea -AU - Roshkovan, Leonid -AU - Katz, Sharyn I. -AU - Noel, Peter -AU - Shinohara, Russell T. -AU - Kontos, Despina -TI - Resampling and harmonization for mitigation of heterogeneity in image parameters of baseline scans -T2 - SCIENTIFIC REPORTS -M3 - Article -AB - Our study investigates the effects of heterogeneity in image parameters on the reproducibility of prognostic performance of models built using radiomic biomarkers. We compare the prognostic performance of models derived from the heterogeneity-mitigated features with that of models obtained from raw features, to assess whether reproducibility of prognostic scores improves upon application of our methods. We used two datasets: The Breast I-SPY1 dataset-Baseline DCE-MRI scans of 156 women with locally advanced breast cancer, treated with neoadjuvant chemotherapy, publicly available via The Cancer Imaging Archive (TCIA); The NSCLC IO dataset-Baseline CT scans of 107 patients with stage 4 non-small cell lung cancer (NSCLC), treated with pembrolizumab immunotherapy at our institution. Radiomic features (n=102) are extracted from the tumor ROIs. We use a variety of resampling and harmonization scenarios to mitigate the heterogeneity in image parameters. The patients were divided into groups based on batch variables. For each group, the radiomic phenotypes are combined with the clinical covariates into a prognostic model. The performance of the groups is assessed using the c-statistic, derived from a Cox proportional hazards model fitted on all patients within a group. The heterogeneity-mitigation scenario (radiomic features, derived from images that have been resampled to minimum voxel spacing, are harmonized using the image acquisition parameters as batch variables) gave models with highest prognostic scores (for e.g., IO dataset; batch variable: high kernel resolution-c-score: 0.66). The prognostic performance of patient groups is not comparable in case of models built using non-heterogeneity mitigated features (for e.g., I-SPY1 dataset; batch variable: small pixel spacing-c-score: 0.54, large pixel spacing-c-score: 0.65). The prognostic performance of patient groups is closer in case of heterogeneity-mitigated scenarios (for e.g., scenario-harmonize by voxel spacing parameters: IO dataset; thin slice-c-score: 0.62, thick slice-c-score: 0.60). Our results indicate that accounting for heterogeneity in image parameters is important to obtain more reproducible prognostic scores, irrespective of image site or modality. For non-heterogeneity mitigated models, the prognostic scores are not comparable across patient groups divided based on batch variables. This study can be a step in the direction of constructing reproducible radiomic biomarkers, thus increasing their application in clinical decision making. -PU - NATURE PORTFOLIO -PI - BERLIN -PA - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY -SN - 2045-2322 -DA - 2022 DEC 13 -PY - 2022 -VL - 12 -IS - 1 -C7 - 21505 -DO - 10.1038/s41598-022-26083-4 -AN - WOS:000990207700066 -AD - Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA -AD - Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA -AD - Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA -AD - Univ Penn, Dept Radiol, Ctr Biomed Image Comp & Analyt CBICA, Rm D702 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA -Y2 - 2023-07-16 -ER - - -TY - JOUR -AU - Mitchell, P. -AU - O'Byrne, K. J. -AU - Brown, C. -AU - Jurkovic, H. -AU - Karapetis, C. S. -AU - Kok, P. S. -AU - Lao, L. -AU - Le, H. V. -AU - Pavlakis, N. -AU - Ab Rahman, A. S. -AU - Subramaniam, S. -AU - Walker, M. -AU - Yip, S. -AU - Stockler, M. R. -AU - Siva, S. -TI - A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD) -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 18 -SP - S10 -EP - S11 -AN - WOS:000715803801359 -AD - Austin Hosp, Dept Med Oncol, Melbourne, Vic, Australia -AD - Princess Alexandra Hosp, Dept Med Oncol, Brisbane, Qld, Australia -AD - Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia -AD - Flinders Univ S Australia, Flinders Med Ctr, Adelaide, SA, Australia -AD - Auckland City Hosp, Auckland, New Zealand -AD - Royal Adelaide Hosp, Adelaide, SA, Australia -AD - Royal North Shore Hosp, Sydney, NSW, Australia -AD - Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Economopoulou, Panagiota -AU - Kotsantis, Ioannis -AU - Psyrri, Amanda -TI - Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers -T2 - CURRENT TREATMENT OPTIONS IN ONCOLOGY -M3 - Review -AB - The discovery and antibody targeting of immune regulatory molecules such as programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) pathways have led to clinically meaningful anti-cancer results. Rapid advances are being made in a variety of tumor types resulting in regulatory approvals in melanoma, non small cell lung cancer, and renal cell cancer. Numerous ongoing studies are expected to establish the worth of PD-1 pathway inhibitors in other tumor types as well as in combinations with approved agents. Head and neck squamous cell carcinoma (HNSCC) represents a complex group of malignancies characterized by profound immunosuppression and is an excellent candidate for investigation in this exciting field. However, given the fact that a subset of patients will likely benefit, it is critical to focus on biomarker development for appropriate patient selection and facilitation of trial design. As immunotherapy is settling in cancer treatment, immune checkpoint inhibitors are emerging as one of the most promising agents. -PU - SPRINGER -PI - NEW YORK -PA - 233 SPRING ST, NEW YORK, NY 10013 USA -SN - 1527-2729 -SN - 1534-6277 -DA - 2016 AUG -PY - 2016 -VL - 17 -IS - 8 -C7 - 40 -DO - 10.1007/s11864-016-0419-z -AN - WOS:000380165300006 -AD - Univ Athens, Sch Med, Attikon Univ Hosp, Dept Internal Med,Sect Med Oncol, 1St Rimini St, Athens 12462, Greece -Y2 - 2016-09-11 -ER - - -TY - JOUR -AU - Addeo, Alfredo -AU - Miranda-Morales, Ernesto -AU - den Hollander, Petra -AU - Friedlaender, Alex -AU - Sintim, Herman O. -AU - Wu, Jie -AU - Mani, Sendurai A. -AU - Subbiah, Vivek -TI - RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives -T2 - PHARMACOLOGY & THERAPEUTICS -M3 - Review -AB - Precision oncology informed by genomic information has evolved in leaps and bounds over the last decade. Al-though non-small cell lung cancer (NSCLC) has moved to center-stage as the poster child of precision oncology, multiple targetable genomic alterations have been identified in various cancer types. RET alterations occur in roughly 2% of all human cancers. The role of RET as oncogenic driver was initially identified in 1985 after the dis-covery that transfection with human lymphoma DNA transforms NIH-3T3 fibroblasts. Germline RET mutations are causative of multiple endocrine neoplasia type 2 syndrome, and RET fusions are found in 10-20% of papillary thyroid cases and are detected in most patients with advanced sporadic medullary thyroid cancer. RET fusions are oncogenic drivers in 2% of Non-small cell lung cancer. Rapid translation and regulatory approval of selective RET inhibitors, selpercatinib and pralsetinib, have opened up the field of RET precision oncology. This review provides an update on RET precision oncology from bench to bedside and back. We explore the impact of selective RET in-hibitor in patients with advanced NSCLC, thyroid cancer, and other cancers in a tissue-agnostic fashion, resistance mechanisms, and future directions.(c) 2023 Published by Elsevier Inc. -PU - PERGAMON-ELSEVIER SCIENCE LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND -SN - 0163-7258 -SN - 1879-016X -DA - 2023 FEB -PY - 2023 -VL - 242 -C7 - 108344 -DO - 10.1016/j.pharmthera.2023.108344 -AN - WOS:000953434400001 -C6 - FEB 2023 -AD - Univ Hosp Geneva HUG, Oncol Dept, Geneva, Switzerland -AD - Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA -AD - Purdue Inst Canc Res, Inst Drug Discovery, Dept Chem, W Lafayette, IN USA -AD - Univ Oklahoma Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Div Canc Med, Unit 455, 1515 Holcombe Blvd, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX USA -AD - Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Network, Houston, TX USA -AD - Brown Univ, Warren Alpert Med Sch, Dept Pathol, Providence, RI 02903 USA -AD - Brown Univ, Warren Alpert Med Sch, Lab Med, Providence, RI 02903 USA -AD - Brown Univ, Legorreta Canc Ctr, Warren Alpert Med Sch, Providence, RI 02903 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, PhaseClin Trials Program 1, Div Canc Med,Unit 455, 1515 Holcombe Blvd, Houston, TX 77030 USA -Y2 - 2023-04-06 -ER - - -TY - JOUR -AU - Lemjabbar-Alaoui, Hassan -AU - Hassan, Omer Ui -AU - Yang, Yi-Wei -AU - Buchanan, Petra -TI - Lung cancer: Biology and treatment options -T2 - BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER -M3 - Review -AB - Lung cancer remains the leading cause of cancer mortality in men and women in the U.S. and worldwide. About 90% of lung cancer cases are caused by smoking and the use of tobacco products. However, other factors such as radon gas, asbestos, air pollution exposures, and chronic infections can contribute to lung carcinogenesis. In addition, multiple inherited and acquired mechanisms of susceptibility to lung cancer have been proposed. Lung cancer is divided into two broad histologic classes, which grow and spread differently: small-cell lung carcinomas (SCLCs) and non-small cell lung carcinomas (NSCLCs). Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, and targeted therapy. Therapeutic-modalities recommendations depend on several factors, including the type and stage of cancer. Despite the improvements in diagnosis and therapy made during the past 25 years, the prognosis for patients with lung cancer is still unsatisfactory. The responses to current standard therapies are poor except for the most localized cancers. However, a better understanding of the biology pertinent to these challenging malignancies, might lead to the development of more efficacious and perhaps more specific drugs. The purpose of this review is to summarize the recent developments in lung cancer biology and its therapeutic strategies, and discuss the latest treatment advances including therapies currently under clinical investigation. (C) 2015 Elsevier B.V. All rights reserved. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 0304-419X -SN - 1879-2561 -DA - 2015 DEC -PY - 2015 -VL - 1856 -IS - 2 -SP - 189 -EP - 210 -DO - 10.1016/j.bbcan.2015.08.002 -AN - WOS:000366226000003 -AD - Univ Calif San Francisco, Dept Surg, Thorac Oncol Div, San Francisco, CA 94143 USA -Y2 - 2015-12-01 -ER - - -TY - JOUR -AU - Mamdani, Hirva -AU - Jalal, Shadia I. -AU - Hanna, Nasser -TI - Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration -T2 - CURRENT TREATMENT OPTIONS IN ONCOLOGY -M3 - Review -AB - Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in the USA. The treatment of locally advanced NSCLC (LA-NSCLC) is challenging and must be individualized. For patients with completely resected stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4 cycles is recommended. For patients with inoperable or unresectable stage III NSCLC, chemoradiation is the preferred treatment. Patients with a good performance status, minimal or no weight loss, and adequate pulmonary function should be offered concurrent chemoradiation. The optimal chemotherapeutic agents to be used concurrently with radiation remain undefined. In the USA, cisplatin plus etoposide or carboplatin plus paclitaxel are the most commonly used regimens. In addition, the optimal duration of therapy remains undefined, including the role of consolidation chemotherapy. Thus far, randomized phase III trials have failed to identify a survival advantage for administering chemotherapy beyond that delivered during radiation therapy. Molecularly targeted agents, angiogenesis inhibitors, and immunotherapy have a defined role for patients with metastatic disease. The role, if any, of these new classes of agents is undergoing investigation for patients with earlier stage disease, including stage III disease. -PU - SPRINGER -PI - NEW YORK -PA - 233 SPRING ST, NEW YORK, NY 10013 USA -SN - 1527-2729 -SN - 1534-6277 -DA - 2015 OCT -PY - 2015 -VL - 16 -IS - 10 -C7 - 47 -DO - 10.1007/s11864-015-0364-2 -AN - WOS:000361610300001 -AD - Indiana Univ, Melvin & Bren Simon Canc Ctr, Hematol Oncol, Indianapolis, IN 46202 USA -AD - Indiana Univ, Melvin & Bren Simon Canc Ctr, Div Hematol Oncol, Indianapolis, IN 46202 USA -Y2 - 2015-10-15 -ER - - -TY - JOUR -AU - Levy, A. -AU - Doyen, J. -AU - Botticella, A. -AU - Bourdais, R. -AU - Achkar, S. -AU - Giraud, P. -AU - Du, C. -AU - Naltet, C. -AU - Lavaud, P. -AU - Besse, B. -AU - Pradere, P. -AU - Mercier, O. -AU - Caramella, C. -AU - Planchard, D. -AU - Deutsch, E. -AU - Le Pechoux, C. -TI - Role of immunotherapy in locally advanced non-small cell lung cancer -T2 - CANCER RADIOTHERAPIE -M3 - Article -AB - Concomitant radiochemotherapy has been the standard of care for unresectable stage III non-small cell lung cancer (NSCLC), irrespective of histological sub-type or molecular characteristics. Currently, only 15-30 % of patients are alive five years after radiochemotherapy, and this figure remains largely unchanged despite multiple phase III randomised trials. In recent years, immune-checkpoint blockades with anti-PD-(L)1 have revolutionised the care of metastatic NSCLC, becoming the standard front- and second-line strategy. Several preclinical studies reported an increased tumour antigen release, improved antigen presentation, and T-cell infiltration in irradiated tumours. Immunotherapy has therefore recently been evaluated for patients with locally advanced stage III NSCLC. Following the PACIFIC trial, the anti-PD-L1 durvalumab antibody has emerged as a new standard consolidative treatment for patients with unresectable stage III NSCLC whose disease has not progressed following concomitant platinum-based chemoradiotherapy. Immunoradiotherapy therefore appears to be a promising association in patients with localised NSCLC. Many trials are currently evaluating the value of concomitant immunotherapy and chemoradiotherapy and/or consolidative chemotherapy with immunotherapy in patients with locally advanced unresectable NSCLC. (C) 2020 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved. -PU - ELSEVIER -PI - BRIDGEWATER -PA - 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA -SN - 1278-3218 -SN - 1769-6658 -DA - 2020 FEB -PY - 2020 -VL - 24 -IS - 1 -SP - 67 -EP - 72 -DO - 10.1016/j.canrad.2019.09.007 -AN - WOS:000527990500011 -AD - Univ Paris Saclay, IOT, Dept Oncol Radiotherapie, Gustave Roussy, F-94805 Villejuif, France -AD - Univ Paris Saclay, Univ Paris Sud, F-94270 Le Kremlin Bicetre, France -AD - Ctr Antoine Lacassagne, Dept Oncol Radiotherapie, 33 Ave Valombrose, F-06189 Nice 2, France -AD - Univ Cote Azur, Federat Claude Lalanne, Nice 2, France -AD - Univ Paris Saclay, IOT, Dept Med Oncol, Gustave Roussy, F-94805 Villejuif, France -AD - Univ Paris Saclay, Hop Marie Lannelongue, Dept Chirurg Vasc & Thorac, Le Plessis Robinson, France -AD - Univ Paris Saclay, IOT, Dept Imagerie, Gustave Roussy, F-94805 Villejuif, France -Y2 - 2020-05-07 -ER - - -TY - JOUR -AU - Dehghani, Tannaz -AU - Shahrjerdi, Alireza -AU - Kahrizi, Mohammad Saeed -AU - Soleimani, Elnaz -AU - Ravandeh, Saeideh -AU - Merza, Muna S. -AU - Rahnama, Negin -AU - Ebrahimzadeh, Farnoosh -AU - Bakhshesh, Morteza -TI - Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances -T2 - PATHOLOGY RESEARCH AND PRACTICE -M3 - Article -AB - The immune system uses various immune checkpoint axes to adjust responses, support homeostasis, and deter self-reactivity and autoimmunity. Nevertheless, non-small-cell lung carcinoma (NSCLC) can use protective mechanisms to facilitate immune evasion, which leads to potentiated cancer survival and proliferation. In this light, many blocking anti-bodies have been developed to negatively regulate checkpoint molecules, in particular, programmed cell death protein 1 (PD-1) / PD-ligand 1 (L1), and bypass these immune suppressive mechanisms. Meanwhile, anti-PD-1 anti-bodies such as nivolumab, pembrolizumab, cemiplimab, and sintilimab have shown excellent competence in successfully inspiring immune responses versus NSCLC. Accordingly, the United States Food and Drug Administration (FDA) has recently approved nivolumab (alone or in combination with ipilimumab) and pembrolizumab (alone or in combination with chemotherapy) as first-line treatment for advanced NSCLC patients. However, PD-1 blockade monotherapy remains inefficient in more than 60% of NSCLC patients, and many patients don't respond or acquire resistance to this modality. Also, toxicities related to anti-PD-1 antibody have been progressively identified in clinical trials and oncology practice. Herein, we will outline the clinical benefits of PD-1 blockade therapy alone or in combination with other treatments (e.g., chemotherapy, radiotherapy, anti-angiogenic therapy) in NSCLC patients. Moreover, we will take a glimpse into the recently identified predictive biomarkers to determine patients most likely to suffer serious adverse events to decrease untoward toxicity risk and diminish treatment costs. -PU - ELSEVIER GMBH -PI - MUNICH -PA - HACKERBRUCKE 6, 80335 MUNICH, GERMANY -SN - 0344-0338 -SN - 1618-0631 -DA - 2023 JUN -PY - 2023 -VL - 246 -C7 - 154470 -DO - 10.1016/j.prp.2023.154470 -AN - WOS:001041309300001 -C6 - MAY 2023 -AD - Lorestan Univ Med Sci, Dept Internal Med, Lorestan, Iran -AD - Natl Inst Genet Engn & Biotechnol NIGEB, POB 14965-161, Tehran, Iran -AD - Alborz Univ Med Sci, Dept Surg, Karaj, Alborz, Iran -AD - Babol Univ Med Sci, Departmant Genet, Babol, Iran -AD - Colife Pathobiol Lab, Tehran, Iran -AD - Al Mustaqbal Univ Coll, Prosthet Dent Tech Dept, Babylon 51001, Iraq -AD - Semnan Univ Med Sci, Dept Internal Med & Hlth Serv, Semnan, Iran -AD - Mashhad Univ Med Sci, Fac Med, Dept Internal Med, Mashhad, Iran -AD - Khomein Univ Med Sci, Mol & Med Res Ctr, Khomein, Iran -M2 - Natl Inst Genet Engn & Biotechnol NIGEB -M2 - Alborz Univ Med Sci -M2 - Colife Pathobiol Lab -M2 - Khomein Univ Med Sci -Y2 - 2023-09-06 -ER - - -TY - JOUR -AU - Koffer, P. P. -AU - Belani, N. -AU - DiPetrillo, T. A. -AU - Hepel, J. T. -AU - Khurshid, H. -AU - Azzoli, C. -TI - Risk of Pneumonitis in Patients With Stage III Non-Small Cell Lung Cancer Treated With Definitive Chemo-RT and Durvalumab Consolidation -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 2913 -SP - E442 -EP - E442 -AN - WOS:000715803800908 -AD - Lifespan Canc Inst, Dept Radiat Oncol, Providence, RI USA -AD - Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Radiat Oncol, Providence, RI 02912 USA -AD - Rhode Isl Hosp, Warren Alpert Sch Med, Dept Internal Med, Providence, RI USA -AD - Brown Univ, Rhode Isl Hosp, Lifespan Canc Inst, Warren Alpert Med Sch,Dept Radiat Oncol, Providence, RI 02903 USA -AD - Brown Univ, Alpert Med Sch, Providence, RI 02912 USA -AD - Lifespan Canc Inst, Dept Med Oncol, Providence, RI USA -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - PALENA, CLAUDIA -TI - Novel Targets for Vaccine Therapy -M3 - Awarded Grant -DA - 2018 -PY - 2018 -AN - GRANTS:10214272 -G1 - 1ZICBC010937-11; 9780214; ZICBC010937 -AD - DIVISION OF BASIC SCIENCES - NCI -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Zhou, Caicun -AU - Wang, Jie -AU - Wang, Baocheng -AU - Cheng, Ying -AU - Wang, Zhehai -AU - Han, Baohui -AU - Lu, You -AU - Wu, Gang -AU - Zhang, Li -AU - Song, Yong -AU - Zhu, Bo -AU - Hu, Yi -AU - Wang, Ziping -AU - Song, Qibin -AU - Ren, Shengxiang -AU - He, Yayi -AU - Hu, Xiaohua -AU - Zhang, Jian -AU - Yao, Yu -AU - Zhao, Hongyun -AU - Wang, Zhijie -AU - Chu, Qian -AU - Duan, Jianchun -AU - Liu, Jingjing -AU - Qin, Shukui -TI - [Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)]. -T2 - Zhongguo fei ai za zhi = Chinese journal of lung cancer -M3 - Consensus Development Conference -M3 - Journal Article -AB - Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. The systemic antitumor therapy of advanced NSCLC has undergone renovations of chemotherapy, targeted therapy and immunotherapy, which results in greatly improved survival for patients with advanced NSCLC. Immune checkpoint inhibitors (ICIs), especially targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1), has changed the treatment paradigm of NSCLC. ICIs have become the standard treatment for advanced NSCLC without epidermal growth factor receptor(EGFR) mutation or anaplastic lymphomakinase(ALK) translocation in the first- or second-line setting, and for locally advanced NSCLC following concurrent radiotherapy and chemotherapy. ICIs are also promising in adjuvant/neoadjuvant therapy. More and more ICIs have been approved domestically for the treatment of NSCLC. Led by the NSCLC expert committee of Chinese Society of Clinical Oncology (CSCO), this consensus was developed and updated based on thoroughly reviewing domestic and foreign literatures, clinical trial data, systematic reviews, experts' discussion and the consensus(2019 version). This consensus will aid domestic clinicians in the treatment of NSCLC with ICIs.
. -AB - 【中文题目:中国非小细胞肺癌免疫检查点抑制剂治疗
专家共识(2020年版)】 【中文摘要:非小细胞肺癌(non-small cell lung cancer, NSCLC)是肺癌最常见的病理类型。晚期NSCLC的系统性抗肿瘤治疗经历了化疗、靶向治疗及免疫治疗的变革,患者总体生存时间不断延长。免疫检查点抑制剂(immune checkpoint inhibitors, ICIs),尤其是程序性死亡分子-1(programmed cell death protein 1, PD-1)/程序性死亡分子配体-1(programmed death-ligand 1, PD-L1)抗体已成为表皮生长因子受体(epidermal growth factor receptor, EGFR)/间变性淋巴瘤激酶(anaplastic lymphoma kinase, ALK)阴性晚期NSCLC一线及二线的标准治疗和局部晚期NSCLC同步放化疗后标准治疗,并在辅助/新辅助治疗中显示出可喜的结果,改变了NSCLC整体治疗格局。随着越来越多的ICIs在国内获批肺癌适应证,中国临床肿瘤学会(Chinese Society of Clinical Oncology, CSCO)NSCLC专家委员会牵头,组织该领域的专家,结合2019年版专家共识,参考最新国内外文献、临床研究数据及系统评价,在专家共同讨论的基础上,达成统一意见并制定、更新本共识,为国内同行更好地应用ICIs治疗NSCLC提供参考意见。
】 【中文关键词:肺肿瘤;免疫治疗;程序性死亡分子-1/程序性死亡分子配体-1;专家共识】. -SN - 1999-6187 -DA - 2021 Apr 20 (Epub 2021 Apr 26) -PY - 2021 -VL - 24 -IS - 4 -SP - 217 -EP - 235 -DO - 10.3779/j.issn.1009-3419.2021.101.13 -AN - MEDLINE:33896153 -AD - Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China. -AD - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. -AD - No. 960 Hospital of PLA, Jinan 250031, China. -AD - Jilin Cancer Hospital, Changchun 130012, China. -AD - Shandong Cancer Hospital and Institute, Jinan 250117, China. -AD - Shanghai Chest Hospital, Shanghai 200030, China. -AD - West China Hospital, Sichuan University, Chengdu 610041, China. -AD - Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. -AD - Peking Union Medical College Hospital, Beijing 100010, China. -AD - General Hospital of Eastern Theater Command, Nanjing 210002, China. -AD - Xinqiao Hospital, The Army Medical University, Chongqing 400037, China. -AD - Chinese PLA General Hospital, Beijing 100853, China. -AD - Beijing Cancer Hospital, Beijing 100142, China. -AD - Renmin Hospital of Wuhan University, Wuhan 430060, China. -AD - The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China. -AD - Xijing Hospital, Xi'an 710032, China. -AD - The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. -AD - Sun Yat-sen University Cancer Center, Guangzhou 510060, China. -AD - Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. -AD - Cancer Center, Eastern Theater General Hospital of the Chinese PLA, Nanjing 210002, China. -Y2 - 2021-04-30 -ER - - -TY - JOUR -AU - Bui, Nam -AU - Woodward, Brian -AU - Johnson, Anna -AU - Husain, Hatim -TI - Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer -T2 - CURRENT TREATMENT OPTIONS IN ONCOLOGY -M3 - Review -AB - Brain metastases are common in patients with non-small cell lung cancer (NSCLC), and due to associated poor prognosis, this field is an important area of need for the development of innovative medical therapies. Therapies including local approaches through surgical intervention and/or radiation and evolving systemic therapies have led to improvements in the treatment of brain metastases in patients with lung cancer. Strategies that consider applying advanced radiation techniques to minimize toxicity, intervening early with effective systemic therapies to spare radiation/surgery, testing radiosensitization combinations, and developing drug penetrant molecules have and will continue to define new practice patterns. We believe that in carefully considered asymptomatic patients, first-line systemic therapy may be considered before radiation therapy and small-molecule targeted therapy may provide an opportunity to defer radiation therapy for recurrence or progression of disease. The next several years in oncology drug development will see the reporting on of brain penetrant molecules in oncogene-defined non-small cell lung cancer. Ongoing studies will evaluate immunotherapies in patients with brain metastases with associated endpoints. We hope that continued drug development and carefully designed clinical trials may afford an opportunity to improve the lives of patients with brain metastases. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1527-2729 -SN - 1534-6277 -DA - 2016 MAY -PY - 2016 -VL - 17 -IS - 5 -C7 - 25 -DO - 10.1007/s11864-016-0400-x -AN - WOS:000374565200002 -AD - Univ Calif San Diego, Sch Med, UCSD Moores Canc Ctr, Div Hematol & Oncol, San Diego, CA 92103 USA -AD - UCSD Moores Canc Ctr, Ctr Personalized Canc Therapy, San Diego, CA USA -AD - 3855 Hlth Sci Dr 0987, La Jolla, CA 92093 USA -M2 - UCSD Moores Canc Ctr -Y2 - 2016-05-01 -ER - - -TY - JOUR -AU - De Giglio, Andrea -AU - Di Federico, Alessandro -AU - Nuvola, Giacomo -AU - Deiana, Chiara -AU - Gelsomino, Francesco -TI - The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) -T2 - CURRENT ONCOLOGY REPORTS -M3 - Review -AB - Purpose of Review In this review, we analyzed the current landscape of non-PD-(L)1 targeting immunotherapy. Recent Findings The advent of immunotherapy has completely changed the standard approach toward advanced NSCLC. Inhibitors of the PD-1/PD-L1 axis have quickly taken place as first-line treatment for NSCLC patients without targetable "driver" mutations. However, a non-negligible portion of patients derive modest benefit from immune-checkpoint inhibitors, and valid second-line alternatives are lacking, pushing researchers to analyze other molecules and pathways as potentially viable targets in the struggle against NSCLC. Starting from the better characterized CTLA-4 inhibitors, we then critically collected the actual knowledge on NSCLC vaccines as well as on other emerging molecules, many of them in their early phase of testing, to provide to the reader a comprehensive overview of the state of the art of immunotherapy in NSCLC beyond PD-1/PD-L1 inhibitors. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1523-3790 -SN - 1534-6269 -DA - 2021 NOV -PY - 2021 -VL - 23 -IS - 11 -C7 - 126 -DO - 10.1007/s11912-021-01124-9 -AN - WOS:000690898200005 -AD - IRCCS Azienda Osped Univ Bologna, Div Med Oncol, Via Albertoni 15, Bologna, Italy -AD - Alma Mater Studiorum Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy -Y2 - 2021-11-01 -ER - - -TY - JOUR -AU - Bryant, Alex K. -AU - Yin, Huiying -AU - Schipper, Matthew J. -AU - Paximadis, Peter A. -AU - Boike, Thomas P. -AU - Bergsma, Derek P. -AU - Movsas, Benjamin -AU - Dess, Robert T. -AU - Mietzel, Melissa A. -AU - Kendrick, Randi -AU - Seferi, Merita -AU - Dominello, Michael M. -AU - Matuszak, Martha M. -AU - Jagsi, Reshma -AU - Hayman, James A. -AU - Pierce, Lori J. -AU - Jolly, Shruti -A1 - Michigan Radiation Oncology Qualit -TI - Uptake of Adjuvant Durvalumab After Definitive Concurrent Chemoradiotherapy for Stage III Nonsmall-cell Lung Cancer -T2 - AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS -M3 - Article -AB - Objectives: The addition of adjuvant durvalumab improves overall survival in locally advanced nonsmall-cell lung cancer (NSCLC) patients treated with definitive chemoradiation, but the real-world uptake of adjuvant durvalumab is unknown. Materials and Methods: We identified patients with stage III NSCLC treated with definitive concurrent chemoradiation from January 2018 to October 2020 from a statewide radiation oncology quality consortium, representing a mix of community (n=22 centers) and academic (n=5) across the state of Michigan. Use of adjuvant durvalumab was ascertained at the time of routine 3-month or 6-month follow-up after completion of chemoradiation. Results: Of 421 patients with stage III NSCLC who completed chemoradiation, 322 (76.5%) initiated adjuvant durvalumab. The percentage of patients initiating adjuvant durvalumab increased over time from 66% early in the study period to 92% at the end of the study period. There was substantial heterogeneity by treatment center, ranging from 53% to 90%. In multivariable logistic regression, independent predictors of durvalumab initiation included more recent month (odds ratio [OR]: 1.05 per month, 95% confidence interval [CI]: 1.02-1.08, P=0.003), lower Eastern Cooperative Oncology Group score (OR: 4.02 for ECOG 0 vs. 2+, 95% CI: 1.67-9.64, P=0.002), and a trend toward significance for female sex (OR: 1.66, 95% CI: 0.98-2.82, P=0.06). Conclusion: Adjuvant durvalumab for stage III NSCLC treated with definitive chemoradiation was rapidly and successfully incorporated into clinical care across a range of community and academic settings in the state of Michigan, with over 90% of potentially eligible patients starting durvalumab in more recent months. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0277-3732 -SN - 1537-453X -DA - 2022 APR -PY - 2022 -VL - 45 -IS - 4 -SP - 142 -EP - 145 -DO - 10.1097/COC.0000000000000899 -AN - WOS:000772085000002 -AD - Univ Michigan, Dept Radiat Oncol, Rogel Comprehens Canc Ctr, Ann Arbor, MI 48109 USA -AD - Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA -AD - Spectrum Hlth Lakeland, St Joseph, MO USA -AD - 21st Century Oncol, Clarkston, MI USA -AD - Mercy Hlth St Marys, Dept Radiat Oncol, Grand Rapids, MI USA -AD - Henry Ford Hosp, Dept Radiat Oncol, Detroit, MI USA -AD - Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Radiat Oncol, Sch Med, Detroit, MI USA -M2 - Spectrum Hlth Lakeland -M2 - 21st Century Oncol -M2 - Mercy Hlth St Marys -Y2 - 2022-04-01 -ER - - -TY - JOUR -AU - Declerck, Sarah -AU - Vansteenkiste, Johan -TI - Immunotherapy for lung cancer: ongoing clinical trials -T2 - FUTURE ONCOLOGY -M3 - Review -AB - Modulation of a patient's immune system so that it acts against lung cancer cells has not been successful in the past decades. Advances in our understanding of the immune response to tumors resulted in the development of different kinds of novel immunotherapeutic agents. This has resulted in the development of two major approaches. First, antigen-specific immunotherapy or cancer vaccination, with the MAGE-A3 vaccine in resected early-stage non-small-cell lung cancer (NSCLC), the L-BLP25 vaccine in locally advanced NSCLC after chemoradiotherapy and belagenpumatucel-L and the TG4010 vaccine in advanced-stage NSCLC. Second, non-antigen-specific immunotherapy or cancer immunomodulation is reviewed, including how monoclonal antibodies modulate the interaction between antigen-presenting cells, T-lymphocytes and tumor cells (e.g., antibodies against CTLA-4, or against PD-1 receptor or its ligands). Recent Phase II trials with these treatments have shown promising results of efficacy and tolerability, which has led to testing in several large Phase III trials. Some of these are fully recruited, while others are still ongoing, and important results are be expected in the near future. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1479-6694 -SN - 1744-8301 -DA - 2014 JAN -PY - 2014 -VL - 10 -IS - 1 -SP - 91 -EP - 105 -DO - 10.2217/FON.13.166 -AN - WOS:000337221000015 -AD - Univ Hosp KU Leuven, Dept Pulmonol, Resp Oncol Unit, Louvain, Belgium -AD - Univ Hosp KU Leuven, Leuven Lung Canc Grp, Louvain, Belgium -Y2 - 2014-01-01 -ER - - -TY - JOUR -AU - De Felice, Marco -AU - Turitto, Giacinto -AU - Borrelli, Carola -AU - Menditto, Carmine -AU - Cangiano, Rodolfo -TI - Combination of immunotherapy, radiotherapy and denosumab as the best approach even for NSCLC poor prognosis patients: a case report with strong response, prolonged survival and a review of literature -T2 - CURRENT PROBLEMS IN CANCER -M3 - Review -AB - Non-Small Cell Lung Cancer (NSCLC) with bone metastasis and poor performance status has the worst prognosis even in strong PD-L1 expression patients. Treatment approach includes immuno-or chemo-immunotherapy, Radiotherapy (RT) and Bone-Targeted Therapy (BTT) but there is insufficient data to sug -gest the best time to use each of them, alone or in combination. Using an integrated and synergistic treat-ment strategy with immunotherapy, radiotherapy, and Denosumab as BTT is probably the best treatment planning for metastatic NSCLC for both good and poor performance status patients, although more data are needed to confirm this approach. Here we describe an interesting case report on patient with ex-tensive bone involvement from NSCLC and PS > 2 treated simultaneously with radiotherapy, immunother-apy and BTT, achieving an excellent clinical benefit, radiological and metabolic complete response, as a sort of Lazarus effect. We analyzed our result comparing with currently published data about radio-immunotherapy or immunotherapy and BTT combination even though there is no published experience about integration of all 3 treatments. Approval studies often do not represent real-world experience (RWE), so we analyzed data from both RWE and clinical trials. (c) 2023 Elsevier Inc. All rights reserved. -PU - MOSBY-ELSEVIER -PI - NEW YORK -PA - 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA -SN - 0147-0272 -SN - 1535-6345 -DA - 2023 DEC -PY - 2023 -VL - 47 -IS - 6 -C7 - 100947 -DO - 10.1016/j.currproblcancer.2022.100947 -AN - WOS:001125409000001 -C6 - NOV 2023 -AD - AGP Hosp, Dept Med Oncol, ASL Caserta, I-81016 Piedimonte Matese, Italy -AD - Univ Campania Luigi Vanvitelli, Dept Precis Med, Med Oncol, Naples, Italy -AD - AORN St Anna & San Sebastiano, Div Oncol, Caserta, Italy -M2 - AGP Hosp -M2 - AORN St Anna & San Sebastiano -Y2 - 2023-12-29 -ER - - -TY - JOUR -AU - Rajappa, Senthil -AU - Sharma, Sanjiv -AU - Prasad, Krishna -TI - Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes -T2 - ADVANCES IN THERAPY -M3 - Review -AB - Stage III locally advanced non-small cell lung cancer (LA NSCLC) comprises the most heterogeneous group of patients, accounts for one-third of patients with lung cancer, and is unresectable at presentation. Multiple treatment approaches have evolved over the past few decades focusing on timing of chemoradiation (concurrent vs. sequential) and sequencing of therapy (induction vs. consolidation). Concurrent chemoradiation (CCRT) emerged as the standard of care for the majority of the patients worldwide. Despite improvements in median and overall survival (OS) using the concurrent approach, the rate of distant failure remains high. Consolidation with chemotherapy or targeted agents, adding more radiation dose, or induction chemotherapy did not improve OS. With continued research on defining optimal radiation doses and schedules and integrating novel systemic agents, immunotherapy consolidation has renewed optimism. Synergistic use of radiation and immunotherapy can prevent micrometastatic disease and reduce local failure and may have an abscopal effect in addition to survival benefits. The PACIFIC study reported an absolute progression-free survival benefit of 11.2 months with durvalumab consolidation after standard CCRT compared with placebo. The OS data with durvalumab consolidation are encouraging. Durvalumab is the only approved immunotherapy for unresectable stage III LA NSCLC. Improved survival confirms the definitive role of durvalumab as an effective adjuvant therapy after CCRT with no new safety signals. However, the potential mechanisms driving interaction between immunotherapy and chemoradiotherapy require definitive investigation. These mechanisms may help define the timing of immunotherapy initiation as neoadjuvant, adjuvant, or consolidation and maintenance therapy after progression. -PU - SPRINGER -PI - NEW YORK -PA - 233 SPRING ST, NEW YORK, NY 10013 USA -SN - 0741-238X -SN - 1865-8652 -DA - 2019 MAR -PY - 2019 -VL - 36 -IS - 3 -SP - 563 -EP - 578 -DO - 10.1007/s12325-019-0876-4 -AN - WOS:000462129500004 -AD - Basavatarakam Indo Amer Canc Hosp & Res Inst, Hyderabad, Telangana, India -AD - Manipal Hosp, Bengaluru, India -AD - Mangalore Inst Oncol, Mangalore, India -M2 - Basavatarakam Indo Amer Canc Hosp & Res Inst -M2 - Manipal Hosp -M2 - Mangalore Inst Oncol -Y2 - 2019-04-05 -ER - - -TY - JOUR -AU - Li, Y. -AU - Jing, W. -AU - Jing, X. -AU - Sun, Y. -AU - Tang, X. -AU - Guo, J. -AU - Zhang, Y. -AU - Zhu, H. -TI - Outcomes of Consolidative Thoracic Radiation within FirstLine Chemoimmunotherapy in Extensive-Stage Small -Cell Lung Cancer: Results from a Single Cancer Center -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2081 -SP - E37 -EP - E38 -AN - WOS:001079706800077 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Hosp, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Jinan 250021, Shandong, Peoples R China -AD - Shandong First Med Univ, Dept Radiat Oncol, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Dept Med Oncol, Shandong Canc Hosp & Inst, Jinan 250117, Shandong, Peoples R China -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Tsukita, Yoko -AU - Yamamoto, Takaya -AU - Mayahara, Hiroshi -AU - Hata, Akito -AU - Takeda, Yuichiro -AU - Nakayama, Hidetsugu -AU - Tanaka, Satoshi -AU - Uchida, Junji -AU - Usui, Kazuhiro -AU - Toyoda, Tatsuya -AU - Tamiya, Motohiro -AU - Morimoto, Masahiro -AU - Oya, Yuko -AU - Kodaira, Takeshi -AU - Miyauchi, Eisaku -AU - Jingu, Keiichi -AU - Sugiura, Hisatoshi -TI - Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study -T2 - RADIOTHERAPY AND ONCOLOGY -M3 - Article -AB - Background and purpose: Intensity-modulated radiation therapy (IMRT) is increasingly applied in concur-rent chemoradiotherapy (CCRT) for locally-advanced non-small cell lung cancer (NSCLC), with improve-ment of target coverage and better sparing of normal tissue. IMRT tends to have a larger low-dose irradiation volume than 3D conformal radiotherapy, but the incidence of and risk factors for pneumonitis remain unclear, especially following the approval of durvalumab. Materials and methods: We retrospectively reviewed the records of NSCLC patients treated by CCRT using IMRT at seven Japanese institutions. Primary outcomes were incidence of symptomatic pneumonitis and progression-free survival (PFS). Multivariate logistic regression analysis was used to identify risk factors for >grade 2 pneumonitis. Results: Median follow-up from the start of CCRT was 14.3 months (n = 107 patients; median age 70 years, 29% female). Median lung V5 and V20 was 49.2% and 19.5%, respectively. Durvalumab was administered to 87 patients (81%). Pneumonitis developed in 95 (89%) patients of which 53% had grade 1, 28% grade 2, 6.5% grade 3, and 0.9% grade 4. Durvalumab had been discontinued in 16 patients (18.4%) due to pneu-monitis. By multivariate analysis, age >70 years, male sex, and V5 >58.9% were identified as significantly associated with >grade 2 pneumonitis (p = 0.0065, 0.036 and 0.0013 respectively). The median PFS from the start of CCRT was not reached (95% CI, 14.2 months to not reached) in patients receiving durvalumab. Conclusion: CCRT using IMRT followed by durvalumab was generally effective and tolerable; V5 <60% would be recommended to avoid symptomatic pneumonitis. (c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 160 (2021) 266-272 -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0167-8140 -SN - 1879-0887 -DA - 2021 JUL -PY - 2021 -VL - 160 -SP - 266 -EP - 272 -DO - 10.1016/j.radonc.2021.05.016 -AN - WOS:000669800200008 -C6 - MAY 2021 -AD - Tohoku Univ, Dept Resp Med, Grad Sch Med, Sendai, Miyagi, Japan -AD - Tohoku Univ, Dept Radiat Oncol, Grad Sch Med, Sendai, Miyagi, Japan -AD - Kobe Minimally Invas Canc Ctr, Dept Radiat Oncol, Kobe, Hyogo, Japan -AD - Kobe Minimally Invas Canc Ctr, Dept Resp Med Oncol, Kobe, Hyogo, Japan -AD - Natl Ctr Global Hlth & Med, Dept Resp Med, Tokyo, Japan -AD - Natl Ctr Global Hlth & Med, Dept Radiat Oncol, Tokyo, Japan -AD - Osaka Gen Med Ctr, Dept Resp Med, Osaka, Japan -AD - NTT Med Ctr Tokyo, Div Respirol, Tokyo, Japan -AD - NTT Med Ctr Tokyo, Dept Radiol, Tokyo, Japan -AD - Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan -AD - Osaka Int Canc Inst, Dept Radiat Oncol, Osaka, Japan -AD - Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan -AD - Aichi Canc Ctr Hosp, Dept Radiat Oncol, Nagoya, Aichi, Japan -M2 - Kobe Minimally Invas Canc Ctr -M2 - Kobe Minimally Invas Canc Ctr -M2 - Osaka Gen Med Ctr -M2 - Osaka Int Canc Inst -M2 - Osaka Int Canc Inst -Y2 - 2021-07-16 -ER - - -TY - JOUR -AU - Liu, H. -AU - Qiu, B. -AU - Wang, D. -AU - Zhang, X. -AU - Liu, H. -AU - Zhou, Y. -AU - Li, Q. -AU - Chu, C. -AU - Liu, F. -AU - Chen, N. -AU - Hu, N. -AU - Ai, X. -AU - Guo, J. -AU - Fan, W. -TI - Dynamic 18F-FDG Total Body PET Imaging as a Predictive Marker of Induction Chemo-Immunotherapy Followed by Concurrent Chemoradiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 2920 -SP - E445 -EP - E445 -AN - WOS:000715803800915 -AD - Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Radiat Oncol,Canc Ctr, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Nucl Med,Canc Ctr, Guangzhou, Peoples R China -AD - United Imaging Healthcare, Mol Imaging Business Unit, Shanghai, Peoples R China -AD - SuZhou TongDiao Co, Suzhou, Peoples R China -AD - Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China -M2 - United Imaging Healthcare -M2 - SuZhou TongDiao Co -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Ratto, GB -AU - Cafferata, MA -AU - Scolaro, G -AU - Bruzzi, P -AU - Alloisio, A -AU - Costa, R -AU - Spessa, E -AU - Semino, C -AU - Melioli, G -TI - Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer -T2 - JOURNAL OF IMMUNOTHERAPY -M3 - Article -AB - The association of adoptive immunotherapy (AI) and radiotherapy has been shown to be effective in the control of residual intrathoracic disease, while having no systemic advantages, in patients operated on for locally advanced non-small-cell lung cancer (NSCLC). The potential synergy of coupling immunotherapy and chemotherapy has been emphasized in several tumors including NSCLC, The aim of this work was to determine the feasibility and activity of a combined therapeutic program, including Al, chemotherapy, and radiotherapy in patients who had undergone incomplete resections for NSCLC, In a phase II trial, 13 patients received the combined treatment. Al was given from week 4 after surgery until week 8. Concurrent chemo(cisplatin and etoposide)-radiotherapy (60 Gy) was given from week 9 to week 14. Twenty eligible patients received chemoradiotherapy only and were used as a nonrandomized concomitant group for merely descriptive purposes. At 9-month followup, 10 of the 13 patients had progression of disease and the study was stopped. Progression-free survival and survival were similar to those of the chemoradiotherapy group. The present study showed that the sequence of immunotherapy followed by chemotherapy is not effective as adjuvant treatment in patients operated on for stage In. NSCLC, at least when used according to the adopted schedule. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA -SN - 1053-8550 -DA - 2000 JAN -PY - 2000 -VL - 23 -IS - 1 -SP - 161 -EP - 167 -DO - 10.1097/00002371-200001000-00019 -AN - WOS:000085127500018 -AD - Univ Genoa, Cattedra Chirurg Torac, I-16132 Genoa, Italy -AD - Ist Nazl Ric Canc, Unita Immunoterapia Cellulare, I-16132 Genoa, Italy -AD - Ist Nazl Ric Canc, Unita Oncol Med 1, I-16132 Genoa, Italy -AD - Ist Nazl Ric Canc, Unita Radioterapia, I-16132 Genoa, Italy -AD - Ist Nazl Ric Canc, Unita Epidemiol Clin, I-16132 Genoa, Italy -Y2 - 2000-01-01 -ER - - -TY - JOUR -AU - Siringo, Marco -AU - Baena, Javier -AU - de Cabo, Helena Bote -AU - Torres-Jimenez, Javier -AU - Zurera, Maria -AU - Zugazagoitia, Jon -AU - Paz-Ares, Luis -TI - Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer -T2 - CANCERS -M3 - Review -AB - Simple Summary Despite the use of novel agents in the first-line therapeutic setting, such as PD-1/PDL1 axis blockers for non-oncogene addicted non-small-cell lung cancer, most patients with advanced disease experience progression will succumb to the illness within a short period of time. Currently, the standard second-line treatment consists primarily of systemic cytotoxic therapies, which typically yield poor outcomes. Recently, several novel therapeutic strategies have emerged that may improve patient outcomes. This article reviews current state-of-the-art treatments in this scenario and highlights potential future options.Abstract Immune checkpoint inhibitors (ICIs) have revolutionized the management of non-oncogene addicted non-small-cell lung cancer (NSCLC). Blocking the anti-PD-1 axis represents the current standard of care in the first-line setting, with drugs administered either as monotherapy or in combination with chemotherapy. Despite notable successes achieved with ICIs, most of their long-term benefits are restricted to approximately 20% of patients. Consequently, the post-failure treatment landscape after failure to first-line treatment remains a complex challenge. Currently, docetaxel remains the preferred option, although its benefits remain modest as most patients do not respond or progress promptly. In recent times, novel agents and treatment combinations have emerged, offering fresh opportunities to improve patient outcomes. ICIs combined either with antiangiogenic or other novel immunotherapeutic compounds have shown promising preliminary activity. However, more mature data concerning specific combinations do not support their benefit over standard of care. In addition, antibody-drug conjugates seem to be the most promising alternative among all available compounds according to already-published phase I/II data that will be confirmed in soon-to-be-published phase III trial data. In this report, we provide a comprehensive overview of the current second-line treatment options and discuss future therapeutic perspectives. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2023 DEC -PY - 2023 -VL - 15 -IS - 23 -C7 - 5505 -DO - 10.3390/cancers15235505 -AN - WOS:001116485200001 -AD - 12 Octubre Hosp, Dept Med Oncol, Madrid 28041, Spain -AD - Sapienza Univ Rome, Dept Med Oncol, I-00100 Rome, Italy -AD - Spanish Natl Canc Res Ctr CNIO, Lung Canc Clin Res Grp, Madrid 28029, Spain -AD - Ciberonc, Madrid 28029, Spain -AD - Univ Complutense Madrid, Med Fac, Med Dept, Madrid 28040, Spain -Y2 - 2023-12-21 -ER - - -TY - JOUR -AU - Chua, YJ -AU - Steer, C -AU - Yip, C -TI - Recent advances in management of small-cell lung cancer -T2 - CANCER TREATMENT REVIEWS -M3 - Review -AB - Small-cell, Lung cancer (SCLC) is a smoking-related disease with a poor prognosis. While SCLC is usually initially sensitive to chemotherapy and radiotherapy, responses are rarely Long Lasting. Frustratingly, most patients ultimately relapse, often with increasingly treatment resistant disease. Many strategies have been developed in an attempt to improve treatment outcomes, which have plateaued since the introduction of combination chemotherapy in the 1980s. These include trials of maintenance therapy, and dose intensification, the latter by means of increasing dose density, growth factor support and high dose chemotherapy with autologous stern cell rescue. None have been shown to improve patient survival. On the other hand, the integration of concurrent thoracic radiation and prophylactic cranial irradiation has improved the survival outcomes in patients with Limited disease. In extensive disease, irinotecan combined with cisplatin has shown promise in improving survival over conventional ptatinum/etoposide chemotherapy schedules and a confirmatory study is awaited. The future of SCLC treatment may however Lie with molecularly targeted therapies, such as antiangiogenesis agents and signal transduction inhibitors, which are being studied at present. (C) 2004 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCI LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND -SN - 0305-7372 -SN - 1532-1967 -DA - 2004 OCT -PY - 2004 -VL - 30 -IS - 6 -SP - 521 -EP - 543 -DO - 10.1016/j.ctrv.2004.06.003 -AN - WOS:000223682300003 -AD - Canberra Hosp, Med Oncol Unit, Woden, ACT 2606, Australia -AD - Border Med Oncol, Albury, NSW, Australia -AD - Univ New S Wales, Sch Rural Med, Albury, NSW, Australia -AD - Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia -M2 - Border Med Oncol -Y2 - 2004-10-01 -ER - - -TY - JOUR -AU - Landman, Yosef -AU - Jacobi, Oded -AU - Kurman, Noga -AU - Yariv, Orly -AU - Peretz, Idit -AU - Rotem, Ofer -AU - Dudnik, Elizabeth -AU - Zer, Alona -AU - Allen, Aaron M. -TI - Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer -T2 - ONCOIMMUNOLOGY -M3 - Article -AB - The standard of care for stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by durvalumab. Although doses higher than 66 Gy are standard in our center, they were used in only 6.9% of patients in the PACIFIC trial. We report our experience with durvalumab after high-dose radiotherapy. The database of a tertiary hospital for patients with stage III NSCLC who were treated with CRT and adjuvant durvalumab was evaluated. Progression-free survival (PFS), overall survival (OS), and local-regional failure (LRF) were measured from the administration of durvalumab. Thirty-nine patients were included. All were treated with intensity-modulated radiation (mean dose 69.9 Gy); Median follow-up time was 20.4 months (range 1-35.4). At 12 months, PFS was 49%, OS 79%, and LRF 14%. Intrathoracic failure at first progression was demonstrated in 8 (21%) patients. Adverse events requiring corticosteroids occurred in 10(25.6%) patients: pneumonitis - 6 (15.4%), hepatitis - 2 (5.1%), and arthralgia and pericarditis - 1 (2.6%). One patient (2.6%) died of pneumonitis. The occurrence of pneumonitis was significantly associated with lung V5 (55% vs. 42%, p = .04) and V20 (28% vs. 19%, p = .01) and mean lung dose (14.8 Gy vs.11.6 Gy, p = .05). The similar 12-month PFS and OS rates of our cohort and the PACIFIC trial support the use of high-dose radiotherapy in patients with stage III NSCLC. Treatment-related mortality was similar to the PACIFIC results. The intrathoracic failure rate in our cohort was lower than that reported from the PACIFIC trial, suggesting that radiation dose escalation may improve local control. -PU - TAYLOR & FRANCIS INC -PI - PHILADELPHIA -PA - 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA -SN - 2162-402X -DA - 2021 JAN 1 -PY - 2021 -VL - 10 -IS - 1 -C7 - 1959979 -DO - 10.1080/2162402X.2021.1959979 -AN - WOS:000683585900001 -AD - Rabin Med Ctr, Davidoff Canc Ctr, Thorac Oncol Serv, Beilinson Hosp, Petah Tiqwa, Israel -AD - Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel -Y2 - 2021-08-18 -ER - - -TY - JOUR -AU - Zhao, Ze-Rui -AU - Yang, Chao-Pin -AU - Chen, Si -AU - Yu, Hui -AU - Lin, Yong-Bin -AU - Lin, Yao-Bin -AU - Qi, Han -AU - Jin, Jie-Tian -AU - Lian, Shan-Shan -AU - Wang, Yi-Zhi -AU - You, Jin-Qi -AU - Zhai, Wen-Yu -AU - Long, Hao -TI - Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer -T2 - ONCOIMMUNOLOGY -M3 - Article -AB - Multimodality treatment provides modest survival benefits for patients with locally advanced (stage III) non-small-cell lung cancer (NSCLC). Nevertheless, preoperative immunotherapy has continuously been shown to be promising in treating resectable NSCLC.This phase 2 trial enrolled patients with AJCC-defined stage IIIA or T3-4N2 IIIB NSCLC deemed surgically resectable. Patients received three cycles of neoadjuvant treatment with intravenous PD-1 inhibitor toripalimab (240 mg), carboplatin (area under the curve 5), and pemetrexed (500 mg/m(2) for adenocarcinoma) or nab-paclitaxel (260 mg/m(2) for other subtypes) on day 1 of each 21-day cycle. Surgical resection was performed 4-5 weeks afterward. The primary endpoint was major pathological response (MPR), defined as less than 10% residual tumor remaining at the time of surgery.Thirty-three patients were enrolled, of whom 13 (39.4%) had T3-4N2 stage IIIB disease. Thirty (90.9%) patients underwent resection and all except one (96.7%) achieved R0 resection. Twenty patients (60.6%) in the intention-to-treat population achieved an MPR, including 15 patients (45.5%) who achieved a pathological complete response (pCR). The MPR and pCR rates in the per-protocol population were 66.7% and 50.0%, respectively. The surgical complications included three cases of arrhythmias, one case of a prolonged air leak, and one case of chylothorax. The most common grade 3 treatment-related adverse event (TRAE) was anemia (2, [6.1%]). Severe TRAEs included one (3.0%) case of grade 3 peripheral neuropathy that resulted in surgical cancellation.Toripalimab plus platinum-based doublet chemotherapy yields a high MPR rate, manageable toxicity, and feasible resection in stage III NSCLC.Trial ClinicalTrials.gov (NCT04304248) -PU - TAYLOR & FRANCIS INC -PI - PHILADELPHIA -PA - 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA -SN - 2162-402X -DA - 2021 JAN 1 -PY - 2021 -VL - 10 -IS - 1 -C7 - 1996000 -DO - 10.1080/2162402X.2021.1996000 -AN - WOS:000710718300001 -AD - Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol Southern China, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China -AD - Sun Yat Sen Univ Canc Ctr, Dept Thorac Surg, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China -AD - Sun Yat Sen Univ, Lung Canc Res Ctr, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ Canc Ctr, Dept Biotherapy, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ Canc Ctr, Dept Minimally Invas Intervent Therapy, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ Canc Ctr, Dept Radiol, Guangzhou, Peoples R China -Y2 - 2021-01-01 -ER - - -TY - JOUR -AU - Dziadziuszko, R. -AU - Ahn, M. J. -AU - Kelly, K. -AU - Popat, S. -AU - Wakelee, H. A. -AU - Baird, A. M. -AU - Rooney, I. -AU - Afshari, M. -AU - Coleman, S. -AU - Zhang, Z. -AU - Kiruki, H. -AU - Patil, N. -AU - Wen, X. -AU - Bradley, J. D. -TI - SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 2867 -SP - E420 -EP - E421 -DO - 10.1016/j.ijrobp.2021.07.1203 -AN - WOS:000715803800863 -C6 - OCT 2021 -AD - Med Univ Gdansk, Gdansk, Poland -AD - Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea -AD - Univ Calif Davis, Med Ctr, Sacramento, CA USA -AD - Royal Marsden, London, England -AD - Stanford Univ, Med Ctr, Stanford, CA 94305 USA -AD - Trinity Coll Dublin, Dublin, Ireland -AD - Genentech Inc, San Francisco, CA USA -AD - Emory Univ, Sch Med, Atlanta, GA USA -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Shibata, Yuji -AU - Murakami, Shuji -TI - Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer -T2 - EXPERT OPINION ON DRUG SAFETY -M3 - Article -AB - Introduction: The development of immune checkpoint inhibitors (ICIs), such as anti-programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors, has been a breakthrough in the treatment of non-small-cell lung cancer (NSCLC). Durvalumab, a PD-L1 inhibitor, has shown survival benefit as a maintenance therapy for patients with unresectable stage III NSCLC following definitive chemoradiotherapy, and is approved by the U.S. Food and Drug Administration and the European Medicines Agency. Areas covered: In this article, we review the development of durvalumab, its pharmacology, and its safety profile as a monotherapy and in combination with other agents, including epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), ICIs such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) blockers, and cytotoxic chemotherapy. Expert opinion: ICIs, including durvalumab, cause unique side effects, known as immune-mediated adverse events, which are commonly manageable with standard treatment algorithms. The safety profile of durvalumab monotherapy is similar to those of other PD-1/PD-L1 inhibitors. In the PACIFIC trial, durvalumab after radiotherapy resulted in a slight increase in pulmonary toxicity, but most cases were mild. The enhanced effect of ICIs when used in combination therapies is accompanied by an increased risk of side effects. Therefore, the authors evaluated the safety profile and risk-benefit balance of durvalumab combined with various agents. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1474-0338 -SN - 1744-764X -DA - 2020 JUN 2 -PY - 2020 -VL - 19 -IS - 6 -SP - 653 -EP - 659 -DO - 10.1080/14740338.2020.1764936 -AN - WOS:000534171000001 -C6 - MAY 2020 -AD - Yokohama Med Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan -AD - Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan -M2 - Yokohama Med Ctr -Y2 - 2020-05-28 -ER - - -TY - JOUR -AU - Jabbour, S. K. -AU - Lee, K. H. -AU - Frost, N. -AU - Breder, V. -AU - Kowalski, D. -AU - Alawin, I. -AU - Levchenko, E. -AU - Reguart, N. -AU - Martinez-Marti, A. -AU - Houghton, B. -AU - Paoli, J. B. -AU - Safina, S. -AU - Park, K. -AU - Komiya, T. -AU - Sanford, A. -AU - Boolell, V. -AU - Liu, H. -AU - Samkari, A. -AU - Keller, S. -AU - Reck, M. -TI - Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy for Unresectable, Locally Advanced, Stage 3 NSCLC: KEYNOTE-799 -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 16 -SP - S9 -EP - S10 -DO - 10.1016/j.ijrobp.2021.07.054 -AN - WOS:000715803801357 -C6 - OCT 2021 -AD - Rutgers State Univ, Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA -AD - Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA -AD - Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea -AD - Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany -AD - Corp member Freie Univ Berlin, Berlin, Germany -AD - Humboldt Univ, Berlin, Germany -AD - Berlin Inst Hlth, Berlin, Germany -AD - NN Blokhin Russian Canc Res Ctr, Moscow, Russia -AD - Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland -AD - SouthWestern Reg Med Ctr Inc, Canc Treatment Centers Amer, Tulsa, OK USA -AD - Petrov Res Inst Oncol, St Petersburg, Russia -AD - Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain -AD - Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Barcelona, Spain -AD - Port Macquarie Base Hosp, Mid North Coast Canc Inst, Port Macquarie, NSW, Australia -AD - Clin Clairval, Radiotherapie, Marseille, France -AD - Republican Dispensary Tatarstan MoH, Med Oncol, Kazan, Russia -AD - Sungkyunkwan Univ, Sch Med, Oncol Samsung Med Ctr, Div Hematol, Seoul, South Korea -AD - Parkview Canc Inst, Hematol Med Oncol, Ft Wayne, IN USA -AD - Sanford Hlth, Sioux Falls, SD USA -AD - Ballarat Hlth Serv, Ballarat, Vic, Australia -AD - Merck & Co Inc, Kenilworth, NJ USA -AD - Lungen Clin Grosshansdorf, Airway Res Ctr North ARCN, German Ctr Lung Res DZL, Grosshansdorf, Germany -M2 - Corp member Freie Univ Berlin -M2 - Maria Sklodowska Curie Natl Res Inst Oncol -M2 - SouthWestern Reg Med Ctr Inc -M2 - Clin Clairval -M2 - Republican Dispensary Tatarstan MoH -M2 - Parkview Canc Inst -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Lazzari, Chiara -AU - Karachaliou, Niki -AU - Gregorc, Vanesa -AU - Bulotta, Alessandra -AU - Gonzalez-Cao, Maria -AU - Verlicchi, Alberto -AU - Altavilla, Giuseppe -AU - Rosell, Rafael -AU - Santarpia, Mariacarmela -TI - Second-line therapy of squamous non-small cell lung cancer: an evolving landscape -T2 - EXPERT REVIEW OF RESPIRATORY MEDICINE -M3 - Article -AB - Introduction: The treatment of lung cancer has radically changed over the last few years. The discovery of druggable oncogenic alterations and the introduction of immunotherapy have provided lung cancer patients with the possibility of more efficient and less toxic therapeutic alternatives than chemotherapy. In the case of lung squamous cell carcinoma (LSCC), the treatment progress is slower than adenocarcinoma, for which several targeted agents have been already approved. The standard first-line therapy for LSCC, in most sites of the world, is platinum-based chemotherapy. After disease progression, these patients now have novel treatment options, including antiangiogenic agents and immune checkpoint blockade.Areas covered: We provide a summary of the recent novelties for the second-line therapy of LSCC, emphasizing on the results of the most important clinical trials that have led to regulatory approvals.Expert commentary: Immune checkpoint inhibitors have changed the therapeutic algorithm for LSCC patients. Other treatment options in the second-line setting include ramucirumab in combination with docetaxel and afatinib. However, we still lack biomarkers to predict which patients could respond better to each treatment. Despite the identification of several actionable molecular alterations, there are no approved targeted agents specific for advanced LSCC. Results from ongoing biomarker-driven studies are eagerly awaited to establish effective treatments for molecularly selected subgroups of patients. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1747-6348 -SN - 1747-6356 -DA - 2017 -PY - 2017 -VL - 11 -IS - 6 -SP - 469 -EP - 479 -DO - 10.1080/17476348.2017.1326822 -AN - WOS:000402018700004 -AD - IRCCS San Raffaele, Div Expt Med, Dept Oncol, Milan, Italy -AD - Univ Hosp Sagrat Cor, Inst Oncol Rosell, Dept Med Oncol, Barcelona, Spain -AD - Dexeus Univ Hosp, Inst Oncol Dr Rosell, Translat Canc Res Unit, Quironsalud Grp, Barcelona, Spain -AD - Fdn IRCCS Policlin San Matteo, SC Oncol, Pavia, Italy -AD - Univ Messina, Dept Human Pathol G Barresi, Med Oncol Unit, Via Consolare Valeria 1, I-98122 Messina, Italy -AD - Germans Trias & Pujol Res Inst, Badalona, Spain -AD - Germans Trias & Pujol Univ Hosp, Catalan Inst Oncol, Badalona, Spain -M2 - Univ Hosp Sagrat Cor -M2 - Germans Trias & Pujol Res Inst -Y2 - 2017-06-07 -ER - - -TY - JOUR -AU - Losanno, Tania -AU - Rossi, Antonio -AU - Maione, Paolo -AU - Napolitano, Alba -AU - Gridelli, Cesare -TI - Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer -T2 - EXPERT OPINION ON BIOLOGICAL THERAPY -M3 - Review -AB - Introduction: In recent years, several clinical trials have evaluated the efficacy and safety of biological therapies in lung cancer. Epidermal growth factor receptor (EGFR) and the axis vascular endothelial growth factor receptor (VEGF/VEGFR) are targeted by small molecules and monoclonal antibodies (mAbs), especially in non-squamous non-small-cell lung cancer (NSCLC).Areas covered: The current state of the art of anti-EGFR and antiangiogenic monoclonal antibodies in metastatic NSCLC is reviewed and discussed.Expert opinion: Bevacizumab and cetuximab are the most studied mAbs in NSCLC, but only bevacizumab is in clinical practice in the first-line setting. Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. Ramucirumab, an antiangiogenic drug binding with high affinity to VEGFR-2, improves the results of chemotherapy alone when administered with docetaxel and has been approved in second-line setting. Moreover, the novel combination of bevacizumab and erlotinib is very promising for the treatment of patients with NSCLC harbouring EGFR mutations. The association of antiangiogenic mAbs and immunotherapy is under investigation too. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1471-2598 -SN - 1744-7682 -DA - 2016 -PY - 2016 -VL - 16 -IS - 6 -SP - 747 -EP - 758 -DO - 10.1517/14712598.2016.1163333 -AN - WOS:000375619800003 -AD - Univ Roma La Sapienza, Dept Expt Med, Rome, Italy -AD - SG Moscati Hosp, Div Med Oncol, I-83100 Avellino, Italy -AD - SG Moscati Hosp, Div Pharm, I-83100 Avellino, Italy -Y2 - 2016-01-01 -ER - - -TY - JOUR -AU - Kashihara, Tairo -AU - Nakayama, Yuko -AU - Okuma, Kae -AU - Takahashi, Ayaka -AU - Kaneda, Tomoya -AU - Katagiri, Mika -AU - Nakayama, Hiroki -AU - Kubo, Yuko -AU - Ito, Kimiteru -AU - Nakamura, Satoshi -AU - Takahashi, Kana -AU - Inaba, Koji -AU - Murakami, Naoya -AU - Saito, Tetsuo -AU - Okamoto, Hiroyuki -AU - Itami, Jun -AU - Kusumoto, Masahiko -AU - Ohe, Yuichiro -AU - Igaki, Hiroshi -TI - Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer -T2 - RADIOTHERAPY AND ONCOLOGY -M3 - Article -AB - Introduction: Concurrent chemoradiotherapy (CCRT) has been the standard of care for patients with locally advanced non-small cell lung cancer (LA-NSCLC). Background and Purpose: The results of the PACIFIC trial established the use of consolidative durvalumab after concurrent chemoradiotherapy (CCRT) as the standard of care for patients with locally advanced non-small cell lung cancer (LA-NSCLC). A subgroup analysis of the PACIFIC trial reported a better progression-free survival (PFS) in Asians. Although real-world data on LA-NSCLC patients who received CCRT plus durvalumab have been reported, there have been few large-scale reports on Asians. In this study, we investigated prognostic factors in the largest real-world data set in Asia of only Japanese LA-NSCLC patients treated with CCRT plus durvalumab. Materials and Methods: One hundred and thirteen LA-NSCLC patients who received definitive CCRT and consolidative durvalumab at our institution between May 2018 and April 2021 were analyzed. Overall survival (OS), cause-specific survival (CSS), PFS, distant metastasis-free survival (DMFS), and in-field progression-free survival (IFPFS) were investigated as treatment outcomes using competing risk analyses. Results: During a median follow-up of 24 months (range, 5-47) after the initiation of durvalumab ther-apy, 31 patients died, of whom 23 died of lung cancer. In the multivariate analysis, the pretreatment fac-tors that correlated with OS were ILA scores, adenocarcinoma, and performance status at the initiation of durvalumab. Furthermore, ILA score and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) >= 1 % were significantly correlated with CSS, and PD-L1 TPS >= 1 % was significantly correlated with PFS and IFPFS. Conclusion: Pretreatment ILA, adenocarcinoma, and performance status may have an impact on OS of LA-NSCLC patients receiving CCRT plus durvalumab. (c) 2022 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology xxx (2023) xxx-xxx This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0167-8140 -SN - 1879-0887 -DA - 2023 MAR -PY - 2023 -VL - 180 -C7 - 109454 -DO - 10.1016/j.radonc.2022.109454 -AN - WOS:000934800200001 -C6 - JAN 2023 -AD - Natl Canc Ctr, Dept Radiat Oncol, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan -AD - Natl Canc Ctr, Dept Thorac Oncol, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan -AD - Natl Canc Ctr, Dept Radiol, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan -AD - Arao Municipal Hosp, Dept Radiat Oncol, 2600 Arao, Arao, Kumamoto 8640041, Japan -M2 - Arao Municipal Hosp -Y2 - 2023-03-12 -ER - - -TY - JOUR -AU - Meriggi, Fausto -TI - Second-Line Treatment Options for Small-Cell Lung Cancer: A Light at the End of the Tunnel -T2 - CANCERS -M3 - Article -AB - Simple Summary Small-cell lung cancer accounts for approximately 15% of all lung cancers and for about 30 years it has relied on the same chemo- and radiotherapeutic treatment strategies. Recently, there have been new promising and effective options introduced in the first-line treatment of the extensive stage of the disease, such as immunotherapy with atezolizumab or durvalumab added to standard chemotherapy, and moreover in heavily pretreated patients with new agents such as tarlatamab. This review aims to provide an overview of the current therapeutic strategies in the second-line treatment of small-cell lung cancer with the hope that we will finally begin to see a light at the end of the tunnel.Abstract Small-cell lung cancer (SCLC) is a subtype of lung tumor characterized by rapid growth and early metastatic dissemination. It represents approximately 15% of all diagnosed lung cancers, with an annual incidence of over 200,000 cases worldwide. At the time of initial diagnosis, approximately 75-80% of patients already have extrathoracic spread. Almost all patients with SCLC also relapse after achieving a complete response with first-line treatment. Outcomes achievable in second-line treatment are related to the length of time between completion of first-line therapy and disease progression. While first-line chemo-immunotherapy remains the standard of care for initial management, the role of second-line treatment strategies in SCLC has been a topic of significant research and discussion. Second-line treatment options are limited and the results are still disappointing. Several molecules are currently being studied in lines following the first, using immunological targets and cell cycle checkpoints. Among these, particular interest has been placed on anti-PD-1 (programmed cell death-1 protein) and anti-PD-L1 (programmed cell death-ligand 1) monoclonal antibodies, and DLL3 (Delta-like ligand 3), which are being evaluated alone or in combination. Tarlatamab is a novel promising therapeutic antibody currently under investigation for its potential use in previously treated SCLC patients. This mini-review will explore the current state of second-line treatment options for SCLC, their clinical efficacy, and future directions. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2024 JAN -PY - 2024 -VL - 16 -IS - 2 -C7 - 255 -DO - 10.3390/cancers16020255 -AN - WOS:001149179000001 -AD - Ist Osped Fdn Poliambulanza, Oncol Dept, Via Leonida Bissolati 57, I-25124 Brescia, Italy -M2 - Ist Osped Fdn Poliambulanza -Y2 - 2024-02-04 -ER - - -TY - JOUR -AU - Rossi, Antonio -AU - Sacco, Paola Claudia -AU - Sgambato, Assunta -AU - Casaluce, Francesca -AU - Santabarbara, Giuseppe -AU - Palazzolo, Giovanni -AU - Maione, Paolo -AU - Gridelli, Cesare -TI - Optimal drugs for second-line treatment of patients with small-cell lung cancer -T2 - EXPERT OPINION ON PHARMACOTHERAPY -M3 - Review -AB - Introduction: Despite the high response rate to chemotherapy, there have been few advances in the treatment of small-cell lung cancer (SCLC) in the last decades. The state-of-the-art second-line therapy and future research developments in relapsed SCLC are reviewed.Areas covered: There are no optimal drugs for second-line treatment of recurrent SCLC but only agents registered for this use. Topotecan remains the standard-of-care for the treatment of second-line platinum-sensitive SCLC patients worldwide, while amrubicin is another option, but registered only in Japan. To date, no targeted agents reporting interesting results in second-line SCLC treatment are available. The next-generation DNA sequencing should discover somatic gene alterations and their roles in SCLC to help in selecting patients who could benefit from a targeted agent. Two immunotherapeutics, ipilimumab and nivolumab, have shown promising preliminary results and are being investigated in ongoing trials.Expert opinion: Second-line treatment is not an option for most SCLC patients. Given the evidence up to now, the potentials for immuno-oncology in SCLC are high. The hope is that these expectations are met, and that all drugs being developed will offer new and improved treatment options for SCLC patients. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1465-6566 -SN - 1744-7666 -DA - 2016 -PY - 2016 -VL - 17 -IS - 7 -SP - 969 -EP - 976 -DO - 10.1517/14656566.2016.1154539 -AN - WOS:000374999200008 -AD - SG Moscati Hosp, Div Med Oncol, Contrada Amoretta 8, I-83100 Avellino, Italy -AD - Univ Naples 2, Dept Clin & Expt Med, Naples, Italy -AD - USLL5, Div Med Oncol, Cittadella, PD, Italy -M2 - USLL5 -Y2 - 2016-05-25 -ER - - -TY - JOUR -AU - Heinzerling, J. H., II -AU - Mileham, K. -AU - Robinson, M. -AU - Symanowski, J. T. -AU - Induru, R. -AU - Corso, C. D. -AU - Brouse, G. -AU - Prabhu, R. S. -AU - Haggstrom, D. -AU - Moeller, B. J. -AU - Bobo, W. E. -AU - Fasola, C. -AU - Thakkar, V. V. -AU - Gregory, J. -AU - Burri, S. H. -AU - Simone, C. B., II -TI - Prospective Phase II Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy (SBRT) Followed By Concurrent Mediastinal Chemoradiation and Adjuvant Immunotherapy for Locally-Advanced Non -Small Cell Lung Cancer (LA NSCLC) -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 145 -SP - S27 -EP - S28 -AN - WOS:001079706803053 -AD - Atrium Hlth, Levine Canc Inst, Wake Forest Sch Med, Charlotte, NC USA -AD - Southeast Radiat Oncol Grp, Charlotte, NC USA -AD - Atrium Hlth, Levine Canc Inst, Charlotte, NC USA -AD - New York Proton Ctr, New York, NY USA -M2 - Atrium Hlth -M2 - Southeast Radiat Oncol Grp -M2 - Atrium Hlth -M2 - New York Proton Ctr -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Rossi, Sabrina -AU - Pagliaro, Arianna -AU - Michelini, Angelica -AU - Navarria, Pierina -AU - Clerici, Elena -AU - Franceschini, Davide -AU - Toschi, Luca -AU - Finocchiaro, Giovanna -AU - Scorsetti, Marta -AU - Santoro, Armando -TI - The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light? -T2 - CANCERS -M3 - Review -AB - Simple Summary Small-cell lung cancer is the most aggressive form of lung neoplasia, treated in recent decades with chemotherapy alone. In the last few years, the advent of immunotherapy has changed the landscape in the treatment of non-small-cell lung cancer, and in small-cell lung cancer as well. However, the effectiveness of immunotherapy and the potential predictors of the response are still not completely established. This review aims to investigate the current knowledge in this field.Abstract Small-cell lung cancer is an extremely chemo-sensitive disease; the addition of immunotherapy to chemotherapy has demonstrated a slight clinical benefit in pivotal trials, even with a statistically significant difference in terms of survival outcomes when compared to chemotherapy alone. In this scenario, the role of radiotherapy as a consolidation treatment in thoracic disease or as a prophylactic therapy in the brain should be clarified. In addition, due to the frailty and the poor prognostic characteristics of these patients, the need for predictive biomarkers that could support the use of immunotherapy is crucial. PD-L1 and TMB are not actually considered definitive biomarkers due to the heterogeneity of results in the literature. A new molecular classification of small-cell lung cancer based on the expression of key transcription factors seems to clarify the disease behavior, but the knowledge of this molecular subtype is still insufficient and the application in clinical practice far from reality; this classification could lead to a better understanding of SCLC disease and could provide the right direction for more personalized treatment. The aim of this review is to investigate the current knowledge in this field, evaluating whether there are predictive biomarkers and clinical patient characteristics that could help us to identify those patients who are more likely to respond to immunotherapy. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2023 DEC -PY - 2023 -VL - 15 -IS - 24 -C7 - 5761 -DO - 10.3390/cancers15245761 -AN - WOS:001131404500001 -AD - IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Via Manzoni 56, I-20089 Milan, Italy -AD - Humanitas Univ, Dept Biomed Sci, Via R Levi Montalcini 4, I-20072 Milan, Italy -AD - IRCCS Humanitas Res Hosp, Dept Radiotherapy & Radiosurg, Via Manzoni 56, I-20089 Milan, Italy -M2 - IRCCS Humanitas Res Hosp -M2 - IRCCS Humanitas Res Hosp -Y2 - 2024-01-15 -ER - - -TY - JOUR -AU - Inarrairaegui, Mercedes -AU - Melero, Ignacio -AU - Sangro, Bruno -TI - Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes -T2 - CLINICAL CANCER RESEARCH -M3 - Review -AB - Treatment of patients with hepatocellular carcinoma (HCC) in the advanced stage remains a great challenge, with very few drugs approved. After decades of failure of immune therapies, immune checkpoint inhibitors have emerged as potentially effective treatments for patients with HCC in the advanced stage. Immune checkpoints, including human cancer, cytotoxic T-lymphocyte protein 4 (CTLA-4), and programmed cell death protein 1 (PD-1), are surface proteins expressed in a variety of immune cells and mostly provide immunosuppressive signals. Monoclonal antibodies able to block these molecules have shown antitumor activity against a wide spectrum of human cancers. Clinical experience with checkpoint inhibitors in HCC includes early trials with the anti-CTLA-4 agent tremelimumab and a large phase II trial with the anti-PD-1 agent nivolumab. The latter has shown strong activity particularly as second-line therapy, both in terms of tumor response and patient survival. At least three topics should be the focus of future research: (i) the search for activity in patients at less-advanced stages, including the adjuvant treatment of patients with resectable or ablatable tumors; (ii) the enhanced efficacy of combination therapies, including particularly the combination with those targeted and locoregional therapies that may have a synergistic effect or act upon mechanisms of primary or acquired resistance to checkpoint inhibitors; and (iii) the identification of clinical features and serumor tissue biomarkers that would allow a better patient selection for individual treatments. Hopefully, ongoing trials will help to design better treatments in the future. (C) 2017 AACR. -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 1078-0432 -SN - 1557-3265 -DA - 2018 APR 1 -PY - 2018 -VL - 24 -IS - 7 -SP - 1518 -EP - 1524 -DO - 10.1158/1078-0432.CCR-17-0289 -AN - WOS:000429050000003 -AD - Clin Univ Navarra, IDISNA, Liver Unit, Pamplona, Spain -AD - CIBEREHD, Pamplona, Spain -AD - Clin Univ Navarra, Dept Immunol & Immunotherapy, IDISNA, Pamplona, Spain -AD - CIBERONC, Pamplona, Spain -Y2 - 2018-04-16 -ER - - -TY - JOUR -AU - Kagawa, Yusuke -AU - Furuta, Hiromi -AU - Uemura, Takehiro -AU - Watanabe, Naohiro -AU - Shimizu, Junichi -AU - Horio, Yoshitsugu -AU - Kuroda, Hiroaki -AU - Inaba, Yoshitaka -AU - Kodaira, Takeshi -AU - Masago, Katsuhiro -AU - Fujita, Shiro -AU - Niimi, Akio -AU - Hida, Toyoaki -TI - Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer -T2 - CANCER SCIENCE -M3 - Article -AB - Immune checkpoint inhibitors (ICIs) have dramatically changed the strategy used to treat patients with non-small-cell lung cancer (NSCLC); however, the vast majority of patients eventually develop progressive disease (PD) and acquire resistance to ICIs. Some patients experience oligoprogressive disease. Few retrospective studies have evaluated clinical efficacy in patients with oligometastatic progression who received local therapy after ICI treatment. We conducted a retrospective analysis of advanced NSCLC patients who received PD-1 inhibitor monotherapy with nivolumab or pembrolizumab to evaluate the effects of ICIs on the patterns of progression and the efficacy of local therapy for oligoprogressive disease. Of the 307 patients treated with ICIs, 148 were evaluated in our study; 42 were treated with pembrolizumab, and 106 were treated with nivolumab. Thirty-eight patients showed oligoprogression. Male sex, a lack of driver mutations, and smoking history were significantly correlated with the risk of oligoprogression. Primary lesions were most frequently detected at oligoprogression sites (15 patients), and 6 patients experienced abdominal lymph node (LN) oligoprogression. Four patients showed evidence of new abdominal LN oligometastases. There was no significant difference in overall survival (OS) between the local therapy group and the switch therapy group (reached vs. not reached, P = .456). We summarized clinical data on the response of oligoprogressive NSCLC to ICI therapy. The results may help to elucidate the causes of ICI resistance and indicate that the use of local therapy as the initial treatment in this setting is feasible treatment option. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1347-9032 -SN - 1349-7006 -DA - 2020 DEC -PY - 2020 -VL - 111 -IS - 12 -SP - 4442 -EP - 4452 -DO - 10.1111/cas.14605 -AN - WOS:000582979000001 -C6 - OCT 2020 -AD - Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan -AD - Nagoya City Univ, Dept Resp Med Allergy & Clin Immunol, Grad Sch Med Sci, Nagoya, Aichi, Japan -AD - Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi, Japan -AD - Aichi Canc Ctr Hosp, Dept Diagnost & Intervent Radiol, Nagoya, Aichi, Japan -AD - Aichi Canc Ctr Hosp, Dept Radiat Oncol, Nagoya, Aichi, Japan -AD - Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan -M2 - Aichi Canc Ctr Hosp -Y2 - 2020-11-11 -ER - - -TY - JOUR -AU - Worden, FP -AU - Kalemkerian, GP -TI - Therapeutic advances in small cell lung cancer -T2 - EXPERT OPINION ON INVESTIGATIONAL DRUGS -M3 - Review -AB - Small cell lung cancer (SCLC) is characterised by neuroendocrine differentiation, early metastatic potential and initial responsiveness to cytotoxic therapy. Unfortunately, despite recent therapeutic advances, most patients relapse and the overall five-year survival rate is only 5%. Standard treatment of SCLC consists of platinum-based combination chemotherapy, with thoracic irradiation added for patients with limited-stage disease. Several newer chemotherapeutic drugs have recently been shown to have significant activity in patients with untreated or relapsed SCLC. These agents include: the topoisomerase I inhibitors, topotecan and irinotecan; the taxanes, paclitaxel and docetaxel; the pyrimidine analogue, gemcitabine; and the vinca alkaloid, vinorelbine. Recent advances in our understanding of the molecular events involved in the pathogenesis and progression of SCLC have led to the identification of a variety of potential targets for novel therapeutic intenrentions. Strategies aimed at inhibiting the myriad of growth factor pathways that. control the proliferation of SCLC cells, include: broad spectrum neuropeptide antagonists (e.g., substance P analogues); growth factor/receptor-specific inhibitors (e.g., anti-GRP monoclonal antibodies, bradykinin antagonist dimers); and a variety of selective protein kinase inhibitors. The importance of cell death pathways in carcinogenesis and treatment-resistance has led to several novel strategies targeting apoptotic mediators, such as bcl-2, that are frequently dysregulated in SCLC (e.g., bcl-2 antisense). Our current challenges are to further refine these promising therapeutic strategies, efficiently evaluate their activity in the clinical setting and integrate them into more effective treatment regimens to improve the overall prognosis of patients with SCLC. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1354-3784 -SN - 1744-7658 -DA - 2000 MAR -PY - 2000 -VL - 9 -IS - 3 -SP - 565 -EP - 579 -DO - 10.1517/13543784.9.3.565 -AN - WOS:000088780300011 -AD - Univ Michigan, Ctr Canc, Canc Ctr 1366, Ann Arbor, MI 48109 USA -Y2 - 2000-03-01 -ER - - -TY - JOUR -AU - Meng, Xiangjiao -AU - Liu, Yanli -AU - Zhang, Jianjun -AU - Teng, Feifei -AU - Xing, Ligang -AU - Yu, Jinming -TI - PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges -T2 - CANCER LETTERS -M3 - Review -AB - PD-1/PD-L1 checkpoint blockades have dramatically changed the landscape for second-line treatment of non-small cell lung cancer (NSCLC). Based on the promising results of Keynote-024 presented so far, pembrolizumab has been approved as first-line treatment for advanced PD-L1 positive NSCLC patients. However, overall response rate (ORR) is limited to PD-1/PD-L1 checkpoint blockades when used as single agent. Combining with chemotherapy, anti-CTLA-4 antibodies, targeted therapy, radiotherapy or other treatment options is perceived as an appealing method aimed at achieving higher efficacy. There are many clinical trials on going or finished assessing the efficacy and safety of the PD-1/PD-L1 blockades alone or combining with other approaches in first-line or second-line treatments. A lot of challenges need to be overcome before PD-1/PD-L1 checkpoint blockades are widely used in the patients with NSCLC including the identification of optimal combination, treatment-related adverse effects, the high cost and lack of effective predictive markers. In this review, we focus on outlining current clinical trials and challenges for future research of PD-1/PD-L1 pathway checkpoint blockades in NSCLC. (c) 2017 Elsevier B.V. All rights reserved. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0304-3835 -SN - 1872-7980 -DA - 2017 OCT 1 -PY - 2017 -VL - 405 -SP - 29 -EP - 37 -DO - 10.1016/j.canlet.2017.06.033 -AN - WOS:000412036200004 -AD - Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China -AD - Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Prov Key Lab Radiooncol, Jinan 250117, Shandong, Peoples R China -AD - Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Dept Chemotherapy, Jinan 250117, Shandong, Peoples R China -Y2 - 2017-10-20 -ER - - -TY - JOUR -AU - Karantanos, T. -AU - Karanika, S. -AU - Seth, B. -AU - Gignac, G. -TI - The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study -T2 - CLINICAL & TRANSLATIONAL ONCOLOGY -M3 - Article -AB - IntroductionThe neutrophil-to-lymphocyte (ANC/ALC) ratio is associated with worse prognosis in patients with NSCLC on immunotherapies, but the role of ALC remains unclear. The previous radiation therapy causes lymphopenia, and given approaches of combining radiation with immunotherapies, it is critical to better understand the impact of peripheral lymphocytes.Patients and methodsWe evaluated retrospectively 22 patients with advanced NSCLC treated with nivolumab at Boston Medical Center from January 2014 to September 2016 and correlated the peripheral blood counts with the overall survival (OS) and overall time on treatment. We assessed the effect of the previous radiation on peripheral blood counts and clinical outcomes.ResultsBaseline ALC and ANC/ALC ratios are positively and negatively correlated, respectively, with the OS on nivolumab. The ALC and ALC/WBC ratios at 6weeks on treatment are positively associated with the OS. Kaplan-Meier analysis at baseline and at 6weeks showed significantly increased OS in the group of patients with the highest ALC. The previous radiation therapy was positively correlated with the ANC and negatively correlated with the ALC/WBC ratio at 8weeks after the initiation of nivolumab.ConclusionOur finding that ALC at baseline and at 6weeks on treatment is positively correlated with the OS provides an easily obtained predictive marker. Our result that the previous radiation is associated with higher ANC and lower ALC during treatment supports that the combination of radiation therapy with immunotherapy should be carefully applied and potentially peripheral blood counts can be utilized to stratify patients for this approach. -PU - SPRINGER INTERNATIONAL PUBLISHING AG -PI - CHAM -PA - GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND -SN - 1699-048X -SN - 1699-3055 -DA - 2019 FEB -PY - 2019 -VL - 21 -IS - 2 -SP - 206 -EP - 212 -DO - 10.1007/s12094-018-1908-2 -AN - WOS:000457562500010 -AD - Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Dept Med Oncol, 401 North Broadway Ave, Baltimore, MD 21287 USA -AD - Boston Univ, Sch Med, Boston Med Ctr, Gen Internal Med Dept, 850 Harrison Ave, Boston, MA 02118 USA -AD - Boston Univ, Sch Med, Boston Med Ctr, Hematol Oncol,Dept Internal Med, 820 Harrison Ave,FGH Bldg,1st Floor, Boston, MA 02118 USA -Y2 - 2019-02-15 -ER - - -TY - JOUR -AU - Furqan, Muhammad -AU - Abu-Hejleh, Taher -AU - Stephens, Laura M. -AU - Hartwig, Stacey M. -AU - Mott, Sarah L. -AU - Pulliam, Casey F. -AU - Petronek, Michael -AU - Henrich, John B. -AU - Fath, Melissa A. -AU - Houtman, Jon C. -AU - Varga, Steven M. -AU - Bodeker, Kellie L. -AU - Bossler, Aaron D. -AU - Bellizzi, Andrew M. -AU - Zhang, Jun -AU - Monga, Varun -AU - Mani, Hariharasudan -AU - Ivanovic, Marina -AU - Smith, Brian J. -AU - Byrne, Margaret M. -AU - Zeitler, William -AU - Wagner, Brett A. -AU - Buettner, Garry R. -AU - Cullen, Joseph J. -AU - Buatti, John M. -AU - Spitz, Douglas R. -AU - Allen, Bryan G. -TI - Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer -T2 - REDOX BIOLOGY -M3 - Article -AB - Purpose: Platinum-based chemotherapy with or without immunotherapy is the mainstay of treatment for advanced stage non-small cell lung cancer (NSCLC) lacking a molecular driver alteration. Pre-clinical studies have reported that pharmacological ascorbate (P-AscH-) enhances NSCLC response to platinum-based therapy. We conducted a phase II clinical trial combining P-AscH-with carboplatin-paclitaxel chemotherapy. Experimental design: Chemotherapy naive advanced stage NSCLC patients received 75 g ascorbate twice per week intravenously with carboplatin and paclitaxel every three weeks for four cycles. The primary endpoint was to improve tumor response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 compared to the historical control of 20%. The trial was conducted as an optimal Simon's two-stage design. Blood samples were collected for exploratory analyses. Results: The study enrolled 38 patients and met its primary endpoint with an objective response rate of 34.2% (p = 0.03). All were confirmed partial responses (cPR). The disease control rate was 84.2% (stable disease + cPR). Median progression-free and overall survival were 5.7 months and 12.8 months, respectively. Treatment-related adverse events (TRAE) included one grade 5 (neutropenic fever) and five grade 4 events (cytopenias). Cytokine and chemokine data suggest that the combination elicits an immune response. Immunophenotyping of peripheral blood mononuclear cells demonstrated an increase in effector CD8 T-cells in patients with a progression-free survival (PFS) >= 6 months. Conclusions: The addition of P-AscH-to platinum-based chemotherapy improved tumor response in advanced stage NSCLC. P-AscH-appears to alter the host immune response and needs further investigation as a potential adjuvant to immunotherapy. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 2213-2317 -DA - 2022 JUL -PY - 2022 -VL - 53 -C7 - 102318 -DO - 10.1016/j.redox.2022.102318 -AN - WOS:000805648100003 -C6 - MAY 2022 -AD - Univ Iowa, Dept Internal Med, 200 Hawkins Dr, Iowa City, IA 52242 USA -AD - Univ Iowa, Holden Comprehens Canc Ctr, 200 Hawkins Dr, Iowa City, IA 52242 USA -AD - Univ Iowa, Interdisciplinary Grad Program Immunol, 200 Hawkins Dr, Iowa City, IA 52242 USA -AD - Univ Iowa, Dept Microbiol & Immunol, 51 Newton Rd, Iowa City, IA 52242 USA -AD - Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, 200 Hawkins Dr, Iowa City, IA 52242 USA -AD - Univ Iowa, Dept Pathol, 200 Hawkins Dr, Iowa City, IA 52242 USA -AD - Univ Iowa, Coll Publ Hlth, Dept Biostat, 145 N Riverside Dr, Iowa City, IA 52242 USA -AD - Univ Iowa, Dept Internal Med, 200 Hawkins Dr,C21-K GH, Iowa City, IA 52242 USA -Y2 - 2022-06-16 -ER - - -TY - JOUR -AU - Rossi, Giovanni -AU - Bauckneht, Matteo -AU - Genova, Carlo -AU - Rijavec, Erika -AU - Biello, Federica -AU - Mennella, Simone -AU - Bello, Maria Giovanna Dal -AU - Cittadini, Giuseppe -AU - Bruzzi, Paolo -AU - Piva, Roberta -AU - Ceriani, Valentina -AU - Sambuceti, Gianmario -AU - Lopci, Egesta -AU - Morbelli, Silvia -AU - Grossi, Francesco -TI - Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab -T2 - JOURNAL OF NUCLEAR MEDICINE -M3 - Article -AB - Because of the peculiar mechanism of action of immune checkpoint inhibitors (ICIs), evaluation of the radiologic response to them in solid tumors presents many challenges. We aimed to compare evaluation of the first response to nivolumab by means of CT-based criteria with respect to F-18-FDG PET response criteria in non-small cell lung cancer (NSCLC) patients. Methods: Seventy-two patients with advanced NSCLC were recruited in a single-institution ancillary trial within the expanded-access program (NCT02475382) for nivolumab. Patients underwent CT and F-18-FDG PET at baseline and after 4 cycles (the first evaluation). In cases of progressive disease, an additional evaluation was performed after 2 further cycles to confirm progression. We evaluated the treatment response on CT using RECIST 1.1 and the immune-related response criteria (irRC) and on F-18-FDG PET using PERCIST and immunotherapy-modified PERCIST. The concordance between CT- and PET-based criteria and the capability of each method to predict overall survival were evaluated. Results: Forty-eight of 72 patients were evaluable for a first response assessment with both PET- and CT-based criteria. We observed low concordance between CT- and PET-based criteria (K-value of 0.346 and 0.355 between PERCIST and imPERCIST and RECIST, respectively. K-value of 0.128 and 0.198 between PERCIST and imPERCIST and irRC, respectively). Regarding overall survival, irRC could more reliably distinguish responders from nonresponders. However, thanks to the prognostic value of partial metabolic response assessed by both PERCIST and immunotherapy-modified PERCIST, PET-based response maintained prognostic significance in patients classified as having progressive disease on the basis of irRC. Conclusion: Even though the present study did not support the routine use of F-18-FDG PET in the general population of NSCLC patients treated with ICIs, the findings suggest that metabolic response assessment has added prognostic value, potentially improving therapeutic decision making. -PU - SOC NUCLEAR MEDICINE INC -PI - RESTON -PA - 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA -SN - 0161-5505 -SN - 1535-5667 -DA - 2020 JUL 1 -PY - 2020 -VL - 61 -IS - 7 -SP - 990 -EP - 998 -DO - 10.2967/jnumed.119.233056 -AN - WOS:000548809100010 -AD - IRCCS Policlin San Martino, Lung Canc Unit, Genoa, Italy -AD - Univ Sassari, Div Expt Pathol & Oncol, Dept Clin Surg & Expt Sci, Sassari, Italy -AD - IRCCS Policlin San Martino, Nucl Med Unit, Genoa, Italy -AD - Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy -AD - IRCCS Policlin San Martino, Radiol Unit, Genoa, Italy -AD - IRCCS Policlin San Martino, Epidemiol Unit, Genoa, Italy -AD - Univ Genoa, Dept Hlth Sci DISSAL, Genoa, Italy -AD - Humanitas Clin & Res Ctr IRCCS, Nucl Med Unit, Rozzano, Italy -M2 - IRCCS Policlin San Martino -M2 - IRCCS Policlin San Martino -M2 - IRCCS Policlin San Martino -M2 - IRCCS Policlin San Martino -M2 - Humanitas Clin & Res Ctr IRCCS -Y2 - 2020-07-28 -ER - - -TY - JOUR -AU - Sabari, Joshua K. -AU - Lok, Benjamin H. -AU - Laird, James H. -AU - Poirier, John T. -AU - Rudin, Charles M. -TI - Unravelling the biology of SCLC: implications for therapy -T2 - NATURE REVIEWS CLINICAL ONCOLOGY -M3 - Review -AB - Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor prognosis. First-line treatment has remained unchanged for decades, and a paucity of effective treatment options exists for recurrent disease. Nonetheless, advances in our understanding of SCLC biology have led to the development of novel experimental therapies. Poly [ ADP-ribose] polymerase (PARP) inhibitors have shown promise in preclinical models, and are under clinical investigation in combination with cytotoxic therapies and inhibitors of cell-cycle checkpoints. Preclinical data indicate that targeting of histone-lysine N-methyltransferase EZH2, a regulator of chromatin remodelling implicated in acquired therapeutic resistance, might augment and prolong chemotherapy responses. High expression of the inhibitory Notch ligand Delta-like protein 3 (DLL3) in most SCLCs has been linked to expression of Achaete-scute homologue 1 (ASCL1; also known as ASH-1), a key transcription factor driving SCLC oncogenesis; encouraging preclinical and clinical activity has been demonstrated for an anti-DLL3-antibody-drug conjugate. The immune microenvironment of SCLC seems to be distinct from that of other solid tumours, with few tumour-infiltrating lymphocytes and low levels of the immune-checkpoint protein programmed cell death 1 ligand 1 (PD-L1). Nonetheless, immunotherapy with immune-checkpoint inhibitors holds promise for patients with this disease, independent of PD-L1 status. Herein, we review the progress made in uncovering aspects of the biology of SCLC and its microenvironment that are defining new therapeutic strategies and offering renewed hope for patients. -PU - NATURE PORTFOLIO -PI - BERLIN -PA - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY -SN - 1759-4774 -SN - 1759-4782 -DA - 2017 SEP -PY - 2017 -VL - 14 -IS - 9 -SP - 549 -EP - 561 -DO - 10.1038/nrclinonc.2017.71 -AN - WOS:000408137100013 -AD - Mem Sloan Kettering Canc Ctr, Dept Med, 300 East 66th St, New York, NY 10065 USA -AD - Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 300 East 66th St, New York, NY 10065 USA -AD - NYU, Sch Med, 550 1st Ave, New York, NY 10016 USA -AD - Mem Sloan Kettering Canc Ctr, Mol Pharmacol Program, 1300 York Ave, New York, NY 10065 USA -AD - Weill Cornell Med Coll, 1300 York Ave, New York, NY 10065 USA -Y2 - 2017-09-01 -ER - - -TY - JOUR -AU - Faehling, Martin -AU - Schumann, Christian -AU - Christopoulos, Petros -AU - Hoffknecht, Petra -AU - Alt, Jurgen -AU - Horn, Marlitt -AU - Eisenmann, Stephan -AU - Schlenska-Lange, Anke -AU - Schutt, Philipp -AU - Steger, Felix -AU - Bruckl, Wolfgang M. -AU - Christoph, Daniel C. -TI - Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP -T2 - DATA IN BRIEF -M3 - Article -M3 - Data Paper -AB - Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy and safety.211 patients were registered by 90 German centres. Data were collected retrospectively by questionnaire and queries. 56 centres reported data on 126 patients who actually received at least one cycle of durvalumab. In contrast to the PACIFIC-trial population, some patients with oligometastatic disease and a history of autoimmune disease are included in the EAP population. Information on PD-L1 status was obtained for 111 patients. Baseline data include age, gender, ECOG, stage (IASLC 8th ed.), and smoking history. Treatment data include mode of chemoradiotherapy, used chemotherapy agent, and duration of durvalumab therapy. Adverse evants were documented according to CTAEC 5.0. Data were analysed for progression-free survival (PFS), overall survival (OS), and adverse events (AE). The results were published in Lung Cancer [1]. (C) 2020 The Author(s). Published by Elsevier Inc. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 2352-3409 -DA - 2021 FEB -PY - 2021 -VL - 34 -C7 - 106556 -DO - 10.1016/j.dib.2020.106556 -AN - WOS:000617525400001 -AD - Klinikum Esslingen, Klin Kardiol & Pneumol, D-73730 Esslingen, Germany -AD - Klinikum Kempten, Klin Pneumol Thoraxonkol Schlaf & Beatmungsmed, D-87439 Kempten, Germany -AD - Thoraxklinik Heidelberg, D-69126 Heidelberg, Germany -AD - Franziskus Hosp Harderberg, Klin Thoraxonkol & Palliativstat, D-49124 Georgsmarienhutte, Germany -AD - Johannes Gutenberg Univ Mainz, Med Klin & Poliklin 3, D-55131 Mainz, Germany -AD - LungenClin Grosshansdorf, Grosshansdorf, Germany -AD - Univ Klinikum Halle Saale, Univ Klin & Poliklin Innere Med Gastroenterol & P, D-06120 Halle, Germany -AD - Krankenhaus Barmherzige Bruder Regensburg, Klin Onkol & Hamatol, D-93049 Regensburg, Germany -AD - Onkolog Gemeinschaftspraxis, Gutersloh, Germany -AD - Univ Klinikum Regensburg, Klin & Poliklin Strahlentherapie, D-93053 Regensburg, Germany -AD - Klinikum Nurnberg Nord, Klin Innere Med 3, D-90419 Nurnberg, Germany -AD - Evang Kliniken Essen Mitte, Klin Internist Onkol & Hamatol Integrierter Palli, D-45136 Essen, Germany -M2 - Klinikum Esslingen -M2 - Klinikum Kempten -M2 - Thoraxklinik Heidelberg -M2 - Franziskus Hosp Harderberg -M2 - Krankenhaus Barmherzige Bruder Regensburg -M2 - Onkolog Gemeinschaftspraxis -M2 - Evang Kliniken Essen Mitte -Y2 - 2021-03-08 -ER - - -TY - JOUR -AU - Wu, Jia-Jun -AU - Huang, Jing-Wen -AU - Hsu, Kuo-Hsuan -AU - Huang, Yen-Hsiang -AU - Chen, Kun-Chieh -AU - Tseng, Jeng-Sen -AU - Yang, Tsung-Ying -AU - Chang, Gee-Chen -TI - Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy -T2 - ANTI-CANCER DRUGS -M3 - Article -AB - Objective Immunotherapy plus etoposide and platinum (EP)-based chemotherapy is the standard of care for patients with extensive stage-small cell lung carcinoma (ES-SCLC). In the era of immunotherapy, the role of thoracic radiotherapy for ES-SCLC remains unclear. Methods We retrospectively included ES-SCLC patients treated with first-line EP-based chemotherapy plus atezolizumab or durvalumab at Taichung Veterans General Hospital to evaluate the prognostic role and safety of thoracic radiotherapy. Results A total of 22 patients were included. The median age was 64 years and most of them were male and smokers. Sixteen patients (72.7%) received durvalumab, while the other 6 patients (27.3%) underwent atezolizumab treatment. Among these patients, 11 (50.0%) had a history of thoracic radiotherapy. There was no significant difference in baseline characteristics between patients with and without thoracic radiotherapy. In the overall population, the objective response rate to immunotherapy plus chemotherapy was 73.7%. The progression-free survival and overall survival were 6.0 months (95% CI: 4.0-7.9) and 13.8 months (95% CI: 8.0-19.6), respectively. The overall survival was significantly longer in patients with thoracic radiotherapy (not-reached [NR] [95% CI NR-NR] vs. 9.6 months [95% CI 2.5-16.6]), respectively (P value by log-rank test <0.001). Both multivariate analysis and subgroup analysis specifically comparing patients with consolidative thoracic radiotherapy and patients with clinical benefits to systemic therapy who did not undergo thoracic radiotherapy indicated that thoracic radiotherapy improved survival. Conclusion The real-world efficacy of EP-based chemotherapy plus atezolizumab or durvalumab was comparable with that of clinical trials. Thoracic radiotherapy may improve the outcome of ES-SCLC. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0959-4973 -SN - 1473-5741 -DA - 2022 NOV -PY - 2022 -VL - 33 -IS - 10 -SP - E842 -EP - E849 -DO - 10.1097/CAD.0000000000001374 -AN - WOS:000869257200001 -AD - Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, 1650,Sect 4,Taiwan Blvd, Taichung 407, Taiwan -AD - Taipei Vet Gen Hosp, Taoyuan Branch, Taoyuan, Taiwan -AD - Natl Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan -AD - Taichung Vet Gen Hosp, Dept Radiat Oncol, Taichung, Taiwan -AD - Taichung Vet Gen Hosp, Dept Internal Med, Div Crit Care & Resp Therapy, Taichung, Taiwan -AD - Natl Yang Ming Chiao Tung Univ, Coll Med, Taipei, Taiwan -AD - Chung Shan Med Univ Hosp, Dept Internal Med, Div Pulm Med, Taichung, Taiwan -AD - Chung Shan Med Univ, Sch Med, Taichung, Taiwan -AD - Chung Shan Med Univ, Inst Med, Taichung, Taiwan -AD - Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung, Taiwan -AD - Natl Chung Hsing Univ, Dept Life Sci, Taichung, Taiwan -Y2 - 2022-10-29 -ER - - -TY - JOUR -AU - Korytowsky, Beata -AU - Radtchenko, Janna -AU - Nwokeji, Esmond D. -AU - Tuell, Kenneth W. -AU - Kish, Jonathan K. -AU - Feinberg, Bruce A. -TI - Understanding Total Cost of Care in Advanced Non-Small Cell Lung Cancer Pre- and Postapproval of Immuno-Oncology Therapies -T2 - AMERICAN JOURNAL OF MANAGED CARE -M3 - Article -AB - This study assesses resource utilization and total direct medical cost among patients in the United States starting systemic antineoplastic therapy (ST) pre- and postapproval of immuno-oncology (IO) agents for advanced non-small cell lung cancer. Adults diagnosed with lung cancer initiating first-line ST within 6 months of diagnosis during either the pre-(March 2013-March 2014) or post-IO (March 2015-December 2016) approval period were identified in a US-based multipayer administrative claims database. Excluded were patients with small cell lung cancer, secondary malignancies, less than 1 month follow-up, and those in clinical trials. Total cost (TC) was calculated from the date of initiation of treatment until the last follow-up. Propensity score matching was adjusted for differences in patient cohorts, including follow-up time. Binary multiple logistic regression assessed predictors of high TC (above mean) pre- and post IO. Mean TC per patient was higher pre-IO versus post IO in both unmatched ($165,548 vs $95,715) and matched analyses ($129,977 vs $113,177). Hospitalization and emergency department (ED) visit rates were higher pre-IO versus postapproval. Predictors of high TC pre-IO included use of first-line combination therapy, radiation, targeted therapy, maintenance therapy, biomarker testing, more comorbidities, longer follow-up, first-line hospitalization, first-line cost above mean, and age 65 years and older. In the post-IO period, additional predictors of higher TC included use of IO, having mild liver disease or hemiplegia, and longer time to ST initiation. Early data show lower ED visit and hospitalization rates and associated lower TC in the post-IO era. -PU - MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC -PI - PLAINSBORO -PA - 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA -SN - 1088-0224 -DA - 2018 OCT -PY - 2018 -VL - 24 -IS - 20 -SP - S439 -EP - S447 -AN - WOS:000454862300001 -AD - Bristol Myers Squibb, Lawrenceville, NJ 08648 USA -AD - Cardinal Hlth Specialty Solut, Dublin, OH USA -M2 - Cardinal Hlth Specialty Solut -Y2 - 2019-01-22 -ER - - -TY - JOUR -AU - Kalemkerian, Gregory P. -TI - Small Cell Lung Cancer -T2 - SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE -M3 - Review -AB - Small cell lung cancer (SCLC) is a high-grade neuroendocrine tumor characterized by rapid growth, early metastatic spread, and initial responsiveness to therapy. Although the incidence of SCLC is declining, it remains one of the common causes of cancer related mortality. Initial evaluation of patients with SCLC should focus on determining the extent of disease and the ability of the patient to tolerate specific therapy. Positron emission tomography (PET) can improve the accuracy of staging and treatment planning in many patients. Limited-stage (LS) SCLC is a potentially curable disease with long-term survival of 20 to 25% when treated with platinum-based chemotherapy plus concurrent thoracic radiation. Hyperfractionated (twice daily) thoracic radiation and prophylactic cranial irradiation (PCI) may improve survival in selected patients with LS-SCLC. For patients with extensive-stage (ES) SCLC, combination chemotherapy prolongs survival and improves quality of life, but long-term survival is rare. The use of PCI and sequential thoracic radiation has been reported to improve survival in selected patients with ES-SCLC. Many chemotherapeutic drugs have activity in SCLC, but little progress has been made in the systemic treatment of SCLC in almost three decades. Although many potential molecular targets have been identified in the preclinical studies of SCLC, molecularly targeted therapy has yet to demonstrate consistent clinical activity. Nevertheless, future advances in SCLC will depend on the development of rational therapeutic strategies which target the molecular mechanisms that drive cellular proliferation, survival, and immunological avoidance. -PU - THIEME MEDICAL PUBL INC -PI - NEW YORK -PA - 333 SEVENTH AVE, NEW YORK, NY 10001 USA -SN - 1069-3424 -SN - 1098-9048 -DA - 2016 OCT -PY - 2016 -VL - 37 -IS - 5 -SP - 783 -EP - 795 -DO - 10.1055/s-0036-1592116 -AN - WOS:000384033200014 -AD - Univ Michigan, Div Hematol Oncol, C350 Med Inn,SPC 5848,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA -Y2 - 2016-10-19 -ER - - -TY - JOUR -AU - Tsang, KW -AU - Lam, CL -AU - Yan, C -AU - Mak, JC -AU - Ooi, GC -AU - Ho, JC -AU - Lam, B -AU - Man, R -AU - Sham, JS -AU - Lam, WK -TI - Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer -T2 - RESPIRATORY MEDICINE -M3 - Article -AB - Background: Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths, and over 60% of patients present with advanced stages. Although polysaccharide peptides (PSP), isolated from the fungus Coriolus versicolor, have been reported to have anti-tumor effects, its clinical efficacy has not been properly evaluated. Methods: Double-blind placelbo-controlled randomized study to evaluate the effects of 28-day administration of PSP (Windsor Pharmaceutical, Hong Kong) on patients, who had completed conventional treatment for advanced NSCLC. Results: Thirty-four patients, with no significant difference in their baseline demographic, clinical or tumor characteristics, or previous treatment regimes (P>0.05), were recruited into each of the PSP and control arms. After 28-day treatment, there was a significant improvement in blood leukocyte and neutrophil counts, serum IgG and IgM, and percent of body fat among the PSP, but not the control, patients (P<0.05). Although the evaluable PSP patients did not improve in NSCLC-reated symptoms, there were significantly less PSP patients withdrawn due to disease progression, than their control counterparts (5.9 and 23.5%, respectively; P=0.04; OR 4.00). There was no reported adverse reaction attributable to the trial medications. Conclusion: PSP treatment appears to be associated with slower deterioration in patients with advanced NSCLC. (C) 2003 Elsevier Science Ltd. All rights reserved. -PU - W B SAUNDERS CO LTD -PI - LONDON -PA - 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND -SN - 0954-6111 -SN - 1532-3064 -DA - 2003 JUN -PY - 2003 -VL - 97 -IS - 6 -SP - 618 -EP - 624 -DO - 10.1053/rmed.2003.1490 -AN - WOS:000183387800005 -AD - Univ Hong Kong, Queen Mary Hosp, Div Resp & Crit Care Med, Dept Med, Pokfulam, Hong Kong, Peoples R China -AD - Univ Hong Kong, Queen Mary Hosp, Dept Diagnost Radiol, Pokfulam, Hong Kong, Peoples R China -AD - Univ Hong Kong, Queen Mary Hosp, Sch Chinese Med, Pokfulam, Hong Kong, Peoples R China -Y2 - 2003-06-01 -ER - - -TY - JOUR -AU - Cho, Yeona -AU - Park, Sangjoon -AU - Byun, Hwa Kyung -AU - Lee, Chang Geol -AU - Cho, Jaeho -AU - Hong, Min Hee -AU - Kim, Hye Ryun -AU - Cho, Byoung Chul -AU - Kim, Sinae -AU - Park, Juyoung -AU - Yoon, Hong In -TI - Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Article -AB - Purpose: The interest in combining radiation therapy (RT) with immunotherapy is increasing. We investigated the significance of lymphopenia in patients receiving immunotherapy for non-small cell lung cancer (NSCLC), and the factors associated with treatment-related lymphopenia, with particular emphasis on RT.Methods and Methods: In this retrospective single institution study, 268 patients with advanced NSCLC received immunotherapy, of whom 146 received RT. Lymphopenia was defined as an absolute lymphocyte count <1000cells/mm.(3) Patients were divided into 2 groups depending on the presence of peri-immunotherapy lymphopenia at the start of immunotherapy or during immunotherapy.Results: At median 6.4 months of follow-up, patients with peri-immunotherapy lymphopenia (n = 146; 54.5%) showed significantly poorer progression-free survival (PFS) (median PFS: 2.2 vs 5.9 months, P<.001) and overall survival (OS) (median OS: 5.7 vs 12.1 months, P<.001). On multivariate analysis, peri-immunotherapy lymphopenia remained a significant prognostic factor for both PFS and OS. RT significantly increased peri-immunotherapy lymphopenia with an odds ratio (OR) of 1.91 (P = .025). Factors associated with the development of RT-associated lymphopenia included multiple courses (OR, 3.78; P<.001), multiple irradiated sites (OR, 4.77; P = .018), and higher dose (>= 50Gy) (OR, 3.75; P = .004). Conversely, stereotactic body RT/radiosurgery reduced the risk (OR 0.21; P = .002).Conclusions: Lymphopenia was indicative of poor prognosis in NSCLC patients receiving immunotherapy and was significantly associated with more intensive RT. Choosing appropriate RT regimens and techniques may be essential in reducing lymphopenia. Promising results are expected in the era of precision RT. (C) 2019 Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2019 DEC 1 -PY - 2019 -VL - 105 -IS - 5 -SP - 1065 -EP - 1073 -DO - 10.1016/j.ijrobp.2019.08.047 -AN - WOS:000496929900021 -AD - Yonsei Univ Hlth Syst, Yonsei Univ, Coll Med, Dept Radiat Oncol, Seoul, South Korea -AD - Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon, South Korea -AD - Yonsei Univ, Yonsei Canc Ctr, Coll Med, Dept Med Oncol, Seoul, South Korea -AD - Yonsei Univ, Coll Med, Biostat Collaborat Unit, Seoul, South Korea -Y2 - 2019-11-29 -ER - - -TY - JOUR -AU - Wang, L. -AU - Zou, B. -AU - Huang, W. -AU - Shao, Q. -AU - Meng, X. -AU - Tang, X. -AU - Zhang, P. -AU - Hu, X. -AU - Zhang, Y. -AU - Guo, J. -AU - Fu, L. -AU - Zhao, W. -AU - Zhao, C. -AU - Yuan, J. -AU - Yu, J. -AU - Chen, D. -TI - Safety and Efficacy Analysis of Patients with ExtensiveStage Small Cell Lung Cancer (ES-SCLC) Treated with SHR-1316 Plus Chemotherapy and Sequential Chest Radiotherapy as First-Line Therapy from a Phase II Trial -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 212 -SP - S58 -EP - S59 -AN - WOS:001079706803114 -AD - Shandong Univ, Shandong Canc Hosp, Jinan, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China -AD - Shandong Canc Hosp & Inst, Jinan, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Med Oncol, Jinan 250117, Shandong, Peoples R China -AD - Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China -AD - Shandong Univ, Shandong Canc Hosp, Jinan, Shandong, Peoples R China -M2 - Jiangsu Hengrui Pharmaceut Co Ltd -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Crino, Lucio -AU - Bronte, Giuseppe -AU - Bidoli, Paolo -AU - Cravero, Paola -AU - Minenza, Elisa -AU - Cortesi, Enrico -AU - Garassino, Marina C. -AU - Proto, Claudia -AU - Cappuzzo, Federico -AU - Grossi, Francesco -AU - Tonini, Giuseppe -AU - Sarobba, Maria Giuseppina -AU - Pinotti, Graziella -AU - Numico, Gianmauro -AU - Samaritani, Riccardo -AU - Ciuffreda, Libero -AU - Frassoldati, Antonio -AU - Bregni, Marco -AU - Santo, Antonio -AU - Piantedosi, Francovito -AU - Illiano, Alfonso -AU - De Marinis, Filippo -AU - Tamberi, Stefano -AU - Giannarelli, Diana -AU - Delmonte, Angelo -TI - Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer -T2 - LUNG CANCER -M3 - Article -AB - Objectives: Brain metastases are common among patients with non-squamous non-small-cell lung cancer (NSCLC) and result in a poor prognosis. Consequently, such patients are often excluded from clinical trials. In Italy an expanded access program (EAP) was used to evaluate nivolumab efficacy and safety in this sub population outside a clinical trial.Materials and methods: In this EAP, nivolumab was available for patients with non-squamous NSCLC in progression after at least one systemic treatment for stage IIIB/IV disease. Nivolumab 3 mg/kg was administered intravenously every 2 weeks. Patients with brain metastases could be included if they were asymptomatic, neurologically stable and either off corticosteroids or on a stable or decreasing dose of <= 10 mg/day prednisone.Results: 409 out of 1588 patients included had asymptomatic or controlled brain metastases. A median of 7 doses (range 1-45) were delivered. Median follow-up was 6.1 months (range 0.1-21.9). The disease control rate was 39%: 4 patients had a complete response, 64 a partial response and 96 showed stable disease. At baseline, 118 patients were on corticosteroids and 74 were undergoing concomitant radiotherapy. The median overall survival in this subpopulation was 8.6 months (95% CI: 6.4-10.8). 337 discontinued treatment for various reasons, 23 (7%) of whom due to adverse events, in line with that observed in the overall population and in previous studies.Conclusions: Our results confirm that nivolumab is active in non-squamous NSCLC patients with brain metastases, despite their poor prognosis. Its safety profile is also concordant with results in the EAP overall population and in patients with other malignancies. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2019 MAR -PY - 2019 -VL - 129 -SP - 35 -EP - 40 -DO - 10.1016/j.lungcan.2018.12.025 -AN - WOS:000461405800006 -AD - Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy -AD - Osped San Gerardo, Monza, Italy -AD - AO Santa Maria, Terni, Italy -AD - Policlin Umberto 1, Rome, Italy -AD - Fdn IRCCS Ist Nazl Tumori, Milan, Italy -AD - AUSL Romagna, Ravenna, Italy -AD - IRCCS AOU San Martino IST, Genoa, Italy -AD - Policlin Univ Campus Biomed, Rome, Italy -AD - ASL 3 S Francesco, Nuoro, Italy -AD - Osped Circolo & Fdn Macchi, Varese, Italy -AD - AO SS Antonio & Biagio & C Arrigo, Alessandria, Italy -AD - Presidio Nuovo Regina Margherita, Rome, Italy -AD - AOU Citta Salute & Sci Torino, Turin, Italy -AD - Arcispedale S Anna Ferrara, Ferrara, Italy -AD - Presidio Osped Busto Arsizio, Varese, Italy -AD - AO Univ Integrata Verona, Verona, Italy -AD - AO Colli, Monaldi Cotugno CTO, Naples, Italy -AD - European Inst Oncol, Milan, Italy -AD - Infermi Hosp, Faenza, Italy -AD - Regina Elena Natl Canc Inst IRCCS, Rome, Italy -M2 - AO Santa Maria -M2 - ASL 3 S Francesco -M2 - Presidio Nuovo Regina Margherita -M2 - AO Colli -M2 - Regina Elena Natl Canc Inst IRCCS -Y2 - 2019-03-28 -ER - - -TY - JOUR -AU - Shirasawa, Masayuki -AU - Yoshida, Tatsuya -AU - Imabayashi, Tatsuya -AU - Okuma, Kae -AU - Matsumoto, Yuji -AU - Masuda, Ken -AU - Shinno, Yuki -AU - Okuma, Yusuke -AU - Goto, Yasushi -AU - Horinouchi, Hidehito -AU - Tsuchida, Takaaki -AU - Yamamoto, Noboru -AU - Nakayama, Yuko -AU - Watanabe, Shun-ichi -AU - Motoi, Noriko -AU - Ohe, Yuichiro -TI - Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer -T2 - EUROPEAN JOURNAL OF CANCER -M3 - Article -AB - Background: Chemoradiotherapy (CRT) followed by durvalumab treatment improved prognosis in unresectable locally advanced non-small-cell lung cancer (LANSCLC). This study aimed to evaluate whether the status of the immune-related tumour microenvironment (TME) at baseline associates with the efficacy.Methods: This retrospective study evaluated immune-related TME factors, including programmed cell death ligand 1 (PD-L1) (clone: 22C3) expression on tumour cells and the density of CD8-positive tumour-infiltrating lymphocytes (TILs) at pre-CRT in patients with unresectable LA-NSCLC treated with CRT only (CRT alone group) and those treated with CRT followed by durvalumab (Durva group).Results: A total of 551 patients were included (N = 113 in the Durva group). Progression-free survival (PFS) in the Durva group was significantly greater than that in the CRT alone group (not reached [NR] vs 12.9 months; p = 0.002). In the CRT alone group, neither PD-L1 expres-sion nor TIL status affected PFS; in contrast, in the Durva group, high density of CD8-positive TILs (TILHigh >100/mm2) and PD-L1-positive expression (tumour proportion score >1%; PD-L1+) was significantly associated with longer PFS (TIL: NR vs 9.5 months; p = 0.002; and PD-L1: NR vs 7.7 months; p = 0.003). On the other hand, in patients with epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, there was no significant difference in PFS between the groups (Durva vs CRT alone: 9.9 months vs 14.0 months; p = 0.77).Conclusions: PD-L1+ and TILHigh at baseline could be predictive markers of the efficacy of CRT followed by durvalumab.(c) 2021 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCI LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND -SN - 0959-8049 -SN - 1879-0852 -DA - 2022 FEB -PY - 2022 -VL - 162 -SP - 1 -EP - 10 -DO - 10.1016/j.ejca.2021.11.013 -AN - WOS:000796006400001 -AD - Natl Canc Ctr, Dept Thorac Oncol, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan -AD - Kitasato Univ, Dept Resp Med, Sch Med, 1-15-1 Kitasato,Minami Ku, Sagamihara, Kanagawa 2520375, Japan -AD - Natl Canc Ctr, Dept Expt Therapeut, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan -AD - Natl Canc Ctr, Dept Endoscopy, Resp Endoscopy Div, Tokyo 1040045, Japan -AD - Natl Canc Ctr, Dept Radiat Therapy, Tokyo 1040045, Japan -AD - Natl Canc Ctr, Dept Thorac Surg, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan -AD - Natl Canc Ctr, Dept Diagnost Pathol, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan -Y2 - 2022-06-06 -ER - - -TY - JOUR -AU - Farhat, Raed -AU - Asna, Noam -AU - Avraham, Yaniv -AU - Khater, Ashraf -AU - Asakla, Majd -AU - Safia, Alaa -AU - Szvalb, Sergio -AU - Elkhatib, Nidal -AU - Merchavy, Shlomo -TI - Pembrolizumab as a first line therapy in a patient with extensive mucoepidermoid salivary gland carcinoma. A complete clinical, radiological and pathological response. A very specific case -T2 - DISCOVER ONCOLOGY -M3 - Article -AB - Background Patients with advanced salivary gland malignancies (SGCs) have few therapy options. Although results from newly published trials suggest that checkpoint inhibition may be useful in a subgroup of patients, there are no clear criteria for PD-L1 score in SGCs. Chemotherapy benefits were observed to be limited, with a dismal prognosis in unresectable and high-grade SGC. Immunotherapies have demonstrated extraordinary efficacy in a variety of cancers, including non-small cell lung cancer and malignant melanoma. Anti-PD-1 antibody pembrolizumab has been shown to have potent anti-tumor action in a number of clinical trials. Case presentation We report a unique case of advanced high grade mucoepidermoid carcinoma of the parotid salivary gland after Pembrolizumab treatment as a first line therapy. The tumor was downstaged as a result of the pembrolizumab treatment, allowing for a successful surgical excision with no facial nerve sacrifice and no major neoadjuvant treatment adverse effects, and the final specimen pathology was tumor-free. In these types of malignancies, a similar technique resulted in a complete response (CR) radiologically and pathologically has never been discussed before. Conclusions In pretreated patients with high-grade salivary gland mucoepidermoid carcinoma, pembrolizumab showed good anticancer activity and provided a clinically, radiologically, and pathological response with a viable treatment choice. More research is needed to bring Pembrolizumab to the front-line of treatment. The time and duration of medication should be compared to the time required for surgery in these investigations. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1868-8497 -SN - 2730-6011 -DA - 2022 MAY 28 -PY - 2022 -VL - 13 -IS - 1 -C7 - 37 -DO - 10.1007/s12672-022-00502-4 -AN - WOS:000800764100001 -AD - Ziv Med Ctr, Otolaryngol Head & Neck Surg Unit, IL-1028 Golan Hts, Safed, Israel -AD - Ziv Med Ctr, Oncol Inst, Safed, Israel -AD - Ziv Med Ctr, Pathol Inst, Safed, Israel -Y2 - 2022-06-05 -ER - - -TY - JOUR -AU - BUNN, PA -AU - COHEN, MH -AU - IHDE, DC -AU - FOSSIECK, BE -AU - MATTHEWS, MJ -AU - MINNA, JD -TI - ADVANCES IN SMALL CELL BRONCHOGENIC CARCINOMA -T2 - CANCER TREATMENT REPORTS -M3 - Review -AB - All lung cancer patients should have slides reviewed by a pathologist familiar with a WHO oriented classification system. Serial measurements of levels of marker substances to determine their value in assessing completeness of remission and early relapses should be performed. Routine staging procedures should include evaluation of liver, bone, bone marrow, and brain. Other staging procedures including peritoneoscopy, lymphangiography and radionuclide scanning should be further evaluated in clinical investigation protocols. The prognostic importance of metastases to each organ should be determined. Bronchoscopy is a useful tool for evaluating response to therapy. Extent of disease, age, sex, performance status, prior therapy and immune status should be reported in all trials. Surgery appears to have little value except in peripheral solitary nodules. Adjuvant chemotherapy should be studied in these cases. Chemotherapy plus radiotherapy is superior to radiotherapy alone, even in limited disease. When effective combination chemotherapy is used, radiotherapy to the chest does not clearly increase survival over chemotherapy alone. Prophylactic CNS therapy with cranial irradiation or a systemic nitrosourea is useful in reducing brain metastases. Despite the increased response rates and survivals attributed to combination chemotherapy with or without radiotherapy, few patients are cured and long periods of treatment are necessary. New chemotherapeutic and radiotherapeutic tactics are necessary for further improvements. Increasing the intensity of induction therapy has led to considerable increases in response rate, survival and toxicity. -PU - PUBLIC HEALTH SERVICE, US DEPTHEALTH & HUMAN SERVICES -PI - BETHESDA -PA - RA BLOCH INT CANCER INF CENTER ROOM 213 9030 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA -SN - 0361-5960 -DA - 1977 -PY - 1977 -VL - 61 -IS - 3 -SP - 333 -EP - 342 -AN - WOS:A1977DM73400001 -AD - VET ADM HOSP, NCI, MED ONCOL BRANCH, WASHINGTON, DC 20422 USA -M2 - VET ADM HOSP -Y2 - 1977-01-01 -ER - - -TY - JOUR -AU - Iocolano, Michelle -AU - Yegya-Raman, Nikhil -AU - Friedes, Cole -AU - Wang, Xingmei -AU - Kegelman, Timothy -AU - Lee, Sang Ho -AU - Duan, Lian -AU - Li, Bolin -AU - Levin, William P. -AU - Cengel, Keith A. -AU - Konski, Andre -AU - Langer, Corey J. -AU - Cohen, Roger B. -AU - Sun, Lova -AU - Aggarwal, Charu -AU - Doucette, Abigail -AU - Xiao, Ying -AU - Kevin Teo, Boon-Keng -AU - O'Reilly, Shannon -AU - Zou, Wei -AU - Bradley, Jeffrey D. -AU - Simone II, Charles B. -AU - Feigenberg, Steven J. -TI - Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era -T2 - CANCER -M3 - Article -AB - Introduction It was hypothesized that use of proton beam therapy (PBT) in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiation and consolidative immune checkpoint inhibition is associated with fewer unplanned hospitalizations compared with intensity-modulated radiotherapy (IMRT). Methods Patients with locally advanced non-small cell lung cancer treated between October 2017 and December 2021 with concurrent chemoradiation with either IMRT or PBT +/- consolidative immune checkpoint inhibition were retrospectively identified. Logistic regression was used to assess the association of radiation therapy technique with 90-day hospitalization and grade 3 (G3+) lymphopenia. Competing risk regression was used to compare G3+ pneumonitis, G3+ esophagitis, and G3+ cardiac events. Kaplan-Meier method was used for progression-free survival and overall survival. Inverse probability treatment weighting was applied to adjust for differences in PBT and IMRT groups. Results Of 316 patients, 117 (37%) received PBT and 199 (63%) received IMRT. The PBT group was older (p < .001) and had higher Charlson Comorbidity Index scores (p = .02). The PBT group received a lower mean heart dose (p < .0001), left anterior descending artery V15 Gy (p = .001), mean lung dose (p = .008), and effective dose to immune circulating cells (p < .001). On inverse probability treatment weighting analysis, PBT was associated with fewer unplanned hospitalizations (adjusted odds ratio, 0.55; 95% CI, 0.38-0.81; p = .002) and less G3+ lymphopenia (adjusted odds ratio, 0.55; 95% CI, 0.37-0.81; p = .003). There was no difference in other G3+ toxicities, progression-free survival, or overall survival. Conclusions PBT is associated with fewer unplanned hospitalizations, lower effective dose to immune circulating cells and less G3+ lymphopenia compared with IMRT. Minimizing dose to lymphocytes may be warranted, but prospective data are needed. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0008-543X -SN - 1097-0142 -DA - 2024 JUN 1 -PY - 2024 -VL - 130 -IS - 11 -SP - 2031 -EP - 2041 -DO - 10.1002/cncr.35230 -AN - WOS:001154999600001 -C6 - JAN 2024 -AD - Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA USA -AD - Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA USA -AD - Dept Radiat Oncol, Delaware Radiat Oncol Associates, Christiana Care Hlth Syst, Newark, DE USA -AD - Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Div Phys, Philadelphia, PA USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX USA -AD - Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA USA -AD - Univ Penn, Perelman Sch Med, Div Hematol & Oncol, Philadelphia, PA USA -AD - Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA -AD - New York Proton Ctr, New York, NY USA -AD - Perelman Ctr Adv Med, Dept Radiat Oncol, 2 West 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA -M2 - New York Proton Ctr -Y2 - 2024-02-09 -ER - - -TY - JOUR -AU - Zhu, Lingling -AU - Yu, Xianzhe -AU - Tang, Xiaojun -AU - Hu, Chenggong -AU - Wu, Lei -AU - Liu, Yanyang -AU - Zhou, Qinghua -TI - Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer -T2 - CHINESE MEDICAL JOURNAL -M3 - Review -AB - Liver metastases (LMs) are common in lung cancer. Despite substantial advances in diagnosis and treatment, the survival rate of patients with LM remains low as the immune-suppressive microenvironment of the liver allows tumor cells to evade the immune system. The impact of LMs on the outcomes of immune checkpoint inhibitors in patients with solid tumors has been the main focus of recent translational and clinical research. Growing evidence indicates that the hepatic microenvironment delivers paracrine and autocrine signals from non-parenchymal and parenchymal cells. Overall, these microenvironments create pre- and post-metastatic conditions for the progression of LMs. Herein, we reviewed the epidemiology, physiology, pathology and immunology, of LMs associated with non-small cell lung cancer and the role and potential targets of the liver microenvironment in LM in each phase of metastasis. Additionally, we reviewed the current treatment strategies and challenges that should be overcome in preclinical and clinical investigations. These approaches target liver elements as the basis for future clinical trials, including combinatorial interventions reported to resolve hepatic immune suppression, such as immunotherapy plus chemotherapy, immunotherapy plus radiotherapy, immunotherapy plus anti-angiogenesis therapy, and surgical resection. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0366-6999 -SN - 2542-5641 -DA - 2024 MAY 5 -PY - 2024 -VL - 137 -IS - 9 -SP - 1019 -EP - 1032 -DO - 10.1097/CM9.0000000000002981 -AN - WOS:001245536500008 -AD - Sichuan Univ, West China Hosp, Lung Canc Inst, Lung Canc Ctr, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China -AD - Sichuan Univ, West China Sch Pharm, Coll Polymer Sci & Engn, Minist Educ,Key Lab Drug Targeting & Drug Delivery, Chengdu 610041, Sichuan, Peoples R China -AD - Chengdu Second Peoples Hosp, Dept Gastrointestinal Surg, Chengdu 610041, Sichuan, Peoples R China -AD - Sichuan Univ, West China Hosp, Dept Crit Care Med, Chengdu 610041, Sichuan, Peoples R China -AD - Sichuan Univ, West China Hosp, Core Facil, Chengdu 610041, Sichuan, Peoples R China -AD - Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China -M2 - Chengdu Second Peoples Hosp -Y2 - 2024-06-21 -ER - - -TY - JOUR -AU - Remon, J. -AU - Vilarino, N. -AU - Reguart, N. -TI - Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions -T2 - CANCER TREATMENT REVIEWS -M3 - Review -AB - Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment strategy of advanced non small cell lung cancer (NSCLC). Beyond the already approved indications in first- and second-line setting of advanced NSCLC, new data has recently emerged demonstrating its efficacy in locally advanced disease as maintenance after chemo-radiotherapy and currently several trials are also exploring its efficacy in earlier stages of the disease to evaluate whether these results could be extrapolated to the adjuvant setting. With the advent of all these new therapies, their potential in other thoracic malignancies such as mesothelioma and small-cell lung cancer are also being evaluated with encouraging preliminary data that endorses their short-term incorporation as new therapeutic options in these thoracic malignancies. However, despite all these new evidence, there are still several open questions that remain to be solved like the use of immune agents in special subpopulations such as elderly or fragile patients or the case of patients with brain metastases or autoimmune disorders. In addition some other open questions remain with regards ICIs activity in patients receiving corticosteroid or antibiotics, the potential use in oncogenic addicted tumours, as well as the safety of retreatment after the onset of immune-related adverse events (ir-AE) or the optimal dose schedule or time on treatment for ICIs administration. Herein, we propose to address all these questions, reviewing most recent evidence available in order to give readers some practical advises and guidance on how to deal with these challenges when treating NSCLC patients with immunotherapy. (C) 2018 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCI LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND -SN - 0305-7372 -SN - 1532-1967 -DA - 2018 MAR -PY - 2018 -VL - 64 -SP - 21 -EP - 29 -DO - 10.1016/j.ctrv.2018.02.002 -AN - WOS:000428835000003 -AD - Hosp Valle De Hebron, Dept Med Oncol, Passeig Vall dHebron 119-129, Barcelona 08035, Spain -AD - Hosp Clin Barcelona, Barcelona, Spain -AD - Hosp Clin Barcelona, Dept Med Oncol, Villarroel 170, E-08036 Barcelona, Spain -Y2 - 2018-04-13 -ER - - -TY - JOUR -AU - Kokowski, Konrad -AU - Stangl, Stefan -AU - Seier, Sophie -AU - Hildebrandt, Martin -AU - Vaupel, Peter -AU - Multhoff, Gabriele -TI - Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in apatient with NSCLC stage IIIb inducing long-term tumor control: acase study -T2 - STRAHLENTHERAPIE UND ONKOLOGIE -M3 - Article -AB - BackgroundMembrane heat shock protein 70 (mHsp70) is indicative of high-risk tumors and serves as atumor-specific target for natural killer (NK) cells stimulated with Hsp70 peptide (TKD) and Interleukin(IL)-2. Radiochemotherapy (RCT), mHsp70-targeting NK cells, and programmed death(PD)-1 inhibition were combined to improve the efficacy of tumor-specific immune cells in anon-small cell lung carcinoma (NSCLC) patient.PatientFollowing simultaneous RCT (64.8Gy), apatient with inoperable NSCLC (cT4, cN3, cM0, stage IIIb) was treated with 4cycles of autologous ex vivo TKD/IL-2-activated NK cells and the PD-1 antibody nivolumab as asecond-line therapy. Blood samples were taken for immunophenotyping during the course of therapy.ResultsAdoptive transfer of ex vivo TKD/IL-2-activated NK cells after RCT combined with PD-1 blockade is well tolerated and results in superior overall survival (OS). No viable tumor cells but amassive immune cell infiltration in fibrotic tissue was detected after therapy. Neither tumor progression nor distant metastases were detectable by CT scanning 33months after diagnosis. Therapy response was associated with significantly increased CD3(-)/NKG2D(+)/CD94(+) NK cell counts, elevated CD8(+) to CD4(+) Tcell and CD3(-)/CD56(bright) to CD3(-)/CD56(dim) NK cell ratios, and significantly reduced regulatory Tcells (Tregs) in the peripheral blood.ConclusionAcombined therapy consisting of RCT, mHsp70-targeting NK cells, and PD-1 antibody inhibition is well tolerated, induces anti-tumor immunity, and results in long-term tumor control in one patient with advanced NSCLC. Further, randomized studies are necessary to confirm the efficacy of this combination therapy. -PU - SPRINGER HEIDELBERG -PI - HEIDELBERG -PA - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY -SN - 0179-7158 -SN - 1439-099X -DA - 2019 APR -PY - 2019 -VL - 195 -IS - 4 -SP - 352 -EP - 361 -DO - 10.1007/s00066-019-01434-9 -AN - WOS:000462515100011 -AD - Klinikum Bogenhausen, Pneumol & Pneumol Oncol, Munich, Germany -AD - Ctr Translat Canc Res TUM TranslaTUM, Radiat Immunooncol, Einsteinstr 25, D-81675 Munich, Germany -AD - TUM Sch Med, TUMCells, Munich, Germany -AD - TUM, Klinikum Rechts Isar, Dept Radiat Oncol, Munich, Germany -AD - Helmholtz Ctr Munich HMGU, DRS, Inst Innovat Radiotherapy iRT, Munich, Germany -AD - DKTK, Partner Site Munich, Munich, Germany -AD - TUM, Klinikum Rechts Isar, Inst Clin Chem & Pathobiochem, Munich, Germany -M2 - Ctr Translat Canc Res TUM TranslaTUM -M2 - TUM Sch Med -M2 - Helmholtz Ctr Munich HMGU -M2 - DKTK -Y2 - 2019-04-10 -ER - - -TY - JOUR -AU - Trinh, Jonathan Q. -AU - Xiong, Ying -AU - Smith, Lynette M. -AU - Abughanimeh, Omar -AU - Marr, Alissa S. -AU - Ganti, Apar K. -TI - Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study -T2 - ANTICANCER RESEARCH -M3 - Article -AB - Background/Aim: The PACIFIC trial demonstrated improved survival in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with durvalumab following definitive concurrent chemoradiotherapy (CRT). This study sought to explore real- world outcomes with durvalumab consolidation therapy at our institution. Patients and Methods: We retrospectively identified patients diagnosed with stage III NSCLC at our institution from January 2012 to January 2022. We created two cohorts: one who received durvalumab following definitive CRT and a historical one who did not. Primary outcomes of interest included median progression-free survival (PFS) and overall survival (OS). Additionally, we performed subgroup analysis on the durvalumab cohort to explore the associations between survival and time to durvalumab initiation, PD-L1 expression, and neutrophil- to-lymphocyte ratio ( NLR). Results: We identified 79 patients with locally advanced NSCLC who were not surgical candidates. Patients treated with durvalumab (n=44) had significantly improved survival compared to the historical cohort (n= 35) including a median PFS of 17.4 months versus 8.0 months (p=0.0019) and a median OS of 37.0 months versus 17.0 months (log-rank p-value=0.07, Wilcoxon p-value=0.02). Within the durvalumab group, outcomes did not significantly differ between those who initiated therapy before or after 42 days of finishing between various PD-L1 expression levels, or between high or low NLR. Conclusion: Patients who received durvalumab as consolidation therapy following definitive CRT demonstrated significantly improved survival compared to a historical cohort who did not receive durvalumab. Furthermore, durvalumab appears to benefit patients regardless of time to initiation, PD-L1 expression, or NLR. -PU - INT INST ANTICANCER RESEARCH -PI - ATHENS -PA - EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE -SN - 0250-7005 -SN - 1791-7530 -DA - 2024 FEB -PY - 2024 -VL - 44 -IS - 2 -SP - 605 -EP - 612 -DO - 10.21873/anticanres.16849 -AN - WOS:001160637200006 -AD - Univ Nebraska Med Ctr, Dept Internal Med, 982055 Nebraska Med Ctr, Omaha, NE 68198 USA -AD - Univ Nebraska Med Ctr, Dept Biostatist, Omaha, NE USA -AD - Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA -AD - VA Nebraska Western Iowa Hlth Syst, Dept Internal Med, Omaha, NE USA -Y2 - 2024-03-22 -ER - - -TY - JOUR -AU - Ren, Wei -AU - Fang, Yingying -AU - He, Yujing -AU - Ren, Yifeng -AU - Wang, Minfang -AU - Xu, Anyi -AU - Ruan, Jiale -AU - Tao, Qinghua -TI - Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials -T2 - THERAPEUTIC DRUG MONITORING -M3 - Review -AB - Background: This meta-analysis aims to investigate the efficacy and safety of programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) combined with cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors for patients with advanced or metastatic non-small cell lung cancer (NSCLC). Methods: Authors conducted a comprehensive search of PubMed, Embase, Cochrane Library, Web of Science, Scopus, and Medline for randomized controlled trials comparing the prognosis and safety of PD-1/PD-L1 plus CTLA-4 inhibitors with other therapies for advanced or metastatic NSCLC. Hazard ratios (HRs) and 95% confidence intervals (CIs) were used as effect sizes. The primary outcomes of this study were overall survival (OS) and progression-free survival. Results: A total of 4943 patients diagnosed with stage III/IV advanced or metastatic NSCLC were included in the analysis of the 6 randomized controlled trials. The results showed that patients receiving dual immunotherapy with PD-1/PD-L1 plus CTLA-4 inhibitors had a longer survival time compared with the control group (HR = 0.88, P = 0.044). However, no statistically significant difference was observed in progression-free survival (HR = 0.95, P = 0.579). Subgroup analysis revealed better OS in the interventional group for patients aged >65 years (HR = 0.88, P = 0.076), smokers (HR = 0.81, P = 0.036), and those with a tumor mutational burden (TMB) >= 20 mut/Mb (HR = 0.66, P < 0.001). Conversely, the control group demonstrated superior OS in patients with TMB <20 mut/Mb (HR = 1.14, P = 0.048). In addition, the statistical results indicated a lower incidence rate of any-grade anemia in the dual immunotherapy group compared with the control group (RR = 0.32, P = 0.04). Conclusions: This meta-analysis demonstrates the effectiveness and safety of dual immunotherapy with PD-1/PD-L1 plus CTLA-4 inhibitors for treating advanced or metastatic NSCLC. Its efficacy is influenced by certain clinical and pathological factors, such as age, smoking status, and TMB. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0163-4356 -SN - 1536-3694 -DA - 2024 AUG -PY - 2024 -VL - 46 -IS - 4 -SP - 422 -EP - 433 -DO - 10.1097/FTD.0000000000001228 -AN - WOS:001266130600002 -AD - Ningbo Yinzhou 2 Hosp, Gen Family Med, Ningbo, Zhejiang, Peoples R China -AD - Zhejiang Chinese Med Univ, Clin Med Coll 1, Hangzhou, Zhejiang, Peoples R China -AD - Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Zhejiang, Peoples R China -AD - Ningbo Yinzhou 2 Hosp, Dept Resp & Crit Care Med, Ningbo, Zhejiang, Peoples R China -AD - Ningbo Yinzhou 2 Hosp, Emergency Med Ctr, 998 North Qianhe Rd, Ningbo 315100, Zhejiang, Peoples R China -M2 - Ningbo Yinzhou 2 Hosp -M2 - Ningbo Yinzhou 2 Hosp -M2 - Ningbo Yinzhou 2 Hosp -Y2 - 2024-07-18 -ER - - -TY - JOUR -AU - McCall, Neal S. -AU - Janopaul-Naylor, James R. -AU - McGinnis, H. Scott -AU - Kesarwala, Aparna H. -AU - Tian, Sibo -AU - Stokes, William A. -AU - Shelton, Joseph W. -AU - Steuer, Conor E. -AU - Carlisle, Jennifer W. -AU - Leal, Ticiana A. -AU - Ramalingam, Suresh S. -AU - Bradley, Jeffrey D. -AU - Higgins, Kristin A. -TI - Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer -T2 - CANCER -M3 - Article -AB - BackgroundThe PACIFIC trial established consolidative durvalumab after concurrent chemoradiation as standard-of-care in patients with stage III or unresectable non-small cell lung cancer (NSCLC). Black patients, however, comprised just 2% (n = 14) of randomized patients in this trial, warranting real-world evaluation of the PACIFIC regimen in these patients. MethodsThis single-institution, multi-site study included 105 patients with unresectable stage II/III NSCLC treated with concurrent chemoradiation followed by durvalumab between 2017 and 2021. Overall survival (OS), progression-free survival (PFS), and grade & GE;3 pneumonitis-free survival (PNFS) were compared between Black and non-Black patients using Kaplan-Meier and Cox regression analyses. ResultsA total of 105 patients with a median follow-up of 22.8 months (interquartile range, 11.3-37.3 months) were identified for analysis, including 57 Black (54.3%) and 48 (45.7%) non-Black patients. The mean radiation prescription dose was higher among Black patients (61.5 & PLUSMN; 2.9 Gy vs. 60.5 & PLUSMN; 1.9 Gy; p = .031), but other treatment characteristics were balanced between groups. The median OS (not-reached vs. 39.7 months; p = .379) and PFS (31.6 months vs. 19.3 months; p = .332) were not statistically different between groups. Eight (14.0%) Black patients discontinued durvalumab due to toxicity compared to 13 (27.1%) non-Black patients (p = .096). The grade & GE;3 pneumonitis rate was similar between Black and non-Black patients (12.3% vs. 12.5%; p = .973), and there was no significant difference in time to grade & GE;3 PNFS (p = .904). Three (5.3%) Black patients and one (2.1%) non-Black patient developed grade 5 pneumonitis. ConclusionsThe efficacy and tolerability of consolidative durvalumab after chemoradiation appears to be comparable between Black and non-Black patients. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0008-543X -SN - 1097-0142 -DA - 2023 DEC 1 -PY - 2023 -VL - 129 -IS - 23 -SP - 3713 -EP - 3723 -DO - 10.1002/cncr.34915 -AN - WOS:001011964900001 -C6 - JUN 2023 -AD - Emory Univ, Dept Radiat Oncol, Winship Canc Inst, Atlanta, GA USA -AD - Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA -AD - 100 Woodruff Circle,Ste 327, Atlanta, GA 30322 USA -Y2 - 2023-07-02 -ER - - -TY - JOUR -AU - Arcidiacono, Fabio -AU - Anselmo, Paola -AU - Casale, Michelina -AU - Zannori, Cristina -AU - Ragusa, Mark -AU - Mancioli, Francesco -AU - Marchetti, Giovanni -AU - Loreti, Fabio -AU - Italiani, Marco -AU - Bracarda, Sergio -AU - Maranzano, Ernesto -AU - Trippa, Fabio -TI - STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Article -AB - Purpose: This is a single arm phase 2 trial (Clinical trials.gov NCT05291780) to assess local control (LC) and safety of SAbR in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) unfit for concurrent chemo-radiation therapy (ChT-RT).Methods: Neoadjuvant ChT was prescribed in fit patients. The tumor volume included primary tumor and any regionally pos-itive node/s. The coprimary study endpoints were LC and safety.Results: Between December 31, 2015, and December 31, 2020, 50 patients with LA-NSCLC were enrolled. Histology was squa-mous cell carcinoma and adenocarcinoma (ADC) in 52% and 48%, respectively. Forty (80%) patients had ultracentral tumor. Twenty-seven (54%) received neoadjuvant ChT and 7 (14%) adjuvant durvalumab. Median prescribed dose was 45 Gy (range, 35-55) and 40 Gy (35-45) in 5 daily fractions to tumor and node/s, respectively. After a median follow-up of 38 months (range, 12-80), 19 (38%) patients had experienced local recurrence (LR) at a median time of 13 months (range, 7-34). The median LR-free survival (FS) was not reached (95% confidence interval [CI], 28 to not reached). The 1-, 2-, and 3-year LR-FS rates were 86% +/- 5%, 66% +/- 7%, and 56% +/- 8%, respectively. At last follow-up, 33 (66%) patients were alive. Median overall survival (OS) was 55 months (95% CI, 43-55 months). The 1-, 2-, and 3-year OS rates were 94% +/- 3%, 79% +/- 6%, and 72% +/- 7%, respectively. No patients developed >= grade (G) 3 toxicity. ADC (hazard ratio [HR], 3.61; 95% CI, 1.15-11.35) was a significant predictor of better LC, while OS was significantly conditioned by smaller planning target volumes (HR, 1.004; 95% CI, 1.001-1.010) and tumor, node, and metastasis stage (HR, 4.8; 95% CI, 1.34-17). Conclustions: Patients with LA-NSCLC treated with SABR had optimal LC and promising OS in absence of >= G3 toxicity. Our early outcomes would suggest the feasibility of using this approach in patients with LA-NSCLC unfit for concurrent ChT-RT. (c) 2022 Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 MAR 15 -PY - 2023 -VL - 115 -IS - 4 -SP - 886 -EP - 896 -DO - 10.1016/j.ijrobp.2022.10.025 -AN - WOS:000991104900001 -C6 - FEB 2023 -AD - S Maria Hosp, Radiotherapy Oncol Ctr, Terni, Italy -AD - S Maria Hosp, Med Oncol, Terni, Italy -AD - S Maria Hosp, Thorac Surg Div, Terni, Italy -AD - S Maria Hosp, Radiol Serv, Terni, Italy -AD - S Maria Hosp, Pathol Unit, Terni, Italy -AD - S Maria Hosp, Nucl Med Serv, Terni, Italy -M2 - S Maria Hosp -M2 - S Maria Hosp -M2 - S Maria Hosp -M2 - S Maria Hosp -M2 - S Maria Hosp -M2 - S Maria Hosp -Y2 - 2023-05-28 -ER - - -TY - JOUR -AU - Huo, LanQing -AU - Chu, Chu -AU - Jiang, XiaoBo -AU - Zheng, ShiYang -AU - Zhang, PengXin -AU - Zhou, Rui -AU - Chen, NaiBin -AU - Guo, JinYu -AU - Qiu, Bo -AU - Liu, Hui -TI - A pilot trial of consolidation bevacizumab after hypo-fractionated concurrent chemoradiotherapy in patients with unresectable locally advanced non-squamous non-small-cell lung cancer -T2 - CANCER MEDICINE -M3 - Article -AB - Purpose: To determine the feasibility of incorporating bevacizumab consolidation into hypo-fractionated concurrent chemoradiotherapy (hypo-CCRT) for patients with unresectable locally advanced non-squamous non-small-cell lung cancer (LA-NS-NSCLC).Patients and Methods: Eligible patients were treated with hypo-RT (40Gy in 10 fractions) followed by hypo-boost (24-28Gy in 6-7 fractions), along with concurrent weekly chemotherapy. Patients who completed the hypo-CCRT without experiencing =G2 toxicities received consolidation bevacizumab every 3 weeks for up to 1 year, until disease progression or unacceptable treatment-related toxicities.The primary endpoint was the risk of G4 or higher hemorrhage. Secondary endpoints included progression-free survival (PFS), overall survival (OS), locoregional failure-free survival (LRFS), distant metastasis-free survival (DMFS), and objective response rate (ORR). All time-to-event endpoints (OS, PFS, LRFS, and DMFS) were measured from the start of radiotherapy.Results: Between December 2017 and July 2020, a total of 27 patients were included in the analysis, with a median follow-up duration of 28.0 months. One patient (3.7%) developed G5 hemorrhage during bevacizumab consolidation. Additionally, seven patients (25.9%) had G3 cough and three patients (11.1%) experienced G3 pneumonitis. The ORR for the entire cohort was 92.6%. The median OS was 37.0 months (95% confidence interval, 8.9-65.1 months), the median PFS was 16.0 months (95% confidence interval, 14.0-18.0 months), the median LRFS was not reached, and the median DMFS was 18.0 months.Conclusions: This pilot study met its goal of demonstrating the tolerability of consolidation bevacizumab after hypo-CCRT. Further investigation of antiangiogenic and immunotherapy combinations in LA-NSCLC is warranted, while the potential for grade 3 respiratory toxicities should be taken into consideration. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2045-7634 -DA - 2023 SEP -PY - 2023 -VL - 12 -IS - 17 -SP - 17638 -EP - 17647 -DO - 10.1002/cam4.6381 -AN - WOS:001042588800001 -C6 - AUG 2023 -AD - Sun Yat Sen Univ Canc Ctr, Dept Radiat Oncol, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ, Lung Canc Inst, Guangzhou, Peoples R China -AD - Guangdong Assoc Study Thorac Oncol, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol, State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China -M2 - Guangdong Assoc Study Thorac Oncol -Y2 - 2023-08-19 -ER - - -TY - JOUR -AU - Wojas-Krawczyk, Kamila -AU - Krawczyk, Pawel -AU - Gil, Michal -AU - Strzemski, Maciej -TI - Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients-Mechanism of Action and Future Concepts -T2 - CANCERS -M3 - Review -AB - Simple SummaryHere, we focused on the most important mechanisms of action of combined immunotherapy with modern anticancer approaches in patients with non-small-cell lung cancer. This knowledge is extremely important for lung cancer clinicians. First, it facilitates proper involvement of the patient in the treatment and monitoring its effectiveness. More importantly, the knowledge of the immunotherapy mechanisms will certainly allow quick recognition of the side effects of such a therapy, which are totally different of those observed after chemotherapy. Side effects of combination therapies can occur at any stage of treatment, and even after completion thereof. This review article could particularly explain the mechanism of action of combined immunotherapy, which have different targets in patients.Due to the limited effectiveness of immunotherapy used as first-line monotherapy in patients with non-small-cell lung cancer (NSCLC), the concepts of combining classical immunotherapy based on immune checkpoint antibodies with other treatment methods have been developed. Pembrolizumab and atezolizumab were registered in combination with chemotherapy for the treatment of metastatic NSCLC, while durvalumab found its application in consolidation therapy after successful chemoradiotherapy in patients with locally advanced NSCLC. Exceptionally attractive, due to their relatively low toxicity and high effectiveness, are treatment approaches in which a combination of two different immunotherapy methods is applied. This method is based on observations from clinical trials in which nivolumab and ipilimumab were used as first-line therapy for advanced NSCLC. It turned out that the dual blockade of immune checkpoints activated T lymphocytes in different compartments of the immune response, at the same time affecting the downregulation of immune suppressor cells (regulatory T cells). These experiments not only resulted in the registration of combination therapy with nivolumab and ipilimumab, but also initiated other clinical trials using immune checkpoint inhibitors (ICIs) in combination with other ICIs or activators of costimulatory molecules found on immune cells. There are also studies in which ICIs are associated with molecules that modify the tumour environment. This paper describes the mechanism of the synergistic effect of a combination of different immunotherapy methods in NSCLC patients. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2021 JUN -PY - 2021 -VL - 13 -IS - 11 -C7 - 2836 -DO - 10.3390/cancers13112836 -AN - WOS:000659609300001 -AD - Med Univ Lublin, Pneumonol Oncol & Allergol Dept, PL-20954 Lublin, Poland -AD - GENIM Ltd, Genet & Immunol Inst, PL-20609 Lublin, Poland -AD - Med Univ Lublin, Analyt Chem Dept, PL-20093 Lublin, Poland -M2 - GENIM Ltd -Y2 - 2021-06-20 -ER - - -TY - JOUR -AU - Xu, Ting -AU - Wu, Lirong -AU - Gandhi, Saumil -AU - Jing, Wang -AU - Nguyen, Quyhn-Nhu -AU - Chen, Aileen -AU - Chang, Joe Y. -AU - Nurieva, Roza -AU - Sheshadri, Ajay -AU - Altan, Mehmet -AU - Lee, Percy P. -AU - Lin, Steven H. -AU - Liao, Zhongxing -TI - Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer -T2 - RADIOTHERAPY AND ONCOLOGY -M3 - Article -AB - Purpose: We compared treatment-related pulmonary adverse events (TRPAE), progression-free survival (PFS), and overall survival (OS) among locally advanced non-small cell lung cancer (NSCLC) patients who received concurrent chemoradiotherapy (CRT) versus CRT followed by immune check point inhibitor (ICI) immunotherapy (CRTI).Materials and methods: TRPAE was defined as any pulmonary events as defined in CTCAE v.5 occurring within 12 months after completion of radiotherapy. Outcomes were compared between CRT and CTRI by Cox proportional hazard regression and Kaplan-Meier analyses. We also assessed if TRPAE-induced discontinuation of ICI affected survival.Results: We analyzed 326 patients treated between July 2010 and November 2019; 195 patients received CRT and 131 received CRTI. The incidences of severe grade >= 3 TRPAE were similar between the two groups, however, symptomatic TRPAE was almost doubled in CRTI group (65.7 % CTRI vs 35.9 % CRT, P < 0.0001). The rates of 4-year OS and PFS were 54.5 % vs 36.7 % (P = 0.0003) and 43.8 % vs 35.8 % (P = 0.038) in CRT + Durvalumab and CRT group, respectively. Receipt of ICI Durvalumab was associated with better 4-year OS (HR 0.53, 95 % CI 0.36-0.78, P = 0.001) and PFS (HR 0.55, 95 % CI 0.38-0.80, P = 0.002). Patients who discontinued ICI because of TRPAE had worse 4-year OS (P = 0.001) and higher rates of distant metastasis (P = 0.003) than those who completed planned ICI after developing TRPAE.Conclusion: CRT followed by adjuvant ICI led to improved 4-year OS and PFS consistent with published data. CRTI was associated with higher incidence of grade >= 2 TRPAE in both high and low mean lung dose groups without significant difference in grade >= 3 TRPAE. Discontinuation of ICI due to TRPAE was asso-ciated with poorer OS and distant disease control than completing ICI as planned after developing TRPAE.(c) 2022 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 176 (2022) 149-156 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0167-8140 -SN - 1879-0887 -DA - 2022 NOV -PY - 2022 -VL - 176 -SP - 149 -EP - 156 -DO - 10.1016/j.radonc.2022.10.002 -AN - WOS:000879180600001 -C6 - OCT 2022 -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA -AD - Nanjing Med Univ, Jiangsu Canc Hosp, Dept Radiat Oncol, Nanjing, Peoples R China -AD - Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing, Peoples R China -AD - Nanjing Med Univ, Affiliated Canc Hosp, Nanjing, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China -AD - Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 1422,1400 Pressler St, Houston, TX 77030 USA -Y2 - 2022-11-15 -ER - - -TY - JOUR -AU - Liu, Qi -AU - Zhang, Chenan -AU - Huang, Yue -AU - Huang, Ruihao -AU - Huang, Shiew-Mei -AU - Larkins, Erin -AU - Stapleford, Liza -AU - Rivera, Donna R. -AU - Kluetz, Paul G. -AU - Wang, Shenggang -AU - Zhu, Hao -AU - Weese, James -AU - Cromartie, Elizabeth -AU - Teka, Mahder -AU - Walters, Sheetal -AU - Wolf, Frank -AU - Brown, Thomas D. -TI - Evaluating Pneumonitis Incidence in Patients with Non-small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data -T2 - CANCER RESEARCH COMMUNICATIONS -M3 - Article -AB - Pneumonitis is a potentially life-threatening complication of anticancer therapy, and future treatment decisions may be informed by characterizing patients receiving therapies in the real-world setting. In this study, the inci-dence of treatment-associated pneumonitis (TAP) was compared among patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors (ICI) or chemotherapies in either of two settings: randomized clinical trials (RCT) or real world data (RWD)-based clinical practice. Pneumonitis cases were identified using International Classifica-tion of Diseases codes (for RWD), or the Medical Dictionary for Regulatory Activities preferred terms (for RCTs). TAP was defined as pneumonitis diagnosed during treatment or within 30 days of the last treatment ad-ministration. Overall TAP rates in the RWD cohort were lower [ICI: 1.9%; 95% confidence interval (CI), 1.2-3.2; chemotherapy: 0.8%; 95% CI, 0.4- 1.6] than overall rates in the RCT cohort (ICI: 5.6%; 95% CI, 5.0-6.2; chemotherapy: 1.2%; 95% CI, 0.9-1.5). Overall RWD TAP rates were similar to grade 3+ RCT TAP rates (ICI: 2.0%; 95% CI, 1.6-2.3; chemotherapy: 0.6%; 95% CI, 0.4-0.9). In both cohorts, higher TAP incidence was ob-served among patients with a past medical history of pneumonitis than those without, regardless of treatment group. On the basis of this sizable study leveraging RWD, TAP incidence was low in the RWD cohort, likely in part due to methodology used for RWD focusing on clinically significant cases. Past medical history of pneumonitis was associated with TAP in both cohorts.Significance: Pneumonitis is a potentially life-threatening complication of anticancer treatment. As treatment options expand, management decisions become increasingly complex, and there is a greater need to understand the safety profiles of the treatment options in the real-world setting. Real-world data serve as an additional source of valuable information to complement clinical trial data and inform understanding of toxicity in patients with non-small cell lung cancer receiving ICIs or chemotherapies. -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 2767-9764 -DA - 2023 FEB -PY - 2023 -VL - 3 -IS - 2 -SP - 258 -EP - 266 -DO - 10.1158/2767-9764.CRC-22-0370 -AN - WOS:001033743700001 -AD - FDA, Off Clin Pharmacol, Silver Spring, MD USA -AD - Syapse, San Francisco, CA USA -AD - FDA, Off Oncol Dis, Silver Spring, MD USA -AD - FDA, Oncol Ctr Excellence, Silver Spring, MD USA -AD - Advocate Aurora Hlth, Milwaukee, WI USA -AD - Syapse, San Francisco, CA 94116 USA -M2 - Syapse -M2 - Advocate Aurora Hlth -M2 - Syapse -Y2 - 2023-08-08 -ER - - -TY - JOUR -AU - Schulz, Christian -TI - Advances in Lung Cancer Treatment -T2 - DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT -M3 - Article -AB - Immuno-oncologic monotherapy for NSCLC 5-year survival data from the KEYNOTE-024 trial confirm the sustained efficacy of immuno-oncologic monotherapy in patients with NSCLC with high PD-L1 expression (>= 50%).Dual immunotherapy in combination with chemotherapy as first-line therapy for NSCLC Nivolumab plus impilimumab in combination with 2 cycles of platinum-containing chemotherapy improves survival in NSCLC patients.Novel targets and treatment options Entrectinib and larotrectinib with efficacy in NTRK fusion-positive NSCLC. Selpercatinib and pralsetinib with efficacy in RET fusion-positive NSCLC. Mobocertinib with efficacy in EGFRex20ins mutation of the EGFR gene. Sotorasib with efficacy in kRAS-G12C mutation of NSCLC.National Network Genomic Medicine Lung Cancer (nNGM) The nationwide network nNGM provides NSCLC patients with access to state-of-the-art molecular diagnostics and the latest treatment options. -PU - GEORG THIEME VERLAG KG -PI - STUTTGART -PA - RUDIGERSTR 14, D-70469 STUTTGART, GERMANY -SN - 0012-0472 -SN - 1439-4413 -DA - 2021 OCT -PY - 2021 -VL - 146 -IS - 19 -SP - 1283 -EP - 1286 -DO - 10.1055/a-1393-7697 -AN - WOS:000697822700010 -AD - Univ Klinikum Regensburg, Comprehens Canc Ctr Ostbayern CCCO, Regensburg, Germany -Y2 - 2021-10-02 -ER - - -TY - JOUR -AU - McCall, Neal S. -AU - McGinnis, Hamilton S. -AU - Janopaul-Naylor, James R. -AU - Kesarwala, Aparna H. -AU - Tian, Sibo -AU - Stokes, William A. -AU - Shelton, Joseph W. -AU - Steuer, Conor E. -AU - Carlisle, Jennifer W. -AU - Leal, Ticiana -AU - Ramalingam, Suresh S. -AU - Bradley, Jeffrey D. -AU - Higgins, Kristin A. -TI - Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era -T2 - RADIOTHERAPY AND ONCOLOGY -M3 - Article -AB - Background/purpose: Higher estimated radiation doses to immune cells (EDIC) have correlated with worse overall survival (OS) in patients with locally-advanced non-small cell lung cancer (NSCLC) prior to the PACIFIC trial, which established consolidative durvalumab as standard-of-care. Here, we examine the prognostic impact of EDIC in the durvalumab era.Materials/methods: This single-institution, multi-center study included patients with unresectable stage II/III NSCLC treated with chemoradiation followed by durvalumab. Associations between EDIC [analyzed continuously and categorically (<= 6 Gy vs > 6 Gy)] and OS, progression-free survival (PFS), and locore-gional control (LRC) were evaluated by Kaplan-Meier and Cox proportional methods.Results: 100 patients were included with median follow-up of 23.7 months. The EDIC > 6 Gy group had a significantly greater percentage of stage IIIB/IIIC disease (76.0 % vs 32.6 %; p < 0.001) and larger tumor volumes (170 cc vs 42 cc; p < 0.001). There were no differences in early durvalumab discontinuation from toxicity (24.1 % vs 15.2 %; p = 0.27). Median OS was shorter among the EDIC > 6 Gy group (29.6 months vs not reached; p < 0.001). On multivariate analysis, EDIC > 6 Gy correlated with worse OS (HR: 4.15, 95 %CI: 1.52-11.33; p = 0.006), PFS (HR: 3.79; 95 %CI: 1.80-8.0; p < 0.001), and LRC (HR: 2.66, 95 %CI: 1.15-6.18; p = 0.023). Analyzed as a continuous variable, higher EDIC was associated with worse OS (HR: 1.34; 95 % CI: 1.16-1.57; p < 0.001), PFS (HR: 1.52; 95 %CI: 1.29-1.79; p < 0.001), and LRC (HR: 1.34, 95 %CI: 1.13- 1.60; p = 0.007).Conclusions: In the immunotherapy era, EDIC is an independent predictor of OS and disease control in locally advanced NSCLC, warranting investigation into techniques to reduce dose to the immune compartment.(c) 2022 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 174 (2022) 133-140 -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0167-8140 -SN - 1879-0887 -DA - 2022 SEP -PY - 2022 -VL - 174 -SP - 133 -EP - 140 -DO - 10.1016/j.radonc.2022.07.015 -AN - WOS:000838591300018 -C6 - AUG 2022 -AD - Winship Canc Inst Emory Univ, Dept Radiat Oncol, Atlanta, GA USA -AD - Winship Canc Inst Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA USA -AD - 100 Woodruff Circle,Suite 327, Atlanta, GA 30322 USA -M2 - Winship Canc Inst Emory Univ -M2 - Winship Canc Inst Emory Univ -Y2 - 2022-08-28 -ER - - -TY - JOUR -AU - Faehling, Martin -AU - Kopp, Marcel -AU - Schwenk, Birgit -AU - Fallscheer, Sabine -AU - Kramberg, Sebastian -AU - Eckert, Robert -TI - Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice -T2 - ONCOLOGY -M3 - Article -AB - Background: Immuno-oncological (IO) therapies such as PD-1 and PD-L1 antibodies have been introduced in the treatment of advanced non-small cell lung cancer (NSCLC) since 2015 based on randomized trials showing unprecedented advantages in overall survival (OS) with hazard ratios (HRs) between 0.5 and 0.7. The impact of these treatments on OS in routine clinical practice and the role of tumor mass have not been studied. Methods: 557 consecutive patients with inoperable stage III or stage IV NSCLC diagnosed in our certified lung cancer center from 2006 to 2018 were included if they had received at least one line of systemic treatment. OS of immuno-oncologically treated patients (IO patients, n = 144) who received treatment with a PD-1 antibody (nivolumab [n = 77] or pembrolizumab [n = 51]) or a PD-L1 antibody (atezolizumab [n = 4] or durvalumab [n = 12]) was compared to historic controls treated before availability of IO treatment (n = 413) using case-control analysis. IO patients and historic controls were individually matched for stage, performance state, histology, smoking status, gender, age, and initial treatment mode (palliative vs. definitive radio-chemotherapy). Results: Case-control analysis of 91 matched pairs showed significantly longer OS in IO patients compared to historic controls (21.2 vs. 10.9 months, HR 0.526, CI 0.373-0.723). The benefit was more pronounced in patients with lower tumor stage (HR 0.48 [stage III], 0.40 [IVA], 0.63 [IVB]) or smaller tumor size (HR 0.38 [RECIST <= 57 mm], 0.40 [RECIST 58-94 mm], 0.59 [RECIST 95-141 mm], 0.75 [RECIST >= 142 mm]). Conclusions: IO patients showed significant benefit in OS with HRs comparable to those reported in phase III trials. The benefit tended to be greater in patients with lower tumor mass. (C) 2019 S. Karger AG, Basel -PU - KARGER -PI - BASEL -PA - ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND -SN - 0030-2414 -SN - 1423-0232 -DA - 2019 -PY - 2019 -VL - 97 -IS - 4 -SP - 228 -EP - 235 -DO - 10.1159/000500885 -AN - WOS:000489742900007 -AD - Hosp Esslingen, Dept Cardiol & Pneumol, Hirschlandstr 97, DE-73730 Esslingen, Germany -AD - Outpatient Canc Treatment Clin Esslingen, Esslingen, Germany -M2 - Hosp Esslingen -M2 - Outpatient Canc Treatment Clin Esslingen -Y2 - 2019-10-24 -ER - - -TY - JOUR -AU - Yu, Chengqi -AU - Jiang, Leilei -AU - Yang, Dan -AU - Dong, Xin -AU - Yu, Rong -AU - Yu, Huiming -TI - Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment -T2 - ONCOTARGETS AND THERAPY -M3 - Article -AB - Purpose: As for local advanced non-small cell lung cancer (NSCLC), synchronous radiotherapy and chemotherapy is the standard treatment mode. But for patients with progress in half a year, which means the second-line chemotherapy effect is not ideal for them. We observed the efficacy and safety of anlotinib hydrochloride combined with PD-1 blockade as the second-line treatment for those patients in this trial.Patients and Methods: From January 2018 to December 2019, 57 patients with the progress of local advanced NSCLC treated with anlotinib plus PD-1 blockade until disease progression or intolerance as a result of adverse events. Patients have been assessed using computed tomography prior to treatment and during follow-up every 2 months until disease progression or death. The primary endpoint was objective response rate (ORR). The secondary endpoints included overall survival (OS), progression-free survival (PFS) and safety. Survival curves were created using the Kaplan-Meier method.Results: 57 patients were enrolled. The median age was 64 years, and 61.4% of the patients were men. The ORR was 50.9% with a median OS time of 14 months and the 1-year OS rates and PFS rates were 81.8% and 33.3%, respectively. The patients with squamous cell carcinoma, no brain or liver metastases had longer PFS than patients with liver metastasis. When the PFS was calculated from the time of second treatment, the median PFS was 9 months. Most adverse events (AEs) were grade 1-3, one drug -related death was noted.Conclusion: The expected outcome of this study is that anlotinib combined with PD-1 blockade has tolerable toxicity and better ORR, OS than second-line chemotherapy. The results may indicate additional treatment options for patients with progress of local advance NSCLC in half a year after standard treatment. -PU - DOVE MEDICAL PRESS LTD -PI - ALBANY -PA - PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND -SN - 1178-6930 -DA - 2022 -PY - 2022 -VL - 15 -SP - 1221 -EP - 1228 -DO - 10.2147/OTT.S380615 -AN - WOS:000871058700001 -AD - Capital Med Univ, Sch Basic Med Sci, Beijing 100069, Peoples R China -AD - Peking Univ, Canc Hosp & Inst, Dept Radiat Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China -AD - Peking Univ, Dept Radiat Oncol, Canc Hosp & Inst, 52 Fucheng Rd, Beijing 100142, Peoples R China -Y2 - 2022-10-29 -ER - - -TY - JOUR -AU - Zhou, Rui -AU - Qiu, Bo -AU - Xiong, Mai -AU - Liu, Yimei -AU - Peng, Kangqiang -AU - Luo, Yifeng -AU - Wang, Daquan -AU - Liu, Fangjie -AU - Chen, Naibin -AU - Guo, Jinyu -AU - Zhang, Jun -AU - Huang, Xiaoyan -AU - Rong, Yuming -AU - Liu, Hui -TI - Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049) -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Article -AB - Purpose: We launched a prospective phase 2 clinical trial to explore the safety and efficacy of hypofractionated radiation therapy (hypo-RT) followed by hypofractionated boost (hypo-boost) combined with concurrent weekly chemotherapy in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC).Methods and Materials: Patients with newly diagnosed LA-NSCLC with unresectable stage III disease were recruited between June 2018 and June 2020. Patients were treated with hypo-RT (40 Gy in 10 fractions) followed by hypo-boost (24-28 Gy in 6-7 fractions) combined with concurrent weekly chemotherapy (docetaxel 25 mg/m(2) and nedaplatin 25 mg/m(2)). The primary endpoint of the study was progression-free survival (PFS), and the secondary endpoints included overall survival (OS), locoregional failure-free survival (LRFS), distant metastasis-free survival (DMFS), objective response rate (ORR), and toxicities.Results: From June 2018 to June 2020, 75 patients were enrolled with a median follow-up duration of 28.0 months. The ORR of the whole cohort was 94.7%. Disease progression or death was recorded in 44 (58.7%) patients, with a median PFS of 21.6 months (95% confidence interval [CI], 15.6-27.6 months). The 1-and 2-year PFS rates were 81.3% (95% CI, 72.5%-90.1%) and 43.3% (95% CI, 31.5%-55.1%), respectively. The median OS, DMFS, and LRFS had not been reached at the time of the last follow-up. The 1-and 2-year OS rates were 94.7% (95% CI, 89.6%-99.8%) and 72.4% (95% CI, 62.0%-82.8%), respectively. The most frequent acute nonhematologic toxicity was radiation esophagitis. Grade (G) 2 and G3 acute radiation esophagitis were observed in 20 (26.7%) and 4 (5.3%) patients, respectively. Thirteen patients (13/75, 17.3%) had G2 pneumonitis and no G3-G5 acute pneumonitis occurred during follow-up.Conclusions: Hypo-RT followed by hypo-boost combined with concurrent weekly chemotherapy could yield satisfactory local control and survival outcomes with moderate radiation-induced toxicity in patients with LA-NSCLC. The new potent hypo-CCRT regimen significantly shortened treatment time and provided the potential opportunity for the combination of consolidative immunotherapy. (c) 2023 Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -SP - 387 -EP - 399 -DO - 10.1016/j.ijrobp.2023.04.021 -AN - WOS:001068285300001 -C6 - AUG 2023 -AD - Sun Yat Sen Univ, Canc Ctr, Dept Radiat Oncol, Guangzhou, Peoples R China -AD - State Key Lab Oncol South China, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ, Lung Canc Inst, Guangzhou, Peoples R China -AD - Guangdong Assoc Study Thorac Oncol, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ, Canc Ctr, Dept Med Imaging, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ, Canc Ctr, Dept VIP Reg, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ, Affiliated Hosp 1, Dept Cardiac Surg, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ, Affiliated Hosp 1, Pulm & Crit Care Med, Guangzhou, Peoples R China -M2 - Guangdong Assoc Study Thorac Oncol -Y2 - 2023-10-12 -ER - - -TY - JOUR -AU - Gao, Xuetian -AU - Peng, Ling -AU - Zhang, Li -AU - Huang, Kai -AU - Yi, Cuihua -AU - Li, Bei -AU - Meng, Xue -AU - Li, Jisheng -TI - Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer -T2 - JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY -M3 - Article -AB - Purpose As a novel antiangiogenic multi-target tyrosine kinase inhibitor recently approved in China, anlotinib has exhibited promising anticancer efficacy and acceptable safety profile in the salvage treatment of small cell lung cancer (SCLC) in clinical trials. Here we retrospectively investigated the efficacy and safety of anlotinib as third- or further-line treatment in patients with refractory SCLC. Patients and methods A total of 40 patients with refractory SCLC treated with anlotinib monotherapy were included in this study. The clinicopathological data, treatment information, survival data and safety data were retrospectively collected. Survival curves were constructed using the Kaplan-Meier method. Univariate analysis was performed by log-rank testing. Results Altogether, 40 patients of extensive-stage SCLC or progressive limited-stage SCLC received anlotinib monotherapy as third- or further-line treatment from July 2018 to June 2020. Four patients achieved partial response (PR), 14 patients achieved stable disease (SD), no complete response (CR) was recorded, and 22 patients experienced progressive disease (PD). The disease control rate (DCR) was 45.0%. The median progression-free survival (PFS) was 3.0 months (95% CI 2.241-3.759), and the median overall survival (OS) was 7.8 months (95% CI 3.190-12.410). The common adverse effects (AEs) included hypertension, fatigue, anorexia, cough, rash and nausea. Grade 3 treatment-related AEs occurred in 3 (7.5%) patients. One patient interrupted anlotinib treatment due to repeated grade 1 epistaxis. Univariate analysis revealed that patients without liver metastases, previously treated with radiotherapy or with Eastern Cooperative Oncology Group (ECOG) scores of 0 or 1 had longer OS with anlotinib treatment. Cox regression analysis demonstrated that patients without liver metastases and patients with ECOG score <= 1 had longer PFS, while patients without liver metastases had longer OS. Conclusion Anlotinib is beneficial to refractory SCLC as third- or further-line treatment, especially in patients without liver metastasis and with better physical status. Related adverse effects are tolerable and manageable. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 0171-5216 -SN - 1432-1335 -DA - 2022 OCT -PY - 2022 -VL - 148 -IS - 10 -SP - 2661 -EP - 2671 -DO - 10.1007/s00432-021-03848-4 -AN - WOS:000715635300001 -C6 - NOV 2021 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China -AD - Zhejiang Prov Peoples Hosp, Dept Resp Dis, Hangzhou 310000, Zhejiang, Peoples R China -AD - Yunyang Cty Peoples Hosp, Dept Oncol, Chongqing 404599, Peoples R China -AD - Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Med Oncol, Jinan 250012, Shandong, Peoples R China -M2 - Yunyang Cty Peoples Hosp -Y2 - 2021-11-13 -ER - - -TY - JOUR -AU - Guo, Jhe-Cyuan -AU - Huang, Ta-Chen -AU - Kuo, Hung-Yang -AU - Lin, Chia-Chi -AU - Hsu, Feng-Ming -AU - Cheng, Jason Chia-Hsien -AU - Huang, Yen-Lin -AU - Hsieh, Min-Shu -AU - Huang, Pei-Ming -AU - Lee, Jang-Ming -AU - Wu, Shu-Ling -AU - Hsu, Chih-Hung -TI - Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study -T2 - CANCER IMMUNOLOGY IMMUNOTHERAPY -M3 - Article -AB - BackgroundAdjuvant nivolumab reduces recurrence in patients with locoregional esophageal cancer who had pathological residual disease after neoadjuvant chemoradiotherapy and R0 resection. However, the efficacy of adjuvant anti-PD-1 therapy in patients at higher risk of recurrence remains unclear.MethodsThis phase II trial (ClinicalTrials.gov identifier: NCT03322267) enrolled patients with locally advanced esophageal squamous cell carcinoma (ESCC) received neoadjuvant chemoradiotherapy plus esophagectomy but still had various risk factors for recurrence, such as involved or close margins (<= 1 mm), extranodal extension of the involved lymph nodes, and the ypN2-3 stage. Patients received adjuvant therapy composed of a course of cisplatin-based chemoradiotherapy and pembrolizumab (200 mg, IV every 3 weeks) for 18 cycles. The primary endpoint was 1-year relapse-free survival (RFS) rate.ResultsTwenty-five patients were enrolled. The risk factors were tumor margins of <= 1 mm (18 patients), extranodal extension of the involved lymph nodes (9 patients), and the ypN2-3 stage (9 patients). The median follow-up duration was 21.6 months (95% CI: 18.7-33.2). The rate of 1-year RFS was 60.0%. The median duration of RFS and overall survival was 14.3 (95% CI: 9.0-19.5) and 21.6 (95% CI: 0.0-45.5) months, respectively. Treatment-emergent adverse events of any grade and those of >= 3 grade occurred in 56% and 8% of all patients receiving cisplatin-based chemoradiotherapy and in 79.2% and 12.5% of those receiving pembrolizumab.ConclusionsAdjuvant chemoradiotherapy followed by pembrolizumab is feasible and may be associated with improved 1-year RFS rate in patients at high risk of recurrence after trimodality therapy for locally advanced ESCC.Trial registration number ClinicalTrials.gov (No. NCT03322267).ConclusionsAdjuvant chemoradiotherapy followed by pembrolizumab is feasible and may be associated with improved 1-year RFS rate in patients at high risk of recurrence after trimodality therapy for locally advanced ESCC.Trial registration number ClinicalTrials.gov (No. NCT03322267). -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 0340-7004 -SN - 1432-0851 -DA - 2024 SEP 9 -PY - 2024 -VL - 73 -IS - 11 -C7 - 230 -DO - 10.1007/s00262-024-03826-y -AN - WOS:001309456600002 -AD - Natl Taiwan Univ, Dept Med Oncol, Canc Ctr, Taipei, Taiwan -AD - Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan -AD - Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan -AD - Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei, Taiwan -AD - Natl Taiwan Univ, Canc Ctr, Dept Pathol, Taipei, Taiwan -AD - Natl Taiwan Univ Hosp, Dept Pathol, Taipei, Taiwan -AD - Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan -Y2 - 2024-09-15 -ER - - -TY - JOUR -AU - Li, Dan -AU - Zou, Sijuan -AU - Chong, Siyuan -AU - Song, Shuang -AU - Wang, Pilin -AU - Zhu, Xiaohua -TI - Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging -T2 - MOLECULAR PHARMACEUTICS -M3 - Article -AB - Accumulating evidence has suggested that the tumor micro-environment of nonsmall-cell lung cancer (NSCLC) may be impacted by chemotherapy, radiotherapy, or epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). PD-L1 is an important biomarker in the tumor microenvironment that can predict patient response to immunotherapies. Therefore, it is highly desirable to achieve a real-time, noninvasive assessment of PD-L1 expression, which can provide critical information for recruiting patients as well as monitoring therapeutic efficacy. We herein studied the EGFR-TKI-induced effects on PD-L1 levels in NSCLC tumor models using immuno-PET imaging with Zr-89-Df-KN035, an imaging tracer previously established by our group. A549 human NSCLC xenografts were established in BALB/c nude mice and treated with different doses of an EGFR-TKI gefitinib. PET imaging with Zr-89-Df-KN035 was performed before and after the treatment to evaluate PD-L1 expression, which was further verified by immunohistochemical staining. Our results demonstrate that Zr-89-Df-KN035 can specifically evaluate PD-L1 levels in NSCLC tumor models. Compared to the untreated control, the high dose of gefitinib inhibited tumor growth and lowered the tumor uptake of Zr-89-Df-KN035. In comparison, the low dose of gefitinib did not affect tumor growth, although the extensive tumor necrosis also led to the lower uptake of Zr-89-Df-KN035. In conclusion, our results demonstrate that immuno-PET imaging with Zr-89-Df-KN035 is a promising tool to noninvasively monitor PD-L1 expression in NSCLC treated with EGFR-TKIs and can be used to optimize treatment plans for immunotherapy. -PU - AMER CHEMICAL SOC -PI - WASHINGTON -PA - 1155 16TH ST, NW, WASHINGTON, DC 20036 USA -SN - 1543-8384 -DA - 2019 AUG -PY - 2019 -VL - 16 -IS - 8 -SP - 3469 -EP - 3476 -DO - 10.1021/acs.molpharmaceut.9b00307 -AN - WOS:000480371700014 -AD - Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Nucl Med, Wuhan 430030, Hubei, Peoples R China -AD - Alphamab Co Ltd, Suzhou 215000, Peoples R China -M2 - Alphamab Co Ltd -Y2 - 2019-08-26 -ER - - -TY - JOUR -AU - O'Sullivan, Joe M. -AU - Abramowitz, Elliot -AU - Sierra-Scacalossi, Len -TI - Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary -T2 - FUTURE ONCOLOGY -M3 - Article -AB - What is this summary about?Few life-prolonging treatment options are available for patients with metastatic castration-resistant prostate cancer (mCRPC). This article provides an overview of the current systemic treatments available for mCRPC and reviews studies that investigate the optimal timing for the use of radium-223. The aim is to illustrate possible systemic treatment sequences to maximize benefit from radium-223 therapy.What is metastatic castration-resistant prostate cancer & how is it treated?Prostate cancer is called mCRPC when it spreads to organs outside of the prostate (such as the lymph nodes, bones, liver, or lungs) and no longer responds to hormonal therapy. There are several treatment options available for mCRPC, such as abiraterone, enzalutamide, radium-223, docetaxel, cabazitaxel, olaparib, rucaparib, sipuleucel-T, and 177Lu-PSMA. It is important to understand the risks and benefits associated with each treatment and whether current use may have an impact on future treatment options, including eligibility in certain clinical trials. Maintaining bone health is also an important part of prostate cancer care.What is radium-223?Radium-223 is a radioactive molecule that releases strong radiation within a very small range around itself. It mainly travels to the bone where the prostate cancer has spread and kills the cancer cells in that area. Results from a clinical study named ALSYMPCA showed that men who received radium-223 lived longer in addition to having less bone pain. The most common side effects of radium-223 are nausea, vomiting, and diarrhea. Radium-223 minimally suppresses the bone marrow, which means that it slightly reduces the levels of red and white blood cells. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1479-6694 -SN - 1744-8301 -DA - 2023 MAY -PY - 2023 -VL - 19 -IS - 15 -SP - 1021 -EP - 1028 -DO - 10.2217/fon-2022-1296 -AN - WOS:000956974400001 -C6 - MAR 2023 -AD - Queen Univ, Belfast, North Ireland -AD - Answer Canc Fdn, Hagerstown, MD USA -M2 - Queen Univ -M2 - Answer Canc Fdn -Y2 - 2023-04-12 -ER - - -TY - JOUR -AU - Takeda, Takayuki -AU - Yamada, Tadaaki -AU - Kunimatsu, Yusuke -AU - Tanimura, Keiko -AU - Morimoto, Kenji -AU - Shiotsu, Shinsuke -AU - Chihara, Yusuke -AU - Okada, Asuka -AU - Horiuchi, Shigeto -AU - Hibino, Makoto -AU - Uryu, Kiyoaki -AU - Honda, Ryoichi -AU - Yamanaka, Yuta -AU - Yoshioka, Hiroshige -AU - Kurata, Takayasu -AU - Takayama, Koichi -TI - Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study -T2 - CANCERS -M3 - Article -AB - Simple Summary Chemoimmunotherapy improved overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC) in two phase III trials, which set the age-stratified subgroup analyses at 65 years. Considering the super-aged society of Japan, treatment efficacy and safety in elderly patients >= 75 years with ES-SCLC should be validated through real-world Japanese evidence. Consecutive 225 Japanese patients with SCLC were evaluated, and 155 received chemoimmunotherapy (98 non-elderly and 57 elderly patients). The dose reduction at initiating the first cycle was significantly higher in the elderly (47.4%) than in the non-elderly (20.4%) patients (p = 0.03). The median PFS and OS in the non-elderly and the elderly were 5.1 and 14.1 months and 5.5 and 12.0 months, respectively, without significant differences. Multivariate analyses revealed that age, the baseline Eastern Cooperative Oncology Group performance status, and dose reduction at initiating the first chemoimmunotherapy cycle were not correlated with PFS or OS. Chemoimmunotherapy improved overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC) in two phase III trials. They set the age-stratified subgroup analyses at 65 years; however, over half of the patients with lung cancer were newly diagnosed at >= 75 years in Japan. Therefore, treatment efficacy and safety in elderly patients >= 75 years with ES-SCLC should be evaluated through real-world Japanese evidence. Consecutive Japanese patients with untreated ES-SCLC or limited-stage SCLC unfit for chemoradiotherapy between 5 August 2019 and 28 February 2022 were evaluated. Patients treated with chemoimmunotherapy were divided into the non-elderly (<75 years) and elderly (>= 75 years) groups, and efficacy, including PFS, OS, and post-progression survival (PPS) were evaluated. In total, 225 patients were treated with first-line therapy, and 155 received chemoimmunotherapy (98 non-elderly and 57 elderly patients). The median PFS and OS in non-elderly and elderly were 5.1 and 14.1 months and 5.5 and 12.0 months, respectively, without significant differences. Multivariate analyses revealed that age and dose reduction at the initiation of the first chemoimmunotherapy cycle were not correlated with PFS or OS. In addition, patients with an Eastern Cooperative Oncology Group performance status (ECOG-PS) = 0 who underwent second-line therapy had significantly longer PPS than those with ECOG-PS = 1 at second-line therapy initiation (p < 0.001). First-line chemoimmunotherapy had similar efficacy in elderly and non-elderly patients. Individual ECOG-PS maintenance during first-line chemoimmunotherapy is crucial for improving the PPS of patients proceeding to second-line therapy. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2023 MAR -PY - 2023 -VL - 15 -IS - 5 -C7 - 1543 -DO - 10.3390/cancers15051543 -AN - WOS:000946869100001 -AD - Japanese Red Cross Kyoto Daini Hosp, Dept Resp Med, Kyoto 6028026, Japan -AD - Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto 6028566, Japan -AD - Japanese Red Cross Kyoto Daiichi Hosp, Dept Resp Med, Kyoto 6050981, Japan -AD - Uji Tokushukai Med Ctr, Dept Resp Med, Kyoto 6110041, Japan -AD - Saiseikai Suita Hosp, Dept Resp Med, Osaka 5640013, Japan -AD - Shonan Fujisawa Tokushukai Hosp, Dept Resp Med, Fujisawa, Kanagawa 2510041, Japan -AD - Yao Tokushukai Gen Hosp, Dept Resp Med, Osaka 5810011, Japan -AD - Asahi Gen Hosp, Dept Resp Med, Chiba 2892511, Japan -AD - Kansai Med Univ Hosp, Dept Thorac Oncol, Osaka 5731191, Japan -M2 - Japanese Red Cross Kyoto Daini Hosp -M2 - Japanese Red Cross Kyoto Daiichi Hosp -M2 - Uji Tokushukai Med Ctr -M2 - Saiseikai Suita Hosp -M2 - Shonan Fujisawa Tokushukai Hosp -M2 - Yao Tokushukai Gen Hosp -M2 - Asahi Gen Hosp -Y2 - 2023-03-30 -ER - - -TY - JOUR -AU - Bryant, Alex K. -AU - Sankar, Kamya -AU - Zhao, Lili -AU - Strohbehn, Garth W. -AU - Elliott, David -AU - Moghanaki, Drew -AU - Kelley, Michael J. -AU - Ramnath, Nithya -AU - Green, Michael D. -TI - De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer -T2 - EUROPEAN JOURNAL OF CANCER -M3 - Article -AB - Background: One year of adjuvant durvalumab following concurrent chemoradiotherapy significantly improves progression-free survival (PFS) and overall survival (OS) for patients with stage III non-small cell lung cancer (NSCLC). However, the optimal length of adjuvant therapy has not been determined.Methods: We identified patients with stage III NSCLC treated with definitive chemoradiation and adjuvant durvalumab from November 2017 to April 2021 from the United States Veterans Affairs system. Predictors of early durvalumab discontinuation were evaluated with Cox proportional hazards regression. The effect of differing durations of durvalumab treatment (up to 6, 9, and 12 months) on PFS and OS were compared with a marginal structural model and time-dependent Cox modelling.Results: We included 1006 patients with stage III non-small cell lung cancer who received concurrent chemoradiotherapy and at least one dose of adjuvant durvalumab. The median duration of durvalumab treatment was 7 months (interquartile range 2.8-11.5) and 31% completed the intended durvalumab course. The most common reasons for early discontinuation were tumour progression (22%), immune-related adverse events (15%), and non-immune-related toxicity (6.0%), Marginal structural models suggested similar PFS for 9 months versus 12 months of durvalumab treatment and inferior PFS for 6 months versus 12 months.Conclusions: A substantial proportion of patients undergoing adjuvant durvalumab discontinue therapy early due to toxicity, and shorter durvalumab treatment durations may provide similar disease control to 12 months of therapy. Prospective randomised controlled studies are needed to characterise the optimal durvalumab treatment duration in locally advanced NSCLC patients. (C) 2022 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCI LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND -SN - 0959-8049 -SN - 1879-0852 -DA - 2022 AUG -PY - 2022 -VL - 171 -SP - 55 -EP - 63 -DO - 10.1016/j.ejca.2022.04.033 -AN - WOS:000877532100008 -C6 - JUN 2022 -AD - Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA -AD - Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA -AD - Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA -AD - Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA -AD - Vet Affairs Ann Arbor Healthcare Syst, Sect Hematol Oncol, Ann Arbor, MI USA -AD - Vet Affairs Ann Arbor Healthcare Syst, Dept Radiat Oncol, Ann Arbor, MI USA -AD - VA Greater Los Angeles, Dept Radiat Oncol, Los Angeles, CA USA -AD - UCLA Jonsson Canc Ctr, Los Angeles, CA USA -AD - Duke Univ, Dept Med, Div Hematol Oncol, Durham, NC USA -AD - VA Med Ctr Durham, Durham, NC USA -AD - Vet Affairs Ann Arbor, VA Ctr Clin Management Res, Ann Arbor, MI USA -M2 - VA Med Ctr Durham -Y2 - 2022-11-18 -ER - - -TY - JOUR -AU - Jiang, Xiaotong -AU - Chen, Jinyu -AU - Zheng, Min -AU - Jia, Hanxue -TI - Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage III nsclc in china -T2 - PLOS ONE -M3 - Article -AB - ObjectiveThe aim of this study was to evaluate the cost-effectiveness of durvalumab compared with Best supportive care (BSC) after chemoradiotherapy in patients with stage III non-small cell lung cancer from healthcare system perspective in China.MethodsA dynamic state transition model was adopted to simulate life time, direct medical costs and QALYs. In the base case scenario, for patients with unresectable, stage III non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiation therapy, the treatment group would use durvalumab whereas the control group would use BSC. Clinical data and health utility were derived from the patient-level data of Asian ethnicity in the PACIFIC trial. Cost of drug acquisition, follow-up, medical service, inspection, terminal care and adverse event treatment were considered in this model. The cost of durvalumab was calculated based on retail prices and Patient Assistance Program.ResultsIn the base case, the durvalumab group yielded an additional 2.60 LYs and 2.37QALYs (discounted), causing an additional cost of 0.459 million RMB and 0.109 million RMB without and with PAP, so the ICER was 193,898 RMB/QALY and 46,093.12 RMB/QALY respectively.ConclusionsThis study demonstrated that durvalumab can improve the survival of patients with unresectable, stage III non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiation therapy and would be a cost-effective option compared with BSC at a willingness to pay (WTP) threshold of 212676 RMB (three times GDP per capita of China in 2019). -PU - PUBLIC LIBRARY SCIENCE -PI - SAN FRANCISCO -PA - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA -SN - 1932-6203 -DA - 2022 JUN 30 -PY - 2022 -VL - 17 -IS - 6 -C7 - e0270118 -DO - 10.1371/journal.pone.0270118 -AN - WOS:000892027900053 -AD - Chinese Acad Med Sci, Inst Med Informat, Beijing, Peoples R China -AD - China Hlth Econ Assoc, Beijing, Peoples R China -AD - Natl Ctr Med & Hlth Technol Assessment, Beijing, Peoples R China -AD - Shenyang Pharmaceut Univ, Shenyang, Peoples R China -M2 - China Hlth Econ Assoc -M2 - Natl Ctr Med & Hlth Technol Assessment -Y2 - 2022-06-30 -ER - - -TY - JOUR -AU - Riudavets, Mariona -AU - Auclin, Edouard -AU - Mosteiro, Miguel -AU - Dempsey, Naomi -AU - Majem, Margarita -AU - Prelaj, Arsela -AU - Lopez-Castro, Rafael -AU - Bosch-Barrera, Joaquim -AU - Pilotto, Sara -AU - Escalera, Elena -AU - Tagliamento, Marco -AU - Mosquera, Joaquin -AU - Zalcman, Gerard -AU - Nana, Frank Aboubakar -AU - Ponce, Santiago -AU - Albarran-Artahona, Victor -AU - Dal Maso, Alessandro -AU - Spotti, Martina -AU - Mielgo, Xabier -AU - Mussat, Elodie -AU - Reyes, Roxana -AU - Benitez, Jose -Carlos -AU - Lupinacci, Lorena -AU - Duchemann, Boris -AU - De Giglio, Andrea -AU - Blaquier, Juan Bautista -AU - Audigier-Valette, Clarisse -AU - Scheffler, Matthias -AU - Nadal, Ernest -AU - Lopes, Gilberto -AU - Signorelli, Diego -AU - Garcia-Campelo, Rosario -AU - Menis, Jessica -AU - Bluthgen, Virginia -AU - Campayo, Marc -AU - Recondo, Gonzalo -AU - Besse, Benjamin -AU - Mezquita, Laura -AU - Planchard, David -TI - Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - Chemotherapy and radiotherapy followed by immunotherapy is standard treatment in unresectable stage III non -small cell lung cancer. LIPI score may improve the prediction of outcomes with treatment. We performed a retrospective study with 330 patients assessing this. We found a correlation between LIPI score and survival, providing evidence of its role as prognostic and predictive tool in these patients. Introduction: The LIPI, based on pretreatment derived neutrophils/[leukocytes-neutrophils] ratio (dNLR) and LDH, is associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-small-cell lung cancer (NSCLC). We aimed to assess baseline LIPI correlation with durvalumab consolidation outcomes in the locally advanced setting. Material and Methods: Multicentre retrospective study (330 patients) with stage III unresectable NSCLC treated with durvalumab after chemo-radiotherapy between April 2015 and December 2020; 65 patients treated with chemo-radiotherapy only. Baseline LIPI characterized 3 groups: good (dNLR <3 + LDH 3/LDH > ULN) and poor (dNLR > 3 + LDH > ULN). Primary endpoint was overall survival (OS). Results: In the durvalumab cohort, median age was 67 years, 95% smokers, 98% with a performance status of 0-1; 60% had nonsquamous histology and 16% a PD -L1 expression < 1%. Radiotherapy was delivered concurrently in 81%. LIPI was evaluable in 216 patients: 66% good, 31% intermediate, 3% poor. LIPI significantly correlated with median OS (median followup: 19 months): 18.1 months vs. 47.0 months vs. not reached in poor, intermediate and good LIPI groups, respectively ( P = .03). A trend between objective response rate and LIPI groups was observed: 0% vs. 41% vs. 45%, respectively ( P = .05). The pooled intermediate/poor LIPI group was associated with shorter OS (HR 1.97; P = .03) and higher risk of progressive disease (OR 2.68; P = .047). Survivals and response were not influenced in the control cohort. Conclusion: Baseline LIPI correlated with outcomes in patients with locally advanced NSCLC treated with durvalumab consolidation, but not in those who only received chemo-radiotherapy, providing further evidence of its prognostic and potential predictive role of ICI benefit in NSCLC. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2024 MAY -PY - 2024 -VL - 25 -IS - 3 -DO - 10.1016/j.cllc.2023.11.007 -AN - WOS:001248366200001 -C6 - MAY 2024 -AD - Gustave Roussy Canc campus, Med Oncol Dept, Villejuif, France -AD - Univ Paris Cite, Hop Europeen Georges Pompidou, AP HP Ctr, Med Oncol Dept, Paris, France -AD - ICO Hosp, Med Oncol Dept, Inst Catala Oncol, Barcelona, Spain -AD - Jackson Mem Hosp, Med Oncol Dept, Miami, FL USA -AD - Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain -AD - Fdn IRCCS Ist Nazl Tumori Milan, Med Oncol Dept, Milan, Italy -AD - Hosp Clin Univ Valladolid, Med Oncol Dept, Valladolid, Spain -AD - Hosp Univ Josep Trueta, Catalan Inst Oncol, Med Oncol Dept, Girona, Spain -AD - Univ & Hosp Trust Verona, Med Oncol Dept, Verona, Italy -AD - Hosp Clin Salamanca, Med Oncol Dept, Salamanca, Spain -AD - Univ Genoa, Internal Med & Med Specialties Dept, Genoa, Italy -AD - Hosp Univ A Coruna, Med Oncol Dept, La Coruna, Spain -AD - Univ Paris Cite, Hop Bichat Claude Bernard, Thorac Oncol Dept, CIC Inserm 1425, Paris, France -AD - Clin Univ St Luc, Div Pneumol, Brussels, Belgium -AD - Hosp 12 Octubre, Med Oncol Dept, Madrid, Spain -AD - Univ Barcelona, Hosp Clin, Lab Translat Genom & Targeted Therapies Solid Tumo, Med Oncol Dept,Dept Med,IDIBAPS, Carrer De Villarroel 170, Barcelona 08036, Spain -AD - Ist Oncol Veneto IRCCS, Med Oncol Dept, Padua, Italy -AD - Hosp Aleman, Med Oncol Dept, Buenos Aires, Argentina -AD - Hosp Univ Fdn Alcorcon, Med Oncol Dept, Madrid, Spain -AD - Hosp Univ Mutua Terrassa, Med Oncol Dept, Terrassa, Barcelona, Spain -AD - Hosp Italiano Buenos Aires, Med Oncol Dept, Buenos Aires, Argentina -AD - Hop Avicenne, Med Oncol Dept, Bobigny, France -AD - IRCCS Azienda Osped Univ Bologna, Med Oncol Dept, Bologna, Italy -AD - Ctr Educ Med & Invest Clin CEMIC, Med Oncol Dept, Buenos Aires, Argentina -AD - Ctr Hosp Toulon Sainte Mousse, Med Oncol Dept, Toulon, France -AD - Univ Cologne, Fac Med, Internal Med Dept 1, Cologne, Germany -AD - Univ Cologne, Univ Hosp Cologne, Cologne, Germany -AD - Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy -M2 - Jackson Mem Hosp -M2 - Hosp Clin Univ Valladolid -M2 - Hosp Clin Salamanca -M2 - Ctr Hosp Toulon Sainte Mousse -M2 - Grande Osped Metropolitano Niguarda -Y2 - 2024-06-29 -ER - - -TY - JOUR -AU - Keung, Emily Z. -AU - Lazar, Alexander J. -AU - Torres, Keila E. -AU - Wang, Wei-Lien -AU - Cormier, Janice N. -AU - Guadagnolo, B. Ashleigh -AU - Bishop, Andrew J. -AU - Lin, Heather -AU - Hunt, Kelly K. -AU - Bird, Justin -AU - Lewis, Valerae O. -AU - Patel, Shreyaskumar R. -AU - Wargo, Jennifer A. -AU - Somaiah, Neeta -AU - Roland, Christina L. -TI - Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma -T2 - BMC CANCER -M3 - Article -AB - Background: Soft tissue sarcomas are a heterogeneous and rare group of solid tumors of mesenchymal origin that can arise anywhere in the body. Although surgical resection is the mainstay of treatment for patients with localized disease, disease recurrence is common and 5-year overall survival is poor (similar to 65%). Both radiation therapy and conventional chemotherapy are used to reduce local and distant recurrence. However, the utility of radiation therapy is often limited by disease location (in the case of retroperitoneal sarcomas, for instance) while systemic therapy with conventional lines of chemotherapy offer limited efficacy and are often poorly tolerated and associated with significant toxicity. Within the past decade, major advances have been made in the treatment of other malignancies including melanoma, renal cell carcinoma, and non-small cell lung carcinoma with the advent of immune-checkpoint inhibitors such as ipilimumab (anti-CTLA4), pembrolizumab (anti-PD1), and nivolumab (anti-PD1). The recently published SARC028 (NCT02301039), an open label, phase II, multicenter trial of pembrolizumab in patients with advanced bone and soft tissue sarcomas reported promising activity in select histologic subtypes of advanced STS, including undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.Methods: There is a clear need for novel and effective adjuncts in the treatment of STS. We hypothesize that immune checkpoint blockade will be effective in patients with surgically resectable primary or locally recurrent dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma when administered in the neoadjuvant setting. The primary aim of this phase II, single-center, open label, randomized non-comparative trial is to determine the pathologic response to neoadjuvant nivolumab monotherapy and combination nivolumab/ipilimumab in patients with resectable dedifferentiated liposarcoma of the retroperitoneum or undifferentiated pleomorphic sarcoma of the trunk or extremity treated with concurrent standard of care neoadjuvant radiation therapy.Discussion: This study will help define the role of single agent anti-PD1 and combination anti-CTLA4 and anti-PD1 therapy in patients with surgically resectable dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2018 SEP 24 -PY - 2018 -VL - 18 -C7 - 913 -DO - 10.1186/s12885-018-4829-0 -AN - WOS:000445491600001 -AD - Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1400 Pressler St,FCT17-6054,Unit 1484, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Orthopaed Oncol, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA -Y2 - 2018-09-24 -ER - - -TY - JOUR -AU - Girard, Nicolas -AU - Bar, Jair -AU - Garrido, Pilar -AU - Garassino, Marina C. -AU - McDonald, Fiona -AU - Mornex, Francoise -AU - Filippi, Andrea R. -AU - Smit, Hans J. M. -AU - Peters, Solange -AU - Field, John K. -AU - Christoph, Daniel C. -AU - Sibille, Anne -AU - Fietkau, Rainer -AU - Haakensen, Vilde D. -AU - Chouaid, Christos -AU - Markman, Ben -AU - Hiltermann, T. Jeroen N. -AU - Taus, Alvaro -AU - Sawyer, William -AU - Allen, Allison -AU - Chander, Pratibha -AU - Licour, Muriel -AU - Solomon, Benjamin -TI - Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study -T2 - JOURNAL OF THORACIC ONCOLOGY -M3 - Article -AB - Introduction: The phase 3 PACIFIC trial established consoli-dation therapy with durvalumab as standard of care for patients with unresectable, stage III NSCLC and no disease progression after definitive chemoradiotherapy (CRT). The observational PACIFIC-R study assesses the real-world effectiveness of dur-valumab in patients from an early access program. Here, we report treatment characteristics and a preplanned analysis of real-world progression-free survival (rwPFS).Methods: PACIFIC-R (NCT03798535) is an ongoing, inter-national, retrospective study of patients who started dur-valumab (intravenously; 10 mg/kg every 2 wk) within an early access program between September 2017 and December 2018. The primary end points are investigator -assessed rwPFS and overall survival (analyzed by Kaplan- Meier method).Results: As of November 30, 2020, the full analysis set comprised 1399 patients from 11 countries (median follow-up duration, 23.5 mo). Patients received durvalumab for a median of 11.0 months. Median rwPFS was 21.7 months (95% confidence interval: 19.1-24.5). RwPFS was numeri-cally longer among patients who received concurrent versus sequential CRT (median, 23.7 versus 19.3 mo) and among patients with programmed cell death-ligand 1 expression greater than or equal to 1% versus less than 1% (22.4 versus 15.6 mo). Overall, 16.5% of the patients had adverse events leading to treatment discontinuation; 9.5% of all patients discontinued because of pneumonitis or interstitial lung disease.Conclusions: Consolidation durvalumab after definitive CRT was well tolerated and effective in this large, real -world cohort study of patients with unresectable, stage III NSCLC. As expected, rwPFS was longer among patients who received concurrent versus sequential CRT and patients with higher programmed cell death-ligand 1 expression. Nevertheless, favorable rwPFS outcomes were observed regardless of these factors.(c) 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/). -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1556-0864 -SN - 1556-1380 -DA - 2023 FEB -PY - 2023 -VL - 18 -IS - 2 -SP - 181 -EP - 193 -DO - 10.1016/j.jtho.2022.10.003 -AN - WOS:000926003800001 -C6 - JAN 2023 -AD - Inst Curie, Inst Thorax Curie Montsouris, Paris, France -AD - UVSQ, Versailles, France -AD - Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel -AD - Tel Aviv Univ, Fac Med, Tel Aviv, Israel -AD - Univ Alcala, Hosp Ramon & Cajal, Med Oncol Dept, Madrid, Spain -AD - Univ Chicago, Dept Hematol Oncol, Chicago, IL USA -AD - Royal Marsden NHS Fdn Trust, Lung Unit, London, England -AD - Ctr Hosp Univ Lyon, Dept Radiat Oncol, Lyon, France -AD - Fdn Ist Ricovero & Cura Carattere Sci Policlin San, Radiat Oncol Dept, Pavia, Italy -AD - Univ Pavia, Pavia, Italy -AD - Rijnstate Hosp, Dept Pulm Dis, Arnhem, MD, Netherlands -AD - CHU Vaudois, Dept Oncol, Lausanne, Switzerland -AD - Univ Liverpool, Dept Mol & Clin Canc Med, Roy Castle Lung Canc Res Programme, Liverpool, Vic, England -AD - Evang Huyssens Stiftung Essen Huttrop, Evang Kliniken Essen Mitte, Dept Med Oncol Hematol, Essen, Vic, Germany -AD - Ctr Hosp Univ Liege, Dept Pneumol & Allergol, Liege, Belgium -AD - Univ klinikums Erlangen, Dept Radiat Oncol, Erlangen, Germany -AD - Oslo Univ Hosp, Dept Oncol, Oslo, Norway -AD - Oslo Univ Hosp, Inst Canc Res, Oslo, Norway -AD - Ctr Hosp Intercommunal Creteil, Serv Pneumol, Creteil, France -AD - Cabrini Hosp, Melbourne, Vic, Australia -AD - Monash Univ, Melbourne, Vic, Australia -AD - Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, Groningen, Netherlands -AD - Hosp del Mar CIBERONC, Dept Med Oncol, Barcelona, Spain -M2 - Fdn Ist Ricovero & Cura Carattere Sci Policlin San -M2 - Evang Huyssens Stiftung Essen Huttrop -M2 - Hosp del Mar CIBERONC -Y2 - 2023-02-26 -ER - - -TY - JOUR -AU - Somasundaram, Ashwin -AU - Burns, Timothy F. -TI - The next generation of immunotherapy: keeping lung cancer in check -T2 - JOURNAL OF HEMATOLOGY & ONCOLOGY -M3 - Review -AB - Lung cancer is the deadliest malignancy with more cancer deaths per year than the next three cancers combined. Despite remarkable advances in targeted therapy, advanced lung cancer patients have not experienced a significant improvement in mortality. Lung cancer has been shown to be immunogenic and responsive to checkpoint blockade therapy. Checkpoint signals such as CTLA-4 and PD-1/PD-L1 dampen T cell activation and allow tumors to escape the adaptive immune response. Response rates in patients with pretreated, advanced NSCLC were much higher and more durable with PD-1 blockade therapy compared to standard-of-care, cytotoxic chemotherapy. Therefore, PD-1 inhibitors such as nivolumab and pembrolizumab were rapidly approved for both squamous and nonsquamous lung cancer in the pretreated population. The advent of these new therapies have revolutionized the treatment of lung cancer; however, the majority of NSCLC patients still do not respond to PD-1/PD-L1 inhibition leaving an unmet need for a large and growing population.Immunotherapy combinations with chemotherapy, radiation therapy, or novel immunomodulatory agents are currently being examined with the hope of achieving higher response rates and improving overall survival rate. Chemotherapy and radiation therapy has been theorized to increase the release of tumor antigen leading to increased responses with immunotherapy. However, cytotoxic chemotherapy and radiation therapy may also destroy actively proliferating T cells. The correct combination and order of therapy is under investigation. The majority of patients who do respond to immunotherapy have a durable response attributed to the effect of adaptive immune system's memory. Unfortunately, some patients' tumors do progress afterward and investigation of checkpoint blockade resistance is still nascent.This review will summarize the latest efficacy and safety data for early and advanced NSCLC in both the treatment-naive and pretreated settings. The emerging role of immunotherapy for the treatment of small cell lung cancer and malignant mesothelioma will also be discussed. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1756-8722 -DA - 2017 APR 24 -PY - 2017 -VL - 10 -C7 - 87 -DO - 10.1186/s13045-017-0456-5 -AN - WOS:000399956600002 -AD - Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA -AD - Univ Pittsburgh, Div Hematol Oncol, Dept Med, Hillman Canc Ctr, Res Pavil,5117 Ctr Ave, Pittsburgh, PA 15213 USA -Y2 - 2017-04-24 -ER - - -TY - JOUR -AU - Deeks, Emma D. -TI - Pembrolizumab: A Review in Advanced Melanoma -T2 - DRUGS -M3 - Review -AB - Pembrolizumab (Keytruda (R)) is a humanized monoclonal antibody against programmed death receptor-1 (PD-1), a key immunoinhibitory checkpoint protein implicated in down-regulating anti-tumour immune responses. This intravenous drug is indicated for the treatment of advanced (unresectable or metastatic) melanoma, on the basis of its clinical benefit in this setting in the phase I KEYNOTE 001 trial (expansion cohorts) and the phase II and III trials, KEYNOTE 002 and 006. These studies were conducted in ipilimumab-naive and/or ipilimumab-experienced patients and assessed varying pembrolizumab regimens administered every 2 or 3 weeks, all of which helped to determine the recommended dosage of 2 mg/kg every 3 weeks. In the trials with active comparator arms, pembrolizumab regimens significantly improved progression-free survival (PFS), overall survival (OS) and overall response rates (ORR) relative to ipilimumab in ipilimumab-naive patients (KEYNOTE 006), and significantly improved PFS and ORR, but not OS (although OS data are immature), relative to chemotherapy in ipilimumab-refractory patients, who had also received BRAF/MEK inhibitor therapy if BRAF-mutation positive (KEYNOTE 002). Pembrolizumab has an acceptable tolerability profile, with immune-related adverse events that are generally manageable/reversible. Thus, pembrolizumab is a valuable treatment option for patients with advanced melanoma, including those who have progressed on ipilimumab and BRAF/MEK inhibitors. -PU - ADIS INT LTD -PI - NORTHCOTE -PA - 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND -SN - 0012-6667 -SN - 1179-1950 -DA - 2016 MAR -PY - 2016 -VL - 76 -IS - 3 -SP - 375 -EP - 386 -DO - 10.1007/s40265-016-0543-x -AN - WOS:000372531800007 -AD - Springer, Private Bag 65901, Auckland 0754, New Zealand -Y2 - 2016-04-13 -ER - - -TY - JOUR -AU - Filippi, A. R. -AU - Bar, J. -AU - Chouaid, C. -AU - Christoph, D. C. -AU - Field, J. K. -AU - Fietkau, R. -AU - Garassino, M. C. -AU - Garrido, P. -AU - Haakensen, V. D. -AU - Kao, S. -AU - Markman, B. -AU - Mcdonald, F. -AU - Mornex, F. -AU - Moskovitz, M. -AU - Peters, S. -AU - Sibille, A. -AU - Siva, S. -AU - Heuvel, M. van den -AU - Vercauter, P. -AU - Anand, S. -AU - Chander, P. -AU - Licour, M. -AU - Lima, A. R. de -AU - Qiao, Y. -AU - Girard, N. -TI - Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R -T2 - ESMO OPEN -M3 - Article -AB - Background: Based on the findings of the PACIFIC trial, consolidation durvalumab following platinum-based chemoradiotherapy (CRT) is a global standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC). An earlier analysis from the ongoing PACIFIC-R study (NCT03798535) demonstrated the effectiveness of this regimen in terms of progression-free survival (PFS). Here, we report the first planned overall survival (OS) analysis.Patients and methods: PACIFIC-R is an observational/non-interventional, retrospective study of patients with unresectable, stage III NSCLC who started durvalumab (10 mg/kg intravenously every 2 weeks) within an AstraZeneca-initiated early access program between September 2017 and December 2018. Primary endpoints are OS and investigator-assessed PFS, estimated using the Kaplan-Meier method.Results: By 30 November 2021, the full analysis set included 1154 participants from 10 countries (median follow-up in censored patients: 38.7 months). Median OS was not reached, and the 3-year OS rate was 63.2% (95% confidence interval 60.3% to 65.9%). Three-year OS rates were numerically higher among patients with programmed death-ligand 1 (PD-L1) expression on >= 1% versus <1% of tumor cells (TCs; 67.0% versus 54.4%) and patients who received concurrent CRT (cCRT) versus sequential CRT (sCRT) (64.8% versus 57.9%).Conclusions: PACIFIC-R data continue to provide evidence for the effectiveness of consolidation durvalumab after CRT in a large, diverse, real-world population. Better outcomes were observed among patients with PD-L1 TCs >= 1% and patients who received cCRT. Nevertheless, encouraging outcomes were still observed among patients with TCs <1% and patients who received sCRT, supporting use of consolidation durvalumab in a broad population of patients with unresectable, stage III NSCLC. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 2059-7029 -DA - 2024 JUN -PY - 2024 -VL - 9 -IS - 6 -C7 - 103464 -DO - 10.1016/j.esmoop.2024.103464 -AN - WOS:001251670400001 -AD - Fdn Ist Ricovero & Cura Carattere Sci Policlin San, Radiat Oncol Dept, Pavia, Italy -AD - Univ Pavia, Pavia, Italy -AD - Inst Oncol, Sheba Med Ctr, Ramat Gan, Israel -AD - Tel Aviv Univ, Fac Med, Tel Aviv, Israel -AD - Ctr Hosp Intercommunal Creteil, Serv Pneumol, Creteil, France -AD - Evang Huyssens Stiftung Essen Huttrop, Dept Med Oncol, Evang Kliniken Essen Mitte, Essen, Germany -AD - Univ Liverpool, Dept Mol & Clin Canc Med, Roy Castle Lung Canc Res Programme, Liverpool, England -AD - Univ Klinikum Erlangen, Dept Radiat Oncol, Erlangen, Germany -AD - Univ Chicago, Dept Hematol Oncol, Chicago, IL USA -AD - Univ Alcala, Hosp Ramon & Cajal, Med Oncol Dept, Madrid, Spain -AD - Oslo Univ Hosp, Dept Oncol, Oslo, Norway -AD - Oslo Univ Hosp, Inst Canc Res, Oslo, Norway -AD - Chris OBrien Lifehouse, Sydney, Australia -AD - Cabrini Hosp, Melbourne, Australia -AD - Monash Univ, Melbourne, Australia -AD - Royal Marsden NHS Fdn Trust, Lung Unit, London, England -AD - Ctr Hosp Univ Lyon, Dept Radiat Oncol, Lyon, France -AD - Rambam Hlth Care Campus, H_efa, Israel -AD - CHU Vaudois, Dept Oncol, Lausanne, Switzerland -AD - Ctr Hosp Univ Liege, Dept Pneumol, Liege, Belgium -AD - Peter MacCallum Canc Ctr, Melbourne, Australia -AD - Univ Melbourne, Melbourne, Australia -AD - Radboud Univ Nijmegen Med Ctr, Dept Pulm Dis, Nijmegen, Netherlands -AD - OLV Hosp Aalst, Dept Pneumol, Aalst, Belgium -AD - AstraZeneca, Gaithersburg, MD USA -AD - AstraZeneca, Courbevoie, France -AD - Inst Curie, Inst Thorax Curie Montsouris, Paris, France -AD - UVSQ, Paris Saclay, Versailles, France -AD - Ist Nazl Tumori, ViaVenezian 1, I-20133 Milan, Italy -M2 - Fdn Ist Ricovero & Cura Carattere Sci Policlin San -M2 - Evang Huyssens Stiftung Essen Huttrop -M2 - OLV Hosp Aalst -Y2 - 2024-07-02 -ER - - -TY - JOUR -AU - Bansal, Dhruv -AU - Reimers, Melissa A. -AU - Knoche, Eric M. -AU - Pachynski, Russell K. -TI - Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer -T2 - CANCERS -M3 - Review -AB - Simple SummaryImmunotherapy has changed the treatment paradigm of numerous malignancies such as non-small cell lung cancer and melanoma. To date, there has been only modest demonstrable efficacy of immunotherapy for prostate cancer. This lack of efficacy is likely due to the immunosuppressive tumor microenvironment. When we consider the fact that metastatic castrate-resistant state is the most lethal form of prostate cancer, there is an unmet need to increase the efficacy of immune therapies for this disease. The treatment paradigm has now shifted towards combinatorial regimens to enhance the anti-tumor immune response. These combinations with immunomodulatory agents in ongoing clinical trials include conventional agents such as chemotherapy and numerous novel agents. This review summarizes the clinical trials recruiting patients with metastatic castrate-resistant prostate cancer utilizing immunotherapeutic approaches.Although most prostate cancers are localized, and the majority are curable, recurrences occur in approximately 35% of men. Among patients with prostate-specific antigen (PSA) recurrence and PSA doubling time (PSADT) less than 15 months after radical prostatectomy, prostate cancer accounted for approximately 90% of the deaths by 15 years after recurrence. An immunosuppressive tumor microenvironment (TME) and impaired cellular immunity are likely largely responsible for the limited utility of checkpoint inhibitors (CPIs) in advanced prostate cancer compared with other tumor types. Thus, for immunologically "cold" malignancies such as prostate cancer, clinical trial development has pivoted towards novel approaches to enhance immune responses. Numerous clinical trials are currently evaluating combination immunomodulatory strategies incorporating vaccine-based therapies, checkpoint inhibitors, and chimeric antigen receptor (CAR) T cells. Other trials evaluate the efficacy and safety of these immunomodulatory agents' combinations with standard approaches such as androgen deprivation therapy (ADT), taxane-based chemotherapy, radiotherapy, and targeted therapies such as tyrosine kinase inhibitors (TKI) and poly ADP ribose polymerase (PARP) inhibitors. Here, we will review promising immunotherapies in development and ongoing trials for metastatic castration-resistant prostate cancer (mCRPC). These novel trials will build on past experiences and promise to usher a new era to treat patients with mCRPC. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2021 JAN -PY - 2021 -VL - 13 -IS - 2 -C7 - 334 -DO - 10.3390/cancers13020334 -AN - WOS:000611118200001 -AD - Washington Univ, Sch Med, Dept Internal Med, Div Med Oncol, St Louis, MO 63110 USA -Y2 - 2021-02-09 -ER - - -TY - JOUR -AU - Chu Chia-Hsun -AU - Chiu Tzu-Hsuan -AU - Wang Chin-Chou -AU - Chang Wen-Chen -AU - Huang Allen Chung-Cheng -AU - Liu Chien-Ying -AU - Wang Chih-Liang -AU - Ko Ho-Wen -AU - Chung Fu-Tsai -AU - Hsu Ping-Chih -AU - Guo Yi-Ke -AU - Kuo, Chih-Hsi S. -AU - Yang Cheng-Ta -TI - Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer -T2 - THORACIC CANCER -M3 - Article -AB - Background Treatment for stage III non-small cell lung cancer (NSCLC) of unresectable disease mainly involves concurrent chemoradiation (CRT). Post-CRT consolidation treatment with durvalumab is a major therapeutic advance that provides survival benefit in this group of patients. However, the performance of this treatment strategy remains to be studied in a real-world setting.Methods A total of 31 patients who had disease control post-CRT were included in the durvalumab early access program (EAP) as an intent-to-treat cohort and retrospectively reviewed for post-CRT progression-free survival (PFS) and time to metastatic disease or death (TMDD). The neutrophil-to-lymphocyte ratio (NLR) at the initiation of durvalumab was analyzed in 29 patients.Results The median time from the completion of concurrent CRT to the initiation of durvalumb was 2.8 months. The objective response was 25.8% and the 12 month PFS and TMDD-free rate were 56.4% and 66.9%, respectively. The low NLR patients showed a significantly longer post-CRT PFS (not reach vs. 12.0 months [95% CI: 5.5-not estimable]; P = 0.040; the hazard ratio for disease progression or death, 0.23 [95% CI: 0.05-1.00]; P = 0.048) and the 12 month post-CRT PFS rate (82.5 vs. 42.6%). The post-CRT TMDD (not reach vs. 12.6 months, [95% CI: 10.8-not estimable]; P = 0.010; the hazard ratio for distant metastasis or death, 0.11 [95% CI: 0.01-0.88]; P = 0.037) and 12 month post-CRT TMDD-free rate (90.9 vs. 57.1%) were also significantly higher in the low NLR patients.Conclusions Durvalumab consolidation treatment in real-world patients showed substantial efficacy and the correlation with the NLR level warrants further investigation. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1759-7706 -SN - 1759-7714 -DA - 2020 JUN -PY - 2020 -VL - 11 -IS - 6 -SP - 1541 -EP - 1549 -DO - 10.1111/1759-7714.13426 -AN - WOS:000526013700001 -C6 - APR 2020 -AD - Chang Gung Univ, Dept Thorac Med, Div Thorac Oncol, Chang Gung Mem Hosp,Coll Med, Taoyuan, Taiwan -AD - Chang Gung Mem Hosp, Ctr Canc, Thorac Oncol Unit, Taoyuan, Taiwan -AD - Kaohsiung Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Kaohsiung, Taiwan -AD - Chang Gung Univ, Chang Gung Mem Hosp, Dept Med Oncol, Taoyuan, Taiwan -AD - Imperial Coll London, Data Sci Inst, Dept Comp, London, England -Y2 - 2020-04-13 -ER - - -TY - JOUR -AU - Barsouk, Adam -AU - Friedes, Cole -AU - Iocolano, Michelle -AU - Doucette, Abigail -AU - Cohen, Roger B. -AU - Robinson, Kyle W. -AU - D'Avella, Christopher A. -AU - Marmarelis, Melina E. -AU - Kosteva, John A. -AU - Singh, Aditi P. -AU - Ciunci, Christine A. -AU - Levin, William P. -AU - Cengel, Keith A. -AU - Bradley, Jeffrey D. -AU - Feigenberg, Steven J. -AU - Sun, Lova -AU - Aggarwal, Charu -AU - Langer, Corey J. -AU - Yegya-Raman, Nikhil -TI - Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - We present one of the largest, real-world KRAS -mutated cohorts following chemoradiation and durvalumab consolidation (per the PACIFIC trial) in unresectable, locally-advanced non-small cell lung cancer (NSCLC), comparing 42 KRAS -mt with 114 patients KRAS -wt patients. We found KRAS -mt patients are more likely to sustain progression prior to durvalumab initiation; however, in those who receive durvalumab consolidation, PFS and OS are similar to KRAS -wt. tially improved progression free survival (PFS) and overall survival (OS) in the PACIFIC trial becoming the standard of care in locally-advanced, unresectable NSCLC. KRAS mutation may influence response to ICI. Methods: In this single-institution, retrospective analysis, we compared treatment outcomes for patients with unresectable KRAS mutated ( KRAS -mt) and wild-type ( KRAS -wt) NSCLC treated with CRT between October 2017 and December 2021. Kaplan- Meier analysis was conducted comparing median progression free survival and median overall survival from completion of radiotherapy in all KRAS -mt patients and KRAS-G12C- mutated patients. Outcomes were also compared with and without ICI consolidation. Results: Of 156 patients, 42 (26.9%) were KRAS -mt and 114 (73.1%) were KRAS wt. Baseline characteristics differed only in histology; KRAS -mt NSCLC more likely to be adenocarcinoma. KRAS -mt patients had worse PFS (median 6.3 vs. 10.7 months, P = .041) but similar OS (median 23.1 vs. 27.3 months, P = .237). KRAS -mt patients were more likely to not receive ICI due to rapid disease progression post-CRT (23.8% vs. 4.4%, P = .007). Among patients who received ICI (n = 114), KRAS -mt was not associated with inferior PFS (8.1 vs. 11.9 months, P = .355) or OS (30.5 vs. 31.7 months, P = .692). KRAS-G12C patients (n = 22) had similar PFS and OS to other KRAS -mt. Conclusion: In one of the largest post-CRT KRAS -mt cohort published, KRAS -mt was associated with inferior PFS, largely due to rapid progression prior to ICI consolidation, but did not affect OS. Among those who received ICI consolidation, outcomes were comparable regardless of KRAS -mt status. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2024 MAY -PY - 2024 -VL - 25 -IS - 3 -SP - e161 -EP - e171 -DO - 10.1016/j.cllc.2023.12.009 -AN - WOS:001243891900001 -C6 - MAY 2024 -AD - Univ Penn, Perelman Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA USA -AD - Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA USA -AD - Ctr Adv Med, Dept Radiat Oncol Perelman, 2 West 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA -AD - Ctr Adv Med, Dept Med Perelman, 2 West 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA -M2 - Ctr Adv Med -M2 - Ctr Adv Med -Y2 - 2024-06-17 -ER - - -TY - JOUR -AU - Qiu, Bo -AU - Wang, DaQuan -AU - Li, QiWen -AU - Wu, YingJia -AU - Guo, SuPing -AU - Jiang, XiaoBo -AU - Fang, JianLan -AU - Guo, JinYu -AU - Liu, FangJie -AU - Chu, Chu -AU - Wang, Bin -AU - Chen, Li -AU - Zhang, Jun -AU - Liu, YiMei -AU - Hu, YongHong -AU - Liu, Hui -TI - Concurrent Chemoradiation Therapy With or Without Nimotuzumab in Locally Advanced Squamous Cell Lung Cancer: A Phase 2 Randomized Trial -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Article -AB - Purpose: The study aimed to evaluate the efficacy and safety of concurrent chemoradiation therapy (CCRT) combined with nimotuzumab in patients with unresectable stage III squamous cell lung cancer (SqCLC).Methods and Materials: A prospective, single-center, open-label, randomized phase 2 trial was performed in patients with unresectable stage III SqCLC. Patients were randomized to receive 65 Gy thoracic radiation over 5 weeks concurrent with docetaxel and cisplatin or the same CCRT regimen combined with 200 mg of nimotuzumab (NIMO-CCRT), administered weekly by intravenous infusion. The primary endpoint was overall survival. The secondary endpoints were progression-free survival, objective response rate, failure patterns, and treatment-related toxicity.Results: From August 2015 to June 2020, 126 patients with SqCLC were randomized. Four patients withdrew consent before the start of treatment, and 122 patients were included for analysis, including 57 in the NIMO-CCRT group and 65 in the CCRT group. The median OS was 24.9 months in the NIMO-CCRT group and 23.5 months in the CCRT group (P = .655). The median PFS was 12.1 months in the NIMO-CCRT group and 13.7 months in the CCRT group (P = .968). The NIMO-CCRT group had a significantly lower risk of brain metastasis, with adjusted subdistribution hazard ratio of 0.099 (95% confidence interval, 0.012-0.81; P = .031). The incidence of grade >= 3 pneumonitis (P = .894) and esophagitis (P = .974) was similar between the 2 arms. There was no grade 2 or higher skin toxicity in NIMO-CCRT group.Conclusions: The coincident application of nimotuzumab with CCRT was well tolerated for locally advanced SCCL. The NIMO-CCRT group had an OS and PFS similar to that in the CCRT group, but a lower risk of brain metastasis. Further investigations are warranted. (C) 2021 Published by Elsevier Inc. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 15 -PY - 2021 -VL - 111 -IS - 4 -SP - 917 -EP - 925 -DO - 10.1016/j.ijrobp.2021.06.032 -AN - WOS:000709807000012 -C6 - OCT 2021 -AD - Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Guangdong, Peoples R China -AD - GuangDong Assoc Study Thorac Oncol, Guangzhou, Guangdong, Peoples R China -M2 - GuangDong Assoc Study Thorac Oncol -Y2 - 2021-11-03 -ER - - -TY - JOUR -AU - Peng, J. -AU - Zhang, L. -AU - Wang, L. -AU - Feng, H. -AU - Yao, D. -AU - Meng, R. -AU - Liu, X. -AU - Li, X. -AU - Liu, N. -AU - Tan, B. -AU - Huang, Z. -AU - Li, S. -AU - Meng, X. -TI - PD-L1 Inhibitors Combined with Thoracic Radiotherapy in First-Line Treatment of Extensive Stage Small Cell Lung Cancer: A Propensity Score-Matched, Real -World Study -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 1072 -SP - S127 -EP - S128 -AN - WOS:001079706803251 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China -AD - Hunan Canc Hosp, Dept Thorac Dept, Changsha, Peoples R China -AD - Baotou Canc Hosp, Dept Med Oncol, Baotou, Peoples R China -AD - Qingdao Univ, Dept Clin Oncol, Affiliated Hosp, Qingdao, Peoples R China -AD - Chaoyang Second Hosp, Dept Med Oncol, Chaoyang, Peoples R China -AD - Huazhong Univ Sci & Technol, Union Hosp, Dept Canc Ctr, Tongji Med Coll, Wuhan, Peoples R China -AD - Jinzhou Med Univ, Dept Oncol Dept, Jinzhou, Peoples R China -AD - Chifeng Municipal Hosp, Dept Resp & Crit Care, Chifeng, Peoples R China -AD - Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China -AD - SHANDONG Univ, QILU Hosp, Jinan, Peoples R China -AD - Shandong First Med Univ, Shandong Prov Hosp, Jinan, Peoples R China -AD - Zibo Municipal Hosp, Dept Oncol, Zibo, Peoples R China -M2 - Hunan Canc Hosp -M2 - Baotou Canc Hosp -M2 - Chaoyang Second Hosp -M2 - Chifeng Municipal Hosp -M2 - Zibo Municipal Hosp -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Jairam, V. -AU - Soulos, P. R. -AU - Kc, M. -AU - Gross, C. P. -AU - Slotman, B. J. -AU - Chiang, A. C. -AU - Park, H. S. M. -TI - Differential Impact of Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer Based on Systemic Therapy Type and Sex -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2059 -SP - E27 -EP - E28 -AN - WOS:001079706800056 -AD - Yale Sch Med, New Haven, CT USA -AD - Yale Univ, Canc Outcomes Publ Policy & Effectiveness Res COP, New Haven, CT 06520 USA -AD - Amsterdam Univ Med Ctr, Dept Radiat Oncol, Amsterdam, Netherlands -AD - Yale Sch Med, Sect Med Oncol, New Haven, CT USA -AD - Yale Sch Med, Dept Therapeut Radiol, New Haven, CT USA -M2 - Amsterdam Univ Med Ctr -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - SIGALOV, ALEXANDER B -TI - First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer -M3 - Awarded Grant -AB - Project Summary/AbstractCarcinoma of the pancreas, or pancreatic cancer (PC), is the fourth leading cause of cancer-related deathin the United States. According to the American Cancer Society, 55,300 new cases are expected in 2016.Despite advances in therapy, the 5-year survival rate is less than 4%. Current treatments of PC includesurgery, radiation therapy, chemotherapy, and immunotherapy but they all only slightly prolong survival orrelieve symptoms in patients with PC. Gemcitabine (GEM), first line therapy for advanced PC, is onlymodestly effective with a median survival of about 6 months in randomized clinical trials, The combinationof GEM with different anticancer agents does not show significant survival advantage as compared withGEM alone. These limitations in efficacy of available treatments highlight the need for new treatments. Pancreatic inflammation is known to increase the risk of PC. High macrophage infiltration into the tumormass correlates with the promotion of tumor growth and metastasis development. Triggering receptorexpressed on myeloid cells (TREM-1), an inflammation amplifier, plays a role in PC progression.Expression of TREM-1 on tumor-associated macrophages (TAMs), is upregulated in patients with PC andcorrelates to disease severity. Recently, we demonstrated that a first-in-class TREM-1 inhibitory peptideGF9 in free form and bound to macrophage-targeted lipopeptide complexes that mimic human high densitylipoproteins (GF9-HDL) inhibits tumor growth in animal models of PC. We also showed that blockade ofTREM-1 inhibits release of cytokines and M-CSF in these animal models. The main hypothesis of this project is that a combination therapy that includes TREM-1 inhibitors andanticancer agents and targets cancer-related inflammation and tumor cells directly can synergisticallyimprove survival of PC patients. We also hypothesize that this effect will be especially pronounced in PCpatients with high intratumoral macrophage infiltration. Our preliminary studies strongly support thishypothesis. The long-term objective of the proposed project is to develop a novel combinatorial approachto efficiently target PC. The major goal of the Phase I study is to demonstrate that specific inactivation ofTREM-1 with first-in-class inhibitory peptides in combination with GEM or nanoparticle albumin (nab)-bound paclitaxel (nab-PTX), another promising agent that directly targets cancer cells and is widelyapproved for the treatment of metastatic breast cancer (BC), synergistically suppresses PC tumorprogression in animal model system and improves survival. Phase I specific aims are to: 1) evaluate effectsand mechanisms of GF9-GEM and GF9-nab-PTX combinations in vitro, and 2) test GF9-GEM and GF9-nab-PTX combinations in two xenograft mouse models of PC. Non-toxic peptide GF9, which employs novel,ligand-independent mechanisms of TREM-1 inhibition, is anticipated to have less severe side effects. Inorder to increase peptide solubility, bioavailability and targeting to TAMs, we will utilize SignaBlok'sproprietary HDL-based nanosystem for macrophage-targeted delivery of water insoluble and poorly watersoluble drugs. We will use in vitro macrophage uptake assay to elucidate the molecular mechanisms of aputative receptor-mediated process of targeted delivery of GF9 to macrophages. We will optimize GF9formulations based upon their stability, GF9 content, and macrophage uptake in vitro. We will use an invitro cytotoxicity assay and immunoblot analysis to test proliferation of BxPC-3 and AsPC-1 cells as well asexpression of phospho-stathmin and alpha-tubulin in the presence of GEM, nab-PTX or their combinationswith GF9 formulations. We will use BxPC-3 and AsPC-1 mouse xenograft models to test the ability of GF9-GEM and GF9-nab-PTX combinations to synergistically inhibit tumor progression and promote survival ascompared with GF9, GEM, and nab-PTX alone. Free GF9 and GF9-HDL will be tested. Comprehensivehistology and immunohistochemistry studies will be performed to analyze angiogenesis, intratumoralmacrophage infiltration, and potential non-specific toxicity for organ/tissues. It is anticipated that the proposed research will identify a novel anticancer combination approach thatwill set the stage for the development of new targeted combination therapies of PC, thereby leading to ahigher survival rate of the patients. If successful, the Phase I will be followed in the Phase II by toxicology,absorption/ disposition/ metabolism/ excretion (ADME), pharmacology and chemistry/ manufacturing/control (CMC) studies, filing an Investigational New Drug (IND) application with the US Food and DrugAdministration (FDA) and subsequent evaluation in humans. Final product will be the stable TREM-1-targeted lipopeptide formulation that can be used in combination therapies of PC patients to prolong theirsurvival. Importantly, our recent data demonstrate that blockade of TREM-1 suppresses in vivo progressionof not only PC but also non-small cell lung cancer (NSCLC). Thus, successful completion of Phase I willprovide the proof of concept of the hypothesis that might be applicable to a variety of inflammation-associated tumors such as NSCLC, BC, colon cancer, and others. -DA - 2019 -PY - 2019 -AN - GRANTS:14962501 -G1 - 3R43CA217400-01A1S1; 9984628; R43CA217400 -AD - SIGNABLOK, INC. -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Kobayashi, Keigo -AU - Nakachi, Ichiro -AU - Naoki, Katsuhiko -AU - Satomi, Ryosuke -AU - Nakamura, Morio -AU - Inoue, Takashi -AU - Tateno, Hiroki -AU - Sakamaki, Fumio -AU - Sayama, Koichi -AU - Terashima, Takeshi -AU - Koh, Hidefumi -AU - Abe, Takayuki -AU - Nishino, Makoto -AU - Arai, Daisuke -AU - Yasuda, Hiroyuki -AU - Kawada, Ichiro -AU - Soejima, Kenzo -AU - Betsuyaku, Tomoko -A1 - KLOG -TI - Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - We evaluated the real-world efficacy and safety of nivolumab in 142 patients with advanced non-small-cell lung cancer in Japan and identified the clinical characteristics that influence the efficacy. Negative EGFR/ALK mutation status and previous radiotherapy were significantly associated statistically with the treatment response. These findings might aid in the efficient immunotherapeutic management of lung cancer.Background: Nivolumab, an immune checkpoint inhibitor, is now a standard treatment for previously treated advanced non-small-cell lung cancer based on the results from phase III clinical trials. We evaluated the real-world efficacy and safety of nivolumab in a nonselected population and identified the clinical characteristics that influence efficacy. Materials and Methods: A total of 142 patients with advanced non-small-cell lung cancer who were administered nivolumab at Keio University and affiliated hospitals in Japan from January to July 2016 were enrolled. The treatment efficacy and adverse events were retrospectively reviewed, and the clinical characteristics associated with the nivolumab response were evaluated using univariate and stratified analyses and the Cochran-Mantel-Haenszel test. Results: The objective response rate was 17.0% (95% confidence interval [CI], 12.0%-24.0%), the median progression-free survival (PFS) was 58 days (95% CI, 50-67 days), and the proportion of patients with adverse events of any grade was 45.0%. EGFR/ALK mutation status was inversely associated with the treatment response (P < .05), and the difference in PFS for the mutation-positive versus mutation-negative patients was statistically significant (49 vs. 63 days; hazard ratio, 1.9; 95% CI, 1.1-5.2; P = .029). Previous radiotherapy also had a positive association with the treatment response (P = .012). Conclusion: The objective response rate, PFS, and adverse event profiles were comparable to those observed in previous clinical trials. EGFR/ALK mutation-negative status and previous radiotherapy might be key clinical characteristics associated with a positive treatment response. Our findings could aid in the efficient immunotherapeutic management of lung cancer. (C) 2017 Elsevier Inc. All rights reserved. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2018 MAY -PY - 2018 -VL - 19 -IS - 3 -SP - E349 -EP - E358 -DO - 10.1016/j.cllc.2018.01.001 -AN - WOS:000430510300008 -AD - Keio Univ, Sch Med, Dept Med, Div Pulm Med, Tokyo, Japan -AD - Saiseikai Utsunomiya Hosp, Dept Internal Med, Pulm Div, 911-1 Takebayashimachi, Utsunomiya, Tochigi 3210974, Japan -AD - Tokyo Med Ctr, Natl Hosp Org, Tokyo, Japan -AD - Tokyo Saiseikai Cent Hosp, Tokyo, Japan -AD - Sano Kousei Gen Hosp, Sano, Japan -AD - Saitama City Hosp, Saitama, Japan -AD - Tokai Univ, Hachioji Hosp, Tokyo, Japan -AD - Kawasaki Municipal Hosp, Kawasaki, Kanagawa, Japan -AD - Ichikawa Gen Hosp, Tokyo Dent Coll, Ichikawashi, Japan -AD - Tachikawa Hosp, Tachikawa, Tokyo, Japan -AD - Keio Univ, Sch Med, Dept Prevent Med & Publ Hlth, Tokyo, Japan -M2 - Saiseikai Utsunomiya Hosp -M2 - Tokyo Med Ctr -M2 - Sano Kousei Gen Hosp -M2 - Saitama City Hosp -M2 - Kawasaki Municipal Hosp -Y2 - 2018-05-02 -ER - - -TY - JOUR -AU - Grambozov, Brane -AU - Stana, Markus -AU - Kaiser, Bernhard -AU - Karner, Josef -AU - Gerum, Sabine -AU - Ruznic, Elvis -AU - Zellinger, Barbara -AU - Moosbrugger, Raphaela -AU - Studnicka, Michael -AU - Fastner, Gerd -AU - Sedlmayer, Felix -AU - Zehentmayr, Franz -TI - High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC -T2 - CANCERS -M3 - Review -AB - Simple Summary Since the early 1980s, there has been a trend towards escalating radiation doses in pulmonary tumor recurrences with the aim of improving survival. In this context, we performed a literature search in order to summarize the evidence of curative thoracic re-irradiation for centrally recurrent lung cancer. Tumor relapse in this specific situation poses a major problem because of the proximity to mediastinal organs. Of the initial 227 studies, 11 fulfilled the inclusion criteria for this analysis. The median overall survival (mOS) was 18.1 months (range 9.3-25.1), the median progression-free survival (mPFS) was nine months (range 4.5-16), and the median locoregional control (mLRC) was 12.1 months (range 6.5-20). The total re-irradiation dose correlated with both mLRC (p-value = 0.012) and mOS (p-value = 0.007). As large-scale prospective trials in the field are missing, this literature review is primarily based on retrospective data. In today's age of enhanced long-term survival rates after chemoradiotherapy followed by immune checkpoint inhibition, the current analysis provides valuable insights into radiation treatment options for patients with loco-regional lung cancer recurrence. Introduction: Thoracic re-irradiation for recurrent lung cancer dates back four decades, when the first small series on 29 patients receiving palliative doses was published. With 5-year overall survival rates of 57% in PDL-1 positive patients after primary chemo-radio-immunotherapy, the number of patients who experience loco-regional relapse will increase in the near future. In this context, centrally recurring lung tumors pose a major treatment challenge. Hence, the aim of the current review is to compile the available evidence on curatively intended thoracic re-irradiation for this special clinical situation. Methods: A systematic literature search according to the PRISMA guidelines was performed. A study was included when the following criteria were met: (1) 66% of the patients had NSCLC, (2) a total dose of 50 Gy in the second course and/or a biologically effective dose of at least 100 Gy in both treatment courses was administered, (3) re-irradiation was administered with modern radiation techniques, (4) 50% or more of the patients had a centrally located relapse, (5) the minimum cohort size was 30 patients. Results: Of the initial 227 studies, 11 were analyzed, 1 of which was prospective. Median overall survival (OS) was 18.1 months (range 9.3-25.1), median progression free survival (PFS) was nine months (range 4.5-16), and median loco-regional control (LRC) was 12.1 months (range 6.5-20). Treatment-related mortality rates ranged from 2% to 14%. The total dose at re-irradiation correlated with both LRC (p-value = 0.012) and OS (p-value = 0.007) with a close relation between these two clinical endpoints (p-value = 0.006). The occurrence of acute toxicity grade 1 to 4 depended on the PTV size at re-irradiation (p-value = 0.033). Conclusion: The evidence regarding curative re-irradiation for centrally recurrent NSCLC is primarily based on scarce retrospective data, which are characterized by a high degree of heterogeneity. The OS in this clinically challenging situation is expected to be around 1.5 years after re-treatment. Patients with a good performance score, younger age, small tumors, and a longer interval to recurrence potentially benefit most from re-irradiation. In this context, prospective trials are warranted to achieve substantial advances in the field. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2022 FEB -PY - 2022 -VL - 14 -IS - 3 -C7 - 573 -DO - 10.3390/cancers14030573 -AN - WOS:000759962100001 -AD - Paracelsus Med Univ, Dept Radiat Oncol, SALK, A-5020 Salzburg, Austria -AD - Paracelsus Med Univ, Dept Pneumol, SALK, A-5020 Salzburg, Austria -AD - Paracelsus Med Univ, Inst Pathol, SALK, A-5020 Salzburg, Austria -Y2 - 2022-03-04 -ER - - -TY - JOUR -AU - Mayahara, Hiroshi -AU - Uehara, Kazuyuki -AU - Harada, Aya -AU - Kitatani, Keiji -AU - Yabuuchi, Tomonori -AU - Miyazaki, Shuichirou -AU - Ishihara, Takeaki -AU - Kawaguchi, Hiroki -AU - Kubota, Hikaru -AU - Okada, Hideaki -AU - Ninomaru, Taira -AU - Shindo, Chihiro -AU - Hata, Akito -TI - Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer -T2 - RADIATION ONCOLOGY -M3 - Article -AB - Background Concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard of care for unresectable locally-advanced non-small cell carcinoma (LA-NSCLC). However, a major concern about administration of durvalumab after CCRT is whether the incidence of symptomatic radiation pneumonitis (RP) may increase or not. In the present analysis, we report the initial results of CCRT followed by durvalumab in patients with LA-NSCLC in a real-world setting with focus on predicting factors for symptomatic RP. Methods Patients who were pathologically diagnosed as NSCLC and initiated treatment with CCRT followed by durvalumab between July 2018 to December 2019 were eligible for this study. Patients were included if they completed the planned CRT course and administered at least one course of durvalumab. We retrospectively investigated the preliminary survival outcome and incidence and predicting factors for symptomatic RP. Results Of the 67 patients who planned CCRT, 63 patients completed the entire CCRT course. Of these, 56 patients proceeded to consolidation with durvalumab. The median time to eternal discontinuation of durvalumab was 9.7 months. The cumulative proportion of the patients who exhibited symptomatic RP was 30, 40 and 44% at 3, 6 and 12 months, respectively. In multivariate analyses, pulmonary fibrosis score and lung V40 were significant predictive factors for symptomatic RP (p < 0.001, HR: 7.83, 95% CI: 3.38-18.13, and p = 0.034, HR: 3.17, 95% CI: 1.09-9.19, respectively). Conclusions Pulmonary fibrosis sore and lung V40 were significant predictive factors for symptomatic RP. We should be cautious about the administration of durvalumab for patients having subclinical pulmonary fibrosis. To our best knowledge, this is one of the first report showing the predictive value of high dose volumes to the lung in patients with LA-NSCLC who received CCRT followed by durvalumab. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1748-717X -DA - 2022 JAN 15 -PY - 2022 -VL - 17 -IS - 1 -C7 - 7 -DO - 10.1186/s13014-021-01979-z -AN - WOS:000742904900001 -AD - Kobe Minimally Invas Canc Ctr, Dept Radiat Oncol, Chuo Ku, 8-5-1 Minatojima Nakamachi, Kobe, Hyogo 6500046, Japan -AD - Kobe Univ, Div Radiat Oncol, Grad Sch Med, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo, Japan -AD - Kobe Minimally Invas Canc Ctr, Dept Resp Med Oncol, Chuo Ku, 8-5-1 Minatojima Nakamachi, Kobe, Hyogo, Japan -AD - Kobe Minimally Invas Canc Ctr, Dept Diagnost Radiol, Chuo Ku, 8-5-1 Minatojima Nakamachi, Kobe, Hyogo, Japan -M2 - Kobe Minimally Invas Canc Ctr -M2 - Kobe Minimally Invas Canc Ctr -M2 - Kobe Minimally Invas Canc Ctr -Y2 - 2022-01-21 -ER - - -TY - JOUR -AU - Amorelli, F. -AU - Martinez, A. -AU - Liu, F. -AU - Foro, P. -AU - Algara, M. -AU - Sanz, J. -AU - Membrive, I. -AU - Taus, A. -AU - Arriola, E. -AU - Masfarre, L. -AU - Navarro, N. -AU - Rodriguez De Dios, N. -TI - Impact of Lymphopenia on Treatment Outcomes in Unresectable Non-Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2003 -SP - E2 -EP - E3 -AN - WOS:001079706800005 -AD - Hosp Del Mar, Radiat Oncol Dept, Barcelona, Spain -AD - Hosp Del Mar, Med Oncol Dept, Barcelona, Spain -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - DEORE, SAPNA -TI - Design and Development of Targeted-Liposome for drug delivery to lung cancer by exploiting a vulnerability induced by radiotherapy -M3 - Awarded Grant -AB - AbstractThe proposed drug development will result in the design and development of a ligand-targetedliposome (LTL) that will aid in the targeted delivery of therapeutics to patients with Non-Small CellLung Cancer (NSCLC). We propose an innovative active targeting strategy and our technologyexploits the stress response that occurs within the cancer cells following exposure to ionizingradiation. This liposome targets the neoantigen Glucose-Regulated Protein 78 (GRP78) which isoverexpressed in NSCLC and is further induced when cancer cells are exposed to radiation, astandard of care for patients with NSCLSC. For patients with NSCLC, the 5-year overall survivalrate is 15%. The difficulty in treatment is partly due to genetic tumor heterogeneity, patientheterogeneity, induced immunosuppression, and limited drug penetration. The impact of currentcytotoxic chemotherapies on NSCLC is limited by lack of specificity hence the attendantcytotoxicity to normal cells, resistance to therapy and disease recurrence. We identified GRP78through the use of bacteriophage displayed peptide libraries and subsequent affinity purificationof surface proteins from cancer. The proposed research will advance our lead LTL’s towards INDenabling studies. We will design and optimize a new peptidomimetic based on modeling of ourparent peptide to achieve stronger specificity and prolonged circulation. We will synthesize thepeptidomimetics and generate the LTL and characterize the same. Furthermore, we willdemonstrate cancer specificity and sensitivity of the LTL’s using in vitro and in vivo assays. Atthe end of the project term, we will have determined and validated the feasibility of ournew LTL as an effective payload carrier and hence a therapeutic agent in NSCLC. In linewith our long-term goal in the next phase of the project, we study the bio-distribution anddrug loading capability and efficacy by conducting studies that will determine thetherapeutic effects of peptide-conjugated cancer pharmaceuticals. -DA - 2019 -PY - 2019 -AN - GRANTS:15049238 -G1 - 1R41CA233020-01A1; 9844636; R41CA233020 -AD - MEDICAL GUIDANCE SYSTEMS, LLC -M2 - MEDICAL GUIDANCE SYSTEMS, LLC -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Zhao, Zhiting -AU - Hu, Ran -AU - Chen, Yan -AU - Zhou, Guoren -AU - Yu, Shaorong -AU - Feng, Jifeng -TI - Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection -T2 - ONCOLOGY RESEARCH AND TREATMENT -M3 - Article -AB - Background: Immune checkpoint inhibitors have become new research hot spots in the treatment of non-small-cell lung cancer (NSCLC), but the efficacy and safety of immunotherapy for patients with chronic infection are still unclear because existing clinical trials often exclude those patients. Materials and Methods: We identified 78 locally advanced or advanced NSCLC patients with chronic infection treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors alone or combined with the chemotherapy/bevacizumab therapy, of whom 60 with hepatitis B, 2 with hepatitis C, and 16 with syphilis. Objective response rates were assessed using the RECIST v1.1. Adverse events (AEs) were graded following the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Results: Objective responses were observed in 19 out of 78 (24.36%) patients, and the disease control rate was 69.23% (54/78). No patient achieved a complete response. The median progression-free survival (PFS) was 6.49 months (95% CI: 3.71-9.27). PFS was 1.44 months (95% CI: 0.00-4.34) for monotherapy versus 7.34 months (95% CI: 4.50-10.18) for combination therapy (p = 0.053). Patients in the first-line treatment group revealed relatively higher ORR and longer PFS (ORR: 48.00% vs. 13.20%, p = 0.001; PFS: 7.67 vs. 5.57 months, p = 0.129). Patients with combined radiotherapy showed longer PFS than those without combined radiotherapy (14.07 vs. 4.62, p = 0.027). The incidence of AEs of any grade was 73.07% (57/78), among which there were 7 cases of grade 4 AEs. The incidence of leukopenia in any grade of AEs was the highest (57.69%), followed by anemia (25.64%), elevated alanine aminotransferase or aspartate aminotransferase (24.36%), and fatigue (21.79%). Hepatic transaminase increased in 26.7% (16/60) of HBV-infected patients and remained unchanged in 65.0% (39/60) patients. Conclusions: The PD-1 inhibitor showed an acceptable toxicity profile and moderate efficacy on NSCLC patients with chronic infection, but still has the potential to increase the incidence of hepatitis. (C) 2022 S. Karger AG, Basel -PU - KARGER -PI - BASEL -PA - ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND -SN - 2296-5270 -SN - 2296-5262 -DA - 2022 JUN -PY - 2022 -VL - 45 -IS - 6 -SP - 366 -EP - 373 -DO - 10.1159/000523854 -AN - WOS:000836662600006 -AD - Nanjing Med Univ, Dept Med Oncol, Affiliated Canc Hosp, Nanjing, Peoples R China -AD - Jiangsu Canc Hosp, Nanjing, Peoples R China -AD - Jiangsu Inst Canc Res, Nanjing, Peoples R China -AD - Nanjing Med Univ, Dept Pathol, Affiliated Canc Hosp, Nanjing, Peoples R China -Y2 - 2022-08-24 -ER - - -TY - JOUR -AU - Nobashi, Tomomi W. -AU - Nishimoto, Yuko -AU - Kawata, Yujiro -AU - Yutani, Hidetaka -AU - Nakamura, Masaki -AU - Tsuji, Yuichi -AU - Yoshida, Atsushi -AU - Sugimoto, Akihiko -AU - Yamamoto, Takayuki -AU - Alam, Israt S. -AU - Noma, Satoshi -TI - Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers -T2 - BRITISH JOURNAL OF RADIOLOGY -M3 - Article -AB - Objective: To investigate the clinical and radiological features of immune checkpoint inhibitor-related pneumonitis (ICI-P), a rare but serious pulmonary complication of cancer immunotherapy and to evaluate key differences between lung cancer (LC) and non-LC patients.Methods: 247 patients (LC, n = 151) treated with ICI for malignancies were retrospectively screened in a single institute. The number of patients, history of other immune-related adverse events (irAE), the onset, serum KL-6 levels, and chest CT features (types of pneumonitis, symmetry, laterality, location) were recorded for the ICI-P population and compared for LC and non-LC groups.Results: ICI-P was identified in 26 patients in total (LC, n = 19; non-LC, n = 7). The incidence of other irAE was significantly higher in ICI-P group (63%) compared with patients without ICI-P (34%) (p = 0.0056). An earlier onset of ICI-P was recorded in LC (78 days) compared to non-LC patients (186 days) (p = 0.0034). Serum KL-6 was significantly elevated only in the non-LC group when ICI-P was noticed (p = 0.029). Major CT findings of ICI-P, irrespective of primary disease, were organizing pneumonia pattern and ground glass opacities. LC patients commonly exhibited consolidation and traction bronchiectasis and were prone to asymmetrical shadows (p < 0.001). Non-LC patients were more likely to exhibit symmetrical infiltrations. A small fraction of both groups experienced relapse or moving patterns of ICI-P.Conclusion: ICI-P patients more often experienced other irAE prior to the development of ICI-P. The characteristics of ICI-P can differ in terms of the onset, KL-6 reliability, and chest CT findings between LC and non-LC patients.Advances in knowledge: In ICI-P patients, a history of other irAE can be more frequently observed. Differences in disease onset and radiological patterns between LC and non-LC patients might be helpful to make a diagnosis of ICI-P; however, longitudinal observation of chest CT scans is advised to observe the pneumonitis activity irrespective of cancer types. -PU - BRITISH INST RADIOLOGY -PI - LONDON -PA - 48-50 ST JOHN ST, LONDON, ENGLAND -SN - 0007-1285 -SN - 1748-880X -DA - 2020 -PY - 2020 -VL - 93 -IS - 1115 -C7 - 20200409 -DO - 10.1259/bjr.20200409 -AN - WOS:000592668600019 -AD - Tenri Hosp, Dept Radiol, Nara, Japan -AD - Stanford Univ, Sch Med, Dept Radiol, Mol Imaging Program Stanford MIPS, Stanford, CA USA -Y2 - 2020-12-09 -ER - - -TY - JOUR -AU - Frak, Malgorzata -AU - Krawczyk, Pawel -AU - Kalinka, Ewa -AU - Milanowski, Janusz -TI - Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients -T2 - CANCERS -M3 - Review -AB - Simple SummaryImmunotherapy is one of the most effective systemic treatment methods for many types of cancers. Unfortunately, cancer cells developed a number of defense mechanisms e.g., the absence of NK cells, macrophages or T lymphocytes in the tumor stroma, lack of pro-inflammatory cytokines in the tumor microenvironment (IL-6, IL-2, IL-12, TNF-alpha), production of immunosuppressive compounds (TGF-beta, indoleamine dioxygenase or neutralization of immune cells through direct immune checkpoints interactions (CD80/CD86 with CTLA-4 and PD-L1 with PD-1) that eventually make treatment ineffective. In this way, non-immunogenic, "cold" tumors are formed. The paper presents those mechanisms in details and focuses on the radiochemotherapy technique which, by neoantigen production, abscopal effect and activation of interferon synthesis pathways (STING), affects the production of cytokines and chemokines and transforms "cold" tumors into highly immunogenic "hot", inflammatory tumors, susceptible to immunotherapy. Results are based on clinical trials conducted to date, which showed high effectiveness of the combination therapy consisting of radiochemotherapy and immunotherapy in NSCLC patients.Non-small cell lung cancer (NSCLC) is one of the most common malignancies around the world. Due to the advanced stage of the disease at the time of diagnosis, most patients require systemic treatment. Immunotherapy with immune checkpoints inhibitors is becoming the main treatment method for many cancers, including NSCLC. Numerous studies have shown greater efficacy of immunotherapy used monoclonal antibodies anti-PD-1 (pembrolizumab and nivolumab) or anti-PD-L1 (atezolizumab and durvalumab) compared to chemotherapy. Unfortunately, cancer cells can develop a number of mechanisms to escape from immune surveillance, including avoidance of cancer cells by the immune system (immune desert), production of immunosuppressive compounds (prostaglandins, IDO, TGF-beta), or direct immune checkpoints interactions. Therapy based on the use of radiochemotherapy with subsequent immunotherapy is becoming the main focus of research in the field of new NSCLC therapies. Radiation therapy stimulates the immune response multidirectionally, affects production of neoantigens and proinflammatory compounds, which transform non-immunogenic ("cold") tumors into highly immunogenic ("hot") tumors. As a result, the mechanisms of escape of cancer cells from immune surveillance break down and the effectiveness of immunotherapy increases significantly. The results of clinical trials in this area bring new hope and indicate greater effectiveness of such treatment in terms of prolongation of progression-free survival and overall survival. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2021 MAR -PY - 2021 -VL - 13 -IS - 6 -C7 - 1222 -DO - 10.3390/cancers13061222 -AN - WOS:000634349800001 -AD - Med Univ Lublin, Chair & Dept Pneumol Oncol & Allergol, PL-20954 Lublin, Poland -AD - Polish Mothers Mem Hosp, Res Inst Lodz, Dept Oncol, PL-93338 Lodz, Poland -Y2 - 2021-04-16 -ER - - -TY - JOUR -AU - Chen, Yuh-Min -AU - Yang, James Chih-Hsin -AU - Su, Wu-Chou -AU - Chong, Inn-Wen -AU - Hsia, Te-Chun -AU - Lin, Meng-Chih -AU - Chang, Gee-Chen -AU - Chiu, Chao-Hua -AU - Ho, Chao-Chi -AU - Wu, Shang-Yin -AU - Hung, Jen-Yu -AU - Wang, Chin-Chou -AU - Yang, Tsung-Ying -AU - Yu, Chong-Jen -TI - Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan -T2 - JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION -M3 - Article -AB - Background/Purpose: There is a lack of data on nivolumab treatment outcomes in Taiwanese patients with advanced or recurrent non-small cell lung cancer (NSCLC) ineligible for radical radiotherapy and resistant to platinum-based chemotherapy. We investigated the safety and efficacy of nivolumab in this population.Methods: In this ongoing, multicenter, open-label, single-arm, phase II study, patients aged >= 20 years with a performance status of 0-1 and stage IIIB/IV or recurrent NSCLC received nivolumab 3 mg/kg every 2 weeks in 6-week cycles. Interim data obtained between 27 January 2016 and 21 May 2017 were analyzed. Safety, based on adverse event (AE) reporting, was the primary endpoint. Efficacy assessment parameters included overall response rate (ORR), overall survival (OS), and progression-free survival (PFS).Results: Among 53 treated patients with advanced NSCLC (median age 61.0 years; 62.3% male), mean treatment duration was 99.7 days. AEs (any grade) and serious AEs were reported by 92.5% and 47.2% of patients, respectively. Adverse drug reactions (ADRs; any) occurred in 58.5% of patients; grade >= 3 ADRs occurred in 13.2% of patients. Five deaths occurred; two cases (neoplasm progression and septic shock) were considered treatment-emergent. Common ADRs were fatigue (17.0%) and rash (13.2%). Common immune-related treatment-emergent AEs were rash (17.0%) and pruritus (13.2%). The centrally assessed ORR was 9.4% (5/53). The median OS and median PFS were 11.5 months and 1.4 months, respectively.Conclusion: Nivolumab appeared to be safe and effective in Taiwanese patients. These interim results suggest that nivolumab is a suitable treatment option for this population. Copyright (C) 2020, Formosan Medical Association. Published by Elsevier Taiwan LLC. -PU - ELSEVIER TAIWAN -PI - TAIPEI -PA - RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN -SN - 0929-6646 -SN - 1876-0821 -DA - 2020 DEC -PY - 2020 -VL - 119 -IS - 12 -SP - 1817 -EP - 1826 -DO - 10.1016/j.jfma.2020.01.004 -AN - WOS:000591733800012 -AD - Natl Yang Ming Univ, Fac Med, Sch Med, Taipei, Taiwan -AD - Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan -AD - Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan -AD - Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan -AD - Kaohsiung Med Univ Hosp, Div Pulm & Crit Care Med, Kaohsiung, Taiwan -AD - China Med Univ, China Med Univ Hosp, Taichung, Taiwan -AD - China Med Univ, Dept Resp Therapy, Taichung, Taiwan -AD - Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Kaohsiung, Taiwan -AD - Chang Gung Univ, Dept Internal Med, Taoyuan, Taiwan -AD - Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan -AD - Natl Taiwan Univ Hosp, Dept Internal Med, 7 Zhongshan South Rd, Taipei 100, Taiwan -Y2 - 2020-12-08 -ER - - -TY - JOUR -AU - Boothman, Anne-Marie -AU - Scott, Marietta -AU - Ratcliffe, Marianne -AU - Whiteley, Jessica -AU - Dennis, Phillip A. -AU - Wadsworth, Catherine -AU - Sharpe, Alan -AU - Rizvi, Naiyer A. -AU - Garassino, Marina Chiara -AU - Walker, Jill -TI - Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study -T2 - JOURNAL OF THORACIC ONCOLOGY -M3 - Article -AB - Introduction: We evaluated the impact of patient characteristics, sample types, and prior non-immunotherapy treatment on tumor cell (TC) programmed cell death ligand 1 (PD-L1) expression using samples from patients with advanced NSCLC.Methods: Patients (N = 1590) screened for the ATLANTIC study submitted a recently acquired (<= 3 months) or archival (> 3 months to > 3 years old) tumor sample for PD-L1 assessment using the VENTANA PD-L1 (SP263) Assay with a cutoff of >25% of TCs expressing PD-L1 (TC >= 25%). Samples were acquired either before or after the two or more treatment regimens required for study entry and sample age varied among patients. A subset of patients (n = 123) provided both recent and archival samples.Results: A total of 517 of 1590 (32.5%) patients had TC greater than or equal to 25%: prevalence was greater in smokers versus nonsmokers (p = 0.0005) and those with EGFR- versus EGFR+ tumors (p = 0.0002); these effects were independent. Prevalence of TC greater than or equal to 25% was increased in recent metastatic versus primary (p = 0.005) and recent versus archival (p = 0.039) samples. Chemotherapy or radiotherapy, but not tyrosine kinase inhibition, before sampling was associated with significantly increased PD-L1 prevalence. PD-L1 status (TC >= 25% cutoff) remained unchanged in 74.0% of patients with recent and archival samples; where PD-L1 status changed, it was more likely to increase than decrease over time or with inter-vening treatment.Conclusions: Several factors potentially impact PD-L1 TC greater than or equal to 25% prevalence in advanced NSCLC; however, no characteristic can be considered a surrogate for PD-L1 expression. Fresh biopsy may provide more accurate assessment of current tumoral PD-L1 expression where a low/negative result is seen in an archival sample, especially if the patient has received intervening therapy. (C) 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1556-0864 -SN - 1556-1380 -DA - 2019 AUG -PY - 2019 -VL - 14 -IS - 8 -SP - 1390 -EP - 1399 -DO - 10.1016/j.jtho.2019.04.025 -AN - WOS:000476595900022 -AD - AstraZeneca, IMED Biotech Unit, Precis Med & Genom, Cambridge, England -AD - AstraZeneca, Global Med Dev, Gaithersburg, MD USA -AD - AstraZeneca, Global Med Dev, Alderley Pk, Macclesfield, Cheshire, England -AD - AstraZeneca, IMED Biotech Unit, Discovery Sci, Cambridge, England -AD - Columbia Univ, Med Ctr, Div Hematol & Oncol, New York, NY USA -AD - Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Thorac Oncol Unit, Milan, Italy -Y2 - 2019-08-02 -ER - - -TY - JOUR -AU - Dudnik, Elizabeth -AU - Moskovitz, Mor -AU - Rottenberg, Yakir -AU - Lobachov, Anastasiya -AU - Mandelboim, Rinat -AU - Shochat, Tzippy -AU - Urban, Damien -AU - Wollner, Mira -AU - Nechushtan, Hovav -AU - Rotem, Ofer -AU - Zer, Alona -AU - Daher, Sameh -AU - Bar, Jair -A1 - Israel Lung Canc Grp -TI - Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data -T2 - ONCOIMMUNOLOGY -M3 - Article -AB - Both pembrolizumab (P) and combination of pembrolizumab with platinum-based chemotherapy (PCT) represent standard 1(st)-line options for advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumor proportion score (TPS) >= 50%. The two strategies have never been compared in a randomized trial. 256 consecutive patients with EGFR/ALK/ROS1-wild-type PD-L1 TPS >= 50% aNSCLC receiving P (group P, n = 203) or PCT (group PCT, n = 53) as a 1(st)-line treatment were identified in the electronic databases of 4 Israeli cancer centers. Time-to-treatment discontinuation (TTD) and overall survival (OS) were assessed. Baseline characteristics were well balanced, except for age and ECOG PS differences in favor of group PCT. Median (m)TTD was 4.9 months (mo) (95% CI, 3.1-7.6) vs 8.0mo (95% CI, 4.7-15.6) (p-0.09), mOS was 12.5mo (95% CI, 9.8-16.4) vs 20.4mo (95% CI, 10.8-NR) (p-0.08), with P and PCT, respectively. In the propensity score matching analysis (n = 106; 53 patients in each group matched for age, sex and ECOG PS), mTTD was 7.9mo (95% CI, 2.8-12.7) vs 8.0mo (95% CI, 4.7-15.6) (p-0.41), and mOS was 13.3mo (95% CI, 6.8-20.3) vs 20.4mo (95% CI, 10.8-NR) (p-0.18), with P and PCT, respectively. Among various subgroups of patients examined, only in females (n = 86) mOS differed significantly between treatments (10.2mo (95% CI, 6.8-17.2) with P vs NR (95% CI, 11.4-NR) with PCT; p-0.02). In the real-world setting, no statistically significant differences in long-term outcomes with P vs PCT were observed; a prospective randomized trial addressing the comparative efficacy of P and PCT in different patient subgroups is highly anticipated. -PU - TAYLOR & FRANCIS INC -PI - PHILADELPHIA -PA - 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA -SN - 2162-402X -DA - 2021 -PY - 2021 -VL - 10 -IS - 1 -C7 - 1865653 -DO - 10.1080/2162402X.2020.1865653 -AN - WOS:000614319200001 -AD - Rabin Med Ctr, Davidoff Canc Ctr, Thorac Canc Serv, Beilinson Campus, Petah Tiqwa, Israel -AD - Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel -AD - Rambam Hlth Care Campus, Thorac Canc Serv, Oncol Dept, Haifa, Israel -AD - Hadassah Med Ctr, Oncol Dept, Jerusalem, Israel -AD - Hebrew Univ Jerusalem, Hadassah Med Ctr, Jerusalem, Israel -AD - Sheba Med Ctr, Inst Oncol, Thorac Canc Serv, Ramat Gan, Israel -AD - Rabin Med Ctr, Stat Consulting Unit, Beilinson Campus, Petah Tiqwa, Israel -Y2 - 2021-02-17 -ER - - -TY - JOUR -AU - Facchinetti, Francesco -AU - Mazzaschi, Giulia -AU - Barbieri, Fausto -AU - Passiglia, Francesco -AU - Mazzoni, Francesca -AU - Berardi, Rossana -AU - Proto, Claudia -AU - Cecere, Fabiana Letizia -AU - Pilotto, Sara -AU - Scotti, Vieri -AU - Rossi, Sabrina -AU - Del Conte, Alessandro -AU - Vita, Emanuele -AU - Bennati, Chiara -AU - Ardizzoni, Andrea -AU - Cerea, Giulio -AU - Migliorino, Maria Rita -AU - Sala, Elisa -AU - Camerini, Andrea -AU - Bearz, Alessandra -AU - De Carlo, Elisa -AU - Zanelli, Francesca -AU - Guaitoli, Giorgia -AU - Garassino, Marina Chiara -AU - Ciccone, Lucia Pia -AU - Sartori, Giulia -AU - Toschi, Luca -AU - Dall'Olio, Filippo Gustavo -AU - Landi, Lorenza -AU - Pizzutilo, Elio Gregory -AU - Bartoli, Gabriele -AU - Baldessari, Cinzia -AU - Novello, Silvia -AU - Bria, Emilio -AU - Cortinovis, Diego Luigi -AU - Rossi, Giulio -AU - Rossi, Antonio -AU - Banna, Giuseppe Luigi -AU - Camisa, Roberta -AU - Di Maio, Massimo -AU - Tiseo, Marcello -TI - First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status -T2 - EUROPEAN JOURNAL OF CANCER -M3 - Article -AB - Background: Pembrolizumab is the first-line standard of care for advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS) >= 50%. Eastern Cooperative Oncology Group performance status (PS) 2 patients may receive pembrolizumab, despite the absence of sustaining evidence.Patients and methods: GOIRC-2018-01 is a multicentre, retrospective, observational study. PS 2 NSCLC patients with a PD-L1 TPS >= 50% receiving first-line pembrolizumab from June 2017 to December 2018 at 21 Italian institutions were included. Clinical-pathological characteristics were correlated with disease response and survival outcomes; adverse events were recorded. The primary objective was 6-months progression-free rate (6-months PFR).Results: One hundred fifty-three patients (median age 70 years) were enrolled. At a median follow-up of 18.2 months, median progression-free survival (PFS) and overall survival (OS) were 2.4 (95% confidence interval, 95% CI, 1.6-2.5) and 3.0 months (95% CI 2.4-3.5), respectively. 6-months PFR was 27% (95% CI 21-35%). Patients with a PS 2 determined by comorbidities (n = 41) had significantly better outcomes compared with disease burden-induced PS 2 (n = 112). Indeed, 6-months PFR was 49% versus 19%, median PFS 5.6 versus 1.8 months and OS 11.8 versus 2.8 months, respectively. Additional potential prognostic factors (radiotherapy, antibiotics, steroids received before pembrolizumab) correlated with clinical outcomes. The determinant of PS 2 resulted the only factor independently impacting on both PFS and OS. No toxicity issues emerged.Conclusions: Outcomes of PS 2 NSCLC patients with PD-L1 TPS >= 50% receiving first-line pembrolizumab were globally dismal but strongly dependent on the reason conditioning the poor PS itself. (C) 2020 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCI LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND -SN - 0959-8049 -SN - 1879-0852 -DA - 2020 MAY -PY - 2020 -VL - 130 -SP - 155 -EP - 167 -DO - 10.1016/j.ejca.2020.02.023 -AN - WOS:000535711100017 -AD - Univ Hosp Parma, Med Oncol Unit, Parma, Italy -AD - Univ Paris Saclay, Inst Gustave Roussy, Biomarqueurs Predictifs & Nouvelles Strategies Th, INSERM, F-94800 Villejuif, France -AD - Azienda Osped Univ Policlin, Div Med Oncol, Modena, Italy -AD - Univ Turin, San Luigi Hosp, Dept Oncol, Orbassano, Italy -AD - Careggi Univ Hosp, Dept Oncol, Med Oncol Unit, Florence, Italy -AD - Univ Politecn Marche, Osped Riuniti Ancona, Oncol Clin, Ancona, Italy -AD - Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy -AD - IRCCS Regina Elena Natl Canc Inst, Rome, Italy -AD - Univ Verona, Dept Med, Sect Med Oncol, Verona, Italy -AD - Careggi Univ Hosp, Dept Oncol, Radiat Therapy Unit, Florence, Italy -AD - Humanitas Clin & Res Ctr, Dept Oncol & Hematol, Milan, Italy -AD - Ctr Riferimento Oncol Aviano CRO IRCCS, Med Oncol & Immunorelated Tumors, Aviano, Italy -AD - Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli, Comprehens Canc Ctr, IRCCS, Rome, Italy -AD - S Maria Delle Croci Hosp Ravenna, Oncohematol Dept, Ravenna, Italy -AD - Univ Bologna, Dept Oncol, Policlin S Orsola Malpighi, Bologna, Italy -AD - Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy -AD - Azienda Osped San Camillo Forlanini, Pneumol Oncol, Rome, Italy -AD - Osped San Gerardo, Oncol Unit, Monza, Italy -AD - Osped Versilia, Med Oncol, Azienda USL Toscana Nord Ovest, Toscana, Italy -AD - Azienda Unita Sanit Locale IRCCS Reggio Emilia, Oncol Unit, Reggio Emilia, Italy -AD - Univ Milan, Dept Oncol & Hematooncol, Milan, Italy -AD - S Maria Delle Croci Hosp, Pathol Unit, Ravenna, Italy -AD - Fdn IRCCS Casa Sollievo Sofferenza, Div Med Oncol, San Giovanni Rotondo, FG, Italy -AD - United Lincolnshire Hosp NHS Trust, Lincoln, England -AD - Univ Turin, Ordine Mauriziano Hosp, Dept Oncol, Turin, Italy -AD - Univ Parma, Dept Med & Surg, Parma, Italy -M2 - IRCCS Regina Elena Natl Canc Inst -M2 - Humanitas Clin & Res Ctr -M2 - Ctr Riferimento Oncol Aviano CRO IRCCS -M2 - S Maria Delle Croci Hosp Ravenna -M2 - Grande Osped Metropolitano Niguarda -M2 - Osped Versilia -M2 - Azienda Unita Sanit Locale IRCCS Reggio Emilia -M2 - S Maria Delle Croci Hosp -M2 - Fdn IRCCS Casa Sollievo Sofferenza -M2 - United Lincolnshire Hosp NHS Trust -Y2 - 2020-05-01 -ER - - -TY - JOUR -AU - Zhou, Shujie -AU - Xie, Jingjing -AU - Huang, Zhaoqin -AU - Deng, Liufu -AU - Wu, Leilei -AU - Yu, Jinming -AU - Meng, Xiangjiao -TI - Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges -T2 - CANCER LETTERS -M3 - Review -AB - The brain is one of the most common metastatic sites in non-small cell lung cancer (NSCLC), which is associated with an extremely poor prognosis. Despite the availability of several therapeutic options, the treatment efficacy remains unsatisfactory for NSCLC brain metastases. Anti-programmed cell death-1 (PD-1) and its ligand (PD-L1) monoclonal antibodies have reshaped therapeutic strategies in advanced NSCLC. Preliminary evidence has shown that anti-PD-(L)1 monotherapy is also effective in NSCLC patients with brain metastases. However, the traditional view asserted that these therapeutic antibodies were incapable of crossing the blood-brain barrier (BBB) with large molecular size, thus most patients with brain metastases were excluded from most studies on anti-PD-(L)1 immunotherapy. Therefore, the efficacy and its mechanisms of action of anti-PD-(L)1 immunotherapy against brain metastases in NSCLC have not been clarified. In this review, we will survey the underlying mechanisms and current clinical advances of anti-PD-(L)1 immunotherapy in the treatment of brain metastases in NSCLC. The trafficking of activated cytotoxic T cells that are mainly derived from the primary tumor and deep cervical lymph nodes is critical for the intracranial response to anti-PD-(L)1 immunotherapy, which is driven by interferon--gamma (IFN-gamma). Additionally, promising combined strategies with the rationale in the treatment of brain metastases will be presented to provide future directions for clinical study design. Several significant challenges in the preclinical and clinical studies of brain metastases, as well as potential solutions, will also be discussed. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0304-3835 -SN - 1872-7980 -DA - 2021 APR 1 -PY - 2021 -VL - 502 -SP - 166 -EP - 179 -DO - 10.1016/j.canlet.2020.12.043 -AN - WOS:000619210000015 -C6 - JAN 2021 -AD - Shandong Univ, Cheeloo Coll Med, Jinan, Shandong, Peoples R China -AD - Shandong First Med Univ, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China -AD - Shandong Acad Med Sci, Jinan, Shandong, Peoples R China -AD - Shandong First Med Univ, Shandong Prov Hosp, Dept Radiol, Jinan, Shandong, Peoples R China -AD - Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Shanghai, Peoples R China -AD - Shanghai Jiao Tong Univ, Sch Med, Dept Immunol & Microbiol, Shanghai, Peoples R China -Y2 - 2021-03-10 -ER - - -TY - JOUR -AU - Multhoff, Gabriele -AU - Seier, Sophie -AU - Stangl, Stefan -AU - Sievert, Wolfgang -AU - Shevtsov, Maxim -AU - Werner, Caroline -AU - Pockley, A. Graham -AU - Blankenstein, Christiane -AU - Hildebrandt, Martin -AU - Offner, Robert -AU - Ahrens, Norbert -AU - Kokowski, Konrad -AU - Hautmann, Matthias -AU - Roedel, Claus -AU - Fietkau, Rainer -AU - Lubgan, Dorota -AU - Huber, Rudolf -AU - Hautmann, Hubert -AU - Duell, Thomas -AU - Molls, Michael -AU - Specht, Hanno -AU - Haller, Bernhard -AU - Devecka, Michal -AU - Sauter, Andreas -AU - Combs, Stephanie E. -TI - Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial -T2 - CLINICAL CANCER RESEARCH -M3 - Article -AB - Purpose: Non-small cell lung cancer (NSCLC) is a fatal disease with poor prognosis. Amembrane-bound form of Hsp70 (mHsp70) which is selectively expressed on high-risk tumors serves as a target for mHsp70-targeting natural killer (NK) cells. Patients with advanced mHsp70-positive NSCLC may therefore benefit from a therapeutic intervention involving mHsp70-targeting NK cells. The randomized phase II clinical trial (EudraCT2008-002130-30) explores tolerability and efficacy of ex vivo-activated NK cells in patients with NSCLC after radiochemotherapy (RCT).Patients and Methods: Patients with unresectable, mHsp70-positive NSCLC (stage IIIa/b) received 4 cycles of autologous NK cells activated ex vivo with TKD/IL2 [interventional arm (INT)] after RCT (60-70 Gy, platinum-based chemotherapy) or RCT alone [control arm (CTRL)]. The primary objective was progression-free survival (PFS), and secondary objectives were the assessment of quality of life (QoL, QLQ-LC13), toxicity, and immunobiological responses.Results: The NK-cell therapy after RCT was well tolerated, and no differences in QoL parameters between the two study arms were detected. Estimated 1-year probabilities for PFS were 67% [95% confidence interval (CI), 19%-90%] for the INT arm and 33% (95% CI, 5%-68%) for the CTRL arm (P = 0.36, 1-sided logrank test). Clinical responses in the INT group were associated with an increase in the prevalence of activated NK cells in their peripheral blood.Conclusions: Ex vivo TKD/IL2-activated, autologous NK cells are well tolerated and deliver positive clinical responses in patients with advanced NSCLC after RCT. -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 1078-0432 -SN - 1557-3265 -DA - 2020 OCT 15 -PY - 2020 -VL - 26 -IS - 20 -SP - 5368 -EP - 5379 -DO - 10.1158/1078-0432.CCR-20-1141 -AN - WOS:000582352800013 -AD - TUM, Dept Radiat Oncol, TU Munchen, Klinikum Rechts Isar, Munich, Germany -AD - Ctr Translat Canc Res TUM TranslaTUM, Radiat Immunooncol, Munich, Germany -AD - Russian Acad Sci RAS, Inst Cytol, St Petersburg, Russia -AD - Nottingham Trent Univ, John Van Geest Canc Res Ctr, Nottingham, England -AD - Multimmune GmbH, Munich, Germany -AD - TUM, Munchner Studienzentrum CCC, Munich, Germany -AD - TUM Sch Med, TUMCells, Munich, Germany -AD - Univ Hosp Regensburg, Dept Transfus Med, Regensburg, Germany -AD - Klinikum Bogenhausen, Pneumol & Pneumol Oncol, Munich, Germany -AD - Univ Hosp Regensburg, Dept Radiat Oncol, Regensburg, Germany -AD - Goethe Univ Frankfurt, Dept Radiotherapy & Oncol, Frankfurt, Germany -AD - Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Radiat Oncol, Erlangen, Germany -AD - Univ Munich, Div Resp Med, LMU, Munich, Germany -AD - Univ Munich, Thorac Oncol Ctr Munich, LMU, Munich, Germany -AD - TUM, Klinikum Rechts Isar, Pneumol Grp Med 1, Munich, Germany -AD - LMU, Asklepios Lung Hosp Munchen Gauting, Thoracal Pneumol, Munich, Germany -AD - TUM, Inst Med Informat Stat & Epidemiol, Munich, Germany -AD - TUM, Inst Radiol, Munich, Germany -AD - Helmholtz Zentrum Munchen HMGU, Inst Radiat Med IRM, Neuherberg, Germany -AD - Deutsch Konsortium Translat Krebsforsch DKTk, Partner Site Munich, Munich, Germany -M2 - Ctr Translat Canc Res TUM TranslaTUM -M2 - Multimmune GmbH -M2 - TUM Sch Med -M2 - Deutsch Konsortium Translat Krebsforsch DKTk -Y2 - 2020-11-10 -ER - - -TY - JOUR -AU - Biswas, Tithi -AU - Dowlati, Afshin -AU - Kunos, Charles A. -AU - Pink, John J. -AU - Oleinick, Nancy L. -AU - Malik, Shakun -AU - Fu, Pingfu -AU - Cao, Shufen -AU - Bruno, Debora S. -AU - Bajor, David L. -AU - Patel, Monaliben -AU - Gerson, Stanton L. -AU - Machtay, Mitchell -TI - Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed-Platinum-Radiation in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer: Results of a Phase I Trial -T2 - CLINICAL CANCER RESEARCH -M3 - Article -AB - Purpose: TRC102, a small-molecule base-excision repair inhib-itor, potentiates the cytotoxicity of pemetrexed and reverses resis-tance by binding to chemotherapy-induced abasic sites in DNA. We conducted a phase I clinical trial combining pemetrexed and TRC102 with cisplatin-radiation in stage III nonsquamous non- small cell lung cancer (NS-NSCLC).Patients and Methods: Fifteen patients were enrolled from 2015 to 2019. The primary objective was to determine the dose-limiting toxicity and maximum tolerated dose of TRC102 in combination with pemetrexed, cisplatin, and radiotherapy. Secondary objectives were to assess toxicity, tumor response, and progression-free survival at 6 months. Based on our preclinical experiments, pemetrexed- TRC102 was given on day 1, and cisplatin/radiotherapy was initiated on day 3. This schedule was duplicated in the second cycle. After completion, two additional cycles of pemetrexed-cisplatin were given. Toxicities were assessed using NCI CTACAE versions 4/5.Results: The median age was 69 years (45-79) with the median follow-up of 25.7 months (range, 7.9-47.4). No dose-limiting toxicities and no grade 5 toxicity were seen. Hematologic and gastrointestinal toxicities were the most common side effects. No clinical radiation pneumonitis was seen. Of 15 evaluable patients, three had complete response (20%), and 12 had partial response (80%). The 6-month progression-free survival was 80%, and the 2-year overall survival was 83%.Conclusions: Pemetrexed-TRC102 combined with cisplatin/ radiotherapy in NS-NSCLC is safe and well tolerated. The recommended phase II dose is 200 mg TRC102 along with cisplatin-pemetrexed. No additional safety signal was seen beyond the expected CRT risks. A phase II trial, integrating post-CRT immunotherapy with this aggressive DNA-damaging regimen, is warranted. -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 1078-0432 -SN - 1557-3265 -DA - 2022 FEB 15 -PY - 2022 -VL - 28 -IS - 4 -SP - 646 -EP - 652 -DO - 10.1158/1078-0432.CCR-21-2025 -AN - WOS:000756647300001 -AD - Univ Hosp, Seidman Canc Ctr, Cleveland, OH USA -AD - Case Western Reserve Univ, Cleveland, OH 44106 USA -AD - NCI, Rockville, MD USA -AD - Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA -AD - Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA -AD - Case Western Reserve Univ, Sch Med, Cleveland, OH USA -AD - Penn State Univ, State Coll, PA USA -Y2 - 2022-02-15 -ER - - -TY - JOUR -AU - Kareff, Samuel A. -AU - Han, Sunwoo -AU - Haaland, Benjamin -AU - Jani, Chinmay J. -AU - Kohli, Rhea -AU - Aguiar Jr, Pedro Nazareth -AU - Huang, Yiqing -AU - Soo, Ross A. -AU - Rodriguez-Perez, Angel -AU - Garcia-Foncillas, Jesus -AU - Domine, Manuel -AU - de Lima Lopes, Gilberto -TI - International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer -T2 - JAMA NETWORK OPEN -M3 - Article -AB - Importance Standard of care for unresectable locally advanced non-small cell lung cancer (NSCLC) involves definitive chemoradiotherapy followed by maintenance therapy with durvalumab. However, the cost of durvalumab has been cited as a barrier to its use in various health systems. Objective To evaluate the cost-effectiveness of durvalumab vs placebo as maintenance therapy in patients with unresectable stage III NSCLC from 4 international payer perspectives (US, Brazil, Singapore, and Spain). Design, Setting, and Participants In this economic evaluation, a Markov model was designed to compare the lifetime cost-effectiveness of maintenance durvalumab for unresectable stage III NSCLC with that of placebo, using 5-year outcomes data from the PACIFIC randomized placebo-controlled trial. Individual patient data were extracted from the PACIFIC, KEYNOTE-189, ADAURA, ALEX, and REVEL randomized clinical trials to develop a decision-analytic model to determine the cost-effectiveness of durvalumab compared with placebo maintenance therapy over a 10-year time horizon. Direct costs, adverse events, and patient characteristics were based on country-specific payer perspectives and demographic characteristics. The study was conducted from June 1, 2022, through December 27, 2023. Main Outcomes and Measures Life-years, quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratios (ICERs) were estimated at country-specific willingness-to-pay thresholds ([data reported in US$] US: $150 000 per QALY; Brazil: $22 251 per QALY; Singapore: $55 288 per QALY, and Spain: $107 069 per QALY). One-way and probabilistic sensitivity analyses were performed to account for parameters of uncertainty. A cost-threshold analysis was also performed. Results The US base-case model found that treatment with durvalumab was associated with an increased cost of $114 394 and improved effectiveness of 0.50 QALYs compared with placebo, leading to an ICER of $228 788 per QALY. Incremental cost-effectiveness ratios, according to base-case models, were $141 146 for Brazil, $153 461 for Singapore, and $125 193 for Spain. Durvalumab price adjustments to the PACIFIC data improved cost-effectiveness in Singapore, with an ICER of $45 164. The model was most sensitive to the utility of durvalumab. Conclusions and Relevance In this cost-effectiveness analysis of durvalumab as maintenance therapy for unresectable stage III NSCLC, the therapy was found to be cost-prohibitive from the perspective of various international payers according to country-specific willingness-to-pay thresholds per QALY. The findings of the study suggest that discounted durvalumab acquisition costs, as possible in Singapore, might improve cost-effectiveness globally. -PU - AMER MEDICAL ASSOC -PI - CHICAGO -PA - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA -SN - 2574-3805 -DA - 2024 MAY 30 -PY - 2024 -VL - 7 -IS - 5 -C7 - e2413938 -DO - 10.1001/jamanetworkopen.2024.13938 -AN - WOS:001236356200004 -AD - Univ Miami, Sylvester Comprehens Canc Ctr, Jackson Mem Hosp, Miami, FL USA -AD - Univ Miami, Miller Sch Med, Miami, FL USA -AD - Pentara Corp, Salt Lake City, UT USA -AD - Case Western Reserve Univ, Sch Med, Cleveland, OH USA -AD - Oncoclinicas, Sao Paulo, SP, Brazil -AD - Natl Univ, Canc Inst, Singapore, Singapore -AD - Fdn Jimenez Diaz Univ Hosp, Madrid, Spain -M2 - Pentara Corp -M2 - Oncoclinicas -M2 - Fdn Jimenez Diaz Univ Hosp -Y2 - 2024-07-04 -ER - - -TY - JOUR -AU - Song, Peng -AU - Zhang, Jingcheng -AU - Shang, Congcong -AU - Zhang, Li -TI - Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors -T2 - SCIENTIFIC REPORTS -M3 - Article -AB - To summarize the therapeutic effects of PD-1/PD-L1 inhibitors on patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting, we attempted to identify potential molecular biomarkers or clinical factors that reflected the therapeutic effect. The medical records of patients with non-small cell lung cancer who were treated with PD-1/PD-L1 inhibitors were obtained from the outpatient department or inpatient department of Peking Union Medical College Hospital from August 1, 2015, to January 1, 2018. Our follow-up continued until May 1,2018. We chose overall survival (OS) as the primary observation endpoint and progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety as the secondary observation endpoints. Efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The Kaplan-Meier method was used to generate survival curves, and we compared the influence of different factors on PFS and OS by the log-rank test. The median follow-up time was 11 months. At the end of the follow-up, 24 patients (61.5%) were still undergoing immunotherapy, and 7 patients (17.9%) had died. Twenty-six cases (66.7%) employed PD-1/PD-L1 inhibitors as first-line treatment, and 7 cases (17.9%) employed PD-1/PD-L1 inhibitors as second-line treatment. Only 6 cases (15.4%) employed PD-1/PD-L1 inhibitors as third-line treatment. Therapeutic effect evaluation: Complete response (CR): 1 case (2.6%). Partial response (PR): 10 cases (25.6%). Stable disease (SD): 16 cases (41.0%). Progressive disease (PD): 12 cases (30.8%). The ORR was 28.2%, and DCR was 69.2%. The median PFS was 25.5 months (95% CI 6.8-44.1 months), which failed to reach the median OS. PD-1/PD-L1 inhibitor treatment is more effective for advanced non-small cell lung cancer patients in a real-world setting than in clinical trials; PD-1/ PD-Ll inhibitor treatment is more effective for people who are over 70 than for people who are under 70. Additionally, patients who are over 75 years old have a higher response rate, suggesting that elderly patients may receive more benefits from immunotherapy; Patients who have an epidermal growth factor receptor (EGFR) mutation (+) may benefit from immunotherapy after treatment with a tyrosine kinase inhibitor (TKI). It is essential to identify these potential patients from the entire patient pool; PD-1 may have a certain curative effect on brain metastases from NSCLC. Local radiotherapy may help to improve PD-1 intracranial efficacy. -PU - NATURE PORTFOLIO -PI - BERLIN -PA - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY -SN - 2045-2322 -DA - 2019 MAR 12 -PY - 2019 -VL - 9 -C7 - 4278 -DO - 10.1038/s41598-019-40748-7 -AN - WOS:000460924100018 -AD - Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Resp Med, Beijing, Peoples R China -AD - Peking Union Med Coll, Beijing, Peoples R China -AD - Chinese Acad Med Sci, Dept Internal Med, Peking Union Med Coll Hosp, Beijing, Peoples R China -AD - Henan Prov Peoples Hosp, Dept Allergy, Zhengzhou, Henan, Peoples R China -Y2 - 2019-03-28 -ER - - -TY - JOUR -AU - Geng, Yichao -AU - Zhang, Qiuning -AU - Feng, Shuangwu -AU - Li, Chengcheng -AU - Wang, Lina -AU - Zhao, Xueshan -AU - Yang, Zhen -AU - Li, Zheng -AU - Luo, Hongtao -AU - Liu, Ruifeng -AU - Lu, Bing -AU - Wang, Xiaohu -TI - Safety and efficacy of combination therapy using programmed cell death protein-1/programmed cell death ligand-1 inhibitors and radiotherapy in patients with non-small-cell lung cancer: A systematic review and meta-analysis -T2 - CANCER MEDICINE -M3 - Review -AB - Background: A combination of programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors and radiotherapy (RT) is increasingly being used to treat non-small-cell lung cancer (NSCLC). However, the safety and efficacy of this approach remains controversial. We performed a systematic review and meta-analysis to summarize the related research.Methods: We searched the China Biology Medicine, EMBASE, Cochrane Library, and PubMed databases for all the relevant studies. The Stata software, version 12.0 was used for the meta-analysis.Results: The study included 20 clinical trials that enrolled 2027 patients with NSCLC. Compared with non-combination therapy, combination therapy using PD-1/PD-L1 inhibitors and RT was associated with prolonged overall survival (OS) (1-year OS: odds ratio [OR] 1.77, 95% confidence interval [CI] 1.35-2.33, p = 0.000; 2-year OS: OR 1.77, 95% CI 1.35-2.33, p = 0.000) and progression-free survival (PFS) (0.5-year PFS: OR 1.83, 95% CI 1.13-2.98, p = 0.014; 1-year PFS: OR 2.09, 95% CI 1.29-3.38, p = 0.003; 2-year PFS: OR 2.47, 95% CI 1.13-5.37, p = 0.023). Combination therapy also improved the objective response rate (OR 2.76, 95% CI 1.06-7.19, p = 0.038) and disease control rate (OR 1.80, 95% CI 1.21-2.68, p = 0.004). This meta-analysis showed that compared with non-combination therapy, combination therapy using PD-1/PD-L1 inhibitors and RT did not increase the serious adverse event rates (>= grade 3); however, this approach increased the rate of grade 1-2 immune-related or radiation pneumonitis. Subgroup analyses revealed that the sequence of PD-1/PD-L1 inhibitors followed RT outperformed in which concurrent PD-1/PD-L1 inhibitor and RT followed PD-1/PD-L1 inhibitor. Combination of stereotactic body RT or stereotactic radiosurgery with PD-1/PD-L1 inhibitors may be more effective than a combination of conventional RT with PD-1/PD-L1 inhibitors in patients with advanced NSCLC.Conclusion: Combination therapy using PD-1/PD-L1 inhibitors and RT may improve OS, PFS, and tumor response rates without an increase in serious adverse events in patients with advanced NSCLC. However, combination therapy was shown to increase the incidence of mild pneumonitis. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2045-7634 -DA - 2021 FEB -PY - 2021 -VL - 10 -IS - 4 -SP - 1222 -EP - 1239 -DO - 10.1002/cam4.3718 -AN - WOS:000608599900001 -C6 - JAN 2021 -AD - Lanzhou Univ, Sch Clin Med 1, Lanzhou 730000, Peoples R China -AD - Guizhou Med Univ, Affiliated Hosp, Dept Oncol, Guiyang, Peoples R China -AD - Guizhou Canc Hosp, Dept Oncol, Guiyang, Peoples R China -AD - Chinese Acad Sci, Inst Modern Phys, Lanzhou, Peoples R China -AD - Lanzhou Heavy Ion Hosp, Lanzhou, Peoples R China -AD - Lanzhou Univ, Basic Med Coll, Lanzhou, Peoples R China -M2 - Guizhou Canc Hosp -M2 - Lanzhou Heavy Ion Hosp -Y2 - 2021-02-03 -ER - - -TY - JOUR -AU - Schapira, Emily -AU - Hubbeling, Harper -AU - Yeap, Beow Y. -AU - Mehan, William A., Jr. -AU - Shaw, Alice T. -AU - Oh, Kevin -AU - Gainor, Justin F. -AU - Shih, Helen A. -TI - Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Article -AB - Purpose: Despite the emerging role of programmed cell death-1 (PD-1) pathway inhibitors for patients with advanced lung cancer, a paucity of data are available on the activity of these agents among patients with brain metastases. We investigated the outcomes of PD-1 pathway inhibitors and stereotactic radiosurgery (SRS) for the treatment of patients with brain metastases from lung cancer.Methods and Materials: We retrospectively reviewed the medical records of non-small-cell lung cancer patients with brain metastases consecutively treated with PD-1 pathway inhibitors and SRS at our institution from 2012 to 2017. Overall survival (OS), distant brain failure (DBF), and local control (LC) were assessed using Kaplan-Meier estimates and Cox regression models.Results: We identified 37 patients treated with SRS to 85 lesions (90.6% intact and 9.4% resected) and a median total of 7 doses of PD-1 pathway inhibitors (83.8% nivolumab, 10.8% atezolizumab, 5.4% pembrolizumab). Most lesions were treated with 18 Gy in a single fraction (n = 61; 71.8%). Patients treated with concurrent SRS and PD-1 pathway inhibitors had longer OS and reduced rates of DBF compared with patients treated with SRS before or after PD-1 pathway inhibitor therapy (1-year OS, 87.3% vs 70.0% vs 0%, P = .008; 1-year DBF, 38.5% vs 65.8% vs 100%, P = .042). LC was favorable among lesions treated with SRS concurrent with or after PD-1 pathway inhibitor therapy comparedwith before PD-1 pathway inhibitor therapy (1-year LC, 100% vs 72.3%, P = .016). Three lesions transiently enlarged after SRS and then had partially or completely resolved on follow-up imaging. Four patients required steroids for SRS-associated toxicity. No patient experienced grade >= 4 toxicity.Conclusions: Concurrent treatmentwith SRS and PD-1 pathway inhibitors was associated with favorable OS and locoregional disease control. This combination of therapy was well tolerated and merits further evaluation in larger cohorts in a prospective setting. (C) 2018 Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2018 JUL 1 -PY - 2018 -VL - 101 -IS - 3 -SP - 624 -EP - 629 -DO - 10.1016/j.ijrobp.2018.02.175 -AN - WOS:000433877500021 -AD - Harvard Med Sch, Boston, MA USA -AD - Massachusetts Gen Hosp, Dept Radiat Oncol, 30 Fruit St, Boston, MA 02114 USA -AD - Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA -AD - Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA -Y2 - 2018-06-13 -ER - - -TY - JOUR -AU - Tummarello, D -AU - Mari, D -AU - Graziano, F -AU - Isidori, P -AU - Cetto, G -AU - Pasini, F -AU - Santo, A -AU - Cellerino, R -TI - A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses -T2 - CANCER -M3 - Article -AB - BAGKGROUND. Studies of chemotherapy for patients with small cell lung carcinoma (SCLC) have shown that teniposide (T) may have higher activity than etoposide (E). In this randomized, controlled Phase III study, the authors compared cyclophosphamide, doxorubicin, and vincristine (CAV) with E and CAV with T as induction treatments for patients with SCLC. A second objective of the study was to study patients who had achieved complete response (CR). They were considered for a second randomization to maintenance therapy, in which they would receive either recombinant interferon-alpha (rIFN-alpha) or no treatment.METHODS, From Tune 1990 to December 1995, 140 untreated SCLC patients were enrolled in this study. Patients were stratified by either limited disease (LD) or extensive disease (ED) and randomized to one of two treatment arms. The schedules for both arms included cyclophosphamide 1000 mg/m(2) administered intravenously (i.v.), doxorubicin 50 mg/m(2) i.v., and vincristine 2 mg i.v. on Day 1. Arm A (CAV-E) involved the addition of E 100 mg/m(2) i.v. on Days 2, 3, and 4; Arm B (CAV-T) involved the addition of T 60 mg/m(2) i.v. on Days 2, 3, and 4. Courses were repeated every 3 weeks. After 3 courses, patients with LD received chest radiotherapy and 2 additional consolidation courses, whereas patients with ED received 5 consecutive courses only. Patients with CR were considered for the second randomization, which consisted of either maintenance therapy with intramuscular (i.m.) rIFN-alpha-2b, 3 M.U., once a day for 9 months (IFN-alpha arm) or no therapy (control arm).RESULTS. At 5 years from start-up (3-year median observation time and 90% death rate), the study was closed. Results were as follows: 140 patients (71 in Arm A and 69 in Arm B) were eligible for survival analysis; 131 were evaluable for response and toxicity (66 in Arm A and 65 in Arm B), whereas 9 were not (6 early deaths and 3 with protocol violations). Among evaluable patients, 68 showed LD (35 assigned to Arm A and 33 to Arm B); the responses to treatment were 28.5% (10/35) CR and 51% (18/35) partial response (PR) to CAV-E, and 39% (13/33) CR and 39% PR (13/33) to CAV-T. Sixty-three patients showed ED (31 assigned to Arm A and 32 to Arm B); their responses were 22.5% (7/31) CR and 52% (16/31) PR to CAV-E, and 12.5% (4/32) CR and 50% (16/32) PR to CAV-T. Drug-related toxicity was WHO Grade 3-4 myelosuppression in 20% of 292 CAV-E courses and in 27% of 252 CAV-T courses. There were 6 toxic deaths, 1 in Arm A and 5 in Arm B (chi-square = 2.86); 2 patients in Arm A discontinued therapy due to persistent leukopenia and thrombocytopenia. No other remarkable toxicities were observed. Actuarial median survival (MS) was 13.7 months (range, 1.0-62.5 months) for patients with LD receiving CAV-E (Arm A) and 15.2 months (range, 0.5-68.2 months) for those receiving CAV-T (Arm B) (chi-square = 0.89); in patients with ED it was 10.5 months (range, 0.6-30.4 months) and 8.2 months (range, 0.2-24.8 months), respectively (chi-square = 3.42). Overall, MS was 12 months (range, 0.6-62.5 months) in Arm A and 10 months (range, 0.2-68.2 months) in Arm B (chi square = 0.059). Thirty-nine patients with CR (27.8%) were candidates for the second randomization. Among them, 26 patients (18.5%) complied with the program and were randomized as follows: 14 were assigned to the IFN-alpha arm and 12 Co the control arm. Starting from the second randomization, median time to progression was 12 months (range, 3-51 months) for patients in the IFN-alpha arm versus 7 months (range, 1-59 months) for patients in the control arm (chi-square = 0.12). MS was 15 months (range, 5-52.3 months) versus 9 months (range, 2-60.5 months) (chi-square = 0.13).CONCLUSIONS, This study did not show a wide difference inactivity and toxicity between CAV-E and CAV-T. The number of patients who entered the second randomization was too small to reach the second study endpoint. (C) 1997 American Cancer Society. -PU - WILEY-LISS -PI - NEW YORK -PA - DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 -SN - 0008-543X -DA - 1997 DEC 15 -PY - 1997 -VL - 80 -IS - 12 -SP - 2222 -EP - 2229 -AN - WOS:A1997YK93400002 -AD - UNIV VERONA,OSPED BORGO TRENTO,DEPT MED ONCOL,I-37100 VERONA,ITALY -AD - HOSP PESARO,DIV PNEUMOL,PESARO,ITALY -M2 - HOSP PESARO -Y2 - 1997-12-15 -ER - - -TY - JOUR -AU - Shukla, Nikhil Atul -AU - Althouse, Sandra -AU - Meyer, Zachary -AU - Hanna, Nasser -AU - Durm, Greg -TI - Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - Many patients with non-small-cell lung cancer (NSCLC) treated with immunotherapy experience immunerelated adverse events (irAEs). We evaluated the safety and efficacy of consolidation pembrolizumab after chemoradiotherapy in patients with stage III NSCLC. Patients who experienced irAEs did not have reduced in efficacy outcomes, and patients who discontinued therapy early because of irAEs and/or received immunosuppressive therapy for irAEs did not have reduced efficacy outcomes despite receiving fewer cycles of consolidation pembrolizumab. Background: Many patients with non-small-cell lung cancer (NSCLC) treated with immunotherapy experience immunerelated adverse events (irAEs). Patients with metastatic NSCLC who receive checkpoint inhibitors (CPI) and experience irAEs generally receive fewer cycles of CPI without decreased efficacy. However, the association between irAEs and efficacy outcomes in patients with locally advanced NSCLC treated with curative intent with CPI after chemoradiation has never been reported. Here we report a retrospective analysis of the association between irAEs and efficacy outcomes from the Hoosier Cancer Research Network (HCRN) LUN 14-179 single-arm phase 2 trial of consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC. Patients and Methods: A total of 92 eligible patients were enrolled from March 2015 to November 2016. Demographics, disease characteristics, and number of pembrolizumab cycles received were reported in patients with and without irAEs. Chi-square test was used for comparisons for categorical variables and Wilcoxon test for continuous variables. The Kaplan-Meier method was used to analyze time to metastatic disease or death (TMDD), progression-free survival (PFS), and overall survival (OS). A log-rank test was used to compare groups. Results: Any grade irAEs occurred in 55.4% of patients. There was no significant difference in number of pembrolizumab cycles received, TMDD, OS, or PFS in patients with and without irAEs. Patients who discontinued pembrolizumab early because of irAEs received significantly fewer cycles of pembrolizumab (5 vs 15, P 1/4 .0016) without a significant difference in TMDD, PFS, or OS. Similarly, patients who received immunosuppressive therapy received fewer numbers of cycles of pembrolizumab (4 vs 16, P < .001) without significantly reduced TMDD, PFS, or OS. Conclusion: irAEs due to pembrolizumab, regardless of grade or number of irAEs, were not associated with decreased efficacy outcomes. Furthermore, early discontinuation of pembrolizumab because of irAEs and/or treatment of irAEs with immunosuppressive therapy was not associated with a decrease in treatment efficacy. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2021 JUL -PY - 2021 -VL - 22 -IS - 4 -SP - 274 -EP - 281 -DO - 10.1016/j.cllc.2020.12.014 -AN - WOS:000682964900004 -C6 - JUL 2021 -AD - Indiana Univ, Melvin & Bren Simon Canc Ctr, Dept Hematol Oncol, Indianapolis, IN 46204 USA -AD - Indiana Univ, Melvin & Bren Simon Canc Ctr, Dept Biostat, Indianapolis, IN 46204 USA -AD - Indiana Univ Sch Med, Dept Internal Med, Indianapolis, IN 46202 USA -Y2 - 2021-08-19 -ER - - -TY - JOUR -AU - Ferraldeschi, Roberta -AU - Baka, Sofia -AU - Jyoti, Babita -AU - Faivre-Finn, Corinne -AU - Thatcher, Nick -AU - Lorigan, Paul -TI - Modern management of small-cell lung cancer -T2 - DRUGS -M3 - Review -AB - In this article, we review best standard practice for the management of small-cell lung cancer (SCLC) and indicate the likely areas of development over the next 5-10 years. A number of prognostic scores have been developed and these allow more rational decisions on treatment.Treatment with cisplatin plus etoposide with early, concurrent radiotherapy is the standard of care for patients with limited-stage disease (LD) suitable for this approach. A 5-year survival rate of 25% has been reported for concurrent hyperfractionated radiotherapy; however, the applicability of this in most busy hospitals is uncertain and this treatment is currently being compared with a high-dose, once-daily regimen. Patients unsuitable for concurrent chemo-radiotherapy are treated with a sequential approach. Patients with LD responding to treatment should be offered prophylactic cranial irradiation (PCI). A variety of strategies for improving survival have been investigated. Intensification of chemotherapy has not shown any clear survival advantage, but maintenance of dose intensity in patients with good prognosis is important. The evidence around maintenance therapy is conflicting and this is not routinely used.Patients with extensive-stage disease but few other adverse prognostic factors should be treated with a platinum compound plus etoposide, and carboplatin is a reasonable choice. Responding patients should be offered PCI as this is associated with a survival benefit. The initial positive results for irinotecan have not been repeated in a larger study. Age is not a prognostic factor, but caution needs to be exercised as prognostic scores do not reflect co-morbidity.Patients with relapsed disease have a poor prognosis, but there is evidence of a survival benefit for salvage chemotherapy in those fit for treatment. The choice of treatment will depend on a number of factors, including the disease-free interval. Topotecan is the only drug licensed in this indication, but myelosuppression is considerable.A number of new drugs are under evaluation and showing promise in SCLC. One of the most promising of these is amrubicin. A large randomised study has failed to show any benefit from the addition of thalidomide to chemotherapy with carboplatin and etoposide in extensive-stage disease patients responding to chemotherapy. Studies of a number of targeted treatments are also ongoing. The challenge for the future is to identify new targets, overcome drug-resistance mechanisms and redundancy in biological systems, and incorporate these new treatments into concurrent chemo-radiotherapy schedules. -PU - ADIS INT LTD -PI - NORTHCOTE -PA - 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND -SN - 0012-6667 -SN - 1179-1950 -DA - 2007 -PY - 2007 -VL - 67 -IS - 15 -SP - 2135 -EP - 2152 -DO - 10.2165/00003495-200767150-00003 -AN - WOS:000250702400003 -AD - Christie Hosp NHS Fdn Trust, CRUK Dept Med Oncol, Manchester M20 4BX, Lancs, England -Y2 - 2007-01-01 -ER - - -TY - JOUR -AU - Bozorgmehr, Farastuk -AU - Hommertgen, Adriane -AU - Krisam, Johannes -AU - Lasitschka, Felix -AU - Kuon, Jonas -AU - Maenz, Martin -AU - Huber, Peter E. -AU - Koenig, Laila -AU - Kieser, Meinhard -AU - Debus, Juergen -AU - Thomas, Michael -AU - Rieken, Stefan -TI - Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer-study protocol of the FORCE trial -T2 - BMC CANCER -M3 - Article -AB - Background Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free survival at critical sites. Recently introduced, immunotherapy for patients with non-squamous non-small cell lung carcinoma (NSCLC) has significantly improved outcome in this cohort. Preclinical and early clinical data suggest that the combination of photon radiation with programmed death-1 (PD-1) targeting immunotherapies may promote a strong and durable immune response against tumor manifestations both within and beyond radiation targets. Methods/design In the present prospective, two-group, non-randomized, open-label phase II trial, 130 patients with stage IV non-squamous NSCLC in 2nd-line or 3rd-line treatment will be included. 65 patients with a clinical indication for palliative radiotherapy to non-cerebral/non-pulmonary metastatic sites will receive 240 mg nivolumab followed by palliative radiotherapy with 5 x 4 Gray (Gy) = 20 Gy photon radiation, which will be initiated within 72 h after first nivolumab administration (Group A). 65 patients without an indication for radiotherapy will only receive nivolumab (Group B). Nivolumab will be further administered every two weeks in both groups and will be continued until progression and loss of clinical benefit or until occurrence of limiting toxicities. The primary endpoint will be the objective response rate (ORR) according to response evaluation criteria in solid tumors (RECIST) 1.1. Secondary endpoints will be progression-free survival (PFS) according to RECIST 1.1, overall survival, descriptive subgroup analyses according to PD-L1 expression, toxicity and quality of life. Since response patterns following immunotherapies differ from those after conventional cytostatic agents, both objective response rate and progression-free survival will additionally be assessed according to immune-related RECIST (irRECIST) criteria. Discussion The FORCE study will prospectively investigate response rates, progression-free and overall survival (OS), and toxicity of nivolumab with and without hypofractionated palliative radiotherapy in a group of 130 patients with metastatic non-small cell lung cancer (non-squamous histology) in 2nd-line or 3rd-line treatment. This trial will contribute prospective data to the repeatedly published observation that the combination of hypofractionated photon radiotherapy and medical immunotherapy is not only safe but will also promote antitumoral immune responses. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2019 NOV 8 -PY - 2019 -VL - 19 -IS - 1 -C7 - 1074 -DO - 10.1186/s12885-019-6205-0 -AN - WOS:000495640000014 -AD - Thoraxklin Univ Hosp Heidelberg, Dept Thorac Oncol, Rontgenstr 1, D-69126 Heidelberg, Germany -AD - German Ctr Lung Res DZL, TLRCH, Neuenheimer Feld 156, D-69120 Heidelberg, Germany -AD - Univ Hosp Heidelberg, Dept Radiat Oncol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany -AD - German Canc Res Ctr, Abt Mol Radioonkol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany -AD - HIRO, Neuenheimer Feld 280, D-69120 Heidelberg, Germany -AD - Univ Hosp Heidelberg, Inst Med Biometry & Informat, Neuenheimer Feld 130-3, D-69120 Heidelberg, Germany -AD - Univ Hosp Heidelberg, Inst Pathol, Neuenheimer Feld 430, D-69120 Heidelberg, Germany -AD - AIO Studien gGmbH, Berlin, Germany -M2 - Thoraxklin Univ Hosp Heidelberg -M2 - German Ctr Lung Res DZL -M2 - HIRO -M2 - AIO Studien gGmbH -Y2 - 2019-11-22 -ER - - -TY - JOUR -AU - Qin, Angel -AU - Rengan, Ramesh -AU - Lee, Sylvia -AU - Santana-Davila, Rafael -AU - Goulart, Bernardo H. L. -AU - Martins, Renato -AU - Baik, Christina -AU - Kalemkerian, Gregory P. -AU - Hassan, Khaled A. -AU - Schneider, Bryan J. -AU - Hayman, James A. -AU - Jolly, Shruti -AU - Hearn, Jason -AU - Lawrence, Theodore S. -AU - Towlerton, Andrea M. H. -AU - Tewari, Muneesh -AU - Thomas, Dafydd -AU - Zhao, Lili -AU - Brown, Noah -AU - Frankel, Timothy L. -AU - Warren, Edus H. -AU - Ramnath, Nithya -TI - A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Article -AB - Preclinical data and subset analyses from immunotherapy clinical trials indi- cate that prior radiation therapy was associated with better progression-free survival and overall survival when combined with immune checkpoint inhibitors in patients with non-small cell lung cancer. We present a prospective study of hypofractionated image guided radiation therapy (HIGRT) to a single site of metastatic disease concurrently with atezolizumab in patients with metastatic non-small cell lung cancer.Methods and Materials: Patients meeting eligibility criteria received 1200 mg of atezolizumab intravenously every 3 weeks with concurrent 3- or 5-fraction HIGRT starting no later than the second cycle. The 3-fraction regimen employed a minimum of 8 Gy per fraction compared with 6 Gy for the 5-fraction regimen. Imaging was obtained every 12 weeks to assess response.Results: From October 2015 to February 2017, 12 patients were enrolled in the study (median age 64; range, 55-77 years). The best response by the Response Evaluation in Solid Tumors criteria was partial response in 3 and stable disease in 3, for a disease control rate of 50%. Five patients had a grade 3 immune-related adverse event, including choreoretinitis (n = 1), pneumonitis (n = 1), transaminitis (n = 1), fatigue (n = 1), and peripheral neuropathy (n = 1). The median progression-free survival was 2.3 months, and the median overall survival was 6.9 months (range, 0.4-not reached). There was no clear association between peripheral blood T cell repertoire characteristics at baseline, PD-L1, or tumor mutations and response or outcome. One long-term survivor exhibited oligoclonal T cell populations in a baseline tumor biopsy that were consistently detected in peripheral blood over the entire course of the study.Conclusions: HIGRT plus atezolizumab resulted in an overall response rate of 25% and disease control rate of 50% in this pilot study. The incidence of grade 3 adverse events was similar to that of atezolizumab alone. Alhough it was a pilot study with limited sample size, the results generated hypotheses worthy of further investigation. (C) 2019 Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2020 SEP 1 -PY - 2020 -VL - 108 -IS - 1 -SP - 170 -EP - 177 -DO - 10.1016/j.ijrobp.2019.10.047 -AN - WOS:000561895300020 -AD - Univ Michigan, Dept Med Hematol Oncol, Ann Arbor, MI 48109 USA -AD - Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA -AD - Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA -AD - Univ Washington, Dept Med, Seattle, WA USA -AD - Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA -AD - Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA -AD - Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA -AD - Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA -Y2 - 2020-09-04 -ER - - -TY - JOUR -AU - Ojlerta, Asa Kristina -AU - Nebdal, Daniel -AU - Lund-Iversen, Marius -AU - Ellefsen, Renee Astrom -AU - Brustugun, Odd Terje -AU - Gran, Jon Michael -AU - Halvorsen, Ann Rita -AU - Helland, Aslaug -TI - Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy -T2 - ACTA ONCOLOGICA -M3 - Article -AB - BackgroundThe implementation of immune checkpoint inhibitors (ICI) into the standard care of advanced non-small cell lung cancer (NSCLC) has improved prognosis for this group of patients. However, long-term survival is rare. The aim of the study was to identify predictors of response and, especially, to investigate the impact radiotherapy might have on duration of response.Material and methodsThe association between pretreatment patient/tumor characteristics and progression-free survival (PFS), overall survival (OS), and lung cancer-specific survival was investigated in 78 patients receiving an ICI as >= 2nd line treatment for advanced NSCLC, using Cox regression analysis. Due to competing risk, cause-specific deaths were also examined with cumulative incidence plots.ResultsMedian OS was 12.6 months (95% CI 7.8-18.2) and median PFS 4.1 months (95% CI 3.0-6.2), after median follow-up time of 49.7 months (range 20.9-51.5). Increasing CRP and neutrophil/lymphocyte ratio (NLR), were associated with poor PFS (CRP: HR 1.49, 95% CI 1.12-1.98; NLR: HR 1.59, 95% CI 1.22-1.85) and OS (CRP: HR 1.94, 95% CI 1.47-2.56; NLR: HR 1.54, 95% CI 1.27-1.87). Radiotherapy prior to immunotherapy was not significantly associated with patient outcome. However, when the dataset was split at 6 months of follow-up, to be able to identify early and late predictors of prognosis, we found that patients receiving radiotherapy <6 months prior to immunotherapy had better PFS (HR: 0.27, 95% CI 0.09-0.84) and lung cancer-specific survival (HR: 0.41, 95% CI 0.18-0.95) after the first 6 months of follow-up, while increasing CRP (PFS: HR1.61, 95% CI 1.21-2.14; OS: HR2.04, 95% CI 1.51-2.74) and NLR (PFS: HR 1.57, 95% CI 1.29-1.91; OS: HR 1.63, 95% CI 1.35-1.97) were predictors of poor short-term prognosis.ConclusionsRadiotherapy may be of importance to achieve a long-lasting response to immunotherapy, while indicators of systemic inflammation can help in identifying patients with poor short-term prognosis. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 0284-186X -SN - 1651-226X -DA - 2021 FEB 1 -PY - 2021 -VL - 60 -IS - 2 -SP - 149 -EP - 156 -DO - 10.1080/0284186X.2020.1854851 -AN - WOS:000603751900001 -C6 - NOV 2020 -AD - Norwegian Radium Hosp, Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway -AD - Norwegian Radium Hosp, Oslo Univ Hosp, Dept Pathol, Oslo, Norway -AD - Vestre Viken Hosp Trust, Drammen Hosp, Sect Oncol, Drammen, Norway -AD - Univ Oslo, Oslo Ctr Biostat & Epidemiol, Oslo, Norway -AD - Oslo Univ Hosp, Oslo, Norway -AD - Univ Oslo, Dept Clin Med, Oslo, Norway -AD - Norwegian Radium Hosp, Oslo Univ Hosp, Dept Oncol, Oslo, Norway -M2 - Vestre Viken Hosp Trust -Y2 - 2021-01-22 -ER - - -TY - JOUR -AU - WINTERS, IAN PAUL -TI - Relating Drugs to Genotypes to Transform Precision Cancer Therapeutics with Tuba-seq - a Novel, Highly Scalable and Quantitative Preclinical Experimental Oncology Platform -M3 - Awarded Grant -AB - PROJECT SUMMARYD2G Oncology, Inc. proposes to develop a novel preclinical experimental platform that will effectively relatecancer drugs to genotypes (“D2G”) to predict pharmacogenomic interactions. D2G Oncology's innovativeapproach dramatically improves on established autochthonous mouse models of human cancer. These provenmodels allow controlled genomic alterations to initiate tumors in vivo in an appropriate immune-competentmicroenvironment and faithfully recapitulate progression of human cancer. D2G's innovative methods for thefirst time enable these animal models to become truly scalable and rigorously quantitative, and hence prac-tical to support drug discovery. D2G's approach can efficiently interrogate a large matrix of tumor genotypes topredict differential patient responses to therapies. Pharmaceutical companies are eager to obtain this infor-mation. D2G will significantly advance the state of the art in precision cancer therapy by helping pharma torationally select candidate compounds to advance and better match them to patients. D2G's oncology platformwill increase the success rate of clinical trials and lead to more effective personalized cancer treatments.The key innovation is a novel tumor barcoding and sequencing (Tuba-seq) pipeline. Every clonal tumor isuniquely barcoded, so the identity and number of cancer cells in each tumor can be readily quantified frombulk tumor-bearing tissues. Combined with lentiviral-mediated CRISPR/Cas9 somatic genome editing, tumorbarcoding allows many predefined tumor genotypes to be generated all at once in individual animals andtracked separately. Tuba-seq enables many tens of experiments (which would each ordinarily require separatecohorts of mice) to be multiplexed into a single mouse. Compared with conventional genetically engineeredmouse models, this approach enormously enhances scalability, introduces rigorous quantification, and reducessources of variation.The overall goal of the proposed Direct Phase 2 SBIR project is to transform the Tuba-seq pipeline into a robustplatform that can be marketed as a commercial service to pharmaceutical companies. Specific aims are to (1)expand the panel of tumor suppressor genes that the platform interrogates and carefully calibrate their effectsizes and (2) rigorously validate the ability of the platform to resolve small but clinically meaningful differencesin tumor suppressor gene-drug effect sizes with high statistical confidence, relying only on small cohorts of ani-mals.D2G will create the first practical and scalable preclinical experimental modeling approach that can assess howcandidate drugs interact with diverse, precisely-engineered cancer genotypes to predict differential patientresponses to therapy. -DA - 2020 -PY - 2020 -AN - GRANTS:15000973 -G1 - 10007689; 1R44CA250672-01; R44CA250672 -AD - D2G ONCOLOGY, INC. -M2 - D2G ONCOLOGY, INC. -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Nardone, Valerio -AU - Tini, Paolo -AU - Pastina, Pierpaolo -AU - Botta, Cirino -AU - Reginelli, Alfonso -AU - Carbone, Salvatore Francesco -AU - Giannicola, Rocco -AU - Calabrese, Grazia -AU - Tebala, Carmela -AU - Guida, Cesare -AU - Giudice, Aldo -AU - Barbieri, Vito -AU - Tassone, Pierfrancesco -AU - Tagliaferri, Pierosandro -AU - Cappabianca, Salvatore -AU - Capasso, Rosanna -AU - Luce, Amalia -AU - Caraglia, Michele -AU - Mazzei, Maria Antonietta -AU - Pirtoli, Luigi -AU - Correale, Pierpaolo -TI - Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab -T2 - ONCOLOGY LETTERS -M3 - Article -AB - Immune checkpoint blockade is an emerging anticancer strategy, and Nivolumab is a human mAb to PD-1 that is used in the treatment of a number of different malignancies, including non-small cell lung cancer (NSCLC), kidney cancer, urothelial carcinoma and melanoma. Although the use of Nivolumab prolongs survival in a number of patients, this treatment is hampered by high cost. Therefore, the identification of predictive markers of response to treatment in patients is required. In this context, PD-1/PDL1 blockade antitumor effects occur through the reactivation of a pre-existing immune response, and the efficacy of these effects is strictly associated with the presence of necrosis, hypoxia and inflammation at the tumour sites. It has been indicated that these events can be evaluated by specific assessments using a computed tomography (CT) texture analysis (TA) or radiomics. Therefore, a retrospective study was performed, which aimed to evaluate the potential use of this analysis in the identification of patients with NSCLC who may benefit from Nivolumab treatment. A retrospective analysis was performed of 59 patients with metastatic NSCLC who received Nivolumab treatment between January 2015 and July 2017 at Siena University Hospital (35 patients, training dataset), Catanzaro University Hospital and Reggio Calabria Grand Metropolitan Hospital, Italy (24 patients, validation dataset). Pre- and post-contrast CT sequences were used to contour the gross tumour volume (GTV) of the target lesions prior to Nivolumab treatment. The impact of variations on contouring was analysed using two delineations, which were performed on each patient, and the TA parameters were tested for reliability using the Intraclass Coefficient Correlation method (ICC). All analyses for the current study were performed using LifeX Software (c). Imaging, clinical and pathological parameters were correlated with progression free survival and overall survival (OS) using Kaplan Meier analysis. An external validation testing was performed for the TA Score using the validation dataset. A total of 59 patients were included in the analysis of the present study. The reliability ICC analysis of 14 TA parameters indicated a highly reproducibility (ICC >0.70, single measure) in 12 (85%) pre- contrast and 13 (93%) post-contrast exams. A specific cut-off was detected for each of the following parameters: volume (score 1 >36 ml), histogram entropy (score 1 > 1.30), compacity (score 1 <3), gray level co-occurrence matrix (GLCM)-entropy (score 1 >1.80), GLCM-Dissimilarity (score 1 >5) and GLCM-Correlation (score 1<0.54). The global texture score allowed the classification of two subgroups of Low (Score 0-1; 36 patients; 61%) and High Risk patients (Score >1; 23 patients; 39%) that respectively, showed a median OS of 26 (mean +/- SD: 18 +/- 1.98 months; 95% CI 14-21 months) and 5 months (mean +/- SD: 6 +/- 0.99 months; 95% CI: 4-8 months; P=0.002). The current study indicated that TA parameters can identify patients that will benefit from PD-1 blockage by defining the radiological settings that are potentially suggestive of an active immune response. These results require further confirmation in prospective trials. -PU - SPANDIDOS PUBL LTD -PI - ATHENS -PA - POB 18179, ATHENS, 116 10, GREECE -SN - 1792-1074 -SN - 1792-1082 -DA - 2020 FEB -PY - 2020 -VL - 19 -IS - 2 -SP - 1559 -EP - 1566 -DO - 10.3892/ol.2019.11220 -AN - WOS:000508895000055 -AD - Osped Mare, Integrated Dept Diagnost Radiol & Radiotherapy, Unit Radiat Oncol, I-80147 Naples, Italy -AD - Univ Hosp Siena, Oncol Dept, Unit Radiat Oncol, I-53100 Siena, Italy -AD - Magna Graecia Univ Catanzaro, AOU Mater Domini, Integrated Area Med Oncol, I-88100 Catanzaro, Italy -AD - Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy -AD - Univ Campania L Vanvitelli, Dept Precis Med, 7 Via Crecchio, I-80138 Naples, Italy -AD - Univ Hosp Siena, Emergency Dept & Diagnost Serv, Unit Med Imaging, I-53100 Siena, Italy -AD - Grand Metropolitan HospitalBianchi Melacrino More, Oncol Dept, Unit Med Oncol, I-89124 Reggio Di Calabria, Italy -AD - Grand Metropolitan HospitalBianchi Melacrino More, Dept Diagnost Serv, Unit Radiol, I-89124 Reggio Di Calabria, Italy -AD - IRCCS Ist Nazl Tumori Fdn G Pascale, Epidemiol Unit, I-80131 Naples, Italy -M2 - Osped Mare -M2 - Grand Metropolitan HospitalBianchi Melacrino More -M2 - Grand Metropolitan HospitalBianchi Melacrino More -Y2 - 2020-02-04 -ER - - -TY - JOUR -AU - Xu, J. -AU - Wang, P. -AU - Li, Y. -AU - Shi, X. -AU - Yu, J. -AU - Teng, F. -TI - Using MRI Radiomics to Predict the Efficacy of Immunotherapy for Brain Metastasis in Patients with Non-small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2142 -SP - E65 -EP - E65 -AN - WOS:001079706800135 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Shandong Prov Key Lab Radiat Oncol, Jinan, Shandong, Peoples R China -AD - Shandong Univ, Cheeloo Coll Med, Shandong Canc Hosp & Inst, Jinan, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Yao, Y. -AU - Li, B. -AU - Song, R. -AU - Yang, L. -AU - Zou, B. -AU - Wang, L. -TI - Thoracic Radiotherapy Improves the Outcomes of Extensive Stage Small-Cell Lung Cancer Patients Receiving First-Line Immunotherapy: A Multicenter Retrospective Analysis -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 210 -SP - S57 -EP - S57 -AN - WOS:001079706803111 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Jinan, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Olivares-Hernandez, Alejandro -AU - Roldan-Ruiz, Jonnathan -AU - Miramontes-Gonzalez, Jose Pablo -AU - Toribio-Garcia, Irene -AU - Garcia-Hernandez, Juan Luis -AU - Posado-Dominguez, Luis -AU - Bellido-Hernandez, Lorena -AU - Cruz-Hernandez, Juan Jesus -AU - Fonseca-Sanchez, Emilio -AU - del Barco-Morillo, Edel -TI - Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis -T2 - CHINESE CLINICAL ONCOLOGY -M3 - Review -AB - Background: Non-small cell lung cancer (NSCLC) has undergone a major change in the last decade in terms of survival and prognosis due to the introduction of new drugs in the last 10 years. One of the drugs with the most promising preliminary results in NSCLC are PARP inhibitors (iPARPs), whose clinical trials have very heterogeneous results. The use of iPARPs in NSCLC may lead to increased survival in several selected patients, and their use may become a standard in the coming years. However, there is currently controversy about the efficacy and safety of these drugs in NSCLC. Therefore, future studies are needed to evaluate their role in these tumours. The aim of this review is to evaluate the efficacy and safety of iPARPs in the treatment of NSCLC. Methods: We performed a systematic review with meta-analysis using the different clinical trials (PubMed, COCHRANE, Science Direct, EMBASE and the clinical trial registry) that evaluated the efficacy and safety of iPARP in NSCLC by PRISMA criteria. The primary endpoint was to evaluate the efficacy of iPARPs in the treatment of NSCLC through overall and progression-free survival (OS and PFS). Two authors independently reviewed the articles and abstracts (A.O.H. and J.R.R.), with subsequent confirmation by a third independent reviewer (E.B.M.). The heterogeneity of the included studies in the meta-analysis was assessed by using the I2 statistic. Results: A total of 14 articles were included for analysis (2,651 patients). A total of 1,503 patients were randomised in iPARP arms and 1,148 patients were included in control arms. Three clinical trials were conducted in localised or locally advanced NSCLC and 11 in advanced or metastatic stages. The global OS of the meta-analysis showed a hazard ratio (HR) of 0.85 [95% confidence interval (CI): 0.74-0.97] with a heterogeneity (I2) of 0% (P=0.84). PFS showed a HR of 0.93 (95% CI: 0.74-1.17) with an I2=51% (P=0.07). The overall adverse event rate (grade 1-5) was similar in both iPARP and placebo arms. Conclusions: iPARPs are a future promising in the treatment of NSCLC in terms of efficacy and safety. Proper patient selection [homologous recombination deficiency (HRD) positive] is key for future clinical trials. The studies conducted to date open a new approach for a novel treatment modality in NSCLC. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2304-3865 -SN - 2304-3873 -DA - 2023 DEC 18 -PY - 2023 -VL - 12 -IS - 6 -C7 - 62 -DO - 10.21037/cco-23-58 -AN - WOS:001134064200001 -AD - Univ Hosp Salamanca, Dept Med Oncol, Salamanca, Spain -AD - Biomed Res Inst Salamanca IBSAL, Salamanca, Spain -AD - Univ Hosp Rio Hortega, Dept Internal Med, Valladolid, Spain -AD - Univ Valladolid, Fac Med, Valladolid, Spain -AD - Univ Hosp Leon, Dept Cardiol, Leon, Spain -AD - Univ Salamanca, Fac Salamanca, Salamanca, Spain -AD - Univ Hosp Salamanca, Dept Med Oncol, Lung Canc Unit, Paseo San Vicente 182, Salamanca 37007, Spain -AD - Univ Hosp Leon, Dept Cardiol, Calle Altos Nava,S-N, Leon 24008, Spain -AD - Univ Hosp Salamanca, Dept Med Oncol, Paseo San Vicente 182, Salamanca 37007, Spain -M2 - Biomed Res Inst Salamanca IBSAL -M2 - Univ Hosp Salamanca -M2 - Univ Hosp Salamanca -Y2 - 2024-03-18 -ER - - -TY - JOUR -AU - Perez, Bradford A. -AU - Kim, Sungjune -AU - Wang, Minhsuan -AU - Karimi, Ahmad M. -AU - Powell, Chase -AU - Li, Jiannong -AU - Dilling, Thomas J. -AU - Chiappori, Alberto -AU - Latifi, Kujtim -AU - Rose, Trevor -AU - Lannon, Austin -AU - MacMillan, Gretchen -AU - Saller, James -AU - Grass, G. Daniel -AU - Rosenberg, Stephen -AU - Gray, Jhanelle -AU - Haura, Eric -AU - Creelan, Ben -AU - Tanvetyanon, Tawee -AU - Saltos, Andreas -AU - Shafique, Michael -AU - Boyle, Theresa A. -AU - Schell, Michael J. -AU - Conejo-Garcia, Jose R. -AU - Antonia, Scott J. -TI - Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Article -AB - Purpose: Consolidative thoracic radiation therapy (TRT) has been shown to improve outcomes for patients with extensive stage small cell lung cancer. We hypothesized that the addition of ipilimumab (IPI) and nivolumab (NIVO) after TRT would improve outcomes for patients with extensive stage small cell lung cancer.Methods and Materials: Eligibility required stable disease or better after platinum doublet chemotherapy. Study therapy included consolidative TRT to 30 Gy in 10 fractions, targeting residual primary tumor and initially involved regional lymph nodes. Two weeks after TRT, patients received concurrent IPI (3 mg/kg) and NIVO (1 mg/kg) every 3 weeks for 4 doses followed by NIVO monotherapy (480 mg) every 4 weeks until progression or up to 1 year.Results: The study enrolled 21 patients, with 6-month progression-free survival (PFS) of 24% (90% confidence interval [CI], 11%-40%) and a median PFS of 4.5 months (95% CI, 2.7%-4.6%). The 12-month overall survival (OS) was 48% (95% CI, 29%-64%) with a median OS of 11.7 months (95% CI, 4.7%-16.0%). Fifty-two percent of patients had >1 possibly related grade 3 to 4 immune-related adverse event. Grade 3 pulmonary and gastrointestinal immune-related adverse events were recorded in 19% and 24% of patients, respectively. Exploratory analysis showed increased cytotoxic T cell (CD3+CD8+) tumor infiltration was associated with favorable PFS (P = .01) and OS (P = .02). Reduction in peripheral blood CD3+CD8+ from baseline to after first dose of IPI/NIVO was associated with improved PFS (P = .02) and OS (P = .02).Conclusions: Consolidative IPI and NIVO after platinum-based chemotherapy and TRT demonstrated a toxicity profile consistent with the known adverse events attributable to IPI and NIVO. Although the study regimen did not significantly improve PFS, the OS was higher than historic expectations. CD3+CD8+ tumor infiltration and migration may identify patients most likely to have improved outcomes in small cell lung cancer. (C) 2020 Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 FEB 1 -PY - 2021 -VL - 109 -IS - 2 -SP - 425 -EP - 435 -DO - 10.1016/j.ijrobp.2020.09.031 -AN - WOS:000607368300017 -C6 - JAN 2021 -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL 33612 USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL 33612 USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL 33612 USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat, Tampa, FL USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Radiol, Tampa, FL USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Clin Trials Off, Tampa, FL USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA -AD - Duke Univ, Med Ctr, Dept Med Oncol, Duke Canc Inst, Durham, NC 27706 USA -Y2 - 2021-02-09 -ER - - -TY - JOUR -AU - Miyawaki, Taichi -AU - Kenmotsu, Hirotsugu -AU - Harada, Hideyuki -AU - Ohde, Yasuhisa -AU - Chiba, Yasutaka -AU - Haratani, Koji -AU - Okimoto, Tamio -AU - Sakamoto, Tomohiro -AU - Wakuda, Kazushige -AU - Ito, Kentaro -AU - Uemura, Takehiro -AU - Sakata, Shinya -AU - Kogure, Yoshihito -AU - Nishimura, Yasumasa -AU - Nakagawa, Kazuhiko -AU - Yamamoto, Nobuyuki -TI - Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L) -T2 - BMC CANCER -M3 - Article -AB - Background: Synchronous oligometastatic non-small cell lung cancer (NSCLC) is generally characterised by the limited number of metastases at the time of diagnosis. Several clinical trials have shown that local ablative therapy (LAT) at all sites of the disease might be beneficial for patients with oligometastatic NSCLC. In recent years, the combination of programmed cell death 1 (PD-1) inhibitors or programmed cell death ligand 1 with cytotoxic chemotherapy has become a new standard treatment for patients with metastatic NSCLC. Furthermore, multisite LAT would inherently reduce the overall tumour burden, and this could promote T cell reinvigoration to enhance the efficacy of PD-1 inhibitors. Few studies have evaluated the efficacy of the combination of PD-1 inhibitors with LAT at all sites of disease. The aim of the present multicentre single-arm phase II study is to evaluate the efficacy of LAT at all sites of disease following standard platinum doublet chemotherapy with pembrolizumab in patients with oligometastatic NSCLC.Methods: Thirty patients with synchronous oligometastatic NSCLC will be enrolled in the trial. All patients will receive 2-4 cycles of a systemic treatment including pembrolizumab and chemotherapy as induction therapy. Patients who will receive LAT will be determined by a multidisciplinary tumour board, including medical oncologists, radiation oncologists, and thoracic surgeons. LAT will be administered at all sites of disease within 21-56 days of the last dose of induction therapy and will be followed by maintenance therapy within 42 days of the last day of LAT. The primary endpoint is the progression-free survival (PFS) rate of 24 months from the date of initiation of LAT. The secondary endpoints are toxicity, response to induction therapy, PFS, overall survival, and the frequency of LAT.Discussion: This study will provide novel data on the efficacy and safety profile of the combination of LAT and chemotherapy plus immune-checkpoint inhibitors in patients with synchronous oligometastatic NSCLC. If the primary endpoint of this study is met, extensive phase III studies further assessing this strategy will be recommended. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2021 OCT 18 -PY - 2021 -VL - 21 -IS - 1 -C7 - 1121 -DO - 10.1186/s12885-021-08851-z -AN - WOS:000708490200002 -AD - Shizuoka Canc Ctr, Div Thorac Oncol, 1007 Shimonagakubo,Nagaizumi Cho, Shizuoka 4118777, Japan -AD - Juntendo Univ, Dept Resp Med, Grad Sch Med, Tokyo, Japan -AD - Shizuoka Canc Ctr, Radiat & Proton Therapy Ctr, Shizuoka, Japan -AD - Shizuoka Canc Ctr, Div Thorac Surg, Shizuoka, Japan -AD - Kindai Univ Hosp, Clin Res Ctr, Osaka, Japan -AD - Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan -AD - Shimane Univ, Dept Internal Med, Div Med Oncol & Resp Med, Fac Med, Izumo, Shimane, Japan -AD - Tottori Univ, Dept Multidisciplinary Internal Med, Div Resp Med & Rheumatol, Yonago, Tottori, Japan -AD - Matsusaka Municipal Hosp, Resp Centor, Matsusaka, Japan -AD - Nagoya City Univ, Grad Sch Med Sci, Dept Resp Med Allergy & Clin Immunol, Nagoya, Aichi, Japan -AD - Kumamoto Univ Hosp, Dept Resp Med, Kumamoto, Japan -AD - Natl Hosp Org, Dept Resp Med, Nagoya Med Ctr, Nagoya, Aichi, Japan -AD - Kindai Univ, Dept Radiat Oncol, Fac Med, Osaka, Japan -AD - Wakayama Med Univ, Internal Med 3, Wakayama, Japan -M2 - Kindai Univ Hosp -M2 - Matsusaka Municipal Hosp -Y2 - 2021-10-29 -ER - - -TY - JOUR -AU - GEDEON, PATRICK C -TI - Dual targeting of cGAS-STING and splicing to prime lung cancer immunogenicity -M3 - Awarded Grant -AB - Project SummaryLung cancer is the leading cause of cancer-related death in the United States. Non-small cell lung cancer(NSCLC) is the most common type of lung cancer and despite aggressive treatment strategies that includemedical therapy, surgical resection, and radiation therapy, 5-year survival rates for patients with lung cancerremain dismal. Recently, the US Food and Drug Administration (FDA) approved several immune checkpointinhibitor-based therapies for the treatment of NSCLC, establishing immunotherapy as an effective therapeuticoption and standard-of-care treatment for NSCLC. Despite this, many patients fail to respond to immunecheckpoint blockade (ICB) and the subgroup of patients with KRAS and STK11 commutations (KL) hasemerged as a particularly aggressive, immunosuppressive form of NSCLC resistant to ICB. Our group hasrecently discovered that by treating KL-mutated NSCLC with epigenetic de-repressing agents, expression of akey protein in the immune response against lung cancer, stimulator of interferon genes (STING), is restored.When stimulus for the STING pathway is subsequently provided through pulsed inhibition of a spindleassembly checkpoint protein, monopolar spindle 1 (MPS1), potent anti-tumor responses occur, restoringsensitivity to ICB. While these findings have yet to be validated in clinical samples of KL-mutated NSCLC,these samples are now available to use for study. Validation of this therapeutic strategy will show that it ispossible to overcome KL-mutation induced immunosuppression, though, it does not generate neoantigens todrive durable anti-neoplastic immune responses. Fortunately, MPS1 shares kinase homology with CDC2-likekinase (CLK2), a key regulator of mRNA splicing, and dual MPS1/CLK2 inhibitors have been developed. Thisprovides the unique opportunity to additionally dive durable anti-tumor immune responses throughsimultaneous pharmacological disruption of mRNA splicing. Indeed, pharmacological modulation of splicingwas recently demonstrated as a definitive, untapped method to generate neoantigens that elicit anti-tumorimmune responses. The overall goal of this fellowship proposal is, therefore, to provide advanced post-doctoraltraining in translational cancer immunotherapy research while evaluating a novel approach to enhanceimmunogenicity in a highly aggressive and resistant form of NSCLC. We will accomplish this by (1) validatingthe effect of epigenetic de-repression of STING and pulsed MPS1 inhibition in clinical samples of ICB-resistant,KL-mutated NSCLC and (2) examining mRNA splice disruption and neoantigen generation in dual MPS1/CLK2inhibitor treated KL-mutated NSCLC. Together these aims will seek to improve therapeutic outcomes forpatients with NSCLC while enhancing the pool of highly trained physician-scientists. -DA - 2023 -PY - 2023 -AN - GRANTS:17349509 -G1 - 10749760; 1F32CA284615-01; F32CA284615 -AD - BRIGHAM AND WOMEN'S HOSPITAL -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Cortellini, Alessio -AU - Tiseo, Marcello -AU - Banna, Giuseppe L. -AU - Cappuzzo, Federico -AU - Aerts, Joachim G. J., V -AU - Barbieri, Fausto -AU - Giusti, Raffaele -AU - Bria, Emilio -AU - Cortinovis, Diego -AU - Grossi, Francesco -AU - Migliorino, Maria R. -AU - Galetta, Domenico -AU - Passiglia, Francesco -AU - Santini, Daniele -AU - Berardi, Rossana -AU - Morabito, Alessandro -AU - Genova, Carlo -AU - Mazzoni, Francesca -AU - Di Noia, Vincenzo -AU - Signorelli, Diego -AU - Tuzi, Alessandro -AU - Gelibter, Alain -AU - Marchetti, Paolo -AU - Macerelli, Marianna -AU - Rastelli, Francesca -AU - Chiari, Rita -AU - Rocco, Danilo -AU - Gori, Stefania -AU - De Tursi, Michele -AU - Mansueto, Giovanni -AU - Zoratto, Federica -AU - Santoni, Matteo -AU - Tudini, Marianna -AU - Rijavec, Erika -AU - Filetti, Marco -AU - Catino, Annamaria -AU - Pizzutilo, Pamela -AU - Sala, Luca -AU - Citarella, Fabrizio -AU - Marco, Russano -AU - Torniai, Mariangela -AU - Cantini, Luca -AU - Targato, Giada -AU - Sforza, Vincenzo -AU - Nigro, Olga -AU - Ferrara, Miriam G. -AU - D'Argento, Ettore -AU - Buti, Sebastiano -AU - Bordi, Paola -AU - Antonuzzo, Lorenzo -AU - Scodes, Simona -AU - Landi, Lorenza -AU - Guaitoli, Giorgia -AU - Baldessari, Cinzia -AU - Della Gravara, Luigi -AU - Dal Bello, Maria Giovanna -AU - Belderbos, Robert A. -AU - Bironzo, Paolo -AU - Carnio, Simona -AU - Ricciardi, Serena -AU - Grieco, Alessio -AU - De Toma, Alessandro -AU - Proto, Claudia -AU - Friedlaender, Alex -AU - Cantale, Ornella -AU - Ricciuti, Biagio -AU - Addeo, Alfredo -AU - Metro, Giulio -AU - Ficorella, Corrado -AU - Porzio, Giampiero -TI - Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% -T2 - CANCER IMMUNOLOGY IMMUNOTHERAPY -M3 - Article -AB - Background Single-agent pembrolizumab represents the standard first-line option for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of >= 50%. Methods We conducted a multicenter retrospective study aimed at evaluating the clinicopathologic correlates of pembrolizumab effectiveness in patients with treatment-naive NSCLC and a PD-L1 expression of >= 50%. Results One thousand and twenty-six consecutive patients were included. The objective response rate (ORR) was 44.5% (95% CI 40.2-49.1), while the median progression free survival (PFS) and overall survival (OS) were 7.9 months (95% CI 6.9-9.5; 599 events) and 17.2 months (95% CI 15.3-22.3; 598 censored patients), respectively. ECOG-PS >= 2 (p < 0.0001) and bone metastases (p = 0.0003) were confirmed to be independent predictors of a worse ORR. Former smokers (p = 0.0002), but not current smokers (p = 0.0532) were confirmed to have a significantly prolonged PFS compared to never smokers at multivariate analysis. ECOG-PS (p < 0.0001), bone metastases (p < 0.0001) and liver metastases (p < 0.0001) were also confirmed to be independent predictors of a worse PFS. Previous palliative RT was significantly related to a shortened OS (p = 0.0104), while previous non-palliative RT was significantly related to a prolonged OS (p = 0.0033). Former smokers (p = 0.0131), but not current smokers (p = 0.3433) were confirmed to have a significantly prolonged OS compared to never smokers. ECOG-PS (p < 0.0001), bone metastases (p < 0.0001) and liver metastases (p < 0.0001) were also confirmed to be independent predictors of a shortened OS. A PD-L1 expression of >= 90%, as assessed by recursive partitioning, was associated with significantly higher ORR (p = 0.0204), and longer and OS (p = 0.0346) at multivariable analysis. Conclusion Pembrolizumab was effective in a large cohort of NSCLC patients treated outside of clinical trials. Questions regarding the effectiveness in clinical subgroups, such as patients with poorer PS and with liver/bone metastases, still remain to be addressed. We confirmed that the absence of tobacco exposure, and the presence of bone and liver metastasis are associated with worse clinical outcomes to pembrolizumab. Increasing levels of PD-L1 expression may help identifying a subset of patients who derive a greater benefit from pembrolizumab monotherapy. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 0340-7004 -SN - 1432-0851 -DA - 2020 NOV -PY - 2020 -VL - 69 -IS - 11 -SP - 2209 -EP - 2221 -DO - 10.1007/s00262-020-02613-9 -AN - WOS:000536438800001 -C6 - MAY 2020 -AD - St Salvatore Hosp, Med Oncol, Laquila, Italy -AD - Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio, I-67100 Laquila, Italy -AD - Univ Hosp Parma, Med Oncol Unit, Parma, Italy -AD - Univ Parma, Dept Med & Surg, Parma, Italy -AD - United Lincolnshire Hosp NHS Trust, Oncol Dept, Lincoln, England -AD - AUSL Romagna, Dept Oncol & Hematol, Ravenna, Italy -AD - Erasmus MC, Dept Pulm Dis, Rotterdam, Netherlands -AD - Modena Univ Hosp, Dept Oncol & Hematol, Modena, Italy -AD - St Andrea Hosp Fo Rome, Med Oncol Unit, Rome, Italy -AD - Fdn Policlin Univ A Gemelli IRCCS, Comprehens Canc Ctr, Rome, Italy -AD - Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, Rome, Italy -AD - Osped San Gerardo, Med Oncol, Monza, Italy -AD - Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy -AD - St Camillo Forlanini Hosp, Pneumooncol Unit, Rome, Italy -AD - IRCCS Ist Tumori Giovanni Paolo II, Thorac Oncol Unit, Clin Canc Ctr, Bari, Italy -AD - Univ Turin, San Luigi Gonzaga Hosp, Dept Oncol, Orbassano, TO, Italy -AD - Campus Biomed Univ, Med Oncol, Rome, Italy -AD - Univ Politecn Marche, Oncol Clin, Osped Riuniti Ancona, Ancona, Italy -AD - Ist Nazl Tumori Fdn G Pascale, IRCCS, Thorac Med Oncol, Naples, Italy -AD - IRCCS Osped Policlin San Martino, Lung Canc Unit, Genoa, Italy -AD - Careggi Univ Hosp, Dept Oncol, Florence, Italy -AD - Univ Hosp Foggia, Med Oncol, Foggia, Italy -AD - Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy -AD - ASST Sette Laghi, Med Oncol, Varese, Italy -AD - Sapienza Univ Rome, Policlin Umberto I, Med Oncol B, Rome, Italy -AD - Sapienza Univ Rome, Dept Clin & Mol Med, Rome, Italy -AD - Univ Hosp Santa Maria Della Misericordia, Dept Oncol, Udine, Italy -AD - Fermo Area Vasta 4, Med Oncol, Fermo, Italy -AD - Osped Riuniti Padova Sud Madre Teresa Di Calcutta, Med Oncol, Monselice, Italy -AD - Monaldi Hosp, Pneumooncol Unit, Naples, Italy -AD - IRCCS Osped Sacro Cuore Don Calabria, Oncol Unit, Negrar, VR, Italy -AD - Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy -AD - F Spaziani Hosp, Med Oncol, Frosinone, Italy -AD - Santa Maria Goretti Hosp, Med Oncol, Latina, Italy -AD - Macerata Hosp, Dept Oncol, Macerata, Italy -AD - AV2 Fabriano ASUR Marche, Med Oncol, Fabriano, Italy -AD - Univ Hosp Geneva, Oncol Dept, Geneva, Switzerland -AD - Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA -AD - Univ Bologna, S Orsola Malpighi Hosp, Div Med Oncol, I-40138 Bologna, Italy -AD - Azienda Osped Perugia, Santa Maria della Misericordia Hosp, Dept Med Oncol, Perugia, Italy -M2 - St Salvatore Hosp -M2 - United Lincolnshire Hosp NHS Trust -M2 - St Andrea Hosp Fo Rome -M2 - IRCCS Osped Policlin San Martino -M2 - ASST Sette Laghi -M2 - Fermo Area Vasta 4 -M2 - Osped Riuniti Padova Sud Madre Teresa Di Calcutta -M2 - Monaldi Hosp -M2 - F Spaziani Hosp -M2 - Santa Maria Goretti Hosp -M2 - Macerata Hosp -M2 - AV2 Fabriano ASUR Marche -Y2 - 2020-06-11 -ER - - -TY - JOUR -AU - WINTERS, IAN PAUL -TI - Relating Drugs to Genotypes to Transform Precision Cancer Therapeutics with Tuba-seq - a Novel, Highly Scalable and Quantitative Preclinical Experimental Oncology Platform -M3 - Awarded Grant -AB - PROJECT SUMMARYD2G Oncology, Inc. proposes to develop a novel preclinical experimental platform that will effectively relatecancer drugs to genotypes (“D2G”) to predict pharmacogenomic interactions. D2G Oncology's innovativeapproach dramatically improves on established autochthonous mouse models of human cancer. These provenmodels allow controlled genomic alterations to initiate tumors in vivo in an appropriate immune-competentmicroenvironment and faithfully recapitulate progression of human cancer. D2G's innovative methods for thefirst time enable these animal models to become truly scalable and rigorously quantitative, and hence prac-tical to support drug discovery. D2G's approach can efficiently interrogate a large matrix of tumor genotypes topredict differential patient responses to therapies. Pharmaceutical companies are eager to obtain this infor-mation. D2G will significantly advance the state of the art in precision cancer therapy by helping pharma torationally select candidate compounds to advance and better match them to patients. D2G's oncology platformwill increase the success rate of clinical trials and lead to more effective personalized cancer treatments.The key innovation is a novel tumor barcoding and sequencing (Tuba-seq) pipeline. Every clonal tumor isuniquely barcoded, so the identity and number of cancer cells in each tumor can be readily quantified frombulk tumor-bearing tissues. Combined with lentiviral-mediated CRISPR/Cas9 somatic genome editing, tumorbarcoding allows many predefined tumor genotypes to be generated all at once in individual animals andtracked separately. Tuba-seq enables many tens of experiments (which would each ordinarily require separatecohorts of mice) to be multiplexed into a single mouse. Compared with conventional genetically engineeredmouse models, this approach enormously enhances scalability, introduces rigorous quantification, and reducessources of variation.The overall goal of the proposed Direct Phase 2 SBIR project is to transform the Tuba-seq pipeline into a robustplatform that can be marketed as a commercial service to pharmaceutical companies. Specific aims are to (1)expand the panel of tumor suppressor genes that the platform interrogates and carefully calibrate their effectsizes and (2) rigorously validate the ability of the platform to resolve small but clinically meaningful differencesin tumor suppressor gene-drug effect sizes with high statistical confidence, relying only on small cohorts of ani-mals.D2G will create the first practical and scalable preclinical experimental modeling approach that can assess howcandidate drugs interact with diverse, precisely-engineered cancer genotypes to predict differential patientresponses to therapy. -DA - 2021 -PY - 2021 -AN - GRANTS:17413903 -G1 - 10256762; 5R44CA250672-02; R44CA250672 -AD - D2G ONCOLOGY, INC. -M2 - D2G ONCOLOGY, INC. -Y2 - 2024-06-01 -ER - - -TY - JOUR -AU - Li, Wei -AU - Wan, Li -TI - A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China -T2 - PLOS ONE -M3 - Article -AB - ObjectiveThe effectiveness of sugemalimab vs. placebo in post-chemoradiotherapy patients with locally advanced, unresectable stage III NSCLC has been demonstrated and approved by China National Medical Products Administration. The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system. MethodsA 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. Only direct medical costs, including costs of drug (maintenance and subsequent treatment), routine follow-up, best supportive care, and terminal care in end of life were considered in this model. Costs and health utilities were obtained from local databases and published articles. Sensitivity and scenario analyses were adopted to evaluate the model uncertainty. Internal and external data sources were used to justify the plausibility of the extrapolated portion of the survival model chosen. ResultsIn comparison with the placebo, sugemalimab consolidation therapy was not cost-effective as it yielded an ICUR value of $90,277 and $49,692 for the concurrent chemoradiotherapy (cCRT) and the sequential chemoradiotherapy (sCRT) population at the willingness-to-pay (WTP) threshold of $37,663/QALYs, respectively. When taking the sugemalimab patient assistance program (PAP) into consideration, sugemalimab consolidation therapy was cost-effective with an ICUR dramatic decreases below the WTP. Sensitivity analyses demonstrated that the ICUR was most sensitive to the discount rate and subsequent treatment. However, none of the sensitive parameters could affect the cost-effective conclusions without or with PAP. Scenario analyses revealed that the model was particularly affected by assumptions regarding discount in sugemalimab, time horizon, mean duration of sugemalimab maintenance treatment. ConclusionsFrom the perspective of Chinese healthcare system, sugemalimab consolidation therapy was not a cost-effective strategy in cCRT and sCRT patients with unresectable stage III NSCLC. Given that the sugemalimab PAP was available, sugemalimab consolidation therapy became a cost-effective option. -PU - PUBLIC LIBRARY SCIENCE -PI - SAN FRANCISCO -PA - 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA -SN - 1932-6203 -DA - 2023 JUN 1 -PY - 2023 -VL - 18 -IS - 6 -C7 - e0286595 -DO - 10.1371/journal.pone.0286595 -AN - WOS:001022246700001 -AD - Huazhong Univ Sci & Technol, Maternal & Child Hlth Hosp Hubei Prov, Tongji Med Coll, Dept Pharm, Wuhan, Peoples R China -Y2 - 2023-07-17 -ER - - -TY - JOUR -AU - Dall'Olio, Filippo G. -AU - Calabro, Diletta -AU - Conci, Nicole -AU - Argalia, Giulia -AU - Marchese, Paola Valeria -AU - Fabbri, Francesca -AU - Fragomeno, Benedetta -AU - Ricci, Dalia -AU - Fanti, Stefano -AU - Ambrosini, Valentina -AU - Ardizzoni, Andrea -TI - Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-D- GLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab -T2 - EUROPEAN JOURNAL OF CANCER -M3 - Article -AB - Introduction: Immune checkpoint inhibitors (ICIs) have become the standard of care in the management of advanced non-small cell lung cancer (NSCLC). Nevertheless, only a small proportion of patients benefit from ICIs. The aim of the present study is to assess whether 2-deoxy-2-[18F]fluoro-D-GLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY ([18F]FDG-PET/CT)-derived parameters may be used as biomarkers in patients with advanced NSCLC receiving first-line pembrolizumab.Materials and methods: This is a monocentric retrospective cohort study including patients with advanced NSCLC (stage IV) and Programmed death-ligand 1 (PD-L1) expression >= 50% treated with pembrolizumab. A control group of patients treated with epidermal growth factor receptor (EGFR) inhibitors for EGFR-mutated NSCLC was also enrolled. Only patients with a positive [18F]18F-FDG PET/CT result within 60 days from treatment initiation were included.Total metabolic tumour volume (tMTV) was calculated for each lesion using a dedicated software (PET VCAR; GE Healthcare), which semiautomatically delineates the tumour's contours with a maximum standardised uptake value (SUVmax) threshold of 42% within the lesion. tMTV was obtained summing each lesion's MTV. Potential prognostic parameters for overall survival (OS) were analysed (tMTV, SUVmax, bone/liver metastasis, neutrophil:lymphocyte ratio >= 4, Eastern Cooperative Oncology Group performance status >= 2, lactate dehydrogenase above the upper limit of normal).Results: Overall, 34 patients treated with first line-pembrolizumab and 40 patients treated with EGFR tyrosine kinase inhibitors were included. In the pembrolizumab group, the median follow- up was 20.3, while the median OS was 4.7 months (95% confidence interval [CI] = 0.3-9.1) for patients with tMTV >= 75 cm(3) vs not reached (NR) for patients with tMTV <75 cm(3) (95% CI Z NReNR; hazard ratio [HR] = 5.37; 95% CI = 1.72-16.77; p = 0.004). No difference was found in the control group (HR = 1.43; 95% CI = 0.61 -3.34; p = 0.411).Conclusion: Our data suggest that tMTV >= 75cm(3) can be used as a prognostic biomarker of poor outcomes in patients with PD-L1-high advanced NSCLC treated with first-line pembrolizumab. This information could be useful for the selection of patients who may require the addition of chemotherapy to pembrolizumab. (C) 2021 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCI LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND -SN - 0959-8049 -SN - 1879-0852 -DA - 2021 JUN -PY - 2021 -VL - 150 -SP - 99 -EP - 107 -DO - 10.1016/j.ejca.2021.03.020 -AN - WOS:000655598300012 -C6 - APR 2021 -AD - Azienda Osped Univ Bologna, Med Oncol, IRCCS, Bologna, Italy -AD - Azienda Osped Univ Bologna, IRCCS, Bologna, Italy -AD - Univ Bologna, Dept Expt Diagnost & Specialty Med, Nucl Med, Bologna, Italy -Y2 - 2021-06-09 -ER - - -TY - JOUR -AU - Liang, Jiali -AU - Hong, Jiaze -AU - Tang, Xin -AU - Qiu, Xinyi -AU - Zhu, Keying -AU - Zhou, Liyuan -AU - Guo, Dina -TI - Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis -T2 - ANNALS OF MEDICINE -M3 - Review -AB - Background Studying sex differences in the efficacy of immunotherapy may contribute to the practice of the precision medicine, especially in non-small cell lung cancer (NSCLC), a kind of cancer with sexual bimorphism. Methods Published randomized controlled trials (RCTs), published by PubMed, Medline, Embase, and Scopus, before 15 June 2022, testing immunotherapy (CTLA-4 or PD-1/L1 inhibitor alone, combination or with chemotherapy) versus non-immunotherapy (receiving chemotherapy or placebo only) were included to assess different efficacy between males and females. The primary endpoint was overall survival (OS). This meta-analysis was registered with PROSPERO (CRD42022298439). Results Sixteen RCTs, involving 10,155 patients with advanced NSCLC, was collected in this meta-analysis. The pooled HR comparing immunotherapy vs non-immunotherapy were 0.76 (95%CI 0.71-0.81) for males and 0.74 (95%CI 0.63-0.87) for females. The pooled HRs comparing immune-checkpoint inhibitors (ICIs) plus chemotherapy versus chemotherapy were 0.79 (95%CI 0.70-0.89) for males and 0.63 (95%CI 0.42-0.92) for females. The pooled HRs comparing ICIs versus chemotherapy were 0.74 (95%CI 0.67-0.81) for males and 0.83 (95%CI 0.73-0.95) for females. In squamous NSCLC, the pooled HRs comparing immunotherapy vs non-immunotherapy were 0.73 (95%CI 0.58-0.91) for males and 0.74 (95%CI 0.37-1.48) for females. In non-squamous NSCLC, the pooled HRs comparing immunotherapy versus non-immunotherapy were 0.62 (95%CI 0.71-0.94) for males and 0.59 (95%CI 0.39-0.89) for females. Conclusion Compared to chemotherapy, immunotherapy can improve the prognosis of patients with advanced NSCLC. Meanwhile, there are sex differences in the efficacy of immunotherapy. KEY MESSAGE Compared to chemotherapy, immunotherapy can improve the prognosis of patients with advanced NSCLC. The most interesting thing in this study is that immunotherapy showed significant sex differences in the treatment of squamous NSCLC. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 0785-3890 -SN - 1365-2060 -DA - 2022 DEC 31 -PY - 2022 -VL - 54 -IS - 1 -SP - 2606 -EP - 2616 -DO - 10.1080/07853890.2022.2124449 -AN - WOS:000855957300001 -AD - Zhejiang Chinese Med Univ, Sch Clin Med 1, Hangzhou, Zhejiang, Peoples R China -AD - Zhejiang Chinese Med Univ, Sch Clin Med 2, Hangzhou, Zhejiang, Peoples R China -AD - Ningbo Yinzhou 2 Hosp, Dept Infect Dis, 998 North Qianhe Rd, Ningbo 315100, Zhejiang, Peoples R China -M2 - Ningbo Yinzhou 2 Hosp -Y2 - 2022-09-25 -ER - - -TY - JOUR -AU - Gkika, Eleni -AU - Lenz, Stefan -AU - Schimek-Jasch, Tanja -AU - Waller, Cornelius F. -AU - Kremp, Stephanie -AU - Schaefer-Schuler, Andrea -AU - Mix, Michael -AU - Kuesters, Andreas -AU - Tosch, Marco -AU - Hehr, Thomas -AU - Eschmann, Susanne Martina -AU - Bultel, Yves-Pierre -AU - Hass, Peter -AU - Fleckenstein, Jochen -AU - Thieme, Alexander Henry -AU - Stockinger, Marcus -AU - Dieckmann, Karin -AU - Miederer, Matthias -AU - Holl, Gabriele -AU - Rischke, Hans Christian -AU - Adebahr, Sonja -AU - Koenig, Jochem -AU - Binder, Harald -AU - Grosu, Anca-Ligia -AU - Nestle, Ursula -TI - Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer-A Secondary Analysis of the PET Plan Trial -T2 - CANCERS -M3 - Article -AB - Simple SummaryConcurrent chemoradiation (cCRT) with a platinum-based doublet, followed by immunotherapy, is the treatment of choice in locally advanced non-small cell lung cancer. A remaining open question is the difference between cisplatin and carboplatin in combination with second and third generation agents for concurrent chemoradiation, as they have a substantially different toxicity profile and data are scarce and inconclusive concerning cCRT. We here present a secondary analysis of the international PET Plan trial in order to assess the efficacy and toxicity of different chemotherapy regimens as well as the difference between the commonly used platinum based agents, cisplatin and carboplatin. All regimens were well tolerated and cisplatin in combination with vinorelbin either as a single dose or daily doses per cycle showed comparable efficacy. Patients treated with carboplatin doublets had a worse survival, but after adjusting for possibly relevant factors, this difference became non-significant, probably due to existing selection bias.(1) Background: The optimal chemotherapy (CHT) regimen for concurrent chemoradiation (cCRT) is not well defined. In this secondary analysis of the international randomized PET-Plan trial, we evaluate the efficacy of different CHT. (2) Methods: Patients with inoperable NSCLC were randomized at a 1:1 ratio regarding the target volume definition and received isotoxically dose-escalated cCRT using cisplatin 80 mg/m(2) (day 1, 22) and vinorelbin 15 mg/m(2) (day 1, 8, 22, 29) (P1) or cisplatin 20 mg/m(2) (day 1-5, 29-33) and vinorelbin 12.5 mg/m(2) (day 1, 8, 15, 29, 36, 43) (P2) or carboplatin AUC1 (day 1-5, 29-33) and vinorelbin 12.5 mg/m(2) (day 1, 8, 15, 29, 36, 43) (P3) or other CHT at the treating physician's discretion. (3) Results: Between 05/2009 and 11/2016, 205 patients were randomized and 172 included in the per-protocol analysis. Patients treated in P1 or P2 had a better overall survival (OS) compared to P3 (p = 0.015, p = 0.01, respectively). Patients treated with carboplatin had a worse OS compared to cisplatin (HR 1.78, p = 0.03), but the difference did not remain significant after adjusting for age, ECOG, cardiac function creatinine and completeness of CHT. (4) Conclusions: Carboplatin doublets show no significant difference compared to cisplatin, after adjusting for possibly relevant factors, probably due to existing selection bias. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2020 NOV -PY - 2020 -VL - 12 -IS - 11 -C7 - 3359 -DO - 10.3390/cancers12113359 -AN - WOS:000592782700001 -AD - Univ Freiburg, Dept Radiat Oncol, Med Ctr, Robert Koch Str 3, D-79106 Freiburg, Germany -AD - German Canc Res Ctr, German Canc Consortium DKTK Partner Site Freiburg, Neuenheimer Feld 280, D-69120 Heidelberg, Germany -AD - Univ Freiburg, Fac Med, D-79106 Freiburg, Germany -AD - Univ Freiburg, Inst Med Biometry & Stat, Fac Med, D-79106 Freiburg, Germany -AD - Univ Freiburg, Med Ctr, D-79106 Freiburg, Germany -AD - Univ Freiburg, Dept Med Hematol Oncol & Stem Cell Transplantat 1, Med Ctr, D-79106 Freiburg, Germany -AD - Saarland Univ, Dept Radiotherapy & Radiat Oncol, Med Ctr, D-66421 Homburg, Germany -AD - Saarland Univ, Dept Radiotherapy & Radiat Oncol, Fac Med, D-66421 Homburg, Germany -AD - Saarland Univ, Dept Nucl Med, Med Ctr, D-66421 Homburg, Germany -AD - Saarland Univ, Dept Nucl Med, Fac Med, D-66421 Homburg, Germany -AD - Univ Freiburg, Dept Nucl Med, Med Ctr, D-79106 Freiburg, Germany -AD - Kliniken Maria Hilf, Dept Radiat Oncol, D-41063 Monchengladbach, Germany -AD - Helios Univ Hosp Wuppertal, Dept Nucl Med, D-42283 Wuppertal, Germany -AD - Univ Witten Herdecke, Fac Hlth, Dept Med, D-58448 Witten, Germany -AD - Marienhospital, Dept Radiat Oncol, D-70199 Stuttgart, Germany -AD - Marienhospital, Dept Nucl Med, D-70199 Stuttgart, Germany -AD - Klinikum Mutterhaus Boromaerinnen, Dept Radiat Oncol, D-54290 Trier, Germany -AD - Univ Hosp Magdeburg, Dept Radiat Oncol, D-39120 Magdeburg, Germany -AD - Charite Univ Med Berlin, Dept Radiat Oncol, D-13353 Berlin, Germany -AD - Univ Hosp Mainz, Dept Radiat Oncol, D-55131 Mainz, Germany -AD - Med Univ Vienna, Vienna Gen Hosp, Dept Radiotherapy, A-1090 Vienna, Austria -AD - Univ Hosp Mainz, Dept Nucl Med, D-55131 Mainz, Germany -AD - Kliniken Schwerin, Dept Nucl Med, D-19055 Schwerin, Germany -AD - Univ Hosp Mainz, Inst Med Biostat Epidemiol & Informat IMBEI, D-55131 Mainz, Germany -M2 - Kliniken Maria Hilf -M2 - Helios Univ Hosp Wuppertal -M2 - Klinikum Mutterhaus Boromaerinnen -M2 - Kliniken Schwerin -Y2 - 2020-12-10 -ER - - -TY - JOUR -AU - Tanimura, Keiko -AU - Takeda, Takayuki -AU - Yoshimura, Akihiro -AU - Honda, Ryoichi -AU - Goda, Shiho -AU - Shiotsu, Shinsuke -AU - Fukui, Mototaka -AU - Chihara, Yusuke -AU - Uryu, Kiyoaki -AU - Takei, Shota -AU - Katayama, Yuki -AU - Hibino, Makoto -AU - Yamada, Tadaaki -AU - Takayama, Koichi -TI - Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study -T2 - CANCERS -M3 - Article -AB - Simple Summary: Durvalumab consolidation after chemoradiotherapy (CRT) is a standard treatment for locally advanced non-small cell lung cancer, which sometimes encounters early recurrence. This retrospective study aimed to identify the predictors of durvalumab consolidation after CRT. A prognostic risk classification was created combining modified Glasgow Prognostic Score (mGPS) before CRT and C-reactive protein (CRP) level after CRT. When patients with pre-CRT mGPS of 0 or mGPS of 1 with post-CRT CRP <= 1 mg/dL were classified as the "low-risk" group, and patients with pre-CRT mGPS of 2 or mGPS of 1 with post-CRT CRP >1 mg/dL were classified as the "high-risk" group, the high-risk group had a significantly shorter median progression-free survival (PFS, hazard ratio [HR]: 2.47, p < 0.001) and overall survival (OS, HR: 3.62, p < 0.001) compared with those in the low-risk group. The prognostic risk classification helps to predict the PFS and OS of durvalumab consolidation after CRT.Background: Durvalumab consolidation after chemoradiotherapy (CRT) is a standard treatment for locally advanced non-small cell lung cancer (NSCLC). However, studies on immunological and nutritional markers to predict progression-free survival (PFS) and overall survival (OS) are inadequate. Systemic inflammation causes cancer cachexia and negatively affects immunotherapy efficacy, which also reflects survival outcomes. Patients and Methods: We retrospectively investigated 126 patients from seven institutes in Japan. Results: The modified Glasgow Prognostic Score (mGPS) values, before and after CRT, were the essential predictors among the evaluated indices. A systemic inflammation-based prognostic risk classification was created by combining mGPS values before CRT, and C-reactive protein (CRP) levels after CRT, to distinguish tumor-derived inflammation from CRT-induced inflammation. Patients were classified into high-risk (n = 31) and low-risk (n = 95) groups, and the high-risk group had a significantly shorter median PFS of 7.2 months and an OS of 19.6 months compared with the low-risk group. The hazard ratios for PFS and OS were 2.47 (95% confidence interval [CI]: 1.46-4.19, p < 0.001) and 3.62 (95% CI: 1.79-7.33, p < 0.001), respectively. This association was also observed in the subgroup with programmed cell death ligand 1 expression of >= 50%, but not in the <50% subgroup. Furthermore, durvalumab discontinuation was observed more frequently in the high-risk group than in the low-risk group. Conclusion: Combining pre-CRT mGPS values with post-CRT CRP levels in patients with locally advanced NSCLC helps to predict the PFS and OS of durvalumab consolidation after CRT. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2023 SEP -PY - 2023 -VL - 15 -IS - 17 -C7 - 4358 -DO - 10.3390/cancers15174358 -AN - WOS:001064079200001 -AD - Japanese Red Cross Kyoto Daini Hosp, Dept Resp Med, Kyoto 6028026, Japan -AD - Asahi Gen Hosp, Dept Resp Med, Asahi 2892511, Japan -AD - Japanese Red Cross Kyoto Daiichi Hosp, Dept Resp Med, Kyoto 6050981, Japan -AD - Uji Tokushukai Med Ctr, Dept Resp Med, Uji 6110041, Japan -AD - Yao Tokushukai Gen Hosp, Dept Resp Med, Yao 5810011, Japan -AD - Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto 6028566, Japan -AD - Shonan Fujisawa Tokushukai Hosp, Dept Resp Med, Fujisawa 2510041, Japan -M2 - Japanese Red Cross Kyoto Daini Hosp -M2 - Asahi Gen Hosp -M2 - Japanese Red Cross Kyoto Daiichi Hosp -M2 - Uji Tokushukai Med Ctr -M2 - Yao Tokushukai Gen Hosp -M2 - Shonan Fujisawa Tokushukai Hosp -Y2 - 2023-10-10 -ER - - -TY - JOUR -AU - Yang, G. -AU - Yoon, H. I. -AU - Lee, J. G. -AU - Kim, J. -AU - Kim, J. -AU - Kim, K. H. -TI - Prediction of Lymphopenia and Survival with Baseline Absolute Lymphocyte Count and Irradiated Dose to Immune Cells in Patients with Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2170 -SP - E77 -EP - E78 -AN - WOS:001079706800163 -AD - Yonsei Univ, Heavy Ion Therapy Res Inst, Dept Radiat Oncol, Yonsei Canc Ctr,Coll Med, Seoul, South Korea -AD - Yonsei Univ, Dept Radiat Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea -AD - Yonsei Univ, Dept Radiat Oncol, Coll Med, Seoul, South Korea -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Wang, Y. -AU - Yang, Y. -AU - Zhang, T. -AU - Wang, J. -AU - Wang, L. -AU - Bi, N. -TI - Improved Prediction of Chemoradiation and Immune Checkpoint Blockade Efficacy with Dynamic bTMB Combined with ctDNA in Unresectable Locally Advanced NSCLC -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2159 -SP - E72 -EP - E73 -AN - WOS:001079706800152 -AD - Chinese Acad Med Sci & Peking Union Med Coll, Dept Radiat Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China -AD - Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Radiat Oncol, Canc Hosp, Shenzhen, Peoples R China -AD - Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Jang, Jeong Yun -AU - Song, Si Yeol -AU - Shin, Young Seob -AU - Kim, Ha Un -AU - Choi, Eun Kyung -AU - Kim, Sang-We -AU - Lee, Jae Cheol -AU - Lee, Dae Ho -AU - Choi, Chang-Min -AU - Yoon, Shinkyo -AU - Kim, Su Ssan -TI - Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Insights from Real-World Data -T2 - CANCER RESEARCH AND TREATMENT -M3 - Article -AB - Purpose This study aimed to assess the real-world clinical outcomes of consolidative durvalumab in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) and to explore the role of radiotherapy in the era of immunotherapy. Materials and Methods This retrospective study assessed 171 patients with unresectable LA-NSCLC who underwent concurrent chemoradiotherapy (CCRT) with or without consolidative durvalumab at Asan Medical Center between May 2018 and May 2021. Primary outcomes included freedom from locoregional failure (FFLRF), distant metastasis-free survival (DMFS), progression-free survival Results Durvalumab following CCRT demonstrated a prolonged median PFS of 20.9 months (p=0.048) and a 3-year FFLRF rate of 57.3% (p=0.008), compared to 13.7 months and 38.8%, respectively, with CCRT alone. Furthermore, the incidence of in-field recurrence was significantly greater in the CCRT-alone group compared to the durvalumab group (26.8% vs. 12.4%, p=0.027). While median OS was not reached with durvalumab, it was 35.4 months in patients receiving CCRT alone (p=0.010). Patients positive for programmed cell death ligand 1 (PD-L1) expression showed notably better outcomes, including FFLRF, DMFS, PFS, and OS. Adherence to PACIFIC trial eligibility criteria identified 100 patients (58.5%) as ineligible. The use of durvalumab demonstrated better survival regardless of eligibility criteria. Conclusion The use of durvalumab consolidation following CCRT significantly enhanced locoregional control and OS in patients with unresectable LA-NSCLC, especially in those with PD-L1-positive tumors, thereby validating the role of durvalumab in standard care. -PU - KOREAN CANCER ASSOCIATION -PI - SEOUL -PA - RM 1824, GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 110-999, SOUTH KOREA -SN - 1598-2998 -SN - 2005-9256 -DA - 2024 JUL -PY - 2024 -VL - 56 -IS - 3 -DO - 10.4143/crt.2023.1014 -AN - WOS:001273353300008 -AD - Konkuk Univ, Med Ctr, Sch Med, Dept Radiat Oncol, Seoul, South Korea -AD - Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, 88 Olympic Ro 43 Gil, Seoul 05505, South Korea -AD - Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea -AD - Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pulmonol & Crit Care Med, Seoul, South Korea -Y2 - 2024-07-28 -ER - - -TY - JOUR -AU - Luecke, E. -AU - Ganzert, C. -AU - Foellner, S. -AU - Waesche, A. -AU - Jechorek, D. -AU - Schoeder, V. -AU - Walles, T. -AU - Genseke, P. -AU - Schreiber, J. -TI - Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition -T2 - PNEUMOLOGIE -M3 - Article -AB - Background The blockade of immune escape mechanisms (e. g. PD1 /PD-L1) using immune checkpoint inhibition (ICI) can significantly prolong survival and induce remission in patients with advanced non-small cell lung cancer (NSCLC). Less is known about neoadjuvant ICI in patients with resectable (UICC stage III) or oligometastatic (UICC stage IVa) NSCLC. Methods Tissue biopsies from patients with advanced or oligometastatic NSCLC were screened for PD-L1 expression. In case of PD-L1-expression > 50 %, ECOG status of 0 or 1 and expected operability, patients received ICI. After about four weeks, patients underwent thoracic surgical resection. In all patients, a complete staging, including PET-CT, cMRI, and endobronchial ultrasound, was performed. The tolerability, the radiological and the histopathological tumor response as well as the surgical and oncological outcomes were analyzed. Findings Four patients (2 male, 2 female, age 56 - 78 years, n = 3 adenocarcinoma, n = 1 squamous cell carcinoma) with local advanced tumors received ICI before surgical resection. In three cases the mediastinal lymph nodes were positive. One patient had a single cerebral metastasis which was treated with radiotherapy. All four patients underwent therapy with two to six cycles of ICI (3 x pembrolizumab, 1 x atezolizumab) without any complication, and ICI did not delay the time of surgical resection. According to iRECIST, three patients showed partial response (PR), one patient had stable disease (SD). All tumors were completely resected. The thoracic surgical procedures proved to be technically unproblematic despite inflammatory changes. There were neither treatment-related deaths nor perioperative complications. In the resectates, complete pathological response (CPR, regression grade III ) and regression grade IIb were detected twice. The average time of follow-up was 12 (1 - 24) months. Patients with PPR developed distant metastasis after six months or a local recurrence after four months. The CPR patient is relapse free to date. Conclusion In selected patients, neoadjuvant therapy with ICI is well tolerated and can induce a complete remission of the tumor. Treatment with ICI has no negative impact on the surgical procedure. Prognosis seems to be promising in CPR and limited in PPR. -PU - GEORG THIEME VERLAG KG -PI - STUTTGART -PA - RUDIGERSTR 14, D-70469 STUTTGART, GERMANY -SN - 0934-8387 -SN - 1438-8790 -DA - 2020 NOV -PY - 2020 -VL - 74 -IS - 11 -SP - 766 -EP - 772 -DO - 10.1055/a-1199-2029 -AN - WOS:000561072800002 -C6 - AUG 2020 -AD - Otto von Guericke Univ, Klin Pneumol, Magdeburg, Germany -AD - Otto von Guericke Univ, Inst Pathol, Magdeburg, Germany -AD - Otto von Guericke Univ, Abt Thoraxchirurg, Klin Herz & Thoraxchirurg, Magdeburg, Germany -AD - Otto von Guericke Univ, Klin Radiol & Nuklearmed, Magdeburg, Germany -Y2 - 2020-09-02 -ER - - -TY - JOUR -AU - Gulley, James L. -AU - Rajan, Arun -AU - Spigel, David R. -AU - Iannotti, Nicholas -AU - Chandler, Jason -AU - Wong, Deborah J. L. -AU - Leach, Joseph -AU - Edenfield, W. Jeff -AU - Wang, Ding -AU - Grote, Hans Juergen -AU - von Heydebreck, Anja -AU - Chin, Kevin -AU - Cuillerot, Jean-Marie -AU - Kelly, Karen -TI - Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial -T2 - LANCET ONCOLOGY -M3 - Article -AB - Background Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and approved in the USA for the treatment of metastatic Merkel cell carcinoma, has shown antitumour activity and an acceptable safety profile in patients with advanced solid tumours in a dose-escalation phase 1a trial. In this dose-expansion cohort of that trial, we assess avelumab treatment in a cohort of patients with advanced, platinum-treated non-small-cell lung cancer (NSCLC).Methods In this dose-expansion cohort of a multicentre, open-label, phase 1 study, patients with progressive or platinum-resistant metastatic or recurrent NSCLC were enrolled at 58 cancer treatment centres and academic hospitals in the USA. Eligible patients had confirmed stage IIIB or IV NSCLC with squamous or non-squamous histology, measurable disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), tumour biopsy or archival sample for biomarker assessment, and Eastern Cooperative Oncology Group performance status 0 or 1, among other criteria. Patient selection was not based on PD-L1 expression or expression of other biomarkers, including EGFR or KRAS mutation or ALK translocation status. Patients received infusional avelumab monotherapy 10 mg/kg every 2 weeks until disease progression or toxicity. The primary objective was to assess safety and tolerability. This trial is registered with ClinicalTrials.gov, number NCT01772004; enrolment in this cohort is closed and the trial is ongoing.Findings Between Sept 10, 2013, and June 24, 2014, 184 patients were enrolled and initiated treatment with avelumab. Median follow-up duration was 8.8 months (IQR 7.2-11.9). The most common treatment-related adverse events of any grade were fatigue (46 [25%] of 184 patients), infusion-related reaction (38 [21%]), and nausea (23 [13%]). Grade 3 or worse treatment-related adverse events occurred in 23 (13%) of 184 patients; the most common (occurring in more than two patients) were infusion-related reaction (four [2%] patients) and increased lipase level (three [2%]). 16 (9%) of 184 patients had a serious adverse event related to treatment with avelumab, with infusion-related reaction (in four [2%] patients) and dyspnoea (in two [1%]) occurring in more than one patient. Serious adverse events irrespective of cause occurred in 80 (44%) of 184 patients. Those occurring in more than five patients (>= 3%) were dyspnoea (ten patients [5%]), pneumonia (nine [5%]), and chronic obstructive pulmonary disease (six [3%]). Immune-related treatment-related events occurred in 22 patients (12%). Of 184 patients, 22 (12% [95% CI 8-18]) achieved a confirmed objective response, including one complete response and 21 partial responses. 70 (38%) had stable disease. Overall, 92 (50%) of 184 patients achieved disease control (they had a confirmed response or stable disease as their best overall response). One patient was initially thought to have died from grade 5 radiation pneumonitis during the study; however, this adverse event was subsequently regraded to grade 3 and the death was attributed to disease progression.Interpretation Avelumab showed an acceptable safety profile and antitumour activity in patients with progressive or treatment-resistant NSCLC, providing a rationale for further studies of avelumab in this disease setting. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA -SN - 1470-2045 -SN - 1474-5488 -DA - 2017 MAY -PY - 2017 -VL - 18 -IS - 5 -SP - 599 -EP - 610 -DO - 10.1016/S1470-2045(17)30240-1 -AN - WOS:000400401100048 -AD - NCI, Genitourinary Malignancies Branch, NIH, Bethesda, MD 20892 USA -AD - NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA -AD - NCI, Thorac & Gastrointestinal Oncol Branch, NIH, Bethesda, MD 20892 USA -AD - Sarah Cannon Res Inst Tennessee Oncol, North Nashville, TN USA -AD - Associates Treasure Coast, Hematol Oncol, Port St Lucie, FL USA -AD - West Canc Ctr, Memphis, TN USA -AD - Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA -AD - Virginia Piper Canc Inst, Minneapolis, MN USA -AD - Inst Translat Oncol Res, Greenville, SC USA -AD - Henry Ford Hosp, Detroit, MI 48202 USA -AD - Merck KGaA, Darmstadt, Germany -AD - EMD Serono, Billerica, MA USA -AD - Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA -M2 - Associates Treasure Coast -M2 - West Canc Ctr -M2 - Virginia Piper Canc Inst -M2 - Inst Translat Oncol Res -M2 - EMD Serono -Y2 - 2017-05-01 -ER - - -TY - JOUR -AU - KAHL, BRAD -TI - EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES -M3 - Awarded Grant -DA - 2008 -PY - 2008 -AN - GRANTS:11289579 -G1 - 5U10CA021076-33; 7426841; U10CA021076 -AD - UNIVERSITY OF WISCONSIN MADISON -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - SAHU, AVINASH DAS -TI - Identifying drug synergistic with cancer immunotherapy -M3 - Awarded Grant -AB - PROJECT SUMMARYAvinash D Sahu, Ph.D., is a computational biologist whose overarching career goal is to solve longstanding problems incancer immunology and translational precision oncology using artificial intelligence (AI) and to devise new therapeuticstrategies for late-stage cancer patients. Entitled Identifying drug synergistic with cancer immunotherapy, the proposedresearch combines cutting-edge AI technology with Immuno-oncology (IO) to produce a systematic approach toidentifying drugs that synergize with immunotherapy, and prioritize them for clinical trials for advanced melanoma,bladder, kidney, and lung cancer.Career development plan: Dr. Sahu is a recipient of the Michelson Prize, and his research mission is to initiate precisionimmuno-oncology by moving patients away from palliative chemotherapy to more personalized IO treatments. Hisprevious training in AI, statistics, method development, cancer, and translation biology have prepared him to conduct theproposed research. Dr. Sahu has outlined specific training activities to expand his skill set in four areas: 1) cancerimmunology, 2) AI, 3) translation research and 4) new immunological assays. This skill set will be necessary to gainresearch independence. Mentors/Environment: Dr. Sahu mentoring and the advisory team assembles world-leadingexperts in computational biology, translation and clinical research, AI, statistics, and immunology. Also, Dr. Sahu hasdeveloped academic collaborations and industry partners to provide him experimental support for the proposal.Leveraging the state-of-art software and google-cloud infrastructure provided by Cancer Immune Data Commons (CIDC);computational resources from DFCI, Harvard, and Broad Institute; as well as unique access to largest immunotherapypatient data from collaborators, Dr. Sahu is uniquely placed to identify most promising IO drug combinations.Research: There is a lack of a principled approach to identify promising IO drug combinations that has often led toarbitrarily designed IO clinical trials without a sound biological basis. The proposal formulates the first in silico predictorto estimate drug’s immunomodulatory effect and potential to synergize with immunotherapies. Aim 1 builds a novel deeplearning predictor —DeepImmune— to predict immunotherapy response from transcriptomes. Aim 2 estimates theimmunomodulatory effects of drugs from for its drug-induced transcriptomic changes using DeepImmune. Aim 3prioritize top predicted immunomodulatory drugs and validate their effect in pre-clinical models.Outcomes/Impact: The successful completion of the proposal will result in a robust predictor to rationally combinecancer therapies with immunotherapy and set the basis for a clinical trial to test the most promising combination therapy.The career development award and mentored research will enable Dr. Sahu to become a leader in the new field of researchat the intersection of precision immuno-oncology and AI. -DA - 2023 -PY - 2023 -AN - GRANTS:17762638 -G1 - 10828594; 4R00CA248953-03; R00CA248953 -AD - UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - SAHU, AVINASH DAS -TI - Identifying drug synergistic with cancer immunotherapy -M3 - Awarded Grant -AB - PROJECT SUMMARYAvinash D Sahu, Ph.D., is a computational biologist whose overarching career goal is to solve longstanding problems incancer immunology and translational precision oncology using artificial intelligence (AI) and to devise new therapeuticstrategies for late-stage cancer patients. Entitled Identifying drug synergistic with cancer immunotherapy, the proposedresearch combines cutting-edge AI technology with Immuno-oncology (IO) to produce a systematic approach toidentifying drugs that synergize with immunotherapy, and prioritize them for clinical trials for advanced melanoma,bladder, kidney, and lung cancer.Career development plan: Dr. Sahu is a recipient of the Michelson Prize, and his research mission is to initiate precisionimmuno-oncology by moving patients away from palliative chemotherapy to more personalized IO treatments. Hisprevious training in AI, statistics, method development, cancer, and translation biology have prepared him to conduct theproposed research. Dr. Sahu has outlined specific training activities to expand his skill set in four areas: 1) cancerimmunology, 2) AI, 3) translation research and 4) new immunological assays. This skill set will be necessary to gainresearch independence. Mentors/Environment: Dr. Sahu mentoring and the advisory team assembles world-leadingexperts in computational biology, translation and clinical research, AI, statistics, and immunology. Also, Dr. Sahu hasdeveloped academic collaborations and industry partners to provide him experimental support for the proposal.Leveraging the state-of-art software and google-cloud infrastructure provided by Cancer Immune Data Commons (CIDC);computational resources from DFCI, Harvard, and Broad Institute; as well as unique access to largest immunotherapypatient data from collaborators, Dr. Sahu is uniquely placed to identify most promising IO drug combinations.Research: There is a lack of a principled approach to identify promising IO drug combinations that has often led toarbitrarily designed IO clinical trials without a sound biological basis. The proposal formulates the first in silico predictorto estimate drug’s immunomodulatory effect and potential to synergize with immunotherapies. Aim 1 builds a novel deeplearning predictor —DeepImmune— to predict immunotherapy response from transcriptomes. Aim 2 estimates theimmunomodulatory effects of drugs from for its drug-induced transcriptomic changes using DeepImmune. Aim 3prioritize top predicted immunomodulatory drugs and validate their effect in pre-clinical models.Outcomes/Impact: The successful completion of the proposal will result in a robust predictor to rationally combinecancer therapies with immunotherapy and set the basis for a clinical trial to test the most promising combination therapy.The career development award and mentored research will enable Dr. Sahu to become a leader in the new field of researchat the intersection of precision immuno-oncology and AI. -DA - 2021 -PY - 2021 -AN - GRANTS:17416216 -G1 - 10266758; 5K99CA248953-02; K99CA248953 -AD - DANA-FARBER CANCER INST -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - SAHU, AVINASH DAS -TI - Identifying drug synergistic with cancer immunotherapy -M3 - Awarded Grant -AB - PROJECT SUMMARYAvinash D Sahu, Ph.D., is a computational biologist whose overarching career goal is to solve longstanding problems incancer immunology and translational precision oncology using artificial intelligence (AI) and to devise new therapeuticstrategies for late-stage cancer patients. Entitled Identifying drug synergistic with cancer immunotherapy, the proposedresearch combines cutting-edge AI technology with Immuno-oncology (IO) to produce a systematic approach toidentifying drugs that synergize with immunotherapy, and prioritize them for clinical trials for advanced melanoma,bladder, kidney, and lung cancer.Career development plan: Dr. Sahu is a recipient of the Michelson Prize, and his research mission is to initiate precisionimmuno-oncology by moving patients away from palliative chemotherapy to more personalized IO treatments. Hisprevious training in AI, statistics, method development, cancer, and translation biology have prepared him to conduct theproposed research. Dr. Sahu has outlined specific training activities to expand his skill set in four areas: 1) cancerimmunology, 2) AI, 3) translation research and 4) new immunological assays. This skill set will be necessary to gainresearch independence. Mentors/Environment: Dr. Sahu mentoring and the advisory team assembles world-leadingexperts in computational biology, translation and clinical research, AI, statistics, and immunology. Also, Dr. Sahu hasdeveloped academic collaborations and industry partners to provide him experimental support for the proposal.Leveraging the state-of-art software and google-cloud infrastructure provided by Cancer Immune Data Commons (CIDC);computational resources from DFCI, Harvard, and Broad Institute; as well as unique access to largest immunotherapypatient data from collaborators, Dr. Sahu is uniquely placed to identify most promising IO drug combinations.Research: There is a lack of a principled approach to identify promising IO drug combinations that has often led toarbitrarily designed IO clinical trials without a sound biological basis. The proposal formulates the first in silico predictorto estimate drug’s immunomodulatory effect and potential to synergize with immunotherapies. Aim 1 builds a novel deeplearning predictor —DeepImmune— to predict immunotherapy response from transcriptomes. Aim 2 estimates theimmunomodulatory effects of drugs from for its drug-induced transcriptomic changes using DeepImmune. Aim 3prioritize top predicted immunomodulatory drugs and validate their effect in pre-clinical models.Outcomes/Impact: The successful completion of the proposal will result in a robust predictor to rationally combinecancer therapies with immunotherapy and set the basis for a clinical trial to test the most promising combination therapy.The career development award and mentored research will enable Dr. Sahu to become a leader in the new field of researchat the intersection of precision immuno-oncology and AI. -DA - 2020 -PY - 2020 -AN - GRANTS:15040697 -G1 - 1K99CA248953-01; 9953596; K99CA248953 -AD - DANA-FARBER CANCER INST -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Jabbour, Salma K. -AU - Berman, Abigail T. -AU - Decker, Roy H. -AU - Lin, Yong -AU - Feigenberg, Steven J. -AU - Gettinger, Scott N. -AU - Aggarwal, Charu -AU - Langer, Corey J. -AU - Simone, Charles B., II -AU - Bradley, Jeffrey D. -AU - Aisner, Joseph -AU - Malhotra, Jyoti -TI - Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer A Nonrandomized Controlled Trial -T2 - JAMA ONCOLOGY -M3 - Article -AB - Question What is the preliminary evidence of safety and tolerability of programmed cell death 1 inhibition concurrently with definitive chemoradiotherapy for stage III non-small cell lung cancer? Findings In this phase 1 nonrandomized controlled trial of chemoradiotherapy with concurrent programmed cell death 1 blockade, grade 4 pneumonitis was the predetermined dose-limiting toxic effect used to define safety. Programmed cell death 1 inhibition and chemoradiotherapy for stage III non-small cell lung cancer was tolerable and showed an 18% rate of grade 3 or greater immune-related adverse events, including grades 3 and 5 pneumonitis, grade 3 interstitial nephritis, and type 1 diabetes. Meaning First-line therapy with programmed cell death 1 inhibition and chemoradiotherapy for stage III non-small cell lung cancer appears to be tolerable and should continue to be evaluated in phase 2 and 3 clinical trials.IMPORTANCE Consolidative programmed death ligand-1 (PD-L) inhibition after chemoradiotherapy improves overall survival and progression-free survival (PFS) for stage III non-small cell lung cancer (NSCLC) and requires safety evaluation for incorporation of programmed cell death 1 (PD-1) inhibition at the onset of chemoradiotherapy.OBJECTIVE To determine the safety and tolerability of PD-1 inhibition concurrently with definitive chemoradiotherapy for NSCLC.DESIGN, SETTING, AND PARTICIPANTS This phase 1 prospective multicenter nonrandomized controlled trial using a 3 plus 3 design was performed from August 30, 2016, to October 24, 2018, with a median follow-up of 16.0 (95% CI, 12.0-22.6) months and data locked on July 25, 2019. Twenty-one participants had locally advanced, unresectable, stage III NSCLC as determined by multidisciplinary review, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate hematologic, renal, and hepatic function. Data were analyzed from October 17, 2016, to July 19, 2019.INTERVENTIONS Pembrolizumab was combined with concurrent chemoradiotherapy (weekly carboplatin and paclitaxel with 60 Gy of radiation in 2 Gy per d). Dose cohorts evaluated included full-dose pembrolizumab (200 mg intravenously every 3 weeks) 2 to 6 weeks after chemoradiotherapy (cohort 1); reduced-dose pembrolizumab (100 mg intravenously every 3 weeks) starting day 29 of chemoradiotherapy (cohort 2); full-dose pembrolizumab starting day 29 of chemoradiotherapy (cohort 3); reduced-dose pembrolizumab starting day 1 of chemoradiotherapy (cohort 4); and full-dose pembrolizumab starting day 1 of chemoradiotherapy (cohort 5). A safety expansion cohort of 6 patients was planned based on the maximum tolerated dose of pembrolizumab. Dose-limiting toxic effects were defined as pneumonitis of at least grade 4 within cycle 1 of pembrolizumab treatment.MAIN OUTCOMES AND MEASURES Safety and tolerability of PD-1 inhibition with chemoradiotherapy for NSCLC. Secondary outcomes included PFS and pneumonitis rates.RESULTS Among the 21 patients included in the analysis (11 female [52%]; median age, 69.5 [range, 53.0-85.0] years), no dose-limiting toxic effects in any cohort were observed. One case of grade 5 pneumonitis occurred in the safety expansion cohort with the cohort 5 regimen. Immune-related adverse events of at least grade 3 occurred in 4 patients (18%). Median PFS for patients who received at least 1 dose of pembrolizumab (n = 21) was 18.7 (95% CI, 11.8-29.4) months, and 6- and 12-month PFS were 81.0% (95% CI, 64.1%-97.7%) and 69.7% (95% CI, 49.3%-90.2%), respectively. Median PFS for patients who received at least 2 doses of pembrolizumab (n = 19) was 21.0 (95% CI, 15.3 to infinity) months.CONCLUSIONS AND RELEVANCE These findings suggest that combined treatment with PD-1 inhibitors and chemoradiotherapy for stage III NSCLC is tolerable, with promising PFS of 69.7% at 12 months, and requires further study.This phase 1 nonrandomized controlled trial assesses the safety and tolerability of programmed cell death 1 inhibition concurrently with definitive chemoradiotherapy compared with programmed cell death 1 inhibition and radiotherapy in patients with non-small cell lung cancer. (c) 2020 American Medical Association. All rights reserved. -PU - AMER MEDICAL ASSOC -PI - CHICAGO -PA - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA -SN - 2374-2437 -SN - 2374-2445 -DA - 2020 JUN -PY - 2020 -VL - 6 -IS - 6 -SP - 848 -EP - 855 -DO - 10.1001/jamaoncol.2019.6731 -AN - WOS:000542037700009 -AD - Rutgers State Univ, Rutgers Canc Inst New Jersey, Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ USA -AD - Univ Penn, Dept Radiat Oncol, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA -AD - Yale Univ, Dept Therapeut Radiol, Smilow Canc Ctr, Yale Sch Med, New Haven, CT USA -AD - Rutgers Sch Publ Hlth, Dept Biostat & Epidemiol, Piscataway, NJ USA -AD - Rutgers State Univ, Div Biometr, Rutgers Canc Inst New Jersey, Piscataway, NJ USA -AD - Yale Univ, Dept Med, Sect Med Oncol, Smilow Canc Ctr,Yale Sch Med, New Haven, CT 06520 USA -AD - Univ Penn, Dept Med, Div Hematol Oncol, Abramson Canc Ctr,Perelman Sch Med, Philadelphia, PA 19104 USA -AD - New York Proton Ctr, Dept Radiat Oncol, New York, NY USA -AD - Emory Univ, Dept Radiat Oncol, Winship Canc Inst, Emory Sch Med, Atlanta, GA 30322 USA -AD - Rutgers State Univ, Div Med Oncol, Rutgers Canc Inst New Jersey, Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA -M2 - New York Proton Ctr -Y2 - 2020-07-07 -ER - - -TY - JOUR -AU - Shirasawa, Masayuki -AU - Yoshida, Tatsuya -AU - Matsumoto, Yuji -AU - Shinno, Yuki -AU - Okuma, Yusuke -AU - Goto, Yasushi -AU - Horinouchi, Hidehito -AU - Yamamoto, Noboru -AU - Watanabe, Shun-ichi -AU - Ohe, Yuichiro -AU - Motoi, Noriko -TI - Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer -T2 - EUROPEAN JOURNAL OF CANCER -M3 - Article -AB - Background: A history of radiotherapy and chemoradiotherapy (CRT) reportedly increases the efficacy of the PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC). We investigated the efficacy of anti-PD-(L)1 therapy after CRT failure and how CRT changes the status of PD-L1 expression on tumours and on tumour-infiltrated lymphocytes (TILs).Methods: We retrospectively reviewed patients with unresectable locally advanced NSCLC (LA-NSCLC) who were treated with CRT between 2007 and 2018 and evaluated the efficacy of the PD-(L)1 blockade after CRT failure. We also compared the PD-L1 (clone: 22C3) expression levels and the tumoral and stromal distributions of CD8-positive TILs using paired formalin-fixed, paraffin-embedded specimens obtained before and after CRT.Results: We identified 422 patients and 65 patients who had relapsed after CRT received anti-PD-(L)1 therapy. The objective response rate (ORR) and the progression-free survival (PFS) after anti-PD-(L)1 therapy were 48% and 8.7 months (95% CI, 4.5-13), respectively. The RR and PFS did not differ according to the pre-CRT PD-L1 expression levels. PD-L1 expression changed in 16 of the 18 patients between before and after CRT, but a specific trend was not seen (increased, 9 patients; decreased, 7 patients; no change, 2 patients). In contrast, the density of tumoral CD8-positive TILs increased after CRT treatment (pre-CRT median, 110/mm(2) versus post-CRT median, 470/mm(2); p = 0.025).Conclusions: Anti-PD-(L)1 therapy was effective in patients with LA-NSCLC who had progressed after CRT regardless of their pre-CRT PD-L1 expression. The efficacy of anti-PD(L)1 therapy for patients with NSCLC with CRT failure was superior to that of standard second-line treatment for patients with advanced NSCLC. (C) 2020 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCI LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND -SN - 0959-8049 -SN - 1879-0852 -DA - 2020 NOV -PY - 2020 -VL - 140 -SP - 28 -EP - 36 -DO - 10.1016/j.ejca.2020.08.028 -AN - WOS:000588150600004 -AD - Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan -AD - Natl Canc Ctr, Dept Expt Therapeut, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan -AD - Natl Canc Ctr, Dept Thorac Surg, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan -AD - Natl Canc Ctr, Dept Diagnost Pathol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan -Y2 - 2020-11-27 -ER - - -TY - JOUR -AU - Page, Simon -AU - Milner-Watts, Charlotte -AU - Perna, Marco -AU - Janzic, Urska -AU - Vidal, Natalia -AU - Kaudeer, Naila -AU - Ahmed, Merina -AU - McDonald, Fiona -AU - Locke, Imogen -AU - Minchom, Anna -AU - Bhosle, Jaishree -AU - Welsh, Liam -AU - O'Brien, Mary -TI - Systemic treatment of brain metastases in non-small cell lung cancer -T2 - EUROPEAN JOURNAL OF CANCER -M3 - Review -AB - Brain metastases (BrMs) are associated with significant morbidity and are found in up to 50% of patients with advanced non-small cell lung cancer (NSCLC).Most of the literature focuses on symptomatic BrMs, with a lack of baseline brain imaging in asymptomatic patients. Unfortunately, much of the data on local treatments with or without systemic treatment is retrospective. Clinical trials of systemic treatments largely exclude patients with BrMs.Chemotherapy is an active treatment for BrM with response rates in the brain similar to other sites of disease. Targeted systemic treatments in patients with driver mutations (EGFR and ALK-MET to date) have impressive central nervous system (CNS) penetrance and response rates. Unfortunately, no prospective data can currently guide the timings or modality of local therapies with systemic treatments in these patients who have a high incidence of CNS disease, but retrospective data suggest that early local therapies may give better intracranial progression-free survival (ICPFS).Recent immunotherapy trials have included patients with BrMs. These patients have largely been pre-treated with local therapies and are asymptomatic. Thus, the current standard is becoming, early local therapies before or in conjunction with immunotherapy agents. The approach seems to be safe.Prospective studies are needed in NSCLC BrMs patients to make sure any benefit from local therapies on the ICPFS and quality of life is not overlooked. Here we report what we think are reasonable conclusions from the available data and make suggestions for future clinical trials in the management of NSCLC BrMs. (C) 2020 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCI LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND -SN - 0959-8049 -SN - 1879-0852 -DA - 2020 JUN -PY - 2020 -VL - 132 -SP - 187 -EP - 198 -DO - 10.1016/j.ejca.2020.03.006 -AN - WOS:000535714200026 -AD - Royal Marsden NHS Trust, London, England -AD - Azienda Osped Univ Careggi, Florence, Italy -AD - Klin Golnik, Golnik, Slovenia -AD - Hosp Clin Univ San Carlos, Madrid, Spain -M2 - Hosp Clin Univ San Carlos -Y2 - 2020-06-09 -ER - - -TY - JOUR -AU - Corrao, Giulia -AU - Franchi, Matteo -AU - Zaffaroni, Mattia -AU - Vincini, Maria Giulia -AU - de Marinis, Filippo -AU - Spaggiari, Lorenzo -AU - Orecchia, Roberto -AU - Marvaso, Giulia -AU - Jereczek-Fossa, Barbara Alicja -TI - Upfront Advanced Radiotherapy and New Drugs for NSCLC Patients with Synchronous Brain Metastases: Is the Juice Worth the Squeeze? A Real-World Analysis from Lombardy, Italy -T2 - CANCERS -M3 - Article -AB - Simple Summary This study aims to compare effectiveness and cost profile in non-small-cell lung cancer (NSCLC) patients harboring synchronous brain metastases (BMs) who received non-chemo first-line systemic therapy with or without advanced radiotherapy (aRT). A total of 177 lung cancer patients, of whom 58 were treated with systemic treatment (either TKIs or pembrolizumab) plus aRT (STRT) and 119 with systemic treatment alone, were selected. The addition of aRT to systemic treatment was associated with a significantly better OS (p = 0.020) and PFS (p = 0.041) than systemic therapy alone. The incremental cost-effectiveness ratio (ICER) value indicated an average cost of euro3792 for each month of survival after STRT and confirmed clinical effectiveness but higher healthcare costs. This real-world study suggests that upfront aRT in this setting represents a valid treatment strategy, boosting the efficacy of emerging drug classes with sustainable costs for the health service. Aim: Healthcare administrative databases represent a valuable source for real-life data analysis. The primary aim of this study is to compare effectiveness and cost profile in non-small-cell lung cancer (NSCLC) patients harboring synchronous brain metastases (BMs) who received non-chemo first-line systemic therapy with or without advanced radiotherapy (aRT). Methods: Diagnostic ICD-9-CM codes were used for identifying all patients with a new diagnosis of lung cancer between 2012 and 2019. Among these, patients who had started a first-line systemic treatment with either TKIs or pembrolizumab, alone or in combination with intensity-modulated or stereotactic RT, were selected. Clinical outcomes investigated included overall survival (OS), progression-free survival (PFS), and time-to-treatment failure (TTF). The cost outcome was defined as the average per capita cumulative healthcare direct costs of the treatment, including all inpatient and outpatient costs. Results: The final cohort included 177 patients, of whom 58 were treated with systemic treatment plus aRT (STRT) and 119 with systemic treatment alone. The addition of aRT to systemic treatment was associated with a significantly better OS (p = 0.020) and PFS (p = 0.041) than systemic therapy alone. The ICER (incremental cost-effectiveness ratio) value indicated an average cost of euro3792 for each month of survival after STRT treatment and confirmed clinical effectiveness but higher healthcare costs. Conclusions: This real-world study suggests that upfront aRT for NCLSC patients with synchronous BMs represents a valid treatment strategy, boosting the efficacy of novel and emerging drug classes with sustainable costs for the health service. Translational relevance: The present real-world study reports that the use of upfront advanced radiotherapyaRT and new-generation systemic agents, such as TKIs and pembrolizumab, may have higher oncological control and an improved cost-effectiveness profile than the use of new-generation systemic agents alone in NCLSC patients with synchronous brain metastases. Acquired evidence can also be used to inform policymakers that adding advanced radiotherapy results is a sustainable cost for the health service.Since approximately 50% of patients do not meet RCT inclusion criteria, a significant proportion of them is receiving treatment that is not evidence-informed; therefore, these results warrant further studies to identify the best radiotherapy timing and possible dose escalation approaches to improving treatment efficacy in patient subgroups not typically represented in randomized controlled trials. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2023 FEB -PY - 2023 -VL - 15 -IS - 4 -C7 - 1103 -DO - 10.3390/cancers15041103 -AN - WOS:000944665200001 -AD - IRCCS, IEO European Inst Oncol, Div Radiat Oncol, I-20141 Milan, Italy -AD - Univ Milano Bicocca, Natl Ctr Healthcare Res & Pharmacoepidemiol, I-20126 Milan, Italy -AD - Univ Milano Bicocca, Dept Stat & Quantitat Methods, Unit Biostat Epidemiol & Publ Hlth, I-20126 Milan, Italy -AD - IRCCS, IEO European Inst Oncol, Div Thorac Oncol, I-20141 Milan, Italy -AD - IRCCS, IEO European Inst Oncol, Dept Thorac Surg, I-20141 Milan, Italy -AD - Univ Milan, Dept Oncol & Hemato Oncol, I-20122 Milan, Italy -AD - IRCCS, IEO European Inst Oncol, Sci Directorate, I-20141 Milan, Italy -Y2 - 2023-03-28 -ER - - -TY - JOUR -AU - Shaverdian, Narek -AU - Lisberg, Aaron E. -AU - Bornazyan, Krikor -AU - Veruttipong, Darlene -AU - Goldman, Jonathan W. -AU - Formenti, Silvia C. -AU - Garon, Edward B. -AU - Lee, Percy -TI - Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial -T2 - LANCET ONCOLOGY -M3 - Article -AB - Background Preclinical studies have found radiotherapy enhances antitumour immune responses. We aimed to assess disease control and pulmonary toxicity in patients who previously received radiotherapy for non-small-cell lung cancer (NSCLC) before receiving pembrolizumab.Methods We assessed patients with advanced NSCLC treated on the phase 1 KEYNOTE-001 trial at a single institution (University of California, Los Angeles, CA, USA). Patients were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status of 1 or less, had adequate organ function, and no history of pneumonitis. Patients received pembrolizumab at a dose of either 2 mg/kg of bodyweight or 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks, until disease progression, unacceptable toxicity, or other protocol-defined reasons for discontinuation. Disease response and pulmonary toxicity were prospectively assessed by Immune-related Response Criteria and Common Terminology Criteria for Adverse Events version 4.0. The primary objective of the KEYNOTE-001 trial was to assess the safety, side-effect profile, and antitumour activity of pembrolizumab. For our secondary analysis, patients were divided into subgroups to compare patients who previously received radiotherapy with patients who had not. Our primary objective was to determine whether previous radiotherapy affected progression-free survival, overall survival, and pulmonary toxicity in the intention-to-treat population. The KEYNOTE-001 trial was registered with ClinicalTrials.gov, number NCT01295827.Findings Between May 22, 2012, and July 11, 2014, 98 patients were enrolled and received their first cycle of pembrolizumab. One patient was lost to follow-up. 42 (43%) of 97 patients had previously received any radiotherapy for the treatment of NSCLC before the first cycle of pembrolizumab. 38 (39%) of 97 patients received extracranial radiotherapy and 24 (25%) of 97 patients received thoracic radiotherapy. Median follow-up for surviving patients was 32.5 months (IQR 29.8-34.1). Progression-free survival with pembrolizumab was significantly longer in patients who previously received any radiotherapy than in patients without previous radiotherapy (hazard ratio [HR] 0.56 [95% CI 0.34-0.91], p= 0.019; median progression-free survival 4.4 months [95% CI 2.1-8.6] vs 2.1 months [1.6-2.3]) and for patients who previously received extracranial radiotherapy compared with those without previous extracranial radiotherapy (HR 0.50 [0.30-0.84], p= 0.0084; median progression-free survival 6.3 months [95% CI 2.1-10.4] vs 2.0 months [1.8-2.1]). Overall survival with pembrolizumab was significantly longer in patients who previously received any radiotherapy than in patients without previous radiotherapy (HR 0.58 [95% CI 0.36-0.94], p= 0.026; median overall survival 10.7 months [95% CI 6.5-18.9] vs 5.3 months [2.7-7.7]) and for patients who previously received extracranial radiotherapy compared with those without previous extracranial radiotherapy (0.59 [95% CI 0.36-0.96], p=0.034; median overall survival 11.6 months [95% CI 6.5-20.5] vs 5.3 months [3.0-8.5]). 15 (63%) of 24 patients who had previously received thoracic radiotherapy had any recorded pulmonary toxicity versus 29 (40%) of 73 patients with no previous thoracic radiotherapy. Three (13%) patients with previous thoracic radiotherapy had treatment-related pulmonary toxicity compared with one (1%) of those without; frequency of grade 3 or worse treatment-related pulmonary toxicities was similar (one patient in each group).Interpretation Our data suggest that previous treatment with radiotherapy in patients with advanced NSCLC results in longer progression-free survival and overall survival with pembrolizumab treatment than that seen in patients who did not have previous radiotherapy, with an acceptable safety profile. Further clinical trials investigating this combination are needed to determine the optimal treatment strategy for patients with advanced NSCLC. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1470-2045 -SN - 1474-5488 -DA - 2017 JUL -PY - 2017 -VL - 18 -IS - 7 -SP - 895 -EP - 903 -DO - 10.1016/S1470-2045(17)30380-7 -AN - WOS:000404257800045 -AD - Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90024 USA -AD - Univ Calif Los Angeles, Dept Hematol & Oncol, Los Angeles, CA 90024 USA -AD - Weill Cornell Med, Dept Radiat Oncol, New York, NY USA -Y2 - 2017-07-01 -ER - - -TY - JOUR -AU - Levy, Antonin -AU - Massard, Christophe -AU - Soria, Jean-Charles -AU - Deutsch, Eric -TI - Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial -T2 - EUROPEAN JOURNAL OF CANCER -M3 - Article -AB - Purpose: To assess preliminary safety and efficacy results of the anti-programmed cell death ligand-1 (anti-PD-L1) durvalumab in combination with radiotherapy (RT) in an expansion cohort of patients included in a phase 1/2 trial at our institution.Patients and methods: Data from patients who received concurrent palliative RT with durvalumab (10 mg/kg every 2 weeks via intravenous infusion) were analysed in terms of safety (CTCAE v4.0) and efficacy (RECIST v1.1 and tumour growth rate [TGR]).Results: Between 02/2014 and 04/2016, 10 patients received palliative local irradiation of 15 isolated lesions. Most patients (90%) had received one or more prior lines of systemic therapy for advanced disease. The median duration of exposure to durvalumab was 5.2 months with a median delivery of 11 cycles (range, 4-38 cycles). RT (conformal 3D RT, 79% and intracranial stereotactic RT, 21%) was delivered at a median biologically-effective dose of 28 Gy (range, 6-92), in a median number of five fractions (range, 1-10) and over a median duration of 6 d (range, 1-14). Five patients (50%) reported an irradiation-related adverse event (AE) grade (G) 1 or 2 and one patient had two G2 AEs. The most frequently reported AE (3/6) was G2 mucositis. There was no G3 or more RT-related AEs. All AEs were transient, lasted less than one week, and were manageable by standard guidelines. There was no unexpected AE. On 10/15 in-field (IF) evaluable lesions, the objective response (OR) rate was 60% (complete response, 2/10 and partial response, 4/10) and 4/10 stable disease (SD). All evaluated IF lesions had a TGR decrease resulting in a significant decrease in the TGR between the two periods (before versus after RT; p < 0.01). Outfields disease evaluation retrieved 10/14 SD and 4/14 progressive disease (PD). There was no out-field OR, no abscopal effect and no out-field difference between the two periods according to TGR (p = 0.09).Conclusion: In this small data set of patients, concurrent palliative RT with the anti-PD-L1 durvalumab was well tolerated. (C) 2016 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCI LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND -SN - 0959-8049 -SN - 1879-0852 -DA - 2016 NOV -PY - 2016 -VL - 68 -SP - 156 -EP - 162 -DO - 10.1016/j.ejca.2016.09.013 -AN - WOS:000387811600017 -AD - Univ Paris Saclay, Gustave Roussy, Dept Radiat Oncol, F-94805 Villejuif, France -AD - Univ Paris Saclay, Gustave Roussy, DITEP, F-94805 Villejuif, France -AD - Univ Paris Saclay, Gustave Roussy, Mol Radiotherapy, INSERM,U1030, F-94805 Villejuif, France -AD - Univ Paris Saclay, Univ Paris Sud, F-94270 Le Kremlin Bicetre, France -Y2 - 2016-11-01 -ER - - -TY - JOUR -AU - Wang, Yu -AU - Zhang, Tao -AU - Wang, Jianyang -AU - Zhou, Zongmei -AU - Liu, Wenyang -AU - Xiao, Zefen -AU - Deng, Lei -AU - Feng, Qinfu -AU - Wang, Xin -AU - Lv, Jima -AU - Ma, Xiangyu -AU - Xue, Qi -AU - Wang, Jie -AU - Wang, Zhijie -AU - Bi, Nan -TI - Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Article -AB - Purpose: In the era of immunotherapy, the treatment for bulky, locally advanced non-small cell lung cancer (LA-NSCLC) remains challenging. This study explored the feasibility of induction immune checkpoint inhibitors (ICIs) plus chemotherapy before definitive chemoradiation therapy (CRT) for bulky LA-NSCLC.Methods and Materials: Patients with bulky, unresectable stage III NSCLC (primary tumor =5 cm in greatest dimension or metastatic lymph nodes =2 cm in shortest diameter) receiving ICIs and chemotherapy before CRT from 2018 to 2022 were identified. Survival outcomes and toxic effects were analyzed. Radiation therapy plans on computed tomography images before and after 2 cycles of induction chemoimmunotherapy were simulated to evaluate dosimetric outcomes. Results: Seventy-five patients were included. One- and 2-year overall-survival (OS) rates were 91.5% (95% CI, 85.2%-98.3%) and 75.1% (95% CI, 64.1%-88.0%), respectively. One- and 2-year progression-free-survival (PFS) rates were 85.8% (95% CI, 78.0%-94.4%) and 64.2% (95% CI, 52.5%-78.6%), respectively. Median OS was not reached (NR). Median PFS was 30.6 months (95% CI, 25.9 months to NR). Grade 2 and =3 pneumonitis occurred in 26.7% and 9.3% of patients, respectively. Grade =3 pneumonitis was significantly associated with poorer OS (P =.003) and PFS (P =.018). Treatment discontinuation was significantly associated with shorter OS (P =.023) and PFS (P =.047). Patients with consolidation ICIs exhibited numerically better OS than those without consolidation ICIs (2-year OS, 85.8% vs 64.2%; P =.170). The objective response rate was 76.1% for induction treatment and 86.7% for induction treatment plus CRT. The disease control rate after 2 cycles of induction therapywas significantly greater than after 4 (P =.046) or more cycles (P =.025). Simulated radiation plans indicated that all target volumes, mean lung dose, and volume of lung parenchyma receiving =5 Gy, =20 Gy, and =30 Gy significantly decreased after 2 cycles (all P <.005).Conclusions: Two cycles of induction ICIs plus chemotherapy before definitive CRT were feasible for bulky LA-NSCLC, with significant tumor reduction and normal lung protection. Further investigations on CRT combined with induction and consolidation ICIs are warranted. (c) 2023 Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 JUL 1 -PY - 2023 -VL - 116 -IS - 3 -SP - 590 -EP - 600 -DO - 10.1016/j.ijrobp.2022.12.042 -AN - WOS:001056167200001 -C6 - JUN 2023 -AD - Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Dept Radiat Oncol,Canc Hosp, Beijing, Peoples R China -AD - Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Thorac Surg,Canc Hosp, Beijing, Peoples R China -AD - Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, State Key Lab Mol Oncol, Natl Clin Res Ctr Canc,Canc Hosp,Dept Med Oncol, Beijing, Peoples R China -Y2 - 2023-09-22 -ER - - -TY - JOUR -AU - Ferro, Alessandra -AU - Sepulcri, Matteo -AU - Schiavon, Marco -AU - Scagliori, Elena -AU - Mancin, Edoardo -AU - Lunardi, Francesca -AU - Gennaro, Gisella -AU - Frega, Stefano -AU - Dal Maso, Alessandro -AU - Bonanno, Laura -AU - Paronetto, Chiara -AU - Caumo, Francesca -AU - Calabrese, Fiorella -AU - Rea, Federico -AU - Guarneri, Valentina -AU - Pasello, Giulia -TI - The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments -T2 - CANCERS -M3 - Article -AB - Simple Summary Stage III non-small cell lung cancer (NSCLC) is a highly heterogeneous group of diseases with wide differences in tumor size and in nodal involvement and, although the intent of treatments is potentially curative, survival data still remain disappointing in some cases. The treatment of locally advanced NSCLC involves a multidisciplinary approach to determine which patients might benefit from a trimodality treatment that includes tumour resection and to identify patients with unresectable stage III NSCLC who are candidates for definitive chemo-radiation therapy (CRT). The main aim of this work was to provide a real-world description of treatment evolution and survival outcomes of stage III NSCLC patients referred to the Veneto Institute of Oncology-IRCCS and University Hospital of Padova for about 10 years. Background: About 30% of new non-small cell lung cancer (NSCLC) cases are diagnosed at a locally advanced stage, which includes a highly heterogeneous group of patients with a wide spectrum of treatment options. The management of stage III NSCLC involves a multidisciplinary team, adequate staging, and a careful patient selection for surgery or radiation therapy integrated with systemic treatment. Methods: This is a single-center observational retrospective and prospective study including a consecutive series of stage III NSCLC patients who were referred to the Veneto Institute of Oncology and University Hospital of Padova (Italy) between 2012 and 2021. We described clinico-pathological characteristics, therapeutic pathways, and treatment responses in terms of radiological response in the entire study population and in terms of pathological response in patients who underwent surgery after induction therapy. Furthermore, we analysed survival outcomes in terms of relapse-free survival (RFS) and overall survival (OS). Results: A total of 301 patients were included. The majority of patients received surgical multimodality treatment (n = 223, 74.1%), while the remaining patients (n = 78, 25.9%) underwent definitive CRT followed or not by durvalumab as consolidation therapy. At data cut-off, 188 patients (62.5%) relapsed and the median RFS (mRFS) of the entire population was 18.2 months (95% CI: 15.83-20.57). At the time of analyses 140 patients (46.5%) were alive and the median OS (mOS) was 44.7 months (95% CI: 38.4-51.0). A statistically significant difference both in mRFS (p = 0.002) and in mOS (p < 0.001) was observed according to the therapeutic pathway in the entire population, and selecting patients treated after 2018, a significant difference in mRFS (p = 0.006) and mOS (p < 0.001) was observed according to treatment modality. Furthermore, considering only patients diagnosed with stage IIIB-C (N = 131, 43.5%), there were significant differences both in mRFS (p = 0.047) and in mOS (p = 0.022) as per the treatment algorithm. The mRFS of the unresectable population was 16.3 months (95% CI: 11.48-21.12), with a significant difference among subgroups (p = 0.030) in favour of patients who underwent the PACIFIC-regimen; while the mOS was 46.5 months (95% CI: 26.46-66.65), with a significant difference between two subgroups (p = 0.003) in favour of consolidation immunotherapy. Conclusions: Our work provides insights into the management and the survival outcomes of stage III NSCLC over about 10 years. We found that the choice of radical treatment impacts on outcome, thus suggesting the importance of appropriate staging at diagnosis, patient selection, and of the multidisciplinary approach in the decision-making process.Our results confirmed that the PACIFIC trial and the following introduction of durvalumab as consolidation treatment may be considered as a turning point for several improvements in the diagnostic-therapeutic pathway of stage III NSCLC patients. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2022 NOV -PY - 2022 -VL - 14 -IS - 22 -C7 - 5700 -DO - 10.3390/cancers14225700 -AN - WOS:000887151900001 -AD - Veneto Inst Oncol IOV IRCCS, Div Med Oncol 2, I-35128 Padua, Italy -AD - Veneto Inst Oncol IOV IRCCS, Dept Radiat Oncol, I-35128 Padua, Italy -AD - Univ Padua, Dept Cardiac Thorac & Vasc Sci & Publ Hlth, Thorac Surg Unit, I-35128 Padua, Italy -AD - Veneto Inst Oncol IOV IRCCS, Oncol Radiol Unit, I-35128 Padua, Italy -AD - Univ Padua, Dept Surg Oncol & Gastroenterol, I-35128 Padua, Italy -AD - Univ Padua, Dept Cardiac Thorac & Vasc Sci & Publ Hlth, Pathol Unit, I-35128 Padua, Italy -AD - Veneto Inst Oncol IRCCS, Breast Radiol Unit, I-35128 Padua, Italy -Y2 - 2022-12-06 -ER - - -TY - JOUR -AU - Antonia, S. J. -AU - Villegas, A. -AU - Daniel, D. -AU - Vicente, D. -AU - Murakami, S. -AU - Hui, R. -AU - Yokoi, T. -AU - Chiappori, A. -AU - Lee, K. H. -AU - de Wit, M. -AU - Cho, B. C. -AU - Bourhaba, M. -AU - Quantin, X. -AU - Tokito, T. -AU - Mekhail, T. -AU - Planchard, D. -AU - Kim, Y. -C. -AU - Karapetis, C. S. -AU - Hiret, S. -AU - Ostoros, G. -AU - Kubota, K. -AU - Gray, J. E. -AU - Paz-Ares, L. -AU - de Castro Carpeno, J. -AU - Wadsworth, C. -AU - Melillo, G. -AU - Jiang, H. -AU - Huang, Y. -AU - Dennis, P. A. -AU - Ozguroglu, M. -A1 - PACIFIC Investigators -TI - Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer -T2 - NEW ENGLAND JOURNAL OF MEDICINE -M3 - Article -AB - BACKGROUNDMost patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy.METHODSWe randomly assigned patients, in a 2: 1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety.RESULTSOf 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events.CONCLUSIONSProgression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. -PU - MASSACHUSETTS MEDICAL SOC -PI - WALTHAM -PA - WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA -SN - 0028-4793 -SN - 1533-4406 -DA - 2017 NOV 16 -PY - 2017 -VL - 377 -IS - 20 -SP - 1919 -EP - 1929 -DO - 10.1056/NEJMoa1709937 -AN - WOS:000415228800005 -AD - H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr,MRC 3-E, Tampa, FL 33612 USA -AD - Canc Specialists North Florida, Jacksonville, FL USA -AD - Florida Hosp, Inst Canc, Orlando, FL USA -AD - Tennessee Oncol, Chattanooga, TN USA -AD - Sarah Cannon Res Inst, Nashville, TN USA -AD - Hosp Univ Virgen Macarena, Seville, Spain -AD - Univ Complutense, Hosp Univ Octubre 12, Ctr Invest Biomed Red Canc, Madrid, Spain -AD - Spanish Natl Canc Res Ctr, Madrid, Spain -AD - Hosp Univ La Paz, Madrid, Spain -AD - Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan -AD - Kansai Med Univ Hosp, Hirakata, Osaka, Japan -AD - Kurume Univ Hosp, Kurume, Fukuoka, Japan -AD - Nippon Med Coll Hosp, Tokyo, Japan -AD - Westmead Hosp, Sydney, NSW, Australia -AD - Univ Sydney, Sydney, NSW, Australia -AD - Flinders Univ S Australia, Bedford Pk, SA, Australia -AD - Flinders Med Ctr, Bedford Pk, SA, Australia -AD - Chungbuk Natl Univ, Coll Med, Chungbuk Natl Univ Hosp, Cheongju, South Africa -AD - Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea -AD - Chonnam Natl Univ, Med Sch, Hwasun Hosp, Gwangju, South Korea -AD - Vivantes Klinikum Neukolln, Berlin, Germany -AD - Ctr Hosp Univ Liege, Liege, Belgium -AD - CHU Montpellier, Montpellier, France -AD - Canc Inst Montpellier Val Aurelle, Montpellier, France -AD - Inst Gustave Roussy, Villejuif, France -AD - Inst Cancerol Ouest, Site Rene Gauducheau, St Herblain, France -AD - Natl Koranyi Inst Pulmonol, Budapest, Hungary -AD - AstraZeneca, Alderley Pk, England -AD - AstraZeneca, Gaithersburg, MD USA -AD - Istanbul Univ, Cerrahpasa Med Sch, Istanbul, Turkey -M2 - Canc Specialists North Florida -M2 - Canc Inst Montpellier Val Aurelle -M2 - Natl Koranyi Inst Pulmonol -M2 - AstraZeneca -Y2 - 2017-11-16 -ER - - -TY - JOUR -AU - MILLER, THOMAS PATRICK -TI - SOUTHWEST ONCOLOGY GROUP -M3 - Awarded Grant -DA - 2008 -PY - 2008 -AN - GRANTS:12236591 -G1 - 5U10CA013612-35; 7363699; U10CA013612 -AD - UNIVERSITY OF ARIZONA -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Goldkuhle, Marius -AU - Dimaki, Maria -AU - Gartlehner, Gerald -AU - Monsef, Ina -AU - Dahm, Philipp -AU - Glossmann, Jan-Peter -AU - Engert, Andreas -AU - von Tresckow, Bastian -AU - Skoetz, Nicole -TI - Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) -T2 - COCHRANE DATABASE OF SYSTEMATIC REVIEWS -M3 - Review -AB - BackgroundHodgkin's lymphoma (HL) is a cancer of the lymphatic system, and involves the lymph nodes, spleen and other organs such as the liver, lung, bone or bone marrow, depending on the tumour stage. With cure rates of up to 90%, HL is one of the most curable cancers worldwide. Approximately 10% of people with HL will be refractory to initial treatment or will relapse; this is more common in people with advanced stage or bulky disease. Standard of care for these people is high-dose chemotherapy and autologous stem cell transplantation (ASCT), but only 55% of participants treated with high-dose chemotherapy and ASCT are free from treatment failure at three years, with an overall survival (OS) of about 80% at three years.Checkpoint inhibitors that target the interaction of the programmed death (PD)-1 immune checkpoint receptor, and its ligands PDL1 and PD-L2, have shown remarkable activity in a wide range of malignancies. Nivolumab is an anti-(PD)-1 monoclonal antibody and currently approved by the US Food and Drug Administration (FDA) for the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and, since 2016, for classical Hodgkin's lymphoma (cHL) after treatment with ASCT and brentuximab vedotin.Objectives To assess the benefits and harms of nivolumab in adults with HL (irrespective of stage of disease).Search methodsWe searched CENTRAL, MEDLINE, Embase, International Pharmaceutical Abstracts, conference proceedings and six study registries from January 2000 to May 2018 for prospectively planned trials evaluating nivolumab.Selection criteriaWe included prospectively planned trials evaluating nivolumab in adults with HL. We excluded trials in which less than 80% of participants had HL, unless the trial authors provided the subgroup data for these participants in the publication or after we contacted the trial authors.Data collection and analysisTwo review authors independently extracted data and assessed potential risk of bias. We used the software RobotReviewer to extract data and compared results with our findings. As we did not identify any randomised controlled trials (RCTs) or non-RCTs, we did not meta-analyse data.Main resultsOur search found 782 potentially relevant references. Fromthese, we included three trialswithout a control group, with 283 participants. In addition, we identified 14 ongoing trials evaluating nivolumab, of which two are randomised. Risk of bias of the three included studies was moderate to high. All of the participants were in relapsed stage, most of them were heavily pretreated and had received at least two previous treatments, most of them had also undergone ASCT. As we did not identify any RCTs, we could not use the software RobotReviewer to assess risk of bias. The software identified correctly that one study was not an RCT and did not extract any trial data, but extracted characteristics of the other two studies (although also not RCTs) in a sufficient way.Two studies with 260 participants evaluated OS. After six months, OS was 100% in one study and median OS (the timepoint when only 50% of participants were alive) was not reached in the other trial after a median follow-up of 18 months (interquartile range (IQR) 15 to 22 months) (very low certainty evidence, due to observational trial design, heterogenous patient population in terms of pretreatments and various follow-up times (downgrading by 1 point)). In one study, one out of three cohorts reported quality of life. It was unclear whether there was an effect on quality of life as only a subset of participants filled out the follow-up questionnaire (very low certainty evidence). Three trials (283 participants) evaluated progression-free survival (PFS) (very low certainty evidence). Six-month PFS ranged between 60% and 86%, and median PFS ranged between 12 and 18 months. All three trials (283 participants) reported complete response rates, ranging from 12% to 29%, depending on inclusion criteria and participants' previous treatments (very low certainty evidence).One trial (243 participants) reported drug-related grade 3 or 4 adverse events (AEs) only after a median follow-up of 18 months (IQR 15 to 22 months); these were fatigue (23%), diarrhoea (15%), infusion reactions (14%) and rash (12%). The other two trials (40 participants) reported 23% to 52% grade 3 or 4 AEs after six months' follow-up (very low certainty evidence). Only one trial (243 participants) reported drug-related serious AEs; 2% of participants developed infusion reactions and 1% pneumonitis (very low certainty evidence).None of the studies reported treatment-related mortality.Authors' conclusionsTo date, data on OS, quality of life, PFS, response rate, or short-and long-term AEs are available from small uncontrolled trials only. The three trials included heavily pretreated participants, which had previously undergone regimens of BV or ASCT. For these participants, median OS was not reached after follow-up times of at least 16 months (more than 50% of participants with a limited life expectancy were alive at this timepoint). Only one cohort out of three only reported quality of life, with limited follow-up data so that meaningful conclusions were not possible. Serious adverse events occurred rarely. Currently, data are too sparse to make a clear statement on nivolumab for people with relapsed or refractory HL except for heavily pretreated people, which had previously undergone regimens of BV or ASCT. When interpreting these results, it is important to consider that proper RCTs should confirm these findings.As there are 14 ongoing trials evaluating nivolumab, of which two are RCTs, it is possible that an update of this review will be published in the near future and that this update will show different results to those reported here. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1469-493X -SN - 1361-6137 -DA - 2018 -PY - 2018 -IS - 7 -C7 - CD012556 -DO - 10.1002/14651858.CD012556.pub2 -AN - WOS:000440415900025 -AD - Univ Hosp Cologne, Cochrane Haematol Malignancies Grp, Dept Internal Med 1, Kerpener Str 62, Cologne, Germany -AD - Danube Univ Krems, Cochrane Austria, Krems, Austria -AD - Minneapolis VA Hlth Care Syst, Urol Sect, Minneapolis, MN USA -AD - Univ Hosp Cologne, Ctr Integrated Oncol Koln Bonn, Dept Internal Med 1, Cologne, Germany -AD - Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany -Y2 - 2018-12-28 -ER - - -TY - JOUR -AU - Den Otter, Willem -AU - Jacobs, John J. L. -AU - Battermann, Jan J. -AU - Hordijk, Gerrit Jan -AU - Krastev, Zachary -AU - Moiseeva, Ekaterina V. -AU - Stewart, Rachel J. E. -AU - Ziekman, Paul G. P. M. -AU - Koten, Jan Willem -TI - Local therapy of cancer with free IL-2 -T2 - CANCER IMMUNOLOGY IMMUNOTHERAPY -M3 - Article -AB - This is a position paper about the therapeutic effects of locally applied free IL-2 in the treatment of cancer. Local therapy: IL-2 therapy of cancer was originally introduced as a systemic therapy. This therapy led to about 20% objective responses. Systemic therapy however was very toxic due to the vascular leakage syndrome. Nevertheless, this treatment was a break-through in cancer immunotherapy and stimulated some interesting questions: Supposing that the mechanism of IL-2 treatment is both proliferation and tumoricidal activity of the tumor infiltrating cells, then locally applied IL-2 should result in a much higher local IL-2 concentration than systemic IL-2 application. Consequently a greater beneficial effect could be expected after local IL-2 application (peritumoral = juxtatumoral, intratumoral, intra-arterial, intracavitary, or intratracheal = inhalation). Free IL-2: Many groups have tried to prepare a more effective IL-2 formulation than free IL-2. Examples are slow release systems, insertion of the IL-2 gene into a tumor cell causing prolonged IL-2 release. However, logistically free IL-2 is much easier to apply; hence we concentrated in this review and in most of our experiments on the use of free IL-2. Local therapy with free IL-2 may be effective against transplanted tumors in experimental animals, and against various spontaneous carcinomas, sarcomas, and melanoma in veterinary and human cancer patients. It may induce rejection of very large, metastasized tumor loads, for instance advanced clinical tumors. The effects of even a single IL-2 application may be impressive. Not each tumor or tumor type is sensitive to local IL-2 application. For instance transplanted EL4 lymphoma or TLX9 lymphoma were not sensitive in our hands. Also the extent of sensitivity differs: In Bovine Ocular Squamous Cell Carcinoma (BOSCC) often a complete regression is obtained, whereas with the Bovine Vulval Papilloma and Carcinoma Complex (BVPCC) mainly stable disease is attained. Analysis of the results of local IL-2 therapy in 288 cases of cancer in human patients shows that there were 27% Complete Regressions (CR), 23% Partial Regressions (PR), 18% Stable Disease (SD), and 32% Progressive Disease (PD). In all tumors analyzed, local IL-2 therapy was more effective than systemic IL-2 treatment. Intratumoral IL-2 applications are more effective than peritumoral application or application at a distant site. Tumor regression induced by intratumoral IL-2 application may be a fast process (requiring about a week) in the case of a highly vascular tumor since IL-2 induces vascular leakage/edema and consequently massive tumor necrosis. The latter then stimulates an immune response. In less vascular tumors or less vascular tumor sites, regression may require 9-20 months; this regression is mainly caused by a cytotoxic leukocyte reaction. Hence the disadvantageous vascular leakage syndrome complicating systemic treatment is however advantageous in local treatment, since local edema may initiate tumor necrosis. Thus the therapeutic effect of local IL-2 treatment is not primarily based on tumor immunity, but tumor immunity seems to be useful as a secondary component of the IL-2 induced local processes. If local IL-2 is combined with surgery, radiotherapy or local chemotherapy the therapeutic effect is usually greater than with either therapy alone. Hence local free IL-2 application can be recommended as an addition to standard treatment protocols.Local treatment with free IL-2 is straightforward and can readily be applied even during surgical interventios. Local IL-2 treatment is usually without serious side effects and besides minor complaints it is generally well supported. Only small quantities of IL-2 are required. Hence the therapy is relatively cheap. A single IL-2 application of 4.5 million U IL-2 costs about 70 Euros. Thus combined local treatment may offer an alternative in those circumstances when more expensive forms of treatment are not available, for instance in resource poor countries. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 0340-7004 -SN - 1432-0851 -DA - 2008 JUL -PY - 2008 -VL - 57 -IS - 7 -SP - 931 -EP - 950 -DO - 10.1007/s00262-008-0455-z -AN - WOS:000255397600001 -AD - Univ Utrecht, Fac Vet Med, Dept Pathobiol, NL-3584 CL Utrecht, Netherlands -AD - Utrecht Med Ctr, Dept Radiat Oncol, Utrecht, Netherlands -AD - Utrecht Med Ctr, Dept Otolaryngol, Utrecht, Netherlands -AD - Gastroenterol Clin, Fac Med, Sofia 1431, Bulgaria -AD - Russian Acad Sci, Schemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117871, Russia -AD - Univ Zimbabwe, Dept Clin Vet Studies, Harare, Zimbabwe -Y2 - 2008-07-01 -ER - - -TY - JOUR -AU - FIGG, WILLIAM DOUGLAS -TI - Using Clinical Pharmacology Principles to Develop New Anticancer Therapies -M3 - Awarded Grant -AB - Over the years, the CPP has developed analytical methods for a wide range of therapeutics that include the following: depsipeptide, TNP-470, phenylacetate, phenylbutyrate, tamoxifen, UCN-01, CAI, thalidomide, COL-3, suramin, melphalan, erlotinib, perifosine, SU5416, 2ME, MS-275, ketoconazole, lenalidomide, romidepsin, AZD2281, gemicitabine, sorafenib, finasteride, nelfinavir, 17-DMAG, clopidogrel, Hsp90 inhibitor PF-04928473, irinotecan (its active metabolite SN38 and glucuronidated SN38), Trk kinase inhibitor AZD7451, pomalidomide, olaparib, sorafenib, belinostat, cediranib, abiraterone, cabozantinib, carfilzomib, midazolam, lapatinib, temozolomide, perifosine, valproic acid, temozolomide, cyclophosphamide and its 4-hydroxycyclophosphamide metabolite, NLG207 (formerly CRLX-101, nanoparticle-drug conjugate of camptothecin), and ONC206. The CPP has provided PK support for various agents in phase I/II trials: suramin, TNP-470, CAI, UCN-01, docetaxel, flavopiridol, thalidomide, lenalidomide, pomalidomide, intraperitoneal cisplatin/carboplatin, paclitaxel, 17-DMAG, imatinib, sorafenib, nelfinavir, bevacizumab, romidepsin, clopidrogrel, bortezomib, TRC-105, vandetanib, olaparib, topotecan, irinotecan, mithramycin, durvalumab, abiraterone, belinostat with cisplatin and etoposide, temozolomide, seviteronel, selumetinib, and immunotoxin LMB-100. During the current fiscal year, the CPP provided PK support for several phase I/II clinical studies, including a first-in-human phase I study of LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin; phase I trial of zotiraciclib in combination with temozolomide for patients with recurrent high-grade astrocytomas; phase I study of lenalidomide and radiotherapy in children with gliomas; phase II trial of M6620 (a first-in-class competitive inhibitor of ATR) and topotecan in relapsed SCLC patients; phase II study of pomalidomide in patients with refractory chronic graft-versus-host disease; phase I/II of cabozantinib and docetaxel in patients with mCRPC; checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma; phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors; phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Over the years, we have conducted population PK (popPK) modeling of the following compounds: depsipeptide, romidepsin, sorafenib, olaparib, docetaxel in combination with the p-glycoprotein antagonist tariquidar, TRC105, TRC102, belinostat, mithramycin and seviteronel. Recent efforts have focused on characterizing the complex PK of NLG207, a nanoparticle-drug conjugate of the potent topoisomerase I inhibitor camptothecin (CPT), in order to better describe CPT release from nanoparticles using a popPK model. In collaboration with Drs. Mark Ratain and Daniel Goldstein, we're evaluating in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. Based on patient-specific estimates for clearance, optimal alternative dosing strategies can be simulated to lower drug and cost burden yet maintain therapeutic levels, especially as the clearance of the drug decreases over time. We hypothesize that longer dosing intervals than those currently approved (without commensurate dose increases) will maintain efficacy. To this end, we are collaborating on a multi-institutional, randomized, non-inferiority trial to investigate the PK of standard interval dosing compared to extended interval dosing of nivolumab or pembrolizumab in locally advanced or metastatic cancers. The primary objective is to assess the noninferiority of extended interval dosing relative to standard dosing, as assessed by drug trough levels above the target concentration of 1.5 ug/ml for both nivolumab and pembrolizumab. Nivolumab and pembrolizumab, anti-programmed cell death protein 1 monoclonal antibodies, have revolutionized oncology but are expensive. Using an interventional pharmacoeconomic approach, these drugs can be administered less often to reduce costs and increase patient convenience while maintaining efficacy. Both drugs are good candidates for less frequent dosing because of long half-lives and no evidence of a relationship of dose to efficacy. Established population pharmacokinetic models for both nivolumab and pembrolizumab were used to simulate profiles for multiple dosing regimens on 1000 randomly generated virtual patients. Simulations were initially performed on standard dose regimens to validate these in silico predictions. Next, simulations of nivolumab 0.3 mg/kg every 3 weeks revealed that 95% of patients maintained greater than or equal to 1.5 ug/mL at steady state, which was inferred as the minimum effective concentration (MEC) for both drugs. Various alternative dosing regimens were simulated for both drugs to determine which regimen(s) can maintain this MEC in 95% of patients. Extended dosing regimens of nivolumab 240 mg every 4 weeks and 480 mg every 8 weeks along with pembrolizumab 200 mg every 6 weeks were simulated, showing that 95% of patients maintained MEC or greater. These simulations demonstrate the potential to reduce drug exposure by at least 50%, thus substantially reducing patient visits (as well as costs), while maintaining equivalent efficacy. These models provide the scientific justification for an ongoing prospective randomized clinical trial comparing standard interval fixed dosing with extended interval fixed dosing, and ultimately an efficacy-driven comparative trial. The CPP participates in several preclinical pharmacology projects in order to study drug metabolism, PK, drug formulation and bioavailability, as well as efficacy in preclinical models of drug development to allow for more accurate dosing estimates for future first-in-human studies. The CPP has validated assays and conducted PK analysis for the following compounds: 3-deazaneplanocin (DZ-Nep), PV1162, schweinfurthin G, englerin A, aza-englerin, XZ-419, aurora kinase A/B inhibitor SCH-1473759, and a long-acting prodrug of talazoparib. We have conducted bioavailability studies for schweinfurthin G, englerin A, and aza-englerin. We collaborate with both intramural and extramural investigators to evaluate the preclinical PK of various novel therapeutics in mouse tumor models and/or non-human primate (NHP) models including 5-azacytidine, pexidartinib, photo-activatable paclitaxel prodrug, and panobinostat. We evaluated the preclinical PK of sapanisertib (mTORC1/2 inhibitor) and trametinib (MEK inhibitor) in mucosal melanoma xenograft models. We also investigated how dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors. In collaboration with the Molecular Targets Laboratory and the Natural Products Branch, the CPP provided preclinical PK support to study the bioavailability of two new classes of analogs of englerin A (extracted from the Tanzanian plant Phyllanthus engleri Pax on the basis of its high potency and selectivity for inhibiting renal cancer cell growth). The first class of analogs are modified at the esters to improve stability and oral bioavailability, while the second class of analogs are modified on the bridgehead of the seven-membered ring within the main englerin body of the compound. Replacement of the isopropyl group by other, larger substituents yielded compounds *TRUNCATED* -DA - 2022 -PY - 2022 -AN - GRANTS:17493204 -G1 - 10703095; 1ZICSC006537-29; ZICSC006537 -AD - DIVISION OF CLINICAL SCIENCES - NCI -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - FIGG, WILLIAM DOUGLAS -TI - Using Clinical Pharmacology Principles to Develop New Anticancer Therapies -M3 - Awarded Grant -AB - Over the years, the CPP has developed analytical methods for a wide range of therapeutics that include the following: depsipeptide, TNP-470, phenylacetate, phenylbutyrate, tamoxifen, UCN-01, CAI, thalidomide, COL-3, suramin, melphalan, erlotinib, perifosine, SU5416, 2ME, MS-275, ketoconazole, lenalidomide, romidepsin, AZD2281, gemicitabine, sorafenib, finasteride, nelfinavir, 17-DMAG, clopidogrel, Hsp90 inhibitor PF-04928473, irinotecan (its active metabolite SN38 and glucuronidated SN38), Trk kinase inhibitor AZD7451, pomalidomide, olaparib, sorafenib, belinostat, cediranib, abiraterone, cabozantinib, carfilzomib, midazolam, lapatinib, temozolomide, perifosine, valproic acid, temozolomide, cyclophosphamide and its 4-hydroxycyclophosphamide metabolite, as well as NLG207 (formerly CRLX-101, nanoparticle-drug conjugate of camptothecin). The CPP has provided PK support for various agents in phase I/II trials: suramin, TNP-470, CAI, UCN-01, docetaxel, flavopiridol, thalidomide, lenalidomide, pomalidomide, intraperitoneal cisplatin/carboplatin, paclitaxel, 17-DMAG, imatinib, sorafenib, nelfinavir, bevacizumab, romidepsin, clopidrogrel, bortezomib, TRC-105, vandetanib, olaparib, topotecan, irinotecan, mithramycin, durvalumab, abiraterone, belinostat with cisplatin and etoposide, temozolomide, seviteronel, selumetinib, and immunotoxin LMB-100. During the current fiscal year, the CPP provided PK support for several phase I/II clinical studies, including a first-in-human phase I study of LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin; phase I trial of zotiraciclib in combination with temozolomide for patients with recurrent high-grade astrocytomas; phase I study of lenalidomide and radiotherapy in children with gliomas; phase II trial of M6620 (a first-in-class competitive inhibitor of ATR) and topotecan in relapsed SCLC patients; phase II study of pomalidomide in patients with refractory chronic graft-versus-host disease; phase I/II of cabozantinib and docetaxel in patients with mCRPC. Over the years, we have conducted population PK (popPK) modeling of the following compounds: depsipeptide, romidepsin, sorafenib, olaparib, docetaxel in combination with the p-glycoprotein antagonist tariquidar, TRC105, TRC102, belinostat, mithramycin and seviteronel. Recent efforts have focused on characterizing the complex PK of NLG207, a nanoparticle-drug conjugate of the potent topoisomerase I inhibitor camptothecin (CPT), in order to better describe CPT release from nanoparticles using a popPK model. The PK of NLG207 was characterized by combining two linear two-compartment models with first-order kinetics each to describe nanoparticle-bound (conjugated) and free CPT. CPT release from the nanoparticle formulation was characterized via an initial rapid clearance of 5.71 L/h, which decreased via first-order decay (estimated half-life of 0.307 h) to the steady-state value of 0.0988 L/h by 4 h after end of infusion. Renal clearance of free CPT was 0.874 L/h. The popPK model confirmed nanoparticle behavior of conjugated CPT and mechanistically characterized CPT release from NLG207. The current analysis provides a strong foundation for future study as a potential predictive tool in ongoing NLG207 clinical trials. In collaboration with Drs. Mark Ratain and Daniel Goldstein, we're evaluating in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. Based on patient-specific estimates for clearance, optimal alternative dosing strategies can be simulated to lower drug and cost burden yet maintain therapeutic levels, especially as the clearance of the drug decreases over time. We hypothesize that longer dosing intervals than those currently approved (without commensurate dose increases) will maintain efficacy. To this end, we are collaborating on a multi-institutional, randomized, non-inferiority trial to investigate the PK of standard interval dosing compared to extended interval dosing of nivolumab or pembrolizumab in locally advanced or metastatic cancers. The primary objective is to assess the noninferiority of extended interval dosing relative to standard dosing, as assessed by drug trough levels above the target concentration of 1.5 ug/ml for both nivolumab and pembrolizumab. We are also interested in alternative methods of drug delivery and/or drug formulations. Enzalutamide is an established standard-of-care treatment for advanced prostate cancer with a commercially available formulation that may be inconvenient for some patients. We proposed a study to evaluate the bioequivalence of a liquid formulation to provide an alternative method of administration. This was a single-dose, randomized, open-label, two-way crossover pilot bioequivalence study to compare two oral formulations of enzalutamide: four enzalutamide 40 mg liquid-filled soft-gelatin capsules (commercially available) administered whole versus enzalutamide 160 mg liquid (extracted from capsules) administered via oral syringe. To assess bioequivalence, patients were randomized to receive a single dose of one formulation, then cross over to receive the alternative formulation following a 42-day washout period. The study did not meet proposed accrual, with only one patient enrolled, thus limiting the bioequivalence evaluation. Although both formulations appeared well tolerated with no adverse events reported, the tolerability assessment questionnaire revealed an unpleasant taste of the liquid formulation. Preliminary evidence suggests a similar pharmacokinetic profile when administering liquid extracted from enzalutamide soft-gelatin capsules compared with intact capsules in patients with prostate cancer. Tolerability may limit use in clinical practice. The CPP participates in several preclinical pharmacology projects in order to study drug metabolism, PK, drug formulation and bioavailability, as well as efficacy in preclinical models of drug development to allow for more accurate dosing estimates for future first-in-human studies. The CPP has validated assays and conducted PK analysis for the following compounds: 3-deazaneplanocin (DZ-Nep), PV1162, schweinfurthin G, englerin A, aza-englerin, XZ-419, aurora kinase A/B inhibitor SCH-1473759, and a long-acting prodrug of talazoparib. We have conducted bioavailability studies for schweinfurthin G, englerin A, and aza-englerin. We collaborate with both intramural and extramural investigators to evaluate the preclinical PK of various novel therapeutics in mouse tumor models and/or non-human primate (NHP) models including 5-azacytidine, pexidartinib, photo-activatable paclitaxel prodrug, and panobinostat. We evaluated the preclinical PK of sapanisertib (mTORC1/2 inhibitor) and trametinib (MEK inhibitor) in mucosal melanoma xenograft models. In collaboration with the Molecular Targets Laboratory and the Natural Products Branch, the CPP provided preclinical PK support to study the bioavailability of two new classes of analogs of englerin A (extracted from the Tanzanian plant Phyllanthus engleri Pax on the basis of its high potency and selectivity for inhibiting renal cancer cell growth). The first class of analogs are modified at the esters to improve stability and oral bioavailability, while the second class of analogs are modified on the bridgehead of the seven-membered ring within the main englerin body of the compound. Replacement of the isopropyl group by other, larger substituents yielded compounds which displayed excellent selectivity and potency comparable to the natural product. Selected compounds were also evaluated for their effect on the ion channel TRPC4 and for intravenous toxicity in mice, and these had lower potency in both assays compared to englerin A. -DA - 2021 -PY - 2021 -AN - GRANTS:17427359 -G1 - 10487279; 1ZICSC006537-28; ZICSC006537 -AD - DIVISION OF CLINICAL SCIENCES - NCI -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - MIODOVNIK, MENACHEM -TI - Washington Obstetric-Fetal Pharmacology Research Unit -M3 - Awarded Grant -DA - 2008 -PY - 2008 -AN - GRANTS:11386508 -G1 - 3U10HD047890-05S1; 7695403; U10HD047890 -AD - GEORGETOWN UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - MITSUYASU, RONALD T -TI - AIDS Malignancy Clinical Trials Consortium -M3 - Awarded Grant -DA - 2008 -PY - 2008 -AN - GRANTS:11732592 -G1 - 3U01CA121947-03S2; 7689546; U01CA121947 -AD - UNIVERSITY OF CALIFORNIA LOS ANGELES -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - MITSUYASU, RONALD T -TI - AIDS Malignancy Clinical Trials Consortium -M3 - Awarded Grant -DA - 2008 -PY - 2008 -AN - GRANTS:10014296 -G1 - 3U01CA121947-03S3; 7689549; U01CA121947 -AD - UNIVERSITY OF CALIFORNIA LOS ANGELES -Y2 - 2023-12-08 -ER - - -TY - JOUR -AU - MITSUYASU, RONALD T -TI - AIDS Malignancy Clinical Trials Consortium -M3 - Awarded Grant -DA - 2008 -PY - 2008 -AN - GRANTS:10141308 -G1 - 3U01CA121947-03S1; 7689545; U01CA121947 -AD - UNIVERSITY OF CALIFORNIA LOS ANGELES -Y2 - 2023-12-14 -ER - - -TY - JOUR -Z2 - 刘文扬 -Z2 - 韩梓铭 -Z2 - 王健仰 -Z2 - 张涛 -Z2 - 陈东福 -Z2 - 冯勤付 -Z2 - 肖泽芬 -Z2 - 吕纪马 -Z2 - 王鑫 -Z2 - 邓垒 -Z2 - 王文卿 -Z2 - 翟医蕊 -Z2 - 王志杰 -Z2 - 王洁 -Z2 - 毕楠 -Z2 - 周宗玫 -AU - Liu Wenyang -AU - Han Ziming -AU - Wang Jianyang -AU - Zhang Tao -AU - Chen Dongfu -AU - Feng Qinfu -AU - Xiao Zefen -AU - Lyu Jima -AU - Wang Xin -AU - Deng Lei -AU - Wang Wenqing -AU - Zhai Yirui -AU - Wang Zhijie -AU - Wang Jie -AU - Bi Nan -AU - Zhou Zongmei -TI - Safety of thoracic radiotherapy followed by PD-1/PD-L1 inhibitor after induction therapy for extensive-stage small cell lung cancer -T2 - Chinese Journal of Radiation Oncology -M3 - Article -AB - Objective To evaluate the safety and tolerance of sequential thoracic radiotherapy combined with PD-1/PD-L1 inhibitors in patients with extensive-stage small cell lung cancer (ES-SCLC) after induction systemic therapy.Methods ES-SCLC patients from a phase I trial and a real-world study were enrolled for those who received thoracic radiotherapy after induction systemic treatment (chemotherapy/chemotherapy combined with PD-1/PD-L1 inhibitors) and consolidated with PD-1/PD-L1 inhibitors.These two studies were both approved by the Ethics Committee of Chinese Academy of Medical Sciences Cancer Hospital (Clinical Trials,gov number,NCT03971214,NCT04947774).Results Between January 2019 and March 2021,a total of 11 patients with ES-SCLC were analyzed,aged 52-73 years,with a median age of 62 years.Among them,five patients (45.5%) received induction chemotherapy and six patients (54.5%) received chemotherapy combined with PD-1/PD-L1 inhibitor,and then all received intensity-modulated thoracic radiotherapy after evaluation of systemic treatment efficacy.Two patients developed treatment-related grade G3-5 toxicity (18.2%,1 treatment-related pneumonitis and 1 radiation esophagitis).G1-G2 hematologic toxicity,pneumonia,and anorexia were common mild toxicities.Only one patient (9.1%) terminated immunotherapy due to immune-related pneumonitis.During a median follow-up time of 12.5 months (range:3.5-16.4 months),the median disease progression-free survival and overall survival was 7.4 months (95%CI:6.9-8.0 months) and 14.6 months (95%CI:9.0-20.2 months),respectively.Conclusions Sequential thoracic radiotherapy followed by PD-1/PD-L1 inhibitor is safe and feasible in patients with ES-SCLC after induction therapy.Given that both thoracic radiotherapy and immunotherapy benefits the ES-SCLC in survival,this comprehensive treatment modality warrants further investigation. -SN - 1004-4221 -DA - 2022 -PY - 2022 -VL - 31 -IS - 3 -SP - 236 -EP - 241 -C7 - 1004-4221(2022)31:3<236:GFQXXB>2.0.TX;2-D -AN - CSCD:7176141 -AD - 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院放疗科, 国家肿瘤临床医学研究中心, 北京 100021, 中国 -AD - 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院肿瘤内科, 国家肿瘤临床医学研究中心, 北京 100021, 中国 -AD - Department of Radiation Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Cancer, Beijing 100021, China -AD - Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Cancer, Beijing 100021, China -M2 - 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院放疗科 -M2 - 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院肿瘤内科 -M2 - Department of Radiation Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College -M2 - Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College -Y2 - 2022-06-03 -ER - - -TY - JOUR -AU - Fitzgerald, Kelly -AU - Simone, Charles B., II -TI - Combining Immunotherapy with Radiation Therapy in Non- Small Cell Lung Cancer -T2 - THORACIC SURGERY CLINICS -M3 - Article -AB - Immune checkpoint inhibitors have recently been demonstrated to improve survival in metastatic and locally advanced non-small cell lung cancer (NSCLC). Radiation therapy has a well-established role in the treatment of NSCLC and has more recently been shown to be immunostimulatory, with the potential to enhance the efficacy of immunotherapy. This comprehensive review details the current roles of radiation therapy and immune checkpoint inhibitors in NSCLC, discusses the intersection of these two modalities and their potential to have combined synergistic responses, and highlights existing preclinical and clinical data and ongoing clinical trials of combined immunotherapy and radiotherapy across all NSCLC stages. -PU - W B SAUNDERS CO-ELSEVIER INC -PI - PHILADELPHIA -PA - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA -SN - 1547-4127 -SN - 1558-5069 -DA - 2020 MAY -PY - 2020 -VL - 30 -IS - 2 -SP - 221 -EP - 239 -DO - 10.1016/j.thorsurg.2020.01.002 -AN - WOS:000528218000014 -AD - Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 First Ave,Mezzanine Level, New York, NY 10065 USA -AD - New York Proton Ctr, 225 East 126th St, New York, NY 10035 USA -M2 - New York Proton Ctr -Y2 - 2020-05-07 -ER - - -TY - JOUR -AU - Imano, Nobuki -AU - Kimura, Tomoki -AU - Kawahara, Daisuke -AU - Nishioka, Riku -AU - Fukumoto, Wataru -AU - Kawano, Reo -AU - Kubo, Katsumaro -AU - Katsuta, Tsuyoshi -AU - Takeuchi, Yuki -AU - Nishibuchi, Ikuno -AU - Murakami, Yuji -AU - Horimasu, Yasushi -AU - Masuda, Takeshi -AU - Fujitaka, Kazunori -AU - Hattori, Noboru -AU - Nagata, Yasushi -TI - Potential benefits of volumetric modulated arc therapy to reduce the incidence of ≥ grade 2 radiation pneumonitis in radiotherapy for locally advanced non-small cell lung cancer patients -T2 - JAPANESE JOURNAL OF CLINICAL ONCOLOGY -M3 - Article -AB - Background: The use of volumetric modulated arc therapy is gradually widespread for locally advanced non-small cell lung cancer. The purpose of this study was to identify the factors that caused >= grade 2 radiation pneumonitis and evaluate the impact of using volumetric modulated arc therapy on the incidence of >= grade 2 radiation pneumonitis by comparing three-dimensional conformal radiation therapy.Methods: We retrospectively evaluated 124 patients who underwent radical radiotherapy for locally advanced non-small cell lung cancer in our institution between 2008 and 2019. The following variables were analysed to detect the factors that affected >= grade 2 radiation pneumonitis; age, sex, the presence of interstitial lung disease, pulmonary emphysema, tumour location, stage, PTV/lung volume, lung V-20Gy, total dose, concurrent chemoradiotherapy, adjuvant immune checkpoint inhibitor, radiotherapy method. Radiation pneumonitis was evaluated using the common terminology criteria for adverse events (version 5.0).Results: A total of 84 patients underwent three-dimensional conformal radiation therapy (3D-CRT group) and 40 patients underwent volumetric modulated arc therapy (VMAT group). The cumulative incidence of >= grade 2 radiation pneumonitis at 12 months was significantly lower in the VMAT group than in the 3D-CRT group (25% vs. 49.1%). The use of volumetric modulated arc therapy was a significant factor for >= grade 2 radiation pneumonitis (HR:0.32, 95% CI: 0.15-0.65, P = 0.0017) in addition to lung V-20Gy (>= 24%, HR:5.72 (95% CI: 2.87-11.4), P < 0.0001) and total dose (>= 70 Gy, HR:2.64 (95% CI: 1.39-5.03), P = 0.0031) even after adjustment by multivariate analysis.Conclusions: We identified factors associated with >= grade 2 radiation pneumonitis in radiotherapy for patients with locally advanced non-small cell lung cancer. Volumetric modulated arc therapy has potential benefits to reduce the risk of >= grade 2 radiation pneumonitis. -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 0368-2811 -SN - 1465-3621 -DA - 2021 DEC -PY - 2021 -VL - 51 -IS - 12 -SP - 1729 -EP - 1735 -DO - 10.1093/jjco/hyab163 -AN - WOS:000753498500006 -C6 - OCT 2021 -AD - Hiroshima Univ, Grad Sch Biomed Hlth Sci, Dept Radiat Oncol, Hiroshima, Japan -AD - Kochi Univ, Kochi Med Sch, Dept Radiat Oncol, Nankoku, Kochi, Japan -AD - Hiroshima Univ, Grad Sch Biomed Hlth Sci, Dept Diagnost Radiol, Hiroshima, Japan -AD - Hiroshima Univ Hosp, Clin Res Ctr Hiroshima, Hiroshima, Japan -AD - Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Mol & Internal Med, Hiroshima, Japan -Y2 - 2022-03-01 -ER - - -TY - JOUR -AU - Melosky, Barbara -AU - Cheema, Parneet K. -AU - Brade, Anthony -AU - McLeod, Deanna -AU - Liu, Geoffrey -AU - Price, Paul Wheatley -AU - Jao, Kevin -AU - Schellenberg, Devin D. -AU - Juergens, Rosalyn -AU - Leighl, Natasha -AU - Chu, Quincy -TI - Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment ofExtensive-StageSmall Cell Lung Cancer -T2 - ONCOLOGIST -M3 - Article -AB - Background Small cell lung cancer (SCLC) represents approximately 15% of lung cancers, and approximately 70% are diagnosed as extensive-stage SCLC (ES-SCLC). Although ES-SCLC is highly responsive to chemotherapy, patients typically progress rapidly, and there is an urgent need for new therapies. Immune checkpoint inhibitors (ICIs) have recently been investigated in SCLC, and this review provides guidance on the use of these agents in ES-SCLC based on phase III evidence. Methods Published and presented literature on phase III data addressing use of ICIs in ES-SCLC was identified using the key search terms "small cell lung cancer" AND "checkpoint inhibitors" (OR respective aliases). Directed searches of eligible studies were periodically performed to ensure capture of the most recent data. Results Six phase III trials were identified, with four assessing the benefits of ICIs plus chemotherapy first-line, one evaluating ICIs as first-line therapy maintenance, and one assessing ICI monotherapy after progression on platinum-based chemotherapy. The addition of ipilimumab or tremelimumab to first-line treatment or as first-line maintenance did not improve survival. Two out of three studies combining PD-1/PD-L1 inhibitors with first-line platinum-based chemotherapy demonstrated significant long-lasting survival benefits and improved quality of life with no unexpected safety concerns. PD-1/PD-L1 inhibitors as first-line maintenance or in later lines of therapy did not improve survival. Biomarker research is ongoing as well as research into the role of ICIs in combination with radiation therapy in limited-stage SCLC. Conclusion The addition of atezolizumab or durvalumab to first-line platinum-based chemotherapy for ES-SCLC prolongs survival and improves quality of life. Implications for Practice Platinum-based chemotherapy has been standard of care for extensive-stage small cell lung cancer (ES-SCLC) for more than a decade. Six recent phase III trials investigating immune checkpoint inhibitors (ICIs) have clarified the role of these agents in this setting. Although ICIs were assessed first-line, as first-line maintenance, and in later lines of therapy, the additions of atezolizumab or durvalumab to first-line platinum-based chemotherapy were the only interventions that significantly improved overall survival and increased quality of life. These combinations should therefore be considered standard therapy for first-line ES-SCLC. Biomarker research and investigations into the role of ICIs for limited-stage disease are ongoing. -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 1083-7159 -SN - 1549-490X -DA - 2020 NOV -PY - 2020 -VL - 25 -IS - 11 -SP - 981 -EP - 992 -DO - 10.1634/theoncologist.2020-0193 -AN - WOS:000571815500001 -C6 - SEP 2020 -AD - Univ British Columbia, Vancouver Ctr, BC Canc, Vancouver, BC, Canada -AD - Univ Toronto, William Osler Hlth Syst, Brampton, ON, Canada -AD - Univ Toronto, William Osler Hlth Syst, Toronto, ON, Canada -AD - Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada -AD - Univ Toronto, Trillium Hlth Partners, Mississauga, ON, Canada -AD - Kaleidoscope Strategic Inc, Toronto, ON, Canada -AD - Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada -AD - Univ Montreal, Hop Sacre Coeur, Montreal, PQ, Canada -AD - Univ British Columbia, Surrey Ctr, BC Canc, Surrey, BC, Canada -AD - McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada -AD - Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada -M2 - Kaleidoscope Strategic Inc -Y2 - 2020-10-06 -ER - - -TY - JOUR -AU - Kalemkerian, Gregory P. -AU - Schneider, Bryan J. -TI - Advances in Small Cell Lung Cancer -T2 - HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA -M3 - Article -AB - Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by early metastatic spread and responsiveness to initial therapy. The incidence of SCLC has been declining in the United States in parallel with the decreasing prevalence of cigarette smoking. Limited stage disease is potentially curable with chemoradiotherapy followed by cranial irradiation. Extensive stage disease is incurable, but systemic chemotherapy can improve quality of life and prolong survival. Nearly all patients relapse with chemoresistant disease. Molecularly targeted therapy has failed to yield convincing clinical benefits. Nevertheless, many biologically rational strategies, including immune checkpoint inhibition, show promise in ongoing clinical trials. -PU - W B SAUNDERS CO-ELSEVIER INC -PI - PHILADELPHIA -PA - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA -SN - 0889-8588 -SN - 1558-1977 -DA - 2017 FEB -PY - 2017 -VL - 31 -IS - 1 -SP - 143 -EP - + -DO - 10.1016/j.hoc.2016.08.005 -AN - WOS:000390984800012 -AD - Univ Michigan, Dept Internal Med, Div Hematol Oncol, C350 Med Inn SPC 5848,1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA -AD - Univ Michigan, Dept Internal Med, Div Hematol Oncol, C411 Med Inn SPC 5848,1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA -Y2 - 2017-01-25 -ER - - -TY - JOUR -AU - Levy, Antonin -AU - Botticella, Angela -AU - Le Pechoux, Cecile -AU - Faivre-Finn, Corinne -TI - Thoracic radiotherapy in small cell lung cancer-a narrative review -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Small-cell lung cancer (SCLC) represents 10?15% of all lung cancers and has a poor prognosis. Thoracic radiotherapy plays a central role in current SCLC management. Concurrent chemoradiotherapy (CTRT) is the standard of care for localised disease (stage I?III, limited-stage, LS). Definitive thoracic radiotherapy may be offered in metastatic patients (stage IV, extensive stage, ES-SCLC) after chemotherapy. For LS-SCLC, the gold standard is early accelerated hyperfractionated twice-daily CTRT (4 cycles of cisplatin etoposide, starting with the first or second chemotherapy cycle). Modern radiation techniques should be used with involved-field radiotherapy based on baseline CT and PET/CT scans. In ES-SCLC, thoracic radiotherapy should be discussed in cases of initial bulky mediastinal disease/residual thoracic disease not progressing after induction chemotherapy. This strategy was however not assessed in recent trials establishing chemo-immunotherapy as the standard first line treatment in ES-SCLC. Future developments include technical radiotherapy advances and the incorporation of new drugs. Thoracic irradiation is delivered more precisely given technical developments (IMRT, image-guided radiotherapy, stereotactic radiotherapy), reducing the risks of severe adverse events. Stereotactic ablative radiotherapy may be discussed in rare early stage (T1 to 2, N0) inoperable patients. A number of current clinical trials are investigating immunoradiotherapy. In this review, we highlight the current role of thoracic radiotherapy and describe ongoing research in the integration of biological surrogate markers, advanced radiotherapy technologies and novel drugs in SCLC patients. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2021 APR -PY - 2021 -VL - 10 -IS - 4 -SP - 2059 -EP - 2070 -DO - 10.21037/tlcr-20-305 -AN - WOS:000646137600021 -AD - Inst Oncol Thorac IOT, Gustave Roussy, Dept Radiat Oncol, Villejuif, France -AD - Univ Paris Saclay, Univ Paris Sud, Le Kremlin Bicetre, France -AD - Univ Paris Saclay, Gustave Roussy, INSERM, U1030,Mol Radiotherapy, Villejuif, France -AD - Univ Manchester, Fac Biol Med & Hlth, Sch Med Sci, Div Canc Sci, Manchester, Lancs, England -AD - Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England -AD - Univ Manchester, Div Canc Sci, Manchester, Lancs, England -Y2 - 2021-06-01 -ER - - -TY - JOUR -AU - Tian, Yaru -AU - Ma, Ji -AU - Jing, Xuquan -AU - Zhai, Xiaoyang -AU - Li, Yuying -AU - Guo, Zhijun -AU - Yu, Jinming -AU - Zhu, Hui -TI - Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy -T2 - CANCER LETTERS -M3 - Article -AB - Unlike non-small-cell lung cancer (NSCLC), the progression of small-cell lung cancer (SCLC) is slow. Extensivestage SCLC (ES-SCLC) is a serious threat to human health, with a 5-year survival rate of <7%. Chemotherapy has been the first-line treatment for the past 30 years. The anti-PD-L1 checkpoint blockades durvalumab and atezolizumab have greatly prolonged overall survival and have become the standard first-line therapy for ES-SCLC since the CASPIAN and IMpower133 trials. In the era of chemotherapy, radiation therapy (RT), including thoracic radiation therapy (TRT) and brain radiation therapy (BRT), has shown clinical effects in randomized and retrospective studies on ES-SCLC. RT-immunotherapy has shown exciting synergistic effects in NSCLC. For ESSCLC, the clinical effects of combining TRT/BRT with immunotherapy have not yet been systematically explored. In this review, we found that studies on RT-immunotherapy in ES-SCLC are relatively few and limited to early phase studies focusing on toxicity. The efficacy and safety profiles of early phase studies encourage prospective clinical trials. In this review, we discuss the best population, optimum TRT dose, proper TRT time, and strategies for reducing radiation-induced neurotoxicity. Furthermore, we suggest that biomarkers and patient performance status should be fully assessed before RT-immunotherapy treatment. Prospective trials are needed to provide more evidence for RT-immunotherapy applications in ES-SCLC. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0304-3835 -SN - 1872-7980 -DA - 2022 AUG 10 -PY - 2022 -VL - 541 -C7 - 215719 -DO - 10.1016/j.canlet.2022.215719 -AN - WOS:000810210500003 -C6 - MAY 2022 -AD - Shandong First Med Univ, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China -AD - Peoples Hosp Leling, Dept Oncol, Leling, Shandong, Peoples R China -AD - Shandong First Med Univ, Shandong Canc Hosp & Inst, Dept Intens Care Unit, Jinan, Shandong, Peoples R China -AD - Shandong First Med Univ, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China -AD - Chinese Acad Med Sci, Res Unit Radiat Oncol, Jinan, Shandong, Peoples R China -AD - 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China -AD - Shandong First Med Univ, Shandong Acad Med Sci, Jinan, Shandong, Peoples R China -M2 - Peoples Hosp Leling -Y2 - 2022-06-24 -ER - - -TY - JOUR -AU - Zhang, Shanshan -AU - Bi, Minghong -TI - The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis -T2 - ANNALS OF PALLIATIVE MEDICINE -M3 - Article -AB - Background: Small cell lung cancer (SCLC) is highly invasive and fatal, sensitive to chemotherapy and radiotherapy but prone to relapse, with a poor overall survival rate. It is particularly urgent for SCLC patients to receive effective follow-up treatment. In the past 20 years, there has been no breakthrough in clinical treatment of SCLC. Currently, clinical studies on immunotherapy for SCLC with extensive stage disease (ED) have achieved good efficacy, bringing new hope for the treatment of small-cell lung cancer. PD-1 inhibitors used to treat small cell lung cancer include Pembrolizumab and Nivolumab. PD-L1 inhibitors mainly include Atezolizumab and Durvalumab. Other PD-1/PD-L1 inhibitors, such as Avelumab, are currently being tried for SCLC and the results have not yet been published. This study is to evaluate the efficacy and safety of immunotherapy in patients with ED SCLC.Methods: A literature search of the PubMed, Embase, and Cochrane Library databases were performed. Two reviewers independently screened the literature, extracted the data, and evaluated the risk of bias of the included studies. RevMan 5.3 software was used for meta-analysis.Results: Four studies involving 1,981 patients with ED SCLC were included. Both overall survival (OS) [hazard ratio (HR)=0.80, 95% confidence interval (CI) (0.68, 0.95), P=0.009] and progression-free survival (PFS) [HR=0.82, 95% CI (0.75, 0.90), P<0.00001] were longer in the immunotherapy group than in the chemotherapy group. The incidence of total treatment-related adverse events in the immunotherapy group were lower than those in the chemotherapy group [relative risk (RR)=1.050, 95% CI (1.010, 1.080), P=0.007], and the differences were statistically significant.Conclusions: Immunotherapy has better efficacy and safety than chemotherapy for the treatment of ED SCLC. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2224-5820 -SN - 2224-5839 -DA - 2020 NOV -PY - 2020 -VL - 9 -IS - 6 -SP - 4081 -EP - 4088 -DO - 10.21037/apm-20-2011 -AN - WOS:000595542800042 -AD - Bengbu Med Coll, Affiliated Hosp 1, Dept Oncol, Bengbu, Peoples R China -Y2 - 2021-01-11 -ER - - -TY - JOUR -AU - Abe, Takanori -AU - Iino, Misaki -AU - Saito, Satoshi -AU - Aoshika, Tomomi -AU - Ryuno, Yasuhiro -AU - Ohta, Tomohiro -AU - Igari, Mitsunobu -AU - Hirai, Ryuta -AU - Kumazaki, Yu -AU - Miura, Yu -AU - Kaira, Kyoichi -AU - Kagamu, Hiroshi -AU - Noda, Shin-ei -AU - Kato, Shingo -TI - Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer -T2 - JOURNAL OF RADIATION RESEARCH -M3 - Article -AB - The feasibility of intensity modulated radiotherapy (IMRT) with involved field radiotherapy (IFRT) for Japanese patients with locally advanced non-small cell lung cancer (LA-NSCLC) remains unclear. Here we reviewed our initial experience of IMRT with IFRT for Japanese patients with LA-NSCLC to evaluate the feasibility of the treatment. Twenty LA-NSCLC patients who were treated with IMRT with IFRT during November 2019 to October 2020 were retrospectively analyzed. All patients received 60 Gy in 30 fractions of IMRT and were administered concurrent platinum-based chemotherapy. The median patient age was 71 years old and the group included 15 men and 5 women. The patient group included 2 patients with stage IIB, 11 patients with stage IIIA, 5 patients with stage IIIB, and 2 patients with stage IIIC disease. Histological diagnosis was squamous cell carcinoma in 14 patients, adenocarcinoma in 5 patients, and non-small cell lung cancer in 1 patient. The median follow-up period was 8 months. The incidence of grade 3 or greater pneumonitis was 5%, and grade 3 or greater esophagitis was not observed. None of the patients developed regional lymph node, with only recurrence reported so far. These findings indicate that IMRT with IFRT for Japanese patients with LA-NSCLC is feasible in terms of acute toxicity. Further study with a larger number of patients and longer follow-up to clarify the effect of treatment on patient prognosis is required. -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 0449-3060 -SN - 1349-9157 -DA - 2021 SEP -PY - 2021 -VL - 62 -IS - 5 -SP - 894 -EP - 900 -DO - 10.1093/jrr/rrab063 -AN - WOS:000700078300019 -C6 - JUL 2021 -AD - Saitama Med Univ, Int Med Ctr, Dept Radiat Oncol, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan -AD - Saitama Med Univ, Int Med Ctr, Dept Resp Med, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan -Y2 - 2021-10-03 -ER - - -TY - JOUR -AU - Xue, Lei -AU - Chen, Baishen -AU - Lin, Junshuang -AU - Peng, Jiangzhou -TI - Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report -T2 - ANNALS OF PALLIATIVE MEDICINE -M3 - Article -AB - The conventional etoposide-platinum (EP) regimen and adjuvant radiotherapy remain the gold-standard treatment for small cell lung cancer (SCLC). However, most patients already have multiple metastases when they are first diagnosed with SCLC. The objective response rate (ORR) and 1-year survival rate are low in these patients despite active radiotherapy and chemotherapy. SCLC is oncologically featured by the high tumor mutational burden (TMB) of multiple genes, which makes immunotherapy a possible new treatment strategy for SCLC. New data from the IMpower 133 and CASPIAN trials will shed new light on the treatment of SCLC. In 2020, the results from the phase 3 CASPIAN trial have already suggested that programmed cell death-ligand 1 (PD-L1) inhibitors may represent breakthroughs in the management of SCLC. Here, we report a patient with extensive-stage SCLC (ES-SCLC) treated with first-line anti- PD-L1 immune checkpoint inhibitor (PD-L1 inhibitor) (i.e., durvalumab) combined with the EP regimen for 6 cycles. The patient consistently achieved partial response (PR) [nearly complete response (CR)], and no immune-related adverse events were noted during this period. The Karnofsky performance status (PS) score maintained at 1-2 points. We further review the history of SCLC treatment and elucidate the role of combination with immunotherapy in treating SCLC in the coming years. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2224-5820 -SN - 2224-5839 -DA - 2021 JAN -PY - 2021 -VL - 10 -IS - 1 -SP - 828 -EP - 835 -DO - 10.21037/apm-20-2574 -AN - WOS:000614549600090 -AD - Southern Med Univ, Dept Thorac Surg, Affiliated Hosp 3, Guangzhou 510630, Peoples R China -AD - Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Thorac Surg, Guangzhou, Peoples R China -Y2 - 2021-03-16 -ER - - -TY - JOUR -AU - Li, Huanhuan -AU - Zhao, Yangzhi -AU - Ma, Tiangang -AU - Shao, Hao -AU - Wang, Tiejun -AU - Jin, Shunzi -AU - Liu, Zhongshan -TI - Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era -T2 - FRONTIERS IN IMMUNOLOGY -M3 - Review -AB - Currently, chemoimmunotherapy is the first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, only 0.8%-2.5% of the patients presented complete response after chemoimmunotherapy. Considering that ES-SCLC is highly sensitive to radiotherapy, the addition of radiotherapy after first-line treatment for ES-SCLC could further improve local control, which may be beneficial for patients' survival. Prior studies have shown that consolidative thoracic radiotherapy (cTRT) can decrease disease progression and improve overall survival in patients with ES-SCLC who respond well to chemotherapy. However, the efficacy and safety of cTRT in the immunotherapy era remain unclear owing to a lack of prospective studies. Prophylactic cranial irradiation (PCI) has been shown to decrease brain metastasis (BM) and prolong survival in patients with limited-stage SCLC in previous reports. However, according to current guidelines, PCI is not commonly recommended for ES-SCLC. Immunotherapy has the potential to reduce the incidence of BM. Whether PCI can be replaced with regular magnetic resonance imaging surveillance for ES-SCLC in the era of immunotherapy remains controversial. Whole brain radiation therapy (WBRT) is the standard treatment for BM in SCLC patients. Stereotactic radiosurgery (SRS) has shown promise in the treatment of limited BM. Considering the potential of immunotherapy to decrease BM, it is controversial whether SRS can replace WBRT for limited BM in the immunotherapy era. Additionally, with the addition of immunotherapy, the role of palliative radiotherapy may be weakened in patients with asymptomatic metastatic lesions. However, it is still indispensable and urgent for patients with obvious symptoms of metastatic disease, such as spinal cord compression, superior vena cava syndrome, lobar obstruction, and weight-bearing metastases, which may critically damage the quality of life and prognosis. To improve the outcome of ES-SCLC, we discuss the feasibility of radiotherapy, including cTRT, PCI, WBRT/SRS, and palliative radiotherapy with immunotherapy based on existing evidence, which may offer specific prospects for further randomized trials and clinical applications. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1664-3224 -DA - 2023 AUG 28 -PY - 2023 -VL - 14 -C7 - 1132482 -DO - 10.3389/fimmu.2023.1132482 -AN - WOS:001062028200001 -AD - Jilin Univ, Dept Radiat Oncol, Affiliated Hosp 2, Changchun, Peoples R China -AD - First Hosp Jilin Univ, Dept Hematol, Changchun, Peoples R China -AD - Jilin Univ, Dept Resp & Crit Care Med, Affiliated Hosp 2, Changchun, Peoples R China -AD - Jilin Univ, NHC Key Lab Radiobiol, Changchun, Peoples R China -Y2 - 2023-09-25 -ER - - -TY - JOUR -AU - Kang, Kai -AU - Wu, Yijun -AU - Yao, Zhuoran -AU - Lu, You -TI - Tackling the current dilemma of immunotherapy in extensive-stage small cell lung cancer: A promising strategy of combining with radiotherapy -T2 - CANCER LETTERS -M3 - Article -AB - Progress in the treatment of small cell lung cancer (SCLC) has been modest over the past decades until the advent of immune checkpoint inhibitors, which have redefined the standard first-line treatment for extensive-stage SCLC (ES-SCLC). However, despite the positive results of several clinical trials, the limited survival benefit achieved suggests that the priming and sustaining of immunotherapeutic efficacy are poor and further investigation is urgently needed. In this review, we aim to summarize the potential mechanisms underlying the limited efficacy of immunotherapy and intrinsic resistance in ES-SCLC, including impaired antigen presentation and limited T cell infiltration. Moreover, to tackle the current dilemma, given the synergistic effects of radiotherapy on immunotherapy, especially the unique advantages of low-dose radiotherapy (LDRT), such as less immunosup-pression and lower radiation toxicity, we propose radiotherapy as a booster to enhance the immunotherapeutic efficacy by overcoming the poor priming effect. Recent clinical trials, including ours, have also focused on adding radiotherapy, including LDRT, to first-line treatment of ES-SCLC. Additionally, we also suggest combination strategies to sustain the immunostimulatory effect of radiotherapy, as well as the cancer-immunity cycle, and further improve survival outcomes. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0304-3835 -SN - 1872-7980 -DA - 2023 JUL 1 -PY - 2023 -VL - 565 -C7 - 216239 -DO - 10.1016/j.canlet.2023.216239 -AN - WOS:001011993000001 -C6 - MAY 2023 -AD - Sichuan Univ, Canc Ctr, Div Thorac Tumor Multimodal Treatment, Chengdu, Sichuan, Peoples R China -AD - Sichuan Univ, West China Hosp, Lab Clin Cell Therapy, Chengdu, Sichuan, Peoples R China -AD - Sichuan Univ, West China Hosp, Canc Ctr, Dept Radiat Oncol, Chengdu, Sichuan, Peoples R China -AD - 37 Guoxue Lane, Chengdu 610000, Sichuan, Peoples R China -Y2 - 2023-07-02 -ER - - -TY - JOUR -AU - Kaesmann, Lukas -AU - Eze, Chukwuka -AU - Taugner, Julian -AU - Roengvoraphoj, Olarn -AU - Dantes, Maurice -AU - Schmidt-Hegemann, Nina-Sophie -AU - Schiopu, Sanziana -AU - Belka, Claus -AU - Manapov, Farkhad -TI - Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy -T2 - RADIATION ONCOLOGY -M3 - Review -AB - Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor control probability and have resulted in the development of novel therapeutic strategies. For advanced non-small cell lung cancer (NSCLC), targeting immune checkpoint pathways has proven to be less toxic with more durable treatment response than conventional chemotherapy. In inoperable Stage III NSCLC, consolidation immune checkpoint inhibition with the PD-L1 inhibitor durvalumab after completion of concurrent platinum-based chemoradiotherapy resulted in remarkable improvement of progression-free and overall survival. This new tri-modal therapy has become a new treatment standard. Development of predictive biomarkers and improvement of patient selection and monitoring is the next step in order to identify patients most likely to derive maximal benefit from this new multimodal approach. In this review, we discuss the immunological rationale and current trials investigating chemoradioimmunotherapy for inoperable stage III NSCLC. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1748-717X -DA - 2020 JUL 9 -PY - 2020 -VL - 15 -IS - 1 -C7 - 167 -DO - 10.1186/s13014-020-01595-3 -AN - WOS:000552055100003 -AD - Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiat Oncol, Marchioninistr 15, D-81377 Munich, Germany -AD - German Ctr Lung Res DZL, Comprehens Pneumol Ctr Munich CPC M, Munich, Germany -AD - German Canc Consortium DKTK, Partner Site Munich, Munich, Germany -AD - Ludwig Maximilians Univ Munchen, Dept Internal Med 5, Munich, Germany -M2 - German Ctr Lung Res DZL -Y2 - 2020-08-06 -ER - - -TY - JOUR -AU - Tsui, David Chun Cheong -AU - Camidge, D. Ross -AU - Rusthoven, Chad G. -TI - Managing Central Nervous System Spread of Lung Cancer: The State of the Art -T2 - JOURNAL OF CLINICAL ONCOLOGY -M3 - Review -AB - Brain metastases (BrM) are common in both non-small-cell lung cancer and small-cell lung cancer. Substantial progress in BrM management has occurred in the past decade related to advances in both radiation and medical oncology. Recent and ongoing radiation trials have focused on increasing the candidacy for focal therapy of BrM with stereotactic radiosurgery; reducing the toxicity and improving patient selection for whole brain radiotherapy; and, in small-cell lung cancer, evaluating brain magnetic resonance imaging surveillance without prophylactic cranial irradiation, hippocampal avoidance in prophylactic cranial irradiation and whole brain radiotherapy, and the role of upfront stereotactic radiosurgery for BrM. In medical oncology, the development of multiple tyrosine kinase inhibitors with encouraging CNS activity and emerging data on the CNS activity of immune checkpoint inhibitors in some patients have opened the door to novel systemic and multidisciplinary treatment strategies for the management of BrM. Future research will focus on more robust characterizations of the CNS activity of targeted therapy and immunotherapies, as well as optimal integration and patient selection for multidisciplinary strategies involving CNS-active drugs, radiation therapy, and CNS surveillance. (c) 2022 by American Society of Clinical Oncology -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0732-183X -SN - 1527-7755 -DA - 2022 FEB 20 -PY - 2022 -VL - 40 -IS - 6 -SP - 642 -EP - + -DO - 10.1200/JCO.21.01715 -AN - WOS:000755949300013 -AD - Univ Colorado, Div Med Oncol, Canc Ctr, Anschutz Med Campus, Aurora, CO 80045 USA -AD - Univ Colorado, Dept Radiat Oncol, Canc Ctr, Anschutz Med Campus, Aurora, CO 80045 USA -Y2 - 2022-03-05 -ER - - -TY - JOUR -AU - Bogart, Jeffrey A. -AU - Waqar, Saiama N. -AU - Mix, Michael D. -TI - Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer -T2 - JOURNAL OF CLINICAL ONCOLOGY -M3 - Review -AB - Progress in the overall treatment of small-cell lung cancer (SCLC) has moved at a slower pace than non-small-cell lung cancer. In fact, the standard treatment regimen for limited stage SCLC has not appreciably shifted in more than 20 years, consisting of four to six cycles of cisplatin and etoposide chemotherapy concurrent with thoracic radiotherapy (TRT) followed by prophylactic cranial irradiation (PCI) for responsive disease. Nevertheless, long-term outcomes have improved with median survival approaching 25-30 months, and approximately one third of patients now survive 5 years. This is likely attributable in part to improvements in staging, including use of brain magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography imaging, advances in radiation treatment planning, and supportive care. The CONVERT and CALGB 30610 phase III trials failed to demonstrate a survival advantage for high-dose, once-daily TRT compared with standard 45 Gy twice-daily TRT, although high-dose, once-daily TRT remains common in practice. A phase III comparison of high-dose 60 Gy twice-daily TRT versus 45 Gy twice-daily TRT aims to confirm the provocative outcomes reported with 60 Gy twice daily in the phase II setting. Efforts over time have shifted from intensifying PCI, to attempting to reduce treatment-related neurotoxicity, to more recently questioning whether careful magnetic resonance imaging surveillance may obviate the routine need for PCI. The addition of immunotherapy has resulted in mixed success in extensive-stage SCLC with modest benefit observed with programmed death-ligand 1 inhibitors, and several ongoing trials assess programmed death-ligand 1 inhibition concurrent or adjuvant to chemoradiotherapy in limited-stage SCLC. Major advances in future treatment will likely depend on a better understanding and exploiting of molecular characteristics of SCLC with increasing personalization of therapy. (c) 2022 by American Society of Clinical Oncology -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0732-183X -SN - 1527-7755 -DA - 2022 FEB 20 -PY - 2022 -VL - 40 -IS - 6 -SP - 661 -EP - + -DO - 10.1200/JCO.21.01639 -AN - WOS:000755949300014 -AD - SUNY Upstate Med Univ, 750 East Adams St, Syracuse, NY 13210 USA -AD - Washington Univ, Sch Med, St Louis, MO USA -Y2 - 2022-03-05 -ER - - -TY - JOUR -AU - Fleckenstein, J. -AU - Poettgen, C. -AU - Reinmuth, N. -TI - Modern definitive radiochemotherapy-state of the art implementation and new consolidation strategies -T2 - ZEITSCHRIFT FUR PNEUMOLOGIE -M3 - Article -AB - Background In locally advanced non-small-cell lung cancer (NSCLC), the addition of chemotherapy to radiotherapy and consolidation with durvalumab leads to a significant increase in overall survival and represents the most profound innovation of the last decade.Objectives Analysis of new possibilities for the state-of-the-art implementation of definitive radiochemotherapy concepts.Materials and methods Evaluation of prospective and randomised studies regarding improvements in treatment outcomes.Results Overall survival benefit of consolidating checkpoint inhibitor therapy after combined radiochemotherapy with durvalumab is 43% (95% confidence interval 38-47%) versus 33% (27-40%) in the placebo group in an updated analysis of the PACIFIC trial for 5-year survival; stratified hazard ratio for death is 0.72 (95% CI 0.59-0.89, p = 0.0025). In the dose escalation studies, increased pulmonary and oesophageal side effects were observed, so no immediate clinical benefit could be derived from the increase in local efficacy. Improved imaging before and during therapy and optimised possibilities of dose application, especially by using intensity-modulated radiotherapy (IMRT), allow selective sparing of healthy structures, which increases the ability to safely intensify radiotherapy also in connection with new immunomodulatory substance combinations.Conclusion The integration of immunotherapy, the stringent use of fluorodeoxyglucose positron emission tomography (FDG-PET) in staging and radiation planning, the widespread use of highly conformal radiation techniques (IMRT; volumetric modulated arc therapy, VMAT) and the consistent application of image-guided radiotherapy have led to significant improvements in treatment outcomes. -PU - SPRINGER HEIDELBERG -PI - HEIDELBERG -PA - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY -SN - 2731-7404 -SN - 2731-7412 -DA - 2023 SEP -PY - 2023 -VL - 20 -IS - 5 -SP - 267 -EP - 272 -DO - 10.1007/s10405-023-00522-z -AN - WOS:001047085100002 -C6 - AUG 2023 -AD - Univ Klinikum Saarlandes Homburg, Klin Strahlentherapie & Radioonkol, Homburg, Germany -AD - Univ Klinikum Essen, Klin Strahlentherapie, Essen, Germany -AD - Deutsch Zentrums Lungenforsch DZL Gauting, Thorakale Onkol, Asklepios Fachkliniken Munchen Gauting, Gauting, Germany -AD - Univ Klinikum Essen, Klin Strahlentherapie, Hufelandstr 55, D-45122 Essen, Germany -M2 - Deutsch Zentrums Lungenforsch DZL Gauting -Y2 - 2023-08-27 -ER - - -TY - JOUR -AU - Fleckenstein, J. -AU - Poettgen, C. -AU - Reinmuth, N. -TI - Modern definitive radiochemotherapy-state of the art implementation and new consolidation strategies -T2 - ONKOLOGIE -M3 - Article -AB - Background In locally advanced non-small-cell lung cancer (NSCLC), the addition of chemotherapy to radiotherapy and consolidation with durvalumab leads to a significant increase in overall survival and represents the most profound innovation of the last decade. Objectives Analysis of new possibilities for the state-of-the-art implementation of definitive radiochemotherapy concepts. Materials and methods Evaluation of prospective and randomised studies regarding improvements in treatment outcomes. Results Overall survival benefit of consolidating checkpoint inhibitor therapy after combined radiochemotherapy with durvalumab is 43% (95% confidence interval 38-47%) versus 33% (27-40%) in the placebo group in an updated analysis of the PACIFIC trial for 5-year survival; stratified hazard ratio for death is 0.72 (95% CI 0.59-0.89, p = 0.0025). In the dose escalation studies, increased pulmonary and oesophageal side effects were observed, so no immediate clinical benefit could be derived from the increase in local efficacy. Improved imaging before and during therapy and optimised possibilities of dose application, especially by using intensity-modulated radiotherapy (IMRT), allow selective sparing of healthy structures, which increases the ability to safely intensify radiotherapy also in connection with new immunomodulatory substance combinations. Conclusion The integration of immunotherapy, the stringent use of fluorodeoxyglucose positron emission tomography (FDG-PET) in staging and radiation planning, the widespread use of highly conformal radiation techniques (IMRT; volumetric modulated arc therapy, VMAT) and the consistent application of image-guided radiotherapy have led to significant improvements in treatment outcomes. -PU - SPRINGER HEIDELBERG -PI - HEIDELBERG -PA - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY -SN - 2731-7226 -SN - 2731-7234 -DA - 2022 DEC -PY - 2022 -VL - 28 -IS - 12 -SP - 1071 -EP - 1077 -DO - 10.1007/s00761-022-01250-4 -AN - WOS:000887969200002 -C6 - NOV 2022 -AD - Univ Klinikum Saarlandes Homburg, Klin Strahlentherapie & Radioonkol, Homburg, Germany -AD - Univ Klinikum Essen, Klin Strahlentherapie, Hufelandstr 55, D-45122 Essen, Germany -AD - Mitglied Deutsch Zentrums Lungenforsch DZL Gautin, Asklepios Fachkliniken Munchen Gauting, Thorakale Onkol, Gauting, Germany -M2 - Mitglied Deutsch Zentrums Lungenforsch DZL Gautin -Y2 - 2022-12-12 -ER - - -TY - JOUR -AU - Huang, Chengliang -AU - Gan, Gregory N. -AU - Zhang, Jun -TI - IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer -T2 - JOURNAL OF HEMATOLOGY & ONCOLOGY -M3 - Letter -AB - The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2-3 decades until two recent trials (CASPIAN and IMpower133) showing the addition of anti-programmed death ligand (PD-L1) therapy to chemotherapy has survival benefit over chemotherapy alone. However, such benefit is relatively small and was not even observed in some other trials using immunotherapy, raising the question of optimal chemoimmunotherapy combination in the 1st-line setting for ES-SCLC. Here, we discussed several thought-provoking questions with the focus on IMpower133 and CASPIAN trials. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1756-8722 -DA - 2020 JUN 5 -PY - 2020 -VL - 13 -IS - 1 -C7 - 69 -DO - 10.1186/s13045-020-00898-y -AN - WOS:000540228600004 -AD - Southwest Med Univ, Affiliated Hosp, Dept Resp & Crit Care Med 2, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China -AD - Univ Kansas, Dept Internal Med, Div Med Oncol, Canc Ctr,Med Ctr, 3005 Wahl Hall East,3901 Rainbow Blvd, Kansas City, KS 66160 USA -AD - Univ Kansas, Dept Radiat Oncol, Canc Ctr, Med Ctr, 3005 Wahl Hall East,3901 Rainbow Blvd, Kansas City, KS 66160 USA -AD - Univ Kansas, Med Ctr, Canc Ctr, Dept Canc Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA -Y2 - 2020-06-26 -ER - - -TY - JOUR -AU - Paczkowski, Freeman -AU - Raphael, Jacques -AU - Browne, Claire -TI - Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report -T2 - CURRENT ONCOLOGY -M3 - Article -AB - Small-cell lung cancer (SCLC) remains a disease with poor prognosis, particularly in extensive-stage SCLC (ES-SCLC). Current standard-of-care treatment includes chemotherapy with platinum agents and etoposide plus immunotherapy with atezolizumab or durvalumab, which has achieved a mean overall survival of 12-13 months in clinical trials. However, long-term survival in ES-SCLC, even with the addition of immunotherapy, continues to be rare. We present the case of a middle-aged male patient diagnosed with ES-SCLC who was treated with four cycles of induction chemotherapy (carboplatin and etoposide) and atezolizumab, starting maintenance atezolizumab every 21 days thereafter, and thoracic radiotherapy. After 9 months, he experienced mild disease progression and was rechallenged with six cycles of carboplatin and etoposide with continued atezolizumab. Subsequent imaging showed near-complete disease resolution which has been sustained since. He has continued on maintenance atezolizumab since diagnosis and has achieved 60 months overall survival and 44 months progression-free survival. Throughout treatment, he has maintained a high functional capacity and only experienced one immune-related adverse event. Our patient is representative of a small subset who are capable of achieving durable responses to immunotherapy and his case highlights the need for further research to elucidate the clinical and biological factors driving this response. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1198-0052 -SN - 1718-7729 -DA - 2024 JUL -PY - 2024 -VL - 31 -IS - 7 -SP - 3682 -EP - 3689 -DO - 10.3390/curroncol31070271 -AN - WOS:001276725300001 -AD - Western Univ, Schulich Sch Med & Dent, London, ON N6A 3K7, Canada -AD - Western Univ, London Hlth Sci Ctr, Dept Oncol, Div Med Oncol, London, ON N6A 5W9, Canada -Y2 - 2024-08-01 -ER - - -TY - JOUR -AU - Liu, Xingyu -AU - Xing, Huifang -AU - Liu, Baoxing -TI - Current status and future perspectives of immune checkpoint inhibitors in extensive-stage small cell lung cancer -T2 - AMERICAN JOURNAL OF CANCER RESEARCH -M3 - Review -AB - Small-cell lung cancer (SCLC) is a type of neuroendocrine neoplasms with high aggressiveness and poor prognosis. Chemotherapy has been the standard first-line therapy for SCLC over the past several decades. In recent years, results of randomized phase III CASPIAN and IMpower-133 trials indicated that the combination of immune checkpoint inhibitors (ICIs) with platinum-etoposide chemotherapy improved the overall survival (OS) of patients with extensive stage small-cell lung cancer (ES-SCLC), which has transformed the treatment model for ES-SCLC. ICIs combined with chemotherapy has become the new first-line standard treatment of ES-SCLC with the latest research results from CASPIAN and ASTRUM-005 studies. This review summarizes the recent progress of ICIs in the treatment of ES-SCLC and expounds the mode and efficacy of immunotherapy for ES-SCLC. Future research focused on exploring basic SCLC biology and identifying novel predictive biomarkers in response to ICIs in ES-SCLC is essential. Double-ICIs treatment strategies, bispecific antibodies, and ICIs combined with other therapies, such as chemotherapy, radiotherapy, and targeted therapy, represent a new modality and show great promise for the treatment of ES-SCLC, which should achieve greater therapeutic effects through multiple synergistic mechanisms. -PU - E-CENTURY PUBLISHING CORP -PI - MADISON -PA - 40 WHITE OAKS LN, MADISON, WI 53711 USA -SN - 2156-6976 -DA - 2022 -PY - 2022 -VL - 12 -IS - 6 -SP - 2447 -EP - 2464 -AN - WOS:000820205900003 -AD - Zhengzhou Univ, Henan Canc Hosp, Dept Thorac Surg, Affiliated Canc Hosp, Zhengzhou 45008, Peoples R China -AD - Zhengzhou Univ, Dept Geriatr Med, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China -Y2 - 2022-07-18 -ER - - -TY - JOUR -AU - Jiang, Liyang -AU - Meng, Xiangjiao -TI - Is there role of adjuvant radiotherapy after complete resection of locally advanced nonsmall cell lung cancer? -T2 - CURRENT OPINION IN ONCOLOGY -M3 - Review -AB - Purpose of reviewThis review aims to provide a timely and relevant overview of the role of postoperative radiotherapy (PORT) in completely resected stage IIIA-N2 nonsmall cell lung cancer (NSCLC). Given the controversy surrounding the use of PORT and the emergence of advanced radiation techniques and therapies, this review provides valuable insight into current and potential treatment strategies.Recent findingsThe Lung ART and PORT-C trials have provided valuable insights into the efficacy of PORT in stage IIIA-N2 NSCLC. While the results have been mixed, studies have shown that advanced radiation techniques, such as intensity-modulated radiotherapy (IMRT) and proton therapy, can reduce cardiopulmonary toxicities associated with PORT. Molecular targeted therapies and immunotherapies have also shown potential in improving NSCLC treatment outcomes.SummaryThe role of radiotherapy becomes smaller and smaller in new era. However, it is too early to abolish radiotherapy for all the patients after complete resection of locally advanced NSCLC. Nowadays, it is recommended to adopt individualized treatment approaches guided by multidisciplinary team consultations. The integration of IMRT, proton therapy, and emerging therapies offers the potential to enhance treatment efficacy while minimizing toxicity. Further research is needed to optimize the use of PORT and explore the method to identify the patients who can really benefit from PORT. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1040-8746 -SN - 1531-703X -DA - 2024 JAN -PY - 2024 -VL - 36 -IS - 1 -SP - 44 -EP - 50 -DO - 10.1097/CCO.0000000000001004 -AN - WOS:001154635000004 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China -Y2 - 2024-02-18 -ER - - -TY - JOUR -AU - Sham, Nelson Ow -AU - Zhao, Lei -AU - Zhu, Ziwen -AU - Roy, Tanner M. -AU - Xiao, Huaping -AU - Bai, Qian -AU - Wakefield, Mark R. -AU - Fang, Yujiang -TI - Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets -T2 - ANTICANCER RESEARCH -M3 - Review -AB - From radiation therapy and surgery to chemotherapy and targeted therapy, the treatment of non-small cell lung cancer (NSCLC) has remarkably evolved over the past few decades. In recent years, immunotherapy has become an increasingly attractive area of interest in the treatment of NSCLC, especially those in advanced stages. Cytokine and immune checkpoint inhibitors are among the most studied immunotherapies for many cancer types. Herein, we provide an overview of current popular cytokine and checkpoint inhibitor treatment regimens available for patients with NSCLC. Ongoing clinic trials and novel molecular targets that are discussed here could lead to promising new treatment options for NSCLC. The evidence summarized in this review might be helpful for clinicians to better manage patients with NSCLC. -PU - INT INST ANTICANCER RESEARCH -PI - ATHENS -PA - EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE -SN - 0250-7005 -SN - 1791-7530 -DA - 2022 JUL -PY - 2022 -VL - 42 -IS - 7 -SP - 3275 -EP - 3284 -DO - 10.21873/anticanres.15816 -AN - WOS:000829941200004 -AD - Des Moines Univ, Dept Microbiol Immunol & Pathol, Des Moines, IA 50312 USA -AD - Anhui Med Univ, Dept Resp Med, Peoples Hosp Hefei 2, Hefei, Peoples R China -AD - Anhui Med Univ, Hefei Hosp, Hefei, Peoples R China -AD - Univ Missouri, Sch Med, Dept Surg, Columbia, MO USA -M2 - Des Moines Univ -Y2 - 2022-08-02 -ER - - -TY - JOUR -AU - Schlick, Brian -AU - Shields, Misty Dawn -AU - Marin-Acevedo, Julian A. -AU - Patel, Ishika -AU - Pellini, Bruna -TI - Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer -T2 - CURRENT TREATMENT OPTIONS IN ONCOLOGY -M3 - Review -AB - Opinion statement Limited-stage small cell lung cancer (LS-SCLC) is a potentially curable disease. However, most patients develop disease relapse shortly after definitive treatment. The landmark trials IMpower133 and CASPIAN demonstrated a survival benefit with the addition of immunotherapy to first-line platinum/etoposide for extensive-stage small cell lung cancer. Therefore, it is critical to determine whether advancements in overall survival with immunotherapy can be translated earlier into the treatment paradigm for LS-SCLC. Decades of robust preclinical research into the synergism of radiation therapy and immunotherapy set the stage for the combination of these treatment modalities. Recently published data suggests tolerability of single agent immunotherapy concurrent with chemoradiation in LS-SCLC, along with promising efficacy. However, combination immunotherapy in the consolidation setting appears too toxic, although this may be reflective of the dosing schedule rather than inherent to any combination immune checkpoint blockade. Here, we review underlying mechanisms of synergy with the combination of radiation and immunotherapy, the safety and efficacy of respective treatment modalities, and the ongoing trials that are exploring novel therapeutic approaches for LS-SCLC. Pivotal trials in LS-SCLC are ongoing and anticipated to aid in understanding efficacy and safety of immunotherapy with concurrent platinum-based chemoradiotherapy. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1527-2729 -SN - 1534-6277 -DA - 2022 AUG -PY - 2022 -VL - 23 -IS - 8 -SP - 1104 -EP - 1120 -DO - 10.1007/s11864-022-00989-7 -AN - WOS:000812645000001 -C6 - JUN 2022 -AD - Univ S Florida, Morsani Coll Med, Dept Oncol Sci, GME Off, 12902 Magnolia Dr, Tampa, FL 33612 USA -AD - Univ S Florida, Dept Publ Hlth, 4202 E Fowler Ave, Tampa, FL 33620 USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, 12902 Magnolia Dr,CSB 6 THOR PROG, Tampa, FL 33612 USA -Y2 - 2022-06-26 -ER - - -TY - JOUR -AU - Kievit, H. -AU - Muntinghe-Wagenaar, M. B. -AU - Hijmering-Kappelle, L. B. M. -AU - Hiddinga, B. I. -AU - Ubbels, J. F. -AU - Wijsman, R. -AU - Slingers, G. -AU - de Vries, R. -AU - Groen, H. J. M. -AU - Kerstjens, H. A. M. -AU - van der Wekken, A. J. -AU - Hiltermann, T. J. N. -TI - Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial -T2 - LUNG CANCER -M3 - Article -AB - Introduction: This phase I study primarily addresses the safety and tolerability of Stereotactic radiotherapy on the primary tumor combined with double Immune Checkpoint Inhibition (SICI) in patients with non-small cell lung cancer (NSCLC). Increasing the release of neoantigens by radiotherapy might enhance response to immunotherapy. Especially, by targeting trunk mutations in the primary tumor. Materials and Methods: In three sequential cohorts, immunotherapy regimes combined with stereotactic body radiotherapy (SBRT) on the primary tumor (1x20 Gy on 9 cc) were studied in stage IIIB/IV NSCLC patients progressing on chemotherapy. The first cohort (n = 3) received durvalumab. The second (n = 6) received a combination of tremelimumab and durvalumab followed by durvalumab monotherapy. The third cohort (n = 6) was similar except that the combination was reversed. Descriptive statistics were used to assess safety parameters and the exploratory outcomes of efficacy. Adverse events were reported using NCI CTCAE version 4.03. Exhaled breath was analyzed at baseline. Results: Fifteen patients were included. Median irradiated volume was 9.13 cc, on a median primary tumor volume of 79 cc. There were seven patients with grade 1-2, and two patients with grade 3 treatment related adverse events. There was 1 dose limiting toxicity (colitis) with double immunotherapy. Conclusion: The combination of SBRT to the primary tumor and double immunotherapy in advanced NSCLC patients is safe and feasible. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2023 APR -PY - 2023 -VL - 178 -SP - 96 -EP - 102 -DO - 10.1016/j.lungcan.2023.02.004 -AN - WOS:000943229500001 -C6 - FEB 2023 -AD - Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, Groningen, Netherlands -AD - Univ Groningen, Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands -AD - Breathomix BV, Leiden, Netherlands -AD - Univ Med Ctr Groningen, Postbus 30001, HPC AA11, NL-9700 RB Groningen, Netherlands -M2 - Breathomix BV -Y2 - 2023-03-20 -ER - - -TY - JOUR -AU - Fang, Min -AU - Wang, Le -AU - Gu, Qing -AU - Wu, Huiwen -AU - Du, Xianghui -AU - Lai, Xiaojing -TI - Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world -T2 - CLINICAL & EXPERIMENTAL METASTASIS -M3 - Article -AB - The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive-stage small lung cancer (ES-SCLC). The CREST trial reported consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for ES-SCLC with intrathoracic residual after chemotherapy. In this study, patients with ES-SCLC who received immunotherapy were assigned to receive either TRT or no TRT. TRT significantly improved progression-free survival (PFS), local recurrence-free survival (LRFS) and OS with well tolerated toxicity. Further sub-cohort analysis, TRT significantly improved LRFS in patients with oligo-metastasis and without liver metastasis. -PU - SPRINGER -PI - DORDRECHT -PA - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS -SN - 0262-0898 -SN - 1573-7276 -DA - 2023 OCT -PY - 2023 -VL - 40 -IS - 5 -SP - 423 -EP - 429 -DO - 10.1007/s10585-023-10227-5 -AN - WOS:001048619300001 -C6 - AUG 2023 -AD - Zhejiang Canc Hosp, Dept Thorac Radiotherapy, Key Lab Radiat Oncol Zhejiang Prov, Hangzhou 310022, Peoples R China -AD - Chinese Acad Sci, Hangzhou Inst Med HIM, Hangzhou 310018, Peoples R China -AD - Zhejiang Canc Hosp, Dept Canc Prevent, Hangzhou 310022, Peoples R China -Y2 - 2023-08-26 -ER - - -TY - JOUR -AU - Xia, Liliang -AU - Liu, Yuanyong -AU - Wang, Ying -TI - PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions -T2 - ONCOLOGIST -M3 - Article -AB - The use of immune checkpoint inhibitors (ICIs) has become one of the most promising approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells, such as chemotherapy, radiotherapy, or targeted therapy, ICIs directly restore the exhausted host antitumor immune responses mediated by the tumors. Among multiple immune modulators identified, the programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis leading to the exhaustion of T-cell immunity in chronic infections and tumors has been widely investigated. Therefore, blocking antibodies targeting PD-1 or PD-L1 have been developed and approved for the treatment of various advanced cancers, including non-small-cell lung cancer (NSCLC), making them the most successful ICIs. Compared with chemotherapy or radiotherapy, PD-1/PD-L1 blockade therapy significantly improves the durable response rate and prolongs long-term survival with limited adverse effects in both monotherapy and combination therapy for advanced NSCLC. However, extensive challenges exist for further clinical applications, such as a small fraction of benefit population, primary and acquired resistance, the lack of predictive and prognostic biomarkers, and treatment-related adverse effects. In this article, we summarize the latest clinical applications of PD-1/PD-L1 blockade therapy in advanced NSCLC worldwide, as well as in China, and discuss the bottlenecks related to the use of this therapy in clinical practice. An exploration of the underlying mechanism of PD-1/PD-L1 blockade therapy and biomarker identification will maximize the application of ICIs in advanced NSCLC and facilitate bedside-to-bench studies in cancer immunotherapy as well. -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 1083-7159 -SN - 1549-490X -DA - 2019 FEB -PY - 2019 -VL - 24 -SP - S31 -EP - S41 -DO - 10.1634/theoncologist.2019-IO-S1-s05 -AN - WOS:000459915800005 -AD - Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Dept Immunol & Microbiol, Shanghai, Peoples R China -AD - Changchun Univ Sci & Technol, Sch Life Sci & Technol, Changchun, Jilin, Peoples R China -AD - Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Hlth & Dis Genom, Shanghai, Peoples R China -M2 - Chinese Natl Human Genome Ctr Shanghai -Y2 - 2019-03-12 -ER - - -TY - JOUR -AU - Doyen, Jerome -AU - Besse, Benjamin -AU - Texier, Matthieu -AU - Bonnet, Naima -AU - Levy, Antonin -TI - PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - Advanced non-small cell lung cancer (NSCLC) remains a high unmet medical need. The first line standard-of care therapy comprises concurrent chemotherapy-immunotherapy with pembrolizumab. Concurrent irradiation with pembrolizumab has been shown to significantly improve survival benefit compared with immunotherapy alone in a pooled analysis of 2 randomized phase 2 trials. We present the rationale and study design of the ???PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer??? (NIRVANA Lung) tr ial (ClinicalTr ials.gov identifier, NCT03774732). This study is a national multicenter 1:1 randomized phase III trial testing in 460 patients, the addition of multisite radiotherapy in advanced NSCLC treated with standard immune checkpoint inhibitors (pembrolizumab)-chemotherapy in first line. The pr imary objective of the tr ial is to compare the overall survival between the 2 arms at year 1 of the study. The secondary objective is to compare the progression-free survival and cancer-specific survival at year 1 and 2, as well as to determine quality of life, local and distant control in irradiated and nonirradiated sites at 6 months and year 1. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2022 MAY -PY - 2022 -VL - 23 -IS - 3 -SP - E252 -EP - E256 -DO - 10.1016/j.cllc.2021.10.008 -AN - WOS:000799215100021 -C6 - MAY 2022 -AD - Univ Cote dAzur, Ctr Antoine Lacassagne, Dept Radiat Oncol, Federat Claude Lalanne, Nice, France -AD - Gustave Roussy, Dept Med Oncol, Villejuif, France -AD - Univ Paris Saclay, Fac Med, Le Kremlin Bicetre, France -AD - Gutave Roussy, Dept Stat, Villejuif, France -AD - UNICANCER, Res Grp Radiotherapy Unicanc UNITRAD, Paris, France -AD - Gustave Roussy, Dept Radiat Oncol, Int Ctr Thorac Canc CICT, Villejuif, France -AD - Univ Paris Saclay, INSERM U1030, Mol Radiotherapy, Villejuif, France -M2 - Gutave Roussy -Y2 - 2022-06-03 -ER - - -TY - JOUR -AU - Pike, Luke R. G. -AU - Bang, Andrew -AU - Ott, Patrick -AU - Balboni, Tracy -AU - Taylor, Allison -AU - Catalano, Paul -AU - Rawal, Bhupendra -AU - Spektor, Alexander -AU - Krishnan, Monica -AU - Cagney, Daniel -AU - Alexander, Brian -AU - Aizer, Ayal A. -AU - Buchbinder, Elizabeth. -AU - Awad, Mark -AU - Gandhi, Leena -AU - Hodi, F. Stephen -AU - Schoenfeld, Jonathan D. -TI - Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation -T2 - RADIOTHERAPY AND ONCOLOGY -M3 - Article -AB - Background and purpose: Patients with metastatic melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) are increasingly treated with immune checkpoint blockade targeting the programed death (PD)-1 receptor, often with palliative radiation therapy. Outcome data are limited in this population.Material and methods: We retrospectively reviewed consecutive patients with metastatic NSCLC, melanoma, and RCC who received radiation and a nti-PD-1 therapy at four centers.Results: We identified 137 patients who received radiation and PD-1 inhibition. Median survival from first PD-1 therapy was 192, 394, and 121 days for NSCLC, melanoma, and RCC patients. Among 59 patients who received radiation following the start of PD-1 blockade, 25 continued to receive PD-1 inhibition for a median of 179 days and survived for a median of 238 additional days. Median survival following first course of radiation for brain metastases was 634 days. Melanoma patients received brain directed radiation relatively less frequently following the start of PD-1 inhibitor treatment.Conclusions: Incorporation of palliative radiation does not preclude favorable outcomes in patients treated with PD-1 inhibitors; patients irradiated after the start of PD-1 inhibition can remain on therapy and demonstrate prolonged survival. Of note, patients irradiated for brain metastases demonstrate favorable outcomes compared with historical controls. (C) 2017 Elsevier B.V. All rights reserved. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0167-8140 -DA - 2017 JUL -PY - 2017 -VL - 124 -IS - 1 -SP - 98 -EP - 103 -DO - 10.1016/j.radonc.2017.06.006 -AN - WOS:000407541500015 -AD - Massachusetts Gen Hosp, Harvard Radiat Oncol Program, Boston, MA 02114 USA -AD - Univ Ottawa, Div Radiat Oncol, Ottawa, ON, Canada -AD - Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA -AD - Dana Farber Harvard Canc Ctr, Boston, MA USA -AD - NYU, Med Ctr, New York, NY 10016 USA -Y2 - 2017-07-01 -ER - - -TY - JOUR -AU - Peng, Jianfeng -AU - Zhang, Lemeng -AU - Wang, Liping -AU - Feng, Hui -AU - Yao, Dongmei -AU - Meng, Rui -AU - Liu, Xiaomei -AU - Li, Xiaohua -AU - Liu, Ningbo -AU - Tan, Bingxu -AU - Huang, Zhaoqin -AU - Li, Shanshan -AU - Meng, Xiangjiao -TI - Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer -T2 - RADIATION ONCOLOGY -M3 - Article -AB - BackgroundThe CREST study showed that the addition of thoracic radiotherapy (TRT) could improve the survival rate in patients with extensive stage small cell lung cancer (ES-SCLC), but whether TRT can bring survival benefit in the era of immunotherapy remains controversial. This study aimed to explore the efficacy and safety of adding TRT to the combination of PD-L1 inhibitors and chemotherapy.MethodsThe patients who received durvalumab or atezolizumab combined with chemotherapy as the first-line treatment of ES-SCLC from January 2019 to December 2021 were enrolled. They were divided into two groups, based on whether they received TRT or not. Propensity score matching (PSM) with a 1:1 ratio was performed. The primary endpoints were progression-free survival (PFS), overall survival (OS) and safety.ResultsA total of 211 patients with ES-SCLC were enrolled, of whom 70 (33.2%) patients received standard therapy plus TRT as first-line treatment, and 141 (66.8%) patients in the control group received PD-L1 inhibitors plus chemotherapy. After PSM, a total of 57 pairs of patients were enrolled in the analysis. In all patients, the median PFS (mPFS) in the TRT and non-TRT group was 9.5 and 7.2 months, respectively, with HR = 0.59 (95%CI 0.39-0.88, p = 0.009). The median OS (mOS) in the TRT group was also significantly longer than that in the non-TRT group (24.1 months vs. 18.5 months, HR = 0.53, 95%CI 0.31-0.89, p = 0.016). Multivariable analysis showed that baseline liver metastasis and the number of metastases & GE; 3 were independent prognostic factors for OS. Addition of TRT increased the incidence of treatment-related pneumonia (p = 0.018), most of which were grade 1-2.ConclusionsAddition of TRT to durvalumab or atezolizumab plus chemotherapy significantly improves survival in ES-SCLC. Although it may leads to increased incidence of treatment-related pneumonia, a majority of the cases can be relieved after symptomatic treatment. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1748-717X -DA - 2023 JUL 4 -PY - 2023 -VL - 18 -IS - 1 -C7 - 111 -DO - 10.1186/s13014-023-02308-2 -AN - WOS:001022947500003 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jiyan Rd 440, Jinan 250117, Shandong, Peoples R China -AD - Hunan Canc Hosp, Dept Thorac Dept, Changsha, Peoples R China -AD - Baotou Canc Hosp, Dept Med Oncol, Baotou, Peoples R China -AD - Qingdao Univ, Dept Clin Oncolygy, Affiliated Hosp, Qingdao, Peoples R China -AD - Chaoyang Second Hosp, Dept Med Oncol, Chaoyang, Peoples R China -AD - Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Canc Ctr, Wuhan, Peoples R China -AD - Jinzhou Med Univ, Dept Oncol Dept, Jinzhou, Peoples R China -AD - Chifeng Municipal Hosp, Dept Resp & Crit Care, Chifeng, Inner Mongolia, Peoples R China -AD - Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Tianjin, Peoples R China -AD - Shandong Univ, Dept Radiat Oncol, Qilu Hosp, Jinan, Peoples R China -AD - Shandong Prov Hosp, Dept Radiol, Jinan, Peoples R China -AD - Zibo Municipal Hosp, Dept Oncol, Zibo, Peoples R China -M2 - Hunan Canc Hosp -M2 - Baotou Canc Hosp -M2 - Chaoyang Second Hosp -M2 - Chifeng Municipal Hosp -M2 - Zibo Municipal Hosp -Y2 - 2023-07-18 -ER - - -TY - JOUR -AU - van Dams, Ritchell -AU - Yuan, Ye -AU - Robinson, Clifford G. -AU - Lee, Percy -TI - Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer-A Stimulating Partnership -T2 - SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE -M3 - Review -AB - Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer and the leading cause of cancer-related death. Although durable local control rates are high after surgical resection or definitive radiotherapy for early-stage disease, a substantial proportion of these patients eventually experience regional and/or distant failure and succumb to their metastatic disease. The discovery of immunotherapeutics and targeted biologics has revolutionized the treatment of locally advanced and metastatic disease, improving progression-free and overall survival when incorporated with the current standards of care. Notably, post-hoc analyses and early clinical trials provide a growing body of evidence to support a synergistic effect between radiation and immunotherapy for the treatment of NSCLC from early-stage to metastatic disease. Radiotherapy appears to be capable of not only potentiating the effect of immunotherapy in targeted lesions, but also eliciting an antitumor response in distant lesions without any direct exposure to radiation. This review explores the biologic basis of immunotherapy, targeted biologics, and radiotherapy as well as the preclinical and clinical data that support the combined use of radioimmunotherapy for early-stage, locally advanced, and metastatic NSCLC. -PU - THIEME MEDICAL PUBL INC -PI - NEW YORK -PA - 333 SEVENTH AVE, NEW YORK, NY 10001 USA -SN - 1069-3424 -SN - 1098-9048 -DA - 2020 JUN -PY - 2020 -VL - 41 -IS - 3 -SP - 360 -EP - 368 -DO - 10.1055/s-0039-3399578 -AN - WOS:000537106400005 -AD - Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90024 USA -AD - Washington Univ, Sch Med St Louis, Dept Radiol, St Louis, MO USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Thorac Radiat Oncol, 1515 Holcombe Blvd,Unit 1422, Houston, TX 77030 USA -Y2 - 2020-06-12 -ER - - -TY - JOUR -AU - Tuli, Hardeep Singh -AU - Garg, Vivek K. -AU - Choudhary, Renuka -AU - Iqubal, Ashif -AU - Sak, Katrin -AU - Saini, Adesh K. -AU - Saini, Reena V. -AU - Vashishth, Kanupriya -AU - Dhama, Kuldeep -AU - Mohapatra, Ranjan K. -AU - Gupta, Dhruv Sanjay -AU - Kaur, Ginpreet -TI - Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives -T2 - MOLECULAR BIOLOGY REPORTS -M3 - Review -AB - Background Lung cancer is one of the highly lethal forms of cancer whose incidence has worldwide rapidly increased over the past few decades. About 80-85% of all lung cancer cases constitute non-small cell lung cancer (NSCLC), with adenocarcinoma, squamous cell carcinoma and large cell carcinoma as the main subtypes. Immune checkpoint inhibitors have led to significant advances in the treatment of a variety of solid tumors, significantly improving cancer patient survival rates.Methods and Results The cytotoxic drugs in combination with anti-PD-(L)1 antibodies is a new method that aims to reduce the activation of immunosuppressive and cancer cell prosurvival responses while also improving direct cancer cell death. The most commonly utilized immune checkpoint inhibitors for patients with non-small cell lung cancer are monoclonal antibodies (Atezolizumab, Cemiplimab, Ipilimumab, Pembrolizumab etc.) against PD-1, PD-L1, and CTLA-4. Among them, Atezolizumab (TECENTRIQ) and Cemiplimab (Libtayo) are engineered monoclonal anti programmed death ligand 1 (PD-L1) antibodies that inhibit binding of PD-L1 to PD-1 and B7.1. As a result, T-cell proliferation and cytokine synthesis are inhibited leading to restoring the immune homeostasis to fight cancer cells.Conclusions In this review article, the path leading to the introduction of immunotherapeutic options in lung cancer treatment is described, with analyzing the benefits and shortages of the current immunotherapeutic drugs. In addition, possibilities to co-administer immunotherapeutic agents with standard cancer treatment modalities are also considered. -PU - SPRINGER -PI - DORDRECHT -PA - VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS -SN - 0301-4851 -SN - 1573-4978 -DA - 2023 MAR -PY - 2023 -VL - 50 -IS - 3 -SP - 2685 -EP - 2700 -DO - 10.1007/s11033-022-08180-9 -AN - WOS:000900817600006 -C6 - DEC 2022 -AD - Maharishi Markandeshwar, Dept Biotechnol, Maharishi Markandeshwar Engn Coll, Mullana Ambala 133207, Haryana, India -AD - Chandigarh Univ, Univ Inst Appl Hlth Sci, Dept Med Lab Technol, Mohali 140413, Punjab, India -AD - Jamia Hamdard, Dept Pharmacol, Sch Pharmaceut Educ & Res, Fac Pharm, Delhi, India -AD - NGO Praeventio, EE-50407 Tartu, Estonia -AD - Post Grad Inst Med Educ & Res PGIMER, Adv Cardiac Ctr Dept Cardiol, Chandigarh 160012, India -AD - ICAR Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India -AD - Govt Coll Engn, Dept Chem, Keonjhar 758002, Odisha, India -AD - SVKMs NMIMS, Shobhaben Pratapbhai Patel Sch Pharm & Technol Man, Mumbai 40056, Maharashtra, India -M2 - Maharishi Markandeshwar -M2 - NGO Praeventio -M2 - Govt Coll Engn -Y2 - 2023-01-07 -ER - - -TY - JOUR -AU - Weller, Michael -AU - Remon, Jordi -AU - Rieken, Stefan -AU - Vollmuth, Philipp -AU - Ahn, Myung-Ju -AU - Minniti, Giuseppe -AU - Le Rhun, Emilie -AU - Westphal, Manfred -AU - Brastianos, Priscilla K. -AU - Soo, Ross A. -AU - Kirkpatrick, John P. -AU - Goldberg, Sarah B. -AU - Ohrling, Katarina -AU - Hegi-Johnson, Fiona -AU - Hendriks, Lizza E. L. -TI - Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape -T2 - CANCER TREATMENT REVIEWS -M3 - Review -AB - Up to 40% of patients with non-small cell lung cancer (NSCLC) develop central nervous system (CNS) metastases. Current treatments for this subgroup of patients with advanced NSCLC include local therapies (surgery, stereotactic radiosurgery, and, less frequently, whole-brain radiotherapy), targeted therapies for oncogene-addicted NSCLC (small molecules, such as tyrosine kinase inhibitors, and antibody-drug conjugates), and immune checkpoint inhibitors (as monotherapy or combination therapy), with multiple new drugs in development. However, confirming the intracranial activity of these treatments has proven to be challenging, given that most lung cancer clinical trials exclude patients with untreated and/or progressing CNS metastases, or do not include prespecified CNS-related endpoints. Here we review progress in the treatment of patients with CNS metastases originating from NSCLC, examining local treatment options, systemic therapies, and multimodal therapeutic strategies. We also consider challenges regarding assessment of treatment response and provide thoughts around future directions for managing CNS disease in patients with advanced NSCLC. -PU - ELSEVIER SCI LTD -PI - London -PA - 125 London Wall, London, ENGLAND -SN - 0305-7372 -SN - 1532-1967 -DA - 2024 NOV -PY - 2024 -VL - 130 -C7 - 102807 -DO - 10.1016/j.ctrv.2024.102807 -AN - WOS:001297216900001 -C6 - AUG 2024 -AD - Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland -AD - Paris Saclay Univ, Gustave Roussy, Dept Canc Med, Villejuif, France -AD - Univ Hosp Erlangen UMG, Dept Radiat Oncol, Gottingen, Germany -AD - Univ Hosp Gottingen UMG, Comprehens Canc Ctr Lower Saxony CCC N, Gottingen, Germany -AD - Univ Hosp Bonn, Div Computat Radiol & Clin AI, Clin Neuroradiol, Bonn, Germany -AD - German Canc Res Ctr, Div Med Image Comp, Heidelberg, Germany -AD - Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea -AD - Sapienza Univ Rome, Dept Radiol Sci Oncol & Anat Pathol, Rome, Italy -AD - IRCCS Neuromed, Pozzilli, Italy -AD - Univ Hosp, Dept Neurosurg & Neurol, Zurich, Switzerland -AD - Univ Zurich, Zurich, Switzerland -AD - Univ Hosp Hamburg Eppendorf, Dept Neurosurg, Hamburg, Germany -AD - Univ Hosp Hamburg Eppendorf, Inst Tumor Biol, Hamburg, Germany -AD - Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA -AD - Natl Univ Singapore Hosp, Dept Hematol Oncol, Singapore, Singapore -AD - Duke Univ, Dept Radiat Oncol, Durham, NC USA -AD - Duke Univ, Dept Neurosurg, Durham, NC USA -AD - Yale Canc Ctr, Yale Sch Med, Dept Med, New Haven, CT USA -AD - Yale Canc Ctr, Yale Sch Med, Dept Med Oncol, New Haven, CT USA -AD - Amgen Europe GmbH, Rotkreuz, Switzerland -AD - Univ Melbourne, Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Australia -AD - Univ Melbourne, Sir Peter MacCallum Dept Clin Oncol, Melbourne, Australia -AD - Maastricht Univ, Med Ctr, GROW Sch Oncol & Reprod, Dept Resp Med, Maastricht, Netherlands -M2 - Univ Hosp Erlangen UMG -M2 - Univ Hosp Gottingen UMG -Y2 - 2024-08-28 -ER - - -TY - JOUR -AU - Lahiri, Aritraa -AU - Maji, Avik -AU - Potdar, Pravin D. -AU - Singh, Navneet -AU - Parikh, Purvish -AU - Bisht, Bharti -AU - Mukherjee, Anubhab -AU - Paul, Manash K. -TI - Lung cancer immunotherapy: progress, pitfalls, and promises -T2 - MOLECULAR CANCER -M3 - Review -AB - Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading to relapse. Immunotherapy is profoundly altering the approach to cancer treatment owing to its tolerable safety profile, sustained therapeutic response due to immunological memory generation, and effectiveness across a broad patient population. Different tumor-specific vaccination strategies are gaining ground in the treatment of lung cancer. Recent advances in adoptive cell therapy (CAR T, TCR, TIL), the associated clinical trials on lung cancer, and associated hurdles are discussed in this review. Recent trials on lung cancer patients (without a targetable oncogenic driver alteration) reveal significant and sustained responses when treated with programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint blockade immunotherapies. Accumulating evidence indicates that a loss of effective anti-tumor immunity is associated with lung tumor evolution. Therapeutic cancer vaccines combined with immune checkpoint inhibitors (ICI) can achieve better therapeutic effects. To this end, the present article encompasses a detailed overview of the recent developments in the immunotherapeutic landscape in targeting small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Additionally, the review also explores the implication of nanomedicine in lung cancer immunotherapy as well as the combinatorial application of traditional therapy along with immunotherapy regimens. Finally, ongoing clinical trials, significant obstacles, and the future outlook of this treatment strategy are also highlighted to boost further research in the field. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1476-4598 -DA - 2023 FEB 21 -PY - 2023 -VL - 22 -IS - 1 -C7 - 40 -DO - 10.1186/s12943-023-01740-y -AN - WOS:000936285100005 -AD - Indian Inst Sci Educ & Res Kolkata, Dept Biol Sci, Mohanpur 741246, West Bengal, India -AD - NRS Med Coll & Hosp, Dept Radiat Oncol, 138 AJC Bose Rd, Kolkata 700014, India -AD - Jaslok Hosp & Res Ctr, Dept Mol Med & Stem Cell Biol, Mumbai 400026, India -AD - Postgrad Inst Med Educ & Res, Dept Pulm Med, Chandigarh 160012, India -AD - Mahatma Gandhi Med Coll & Hospital, Dept Clin Hematol, Jaipur 302022, Rajasthan, India -AD - Tata Mem Hosp, Dept Med Oncol, Mumbai 400012, Maharashtra, India -AD - Univ Calif Los Angeles, David Geffen Sch Med, Div Thorac Surg, Los Angeles, CA 90095 USA -AD - Esperer Onco Nutr Pvt Ltd, Gundecha Onclave, 4BA,4Th Floor,B Wing,Khairani Rd, Mumbai 400072, Maharashtra, India -AD - Univ Calif Los Angeles, David Geffen Sch Med, Dept Pulm & Crit Care Med, Manipal, CA USA -AD - Manipal Acad Higher Educ, Dept Microbiol, Kasturba Med Coll, Manipal 576104, Karnataka, India -M2 - NRS Med Coll & Hosp -M2 - Jaslok Hosp & Res Ctr -M2 - Mahatma Gandhi Med Coll & Hospital -M2 - Esperer Onco Nutr Pvt Ltd -Y2 - 2023-03-20 -ER - - -TY - JOUR -AU - Stanley, D. N. -AU - Harms, J. -AU - Kole, A. J. -AU - Dobelbower, M. C. -AU - McCann, C. -AU - Levin, L. -AU - Russell, K. -AU - McDonald, A. M. -TI - Daily Adaptive vs. Non -Adaptive External Beam Radiation Therapy with Concurrent Chemotherapy for Locally Advanced Non -Small Cell Lung Cancer (NSCLC): A Prospective Randomized Trial of an Individualized Approach for Toxicity Reduction (ARTIA-Lung) -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2090 -SP - E41 -EP - E42 -AN - WOS:001079706800086 -AD - Univ Albama Birmigham, Birmingham, AL USA -AD - A Siemens Healthineers Co, Varian Med Syst, Palo Alto, CA USA -AD - Varian Med Syst, Palo Alto, CA USA -M2 - Univ Albama Birmigham -M2 - A Siemens Healthineers Co -M2 - Varian Med Syst -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Verma, Saurav -AU - Young, Sympascho -AU - Louie, Alexander V. -AU - Palma, David -AU - Breadner, Daniel -TI - The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer -T2 - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY -M3 - Review -AB - The improvement in treatment strategies and outcomes in small cell lung cancer (SCLC) has lagged behind other cancers. The addition of immune checkpoint inhibitors (ICIs), durvalumab and atezolizumab, to the platinum-based chemotherapy in frontline setting has improved the survival in extensive stage SCLC, (ES-SCLC), albeit modestly, and is now the new standard of care. Prior to advent of immunotherapy into the therapeutic armamentarium in ES-SCLC, consolidative thoracic radiotherapy (TRT) was associated with improved thoracic control and survival outcomes. In the era of ICIs, the role of TRT is not well defined, chiefly because TRT was not incorporated in any immunotherapy trials, secondly due to concerns regarding the increased risks of pneumonitis, and finally uncertain magnitude of benefit with this combined approach. In principle, radiation can increase in the immunogenicity of tumor and hence the activity of immune checkpoint blockade, thereby increasing efficacy both locally and distantly. Such an approach has been promising in non-small cell lung cancer with ICIs improving outcomes after concurrent chemoradiation, but remains unanswered in ES-SCLC. It is, thus, possible that the modest improvement in survival by addition of ICIs to chemotherapy in ES-SCLC can be further improved by the incorporation of consolidative TRT in selected patients. Several early phase trials and retrospective studies have suggested that such an approach may be feasible and safe. Prospective trials are ongoing to answer whether adding radiation therapy to chemoimmunotherapy will improve outcomes in ES-SCLC. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1758-8340 -SN - 1758-8359 -DA - 2023 -PY - 2023 -VL - 15 -C7 - 17588359231192399 -DO - 10.1177/17588359231192399 -AN - WOS:001057890300001 -AD - Western Univ, Schulich Sch Med & Dent, Dept Oncol, Div Med Oncol, A3-913 800 Commissioners Rd East, London, ON N6A 5W9, Canada -AD - London Hlth Sci Ctr, London Reg Canc Program, London, ON, Canada -AD - Western Univ, Schulich Sch Med & Dent, Dept Oncol, Div Radiat Oncol, London, ON, Canada -AD - Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada -Y2 - 2023-09-12 -ER - - -TY - JOUR -AU - Arellano, Esperanza Arriola -AU - Diaz, Veronica Diaz -AU - Rodriguez, Joaquin Jose Cabrera -TI - Current status and future directions in unresectable stage III non-small cell lung cancer. -T2 - Journal of clinical and translational research -M3 - Journal Article -M3 - Review -AB - BACKGROUND: Patients with unresectable stage III non-small-cell lung cancer constitute a heterogeneous group in which the available treatments may range from radical therapies with radio-chemotherapy to supportive treatments depending on the extent of the disease and comorbidities present. For years the standard treatment based on the combination of chemotherapy and radiotherapy (RT) has remained unchanged and survival outcomes have been poor.AIM: Recent advances in molecular biology and RT technology have resulted in improved survival. This article reviews the treatments that constitute current standard treatment in unresectable advanced lung cancer and the situations and indications for the management of patients who are not candidates for radical therapy.RELEVANCE FOR PATIENTS: Although unresectable lung cancer does not have a good prognosis, new drugs and new technologies in radiation oncology can offer treatment options adapted to the patient's clinical situation, ranging from therapies administered with radical intent to others aimed mainly at improving the patient's quality of life, which, judiciously chosen, will provide optimal management of the patient. -SN - 2424-810X -DA - 2020 Oct 29 -PY - 2020 -VL - 6 -IS - 4 -SP - 109 -EP - 120 -AN - MEDLINE:33521371 -AD - Department Medical Oncology, Universitary Hospital Puerta del Mar, Cadiz, Spain. -AD - Department of Radiation Oncology, Universitary Hospital Puerta del Mar, Cadiz, Spain. -AD - Department of Radiation Oncology, Universitary Hospital of Badajoz, Badajoz, Spain. -Y2 - 2021-02-03 -ER - - -TY - JOUR -AU - Heinzerling, John H. -AU - Pen, Olga, V -AU - Robinson, Myra -AU - Foster, Ryan -AU - Kelly, Brian -AU - Mileham, Kathryn F. -AU - Moeller, Benjamin -AU - Prabhu, Roshan S. -AU - Corso, Christopher -AU - Ward, Matt W. -AU - Sullivan, Cara M. -AU - Burri, Stuart -AU - Simone II, Charles B. -TI - Full Dose SBRT in Combination With Mediastinal Chemoradiation for Locally Advanced, Non-Small Cell Lung Cancer: A Practical Guide for Planning, Dosimetric Results From a Phase 2 Study, and a Treatment Planning Guide for the Phase 3 NRG Oncology LU-008 Trial -T2 - PRACTICAL RADIATION ONCOLOGY -M3 - Article -AB - Purpose: Stereotactic body radiation therapy (SBRT) has been used with high effectiveness in early-stage non-small cell lung cancer (NSCLC) but has not been studied extensively in locally advanced NSCLC. We conducted a phase 2 study delivering SBRT to the pri-mary tumor followed by conventionally fractionated chemoradiation to the involved lymph nodes for patients with node-positive locally advanced NSCLC. This manuscript serves as both a guide to planning techniques used on this trial and the subsequent phase 3 study, NRG Oncology LU-008, and to report patient dosimetry and toxicity results.Methods and Materials: We initiated a phase 2 multicenter single arm study evaluating SBRT to the primary tumor (50-54 Gy in 3-5 fractions) followed by conventionally fractionated chemoradiation to 60 Gy in 2 Gy fractions with doublet chemotherapy to the involved lymph nodes for patients with stage III or unresectable stage II NSCLC. Patients eligible for adjuvant immunotherapy received up to 12 months of durvalumab. We report a detailed guide for the entire treatment process from computed tomography simulation through treat-ment planning and delivery. The dosimetric outcomes from the 60 patients who completed therapy on study are reported both for target coverage and normal structure doses. We also report correlation between radiation-related toxicities and dosimetric parameters.Results: Sixty patients were enrolled between 2017 and 2022. Planning techniques used were primarily volumetric modulated arc ther-apy for SBRT to the primary tumor and conventionally fractionated radiation to the involved nodes, with a minority of cases using dynamic conformal arc technique or static dynamic multileaf collimator intensity modulated radiation therapy. Grade 2 or higher pneumonitis was associated with lung dose V5 Gy > 70% and grade 2 or higher pulmonary toxicity was associated with lung dose V10 Gy > 50%. Only 3 patients (5%) experienced grade 3 or higher pneumonitis. Grade 2 or higher esophagitis was associated with esoph-ageal doses, including mean dose > 20 Gy, V60 Gy > 7%, and D1cc > 55 Gy. Only 1 patient (1.7%) experienced grade 3 esophagitis.Conclusions: SBRT to the primary tumor followed by conventionally fractionated chemoradiation to the involved lymph nodes is feasi-ble with planning techniques as described. Radiation-related toxicity on this phase 2 study was low. This manuscript serves as a guide-line for the recently activated NRG Oncology LU-008 phase 3 trial evaluating this experimental regimen.(c) 2023 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1879-8500 -DA - 2023 NOV -PY - 2023 -VL - 13 -IS - 6 -SP - 531 -EP - 539 -DO - 10.1016/j.prro.2023.04.014 -AN - WOS:001110058000001 -C6 - NOV 2023 -AD - Atrium Hlth, Levine Canc Inst, Southeast Radiat Oncol, Charlotte, NC 28204 USA -AD - Atrium Hlth, Levine Canc Inst, Charlotte, NC USA -AD - Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA -AD - New York Proton Ctr, New York, NY USA -M2 - Atrium Hlth -M2 - Atrium Hlth -M2 - New York Proton Ctr -Y2 - 2023-12-05 -ER - - -TY - JOUR -AU - Saowapa, Sakditad -AU - Polpichai, Natchaya -AU - Siladech, Pharit -AU - Wannaphut, Chalothorn -AU - Tanariyakul, Manasawee -AU - Wattanachayakul, Phuuwadith -AU - Lalitnithi, Pakin -TI - Pneumonitis Incidence in Patients With Metastatic Non-small Cell Lung Cancer on Immunotherapy: A Systematic Review and Meta-Analysis -T2 - CUREUS JOURNAL OF MEDICAL SCIENCE -M3 - Review -AB - Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, often diagnosed at the advanced stage (metastatic). Treatment options for metastatic NSCLC include radiotherapy, chemotherapy, target drug therapy, and immunotherapy. Immunotherapy (utilization of checkpoint inhibitors) boosts the immune system to recognize and destroy cancer cells. However, it is often associated with immune-related complications such as pneumonitis. This review aims to determine the incidence of pneumonitis in metastatic NSCLC patients treated with different immunotherapy drugs. PubMed, Cochrane Library, and Embase databases were scoured for randomized controlled trials (RCTs) until October 2023. Published RCTs with similar research objectives were included, while non-English articles, reviews, case reports, ongoing trials, non-randomized studies, conference abstracts, and studies on small cell lung cancer (SCLC) were excluded. The Cochrane risk-of-bias tool for randomized trials (RoB 2) was used to assess the risk of bias among the included studies. The statistical analyses were performed with the Comprehensive Meta-Analysis software. The subgroup analysis of the 16 included RCTs showed that metastatic NSCLC patients treated with nivolumab and pembrolizumab had a higher incidence of any grade pneumonitis than those treated with atezolizumab (4.5% and 5.1% vs. 1.6%, respectively). Similarly, the incidence of grade >= 3 pneumonitis was higher among patients receiving nivolumab (1.3%) and pembrolizumab (2.4%) than those receiving atezolizumab (0.7%). Furthermore, the subgroup analysis showed that patients with naive-treated NSCLC on immunotherapy had a higher incidence of any grade pneumonitis than those with previously treated NSCLC (6.5% vs. 3.9%). Treatment-naive patients recorded higher grade >= 3 pneumonitis incidences than those previously treated (3.1% vs. 1.3%). Programmed death 1 (PD-1) inhibitors (i.e., pembrolizumab and nivolumab) have higher incidences of pneumonitis than programmed death-ligand 1 inhibitors (atezolizumab). -PU - SPRINGERNATURE -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND -SN - 2168-8184 -DA - 2024 JUL 1 -PY - 2024 -VL - 16 -IS - 7 -C7 - e63615 -DO - 10.7759/cureus.63615 -AN - WOS:001266651600041 -AD - Texas Tech Univ, Hlth Sci Ctr, Internal Med, Lubbock, TX 79409 USA -AD - Weiss Mem Hosp, Internal Med, Chicago, IL USA -AD - Ramathibodi Hosp, Internal Med, Chiang Mai, Thailand -AD - Univ Hawaii, John A Burns Sch Med, Internal Med, Honolulu, HI USA -AD - Einstein Med Ctr, Internal Med, Philadelphia, PA USA -AD - St Elizabeths Med Ctr, Internal Med, Boston, MA USA -M2 - Weiss Mem Hosp -M2 - Ramathibodi Hosp -M2 - Einstein Med Ctr -Y2 - 2024-09-11 -ER - - -TY - JOUR -AU - Saowapa, Sakditad -AU - Polpichai, Natchaya -AU - Siladech, Pharit -AU - Wannaphut, Chalothorn -AU - Tanariyakul, Manasawee -AU - Wattanachayakul, Phuuwadith -AU - Lalitnithi, Pakin -TI - Pneumonitis Incidence in Patients With Metastatic Non-small Cell Lung Cancer on Immunotherapy: A Systematic Review and Meta-Analysis -T2 - CUREUS JOURNAL OF MEDICAL SCIENCE -M3 - Review -AB - Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, often diagnosed at the advanced stage (metastatic). Treatment options for metastatic NSCLC include radiotherapy, chemotherapy, target drug therapy, and immunotherapy. Immunotherapy (utilization of checkpoint inhibitors) boosts the immune system to recognize and destroy cancer cells. However, it is often associated with immune-related complications such as pneumonitis. This review aims to determine the incidence of pneumonitis in metastatic NSCLC patients treated with different immunotherapy drugs. PubMed, Cochrane Library, and Embase databases were scoured for randomized controlled trials (RCTs) until October 2023. Published RCTs with similar research objectives were included, while non-English articles, reviews, case reports, ongoing trials, non-randomized studies, conference abstracts, and studies on small cell lung cancer (SCLC) were excluded. The Cochrane risk-of-bias tool for randomized trials (RoB 2) was used to assess the risk of bias among the included studies. The statistical analyses were performed with the Comprehensive Meta-Analysis software. The subgroup analysis of the 16 included RCTs showed that metastatic NSCLC patients treated with nivolumab and pembrolizumab had a higher incidence of any grade pneumonitis than those treated with atezolizumab (4.5% and 5.1% vs. 1.6%, respectively). Similarly, the incidence of grade >= 3 pneumonitis was higher among patients receiving nivolumab (1.3%) and pembrolizumab (2.4%) than those receiving atezolizumab (0.7%). Furthermore, the subgroup analysis showed that patients with naive-treated NSCLC on immunotherapy had a higher incidence of any grade pneumonitis than those with previously treated NSCLC (6.5% vs. 3.9%). Treatment-naive patients recorded higher grade >= 3 pneumonitis incidences than those previously treated (3.1% vs. 1.3%). Programmed death 1 (PD-1) inhibitors (i.e., pembrolizumab and nivolumab) have higher incidences of pneumonitis than programmed death-ligand 1 inhibitors (atezolizumab). -PU - SPRINGERNATURE -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND -SN - 2168-8184 -DA - 2024 JUL 1 -PY - 2024 -VL - 16 -IS - 7 -C7 - e63615 -DO - 10.7759/cureus.63615 -AN - WOS:001266323100005 -AD - Texas Tech Univ, Hlth Sci Ctr, Internal Med, Lubbock, TX 79409 USA -AD - Weiss Mem Hosp, Internal Med, Chicago, IL USA -AD - Ramathibodi Hosp, Internal Med, Chiang Mai, Thailand -AD - Univ Hawaii, John A Burns Sch Med, Internal Med, Honolulu, HI USA -AD - Einstein Med Ctr, Internal Med, Philadelphia, PA USA -AD - St Elizabeths Med Ctr, Internal Med, Boston, MA USA -M2 - Weiss Mem Hosp -M2 - Ramathibodi Hosp -M2 - Einstein Med Ctr -Y2 - 2024-09-13 -ER - - -TY - JOUR -AU - Tjong, Michael C. -AU - Mak, David Y. -AU - Shahi, Jeevin -AU - Li, George J. -AU - Chen, Hanbo -AU - Louie, Alexander, V -TI - Current Management and Progress in Radiotherapy for Small Cell Lung Cancer -T2 - FRONTIERS IN ONCOLOGY -M3 - Review -AB - Radiotherapy (RT) and chemotherapy continue to be widely utilized in small cell lung cancer (SCLC) management. In most limited stage (LS)-SCLC cases, the standard initial therapy remains concurrent chemoradiotherapy (CRT), typically with an etoposide and platinum-based regimen. Hyperfractionated twice daily (BID) RT remains the standard of care, though conventional daily (QD) RT is now a viable alternative supported by randomized evidence. In LS-SCLC patients who experienced good response to CRT, prophylactic cranial irradiation (PCI) remains the standard of care. Brain imaging, ideally with MRI, should be performed prior to PCI to screen for clinically apparent brain metastases that may require a higher dose of cranial irradiation. Platinum doublet chemotherapy alone is the historic standard initial therapy in extensive stage (ES)-SCLC. Addition of immunotherapy such as atezolizumab and durvalumab to chemotherapy is now recommended after their benefits were demonstrated in recent trials. In patients with response to chemotherapy, consolidation thoracic RT and PCI could be considered, though with caveats. Emergence of hippocampal avoidance cranial irradiation and SRS in SCLC patients may supplant whole cranial irradiation as future standards of care. Incorporation of novel systemic therapies such as immunotherapies has changed the treatment paradigm and overall outlook of patients with SCLC. This narrative review summarizes the current state, ongoing trials, and future directions of radiotherapy in management of SCLC. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2020 JUL 14 -PY - 2020 -VL - 10 -C7 - 1146 -DO - 10.3389/fonc.2020.01146 -AN - WOS:000556573600001 -AD - Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Toronto, ON, Canada -AD - Univ Toronto, Fac Med, Toronto, ON, Canada -Y2 - 2020-08-19 -ER - - -TY - JOUR -AU - Berta, Judit -AU - Rozsas, Anita -AU - Megyesfalvi, Zsolt -AU - Ostoros, Gyula -AU - Dome, Balazs -TI - Thoracic irradiation as consolidation therapy in patients with extensive-stage small cell lung cancer -T2 - CURRENT OPINION IN ONCOLOGY -M3 - Review -AB - Purpose of reviewSmall cell lung cancer (SCLC) is marked by an exceptionally high proliferative rate and poor prognosis. Given its high propensity to metastasize, nearly two-thirds of SCLC patients are diagnosed with extensive-stage (ES) disease when surgery is not a treatment option anymore. Over several decades, only minimal changes have been made in the therapeutic armamentarium of ES-SCLC. Recently, however, several new therapeutic avenues were defined, thus renewing the hope for patients with this recalcitrant cancer. Here, we present an overview of the most current therapeutic advances in ES-SCLC focusing in particular on consolidative thoracic radiation therapy (cTRT) and chemo-immunotherapy.Recent findingsThe incorporation of immunotherapy in the standard-of-care of ES-SCLC patients and the resulting outcomes are both a remarkable hallmark of progress and a disappointment. Indeed, chemo-immunotherapy with or without cTRT and prophylactic cranial irradiation contributes to longer survival outcomes with minimal toxicity rates in well selected and properly monitored patients. Nevertheless, the gain in overall survival is still modest relative to that seen in many other solid tumors.Despite the encouraging results, further clinical trials are needed to determine the efficacy and safety of these therapeutic approaches, and moreover, to identify new predictive biomarkers of response. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1040-8746 -SN - 1531-703X -DA - 2023 JAN -PY - 2023 -VL - 35 -IS - 1 -SP - 54 -EP - 60 -DO - 10.1097/CCO.0000000000000911 -AN - WOS:000905204400009 -AD - Natl Koranyi Inst Pulmonol, 1121 Koranyi Frigyes Ut 1, Budapest, Hungary -AD - Semmelweis Univ, Dept Thorac Surg, Budapest, Hungary -AD - Natl Inst Oncol, Budapest, Hungary -AD - Med Univ Vienna, Comprehens Canc Ctr Vienna, Dept Thorac Surg, Vienna, Austria -AD - Lund Univ, Dept Translat Med, Lund, Sweden -M2 - Natl Koranyi Inst Pulmonol -Y2 - 2023-01-22 -ER - - -TY - JOUR -AU - D'Aiello, Angelica -AU - Stiles, Brendon -AU - Ohri, Nitin -AU - Levy, Benjamin -AU - Cohen, Perry -AU - Halmos, Balazs -TI - Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - Immune checkpoint inhibition, with or without chemotherapy, is an established standard of care for metastatic non-small cell lung cancer (NSCLC). For locally advanced NSCLC treated with chemoradiotherapy, consolidation immunotherapy has dramatically improved outcomes. Recently, immunotherapy has also been established as a valuable component of treatment for resectable NSCLC with pembrolizumab, atezolizumab, and nivolumab all approved for use in this setting. As more results read out from ongoing per ioperative clinical tr ials, navigating treatment options will likely become increasingly complex for the practicing oncologist. In this paper, we distill key outcomes from major perioperative trials and highlight current knowledge gaps. In addition, we provide practical considerations for incorporating perioperative immunotherapy into the clinical management of operable NSCLC. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2024 MAY -PY - 2024 -VL - 25 -IS - 3 -SP - 197 -EP - 214 -DO - 10.1016/j.cllc.2024.02.004 -AN - WOS:001242354000001 -C6 - MAY 2024 -AD - Albert Einstein Coll Med, Montefiore Einstein Comprehens Canc Ctr, Dept Oncol, Bronx, NY USA -AD - Albert Einstein Coll Med, Montefiore Einstein Comprehens Canc Ctr, Div Thorac Surg & Surg Oncol, Bronx, NY USA -AD - Albert Einstein Coll Med, Montefiore Einstein Comprehens Canc Ctr, Dept Radiat Oncol, Bronx, NY USA -AD - Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA -AD - Albert Einstein Coll Med, Montefiore Einstein Comprehens Canc Ctr, Dept Pathol, Div Anat & Clin Pathol, Bronx, NY USA -AD - Montefiore Einstein Comprehens Canc Ctr, Dept Oncol, 1695 Eastchester Rd, Bronx, NY 10461 USA -M2 - Montefiore Einstein Comprehens Canc Ctr -Y2 - 2024-06-16 -ER - - -TY - JOUR -AU - Bestvina, Christine M -AU - Hara, Jared H L -AU - Karrison, Theodore -AU - Bowar, Benjamen -AU - Chin, Janet -AU - Garassino, Marina C -AU - Pitroda, Sean P -AU - Thawani, Rajat -AU - Vokes, Everett E -AU - Gan, Gregory -AU - Zhang, Jun -AU - Baschnagel, Andrew M -AU - Campbell, Toby C -AU - Chmura, Steven -AU - Juloori, Aditya -TI - DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. -T2 - Clinical lung cancer -M3 - Journal Article -AB - BACKGROUND: Immunotherapy in combination with chemotherapy is first-line treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC). Growing evidence suggests that radiation, specifically stereotactic body radiation therapy (SBRT), may enhance the immunogenic response as well as cytoreduce tumor burden. The primary objective of the study is to determine the progression free survival for patients with newly diagnosed ES-SCLC treated with combination multisite SBRT and chemo-immunotherapy (carboplatin, etoposide, and durvalumab).METHODS: This is a multicenter, single arm, phase 2 study. Patients with treatment-naive, ES-SCLC will be eligible for this study. Patients will receive durvalumab 1500mg IV q3w, carboplatin AUC 5 to 6 mg/mL q3w, and etoposide 80 to 100 mg/m2 on days 1 to 3 q3w for four cycles, followed by durvalumab 1500mg IV q4w until disease progression or unacceptable toxicity. Ablative radiation will be delivered 1 to 4 extracranial sites in 3 or 5 fractions, determined by location, during cycle 2. The primary endpoint is progression-free survival, measured from day 1 of chemoimmunotherapy. Secondary endpoints include grade ≥3 toxicity by CTCAE v5.0 within three months of RT, overall survival, response rate, time to second line systemic therapy, and time to new distant progression.CONCLUSIONS: Now that immunotherapy is an established part of ES-SCLC management, it is important to further optimize its use and effect. This study will investigate the progression-free survival of combined SBRT and chemo-immunotherapy in patients with ES-SCLC. In addition, the data from this study may further inform the immunogenic role of SBRT with chemo-immunotherapy, as well as identify clinical, biological, or radiomic prognostic features. -SN - 1938-0690 -DA - 2024 Aug 13 (Epub 2024 Aug 13) -PY - 2024 -DO - 10.1016/j.cllc.2024.08.004 -AN - MEDLINE:39242330 -AD - Department of Medicine, Section of Hematology and Oncology, The University of Chicago Medicine, Chicago, IL. -AD - Department of Radiation Oncology, The Queen's Medical Center, Honolulu, HI. -AD - Department of Public Health Sciences, The University of Chicago, Chicago, IL. -AD - Department of Pharmacy, University of Chicago Medical Center, Chicago, IL. -AD - Department of Radiation and Cellular Oncology, The University of Chicago Medicine, Chicago, IL. -AD - Department of Radiation Oncology, Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS. -AD - Department of Internal Medicine, Division of Medical Oncology; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS. -AD - Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI. -AD - Department of Medicine, University of Wisconsin-Madison, Madison, WI. -AD - Department of Radiation and Cellular Oncology, The University of Chicago Medicine, Chicago, IL. Electronic address: ajuloori@radonc.uchicago.edu. -Y2 - 2024-09-10 -ER - - -TY - JOUR -AU - Conibear, John -A1 - AstraZeneca UK Ltd -TI - Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer -T2 - BRITISH JOURNAL OF CANCER -M3 - Review -AB - When treating patients with unresectable stage III non-small-cell lung cancer (NSCLC), those with a good performance status and disease measured within a radical treatment volume should be considered for definitive concurrent chemoradiotherapy (cCRT). This guidance is based on key scientific rationale from two large Phase 3 randomised studies and meta-analyses demonstrating the superiority of cCRT over sequential (sCRT). However, the efficacy of cCRT comes at the cost of increased acute toxicity versus sequential treatment. Currently, there are several documented approaches that are addressing this drawback, which this paper outlines. At the point of diagnosis, a multidisciplinary team (MDT) approach can enable accurate assessment of patients, to determine the optimal treatment strategy to minimise risks. In addition, reviewing the Advisory Committee on Radiation Oncology Practice (ACROP) guidelines can provide clinical oncologists with additional recommendations for outlining target volume and organ-at-risk delineation for standard clinical scenarios in definitive cCRT (and adjuvant radiotherapy). Furthermore, modern advances in radiotherapy treatment planning software and treatment delivery mean that radiation oncologists can safely treat substantially larger lung tumours with higher radiotherapy doses, with greater accuracy, whilst minimising the radiotherapy dose to the surrounding healthy tissues. The combination of these advances in cCRT may assist in creating comprehensive strategies to allow patients to receive potentially curative benefits from treatments such as immunotherapy, as well as minimising treatment-related risks. -PU - SPRINGERNATURE -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND -SN - 0007-0920 -SN - 1532-1827 -DA - 2020 DEC 1 -PY - 2020 -VL - 123 -IS - SUPPL 1 -SP - 10 -EP - 17 -DO - 10.1038/s41416-020-01070-6 -AN - WOS:000600554700002 -AD - St Bartholomews Hosp, Dept Clin Oncol, London, England -Y2 - 2021-01-11 -ER - - -TY - JOUR -AU - Carlisle, Jennifer W. -AU - Leal, Ticiana -TI - Advancing immunotherapy in small cell lung cancer -T2 - CANCER -M3 - Review -AB - Small cell lung cancer (SCLC) is a rapidly progressive neuroendocrine carcinoma that, until recently, had a very small armamentarium of effective treatments. Advances in DNA sequencing and whole transcriptomics have delineated key subtypes; therefore, SCLC is no longer viewed as a homogeneous cancer. Chemoimmunotherapy with PD1 blockade is now the standard of care for advanced disease, and ongoing research efforts are moving this strategy into the limited stage setting. Combination strategies of immunotherapy with radiation are also under active clinical trial in both limited and extensive stage disease. Plain Language Summary Small cell lung cancer (SCLC) is a rapidly progressive neuroendocrine carcinoma that, until recently, had a very small armamentarium of effective treatments.Chemoimmunotherapy with immune check point inhibitors is now the standard of care for advanced disease.This comprehensive review provides an overview of current treatment strategies for SCLC, unmet needs in this patient population, and emerging treatment strategies incorporating immunotherapy that will hopefully further improve outcomes for patients. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0008-543X -SN - 1097-0142 -DA - 2023 NOV 15 -PY - 2023 -VL - 129 -IS - 22 -SP - 3525 -EP - 3534 -DO - 10.1002/cncr.34977 -AN - WOS:001051292100001 -C6 - AUG 2023 -AD - Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA USA -AD - Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Thorac Med Oncol Program,Sch Med, Atlanta, GA 30322 USA -Y2 - 2023-08-31 -ER - - -TY - JOUR -AU - Saowapa, Sakditad -AU - Polpichai, Natchaya -AU - Siladech, Pharit -AU - Wannaphut, Chalothorn -AU - Tanariyakul, Manasawee -AU - Wattanachayakul, Phuuwadith -AU - Lalitnithi, Pakin -TI - Pneumonitis Incidence in Patients With Metastatic Non-small Cell Lung Cancer on Immunotherapy: A Systematic Review and Meta-Analysis. -T2 - Cureus -M3 - Journal Article -M3 - Review -AB - Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, often diagnosed at the advanced stage (metastatic). Treatment options for metastatic NSCLC include radiotherapy, chemotherapy, target drug therapy, and immunotherapy. Immunotherapy (utilization of checkpoint inhibitors) boosts the immune system to recognize and destroy cancer cells. However, it is often associated with immune-related complications such as pneumonitis. This review aims to determine the incidence of pneumonitis in metastatic NSCLC patients treated with different immunotherapy drugs. PubMed, Cochrane Library, and Embase databases were scoured for randomized controlled trials (RCTs) until October 2023. Published RCTs with similar research objectives were included, while non-English articles, reviews, case reports, ongoing trials, non-randomized studies, conference abstracts, and studies on small cell lung cancer (SCLC) were excluded. The Cochrane risk-of-bias tool for randomized trials (RoB 2) was used to assess the risk of bias among the included studies. The statistical analyses were performed with the Comprehensive Meta-Analysis software. The subgroup analysis of the 16 included RCTs showed that metastatic NSCLC patients treated with nivolumab and pembrolizumab had a higher incidence of any grade pneumonitis than those treated withatezolizumab (4.5% and 5.1% vs. 1.6%, respectively). Similarly, the incidence of grade ≥3 pneumonitis was higher among patients receiving nivolumab (1.3%) and pembrolizumab (2.4%) than those receiving atezolizumab (0.7%). Furthermore, the subgroup analysis showed that patients with naive-treated NSCLC on immunotherapy had a higher incidence of any grade pneumonitis than those with previously treated NSCLC (6.5% vs. 3.9%). Treatment-naive patients recorded higher grade ≥3 pneumonitis incidences than those previously treated (3.1% vs. 1.3%). Programmed death 1 (PD-1) inhibitors (i.e., pembrolizumab and nivolumab) have higher incidences of pneumonitis than programmed death-ligand 1 inhibitors (atezolizumab). -SN - 2168-8184 -DA - 2024 Jul -PY - 2024 -VL - 16 -IS - 7 -SP - e63615 -EP - e63615 -DO - 10.7759/cureus.63615 -AN - MEDLINE:39092378 -AD - Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, USA. -AD - Internal Medicine, Weiss Memorial Hospital, Chicago, USA. -AD - Internal Medicine, Ramathibodi Hospital, Chiang Mai, THA. -AD - Internal Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, USA. -AD - Internal Medicine, Einstein Medical Center Philadelphia, Philadelphia, USA. -AD - Internal Medicine, St. Elizabeth's Medical Center, Boston, USA. -Y2 - 2024-09-11 -ER - - -TY - JOUR -AU - Reddy, Haritha G. -AU - Qin, Angel -AU - Kalemkerian, Gregory P. -TI - Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors -T2 - EXPERT OPINION ON EMERGING DRUGS -M3 - Review -AB - Introduction Small cell lung cancer (SCLC) is an aggressive malignancy that accounts for 15% of all lung cancers. It is characterized by initial responsiveness to therapy followed by rapid disease progression that is relatively resistant to further treatment. Recently, the addition of an immune checkpoint inhibitor (ICI) to chemotherapy has improved survival in patients with advanced disease, the first advance in systemic therapy in SCLC in over 30 years. Areas covered In this review, we present an overview of SCLC with a focus on the scope of the problem and standard treatment, followed by a critical assessment of scientific rationale for immunotherapy in SCLC and the clinical trials that have been performed with ICIs in SCLC. Finally, we address ongoing hurdles for the development of ICIs in SCLC and potential avenues for further study. Expert opinion Despite solid biological rationale, the results of clinical trials of ICIs in SCLC have yielded modest benefits. A small subset of patients does achieve long-term benefit, but further development of ICIs in SCLC will depend on the identification of predictive biomarkers and the design of combination regimens that take advantage of the molecular alterations that drive the immune-avoidance mechanisms and survival of SCLC cells. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1472-8214 -SN - 1744-7623 -DA - 2020 JUL 2 -PY - 2020 -VL - 25 -IS - 3 -SP - 353 -EP - 366 -DO - 10.1080/14728214.2020.1798929 -AN - WOS:000555635700001 -C6 - AUG 2020 -AD - Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA -Y2 - 2020-08-17 -ER - - -TY - JOUR -AU - Lauko, Adam -AU - Thapa, Bicky -AU - Venur, Vyshak Alva -AU - Ahluwalia, Manmeet S. -TI - Management of Brain Metastases in the New Era of Checkpoint Inhibition -T2 - CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS -M3 - Review -AB - Purpose of the Review Brain metastasis is a common complication of advanced malignancies, especially, lung cancer, breast cancer, renal cell carcinoma, and melanoma. Traditionally surgery, when indicated, and radiation therapy, either as whole-brain radiation therapy or stereotactic radiosurgery, constituted the major treatment options for brain metastases. Until recently, most of the systemic chemotherapy agents had limited activity for brain metastases. However, with the advent of small molecule tyrosine kinase inhibitors and immunotherapy agents, there has been renewed interest in using these agents in the management of brain metastases.Recent Findings Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, lung cancer, kidney cancer, and bladder cancer among others. They modulate the immune system to recognize tumor antigens as "non-self" antigens and mount an immune response against them.Summary Initial studies of using immune checkpoint inhibitors in brain metastases have shown promising activity, and several clinical trials are currently underway. Studies are also assessing the combination of radiation therapy and immunotherapy in brain metastases. The results of these ongoing clinical trials have the potential to change the therapeutic paradigm in patients with brain metastases. -PU - SPRINGER -PI - NEW YORK -PA - 233 SPRING ST, NEW YORK, NY 10013 USA -SN - 1528-4042 -SN - 1534-6293 -DA - 2018 OCT -PY - 2018 -VL - 18 -IS - 10 -C7 - 70 -DO - 10.1007/s11910-018-0877-8 -AN - WOS:000441999600001 -AD - Cleveland Clin, Neurol Inst, Burkhardt Brain Tumor & Neurooncol Ctr, 9500 Euclid Ave,S73, Cleveland, OH 44195 USA -AD - Cleveland Clin, Fairview Hosp, Cleveland, OH 44106 USA -AD - Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA -Y2 - 2018-08-31 -ER - - -TY - JOUR -AU - Jie, Chen -AU - Chen, Yeshan -AU - Yang, Yong -AU - Li, Rumeng -AU - Yang, Bin -AU - Yip, Connie -AU - Yu, Jing -TI - Feasibility and long-term outcomes of post-chemotherapy-based consolidation radiotherapy in extensive stage small-cell lung cancer -T2 - JOURNAL OF THE NATIONAL CANCER CENTER -M3 - Article -AB - Background: The target definition of consolidation radiotherapy (RT) for extensive stage small-cell lung cancer (ES-SCLC) has not been standardized. This study aimed to demonstrate the feasibility of post-chemotherapy based consolidation RT in ES-SCLC.Methods: All ES-SCLC patients without initial brain metastases who completed >= 4 cycles of systemic therapy at Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University from 2012 to 2021 were included in this retrospective study. We correlated the site of first recurrence to the post-chemotherapy-based radiation volume (small-field). Relapse pattern, progression-free survival (PFS) and overall survival (OS) were compared between those received and did not receive consolidation RT.Results: A total of 152 patients were followed up for a median of 31.7 months (interquartile range [IQR], 23.9- 39.6 months). The median PFS and OS of the cohort were 8.3 months (IQR, 6.1-11.2 months) and 16.2 months (IQR, 9.9-24.9 months), respectively. Thoracic consolidation RT served not only as an independent prognostic factor for improved PFS in the entire cohort, but also significantly prolonged OS in the subgroup without syn-chronous liver metastases. Small-field consolidation RT markedly reduced in-field recurrences (hazard ratio [HR], 0.28 [95% CI, 0.12-0.38]; P < 0.001) without increasing out-of-field recurrences (HR, 0.40 [95% CI, 0.13-1.16]; P = 0.080). No relapse was observed at the margin of the targets. Treatment-related toxicities were moderate, with grade 3 acute radiation pneumonia, radiation esophagitis, and bone marrow suppression rates of 8.3%, 3.1%, and 12.5%, respectively. No grade 5 toxicity occurred.Conclusion: Small-field consolidation RT based on post-chemotherapy volume is safe and can significantly im -prove local control in ES-SCLC. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 2667-0054 -DA - 2023 SEP -PY - 2023 -VL - 3 -IS - 3 -SP - 161 -EP - 166 -DO - 10.1016/j.jncc.2023.07.003 -AN - WOS:001091679900001 -C6 - SEP 2023 -AD - Wuhan Univ, Hubei Canc Clin Study Ctr, Dept Radiat & Med Oncol, Hubei Key Lab Tumor Biol Behav,Zhongnan Hosp, Wuhan, Peoples R China -AD - Huazhong Univ Sci & Technol, Union Hosp, Inst Radiat Oncol, Tongji Med Coll, Wuhan, Peoples R China -AD - Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China -AD - Fujian Med Univ, Union Hosp, Dept Radiat Oncol, Fuzhou, Peoples R China -AD - Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Thorac Oncol, Wuhan, Peoples R China -AD - Natl Canc Ctr Singapore, Dept Head & Neck & Thorac, Div Radiat Oncol, Singapore, Singapore -Y2 - 2023-11-13 -ER - - -TY - JOUR -AU - Chen, Peixin -AU - Liu, Yunhuan -AU - Wen, Yaokai -AU - Zhou, Caicun -TI - Non-small cell lung cancer in China -T2 - CANCER COMMUNICATIONS -M3 - Review -AB - In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early-stage non-small cell lung cancer (NSCLC) patients miss the optimal timing for treatment due to the lack of clinical presentations. Population-based nationwide screening programs are of significant help in increasing the early detection and survival rates of NSCLC in China. The understanding of molecular carcinogenesis and the identification of oncogenic drivers dramatically facilitate the development of targeted therapy for NSCLC, thus prolonging survival in patients with positive drivers. In the exploration of immune escape mechanisms, programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor monotherapy and PD-1/PD-L1 inhibitor plus chemotherapy have become a standard of care for advanced NSCLC in China. In the Chinese Society of Clinical Oncology's guidelines for NSCLC, maintenance immunotherapy is recommended for locally advanced NSCLC after chemoradiotherapy. Adjuvant immunotherapy and neoadjuvant chemoimmunotherapy will be approved for resectable NSCLC. In this review, we summarized recent advances in NSCLC in China in terms of epidemiology, biology, molecular pathology, pathogenesis, screening, diagnosis, targeted therapy, and immunotherapy. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2523-3548 -DA - 2022 OCT -PY - 2022 -VL - 42 -IS - 10 -SP - 937 -EP - 970 -DO - 10.1002/cac2.12359 -AN - WOS:000851478200001 -C6 - SEP 2022 -AD - Tongji Univ, Sch Med, Shanghai 200092, Peoples R China -AD - Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Med Oncol, Shanghai 200433, Peoples R China -AD - Fudan Univ, Huadong Hosp, Dept Resp & Crit Care Med, Shanghai 200040, Peoples R China -Y2 - 2022-09-14 -ER - - -TY - JOUR -AU - Ma, Lin -AU - Deng, Liufu -AU - Peng, Jianfeng -AU - Yu, Jinming -AU - Meng, Xiangjiao -TI - Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer? -T2 - CANCER BIOLOGY & MEDICINE -M3 - Review -AB - Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches for LA-NSCLC. Several recent investigations involving the synergistic potential of immunotherapy combined with radiotherapy (iRT) have generated encouraging results. This review discusses the existing studies and prospective directions of chemotherapy-free iRT strategies in unresectable LA-NSCLC. Although the initial findings of chemotherapy-free iRT strategies have shown promising efficacy, we must consider the methodologic limitations of current studies and the myriad of challenges that accompany the implementation of chemotherapy-free iRT. These challenges include determining the optimal dose and fractionation, precise target volume delineation, and identification of additional suitable patient cohorts. Furthermore, the feasibility of chemotherapy-free iRT as a novel treatment modality for select patients with LA-NSCLC is contingent upon validation through randomized phase III trials. -PU - CHINA ANTI-CANCER ASSOC -PI - TIANJIN -PA - TIANJIN MEDICAL UNIV, CANCER INST & HOSPITAL TI-YUAN-BEI, HUANHU XI LU, HEXIQU, TIANJIN, 300060, PEOPLES R CHINA -SN - 2095-3941 -DA - 2023 DEC 15 -PY - 2023 -VL - 20 -IS - 12 -SP - 1035 -EP - 1046 -DO - 10.20892/j.issn.2095-3941.2023.0402 -AN - WOS:001180656200018 -AD - Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan 430000, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan 250117, Peoples R China -AD - Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200240, Peoples R China -Y2 - 2024-03-16 -ER - - -TY - JOUR -AU - Taylor, James M. -AU - Rusthoven, Chad G. -AU - Moghanaki, Drew -TI - Prophylactic cranial irradiation or MRI surveillance for extensive stage small cell lung cancer -T2 - JOURNAL OF THORACIC DISEASE -M3 - Review -AB - The treatment paradigm for extensive stage small cell lung cancer (ES-SCLC) is evolving. Prophylactic cranial irradiation (PCI) has long been considered a component of standard treatment in patients with extensive stage disease who respond to chemotherapy. However, in the modern era of magnetic resonance imaging, the role of PCI has become an area of controversy following conflicting level I evidence. Due to conflicting data and toxicity concerns, the routine use of PCI has declined. Recent improvements in systemic disease control with the use of immunotherapy and reductions in the toxicity attributable to PCI with hippocampal avoidance and memantine have reignited the discussion. As such, we present here a narrative review of PCI with a focus on historical milestones, randomized data, risk mitigation and future directions. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2020 OCT -PY - 2020 -VL - 12 -IS - 10 -SP - 6225 -EP - 6233 -DO - 10.21037/jtd.2020.03.80 -AN - WOS:000583404900106 -AD - Thomas Jefferson Univ, Dept Radiat Oncol, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA -AD - Thomas Jefferson Univ, Canc Ctr, Philadelphia, PA 19107 USA -AD - Univ Colorado Denver, Dept Radiat Oncol, Aurora, CO USA -AD - Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta VA Hlth Care Syst, Atlanta, GA USA -Y2 - 2020-11-30 -ER - - -TY - JOUR -AU - Simone, Charles B., II -AU - Bogart, Jeffrey A. -AU - Cabrera, Alvin R. -AU - Daly, Megan E. -AU - DeNunzio, Nicholas J. -AU - Detterbeck, Frank -AU - Faivre-Finn, Corinne -AU - Gatschet, Nancy -AU - Gore, Elizabeth -AU - Jabbour, Salma K. -AU - Kruser, Tim J. -AU - Schneider, Bryan J. -AU - Slotman, Ben -AU - Turrisi, Andrew -AU - Wu, Abraham J. -AU - Zeng, Jing -AU - Rosenzweig, Kenneth E. -TI - Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline -T2 - PRACTICAL RADIATION ONCOLOGY -M3 - Article -AB - Purpose: Several sentinel phase III randomized trials have recently been published challenging traditional radiation therapy (RT) practices for small cell lung cancer (SCLC). This American Society for Radiation Oncology guideline reviews the evidence for thoracic RT and prophylactic cranial irradiation (PCI) for both limited-stage (LS) and extensive-stage (ES) SCLC.Methods: The American Society for Radiation Oncology convened a task force to address 4 key questions focused on indications, dose fractionation, techniques and timing of thoracic RT for LS-SCLC, the role of stereotactic body radiation therapy (SBRT) compared with conventional RT in stage I or II node negative SCLC, PCI for LS-SCLC and ES-SCLC, and thoracic consolidation for ES-SCLC. Recommendations were based on a systematic literature review and created using a consensus-building methodology and system for grading evidence quality and recommendation strength.Results: The task force strongly recommends definitive thoracic RT administered once or twice daily early in the course of treatment for LS-SCLC. Adjuvant RT is conditionally recommended in surgically resected patients with positive margins or nodal metastases. Involved field RT delivered using conformal advanced treatment modalities to postchemotherapy volumes is also strongly recommended. For patients with stage I or II node negative disease, SBRT or conventional fractionation is strongly recommended, and chemotherapy should be delivered before or after SBRT. In LS-SCLC, PCI is strongly recommended for stage II or III patients who responded to chemoradiation, conditionally not recommended for stage I patients, and should be a shared decision for patients at higher risk of neurocognitive toxicities. In ES-SCLC, radiation oncologist consultation for consideration of PCI versus magnetic resonance surveillance is strongly recommended. Lastly, the use of thoracic RT is strongly recommended in select patients with ES-SCLC after chemotherapy treatment, including a conditional recommendation in those responding to chemotherapy and immunotherapy.Conclusions: RT plays a vital role in both LS-SCLC and ES-SCLC. These guidelines inform best clinical practices for local therapy in SCLC. (C) 2020 Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1879-8500 -DA - 2020 MAY-JUN -PY - 2020 -VL - 10 -IS - 3 -SP - 158 -EP - 173 -DO - 10.1016/j.prro.2020.02.009 -AN - WOS:000534515800014 -AD - New York Proton Ctr, New York, NY USA -AD - SUNY Upstate Med Univ, Dept Radiat Oncol, Syracuse, NY 13210 USA -AD - Kaiser Permanente, Dept Radiat Oncol, Seattle, WA USA -AD - Univ Calif Davis, Dept Radiat Oncol, Sacramento, CA 95817 USA -AD - Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA -AD - Yale Univ, Sch Med, Dept Thorac Surg, New Haven, CT USA -AD - Univ Manchester, Manchester, Lancs, England -AD - Christie NHS Fdn Trust, Div Canc Sci, Manchester, Lancs, England -AD - Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA -AD - Rutgers State Univ, Dept Radiat Oncol, New Brunswick, NJ USA -AD - Northwestern Mem Hosp, Dept Radiat Oncol, Chicago, IL USA -AD - Univ Michigan, Dept Med Oncol, Ann Arbor, MI 48109 USA -AD - Vrije Univ Amsterdam Med Ctr, Dept Radiat Oncol, Amsterdam, Netherlands -AD - James H Quillen VA Med Ctr, Dept Radiat Oncol, Mountain Home, TN USA -AD - Mem Sloan Kettering, Dept Radiat Oncol, New York, NY USA -AD - Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA -AD - Mt Sinai Med Ctr, Dept Radiat Oncol, New York, NY 10029 USA -M2 - New York Proton Ctr -M2 - James H Quillen VA Med Ctr -Y2 - 2020-06-02 -ER - - -TY - JOUR -AU - Bozorgmehr, Farastuk -AU - Christopoulos, Petros -AU - Chung, Inn -AU - Cvetkovic, Jelena -AU - Feisst, Manuel -AU - Krisam, Johannes -AU - Schneider, Marc A. -AU - Heussel, Claus Peter -AU - Kreuter, Michael -AU - Mueller, Daniel W. -AU - Thomas, Michael -AU - Rieken, Stefan -TI - Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial -T2 - BMC CANCER -M3 - Article -AB - Background: Recently, the combination of the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab with first-line chemotherapy has demonstrated to improve outcome for patients with advanced small cell lung cancer (SCLC), leading to approval of this regimen. At the same time, accumulating (pre-)clinical data suggest synergisms of radiotherapy and immunotherapy via the radiation-mediated induction of anti-tumor immunogenicity. Combining the recent findings, the TREASURE trial aims at further enhancing response to upfront chemo-immunotherapy by the addition of thoracic radiotherapy ( TRT).Methods/design: The TREASURE trial is a randomized, multicenter, phase II clinical trial (ClinicalTrials.gov identifier, NCT04462276). One hundred four patients suffering from extensive disease (ED) SCLC, with any response to the standard of care induction chemo-immunotherapy will be randomized to receive atezolizumab maintenance therapy with or without TRT. The primary endpoint of this study is overall survival (OS). Secondary endpoints include further measures of efficacy, safety, and the collection of biomarker samples. A safety interim analysis will take place after n = 23 patients receiving TRT have been observed for three months after the end of TRT.Discussion: This trial will investigate whether treatment efficacy can be improved by adding TRT to atezolizumab maintenance therapy in ED SCLC patients with any response after chemo-immunotherapy. Safety and feasibility of such a regimen will be evaluated, and biomaterials for a translational research project will be collected. Together, the results of this trial will deepen our comprehension of how checkpoint inhibition and radiotherapy interact and contribute to the evolving landscape of SCLC therapy. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2022 SEP 24 -PY - 2022 -VL - 22 -IS - 1 -C7 - 1011 -DO - 10.1186/s12885-022-10074-9 -AN - WOS:000857836900005 -AD - Univ Hosp Heidelberg, Thoraxklin, Dept Thorac Oncol, Rontgenstr 1, D-69126 Heidelberg, Germany -AD - Translat Lung Res Ctr Heidelberg TLRCH, Neuenheimer Feld 156, D-69120 Heidelberg, Germany -AD - German Ctr Lung Res DZL, Neuenheimer Feld 156, D-69120 Heidelberg, Germany -AD - Univ Hosp Heidelberg, Inst Med Biometry, Neuenheimer Feld 130-3, D-69120 Heidelberg, Germany -AD - Thoraxklin Univ Hosp Heidelberg, Translat Res Unit STF, Rontgenstr 1, D-69126 Heidelberg, Germany -AD - Univ Hosp Heidelberg, Thoraxklin, Diagnost & Intervent Radiol Nucl Med, Rontgenstr 1, D-69126 Heidelberg, Germany -AD - Univ Hosp Heidelberg, Thoraxklin, Ctr Interstitial & Rare Lung Dis Pneumol & Resp C, Rontgenstr 1, D-69126 Heidelberg, Germany -AD - Northwest Hosp, Inst Clin Canc Res IKF GmbH, Steinbacher Hohl 2-26, D-60488 Frankfurt, Germany -AD - Univ Med Ctr Gottingen, Dept Radiat Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany -M2 - Translat Lung Res Ctr Heidelberg TLRCH -M2 - German Ctr Lung Res DZL -M2 - Thoraxklin Univ Hosp Heidelberg -Y2 - 2022-09-30 -ER - - -TY - JOUR -AU - Welsh, J. W. -AU - Heymach, J. -AU - Cadena, A. -AU - Cushman, T. R. -AU - Hess, K. -AU - Shroff, G. -AU - Tang, C. -AU - Skoulidis, F. -AU - Jeter, M. D. -AU - Nguyen, Q. N. -AU - Chang, J. Y. -AU - Papadimitrakopoulou, V. -AU - Gomez, D. R. -AU - Sharma, P. -AU - Allison, J. P. -AU - Raju, U. -AU - Shabaan, S. -AU - Byers, L. -AU - Glisson, B. S. -TI - Phase I Trial of MK-3475 and Concurrent Radiation for the Elimination of Extensive-Stage Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 60th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - San Antonio, TX -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2018 NOV 1 -PY - 2018 -VL - 102 -IS - 3 -MA - 33 -SP - S18 -EP - S18 -DO - 10.1016/j.ijrobp.2018.06.133 -AN - WOS:000447811602283 -AD - Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA -Y2 - 2018-11-27 -ER - - -TY - JOUR -AU - Cho, Ju Hwan -TI - Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles -T2 - IMMUNE NETWORK -M3 - Review -AB - Lung cancer is one of the leading causes of death worldwide. There are 2 major subtypes of lung cancer, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Studies show that NSCLC is the more prevalent type of lung cancer that accounts for approximately 80%-85% of cases. Although, various treatment methods, such as chemotherapy, surgery, and radiation therapy have been used to treat lung cancer patients, there is an emergent need to develop more effective approaches to deal with advanced stages of tumors. Recently, immunotherapy has emerged as a new approach to combat with such tumors. The development and success of programmed cell death 1 (PD-1)/program death-ligand 1 (PD-L1) inhibitors and cytotoxic T-lymphocyte antigen 4 (CTLA-4) blockades in treating metastatic cancers opens a new pavement for the future research. The current mini review discusses the significance of immune checkpoint inhibitors in promoting the death of tumor cells. Additionally, this review also addresses the importance of tumor-specific antigens (neoantigens) in the development of cancer vaccines and major challenges associated with this therapy. Immunotherapy can be a promising approach to treat NSCLC because it stimulates host's own immune system to recognize cancer cells. Therefore, future research should focus on the development of new methodologies to identify novel checkpoint inhibitors and potential neoantigens. -PU - KOREA ASSOC IMMUNOLOGISTS -PI - SEOUL -PA - KOREA SCIENCE & TECHNOLOGY CENTER, RM 701, 7 GIL 22, TEHERAN-RO, (635-4 YEOKSAM-DONG) GANGMAN-GU, SEOUL, 06130, SOUTH KOREA -SN - 1598-2629 -SN - 2092-6685 -DA - 2017 DEC -PY - 2017 -VL - 17 -IS - 6 -SP - 378 -EP - 391 -DO - 10.4110/in.2017.17.6.378 -AN - WOS:000424419700002 -AD - Ohio State Univ, Arthur G James Canc Hosp, Comprehens Canc Ctr, Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USA -Y2 - 2018-02-20 -ER - - -TY - JOUR -AU - Finazzi, Tobias -AU - Schneiders, Famke L. -AU - Senan, Suresh -TI - Developments in radiation techniques for thoracic malignancies -T2 - EUROPEAN RESPIRATORY REVIEW -M3 - Article -AB - Radiation therapy is a cornerstone of modern lung cancer treatment alongside surgery, chemotherapy, immunotherapy and targeted therapies. Advances in radiotherapy techniques have enhanced the accuracy of radiation delivery, which has contributed to the evolution of radiation therapy into a guideline-recommended treatment in both early-stage and locally advanced nonsmall cell lung cancer. Furthermore, although radiotherapy has long been used for palliation of disease in advanced lung cancer, it is increasingly having a role as a locally ablative treatment in patients with oligometastatic disease.This review provides an overview of recent developments in radiation techniques, particularly for non-radiation oncologists who are involved in the care of lung cancer patients. Technical advances are discussed, and findings of recent clinical trials are highlighted, all of which have led to a changing perception of the role of radiation therapy in multidisciplinary care. -PU - EUROPEAN RESPIRATORY SOC JOURNALS LTD -PI - SHEFFIELD -PA - 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND -SN - 0905-9180 -SN - 1600-0617 -DA - 2021 JUN 30 -PY - 2021 -VL - 30 -IS - 160 -C7 - 200224 -DO - 10.1183/16000617.0224-2020 -AN - WOS:000672820600005 -AD - Univ Hosp Basel, Clin Radiotherapy & Radiat Oncol, Basel, Switzerland -AD - Univ Amsterdam, Dept Radiat Oncol, Locat VUmc, Med Ctr, Amsterdam, Netherlands -Y2 - 2021-07-22 -ER - - -TY - JOUR -AU - Schild, Steven E. -AU - Wang, Xiaofei -AU - Bestvina, Christine M. -AU - Williams, Terence -AU - Masters, Greg -AU - Singh, Anurag K. -AU - Stinchcombe, Thomas E. -AU - Salama, Joseph K. -AU - Wolf, Steven -AU - Zemla, Tyler -AU - Duma, Narjust -AU - Chun, Stephen G. -AU - Amini, Arya -AU - Kozono, David -AU - Watt, Colleen -TI - Alliance A082002-a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - Introduction: Treatment of advanced stage non-small cell lung cancer (NSCLC) has changed dramatically due to immunotherapy. However, patients without Programmed Death-Ligand 1 (PD-L1) protein expression often benefit less from immunotherapy. This trial is designed to test if stereotactic body radiation therapy (SBRT) to a single tumor site can significantly enhance the outcome of patients with advanced stage PD-L1(-) NSCLC when added to systemic therapy including immunotherapy. Materials and Methods: Alliance A082002 is based on subgroup analysis from the randomized phase II PEMBRO-RT trial., PEMBRO-RT compared pembrolizumab alone or with SBRT and revealed improved progression-free and overall survival (PFS and OS, respectively) in PD-L1(-) patients when adding SBRT (8 Gy x 3 fractions). In A082002, patients without PD-L1 expression will be randomized to SBRT (8 Gy x3) plus systemic therapy vs. systemic therapy alone. The pr imary endpoint of the phase II portion of the tr ial is PFS and will require 100 patients. The primary endpoint of the phase III portion of the trial is OS and will require an additional 284 patients. This trial will clarify whether adding SBRT to systemic therapy can improve PFS and OS in a larger multi-institutional cohort. Several systemic treatment options are allowed including either immunotherapy alone or chemo-immunotherapy. Conclusions: This phase II/III Alliance trial A082002 will test whether the addition of SBRT to a single tumor site will enhance the anti-tumor activity of systemic immunotherapy or chemo-immunotherapy in patients with stage IV PD-L1(-) NSCLC. It is now open in the National Clinical Trials Network (NCTN). -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2022 JUL -PY - 2022 -VL - 23 -IS - 5 -SP - E317 -EP - E320 -DO - 10.1016/j.cllc.2022.04.004 -AN - WOS:000824570500001 -C6 - JUN 2022 -AD - Mayo Clin, Dept Radiat Oncol, 13400 E Shea Blvd, Phoenix, AZ 85054 USA -AD - Duke Univ, Alliance Stat & Data Management Ctr, Durham, NC USA -AD - Univ Chicago Med, Dept Hematol & Oncol, Chicago, IL USA -AD - City Hope Comprehens Canc Ctr, Dept Radiat Oncol, Duarte, CA USA -AD - Christiana Care Hosp, Dept Med Oncol, Newark, DE USA -AD - Roswell Park Comprehens Canc Ctr, Dept Radiat Oncol, Buffalo, NY USA -AD - Duke Canc Inst, Dept Med Oncol, Durham, NC USA -AD - Mayo Clin, Alliance Stat & Data Management Ctr, Rochester, MN USA -AD - Univ Wisconsin, Dept Med Oncol, Madison, WI USA -AD - Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA -AD - Dana Farber Partners Canc Care, Dept Radiat Oncol, Boston, MA USA -AD - Univ Chicago, Alliance Protocol Operat Cent Off, Chicago, IL 60637 USA -M2 - Univ Chicago Med -Y2 - 2022-07-21 -ER - - -TY - JOUR -AU - Zhu, Kui-kui -AU - Wei, Jie-lin -AU - Xu, Yun-hong -AU - Li, Jun -AU - Rao, Xin-rui -AU - Xu, Ying-zhuo -AU - Xing, Bi-yuan -AU - Zhang, Si-jia -AU - Chen, Lei-chong -AU - Dong, Xiao-rong -AU - Zhang, Sheng -AU - Li, Zheng-yu -AU - Liu, Cui-wei -AU - Meng, Rui -AU - Wu, Gang -TI - Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors -T2 - CURRENT MEDICAL SCIENCE -M3 - Article -AB - ObjectiveThe combination of stereotactic body radiation therapy (SBRT) and immune checkpoint inhibitors (ICIs) is actively being explored in advanced non-small-cell lung cancer (NSCLC) patients. However, little is known about the optimal fractionation and radiotherapy target lesions in this scenario. This study investigated the effect of SBRT on diverse organ lesions and radiotherapy dose fractionation regimens on the prognosis of advanced NSCLC patients receiving ICIs.MethodsThe medical records of advanced NSCLC patients consecutively treated with ICIs and SBRT were retrospectively reviewed at our institution from Dec. 2015 to Sep. 2021. Patients were grouped according to radiation sites. Progression-free survival (PFS) and overall survival (OS) were recorded using the Kaplan-Meier method and compared between different treatment groups using the log-rank (Mantel-Cox) test.ResultsA total of 124 advanced NSCLC patients receiving ICIs combined with SBRT were identified in this study. Radiation sites included lung lesions (lung group, n=43), bone metastases (bone group, n=24), and brain metastases (brain group, n=57). Compared with the brain group, the mean PFS (mPFS) in the lung group was significantly prolonged by 13.3 months (8.5 months vs. 21.8 months, HR=0.51, 95%CI: 0.28-0.92, P=0.0195), and that in the bone group prolonged by 9.5 months with a 43% reduction in the risk of disease progression (8.5 months vs. 18.0 months, HR=0.57, 95%CI: 0.29-1.13, P=0.1095). The mPFS in the lung group was prolonged by 3.8 months as compared with that in the bone group. The mean OS (mOS) in the lung and bone groups was longer than that of the brain group, and the risk of death decreased by up to 60% in the lung and bone groups as compared with that of the brain group. When SBRT was concurrently given with ICIs, the mPFS in the lung and brain groups were significantly longer than that of the bone group (29.6 months vs. 16.5 months vs. 12.1 months). When SBRT with 8-12 Gy per fraction was combined with ICIs, the mPFS in the lung group was significantly prolonged as compared with that of the bone and brain groups (25.4 months vs. 15.2 months vs. 12.0 months). Among patients receiving SBRT on lung lesions and brain metastases, the mPFS in the concurrent group was longer than that of the SBRT -> ICIs group (29.6 months vs. 11.4 months, P=0.0003 and 12.1 months vs. 8.9 months, P=0.2559). Among patients receiving SBRT with <8 Gy and 8-12 Gy per fraction, the mPFS in the concurrent group was also longer than that of the SBRT -> ICIs group (20.1 months vs. 5.3 months, P=0.0033 and 24.0 months vs. 13.4 months, P=0.1311). The disease control rates of the lung, bone, and brain groups were 90.7%, 83.3%, and 70.1%, respectively.ConclusionThe study demonstrated that the addition of SBRT on lung lesions versus bone and brain metastases to ICIs improved the prognosis in advanced NSCLC patients. This improvement was related to the sequence of radiotherapy combined with ICIs and the radiotherapy fractionation regimens. Dose fractionation regimens of 8-12 Gy per fraction and lung lesions as radiotherapy targets might be the appropriate choice for advanced NSCLC patients receiving ICIs combined with SBRT. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 2096-5230 -SN - 2523-899X -DA - 2023 APR -PY - 2023 -VL - 43 -IS - 2 -SP - 344 -EP - 359 -DO - 10.1007/s11596-023-2702-0 -AN - WOS:000961181600001 -C6 - MAR 2023 -AD - Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China -Y2 - 2023-04-14 -ER - - -TY - JOUR -AU - Rico, M. -AU - Flamarique Andueza, S. -AU - Martin Martinez, A. -AU - Rodriguez Mendizabal, M. A. -AU - Rosas Gutierrez, L. -AU - Martinez Lopez, E. -TI - How to integrate stereotactic body radiation therapy and hypofractionation in the management of stage III lung cancer in the age of immunotherapy -T2 - ANALES DEL SISTEMA SANITARIO DE NAVARRA -M3 - Review -AB - The constant advances in the field of lung cancer immunotherapy have recently reached the treatment of locally advanced disease with the approval of durvalumab after concurrent chemoradiation. However, radiation therapy continues to be key for controlling the disease at this stage. Over the years, different strategies have been employed to try to optimize outcomes using radiotherapy, with cardiac and pulmonary toxicity as the main limitation on its success. The interest in the use of hypofractionation and stereotactic body radiation therapy for stage III non-small cell lung cancer has increased as knowledge regarding these kinds of treatments has been enhanced. Hypofractionation is a relatively frequent treatment, although the level of evidence that supports it is limited. For its part, stereotactic body radiation therapy has been particularly studied as a boost after chemoradiation, with encouraging results. In both cases, study of how to integrate these tools with chemotherapy and particularly with immunotherapy is essential, as they may have an immunomodulatory role.YY -PU - GOBIERNO DE NAVARRA -PI - PAMPLONA -PA - NAVAS TOLOSA 21, PAMPLONA, 31002, SPAIN -SN - 1137-6627 -DA - 2020 MAY-AUG -PY - 2020 -VL - 43 -IS - 2 -SP - 225 -EP - 234 -DO - 10.23938/ASSN.0855 -AN - WOS:000610797300012 -AD - Complejo Hosp Navarra, Oncol Radiotherapy Dept, C Irunlarrea 3, Pamplona 31008, Spain -Y2 - 2021-02-10 -ER - - -TY - JOUR -AU - Liu, Chaoyuan -AU - Zeng, Liang -AU - Deng, Chao -AU - Jiang, Wenjuan -AU - Wang, Yapeng -AU - Zhou, Yiguang -AU - Liu, Li -AU - Wang, Sisi -AU - Zhou, Chunhua -AU - Qiu, Zhenhua -AU - Zeng, Fanxu -AU - Wu, Fang -AU - Weng, Jie -AU - Liu, Xianling -AU - Yang, Nong -AU - Ma, Fang -TI - Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer -T2 - FRONTIERS IN IMMUNOLOGY -M3 - Article -AB - IntroductionThe combination of a PD-L1 inhibitor plus carboplatin/cisplatin and etoposide (EC/EP) has become a new standard first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). Combining concurrent palliative hypofractionated radiotherapy of the thorax (HFRT) and immunochemotherapy may have a synergistic effect. In this study, we explored an optimal model of combination radiotherapy with immunochemotherapy as first-line treatment of ES-SCLC. Patients and methodsIn this multicenter single-arm phase 2 trial, patients with ES-SCLC received atezolizumab with EC/EP for two cycles (induction phase), then, those who did not progress received concurrent palliative HFRT and two cycles of atezolizumab with EC/EP (combination phase). Afterward they received atezolizumab every 3 weeks for a maximum of 2 years after study enrolment (maintenance phase). Prophylactic cranial irradiation (PCI) was recommended. The primary endpoints were safety and tolerance; the second endpoints were progression-free survival (PFS). ResultsForty patients were enrolled, and all had completed palliative HFRT and four cycles of immunochemotherapy. There were seven grade 3 adverse events (3 decreased neutrophil count, 1 anemia, 2 pneumonitis, 1 esoenteritis), two grade 4 adverse events (2 decreased white cell count) and no grade 5 toxicities. The pneumonitis rate was 12.5% (three grade 2 and two grade 3 events). At the median follow-up of 14.2 months (range, 6.8-28.7), the median PFS was 8.6 months (95%CI, 6.1-11.1). ConclusionThe addition of concurrent hypofractionated thoracic radiotherapy to first-line immunochemotherapy for ES-SCLC was well tolerated and showed promising clinical efficacy. Additional randomized trials are needed to validate benefits. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1664-3224 -DA - 2023 JUN 7 -PY - 2023 -VL - 14 -C7 - 1175960 -DO - 10.3389/fimmu.2023.1175960 -AN - WOS:001010201200001 -AD - Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha, Hunan, Peoples R China -AD - Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Med Oncol,Xiangya Sch Med,Lung Canc & Gastroi, Changsha, Peoples R China -AD - Yueyang Ctr Hosp, Dept Oncol, Yueyang, Peoples R China -AD - Cent South Univ, Xiangya Hosp 2, Dept Oncol, Guilin Hosp, Guilin, Peoples R China -M2 - Yueyang Ctr Hosp -M2 - Cent South Univ -Y2 - 2023-06-29 -ER - - -TY - JOUR -AU - Rodriguez de Dios, N. -AU - Calvo, P. -AU - Rico, M. -AU - Martin, M. -AU - Counago, F. -AU - Sotoca, A. -AU - Taboada, B. -AU - Rodriguez, A. -TI - Recent developments in radiotherapy for small-cell lung cancer: a review by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society) -T2 - CLINICAL & TRANSLATIONAL ONCOLOGY -M3 - Review -AB - Small-cell lung cancer (SCLC) accounts for 13% of all lung tumours. The standard treatment in patients with limited-stage disease is radiotherapy combined with chemotherapy. In extensive SCLC, the importance of consolidation thoracic radiotherapy in patients with a good treatment response has become increasingly recognized. In both limited and extensive disease, prophylactic cranial irradiation is recommended in patients who respond to treatment. New therapeutic approaches such as immunotherapy are being increasingly incorporated into the treatment of SCLC, although more slowly than in non-small cell lung cancer (NSCLC). Diverse radiation dose and fractionation schemes, administered in varying combinations with these new drugs, are being investigated. In the present study we review and update the role of radiotherapy in the treatment of SCLC. We also discuss the main clinical trials currently underway in order to identify future trends. -PU - SPRINGER INTERNATIONAL PUBLISHING AG -PI - CHAM -PA - GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND -SN - 1699-048X -SN - 1699-3055 -DA - 2017 OCT -PY - 2017 -VL - 19 -IS - 10 -SP - 1183 -EP - 1192 -DO - 10.1007/s12094-017-1667-5 -AN - WOS:000410772600002 -AD - Hosp del Mar, Dept Radiat Oncol, Parc Salut MAR,Passeig Maritim,25-29, Barcelona 08003, Spain -AD - Hosp del Mar Med Res Inst IMIM, Doctor Aiguader 88, Barcelona 08003, Spain -AD - Pompeu Fabra Univ, Doctor Aiguader 80, Barcelona 08003, Spain -AD - Hosp Univ Santiago de Compostela, Dept Radiat Oncol, Tr Choupana S-N, Santiago De Compostela 15706, Spain -AD - Complejo Hosp Navarra, Dept Radiat Oncol, Calle Irunlarrea 3, Pamplona 31008, Spain -AD - Hosp Univ Ramon y Cajal, Dept Radiat Oncol, Carretera Colmenar KM 9,1, Madrid 28034, Spain -AD - Hosp Univ Quiron Madrid, Dept Radiat Oncol, Diego de Velazquez 1, Madrid 28223, Spain -AD - Hosp Ruber Int, Dept Radiat Oncol, Calle Maso 38, Madrid 28034, Spain -M2 - Hosp Univ Quiron Madrid -M2 - Hosp Ruber Int -Y2 - 2017-09-29 -ER - - -TY - JOUR -AU - Huang, Litang -AU - Chen, Shen -AU - Liu, Hui -AU - Meng, Lu -AU - Liu, Chengxing -AU - Wu, Xiaoting -AU - Wang, Yingying -AU - Luo, Shilan -AU - Tu, Hongbin -AU - Wang, Chunlei -AU - Zhang, Ming -AU - Gong, Xiaomei -TI - PD-L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence -T2 - CANCER MEDICINE -M3 - Article -AB - Background: Numerous studies have demonstrated that brain metastases patients may benefit from intracranial radiotherapy combined with immune checkpoint inhibitors (ICIs). However, it is unclear whether this treatment is effective for patients with small cell lung cancer brain metastases (SCLC-BMs). Methods: We conducted a retrospective study by analyzing medical records of patients with SCLC-BMs from January 1, 2017 to June 1, 2022. Data related to median overall survival (mOS), median progression-free survival (mPFS), and intracranial progression-free survival (iPFS) were analyzed. Results: A total of 109 patients were enrolled, of which 60 received WBRT and 49 received WBRT-ICI. Compared to the WBRT alone cohort, the WBRT-ICI cohort showed longer mOS (20.4 months vs. 29.3 months, p = 0.021), mPFS (7.9 months vs. 15.1 months, p < 0.001), and iPFS (8.3 months vs. 16.5 months, p < 0.001). Furthermore, WBRT-ICI cohort had a better response rate for both BMs. (p = 0.035) and extracranial diseases (p < 0.001) compared to those receiving WBRT alone. Notably, the use of WBRT before ICI was associated with longer mOS compared to the use of WBRT after ICI (23.3 months for the ICI-WBRT group vs. 34.8 months for the WBRT-ICI group, p = 0.020). Conclusion: Our results indicated that WBRT combined with immunotherapy improved survival in SCLC-BMs patients compared to WBRT monotherapy. Administering WBRT prior to ICI treatment is associated with improved survival outcomes compared to WBRT following ICI treatment, for patients with SCLC-BMs. These findings highlight the significance of conducting further prospective researches on combination strategies of intracranial radiotherapy and ICI in SCLC-BMs patients. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2045-7634 -DA - 2024 APR -PY - 2024 -VL - 13 -IS - 7 -C7 - e7125 -DO - 10.1002/cam4.7125 -AN - WOS:001201733400001 -AD - Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Radiat Oncol, Shanghai, Peoples R China -AD - Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China -AD - Tongji Univ, Tongji Hosp, Sch Med, Dept Cardiol, Shanghai, Peoples R China -AD - Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Integrated TCM & Western Med, Shanghai, Peoples R China -AD - Nantong Univ, Dept Endocrinol, Affiliated Hosp 4, Nantong, Jiangsu, Peoples R China -AD - Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Integrated Tradit Chinese & Western Med, Sch Med, Shanghai, Peoples R China -AD - Tongji Univ, Shanghai Pulm Hosp, Dept Radiat Oncol, Sch Med, 507 Zhengmin Rd, Shanghai 200092, Peoples R China -AD - Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Integrated Tradit Chinese & Western Med, Sch Med, 241 West Huaihai Rd, Shanghai 200030, Peoples R China -Y2 - 2024-04-19 -ER - - -TY - JOUR -AU - Tang, C. -AU - Naing, A. -AU - de Groot, P. -AU - Chang, J. Y. -AU - Massarelli, E. -AU - Parkhurst, K. -AU - Erdman, D. -AU - Barrientes, S. -AU - Fok, J. -AU - Subbiah, V. -AU - Fu, S. -AU - Tsimberidou, A. -AU - Karp, D. -AU - Gomez, D. R. -AU - Heymach, J. -AU - Hahn, S. M. -AU - Komaki, R. U. -AU - Hong, D. -AU - Welsh, J. W. -TI - Phase 1 Study of Ipilimumab and Stereotactic Radiation Targeting Liver or Lung Lesions in Patients With Advanced Malignancies -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 57th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - San Antonio, TX -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2015 NOV 1 -PY - 2015 -VL - 93 -IS - 3 -MA - 1126 -SP - S208 -EP - S208 -DO - 10.1016/j.ijrobp.2015.07.500 -AN - WOS:000373215302178 -AD - Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA -Y2 - 2016-05-04 -ER - - -TY - JOUR -AU - D'Andrea, Mark A. -AU - Reddy, G. Kesava -TI - Systemic Immunostimulatory Effects of Radiation Therapy Improves the Outcomes of Patients With Advanced NSCLC Receiving Immunotherapy -T2 - AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS -M3 - Article -AB - The understanding of localized radiation therapy's immunostimulatory properties combined with its well-known effects on the cell cycle and insights into the immunomodulation mechanisms that occur at the molecular and cellular levels has changed our traditional view of the anticancer effects of ionizing radiation. The potential interactions between the tumor's immune system and radiation therapy have revealed that local radiation has the ability to induce systemic antitumor responses in patients with advanced cancers. The recognition of systemic antitumor effects of radiation therapy has allowed investigators to begin uncovering the integral players in these pathways. Parallel to this, there has been progress in understanding how tumor immunology leads to the development of novel immunotherapies using immune checkpoint blockade therapies in the treatment of advanced cancers. To date there has been limited success in this benefiting only a small fraction of patients. The concept of priming the body's immune system by radiation to make less responsive tumors more responsive to immunotherapy provides an opportunity to explore the use of the combination of radiation therapy and immunotherapy for the treatment of advanced non-small cell lung cancer and other cancers. This article provides an overview of the current state of knowledge of the clinical experience using radiation therapy in combination with immune therapy and discusses the rationale for integrating these 2 modalities in the treatment of advanced non-small cell lung cancer. Available data supports the use of radiation therapy in combination with immunotherapy to achieve improved local and systemic tumor control. Evidence from the early clinical trials has shown that using radiation therapy and immune checkpoint blockade therapies together produces a greater clinical effect than using either modality alone. To maximize the clinical benefit and successful integration of these two modalities as well as optimizing radiation therapy dosing and its schedule, improvement in its field design and the development of reliable predictors of clinical tumor response needs to be established. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0277-3732 -SN - 1537-453X -DA - 2020 MAR -PY - 2020 -VL - 43 -IS - 3 -SP - 218 -EP - 228 -DO - 10.1097/COC.0000000000000651 -AN - WOS:000522184100011 -AD - Univ Canc & Diagnost Ctr, 12811 Beamer Rd, Houston, TX 77089 USA -M2 - Univ Canc & Diagnost Ctr -Y2 - 2020-04-10 -ER - - -TY - JOUR -AU - Merie, R. -AU - Gee, H. -AU - Hau, E. -AU - Vinod, S. -TI - An Overview of the Role of Radiotherapy in the Treatment of Small Cell Lung Cancer- A Mainstay of Treatment or a Modality in Decline? -T2 - CLINICAL ONCOLOGY -M3 - Article -AB - Aims: Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers. Chemotherapy, immunotherapy and radiotherapy all play important roles in the management of SCLC. The aim of this study was to provide a comprehensive overview of the role and evidence of radiotherapy in the cure and palliation of SCLC.Materials and methods: The search strategy included a search of the PubMed database, hand searches, reference lists of relevant review articles and relevant published abstracts. ClinicalTrials.gov was also queried for relevant trials.Results: Thoracic radiotherapy improves overall survival in limited stage SCLC, but the timing and dose remain controversial. The role of thoracic radiotherapy in extensive stage SCLC with immunotherapy is the subject of several ongoing trials. Current evidence supports the use of prophylactic cranial irradiation (PCI) for limited stage SCLC but the evidence is equivocal in extensive stage SCLC. Whole brain radiotherapy is well established for the treatment of brain metastases but evidence is rapidly accumulating for the use of stereotactic radiosurgery. Further studies will define the role of PCI, whole brain radiotherapy and hippocampal avoidant PCI in the immunotherapy era.Conclusion: Radiotherapy is an essential component in the multimodality management of SCLC. Technological advances have allowed safer delivery of radiotherapy with reduced toxicities. Discussion at multidisciplinary team meetings is important to ensure radiotherapy is considered and offered in appro-priate patients.Crown Copyright (c) 2022 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. All rights reserved. -PU - ELSEVIER SCIENCE LONDON -PI - LONDON -PA - 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND -SN - 0936-6555 -SN - 1433-2981 -DA - 2022 NOV -PY - 2022 -VL - 34 -IS - 11 -SP - 741 -EP - 752 -DO - 10.1016/j.clon.2022.08.024 -AN - WOS:000868519200010 -C6 - OCT 2022 -AD - Concord Repatriat Gen Hosp, Icon Canc Ctr, Concord, NSW, Australia -AD - Univ NSW, South West Sydney Clin Campuses, Liverpool, NSW, Australia -AD - Sydney West Radiat Oncol Network SWRON, Sydney, NSW, Australia -AD - Univ Sydney, Westmead Hosp, Sydney Med Sch, Sydney, NSW, Australia -AD - Univ Sydney, Childrens Med Res Inst CMRI, Sydney, NSW, Australia -AD - Westmead Inst Med Res WIMR, Westmead, NSW, Australia -AD - Liverpool Hosp, Canc Therapy Ctr, Liverpool, NSW, Australia -AD - Ingham Inst Appl Med Res, Liverpool, NSW, Australia -AD - Concord Repatriat Gen Hosp, Icon Canc Ctr, Hosp Rd, Concord, NSW 2139, Australia -M2 - Sydney West Radiat Oncol Network SWRON -M2 - Westmead Inst Med Res WIMR -Y2 - 2022-11-02 -ER - - -TY - JOUR -AU - Myall, Nathaniel J. -AU - Das, Millie -TI - Advances in the Treatment of Stage III Non-Small Cell Lung Cancer -T2 - CLINICS IN CHEST MEDICINE -M3 - Review -AB - Treatment of stage III non-small cell lung cancer (NSCLC) traditionally has involved combinations of chemotherapy, radiation, and surgical resection. Although the multimodality approach remains standard, only a fraction of patients with stage III lung cancer can undergo complete resection, and long-term prognosis remains poor. The PACIFIC trial generated significant enthusiasm when it demonstrated that the programmed death ligand-1 inhibitor, durvalumab, improved survival in patients with unresectable stage III NSCLC after completion of definitive concurrent chemoradiation. This article reviews the indications for traditional therapies in stage III NSCLC and highlights ongoing advances that have led to the incorporation of novel therapeutic agents. -PU - W B SAUNDERS CO-ELSEVIER INC -PI - PHILADELPHIA -PA - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA -SN - 0272-5231 -SN - 1557-8216 -DA - 2020 JUN -PY - 2020 -VL - 41 -IS - 2 -SP - 211 -EP - + -DO - 10.1016/j.ccm.2020.02.008 -AN - WOS:000532666100006 -AD - Stanford Canc Inst, Dept Med, Div Med Oncol, Stanford, CA 94305 USA -AD - VA Palo Alto Hlth Care Syst, Dept Med, 3801 Miranda Ave 111ONC, Palo Alto, CA 94304 USA -Y2 - 2020-06-01 -ER - - -TY - JOUR -AU - Choi, Myeong Geun -AU - Kim, Yeon Joo -AU - Lee, Jae Cheol -AU - Ji, Wonjun -AU - Oh, In-Jae -AU - Lee, Sung Yong -AU - Yoon, Seong Hoon -AU - Lee, Shin Yup -AU - Lee, Jeong Eun -AU - Kim, Eun Young -AU - Choi, Chang-Min -TI - The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study -T2 - CANCER RESEARCH AND TREATMENT -M3 - Article -AB - Purpose The addition of immune checkpoint inhibitors to chemotherapy has improved survival outcomes in patients with extensivestage small cell lung cancer (ES-SCLC). However, their real -world effectiveness remains unknown. Therefore, we investigated the effectiveness of atezolizumab plus chemotherapy in ES-SCLC in actual clinical settings. Materials and Methods In this multicenter prospective cohort study, patients with ES-SCLC receiving or scheduled to receive atezolizumab in combination with etoposide and carboplatin were enrolled between June 2021 and August 2022. The primary outcomes were progression -free survival (PFS) and the 1 -year overall survival (OS) rate. Results A total of 100 patients with ES-SCLC were enrolled from seven centers. Median age was 69 years, and 6% had an Eastern Cooperative Oncology Group performance status (ECOG PS) >= 2. The median PFS was 6.0 months, the 1 -year OS rate was 62.2%, and the median OS was 13.5 months. An ECOG PS of 2-3 and progressive disease as the best response were poor prognostic factors for PFS, while an ECOG PS of 2-3 and brain metastasis were associated with poor prognosis for OS. In addition, consolidative thoracic radiotherapy was found to be an independent favorable prognostic factor for OS (hazard ratio, 0.336; p=0.021). Grade >= 3 treatmentrelated adverse events were observed in 7% of patients, with treatment -related deaths occurring in 2% of patients. Conclusion We provided evidence of the favorable real -world effectiveness and safety of atezolizumab plus chemotherapy in ES-SCLC patients, including in the elderly and those with poor ECOG PS. Additional consolidative thoracic radiotherapy may also benefit ES-SCLC patients. -PU - KOREAN CANCER ASSOCIATION -PI - SEOUL -PA - RM 1824, GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 110-999, SOUTH KOREA -SN - 1598-2998 -SN - 2005-9256 -DA - 2024 APR -PY - 2024 -VL - 56 -IS - 2 -SP - 422 -EP - 429 -DO - 10.4143/crt.2023.913 -AN - WOS:001208949300008 -AD - Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea -AD - Ewha Womans Univ, Dept Internal Med, Coll Med, Div Pulm & Crit Care Med,Mokdong Hosp, Seoul, South Korea -AD - Eulji Univ, Nowon Eulji Med Ctr, Dept Pulmonol, Sch Med, Seoul, South Korea -AD - Univ Ulsan Coll Med, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea -AD - Chonnam Natl Univ, Hwasun Hosp, Med Sch, Dept Internal Med, Hwasun, South Korea -AD - Korea Univ, Guro Hosp, Dept Internal Med, Div Pulm Allergy & Crit Care Med,Coll Med, Seoul, South Korea -AD - Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Div Pulmonol Allergy & Crit Care Med, Yangsan, South Korea -AD - Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea -AD - Chungnam Natl Univ, Coll Med, Dept Internal Med, Div Pulmonol, Daejeon, South Korea -AD - Yonsei Univ, Coll Med, Severance Hosp, Dept Internal Med,Div Pulm & Crit Care Med, Seoul, South Korea -Y2 - 2024-06-07 -ER - - -TY - JOUR -AU - Spaas, Mathieu -AU - Sundahl, Nora -AU - Hulstaert, Eva -AU - Kruse, Vibeke -AU - Rottey, Sylvie -AU - De Maeseneer, Daan -AU - Surmont, Veerle -AU - Meireson, Annabel -AU - Brochez, Lieve -AU - Reynders, Dries -AU - Goetghebeur, Els -AU - Van den Begin, Robbe -AU - Van Gestel, Dirk -AU - Renard, Vincent -AU - Dirix, Piet -AU - Mestdagh, Pieter -AU - Ost, Piet -TI - Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial -T2 - BMC CANCER -M3 - Article -AB - Background: While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for various tumor types has led to considerable improvements in clinical outcome, the majority of patients still fail to respond. Preclinical data suggest that stereotactic body radiotherapy (SBRT) could work synergistically with CPIs by acting as an in situ cancer vaccine, thus potentially increasing response rates and prolonging disease control. Though SBRT administered concurrently with CPIs has been shown to be safe, evidence of its efficacy from large randomized trials is still lacking. The aim of this multicenter randomized phase II trial is to assess whether SBRT administered concurrently with CPIs could prolong progression-free survival as compared to standard of care in patients with advanced solid tumors.Methods/design: Ninety-eight patients with locally advanced or metastatic disease will be randomized in a 1:1 fashion to receive CPI treatment combined with SBRT (Arm A) or CPI monotherapy (Arm B). Randomization will be stratified according to tumor histology (melanoma, renal, urothelial, head and neck squamous cell or non-small cell lung carcinoma) and disease burden (<= or > 3 cancer lesions). The recommended SBRT dose is 24Gy in 3 fractions, which will be administered to a maximum of 3 lesions and is to be completed prior to the second or third CPI cycle (depending on CPI treatment schedule). The study's primary endpoint is progression-free survival as per iRECIST. Secondary endpoints include overall survival, objective response, local control, quality of life and toxicity. Translational analyses will be performed using blood, fecal and tissue samples. Discussion: The CHEERS trial will provide further insights into the clinical and immunological impact of SBRT when combined with CPIs in patients with advanced solid tumors. Furthermore, study results will inform the design of future immuno-radiotherapy trials. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2021 MAY 7 -PY - 2021 -VL - 21 -IS - 1 -C7 - 514 -DO - 10.1186/s12885-021-08088-w -AN - WOS:000734340700004 -AD - Ghent Univ Hosp, Radiat Oncol, C Heymanslaan 10, B-9000 Ghent, Belgium -AD - Ghent Univ Hosp, Dermatol, Ghent, Belgium -AD - Univ Ghent, Ctr Med Genet CMGG, Ghent, Belgium -AD - Univ Ghent, Canc Res Inst Ghent CRIG, Ghent, Belgium -AD - Ghent Univ Hosp, Med Oncol, Ghent, Belgium -AD - AZ St Lucas, Med Oncol, Brugge, Belgium -AD - Ghent Univ Hosp, Pulm Med, Ghent, Belgium -AD - Univ Ghent, Dept Appl Math Comp Sci & Stat, Ghent, Belgium -AD - Univ Ghent, Stat Gent CRESCENDO Consortium, Ghent, Belgium -AD - Univ Libre Bruxelles, Jules Bordet Inst, Radiat Oncol, Brussels, Belgium -AD - AZ St Lucas, Med Oncol, Ghent, Belgium -AD - Iridium Canc Network, Radiat Oncol, Antwerp, Belgium -M2 - AZ St Lucas -M2 - AZ St Lucas -M2 - Iridium Canc Network -Y2 - 2022-01-03 -ER - - -TY - JOUR -AU - King, J. -AU - Patel, K. -AU - Woolf, D. -AU - Hatton, M. Q. -TI - The Use of Palliative Radiotherapy in the Treatment of Lung Cancer -T2 - CLINICAL ONCOLOGY -M3 - Article -AB - There have been significant advances in the systemic treatment of stage IV lung cancer, which is now recommended first line in patients with adequate fitness. This includes some patients with brain metastases due to the increased understanding of the central nervous system penetration of targeted therapies. The trials evidence base for palliative radiotherapy pre-dated this routine use of systemic therapy in our practice, which means that the sequence and role of palliative radiotherapy are not currently well defined in the first-line treatment setting. However, due to its efficacy in symptom control, radiotherapy remains a core component in the palliative management of lung cancer, particularly in the second-line setting and those unsuited to primary systemic treatment. This overview focuses on the evidence behind palliative radiotherapy to the thorax and brain for non-small cell and small cell lung cancer and the potential for future studies, including the TOURIST Trial Platform, to guide the future direction of these treatments.Crown Copyright (c) 2022 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. All rights reserved. -PU - ELSEVIER SCIENCE LONDON -PI - LONDON -PA - 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND -SN - 0936-6555 -SN - 1433-2981 -DA - 2022 NOV -PY - 2022 -VL - 34 -IS - 11 -SP - 761 -EP - 770 -DO - 10.1016/j.clon.2022.08.032 -AN - WOS:000868519200012 -C6 - OCT 2022 -AD - Christie Hosp NHS Fdn Trust, Manchester, England -AD - Sheffield Teaching Hosp NHS Fdn Trust, Royal Hallamshire Hosp, Sheffield, England -AD - Christie Hosp NHS Fdn Trust, Wilmslow Rd, Manchester M20 4BX, England -Y2 - 2022-11-02 -ER - - -TY - JOUR -AU - Baldini, E. -AU - Tibaldi, C. -AU - Delli Paoli, C. -TI - Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: a review -T2 - CLINICAL & TRANSLATIONAL ONCOLOGY -M3 - Review -AB - Approximately one-third of all non-small-cell lung cancer (NSCLC) are locally-advanced at diagnosis, and 15-17% of these tumors are unresectable at presentation. Definitive chemo-radiotherapy (CRT) represents the standard therapeutic approach. However, the literature has shown that only 15% of patients are alive at 5 years and this percentage has remained unchanged despite various attempts of improvement. The recent introduction of immunotherapy has not only strongly changed the clinical scenario but has also drawn attention to a stage of disease apparently forgotten for decades. Stage III NSCLC can represent an interesting setting for the combined use of chemo-radiation and immunotherapy, due to the potential synergistic effect between radiation and immune checkpoint inhibitors. We reviewed the available literature in order to report the state of art of stage III NSCLC, by focusing on trials that evaluate different combinations of CRT and new drugs of PD-1/PD-L1 axis, and anti-CTLA-4. The future goal in the management of unresectable stage III NSCLC will be the optimal patients' selection combined with the use of individualized immuno/chemotherapies that could potentially improve clinical outcomes. -PU - SPRINGER INTERNATIONAL PUBLISHING AG -PI - CHAM -PA - GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND -SN - 1699-048X -SN - 1699-3055 -DA - 2020 OCT -PY - 2020 -VL - 22 -IS - 10 -SP - 1681 -EP - 1686 -DO - 10.1007/s12094-020-02326-6 -AN - WOS:000518073500001 -C6 - MAR 2020 -AD - S Luca Hosp, Med Oncol Div, Dept Oncol, Via Guglielmo Lippi Francesconi 1, I-55100 Lucca, Italy -M2 - S Luca Hosp -Y2 - 2020-03-17 -ER - - -TY - JOUR -AU - Lukas, Rimas V. -AU - Kumthekar, Priya -AU - Rizvi, Syeda -AU - Salgia, Ravi -TI - Systemic therapies in the treatment of non-small-cell lung cancer brain metastases -T2 - FUTURE ONCOLOGY -M3 - Review -AB - Non-small-cell lung cancer (NSCLC) brain metastases are common. Even though there are various subsets of NSCLC with molecular alterations, there is a common theme of brain metastases. Current treatment modalities are suboptimal. Systemic therapies for the treatment of NSCLC brain metastases have been explored and recent advances may pave the way for their successful employment in this patient population. While no specific agents have been associated with a marked benefit, stability of disease as well as radiographic responses have been noted in some patients. Biological activity of systemic therapies in some patients with NSCLC brain metastases raises hope for future advances and supports further investigation for this patient population with limited treatment options. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1479-6694 -SN - 1744-8301 -DA - 2016 -PY - 2016 -VL - 12 -IS - 8 -SP - 1045 -EP - 1058 -DO - 10.2217/fon.16.17 -AN - WOS:000372796900008 -AD - Univ Chicago, Dept Neurol, 5841 S Maryland Ave, Chicago, IL 60637 USA -AD - Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA -AD - City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA -Y2 - 2016-01-01 -ER - - -TY - JOUR -AU - Luciani, Andrea -AU - Blasi, Miriam -AU - Provenzano, Leonardo -AU - Zonato, Sabrina -AU - Ferrari, Daris -TI - Recent advances in small cell lung cancer: the future is now? -T2 - MINERVA ENDOCRINOLOGY -M3 - Review -AB - Small cell lung cancer is a relevant clinical issue as it is a highly malignant cancer, often diagnosed in advanced stage. Similarly to non-small cell lung cancer, tobacco smoking is currently the main risk factor. Its incidence, at least in males, has declined over the past decades, due to the worldwide decreased percentage of active smokers. The typical small cells of this tumor type are characterized by a high Proliferation Index, chromosomal deletions such as 3p(14-23) involving the tumor-suppressor gene FHIT, alterations of the MYC or Notch family proteins and the frequent expression of neu-roendocrine markers. The combination of thoracic radiotherapy and chemotherapy is the standard treatment for limited stage disease, while platinum-based chemotherapy is the most effective choice for extensive stage disease. Unfortunately, whatever chemotherapy is used, the results are disappointing. No regimen has proved to be effective in the long run, in-deed small cell lung cancer rapidly progresses after a frequent initial strong response, and the mortality rate remains still high. The advent of immunotherapy is actually changing the landscape in oncology. As well as in other cancers, recent trials have demonstrated the efficacy of the combination of immune checkpoint inhibitors and chemotherapy, opening new perspectives for the future of our patients. -PU - EDIZIONI MINERVA MEDICA -PI - TURIN -PA - CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY -SN - 2724-6507 -SN - 2724-6116 -DA - 2022 DEC -PY - 2022 -VL - 47 -IS - 4 -SP - 460 -EP - 474 -DO - 10.23736/S2724-6507.20.03213-7 -AN - WOS:000964347600010 -AD - San Paolo Hosp, Unit Med Oncol, Via Rudini 8, I-20142 Milan, Italy -Y2 - 2023-04-24 -ER - - -TY - JOUR -AU - Nesbit, Eric G. -AU - Leal, Ticiana A. -AU - Kruser, Tim J. -TI - What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era? -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Small cell lung cancer has been a difficult disease to treat with poor survival and few significant improvements in outcomes in the last three decades. Most recently the addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) resulted in improved overall survival and progression-free survival compared to chemotherapy alone. Recent randomized studies examining both consolidative thoracic radiotherapy and prophylactic cranial irradiation (PCI) in ES-SCLC have impacted the utilization of these interventions. The approval of immune checkpoint inhibitors (ICIs) to platinum/etoposide chemotherapy for the treatment of ES-SCLC in the front-line setting may also further impact the role of radiotherapy in this disease. In this article, we review the current evidence supporting thoracic radiotherapy in ES-SCLC and discuss the promising therapeutic implications of thoracic radiation in light of the inclusion of ICIs. We also address how the increasing routine use of surveillance brain magnetic resonance imaging (MRI) and ICIs may diminish the use of PCI in ES-SCLC. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2019 SEP -PY - 2019 -VL - 8 -SP - S153 -EP - S162 -DO - 10.21037/tlcr.2019.05.01 -AN - WOS:000485805900006 -AD - Northwestern Univ, Feinberg Sch Med, Dept Radiat Oncol, 251 East Huron St,Gaiter Pavil LC-178, Chicago, IL 60611 USA -AD - Univ Wisconsin, Carbone Canc Ctr, Div Hematol & Oncol, Madison, WI USA -Y2 - 2019-09-30 -ER - - -TY - JOUR -AU - Alvarez, Jean G. Bustannante -AU - Gonzalez-Cao, Maria -AU - Karachaliou, Niki -AU - Santarpia, Mariacarmela -AU - Viteri, Santiago -AU - Teixido, Cristina -AU - Rosell, Rafael -TI - Advances in immunotherapy for treatment of lung cancer -T2 - CANCER BIOLOGY & MEDICINE -M3 - Review -AB - Different approaches for treating lung cancer have been developed over time, including chemotherapy, radiotherapy and targeted therapies against activating mutations. Lately, better understanding of the role of the immunological system in tumor control has opened multiple doors to implement different strategies to enhance immune response against cancer cells. It is known that tumor cells elude immune response by several mechanisms. The development of monoclonal antibodies against the checkpoint inhibitor programmed cell death protein 1 (PD-1) and its ligand (PD-L1), on T cells, has led to high activity in cancer patients with long lasting responses. Nivolumab, an anti PD-1 inhibitor, has been recently approved for the treatment of squamous cell lung cancer patients, given the survival advantage demonstrated in a phase III trial. Pembrolizumab, another anti PD-1 antibody, has received FDA breakthrough therapy designation for treatment of non-small cell lung cancer (NSCLC), supported by data from a phase I trial. Clinical trials with anti PD-1/PD-L1 antibodies in NSCLC have demonstrated very good tolerability and activity with response rates around 20% and a median duration of response of 18 months. -PU - CHINA ANTI-CANCER ASSOC -PI - TIANJIN -PA - TIANJIN MEDICAL UNIV, CANCER INST & HOSPITAL TI-YUAN-BEI, HUANHU XI LU, HEXIQU, TIANJIN, 300060, PEOPLES R CHINA -SN - 2095-3941 -DA - 2015 SEP -PY - 2015 -VL - 12 -IS - 3 -SP - 209 -EP - 222 -DO - 10.7497/j.issn.2095-3941.2015.0032 -AN - WOS:000362624800009 -AD - Albert Einstein Med Ctr, Philadelphia, PA 19141 USA -AD - Quiron Dexeus Univ Hosp, Inst Oncol Dr Rosell, Translat Canc Res Unit, Barcelona 08028, Spain -AD - Univ Messina, Human Pathol Dept, Med Oncol Unit, I-98100 Messina, Italy -AD - Pangaea Biotech SL, Barcelona 08028, Spain -AD - Germans Trias & Pujol Hlth Sci Inst & Hosp, Catalan Inst Oncol, Canc Biol & Precis Med Program, Barcelona 08916, Spain -AD - Fdn Mol Oncol Res, Barcelona 08028, Spain -M2 - Quiron Dexeus Univ Hosp -M2 - Pangaea Biotech SL -M2 - Fdn Mol Oncol Res -Y2 - 2015-09-01 -ER - - -TY - JOUR -AU - Varlotto, John Michael -AU - Sun, Zhuoxin -AU - Ky, Bonnie -AU - Upshaw, Jenica -AU - Fitzgerald, Thomas J. -AU - Diehn, Max -AU - Lovly, Christine -AU - Belani, Chandra -AU - Oettel, Kurt -AU - Masters, Gregory -AU - Harkenrider, Matthew -AU - Ross, Helen -AU - Ramalingam, Suresh -AU - Pennell, Nathan A. -TI - A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181 -T2 - CLINICAL LUNG CANCER -M3 - Review -AB - ECOG-ACRIN EA5181 is a current prospective, randomized trial that is investigating whether the addition of concomitant durvalumab to standard chemo/radiation followed by 1 year of consolidative durvalumab results in an overall survival benefit over standard chemo/radiation alone followed by 1 year of consolidative durvalumab in patients with locally advanced, unresectable non-small cell lung cancer (NSCLC). Because multiple phase I/II trials have shown the relative safety of adding immunotherapy to chemo/radiation and due to the known synergism between chemotherapy and immunotherapy, it is hoped that concomitant durvalumab can reduce the relatively high incidence of local failure (38%46%) as seen in recent prospective, randomized trials of standard chemo/radiation in this patient population. We will review the history of radiation for LA-NSCLC and discuss the role of induction, concurrent and consolidative chemotherapy as well as the concerns for late cardiac and pulmonary toxicities associated with treatment. Furthermore, we will review the potential role of next generation sequencing, PD-L1, ctDNA and tumor mutation burden and their possible impact on this trial. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2022 NOV -PY - 2022 -VL - 23 -IS - 7 -SP - 547 -EP - 560 -DO - 10.1016/j.cllc.2022.06.005 -AN - WOS:000928437600001 -C6 - OCT 2022 -AD - Marshall Univ, Dept Oncol, Edwards Comprehens Canc Ctr, Huntington, WV 25701 USA -AD - Dana Farber Canc Inst, ECOG ACRIN Biostat Ctr, Boston, MA 02115 USA -AD - Univ Penn, Div Cardiovasc Med, Philadelphia, PA 19104 USA -AD - Tufts Univ, Dept Med, Boston, MA 02111 USA -AD - Imaging & Radiat Oncol Core IROC, Lincoln, RI USA -AD - Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA -AD - Vanderbilt Univ, Div Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA -AD - Penn State Canc Inst, Dept Med Oncol, Hershey, PA USA -AD - Gundersen Lutheran Med Ctr, Dept Med Oncol, La Crosse, WI USA -AD - Delaware Christiana Care NCORP, Newark, DE USA -AD - Loyola Univ Chicago, Dept Radiat Oncol, Stritch Sch Med, Maywood, IL USA -AD - Banner MD Anderson Canc Ctr, Dept Med Oncol, Gilbert, AZ USA -AD - Emory Univ, Div Med Oncol, Atlanta, GA 30322 USA -AD - Cleveland Clin, Dept Hematol Oncol, Cleveland, OH 44106 USA -M2 - Imaging & Radiat Oncol Core IROC -Y2 - 2023-03-01 -ER - - -TY - JOUR -AU - Leung, John Hang -AU - Chih-Wen Chang -AU - Chan, Agnes L. F. -AU - Hui-Chu Lang -TI - Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan -T2 - FUTURE ONCOLOGY -M3 - Article -AB - Objectives: To evaluate the cost-effectiveness of immune checkpoint inhibitors versus docetaxel in patients with advanced non-small-cell lung cancer. Methods: A Markov model was constructed to simulate the clinical outcomes and costs of advanced non-small-cell lung cancer. Clinical outcomes data were derived from randomized clinical trials. Drug acquisition cost and other health resource use were obtained from the claim data of a tertiary hospital and the National Health Insurance. The outcome was an incremental cost-effectiveness ratio expressed as cost per quality-adjusted life year gained. One-way and probabilistic sensitivity analyses were performed to evaluate the uncertainty of the model parameters. Results: In the base case, patients treated with immunotherapies in the second line were associated with higher costs and higher mean survival. The incremental costs per quality-adjusted life year gained for pembrolizumab, nivolumab, or atezolizumab compared to docetaxel were NT$416,102, NT$1,572,912 and NT$1,580,469, respectively. Conclusion: The results showed that pembrolizumab was more cost effective than nivolumab and atezolizumab compared with docetaxel as a second-line regimen for patients with previously treated advanced non-small-cell lung cancer at willingness to pay threshold in Taiwan.Plain language summary Lung cancer is the first leading cause of cancer death in Taiwan. About 75% of patients have advanced disease at the time of diagnosis (stage III/IV) with a median survival of 13.2 months. Most non-small-cell lung cancer (NSCLC) patients are usually diagnosed at a late stage. The conventional chemotherapy, surgery or radiation regimens may not be of significant benefits. Fortunately, newer immunotherapies or targeted therapies have improved the 5-year survival rates of advanced NSCLC from 15 to 50% with high cost. This study aimed to assess if the newer targeted therapies are cost effective and provide 'value for money' compared with chemotherapy in NSCLC patients with advanced stage. A cost-effectiveness model was created based on the data from the real-world and published phase III randomized controlled trials. The results showed that pembrolizumab is more cost effective than nivolumab and atezolizumab compared with docetaxel as a second-line regimen for patients with previously treated advanced NSCLC at willingness to pay threshold in Taiwan. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1479-6694 -SN - 1744-8301 -DA - 2022 MAR -PY - 2022 -VL - 18 -IS - 7 -SP - 859 -EP - 870 -DO - 10.2217/fon-2021-0785 -AN - WOS:000749682000001 -C6 - FEB 2022 -AD - Ditmanson Med Fdn Chia Yi Christian Hosp, Dept Obstet & Gynecol, Chiayi 600, Taiwan -AD - Natl Yang Ming Chiao Tung Univ, Inst Hosp & Healthcare Adm, Taipei 112, Taiwan -AD - China Med Univ, An Nan Hosp, Dept Pharm, Tainan 709, Taiwan -M2 - Ditmanson Med Fdn Chia Yi Christian Hosp -Y2 - 2022-02-08 -ER - - -TY - JOUR -AU - Mirestean, Camil Ciprian -AU - Iancu, Roxana Irina -AU - Iancu, Dragos Teodor -TI - Radiotherapy and Immunotherapy-A Future Partnership towards a New Standard -T2 - APPLIED SCIENCES-BASEL -M3 - Article -AB - The impressive results in terms of survival brought by immune checkpoint inhibitors (ICI) in metastatic malignant melanoma and the transformation of this disease with a poor prognosis into a chronic disease even with long-term survival cases have opened horizons for a new era in cancer treatments. Later, therapy with CTLA-4 and PD-1/PD-L1 inhibitors became standard in other solid tumors, especially in relapsed and metastatic settings. The PACIFIC clinical trial revolutionized the concept of consolidation immunotherapy after the favorable response to curative chemoradiotherapy in non-small cell lung carcinoma (NSCLC). Two new effects will govern the future of the immunotherapy-radiotherapy association: the local "in situ" vaccination effect and the systemic remote "abscopal" response. Even if stereotactic body irradiation (SBRT) or stereotactic radiosurgery (SRT) seems to be more effective in generating the synergistic effect, the PACIFIC trial demonstrates the role of conventional irradiation in combination with chemotherapy in modulating the host's immune response. Thus, the radiotherapy-chemotherapy-immunotherapy triad may become the future standard in locally advanced disease. The different mechanisms of producing immune-mediated cell death and the indirect role of augmenting the immune effect induced by radiotherapy make the old theories related to the therapeutic sequence, fractionation, doses, and target volumes as well as the protection of healthy tissues to be re-evaluated. The new concept of immuno-radiotherapy in synergistic association has as its physiopathological substrate the dual immunosuppressive and enhancement of antitumor response to irradiation, including the activation of the immune effectors in the tumor microenvironment (TME). The choice of sequential treatment, a hypofractionated irradiation regime, and the possible omission of lymph node irradiation with the limitation of lymphopenia could tilt the balance in favor of the activation and potentiation of the antitumor immune response. The selection of therapeutic targets chosen for the combination of immunotherapy and associated radiotherapy can be conducted based on the classification of tumors in the three immune phenotypes that characterize "cold" and "hot" tumors from the point of view of the response to therapy. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2076-3417 -DA - 2023 MAY 4 -PY - 2023 -VL - 13 -IS - 9 -C7 - 5643 -DO - 10.3390/app13095643 -AN - WOS:000985419800001 -AD - Univ Med & Pharm Craiova, Dept Med Oncol & Radiotherapy, Craiova 200349, Romania -AD - Railways Clin Hosp, Dept Surg, Iasi 700506, Romania -AD - Gr T Popa Univ Med & Pharm, Oral Pathol Dept, Iasi 700115, Romania -AD - St Spiridon Emergency Hosp, Clin Lab Dept, 16th Univ St, Iasi 700111, Romania -AD - Grigore T Popa Univ Med & Pharm, Dept Med Oncol & Radiotherapy, Iasi 700115, Romania -AD - Reg Inst Oncol, Dept Radiat Oncol, Iasi 700483, Romania -M2 - Railways Clin Hosp -Y2 - 2023-05-21 -ER - - -TY - JOUR -AU - Gao, Jingyi -AU - Zhang, Chao -AU - Wei, Zhigang -AU - Ye, Xin -TI - Immunotherapy for early-stage non-small cell lung cancer: A system review -T2 - JOURNAL OF CANCER RESEARCH AND THERAPEUTICS -M3 - Review -AB - With the addition of immunotherapy, lung cancer, one of the most common cancers with high mortality rates, has broadened the treatment landscape. Immune checkpoint inhibitors have demonstrated significant efficacy in the treatment of non-small cell lung cancer (NSCLC) and are now used as the first-line therapy for metastatic disease, consolidation therapy after radiotherapy for unresectable locally advanced disease, and adjuvant therapy after surgical resection and chemotherapy for resectable disease. The use of adjuvant and neoadjuvant immunotherapy in patients with early-stage NSCLC, however, is still debatable. We will address several aspects, namely the initial efficacy of monotherapy, the efficacy of combination chemotherapy, immunotherapy-related biomarkers, adverse effects, ongoing randomized controlled trials, and current issues and future directions for immunotherapy in early-stage NSCLC will be discussed here. -PU - WOLTERS KLUWER MEDKNOW PUBLICATIONS -PI - MUMBAI -PA - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA -SN - 0973-1482 -SN - 1998-4138 -DA - 2023 AUG -PY - 2023 -VL - 19 -IS - 4 -SP - 849 -EP - 865 -DO - 10.4103/jcrt.jcrt_723_23 -AN - WOS:001066565500001 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Jinan, Shandong, Peoples R China -AD - Shandong First Med Univ & Shandong Prov Qianfoshan, Shandong Lung Canc Inst, Shandong Key Lab Rheumat Dis & Translat Med, Dept Oncol,Affiliated Hosp 1, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China -AD - Kunming Med Univ, Affiliated Qujing Hosp, Dept Oncol, Qujing, Yunnan, Peoples R China -M2 - Shandong First Med Univ & Shandong Prov Qianfoshan -Y2 - 2023-10-14 -ER - - -TY - JOUR -AU - Stinchcombe, Thomas E. -TI - Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer -T2 - ONCOLOGIST -M3 - Article -AB - The prevalence of small cell lung cancer (SCLC) has declined in the U.S. as the prevalence of tobacco use has declined. However, a significant number of people in the U.S. are current or former smokers and are at risk of developing SCLC. Routine histological or cytological evaluation can reliably make the diagnosis of SCLC, and immunohistochemistry stains (thyroid transcription factor-1, chromogranin, synaptophysin, and CD56) can be used if there is uncertainty about the diagnosis. Rarely do patients present with SCLC amendable to surgical resection, and evaluation requires a meticulous workup for extra-thoracic metastases and invasive staging of the mediastinum. Resected patients require adjuvant chemotherapy and/or thoracic radiation therapy (TRT), and prophylactic cranial radiation (PCI) should be considered depending on the stage. For limited-stage disease, concurrent platinum-etoposide and TRT followed by PCI is the standard. Thoracic radiation therapy should be started early in treatment, and can be given twice daily to 45 Gy or once daily to 60-70 Gy. For extensive-stage disease, platinum-etoposide remains the standard first-line therapy, and the standard second-line therapy is topotecan. Preliminary studies have demonstrated the activity of immunotherapy, and the response rate is approximately 10-30% with some durable responses observed. Rovalpituzumab tesirine, an antibody drug conjugate, has shown promising activity in patients with high delta-like protein 3 tumor expression (approximately 70% of patients with SCLC). The emergence of these and other promising agents has rekindled interest in drug development in SCLC. Several ongoing trials are investigating novel agents in the first-line, maintenance, and second-line settings. -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 1083-7159 -SN - 1549-490X -DA - 2017 DEC -PY - 2017 -VL - 22 -IS - 12 -SP - 1510 -EP - 1517 -DO - 10.1634/theoncologist.2017-0204 -AN - WOS:000417923100016 -AD - Duke Canc Inst, DUMC 3198,25178 Morris Bldg, Durham, NC 27710 USA -Y2 - 2017-12-27 -ER - - -TY - JOUR -AU - Guo, Tiantian -AU - Zou, Liqing -AU - Ni, Jianjiao -AU - Chu, Xiao -AU - Zhu, Zhengfei -TI - Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Significant recent advances have occurred in the use of radiation therapy for locally advanced non-small cell lung cancer (LA-NSCLC). In fact, the past few decades have seen both therapeutic gains and setbacks in the evolution of radiotherapy for LA-NSCLC. The PACIFIC trial has heralded a new era of immunotherapy and has raised important questions for future study, such as the future directions of radiation therapy for LA-NSCLC in the era of immunotherapy. Modern radiotherapy techniques such as three-dimensional (3D) conformal radiotherapy and intensity-modulated radiotherapy (IMRT) provide opportunities for improved target conformity and reduced normal-tissue exposure. However, the low-dose radiation volume brought by IMRT and its effects on the immune system deserve particular attention when combing radiotherapy and immunotherapy. Particle radiotherapy offers dosimetric advantages and exhibits great immunoregulatory potential. With the ongoing improvement in particle radiotherapy techniques and knowledge, the combination of immunotherapy and particle radiotherapy has tremendous potential to improve treatment outcomes. Of particular importance are questions on the optimal radiation schedule in the settings of radio-immunotherapy. Strategies for the reduction of the irradiated field such as involved-field irradiation (IFI) and omission of clinical target volume (CTV) hold promise for better preservation of immune function while not compromising locoregional and distant control. In addition, different dose-fractionation regimens can have diverse effects on the immune system. Thus, prospective trials are urgently needed to establish the optimal dose fractionation regimen. Moreover, personalized radiotherapy which allows the tailoring of radiation dose to each individual's genetic background and immune state is of critical importance in maximizing the benefit of radiation to patients with LA-NSCLC. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2020 OCT -PY - 2020 -VL - 9 -IS - 5 -SP - 2097 -EP - 2112 -DO - 10.21037/tlcr-20-511 -AN - WOS:000582799700039 -AD - Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China -AD - Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China -AD - Fudan Univ, Inst Thorac Oncol, Shanghai, Peoples R China -Y2 - 2020-11-11 -ER - - -TY - JOUR -AU - Riano, Ivy -AU - Patel, Shruti R. -AU - Liu, Stephen V. -AU - Duma, Narjust -TI - Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer -T2 - CLINICS AND PRACTICE -M3 - Review -AB - Small-cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by a rapid initial response and early development of resistance to systemic therapy and radiation. The management of SCLC significantly changed for the first time in decades with the introduction of immune checkpoint inhibitors. Pembrolizumab, a humanized IgG4 isotype antibody, targets the programmed cell death protein 1 (PD-1) pathway to restore anti-tumor immunity. Prospective trials of pembrolizumab in patients with previously treated SCLC showed significant durability of responses. These results led to the U.S. Food and Drug Administration (FDA) granting pembrolizumab accelerated approval as second- or third-line monotherapy for patients with extensive-stage (ES) SCLC. In a recent clinical trial that included patients with previously untreated ES-SCLC, pembrolizumab in combination with platinum/etoposide met its progression-free survival endpoint, but overall survival (OS) did not cross the threshold for superiority. With the therapeutic landscape for SCLC rapidly evolving, we review prior experience and future directions of pembrolizumab in ES-SCLC. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2039-7275 -SN - 2039-7283 -DA - 2021 SEP -PY - 2021 -VL - 11 -IS - 3 -SP - 441 -EP - 454 -DO - 10.3390/clinpract11030059 -AN - WOS:000702392200001 -AD - Tufts Univ, Sch Med, MetroWest Med Ctr, Dept Med, Framingham, MA 01702 USA -AD - Mayo Clin, Dept Med, Rochester, MN 55902 USA -AD - Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med Oncol, Washington, DC 20057 USA -AD - Univ Wisconsin, Div Med Oncol Hematol & Palliat Care, Madison, WI 53706 USA -Y2 - 2021-10-08 -ER - - -TY - JOUR -AU - Wang, Yu -AU - Deng, Lei -AU - Wang, Jianyang -AU - Zhang, Tao -AU - Wang, Wenqing -AU - Wang, Xin -AU - Liu, Wenyang -AU - Wu, Yuqi -AU - Lv, Jima -AU - Feng, Qinfu -AU - Zhou, Zongmei -AU - Wang, Jie -AU - Wang, Luhua -AU - Wang, Zhijie -AU - Bi, Nan -TI - Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study) -T2 - FRONTIERS IN IMMUNOLOGY -M3 - Article -AB - Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for locally advanced non-small-cell lung cancer (LA-NSCLC), whereas responses to anti-programmed cell death-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) are heterogeneous. Though consolidation ICI following concurrent chemoradiotherapy (cCRT) improves survival of NSCLC, this regimen is challenging for patients with bulky tumors due to excessive target volumes and radiation-resistant hypoxia during upfront cCRT, leading to higher risk of pneumonitis and inferior local-regional control. Recent trials have demonstrated neoadjuvant ICI brought greater benefit to stage III than stage I-II NSCLC. Our previous study also supported the therapeutic advantage of 2-cycle induction ICI for patients with bulky unresectable stage III NSCLC. In the context of induction immunotherapy, radiotherapy is more likely to exert immune synergistic effects, reverse anti-PD-1 resistance, and activate abscopal immune responses. Prospective trials to determine the efficacy and safety of induction ICI for bulky LA-NSCLC are necessary. Methods: This randomized, open-label, two-arm phase II study aims to explore whether 2 cycles of induction anti-PD-1 toripalimab plus chemotherapy can improve progression-free survival (PFS) in bulky LA-NSCLC. Bulky tumors are defined as primary lesion >= 5 cm in greatest dimension or metastatic lymph nodes >= 2 cm in shortest diameter. A total of 50 patients with bulky unresectable stage III NSCLC will be recruited and 1:1 randomized into the experimental arm: 2-cycle induction PD-1 inhibitor toripalimab plus chemotherapy followed by cCRT and consolidation toripalimab; or control arm: 2-cycle induction chemotherapy followed by cCRT and consolidation toripalimab. Patients are stratified by pathology (squamous versus non-squamous). The primary endpoint is PFS. Secondary endpoints are overall survival, overall response rate, disease control rate, duration of response, and incidence of adverse events. Exploratory analyses include PD-L1 expression and liquid biopsy-based biomarker testing, tumor microenvironment profiling at single-cell levels, and quality-of-life assessments. Discussion: The InTRist study is the first randomized phase II trial to investigate the feasibility of induction anti-PD-1 toripalimab plus chemotherapy followed by cCRT and consolidation toripalimab in bulky LA-NSCLC, providing novel evidence for the synergistic strategy combining anti-PD-1 blockade with radiotherapy to prolong immunotherapy benefits, overcome resistance, and enhance abscopal immune response. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1664-3224 -DA - 2024 JAN 15 -PY - 2024 -VL - 14 -C7 - 1341584 -DO - 10.3389/fimmu.2023.1341584 -AN - WOS:001152112300001 -AD - Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Radiat Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc, Beijing, Peoples R China -AD - Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, State Key Lab Mol Oncol, Natl Clin Res Ctr Canc,Canc Hosp,Dept Med Oncol, Beijing, Peoples R China -AD - Canc Hosp & Shenzhen Hosp, Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Radiat Oncol, Shenzhen, Peoples R China -AD - Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Canc Hosp, Beijing, Peoples R China -Y2 - 2024-02-06 -ER - - -TY - JOUR -AU - Skrzypski, Marcin -AU - Jassem, Jacek -TI - Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer -T2 - CANCER TREATMENT REVIEWS -M3 - Review -AB - The majority of stage HI NSCLC patients managed with a combination of radiotherapy and chemotherapy will develop a locoregional or distant relapse. Concomitant radiochemotherapy allows for improved local control but has no impact on extrathoracic recurrences. To ameliorate this inefficiency the concept of consolidation treatment has been put forward, whereby systemically active doses of chemotherapy, targeted therapy or immune therapy are administered after completion of radiochemotherapy. Randomized trials failed to provide support for consolidation chemotherapy or anti-EGFR therapies. Recently durvalumab, an anti-PD-L1 checkpoint inhibitor, administered as consolidation treatment, was shown to substantially improve progression-free survival. This article critically reviews major studies addressing the role of consolidation systemic therapies following definitive concurrent radiochemotherapy and discusses prospects for future research. -PU - ELSEVIER SCI LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND -SN - 0305-7372 -SN - 1532-1967 -DA - 2018 MAY -PY - 2018 -VL - 66 -SP - 114 -EP - 121 -DO - 10.1016/j.ctrv.2018.04.001 -AN - WOS:000435054400012 -AD - Med Univ Gdansk, Dept Oncol & Radiotherapy, 7 Debinki St, PL-80211 Gdansk, Poland -Y2 - 2018-12-28 -ER - - -TY - JOUR -AU - Wu, Yuqi -AU - Zhang, Tao -AU - Liu, Yutao -AU - Wang, Jianyang -AU - Bi, Nan -TI - Anlotinib combined with durvalumab in a patient with recurrent multifocal brain metastases of small cell lung cancer after definitive concurrent chemoradiotherapy and palliative radiotherapy of the lung and brain: a case report -T2 - ANNALS OF PALLIATIVE MEDICINE -M3 - Article -AB - The brain is a common metastatic site of small cell lung cancer (SCLC), but systematic treatment options are limited by the blood-brain barrier. Currently, the optimal treatment regimen remains controversial, especially for patients already treated by brain radiotherapy. Anlotinib is a novel oral multitarget tyrosine kinase inhibitor which has shown significant improvement in progression-free survival and overall survival in third-line or beyond therapy of advanced SCLC in a randomized, double-blind phase II study (ALTER1202 trial) based on a Chinese population sample. Emerging data has also suggested that immunotherapy, such as the programmed death ligand 1 (PD-L1) inhibitor, has a relatively high response rate in brain metastatic SCLC, although there is a lack of large sample-size studies. Integrating anlotinib and immunotherapy for recurrent or relapsing brain metastases (BMs) of SCLC has not been previously reported, but it is possible that these two treatments may have synergistic effects and provide even better outcomes. Here, we present a case of stage III SCLC who developed lung and BMs after concurrent chemoradiotherapy (cCRT) and achieved radiographic locally complete regression following whole brain irradiation (WBI) with a simultaneous integrated boost (SIB) technique. Durvalumab was delivered as maintenance therapy. Asymptomatic multifocal recurrence of BMs occurred after the administration of the second dose of durvalumab. After administration of combined durvalumab and anlotinib, the BMs achieved near-complete regression and no severe toxicity was reported. This suggests a potential synergistic effect of combined durvalumab and anlotinib in previously treated BMs in a patient with SCLC and may provide a direction for future clinical decisions. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2224-5820 -SN - 2224-5839 -DA - 2021 FEB -PY - 2021 -VL - 10 -IS - 2 -SP - 2379 -EP - 2386 -DO - 10.21037/apm-20-2390 -AN - WOS:000624549600145 -AD - Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Radiat Oncol,Natl Canc Ctr, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China -AD - Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Oncol,Natl Canc Ctr, Beijing, Peoples R China -Y2 - 2021-03-28 -ER - - -TY - JOUR -AU - Chaft, Jamie E. -AU - Rimner, Andreas -AU - Weder, Walter -AU - Azzoli, Christopher G. -AU - Kris, Mark G. -AU - Cascone, Tina -TI - Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer -T2 - NATURE REVIEWS CLINICAL ONCOLOGY -M3 - Review -AB - The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary discussions of surgical resectability and medical operability determine the modality of definitive local treatment (surgery or radiotherapy) and the associated systemic therapies to further improve the likelihood of cure. Trial evidence supports cisplatin-based adjuvant therapy either after surgical resection or concurrently with radiotherapy. Consensus guidelines support neoadjuvant chemotherapy in lieu of adjuvant chemotherapy and carboplatin-based regimens for patients who are ineligible for cisplatin. The incorporation of newer agents, now standard for patients with stage IV lung cancer, into the curative therapy paradigm has lagged owing to inefficient trial designs, the lengthy follow-up needed to assess survival end points and a developmental focus on the advanced-stage disease setting. Surrogate end points, such as pathological response, are being studied and might shorten trial durations. In 2018, the anti-PD-L1 antibody durvalumab was approved for patients with stage III lung cancer after concurrent chemoradiotherapy. Since then, the study of targeted therapies and immunotherapies in patients with early-stage lung cancer has rapidly expanded. In this Review, we present the current considerations in the treatment of patients with early-stage lung cancer and explore the current and future state of clinical research to develop systemic therapies for non-metastatic lung cancer. -PU - NATURE PORTFOLIO -PI - BERLIN -PA - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY -SN - 1759-4774 -SN - 1759-4782 -DA - 2021 SEP -PY - 2021 -VL - 18 -IS - 9 -SP - 547 -EP - 557 -DO - 10.1038/s41571-021-00501-4 -AN - WOS:000645170800001 -C6 - APR 2021 -AD - Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA -AD - Weill Cornell Med Coll, New York, NY 10065 USA -AD - Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA -AD - Klin Bethanien Zurich, Thorac Surg, Zurich, Switzerland -AD - Brown Univ, Lifespan Canc Inst, Div Hematol Oncol, Providence, RI 02912 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA -M2 - Klin Bethanien Zurich -Y2 - 2021-04-28 -ER - - -TY - JOUR -AU - Yan, Xin -AU - Qu, Fanjie -AU - Zhou, Yi -TI - Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases -T2 - LUNG CANCER -M3 - Review -AB - About 40% of patients with non-small cell lung cancer (NSCLC) develop brain metastases (BMs) throughout the disease, and the occurrence of BMs is considered to have a fairly high mortality rate. Therefore, the management of brain metastases in NSCLC patients is a clinical challenge. Currently, multidisciplinary diagnosis and treatment methods are often used to achieve effective control of intracranial disease and prolong survival. Immunotherapy (IT) is one of the core therapies for NSCLC. Single or combined IT represented by immune checkpoint inhibitors(ICIs) of programmed death-1(PD-1)/ programmed cell death-ligand 1 (PD-L1) can significantly improve the prognosis of patients with advanced NSCLC.ICIs has been shown to be safe and effective in patients with BMs, although patients with BMs are mostly underrepresented in randomized clinical trials. In this review, we summarized the mechanism of ICIs in the treatment of BMs, and the clinical research and treatment progress of ICIs and their combination with other therapies in patients with BMs s from NSCLC. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2023 OCT -PY - 2023 -VL - 184 -C7 - 107322 -DO - 10.1016/j.lungcan.2023.107322 -AN - WOS:001065584600001 -C6 - AUG 2023 -AD - Dalian Med Univ, Affiliated Dalian Peoples Hosp 3, Dept Oncol, Dalian 116033, Peoples R China -AD - Dalian Med Univ, Affiliated Dalian Peoples Hosp 3, Dept Oncol, 40 QianShan Rd, Dalian 116033, Liaoning, Peoples R China -Y2 - 2023-09-26 -ER - - -TY - JOUR -AU - Sun, Alexander -AU - Abdulkarim, Bassam -AU - Blais, Normand -AU - Greenland, Jonathan -AU - Louie, Alexander V. -AU - Melosky, Barbara -AU - Schellenberg, Devin -AU - Snow, Stephanie -AU - Liu, Geoffrey -TI - Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations -T2 - LUNG CANCER -M3 - Article -AB - Objectives: Thoracic radiation therapy (TRT) and prophylactic cranial irradiation (PCI) are commonly used in the management of extensive-stage small-cell lung cancer (ES-SCLC); however, Phase III trials of first-line immu-notherapy often excluded these options. Guidance is needed regarding appropriate use of TRT, PCI, and magnetic resonance imaging (MRI) surveillance while new data are awaited.Materials and methods: In two web-based meetings, a pan-Canadian expert working group of five radiation on-cologists and four medical oncologists addressed eight clinical questions regarding use of radiation therapy (RT) and MRI surveillance among patients with ES-SCLC receiving immunotherapy. A targeted literature review was conducted using PubMed and conference proceedings to identify recent (January 2019-April 2022) publications in this setting. Fifteen recommendations were developed; online voting was conducted to gauge agreement with each recommendation.Results: After considering recently available evidence across lung cancer populations and clinical experience, the experts recommended that all patients with a response to chemo-immunotherapy, good performance status (PS), and limited metastases be considered for consolidation TRT (e.g., 30 Gy in 10 fractions). When considered appropriate after multidisciplinary team discussion, TRT can be initiated during maintenance immunotherapy. All patients who respond to concurrent chemo-immunotherapy should undergo restaging with brain MRI to guide decision-making regarding PCI versus MRI surveillance alone. MRI surveillance should be conducted for two years after response to initial therapy. PCI (e.g., 25 Gy in 10 fractions or 20 Gy in 5 fractions) can be considered for patients without central nervous system involvement who have a response to chemo-immunotherapy and good PS. Concurrent treatment with PCI and immunotherapy or with TRT, PCI, and immunotherapy is appropriate after completion of initial therapy. All recommendations were agreed upon unanimously.Conclusions: These consensus recommendations provide practical guidance regarding appropriate use of RT and immunotherapy in ES-SCLC while awaiting new clinical trial data. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2023 MAY -PY - 2023 -VL - 179 -C7 - 107166 -DO - 10.1016/j.lungcan.2023.03.002 -AN - WOS:000956130600001 -C6 - MAR 2023 -AD - Princess Margaret Canc Ctr, 700 Univ Ave, Toronto, ON M5G 1Z5, Canada -AD - McGill Univ, Hlth Ctr, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada -AD - Univ Montreal, CHU Montreal, 1051 Rue Sanguinet, Montreal, PQ H2X 3E4, Canada -AD - Eastern Hlth, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada -AD - Sunnybrook Hlth Sci Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada -AD - BC Canc Vancouver Ctr, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada -AD - BC Canc Surrey Ctr, 13750 96 Ave, Surrey, BC V3V 1Z2, Canada -AD - Dalhousie Univ, QEII Hlth Sci Ctr, 5788 Univ Ave, Halifax, NS B3H 1V8, Canada -AD - Univ Hlth Network, Princess Margaret Canc Ctr, 610 Univ Ave, Toronto, ON M5G 2M9, Canada -M2 - Eastern Hlth -M2 - BC Canc Vancouver Ctr -M2 - BC Canc Surrey Ctr -Y2 - 2023-04-12 -ER - - -TY - JOUR -AU - Mesko, Shane -AU - Gomez, Daniel -TI - Proton Therapy in Non-small Cell Lung Cancer -T2 - CURRENT TREATMENT OPTIONS IN ONCOLOGY -M3 - Review -AB - Opinion statementNon-small cell lung cancer (NSCLC) accounts for 85% of new lung cancer cases and has 5-year survival rates ranging from 92% in early-stage disease to as low as 13% in locally advanced cases. Radiation therapy is a key component in the treatment repertoire for NSCLC, where it is currently used alone or in combinations with chemotherapy and surgery. Despite the broad use of modern photon radiation techniques, as many as 25% of patients experience isolated locoregional recurrences, and toxicity has been proven to be a limiting factor in many cases. Proton beam therapy (PBT) has emerged as a potential solution to improve upon clinical outcomes in both early-stage and locally advanced disease. The proton beam allows for a sharp dose build-up and drop-off, which is particularly important in lung cancer where nearby structures include the heart, spinal cord, esophagus, and uninvolved lung. There are now numerous studies showing dosimetric advantages of PBT in early and locally advanced NSCLC, particularly in the heart and lung doses. Randomized data comparing clinical outcomes between proton and photon radiation are limited to a small number of studies. Despite early results suggesting improvements or at least comparable outcomes with PBT, the most recent randomized comparisons have failed to show significant differences in toxicity and local control between photon and proton therapy. As newer PBT techniques (e.g., intensity-modulated proton therapy) are increasingly utilized, more dramatic improvements in tumor control and toxicity may be demonstrated. It is also important to recognize that there may be certain subpopulations in which the benefits of proton therapy are greater, such as central early-stage tumors, previously irradiated tumors, and locally advanced tumors, while others may best be treated with traditional photon techniques. As immunotherapy becomes more prevalent in the treatment of NSCLC, improving local control and limiting the toxicity contributed by radiation will be increasingly important. The unique dosimetric advantages of PBT may allow for tumor dose escalation while maintaining normal tissue doses to improve local control, or treating the tumor to the standard dose while decreasing normal tissue doses to improve toxicity. Finally, given the high costs of proton therapy, where low insurance approval rates have limited trial enrollment, it will be important to determine the overall cost-benefit ratio. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1527-2729 -SN - 1534-6277 -DA - 2018 DEC -PY - 2018 -VL - 19 -IS - 12 -C7 - 76 -DO - 10.1007/s11864-018-0588-z -AN - WOS:000451413700001 -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA -Y2 - 2018-12-28 -ER - - -TY - JOUR -AU - Vrana, D -TI - Advances in the therapy of small cell lung cancer. -T2 - Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti -M3 - Journal Article -M3 - Review -AB - Small cell lung cancer represents a disease with poor prognosis. Despite rapid progress in the fields of medical or radiation oncology, the treatment strategy of the small cell lung cancer has remained almost unchanged for over the last 30 years. Prophylactic cranial irradiation and irradiation of the primary lung tumor according to CREST clinical trial improved the median overall survival in months. Until the launch on immunotherapy, the systemic treatment didnt make significant progress, unfortunately including targeted therapy. Immunotherapy significantly changed the treatment outcomes of the several tumor types and finally even the prognosis of small cell lung cancer. Clinical trials with atezolizumab and durvalumab have further moved forward the median overall survival by more than 2 months without significant increase in the treatment toxicity and worsening of the patients quality of life. In the combination with chemotherapy, atezolizumab and durvalumab represents a new gold standard in the treatment of small cell lung cancer. -SN - 1802-5307 -DA - 2021 -PY - 2021 -VL - 34 -IS - Supplementum 1 -SP - 66 -EP - 70 -DO - 10.48095/ccko2021S66 -AN - MEDLINE:34154332 -Y2 - 2021-06-23 -ER - - -TY - JOUR -AU - Splinter, T A -TI - Therapy for small cell and non-small cell lung cancer. -T2 - Current opinion in oncology -M3 - Journal Article -M3 - Review -AB - This review addresses means for improving treatment results in small cell and non-small cell lung cancer. In small cell lung cancer lactate dehydrogenase and neuron-specific enolase seem to be important prognostic factors that may reflect not only tumor load but also growth rate. Chemotherapy seems to induce or select differentiated cells in small cell lung cancer, which focuses attention on other treatment modalities such as drugs, which can induce terminally differentiated nonproliferating cells. Scheduling of chemotherapy may improve survival, especially in extensive disease patients. Exciting new techniques for tumor targeting by a radiolabelled somatostatin-analogue and radiolabelled murine anti-epidermal growth factor are reported. The possible adverse effect of heterologous blood transfusions on survival after surgery of stage I and II non-small cell lung cancer remains a very important subject for investigation to solve the essential question whether the need for transfusion or the transfusion itself is the adverse prognostic factor. A possible improvement of survival of non-small cell lung cancer patients by chemotherapy should be investigated in patients with an excellent performance score and a small tumor load, eg, stage IIIa and IIIb patients. Neoadjuvant chemotherapy in such patients may improve survival but a better and especially more uniform design of the trials is urgently needed. Finally, the development of techniques to palliate terminally ill patients quickly and easily by reopening a closed bronchial lumen should be encouraged. -SN - 1040-8746 -DA - 1992 Apr -PY - 1992 -VL - 4 -IS - 2 -SP - 315 -EP - 22 -DO - 10.1097/00001622-199204000-00013 -AN - MEDLINE:1317220 -AD - University Hospital Dijkzigt, Rotterdam, The Netherlands. -Y2 - 1992-04-01 -ER - - -TY - JOUR -AU - Miao, Da -AU - Zhao, Jing -AU - Han, Ying -AU - Zhou, Jiaqi -AU - Li, Xiuzhen -AU - Zhang, Ting -AU - Li, Wen -AU - Xia, Yang -TI - Management of locally advanced non-small cell lung cancer: state of the art and future directions -T2 - CANCER COMMUNICATIONS -M3 - Review -AB - Lung cancer is the second most common and the deadliest type of cancer worldwide. Clinically, non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer; approximately one-third of affected patients have locally advanced NSCLC (LA-NSCLC, stage III NSCLC) at diagnosis. Because of its heterogeneity, LA-NSCLC often requires multidisciplinary assessment. Moreover, the prognosis of affected patients is much below satisfaction, and the efficacy of traditional therapeutic strategies has reached a plateau. With the emergence of targeted therapies and immunotherapies, as well as the continuous development of novel radiotherapies, we have entered an era of novel treatment paradigm for LA-NSCLC. Here, we reviewed the landscape of relevant therapeutic modalities, including adjuvant, neoadjuvant, and perioperative targeted and immune strategies in patients with resectable LA-NSCLC with/without oncogenic alterations; as well as novel combinations of chemoradiation and immunotherapy/targeted therapy in unresectable LA-NSCLC. We addressed the unresolved challenges that remain in the field, and examined future directions to optimize clinical management and increase the cure rate of LA-NSCLC. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2523-3548 -DA - 2024 JAN -PY - 2024 -VL - 44 -IS - 1 -SP - 23 -EP - 46 -DO - 10.1002/cac2.12505 -AN - WOS:001104420600001 -C6 - NOV 2023 -AD - Zhejiang Univ, Dept Resp & Crit Care Med, Key Lab Resp Dis Zhejiang Prov, Sch Med,Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China -AD - Shaoxing Second Hosp, Dept Oncol, Shaoxing, Zhejiang, Peoples R China -AD - Zhejiang Univ, Affiliated Hosp 2, Dept Med Oncol, Sch Med, Hangzhou, Zhejiang, Peoples R China -AD - Ningbo Univ, Affiliated Peoples Hosp, Dept Chemoradiotherapy, Ningbo, Zhejiang, Peoples R China -AD - Jiaxing Univ, Affiliated Hosp, Key Discipline Jiaxing Resp Med Construct Project, Jiaxing Key Lab Precis Treatment Lung Canc, Jiaxing, Zhejiang, Peoples R China -AD - Zhejiang Univ, Affiliated Hosp 2, Dept Pathol, Sch Med, Hangzhou, Zhejiang, Peoples R China -AD - Zhejiang Univ, Affiliated Hosp 2, Dept Radiat Oncol, Sch Med, Hangzhou, Zhejiang, Peoples R China -AD - Zhejiang Univ, Canc Ctr, Hangzhou, Zhejiang, Peoples R China -AD - Zhejiang Univ, Affiliated Hosp 2, Dept Resp & Crit Care Med, Sch Med, Hangzhou 310052, Zhejiang, Peoples R China -M2 - Shaoxing Second Hosp -Y2 - 2023-12-05 -ER - - -TY - JOUR -AU - Chauhan, Ayushi F. -AU - Liu, Stephen V. -TI - Small Cell Lung Cancer: Advances in Diagnosis and Management -T2 - SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE -M3 - Review -AB - Small cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by rapid growth and early spread. It is a highly lethal disease that typically is diagnosed at a late stage. Surgery plays a very small role in this cancer, and management typically involves chemotherapy, delivered with thoracic radiation in early-stage disease. Platinum-based chemotherapy is initially very effective, inducing rapid and often deep responses. These responses, though, are transient, and upon relapse, SCLC is highly refractory to therapy. Immunotherapy has shown promise in delivering meaningful, durable responses and the addition of immunotherapy to first-line chemotherapy has led to the first improvements in survival in decades. Still, the disease remains difficult to manage. Incorporating radiation therapy at specific points in patient management may improve disease control. The development of predictive biomarkers and novel targeted therapies will hopefully improve options for patients in the near future. This review focuses on the current standards of care and future directions. -PU - THIEME MEDICAL PUBL INC -PI - NEW YORK -PA - 333 SEVENTH AVE, NEW YORK, NY 10001 USA -SN - 1069-3424 -SN - 1098-9048 -DA - 2020 JUN -PY - 2020 -VL - 41 -IS - 3 -SP - 435 -EP - 446 -DO - 10.1055/s-0039-1700566 -AN - WOS:000537106400011 -AD - Georgetown Univ, Div Med Oncol, Washington, DC USA -Y2 - 2020-06-01 -ER - - -TY - JOUR -AU - Mulherkar, Ria -AU - Grewal, Amardeep S. -AU - Berman, Abigail T. -TI - Emerging Role of Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer -T2 - CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY -M3 - Article -AB - Non-small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC have locally advanced or metastatic disease at the time of diagnosis. The 5-year overall survival rate for patients with locally advanced NSCLC is 15% to 20%. The traditional treatment paradigm for unresectable locally advanced NSCLC consists of platinum-based chemotherapy with concurrent radiation. Evidence from phase 3 clinical trials has established a role for immunotherapy after chemoradiation, and emerging data continue to elucidate the expanding role of immunotherapy. -PU - MILLENNIUM MEDICAL PUBLISHING, INC -PI - NEW YORK -PA - 611 BROADWAY, STE 310, NEW YORK, NY 10012 USA -SN - 1543-0790 -DA - 2020 APR -PY - 2020 -VL - 18 -IS - 4 -SP - 212 -EP - 217 -AN - WOS:000523364200009 -AD - Hosp Univ Penn, Dept Radiat Oncol, 3400 Spruce St, Philadelphia, PA 19104 USA -Y2 - 2020-04-14 -ER - - -TY - JOUR -AU - Verma, Vivek -AU - Choi, J. Isabelle -AU - Simone, Charles B., II -TI - Proton therapy for small cell lung cancer -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - The prognosis of limited-stage small cell lung cancer (LS-SCLC) continues to improve and is now roughly comparable to that of locally advanced non-small cell lung cancer (NSCLC). This shift, taken together with the decreased toxicities of modern radiotherapy (RT) for LS-SCLC compared with those reported in historical trials, necessitates further evaluation of whether proton beam therapy (PBT) could further reduce both acute and late toxicities for patients receiving concurrent chemoradiotherapy forLSSCLC. These notions are discussed theoretically, with an emphasis on cardiac events. This is followed by a review of the published evidence to date demonstrating improved dosimetry with PBT over intensity-modulated RT and encouraging safety and efficacy profiles seen in early clinical reports. In addition to covering technical aspects of PBT for LS-SCLC such as intensity-modulated PBT, image-guidance for PBT, and adaptive planning, this review also discusses the need for increased data on intensity-modulated PBT for LS-SCLC, economic and quality of life analyses for future PBT SCLC studies, careful categorization of cardiac events in these patients, and the role for immunotherapy combined with photon-or proton-based RT for LS-SCLC. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2018 APR -PY - 2018 -VL - 7 -IS - 2 -SP - 134 -EP - 140 -DO - 10.21037/tlcr.2018.04.02 -AN - WOS:000431617800005 -AD - Univ Nebraska Med Ctr, Dept Radiat Oncol, Omaha, NE USA -AD - Univ Maryland, Med Ctr, Dept Radiat Oncol, Baltimore, MD 21201 USA -Y2 - 2018-12-28 -ER - - -TY - JOUR -AU - Leal, Jose Luis -AU - John, Thomas -TI - Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options -T2 - CLINICAL LUNG CANCER -M3 - Review -AB - The treatment paradigm of non-small-cell lung cancer without oncogenic drivers has varied dramatically in recent years and is constantly evolving. Immune-checkpoint inhibitors have demonstrated unprecedented durable efficacy in a subset of these patients, so these drugs have become the standard of care in most cases. There are different ways to deliver these agents, such as monotherapy and combinations of immunotherapy or chemotherapy plus immunother-apy. Treatment selection is complicated by an absence of head-to-head comparisons in randomized trials because these agents have gained approval by demonstrating super ior ity to platinum-doublet chemotherapy alone. Unfortu-nately, most patients will progress and die from their disease despite advances. Furthermore, after progression on these agents, there is a lack of randomized controlled data to support further management, constituting an unmet need. This review discusses the therapeutic alternatives after progression, summarizes mechanisms of resistance and progression patterns, and describes the main approaches under clinical investigation in the field. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2022 DEC -PY - 2022 -VL - 23 -IS - 8 -SP - 643 -EP - 658 -DO - 10.1016/j.cllc.2022.08.009 -AN - WOS:000905581000012 -C6 - NOV 2022 -AD - Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia -AD - Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia -AD - Peter MacCallum Canc Ctr, 305 Grattan St, Melbourne, Vic 3000, Australia -Y2 - 2023-01-16 -ER - - -TY - JOUR -AU - Han, Chong -AU - Qiu, Jingping -AU - Bai, Lu -AU - Liu, Tingting -AU - Chen, Jun -AU - Wang, He -AU - Dang, Jun -TI - Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Article -AB - Purpose: Chemoradiotherapy (CRT) combined with immune checkpoint inhibitors (ICIs) is the standard of care for patients with unresectable and locally advanced non-small cell lung cancer. This study aimed to determine whether the addition of ICIs to CRT is associated with an increased risk of pneumonitis. Methods and Materials: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published between January 1, 2015, and July 31, 2023. The outcome of interest was the incidence rate of pneumonitis. A random-effects model was used for statistical analysis. Results: A total of 185 studies with 24,527 patients were included. The pooled rate of grade >= 2 pneumonitis for CRT plus ICIs was significantly higher than that for CRT alone (29.6%; 95% CI, 25.7%-33.6% vs 20.2%; 95% CI, 17.7%-22.8%; P < .0001) but not that of grade >= 3 (5.7%; 95% CI, 4.8%-6.6% vs 5.6%; 95% CI, 4.7%-6.5%; P = .64) or grade 5 (0.1%; 95% CI, 0.0%-0.2% vs 0.3%; 95% CI, 0.1%-0.4%; P = .68). The results from the subgroup analyses of prospective studies, retrospective studies, Asian and non-Asian studies, concurrent CRT (cCRT), and durvalumab consolidation were comparable to the overall results. However, CRT or cCRT plus PD-1 inhibitors not only significantly increased the incidence of grade >= 2 but also that of grade >= 3 pneumonitis compared to CRT alone or cCRT plus PD-L1 inhibitors. Conclusions: Compared with CRT alone, durvalumab consolidation after CRT appears to be associated with a higher incidence of moderate pneumonitis and CRT plus PD-1 inhibitors with an increased risk of severe pneumonitis. Nevertheless, these findings are based on observational studies and need to be validated in future large head-to-head studies. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2024 JAN 28 -PY - 2024 -VL - 119 -IS - 4 -SP - 1179 -EP - 1207 -DO - 10.1016/j.ijrobp.2024.01.217 -AN - WOS:001258729500001 -C6 - JUN 2024 -AD - China Med Univ, Hosp 1, Dept Radiat Oncol, Shenyang, Peoples R China -AD - Anshan Canc Hosp, Dept Radiat Oncol, Anshan, Peoples R China -AD - Shenyang Tenth Peoples Hosp, Dept Radiat Oncol, Shenyang, Peoples R China -M2 - Anshan Canc Hosp -M2 - Shenyang Tenth Peoples Hosp -Y2 - 2024-07-08 -ER - - -TY - JOUR -AU - Kim, Dowook -AU - Kim, Hak Jae -AU - Wu, Hong-Gyun -AU - Lee, Joo Ho -AU - Kim, Suzy -AU - Kim, Tae Min -AU - Kim, Jin-Soo -AU - Kim, Byoung Hyuck -TI - Intrathoracic Progression Is Still the Most Dominant Failure Pattern after First-Line Chemo-immunotherapy in Extensive-Stage Small-Cell Lung Cancer: Implications for Thoracic Radiotherapy -T2 - CANCER RESEARCH AND TREATMENT -M3 - Article -AB - Purpose This study aimed to compare the failure patterns before and after the introduction of immunotherapy and to determine the role of thoracic radiotherapy (TRT) in extensive -stage small -cell lung cancer (ES-SCLC) treatment. Materials and Methods We retrospectively reviewed 294 patients with ES-SCLC, of which 62.2% underwent chemotherapy alone, 13.3% underwent chemotherapy followed by consolidative TRT (TRT group), and 24.5% underwent chemotherapy with immune checkpoint inhibitor (ICI group). We performed propensity -score matching (PSM) to compare each treatment group. Results The median follow-up duration was 10.4 months. At the first relapse, in the cohort showing objective response, the proportion of cases showing intrathoracic progression was significantly lower in the TRT group (37.8%) than in the chemotherapy -alone (77.2%, p < 0.001) and the ICI (60.3%, p=0.03) groups. Furthermore, in the subgroup analysis, TRT showed benefits related to intrathoracic progression -free survival (PFS) in comparison with ICI in patients with less than two involved extrathoracic sites (p=0.008) or without liver metastasis (p=0.02) or pleural metastasis (p=0.005) at diagnosis. After PSM, the TRT group showed significantly better intrathoracic PFS than both chemotherapy -alone and ICI groups (p < 0.001 and p=0.04, respectively), but showed no significant benefit in terms of PFS and overall survival in comparison with the ICI group (p=0.17 and p=0.31, respectively). Conclusion In ES-SCLC, intrathoracic progression was the most dominant failure pattern after immunotherapy. In the era of chemoimmunotherapy, consolidative TRT can still be considered a useful treatment strategy for locoregional control. -PU - KOREAN CANCER ASSOCIATION -PI - SEOUL -PA - RM 1824, GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 110-999, SOUTH KOREA -SN - 1598-2998 -SN - 2005-9256 -DA - 2024 APR -PY - 2024 -VL - 56 -IS - 2 -SP - 430 -EP - 441 -DO - 10.4143/crt.2023.931 -AN - WOS:001208949300019 -AD - Chungnam Natl Univ Hosp, Dept Radiat Oncol, Daejeon, South Korea -AD - Seoul Natl Univ, Dept Radiat Oncol, Coll Med, Seoul, South Korea -AD - Seoul Natl Univ, Canc Res Inst, Seoul, South Korea -AD - Seoul Natl Univ Hosp, Dept Radiat Oncol, Seoul, South Korea -AD - Seoul Natl Univ, Dept Radiat Oncol, Boramae Med Ctr, Seoul Metropolitan Govt, Seoul, South Korea -AD - Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea -AD - Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Seoul, South Korea -AD - Seoul Natl Univ, Coll Med, Dept Radiat Oncol, Seoul Metropolitan Govt,Boramae Med Ctr, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea -Y2 - 2024-06-07 -ER - - -TY - JOUR -AU - Senan, Suresh -AU - Okamoto, Isamu -AU - Lee, Gyeong-Won -AU - Chen, Yuanbin -AU - Niho, Seiji -AU - Mak, Gabriel -AU - Yao, Wenliang -AU - Shire, Norah -AU - Jiang, Haiyi -AU - Cho, Byoung Chul -TI - Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - Limited-stage (LS) small-cell lung cancer (SCLC) remains an area of high unmet medical need. The standard-of-care therapy comprises curative-intent platinum-based chemotherapy with concurrent radiotherapy (cCRT), which can be followed by prophylactic brain irradiation and then observation. However, most patients will relapse. Durvalumab (antiprogrammed cell death ligand-1) has enhanced the efficacy outcomes after cCRT for patients with unresectable, stage III non-small-cell lung cancer. Recently, durvalumab combined with platinum-etoposide demonstrated a significant survival benefit compared with platinum-etoposide as first-line treatment of patients with extensive-stage SCLC and has also shown antitumor activity as monotherapy and combined with tremelimumab (anticytotoxic T-lymphocyte eassociated antigen-4) in pretreated patients with extensive-stage SCLC. ADRIATIC, a phase III, randomized, double-blind, placebo-controlled, multicenter, global study (ClinicalTrials.gov identifier, NCT03703297), is designed to investigate the efficacy of durvalumab, with or without tremelimumab, as consolidation therapy for patients with LS-SCLC without disease progression after cCRT. Approximately 600 patients with documented histologic or cytologic LS-SCLC, World Health Organization/Eastern Cooperative Oncology Group performance status 0 or 1, and no progression after 4 cycles of cCRT will be randomized (1:1:1) to treatment (durvalumab 1500 mg plus placebo every 4 weeks [q4w] for 4 cycles, followed by durvalumab 1500 mg q4w; durvalumab 1500 mg plus tremelimumab 75 mg q4w for 4 cycles, followed by durvalumab 1500 mg q4w; or dual placebo q4w for 4 cycles, followed by single placebo q4w) within 1 to 42 days of completing cCRT, stratified by stage and receipt of prophylactic brain irradiation. The primary endpoints are progression-free survival and overall survival. The secondary endpoints are overall survival and progression-free survival rates, objective response rate, and safety and tolerability. Recruitment began in September 2018. (C) 2020 Published by Elsevier Inc. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2020 MAR -PY - 2020 -VL - 21 -IS - 2 -SP - E84 -EP - E88 -DO - 10.1016/j.cllc.2019.12.006 -AN - WOS:000518474100010 -AD - Vrije Univ Amsterdam, Amsterdam Univ, Canc Ctr Amsterdam, Dept Radiat Oncol,Med Ctr, Amsterdam, Netherlands -AD - Kyushu Univ, Grad Sch Med Sci, Res Inst Dis Chest, Fukuoka, Japan -AD - Gyeongsang Natl Univ, Gyeongsang Natl Univ Hosp, Dept Internal Med, Coll Med, Jinju, Gyeongsang, South Korea -AD - Canc & Hematol Ctr Western Michigan, Grand Rapids, MI USA -AD - Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan -AD - AstraZeneca, Gaithersburg, MD USA -AD - Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea -M2 - Canc & Hematol Ctr Western Michigan -Y2 - 2020-03-24 -ER - - -TY - JOUR -AU - Chae, Young Kwang -AU - Arya, Ayush -AU - Iams, Wade -AU - Cruz, Marcelo R. -AU - Chandra, Sunandana -AU - Choi, Jaehyuk -AU - Giles, Francis -TI - Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) -T2 - JOURNAL FOR IMMUNOTHERAPY OF CANCER -M3 - Review -AB - Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens. Preliminary trials assessing combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 immune-checkpoint inhibitors have documented considerable advantages in survival indices over single-agent immunotherapy. The therapeutic potential of combinatorial approaches is highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients with advanced melanoma. Presently, dual-immune checkpoint inhibition with anti-programmed death receptor-1/programmed cell death receptor-ligand-1 (anti-PD-1/PD-L1) plus anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) monoclonal antibodies (MoAbs) is being evaluated for a wide range of tumor histologies. Furthermore, several ongoing clinical trials are investigating combination checkpoint inhibition in association with traditional treatment modalities such as chemotherapy, surgery, and radiation. In this review, we summarize the current landscape of combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 MoAbs for patients with melanoma and non-small cell lung cancer (NSCLC). We present a synopsis of the prospects for expanding the indications of dual immune-checkpoint inhibition therapy to a more diverse set of tumor histologies. -PU - BIOMED CENTRAL LTD -PI - LONDON -PA - 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND -SN - 2051-1426 -DA - 2018 MAY 16 -PY - 2018 -VL - 6 -C7 - 39 -DO - 10.1186/s40425-018-0349-3 -AN - WOS:000432557700001 -AD - Div Hematol Oncol, Dev Therapeut Program, Early Phase Clin Trials Unit, 645 N Michigan Ave,Suite 1006, Chicago, IL 60611 USA -AD - Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, 645 N Michigan Ave,Suite 1006, Chicago, IL 60611 USA -AD - Northwestern Univ, Feinberg Sch Med, 645 N Michigan Ave,Suite 1006, Chicago, IL 60611 USA -M2 - Div Hematol Oncol -Y2 - 2018-05-16 -ER - - -TY - JOUR -AU - Yang, Linlin -AU - Li, Butuo -AU - Xu, Yiyue -AU - Zou, Bing -AU - Fan, Bingjie -AU - Wang, Chunni -AU - Wang, Linlin -TI - Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis -T2 - FUTURE ONCOLOGY -M3 - Review -AB - Plain language summaryCombined immune checkpoint inhibitors (ICI) and chemoradiotherapy (CRT) may cause severe pneumonitis due to overlapped pulmonary toxicity. However, the safety data on pneumonitis are limited to a small number of prospective clinical trials and retrospective studies with limited evidence. Thus we conducted a systematic review of pneumonitis in relation to the combination treatment. A total of 35 studies, involving 5000 patients, were included for the final analysis. The pooled rates of all-grade, grade 3-5 and grade 5 pneumonitis were 33.0, 6.1 and 0.8%, respectively, and 7.6% of patients stopped taking ICIs because of pneumonitis. The pneumonitis rates following combined CRT and ICIs for LA-NSCLC were acceptable, but the pulmonary toxicity of concurrent CRT and nivolumab plus ipilimumab should be noted.Aims: This study systematically evaluated cases of pneumonitis following combined immune checkpoint inhibitors (ICI) and chemoradiotherapy (CRT) for locally advanced non-small-cell lung cancer (LA-NSCLC). Methods: Studies from Embase, PubMed and the Cochrane Library on patients with LA-NSCLC who received CRT and ICIs were reviewed. The primary outcomes were rates of all-grade, grade 3-5 and grade 5 pneumonitis. Results: Overall, 35 studies involving 5000 patients were enrolled. The pooled rates of all-grade, grade 3-5 and grade 5 pneumonitis were 33.0% (95% CI: 23.5-42.6), 6.1% (95% CI: 4.7-7.4) and 0.8% (95% CI: 0.3-1.2), respectively, with 7.6% of patients discontinuing ICIs because of pneumonitis. Conclusion: The incidence rates of pneumonitis following combined CRT and ICIs for LA-NSCLC were acceptable. However, the pulmonary toxicity of concurrent CRT and nivolumab plus ipilimumab should be noted. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1479-6694 -SN - 1744-8301 -DA - 2023 MAY -PY - 2023 -VL - 19 -IS - 16 -SP - 1151 -EP - 1160 -DO - 10.2217/fon-2022-1274 -AN - WOS:001002522100001 -C6 - JUN 2023 -AD - Shandong First Med Univ, Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan 250117, Peoples R China -Y2 - 2023-06-16 -ER - - -TY - JOUR -AU - Prasad, Rahul N. -AU - Williams, Terence M. -TI - A narrative review of toxicity of chemoradiation and immunotherapy for unresectable, locally advanced non-small cell lung cancer -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Despite declining smoking rates, lung cancer remains the second most common malignancy in the United States and the leading cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) comprises roughly 85% of cases, and patients tend to present with advanced disease. Historically, concurrent chemoradiotherapy (CRT) has been the standard of care for stage III unresectable NSCLC but outcomes even with multimodal therapy have remained relatively poor. Efforts to improve outcomes through radiation dose escalation with conventional dose fractionation were unsuccessful with RTOG 0617, demonstrating significantly decreased overall survival (OS) with high dose radiation with respect to standard therapy. The recent PACIFIC trial established a new role for consolidative immune checkpoint blockade therapy after CRT using the programmed death ligand 1 (PD-L1) inhibitor durvalumab, by demonstrating significantly improved progression free survival and OS. Although promising, the addition of immunotherapy to multimodal therapy has generated debate regarding the most effective immune pathways to target, appropriate sequencing of therapy, most effective radiation techniques, and toxicity-related concerns. This review will highlight recent and ongoing trials in unresectable, locally advanced NSCLC that incorporate chemotherapy, radiation, and immunotherapy with an emphasis on analysis of treatment-related toxicities and implications for future study design. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2020 OCT -PY - 2020 -VL - 9 -IS - 5 -SP - 2040 -EP - 2050 -DO - 10.21037/tlcr-20-638 -AN - WOS:000582799700034 -AD - Ohio State Univ, Ctr Comprehens Canc, Dept Radiat Oncol, Arthur G James Canc Hosp, Columbus, OH 43210 USA -AD - Richard J Solove Res Inst, Columbus, OH 43210 USA -Y2 - 2020-11-11 -ER - - -TY - JOUR -AU - Kubo, Nobuteru -AU - Kobayashi, Daijiro -AU - Iwanaga, Mototaro -AU - Matsuura, Masana -AU - Higuchi, Keiko -AU - Eishima, Jun -AU - Muramatsu, Hiroyuki -AU - Okano, Naoko -AU - Shioya, Mariko -AU - Onishi, Masahiro -AU - Aoki, Tetsuya -AU - Oike, Takahiro -AU - Ohno, Tatsuya -A1 - Gunma Soc Radiation Oncology GUSTR -TI - Radiotherapy Patterns of Care for Locally-advanced Non-small Cell Lung Cancer in the Pre- and Post-durvalumab Era: A Region-wide Survey in a Japanese Prefecture -T2 - JOURNAL OF RADIATION RESEARCH -M3 - Article -AB - The promising results of the PACIFIC study led to the approval of consolidation durvalumab for coverage by the National Health Insurance (NHI) in 2018 for patients with locally-advanced unresectable non-small cell lung carcinoma (NSCLC) treated with definitive concurrent chemoradiotherapy (CCRT). However, the effect of NHI coverage on the patterns of care for this population remains unclear. Here, we conducted a questionnaire-based survey to determine the patterns of care for patients with stage II-III NSCLC treated with definitive radiotherapy in 2017 (pre-durvalumab era) or in 2019 (post-durvalumab era). Data were obtained from 11 radiotherapy facilities in Gunma prefecture, which has a population of 1.94 million. We identified 80 and 83 patients with stage II-III NSCLC who received definitive radiotherapy in Gunma in 2017 and 2019, respectively. At a given facility, CCRT was the treatment of choice in a significantly greater proportion of patients in 2019 than in 2017 (66% +/- 20% vs 51% +/- 29%, P = 0.041). Intensity-modulated radiotherapy (IMRT) was more frequent in 2019 than in 2017 (24% vs 1.2%). Carboplatin plus paclitaxel was used for CCRT at higher rate in 2019 than in 2017 (73% vs 44%). Consolidation durvalumab was performed in 73% (40/55) of CCRT-treated patients in 2019, and the treatment was performed for the planned 12 months in 45% (18/40) of patients. These data indicate that NHI coverage of durvalumab might be a possible reason for choosing CCRT in patients with stage II-III NSCLC in the real-world setting. -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 0449-3060 -SN - 1349-9157 -DA - 2022 MAR 17 -PY - 2022 -VL - 63 -IS - 2 -SP - 264 -EP - 271 -DO - 10.1093/jrr/rrab116 -AN - WOS:000764637300001 -C6 - DEC 2021 -AD - Gunma Univ, Dept Radiat Oncol, Grad Sch Med, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan -AD - Gunma Univ, Heavy Ion Med Ctr, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan -AD - Gunma Prefectural Canc Ctr, Dept Radiat Oncol, 617-1 Takahayashi Nishicho, Ota, Gunma 3738550, Japan -AD - Japanese Red Cross Maebashi Hosp, Dept Radiat Oncol, 389-1 Asakura Machi, Maebashi, Gunma 3710811, Japan -AD - Natl Hosp Org, Dept Radiat Therapy, Shibukawa Med Ctr, 383 Shirai, Shibukawa, Gunma 3770280, Japan -AD - Isesaki City Hosp, Dept Radiat Oncol, 12-1 Tsunatorimoto Machi, Isesaki, Gunma 3720817, Japan -AD - Natl Hosp Org, Dept Radiat Oncol, Takasaki Gen Med Ctr, 36 Takamatsu Cho, Takasaki, Gumma 3700829, Japan -AD - Kiryu Kosei Gen Hosp, Dept Radiol, 6-3 Orihime Cho, Kiryu, Gunma 3760024, Japan -AD - Publ Tomioka Gen Hosp, Dept Radiotherapy, 2073-1 Tomioka, Tomioka, Gunma, Japan -AD - Fujioka Gen Hosp, Dept Radiat Oncol, 813-1 Nakakurisu, Fujioka, Gunma 3758503, Japan -AD - Hidaka Hosp, Oncol Ctr, 886 Nakao Machi, Takasaki, Gumma 3700001, Japan -AD - Tatebayashi Kosei Gen Hosp, Dept Radiat Oncol, 262-1 Narushima Cho, Tatebayashi, Gunma 3748533, Japan -M2 - Gunma Prefectural Canc Ctr -M2 - Natl Hosp Org -M2 - Isesaki City Hosp -M2 - Natl Hosp Org -M2 - Kiryu Kosei Gen Hosp -M2 - Publ Tomioka Gen Hosp -M2 - Fujioka Gen Hosp -M2 - Hidaka Hosp -M2 - Tatebayashi Kosei Gen Hosp -Y2 - 2022-03-14 -ER - - -TY - JOUR -AU - Ilhan, Yusuf -AU - Ucar, Gokhan -AU - Baser, Mehmet Nuri -AU - Guzel, Halil Goksel -AU - Efil, Safa Can -AU - Demir, Bilgin -AU - Uzundal, Duygu Ercan -AU - Karacelik, Tuba -AU - Sever, Nadiye -AU - Balcik, Onur Yazdan -AU - Arvas, Hayati -AU - Karadag, Ibrahim -AU - Kadioglu, Ahmet -AU - Ekinci, Omer Burak -AU - Karacin, Cengiz -AU - Urakci, Zuhat -AU - Kostek, Osman -AU - Eryilmaz, Melek Karakurt -AU - Yazici, Ozan -AU - Sendur, Mehmet Ali Nahit -AU - Ozturk, Banu -AU - Uncu, Dogan -AU - Ergun, Yakup -TI - Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy -T2 - EXPERT OPINION ON PHARMACOTHERAPY -M3 - Article -AB - ObjectivesWe aimed to evaluate the efficacy and safety of granulocyte-colony stimulating factor (G-CSF) prophylaxis during chemoimmunotherapy with carboplatin plus etoposide and atezolizumab in extensive-stage small cell lung cancer (ES-SCLC).MethodsThis retrospective, multicenter study enrolled ES-SCLC patients receiving carboplatin plus etoposide and atezolizumab, categorized into G-CSF and non-G-CSF groups. Demographic and disease-related data were collected. Response rates, progression-free survival (PFS), overall survival (OS), and toxicity were analyzed.ResultsOf 119 patients (median age: 63 years), the overall response rate (ORR) and disease control rate (DCR) were 72.3% and 81.5%, respectively. In the G-CSF group, the ORR was 76.4% compared to 60.0% in the non-G-CSF group (p = 0.33), and the DCR was 85.4% versus 70.0%, respectively (p = 0.46). Median PFS was 8.3 months (95% CI, 6.8-9.8) in the G-CSF group and 6.8 months (95% CI, 6.2-7.5) in the non-G-CSF group (p = 0.24). Median OS was 13.8 months (95% CI, 9.6-18.1) for the G-CSF group and 10.6 months (95% CI, 7.9-13.3) for the non-G-CSF group (p = 0.47). Grade 3 >= adverse events were similar between groups (49.4% vs. 33.3%, respectively, p = 0.12).ConclusionG-CSF prophylaxis can be safely used in ES-SCLC patients undergoing carboplatin plus etoposide and atezolizumab regimen without significantly altering efficacy or increasing toxicity. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1465-6566 -SN - 1744-7666 -DA - 2024 JUL 23 -PY - 2024 -VL - 25 -IS - 11 -SP - 1555 -EP - 1563 -DO - 10.1080/14656566.2024.2391007 -AN - WOS:001289341300001 -C6 - AUG 2024 -AD - Antalya City Hosp, Dept Med Oncol, 5379 St, TR-07080 Antalya, Turkiye -AD - Ankara Bilkent City Hosp, Dept Med Oncol, Ankara, Turkiye -AD - Adnan Menderes Univ, Dept Med Oncol, Aydin, Turkiye -AD - Hlth Sci Univ, Antalya Educ & Res Hosp, Dept Med Oncol, Antalya, Turkiye -AD - Gazi Univ, Fac Med, Dept Med Oncol, Ankara, Turkiye -AD - Necmettin Erbakan Univ, Fac Med, Dept Med Oncol, Konya, Turkiye -AD - Marmara Univ, Fac Med, Dept Med Oncol, Istanbul, Turkiye -AD - Mardin Training & Res Hosp, Dept Med Oncol, Mardin, Turkiye -AD - Dicle Univ, Fac Med, Dept Med Oncol, Diyarbakir, Turkiye -AD - Hitit Univ, Erol Olcok Educ & Res Hosp, Dept Med Oncol, Corum, Turkiye -AD - Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hosp, Dept Med Oncol, Ankara, Turkiye -AD - Cemil Tascioglu City Hosp, Dept Med Oncol, Istanbul, Turkiye -M2 - Antalya City Hosp -M2 - Ankara Bilkent City Hosp -M2 - Mardin Training & Res Hosp -M2 - Cemil Tascioglu City Hosp -Y2 - 2024-08-17 -ER - - -TY - JOUR -AU - Sands, Jacob -AU - Subramanian, Janakiraman -TI - Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting -T2 - FRONTIERS IN ONCOLOGY -M3 - Article -AB - Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive disease with poor 5-year survival. The first-line standard-of-care for ES-SCLC is platinum plus etoposide, along with 1 of the immune checkpoint inhibitors atezolizumab or durvalumab. Although SCLC first-line therapy often leads to rapid responses, treatment becomes more challenging at progression, particularly for those with a chemotherapy-free interval (CTFI) of <= 6 months. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines (R)) for SCLC no longer specify treatment recommendations in this setting, but options approved by the US Food and Drug Administration include topotecan and lurbinectedin. Participation in a clinical trial is recommended as an option regardless of CTFI. Other NCCN-recommended regimens are paclitaxel, irinotecan, temozolomide, and cyclophosphamide/doxorubicin/vincristine, among others. Nivolumab and pembrolizumab are options in those not previously treated with a checkpoint inhibitor. For patients with platinum-sensitive SCLC (CTFI >6 months), preferred treatment per the NCCN Guidelines (R) for SCLC is retreatment with platinum and etoposide, although the use of immune checkpoint inhibitors is discouraged if there is progression on a drug in this class. Further research on immunotherapies and combination regimens is ongoing, and continuing work on the subcharacterization of SCLC may lead to better precision of therapies that promote more durable responses in individual patients with ES-SCLC. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2023 DEC 22 -PY - 2023 -VL - 13 -C7 - 1161931 -DO - 10.3389/fonc.2023.1161931 -AN - WOS:001140938200001 -AD - Dana Farber Canc Inst, Thorac Oncol, Boston, MA USA -AD - St Lukes Canc Inst, Div Oncol, Kansas City, MO 64111 USA -AD - St Lukes Canc Inst, Ctr Precis Oncol, Kansas City, MO 64111 USA -M2 - St Lukes Canc Inst -M2 - St Lukes Canc Inst -Y2 - 2024-01-20 -ER - - -TY - JOUR -AU - Li, Ji -AU - Wang, Min -AU - Xu, Shuhui -AU - Li, Yuying -AU - Li, Jiatong -AU - Yu, Jinming -AU - Zhu, Hui -TI - The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC -T2 - FRONTIERS IN PHARMACOLOGY -M3 - Review -AB - Brain metastases are more and more common among patients with non-small cell lung cancer (NSCLC). TKI therapy could provide ideal outcomes for patients harboring epidermal growth factor receptor or ALK mutations. For wild-type patients, however, survival is poor because there are few effective treatments other than radiotherapy. Immune checkpoint inhibitors (ICIs) have changed the management of advanced NSCLC. However, the exclusion of patients with active brain metastasis (BM) from most ICI trials precludes the generalization of results. Accordingly, a variety of appropriate real-world studies and clinical trials are being developed to evaluate tumor response. Increasingly encouraging results have suggested that ICIs could be active in the central nervous system (CNS) in select patients with high PD-L1 expression and low CNS disease burden. With the extensive use of ICIs in NSCLC patients with BM, many important questions have emerged concerning issues such as the clinical response to a single ICI, use of ICIs combined with chemotherapy or radiation, the biological mechanism and appropriate sequencing of local and systemic therapy combinations, and safety and toxicity. The present review summarizes the advances in systemic ICIs for the treatment of NSCLC patients with BM, discusses factors associated with efficacy and toxicity, and explores future directions. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1663-9812 -DA - 2022 MAY 17 -PY - 2022 -VL - 13 -C7 - 841623 -DO - 10.3389/fphar.2022.841623 -AN - WOS:000804986100001 -AD - Renmin Hosp Wuhan Univ, Dept Oncol, Wuhan, Peoples R China -AD - Shandong First Med Univ, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China -AD - Shandong Acad Med Sci, Jinan, Peoples R China -AD - Shandong Univ, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China -Y2 - 2022-06-11 -ER - - -TY - JOUR -AU - Parekh, Jay -AU - Parikh, Kaushal -AU - Reuss, Joshua E. -AU - Friedlaender, Alex -AU - Addeo, Alfredo -TI - Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer -T2 - CURRENT ONCOLOGY REPORTS -M3 - Review -AB - Purpose of Review For decades, early-stage resectable non-small cell lung cancer (NSCLC), while potentially curable, has been marred by unacceptably high recurrence rates.Recent Findings Anti-PD(L)1 immune checkpoint blockade (ICB) has revolutionized the treatment of advanced NSCLC, and with recent approvals in the peri-operative space, is now poised to transform the systemic treatment paradigm for localized and locally-advanced NSCLC.Summary In this review, we focus on neoadjuvant ICB in resectable NSCLC, highlighting the pre-clinical rationale for neoadjuvant ICB, early clinical trials, randomized phase 3 trial data, and future directions for resectable NSCLC. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1523-3790 -SN - 1534-6269 -DA - 2023 AUG -PY - 2023 -VL - 25 -IS - 8 -SP - 913 -EP - 922 -DO - 10.1007/s11912-023-01430-4 -AN - WOS:000999612300001 -C6 - MAY 2023 -AD - Yale New Haven Hlth Syst, Bridgeport Hosp, Bridgeport, CT USA -AD - Mayo Clin, Rochester, MN USA -AD - Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA -AD - Clin Gen Beaulieu, Geneva, Switzerland -AD - Univ Hosp Geneva, Geneva, Switzerland -M2 - Georgetown Lombardi Comprehens Canc Ctr -M2 - Clin Gen Beaulieu -Y2 - 2023-06-27 -ER - - -TY - JOUR -AU - Tao, D. -AU - Sun, L. -AU - Wang, L. L. -AU - Yang, D. -AU - Jiang, Y. -AU - Zhou, W. -AU - Wang, Y. -AU - Wu, Y. Z. -TI - Early Stereotactic Body Radiotherapy to the Primary Lung Lesion for Patients with Advanced NSCLC Treated with First-Line Systemic Therapy -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 1076 -SP - S128 -EP - S128 -AN - WOS:001079706803253 -AD - Chongqing Univ Canc Hosp, Dept Radiat Oncol, Chongqing, Peoples R China -AD - Chongqing Univ Canc Hosp, Radiat Oncol Ctr, Chongqing, Peoples R China -M2 - Chongqing Univ Canc Hosp -M2 - Chongqing Univ Canc Hosp -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Domine, M. -AU - Moran, T. -AU - Isla, D. -AU - Marti, J. L. -AU - Sullivan, I. -AU - Provencio, M. -AU - Olmedo, M. E. -AU - Ponce, S. -AU - Blasco, A. -AU - Cobo, M. -TI - SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019) -T2 - CLINICAL & TRANSLATIONAL ONCOLOGY -M3 - Article -AB - Small-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients are diagnosed at limited stage. The median survival remains to be around 15-20 months without significative changes in the strategies of treatment for many years. In stage I and IIA, the standard treatment is the surgery followed by adjuvant therapy with platinum-etoposide. In stage IIB-IIIC, the recommended treatment is early concurrent chemotherapy with platinum-etoposide plus thoracic radiotherapy followed by prophylactic cranial irradiation in patients without progression. However, in the extensive stage, significant advances have been observed adding immunotherapy to platinum-etoposide chemotherapy to obtain a significant increase in overall survival, constituting the new recommended standard of care. In the second-line treatment, topotecan remains as the standard treatment. Reinduction with platinum-etoposide is the recommended regimen in patients with sensitive relapse (>= 3 months) and new drugs such as lurbinectedin and immunotherapy are new treatment options. New biomarkers and new clinical trials designed according to the new classification of SCLC subtypes defined by distinct gene expression profiles are necessary. -PU - SPRINGER INT PUBL AG -PI - CHAM -PA - GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND -SN - 1699-048X -SN - 1699-3055 -DA - 2020 FEB -PY - 2020 -VL - 22 -IS - 2 -SP - 245 -EP - 255 -DO - 10.1007/s12094-020-02295-w -AN - WOS:000514525700009 -AD - Hosp Univ Fdn Jimenez Diaz, IIS FJD, Oncohealth Inst, Med Oncol Dept, Av Reyes Catol, 2, E-28040 Madrid, Spain -AD - Univ Autonoma Barcelona, Hosp Univ Germans Trias Pujol, Catalan Inst Oncol,Med Oncol Dept, B ARGO,IGTP, Barcelona, Spain -AD - Hosp Clin Univ Lozano Blesa, Med Oncol Dept, Zaragoza, Spain -AD - Hosp Gen Alicante, Med Oncol Dept, Alicante, Spain -AD - Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain -AD - Hosp Univ Puerta Hierro Majadahonda, Med Oncol Dept, Madrid, Spain -AD - Hosp Univ Ramon Cajal, Med Oncol Dept, Madrid, Spain -AD - Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain -AD - Consorcio Hosp Gen Univ Valencia, Med Oncol Dept, CIBERONC, Valencia, Spain -AD - Hosp Reg Univ Malaga Carlos Haya, Med Oncol Dept, Malaga, Spain -M2 - Hosp Reg Univ Malaga Carlos Haya -Y2 - 2020-03-04 -ER - - -TY - JOUR -AU - Megyesfalvi, Zsolt -AU - Gay, Carl M. -AU - Popper, Helmut -AU - Pirker, Robert -AU - Ostoros, Gyula -AU - Heeke, Simon -AU - Lang, Christian -AU - Hoetzenecker, Konrad -AU - Schwendenwein, Anna -AU - Boettiger, Kristiina -AU - Bunn Jr, Paul A. A. -AU - Renyi-Vamos, Ferenc -AU - Schelch, Karin -AU - Prosch, Helmut -AU - Byers, Lauren A. -AU - Hirsch, Fred R. -AU - Dome, Balazs -TI - Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions -T2 - CA-A CANCER JOURNAL FOR CLINICIANS -M3 - Review -AB - Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity. It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority of SCLCs exhibit neuroendocrine features, an important subset of tumors lacks these properties. Genomic profiling of SCLC reveals genetic instability, almost universal inactivation of the tumor suppressor genes TP53 and RB1, and a high mutation burden. Because of early metastasis, only a small fraction of patients are amenable to curative-intent lung resection, and these individuals require adjuvant platinum-etoposide chemotherapy. Therefore, the vast majority of patients are currently being treated with chemoradiation with or without immunotherapy. In patients with disease confined to the chest, standard therapy includes thoracic radiotherapy and concurrent platinum-etoposide chemotherapy. Patients with metastatic (extensive-stage) disease are treated with a combination of platinum-etoposide chemotherapy plus immunotherapy with an anti-programmed death-ligand 1 monoclonal antibody. Although SCLC is initially very responsive to platinum-based chemotherapy, these responses are transient because of the development of drug resistance. In recent years, the authors have witnessed an accelerating pace of biologic insights into the disease, leading to the redefinition of the SCLC classification scheme. This emerging knowledge of SCLC molecular subtypes has the potential to define unique therapeutic vulnerabilities. Synthesizing these new discoveries with the current knowledge of SCLC biology and clinical management may lead to unprecedented advances in SCLC patient care. Here, the authors present an overview of multimodal clinical approaches in SCLC, with a special focus on illuminating how recent advancements in SCLC research could accelerate clinical development. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0007-9235 -SN - 1542-4863 -DA - 2023 NOV -PY - 2023 -VL - 73 -IS - 6 -SP - 620 -EP - 652 -DO - 10.3322/caac.21785 -AN - WOS:001009707000001 -C6 - JUN 2023 -AD - Med Univ Vienna, Comprehens Canc Ctr, Dept Thorac Surg, Vienna, Austria -AD - Semmelweis Univ, Dept Thorac Surg, Budapest, Hungary -AD - Natl Korany Inst Pulmonol, Budapest, Hungary -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA -AD - Med Univ Graz, Diagnost & Res Inst Pathol, Graz, Austria -AD - Med Univ Vienna, Dept Med 1, Vienna, Austria -AD - Med Univ Vienna, Dept Med 2, Div Pulmonol, Vienna, Austria -AD - Univ Colorado, Sch Med, Aurora, CO USA -AD - Med Univ Vienna, Ctr Canc Res, Vienna, Austria -AD - Med Univ Vienna, Vienna Gen Hosp, Dept Biomed Imaging & Image Guided Therapy, Vienna, Austria -AD - Univ Colorado Anschutz Med Campus, Div Med Oncol, Aurora, CO USA -AD - Mt Sinai Hlth Syst, Tisch Canc Inst, Ctr Thorac Oncol, New York, NY 10029 USA -AD - Lund Univ, Dept Translat Med, Lund, Sweden -M2 - Natl Korany Inst Pulmonol -Y2 - 2023-07-01 -ER - - -TY - JOUR -AU - Higgins, Kristin A. -AU - Simone, Charles B., II -AU - Amini, Arya -AU - Chetty, Indrin J. -AU - Donington, Jessica -AU - Edelman, Martin J. -AU - Chun, Stephen G. -AU - Kestin, Larry L. -AU - Movsas, Benjamin -AU - Rodrigues, George B. -AU - Rosenzweig, Kenneth E. -AU - Slotman, Ben J. -AU - Rybkin, Igor I. -AU - Wolf, Andrea -AU - Chang, Joe Y. -TI - American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC -T2 - JOURNAL OF THORACIC ONCOLOGY -M3 - Article -AB - Introduction: The standard-of-care therapy for extensive-stage SCLC has recently changed with the results of two large randomized trials revealing improved survival with the addition of immunotherapy to first-line platinum or etoposide chemotherapy. This has led to a lack of clarity around the role of consolidative thoracic radiation and prophylactic cranial irradiation in the setting of chemoimmunotherapy.Methods: The American Radium Society Appropriate Use Criteria are evidence-based guidelines for specific clinical conditions that are reviewed by a multidisciplinary expert panel. The guidelines include a review and analysis of current evidence with the application of consensus methodology (modified Delphi) to rate the appropriateness of treatments recommended by the panel for extensive-stage SCLC.Results: Current evidence supports either prophylactic cranial irradiation or surveillance with magnetic resonance imaging every 3 months for patients without evidence of brain metastases. Patients with brain metastases should receive whole-brain radiation with a recommended dose of 30 Gy in 10 fractions. Consolidative thoracic radiation can be considered in selected cases with the recommended dose ranging from 30 to 54 Gy; this recommendation was driven by expert opinion owing to the limited strength of evidence, as clinical trials addressing this question remain ongoing.Conclusions: Radiation therapy remains an integral component in the treatment paradigm for ES-SCLC. (C) 2020 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1556-0864 -SN - 1556-1380 -DA - 2021 JAN -PY - 2021 -VL - 16 -IS - 1 -SP - 54 -EP - 65 -DO - 10.1016/j.jtho.2020.09.013 -AN - WOS:000610460000012 -AD - Emory Univ, Winship Canc Inst, Dept Radiat Oncol, 1365 Clifton RD NE, Atlanta, GA 30322 USA -AD - New York Proton Ctr, New York, NY USA -AD - City Hope Comprehens Canc Ctr, Dept Radiat Oncol, Duarte, CA USA -AD - Henry Ford Hlth Syst, Dept Radiat Oncol, Detroit, MI USA -AD - Univ Chicago, Dept Thorac Surg, Chicago, IL 60637 USA -AD - Fox Chase Comprehens Canc Ctr, Dept Med Oncol, Philadelphia, PA USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA -AD - MHP Canc Inst, Dept Radiat Oncol, Pontiac, MI USA -AD - London Hlth Sci Ctr, Dept Radiat Oncol, London, ON, Canada -AD - Mt Sinai Sch Med, Dept Radiat Oncol, New York, NY USA -AD - Amsterdam Univ Med Ctr, Dept Radiat Oncol, Amsterdam, Netherlands -AD - Henry Ford Hlth Syst, Dept Med Oncol, Detroit, MI USA -M2 - New York Proton Ctr -M2 - MHP Canc Inst -M2 - Amsterdam Univ Med Ctr -Y2 - 2021-02-26 -ER - - -TY - JOUR -AU - Yao, Yueyuan -AU - Li, Butuo -AU - Song, Ruiting -AU - Yang, Linlin -AU - Zou, Bing -AU - Wang, Linlin -TI - Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis -T2 - RADIATION ONCOLOGY -M3 - Article -AB - BackgroundPlatinum-etoposide chemotherapy combined with immune checkpoint inhibitors (ICIs) has been recommended as the first-line standard treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, the effect of thoracic radiotherapy (TRT) on these patients is still unknown. This study aimed to evaluate the efficacy and safety of TRT for ES-SCLC patients who responded to first-line ICIs and chemotherapy (CHT).MethodsPatients who received 4 to 6 cycles of ICIs and CHT as first-line therapy at three hospitals between 2018 and 2022 were included in the analysis. All patients were divided into two groups based on whether they received TRT as first-line treatment, and propensity score matching (PSM) was performed to ensure that the characteristics of two groups were well-balanced. The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoint was toxic effects.ResultsA total of 276 patients were included, and the median follow-up time was 22.3 (range, 4.0-53.73) months. After PSM, 197 patients were further analysed, and 99 of whom received TRT. The baseline characteristics were well-balanced between patients in the TRT and non-TRT groups. There were significant differences in PFS between the TRT and non-TRT groups, with the median PFS of 10.76 and 7.63 months, respectively (P = 0.014). Significantly improved OS was observed in the TRT group (21.67 vs. 16.6 months, P = 0.009). In addition, the use of TRT was an independent prognostic factor for PFS and OS of ES-SCLC patients receiving ICIs plus CHT. In terms of safety, no significant increase of any grades adverse event (AE) (P = 0.874) and G3-4 AE (P = 0.909) was observed for patients receiving TRT. Radiation esophagitis, gastrointestinal and hematologic toxicities were the most common AEs in TRT group, which were tolerable. And high-dose radiotherapy was associated with higher incidence of pneumonitis.ConclusionAddition of TRT showed significant survival benefits and well tolerability in ES-SCLC patients receiving platinum-etoposide CHT and ICIs, which could be a feasible first-line treatment strategy for ES-SCLC patients. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1748-717X -DA - 2024 FEB 27 -PY - 2024 -VL - 19 -IS - 1 -C7 - 25 -DO - 10.1186/s13014-024-02420-x -AN - WOS:001173103000001 -AD - Shandong First Med Univ, Shandong Acad Med Sci, Jinan 271016, Shandong, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, 440 Jiyan Rd, Jinan 250117, Peoples R China -Y2 - 2024-03-08 -ER - - -TY - JOUR -AU - Chen, Weilin -AU - Zhang, Haoyi -AU - Huang, Weifeng -AU - Lan, Tingting -TI - A case report of sustained clinical remission in patients with locally advanced lung adenocarcinoma after sequential immunotherapy following concurrent chemoradiotherapy -T2 - ANNALS OF PALLIATIVE MEDICINE -M3 - Article -AB - Lung cancer is the most common cause of cancer-related deaths worldwide. Pathologically, lung cancer can be non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC), while NSCLC accounts for approximately 85% of lung cancer patients. Stage III NSCLC represents a heterogeneous group of disease entities that are potentially curable and are usually dealt with multimodality treatments involving radiotherapy, chemotherapy, and surgical resection. Immune checkpoint inhibitors (ICIs) target programmed cell death receptor-1 (PD-1) and programmed death-ligand 1 (PD-L1). Studies have shown that ICIs have excellent and long-lasting anti-cancer effects in many cancers. The PACIFIC study is the first in the systemic treatment of stage III unresectable NSCLC in the past few decades that both progression-free survival (PFS) and overall survival (OS) have obtained positive results, However, the performance of this treatment strategy remains to be studied in a real-world setting. Such as who will benefit from treatment is still worthy of our continuous exp loration. In this paper, a patient with locally advanced unresectable NSCLC who underwent concurrent chemoradiotherapy followed by sequential immunotherapy (durvalumab) was reported. The patient obtained sustained clinical benefits despite low PD-L1 expression. This case report may serve as a reference for clinicians to make diagnostic and treatment decisions in clinical practice. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2224-5820 -SN - 2224-5839 -DA - 2020 NOV -PY - 2020 -VL - 9 -IS - 6 -SP - 4346 -EP - 4352 -DO - 10.21037/apm-20-1773 -AN - WOS:000595542800071 -AD - Fujian Med Univ, Zhangzhou Affiliated Hosp, Dept Radiat Oncol, Zhangzhou 363000, Peoples R China -Y2 - 2021-01-11 -ER - - -TY - JOUR -AU - Bartolomeo, Valentina -AU - Cortiula, Francesco -AU - Hendriks, Lizza E. L. -AU - De Ruysscher, Dirk -AU - Filippi, Andrea R. -TI - A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Editorial Material -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2024 APR 1 -PY - 2024 -VL - 118 -IS - 5 -SP - 1455 -EP - 1460 -DO - 10.1016/j.ijrobp.2023.11.005 -AN - WOS:001220524600001 -C6 - MAR 2024 -AD - Fdn IRCCS Policlin San Matteo, Radiat Oncol, Pavia, Italy -AD - Univ Pavia, Dept Clin Surg Diag & Pediat Sci, Pavia, Italy -AD - Maastricht Univ, GROW Sch Oncol & Reprod, Dept Radiat Oncol, Maastro Clin,Med Ctr, Maastricht, Netherlands -AD - Udine Univ Hosp, Dept Med Oncol, Udine, Italy -AD - Maastricht Univ, GROW Sch Oncol & Reprod, Dept Pulm Dis, Med Ctr, Maastricht, Netherlands -Y2 - 2024-05-19 -ER - - -TY - JOUR -AU - Wu, Leilei -AU - Zhang, Zhenshan -AU - Bai, Menglin -AU - Yan, Yujie -AU - Yu, Jinming -AU - Xu, Yaping -TI - Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations -T2 - CELL COMMUNICATION AND SIGNALING -M3 - Review -AB - Until the advent of immune checkpoint inhibitors (ICIs), definitive radiotherapy (RT) concurrently with chemotherapy was recommended for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC). The trimodality paradigm with consolidation ICIs following definitive concurrent chemoradiotherapy has been the standard of care since the PACIFIC trial. Preclinical evidence has demonstrated the role of RT in the cancer-immune cycle and the synergistic effect of RT combined with ICIs (iRT). However, RT exerts a double-edged effect on immunity and the combination strategy still could be optimized in many areas. In the context of LA-NSCLC, optimized RT modality, choice, timing, and duration of ICIs, care for oncogenic addicted tumors, patient selection, and novel combination strategies require further investigation. Targeting these blind spots, novel approaches are being investigated to cross the borders of PACIFIC. We discussed the development history of iRT and summarized the updated rationale for the synergistic effect. We then summarized the available research data on the efficacy and toxicity of iRT in LA-NSCLC for cross-trial comparisons to eliminate barriers. Progression during and after ICIs consolidation therapy has been regarded as a distinct resistance scenario from primary or secondary resistance to ICIs, the subsequent management of which has also been discussed. Finally, based on unmet needs, we probed into the challenges, strategies, and auspicious orientations to optimize iRT in LA-NSCLC. In this review, we focus on the underlying mechanisms and recent advances of iRT with an emphasis on future challenges and directions that warrant further investigation. Taken together, iRT is a proven and potential strategy in LA-NSCLC, with multiple promising approaches to further improve the efficacy. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1478-811X -DA - 2023 MAY 23 -PY - 2023 -VL - 21 -IS - 1 -C7 - 119 -DO - 10.1186/s12964-023-01139-8 -AN - WOS:000994289600001 -AD - Tongji Univ, Shanghai Pulm Hosp, Dept Radiat Oncol, Sch Med, Shanghai, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Shandong Prov Key Lab Radiat Oncol, Jinan, Shandong, Peoples R China -AD - Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China -AD - Fudan Univ Canc Hosp, Shanghai Proton & Heavy Ion Ctr, Dept Radiat Oncol, Shanghai, Peoples R China -Y2 - 2023-06-25 -ER - - -TY - JOUR -AU - Kumar, Suraj -AU - Malviya, Rishabha -AU - Uniyal, Prerna -TI - Vaccine for Targeted Therapy of Lung Cancer: Advances and Developments -T2 - CURRENT DRUG TARGETS -M3 - Review -AB - Considering that lung cancer is a leading global perpetrator, novel treatment approaches must be investigated. Due to the broad spectrum of lung cancer, conventional therapies including chemotherapy, radiotherapy, and surgeries, are not always effective and can have adverse consequences. The present study's overarching objective was to enhance the development of a personalized vaccine for targeted lung cancer therapy. Vaccination functions by eliciting a strong and targeted immune response defense by taking advantage of the specific antigens that are expressed by lung cancer cells. Crucial antigens associated with tumor cells have been identified with the recognition of the genetic and immunological circumstances of lung cancer in this review. The vaccine includes these antigens to prime the immune system, directing it toward recognizing and attacking cancerous cells. In this review, we have addressed the possible benefits of a targeted vaccine strategy, which include a reduction in off-target effects and an improvement in health outcomes for patients. These studies highlight the promise of a tailored vaccine in a novel way for the treatment of lung cancer. The integration of molecular profiling and immunological insights offers a rationale for the design and implementation of personalized vaccines. While challenges exist, the promise of improved treatment outcomes and reduced side effects positions targeted vaccine therapy as a compelling avenue for advancing lung cancer treatment. -PU - BENTHAM SCIENCE PUBL LTD -PI - SHARJAH -PA - EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES -SN - 1389-4501 -SN - 1873-5592 -DA - 2024 -PY - 2024 -VL - 25 -IS - 8 -SP - 526 -EP - 529 -DO - 10.2174/0113894501306103240426131249 -AN - WOS:001285268600002 -AD - Galgotias Univ, Sch Med & Allied Sci, Dept Pharm, Greater Noida, UP, India -AD - Graph Era Hill Univ, Sch Pharm, Dehra Dun, India -M2 - Graph Era Hill Univ -Y2 - 2024-08-13 -ER - - -TY - JOUR -AU - ROSE, LJ -TI - NEOADJUVANT AND ADJUVANT THERAPY OF NON-SMALL-CELL LUNG-CANCER -T2 - SEMINARS IN ONCOLOGY -M3 - Article -PU - W B SAUNDERS CO-ELSEVIER INC -PI - PHILADELPHIA -PA - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA -SN - 0093-7754 -SN - 1532-8708 -DA - 1991 DEC -PY - 1991 -VL - 18 -IS - 6 -SP - 536 -EP - 542 -AN - WOS:A1991GW97200005 -Y2 - 1991-12-01 -ER - - -TY - JOUR -AU - Mi, Song -AU - Yang, Yunxin -AU - Liu, Xin -AU - Tang, Shaotong -AU - Liang, Ning -AU - Sun, Jinyue -AU - Liu, Chao -AU - Ren, Qidong -AU - Lu, Jihong -AU - Hu, Pingping -AU - Zhang, Jiandong -TI - Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer -T2 - CLINICAL & TRANSLATIONAL ONCOLOGY -M3 - Article -AB - Background The application of immune checkpoint inhibitors (ICIs) in treating patients with extensive-stage small-cell lung cancer (ES-SCLC) has brought us new hope, but the real-world outcome is relatively lacking. Our aim was to investigate the clinical use, efficacy, and survival benefit of ICIs in ES-SCLC from real-world data analysis. Methods A retrospective analysis of ES-SCLC patients was conducted between 2012 and 2022. Progression-free survival (PFS) and overall survival (OS) were assessed between groups to evaluate the value of ICIs at different lines of treatment. PFS1 was defined as the duration from initial therapy to disease progression or death. PFS2 was defined as the duration from the first disease progression to the second disease progression or death. Results One hundred and eighty patients with ES-SCLC were included. We performed landmark analysis, which showed that compared to the second-line and subsequent-lines ICIs-combined therapy group (2SL-ICIs) and non-ICIs group, the first-line ICIs-combined therapy group (1L-ICIs) prolonged OS and PFS1. There was a trend toward prolonged OS in the 2SL-ICIs group than in the non-ICIs group, but the significance threshold was not met (median OS 11.94 months vs. 11.10 months, P = 0.14). A longer PFS2 was present in the 2SL-ICIs group than in the non-ICIs group (median PFS2 4.13 months vs. 2.60 months, P < 0.001). Conclusion First-line ICIs plus chemotherapy should be applied in clinical practice. If patients did not use ICIs plus chemotherapy in first-line therapy, the use of ICIs in the second line or subsequent lines of treatment could prolong PFS2. -PU - SPRINGER INT PUBL AG -PI - CHAM -PA - GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND -SN - 1699-048X -SN - 1699-3055 -DA - 2024 SEP -PY - 2024 -VL - 26 -IS - 9 -SP - 2339 -EP - 2350 -DO - 10.1007/s12094-024-03471-y -AN - WOS:001200737200003 -C6 - APR 2024 -AD - Shandong Univ Tradit Chinese Med, Shandong Prov Qianfoshan Hosp, Dept Oncol, Jinan, Peoples R China -AD - Shandong First Med Univ, Affiliated Hosp 1, Dept Oncol, Jinan, Peoples R China -AD - Shandong Prov Qianfoshan Hosp, Shandong Lung Canc Inst, Shandong Key Lab Rheumat Dis & Translat Med, Jinan, Peoples R China -AD - Shandong Univ, Cheeloo Coll Med, Shandong Prov Qianfoshan Hosp, Dept Oncol, Jinan, Peoples R China -AD - Weifang Med Univ, Sch Clin Med, Weifang, Peoples R China -AD - Shandong Acad Agr Sci, Key Lab Novel Food Resources Proc, Key Lab Agroprod Proc Technol Shandong Prov, Minist Agr & Rural Affairs,Inst Agrofood Sci & Tec, Jinan, Peoples R China -AD - Shandong First Med Univ, Coll Clin & Basic Med, Jinan, Peoples R China -Y2 - 2024-04-24 -ER - - -TY - JOUR -AU - Li, Chu-Ling -AU - Song, Yong -TI - Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges -T2 - CHINESE MEDICAL JOURNAL -M3 - Review -AB - Immunotherapy has dramatically altered the treatment of non-small cell lung cancer. Currently, the emergence of combination strategies in immunotherapy has brightened the prospects of improved clinical outcomes and manageable safety profiles in the first/second-line settings. However, sub-optimal response rates are still observed in several clinical trials. Hence, alternative combination models and candidate selection strategies need to be explored. Herein, we have critically reviewed and commented on the published data from several clinical trials, including combined immunotherapy and chemotherapy, anti-angiogenic agents, epidermal growth factor receptor/anaplastic lymphoma kinase tyrosine kinase inhibitors, radiotherapy, and other immune checkpoint inhibitors. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0366-6999 -SN - 2542-5641 -DA - 2021 AUG 20 -PY - 2021 -VL - 134 -IS - 16 -SP - 1908 -EP - 1919 -DO - 10.1097/CM9.0000000000001610 -AN - WOS:000691347300004 -AD - Nanjing Med Univ, Jinling Hosp, Dept Resp Med, Nanjing 210000, Jiangsu, Peoples R China -Y2 - 2021-09-06 -ER - - -TY - JOUR -AU - Schild, S. E. -AU - Vokes, E. E. -TI - Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer -T2 - ANNALS OF ONCOLOGY -M3 - Review -AB - Recent progress in the fields of molecular biology and immunology has improved survival for patients with advanced disease. There have also been improvements in radiotherapy including more precise targeting, modified fractionation, and the use of newer beams. It is hoped that these tools can be successfully employed to better care for patients with stage III disease.Lung cancer is the leading cause of cancer deaths, having caused an estimated 1.6 million deaths worldwide in 2012 [Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386].Although the majority of patients are not cured with currently available therapies, there have been significant improvements in stage-specific outcomes over time [Videtic G, Vokes E, Turrisi A et al. The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years. In The 39th Annual Meeting of the American Society of Clinical Oncology, ASCO 2003, Chicago, IL. Abstract 2557. p. 291]. This review focuses on past progress and ongoing research in the treatment of locally advanced, inoperable nonsmall-cell lung cancer (NSCLC).In the past, randomized trials revealed advantages to the use of thoracic radiotherapy (TRT) and then, the addition of induction chemotherapy. This was followed by studies that determined concurrent chemoradiotherapy to be superior to sequential therapy. A recent large phase III trial found that the administration of 74 Gy of conventionally fractionated photon-based TRT provided poorer survival than did the standard 60 Gy. However, further research on other methods of applying radiotherapy (hypofractionation, adaptive TRT, proton therapy, and stereotactic TRT boosting) is proceeding and may improve outcomes. The molecular characterization of tumors has provided more effective and less toxic targeted treatments in the stage IV setting and these agents are currently under investigation for earlier stage disease. Similarly, immune-enhancing therapies have shown promise in stage IV disease and are also being tested in the locally advanced setting.For locally advanced, inoperable NSCLC, standard therapy has evolved from TRT alone to combined modality therapy. We summarize the recent clinical trial experience and outline promising areas of investigation in an era of greater molecular and immunologic understanding of cancer care. -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 0923-7534 -SN - 1569-8041 -DA - 2016 APR -PY - 2016 -VL - 27 -IS - 4 -SP - 590 -EP - 599 -DO - 10.1093/annonc/mdv621 -AN - WOS:000374237700006 -AD - Mayo Clin, Dept Radiat Oncol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA -AD - Univ Chicago Med & Biol Sci, Dept Med, Chicago, IL USA -AD - Univ Chicago Med & Biol Sci, Ctr Comprehens Canc, Chicago, IL USA -M2 - Univ Chicago Med & Biol Sci -Y2 - 2016-05-11 -ER - - -TY - JOUR -AU - Varlotto, John M. -AU - Sun, Zhuoxin -AU - Ky, Bonnie -AU - Upshaw, Jenica -AU - Katz, Sharyn, I -AU - Fitzgerald, Thomas J. -AU - Wakelee, Heather -AU - Diehn, Maximilian -AU - Mankoff, David A. -AU - Lovely, Christine -AU - Belani, Chandra -AU - Oettel, Kurt -AU - Masters, Gregory -AU - Ramalingam, Suresh -AU - Pennell, Nathan A. -TI - A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study -T2 - ONCOLOGIST -M3 - Review -AB - ECOG-ACRIN EA5181 is a phase III prospective, randomized trial that randomizes patients undergoing chemo/radiation for locally advanced non-small cell lung cancer (LA-NSCLC) to concomitant durvalumab or no additional therapy, with both arms receiving 1 year of consolidative durvalumab. Radiation dose escalation failed to improve overall survival in RTOG 0617. However, conventionally fractionated radiation to 60 Gy with concomitant chemotherapy is associated with a high risk of local failure (38%-46%). It is hoped that concomitant immunotherapy during chemo/radiation can help decrease the risk of local failure, thereby improving overall survival and progression-free survival with acceptable toxicity. In this article, we review conventional chemo/radiation therapy for LA-NSCLC, as well as the quickly evolving world of immunotherapy in the treatment of non-small cell lung cancer and discuss the rationale and study design of EA5181.Implications for Practice This article provides an up-to-date assessment of how immunotherapy is reshaping the landscape of metastatic non-small cell lung cancer (NSCLC) and how the impact of this therapy is now rapidly moving into the treatment of patients with locally advanced NSCLC who are presenting for curative treatment. This article reviews the recent publications of chemo/radiation as well as those combining immunotherapy with chemotherapy and chemo/radiation, and provides a strategy for improving overall survival of patients with locally advanced NSCLC by using concomitant immunotherapy with standard concurrent chemo/radiation. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1083-7159 -SN - 1549-490X -DA - 2021 JUN -PY - 2021 -VL - 26 -IS - 6 -SP - 523 -EP - 532 -DO - 10.1002/onco.13725 -AN - WOS:000627459300001 -C6 - MAR 2021 -AD - Marshall Univ, Div Radiat Oncol, Huntington, WV USA -AD - Dana Farber Canc Inst, Boston, MA 02115 USA -AD - ECOG ACRIN Biostat Ctr, Boston, MA USA -AD - Univ Penn, Div Cardiovasc Med, Philadelphia, PA 19104 USA -AD - Tufts Univ, Dept Med, Boston, MA 02111 USA -AD - Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA -AD - Imaging & Radiat Oncol Core IROC, Lincoln, RI USA -AD - Stanford Univ, Div Oncol, Stanford, CA 94305 USA -AD - Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA -AD - Vanderbilt Univ, Div Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA -AD - Penn State Canc Inst, Dept Med Oncol, Hershey, PA USA -AD - Gundersen Lutheran Med Ctr, Dept Med Oncol, La Crosse, WI USA -AD - Delaware Christiana Care NCORP, Newark, DE USA -AD - Emory Univ, Div Med Oncol, Atlanta, GA 30322 USA -AD - Cleveland Clin, Dept Hematol Oncol, Cleveland, OH 44106 USA -M2 - ECOG ACRIN Biostat Ctr -M2 - Imaging & Radiat Oncol Core IROC -Y2 - 2021-03-21 -ER - - -TY - JOUR -AU - Pelaez Bejarano, Ana -AU - Montero Perez, Olalla -TI - Successful treatment with durvalumab: A case report and review -T2 - JOURNAL OF CANCER RESEARCH AND THERAPEUTICS -M3 - Review -AB - Stage III non-small-cell lung cancer (NSCLC) represents a heterogeneous group of disease entities with multimodality treatments. For most patients, platinum-based doublet with concurrent chemoradiotherapy (CRT) has become the first-choice treatment over the past decade. Immune checkpoint inhibition has revolutionized the management of metastatic NSCLC; however, no major advances in systemic therapy for Stage III NSCLC have been made. The following report is the case of a patient with unresectable Stage IIIA NSCLC successfully treated with durvalumab. The patient completed 1 year of treatment without interruptions, and disease control has been maintained for more than 20 months since the start of durvalumab. -PU - WOLTERS KLUWER MEDKNOW PUBLICATIONS -PI - MUMBAI -PA - WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA -SN - 0973-1482 -SN - 1998-4138 -DA - 2023 JAN-MAR -PY - 2023 -VL - 19 -IS - 2 -SP - 470 -EP - 473 -DO - 10.4103/jcrt.jcrt_1430_21 -AN - WOS:001107250300048 -AD - Hosp Juan Ramon Jimenez, Unidad Gest Clin Farm, Hosp Pharm, Huelva, Spain -AD - Hosp Juan Ramon Jimenez, Unidad Gest Clin Farm, Norte S-N, Huelva 21005, Spain -Y2 - 2023-12-16 -ER - - -TY - JOUR -AU - Chu, Xiao -AU - Zhu, Zhengfei -TI - Prophylactic cranial irradiation in small cell lung cancer: an update -T2 - CURRENT OPINION IN ONCOLOGY -M3 - Review -AB - Purpose of reviewThe current review presents recent updates in the seminal literature of research on prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC).Recent findingsBrain MRI restaging before the administration of PCI reveals a substantial proportion of brain metastasis in baseline brain metastasis free extensive-stage SCLC (ES-SCLC) and limited-stage SCLC (LS-SCLC). Posthoc analyses from the CASPIAN and IMpower133 trials revealed decreases in brain metastasis rates in ES-SCLC treated with chemoimmunotherapy relative to the brain metastasis rates in ES-SCLC treated with chemotherapy alone. A recent meta-analysis of literature published after the landmark 1999 Auperin meta-analysis confirmed the survival benefit of PCI in LS-SCLC patients. A recent study employing PET before and after PCI demonstrated that hippocampal avoidance -PCI (HA-PCI) preserved the metabolic activity of the hippocampi compared with regular PCI. Two phase III trials evaluating neurocognitive functions after HA-PCI versus PCI have yielded conflicting results. Ongoing clinical trials (MAVERICK, PRIMALung, NRG CC003, NCT04535739, NCT04829708 and NCT03514849) regarding PCI versus MRI surveillance and HA-PCI versus PCI were also discussed.Currently, the indications for PCI in SCLC are under question in the modern MRI era. Result from prospective phase III, MRI staged and MRI monitored RCTs are expected to elucidate the role of PCI in LS-SCLC and ES-SCLC. Preliminary results indicated that adding immunotherapy to chemotherapy may reduce brain metastasis rate in SCLC. Further data to this aspect are warranted to determine the role of PCI in the immuno-chemotherapy era. The future direction for PCI should be the comprehensive integration of personalized patient selection, HA-PCI utilization and potential employment of other neurocognitive preservation strategies. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1040-8746 -SN - 1531-703X -DA - 2023 JAN -PY - 2023 -VL - 35 -IS - 1 -SP - 61 -EP - 67 -DO - 10.1097/CCO.0000000000000910 -AN - WOS:000905204400010 -AD - Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai, Peoples R China -AD - Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China -AD - Shanghai Clin Res Ctr Radiat Oncol, Shanghai, Peoples R China -AD - Shanghai Key Lab Radiat Oncol, Shanghai, Peoples R China -AD - Fudan Univ, Shanghai Canc Ctr, Shanghai 200032, Peoples R China -M2 - Shanghai Clin Res Ctr Radiat Oncol -M2 - Shanghai Key Lab Radiat Oncol -Y2 - 2023-01-22 -ER - - -TY - JOUR -AU - Shang, Shijie -AU - Liu, Jie -AU - Verma, Vivek -AU - Wu, Meng -AU - Welsh, James -AU - Yu, Jinming -AU - Chen, Dawei -TI - Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates -T2 - CANCER COMMUNICATIONS -M3 - Review -AB - The efficacy of immunotherapy for advanced non-small cell lung cancer (NSCLC) remains unsatisfactory, as the majority of patients either do not experience an objective response or acquire secondary resistance. As a result, several methods to enhance the systemic efficacy of immunotherapy have been investigated, including a large area of active research by combining immunotherapy with radiation therapy (RT). Given the rapidly burgeoning concept of combining immunotherapy and RT for increasing therapeutic benefit, we review the progress in this field thus far and explore further avenues for enhancing this combination. This review commences with a discussion of the only two existing randomized trials (and a pooled analysis) showing that the addition of RT to immunotherapy improves the abscopal response rate, progression-free survival, and overall survival in metastatic NSCLC patients. We then discussed factors and biomarkers that may be associated with a proportionally greater benefit to additional RT, such as low programmed cell death protein ligand 1 (PD-L1) status, tumor mutational burden (TMB), and patient's immune function. Next, the implementation of RT to overcome immunotherapy resistance is discussed, including a mechanistic discussion and methods with which these mechanisms could be exploited. Lastly, the emerging role of low-dose RT is discussed, which may help to overcome inhibitory signals in the tumor stroma that limit T-cell infiltration. Taken together, given the current state of this rapidly expanding realm, these futuristic strategies may be reflected upon to further enhance the efficacy of immunotherapy for a wider group of patients. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2523-3548 -DA - 2021 NOV -PY - 2021 -VL - 41 -IS - 11 -SP - 1086 -EP - 1099 -DO - 10.1002/cac2.12226 -AN - WOS:000707730200001 -C6 - OCT 2021 -AD - Shandong Univ, Shandong Canc Hosp, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China -AD - Shandong First Med Univ, Shandong Canc Hosp & Inst, Lab Radio Immunol, Dept Radiat Oncol,Canc Res Ctr, Jiyan Rd 440, Jinan 250117, Shandong, Peoples R China -AD - Shandong Acad Med Sci, Jiyan Rd 440, Jinan 250117, Shandong, Peoples R China -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA -Y2 - 2021-10-26 -ER - - -TY - JOUR -AU - Kumar, Sameera S. -AU - Higgins, Kristin A. -AU - McGarry, Ronald C. -TI - Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy -T2 - FRONTIERS IN ONCOLOGY -M3 - Review -AB - The current standard of care for locally advanced non-small cell lung cancer (NSCLC) includes radiation, chemotherapy, and surgery in certain individualized cases. In unresectable NSCLC, chemoradiation has been the standard of care for the past three decades. Local and distant failure remains high in this group of patients, so dose escalation has been studied in both single institution and national clinical trials. Though initial studies showed a benefit to dose escalation, phase III studies examining dose escalation using standard fractionation or hyperfractionation have failed to show a benefit. Over the last 17 years, stereotactic body radiation therapy (SBRT) has shown a high degree of safety and local control for stage I lung cancers and other localized malignancies. More recently, phase I/II studies using SBRT for dose escalation after conventional chemoradiation in locally advanced NSCLC have been promising with good apparent safety. Immunotherapy also offers opportunities to address distant disease and preclinical data suggest immunotherapy in tandem with SBRT may be a rational way to induce an "abscopal effect" although there are little clinical data as yet. By building on the proven concept of conventional chemoradiation for patients with locally advanced NSCLC with a subsequent radiation dose intensification to residual disease with SBRT concurrent with immunotherapy, we hope address the issues of metastatic and local failures. This "quadmodality" approach is still in its infancy but appears to be a safe and rational approach to the improving the outcome of NSCLC therapy. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2017 SEP 4 -PY - 2017 -VL - 7 -C7 - 197 -DO - 10.3389/fonc.2017.00197 -AN - WOS:000408986000001 -AD - Univ Kentucky, Dept Radiat Med, Lexington, KY 40506 USA -AD - Emory Univ, Emory Clin, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA -Y2 - 2017-09-15 -ER - - -TY - JOUR -AU - Jumeau, Raphael -AU - Vilotte, Florent -AU - Durham, Andre-Dante -AU - Ozsahin, Esat-Mahmut -TI - Current landscape of palliative radiotherapy for non-small-cell lung cancer -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Radiotherapy (RT) is a cornerstone in the management of advanced stage III and stage IV non-small-cell lung cancer (NSCLC) patients. Despite international guidelines, clinical practice remains heterogeneous. Additionally, the advent of stereotactic ablative RT (SABR) and new systemic treatments such as immunotherapy have shaken up dogmas in the approach of these patients. This review will focus on palliative thoracic RT for NSCLC but will also discuss the role of stereotactic radiotherapy, endobronchial brachytherapy (EBB), the interest of concomitant treatments (chemotherapy and immunotherapy), and the role of RT in lung cancer emergencies with palliative intent. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2019 SEP -PY - 2019 -VL - 8 -SP - S192 -EP - S201 -DO - 10.21037/tlcr.2019.08.10 -AN - WOS:000485805900010 -AD - Lausanne Univ Hosp, Dept Radiat Oncol, Lausanne, Switzerland -AD - Univ Lausanne, Lausanne, Switzerland -Y2 - 2019-09-30 -ER - - -TY - JOUR -AU - Jachowski, Andrzej -AU - Marcinkowski, Mikolaj -AU - Szydlowski, Jakub -AU - Grabarczyk, Oskar -AU - Nogaj, Zuzanna -AU - Marcin, Laz -AU - Plawski, Andrzej -AU - Jagodzinski, Pawel Piotr -AU - Slowikowski, Bartosz Kazimierz -TI - Modern therapies of nonsmall cell lung cancer -T2 - JOURNAL OF APPLIED GENETICS -M3 - Review -AB - Lung cancer (LC), particularly nonsmall cell lung cancer (NSCLC), is one of the most prevalent types of neoplasia worldwide, regardless of gender, with the highest mortality rates in oncology. Over the years, treatment for NSCLC has evolved from conventional surgery, chemotherapy, and radiotherapy to more tailored and minimally invasive approaches. The use of personalised therapies has increased the expected efficacy of treatment while simultaneously reducing the frequency of severe adverse effects (AEs). In this review, we discuss established modern approaches, including immunotherapy and targeted therapy, as well as experimental molecular methods like clustered regularly interspaced short palindromic repeat (CRISPR) and nanoparticles. These emerging methods offer promising outcomes and shorten the recovery time for various patients. Recent advances in the diagnostic field, including imaging and genetic profiling, have enabled the implementation of these methods. The versatility of these modern therapies allows for multiple treatment options, such as single-agent use, combination with existing conventional treatments, or incorporation into new regimens. As a result, patients can survive even in the advanced stages of NSCLC, leading to increased survival indicators such as overall survival (OS) and progression-free survival (PFS). -PU - SPRINGER HEIDELBERG -PI - HEIDELBERG -PA - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY -SN - 1234-1983 -SN - 2190-3883 -DA - 2023 DEC -PY - 2023 -VL - 64 -IS - 4 -SP - 695 -EP - 711 -DO - 10.1007/s13353-023-00786-4 -AN - WOS:001067506300001 -C6 - SEP 2023 -AD - Poznan Univ Med Sci, Dept Biochem & Mol Biol, Swiecickiego 6 St, PL-60781 Poznan, Poland -AD - Polish Acad Sci, Inst Human Genet, Strzeszynska 32 St, PL-60479 Poznan, Poland -Y2 - 2023-09-29 -ER - - -TY - JOUR -AU - Qu, Jingjing -AU - Kalyani, Farhin Shaheed -AU - Shen, Qian -AU - Yang, Guangdie -AU - Cheng, Tianli -AU - Liu, Li -AU - Zhou, Jianya -AU - Zhou, Jianying -TI - Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study -T2 - JOURNAL OF ONCOLOGY -M3 - Article -AB - Background. Most patients with small-cell lung cancer (SCLC) have extensive-stage (ES) disease with a poor prognosis. Immunotherapy has shown good therapeutic effects in the treatment of ES-SCLC. We performed a real-world retrospective study to evaluate the safety and efficacy of PD-L1 inhibitors plus chemotherapy in patients with ES-SCLC. Method. A total of 224 patients diagnosed with ES-SCLC between March 2017 and April 2021 were included, of which 115 received only etoposide-platinum (EP) chemotherapy,and 109 received programmed cell-death ligand 1 (PD-L1) inhibitors and EP. Results. Immune checkpoint inhibitors (ICIs) plus platinum were associated with a significant improvement in overall survival (OS), with a hazard ratio (HR) of 0.60 (95% CI, 0.42-0.85; P=0.0054); median OS was 19 months in the ICIs plus EP group vs. 12 months in the EP group. The median progression-free survival (PFS) was 8.5 and 5.0 months, respectively (HR for disease progression or death, 0.42; 95% CI, 0.31-0.57; P < 0.0001). Male patients < 65 years old, Stage IV, PS 0-1, without liver and brain metastasis had a better OS in the ICIs plus EP group than the EP group. The PFS and OS in the durvalumab plus chemotherapy group were insignificantly longer than that of the atezolizumab plus chemotherapy group. Any adverse effects (AEs) of grade 3 or 4 occurred in 50 patients (45.9%) in the ICIs plus EP group and 48 patients (41.7%) in the EP alone group. The most common immune-related AEs (irAEs) were immune hypothyroidism events (17.1%, 7/41), immune dermatitis (9.8%, 4/41), and immune pneumonia (9.8%, 4/41) in the durvalumab plus platinum-etoposide group. Immune liver insufficiency (10.3%, 7/68) and immune hypothyroidism (8.8%, 6/68) were the most common irAEs in the atezolizumab plus platinum-etoposide group. Conclusion. This study shows that adding PD-L1 inhibitors to chemotherapy can significantly improve PFS and OS in patients with ES-SCLC and demonstrates its safety without additional AEs. -PU - HINDAWI LTD -PI - LONDON -PA - ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND -SN - 1687-8450 -SN - 1687-8469 -DA - 2022 SEP 26 -PY - 2022 -VL - 2022 -C7 - 3645489 -DO - 10.1155/2022/3645489 -AN - WOS:000868908500005 -AD - Zhejiang Univ, Affiliated Hosp 1, Thorac Dis Ctr, Dept Resp Dis,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China -AD - Clin Res Ctr Resp Dis Zhejiang Prov, Hangzhou 310003, Zhejiang, Peoples R China -AD - Cent South Univ, Hunan Canc Hosp, Thorac Med Dept 1, Affiliated Tumor Hosp,Xiangya Med Sch, Changsha 410008, Hunan, Peoples R China -AD - Cent South Univ, Hunan Canc Hosp, Lung Canc & Gastroenterol Dept, Affiliated Tumor Hosp,Xiangya Med Sch, Changsha 410008, Hunan, Peoples R China -M2 - Clin Res Ctr Resp Dis Zhejiang Prov -Y2 - 2022-10-31 -ER - - -TY - JOUR -AU - Altorki, Nasser K. -AU - McGraw, Timothy E. -AU - Borczuk, Alain C. -AU - Saxena, Ashish -AU - Port, Jeffrey L. -AU - Stiles, Brendon M. -AU - Lee, Benjamin E. -AU - Sanfilippo, Nicholas J. -AU - Scheff, Ronald J. -AU - Pua, Bradley B. -AU - Gruden, James F. -AU - Christos, Paul J. -AU - Spinelli, Cathy -AU - Gakuria, Joyce -AU - Uppal, Manik -AU - Binder, Bhavneet -AU - Elemento, Olivier -AU - Ballman, Karla, V -AU - Formenti, Silvia C. -TI - Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial -T2 - LANCET ONCOLOGY -M3 - Article -AB - Background Previous phase 2 trials of neoadjuvant anti-PD-1 or anti-PD-L1 monotherapy in patients with early-stage non-small-cell lung cancer have reported major pathological response rates in the range of 15-45%. Evidence suggests that stereotactic body radiotherapy might be a potent immunomodulator in advanced non-small-cell lung cancer (NSCLC). In this trial, we aimed to evaluate the use of stereotactic body radiotherapy in patients with early-stage NSCLC as an immunomodulator to enhance the anti-tumour immune response associated with the anti-PD-Ll antibody durvalumab.Methods We did a single-centre, open-label, randomised, controlled, phase 2 trial, comparing neoadjuvant durvalumab alone with neoadjuvant durvalumab plus stereotactic radiotherapy in patients with early-stage NSCLC, at NewYork-Presbyterian and Weill Cornell Medical Center (New York, NY, USA). We enrolled patients with potentially resectable early-stage NSCLC (clinical stages I-IIIA as per the 7th edition of the American joint Committee on Cancer) who were aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0 or 1. Eligible patients were randomly assigned (1:1) to either neoadjuvant durvalumab monotherapy or neoadjuvant durvalumab plus stereotactic body radiotherapy (8 Gy x 3 fractions), using permuted blocks with varied sizes and no stratification for clinical or molecular variables. Patients, treating physicians, and all study personnel were unmasked to treatment assignment after all patients were randomly assigned. All patients received two cycles of durvalumab 3 weeks apart at a dose of 1.12 g by intravenous infusion over 60 min. Those in the durvalumab phis radiotherapy group also received three consecutive daily fractions of 8 Gy stereotactic body radiotherapy delivered to the primary tumour immediately before the first cycle of durvalumab. Patients without systemic disease progression proceeded to surgical resection. The primary endpoint was major pathological response in the primary tumour. All analyses were done on an intention-to-treat basis. This trial is registered with ClinicalTrial.gov, NCT02904954, and is ongoing but closed to accrual.Findings Between Jan 25, 2017, and Sept 15, 2020, 96 patients were screened and 60 were enrolled and randomly assigned to either the durvalumab monotherapy group (n=30) or the durvalumab plus radiotherapy group (n=30). 26 (87%) of 30 patients in each group had their tumours surgically resected. Major pathological response was observed in two (6.7% [95% CI 0. 8-22- 1]) of 30 patients in the durvalumab monotherapy group and 16 (53.3% [34.3-71.7]) of 30 patients in the durvalumab plus radiotherapy group. The difference in the major pathological response rates between both groups was significant (crude odds ratio 16.0 [95% CI 3- 2-79- 6]; p<0.0001). In the 16 patients in the dual therapy group with a major pathological response, eight (50%) had a complete pathological response. The second cycle of durvalumab was withheld in three (10%) of 30 patients in the dual therapy group due to immune-related adverse events (grade 3 hepatitis, grade 2 pancreatitis, and grade 3 fatigue and thrombocytopaenia). Grade 3-4 adverse events occurred in five (17%) of 30 patients in the durvalumab monotherapy group and six (20%) of 30 patients in the durvalumab plus radiotherapy group. The most frequent grade 3-4 events were hyponatraemia (three 110%1 patients in the durvalumab monotherapy group) and hyperlipasaemia (three [10%] patients in the durvalumab plus radiotherapy group). Two patients in each group had serious adverse events (pulmonary embolism In=11 and stroke [n=1] in the durvalumab monotherapy group, and pancreatitis [n=1] and fatigue [n=1] in the durvalumab plus radiotherapy group). No treatment-related deaths or deaths within 30 days of surgery were reported.Interpretation Neoadjuvant durvalumab combined with stereotactic body radiotherapy is well tolerated, safe, and associated with a high major pathological response rate. This neoadjuvant strategy should be validated in a larger trial. Copyright (C) 2021 Elsevier Ltd. All nghts reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1470-2045 -SN - 1474-5488 -DA - 2021 JUN -PY - 2021 -VL - 22 -IS - 6 -SP - 824 -EP - 835 -DO - 10.1016/S1470-2045(21)00149-2 -AN - WOS:000657432100049 -C6 - JUN 2021 -AD - Weill Cornell Med New York Presbyterian Hosp, Dept Cardiothorac Surg, New York, NY 10023 USA -AD - Weill Cornell Med New York Presbyterian Hosp, Dept Biochem, New York, NY 10023 USA -AD - Weill Cornell Med New York Presbyterian Hosp, Dept Pathol & Lab Med, New York, NY 10023 USA -AD - Weill Cornell Med New York Presbyterian Hosp, Div Hematol Oncol, New York, NY 10023 USA -AD - Weill Cornell Med New York Presbyterian Hosp, Dept Radiat Oncol, New York, NY 10023 USA -AD - Weill Cornell Med New York Presbyterian Hosp, Dept Radiol, New York, NY 10023 USA -AD - Weill Cornell Med New York Presbyterian Hosp, Dept Populat Hlth Sci, New York, NY 10023 USA -AD - Weill Cornell Med New York Presbyterian Hosp, Dept Physiol & Biophys, New York, NY 10023 USA -Y2 - 2021-06-01 -ER - - -TY - JOUR -AU - Huber, Rudolf M. -AU - Kauffmann-Guerrero, Diego -AU - Hoffmann, Hans -AU - Flentje, Michael -TI - New developments in locally advanced nonsmall cell lung cancer -T2 - EUROPEAN RESPIRATORY REVIEW -M3 - Article -AB - Locally advanced nonsmall cell lung cancer, due to its varying prognosis, is grouped according to TNM stage IIIA, IIIB and IIIC. Developments over the last 3 years have been focused on the integration of immunotherapy into the combination treatment of a locally definitive therapy (surgery or radiotherapy) and chemotherapy. For concurrent chemoradiotherapy, consolidation therapy with durvalumab was established. Adjuvant targeted therapy has again gained increasing interest. In order to adapt treatment to the specific stage subgroup and its prognosis, fluorodeoxyglucose positron emission tomography/computed tomography and pathological evaluation of the mediastinum are important. Tumours should be investigated for immunological features and driver mutations. Regarding toxicity, evaluation of pulmonary and cardiac function, as well as symptoms and quality of life, is of increasing importance. To improve the management and prognosis of this heterogeneous entity, clinical trials and registries should take these factors into account. -PU - EUROPEAN RESPIRATORY SOC JOURNALS LTD -PI - SHEFFIELD -PA - 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND -SN - 0905-9180 -SN - 1600-0617 -DA - 2021 JUN 30 -PY - 2021 -VL - 30 -IS - 160 -C7 - 200227 -DO - 10.1183/16000617.0227-2020 -AN - WOS:000672820600006 -AD - Univ Munich, Dept Med, Div Resp Med & Thorac Oncol, Comprehens Pneumol Ctr Munich CPC, Campus Innenstadt, Munich, Germany -AD - Thorac Oncol Ctr Munich, Munich, Germany -AD - German Ctr Lung Res, Munich, Germany -AD - Tech Univ Munich, Div Thorac Surg, Munich, Germany -AD - Univ Wurzburg, Dept Radiat Oncol & Palliat Med, Wurzburg, Germany -M2 - Thorac Oncol Ctr Munich -M2 - German Ctr Lung Res -Y2 - 2021-07-22 -ER - - -TY - JOUR -AU - Ding, Ruilin -AU - Chen, Longxia -AU - Su, Zhou -AU - Xiong, Tengqiong -AU - Wen, Qinglian -AU - Peng, Qing -AU - Jiang, Feng -TI - Development of immunotherapy for brain metastasis (Review) -T2 - INTERNATIONAL JOURNAL OF ONCOLOGY -M3 - Review -AB - Brain metastasis (BM) is associated with a poor prognosis, with the typical overall survival rate ranging from weeks to months in the absence of treatment. Although the concept of immune privilege in the central nervous system has eroded over time, the advent of immunotherapy has opened a new set of potential therapeutic options for patients with BM. Recently, immunotherapy has been demonstrated to confer survival advantages to patients with multiple malignancies commonly associated with BMs. Data from a number of clinical trials have demonstrated that immune checkpoint inhibitors are effective for patients with BM. In addition, cellular therapies, including the application of chimeric antigen receptors T-cell therapy and dendritic cell vaccine, have also been utilized in the treatment of BM. In the present review, preclinical and clinical evidence supporting the applicability of immunotherapy for the treatment of BMs from melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) were examined, where the challenges and safety of this treatment modality were also discussed. -PU - SPANDIDOS PUBL LTD -PI - ATHENS -PA - POB 18179, ATHENS, 116 10, GREECE -SN - 1019-6439 -SN - 1791-2423 -DA - 2020 SEP -PY - 2020 -VL - 57 -IS - 3 -SP - 665 -EP - 677 -DO - 10.3892/ijo.2020.5091 -AN - WOS:000563562900004 -AD - Southwest Med Univ, Affiliated Hosp, Inst Drug Clin Trial, GCP Ctr, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China -AD - Sichuan Mianyang 404 Hosp, Dept Oncol, Mianyang 621000, Sichuan, Peoples R China -AD - Southwest Med Univ, Affiliated Hosp, Dept Oncol, Luzhou 646000, Sichuan, Peoples R China -AD - Southwest Med Univ, Affiliated Hosp, Dept Cardiol, Luzhou 646000, Sichuan, Peoples R China -M2 - Sichuan Mianyang 404 Hosp -Y2 - 2020-09-10 -ER - - -TY - JOUR -AU - Daly, Megan E. -AU - Monjazeb, Arta M. -AU - Kelly, Karen -TI - Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer -T2 - JOURNAL OF THORACIC ONCOLOGY -M3 - Review -AB - Methods of harnessing the immune system to treat cancer have been investigated for decades, but yielded little clinical progress. However, in recent years, novel drugs that allow immune recognition and destruction of tumor cells are emerging as potent cancer therapies. Building upon previous immunotherapy strategies that included therapeutic vaccines, recombinant cytokines, and other immunostimulatory agents, newer immunotherapy agents targeting immune checkpoints including programmed cell death 1, programmed cell death ligand-1, and cytotoxic T-lymphocyte-associated protein 4, among others, have garnered substantial enthusiasm after demonstrating clinical activity in a broad spectrum of tumor types. Trials evaluating immune checkpoint inhibitors in metastatic non-small-cell lung cancer (NSCLC) demonstrate robust and durable responses in a subset of patients. However, with overall response rates less than 20%, combinatorial strategies that extend the benefit of these agents to more patients are desirable. The integration of radiotherapy with immunotherapy is a conceptually promising strategy, as radiotherapy has potent immunomodulatory effects and may contribute not only to local control but may also augment systemic antitumor immune response. Preclinical data and case reports suggest the potential for robust clinical responses in metastatic NSCLC patients using this strategy, but prospective clinical trials evaluating the integration of radiation and immunotherapy are limited. The use of immunotherapy in nonmetastatic settings is also intriguing but understudied. We review the potential clinical settings of interest for the partnering of immunotherapy and radiation in NSCLC, including early stage, locally advanced, and metastatic disease, and review completed, accruing, and developing clinical trials. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1556-0864 -SN - 1556-1380 -DA - 2015 DEC -PY - 2015 -VL - 10 -IS - 12 -SP - 1685 -EP - 1693 -DO - 10.1097/JTO.0000000000000686 -AN - WOS:000365575100006 -AD - Univ Calif Davis, Dept Radiat Oncol, Ctr Comprehens Canc, Sacramento, CA 95817 USA -AD - Univ Calif Davis, Div Med Oncol, Dept Med, Ctr Comprehens Canc, Sacramento, CA 95817 USA -Y2 - 2015-12-25 -ER - - -TY - JOUR -AU - Chao, Angel -AU - Wu, Ren-Chin -AU - Lin, Chiao-Yun -AU - Chang, Ting-Chang -AU - Lai, Chyong-Huey -TI - Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances -T2 - BIOMEDICAL JOURNAL -M3 - Review -AB - Small cell neuroendocrine carcinoma of the cervix (SCNECC) is an uncommon but aggressive uterine malignancy, the cause of which is generally associated with human papillomavirus (HPV) infection. A lack of clinical trials and evidence-based treatment guidelines poses therapeutic challenges to this rare tumor. At present, published data remain limited to case series and case reports. While clinical management has tradition-ally followed those of small cell neuroendocrine (SCNE) lung cancer relying on surgery, chemoradiation, and systemic chemotherapy, the prognosis remains dismal. Immune checkpoint inhibitors (ICIs), such as monoclonal antibodies that target programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1), atezolizumab and durvalumab have proven effective in extensive-stage SCNE lung cancer. Moreover, pembrolizumab has also proven beneficial effects when added onto chemotherapy in metastatic and recurrent HPV-associated non-SCNE cervical cancer. It holds promise to use ICIs in combination with chemoradiation to improve the clinical outcomes of patients with SCNECC. Future ad-vances in our understanding of SCNECC biology -associated with the study of its genomic and molecular aberrations as well as knowledge from SCNE of lung and other extrap-ulmonary sites-would be helpful in discovering new molecular targets for drug devel-opment. Collaborative efforts and establishment of a SCNECC-specific biobank will be essential to achieve this goal. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 2319-4170 -SN - 2320-2890 -DA - 2023 OCT -PY - 2023 -VL - 46 -IS - 5 -C7 - 100633 -DO - 10.1016/j.bj.2023.100633 -AN - WOS:001084552800001 -C6 - SEP 2023 -AD - Chang Gung Mem Hosp Linkou, Dept Obstet & Gynecol, Taoyuan, Taiwan -AD - Chang Gung Mem Hosp Linkou, Gynecol Canc Res Ctr, Taoyuan, Taiwan -AD - Chang Gung Mem Hosp Linkou, Dept Pathol, Taoyuan, Taiwan -AD - Chang Gung Univ, Coll Med, Taoyuan, Taiwan -Y2 - 2023-11-01 -ER - - -TY - JOUR -AU - Wagner, Jan Nicolai -AU - Roeper, Julia -AU - Heukamp, Lukas -AU - Falk, Markus -AU - Willborn, Kay -AU - Griesinger, Frank -TI - Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy -T2 - BIOMEDICINES -M3 - Article -AB - Background: The PACIFIC study showed that after radio-chemotherapy, patients with NSCLC derived a benefit in PFS and OS when treated with durvalumab. This effect was limited to patients with a PD-L1 expression of >1%, partly because the outcome in the observational control arm was surprisingly favorable. Thus, it could be speculated that a lack of PD-L1 expression confers a favorable outcome for patients with stage III NSCLC. Methods: Clinical data, PD-L1 expression, predictive blood markers, and the outcomes of 99 homogeneously treated patients with stage III NSCLC were retrospectively captured. Statistical analyses using the log rank test were performed. Results: The median OS of patients with an expression of PD-L1 < 1% was 20 months (CI 10.5-29.5) and the median OS of patients with an expression of PD-L1 >= 1% was 28 months (CI 16.5-39.2) (p = 0.734). The median PFS of patients with an expression of PD-L1 < 1% was 9 months (CI 6.3-11.6) and the median PFS of patients with an expression of PD-L1 >= 1% was 12 months (CI 9.8-14.2) (p = 0.112). Conclusions: The assumption that the lack of PD-L1 expression represents a favorable prognostic factor after radio-chemotherapy vs. PD-L1 expression > 1% was not confirmed. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2227-9059 -DA - 2024 MAR -PY - 2024 -VL - 12 -IS - 3 -C7 - 688 -DO - 10.3390/biomedicines12030688 -AN - WOS:001192010100001 -AD - Carl von Ossietzky Univ Oldenburg, Fac Med & Hlth Sci 6, European Med Sch, Ammerlander Heerstr 114-118, D-26129 Oldenburg, Germany -AD - Hematopathol Hamburg, Fangdieckstr 75A, D-22547 Hamburg, Germany -AD - Pius Hosp Oldenburg, Univ Dept Med Radiat Phys, Dept Radiotherapy & Radiooncol, Georgstr 12, D-26121 Oldenburg, Germany -AD - Pius Hosp Oldenburg, Univ Dept Internal Med Oncol, Dept Hematol & Oncol, Georgstr 12, D-26121 Oldenburg, Germany -M2 - Hematopathol Hamburg -Y2 - 2024-03-31 -ER - - -TY - JOUR -AU - Montenegro, Gabriela Bravo -AU - Farid, Saira -AU - Liu, Stephen V. -TI - Immunotherapy in lung cancer -T2 - JOURNAL OF SURGICAL ONCOLOGY -M3 - Review -AB - Immunotherapy has emerged as an important treatment modality throughout oncology with a particularly important role in the treatment of lung cancer. Early signals showed responses could be achieved in nonsmall cell lung cancer and small cell lung cancer and these monoclonal antibodies have become standards of care for advanced stage disease. They have also shown promise in earlier-stage disease as complements to radiation or surgery, offering the potential for durable, meaningful survival gains. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0022-4790 -SN - 1096-9098 -DA - 2021 MAR -PY - 2021 -VL - 123 -IS - 3 -SP - 718 -EP - 729 -DO - 10.1002/jso.26347 -AN - WOS:000618810500003 -AD - Georgetown Univ, Div Med Oncol, 3800 Reservoir Rd NW, Washington, DC 20007 USA -AD - Washington Hosp Ctr, Dept Med, Washington, DC 20010 USA -Y2 - 2021-03-10 -ER - - -TY - JOUR -AU - Zhang, Yun -AU - Lin, Qin -AU - Xu, Ting -AU - Deng, Weiye -AU - Yu, Jinming -AU - Liao, Zhongxing -AU - Yue, Jinbo -TI - Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer -T2 - CANCER LETTERS -M3 - Review -AB - The standard treatment for locally advanced non-small cell lung cancer (LA NSCLC) includes surgery, radiotherapy, chemotherapy, or some combination of these modalities. Many clinical trials have been conducted in attempts to intensify treatment for LA NSCLC, but with little improvement. A therapeutic plateau had been reached, with no major progress in extending survival for patients with this disease. However, several recent trials of newer targeted therapies and immunotherapies may shed new light on potential therapeutic breakthroughs. The potential benefits from new targeted therapies and immunotherapies in combination with other forms of therapy for LA NSCLC are sufficiently striking as to change current treatment paradigms. Trials of these agents are moving forward from patients with advanced disease to those with earlier stage disease, and from palliative intent to curative intent, which may well revolutionize treatment strategies that have been considered standard over the past several decades. Future studies are needed to explore the role of targeted therapies and immunotherapies in combination with existing therapies for earlier stage disease and for frontline treatment, either as concurrent or perhaps neoadjuvant or adjuvant approaches. (c) 2018 Elsevier B.V. All rights reserved. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0304-3835 -SN - 1872-7980 -DA - 2018 -PY - 2018 -VL - 421 -SP - 59 -EP - 62 -DO - 10.1016/j.canlet.2018.02.003 -AN - WOS:000428830700009 -AD - Univ finan, Shandong Acad Med Sci, Sch Med & Life Sci, Jinan, Shandong, Peoples R China -AD - Shandong Univ, Shandong Canc Hosp Affiliated, Shandong Canc Hosp & Inst, Dept Radiat Oncol, 440 Jinyan Rd, Jinan 250117, Shandong, Peoples R China -AD - Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Hosp, Dept Radiat Oncol, Zhen Hai Rd 55, Xiamen 361003, Fujian, Peoples R China -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA -AD - Univ Texas Sch Publ Hlth Houston, Div Epidemiol Human Genet & Environm Sci, 1200 Hermann Pressler St, Houston, TX 77030 USA -Y2 - 2018-04-13 -ER - - -TY - JOUR -AU - Sheikh, Saad -AU - Dey, Asoke -AU - Datta, Sujay -AU - Podder, Tarun K. -AU - Jindal, Charulata -AU - Dowlati, Afshin -AU - Efird, Jimmy Tf -AU - Machtay, Mitchell -AU - Biswas, Tithi -TI - Role of radiation in extensive stage small cell lung cancer: a National Cancer Database registry analysis -T2 - FUTURE ONCOLOGY -M3 - Article -AB - The role of prophylactic cranial irradiation (PCI) and thoracic radiation therapy (TRT) in extensive-stage small cell lung cancer remains controversial. The authors examined the National Cancer Database and identified patients with extensive-stage small cell lung cancer with no brain metastasis. Patients were excluded if they died 30 days from diagnosis, did not receive polychemotherapy, had other palliative radiation or had missing information. A propensity score-matched analysis was also performed. A total of 21,019 patients were identified. The majority of patients did not receive radiation (69%), whereas 10% received PCI and 21% received TRT. The addition of PCI and TRT improved median survival and survival at 1 and 2 years (p <= 0.05). The propensity score-matched analysis confirmed the same overall survival benefit with both PCI and TRT. This registry-based analysis of >1500 accredited cancer programs shows that PCI and TRT are not commonly utilized for extensive-stage small cell lung cancer patients who are treated with multiagent chemotherapy. The addition of PCI and TRT significantly improves overall survival in this otherwise poor prognostic group. Further research is needed to confirm the role of PCI and TRT, especially in the era of improved systemic therapy.Lay abstractThe role of radiation therapy in patients with metastatic small cell lung cancer remains controversial. The authors examined the National Cancer Database and identified patients with metastatic small cell lung cancer without brain metastasis. Patients were excluded if they died 30 days from diagnosis, did not receive multiagent chemotherapy, had other palliative radiation or had missing information regarding treatment. A total of 21,019 patients were identified. The majority of patients did not receive radiation (69%), whereas 10% received radiation to the brain and 21% received radiation to their lungs. The addition of brain and lung radiation therapy improved median survival and survival at 1 and 2 years. The addition of prophylactic cranial irradiation and thoracic radiation therapy improves survival in extensive-stage small cell lung cancer. Future research is needed to evaluate the role of radiation in the era of chemoimmunotherapy. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1479-6694 -SN - 1744-8301 -DA - 2021 JUL -PY - 2021 -VL - 17 -IS - 21 -SP - 2713 -EP - 2724 -DO - 10.2217/fon-2020-1095 -AN - WOS:000648013400001 -C6 - MAY 2021 -AD - Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Dept Radiat Oncol, Cleveland, OH 44106 USA -AD - Univ Akron, Dept Management, Akron, OH 44325 USA -AD - Univ Akron, Dept Stat, Akron, OH 44325 USA -AD - Univ Newcastle, Sch Med & Publ Hlth, Prior Res Ctr Generat Hlth & Ageing, Newcastle, NSW 2308, Australia -AD - Univ Newcastle, Sch Med & Publ Hlth, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2308, Australia -AD - Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Dept Med, Cleveland, OH 44106 USA -AD - Durham VA Hlth Care Syst, Cooperat Studies Program Epidemiol Ctr Durham, Asheboro, NC 27203 USA -M2 - Durham VA Hlth Care Syst -Y2 - 2021-05-20 -ER - - -TY - JOUR -AU - Brade, Anthony -AU - Jao, Kevin -AU - Yu, Simon -AU - Cheema, Parneet -AU - Doucette, Sarah -AU - Christofides, Anna -AU - Schellenberg, Devin -TI - A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer -T2 - CURRENT ONCOLOGY -M3 - Article -AB - Stage III non-small cell lung cancer (NSCLC) comprises a highly heterogenous group of patients with regards to patient fitness and tumour size and distribution, resulting in a wide range of treatment goals and therapy options. Curative-intent multimodality treatment should be considered in all patients with stage III NSCLC. For patients with unresectable disease who are fit, have adequate lung function, and have a disease that can be encompassed within a radical radiation volume, concurrent chemoradiation therapy (cCRT) is the standard of care and can produce cure rates of 20-30%. Recently, consolidation immunotherapy with durvalumab has been recognized as the standard of care following cCRT based on significant improvement rates in overall survival at 4 years. The large heterogeneity of the stage III NSCLC population, along with the need for extensive staging procedures, multidisciplinary care, intensive cCRT, and now consolidation therapy makes the delivery of timely and optimal treatment for these patients complex. Several logistical, communication, and education factors hinder the delivery of guideline-recommended care to patients with stage III unresectable NSCLC. This commentary discusses the potential challenges patients may encounter at different points along their care pathway that can interfere with delivery of curative-intent therapy and suggests strategies for improving care delivery. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1198-0052 -SN - 1718-7729 -DA - 2021 JUN -PY - 2021 -VL - 28 -IS - 3 -SP - 1618 -EP - 1629 -DO - 10.3390/curroncol28030151 -AN - WOS:000667211400001 -AD - Peel Reg Canc Ctr, Dept Radiat Oncol, Mississauga, ON L5M 2N1, Canada -AD - Hop Sacre Coeur Montreal, Dept Hematol & Oncol, Montreal, PQ H4J 1C5, Canada -AD - Burnaby Hosp Canc Ctr, Dept Med, Burnaby, BC V5G 2X6, Canada -AD - Univ Toronto, Div Med Oncol, Dept Med, Toronto, ON M5S 3H2, Canada -AD - William Osler Hlth Syst, Brampton, ON L6R 3J7, Canada -AD - IMPACT Medicom Inc, Toronto, ON M6S 3K2, Canada -AD - BC Canc Agcy, Dept Radiat Oncol, Surrey, BC V2V 1Z2, Canada -M2 - Peel Reg Canc Ctr -M2 - Burnaby Hosp Canc Ctr -M2 - William Osler Hlth Syst -M2 - IMPACT Medicom Inc -Y2 - 2021-07-13 -ER - - -TY - JOUR -AU - Zangemeister-Wittke, U -AU - Stahel, RA -TI - Novel approaches to the treatment of small-cell lung cancer -T2 - CELLULAR AND MOLECULAR LIFE SCIENCES -M3 - Review -AB - Small-cell lung cancer (SCLC) is characterized by its initial responsiveness to chemotherapy and the appearance of early metastases. Although combination chemotherapy, in some instances together with radiation, has improved the prognosis of this disease, in most patients SCLC ultimately recurs in a drug-resistant form. Several new strategies for the eradication of SCLC are being explored at the preclinical level. The identification of selective target molecules on the surface of SCLC cells, together with the progress made in antibody engineering, have provided new generations of antibodies and immunoconjugates as well as growth factor antagonists and inhibitors. In addition, recent advances in understanding the biology of SCLC have stimulated new investigations searching to counter the molecular basis underlying the increased proliferation and the apoptosis deficiency of SCLC cells. This can be achieved using antisense oligodeoxynucleotides that repress the expression of growth factor receptors and anti-apoptosis genes, or by gene replacement to compensate for the loss or inactivation of tumor suppressor genes. -PU - SPRINGER BASEL AG -PI - BASEL -PA - PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND -SN - 1420-682X -SN - 1420-9071 -DA - 1999 SEP -PY - 1999 -VL - 55 -IS - 12 -SP - 1585 -EP - 1598 -DO - 10.1007/s000180050398 -AN - WOS:000082971200009 -AD - Univ Zurich Hosp, Dept Internal Med, Div Oncol, CH-8044 Zurich, Switzerland -Y2 - 1999-09-01 -ER - - -TY - JOUR -AU - Li, Yuying -AU - Jing, Wang -AU - Jing, Xuquan -AU - Sun, Yulan -AU - Tang, Xiaoyong -AU - Guo, Jun -AU - Zhang, Yan -AU - Zhu, Hui -TI - Role of consolidative thoracic radiation in extensive-stage small-cell lung cancer with first-line chemoimmunotherapy: a retrospective study from a single cancer center -T2 - DISCOVER ONCOLOGY -M3 - Article -AB - ObjectiveTo investigate the role of consolidative thoracic radiation (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line chemo-immunotherapy followed by immunotherapy maintenance.Patients and methodsOutcomes of patients without disease progression after first-line chemotherapy were retrospectively reviewed (January 2020 to December 2021). Based on TRT or not, patients were allocated to TRT group or non-TRT group. Progression-free survival (PFS), overall survival (OS) and local-recurrence free survival (LRFS) were calculated by the Kaplan-Meier method and compared by log-rank test.ResultsOf 100 patients, 47 received TRT and 53 non-TRT. The median follow-up was 20.3 months. The median PFS and OS in TRT were 9.1 months and 21.8 months, versus 8.8 months (p = 0.93) and 24.3 months (p = 0.63), respectively, in non-TRT. The median LRFS time in TRT was not reached, but significantly longer than 10.8 months in non-TRT (HR = 0.27, p < 0.01). Second-line chemotherapy significantly prolonged survival compared to that with chemo-free patients (mOS: 24.5 vs. 21.4 months, p = 0.026). The subgroup analysis showed a trend of patients with brain metastases benefit from TRT (21.8 versus 13.7 months, HR 0.61, p = 0.38) while liver metastases did not. Of 47 patients with TRT, only 10.6% of patients experienced grade 3 radiation-induced pneumonitis, while no grade 4 or 5 adverse events occurred.ConclusionConsolidative TRT in the period of immunotherapy maintenance followed first-line chemo-immunotherapy did not prolong OS and PFS but associated with improved LRFS in ES-SCLC. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1868-8497 -SN - 2730-6011 -DA - 2023 MAY 4 -PY - 2023 -VL - 14 -IS - 1 -C7 - 55 -DO - 10.1007/s12672-023-00666-7 -AN - WOS:000981594600001 -AD - Shandong First Med Univ, Shandong Canc Hosp & Inst, Shandong Acad Med Sci, Jinan 250117, Shandong, Peoples R China -AD - Shandong First Med Univ, Shandong Acad Med Sci, Jinan 250021, Shandong, Peoples R China -AD - Shandong First Med Univ, Shandong Canc Hosp & Inst, Shandong Acad Med Sci, Jinan 250117, Shandong, Peoples R China -Y2 - 2023-05-21 -ER - - -TY - JOUR -AU - Qin, Boyu -AU - Xin, Lingli -AU - Liang, Chen -AU - Li, Lingling -AU - Song, Qi -AU - Long, Yaping -AU - Zhang, Xiaoling -AU - Wang, Dan -AU - Shi, Weiwei -AU - Zhang, Jing -AU - Hu, Yi -AU - Yang, Bo -AU - Xiong, Qi -TI - Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study -T2 - BMC CANCER -M3 - Article -AB - BackgroundImmunotherapy targeting PD-1/PD-L1 has revolutionized the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, clinical trials suggest differential efficacy of anti-PD-1 agents and anti-PD-L1 agents in first-line treatment of ES-SCLC. This retrospective multicenter study aimed to compare the efficacy and safety of anti-PD-1 agents versus anti-PD-L1 agents in first-line treatment of ES-SCLC in real-world practice.MethodsPatients with pathologically or cytologically confirmed ES-SCLC treated with platinum plus etoposide combined with anti-PD-1 or PD-L1 agents as first-line treatment in different centers of PLA General Hospital between January 2017 and October 2021 were included for this study. Survival outcomes and safety were compared between patients receiving anti-PD-1 and PD-L1 agents.ResultsOf the total 154 included patients, 68 received anti-PD-1 agents plus chemotherapy (PD-1 group), and 86 received anti-PD-L1 agents plus chemotherapy (PD-L1 group). Progression-free survival (PFS) and overall survival (OS) in the entire cohort were 7.6 months (95% confidence interval [CI]: 6.5-8.2 months) and 17.4 months (95% CI: 15.3-19.3 months), respectively. Median PFS and OS were comparable between the PD-1 group and PD-L1 group (PFS: 7.6 months vs. 8.3 months, HR = 1.13, 95% CI: 0.79-1.62, p = 0.415; OS: 26.9 months vs. 25.6 months, HR = 0.96, 95% CI: 0.63-1.47, p = 0.859. The objective response rate and disease control rate were comparable between the two groups: 79.4% vs. 79.1% and 92.6% vs. 94.2%, respectively. The 6-month, 12-month, and 18-month PFS and OS rates were slightly higher in the PD-L1 group than in the PD-1 group, while the 24-month PFS rate was slightly higher in the PD-1 group than in the PD-L1 group. Stratified analysis showed that locoregional thoracic radiotherapy and normal lactate dehydrogenase level were independent predictors of better OS in ES-SCLC patients treated with first-line chemotherapy plus ICI. Adverse events were not significantly different between the two groups.ConclusionsAnti-PD-1 agents and anti-PD-L1 agents combined with chemotherapy as first-line treatment for ES-SCLC are comparably effective and well tolerated. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2024 JAN 17 -PY - 2024 -VL - 24 -IS - 1 -C7 - 100 -DO - 10.1186/s12885-024-11833-6 -AN - WOS:001144652200006 -AD - Fifth Med Ctr PLA Gen Hosp, Sr Dept Hepatol, 100,Middle Rd West 4th Ring, Beijing 100039, Peoples R China -AD - PLA Rocket Force Characterist Med Ctr, Dept Obstet & Gynecol, Xinjiekou Outer St 16, Beijing 100088, Peoples R China -AD - Peoples Liberat Army Gen Hosp, Dept Grad Adm, Fuxing Rd 28, Beijing 100853, Peoples R China -AD - Peoples Liberat Army Gen Hosp, Med Serv Dept, Fuxing Rd 28, Beijing 100853, Peoples R China -AD - Peoples Liberat Army Gen Hosp, Dept Oncol, Med Ctr 1, Fuxing Rd 28, Beijing 100853, Peoples R China -M2 - Fifth Med Ctr PLA Gen Hosp -M2 - PLA Rocket Force Characterist Med Ctr -Y2 - 2024-02-27 -ER - - -TY - JOUR -AU - Saltos, Andreas -AU - Antonia, Scott -TI - Breaking the Impasse Advances in Treatment of Small Cell Lung Cancer -T2 - CLINICS IN CHEST MEDICINE -M3 - Review -AB - Small cell lung cancer (SCLC) is an aggressive malignancy and carries a poor prognosis with limited effective treatments in the advanced setting. SCLC is characterized by a high tumor mutation burden and alterations in Notch signaling and DNA damage repair pathways, providing rationale for the use of immunotherapy and targeted therapies. Immunotherapies have led to the most significant advances in treating SCLC in decades, and several promising targeted approaches have emerged from the increased understanding of the biology of SCLC. However, responses to these novel approaches are far from universal, and efforts to refine these therapies are ongoing. -PU - W B SAUNDERS CO-ELSEVIER INC -PI - PHILADELPHIA -PA - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA -SN - 0272-5231 -SN - 1557-8216 -DA - 2020 JUN -PY - 2020 -VL - 41 -IS - 2 -SP - 269 -EP - + -DO - 10.1016/j.ccm.2020.02.011 -AN - WOS:000532666100011 -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA -AD - Duke Canc Inst, Ctr Canc Immunotherapy, 20 Duke Med Circle, Durham, NC 27710 USA -Y2 - 2020-05-27 -ER - - -TY - JOUR -AU - Vinh-Hung, Vincent -AU - Gorobets, Olena -AU - Duerinkcx, Andre -AU - Dutta, Suresh -AU - Oboite, Eromosele -AU - Oboite, Joan -AU - Ali, Ahmed -AU - Mazibuko, Thandeka -AU - Karlsson, Ulf -AU - Chi, Alexander -AU - Lehrman, David -AU - Mohammed, Omer Hashim -AU - Mohammadianpanah, Mohammad -AU - Loganadane, Gokoulakrichenane -AU - Migliore, Natalia -AU - Vasileiou, Maria -AU - Nguyen, Nam P. -AU - Giap, Huan -TI - Is immunotherapy at reduced dose and radiotherapy for older patients with locally advanced non-small lung cancer feasible?-a narrative review by the international geriatric radiotherapy group -T2 - TRANSLATIONAL CANCER RESEARCH -M3 - Review -AB - Background and Objective The standard of care for locally advanced non-small cell lung cancer (NSCLC) is either surgery followed by adjuvant chemotherapy with or without radiotherapy or concurrent chemotherapy and radiotherapy. However, older patients (70 years old or above) with multiple co-morbidities may not be able to tolerate the combined treatment due to its toxicity. Since lung cancer prevalence increases significantly with age, a new algorithm needs to be investigated to allow curative treatment for those with locally advanced disease.Methods: A literature search of the literature was conducted through PubMed and Google Scholar using search terms such as locally advanced NSCLC, older cancer patients, immunotherapy with check point inhibitors (CPI), and image-guided radiotherapy (IGRT). Abstracts were screened, full articles fitting the article topic were reviewed, and duplicated and non-English articles were excluded.Key Content and Findings: Recently, CPI has been introduced and proven effective for selected patients with increased program death ligand 1 (PD-L1) expression (50% or above). A reduced dose for CPI (RDCPI) may be as effective as a full dose and may decrease treatment cost. New radiation technique such as IGRT may also minimize radiotherapy complication through normal lung and cardiac sparing.Conclusions: IGRT and RDCPI may be an innovative option for older patients with locally advanced NSCLC and high PD-L1 expression and needs to be investigated in future prospective studies. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-676X -SN - 2219-6803 -DA - 2022 SEP -PY - 2022 -VL - 11 -IS - 9 -SP - 3298 -EP - 3308 -DO - 10.21037/tcr-22-821 -AN - WOS:000862926100001 -C6 - AUG 2022 -AD - Ctr Hosp Polynesie Francaise, Dept Radiat Oncol, Tahiti, French Polynesi, France -AD - Ctr Hosp Univ Martin, Dept Oral Surg, Le Lamentin, Martinique, France -AD - Howard Univ, Dept Radiol, Washington, DC USA -AD - Int Geriatr Radiotherapy Grp, Dept Radiat Oncol, Washington, DC USA -AD - Capital Med Univ, Beijing Chest Hosp, Dept Radiat Oncol, Beijing, Peoples R China -AD - Port Sudan Oncol, Dept Radiat Oncol, Khartoum, Sudan -AD - Shiraz Univ Med Sci, Namazi Hosp, Dept Radiat Oncol, Shiraz, Iran -AD - Univ Paris Est Creteil, Dept Radiat Oncol, CHU Mondor, Creteil, France -AD - Barretos Sch Hlth Sci Dr Paulo Prata, Barretos, SP, Brazil -AD - Natl & Kapodistrian Univ Athens, Sch Hlth Sci, Dept Pharm, Athens, Greece -AD - Med Univ South Carolina, Dept Radiat Oncol, Charleston, SC USA -M2 - Ctr Hosp Polynesie Francaise -M2 - Ctr Hosp Univ Martin -M2 - Int Geriatr Radiotherapy Grp -M2 - Port Sudan Oncol -M2 - Barretos Sch Hlth Sci Dr Paulo Prata -Y2 - 2022-10-13 -ER - - -TY - JOUR -AU - Buriolla, Silvia -AU - Pelizzari, Giacomo -AU - Corvaja, Carla -AU - Alberti, Martina -AU - Targato, Giada -AU - Bortolot, Martina -AU - Torresan, Sara -AU - Cortiula, Francesco -AU - Fasola, Gianpiero -AU - Follador, Alessandro -TI - Immunotherapy in NSCLC Patients with Brain Metastases -T2 - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES -M3 - Review -AB - Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases (BMs) during their disease, with considerable morbidity and mortality. The management of BMs in patients with NSCLC is a clinical challenge and requires a multidisciplinary approach to gain effective intracranial disease control. Over the last decade, immune checkpoint inhibitors (ICIs) have emerged as a game-changer in the treatment landscape of advanced NSCLC, with significant improvements in survival outcomes, although patients with BMs are mostly underrepresented in randomized clinical trials. Moreover, the safety and activity of ICIs and radiotherapy combinations compared with single-agent or sequential modalities is still under evaluation to establish the optimal management of these patients. The aim of this review is to summarize the state-of-the-art of clinical evidence of ICIs intracranial activity and the main challenges of incorporating these agents in the treatment armamentarium of NSCLC patients with BMs. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1422-0067 -DA - 2022 JUL -PY - 2022 -VL - 23 -IS - 13 -C7 - 7068 -DO - 10.3390/ijms23137068 -AN - WOS:000824323500001 -AD - Univ Udine, Dept Med DAME, I-33100 Udine, Italy -AD - Azienda Sanitaria Univ Friuli Cent ASUFC, Dept Oncol, I-33100 Udine, Italy -M2 - Azienda Sanitaria Univ Friuli Cent ASUFC -Y2 - 2022-07-20 -ER - - -TY - JOUR -AU - Patel, Monaliben -AU - Bruno, Debora -AU - Grubb, William -AU - Biswas, Tithi -TI - The changing landscape of stage III lung cancer: a literature review -T2 - EXPERT REVIEW OF ANTICANCER THERAPY -M3 - Review -AB - Introduction The treatment of stage III non-small cell lung cancer (NSCLC) remains challenging and associated with overall poor outcomes. Since seminal studies in the early 90s introduced concurrent chemo-radiotherapy as standard of care for treatment of this disease, no major advances have been introduced in this landscape. Both radiation dose escalation and neoadjuvant/adjuvant chemotherapy strategies were unsuccessful to improve the survival over standard of care radiation dose and chemotherapy schedule: five-year overall survival (OS) ranging from 15-20%. However, in 2017 the PACIFIC Trial demonstrated that the addition of consolidative immune checkpoint inhibitor durvalumab for 1 year led to superior progression-free survival (PFS) and 3-year overall survival with no significant increase in toxicity compared to placebo in patients who achieved disease control with concurrent chemo-RT. Areas covered This article reviews the treatment evolution of stage III NSCLC over the past decades, discusses current standard of care strategies, and highlights potential future directions for the management of this condition. Expert opinion Ongoing trials incorporating upfront checkpoint inhibitors with radiotherapy will answer whether adding checkpoint inhibitors to chemotherapy or substituting them for chemotherapy altogether will improve long-term outcome. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1473-7140 -SN - 1744-8328 -DA - 2020 AUG 2 -PY - 2020 -VL - 20 -IS - 8 -SP - 675 -EP - 686 -DO - 10.1080/14737140.2020.1796645 -AN - WOS:000555257500001 -C6 - JUL 2020 -AD - Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA -Y2 - 2020-08-17 -ER - - -TY - JOUR -AU - Tabchi, Samer -AU - Kassouf, Elie -AU - El Rassy, Elie -AU - Kourie, Hampig Raphael -AU - Martin, Jocelyne -AU - Campeau, Marie-Pierre -AU - Tehfe, Mustapha -AU - Blais, Normand -TI - Management of stage III non-small cell lung cancer -T2 - SEMINARS IN ONCOLOGY -M3 - Review -AB - Optimal management of patients with locally advanced non-small cell lung cancer remains challenging in the context of this heterogeneous disease. Despite aggressive therapeutic approaches, survival benefits are still unsatisfactory for what might be viewed as a localized malignancy. A combined modality approach offers patients superior outcomes, especially because technological advances and refined surgical procedures now provide better results with fewer complications. Nevertheless, several features of therapy remain controversial and lack formal prospective data. Traditional cytotoxic chemoradiation therapy may have reached a plateau and future perspectives opting to integrate molecularly targeted agents and immunotherapy might be the way to improve outcomes in this disease subset. (C) 2017 Elsevier Inc. All rights reserved. -PU - W B SAUNDERS CO-ELSEVIER INC -PI - PHILADELPHIA -PA - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA -SN - 0093-7754 -SN - 1532-8708 -DA - 2017 JUN -PY - 2017 -VL - 44 -IS - 3 -SP - 163 -EP - 177 -DO - 10.1053/j.seminoncol.2017.10.009 -AN - WOS:000418634400001 -AD - Ctr Hosp Univ Montreal, Med Oncol Dept, Montreal, PQ, Canada -AD - St Joseph Univ, Fac Med, Hotel Dieu France, Univ Hosp, Beirut, Lebanon -AD - Univ Libre Bruxelles, Jules Bordet Inst, Oncol Dept, Brussels, Belgium -AD - Ctr Hosp Univ Montreal, Dept Thorac Surg, Montreal, PQ, Canada -AD - Ctr Hosp Univ Montreal, Radiat Oncol Dept, Montreal, PQ, Canada -M2 - St Joseph Univ -Y2 - 2017-06-01 -ER - - -TY - JOUR -AU - Bergsma, Derek P. -AU - Salama, Joseph K. -AU - Singh, Deepinder P. -AU - Chmura, Steven J. -AU - Milano, Michael T. -TI - Radiotherapy for Oligometastatic Lung Cancer -T2 - FRONTIERS IN ONCOLOGY -M3 - Review -AB - Non-small cell lung cancer (NSCLC) typically presents at an advanced stage, which is often felt to be incurable, and such patients are usually treated with a palliative approach. Accumulating retrospective and prospective clinical evidence, including a recently completed randomized trial, support the existence of an oligometastatic disease state wherein select individuals with advanced NSCLC may experience historically unprecedented prolonged survival with aggressive local treatments, consisting of radiotherapy and/or surgery, to limited sites of metastatic disease. This is reflected in the most recent AJCC staging subcategorizing metastatic disease into intra-thoracic (M1a), a single extra thoracic site (M1b), and more diffuse metastases (M1c). In the field of radiation oncology, recent technological advances have allowed for the delivery of very high, potentially ablative, doses of radiotherapy to both intra-and extra-cranial disease sites, referred to as stereotactic radiosurgery and stereotactic body radiotherapy (or SABR), in much shorter time periods compared to conventional radiation and with minimal associated toxicity. At the same time, significant improvements in systemic therapy, including platinum-based doublet chemotherapy, molecular agents targeting oncogene-addicted NSCLC, and immunotherapy in the form of checkpoint inhibitors, have led to improved control of micro-metastatic disease and extended survival sparking newfound interest in combining these agents with ablative local therapies to provide additive, and in the case of radiation and immunotherapy, potentially synergistic, effects in order to further improve progression-free and overall survival. Currently, despite the tantalizing potential associated with aggressive local therapy in the setting of oligometastatic NSCLC, well-designed prospective randomized controlled trials sufficiently powered to detect and measure the possible added benefit afforded by this approach are desperately needed. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2017 SEP 19 -PY - 2017 -VL - 7 -C7 - 210 -DO - 10.3389/fonc.2017.00210 -AN - WOS:000411107300001 -AD - Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA -AD - Duke Univ Hlth Syst, Dept Radiat Oncol, Raleigh, NC USA -AD - Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA -M2 - Duke Univ Hlth Syst -Y2 - 2017-09-28 -ER - - -TY - JOUR -AU - Vaes, Rianne D. W. -AU - Reynders, Kobe -AU - Sprooten, Jenny -AU - Nevola, Kathleen T. -AU - Rouschop, Kasper M. A. -AU - Vooijs, Marc -AU - Garg, Abhishek D. -AU - Lambrecht, Maarten -AU - Hendriks, Lizza E. L. -AU - Rucevic, Marijana -AU - De Ruysscher, Dirk -TI - Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study -T2 - CANCERS -M3 - Article -AB - Simple Summary Over the last 5 years, immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of non-small cell lung cancer (NSCLC) as either monotherapy or in combination with chemo- and/or radiotherapy. However, despite these advances, outcome still remains poor for most patients and there is still a lot of room to improve prognosis in these patients. To date, we have no tools that allow us to identify the patients that will benefit from chemo- and/or radiotherapy combined with immunotherapy, what treatment-induced immune changes can be expected, and what are the most optimal treatment combinations. Therefore, prognostic and predictive immunological biomarkers are urgently needed. This prospective exploratory study aimed to identify potential prognostic and predictive immune-related proteins that are associated with progression-free survival in patients with stage I/III NSCLC. The results of this trial provide a good starting point to implement blood-based immune profiling analyses in future clinical trials. Radiotherapy (RT) and chemotherapy can induce immune responses, but not much is known regarding treatment-induced immune changes in patients. This exploratory study aimed to identify potential prognostic and predictive immune-related proteins associated with progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC). In this prospective study, patients with stage I NSCLC treated with stereotactic body radiation therapy (n = 26) and patients with stage III NSCLC treated with concurrent chemoradiotherapy (n = 18) were included. Blood samples were collected before (v1), during (v2), and after RT (v3). In patients with stage I NSCLC, CD244 (HR: 10.2, 95% CI: 1.8-57.4) was identified as a negative prognostic biomarker. In patients with stage III NSCLC, CR2 and IFNGR2 were identified as positive prognostic biomarkers (CR2, HR: 0.00, 95% CI: 0.00-0.12; IFNGR2, HR: 0.04, 95% CI: 0.00-0.46). In addition, analysis of the treatment-induced changes of circulating protein levels over time (Delta v2/v3-v1) also identified CXCL10 and IL-10 as negative predictive biomarkers (CXCL10, HR: 3.86, 95% CI: 1.0-14.7; IL-10, HR: 16.92 (2.74-104.36)), although serum-induced interferon (IFN) response was a positive prognostic. In conclusion, we identified several circulating immunogenic proteins that are correlated with PFS in patients with stage I and stage III NSCLC before and during treatment. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2021 DEC -PY - 2021 -VL - 13 -IS - 24 -C7 - 6259 -DO - 10.3390/cancers13246259 -AN - WOS:000736135600001 -AD - Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Radiat Oncol MAASTRO, NL-6200 MD Maastricht, Netherlands -AD - Katholieke Univ Leuven, Dept Cellular & Mol Med, Cell Stress & Immun CSI Lab, B-3000 Leuven, Belgium -AD - OLINK Proteom Inc, Waltham, MA 02453 USA -AD - Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Radiotherapy, NL-6200 MD Maastricht, Netherlands -AD - Univ Ziekenhuis UZ Gasthuisberg, Leuven Kanker Inst, Dept Radiotherapy Oncol, B-3000 Leuven, Belgium -AD - Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Pulm Dis, NL-6200 MD Maastricht, Netherlands -M2 - OLINK Proteom Inc -M2 - Univ Ziekenhuis UZ Gasthuisberg -Y2 - 2022-01-06 -ER - - -TY - JOUR -AU - Lehman, M. -TI - Improving Therapeutic Outcomes in Non-small Cell Lung Cancer not Suitable for Curative Intent Therapy - A Review of the Role of Radiation Therapy in an Era of Increasing Systemic Therapy Options -T2 - CLINICAL ONCOLOGY -M3 - Review -AB - Lung cancer is the highest cause of mortality from cancer worldwide. Most patients present with disease not suitable for curative therapeutic options. In these patients, radiation therapy provides durable palliation of symptoms due to intrathoracic disease, whereas systemic chemotherapy improves survival compared with best supportive care. Over recent years the systemic therapeutic options available for the non-curative management of advanced lung cancer, particularly non-small cell lung cancer, have expanded to include molecularly targeted agents and immune modulating agents. The aim of this overview is to review the role and future of radiation therapy in this era of increasing systemic therapy options with particular emphasis on how radiation therapy can be used to improve therapeutic outcomes. (C) 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCIENCE LONDON -PI - LONDON -PA - 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND -SN - 0936-6555 -SN - 1433-2981 -DA - 2016 MAY -PY - 2016 -VL - 28 -IS - 5 -SP - 327 -EP - 333 -DO - 10.1016/j.clon.2015.11.015 -AN - WOS:000373606000042 -AD - Univ Queensland, Sch Med, Brisbane, Qld, Australia -AD - Princess Alexandra Hosp, Dept Radiat Oncol, Brisbane, Qld 4102, Australia -Y2 - 2016-04-27 -ER - - -TY - JOUR -AU - Khan, Raza -AU - Coleman, Niamh -TI - Challenges and opportunities in the immunotherapy era: balancing expectations with hope in small-cell lung cancer -T2 - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY -M3 - Review -AB - Small-cell lung cancer (SCLC) is a biologically aggressive subtype of lung cancer, a lethal disease characterized by rapid tumor growth, early relapse, a strong tendency for early widespread metastasis, and high genomic instability, making it a formidable foe in modern oncology practice. While the management of non-SCLC has been revolutionized in the era of immunotherapy, progress in SCLC has been more muted. Recent randomized phase III clinical trials have combined programmed death ligand-1 inhibitors to a chemotherapy backbone and demonstrated improved survival; however, the absolute benefit observed is short months. There is an undeniable urgent need for better responses, better agents, novel therapeutic approaches, and more rational, biomarker-driven clinical trials in SCLC. In this review, we discuss the rationale and current understanding of the biology of SCLC in the modern era of immunotherapy, discuss recent advances in front-line immunotherapeutic approaches that have changed clinical practice globally, provide an overview of some of the challenges and limitations that have staggered immune checkpoint blockade in SCLC, and explore some of the novel immunotherapeutic approaches currently being investigated. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1758-8340 -SN - 1758-8359 -DA - 2024 -PY - 2024 -VL - 16 -C7 - 17588359241249627 -DO - 10.1177/17588359241249627 -AN - WOS:001225644100001 -AD - Trinity Coll Dublin, Sch Med, Dublin, Ireland -AD - St James Hosp, Dublin, Ireland -AD - Trinity St Jamess Canc Inst, Dublin D08NHY1, Ireland -M2 - Trinity St Jamess Canc Inst -Y2 - 2024-05-25 -ER - - -TY - JOUR -AU - Shiarli, A-M -AU - McDonald, F. -AU - Gomez, D. R. -TI - When Should we Irradiate the Primary in Metastatic Lung Cancer? -T2 - CLINICAL ONCOLOGY -M3 - Article -AB - Metastatic lung cancer encompasses a heterogenous group of patients in terms of burdens of disease, ranging from patients with extensive metastases to those with a limited number of metastatic lesions (oligometastatic disease). Histopathological heterogeneity also exists within two broad categories, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), portraying different patterns and evolution of disease. Local consolidative therapy to the primary tumour and metastatic sites, including surgery and/or radical dose radiotherapy, is increasingly being used to improve survival outcomes, particularly in the context of oligometastatic disease, with or without the use of molecular targeted therapy and immunotherapy. Recently, randomised studies in oligometastatic NSCLC have shown that local consolidative therapy may confer a survival advantage. This review explores whether treating just the primary tumour with radiotherapy may similarly produce improved clinical outcomes. Such a treatment strategy may carry less potential toxicity than treating multiple sites upfront. The biological rationale behind the potential benefits of treating just the primary in metastatic malignancy is discussed. The clinical evidence of such an approach across tumour sites, such as breast and prostate cancer, is also explored. Then the review focuses on treating the primary in NSCLC and SCLC with radiotherapy, by first exploring patterns of failure in metastatic NSCLC and second exploring evidence on survival outcomes from studies in metastatic NSCLC and SCLC. It is challenging to draw conclusions on the clinical benefit of treating the primary cancer in isolation from the evidence available. This highlights the need to collect data within the ongoing clinical trials on the clinical outcome and toxicity of radiotherapy delivery to primary thoracic disease specifically. This challenge also identifies the need to design future clinical trials to produce randomised evidence for such an approach. (C) 2019 The Royal College of Radiologists. Published by Elsevier Ltd. -PU - ELSEVIER SCIENCE LONDON -PI - LONDON -PA - 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND -SN - 0936-6555 -SN - 1433-2981 -DA - 2019 DEC -PY - 2019 -VL - 31 -IS - 12 -SP - 815 -EP - 823 -DO - 10.1016/j.clon.2019.07.012 -AN - WOS:000496744700004 -AD - Royal Marsden Hosp, Radiotherapy Dept, Sutton, Surrey, England -AD - Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA -Y2 - 2019-11-28 -ER - - -TY - JOUR -AU - Qin, Haifeng -AU - Wang, Fang -AU - Liu, Hui -AU - Zeng, Zhen -AU - Wang, Shasha -AU - Pan, Xin -AU - Gao, Hongjun -TI - New advances in immunotherapy for non-small cell lung cancer -T2 - AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH -M3 - Review -AB - Immunotherapy is one of the methods that can change the survival rate of patients with malignant tumors, in addition to surgery therapy, radiotherapy, chemotherapy and targeted therapy. Among various immunotherapy methods, immunoprecipitation inhibitors have been the most effective medications developed in recent years. At present, more in-depth studies have been conducted for two immune checkpoint inhibitor pathways, programmed cell death protein 1 (PD-1)/Programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and a variety of medications for those above mentioned. The present study briefly reviews the results of clinical trials for relevant immune checkpoint inhibitors in lung cancer. -PU - E-CENTURY PUBLISHING CORP -PI - MADISON -PA - 40 WHITE OAKS LN, MADISON, WI 53711 USA -SN - 1943-8141 -DA - 2018 -PY - 2018 -VL - 10 -IS - 8 -SP - 2234 -EP - 2245 -AN - WOS:000443724100002 -AD - 307th Hosp Chinese Peoples Liberat Army, Dept Lung Canc, 8 East St, Beijing 100071, Peoples R China -M2 - 307th Hosp Chinese Peoples Liberat Army -Y2 - 2018-09-13 -ER - - -TY - JOUR -AU - Freeman-Keller, Morganna -AU - Goldman, Jamie -AU - Gray, Jhanelle -TI - Vaccine immunotherapy in lung cancer: Clinical experience and future directions -T2 - PHARMACOLOGY & THERAPEUTICS -M3 - Review -AB - Lung cancer remains the most common cause of cancer-related deaths in the United States, with SEER data showing lung cancer accounting for 29% of all male-related cancer mortality and 26% of all female-related mortality. Patients with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) who have localized disease both have 5-year survival rates of 52.2%, whereas patients with metastatic disease have 5-year survival rates of only 3.7%. Traditional anti-cancer therapies (surgery, radiotherapy, and chemotherapy) have limited effectiveness in curbing progression. However, advances in immunology and molecular biology in the past two decades have resulted in improved prognosis for those with SCLC and NSCLC, although novel therapies are still needed to make significant improvements in median overall and progression-free survival rates. Notable progress on the importance of tumor immunology has included work on immune surveillance, antigenic targets, and immune checkpoints. Immunotherapies, including vaccines, which can induce antitumor responses by harnessing the power of the immune system, may help to fill this void, and the cancer vaccine continues to be studied as adjunctive therapy. Here, we review recently reported results from clinical trials as well as the possible future roles of vaccine therapy in the treatment of SCLC and NSCLC patients. (C) 2015 Published by Elsevier Inc. -PU - PERGAMON-ELSEVIER SCIENCE LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND -SN - 0163-7258 -SN - 1879-016X -DA - 2015 SEP -PY - 2015 -VL - 153 -SP - 1 -EP - 9 -DO - 10.1016/j.pharmthera.2015.05.004 -AN - WOS:000359882500001 -AD - Univ S Florida, Dept Grad Med Educ, Tampa, FL 33620 USA -AD - Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL 33612 USA -Y2 - 2015-09-09 -ER - - -TY - JOUR -AU - Rusch, Valerie W. -AU - Nicholas, Alan -AU - Patterson, G. Alexander -AU - Waqar, Salama N. -AU - Toloza, Eric M. -AU - Haura, Eric B. -AU - Raz, Dan J. -AU - Reckamp, Karen L. -AU - Merritt, Robert E. -AU - Owen, Dwight H. -AU - Finley, David J. -AU - McNamee, Ciaran J. -AU - Blasberg, Justin D. -AU - Garon, Edward B. -AU - Mitchell, John D. -AU - Doebele, Robert C. -AU - Baciewicz, Frank -AU - Nagasaka, Misako -AU - Pass, Harvey I. -AU - Schulze, Katja -AU - Johnson, Ann -AU - Bunn, Paul A. -AU - Johnson, Bruce E. -AU - Kris, Mark G. -AU - Kwiatkowski, David J. -AU - Wistuba, Ignacio I. -AU - Chaft, Jamie E. -AU - Carbone, David P. -AU - Lee, Jay M. -TI - Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer -T2 - JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY -M3 - Article -AB - Objective: Multimodality treatment for resectable non-small cell lung cancer has long remained at a therapeutic plateau. Immune checkpoint inhibitors are highly effective in advanced non-small cell lung cancer and promising preoperatively in small clinical trials for resectable non-small cell lung cancer. This large multicenter trial tested the safety and efficacy of neoadjuvant atezolizumab and surgery.Methods: Patients with stage IB to select IIIB resectable non-small cell lung cancer and Eastern Cooperative Oncology Group performance status 0/1 were eligible. Patients received atezolizumab 1200 mg intravenously every 3 weeks for 2 cycles or less followed by resection. The primary end point was major pathological response in patients without EGFR/ALKthorn alterations. Pre- and post-treatment computed tomography, positron emission tomography, pulmonary function tests, and bio-specimens were obtained. Adverse events were recorded by Common Terminology Criteria for Adverse Events v.4.0.Results: From April 2017 to February 2020, 181 patients were entered in the study. Baseline characteristics were mean age, 65.1 years; female, 93 of 181 (51%); nonsquamous histology, 112 of 181 (62%); and clinical stages IIB to IIIB, 147 of 181 (81%). In patients without EGFR/ALK alterations who underwent surgery, the major pathological response rate was 20% (29/143; 95% confidence interval, 14-28) and the pathological complete response rate was 6% (8/143; 95% confidence interval, 2-11). There were no grade 4/5 treatment-related adverse events preoperatively. Of 159 patients (87.8%) undergoing surgery, 145 (91%) had pathologic complete resection. There were 5 (3%) intraoperative complications, no intraoperative deaths, and 2 postoperative deaths within 90 days, 1 treatment related. Median disease-free and overall survival have not been reached.Conclusions: Neoadjuvant atezolizumab in resectable stage IB to IIIB non-small cell lung cancer was well tolerated, yielded a 20% major pathological response rate, and allowed safe, complete surgical resection. These results strongly support the further development of immune checkpoint inhibitors as preoperative therapy in locally advanced non-small cell lung cancer. -PU - MOSBY-ELSEVIER -PI - NEW YORK -PA - 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA -SN - 0022-5223 -SN - 1097-685X -DA - 2023 MAR -PY - 2023 -VL - 165 -IS - 3 -SP - 828 -EP - + -DO - 10.1016/j.jtcvs.2022.10.007 -AN - WOS:001046479500001 -C6 - FEB 2023 -AD - Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, New York, NY USA -AD - Genentech Inc, San Francisco, CA USA -AD - Washington Univ, Sch Med, St Louis, MO USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA -AD - Cedars Sinai City Hope Comprehens Canc Ctr, Los Angeles, CA USA -AD - Ohio State Med Ctr, Columbus, OH USA -AD - Pelotonia Inst Immune Oncol, Columbus, OH USA -AD - Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA -AD - Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA -AD - Yale Sch Med, New Haven, CT USA -AD - Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA -AD - Univ Colorado, Canc Ctr, Aurora, CO USA -AD - Wayne State Univ, Detroit, MI USA -AD - Karmanos Canc Inst, Detroit, MI USA -AD - NYU, New York, NY USA -AD - Dana Farber Canc Inst, Boston, MA 02115 USA -AD - Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA -AD - Rain Therapeut, CSO, Newark, DE USA -AD - Univ Calif Irvine Hlth, Orange, CA USA -M2 - Cedars Sinai City Hope Comprehens Canc Ctr -M2 - Pelotonia Inst Immune Oncol -M2 - Rain Therapeut -Y2 - 2023-09-02 -ER - - -TY - JOUR -AU - Yoneda, Kazue -AU - Imanishi, Naoko -AU - Ichiki, Yoshinobu -AU - Tanaka, Fumihiro -TI - Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). -T2 - Journal of UOEH -M3 - Journal Article -M3 - Research Support, Non-U.S. Gov't -M3 - Review -AB - Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has become a "game changer" in the treatment of advanced non-small cell lung cancer (NSCLC). Its most clinically important advantage over traditional chemotherapy using cytotoxic agents are its long-term survival benefits, and some advanced NSCLC patients treated with an antibody against programmed cell death 1 (PD-1) have survived for 5 years or longer. Immune checkpoint inhibitors (ICIs) are also potentially useful for earlier-stage NSCLC when used in combination with surgery or radiotherapy. A recent clinical trial has shown that consolidation treatment with an antibody against a ligand of PD-1 (PD-L1) following chemo-radiotherapy significantly improves progression-free survival for patients with locally advanced NSCLC. However, current single-agent treatment with an anti-PD-1/PD-L1 antibody may provide significant survival benefits only in a small subset of patients. PD-L1 expression status on tumor cells is an approved biomarker to predict response to ICIs, but is not enough for optimal patient selection. To improve the therapeutic outcomes, development of novel biomarkers other than PD-L1 expression status is essential. Combination treatment strategies based on blockade of PD-1/PD-L1 may also be promising, and a variety of combinations, such as ICIs plus chemotherapy, are being examined in ongoing clinical trials. Here we review and discuss the current status and future perspectives of immunotherapy with ICIs. -SN - 0387-821X -DA - 2018 -PY - 2018 -VL - 40 -IS - 2 -SP - 173 -EP - 189 -DO - 10.7888/juoeh.40.173 -AN - MEDLINE:29925736 -AD - Second Department of Surgery (Chest Surgery), School of Medicine, University of Occupational and Environmental Health, Japan. -Y2 - 2018-06-29 -ER - - -TY - JOUR -AU - Pakkala, Suchita -AU - Owonikoko, Taofeek K. -TI - Immune checkpoint inhibitors in small cell lung cancer -T2 - JOURNAL OF THORACIC DISEASE -M3 - Review -AB - Small cell lung cancer (SCLC) is a rapidly progressive cancer that often debilitates patients within months of detection and quickly becomes refractory to the limited options of therapy. While SCLC is not generally considered an immunogenic tumor, clinical experience suggests that patients with robust immune response manifesting as paraneoplastic syndrome are more likely to present with limited stage of the disease and tend to have a better prognosis. Monoclonal antibodies targeting critical negative regulators of immune response, so called immune checkpoints, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) have expanded the application of immune-based therapies to increasing number of advanced stage cancers. These agents overcome the inhibitory immune signals leading to a heightened immune response against cancer cells. These immune checkpoint inhibitors have established efficacy leading to regulatory approval for their use in many cancer types including non-small cell lung cancer (NSCLC). Evaluation of the CTLA-4 inhibitor, ipilimumab and PD-1 inhibitors, nivolumab and pembrolizumab in SCLC have shown encouraging signal but definitive studies are still ongoing. In this review, we discuss the rationale behind the use of checkpoint inhibitors in SCLC, contextualize the results of early trials of immunotherapy agents in SCLC and project the future evolution of this strategy. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2018 FEB -PY - 2018 -VL - 10 -SP - S460 -EP - S467 -DO - 10.21037/jtd.2017.12.51 -AN - WOS:000427730600008 -AD - Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, 1365 Clifton Rd NE, Atlanta, GA 30322 USA -Y2 - 2018-12-28 -ER - - -TY - JOUR -AU - Duma, Narjust -AU - Santana-Davila, Rafael -AU - Molina, Julian R. -TI - Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment -T2 - MAYO CLINIC PROCEEDINGS -M3 - Review -AB - Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non-small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. The National Lung Screening Trial found a lung cancer mortality benefit of 20% and a 6.7% decrease in all-cause mortality with the use of low-dose chest computed tomography in high-risk individuals. The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. Similarly, immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of NSCLC treatment. Furthermore, the results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLC. Expression of programmed cell death protein-ligand 1 in malignant cells has been studied as a potential biomarker for response to ICIs. However, important drawbacks exist that limit its discriminatory potential. Identification of accurate predictive biomarkers beyond programmed cell death protein-ligand 1 expression remains essential to select the most appropriate candidates for ICI therapy. Many questions remain unanswered regarding the proper sequence and combinations of these new agents; however, the field is moving rapidly, and the overall direction is optimistic. (C) 2019 Mayo Foundation for Medical Education and Research -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0025-6196 -SN - 1942-5546 -DA - 2019 AUG -PY - 2019 -VL - 94 -IS - 8 -SP - 1623 -EP - 1640 -DO - 10.1016/j.mayocp.2019.01.013 -AN - WOS:000478016900031 -AD - Mayo Clin, Div Med Oncol, Rochester, MN USA -AD - Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA -Y2 - 2019-08-01 -ER - - -TY - JOUR -AU - Martin, Margarita -AU - Hernanz, Raul -AU - Vallejo, Carmen -AU - Guerrero, Leonardo -AU - Mielgo, Xabier -AU - Lopez, Ana -AU - Trujillo-Reyes, Juan Carlos -AU - Counago, Felipe -TI - Brain metastases from non-small cell lung carcinoma: an overview of classical and novel treatment strategies -T2 - REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY -M3 - Article -AB - Background: The development of brain metastases is a common problem in patients diagnosed with non-small cell lung carcinoma (NSCLC). Technological advances in surgery and radiotherapy have allowed greater local control. Moreover, the emergence of targeted therapies and immunotherapy with greater activity on the central nervous system than classical chemotherapy have given way to new strategies in the treatment of brain metastases. We review the current role of local treatments, surgery and radiotherapy, and the most effective combination strategies with the new systemic treatments. Relevance for patients: Brain metastases frequently occur during the course of NSCLC. In recent years, a range of treatments have appeared, such as targeted treatments or immunotherapy, with greater activity at the brain level than classical chemotherapy. Radiotherapy treatment is also now much more conformal and ablative doses can be delivered to the volume of the metastatic area, providing greater local control and less neurological toxicity. However, surgery is still required in cases where anatomopathological specimens are needed and when compressive effects appear. An important challenge is how to combine these treatments to achieve the best control and minimise patients' neurological impairments, especially because of limited experience with the new target drugs, and the unknown toxicity of the different combinations. Future research should therefore focus on these areas in order to establish the best strategies for the treatment of brain metastases from non-small cell lung cancer. Core tips: In this work, we intend to elucidate the best therapeutic options for patients diagnosed with brain metastases of NSCL, which include: surgery, WBRT, radiosurgery or systemic treatment, and the most effective combinations and timings of them, and the ones with the lowest associated toxicity. -PU - VIA MEDICA -PI - GDANSK -PA - UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND -SN - 1507-1367 -SN - 2083-4640 -DA - 2022 MAY-JUN -PY - 2022 -VL - 27 -IS - 3 -SP - 527 -EP - 544 -DO - 10.5603/RPOR.a2022.0050 -AN - WOS:000861831200001 -AD - Hosp Univ Ramon y Cajal, Serv Oncol Radioterap, Radiat Oncol, Madrid, Spain -AD - Hosp La Luz, Oncol Radioterap, Grp Quironsalud, Madrid, Spain -AD - Hosp Univ Fdn Alcorcon, Med Oncol, Alcorcon, Spain -AD - Hosp Severo Ochoa, Med Oncol, Leganes, Spain -AD - Hosp Santa Creu & Sant Pau, Thorac Surg, Barcelona, Spain -AD - Univ Europea Madrid, Madrid, Spain -AD - Hosp Univ Ramon y Cajal, Serv Oncol Radioterap, Radiat Oncol, Carretera Colmenar Viejo Km 9,100, Madrid 28034, Spain -Y2 - 2022-10-08 -ER - - -TY - JOUR -AU - Ahuja, Jitesh -AU - Shroff, Girish S. -AU - Strange, Chad D. -AU - Vlahos, Ioannis -AU - Benveniste, Marcelo F. K. -AU - Truong, Mylene T. -TI - Pearls and Pitfalls in the Imaging of Targeted Therapy and Immunotherapy in Lung Cancer -T2 - SEMINARS IN ULTRASOUND CT AND MRI -M3 - Article -AB - Most lung cancers are diagnosed at advanced stage when the cancer has metastasized outside the lung. These patients are not eligible for curative surgery or radiation therapy and treated with systemic therapy. Advances in the understanding of the biology of lung cancer has resulted in the development of targeted therapy aimed at specific genetic mutations identified with non-small cell lung cancer and immunotherapy that helps the immune system recognize tumors as foreign, stimulates the immune system, and removes the inhibition that allows growth and spread of cancer cells. Tumors treated with targeted or immunotherapies respond differently when compared with traditional chemotherapy and not captured by conventional response criteria such as the World Health Organization criteria and Response Evaluation Criteria in Solid Tumors. Therefore, several modified criteria have been developed to appropriately address the treatment response when using these novel agents. Numerous treatment-related side effects have been described that are important to recognize to avoid misinterpretation as worsening tumor and to ensure appropriate management. (C) 2021 Elsevier Inc. All rights reserved. -PU - W B SAUNDERS CO-ELSEVIER INC -PI - PHILADELPHIA -PA - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA -SN - 0887-2171 -SN - 1558-5034 -DA - 2021 DEC -PY - 2021 -VL - 42 -IS - 6 -SP - 552 -EP - 562 -DO - 10.1053/j.sult.2021.04.015 -AN - WOS:000756248400005 -C6 - DEC 2021 -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Imaging, 1400 Pressler St,Pickens Tower, Houston, TX 77030 USA -Y2 - 2022-02-25 -ER - - -TY - JOUR -AU - Avrillon, Virginie -AU - Daniel, Catherine -AU - Boisselier, Pierre -AU - Le Pechoux, Cecile -AU - Chouaid, Christos -TI - Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program -T2 - LUNG -M3 - Article -AB - Purpose Consolidation immunotherapy with the PD-L1 inhibitor durvalumab following concurrent chemoradiotherapy (cCRT) has shown a significant survival improvement and is now a standard of care in patients with unresectable stage III or non-operable non-small cell lung cancer (NSCLC). Methods In this early access program cohort, demographic, disease characteristics and safety data were collected for 576 patients from 188 centers, who received durvalumab 10 mg/kg intravenous infusion every 2 weeks, until disease progression or unacceptable toxicity or for a maximum of 12 months following cCRT. Durvalumab exposure data were available for 402 patients. Results Overall, 576 patients were included, 72.9% were men, median age 64.0 years, 52.3% had a stage IIIB disease. PD-L1 status captured in 445 (77%) patients was positive (48.1%), negative (32.6%), unknown (19.3%). At the end of cCRT, adverse events (AEs) all grade <= 2, were reported in 22.7% of patients, mainly esophagitis (6.3%). The main reasons of discontinuation were completion of the planned 12 months of consolidation treatment (42.1% patients), disease progression (28.6%) and adverse events (19.5%). Treatment completion was similar in PDL-1 positive and PDL-1 negative patients groups. 20.7% patients had a SAE drug reaction and 17.7% stopped treatment mainly due to SAE. ADR rate and early treatment discontinuation were higher in patients > 70 years old. Death due to AEs occurred in 7 patients, 2 had interstitial lung disease. Conclusion Safety data with durvalumab consolidation after cCRT in a large cohort of patients with stage III NSCLC are reported in this real-life cohort. Consistent data were reported both in the PD-L1 positive and PD-L1 negative NSCLC patients in daily practice. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 0341-2040 -SN - 1432-1750 -DA - 2022 FEB -PY - 2022 -VL - 200 -IS - 1 -SP - 95 -EP - 105 -DO - 10.1007/s00408-022-00511-8 -AN - WOS:000753230500001 -C6 - FEB 2022 -AD - Ctr Leon Berard, Lyon, France -AD - Inst Curie, Paris, France -AD - Inst Canc Montpellier, Montpellier, France -AD - Inst Gustave Roussy, Villejuif, France -AD - Ctr Hosp Intercommunal Creteil, Creteil, France -Y2 - 2022-02-26 -ER - - -TY - JOUR -AU - Mielgo-Rubio, Xabier -AU - Calvo, Virginia -AU - Luna, Javier -AU - Remon, Jordi -AU - Martin, Margarita -AU - Berraondo, Pedro -AU - Jarabo, Jose Ramon -AU - Higuera, Oliver -AU - Conde, Esther -AU - De Castro, Javier -AU - Provencio, Mariano -AU - Hernando Trancho, Florentino -AU - Lopez-Rios, Fernando -AU - Counago, Felipe -TI - Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers -T2 - CANCERS -M3 - Review -AB - Simple SummaryIn recent years there has been a trend towards an increase in the proportion of non-small cell lung cancer patients diagnosed with localized stage instead of advanced. However, 5-year survival rates continue to be low, even among patients diagnosed at early stages. In recent years major advances have been made in the treatment of advanced NSCLC, in large part due to the irruption of immunotherapy. PD-1 axis blocking-based immunotherapy is already a well-established standard of care treatment for patients with advances NSCLC, in frontline setting and in pretreated patients. Our greatest challenge now is to move the benefit of immunotherapy to patients with early-stage NSCLC so as to increase 5-year survival rate. The aim of this manuscript is to make a comprehensive review of available evidence, make a critical review of the results of published and ongoing studies, and analyze the role of biomarkers, main areas of controversy and future challenges.Despite numerous advances in targeted therapy and immunotherapy in the last decade, lung cancer continues to present the highest mortality rate of all cancers. Targeted therapy based on specific genomic alterations, together with PD-1 and CTLA-4 axis blocking-based immunotherapy, have significantly improved survival in advanced non-small cell lung cancer (NSCLC) and both therapies are now well-established in this clinical setting. However, it is time for immunotherapy to be applied in patients with early-stage disease, which would be an important qualitative leap in the treatment of lung cancer patients with curative intent. Preliminary data from a multitude of studies are highly promising, but therapeutic decision-making should be guided by an understanding of the molecular features of the tumour and host. In the present review, we discuss the most recently published studies and ongoing clinical trials, controversies, future challenges and the role of biomarkers in the selection of best therapeutic options. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2020 NOV -PY - 2020 -VL - 12 -IS - 11 -C7 - 3459 -DO - 10.3390/cancers12113459 -AN - WOS:000592866900001 -AD - Hosp Univ Fdn Alcorcon, Dept Med Oncol, Budapest 1 Alcorcon, Madrid 28922, Spain -AD - Puerta Hierro Hosp, Dept Med Oncol, Joaquin Rodrigo 1, Madrid 28222, Spain -AD - Fdn Jimenez Diaz, Dept Radiat Oncol, Oncohlth Inst, Avda Reyes Catolicos 2, Madrid 28040, Spain -AD - HM Hosp, Hosp HM Delfos, Ctr Integral Oncol Clara Campal HM CIOCC, Dept Med Oncol, Barcelona 08023, Spain -AD - Ramon y Cajal Univ Hosp, Dept Radiat Oncol, M-607,100, Madrid 28034, Spain -AD - Cima Univ Navarra, Div Immunol & Immunotherapy, Pamplona 31008, Spain -AD - Inst Invest Sanitaria Navarra IdISNA, Pamplona 31008, Spain -AD - Hosp Clin San Carlos, Dept Thorac Surg, Calle Prof Martin Lagos S-N, Madrid 28040, Spain -AD - Hosp Univ La Paz, Dept Med Oncol, Paseo Castellana 261, Madrid 28046, Spain -AD - HM Hosp, Pathol Targeted Therapies Lab, Madrid 28015, Spain -AD - Hosp Univ Quironsalud Madrid, Dept Radiat Oncol, Madrid 28223, Spain -AD - Hosp La Luz, Dept Radiat Oncol, Madrid 28003, Spain -AD - Univ Europea Madrid, Dept Radiat Oncol, Madrid 28670, Spain -M2 - Fdn Jimenez Diaz -M2 - HM Hosp -M2 - Inst Invest Sanitaria Navarra IdISNA -M2 - HM Hosp -M2 - Hosp La Luz -Y2 - 2020-12-10 -ER - - -TY - JOUR -AU - Zhang, Xiaofei -AU - Zhang, Jianguo -AU - Liu, Peiyi -AU - Wang, Juan -AU - Zhao, Kuaile -AU - Zhu, Zhengfei -AU - Gu, Kangsheng -AU - Zhao, Weixin -TI - Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer -T2 - FRONTIERS IN ONCOLOGY -M3 - Review -AB - Non-small cell lung cancer negative for actionable molecular markers entered the splendid era of immunotherapy. This review aims to provide an evidence-based summary for immunotherapy for unresectable locally advanced non-small cell lung cancer, and references for clinical strategies of immunotherapy. Through literature review, the standard treatment for unresectable locally advanced non-small cell lung cancer should be radical concurrent radiotherapy and chemotherapy followed by consolidation immunotherapy. However, the efficacy of concurrent radiotherapy, chemotherapy combined with immunotherapy has not been improved, and its safety should be further validated. It is believed that induction immunotherapy plus concurrent radiotherapy and chemotherapy plus consolidation immunotherapy is promising. In clinical practice, the delineation of radiotherapy target should be relatively small. Pemetrexed combined with PD-1 inhibitor induces the strongest immunogenicity in chemotherapy, which is suggested by preclinical pathway study. Although there is no significant difference between PD1 and PD1 for effect, PD-L1 inhibitor is better in the combination treatment of radiotherapy which presents significantly less adverse events. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2023 FEB 8 -PY - 2023 -VL - 13 -C7 - 1022042 -DO - 10.3389/fonc.2023.1022042 -AN - WOS:000935884700001 -AD - Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China -AD - Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China -AD - Luan Civily Hosp, Dept Oncol, Luan, Anhui, Peoples R China -AD - Shanghai Jiao Tong Univ, TongRen Hosp, Dept Orthoped, Sch Med, Shanghai, Peoples R China -AD - Second Peoples Hosp Kashgar, Dept Oncol, Kashgar, Peoples R China -AD - Anhui Med Univ, Dept Oncol, Affiliated Hosp 1, Hefei, Peoples R China -M2 - Luan Civily Hosp -M2 - Second Peoples Hosp Kashgar -Y2 - 2023-03-10 -ER - - -TY - JOUR -AU - Wu, Min -AU - Wu, Shihao -AU - Chen, Yuetong -AU - Sun, Liangchao -AU - Zhou, Jundong -TI - Immune Activation Effects at Different Irradiated Sites and Optimal Timing of Radioimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer: a Real-World Analysis -T2 - BIOLOGICAL PROCEDURES ONLINE -M3 - Article -AB - BackgroundIn view of the limited data on radiotherapy (RT) combined with immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC), this study aimed to identify the immune activation effect on different sites and the survival outcomes of radioimmunotherapy at different treatment stages.MethodsForty-five patients diagnosed with ES-SCLC were included in this retrospective analysis. We collected the overall survival (OS) of the patients,, recorded the blood cell counts before, during, and after RT, and derived blood index ratios such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). The datasets were analyzed using the Spearman rank correlation test, Kruskal-Wallis rank sum test and logistic regression.ResultsAmong the selected blood indices, the delta-NLR/PLR/Sll correlated with different irradiated organs, and the mean ranks of these three indices were the lowest in the brain-irradiated group during immunotherapy. Additionally, adjunct first-line immunotherapy with RT demonstrated a significant improvement compared to second- or third-line therapy and subsequent therapies.ConclusionOur findings suggest that compared to other organs, the strongest immune activation effect occurs with brain RT, and ES-SCLC patients who received radioimmunotherapy (RIT) earlier achieved higher OS rates. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1480-9222 -DA - 2023 SEP 14 -PY - 2023 -VL - 25 -IS - 1 -C7 - 24 -DO - 10.1186/s12575-023-00217-y -AN - WOS:001065531000001 -AD - Nanjing Med Univ, Dept Radiat Oncol, Nanjing, Jiangsu, Peoples R China -AD - Nanjing Med Univ, Suzhou Canc Ctr, Core Lab, Affiliated Suzhou Hosp, Suzhou, Jiangsu, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China -AD - Anhui Univ Sci & Technol, Med Sch, Huainan, Peoples R China -Y2 - 2023-09-23 -ER - - -TY - JOUR -AU - Upadhya, Archana -AU - Yadav, Khushwant S. -AU - Misra, Ambikanandan -TI - Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I -T2 - EXPERT OPINION ON DRUG DELIVERY -M3 - Review -AB - Introduction Non-small cell lung cancer (NSCLC) comprises of 84% of all lung cancer cases. The treatment options for NSCLC at advanced stages are chemotherapy and radiotherapy. Chemotherapy involves conventional nonspecific chemotherapeutics, and targeted-protein/receptor-specific small molecule inhibitors. Biologically targeted therapies such as an antibody-based immunotherapy have been approved in combination with conventional therapeutics. Approved targeted chemotherapy is directed against the kinase domains of mutated cellular receptors such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinases (ALK), neurotrophic receptor kinases (NTRK) and against downstream signaling molecules such as BRAF (v-raf murine sarcoma viral oncogene homolog B1). Approved biologically targeted therapy involves the use of anti-angiogenesis antibodies and antibodies against immune checkpoints. Areas covered The rationale for the employment of targeted therapeutics and the resistance that may develop to therapy are discussed. Novel targeted therapeutics in clinical trials are also included. Expert opinion Molecular and histological profiling of a given tumor specimen to determine the aberrant onco-driver is a must before deciding a targeted therapeutic regimen for the patient. Periodic monitoring of the patients response to a given therapeutic regimen is also mandatory so that any semblance of resistance to therapy can be deciphered and the regimen may be accordingly altered. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1742-5247 -SN - 1744-7593 -DA - 2021 JAN 2 -PY - 2021 -VL - 18 -IS - 1 -SP - 73 -EP - 102 -DO - 10.1080/17425247.2021.1825377 -AN - WOS:000573657100001 -C6 - OCT 2020 -AD - SVKMS NMIMS, Shobhaben Pratapbhai Patel Sch Pharm & Technol Ma, Mumbai, Maharashtra, India -Y2 - 2020-10-13 -ER - - -TY - JOUR -AU - Ma, Kui -AU - Tang, Ya H. -TI - Therapeutic Vaccines Explored in Patients with Non-Small Cell Lung Cancer -T2 - ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY -M3 - Article -AB - Traditional anti-cancer therapies (surgery, radiotherapy and chemotherapy) have limited effectiveness in curbing progression of advanced tumors. However, with advances in immunology and molecular biology in the last two decades, the prognosis of cancer immunotherapy has improved. An emerging therapy is the cancer vaccine as adjunctive therapy. The purpose of this paper is to review this therapeutic modality for non-small cell lung cancer. -PU - BENTHAM SCIENCE PUBL LTD -PI - SHARJAH -PA - EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES -SN - 1871-5206 -SN - 1875-5992 -DA - 2014 FEB -PY - 2014 -VL - 14 -IS - 2 -SP - 256 -EP - 264 -DO - 10.2174/18715206113136660378 -AN - WOS:000331462800009 -AD - LSU Hlth Sci Ctr, Sch Med, Shreveport, LA 71130 USA -Y2 - 2014-03-19 -ER - - -TY - JOUR -AU - Yang, Fujun -AU - Zhao, Huan -TI - Progress in radiotherapy for small-cell lung cancer -T2 - PRECISION RADIATION ONCOLOGY -M3 - Review -AB - Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor that is prone to spread extensively. Compared to non-small-cell lung cancer (NSCLC), SCLC treatment progresses slowly. Although SCLC is highly sensitive to chemotherapy during the initial treatment, most patients still experience resistance and recurrence after receiving chemotherapy. A meta-analysis demonstrated that thoracic radiotherapy (TRT) improves overall survival in SCLC. The results of the CALGB and CONVERT trials provide evidence for the efficacy of once-daily high-dose TRT. TRT at 60 Gy administered twice daily significantly improved survival without increasing toxicity. The long-standing debate over the optimal timing of radiotherapy has not been fully resolved. SBRT has excellent local control rates and is a safe and effective treatment option for patients with stage I or II SCLC. Prophylactic cranial irradiation (PCI) is used to reduce treatment-related neurotoxicity to the extent that there has been a recent discussion on whether magnetic resonance imaging (MRI) monitoring can replace PCI. Radiotherapy combined with immunotherapy significantly improves the survival rate of patients with NSCLC; however, its clinical effectiveness has not been systematically explored in patients with SCLC. Therefore, we summarize the evolving therapeutic strategies, (TRT for limited stage-SCLC and consolidative TRT for extensive stage-SCLC) and improved radiotherapy techniques (role of SBRT in stage I or II node-negative SCLC, progress of PCI, and stereotactic radiosurgery), and discuss the possibilities and prospects of radiotherapy combined with immunotherapy for SCLC.Small cell lung cancer (SCLC) is a highly malignant neuroendocrine tumor that is prone to extensive metastasis. Compared to non-small cell lung cancer (NSCLC), the overall treatment of SCLC is slow to progress.Therefore, we summarize the new evolving therapeutic strategies (fractionation and dose, sequencing and timing) , improved radiotherapy techniques (progress of PCI and SRS) and discuss the possibilities and prospects of radiotherapy combined with immunotherapy for SCLC. image -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2398-7324 -DA - 2023 SEP -PY - 2023 -VL - 7 -IS - 3 -SP - 207 -EP - 217 -DO - 10.1002/pro6.1205 -AN - WOS:001327930200004 -AD - Weihai Municipal Hosp, Dept Oncol, Key Lab Precis Diag & Treatment Oncol Weihai, 70,Heping Rd, Weihai 264200, Shandong, Peoples R China -AD - Binzhou Med Univ, Med Coll 2, Yantai, Shandong, Peoples R China -M2 - Weihai Municipal Hosp -Y2 - 2023-09-01 -ER - - -TY - JOUR -AU - Tsuboi, Masahiro -AU - Goldman, Jonathan W. -AU - Wu, Yi-Long -AU - Johnson, Melissa L. -AU - Paz-Ares, Luis -AU - Yang, James Chih-Hsin -AU - Besse, Benjamin -AU - Su, Weiji -AU - Chao, Bo H. -AU - Drilon, Alexander -TI - LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer -T2 - FUTURE ONCOLOGY -M3 - Article -AB - Selpercatinib, a first-in-class, highly selective and potent central nervous system-active RET kinase inhibitor demonstrated clinically meaningful activity with manageable toxicity in pretreated and treatment-naive advanced/metastatic RET fusion-positive non-small-cell lung cancer (NSCLC). LIBRETTO-432 is a global, randomized, double-blind, phase III trial evaluating selpercatinib versus placebo in stage IB-IIIA, RET fusion-positive NSCLC, previously treated with definitive surgery or radiation; participants must have undergone available anti-cancer therapy (including chemotherapy or durvalumab) or not be suitable for it, per investigator's discretion. The primary end point is investigator-assessed event-free survival (EFS) in the primary analysis population (stage II-IIIA RETfusion-positive NSCLC). Key secondary end points include EFS in the overall population, overall survival, and time to distant disease recurrence in the central nervous system.Plain language summary: Selpercatinib is approved in multiple countries for the treatment of advanced or metastatic RET-altered lung cancers. Selpercatinib has shown promising efficacy and safety results in patients with advanced/metastatic RET fusion-positive NSCLC. This is a summary of the LIBRETTO-432 study which compares selpercatinib with placebo in patients with earlier stages (stage IB-IIIA) of RET fusion-positive NSCLC, who have already undergone surgery or radiotherapy and applicable adjuvant chemotherapy. This study is active and currently recruiting new participants. This trial will evaluate how long people live without evidence of cancer recurrence, both during and after treatment. Side effects will also be evaluated in this study. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1479-6694 -SN - 1744-8301 -DA - 2022 SEP -PY - 2022 -VL - 18 -IS - 28 -SP - 3133 -EP - 3141 -DO - 10.2217/fon-2022-0656 -AN - WOS:000838720700001 -C6 - AUG 2022 -AD - Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan -AD - Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA -AD - Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China -AD - Guangdong Acad Med Sci, Guangzhou, Peoples R China -AD - Sarah Cannon Res Inst, Nashville, TN 37203 USA -AD - Univ Complutense, Hosp Univ 12 Octubre, Dept Med Oncol, CNIO Lung Canc Unit H120, Madrid, Spain -AD - Ciberonc, Madrid, Spain -AD - Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan -AD - Natl Taiwan Univ, Grad Inst Oncol, Taipei, Taiwan -AD - Gustave Roussy, Villejuif, France -AD - Paris Saclay Univ, Paris, France -AD - Eli Lilly & Co, Indianapolis, IN 46225 USA -AD - Eli Lilly & Co, New York, NY 10016 USA -AD - Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA -AD - Weill Cornell Med Coll, New York, NY 10065 USA -Y2 - 2022-08-26 -ER - - -TY - JOUR -AU - Chen, Hanxiao -AU - Ma, Xiangjuan -AU - Liu, Jie -AU - Yang, Yu -AU - He, Yanhui -AU - Fang, Yong -AU - Wang, Liping -AU - Fang, Jian -AU - Zhao, Jun -AU - Zhuo, Minglei -TI - Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis -T2 - CLINICAL & TRANSLATIONAL ONCOLOGY -M3 - Article -AB - PurposeA previous real-world study conducted in China confirmed that first-line atezolizumab, in combination with etoposide/platinum (EP), leads to significantly longer progression-free survival (PFS) compared to EP alone in patients with extensive-stage small-cell lung cancer (ES-SCLC). The present study aimed to provide updated survival outcome data and evaluate the clinical efficacy of atezolizumab plus chemotherapy in ES-SCLC patients with brain metastasis (BM).MethodsThis retrospective study included 225 patients with ES-SCLC who were treated with EP alone (EP group) or a combination of EP + atezolizumab (atezolizumab group). Survival outcomes for the total study sample and patients in the BM subgroup were estimated using the Kaplan-Meier method.ResultsThe atezolizumab group continued to demonstrate significantly longer PFS than the EP group (hazard ratio [HR], 0.68). The median overall survival (OS) was 26.2 months in the atezolizumab group vs. 14.8 months in the EP group (HR, 0.63). Additionally, among the BM patients in our study, the median PFS was found to be longer in the atezolizumab group (7.0 months) than in the EP group (4.1 months) (HR, 0.46). The OS of the BM patients did not differ significantly between the two treatment groups.ConclusionsThe addition of atezolizumab to EP as a first-line treatment for ES-SCLC was found to improve survival outcomes. This treatment combination may also prolong PFS in patients with BM, regardless of the administration of cranial irradiation. However, among the BM patients in our study, there was no significant difference in OS between the two treatment groups. -PU - SPRINGER INT PUBL AG -PI - CHAM -PA - GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND -SN - 1699-048X -SN - 1699-3055 -DA - 2024 JUL -PY - 2024 -VL - 26 -IS - 7 -SP - 1664 -EP - 1673 -DO - 10.1007/s12094-024-03387-7 -AN - WOS:001158640100002 -C6 - FEB 2024 -AD - Peking Univ Canc Hosp & Inst, Dept Thorac Oncol 1, Key Lab Carcinogenesis & Translat Res, MInist Educ Beijing, Beijing, Peoples R China -AD - Peking Univ Canc Hosp & Inst, MInist Educ Beijing, Dept Thorac Oncol 2, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China -AD - Shandong Univ, Canc Ctr, Shandong Publ Hlth Clin Ctr, Publ Hlth Clin Ctr, Jinan, Peoples R China -AD - Harbin Med Univ, Dept Oncol, Affiliated Hosp 2, Harbin, Peoples R China -AD - Zhejiang Univ, Dept Oncol, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China -AD - Baotou Canc Hosp, Dept Oncol, Baotou, Peoples R China -M2 - Peking Univ Canc Hosp & Inst -M2 - Baotou Canc Hosp -Y2 - 2024-02-19 -ER - - -TY - JOUR -AU - Sudmeier, Lisa -AU - Tian, Sibo -AU - Higgins, Kristin A. -TI - Multidisciplinary Management of Brain Metastases from Non-Small Cell Lung Cancer in the Era of Immunotherapy -T2 - CURRENT TREATMENT OPTIONS IN ONCOLOGY -M3 - Review -AB - Opinion statement Brain metastases from non-small cell lung cancer often cause neurologic symptoms which lead to initial diagnosis or identification of recurrence. In other patients, they are identified on surveillance imaging or when a patient undergoing treatment develops neurological symptoms. Patients with symptomatic lesions should be started on dexamethasone and evaluated by a neurosurgeon as soon as possible. If feasible, surgery should be offered to decrease intracranial pressure, alleviate symptoms, and prevent irreversible neurological damage. Postoperative stereotactic radiosurgery (SRS) to the resection cavity and any additional brain metastases should follow within 4 weeks of surgery, as early as 2 weeks post-op. Tissue from surgery is used to confirm the diagnosis and test for targetable oncogenic driver mutations. Treatment response and surveillance for development of additional lesions is assessed with MRI of the brain 1 month after SRS and every 3 months thereafter. Patients who are not surgical candidates or who have small, asymptomatic brain metastases should proceed with SRS, the preferred treatment, or sometimes whole-brain radiation therapy (WBRT) if multifocal disease requires more extensive treatment, such as for leptomeningeal spread of disease. The number of brain metastases that warrants use of WBRT over SRS is controversial and a topic of ongoing investigation, and is discussed in this review. When possible, SRS is preferred over WBRT due to reduce morbidity and cognitive side effects. When patients are already on systemic therapy at time of brain metastases diagnosis, systemic therapy should continue, with radiation therapy occurring between cycles. Regarding systemic therapy for new diagnosis at time of brain metastases presentation, molecular testing will guide treatment choice, when available. If there is no neurosurgical intervention, biopsy of another site of disease may provide tissue for molecular testing. If there are no targetable oncogenic driver mutations, concurrent immune checkpoint blockade (ICB) and chemotherapy is preferable for patients who can tolerate it. Single-agent ICB is an alternative option for patients who cannot tolerate chemotherapy. Systemic therapy should start as soon as possible. In some patients with poor performance status, best supportive care may be the most appropriate choice. Treatment decisions should always incorporate patients' goals of care and in many cases should be discussed in a multidisciplinary setting. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1527-2729 -SN - 1534-6277 -DA - 2021 SEP -PY - 2021 -VL - 22 -IS - 9 -C7 - 77 -DO - 10.1007/s11864-021-00871-y -AN - WOS:000669207100008 -AD - Emory Univ, Winship Canc Inst, Dept Radiat Oncol, 1365 Clifton Rd, Atlanta, GA 30322 USA -Y2 - 2021-07-15 -ER - - -TY - JOUR -AU - Palumbo, Giuliano -AU - Carillio, Guido -AU - Manzo, Anna -AU - Montanino, Agnese -AU - Sforza, Vincenzo -AU - Costanzo, Raffaele -AU - Sandomenico, Claudia -AU - La Manna, Carmine -AU - De Luca, Giuseppe -AU - Piccirillo, Maria Carmela -AU - Daniele, Gennaro -AU - De Cecio, Rossella -AU - Botti, Gerardo -AU - Totaro, Giuseppe -AU - Muto, Paolo -AU - Picone, Carmine -AU - Esposito, Giovanna -AU - Normanno, Nicola -AU - Morabito, Alessandro -TI - Pembrolizumab in lung cancer: current evidence and future perspectives -T2 - FUTURE ONCOLOGY -M3 - Article -AB - Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-smallcell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 >= 1% (KEYNOTE-010), in first-line setting PD-L1 >= 50% (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1479-6694 -SN - 1744-8301 -DA - 2019 OCT -PY - 2019 -VL - 15 -IS - 29 -SP - 3327 -EP - 3336 -DO - 10.2217/fon-2019-0073 -AN - WOS:000498639100003 -AD - Fdn G Pascale, IRCCS, Ist Nazl Tumori, Thorac Med Oncol, Naples, Italy -AD - Azienda Osped Pugliese Ciaccio, Dept Oncol & Hematol, Catanzaro, Italy -AD - Fdn G Pascale, IRCCS, Ist Nazl Tumori, Thorac Surg, Naples, Italy -AD - Fdn G Pascale, Clin Trials Unit, IRCCS, Ist Nazl Tumori, Naples, Italy -AD - Fdn G Pascale, IRCCS, Ist Nazl Tumori, Pathol, Naples, Italy -AD - Fdn G Pascale, IRCCS, Ist Nazl Tumori, Sci Directorate, Naples, Italy -AD - Fdn G Pascale, IRCCS, Ist Nazl Tumori, Radiotherapy, Naples, Italy -AD - Fdn G Pascale, IRCCS, Ist Nazl Tumori, Radiol, Naples, Italy -AD - Fdn G Pascale, IRCCS, Ist Nazl Tumori, Cellular Biol & Biotherapy, Naples, Italy -M2 - Azienda Osped Pugliese Ciaccio -Y2 - 2019-12-06 -ER - - -TY - JOUR -AU - FLAHERTY, LAWRENCE E -TI - Southwest Oncology Group -M3 - Awarded Grant -DA - 2008 -PY - 2008 -AN - GRANTS:10266825 -G1 - 5U10CA014028-35; 7405339; U10CA014028 -AD - WAYNE STATE UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Mu, Xiaoli -AU - Zhou, Yixin -AU - Liu, Qing -AU - Wang, Jiantao -AU - Xu, Feng -AU - Luo, Feng -AU - Wang, Ke -AU - Li, Lu -AU - Tian, Panwen -AU - Li, Yalun -AU - Liu, Jiewei -AU - Zhang, Yan -AU - Liu, Jiyan -AU - Li, Yan -TI - Impact of thoracic radiotherapy on first-line treatment outcomes in ES-SCLC patients -T2 - CANCER MEDICINE -M3 - Article -AB - Background: The therapeutic advantage of thoracic radiotherapy (tRT) as an adjunct to first-line immunotherapy and chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) remains unclear. We sought to elucidate this in a retrospective cohort study comparing the effectiveness and safety of tRT in combination with first-line immunotherapy and chemotherapy. Methods: Our retrospective study included patients with ES-SCLC, treated at the West China Hospital between January 2019 and December 2022. They received first-line immunotherapy and chemotherapy and were categorized into two cohorts based on the administration of tRT. The primary outcomes were overall survival (OS) and progression-free survival (PFS). Cox regression analysis was utilized to identify potential independent predictors of prognosis and to compare the treatment outcomes across various patient subgroups. Treatment-related toxicities across both cohorts were compared using the Chi-squared test. Results: A total of 99patients were eligible for the study, out of which 55 received tRT. The medianduration of follow-up was 39 months. Remarkably, patients who received tRTdemonstrated superior OS and PFS in comparison to those who did not (P < 0.05). Subgroup analysis further confirmed these findings. Multivariate analysisidentified treatment group and liver metastasis as independent prognosticfactors (P < 0.05). The incidence of grade 3-4 adverse events showed nostatistically significant difference between the two cohorts. Conclusions: Thus, weconfirmed that the addition of tRT to the conventional regimen of first-linechemotherapy and immunotherapy yields better survival outcomes without asignificant increase in toxicity. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2045-7634 -DA - 2024 SEP -PY - 2024 -VL - 13 -IS - 17 -C7 - e70175 -DO - 10.1002/cam4.70175 -AN - WOS:001307766100001 -AD - Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Sichuan, Peoples R China -AD - Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Sichuan, Peoples R China -Y2 - 2024-09-14 -ER - - -TY - JOUR -AU - Shintani, Takashi -AU - Kishi, Noriko -AU - Matsuo, Yukinori -AU - Ogura, Masakazu -AU - Mitsuyoshi, Takamasa -AU - Araki, Norio -AU - Fujii, Kota -AU - Okumura, Setsuko -AU - Nakamatsu, Kiyoshi -AU - Kishi, Takahiro -AU - Atsuta, Tomoko -AU - Sakamoto, Takashi -AU - Narabayashi, Masaru -AU - Ishida, Yuichi -AU - Sakamoto, Masato -AU - Fujishiro, Satsuki -AU - Katagiri, Tomohiro -AU - Kim, Young Hak -AU - Mizowaki, Takashi -TI - Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - Consolidation durvalumab therapy following concurrent chemoradiotherapy is a new standard treatment for unresectable locally advanced non-small-cell lung cancer. Understanding the risk of radiation pneumonitis (RP) in this setting is important for both radiation treatment planning and the monitoring and management of patients. We found that elevations in lung volume receiving >= 20 Gy increased the RP risk.Introduction: Data on the risk factors for symptomatic radiation pneumonitis (RP) in non-small-cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT) and consolidation durvalumab are limited; we aimed to investigate these risk factors. Materials and Methods: This multicenter retrospective study, conducted at 15 institutions in Japan, included patients who were >= 20 years of age; who started definitive CCRT for NSCLC between July 1, 2018, and July 31, 2019; and who then received durvalumab. The primary endpoint was grade 2 or worse (grade 2+) RP.Results: In the 146 patients analyzed, the median follow-up period was 16 months. A majority of the patients had stage III disease (86%), received radiation doses of 60 to 66 Gy equivalent in 2-Gy fractions (93%) and carboplatin and paclitaxel/nab-paclitaxel (77%), and underwent elective nodal irradiation (71%) and 3-dimensional conformal radiotherapy (75%). RP grade 2 was observed in 44 patients (30%); grade 3, in four patients (3%); grade 4, in one patient (1%); and grade 5, in one patient (1%). In the multivariable analysis, lung V20 was a significant risk factor, whereas age, sex, smoking history, irradiation technique, and chemotherapy regimen were not. The 12-month grade 2+ RP incidence was 34.4% (95% confidence interval [CI], 26.7%-42.1%); the values were 50.0% (95% CI, 34.7%-63.5%) and 27.1% (95% CI, 18.8%-36.2%) in those with lung V20 >= 26% and < 26%, respectively (P=.007). Conclusion: The incidence of grade 2+ RP was relatively high in this multicenter real-world study, and its risk increased remarkably at elevated lung V20. Our findings can aid in RP risk prediction and the safe radiotherapy treatment planning. of grade 2+ RP was relatively high in this multicenter real-world study, and its risk increased remarkably at elevated lung V20. Our findings can aid in RP risk prediction and the safe radiotherapy treatment planning. (C) 2021 Elsevier Inc. All rights reserved. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2021 SEP -PY - 2021 -VL - 22 -IS - 5 -SP - 401 -EP - 410 -DO - 10.1016/j.cllc.2021.01.017 -AN - WOS:000729299500004 -C6 - SEP 2021 -AD - Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto, Japan -AD - Japanese Red Cross Fukui Hosp, Dept Radiol, Fukui, Japan -AD - Kishiwada City Hosp, Dept Radiat Oncol, Kishiwada, Japan -AD - Kobe City Med Ctr Gen Hosp, Dept Radiat Oncol, Kobe, Hyogo, Japan -AD - Natl Hosp Org Kyoto Med Ctr, Dept Radiol, Kyoto, Japan -AD - Kurashiki Cent Hosp, Dept Radiat Oncol, Kurashiki, Okayama, Japan -AD - Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Radiat Oncol, Amagasaki, Hyogo, Japan -AD - Kindai Univ, Fac Med, Dept Radiat Oncol, Osakasayama, Japan -AD - Osaka Red Cross Hosp, Dept Radiat Oncol, Osaka, Japan -AD - Tazuke Kofukai Med Res Inst, Dept Radiol, Osaka, Japan -AD - Kyoto Katsura Hosp, Dept Radiat Oncol, Kyoto, Japan -AD - Kyoto City Hosp, Dept Radiat Oncol, Kyoto, Japan -AD - Tenri Hosp, Dept Radiat Oncol, Tenri, Nara, Japan -AD - Shinko Hosp, Dept Radiat Oncol, Kobe, Hyogo, Japan -AD - Shizuoka City Shizuoka Hosp, Dept Radiat Oncol, Shizuoka, Japan -AD - Kyoto Univ, Grad Sch Med, Dept Resp Med, Kyoto, Japan -AD - Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan -M2 - Japanese Red Cross Fukui Hosp -M2 - Kishiwada City Hosp -M2 - Natl Hosp Org Kyoto Med Ctr -M2 - Hyogo Prefectural Amagasaki Gen Med Ctr -M2 - Kindai Univ -M2 - Tazuke Kofukai Med Res Inst -M2 - Kyoto Katsura Hosp -M2 - Shinko Hosp -M2 - Shizuoka City Shizuoka Hosp -Y2 - 2021-12-18 -ER - - diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/web of science 501-1112.ris" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/web of science 501-1112.ris" deleted file mode 100644 index 8a1f8a7..0000000 --- "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/web of science 501-1112.ris" +++ /dev/null @@ -1,18694 +0,0 @@ -TY - JOUR -AU - Cuppens, Kristof -AU - Vansteenkiste, Johan -TI - Vaccination therapy for non-small-cell lung cancer -T2 - CURRENT OPINION IN ONCOLOGY -M3 - Review -AB - Purpose of reviewRecent advances in our understanding of cancer immunology resulted in the development of promising therapeutic agents for either nonantigen-specific immunotherapy, for example, monoclonal antibodies targeting immune checkpoints on the T-cell lymphocyte, and antigen-specific immunotherapy or vaccination. Here, we review the recently reported results from randomized controlled trials (RCTs) with the latter approach.Recent findingsSeveral trials indicated feasibility, safety, and potential for better patient outcomes. In resected early stage non-small-cell lung cancer, a phase II RCT with the MAGE-A3 vaccine showed a trend for improved disease-free interval (hazard ratio 0.75), now further evaluated in the large MAGRIT (MAGE-A3 as Adjuvant NSCLC Immunotherapy Trial) study. In stage III after chemoradiotherapy, the phase III START (Stimulating Targeted Antigenic Responses to NSCLC) trial with L-BLP25 vaccine resulted in a remarkable 10-month improvement in median survival in the concurrent chemoradiotherapy subgroup. In the advanced setting, the phase III study with the allogeneic tumor cell vaccine belagenpumatucel-L did not improve survival in the whole study, but interesting effects were seen in subgroups.SummaryRecent non-small-cell lung cancer vaccination trials did not meet their primary endpoint, but showed clear patient benefits in subgroup analyses. Confirmatory trials and identifying patients who will benefit using predictive factors, will hopefully bring these approaches in the clinic in the near future. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1040-8746 -SN - 1531-703X -DA - 2014 MAR -PY - 2014 -VL - 26 -IS - 2 -SP - 165 -EP - 170 -DO - 10.1097/CCO.0000000000000052 -AN - WOS:000333451500006 -AD - Univ Hosp KU Leuven, Resp Oncol Unit, Dept Pulmonol, Louvain, Belgium -AD - Univ Hosp KU Leuven, Leuven Lung Canc Grp, Louvain, Belgium -Y2 - 2014-05-11 -ER - - -TY - JOUR -AU - Byers, Lauren Averett -AU - Rudin, Charles M. -TI - Small Cell Lung Cancer: Where Do We Go From Here? -T2 - CANCER -M3 - Review -AB - Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately 14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed annually with SCLC. Despite numerous clinical trials, including at least 40 phase 3 trials since the 1970s, systemic treatment for patients with SCLC has not changed significantly in the past several decades. Consequently, the 5-year survival rate remains low at <7% overall, and most patients survive for only 1 year or less after diagnosis. Unlike nonsmall cell lung cancer (NSCLC), in which major advances have been made using targeted therapies, there are still no approved targeted drugs for SCLC. Significant barriers to progress in SCLC include 1) a lack of early detection modalities, 2) limited tumor tissue for translational research (eg, molecular profiling of DNA, RNA, and/or protein alterations) because of small diagnostic biopsies and the rare use of surgical resection in standard treatment, and 3) rapid disease progression with poor understanding of the mechanisms contributing to therapeutic resistance. In this report, the authors review the current state of SCLC treatment, recent advances in current understanding of the underlying disease biology, and opportunities to advance translational research and therapeutic approaches for patients with SCLC. Cancer 2015;121:664-672. (c) 2014 American Cancer Society.The treatment of small cell lung cancer has not changed significantly in 3 decades. In this review, the authors discuss the current challenges and opportunities to accelerate progress in this highly lethal disease. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0008-543X -SN - 1097-0142 -DA - 2015 MAR 1 -PY - 2015 -VL - 121 -IS - 5 -SP - 664 -EP - 672 -DO - 10.1002/cncr.29098 -AN - WOS:000349986100005 -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA -AD - Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA -Y2 - 2015-03-01 -ER - - -TY - JOUR -AU - Deboever, Nathaniel -AU - Mitchell, Kyle G. -AU - Feldman, Hope A. -AU - Cascone, Tina -AU - Sepesi, Boris -TI - Current Surgical Indications for Non-Small-Cell Lung Cancer -T2 - CANCERS -M3 - Article -AB - The management strategy for the treatment of non-small-cell lung cancer (NSCLC) has been transformed by our improved understanding of the cancer biology and concomitant development of novel systemic therapies. Complete surgical resection of NSCLC continues to offer the best chance for cure or local and regional disease control, and with improvements in minimally invasive techniques and enhanced recovery, the morbidity associated with surgical resection has been reduced. Patient-centered multi-disciplinary discussions that consider surgical therapy are associated with improved outcomes. Provided with promising novel therapeutic modalities including immune checkpoint inhibitors with or without chemotherapy, stereotactic radiotherapy, and targeted systemic therapies, indications for surgery continue to evolve and have expanded to include selected patients with advanced and metastatic disease.With recent strides made within the field of thoracic oncology, the management of NSCLC is evolving rapidly. Careful patient selection and timing of multi-modality therapy to permit the optimization of therapeutic benefit must be pursued. While chemotherapy and radiotherapy continue to have a role in the management of lung cancer, surgical therapy remains an essential component of lung cancer treatment in early, locally and regionally advanced, as well as in selected, cases of metastatic disease. Recent and most impactful advances in the treatment of lung cancer relate to the advent of immunotherapy and targeted therapy, molecular profiling, and predictive biomarker discovery. Many of these systemic therapies are a part of the standard of care in metastatic NSCLC, and their indications are expanding towards surgically operable lung cancer to improve survival outcomes. Numerous completed and ongoing clinical trials in the surgically operable NSCLC speak to the interest and importance of the multi-modality therapy even in earlier stages of NSCLC. In this review, we focus on the current standard of care indications for surgical therapy in stage I-IV NSCLC as well as on the anticipated future direction of multi-disciplinary lung cancer therapy. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2022 MAR -PY - 2022 -VL - 14 -IS - 5 -C7 - 1263 -DO - 10.3390/cancers14051263 -AN - WOS:000768931400001 -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA -Y2 - 2022-03-24 -ER - - -TY - JOUR -AU - McGranahan, Tresa -AU - Nagpal, Seema -TI - A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer -T2 - CURRENT TREATMENT OPTIONS IN ONCOLOGY -M3 - Review -AB - Management of non-small cell lung cancer (NSCLC) with brain metastasis (BrM) has been revolutionized by identification of molecular subsets that have targetable oncogenes. Historically, survival for NSCLC with symptomatic BrM was weeks to months. Now, many patients are surviving years with limited data to guide treatment decisions. Tumors with activating mutations in epidermal growth factor receptor (EGFRact+) have a higher incidence of BrM, but a longer overall survival. The high response rate of both systemic and BrM EGFRact+ NSCLC to tyrosine kinase inhibitors (TKIs) has led to the rapid incorporation of new therapies but is outpacing evidence-based decisions for BrM in NSCLC. While whole brain radiation therapy (WBRT) was the foundation of management of BrM, extended survival raises concerns for the subacute and late effects radiotherapy. We favor the use of TKIs and delaying the use of WBRT when able. At inevitable disease progression, we consider alternative dosing schedules to increase CNS penetration (such as pulse dosing of erlotinib) or advance to next generation TKI if available. We utilize local control options of surgery or stereotactic radiosurgery (SRS) for symptomatic accessible lesions based on size and edema. At progression despite available TKIs, we use pemetrexed-based platinum doublet chemotherapy or immunotherapy if the tumor has high expression of PDL-1. We reserve the use of WBRT for patients with more than 10 BrM and progression despite TKI and conventional chemotherapy, if performance status is appropriate. -PU - SPRINGER -PI - NEW YORK -PA - 233 SPRING ST, NEW YORK, NY 10013 USA -SN - 1527-2729 -SN - 1534-6277 -DA - 2017 APR -PY - 2017 -VL - 18 -IS - 4 -C7 - 22 -DO - 10.1007/s11864-017-0466-0 -AN - WOS:000402379200002 -AD - Stanford Univ, Sch Med, Dept Neurol, Stanford, CA 94305 USA -Y2 - 2017-06-13 -ER - - -TY - JOUR -AU - Krol, Katarzyna -AU - Mazur, Anna -AU - Stachyra-Strawa, Paulina -AU - Grzybowska-Szatkowska, Ludmila -TI - Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy-A Review -T2 - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES -M3 - Review -AB - Lung cancer is the leading cause of death worldwide for both men and women. Surgery can be offered as a radical treatment at stages I and II and selected cases of stage III (III A). Whereas at more advanced stages, combined modalities of treatment are applied: radiochemotherapy (IIIB) and molecularly targeted treatment (small molecule tyrosine kinase inhibitors, VEGF receptor inhibitors, monoclonal antibodies, and immunological treatment with monoclonal antibodies). Combination treatment, composed of radiotherapy and molecular therapy, is increasingly employed in locally advanced and metastatic lung cancer management. Recent studies have indicated a synergistic effect of such treatment and modification of immune response. The combination of immunotherapy and radiotherapy may result in the enhancement of the abscopal effect. Anti-angiogenic therapy, in combination with RT, is associated with high toxicity and should be not recommended. In this paper, the authors discuss the role of molecular treatment and the possibility of its concurrent use with radiotherapy in non-small cell lung cancer (NSCLC). -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1422-0067 -DA - 2023 MAR -PY - 2023 -VL - 24 -IS - 6 -C7 - 5858 -DO - 10.3390/ijms24065858 -AN - WOS:000955456500001 -AD - St Johns Canc Ctr, Reg Oncol Ctr Lublin, Dept Radiotherapy, Jaczewskiego 7, PL-20090 Lublin, Poland -AD - Med Univ Lublin, Dept Radiotherapy, Chodzki 7, PL-20093 Lublin, Poland -M2 - St Johns Canc Ctr -Y2 - 2023-04-07 -ER - - -TY - JOUR -AU - Shao, Weipeng -AU - Wang, Xiaowei -AU - Liu, Deruo -TI - [Recent Advances and Future Strategies for Small Cell Lung Cancer]. -T2 - Zhongguo fei ai za zhi = Chinese journal of lung cancer -M3 - Journal Article -M3 - Review -AB - Small cell lung cancer (SCLC) is a malignant tumor with a very high mortality rate. The current standard of care includes surgery, chemotherapy and radiotherapy. The clinical benefit of therapies was disappointing. Recently, many clinical trials about target therapy and immunotherapy are processing. This review will focus on current therapy and future research direction of SCLC. -AB - 小细胞肺癌是一种致死率较高的恶性肿瘤,现阶段的治疗方式有手术,化疗和放疗,但预后极差。近些年来涌现的靶向治疗和免疫治疗也都在进行着大量的临床试验,本文将对小细胞肺癌目前的治疗策略以及未来研究的方向进行综述。. -SN - 1999-6187 -DA - 2017 Jun 20 -PY - 2017 -VL - 20 -IS - 6 -SP - 421 -EP - 426 -DO - 10.3779/j.issn.1009-3419.2017.06.09 -AN - MEDLINE:28641701 -AD - Department of Thoracic Surgery, China-Japan Friendship Hospital, Peking University Health Science Center (PUSHC), 
Beijing 100029, China. -Y2 - 2017-07-06 -ER - - -TY - JOUR -AU - Higgins, Kristin A. -AU - Puri, Sonam -AU - Gray, Jhanelle E. -TI - Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer -T2 - JOURNAL OF CLINICAL ONCOLOGY -M3 - Review -AB - The treatment for locally advanced non-small-cell lung cancer has changed dramatically over the past several years, with consolidative immunotherapy after concurrent chemoradiation becoming the new standard of care. Five-year survival outcomes have substantially improved with this approach. Despite these advances, further improvements are needed as the majority of patients ultimately develop progression of disease. The next-generation immunotherapy trials are currently being conducted that include approaches such as concurrent immunotherapy and addition of other therapeutic agents in the concurrent and consolidative settings. Specific unmet needs continue to exist for patients who develop disease progression after concurrent chemoradiation and immunotherapy, as well as defining the best treatment for patients with driver mutations. Future directions also include refinement of radiation techniques to reduce toxicities as much as possible, as well as the use of circulating tumor DNA in the surveillance setting. The current scientific landscape shows promising approaches that may further improve outcomes for patients with locally advanced non-small-cell lung cancer. (c) 2022 by American Society of Clinical Oncology -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0732-183X -SN - 1527-7755 -DA - 2022 FEB 20 -PY - 2022 -VL - 40 -IS - 6 -SP - 576 -EP - + -DO - 10.1200/JCO.21.01707 -AN - WOS:000755949300007 -AD - Emory Univ, Dept Radiat Oncol, Winship Canc Inst, 1365 Clifton RD NE, Atlanta, GA 30322 USA -AD - Univ Utah, Div Med Oncol, Huntsman Canc Inst, Salt Lake City, UT USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA -Y2 - 2022-03-05 -ER - - -TY - JOUR -AU - Tamiya, Akihiro -AU - Tamiya, Motohiro -AU - Nakahama, Kenji -AU - Taniguchi, Yoshihiko -AU - Shiroyama, Takayuki -AU - Isa, Shun-Ichi -AU - Inoue, Takako -AU - Okishio, Kyoichi -AU - Nishino, Kazumi -AU - Kumagai, Toru -AU - Suzuki, Hidekazu -AU - Hirashima, Tomonori -AU - Imamura, Fumio -AU - Atagi, Shinji -TI - Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer -T2 - ANTICANCER RESEARCH -M3 - Article -AB - Background/Aim: Nivolumab has a promising efficacy for patients with non-small-cell lung cancer (NSCLC) as second-line or later treatment, and after radiotherapy as abscopal effect. However, the effects of radiation pneumonitis history before nivolumab have not been clarified. Therefore, we retrospectively analyzed the correlation of a history of radiation pneumonitis before nivolumab with onset of interstitial lung disease (ILD) and progression-free survival (PFS) after nivolumab treatment in patients with previously treated NSCLC. Patients and Methods: A total of 201 patients treated with nivolumab were retrospectively reviewed. We collected clinical data of patients at the time of starting nivolumab and we evaluated ILD incidence and PFS in relation to patient characteristics, including radiation pneumonitis history. Results: The median age was 68 years; 135 patients were men, 157 had a smoking history, and 153 had performance status of 0 or 1. Thirty-four patients experienced radiation pneumonitis before nivolumab, and 50 patients received radiotherapy to the chest (31 patients received curative radiotherapy). The overall median PFS was 2.8 months and the overall ILD rate was 12.4%. Higher ILD incidence was observed in the group with a history of radiation pneumonitis (26.5%) compared to the group without radiation pneumonitis (9.6%). The median PFS was 3.6 and 2.3 months, respectively. On multivariate analysis, a history of radiation pneumonitis was also significantly correlated with good PFS (p= 0.023). Conclusion: Although increasing the risk of ILD, a history of radiation pneumonitis before nivolumab also contributes to the prolongation of PFS after nivolumab. -PU - INT INST ANTICANCER RESEARCH -PI - ATHENS -PA - EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE -SN - 0250-7005 -SN - 1791-7530 -DA - 2017 SEP -PY - 2017 -VL - 37 -IS - 9 -SP - 5199 -EP - 5205 -DO - 10.21873/anticanres.11943 -AN - WOS:000412578200066 -AD - Natl Hosp Org, Kinki Chuo Chest Med Ctr, Dept Internal Med, Osaka, Japan -AD - Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan -AD - Osaka Habikino Med Ctr, Dept Thorac Malignancy, Osaka, Japan -AD - Natl Hosp Org, Kinki Chuo Chest Med Ctr, Dept Clin Res Ctr, Osaka, Japan -M2 - Natl Hosp Org -M2 - Osaka Int Canc Inst -M2 - Osaka Habikino Med Ctr -M2 - Natl Hosp Org -Y2 - 2017-11-19 -ER - - -TY - JOUR -AU - Abunasser, Abdulhakim A. A. -AU - Xue, Jinmin -AU - Balawi, Ehab J. A. -AU - Zhu, Yuxi -TI - Combination of the EP and Anti-PD-1 Pathway or Anti-CTLA-4 for the Phase III Trial of Small-Cell Lung Cancer: A Meta-Analysis -T2 - JOURNAL OF ONCOLOGY -M3 - Article -AB - The morbidity and mortality of lung cancer remain one of the highest among multiple cancers, respectively. Small-Cell Lung Cancer (SCLC) accounts for around 10%-15% of all lung cancers. Approximately two-thirds of the diagnosed SCLCs are in extensive stage (ES). Decades later, we still rely on the same traditional regimen with etoposide and platinum (EP) as the mainstay of treatment with poor prognosis. This meta-analysis aims to assess the effect of adding Immune Checkpoint Inhibitors (CPIs) such as (ipilimumab, atezolizumab, pembrolizumab, and durvalumab) to the traditional EP regimen for small-cell lung cancer extensive stage (ES-SCLC). We searched through PubMed looking for studies that compare between EP and CPIs, with EP alone, and only Phase III randomized controlled trials were considered eligible for this study. A total of 3645 papers were the results of the initial search, and only 4 studies met our criteria. Each investigator extracted the data independently using the PRISMA MODEL (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guideline. Each author used a prespecified sheet. The primary endpoint was to calculate OS (overall survival) and PFS (progression-free survival) hazard ratios for both arms. We found that adding EP plus CPIs increased both OS (HR, 95% CI 0.80 [0.70, 0.93], P = 0.0001, I-2 = 49%) and PFS (HR95% CI 0.81 [0.74, 0.88], P < 0.00001, I-2 = 0%). On the other hand, ORR (overall response rate) was not affected by the addition of CPIs to EP compared to EP alone, and the same was true for adverse events. To conclude, CTLA-4 alone is not encouraging, but PD-1/PD-L1 adds survival benefits. A combined treatment regimen shows to be more effective, improving overall survival rate Durvalumab and atezolizumab showed improvement for OS, but pembrolizumab and ipilimumab did not show a significant increase of OS over EP; however, pembrolizumab showed significant prolongation of the disease-free period. -PU - HINDAWI LTD -PI - LONDON -PA - ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND -SN - 1687-8450 -SN - 1687-8469 -DA - 2021 MAY 24 -PY - 2021 -VL - 2021 -C7 - 6662344 -DO - 10.1155/2021/6662344 -AN - WOS:000664991700001 -AD - Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, 1 Youyi Rd, Chongqing 400016, Peoples R China -AD - Chongqing Med Univ, Affiliated Hosp 1, Jinshan Hosp, Dept Oncol, Chongqing 400016, Peoples R China -AD - Chongqing Clin Canc Res Ctr, Chongqing 400016, Peoples R China -AD - Chongqing Med Univ, Affiliated Hosp 1, Spine Surg Dept, Dept Neurosurg, Chongqing 400016, Peoples R China -M2 - Chongqing Clin Canc Res Ctr -Y2 - 2021-07-05 -ER - - -TY - JOUR -AU - Loh, Jerold -AU - Low, Jia Li -AU - Sachdeva, Manavi -AU - Low, Peter Q. J. -AU - Wong, Rachel Su Jen -AU - Huang, Yiqing -AU - Chia, Puey Ling -AU - Soo, Ross A. -TI - Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer -T2 - EXPERT REVIEW OF ANTICANCER THERAPY -M3 - Review -AB - IntroductionThe current standard of care of locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiation, followed by consolidation durvalumab. However, there is evidence that the efficacy of chemoradiation and also immunotherapy in many oncogene-positive LA-NSCLC are attenuated, and dependent on the subgroup.Areas coveredWe will firstly review the outcomes of standard-of-care therapy in oncogene-driven LA-NSCLC. We looked at various oncogene driven subgroups and the tumor microenvironment that may explain differential response. Finally, we review the role of targeted therapy in the treatment of LA-NSCLC.Expert opinionEach oncogene-positive subgroup should be treated as its own entity, and continued efforts should be undertaken to incorporate targeted therapy, which is likely to yield superior survival outcomes if trial design can be optimized and toxicities can be managed. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1473-7140 -SN - 1744-8328 -DA - 2023 SEP 2 -PY - 2023 -VL - 23 -IS - 9 -SP - 913 -EP - 926 -DO - 10.1080/14737140.2023.2245140 -AN - WOS:001047655900001 -C6 - AUG 2023 -AD - Natl Univ Hlth Syst, Natl Univ Canc Inst, Singapore NCIS, Dept Haematol Oncol, Singapore, Singapore -AD - Tan Tock Seng Hosp, Dept Med Oncol, Singapore, Singapore -Y2 - 2023-08-25 -ER - - -TY - JOUR -AU - Nigen, B. -AU - Bodergat, T. -AU - Vaugier, L. -AU - Pons-Tostivint, E. -TI - First-line immunotherapy in non-small cell lung cancer diagnosed with brain metastases -T2 - REVUE DES MALADIES RESPIRATOIRES -M3 - Article -AB - Introduction. - Up to 30% patients newly diagnosed with advanced non-small cell lung cancer (NSCLC) present with brain metastases. In the absence of oncogenic addiction, first-line immunotherapy, alone or in combination with chemotherapy, is the current standard of care. This review aims to synthesize the available data regarding the efficacy of immunotherapy in these patients, and to discuss the possibility of its being coordinated with local treatments such as radiotherapy. State of the art. - NSCLC patients with brain metastases appear to have survival benefits with immunotherapy similar to those of NSCLC patients without brain metastases. However, this finding is based on mainly prospective studies having included highly selected patients with pre-treated and stable brain metastases. Several retrospective studies and two prospective single-arm studies have confirmed the intracranial efficacy of immunotherapy, either alone or in combination with chemotherapy. Perspectives. - The indications and optimal timing for cerebral radiotherapy remain subjects of debate. To date, there exists no randomized study assessing the addition of brain radiotherapy to first-line immunotherapy. That said, a recent meta-analysis showed increased intracerebral response when radiotherapy complemented immunotherapy. Conclusions. - For NSCLC patients with brain metastases, the available data suggest a clear benefit of first-line immunotherapy, whether alone or combined with chemotherapy. However, most of these data are drawn from retrospective, non-randomized studies with small sample sizes. (c) 2024 SPLF. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies. -PU - MASSON EDITEUR -PI - MOULINEAUX CEDEX 9 -PA - 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE -SN - 0761-8425 -SN - 1776-2588 -DA - 2024 OCT -PY - 2024 -VL - 41 -IS - 8 -SP - 571 -EP - 582 -DO - 10.1016/j.rmr.2024.05.004 -AN - WOS:001329098900001 -AD - Ctr Hospitalier Les Sables dOlonn, Serv Pneumol, Les Sables Olonne, France -AD - Nantes Univ, Ctr Hosp, Oncol Med, Nantes, France -AD - Inst Cancerol Ouest, Dept Radiotherapie, Saint Herblain, France -AD - Nantes Univ, Univ Angers, Inserm, CRCI2NA,CNRS,UMR 6075,UMR1307, Nantes, France -M2 - Ctr Hospitalier Les Sables dOlonn -M2 - Inst Cancerol Ouest -Y2 - 2024-10-14 -ER - - -TY - JOUR -AU - Bonanno, Laura -AU - Attili, Ilaria -AU - Pavan, Alberto -AU - Sepulcri, Matteo -AU - Pasello, Giulia -AU - Rea, Federico -AU - Guarneri, Valentina -AU - Conte, PierFranco -TI - Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice -T2 - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY -M3 - Review -AB - Treatment of locally advanced NSCLC (LA-NSCLC) is focused on multimodal strategy, including chemotherapy and radiotherapy (in combination or as alternative treatments), followed by surgery in selected cases. Recently, durvalumab consolidation after definitive chemo-radiation has shown a meaningful overall survival benefit. However, it is important to note that elderly patients represent a high proportion of NSCLC population and frailty and comorbidities can significantly limit treatment options. Indeed, elderly patients are under-represented in clinical trials and data to drive treatment selection in this category of patients are scanty. Available data, main issues and controversies on multimodal treatment in elderly LA-NSCLC patients will be reviewed in this paper. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1040-8428 -SN - 1879-0461 -DA - 2021 JUL -PY - 2021 -VL - 163 -C7 - 103378 -DO - 10.1016/j.critrevonc.2021.103378 -AN - WOS:000671294100006 -C6 - JUN 2021 -AD - IRCCS, Med Oncol 2, Ist Oncol Veneto, Via Gattamelata 64, I-35128 Padua, Italy -AD - IRCSS, Div Thorac Oncol, European Inst Oncol, Milan, Italy -AD - IRCCS, Radiotherapy, Ist Oncol Veneto, Padua, Italy -AD - Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy -AD - Univ Padua, Dept Cardiothorac Surg & Vasc Sci, Thorac Surg, Padua, Italy -Y2 - 2021-07-20 -ER - - -TY - JOUR -AU - Oh, In-Jae -AU - Ahn, Sung-Ja -TI - Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision. -T2 - Radiation oncology journal -M3 - Journal Article -M3 - Review -AB - Locally advanced non-small cell lung cancer (LA-NSCLC) is composed of heterogeneous subgroups that require a multidisciplinary team approach in order to ensure optimal therapy for each patient. Since 2010, the National Comprehensive Cancer Network has recommended chemoradiation therapy (CRT) for bulky mediastinal disease and surgical combination for those patients with single-station N2 involvement who respond to neoadjuvant therapy. According to lung cancer tumor boards, thoracic surgeons make a decision on the resectability of the tumor, if it is determined to be unresectable, concurrent CRT (CCRT) is considered the next choice. However, the survival benefit of CCRT over sequential CRT or radiotherapy alone carries the risk of additional toxicity. Considering severe adverse events that may lead to death, fit patients who are able to tolerate CCRT must be identified by multidisciplinary tumor board. Decelerated approaches, such as sequential CRT or high-dose radiation alone may be a valuable alternative for patients who are not eligible for CCRT. As a new treatment strategy, investigators are interested in the application of the innovative radiation techniques, trimodality therapy combining surgery after high-dose definitive CCRT, and the combination of radiation with targeted or immunotherapy agents. The updated results and on-going studies are thoroughly reviewed in this article. -SN - 2234-1900 -DA - 2017 Mar (Epub 2017 Mar 31) -PY - 2017 -VL - 35 -IS - 1 -SP - 16 -EP - 24 -DO - 10.3857/roj.2017.00108 -AN - MEDLINE:28395501 -AD - Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea. -AD - Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea. -Y2 - 2017-04-20 -ER - - -TY - JOUR -AU - Lantuejoul, Sylvie -AU - Damotte, Diane -AU - Hofman, Veronique -AU - Adam, Julien -TI - Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma -T2 - JOURNAL OF THORACIC DISEASE -M3 - Review -AB - Lung cancer is the leading cause of cancer death worldwide with low response rates to conventional chemotherapy. New promising therapies have emerged based on programmed cell death protein 1 (PD-1) immunity checkpoint inhibitors (ICI), including anti-PD-1, such as nivolumab and pembrolizumab, or programmed death ligand 1 (PD-L1) inhibitors, such as atezolizumab, durvalumab, and avelumab. The prescription of pembrolizumab has been approved by FDA and EMA for advanced stages non-small cell lung carcinoma (NSCLC), restricted for first-line setting to patients whose tumor presents >= 50% of PD-L1 positive tumor cells (TC), and >= 1% for second-line and beyond, leading to consider PD-L1 assay as a companion diagnostic tool for pembrolizumab. Very recently, the EMA has approved durvalumab for the treatment of patients with unresectable stage III NSCLC not progressing after chemoradiotherapy and whose tumors express PD-L1 on >= 1% of TC. Four standardized PD-L1 immunohistochemistry assays have been used in clinical trials; 22C3 and 28-8 PharmDx assays on Dako/Agilent platforms, and SP142 and SP263 assays on Ventana platforms, each test having been developed initially for a specific ICI. They differ in terms of primary monoclonal antibody, platform, detection system and scoring methods with different thresholds of positivity validated in clinical trials. Several studies have shown a close analytical performance of the 22C3, 28-8 and SP263 assays regarding TC staining in NSCLC, with poor concordance with SP142 assay and for immune cells. However, as dedicated platforms are not available in all pathology laboratories and because of the high cost of these assays, laboratory developed tests are widely used in many countries. Their validation must guarantee the same sensitivities and specificities as compared to standardized assays. Overall, PD-L1 test is of great help to select patients who could benefit for ICI and most pathologists have included this test in their daily practice for advanced stages NSCLC, besides ALK and ROS1 IHC. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2019 JAN -PY - 2019 -VL - 11 -SP - S89 -EP - S101 -DO - 10.21037/jtd.2018.12.103 -AN - WOS:000456826600011 -AD - UNICANCER, Ctr Leon Berard, Dept Biopathol, Lyon, France -AD - UNICANCER, Ctr Leon Berard, Dept Rech Translat & Innovat, Lyon, France -AD - Univ Grenoble Alpes, Inst Adv Biosci, Grenoble, France -AD - Synergie Lyon Canc Fdn, PATTERN Grp French Thorac Pathologists Innovat &, Lyrican, France -AD - Hop Cochin, AP HP, Dept Pathol, Paris, France -AD - Univ Paris 05, Ctr Rech Cordeliers, Paris, France -AD - Univ Cote Azur, Lab Clin & Expt Pathol, Nice, France -AD - Univ Cote Azur, Biobank BB 0033 0025, FHU OncoAge, Nice Hosp, Nice, France -AD - Gustave Roussy, Dept Biol & Pathol Med, Villejuif, France -M2 - Synergie Lyon Canc Fdn -Y2 - 2019-02-13 -ER - - -TY - JOUR -AU - Yang, Guanqun -AU - Xing, Ligang -AU - Sun, Xiaorong -TI - Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases -T2 - FRONTIERS IN IMMUNOLOGY -M3 - Review -AB - Brain metastases (BMs) in non-small-cell lung cancer (NSCLC) patients are associated with significant morbidity and poor prognosis. Immune checkpoint inhibitors (ICIs) have resulted in a paradigm shift in the management of advanced NSCLC. However, the value of ICIs in NSCLC patients with BMs remains unclear because patients with BMs are routinely excluded in numerous prospective trials on ICIs. Here, starting from the mechanisms of ICIs for BMs, we will reveal the value of ICIs by reviewing the efficacy and adverse effects of ICIs monotherapy as well as promising combination strategies, such as combinations with chemotherapy, radiotherapy, and anti-angiogenic drugs, etc. In addition, the methods of patient selection and response assessment will be summarized to assist clinical practice and further studies. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1664-3224 -DA - 2022 MAR 29 -PY - 2022 -VL - 13 -C7 - 852811 -DO - 10.3389/fimmu.2022.852811 -AN - WOS:000783640700001 -AD - Shandong Univ, Cheeloo Coll Med, Jinan, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Nucl Med, Jinan, Peoples R China -Y2 - 2022-04-27 -ER - - -TY - JOUR -AU - Qiu, Yan-Fang -AU - Liu, Zhi-gang -AU - Yang, Wen-juan -AU - Zhao, Yu -AU - Tang, Jiao -AU - Tang, Wei-zhi -AU - Jin, Yi -AU - Li, Fang -AU - Zhong, Rui -AU - Wang, Hui -TI - Research progress in the treatment of small cell lung cancer -T2 - JOURNAL OF CANCER -M3 - Article -AB - Small cell lung cancer (SCLC) accounts for approximately 10-15% of all lung cancers. No significant improvement has been made for patients with SCLC in the past several decades. The main progresses were the thoracic radiation and prophylactic cranial irradiation (PCI) that improved the patient survival rate. For patients with limited disease and good performance status (PS), concurrent chemoradiotherapy (CCRT) followed by PCI should be considered. For extensive disease, the combination of etoposide and platinum-based chemotherapy remains the standard treatment and consolidative thoracic radiotherapy is beneficial for patients who have a significant respond to initial chemotherapy. However, the prognosis still remains poor. Recently, efforts have been focused on molecular targets and immunotherapy. But numerous molecular targets methods have failed to show a significant clinical benefit in patients with SCLC. It is anticipated that further development of research will depend on the on-going trials for molecular targeted therapy and immunotherapy which are promising and may improve the outcomes for SCLC in the next decade. -PU - IVYSPRING INT PUBL -PI - LAKE HAVEN -PA - PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA -SN - 1837-9664 -DA - 2017 -PY - 2017 -VL - 8 -IS - 1 -SP - 29 -EP - 38 -DO - 10.7150/jca.16822 -AN - WOS:000396576400004 -AD - Cent South Univ, Hunan Canc Hosp, Dept Radiat Oncol, Key Lab Translat Radiat Oncol,Xiangya Sch Med, Changsha, Hunan, Peoples R China -AD - Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Hunan, Peoples R China -Y2 - 2017-03-29 -ER - - -TY - JOUR -AU - Ma, Ji -AU - Tian, Yaru -AU - Hao, Shaoyu -AU - Zheng, Liangjie -AU - Hu, Weibo -AU - Zhai, Xiaoyang -AU - Meng, Dongfang -AU - Zhu, Hui -TI - Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis -T2 - JOURNAL OF NEURO-ONCOLOGY -M3 - Article -AB - Introduction Anti-programmed cell death-ligand 1 (Anti-PD-L1) blockades have become the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) from CASPIAN and IMpower133 trials. SCLC has a high incidence of brain metastasis (BM) and brain radiotherapy (BRT) is the main local treatment method, but there is limited data on the BRT-immunotherapy scheme. The aim of the retrospective study is to investigate the clinical efficacy and safety of the first-line anti-PD-L1 blockades combined with BRT in ES-SCLC with BM. Methods Patients with newly diagnosed ES-SCLC with baseline BMs at Shandong Cancer Hospital and Research Institute between 2017 and 2021 were selected. Patients were divided into the anti-PD-L1+BRT group and BRT group. We also assessed the leukoencephalopathy in both groups. Results A total of 46 patients were selected. Fifteen were divided into anti-PD-L1+BRT group and 31 to BRT group. The median overall survival (OS) was not reached (NR) vs 15.9 m (P = 0.172). Progression-free survival (PFS) was numerically prolonged with anti-PD-L1 blockades, but the significance was not reached (median: 9.4 m vs 7.4 m, P = 0.362). The median intracranial PFS was not improved, neither (median: 8.2 m vs 8.9 m, P = 0.620). Objective response rate (ORR) in the two groups was 73.33% vs 77.42% (P = 0.949) and disease control rate (DCR) was both 100%. Intracranial ORR and DCR were 53.33% vs 70.97% (P = 0.239) and 73.33% vs 80.65% (P = 0.855), respectively. There was no significant difference in leukoencephalopathy incidence between the two groups. Conclusion The combination of first-line anti-PD-L1 blockades with BRT did not confer a significant survival benefit in ES-SCLC with BM, without enhancing cranial neurotoxicity. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 0167-594X -SN - 1573-7373 -DA - 2022 SEP -PY - 2022 -VL - 159 -IS - 3 -SP - 685 -EP - 693 -DO - 10.1007/s11060-022-04111-7 -AN - WOS:000843819300002 -C6 - AUG 2022 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China -AD - Peoples Hosp Leling, Dept Oncol, Leling, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Thorac Surg, Jinan, Peoples R China -M2 - Peoples Hosp Leling -Y2 - 2022-08-30 -ER - - -TY - JOUR -AU - Li, Q. -AU - Yuan, D. -AU - Ma, C. -AU - Liu, Y. -AU - Ma, L. -AU - Lv, T. -AU - Song, Y. -TI - A new hope: the immunotherapy in small cell lung cancer -T2 - NEOPLASMA -M3 - Review -AB - Small cell lung cancer (SCLC) is of a high-grade malignancy with a high metastatic potential and poor clinical prognosis. Unfortunately, SCLC initially exhibits a good response to chemotherapy and radiation therapy, but inevitably, relapses decrease patients' chance of survival. Despite tremendous advances on the development of new chemotherapeutic agents, the prognosis of this disease remains poor. Immunotherapy plays a role in eliciting an anticancer response by modulating the patient's immune response of the tumor. Several studies have demonstrated that abnormal autoimmune regulation has a close relationship with SCLC. Thus, several immunotherapy trials are focused on SCLC treatment, including such approaches as immune checkpoints blockers, tumor vaccine, antigenic targets and adoptive cellular immunotherapy to benefit patients with SCLC. To date, the results from immunotherapy in SCLC have not been promising. For example, tumor vaccines have not been demonstrated to have a significant survival benefit. However, there have been many promising advances with immune checkpoints blockers. This review will provide a general overview of immunotherapy in SCLC. The landmark clinical trials in previous successful immunotherapy studies are summarized here. Finally, the challenges of immunotherapy in SCLC are discussed to facilitate the prediction of possible and valuable strategies for future therapy. -PU - AEPRESS SRO -PI - BRATISLAVA -PA - BAJZOVA 7, BRATISLAVA, 821 08, SLOVAKIA -SN - 0028-2685 -SN - 1338-4317 -DA - 2016 -PY - 2016 -VL - 63 -IS - 3 -SP - 342 -EP - 350 -DO - 10.4149/302_151001N511 -AN - WOS:000377058000002 -AD - Nanjing Univ, Sch Med, Jinling Hosp, Dept Resp & Crit Care Med, Nanjing 210008, Jiangsu, Peoples R China -AD - Southern Med Univ Guangzhou, Jinling Hosp, Dept Resp Med, Nanjing, Jiangsu, Peoples R China -Y2 - 2016-06-22 -ER - - -TY - JOUR -AU - Molinier, O. -AU - Besse, B. -AU - Barlesi, F. -AU - Audigier-Valette, C. -AU - Friard, S. -AU - Monnet, I -AU - Jeannin, G. -AU - Mazieres, J. -AU - Cadranel, J. -AU - Hureaux, J. -AU - Hilgers, W. -AU - Quoix, E. -AU - Coudert, B. -AU - Moro-Sibilot, D. -AU - Fauchon, E. -AU - Westeel, V -AU - Brun, P. -AU - Langlais, A. -AU - Morin, F. -AU - Souquet, P. J. -AU - Girard, N. -TI - IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer -T2 - ESMO OPEN -M3 - Article -AB - Background: Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard of care in patients with advanced non-small-cell lung cancer (NSCLC).Materials and methods: We carried out a nationwide cohort retrospective study of consecutive patients with advanced, refractory NSCLC who received nivolumab as second to later lines of treatment as part of the expanded access program. Key objectives were to assess the efficacy and safety of nivolumab and the efficacy of first postnivolumab treatment.Results: Nine hundred and two patients were enrolled: 317 (35%) with squamous cell carcinoma and 585 (65%) with nonsquamous cell carcinoma. Median age was 64 years; there were 630 (70%) men, 795 (88%) smokers, 723 (81%) patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0/1, 197 (22%) patients with brain metastases, and 212 (27%) with liver metastases. Best response was partial response for 16.2% and stable disease (SD) for 30.5%. Progression-free survival and overall survival (OS) rates at 2, 3, and 5 years were 8% and 25%, 6% and 16%, and 4% and 10%, respectively. At multivariate analysis, ECOG PS >= 2 [hazard ratio (HR) = 2.13, 95% confidence interval (95% CI) 1.78-2.55, P < 0.001], squamous histology (HR = 1.17, 95% CI 1.01-1.36, P = 0.04), and presence of central nervous system metastases (HR = 1.29, 95% CI 1.08-1.54, P = 0.005) were significantly associated with lower OS. Four hundred and ninety-two patients received at least one treatment after discontinuation of nivolumab, consisting of systemic therapies in 450 (91%). Radiation therapy was delivered to 118 (24%) patients.Conclusion: The CLINIVO cohort represents the largest real-world evidence cohort with the use of immune checkpoint inhibitor in advanced, metastatic NSCLC after failure of first-line chemotherapy, with long-term follow-up and analysis of subsequent therapies. Our data confirm the efficacy of nivolumab in a cohort larger than that reported in landmark clinical trials and identify prognostic factors, which reinforces the need for accurate selection of patients for treatment with immune checkpoint inhibitors. Our data indicate that oligoprogression is frequent after nivolumab exposure and provide a unique insight into the long-term survival. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 2059-7029 -DA - 2022 FEB -PY - 2022 -VL - 7 -IS - 1 -DO - 10.1016/j.esmoop.2021.100353 -AN - WOS:000819873600022 -AD - Ctr Hosp Mans, Pneumol, Le Mans, France -AD - Gustave Roussy, Canc Med Dept, Villejuif, France -AD - Paris Saclay Univ, Orsay, France -AD - Aix Marseille Univ, CRCM, INSERM, CNRS, Marseille, France -AD - Gustave Roussy Canc Campus, Villejuif, France -AD - Ctr Hosp Toulon St Musse, Pneumol Dept, Toulon, France -AD - Hop Foch, Chest Dept, Suresnes, France -AD - CHI Creteil, Pneumol Serv, Creteil, France -AD - CHU Gabriel Montpied, Pneumol Serv, Clermont Ferrand, France -AD - Ctr Hosp Univ Toulouse, Pneumol Serv, Pole Voies Resp, Hop Larrey, Toulouse, France -AD - Hop Tenon, AP HP, Pneumol Serv, Paris, France -AD - Sorbonne Univ, UPMC, Univ Paris 06, GRC 04, Paris, France -AD - CHU Angers, Pole Hippocrate, Angers, France -AD - St Catherine Canc Inst, Med Oncol, Avignon Provence, France -AD - Hop Univ Strasbourg Unistra, Pneumol Serv, Strasbourg, France -AD - Ctr Georges Francois Leclerc, Med Oncol Dept, Dijon, France -AD - CHU Grenoble Alpes, Pneumol & Thorac Oncol Dept, La Tronche, France -AD - CHI, Pneumol Serv, St Julien En Genevois, France -AD - Hop Jean Minjoz, Pneumol Serv, Ctr Hosp Reg Univ Besancon, Besancon, France -AD - CH Valence, Pneumol Serv, Valence, France -AD - French Cooperat Thorac Intergrp IFCT, Biostat Dept, Paris, France -AD - French Cooperat Thorac Intergrp IFCT, Clin Res Unit, Paris, France -AD - Ctr Hosp Lyon Sud, Pneumol Serv, Pierre Benite, France -AD - Inst Curie, Inst Thorax Curie Montsouris, Paris, France -M2 - Ctr Hosp Toulon St Musse -M2 - St Catherine Canc Inst -M2 - Hop Univ Strasbourg Unistra -M2 - CHI -M2 - CH Valence -M2 - French Cooperat Thorac Intergrp IFCT -M2 - French Cooperat Thorac Intergrp IFCT -Y2 - 2022-07-15 -ER - - -TY - JOUR -AU - Grambow-Velilla, Julia -AU - Seban, Romain-David -AU - Chouahnia, Kader -AU - Assie, Jean-Baptiste -AU - Champion, Laurence -AU - Girard, Nicolas -AU - Bonardel, Gerald -AU - Matton, Lise -AU - Soussan, Michael -AU - Chouaid, Christos -AU - Duchemann, Boris -TI - Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy -T2 - CANCERS -M3 - Article -AB - Simple Summary Chemotherapy with immune checkpoint inhibitors is the new standard of care for first-line systemic therapy in extensive small-cell lung cancer. The identification of biomarkers for patients that are likely or not likely to respond to such therapy is critical. We aimed at determining whether imaging could help to predict outcomes among these patients. We showed that the total metabolic tumor burden, extracted from pre-treatment 18-FDG PET/CT imaging, may be a useful biomarker associated with survival. Finally, we think that this result should be taken into account in clinical trials, and that it might need further validation through large, independent, and prospective cohorts. Background: We aimed to evaluate the prognostic value of imaging biomarkers on 18F-FDG PET/CT in extensive-stage small-cell lung cancer (ES-SCLC) patients undergoing first-line chemo-immunotherapy. Methods: In this multicenter and retrospective study, we considered two cohorts, depending on the type of first-line therapy: chemo-immunotherapy (CIT) versus chemotherapy alone (CT). All patients underwent baseline 18-FDG PET/CT before therapy between June 2016 and September 2021. We evaluated clinical, biological, and PET parameters, and used cutoffs from previously published studies or predictiveness curves to assess the association with progression-free survival (PFS) or overall survival (OS) with Cox prediction models. Results: Sixty-eight patients were included (CIT: CT) (36: 32 patients). The median PFS was 5.9:6.5 months, while the median OS was 12.1:9.8 months. dNLR (the derived neutrophils/(leucocytes-neutrophils) ratio) was an independent predictor of short PFS and OS in the two cohorts (p < 0.05). High total metabolic tumor volume (TMTVhigh if > 241 cm(3)) correlated with outcomes, but only in the CIT cohort (PFS for TMTVhigh in multivariable analysis: HR 2.5; 95%CI 1.1-5.9). Conclusion: Baseline 18F-FDG PET/CT using TMTV could help to predict worse outcomes for ES-SCLC patients undergoing first-line CIT. This suggests that baseline TMTV may be used to identify patients that are unlikely to benefit from CIT. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2023 APR -PY - 2023 -VL - 15 -IS - 8 -C7 - 2223 -DO - 10.3390/cancers15082223 -AN - WOS:000977384500001 -AD - Avicenne Univ Hosp, AP HP, Dept Nucl Med, F-93000 Bobigny, France -AD - Univ Paris, European Hosp Georges Pompidou, AP HP, Dept Nucl Med, F-75015 Paris, France -AD - Inst Curie, Dept Nucl Med, F-92210 St Cloud, France -AD - Inst Curie, Lab Imagerie Translat Oncol, Inserm, F-91401 Orsay, France -AD - Avicenne Univ Hosp, AP HP, Dept Med Thorac & Med Oncol, F-93000 Bobigny, France -AD - UPEC, CHU Henri Mondor, Unite Pneumol, F-94000 Creteil, France -AD - Inst Thorax Curie Montsouris, Inst Curie, F-75005 Paris, France -AD - UVSQ, Paris Saclay, UFR Simone Veil, F-78180 Versailles, France -AD - Ctr Cardiol Nord, Nucl Med, F-93200 St Denis, France -AD - Paris Est Univ, Ctr Hosp Intercommunal Creteil, Dept Pneumol, F-94010 Paris, France -AD - Univ Sorbonne Paris Nord, Inserm UMR 1272 Hypoxie & Poumon, UFR SMBH Leonard Vinci, F-93000 Bobigny, France -M2 - Ctr Cardiol Nord -M2 - Univ Sorbonne Paris Nord -Y2 - 2023-05-21 -ER - - -TY - JOUR -AU - Porte, J. -AU - St Martin, C. -AU - Moreau, T. Frederic -AU - Massiani, M. A. -AU - Jadaud, E. -AU - Otz, J. -AU - Verrelle, P. -AU - Girard, N. -AU - Crehange, G. -AU - Beddok, A. -TI - Loco-Regional Control and Survival Outcomes After Combined Stereotactic Radiation Therapy and Immune Checkpoint Inhibitors for Brain Metastases From Non-Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 3215 -SP - E577 -EP - E577 -AN - WOS:000715803801206 -AD - Inst Curie, Dept Radiat Oncol, St Cloud, France -AD - Inst Curie, Dept Stat, Paris, France -AD - Inst Curie, Dept Thorac Oncol, St Cloud, France -AD - Inst Curie, St Cloud, Ile De Fra, France -AD - Inst Curie, Paris, France -AD - Inst Thorax, Dept Thorac Oncol, Site Curie, Paris, France -AD - Inst Curie, Dept Radiat Oncol, Paris, France -AD - Inst Curie, Dept Proton Therapy, Paris, France -M2 - Inst Thorax -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Heigener, David F. -AU - Reck, Martin -TI - Giant steps and stumbling blocks -T2 - NATURE REVIEWS CLINICAL ONCOLOGY -M3 - Editorial Material -AB - In 2017, major advances in the treatment of non-small-cell lung cancer (NSCLC) continued to emanate from the fields of molecularly targeted therapy and immunotherapy. In the former, new drugs with improved efficacy and reduced toxicity entered the clinic; in the latter, immune-checkpoint inhibition proved efficacious after chemoradiotherapy for stage III disease, but had disparate results in the frontline treatment of stage IV disease. -PU - NATURE PUBLISHING GROUP -PI - NEW YORK -PA - 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA -SN - 1759-4774 -SN - 1759-4782 -DA - 2018 FEB -PY - 2018 -VL - 15 -IS - 2 -SP - 71 -EP - 72 -DO - 10.1038/nrclinonc.2017.178 -AN - WOS:000422916700011 -AD - German Ctr Lung Res DZL, ARCN, LungenClin Grosshansdorf, Dept Thorac Oncol, Woehrendamm 80, D-22927 Grosshansdorf, Schleswig Holst, Germany -Y2 - 2018-02-01 -ER - - -TY - JOUR -AU - Seetharamu, Nagashree -AU - Preeshagul, Isabel R -AU - Sullivan, Kevin M -TI - New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab. -T2 - Lung Cancer (Auckland, N.Z.) -M3 - Journal Article -M3 - Review -AB - The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies. Lung cancer has been in the forefront of checkpoint inhibition for the past 2 years and has paved the path for other subspecialties. While PD-1 inhibitors nivolumab and pembrolizumab have been approved for non-small cell lung cancer (NSCLC), this review focuses on atezolizumab, its landmark studies, and ongoing trials. Atezolizumab is the first programmed death ligand 1 (PD-L1) inhibitor to receive US Food and Drug Administration (FDA) approval for metastatic NSCLC patients who have progressed on frontline chemotherapy. This approval was based on two open-label Phase II multicenter trials, POPLAR (NCT01903993) and BIRCH (NCT02031458). Both studies revealed a benefit in overall survival (OS), progression-free survival, and response rate in the atezolizumab arm when compared to single-agent docetaxol. There were also fewest Grade 3-5 treatment-related adverse events (TRAEs) in the atezolizumab cohort. The open-label randomized Phase III OAK trial (NCT02008227) further established the role of atezolizumab in previously treated NSCLC. This study compared atezolizumab with docetaxel in patients with advanced NSCLC (squamous or nonsquamous histologies) who had progressed on one to two prior chemotherapy regimens. OS in the PD-L1-enriched population was superior in the atezolizumab arm (n=241) at 15.7 months compared with docetaxel (n=222) at 10.3 months (hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.58-0.93; p=0.0102). Patients lacking PD-L1 also had survival benefit with atezolizumab with a median OS (mOS) of 12.6 months versus 8.9 months with chemotherapy (HR 0.75, 95% CI 0.59-0.96). Benefit was noted in both squamous and nonsquamous NSCLC subsets and regardless of PD-L1 expressivity. As seen in the POPLAR and BIRCH studies, the toxicity profile was significantly better with immunotherapy. The future is unfolding rapidly as new checkpoint inhibitors are gaining FDA approval. It is still not known if these agents will be used in combination with chemotherapy, with other immune-modulating agents, radiation therapy, or all of the above. The results of these studies investigating their use in combination with chemotherapy agents, with other immunotherapy agents such as CTLA-4 inhibitors, and with radiation therapy, are eagerly awaited. -SN - 1179-2728 -DA - 2017 -PY - 2017 -VL - 8 -SP - 67 -EP - 78 -DO - 10.2147/LCTT.S113177 -AN - MEDLINE:28761384 -AD - Monter Cancer Center, Hofstra-Northwell Health School of Medicine, Lake Success, NY, USA. -Y2 - 2017-08-31 -ER - - -TY - JOUR -AU - Malhotra, Jyoti -AU - Jabbour, Salma K. -AU - Aisner, Joseph -TI - Current state of immunotherapy for non-small cell lung cancer -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Lung cancer is the leading cause of cancer mortality and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers. Platinum-based doublet chemotherapy is the standard first-line treatment for metastatic NSCLC when genomic testing reveals no targetable alteration such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) or ROS1 translocation/re-arrangements. But, chemotherapy produces response rates ranging only between 15-30%. For patients whose disease progresses on first-line chemotherapy, second-line therapy historically consists of taxane-based salvage chemotherapy with a response rate of less than 25%. Recently, immunotherapy with checkpoint inhibitor agents have demonstrated responses in advanced NSCLC, with some patients exhibiting durable responses after discontinuing therapy. In 2015, two immune checkpoint inhibitors targeting programmed cell death-1 (PD-1), nivolumab and pembrolizumab were approved for secondline therapy of NSCLC. In 2016, another checkpoint inhibitor targeting program death-ligand 1 (PD-L1), atezolizumab was approved for the same indication. Moreover, pembrolizumab also received approval in 2016 for first-line NSCLC treatment in patients with high PD-L1 expressing tumors. Immunotherapy for NSCLC has therefore, recently evolved into a true treatment modality with the acceptance of PD-1 and PD-L1 inhibitors as the new standard of care for second-line treatment. However, it is still at the discretion of the treating physician whether to use PD-1 or PD-L1 inhibitor as data to compare these two pathways is lacking. Focus is now also on exploring their role in the adjuvant and consolidation settings for NSCLC as well as on exploring novel combinations combining these agents with chemotherapy or radiation. Research is also needed in the development of predictive and prognostic biomarkers for these agents. While vaccine therapy trials in NSCLC have so far failed to show significant clinical benefit, the demonstration of enhanced immune response in these trials suggest the vaccine therapy needs additional evaluation in combination with other therapeutic modalities especially checkpoint inhibition. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2017 APR -PY - 2017 -VL - 6 -IS - 2 -SP - 196 -EP - 211 -DO - 10.21037/tlcr.2017.03.01 -AN - WOS:000403489800010 -AD - Rutgers Canc Inst New Jersey, New Brunswick, NJ USA -Y2 - 2017-04-01 -ER - - -TY - JOUR -AU - Fukui, Tomoya -AU - Hosotani, Shinji -AU - Soda, Itaru -AU - Ozawa, Takahiro -AU - Kusuhara, Seiichiro -AU - Kakegawa, Mikiko I. -AU - Kasajima, Masashi -AU - Hiyoshi, Yasuhiro -AU - Igawa, Satoshi -AU - Yokoba, Masanori -AU - Mitsufuji, Hisashi -AU - Kubota, Masaru -AU - Katagiri, Masato -AU - Sasaki, Jiichiro -AU - Ishiyama, Hiromichi -AU - Naoki, Katsuhiko -TI - Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab -T2 - THORACIC CANCER -M3 - Article -AB - Background The standard treatment for patients with unresectable locally advanced (LA) non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT). Consolidation therapy with durvalumab after CRT demonstrated survival benefits and was approved in Japan in July 2018. The use of immune checkpoint inhibitors (ICIs) is entering routine oncological practice, and here we investigate the feasibility of concurrent CRT for LA-NSCLC patients based on the PACIFIC criteria.Methods We performed a retrospective study to evaluate the feasibility and efficacy of concurrent CRT prior to the approval of durvalumab. We assessed consecutive patients with LA-NSCLC treated with CRT between January 2012 and June 2018.Results We analyzed a total of 108 consecutive patients who received radical thoracic radiotherapy and concurrent platinum-based chemotherapy. Of those patients, 105 (97%) completed the planned radiotherapy. Radiation pneumonitis was observed in 93 patients (85%), with a median of 130 days (range: 41-317 days) from the initiation of radiation to the onset of the complication. Among the patients, 74 (69%) were considered eligible for consolidation therapy with durvalumab. The overall response rate was 64%, and the two-year survival rate was 63%. Patients who received an ICI after relapse were associated with significantly better survival than those who did not receive an ICI (two-year survival rate: 87% vs. 41%, respectively; P = 0.001).Conclusions Prior to the approval of durvalumab, the clinical application of ICIs improved the outcome of patients with relapsed NSCLC after CRT for LA-NSCLC. The management of radiation pneumonitis remains a challenge following the approval of durvalumab. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1759-7706 -SN - 1759-7714 -DA - 2020 APR -PY - 2020 -VL - 11 -IS - 4 -SP - 1005 -EP - 1014 -DO - 10.1111/1759-7714.13357 -AN - WOS:000522621100020 -AD - Kitasato Univ, Dept Resp Med, Sch Med, Sagamihara, Kanagawa, Japan -AD - Kitasato Univ, Sch Med, Dept Radiol & Radiat Oncol, Sagamihara, Kanagawa, Japan -AD - Kitasato Univ, Sch Allied Hlth Sci, Dept Lab Med, Sagamihara, Kanagawa, Japan -AD - Kitasato Univ, Sch Nursing, Fundamental Nursing, Sagamihara, Kanagawa, Japan -AD - Kitasato Univ, Sch Med, Res & Dev Ctr New Med Frontiers, Sagamihara, Kanagawa, Japan -Y2 - 2020-04-10 -ER - - -TY - JOUR -AU - Papavasileiou, Sotirios -AU - Kouvela, Marousa -AU - Charpidou, Andriani -TI - New therapies in small cell lung cancer: A narrative review -T2 - PNEUMON -M3 - Article -AB - Lung cancer overall is the second most common malignancy in both men and women in the United States and remains the leading cause of cancer death. Small cell lung cancer (SCLC) accounts for approximately 10-15% of all cases. Chemotherapy with a platinum agent and etoposide remains the standard of care for limited -stage patients. In the past few years, several clinical trials have evaluated the efficacy of immunotherapy, when added to conventional chemotherapy, in extensive -stage patients, and two anti -PD -L1 monoclonal antibodies, atezolizumab and durvalumab, have already been approved by the USA Food and Drug Administration (FDA) for use in this setting. Moreover, numerous other new agents are currently being investigated while new molecular features of SCLC subtypes come to light. Further analysis of predictive biomarkers needs to be done as well as evaluation of immune checkpoint inhibitors in early -stage disease. -PU - EUROPEAN PUBLISHING -PI - HERAKLION -PA - SCIENCE & TECHNOLGY PARK CRETE, (STEP-C), N PLASTIRA 100, VASSILIKA VOUTWN, HERAKLION, CRETE 00000, GREECE -SN - 1105-848X -SN - 1791-4914 -DA - 2024 JAN-MAR -PY - 2024 -VL - 37 -IS - 1 -C7 - 13 -DO - 10.18332/pne/183168 -AN - WOS:001184629500001 -C6 - MAR 2024 -AD - Gen Hosp Thessaloniki G Papanikolaou, Internal Med Dept, Thessaloniki, Greece -AD - Natl & Kapodistrian Univ Athens, Sotiria Gen Hosp Chest Dis, Sch Med, Oncol Unit,Dept Internal Med 3,Sch Hlth Sci, Athens, Greece -AD - Gen Hosp G Papanikolaou, Internal Med Dept, Thessaloniki 57010, Greece -M2 - Gen Hosp G Papanikolaou -Y2 - 2024-03-20 -ER - - -TY - JOUR -AU - Zou, Yuxia -AU - Ren, Xueru -AU - Zhang, Huanhuan -AU - Wang, Yuenan -AU - Wang, Hanqi -AU - Bai, Rubing -AU - Zhang, Zhihong -AU - Sun, Gengyun -AU - Xu, Ling -TI - Efficacy and safety of durvalumab plus chemotherapy vs. atezolizumab plus chemotherapy in the treatment of small-cell lung cancer: a retrospective comparative cohort study -T2 - JOURNAL OF THORACIC DISEASE -M3 - Article -AB - Background: Durvalumab and atezolizumab have recently been approved in extensive small cell lung cancer (SCLC) with moderate median overall survival (OS) improvements. However, only limited data exist regarding the impact of immunotherapy in real-world SCLC patients. This study sought to assess the efficacy and safety of atezolizumab plus chemotherapy and durvalumab plus chemotherapy in the treatment of SCLC in a real-world setting.Methods: A retrospective cohort study of all patients treated for SCLC with chemotherapy with PD-L1 inhibitor, at 3 centers in China between February 1, 2020 and April 30, 2022. Patient characteristics, adverse-events and survival analyses were conducted.Results: A total of 143 patients were enrolled in this study, 100 were treated with durvalumab and the remainder with atezolizumab. The baseline characteristics of the two groups were fundamentally balanced before using PD-L1 inhibitors (P>0.05). The median OS (mOS) of the patients who received durvalumab or atezolizumab as the first-line treatment were 22.0 and 10.0 months, respectively (P=0.03). Survival analysis of patients with brain metastasis (BM) revealed that the median progression-free survival (mPFS) of patients without BM treated with durvalumab plus chemotherapy (5.5 months) was longer than that of those with BM (4.0 months) (P=0.03). In contrast, in the atezolizumab plus chemotherapy regimen, BM did not affect survival. In addition, the addition of radiotherapy to treatment with PD-L1 inhibitors in combination with chemotherapy has a tendency to improve long-term survival. As for safety analysis, there was no significant difference in the incidence of immune-related adverse events (IRAEs) during PD-L1 inhibitor therapy between the 2 groups (P>0.05). And during treatment with immunochemotherapy, radiotherapy was not associated with the development of IRAE (P=0.42) but increased the risk of immune-related pneumonitis (P=0.026).Conclusions: The implication of this study for clinical practice is a preference for durvalumab in first-line immunotherapy for SCLC. In addition, appropriate radiotherapy during treatment with PD-L1 inhibitors in combination with chemotherapy may prolong long-term survival, but the occurrence of immune-related pneumonitis should be vigilant. Data from this study are limited and the baseline characteristics of the two populations still need to be more finely classified. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2023 JUN -PY - 2023 -VL - 15 -IS - 6 -SP - 3339 -EP - 3349 -DO - 10.21037/jtd-23-588 -AN - WOS:001023390200001 -C6 - JUN 2023 -AD - Univ Sci & Technol China USTC, Affiliated Hosp 1, Anhui Prov Canc Hosp, Dept Resp Oncol, 107 East Huanhu Rd, Hefei 230088, Peoples R China -AD - Anhui Med Univ, Affiliated Hosp 1, Dept Resp Med, 218 Jixi Rd, Hefei 230022, Peoples R China -AD - Anhui Chest Hosp, Dept Intervent Pulm Dis, 397 Jixi Rd, Hefei 230031, Peoples R China -M2 - Anhui Chest Hosp -Y2 - 2023-07-19 -ER - - -TY - JOUR -AU - Martinez, Pablo -AU - Martinez-Marti, Alex -AU - Navarro, Alejandro -AU - Cedres, Susana -AU - Felip, Enriqueta -TI - Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate? -T2 - LUNG CANCER -M3 - Editorial Material -AB - Non-small-cell lung cancer (NSCLC) represents approximately 85% of all lung cancer cases, with a worldwide annual incidence of around 1.3 million. Surgery remains the corner stone of treatment in early-stage NSCLC when feasible, and the addition of adjuvant cisplatin-based chemotherapy has improved these results in resected NSCLC patients. For those patients with non-metastatic NSCLC not suitable for complete surgical resection, chemotherapy plus radiotherapy remains the best treatment option. For patients with metastatic NSCLC, molecular targeted agents have become part of the therapeutic arsenal in recent years. However, to date no targeted agent has been approved for patients with early or locally-advanced stages of NSCLC. Here, we review the rationale, literature and studies addressing the role of targeted agents used in the adjuvant setting or as part of chemoradiotherapy regimens. (C) 2014 Elsevier Ireland Ltd. All rights reserved. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2014 MAY -PY - 2014 -VL - 84 -IS - 2 -SP - 97 -EP - 100 -DO - 10.1016/j.lungcan.2014.01.018 -AN - WOS:000336346200001 -AD - Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain -Y2 - 2014-05-01 -ER - - -TY - JOUR -AU - Gustin, P. -AU - Botticella, A. -AU - Tselikas, L. -AU - Mercier, O. -AU - Le Pechoux, C. -AU - Levy, A. -TI - Therapeutic options for oligoprogressive non-small cell lung cancer -T2 - REVUE DES MALADIES RESPIRATOIRES -M3 - Review -AB - Lung cancer is the leading cause of cancer-related mortality and more than half of the cases are diagnosed at a metastatic stage. Major progress in terms of systemic treatments has been achieved in recent decades. Access to new anti-PD-(L) 1 immunotherapies and targeted therapies for non-small cell lung cancer (NSCLC) with oncogenic addiction such as EGFR mutation or ALK rearrangement have led to improved outcomes. Patients with limited progression of their disease during systemic treatment may be a particular subgroup. This oligoprogressive state is characterized by a limited number of sites in progression, implying that the other sites remain controlled and therefore sensitive to systemic treatments. The advent of non-invasive techniques such as stereotactic radiotherapy, radiofrequency, and mini-invasive surgery has led to a precise re-evaluation of local ablative treatments in this situation. Local treatment of the oligoprogressive lesion(s) may allow modification of the natural history of the disease, maintenance of effective systemic targeted treatment and, ultimately, to improved survival. Data validating an aggressive local therapeutic approach in oligoprogressive NSCLC patients are currently limited and essentially retrospective. Several international trials are underway that could confirm the clinical benefit of radical local treatment in oligoprogressive advanced NSCLC patients. (C) 2019 SPLF. Published by Elsevier Masson SAS. All rights reserved. -PU - MASSON EDITEUR -PI - MOULINEAUX CEDEX 9 -PA - 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE -SN - 0761-8425 -SN - 1776-2588 -DA - 2019 APR -PY - 2019 -VL - 36 -IS - 4 -SP - 519 -EP - 526 -DO - 10.1016/j.rmr.2018.04.011 -AN - WOS:000467816700014 -AD - Univ Paris Saclay, Gustave Roussy, IOT, Dept Oncol Radiotherapie, 114 Rue Vaillant, F-94805 Villejuif, France -AD - Univ Paris Saclay, Univ Paris Sud, F-94270 Le Kremlin Bicetre, France -AD - Univ Paris Saclay, Gustave Roussy, Dept Radiol Intervent, F-94805 Villejuif, France -AD - Univ Paris Saclay, Univ Paris Sud, Hop Marie Lannelongue,IOT, Dept Chirurg Thorac & Vasc & Transplantat Cardiop, F-92350 Le Plessis Robinson, France -AD - INSERM, U1030, Radiotherapie Mol, F-94805 Villejuif, France -Y2 - 2019-06-04 -ER - - -TY - JOUR -AU - Yu, Da-Ping -AU - Cheng, Xu -AU - Liu, Zhi-Dong -AU - Xu, Shao-Fa -TI - Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review -T2 - ONCOLOGY LETTERS -M3 - Review -AB - Lung cancer is the most commonly diagnosed cancer among men and it is the third ranked in women. There are two major types of lung cancer, namely, small cell lung cancer (SCLC), which accounts for similar to 20% of the cases, and non-small cell lung cancer (NSCLC), which is the most common. Chemotherapy and chemoradiotherapy have been used as the first-line therapies but suffer from lack of efficacy and also of several toxic adverse effects. Immunotherapeutic approaches including tumor antigen vaccination, monoclonal antibodies targeting checkpoint pathways and also activated immune cells are being developed and have been shown to be effective in treating NSCLC. Despite their promise, efficacy of several immunotherapies has not been consistent. We undertook this meta-analysis study to analyze results from clinical trials that compared efficacy and safety of immunotherapies with placebo or chemotherapy/radiotherapy in improving overall survival (OS) and progression-free survival (PFS) of NSCLC patients. Various databases were searched to identify randomized clinical studies examining the efficacy and safety of antibody-and vaccine-based immunotherapies in NSCLC patients in comparison to chemotherapy or chemoradiotherapy or placebo. Effects on OS and PFS and also adverse events have been compared. In accordance with the selection criteria, a total of 13 studies with 3,513 patients in immunotherapy and 3,072 patients in chemotherapy/placebo, were selected. PFS (odds ratio 1.81, 95% CI 1.36, 2.42; P<0.0001) and OS (P<0.0001) are found to be greatly improved by immunotherapies. Immunotherapy of NSCLC patients was also found to prevent several adverse effects and to improve daily living ability of the patients. The present meta-analysis strongly suggests that immunotherapy improves OS and PFS of patients with NSCLC. -PU - SPANDIDOS PUBL LTD -PI - ATHENS -PA - POB 18179, ATHENS, 116 10, GREECE -SN - 1792-1074 -SN - 1792-1082 -DA - 2017 AUG -PY - 2017 -VL - 14 -IS - 2 -SP - 1568 -EP - 1580 -DO - 10.3892/ol.2017.6274 -AN - WOS:000407904600050 -AD - Capital Med Univ, Beijing Chest Hosp, Dept Thorac Surg, 97 Machang Rd, Beijing 101149, Peoples R China -Y2 - 2017-09-01 -ER - - -TY - JOUR -AU - Kim, Kyung Hwan -AU - Pyo, Hongryull -AU - Lee, Hoyoung -AU - Oh, Dongryul -AU - Noh, Jae Myoung -AU - Ahn, Yong Chan -AU - Yoon, Hong In -AU - Moon, Hyowon -AU - Lee, Jiyun -AU - Park, Sehhoon -AU - Jung, Hyun-Ae -AU - Sun, Jong-Mu -AU - Lee, Se-Hoon -AU - Ahn, Jin Seok -AU - Park, Keunchil -AU - Ku, Bo Mi -AU - Ahn, Myung-Ju -AU - Shin, Eui-Cheol -TI - Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Article -AB - Purpose: Chemoradiotherapy (CRT) followed by consolidation immune checkpoint inhibitors significantly improves survival in unresectable locally advanced non-small cell lung cancer. However, the optimal sequence for CRT and immune checkpoint inhibitors has not yet been established. We investigated the dynamics of peripheral blood immune cells during CRT to determine the best sequence for treatment.Methods and Materials: Peripheral blood samples were prospectively collected pretreatment, weekly during CRT for 6 weeks, and 1 month posttreatment in 24 patients with locally advanced non-small cell lung cancer who received definitive CRT. Immune cell analysis was performed by flow cytometry. Ex vivo PD-1 blockade assays were performed by IFN-gamma intracellular cytokine staining.Results: Lymphopenia was prominently observed during CRT and mostly recovered 1 month post-CRT. Robust proliferation of CD8(+) T cells was induced, peaking in the last week during CRT and decreasing post-CRT. The robust proliferation of CD8(+) T cells led to an increase in the frequency of CD28-CD57(+) replicative senescent and terminally differentiated cells post-CRT. Tumor-reactive CD8(+) T cells increased during CRT and peaked in the last week. One month post-CRT, the frequency of tumor-reactive CD8(+) T cells decreased and TOXhiTCF1lo terminally exhausted CD8(+) T cells significantly increased. Anti-PD-1-induced functional restoration of PD-1+CD8(+) T cells was maximized in the last week of CRT and significantly decreased post-CRT.Conclusions: The findings suggest that earlier administration of PD-1 blockade may be associated with superior efficacy compared with delayed administration after completion of CRT. These findings provide an immunologic rationale for optimal timing of combining immune checkpoint inhibitors with CRT in clinical trials.(C) 2022 Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2022 JUN 1 -PY - 2022 -VL - 113 -IS - 2 -SP - 415 -EP - 425 -DO - 10.1016/j.ijrobp.2022.02.003 -AN - WOS:000808134300025 -C6 - MAY 2022 -AD - Yonsei Univ, Yonsei Canc Ctr, Dept Radiat Oncol, Coll Med, Seoul, South Korea -AD - Sungkyunkwan Univ, Samsung Med Ctr, Dept Radiat Oncol, Sch Med, Seoul, South Korea -AD - Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon, South Korea -AD - Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea -AD - Sungkyunkwan Univ, Samsung Med Ctr, Res Inst Future Med, Sch Med, Seoul, South Korea -Y2 - 2022-07-08 -ER - - -TY - JOUR -AU - Goldberg, Sarah B. -AU - Contessa, Joseph N. -AU - Omay, Sacit B. -AU - Chiang, Veronica -TI - Lung Cancer Brain Metastases -T2 - CANCER JOURNAL -M3 - Review -AB - Brain metastases are common among patients with lung cancer and have been associated with significant morbidity and limited survival. However, the treatment of brain metastases has evolved as the field has advanced in terms of central nervous system imaging, surgical technique, and radiotherapy technology. This has allowed patients to receive improved treatment with less toxicity and more durable benefit. In addition, there have been significant advances in systemic therapy for lung cancer in recent years, and several treatments including chemotherapy, targeted therapy, and immunotherapy exhibit activity in the central nervous system. Utilizing systemic therapy for treating brain metastases can avoid or delay local therapy and often allows patients to receive effective treatment for both intracranial and extracranial disease. Determining the appropriate treatment for patients with lung cancer brain metastases therefore requires a clear understanding of intracranial disease burden, tumor histology, molecular characteristics, and overall cancer prognosis. This review provides updates on the current state of surgery and radiotherapy for the treatment of brain metastases, as well as an overview of systemic therapy options that may be effective in select patients with intracranial metastases from lung cancer. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1528-9117 -SN - 1540-336X -DA - 2015 SEP-OCT -PY - 2015 -VL - 21 -IS - 5 -SP - 398 -EP - 403 -DO - 10.1097/PPO.0000000000000146 -AN - WOS:000362178300008 -AD - Yale Univ, Sch Med, New Haven, CT 06520 USA -Y2 - 2015-09-01 -ER - - -TY - JOUR -AU - Heinzerling, John H. -AU - Mileham, Kathryn F. -AU - Simone, Charles B., II -TI - The utilization of immunotherapy with radiation therapy in lung cancer: a narrative review -T2 - TRANSLATIONAL CANCER RESEARCH -M3 - Review -AB - Despite decreasing smoking rates, lung cancer remains the leading cause of death from cancer in the United States. Radiation therapy has been established as an effective locoregional therapy for both early stage and locally advanced disease and is known to stimulate local immune response. Past treatment paradigms have established the role of combining cytotoxic chemotherapy regimens and radiation therapy to help address the local and systemic nature of lung cancer. However, these regimens have limitations in their tolerability due to toxicity. Additionally, cytotoxic chemotherapy has limited efficacy in preventing systemic spread of lung cancer. Newer systemic agents such as immune checkpoint inhibitors have shown improved survival in metastatic and locally advanced lung cancer and have the advantage of more limited toxicity profiles compared to cytotoxic chemotherapy. Furthermore, improved overall response rates and systemic tumor responses have been observed with the combination of radiation therapy and immunotherapy, leading to numerous active clinical trials evaluating the combination of immune checkpoint inhibition with radiotherapy. This comprehensive review discusses the current clinical data and ongoing studies evaluating the combination of radiation therapy and immunotherapy in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-676X -SN - 2219-6803 -DA - 2021 MAY -PY - 2021 -VL - 10 -IS - 5 -SP - 2596 -EP - 2608 -DO - 10.21037/tcr-20-2241 -AN - WOS:000656696500056 -AD - Atrium Hlth, Southeast Radiat Oncol, Levine Canc Inst, Charlotte, NC USA -AD - Atrium Hlth, Levine Canc Inst, Charlotte, NC USA -AD - Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA -AD - New York Proton Ctr, 225 East 126th St, New York, NY 10035 USA -M2 - Atrium Hlth -M2 - Atrium Hlth -M2 - New York Proton Ctr -Y2 - 2021-06-20 -ER - - -TY - JOUR -AU - Zhou, Rui -AU - Liu, Fangjie -AU - Zhang, Hongmei -AU - Wang, Daquan -AU - Zhang, Pengxin -AU - Zheng, Shiyang -AU - Liu, Yimei -AU - Chen, Li -AU - Guo, Jinyu -AU - Zou, Yingyi -AU - Rong, Yu-Ming -AU - Liu, Hui -AU - Qiu, Bo -TI - Fraction Dose Escalation of Hypofractionated Radiotherapy with Concurrent Chemotherapy and Subsequent Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer: A Phase I Study -T2 - CLINICAL CANCER RESEARCH -M3 - Article -AB - Purpose: This phase I trial aimed to determine the maximum tolerated fraction dose (MTFD) of hypofractionated radiotherapy (hypo-RT) combined with concurrent chemotherapy and subsequent consolidation immune checkpoint inhibitors (cICI) for patients with locally advanced non-small cell lung cancer.Patients and Methods: Split-course hypo-RT and hypoboost combined with concurrent chemotherapy was administered at three dose levels (DL), using a stepwise dose-escalation protocol. The sophisticated esophagus-sparing technique was implemented to restrict the dose to the esophagus. Patients who did not experience disease progression or unresolved >= grade 2 (G2+) toxicities after RT received cICI. Each DL aimed to treat six patients. The MTFD was defined as the highest DL at which <= 2 patients of the six who were treated experienced treatment-related G3+ toxicity and <= 1 patient experienced G4+ toxicity within 12 months post-RT.Results: Eighteen patients were enrolled, with six patients in each DL. All patients completed hypo-RT and concurrent chemotherapy, and 16 (88.9%) received at least one infusion of cICI, with a median of 10 infusions. Within the 12-month assessment period, one patient in DL1 experienced G3 pneumonitis, and one patient in DL3 developed G3 tracheobronchitis. The MTFD was not reached. The objective response rate was 100%. With a median follow-up of 20.9 months, the 1-year overall survival and progression-free survival rates were 94.4% and 83.3%, respectively.Conclusions: Utilizing the split-course hypo-RT and hypoboost approach, a fraction dose of 5 Gy to a total dose of 60 Gy, combined with concurrent chemotherapy and subsequent cICI, was well tolerated and yielded a promising objective response rate and survival outcomes. -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 1078-0432 -SN - 1557-3265 -DA - 2024 JUL 1 -PY - 2024 -VL - 30 -IS - 13 -SP - 2719 -EP - 2728 -DO - 10.1158/1078-0432.CCR-23-3600 -AN - WOS:001261378000010 -AD - Sun Yat sen Univ, Dept Radiat Oncol, Canc Ctr, 651 Dongfeng Rd East, Guangdong 510060, Peoples R China -AD - State Key Lab Oncol South China, Guangzhou, Peoples R China -AD - Guangdong Prov Clin Res Ctr Canc, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ, Lung Canc Inst, Guangzhou, Peoples R China -AD - Guangdong Assoc Study Thorac Oncol, Guangzhou, Peoples R China -AD - AF Hosp Southern Theater Command Peoples Liberat A, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ, Canc Ctr, Dept VIP Reg, Guangzhou, Peoples R China -M2 - Guangdong Prov Clin Res Ctr Canc -M2 - Guangdong Assoc Study Thorac Oncol -M2 - AF Hosp Southern Theater Command Peoples Liberat A -Y2 - 2024-07-12 -ER - - -TY - JOUR -AU - Kaur, Prabhjot -AU - Singh, Santosh Kumar -AU - Mishra, Manoj K. -AU - Singh, Shailesh -AU - Singh, Rajesh -TI - Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer -T2 - CANCERS -M3 - Review -AB - Simple Summary Lung cancer treatment options vary depending on the type and stage of the cancer. For non-small cell lung cancer (NSCLC), treatments may include surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these methods. Targeted therapies have demonstrated efficacy as adjuvant treatment in early-stage NSCLC when used alongside primary interventions such as surgery. In advanced stages of NSCLC, targeted therapies serve as a means of palliative care, enhancing quality of life and extending survival time. Our review article focuses on recent evidence of various treatment approaches and their impact on overall and progression-free survival in NSCLC patients, particularly targeting specific molecular and genetic alterations associated with NSCLC.Abstract Non-small cell lung cancer (NSCLC) presents a complex and diverse disease, exhibiting variations at individuals' cellular and histological levels. This complexity gives rise to different subtypes and genetic mutations, posing challenges for accurate diagnosis and effective treatment. Nevertheless, continuous progress in medical research and therapies is continually shaping the landscape of NSCLC diagnosis and management. The treatment of NSCLC has undergone significant advancements in recent years, especially with the emergence of targeted therapies that have shown remarkable efficacy in patients with actionable mutations. This has ushered in the era of personalized medicine in NSCLC treatment, with improvements in molecular and immunohistochemical techniques contributing to enhanced progression-free survival. This review focuses on the latest progress, challenges, and future directions in developing targeted therapies for NSCLC, including tyrosine kinase inhibitors (TKIs), DNA-damaging agents, immunotherapy regimens, natural drug therapy, and nanobodies. Furthermore, recent randomized studies have demonstrated enhanced overall survival in patients receiving different targeted and natural drug therapies. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2024 JUN -PY - 2024 -VL - 16 -IS - 12 -C7 - 2205 -DO - 10.3390/cancers16122205 -AN - WOS:001254469800001 -AD - Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA -AD - Alabama State Univ, Dept Biol Sci, Canc Biol Res & Training, Montgomery, AL 36014 USA -AD - Morehouse Sch Med, Canc Hlth Equ Inst, Atlanta, GA 30310 USA -Y2 - 2024-07-02 -ER - - -TY - JOUR -AU - Kaira, Kyoichi -AU - Mouri, Atsuto -AU - Kato, Shingo -AU - Yoshimura, Kenichi -AU - Kagamu, Hiroshi -AU - Kobayashi, Kunihiko -TI - A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74years old and patients with PS 0 or 1 from 75years: NEJ039A (trial in progress) -T2 - BMC CANCER -M3 - Article -AB - Background: Durvalumab is a standard drug used during maintenance therapy after chemoradiotherapy in patients with locally advanced non-small cell lung cancer (LA-NSCLC). However, little is known about the clinical benefits of durvalumab after chemoradiotherapy in patients with LA-NSCLC with a performance status (PS) of 2 and/or aged >75years. As daily carboplatin plus concurrent thoracic radiotherapy is recommended for elderly patients according to guideline, the current phase II study aims to investigate the effect of daily carboplatin plus radiotherapy followed by durvalumab for patients with stage III NSCLC who have a PS of 2 and/or are older.Methods: Daily carboplatin plus radiotherapy followed by durvalumab is performed for the patients with stage III NSCLC who have a PS of 2 and/or are older. This is a trial in progress manuscript.Study treatment: Daily, intravenous, low-dose carboplatin (30mg/m(2) in a 30-min infusion) is administered to patients 1h before radiotherapy for the first 20 fractions. Radiotherapy for all patients consisted of 60Gy administered as 30 fractions over 6weeks. Durvalumab at a dose of 10mg/kg/body is intravenously administered every 2weeks for up to 12months after chemoradiotherapy.Exploratory assessment: In the future, an exploratory investigation will be performed to determine whether the combined assessment of T-cell markers, PD-L1 expression, and tumor mutation burden could predict the outcomes of the regimen.Discussion: The results of our study will exhibit the efficacy and tolerability of durvalumab as maintenance therapy after daily carboplatin plus radiotherapy.Trial registration: During the first registration (before induction chemoradiotherapy), 70 patients will be included; then, we include 58 patients during the second registration (before durvalumab treatment after chemoradiotherapy). https://jcrb.niph.go.jp/.Primary endpoint: The primary endpoint of the current study is the 12-month progression-free survival (PFS) rate after the initiation of durvalumab.Secondary endpoints: The secondary endpoints are the feasibility, objective response, PFS, overall survival, and adverse events. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2020 OCT 6 -PY - 2020 -VL - 20 -IS - 1 -C7 - 961 -DO - 10.1186/s12885-020-07406-y -AN - WOS:000578421400002 -AD - Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, 1397-1 Yamane, Hidaka City, Saitama 3501298, Japan -AD - Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Radiat Oncol, 1397-1 Yamane, Hidaka City, Saitama 3501298, Japan -AD - Hiroshima Univ, Hiroshima Univ Hosp, Ctr Integrated Med Res, Minami Ku, 1-2-3 Kasumi, Hiroshima 7328551, Japan -Y2 - 2020-10-28 -ER - - -TY - JOUR -AU - Gross, Andrew J. -AU - Sheikh, Saad -AU - Kharouta, Michael -AU - Chaung, Kevin -AU - Choi, Serah -AU - Margevicius, Seunghee -AU - Fu, Pingfu -AU - Machtay, Mitchell -AU - Bruno, Debora S. -AU - Dowlati, Afshin -AU - Biswas, Tithi -TI - The Impact of Prophylactic Cranial Irradiation and Consolidative Thoracic Radiation Therapy for Extensive Stage Small-Cell Lung Cancer in the Transition to the Chemo-Immunotherapy Era: A Single Institution Series -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - The role of consolidative thoracic radiation therapy (TRT) and prophylactic cranial irradiation (PCI) in extensivestage small-cell lung cancer is a topic of controversy even in the current era. We report outcomes of PCI and TRT in 163 ES-SCLC patients from a single institution large database who completed chemotherapy with or without immunotherapy based on the appropriate standard of care at the time of the treatment. PCI was associated with improved overall survival and progression-free survival while thoracic radiation was not. In addition, older age and liver involvement were adverse prognostic factors. Introduction: Extensive-stage small-cell lung cancer (ES-SCLC) continues to have poor survival due to its aggressive behavior, despite improvements with incorporation of immunotherapy with standard chemotherapy. Controversy exists regarding the role of consolidative thoracic radiation therapy (TRT) and prophylactic cranial irradiation (PCI) in ES-SCLC due to high recurrence rates. We report our institutional result of the benefit of PCI and TRT in ES-SCLC. Methods: Patients with ES-SCLC without intracranial metastasis at diagnosis (N = 163) were included. All patients completed systemic therapy with or without immunotherapy based on time of standard of care. Cohorts were divided by systemic therapy use and further subdivided by treatment with PCI and TRT. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method with log-rank test for comparison. The effects of TRT and PCI were estimated by multivariable (MVA) Cox regression. Results: Seventy-four patients (45.4%) received TRT, and 33.1% (n = 54) received PCI. The median follow-up was 11 months (3-85 months). PCI improved median OS to 15 months from 10 months, P = .02) and median PFS to 8.5 months from 5 months ( P = .02) which remained significant on MVA, P = .02 and P = .02, respectively. TRT improved OS on UVA ( P = 0.002) but was not significant on MVA. TRT did not improve PFS. Conclusion: This study including chemotherapy and chemo-immunotherapy suggests improved outcomes with addition of PCI in patients with ES-SCLC while TRT did not show benefit to either OS or PFS. A future trial is needed to evaluate the role of TRT and PCI in the era of chemo-immunotherapy. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2023 DEC -PY - 2023 -VL - 24 -IS - 8 -SP - 696 -EP - 705 -DO - 10.1016/j.cllc.2023.08.009 -AN - WOS:001122069500001 -C6 - NOV 2023 -AD - Univ Hosp Cleveland Med Ctr, Seidman Canc Ctr, Dept Radiat Oncol, Cleveland, OH 44106 USA -AD - Advocate Illinois Masonic Hosp, Dept Radiat Oncol, Chicago, IL USA -AD - Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA -AD - Penn State Coll Med, Dept Radiat Oncol, Hershey, PA USA -AD - Univ Hosp Cleveland Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA -AD - Case Western Sch Med, Cleveland, OH USA -AD - 11100 Euclid Ave, Cleveland, OH 44106 USA -M2 - Advocate Illinois Masonic Hosp -Y2 - 2023-12-23 -ER - - -TY - JOUR -AU - Coster, Jenalee N. -AU - Groth, Shawn S. -TI - Surgery for Locally Advanced and Oligometastatic Non-Small Cell Lung Cancer -T2 - SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA -M3 - Review -AB - Locally advanced NSCLC is a complex, heterogeneous disease process that requires a thoughtful, multidisciplinary approach. In highly select patients with an excellent performance status and the absence of N2 disease, surgical resection of locally advanced and limited oligometastatic NSCLC offers a survival benefit when combined with a multimodal treatment strategy. With advancements in and the increasing application of immunotherapy, the multidisciplinary perspective of locally advanced NSCLC will continue to evolve. -PU - W B SAUNDERS CO-ELSEVIER INC -PI - PHILADELPHIA -PA - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA -SN - 1055-3207 -SN - 1558-5042 -DA - 2020 OCT -PY - 2020 -VL - 29 -IS - 4 -SP - 543 -EP - 554 -DO - 10.1016/j.soc.2020.07.001 -AN - WOS:000567836000006 -AD - Baylor Coll Med, Micheal E DeBakey Dept Surg, Div Thorac Surg, 7200 Cambridge St,Ste 6A, Houston, TX 77030 USA -Y2 - 2020-09-23 -ER - - -TY - JOUR -AU - Kamran, Sophia C. -AU - Yeap, Beow Y. -AU - Ulysse, Christine A. -AU - Cronin, Catherine -AU - Bowes, Cynthia L. -AU - Durgin, Brittany -AU - Gainor, Justin F. -AU - Khandekar, Melin J. -AU - Tansky, Joanna Y. -AU - Keane, Florence K. -AU - Olsen, Christine C. -AU - Willers, Henning -TI - Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation A Phase 1 Nonrandomized Clinical Trial -T2 - JAMA ONCOLOGY -M3 - Article -AB - IMPORTANCE Severe acute esophagitis occurs in up to 20% of patients with locally advanced lung cancer treated with chemoradiation therapy to at least 60 Gy once daily and represents a dose-limiting toxic event associated with poor outcomes.OBJECTIVE To assess whether formalized sparing of the contralateral esophagus (CE) is associated with reduced risk of severe acute esophagitis.DESIGN, SETTING, AND PARTICIPANTS This single-center phase 1 nonrandomized clinical trial assessing an empirical CE-sparing technique enrolled patients from July 2015 to January 2019. In total, 27 patients with locally advanced non-small cell lung carcinoma (with or without solitary brain metastasis) or limited-stage small cell lung carcinoma with gross tumor within 1 cmof the esophagus were eligible.INTERVENTIONS Intensity-modulated radiation therapy to 70 Gy at 2 Gy/fraction concurrent with standard chemotherapy with or without adjuvant durvalumab. The esophageal wall contralateral to gross tumor was contoured as an avoidance structure to guide a steep dose falloff gradient. Target coverage was prioritized over CE sparing, and 99% of internal and planning target volumes had to be covered by 70 Gy and at least 63 Gy, respectively.MAIN OUTCOMES AND MEASURES The primary end point was the rate of at least grade 3 acute esophagitis as assessed by Common Terminology Criteria for Adverse Events, version 4.RESULTS Of 27 patients enrolled, 25 completed chemoradiation therapy. Nineteen patients had non-small cell lung carcinoma, and 6 had small cell lung carcinoma. The median age at diagnosis was 67 years (range, 51-81 years), and 15 patients (60%) were men. Thirteen patients (52%) had stage IIIA cancer, 10 (40%) had stage IIIB cancer, and 2 (8%) had stage IV cancer. The median CE maximum dose was 66 Gy (range, 44-71 Gy); the median volume of CE receiving at least 55 Gy was 1.4 cm(3) (range, 0-5.3 cm(3)), and the median volume of CE receiving at least 45 Gy was 2.7 cm(3) (range, 0-9.2 cm(3)). The median combined percentage of lung receiving at least 20 Gy was 25%(range, 11%-37%). The median follow-up was 33.3 months (range, 11.1-52.2 months). Among the 20 patients who had treatment breaks of 0 to 3 days and were thus evaluable for the primary end point, the rate of at least grade 3 esophagitis was 0%. Other toxic events observed among all 25 patients included 7 (28%) with grade 2 esophagitis, 3 (12%) with at least grade 2 pneumonitis (including 1 with grade 5), and 2 (8%) with at least grade 3 cardiac toxic event (including 1 with grade 5). There was no isolated local tumor failure. The 2-year progression-free survival rate was 57%(95% CI, 33%-75%), and the 2-year overall survival rate was 67%(95% CI, 45%-82%).CONCLUSIONS AND RELEVANCE This phase 1 nonrandomized clinical trial found that the CE-sparing technique was associated with reduced risk of esophagitis among patients treated uniformly with chemoradiation therapy (to 70 Gy), with no grade 3 or higher esophagitis despite tumor within 1 cmof the esophagus. This technique may be translated into clinical practice. -PU - AMER MEDICAL ASSOC -PI - CHICAGO -PA - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA -SN - 2374-2437 -SN - 2374-2445 -DA - 2021 JUN -PY - 2021 -VL - 7 -IS - 6 -SP - 910 -EP - 914 -DO - 10.1001/jamaoncol.2021.0281 -AN - WOS:000638293500003 -C6 - APR 2021 -AD - Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St,Cox 3, Boston, MA 02114 USA -AD - Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA -AD - Newton Wellesley Hosp, Dept Radiat Oncol, Newton, MA USA -Y2 - 2021-04-28 -ER - - -TY - JOUR -AU - Livingston, RB -TI - Combined modality therapy of lung cancer -T2 - CLINICAL CANCER RESEARCH -M3 - Article -M3 - Proceedings Paper -CP - Symposium on Foundations of Clinical Cancer Research - Perspective for the 21st-Century -CL - HOUSTON, TX -AB - Combined modality therapy for lung cancer was first demonstrated to be successful in limited-stage small cell lung cancer, Concurrent administration of chemotherapy with chest and elective brain irradiation appears to produce the best results, with cisplatin/etoposide as the core chemotherapy, Using such programs, 2-year survival in the 40% range and 5-year survivals in excess of 20% may be expected, based on the results of multiple studies, Attempts to improve on these results through the use of altered schemes of chest irradiation or the delivery of high-dose consolidation chemotherapy are ongoing but to date have not been shown to affect survival significantly, We remain at a plateau in the effectiveness of combined modality therapy for small cell lung cancer, with little evidence that it impacts survival at all in extensive-stage disease, The incorporation of new agents in combination chemotherapy regimens, more "specific" immunotherapy directed at tumor-associated antigens, and the potential adjunctive use of broad-spectrum neuropeptide antagonists offer promise for the future.In non-small cell lung cancer, the sequential use of platinum-based chemotherapy and chest irradiation appears superior in survival to standard, daily fractionated radiation therapy used alone, with long-term survival increased from 5-10% to 15-20%. Concurrent administration of chemotherapy with cisplatin/etoposide and chest irradiation produces 2-year survival in the range of 30%, about twice that would be expected for radiation therapy alone, but has not been compared to it in the setting of a randomized trial.Low-dose cisplatin on a daily basis has been combined as a "sensitizer" with chest irradiation, producing initial results that appeared encouraging, However, these have not been reproduced in subsequent, randomized trials.Another approach to combined modalities has been to give chemotherapy or chemotherapy/radiation therapy as induction, followed by surgical resection, with or without subsequent additional treatment, Most patients (80-85%) can be resected, with encouraging survival at 2 and 3 years in the Southwest Oncology Group experience (37 and 26%, respectively), However, toxicity is greater, and such an approach is associated with an overall mortality risk in the range of 10%, A current intergroup study attempts to define the role of surgery in this setting.The major recent development that is likely to influence the future of combined modality therapy for this disease is the advent of multiple new chemotherapeutic agents, such as the taxanes, gemcitabine, vinorelbine, and the topoisomerase-I inhibitors, which have activity in stage IV disease, The immediate challenge is how to combine these agents with platinum analogues, radiation, and surgery, Aiding this process may be the use of molecular biological "markers" that may predict the chance of success or failure with a given systemic agent. The next decade is likely to see substantial improvements in the outcome of treatment for patients with stages I-III non-small cell lung cancer, based on the systemic exploration of combined modalities. -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 1078-0432 -SN - 1557-3265 -DA - 1997 DEC -PY - 1997 -VL - 3 -IS - 12 -SP - 2638 -EP - 2647 -AN - WOS:000071136800017 -AD - Univ Washington, Div Oncol, Seattle, WA 98195 USA -Y2 - 1997-12-01 -ER - - -TY - JOUR -AU - Martel-Lafay, I. -TI - Radiation therapy and combined treatment for locally advanced non-small cell lung cancer -T2 - ONCOLOGIE -M3 - Article -AB - Non-small cell lung cancer accounts for 80% of all lung cancers. Nearly one-third of such patients presents as locally advanced stages. Standard of care associates chemotherapy and radiotherapy, in a concurrent setting in selected patients. Usual drugs and radiation combinations are described, as well as emerging data on targeted therapies or immunotherapy associated with radiation therapy. Papers aiming to improve quality and standardization of daily life thoracic radiotherapy are reviewed. Technological advances offering clinical benefit in the near future (local control improvement or severe toxicity decrease) are presented. -PU - SPRINGER FRANCE -PI - PARIS -PA - 22 RUE DE PALESTRO, PARIS, 75002, FRANCE -SN - 1292-3818 -SN - 1765-2839 -DA - 2016 JUN -PY - 2016 -VL - 18 -IS - 6 -SP - 385 -EP - 391 -DO - 10.1007/s10269-016-2640-6 -AN - WOS:000380065200007 -AD - Ctr Leon Berard, Dept Radiotherapie, 28 Rue Laennec, F-69373 Lyon, France -Y2 - 2016-09-28 -ER - - -TY - JOUR -AU - Shiraishi, Yoshimasa -AU - Shimose, Takayuki -AU - Tsuchiya-Kawano, Yuko -AU - Ishii, Hidenobu -AU - Daga, Haruko -AU - Ito, Kentaro -AU - Saruwatari, Koichi -AU - Okamoto, Isamu -TI - Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases -T2 - CANCER MANAGEMENT AND RESEARCH -M3 - Article -AB - Background: The standard of care for extensive-stage small cell lung cancer (ES-SCLC) is an immune checkpoint inhibitor (ICI) combined with platinum-etoposide (PE) chemotherapy. At initial diagnosis, about 25% of ES-SCLC patients have brain metastases, which are associated with a poor prognosis. The decision as to whether to treat brain metastases with local therapies such as surgery or radiotherapy before initiation of systemic chemoimmunotherapy is based on symptoms due to the brain lesions and the general condition of the patient. Subset analysis of the CASPIAN study showed that combination therapy with PE plus durvalumab (MEDI4736) is promising for ES-SCLC with brain metastases. However, data required in daily clinical practice, such as intracranial response rate and duration of intracranial response, are insufficient for such patients. Patients and Methods: We have designed a single-arm phase II trial of durvalumab plus PE for patients aged >= 20 years with chemotherapy-naive ES-SCLC and at least one brain metastasis >= 5 mm in size that has not been previously treated. Patients receive durvalumab intravenously combined with four cycles of PE. Enrollment of 50 patients over 2 years at 25 oncology facilities in Japan is planned. The primary endpoint is intracranial response rate. Conclusion: This is the first prospective study to evaluate the effects of an ICI with PE specifically in ES-SCLC patients with brain metastases. If it demonstrates intracranial efficacy, this regimen will be a potential treatment option for such individuals, and radiation therapy or surgery for brain metastases can be avoided or postponed. -PU - DOVE MEDICAL PRESS LTD -PI - ALBANY -PA - PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND -SN - 1179-1322 -DA - 2022 -PY - 2022 -VL - 14 -SP - 3449 -EP - 3453 -DO - 10.2147/CMAR.S391220 -AN - WOS:000897040400001 -AD - Kyushu Univ, Grad Sch Med Sci, Dept Resp Med, Fukuoka, Japan -AD - Clin Res Support Ctr Kyushu, Dept Stat, Fukuoka, Japan -AD - Clin Res Support Ctr Kyushu, Data Ctr, Fukuoka, Japan -AD - Kitakyushu Municipal Med Ctr, Dept Resp Med, Kitakyushu, Japan -AD - Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Fukuoka, Japan -AD - Osaka City Gen Hosp, Dept Med Oncol, Osaka, Japan -AD - Matsusaka Municipal Hosp, Resp Ctr, Matsusaka, Mie, Japan -AD - Kumamoto Univ, Kumamoto Univ Hosp, Fac Life Sci, Dept Resp Med, Kumamoto, Japan -AD - Kyushu Univ, Grad Sch Med Sci, Dept Resp Med, 3 1 1 Maidashi,Higashi ku, Fukuoka 8128582, Japan -M2 - Clin Res Support Ctr Kyushu -M2 - Clin Res Support Ctr Kyushu -M2 - Kitakyushu Municipal Med Ctr -M2 - Matsusaka Municipal Hosp -Y2 - 2022-12-24 -ER - - -TY - JOUR -AU - Berman, Abigail T. -AU - Simone, Charles B., II -TI - Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation? -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Editorial Material -AB - Locally-advanced non-small cell lung cancer (LA-NSCLC) is optimally treated with definitive chemoradiation or surgery in combination with chemotherapy or chemoradiation. Prognosis, however, remains poor, and attempts to improve outcomes using consolidation or maintenance chemotherapy have not improved overall survival. Given the limited success of traditional cytotoxic chemotherapies as maintenance therapy for LA-NSCLC, recent studies have investigated the role of novel agents such as maintenance or consolidation, including antiangiogenic agents and molecular targeted therapy. With multiple newly reported trials demonstrating improved outcomes with immunotherapy over cytotoxic chemotherapy for stage IV NSCLC, integrating immunotherapy with definitive chemoradiation regimens or as consolidative therapy for LA-NSCLC is an attractive option. The recently published START trial is the first to test immunotherapy in LA-NSCLC in a randomized, phase III setting. In that trial, the administration of maintenance tecemotide (L-BLP25), which induces a T-cell response to the mucin 1 (MUC1) glycoprotein, was found to be well tolerated and improve overall survival compared with placebo among patients receiving concurrent, but not sequential, chemoradiation. Despite the promising findings of this trial, numerous questions regarding immunotherapy for LA-NSCLC remain, and several additional immunotherapy trials are underway or planned in this patient population. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2016 FEB -PY - 2016 -VL - 5 -IS - 1 -SP - 138 -EP - 142 -DO - 10.3978/j.issn.2218-6751.2016.01.11 -AN - WOS:000371133700021 -AD - Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA -Y2 - 2016-02-01 -ER - - -TY - JOUR -AU - Zenke, Yoshitaka -AU - Hakozaki, Taiki -AU - Nakahara, Yoshiro -AU - Horinouchi, Hidehito -AU - Ohe, Yuichiro -A1 - Japan Clinical Oncology Grp -TI - Medical management of older patients with lung cancer -T2 - JAPANESE JOURNAL OF CLINICAL ONCOLOGY -M3 - Review -AB - Lung cancer is the most common cause of cancer-related death globally. In addition, its incidence increases with age, with approximately half of all cases diagnosed in patients aged >= 70. Molecular targeted therapies and immunotherapies for advanced non-small-cell lung cancer have markedly improved outcomes over the past two decades. Despite the high incidence of lung cancer in older people, most trials excluded such patients from enrollment. Therefore, the optimal treatment strategies for older patients remain unclear. The present review summarizes the published literature and provides guidance on the treatment of older patients with lung cancer within three broad stages: (i) early-stage lung cancer, (ii) locally advanced lung cancer and (iii) metastatic lung cancer. We also discuss the use of the latest evidence for older patients.The present review summarizes the published literature and provides guidance on the treatment of older patients with lung cancer based on the latest evidence. -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 0368-2811 -SN - 1465-3621 -DA - 2022 OCT 6 -PY - 2022 -VL - 52 -IS - 10 -SP - 1082 -EP - 1088 -DO - 10.1093/jjco/hyac135 -AN - WOS:000841270500001 -C6 - AUG 2022 -AD - Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan -AD - Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Thorac Oncol & Resp Med, Tokyo, Japan -AD - Kitasato Univ, Sch Med, Dept Resp Med, Sagamihara, Kanagawa, Japan -AD - Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan -Y2 - 2022-08-25 -ER - - -TY - JOUR -AU - Miller, Meagan -AU - Hanna, Nasser -TI - Advances in systemic therapy for non-small cell lung cancer -T2 - BMJ-BRITISH MEDICAL JOURNAL -M3 - Review -AB - Lung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. The optimal treatment for all patients with locally advanced, but surgically resectable, NSCLC contains at least chemoradiation. Trimodality treatment with surgical resection has been a subject of debate for decades. For patients with unresectable or inoperable locally advanced disease, the incorporation of immunotherapy consolidation after chemoradiation has defined a new standard of care. For decades, the standard of care treatment for advanced stage NSCLC included only cytotoxic chemotherapy. However, with the introduction of targeted therapies and immunotherapy, the landscape of treatment has rapidly evolved. This review discusses the integration of these innovative therapies in the management of patients with newly diagnosed NSCLC. -PU - BMJ PUBLISHING GROUP -PI - LONDON -PA - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND -SN - 0959-535X -SN - 1756-1833 -DA - 2021 NOV 9 -PY - 2021 -VL - 375 -C7 - n2363 -DO - 10.1136/bmj.n2363 -AN - WOS:000718264400012 -AD - Indiana Univ Sch Med, Indianapolis, IN 46208 USA -Y2 - 2021-11-09 -ER - - -TY - JOUR -AU - Reguart, Noemi -AU - Marin, Elba -AU - Remon, Jordi -AU - Reyes, Roxana -AU - Teixido, Cristina -TI - In Search of the Long-Desired 'Copernican Therapeutic Revolution' in Small-Cell Lung Cancer -T2 - DRUGS -M3 - Review -AB - Small-cell lung cancer has defied our scientific community for decades. Chemotherapy has been the mainstay treatment for small-cell lung cancer (SCLC) and unlike its counterpart, non-small cell lung cancer, no significant therapeutic breakthroughs have been made since the 1970s. Among the reasons for this slow-paced therapeutic development, one that stands out is the distinctive and almost universal loss of function of the tumour suppressor genes TP53 and RB1 in this disease, for which pharmacological activation has yet to be achieved, despite having been highly sought after. Although no molecularly targeted approach has been approved for clinical practice thus far, several strategies are currently exploring the potential to drug the tumour's "Achilles heel" that stems from essential pathways regulating DNA-damage response. Most recently, we have witnessed newfound reasons to hope, as the combination of immunotherapy and systemic chemotherapy has improved survival outcomes, representing the first landmark achievement in decades and a new standard of care for patients with extensive disease SCLC. However, continuous efforts are still needed towards a better understanding of the molecular pathways that singularise this tumour to eventually identify the predictive biomarkers that might result in the development of a more rational therapeutic approach, including the use of immunotherapy combinations. In this review we aim to uncover critical aspects of the immune microenvironment and biology of SCLC and provide an overview of the current and future landscape of promising therapeutic opportunities. The challenge still stands, but regardless, we are living in exciting times to finally check SCLC off the "bucket list" of our scientific community. -PU - ADIS INT LTD -PI - NORTHCOTE -PA - 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND -SN - 0012-6667 -SN - 1179-1950 -DA - 2020 FEB -PY - 2020 -VL - 80 -IS - 3 -SP - 241 -EP - 262 -DO - 10.1007/s40265-019-01240-8 -AN - WOS:000514805600003 -AD - Hosp Clin Barcelona, Med Oncol Dept, Div Med Oncol, Villarroel 170, E-08036 Barcelona, Spain -AD - Inst Invest Biomed August Pi & Sunyer IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumours, Barcelona, Spain -AD - HM Delfos, Ctr Integral Oncol Clara Campal Bacelona, Div Med Oncol, Barcelona, Spain -AD - Hosp Clin Barcelona, Dept Pathol, Barcelona, Spain -M2 - HM Delfos -Y2 - 2020-03-04 -ER - - -TY - JOUR -AU - Houssaini, Mohammed Sqalli -AU - Damou, Meriem -AU - Ismaili, Nabil -TI - Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting. -T2 - Cancer treatment and research communications -M3 - Historical Article -M3 - Congress -AB - At the meeting of the American Society of Clinical Oncology (ASCO 2020), held this year virtually on May 29-31, investigators presented important practice changing findings in non-small cell lung cancer (NSCLC). In the early-stage resectable NSCLC, the key presentation was ADAURA study. This phase III clinical trial showed that the use of adjuvant osimertinib in stage IB-IIIA NSCLC patients harboring EGFR mutations had a clinically meaningful benefit. In locally advanced NSCLC, the recent studies investigated the role of immune checkpoint inhibitors (ICIs) administred early with or before concurrent chemoradiotherapy. In advanced-stage NSCLC with driver mutations, new targets and drugs were explored. The major step forward was the approval of personalized treatment in very uncommon genomic alterations, as RET fusions or MET mutations. In advanced NSCLC without targetable mutations, some new immunotherapy combination strategies have been presented. One of such combination was tiragolumab, an immune checkpoint inhibitor binding to TIGIT, evaluated with atezolizumab. There were also data from the Checkmate 227 and Checkmate 9LA trials that led to recent approvals. -SN - 2468-2942 -DA - 2020 (Epub 2020 Nov 14) -PY - 2020 -VL - 25 -SP - 100239 -EP - 100239 -DO - 10.1016/j.ctarc.2020.100239 -AN - MEDLINE:33271494 -AD - Medical oncology Department, Cheikh Khalifa University Hospital, Casablanca, Morocco; Faculty of medicine, Mohammed VI university of health sciences, Casablanca, Morocco. Electronic address: msqallihoussaini@um6ss.ma. -AD - Medical oncology Department, Cheikh Khalifa University Hospital, Casablanca, Morocco; Faculty of medicine, Mohammed VI university of health sciences, Casablanca, Morocco. -AD - Medical oncology Department, Cheikh Khalifa University Hospital, Casablanca, Morocco; Faculty of medicine, Mohammed VI university of health sciences, Casablanca, Morocco. Electronic address: nismaili@um6ss.ma. -Y2 - 2020-12-07 -ER - - -TY - JOUR -AU - Albertelli, Manuela -AU - Dotto, Andrea -AU - Nista, Federica -AU - Veresani, Alessandro -AU - Patti, Luca -AU - Gay, Stefano -AU - Sciallero, Stefania -AU - Boschetti, Mara -AU - Ferone, Diego -TI - "Present and future of immunotherapy in Neuroendocrine Tumors" -T2 - REVIEWS IN ENDOCRINE & METABOLIC DISORDERS -M3 - Article -AB - Immunotherapy, so promising in many neoplasms, still does not have a precise role in the treatment of neuroendocrine neoplasms (NENs). In this article, we provide an overview on the current knowledge about immunotherapy with immune checkpoint inhibitors (ICIs) applied to NENs, evaluating future perspectives in this setting of tumors. Evidence so far available for ICIs in gastroenteropancreatic (GEP)-NENs is definitively not as robust as for other tumors such as Small Cell Lung Cancer or Merkel Cell Carcinoma. In fact, with regard to the well-differentiated forms of NENs (NETs), the results obtained nowadays have been disappointing. However, the near future, might reserve interesting results for ICIs in GEP-NEN from a total of nine different ICI drugs, used throughout 19 randomised controlled trials. Such numbers highlight the growing attention gathering around NENs and ICIs, in response to the need of stronger evidences supporting such therapy. For the future, the most important aspect will be to study strategies that can make NETs more susceptible to response to ICI and, thus, enhance the effectiveness of these treatments. Therefore, the combination of conventional therapy, target therapy and immunotherapy deserve attention and warrant to be explored. A sequential chemotherapy, possibly inducing an increase in tumor mutational burden and tested before immunotherapy, could be a hypothesis deserving more consideration. A radiation treatment that increases tumor-infiltrating lymphocytes, could be another approach to explore before ICIs in NENs. Equally essential will be the identification of biomarkers useful for selecting patients potentially responsive to this type of treatment. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1389-9155 -SN - 1573-2606 -DA - 2021 SEP -PY - 2021 -VL - 22 -IS - 3 -SP - 615 -EP - 636 -DO - 10.1007/s11154-021-09647-z -AN - WOS:000639755400002 -C6 - APR 2021 -AD - IRCCS AOU San Martino, Endocrinol Unit, Genoa, Italy -AD - Univ Genoa, Ctr Excellence Biomed Res CEBR, Dept Internal Med & Med Specialties DiMI, Endocrinol Unit, Genoa, Italy -AD - IRCCS AOU San Martino, Med Oncol Unit 1, Genoa, Italy -M2 - IRCCS AOU San Martino -M2 - IRCCS AOU San Martino -Y2 - 2021-04-14 -ER - - -TY - JOUR -AU - Porte, Marie -AU - Vaudron, Adrien -AU - Crequit, Perrine -AU - Vaugier, Loig -AU - Chatellier, Thierry -AU - Fronteau, Clementine -AU - Raimbourg, Judith -AU - Goronflot, Thomas -AU - Bennouna, Jaafar -AU - Pons-Tostivint, Elvire -TI - A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - Background: First-line chemotherapy plus immunotherapy (CT-IO) has recently demonstrated survival benefits over CT alone in extensive-stage small-cell lung cancer (ES-SCLC), based on randomized phase III studies. This retrospective multicenter study assessed the real-world use and effectiveness of CT-IO in ES-SCLC patients. Patients and Methods: All newly diagnosed ES-SCLC patients from 4 French hospitals treated with CT alone or CT-IO between May 2020 and December 2021 were included. Overall survival (OS) and real-world progression-free survival (rwPFS) were estimated using the Kaplan-Meier method. Cox proportional hazard models were performed to estimate hazard ratios (HRs) with 95 % confidence intervals (CIs) in univariate and multivariate models. The aim was not to compare efficacy between groups. Results: Among 104 patients, 75 (72.1%) received CT-IO. Brain metastases were diagnosed in 28.3% of patients, and 29.8% were performance status (PS) >= 2. At a median follow-up of 16.8 months (95%CI, 14.9-23.4), the median OS was 11.4 months (95%CI, 7.7-14.7) in the CT-IO group, and the 12-month OS rate was 43.6% (95%CI, 33.3-57.2). In the CT group, the median OS was 7.8 months (95%CI, 5.4-11.8) and the 12-month OS rate was 15.3% (95%CI, 5.7-41.0). In multivariate analyses, baseline brain and liver metastases were associated with a shorter OS for patients treated in the CT-IO group (HR, 3.80 [95%CI, 1.90-7.60] and 3.12 [95%CI, 1.60-6.08] respectively; P < 0.001 for both). Conclusion: We showed that clinicians have chosen to use IO beyond the specific cr iter ia defined in guidelines. Survival data appeared promising with a median OS comparable to the one previously demonstrated in clinical trials. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2024 MAR -PY - 2024 -VL - 25 -IS - 2 -DO - 10.1016/j.cllc.2023.11.009 -AN - WOS:001195921500001 -C6 - FEB 2024 -AD - Nantes Univ, Ctr Hosp Univ Nantes, Dept Med Oncol, Nantes, France -AD - Nantes Univ, CHU Nantes, Pole Hosp Univ Sante Publ 11, INSERM,Clin Donnees, Nantes, France -AD - Hosp Foch, Dept Med Oncol, Suresnes, France -AD - Inst Cancerol Ouest, Comprehens Canc Ctr, Dept Radiotherapy, St Herblain, France -AD - Clin Mutualiste Estuaire, Med Oncol Unit, St Nazaire, France -AD - Nantes Univ Hosp, Clin Pharm Unit, Nantes, France -AD - Inst Cancerol Ouest, Comprehens Canc Ctr, Dept Med Oncol, St Herblain, France -AD - Nantes Univ, Angers Univ, CNRS UMR 6075, Inserm UMR 1307,CRCI2NA, Nantes, France -AD - CHU Nantes, Hop Laennec, Blvd Prof Jacques Monod, F-44800 St Herblain, France -M2 - Clin Mutualiste Estuaire -Y2 - 2024-04-12 -ER - - -TY - JOUR -AU - van der Woude, Lieke L. -AU - Gorris, Mark A. J. -AU - Wortel, Inge M. N. -AU - Creemers, Jeroen H. A. -AU - Verrijp, Kiek -AU - Monkhorst, Kim -AU - Grunberg, Katrien -AU - van den Heuvel, Michel M. -AU - Textor, Johannes -AU - Figdor, Carl G. -AU - Piet, Berber -AU - Theelen, Willemijn S. M. E. -AU - de Vries, I. Jolanda M. -TI - Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination -T2 - JOURNAL FOR IMMUNOTHERAPY OF CANCER -M3 - Article -AB - Background Immunotherapy is currently part of the standard of care for patients with advanced-stage non-small cell lung cancer (NSCLC). However, many patients do not respond to this treatment, therefore combination strategies are being explored to increase clinical benefit. The PEMBRO-RT trial combined the therapeutic programmed cell death 1 (PD-1) antibody pembrolizumab with stereotactic body radiation therapy (SBRT) to increase the overall response rate and study the effects on the tumor microenvironment (TME). Methods Here, immune infiltrates in the TME of patients included in the PEMBRO-RT trial were investigated. Tumor biopsies of patients treated with pembrolizumab alone or combined with SBRT (a biopsy of the non-irradiated site) at baseline and during treatment were stained with multiplex immunofluorescence for CD3, CD8, CD20, CD103 and FoxP3 for lymphocytes, pan-cytokeratin for tumors, and HLA-ABC expression was determined. Results The total number of lymphocytes increased significantly after 6 weeks of treatment in the anti-PD-1 group (fold change: 1.87, 95% CI: 1.06 to 3.29) and the anti-PD-1+SBRT group (fold change: 2.29, 95% CI: 1.46 to 3.60). The combination of SBRT and anti-PD-1 induced a 4.87-fold increase (95% CI: 2.45 to 9.68) in CD103(+) cytotoxic T-cells 6 weeks on treatment and a 2.56-fold increase (95% CI: 1.03 to 6.36) after anti-PD-1 therapy alone. Responders had a significantly higher number of lymphocytes at baseline than non-responders (fold difference 1.85, 95% CI: 1.04 to 3.29 for anti-PD-1 and fold change 1.93, 95% CI: 1.08 to 3.44 for anti-PD-1+SBRT). Conclusion This explorative study shows that that lymphocyte infiltration in general, instead of the infiltration of a specific lymphocyte subset, is associated with response to therapy in patients with NSCLC. Furthermore, anti-PD-1+SBRT combination therapy induces an immunological abscopal effect in the TME represented by a superior infiltration of cytotoxic T cells as compared with anti-PD-1 monotherapy. -PU - BMJ PUBLISHING GROUP -PI - LONDON -PA - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND -SN - 2051-1426 -DA - 2022 OCT -PY - 2022 -VL - 10 -IS - 10 -C7 - e005248 -DO - 10.1136/jitc-2022-005248 -AN - WOS:000870720000005 -AD - Radboudumc, Dept Tumour Immunol, Nijmegen, Netherlands -AD - Radboudumc, Dept Pathol, Nijmegen, Netherlands -AD - Radboudumc, Div Immunotherapy, Oncode Inst, Nijmegen, Netherlands -AD - Radboud Univ Nijmegen, Inst Comp & Informat Sci, Data Sci, Nijmegen, Netherlands -AD - Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands -AD - Radboudumc, Dept Pulm Dis, Nijmegen, Netherlands -AD - Netherlands Canc Inst, Dept Pulmonol, Amsterdam, Netherlands -Y2 - 2022-10-31 -ER - - -TY - JOUR -AU - Tini, Paolo -AU - Nardone, Valerio -AU - Pastina, Pierpaolo -AU - Pirtoli, Luigi -AU - Correale, Pierpaolo -AU - Giordano, Antonio -TI - The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer -T2 - EXPERT REVIEW OF ANTICANCER THERAPY -M3 - Review -AB - Introduction: Lung cancer represents the leading cause of cancer mortality across the worlds. At present, less than 30% of the patients can undergo curative surgery, while the majority of them (65%) are diagnosed with metastatic disease and directed to systemic treatments. In this context there is a subset of patients (25%) with locally advanced stage disease whose outcome might be improved by using combined strategies of treatment including chemotherapy, radiotherapy and surgery.Areas covered: Here we reviewed possible combination strategies aimed to improve the outcome of lung cancer patients, focusing on the role of radiotherapy both in the adjuvant and oligo-metastatic setting and in synergy with immunotherapy, and finally, we afforded the new challenges concerning the advanced RT and precision oncology. We carried out a focused analysis concerning the key clinical management weaknesses as well as the potential that current research holds.Expert commentary: We believe that the most promising clinical trials in this specific patient subset will build their rationale on the results of well-designed translational models aimed to test the combination of cytotoxic drugs, radiobiology, and immune-pharmacology. In this context, remarkable investigational fields are focused on the attempt to combine radiotherapy with chemo-immunological strategies and precision medicine protocols. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1473-7140 -SN - 1744-8328 -DA - 2018 -PY - 2018 -VL - 18 -IS - 6 -SP - 593 -EP - 602 -DO - 10.1080/14737140.2018.1458615 -AN - WOS:000432157300009 -AD - Univ Hosp Siena, Unit Radiat Oncol, Viale Bracci, I-53100 Siena, Italy -AD - Ist Toscano Tumori, Florence, Italy -AD - Temple Univ, Sbarro Hlth Res Org, Philadelphia, PA 19122 USA -AD - Univ Siena, Dept Med Surg & Neurosci, Siena, Italy -AD - Temple Univ, Dept Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA -AD - Grand Metropolitan Hosp Bianchi Melacrino Morelli, Unit Med Oncol, Reggio Di Calabria, Italy -M2 - Grand Metropolitan Hosp Bianchi Melacrino Morelli -Y2 - 2018-05-28 -ER - - -TY - JOUR -AU - Di Lorenzo, Rodica -AU - Ahluwalia, Manmeet S. -TI - Targeted therapy of brain metastases: latest evidence and clinical implications -T2 - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY -M3 - Review -AB - Brain metastases (BM) occur in 20-40% of patients with cancer and 60-75% of patients with BM become symptomatic. Due to an aging population and advances in the treatment of primary cancers, patients are living longer and are more likely to experience complications from BM. The diagnosis of BM drastically worsens long-term survival rates, with multiple metastases being a poor prognostic factor. Until recently, the mainstay of treatment consisted of stereotactic radiosurgery (SRS), surgical resection, whole brain radiation therapy (WBRT), or a combination of these modalities. Systemic chemotherapy has been felt largely ineffective in the treatment of BM due to the presence of the blood-brain barrier (BBB), which includes efflux pumps on brain capillaries. Over the past decade however, researchers have identified therapeutic agents that are able to cross the BBB. These findings could make a multimodality treatment approach possible, consisting of surgery, radiation, immunotherapy, and targeted therapy, which could lead to better disease control in this patient population and prolong survival. In this review, we discuss present evidence on available targeted therapies and their role in the treatment of BM from primary tumors with the highest prevalence of central nervous system (CNS) involvement, specifically non-small cell lung cancer (NSCLC), breast cancer melanoma, and renal cell carcinoma. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1758-8340 -SN - 1758-8359 -DA - 2017 DEC -PY - 2017 -VL - 9 -IS - 12 -SP - 781 -EP - 796 -DO - 10.1177/1758834017736252 -AN - WOS:000418557100005 -AD - Cleveland Clin Fdn, Brain Tumor & Neurooncol Ctr, 9500 Euclid Ave,CA-51, Cleveland, OH 44195 USA -Y2 - 2017-12-01 -ER - - -TY - JOUR -AU - Ni, Jianjiao -AU - Zhou, Yue -AU - Wu, Lin -AU - Ai, Xinghao -AU - Dong, Xiaorong -AU - Chu, Qian -AU - Han, Chengbo -AU - Wang, Xiaofei -AU - Zhu, Zhengfei -TI - Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial -T2 - RADIATION ONCOLOGY -M3 - Article -AB - Objectives The SWORD trial is the first multicenter, single arm, phase II study assessing the safety and efficacy of a PD-1 inhibitor (Sintilimab), stereotactic body radiotherapy (SBRT) and granulocyte-macrophage colony stimulating factor (GM-CSF) in advanced non-small cell lung cancer (NSCLC) without sensitizing driver mutations. A safety run-in phase was conducted to determine the tolerability of the experimental treatment. Materials and methods Twenty metastatic NSCLC patients who failed first-line chemotherapy were enrolled, and they received SBRT (8 Gy x 3) to one lesion, followed by Sintilimab (200 mg d1, every 3 weeks, until disease progression, unacceptable toxicity, or up to 35 cycles) and GM-CSF (125 mu g/m(2) d1-d14, cycle 1) within 2 weeks after SBRT. In addition, blood and tissue samples were serially collected for translational research. Results Median age of the patients was 61 and all of them had more than 5 lesions at baseline. The sites of SBRT included lung (n = 11), mediastinal lymph node (n = 5), liver (n = 1), abdominal lymph node (n = 1), pleural nodule (n = 1) and vertebra (n = 1). No patients had dose-limiting toxicities (DLTs) and 18 patients experienced treatment-related adverse event (TRAE). The most common TRAEs were fatigue (50%), fever (30%), and ostealgia (20%), and they all were grade 1. Only 2 grade 3 TRAEs were observed, including elevation of liver enzymes in one and transient acute heart failure in another. No grade 4 or 5 AE was observed. Conclusion Sintilimab, SBRT and GM-CSF for advanced NSCLC is safe with manageable TRAEs and the trial continues to recruit participants. Trial registration ClinicalTrials.gov, NCT04106180. Registered 26 September 2019, SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC-Tabular View-ClinicalTrials.gov. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1748-717X -DA - 2021 SEP 15 -PY - 2021 -VL - 16 -IS - 1 -C7 - 177 -DO - 10.1186/s13014-021-01905-3 -AN - WOS:000696211900001 -AD - Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China -AD - Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China -AD - Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp Xiangya Sch Med, Dept Thorac Oncol 2, Changsha, Peoples R China -AD - Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China -AD - Huazhong Univ Sci & Technol, Union Hosp, Canc Ctr, Tongji Med Sch, Wuhan, Peoples R China -AD - Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China -AD - China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang, Peoples R China -AD - Duke Univ, Dept Biostat & Bioinformat, Sch Med, Durham, NC USA -AD - Fudan Univ, Inst Thorac Oncol, 270 Dong An Rd, Shanghai 200032, Peoples R China -Y2 - 2021-09-23 -ER - - -TY - JOUR -AU - Wurstbauer, Karl -AU - Kazil, Margit -AU - Meinschad, Marco -AU - Pinter, Raoul -AU - De Vries, Catharina -AU - Clemens, Patrick -AU - Kreuter, Christof -AU - Hernler, Tamara -AU - Hitzl, Wolfgang -AU - Cerkl, Peter -AU - Kuenzler, Thomas -AU - De Vries, Alexander -TI - Locally advanced NSCLC: a plea for sparing the ipsilateral normal lung-prospective, clinical trial with DART-bid (dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily) by VMAT -T2 - RADIATION ONCOLOGY -M3 - Article -AB - Background: In radiation treatment of locally advanced non-small cell lung cancer (LA-NSCLC), 'margins' from internal target volumes to planning target volumes in the range of 12 to 23 mm are reported, and avoiding exposure of the contralateral lung is common practice. We investigated prospectively an approach with tight margins (7 mm) and maximal sparing of the ipsilateral normal lung. Mature results for the first endpoint (pneumonitis) and further toxicities are reported.Methods: Primary tumors were treated by VMAT with 73.8-90.0 Gy in positive correlation to tumor volumes, nodes with 61.2 Gy, a restricted volume of nodes electively with 45 Gy. Fractional doses of 1.8 Gy bid, interval 8 h. Before radiotherapy, two cycles platin-based chemotherapy were given. 12 patients finished maintenance therapy with Durvalumab. Median follow up time for all patients is 19.4 months, for patients alive 27.0 months (3.4-66.5 months).Results: 100 consecutive, unselected patients with LA-NSCLC in stages II through IVA were enrolled (UICC/AJCC, 8th edition). No acute grade 4/5 toxicity occurred. Pneumonitis grade 2 and 3 was observed in 12% and 2% of patients, respectively; lowering the risk of pneumonitis grade >= 2 in comparison to the largest study in the literature investigating pneumonitis in LA-NSCLC, is significant (p < 0.0006). Acute esophageal toxicity grade 1, 2 and 3 occurred in 12%, 57% and 3% of patients, respectively. Two patients showed late bronchial stricture/atelectasis grade 2. In two patients with lethal pulmonary haemorrhages a treatment correlation cannot be excluded. Median overall survival for all stage III patients, and for those with 'RTOG 0617 inclusion criteria' is 46.6 and 50.0 months, respectively.Conclusions: Overall toxicity is low. In comparison to results in the literature, maximal sparing the ipsilateral normal lung lowers the risk for pneumonitis significantly. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1748-717X -DA - 2022 JUL 7 -PY - 2022 -VL - 17 -IS - 1 -C7 - 120 -DO - 10.1186/s13014-022-02083-6 -AN - WOS:000825382900003 -AD - Acad Teaching Hosp, Dept Radiat Oncol, Carinagasse 47, A-6800 Feldkirch, Austria -AD - Acad Teaching Hosp, Inst Med Phys, Feldkirch, Austria -AD - Acad Teaching Hosp, Dept Pneumol, Hohenems, Austria -AD - Paracelsus Med Univ, Team Biostat & Publicat Clincial Studies, FM&TT, Salzburg, Austria -M2 - Acad Teaching Hosp -M2 - Acad Teaching Hosp -M2 - Acad Teaching Hosp -Y2 - 2022-07-21 -ER - - -TY - JOUR -AU - Yamaguchi, Ou -AU - Kaira, Kyoichi -AU - Hashimoto, Kosuke -AU - Mouri, Atsuto -AU - Miura, Yu -AU - Shiono, Ayako -AU - Nishihara, Fuyumi -AU - Murayama, Yoshitake -AU - Noda, Shin-ei -AU - Kato, Shingo -AU - Kobayashi, Kunihiko -AU - Kagamu, Hiroshi -TI - Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab -T2 - THORACIC CANCER -M3 - Article -AB - BackgroundIt remains unclear why radiation clinically provides a synergistic effect when combined with immune checkpoint inhibitors such as nivolumab. The purpose of our study was to retrospectively evaluate whether the therapeutic efficacy of nivolumab is improved as a result of a history of radiotherapy (RT) in patients with previously treated advanced non-small cell lung cancer (NSCLC).MethodsFrom February 2016 to December 2017, 124 consecutive patients were administered nivolumab for pretreated advanced NSCLC. The patients were divided into RT and non-RT groups.ResultsSixty-six (53%) of the 124 patients had been administered RT before the initiation of nivolumab, 52 (42%) received extracranial RT, and 40 (32%) were treated with thoracic RT. The median number of nivolumab cycles was 4 (range: 1-43). The overall response rate (ORR) and disease control rate (DCR) of nivolumab in all patients were 28.0% and 58.4%, respectively. The ORR (36.4%) was significantly higher in patients who had received previous RT than in patients who had not received any RT (19%). The therapeutic efficacy of nivolumab was particularly noteworthy in patients with non-adenocarcinoma and squamous cell carcinoma histology administered extracranial RT, with ORRs of 48.3% and 52.6%, and DCRs of 87.1% and 84.2%, respectively.ConclusionPrevious RT was an independent prognostic marker of favorable prognosis after nivolumab administration and improved the response rate to nivolumab treatment. Previous RT was clinically identified to have a synergistic effect with nivolumab treatment, increasing the response rate and improving the outcome of patients with advanced NSCLC. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1759-7706 -SN - 1759-7714 -DA - 2019 APR -PY - 2019 -VL - 10 -IS - 4 -SP - 992 -EP - 1000 -DO - 10.1111/1759-7714.13044 -AN - WOS:000465162800049 -AD - Saitama Med Univ, Int Med Ctr, Ctr Comprehens Canc, Dept Resp Med, 1397-1 Yamane, Hidaka City, Saitama 3501298, Japan -AD - Saitama Med Univ, Int Med Ctr, Ctr Comprehens Canc, Dept Radiat Oncol, Hidaka City, Saitama, Japan -Y2 - 2019-05-08 -ER - - -TY - JOUR -AU - Huang, Huei-Tyng -AU - Brand, Douglas H. -AU - Fenwick, John D. -AU - Hawkins, Maria A. -TI - ImmunoChemoradiation for Non-Small Cell Lung Cancer: A Meta-Analysis of Factors Influencing fl uencing Survival Benefit fi t in Combination Trials -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Article -AB - Purpose: Adding immune checkpoint blockade (ICB) to concurrent chemoradiotherapy (cCRT) has improved overall survival (OS) for inoperable locally advanced non-small cell lung cancer. Trials of cCRT-ICB are heterogeneous for factors such as tumor stage and histology, programmed cell death ligand-1 (PDL-1) status, and cCRT-ICB schedules. We therefore aimed to determine the ICB contribution to survival across studies and identify factors associated with survival gain. Methods and Materials: Data were collated from cCRT-ICB clinical studies published 2018 to 2022 that treated 2196 patients with non-small cell lung cancer (99% stage 3). Associations between 2-year OS and ICB, CRT, patient and tumor factors were investigated using metaregression. A published model of survival after radiation therapy (RT) or CRT was extended to include ICB effects. The model was fi tted simultaneously to the cCRT-ICB data and data previously compiled for RT/CRT treatments alone. The net ICB contribution (OS gain) and its associations with factors were described by fi tted values of ICB terms added to the model. Statistical significance fi cance was determined by likelihood-ratio testing. Results: The gain in 2-year OS from ICB was 9.9% overall (95% CI, 7.6%, 12.2%; P = .018). Both OS gain and 2-year OS itself rose with increasing planned ICB duration (P = .008, .002, respectively) and with tumor PDL-1 >= 1% (P = .034, .023). Fitted OS gains were also greater for patients with stage 3B/C disease (P = .021). OS gain was not associated with tumor histology, patient performance status, radiation therapy dose, ICB drug type (anti-PDL-1 vs anti-programmed cell death-1), or whether ICB began concurrently with or after cCRT. Conclusions: Fitted gains in 2-year OS due to ICB were higher in cohorts with greater fractions of stage 3B/C patients and patients with tumor PDL-1 > 1%. OS gain was also significantly fi cantly higher in a single cohort with a planned ICB duration of 2 years rather than 1, but was not associated with whether ICB treatment began during versus after CRT. (c) 2024 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/) -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2024 OCT 1 -PY - 2024 -VL - 120 -IS - 2 -SP - 409 -EP - 421 -DO - 10.1016/j.ijrobp.2024.03.029 -AN - WOS:001310149200001 -C6 - SEP 2024 -AD - UCL, Dept Med Phys & Biomed Engn, London, England -AD - Univ Coll London Hosp NHS Fdn Trust, London, England -Y2 - 2024-09-16 -ER - - -TY - JOUR -AU - Kepka, Lucyna -TI - Palliative extracranial radiotherapy in patients receiving immunotherapy for non-small cell lung cancer: a narrative review -T2 - TRANSLATIONAL CANCER RESEARCH -M3 - Review -AB - Background and Objective: Role of radiotherapy (RT) in the era of immuno-oncology (IO) in advanced non-small cell lung cancer (NSCLC) is rapidly changing. RT is not only intended for addressing palliation symptoms but also is considered as a potential tool potentializing an immunogenic effect of given drugs. However, the best timing, techniques, doses, volumes, and its use for asymptomatic patients is a subject of research. We performed a review on the role of palliative RT schedules in combination with IO for advanced NSCLC. Indications in symptomatic and asymptomatic patients, outcomes, toxicity, and possible developments are discussed.Methods: A literature search was conducted in MEDLINE and PubMed databases and clinicaltrials.gov using the keywords 'lung cancer' AND "immunotherapy" AND 'radiotherapy' OR "palliative radiotherapy".Key Content and Findings: Body of evidence indicate that palliative RT used in combination with IO is effective in terms of symptom management and safe; does not increase the risk of serious side effects, including serious pulmonary toxicity. We have limited data evidencing improvement of survival by addition of short ablative RT dose to one site of the disease to IO in oligometastatic NSCLC. Some data indicate that short ablative doses of stereotactic body radiation therapy (SBRT) are more effective with regard to treatment response and survival than protracted RT schedule with lower fractional doses. However, this may be a selection bias of better prognostic patients who underwent SBRT. The use of steroids being a potential concern during IO should not be prohibited if clinically indicated during palliative RT. Its detrimental effect shown in some studies may also be a result of selection bias, because steroids given for not cancer-related causes during IO did not decrease survival.Conclusions: RT for symptom management may be used during, directly before or after IO. This has a potential to ease symptom burdens and improve performance status ( PS). However, still more studies are needed to establish optimal guidelines in asymptomatic patients for appropriate timing, volumes, dose, and fractionation schedules of palliative RT use in combination with IO. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-676X -SN - 2219-6803 -DA - 2023 JAN -PY - 2023 -VL - 12 -IS - 1 -SP - 163 -EP - 176 -DO - 10.21037/tcr-22-1969 -AN - WOS:000904007600001 -C6 - DEC 2022 -AD - Mil Inst Med, Dept Radiotherapy, Szaserow St 128, Warsaw, Poland -Y2 - 2023-01-07 -ER - - -TY - JOUR -AU - LU, BO -TI - ROLE OF SMAC IN LUNG CARCINOGENESIS AND THERAPY -M3 - Awarded Grant -AB - Background: Localized advanced and metastatic non-small cell lung cancers (NSCLC) are treated with chemotherapy and radiotherapy. However, resistance to standard therapy has been a major challenge in curing these patients. Combining immunotherapy and radiotherapy can rescue therapeutic immunity against lung cancer as recent clinical trials utilizing immune checkpoint inhibitors, such as anti-CTLA4 or anti-PD-1, have yielded impressive responses in lung cancer patients. In this case, the release of cancer antigens following radiotherapy may synergize in the induction of cancer-specific immune responses, which impact distant metastases. While confirming the merit of this approach, clinical trials have documented that only 20%-30% of patients with NSCLC responded to PD-1 inhibitors, highlighting the need for alternative approaches to improve the outcome, particularly for poor responders to PD1 inhibitors. As the leader for the lung cancer working group through the National Cancer Institute radiation research branch, we intend to promote the development of novel therapeutics to be combined with radiotherapy. In this proposal, we show preliminary data that the combined use of a SMAC mimetic and radiotherapy results in therapeutic synergism in a lung cancer model through a CD8-dependent mechanism. We propose to extend this work by determining the role of SMAC in lung cancer progression and its resistance to therapy. We will also determine immunological mechanism by which combining a SMAC mimetic and radiotherapy yields therapeutic synergy and whether and how this combination yields abscopal effects from radiotherapy in our lung cancer model.Objectives/Hypothesis: An active host immune system can deter cancer progression and enhance the efficacy of cytotoxic cancer therapy. We are encouraged by our preliminary data showing that Smac mimetics and radiotherapy activate host immune system and synergize the therapeutic effect in a CD8+ lymphocyte-dependent manner. We hypothesize that Smac modulates both lung carcinogenesis and subsequent therapeutic response to chemotherapy and radiotherapy. Furthermore, we hypothesize that combining a Smac mimetic with SBRT induces abscopal effect. We will test these hypotheses in part through the generation of a novel transgenic mouse model, in the following specific aims.Specific Aims: (1) Determine the role of Smac in carcinogenesis and therapeutic response of lung cancer. (2) Determine the abscopal effect and optimize the therapeutic ratio of combining a SMAC mimetics and Stereotactic Body Radiotherapy (SBRT) in mouse models of lung cancer.Study Design: In Aim 1, we will generate a mouse model that develops Kras-G12D driven lung cancer on a Smac null background. To do so, we will cross Kras-G12D transgenic mice with Smac-/- mice. The resulting Kras-G12D+/- Smac-/-mice will allow us to determine whether the loss of Smac alters lung cancer progression by escaping immune surveillance and determine whether it alters therapeutic response to cisplatin (CDDP). Our Aim 2 is based on our previous demonstration of radiosensitizing-property of a SMAC mimetic, Debio1143, in human lung cancer cell models. As shown in our preliminary data, combination of Debio1143 with radiotherapy generates synergistic anti-tumor effects in a CD8+ T cell-dependent manner. We will test the hypothesis that combining SBRT and Debio1143 induces abscopal effects, likely mediated by effective induction of tumor immunity including tumor-specific cytotoxic lymphocytes (CTL), the eradication of residual irradiated tumors, as well as an abscopal effect on non-irradiated distant disease. We will test this hypothesis using the transgenic model generated in the Aim 1.Innovation: The proposed study investigates a novel therapeutic approach of combining a SMAC mimetic and radiotherapy in inducing host immune response again lung cancer. This study will be conducted through utilization of an image-guided mouse irradiator and novel mouse lung cancer model with and without SMAC.Impact: By investigating a novel approach of activating host immune response against lung cancer, we aim to eradicate deaths from lung cancer.Relevance: This project will investigate whether SMAC mediates lung cancer progression and aims to eliminate lung cancer resistance to standard therapy by activate host immune system. Outcomes of this project may benefit military Service members, Veterans, and their families, who suffer from lung cancer. -DA - 2016 -PY - 2016 -AN - GRANTS:12844742 -G1 - 893442; LC150118 -AD - THOMAS JEFFERSON UNIVERSITY HOSPITALS INC -Y2 - 2023-12-08 -ER - - -TY - JOUR -AU - Ganti, Apar Kishor -TI - Updates in the Management of Small Cell Lung Cancer -T2 - JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK -M3 - Article -M3 - Proceedings Paper -CP - Annual Meeting of the National Comprehensive Cancer Network (NCCN) -CL - Orlando, FL -AB - The standard treatment for limited-stage small cell lung cancer (SCLC) is concurrent chemoradiation, with a small subset of patients that could potentially benefit from surgery. For extensive-stage SCLC, the current standard of care is chemoimmunotherapy with a PD-1/PD-L1 inhibitor. The role of prophylactic cranial irradiation in SCLC is currently under debate, and is being investigated in the ongoing MAVERICK trial. Despite high initial response rates to chemoradiotherapy, relapse is common, and outcomes for these patients remain poor. However, recent advances in understanding the molecular biology of SCLC have led to the identification of potential new targets for treatment, including the combination of temozolomide with PARP inhibitors and DLL3-targeted bispecific T-cell engager therapy, both of which have shown activity in early studies. -PU - HARBORSIDE PRESS -PI - HUNTINGTON -PA - 94 NORTH WOODHULL RD, HUNTINGTON, NY 11743 USA -SN - 1540-1405 -SN - 1540-1413 -DA - 2024 MAY -PY - 2024 -VL - 22 -C7 - e245021 -DO - 10.6004/jnccn.2024.5021 -AN - WOS:001276868500021 -Y2 - 2024-08-11 -ER - - -TY - JOUR -AU - Pistamaltzian, Nikolaos F. -AU - Georgoulias, Vassilis -AU - Kotsakis, Athanasios -TI - The role of immune checkpoint inhibitors in advanced non-small cell lung cancer -T2 - EXPERT REVIEW OF RESPIRATORY MEDICINE -M3 - Review -AB - Introduction: Cancer immunotherapy represents a major therapeutic breakthrough. Immune checkpoint inhibitors alone or in the context of a combination are considered the new standard of care in advanced non-small cell lung cancer (NSCLC). Areas covered: This review explains the biologic rationale behind the implementation of immune checkpoint inhibitors for the therapy of advanced NSCLC. It provides a detailed description of the clinical trials that have studied the various agents now in use and the results that lead to the currently approved indications. It also explores the area of established and developing biomarkers, and the trends of combining immunotherapy with other treatment modalities (chemotherapy, antiangiogenic agents, radiotherapy), or with other immune modulators. Expert opinion: Immune checkpoint inhibitors have been established as the new standard of care for patients with advanced NSCLC. They can be administered according to PD-L1 expression upfront as monotherapy or in combination with chemotherapy- regardless of PD-L1 status - or in the later lines of therapy. They also represent a less toxic and more effective treatment choice than chemotherapy alone. The development of reliable biomarkers for patient selection and the subsequent use of the appropriate immune-based approach for each patient will define the role of immunotherapy in the years to come. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1747-6348 -SN - 1747-6356 -DA - 2019 MAY 4 -PY - 2019 -VL - 13 -IS - 5 -SP - 435 -EP - 447 -DO - 10.1080/17476348.2019.1593828 -AN - WOS:000463569800001 -C6 - MAR 2019 -AD - MITERA Hosp, Dept Med Oncol, Athens, Greece -AD - Univ Crete, Sch Med, Iraklion, Crete, Greece -AD - Univ Hosp Larissa, Dept Med Oncol, GR-41110 Mezourlo, Larissa, Greece -M2 - MITERA Hosp -Y2 - 2019-04-18 -ER - - -TY - JOUR -AU - Takada, Kazuki -AU - Toyokawa, Gouji -AU - Shoji, Fumihiro -AU - Okamoto, Tatsuro -AU - Maehara, Yoshihiko -TI - The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers -T2 - CLINICAL LUNG CANCER -M3 - Review -AB - Lung cancer is the leading cause of death due to cancer worldwide. Surgery, chemotherapy, and radiotherapy have been the standard treatment for lung cancer, and targeted molecular therapy has greatly improved the clinical course of patients with non-small-cell lung cancer (NSCLC) harboring driver mutations, such as in epidermal growth factor receptor and anaplastic lymphoma kinase genes. Despite advances in such therapies, the prognosis of patients with NSCLC without driver oncogene mutations remains poor. Immunotherapy targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) has recently been shown to improve the survival in advanced NSCLC. The PD-L1 expression on the surface of tumor cells has emerged as a potential biomarker for predicting responses to immunotherapy and prognosis after surgery in NSCLC. However, the utility of PD-L1 expression as a predictive and prognostic biomarker remains controversial because of the existence of various PD-L1 antibodies, scoring systems, and positivity cutoffs. In this review, we summarize the data from representative clinical trials of PD-1/PD-L1 immune checkpoint inhibitors in NSCLC and previous reports on the association between PD-L1 expression and clinical outcomes in patients with NSCLC. Furthermore, we discuss the future perspectives of immunotherapy and immune checkpoint factors. (C) 2017 Elsevier Inc. All rights reserved. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2018 MAR -PY - 2018 -VL - 19 -IS - 2 -SP - 120 -EP - 129 -DO - 10.1016/j.cllc.2017.10.014 -AN - WOS:000427673600019 -AD - Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan -Y2 - 2018-12-28 -ER - - -TY - JOUR -AU - Gerber, David E. -AU - Urbanic, James J. -AU - Langer, Corey -AU - Hu, Chen -AU - Chang, I-Fen -AU - Lu, Bo -AU - Movsas, Benjamin -AU - Jeraj, Robert -AU - Curran, Walter J. -AU - Bradley, Jeffrey D. -TI - Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505) -T2 - CLINICAL LUNG CANCER -M3 - Editorial Material -AB - Radiation Therapy Oncology Group (RTOG) 3505 is a randomized phase 3 study of concurrent chemoradiation followed by immune checkpoint inhibitor therapy or placebo in patients with locally advanced non-small-cell lung cancer (NSCLC). Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy to 60 Gy with concurrent cisplatin 50 mg/m(2) intravenously (I. V.) on days 1, 8, 29, and 36, and etoposide 50 mg/m(2) I. V. on days 1 to 5 and days 29 to 33. Between 4 and 12 weeks after completion of concurrent chemoradiation, eligible patients will be randomized to the anti-programmed death 1 (PD-1) monoclonal antibody nivolumab 240 mg I. V. or placebo every 2 weeks for up to 1 year. The primary end points are overall survival (OS) and progression-free survival (PFS), as determined by central independent radiology review. Secondary objectives include toxicity assessment, patient-reported outcomes and quality of life, and OS and PFS in programmed death ligand 1 (PD-L1) expressors (>= 1%) and PD-L1 nonexpressors (< 1%). Assuming a rate of 16.7% due to ineligibility and dropout before randomization, a total of 660 patients will be enrolled to ensure 550 patients will be randomized after completion of chemoradiation. This sample size will provide >= 90% power to detect a hazard ratio of 0.7 for OS with 2-sided type I error of 0.04, and to detect a hazard ratio of 0.667 for PFS 2-sided type I error of 0.01. (NCT02768558) -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2017 MAY -PY - 2017 -VL - 18 -IS - 3 -SP - 333 -EP - 339 -DO - 10.1016/j.cllc.2016.10.009 -AN - WOS:000401111800022 -AD - Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA -AD - Univ Calif San Diego, San Diego, CA 92103 USA -AD - Univ Penn, Philadelphia, PA 19104 USA -AD - Johns Hopkins Univ, Baltimore, MD USA -AD - RTOG Fdn, Philadelphia, PA USA -AD - Bristol Myers Squibb Co, New York, NY 10154 USA -AD - Thomas Jefferson Univ, Philadelphia, PA 19107 USA -AD - Henry Ford Hosp, Detroit, MI 48202 USA -AD - Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA -AD - Emory Univ, Med Ctr, Atlanta, GA 30322 USA -AD - Washington Univ, Sch Med, St Louis, MO USA -M2 - RTOG Fdn -Y2 - 2017-05-01 -ER - - -TY - JOUR -AU - Lim, Jeong Uk -AU - Yeo, Chang Dong -TI - Update on adjuvant therapy in completely resected NSCLC patients -T2 - THORACIC CANCER -M3 - Review -AB - In patients with completely resected non-small cell lung cancer (NSCLC), postoperative adjuvant chemotherapy has been associated with improvement in survival by minimizing the risk of recurrence. For years, systemic chemotherapy including platinum based regimen has been a mainstay treatment modality of adjuvant treatment after complete resection. ADAURA study showed that among completely resected IB to IIIA NSCLC, disease-free survival was significantly better in patients under adjuvant osimertinib than a placebo group. After the advent of a variety of new treatment regimens, such as third generation TKI and immunotherapy, the landscape of postoperative adjuvant treatment has been changing. In this review, we discuss some key issues regarding choice of adjuvant treatment after complete resection in NSCLC, and provide further updates on recent advances in treatment modalities. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1759-7706 -SN - 1759-7714 -DA - 2022 FEB -PY - 2022 -VL - 13 -IS - 3 -SP - 277 -EP - 283 -DO - 10.1111/1759-7714.14277 -AN - WOS:000729370300001 -C6 - DEC 2021 -AD - Catholic Univ Korea, Yeouido St Marys Hosp, Div Pulm Allergy & Crit Care Med, Dept Internal Med,Coll Med, Seoul, South Korea -AD - Catholic Univ Korea, Eunpyeong St Marys Hosp, Div Pulm Crit Care & Sleep Med, Dept Internal Med,Coll Med, 1021 Tongil Ro, Seoul 03312, South Korea -Y2 - 2021-12-18 -ER - - -TY - JOUR -AU - Goldman, Jonathan W. -AU - Dvorkin, Mikhail -AU - Chen, Yuanbin -AU - Reinmuth, Niels -AU - Hotta, Katsuyuki -AU - Trukhin, Dmytro -AU - Statsenko, Galina -AU - Hochmair, Maximilian J. -AU - Ozguroglu, Mustafa -AU - Ji, Jun Ho -AU - Garassino, Marina Chiara -AU - Voitko, Oleksandr -AU - Poltoratskiy, Artem -AU - Ponce, Santiago -AU - Verderame, Francesco -AU - Havel, Libor -AU - Bondarenko, Igor -AU - Kazarnowicz, Andrzej -AU - Losonczy, Gyorgy -AU - Conev, Nikolay V. -AU - Armstrong, Jon -AU - Byrne, Natalie -AU - Thiyagarajah, Piruntha -AU - Jiang, Haiyi -AU - Paz-Ares, Luis -A1 - CASPIAN Investigators -TI - Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial -T2 - LANCET ONCOLOGY -M3 - Article -AB - Background First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stage smallcell lung cancer (ES-SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide alone.Methods CASPIAN is an ongoing, open-label, sponsor-blind, randomised, controlled phase 3 trial at 209 cancer treatment centres in 23 countries worldwide. Eligible patients were aged 18 years or older (20 years in Japan) and had treatment-naive, histologically or cytologically documented ES-SCLC, with a WHO performance status of 0 or 1. Patients were randomly assigned (1:1:1) in blocks of six, stratified by planned platinum, using an interactive voice-response or web-response system to receive intravenous dunraluinab plus tremeliinuinab plus platinum-etoposide, durvalumab plus platinum-etoposide, or platinum-etoposide alone. In all groups, patients received etoposide 80-100 mg/m(2) on days 1-3 of each cycle with investigator's choice of either carboplatin area under the curve 5-6 rng/rnL/min or cisplatin 75-80 mg/m(2) on day 1 of each cycle. Patients in the platinum-etoposide group received up to six cycles of platinum-etoposide every 3 weeks and optional prophylactic cranial irradiation (investigator's discretion). Patients in the immunotherapy groups received four cycles of platinum-etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks. The two primary endpoints were overall survival for durvalumab plus platinum-etoposide versus platinum-etoposide and for durvalumab plus tremelimumab plus platinum-etoposide versus platinum- etoposide in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered at ClinicalTrials.gov, NCT03043872.Findings Between March 27,2017, and May 29,2018,972 patients were screened and 805 were randomly assigned (268 to durvalumab plus tremelimumab plus platinum-etoposide, 268 to durvalumab plus platinum-etoposide, and 269 to platinum-etoposide). As of Jan 27, 2020, the median follow-up was 25.1 months (IQR 22.3-27.9). Durvalumab plus treinelimuinab plus platinurn-etoposide was not associated with a significant improvement in overall survival versus platinum-etoposide (hazard ratio [HR] 0.82 [95% CI 0.68-1-00]; p=0.045); median overall survival was 10.4 months (95% CI 9.6-12.0) versus 10.5 months (9.3-11.2). Durvalumab plus platinum-etoposide showed sustained improvement in overall survival versus platinum-etoposide (HR 0.75 [95% CI 0-62-0.91]; nominal p=0.0032); median overall survival was 12.9 months (95% CI 11.3-14.7) versus 10.5 months (9.3-11.2). The most common any-cause grade 3 or worse adverse events were neutropenia (85 [32%] of 266 patients in the durvalumab plus tremelimumab plus platinum-etoposide group, 64 [24%] of 265 patients in the durvalumab plus platinum-etoposide group, and 88 [33%] of 266 patients in the platinum-etoposide group) and anaemia (34[13%], 24[9%], and 48 [18%]). Any-cause serious adverse events were reported in 121 (45%) patients in the durvalumab plus tremelimumab plus platinum-etoposide group, 85 (32%) in the durvalumab plus platinum-etoposide group, and 97 (36%) in the platinum-etoposide group. Treatment-related deaths occurred in 12 (5%) patients in the durvalumab plus tremeliinumab plus platinum-etoposide group (death, febrile neutropenia, and pulmonary embolism [n=2 each]; enterocolitis, general physical health deterioration and multiple organ dysfunction syndrome, pneumonia, pneumonitis and hepatitis, respiratory failure, and sudden death [n=1 each]), six (2%) patients in the durvalumab plus platinum-etoposide group (cardiac arrest, dehydration, hepatotoxicity, interstitial lung disease, pancytopenia, and sepsis In=1 each]), and two (1%) in the platinum-etoposide group pancytopenia and thrombocytopenia [n=1 each]).Interpretation First-line durvalumab plus platinum-etoposide showed sustained overall survival improvement versus platinum-etoposide but the addition of tremelimumab to durvalumab plus platinurn-etoposide did not significantly improve outcomes versus platinum-etoposide. These results support the use of durvarlumab plus platinum-etoposide as a new standard of care for the first-line treatment of ES-SCLC. Copyright (C) 2020 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1470-2045 -SN - 1474-5488 -DA - 2021 JAN -PY - 2021 -VL - 22 -IS - 1 -SP - 51 -EP - 65 -DO - 10.1016/S1470-2045(20)30539-8 -AN - WOS:000610553800048 -AD - Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA -AD - BHI Omsk Reg Clin Oncol Dispensary, Omsk, Russia -AD - Canc & Hematol Ctr Western Michigan, Grand Rapids, MI USA -AD - Asklepios Lung Clin, Munich, Germany -AD - Okayama Univ Hosp, Okayama, Japan -AD - Odessa Reg Oncol Dispensary, Odessa, Ukraine -AD - Omsk Reg Canc Ctr, Omsk, Russia -AD - Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria -AD - Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Istanbul, Turkey -AD - Sungkyunkwan Univ, Samsung Changwon Hosp, Sch Med, Chang Won, South Korea -AD - Fdn IRCCS Ist Nazl Tumori, Milan, Italy -AD - Kyiv City Clin Oncol Ctr, Kiev, Ukraine -AD - Petrov Res Inst Oncol, St Petersburg, Russia -AD - Univ Complutense, Dept Med Oncol, Hosp Univ 12 Octubre, H120 CNIO Lung Canc Unit, Madrid, Spain -AD - Ciberonc, Madrid, Spain -AD - Azienda Osped Osped Riuniti PO Vincenzo Cervello, Palermo, Italy -AD - Charles Univ Prague, Thomayer Hosp, Fac Med 1, Prague, Czech Republic -AD - Dnipropetrovsk Med Acad, Dnipro, Ukraine -AD - TB & Lung Dis Hosp, Olsztyn, Poland -AD - Semmelweis Univ, Dept Pulmonol, Budapest, Hungary -AD - Univ Multiprofile Hosp Act Treatment St Marina, Clin Med Oncol, Varna, Bulgaria -AD - AstraZeneca, Cambridge, England -AD - AstraZeneca, Gaithersburg, MD USA -M2 - BHI Omsk Reg Clin Oncol Dispensary -M2 - Canc & Hematol Ctr Western Michigan -M2 - Asklepios Lung Clin -M2 - Odessa Reg Oncol Dispensary -M2 - Omsk Reg Canc Ctr -M2 - Karl Landsteiner Inst Lung Res & Pulm Oncol -M2 - Kyiv City Clin Oncol Ctr -M2 - Azienda Osped Osped Riuniti PO Vincenzo Cervello -M2 - TB & Lung Dis Hosp -M2 - AstraZeneca -Y2 - 2021-01-01 -ER - - -TY - JOUR -AU - Jung, Hyun Ae -AU - Noh, Jae Myoung -AU - Sun, Jong-Mu -AU - Lee, Se-Hoon -AU - Ahn, Jin Seok -AU - Ahn, Myung-Ju -AU - Pyo, Hongryull -AU - Ahn, Yong Chan -AU - Park, Keunchil -TI - Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer -T2 - LUNG CANCER -M3 - Article -AB - Objectives: The PACIFIC study demonstrated the benefits of durvalumab consolidation on progression-free survival (PFS) and overall survival (OS) among patients with unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). However, in real-world practice, patients with unresectable LA-NSCLC are heterogeneous with diverse tumor burdens and clinical factors; thus, it is important to examine the effectiveness and side effects of durvalumab when used in real clinical practice.Materials and methods: We investigated the efficacy of durvalumab consolidation and the incidence of radiation pneumonitis in patients who received concurrent chemo-radiotherapy (CCRT) for unresectable LA-NSCLC in a single institute.Results: Overall, 55.3 % of patients did not meet the criteria of the PACIFIC study; however, they still received consolidation durvalumab in real-world practice. Durvalumab consolidation was associated with favorable PFS in the total population as well as in the subgroup of patients who did not meet the criteria of the PACIFIC study. However, radiation pneumonitis occurred more frequently in the durvalumab group, especially within 3-6 months after CCRT. The incidence of grade 3 radiation pneumonitis was 14.3 % in the durvalumab group versus 2.5 % in the observation group.yConclusions: Durvalumab consolidation was associated with favorable PFS in patients with LA-NSCLC in clinical practice. However, careful selection of candidates for durvalumab treatment and active surveillance and appropriate management for radiation pneumonitis are needed. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2020 AUG -PY - 2020 -VL - 146 -SP - 23 -EP - 29 -DO - 10.1016/j.lungcan.2020.05.035 -AN - WOS:000551485600005 -AD - Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea -AD - Sungkyunkwan Univ, Samsung Med Ctr, Dept Radiat Oncol, Sch Med, Seoul, South Korea -Y2 - 2020-08-01 -ER - - -TY - JOUR -AU - Longo, Vito -AU - Pizzutilo, Pamela -AU - Catino, Annamaria -AU - Montrone, Michele -AU - Pesola, Francesco -AU - Marerch, Ilaria -AU - Galetta, Domenico -TI - Prognostic factors for survival in extensive-stage small cell lung cancer: An Italian real-world retrospective analysis of 244 patients treated over the last decade -T2 - THORACIC CANCER -M3 - Article -AB - Background Potential relationships with the prognosis of patients with extensive-stage non-small cell lung cancer (ES-SCLC) have been investigated without valid results. Methods A retrospective analysis of real-world data of consecutive patients with ES-SCLC admitted to our Medical Thoracic Oncology Unit was carried out from 2010 to 2020, focusing on identification of prognostic factors. Kaplan-Meier analysis was used to represent progression-free survival (PFS) and overall survival (OS). Univariable and multivariable Cox models were used to investigate prognostic factors. Results The analysis included 244 patients. The median OS was 8 months (95% confidence interval [CI]: 8-10) and the median PFS was 5 months (95% CI: 5-6). The univariable analysis showed that factors associated with shorter OS were older age (p = 0.047), TNM stage 4 versus 3 (p < 0.001), Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 and 2 versus 0 (p < 0.001), and >2 metastatic sites (p = 0.004). Mediastinal radiotherapy (RT) (p < 0.001), >1 irradiated site (p = 0.026), 3 and 4 chemotherapy (CT) lines versus 1 (p = 0.044 and 0.001, respectively), prophylactic cranial irradiation (PCI) (p < 0.001), and surgery (p = 0.001) correlated with longer OS. The multivariable analysis revealed statistically significant associations for TNM, ECOG PS 2 versus 0, number of CT lines, PCI, and surgery. A total of 23 patients (9.4%) survived >= 24 months, 39% of whom had received four CT lines and 48% had mediastinal RT. Conclusions Our data suggest that tumor burden, PS, and mediastinal RT strongly correlate with outcome. With the addition of immunotherapy to CT, the identification of new biomarkers as predictive factors is urgently required. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1759-7706 -SN - 1759-7714 -DA - 2022 DEC -PY - 2022 -VL - 13 -IS - 24 -SP - 3486 -EP - 3495 -DO - 10.1111/1759-7714.14712 -AN - WOS:000879090600001 -C6 - NOV 2022 -AD - IRCCS Ist Tumori Giovanni Paolo II, Med Thorac Oncol Unit, Bari, Italy -Y2 - 2022-11-18 -ER - - -TY - JOUR -AU - Giunta, Emilio Francesco -AU - Addeo, Alfredo -AU - Rizzo, Alessio -AU - Banna, Giuseppe Luigi -TI - First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy -T2 - FRONTIERS IN MEDICINE -M3 - Review -AB - Small cell lung cancer (SCLC) is still a lethal disease. Three phase III randomized clinical trials (IMpower133, CASPIAN, and KEYNOTE-604) have highlighted the survival gain of adding immune checkpoint inhibitors to first-line standard chemotherapy in advanced SCLC patients. In this review, we discuss the data from the three trials above. Furtherly, we analyze issues that still need to be elucidated, like the role of biomarkers, poor performance status at baseline, the presence of brain metastases, and the platinum compound's choice. Moreover, we depict the future of SCLC first-line therapy management, focusing on new therapeutic strategies currently under investigation. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2296-858X -DA - 2022 MAY 25 -PY - 2022 -VL - 9 -C7 - 924853 -DO - 10.3389/fmed.2022.924853 -AN - WOS:000807890500001 -AD - FPO IRCCS, Dept Med Oncol, Candiolo Canc Inst, Turin, Italy -AD - Univ Hosp Geneva, Oncol Dept, Geneva, Switzerland -AD - FPO IRCCS, Dept Nucl Med, Candiolo Canc Inst, Turin, Italy -Y2 - 2022-06-16 -ER - - -TY - JOUR -AU - Banna, Giuseppe Luigi -AU - Passiglia, Francesco -AU - Colonese, Francesca -AU - Canova, Stefania -AU - Menis, Jessica -AU - Addeo, Alfredo -AU - Russo, Antonio -AU - Cortinovis, Diego Luigi -TI - Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection -T2 - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY -M3 - Review -AB - The identification of reliable predictive biomarkers of efficacy or resistance to immune-oncology (I-O) agents is a major issue for translational research and clinical practice. However, along with PDL1 and molecular features other clinical, radiological and laboratory factors can be considered for the selection of those patients who would not be the best candidate for immune-checkpoint inhibitors (ICPIs). We examined these factors, emerging from the results of currently available studies in non-small cell lung cancer (NSCLC), aiming to provide a useful and manageable tool which can help Oncologists in their everyday clinical practice.A thorough patient evaluation and close clinical monitoring, due to limited, early or inconclusive currently available data, should be deserved for patients with a pre-existing symptomatic chronic obstructive pulmonary disease, age > 75 years, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1, a time to progression (TTP) < three months and progressive disease (PD) as the best response to the previous treatment, hepatitis or HIV-infections, high neutrophil to lymphocyte ratio (NLR), or on treatment with high-dose steroids, when the use of ICPIs is considered. Limited data are available to consider that ICPIs are safe in patients with interstitial lung disease, bronchiolitis obliterans organizing pneumonia and autommune diseases. Early evidence on steroids, vaccinations and antibiotics suggest their possible interaction with ICPIs and need to be more investigated in clinical trials. Oncogene-addicted NSCLC harboring EGFR-mutations and low tumor-infiltrating T-lymphocytes (TILs) seems not to gain benefit from I-O. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1040-8428 -SN - 1879-0461 -DA - 2018 SEP -PY - 2018 -VL - 129 -SP - 27 -EP - 39 -DO - 10.1016/j.critrevonc.2018.06.016 -AN - WOS:000442333100003 -AD - Cannizzaro Hosp, Div Med Oncol, Via Messina 829, I-95126 Catania, Italy -AD - Univ Palermo, Dept Surg Ontol & Stomatol Disciplines, Palermo, Italy -AD - San Gerardo Hosp, Med Oncol Unit, Monza, Italy -AD - Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, Villejuif, France -AD - Univ Hosp Geneva, Dept Oncol, CH-1205 Geneva, Switzerland -M2 - Cannizzaro Hosp -Y2 - 2018-12-28 -ER - - -TY - JOUR -AU - de Dios, N Rodriguez -AU - Murcia-Mejia, M -TI - Current and future strategies in radiotherapy for small-cell lung cancer. -T2 - Journal of clinical and translational research -M3 - Journal Article -M3 - Review -AB - Small-cell lung cancer (SCLC) accounts for 13% of all lung tumors. The standard treatment in patients with limited-stage (LS) disease is thoracic radiotherapy (TRT) combined with chemotherapy. In extensive-stage (ES) SCLC, the importance of consolidation TRT in patients with a good treatment response has become increasingly recognized. In both LS and ES disease, prophylactic cranial irradiation is recommended in patients who respond to treatment. New therapeutic approaches such as immunotherapy are being increasingly incorporated into the treatment of SCLC, although more slowly than in non-small cell lung cancer. Diverse radiation dose and fractionation schemes, administered in varying combinations with these new drugs, are being investigated. In the present article, we review and update the role of radiotherapy in the treatment of SCLC. We also discuss the main clinical trials currently underway to identify future trends.RELEVANCE FOR PATIENTS: Radiotherapy is a critical component of multimodality treatment of SCLC. This article can help physicians to improve medical knowledge and find better ways to treat their SCLC patients. -SN - 2424-810X -DA - 2020 Oct 29 -PY - 2020 -VL - 6 -IS - 4 -SP - 97 -EP - 108 -AN - MEDLINE:33521370 -AD - Department of Radiation Oncology, Hospital del Mar, Barcelona, Spain. -AD - Hospital del Mar Medical Research Institute, Barcelona, Spain. -AD - Pompeu Fabra University, Barcelona, Spain. -AD - Department of Radiation Oncology, Hospital Sant Joan Reus, Tarragona. -Y2 - 2021-02-03 -ER - - -TY - JOUR -AU - Mohamed, Shehab -AU - Bertolaccini, Luca -AU - Galetta, Domenico -AU - Petrella, Francesco -AU - Casiraghi, Monica -AU - de Marinis, Filippo -AU - Spaggiari, Lorenzo -TI - The Role of Immunotherapy or Immuno-Chemotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review -T2 - CANCERS -M3 - Review -AB - Many new treatment modalities for non-small-cell carcinoma (NSCLC) have been described in the last two decades. Surgical resections remain the gold standard for early stages and may be considered for locally advanced tumors. Medical treatment has changed drastically in recent years, especially for advanced stages, for which the development of immunotherapy and molecular targeted therapy significantly increased survival and quality of life. The addition of radical surgical resection following immunotherapy or immuno-chemotherapy is feasible and safe with low surgical-related mortality and morbidity in selected patients with initially unresectable NSCLC. However, data from multiple ongoing trials with overall survival as the primary endpoint should be awaited before this strategy is introduced into the standard of care. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2023 APR 26 -PY - 2023 -VL - 15 -IS - 9 -C7 - 2476 -DO - 10.3390/cancers15092476 -AN - WOS:000986987400001 -AD - European Inst Oncol IRCCS, Dept Thorac Surg, IEO, I-20141 Milan, Italy -AD - Univ Milan, Dept Oncol & Hematooncol, I-20122 Milan, Italy -AD - European Inst Oncol IRCCS, Dept Thorac Oncol, IEO, I-20141 Milan, Italy -Y2 - 2023-05-29 -ER - - -TY - JOUR -AU - Qian, Haili -AU - Wang, Haijuan -AU - Guan, Xiuwen -AU - Yi, Zongbi -AU - Ma, Fei -TI - Adoptive immunotherapy combined chemoradiotherapy for non-small-cell lung cancer: a meta-analysis -T2 - ANTI-CANCER DRUGS -M3 - Article -AB - The aim of this study was to compare the efficacies between adoptive immunotherapy combined chemoradiotherapy and chemoradiotherapy alone in patients with non-small-cell lung cancer (NSCLC). The databases PubMed, EMBASE, and Cochrane database were searched to identify eligible clinical trials. Data analyses were carried out using a comprehensive meta-analysis program, version 2 software. A total of seven articles were finally included in the analysis. Meta-analyses showed that compared with chemoradiotherapy alone, adoptive immunotherapy combined with chemoradiotherapy could improve the 2-year overall survival [odds ratio (OR)=2.45, 95% confidence interval (CI): 1.60-3.75, P<0.001], but not 2-year progression-free survival (OR=1.81, 95% CI: 0.61-5.36, P=0.284). Specifically, early (OR=3.32, 95% CI: 1.38-7.95, P<0.01) but not advanced (OR=3.75, 95% CI: 0.96-14.68, P=0.057) NSCLC patients were likely to gain a large benefit from the adoptive immunotherapy. Most of the adoptive immunotherapy-induced adverse effects were self-limited, mainly including fever, shiver, nausea, fatigue, etc. and severe toxicities were not observed. Adoptive immunotherapy combined with chemoradiotherapy can delay the recurrence of NSCLC and improve survival in patients, where the benefits are even more significant in patients with early-stage NSCLC. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0959-4973 -SN - 1473-5741 -DA - 2016 JUN -PY - 2016 -VL - 27 -IS - 5 -SP - 433 -EP - 438 -DO - 10.1097/CAD.0000000000000346 -AN - WOS:000374759400007 -AD - Canc Hosp, State Key Lab Mol Oncol, Beijing, Peoples R China -AD - Peking Union Med Coll, Canc Inst Hosp, Dept Med Oncol, Beijing 100021, Peoples R China -AD - Chinese Acad Med Sci, Beijing 100021, Peoples R China -M2 - Canc Hosp -Y2 - 2016-06-01 -ER - - -TY - JOUR -AU - Kim, Tae-Hun -AU - Park, Sun Hyo -AU - Hwang, Ilseon -AU - Lee, Jin Hee -AU - Kim, Jin Hee -AU - Kim, Hae Won -AU - Kim, Hyun Jung -TI - Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report -T2 - RESPIROLOGY CASE REPORTS -M3 - Article -AB - Pulmonary pleomorphic carcinoma (PPC) is a rare type of non-small cell lung cancer (NSCLC) with a more aggressive clinical course and a worse outcome than other types of NSCLC. Pembrolizumab, a monoclonal antibody targeting programmed cell death-1 (PD-1), has been approved as the first-line treatment for advanced NSCLC with robust PD-L1 expression in at least 50% of tumour cells, without epidermal growth factor receptor gene (EGFR) mutations or anaplastic lymphoma kinase gene (ALK) rearrangement. Here, we report the case of an 81-year-old man with multiple comorbidities who was diagnosed with PPC and showed a robust response to pembrolizumab followed by radiation therapy without adverse effects. In the absence of randomized clinical trials for PPCs, our case report demonstrates the potential application of pembrolizumab and radiation therapy for the treatment of PPCs. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2051-3380 -DA - 2021 DEC -PY - 2021 -VL - 9 -IS - 12 -C7 - e0875 -DO - 10.1002/rcr2.875 -AN - WOS:000722303800003 -AD - Keimyung Univ, Div Pulm Dis & Crit Care Med, Dept Internal Med, Dongsan Hosp,Sch Med, 1095 Dalgubeol Daero, Daegu 42601, South Korea -AD - Keimyung Univ, Dongsan Hosp, Dept Pathol, Sch Med, Daegu, South Korea -AD - Keimyung Univ, Dongsan Hosp, Dept Radiol, Sch Med, Daegu, South Korea -AD - Keimyung Univ, Dongsan Hosp, Dept Radiat Oncol, Sch Med, Daegu, South Korea -AD - Keimyung Univ, Dongsan Hosp, Dept Nucl Med, Sch Med, Daegu, South Korea -Y2 - 2021-12-01 -ER - - -TY - JOUR -AU - Sathiyapalan, Arani -AU - Baloush, Ziad -AU - Ellis, Peter M. -TI - Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease -T2 - CURRENT ONCOLOGY -M3 - Review -AB - Background: Stage III nonsmall cell lung cancer (NSCLC) represents a heterogeneous group of patients. Many patients are treated with curative intent multimodality therapy, either surgical resection plus systemic therapy or chemoradiation plus immunotherapy. However, many patients are not suitable for curative intent therapy and are treated with palliative systemic therapy or best supportive care. Methods: This paper is a review of recent advances in the management of patients with curative intent disease. Results: There have been significant advances in curative intent therapy for patients with stage III NSCLC in recent years. These include both adjuvant and neoadjuvant systemic therapies. For patients with resectable NSCLC, two trials have demonstrated that adjuvant atezolizumab or pembrolizumab, following chemotherapy, significantly improved disease-free survival (DFS). In patients with tumours harbouring a common mutation of the EGFR gene, adjuvant osimertinib therapy was associated with a large improvement in both DFS and overall survival (OS). Five randomized trials have evaluated chemotherapy plus nivolumab, pembrolizumab, durvalumab, or toripalimab, either as neoadjuvant or perioperative (neoadjuvant plus adjuvant) therapy. All five trials show significant improvements in the rate of pathologic complete response (pCR) and event-free survival (EFS). OS data are currently immature. This would now be considered the standard of care for resectable stage III NSCLC. The addition of durvalumab to chemoradiation has also become the standard of care in unresectable stage III NSCLC. One year of consolidation durvalumab following concurrent chemoradiation has demonstrated significant improvements in both progression-free and overall survival. Conclusions: Immune checkpoint inhibitor (ICI) therapy has become a standard recommendation in curative intent therapy for stage III NSCLC. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1198-0052 -SN - 1718-7729 -DA - 2023 NOV -PY - 2023 -VL - 30 -IS - 11 -SP - 9514 -EP - 9529 -DO - 10.3390/curroncol30110689 -AN - WOS:001119589700001 -AD - Juravinski Canc Ctr Hamilton Hlth Sci, Hamilton, ON L8V 5C2, Canada -AD - McMaster Univ, Dept Oncol, Hamilton, ON L8S 4L8, Canada -Y2 - 2023-12-21 -ER - - -TY - JOUR -AU - Gabri, Mariano R. -AU - Cacciavillano, Walter -AU - Chantada, Guillermo L. -AU - Alonso, Daniel F. -TI - Racotumomab for treating lung cancer and pediatric refractory malignancies -T2 - EXPERT OPINION ON BIOLOGICAL THERAPY -M3 - Article -AB - Introduction: Racotumomab (originally known as 1E10 mAb) is an anti-idiotype murine IgG1 directed to membrane glycoconjugates expressed in aggressive solid tumors. It was developed as a mirror image of the idiotype of another antibody against N-glycolyl-containing molecules, such as the NeuGcGM3 ganglioside. After a successful phase II/III study, racotumomab formulated in alum was conditionally approved in Latin American countries as maintenance therapy for advanced non-small cell lung cancer.Areas covered: This review analyzes the biology of the target antigen, summarizes preclinical studies and discusses clinical trials in adults and the pediatric experience with racotumomab.Expert opinion: Proper patient selection and combination with chemotherapy, radiotherapy or checkpoint inhibitors appear to be critical issues to maximize the effects of racotumomab vaccination in lung cancer. In a recent phase I clinical trial in children with relapsed or resistant neuroectodermal malignancies, racotumomab was well tolerated and immunogenic, and its evaluation as immunotherapy for high-risk neuroblastoma is warranted. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1471-2598 -SN - 1744-7682 -DA - 2016 APR 2 -PY - 2016 -VL - 16 -IS - 4 -SP - 573 -EP - 578 -DO - 10.1517/14712598.2016.1157579 -AN - WOS:000371686400003 -AD - Natl Univ Quilmes, Lab Mol Oncol, Buenos Aires, DF, Argentina -AD - Pediat Hosp Prof Dr Juan P Garrahan, Hematol Oncol Serv, Buenos Aires, DF, Argentina -M2 - Natl Univ Quilmes -Y2 - 2016-03-31 -ER - - -TY - JOUR -AU - Jung, Chi Young -AU - Antonia, Scott J -TI - Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. -T2 - Tuberculosis and respiratory diseases -M3 - Journal Article -M3 - Review -AB - Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths worldwide. Although progress in the treatment of advanced non-small cell lung cancer (NSCLC) has been made over the past decade, the 5-year survival rate in patients with lung cancer remains only 10%-20%. Obviously, new therapeutic options are required for patients with advanced NSCLC and unmet medical needs. Cancer immunotherapy is an evolving treatment modality that uses a patient's own immune systems to fight cancer. Theoretically, cancer immunotherapy can result in long-term cancer remission and may not cause the same side effects as chemotherapy and radiation. Immuno-oncology has become an important focus of basic research as well as clinical trials for the treatment of NSCLC. Immune checkpoint inhibitors are the most promising approach for cancer immunotherapy and they have become the standard of care for patients with advanced NSCLC. This review summarizes basic tumor immunology and the relevant clinical data on immunotherapeutic approaches, especially immune checkpoint inhibitors in NSCLC. -SN - 1738-3536 -DA - 2018 Jan -PY - 2018 -VL - 81 -IS - 1 -SP - 29 -EP - 41 -DO - 10.4046/trd.2017.0120 -AN - MEDLINE:29332322 -AD - Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea. -AD - Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. scott.antonia@moffitt.org. -Y2 - 2018-01-18 -ER - - -TY - JOUR -AU - Tang, Cuiping -AU - Qin, Si -AU - Li, Qian -AU - Huang, Yusheng -TI - Therapeutic effectiveness and safety of sequential ICIs with radiotherapy for symptomatic brain and bone metastases in NSCLC patients -T2 - MEDICINE -M3 - Article -AB - In advanced non-small cell lung cancer (NSCLC), the brain and bones are common metastatic sites, and the disease seriously affects the survival time and quality of life. For metastatic lesions with symptoms, local treatment often precedes systemic treatment. However, in clinical trials, patients with symptomatic brain or bone metastases are often excluded. Therefore, limited data are available on the efficacy of immune checkpoint inhibitors (ICIs) in those patients. We aimed to evaluate the effectiveness and safety of local radiotherapy followed by ICIs in driver gene-negative NSCLC patients with symptomatic local metastasis in the brain and bone. This is a 29-month 2 centered retrospective cohort study performed in China between March 2019 and August 2021. A total of 22 patients with advanced NSCLC were included. All patients received radiotherapy in the brain or bone before the administration of ICIs. For all patients, the overall response rate was 59.09%, the median progression-free survival (PFS) was 7.5 months, the PFS rate at 6 months was 72.73%, and the PFS rate at 1 year was 13.64%. Waterfall plots showed that tumor size was mostly reduced compared with baseline. The spider map showed that the tumor continued to shrink. In terms of symptom improvement, 100% pain control and 83.33% improvement were observed in epilepsy and neurological function. Sequential ICIs with local radiotherapy is effective for the treatment of patients with symptomatic brain and bone metastases of driver gene-negative NSCLC, which will benefit patients and improve their symptoms. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0025-7974 -SN - 1536-5964 -DA - 2022 NOV 18 -PY - 2022 -VL - 101 -IS - 46 -C7 - e31665 -DO - 10.1097/MD.0000000000031665 -AN - WOS:000890207100125 -AD - Chongqing Med Univ, Clin Coll 2, Chongqing, Peoples R China -AD - Chongqing Med Univ, Dept Oncol, Affiliated Hosp 2, Chongqing, Peoples R China -AD - Army Mil Med Univ, Xinqiao Hosp, Dept Oncol, Chongqing, Peoples R China -AD - Army Mil Med Univ, Southwest Hosp, Dept Pathol, Chongqing, Peoples R China -Y2 - 2022-12-11 -ER - - -TY - JOUR -AU - Suh, Yang-Gun -AU - Cho, Jaeho -TI - Local ablative radiotherapy for oligometastatic non-small cell lung cancer -T2 - RADIATION ONCOLOGY JOURNAL -M3 - Review -AB - In metastatic non-small cell lung cancer (NSCLC), the role of radiotherapy (RT) has been limited to palliation to alleviate the symptoms. However, with the development of advanced RT techniques, recent advances in immuno-oncology therapy targeting programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) and targeted agents for epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation allowed new roles of RT in these patients. Within this metastatic population, there is a subset of patients with a limited number of sites of metastatic disease, termed as oligometastasis that can achieve long-term survival from aggressive local management. There is no consensus on the definition of oligometastasis; however, most clinical trials define oligometastasis as having 3 to 5 metastatic lesions. Recent phase II randomized clinical trials have shown that ablative RT, including stereotactic ablative body radiotherapy (SABR) and hypofractionated RT, to primary and metastatic sites improved progression-free survival (PFS) and overall survival (OS) in patients with oligometastatic NSCLC. The PEMBRO-RT study, a randomized phase II study comparing SABR prior to pembrolizumab therapy and pembrolizumab therapy alone, revealed that the addition of SABR improved the overall response, PFS, and OS in patients with advanced NSCLC. The efficacy of RT in oligometastatic lung cancer has only been studied in phase II studies; therefore, large-scale phase III studies are needed to confirm the benefit of local ablative RT in patients with oligometastatic NSCLC. Local intensified RT to primary and metastatic lesions is expected to become an important treatment paradigm in the near future in patients with metastatic lung cancer. -PU - KOREAN SOC THERAPEUTIC RADIOLOGY & ONCOLOGY -PI - SEOUL -PA - DEPT RADIATION ONCOLOGY, SEOUL NATL UNIV HOSPITAL, SEOUL, 110-744, SOUTH KOREA -SN - 2234-3156 -DA - 2019 SEP -PY - 2019 -VL - 37 -IS - 3 -SP - 149 -EP - 155 -DO - 10.3857/roj.2019.00514 -AN - WOS:000488453900001 -AD - Natl Canc Ctr, Res Inst & Hosp, Proton Therapy Ctr, Goyang, South Korea -AD - Yonsei Univ, Dept Radiat Oncol, Coll Med, 50 Yonsei Ro, Seoul 03722, South Korea -Y2 - 2019-10-16 -ER - - -TY - JOUR -AU - Verma, N. -AU - Ninia, J. G. -AU - Hayman, T. J. -AU - Housri, N. -AU - Peters, G. W. -AU - Knowlton, C. A. -AU - Campbell, A. M. -AU - Park, H. S. M. -TI - Survival Outcomes for Oligometastatic vs. Polymetastatic Extensive-Stage Small Cell Lung Cancer Following Consolidative Thoracic Radiotherapy -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2149 -SP - E68 -EP - E69 -AN - WOS:001079706800142 -AD - Yale Sch Med, Dept Therapeut Radiol, New Haven, CT USA -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Rybarczyk-Kasiuchnicz, Agnieszka -AU - Ramlau, Rodryg -AU - Stencel, Katarzyna -TI - Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma -T2 - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES -M3 - Review -AB - Lung cancer is one of the most common malignant neoplasms. As a result of the disease's progression, patients may develop metastases to the central nervous system. The prognosis in this location is unfavorable; untreated metastatic lesions may lead to death within one to two months. Existing therapies-neurosurgery and radiation therapy-do not improve the prognosis for every patient. The discovery of Epidermal Growth Factor Receptor (EGFR)-activating mutations and Anaplastic Lymphoma Kinase (ALK) rearrangements in patients with non-small cell lung adenocarcinoma has allowed for the introduction of small-molecule tyrosine kinase inhibitors to the treatment of advanced-stage patients. The Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein with tyrosine kinase-dependent activity. EGFR is present in membranes of all epithelial cells. In physiological conditions, it plays an important role in the process of cell growth and proliferation. Binding the ligand to the EGFR causes its dimerization and the activation of the intracellular signaling cascade. Signal transduction involves the activation of MAPK, AKT, and JNK, resulting in DNA synthesis and cell proliferation. In cancer cells, binding the ligand to the EGFR also leads to its dimerization and transduction of the signal to the cell interior. It has been demonstrated that activating mutations in the gene for EGFR-exon19 (deletion), L858R point mutation in exon 21, and mutation in exon 20 results in cancer cell proliferation. Continuous stimulation of the receptor inhibits apoptosis, stimulates invasion, intensifies angiogenesis, and facilitates the formation of distant metastases. As a consequence, the cancer progresses. These activating gene mutations for the EGFR are present in 10-20% of lung adenocarcinomas. Approximately 3-7% of patients with lung adenocarcinoma have the echinoderm microtubule-associated protein-like 4 (EML4)/ALK fusion gene. The fusion of the two genes EML4 and ALK results in a fusion gene that activates the intracellular signaling pathway, stimulates the proliferation of tumor cells, and inhibits apoptosis. A new group of drugs-small-molecule tyrosine kinase inhibitors-has been developed; the first generation includes gefitinib and erlotinib and the ALK inhibitor crizotinib. These drugs reversibly block the EGFR by stopping the signal transmission to the cell. The second-generation tyrosine kinase inhibitor (TKI) afatinib or ALK inhibitor alectinib block the receptor irreversibly. Clinical trials with TKI in patients with non-small cell lung adenocarcinoma with central nervous system (CNS) metastases have shown prolonged, progression-free survival, a high percentage of objective responses, and improved quality of life. Resistance to treatment with this group of drugs emerging during TKI therapy is the basis for the detection of resistance mutations. The T790M mutation, present in exon 20 of the EGFR gene, is detected in patients treated with first- and second-generation TKI and is overcome by Osimertinib, a third-generation TKI. The I117N resistance mutation in patients with the ALK mutation treated with alectinib is overcome by ceritinib. In this way, sequential therapy ensures the continuity of treatment. In patients with CNS metastases, attempts are made to simultaneously administer radiation therapy and tyrosine kinase inhibitors. Patients with lung adenocarcinoma with CNS metastases, without activating EGFR mutation and without ALK rearrangement, benefit from immunotherapy.This therapeutic option blocks the PD-1 receptor on the surface of T or B lymphocytes or PD-L1 located on cancer cells with an applicable antibody. Based on clinical trials, pembrolizumab and all antibodies are included in the treatment of non-small cell lung carcinoma with CNS metastases. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1661-6596 -SN - 1422-0067 -DA - 2021 JAN -PY - 2021 -VL - 22 -IS - 2 -C7 - 593 -DO - 10.3390/ijms22020593 -AN - WOS:000611331000001 -AD - Poznan Univ Med Sci, Clin Hosp Lord Transfigurat, Dept Chemotherapy, PL-61848 Poznan, Poland -Y2 - 2021-02-09 -ER - - -TY - JOUR -AU - Wu, Zuohong -AU - Xian, Xinghong -AU - Wang, Ke -AU - Cheng, Deyun -AU - Li, Weimin -AU - Chen, Bojiang -TI - Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma -T2 - FRONTIERS IN ONCOLOGY -M3 - Article -AB - Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of non-small cell lung cancer (NSCLC) for which there is currently no recognized treatment. Recently, favorable immune checkpoint blockade responses have been observed in PPLELC. This study aimed to review the effects of this regimen in patients with advanced PPLELC. PPLELC patients treated with immune checkpoint inhibitors at West China Hospital between January 2008 and December 2019 were retrospectively identified. Demographic parameters and antitumor treatment details were retrieved and reviewed. Among 128 patients diagnosed with PPLELC, 5 who received immune checkpoint inhibitors at advanced stages were included in the analysis. All of these patients were female nonsmokers with a median age of 55.6 (range 53-58) years at diagnosis. Their median PD-L1 expression was 40% (range, 30-80%). Although the patients underwent surgeries, chemotherapy and radiotherapy, all the treatments failed. Immune checkpoint inhibitors were administered palliatively, and three patients responded favorably, with the best overall response being partial remission (PR). Thus, immune checkpoint inhibitors may be a promising treatment for advanced PPLELC, and large clinical trials are warranted to obtain more evidence regarding this regimen. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2021 APR 26 -PY - 2021 -VL - 11 -C7 - 626566 -DO - 10.3389/fonc.2021.626566 -AN - WOS:000648615300001 -AD - Sichuan Univ, West China Hosp, Dept Resp & Crit Care Med, Chengdu, Peoples R China -AD - Sichuan Univ, West China Sch Med, Chengdu, Peoples R China -Y2 - 2021-05-20 -ER - - -TY - JOUR -AU - Chen, Dawei -AU - Zou, Bing -AU - Li, Butuo -AU - Gao, Aiqin -AU - Huang, Wei -AU - Shao, Qian -AU - Meng, Xiangjiao -AU - Zhang, Pinliang -AU - Tang, Xiaoyong -AU - Hu, Xudong -AU - Zhang, Yan -AU - Guo, Jun -AU - Zhao, Changhong -AU - Yuan, Jiajia -AU - Li, Qian -AU - Zhu, Changbin -AU - Yu, Jinming -AU - Wang, Linlin -TI - Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as fi rst-line therapy for extensive-stage small-cell - cell lung cancer (ES-SCLC): a phase II trial -T2 - ECLINICALMEDICINE -M3 - Article -AB - Background This phase II prospective trial aimed to investigate the efficacy and safety of adebrelimab (PD-L1 antibody) plus first-line chemotherapy followed by sequential thoracic radiotherapy (TRT) combined with adebrelimab in extensive-stage small-cell lung cancer (ES-SCLC). Biomarkers associated with potential therapeutic effects were also explored. Methods Patients with previously untreated ES-SCLC were enrolled at Shandong Cancer Hospital and Institute (Jinan, China). Patients received 4-6 cycles of adebrelimab (20 mg/kg, D1, Q3W) combined with EP/EC (etoposide, 100 mg/m(2), D1-3, Q3W and cisplatin, 75 mg/m(2), D1, Q3W or carboplatin, AUC = 5, D1, Q3W). Then patients with response sequentially underwent consolidative TRT (>= 30 Gy in 10 fractions or >= 50 Gy in 25 fractions, involved-field irradiation), and maintenance adebrelimab until disease progression or intolerable adverse events (AEs). The primary endpoint was overall survival (OS). Genomic and circulating tumour DNA (ctDNA) profiling were also analyzed with tumour tissues and peripheral blood. This trial was registered with ClinicalTrials.gov, NCT04562337. Findings From October 2020 to April 2023, 67 patients diagnosed with ES-SCLC were enrolled and received at least one dose of study treatment. All patients were included in the efficacy and safety analyses. 45 patients received sequential TRT as planned. The median OS and progression-free survival (PFS) was 21.4 months (95% CI: 17.2-not reached months) and 10.1 months (95% CI: 6.9-15.5 months), respectively. The confirmed objective response rate was 71.6% (48/67, 95% CI: 59.3-82.0%) and disease control rate was 89.6% (60/67, 95% CI: 79.7-95.7%). There were no treatment-related deaths. The most common grade 3 or higher treatment-related adverse events (TRAEs) were hematological toxicities. The incidence of any grade and G3+ pneumonitis was 25% (17/67) and 6% (4/67), respectively. No unexpected adverse events were observed. Patients without co-mutations of TP53/RB1 in both tissue and peripheral blood displayed longer PFS (tissue, P = 0.071; ctDNA, P = 0.060) and OS (tissue, P = 0.032; ctDNA, P = 0.031). Interpretation Adebrelimab plus chemotherapy and sequential TRT as first-line therapy for ES-SCLC showed promising efficacy and acceptable safety. Funding This study was funded by the National Natural Science Foundation of China (82172865), Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Amoy Diagnostics Co., Ltd. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 2589-5370 -DA - 2024 SEP -PY - 2024 -VL - 75 -C7 - 102795 -DO - 10.1016/j.eclinm.2024.102795 -AN - WOS:001300974900001 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Dept Radiat Oncol, Shandong Canc Hosp & Inst, Jinan 250117, Shandong, Peoples R China -AD - Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China -AD - Amoy Diagnost Co Ltd, Xiamen, Fujian, Peoples R China -M2 - Jiangsu Hengrui Pharmaceut Co Ltd -M2 - Amoy Diagnost Co Ltd -Y2 - 2024-09-04 -ER - - -TY - JOUR -AU - Mielgo-Rubio, Xabier -AU - Martin, Margarita -AU - Remon, Jordi -AU - Higuera, Oliver -AU - Calvo, Virginia -AU - Jarabo, Jose Ramon -AU - Conde, Esther -AU - Luna, Javier -AU - Provencio, Mariano -AU - De Castro, Javier -AU - Lopez-Rios, Fernando -AU - Hernando-Trancho, Florentino -AU - Counago, Felipe -TI - Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges -T2 - FUTURE ONCOLOGY -M3 - Review -AB - Lung cancer continues to be the leading cause of cancer mortality and a serious health problem despite the numerous advances made in the last decade and the rapid advance of research in this field. In recent years, there has been a decrease in mortality from lung cancer coinciding with the approval times of targeted therapy. To date, targeted therapy has been used in the context of advanced disease in clinical practice, with great benefits in survival and quality of life. The next step will be to incorporate targeted therapy into the treatment of earlier stages of non-small-cell lung cancer, and there is already a randomized trial showing a disease-free survival benefit. However, there are many questions that need to be resolved first. In the present review, the authors discuss the findings of published reports and ongoing clinical trials assessing the role of targeted therapies in nonmetastatic disease.Lay abstract Despite major therapeutic advances over the last decade, lung cancer continues to present the highest mortality rate of all cancers. Precision and personalized therapy directed at specific alterations in the genetic material of the tumor as well as immunotherapy has significantly improved survival in metastatic non-small-cell lung cancer. The next step will be to incorporate precision medicine into the treatment of earlier stages of non-small-cell lung cancer. The recent publication of the results of the ADAURA phase III trial showing a significant improvement in disease-free survival in patients with resected EGFR-mutated non-small-cell lung cancer who received an adjuvant EGFR-directed tyrosine kinase inhibitor called osimertinib has opened the doors to the incorporation of this novel agent into routine clinical practice. However, there are many questions that need to be resolved first. In the present review, the authors discuss the findings of published reports and ongoing clinical trials assessing the role of precision medicine in nonmetastatic disease.Tweetable abstract The time has come to offer targeted therapy to patients with earlier-stage non-small-cell lung cancer, which could represent an important qualitative leap in the treatment of lung cancer patients. Review of evidence and discussion. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1479-6694 -SN - 1744-8301 -DA - 2021 JUN -PY - 2021 -VL - 17 -IS - 30 -SP - 4011 -EP - 4025 -DO - 10.2217/fon-2020-1255 -AN - WOS:000680057100001 -C6 - AUG 2021 -AD - Hosp Univ Fdn Alcorco, Dept Med Oncol, Budapest 1 Alcorcon, Madrid 28922, Spain -AD - Ramon y Cajal Univ Hosp, Dept Radiat Oncol, M-607,Km 9,100, Madrid 28034, Spain -AD - HM Hosp, Hosp HM Delfos, Ctr Integral Oncol Clara Campal, Dept Med Oncol, Barcelona, Spain -AD - Hosp Univ La Paz, Dept Med Oncol, Paseo Castellana 261, Madrid 28046, Spain -AD - Puerta Hierro Hosp, Dept Med Oncol, Joaquin Rodrigo 1, Madrid 28222, Spain -AD - Hosp Clin San Carlos, Dept Thorac Surg, Calle Prof Martin Lagos S-N, Madrid 28040, Spain -AD - Hosp Univ 12 Octubre, Dept Pathol, Madrid 28041, Spain -AD - Fdn Jimenez Diaz, Oncohlth Inst, Dept Radiat Oncol, Avda Reyes Catolicos 2, Madrid 28040, Spain -AD - Hosp Univ Quironsalud Madrid, Dept Radiat Oncol, Madrid 28223, Spain -AD - Hosp La Luz, Dept Radiat Oncol, Madrid 28003, Spain -AD - Univ Europea Madrid, Sch Biomed Sci, Med Dept, Villaviciosa De Odon 28670, Spain -M2 - HM Hosp -M2 - Fdn Jimenez Diaz -M2 - Hosp La Luz -Y2 - 2021-08-10 -ER - - -TY - JOUR -AU - Wu, Min -AU - Liu, Jie -AU - Wu, Shihao -AU - Liu, Jingru -AU - Wu, Hui -AU - Yu, Jinming -AU - Meng, Xue -TI - Systemic Immune Activation and Responses of Irradiation to Different Metastatic Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer -T2 - FRONTIERS IN IMMUNOLOGY -M3 - Article -AB - PurposeConsidering the limited data, we aimed to identify the greatest immune activation irradiated site of common metastases and response to immune checkpoint inhibitors simultaneously in non-small cell lung cancer (NSCLC). MethodsA total of 136 patients with advanced NSCLC who had received radiation to a primary or metastatic solid tumor were enrolled. We recorded blood cell counts in three time periods, before, during, and after radiotherapy (RT), and derived some blood index ratios including monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). The delta-IBs were calculated as medio-IBs divided by pre-IBs - 1. We analyzed the changes before and during RT using Spearman rank correlation test, Kruskal-Wallis rank sum test, and logistic regression analyzing their correlation with efficacy. ResultsThe medians of delta-MLR and delta-PLR were both the lowest while the median of delta-L was the highest in brain. Therapeutic effect evaluation showed that the objective response rate (ORR) of 48.65% (18/37) in the brain irradiation group was the highest, compared with 17.07% (7/41) in bone and 41.94% (13/31) in lung. ConclusionsIn this study, results suggested that irradiation to brain has the best immune activation effect and patient outcome compared with other organs in NSCLC, and when the earlier-line ICIs were combined with RT, a better patient outcome was reached. Prospective studies are also necessary to provide more convincing evidence and standards for clinical irradiation metastases selection. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1664-3224 -DA - 2021 DEC 14 -PY - 2021 -VL - 12 -C7 - 803247 -DO - 10.3389/fimmu.2021.803247 -AN - WOS:000742886100001 -AD - Shandong Univ, Cheeloo Coll Med, Jinan, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Dept Radiat Oncol, Shandong Canc Hosp & Inst, Jinan, Peoples R China -AD - Anhui Univ Sci & Technol, Sch Med, Huainan, Peoples R China -AD - Zhengzhou Univ, Dept Radiat Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China -Y2 - 2022-01-21 -ER - - -TY - JOUR -AU - Kaul, David -AU - Berghoff, Anna Sophie -AU - Grosu, Anca-Ligia -AU - Lucas, Carolin Weiss -AU - Guckenberger, Matthias -TI - Focal Radiotherapy of Brain Metastases in Combination With Immunotherapy and Targeted Drug Therapy -T2 - DEUTSCHES ARZTEBLATT INTERNATIONAL -M3 - Review -AB - Background: Advances in systemic treatment and in brain imaging have led to a higher incidence of diagnosed brain metastases. In the treatment of brain metastases, stereotactic radiotherapy and radiosurgery, systemic immunotherapy, and targeted drug therapy are important evidence-based options. In this review. we summarize the available evidence on the treatment of brain metastases of the three main types of cancer that give rise to them: non-small-cell lung cancer, breast cancer, and malignant melanoma.Methods: This narrative review is based on pertinent original articles. meta-analyses. and systematic reviews that were retrieved by a selective search in PubMed. These publications were evaluated and discussed by an expert panel including radiation oncologists. neurosurgeons. and oncologists.Results: There have not yet been any prospective randomized trials concerning the optimal combination of local stereotactic radiotherapy/radiosurgery and systemic immunotherapy or targeted therapy. Retrospective studies have consistently shown a benefit from early combined treatment with systemic therapy and (in particular) focal radiotherapy. compared to sequential treatment. Two meta-analyses of retrospective data from cohorts consisting mainly of patients with non-small-cell lung cancer and melanoma revealed longer overall survival after combined treatment with focal radiotherapy and checkpoint inhibitor therapy (rate of 12-month overall survival for combined versus non-combined treatment: 64.6% vs. 51.6%, p <0.001). In selected patients with small, asymptomatic brain metastases in non-critical locations. systemic therapy without focal radiotherapy can be considered, as long as follow-up with cranial magnetic resonance imaging can be performed at close intervals.Conclusion: Brain metastases should be treated by a multidisciplinary team, so that the optimal sequence of local and systemic therapies can be determined for each individual patient. -PU - DEUTSCHER AERZTE-VERLAG GMBH -PI - COLOGNE -PA - DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY -SN - 1866-0452 -DA - 2021 NOV 12 -PY - 2021 -VL - 118 -IS - 45 -SP - 759 -EP - + -DO - 10.3238/arztebl.m2021.0332 -AN - WOS:000752419400001 -AD - Charite, Dept Radiat Oncol & Radiotherapy, Berlin, Germany -AD - Free Univ Berlin, Berlin, Germany -AD - Humboldt Univ, Berlin, Germany -AD - Berlin Inst Hlth, Berlin, Germany -AD - Med Univ Vienna, Dept Med 1, Vienna, Austria -AD - Med Univ Vienna, Comprehens Canc Ctr Vienna, Vienna, Austria -AD - Univ Med Ctr Freiburg, Dept Radiat Oncol, Freiburg, Germany -AD - Univ Cologne, Fac Med, Ctr Neurosurg, Cologne, Germany -AD - Univ Hosp Cologne, Cologne, Germany -AD - Univ Zurich, Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland -Y2 - 2022-02-16 -ER - - -TY - JOUR -AU - Heynemann, Sarah -AU - Mitchell, Paul -TI - Developments in systemic therapies for the management of lung cancer -T2 - INTERNAL MEDICINE JOURNAL -M3 - Article -AB - Lung cancer accounts for approximately 1 in 10 new cancer diagnoses annually and is responsible for the most cancer-associated deaths in Australia. Despite such figures, there is reason for optimism with many practice-changing developments to report for the management of patients with thoracic malignancies over the last few years. We outline such changes, including the emerging role of immunotherapy in the neoadjuvant and adjuvant setting for patients with localised non-small-cell lung cancer, as well as the established standard of consolidation immunotherapy following definitive chemoradiotherapy for those with locally advanced disease. In the metastatic setting, combination chemotherapy-immunotherapy approaches have become the new paradigm for most patients in the absence of a recognised driver mutation. A range of novel targeted therapies now exist and are Pharmaceutical Benefits Scheme (PBS)-subsidised for targets such as EGFR, ALK and ROS1, with many others, such as KRAS G12C, NTRK, MET, RET and HER2, also with therapies rapidly being developed. Even among patients with small-cell lung cancer, who account for the worst prognoses and until recently have received a chemotherapy regimen that has remained unchanged in over 20 years, there is a new standard-of-care in combination chemotherapy-immunotherapy. Furthermore, immunotherapy and potentially anti-vascular endothelial growth factor agents now also play a role in mesothelioma treatment. Last, given recent developments in immunotherapy, targeted therapy and combination approaches in the non-small-cell lung cancer space, there is an increasing recognition of the diversity of lived experience for such patients and need for survivorship programmes to acknowledge such nuances. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1444-0903 -SN - 1445-5994 -DA - 2021 DEC -PY - 2021 -VL - 51 -IS - 12 -SP - 2012 -EP - 2020 -DO - 10.1111/imj.15609 -AN - WOS:000732964600005 -AD - Chris OBrien Lifehouse, Dept Med Oncol, Sydney, NSW, Australia -AD - Austin Hlth, Dept Med Oncol, Olivia Newton John Canc Wellness & Res Ctr, Melbourne, Vic, Australia -AD - Univ Melbourne, Dept Med, Austin Hlth, Melbourne, Vic, Australia -Y2 - 2021-12-29 -ER - - -TY - JOUR -AU - Zhou, Yu M. -AU - Shin, Jacob -AU - Jelinek, Michael -AU - Fidler, Mary J. -AU - Batus, Marta -AU - Bonomi, Philip D. -AU - Marwaha, Gaurav -TI - Four-Phase, Definitive Chemoradiation for a Real-World (Poor Risk and/or Elderly) Patient Population With Locally Advanced Non-small Cell Lung Cancer -T2 - CUREUS JOURNAL OF MEDICAL SCIENCE -M3 - Article -AB - IntroductionWith the incorporation of modernized radiotherapy, chemotherapy, and immunotherapy, treatment outcomes have improved for patients with locally advanced, unresectable diseases. Elderly or poor performance status patients comprise more than half of non-small cell lung cancer (NSCLC) patients, but they are often underrepresented or excluded in clinical trials. Split-course concurrent chemoradiotherapy can be an effective treatment, showing good adherence and a favorable toxicity profile for unresectable, locally advanced NSCLC.MethodWe identified locally advanced NSCLC cancer patients via a single institution retrospective study. Patients were treated using a four-phase, split-course external beam radiotherapy approach with concurrent chemotherapy. The primary endpoints analyzed were completion rate, incidence, and severity of treatment-related toxicities, progression-free survival (PFS), and median overall survival (OS).ResultsThirty-nine locally advanced lung cancer patients were treated with split-course chemoradiation (CRT). The median age at diagnosis was 73 years old. Seventeen patients had an Eastern Cooperative Oncology Group (ECOG) performance score of 2. Twenty-three patients had a clinical diagnosis of chronic obstructive pulmonary disease (COPD), and 10 patients were on home oxygen at the time of diagnosis. All patients completed 6000 centigrays (cGy) of radiation, and 95% of the patients completed at least three cycles of concurrent chemotherapy. No patients experienced grade 3 to 5 acute thoracic toxicities. Overall median survival was 12.7 months, and PFS was 7.5 months.ConclusionOur retrospective analysis of 39 poor risk and/or elderly patients with locoregional NSCLC treated with concurrent CRT via a split-course regimen suggests favorable oncologic outcomes and superb treatment completion rates and toleration. -PU - SPRINGERNATURE -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND -SN - 2168-8184 -DA - 2022 SEP 21 -PY - 2022 -VL - 14 -IS - 9 -DO - 10.7759/cureus.29423 -AN - WOS:000862753100038 -AD - Rush Univ, Med Ctr, Radiat Oncol, Chicago, IL 60612 USA -AD - Mem Sloan Kettering Canc Ctr, Radiat Oncol, New York, NY USA -AD - Rush Univ, Med Ctr, Med Oncol, Chicago, IL USA -Y2 - 2022-10-21 -ER - - -TY - JOUR -AU - Simone, Charles B 2nd -AU - Burri, Stuart H -AU - Heinzerling, John H -TI - Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. -T2 - Translational lung cancer research -M3 - Journal Article -M3 - Review -AB - Targeted therapies and immunotherapies have quickly become fixtures in the treatment armamentarium for metastatic non-small cell lung cancer (NSCLC). Targeted therapies directed against epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations, and ROS-1 rearrangements have demonstrated improved progression free survival (PFS) and, in selected populations, improved overall survival (OS) compared with cytotoxic chemotherapy. Immunotherapies, including checkpoint inhibitor monoclonal antibodies against programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1), have now also demonstrated improved survival compared with chemotherapy. The use of these novel systemic agents in non-metastatic patient populations and in combination with radiation therapy is not well defined. As radiation therapy has become more effective and more conformal with fewer toxicities, it has increasingly been used in the oligometastatic or oligoprogression setting. This has allowed improvement in PFS and potentially OS, and in the oligoprogressive setting may overcome acquired drug resistance of a specific lesion(s) to allow patients to remain on their targeted therapies. Molecularly targeted therapies and immunotherapies for patients with metastatic NSCLC have demonstrated much success. Advances in radiation therapy and stereotactic body radiotherapy, radiation therapy have led to combination strategies with targeted therapies among patients with lung cancer. Radiation therapy has also been combined with immunotherapies predominantly in the metastatic setting. In the metastatic population, radiation therapy has the ability to provide durable local control and also augment the immune response of systemic agents, which may lead to an abscopal effect of immune-mediated tumor response in disease sites outside of the radiation field in select patients. -SN - 2218-6751 -DA - 2015 Oct -PY - 2015 -VL - 4 -IS - 5 -SP - 545 -EP - 52 -DO - 10.3978/j.issn.2218-6751.2015.10.05 -AN - MEDLINE:26629423 -AD - 1 Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA ; 2 Department of Radiation Oncology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA. -Y2 - 2016-09-09 -ER - - -TY - JOUR -AU - Larrea, L. -AU - Gonzalez, V. -AU - Antonini, P. -AU - Lopez, E. -AU - Banos, M. C. -TI - Lattice Radiotherapy (LRT)-Spatially Fractionated Radiotherapy (SFRT): Advanced Non-Small Cell Lung Cancer (NSCLC): Early Experience -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 2916 -SP - E443 -EP - E443 -AN - WOS:000715803800911 -AD - Hosp NISA Virgen Consuelo, Valencia, Spain -AD - Hosp Vithas Valencia Consuelo, Valencia, Spain -M2 - Hosp NISA Virgen Consuelo -M2 - Hosp Vithas Valencia Consuelo -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Ruiz, Rossana -AU - Hunis, Brian -AU - Raez, Luis E. -TI - Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines -T2 - CURRENT ONCOLOGY REPORTS -M3 - Article -AB - Non-small-cell lung cancer usually carries a dismal prognosis. Novel treatment approaches are clearly warranted. Immunotherapy has emerged as a promising area of research developing agents that manipulate the immune system to induce antitumor responses while avoiding major toxicity. New vaccines and checkpoint inhibitors are currently undergoing investigation in phase II and phase III clinical trials. In advanced non-small-cell lung cancer (NSCLC), belagenpumatucel-L, an allogeneic cell vaccine directed against transforming growth factor beta in the tumor microenvironment, knocks down the immune suppression caused by the tumor and has demonstrated a doseand time-dependent efficacy in some subgroups of patients. L-BLP25 and TG4010 are both antigenic vaccines that target mucin 1, whose encoding proto-oncogene is commonly mutated in solid tumors. The L-BLP25 vaccine achieved a significant improvement in overall survival in the subgroup of patients with stage IIIB NSCLC treated with chemoradiotherapy. TG4010 vaccination resulted in better progression-free survival when added to cisplatin-gemcitabine chemotherapy. These results are being addressed in the currently ongoing phase III TIME trial. In the adjuvant setting, MAGE-A3, an antigen-based vaccine, showed promising results in melanoma-associated antigen A3 positive lung cancer patients who underwent resection in the phase II study; however, no improvement in progressionfree survival was observed in the phase III MAGRIT study. CIMAVax is a recombinant human epidermal growth factor (EGF) vaccine that induces anti-EGF antibody production and prevents EGF from binding to its receptor. It has improved overall survival in patients with advanced NSCLC who achieve seroconversion. Ipilimumab, an immune checkpoint inhibitor that targets cytotoxic T-lymphocyte antigen 4, demonstrated improved progression-free survival in advanced NSCLC patients who received the drug after chemotherapy in a phased regimen. Finally, anti-programmed death receptor 1 agents have achieved durable response rates in phase I studies. This review gives an overview of the current data and the most promissory immunotherapeutic agents for NSCLC. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1523-3790 -SN - 1534-6269 -DA - 2014 SEP -PY - 2014 -VL - 16 -IS - 9 -C7 - 400 -DO - 10.1007/s11912-014-0400-6 -AN - WOS:000341081600005 -AD - Inst Nacl Enfermedades Neoplas, Dept Med Oncol, Lima, Peru -AD - Florida Int Univ, Herbert Wertheim Coll Med, Mem Hlth Care Syst, Thorac Oncol Program,Mem Canc Inst, Pembroke Pines, FL 33028 USA -AD - Florida Int Univ, Herbert Wertheim Coll Med, Mem Hlth Care Syst, Mem Canc Inst, Pembroke Pines, FL 33028 USA -Y2 - 2014-09-17 -ER - - -TY - JOUR -AU - Mao, Yunye -AU - Sheng, Shu -AU - Wang, An -AU - Zhai, Jinzhao -AU - Ge, Xiangwei -AU - Lu, Di -AU - Wang, Jinliang -TI - [Current Status and Prospect of PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy 
in Elderly Patients with Advanced NSCLC]. -T2 - Zhongguo fei ai za zhi = Chinese journal of lung cancer -M3 - Journal Article -M3 - Review -M3 - English Abstract -AB - The incidence of cancer is closely correlated with age, as 75% of non-small cell lung cancer (NSCLC) patients are aged at least 65 years. The availability of immune checkpoint inhibitors (ICIs) has altered the available NSCLC therapeutic pattern. Limited studies on elderly patients have demonstrated that ICIs as monotherapy provide substantial benefits for patients aged 65-75 years, showing no significant difference compared to younger patients. This benefit is also observed in combination with immune-combined chemotherapy or radiotherapy. For individuals older than 75 years, the survival effect was not evident, though. Immune-related adverse events (irAEs) with ICIs alone were similar in incidence across age categories. Immune-combination chemotherapy resulted in a higher incidence of irAEs than chemotherapy alone, and patients ≥75 years of age were more likely to experience higher-grade irAEs. Besides the fact that immunosenescence in older patients influences the immune milieu in a multifaceted manner, which in turn impacts the effectiveness of immunotherapy, the prognosis is also influenced by the Eastern Cooperative Oncology Group performance status (ECOG PS) score, among other factors. For certain individuals aged ≥75 years or in poor physical health, immunotherapy combined with low-intensity chemotherapy has emerged as a viable treatment option. However, there are fewer related studies, so there should be a conscious effort to increase the number of elderly patients enrolled in the trial and a comprehensive assessment to explore individualized treatment options. To provide additional references and guidance for immunotherapy in elderly NSCLC patients and to propose new therapeutic perspectives in combination with their characteristics, this review aims to summarize and analyze the pertinent studies on the application of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors in these patients.
. -AB - 【中文题目:老年晚期NSCLC患者PD-1/PD-L1
免疫检查点抑制剂治疗现状及展望】 【中文摘要:癌症发病率与年龄密切相关,75%的非小细胞肺癌(non-small cell lung cancer, NSCLC)患者年龄均≥65岁。免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)的出现改变了NSCLC的治疗格局。针对老年患者有限的研究发现对于65-75岁的患者,ICIs单药显示出良好的获益,与年轻患者无明显差异,这种获益在免疫联合化疗或放疗中也有所体现。但是对于≥75岁的患者来说生存获益不明显。ICIs单药在不同年龄段的患者中免疫相关不良反应(immune-related adverse events, irAEs)发生率相似,免疫联合化疗对比单纯化疗导致irAEs的发生率高,≥75岁患者发生更高级别irAEs的可能性更大。除了老年患者免疫衰老会从多维度影响免疫微环境从而影响免疫治疗疗效外,东部肿瘤协作组体力状态(Eastern Cooperative Oncology Group performance status, ECOG PS)评分等也会影响预后。对于部分≥75岁或身体状况较差的患者,免疫联合低强度化疗成为有潜力的治疗方式之一,但相关研究较少,所以应有意识增加老年患者入组试验的人数,同时综合评估,探索个体化治疗方案。本综述拟对老年NSCLC患者应用抗程序性死亡受体1(programmed cell death protein 1, PD-1)及其配体(programmed cell death ligand 1, PD-L1)的相关研究进行汇总分析,以期为老年NSCLC患者的免疫治疗提供更多参考和指导,并结合其特点提出新的治疗展望。
】 【中文关键词:肺肿瘤;老年非小细胞肺癌;免疫衰老;免疫治疗;免疫联合低强度化疗】. -SN - 1999-6187 -DA - 2024 May 20 -PY - 2024 -VL - 27 -IS - 5 -SP - 367 -EP - 375 -DO - 10.3779/j.issn.1009-3419.2024.106.10 -AN - MEDLINE:38880924 -AD - Department of Oncology, Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing 100071, China. -AD - Chinese PLA Medical School, Beijing 100853, China. -Y2 - 2024-06-19 -ER - - -TY - JOUR -AU - Longo, Vito -AU - Della Corte, Carminia Maria -AU - Russo, Alessandro -AU - Spinnato, Francesca -AU - Ambrosio, Francesca -AU - Ronga, Riccardo -AU - Marchese, Antonella -AU - Del Giudice, Teresa -AU - Sergi, Concetta -AU - Casaluce, Francesca -AU - Gilli, Marina -AU - Montrone, Michele -AU - Gristina, Valerio -AU - Sforza, Vincenzo -AU - Reale, Maria Lucia -AU - Di Liello, Raimondo -AU - Servetto, Alberto -AU - Lipari, Helga -AU - Longhitano, Claudio -AU - Vizzini, Laura -AU - Manzo, Anna -AU - Cristofano, Antonella -AU - Paolelli, Loretta -AU - Nardone, Annalisa -AU - De Summa, Simona -AU - Perrone, Antonella -AU - Bisceglia, Carmela -AU - Derosa, Caterina -AU - Nardone, Valerio -AU - Viscardi, Giuseppe -AU - Galetta, Domenico -AU - Vitiello, Fabiana -TI - Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy -T2 - FRONTIERS IN IMMUNOLOGY -M3 - Article -AB - Background: Consolidative thoracic radiotherapy (TRT) has been commonly used in the management of extensive-stage small cell lung cancer (ES-SCLC). Nevertheless, phase III trials exploring first-line chemoimmunotherapy have excluded this treatment approach. However, there is a strong biological rationale to support the use of radiotherapy (RT) as a boost to sustain anti-tumor immune responses. Currently, the benefit of TRT after chemoimmunotherapy remains unclear. The present report describes the real-world experiences of 120 patients with ES-SCLC treated with different chemoimmunotherapy combinations. Preclinical data supporting the hypothesis of anti-tumor immune responses induced by RT are also presented. Methods: A total of 120 ES-SCLC patients treated with chemoimmunotherapy since 2019 in the South of Italy were retrospectively analyzed. None of the patients included in the analysis experienced disease progression after undergoing first-line chemoimmunotherapy. Of these, 59 patients underwent TRT after a multidisciplinary decision by the treatment team. Patient characteristics, chemoimmunotherapy schedule, and timing of TRT onset were assessed. Safety served as the primary endpoint, while efficacy measured in terms of overall survival (OS) and progression-free survival (PFS) was used as the secondary endpoint. Immune pathway activation induced by RT in SCLC cells was explored to investigate the biological rationale for combining RT and immunotherapy. Results: Preclinical data supported the activation of innate immune pathways, including the STimulator of INterferon pathway (STING), gamma-interferon-inducible protein (IFI-16), and mitochondrial antiviral-signaling protein (MAVS) related to DNA and RNA release. Clinical data showed that TRT was associated with a good safety profile. Of the 59 patients treated with TRT, only 10% experienced radiation toxicity, while no >= G3 radiation-induced adverse events occurred. The median time for TRT onset after cycles of chemoimmunotherapy was 62 days. Total radiation dose and fraction dose of TRT include from 30 Gy in 10 fractions, up to definitive dose in selected patients. Consolidative TRT was associated with a significantly longer PFS than systemic therapy alone (one-year PFS of 61% vs. 31%, p<0.001), with a trend toward improved OS (one-year OS of 80% vs. 61%, p=0.027). Conclusion: Multi-center data from establishments in the South of Italy provide a general confidence in using TRT as a consolidative strategy after chemoimmunotherapy. Considering the limits of a restrospective analysis, these preliminary results support the feasibility of the approach and encourage a prospective evaluation. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1664-3224 -DA - 2024 JAN 18 -PY - 2024 -VL - 14 -C7 - 1289434 -DO - 10.3389/fimmu.2023.1289434 -AN - WOS:001154316800001 -AD - IRCCS Ist Tumori Giovanni Paolo II, Med Thorac Oncol Unit, Bari, Italy -AD - Univ Campania Luigi Vanvitelli, Dept Precis Med, Naples, Italy -AD - Papardo Hosp, Dept Hematol Oncol, Messina, Italy -AD - UOC Oncol Med Osped Riuniti Villa Sofia Cervello, Palermo, Italy -AD - Hosp Antonio Cardarelli, UOC Oncol AORN Cardarelli, Naples, Italy -AD - Osped La Maddalena, Palermo, Italy -AD - AOU Renato Dubecco Lellis Hosp, Med Oncol Unit, Catanzaro, Italy -AD - Azienda Sanit Prov Catania, Azienda Sanit Provinciale Catania, Catania, Italy -AD - AORN SG Moscati Hosp, San Giuseppe Moscati Hosp Natl Importance & High S, Divison Med Oncol, Avellino, Italy -AD - AORN Azienda Osped Colli Monaldi, AORN Azienda Ospedaliera Colli Monaldi, Naples, Italy -AD - Univ Palermo, Univ Palermo, Palermo, Italy -AD - G Pascale Natl Canc Inst Fdn IRCCS, Oncol Clin Sperimentale Toraco Polmonare, Naples, Italy -AD - Vito Fazzi Hosp, Med Oncol Unit, Lecce, Italy -AD - Oncol Unit Osped Mare, ASL Napoli 1, Naples, Italy -AD - Univ Naples Federico II, Sch Med & Surg, Dept Clin Med & Surg, Naples, Italy -AD - Cannizzaro Hosp, Oncol Osped Cannizzaro Catania, Med Oncol Unit, Catania, Italy -AD - UOC Oncol Osped Maria Paterno Arezzo OMPA, Ragusa, Italy -AD - UOC Oncol Agrigento Hlth Author, Agrigento, Italy -AD - Osped Gen Regionale F Miulli, Dipartimento Oncol & Oncoematol, Acquaviva, Italy -AD - Unita Opert Complessa Radioterapia, IRCCS Ist Tumori Giovanni Paolo II, Bari, Italy -AD - IRCCS Ist Tumori Giovanni Paolo II, Mol Diagnost & Pharmacogenet Unit, Bari, Italy -M2 - Papardo Hosp -M2 - UOC Oncol Med Osped Riuniti Villa Sofia Cervello -M2 - Osped La Maddalena -M2 - AOU Renato Dubecco Lellis Hosp -M2 - Azienda Sanit Prov Catania -M2 - AORN Azienda Osped Colli Monaldi -M2 - G Pascale Natl Canc Inst Fdn IRCCS -M2 - Oncol Unit Osped Mare -M2 - Cannizzaro Hosp -M2 - UOC Oncol Osped Maria Paterno Arezzo OMPA -M2 - UOC Oncol Agrigento Hlth Author -M2 - Osped Gen Regionale F Miulli -Y2 - 2024-02-09 -ER - - -TY - JOUR -AU - Manzo, Anna -AU - Carillio, Guido -AU - Montanino, Agnese -AU - Sforza, Vincenzo -AU - Palumbo, Giuliano -AU - Esposito, Giovanna -AU - Costanzo, Raffaele -AU - Sandomenico, Claudia -AU - La Manna, Carmine -AU - Martucci, Nicola -AU - La Rocca, Antonello -AU - De Luca, Giuseppe -AU - Piccirillo, Maria Carmela -AU - De Cecio, Rossella -AU - Botti, Gerardo -AU - Totaro, Giuseppe -AU - Muto, Paolo -AU - Picone, Carmine -AU - Normanno, Nicola -AU - Morabito, Alessandro -TI - The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer -T2 - EXPERT OPINION ON DRUG SAFETY -M3 - Article -AB - Introduction Atezolizumab is a humanized monoclonal antibody against PD-L1 capable of enhancing antitumor immune activity, with a demonstrated activity as single agent in patients with advanced non-small-cell lung cancer (NSCLC). Areas covered This review summarizes the clinical data emerging from randomized clinical studies with atezolizumab in NSCLC and small-cell lung cancer (SCLC), focusing in particular on the efficacy and safety data regarding the combinations of atezolizumab plus chemotherapy in the IMpower studies. Expert opinion A significant improvement in progression-free survival and in overall survival was observed in IMpower 130 and 150 (NSCLC non-squamous) and 133 (SCLC), with an acceptable safety profile. In particular, the most common immune-related adverse events were rash (18-28% of patients), hypothyroidism (8-15%), hepatitis (5-17%), pneumonitis (2-7%), and colitis (1.5-2.3%). The safety profile of atezolizumab in combination with chemotherapy was consistent with the known adverse events related to single-agent atezolizumab and no new adverse events were observed. Ongoing studies will evaluate the role of atezolizumab in other settings (adjuvant and neoadjuvant) and in combination with chemotherapy and radiotherapy for patients with locally advanced NSCLC and the role of predictive factors (B-FAST study). -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1474-0338 -SN - 1744-764X -DA - 2020 JUL 2 -PY - 2020 -VL - 19 -IS - 7 -SP - 775 -EP - 783 -DO - 10.1080/14740338.2020.1767584 -AN - WOS:000540124700001 -C6 - MAY 2020 -AD - IRCCS, Ist Nazl Tumori, Thorac Med Oncol, Fdn G Pascale, Naples, Italy -AD - Azienda Osped Pugliese Ciaccio, Dept Oncol & Hematol, Catanzaro, Italy -AD - Osped S Maria Della Pieta, Oncol, Naples, Italy -AD - IRCCS, Ist Nazl Tumori, Thorac Surg, Fdn G Pascale, Naples, Italy -AD - IRCCS, Clin Trials Unit, Ist Nazl Tumori, Fdn G Pascale, Naples, Italy -AD - IRCCS, Ist Nazl Tumori, Pathol, Fdn G Pascale, Naples, Italy -AD - IRCCS, Ist Nazl Tumori, Sci Directorate, Fdn G Pascale, Naples, Italy -AD - IRCCS, Ist Nazl Tumori, Radiotherapy, Fdn G Pascale, Naples, Italy -AD - IRCCS, Ist Nazl Tumori, Radiol, Fdn G Pascale, Naples, Italy -AD - IRCCS, Ist Nazl Tumori, Cell Biol & Biotherapy, Fdn G Pascale, Naples, Italy -M2 - Azienda Osped Pugliese Ciaccio -M2 - Osped S Maria Della Pieta -Y2 - 2020-06-25 -ER - - -TY - JOUR -AU - Alaswad, Mohammed -TI - Locally advanced non-small cell lung cancer: current issues and recent trends -T2 - REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY -M3 - Review -AB - The focus of this paper was to review and summarise the current issues and recent trends within the framework of locally advanced (LA) non-small cell lung cancer (NSCLC). The recently proposed 8th tumour-node-metastases (TNM) staging system exhibited significant amendments in the distribution of the T and M descriptors. Every revision to the TNM classification should contribute to clinical improvement. This is particularly necessary regarding LA NSCLC stratification, therapy and outcomes. While several studies reported the superiority of the 8th TNM edition in comparison to the previous 7th TNM edition, in terms of both the discrimination ability among the various T subgroups and clinical outcomes, others argued against this interpretation. Synergistic cytotoxic chemotherapy with radiotherapy is most prevalent in treating LA NSCLC. Clinical trial experience from multiple references has reported that the risk of locoregional relapse and distant metastasis was less evident for patients treated with concomitant radiochemotherapy than radiotherapy alone. Nevertheless, concern persists as to whether major incidences of toxicity may occur due to the addition of chemotherapy. Cutting-edge technologies such as four-dimensional computed tomography (4D-CT) and volumetric modulated arc therapy (VMAT) should yield therapeutic gains due to their capability to conform radiation doses to tumours. On the basis of the preceding notion, the optimum radiotherapy technique for LA NSCLC has been a controversial and much-disputed subject within the field of radiation oncology. Notably, no single-perspective research has been undertaken to determine the optimum radiotherapy modality for LA NSCLC. The landscape of immunotherapy in lung cancer is rapidly expanding. Currently, the standard of care for patients with inoperable LA NSCLC is concurrent chemoradiotherapy followed by maintenance durvalumab according to clinical outcomes from the PACIFIC trial. An estimated 42.9% of patients randomly assigned to durvalumab remained alive at five years, and free of disease progression, thereby establishing a new benchmark for the standard of care in this setting. -PU - VIA MEDICA -PI - GDANSK -PA - UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND -SN - 1507-1367 -SN - 2083-4640 -DA - 2023 -PY - 2023 -VL - 28 -IS - 2 -SP - 286 -EP - 303 -DO - 10.5603/RPOR.a2023.0019 -AN - WOS:001030455200001 -AD - King Fahad Med City, Comprehens Canc Ctr, Radiat Oncol, Riyadh, Saudi Arabia -AD - Princess Nourah Bint Abdulrahman Univ, Riyadh, Saudi Arabia -AD - King Fahad Med City, Comprehens Canc Ctr, Radiat Oncol, Riyadh 11525, Saudi Arabia -Y2 - 2023-08-01 -ER - - -TY - JOUR -AU - Chen, Liyao -AU - Hou, Yu -AU - Xia, Yaoxiong -AU - Chang, Li -AU - Diao, Xianmin -AU - Wang, Li -AU - Li, Lan -AU - Long, Qing -AU - Liu, Ying -AU - Liu, Yan -AU - Li, Wenhui -TI - Radiotherapy Dose and Induction Chemotherapy Cycles Are Associated With Prognosis and Toxicity Risk: A Retrospective Study of 227 Patients With Unresectable Stage III Non-Small-Cell Lung Cancer -T2 - TECHNOLOGY IN CANCER RESEARCH & TREATMENT -M3 - Article -AB - Objective: Concurrent chemoradiation (cCHRT) has been confirmed as the standard treatment for local advanced non-small-cell lung cancer (NSCLC). This study is to assess the appropriate timing of radiotherapy and cycles of induction chemotherapy for those patients. Methods: 227 inoperable stage III NSCLC patients were selected, we analyzed the potential prognostic factors and the influence of induction chemotherapy was evaluated. Results: The median survival time was 20.7 months; only 25 patients chose chemotherapy alone (11.0%), 137 patients underwent sequential chemoradiation (sCHRT, 60.4%), and 65 patients received cCHRT (28.6%). Multivariate analyses showed radiation therapy (P = 0.001), the Eastern Cooperative Oncology Group (ECOG) score (P = 0.000) and the lymph node stage (P = 0.001) were independent prognostic factors. cCHRT was not found to be superior (P = 0.330). We selected patients received 60-66 Gy and found the cCHRT groups achieved a relatively better outcome, with a median Overall Survival (OS) of 25.2 months vs 20.1 months in the sCHRT group (P = 0.019). We also found cycles of induction chemotherapy did not compromise survival; however, >= 3 cycles resulted in more grade 3-4 hematology toxicities, with a proportion of 18/99 compared with 53/103 among patients who underwent <= 3 cycles. In addition, higher grade hematology toxicities and poor ECOG were also the most common reasons for abandoning cCHRT. Conclusions: For inoperable stage III NSCLC, cCHRT showed its superiority only when the radiotherapy dose was 60-66 Gy. Cycles of induction chemotherapy did not interfere with survival; however, >= 3 cycles resulted in more grade 3-4 hematology toxicities, leading to the cessation of cCHRT. -PU - SAGE PUBLICATIONS INC -PI - THOUSAND OAKS -PA - 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA -SN - 1533-0346 -SN - 1533-0338 -DA - 2020 OCT 16 -PY - 2020 -VL - 19 -C7 - 1533033820951802 -DO - 10.1177/1533033820951802 -AN - WOS:000583288800001 -AD - Peoples Hosp Yuxi City, Dept Radiotherapy Oncol, Yuxi, Yunnan, Peoples R China -AD - Kunming Med Univ, Dept Radiotherapy Oncol, Affiliated Hosp 3, Tumor Hosp Yunnan Prov, Kunming, Yunnan, Peoples R China -M2 - Peoples Hosp Yuxi City -Y2 - 2020-11-17 -ER - - -TY - JOUR -AU - Harada, Daijiro -AU - Shimonishi, Atsushi -AU - Saeki, Kazuhiko -AU - Ninomiya, Takashi -AU - Kanzaki, Hiromitsu -AU - Nagasaki, Kei -AU - Ogura, China -AU - Tsutsui, Yoko -AU - Kojin, Kazuhiro -AU - Hamamoto, Yasushi -AU - Kozuki, Toshiyuki -TI - Early administration of durvalumab after chemoradiotherapy increased risk of pneumonitis in patients with locally advanced non-small cell lung cancer -T2 - ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY -M3 - Article -AB - Aims Durvalumab (Durva) administration after chemoradiation therapy (CRT) in locally advanced non-small-cell lung cancer (NSCLC) is the standard of care, associated with relatively prolonged progression-free (PFS) and overall survival. However, pneumonitis occurs in 73.6% of Japanese patients. This retrospective study aimed to identify factors associated with Durva efficacy and safety, specifically, the risk of pneumonitis. Methods This study included data from 26 consecutive patients with locally advanced NSCLC who underwent CRT followed by Durva. The rates of adverse events and PFS were examined. Results The median PFS time was 15.6 months (95% confidence interval [CI]: 8.7-not available). Patients developed pneumonitis of grade 1, 2, 3, and 4 at the rate of 62%, 27%, 12%, and 0%, respectively. The median PFS time was 6.4 months for patients with programmed death ligand 1 (PD-L1) expression level of <50% and not reached for patients with PD-L1 expression level of >= 50% (hazard ratio [HR], 0.19; 95% CI: 0.04-0.89), which was significantly prolonged. The cumulative incidence of pneumonitis grade 2 or above was significantly higher when the time between the last day of thoracic radiotherapy (TRT) and the start of Durva therapy was within 14 days compared to >14 days (HR: 0.19; 95% CI: 0.06-0.59). This association was statistically significant in multivariate analysis. Conclusions The initiation of Durva therapy within 14 days after TRT may increase the risk of pneumonitis grade 2 or above. Careful observation and suitable treatment are recommended. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1743-7555 -SN - 1743-7563 -DA - 2023 APR -PY - 2023 -VL - 19 -IS - 2 -SP - E111 -EP - E117 -C7 - e13803 -DO - 10.1111/ajco.13803 -AN - WOS:000808506200001 -C6 - JUN 2022 -AD - Natl Hosp Organizat Shikoku Canc Ctr, Dept Thorac Oncol, 160 Minami Umemoto Machi, Matsuyama, Ehime 7910280, Japan -AD - Natl Hosp Organizat Shikoku Canc Ctr, Dept Radiotherapy, Matsuyama, Ehime, Japan -AD - Natl Hosp Org Shikoku Canc Ctr, Dept Pharm, Matsuyama, Ehime, Japan -M2 - Natl Hosp Organizat Shikoku Canc Ctr -M2 - Natl Hosp Organizat Shikoku Canc Ctr -M2 - Natl Hosp Org Shikoku Canc Ctr -Y2 - 2022-06-20 -ER - - -TY - JOUR -AU - Sun, Meiling -AU - Ji, Huaijun -AU - Deng, Fang -AU - Li, Jingyi -AU - Xu, Ning -AU - Li, Yu -TI - Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: a real-world study -T2 - BMC CANCER -M3 - Article -AB - Background Patients with extensive-stage small cell lung cancer (ES-SCLC) experience significant therapeutic challenges and limited survival rates. This study aimed to investigate the efficacy of combining immunotherapy (IT) with chemotherapy (CT) for treating ES-SCLC and to explore the synergistic effect between radiotherapy (RT) and IT. Methods This retrospective analysis examined patients with ES-SCLC who received treatment at three centers. Furthermore, propensity score-matched (PSM) analysis was conducted. The Kaplan-Meier method and Cox proportional hazards regression were used to compare the survival outcomes. Results A total of 257 eligible patients with ES-SCLC were included in the analysis. Among all patients, the median overall survival (mOS) was 18.0 m in the chemoimmunotherapy (CT + IT) group and 15.7 m in the CT group (p = 0.208). The median real-world progression-free survival (mrwPFS) was 7.7 m and 6.8 m (p = 0.043) in the CT + IT and CT group, respectively. Moreover, the mOS was 22.0 m in the chemoradiotherapy (CT + RT) group and 13.6 m in the CT group (p < 0.001). The mrwPFS was 7.4 m and 6.0 m (p = 0.175) in the CT + RT group and CT group, respectively. The multivariate analyses revealed that sex, liver metastasis and RT were independent prognostic factors for OS (p < 0.05), while liver metastasis and IT were found to be independent predictive factors of real-world progression-free survival (rwPFS) (p < 0.05). After PSM, the mOS was 23.2 m in the CT + IT group and 13.0 m in the CT group (p = 0.008). The mrwPFS was 7.3 m and 6.2 m (p = 0.096) in the CT + IT group and the CT group, respectively. Moreover, the mOS was 21.4 m in the CT + RT group and 12.5 m in the CT group (p < 0.001). The mrwPFS was 7.3 m and 5.2 m (p = 0.220) in the CT + RT group and the CT group, respectively. Additionally, our study revealed that in the PD-1 group, RT significantly improved patient survival (36.0 m vs. 15.8 m, p = 0.041). Conclusion An increasing number of treatment options are being explored for ES-SCLC, and CT is the cornerstone of treatment for this disease. Combining CT with IT and RT has demonstrated remarkable efficacy and excellent safety profiles, and such treatments are worthy of further exploration. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2024 SEP 30 -PY - 2024 -VL - 24 -IS - 1 -C7 - 1206 -DO - 10.1186/s12885-024-12942-y -AN - WOS:001325835400005 -AD - Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Pulm & Crit Care Med, 107 Wenhua Xilu, Jinan 250012, Shandong, Peoples R China -AD - Shandong Univ, Weihai Municipal Hosp, Cheeloo Coll Med, Dept Resp Med, 70 Heping Rd, Weihai 264200, Shandong, Peoples R China -AD - Shandong Univ, Weihai Municipal Hosp, Cheeloo Coll Med, Dept Thorac Surg, 70 Heping Rd, Weihai 264200, Shandong, Peoples R China -AD - Shandong Univ, Qilu Hosp, Dezhou Hosp, Dept Oncol, Dezhou 254300, Shandong, Peoples R China -AD - Shandong Univ, Weihai Municipal Hosp, Cheeloo Coll Med, Dept Radiat Oncol, 70 Heping Rd, Weihai 264200, Shandong, Peoples R China -Y2 - 2024-10-10 -ER - - -TY - JOUR -AU - Yang, Hui -AU - Jin, Tao -AU - Li, Mengqian -AU - Xue, Jianxin -AU - Lu, Bo -TI - Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges -T2 - PRECISION CLINICAL MEDICINE -M3 - Review -AB - Lately, the success of ICIs has drastically changed the landscape of cancer treatment, and several immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration (FDA) for advanced non-small cell lung cancer (NSCLC). However, numerous patients are resistant to ICIs and require additional procedures for better efficacy results. Thus, combination therapy is urgently needed to strengthen the anti-tumor immunity. A variety of preclinical and clinical studies combining ICIs with radiotherapy (RT) have demonstrated that the combination could induce synergistic effects, as RT overcomes the resistance to ICIs. However, the underlying mechanism of the synergistic effect and the optimal arrangement of the combination therapy are indecisive now. Hence, this review was conducted to provide an update on the current clinical trial results and highlighted the ongoing trials. We also discussed the optimal parameters in clinical trials, including radiation dose, radiation fractionation, radiation target field, and sequencing of combination therapy. In this review, we found that combination therapy showed stronger anti-tumor immunity with tolerable toxicities in clinical trials. However, the best combination mode and potential biomarkers for the target patients in combination therapy are still unclear. -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 2096-5303 -SN - 2516-1571 -DA - 2019 MAR -PY - 2019 -VL - 2 -IS - 1 -SP - 57 -EP - 70 -DO - 10.1093/pcmedi/pbz004 -AN - WOS:000661520900005 -AD - Sichuan Univ, West China Hosp, Canc Ctr, Dept Thorac Oncol, Chengdu 610041, Peoples R China -AD - Sichuan Univ, West China Hosp, Dept Urol, Inst Urol,Lab Reconstruct Urol, Chengdu 610041, Peoples R China -AD - Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA -Y2 - 2019-03-01 -ER - - -TY - JOUR -AU - Xu, Jun-kai -TI - Effect of Intensity Modulated Radiotherapy (IMRT) on the immunity, physical status and clinical effect of locally advanced NSCLC patients -T2 - PAKISTAN JOURNAL OF MEDICAL SCIENCES -M3 - Article -AB - Objectives: To evaluate the clinical value of radiotherapy combined with Camrelizumab in treating locally advanced non-small cell lung cancer (NSCLC) patients. Methods: 80 locally advanced NSCLC patients were randomly divided into two groups (n=40). The control group was administered with intensity modulated radiation therapy (IMRT), whereas the experimental group with Camrelizumab in addition to IMRT. All the patients underwent clinical efficacy evaluation in terms of adverse drug reaction (ADR), physical status improvement after the treatment, and changes in T lymphocyte subpopulations (incl. CD3+, CD4+, CD8+, CD4+/CD8+). Results: The efficacy was found to be 70% and 47.5 in experimental group and control group, respectively, with the former being significantly better than the latter (p=0.03). The ADR rates were 50% and 37.5% in the experimental group and control group, respectively; but the difference remained insignificant (p= 0.26). As for physical status improvement, experimental group evidently excelled the control group (p= 0.04). The post-treatment indicators such as CD3+, CD4+, CD8+, CD4+/CD8+ were significantly more improved in the experimental group than the control group (CD3+, p= 0.02; CD4+, p= 0.00; and CD4+/CD8+, p= 0.01). However, the changes in CD8+ were not significant at all (p= 0.46). Conclusions: The combined therapy of IMRT with Camrelizumab appeared effective in dealing with the locally advanced NSCLC patients, as such patients presented significantly better immune state and physical status improvement but not increased ADR. The therapy is both safe and effective. -PU - PROFESSIONAL MEDICAL PUBLICATIONS -PI - SADDAR -PA - PANORAMA CENTRE, RM 522, 5TH FLOOR, BLDG 2, RAJA GHAZANFAR ALI RD, PO BOX 8766, SADDAR, KARACHI 00000, PAKISTAN -SN - 1682-024X -SN - 1681-715X -DA - 2021 SEP-OCT -PY - 2021 -VL - 37 -IS - 5 -SP - 1480 -EP - 1485 -DO - 10.12669/pjms.37.5.4188 -AN - WOS:000692619600028 -AD - Putian Univ, Affiliated Hosp Grp, Dept Radiotherapy, Putian 351100, Peoples R China -Y2 - 2021-09-17 -ER - - -TY - JOUR -AU - Akash -AU - Mishra, Mamta -AU - Hoque, M. -AU - Amarpal -TI - Advancement in Cancer Immunotherapy in Veterinary Medicine: A Review -T2 - INDIAN JOURNAL OF ANIMAL RESEARCH -M3 - Review -AB - Cancer is one of the leading cause of death in human beings throughout the world. Attempts to treat cancer are made but not effectively. Surgical removal, use of radiation therapy, chemotherapy and combination of these therapies have been tried to cure cancer but every therapy had its own side effects. Due to potential side effects, these therapies failed to develop as the permanent cure for cancer. Stem cell transplantation has also been attempted as an alternative but the recovery rate was very low. The most recent therapy, nowadays, to treat cancer is immunotherapy in which utilises the immunity of the patient to get modulated in such a way that cancerous cells get killed. So this review enlightens the eminent immunotherapies used for veterinary patients. T cell checkpoint inhibitors, engineered T cells, cancer vaccines and anti-B and anti-T cell antibodies are amongst the important immunotherapies used in human as well as veterinary patient. Inhibition of T cell checkpoint molecules, such as PD-1 and CTLA-4, using monoclonal antibodies are the most advanced techniques developed in humans. These significant immunotherapies have achieved notable success against some of the advanced tumors in humans, including melanoma, renal cell carcinoma and non small cell lung cancer. However, a recent clinical trial with a caninized monoclonal antibody against canine PD-L1 showed response in canine melanoma. -PU - AGRICULTURAL RESEARCH COMMUNICATION CENTRE -PI - KARNAL -PA - 1130 SADAR BAZAR, POST OFFICE MARG, KARNAL 132 001, INDIA -SN - 0367-6722 -DA - 2021 SEP -PY - 2021 -VL - 55 -IS - 9 -SP - 993 -EP - 998 -DO - 10.18805/ijar.B-4141 -AN - WOS:000711322000001 -AD - ICAR Indian Vet Res Inst, Div Surg, Bareilly 243122, Uttar Pradesh, India -Y2 - 2021-11-08 -ER - - -TY - JOUR -AU - Faehling, Martin -AU - Fallscheer, Sabine -AU - Kramberg, Sebastian -AU - Straeter, Jorn -AU - Eschmann, Susanne -AU - Saetzler, Rainer -AU - Heinzelmann, Frank -TI - Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option -T2 - EUROPEAN JOURNAL OF CANCER -M3 - Article -AB - Background: Recent phase II-III trials of immuno(chemo)therapy before resection in locally advanced resectable non-small cell lung cancer (NSCLC) report high rates of path-ological response and promising survival. However, primarily, patients who did not undergo resection were excluded from these studies. Moreover, there are no data on chemoradiother-apy (CRT) after immuno(chemo)therapy in patients who are primarily not amenable to CRT. We hypothesised that induction immuno(chemo)therapy may enable patients with NSCLC with a potentially curative stage (III-IVA), for whom primary curative treatment (either resection or CRT) is not possible for anatomical or functional reasons, to receive curative treatment. Patients and methods: We enrolled 35 patients with NSCLC with aforementioned characteris-tics into a prospective real-world trial of induction immuno(chemo)therapy followed by morphologic and metabolic reassessment and multidisciplinary board-guide d curative treatment (resection [preferred] or CRT) or palliative therapy. The primary end-point was the proportion of patients receiving curative treatment. Results: Thirty-two patients (91%) received curative treatment (11 resections and 21 CRT). 73% and 64% of patients who underwent resection had a major or complete pathological response, respectively. There were 14 recurrences: 2 (18%) in patients who underwent resection, 9 (43%) in patients who received CRT and 3 (100%) in patients who received palliative therapy (median follow-up 17 months). Eight tumour-related deaths occurred: 5 (24%) in patients who received CRT; and 3 (100%) in patients who received palliative therapy. There were no treatment-related deaths. Conclusions: In locally advanced or oligometastatic NSCLC without a primary curative option, induction immuno(chemo)therapy results in a high rate of curative treatment with promising early survival data. patients who underwent resection achieved a high rate of prognostically favourable pathological response. (c) 2021 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCI LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND -SN - 0959-8049 -SN - 1879-0852 -DA - 2021 OCT -PY - 2021 -VL - 156 -SP - 175 -EP - 186 -DO - 10.1016/j.ejca.2021.07.035 -AN - WOS:000703177400018 -C6 - AUG 2021 -AD - Klinikum Esslingen, Klin Kardiol & Pneumol, Hirschlandstr 97, D-73730 Esslingen, Germany -AD - Inst Pathol, Esslingen, Germany -AD - Marien Hosp, MVZ Nukl Med, Stuttgart, Germany -AD - Klinikum Esslingen, Klin Gefass & Thoraxchirurg, Esslingen, Germany -AD - Klinikum Esslingen, MVZ Strahlentherapie, Esslingen, Germany -M2 - Klinikum Esslingen -M2 - Inst Pathol -M2 - Klinikum Esslingen -M2 - Klinikum Esslingen -Y2 - 2021-10-14 -ER - - -TY - JOUR -AU - Schild, Steven E. -AU - Zhao, Liming -AU - Wampfler, Ason A. -AU - Daniels, Thomas B. -AU - Sio, Terence -AU - Ross, Helen J. -AU - Paripati, Harshita -AU - Marks, Randolph S. -AU - Yi, Joanne -AU - Liu, Han -AU - He, Yanqi -AU - Yang, Ping -TI - Small-cell Lung Cancer in Very Elderly (≥ 80 Years) Patients -T2 - CLINICAL LUNG CANCER -M3 - Article -M3 - Proceedings Paper -CP - 18th Conference of the International-Society-of-Geriatric-Oncology (SIOG) -CL - Amsterdam, NETHERLANDS -AB - This study found that the survival of very elderly (>= 80 years) patients with small-cell lung cancer was associated with stage, performance status, and treatment option. Very elderly patients with small-cell lung cancer are a growing patient population who have not been previously reported on. Future progress will require trials specific to the elderly, integration of immunotherapy, greater supportive care, better geriatric assessment, and less toxic regimens.Background: This analysis was performed to describe the outcome of very elderly (>= 80 years) patients with small-cell lung cancer (SCLC) as there is no published data regarding these patients. Materials and Methods: One hundred forty-six very elderly patients with SCLC were identified from the Institutional Lung Cancer Database ranging in age from 80 to 92 years (median, 82 years). Of these, 47 (32%) patients had limited-stage SCLC (L-SCLC), and 99 (68%) had extensive-stage SCLC (E-SCLC). All were Caucasian, and the majority (64%) were female. Sixty-seven (46%) patients had Zubrod performance status (PS) of 0 to 1. Results: Of the 146 patients, 44 (30%) received no therapy, 65 (45%) received chemotherapy alone, 27 (19%) received chemotherapy plus local therapy (thoracic radiotherapy [TRT] or surgery), and 10 (7%) received local therapy alone. The median survival was 5.4 months. On univariable analysis, age (P = .019), stage (L-SCLC vs. E-SCLC; P = .0002), PS (P < .0001), and treatment option (P <.0001) were associated with survival. On multivariable analysis, stage (P = .011), PS (P = .029), and treatment option (P <.0001) maintained significance. For entire cohort, the median survival was 1.3 months without active therapy, 6 months with local therapy alone, 7.2 months with chemotherapy alone, and 14.4 months with chemotherapy plus local therapy (P <.0001, univariable and multivariable). Similar survival findings in response to treatment were found when the L-SCLC and E-SCLC cohorts were separately analyzed. Conclusions: The survival of very elderly patients with SCLC was associated with stage (L-SCLC vs. E-SCLC), PS, and treatment option. Very elderly patients with SCLC often have limited functional reserve required to tolerate aggressive multimodality therapy but appeared to benefit from it. Geriatric assessments, careful monitoring, and extra support are warranted in elderly patients. Care should be individualized based on the desires and needs of each patient. (C) 2019 Elsevier Inc. All rights reserved. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2019 JUL -PY - 2019 -VL - 20 -IS - 4 -SP - 313 -EP - 321 -DO - 10.1016/j.cllc.2019.05.007 -AN - WOS:000475296800025 -AD - Mayo Clin, Dept Radiat Oncol, 5777 E Mayo Blvd, Phoenix, AZ 85054 USA -AD - Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA -AD - Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA -AD - Mayo Clin, Div Med Oncol, Phoenix, AZ USA -AD - Mayo Clin, Dept Med Oncol, Rochester, MN USA -AD - Mayo Clin, Dept Pathol, Rochester, MN USA -AD - Mayo Clin, Dept Hlth Sci Res, Scottsdale, AZ USA -AD - Jilin Univ, Dept Resp Med, Hosp 1, Changchun, Jilin, Peoples R China -AD - Sichuan Univ, West China Hosp, Dept Resp Med, Chengdu, Sichuan, Peoples R China -Y2 - 2019-07-01 -ER - - -TY - JOUR -AU - Antonia, S. J. -AU - Villegas, A. -AU - Daniel, D. -AU - Baz, D. Vincente -AU - Murakami, S. -AU - Hui, R. -AU - Yokoi, T. -AU - Chiappori, A. -AU - Lee, K. H. -AU - de Wit, M. -AU - Cho, B. C. -AU - Bourhaba, M. -AU - Quantin, X. -AU - Tokito, T. -AU - Mekhail, T. -AU - Planchard, D. -AU - Jiang, H. -AU - Huang, Y. -AU - Dennis, P. A. -AU - Ozguroglu, M. -TI - PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 59th Annual Meeting of the American-Society-for-Therapeutic-Radiation-Oncology (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2017 DEC 1 -PY - 2017 -VL - 99 -IS - 5 -MA - LBA-4 -SP - 1314 -EP - 1315 -DO - 10.1016/j.ijrobp.2017.09.011 -AN - WOS:000416919400051 -AD - H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA -AD - Canc Specialists North Florida, Jacksonville, FL USA -AD - Tennessee Oncol, Chattanooga, TN USA -AD - Sarah Cannon Res Inst, Nashville, TN USA -AD - Hosp Univ Virgen Macarena, Seville, Spain -AD - Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan -AD - Westmead Hosp, Sydney, NSW, Australia -AD - Univ Sydney, Sydney, NSW, Australia -AD - Kansai Med Univ Hosp, Hirakata, Osaka, Japan -AD - Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea -AD - Vivantes Klinikum Neukoelln, Berlin, Germany -AD - Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea -AD - Ctr Hosp Univ Liege, Liege, Belgium -AD - CHU Montpellier, Montpellier, France -AD - ICM Val dAurelle, Montpellier, France -AD - Kurume Univ Hosp, Kurume, Fukuoka, Japan -AD - Florida Hosp, Inst Canc, Orlando, FL USA -AD - Gustave Roussy, Villejuif, France -AD - AstraZeneca, Gaithersburg, MD USA -AD - Istanbul Univ, Cerrahpasa Med Sch, Istanbul, Turkey -M2 - Canc Specialists North Florida -Y2 - 2017-12-14 -ER - - -TY - JOUR -AU - Wiesweg, Marcel -AU - Eberhardt, Wilfried E. -AU - Schuler, Martin -AU - Ploenes, Till -TI - Treatment of early and locally advanced stages of non-small cell lung cancer -T2 - INNERE MEDIZIN -M3 - Review -AB - Treatment concepts for patients with localized and locally advanced non-small cell lung cancer (NSCLC) are based on local treatment, surgery and/or radiotherapy, with curative intent. An adjuvant systemic treatment is added after primary resection of an operable NSCLC primarily to reduce the systemic risk of relapse. Locally advanced stages with mediastinal lymph node involvement carry a substantial risk of local and distant recurrence and require multimodal treatment strategies in an interdisciplinary approach. Recently, immunotherapy with programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) checkpoint inhibitors is increasingly being integrated into adjuvant, neoadjuvant or perioperative treatment concepts. -PU - SPRINGER MEDIZIN -PI - Berlin -PA - Heidelbergerplatz 3, Berlin, GERMANY -SN - 2731-7080 -SN - 2731-7099 -DA - 2022 JUL -PY - 2022 -VL - 63 -IS - 7 -SP - 717 -EP - 723 -DO - 10.1007/s00108-022-01366-0 -AN - WOS:000819250800006 -AD - Univ Duisburg Essen, Univ Klinikum Essen, Innere Klin Tumorforsch, Westdeutsch Tumorzentrum, Hufelandstr 55, D-45147 Essen, Germany -AD - Univ Duisburg Essen, Univ Med Essen, Thorakale Onkol, Westdeutsch Tumorzentrum,Ruhrlandklin, Essen, Germany -AD - Univ Duisburg Essen, Klin Thoraxchirurg & Thorakale Endoskopie, Westdeutsch Tumorzentrum, Univ Med Essen,Ruhrlandklin, Essen, Germany -Y2 - 2022-07-23 -ER - - -TY - JOUR -AU - Welsh, James W. -AU - Heymach, John V. -AU - Chen, Dawei -AU - Verma, Vivek -AU - Cushman, Taylor R. -AU - Hess, Kenneth R. -AU - Shroff, Girish -AU - Tang, Chad -AU - Skoulidis, Ferdinandos -AU - Jeter, Melenda -AU - Menon, Hari -AU - Quynh-Nhu Nguyen -AU - Chang, Joe Y. -AU - Altan, Mehmet -AU - Papadimitrakopoulou, Vassiliki A. -AU - Simon, George R. -AU - Raju, Uma -AU - Byers, Lauren -AU - Glisson, Bonnie -TI - Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer -T2 - JOURNAL OF THORACIC ONCOLOGY -M3 - Article -M3 - Proceedings Paper -CP - 60th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - San Antonio, TX -AB - Intruduction: Radiation and immunotherapy have separately been shown to confer survival advantages to patients with extensive-stage small cell lung cancer (ESCLC), but failure rates remain high and combination therapy has been understudied. In this single-arm phase I trial (NCT02402920), we assessed the safety of combining pembrolizumab with thoracic radiotherapy (TRT) after induction chemotherapy for SCLC.Methods: Patients with ESCLC who had completed chemotherapy received TRT with pembrolizumab. The maximum tolerated dose of pembrolizumab was assessed by 3+3 dose-escalation; doses began at 100 mg and increased in 50 mg increments to 200 mg. Pembrolizumab was given every 3 weeks for up to 16 cycles; TRT was prescribed as 45 Gy in 15 daily fractions. Toxicity was evaluated with the Common Terminology Criteria for Adverse Events v4.0. The primary endpoint was safety of the combined therapy based on the incidence of doselimiting toxicity in the 35 days following initiation of treatment.Results: Thirty-eight patients with ESCLC (median age 65 years, range: 37-79 years) were enrolled from September 2015 through September 2017; 33 received per-protocol treatment, and all tolerated pembrolizumab at 100 to 200 mg with no dose-limiting toxicity in the 35-day window. There were no grade 4-5 toxicities; 2 (6%) patients experienced grade 3 events (n = 1 rash, n = 1 asthenia/paresthesia/autoimmune disorder) that were unlikely/doubtfully related to protocol therapy. The median followup time was 7.3 months (range: 1-13 months); median progression-free and overall survival times were 6.1 months (95% confidence interval: 4.1-8.1) and 8.4 months (95% confidence interval: 6.7-10.1).Conclusions: Concurrent pembrolizumab-TRT was tolerated well with few high-grade adverse events in the short-term; progression-free and overall survival rates are difficult to interpret due to heterogeneity in eligibility criteria (e.g., enrolling progressors on induction chemotherapy). Although randomized studies have shown benefits to TRT alone and immunotherapy alone, the safety of the combined regimen supports further investigation as a foundational approach for future prospective studies. (C) 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1556-0864 -SN - 1556-1380 -DA - 2020 FEB -PY - 2020 -VL - 15 -IS - 2 -SP - 266 -EP - 273 -DO - 10.1016/j.jtho.2019.10.001 -AN - WOS:000509465700018 -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 97,1515 Holcombe Blvd, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Oncol, Houston, TX 77030 USA -AD - Shandong Univ, Shandong Canc Hosp, Dept Radiat Oncol, Jinan, Peoples R China -AD - Alleghany Gen Hosp, Dept Radiat Oncol, Pittsburgh, PA USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA -Y2 - 2020-02-04 -ER - - -TY - JOUR -AU - Jing, Zhao -AU - Zhou, Rongjin -AU - Zhang, Ni -TI - Achievement of long-term local control after radiation and anti-PD-1 immunotherapy in locally advanced non-small cell lung cancer -T2 - THERAPEUTIC ADVANCES IN CHRONIC DISEASE -M3 - Article -AB - Although concurrent chemoradiotherapy (CRT) is recommended as standard of care in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC), many patients who refuse or are not eligible for chemotherapy received radiotherapy (RT) alone with 5-year overall survival (OS) rate of about 5-6%. Immune-checkpoint inhibitors have demonstrated objective antitumor responses in patients with advanced NSCLC, but it is unclear how these agents can be used in the curative therapy with concurrent radiation. We report three cases of stage III unresectable NSCLC patients who refused chemotherapy received radiation and pembrolizumab immunotherapy. All patients had no local-regional recurrence with acceptable tolerance. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 2040-6223 -SN - 2040-6231 -DA - 2021 SEP -PY - 2021 -VL - 12 -C7 - 20406223211047306 -DO - 10.1177/20406223211047306 -AN - WOS:000703269800001 -AD - Zhejiang Hosp, Dept Oncol, 12 Lingyin Rd, Hangzhou 310000, Zhejiang, Peoples R China -AD - Hangzhou Canc Hosp, Dept Pathol, Hangzhou, Peoples R China -AD - Hangzhou Canc Hosp, Dept Radiat Oncol, Hangzhou, Peoples R China -M2 - Zhejiang Hosp -M2 - Hangzhou Canc Hosp -M2 - Hangzhou Canc Hosp -Y2 - 2021-10-11 -ER - - -TY - JOUR -AU - Kim, Dong-Wan -AU - Cho, Byoung Chul -AU - Pachipala, Krishna -AU - Kim, Sang-We -AU - Wang, Chih-Liang -AU - Chang, Gee -Chen -AU - Ahn, Myung-Ju -AU - Alvarez, Rosa -AU - Chiu, Chao-Hua -AU - Trigo, Jose -AU - Estival, Anna -AU - Karam, Sana D. -AU - O'Brien, Cathy -AU - Gowda, Hema -AU - Jiang, Haiyi -AU - Bauman, Julie E. -TI - Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study -T2 - LUNG CANCER -M3 - Article -AB - Introduction: For patients with unresectable, stage III non -small -cell lung cancer (NSCLC), current standard of care is concurrent chemoradiotherapy (cCRT) followed by consolidation durvalumab. However, earlier initiation of durvalumab simultaneously with cCRT may increase antitumor activity relative to initiation after cCRT. The phase 1 CLOVER study (NCT03509012) evaluated durvalumab combined with cCRT in patients with advanced solid tumors; we report findings from the NSCLC cohort. Methods: CLOVER comprised a dose -limiting toxicity (DLT) assessment part, followed by an expansion part. In the NSCLC cohort, patients with previously untreated, unresectable, stage III NSCLC were enrolled in three treatment arms: durvalumab every 4 weeks (Q4W) + cisplatin + etoposide + radiotherapy (Arm 1); durvalumab Q4W + carboplatin + paclitaxel + radiotherapy (Arm 2); or durvalumab Q4W + carboplatin or cisplatin + pemetrexed + radiotherapy (non-squamous histology only; Arm 3). Patients received durvalumab until disease progression or unacceptable toxicity. The primary endpoint was safety and tolerability. Results: Sixty-four patients were enrolled: 21, 22, and 21 in Arms 1, 2, and 3, respectively. One patient in Arm 1 had DLT (grade 3 aspartate aminotransferase increase and grade 4 alanine aminotransferase increase); no DLTs were observed in Arms 2 or 3. Grade 3/4 adverse events occurred in 76.6 % of patients overall; the most common were neutropenia (51.6 %), leukopenia (20.3 %), and anemia (17.2 %). In a post -hoc analysis, 7.8 % of patients had grade 3 pneumonitis/radiation pneumonitis (grouped term) events. Overall, the objective response rate was 60.9 % (95 % confidence interval [CI], 47.9-72.9); median duration of response was 15.8 months (95 % CI, 9.0-not estimable [NE]). Median progression -free survival was 13.4 months (95 % CI, 8.8-20.1) and median overall survival was not reached (95 % CI, 21.9-NE). Conclusion: Durvalumab in combination with cCRT was well tolerated, with a manageable safety profile and showed encouraging antitumor activity in patients with unresectable, stage III NSCLC. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2024 APR -PY - 2024 -VL - 190 -C7 - 107530 -DO - 10.1016/j.lungcan.2024.107530 -AN - WOS:001220847600001 -C6 - MAR 2024 -AD - Seoul Natl Univ, Coll Med, Seoul, South Korea -AD - Seoul Natl Univ Hosp, Seoul, South Korea -AD - Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea -AD - Millenium Oncol, Houston, TX USA -AD - Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea -AD - Chang Gung Med Fdn Linkou, Taoyuan City, Taiwan -AD - Chung Shan Med Univ, Sch Med, Taichung, Taiwan -AD - Chung Shan Med Univ, Inst Med, Taichung, Taiwan -AD - Chung Shan Med Univ Hosp, Dept Internal Med, Div Pulm Med, Taichung, Taiwan -AD - Natl Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan -AD - Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan -AD - Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea -AD - Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain -AD - Taipei Vet Gen Hosp, Taipei, Taiwan -AD - UGC Interctr Oncol Hosp Reg & Virgen de la Victor, Malaga, Spain -AD - Hosp Badalona Germans Trias & Pujol, Barcelona, Spain -AD - Univ Colorado, Anschutz Med Campus, Aurora, CO USA -AD - AstraZeneca, Cambridge, England -AD - AstraZeneca, Gaithersburg, MD USA -AD - Univ Arizona, Canc Ctr, Tucson, AZ USA -AD - Taipei Med Univ Hosp, Taipei Canc Ctr, Taipei, Taiwan -AD - George Washington Univ, Ctr Canc, Washington, DC USA -M2 - Millenium Oncol -M2 - Chang Gung Med Fdn Linkou -M2 - UGC Interctr Oncol Hosp Reg & Virgen de la Victor -M2 - AstraZeneca -Y2 - 2024-05-18 -ER - - -TY - JOUR -AU - Sun, Bochen -AU - Hou, Qing -AU - Liang, Yu -AU - Xue, Shuqin -AU - Yao, Ningning -AU - Wei, Lijuan -AU - Cao, Xin -AU - Li, Hongwei -AU - Si, Hongwei -AU - Cao, Jianzhong -TI - Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer -T2 - BMC CANCER -M3 - Article -AB - Background Lung immune prognostic index (LIPI) is a prognostic marker of extensive-stage small cell lung cancer (ES-SCLC) patients received immunotherapy or chemotherapy. However, its ability in limited-stage SCLC (LS-SCLC) should be evaluated extensively. Methods We retrospectively enrolled 497 patients diagnosed as LS-SCLC between 2015 and 2018, and clinical data included pretreatment lactate dehydrogenase (LDH), white blood cell count, and absolute neutrophil count levels were collected. According to the LIPI scores, the patients were stratified into low-risk (0 points) and high-risk (1-2 points). The correlations between LIPI and overall survival (OS) or progression-free survival (PFS) were analyzed by the Cox regression. Additionally, the propensity score matching (PSM) and inverse probability of treatment weight (IPTW) methods were used to reduce the selection and confounding bias. A nomogram was constructed using on multivariable Cox model. Results Two hundred fifty and 247 patients were in the LIPI high-risk group and low-risk group, and their median OS was 14.67 months (95% CI: 12.30-16.85) and 20.53 months (95% CI: 17.67-23.39), respectively. In the statistical analysis, High-risk LIPI was significantly against worse OS (HR = 1.377, 95%CI:1.114-1.702) and poor PFS (HR = 1.338, 95%CI:1.1-1.626), and the result was similar after matching and compensating with the PSM or IPTW method. A novel nomogram based on LIPI has a decent level of predictive power. Conclusion LIPI stratification was a significant factor against OS or PFS of LS-SCLC patients. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2022 NOV 29 -PY - 2022 -VL - 22 -IS - 1 -C7 - 1233 -DO - 10.1186/s12885-022-10351-7 -AN - WOS:000890303900002 -AD - Shanxi Med Univ, Chinese Acad Med Sci,Canc Hosp, Shanxi Prov Canc Hosp, Dept Radiat Oncol, Zhigongxin St, Taiyuan 030010, Shanxi, Peoples R China -AD - Anhui Med Univ, Dept Nucl Med, Affiliated Hosp 1, Hefei 230022, Anhui, Peoples R China -Y2 - 2022-12-17 -ER - - -TY - JOUR -AU - Petty, W. Jeffrey -AU - Paz-Ares, Luis -TI - Emerging Strategies for the Treatment of Small Cell Lung Cancer A Review -T2 - JAMA ONCOLOGY -M3 - Review -AB - Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by rapid growth and the early development of metastases. Patients typically respond to initial chemotherapy but quickly experience relapse, resulting in a poor long-term outcome. Therapeutic innovations that substantially improve survival have historically been limited, and reliable, predictive biomarkers are lacking.Observations This review examines the biologic characteristics of SCLC, the current treatment landscape, and ongoing efforts to identify novel therapeutic targets. Ongoing research has advanced the understanding of molecular categories and the immunologic microenvironment of SCLC, which in turn has helped improve disease classification and staging. Recently, immunotherapy-based regimens have become available for the management of SCLC, with 2 programmed cell death 1 ligand 1 inhibitors approved in combination with chemotherapy for first-line treatment of extensive-stage disease. For second-line treatment, a novel alkylating agent, lurbinectedin, which inhibits oncogenic transcription, has been approved for use in patients with metastatic SCLC. Furthermore, a wide variety of therapies and innovative combination regimens are being continuously evaluated. Potential therapeutic strategies, including aurora kinase A inhibitors, polyadenosine diphosphate-ribose polymerase inhibitors, ataxia telangiectasia and Rad3-related inhibitors, cyclin-dependent kinase 7 inhibitors, delta-like protein 3 agents, antiganglioside agents, CD47 inhibitors, and lysine-specific histone demethylase 1a inhibitors, are also being examined.Conclusions and Relevance Therapeutic optimization of SCLC remains a challenge, but recent trial results and drug approvals are encouraging. Advances in research have revealed critical information regarding biologic characteristics of the disease, which may lead to the identification of vulnerabilities and the development of new therapies. Further research focused on identifying biomarkers and evaluating innovative therapies will be paramount to improving treatment outcomes for patients with SCLC. -PU - AMER MEDICAL ASSOC -PI - CHICAGO -PA - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA -SN - 2374-2437 -SN - 2374-2445 -DA - 2023 MAR -PY - 2023 -VL - 9 -IS - 3 -SP - 419 -EP - 429 -DO - 10.1001/jamaoncol.2022.5631 -AN - WOS:000929626900006 -C6 - DEC 2022 -AD - Wake Forest Univ, Wake Forest Sch Med, Dept Internal Med, Sect Hematol & Oncol,Comprehens Canc Ctr, Winston Salem, NC USA -AD - Hosp Univ 12 Octubre, Madrid, Spain -AD - H120 CNIO Lung Canc Unit, Madrid, Spain -AD - Univ Complutense Madrid, Ctr Invest Biomed Red Canc, Madrid, Spain -M2 - H120 CNIO Lung Canc Unit -Y2 - 2023-02-28 -ER - - -TY - JOUR -AU - Lee, Gyeong-Won -TI - Current advances in the treatment of lung cancer with immune checkpoint inhibitors -T2 - JOURNAL OF THE KOREAN MEDICAL ASSOCIATION -M3 - Article -AB - Lung cancer is the leading cause of cancer-related deaths worldwide despite major advances in platinum-based chemotherapy and targeted therapy based on activating driving mutations. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigms in lung cancers. When used as a second-line or later treatment for non-small cell lung cancer (NSCLC), ICIs improve overall survival and exhibit better safety profiles than the standard chemotherapeutic agent, docetaxel. In front-line treatment, ICI monotherapy is significantly associated with improved clinical outcomes and fewer adverse events than platinum-based chemotherapy in patients with advanced NSCLC, who express programmed death-ligand 1 in at least 50% of all tumor cells. Moreover, ICIs combined with platinum-based chemotherapy have become the standard first-line treatment for patients with metastatic NSCLC without sensitizing mutations in the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene, regardless of programmed death-ligand 1 expression. Additionally, maintenance treatment using ICIs has also been demonstrated to improve clinical outcomes in patients with stage III unresectable NSCLC following chemoradiotherapy. Recently, the addition of ICIs to chemotherapy as the first-line treatment for extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival compared with chemotherapy alone. Although immune checkpoint inhibitors significantly improved overall survival and showed a durable response in lung cancer compared with platinum-based chemotherapy, we should foster further prospective studies to identify predictive biomarkers to determine those individuals who may benefit more from ICIs. It is also essential to overcome the development of drug resistance in patients treated with ICIs. -PU - KOREAN MEDICAL ASSOC -PI - SEOUL -PA - 302-75 INCHON-1 DONG, YONGSAN-GU, SEOUL, 140-721, SOUTH KOREA -SN - 1975-8456 -SN - 2093-5951 -DA - 2021 MAY -PY - 2021 -VL - 64 -IS - 5 -SP - 333 -EP - 341 -DO - 10.5124/jkma.2021.64.5.333 -AN - WOS:000653681800002 -AD - Gyeongsang Natl Univ, Gyeongsang Natl Univ Hosp, Dept Internal Med, Div Hematol Oncol,Coll Med, Jinju, South Korea -Y2 - 2021-06-05 -ER - - -TY - JOUR -AU - Subbiah, Shanmuga -AU - Nam, Arin -AU - Garg, Natasha -AU - Behal, Amita -AU - Kulkarni, Prakash -AU - Salgia, Ravi -TI - Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research -T2 - JOURNAL OF CLINICAL MEDICINE -M3 - Review -AB - Small cell lung cancer (SCLC) is an aggressive, complex disease with a distinct biology that contributes to its poor prognosis. Management of SCLC is still widely limited to chemotherapy and radiation therapy, and research recruitment still poses a considerable challenge. Here, we review the current standard of care for SCLC and advances made in utilizing immunotherapy. We also highlight research in the development of targeted therapies and emphasize the importance of a team-based approach to make clinical advances. Building an integrative network between an academic site and community practice sites optimizes biomarker and drug target discovery for managing and treating a difficult disease like SCLC. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2077-0383 -DA - 2020 AUG -PY - 2020 -VL - 9 -IS - 8 -C7 - 2433 -DO - 10.3390/jcm9082433 -AN - WOS:000565674200001 -AD - City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA -Y2 - 2020-09-15 -ER - - -TY - JOUR -AU - AWAN, MUSADDIQ -TI - DEHART: Dose-Escalated Hypofractionated Adaptive Radiation Therapy for Head and Neck Cancers -M3 - Awarded Grant -AB - AbstractLocoregional failure remains the principal mode of mortality in head and neck squamous cell carcinomas(HNSCCs) treated with conventional chemoradiation therapy over 7 weeks. Radiation dose escalation withhypofractionation has shown unparalleled local control in many other malignancies, such as non-small cell lungcancer, but has been stymied in HNSCCs due to toxicity concerns. MR-guided radiation therapy (MRgRT)allows for adaptive radiation dose escalation based on tumor response, which may improve therapeuticoutcomes while limiting toxicities.Our proposal, titled Dose-Escalated Hypofractionated Adaptive Radiotherapy (DEHART), evaluates a novelframework for radiation delivery using MRgRT with concurrent PD-1/PD-L1 targeted immunotherapy in patientswith advanced HNSCCs. Unlike conventional radiotherapy, DEHART modifies radiation dose using MRgRT byadapting the radiation plan weekly during the course of treatment, escalating radiation dose to residual tumorwhile deescalating radiation dose to areas of tumor regression. We hypothesize that DEHART will safelydeliver ablative radiation doses in 15 fractions over 3 weeks while limiting both toxicity and the effect of tumorrepopulation by resistant clonogens, thus resulting in an improved therapeutic ratio.We aim to test this hypothesis through a Phase I clinical trial with the following specific aims: (1) Determine themaximum tolerated dose (MTD) of the DEHART regimen delivered using MRgRT with concurrentimmunotherapy in a population of patients who are not candidates or unsuitable for definitive chemoradiationtherapy; (2) Evaluate the toxicity and functional outcomes of the DEHART regimen including changes inbaseline speech, swallow and quality of life; and (3) Assess the efficacy of DEHART and obtain volumetric andfunctional imaging correlates of efficacy using MRgRT to serve as hypothesis-generating data for future trialsof radiation dose adaptation. To determine the MTD of the DEHART regimen, we propose an 18 patient studyusing a modified Time-to Event Continual Reassessment (TITE-CRM) Phase I Design with three radiationdose levels delivered to regressing disease: 50 Gy in 15 fractions, 55 Gy in 15 fractions and 60 Gy in 15fractions.If DEHART is found to be safe and shows a signal of efficacy in this study, we will conduct a future Phase IItrial to compare this novel treatment strategy to standard-of care conventionally fractionated chemoradiation inpatients with locally advanced HNSCCs. -DA - 2022 -PY - 2022 -AN - GRANTS:17434473 -G1 - 10323293; 5R21CA256144-02; R21CA256144 -AD - MEDICAL COLLEGE OF WISCONSIN -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - AWAN, MUSADDIQ -TI - DEHART: Dose-Escalated Hypofractionated Adaptive Radiation Therapy for Head and Neck Cancers -M3 - Awarded Grant -AB - AbstractLocoregional failure remains the principal mode of mortality in head and neck squamous cell carcinomas(HNSCCs) treated with conventional chemoradiation therapy over 7 weeks. Radiation dose escalation withhypofractionation has shown unparalleled local control in many other malignancies, such as non-small cell lungcancer, but has been stymied in HNSCCs due to toxicity concerns. MR-guided radiation therapy (MRgRT)allows for adaptive radiation dose escalation based on tumor response, which may improve therapeuticoutcomes while limiting toxicities.Our proposal, titled Dose-Escalated Hypofractionated Adaptive Radiotherapy (DEHART), evaluates a novelframework for radiation delivery using MRgRT with concurrent PD-1/PD-L1 targeted immunotherapy in patientswith advanced HNSCCs. Unlike conventional radiotherapy, DEHART modifies radiation dose using MRgRT byadapting the radiation plan weekly during the course of treatment, escalating radiation dose to residual tumorwhile deescalating radiation dose to areas of tumor regression. We hypothesize that DEHART will safelydeliver ablative radiation doses in 15 fractions over 3 weeks while limiting both toxicity and the effect of tumorrepopulation by resistant clonogens, thus resulting in an improved therapeutic ratio.We aim to test this hypothesis through a Phase I clinical trial with the following specific aims: (1) Determine themaximum tolerated dose (MTD) of the DEHART regimen delivered using MRgRT with concurrentimmunotherapy in a population of patients who are not candidates or unsuitable for definitive chemoradiationtherapy; (2) Evaluate the toxicity and functional outcomes of the DEHART regimen including changes inbaseline speech, swallow and quality of life; and (3) Assess the efficacy of DEHART and obtain volumetric andfunctional imaging correlates of efficacy using MRgRT to serve as hypothesis-generating data for future trialsof radiation dose adaptation. To determine the MTD of the DEHART regimen, we propose an 18 patient studyusing a modified Time-to Event Continual Reassessment (TITE-CRM) Phase I Design with three radiationdose levels delivered to regressing disease: 50 Gy in 15 fractions, 55 Gy in 15 fractions and 60 Gy in 15fractions.If DEHART is found to be safe and shows a signal of efficacy in this study, we will conduct a future Phase IItrial to compare this novel treatment strategy to standard-of care conventionally fractionated chemoradiation inpatients with locally advanced HNSCCs. -DA - 2021 -PY - 2021 -AN - GRANTS:15578969 -G1 - 10110912; 1R21CA256144-01; R21CA256144 -AD - MEDICAL COLLEGE OF WISCONSIN -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Yeh, Justin -AU - Marrone, Kristen A. -AU - Forde, Patrick M. -TI - Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer -T2 - JOURNAL OF THORACIC DISEASE -M3 - Review -AB - Lung cancer continues to be the leading cause of cancer death worldwide. Recently, immunotherapy for non-small cell lung cancer (NSCLC) has emerged as a powerful treatment option for advanced lung cancer. The relative success of programmed death 1 (PD-1) and/or programmed death ligand 1 (PD-L1) antibodies in metastatic disease have increased interest in expanding their use to earlier stage NSCLC. The complex and diverse nature of stage III disease also invites the incorporation of immunotherapy into treatment plans in both the neoadjuvant and consolidation settings. Currently available data of anti-PD-(L)1 therapies in stage III NSCLC are limited. However, interim results from two studies are encouraging: a phase II neoadjuvant nivolumab trial demonstrated early signals of efficacy, and the phase III PACIFIC trial of durvalumab recently showed significant improvement in progression-free survival (PFS). Preliminary results for the phase II DETERRED trial of durvalumab have also been reported. Many studies are testing anti-PD-(L)1 therapies in the neoadjuvant and consolidation settings for stage III NSCLC, and will be discussed. As these studies mature they may provide further treatment options in management of stage III NSCLC. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2018 FEB -PY - 2018 -VL - 10 -SP - S451 -EP - S459 -DO - 10.21037/jtd.2018.01.109 -AN - WOS:000427730600007 -AD - Augusta Univ, Med Coll Georgia, Augusta, GA USA -AD - Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Upper Aerodigest Malignancies Div, 1650 Orleans St, Baltimore, MD 21287 USA -Y2 - 2018-12-28 -ER - - -TY - JOUR -AU - Loureiro, Hugo -AU - Roller, Andreas -AU - Schneider, Meike -AU - Talavera-Lopez, Carlos -AU - Becker, Tim -AU - Bauer-Mehren, Anna -TI - Matching by OS Prognostic Score to Construct External Controls in Lung Cancer Clinical Trials -T2 - CLINICAL PHARMACOLOGY & THERAPEUTICS -M3 - Article -AB - External controls (eControls) leverage historical data to create non-randomized control arms. The lack of randomization can result in confounding between the experimental and eControl cohorts. To balance potentially confounding variables between the cohorts, one of the proposed methods is to match on prognostic scores. Still, the performance of prognostic scores to construct eControls in oncology has not been analyzed yet. Using an electronic health record-derived de-identified database, we constructed eControls using one of three methods: ROPRO, a state-of-the-art prognostic score, or either a propensity score composed of five (5Vars) or 27 covariates (ROPROvars). We compared the performance of these methods in estimating the overall survival (OS) hazard ratio (HR) of 11 recent advanced non-small cell lung cancer. The ROPRO eControls had a lower OS HR error (median absolute deviation (MAD), 0.072, confidence interval (CI): 0.036-0.185), than the 5Vars (MAD 0.081, CI: 0.025-0.283) and ROPROvars eControls (MAD 0.087, CI: 0.054-0.383). Notably, the OS HR errors for all methods were even lower in the phase III studies. Moreover, the ROPRO eControl cohorts included, on average, more patients than the 5Vars (6.54%) and ROPROvars cohorts (11.7%). The eControls matched with the prognostic score reproduced the controls more reliably than propensity scores composed of the underlying variables. Additionally, prognostic scores could allow eControls to be built on many prognostic variables without a significant increase in the variability of the propensity score, which would decrease the number of matched patients. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0009-9236 -SN - 1532-6535 -DA - 2024 FEB -PY - 2024 -VL - 115 -IS - 2 -SP - 333 -EP - 341 -DO - 10.1002/cpt.3109 -AN - WOS:001111450900001 -C6 - NOV 2023 -AD - Roche Innovat Ctr Munich RICM, Pharmaceut Res & Early Dev, Data & Analyt, Penzberg, Germany -AD - Helmholtz Munich, Comprehens Pneumol Ctr, Munich, Germany -AD - Tech Univ Munich, TUM Sch Life Sci Weihenstephan, Freising Weihenstephan, Germany -AD - Roche Innovat Ctr Basel RICB, Early Dev Oncol Pharm Res & Early Dev, Basel, Switzerland -M2 - Roche Innovat Ctr Munich RICM -M2 - Helmholtz Munich -M2 - Roche Innovat Ctr Basel RICB -Y2 - 2023-12-16 -ER - - -TY - JOUR -AU - Ying, Xixi -AU - You, Guangxian -AU - Shao, Rongjun -TI - The analysis of the efficacy and safety of stereotactic body radiotherapy with sequential immune checkpoint inhibitors in the management of oligoprogressive advanced non-small cell lung cancer -T2 - TRANSLATIONAL CANCER RESEARCH -M3 - Article -AB - Background: No standardized treatment strategy exists for managing oligoprogression during maintenance therapy in driver -negative advanced non -small cell lung cancer (NSCLC). Similarly, a uniform response to oligoprogression during maintenance therapy using immune checkpoint inhibitors (ICIs) has not been established. Consequently, our investigation focused on assessing the efficacy and safety of employing stereotactic total body radiotherapy in conjunction with ICIs to address oligoprogression in advanced NSCLC. Methods: We conducted a retrospective analysis of patients diagnosed with driver -negative advanced NSCLC who received stereotactic body radiotherapy (SBRT) in combination with ICIs to manage oligoprogressive lesions within the period from October 2018 to October 2023 at our institution. Oligoprogression, defined as progression occurring in three or fewer disease sites, was the focus of our investigation. Our assessment encompassed various parameters including the local control rate (LCR), progression-free survival post-oligoprogression (PFS-P), overall survival post-oligoprogression (OS -P), progression-free survival (PFS), overall survival (OS), and the safety profile associated with SBRT followed by sequential ICIs after oligoprogression. Results: A total of 15 patients were enrolled in this study, all at stage IV, with 12 (80%) receiving a diagnosis of adenocarcinoma. Before oligoprogression, 11 (73.3%) patients had undergone immunotherapy. Following the treatment of oligoprogressed lung cancer with SBRT sequential ICIs, the median PFS-P and OS -P were 8 months (95% CI: 2.7-13.3) and 12 months (95% CI: 7.3-16.7), respectively. Additionally, the median PFS and OS were 26 months (95% CI: 8.0-44.0) and 30 months (not reached), respectively. The median local control (LC) of 15 oligoprogressed lesions was 13 months (95% CI: 5.3-20.2), with a 1 -year LCR of 77.9%. Notably, patients with a performance status (PS) score of less than 2 demonstrated a more favorable survival benefit. Conclusions: Stereotactic systemic radiation therapy, combined with sequential ICIs, enhances both LC and survival in advanced NSCLC characterized by oligoprogression and negative driver gene mutations. This approach also exhibits the potential to postpone the transition between systemic chemotherapy regimens. Manageable adverse reactions were observed, with the absence of grade 4 reactions. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-676X -SN - 2219-6803 -DA - 2024 MAY -PY - 2024 -VL - 13 -IS - 5 -SP - 2408 -EP - 2418 -DO - 10.21037/tcr-23-2232 -AN - WOS:001261741900003 -AD - Taizhou Canc Hosp, Dept Radiol & Oncol, Taizhou, Peoples R China -AD - Taizhou Key Lab Minimally Invas Intervent & Big Da, Taizhou, Peoples R China -M2 - Taizhou Canc Hosp -M2 - Taizhou Key Lab Minimally Invas Intervent & Big Da -Y2 - 2024-09-09 -ER - - -TY - JOUR -AU - Yavas, Guler -AU - Yavas, Cagdas -TI - Thoracic radiotherapy for extensive-stage small-cell lung cancer: what is the optimal dose and timing? -T2 - JOURNAL OF RADIATION ONCOLOGY -M3 - Review -AB - Small-cell lung cancer (SCLC) is a neuroendocrine tumor that represents about 12-20% of all lung cancers. Most of the SCLC patients present with extensive-stage (ES) disease. Primary therapy for ES-SCLC is 4-6 cycles of platinum-based chemotherapy (CT) followed by prophylactic cranial irradiation (PCI) in selected cases. Although the response rate to CT is approximately 60-70%, median survival times are very limited. The main problem of ES-SCLC patients after CT is intra-thoracic tumor recurrence since 75% of the patients had persisting intra-thoracic disease after CT, and approximately 90% of the patients had intra-thoracic progressive disease within the first year after diagnosis. Such high rate of intra-thoracic disease progression explains the need of local treatment in selected patients. There are three randomized studies and two meta-analyses evaluating the role of thoracic radiotherapy (TRT) in patients with ES-SCLC who responded to CT. Two of the randomized trials and one of the meta-analyses showed survival benefit of TRT. According to the results of relevant studies, the patients who responded to CT and have intra-thoracic residual disease after CT, who had limited metastatic sites (<= 2), and who have good performance status and limited weight loss have more benefit from TRT. We need novel studies evaluating the optimal dose fractionation schedules, optimal timing of RT, impact of time interval between RT and CT, immunotherapy and RT combinations, and number of CT cycles. -PU - SPRINGER HEIDELBERG -PI - HEIDELBERG -PA - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY -SN - 1948-7894 -SN - 1948-7908 -DA - 2019 SEP -PY - 2019 -VL - 8 -IS - 3 -SP - 251 -EP - 258 -DO - 10.1007/s13566-019-00406-x -AN - WOS:000494069300001 -C6 - OCT 2019 -AD - Selcuk Univ, Fac Med, Dept Radiat Oncol, TR-42075 Konya, Turkey -Y2 - 2019-11-18 -ER - - -TY - JOUR -AU - Yan, Bo -AU - Hooper, D. Craig -AU - Yuan, Zhiyong -AU - Wang, Changli -AU - Chen, Yulong -AU - Lu, Bo -TI - Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade -T2 - CANCER IMMUNOLOGY RESEARCH -M3 - Article -AB - Concurrent PD-1 blockade and thoracic radiotherapy is being investigated in clinical trials for locally advanced, non-small cell lung cancer and small cell lung cancer, despite a potential overlapping risk of cardiotoxicity. Our prior studies demonstrate that cardiotoxicity from concurrent cardiac irradiation and anti- PD-1 administration in a mouse model is CD8+ T-cell dependent. The objective of this study was to determine whether humoral immunity contributed to the observed cardiac tissue damage, as measured by creatine kinase MB and cardiac troponin 1 release and decline in cardiac function. In the current study, we demonstrate the presence of cardiac autoantibodies, which were essential for the occurrence of cardiotoxicity from the combined therapy. Mice subjected to cardiac irradiation, while being treated with anti-PD-1, developed high levels of antibodies that reacted with cardiac tissues in vivo and cardiac antigens in vitro. More-over, mice deficient in B cells were protected against cardiotoxi-city, whereas the transfer of autoantibody-containing sera from mice that had received combined treatment reproduced the same pathologic phenotype in mice exposed to cardiac irradiation but was not observed in normal recipients. The cardiotoxic effect of the sera, which associated with CD8+ T-cell accumulation in cardiac tissue, was limited by IgG depletion. In conclusion, concurrent cardiac irradiation and PD-1 blockade leads to production of cardiac autoantibodies, likely due to antigen exposure within the irradiated cardiac tissues, which play a key role in the resulting cardiotoxicity. -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 2326-6066 -SN - 2326-6074 -DA - 2023 APR -PY - 2023 -VL - 11 -IS - 4 -SP - 546 -EP - 555 -DO - 10.1158/2326-6066.CIR-21-0839 -AN - WOS:000967333300001 -AD - Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China -AD - Thomas Jefferson Univ, Dept Pharmacol Physiol & Canc Biol, Philadelphia, PA USA -AD - Tianjin Med Univ Canc Inst, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Lung Canc, Tianjin, Peoples R China -AD - Univ Missouri Columbia, Dept Radiat Oncol, Columbia, MO USA -AD - Univ Missouri Columbia, Dept Radiat Oncol, Columbia, MO 65257 USA -M2 - Tianjin Med Univ Canc Inst -Y2 - 2023-04-22 -ER - - -TY - JOUR -AU - Eberhardt, W -AU - Bildat, S -AU - Korfee, S -TI - Combined modality therapy in NSCLC -T2 - ANNALS OF ONCOLOGY -M3 - Article -PU - KLUWER ACADEMIC PUBL -PI - DORDRECHT -PA - SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS -SN - 0923-7534 -DA - 2000 -PY - 2000 -VL - 11 -SP - 85 -EP - 95 -AN - WOS:000090112800014 -AD - Univ Essen Gesamthsch, Sch Med, Dept Internal Med Canc Res, Essen, Germany -Y2 - 2000-01-01 -ER - - -TY - JOUR -AU - Filippi, Andrea Riccardo -AU - Di Muzio, Jacopo -AU - Badellino, Serena -AU - Mantovani, Cristina -AU - Ricardi, Umberto -TI - Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance? -T2 - JOURNAL OF THORACIC DISEASE -M3 - Review -AB - Locally advanced non-small cell lung cancer (NSCLC) represents approximately one third of presentations at diagnosis. Most patients are judged non-surgical due to disease extension, and chemo-radiotherapy still represents the standard therapeutic option, with unsatisfactory results in terms of overall survival (OS) despite advances in staging and radiation therapy planning and delivery. Immunotherapy, and in particular immune-checkpoint inhibitors targeting the PD-1/PD-L1 axis, gained wide popularity for NSCLC in light of the positive findings of several trials in metastatic disease. Stage III unresectable NSCLC is a remarkably interesting setting for the combined use of chemo-radiation and immunotherapy, also considering the multiple experimental evidences in favor of a synergistic effect between radiation and immune checkpoint inhibitors, with the potential of enhancing immuno-modulating effects and overcoming resistance. We here summarized the biological rationale and the initial clinical experiences testing for this combination, and we briefly discussed ongoing trials and future options in this field. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2018 MAY -PY - 2018 -VL - 10 -SP - S1461 -EP - S1467 -DO - 10.21037/jtd.2017.12.53 -AN - WOS:000433411200005 -AD - Univ Torino, Dept Oncol, Regione Gonzole 10, I-10043 Turin, Italy -AD - Citta Salute & Sci Univ Hosp, Radiat Oncol Dept, Turin, Italy -Y2 - 2018-06-12 -ER - - -TY - JOUR -AU - Alexander, Mariam -AU - Ko, Brian -AU - Lambert, Remy -AU - Gadgeel, Shirish -AU - Halmos, Balazs -TI - The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer -T2 - EXPERT REVIEW OF RESPIRATORY MEDICINE -M3 - Article -AB - Introduction: The immune checkpoint inhibitor, pembrolizumab, has revolutionized the treatment of non-small cell lung cancer (NSCLC). It is currently approved and widely used in patients with advanced NSCLC whose tumors have no EGFR or ALK genomic aberrations that express PD-L1 as single-agent treatment and irrespective of PD-L1 expression in combination with platinum-based doublet chemotherapy in the first-line setting. Areas covered: The authors have reviewed articles discussing pembrolizumab and NSCLC in MEDLINE between July 2013 to August 2019 and focus on recent advances in combining pembrolizumab with chemotherapy, radiotherapy and other novel agents in various stages of NSCLC. Expert opinion: Although pembrolizumab has revolutionized the treatment of advanced NSCLC, only a subset of patients benefit from single-agent therapy. Numerous trials combining pembrolizumab with chemotherapy and radiation have shown benefit and a large spectrum of novel combination strategies are being explored for improved synergies. In addition to PD-L1 tumor proportion score, validation of other biomarkers would be beneficial in stratifying patients and improving the predictive value of combining immune check point inhibitors and chemotherapy. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1747-6348 -SN - 1747-6356 -DA - 2020 FEB 1 -PY - 2020 -VL - 14 -IS - 2 -SP - 137 -EP - 147 -DO - 10.1080/17476348.2020.1702526 -AN - WOS:000503138700001 -C6 - DEC 2019 -AD - Albert Einstein Coll Med, Montefiore Med Ctr, Dept Oncol, Bronx, NY 10467 USA -AD - Univ Michigan, Sch Med, Dept Med, Div Oncol, Ann Arbor, MI 48104 USA -Y2 - 2019-12-31 -ER - - -TY - JOUR -AU - Saalfeld, Felix Carl -AU - Wermke, Martin -TI - Gegenwärtiger Einsatz und aktuelle Entwicklungen der Immuncheckpointinhibition beim metastasierten und lokalisierten kleinzelligen Lungenkarzinom -T2 - ONKOLOGIE -M3 - Review -AB - Small cell lung cancer (SCLC) is characterized by aggressive proliferation kinetics, early development of distant metastasis, and an overall dismal prognosis. Addition of the PD-L1 antibodies atezolizumab and durvalumab to platinum-/etoposide-based chemotherapy improves overall survival and represents the first change in therapeutic standards for almost 30 years in metastasized SCLC (stage IV or extensive disease [ED] according to the Veterans Administration Lung Study Group [VALG]). Although the numeric gains in median overall survival are limited (approximately 3 months), the addition of a PD-L1 antibody led to a clinically relevant increase in 3-year overall survival from 5.8 to 17.6%. Therefore, anti-PD-L1-based immunochemotherapy represents the current standard for ED-SCLC and should be applied irrespective of PD-L1 expression and other biomarkers. Standard of care in curatively treatable SCLC limited to the hemithorax (limited stage [LD] according to VALG) remains is accelerated concurrent chemoradiotherapy. The recently presented findings of the ADRIATIC study demonstrate a benefit from consolidation therapy with the PD-L1 antibody durvalumab. A corresponding expansion of the drug's approval can be expected. In conclusion, treatment of SCLC remains a challenge and improvements in therapeutic standards are much slower than those seen in NSCLC. -PU - SPRINGER HEIDELBERG -PI - HEIDELBERG -PA - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY -SN - 2731-7226 -SN - 2731-7234 -DA - 2024 SEP -PY - 2024 -VL - 30 -IS - 9 -SP - 801 -EP - 808 -DO - 10.1007/s00761-024-01566-3 -AN - WOS:001273147800001 -C6 - JUL 2024 -AD - Univ Klinikum Carl Gustav Carus, TU Dresden Med Fak, NCT UCC Early Clin Trial Unit Med Klin 1, Fetscherstr 74, D-01307 Dresden, Germany -Y2 - 2024-07-28 -ER - - -TY - JOUR -AU - Katakura, Seigo -AU - Murakami, Shuji -TI - Clinically-meaningful improvements in therapy for unresectable NSCLC -T2 - EXPERT REVIEW OF ANTICANCER THERAPY -M3 - Review -AB - Introduction The ideal management of patients with unresectable non-small-cell lung cancer (NSCLC) is still developing. Unresectable NSCLC has a high mortality rate and poor prognosis. The development of immune checkpoint inhibitors (ICIs) and molecular-targeted therapies has been a breakthrough in the treatment. The correct treatment of this patient population is crucial to maximize the clinical benefits without compromising quality of life (QOL). Areas covered We review the chemoradiotherapies, cytotoxic chemotherapies, immunotherapies, and molecular-targeted therapies available for unresectable NSCLC, focusing on their effects on overall survival, progression-free survival, and QOL. Expert opinion Although cure is the ultimate goal of cancer treatment, it is often difficult to achieve in advanced NSCLC. Biomarker surveillance techniques, such as next-generation sequencing, have made it possible to provide the most appropriate treatment for each patient. This has led to clinically-meaningful improvements in therapies for unresectable NSCLC. The development of new molecular-targeted therapies and the establishment of treatment for patients who acquired drug resistance after initial treatment have a positive impact on patients' long-term survival. ICIs lead the long-term survival that can be considered a cure of some patients with advanced NSCLC, but such curative survival is difficult to achieve with cytotoxic chemotherapies and molecular-targeted therapies. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1473-7140 -SN - 1744-8328 -DA - 2022 SEP 2 -PY - 2022 -VL - 22 -IS - 9 -SP - 927 -EP - 937 -DO - 10.1080/14737140.2022.2102483 -AN - WOS:000828985900001 -C6 - JUL 2022 -AD - Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan -Y2 - 2022-07-29 -ER - - -TY - JOUR -AU - Huang, Huei-Tyng -TI - Parallel explorations in LA-NSCLC: Chemoradiation dose-response optimisation considering immunotherapy and cardiac toxicity sparing -T2 - RADIOTHERAPY AND ONCOLOGY -M3 - Article -AB - Background and purpose: Chemoradiotherapy (CRT) for locally-advanced non-small cell lung cancer (LA-NSCLC) has undergone advances, including increased overall survival (OS) when combined with immune checkpoint blockade (ICB), and using cardiac-sparing techniques to reduce the radiotoxicity. This research investigated 1) how radiotherapy schedules can be optimised with CRT-ICB schemes, and 2) how cardiac-sparing might change the OS for concurrent CRT (cCRT). Methods and materials: Survival data and dosimetric indices were sourced from published studies, with 2-year OS standardised and the hazard ratio of mean heart dose (MHD) against radiotoxicity tabulated in purpose. A published CRT dose-response model was selected, then modified with ICB and cardiac-sparing hypotheses. Models were maximum likelihood fitted, then visualised the prediction outcomes after bootstrapping. Results: The modelled 2-year OS rate of cCRT-ICB reached 71 % (95 % confidence intervals, CI 62 %, 84 %) and 66 % (95 % CI: 53 %, 81 %) for stage IIIA and IIIB/C, respectively, given 60 Gy in 2 Gy-per-fraction. 60 Gy in 30 fractions remained the best schedule for cCRT-ICB, whereas modest dose de-escalation to 55 Gy only reduced the OS in 2 %. Sequential CRT (sCRT)-ICB provided 6 % OS increases versus the best OS rate achieved by sCRT alone. Photon MHD-sparing achieved a 5-10 % increase in modelled 2-year OS, with protons providing a further roughly 5-10 % increase. Conclusion: Neither dose-escalation nor de-escalation relative to 60 Gy in 30 fractions influenced the survival with cCRT-ICB, while 5 Gy dose de-escalation might benefit patients with heavily irradiated organs at risk. Cardiac-sparing improved OS, and protons provided advantages for tumours anatomically overlapped or lay below the heart. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0167-8140 -SN - 1879-0887 -DA - 2024 NOV -PY - 2024 -VL - 200 -C7 - 110477 -DO - 10.1016/j.radonc.2024.110477 -AN - WOS:001298049400001 -C6 - AUG 2024 -AD - UCL, Dept Med Phys & Biomed Engn, London, England -Y2 - 2024-09-10 -ER - - -TY - JOUR -AU - Taunk, Neil K. -AU - Rimner, Andreas -AU - Culligan, Melissa -AU - Friedberg, Joseph S. -AU - Brahmer, Julie -AU - Chaft, Jamie -TI - Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Non-small cell lung cancer (NSCLC) is the most common cause of cancer mortality. Although a significant proportion of patients can be cured with surgery, with or without adjuvant or neoadjuvant chemotherapy and radiation, a significant proportion of patients will fail, particularly distantly. Over fifty percent of patients present with stage IV disease. There are multiple forms of immunotherapy available including T-cell transfer, cytokine therapy, and oncolytic viruses. Checkpoint inhibitors have shown tremendous activity in NSCLC and are currently under intense study given promising data on response. Immunotherapy and radiation therapy (RT) both show significant immune editing activity in NSCLC that may allow the innate and adaptive immune system to help control systemic disease by both radiosensitization and a sustained systemic immune response. Multiple clinical trials are underway exploring the role of adjuvant or neoadjuvant immunotherapy in operable NSCLC. A substantial amount of progress is to be made in terms of optimizing radiation dose and fractionation, immunotherapy type and dose, and integrating both to best realize the benefits of immunotherapy and radiation in operable lung cancer. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2017 APR -PY - 2017 -VL - 6 -IS - 2 -SP - 178 -EP - 185 -DO - 10.21037/tlcr.2017.03.05 -AN - WOS:000403489800008 -AD - Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA -AD - Univ Maryland, Sch Med, Dept Surg, Div Thorac Surg, Baltimore, MD 21201 USA -AD - Johns Hopkins Univ, Thorac Oncol Program, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA -AD - Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA -AD - Weill Cornell Med Coll, New York, NY USA -Y2 - 2017-04-01 -ER - - -TY - JOUR -AU - Azar, Ibrahim -AU - Yazdanpanah, Omid -AU - Jang, Hyejeong -AU - Austin, Adam -AU - Kim, Seongho -AU - Chi, Jie -AU - Alkassis, Samer -AU - Saha, Biplab K. -AU - Chopra, Amit -AU - Neu, Kristoffer -AU - Mehdi, Syed -AU - Mamdani, Hirva -TI - Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans -T2 - JAMA NETWORK OPEN -M3 - Article -AB - IMPORTANCE The current standard of care for the treatment of small cell lung cancer (SCLC) is concurrent chemoradiation for patients with limited-stage SCLC (LS-SCLC) and chemoimmunotherapy for extensive-stage SCLC (ES-SCLC). The backbone of chemotherapy regimens in both is a platinum-etoposide doublet: cisplatin is traditionally the preferred platinum agent in the curative intent setting, whereas carboplatin is preferred in ES-SCLC because of its favorable toxicity profile.OBJECTIVE To determine whether cisplatin is associated with better survival outcomes than carboplatin in treating LS-SCLC and ES-SCLC.DESIGN, SETTING, AND PARTICIPANTS In this cohort study, data were compiled from the National Veterans Affairs Central Cancer Registry for patients with SCLC who received platinum-based multiagent chemotherapy between 2000 and 2020 for ES-SCLC and 2000 and 2021 for LS-SCLC. Only patients with pathologically confirmed cases of LS-SCLC who received concurrent chemoradiation and ES-SCLC who received chemotherapy were included.MAIN OUTCOMES AND MEASURES The primary end point was overall survival (OS). The secondary end points included OS by Eastern Cooperative Oncology Group performance status, age, and laterality. Interval-censored Weibull and Cox proportional hazard regression models were used to estimate median OS and hazard ratios (HRs), respectively. Survival curves were compared by a Wald test.RESULTS A total of 4408 SCLC cases were studied. Most patients were White (3589 patients [81.4%]), male (4252 [96.5%]), and non-Hispanic (4142 [94.0%]); 2262 patients (51.3%) were 60 to 69 years old, followed by 1476 patients (33.5%) aged 70 years or older, 631 patients (14.3%) aged 50 to 59 years, and 39 patients (0.9%) aged 30 to 49 years. Among 2652 patients with ES-SCLC, 2032 were treated with carboplatin-based therapy and 660 received cisplatin; the median OS was 8.45 months (95% CI, 7.75-9.20 months) for cisplatin and 8.51 months (95% CI, 8.07-8.97 months) for carboplatin (HR, 1.01; 95% CI, 0.91-1.12; P = .90). Subset analysis showed no survival difference between the 2 agents in different age or performance status groups except for patients aged 70 years and older, for whom the median OS was 6.36 months (95% CI, 5.31-7.56 months) for cisplatin and 8.47 months (95% CI, 7.79-9.19 months) for carboplatin (HR, 0.77; 95% CI, 0.61-0.96; P = .02). Multivariable analysis of performance status and age did not show a significant difference in survival between the 2 groups (HR, 0.96; 95% CI, 0.83-1.10; P = .54). Of 1756 patients with LS-SCLC, 801 received carboplatin, and 1018 received cisplatin. The median OS was 26.92 months (95% CI, 25.03-28.81 months) for cisplatin and 25.58 months (95% CI, 23.64-27.72 months) for carboplatin (HR, 1.04; 95% CI, 0.94-1.16; P = .46). The median OS was not significantly different between 2 agents according to cancer stage (I-III), performance status, and age groups. A multivariable analysis of factors associated with OS accounting for stage (I-III), performance status, and age did not demonstrate a significant difference in survival between carboplatin and cisplatin in patients with LS-SCLC (HR, 0.995; 95% CI, 0.86-1.15; P = .95).CONCLUSIONS AND RELEVANCE Cisplatin is not associated with a survival advantage over carboplatin among patients with either ES-SCLC or LS-SCLC, irrespective of performance status and age. The favorable toxicity profile of carboplatin and comparable OS support its use in both LS-SCLC and ES-SCLC in clinical practice and may allow more room for combination with novel treatment strategies in clinical trials. -PU - AMER MEDICAL ASSOC -PI - CHICAGO -PA - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA -SN - 2574-3805 -DA - 2022 OCT 20 -PY - 2022 -VL - 5 -IS - 10 -C7 - e2237699 -DO - 10.1001/jamanetworkopen.2022.37699 -AN - WOS:000870802500010 -AD - Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Oncol, Detroit, MI USA -AD - IHA Hematol Oncol, Pontiac, MI USA -AD - Univ Florida, Div Pulm & Crit Care Med, Gainesville, FL USA -AD - Albany Med Ctr, Div Pulm & Crit Care Med, Albany, NY USA -AD - Albany Vet Affairs Med Ctr, Div Pulm & Crit Care Med, Albany, NY USA -AD - Albany Vet Affairs Med Ctr, Div Med Oncol, Albany, NY USA -M2 - IHA Hematol Oncol -M2 - Albany Vet Affairs Med Ctr -M2 - Albany Vet Affairs Med Ctr -Y2 - 2022-11-04 -ER - - -TY - JOUR -AU - Dickhoff, Chris -AU - Senan, Suresh -AU - Schneiders, Famke L. -AU - Veltman, Joris -AU - Hashemi, Sayed -AU - Daniels, Johannes M. A. -AU - Fransen, Marieke -AU - Heineman, David J. -AU - Radonic, Teodora -AU - van de Ven, Peter M. -AU - Bartelink, Imke H. -AU - Meijboom, Lilian J. -AU - Garcia-Vallejo, Juan J. -AU - Oprea-Lager, Daniela E. -AU - de Gruijl, Tanja D. -AU - Bahce, Idris -TI - Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial -T2 - BMC CANCER -M3 - Article -AB - Background The likelihood of a tumor recurrence in patients with T3-4N0-1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due distant metastases. As pathological complete responses (pCR) in resected specimens are seen in only a minority (28-38%) of patients following chemoradiotherapy, we designed the INCREASE trial (EudraCT-Number: 2019-003454-83; Netherlands Trial Register number: NL8435) to assess if pCR rates could be further improved by adding short course immunotherapy to induction chemoradiotherapy. Translational studies will correlate changes in loco-regional and systemic immune status with patterns of recurrence.Methods/design This single-arm, prospective phase II trial will enroll 29 patients with either resectable, or borderline resectable, T3-4N0-1 NSCLC. The protocol was approved by the institutional ethics committee. Study enrollment commenced in February 2020.On day 1 of guideline-recommended concurrent chemoradiotherapy (CRT), ipilimumab (IPI, 1 mg/kg IV) and nivolumab (NIVO, 360 mg flat dose IV) will be administered, followed by nivolumab (360 mg flat dose IV) after 3 weeks. Radiotherapy consists of once-daily doses of 2 Gy to a total of 50 Gy, and chemotherapy will consist of a platinum-doublet. An anatomical pulmonary resection is planned 6 weeks after the last day of radiotherapy. The primary study objective is to establish the safety of adding IPI/NIVO to pre-operative CRT, and its impact on pathological tumor response. Secondary objectives are to assess the impact of adding IPI/NIVO to CRT on disease free and overall survival. Exploratory objectives are to characterize tumor inflammation and the immune contexture in the tumor and tumor-draining lymph nodes (TDLN), and to explore the effects of IPI/NIVO and CRT and surgery on distribution and phenotype of peripheral blood immune subsets.Discussion The INCREASE trial will evaluate the safety and local efficacy of a combination of 4 modalities in patients with resectable, T3-4N0-1 NSCLC. Translational research will investigate the mechanisms of action and drug related adverse events. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2020 AUG 14 -PY - 2020 -VL - 20 -IS - 1 -C7 - 764 -DO - 10.1186/s12885-020-07263-9 -AN - WOS:000563403500005 -AD - Univ Amsterdam, Med Ctr, Dept Surg & Cardiothorac Surg, Locat VUmc,Canc Ctr Amsterdam, de Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands -AD - Univ Amsterdam, Canc Ctr Amsterdam, Dept Radiat Oncol, Locat VUmc,Med Ctr, de Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands -AD - Univ Amsterdam, Locat VUmcCanc Ctr Amsterdam, Dept Pulm Dis, Med Ctr, de Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands -AD - Univ Amsterdam, Canc Ctr Amsterdam, Dept Pathol, Locat VUmc,Med Ctr, de Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands -AD - Univ Amsterdam, Canc Ctr Amsterdam, Dept Epidemiol & Biostat, Locat VUmc,Med Ctr, de Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands -AD - Univ Amsterdam, Canc Ctr Amsterdam, Dept Clin Pharmacol & Pharm, Locat VUmc,Med Ctr, de Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands -AD - Univ Amsterdam, Canc Ctr Amsterdam, Dept Radiol & Nucl Med, Locat VUmc,Med Ctr, de Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands -AD - Univ Amsterdam, Canc Ctr Amsterdam, Dept Mol Cell Biol & Immunol, Locat VUmc,Med Ctr, de Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands -AD - Univ Amsterdam, Canc Ctr Amsterdam, Dept Med Oncol, Locat VUmc,Med Ctr, de Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands -Y2 - 2020-09-10 -ER - - -TY - JOUR -AU - AISNER, J -AU - WHITACRE, M -AU - VANECHO, DA -AU - WESLEY, M -AU - WIERNIK, PH -TI - DOXORUBICIN, CYCLOPHOSPHAMIDE AND VP16-213 (ACE) IN THE TREATMENT OF SMALL CELL LUNG-CANCER -T2 - CANCER CHEMOTHERAPY AND PHARMACOLOGY -M3 - Article -PU - SPRINGER VERLAG -PI - NEW YORK -PA - 175 FIFTH AVE, NEW YORK, NY 10010 -SN - 0344-5704 -DA - 1982 -PY - 1982 -VL - 7 -IS - 2-3 -SP - 187 -EP - 193 -AN - WOS:A1982NN92700023 -Y2 - 1982-01-01 -ER - - -TY - JOUR -AU - Guven, Deniz Can -AU - Sahin, Taha Koray -AU - Kilickap, Saadettin -TI - The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer -T2 - CANCERS -M3 - Review -AB - Background: After the success of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC), the benefit of neoadjuvant chemoimmunotherapy was compared with chemotherapy for localized NSCLC in several trials. However, the available studies had variable study designs, and study cohorts had limited follow-up times. Therefore, we conducted a systematic review and meta-analysis to evaluate the benefit of adding immunotherapy to neoadjuvant chemotherapy in patients with localized NSCLC. Methods: We conducted a systematic review using Pubmed, Web of Science, and Scopus databases for studies published until 5 December 2023. This protocol was registered in the PROSPERO database (Registration Number: CRD42023466337). We performed the meta-analyses with the generic inverse-variance method with a fixed effects model. Results: Overall, 7 studies encompassing 2993 patients were included in the analyses. The use of neoadjuvant chemoimmunotherapy was associated with a 41% reduction in the risk of progression or death compared to neoadjuvant chemotherapy (HR: 0.59, 95% CI: 0.52-0.66, p < 0.0001) and a lower risk of death (HR: 0.67, 95% CI: 0.55-0.82, p < 0.0001). The neoadjuvant chemoimmunotherapy improved pCR rates compared to chemotherapy (21.8% vs. 3.8%, OR: 7.04, 95% CI: 5.23-9.47, p < 0.0001), while high-grade adverse events were higher with neoadjuvant chemoimmunotherapy (OR: 1.18, 95% CI: 1.02-1.36, p = 0.0300). Conclusions: The available evidence demonstrates a statistically significant and clinically meaningful event-free survival benefit and possibly an overall survival benefit with neoadjuvant chemoimmunotherapy with a slight increase in high-grade toxicities. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2024 JAN -PY - 2024 -VL - 16 -IS - 1 -C7 - 156 -DO - 10.3390/cancers16010156 -AN - WOS:001139752900001 -AD - Elazig City Hosp, Hlth Sci Univ, Med Oncol Clin, TR-23280 Elazig, Turkiye -AD - Sultanhanı Hosp, Internal Med Clin, TR-68000 Aksaray, Turkiye -AD - Istinye Univ, Dept Med Biol, Fac Med, TR-34010 Istanbul, Turkiye -M2 - Sultanhanı Hosp -Y2 - 2024-01-26 -ER - - -TY - JOUR -AU - Zimmerman, Stefan -AU - Das, Arundhati -AU - Wang, Shuhang -AU - Julian, Ricklie -AU - Gandhi, Leena -AU - Wolf, Juergen -TI - 2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer -T2 - JOURNAL OF THORACIC ONCOLOGY -M3 - Review -AB - SCLC remains an aggressive, deadly cancer with only modest effect on survival from standard chemotherapy. However, with the advent of immunotherapy and comprehensive genomic and transcriptomic profiling, multiple new targets are showing promise in the clinical arena, and just recently programmed death ligand 1 inhibition has been shown to improve the efficacy of standard chemotherapy in extended-disease SCLC. Our increasing understanding of the interactions between different pathways will enable more tailored immunotherapy and targeted therapies based on specific biomarkers and rational combinations. Here we discuss the preclinical and clinical strides in 2017 and 2018 that put us on the threshold of a new era in therapeutics and will, it is hoped, translate into significant improvements in survival. (C) 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1556-0864 -SN - 1556-1380 -DA - 2019 MAY -PY - 2019 -VL - 14 -IS - 5 -SP - 768 -EP - 783 -DO - 10.1016/j.jtho.2019.01.022 -AN - WOS:000465298700017 -AD - Lausanne Univ Hosp, Oncol Dept, Serv Immunooncol, Lausanne, Switzerland -AD - NYU, Langone Hlth, New York, NY USA -AD - Peking Univ Canc Hosp, Beijing, Peoples R China -AD - Laura & Isaac Perlmutter Canc Ctr, New York, NY USA -AD - NYU, Sch Med, New York, NY USA -AD - Univ Clin Koln, Ctr Integrated Oncol Koln Bonn, Cologne, Germany -M2 - Laura & Isaac Perlmutter Canc Ctr -Y2 - 2019-05-15 -ER - - -TY - JOUR -AU - Cruz-Chamorro, R. J. -AU - Rishi, A. -AU - Liveringhouse, C. -AU - Bryant, J. M. M. -AU - Perez, B. A. -AU - Rosenberg, S. A. -AU - Dilling, T. J. -TI - Real World Rates and Predictive Factors of Pneumonitis in Advanced, Non-Resectable NSCLC Treated with Concurrent Chemoradiation and Durvalumab -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - ELECTR NETWORK -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2022 NOV 1 -PY - 2022 -VL - 114 -IS - 3 -MA - 2829 -SP - E370 -EP - E370 -AN - WOS:000892639301156 -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL USA -AD - Univ S Florida, Tampa, FL USA -AD - Miami Canc Inst, Miami, FL USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL USA -M2 - Miami Canc Inst -Y2 - 2023-03-09 -ER - - -TY - JOUR -AU - Young, Robert W. C. -AU - Rodriguez, Gustavo R. -AU - Kucera, John -AU - Carrera, Daniel -AU - Antevil, Jared L. -AU - Trachiotis, Gregory D. -TI - Molecular Markers, Immune Therapy, and Non-Small Cell Lung Cancer-State-of-the-Art Review for Surgeons -T2 - JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES -M3 - Article -AB - Background: Lung cancer is a leading cause of cancer deaths in the United States. An increasing understanding of relevant non-small cell lung cancer (NSCLC) biomarkers has led to the recent development of molecular-targeted therapies and immune checkpoint inhibitors that have revolutionized treatment for patients with advanced and metastatic disease. The purpose of this review is to provide surgeons with a state-of-the-art understanding of the current medical and surgical treatment trends and their implications in the future of management of NSCLC.Materials and Methods: A systematic search of PubMed was conducted to identify English language articles published between January 2010 and March 2024 focusing on molecular markers, tumor targeting, and immunotherapy in the diagnosis and treatment of NSCLC. Case series, observational studies, randomized trials, guidelines, narrative reviews, systematic reviews, and meta-analyses were included.Results: There is now increasing data to suggest that molecular-targeted therapies and immune therapies have a role in the neoadjuvant setting. Advances in intraoperative imaging allow surgeons to perform increasingly parenchymal-sparing lung resections without compromising tumor margins. Liquid biopsies can noninvasively detect targetable mutations in cancer cells and DNA from a blood draw, potentially allowing for earlier diagnosis, personalized therapy, and long-term monitoring for disease recurrence.Conclusions: The management of NSCLC has advanced dramatically in recent years fueled by a growing understanding of the cancer biology of NSCLC. Advances in medical therapies, surgical techniques, and diagnostic and surveillance modalities continue to evolve but have already impacted current treatment strategies for NSCLC, which are encompassed in this review. -PU - MARY ANN LIEBERT, INC -PI - NEW ROCHELLE -PA - 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA -SN - 1092-6429 -SN - 1557-9034 -DA - 2024 SEP 1 -PY - 2024 -VL - 34 -IS - 9 -SP - 786 -EP - 797 -DO - 10.1089/lap.2024.0164 -AN - WOS:001251670500001 -C6 - JUN 2024 -AD - George Washington Univ Hosp, Dept Surg, Washington, DC USA -AD - Walter Reed Natl Mil Med Ctr, Dept Surg, Bethesda, MD USA -AD - Washington DC Vet Affairs Med Ctr, Div Cardiothorac Surg, 50 Irving St NW, Washington, DC 20422 USA -AD - Washington DC Vet Affairs Med Ctr, Heart Ctr, 50 Irving St NW, Washington, DC 20422 USA -M2 - Washington DC Vet Affairs Med Ctr -M2 - Washington DC Vet Affairs Med Ctr -Y2 - 2024-06-27 -ER - - -TY - JOUR -AU - De Ruysscher, Dirk -AU - Ramalingam, Suresh -AU - Urbanic, James -AU - Gerber, David E. -AU - Tan, Daniel S. W. -AU - Cai, Junliang -AU - Li, Ang -AU - Peters, Solange -TI - CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - Introduction: The 5 year survival rate for patients with locally advanced non-small-cell lung cancer (NSCLC) not amenable for definitive resection with historical standard-of-care concurrent chemoradiotherapy (cCRT) ranges from 15% to 32%. cCRT primes anti-tumor immunity and also upregulates programmed death ligand-1 (PD-L1), providing a rationale for combining an immune checkpoint inhibitor with cCRT to improve outcomes. In the PACIFIC trial, consolidation therapy with the PD-L1 inhibitor durvalumab improved progression-free survival (PFS) and overall survival (OS) vs. placebo in patients with stage III NSCLC who did not have disease progression after cCRT. CheckMate73L (NCT04026412), a randomized phase 3 study, evaluates the efficacy of nivolumab plus cCRT followed by nivolumab with or without ipilimumab vs. cCRT followed by durvalumab for untreated, stage III NSCLC. Patients and Methods: Patients with untreated, stage III NSCLC will be randomized 1:1:1 to nivolumab plus cCRT followed by nivolumab in combination with ipilimumab (Arm A) or nivolumab alone (Arm B); or cCRT followed by durvalumab (Arm C). Primary endpoints are PFS and OS (Arm A vs. Arm C). Secondary endpoints include additional analyses of PFS and OS (Arm A vs. Ar m B; Ar m B vs. Ar m C), as well as objective response rate, complete response rate, time to response, duration of response, time to death or distant metastases, and safety and tolerability. Recruitment began on August 20, 2019, and the estimated primary completion date is October 17, 2022. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2022 MAY -PY - 2022 -VL - 23 -IS - 3 -SP - E264 -EP - E268 -DO - 10.1016/j.cllc.2021.07.005 -AN - WOS:000799215100025 -C6 - MAY 2022 -AD - Maastricht Univ Med Ctr, GROW Sch Oncol & Dev Biol, Dept Radiat Oncol Maastro, Doctor Tanslaan 12, NL-6229 ET Maastricht, Netherlands -AD - Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA -AD - Univ Calif San Diego, Dept Radiat Med & Appl Sci, La Jolla, CA 92093 USA -AD - Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Div Hematol Oncol, Dallas, TX 75390 USA -AD - Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore -AD - Bristol Myers Squibb, Oncol Clin Dev Biometr & Data Sci, Lawrenceville, NJ USA -AD - Lausanne Univ, Ctr Hosp Univ Vaudois CHUV, Oncol Dept, Lausanne, Switzerland -Y2 - 2022-06-03 -ER - - -TY - JOUR -AU - Ko, Eric C. -AU - Raben, David -AU - Formenti, Silvia C. -TI - The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer -T2 - CLINICAL CANCER RESEARCH -M3 - Review -AB - Five-year survival rates for non-small cell lung cancer (NSCLC) range from 14% to 49% for stage I to stage IIIA disease, and are <5% for stage IIIB/IV disease. Improvements have been made in the outcomes of patients with NSCLC due to advancements in radiotherapy (RT) techniques, the use of concurrent chemotherapy with RT, and the emergence of immunotherapy as first-and second-line treatment in the metastatic setting. RT remains the mainstay treatment in patients with inoperable early-stage NSCLC and is given concurrently or sequentially with chemotherapy in patients with locally advanced unresectable disease. There is emerging evidence that RT not only provides local tumor control but also may influence systemic control. Multiple preclinical studies have demonstrated that RT induces immunomodulatory effects in the local tumor microenvironment, supporting a synergistic combination approach with immunotherapy to improve systemic control. Immunotherapy options that could be combined with RT include programmed cell death-1/programmed cell death ligand-1 blockers, as well as investigational agents such as OX-40 agonists, toll-like receptor agonists, indoleamine 2,3-dioxygenase-1 inhibitors, and cytokines. Here, we describe the rationale for the integration of RT and immunotherapy in patients with NSCLC, present safety and efficacy data that support this combination strategy, review planned and ongoing studies, and highlight unanswered questions and future research needs. (C) 2018 AACR. -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 1078-0432 -SN - 1557-3265 -DA - 2018 DEC 1 -PY - 2018 -VL - 24 -IS - 23 -SP - 5792 -EP - 5806 -DO - 10.1158/1078-0432.CCR-17-3620 -AN - WOS:000452374700003 -AD - Weill Cornell Med, Dept Radiat Oncol, New York, NY USA -AD - Univ Colorado Anschutz Med Campus, Dept Radiat Oncol, Aurora, CO USA -Y2 - 2018-12-28 -ER - - -TY - JOUR -AU - Krug, LM -AU - Grant, SC -AU - Miller, VA -AU - Ng, KK -AU - Kris, MG -TI - Strategies to eradicate minimal residual disease in small cell lung cancer: High-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination -T2 - SEMINARS IN ONCOLOGY -M3 - Review -PU - W B SAUNDERS CO-ELSEVIER INC -PI - PHILADELPHIA -PA - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA -SN - 0093-7754 -SN - 1532-8708 -DA - 1999 OCT -PY - 1999 -VL - 26 -IS - 5 -SP - 55 -EP - 61 -AN - WOS:000083572200011 -AD - Cornell Univ, Mem Sloan Kettering Canc Ctr, Coll Med, Dept Med,Thorac Oncol Serv,Div Solid Tumor Oncol, New York, NY 10021 USA -Y2 - 1999-10-01 -ER - - -TY - JOUR -AU - Berkowitz, A. C. -AU - Bodner, W. R., III -AU - Cheng, H. -AU - Halmos, B. -AU - Ohri, N. -TI - Definitive Radiotherapy without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Modern Experience -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 61st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - Chicago, IL -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2019 SEP 1 -PY - 2019 -VL - 105 -IS - 1 -MA - 3138 -SP - E496 -EP - E496 -DO - 10.1016/j.ijrobp.2019.06.1405 -AN - WOS:000485671501424 -AD - Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10467 USA -AD - Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA -AD - Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA -Y2 - 2019-09-30 -ER - - -TY - JOUR -AU - Cortiula, F. -AU - Reymen, B. -AU - Peters, S. -AU - Van Mol, P. -AU - Wauters, E. -AU - Vansteenkiste, J. -AU - De Ruysscher, D. -AU - Hendriks, L. E. L. -TI - Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches -T2 - ANNALS OF ONCOLOGY -M3 - Review -AB - The standard of care for patients with stage III non-small-cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT) followed by 1 year of adjuvant durvalumab. Despite the survival benefit granted by immunotherapy in this setting, only 1/3 of patients are alive and disease free at 5 years. Novel treatment strategies are under development to improve patient outcomes in this setting: different anti-programmed cell death protein 1/programmed death-ligand 1 [anti-PD-(L)1] antibodies after CCRT, consolidation immunotherapy after sequential chemoradiotherapy, induction immunotherapy before CCRT and immunotherapy concurrent with CCRT and/or sequential chemoradiotherapy. Cross-trial comparison is particularly challenging in this setting due to the different timing of immunotherapy delivery and different patients' inclusion and exclusion criteria. In this review, we present the results of clinical trials investigating immune therapy in unresectable stage III NSCLC and discuss in-depth their biological rationale, their pitfalls and potential benefits. Particular emphasis is placed on the potential mechanisms of synergism between chemotherapy, radiation therapy and different monoclonal antibodies, and how this affects the tumor immune microenvironment. The designs and questions tackled by ongoing clinical trials are also discussed. Last, we address open questions and unmet clinical needs, such as the necessity for predictive biomarkers (e.g. radiomics and circulating tumor DNA). Identifying distinct subsets of patients to tailor anticancer treatment is a priority, especially in a heterogeneous disease such as stage III NSCLC. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 0923-7534 -SN - 1569-8041 -DA - 2022 SEP -PY - 2022 -VL - 33 -IS - 9 -SP - 893 -EP - 908 -DO - 10.1016/j.annonc.2022.06.013 -AN - WOS:000860748300005 -C6 - SEP 2022 -AD - Maastricht Univ, GROW Sch Oncol & Reprod, Med Ctr, Dept Radiat Oncol Maastro, Maastricht, Netherlands -AD - Udine Univ Hosp, Dept Med Oncol, Udine, Italy -AD - Lausanne Univ Hosp, Oncol Dept, Lausanne, Switzerland -AD - Univ Hosp KU Leuven, Dept Resp Dis KU Leuven, Resp Oncol Unit, Leuven, Belgium -AD - Maastricht Univ, GROW Sch Oncol & Reprod, Med Ctr, Dept Pulm Dis, Maastricht, Netherlands -Y2 - 2022-10-15 -ER - - -TY - JOUR -AU - Huynh, Caroline -AU - Walsh, Logan A. -AU - Spicer, Jonathan D. -TI - Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Surgery is the standard of care for patients with operable non-small cell lung cancer (NSCLC). However, as a single modality, surgery for early stage or locally advanced NSCLC remains associated with high rates of local and distant recurrence. The addition of neoadjuvant or adjuvant chemotherapy has modestly improved outcomes. While systemic therapy paired with surgery for other malignancies such as breast cancer have resulted in far better outcomes for equivalent stage designations, outcome improvements for operable NSCLC have lagged in part as a result of trials where adjuvant chemotherapy seemed to incur harm for stage IA patients and only modest survival benefit for stage IB-IIIA patients (AJCC 7th ed.). In recent years, immunotherapy for NSCLC has emerged as a systemic therapy with significant benefit over traditional chemotherapy regimens. These advances with immune checkpoint inhibitors (ICIs) have opened the door to administering peri-operative immunotherapy for operable NSCLC. As a result, a great multitude of studies investigating the use of immunotherapy in combination with surgery for NSCLC as well as several other malignancies have emerged. In this review, we outline the rationale for neoadjuvant immunotherapy in the treatment of operable NSCLC and summarize the available evidence that include preoperative ICI as a single modality or in combination with systemic agents and/or radiotherapy. Further, we summarize how such treatment trajectories open multiple unique windows of opportunity for scientific discovery and potential therapeutic gains for these vulnerable patients. -PU - AME PUBL CO -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2021 JAN -PY - 2021 -VL - 10 -IS - 1 -SP - 563 -EP - 580 -DO - 10.21037/tlcr-20-509 -AN - WOS:000616118200031 -AD - McGill Univ, Hlth Ctr, Res Inst, Montreal, PQ, Canada -AD - McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ, Canada -AD - McGill Univ, Dept Human Genet, Montreal, PQ, Canada -AD - McGill Univ, Div Thorac & Upper Gastrointestinal Surg, Dept Surg, Montreal, PQ, Canada -Y2 - 2021-03-16 -ER - - -TY - JOUR -AU - Belluomini, Lorenzo -AU - Dionisi, Valeria -AU - Palmerio, Silvia -AU - Vincenzi, Sofia -AU - Avancini, Alice -AU - Casali, Miriam -AU - Riva, Silvia Teresa -AU - Menis, Jessica -AU - Mazzarotto, Renzo -AU - Pilotto, Sara -AU - Milella, Michele -TI - Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - Background: Improvement in radiotherapy techniques and expected outcomes, as well as in understanding the underlying biological mechanisms contributing to its action (immunomodulation in primis), led to the integration of this therapeutical approach in the current management of advanced non-small cell lung cancer (NSCLC), not only in oncogene-driven tumors, but also in non-oncogene addicted NSCLC where the combination of platinum-based chemotherapy plus pembrolizumab represents nowadays the pivotal strategy. In this light, we have designed a randomized phase II (ESPERa) trial to evaluate the efficacy and safety of adding Stereotactic Body Radiotherapy (SBRT) to pembrolizumab-pemetrexed maintenance in advanced NSCLC patients experiencing disease response or stability after chemo-immunotherapy induction. Patients and Methods: Advanced non-oncogene addicted NSCLC patients with ECOG performance status of 0 or 1, who obtained disease response or stability after 4 cycles of platinum-based chemotherapy plus pembrolizumab will be randomized 2:1 to receive pembrolizumab-pemetrexed maintenance plus SBRT vs pembrolizumab-pemetrexed alone. The primary endpoint is progression-free survival (PFS). Concomitant translational researches will be performed to identify potential prognostic and/or predictive biomarkers, as well as to analyze and monitor tumour microenvironment and tumor-host interactions. Conclusions: Although available data suggest the safety and efficacy of combining immunotherapy and radiotherapy, their systematic integration in the current first-line landscape still remains to be explored. If the pre-planned endpoints of the ESPERa trial will be achieved, the addition of SBRT to pembrolizumab-pemetrexed maintenance as a strategy to consolidate and ideally improve the awaited benefit could be considered as a promising strategy in NSCLC undergoing first-line therapy, as well as an interesting approach to be evaluated in other disease setting, as well as in other oncological malignancies where immunotherapy represents nowadays the standard-of-care. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2022 MAY -PY - 2022 -VL - 23 -IS - 3 -SP - E269 -EP - E272 -DO - 10.1016/j.cllc.2021.07.004 -AN - WOS:000799215100026 -C6 - MAY 2022 -AD - Univ Verona, Dept Med, Sect Oncol, Sch Med, Verona, Italy -AD - Verona Univ Hosp Trust, Verona, Italy -AD - Univ Verona, Dept Surg & Oncol, Sect Radiotherapy, Sch Med, Verona, Italy -AD - Univ Verona Hosp Trust, Dept Med, Biomed Clin & Expt Sci, Verona, Italy -Y2 - 2022-06-03 -ER - - -TY - JOUR -AU - Wang, Bin -AU - Cui, Enhai -AU - Lu, Huadong -AU - Li, Xiaoyong -TI - Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on human non-small cell lung cancer through EGFR signaling pathway -T2 - INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY -M3 - Article -AB - The death rates of lung cancer have ranked first in the world. Many patients are at advanced stage when diagnosed; therefore, they miss optimal operative period. And some patients cannot endure radiotherapy or chemotherapy. The present study investigated the antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on human non small cell lung cancer (NSCLC) and the potential underlying mechanisms. Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells suppressed the cell proliferation, increased the cytotoxicity, induced the apoptosis and promoted caspase-3/9 activities in NSCLC. Meanwhile, the effects of cocultured dendritic cells and cytokine-induced killer cells suppressed the protein expression of TGF-beta, inhibited IL-4 activity, enhanced IL-10 and PGE-2 activities and activated the protein expression of IFN-gamma and suppressed EGFR protein expression of NSCLC. This study provides a theoretical and experimental basis for clinical immunotherapy using the effect of cocultured dendritic cells and cytokine-induced killer cells on NSCLC through activating of caspases, IL-10 activity, PGE-2, IFN-gamma and EGFR expression, and suppression of IL-4 activity and TGF-beta protein expression. -PU - E-CENTURY PUBLISHING CORP -PI - MADISON -PA - 40 WHITE OAKS LN, MADISON, WI 53711 USA -SN - 1936-2625 -DA - 2016 -PY - 2016 -VL - 9 -IS - 11 -SP - 10906 -EP - 10913 -AN - WOS:000392059400006 -AD - Cent Hosp Huzhou, Dept Resp Med, Huzhou 313000, Zhejiang, Peoples R China -Y2 - 2017-02-15 -ER - - -TY - JOUR -AU - Sebastian, Martin -AU - Papachristofilou, Alexandros -AU - Weiss, Christian -AU - Fruh, Martin -AU - Cathomas, Richard -AU - Hilbe, Wolfgang -AU - Wehler, Thomas -AU - Rippin, Gerd -AU - Koch, Sven D. -AU - Scheel, Birgit -AU - Fotin-Mleczek, Mariola -AU - Heidenreich, Regina -AU - Kallen, Karl-Josef -AU - Gnad-Vogt, Ulrike -AU - Zippelius, Alfred -TI - Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer -T2 - BMC CANCER -M3 - Article -AB - Background: Advanced non-small cell lung cancer (NSCLC) represents a significant unmet medical need. Despite advances with targeted therapies in a small subset of patients, fewer than 20% of patients survive for more than two years after diagnosis. Cancer vaccines are a promising therapeutic approach that offers the potential for durable responses through the engagement of the patient's own immune system. CV9202 is a self adjuvanting mRNA vaccine that targets six antigens commonly expressed in NSCLC (NY-ESO-1, MAGEC1, MAGEC2, 5 T4, survivin, and MUC1).Methods/Design: The trial will assess the safety and tolerability of CV9202 vaccination combined with local radiation designed to enhance immune responses and will include patients with stage IV NSCLC and a response or stable disease after first-line chemotherapy or therapy with an EGFR tyrosine kinase inhibitor. Three histological and molecular subtypes of NSCLC will be investigated (squamous and non-squamous cell with/without EGFR mutations). All patients will receive two initial vaccinations with CV9202 prior to local radiotherapy (5 GY per day for four successive days) followed by further vaccinations until disease progression. The primary endpoint of the study is the number of patients experiencing Grade >3 treatment-related adverse events. Pharmacodynamic analyses include the assessment of immune responses to the antigens encoded by CV9202 and others not included in the panel (antigen spreading) and standard efficacy assessments.Discussion: RNActive self-adjuvanted mRNA vaccines offer the potential for simultaneously inducing immune responses to a wide panel of antigens commonly expressed in tumors. This trial will assess the feasibility of this approach in combination with local radiotherapy in NSCLC patients. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2014 OCT 6 -PY - 2014 -VL - 14 -C7 - 748 -DO - 10.1186/1471-2407-14-748 -AN - WOS:000343257500001 -AD - Goethe Univ Frankfurt, Dept Hematol & Oncol, D-60054 Frankfurt, Germany -AD - Univ Basel Hosp, Dept Radiat Oncol, CH-4031 Basel, Switzerland -AD - Goethe Univ Frankfurt, Dept Radiat Therapy & Oncol, D-60054 Frankfurt, Germany -AD - Kantonsspital St Gallen, Dept Med Oncol & Hematol, St Gallen, Switzerland -AD - Kantonsspital Graubunden, Chur, Switzerland -AD - Univ Innsbruck Hosp, Dept Gen Internal Med, A-6020 Innsbruck, Austria -AD - Univ Hosp Mainz, Dept Internal Med 3, Mainz, Germany -AD - Rippin Consulting, Solingen, Germany -AD - CureVac GmbH, Tubingen, Germany -AD - Univ Basel Hosp, Dept Oncol, CH-4031 Basel, Switzerland -M2 - Rippin Consulting -Y2 - 2014-11-12 -ER - - -TY - JOUR -AU - Merlotti, Anna -AU - Bruni, Alessio -AU - Borghetti, Paolo -AU - Ramella, Sara -AU - Scotti, Vieri -AU - Trovo, Marco -AU - Chiari, Rita -AU - Lohr, Frank -AU - Ricardi, Umberto -AU - Bria, Emilio -AU - Pappagallo, Giovanni L. -AU - D'Angelillo, Rolando M. -AU - Arcangeli, Stefano -TI - Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) -T2 - RADIOLOGIA MEDICA -M3 - Review -AB - Introduction Almost 30% of non-small cell lung cancer (NSCLC) patients have locally advanced-stage disease. In this setting, definitive radiotherapy concurrent to chemotherapy plus adjuvant immunotherapy (cCRT + IO) is the standard of care, although only 40% of these patients are eligible for this approach. Aims A comparison between cCRT and hypofractionated radiotherapy regimens (hypo-fx RT) with the addition of sequential chemotherapy (sCHT) could be useful for future combinations with immunotherapy. We developed a recommendation about the clinical question of whether CHT and moderately hypo-fx RT are comparable to cCRT for locally advanced NSCLC Materials and methods The panel used GRADE methodology and the Evidence to Decision (EtD) framework. After a systematic literature search, five studies were eligible. We identified the following outcomes: progression-free survival (PFS), overall survival (OS), freedom from locoregional recurrence (FFLR), deterioration of quality of life (QoL), treatment-related deaths, severe G3-G4 toxicity, late pulmonary toxicity G3-G4, and acute esophageal toxicity G3-G4. Results The probability of OS and G3-G4 late lung toxicity seems to be worse in patients submitted to sCHT and hypo-fx RT. The panel judged unfavorable the balance benefits/harms. Conclusions The final recommendation was that sCHT followed by moderately hypo-fx RT should not be considered as an alternative to cCRT in unresectable stage III NSCLC patients. -PU - SPRINGER-VERLAG ITALIA SRL -PI - MILAN -PA - VIA DECEMBRIO, 28, MILAN, 20137, ITALY -SN - 0033-8362 -SN - 1826-6983 -DA - 2021 AUG -PY - 2021 -VL - 126 -IS - 8 -SP - 1117 -EP - 1128 -DO - 10.1007/s11547-021-01362-8 -AN - WOS:000647550600006 -C6 - MAY 2021 -AD - S Croce & Carle Teaching Hosp, Dept Radiat Oncol, Via M Coppino 26, I-12100 Cuneo, Italy -AD - Univ Hosp Modena, Dept Hematol & Oncol, Radiotherapy Unit, Modena, Italy -AD - Spedali Civili Hosp, Dept Radiat Oncol, Ist Radio O Alberti, Brescia, Italy -AD - Brescia Univ, Brescia, Italy -AD - Campus Biomed Univ, Dept Radiat Oncol, Rome, Italy -AD - Azienda Osped Univ Careggi, Radiotherapy Unit V Scotti, Thorac Surg Unit L Voltolini, Florence, Italy -AD - Azienda Sanit Univ Integrata UD, Dept Radiat Oncol, Udine, Italy -AD - Osped Riuniti Padova Sud, Med Oncol, Padua, Italy -AD - AOU Modena, Dept Oncol, Radiotherapy Unit, Modena, Italy -AD - Univ Torino, Dept Oncol, Turin, Italy -AD - Univ Cattolica Sacro Cuore, Ctr Comprehens Canc, Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy -AD - Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy -AD - Policlin S Gerardo, Dept Radiat Oncol, Milan, Italy -AD - Univ Milano Bicocca, Milan, Italy -M2 - S Croce & Carle Teaching Hosp -M2 - Azienda Sanit Univ Integrata UD -M2 - Osped Riuniti Padova Sud -M2 - AOU Modena -M2 - Policlin S Gerardo -Y2 - 2021-05-23 -ER - - -TY - JOUR -AU - Lamy, Deborah -AU - Mouillot, Pierre -AU - Mariet, Anne-Sophie -AU - Barnestein, Robby -AU - Quilot, Fleur-Marie -AU - Fraisse, Clea -AU - Ghiringhelli, Francois -AU - Bonniaud, Philippe -AU - Zouak, Ayoube -AU - Foucher, Pascal -TI - Real-world comparison of chemo-immunotherapy and chemotherapy alone in the treatment of extensive-stage small-cell lung cancer -T2 - RESPIRATORY MEDICINE AND RESEARCH -M3 - Article -AB - Introduction: Small cell lung cancer (SCLC) is a high-grade neuroendocrine carcinoma responsible for 200,000 deaths per year worldwide. Platinum-etoposide-based chemotherapy has been the standard of treatment for the past 40 years, with an overall survival of 10 months. Since 2019, the addition of immunotherapy (atezolizumab or durvalumab) to chemotherapy has become the standard of care for first-line treatment of extensive-stage SCLC following the demonstration of an improvement in overall survival in phase 3 studies. We aimed to evaluate the efficacy and safety of chemo-immunotherapy compared with chemotherapy alone in a "real-world" setting. Methods: Retrospective observational study including patients undergoing first-line treatment for extensivestage SCLC between 2014 and 2022. We separated the study population into two arms (chemo-immunotherapy/chemotherapy). For each arm, progression-free survival (PFS), overall survival (OS) and serious side effects were collected. Associations between treatments and survival outcomes were adjusted for potential confounders. Consolidative palliative thoracic radiotherapy was introduced in the models as a time-dependent variable. Results: A total of 118 patients with a median age of 63 years were included. 65.2 % of patients were performance status 0 or 1. In univariate analysis, PFS and OS were not significantly different between the chemoimmunotherapy and chemotherapy alone groups (p = 0.70 and 0.24 respectively). In multivariate analysis, the addition of immunotherapy to chemotherapy was not significantly associated with better PFS (HR 0.76, IC (0.49 - 1.19), p = 0.23), but it was significantly associated with better OS (HR 0.61, IC (0.38 - 0.98), p = 0.04). Consolidative palliative thoracic radiotherapy (time-dependent variable), when applied (almost only in the chemotherapy alone group), was significantly associated with better PFS and OS. Discussion: In this real-world study, chemo-immunotherapy was associated with slightly better OS compared to chemotherapy alone as a first-line treatment in ES-SCLC patients in multivariate analysis, which is not explained by a benefit in PFS. However, consolidative palliative thoracic radiotherapy seems to be significantly associated with better OS and PFS, suggesting that we should also consider using it in patients receiving chemo-immunotherapy. (c) 2024 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) -PU - ELSEVIER -PI - BRIDGEWATER -PA - 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA -SN - 2590-0412 -DA - 2024 NOV -PY - 2024 -VL - 86 -C7 - 101125 -DO - 10.1016/j.resmer.2024.101125 -AN - WOS:001275824200001 -AD - Hop Dijon Bourgogne, Serv Oncol Thorac, Dijon, France -AD - Hop Dijon Bourgogne, Serv Pneumol & Soins Intens Resp, Dijon, France -AD - Univ Burgundy, Fac Med & Pharm, Dijon, France -AD - CHU Dijon Bourgogne, Serv Biostat & Informat Med, Dijon, France -AD - Univ Bourgogne, CHU Dijon Bourgogne, INSERM, CIC 1432,Module Epidemiol Clin, Dijon, France -AD - CHU Dijon Bourgogne, ResAM, Dijon, France -AD - INSERM, Labex LIPST, U1231, CTM, Paris, France -AD - Ligue Natl Canc, Label Excellence, Paris, France -M2 - Hop Dijon Bourgogne -M2 - Hop Dijon Bourgogne -M2 - Ligue Natl Canc -Y2 - 2024-07-31 -ER - - -TY - JOUR -AU - Khorana, Alok A. -AU - Palaia, Jennell -AU - Rosenblatt, Lisa -AU - Pisupati, Radhika -AU - Huang, Ning -AU - Nguyen, Chi -AU - Barron, John -AU - Gallagher, Kerrin -AU - Bond, T. Christopher -TI - Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer -T2 - JOURNAL FOR IMMUNOTHERAPY OF CANCER -M3 - Article -AB - BackgroundVenous thromboembolism (VTE) is a significant cause of morbidity and mortality in patients with lung cancer. Systemic therapies, such as chemotherapy (chemo), are associated with increased risk of VTE. Immune checkpoint inhibitors (ICIs) are a new standard of care for the treatment of lung cancer, but their association with VTE is not fully understood. We evaluated the incidence of VTE and risk factors for patients with advanced non-small cell lung cancer (aNSCLC) treated with first-line ICI-based, chemo-based, or ICI+chemo regimens.MethodsThis retrospective cohort study used HealthCore Integrated Research Environment - Oncology data, an integrated database of administrative claims, coupled with clinical data from a cancer-care quality program. Patients with first-line treatment of stage IV non-small cell lung cancer from July 2014 to August 2020 were grouped based on three treatment types: ICI-based, chemo-based, or ICI+chemo. Patients with VTE before initiation of systemic treatment were excluded. Newly diagnosed VTE events were identified via inpatient and outpatient diagnosis codes. Cox proportional hazards models were used to investigate the factors associated with VTE risk.ResultsAmong 2299 eligible patients (ICI-based, n=605; chemo-based, n=1092; ICI+chemo, n=602) with a median follow-up of 9.1 months, the VTE incidence rates (95% CI) per 100 person-years were 17.8 (95% CI 16.0 to 19.5) overall, 13.5 (95% CI 10.6 to 16.5) for ICI-based, 18.0 (95% CI 15.5 to 20.5) for chemo-based, and 22.4 (95% CI 20.2 to 24.5) for ICI+chemo. The 6-month cumulative incidence of VTE was 8.1% for ICI-based, 10.9% for chemo-based, and 12.8% for ICI+chemo. Pulmonary embolism was most common, accounting for 63% of the VTE events. After controlling for baseline patient characteristics, the risk of VTE was 26% lower for ICI-based regimens than for chemo-based regimens (HR 0.74, p=0.03). There was no meaningful difference in the risk between ICI+chemo and chemo-based regimens (HR 1.12, p=0.36). Previous radiation and severe obesity (body mass index >= 40) were associated with VTE.ConclusionsVTE incidence rate per 100 person-years was common across regimens in patients with aNSCLC, but numerically lower for patients receiving ICI-based regimens compared with those receiving chemo-based and ICI+chemo regimens. VTE is a common complication of lung cancer, and there is a continued need for awareness of VTE as a comorbidity in this population. -PU - BMJ PUBLISHING GROUP -PI - LONDON -PA - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND -SN - 2051-1426 -DA - 2023 JAN -PY - 2023 -VL - 11 -IS - 1 -C7 - e006072 -DO - 10.1136/jitc-2022-006072 -AN - WOS:000922328400001 -AD - Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH 44195 USA -AD - Bristol Myers Squibb, Worldwide Hlth Econ & Outcomes Res, Princeton, NJ USA -AD - Bristol Myers Squibb, US Med Oncol, Princeton, NJ USA -AD - Bristol Myers Squibb, Worldwide Patient Safety Med Safety Assessment, Princeton, NJ USA -AD - HealthCore Inc, Hlth Econ & Outcomes Res, Wilmington, DE USA -AD - Bristol Myers Squibb, Worldwide Patient Safety Epidemiol, Princeton, NJ USA -Y2 - 2023-02-25 -ER - - -TY - JOUR -AU - Mostafa, Ahmed A -AU - Morris, Don G -TI - Immunotherapy for Lung Cancer: Has it Finally Arrived? -T2 - Frontiers in oncology -M3 - Journal Article -M3 - Review -AB - The possible link between infection/inflammation/immune activation and a cancer patient's outcome from both a causative and outcome point of view has long been postulated. Substantial progress in the understanding of tumor-associated antigens/epitopes, immune cellular subpopulations, cytokine pathways/expression, the tumor microenvironment, and the balance between tumor-immune suppression and stimulation have been made over the past decade. This knowledge has heralded a new era of tumor immunotherapy utilizing vaccines, immune checkpoint inhibition, and oncolytic viruses. Despite significant progress in the molecular era now with targeted therapeutics such as EGFR tyrosine kinase inhibitors and ALK fusion protein inhibitors that have significantly improved the outcome of these specific lung cancer subpopulations, the overall 5year survival for all non-small cell lung cancer (NSCLC) is still <20%. Unlike malignancies such as malignant melanoma, renal cell carcinoma, and neuroblastoma given their documented spontaneous remission rates lung cancer historically has been felt to be resistant to immune approaches likely related to an immunosuppressive tumor microenvironment and/or lack of immune recognition. Defining responding populations, understanding the mechanism(s) underlying durable immune responses, and the role of chemotherapy, radiation, oncolytic viruses, and other tumor disrupting agents in augmenting immune responses have led to improved optimization of immune therapeutic strategies. The purpose of this review is to focus on the recent advances in lung immunotherapy with an emphasis on recent clinical trials in the last 5years in NSCLC. -SN - 2234-943X -DA - 2014 -PY - 2014 -VL - 4 -SP - 288 -EP - 288 -DO - 10.3389/fonc.2014.00288 -AN - MEDLINE:25374843 -AD - Department of Oncology, University of Calgary , Calgary, AB , Canada. -Y2 - 2014-11-13 -ER - - -TY - JOUR -AU - Watanabe, Y -TI - [Combined multimodality treatment for non-small cell lung cancer--with special reference to pre- and post-operative adjuvant therapy]. -T2 - Gan to kagaku ryoho. Cancer & chemotherapy -M3 - English Abstract -M3 - Journal Article -M3 - Review -AB - Surgical resection is the treatment of choice for patients with localized non-small cell lung cancer. However, the long-term survival rate of patients after such surgery is disappointing. Even in stage I patients who have undergone potentially curative operation, over 30% of them recur within five years. Most of the recurrences are caused by hematogenous metastases to the distant organs. However, all of the comparative study to evaluate postoperative adjuvant therapy, ie, chemotherapy, immunotherapy, radiotherapy, or their combination, showed negative results, except for a few positive outcomes. To date, there is no evidence that pre- and postoperative adjuvant therapy have shown a favorable impact on survival of postoperative patients with stage I disease. LCSG has had reportedly favorable results on survival of stage II and III adenocarcinoma and large cell carcinoma by postoperative CAP-chemotherapy. Postoperative chemotherapy and/or radiotherapy showed no impact on survival of stage III patients who underwent surgical intervention. However, preoperative induction therapy (IT) using combination chemotherapy (with or without radiotherapy) has improved the survival of patients with resected stage III disease, although most reports are of phase II trial or interim results. It seems to be true that the IT can render an advanced lung cancer resectable and also can control pre-existing micro-metastases in the distant organs. However, randomized prospective trials are required for evaluating an impact on the survival rate of the advanced non-small cell lung cancer. -SN - 0385-0684 -DA - 1994 Nov -PY - 1994 -VL - 21 -IS - 15 -SP - 2555 -EP - 63 -AN - MEDLINE:7979413 -AD - Dept. of Surgery I, Kanazawa University School of Medicine. -Y2 - 1994-11-01 -ER - - -TY - JOUR -AU - Bjornhart, Birgitte -AU - Hansen, Karin Holmskov -AU - Asmussen, Jon Thor -AU - Jorgensen, Trine Lembrecht -AU - Herrstedt, Jorn -AU - Schytte, Tine -TI - Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis -T2 - CANCERS -M3 - Article -AB - Simple Summary Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of non-small cell lung cancer (NSCLC). Most randomized clinical trials have excluded patients with brain metastasis (BM), and real-life patients with NSCLC who receive ICIs are not routinely scanned with magnetic resonance imaging (MR-C) of the brain prior to ICI. This means that there are no prospective data available on the prevalence of BM or on the rate of intracranial response (ICR) attributable to ICIs. To evaluate this along with the impact of BM on quality of life and overall survival, we used MR-C as a screening tool in 159 ICI-eligible patients with advanced NSCLC prior to first ICI. At the time of ICI initiation, 28% of patients had BM. Of those who received ICI without additional early local radiotherapy or surgery, 50% had intracranial response at their first MR-C assessment. Long-term survival of patients with BM was comparable to those without. Sparse data exist on immune checkpoint inhibition (ICI) in NSCLC patients with brain metastasis (BM), especially for those with no local therapy (LT) (whole brain radiation therapy (WBRT), stereotactic RT (SRT) or neurosurgery) preceding ICI. Our aims were to investigate the prevalence of BM, rate of intracranial response (ICR), and survival and quality of life (QoL) in real-life patients with advanced NSCLC undergoing palliative ICI. This was a prospective non-randomized study (NCT03870464) with magnetic resonance imaging of the brain (MR-C) performed at baseline resulting in a clinical decision to administer LT or not. ICR evaluation (MR-C) at week 8-9 (mRECIST criteria) for group A (LT) and group B (untreated) was assessed. Change in QoL was assessed using EQ-5D-5L. Of 159 included patients, 45 (28%) had baseline BM. Median follow-up was 23.2 months (IQR 16.4-30.2). Of patients in group A (21) and B (16), 16/37 (43%) had symptomatic BM. ICR was 8/21, 38% (complete or partial response) for group A versus 8/16, 50% for group B. No statistical difference in median overall survival of patients with BM (group A: 12.3 (5.2-NR), group B: 20.5 months (4.9-NR)) and without (22.4 months (95% 16.2-26.3)) was obtained. Baseline QoL was comparable regardless of BM, but an improved QoL (at week 9) was found in those without BM. Patients with NSCLC and BM receiving ICI had long-term survival comparable to those without BM. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2022 APR -PY - 2022 -VL - 14 -IS - 7 -C7 - 1682 -DO - 10.3390/cancers14071682 -AN - WOS:000781137400001 -AD - Odense Univ Hosp, Dept Oncol, Sdr Blvd 29, DK-5000 Odense, Denmark -AD - Univ Southern Denmark, Dept Clin Res, JB Winslvs Vej 19, DK-5000 Odense 3, Denmark -AD - Odense Univ Hosp, Odense Patient Data Explorat Network, OPEN, JB Winslws Vej 9a, DK-5000 Odense, Denmark -AD - Odense Univ Hosp, Acad Geriatr Canc Res AgeCare, Sdr Blvd 29, DK-5000 Odense, Denmark -AD - Odense Univ Hosp, Dept Radiol, JB Winslowsvej 4, DK-5000 Odense, Denmark -AD - Zealand Univ Hosp Roskilde, Dept Clin Oncol & Palliat Care, Sygehusvej 10, DK-4000 Roskilde, Denmark -M2 - Zealand Univ Hosp Roskilde -Y2 - 2022-04-24 -ER - - -TY - JOUR -AU - Perrotta, Fabio -AU - Rocco, Danilo -AU - Vitiello, Fabiana -AU - De Palma, Raffaele -AU - Guerra, Germano -AU - De Luca, Antonio -AU - Navani, Neal -AU - Bianco, Andrea -TI - Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients -T2 - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES -M3 - Review -AB - The therapeutic scenario for elderly patients with advanced NSCLC has been limited to radiotherapy and chemotherapy. Recently, a novel therapeutic approach based on targeting the immune-checkpoints has showed noteworthy results in advanced NSCLC. PD1/PD-L1 pathway is co-opted by tumor cells through the expression of PD-L1 on the tumor cell surface and on cells within the microenvironment, leading to suppression of anti-tumor cytolytic T-cell activity by the tumor. The success of immune-checkpoints inhibitors in clinical trials led to rapid approval by the FDA and EMA. Currently, data regarding efficacy and safety of ICIs in older subjects is limited by the poor number of elderly recruited in clinical trials. Careful assessment and management of comorbidities is essential to achieve better outcomes and limit the immune related adverse events in elderly NSCLC patients. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1422-0067 -DA - 2019 MAY 1 -PY - 2019 -VL - 20 -IS - 9 -C7 - 2258 -DO - 10.3390/ijms20092258 -AN - WOS:000469753500205 -AD - Univ Molise, Dept Med & Hlth Sci V Tiberio, I-86100 Campobasso, Italy -AD - AO Colli Monaldi Hosp, Pneumooncol Unit, I-80131 Naples, Italy -AD - Univ Campania L Vanvitelli, Dept Precis Med, I-80131 Naples, Italy -AD - Univ Campania L Vanvitelli, Sect Human Anat, Dept Mental & Phys Hlth & Prevent Med, I-80131 Naples, Italy -AD - Univ Coll London Hosp, Lungs Living Res Ctr, UCL Resp, London WC1E6JF, England -AD - Univ Coll London Hosp, Dept Thorac Med, London WC1E6JF, England -AD - Univ Campania L Vanvitelli, Dept Translat Med Sci, I-80131 Naples, Italy -M2 - AO Colli Monaldi Hosp -Y2 - 2019-06-14 -ER - - -TY - JOUR -AU - Melosky, Barbara -AU - Vincent, Mark D. -AU - Mcguire, Anna L. -AU - Brade, Anthony M. -AU - Chu, Quincy -AU - Cheema, Parneet -AU - Martins, Ilidio -AU - Spicer, Jonathan D. -AU - Snow, Stephanie -AU - Juergens, Rosalyn A. -TI - Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancer -T2 - INTERNATIONAL JOURNAL OF CANCER -M3 - Review -AB - Cure of cancer is a sensitive and multidimensional concept that is challenging to define, difficult to assert at the individual patient level, and often surrounded by controversy. The notion of cure in non-small cell lung cancer (NSCLC) has changed and continues to evolve with improvements in diagnosis and treatment. Targeted and immune therapies have recently entered the treatment landscape of stage I-III NSCLC. While some initial pivotal trials of such agents failed to improve survival, recently approved epidermal growth factor receptor (EGFR) inhibitors (in EGFR-mutated NSCLC) and immune checkpoint inhibitors have shown delays in disease recurrence or progression and unprecedented survival gains compared to previous standards of care. Additional data is now emerging supporting the benefit of treatment strategies based on alternation-matched targeting (anaplastic lymphoma kinase [ALK] inhibition in ALK-altered disease) and immune checkpoint inhibition in stage I-III NSCLC. Similar to previous developments in the treatment of early and locally advanced NSCLC, it is expected that statistically significant and clinically meaningful trial-level benefits will translate into real-world benefits, including improvements in cure measures. Parallel advances in molecular testing (e.g., circulating tumor DNA analyses) are also allowing for a deeper and more comprehensive characterization of disease status and treatment response. Given the impact that curative-intent treatments have on survival, it is critical that various stakeholders, including clinicians and patients, are aware of new opportunities to pursue cure in stage I-III NSCLC.image -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0020-7136 -SN - 1097-0215 -DA - 2024 SEP 15 -PY - 2024 -VL - 155 -IS - 6 -SP - 963 -EP - 978 -DO - 10.1002/ijc.35031 -AN - WOS:001250530900001 -C6 - JUN 2024 -AD - Univ British Columbia, BCCA Vancouver Ctr, Vancouver, BC, Canada -AD - Univ Western Ontario, London Reg Canc Ctr, London, ON, Canada -AD - Univ British Columbia, Vancouver Coastal Hlth Res Inst, Vancouver, BC, Canada -AD - Univ Toronto, Trillium Hlth Partners, Mississauga, ON, Canada -AD - Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada -AD - Univ Toronto, William Osler Hlth Syst, Brampton, ON, Canada -AD - Kaleidoscope Strateg Inc, Toronto, ON, Canada -AD - McGill Univ, Hlth Ctr, Montreal, PQ, Canada -AD - Dalhousie Univ, QEII Hlth Sci Ctr, Halifax, NS, Canada -AD - McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada -AD - Univ British Columbia, Vancouver Ctr, Med Oncol, British Columbia Canc Agcy, 600 West 10th Ave, Vancouver, BC V5Z 4E6, Canada -M2 - Kaleidoscope Strateg Inc -Y2 - 2024-06-25 -ER - - -TY - JOUR -AU - Zhang, Luping -AU - Xu, Zihan -AU - Chen, Xiewan -AU - Duan, Yuzhong -AU - Chen, Zhengtang -AU - Sun, Jianguo -TI - Clinical benefits of Livin peptide-loaded DCs/CIKs combined with chemotherapy in advanced non-small cell lung cancer -T2 - AMERICAN JOURNAL OF CANCER RESEARCH -M3 - Article -AB - Previous studies showed that Livin, a member of inhibitors of apoptosis protein (IAP), played an important role in drug and radiation resistance. When the expression of Livin was blocked, the sensitivity to both chemotherapy and radiotherapy was improved in lung cancer cells. A total of 79 patients diagnosed with non-small cell lung cancer (NSCLC) were enrolled into the current study from Jan 2012 to Apr 2016. The Livin and MUC-1 groups received one-cycle autologous DCs/CIKs infusion on days 11 to 14 additionally. The clinical efficacy, immune index, KPS score and adverse events were compared among the three groups. Median progression-free survival (mPFS) in Livin and MUC-1 groups was significantly longer than that in Chemo group (195 and 211 vs 138 days, P < 0.05), and the objective response rate (ORR) in Livin and MUC-1 groups was significantly higher than that in Chemo group (23.1% and 22.2% vs 5.1%, P < 0.05). The Tetramer value after treatment in Livin group was significantly higher than that before treatment (4.07 +/- 3.77 vs 3.16 +/- 3.82, P < 0.05). The concentration of Livin antibody in patients' peripheral blood before and after treatment in Livin group had no significant difference (P > 0.05). As for KPS score, scarce decrease was found in Livin and MUC-1 groups after chemotherapy treatment (0.77 +/- 6.41 and 0.37 +/- 5.18, respectively). However, obvious decrease of KPS score (P < 0.039) was recorded in Chemo group (3.85 +/- 6.33). There was no significant difference in disease control rate (DCR), overall survival (OS), T cell subsets, cytokine levels (IFN-gamma and IL-2) and adverse events between the three groups (P > 0.05). Livin peptide could be a novel substitute to trigger cell immunity by loading DCs in combination with chemotherapy in NSCLC. -PU - E-CENTURY PUBLISHING CORP -PI - MADISON -PA - 40 WHITE OAKS LN, MADISON, WI 53711 USA -SN - 2156-6976 -DA - 2019 -PY - 2019 -VL - 9 -IS - 2 -SP - 406 -EP - 414 -AN - WOS:000459916100016 -AD - Army Med Univ, Canc Inst Peoples Liberat Army, Xinqiao Hosp, Chongqing, Peoples R China -AD - Army Med Univ, Coll Basic Med, Dept Med English, Chongqing, Peoples R China -Y2 - 2019-03-11 -ER - - -TY - JOUR -AU - Josephides, Eleni -AU - Dunn, Roberta -AU - Henry, Annie-Rose -AU - Pilling, John -AU - Harrison-Phipps, Karen -AU - Patel, Akshay -AU - Ahmad, Shahreen -AU - Skwarski, Michael -AU - Spicer, James -AU - Georgiou, Alexandros -AU - Ghosh, Sharmistha -AU - Van Hemelrijck, Mieke -AU - Karapanagiotou, Eleni -AU - Smith, Daniel -AU - Bille, Andrea -TI - Real-World Analysis of Survival and Treatment Efficacy in Stage IIIA-N2 Non-Small Cell Lung Cancer -T2 - CANCERS -M3 - Article -AB - Simple Summary This study focuses on Stage IIIA-N2 non-small cell lung cancer (NSCLC), which occurs when lung cancer has spread to lymph nodes in the centre of the chest but not to distant parts of the body. This type of cancer is difficult to treat, and survival rates remain low despite advances in therapy. The research is based on real-world data from Guy's Thoracic Cancer Database and aims to enhance our understanding of patient outcomes and identify important factors that impact survival and disease progression. By examining various treatment strategies, the study aims to offer insights that could help tailor treatment approaches to individual patients. The findings underscore the need for personalised care and the potential benefits of incorporating newer therapeutic options, ultimately leading to better survival outcomes for patients with this challenging form of lung cancer.Abstract Background: Stage IIIA-N2 non-small cell lung cancer (NSCLC) poses a significant clinical challenge, with low survival rates despite advances in therapy. The lack of a standardised treatment approach complicates patient management. This study utilises real-world data from Guy's Thoracic Cancer Database to analyse patient outcomes, identify key predictors of overall survival (OS) and disease-free survival (DFS), and address the limitations of randomised controlled trials. Methods: This observational, single-centre, non-randomised study analysed 142 patients diagnosed with clinical and pathological T1/2 N2 NSCLC who received curative treatment from 2015 to 2021. Patients were categorised into three groups: Group A (30 patients) underwent surgery for clinical N2 disease, Group B (54 patients) had unsuspected N2 disease discovered during surgery, and Group C (58 patients) received radical chemoradiation or radiotherapy alone (CRT/RT) for clinical N2 disease. Data on demographics, treatment types, recurrence, and survival rates were analysed. Results: The median OS for the cohort was 31 months, with 2-year and 5-year OS rates of 60% and 30%, respectively. Group A had a median OS of 32 months, Group B 36 months, and Group C 25 months. The median DFS was 18 months overall, with Group A at 16 months, Group B at 22 months, and Group C at 17 months. Significant predictors of OS included ECOG performance status, lymphovascular invasion, and histology. No significant differences in OS were found between treatment groups (p = 0.99). Conclusions: This study highlights the complexity and diversity of Stage IIIA-N2 NSCLC, with no single superior treatment strategy identified. The findings underscore the necessity for personalised treatment approaches and multidisciplinary decision-making. Future research should focus on integrating newer therapeutic modalities and conducting multi-centre trials to refine treatment strategies. Collaboration and ongoing data collection are crucial for improving personalised treatment plans and survival outcomes for Stage IIIA-N2 NSCLC patients. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2024 SEP -PY - 2024 -VL - 16 -IS - 17 -C7 - 3058 -DO - 10.3390/cancers16173058 -AN - WOS:001310943400001 -AD - Guys & St Thomas NHS Fdn Trust, London SE1 9RT, England -AD - Kings Coll London, Comprehens Canc Ctr, London SE1 9RT, England -Y2 - 2024-09-21 -ER - - -TY - JOUR -AU - Neninger, Elia -AU - Diaz, Rosa M. -AU - de la Torre, Ana -AU - Rives, Rolando -AU - Diaz, Alain -AU - Saurez, Giselle -AU - Gabri, Mariano R. -AU - Alonso, Daniel F. -AU - Wilkinson, Barbara -AU - Alfonso, Angel M. -AU - Combet, Tania -AU - Perez, Rolando -AU - Vazquez, Ana M. -TI - Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer -: Report of a phase I trial -T2 - CANCER BIOLOGY & THERAPY -M3 - Article -AB - 1E10 is an anti-idiotype murine monoclonal antibody (Ab2 MAb) specific to an Ab1 MAb which reacts with NeuGc - containing gangliosides, sulfatides and with antigens expressed in some human tumors. Preparations containing this Ab2 were capable to induce a strong anti - metastatic effect in tumor - bearing mice. We conducted a Phase I clinical trial to evaluate the toxicity and humoral immune response elicited by 1E10 vaccine in patients with small cell lung cancer (SCLC). Eligible patients were those who after received chemotherapy and/or radiotherapy had partial or complete response to treatment. Patients received four biweekly injections with 2 mg of aluminum hydroxide - precipitated 1E10 MAb, then other six doses at 28 - day intervals, and later the patients who maintained a good performance status were reimmunized. Six patients with limited - stage disease and three with extensive - stage disease were enrolled in the study. Most of the patients who received at least four doses of 1E10 vaccine developed strong specific antibody responses against 1E10 MAb and NeuGc - GM3 ganglioside. Antibodies able to react with lung carcinoma tissue sections were detected in sera from vaccinated patients. A prolonged survival was observed in several patients treated with the anti - idiotype vaccine. No evidence of serious adverse effects was found. -PU - TAYLOR & FRANCIS INC -PI - PHILADELPHIA -PA - 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA -SN - 1538-4047 -SN - 1555-8576 -DA - 2007 FEB -PY - 2007 -VL - 6 -IS - 2 -SP - 145 -EP - 150 -DO - 10.4161/cbt.6.2.3574 -AN - WOS:000245851800014 -AD - Hermanos Ameijeiras Hosp, Dept Med Oncol, Havana 10300, Cuba -AD - Ctr Mol Immunol, Havana, Cuba -AD - Celestino Hernandez Hosp, Villa Clara, Cuba -AD - Neumol Hosp, Havana, Cuba -AD - Quilmes Natl Univ, Oncol Mol Lab, Buenos Aires, DF, Argentina -M2 - Hermanos Ameijeiras Hosp -M2 - Ctr Mol Immunol -M2 - Celestino Hernandez Hosp -M2 - Neumol Hosp -M2 - Quilmes Natl Univ -Y2 - 2007-02-01 -ER - - -TY - JOUR -AU - Yang, Zhenyi -AU - Zhong, Wen -AU - Luo, Yixuan -AU - Wu, Chunli -TI - The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis -T2 - BMC CANCER -M3 - Review -AB - PurposeThe PACIFIC study has demonstrated that the administration of durvalumab following concurrent chemoradiotherapy can significantly improve both overall survival and progression-free survival rates in patients with locally advanced unresectable non-small cell lung cancer. While the latest NCCN guidelines recommend this combination regimen, they do not specify the optimal timing for administering durvalumab after completing radiotherapy. The PACIFIC study suggested initiating durvalumab within 42 days of completing radiotherapy, but early administration of the drug may increase the incidence of pneumonitis. Therefore, we conducted this study to investigate whether the time interval between completion of radiotherapy and initiation of durvalumab treatment is associated with the risk of pneumonitis (Grade >= 3), which is the primary endpoint, as well as progression-free survival, which is the secondary endpoint.MethodsA comprehensive search of clinical trials in PubMed and EMBASE was conducted up to March 2023 to identify clinical trials involving locally advanced unresectable non-small cell lung cancer patients who were treated with durvalumab following chemoradiotherapy. Meta-analysis was performed on single-arm studies to estimate the incidence of pneumonitis (Grade >= 3) and progression-free survival in all studies, as well as in studies that administered durvalumab within 42 days after completion of radiotherapy.ResultsThis meta-analysis consisted of nine studies with a total of 2560 patients. The analysis showed that the incidence of pneumonitis (Grade >= 3) was 5.36% [95%CI (0.03, 0.08), I2 = 18.41%, p = 0.29], while the 1-year progression-free survival rate was 57.91% [95%CI (0.53, 0.63), I2 = 10.57%, p = 0.35]. Furthermore, when the duration between completion of radiotherapy and initiation of durvalumab treatment was shorter than 42 days, the incidence of pneumonitis (Grade >= 3) was 4.12% [95%CI (0.02, 0.06), I2 = 0.00%, p = 0.56], with a 1-year progression-free survival rate of 61.03% [95%CI (0.51, 0.71), I2 = 59.06%, p = 0.09].ConclusionOverall, based on the available evidence, it appears that there is no significant increase in pneumonitis or decrease in progression-free survival (PFS) when the time interval is less than 42 days and a shorter interval between treatment sessions does not necessarily have a detrimental effect on the rate of pneumonitis. We recommend that clinicians carefully evaluate the specific circumstances of each patient to determine the optimal timing for initiating immunotherapy. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2023 OCT 10 -PY - 2023 -VL - 23 -IS - 1 -C7 - 962 -DO - 10.1186/s12885-023-11472-3 -AN - WOS:001081384600004 -AD - China Med Univ, Affiliated Hosp 4, Chongshan East Rd 4, Shenyang 110032, Liaoning, Peoples R China -Y2 - 2023-10-28 -ER - - -TY - JOUR -AU - Billing, D. -AU - Rimner, A. -AU - Shepherd, A. F. -AU - Gelblum, D. -AU - Shaverdian, N. -AU - Simone, C. B., II -AU - Lai, V. -AU - Rudin, C. M. -AU - Gomez, D. R. -AU - Wu, A. J. -TI - Standard vs. Higher-Dose Consolidative Thoracic Radiation in Extensive-Stage Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 2963 -SP - E464 -EP - E465 -AN - WOS:000715803800958 -AD - Mem Sloan Kettering Canc Ctr, New York, NY USA -AD - Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA -AD - New York Proton Ctr, New York, NY USA -M2 - New York Proton Ctr -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - de Jong, Dorine -AU - Das, Jeeban P. -AU - Ma, Hong -AU - Pailey Valiplackal, Jacienta -AU - Prendergast, Conor -AU - Roa, Tina -AU - Braumuller, Brian -AU - Deng, Aileen -AU - Dercle, Laurent -AU - Yeh, Randy -AU - Salvatore, Mary M. -AU - Capaccione, Kathleen M. -TI - Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer -T2 - CANCERS -M3 - Review -AB - Non-small cell lung cancer treatment has undergone a revolution in the past decade owing to the discovery of mutations that drive carcinogenesis and the development of molecular testing and treatments that act on them. Here, we detail the way in which lung cancer is currently diagnosed and treated in light of these developments. We focus on some of the key mutations for which targeted therapies have been developed and the trials that led to their approval. We hope to provide a comprehensive review of the current diagnosis and management of non-small cell lung cancer.Abstract: Treatment of non-small cell lung cancer (NSCLC) has undergone a paradigm shift. Once a disease with limited potential therapies, treatment options for patients have exploded with the availability of molecular testing to direct management and targeted therapies to treat tumors with specific driver mutations. New in vitro diagnostics allow for the early and non-invasive detection of disease, and emerging in vivo imaging techniques allow for better detection and monitoring. The development of checkpoint inhibitor immunotherapy has arguably been the biggest advance in lung cancer treatment, given that the vast majority of NSCLC tumors can be treated with these therapies. Specific targeted therapies, including those against KRAS, EGFR, RTK, and others have also improved the outcomes for those individuals bearing an actionable mutation. New and emerging therapies, such as bispecific antibodies, CAR T cell therapy, and molecular targeted radiotherapy, offer promise to patients for whom none of the existing therapies have proved effective. In this review, we provide the most up-to-date survey to our knowledge regarding emerging diagnostic and therapeutic strategies for lung cancer to provide clinicians with a comprehensive reference of the options for treatment available now and those which are soon to come. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2023 MAY 21 -PY - 2023 -VL - 15 -IS - 10 -C7 - 2855 -DO - 10.3390/cancers15102855 -AN - WOS:000997893400001 -AD - Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, 1275 York Ave, New York, NY 10065 USA -AD - Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10065 USA -AD - Columbia Univ Irving Med Ctr, Dept Radiol, New York, NY 10032 USA -AD - Dept Hematol & Oncol, Novant Hlth, 170 Med Pk Rd, Mooresville, NC 28117 USA -M2 - Dept Hematol & Oncol -Y2 - 2023-06-09 -ER - - -TY - JOUR -AU - Gu, Yuanlong -AU - Lv, Huimin -AU - Zhao, Juan -AU - Li, Qi -AU - Mu, Guannan -AU - Li, Jiade -AU - Jiazi Wuyang -AU - Lou, Ge -AU - Wang, Ruitao -AU - Zhang, Yanqiao -AU - Huang, Xiaoyi -TI - Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non small-cell lung cancer (NSCLC) -T2 - INTERNATIONAL IMMUNOPHARMACOLOGY -M3 - Article -AB - Objective: Cytokine-induced killer (CIK) cells have important therapeutic effects in adoptive cell transfer (ACT) for the treatment of various malignancies. In this study, we focused on in vitro expansion of CIK cells and their clinical efficacy in combination with chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC).Methods: A total of 64 patients with NSCLC (enrolled from 2011 to 2012), including 32 patients who received chemotherapy alone or with sequential radiotherapy (conventional treatment, control group) and 32 patients who received conventional treatment and sequential CIK infusion (study group), were retrospectively analyzed. The time to progression (TTP), overall survival (OS) and adverse effects were analyzed and the phenotype of lymphocytes in CIK population was also determined by flow cytometry.Results: After in vitro expansion, the average percentage of CIK cells was 26.35%. During the 54-month follow up, the median OS and rip were significantly longer in the study group than in the control group (P = 0.0189 and P = 0.0129, respectively). The median OS of the ACT >= 4 cycles subgroup was significantly longer than that of the ACT < 4 cycles subgroup (P = 0.0316). The percentage of CIK cells in patients who received >= 4 cycles of ACT was higher than that in patients treated with < 4 cycles of ACT (P = 0.0376). Notably, CIK cells were difficult to expand in vitro in some patients after the first ACT cycle but became much easier as the treatment cycles increased monthly. Longer treatment interval negatively impacted the expansion of CIK cells.Conclusions: Systematic immune levels can be increasingly boosted by reinfusion of ACT. Conventional treatment plus CIK cells is an effective therapeutic strategy to prevent progression and prolong survival of patients with advanced NSCLC. -PU - ELSEVIER SCIENCE BV -PI - AMSTERDAM -PA - PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS -SN - 1567-5769 -SN - 1878-1705 -DA - 2017 SEP -PY - 2017 -VL - 50 -SP - 263 -EP - 269 -DO - 10.1016/j.intimp.2017.07.006 -AN - WOS:000408073200033 -AD - Harbin Med Univ, Canc Hosp, Dept Gastrointestinal Med Oncol, Harbin 150081, Heilongjiang, Peoples R China -AD - Harbin Med Univ, Canc Hosp, Biotherapy Ctr, 150 Haping Rd, Harbin 150081, Heilongjiang, Peoples R China -AD - Harbin Med Univ, Canc Hosp, Dept Gynecol, Harbin 150081, Heilongjiang, Peoples R China -AD - Harbin Med Univ, Canc Hosp, Dept Internal Med, Harbin 150081, Heilongjiang, Peoples R China -AD - Harbin Med Univ, Ctr Translat Med, Harbin 150086, Heilongjiang, Peoples R China -Y2 - 2017-09-01 -ER - - -TY - JOUR -AU - Keller, SM -TI - Adjuvant therapy for locally advanced non-small cell lung cancer -T2 - LUNG CANCER -M3 - Article -M3 - Proceedings Paper -CP - Workshop on the Management of Locally Advanced Non-Small Cell Lung Cancer -CL - TAIPEI, TAIWAN -PU - ELSEVIER SCI IRELAND LTD -PI - CLARE -PA - CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND -SN - 0169-5002 -DA - 2003 DEC -PY - 2003 -VL - 42 -SP - S29 -EP - S34 -DO - 10.1016/j.lungcan.2003.08.008 -AN - WOS:000187788900008 -AD - Montefiore Med Ctr, Albert Einstein Coll Med, Dept Cardiothorac Surg, Bronx, NY 10467 USA -Y2 - 2003-12-01 -ER - - -TY - JOUR -AU - Thatcher, Nicholas -AU - Heighway, Jim -TI - Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer -T2 - ONCOLOGIST -M3 - Article -AB - Globally, lung cancer is the leading cause of cancer-related mortality. Current chemotherapy combinations for the first-line treatment of advanced disease (stage IIIB with malignant pleural effusion/stage IV) and chemoradiotherapy regimens for the treatment of unresectable locally advanced disease (stage MA and IIIB without malignant pleural effusion) appear to have reached an efficacy plateau. The addition of new compounds including targeted agents to standard first-line cytotoxic doublets, administered concurrently and/or as maintenance therapy in patients who have not experienced disease progression after such treatment, has been shown to improve efficacy beyond this plateau in patients with advanced disease. However, to date, such approaches have been less successful in the treatment of patients with unresectable locally advanced stage III disease. The purpose of this review is to summarize the data from recent randomized phase III studies involving agents administered as maintenance or consolidation therapy in the treatment of unresectable stage non-small cell lung cancer (NSCLC). A possible alternative approach to the use of cytotoxic or molecularly targeted agents in this setting is the administration of therapeutic anticancer vaccines, which are designed to stimulate a host immunological response against the tumor. Current data in relation to the potential of vaccine therapy for NSCLC are therefore also reviewed, with a particular focus on belagenpumatucel-L and L-BLP25 vaccines, which are currently undergoing phase III evaluation as maintenance therapies in patients with unresectable stage III/IV NSCLC who have tumor control following first-line therapy. The Oncologist 2010;15:1034-1042 -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1083-7159 -SN - 1549-490X -DA - 2010 OCT -PY - 2010 -VL - 15 -IS - 10 -SP - 1034 -EP - 1042 -DO - 10.1634/theoncologist.2009-0292 -AN - WOS:000284123900003 -AD - Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England -AD - Canc Commun & Consultancy Ltd, Knutsford, England -M2 - Canc Commun & Consultancy Ltd -Y2 - 2010-10-01 -ER - - -TY - JOUR -AU - Singhi, Eric K. -AU - Mott, Frank -AU - Worst, Michelle -AU - Leung, Cheuk Hong -AU - Lee, J. Jack -AU - Carter, Brett -AU - Presley, Carolyn J. -AU - Heymach, John V. -AU - Altan, Mehmet -TI - Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non-small cell lung cancer -T2 - ONCOLOGY LETTERS -M3 - Article -AB - Immunotherapy is an effective and generally well-tolerated treatment strategy for older adult patients (aged >= 70 years) with advanced non-small cell lung cancer (NSCLC). Unfortunately, most patients who receive immunotherapy eventually exhibit disease progression during treatment. The present study reports on a subset of older adult patients with advanced NSCLC who could effectively continue immunotherapy beyond radiographic disease progression due to perceived clinical benefit. Local consolidative radiotherapy may be used in select older adult patients to prolong the duration of immunotherapy they receive, with a particular consideration of their preexisting co-morbidities, performance status and tolerance of potential toxicities associated with combined modality therapy. However, prospective research is needed to determine which patients benefit most from the addition of local consolidative radiotherapy, including whether type of disease progression (i.e., sites of progression, pattern of progression) and/or extent of consolidation offered (i.e., complete or incomplete) impact clinical outcomes. Further research is also warranted to determine which patients would most benefit from the continuation of immunotherapy beyond documented radiographic disease progression. -PU - SPANDIDOS PUBL LTD -PI - ATHENS -PA - POB 18179, ATHENS, 116 10, GREECE -SN - 1792-1074 -SN - 1792-1082 -DA - 2023 JUN -PY - 2023 -VL - 25 -IS - 6 -C7 - 262 -DO - 10.3892/ol.2023.13848 -AN - WOS:000990497700001 -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA -AD - Medscape Oncol, New York, NY 10014 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Imaging, Houston, TX 77030 USA -AD - Ohio State Univ, Thorac Oncol Ctr, Comprehens Canc Ctr, Columbus, OH 43210 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1400 Holcombe Blvd,Unit 462,FC12-2018, Houston, TX 77030 USA -M2 - Medscape Oncol -Y2 - 2023-05-28 -ER - - -TY - JOUR -AU - Xu, Yan -AU - Wang, Mengzhao -TI - [Progress in immunotherapy for non-small cell lung cancer]. -T2 - Zhongguo fei ai za zhi = Chinese journal of lung cancer -M3 - English Abstract -M3 - Journal Article -M3 - Review -AB - In recent years, the five-year survival rate of patients with advanced stage non-small cell lung cancer (NSCLC) remains low despite recent advances in surgery, irradiation, chemotherapy, and targeted therapy. Immunotherapy which utilizes the immune system to control and eradicate cancer is a viable treatment approach for malignancy. Immunotherapy in patients with lung cancer has made breakthrough progress recently. Novel immunotherapeutic agents, such as antigen-specific tumour vaccines, checkpoint inhibitors, etc, have all been evaluated in lung cancer, and some have shown prolonged survival time in phase II trials and III trails. The immune-related response criteria for the evaluation of antitumor responses with immunotherapeutic agents have been made. Now, immunotherapy will likely be a fundamentally new concept for the treatment of NSCLC. -AB - 近年来,非小细胞肺癌(non-small cell lung cancer, NSCLC)在手术治疗、放疗、化疗及靶向治疗方面均取得了很大的进展,但晚期NSCLC患者的5年生存率仍然很低。免疫治疗利用免疫系统来控制和清除瘤细胞,已成为肿瘤治疗的一种重要手段。NSCLC的免疫治疗近期取得了突破性的进展,抗原特异性肿瘤疫苗、检查点阻滞剂等多种新型抗肿瘤免疫治疗药物已进行NSCLC治疗的临床试验,并在II期和III期临床试验中取得一定的成果。目前已完善了免疫治疗疗效评估标准,成为免疫治疗药物抗肿瘤评价标准。免疫治疗将成为NSCLC治疗的一种重要手段。 -SN - 1999-6187 -DA - 2014 Jan -PY - 2014 -VL - 17 -IS - 1 -SP - 34 -EP - 41 -DO - 10.3779/j.issn.1009-3419.2014.01.06 -AN - MEDLINE:24398312 -AD - Department of Respiratory Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Science 
and Peking Union Medical College, Beijing 100730, China. -Y2 - 2014-04-24 -ER - - -TY - JOUR -AU - Xia, Wu-Yan -AU - Feng, Wen -AU - Zhang, Chen-Chen -AU - Shen, Yu-Jia -AU - Zhang, Qin -AU - Yu, Wen -AU - Cai, Xu-Wei -AU - Fu, Xiao-Long -TI - Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Immunotherapy has radically changed the clinical management of patients with cancer in recent years. Immune checkpoint inhibitors (ICIs) reversing the immunosuppressive effects of the tumor microenvironment are one type of immunotherapy, several of which are approved by the US Food and Drug Administration (FDA) as first-line treatments for patients with non-small cell lung cancer (NSCLC). However, response rates to ICIs are around 19-47% among patients with advanced NSCLC. As a result, the development of combined ICI and radiotherapy has begun with the aim of strengthening patients' antitumor immunity. Radiotherapy with substantial technological improvements not only achieves local tumor control through the induction of deoxyribonucleic acid (DNA) damage in irradiated regions, but also has the potential to mediate immunostimulatory effects that could result in tumor regression beyond irradiated regions. At present, numerous preclinical and clinical research are investigating the efficiency and safety of combining ICI with radiotherapy. The PACIFIC trial showed that combining chemoradiotherapy with ICI could improve clinical outcomes. In this review, we summarize the rationale for combining radiotherapy with immunotherapy. We also discuss the opportunities and challenges of combination therapy, including the timing of radiotherapy, optimal dose and fractionations, radiotherapy target and target volume, acquired resistance, patient selection, and radioimmunotherapy toxicity. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2020 OCT -PY - 2020 -VL - 9 -IS - 5 -SP - 2120 -EP - 2136 -DO - 10.21037/tlcr-20-827 -AN - WOS:000582799700041 -AD - Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Radiat Oncol, 241 West Huaihai Rd, Shanghai 200030, Peoples R China -Y2 - 2020-11-11 -ER - - -TY - JOUR -AU - Andraos, T. Y. -AU - Shirvani, S. -AU - Cornwell, T. -AU - Ohri, N. -TI - Characterization of the Entire Metastatic Spectrum for Non-Small Cell Lung Cancer in the Immunotherapy Era -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 2884 -SP - E428 -EP - E429 -AN - WOS:000715803800880 -AD - Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10467 USA -AD - Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA -AD - RefleXion Med Inc, Hayward, CA USA -M2 - RefleXion Med Inc -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Allaeys, Toon -AU - Berzenji, Lawek -AU - Van Schil, Paul E. -TI - Surgery after Induction Targeted Therapy and Immunotherapy for Lung Cancer -T2 - CANCERS -M3 - Review -AB - Simple SummaryFor patients with locally advanced non-small cell lung cancer (NSCLC) or positive N1 nodes, multimodality treatment is indicated. However, the optimal management of patients presenting with ipsilateral positive mediastinal nodes (N2 disease) has not been determined yet. Different treatment regimens consisting of chemotherapy, radiation therapy, and surgery have been proposed and implemented previously. In more recent years, immunotherapy and targeted therapies have been added as therapeutic options. The introduction of these newer modalities has raised questions on the role of surgery after targeted therapy or immunotherapy. Recent studies have shown that surgical resection after induction immunotherapy or targeted therapy is indeed feasible, but is associated with a higher risk of conversion and increased morbidity due to hilar inflammation. In this review, we summarize the latest data on outcomes of patients undergoing surgical resection after induction immunotherapy and/or targeted therapy. Treatment outcomes have to be carefully evaluated to determine the contribution of surgery in multimodality treatment regimens including immunotherapy and targeted therapies.Multimodality therapy for locally advanced non-small cell lung cancer (NSCLC) is a complex and controversial issue, especially regarding optimal treatment regimens for patients with ipsilateral positive mediastinal nodes (N2 disease). Many trials investigating neoadjuvant immunotherapy and targeted therapy in this subpopulation have shown promising results, although concerns have risen regarding surgical feasibility. A thorough literature review was performed, analyzing all recent studies regarding surgical morbidity and mortality. Despite the fact that two major trials investigating this subject were terminated early, the overall consensus is that surgical management seems feasible. However, dissection of hilar vessels may be challenging due to hilar fibrosis. Further research is necessary to identify the role of surgery in these multimodality treatment regimens, and to define matters such as the optimal treatment regimen, the dosage of the different agents used, the interval between induction therapy and surgery, and the role of adjuvant therapy. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2021 JUN -PY - 2021 -VL - 13 -IS - 11 -C7 - 2603 -DO - 10.3390/cancers13112603 -AN - WOS:000659603100001 -AD - Antwerp Univ Hosp, Dept Thorac & Vasc Surg, Drie Eikenstr 655, B-2650 Antwerp, Belgium -Y2 - 2021-06-21 -ER - - -TY - JOUR -AU - HASSAN, RAFFIT -TI - Thoracic and Gastrointestinal Malignancies Branch Clinical Core -M3 - Awarded Grant -AB - The medical TGMB has a robust clinical program for treatment of patients with advanced thoracic and GI cancers who have failed standard therapies. The thoracic team is conducting innovative studies for patients with non-small cell lung cancer, small cell lung cancer, malignant mesothelioma and thymic cancers. These include use of novel treatments developed by scientists at the NCI. A major focus of our team is the development of drugs targeting the tumor antigen, mesothelin that is highly expressed in many cancers. We are using an immunotoxin -LMB-100, an antibody drug conjugate- BAY 94-9343, thorium-227 labeled antibody-chelator conjugate-BAY 2287411 and mesothelin targeting CAR-T cells to treat these cancers. In addition, we are conducting clinical trials using immunotherapy agents including immune checkpoint inhibitors to treat patients with thoracic cancers who have failed standard treatments. The TGMB is also conducting studies for treatment of gastrointestinal cancers with a special emphasis on liver and pancreatic cancer. Investigators within the TGMB have established a robust program for treatment of patients with liver cancer including use of immunotherapy agents either alone or in combination with radiation therapy or locally ablative therapies for liver cancer. The gastrointestinal group is also conducting clinical trials of novel agents for treatment of pancreatic cancer. -DA - 2022 -PY - 2022 -AN - GRANTS:17493218 -G1 - 10703109; 1ZIDBC011540-09; ZIDBC011540 -AD - DIVISION OF BASIC SCIENCES - NCI -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - HASSAN, RAFFIT -TI - Thoracic and Gastrointestinal Malignancies Branch Clinical Core -M3 - Awarded Grant -AB - The medical TGMB has a robust clinical program for treatment of patients with advanced thoracic and GI cancers who have failed standard therapies. The thoracic team is conducting innovative studies for patients with non-small cell lung cancer, small cell lung cancer, malignant mesothelioma and thymic cancers. These include use of novel treatments developed by scientists at the NCI. A major focus of our team is the development of drugs targeting the tumor antigen, mesothelin that is highly expressed in many cancers. We are using an immunotoxin -LMB-100, an antibody drug conjugate- BAY 94-9343, thorium-227 labeled antibody-chelator conjugate-BAY 2287411 and mesothelin targeting CAR-T cells to treat these cancers. In addition, we are conducting clinical trials using immunotherapy agents including immune checkpoint inhibitors to treat patients with thoracic cancers who have failed standard treatments. The TGMB is also conducting studies for treatment of gastrointestinal cancers with a special emphasis on liver and pancreatic cancer. Investigators within the TGMB have established a robust program for treatment of patients with liver cancer including use of immunotherapy agents either alone or in combination with radiation therapy or locally ablative therapies for liver cancer. The gastrointestinal group is also conducting clinical trials of novel agents for treatment of pancreatic cancer. -DA - 2021 -PY - 2021 -AN - GRANTS:17427374 -G1 - 10487294; 1ZIDBC011540-08; ZIDBC011540 -AD - DIVISION OF BASIC SCIENCES - NCI -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - Hu, Meng -AU - Zhong, Congying -AU - Wang, Jiabing -AU - Chen, JinQin -AU - Zhou, Tao -TI - Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations -T2 - FRONTIERS IN IMMUNOLOGY -M3 - Review -AB - Recently, targeted therapy and immunotherapy have emerged as effective treatment options for non-small cell lung cancer (NSCLC). This progress has been facilitated by the rapid development of diagnostic and therapeutic technologies and the continuous research and development of new drugs, leading to a new era in precision medicine for NSCLC. This is a breakthrough for patients with common mutations in the human epidermal growth factor receptor (EGFR) gene in NSCLC. Consequently, the use of targeted drugs has significantly improved survival. Nevertheless, certain rare genetic mutations are referred to as EGFR exon 20 insertion (ex20ins) mutations, which differ in structure from conventional EGFR gene mutations, namely, exon 19 deletion mutations (19-Del) and exon 21 point mutations. Owing to their distinct structural characteristics, patients harboring these EGFR ex20ins mutations are unresponsive to traditional tyrosine kinase inhibitor (TKI) therapy. This particular group of patients did not fall within the scope of their applicability. However, the activating A763_Y764insFQEA mutation elicits a more pronounced response than mutations in the near and far regions of the C-helix immediately following it and should, therefore, be treated differently. Currently, there is a lack of effective treatments for EGFR ex20ins mutations NSCLC. The efficacy of chemotherapy has been relatively favorable, whereas the effectiveness of immunotherapy remains ambiguous owing to inadequate clinical data. In addition, the efficacy of the first- and second-generation targeted drugs remains limited. However, third-generation and novel targeted drugs have proven to be effective. Although novel EGFR-TKIs are expected to treat EGFR ex20ins mutations in patients with NSCLC, they face many challenges. The main focus of this review is on emerging therapies that target NSCLC with EGFR ex20ins and highlight major ongoing clinical trials while also providing an overview of the associated challenges and research advancements in this area. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1664-3224 -DA - 2024 MAY 7 -PY - 2024 -VL - 15 -C7 - 1399975 -DO - 10.3389/fimmu.2024.1399975 -AN - WOS:001227470600001 -AD - Nanchang Med Coll, Affiliated Hosp Nanchang Med Coll 1, Dept Oncol, Affiliated Hosp 1, Nanchang, Peoples R China -AD - Nanchang Univ, Jiangxi Med Coll, Nanchang, Peoples R China -AD - Jiangxi Prov Peoples Hosp, Dept Chinese & Western Med Oncol, Nanchang, Peoples R China -M2 - Nanchang Med Coll -M2 - Jiangxi Prov Peoples Hosp -Y2 - 2024-05-31 -ER - - -TY - JOUR -AU - Seo, Sang Hoon -AU - Pyo, Hongryull -AU - Ahn, Yong Chan -AU - Oh, Dongryul -AU - Yang, Kyungmi -AU - Kim, Nalee -AU - Sun, Jong-Mu -AU - Park, Sehhoon -AU - Jung, Hyun Ae -AU - Lee, Se-Hoon -AU - Ahn, Jin Seok -AU - Ahn, Myung-Ju -AU - Noh, Jae Myoung -TI - Pulmonary function and toxicities of proton versus photon for limited-stage small cell lung cancer -T2 - RADIATION ONCOLOGY JOURNAL -M3 - Article -AB - Purpose: We aimed to compare the oncological outcomes and toxicities of definitive proton beam therapy (PBT) and photon beam therapy in patients with limited-stage small cell lung cancer (LSSCLC). Materials and Methods: We retrospectively reviewed 262 patients with newly diagnosed LS-SCLC who underwent definitive PBT (n = 20; proton group) or photon beam therapy (n = 242; photon group) with concurrent chemotherapy between January 2016 and February 2021 and compared overall survival (OS), progression-free survival (PFS), dose-volume parameters, and toxicities between the groups. Results: The median follow-up duration was 24.5 months (range, 3.7 to 78.7). Baseline lung function was significantly worse and clinical target volume (CTV) was larger in the proton group (CTV: 296.6 vs. 215.3 mL; p = 0.080). The mean lung V10 was 37.7% +/- 16.8% and 51.6% +/- 24.5% in the proton and photon groups, respectively (p = 0.002). Two-year OS and PFS rates were 57.2% and 35.7% in the proton group and 65.3% and 40.8% in the photon group, respectively (p = 0.542 and 0.748, respectively). Grade =2 radiation pneumonitis and esophagitis occurred in 5 (25.0%) and 7 (35.0%) PBT-treated patients and 66 (27.3%) and 40 (16.5%) photon beam therapy-treated patients, respectively (p = 0.826 and 0.062, respectively). Conclusion: Although the proton group had poorer lung function and a larger CTV than that in the photon group, both groups exhibited comparable treatment outcomes and radiation-related toxicities in LS-SCLC. PBT may be a valuable therapeutic modality in patients with poor pulmonary function or extensive disease burden owing to its lung-sparing ability. -PU - KOREAN SOC THERAPEUTIC RADIOLOGY & ONCOLOGY -PI - SEOUL -PA - DEPT RADIATION ONCOLOGY, SEOUL NATL UNIV HOSPITAL, SEOUL, 110-744, SOUTH KOREA -SN - 2234-3156 -DA - 2023 DEC -PY - 2023 -VL - 41 -IS - 4 -SP - 274 -EP - 282 -DO - 10.3857/roj.2023.00773 -AN - WOS:001167401300007 -AD - Sungkyunkwan Univ, Dept Radiat Oncol, Samsung Med Ctr, Sch Med, Seoul, South Korea -AD - Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea -Y2 - 2024-03-12 -ER - - -TY - JOUR -AU - HASSAN, RAFFIT -TI - Thoracic and Gastrointestinal Malignancies Branch Clinical Core -M3 - Awarded Grant -AB - The medical TGMB has a robust clinical program for treatment of patients with advanced thoracic and GI cancers who have failed standard therapies. The thoracic team is conducting innovative studies for patients with non-small cell lung cancer, small cell lung cancer, malignant mesothelioma and thymic cancers. These include use of novel treatments developed by scientists at the NCI. A major focus of our team is the development of drugs targeting the tumor antigen, mesothelin that is highly expressed in many cancers. We are using an immunotoxin -LMB-100, an antibody drug conjugate- BAY 94-9343, thorium-227 labeled antibody-chelator conjugate-BAY 2287411 and mesothelin targeting CAR-T cells to treat these cancers. In addition, we are conducting clinical trials using immunotherapy agents including immune checkpoint inhibitors to treat patients with thoracic cancers who have failed standard treatments. The TGMB is also conducting studies for treatment of gastrointestinal cancers with a special emphasis on liver and pancreatic cancer. Investigators within the TGMB have established a robust program for treatment of patients with liver cancer including use of immunotherapy agents either alone or in combination with radiation therapy or locally ablative therapies for liver cancer. The gastrointestinal group is also conducting clinical trials of novel agents for treatment of pancreatic cancer. -DA - 2023 -PY - 2023 -AN - GRANTS:17767794 -G1 - 10926685; 1ZIDBC011540-10; ZIDBC011540 -AD - BASIC SCIENCES -M2 - BASIC SCIENCES -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - HASSAN, RAFFIT -TI - Thoracic and Gastrointestinal Malignancies Branch Clinical Core -M3 - Awarded Grant -AB - The medical TGMB has a robust clinical program for treatment of patients with advanced thoracic and GI cancers who have failed standard therapies. The thoracic team is conducting innovative studies for patients with non-small cell lung cancer, small cell lung cancer, malignant mesothelioma and thymic cancers. These include use of novel treatments developed by scientists at the NCI. A major focus of our team is the development of drugs targeting the tumor antigen, mesothelin that is highly expressed in many cancers. We are using an immunotoxin -LMB-100, an antibody drug conjugate- BAY 94-9343, thorium-227 labeled antibody-chelator conjugate-BAY 2287411 and mesothelin targeting CAR-T cells to treat these cancers. In addition, we are conducting clinical trials using immunotherapy agents including immune checkpoint inhibitors to treat patients with thoracic cancers who have failed standard treatments. The TGMB is also conducting studies for treatment of gastrointestinal cancers with a special emphasis on liver and pancreatic cancer. Investigators within the TGMB have established a robust program for treatment of patients with liver cancer including use of immunotherapy agents either alone or in combination with radiation therapy or locally ablative therapies for liver cancer. The gastrointestinal group is also conducting clinical trials of novel agents for treatment of pancreatic cancer. -DA - 2020 -PY - 2020 -AN - GRANTS:15554667 -G1 - 10262804; 1ZIDBC011540-07; ZIDBC011540 -AD - DIVISION OF BASIC SCIENCES - NCI -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Xu, Wei -AU - Zhao, Jing -AU - Luan, Fang -AU - Zhang, Zhizhao -AU - Liu, Lei -AU - Zhao, Hui -AU - Feng, Bin -AU - Fu, Guobin -TI - Survival and safety analysis of COVID-19 vaccine in Chinese patients with non-small cell lung cancer -T2 - CANCER MEDICINE -M3 - Article -AB - Background: Severe acute respiratory syndrome coronavirus 2 disease (COVID-19) has caused a worldwide challenging and threatening pandemic. We aimed to assess the safety and efficacy of the COVID-19 vaccines in Non-Small Cell Lung Cancer (NSCLC) patients. Methods: Patient self-reported adverse events related to vaccines were recorded by follow-up through a uniform questionnaire. Survival analysis was performed by Kaplan-Meier method. A multivariate analysis was performed by the Cox proportional hazard regression model to determine the effect of each variable on the survival of lung cancer patients. Results: A total of 860 patients with NSCLC on treatment were enrolled. Mean age was 57 years in patients with early stage group and 62 years in advanced stage group. The vaccination rate was 71.11% for early-stage patients and 19.48% for advanced-stage patients; most of them (86.5%) received the COVID-19 inactivated virus (Vero cell) vaccine (Coronavac; Sinovac). The most common systemic adverse reaction was weakness. The main reason for vaccine refusal in those unvaccinated patients was concern about the safety of vaccination in the presence of a tumor and undergoing treatment (56.9% and 53.4%). The 1-year disease-free survival (DFS) rate was 100% for vaccinated and 97.4% for unvaccinated early-stage patients. Then we compared the progression-free survival (PFS) of vaccinated (median PFS 9.0 months) and unvaccinated (median PFS 7.0 months) advanced stage patients (p = 0.815). Advanced NSCLC patients continued to be divided into groups receiving radio-chemotherapy, immunotherapy, and targeted therapy, with no statistical difference in PFS between the groups (p > 0.05). The median overall survival (OS) of vaccinated patients was 20.5 months, and that of unvaccinated patients was 19.0 months (p = 0.478) in advanced NSCLC patients. Conclusions: COVID-19 vaccination is safe for Chinese NSCLC patients actively receiving different antitumor treatments without increasing the incidence of adverse reactions, and vaccination does not affect cancer patient survival. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2045-7634 -DA - 2024 APR -PY - 2024 -VL - 13 -IS - 8 -C7 - e7032 -DO - 10.1002/cam4.7032 -AN - WOS:001206273400001 -AD - Shandong First Med Univ, Shandong Prov Hosp, Dept Med Oncol, 324 Jingwuweiqi Rd, Jinan 250021, Shandong, Peoples R China -AD - Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Med Oncol, Jinan, Shandong, Peoples R China -AD - Shandong First Med Univ, Affiliated Hosp 3, Dept Med Oncol, Jinan, Shandong, Peoples R China -Y2 - 2024-04-26 -ER - - -TY - JOUR -AU - Harris, Jeremy P. -AU - Fujimoto, Dylann K. -AU - Nagasaka, Misako -AU - Ku, Eric -AU - Harada, Garrett -AU - Keshava, Hari -AU - Mahtabifard, Ali -AU - Longoria, Javier -AU - Patel, Niral -AU - Seyedin, Steven -AU - Simon, Aaron -AU - Chen, Allen -TI - Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - We performed a case-based survey of the International Association for the Study of Lung Cancer (IASLC) members to determine practice habits for stage III non???small-cell lung cancer patients. The presence of EGFR/ALK alterations were associated with fewer recommendations for chemoradiation. Despite the lack of reported clinical trial data, many IASLC lung cancer experts favored targeted therapy when actionable driver alterations were present. Introduction: Therapeutic options for stage III non???small-cell lung cancer (NSCLC) consist of definitive chemoradiation, surgery combined with neoadjuvant/adjuvant chemotherapy, and trimodality therapy. More recently, biologically driven systemic therapy options, including immunotherapy and targeted therapy, have become increasingly available. Methods: A customized, case-based survey was designed and distributed to members of the International Association for the Study of Lung Cancer (IASLC) to determine practice habits and preferences for NSCLC patients with stage III disease and N2 to N3 nodal involvement. Results: Data were compiled from 87 respondents from 31 countries, including medical oncologists (49%), surgical oncologists (24%), and radiation oncologists (21%). Definitive chemoradiation was more likely to be recommended for stage IIIC (98.2%) or stage IIIB (75.8%) scenarios compared with stage IIIA (59.6%) without actionable driver alterations ( P < .0001 and .0003, respectively); and chemoradiation was more likely for stage IIIB (57.7%) compared to stage IIIA (39.9%) with actionable EGFR/ALK alterations ( P = .008). Surgery was more likely to be recommended in the presence of an actionable alteration (38.7% vs. 19%, P < .0001). Surgeons were more likely than medical oncologists to recommend surgical approaches in scenarios without actionable alterations (25.6% vs. 11.2%, P < .0001) or with actionable alterations (57.5% vs. 31.1%, P = .0001). Discussion: The dominant recommended strategy for stage III NSCLC was chemoradiation, although respondents were more likely to recommend surgical approaches in the presence of actionable alterations. Despite the lack of reported clinical trial data, many IASLC lung cancer experts favored targeted therapy when actionable driver alterations were present. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2022 JUN -PY - 2022 -VL - 23 -IS - 4 -SP - 333 -EP - 344 -DO - 10.1016/j.cllc.2022.02.001 -AN - WOS:000810868000012 -C6 - MAY 2022 -AD - Univ Calif Irvine, Dept Radiat Oncol, Orange, CA 92868 USA -AD - Univ Calif Irvine, Dept Med, Div Hematol Oncol, Orange, CA 92868 USA -AD - Univ Calif Irvine, Dept Med, Div Pulm Dis & Crit Care Med, Orange, CA 92868 USA -AD - Univ Calif Irvine, Dept Surg, Div Cardiothorac Surg, Orange, CA 92868 USA -Y2 - 2022-06-24 -ER - - -TY - JOUR -AU - AKBAY, ESRA -TI - Overcoming Therapy Resistance in SCLC -M3 - Awarded Grant -AB - PROJECT SUMMARY/ABSTRACTSmall cell lungcancer (SCLC) is a pulmonary neuroendocrine cancer with very poor prognosis and limitedeffective therapeutic options. Chemotherapy has been used for the past 30 years as for the treatment for SCLC.While most SCLCs initially respond to this treatment, nearly all relapse. Recently, immunotherapies have beenintroduced in SCLC treatment. While these treatments have revolutionized the treatment of non-small cell lungcancer (NSCLC), they are only effective in a very small subset of SCLCs. Thoracic radiation is recommended inthe course of both limited stage (LS) and extensive stage (ES) SCLC. Radiation has been shown to inducedurable responses by engaging anti-tumor immunity. However, radiation therapy while effective in someindividuals, does not always convert immunologically non-responsive “cold” tumors to become immuneresponsive “hot”. These observations highlight the need to develop new effective treatments for SCLC.In many cancers, the loss of cell cycle checkpoints, together with oncogene activation, leads to cell survival evenwith high levels of replication stress (RS) and DNA damage. Cellular pathways respond to RS, to ensure thatDNA is properly replicated and to prevent cells from prematurely entering mitosis. However, in most advancedsolid tumors, there is an increase in a variety of errors during DNA synthesis, disruption of the DNA damageresponse, and mitotic catastrophe. This continuous and high degree of RS and dependence on DNA repairprovides a potential cancer vulnerability and therapeutic opportunity. The vast majority of human tumorsincluding nearly all of SCLCs are dependent on telomerase holoenzyme to bypass replicative senescenceresulting from telomere shortening with each cell division and this creates a dependency. We are proposing toutilize a molecule that interferes with the function of telomerase to rapidly stop SCLC growth with minimal or nocytotoxic side effects in normal telomerase silent tissues. In our preliminary studies, we discovered that thismolecule not only can kill cancer cells in culture dish, it can also activate the immune system when givenintermittently to the mice. We propose to discover how this molecule sensitizes SCLCs to radiation orchemotherapy treatment (Aim 1), Induce immune responses (Aim 2), and to determine whether it can overcomeresistance to existing treatments (Aim 3). For this goal, we will utilize fully immunocompetent mouse models.Therapies that activate immune system have been less toxic compared to other treatments and often providemore durable responses in patients. We hope that our studies with this molecule will generate information todevelop rationally designed clinical trials which utilize combinations with minimal toxicity and maximumtherapeutic efficacy in small cell lung cancer -DA - 2024 -PY - 2024 -AN - GRANTS:17496465 -G1 - 10858748; 1R01CA289500-01; R01CA289500 -AD - UT SOUTHWESTERN MEDICAL CENTER -Y2 - 2024-03-25 -ER - - -TY - JOUR -AU - Bryan, Darren S. -AU - Donington, Jessica S. -TI - The Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer -T2 - CURRENT TREATMENT OPTIONS IN ONCOLOGY -M3 - Review -AB - Opinion statementPatients with locally advanced non-small cell lung cancer (NSCLC) are treated for cure, but treatment decisions are not straightforward. Chemotherapy is essential due to the high risk of systemic relapse, but local therapy is also required for cure. In the small subset of stage III patients with N0 or N1 disease, surgery is typically the initial therapy and extended resections are frequent. The majority of IIIA patients present with N2 disease and treatment paradigms for these patients are controversial, particularly concerning the role of resection. Surgery has a limited role in bulky IIIA, IIIB, and IIIC disease, which is typically treated with combined systemic therapy and radiation. The authors believe that in resectable IIIA disease, the addition of surgery to multimodality treatment appears to improve local control and overall survival. Induction therapy is essential, and the use of chemotherapy alone or chemoradiotherapy remains an area of debate. Pneumonectomy should be used with caution in IIIA disease, as numerous prospective trials have noted excessive perioperative mortality. The introduction of immunotherapies in this stage may quickly transform treatment decisions. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1527-2729 -SN - 1534-6277 -DA - 2019 APR -PY - 2019 -VL - 20 -IS - 4 -C7 - 27 -DO - 10.1007/s11864-019-0624-7 -AN - WOS:000461365300003 -AD - Univ Chicago, Dept Surg, Med & Biol Sci, 5841 S Maryland Ave, Chicago, IL 60637 USA -AD - Univ Chicago, Dept Surg, Med & Biol Sci, Sect Thorac Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA -Y2 - 2019-03-28 -ER - - -TY - JOUR -AU - Batra, Ullas -AU - Chufal, Kundan Singh -AU - Nathany, Shrinidhi -AU - Ahmad, Irfan -AU - Chowdhary, Rahul Lal -AU - Sharma, Mansi -AU - Jain, Praveen -AU - Gairola, Munish -TI - Immunotherapy in advanced non-small-cell lung cancer (NSCLC) after progression on chemotherapy: real-world results from a prospective institutional cohort -T2 - IMMUNOTHERAPY -M3 - Article -AB - Objective: To analyze the outcomes of patients receiving immunotherapy (IO) with advanced non-driver mutated non-small-cell lung cancer (NSCLC) after progression on systemic treatment. Methods: The overall survival (OS), progression-free survival (PFS) and best response to IO of 64 patients who met our inclusion criteria were analyzed. Results: Median follow-up, OS and PFS were 35.9, 7.1 and 3.2 months, respectively. On uni- and multi-variable analysis, better ECOG PS and fewer extra-thoracic metastases were associated with prolonged OS and PFS. Response to IO was associated with prolonged OS, while thoracic radiotherapy and isolated CNS involvement were associated with prolonged PFS. ECOG PS, thoracic radiotherapy and PDL1 status significantly influenced the likelihood of response to IO. Overall, 30% patients experienced any grade toxicity. Conclusion: Our results are concordant with reported trial outcomes and support the application of IO in Indian patients.Plain language summary Several clinical trials have demonstrated favorable results with immunotherapy in patients with lung cancer who do not have a mutation in their tumors. However, clinical trials are often designed to provide the best chance for a trial drug/intervention to demonstrate effectiveness. Therefore, they usually include relatively healthier patients compared to what clinicians see in their practice. To demonstrate the efficacy of a drug outside a clinical trial, a real-world analysis is performed, which is reported in this article. We analyzed lung cancer patients treated with immunotherapy at our institution and found comparable efficacy to reported clinical trials. This was important because the trials did not include any patients from our country. We also found that patients with fewer sites of involvement outside the lung and those who received radiotherapy to the lung (either during or before receiving immunotherapy) survived longer without disease progression. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1750-743X -SN - 1750-7448 -DA - 2022 AUG -PY - 2022 -VL - 14 -IS - 11 -SP - 851 -EP - 858 -DO - 10.2217/imt-2021-0170 -AN - WOS:000810460700001 -C6 - JUN 2022 -AD - Rajiv Gandhi Canc Inst & Res Ctr, Dept Med Oncol, New Delhi 110085, India -AD - Rajiv Gandhi Canc Inst & Res Ctr, Dept Radiat Oncol, New Delhi 110085, India -AD - Rajiv Gandhi Canc Inst & Res Ctr, Dept Mol Diagnost, New Delhi 110085, India -M2 - Rajiv Gandhi Canc Inst & Res Ctr -M2 - Rajiv Gandhi Canc Inst & Res Ctr -M2 - Rajiv Gandhi Canc Inst & Res Ctr -Y2 - 2022-06-18 -ER - - -TY - JOUR -AU - Peters, S. -AU - Felip, E. -AU - Dafni, U. -AU - Belka, C. -AU - Guckenberger, M. -AU - Irigoyen, A. -AU - Nadal, E. -AU - Becker, A. -AU - Vees, H. -AU - Pless, M. -AU - Martinez-Marti, A. -AU - Tufman, A. -AU - Lambrecht, M. -AU - Andratschke, N. -AU - Piguet, A. C. -AU - Kassapian, M. -AU - Roschitzki-Voser, H. -AU - Rabaglio-Poretti, M. -AU - Stahel, R. A. -AU - Vansteenkiste, J. -AU - De Ruysscher, D. -TI - Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial -T2 - LUNG CANCER -M3 - Article -AB - Objectives: Chemo-radiotherapy (CRT) and concurrent PD-1 inhibition has shown promising results in preclinical models. So far, the feasibility of delivering concurrent CRT and PD-1/PD-L1 inhibition has never been assessed in a clinical trial.Material and methods: NICOLAS is a phase-II trial evaluating the safety and efficacy of nivolumab combined with CRT in stage III NSCLC. Patients received 3 cycles of platinum-based chemotherapy and concurrent RT (66 Gy/33fractions). Nivolumab started concurrently with RT. The primary endpoint was 6-month post-RT rate of grade- >= 3-pneumonitis. A formal interim safety analysis (IA) was scheduled when the first 21 patients reached 3 months follow-up post-RT. An early positive safety conclusion would be reached at IA if there were no grade >= 3-pneumonitis in those patients. Efficacy evaluation was planned provided the safety conclusion was reached.Results and conclusion: As of 13 December 2018, 82 patients were recruited with median follow-up of 13.4 months. The most frequent adverse events (AEs) were anaemia, fatigue and pneumonitis. No unexpected AEs or increased toxicities were observed. For the first 21 patients, no grade- >= 3-pneumonitis was observed by the end of the 3-month post-RT follow-up period.The early safety IA provides evidence that the addition of nivolumab to concurrent CRT is safe and tolerable regarding the 6-month rate of pneumonitis grade >= 3 at the one-sided significance level of 5%. Following that, the 1-year progression-free survival will be evaluated in an expanded patient cohort NICOLAS trial creates the opportunity for assessing the activity of the combination of checkpoint with concurrent CRT in larger prospective trials for locally advanced NSCLC. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2019 JUL -PY - 2019 -VL - 133 -SP - 83 -EP - 87 -DO - 10.1016/j.lungcan.2019.05.001 -AN - WOS:000474326700014 -AD - CHU Vaudois, Dept Oncol, Lausanne, Switzerland -AD - Vall dHebron Univ Hosp, Inst Oncol VHIO, Barcelona, Spain -AD - Frontier Sci Fdn Hellas, Athens, Greece -AD - Univ Athens, Athens, Greece -AD - Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Univ Hosp, Munich, Germany -AD - Ludwig Maximilians Univ Munchen, DZL Munich, Univ Hosp, Munich, Germany -AD - Univ Zurich, Dept Radiat Oncol, Univ Hosp Zurich, Zurich, Switzerland -AD - Hosp Virgen Salud, Dept Med Oncol, Toledo, Spain -AD - IDIBELL Hosp, Dept Med Oncol, Catalan Inst Oncol, Barcelona, Spain -AD - Univ Amsterdam, Med Ctr, Dept Resp Dis, Amsterdam, Netherlands -AD - Clin Hirslanden, Radiat Oncol, Zurich, Switzerland -AD - Cantonal Hosp Winterthur, Med Oncol, Winterthur, Switzerland -AD - Ludwig Maximilian Univ Munich LMU, Med Klin & Poliklin 5, German Ctr Lung Res, Munich, Germany -AD - Univ Hosp Gasthuisberg, Dept Radiotherapy Oncol, Leuven, Belgium -AD - ETOP, Bern, Switzerland -AD - Univ Hosp Zurich, Dept Haematol & Oncol, Zurich, Switzerland -AD - Univ Hosp Gasthuisberg, Dept Resp Dis, Leuven, Belgium -AD - Maastro Clin, Dept Radiat Oncol Maastricht, Maastricht, Netherlands -M2 - Frontier Sci Fdn Hellas -M2 - Clin Hirslanden -M2 - Cantonal Hosp Winterthur -M2 - ETOP -Y2 - 2019-07-01 -ER - - -TY - JOUR -AU - Beattie, Rory -AU - Furrer, Katarzyna -AU - Dolan, Daniel P. -AU - Curioni-Fontecedro, Alessandra -AU - Lee, Daniel N. -AU - Frauenfelder, Thomas -AU - Hoeller, Sylvia -AU - Weder, Walter -AU - Bueno, Raphael -AU - Opitz, Isabelle -AU - Swanson, Scott -TI - Two centres experience of lung cancer resection in patients with advanced non-small cell lung cancer upon treatment with immune checkpoint inhibitors: safety and clinical outcomes -T2 - EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY -M3 - Article -M3 - Proceedings Paper -CP - 1st Annual Meeting of the European-Society-of-Thoracic-Surgeons (ESTS) -CL - ELECTR NETWORK -AB - OBJECTIVES: Recent trials have begun to explore immune checkpoint inhibitors for non-small cell lung cancer in the neoadjuvant setting, but data on tumour response and surgical outcome remain limited.METHODS: Retrospective evaluation of clinical data from patients with non-small cell lung cancer treated with immune checkpoint inhibitors followed by lung resection was performed at 2 large volume institutions (1 North American, 1 European). Data were analysed using Chi-squared, Fisher's and Wilcoxon rank-sum tests where appropriate.RESULTS: Thirty-seven patients were identified from 2017 to 2019. Forty-nine per cent were Stage IIIB and IV. Forty-six per cent received immunotherapy alone and 54% in combination with chemo- and/or radiotherapy. Sixteen per cent of cases were successfully performed minimally invasively. Twenty patients were operated with lobectomy (6 of these with wedges or segments of a neighbouring lobe, 2 with sleeve resections and 1 with a chest wall resection), 4 with bilobectomies, 11 with pneumonectomy (including 5 extrapleural pneumonectomies and 1 atrial resection) and 1 with a wedge resection. Overall, 10 patients (27%) developed postoperative complications and the 90day mortality was zero. One-year recurrence-free survival was 73% for stage II/IIIA and 55% for stage IIIB/stage IV. The major pathologic response rate was 34%.CONCLUSION: In this retrospective study, lung resection after immunotherapy (alone or in combination) is safe, although often requires complex surgery. Due to increasing number of clinical trials adopting immunotherapy in the neoadjuvant setting, it is likely that this therapy will become part of standard of care. Immunotherapy may also allow surgery to have a role for selected patients with advanced disease. -PU - OXFORD UNIV PRESS INC -PI - CARY -PA - JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA -SN - 1010-7940 -SN - 1873-734X -DA - 2021 DEC -PY - 2021 -VL - 60 -IS - 6 -SP - 1297 -EP - 1305 -DO - 10.1093/ejcts/ezab340 -AN - WOS:000743557800009 -C6 - JUL 2021 -AD - Brigham & Womens Hosp, Dept Thorac Surg, 75 Francis St, Boston, MA 02115 USA -AD - Univ Hosp Zurich, Dept Thorac Surg, Zurich, Switzerland -AD - Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland -AD - Univ Hosp Zurich, Dept Diagnost & Intervent Radiol, Zurich, Switzerland -AD - Univ Hosp Zurich, Dept Pathol & Mol Pathol, Zurich, Switzerland -Y2 - 2022-02-14 -ER - - -TY - JOUR -AU - Bao, Zheming -AU - Yu, Xiuchun -AU - Zheng, Kai -AU - Zhai, Kai -AU - Cui, Haocheng -AU - Xu, Ming -TI - Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC -T2 - FRONTIERS IN IMMUNOLOGY -M3 - Article -AB - Background Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer (NSCLC), which is resistant to chemotherapy and radiotherapy with a poor prognosis. PSC is highly malignant and is prone to recurrence even after surgery. The programmed death-ligand 1 (PD-L1) tumor cell proportion score (TPS) 5%, TERT and TP53 gene mutations were detected in this patient accompanied by multiple metastatic sites. The anlotinib is a novel multitarget tyrosine kinase inhibitor (TKI) that could be effective for advanced NSCLC and some sarcoma patients. Limited clinical trials and case reports have shown that PSC patients with gene mutations and PD-L1 expression have good responses to multitarget antiangiogenic drug and immune checkpoint inhibitors (ICIs). In this article, we reported a case with metastatic PSC diagnosed by Computed Tomography (CT)-guided needle biopsy treated with immunotherapy combined with antiangiogenic drugs as a neoadjuvant chemotherapy (NACT). PSC is controlled and the patient achieves successfully limb salvage treatment by surgical resection. Therefore, targeted therapy and immunotherapy can provide sufficient surgical opportunities for limb salvage in the treatment of metastatic PSC patients.Case summary A 69-year-old male diagnosed with malignant bone tumor in the proximal femur was admitted to our hospital in June 2022 with recurrent fever as well as swelling and pain in the left thigh for twenty days. The initial computed tomography (CT) scan of the chest showed a pulmonary cavity (20 mm x 30 mm) and scattered lung masses. Subsequently, he underwent a CT-guided needle biopsy to distinguish the essence of osteolytic bone destruction and soft tissue mass in the left proximal femur which showed metastatic sarcomatoid carcinoma histology. Genetic testing revealed TERT c.-124C mutation (abundance 8.81%), TP53 p.R342 mutation (abundance 11.35%), tumor mutational burden (TMB) 7.09 muts/Mb, microsatellite stability (MSS), and PD-L1 (SP263) TPS 5% were also detected. The patient was tentatively treated with a combination of antiangiogenic drug and PD-1 inhibitor. After one course, the tumor volume significantly reduced in magnetic resonance imaging (MRI) and pathological fracture occurred in the femur after combined treatment. The patient received proximal femoral tumor resection and prosthesis replacement after defervescence. Sequentially sintilimab with anlotinib were administered for over 1 year. Finally, the local tumor was well controlled, and no obvious drug-related adverse reactions were observed. The lesions in the lung remained in partial response (PR) for more than 16 months and complete response (CR) of metastatic tumor in the proximal femur was observed through imaging examinations.Conclusion This is the first reported case of a metastatic PSC in femur showing a favorable response to the treatment consisting of anlotinib combined with sintilimab. This case suggests that antiangiogenic therapy combined with immunotherapy may benefit patients with metastatic PSC in the preoperative adjuvant therapy for limb salvage. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1664-3224 -DA - 2024 MAY 2 -PY - 2024 -VL - 15 -C7 - 1372279 -DO - 10.3389/fimmu.2024.1372279 -AN - WOS:001223217100001 -AD - Peoples Liberat Army PLA Joint Serv Support Force, Orthoped Dept, Hosp 960, Jinan, Peoples R China -M2 - Peoples Liberat Army PLA Joint Serv Support Force -Y2 - 2024-05-24 -ER - - -TY - JOUR -Z2 - 张超男 -Z2 - 王文卿 -Z2 - 周宗玫 -Z2 - 邓垒 -Z2 - 毕楠 -Z2 - 张涛 -Z2 - 王健仰 -Z2 - 王鑫 -Z2 - 刘文扬 -Z2 - 肖泽芬 -Z2 - 吕纪马 -Z2 - 翟医蕊 -Z2 - 冯勤付 -AU - Zhang Chaonan -AU - Wang Wenqing -AU - Zhou Zongmei -AU - Deng Lei -AU - Bi Nan -AU - Zhang Tao -AU - Wang Jianyang -AU - Wang Xin -AU - Liu Wenyang -AU - Xiao Zefen -AU - Lyu Jima -AU - Zhai Yirui -AU - Feng Qinfu -TI - Efficacy and toxicity analysis of thoracic radiotherapy for extensive-stage small cell lung cancer patients after first-line chemoimmunotherapy -T2 - Chinese Journal of Radiation Oncology -M3 - Article -AB - Objective To evaluate the safety and efficacy of thoracic radiotherapy (TRT) for extensive-stage small cell lung cancer (ES-SCLC) patients in the era of first-line chemoimmunotherapy. Methods Medical records of 56 patients with ES-SCLC who received thoracic radiotherapy after first-line platinum-based chemotherapy plus immunotherapy in Cancer Hospital Chinese Academy of Medical Sciences from January 2018 to December 2021 were retrospectively analyzed. The control group was not established for clinical causes. The overall survival (OS), progression-free survival (PFS) and local recurrence-free survival (LRFS) were calculated using the Kaplan-Meier method. Univariate and multivariate analyses were employed to identify prognostic factors using the Cox proportional hazards model. The cumulative incidence of local regional recurrence (LRR) was estimated using the Fine-Grey competing risks regression model. Results Among 56 patients in our cohort, 47 patients received consolidative TRT (cTRT) before progression and 9 patients received salvage TRT after progression. The median follow-up time was 21 months (95%CI=19.8-22.2 months), the median OS was not reached, the median PFS was 9 months (95%CI=7.0-13.0 months), and the 1-year and 18-month OS rates were 84.9%, 62.1%. In the cTRT group, the 1-year and 18-month OS rates were 84.1%, 64.5%, with the median PFS of 10 months; 1-year and 18-month LRFS rates were 73.6% and 66.0%, respectively; the cumulative incidence of LRR at 1-year and 2-year were 24.9% and 30.8%, respectively. No other 4-5 grade adverse events (AE) were reported except 6 patients presenting with 4 grade hematologic toxicities. Three grade radiation esophagitis occurred in 3 patients (5%). Ten patients (18%) developed 1-2 grade treatment-related pneumonitis, including 5 (9%) patients with immune related pneumonitis and 5 (9%) patients with radiation pneumonitis. Conclusion The application of TRT after first-line chemoimmunotherapy is safe and may has potential survival benefit for patients with ES-SCLC. -SN - 1004-4221 -DA - 2024 -PY - 2024 -VL - 33 -IS - 8 -SP - 703 -EP - 710 -C7 - 1004-4221(2024)33:8<703:GFQSYX>2.0.TX;2-T -AN - CSCD:7774084 -AD - 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院放疗科, 国家肿瘤临床医学研究中心, 北京 100021, 中国 -AD - Department of Radiation Oncology, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Cancer, Beijing 100021, China -M2 - 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院放疗科 -M2 - Department of Radiation Oncology, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College -Y2 - 2024-09-27 -ER - - -TY - JOUR -AU - Wang, Yinhua -AU - Shi, Xiuhua -AU - Qi, Qinghua -AU - Ye, Bin -AU - Zou, Zhaoling -TI - Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers -T2 - JOURNAL OF HEALTHCARE ENGINEERING -M3 - Article -AB - Objective. To explore the safety of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of advanced non-small-cell lung cancer (NSCLC) and their effect on serum tumor markers. Methods. 88 patients with advanced NSCLC treated in the Oncology Department of our hospital from December 2018 to December 2019 were selected as research subjects and randomly and equally split into the single treatment group (STG) and combined treatment group (CTG). The levels of serum tumor markers after treatment were detected in both groups, and the incidence of adverse reactions during treatment was recorded. Results. Compared with the STG, CTG achieved obviously higher total effective rate (P < 0.05), lower total incidence of adverse reactions (P < 0.05), lower levels of serum tumor markers and average CFS score (P < 0.001), and higher average KPS score (P < 0.001). Conclusion. Application of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of advanced NSCLC can effectively reduce the levels of serum tumor markers and cancer fatigue degree of patients, with a better effect than that of simple anlotinib treatment. In addition, further research of the combined treatment is helpful to establish a better therapeutic regimen for patients with advanced NSCLC. -PU - HINDAWI LTD -PI - LONDON -PA - ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND -SN - 2040-2295 -SN - 2040-2309 -DA - 2021 DEC 15 -PY - 2021 -VL - 2021 -C7 - 2338800 -DO - 10.1155/2021/2338800 -AN - WOS:000769480800005 -AD - Second Peoples Hosp Wuhu City, Dept Radiotherapy, Wuhu 241000, Anhui, Peoples R China -AD - Second Peoples Hosp Wuhu City, Dept Hematol, Wuhu 241000, Anhui, Peoples R China -M2 - Second Peoples Hosp Wuhu City -M2 - Second Peoples Hosp Wuhu City -Y2 - 2022-04-03 -ER - - -TY - JOUR -AU - Simone, Charles B. -AU - Bradley, Jeffrey -AU - Chen, Aileen B. -AU - Daly, Megan E. -AU - V. Louie, Alexander -AU - Robinson, Clifford G. -AU - Videtic, Gregory M. M. -AU - Rodrigues, George -TI - ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer -T2 - PRACTICAL RADIATION ONCOLOGY -M3 - Article -AB - Purpose: To develop a radiation therapy summary of recommendations on the management of locally advanced non-small cell lung cancer (NSCLC) based on the Management of Stage III Non-Small Cell Lung Cancer: American Society of Clinical Oncology Guideline, which was endorsed by the American Society for Radiation Oncology (ASTRO).Methods: The American Society of Clinical Oncology, ASTRO, and the American College of Chest Physicians convened a multidisci-plinary panel to develop a guideline based on a systematic review of the literature and a formal consensus process, that has been sepa-rately published. A new panel consisting of radiation oncologists from the original guideline as well as additional ASTRO members was formed to provide further guidance to the radiation oncology community. A total of 127 articles met the eligibility criteria to answer 5 clinical questions. This summary focuses on the 3 radiation therapy questions (neoadjuvant, adjuvant, and unresectable settings). Results: Radiation-specific recommendations are summarized with additional relevant commentary on specific questions regarding the management of preoperative radiation, postoperative radiation, and combined chemoradiation.Conclusions: Patients with stage III NSCLC who are planned for surgical resection, should receive either neoadjuvant chemotherapy or chemoradiation. The addition of neoadjuvant treatment is particularly important in patients planned for surgery in the N2 or superior sulcus settings. Postoperatively, patients who did not receive neoadjuvant chemotherapy should be offered adjuvant chemotherapy. The use of postoperative radiation for completely resected N2 disease is not routinely recommended. Unresectable patients with stage III NSCLC should ideally be managed with combined concurrent chemoradiation using a platinum-based doublet with a standard radia-tion dose of 60 Gy followed by consolidation durvalumab in patients without progression after initial therapy. Patients who cannot tol-erate a concurrent chemoradiation approach can be managed either by sequential chemotherapy followed by radiation or by dose -escalated or hypofractionated radiation alone. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1879-8500 -DA - 2023 MAY-JUN -PY - 2023 -VL - 13 -IS - 3 -SP - 195 -EP - 202 -DO - 10.1016/j.prro.2023.01.005 -AN - WOS:000983321600001 -C6 - APR 2023 -AD - New York Proton Ctr, Dept Radiat Oncol, New York, NY USA -AD - Emory Univ, Dept Radiat Oncol, Sch Med, Atlanta, GA USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA -AD - Univ Calif Davis, Dept Radiat Oncol, Comprehens Canc Ctr, Sacramento, CA USA -AD - Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Toronto, ON, Canada -AD - Washington Univ, Dept Radiat Oncol, Sch Med, St Louis, MO USA -AD - Cleveland Clin, Dept Radiat Oncol, Taussig Canc Inst, Cleveland, OH USA -AD - London Hlth Sci Canc, Dept Radiat Oncol, London, ON, Canada -M2 - New York Proton Ctr -M2 - London Hlth Sci Canc -Y2 - 2023-05-18 -ER - - -TY - JOUR -AU - Kanda, S. -AU - Goto, K. -AU - Shiraishi, H. -AU - Kubo, E. -AU - Tanaka, A. -AU - Utsumi, H. -AU - Sunami, K. -AU - Kitazono, S. -AU - Mizugaki, H. -AU - Horinouchi, H. -AU - Fujiwara, Y. -AU - Nokihara, H. -AU - Yamamoto, N. -AU - Hozumi, H. -AU - Tamura, T. -TI - Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study -T2 - ANNALS OF ONCOLOGY -M3 - Article -AB - Background: The human IgG4 monoclonal antibody nivolumab targets programmed cell death-1 (PD-1) and promotes antitumor response by blocking the interaction of PD-1 with its ligands. This single-center phase Ib study investigated the tolerability, safety, and pharmacokinetics of nivolumab combined with standard chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC).Patients and methods: Patients who had stage IIIB without indication for definitive radiotherapy, stage IV, or recurrent NSCLC were eligible. Regimens were nivolumab 10 mg/kg + gemcitabine/cisplatin (arm A), pemetrexed/cisplatin (arm B), paclitaxel/carboplatin/bevacizumab (arm C), or docetaxel (arm D). Regimens A, B, and D were repeated every 3 weeks for up to four cycles and regimen C was repeated for up to six cycles; nivolumab alone (arm A), with pemetrexed (arm B), bevacizumab (arm C), or docetaxel (arm D) was continued every 3 weeks as maintenance therapy until disease progression or unacceptable toxicity. Dose-limiting toxicity (DLT) was evaluated during the first treatment cycle.Results: As of March 2014, six patients were enrolled in each arm. The combination of nivolumab 10 mg/kg and chemotherapy was well tolerated. DLT was observed in only one patient in arm A (alanine aminotransferase increased). Select adverse events (those with a potential immunologic cause) of any grade were observed in six, four, six, and five patients in arms A, B, C, and D, respectively. Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.Conclusions: Combination of nivolumab 10 mg/kg and chemotherapy showed an acceptable toxicity profile and encouraging antitumor activity in patients with advanced NSCLC. -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 0923-7534 -SN - 1569-8041 -DA - 2016 DEC -PY - 2016 -VL - 27 -IS - 12 -SP - 2242 -EP - 2250 -DO - 10.1093/annonc/mdw416 -AN - WOS:000392825100016 -AD - Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan -AD - ONO Pharmaceut Co Ltd, Osaka, Japan -Y2 - 2017-02-22 -ER - - -TY - JOUR -Z2 - 孟凡伟 -Z2 - 宗丹 -Z2 - 丁乃昕 -Z2 - 许琦涔 -Z2 - 夏国豪 -Z2 - 何侠 -Z2 - 朱向帜 -AU - Meng Fanwei -AU - Zong Dan -AU - Ding Naixin -AU - Xu Qicen -AU - Xia Guohao -AU - He Xia -AU - Zhu Xiangzhi -TI - Clinical research of first - line chemotherapy and immunotherapy combined with chest radiotherapy for extensive-stage small cell lung cancer -T2 - Chinese Journal of Radiation Oncology -M3 - Article -AB - Objective To evaluate the safety and efficacy of sequential consolidation thoracic radiotherapy after first-line chemotherapy combined with immunotherapy for extensive - stage small cell lung cancer (SCLC).Methods A retrospective analysis of patients with extensive - stage SCLC admitted to Jiangsu Cancer Hospital from January 2019 to September 2022 was conducted.Patients who achieved effective chemotherapy combined with immunotherapy received sequential consolidation thoracic radiotherapy.The safety was evaluated according to the common terminology criteria for adverse events (CTCAE) 5.0 standard,and the overall survival (OS) and progression - free survival (PFS) were analyzed by Kaplan - Meier method.Results A total of 33 patients were enrolled,with a median age of 66 years (range,50-79 years).The median follow -up time was 20 months (range,3-33 months).Fifteen patients (46%) had disease progression,and 12 patients (36%) died.The toxicities mainly included leukopenia,thrombocytopenia,radiation esophagitis,anorexia,and fatigue,etc.Six patients (18%) had grade 4 hematological toxicity,mainly leukopenia.One patient (3%) had grade 3 radiation pneumonitis,and 3 patients (9%) had grade 1-2 radiation pneumonitis.No grade 5 toxicity was observed in all patient groups.The median PFS was 12 months (95%CI=3.9-20.1).The 6- month,1- year,and 2- year PFS rates were 78%,49.6%,and 35.6%,respectively.The median OS was 23 months (95%CI=15.98-30.01).The 6-month,1-year,and 2 - year OS rates were 86.2%,74.5%,and 47.2%,respectively.Conclusions Sequential consolidation thoracic radiotherapy after first-line chemotherapy combined with immunotherapy is a safe protocol for extensive-stage SCLC.It brings survival benefits to patients by increasing PFS and OS rates. -SN - 1004-4221 -DA - 2024 -PY - 2024 -VL - 33 -IS - 2 -SP - 110 -EP - 115 -C7 - 1004-4221(2024)33:2<110:GFQXXB>2.0.TX;2-J -AN - CSCD:7648179 -AD - 宿州市第一人民医院放疗科;;南京医科大学附属肿瘤医院放疗科,江苏省肿瘤医院,江苏省肿瘤防治研究所, ;;, 宿州;;南京, ;; 234000;;210009 -AD - 南京医科大学附属肿瘤医院放疗科,江苏省肿瘤医院,江苏省肿瘤防治研究所;;南京医科大学第四临床医学院, ;;, 南京;;南京, ;; 210009;;210009 -AD - Department of Radiation Oncology,Suzhou First People's Hospital;;Department of Radiation Oncology,The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research, ;;, Suzhou;;Nanjing, ;; 234000;;210009 -AD - Department of Radiation Oncology,The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research;;The Fourth Clinical Medical College of Nanjing Medical University, ;;, Nanjing;;Nanjing, ;; 210009;;210009 -M2 - 宿州市第一人民医院放疗科;;南京医科大学附属肿瘤医院放疗科,江苏省肿瘤医院,江苏省肿瘤防治研究所 -M2 - 南京医科大学附属肿瘤医院放疗科,江苏省肿瘤医院,江苏省肿瘤防治研究所;;南京医科大学第四临床医学院 -M2 - Department of Radiation Oncology,Suzhou First People's Hospital;;Department of Radiation Oncology,The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research -M2 - Department of Radiation Oncology,The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research;;The Fourth Clinical Medical College of Nanjing Medical University -Y2 - 2024-04-12 -ER - - -TY - JOUR -AU - HASSAN, RAFFIT -TI - Thoracic and Gastrointestinal Malignancies Branch Clinical Core -M3 - Awarded Grant -AB - The medical TGMB has a robust clinical program for treatment of patients with advanced thoracic and GI cancers who have failed standard therapies. The thoracic team is conducting innovative studies for patients with non-small cell lung cancer, small cell lung cancer, malignant mesothelioma and thymic cancers. These include use of novel treatments developed by scientists at the NCI. A major focus of our team is the development of drugs targeting the tumor antigen, mesothelin that is highly expressed in many cancers. We are using an immunotoxin -LMB-100 and an antibody drug conjugate- BAY 94-9343 to treat these cancers. In addition, we are conducting clinical trials using immunotherapy agents including immune checkpoint inhibitors to treat patients with thoracic cancers who have failed standard treatments. The TGIB is also conducting studies for treatment of gastrointestinal cancers with a special emphasis on liver and pancreatic cancer. Investigators within the TGMB have established a robust program for treatment of patients with liver cancer including use of immunotherapy agents either alone or in combination with radiation therapy or locally ablative therapies for liver cancer. The gastrointestinal group is also conducting clinical trials of novel agents for treatment of pancreatic cancer. -DA - 2019 -PY - 2019 -AN - GRANTS:14989902 -G1 - 10015115; 1ZIDBC011540-06; ZIDBC011540 -AD - DIVISION OF BASIC SCIENCES - NCI -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Chen, N. -AU - Qiu, B. -AU - Zhou, Y. -AU - Luo, Y. -AU - Chu, C. -AU - Li, Q. -AU - Wang, B. -AU - Li, C. -AU - Jiang, H. -AU - Liu, F. -AU - Wang, D. -AU - Huang, X. -AU - Xiong, M. -AU - Liu, H. -TI - Radiomic Features of Tumor and Tumor Organismal Environment in Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy: A Retrospective Analysis of Survival Prediction -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 2190 -SP - E114 -EP - E114 -AN - WOS:000715803800192 -AD - Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China -AD - SuZhou TongDiao Co, Suzhou, Peoples R China -AD - Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China -AD - Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol, Guangzhou, Peoples R China -AD - Homol Med Technol Inc, Ningbo, Peoples R China -M2 - SuZhou TongDiao Co -M2 - Homol Med Technol Inc -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Averbuch, Itamar -AU - Tschernichovsky, Roi -AU - Icht, Oded -AU - Goldstein, Daniel A. -AU - Mutai, Raz -AU - Dudnik, Elizabeth -AU - Rotem, Ofer -AU - Peled, Nir -AU - Allen, Aaron M. -AU - Laufer-Geva, Smadar -AU - Goldberg, Yael -AU - Zer, Alona -TI - Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non-small cell lung cancer: A large real-world cohort and review of the literature -T2 - THORACIC CANCER -M3 - Review -AB - Background: Mutations in genes involved in DNA damage repair (DDR), a hallmark of cancer, are associated with increased cancer cell sensitivity to certain therapies. This study sought to evaluate the association of DDR pathogenic variants with treatment efficacy in patients with advanced non-small cell lung cancer (NSCLC).Methods: A retrospective cohort of consecutive patients with advanced NSCLC attending a tertiary medical center who underwent next-generation sequencing in 01/2015-8/2020 were clustered according to DDR gene status and compared for overall response rate (ORR), progression-free survival (PFS) (patients receiving systemic therapy), local PFS (patients receiving definitive radiotherapy), and overall survival (OS) using log-rank and Cox regression analyses.Results: Of 225 patients with a clear tumor status, 42 had a pathogenic/likely pathogenic DDR variant (pDDR), and 183 had no DDR variant (wtDDR). Overall survival was similar in the two groups (24.2 vs. 23.1 months, p = 0.63). The pDDR group had a higher median local PFS after radiotherapy (median 45 months vs. 9.9 months, respectively; p = 0.044), a higher ORR (88.9% vs. 36.2%, p = 0.04), and a longer median PFS (not reached vs. 6.0 months, p = 0.01) in patients treated with immune checkpoint blockade. There was no difference in ORR, median PFS, and median OS in patients treated with platinum-based chemotherapy.Conclusion: Our retrospective data suggest that in patients with stage 4 NSCLC, pathogenic variants in DDR pathway genes may be associated with higher efficacy of radiotherapy and immune checkpoint inhibitors (ICIs). This should be further explored prospectively. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1759-7706 -SN - 1759-7714 -DA - 2023 JUN -PY - 2023 -VL - 14 -IS - 17 -SP - 1589 -EP - 1596 -DO - 10.1111/1759-7714.14902 -AN - WOS:000977164000001 -C6 - APR 2023 -AD - Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel -AD - Assuta Med Ctr, Oncol Div, Tel Aviv, Israel -AD - Shaare Zedek Med Ctr, Oncol Div, Jerusalem, Israel -AD - Rabin Med Ctr, Raphael Recanati Genet Inst, Petah Tiqwa, Israel -AD - Rambam Hlth Care Campus, Fishman Oncol Inst, Haifa, Israel -AD - Rabin Med Ctr, Davidoff Canc Ctr, 39 Jabotinsky St, IL-4941492 Petah Tiqwa, Israel -M2 - Assuta Med Ctr -Y2 - 2023-05-28 -ER - - -TY - JOUR -AU - Chicas-Sett, Rodolfo -AU - Zafra-Martin, Juan -AU - Morales-Orue, Ignacio -AU - Castilla-Martinez, Juan -AU - Berenguer-Frances, Miguel A. -AU - Gonzalez-Rodriguez, Elisa -AU - Rodriguez-Abreu, Delvys -AU - Counago, Felipe -TI - Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent -T2 - CANCERS -M3 - Review -AB - Lung cancer is one of the main causes of cancer-related mortality worldwide. Over the years, different therapeutic modalities have been adopted depending on tumor stage and patient characteristics, such as surgery, radiotherapy (RT), and chemotherapy. Recently, with the development of immune-checkpoint inhibitors (ICI), the treatment of metastatic and locally advanced non-small cell lung cancer (NSCLC) has experienced a revolution that has resulted in a significant improvement in overall survival with an enhanced toxicity profile. Despite this paradigm shift, most patients present some kind of resistance to ICI. In this setting, current research is shifting towards the integration of multiple therapies, with RT and ICI being one of the most promising based on the potential immunostimulatory synergy of this combination. This review gives an overview of the evolution and current state of the combination of RT and ICI and provides evidence-based data that can improve patient selection. The combination in lung cancer is a safe therapeutic approach that improves local control and progression-free survival, and it has the potential to unleash abscopal responses. Additionally, this treatment strategy seems to be able to re-sensitize select patients that have reached a state of resistance to ICI, further enabling the continuation of systemic therapy. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2020 AUG -PY - 2020 -VL - 12 -IS - 8 -C7 - 2178 -DO - 10.3390/cancers12082178 -AN - WOS:000579031500001 -AD - Dr Negrin Univ Hosp Gran Canaria, Dept Radiat Oncol, Barranco Ballena S-N,Planta 2, Las Palmas Gran Canaria 35010, Spain -AD - IMED Hosp, Dept Radiat Oncol, Ave Nueva Condomina 11, Murcia 30110, Spain -AD - Nisa Vithas Virgen del Consuelo Hosp, Dept Radiat Oncol, Callosa den Sarria 12, Valencia 46007, Spain -AD - Complejo Hosp Univ Insular Maternoinfantil Gran C, Dept Med Oncol, Calle Francisco Hernandez Gonzalez 1, Las Palmas Gran Canaria 35016, Spain -AD - Univ Las Palmas Gran Canaria, Clin Deparment, Fac Biomed, Calle Juan de Quesada 30, Las Palmas Gran Canaria 35001, Spain -AD - Quironsalud Madrid Univ Hosp, Dept Radiat Oncol, Calle Diego de Velazquez 1, Madrid 28223, Spain -AD - La Luz Hosp, Dept Radiat Oncol, Calle Maestro Angel Llorca 8, Madrid 28003, Spain -AD - Univ Europea Madrid, Fac Biomed, Clin Dept, Calle Tajo S-N, Madrid 28670, Spain -M2 - Dr Negrin Univ Hosp Gran Canaria -M2 - Nisa Vithas Virgen del Consuelo Hosp -M2 - Complejo Hosp Univ Insular Maternoinfantil Gran C -M2 - La Luz Hosp -Y2 - 2020-10-30 -ER - - -TY - JOUR -AU - Flakus, Mattison J. -AU - Kent, Sean P. -AU - Wallat, Eric M. -AU - Wuschner, Antonia E. -AU - Tennant, Erica -AU - Yadav, Poonam -AU - Burr, Adam -AU - Yu, Menggang -AU - Christensen, Gary E. -AU - Reinhardt, Joseph M. -AU - Bayouth, John E. -AU - Baschnagel, Andrew M. -TI - Metrics of dose to highly ventilated lung are predictive of radiation-induced pneumonitis in lung cancer patients -T2 - RADIOTHERAPY AND ONCOLOGY -M3 - Article -AB - Purpose: To identify metrics of radiation dose delivered to highly ventilated lung that are predictive of radiation-induced pneumonitis. Methods and Materials: A cohort of 90 patients with locally advanced non-small cell lung cancer treated with standard fractionated radiation therapy (RT) (60-66 Gy in 30-33 fractions) were evaluated. Regional lung ventilation was determined from pre-RT 4-dimensional computed tomography (4DCT) using the Jacobian determinant of a B-spline deformable image registration to estimate lung tissue expansion during respiration. Multiple voxel-wise population- and individual-based thresholds for defining high functioning lung were considered. Mean dose and volumes receiving dose >= 5-60 Gy were analyzed for both total lung-ITV (MLD,V5-V60) and highly ventilated functional lung-ITV (fMLD,fV5-fV60). The primary endpoint was symptomatic grade 2+ (G2+) pneumonitis. Receiver operator curve (ROC) analyses were used to identify predictors of pneumonitis. Results: G2+ pneumonitis occurred in 22.2% of patients, with no differences between stage, smoking status, COPD, or chemo/immunotherapy use between G<2 and G2+ patients (P >= 0.18). Highly ventilated lung was defined as voxels exceeding the population-wide median of 18% voxel-level expansion. All total and functional metrics were significantly different between patients with and without pneumonitis (P <= 0.039). Optimal ROC points predicting pneumonitis from functional lung dose were fMLD <= 12.3 Gy, fV5 <= 54% and fV20 <= 19 %. Patients with fMLD <= 12.3 Gy had a 14% risk of developing G2+ pneumonitis whereas risk significantly increased to 35% for those with fMLD > 12.3 Gy (P = 0.035). Conclusions: Dose to highly ventilated lung is associated with symptomatic pneumonitis and treatment planning strategies should focus on limiting dose to functional regions. These findings provide important metrics to be used in functional lung avoidance RT planning and designing clinical trials. (c) 2023 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 182 (2023) 109553 -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0167-8140 -SN - 1879-0887 -DA - 2023 MAY -PY - 2023 -VL - 182 -C7 - 109553 -DO - 10.1016/j.radonc.2023.109553 -AN - WOS:000954868500001 -C6 - MAR 2023 -AD - Univ Wisconsin Madison, Dept Med Phys, Madison, WI USA -AD - Univ Wisconsin Madison, Dept Stat, Madison, WI USA -AD - Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA -AD - Northwestern Univ, Feinberg Sch Med, Dept Radiat Oncol, Chicago, IL USA -AD - Univ Wisconsin Hosp & Clin, Dept Human Oncol, Madison, WI 53792 USA -AD - Univ Wisconsin Hosp & Clin, Dept Biostat & Med Informat, Madison, WI USA -AD - Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA USA -AD - Univ Iowa, Roy J Carver Dept Biomed Engn, Iowa City, IA USA -AD - Oregon Hlth & Sci Univ, Dept Radiat Med, Portland, OR USA -Y2 - 2023-04-08 -ER - - -TY - JOUR -AU - Yamane, Masaomi -AU - Toyooka, Shinichi -TI - Role of surgery in a novel multimodal therapeutic approach to complete cure of advanced lung cancer: current and future perspectives -T2 - SURGERY TODAY -M3 - Review -AB - Non-small cell lung cancer (NSCLC) is considered potentially curable by multimodal therapy in a subset of patients, including those with locally advanced (LA) disease or nodal spread, who would otherwise have a poor prognosis. Guidelines recommend perioperative chemotherapy with platinum-based regimens, with or without radiotherapy, as the standard treatment modality for high-risk resectable LA-NSCLC. Although the classical regimens of adjuvant chemotherapy have been platinum-based doublet or oral agents such as tegafur/uracil, some molecular targeted therapeutic agents and immune checkpoint inhibitors have been developed recently with an expected favorable effect. Recent trials of perioperative therapy using these agents have demonstrated favourable anticancer efficacy for LA-NSCLC with an acceptable adverse events profile. The ideal timing of perioperative therapy administration, before or after surgery, is still controversial. Because some speculation and concepts have arisen from basic research, several trials are ongoing to clarify the efficacy of newly developed agents in the adjuvant or neoadjuvant setting. This review discusses the role of surgery in the new era and analyzes when and which optimal perioperative multimodal therapy, including chemotherapy, radiotherapy, molecular-targeted therapy, and immunotherapy, should be administered for resectable or potentially resectable NSCLC to provide possible complete cure. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 0941-1291 -SN - 1436-2813 -DA - 2022 JAN -PY - 2022 -VL - 52 -IS - 1 -SP - 1 -EP - 11 -DO - 10.1007/s00595-021-02228-2 -AN - WOS:000630247200002 -C6 - MAR 2021 -AD - Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg, Kita Ku, 2-5-1 Shikata Cho, Okayama, Okayama 7008558, Japan -AD - Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Breast & Endocrinol Surg, Kita Ku, 2-5-1 Shikata Cho, Okayama, Okayama 7008558, Japan -Y2 - 2021-03-25 -ER - - -TY - JOUR -AU - Hotta, K. -AU - Saeki, S. -AU - Yamaguchi, M. -AU - Harada, D. -AU - Bessho, A. -AU - Tanaka, K. -AU - Inoue, K. -AU - Gemba, K. -AU - Shiojiri, M. -AU - Kato, Y. -AU - Ninomiya, T. -AU - Kubo, T. -AU - Kishimoto, J. -AU - Shioyama, Y. -AU - Katsui, K. -AU - Sasaki, J. -AU - Kiura, K. -AU - Sugio, K. -TI - Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study -T2 - ESMO OPEN -M3 - Article -AB - Background: The role of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) induction coupled with standard concurrent chemoradiotherapy (CRT) is unclear in unresectable, stage III, EGFR-mutant non-small-cell lung cancer (NSCLC). Therefore, a phase II trial was conducted to evaluate the efficacy and safety of gefitinib induction followed by CRT in this disease setting.Patients and methods: Patients with unresectable, EGFR-mutant, stage III NSCLC were administered gefitinib monotherapy (250 mg/day) for 8 weeks. Subsequently, patients without disease progression during induction therapy were administered cisplatin and docetaxel (40 mg/m(2) each) on days 1, 8, 29, and 36 with concurrent radiotherapy at a total dose of 60 Gy. The primary endpoint was the 2-year overall survival (OS) rate, which was hypothesized to reach 85%, with a threshold of the lower limit of 60%.Results: Twenty patients (median age: 66 years; male/female: 9/11; histology: 20 adenocarcinoma; stage IIIA/IIIB: 9/11; and exon 19/21: 10/10) were enrolled. The 2-year OS rate was 90% (90% confidence interval: 71.4% to 96.8%), indicating that this trial met the primary objective. The overall response rate and 1- and 2-year progression-free survival rates were 85.0%, 58.1%, and 36.9%, respectively. Grade >= 3 adverse events (>10%) included hepatic toxicity during the induction phase and neutropenia and febrile neutropenia in the CRT phase. Radiation pneumonitis grade >= 3 or treatment-related death did not occur.Conclusions: This is the first prospective study to demonstrate the favorable efficacy and safety of EGFR-TKI induction followed by standard CRT in EGFR-mutant, stage III NSCLC. Further confirmatory studies are needed. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 2059-7029 -DA - 2021 AUG -PY - 2021 -VL - 6 -IS - 4 -C7 - 100191 -DO - 10.1016/j.esmoop.2021.100191 -AN - WOS:000703610200037 -C6 - JUN 2021 -AD - Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Shikata Cho, Okayama 7008558, Japan -AD - Okayama Univ Hosp, Dept Resp Med, Okayama, Japan -AD - Kumamoto Univ Hosp, Dept Resp Med, Kumamoto, Japan -AD - Natl Hosp Org Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan -AD - Natl Hosp Org Shikoku Canc Ctr, Dept Thorac Oncol, Shikoku, Ehime, Japan -AD - Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan -AD - Kyushu Univ Hosp, Dept Resp Med, Fukuoka, Japan -AD - Kitakyushu Municipal Med Ctr, Dept Resp Med, Kitakyushu, Fukuoka, Japan -AD - Chugoku Cent Hosp, Dept Resp Med, Chugo Ku, Fukuyama, Hiroshima, Japan -AD - Ehime Prefectural Cent Hosp, Dept Resp Med, Matsuyama, Ehime, Japan -AD - Kyushu Univ Hosp, Ctr Clin & Translat Res, Fukuoka, Japan -AD - Kyushu Univ, Grad Sch Med Sci, Clin Radiol, Radiol Informat & Network, Fukuoka, Japan -AD - Okayama Univ, Dept Proton Beam Therapy, Dent & Pharmaceut Sci, Grad Sch Med, Okayama, Japan -AD - Kitasato Univ, Res & Dev Ctr New Med Frontiers, Sch Med, Tokyo, Japan -AD - Oita Univ, Dept Thorac & Breast Surg, Oita, Japan -M2 - Natl Hosp Org Shikoku Canc Ctr -M2 - Japanese Red Cross Okayama Hosp -M2 - Kitakyushu Municipal Med Ctr -M2 - Chugoku Cent Hosp -M2 - Ehime Prefectural Cent Hosp -Y2 - 2021-10-17 -ER - - -TY - JOUR -AU - Lang, David -AU - Brauner, Anna -AU - Huemer, Florian -AU - Rinnerthaler, Gabriel -AU - Horner, Andreas -AU - Wass, Romana -AU - Brehm, Elmar -AU - Kaiser, Bernhard -AU - Greil, Richard -AU - Lamprecht, Bernd -TI - Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study -T2 - CANCERS -M3 - Article -AB - Simple Summary Retrospective analyses suggest that men treated with immune-checkpoint inhibitor (ICI) monotherapy for non-small cell lung cancer (NSCLC) have better outcomes than women. However, female patients have more favorable responses when chemotherapy (CHT) is given together with ICI. We aimed to explore the clinical impact of such sex differences in two cohorts, receiving ICI monotherapy or ICI-CHT combination, respectively. We found no significant difference in outcomes between men and women treated with either therapeutic regimen. However, known predictive factors for ICI response such as the expression of programmed-death ligand 1 (PD-L1) on tumor cells or patient performance status had significant implications for men rather than for women. Our results warrant increased research efforts to clarify sex-specific differences in anti-tumor immune response mechanisms and in the efficacy of ICI therapies, especially in women. Men with non-small cell lung cancer (NSCLC) have a more favorable response to immune-checkpoint inhibitor (ICI) monotherapy, while women especially benefit from ICI-chemotherapy (CHT) combinations. To elucidate such sex differences in clinical practice, we retrospectively analyzed two cohorts treated with either ICI monotherapy (n = 228) or ICI-CHT combination treatment (n = 80) for advanced NSCLC. Kaplan-Meier analyses were used to calculate progression-free (PFS) and overall survival (OS), influencing variables were evaluated using Cox-regression analyses. No significant sex differences for PFS/OS could be detected in either cohort. Men receiving ICI monotherapy had a statistically significant independent impact on PFS by Eastern Cooperative Oncology Group performance status (ECOG) >= 2 (hazard ratio (HR) 1.90, 95% confidence interval (CI): 1.10-3.29, p = 0.021), higher C-reactive protein (CRP; HR 1.06, 95%CI: 1.00-1.11, p = 0.037) and negative programmed death-ligand 1 (PD-L1) status (HR 2.04, 95%CI: 1.32-3.15, p = 0.001), and on OS by CRP (HR 1.09, 95%CI: 1.03-1.14, p = 0.002). In men on ICI-CHT combinations, multivariate analyses (MVA) revealed squamous histology (HR 4.00, 95%CI: 1.41-11.2, p = 0.009) significant for PFS; and ECOG >= 2 (HR 5.58, 95%CI: 1.88-16.5, p = 0.002) and CRP (HR 1.19, 95%CI: 1.06-1.32, p = 0.002) for OS. Among women undergoing ICI monotherapy, no variable proved significant for PFS, while ECOG >= 2 had a significant interaction with OS (HR 1.90, 95%CI 1.04-3.46, p = 0.037). Women treated with ICI-CHT had significant MVA findings for CRP with both PFS (HR 1.09, 95%CI: 1.02-1.16, p = 0.007) and OS (HR 1.11, 95%CI: 1.03-1.19, p = 0.004). Although men and women responded similarly to both ICI mono- and ICI-CHT treatment, predictors of response differed by sex. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2022 JAN -PY - 2022 -VL - 14 -IS - 1 -C7 - 93 -DO - 10.3390/cancers14010093 -AN - WOS:000751013800001 -AD - Johannes Kepler Univ Hosp Linz, Dept Pulmonol, Krankenhausstr 9, A-4020 Linz, Austria -AD - Johannes Kepler Univ Linz, Med Fac, Altenberger Str 69, A-4020 Linz, Austria -AD - Paracelsus Med Univ, Oncol Ctr, Dept Internal Med Haematol Med Oncol Haemostaseol, A-5020 Salzburg, Austria -AD - Canc Cluster Salzburg, A-5020 Salzburg, Austria -AD - Salzburg Canc Res Inst Lab Immunol & Mol Canc Res, A-5020 Salzburg, Austria -M2 - Johannes Kepler Univ Hosp Linz -M2 - Canc Cluster Salzburg -M2 - Salzburg Canc Res Inst Lab Immunol & Mol Canc Res -Y2 - 2022-02-10 -ER - - -TY - JOUR -AU - Wang, Chen-xu -AU - Yan, Jie -AU - Lin, Shan -AU - Ding, Yi -AU - Qin, Yan-ru -TI - Mutant-allele dispersion correlates with prognosis risk in patients with advanced non-small cell lung cancer -T2 - JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY -M3 - Article -AB - BackgroundIntra-tumor heterogeneity (ITH) contributes to lung cancer progression and resistance to therapy. To evaluate ITH and determine whether it may be employed as a predictive biomarker of prognosis in patients with advanced non-small cell lung cancer (NSCLC), we used a novel algorithm called mutant-allele dispersion (MAD).MethodsIn the study, 103 patients with advanced NSCLC were enrolled. Using a panel of 425 cancer-related genes, next-generation sequencing (NGS) was performed on tumor specimens that had been collected. From NGS data, we derived MAD values, and we next looked into their relationships with clinical variables and different mutation subtypes.ResultsThe median MAD among 103 NSCLC patients was 0.73. EGFR mutation, tyrosine kinase inhibitor (TKI) therapy, radiotherapy, and chemotherapy cycles were all substantially correlated with the MAD score. In patients with lung adenocarcinoma (LUAD), correlation analysis revealed that the MAD score was substantially linked with Notch pathway mutation (P = 0.021). A significant relationship between high MAD and shorter progression-free survival (PFS) was found (HR = 2.004, 95%CI 1.269-3.163, P = 0.003). In patients with advanced NSCLC, histological type (P = 0.004), SMARCA4 mutation (P = 0.038), and LRP1B mutation (P = 0.006) were all independently associated with prognosis. The disease control rate was considerably greater in the low MAD group compared to the high MAD group in 19 LUAD patients receiving immunotherapy (92.9% vs. 40%, P = 0.037). TKI-PFS was longer in 37 patients with low MAD who received first-line TKI therapy (P = 0.014).ConclusionOur findings suggested that MAD is a practical and simple algorithm for assessing ITH, and populations with high MAD values are more likely to have EGFR mutations. MAD can be used as a potential biomarker to predict not only the prognosis of NSCLC but also the efficacy of immunotherapy and TKI therapy in patients with advanced NSCLC. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 0171-5216 -SN - 1432-1335 -DA - 2023 SEP -PY - 2023 -VL - 149 -IS - 11 -SP - 8545 -EP - 8555 -DO - 10.1007/s00432-023-04801-3 -AN - WOS:000975114600003 -C6 - APR 2023 -AD - Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou 450052, Henan, Peoples R China -AD - Xiamen Univ, Zhongshan Hosp, Dept Oncol, Xiamen 361004, Fujian, Peoples R China -Y2 - 2023-05-19 -ER - - -TY - JOUR -AU - Liu, Yufei -AU - Yao, Luyang -AU - Kalhor, Neda -AU - Carter, Brett W. -AU - Altan, Mehmet -AU - Blumenschein, George -AU - Byers, Lauren A. -AU - Fossella, Frank -AU - Gibbons, Don L. -AU - Kurie, Jonathan M. -AU - Lu, Charles -AU - Skoulidis, Ferdinandos -AU - Chang, Joe Y. -AU - Liao, Zhongxing -AU - Gomez, Daniel R. -AU - O'Reilly, Michael -AU - Heymach, John, V -AU - Tsao, Anne S. -AU - Lin, Steven H. -TI - Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial -T2 - LUNG CANCER -M3 - Article -AB - Introduction: The phase II DETERRED trial assessed the safety and efficacy of consolidation and concurrent immunotherapy with chemoradiation in unresectable locally advanced non-small cell lung cancer. We present updated efficacy analysis of this trial.Methods: The trial was conducted in 2 parts with patients in part 1 (n = 10) receiving chemoradiation with consolidation atezolizumab, while patients in part 2 (n = 30) received concurrent and consolidation atezolizumab. Progression-free survival (PFS), time to second progression (PFS2), and overall survival (OS) were assessed using Kaplan-Meier analysis. Subset analyses were performed by programmed cell death ligand-1 (PD-L1) status and targetable driver oncogene mutation status.Results: At a median follow-up of 39.2 months, the median PFS for part 1 was 18.9 months and 15.1 months for part 2. Median OS for part 1 was 26.5 months and was not reached for part 2. For the cohort, 3-year OS was 53.8%, while 4-year OS was 47.4%. Patients with targetable driver oncogene mutations had a median PFS of 9.4 months and OS of not reached compared to 16.6 months (HR: 3.49, p = 0.02) and 26.9 months (HR: 0.40, p = 0.12) respectively compared to those without targetable driver oncogene mutations. Patients with PD-L1 < 1% had median PFS of 11.0 months and OS of 26.5 months compared to 27.4 months (HR: 2.01, p = 0.10) and not reached (HR: 1.49, p = 0.41) respectively for those with PD-L1 = 1%.Conclusions: In the DETERRED trial, chemoradiation with concurrent and/or consolidative atezolizumab led to comparable efficacy as consolidative durvalumab in the PACIFIC trial. The presence of targetable driver oncogene mutations led to worse PFS, while PD-L1 < 1% trended to worse PFS. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2022 DEC -PY - 2022 -VL - 174 -SP - 112 -EP - 117 -DO - 10.1016/j.lungcan.2022.10.006 -AN - WOS:000934053200005 -C6 - NOV 2022 -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA -AD - Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA -Y2 - 2023-03-06 -ER - - -TY - JOUR -AU - Xie, Zhaoliang -AU - Liu, Jingru -AU - Wu, Min -AU - Wang, Xiaohan -AU - Lu, Yuhan -AU - Han, Chunyan -AU - Cong, Lei -AU - Li, Jisheng -AU - Meng, Xue -TI - Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer -T2 - JOURNAL OF CLINICAL MEDICINE -M3 - Article -AB - (1) Background: At present, the efficacy and safety of thoracic radiotherapy (TRT) after chemo-immunotherapy (CT-IT) in patients with extensive-stage small-cell lung cancer (ES-SCLC) still remain unclear. The purpose of this study was to evaluate the role of TRT after CT-IT in patients with ES-SCLC. (2) Methods: From January 2020 to October 2021, patients with ES-SCLC treated with first-line anti-PD-L1 antibody plus platinum-etoposide chemotherapy were enrolled retrospectively. The survival data and adverse events data of patients treated with or without TRT after CT-IT were collected for analysis. (3) Results: A total of 118 patients with ES-SCLC treated with first-line CT-IT were retrospectively enrolled, with 45 patients with TRT and 73 patients without TRT after CT-IT. The median PFS and OS in the CT-IT + TRT group and CT-IT only group were 8.0 months versus 5.9 months (HR = 0.64, p = 0.025) and 22.7 months versus 14.7 months (HR = 0.52, p = 0.015), respectively. The median PFS and OS in all 118 patients treated with first-line CT-IT were 7.2 and 19.8 months with an ORR of 72.0%. In multivariate analyses, liver metastasis and response to CT-IT were shown to be independent prognostic factors of PFS (p < 0.05), while liver metastasis and bone metastasis were independent predictive factors of OS (p < 0.05). Although TRT was significantly associated with better PFS and OS in univariate analysis, the association of TRT and OS failed to reach statistical significance (HR = 0.564, p = 0.052) in multivariate analysis. There was no significant difference in adverse events (AEs) between two treatment groups (p = 0.58). (4) Conclusions: ES-SCLC patients treated with TRT after first-line CT-IT had prolonged PFS and OS with an acceptable safety profile. Further prospective randomized studies are necessary to explore the efficacy and safety of this treatment modality for ES-SCLC in future. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2077-0383 -DA - 2023 JUN 2 -PY - 2023 -VL - 12 -IS - 11 -C7 - 3828 -DO - 10.3390/jcm12113828 -AN - WOS:001003972700001 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan 250117, Peoples R China -AD - Shandong Univ Canc Ctr, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan 250117, Peoples R China -AD - Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Canc Ctr Core Lab, Suzhou 215000, Peoples R China -AD - First Peoples Hosp Neijiang, Dept Emergency Med, Neijiang 641099, Peoples R China -AD - Shandong First Med Univ, Affiliated Hosp 3, Dept Radiotherapy, Jinan 250031, Peoples R China -AD - Shandong First Med Univ, Shandong Prov Hosp, Dept Oncol, Jinan 250117, Peoples R China -AD - Shandong Univ, Dept Med Oncol, Qilu Hosp, Jinan 250012, Peoples R China -M2 - First Peoples Hosp Neijiang -Y2 - 2023-06-20 -ER - - -TY - JOUR -AU - Pilon, Yohann -AU - Rokah, Merav -AU - Seitlinger, Joseph -AU - Sepesi, Boris -AU - Rayes, Roni F. -AU - Cools-Lartigue, Jonathan -AU - Najmeh, Sara -AU - Sirois, Christian -AU - Mulder, David -AU - Ferri, Lorenzo -AU - Abdulkarim, Bassam -AU - Ezer, Nicole -AU - Fraser, Richard -AU - Camilleri-Broet, Sophie -AU - Fiset, Pierre-Olivier -AU - Wong, Annick -AU - Sud, Shelly -AU - Langleben, Adrian -AU - Agulnik, Jason -AU - Pepe, Carmela -AU - Shieh, Benjamin -AU - Hirsh, Vera -AU - Ofiara, Linda -AU - Owen, Scott -AU - Spicer, Jonathan D. -TI - Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Network -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - Of all 428 resectable stage II and III NSCLC patients included in this study, 25% received neoadjuvant therapy. Perioperative outcomes and 5-year overall survival were similar between patients having received neoadjuvant therapy versus upfront surgery. Establishing a neoadjuvant therapy program for NSCLC is feasible and safe from a surgical perspective. Background: Several regulatory agencies have approved the use of the neoadjuvant chemo-immunotherapy for resectable stage II and III of non -small cell lung cancer (NSCLC) and numerous trials investigating novel agents are underway. However, significant concerns exist around the feasibility and safety of offering curative surgery to patients treated within such pathways. The goal in this study was to evaluate the impact of a transition towards a large-scale neoadjuvant therapy program for NSCLC. Methods: Medical charts of patients with clinical stage II and III NSCLC who underwent resection from January 2015 to December 2020 were reviewed. The primary outcome was perioperative complication rate between neoadjuvant-treated versus upfront surgery patients. Multivariable logistic regression estimated occurrence of postoperative complications and overall survival was assessed as an explorator y secondar y outcome by Kaplan-Meier and Cox -regression analyses. Results: Of the 428 patients included, 106 (24.8%) received neoadjuvant therapy and 322 (75.2%) upfront surgery. Frequency of minor and major postoperative complications was similar between groups ( P = .22). Occurrence in postoperative complication was similar in both cohort (aOR = 1.31, 95% CI 0.73-2.34). Neoadjuvant therapy administration increased from 10% to 45% with a rise in targeted and immuno therapies over time, accompanied by a reduced rate of preoperative radiation therapy use. 1-, 2-, and 5 -year overall survival was higher in neoadjuvant therapy compared to upfront surgery patients (Log -Rank P = .017). Conclusions: No significant differences in perioperative outcomes and survival were observed in resectable NSCLC patients treated by neoadjuvant therapy versus upfront surgery. Transition to neoadjuvant therapy among resectable NSCLC patients is safe and feasible from a surgical perspective. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2024 MAY -PY - 2024 -VL - 25 -IS - 3 -DO - 10.1016/j.cllc.2023.12.005 -AN - WOS:001246454300001 -C6 - MAY 2024 -AD - McGill Univ, Div Thorac Surg, Dept Surg, Hlth Ctr, 1650 Cedar Ave,L9 309, Montreal, PQ, Canada -AD - McGill Univ, Goodman Canc Inst, Montreal, PQ, Canada -AD - McGill Univ, Dept Oncol, Montreal, PQ, Canada -AD - McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada -AD - McGill Univ, Dept Pathol, Montreal, PQ, Canada -AD - Hop Suroit, Salaberry De Valleyfield, PQ, Canada -AD - Gatineau Hosp, Dept Oncol, Gatineau, PQ, Canada -AD - Jewish Gen Hosp, Div Pulm Dis, Montreal, PQ, Canada -M2 - Hop Suroit -M2 - Gatineau Hosp -Y2 - 2024-06-21 -ER - - -TY - JOUR -AU - Mielgo-Rubio, Xabier -AU - Rojo, Federico -AU - Mezquita-Perez, Laura -AU - Casas, Francesc -AU - Wals, Amadeo -AU - Juan, Manel -AU - Aguado, Carlos -AU - Garde-Noguera, Javier -AU - Vicente, David -AU - Counago, Felipe -TI - Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck -T2 - WORLD JOURNAL OF CLINICAL ONCOLOGY -M3 - Review -AB - After publication of the PACIFIC trial results, immune checkpoint inhibitor-based immunotherapy was included in the treatment algorithm of locally advanced non-small cell lung cancer (NSCLC). The PACIFIC trial demonstrated that 12 mo of durvalumab consolidation therapy after radical-intent platinum doublet chemotherapy with concomitant radiotherapy improved both progression-free survival and overall survival in patients with unresectable stage III NSCLC. This is the first treatment in decades to successfully improve survival in this clinical setting, with manageable toxicity and without deterioration in quality of life. The integration of durvalumab in the management of locally advanced NSCLC accentuates the need for multidisciplinary, coordinated decision-making among lung cancer specialists, bringing new challenges and controversies as well as important changes in clinical work routines. The aim of the present article is to review-from a practical, multidisciplinary perspective - the findings and implications of the PACIFIC trial. We evaluate the immunobiological basis of durvalumab as well as practical aspects related to programmed cell death ligand 1 determination. In addition, we comprehensively assess the efficacy and toxicity data from the PACIFIC trial and discuss the controversies and practical aspects of incorporating durvalumab into routine clinical practice. Finally, we discuss unresolved questions and future challenges. In short, the present document aims to provide clinicians with a practical guide for the application of the PACIFIC regimen in routine clinical practice. -PU - BAISHIDENG PUBLISHING GROUP INC -PI - PLEASANTON -PA - 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES -SN - 2218-4333 -DA - 2020 NOV 24 -PY - 2020 -VL - 11 -IS - 11 -SP - 898 -EP - 917 -DO - 10.5306/wjco.v11.i11.898 -AN - WOS:000617175900004 -AD - Hosp Univ Fdn Alcorcon, Dept Med Oncol, Calle Budapest 1, Madrid 28922, Spain -AD - IIS Jimenez Diaz CIBERONC Fdn, Dept Pathol, Madrid 28040, Spain -AD - IDIBAPS, Dept Med Oncol, Hosp Clin, Lab Translat Genom & Targeted Therapeut Solid Tum, Barcelona 08036, Spain -AD - Hosp Clin Barcelona, Dept Radiat Oncol, Barcelona 08036, Spain -AD - Hosp Univ Virgen Macarena, Dept Radiat Oncol, Seville 41009, Spain -AD - Univ Barcelona, Hosp Clin, Dept Immunol Serv, Barcelona 08036, Spain -AD - Hosp Univ Clin San Carlos, Dept Med Oncol, Madrid 28040, Spain -AD - Hosp Arnau Vilanova, Dept Med Oncol, Valencia 46015, Spain -AD - Hosp Univ Virgen Macarena, Dept Med Oncol, Seville 49001, Spain -AD - Univ Europea Madrid, Dept Radiat Oncol, Hosp Univ Quironsalud Madrid, Hosp La Luz, Madrid 28028, Spain -M2 - IIS Jimenez Diaz CIBERONC Fdn -M2 - Hosp Univ Clin San Carlos -M2 - Hosp Arnau Vilanova -Y2 - 2021-02-23 -ER - - -TY - JOUR -AU - Araki, Taisuke -AU - Tateishi, Kazunari -AU - Komatsu, Masamichi -AU - Sonehara, Kei -AU - Wasamoto, Satoshi -AU - Koyama, Shigeru -AU - Yoshiike, Fumiaki -AU - Hama, Mineyuki -AU - Nishie, Kenichi -AU - Kondo, Daichi -AU - Agatsuma, Toshihiko -AU - Kato, Akane -AU - Takata, Munetake -AU - Kanda, Shintaro -AU - Hanaoka, Masayuki -AU - Koizumi, Tomonobu -TI - Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy -T2 - THORACIC CANCER -M3 - Article -AB - Backgrounds The PACIFIC trial established durvalumab consolidation therapy after concurrent chemoradiotherapy (CCRT) as the standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC). However, little is known about the predictive factors of durvalumab efficacy in this population. This study aimed to validate the predictive use of inflammation-related parameters in patients with LA-NSCLC treated with CCRT plus durvalumab. Methods We recruited 76 LA-NSCLC patients who received CCRT followed by durvalumab from 10 Japanese institutions. The neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-albumin ratio (CAR), and prognostic nutrition index (PNI) were measured before (pre-treatment) and 2 months after (post-treatment) durvalumab induction. Cox proportional hazards analysis was used to examine prognostic factors associated with progression-free survival (PFS) after durvalumab therapy. Results The median follow-up time was 17 (range, 3.3-35.8) months. The median PFS and overall survival (OS) times were 26.1 and 33.7 months, respectively. Durvalumab was discontinued in 47 (61.8%) patients, with non-infectious pneumonitis being the most common reason. Post-treatment CAR (cutoff, 0.2) was a significant stratifying factor in survival comparison (<0.2 vs. >= 0.2, median PFS, not-reached vs. 9.6 months. Log-rank, p = 0.002). Multivariate analysis with a Cox proportional hazards model showed that post-treatment CAR was an independent prognostic factor for PFS (hazard ratio, 3.16, p = 0.003). Conclusions This study suggests that post-treatment CAR has predictive value for LA-NSCLC patients treated with CCRT plus durvalumab consolidation therapy. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1759-7706 -SN - 1759-7714 -DA - 2022 JUL -PY - 2022 -VL - 13 -IS - 14 -SP - 2031 -EP - 2040 -DO - 10.1111/1759-7714.14484 -AN - WOS:000800129200001 -C6 - MAY 2022 -AD - Shinshu Univ, Dept Internal Med 1, Sch Med, Matsumoto, Nagano 3908621, Japan -AD - Saku Cent Hosp, Dept Resp Med, Adv Care Ctr, Saku, Nagano, Japan -AD - Japanese Red Cross Soc, Dept Resp Med, Nagano Hosp, Nagano, Japan -AD - Nagano Municipal Hosp, Dept Resp Med, Nagano, Japan -AD - Japanese Red Cross Soc, Dept Resp Med, Suwa Hosp, Suwa, Japan -AD - Iida Municipal Hosp, Dept Resp Med, Iida, Japan -AD - Hokushin Gen Hosp, Dept Resp Med, Nakano, Japan -AD - Shinshu Ueda Med Ctr, Dept Resp Med, Ueda, Nagano, Japan -AD - Ina Cent Hosp, Dept Resp Med, Ina, Saitama, Japan -AD - Jiseikai Aizawa Hosp, Dept Resp Med, Matsumoto, Nagano, Japan -AD - Shinshu Univ, Dept Hematol & Med Oncol, Sch Med, Matsumoto, Nagano, Japan -M2 - Saku Cent Hosp -M2 - Japanese Red Cross Soc -M2 - Nagano Municipal Hosp -M2 - Japanese Red Cross Soc -M2 - Iida Municipal Hosp -M2 - Hokushin Gen Hosp -M2 - Shinshu Ueda Med Ctr -M2 - Ina Cent Hosp -M2 - Jiseikai Aizawa Hosp -Y2 - 2022-06-01 -ER - - -TY - JOUR -AU - Dou, Yan -AU - Jiang, Da -TI - [Research Progress of Small Molecule Anti-angiogenic Drugs 
in Non-small Cell Lung Cancer]. -T2 - Zhongguo fei ai za zhi = Chinese journal of lung cancer -M3 - Journal Article -M3 - Review -AB - Lung cancer is one of the cancers with the highest incidence in the world, and there is no standard treatment plan after second-line progression. Tumor angiogenesis has now been identified as an important therapeutic target for malignant tumors. Small molecule multi-target vascular kinase inhibitors can inhibit tumor angiogenesis by inhibiting angiogenesis-related signal pathways. At present, a lot of clinical trials of small molecule anti-angiogenic drugs for the treatment of non-small cell lung cancer (NSCLC) have been carried out, and some vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) have been approved for the treatment of advanced NSCLC. Based on the development status of multiple small molecule anti-angiogenic drugs at home and abroad for the treatment of NSCLC, this article summarizes the efficacy and safety studies of multiple VEGFR-TKIs and fibroblast growth factor receptor (FGFR)-TKI single agents or combination treatments [including combined with chemotherapy, epidermal growth factor receptor (EGFR)-TKIs, immunotherapy, and radiotherapy, etc.] for NSCLC, and at the same time discussed the possible existence of VEGFR-TKIs drug resistance mechanisms and efficacy predictors, etc., and prospect the future development trend and potential problems of anti-vascular treatment of NSCLC, and provide new ideas for the follow-up precision and individualized treatment of lung cancer.
. -AB - 【中文题目:小分子抗血管生成药物在非小细胞肺癌中的研究进展】 【中文摘要:肺癌是世界上发病率最高的癌症之一,且尚无二线进展后的标准治疗方案,而肿瘤血管生成目前已被确定为恶性肿瘤的重要治疗靶点,小分子多靶点血管激酶抑制剂可通过抑制血管生成相关信号通路,抑制肿瘤血管的生成。目前已开展多项小分子抗血管生成药物治疗非小细胞肺癌的临床试验,且已有部分血管内皮生长因子受体酪氨酸激酶抑制剂(vascular endothelial growth factor receptor-tyrosine kinase inhibitors, VEGFR-TKIs)获批治疗晚期非小细胞肺癌,本文基于国内外多项小分子抗血管生成药物治疗非小细胞肺癌的发展现状,归纳了多个VEGFR-TKIs及成纤维细胞生长因子受体(fibroblast growth factor receptor, FGFR)-TKI单药或联合[包括分别与化疗、表皮生长因子受体(epidermal growth factor receptor, EGFR)-TKIs、免疫治疗、放疗等联合)]治疗非小细胞肺癌的疗效与安全性研究,同时探讨了VEGFR-TKIs可能存在的耐药机制及疗效预测指标等,并对未来抗血管治疗非小细胞肺癌的发展趋势以及存在的潜在问题进行展望,同时为肺癌后续的精准治疗及个体化治疗提供新的思路。
】 【中文关键词:抗血管生成抑制剂;小分子酪氨酸激酶抑制剂;肺肿瘤;进展】. -SN - 1999-6187 -DA - 2021 Jan 20 -PY - 2021 -VL - 24 -IS - 1 -SP - 56 -EP - 62 -DO - 10.3779/j.issn.1009-3419.2021.102.02 -AN - MEDLINE:33478192 -AD - Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China. -Y2 - 2021-09-03 -ER - - -TY - JOUR -AU - Salgaller, ML -TI - The development of immunotherapies for non-small cell lung cancer -T2 - EXPERT OPINION ON BIOLOGICAL THERAPY -M3 - Review -AB - Standard of care for non-small cell lung cancer (NSCLC) (surgery, chemotherapy and radiation) may enhance patient survival but the enhancement is typically transient and quite uncommon with advanced disease. Researchers and medical professionals are using new approaches to improve patient mortality and morbidity. One of these approaches, immunotherapy, seeks to stimulate antitumour immunity above a threshold level needed for tumour regression or to induce stability in the face of progression. Among the most established approaches are vaccines involving monoclonal antibodies (mAbs) or immune effector cells. These approaches stimulate the humoral and cell-mediated arms of the immune system, respectively. As the development of humanised or fully human antibodies has spurred exploration of radioimmunoconjugates and immunotoxins, mAbs have enjoyed a revival of sorts. Cell-based therapies using the tumour cell itself as a vaccine component has resulted in disease stabilisation or regression. In addition, immune cells (e.g., T-lymphocytes and dendritic cells [DCs]) are the focal point of numerous patient trials in which meaningful clinical impact was achieved. In general, there are many tactics under development for the treatment of NSCLC. This review primarily concerns immunotherapeutic cancer treatments that are either already in clinical trial or well progressed into preclinical studies. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1471-2598 -SN - 1744-7682 -DA - 2002 MAR -PY - 2002 -VL - 2 -IS - 3 -SP - 265 -EP - 278 -DO - 10.1517/14712598.2.3.265 -AN - WOS:000174509500004 -AD - NW Biotherapeut Inc, Bothell, WA 98021 USA -M2 - NW Biotherapeut Inc -Y2 - 2002-03-01 -ER - - -TY - JOUR -AU - Ferrari, Giorgia -AU - Del Rio, Benedetta -AU - Novello, Silvia -AU - Passiglia, Francesco -TI - HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging Strategies -T2 - CANCERS -M3 - Review -AB - Simple Summary The introduction of trastuzumab deruxtecan is significantly changing the therapeutic landscape of advanced HER2-mutated non-small cell lung cancer (NSCLC). The results of the DESTINY-Lung04 trial are highly anticipated for their potential to redefine the first-line therapeutic standard for HER2-mutant disease. Furthermore, several studies evaluating combination therapy regimes are currently ongoing. This review outlines the current state of the art in the clinical management of HER2-altered NSCLC and explores potential future perspectives in the field of HER2 targeted strategies.Abstract For patients diagnosed with advanced HER2-altered non-small cell lung cancer (NSCLC), the current standard of care is represented by a platinum-pemetrexed-based chemotherapy, eventually in combination with immunotherapy. Different pan-HER tyrosine kinase inhibitors have been evaluated in limited phase II trials, yielding generally unsatisfactory outcomes, although certain genotypes demonstrated some clinical benefit. Conversely, antibody-drug conjugates (ADCs) targeting HER2, particularly trastuzumab-deruxtecan, have shown promising results against HER2-mutant disease, including a great intracranial activity in patients with brain metastasis. Based on the results obtained from DESTINY-Lung01 and DESTINY-Lung02 trials, trastuzumab deruxtecan received regulatory approval as the first targeted therapy for pre-treated, HER2-mutant, advanced NSCLC patients. More recently, the Food and Drug Administration (FDA) granted the accelerated approval of trastuzumab deruxtecan for advanced, pre-treated HER2-positive solid tumours with no other treatment options. In this scenario, emerging evidence is increasingly pointing towards the exploration of combination regimens with synergistic effects in the advanced disease. In this review, we provide a detailed summary of current approaches and emerging strategies in the management of HER2-altered NSCLC, also focusing on unmet needs, including the treatment of patients with brain metastases. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2024 JUN -PY - 2024 -VL - 16 -IS - 11 -C7 - 2018 -DO - 10.3390/cancers16112018 -AN - WOS:001245649100001 -AD - Univ Turin, San Luigi Hosp, Dept Oncol, I-10124 Orbassano, Italy -Y2 - 2024-06-19 -ER - - -TY - JOUR -AU - Zhang, C. -AU - Zhou, Z. -AU - Deng, L. -AU - Bi, N. -AU - Wang, W. -AU - Xiao, Z. -AU - Wang, J. -AU - Liu, W., Jr. -AU - Wang, X. -AU - Zhang, T. -AU - Lv, J. -TI - Clinical Outcomes with Thoracic Radiotherapy for Extensive-Stage Small-Cell Lung Cancer in the Era of Immunotherapy: A Retrospective Analysis -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2177 -SP - E80 -EP - E80 -AN - WOS:001079706800170 -AD - Chinese Acad Med Sci & Peking Union Med Coll, Dept Radiat Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China -AD - Chinese Acad Med Sci CAMS & Peking Union Med Coll, Dept Radiat Oncol, Natl Canc Ctr Natl Clin Res Ctr Canc Canc Hosp, Beijing, Peoples R China -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Belluomini, Lorenzo -AU - Calvetti, Lorenzo -AU - Inno, Alessandro -AU - Pasello, Giulia -AU - Roca, Elisa -AU - Vattemi, Emanuela -AU - Veccia, Antonello -AU - Menis, Jessica -AU - Pilotto, Sara -TI - SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs -T2 - FRONTIERS IN ONCOLOGY -M3 - Review -AB - Small cell lung cancer (SCLC) represents about 13%-15% of all lung cancers. It has a particularly unfavorable prognosis and in about 70% of cases occurs in the advanced stage (extended disease). Three phase III studies tested the combination of immunotherapy (atezolizumab, durvalumab with or without tremelimumab, and pembrolizumab) with double platinum chemotherapy, with practice-changing results. However, despite the high tumor mutational load and the chronic pro-inflammatory state induced by prolonged exposure to cigarette smoke, the benefit observed with immunotherapy is very modest and most patients experience disease recurrence. Unfortunately, biological, clinical, or molecular factors that can predict this risk have not yet been identified. Thanks to these clinically meaningful steps forward, SCLC is no longer considered an "orphan" disease. Innovative treatment strategies and combinations are currently under investigation to further improve the expected prognosis of patients with SCLC. Following the recent therapeutic innovations, we have reviewed the available literature data about SCLC management, with a focus on current unmet needs and potential predictive factors. In detail, the role of radiotherapy; fragile populations, such as elderly or low-performance status patients (ECOG PS 2), usually excluded from randomized studies; predictive factors of response useful to optimize and guide therapeutic choices; and new molecular targets and future combinations have been explored and revised. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2022 APR 14 -PY - 2022 -VL - 12 -C7 - 840783 -DO - 10.3389/fonc.2022.840783 -AN - WOS:000795464900001 -AD - Univ Verona, Dept Med, Med Oncol, Verona, Italy -AD - San Bortolo Hosp, Med Oncol, Vicenza, Italy -AD - IRCCS Sacro Cuore Don Calabria Hosp, Med Oncol, Verona, Italy -AD - Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy -AD - Ist Oncol Veneto IRCCS, Med Oncol 2, Padua, Italy -AD - P Pederzoli Hosp, Lung Unit, Thorac Oncol, Peschiera del Garda, Italy -AD - Azienda Sanitaria Alto Adige, Med Oncol, Bolzano, Italy -AD - Santa Chiara Hosp, Med Oncol, Trento, Italy -M2 - P Pederzoli Hosp -M2 - Azienda Sanitaria Alto Adige -Y2 - 2022-05-26 -ER - - -TY - JOUR -AU - Yang, Han -AU - Liu, Yufang -AU - Chen, Longqing -AU - Zhao, Juanjuan -AU - Guo, Mengmeng -AU - Zhao, Xu -AU - Wen, Zhenke -AU - He, Zhixu -AU - Chen, Chao -AU - Xu, Lin -TI - MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges? -T2 - BIOMOLECULES -M3 - Review -AB - Lung cancer is a commonly diagnosed cancer and the leading cause of cancer-related deaths, posing a serious health risk. Despite new advances in immune checkpoint and targeted therapies in recent years, the prognosis for lung cancer patients, especially those in advanced stages, remains poor. MicroRNAs (miRNAs) have been shown to modulate tumor development at multiple levels, and as such, miRNA mimics and molecules aimed at regulating miRNAs have shown promise in preclinical development. More importantly, miRNA-based therapies can also complement conventional chemoradiotherapy, immunotherapy, and targeted therapies to reverse drug resistance and increase the sensitivity of lung cancer cells. Furthermore, small interfering RNA (siRNA) and miRNA-based therapies have entered clinical trials and have shown favorable development prospects. Therefore, in this paper, we review recent advances in miRNA-based therapies in lung cancer treatment as well as adjuvant therapy and present the current state of clinical lung cancer treatment. We also discuss the challenges facing miRNA-based therapies in the clinical application of lung cancer treatment to provide new ideas for the development of novel lung cancer therapies. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2218-273X -DA - 2023 JUN -PY - 2023 -VL - 13 -IS - 6 -C7 - 877 -DO - 10.3390/biom13060877 -AN - WOS:001014246100001 -AD - Zunyi Med Univ, Special Key Lab Gene Detect & Therapy Guizhou Prov, Zunyi 563000, Peoples R China -AD - Zunyi Med Univ, Dept Immunol, Zunyi 563000, Peoples R China -AD - Soochow Univ, Inst Biomed Res, Suzhou 563000, Peoples R China -AD - Zunyi Med Univ, Collaborat Innovat Ctr Tissue Damage Repair & Rege, Zunyi 563000, Peoples R China -Y2 - 2023-07-05 -ER - - -TY - JOUR -AU - Decoster, L. -AU - Wauters, I. -AU - Vansteenkiste, J. F. -TI - Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development -T2 - ANNALS OF ONCOLOGY -M3 - Review -AB - The historical results of cancer vaccination for non-small-cell lung cancer (NSCLC) were disappointing. In the current decade, however, new insights in the interaction between tumours and the immune system have led to the development of immunotherapy as a fundamentally new concept for the treatment of NSCLC. Modern NSCLC vaccine strategies rely on better identification of antigenic targets, addition of strong immunoadjuvants, and use of more efficient delivery systems. These treatments have convincingly demonstrated to elicit potent immune responses and have shown promising efficacy signals and excellent tolerability in phase II randomised studies. This-together with recent positive phase III data in indications other than NSCLC-has helped to establish the proof of principle for cancer vaccination. In NSCLC, ongoing phase III trials are investigating this approach in different treatment settings: the Melanoma AntiGEn A3 vaccine in resected early-stage NSCLC, the L-BLP25 vaccine in locally advanced NSCLC after chemoradiotherapy, and belagenpumatucel-L, the epidermal growth factor and the TG4010 vaccine in advanced stage, either as an adjunct to chemotherapy or as maintenance after completion of chemotherapy. Mode of action, development, available clinical data, and currently ongoing phase III studies are reviewed. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 0923-7534 -SN - 1569-8041 -DA - 2012 JUN -PY - 2012 -VL - 23 -IS - 6 -SP - 1387 -EP - 1393 -DO - 10.1093/annonc/mdr564 -AN - WOS:000304534000004 -AD - Univ Hosp Gasthuisberg, Resp Oncol Unit Pulmonol, Leuven Lung Canc Grp, B-3000 Louvain, Belgium -Y2 - 2012-06-21 -ER - - -TY - JOUR -AU - Takamori, Shinkichi -AU - Komiya, Takefumi -AU - Powell, Emily -TI - Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis -T2 - CANCER MEDICINE -M3 - Article -AB - Immunocheckpoint inhibitors (ICIs) have become a standard pharmacological therapy in non-small cell lung cancer (NSCLC). Because brain metastases (BMs) have historically been listed as exclusion criteria in previous clinical trials involving ICIs in advanced NSCLC, the survival benefit from ICI in NSCLC patients with BMs remains unclear. The National Cancer Database was queried for stage IV NSCLC patients with or without BMs between 2014 and 2015. Overall survival (OS) of stage IV NSCLC patients who received immunotherapy and that of stage IV NSCLC patients who did not receive immunotherapy were compared according to the presence or absence of BMs. Multivariable logistic analyses identified the clinical characteristics predictive of overall survival. A propensity score analysis was conducted with the aim of adjusting the potential biases arising from the clinical characteristics. This study included 42,512 patients with stage IV NSCLC; 11,810 patients with BMs and 30,702 patients without BMs. In univariate analysis, stage IV NSCLC patients with BMs treated with immunotherapy had a significantly longer OS than those without immunotherapy after propensity score matching (median OS: 12.8 vs 10.1 months, hazard ratio [HR]: 0.80, 95% confidence interval [CI]: 0.72-0.89, p < 0.0001). Multivariable Cox modeling after propensity score matching confirmed the survival benefit from ICI for stage IV NSCLC patients with BMs (HR: 0.75, 95% CI: 0.67-0.83, p < 0.0001). The HR in NSCLC patients without BMs treated with ICI compared with those without ICI was 0.77 (95% CI: 0.73-0.82, p < 0.0001). Survival in stage IV NSCLC patients with BMs was significantly improved by ICI treatment at levels comparable to those without BMs using a retrospective database. ICI may be one of the promising treatment options for stage IV NSCLC patients with BMs. These findings should be validated in future prospective studies. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2045-7634 -DA - 2021 FEB -PY - 2021 -VL - 10 -IS - 3 -SP - 923 -EP - 932 -DO - 10.1002/cam4.3675 -AN - WOS:000599974400001 -C6 - DEC 2020 -AD - Natl Hosp Org Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan -AD - Parkview Canc Inst, Med Oncol, 11050 Parkview Circle, Ft Wayne, IN 46845 USA -AD - Parkview Res Ctr, Mirro Ctr Res & Innovat, Ft Wayne, IN USA -AD - Parkview Canc Inst, Oncol Res Program, Ft Wayne, IN USA -M2 - Parkview Canc Inst -M2 - Parkview Res Ctr -M2 - Parkview Canc Inst -Y2 - 2020-12-30 -ER - - -TY - JOUR -AU - Pozza, Daniel Humberto -AU - Andrade de Mello, Ramon Bezerra -TI - Treatment Sequencing Strategies in Lung Cancer. -T2 - Zhongguo fei ai za zhi = Chinese journal of lung cancer -M3 - Journal Article -AB - BACKGROUND: The advances in the lung cancer screening methods and therapeutics, together with awareness towards deleterious habits, such as smoking, is increasing the overall survival with better quality of life for the patients. However, lung cancer is still one of the most common and fatal neoplasm with a high incidence and consequently burden to public health worldwide. Thus, based on guidelines and recent phases II and III clinical trials studies, this manuscript summarizes the current treatment sequencing strategies in lung cancer.METHODS: A comprehensive search of related articles was performed focused on phases II and III clinical trials studies.RESULTS: The lung cancer management should take into consideration the tumor characteristics, histology, molecular pathology and be discussed in a multidisciplinary team. Lung cancer treatment options comprises surgery whenever possible, radiotherapy associate with/or chemotherapy and immunotherapy as monotherapy, or combined with chemotherapy and best palliative care.CONCLUSIONS: The screening predictability in more patients, smoking reduction, early diagnosis, better disease understanding and individualized, more effective and tolerable therapeutics are related to an increasing in overall survival and quality of life. In the near future improvement of personalized therapy in precision medicine is expected, enhancing new predictive biomarkers, optimal doses and optimal treatment sequencing as well as anti-cancer vaccines development. -SN - 1999-6187 -DA - 2022 May 20 -PY - 2022 -VL - 25 -IS - 5 -SP - 323 -EP - 336 -DO - 10.3779/j.issn.1009-3419.2022.104.01 -AN - MEDLINE:35599008 -AD - Department of Biomedicine, Faculty of Medicine and i3s, University of Porto, 4200-319 Porto, Portugal. -AD - Discipline of Medical Oncology, Post-graduation Program in Medicine, Nine of July University (UNINOVE), Sao Paulo, Brazil./Nine of July Hospital,
Sao Paulo, Brazil. -Y2 - 2022-05-24 -ER - - -TY - JOUR -AU - Huber, Rudolf M. -AU - De Ruysscher, Dirk -AU - Hoffmann, Hans -AU - Reu, Simone -AU - Tufman, Amanda -TI - Interdisciplinary multimodality management of stage III nonsmall cell lung cancer -T2 - EUROPEAN RESPIRATORY REVIEW -M3 - Review -AB - Stage III nonsmall cell lung cancer (NSCLC) comprises about one-third of NSCLC patients and is very heterogeneous with varying and mostly poor prognosis. It is also called "locoregionally or locally advanced disease". Due to its heterogeneity a general schematic management approach is not appropriate. Usually a combination of local therapy (surgery or radiotherapy, depending on functional, technical and oncological operability) with systemic platinum-based doublet chemotherapy and, recently, followed by immune therapy is used. A more aggressive approach of triple agent chemotherapy or two local therapies (surgery and radiotherapy, except for specific indications) has no benefit for overall survival. Until now tumour stage and the general condition of the patient are the most relevant prognostic factors. Characterising the tumour molecularly and immunologically may lead to a more personalised and effective approach. At the moment, after an exact staging and functional evaluation, an interdisciplinary discussion amongst the tumour board is warranted and offers the best management strategy. -PU - EUROPEAN RESPIRATORY SOC JOURNALS LTD -PI - SHEFFIELD -PA - 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND -SN - 0905-9180 -SN - 1600-0617 -DA - 2019 JUN 30 -PY - 2019 -VL - 28 -IS - 152 -C7 - 190024 -DO - 10.1183/16000617.0024-2019 -AN - WOS:000477993000011 -AD - Univ Munich, Div Resp Med & Thorac Oncol, Dept Med, Campus Innenstadt, Munich, Germany -AD - Thorac Oncol Ctr Munich, Munich, Germany -AD - German Ctr Lung Res, Munich, Germany -AD - Maastricht Univ, Med Ctr, Dept Radiat Oncol, MAASTRO Clin,Grow Sch Oncol & Dev Oncol, Maastricht, Netherlands -AD - Tech Univ Munich, Div Thorac Surg, Munich, Germany -AD - Univ Wurzburg, Inst Pathol, Wurzburg, Germany -M2 - Thorac Oncol Ctr Munich -M2 - German Ctr Lung Res -Y2 - 2019-08-13 -ER - - -TY - JOUR -AU - Jongbloed, Mandy -AU - Khosla, Atulya A. -AU - Bartolomeo, Valentina -AU - Jatwani, Karan -AU - Singh, Rohit -AU - De Ruysscher, Dirk K. M. -AU - Hendriks, Lizza E. L. -AU - Desai, Aakash -TI - Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies -T2 - CURRENT ONCOLOGY REPORTS -M3 - Review -AB - Purpose of ReviewThis review discusses the definitions, treatment modalities, management, future directions, and ongoing clinical trials of oligoprogressive disease in oncogene-driven and non-oncogene-driven NSCLC.Recent FindingsDuring the last decades, diagnostic and treatment modalities for oligometastatic NSCLC have advanced significantly, leading to improved survival. Additionally, our understanding of the tumor biology of oligoprogressive disease has expanded. However, despite the efforts of organizations, such as EORTC, ESTRO, and ASTRO proposing definitions for oligometastatic and oligoprogressive disease, heterogeneity in definitions persists in (ongoing) trials.SummaryRecognizing the significance of subclassification within oligoprogressive disease in NSCLC and the varying risks associated with subsequent metastatic spread, there is a call for tailored management strategies. A consensus on standardized criteria for the definition of oligoprogressive disease is urgently needed and will not only facilitate meaningful comparisons between studies but also pave the way for the development of personalized treatment plans that take into account the heterogeneous nature of oligoprogressive disease. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1523-3790 -SN - 1534-6269 -DA - 2024 JAN -PY - 2024 -VL - 26 -IS - 1 -SP - 80 -EP - 89 -DO - 10.1007/s11912-023-01490-6 -AN - WOS:001136010500001 -C6 - JAN 2024 -AD - Maastricht Univ, GROW Sch Oncol & Reprod, Dept Pulm Dis, Med Ctr, Maastricht, Netherlands -AD - William Beaumont Univ Hosp, Div Internal Med, Royal Oak, MI USA -AD - Fdn IRCCS Policlin San Matteo, Radiat Oncol, Pavia, Italy -AD - Pavia Univ, Dept Clin Surg, Diagnost & Pediat Sci, Pavia, Italy -AD - Maastricht Univ, GROW Sch Oncol & Reprod GROW, Dept Radiat Oncol, Maastro Clin,Med Ctr, Maastricht, Netherlands -AD - Roswell Park Canc Ctr, Div Hematol Oncol, Buffalo, NY USA -AD - Univ Vermont, Div Hematol Oncol, Burlington, VT USA -AD - Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, 1824 6th Ave S, Birmingham, AL 35233 USA -M2 - William Beaumont Univ Hosp -Y2 - 2024-01-11 -ER - - -TY - JOUR -AU - Zhang, Lihong -AU - Yang, Xuejing -AU - Sun, Zhen -AU - Li, Jiali -AU - Zhu, Hui -AU - Li, Jing -AU - Pang, Yan -TI - Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer -T2 - ONCOLOGY LETTERS -M3 - Article -AB - The present study aimed to evaluate the survival time, immune response and safety of a dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell therapy (DC-CIK) in advanced non-small cell lung cancer (NSCLC). The present retrospective study enrolled 507 patients with advanced NSCLC; 99 patients received DC-CIK [immunotherapy group (group I)] and 408 matched patients did not receive DC-CIK, and acted as the control [non-immunotherapy group (group NI)]. Delayed-type hypersensitivity (DTH), quality of life (QOL) and safety were analyzed in group I. The follow-up period for the two groups was 489.2 +/- 160.4 days. The overall survival (OS) time was calculated using the Kaplan-Meier method. DTH was observed in 59 out of 97 evaluated patients (60.8%) and 67 out of 98 evaluated patients (68.4%) possessed an improved QOL. Fever and a skin rash occurred in 36 out of 98 patients (36.7%) and 7 out of 98 patients (7.1%) in group I. DTH occurred more frequently in patients with squamous cell carcinoma compared with patients with adenocarcinoma (77.1 vs. 40.4%; P=0.0013). Radiotherapy was not associated with DC-CIK-induced DTH (72.7 vs. 79.6%; P=0.18), but chemotherapy significantly reduced the rate of DTH (18.2 vs. 79.6%; P=0.00). The OS time was significantly increased in group I compared with group NI (P=0.03). In conclusion, DC-CIK may induce an immune response against NSCLC, improve the QOL, and prolong the OS time of patients, without adverse effects. Therefore, the present study recommends DC-CIK for the treatment of patients with advanced NSCLC. -PU - SPANDIDOS PUBL LTD -PI - ATHENS -PA - POB 18179, ATHENS, 116 10, GREECE -SN - 1792-1074 -SN - 1792-1082 -DA - 2016 APR -PY - 2016 -VL - 11 -IS - 4 -SP - 2605 -EP - 2610 -DO - 10.3892/ol.2016.4273 -AN - WOS:000373478900049 -AD - Nankai Univ, Sch Med, Tianjin 300071, Peoples R China -AD - Tianjin Union Med Ctr, Dept Oncol, 190 Jieyuan Rd, Tianjin 300121, Peoples R China -AD - Shanghai Claison Biotechnol Co Ltd, Shanghai 201201, Peoples R China -M2 - Tianjin Union Med Ctr -M2 - Shanghai Claison Biotechnol Co Ltd -Y2 - 2016-04-27 -ER - - -TY - JOUR -AU - Gong, Jing -AU - Bao, Xiao -AU - Wang, Ting -AU - Liu, Jiyu -AU - Peng, Weijun -AU - Shi, Jingyun -AU - Wu, Fengying -AU - Gu, Yajia -TI - A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer -T2 - ONCOIMMUNOLOGY -M3 - Article -AB - To develop a short-term follow-up CT-based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer (NSCLC) and investigate the prognostic value of radiomics features in predicting progression-free survival (PFS) and overall survival (OS). We first retrospectively collected 224 advanced NSCLC patients from two centers, and divided them into a primary cohort and two validation cohorts respectively. Then, we processed CT scans with a series of image preprocessing techniques namely, tumor segmentation, image resampling, feature extraction and normalization. To select the optimal features, we applied the feature ranking with recursive feature elimination method. After resampling the training dataset with a synthetic minority oversampling technique, we applied the support vector machine classifier to build a machine-learning-based classification model to predict response to immunotherapy. Finally, we used Kaplan-Meier (KM) survival analysis method to evaluate prognostic value of rad-score generated by CT-radiomics model. In two validation cohorts, the delta-radiomics model significantly improved the area under receiver operating characteristic curve from 0.64 and 0.52 to 0.82 and 0.87, respectively (P < .05). In sub-group analysis, pre- and delta-radiomics model yielded higher performance for adenocarcinoma (ADC) patients than squamous cell carcinoma (SCC) patients. Through the KM survival analysis, the rad-score of delta-radiomics model had a significant prognostic for PFS and OS in validation cohorts (P < .05). Our results demonstrated that (1) delta-radiomics model could improve the prediction performance, (2) radiomics model performed better on ADC patients than SCC patients, (3) delta-radiomics model had prognostic values in predicting PFS and OS of NSCLC patients. -PU - TAYLOR & FRANCIS INC -PI - PHILADELPHIA -PA - 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA -SN - 2162-402X -DA - 2022 DEC 31 -PY - 2022 -VL - 11 -IS - 1 -C7 - 2028962 -DO - 10.1080/2162402X.2022.2028962 -AN - WOS:000746702800001 -AD - Fudan Univ, Dept Radiol, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China -AD - Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China -AD - Shanghai Pulm Hosp, Dept Radiol, 507 Zheng Min Rd, Shanghai, Peoples R China -AD - Shanghai Pulm Hosp, Dept Oncol, 507 Zheng Min Rd, Shanghai, Peoples R China -M2 - Shanghai Pulm Hosp -M2 - Shanghai Pulm Hosp -Y2 - 2022-01-30 -ER - - -TY - JOUR -AU - Lim, Chloe Ahryung -AU - Ghosh, Sunita -AU - Morrison, Hali -AU - Meyers, Daniel -AU - Stukalin, Igor -AU - Kerba, Marc -AU - Hao, Desiree -AU - Pabani, Aliyah -TI - Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study -T2 - CURRENT ONCOLOGY -M3 - Article -AB - The PACIFIC trial led to a new standard of care for patients with locally advanced lung cancer, but real-world practice has demonstrated that immune checkpoint inhibitor (ICI) pneumonitis can lead to significant clinical complications. This study aimed to examine the clinical predictors, outcomes, and healthcare utilization data in patients who received consolidation durvalumab. Using the Alberta Immunotherapy Database, NSCLC patients who received durvalumab in Alberta, Canada, from January 2018 to December 2021 were retrospectively evaluated. We examined incidence and predictive values of severe pneumonitis, with overall survival (OS) and time-to-treatment failure (TTF) using exploratory multivariate analyses. Of 189 patients, 91% were ECOG 0-1 and 85% had a partial response from chemoradiation prior to durvalumab. Median TTF and OS were not reached; 1-year OS was 82%. An amount of 26% developed any grade of pneumonitis; 9% had >= grade 3 pneumonitis. Male gender and a pre-existing autoimmune condition were associated with severe pneumonitis. V20 was associated with any grade of pneumonitis. Pneumonitis development was found to be an independent risk factor for worse OS (p = 0.038) and TTF (p = 0.007). Our results suggest clinical and dosimetric predictive factors of durvalumab-associated pneumonitis. These results affirm the importance of careful patient selection for safe completion of consolidation durvalumab in real-world LA-NSCLC population. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1198-0052 -SN - 1718-7729 -DA - 2023 DEC -PY - 2023 -VL - 30 -IS - 12 -SP - 10396 -EP - 10407 -DO - 10.3390/curroncol30120757 -AN - WOS:001130906400001 -AD - Univ Calgary, Internal Med Residency Program, Calgary, AB T2N 4N1, Canada -AD - Univ Alberta, Cross Canc Inst, Edmonton, AB T2S 3C3, Canada -AD - Univ Calgary, Tom Baker Canc Ctr, Calgary, AB T2N 4N2, Canada -Y2 - 2024-01-06 -ER - - -TY - JOUR -AU - Deslypere, Griet -AU - Gullentops, Dorothee -AU - Wauters, Els -AU - Vansteenkiste, Johan -TI - Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages? -T2 - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY -M3 - Review -AB - Over the last decade, several steps forward in the treatment of patients with stage IV non-small cell lung cancer (NCSLC) were made. Examples are the use of pemetrexed, pemetrexed maintenance therapy, or bevacizumab for patients with nonsquamous NSCLC. A big leap forward was the use of tyrosine kinase inhibitors in patients selected on the basis of an activating oncogene, such as epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) translocations. However, all of these achievements could not be translated into survival benefits when studied in randomized controlled trials in patients with nonmetastatic NSCLC. Aside from chemotherapy and targeted therapy, immunotherapy has become the third pillar in the treatment armamentarium of advanced NSCLC. Antigen-specific immunotherapy (cancer vaccination) has been disappointing in large phase III clinical trials in stages I-III NSCLC. Based on the recent breakthroughs with immune checkpoint inhibitor immunotherapy in metastatic NSCLC, much hope currently rests on the use of this approach in patients with stage I-III NSCLC as well. Here we give a brief overview of how most new therapeutic approaches for advanced NSCLC failed in other stages, and then elaborate on the role of immunotherapy in patients with stage I-III NSCLC. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1758-8340 -SN - 1758-8359 -DA - 2018 MAY 4 -PY - 2018 -VL - 10 -SP - 1 -EP - 11 -DO - 10.1177/1758835918772810 -AN - WOS:000442643100001 -AD - Univ Hosp KU Leuven, Resp Oncol Unit, Dept Resp Med, Herestr 49, B-3000 Leuven, Belgium -Y2 - 2018-05-04 -ER - - -TY - JOUR -AU - Tachihara, Motoko -AU - Tsujino, Kayoko -AU - Ishihara, Takeaki -AU - Hayashi, Hidetoshi -AU - Sato, Yuki -AU - Kurata, Takayasu -AU - Sugawara, Shunichi -AU - Shiraishi, Yoshimasa -AU - Teraoka, Shunsuke -AU - Azuma, Koichi -AU - Daga, Haruko -AU - Yamaguchi, Masafumi -AU - Kodaira, Takeshi -AU - Satouchi, Miyako -AU - Shimokawa, Mototsugu -AU - Yamamoto, Nobuyuki -AU - Nakagawa, Kazuhiko -A1 - WJOG -TI - Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer The DOLPHIN Phase 2 Nonrandomized Controlled Trial -T2 - JAMA ONCOLOGY -M3 - Article -AB - IMPORTANCE Administration of durvalumab after concurrent chemoradiotherapy is the standard treatment of unresectable, locally advanced non-small cell lung cancer (NSCLC); however, 20% to 30% of patients do not receive durvalumab because of adverse events (AEs) during concurrent chemoradiotherapy. In addition, radiotherapy and immunotherapy have a synergistic effect. OBJECTIVE To investigate the efficacy and safety of durvalumab immunotherapy plus concurrent radiotherapy followed by maintenance with durvalumab therapy for treatment of locally advanced NSCLC without chemotherapy. DESIGN, SETTING, AND PARTICIPANTS The multicenter, single-arm DOLPHIN (Phase II Study of Durvalumab [MEDI4736] Plus Concurrent Radiation Therapy in Advanced Localized NSCLC Patients) nonrandomized controlled trial was performed by 12 institutions in Japan from September 13, 2019, to May 31, 2022. Participants in the primary registration phase included 74 patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, locally advanced NSCLC. The current analyses were conducted from June 1, 2022, to October 31, 2022. INTERVENTIONS Patients received radiotherapy (60 Gy) in combination with concurrent and maintenance durvalumab immunotherapy, 10mg/kg every 2 weeks, for up to 1 year. MAIN OUTCOMES AND MEASURES The primary end point of the rate of 12-month progression-free survival (PFS), as assessed by an independent central review, was estimated using the Kaplan-Meier method and evaluated with 90% CIs calculated using the Greenwood formula. The key secondary end points were PFS, objective response rate, treatment completion rate, and AEs. RESULTS Data from 35 patients (median [range] age, 72 [44-83] years; 31 [88.6%] men) were included in the full analysis set of the evaluable population. The 12-month PFS rate was 72.1% (90% CI, 59.1%-85.1%), and the median PFS was 25.6 months (95% CI, 13.1 months to not estimable) at a median follow-up of 22.8 months (range, 4.3-31.8 months). Scheduled radiation therapy was completed in 97.1% of patients. The confirmed objective response rate was 90.9%(95% CI, 75.7%-98.1%), and the treatment completion rate was 57.6%(95% CI, 39.2%-74.5%). Among 34 patients evaluated in the safety analysis set, AEs of grade 3 or 4 occurred in 18 patients (52.9%), and of grade 5 in 2 patients (5.9%). Pneumonitis or radiation pneumonitis of any grade occurred in 23 patients (67.6%), and of grades 3 or 4 in 4 patients (11.8%). CONCLUSIONS AND RELEVANCE Findings from this phase 2 nonrandomized controlled trial indicate that durvalumab immunotherapy combined with curative radiotherapy for patients with PD-L1-positive, unresectable, locally advanced NSCLC is a promising treatment with tolerable AEs and is appropriate as a study treatment for phase 3 clinical trials. -PU - AMER MEDICAL ASSOC -PI - CHICAGO -PA - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA -SN - 2374-2437 -SN - 2374-2445 -DA - 2023 NOV -PY - 2023 -VL - 9 -IS - 11 -SP - 1505 -EP - 1513 -DO - 10.1001/jamaoncol.2023.3309 -AN - WOS:001065186900005 -C6 - SEP 2023 -AD - Kobe Univ, Grad Sch Med, Dept Internal Med, Div Resp Med, 7-5-1 Kusunoki Cho,Chuo Ku, Kobe 6500017, Japan -AD - Kobe Univ, Grad Sch Med, Dept Internal Med, Div Resp Med, Kobe, Japan -AD - Hyogo Canc Ctr, Dept Radiat Oncol, Akashi, Japan -AD - Kobe Univ, Grad Sch Med, Div Radiat Oncol, Kobe, Japan -AD - Kindai Univ, Dept Med Oncol, Osakasayama, Japan -AD - Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Japan -AD - Kansai Med Univ Hosp, Dept Thorac Oncol, Hirakata, Japan -AD - Sendai Kousei Hosp, Dept Pulm Med, Sendai, Japan -AD - Kyushu Univ, Grad Sch Med Sci, Dept Resp Med, Fukuoka, Japan -AD - Wakayama Med Univ, Internal Med 3, Wakayama, Japan -AD - Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Fukuoka, Japan -AD - Osaka City Gen Hosp, Dept Med Oncol, Osaka, Japan -AD - Natl Hosp Org Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan -AD - Aichi Canc Ctr Hosp, Dept Radiat Oncol, Nagoya, Aichi, Japan -AD - Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Japan -AD - Yamaguchi Univ, Grad Sch Med, Dept Biostat, Ube, Japan -M2 - Kindai Univ -Y2 - 2023-10-12 -ER - - -TY - JOUR -AU - Van Schil, Paul E. -AU - Yogeswaran, Krishan -AU - Hendriks, Jeroen M. -AU - Lauwers, Patrick -AU - Faivre-Finn, Corinne -TI - Advances in the use of surgery and multimodality treatment for N2 non-small cell lung cancer -T2 - EXPERT REVIEW OF ANTICANCER THERAPY -M3 - Article -AB - Introduction: Stage IIIA-N2 non-small cell lung cancer (NSCLC) represents a heterogeneous group of bronchogenic carcinomas with locoregional involvement. Different categories of N2 disease exist, ranging from unexpectedly encountered N2 involvement after detailed preoperative staging or surprise' N2, to potentially resectable disease treated within a combined modality setting, and finally, bulky N2 involvement treated by chemoradiation.Areas covered: Large randomised controlled trials and meta-analyses on stage IIIA-N2 NSCLC have been published but their implications for treatment remain a matter of debate. No definite recommendations can be provided as diagnostic and therapeutic algorithms vary according to local, national or international guidelines.Expert commentary: From the literature, it is clear that patients with stage IIIA-N2 NSCLC should be treated by combined modality therapy including chemotherapy, radiotherapy and surgery. The relative contribution of each modality has not been firmly established. For patients undergoing induction therapy, adequate restaging is important as only down-staged patients will clearly benefit from surgical resection. Each patient should be discussed within a multidisciplinary team to determine the best diagnostic and therapeutic approach according to the specific local expertise. In the near future, it might be expected that targeted therapies and immunotherapy will be incorporated as possible therapeutic options. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1473-7140 -SN - 1744-8328 -DA - 2017 -PY - 2017 -VL - 17 -IS - 6 -SP - 555 -EP - 561 -DO - 10.1080/14737140.2017.1319766 -AN - WOS:000401757900008 -AD - Antwerp Univ Hosp, Dept Thorac & Vasc Surg, Wilrijkstr 10, B-2650 Antwerp, Belgium -AD - Univ Manchester, Div Mol & Clin Canc Sci, Manchester, Lancs, England -Y2 - 2018-12-28 -ER - - -TY - JOUR -AU - Yasumoto, Kosei -AU - Hanagiri, Takeshi -AU - Takenoyama, Mitsuhiro -TI - Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer. -T2 - General thoracic and cardiovascular surgery -M3 - Journal Article -M3 - Review -AB - Despite recent advances in surgery, irradiation, and chemotherapy, the prognosis of patients with lung cancer is still poor. Therefore, the development and application of new therapeutic strategies are essential for improving the prognosis of this disease. Significant progress in our understanding of tumor immunology and molecular biology has allowed us to identify the tumor-associated antigens recognized by cytotoxic T lymphocytes. Immune responses and tumor-associated antigens against not only malignant melanoma but also lung cancer have been elucidated at the molecular level. In a theoretical sense, tumor eradication is considered possible through antigen-based immunotherapy against such diseases. However, many clinical trials of cancer vaccination with defined tumor antigens have resulted in objective clinical responses in only a small number of patients. Tumor escape mechanisms from host immune surveillance remain a major obstacle for cancer immunotherapy. A better understanding of the immune escape mechanisms employed by tumor cells is necessary before we can develop a more effective immunotherapeutic approach to lung cancer. We review recent studies regarding the identification of tumor antigens in lung cancer, tumor immune escape mechanisms, and clinical vaccine trials in lung cancer. -SN - 1863-6713 -DA - 2009 Sep (Epub 2009 Sep 13) -PY - 2009 -VL - 57 -IS - 9 -SP - 449 -EP - 57 -DO - 10.1007/s11748-008-0433-6 -AN - MEDLINE:19756930 -AD - Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Iseigaoka 1-1, Yahatanishi-ku, Kitakyushu, 807-8555, Japan. k-yasumo@med.uoeh-u.ac.jp -Y2 - 2009-09-01 -ER - - -TY - JOUR -AU - Watanabe, Shun-ichi -AU - Yotsukura, Masaya -AU - Miyoshi, Tomohiro -AU - Hattori, Aritoshi -AU - Isaka, Tetsuya -AU - Maniwa, Tomohiro -AU - Isaka, Mitsuhiro -AU - Yoshioka, Hiroshige -AU - Endo, Makoto -AU - Mimae, Takahiro -AU - Tsutani, Yasuhiro -AU - Nakagawa, Kazuo -AU - Aokage, Keiju -A1 - Lung Canc Surgical Study Grp LCSSG -A1 - Japan Clinical Oncology Grp JCOG -TI - Updated review of perioperative treatment for non-small-cell lung cancer in the new era of immune checkpoint inhibitors: past, present, and future -T2 - JAPANESE JOURNAL OF CLINICAL ONCOLOGY -M3 - Review -M3 - Early Access -AB - The perioperative treatments for non-small cell lung cancer (NSCLC) should control both local and microscopic systemic disease, because the survival of patients with NSCLC who underwent surgical resection alone has been dismal except in stage IA patients. One way to improve surgical outcome is the administration of chemotherapy before or after the surgical procedure. During the last two decades, many clinical studies have focused on developing optimal adjuvant or neoadjuvant cisplatin-based chemotherapy regimens that can be combined with surgical treatment and/or radiotherapy. Based on the results of those clinical studies, multimodality therapy has been considered to be an appropriate treatment approach for locally advanced NSCLC patients. When nodal involvement is discovered postoperatively, adjuvant cisplatin-based chemotherapy has conferred an overall survival benefit. More recently, neoadjuvant and/or adjuvant use of immunotherapy adding to the cisplatin-based chemotherapy has been revealed to improve survival of the patients with locally advanced NSCLC in many large-scale clinical trials; although, optimal treatment strategies are still evolving.The author reviewed the results of clinical studies focused on developing optimal adjuvant or neoadjuvant therapy regimens with or without immunotherapy for advanced lung cancer that can be combined with surgical treatment. -PU - OXFORD UNIV PRESS -PI - OXFORD -PA - GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND -SN - 0368-2811 -SN - 1465-3621 -DA - 2024 AUG 20 -PY - 2024 -DO - 10.1093/jjco/hyae106 -AN - WOS:001293922400001 -C6 - AUG 2024 -AD - Natl Canc Ctr, Dept Thorac Surg, Tsukiji 5-1-1,Chuo Ku, Tokyo 1040045, Japan -AD - Natl Canc Ctr Hosp East, Div Thorac Surg, Chiba, Japan -AD - Juntendo Univ Hosp, Div Gen Thorac Surg, Tokyo, Japan -AD - Kanagawa Canc Ctr, Dept Thorac Surg, Yokohama, Kanagawa, Japan -AD - Osaka Int Canc Inst, Dept Thorac Surg, Osaka, Japan -AD - Shizuoka Canc Ctr Hosp, Dept Thorac Surg, Shizuoka, Japan -AD - Kansai Med Univ Hosp, Dept Thorac Oncol, Osaka, Japan -AD - Yamagata Prefectural Cent Hosp, Dept Thorac Surg, Yamagata, Japan -AD - Hiroshima Univ, Dept Surg Oncol, Hiroshima, Japan -AD - Kindai Univ, Fac Med, Div Thorac Surg, Dept Surg, Osakasayama, Japan -AD - Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Thorac Surg, Tokyo, Japan -M2 - Osaka Int Canc Inst -M2 - Kindai Univ -Y2 - 2024-08-23 -ER - - -TY - JOUR -AU - Chu, Xianjing -AU - Tian, Wentao -AU - Ning, Jiaoyang -AU - Zhou, Rongrong -TI - Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis -T2 - JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE -M3 - Article -AB - Introduction Programmed death 1 (PD-1)/programmed death 1 ligand 1 (PD-L1)-directed immunotherapy has revolutionized the treatments for advanced non-small cell lung cancer (NSCLC), whereas the optimal therapeutic combinations remain uncertain. Methods Our study encompassed phase II/III randomized controlled trials (RCTs) that involved anti-PD-(L)1-based therapies for stage-IV NSCLC. The primary outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and incidences of adverse events. Subgroup analyses were conducted by treatment lines, PD-L1 expression levels, histological types, and metastatic sites. Results Our analysis incorporated 38 publications, covering 14 therapeutic combinations and involving 18 048 participants. PD-(L)1+chemotherapy (CT), PD-(L)1+ cytotoxic T lymphocyte-associated antigen-4 (CTLA4) +CT, and PD-(L)1+ T-cell immunoglobulin and ITIM domain were notably effective in prolonging OS. Overall, PD-(L)1+CT and PD-(L)1+CT+ vascular endothelial growth factor (VEGF) were significantly beneficial for PFS and ORR. As for the subsequent-line treatments, incorporating radiotherapy can enhance PFS and ORR (ranked fourth among enrolled treatments). For patients with PD-L1 <1%, PD-(L)1+CT+VEGF and PD-(L)1+CTLA4+CT were favorable approaches. Conversely, in patients with PD-L1 >= 50%, PD-(L)1+CT represented an effective treatment. Patients with nonsquamous cell carcinoma or liver metastases might benefit from the addition of VEGF. In cases of squamous cell carcinoma or brain metastases, the combination of PD-(L)1+CTLA4+CT yielded superior benefits. Conclusions This study underscores the enhanced efficacy of combination immunotherapies over monotherapy. It highlights the necessity for personalized treatment, considering individual factors. These insights are vital for clinical decision making in the management of advanced NSCLC. -PU - OXFORD UNIV PRESS INC -PI - CARY -PA - JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA -SN - 0027-8874 -SN - 1460-2105 -DA - 2024 JUL 10 -PY - 2024 -VL - 116 -IS - 10 -SP - 1571 -EP - 1586 -DO - 10.1093/jnci/djae137 -AN - WOS:001268492500001 -C6 - JUN 2024 -AD - Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China -AD - Cent South Univ, Xiangya Hosp, Xiangya Lung Canc Ctr, Changsha, Peoples R China -AD - Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China -Y2 - 2024-07-20 -ER - - -TY - JOUR -AU - Grant, SC -AU - Kris, MG -AU - Houghton, AN -AU - Chapman, PB -TI - Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin -T2 - CLINICAL CANCER RESEARCH -M3 - Article -AB - Despite active therapies for small cell lung cancer (SCLC), most patients relapse and die of the disease. The present study evaluates immunization using the anti-idiotypic antibody BEC2, which mimics the ganglioside GD3 expressed on the surface of most SCLC tumors, combined with Bacillus Calmette-Guerin (BCG) as an immune adjuvant, We hypothesized that active immunization could alter the natural history of the disease, Fifteen patients who had completed standard therapy for SCLC received a series of five intradermal immunizations consisting of 2.5 mg of BEC2 plus BCG over a 10-week period. Blood was collected for serological analysis, and outcome was monitored, All patients developed anti-BEC2 antibodies, despite having received chemotherapy with or without thoracic radiation. We detected anti-GD3 antibodies in five patients, including those with the longest relapse-free survival. The median relapse-free survival for patients with extensive stage disease is II months and has not been reached for patients with limited stage disease (>47 months), with only one of seven patients having relapsed after a median follow-up of 47 months. Immunization of patients with SCLC after standard therapy using BEC2 plus BCG can induce anti-GD3 antibodies and is safe. The survival and relapse-free survival in this group of patients are substantially better than those observed in a prior group of similar patients. A Phase III trial is being conducted to evaluate BEC2 plus BCG as adjuvant therapy after chemotherapy and irradiation. -PU - AMER ASSOC CANCER RESEARCH -PI - BIRMINGHAM -PA - PO BOX 11806, BIRMINGHAM, AL 35202 USA -SN - 1078-0432 -DA - 1999 JUN -PY - 1999 -VL - 5 -IS - 6 -SP - 1319 -EP - 1323 -AN - WOS:000080883800009 -AD - Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, Thorac Oncol Serv, New York, NY 10021 USA -AD - Mem Sloan Kettering Canc Ctr, Div Hematol, Clin Immunol Serv, New York, NY 10021 USA -AD - Mem Sloan Kettering Canc Ctr, Dept Med, Clin Immunol Serv, New York, NY 10021 USA -AD - Cornell Univ, Joan & Sanford I Weill Med Coll, New York, NY 10021 USA -Y2 - 1999-06-01 -ER - - -TY - JOUR -AU - Chen, N. -AU - Zhou, R. -AU - Luo, Q. -AU - Liu, Y. -AU - Li, C. -AU - Zhang, J. -AU - Guo, J. -AU - Zhou, Y. -AU - Jiang, H. -AU - Qiu, B. -AU - Liu, H. -TI - Combining Dosimetric and Radiomics Features for the Prediction of Radiation Pneumonitis in Locally Advanced Non -Small Cell Lung Cancer by Machine Learning -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2083 -SP - E38 -EP - E38 -AN - WOS:001079706800079 -AD - Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc, State Key Lab Oncol South China, Guangzhou, Peoples R China -AD - Homol Med Technol Inc, Ningbo, Peoples R China -M2 - Homol Med Technol Inc -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Shafique, Michael R. -AU - Robinson, Lary A. -AU - Antonia, Scott -TI - Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer -T2 - CANCER MANAGEMENT AND RESEARCH -M3 - Review -AB - Lung cancer is the most common cancer worldwide and the most common cause of cancer-related death. Non-small-cell lung cancer comprises similar to 87% of newly diagnosed cases of lung cancer, and nearly one-third of these patients have stage III disease. Despite improvements in the treatment of stage IV lung cancer, particularly with the introduction and dissemination of checkpoint inhibitors, very little progress has been made in the treatment of stage III lung cancer. In this article, we discuss the general staging criteria and treatment options for stage III lung cancer. We review how concurrent radiation and chemotherapy can have immunomodulatory effects, supporting the rationale for incorporating immunotherapy into existing treatment paradigms. Finally, we discuss the results of the PACIFIC trial and implications for the treatment of stage III lung cancer. In the PACIFIC trial, adding durvalumab as a maintenance therapy following the completion of chemoradiotherapy improved progression-free survival in patients with locally advanced unresectable stage III lung cancer. On the strength of these results, durvalumab has been approved by the US Food and Drug Administration for use in this setting, representing the first advance in the treatment of stage III lung cancer in nearly a decade. -PU - DOVE MEDICAL PRESS LTD -PI - ALBANY -PA - PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND -SN - 1179-1322 -DA - 2018 -PY - 2018 -VL - 10 -SP - 931 -EP - 940 -DO - 10.2147/CMAR.S148009 -AN - WOS:000433944500001 -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA -Y2 - 2018-06-28 -ER - - -TY - JOUR -AU - Qiu, Ye -AU - He, Xinyun -AU - Li, Zepei -AU - Jiang, Yulan -AU - Jia, Yuming -TI - Efficacy of early combination of local radiotherapy and GM-CSF for advanced non-small cell lung cancer treated with icotinib -T2 - IRISH JOURNAL OF MEDICAL SCIENCE -M3 - Article -AB - Background Lung cancer is a disease that severely endangers human health. Non-small cell lung cancer (NSCLC) accounts for approximately 4/5 of lung cancers. Aims To investigate the efficacy of early combination of local radiotherapy and granulocyte macrophage colony-stimulating factor (GM-CSF) for advanced NSCLC treated with icotinib. Methods Forty-two patients with stage IV NSCLC complicated with EGFR gene mutation were selected and randomly divided into two groups, with 21 patients in each group. Patients in control group were treated with icotinib, and patients in experimental group were treated with icotinib combined with local radiotherapy and subcutaneous injection of GM-CSF. One-year progression free survival between two groups was compared. Results Three months after treatment, the efficacy in experimental group was significantly better than that in control group, and objective response rate was 95.24% in experimental group, which was higher than the 71.43% in control group. Patients in experimental group had no differences in white blood cell and neutrophil, but had significantly lower carcino-embryonic antigen and neuron-specific enolase levels and higher CD3+, CD4+, and CD4+/CD8+ than those in control group and before treatment. There were no differences in the proportion of patients with adverse reactions between two groups. One-year progression free survival was significantly better in experimental group than in control group. Conclusions Early combination of local radiotherapy and GM-CSF has a significant efficacy for advanced NSCLC accounts for approximately 4/5 of lung cancers treated with icotinib, and it can improve patients' autoimmunity and lengthen progression free survival. -PU - SPRINGER LONDON LTD -PI - LONDON -PA - 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND -SN - 0021-1265 -SN - 1863-4362 -DA - 2020 AUG -PY - 2020 -VL - 189 -IS - 3 -SP - 791 -EP - 797 -DO - 10.1007/s11845-019-02137-x -AN - WOS:000500332300001 -C6 - DEC 2019 -AD - Second Peoples Hosp Yibin, Dept Oncol, 268 Nanguang Rd, Yibin 644000, Sichuan, Peoples R China -AD - Guizhou Prov Peoples Hosp, Dept Oncol, Guiyang, Guizhou, Peoples R China -AD - Second Peoples Hosp Yibin, Dept Gastroenterol, 96 North St, Yibin 644000, Sichuan, Peoples R China -M2 - Second Peoples Hosp Yibin -M2 - Guizhou Prov Peoples Hosp -M2 - Second Peoples Hosp Yibin -Y2 - 2019-12-11 -ER - - -TY - JOUR -AU - Borghaei, Hossein -AU - Langer, Corey J. -AU - Millenson, Michael -AU - Ruth, Karen J. -AU - Litwin, Samuel -AU - Tuttle, Holly -AU - Seldomridge, Judie Sylvester -AU - Rovito, Marc -AU - Mintzer, David -AU - Cohen, Roger -AU - Treat, Joseph -TI - Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Results of OPN-017 -T2 - JOURNAL OF THORACIC ONCOLOGY -M3 - Article -M3 - Proceedings Paper -CP - 12th World Conferene on Lung Cancer -CL - Seoul, SOUTH KOREA -AB - Background: Cetuximab has demonstrated synergy with taxanes in preclinical models; as well as single agent activity. We assessed the activity of cetuximab with carboplatin and paclitaxel given on a 4-week schedule, in advanced, chemo-naive non-small cell lung cancer.Patients and Methods: This phase II, single arm, multi-institution day 1, then Study featured standard dosage of cetuximab 400 mg/m(2) 250 mg/m(2) with paclitaxel (100 mg/m(2)/wk, For 3 weeks), and carboplatin (area under curve = 6) day 1 of each 28 clay cycle. After 4 to 6 cycles, in the absence of disease progression or excess toxicity, cetuximab was Continued weekly. Primary end point was response rate.Results: Fifty-three patients (median age 63, 51% male) participated. Response rate was 57% (3 complete response and 27 partial response). At a median follow-up of 12.5 months, the estimated overall Survival is 13.8 months (95% CI: 9.08-16.02) with an event-free survival rate of 5.53 months (95% CI: 4.77-7.99) 18.9% remain free from progression at 1 year. Improved survival was associated with female gender, absence of prior radiation, PS 0 and epidermal growth factor receptor expression. Toxicities included rash (28% grade 3), nail changes (3.7% grade 3). hypomagnesemia (7.5% grade 3 and 3.7% grade 4), and neutropenia (25% grade 3 and 13% grade 4) in addition to other typical side effects anticipated with paclitaxel/carboplatin. There were no grade 5 toxicities.Conclusion: Combination of cetuximab/paclitaxel/carboplatin in non-small cell lung cancer was well tolerated and clinically active with manageable toxicities. This unique schedule, integrating weekly paclitaxel and cetuximab has not yet been tested in a randomized trial. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA -SN - 1556-0864 -DA - 2008 NOV -PY - 2008 -VL - 3 -IS - 11 -SP - 1286 -EP - 1292 -DO - 10.1097/JTO.0b013e318189f50e -AN - WOS:000261113500012 -AD - Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA -AD - Fox Chase Canc Ctr, Dept Biostat, Philadelphia, PA 19111 USA -AD - Fox Chase Canc Ctr, Extramural Res Program, Philadelphia, PA 19111 USA -AD - Delaware Cty Mem Hosp, Philadelphia, PA USA -AD - Penn Hosp, Philadelphia, PA 19107 USA -AD - Eli Lilly, Philadelphia, PA USA -M2 - Delaware Cty Mem Hosp -Y2 - 2008-11-01 -ER - - -TY - JOUR -AU - Carroll, Nikki M -AU - Eisenstein, Jennifer -AU - Burnett-Hartman, Andrea N -AU - Greenlee, Robert T -AU - Honda, Stacey A -AU - Neslund-Dudas, Christine M -AU - Rendle, Katharine A -AU - Vachani, Anil -AU - Ritzwoller, Debra P -TI - Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer. -T2 - Cancer treatment and research communications -M3 - Journal Article -M3 - Research Support, N.I.H., Extramural -AB - INTRODUCTION/BACKGROUND: Systemic treatment for advanced non-small cell lung cancer (NSCLC) is shifting from platinum-based chemotherapy to immunotherapy and targeted therapies associated with improved survival in clinical trials. As new therapies are approved for use, examining variations in use for treating patients in community practice can generate additional evidence as to the magnitude of their benefit.PATIENTS AND METHODS: We identified 1,442 patients diagnosed with de novo stage IV NSCLC between 3/1/2012 and 12/31/2020. Patient characteristics and treatment patterns are described overall and by type of first- and second-line systemic therapy received. Prevalence ratios estimate the association of patient and tumor characteristics with receipt of first-line therapy.RESULTS: Within 180 days of diagnosis, 949 (66%) patients received first-line systemic therapy, increasing from 53% in 2012 to 71% in 2020 (p=0.0004). The proportion of patients receiving first-line immunotherapy+/-chemotherapy (IMO) increased from 14%-66% (p<0.0001). Overall, 380 (26%) patients received both first- and second-line treatment, varying by year between 16%-36% (p=0.18). The proportion of patients receiving second-line IMO increased from 13%-37% (p<0.0001). Older age and current smoking status were inversely associated with receipt of first-line therapy. Higher BMI, receipt of radiation, and diagnosis year were positively associated with receipt of first-line therapy. No association was found for race, ethnicity, or socioeconomic status.CONCLUSION: The proportion of advanced NSCLC patients receiving first- and second-line treatment increased over time, particularly for IMO treatments. Additional research is needed to better understand the impact of these therapies on patient outcomes, including short-term, long-term, and financial toxicities.MICROABSTRACT: Systemic treatment for non-small cell lung cancer (NSCLC) is shifting from platinum-based therapies to immunotherapy and targeted therapies. Using de novo stage IV NSCLC patients identified from 4 healthcare systems, we examine trends in systemic therapy. We saw an increase in the portion of patients receiving any systemic therapy and a sharp increase in the proportion of patients receiving immunotherapy. -SN - 2468-2942 -DA - 2023 (Epub 2023 Jun 14) -PY - 2023 -VL - 36 -SP - 100730 -EP - 100730 -DO - 10.1016/j.ctarc.2023.100730 -AN - MEDLINE:37352588 -AD - Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, USA. Electronic address: nikki.m.carroll@kp.org. -AD - Colorado Permanente Medical Group, Kaiser Permanente Colorado, Denver, CO, USA. -AD - Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, USA; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA. -AD - Marshfield Clinic Research Institute, Marshfield, WI, USA. -AD - Hawaii Permanente Medical Group and Center for Integrated Healthcare Research, Kaiser Permanente Hawaii, Honolulu, HI, USA. -AD - Henry Ford Health and Henry Ford Cancer Institute, Detroit, MI, USA. -AD - Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. -AD - Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, USA. -Y2 - 2023-06-25 -ER - - -TY - JOUR -AU - Li, Yuchen -AU - Juergens, Rosalyn Anne -AU - Finley, Christian -AU - Swaminath, Anand -TI - Current and Future Treatment Options in the Management of Stage III NSCLC -T2 - JOURNAL OF THORACIC ONCOLOGY -M3 - Review -AB - For much of the past two decades, the treatment options for patients with stage III NSCLC were mostly stagnant. In the past 5 years, ongoing innovations have dovetailed alongside advances in biomarker testing, novel therapeutics, precision surgery, and radiotherapy, all of which are leading to an increase in more personalized option for the treatment. This review article will focus on several completed and ongoing initiatives involving treatment of patients with stage III NSCLC. First, it will tackle the progress made in curative treatment of unresectable stage III NSCLC, starting with PACIFIC, and branching out into topics such as concurrent immunotherapy and chemoradiation, intensification of consolidative immunotherapy, dual immunotherapy consolidation, and a reflection on those subpopulations that may not benefit from consolidative immunotherapy. Second, there will be discussion of novel strategies in the setting of resectable stage III disease, most notably neoadjuvant therapy using combined chemo-immunotherapy and immunotherapy alone before surgical resection. Third, it will delve into recent data evaluating adjuvant immunotherapy for resectable stage III NSCLC, including adjuvant targeted therapy (for those harboring driver mutations) and postoperative radiotherapy. Finally, a look to future trials/initiatives will be interspersed throughout the review, to reveal the ongoing efforts being made to continue to improve outcomes in this group of patients. (c) 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1556-0864 -SN - 1556-1380 -DA - 2023 NOV -PY - 2023 -VL - 18 -IS - 11 -SP - 1478 -EP - 1491 -DO - 10.1016/j.jtho.2023.08.011 -AN - WOS:001106824600001 -C6 - OCT 2023 -AD - McMaster Univ, Juravinski Canc Ctr, Dept Oncol, 699 Concession St, Hamilton, ON L8V 5C2, Canada -AD - McMaster Univ, Dept Surg, St Josephs Healthcare Hamilton, Hamilton, ON, Canada -Y2 - 2023-12-12 -ER - - -TY - JOUR -AU - HEYMACH, JOHN V (contact); WONG, KWOK KIN -TI - Therapeutic approaches for LKB1-deficient non-small cell lung cancer -M3 - Awarded Grant -AB - PUBLIC HEALTH RELEVANCE: Therapeutic advances have been made in the treatment of subpopulations of non-small cell lung cancer (NSCLC) patients who harbor specific genomic alterations (e.g. EGFR mutation and ALK ROS gene rearrangements) which can be targeted with small molecule kinase inhibitors; however, the serine/threonine kinase STK11 (LKB1) is the second most commonly altered tumor suppressors in NSCLC, with genomic loss or inactivating mutations occurring in 20-30% of lung adenocarcinoma and there are currently no treatment strategies tailored for LKB1-deficient NSCLC. The PIs have developed preliminary data showing that in human tumor specimens and in Genetically Engineered Mouse Models of NSCLC with Lkb1 deletion that loss of LKB1 is associated with higher stage of disease at presentation, increased metastasis and poor overall prognosis as well as unique biological characteristics. This proposal will deeply characterize the distinct biology of LKB1- deficient NSCLCs with a focus on the immune microenvironment as a means to develop novel therapeutic approaches for patients with LKB1-deficient NSCLCs. -DA - 2018 -PY - 2018 -AN - GRANTS:12342757 -G1 - 5R01CA205150-03; 9456687; R01CA205150 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Kumar, R. -AU - Almeldin, D. S. -AU - Kim, J. -AU - Deek, M. P. -AU - Jabbour, S. K. -TI - Predictive Value of Dynamic Tumor Volume Changes in Stage Ill Non-Small Cell Lung Cancer Treated with Chemoradiation and Consolidative Immunotherapy -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2069 -SP - E32 -EP - E33 -AN - WOS:001079706800066 -AD - Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA -AD - Cairo Univ, Dept Clin Oncol, Cairo, Egypt -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Aggarwal, Charu -AU - Bubendorf, Lukas -AU - Cooper, Wendy A. -AU - Illei, Peter -AU - Nunes, Paula Borralho -AU - Ong, Boon-Hean -AU - Tsao, Ming-Sound -AU - Yatabe, Yasushi -AU - Kerr, Keith M. -TI - Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges -T2 - LUNG CANCER -M3 - Article -AB - Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with the development of targeted therapies for advanced disease and concomitant molecular testing to inform clinical decision-making. In contrast, routine molecular testing in stage I-III disease has not been required, where standard of care comprises surgery with or without adjuvant or neoadjuvant chemotherapy, or concurrent chemoradiotherapy for unresectable stage III disease, without the integration of targeted therapy. However, the phase 3 ADAURA trial has recently shown that the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, reduces the risk of disease recurrence by 80% versus placebo in the adjuvant setting for patients with stage IB-IIIA EGFR mutation-positive NSCLC following complete tumor resection with or without adjuvant chemotherapy, according to physician and patient choice. Treatment with adjuvant osimertinib requires selection of patients based on the presence of an EGFR-TKI sensitizing mutation. Other targeted agents are currently being evaluated in the adjuvant and neoadjuvant settings. Approval of at least some of these other agents is highly likely in the coming years, bringing with it in parallel, a requirement for comprehensive molecular testing for stage I-III disease. In this review, we consider the implications of integrating molecular testing into practice when managing patients with stage I-III non-squamous NSCLC. We discuss best practices, approaches and challenges from pathology, surgical and oncology perspectives. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2021 DEC -PY - 2021 -VL - 162 -SP - 42 -EP - 53 -DO - 10.1016/j.lungcan.2021.09.003 -AN - WOS:000718120300001 -C6 - OCT 2021 -AD - Univ Penn, Perelman Sch Med, Dept Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA -AD - Univ Penn, Perelman Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA -AD - Univ Basel, Univ Basel Hosp, Inst Med Genet & Pathol, Basel, Switzerland -AD - Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia -AD - NSW Hlth Pathol, Sydney, NSW, Australia -AD - Univ Sydney, Sydney, NSW, Australia -AD - Western Sydney Univ, Campbelltown, NSW, Australia -AD - Johns Hopkins Univ, Sch Med, Dept Pathol & Oncol, Baltimore, MD USA -AD - Univ Lisbon, Fac Med, Lisbon, Portugal -AD - Hosp CUF Descobertas, Lisbon, Portugal -AD - Natl Heart Ctr Singapore, Dept Cardiothorac Surg, Singapore, Singapore -AD - Princess Margaret Canc Ctr, Univ Hlth Network, Dept Pathol, Toronto, ON, Canada -AD - Natl Canc Ctr, Dept Diagnost Pathol, Tokyo, Japan -AD - Univ Aberdeen, Dept Pathol, Sch Med, Foresterhill, Aberdeen, Scotland -AD - Aberdeen Royal Infirm, Foresterhill, Aberdeen, Scotland -M2 - NSW Hlth Pathol -M2 - Hosp CUF Descobertas -M2 - Aberdeen Royal Infirm -Y2 - 2021-11-25 -ER - - -TY - JOUR -AU - Tjong, Michael C. -AU - Ragulojan, Malavan -AU - Poon, Ian -AU - Louie, Alexander V. -AU - Cheng, Susanna Y. -AU - Doherty, Mark -AU - Zhang, Liying -AU - Ung, Yee -AU - Cheung, Patrick -AU - Cheema, Parneet K. -TI - Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience -T2 - CURRENT ONCOLOGY -M3 - Article -AB - Background: The safety impact of radiotherapy (RT) timing relative to immune checkpoint inhibitors (ICIs) for advanced non-small-cell lung cancer (NSCLC) is unclear. We investigated if RT within 14 days (Interval 1) and 90 days (Interval 2) of ICI use is associated with toxicities compared to RT outside these intervals. Methods: Advanced NSCLC patients treated with both RT and ICIs were reviewed. Toxicities were graded as per CTCAE v4.0 and attributed to either ICIs or RT by clinicians. Associations between RT timing and Grade >= 2 toxicities were analyzed using logistic regression models adjusted for patient, disease, and treatment factors (alpha = 0.05). Results: Sixty-four patients were identified. Twenty received RT within Interval 1 and 40 within Interval 2. There were 20 Grade >= 2 toxicities in 18 (28%) patients; pneumonitis (6) and nausea (2) were most prevalent. One treatment-related death (immune encephalitis) was observed. Rates of patients with Grade >= 2 toxicities were 35%/25% in the group with/without RT within Interval 1 and 30%/25% in the group with/without RT within Interval 2. No significant association between RT timing relative to ICI use period and Grade >= 2 toxicities was observed. Conclusion: Albeit limited by the small sample size, the result suggested that pausing ICIs around RT use may not be necessary. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1198-0052 -SN - 1718-7729 -DA - 2022 JAN -PY - 2022 -VL - 29 -IS - 1 -SP - 221 -EP - 230 -DO - 10.3390/curroncol29010021 -AN - WOS:000746248100001 -AD - Sunnybrook Med Ctr, Sunnybrook Odette Canc Ctr, Dept Radiat Oncol, Toronto, ON M4N 3M5, Canada -AD - McMaster Univ, Fac Med, Hamilton, ON L8S 4L8, Canada -AD - Sunnybrook Med Ctr, Sunnybrook Odette Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON M4N 3M5, Canada -AD - William Osler Hlth Syst, Dept Med Oncol & Hematol, Brampton, ON L6R3J7, Canada -M2 - William Osler Hlth Syst -Y2 - 2022-01-29 -ER - - -TY - JOUR -AU - Baudoux, Nathalie -AU - Friedlaender, Alex -AU - Addeo, Alfredo -TI - Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer -T2 - CLINICAL MEDICINE INSIGHTS-ONCOLOGY -M3 - Review -AB - Lung cancer remains the leading cause of cancer-related death with an incidence that continues to increase in both sexes and all ages. However, 80% to 90% of lung cancers are non-small cell lung cancer (NSCLC) and the remaining 10% to 20% are small cell lung cancer. Adenocarcinoma is the most common histologic subtype of lung cancer worldwide. More frequently, lung cancer diagnosis is made in advanced stages. Stage III NSCLC refers to locoregionally advanced disease without metastases and represents about 30% NSCLC cases. Despite the absence of metastases at diagnosis, the outcome is generally poor. Stage III comprises a heterogeneous group and optimal management requires the input of a multidisciplinary team. All modalities of oncologic treatment are involved: surgery, chemotherapy, radiotherapy, and more recently, immunotherapy and targeted therapy. We will discuss the different therapeutic options in stage III NSCLC, both in operable and inoperable scenarios, and the role of immunotherapy and targeted therapy. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1179-5549 -DA - 2023 -PY - 2023 -VL - 17 -C7 - 11795549231152948 -DO - 10.1177/11795549231152948 -AN - WOS:000933179400001 -AD - Geneva Univ Hosp, Oncol Dept, Geneva, Switzerland -AD - Clin Gen Beaulieu, Oncol Serv, Geneva, Switzerland -AD - Geneva Univ Hosp, Oncol Dept, CH-1205 Geneva, Switzerland -M2 - Clin Gen Beaulieu -Y2 - 2023-03-16 -ER - - -TY - JOUR -AU - Parisi, Elisabetta -AU - Arpa, Donatella -AU - Ghigi, Giuglia -AU - Micheletti, Simona -AU - Neri, Elisa -AU - Tontini, Luca -AU - Pieri, Martina -AU - Romeo, Antonino -TI - Complete pathological response in locally advanced non-small-cell lung cancer patient: A case report -T2 - WORLD JOURNAL OF CLINICAL CASES -M3 - Article -AB - BACKGROUND Chemotherapy and radiotherapy followed by durvalumab is currently the standard treatment for locally advanced node-positive non-small-cell lung cancer (NSCLC). We describe the case of a patient with locally advanced node-positive NSCLC (LA-NSCLC) treated in a phase II prospective protocol with chemotherapy, accelerated hypofractionated radiotherapy (AHRT) and surgery in the pre-immunotherapy era.CASE SUMMARY A 69-year-old male, ex-smoker (20 PY), with a Karnofsky performance status of 90, was diagnosed with locally advanced squamous cell lung carcinoma. He was staged by total body computed tomography (CT) scanning, and integrated F-18-fluorodeoxyglucose positron emission tomography/CT scan [cT4 cN3 cM0, stage IIIC according to TNM (tumor-node-metastasis) 8(th) edition] and received AHRT between chemotherapy cycles, in accordance with the study protocol (EudractCT registration 2008-006525-14). At the end of the study the patient underwent surgery, which was not part of the protocol, and showed a complete pathological response.CONCLUSION This case report confirms that AHRT can be used successfully to treat primary LA-NSCLC with bilateral mediastinal lymph node involvement. Our case is of particular interest because of the pathological response after AHRT and the lack of surgical complications. We hypothesize that this radiotherapeutic approach, with its proven efficacy, could be delivered as a short course reducing treatment costs, increasing patient compliance and reducing toxicity. We are currently investigating the possibility of combining hypofractionation, chemotherapy and immunotherapy for patients with LA-NSCLC. -PU - BAISHIDENG PUBLISHING GROUP INC -PI - PLEASANTON -PA - 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES -SN - 2307-8960 -DA - 2021 JUL 16 -PY - 2021 -VL - 9 -IS - 20 -SP - 5540 -EP - 5546 -DO - 10.12998/wjcc.v9.i20.5540 -AN - WOS:000676239400019 -AD - IRCCS Ist Sci Romagnolo Studio Tumori IRST Dino A, Radiotherapy Unit, Via P Maroncelli 40, I-47014 Meldola, Italy -M2 - IRCCS Ist Sci Romagnolo Studio Tumori IRST Dino A -Y2 - 2021-08-01 -ER - - -TY - JOUR -AU - Kassik, Marie-Theres -AU - Vordermark, Dirk -AU - Kornhuber, Christine -AU - Medenwald, Daniel -TI - Factors associated with overall survival, progression-free survival and toxicity in patients with small cell lung cancer and thoracic irradiation in a clinical real-world setting -T2 - RADIATION ONCOLOGY -M3 - Article -AB - Background Small-cell lung cancer (SCLC) is a malignant tumor known for its poor prognosis. In addition to chemotherapy and immunotherapy irradiation plays a big role especially in inoperability. This study evaluated prognostic factors in patients with SCLC, receiving chemotherapy and thoracic irradiation, that may affect overall survival (OS), progression-free survival (PFS) and toxicity.Methods Patients with limited disease (LD) SCLC (n = 57) and extensive disease (ED) SCLC (n = 69) who received thoracic radiotherapy were analyzed retrospectively. The prognostic factors sex, age, Karnofsky performance status (KPS), tumor-, nodal-stage and timepoint of start of irradiation in relation to the first cycle of chemotherapy were evaluated. Start of irradiation was stratified as early (<= 2 cycles of chemotherapy), late (3 or 4 cycles) and very late (>= 5 cycles). Results were analyzed by Cox univariate and multivariate as well as logistic regression analysis.Results The median OS of LD-SCLC patients was 23.7 months in early, and 22.0 months in late start of irradiation. In very late start, median OS was not reached. PFS was 11.8, 15.2 and 47.9 months, respectively. In patients with ED-SCLC OS was 4.3 months in early, 13.0 months in late and 12.2 months in very late start of irradiation. PFS was 6.7, 13.0 and 12.2 months, respectively. Prognosis of patients with LD-or ED-SCLC receiving late or very late start of irradiation was significantly prolonged in OS and PFS compared to an early start (p < 0.05). KPS >= 80 shows a significant increase of OS and PFS in ED-SCLC. Female sex and smaller mean lung dose were associated with lower risk of toxicity.Conclusion Late or very late start of irradiation is a prognosis-enhancing factor in LD-SCLC and ED-SCLC for OS and PFS. KPS >= 80 increases prognosis of OS and PFS in ED-SCLC as well. Toxicity is less common in female sex and patients with low mean lung dose in LD-SCLC. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1748-717X -DA - 2023 APR 18 -PY - 2023 -VL - 18 -IS - 1 -C7 - 70 -DO - 10.1186/s13014-023-02252-1 -AN - WOS:000974884200001 -AD - Univ Hosp Halle Saale, Dept Radiat Therapy, Ernst Grube Str 40, D-06120 Halle, Germany -Y2 - 2023-05-10 -ER - - -TY - JOUR -AU - Shukla, Anuj A. -AU - Podder, Shreya -AU - Chaudry, Sana R. -AU - Benn, Bryan S. -AU - Kurman, Jonathan S. -TI - Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment -T2 - AIMS MEDICAL SCIENCE -M3 - Review -AB - Lung cancer is the most common cancer worldwide and is also one of the leading causes of cancer related deaths. The 5-year survival rate depends largely on stage at diagnosis. Multiple large randomized controlled trials have demonstrated the clinical utility of lung cancer screening. Low dose computed tomography is recommended for lung cancer screening in several guidelines. Lung cancer is often diagnosed at more advanced stages owing to the nonspecific symptoms with which it presents. Diagnosis relies primarily upon imaging and biopsy. Diagnosis and staging should be performed simultaneously, if possible, by performing a biopsy at the site that will confer the highest stage. Sufficient material should be obtained to allow for molecular testing. Liquid biopsy may have a complementary role in detecting actionable mutations in non-small cell lung cancer. Treatment is predicated upon stage and may involve surgery, targeted chemotherapy, radiation therapy, immunotherapy, or some combination thereof. -PU - AMER INST MATHEMATICAL SCIENCES-AIMS -PI - SPRINGFIELD -PA - PO BOX 2604, SPRINGFIELD, MO 65801-2604, UNITED STATES -SN - 2375-1576 -DA - 2022 -PY - 2022 -VL - 9 -IS - 2 -SP - 348 -EP - 361 -DO - 10.3934/medsci.2022016 -AN - WOS:000804101700001 -AD - Med Coll Wisconsin, Div Pulm & Crit Care, Milwaukee, WI 53226 USA -Y2 - 2022-06-11 -ER - - -TY - JOUR -AU - Bi, Ziran -AU - Li, Wen -AU - Zhao, Jie -AU - Pang, Lulian -AU - Jing, Yanyan -AU - Zhang, Xiuqing -AU - Yao, Senbang -AU - Yin, Xiangxiang -AU - Zuo, He -AU - Cheng, Huaidong -TI - Negative correlations of psychological distress with quality of life and immunotherapy efficacy in patients with advanced NSCLC -T2 - AMERICAN JOURNAL OF CANCER RESEARCH -M3 - Article -AB - To evaluate the relationships between psychological distress and immunotherapy efficacy, adverse reactions and quality of life scores in patients with advanced non-small cell lung cancer (NSCLC). A total of 104 NSCLC patients who received 4-6 cycles of standard immunotherapy were enrolled and evaluated with the Distress Thermometer (DT) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). The aim was to analyze the correlation between psychological distress and quality of life and to analyze whether psychological distress affects the efficacy of and adverse reactions to immunotherapy. The objective response rate (ORR) and disease control rate (DCR) of the psychological distress group were 6% and 50%, respectively, and those of the no psychological distress group were 18.5% and 83.3%, respectively. The differences were statistically significant (chi(2) =14.131, P<0.05). The progression-free survival (PFS) of advanced NSCLC patients who received comprehensive immunotherapy and had no psychological distress was significantly better than that of the psychological distress group (HR, 0.338; 95% CI, 0.192-0.592; P<0.05). The PFS of advanced NSCLC patients who received immunotherapy combined with chemotherapy in the no psychological distress group was significantly better than that in the psychological distress group (HR, 0.458; 95% CI, 0.296-0.709; P<0.05). Psychological distress in advanced NSCLC patients affects the efficacy of immunotherapy, and psychological distress is negatively correlated with quality of life during immunotherapy. -PU - E-CENTURY PUBLISHING CORP -PI - MADISON -PA - 40 WHITE OAKS LN, MADISON, WI 53711 USA -SN - 2156-6976 -DA - 2022 -PY - 2022 -VL - 12 -IS - 2 -SP - 805 -EP - 815 -AN - WOS:000765695800024 -AD - Anhui Med Univ, Affiliated Hosp 2, Canc Treatment Ctr, Hefei 230601, Anhui, Peoples R China -Y2 - 2022-03-22 -ER - - -TY - JOUR -AU - Saw, Stephanie P. L. -AU - Ong, Boon-Hean -AU - Chua, Kevin L. M. -AU - Takano, Angela -AU - Tan, Daniel S. W. -TI - Revisiting neoadjuvant therapy in non-small-cell lung cancer -T2 - LANCET ONCOLOGY -M3 - Review -AB - Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer (NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by comparison. Establishing overall survival benefit in the early-stage setting has been challenging because of the need for large trials and long-term survival data. Encouraged by improved treatment outcomes with a biomarker-driven approach in advanced NSCLC, and recognising the need to improve survival outcomes in early-stage NSCLC, there has been renewed interest in revisiting neoadjuvant strategies. Multiple neoadjuvant trials with targeted therapy and immunotherapy, either alone or in combination with chemotherapy, have yielded unique insights into traditional response parameters, such as the discordance between RECIST response and pathological response, and expanded opportunities for biomarker discovery. With further standardisation of trial endpoints across studies, coupled with the implementation of novel technologies including radiomics and digital pathology, individual risk-stratified neoadjuvant treatment approaches are poised to make a striking impact on the outcomes of early-stage NSCLC. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1470-2045 -SN - 1474-5488 -DA - 2021 NOV -PY - 2021 -VL - 22 -IS - 11 -SP - E501 -EP - E516 -AN - WOS:000716464100009 -AD - Natl Canc Ctr Singapore, SingHlth Duke NUS Oncol Acad Clin Programme, Div Med Oncol, Singapore 169610, Singapore -AD - Natl Canc Ctr Singapore, SingHlth Duke NUS Oncol Acad Clin Programme, Div Radiat Oncol, Singapore, Singapore -AD - Natl Heart Ctr Singapore, Dept Cardiothorac Surg, Singapore, Singapore -AD - Singapore Gen Hosp, Dept Anat Pathol, Singapore, Singapore -AD - ASTAR, Genome Institue Singapore, Singapore, Singapore -Y2 - 2021-11-01 -ER - - -TY - JOUR -AU - Jones, Christopher M -AU - Brunelli, Alessandro -AU - Callister, Matthew E -AU - Franks, Kevin N -TI - Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence? -T2 - Current surgery reports -M3 - Journal Article -M3 - Review -AB - PURPOSE OF REVIEW: The majority of patients with non-small cell lung cancer (NSCLC) present with advanced disease and overall survival rates are poor. This article outlines the current and outstanding evidence for the use of multimodality treatment in this group of patients, including in combination with an increasing number of treatment options, such as immunotherapy and genotype-targeted small molecule inhibitors.RECENT FINDINGS: Optimal therapy for surgically resectable stage III disease remains debatable and currently the choice of treatment reflects each individual patient's disease characteristics and the expertise and opinion of the thoracic multi-disciplinary team. Evidence for a distinct oligometastatic state in which improved outcomes can be achieved remains minimal and there is as yet no consensus definition for oligometastatic lung cancer. Whilst there is supporting evidence for the aggressive management of isolated metastases, the use of consolidative therapy for multiple metastases remains unproven.SUMMARY: Evolution of new RT technologies, improved surgical technique and a plethora of interventional-radiology-guided ablative therapies are widening the choice of available treatment modalities to patients with NSCLC. In the setting of resectable locally advanced disease and the oligometastatic state, there is a growing need for randomised comparison of the available treatment modalities to guide both treatment and patient selection. -SN - 2167-4817 -DA - 2018 (Epub 2018 Feb 08) -PY - 2018 -VL - 6 -IS - 2 -SP - 5 -EP - 5 -DO - 10.1007/s40137-018-0202-0 -AN - MEDLINE:29456881 -AD - 1Leeds Institute of Cancer & Pathology, Faculty of Medicine & Health, University of Leeds, Leeds, UK. -AD - 2Radiotherapy Research Group, Leeds Cancer Centre, The Leeds Teaching Hospitals NHS Trust, Leeds, UK. -AD - 3School of Molecular & Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK. -AD - 4Department of Thoracic Surgery, The Leeds Teaching Hospitals NHS Trust, Leeds, UK. -AD - 5Department of Respiratory Medicine, The Leeds Teaching Hospitals NHS Trust, Leeds, UK. -Y2 - 2018-02-22 -ER - - -TY - JOUR -AU - Fujimoto, Daichi -AU - Uehara, Keiichiro -AU - Sato, Yuki -AU - Sakanoue, Ichiro -AU - Ito, Munehiro -AU - Teraoka, Shunsuke -AU - Nagata, Kazuma -AU - Nakagawa, Atsushi -AU - Kosaka, Yasuhiro -AU - Otsuka, Kojiro -AU - Imai, Yukihiro -AU - Hamakawa, Hiroshi -AU - Takahashi, Yutaka -AU - Kokubo, Masaki -AU - Tomii, Keisuke -TI - Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients -T2 - SCIENTIFIC REPORTS -M3 - Article -AB - Concurrent chemoradiation therapy (CCRT) is the treatment of choice for locally advanced non-small cell lung cancer (LA-NSCLC). Several clinical trials that combine programmed cell death 1 (PD-1) axis inhibitors with radiotherapy are in development for patients with LA-NSCLC. However, the effect of CCRT on programmed cell death ligand-1 (PD-L1) expression on tumor cells is unknown. In this study, we analysed paired NSCLC specimens that had been obtained pre- and post-CCRT. PD-L1 expression on tumor cells was studied by immunohistochemistry. A total of 45 patients with LA-NSCLC were included, among which there were sufficient pre- and post-CCRT specimens in 35 patients. Overall, the percentage of tumor cells with PD-L1 expression significantly decreased between pre- and post-CCRT specimens (P = 0.024). Sixteen, 15, and 4 patients had decreased, unchanged, or increased PD-L1 expression after CCRT, respectively. Median OS of patients with decreased, unchanged, or increased PD-L1 expression was 85.1, 92.8, and 14.6 months, respectively (P < 0.001). In conclusion, the percentage of PD-L1-positive tumor cells significantly decreased after CCRT. Alteration of PD-L1 expression after neoadjuvant CCRT was associated with prognosis in patients with LA-NSCLC. These data should be considered when developing the optimal approach of integrating PD-1 axis inhibitors with CCRT. -PU - NATURE PORTFOLIO -PI - BERLIN -PA - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY -SN - 2045-2322 -DA - 2017 SEP 12 -PY - 2017 -VL - 7 -C7 - 11373 -DO - 10.1038/s41598-017-11949-9 -AN - WOS:000410297900087 -AD - Gen Hosp, Kobe City Med Ctr, Dept Resp Med, Kobe, Hyogo, Japan -AD - Gen Hosp, Kobe City Med Ctr, Dept Clin Pathol, Kobe, Hyogo, Japan -AD - Gen Hosp, Kobe City Med Ctr, Dept Thorac Surg, Kobe, Hyogo, Japan -AD - Gen Hosp, Kobe City Med Ctr, Dept Radiat Oncol, Kobe, Hyogo, Japan -Y2 - 2017-09-12 -ER - - -TY - JOUR -AU - Inoue, Hiroyuki -AU - Okamoto, Isamu -TI - Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives -T2 - LUNG CANCER-TARGETS AND THERAPY -M3 - Review -AB - There has been no improvement in outcome for patients with unresectable locally advanced (stage III) non-small cell lung cancer (NSCLC) for more than 10 years. The standard treatment for these patients is definitive concurrent chemotherapy and radiation (CCRT). Although the goal of treatment in this setting is to achieve a cure, most patients progress and their prognosis is poor, with a 5-year survival rate of 15-30%. There is thus an urgent need for the development of novel anticancer treatments in this patient population. Recent advances in cancer immunotherapy have led to a marked improvement in clinical outcome for advanced NSCLC. Such immunotherapy mainly consists of the administration of immune checkpoint inhibitors (ICIs) such as antibodies to cytotoxic T lymphocyte-associated protein-4 (CTLA-4) or to either programmed cell death-1 (PD-1) or its ligand PD-L1. Durvalumab (MEDI4736) is a high-affinity human immunoglobulin G1 monoclonal antibody that blocks the binding of PD-L1 on tumor cells or antigen-presenting cells to PD-1 on T cells. The PACIFIC study recently evaluated consolidation immunotherapy with durvalumab versus placebo administered after concurrent chemoradiotherapy (CCRT) in patients with unresectable stage III NSCLC. It revealed a significant improvement in both progression-free and overall survival with durvalumab, and this improvement was associated with a favorable safety profile. This achievement has made durvalumab a standard of care for consolidation after CCRT in patients with unresectable stage III NSCLC, and it has now been approved in this setting by regulatory agencies in the United States, Canada, Japan, Australia, Switzerland, Malaysia, Singapore, India, and the United Arab Emirates. In this review, we briefly summarize the results of the PACIFIC trial, including those of post hoc analysis, and we address possible molecular mechanisms, perspectives, and remaining questions related to combined treatment with CCRT and ICIs in this patient population. -PU - DOVE MEDICAL PRESS LTD -PI - ALBANY -PA - PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND -SN - 1179-2728 -DA - 2019 -PY - 2019 -VL - 10 -SP - 161 -EP - 170 -DO - 10.2147/LCTT.S184380 -AN - WOS:000513683300001 -AD - Kyushu Univ, Chest Dis Res Inst, Grad Sch Med Sci, Fukuoka, Japan -AD - Kyushu Univ Hosp, Ctr Clin & Translat Res, Fukuoka, Japan -Y2 - 2020-02-28 -ER - - -TY - JOUR -AU - Riano, Ivy -AU - Abuali, Inas -AU - Sharma, Aditya -AU - Durant, Jewelia -AU - Dragnev, Konstantin H. H. -TI - Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer -T2 - PHARMACEUTICALS -M3 - Review -AB - The neoadjuvant use of immune checkpoint inhibitors (ICI) in resectable non-small cell lung cancer (NSCLC) is being increasingly adopted, but questions about the most appropriate applications remain. Although patients with resectable NSCLC are often treated with surgery and adjuvant chemotherapy or targeted therapies +/- radiotherapy, they still have a high risk of recurrence and death. In recent years, immune checkpoint inhibitors (ICI) (anti-PD-1/PD-L1 and anti-CTLA-4) have provided a new and effective therapeutic strategy for the treatment of advanced NSCLC. Therefore, it is possible that ICIs for early-stage NSCLC may follow the pattern established in metastatic disease. Currently, there are several ongoing trials to determine the efficacy in the neoadjuvant setting for patients with local or regional disease. To date, only nivolumab in combination with chemotherapy has been approved by the U.S. FDA in the preoperative setting, but data continue to evolve rapidly, and treatment guidelines need to be determined. In this article, we review the current preclinical and clinical evidence on neoadjuvant ICIs alone and combination in the treatment of early-stage NSCLC. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1424-8247 -DA - 2023 FEB -PY - 2023 -VL - 16 -IS - 2 -C7 - 233 -DO - 10.3390/ph16020233 -AN - WOS:000940021500001 -AD - Dartmouth Canc Ctr, Sect Med Oncol, Dartmouth Hlth, 1 Med Ctr Dr, Lebanon, NH 03756 USA -AD - Dartmouth Coll, Geisel Sch Med, 1 Rope Ferry Rd, Hanover, NH 03755 USA -AD - Massachusetts Gen Hosp, Harvard Med Sch, Div Hematol & Oncol, 55 Fruit St, Boston, MA 02114 USA -AD - Dartmouth Hitchcock Med Ctr, Dept Med, Dartmouth Hlth, 1 Med Dr, Lebanon, NH 03756 USA -M2 - Dartmouth Canc Ctr -Y2 - 2023-03-20 -ER - - -TY - JOUR -AU - Dawe, David E. -AU - Rittberg, Rebekah -AU - Syed, Iqra -AU - Shanahan, Mary Kate -AU - Moldaver, Daniel -AU - Bucher, Oliver -AU - Galloway, Katie -AU - Reynolds, Kayla -AU - Paul, James T. -AU - Harlos, Craig -AU - Kim, Julian O. -AU - Banerji, Shantanu -TI - Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study -T2 - FRONTIERS IN ONCOLOGY -M3 - Article -AB - Background: Extensive-stage small-cell lung cancer (ES-SCLC) is an incurable cancer with poor prognosis in which characteristics predictive of long-term survival are debated. The utility of agents such as immune checkpoint inhibitors highlights the importance of identifying key characteristics and treatment strategies that contribute to long-term survival and could help guide therapeutic decisions.Objective: This real-world analysis examines the characteristics, treatment patterns, and clinical outcomes of patients receiving chemotherapy without immunotherapy for ES-SCLC in Manitoba, Canada.Methods: A retrospective cohort study assessed patient characteristics, treatment, and survival duration (short: <6 months; medium: 6-24 months; long: >24 months) using the Manitoba Cancer Registry and CancerCare Manitoba records. Eligible patients were aged >18 years with cytologically confirmed ES-SCLC diagnosed between January 1, 2004, and December 31, 2018, and received cytotoxic chemotherapy (CT). The one-, two-, and five-year probabilities of overall survival (OS) were assessed relative to patient, disease, and treatment characteristics using Kaplan-Meier methods and Cox proportional hazards models.Results: This analysis included 537 patients. Cisplatin was used in 56.1% of patients, 45.6% received thoracic radiotherapy (RT), and few received prophylactic cranial irradiation (PCI). In the overall cohort, one-, two- and five-year OS rates were 26%, 8%, and 3%, respectively. For patients with Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, OS rates at one, two, and five years were 43%, 17%, and 10%, respectively, vs. 27%, 8%, and 2% for those with ECOG PS 1-2, and 16%, 3%, and 3% for those with ECOG PS 3-4. In long-term survivors, ECOG PS scores were lower and abnormal laboratory test results were less frequent. Overall, 74.4% of long-term survivors received thoracic RT and 53.5% received PCI. Known poor prognostic factors - including brain/liver metastases, high lactate dehydrogenase (LDH), abnormal sodium, and low hemoglobin levels - were less common but still seen in long-term survivors.Conclusion: Although rare, patients with ES-SCLC may experience long-term survival with CT +/- thoracic RT +/- PCI. Factors predicting long-term survival include traditional prognostic factors such as ECOG PS, LDH level, and receipt of thoracic RT or PCI. These findings support current treatment algorithms for ES-SCLC and provide baseline survival estimates to assess the real-world impact of adding immune checkpoint inhibitors in the future. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2023 SEP 18 -PY - 2023 -VL - 13 -C7 - 1191855 -DO - 10.3389/fonc.2023.1191855 -AN - WOS:001079567900001 -AD - Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada -AD - CancerCare Manitoba, Dept Hematol & Med Oncol, Winnipeg, MB, Canada -AD - CancerCare Manitoba, CancerCare Manitoba Res Inst, Winnipeg, MB, Canada -AD - AstraZeneca Canada, Mississauga, ON, Canada -AD - CancerCare Manitoba, Dept Epidemiol, Winnipeg, MB, Canada -AD - CancerCare Manitoba, Canc Registry, Winnipeg, MB, Canada -AD - Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC, Canada -AD - Univ Manitoba, Dept Radiol, Winnipeg, MB, Canada -AD - CancerCare Manitoba, Dept Radiat Oncol, Winnipeg, MB, Canada -Y2 - 2023-10-22 -ER - - -TY - JOUR -AU - Di Nunno, Vincenzo -AU - Nuvola, Giacomo -AU - Mosca, Mirta -AU - Maggio, Ilaria -AU - Gatto, Lidia -AU - Tosoni, Alicia -AU - Lodi, Raffaele -AU - Franceschi, Enrico -AU - Brandes, Alba Ariela -TI - Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases -T2 - IMMUNOTHERAPY -M3 - Review -AB - Brain metastases (BMs) represent a negative prognostic factor for patients with solid malignancies. BMs are generally approached with loco-regional treatments and the blood-brain barrier limits the efficacy of some systemic drugs. The aim of this review is to summarize current knowledge about the role of immune checkpoint inhibitors for the management of brain metastases in patients with solid malignancies. We performed a review of available literature. Immune checkpoint inhibitors represent the standard treatment for several advanced solid malignancies. However, with the exception of melanoma their clinical role in other solid malignancies is not completely clear due to the exclusion of patients with BM from approval clinical trials. Immune-checkpoint inhibitors may be an effective treatment of brain metastases of melanoma while their clinical role on brain metastases from other solid malignancies is uncertain. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1750-743X -SN - 1750-7448 -DA - 2021 APR -PY - 2021 -VL - 13 -IS - 5 -SP - 419 -EP - 432 -DO - 10.2217/imt-2020-0208 -AN - WOS:000609262200001 -C6 - JAN 2021 -AD - Azienda USL, Dept Med Oncol, Bologna, Italy -AD - Alma Mater Studiorum Univ Bologna, S Orsola Malpighi Univ Hosp, Dept Specialized Expt & Diagnost Med, Bologna, Italy -AD - IRCCS Ist Sci Neurol Bologna, Bologna, Italy -Y2 - 2021-02-03 -ER - - -TY - JOUR -AU - Zhang, Jinmeng -AU - Mao, Jiuang -AU - Xu, Dayu -AU - Jiang, Shanshan -AU - Guo, Tiantian -AU - Zhou, Yue -AU - Chu, Li -AU - Yang, Xi -AU - Chu, Xiao -AU - Ni, Jianjiao -AU - Zhu, Zhengfei -TI - Pattern of failure and clinical value of local therapy for oligo-recurrence in locally advanced non-small cell lung cancer after definitive chemoradiation: Impact of driver mutation status -T2 - CANCER MEDICINE -M3 - Article -AB - Introduction: Considerable differences of treatment response and pattern of failure may exist between definitive chemoradiation (CRT) treated locally advanced non-small cell lung cancer (LA-NSCLC) patients. The clinical value of additional tyrosine kinase inhibitors (TKIs) before disease recurrence and salvage local therapy after initial recurrent disease remain controversial. Methods and Materials: Consecutive LA-NSCLC patients receiving definitive CRT and having definite results about driver mutations (EGFR, ALK and ROS1) were retrospectively reviewed. Initial recurrent disease was classified as in-field recurrence, out-of-field recurrence and distant metastasis. Recurrent disease occurred only in the brain or limited to <= 3 extra-cranial organs and <= 5 extra-cranial lesions, was defined as oligo-recurrence. Progression free survival and overall survival (OS) were calculated from diagnosis to disease progression or death, and to death, respectively. OS2 was measured from initial disease recurrence to death among patients who had recurrent disease. Results: Of the 153 enrolled patients, 39 had driver mutations and 13 received additional TKI therapy besides definitive CRT. Patients harboring driver mutations but without additional TKI therapy had a similar PFS and significantly longer OS (p = 0.032) than those without driver mutations. Additional TKI therapy prolonged PFS (p = 0.021) but not OS among patients with driver mutations. No significant difference of pattern of failure was observed between patient subgroups stratified by the status of driver mutations and the usage of additional TKI therapy. Furthermore, 57 of the 95 patients with initial recurrent disease developed oligo-recurrence and salvage local therapy significantly improved OS2 (p = 0.01) among patients with oligo-recurrence disease. Conclusion: LA-NSCLC patients receiving definitive CRT generally had similar PFS and pattern of treatment failure, regardless of driver mutation status. Additional TKI therapy besides definitive CRT could prolong PFS but not OS. The majority of recurrent disease after definitive CRT belongs to oligo-recurrence and salvage local therapy may provide survival benefit. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2045-7634 -DA - 2023 MAR -PY - 2023 -VL - 12 -IS - 6 -SP - 6971 -EP - 6979 -DO - 10.1002/cam4.5493 -AN - WOS:000899740300001 -C6 - DEC 2022 -AD - Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China -AD - Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China -AD - Fudan Univ, Inst Thorac Oncol, Shanghai, Peoples R China -AD - Shanghai Clin Res Ctr Radiat Oncol, Shanghai, Peoples R China -AD - Shanghai Key Lab Radiat Oncol, Shanghai, Peoples R China -AD - Fudan Univ, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China -M2 - Shanghai Clin Res Ctr Radiat Oncol -M2 - Shanghai Key Lab Radiat Oncol -Y2 - 2022-12-29 -ER - - -TY - JOUR -AU - Gross, A. J. -AU - Kharouta, M. Z. -AU - Podder, T. K. -AU - Choi, S. -AU - Biswas, T. -TI - Role of Thoracic Radiotherapy in Extensive Stage Small Cell Lung Cancer (ES-SCLC) in the Immunotherapy Era: A National Hospital-Based Registry Analysis -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 2966 -SP - E466 -EP - E466 -AN - WOS:000715803800961 -AD - Univ Hosp Seidman Canc Ctr, Dept Radiat Oncol, Cleveland, OH USA -AD - Univ Hosp Cleveland, Dept Radiat Oncol, Med Ctr, Cleveland, OH 44106 USA -M2 - Univ Hosp Seidman Canc Ctr -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Tsuchiya-Kawano, Yuko -AU - Shiraishi, Yoshimasa -AU - Tanaka, Kentaro -AU - Tachihara, Motoko -AU - Saito, Ryota -AU - Okamoto, Tatsuro -AU - Sugasaki, Nanae -AU - Nakatomi, Keita -AU - Kiyomi, Fumiaki -AU - Okamoto, Isamu -TI - Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004). -T2 - European journal of cancer (Oxford, England : 1990) -M3 - Journal Article -AB - BACKGROUND: The effect of dual immunotherapy combined with platinum-based chemotherapy on untreated brain metastases derived from non-small cell lung cancer (NSCLC) has remained unclear.METHODS: This multicenter single-arm phase 2 study enrolled patients with chemotherapy-naive advanced NSCLC and at least one brain metastasis ≥5 mm in size that had not been previously treated. Patients received nivolumab plus ipilimumab combined with platinum-doublet chemotherapy (two cycles), followed by nivolumab-ipilimumab alone. The primary endpoint of the study was intracranial response rate as determined by modified Response Evaluation Criteria in Solid Tumors (RECIST) for brain metastases of ≥5 mm as target lesions.RESULTS: A total of 30 patients from 18 institutions was enrolled in this study. The median age was 66.5 years (range, 47-83 years), and 26 patients (87%) had a non-squamous cell carcinoma histology. The median size of all target brain lesions was 8.4mm, with a range of 5-39mm. The intracranial response rate assessed by modified RECIST was 50.0% (95% CI, 33.2-66.8%), with the rate of complete response being 20.0%, and the study met its primary endpoint. The systemic response rate was 53.3% (95% CI, 36.1-69.8%), and responses for intracranial and extracranial lesions were generally consistent. The median intracranial progression-free survival was 8.1 months, and both the median intracranial duration of response and time to brain radiotherapy were not reached.CONCLUSION: Nivolumab plus ipilimumab combined with platinum-based chemotherapy showed promising intracranial activity in NSCLC patients with untreated brain metastases.TRIAL REGISTRATION: jRCT071210019. -SN - 1879-0852 -DA - 2024 Sep 29 (Epub 2024 Sep 29) -PY - 2024 -VL - 212 -SP - 115052 -EP - 115052 -DO - 10.1016/j.ejca.2024.115052 -AN - MEDLINE:39357279 -AD - Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu, Fukuoka 802-0077, Japan. -AD - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. -AD - Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan. -AD - Department of Respiratory Medicine, Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan. -AD - Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan. -AD - Department of Respiratory Medicine, Nagasaki Prefecture Shimabara Hospital, 7895 Shimokawashiri-machi, Shimabara, Nagasaki 855-0861, Japan. -AD - Department of Respiratory Medicine, Kyushu Central Hospital, 3-23-1 Shiobaru, Minami-ku, Fukuoka 815-0032, Japan. -AD - Clinical Research Support Center Kyushu, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. -AD - Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Electronic address: okamoto.isamu.290@m.kyushu-u.ac.jp. -Y2 - 2024-10-05 -ER - - -TY - JOUR -AU - Wang, Xiaohan -AU - Meng, Xue -AU - Cai, Guoxin -AU - Jin, Peng -AU - Bai, Menglin -AU - Fu, Ying -AU - Wang, Zhehai -AU - Guo, Jun -AU - Han, Xiao -TI - Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma -T2 - INTERNATIONAL IMMUNOPHARMACOLOGY -M3 - Article -AB - Background: Locally advanced non -small cell lung cancer (LA-NSCLC) presents unique challenges due to its progression and tumor heterogeneity. The effectiveness of consolidation therapies, particularly in patients with gene mutations, remains an area of active investigation. Methods: In this retrospective cohort study, we examined data from 3,454 patients with unresectable lung adenocarcinoma (LUAD), narrowing our focus to 242 individuals with stage II/III. We gathered patient data, such as demographics, ECOG status, histology, treatment specifics, and gene expression, from patients in China. The study's primary outcome was overall survival (OS), while progression-free survival (PFS) served as the secondary outcome. Results: In this study, 50 % of the 242 patients underwent only radical chemoradiotherapy, with 45.87 % (111/ 242) exhibiting driver gene mutations, predominantly EGFR (58.57 %), followed by KRAS and ALK. Patients with mutations who received either targeted or immune consolidation therapy demonstrated a significantly longer median PFS (42.97 months vs. 24.87 months, p = 0.014) and improved OS (not reached vs. 24.37 months, p = 0.006), compared to those without consolidation therapy. Targeted therapy in mutant patients resulted in an extended median PFS (42.87 months) compared to immune therapy (27.03 months, p = 0.029), with no significant difference in OS. Median PFS and OS were similar between mutant and wild -type patients receiving immune therapy (p = 0.380 and p = 0.928, respectively). Conclusion: This study underscores the efficacy of targeted consolidation therapy in enhancing PFS in LUAD patients with genetic mutations. It also shows that immune consolidation therapy provides similar survival benefits to mutant and wild -type patients. Future research should focus on optimizing these therapies for improved patient outcomes. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 1567-5769 -SN - 1878-1705 -DA - 2024 MAR 10 -PY - 2024 -VL - 129 -C7 - 111684 -DO - 10.1016/j.intimp.2024.111684 -AN - WOS:001187992700001 -C6 - FEB 2024 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Med Oncol, Jinan, Shandong, Peoples R China -Y2 - 2024-03-31 -ER - - -TY - JOUR -AU - Friedes, Cole -AU - Iocolano, Michelle -AU - Lee, Sang Ho -AU - Li, Bolin -AU - Duan, Lian -AU - Levin, William P. -AU - Cengel, Keith A. -AU - Sun, Lova L. -AU - Aggarwal, Charu -AU - Marmarelis, Melina E. -AU - Doucette, Abigail -AU - Cohen, Roger B. -AU - Xiao, Ying -AU - Langer, Corey J. -AU - Bradley, Jeffrey -AU - Feigenberg, Steven J. -AU - Yegya-Raman, Nikhil -TI - Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With De fi nitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Article -AB - Purpose: The objective of this study was to describe the patterns of failure, frequency of low-volume relapse (LVR), and candidacy for ablative therapy at time of disease progression (PD) after chemoradiation and consolidative immunotherapy (CRT + ICI) in patients with stage III non-small cell lung cancer. Methods and Materials: We identi fi ed 229 consecutive patients with stage III non-small cell lung cancer treated with CRT + ICI between October 2017 and December 2021 at a single institution. PD was classi fi ed as isolated locoregional failure (LRF), isolated distant failure (DF), or synchronous LRF + DF. Any LRF was subclassi fied as in - field failure, marginal failure, or out -of - fi eld failure. LVR was de fi ned as 3 or fewer sites of PD in any number of organs. Ablative candidates were defined as having 5 or fewer sites of PD radiographically amenable to high -dose radiation or surgery. Time-to-event data were calculated using cumulative incidence analysis and Kaplan -Meier methods. Multivariable Cox modeling was used to examine the correlations between characteristics of relapse and postprogression survival. Results: Of the 229 patients, 119 (52%) had PD. Of these 119 patients, 20 (21%) had isolated LRF, 28 (24%) had synchronous LRF + DF, and 71 (60%) had isolated DF. Of the 48 patients with any LRF, 28 (58%) had in - fi eld failure, 10 (21%) marginal failure, and 10 (21%) out -of - fi eld failure. The cumulative incidence of LRF and DF was 13% (95% CI, 9.2%-18%) and 32% (95% CI, 26%-38%) at 1 year and 19% (95% CI, 14%-24%) and 39% (95% CI, 33%-46%) at 2 years, respectively. Overall, 64 patients (54%) were considered to have LVR. At time of PD, 60 patients (50%) were eligible for ablative therapy. Patients with LVR had longer median survival versus with high -volume relapse (37.4 vs 15.2 months, P < .001). On multivariable analysis, LVR (hazard ratio, 0.32; 95% CI, 0.18-0.56; P < .001) was associated with improved postprogression survival. Conclusions: After CRT + ICI, approximately half of patients experience LVR at time of PD and are candidates for ablative therapies. Prospective trials are needed to validate the optimal treatment strategy for LVR. (c) 2023 Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2024 APR 1 -PY - 2024 -VL - 118 -IS - 5 -SP - 1435 -EP - 1444 -DO - 10.1016/j.ijrobp.2023.10.005 -AN - WOS:001225860500001 -C6 - MAR 2024 -AD - Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA -AD - Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Div Phys, Philadelphia, PA USA -AD - Univ Penn, Perelman Sch Med, Dept Hematol Oncol, Philadelphia, PA USA -Y2 - 2024-05-24 -ER - - -TY - JOUR -AU - Di Cintio, Federica -AU - Dal Bo, Michele -AU - Baboci, Lorena -AU - De Mattia, Elena -AU - Polano, Maurizio -AU - Toffoli, Giuseppe -TI - The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices -T2 - FRONTIERS IN NEUROSCIENCE -M3 - Review -AB - Glioblastoma (GBM) is the most frequent and aggressive primary central nervous system tumor. Surgery followed by radiotherapy and chemotherapy with alkylating agents constitutes standard first-line treatment of GBM. Complete resection of the GBM tumors is generally not possible given its high invasive features. Although this combination therapy can prolong survival, the prognosis is still poor due to several factors including chemoresistance. In recent years, a comprehensive characterization of the GBM-associated molecular signature has been performed. This has allowed the possibility to introduce a more personalized therapeutic approach for GBM, in which novel targeted therapies, including those employing tyrosine kinase inhibitors (TKIs), could be employed. The GBM tumor microenvironment (TME) exerts a key role in GBM tumor progression, in particular by providing an immunosuppressive state with low numbers of tumor-infiltrating lymphocytes (TILs) and other immune effector cell types that contributes to tumor proliferation and growth. The use of immune checkpoint inhibitors (ICIs) has been successfully introduced in numerous advanced cancers as well as promising results have been shown for the use of these antibodies in untreated brain metastases from melanoma and from non-small cell lung carcinoma (NSCLC). Consequently, the use of PD-1/PD-L1 inhibitors has also been proposed in several clinical trials for the treatment of GBM. In the present review, we will outline the main GBM molecular and TME aspects providing also the grounds for novel targeted therapies and immunotherapies using ICIs for GBM. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1662-453X -DA - 2020 NOV 25 -PY - 2020 -VL - 14 -C7 - 603647 -DO - 10.3389/fnins.2020.603647 -AN - WOS:000596555400001 -AD - Ist Ricovero & Cura Carattere Sci IRCCS, Expt & Clin Pharmacol Unit, Ctr Riferimento Oncol Aviano, Aviano, Italy -AD - Univ Trieste, Dept Life Sci, Trieste, Italy -Y2 - 2020-12-22 -ER - - -TY - JOUR -AU - Denault, Marie-Helene -AU - Feng, Jamie -AU - Kuang, Shelley -AU - Shokoohi, Aria -AU - Leung, Bonnie -AU - Liu, Mitchell -AU - Berthelet, Eric -AU - Laskin, Janessa -AU - Sun, Sophie -AU - Zhang, Tina -AU - Ho, Cheryl -AU - Melosky, Barbara -TI - Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression -T2 - CURRENT ONCOLOGY -M3 - Article -AB - Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory analysis of PACIFIC revealed no OS benefit in the PD-L1 < 1% subgroup. This retrospective analysis assesses the realworld impact of durvalumab on OS according to PD-L1 tumor proportion score (TPS). Patients with stage III, unresectable NSCLC treated by CRT, with available PD-L1 TPS, from 1 March 2018 to 31 December 2020, at BC Cancer, British Columbia, Canada were included. Patients were divided into two groups, CRT + durvalumab and CRT alone. OS and PFS were analyzed in the PD-L1 >= 1% and <1% subgroups. A total of 134 patients were included in the CRT + durvalumab group and 117, in the CRT alone group. Median OS was 35.9 months in the CRT + durvalumab group and 27.4 months in the CRT alone group [HR 0.59 (95% CI 0.42-0.83), p = 0.003]. Durvalumab improved OS in the PD-L1 >= 1% [HR 0.53 (95% CI 0.34-0.81), p = 0.003, n = 175], but not in the <1% subgroup [HR 0.79 (95% CI 0.44-1.42), p = 0.4, n = 76]. This retrospective study demonstrates a statistically significant improvement in OS associated with durvalumab after CRT in PD-L1 >= 1%, but not PD-L1 < 1% NSCLC. Variables not accounted for may have biased the survival analysis. A prospective study would bring more insight. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1198-0052 -SN - 1718-7729 -DA - 2023 AUG -PY - 2023 -VL - 30 -IS - 8 -SP - 7499 -EP - 7507 -DO - 10.3390/curroncol30080543 -AN - WOS:001056035800001 -AD - Vancouver Ctr, BC Canc, 600 West 10th Ave, Vancouver, BC V5Z 4E6, Canada -AD - Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, 2725 Ch Ste Foy, Quebec City, PQ G1V 4G5, Canada -M2 - Vancouver Ctr -Y2 - 2023-09-22 -ER - - -TY - JOUR -AU - Takahara, Yutaka -AU - Tanaka, Takuya -AU - Ishige, Yoko -AU - Shionoya, Ikuyo -AU - Yamamura, Kouichi -AU - Sakuma, Takashi -AU - Nishiki, Kazuaki -AU - Nakase, Keisuke -AU - Nojiri, Masafumi -AU - Kato, Ryo -AU - Shinomiya, Shohei -AU - Oikawa, Taku -AU - Mizuno, Shiro -TI - Early recurrence factors in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy -T2 - THORACIC CANCER -M3 - Article -AB - Background The clinical characteristics and risk factors for cancer recurrence have not been well evaluated regarding early recurrence in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) who receive concurrent chemoradiotherapy (CRT). The aim of this study was to determine the clinical characteristics and risk factors of patients with stage III unresectable LA-NSCLC treated with CRT who developed early recurrence. Methods We retrospectively reviewed the clinical records of 46 patients diagnosed with stage III unresectable LA-NSCLC treated with CRT at our center between July 2012 and July 2021. A tumor proportion score (TPS) < 50% was defined as "low expression" and a TPS > 50% was defined as "high expression." Results A total of 17 (37.0%) patients had a confirmed recurrence within 1 year of treatment. More patients had a lower body mass index in the early recurrence group than in the later recurrence group (p = 0.038). A higher number of patients in the late recurrence group underwent surgery after CRT (p = 0.036). Patients with a higher TPS were more likely to experience late recurrence than early recurrence (p = 0.001), whereas more patients with stage N3 disease were in the early recurrence group (p = 0.011). Multivariate analysis identified lower TPS expression as an independent risk factor for early recurrence after CRT. Overall survival was prolonged in the late recurrence group (p < 0.001). Conclusions A lower TPS may be a predictor of early recurrence after CRT in patients with LA-NSCLC. These patients should be closely monitored for post-treatment recurrence. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1759-7706 -SN - 1759-7714 -DA - 2022 DEC -PY - 2022 -VL - 13 -IS - 24 -SP - 3451 -EP - 3458 -DO - 10.1111/1759-7714.14704 -AN - WOS:000871361400001 -C6 - OCT 2022 -AD - Kanazawa Med Univ, Dept Resp Med, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan -Y2 - 2022-10-29 -ER - - -TY - JOUR -AU - Rekulapelli, Akhil -AU - Flausino, Lucas E. -AU - Iyer, Gayatri -AU - Balkrishnan, Rajesh -TI - Effectiveness of immunological agents in non-small cell lung cancer -T2 - CANCER REPORTS -M3 - Review -AB - Background and aim Non-small cell lung cancer (NSCLC) continues to claim millions of lives worldwide. Although its poor prognosis is largely attributed to the lack of adequate and precise detection technologies, cancer cells' suppression of the immune system adds on to the difficulty of identifying abnormal NSCLC tumors in their early stages. Therefore, cancer immunotherapy, which activates the immune system and helps it fight tumors, has recently become the most sought-after technique, especially in the advanced stages of NSCLC, where surgery or chemotherapy may or may not bring about the desired survival benefits in patients. Methods This review focuses on the various immunotherapeutic interventions and their efficacy in advanced NSCLC clinical trials. Monoclonal antibodies like anti-PD-1/PD-L1 agents and anti-CTLA-4 antibodies, cancer vaccines, oncolytic viruses and adoptive T cell therapy have been discussed in brief. Furthermore, the effects of gender, age, and race on the efficacy of immune checkpoint inhibitors and suggest plausible future approaches in the realm of immuno-oncology. Results Immunotherapy is used alone or in combination either with other immunological agents or with chemotherapy. However, the efficacy of these strategies depends extensively on various demographic variables, as some patients respond perfectly well to immunotherapy, while others do not benefit at all or experience disease progression. By targeting a "hallmark" of cancer (immune evasion), immunotherapy has transformed NSCLC management, though several barriers prevent its complete effectiveness. Conclusions All these immunological strategies should be interpreted in the current setting of synergistic treatment, in which these agents can be combined with chemotherapy, radiotherapy, and, or surgery following patient and tumor characteristics to proportionate the best-individualized treatment and achieve superior results. To better pursue this goal, further investigations on cost-effectiveness and sex-gender, race, and age differences in immunotherapy are needed. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2573-8348 -DA - 2023 JAN -PY - 2023 -VL - 6 -IS - 1 -DO - 10.1002/cnr2.1739 -AN - WOS:000875874300001 -C6 - OCT 2022 -AD - Univ Virginia, Dept Publ Hlth Sci, Sch Med, Charlottesville, VA 22908 USA -AD - Univ Sao Paulo, Fac Med, Sao Paulo, Brazil -AD - Inst Chem Technol, Dept Pharmaceut Sci & Technol, Mumbai, Maharashtra, India -Y2 - 2022-11-13 -ER - - -TY - JOUR -AU - Salahudeen, Ameen Abdulla -AU - Patel, Manali I. -AU - Baas, Paul -AU - Curran, Walter J. -AU - Bradley, Jeffrey D. -AU - Gandara, David R. -AU - Goss, Glenwood D. -AU - Mok, Tony S. -AU - Ramalingam, Suresh S. -AU - Vokes, Everett E. -AU - Malik, Shakun M. -AU - Wakelee, Heather A. -TI - Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe -T2 - CLINICAL LUNG CANCER -M3 - Review -AB - Survival rates of patients with either early and advanced stage non small-cell lung cancer (NSCLC) have improved with newer systemic therapy and radiation techniques, including combination regimens, targeted therapies, and immunotherapies. The cancer cooperative groups have historically played a critical role in the advancement of NSCLC therapy. Annually, representatives from cooperative groups worldwide convene at the International Lung Cancer Congress (ILCC). In summer 2015, the ILCC reached its 16th anniversary. This article highlights the NSCLC studies presented by participating groups in 2015. (C) 2016 Elsevier Inc. All rights reserved. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2017 JAN -PY - 2017 -VL - 18 -IS - 1 -SP - 5 -EP - 12 -DO - 10.1016/j.cllc.2016.06.007 -AN - WOS:000394078900002 -AD - Emory Univ, Sch Med, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA -AD - Emory Univ, Sch Med, Winship Canc Inst, Radiat Oncol, Atlanta, GA USA -AD - Univ Amsterdam AMC UvA, Antoni van Leeuwenhoek Hosp NKI AVL, Netherlands Canc Inst, Thorac Oncol,Fac Med, Amsterdam, Netherlands -AD - Washington Univ, Sch Med, S Lee Kling Ctr Proton Therapy, St Louis, MO USA -AD - Univ Calif Davis, Ctr Comprehens Canc, Thorac Oncol Program, Davis, CA USA -AD - Univ Ottawa, Div Oncol, Dept Med, Ottawa, ON, Canada -AD - Chinese Med Univ Hong Kong, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China -AD - Univ Chicago, Sch Med, Dept Med, Chicago, IL 60637 USA -AD - NCI, Clin Invest Branch, CTEP, DCTD,NIH, Rockville, MD USA -M2 - Chinese Med Univ Hong Kong -Y2 - 2017-03-31 -ER - - -TY - JOUR -AU - Iwata, H. -AU - Akita, K. -AU - Ogino, H. -AU - Yamaba, Y. -AU - Mori, Y. -AU - Yoshihara, M. -AU - Nakajima, K. -AU - Hashimoto, S. -AU - Hattori, Y. -AU - Hayashi, K. -AU - Toshito, T. -AU - Baba, F. -AU - Nakamae, K. -AU - Mizoe, J. E. -AU - Shibamoto, Y. -TI - Phase II Study of Concurrent Chemoproton Therapy Using Adaptive Planning for Stage III Locally Advanced Non-Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 61st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - Chicago, IL -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2019 SEP 1 -PY - 2019 -VL - 105 -IS - 1 -MA - 3172 -SP - E510 -EP - E510 -DO - 10.1016/j.ijrobp.2019.06.1339 -AN - WOS:000485671501457 -AD - Nagoya City West Med Ctr, Nagoya Proton Therapy Ctr, Dept Radiat Oncol, Nagoya, Aichi, Japan -AD - Nagoya City Univ, Grad Sch Med Sci, Dept Radiol, Nagoya, Aichi, Japan -AD - Nagoya City West Med Ctr, Resp Tract Oncol Ctr, Dept Resp Med, Nagoya, Aichi, Japan -AD - Nagoya City West Med Ctr, Nagoya Proton Therapy Ctr, Dept Proton Therapy Technol, Nagoya, Aichi, Japan -AD - Nagoya Proton Therapy Ctr, Dept Proton Therapy Phys, Nagoya, Aichi, Japan -AD - Nagoya City West Med Ctr, Dept Radiotherapy, Nagoya, Aichi, Japan -AD - Nagoya City West Med Ctr, Resp Tract Oncol Ctr, Dept Thorac Surg, Nagoya, Aichi, Japan -AD - Osaka Heavy Ion Therapy Ctr, Osaka, Japan -M2 - Nagoya City West Med Ctr -M2 - Nagoya City West Med Ctr -M2 - Nagoya City West Med Ctr -M2 - Nagoya Proton Therapy Ctr -M2 - Nagoya City West Med Ctr -M2 - Nagoya City West Med Ctr -M2 - Osaka Heavy Ion Therapy Ctr -Y2 - 2019-09-30 -ER - - -TY - JOUR -AU - Zhou, Na -AU - Lin, Yi -AU - Peng, Xianghong -AU - Wang, Yingyi -AU - Wang, Yuzhou -TI - Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease -T2 - LUNG CANCER -M3 - Article -AB - Objective: Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare type of non-small cell lung cancer. The clinical course and prognosis of advanced LELC are largely unknown. Few reports have discussed multimodality treatment for LELC.Materials and methods: This retrospective study identified records from 2007 to 2018 of pulmonary LELCs and other lung cancer subtypes from hospital information systems and collected demographic, treatment, and survival data.Results: In this cohort of 69 LELCs (median age: 55.4), more female, non-smokers, and fewer right upper lobe tumors (4.3%) were observed in the LELC subgroup compared with others. The median overall survival (OS) of LELCs was 40 months, superior to other subtypes (p < 0.05), except adenocarcinoma (p = 0.062). Patients with early stage disease and primary tumor resection tended to have better OS in univariate analysis, but surgery was the independent predictor in multivariate analysis (0.042). The median OS of 52 advanced LELCs was 22.7 months. Platinum-based chemotherapy and radiotherapy with curative purpose were independent predictors for OS of advanced LELCs (p = 0.004 and 0.003, respectively). For patients who received multimodality treatment in advanced setting, the median line of treatments was two. The overall response and disease-control rates were 61.8% and 80.6%, respectively. There were no differences in response or survival between patients receiving taxane-combined and non-taxane-combined chemotherapy. However, patients treated with radiotherapy in upfront settings had significantly favorable response and progression-free survival compared with those without. One case with PD-L1 positivity had pembrolizumab in the 4th line and achieved tumor shrinkage and stable disease for 12 months.Conclusion: Patients who underwent radical resection of primary tumors had better prognoses. Patients with advanced LELC could achieve satisfactory survival by receiving multimodality treatment, including platinum-based chemotherapy and/or radiotherapy. Immune checkpoint inhibitors may be part of future therapies. A well-organized clinical trial should be performed to determine the optimal treatment regimen. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2019 DEC -PY - 2019 -VL - 138 -SP - 116 -EP - 123 -DO - 10.1016/j.lungcan.2019.10.004 -AN - WOS:000503323900017 -AD - Peking Union Med Coll Hosp, Dept Med Oncol, 1 Shuaifuyuan, Beijing, Peoples R China -AD - Ctr Hosp Conde Sao Januario, Dept Oncol, Estr Visconde S Januario, Macau, Peoples R China -M2 - Ctr Hosp Conde Sao Januario -Y2 - 2020-01-03 -ER - - -TY - JOUR -AU - Xing, Rui -AU - Gao, Jinping -AU - Cui, Qi -AU - Wang, Qian -TI - Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma -T2 - FRONTIERS IN IMMUNOLOGY -M3 - Review -AB - Hepatocellular carcinoma (HCC), one of the most fatal malignancies in the world, is usually diagnosed in advanced stages due to late symptom manifestation with very limited therapeutic options, which leads to ineffective intervention and dismal prognosis. For a decade, tyrosine kinase inhibitors (TKIs) have offered an overall survival (OS) benefit when used in a first-line (sorafenib and lenvatinib) and second-line setting (regorafenib and cabozantinib) in advanced HCC, while long-term response remains unsatisfactory due to the onset of primary or acquired resistance. Recently, immunotherapy has emerged as a promising therapy in the treatment of several solid tumors, such as melanoma and non-small cell lung cancer. Moreover, as the occurrence of HCC is associated with immune tolerance and immunosurveillance escape, there is a potent rationale for employing immunotherapy in HCC. However, immunotherapy monotherapy, mainly including immune checkpoint inhibitors (ICIs) that target checkpoints programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and the cytotoxic T lymphocyte antigen-4 (CTLA-4), has a relatively low response rate. Thus, the multi-ICIs or the combination of immunotherapy with other therapies, like antiangiogenic drugs and locoregional therapies, has become a novel strategy to treat HCC. Combining different ICIs may have a synergistical effect attributed to the complementary effects of the two immune checkpoint pathways (CTLA-4 and PD-1/PD-L1 pathways). The incorporation of antiangiogenic drugs in ICIs can enhance antitumor immune responses via synergistically regulating the vasculature and the immune microenvironment of tumor. In addition, locoregional treatments can improve antitumor immunity by releasing the neoplasm antigens from killed tumor cells; in turn, this antitumor immune response can be intensified by immunotherapy. Therefore, the combination of locoregional treatments and immunotherapy may achieve greater efficacy through further synergistic effects for advanced HCC. This review aims to summarize the currently reported results and ongoing trials of the ICIs-based combination therapies for HCC to explore the rational combination strategies and further improve the survival of patients with HCC. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1664-3224 -DA - 2021 NOV 26 -PY - 2021 -VL - 12 -C7 - 783236 -DO - 10.3389/fimmu.2021.783236 -AN - WOS:000728782700001 -AD - China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang, Peoples R China -AD - North War Zone Gen Hosp, Dept Oncol, Shenyang, Peoples R China -AD - Third Mil Med Univ, Army Med Univ, Coll High Altitude Mil Med, Dept Cold Environm Med, Chongqing, Peoples R China -M2 - North War Zone Gen Hosp -Y2 - 2021-12-18 -ER - - -TY - JOUR -AU - Zhang, Luping -AU - Xu, Yanmei -AU - Shen, Jie -AU - He, Feng -AU - Zhang, Dan -AU - Chen, Zhengtang -AU - Duan, Yuzhong -AU - Sun, Jianguo -TI - Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer -T2 - RADIATION ONCOLOGY -M3 - Article -AB - Background: The combination of dendritic cells (DCs) and cytokine-induced killer cells (CIKs) can induce the anti-tumor immune response and radiotherapy may promote the activity. We aimed to explore the feasibility of DCs/CIKs combined with thoracic radiotherapy (TRT) for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC).Method: In this study, patients with unresectable stage III/IV NSCLC and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2 and previously receiving two or more cycles of platinum-based doublet chemotherapy without disease progression received TRT plus DCs/CIKs or TRT alone until disease progression or unacceptable toxicity. The primary endpoint was median progression-free survival (mPFS). In treatment group, patients received four-cycle autologous DCs/CIKs infusion starting from the 6th fraction of irradiation.Results: From Jan 13, 2012 to June 30, 2014, 82 patients were enrolled, with 21 patients in treatment group and 61 in control group. The mPFS in treatment group was longer than that in control group (330 days vs 233 days, hazard ratio 0.51, 95 % CI 0.27-1.0, P < 0.05), and the objective response rate (ORR) of treatment group (47.6 %) was significantly higher that of control group (24.6 %, P < 0.05). There was no significant difference in disease control rate (DCR) and median overall survival (mOS) between two groups (P > 0.05). The side effects in treatment group were mild and there was no treatment-related deaths.Conclusion: The combination of DCs/CIKs with TRT could be a feasible regimen in treating locally advanced or metastatic NSCLC patients. Further investigation of the regimen is warranted. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1748-717X -DA - 2016 APR 21 -PY - 2016 -VL - 11 -C7 - 60 -DO - 10.1186/s13014-016-0635-5 -AN - WOS:000374467100001 -AD - Third Mil Med Univ, Xinqiao Hosp, Inst Canc, PLA, Chongqing 400037, Peoples R China -AD - Leshan Peoples Hosp, Dept Oncol, Leshan 614000, Sichuan, Peoples R China -M2 - Leshan Peoples Hosp -Y2 - 2016-06-01 -ER - - -TY - JOUR -AU - Miao, Keyan -AU - Liu, Weici -AU - Xu, Jingtong -AU - Qian, Zhengtao -AU - Zhang, Qinglin -TI - Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy -T2 - FRONTIERS IN IMMUNOLOGY -M3 - Review -AB - At present, cancer is the largest culprit that endangers human health. The current treatment options for cancer mainly include surgical resection, adjuvant radiotherapy and chemotherapy, but their therapeutic effects and long-term prognosis are unsatisfactory. Immunotherapy is an emerging therapy that has completely transformed the therapeutic landscape of advanced cancers, and has tried to occupy a place in the neoadjuvant therapy of resectable tumors. However, not all patients respond to immunotherapy due to the immunological and molecular features of the tumors. Traditional Chinese Medicine (TCM) provides a new perspective for cancer treatment and is considered to have the potential as promising anti-tumor drugs considering its immunoregulatory properties. This review concludes commonly used TCM monomers and compounds from the perspective of immune regulatory pathways, aiming to clearly introduce the basic mechanisms of TCM in boosting cancer immunotherapy and mechanisms of several common TCM. In addition, we also summarized closed and ongoing trials and presented prospects for future development. Due to the significant role of immunotherapy in the treatment of non-small cell lung cancer (NSCLC), TCM combined with immunotherapy should be emphasized in NSCLC. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1664-3224 -DA - 2023 NOV 15 -PY - 2023 -VL - 14 -C7 - 1277243 -DO - 10.3389/fimmu.2023.1277243 -AN - WOS:001109690000001 -AD - Soochow Univ, Med Coll, Suzhou, Jiangsu, Peoples R China -AD - Nanjing Med Univ, Wuxi Peoples Hosp, Wuxi Med Ctr, Dept Thorac Surg,Affiliated Wuxi Peoples Hosp, Wuxi, Jiangsu, Peoples R China -AD - Nanjing Med Univ, Sch Clin Med 1, Nanjing, Jiangsu, Peoples R China -AD - Changshu Med Examinat Inst, Dept Clin Lab, Changshu, Jiangsu, Peoples R China -AD - Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Wuxi Peoples Hosp, Dept Gastroenterol,Wuxi Med Ctr, Wuxi, Jiangsu, Peoples R China -M2 - Changshu Med Examinat Inst -Y2 - 2023-12-17 -ER - - -TY - JOUR -AU - Silva Almeida Ribeiro, Mauricio Fernando -AU - Machado Alessi, Joao Victor -AU - Carvalho Oliveira, Leandro Jonata -AU - Lara Gongora, Aline Bobato -AU - Sacardo, Karina Perez -AU - Zucchetti, Bruna Migliavacca -AU - Shimada, Andrea Kazumi -AU - Barbosa, Felipe de Galiza -AU - Feher, Olavo -AU - Katz, Artur -TI - Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series -T2 - LUNG CANCER -M3 - Article -AB - Objectives: to report outcomes of four cases of chemo-refractory RET-rearranged non-small cell lung carcinomas (NSCLCs) treated with alectinib in a single center.Materials and methods: we retrospectively assessed and reported the activity and tolerability of alectinib 600 mg twice daily in advanced and chemo-refractory RET-rearranged NSCLC patients treated in a Brazilian institution. Identification of RET rearrangements was performed using the FoundationOne (R) next-generation sequencing (NGS) platform.Results: The four patients herein reported were white, female and non-smokers, ranging between 59-66 years of age. All patients had been previously treated with chemotherapy and were TKI naive; three of them presented disease progression to nivolumab as well. Molecular tumor profiling showed a KIF5B-RET fusion in three patients and a CCDC6-RET in the fourth. One patient exhibited disease progression and clinical deterioration two months after treatment initiation. Disease control was documented in two patients with PFS ranging from 4 to 5 months (one partial metabolic response and one stable disease). In one of the cases, which developed oligoprogression on alectinib, radiation therapy plus post-progression alectinib were able to provide additional disease control for 9 more months. No grade 3/4 adverse events, dose reductions or discontinuation due to toxicity were documented.Conclusion: Although this is a small single center evaluation, alectinib was well tolerated and demonstrated clinical activity against advanced RET-rearranged NSCLCs, suggesting its potential role in this specific subset of malignancies. Clinical trials addressing its efficacy and the optimal dosing schedule in the present context are underway, and results are eagerly awaited. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2020 JAN -PY - 2020 -VL - 139 -SP - 9 -EP - 12 -DO - 10.1016/j.lungcan.2019.10.020 -AN - WOS:000508745400002 -AD - Hosp Sirio Libanes, Oncol Ctr, Rua Dona Adma Jafet 91, BR-01308050 Sao Paulo, SP, Brazil -AD - Hosp Sirio Libanes, Nucl Med Ctr, Rua Dona Adma Jafet 91, BR-01308050 Sao Paulo, SP, Brazil -M2 - Hosp Sirio Libanes -M2 - Hosp Sirio Libanes -Y2 - 2020-02-04 -ER - - -TY - JOUR -AU - Chaunzwa, T. L. -AU - Qian, J. M. -AU - Li, Q. -AU - Ricciuti, B. -AU - Zhang, Z. -AU - Weiss, J. -AU - Mackay, J. -AU - Kagiampakis, I. -AU - Bikiel, D. -AU - Di Federico, A. -AU - Alessi, J. -AU - Mak, R. H. -AU - Jacob, E. -AU - Awad, M. M. -AU - Aerts, H. -TI - Al-Derived CT Body Composition in Advanced Non-Small Cell Lung Cancer: A Multicohort Study -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2020 -SP - E10 -EP - E11 -AN - WOS:001079706800022 -AD - Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA USA -AD - Brigham & Womens Hosp, Boston, MA USA -AD - Dana Farber Canc Inst Harvard, Boston, MA USA -AD - AstraZeneca, Waltham, MA USA -AD - Dana Farber Canc Inst, Boston, MA USA -AD - Harvard Med Sch, Brigham & Womens Hosp, Artif Intelligence Med AIM Program, Boston, MA USA -AD - AstraZeneca, Boston, MA USA -AD - Dana Farber Harvard Canc Ctr, Boston, MA USA -AD - Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA USA -M2 - Dana Farber Canc Inst Harvard -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Zheng, Chenhong -AU - Yu, Ganjun -AU - Wang, Hui -AU - Tang, Airong -AU - Geng, Peiliang -AU - Zhang, Huiming -AU - Zhu, Zhiquan -AU - Li, Fang -AU - Xie, Xiaohua -TI - Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer cells in the treatment of non-small-cell lung cancer -T2 - INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE -M3 - Article -AB - Background: Non-small-cell lung cancer (NSCLC) is one of the most fatal cancers, which leads to large number of people dead. Followed by surgery, chemotherapy and radiotherapy, chemotherapy combined dendritic cells with cytokine-induced killer cells (DC-CIK) immunotherapy has been applied in NSCLC for some time, but little consistent beneficial results are provided. So, it is essential to weigh the pros and cons of the new therapeutic method. Methods: We searched the randomized controlled trials of NSCLC mainly by PubMed database. Terms combination of "cytokine-induced killer cells", "tumor" and "cancer" were used. After evaluating the heterogeneity of selected studies, then we performed the meta-analysis. Pooled risk ratios (RRs) were estimated and 95% confidence intervals (CIs) were calculated using a fixed-effect model. Sensitivity analysis was also performed. Results: Six eligible trials were enrolled. Efficiency and safety of chemotherapy followed by DC-CIK immunotherapy (experimental group) and chemotherapy alone (control group) were compared. 1-year overall survival (OS) (P=0.02) and progression free survival (PFS) (P=0.005) in the experimental group were significantly increased compared with the control. Disease control rate (DCR) (P=0.006) rose significantly in experimental group. However, no significant differences between the two groups were observed in 2-year OS (P=0.21), 2-year PFS (P=0.10), overall response rate (ORR) (P=0.76) and partial response (PR) (P=0.22). Temporary fever, anemia, leukopenia and nausea were the four major adverse events (AEs) treated by chemotherapy. The incidence of anemia, leukopenia and nausea in the experimental group was obviously lower than the control group. Temporary fever rate was higher in experimental group than that in the control, but could be alleviated by taking sufficient rest. Conclusions: Chemotherapy combined with DC-CIK immunotherapy showed superiority in DCR, 1-year OS and PFS, and no more AEs appeared, however, there was no significant improvement in ORR, PR, 2-year OS and PFS. As a whole, the combination therapy is safer but modest in efficacy for advanced NSCLC patients. -PU - E-CENTURY PUBLISHING CORP -PI - MADISON -PA - 40 WHITE OAKS LN, MADISON, WI 53711 USA -SN - 1940-5901 -DA - 2015 -PY - 2015 -VL - 8 -IS - 8 -SP - 14527 -EP - 14537 -AN - WOS:000365271900346 -AD - Chinese Peoples Liberat Army Gen Hosp, Dept Comprehens Surg, Beijing 100853, Peoples R China -AD - Inst Immunol, Natl Key Lab MedicalImmunol, Shanghai 200433, Peoples R China -AD - Second Mil Med Univ, Shanghai 200433, Peoples R China -AD - Management Support Bur, Clin 2, Dept Chinese PLA Gen Logist, Beijing 100071, Peoples R China -AD - Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Plast Surg, Shanghai, Peoples R China -AD - Beijing Tieying Hosp, Dept Gen Med, Beijing 100079, Peoples R China -M2 - Inst Immunol -M2 - Management Support Bur -M2 - Beijing Tieying Hosp -Y2 - 2015-12-09 -ER - - -TY - JOUR -AU - Zhao, Dong -AU - Xie, Bing -AU - Yang, Yong -AU - Yan, Peng -AU - Liang, Sheng-Nan -AU - Lin, Qiang -TI - Progress in immunotherapy for small cell lung cancer -T2 - WORLD JOURNAL OF CLINICAL ONCOLOGY -M3 - Review -AB - Small-cell lung cancer (SCLC) is a special type of lung cancer that belongs to highly aggressive neuroendocrine tumors. At present, radiotherapy and chemotherapy remain the mainstay of treatment for SCLC. Progress in targeted therapies for SCLC with driver mutations has been slow, and these therapies are still under investigation in preclinical or early-phase clinical trials, and research on antiangiogenic tyrosine kinase inhibitors (e.g., anlotinib) has achieved some success. Immunotherapy is becoming an important treatment strategy for SCLC after radiotherapy and chemotherapy. In this article we review the recent advances in immunotherapy for SCLC. -PU - BAISHIDENG PUBLISHING GROUP INC -PI - PLEASANTON -PA - 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES -SN - 2218-4333 -DA - 2020 JUN 24 -PY - 2020 -VL - 11 -IS - 6 -SP - 370 -EP - 377 -DO - 10.5306/wjco.v11.i6.370 -AN - WOS:000557337900005 -AD - Peoples Hosp Lixin Cty, Dept Oncol, Bozhou 236700, Anhui, Peoples R China -AD - Hebei Med Univ, North China Petr Bur, Gen Hosp, Dept Oncol, 8 Huizhan Ave, Renqiu 062552, Hebei, Peoples R China -M2 - Peoples Hosp Lixin Cty -Y2 - 2020-08-21 -ER - - -TY - JOUR -AU - Stevens, CW -AU - Komaki, R -AU - Cox, J -TI - Response to Macbeth and Price concerning our paper "Novel approaches to locally advanced non-small cell lung cancer" -T2 - RADIOTHERAPY AND ONCOLOGY -M3 - Letter -PU - ELSEVIER SCI IRELAND LTD -PI - CLARE -PA - CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND -SN - 0167-8140 -DA - 2001 AUG -PY - 2001 -VL - 60 -IS - 2 -SP - 226 -EP - 227 -DO - 10.1016/S0167-8140(01)00353-X -AN - WOS:000170282400014 -AD - Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA -Y2 - 2001-08-01 -ER - - -TY - JOUR -AU - Tachihara, Motoko -AU - Tsujino, Kayoko -AU - Ishihara, Takeaki -AU - Hayashi, Hidetoshi -AU - Sato, Yuki -AU - Kurata, Takayasu -AU - Sugawara, Shunichi -AU - Okamoto, Isamu -AU - Teraoka, Shunsuke -AU - Azuma, Koichi -AU - Daga, Haruko -AU - Yamaguchi, Masafumi -AU - Kodaira, Takeshi -AU - Satouchi, Miyako -AU - Shimokawa, Mototsugu -AU - Yamamoto, Nobuyuki -AU - Nakagawa, Kazuhiko -A1 - West Japan Oncology Grp WJOG -TI - Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L) -T2 - CANCER MANAGEMENT AND RESEARCH -M3 - Article -AB - Durvalumab (anti-programmed cell death ligand-1) administration after concurrent chemoradiotherapy (cCRT) has improved the survival of patients with unresectable, locally advanced (LA) stage III non-small cell lung cancer (NSCLC). Some patients are unable to complete cCRT and cannot receive immunotherapy due to poor performance status based on adverse events after cCRT. Immunotherapy plays an important role in anti-programmed cell death ligand-1 (PD-L1)-positive advanced NSCLC and is replacing chemotherapy. In addition, radiotherapy and immunotherapy have been reported to have a synergistic effect. This Phase II, multicenter study (DOLPHIN, WJOG11619L, JapicCTI-194840) is designed to assess the efficacy and safety of durvalumab plus concurrent curative radiation therapy for PD-L1-positive unresectable LA-NSCLC without chemotherapy. Unresectable LA stage III NSCLC patients aged 20 years or older with a World Health Organization/Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and PD-L1 positivity are enrolled. The patients will receive curative radiation therapy (60 Gy) plus durvalumab 10 mg/kg every 2 weeks (q2w) for up to 12 months until there is evidence of disease progression (PD) or unacceptable toxicity. The primary endpoint is the 12-month progression-free survival rate as assessed by an independent central review. The secondary endpoints are progression-free survival, overall survival, objective response rate, treatment completion rate, and safety. Recruitment began in September 2019. -PU - DOVE MEDICAL PRESS LTD -PI - ALBANY -PA - PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND -SN - 1179-1322 -DA - 2021 -PY - 2021 -VL - 13 -SP - 9167 -EP - 9173 -DO - 10.2147/CMAR.S336262 -AN - WOS:000744197000003 -AD - Kobe Univ, Dept Internal Med, Div Resp Med, Grad Sch Med, Kobe, Hyogo, Japan -AD - Hyogo Canc Ctr, Dept Radiat Oncol, Akashi, Hyogo, Japan -AD - Kobe Univ, Div Radiat Oncol, Grad Sch Med, Kobe, Hyogo, Japan -AD - Kindai Univ, Dept Med Oncol, Osakasayama City, Japan -AD - Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan -AD - Kansai Med Univ Hosp, Dept Thorac Oncol, Hirakata, Osaka, Japan -AD - Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan -AD - Kyushu Univ, Grad Sch Med Sci, Res Inst Dis Chest, Fukuoka, Japan -AD - Wakayama Med Univ, Internal Med 3, Wakayama, Japan -AD - Kurume Univ, Dept Internal Med, Div Respirol Neurol & Rheumatol, Sch Med, Fukuoka, Japan -AD - Osaka City Gen Hosp, Dept Med Oncol, Osaka, Japan -AD - Natl Hosp Org Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan -AD - Aichi Canc Ctr Hosp, Dept Radiat Oncol, Nagoya, Aichi, Japan -AD - Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan -AD - Yamaguchi Univ, Dept Biostat, Grad Sch Med, Ube, Yamaguchi, Japan -M2 - Kindai Univ -Y2 - 2022-02-01 -ER - - -TY - JOUR -AU - Augustyn, Alexander -AU - Adams, Daniel L. -AU - He, Jianzhong -AU - Qiao, Yawei -AU - Verma, Vivek -AU - Liao, Zhongxing -AU - Tang, Cha-Mei -AU - Heymach, John V. -AU - Tsao, Anne S. -AU - Lin, Steven H. -TI - Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in NoneSmall-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - Development of distant metastatic disease is common in patients with locally advanced nonesmall-cell lung cancer, leading to high rates of cancer-related mortality. Monitoring for early signs of disease recurrence from peripheral blood markers is an attractive avenue toward personalizing cancer care. We identified a novel macrophage-like circulating cell whose size appears to associate with poorer survival and the development of metastatic disease shortly after completion of definitive treatment.Background: Cancer-associated macrophage-like cells (CAMLs) are a potential peripheral blood biomarker for disease progression. This study used data from a phase 2 clinical trial to evaluate prognostic utility of CAMLs for locally advanced nonesmall-cell lung cancer treated with definitive chemoradiotherapy (CRT) and atezolizumab (DETERRED; ClinicalTrials.gov NCT02525757). Patients and Methods: Sample collection occurred at baseline (T0), during CRT (T1), at end of CRT (T2), and at first follow-up (T3). CAMLs were captured and quantified by the CellSieve system using multiplex immunostaining. Giant CAMLs were defined as characteristic CAMLs >= 50 mu m. Kaplan-Meier methodology estimated progression-free survival, distant failure-free survival, relapse-free survival, and overall survival at 30 months. Results: Thirty-nine patients were evaluated between December 2015 and March 2018. Median follow-up was 27 months. Most disease was stage III (85%) and comprised squamous-cell carcinoma (38%) or adenocarcinoma (59%). In total, 267 blood samples were analyzed. Giant CAMLs were identified in 57%, 60%, 64%, and 63% of patients at T0, T1, T2, and T3, respectively. Patients with giant CAMLs at T3, occurring at a median of 30 days after completion of CRT, had significantly worse distant failure-free survival (hazard ratio [HR] 4.9, P = .015), progression-free survival (HR 2.5, P = .025), recurrence-free survival (HR 2.4, P = .036), and overall survival (HR 3.5, P = .034) compared to patients with small or no CAMLs. Conclusions: Presence of giant CAMLs after CRT completion was associated with development of metastatic disease and poorer survival despite the use of maintenance immunotherapy. Monitoring CAMLs may help risk-stratify patients for adaptive treatment strategies. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2021 MAY -PY - 2021 -VL - 22 -IS - 3 -SP - E451 -EP - E465 -DO - 10.1016/j.cllc.2020.06.016 -AN - WOS:000660499500035 -C6 - JUN 2021 -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd,Unit 097, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA -AD - Creatv MicroTech Inc, Monmouth Jct, NJ USA -AD - Allegheny Gen Hosp, Dept Radiat Oncol, Pittsburgh, PA 15212 USA -AD - Creatv MicroTech Inc, Rockville, MD USA -M2 - Creatv MicroTech Inc -M2 - Creatv MicroTech Inc -Y2 - 2021-06-27 -ER - - -TY - JOUR -AU - Chen, Peixin -AU - Kuang, Peng -AU - Wang, Lei -AU - Li, Wei -AU - Chen, Bin -AU - Liu, Yu -AU - Wang, Hao -AU - Zhao, Sha -AU - Ye, Lingyun -AU - Yu, Feng -AU - He, Yayi -AU - Zhou, Caicun -TI - Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Small-cell lung cancer (SCLC), the highest malignant cancer amongst different types of lung cancer, has the feature of lower differentiation, rapid growth, and poor survival rate. Despite the dramatically initial sensitivity of SCLC to various types of treatment methods, including chemotherapy, radiotherapy and immunotherapy, the emergence of drugs-resistance is still a grandly clinical challenge. Therefore, in order to improve the prognosis and develop new therapeutic approaches, having a better understanding of the complex mechanisms of resistance in SCLC is of great clinical significance. This review summarized recent advances in understanding of multiple mechanisms which are involved in the resistance during SCLC treatment, including DNA-related process, RNA-related process, apoptosis-related mechanism, and the process of drug accumulation and metabolism. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2020 JUN -PY - 2020 -VL - 9 -IS - 3 -SP - 768 -EP - 786 -DO - 10.21037/tlcr-19-547 -AN - WOS:000547884300036 -AD - Tongji Univ, Shanghai Pulm Hosp, Canc Inst, Dept Med Oncol,Med Sch, 507 Zhengmin Rd, Shanghai 200433, Peoples R China -AD - Tongji Univ, Dept Med Sch, Shanghai, Peoples R China -AD - Nanchang Univ, Dept Med Oncol, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China -Y2 - 2020-07-28 -ER - - -TY - JOUR -AU - Zeng, Jing -AU - Bowen, Stephen R. -TI - Treatment Intensification in Locally Advanced/Unresectable NSCLC Through Combined Modality Treatment and Precision Dose Escalation -T2 - SEMINARS IN RADIATION ONCOLOGY -M3 - Article -AB - The best survival for patients with unresectable, locally advanced NSCLC is currently achieved through concurrent chemoradiation followed by durvalumab for a year. Despite the best standard of care treatment, the majority of patients still develop disease recurrence, which could be distant and/or local. Trials continue to try and improve outcomes for patients with unresectable NSCLC, typically through treatment intensification, with the addition of more systemic agents, or more radiation dose to the tumor. Although RTOG 0617 showed that uniform dose escalation across an unselected population of patients undergoing chemoradiation is not beneficial, efforts continue to select patients and tumor subsets that are likely to benefit from dose escalation. This review describes some of the ongoing therapeutic trials in unresectable NSCLC, with an emphasis on quantitative imaging and precision radiation dose escalation. Semin Radiat Oncol 31:105-111 (c) 2020 Elsevier Inc. All rights reserved. -PU - W B SAUNDERS CO-ELSEVIER INC -PI - PHILADELPHIA -PA - 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA -SN - 1053-4296 -SN - 1532-9461 -DA - 2021 APR -PY - 2021 -VL - 31 -IS - 2 -SP - 105 -EP - 111 -DO - 10.1016/j.semradonc.2020.11.007 -AN - WOS:000698687200003 -C6 - FEB 2021 -AD - Univ Washington, Dept Radiat Oncol, Sch Med, 1959 NE Pacific St,Box 356043, Seattle, WA 98195 USA -AD - Univ Washington, Dept Radiol, Sch Med, Seattle, WA 98195 USA -Y2 - 2021-10-02 -ER - - -TY - JOUR -AU - Smit, H. J. M. -AU - Aerts, J. -AU - van den Heuvel, M. -AU - Hiltermann, T. J. N. -AU - Bahce, I -AU - Smit, E. F. -AU - Dingemans, A-M C. -AU - Hendriks, L. E. -AU - Stigt, J. A. -AU - Schramel, F. M. N. H. -AU - van Tinteren, H. -AU - Groen, H. J. M. -A1 - NVALT Immunotherapy Register -TI - Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry -T2 - LUNG CANCER -M3 - Article -AB - Objective: Phase III studies of checkpoint inhibitors changed the therapeutic landscape for lung cancer. In 2015 the Dutch Society of Chest Physicians (NVALT) introduced a national immunotherapy registry for patients with lung cancer; quality standards for hospitals were implemented. At population level we studied clinical benefit in daily practice and in patients who are underrepresented in phase III trials.Materials and Methods: From the initial introduction of checkpoint inhibitors in the Netherlands patients were centrally registered. Educational programs and quality control were provided under supervision of NVALT. The largest immunotherapy providing hospitals were compared to hospitals who provided less checkpoint inhibitors as marker of experience. Patients characteristics, treatment and side effects, response rate and survival were studied.Results: A total of 2676 patients were registered, 2302 with follow up data were evaluated. Between October 2015 and December 2017 a gradual increase from 12 to 30 qualified hospitals showed no major toxicity differences. Toxicity led to a hospital admission rate of 9.1 with an average duration of 10.4 days.Overall tumor response was 21.8 % and median overall survival 12.6 months. Overall survival was not significantly different for patients aged >= 75 years, those having brain metastases or selected auto-immune diseases before start checkpoint inhibitors compared to younger patients or those without, respectively. Survival outcomes were worse in patients with PS 2+, non-smokers, and patients who received any palliative radiotherapy (HR 2.1, 95 % CI 1.7-2.7; 1.3, 95 % CI 1.0-1.6 and 1.2, 95 % CI 1.1-1.4, respectively).Conclusions: Changes in the therapeutic landscape did not lead to major differences in quality of care between hospitals. Elderly patients, those with brain metastases or selected auto-immune disease underrepresented in clinical trials did not do worse on checkpoint inhibitors, except for those with PS 2+. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2020 FEB -PY - 2020 -VL - 140 -SP - 107 -EP - 112 -DO - 10.1016/j.lungean.2019.12.011 -AN - WOS:000510532900016 -AD - Rijnstate Hosp, Dept Pulm Dis, Arnhem, Netherlands -AD - Erasmus MC, Dept Pulm Dis, Rotterdam, Netherlands -AD - Radboud Univ Nijmegen, Dept Pulm Dis, Med Ctr, Nijmegen, Netherlands -AD - Univ Groningen, Dept Pulm Dis, Groningen, Netherlands -AD - Univ Med Ctr Groningen, Groningen, Netherlands -AD - Amsterdam Univ Med Ctr, Dept Pulm Dis, Amsterdam, Netherlands -AD - Antoni van Leeuwenhoek Hosp, Dept Thorac Oncol, Amsterdam, Netherlands -AD - Univ Med Ctr Maastricht, Dept Pulm Dis, Maastricht, Netherlands -AD - Isala Hosp, Dept Pulm Dis, Zwolle, Netherlands -AD - St Antonius Hosp, Dept Pulm Dis, Nieuwegein, Netherlands -M2 - Amsterdam Univ Med Ctr -M2 - Antoni van Leeuwenhoek Hosp -M2 - Isala Hosp -Y2 - 2020-02-01 -ER - - -TY - JOUR -AU - De Giglio, Andrea -AU - Mezquita, Laura -AU - Auclin, Edouard -AU - Blanc-Durand, Felix -AU - Riudavets, Mariona -AU - Caramella, Caroline -AU - Martinez, Gala -AU - Benitez, Jose Carlos -AU - Martin-Romano, Patricia -AU - El-Amarti, Lamiae -AU - Hendriks, Lizza -AU - Ferrara, Roberto -AU - Naltet, Charles -AU - Lavaud, Pernelle -AU - Gazzah, Anas -AU - Adam, Julien -AU - Planchard, David -AU - Chaput, Nathalie -AU - Besse, Benjamin -TI - Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI) -T2 - CANCERS -M3 - Article -AB - Simple SummaryRecently, the introduction of immunotherapy radically changed the therapeutic algorithm of non-small-cell lung cancer as an upfront or secondary strategy. Unfortunately, the small amount of patient benefits from immune-checkpoint inhibitors (ICI) and the prognostic role of concomitant treatments are a burning open issue. The use of steroids was associated with poor outcomes during ICI. We investigated the impact of intercurrent steroids, according to clinical indication, which is actually unclear. Interestingly, the use of intercurrent steroids given for cancer-unrelated symptoms has no survival impact on our study cohort.Background: Baseline steroids before ICI have been associated with poor outcomes, particularly when introduced due to cancer symptoms. Methods: Retrospective analysis of advanced NSCLC patients treated with ICI. We collected the use of intercurrent steroids (>= 10 mg of prednisone-equivalent) within the first eight weeks of ICI. We correlated steroid use with patient outcomes according to the indications. Results: 413 patients received ICI, 299 were steroids-naive at baseline. A total of 49 patients received intercurrent steroids (16%), of whom 38 for cancer-related symptoms and 11 for other indications, such as immune-related events. Overall, median (m) progression-free survival (PFS) was 1.9 months (mo.) [95% CI, 1.8-2.4] and overall survival (OS) 10 mo. [95% CI, 8.1-12.9]. Intercurrent steroids under ICI correlated with a shorter PFS/OS (1.3 and 2.3 mo. respectively, both p < 0.0001). Intercurrent steroids for cancer-related symptoms correlated with poorest mPFS [1.1 mo.; 95% CI, 0.9-1.5] and mOS [1.9 mo.; 95%CI, 1.5-2.4; p < 0.0001)]. No mOS and mPFS differences were found between cancer-unrelated-steroid group and no-steroid group. Steroid use for cancer-related symptoms was an independent prognostic factor for poor PFS [HR 2.64; 95% CI, 1.2-5.6] and OS [HR 4.53; 95% CI, 1.8-11.1], both p < 0.0001. Conclusion: Intercurrent steroids during ICI had no detrimental prognostic impact if the indication was unrelated to cancer symptoms. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2020 OCT -PY - 2020 -VL - 12 -IS - 10 -C7 - 2827 -DO - 10.3390/cancers12102827 -AN - WOS:000584106800001 -AD - Gustave Roussy, Dept Canc Med, F-94805 Villejuif, France -AD - Alma Mater Studiorum Univ Bologna, S Orsola Malpighi Univ Hosp, Dept Specialized Expt & Diagnost Med, I-40126 Bologna, Italy -AD - Hosp Clin Barcelona, Dept Med Oncol, Barcelona 08036, Spain -AD - IDIBAPS, Lab Translat Genom & Targeted Therapies Solid Tum, Barcelona 08036, Spain -AD - Georges Pompidou Hosp, Med & Thorac Oncol Dept, F-75015 Paris, France -AD - Gustave Roussy, Dept Radiol, F-94805 Villejuif, France -AD - Gustave Roussy, Early Drug Dev Dept, F-94805 Villejuif, France -AD - Maastricht UMC, GROW Sch Oncol & Dev Biol, Dept Pulm Dis, NL-6229 Maastricht, Netherlands -AD - Med Oncol Dept Fdn IRCCS Ist Nazl Tumori Milano, Thorac Oncol Unit, I-20133 Milan, Italy -AD - Gustave Roussy, Dept Pathol, F-94805 Villejuif, France -AD - Gustave Roussy, Lab Immunomonitoring Oncol, F-94805 Villejuif, France -AD - Gustave Roussy, CNRS, UMS 3655, F-94805 Villejuif, France -AD - Gustave Roussy, INSERM, US23, F-94805 Villejuif, France -AD - Univ Paris Saclay, Fac Pharm, F-92296 Chatenay Malabry, France -AD - Univ Paris Saclay, Fac Med, F-94276 Le Kremlin Bicetre, France -M2 - Med Oncol Dept Fdn IRCCS Ist Nazl Tumori Milano -Y2 - 2020-11-17 -ER - - -TY - JOUR -AU - Medikonda, Ravi -AU - Dunn, Gavin -AU - Rahman, Maryam -AU - Fecci, Peter -AU - Lim, Michael -TI - A review of glioblastoma immunotherapy -T2 - JOURNAL OF NEURO-ONCOLOGY -M3 - Review -AB - Introduction Glioblastoma is a very aggressive cancer with dismal prognosis despite standard of care including surgical resection, radiation therapy, and chemotherapy. There is interest in applying immunotherapy to glioblastoma as this modality has demonstrated remarkable improvements in the management of several solid tumors including melanoma, renal cell carcinoma, and non-small cell lung cancer. This review aims to provide an overview of the current state of glioblastoma immunotherapy. Methods Literature search was performed on PubMed between 1961 and 2020. Results Initial clinical trials of checkpoint inhibitors and vaccine therapy for glioblastoma have largely been disappointing for both primary and recurrent glioblastoma. This failure has been attributed to glioblastoma's highly immunosuppressive environment and multiple mechanisms of therapy resistance including high tumor heterogeneity, low mutational burden, systemic immunosuppression, and local immune dysfunction. Conclusions Current clinical trials are exploring combination therapy and novel treatment strategies beyond immune checkpoint therapies and vaccine therapy such as CAR T cells. There is also an effort to establish synergy between immunotherapy and current standard of care. Furthermore, recent advances in personalized neoantigen vaccines suggest a shift towards personalized, patient-specific GBM treatment. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 0167-594X -SN - 1573-7373 -DA - 2021 JAN -PY - 2021 -VL - 151 -IS - 1 -SP - 41 -EP - 53 -DO - 10.1007/s11060-020-03448-1 -AN - WOS:000524415500001 -C6 - APR 2020 -AD - Johns Hopkins Univ, Sch Med, Dept Neurosurg, 600 N Wolfe St,Phipps 123, Baltimore, MD 21287 USA -AD - Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO USA -AD - Univ Florida, Dept Neurosurg, Gainesville, FL USA -AD - Duke Univ Hosp, Dept Neurosurg, Durham, NC USA -Y2 - 2020-04-06 -ER - - -TY - JOUR -AU - Scilla, Katherine A. -AU - Bentzen, Soren M. -AU - Lam, Vincent K. -AU - Mohindra, Pranshu -AU - Nichols, Elizabeth M. -AU - Vyfhuis, Melissa A. -AU - Bhooshan, Neha -AU - Feigenberg, Steven J. -AU - Edelman, Martin J. -AU - Feliciano, Josephine L. -TI - Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy -T2 - ONCOLOGIST -M3 - Article -AB - Background. Neutrophil-lymphocyte ratio (NLR) is a measure of systemic inflammation that appears prognostic in localized and advanced non-small cell lung cancer (NSCLC). Increased systemic inflammation portends a poorer prognosis in cancer patients. We hypothesized that low NLR at diagnosis is associated with improved overall survival (OS) in locally advanced NSCLC (LANSCLC) patients.Patients and Methods. Records from 276 patients with stage IIIA and IIIB NSCLC treated with definitive chemoradiation with or without surgery between 2000 and 2010 with adequate data were retrospectively reviewed. Baseline demographic data and pretreatment peripheral blood absolute neutrophil and lymphocyte counts were collected. Patients were grouped into quartiles based on NLR. OS was estimated using the Kaplan-Meier method. The log-rank test was used to compare mortality between groups. A linear test-for-trend was used for the NLR quartile groups. The Cox proportional hazards model was used for multivariable analysis.Results. The NLR was prognostic for OS (p < .0001). Median survival in months (95% confidence interval) for the first, second, third, and fourth quartile groups of the population distribution of NLR were 27 (19-36), 28 (22-34), 22 (12-31), and 10 (8-12), respectively. NLR remained prognostic for OS after adjusting for race, sex, stage, performance status, and chemoradiotherapy approach (p=.004).Conclusion. To our knowledge, our series is the largest to demonstrate that baseline NLR is a significant prognostic indicator in LANSCLC patients who received definitive chemoradiation with or without surgery. As an indicator of inflammatory response, it should be explored as a potential predictive marker in the context of immunotherapy and radiation therapy. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1083-7159 -SN - 1549-490X -DA - 2017 JUN -PY - 2017 -VL - 22 -IS - 6 -SP - 737 -EP - 742 -DO - 10.1634/theoncologist.2016-0443 -AN - WOS:000403210700015 -AD - Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA -AD - Johns Hopkins Sch Med, 301 Mason Lord Dr,Suite 4500, Baltimore, MD 21202 USA -Y2 - 2017-06-28 -ER - - -TY - JOUR -AU - Ohri, Nitin -AU - Jolly, Shruti -AU - Cooper, Benjamin T. -AU - Kabarriti, Rafi -AU - Bodner, William R. -AU - Klein, Jonathan -AU - Guha, Chandan -AU - Viswanathan, Shankar -AU - Shum, Elaine -AU - Sabari, Joshua K. -AU - Cheng, Haiying -AU - Gucalp, Rasim A. -AU - Castellucci, Enrico -AU - Qin, Angel -AU - Gadgeel, Shirish M. -AU - Halmos, Balazs -TI - Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT) -T2 - JOURNAL OF CLINICAL ONCOLOGY -M3 - Article -AB - PURPOSEStandard therapy for locally advanced non-small-cell lung cancer (LA-NSCLC) is concurrent chemoradiotherapy followed by adjuvant durvalumab. For biomarker-selected patients with LA-NSCLC, we hypothesized that sequential pembrolizumab and risk-adapted radiotherapy, without chemotherapy, would be well-tolerated and effective.METHODSPatients with stage III NSCLC or unresectable stage II NSCLC and an Eastern Cooperative Oncology Group performance status of 0-1 were eligible for this trial. Patients with a PD-L1 tumor proportion score (TPS) of >= 50% received three cycles of induction pembrolizumab (200 mg, once every 21 days), followed by a 20-fraction course of risk-adapted thoracic radiotherapy (55 Gy delivered to tumors or lymph nodes with metabolic volume exceeding 20 cc, 48 Gy delivered to smaller lesions), followed by consolidation pembrolizumab to complete a 1-year treatment course. The primary study end point was 1-year progression-free survival (PFS). Secondary end points included response rates after induction pembrolizumab, overall survival (OS), and adverse events.RESULTSTwenty-five patients with a PD-L1 TPS of >= 50% were enrolled. The median age was 71, most patients (88%) had stage IIIA or IIIB disease, and the median PD-L1 TPS was 75%. Two patients developed disease progression during induction pembrolizumab, and two patients discontinued pembrolizumab after one infusion because of immune-related adverse events. Using RECIST criteria, 12 patients (48%) exhibited a partial or complete response after induction pembrolizumab. Twenty-four patients (96%) received definitive thoracic radiotherapy. The 1-year PFS rate is 76%, satisfying our efficacy objective. One- and 2-year OS rates are 92% and 76%, respectively. The most common grade 3 adverse events were colitis (n = 2, 8%) and esophagitis (n = 2, 8%), and no higher-grade treatment-related adverse events have occurred.CONCLUSIONPembrolizumab and risk-adapted radiotherapy, without chemotherapy, are a promising treatment approach for patients with LA-NSCLC with a PD-L1 TPS of >= 50%.Prospective study of chemo-free treatment with pembro + RT for biomarker-selected LA-NSCLC patients. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0732-183X -SN - 1527-7755 -DA - 2024 FEB 10 -PY - 2024 -VL - 42 -IS - 5 -DO - 10.1200/JCO.23.00627 -AN - WOS:001235636300012 -AD - Montefiore Einstein Comprehens Canc Ctr, Dept Radiat Oncol, 1625 Poplar St, Bronx, NY 10461 USA -AD - Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI USA -AD - NYU, Perlmutter Canc Ctr, Dept Radiat Oncol, Grossman Sch Med, New York, NY USA -AD - Montefiore Einstein Comprehens Canc Ctr, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA -AD - NYU, Perlmutter Canc Ctr, Dept Med, Div Med Oncol,Grossman Sch Med, New York, NY USA -AD - Montefiore Einstein Comprehens Canc Ctr, Dept Oncol, Bronx, NY 10461 USA -AD - Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI USA -AD - Henry Ford Canc Inst, Dept Internal Med, Henry Ford Hlth Syst, Detroit, MI USA -M2 - Montefiore Einstein Comprehens Canc Ctr -M2 - Montefiore Einstein Comprehens Canc Ctr -M2 - Montefiore Einstein Comprehens Canc Ctr -Y2 - 2024-06-08 -ER - - -TY - JOUR -AU - Wang, Qin -AU - Qi, Chen -AU - Luo, Jing -AU - Xu, Nan -AU - Xu, Mao-tian -AU - Qiang, Yong -AU - Zhang, Chi -AU - Shen, Yi -TI - Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC) -T2 - FRONTIERS IN ONCOLOGY -M3 - Article -AB - BackgroundThe emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in the treatment landscape of non-small cell lung cancer (NSCLC). Despite the promising long-term survival outcomes and optimization of pathological complete response (cPR) demonstrated by various studies such as Impower010 and Checkmate-816, the effectiveness of neoadjuvant immunotherapy in advanced resectable NSCLC remains a subject of debate. Although previous research has explored the connection between the efficacy of neoadjuvant therapy and surgical-related safety, limited studies have specifically investigated the surgical-related safety of neoadjuvant immunotherapy. Therefore, our study aims to assess the efficacy and surgical-related safety of neoadjuvant immunotherapy in advanced resectable non-small cell lung cancer.MethodWe conducted a retrospective study on a cohort of 93 patients with stage IIIA-IIIC NSCLC who underwent neoadjuvant therapy and surgical resection. Among them, 53 patients received neoadjuvant immunotherapy, 18 patients underwent neoadjuvant chemotherapy while the remaining 22 underwent neoadjuvant targeted therapy. The patients were separated into further groups according to their pathological type. Data analyses were performed using Mann-Whitney U test, chi-square test.ResultsAll patients were categorized into six distinct groups. Notably, the neoadjuvant immunotherapy squamous carcinoma group exhibited a favorable edge over the neoadjuvant targeted squamous carcinoma group concerning the duration of drainage tube indwelling and the extent of lymph node dissection. Furthermore, the neoadjuvant immunotherapy adenocarcinoma group outperformed neoadjuvant targeted therapy adenocarcinoma counterpart in terms of achieving complete pathological response (cPR). Simultaneously, the neoadjuvant immunotherapy adenocarcinoma group surpassed the neoadjuvant chemotherapy adenocarcinoma group in the incidence of hydrothorax. Nevertheless, no statistically significant disparities were noted between the neoadjuvant immunotherapy squamous carcinoma group and the neoadjuvant chemotherapy carcinoma group.ConclusionRegarding surgical outcomes, neoadjuvant immunotherapy conferred notable advantages compared to conventional neoadjuvant chemotherapy and neoadjuvant targeted therapy for patients diagnosed with adenocarcinoma. In the case of squamous carcinoma, neoadjuvant immunotherapy exhibited superiority over neoadjuvant targeted therapy, although additional evidence is required to conclusively establish its precedence over neoadjuvant chemotherapy. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2023 DEC 22 -PY - 2023 -VL - 13 -C7 - 1239451 -DO - 10.3389/fonc.2023.1239451 -AN - WOS:001136521800001 -AD - Nanjing Univ, Jinling Hosp, Dept Cardiothorac Surg, Med Sch, Nanjing, Peoples R China -AD - Nanjing Univ, Jinling Hosp, Dept Ultrasound, Med Sch, Nanjing, Peoples R China -AD - Nanjing Med Univ, Jinling Hosp, Sch Clin Med, Dept Cardiothorac Surg, Nanjing, Peoples R China -AD - Southeast Univ, Jinling Hosp, Sch Med, Dept Cardiothorac Surg, Nanjing, Peoples R China -Y2 - 2024-01-12 -ER - - -TY - JOUR -AU - Jeremic, Branislav -AU - Mariamidze, Elene -AU - Shoshiashvili, Inga -AU - Kiladze, Ivane -TI - Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer-How to Identify Patients Which Can Benefit from It? -T2 - CURRENT ONCOLOGY -M3 - Review -AB - Background: Consolidation systemic therapy (ST) given after concurrent radiotherapy (RT) and ST (RT-ST) is frequently practiced in locally advanced inoperable nonsmall cell lung cancer (NSCLC). Little is known, however, about the fate of patients achieving different responses after concurrent phases of the treatment. Methods: we searched the English-language literature to identify full-length articles on phase II and Phase III clinical studies employing consolidation ST after initial concurrent RT-ST. We sought information about response evaluation after the concurrent phase and the outcome of these patient subgroups, the patterns of failure per response achieved after the concurrent phase as well as the outcome of these subgroups after the consolidation phase. Results: Eighty-seven articles have been initially identified, of which 20 studies were excluded for various reasons, leaving, therefore, a total of 67 studies for our analysis. Response evaluation after the concurrent phase was performed in 36 (54%) studies but in only 14 (21%) response data were provided, while in 34 (51%) studies patients underwent a consolidation phase regardless of the response. No study provided any outcome (survivals, patterns of failure) as per response achieved after the concurrent phase. Conclusions: Information regarding the outcome of subgroups of patients achieving different responses after the concurrent phase and before the administration of the consolidation phase is still lacking. This may negatively affect the decision-making process as it remains unknown which patients may preferentially benefit from the consolidation of ST. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1198-0052 -SN - 1718-7729 -DA - 2022 NOV -PY - 2022 -VL - 29 -IS - 11 -SP - 8316 -EP - 8329 -DO - 10.3390/curroncol29110656 -AN - WOS:000894886100001 -AD - Univ Kragujevac, Sch Med, Kragujevac 34000, Serbia -AD - Todua Clin, Dept Oncol & Hematol, Tbilisi 0112, Georgia -AD - Caucasus Med Ctr, Dept Med Oncol, Tbilisi 0186, Georgia -M2 - Todua Clin -M2 - Caucasus Med Ctr -Y2 - 2022-12-21 -ER - - -TY - JOUR -AU - Van Schil, Paul E. -AU - Berzenji, Lawek -AU - Yogeswaran, Suresh K. -AU - Hendriks, Jeroen M. -AU - Lauwers, Patrick -TI - Surgical Management of Stage IIIA Non-Small Cell Lung Cancer -T2 - FRONTIERS IN ONCOLOGY -M3 - Review -AB - According to the eighth edition of the tumor-node-metastasis classification, stage III non-small cell lung cancer is subdivided into stages IIIA, IIIB, and IIIC. They represent a heterogeneous group of bronchogenic carcinomas with locoregional involvement by extension of the primary tumor and/or ipsilateral or contralateral lymph node involvement. Surgical indications have not been definitely established but, in general, long-term survival is only obtained in those patients in whom a complete resection is obtained. This mini-review mainly focusses on stage IIIA disease comprising patients with locoregionally advanced lung cancers. Different subcategories of N2 involvement exist, which range from unexpected N2 disease after thorough preoperative staging or "surprise" N2, to bulky N2 involvement, mostly treated by chemoradiation, and finally, the intermediate category of potentially resectable N2 disease treated with a combined modality regimen. After induction therapy for preoperative N2 involvement, best surgical results are obtained with proven mediastinal downstaging when a lobectomy is feasible to obtain a microscopic complete resection. However, no definite, universally accepted guidelines exist. A relatively new entity is salvage surgery applied for recurrent disease after full-dose chemoradiation when no other therapeutic options exist. Equally, only a small subset of patients with T4N0-1 disease qualify for surgical resection after thorough discussion within a multidisciplinary tumor board on the condition that a complete resection is feasible. Targeted therapies and immunotherapy have recently become part of our therapeutic armamentarium, and it might be expected that they will be incorporated in current regimens after careful evaluation in randomized clinical trials. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND -SN - 2234-943X -DA - 2017 OCT 26 -PY - 2017 -VL - 7 -C7 - 249 -DO - 10.3389/fonc.2017.00249 -AN - WOS:000413742300001 -AD - Antwerp Univ Hosp, Dept Thorac & Vasc Surg, Antwerp, Belgium -AD - Antwerp Univ, Antwerp, Belgium -Y2 - 2017-11-19 -ER - - -TY - JOUR -AU - Li, X. -AU - Wang, J. -AU - Ma, J. -AU - Qian, D. -TI - Hypofraction Radiotherapy Followed by Immune Checkpoint Inhibitors for Locally Advanced Non-Small Cell Lung Cancer: A Phase I/II Clinical Trial -T2 - International Journal of Radiation Oncology, Biology, Physics -M3 - Journal Paper -AB - Purpose/Objective(s)To explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors (ICI) for stage III locally advanced non-small cell lung cancer patients.Materials/MethodsWe anticipated to enrolled 36 patients with stage III locally advanced non-small cell lung cancer, among which 18 patients were supposed to receive high-dose hypofraction radiotherapy (60-68Gy/15-17f) with ICI and another 18 patients for low-dose hypofraction radiotherapy (48Gy/12f) with ICI. The technique of esophagus-sparing simultaneous integrated boost was utilized. Chemotherapy could be given before or concurrent with hypofraction radiotherapy. The primary endpoints were the rate of radiation-induced pneumonitis (Grade III or more), esophagitis and myelosuppression. The second endpoints were 1-year local-regional control rate, 1-year progression-free survival rate, 1-year overall survival rate.ResultsFrom June 1st, 2021 to December 31th 2021, we totally enrolled 13 male patients (51-82 years old) and at present reported the primary outcome of safety and efficacy. All of these 13 patients were squamous cell carcinoma, among which there were 4 patients with stage IIIA, 6 patients with stage IIIB and 3 patients with IIIC. 11 patients received 60Gy/15f, 1 patient received 64Gy/16f and 1 patient received 68Gy/17f. 7 patients received inductive chemotherapy before radiotherapy and 8 patients received concurrent chemotherapy. 6 patients are currently within ICI maintenance (Durvalumab for 3 patients and Tislelizumab for 2 patients). After hypofraction radiotherapy, 4 patients were evaluated as partial response and the remaining 9 patients were evaluated as complete response (ORR=100%). No patients developed Grade III or more radiation-induced pneumonitis. 1 and 3 patients developed Grade I and Grade II esophagitis respectively. 2 patients developed myelosuppression (1 for Grade II and 1 for Grade IV, both patients received concurrent chemotherapy).ConclusionWithin short-term follow-up, hypofraction radiotherapy followed by immune checkpoint inhibitors is safe and efficacious. All rights reserved Elsevier. -SN - 1879-355X -DA - 2022 -PY - 2022 -SP - e379 -EP - e379 -DO - 10.1016/j.ijrobp.2022.07.1521 -AN - INSPEC:23040553 -AD - First Affiliated Hosp. of USTC, Hefei, China -AD - Anhui Provincial Hosp., Hefei, China -Y2 - 2023-05-19 -ER - - -TY - JOUR -AU - Hrinczenko, Borys -AU - Iannotti, Nicholas -AU - Goel, Sanjay -AU - Spigel, David -AU - Safran, Howard -AU - Taylor, Matthew H. -AU - Bennouna, Jaafar -AU - Wong, Deborah J. -AU - Kelly, Karen -AU - Verschraegen, Claire -AU - Bajars, Marcis -AU - Manitz, Juliane -AU - Ruisi, Mary -AU - Gulley, James L. -TI - Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor -T2 - FUTURE ONCOLOGY -M3 - Article -AB - Background: This study examined patients with advanced non-small-cell lung cancer who received long-term avelumab (anti-PD-L1) in a large phase Ib trial (JAVELIN Solid Tumor). Methods: Patients receiving >2 years of avelumab were reviewed and exploratory descriptive analyses were conducted. Results: Individuals with varying baseline characteristics who had received up to 6 years of avelumab were reviewed. Overall, 37/340 (10.9%) had received >= 2 years of treatment; in this subgroup, best response was complete response in 5.4%, partial response in 59.5% and stable disease in 29.7%; 51.4% had continued treatment beyond disease progression. Conclusions: In this study, 11% of patients with advanced non-small-cell lung cancer received >= 2 years of avelumab treatment and experienced prolonged response or continued clinical benefit. -PU - FUTURE MEDICINE LTD -PI - LONDON -PA - UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND -SN - 1479-6694 -SN - 1744-8301 -DA - 2022 APR -PY - 2022 -VL - 18 -IS - 11 -SP - 1333 -EP - 1342 -DO - 10.2217/fon-2021-0930 -AN - WOS:000753883600001 -C6 - FEB 2022 -AD - Michigan State Univ, Div Hematol Oncol, E Lansing, MI 48824 USA -AD - Hematol Oncol Associates Treasure Coast, Port St Lucie, FL 34952 USA -AD - Albert Einstein Coll Med, Montefiore Med Ctr, Dept Med Oncol, Bronx, NY 10461 USA -AD - Sarah Cannon Res Inst, Nashville, TN 37203 USA -AD - Life Span Canc Inst, Providence, RI 02903 USA -AD - Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA -AD - Univ Hosp Nantes, Dept Pneumol, Thorac Oncol Unit, Nantes, France -AD - Univ Calif Los Angeles, Los Angeles Med Ctr, Los Angeles, CA 90095 USA -AD - Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA -AD - Ohio State Univ, Div Med Oncol, Comprehens Canc Ctr, Columbus, OH 43221 USA -AD - Merck Healthcare KGaA, Darmstadt, Germany -AD - EMD Serono Res & Dev Inst Inc, Billerica, MA 01821 USA -AD - Merck KGaA, Darmstadt, Germany -AD - NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA -AD - NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA -AD - Providence Portland Med Ctr, Robert W Franz Canc Ctr, Portland, OR 97213 USA -AD - Vedanta Biosci Inc, Cambridge, MA 02139 USA -M2 - Hematol Oncol Associates Treasure Coast -M2 - Life Span Canc Inst -M2 - Merck Healthcare KGaA -M2 - Vedanta Biosci Inc -Y2 - 2022-02-28 -ER - - -TY - JOUR -AU - Dediu, Mircea -TI - Current trends in small cell lung cancer management-ASCO 2019 update -T2 - MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY -M3 - Review -AB - During the last 30 years the developments in small cell lung cancer (SCLC) have been extremely scarce. Concurrent chemo-radiation associated with prophylactic cranial irradiation in case of complete clinical remission is standard in limited disease. In extensive disease, platinum/etoposide and topotecan remain the standard systemic approaches in the first- and second-line setting, respectively. The only notable improvement was communicated in the IMpower133 trial, by the addition of atezolizumab to the platinum/etoposide chemotherapy backbone. Against this background, the current article aims to review the most important abstracts presented at ASCO 2019 along with their potential impact for current clinical practice. -PU - SPRINGER WIEN -PI - WIEN -PA - SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA -SN - 1865-5041 -SN - 1865-5076 -DA - 2019 DEC -PY - 2019 -VL - 12 -IS - 4 -SP - 297 -EP - 300 -DO - 10.1007/s12254-019-00539-2 -AN - WOS:000494754500002 -C6 - NOV 2019 -AD - Sanador Oncol Ctr, Str Sevastopol 5, Bucharest 010991, Romania -M2 - Sanador Oncol Ctr -Y2 - 2019-11-19 -ER - - -TY - JOUR -AU - Li, Xing -AU - Wang, Lei -AU - Chen, Shanhao -AU - Zhou, Fei -AU - Zhao, Jing -AU - Zhao, Wencheng -AU - Su, Chunxia -TI - Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors -T2 - THORACIC CANCER -M3 - Article -AB - Background Bone metastasis (BoM) is common in patients with advanced non-small cell lung cancer (NSCLC) and considered as one of the negative prognostic factors. However, the impact of BoM on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors (ICIs) remains unclear. Methods A total of 103 patients treated with ICI monotherapy and 101 patients treated with ICIs combined with chemotherapy or antiangiogenesis therapy were retrospectively analyzed. The differences in progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) between BoM+ and BoM- were investigated. Results Of those 101 patients who received combination therapy, no significant difference between BoM- and BoM+ in terms of both median PFS and median OS (median PFS, 10.1 vs. 12.1 months,P= 0.6; median OS, NR vs. 24.6 months,P= 0.713) was determined. In contrast, of the 103 patients who received ICI monotherapy, BoM+ patients had an inferior PFS (4.2 vs. 6.7 months,P= 0.0484) and OS (12.5 vs. 23.9 months,P= 0.0036) compared with BoM- patients. The univariate and multivariate analysis in the ICI monotherapy group also identified BoM as an independent factor attenuating the efficacy of ICI monotherapy. Of all BoM+ patients who received ICI monotherapy, neither palliative radiotherapy nor bisphosphonate drugs improved OS (palliative radiotherapy: 12.5 vs. 16.7 months,P= 0.487; bisphosphonate drugs: 12.5 vs. 9.7 months,P= 0.568). Conclusions BoM attenuated the efficacy of ICI monotherapy in patients with advanced NSCLC. Of BoM+ patients who received ICI monotherapy, neither palliative radiotherapy nor bisphosphonate drugs improved OS. Other therapeutic strategies are needed for patients with BoM. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1759-7706 -SN - 1759-7714 -DA - 2020 OCT -PY - 2020 -VL - 11 -IS - 10 -SP - 2812 -EP - 2819 -DO - 10.1111/1759-7714.13597 -AN - WOS:000557818000001 -C6 - AUG 2020 -AD - Tongji Univ, Dept Med Oncol, Sch Med, Shanghai Pulm Hosp, 507 Zheng Min Rd, Shanghai 200433, Peoples R China -AD - Hebei Med Univ, Dept Immunooncol, Fourth Hosp, Shijiazhuang, Hebei, Peoples R China -Y2 - 2020-08-21 -ER - - -TY - JOUR -AU - Suwinski, Rafal -TI - Prophylactic cranial irradiation in SCLC -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Prophylactic cranial irradiation (PCI) has well established place in therapy for patients with limited-disease small cell lung cancer who responded to treatment. The data from randomized trials document that PCI reduces brain metastases rate from approximately 60% to 30%, and increases 3-year overall survival by approximately 5%. Currently, the dose of 25 Gy in 10 fractions is considered as standard. In attempt to reduce neuropsychological sequelae attributable to PCI hippocampal sparing techniques are employed. The existing studies suggest the benefit of hippocampal sparing in limiting memory and higher neurocognitive function losses, but with a risk of failures in the spared region. Ongoing studies will further validate the role of hippocampal sparing, both in terms of toxicity reduction and metastases prevention. PCI for patients who have undergone resection for stage I small cell lung cancer (SCLC) is not recommended, PCI may be, however, associated with a favourable outcome in SCLC patients who have undergone complete surgery in stages II?III. The role of PCI in extensive-disease (ED) SCLC has been evolving. Most recent evidence indicate that PCI is controversial in ED patients with response to initial chemotherapy and absence of brain metastases confirmed by contrast-enhanced MRI. The patients who do not receive PCI, must, however, receive periodic MRI examination during follow-up, i.e., remain under active surveillance with access to radiotherapy at brain relapse. The assessment of safety and effectiveness of hippocampalsparing PCI, with or without drug neuroprotection in consideration of diverse combinations of radiotherapy, chemotherapy and immunotherapy create a background for future directions of research. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2021 APR -PY - 2021 -VL - 10 -IS - 4 -SP - 2071 -EP - 2078 -DO - 10.21037/tlcr-2020-rtm-05 -AN - WOS:000646137600022 -AD - Maria Sklodowska Curie Natl Res Inst Oncol, Radiotherapy & Chemotherapy Clin, Gliwice Branch, Gliwice, Poland -AD - Maria Sklodowska Curie Natl Res Inst Oncol, Teaching Hosp, Gliwice Branch, Gliwice, Poland -M2 - Maria Sklodowska Curie Natl Res Inst Oncol -M2 - Maria Sklodowska Curie Natl Res Inst Oncol -Y2 - 2021-06-01 -ER - - -TY - JOUR -AU - Gkika, E. -AU - Nestle, U. -AU - Grosu, A. L. -TI - Radiotherapy for small cell lung cancer -T2 - ONKOLOGE -M3 - Article -AB - Background Small cell lung cancers (SCLC) are aggressive tumors, which are typically diagnosed at a late stage with a limited prognosis. Advances in the diagnosis and therapy of SCLC over the past decades have led to a slight improvement in prognosis and survival. Results In limited stage (LS) SCLC, the treatment of choice is combined chemoradiation, either hyper- or conventionally fractionated, followed by a prophylactic cranial irradiation (PCI) in case of response after primary treatment. The chemotherapy combination of choice is a platinum-containing doublet with etoposide, over at least 4 cycles. In the metastatic setting, the role of consolidation mediastinal radiotherapy (RT) and PCI is controversial. The integration of immunotherapy in combination with chemoradiation is currently under investigation in several studies. Concepts for avoiding long-term neurocognitive side effects using whole-brain radiation with hippocampal sparring or radiosurgery in SCLC are also being investigated in prospective studies. Conclusion Radiotherapy plays an important role in the treatment of small cell lung cancer. -PU - SPRINGER HEIDELBERG -PI - HEIDELBERG -PA - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY -SN - 0947-8965 -SN - 1433-0415 -DA - 2021 SEP -PY - 2021 -VL - 27 -IS - 9 -SP - 887 -EP - 894 -DO - 10.1007/s00761-021-00955-2 -AN - WOS:000646468000001 -C6 - MAY 2021 -AD - Univ Klinikum Freiburg, Klin Strahlenheilkunde, Robert Koch Str 3, D-79106 Freiburg, Germany -AD - Kliniken Maria Hilf, Monchengladbach, Germany -M2 - Kliniken Maria Hilf -Y2 - 2021-05-23 -ER - - -TY - JOUR -AU - Turkaj, Ana -AU - Morelli, Anna M. -AU - Vavala, Tiziana -AU - Novello, Silvia -TI - Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer -T2 - FRONTIERS IN ONCOLOGY -M3 - Review -AB - Brain metastases in non-small cell lung cancer (NSCLC) patients are more often detected due to imaging modalities improvements but also emerge because of improved treatments of the primary tumor which lead to a longer survival. In this context, development of leptomeningeal metastases (LM) is a devastating complication and its prognosis remains poor despite advances in systemic and local approaches. Histology characterization of NSCLC and molecular expression influence LM management. For those with "oncogene addiction," new generation epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) were developed to strongly penetrate the blood-brain barrier (BBB) with the aim to prevent central nervous system cancer dissemination, eventually impacting on LM appearance and its subsequent management. Systemic chemotherapy, often combined with intrathecal chemotherapy (when possible), was one of common indications for lung cancer patients affected by LM, without driver mutations and a good performance status but currently, with the advent of innovative systemic approaches treatment solutions in this subgroup of patients are rapidly evolving. Whole brain radiation therapy (WBRT) is the conventional treatment for patients with brain metastases. Furthermore, modern radiation techniques, as stereotactic radiotherapy (SRT), improve outcomes in those cases with a limited number of lesions. However, LM represent a minority of CNS metastases and few literature data are available to drive the radiotherapy approach. Considering all relevant progress made in this setting, after a literature review, the aim of this paper is to discuss about recent developments and therapeutic options in LM management of non-oncogene addicted NSCLC. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2018 JUL 27 -PY - 2018 -VL - 8 -C7 - 278 -DO - 10.3389/fonc.2018.00278 -AN - WOS:000439995800001 -AD - Univ Torino, Osped San Luigi Gonzaga, Dept Oncol, Orbassano, Italy -AD - Osped Civile Saluzzo, SC Oncol, ASL CN1, Saluzzo, Italy -M2 - Osped Civile Saluzzo -Y2 - 2018-08-07 -ER - - -TY - JOUR -AU - Yoon, Shinkyo -AU - Lee, Dae Ho -AU - Kim, Sang-We . -TI - Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505) -T2 - JOURNAL OF THORACIC DISEASE -M3 - Editorial Material -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2017 OCT -PY - 2017 -VL - 9 -IS - 10 -SP - 3525 -EP - 3528 -DO - 10.21037/jtd.2017.09.12 -AN - WOS:000417752900058 -AD - Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, 88 Olymp Ro,43 Gil, Seoul, South Korea -Y2 - 2017-10-01 -ER - - -TY - JOUR -AU - Vivaldi, Caterina -AU - Catanese, Silvia -AU - Massa, Valentina -AU - Pecora, Irene -AU - Salani, Francesca -AU - Santi, Stefano -AU - Lencioni, Monica -AU - Vasile, Enrico -AU - Falcone, Alfredo -AU - Fornaro, Lorenzo -TI - Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist? -T2 - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES -M3 - Review -AB - Esophageal cancer remains a challenging disease due to limited treatment options and poor prognosis. In recent years, immune checkpoint inhibitors (ICI) have been proven to be safe and effective in the treatment of highly lethal malignancies, such as non-small cell lung cancer and melanoma. Recent clinical trials also showed promising activity in immune checkpoint inhibitors in pretreated advanced esophageal carcinoma and a potentially significant impact on the outcome of selected patients, independently of histology. Combination studies evaluating immunotherapy and chemotherapy and, in localized disease, radiotherapy are in progress and will hopefully confirm their promises in the near future. However, reliable predictive biomarkers are still lacking. Indeed, at present, the role of programmed cell death ligand 1 expression and other factors (such as microsatellite instability and tumor mutational burden) as predictive biomarkers of benefit to immune checkpoint inhibitors is still controversial. Our aim was to explore the rationale of ICIs in esophageal cancer, review the results already available in multiple settings, and investigate future perspectives with single-agent and combination strategies. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1661-6596 -SN - 1422-0067 -DA - 2020 MAR -PY - 2020 -VL - 21 -IS - 5 -C7 - 1658 -DO - 10.3390/ijms21051658 -AN - WOS:000524908500109 -AD - Univ Pisa, Dept Translat Res & New Technol Med & Surg, Via Savi 10, I-56126 Pisa, PI, Italy -AD - Pisa Univ Hosp, Unit Med Oncol, Via Roma 67, I-56126 Pisa, Italy -AD - Pisa Univ Hosp, Tuscany Reg Referral Ctr Diag & Treatment Esophag, Esophageal Surg Unit, Via Roma 67, I-56126 Pisa, Italy -Y2 - 2020-04-24 -ER - - -TY - JOUR -AU - Cabrera-Miranda, Luis A. -AU - Diaz-Garcia, Diego A. -AU - Corona-Cruz, Jose F. -AU - Lozano-Ruiz, Francisco J. -AU - Sanchez-Reyes, Roberto -AU - Alvarez-Bojorquez, Mario E. -AU - Blake-Cerda, Monika -AU - Rivera-Marquez, Raul -AU - Lopez-Saucedo, Raul A. -AU - Perez-Alvarez, Sandra I. -AU - Bolano-Guerra, Laura M. -AU - Alatorre-Alexander, Jorge A. -AU - Alexander-Meza, Francisco -AU - Barron-Barron, Feliciano -AU - Blanco-Vazquez, Yazmin C. -AU - Campos-Gomez, Saul -AU - de la Mata-Moya, Dolores -AU - Figueroa-Martinez, Pedro -AU - Gonzalez-Cisneros, Paulina E. -AU - Iniguez-Garcia, Marco A. -AU - Lazaro-Leon, Jesus M. -AU - Loyola-Garcia, Ulises -AU - Morales-Rivera, Marcelino -AU - Olivares-Torres, Carlos -AU - Ramos-Ramirez, Maritza -AU - Saenz-Frias, Julia A. -AU - Silva-Bravo, Fernando -AU - Trejo-Rosales, Rogelio -AU - Bosque, Miguel Souto-del -AU - Arrieta, Oscar -TI - Clinical practice guideline for the management of small cell lung cancer: extensive disease -T2 - GACETA MEXICANA DE ONCOLOGIA -M3 - Article -AB - Background: Small cell lung cancer (SCLC) represents 13-15% of all primary lung neoplasms and is characterized by its rapid growth rate and the rapid development of distant metastases. Objectives: To guide and standardize the treatment of extensive disease small cell lung cancer in Mexico based on national and international clinical evidence. Material and methods: This document was developed as a collaboration between the National Cancer Institute and the Mexican Society of Oncology in compliance with international standards. An interdisciplinary group was formed, including medical oncologists, oncological surgeons, thoracic surgeons, radiation oncologists, and methodologists with experience in systematic reviews of the literature and clinical practice guidelines. Results: A consensus was reached, both by the Delphi method and in remote meetings, of extensive disease recommendations resulting from work questions. The scientific evidence that answers each of these clinical questions was identified and critically evaluated, before being incorporated into the body of evidence of the Guide. Conclusions: This Clinical Practice Guide provides clinical recommendations for the management of extensive disease of SCLC to contribute to the decision-making process of the clinicians involved with its management in our country, hoping that this will contribute to improving the quality of clinical care in these patients. -PU - SOC MEXICANA ONCOLOGIA, A C -PI - MEXICO -PA - TUXPAN NO 59 PH, COL ROMA SUR, MEXICO, DF 06760, MEXICO -SN - 1665-9201 -DA - 2023 APR-JUN -PY - 2023 -VL - 22 -IS - 2 -SP - 55 -EP - 73 -DO - 10.24875/j.gamo.22000122 -AN - WOS:001021384300002 -AD - Inst Nacl Cancerol, Dept Oncol Med, Mexico City, DF, Mexico -AD - Hosp Angeles Carmen, Dept Oncol, Guadalajara, Jalisco, Mexico -AD - Med Sur, Serv Radio Oncol, Mexico City, DF, Mexico -AD - IMSS, Dept Oncol Med, Ctr Med Nacl La Raza, Mexico City, DF, Mexico -AD - Ctr Alta Especialidad Oncol San Jose, Dept Cirugia, Hermosillo, Sonora, Mexico -AD - Ctr Med ABC, Serv Radio Oncol, Mexico City, DF, Mexico -AD - IMSS, Hosp Gen Reg 1, Dept Oncol, Obregon, Mexico -AD - Hosp Adolfo Lopez Mateos, Dept Oncol, ISSSTE, Obregon, Mexico -AD - Centenario Hosp Miguel Hidalgo, Dept Cirugia Oncol, Aguascalientes, Aguascalientes, Mexico -AD - Inst Nacl Ciencias Med Nutr Salvador Zubiran, Dept Radio Oncol, Mexico City, DF, Mexico -AD - Inst Nacl Enfermedades Resp, Dept Oncol Med, Mexico City, DF, Mexico -AD - Dept Oncol, Unidad Cancerol, Guadalajara, Jalisco, Mexico -AD - Inst Seguridad Social Estado Mexico Municipios, Ctr Oncol Estatal, Dept Oncol Med, Toluca, Mexico -AD - ISSSTE, Dept Oncol, Clin Especialidades, San Luis Potosi, San Luis Potosi, Mexico -AD - Hosp Angeles San Luis, Dept Oncol, San Luis Potosi, San Luis Potosi, Mexico -AD - Hosp Gen Mexico Dr Eduardo Liceaga, Dept Oncol Med, Mexico City, DF, Mexico -AD - Hosp Gen Tijuana, Dept Oncol Med, Mexico City, DF, Mexico -AD - Hosp Gen Tijuana, Dept Oncol Med, Tijuana, Mexico -AD - Cirujanos Toracicos Baja Calif, Dept Cirugia, Tijuana, Mexico -AD - IMSS, Dept Radio Oncol, Unidad Med Alta Especialidad 25, Ctr Med Noreste, Monterrey, Mexico -AD - IMSS, Dept Oncol Med, Med Nacl Siglo 21, Mexico City, DF, Mexico -M2 - Hosp Angeles Carmen -M2 - Med Sur -M2 - Ctr Alta Especialidad Oncol San Jose -M2 - Ctr Med ABC -M2 - IMSS -M2 - Hosp Adolfo Lopez Mateos -M2 - Centenario Hosp Miguel Hidalgo -M2 - Inst Nacl Enfermedades Resp -M2 - Dept Oncol -M2 - Inst Seguridad Social Estado Mexico Municipios -M2 - ISSSTE -M2 - Hosp Angeles San Luis -M2 - Hosp Gen Mexico Dr Eduardo Liceaga -M2 - Hosp Gen Tijuana -M2 - Hosp Gen Tijuana -M2 - Cirujanos Toracicos Baja Calif -M2 - IMSS -Y2 - 2023-04-01 -ER - - -TY - JOUR -AU - Yan, Xiaoqi -AU - Zhao, Luqing -AU - Wu, Fei -AU - Shen, Bo -AU - Zhou, Guoren -AU - Feng, Jifeng -AU - Yue, Chao -AU - Zhu, Jingni -AU - Yu, Shaorong -AU - Zhu, Jingni -TI - Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study -T2 - JOURNAL OF THORACIC DISEASE -M3 - Article -AB - Background: Immune checkpoint inhibitors (ICIs) have dramatically changed the first-line treatment pattern of non-small cell lung cancer (NSCLC) without driver gene alterations. However, the optimal choice for second-line treatment after initial treatment with ICIs is unclear. This study aimed to clarify the efficacy and safety of ICI rechallenge therapy in locally advanced and advanced NSCLC. Methods: We retrospectively analyzed the histories of 224 patients with locally advanced or advanced NSCLC treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors alone or in combination with chemotherapy and/or antiangiogenic therapy in first-line treatment. Progression-free survival 2 (PFS2) was the time from the first defined progress disease (PD) to the second disease progression or death. Efficacy evaluation was performed directly in accordance with RECIST v1.1 criteria. Adverse events (AEs) were graded following the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Survival data were estimated using the Kaplan-Meier method or Cox survival regression model and compared using the log-rank test in overall cohort and other subgroups. Results: There were no significant differences in objective response rate (ORR) and median PFS2 (mPFS2) between the ICI rechallenge group and non-rechallenge group (ORR: 10.3% vs. 15.3%, P=0.308; mPFS2: 5.33 vs. 4.40 months, P=0.715). And the ICI rechallenge group showed no new safety signals compared with non-rechallenge group. In ICI rechallenge group, patients resistant to first-line immunotherapy had a lower ORR and shorter PFS2 compared with those who responded to initial ICIs treatment (ORR: 7.0% vs. 17.6%, P=0.038; mPFS2: 3.68 vs. 5.91 months, P=0.014). No significant difference in mPFS2 was observed among different second-line treatment groups (P=0.362). Radiotherapy in second-line treatment and ICI rechallenge therapy were not the main factors affecting PFS2. Conclusions: ICI rechallenge therapy beyond disease progression did not improve clinical outcomes in patients with NSCLC, but no new safety signals emerged. However, patients with favorable response to initial ICIs treatment still showed significant efficacy of subsequent ICI rechallenge therapy. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2024 MAR -PY - 2024 -VL - 16 -IS - 3 -SP - 1787 -EP - 1803 -DO - 10.21037/jtd-23-1767 -AN - WOS:001223217200014 -AD - Nanjing Med Univ, Canc Hosp, Dept Med Oncol, Baiziting 42, Nanjing 210009, Peoples R China -AD - Jiangsu Canc Hosp, Baiziting 42, Nanjing 210009, Peoples R China -AD - Jiangsu Inst Canc Res, Baiziting 42, Nanjing 210009, Peoples R China -AD - Nanjing Med Univ, Canc Hosp, Dept Gen Surg, Baiziting 42, Nanjing 210009, Peoples R China -Y2 - 2024-05-25 -ER - - -TY - JOUR -AU - Wu, Leilei -AU - Cheng, Bo -AU - Sun, Xiaojiang -AU - Zhang, Zhenshan -AU - Kang, Jingjing -AU - Chen, Yun -AU - Xu, Qinghua -AU - Yang, Shuangyan -AU - Yan, Yujie -AU - Ren, Shengxiang -AU - Zhou, Caicun -AU - Xu, Yaping -TI - Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non-small cell lung cancer: a multi-institutional retrospective cohort study -T2 - MEDCOMM -M3 - Article -AB - This study aimed to evaluate the efficacy and safety of induction immunochemotherapy followed by definitive chemoradiotherapy (CRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC). We identified unresectable stage III NSCLC patients who received induction immunochemotherapy. Overall survival (OS) and progression-free survival (PFS) were the primary endpoints. From February 2019 to August 2022, 158 patients were enrolled. Following the completion of induction immunochemotherapy, the objective response rate (ORR) and disease control rate (DCR) were 52.5% and 83.5%, respectively. The ORR of CRT was 73.5%, representing 68.4% of the total cohort. The median PFS was 17.8 months, and the median OS was 41.9 months, significantly higher than in patients who received CRT alone (p < 0.001). Patients with concurrent CRT demonstrated markedly improved PFS (p = 0.012) and OS (p = 0.017) than those undergoing sequential CRT. Additionally, those with a programmed-death ligand 1 (PD-L1) expression of 50% or higher showed significantly elevated ORRs (72.2% vs. 47.2%, p = 0.011) and superior OS (median 44.8 vs. 28.6 months, p = 0.004) compared to patients with PD-L1 expression below 50%. Hematologic toxicities were the primary severe adverse events (grade >= 3) encountered, with no unforeseen treatment-related toxicities. Thus, induction immunochemotherapy followed by definitive CRT demonstrated encouraging efficacy and tolerable toxicities for unresectable LA-NSCLC. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2688-2663 -DA - 2024 MAR -PY - 2024 -VL - 5 -IS - 3 -C7 - e501 -DO - 10.1002/mco2.501 -AN - WOS:001179030500001 -AD - Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Radiat Oncol, Shanghai, Peoples R China -AD - Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Canc & Basic Med IBMC,Dept Radiat Oncol,Canc, Hangzhou, Peoples R China -AD - Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Radiat Oncol, Jinan, Peoples R China -AD - Fudan Univ, Shanghai Proton & Heavy Ion Ctr, Dept Radiat Oncol, Canc Hosp, Shanghai, Peoples R China -AD - Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Med Oncol, Shanghai, Peoples R China -Y2 - 2024-03-23 -ER - - -TY - JOUR -AU - Kegelman, Timothy -AU - Yegya-Raman, Nikhil -AU - Kim, Kristine -AU - Feigenberg, Steven -AU - Adusumalli, Srinath -AU - Langer, Corey -AU - Cohen, Roger -AU - O'Quinn, Rupal -AU - Ky, Bonnie -AU - Kallan, Michael -AU - Denduluri, Srinivas -AU - Cengel, Keith -AU - Singh, Aditi -AU - Aggarwal, Charu -AU - Bauml, Joshua -AU - Levin, William -AU - Berman, Abigail -TI - Cardiac Events Following Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Carcinoma with Photon and Proton Beam Radiotherapy -T2 - AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS -M3 - Meeting Abstract -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0277-3732 -SN - 1537-453X -DA - 2021 OCT -PY - 2021 -VL - 44 -IS - 10 -MA - P116 -SP - S105 -EP - S105 -AN - WOS:000701779700168 -AD - Univ Penn, Philadelphia, PA 19104 USA -Y2 - 2021-10-10 -ER - - -TY - JOUR -AU - Patel, Jyoti D. -AU - Lee, Ju-Whei -AU - Carbone, David P. -AU - Wagner, Henry -AU - Shanker, Anil -AU - de Aquino, Maria Teresa P. -AU - Horn, Leora -AU - Johnson, Melissa L. -AU - Gerber, David E. -AU - Liu, Jane Jijun -AU - Das, Millie S. -AU - Al-Nsour, Mohammed Ali -AU - Dakhil, Christopher S. R. -AU - Ramalingam, Suresh -AU - Schiller, Joan H. -TI - Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508) -T2 - CLINICAL LUNG CANCER -M3 - Article -AB - Despite the fact that chemoradiation is potentially curative for locally advanced non -small-cell lung cancer, many patients suffer from relapse. We studied the combination of tecemotide, a MUC1 antigen-specific immunotherapy vaccine, and bevacizumab after definitive chemoradiation in a single-arm phase II study. This trial demonstrated tolerability and encouraging outcomes and may support further investigation of antiangiogenic and immunotherapy combinations.Introduction: Although chemoradiotherapy (CRT) is the standard of care for patients with unresectable stage III non-small-cell lung cancer (LA- NSCLC), most patients relapse. Tecemotide is a MUC1 antigen- specific cancer immunotherapy vaccine. Bevacizumab improves survival in advanced nonsquamous (NS)-NSCLC and has a role in immune modulation. This phase II trial tested the combination of tecemotide and bevacizumab following CRT in patients with LA- NSCLC. Patients and Methods: Subjects with stage III NS-NSCLC suitable for CRT received carboplatin/paclitaxel weekly + 66 Gy followed by 2 cycles of consolidation carboplatin/paclitaxel <= 4 weeks of completion of CRT (Step 1). Patients with partial response/stable disease after consolidation therapy were registered onto step 2, which was 6 weekly tecemotide injections followed by every 6 weekly injections and bevacizumab every 3 weeks for up to 34 doses. The primary endpoint was to determine the safety of this regimen. Results: Seventy patients were enrolled; 68 patients (median age, 63 years; 56% male; 57% stage IIIA) initiated therapy, but only 39 patients completed CRT and consolidation therapy per protocol, primarily owing to disease progression or toxicity. Thirty-three patients (median age, 61 years; 58% male; 61% stage IIIA) were registered to step 2 (tecemotide + bevacizumab). The median number of step 2 cycles received was 11 (range, 2-25). Step 2 worst toxicity included grade 3, N = 9; grade 4, N = 1; and grade 5, N = 1. Grade 5 toxicity in step 2 was esophageal perforation attributed to bevacizumab. Among the treated and eligible patients (n = 32) who were treated on step 2, the median overall survival was 42.7 months (95% confidence interval, 21.7-63.3 months), and the median progression-free survival was 14.9 months (95% confidence interval, 11.0-20.9 months) from step 1 registration. Conclusions: This cooperative group trial met its endpoint, demonstrating tolerability of bevacizumab + tecemotide after CRT and consolidation. In this selected group of patients, the median progression-free survival and overall survival are encouraging. Given that consolidation immunotherapy is now a standard of care following CRT in patients with LA-NSCLC, these results support a role for continued investigation of antiangiogenic and immunotherapy combinations in LA-NSCLC. (C) 2020 Elsevier Inc. All rights reserved. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2020 NOV -PY - 2020 -VL - 21 -IS - 6 -SP - 520 -EP - 526 -DO - 10.1016/j.cllc.2020.06.007 -AN - WOS:000583316500025 -AD - Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA -AD - Dana Farber Canc Inst, ECOG ACRIN Biostat Ctr, Data Sci, Boston, MA 02115 USA -AD - Ohio State Univ, Dept Med, Comprehens Canc Ctr, Columbus, OH 43210 USA -AD - Penn State Canc Inst, Dept Radiat Oncol, Hershey, PA USA -AD - Meharry Med Coll, Dept Biochem & Canc Biol, Nashville, TN 37208 USA -AD - Vanderbilt Univ, Dept Med, Nashville, TN USA -AD - Sarah Cannon Res Inst, Dept Med, Nashville, TN USA -AD - UT Southwestern Simmons Canc Ctr, Dept Med, Dallas, TX USA -AD - Illinois Canc Care, Peoria, IL USA -AD - VA Palo Alto Hlth Care, Dept Med, Palo Alto, CA USA -AD - Mercy Canc Ctr, Toledo, OH USA -AD - Wichita NCORP, Wichita, KS USA -AD - Emory Univ, Dept Med, Atlanta, GA 30322 USA -AD - Inova Canc Inst, Fairfax, VA USA -M2 - UT Southwestern Simmons Canc Ctr -M2 - Illinois Canc Care -M2 - Mercy Canc Ctr -M2 - Wichita NCORP -M2 - Inova Canc Inst -Y2 - 2020-11-17 -ER - - -TY - JOUR -AU - Prakash, Ajay -AU - Gates, Travis -AU - Zhao, Xianda -AU - Wangmo, Dechen -AU - Subramanian, Subbaya -TI - Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy -T2 - PHARMACOLOGY & THERAPEUTICS -M3 - Review -AB - Despite significant advances in the screening, diagnosis, and treatment of colorectal cancer (CRC) immune checkpoint inhibitors (ICIs) continue to have limited utility outside of microsatellite-high disease. Given the durable response to immunotherapy seen across malignancies, increasing CRC response rates to ICI therapy is an active area of clinical research. An increasing body of work has demonstrated that tumor-derived extracellular vesicles (TEVs) are key modulators in tumor signaling and the determinants of the tumor microenvironment. Pre-clinical models have shown that TEVs are directly involved in antigen presentation and are involved in radiation-induced DNA damage signaling. Both direct and indirect modifications of these TEVs can alter CRC immunogenicity and ICI treatment response, making them attractive targets for potential therapeutic develop-ment. In addition, modified TEVs can be developed using several different mechanisms, with varied cargo including micro-RNAs and small peptide molecules. Recent work has shown strong pre-clinical evidence of injected modified TEV-induced ICI activity, with knockdown of the micro-RNA miR-424 in TEVs improving CRC immunogenicity and increasing anti-PD-1 activity in mouse models. Clinical trials are ongoing in the evalu-ation of modified TEVs in cancer therapy, but they appear to be a promising therapeutic target in CRC.Published by Elsevier Inc. -PU - PERGAMON-ELSEVIER SCIENCE LTD -PI - OXFORD -PA - THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND -SN - 0163-7258 -SN - 1879-016X -DA - 2023 JAN -PY - 2023 -VL - 241 -C7 - 108332 -DO - 10.1016/j.pharmthera.2022.108332 -AN - WOS:000916022000001 -C6 - DEC 2022 -AD - Univ Minnesota, Masonic Canc Ctr, Med Sch, Minneapolis, MN 55455 USA -AD - Univ Minnesota, Med Sch, Dept Surg, Minneapolis, MN USA -AD - Univ Minnesota, Ctr Immunol, Med Sch, Minneapolis, MN USA -Y2 - 2023-02-06 -ER - - -TY - JOUR -AU - KRISHNAN, SUNIL; LIN, STEVEN HSESHENG (contact) -TI - Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches -M3 - Awarded Grant -AB - PROJECT NARRATIVE This proposal aims to select compounds from the CTEP portfolio of molecular agents for further evaluation in realistic preclinical treatment scenarios in preclinical models. The three-step approach includes use of a novel high-throughput screen for replicative cell death of lung and pancreatic cancer cells treated with radiation, chemotherapy and the novel CTEP agent; followed by advancement of promising agents for in vivo testing in autochthonous orthotopic immune-competent animal models and immune-compromised patient-derived xenograft models; and evaluation of mechanisms of resistance to combination therapy using in silico and experimental approaches.  -DA - 2018 -PY - 2018 -AN - GRANTS:10691689 -G1 - 5U01CA216468-02; 9557464; U01CA216468 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - LU, BO -TI - Role of PD-1/PDL-1 in Lung Carcinogenesis and Therapy -M3 - Awarded Grant -AB - PUBLIC HEALTH RELEVANCE: In this proposal, we will investigate whether PD-1 and PDL-1 modulate lung carcinogenesis and determine how lung cancer responds to chemotherapy and radiotherapy in the presence or absence of PD-1 or PDL-1. The significance of this research is to gain understanding of lung cancer biology and develop novel therapeutic strategies to treat lung cancer. -DA - 2013 -PY - 2013 -AN - GRANTS:12074147 -G1 - 1R21CA178229-01; 8567623; R21CA178229 -AD - THOMAS JEFFERSON UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - LU, BO -TI - Role of PD-1/PDL-1 in Lung Carcinogenesis and Therapy -M3 - Awarded Grant -AB - PUBLIC HEALTH RELEVANCE: In this proposal, we will investigate whether PD-1 and PDL-1 modulate lung carcinogenesis and determine how lung cancer responds to chemotherapy and radiotherapy in the presence or absence of PD-1 or PDL-1. The significance of this research is to gain understanding of lung cancer biology and develop novel therapeutic strategies to treat lung cancer. -DA - 2014 -PY - 2014 -AN - GRANTS:11848911 -G1 - 5R21CA178229-02; 8706103; R21CA178229 -AD - THOMAS JEFFERSON UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Brown, Lauren Julia -AU - Ahn, Julie -AU - Gao, Bo -AU - Gee, Harriet -AU - Nagrial, Adnan -AU - Hau, Eric -AU - da Silva, Ines Pires -TI - Site-Specific Response and Resistance Patterns in Patients with Advanced Non-Small-Cell Lung Cancer Treated with First-Line Systemic Therapy -T2 - CANCERS -M3 - Article -AB - Simple Summary Immunotherapy or combined chemoimmunotherapy is currently first-line therapy for patients with metastatic NSCLC without a driver mutation. Despite immunotherapy contributing to improved survival outcomes, the estimated 5-year OS rate for metastatic NSCLC remains poor. The aim of our retrospective study was to assess how patients with different anatomical metastatic sites respond or develop resistance to immunotherapy, combination chemoimmunotherapy, or chemotherapy alone. We confirmed that patients with bone metastases have poorer survival outcomes compared to those without bone metastases. This highlights a group of patients that may benefit from a specific clinical trial evaluation to assess the benefit of additional novel therapeutics or upfront radiotherapy.Abstract Patients with advanced NSCLC have heterogenous responses to immune checkpoint inhibitors (ICIs) with or without chemotherapy. In NSCLC, the impact of the distribution of metastatic sites and the response to systemic therapy combinations remain poorly understood. In a retrospective cohort study of patients with unresectable stage III/IV NSCLC who received first-line systemic therapy, we sought to assess the association between the site of metastases with patterns of response and progression. Data regarding demographics, tumour characteristics (including site, size, and volume of metastases), treatment, and outcomes were examined at two cancer care centres. The endpoints included organ site-specific response rate, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Two-hundred and eighty-five patients were included in the analysis. In a multivariate analysis, patients with bone metastases had a reduced ORR, PFS, and OS. Primary resistance was also more likely in patients with bone metastases. Patients with bone or liver metastases had a shorter OS when receiving ICIs with or without chemotherapy, but not with chemotherapy alone, suggesting an immunological basis for therapeutic resistance. A directed assessment of the tumour microenvironment in these locations and a deeper understanding of the drivers of organ-specific resistance to immunotherapy are critical to optimise novel combination therapies and sequencing in these patients. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2024 JUN -PY - 2024 -VL - 16 -IS - 11 -C7 - 2136 -DO - 10.3390/cancers16112136 -AN - WOS:001245503100001 -AD - Westmead Hosp, Dept Med Oncol, Sydney, NSW 2145, Australia -AD - Blacktown Hosp, Blacktown Canc & Haematol Ctr, Sydney, NSW 2148, Australia -AD - Univ Sydney, Fac Med & Hlth, Camperdown, NSW 2050, Australia -AD - Westmead Inst Med Res, Westmead, NSW 2145, Australia -AD - Sydney West Radiat Oncol Network SWRON, Sydney, NSW 2145, Australia -AD - Childrens Med Res Inst, Westmead, NSW 2145, Australia -AD - Melanoma Inst Australia, Wollstonecraft, NSW 2065, Australia -M2 - Sydney West Radiat Oncol Network SWRON -Y2 - 2024-06-18 -ER - - -TY - JOUR -AU - KRISHNAN, SUNIL; LIN, STEVEN HSESHENG (contact) -TI - Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches -M3 - Awarded Grant -AB - PROJECT NARRATIVE This proposal aims to select compounds from the CTEP portfolio of molecular agents for further evaluation in realistic preclinical treatment scenarios in preclinical models. The three-step approach includes use of a novel high-throughput screen for replicative cell death of lung and pancreatic cancer cells treated with radiation, chemotherapy and the novel CTEP agent; followed by advancement of promising agents for in vivo testing in autochthonous orthotopic immune-competent animal models and immune-compromised patient-derived xenograft models; and evaluation of mechanisms of resistance to combination therapy using in silico and experimental approaches.  -DA - 2017 -PY - 2017 -AN - GRANTS:12021034 -G1 - 1U01CA216468-01A1; 9398238; U01CA216468 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Tarhini, Ahmad A. -AU - Eads, Jennifer R. -AU - Moore, Kathleen N. -AU - Tatard-Leitman, Valerie -AU - Wright, John -AU - Forde, Patrick M. -AU - Ferris, Robert L. -TI - Neoadjuvant immunotherapy of locoregionally advanced solid tumors -T2 - JOURNAL FOR IMMUNOTHERAPY OF CANCER -M3 - Article -AB - Definitive management of locoregionally advanced solid tumors presents a major challenge and often consists of a combination of surgical, radiotherapeutic and systemic therapy approaches. Upfront surgical treatment with or without adjuvant radiotherapy carries the risks of significant morbidities and potential complications that could be lasting. In addition, these patients continue to have a high risk of local or distant disease relapse despite the use of standard adjuvant therapy. Preoperative neoadjuvant systemic therapy has the potential to significantly improve clinical outcomes, particularly in this era of expanding immunotherapeutic agents that have transformed the care of patients with metastatic/unresectable malignancies. Tremendous progress has been made with neoadjuvant immunotherapy in the treatment of several locoregionally advanced resectable solid tumors leading to ongoing phase 3 trials and change in clinical practice. The promise of neoadjuvant immunotherapy has been supported by the high pathologic tumor response rates in early trials as well as the durability of these responses making cure a more achievable potential outcome compared with other forms of systemic therapy. Furthermore, neoadjuvant studies allow the assessment of radiologic and pathological responses and the access to biospecimens before and during systemic therapy. Pathological responses may guide future treatment decisions, and biospecimens allow the conduct of mechanistic and biomarker studies that may guide future drug development. On behalf of the National Cancer Institute Early Drug Development Neoadjuvant Immunotherapy Working Group, this article summarizes the current state of neoadjuvant immunotherapy of solid tumors focusing primarily on locoregionally advanced melanoma, gynecologic malignancies, gastrointestinal malignancies, non-small cell lung cancer and head and neck cancer including recent advances and our expert recommendations related to future neoadjuvant trial designs and associated clinical and translational research questions. -PU - BMJ PUBLISHING GROUP -PI - LONDON -PA - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND -SN - 2051-1426 -DA - 2022 AUG -PY - 2022 -VL - 10 -IS - 8 -C7 - e005036 -DO - 10.1136/jitc-2022-005036 -AN - WOS:000841202800001 -AD - Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Cutaneous Oncol & Immunol, Morsani Coll Med, Tampa, FL 33620 USA -AD - Univ Penn, Med, Abramson Canc Ctr, Philadelphia, PA USA -AD - Univ Oklahoma, Gynecol Oncol, Stephenson Canc Ctr, Oklahoma City, OK USA -AD - Emmes Co LLC, Rockville, MD USA -AD - NCI, Bethesda, MD 20892 USA -AD - Johns Hopkins Univ, Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA -AD - Univ Pittsburgh, Otolaryngol & Immunol, Pittsburgh, PA USA -AD - UPMC, Hillman Canc Ctr, Pittsburgh, PA USA -M2 - Emmes Co LLC -Y2 - 2022-08-23 -ER - - -TY - JOUR -AU - Torasawa, Masahiro -AU - Horinouchi, Hidehito -AU - Yagishita, Shigehiro -AU - Utsumi, Hirofumi -AU - Okuda, Keitaro -AU - Takekoshi, Daisuke -AU - Ito, Saburo -AU - Wakui, Hiroshi -AU - Murata, Saori -AU - Kaku, Sawako -AU - Okuma, Kae -AU - Matsumoto, Yuji -AU - Shinno, Yuki -AU - Okuma, Yusuke -AU - Yoshida, Tatsuya -AU - Goto, Yasushi -AU - Yamamoto, Noboru -AU - Araya, Jun -AU - Ohe, Yuichiro -AU - Fujita, Yu -TI - Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non-small cell lung cancer from proteomic profiling of circulating extracellular vesicles -T2 - THORACIC CANCER -M3 - Article -AB - Background Risk factors for predicting pneumonitis during durvalumab consolidation after chemoradiotherapy (CRT) in locally advanced non-small cell lung cancer (LA-NSCLC) are still lacking. Extracellular vesicles (EVs) play a crucial role in intercellular communication and are potential diagnostic tools for various diseases.Methods We retrospectively collected predurvalumab treatment serum samples from patients treated with durvalumab for LA-NSCLC, isolated EVs using anti-CD9 and anti-CD63 antibodies, and performed proteomic analyses. We examined EV proteins that could predict the development of symptomatic pneumonitis (SP) during durvalumab treatment. Potential EV-protein biomarkers were validated in an independent cohort.Results In the discovery cohort, 73 patients were included, 49 with asymptomatic pneumonitis (AP) and 24 with SP. Of the 5797 proteins detected in circulating EVs, 33 were significantly elevated (fold change [FC] > 1.5, p < 0.05) in the SP group, indicating enrichment of the nuclear factor kappa B (NF-kappa B) pathway. Patients with high levels of EV-RELA, an NF-kappa B subunit, had a higher incidence of SP than those with low levels of EV-RELA (53.8% vs. 13.4%, p = 0.0017). In the receiver operating characteristic analysis, EV-RELA demonstrated a higher area under the curve (AUC) than lung V20 (0.76 vs. 0.62) and was identified as an independent risk factor in the multivariate logistic regression analysis (p = 0.008, odds ratio 7.72). Moreover, high EV-RELA was also a predictor of SP in the validation cohort comprising 43 patients (AUC of 0.80).Conclusions Circulating EV-RELA may be a predictive marker for symptomatic pneumonitis in patients with LA-NSCLC treated with durvalumab. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1759-7706 -SN - 1759-7714 -DA - 2023 OCT -PY - 2023 -VL - 14 -IS - 29 -SP - 2909 -EP - 2923 -DO - 10.1111/1759-7714.15077 -AN - WOS:001080186000001 -C6 - AUG 2023 -AD - Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan -AD - Juntendo Univ, Grad Sch Med, Dept Resp Med, Tokyo, Japan -AD - Natl Canc Ctr, Res Inst, Div Mol Pharmacol, Tokyo, Japan -AD - Jikei Univ, Sch Med, Dept Internal Med, Div Resp Dis, Tokyo, Japan -AD - Natl Canc Ctr, Dept Diagnost Radiol, Tokyo, Japan -AD - Natl Canc Ctr, Dept Radiat Oncol, Tokyo, Japan -AD - Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan -AD - Jikei Univ, Res Ctr Med Sci, Sch Med, Div Next Generat Drug Dev Res, Tokyo, Japan -AD - Jikei Univ, Res Ctr Med Sci, Sch Med, Div Next Generat Drug Dev Res, 3-25-8 Nishi Shimbashi,Minato Ku, Tokyo 1058461, Japan -Y2 - 2023-11-01 -ER - - -TY - JOUR -AU - Cozzi, Salvatore -AU - Bruni, Alessio -AU - Ruggieri, Maria Paola -AU - Borghetti, Paolo -AU - Scotti, Vieri -AU - Franceschini, Davide -AU - Fiore, Michele -AU - Taraborrelli, Maria -AU - Salvi, Fabrizio -AU - Galaverni, Marco -AU - Savoldi, Luisa -AU - Braglia, Luca -AU - Botti, Andrea -AU - Ghersi, Sebastiano Finocchi -AU - Niccolo, Giaj-Levra -AU - Lohr, Frank -AU - Iotti, Cinzia -AU - Ciammella, Patrizia -TI - Thoracic Radiotherapy in Extensive Disease Small Cell Lung Cancer: Multicenter Prospective Observational TRENDS Study -T2 - CANCERS -M3 - Article -AB - Simple Summary Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers, and seventy percent of patients already have advanced disease at diagnosis. In advanced disease, the use of consolidative chest RT should be recommended for patients with good response to platinum-based first-line chemotherapy, but its use has not yet been standardized. This prospective study was carried out with the intention of evaluating the spread in Italy of the use of thoracic RT in ES-SCLC, with a focus on the pattern of care (RT modalities, volumes and doses) and its effectiveness in terms of disease control and tolerability. From January 2017 to December 2019, sixty-four patients were enrolled. An extensive variability in doses, treatment volume and technique were recorded. Nevertheless, consolidative RT was well-tolerated by all patients and, after treatment, over 66% of patients did not experience in-field progression, and it has been shown to be useful in reducing the risk of thoracic disease progression in patients with advanced stage SCLC, with good response after first-line chemotherapy. (1) Introduction: Small cell lung cancer (SCLC) is an aggressive tumor type, accounting for about 15% of all lung cancers. Radiotherapy (RT) plays a fundamental role in both early and advanced stages. Currently, in advanced disease, the use of consolidative chest RT should be recommended for patients with good response to platinum-based first-line chemotherapy, but its use has not yet been standardized. The present prospective study aims to evaluate the pattern of care of consolidative chest RT in patients with advanced stage SCLC, and its effectiveness in terms of disease control and tolerability. (2) Materials and methods: This study was a multicenter prospective observational trial, proposed and conducted within the AIRO lung study group to evaluate the pattern of care of consolidative chest RT after first-line chemotherapy in patients with advanced SCLC. The patient and tumor characteristics, doses, fractionation and volumes of thoracic RT and prophylactic cranial irradiation (PCI), as well as the thoracic and extrathoracic response to the treatment, toxicity and clinical outcomes, were collected and analyzed. (3) Results: From January 2017 to December 2019, sixty-four patients were enrolled. Median follow-up was 33 months. The median age was 68 years (range 42-81); 38 patients (59%) were male and 26 (41%) female. Carboplatin + etoposide for 6 cycles was the most commonly used first-line therapeutic scheme (42%). With regard to consolidative chest RT, 56% of patients (35) received 30 Gy in 10 factions and 16 patients (26%) received 45 Gy in 15 sessions. The modulated intensity technique was used in 84.5% of cases, and post-chemotherapy macroscopic residual disease was the target volume in 87.5% of patients. Forty-four patients (69%) also underwent PCI. At the last follow-up, over 60% of patients did not experience chest disease progression, while 67% showed extrathoracic progression. At the first radiological evaluation after RT, complete response and stable disease were recorded in 6% and 46% of the cases, respectively. Two patients had a long-term complete response to the combined treatment. The brain was the first site of extrathoracic progression in 28%. 1y and 2y OS and PFS were 67%, 19%, 28% and 6%, respectively. Consolidative chest RT was well-tolerated in the majority of patients; it was interrupted in three cases (due to G2 pulmonary toxicity, disease progression and clinical decay, respectively). Only 1 patient developed G3 asthenia.(4) Conclusions: Consolidative chest RT has been shown to be useful in reducing the risk of thoracic disease progression and is absolutely well-tolerated in patients with advanced stage SCLC with good response after first-line chemotherapy. Among the Italian centers that participated in this study, there is still variability in the choice of fractionation and target volumes, although the guidelines contain clear recommendations. The aim of future research should be to clarify the role and modalities of chest RT in the era of immunotherapy in advanced-stage SCLC. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2023 JAN -PY - 2023 -VL - 15 -IS - 2 -C7 - 434 -DO - 10.3390/cancers15020434 -AN - WOS:000917273100001 -AD - IRCCS Reggio Emilia, Radiat Oncol Unit, Azienda USL, I-42123 Reggio Emilia, Italy -AD - Ctr Leon Berard, Radiat Oncol Dept, Lyon, France -AD - Univ Hosp Modena, Dept Oncol & Hematol, Radiat Therapy Unit, I-41125 Modena, Italy -AD - Univ Brescia, Radiat Oncol Dept, I-25123 Brescia, Italy -AD - AOU Careggi Firenze, Radiat Oncol Unit, Oncol Dept, I-50134 Florence, Italy -AD - IRCCS Human Canc Ctr, Radiat Therapy Unit, I-20089 Milan, Italy -AD - Campus Biomed Univ, Fdn Policlin Univ Campus Biomed, Radiat Oncol, I-00128 Rome, Italy -AD - GD Annunzio Univ, SS Annunziata Hosp, Radiat Oncol Unit, I-66100 Chieti, Italy -AD - Bellaria Hosp, Radiat Oncol Unit, I-40139 Bologna, Italy -AD - Azienda Ospedaliera Univ, Radiotherapy Unit, I-43126 Parma, Italy -AD - IRCCS Reggio Emilia, Res & Stat Infrastruct, Azienda Unita Sanit Locale, I-42123 Reggio Emilia, Italy -AD - IRCCS Reggio Emilia, Med Phys Unit, Azienda USL, I-42123 Reggio Emilia, Italy -AD - Univ Sapienza, Fac Med & Psicol, Radiat Oncolgy Unit, AOU St Andrea, I-00185 Rome, Italy -AD - IRCCS Sacro Cuore Don Calabria Hosp, Canc Care Ctr, Adv Radiat Oncol Dept, I-37024 Verona, Italy -AD - Univ Modena & Reggio Emilia, Dept Med & Surg Sci, I-41125 Modena, Italy -M2 - IRCCS Reggio Emilia -M2 - IRCCS Human Canc Ctr -M2 - IRCCS Reggio Emilia -M2 - IRCCS Reggio Emilia -Y2 - 2023-02-09 -ER - - -TY - JOUR -AU - HEYMACH, JOHN V.; Kwok Kin Wong -TI - Therapeutic approaches for LKB1-deficient non-small cell lung cancer -M3 - Awarded Grant -AB -  DESCRIPTION (provided by applicant): Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. In recent years dramatic progress has been made in tailoring therapies for subgroups of patients harboring specific genomic alterations, such as EGFR tyrosine kinase inhibitors for the 10-15% of patients bearing EGFR mutations, and through the use drugs blocking the PD-1/PD-L1 immune checkpoint pathway. Unfortunately, only a minority of patients benefit from these approaches. LKB1 (STK11) is the second most commonly altered tumor suppressor in NSCLC, and is lost in 20-30% of lung adenocarcinoma, resulting in 30,000-40,000 deaths annually. There is a major unmet need for therapeutic strategies tailored for LKB1-deficient (LD) NSCLC. Project investigators have demonstrated that LKB1 loss is associated with increased metastatic potential, chemotherapy resistance, and, more recently, with an immunosuppressed phenotype as well as resistance to checkpoint inhibitors. Given our initial findings, we hypothesize that a) LKB1 loss directly drives a distinctve immunosuppressed phenotype, and that potential underlying mechanisms include reduced antigen presentation and/or altered cytokine production; and b) therapeutic regimens can be developed to enhance the antitumor immune response and overcome resistance to checkpoint inhibition. We will test these hypotheses in the following aims. In Aim 1, we will characterize theimmunosuppressed phenotype of LD-NSCLC, by a) investigating the mechanisms underlying the LD-associated intratumor immunosuppression in preclinical models, including reduced antigen presentation and altered production of immunosuppressive cytokines such as IL-6 and VEGF; and b) comparing the immune phenotype in LD and LKB1-intact (LI) tumors from NSCLC patients. Next, in Aim 2, we will use insights gained from Aim 1 to develop more effective immunotherapy approaches, by testing a) direct and indirect cytokine suppression, b) combinations of cytokine suppression with anti-PD1, to determine whether we can overcome the LD-associated resistance to checkpoint inhibition; and c) combinations with radiotherapy (RT) and other approaches enhancing antigen presentation. Finally, in Aim 3, we will translate this work into the clinic using a recently activated randomized clinical trial testing the anti-PD- antibody pembrolizumab, alone or combined with RT in 104 NSCLC patients. This will enable us to test our preclinical observations regarding the relative resistance of LD-NSCLC to PD-1 inhibition, and determine whether RT can enhance anti-tumor immunity and overcome PD-1 inhibitor resistance in LD NSCLC patients. Clinical significance: LD-NSCLC causes more deaths than pancreatic cancer, and there are critical unmet needs for new treatment approaches and insights into its distinct biology. We have assembled a multidisciplinary team of leading investigators to tackle these needs, with deep expertise in lung cancer genomics, immunotherapy, pathology, mouse models and radiotherapy that is poised to rapidly translate discoveries directly into clinical advances for NSCLC patients. -DA - 2020 -PY - 2020 -AN - GRANTS:15032335 -G1 - 5R01CA205150-05; 9890784; R01CA205150 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Jairam, Vikram -AU - Soulos, Pamela R. -AU - Madhav, K. C. -AU - Gross, Cary P. -AU - Slotman, Ben J. -AU - Chiang, Anne C. -AU - Park, Henry S. -TI - Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex -T2 - ADVANCES IN RADIATION ONCOLOGY -M3 - Article -AB - Purpose: The landmark randomized trial on chest irradiation in extensive disease small cell lung cancer (CREST) demonstrated that consolidative thoracic radiation therapy (cTRT) improved overall (OS) and progression -free survival (PFS) after initial chemotherapy (chemo) in extensive -stage small cell lung cancer, with potentially increased benefit in women compared with men. It is unknown whether similar findings would apply after chemoimmunotherapy became the standard first -line treatment. In this analysis, we report national practice patterns and survival outcomes of cTRT according to patient sex. Methods and Materials: We included patients from de -identified electronic health record -derived database diagnosed with stage IV small cell lung cancer (2014-2021) who completed 4 to 6 cycles of first -line systemic therapy (platinum -doublet chemotherapy or chemoimmunotherapy). We evaluated OS and PFS using multivariable Cox proportional hazards regression with receipt of cTRT as an independent variable and stratified by sex. As a sensitivity analysis, we weighted the models by the inverse probability of receiving cTRT. Results: A total of 1227 patients were included (850 chemotherapy, 377 chemoimmunotherapy). There were no statistically significant differences in baseline characteristics between patients who did and did not receive cTRT. Among women, cTRT was associated with superior OS (adjusted hazard ratio [HR], 0.67; 95% CI, 0.52-0.87) and PFS (HR, 0.63; 95% CI, 0.49-0.82) compared with those not receiving cTRT. Conversely, no OS or PFS benefit with cTRT was observed in men (OS HR, 1.03; 95% CI, 0.80-1.31; PFS HR, 1.12; 95% CI, 0.85-1.47). Findings were similar in weighted analyses. Conclusions: The survival efficacy of cTRT may be moderated by sex, with female patients appearing more likely to benefit than male patients. These findings refiect sex -based survival trends with similar effect sizes to those observed in the CREST trial. Although the underpinnings of this association need to be elucidated, stratification by sex should be considered for randomized -controlled trials studying cTRT in extensive -stage small cell lung cancer. (c) 2023 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). -PU - ELSEVIER INC -PI - SAN DIEGO -PA - 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA -SN - 2452-1094 -DA - 2024 APR -PY - 2024 -VL - 9 -IS - 4 -C7 - 101413 -DO - 10.1016/j.adro.2023.101413 -AN - WOS:001273179400001 -AD - Sutter Med Grp, Dept Radiat Oncol, Sacramento, CA 95816 USA -AD - Yale Sch Med, Canc Outcomes Publ Policy & Effectiveness Res COPP, New Haven, CT USA -AD - Yale Sch Med, Dept Med, Sect Gen Internal Med, New Haven, CT USA -AD - Amsterdam Univ Med Ctr, Dept Radiat Oncol, De Boelelaan, Amsterdam, Netherlands -AD - Yale Sch Med, Dept Med, Sect Med Oncol, New Haven, CT USA -AD - Yale Sch Med, Dept Therapeut Radiol, New Haven, CT USA -M2 - Sutter Med Grp -M2 - Amsterdam Univ Med Ctr -Y2 - 2024-07-28 -ER - - -TY - JOUR -AU - Filippou, Dimitrios -AU - Kleontas, Athanasios -AU - Tentzeris, Vasilios -AU - Emmanouilides, Christos -AU - Tryfon, Stavros -AU - Baka, Sofia -AU - Filippou, Ioanna -AU - Papagiannopoulos, Kostas -TI - Extended resections for the treatment of patients with T4 stage IIIA non-small cell lung cancer (NSCLC) (T4N0-1M0) with or without cardiopulmonary bypass: a 15-year two-center experience -T2 - JOURNAL OF THORACIC DISEASE -M3 - Article -AB - Background: Stage IIIA non-small cell lung cancer (NSCLC) is a heterogeneous group of patients, often requiring variable and individualized approaches. The dilemma to operate or not frequently arises, since more than 75% of the cases of NSCLC are diagnosed in advanced stages (IIIA). The main objective of this study was to assess whether the benefits outweigh surgical risks for the T4N0-1M0 subgroup.Methods: Data from 857 patients with locally advanced T4 NSCLC were retrospectively collected from two different institutions, between 2002 and 2017. Clinical data that were retrieved and analyzed, included demographics, comorbidities, surgical details, neoadjuvant or/and adjuvant therapy and postoperative complications.Results: Twelve patients were in the cardiopulmonary bypass (CPB) group and thirty in the non-CPB. The most common types of lung cancer were squamous cell carcinoma (50.0%) and adenocarcinoma (35.7%). The most frequent invasion of the tumor was seen in main pulmonary artery and the superior vena cava. Significantly more patients of the CPB group underwent pneumonectomy as their primary lung resection (P=0.006). In all patients R0 resection was achieved according to histological reports. The overall 5-year survival was 60%, while the median overall survival was 22.5 months. Analysis revealed that patient age (P=0.027), preoperative chronic obstructive pulmonary disease (COPD) (P=0.001), tumor size (4.0 vs. 6.0 cm) (P=0.001), postoperative respiratory dysfunction (P=0.001) and postoperative atelectasis ( P=0.036) are possible independent variables that are significantly correlated with patient outcome.Conclusions: We suggest that in patients with stage IIIA/T4 NSCLC, complete resection of the T4 tumor, although challenging, can be performed in highly selected patients. Such an approach seems to result in improved long-term survival. More specific studies on this area of NSCLC probably will further enlighten this field, and may result in even better outcomes, as advanced systemic perioperative approaches such as modern chemotherapy, immunotherapy and improvements in radiation therapy have been incorporated in daily practice. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2019 DEC -PY - 2019 -VL - 11 -IS - 12 -SP - 5489 -EP - 5501 -DO - 10.21037/jtd.2019.11.33 -AN - WOS:000505050300062 -AD - European Interbalkan Med Ctr Thessaloniki, Cardiothorac Dept, Thessaloniki, Greece -AD - St James Univ Hosp, Thorac Dept, Leeds, W Yorkshire, England -AD - European Interbalkan Med Ctr Thessaloniki, Oncol Dept, Thessaloniki, Greece -AD - Papanikolaou Gen Hosp Thessaloniki, Pulmonol Dept, Thessaloniki, Greece -M2 - European Interbalkan Med Ctr Thessaloniki -M2 - European Interbalkan Med Ctr Thessaloniki -Y2 - 2020-01-14 -ER - - -TY - JOUR -AU - Nawashiro, Ayako -AU - Tanaka, Fumihiro -AU - Taira, Akihiro -AU - Shinohara, Shinji -AU - Takenaka, Masaru -AU - Kuroda, Koji -AU - Shimajiri, Shohei -TI - Salvage surgery following immuno-chemo-radiotherapy for advanced non-small cell lung cancer -T2 - SURGICAL CASE REPORTS -M3 - Article -AB - Background Salvage surgery following definitive radiotherapy or systemic treatment has become a feasible treatment option in selected patients with advanced initially unresectable non-small cell lung cancer. Recent clinical trials of neoadjuvant treatment have showed that surgery following immuno-chemotherapy is safely performed. Here, we present the first case of salvage surgery following immuno-chemotherapy with concurrent definitive radiotherapy for advanced lung large cell carcinoma. Case presentation A 44-year male was admitted to our hospital for salvage surgery. Ten months prior to this administration, he had been diagnosed with unresectable large cell carcinoma with malignant pericardial effusion (clinical stage IVA/T3N2M1A; no driver-gene alteration) originating from the right upper lobe (RUL). Due to rapid intrabronchial tumor growth causing severe dyspnea, emergency bronchial stenting in the right main bronchus using an expandable metallic stent had been performed. Thereafter, he had received immuno-chemotherapy with concurrent definitive radiotherapy. Despite dramatic radiographic response, he had suffered from persistent and refractory Pseudomonas aeruginosa lung infection associated with bronchial stent placement. As pericardial effusion had disappeared and no distant metastasis had developed, he was diagnosed with a potentially curable disease and was referred to our hospital. An extended sleeve resection was successfully performed, and pathological sections revealed that pathologic complete response was achieved with immuno-chemo-radiotherapy. The patient received no subsequent treatment, and is alive without tumor recurrence at 8 months after surgery. Conclusions Salvage surgery following immuno-chemotherapy with concurrent definitive radiotherapy for advanced non-small cell lung cancer may be feasible in selected patients, and may be considered as a treatment option to control local disease. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 2198-7793 -DA - 2022 JAN 21 -PY - 2022 -VL - 8 -IS - 1 -C7 - 17 -DO - 10.1186/s40792-022-01371-3 -AN - WOS:000745425800001 -AD - Univ Occupat & Environm Hlth, Dept Surg 2, Iseigaoka I-1, Kitakyushu, Fukuoka 8078555, Japan -AD - Univ Occupat & Environm Hlth, Sch Med, Dept Pathol, Iseigaoka I-1, Kitakyushu, Fukuoka 8078555, Japan -Y2 - 2022-01-27 -ER - - -TY - JOUR -AU - HEYMACH, JOHN V (contact); WONG, KWOK KIN -TI - Therapeutic approaches for LKB1-deficient non-small cell lung cancer -M3 - Awarded Grant -AB - PUBLIC HEALTH RELEVANCE: Therapeutic advances have been made in the treatment of subpopulations of non-small cell lung cancer (NSCLC) patients who harbor specific genomic alterations (e.g. EGFR mutation and ALK ROS gene rearrangements) which can be targeted with small molecule kinase inhibitors; however, the serine/threonine kinase STK11 (LKB1) is the second most commonly altered tumor suppressors in NSCLC, with genomic loss or inactivating mutations occurring in 20-30% of lung adenocarcinoma and there are currently no treatment strategies tailored for LKB1-deficient NSCLC. The PIs have developed preliminary data showing that in human tumor specimens and in Genetically Engineered Mouse Models of NSCLC with Lkb1 deletion that loss of LKB1 is associated with higher stage of disease at presentation, increased metastasis and poor overall prognosis as well as unique biological characteristics. This proposal will deeply characterize the distinct biology of LKB1- deficient NSCLCs with a focus on the immune microenvironment as a means to develop novel therapeutic approaches for patients with LKB1-deficient NSCLCs. -DA - 2017 -PY - 2017 -AN - GRANTS:12342961 -G1 - 5R01CA205150-02; 9252446; R01CA205150 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Jiang, Liyang -AU - Meng, Xiangjiao -AU - Zhao, Xianguang -AU - Xing, Ligang -AU - Yu, Jinming -TI - Perspective on treatment for unresectable locally advanced non-small cell lung cancer with oncogene-driven mutation: a narrative review -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - The standard treatment of unresectable locally advanced non-small cell lung cancer (LA NSCLC) is concurrent chemoradiotherapy. With the addition of immunotherapy, patients with LA NSCLC received a significantly prolonged outcome, while patients with harboring epidermal growth factor receptor (EGFR) mutation benefited less. Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of stage IV with harboring EGFR mutation and anaplastic lymphoma kinase rearrangement, but there are few recommendations indicating whether TKI treatment is effective in unresectable NSCLC. Preclinical studies have shown that TKIs could have a radiosensitizing effect, which provided a rationale to consider the application TKI with radiotherapy. In this review, we summarize the clinical studies that have used TKIs in LA-NSCLC as well as ongoing trials, and discuss recent progress in research related to the efficacy of TKI for unresectable LA NSCLC patients. Recent results of small studies evaluating TKI therapy for LA NSCLC patients in combination with radiation or chemoradiation demonstrated promising efficacy, improved outcomes with a tolerable toxicity profile. However, there is a lack of strong evidence for TKI treatment in unresectable LA NSCLC, because of unpowered statistics, lack of molecular selection, or lack of large randomized arms. We prospect the combination of TKI and radiation or chemoradiation therapy might eventually replace the current standard treatment for patients with LA NSCLC harboring oncogene-driven mutation. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2020 OCT -PY - 2020 -VL - 9 -IS - 5 -SP - 2137 -EP - 2144 -DO - 10.21037/tlcr-20-722 -AN - WOS:000582799700042 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, 440 Jiyan Rd, Jinan, Peoples R China -Y2 - 2020-11-11 -ER - - -TY - JOUR -AU - Chen, Xue -AU - Zhang, Qi -AU - Luo, Youjun -AU - Gao, Caixia -AU - Zhuang, Xibing -AU - Xu, Guoxiong -AU - Qiao, Tiankui -TI - High-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-κB signaling pathway in non-small cell lung cancer cells -T2 - ONCOTARGETS AND THERAPY -M3 - Article -AB - Objectives: Irradiation resistance appears as local recurrence and distant metastasis in advanced stages of non-small cell lung cancer (NSCLC). High-dose irradiation combined with immunotherapy improved overall survival and local control of NSCLC. This study explored the underlying molecular mechanism by which the effect of high-dose irradiation plus toll-like receptor 9 (TLR9) agonist CpG oligodeoxynucleotide (CpG ODN) 7909 on NSCLC.Materials and methods: NSCLC H460 cells were exposed to constant high-dose irradiation (6.37 Gy) in irradiation (IR) group and the irradiation plus CpG group. Gene expression was assessed using quantitative reverse transcriptase-polymerase chain reaction and Western blot. Knockdown of nuclear factor kappa B (NF-kappa B) p65 expression was conducted using p65 siRNA.Results: Expression of programmed death-ligand 1 (PD-L1) mRNA was significantly decreased in IR combined with CpG ODN 7909 group compared with the control or IR-alone groups (P<0.05). TLR9 expression was also obviously increased in the combination group compared with the control (P<0.05). Moreover, expression of NF-kappa B p65 was apparently reduced in the combination group compared with the control (P<0.05). However, expression of PD-L1 was significantly decreased after knockdown of p65 in IR group (P<0.05), but increased in the combination group (P<0.05) and slightly increased in CpG ODN-alone group (P<0.05), which was opposite to that without p65 knockdown group.Conclusion: This study demonstrated that radiotherapy combined with CpG ODN 7909 was able to downregulate PD-L1 expression through inhibition via the NF-kappa B signaling pathway. -PU - DOVE MEDICAL PRESS LTD -PI - ALBANY -PA - PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND -SN - 1178-6930 -DA - 2016 -PY - 2016 -VL - 9 -SP - 6511 -EP - 6518 -DO - 10.2147/OTT.S116629 -AN - WOS:000385978200001 -AD - Fudan Univ, Jinshan Hosp, Dept Oncol, Med Ctr, 1508 Longhang Rd, Shanghai 201500, Peoples R China -AD - Fudan Univ, Jinshan Hosp, Dept Ctr Lab, Shanghai, Peoples R China -Y2 - 2016-11-09 -ER - - -TY - JOUR -AU - HEYMACH, JOHN V.; Kwok Kin Wong -TI - Therapeutic approaches for LKB1-deficient non-small cell lung cancer -M3 - Awarded Grant -AB -  DESCRIPTION (provided by applicant): Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. In recent years dramatic progress has been made in tailoring therapies for subgroups of patients harboring specific genomic alterations, such as EGFR tyrosine kinase inhibitors for the 10-15% of patients bearing EGFR mutations, and through the use drugs blocking the PD-1/PD-L1 immune checkpoint pathway. Unfortunately, only a minority of patients benefit from these approaches. LKB1 (STK11) is the second most commonly altered tumor suppressor in NSCLC, and is lost in 20-30% of lung adenocarcinoma, resulting in 30,000-40,000 deaths annually. There is a major unmet need for therapeutic strategies tailored for LKB1-deficient (LD) NSCLC. Project investigators have demonstrated that LKB1 loss is associated with increased metastatic potential, chemotherapy resistance, and, more recently, with an immunosuppressed phenotype as well as resistance to checkpoint inhibitors. Given our initial findings, we hypothesize that a) LKB1 loss directly drives a distinctve immunosuppressed phenotype, and that potential underlying mechanisms include reduced antigen presentation and/or altered cytokine production; and b) therapeutic regimens can be developed to enhance the antitumor immune response and overcome resistance to checkpoint inhibition. We will test these hypotheses in the following aims. In Aim 1, we will characterize theimmunosuppressed phenotype of LD-NSCLC, by a) investigating the mechanisms underlying the LD-associated intratumor immunosuppression in preclinical models, including reduced antigen presentation and altered production of immunosuppressive cytokines such as IL-6 and VEGF; and b) comparing the immune phenotype in LD and LKB1-intact (LI) tumors from NSCLC patients. Next, in Aim 2, we will use insights gained from Aim 1 to develop more effective immunotherapy approaches, by testing a) direct and indirect cytokine suppression, b) combinations of cytokine suppression with anti-PD1, to determine whether we can overcome the LD-associated resistance to checkpoint inhibition; and c) combinations with radiotherapy (RT) and other approaches enhancing antigen presentation. Finally, in Aim 3, we will translate this work into the clinic using a recently activated randomized clinical trial testing the anti-PD- antibody pembrolizumab, alone or combined with RT in 104 NSCLC patients. This will enable us to test our preclinical observations regarding the relative resistance of LD-NSCLC to PD-1 inhibition, and determine whether RT can enhance anti-tumor immunity and overcome PD-1 inhibitor resistance in LD NSCLC patients. Clinical significance: LD-NSCLC causes more deaths than pancreatic cancer, and there are critical unmet needs for new treatment approaches and insights into its distinct biology. We have assembled a multidisciplinary team of leading investigators to tackle these needs, with deep expertise in lung cancer genomics, immunotherapy, pathology, mouse models and radiotherapy that is poised to rapidly translate discoveries directly into clinical advances for NSCLC patients. -DA - 2019 -PY - 2019 -AN - GRANTS:11052023 -G1 - 5R01CA205150-04; 9671847; R01CA205150 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Jun, Soyeong -AU - Shukla, Nikhil A -AU - Durm, Greg -AU - Hui, Angela B -AU - Cao, Sha -AU - Ganti, Apar Kishor -AU - Jabbour, Salma K -AU - Kunder, Christian -AU - Alizadeh, Ash A -AU - Hanna, Nasser H -AU - Diehn, Maximilian -TI - Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC. -T2 - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer -M3 - Journal Article -M3 - Clinical Trial, Phase II -AB - INTRODUCTION: The current standard of care for patients with inoperable stage III non-small cell lung cancer includes chemoradiotherapy (CRT) followed by 1 year of checkpoint inhibitor (CPI) therapy. Nevertheless, the optimal duration of consolidation CPI remains unknown. Here, we characterized the relationship between circulating tumor DNA (ctDNA) minimal residual disease (MRD) and clinical outcomes of patients with unresectable locally advanced non-small cell lung cancer treated on a phase 2 trial of short-course consolidation immunotherapy after CRT, with the goal of testing whether ctDNA may be able toidentify patients who do not require a full year of treatment.METHODS: Plasma samples for ctDNA analysis were collected from patients on the Big Ten Cancer Research Consortium LUN 16-081 trial after completion of CRT, before day 1 of cycle 2 (C2D1) of CPI (i.e., 1 mo after treatment start), and at the end of up to 6 months of treatment. Tumor-informed ctDNA MRD analysis was performed using cancer personalized profiling by deep sequencing. Levels of ctDNA at each time point were correlated with clinical outcomes.RESULTS: Detection of ctDNA predicted significantly inferior progression-free survival after completion of CRT (24-mo 29% versus 65%, p= 0.0048), before C2D1 of CPI (24-mo 0% versus 72%, p < 0.0001) and at the end of CPI (24-mo 15% versus 67%, p= 0.0011). In addition, patients with decreasing or undetectable ctDNA levels after 1 cycle of CPI had improved outcomes compared with patients with increasing ctDNA levels (24-mo progression-free survival 72% versus 0%, p < 0.0001). Progression of disease occurred within less than 12 months of starting CPI in all patients with increasing ctDNA levels at C2D1.CONCLUSIONS: Detection of ctDNA before, during, or after 6 months of consolidation CPI is strongly associated with inferior outcomes. Our findings suggest that analysis of ctDNA MRD may enable personalizing the duration of consolidation immunotherapy treatment. -SN - 1556-1380 -DA - 2024 Oct (Epub 2024 Jul 05) -PY - 2024 -VL - 19 -IS - 10 -SP - 1427 -EP - 1437 -DO - 10.1016/j.jtho.2024.06.024 -AN - MEDLINE:38971369 -AD - Department of Radiation Oncology, Stanford University, Stanford, California; Stanford Cancer Institute, Stanford University, Stanford, California. -AD - Community Hospital Oncology Physicians, Community Health Network MD Anderson Comprehensive Cancer Center, Indianapolis, Indiana. -AD - Division of Hematology/Oncology, IU Simon Comprehensive Cancer Center, Indianapolis, Indiana. -AD - Division of Oncology-Hematology, Department of Internal Medicine, VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska. -AD - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey. -AD - Department of Pathology, Stanford University, Stanford, California. -AD - Stanford Cancer Institute, Stanford University, Stanford, California; Division of Oncology, Department of Medicine, Stanford University, Stanford, California; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California. -AD - Department of Radiation Oncology, Stanford University, Stanford, California; Stanford Cancer Institute, Stanford University, Stanford, California; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California. Electronic address: diehn@stanford.edu. -Y2 - 2024-07-08 -ER - - -TY - JOUR -AU - Rieken, Stefan -AU - Braulke, Friederike -AU - Kuon, Jonas -TI - Challenges to multimodal treatment of elderly patients with lung cancer -T2 - ONKOLOGIE -M3 - Review -AB - Despite continuous improvements in early detection and interdisciplinary treatment approaches, locally advanced non-small cell lung cancer (NSCLC) continues to have a high incidence and dismal prognosis. It is commonly diagnosed in elderly patients, in whom frailty and comorbidities may challenge the feasibility of intensified multimodality treatment. Rather than chronological age, comorbidities should be considered in the design and realization of the recommended treatments. Dose- and substance-adapted chemotherapies and precisely planned and administered radiotherapy may offer attractive treatment options. Genomic analyses should always be performed, as a relevant number of patients may benefit from the commonly less toxic tyrosine or checkpoint inhibitors. Such personalized and interdisciplinary therapies have been shown to be both feasible and highly effective in an aging lung cancer population. -PU - SPRINGER HEIDELBERG -PI - HEIDELBERG -PA - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY -SN - 2731-7226 -SN - 2731-7234 -DA - 2024 FEB -PY - 2024 -VL - 30 -IS - 2 -SP - 113 -EP - 118 -DO - 10.1007/s00761-023-01461-3 -AN - WOS:001222308900005 -AD - UMG, Comprehensive Canc Ctr Gottingen G CCC, Klin & Poliklin Strahlentherapie & Radioonkol, Robert Koch Str 40, D-37075 Gottingen, Germany -AD - Univ Med Gottingen, Comprehensive Canc Ctr Gottingen G CCC, Gottingen, Germany -AD - SLK Fachklin Lowenstein, Klin Thorakale Onkol & Palliat Med, Lowenstein, Germany -M2 - SLK Fachklin Lowenstein -Y2 - 2024-05-22 -ER - - -TY - JOUR -AU - Farwell, Michael D. -AU - Gamache, Raymond F. -AU - Babazada, Hasan -AU - Hellmann, Matthew D. -AU - Harding, James J. -AU - Korn, Ron -AU - Mascioni, Alessandro -AU - Le, William -AU - Wilson, Ian -AU - Gordon, Michael S. -AU - Wu, Anna M. -AU - Ulaner, Gary A. -AU - Wolchok, Jedd D. -AU - Postow, Michael A. -AU - Pandit-Taskar, Neeta -TI - CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody -T2 - JOURNAL OF NUCLEAR MEDICINE -M3 - Article -AB - There is a need for in vivo diagnostic imaging probes that can noninvasively measure tumor-infiltrating CD8+ leukocytes. Such imaging probes could be used to predict early response to cancer immunotherapy, help select effective single or combination immunotherapies, and facilitate the development of new immunotherapies or immunotherapy combinations. This study was designed to optimize conditions for performing CD8 PET imaging with Zr-89-Df-IAB22M2C and determine whether CD8 PET imaging could provide a safe and effective noninvasive method of visualizing the whole-body biodistribution of CD8+ leukocytes. Methods: We conducted a phase 1 first-in humans PET imaging study using an anti-CD8 radiolabeled minibody, Zr-89-Df-IAB22M2C, to detect whole-body and tumor CD8+ leukocyte distribution in patients with metastatic solid tumors. Patients received 111 MBq of Zr-89-Df-IAB22M2C followed by serial PET scanning over 5-7 d. A 2-stage design included a dose-escalation phase and a dose-expansion phase. Biodistribution, radiation dosimetry, and semiquantitative evaluation of Zr-89-Df-IAB22M2C uptake were performed in all patients. Results: Fifteen subjects with metastatic melanoma, non-small cell lung cancer, and hepatocellular carcinoma were enrolled. No drug-related adverse events or abnormal laboratory results were noted except for a transient increase in antidrug antibodies in 1 subject. Zr-89-Df-IAB22M2C accumulated in tumors and CD8rich tissues (e.g., spleen, bone marrow, nodes), with maximum uptake at 24-48 h after injection and low background activity in CD8-poor tissues (e.g., muscle and lung). Radiotracer uptake in tumors was noted in 10 of 15 subjects, including 7 of 8 subjects on immunotherapy, 1 of 2 subjects on targeted therapy, and 2 of 5 treatment-naive subjects. In 3 patients with advanced melanoma or hepatocellular carcinoma on immunotherapy, posttreatment CD8 PET/CT scans demonstrated increased 89Zr-Df-IAB22M2C uptake in tumor lesions, which correlated with response. Conclusion: CD8 PET imaging with Zr-89-Df-IAB22M2C is safe and has the potential to visualize the whole-body biodistribution of CD8+ leukocytes in tumors and reference tissues, and may predict early response to immunotherapy. -PU - SOC NUCLEAR MEDICINE INC -PI - RESTON -PA - 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA -SN - 0161-5505 -SN - 1535-5667 -DA - 2022 MAY 1 -PY - 2022 -VL - 63 -IS - 5 -SP - 720 -EP - 726 -DO - 10.2967/jnumed.121.262485 -AN - WOS:000792496500015 -AD - Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA -AD - Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA -AD - Mem Sloan Kettering Canc Ctr, Parker Inst Canc Immunotherapy, 1275 York Ave, New York, NY 10021 USA -AD - Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA -AD - Weill Cornell Med Coll, Dept Med, New York, NY USA -AD - Imaging Endpoints, Scottsdale, AZ USA -AD - ImaginAb Inc, Inglewood, CA USA -AD - HonorHlth Res Inst, Scottsdale, AZ USA -AD - Beckman Res Inst City Hope, Dept Mol Imaging & Therapy, Duarte, CA USA -AD - Hoag Family Canc Inst, Mol Imaging & Therapy, Newport Beach, CA USA -AD - Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA -AD - Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA -AD - Weill Cornell Med Coll, Dept Radiol, New York, NY USA -M2 - Imaging Endpoints -M2 - ImaginAb Inc -M2 - HonorHlth Res Inst -M2 - Hoag Family Canc Inst -Y2 - 2022-05-30 -ER - - -TY - JOUR -AU - Diamond, Brett H. -AU - Verma, Nipun -AU - Shukla, Utkarsh C. -AU - Park, Henry S. -AU - Koffer, Paul P. -TI - Consolidative Thoracic Radiation Therapy After First-Line Chemotherapy and Immunotherapy in Extensive-Stage Small Cell Lung Cancer: A Multi-Institutional Case Series -T2 - ADVANCES IN RADIATION ONCOLOGY -M3 - Article -AB - Purpose: Survival for patients with extensive-stage small cell lung cancer (ES-SCLC) remains poor. Consolidative thoracic radiation therapy (cTRT) and upfront immunotherapy with chemotherapy have each incrementally improved patient outcomes, but have not yet been combined in clinical trials. We sought to characterize outcomes and toxicities after first-line chemotherapy and immunotherapy followed by cTRT.& nbsp;Methods and Materials: Patients with ES-SCLC who were treated with first-line chemotherapy and immunotherapy followed by cTRT were identified at 2 institutions. Patient outcomes including overall survival (OS), progression-free survival, local progression free survival, distant progression free-survival, and toxicity were assessed.& nbsp;Results: Twenty patients were included in our data set treated from 2018 to 2021 with a median follow-up of 12 months. Median OS in this cohort was 16 months with 6-month OS of 94.7% and 12-month OS of 77.5% (comparable to historical controls). There were also low rates of toxicity, including 0% grade 3+ toxicity, 0% grade 2 pneumonitis, and 5% grade 2 esophagitis.& nbsp;Conclusions: Treatment of ES-SCLC with first-line chemoimmunotherapy followed by cTRT appears to be safe and to have outcomes comparable to published modern clinical trials. Further studies are warranted to determine the therapeutic effect of cTRT after chemoimmunotherapy. (C)& nbsp;2021 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.& nbsp;& nbsp; -PU - ELSEVIER INC -PI - SAN DIEGO -PA - 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA -SN - 2452-1094 -DA - 2022 MAR-APR -PY - 2022 -VL - 7 -IS - 2 -C7 - 100883 -DO - 10.1016/j.adro.2021.100883 -AN - WOS:000797914200027 -C6 - FEB 2022 -AD - Tufts Med Ctr, Dept Radiat Oncol, Boston, MA USA -AD - Rhode Isl Hosp, Dept Radiat Oncol, Providence, RI USA -AD - Yale Sch Med, Dept Therapeut Radiol, New Haven, CT USA -Y2 - 2022-06-09 -ER - - -TY - JOUR -AU - Kumar, Sameera -AU - Chmura, Steven -AU - Robinson, Clifford -AU - Lin, Steven H. -AU - Gadgeel, Shirish M. -AU - Donington, Jessica -AU - Feliciano, Josephine -AU - Stinchcombe, Thomas E. -AU - Werner-Wasik, Maria -AU - Edelman, Martin J. -AU - Moghanaki, Drew -TI - Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic -T2 - JOURNAL OF THORACIC ONCOLOGY -M3 - Review -AB - The coronavirus disease 2019 (COVID-19) pandemic is currently accelerating. Patients with locally advanced NSCLC (LA-NSCLC) may require treatment in locations where resources are limited, and the prevalence of infection is high. Patients with LA-NSCLC frequently present with comorbidities that increase the risk of severe morbidity and mortality from COVID-19. These risks may be further increased by treatments for LA-NSCLC. Although guiding data is scarce, we present an expert thoracic oncology multidisciplinary (radiation oncology, medical oncology, surgical oncology) consensus of alternative strategies for the treatment of LA-NSCLC during a pandemic. The over-arching goals of these approaches are the following: (1) reduce the number of visits to a health care facility, (2) reduce the risk of exposure to severe acute respiratory syndrome-coronavirus-2, (3) attenuate the immunocom-promising effects of lung cancer therapies, and (4) provide effective oncologic therapy. Patients with resectable disease can be treated with de finitive nonoperative management if surgical resources are limited or the risks of perioperative care are high. Nonoperative options include chemotherapy, chemoimmunotherapy, and radiation therapy with sequential schedules that may or may not affect long-term outcomes in an era in which immunotherapy is available. The order of treatments may be on the basis of patient factors and clinical resources. Whenever radiation therapy is delivered without concurrent chemotherapy, hypo-fractionated schedules are appropriate. For patients who are con firmed to have COVID-19, usually, cancer therapies may be withheld until symptoms have resolved with negative viral test results. The risk of severe treatment-related morbidity and mortality is increased for patients undergoing treatment for LA-NSCLC during the COVID-19 pandemic. Adapting alternative treatment stra-tegies as quickly as possible may save lives and should be implemented through communication with the multidisci-plinary cancer team. (C) 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1556-0864 -SN - 1556-1380 -DA - 2020 JUL -PY - 2020 -VL - 15 -IS - 7 -SP - 1137 -EP - 1146 -DO - 10.1016/j.jtho.2020.04.016 -AN - WOS:000550279700021 -AD - Fox Chase Canc Ctr, Dept Radiat Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA -AD - Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA -AD - Washington Univ, Dept Radiat Oncol, St Louis, MO 63110 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA -AD - Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA -AD - Univ Chicago, Dept Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA -AD - Johns Hopkins Univ, Dept Med Oncol, Baltimore, MD USA -AD - Duke Univ, Dept Med Oncol, Durham, NC USA -AD - Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA -AD - Fox Chase Canc Ctr, Dept Hematol & Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA -AD - Emory Univ, Atlanta Vet Affairs Hlth Care Syst, Dept Radiat Oncol, Atlanta, GA 30322 USA -Y2 - 2020-07-01 -ER - - -TY - JOUR -AU - Chen, Hanxiao -AU - Ma, Xiangjuan -AU - Liu, Jie -AU - Yang, Yu -AU - Fang, Yong -AU - Wang, Liping -AU - Fang, Jian -AU - Zhao, Jun -AU - Zhuo, Minglei -TI - Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer: A real-world, multicenter, retrospective, controlled study in China -T2 - CHINESE JOURNAL OF CANCER RESEARCH -M3 - Article -AB - Objective: Atezolizumab along with chemotherapy has prolonged the survival of patients with extensive-stage small-cell lung cancer (ES-SCLC) worldwide, although real-world (RW) data are lacking in China. This study was designed to evaluate the efficacy and clinical outcomes of atezolizumab plus etoposide/platinum (EP). Methods: Data obtained in this retrospective study were captured from six oncology units of five medical facilities from January 2019 to April 2022. For first-line treatments, atezolizumab combined with EP vs. EP alone, we primarily evaluated progression-free survival (PFS); other efficacy indicators, including overall survival (OS), objective response rate (ORR), and patterns of SCLC progression and adverse events (AEs) were assessed. Results: The primary analysis included data from 225 patients, of whom 133 received EP along with atezolizumab (atezolizumab group) and 92 received EP alone (EP group). The PFS duration of the atezolizumab group [7.10 months; 95% confidence interval (95% CI), 6.53-9.00] exceeded that of the EP group (6.50 months; 95% CI, 4.83-7.53). Overall, the hazard ratio (HR) was 0.69 (95% CI, 0.49-0.97) (P=0.029); particularly, the HR was 0.54 (95% CI, 0.36-0.80) among patients undergoing >= 4 chemotherapy cycles and 0.33 (95% CI, 0.20-0.56) among individuals with atezolizumab maintenance. The ORR and disease-control rate (DCR) were similar between the two groups. Because of incomplete OS data, the median OS was not determined for either group. Bone marrow suppression was the most common AE detected (58.6%) in the atezolizumab group. Immune-related AEs occurred in 19 patients in the atezolizumab group (14.3%), with only one case of grade 3 encephalitis. Conclusions: This RW study in China demonstrated improved clinical outcomes of atezolizumab along with EP for ES-SCLC, particularly in the chemosensitive population. These results align with the results of the the of this treatment on OS warrants additional studies. -PU - CHINESE JOURNAL CANCER RESEARCH CO -PI - BEIJING -PA - LTD PEKING U CANCER HOSP & INST, NO 52, FUCHENG RD, HAIDIAN, BEIJING, 100142, PEOPLES R CHINA -SN - 1000-9604 -SN - 1993-0631 -DA - 2022 AUG -PY - 2022 -VL - 34 -IS - 4 -SP - 353 -EP - + -DO - 10.21147/j.issn.1000-9604.2022.04.04 -AN - WOS:000854554600004 -AD - Peking Univ, Canc Hosp & Inst, Dept Thorac Oncol 1, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China -AD - Peking Univ, Canc Hosp & Inst, Dept Thorac Oncol 2, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Pneumol, Jinan 250117, Peoples R China -AD - Harbin Med Univ, Affiliated Hosp 2, Dept Oncol, Harbin 150001, Peoples R China -AD - Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Oncol, Hangzhou 310020, Peoples R China -AD - Baotou Canc Hosp, Dept Oncol, Baotou 014030, Peoples R China -AD - Peking Univ, Canc Hosp & Inst, Dept Thorac Oncol 2, Key Lab Carcinogenesis & Translat Res,Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China -AD - Peking Univ, Canc Hosp & Inst, Dept Thorac Oncol 1, Key Lab Carcinogenesis & Translat Res,Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China -M2 - Baotou Canc Hosp -Y2 - 2022-09-23 -ER - - -TY - JOUR -AU - SCHRUMP, DAVID -TI - Epigenetic Therapy for Thoracic Malignancies -M3 - Awarded Grant -AB - Our published studies pertaining to laboratory experiments and our related clinical protocols have clearly demonstrated that Decitabine and romidepsin alone or in combination can modulate gene expression in thoracic malignancies and induce immune responses against these neoplasms. Our goal has always been to couple epigenetic priming regimens with adoptive immunotherapy for thoracic malignancies. Presently, poor biodistribution and systemic toxicities prevent optimal, chronic administration of epigenetic agents necessary to reprogram thoracic malignancies. To overcome these limitations, we formulated DAC and tetrahydrouridine (a potent, non-toxic inhibitor of cytidine deaminase) for oral administration in collaboration with the Cleveland Clinic. A phase I/II study of oral DAC/THU and pembrolizumab for patients with inoperable NSCLC, esophageal cancers, or malignant pleural mesotheliomas was initialed in late 2017, but was closed this year due to drug stability issues. This was unfortunate as virtually all patients had exhibited evidence of systemic epigenetic reprogramming, and impressive, near complete and durable responses were observed in several patients. To further optimize epigenetic priming of pulmonary malignancies for immune checkpoint blockade while decreasing potential systemic toxicities, we recently initiated preclinical studies to examine the pharmacokinetics and potential efficacy of azacytidine (AZA) administered by aerosolization techniques. We have developed a unique immunocompetent murine pulmonary metastasis model using cancer stem cells isolated from highly lethal syngeneic lung cancer and sarcoma cell lines for systematic, rational evaluation of DNA demethylating agents, LSD1 inhibitors, and cytokines such as IL-12. A phase I/II clinical protocol trial to examine the toxicities and potential efficacy of AZA administered via inhalation techniques in combination with durvalumab as induction therapy for patients with operable NSCLC is presently undergoing FDA review. This trial is intended to establish the paradigm for evaluation of a series of aerosolized epigenetic agents alone or in combination with adoptive immunotherapy for the treatment of locally advanced pulmonary malignancies. No such clinical efforts are currently underway elsewhere in the world. Results of our preclinical and translational research efforts were presented as a formal plenary session talk at the Annual Meeting of the AACR in 2023. Cancer-germline antigens comprise a group of shared tumor antigens that are only expressed in cancers arising from somatic cells or immune-privileged sites such as testes, ovary, or placenta. As such, cancer-germline antigens have emerged as highly attractive targets for cancer immunotherapy. Although cancer-germline antigens are expressed in a variety of human malignancies, immune responses to these proteins are uncommon in thoracic oncology patients due to low level, heterogeneous antigen expression, deficient antigen processing/presentation, and local as well as systemic immunosuppression. Our published studies from cell lines and patient biopsies have demonstrated that thoracic malignancies exhibit diverse patterns of CTA expression and heterogeneous responses to epigenetic regimens that up-regulate these proteins. A strategy to overcome these limitations is to immunize patients against a panel of CTAs that potentially can be upregulated by systemic administration of chromatin remodeling agents. Following positive results of a phase 2.5 First-in-Human trial evaluating the use of a cancer cell lysate vaccine as adjuvant therapy in patients with primary thoracic malignancies or tumors metastatic to the lungs, we have written two new protocols using this lysate vaccine (which was developed in our lab) as adjuvant therapy for patients with lung or esophageal cancers. The lung cancer protocol will evaluate the lysate vaccine in combination with the IL-15 super-agonist N-803 as post-operative adjuvant therapy, while the esophageal cancer protocol will evaluate the lysate in combination with the HDAC inhibitor, entinostat, and the immune checkpoint inhibitor, nivolumab following chemo-radiation +/- surgery. Both protocols have been approved by the FDA and NIH IRB and are expected to be open for patient accrual in early Q1 of FY24. -DA - 2023 -PY - 2023 -AN - GRANTS:17767689 -G1 - 10926579; 1ZIASC010093-27; ZIASC010093 -AD - CLINICAL SCIENCES -M2 - CLINICAL SCIENCES -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - SONDAK, VERNON K. -TI - SWOG Institutional Grant -M3 - Awarded Grant -DA - 2008 -PY - 2008 -AN - GRANTS:11632829 -G1 - 5U10CA073590-12; 7404450; U10CA073590 -AD - H. LEE MOFFITT CANCER CTR &RES INST -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Lott, Anthony -AU - Butler, Marcus -AU - Leigh, Natasha -AU - Cserti-Cazdewich, Christine M. -TI - Evan's Syndrome Associated with Pembrolizumab Therapy in Metastatic Non-Small Cell Lung Cancer -T2 - BLOOD -M3 - Meeting Abstract -CP - 57th Annual Meetings and Exposition of the American-Society-of-Hematology -CL - Orlando, FL -PU - AMER SOC HEMATOLOGY -PI - WASHINGTON -PA - 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA -SN - 0006-4971 -SN - 1528-0020 -DA - 2015 DEC 3 -PY - 2015 -VL - 126 -IS - 23 -DO - 10.1182/blood.V126.23.4543.4543 -AN - WOS:000368021802168 -AD - Univ Toronto, Toronto, ON, Canada -AD - Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada -AD - Univ Hlth Network, Div Hematol Med Oncol, Dept Med, Toronto, ON, Canada -Y2 - 2015-12-03 -ER - - -TY - JOUR -AU - Choi, Juwhan -AU - Lee, Jeong Eun -AU - Choi, Chang-Min -AU - Oh, In-Jae -AU - Lee, Kye Young -AU - Jang, Tae Won -AU - Lee, Seung Hyeun -AU - Kim, Eun Young -AU - Park, Dong Won -AU - Park, Sun Hyo -AU - Lee, Sung Yong -TI - A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial) -T2 - THORACIC CANCER -M3 - Article -AB - Introduction The PACIFIC study demonstrated that durvalumab consolidation therapy significantly improved progression-free survival (PFS) and overall survival (OS) in patients with unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT). However, there was no clinical benefit in both PFS and OS in epidermal growth factor receptor (EGFR) mutation-positive patient groups in a post hoc exploratory analysis. Moreover, the clinical effects of immune checkpoint inhibitors (ICIs) in EGFR mutation-positive stage IV NSCLC were demonstrated to be poor. Personalized treatment according to the mutation status is also required in stage III NSCLC. Lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is newly developed and approved for use in Korea. Methods This prospective, open, single-arm, multicenter, phase II clinical trial aims to evaluate the efficacy and safety of lazertinib as a consolidative therapy after CCRT treatment in unresectable, EGFR mutation-positive NSCLC stage III patients. The primary endpoint of this study is PFS, and the secondary endpoints are OS, objective response rate (ORR), duration of response (DoR), time to death or distant metastasis (TTDM), and safety profiles. Discussion Our study may extend the indications for third-generation EGFR-TKIs to treat patients with stage III NSCLC. Moreover, using this drug to treat stage III NSCLC would emphasize the value of mutation analysis and personalized medicine. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1759-7706 -SN - 1759-7714 -DA - 2022 DEC -PY - 2022 -VL - 13 -IS - 23 -SP - 3431 -EP - 3435 -DO - 10.1111/1759-7714.14663 -AN - WOS:000871353900001 -C6 - OCT 2022 -AD - Korea Univ, Coll Med, Dept Internal Med, Div Pulm Allergy & Crit Care Med,Guro Hosp, 148 Gurodong Ro, Seoul 08308, South Korea -AD - Chungnam Natl Univ, Coll Med, Dept Internal Med, Div Pulmonol, Daejeon, South Korea -AD - Univ Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea -AD - Chonnam Natl Univ, Dept Internal Med, Med Sch, Hwasun, South Korea -AD - Hwasun Hosp, Hwasun, South Korea -AD - Konkuk Univ, Dept Pulm Med, Sch Med, Seoul, South Korea -AD - Kosin Univ, Dept Internal Med, Med Coll, Pusan, South Korea -AD - Kyung Hee Univ, Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med,Coll Med, Seoul, South Korea -AD - Yonsei Univ, Severance Hosp, Dept Internal Med, Div Pulmonol,Coll Med, Seoul, South Korea -AD - Hanyang Univ, Dept Internal Med, Coll Med, Hanyang Univ Hosp, Seoul, South Korea -AD - Keimyung Univ, Sch Med, Resp Ctr, Div Pulmonol,Dongsan Hosp, Daegu, South Korea -M2 - Hwasun Hosp -M2 - Kosin Univ -Y2 - 2022-10-31 -ER - - -TY - JOUR -AU - Takenaka, Masaru -AU - Kuroda, Koji -AU - Tanaka, Fumihiro -TI - Adjuvant and neo-adjuvant therapy for non-small cell lung cancer without EGFR mutations or ALK rearrangements -T2 - INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY -M3 - Review -M3 - Early Access -AB - Surgical resection is the most effective therapeutic option for the cure in early stage resectable non-small-cell lung cancer (NSCLC). However, despite complete resection, up to 70% of patients die within 5 years mainly due to tumor recurrence in extra-thoracic organs. Adjuvant or neoadjuvant platinum-based chemotherapy may improve postoperative survival, but the absolute survival benefit is modest with an around 5% improvement at 5 years. Recent advance in systemic therapy has changed treatment strategy for advanced unresectable NSCLC, and also has provided a paradigm shift in treatment strategy for resectable NSCLC. For NSCLC without oncogenic driver alterations, immunotherapy using immune-checkpoint inhibitors may improve clinical outcomes in preoperative neoadjuvant setting as well as in postoperative adjuvant setting. Here, we overview recent evidence of adjuvant and neoadjuvant therapy and discuss emerging clinical questions in decision-making of treatment for potentially resectable patients with NSCLC harboring no oncogenic alterations. -PU - SPRINGER JAPAN KK -PI - TOKYO -PA - SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN -SN - 1341-9625 -SN - 1437-7772 -DA - 2024 JAN 28 -PY - 2024 -DO - 10.1007/s10147-023-02459-y -AN - WOS:001151683500001 -C6 - JAN 2024 -AD - Univ Occupat & Environm Hlth, Dept Surg Chest Surg 2, Iseigaoka 1-1,Yahata Nishi Ku, Kitakyushu 8078555, Japan -Y2 - 2024-02-05 -ER - - -TY - JOUR -AU - Aly, Zarmeneh -AU - Peereboom, David M. -TI - Combination of Radiotherapy and Targeted Agents in Brain Metastasis: An Update -T2 - CURRENT TREATMENT OPTIONS IN NEUROLOGY -M3 - Review -AB - The combination of radiation therapy and targeted agents (molecular inhibitors or immunotherapy) represents an opportunity to improve the outcomes of patients with brain metastases. The combination of whole-brain radiation therapy (WBRT) with targeted agents takes advantage of radiosensitization, while the combination with stereotactic radiosurgery (SRS) may allow one to substitute an effective systemic agent for adjuvant WBRT, the historical standard of care. This strategy may in turn allow the promotion of secondary prevention paradigms with possibly less cognitive toxicity. At present, the combination of targeted therapy with SRS rather than with WBRT is the more viable option although both avenues will likely have a role in the future management of brain metastases. Patients should be encouraged to enter clinical trials since the off-study use of these combinations will delay the advancement of the field. Caution is advised in the combination of radiation and targeted agents as unexpected toxicities can occur. Clinicians should avail themselves of clinical trials in order to offer patients these promising options and to move the field forward. In the absence of a clinical trial, we recommend the combination of SRS with targeted agents and deferred WBRT. Small, asymptomatic brain metastases may be best managed with single-modality targeted agents with deferred radiation therapy, preferably on a clinical trial. Advances in targeted therapies combined with radiation therapy will most likely improve local control and hopefully the quality of life and survival of patients with brain metastasis. -PU - CURRENT MEDICINE GROUP -PI - PHILADELPHIA -PA - 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA -SN - 1092-8480 -SN - 1534-3138 -DA - 2016 JUL -PY - 2016 -VL - 18 -IS - 7 -C7 - 32 -DO - 10.1007/s11940-016-0416-3 -AN - WOS:000379012600004 -AD - Cleveland Clin, Lerner Coll Med, Rose Ella Burkhardt Brain Tumor & Neurooncol Ctr, 9500 Euclid Ave R35, Cleveland, OH 44195 USA -Y2 - 2016-07-01 -ER - - -TY - JOUR -AU - Pellerino, Alessia -AU - Bruno, Francesco -AU - Ruda, Roberta -AU - Soffietti, Riccardo -TI - Systemic Therapy for Lung Cancer Brain Metastases -T2 - CURRENT TREATMENT OPTIONS IN ONCOLOGY -M3 - Review -AB - Opinion statement Systemic therapy for brain metastases (BM) is quickly moving from conventional cytotoxic chemotherapy toward targeted therapies, that allow a disruption of driver molecular pathways. The discovery of actionable driver mutations has led to the development of an impressive number of tyrosine kinase inhibitors (TKIs), that target the epidermal growth factor receptor (EGFR) mutations, anaplastic-lymphoma-kinase (ALK) rearrangements, and other rare molecular alterations in patients bearing metastatic non-small cell lung cancer (NSCLC) in the brain, with remarkable results in terms of intracranial disease control and overall survival. Moreover, these drugs may delay the use of local therapies, such as stereotactic radiosurgery (SRS) or whole-brain radiotherapy (WBRT). New drugs with higher molecular specificity and ability to cross the CNS barriers (BBB, BTB and blood-CSF) are being developed. Two major issues are related to targeted therapies. First, the emergence of a resistance is a common event, and a deeper understanding of molecular pathways that are involved is critical for the successful development of effective new targeted agents. Second, an early detection of tumor progression is of utmost importance to avoid the prolongation of an ineffective therapy while changing to another drug. In order to monitor over time the treatment to targeted therapies, liquid biopsy, that allows the detection in biofluids of either circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) or exosomes, is increasingly employed in clinical trials: with respect to BM the monitoring of both blood and CSF is necessary. Also, radiomics is being developed to predict the mutational status of the BM on MRI. For patients without druggable mutations or who do not respond to targeted agents, immunotherapy with checkpoint inhibitors is increasingly employed, alone or in combination with radiotherapy. Pseudoprogression after immunotherapy alone maybe a challenge for several months after the start of treatment, and the same is true for radionecrosis after the combination of immunotherapy and SRS. In this regard, the value of advanced MRI techniques and PET imaging for a better distinction of pseudoprogression/radionecrosis and true tumor progression is promising, but needs validation in large prospective datasets. Last, a new frontier in the near future will be chemoprevention (primary and secondary), but we need to identify among solid tumors those subgroups of patients with a higher risk of relapsing into the brain and novel drugs, active on either neoplastic or normal cells of the microenvironment, that are cooperating in the invasion of brain tissue. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1527-2729 -SN - 1534-6277 -DA - 2021 DEC -PY - 2021 -VL - 22 -IS - 12 -C7 - 110 -DO - 10.1007/s11864-021-00911-7 -AN - WOS:000710369600001 -AD - Univ & City Hlth & Sci Hosp, Dept Neuro Oncol, Via Cherasco 15, I-10126 Turin, Italy -AD - Castelfranco Veneto & Treviso Hosp, Dept Neurol, Via St Ambrogio Fiera 37, I-31100 Treviso, Italy -M2 - Castelfranco Veneto & Treviso Hosp -Y2 - 2021-11-04 -ER - - -TY - JOUR -AU - Dieleman, Edith -AU - van der Woude, Lisa -AU - van Os, Rob -AU - van Bockel, Liselotte -AU - Coremans, Ida -AU - van Es, Corine -AU - De Jaeger, Katrien -AU - Knol, Hans Peter -AU - Kolff, Willemijn -AU - Koppe, Frederike -AU - Pomp, Jacqueline -AU - Reymen, Bart -AU - Schinagl, Dominic -AU - Spoelstra, Femke -AU - Tissing-Tan, Caroline -AU - van Zyp, Noelle van der Voort -AU - van der Wel, Antoinet -AU - Wijsman, Robin -AU - Dielwart, Michel -AU - Wiegman, Erwin -AU - Damhuis, Ronald -AU - Belderbos, Jose -TI - The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation -T2 - CLINICAL LUNG CANCER -M3 - Article -M3 - Proceedings Paper -CP - 61st Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology (ASTRO) -CL - Chicago, IL -AB - In this national lung cancer audit of inoperable NSCLC patients, acute toxicity and 3-month mortality of curative chemoradiation was analyzed. Another important question was whether concurrent chemoradiation for elderly stage III NSCLC patients is safe. The results showed that 3-month toxicity was significantly higher in patients treated with concurrent chemoradiation, higher TNM stage IIIC and poor performance (WHO >= 2) patients. Introduction: Chemoradiotherapy (CRT) is the standard of care in inoperable non-small-cell lung cancer (NSCLC) patients, favoring concurrent (cCRT) over sequential CRT (seqCRT), with adjuvant immunotherapy in responders. Elderly and frail NSCLC patients have generally been excluded from trials in the past. In elderly patients however, the higher treatment related morbidity of cCRT, may outweigh the possible lower tumor control of seqCRT. For elderly patients with locally advanced NSCLC real-world data is essential to be able to balance treatment toxicity and treatment outcome. The aim of this study is to analyze acute toxicit y and 3-month mortalit y of curative chemoradiation (CRT) in patients with stage III NSCLC and to analyze whether cCRT for elderly stage III NSCLC patients is safe. Methods: The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R) is a national lung cancer audit that started in 2013 for patients treated with curative intent radiotherapy. All Dutch patients treated for stage III NSCLC between 2015 and 2018 with seqCRT or cCRT for (primary or recurrent) stage III lung cancer are included in this population-based study. Information was collected on patient, tumor- and treatment characteristics and the incidence and severity of acute non-hematological toxicity (CTCAE-4 version 4.03) and mortality within 3 months after the end of radiotherapy. To evaluate the association between prognostic factors and outcome (acute toxicity and mortality within 3 months), an univariable and multivariable analysis was performed. The definition of cCRT was:radiotherapy started within 30 days after the start of chemotherapy. Results: Out of all 20 Dutch departments of radiation oncology, 19 centers participated in the registry. A total of 2942 NSCLC stage III patients were treated with CRT. Of these 67.2% (n = 1977) were treated with cCRT (median age 66 years) and 32.8% (n = 965) were treated with seqCRT (median age 69 years). Good performance status (WHO 0-1) was scored in 88.6% for patients treated with cCRT and in 71.0% in the patients treated with seqCRT. Acute nonhema-tological 3-month toxicity (CTCAE grade >3 or radiation pneumonitis grade >2) was scored in 21.9% of the patients treated with cCRT and in 17.7% of the patients treated with seqCRT. The univariable analysis for acute toxicity showed significantly increased toxicity for cCRT (P = .008), WHO >2 (P = .006), and TNM IIIC (P = .031). The multivari-able analysis for acute toxicity was significant for cCRT (P = .015), WHO >2 (P = .001) and TNM IIIC (P = .016). The univariable analysis for 3-month mortality showed significance for seqCRT (P = .025), WHO >2 (P < .001), higher cumulative radiotherapy dose (P < .001), higher gross tumor volume total (P = .020) and male patients (p < .001). None of these variables reached significance in the multivariable analysis for 3-month mortality. Conclusion: In this national lung cancer audit of inoperable NSCLC patients, 3-month toxicity was significantly higher in patients treated with cCRT (21.9% vs.17.7% for seqCRT) higher TNM stage IIIC, and poor performance (WHO >2) patients.The 3-months mortality was not significantly different for tested parameters. Age was not a risk factor for acute toxicity, nor 3 months mortality. -PU - CIG MEDIA GROUP, LP -PI - DALLAS -PA - 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA -SN - 1525-7304 -SN - 1938-0690 -DA - 2023 MAR -PY - 2023 -VL - 24 -IS - 2 -SP - 130 -EP - 136 -DO - 10.1016/j.cllc.2022.11.008 -AN - WOS:000944221500001 -C6 - FEB 2023 -AD - Amsterdam UMC locat AMC, Radiat Oncol, Amsterdam, Netherlands -AD - RadboudUMC, Cardiothorac Surg, Nijmegen, Netherlands -AD - Dutch Inst Clin Auditing, Leiden, Netherlands -AD - Haga ziekenhuis, Radiat Oncol, The Hague, Netherlands -AD - LUMC, Radiat Oncol, Leiden, Netherlands -AD - UMCU, Radiat Oncol, Utrecht, Netherlands -AD - Catharina Hosp, Radiat Oncol, Eindhoven, Netherlands -AD - Noordwest Ziekenhuis Grp, Radiat Oncol, Alkmaar, Netherlands -AD - Inst Verbeeten, Radiat Oncol, Tilburg, Netherlands -AD - Med Spectrum Twente, Radiat Oncol, Enschede, Netherlands -AD - Maastro, Radiat Oncol, Maastricht, Netherlands -AD - RadboudUMC, Radiat Oncol, Nijmegen, Netherlands -AD - Amsterdam UMC locat VUMC, Radiat Oncol, Amsterdam, Netherlands -AD - Radiotherapiegroep, Radiat Oncol, Arnhem, Netherlands -AD - Univ Med Ctr Groningen, Radiat Oncol, Groningen, Netherlands -AD - Haaglanden MC, Radiat oncol, The Hague, Netherlands -AD - Radiotherapeut Inst Friesland, Radiat Oncol, Leeuwarden, Netherlands -AD - ZRTI, Radiat Oncol, Vlissingen, Netherlands -AD - Isala, Radiat Oncol, Zwolle, Netherlands -AD - Netherlands Comprehens Canc Org, Dept Res, Utrecht, Netherlands -AD - Netherlands Canc Inst, Radiat Oncol, Amsterdam, Netherlands -M2 - Amsterdam UMC locat AMC -M2 - Dutch Inst Clin Auditing -M2 - Noordwest Ziekenhuis Grp -M2 - Amsterdam UMC locat VUMC -M2 - Radiotherapiegroep -M2 - Haaglanden MC -M2 - Radiotherapeut Inst Friesland -M2 - ZRTI -M2 - Isala -M2 - Netherlands Comprehens Canc Org -Y2 - 2023-03-22 -ER - - -TY - JOUR -AU - Evans, Tracey -AU - Ciunci, Christine -AU - Hertan, Lauren -AU - Gomez, Daniel -TI - Special topics in immunotherapy and radiation therapy: reirradiation and palliation -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Immunotherapy has revolutionized the treatment of non-small cell lung cancer (NSCLC). However, thus far, its use has only been established in patients with advanced disease either as first-line therapy in selected patients or following chemotherapy. What is not yet known is how best to incorporate radiation with immunotherapy agents. Many patients with advanced disease can benefit from palliative radiation, but the combination of radiation with immunotherapy has the potential to increase the toxicity of both modalities. Intriguingly, the combination also has the potential to enhance the efficacy of both modalities. For this reason, combining immunotherapy and radiation may help salvage patients with recurrent localized disease who are candidates for re-irradiation. We review the current data evaluating immunotherapy with both palliative radiation as well as definitive re-irradiation in NSCLC. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2017 APR -PY - 2017 -VL - 6 -IS - 2 -SP - 119 -EP - 130 -DO - 10.21037/tlcr.2017.04.03 -AN - WOS:000403489800003 -AD - Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA -AD - Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA -Y2 - 2017-04-01 -ER - - -TY - JOUR -AU - Zhu, Jianwei -AU - Yuan, Yun -AU - Wan, Xiaoyu -AU - Yin, Dan -AU - Li, Rui -AU - Chen, Wenwen -AU - Suo, Chen -AU - Song, Huan -TI - Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent -T2 - COCHRANE DATABASE OF SYSTEMATIC REVIEWS -M3 - Review -AB - BackgroundNon-small cell lung cancer (NSCLC) is the most common lung cancer, accounting for approximately 80% to 85% of all cases. For people with localised NSCLC (stages I to III), it has been speculated that immunotherapy may be helpful for reducing postoperative recurrence rates, or improving the clinical outcomes of current treatment for unresectable tumours. This is an update of a Cochrane Review first published in 2017 and it includes two new randomised controlled trials (RCTs).ObjectivesTo assess the effectiveness and safety of immunotherapy (excluding checkpoint inhibitors) among people with localised NSCLC of stages I to III who received curative intent of radiotherapy or surgery.Search methodsWe searched the following databases (from inception to 19 May 2021): CENTRAL, MEDLINE, Embase, CINAHL, and five trial registers. We also searched conference proceedings and reference lists of included trials.Selection criteriaWe included RCTs conducted in adults (>= 18 years) diagnosed with NSCLC stage I to III after surgical resection, and those with unresectable locally advanced stage III NSCLC receiving radiotherapy with curative intent. We included participants who underwent primary surgical treatment, postoperative radiotherapy or chemoradiotherapy if the same strategy was provided for both intervention and control groups.Data collection and analysisTwo review authors independently selected eligible trials, assessed risk of bias, and extracted data. We used survival analysis to pool time-to-event data, using hazard ratios (HRs). We used risk ratios (RRs) for dichotomous data, and mean differences (MDs) for continuous data, with 95% confidence intervals (CIs). Due to clinical heterogeneity (immunotherapeutic agents with different underlying mechanisms), we combined data by applying random-effects models.Main resultsWe included 11 RCTs involving 5128 participants (this included 2 new trials with 188 participants since the last search dated 20 January 2017). Participants who underwent surgical resection or received curative radiotherapy were randomised to either an immunotherapy group or a control group. The immunological interventions were active immunotherapy Bacillus Calmette-Guerin (BCG) adoptive cell transfer (i.e. transfer factor (TF), tumour-infiltrating lymphocytes (TIL), dendritic cell/cytokine-induced killer (DC/CIK), antigen-specific cancer vaccines (melanoma-associated antigen 3 (MAGE-A3) and L-BLP25), and targeted natural killer (NK) cells. Seven trials were at high risk of bias for at least one of the risk of bias domains. Three trials were at low risk of bias across all domains and one small trial was at unclear risk of bias as it provided insufficient information. We included data from nine of the 11 trials in the meta-analyses involving 4863 participants.There was no evidence of a difference between the immunotherapy agents and the controls on any of the following outcomes: overall survival (HR 0.94, 95% CI 0.84 to 1.05; P = 0.27; 4 trials, 3848 participants; high-quality evidence), progression-free survival (HR 0.94, 95% CI 0.86 to 1.03; P = 0.19; moderate-quality evidence), adverse events (RR 1.12, 95% CI 0.97 to 1.28; P = 0.11; 4 trials, 4126 evaluated participants; low-quality evidence), and severe adverse events (RR 1.14, 95% CI 0.92 to 1.40; 6 trials, 4546 evaluated participants; low-quality evidence).Survival rates at different time points showed no evidence of a diEffrence between immunotherapy agents and the controls. Survival rate at 1-year follow-up (RR 1.02, 95% CI 0.96 to 1.08; I-2 = 57%; 7 trials, 4420 participants; low-quality evidence), 2-year follow-up (RR 1.02, 95% CI 0.93 to 1.12; 7 trials, 4420 participants; moderate-quality evidence), 3-year follow-up (RR 0.99, 95% CI 0.90 to 1.09; 7 trials, 4420 participants; I-2 = 22%; moderate-quality evidence) and at 5-year follow-up (RR 0.98, 95% CI 0.86 to 1.12; I-2 = 0%; 7 trials, 4389 participants; moderate-quality evidence).Only one trial reported overall response rates. Two trials provided health-related quality of life results with contradicting results.Authors' conclusionsBased on this updated review, the current literature does not provide evidence that suggests a survival benefit from adding immunotherapy (excluding checkpoint inhibitors) to conventional curative surgery or radiotherapy, for people with localised NSCLC (stages I to III). Several ongoing trials with immune checkpoints inhibitors (PD-1/PD-L1) might bring new insights into the role of immunotherapy for people with stages I to III NSCLC. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1469-493X -SN - 1361-6137 -DA - 2021 -PY - 2021 -IS - 12 -C7 - CD011300 -DO - 10.1002/14651858.CD011300.pub3 -AN - WOS:000737966900041 -AD - Sichuan Univ, West China Hosp, Dept Orthopaed, Chengdu, Peoples R China -AD - Sichuan Univ, West China Hosp, West China Biomed Big Data Ctr, Chengdu, Peoples R China -AD - Sichuan Univ, West China Hosp, Thorac Oncol Canc Ctr, Chengdu, Peoples R China -AD - Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China -AD - Fudan Univ, Key Lab Publ Hlth Safety, Minist Educ, Shanghai, Peoples R China -AD - Univ Iceland, Fac Med, Ctr Publ Hlth Sci, Reykjavik, Iceland -Y2 - 2022-02-08 -ER - - -TY - JOUR -AU - Sridhar, Arthi -AU - Khan, Hina -AU - Yohannan, Binoy -AU - Chan, Kok Hoe -AU - Kataria, Nilansh -AU - Jafri, Syed Hasan -TI - A Review of the Current Approach and Treatment Landscape for Stage III Non-Small Cell Lung Cancer -T2 - JOURNAL OF CLINICAL MEDICINE -M3 - Review -AB - The therapeutic landscape of the management of stage III non-small cell lung cancer (NSCLC) has drastically evolved with the incorporation of immunotherapy and targeted therapy. Stage III NSCLC accounts for one-third of the cases and the treatment strategy of these locally advanced presentations are diverse, ranging from surgical to non-surgical options; with the incorporation of chemo-immunotherapy, radiation, and targeted therapies wherever applicable. The staging of this disease has also changed, and it is essential to have a strong multidisciplinary approach to do justice to patient care. In this article, we aim to navigate the nuanced approaches in the diagnosis and treatment of stage III NSCLC and expand on the evolution of the management of this disease. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2077-0383 -DA - 2024 MAY -PY - 2024 -VL - 13 -IS - 9 -C7 - 2633 -DO - 10.3390/jcm13092633 -AN - WOS:001220061100001 -AD - Mayo Clin, Dept Oncol, Rochester, MN 55901 USA -AD - Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Div Hematol & Oncol, Houston, TX 77030 USA -AD - Mayo Clin, Dept Hematol, Rochester, MN 55901 USA -AD - MedStar Washington Hosp Ctr, Dept Internal Med, Washington, DC 20010 USA -Y2 - 2024-05-20 -ER - - -TY - JOUR -AU - Yao, Yuanhu -AU - Yao, Nan -AU - Qin, Zhaohui -AU - Ma, Ji -AU - Lu, Jiaying -AU - Cui, Li -AU - Qu, Wanxi -AU - Yuan, Shiwang -AU - Tong, Shaodong -AU - Li, Na -AU - Li, Hao -TI - Extensive-stage small cell lung cancer: Is prophylactic cranial irradiation necessary in the era of immunotherapy with MRI surveillance? -T2 - PRECISION RADIATION ONCOLOGY -M3 - Article -AB - ObjectiveThe role of prophylactic cranial irradiation (PCI) in treating extensive-stage small-cell lung cancer (ES-SCLC) has been controversial. This study aimed to comprehensively analyze the efficacy of PCI for the treatment of ES-SCLC under active brain magnetic resonance imaging (MRI) surveillance.MethodsPatients with ES-SCLC with no brain metastases (BM) confirmed by MRI at the time of diagnosis who responded well to first-line chemoimmunotherapy at three general hospitals were retrospectively included. Overall survival (OS), progression-free survival (PFS), and cumulative incidence of BM were compared between patients who underwent PCI and those who did not.ResultsIn total, 66 consecutive patients treated between March 2019 and December 2021 were included in our dataset. Seventeen patients underwent PCI (PCI group) and 49 patients did not (non-PCI group). In comparison with the non-PCI group, PCI did not provide OS (median OS: 18.53 vs. 17.35 months, p = 0.28) or PFS (median PFS: 8.61 vs. 7.56 months, p = 0.41) benefits. When death was counted as a competing risk, the difference in the cumulative incidence rate of BM was not statistically significant (1-year: 12.79% vs. 38.09%; p = 0.14).ConclusionCompared to active MRI surveillance, first-line chemoimmunotherapy followed by PCI did not improve the prognosis of patients with ES-SCLC. Further studies are warranted to evaluate the therapeutic effects of PCI following chemoimmunotherapy.In the modern era of immunotherapy prolonging overall survival and increasing routine use of surveillance MRI, the use of prophylactic cranial irradiation after first-line chemotherapy and immunotherapy was not associated with an overall survival benefit or a progression-free survival benefit for patients with extensive-stage small-cell lung cancer. The use of prophylactic cranial irradiation was also not associated with a decrease in the risk of developing new brain metastases. image -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2398-7324 -DA - 2023 JUN -PY - 2023 -VL - 7 -IS - 2 -SP - 111 -EP - 117 -DO - 10.1002/pro6.1200 -AN - WOS:001327114700003 -AD - Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Dept Radiat Oncol, 299 Qingyang Rd, Wuxi 214023, Jiangsu, Peoples R China -AD - Xuzhou Med Univ, Grad Sch, Xuzhou, Jiangsu, Peoples R China -AD - Xuzhou Med Univ, Res Ctr Med & Hlth Emergency Rescue, Xuzhou, Jiangsu, Peoples R China -AD - Third Peoples Hosp Xuzhou, Dept Radiat Oncol, Xuzhou, Jiangsu, Peoples R China -AD - Xuzhou Cent Hosp, Dept Radiat Oncol, Xuzhou, Jiangsu, Peoples R China -AD - Xuzhou Cent Hosp, Dept Oncol, Xuzhou, Jiangsu, Peoples R China -M2 - Third Peoples Hosp Xuzhou -M2 - Xuzhou Cent Hosp -M2 - Xuzhou Cent Hosp -Y2 - 2023-06-01 -ER - - -TY - JOUR -AU - Shepard, Matthew J. -AU - Xu, Zhiyuan -AU - Donahue, Joseph -AU - Muttikkal, Thomas J. Eluvathingal -AU - Cordeiro, Diogo -AU - Hansen, Leslie -AU - Mohammed, Nasser -AU - Gentzler, Ryan D. -AU - Larner, James -AU - Fadul, Camilo E. -AU - Sheehan, Jason P. -TI - Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study -T2 - JOURNAL OF NEUROSURGERY -M3 - Article -AB - OBJECTIVE Immune checkpoint inhibitors (ICIs) improve survival in patients with advanced non-small cell lung cancer (NSCLC). Clinical trials examining the efficacy of ICIs in patients with NSCLC excluded patients with untreated brain metastases (BMs). As stereotactic radiosurgery (SRS) is commonly employed for NSCLC-BMs, the authors sought to define the safety and radiological and clinical outcomes for patients with NSCLC-BMs treated with concurrent ICI and SRS.METHODS A retrospective matched cohort study was performed on patients who had undergone SRS for one or more NSCLC-derived BMs. Two matched cohorts were identified: one that received ICI before or after SRS within a 3-month period (concurrent ICI) and one that did not (ICI naive). Locoregional tumor control, peritumoral edema, and central nervous system (CNS) adverse events were compared between the two cohorts.RESULTS Seventeen patients (45 BMs) and 34 patients (92 BMs) composed the concurrent-ICI and ICI-naive cohorts, respectively. There was no statistically significant difference in overall survival (HR 0.99, 95% CI 0.39-2.52, p = 0.99) or CNS progression-free survival (HR 2.18, 95% CI 0.72-6.62, p = 0.11) between the two groups. Similarly, the 12-month local tumor control rate was 84.9% for tumors in the concurrent-ICI cohort versus 76.3% for tumors in the ICI-naive cohort (p = 0.94). Further analysis did reveal that patients receiving concurrent ICI had increased rates of CNS complete response for BMs treated with SRS (8/16 [50%] vs 5/32 [15.6%], p = 0.012) per the Response Assessment in Neuro-Oncology (RANO) criteria. There was also a shorter median time to BM regression in the concurrent-ICI cohort (2.5 vs 3.1 months, p < 0.0001). There was no increased rate of radiation necrosis or intratumoral hemorrhage in the patients receiving concurrent ICI (5.9% vs 2.9% in ICI-naive cohort, p = 0.99). There was no significant difference in the rate of peritumoral edema progression between the two groups (concurrent ICI: 11.1%, ICI naive: 21.7%, p = 0.162).CONCLUSIONS The concurrent use of ICI and SRS to treat NSCLC-BM was well tolerated while providing more rapid BM regression. Concurrent ICI did not increase peritumoral edema or rates of radiation necrosis. Further studies are needed to evaluate whether combined ICI and SRS improves progression-free survival and overall survival for patients with metastatic NSCLC. -PU - AMER ASSOC NEUROLOGICAL SURGEONS -PI - ROLLING MEADOWS -PA - 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA -SN - 0022-3085 -SN - 1933-0693 -DA - 2020 SEP -PY - 2020 -VL - 133 -IS - 3 -SP - 685 -EP - 692 -DO - 10.3171/2019.4.JNS19822 -AN - WOS:000586088300010 -AD - Univ Virginia Hlth Syst, Div Hematol Oncol, Dept Neurol Surg, Charlottesville, VA USA -AD - Univ Virginia Hlth Syst, Div Hematol Oncol, Dept Neuroradiol, Charlottesville, VA USA -AD - Univ Virginia Hlth Syst, Div Hematol Oncol, Dept Med, Charlottesville, VA USA -AD - Univ Virginia Hlth Syst, Div Neurooncol, Dept Radiat Oncol, Charlottesville, VA USA -AD - Univ Virginia Hlth Syst, Div Neurooncol, Dept Neurol, Charlottesville, VA USA -Y2 - 2020-11-23 -ER - - -TY - JOUR -AU - Bando, Hideaki -AU - Kotani, Daisuke -AU - Tsushima, Takahiro -AU - Hara, Hiroki -AU - Kadowaki, Shigenori -AU - Kato, Ken -AU - Chin, Keisho -AU - Yamaguchi, Kensei -AU - Kageyama, Shun-ichiro -AU - Hojo, Hidehiro -AU - Nakamura, Masaki -AU - Tachibana, Hidenobu -AU - Wakabayashi, Masashi -AU - Fukutani, Miki -AU - Togashi, Yosuke -AU - Fuse, Nozomu -AU - Nishikawa, Hiroyoshi -AU - Kojima, Takashi -TI - TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma -T2 - BMC CANCER -M3 - Article -AB - Background The standard treatment for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is definitive chemoradiotherapy (CRT) using 5-FU plus cisplatin. However, complete response (CR) rates are low at 11-25%, resulting in 9-10 months of median overall survival (OS). An improved therapeutic efficacy by combining immunotherapy with radiation has been reported in patients with locally advanced non-small cell lung cancer. The results using ESCC cell lines suggest sequential treatment with anti-PD-L1 agents soon after completion of CRT is the most effective combination. Methods TENERGY trial is a multicenter, phase II, proof-of-concept study to assess the efficacy and safety of atezolizumab following definitive CRT in patients with locally advanced ESCC. The main inclusion criteria are unresectable locally advanced ESCC without distant metastasis, completion of 60 Gy of radiation plus two concomitant cycles of chemotherapy (cisplatin 70 mg/m(2) on day 1 and 5-FU 700 mg/m(2) on days 1-4, every 28 days), and adequate organ function. Within 6 weeks after CRT, participants will start taking 1200 mg of atezolizumab every three weeks and continue until 12 months or disease progression. The primary endpoint is the confirmed CR rate by the investigator's assessment. Secondary endpoints include overall response rate, progression-free survival (PFS), OS, adverse events, and confirmed CR rate by central assessment. We will enroll 50 patients (40 with primary locally advanced ESCC and 10 with postoperative locoregionally recurrent ESCC). We will obtain biopsies from the primary site and will collect blood at 3 time points (before CRT, after CRT, and four weeks after the start of atezolizumab) for an exploratory biomarker study. We will analyze the phenotype of immune-competent cells, neoantigens, tumor mutational burden, PD-L1 status, and Human Leukocyte Antigen haplotyping. Discussion The synergistic efficacies of the sequential combination of CRT and atezolizumab should improve the CR rate, resulting in survival improvement for patients with unresectable locally advanced ESCC. Because CRT is a standard treatment option for patients with early stage to locally advanced ESCC, the sequential combination of CRT and atezolizumab has the potential to change the standard ESCC treatments. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2020 APR 20 -PY - 2020 -VL - 20 -IS - 1 -C7 - 336 -DO - 10.1186/s12885-020-06716-5 -AN - WOS:000529280800001 -AD - Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan -AD - Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan -AD - Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan -AD - Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan -AD - Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan -AD - Japanese Fdn Canc Res, Dept Gastroenterol Med, Canc Inst Hosp, Tokyo, Japan -AD - Natl Canc Ctr Hosp East, Div Radiat Oncol & Particle Therapy, Kashiwa, Chiba, Japan -AD - Natl Canc Ctr Hosp East, Clin Res Support Off, Kashiwa, Chiba, Japan -AD - Natl Canc Ctr Hosp East, Exploratory Oncol Res & Clin Trial Ctr, Div Canc Immunol, Kashiwa, Chiba, Japan -M2 - Saitama Canc Ctr -Y2 - 2020-05-14 -ER - - -TY - JOUR -AU - Chen, Lingjuan -AU - Kong, Yi -AU - Tong, Fan -AU - Zhang, Ruiguang -AU - Ding, Peng -AU - Zhang, Sheng -AU - Wang, Ye -AU - Zhou, Rui -AU - Pu, Xingxiang -AU - Chen, Bolin -AU - Liang, Fei -AU - Tan, Qiaoyun -AU - Xu, Yu -AU - Wu, Lin -AU - Dong, Xiaorong -TI - The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study. -T2 - Chinese medical journal -M3 - Journal Article -AB - BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of subsequent radiotherapy (RT) following first-line treatment with durvalumab plus chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).METHODS: A total of 122 patients with ES-SCLC from three hospitals during July 2019 to December 2021 were retrospectively analyzed. Inverse probability of treatment weighting (IPTW) analysis was performed to address potential confounding factors. The primary focus of our evaluation was to assess the impact of RT on progression-free survival (PFS) and overall survival (OS).RESULTS: After IPTW analysis, 49 patients received durvalumab plus platinum-etoposide(EP) chemotherapy followed by RT (Durva+EP+RT) and 72 patients received immunochemotherapy (Durva+EP). The median OS was 17.2months vs. 12.3months (hazard ratio [HR]: 0.38, 95% CI: 0.17-0.85, P=0.020), and the median PFS was 8.9months vs. 5.9months (HR: 0.56, 95% CI: 0.32-0.97, P=0.030) in Durva+EP+RT and Durva+EP groups, respectively. Thoracic radiation therapy (TRT) resulted in longer OS (17.2months vs. 14.7months) and PFS (9.1months vs. 7.2months) compared to RT directed to other metastatic sites. Among patients with oligo-metastasis, RT also showed significant benefits, with a median OS of 17.4months vs. 13.7months and median PFS of 9.8months vs. 5.9months compared to no RT. Continuous durvalumab treatment beyond progression (TBP) prolonged OS compared to patients without TBP, in both the Durva+EP+RT (NA vs. 15.8months, HR: 0.48, 95% CI: 0.14-1.63, P=0.238) and Durva+EP groups (12.3months vs. 4.3months, HR: 0.29, 95% CI: 0.10-0.81, P=0.018). Grade 3 or 4 adverse events occurred in 13 (26.5%) and 13 (18.1%) patients, respectively, in the two groups; pneumonitis was mostly low-grade.CONCLUSION: Addition of RT after first-line immunochemotherapy significantly improved survival outcomes with manageable toxicity in ES-SCLC. -SN - 2542-5641 -DA - 2024 Sep 23 (Epub 2024 Sep 23) -PY - 2024 -DO - 10.1097/CM9.0000000000003283 -AN - MEDLINE:39307928 -AD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China. -AD - Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, Hubei 430022, China. -AD - Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China. -AD - Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410000, China. -AD - Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai 200000, China. -AD - Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, Hubei 430071, China. -AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China. -Y2 - 2024-09-25 -ER - - -TY - PAT -AU - SHEPPARD D W -AU - TIERNEY J P -AU - MANDABI A -AU - ALROY I -AU - WASSERMANN R -AU - WANG Y -AU - LI H -AU - SHEINBERGER Y -TI - New 7-thia-2,5-diazatricycloodeca-1(12),3,5,8,10-pentaene compound used in pharmaceutical composition for e.g. treating, suppressing, reducing severity, reducing risk of developing or inhibiting cancer -AB - - NOVELTY - A 7-thia-2,5-diazatricyclo(6.4.0.02,6)dodeca-1(12),3,5,8,10-pentaene compound chosen from compounds (I)-(III), is new. - USE - The 7-thia-2,5-diazatricyclo(6.4.0.02,6)dodeca-1(12),3,5,8,10-pentaene compound is used in pharmaceutical composition for treating, suppressing, reducing severity, reducing risk of developing or inhibiting cancer, in subject previously treated with chemotherapy, immunotherapy, radiotherapy, biological therapy and/or surgical intervention, suppressing, reducing or inhibiting tumor growth, modulating c-MYC mRNA translation, transcription and splicing (inclusion or exclusion of untranslated region or alternative usage of exons) in cell, regulating c-MYC mRNA modifications, regulating interaction of RNA binding protein with c-MYC mRNA thereby changing mRNA localization, regulating c-MYC mRNA localization in the cytoplasm, regulating ribosomes or ribosome accessory factor to c-MYC mRNA and/or reducing amount of c-MYC protein in cell. The cancer is chosen from breast cancer, ovarian carcinoma, acute myeloid leukemia, chronic myelogenous leukemia, Hodgkin's and Burkitt's lymphoma, diffuse large B-cell lymphoma, prostate cancer, colon cancer, gastric cancer, primary central nervous system lymphoma, glioblastoma, medulloblastoma, melanoma, non-small cell lung carcinoma, germinal center-derived lymphomas, esophageal squamous cell carcinoma, osteosarcoma, bladder cancer, pancreatic cancer, lung adenocarcinoma, BRAF V600E thyroid cancer, choroid plexus carcinoma, colitis-associated cancer, epithelial ovarian cancer, colorectal cancer, pancreatic cancer and uterine cancer, or early cancer, advanced cancer, invasive cancer, metastatic cancer and/or drug resistant cancer (all claimed). - ADVANTAGE - The 7-thia-2,5-diazatricyclo(6.4.0.02,6)dodeca-1(12),3,5,8,10-pentaene compound has desired stability, and is non-toxic. - DETAILED DESCRIPTION - A 7-thia-2,5-diazatricyclo(6.4.0.02,6)dodeca-1(12),3,5,8,10-pentaene compound chosen from compounds of formula (I)-(III) or its salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, isotopic variant (e.g. deuterated analog) and/or pharmaceutical product, is new.ring F' = absent or 4-8-membered heterocyclyl, preferably pyrrolidinyl, pyridinyl, imidazolyl, pyrimidinyl, triazolyl, oxadiazolyl or pyrazolyl (all optionally saturated and optionally substituted);R1,R2 = e.g. OH;R3,R4 = H, Me, optionally substituted 1-5C alkyl (e.g. methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R10 (e.g. (CH2)2-O-CH3), R8-N(R10)(R11) (e.g. (CH2)2-NH(CH3)), or 3-8C cycloalkyl (e.g. cyclopropyl), 5-7-membered heterocyclyl (e.g. pyrrolidinyl, methyl-pyrrolidinyl or piperidinyl) (all optionally substituted), or R20;X2-X4 = N or CH;X5-X9 = N or C;X10 = N, CH, or C(R);R5 = H or 1-5C linear or branched alkyl (e.g. methyl);R6 = e.g. R8-N(R10)(R11);R7 = e.g. aryl or benzyl (both optionally substituted);R20 = group of formula (i);R = e.g. F;R8 = (CH2)p;p = 1-10;R9 = (CH)q or (C)q;q = 2-10;R10,R11 = e.g. S(O)2R;n = 0-4, preferably 1 or 2;R6' = e.g. group of formula (ii);m = 0 or 1;R12 = H, R20, optionally substituted 1-5C alkyl, or 1-5C C(O)-alkyl;R13 = H, R30, or optionally substituted 1-5C alkyl;ring A',ring B',ring C',ring E' = optionally substituted monocyclic, spiro or fused 3-8-membered heterocyclyl;ring D' = optionally substituted 3-8C cycloalkyl;R30 = e.g. H, R20, F, Cl, Br, I, OH, SH, OH, optionally substituted aryl, or optionally substituted heteroaryl;R7' = e.g. group of formula (iii);X1 = N or O;R1',R2' = H, F, or CF3;R3',R4' = H, Me, or 1-5C alkyl, 3-8C cycloalkyl, cyclopropyl, or 5-7-membered heterocyclyl (all optionally substituted), or R20;andR100 = optionally substituted 1-5C linear or branched alkyl, R8-OH, -R8-O-R10, R8-N(R10)(R11), R20, or optionally substituted 3-8-membered heterocyclyl.(i) If ring F' is aryl, then R1 and/or R3 are absent; and (ii) If X1 is O, then R4 is absent. Full definitions are given in the DEFINITIONS (Full Definitions) Field. An INDEPENDENT CLAIM is included for method for treating, suppressing, reducing severity, reducing risk of developing or inhibiting cancer, which involves administering the 7-thia-2,5-diazatricyclo(6.4.0.02,6)dodeca-1(12),3,5,8,10-pentaene compound. -SN - WO2022150316-A1 -SN - US2022370431-A1 -SN - IL279972-A -SN - CA3199333-A1 -SN - AU2022205591-A1 -SN - CN116635028-A -SN - EP4274569-A1 -SN - JP2024502106-W -SN - AU2022205591-A9 -SN - HK40094259-A0 -AN - DIIDW:202290441Q -Y2 - 2022-09-05 -ER - - -TY - JOUR -AU - Horinouch, Hidehito -TI - Precision radiotherapy for patients with locally advanced non-small cell lung cancer in the era of immunotherapy and precision medicine -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Editorial Material -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2018 APR -PY - 2018 -VL - 7 -SP - S146 -EP - S148 -DO - 10.21037/tlcr.2018.03.13 -AN - WOS:000431619200015 -AD - Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan -Y2 - 2018-04-01 -ER - - -TY - JOUR -AU - Bergot, E -AU - Levallet, G -AU - Zalcman, G -TI - [Stage IV NSCLC. Biological treatments of lung cancer in 2008... and in the near future]. -T2 - Revue des maladies respiratoires -M3 - English Abstract -M3 - Journal Article -AB - Nowadays, biological cancer treatments represent the major advance in non-small cell lung cancer therapeutic strategies. During the last decade, more than 15 randomized trials associating chemo with biological treatments, in first line setting, have included more than 12,073 NSCLC patients, and as much in phase 2-3 trials in second and third line setting. Very few were positive, but currently anti-angiogenic strategy using the humanized monoclonal antibody bevacizumab has been approved in association with chemotherapy, in first line treatment of carefully selected NSCLC patients (with non proximal tumors, without cerebral metastasis, and of non-squamous histology). On the same way, monotherapy by the EGFR tyrosine kinase inhibitor erlotinib has been approved in second and third line setting, with comparable results as chemotherapy. 2008 was the year of new targeted therapies with cetuximab, the chimeric monoclonal antibody directed against EFGR, in association with chemotherapy in first line setting, whereas EGFR TKI are also tested in first line, in patients selected on the ground of the molecular properties of their tumors (with EGFR mutation or positive EGFR FISH). New generation EGFR TKI (more potent if not more selective) are developed in new settings (neo-adjuvant or adjuvant treatment), with promising results in phase 2 trials, whereas active immunotherapy directed toward MUC1 or MAGE-A3 are tested in large phase 3 randomized trials in adjuvant setting (post-surgery or post-radiotherapy), since phase 2 results were appealing. Therefore, during the last few years, targeted therapies quit science-fiction to enter in our current practice, leading clinicians to learn how to treat new kinds of toxicities and to select patients on molecular grounds. -SN - 0761-8425 -DA - 2008 Oct -PY - 2008 -VL - 25 -IS - 8 Pt 2 -SP - 3S119 -EP - 26 -AN - MEDLINE:18971836 -AD - Service de Pneumologie, Pole Coeur-Poumons-Vaisseaux, Universite de Basse-Normandie, CHU de Caen, 1 Avenue de la Cote de Nacre, Caen cedex 05, France. -Y2 - 2008-10-01 -ER - - -TY - JOUR -AU - PEREZ, BRADFORD A. -TI - Finding Synergy with Radiation Therapy and Immunotherapy for Patients with Lung Cancer -M3 - Awarded Grant -AB - 7. PROJECT SUMMARY/ABSTRACTThe proposed career development training award will provide the candidate, Dr. Bradford Perez, with anexcellent opportunity to establish as an independent clinical/translational investigator. As part of his translationaleffort he seeks to characterize tumor infiltrating immune cells to understand mechanism of synergy withradiation and immunotherapy combinations with a specific interest and plan to further evaluate anti-41bbtherapy in conjunction with radiation therapy. An improved understanding of this mechanism is critical torobust and successful implementation of combined modality strategies in the clinic. The work proposed as partof this award application will also allow Dr. Perez to grow and establish independence as a clinical investigator.He currently serves as the principal investigator for an ongoing investigator initiated clinical trial for patients withextensive stage small cell lung cancer. With the support of a strong mentorship team, he was able to draft theprotocol and navigate the necessary regulatory infrastructure to enroll patients on this Phase I/II trial. Thehuman tissue samples (serial peripheral blood and tumor samples) collected as part of this ongoing trial will bethoroughly analyzed as part of Research Aim 2 to help understand the precise mechanism by which RTmodulates the immune system. Through an improved understanding, future clinical studies as proposed inResearch Aim 3 can be rationally designed to maximize the opportunity for synergy with radiation andimmunotherapy.The application includes a robust plan that highlights Dr. Perez's limitations in prior training with a didacticprogram that is specifically designed overcome knowledge gaps in the fields of cancer immunity/immunotherapyand early stage clinical trial design. In working to establish independence, the final training aim includesdedicated career development focus on grant writing and publications. This training will help Dr. Perez to masterthe necessary skills crucial to success as an independent investigator.Drs. Antonia, Conejo-Garcia and Schell will closely advise and oversee Dr. Perez's career development andrepresent a team of international experts in the field of cancer clinical and translational investigation. Theproposed training in this K08 NCI Mentored Clinical Scientist training grant for patient oriented research willallow Dr. Perez to transition to an independent clinical and translational researcher. -DA - 2021 -PY - 2021 -AN - GRANTS:17405404 -G1 - 10226839; 5K08CA231454-03; K08CA231454 -AD - H. LEE MOFFITT CANCER CTR & RES INST -Y2 - 2024-03-01 -ER - - -TY - JOUR -AU - Yolchuyeva, Sevinj -AU - Giacomazzi, Elena -AU - Tonneau, Marion -AU - Lamaze, Fabien -AU - Orain, Michele -AU - Coulombe, Francois -AU - Malo, Julie -AU - Belkaid, Wiam -AU - Routy, Bertrand -AU - Joubert, Philippe -AU - Manem, Venkata S. K. -TI - Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional study -T2 - SCIENTIFIC REPORTS -M3 - Article -AB - With the increasing use of immune checkpoint inhibitors (ICIs), there is an urgent need to identify biomarkers to stratify responders and non-responders using programmed death-ligand (PD-L1) expression, and to predict patient-specific outcomes such as progression free survival (PFS). The current study is aimed to determine the feasibility of building imaging-based predictive biomarkers for PD-L1 and PFS through systematically evaluating a combination of several machine learning algorithms with different feature selection methods. A retrospective, multicenter study of 385 advanced NSCLC patients amenable to ICIs was undertaken in two academic centers. Radiomic features extracted from pretreatment CT scans were used to build predictive models for PD-L1 and PFS (short-term vs. long-term survivors). We first employed the LASSO methodology followed by five feature selection methods and seven machine learning approaches to build the predictors. From our analyses, we found several combinations of feature selection methods and machine learning algorithms to achieve a similar performance. Logistic regression with ReliefF feature selection (AUC = 0.64, 0.59 in discovery and validation cohorts) and SVM with Anova F-test feature selection (AUC = 0.64, 0.63 in discovery and validation datasets) were the best-performing models to predict PD-L1 and PFS. This study elucidates the application of suitable feature selection approaches and machine learning algorithms to predict clinical endpoints using radiomics features. Through this study, we identified a subset of algorithms that should be considered in future investigations for building robust and clinically relevant predictive models. -PU - NATURE PORTFOLIO -PI - BERLIN -PA - HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY -SN - 2045-2322 -DA - 2023 JUL 8 -PY - 2023 -VL - 13 -IS - 1 -C7 - 11065 -DO - 10.1038/s41598-023-38076-y -AN - WOS:001026178300050 -AD - Univ Quebec Trois Rivieres, Dept Math & Comp Sci, Trois Rivieres, PQ, Canada -AD - Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada -AD - Ctr Rech Ctr Hosp Univ Montreal, Montreal, PQ, Canada -AD - Laval Univ, Dept Mol Biol, Med Biochem & Pathol, Quebec City, PQ, Canada -AD - Univ Med Lille, Lille, France -M2 - Inst Univ Cardiol & Pneumol Quebec -M2 - Univ Med Lille -Y2 - 2023-08-20 -ER - - -TY - JOUR -AU - PEREZ, BRADFORD A. -TI - Finding Synergy with Radiation Therapy and Immunotherapy for Patients with Lung Cancer -M3 - Awarded Grant -AB - 7. PROJECT SUMMARY/ABSTRACTThe proposed career development training award will provide the candidate, Dr. Bradford Perez, with anexcellent opportunity to establish as an independent clinical/translational investigator. As part of his translationaleffort he seeks to characterize tumor infiltrating immune cells to understand mechanism of synergy withradiation and immunotherapy combinations with a specific interest and plan to further evaluate anti-41bbtherapy in conjunction with radiation therapy. An improved understanding of this mechanism is critical torobust and successful implementation of combined modality strategies in the clinic. The work proposed as partof this award application will also allow Dr. Perez to grow and establish independence as a clinical investigator.He currently serves as the principal investigator for an ongoing investigator initiated clinical trial for patients withextensive stage small cell lung cancer. With the support of a strong mentorship team, he was able to draft theprotocol and navigate the necessary regulatory infrastructure to enroll patients on this Phase I/II trial. Thehuman tissue samples (serial peripheral blood and tumor samples) collected as part of this ongoing trial will bethoroughly analyzed as part of Research Aim 2 to help understand the precise mechanism by which RTmodulates the immune system. Through an improved understanding, future clinical studies as proposed inResearch Aim 3 can be rationally designed to maximize the opportunity for synergy with radiation andimmunotherapy.The application includes a robust plan that highlights Dr. Perez's limitations in prior training with a didacticprogram that is specifically designed overcome knowledge gaps in the fields of cancer immunity/immunotherapyand early stage clinical trial design. In working to establish independence, the final training aim includesdedicated career development focus on grant writing and publications. This training will help Dr. Perez to masterthe necessary skills crucial to success as an independent investigator.Drs. Antonia, Conejo-Garcia and Schell will closely advise and oversee Dr. Perez's career development andrepresent a team of international experts in the field of cancer clinical and translational investigation. Theproposed training in this K08 NCI Mentored Clinical Scientist training grant for patient oriented research willallow Dr. Perez to transition to an independent clinical and translational researcher. -DA - 2023 -PY - 2023 -AN - GRANTS:17742418 -G1 - 10673037; 5K08CA231454-05; K08CA231454 -AD - H. LEE MOFFITT CANCER CTR & RES INST -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - Pouw, Johanna E. E. -AU - Hashemi, Sayed M. S. -AU - Huisman, Marc C. -AU - Wijngaarden, Jessica E. -AU - Slebe, Maarten -AU - Oprea-Lager, Daniela E. -AU - Zwezerijnen, Gerben J. C. -AU - Vugts, Danielle -AU - Ulas, Ezgi B. -AU - de Gruijl, Tanja D. -AU - Radonic, Teodora -AU - Senan, Suresh -AU - van Oordt, C. Willemien van der Houven -AU - Bahce, Idris -TI - First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET -T2 - JOURNAL FOR IMMUNOTHERAPY OF CANCER -M3 - Article -AB - Background In patients with locally advanced unresectable non-small cell lung cancer (NSCLC), durvalumab, an anti-programmed cell death ligand-1 (PD-L1) antibody, has shown improved overall survival when used as consolidation therapy following concurrent chemoradiotherapy (CRT). However, it is unclear whether CRT itself upregulates PD-L1 expression. Therefore, this study aimed to explore the changes in the uptake of the anti PD-L1 antibody [89Zr]Zr-durvalumab in tumors and healthy organs during CRT in patients with NSCLC.Methods Patients with NSCLC scheduled to undergo CRT were scanned 7 +/- 1 days after administration of 37 +/- 1 MBq [89Zr]Zr-durvalumab at baseline, 1-week on-treatment and 1 week after finishing 6 weeks of CRT. First, [89Zr]Zr-durvalumab uptake was visually assessed in a low dose cohort with a mass dose of 2 mg durvalumab (0.13% of therapeutic dose) and subsequently, quantification was done in a high dose cohort with a mass dose of 22.5 mg durvalumab (1.5% of therapeutic dose). Tracer pharmacokinetics between injections were compared using venous blood samples drawn in the 22.5 mg cohort. Visual assessment included suspected lesion detectability. Positron emission tomography (PET) uptake in tumoral and healthy tissues was quantified using tumor to plasma ratio (TPR) and organ to plasma ratio, respectively.Results In the 2 mg dose cohort, 88% of the 17 identified tumor lesions were positive at baseline, compared with 69% (9/13) for the 22.5 mg cohort. Although the absolute plasma concentrations between patients varied, the intrapatient variability was low. The ten quantitatively assessed lesions in the 22.5 mg cohort had a median TPR at baseline of 1.3 (IQR 0.7-1.5), on-treatment of 1.0 (IQR 0.7-1.4) and at the end of treatment of 0.7 (IQR 0.6-0.7). On-treatment, an increased uptake in bone marrow was seen in three out of five patients together with a decreased uptake in the spleen in four out of five patients.Conclusions This study successfully imaged patients with NSCLC with [89Zr]Zr-durvalumab PET before and during CRT. Our data did not show any increase in [89Zr]Zr-durvalumab uptake in the tumor 1-week on-treatment and at the end of treatment. The changes observed in bone marrow and spleen may be due to an CRT-induced effect on immune cells.Trial registration number EudraCT number: 2019-004284-51 -PU - BMJ PUBLISHING GROUP -PI - LONDON -PA - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND -SN - 2051-1426 -DA - 2024 FEB -PY - 2024 -VL - 12 -IS - 2 -C7 - e007659 -DO - 10.1136/jitc-2023-007659 -AN - WOS:001157792000008 -AD - Vrije Univ Amsterdam Med Ctr, Amsterdam UMC, Dept Med Oncol, Amsterdam, Netherlands -AD - Canc Ctr Amsterdam, Imaging & Biomarkers, Amsterdam, Netherlands -AD - Amsterdam UMC, VUmc, Dept Pulm Med, Amsterdam, Netherlands -AD - Amsterdam UMC, Dept Radiol & Nucl Med, VUmc, Amsterdam, Netherlands -AD - Amsterdam Inst Infect & Immun, Canc Immunol, Amsterdam, Netherlands -AD - Amsterdam UMC, Dept Pathol, VUmc, Amsterdam, Netherlands -AD - Amsterdam UMC, Amsterdam UMC Locatie VUmc, VUmc, Amsterdam, Netherlands -AD - Amsterdam UMC, Amsterdam UMC Locatie VUmc, VUmc, Amsterdam, Netherlands -M2 - Amsterdam Inst Infect & Immun -Y2 - 2024-02-15 -ER - - -TY - JOUR -AU - PEREZ, BRADFORD A. -TI - Finding Synergy with Radiation Therapy and Immunotherapy for Patients with Lung Cancer -M3 - Awarded Grant -AB - 7. PROJECT SUMMARY/ABSTRACTThe proposed career development training award will provide the candidate, Dr. Bradford Perez, with anexcellent opportunity to establish as an independent clinical/translational investigator. As part of his translationaleffort he seeks to characterize tumor infiltrating immune cells to understand mechanism of synergy withradiation and immunotherapy combinations with a specific interest and plan to further evaluate anti-41bbtherapy in conjunction with radiation therapy. An improved understanding of this mechanism is critical torobust and successful implementation of combined modality strategies in the clinic. The work proposed as partof this award application will also allow Dr. Perez to grow and establish independence as a clinical investigator.He currently serves as the principal investigator for an ongoing investigator initiated clinical trial for patients withextensive stage small cell lung cancer. With the support of a strong mentorship team, he was able to draft theprotocol and navigate the necessary regulatory infrastructure to enroll patients on this Phase I/II trial. Thehuman tissue samples (serial peripheral blood and tumor samples) collected as part of this ongoing trial will bethoroughly analyzed as part of Research Aim 2 to help understand the precise mechanism by which RTmodulates the immune system. Through an improved understanding, future clinical studies as proposed inResearch Aim 3 can be rationally designed to maximize the opportunity for synergy with radiation andimmunotherapy.The application includes a robust plan that highlights Dr. Perez's limitations in prior training with a didacticprogram that is specifically designed overcome knowledge gaps in the fields of cancer immunity/immunotherapyand early stage clinical trial design. In working to establish independence, the final training aim includesdedicated career development focus on grant writing and publications. This training will help Dr. Perez to masterthe necessary skills crucial to success as an independent investigator.Drs. Antonia, Conejo-Garcia and Schell will closely advise and oversee Dr. Perez's career development andrepresent a team of international experts in the field of cancer clinical and translational investigation. Theproposed training in this K08 NCI Mentored Clinical Scientist training grant for patient oriented research willallow Dr. Perez to transition to an independent clinical and translational researcher. -DA - 2022 -PY - 2022 -AN - GRANTS:17478418 -G1 - 10480061; 5K08CA231454-04; K08CA231454 -AD - H. LEE MOFFITT CANCER CTR & RES INST -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - Gao, Xiang -AU - Yi, Ling -AU - Jiang, Chang -AU - Li, Shuping -AU - Wang, Xiaojue -AU - Yang, Bin -AU - Li, Weiying -AU - Che, Nanying -AU - Wang, Jinghui -AU - Zhang, Hongtao -AU - Zhang, Shucai -TI - PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer -T2 - FRONTIERS IN IMMUNOLOGY -M3 - Article -AB - Proprotein convertase subtilisin/kexin type 9 (PCSK9) secreted by tumors was reported as a deleterious factor that led to the reduction of lymphocyte infiltration and the poorer efficacy of ICIs in vivo. This study aimed to explore whether PCSK9 expression in tumor tissue could predict the response of advanced non-small cell lung cancer (NSCLC) to anti-PD-1 immunotherapy and the synergistic antitumor effect of the combination of the PCSK9 inhibitor with the anti-CD137 agonist. One hundred fifteen advanced NSCLC patients who received anti-PD-1 immunotherapy were retrospectively studied with PCSK9 expression in baseline NSCLC tissues detected by immunohistochemistry (IHC). The mPFS of the PCSK9(lo) group was significantly longer than that of the PCSK9(hi) group [8.1 vs. 3.6 months, hazard ratio (HR): 3.450; 95% confidence interval (CI), 2.166-5.496]. A higher objective response rate (ORR) and a higher disease control rate (DCR) were observed in the PCSK9(lo) group than in the PCSK9(hi) group (54.4% vs. 34.5%, 94.7% vs. 65.5%). Reduction and marginal distribution of CD8(+) T cells were observed in PCSK9(hi) NSCLC tissues. Tumor growth was retarded by the PCSK9 inhibitor and the anti-CD137 agonist alone in the Lewis lung carcinoma (LLC) mice model and further retarded by the PCSK9 inhibitor in combination with the CD137 agonist with long-term survival of the host mice with noticeable increases of CD8(+) and GzmB(+) CD8(+) T cells and reduction of Tregs. Together, these results suggested that high PCSK9 expression in baseline tumor tissue was a deleterious factor for the efficacy of anti-PD-1 immunotherapy in advanced NSCLC patients. The PCSK9 inhibitor in combination with the anti-CD137 agonist could not only enhance the recruitment of CD8(+) and GzmB(+) CD8(+) T cells but also deplete Tregs, which may be a novel therapeutic strategy for future research and clinical practice. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1664-3224 -DA - 2023 MAR 21 -PY - 2023 -VL - 14 -C7 - 1142428 -DO - 10.3389/fimmu.2023.1142428 -AN - WOS:000962641000001 -AD - Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Canc Res Ctr, Beijing, Peoples R China -AD - Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Dept Med Oncol, Beijing, Peoples R China -AD - Jiangxi Canc Hosp, Dept Thorac Oncol, Nanchang, Peoples R China -AD - Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Dept Cardiol, Beijing, Peoples R China -AD - Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Dept Pathol, Beijing, Peoples R China -M2 - Jiangxi Canc Hosp -Y2 - 2023-04-14 -ER - - -TY - JOUR -AU - Wolf, M. -TI - Adjuvant and inductive systemic treatment in non-small cell lung cancer -T2 - CHIRURG -M3 - Article -AB - A large number of randomized trials have demonstrated an undoubted advantage of adjuvant chemotherapy in comparison to surgery alone. This is true for all lymph node positive cases of non-small cell lung cancer (NSCLC) with a tumor size of 4 cm or more. Worldwide, the application of adjuvant chemotherapy for these indications is regarded as standard treatment. Due to the positive results of adjuvant chemotherapy, nearly all studies focusing on neoadjuvant chemotherapy were stopped early because control arms with surgery alone were no longer regarded as ethically justified; however, in meta-analyses the effect of neoadjuvant chemotherapy seems be as strong as the effect of adjuvant chemotherapy. In clinical practice neoadjuvant chemotherapy is not routinely established in early stage disease. This approach is more often applied in advanced stages, such as N2 lymph node involvement or in patients where the tumor most probably requires pneumectomy for resection. In the last decade the options for systemic treatment of NSCLC have dramatically changed. In addition to chemotherapy, targeted treatment of patients with molecularly altered tumors and immunotherapy have been used very successfully in advanced stages. The options might also have a high impact on survival in early stages and the integration of these treatment modalities in the management of early stage disease is warranted. This article summarizes the established and new options in additive systemic treatment and presents the current state of treatment. -PU - SPRINGER HEIDELBERG -PI - HEIDELBERG -PA - TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY -SN - 0009-4722 -SN - 1433-0385 -DA - 2019 DEC -PY - 2019 -VL - 90 -IS - 12 -SP - 982 -EP - 990 -DO - 10.1007/s00104-019-01063-z -AN - WOS:000495219200002 -C6 - NOV 2019 -AD - Klinikum Kassel, Klin Hamatol Onkol Immunol, Monchebergstr 41-43, D-34125 Kassel, Germany -Y2 - 2019-11-22 -ER - - -TY - JOUR -AU - Uprety, Dipesh -AU - Parikh, Kaushal -AU - Sawkar, Anita -AU - Dimou, Anastasios -AU - Leventakos, Konstantinos -TI - Changing paradigm in advanced and metastatic non-small cell lung cancer -T2 - JOURNAL OF THORACIC DISEASE -M3 - Review -AB - Lung cancer is the most common cancer worldwide. Approximately 18% of all deaths related to cancer are associated with lung cancer. Management of non-small cell lung cancer (NSCLC) has been changing rapidly in last few years. For patients with unresectable non-metastatic disease, maintenance durvalumab is now given after offering chemo-radiation concurrently based on the result from the PACIFIC trial. Management of metastatic disease greatly depends on the status of sensitizing driver mutation and PD L1 level of the tumor cells. In this review article, we will summarize the outcome of various clinical trials and will provide the most up-to-date information on the management of patients with advanced and metastatic NSCLC. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2020 NOV -PY - 2020 -VL - 12 -IS - 11 -SP - 6992 -EP - 7001 -DO - 10.21037/jtd-20-1472 -AN - WOS:000614714500028 -AD - Mayo Clin, Dept Oncol, Rochester, MN USA -AD - Hackensack Univ, Med Ctr, Dept Oncol, Hackensack, NJ USA -AD - Hackensack Univ, Med Ctr, Dept Internal Med, Hackensack, NJ USA -Y2 - 2021-02-23 -ER - - -TY - JOUR -AU - PARK, JAE-IL ; Kwon-Sik Park -TI - CRACD-controlled cell plasticity and small cell lung cancer -M3 - Awarded Grant -AB - PROJECT SUMMARY/ABSTRACTSmall cell lung cancer (SCLC) is an extremely deadly cancer, and current chemo/radiation therapies lack durableeffects. Immunotherapy with immune checkpoint blockades is effective for only ~13% of SCLC patients andrarely results in sustained responses in extensive-stage SCLC. Targeted therapy development for SCLC ischallenging as SCLC tumors typically have few actionable drivers but instead are mainly driven by loss-of-function mutations in RB1 and TP53 (>90%) and frequent loss and inactivation of other potential tumorsuppressors, including a set of epigenetic regulators. Nevertheless, recent discoveries from SCLC genomicsprovide a new framework for understanding the biology of SCLC and identifying the molecular vulnerabilities ofthe disease. Functional characterization of the recurrent mutations in putative tumor suppressor genes is crucialfor defining the mechanisms of tumorigenesis, which will facilitate the discovery of biomarkers for tumorprevention and intervention. We recently identified a new tumor suppressor gene, CRACD (Capping proteininhibiting Regulator of ACtin Dynamics; KIAA1211/CRAD). CRACD encodes a protein that binds to and inhibitsthe capping proteins, thereby facilitating actin polymerization. CRACD is frequently mutated or transcriptionallydownregulated in SCLC patient tumors. Cracd knockout (KO) promotes the transformation of preneoplasticprecursor lung epithelial cells. Cracd KO also significantly accelerates SCLC development in an autochthonousmouse model in which tumor initiation is induced by the deletion of Rb1, Trp53, and Rbl2 triple KO mousemodels. Cracd KO SCLC tumors harbor distinct root cell clusters with aberrant cell lineage trajectories andimpaired antigen presentation. Single-cell transcriptome analysis has further stratified SCLC patients by CRACDinactivation and antigen presentation pathway impairment. Intriguingly, ablation of Cracd alone induceshyperplasia of neuroendocrine cells and aberrant cell lineage plasticity in the mouse lung. These results led tothe hypothesis that CRACD inactivation induces aberrant neuroendocrine cell plasticity to initiate and promoteSCLC tumorigenesis via dysregulated nuclear actin dynamics and subsequent epigenetic reprogramming. Theproposed study will unveil the biology of SCLC initiation and progression and determine the cells-of-origin andtheir relevant cell lineages inducing neuroendocrine cell plasticity, providing novel insight into SCLCtumorigenesis. Additionally, this study will establish a new model system for SCLC initiation and progression andintroduce a novel somatic engineering system, which is technologically innovative. Completing this study willalso lay a solid foundation to determine whether CRACD loss is a molecular signature for specific SCLC patientstratification and immunotherapy response prediction, which will be conceptually and clinically innovative. -DA - 2024 -PY - 2024 -AN - GRANTS:17494910 -G1 - 10800511; 1R01CA278967-01A1; R01CA278967 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2024-03-10 -ER - - -TY - JOUR -AU - Ni, J. -AU - Chu, L. -AU - Chu, X. -AU - Yang, X. -AU - Yang, H. -AU - Deng, J. -AU - Fan, X. -AU - Zhao, W. -AU - Zhang, X. -AU - Lai, S. -AU - Gu, Y. -AU - Zhang, J. -AU - Liu, D. -AU - Mo, M. -AU - Zhu, Z. -TI - STELLAR: A Phase II, Open-Label, Single-Arm, Prospective Clinical Study of Tislelizumab Combined with Sitravatinib as Consolidation Treatment after Chemoradiotherapy in Locally Advanced, Unresectable Non-Small-Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - ELECTR NETWORK -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2022 NOV 1 -PY - 2022 -VL - 114 -IS - 3 -MA - 2863 -SP - E385 -EP - E386 -AN - WOS:000892639301190 -AD - Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China -AD - Fudan Univ, Shanghai Med Coll, Shanghai, Peoples R China -Y2 - 2023-03-09 -ER - - -TY - JOUR -AU - Harada, Taishi -AU - Sasaki, Tomonari -AU - Ishii, Hidenobu -AU - Takemoto, Shinnosuke -AU - Hisamatsu, Yasushi -AU - Saito, Haruhiro -AU - Yoneshima, Yasuto -AU - Komiya, Kazutoshi -AU - Kashiwabara, Kosuke -AU - Naoki, Katsuhiko -AU - Ogawa, Tomohiro -AU - Takeoka, Hiroaki -AU - Saruwatari, Koichi -AU - Ito, Kensaku -AU - Tsuchiya-Kawano, Yuko -AU - Mizuno, Keiko -AU - Shimose, Takayuki -AU - Shioyama, Yoshiyuki -AU - Okamoto, Isamu -TI - A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902) -T2 - THORACIC CANCER -M3 - Article -M3 - Early Access -AB - Background: Concurrent chemoradiotherapy is the standard therapy for locally advanced non-small cell lung cancer (NSCLC). However, there is little evidence supporting its use in older adults. Low-dose daily carboplatin combined with thoracic radiotherapy is considered a standard regimen for this population. To establish a simple and feasible carboplatin administration method, we conducted a study of weekly carboplatin and concurrent radiotherapy for older adults with locally advanced NSCLC. Methods: This prospective, single-arm, multicenter, phase II clinical trial included patients aged >= 75 years with unresectable stage III NSCLC and Eastern Cooperative Oncology Group performance status 0-1. Patients received chemoradiotherapy (60 Gy/30 fractions plus concurrent weekly carboplatin at an area under curve of 2 mg mL(-1) min(-1)). The primary endpoint was the overall response rate (ORR). Key secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Results: From July 2020 to June 2022, 37 patients were enrolled from 15 institutions, and 36 patients were evaluable for efficacy and safety. The ORR was 63.9% (95% confidence interval [CI] = 47.6-77.5). Median PFS was 14.6 months (95% CI = 9.1-18.1). Median OS was 25.5 months (95% CI = 17.4-not reached). Grade 4 leucopenia, neutropenia, and thrombocytopenia were observed in one patient (2.8%) each. Conclusion: Weekly carboplatin and concurrent radiation therapy was safe in older adults with locally advanced NSCLC, and promising activity was observed. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1759-7706 -SN - 1759-7714 -DA - 2024 SEP 8 -PY - 2024 -DO - 10.1111/1759-7714.15444 -AN - WOS:001308471700001 -C6 - SEP 2024 -AD - Japan Community Healthcare Org Kyushu Hosp, Dept Resp Med, 1-8-1 Kishinoura,Yahatanishi ku, Kitakyushu, Fukuoka 8068501, Japan -AD - Iizuka Hosp, Dept Radiat Oncol, Iizuka, Japan -AD - Kurume Univ, Dept Internal Med, Div Respirol Neurol & Rheumatol, Sch Med, Kurume, Japan -AD - Nagasaki Univ, Grad Sch Biomed Sci, Dept Resp Med, Nagasaki, Japan -AD - Oita Prefectural Hosp, Dept Thorac Oncol, Oita, Japan -AD - Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Japan -AD - Kyushu Univ, Grad Sch Med Sci, Dept Resp Med, Fukuoka, Japan -AD - Natl Hosp Org Ureshino Med Ctr, Dept Resp Med, Ureshino, Japan -AD - Kumamoto Reg Med Ctr, Dept Resp Med, Kumamoto, Japan -AD - Kitasato Univ, Sch Med, Dept Resp Med, Sagamihara, Japan -AD - Saiseikai Fukuoka Gen Hosp, Dept Resp Med, Fukuoka, Japan -AD - NHO Kyushu Med Ctr, Dept Resp Med, Fukuoka, Japan -AD - Kumamoto Univ Hosp, Dept Resp Med, Kumamoto, Japan -AD - NHO Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan -AD - Kitakyushu Municipal Med Ctr, Dept Resp Med, Kitakyushu, Japan -AD - Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pulm Med, Kagoshima, Japan -AD - Clin Res Support Ctr Kyushu, Dept Stat & Data Ctr, Fukuoka, Japan -AD - SAGA HIMAT Fdn, Ion Beam Therapy Ctr, Tosu, Japan -M2 - Japan Community Healthcare Org Kyushu Hosp -M2 - Iizuka Hosp -M2 - Oita Prefectural Hosp -M2 - Natl Hosp Org Ureshino Med Ctr -M2 - Kumamoto Reg Med Ctr -M2 - Saiseikai Fukuoka Gen Hosp -M2 - NHO Kyushu Med Ctr -M2 - Kitakyushu Municipal Med Ctr -M2 - Clin Res Support Ctr Kyushu -M2 - SAGA HIMAT Fdn -Y2 - 2024-09-15 -ER - - -TY - JOUR -AU - Bang, Andrew -AU - Schoenfeld, Jonathan D. -AU - Sun, Alexander Y. -TI - PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - The treatment paradigm of stage III, unresectable non-small cell lung cancer (NSCLC) has had few advancement since concurrent chemoradiotherapy was established as standard of care treatment. Despite modifications to radiotherapy, chemotherapy and surgical approaches, loco-regional and distant relapse remain high, which unfortunately has translated to poor survival outcomes. The PACIFIC study introduced immunotherapy to the domain of stage III NSCLC and has emerged as the fourth pillar in cancer treatment for these patients. The positive results of the study have excited both the radiation and medical oncology communities, demonstrating improvements in overall and progression-free survival (PFS). In this review, we discuss the details and impacts of the PACIFIC study, as well as the future implications for the treatment of stage III NSCLC. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2019 SEP -PY - 2019 -VL - 8 -SP - S139 -EP - S146 -DO - 10.21037/tlcr.2019.09.04 -AN - WOS:000485805900004 -AD - Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA -AD - Univ Toronto, Dept Radiat Oncol, Princess Margaret Canc Ctr, 610 Univ Ave, Toronto, ON M5G 2C1, Canada -Y2 - 2019-09-30 -ER - - -TY - JOUR -AU - Wentink, Madelon Q. -AU - Huijbers, Elisabeth J. M. -AU - de Gruijl, Tanja D. -AU - Verheul, Henk M. W. -AU - Olsson, Anna-Karin -AU - Griffioen, Arjan W. -TI - Vaccination approach to anti-angiogenic treatment of cancer -T2 - BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER -M3 - Review -AB - Improvement of patient survival by anti-angiogenic therapy has proven limited. A vaccination approach inducing an immune response against the tumor vasculature combines the benefits of immunotherapy and anti-angiogenesis, and may overcome the limitations of current anti-angiogenic drugs. Strategies to use whole endo: thelial cell vaccines and DNA- or protein vaccines against key players in the VEGF signaling axis, as well as specific markers of tumor endothelial cells, have been tested in preclinical studies. Current clinical trials are now testing the promise of this specific anti-cancer vaccination approach. This review will highlight the state-of-the-art in this exciting field of cancer research. (C) 2015 Elsevier B.V. All rights reserved. -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 0304-419X -SN - 1879-2561 -DA - 2015 APR -PY - 2015 -VL - 1855 -IS - 2 -SP - 155 -EP - 171 -DO - 10.1016/j.bbcan.2015.01.005 -AN - WOS:000355366400004 -AD - Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Angiogenesis Lab, Amsterdam, Netherlands -AD - Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, Uppsala, Sweden -Y2 - 2015-07-02 -ER - - -TY - JOUR -AU - Corrigan, Kelsey L. -AU - Xu, Ting -AU - Sasaki, Yuki -AU - Lin, Ruitao -AU - Chen, Aileen B. -AU - Welsh, James W. -AU - Lin, Steven H. -AU - Chang, Joe Y. -AU - Ning, Matthew S. -AU - Gandhi, Saumil -AU - O'Reilly, Michael S. -AU - Gay, Carl M. -AU - Altan, Mehmet -AU - Lu, Charles -AU - Cascone, Tina -AU - Koutroumpakis, Efstratios -AU - Sheshadri, Ajay -AU - Zhang, Xiaodong -AU - Liao, Li -AU - Zhu, X. Ronald -AU - Heymach, John V. -AU - Nguyen, Quynh-Nhu -AU - Liao, Zhongxing -TI - Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma -T2 - RADIOTHERAPY AND ONCOLOGY -M3 - Article -AB - Introduction: Adjuvant immunotherapy (IO) following concurrent chemotherapy and photon radiation therapy confers an overall survival (OS) benefit for patients with inoperable locally advanced non-small cell lung carcinoma (LA-NSCLC); however, outcomes of adjuvant IO after concurrent chemotherapy with proton beam therapy (CPBT) are unknown. We investigated OS and toxicity after CPBT with adjuvant IO versus CPBT alone for inoperable LA-NSCLC. Materials and methods: We analyzed 354 patients with LA-NSCLC who were prospectively treated with CPBT with or without adjuvant IO from 2009 to 2021. Optimal variable ratio propensity score matching (PSM) matched CPBT with CPBT + IO patients. Survival was estimated with the Kaplan -Meier method and compared with log -rank tests. Multivariable Cox proportional hazards regression evaluated the effect of IO on disease outcomes. Results: Median age was 70 years; 71 (20%) received CPBT + IO and 283 (80%) received CPBT only. After PSM, 71 CPBT patients were matched with 71 CPBT + IO patients. Three-year survival rates for CPBT + IO vs CPBT were: OS 67% vs 30% (P < 0.001) and PFS 59% vs 35% (P = 0.017). Three-year LRFS (P = 0.137) and DMFS (P = 0.086) did not differ. Receipt of adjuvant IO was a strong predictor of OS (HR 0.40, P = 0.001) and PFS (HR 0.56, P = 0.030), but not LRFS (HR 0.61, P = 0.121) or DMFS (HR 0.61, P = 0.136). There was an increased incidence of grade >= 3 esophagitis in the CPBT-only group (6% CPBT + IO vs 17% CPBT, P = 0.037). Conclusion: This study, one of the first to investigate CPBT followed by IO for inoperable LA-NSCLC, showed that IO conferred survival benefits with no increased rates of toxicity. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0167-8140 -SN - 1879-0887 -DA - 2024 APR -PY - 2024 -VL - 193 -C7 - 110121 -DO - 10.1016/j.radonc.2024.110121 -AN - WOS:001183626200001 -C6 - FEB 2024 -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Biostat & Computat Sci, Houston, TX USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac & Head & Neck Med Oncol, Houston, TX USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 1422, 1400 Pressler St, Houston, TX 77030 USA -Y2 - 2024-03-22 -ER - - -TY - JOUR -AU - Faivre-Finn, Corinne -AU - Vicente, David -AU - Kurata, Takayasu -AU - Planchard, David -AU - Paz-Ares, Luis -AU - Vansteenkiste, Johan F. -AU - Spigel, David R. -AU - Garassino, Marina C. -AU - Reck, Martin -AU - Senan, Suresh -AU - Naidoo, Jarushka -AU - Rimner, Andreas -AU - Wu, Yi-Long -AU - Gray, Jhanelle E. -AU - Ozguroglu, Mustafa -AU - Lee, Ki H. -AU - Cho, Byoung C. -AU - Kato, Terufumi -AU - de Wit, Maike -AU - Newton, Michael -AU - Wang, Lu -AU - Thiyagarajah, Piruntha -AU - Antonia, Scott J. -TI - Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial -T2 - JOURNAL OF THORACIC ONCOLOGY -M3 - Article -AB - Introduction: In the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable, stage III NSCLC without disease progression after concurrent chemoradiotherapy, consolidative durvalumab was associated with significant improvements in the primary end points of overall survival (OS) (hazard ratio [HR] = 0.68; 95% confidence interval [CI]: 0.53-0.87; p = 0.00251; data cutoff, March 22, 2018) and progression-free survival (PFS) (blinded independent central review; Response Evaluation Criteria in Solid Tumors version 1.1) (HR = 0.52; 95% CI: 0.42-65; p < 0.0001; February 13, 2017) with manageable safety. Here, we report updated analyses of OS and PFS, approximately 4 years after the last patient was randomized.Methods: Patients with WHO performance status of 0 or 1 (and any tumor programmed death-ligand 1 status) were randomized (2:1) to intravenous durvalumab (10 mg/kg) or placebo, administered every 2 weeks (<= 12 months), stratified by age, sex, and smoking history. OS and PFS were analyzed using a stratified log-rank test in the intent-to-treat population. Medians and 4-year OS and PFS rates were estimated by the Kaplan-Meier method.Results: Overall, 709 of 713 randomized patients received durvalumab (n/N=473/476) or placebo (n/N=236/237). As of March 20, 2020 (median follow-up = 34.2 months; range: 0.2-64.9), updated OS (HR = 0.71; 95% CI: 0.57-0.88) and PFS (HR = 0.55; 95% CI: 0.44-0.67) remained consistent with the primary analyses. The median OS for durvalumab was reached (47.5 mo; placebo, 29.1 months). Estimated 4-year OS rates were 49.6% versus 36.3% for durvalumab versus placebo, and 4-year PFS rates were 35.3% versus 19.5% respectively.Conclusion: These updated exploratory analyses demonstrate durable PFS and sustained OS benefit with durvalumab after chemoradiotherapy. An estimated 49.6% of patients randomized to durvalumab remain alive at 4 years (placebo, 36.3%), and 35.3% remain alive and progression-free (placebo, 19.5%). (C) 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1556-0864 -SN - 1556-1380 -DA - 2021 MAY -PY - 2021 -VL - 16 -IS - 5 -SP - 860 -EP - 867 -DO - 10.1016/j.jtho.2020.12.015 -AN - WOS:000654743200019 -C6 - APR 2021 -AD - Univ Manchester, Manchester, Lancs, England -AD - Christie NHS Fdn Trust, Wilmslow Rd, Manchester M20 4BX, Lancs, England -AD - Hosp Univ Virgen Macarena, Dept Med Oncol, Seville, Spain -AD - Kansai Med Univ Hosp, Dept Internal Med, Hirakata, Osaka, Japan -AD - Gustave Roussy, Dept Med Oncol, Thorac Unit, Villejuif, France -AD - Univ Complutense, CiberOnc, Madrid, Spain -AD - Hosp Univ 12 Octubre, Ctr Nacl Invest Oncol CNIO, Madrid, Spain -AD - Univ Hosp KU Leuven, Dept Chron Dis & Metab, Leuven, Belgium -AD - Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA -AD - Fdn Ist Ricovero & Cura Carattere Sci IRCCS, Ist Nazl Tumori, Div Med Oncol, Milan, Italy -AD - German Ctr Lung Res, Airway Res Ctr North, Lung Clin Grosshansdorf, Grosshansdorf, Germany -AD - Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Radiat Oncol, Amsterdam, Netherlands -AD - Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA -AD - Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA -AD - Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA -AD - Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Dept Pulm Oncol, Guangzhou, Peoples R China -AD - Guangdong Acad Med Sci, Guangzhou, Peoples R China -AD - H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA -AD - Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Dept Internal Med, Div Med Oncol, Istanbul, Turkey -AD - Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Dept Internal Med, Cheongju, South Korea -AD - Yonsei Univ, Yonsei Canc Ctr, Coll Med, Dept Internal Med, Seoul, South Korea -AD - Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan -AD - Vivantes Klinikum Neukolln, Dept Hematol Oncol & Palliat Med, Berlin, Germany -AD - AstraZeneca, Dept Clin Oncol, Gaithersburg, MD USA -AD - AstraZeneca, Dept Clin Oncol, Cambridge, England -M2 - German Ctr Lung Res -Y2 - 2021-04-22 -ER - - -TY - JOUR -AU - Asai, Nobuhiro -AU - Ohkuni, Yoshihiro -AU - Kaneko, Norihiro -AU - Yamaguchi, Etsuro -AU - Kubo, Akihito -TI - Relapsed small cell lung cancer: treatment options and latest developments -T2 - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY -M3 - Review -AB - According to recent analyses, there was a modest yet significant improvement in median survival time and 5-year survival rate of limited stage small cell lung cancer (SCLC) in North America, Europe, Japan and other countries over the last 30 years. The median survival time of limited stage SCLC is 15-20 months and 5-year survival rate is 15% or less. In terms of extensive stage SCLC, a median survival time of 9.4-12.8 months and 2-year survival of 5.2-19.5% are still disappointing. Despite being highly sensitive to first-line chemotherapy and radiotherapy treatments, most patients with SCLC experience relapse within 2 years and die from systemic metastasis. While several clinical trials of cytotoxic chemotherapies and molecular targeting agents have been investigated in the treatment of relapsed SCLC, none showed a significant clinical activity to be able to exceed topotecan as second-line chemotherapy. There are problematic issues to address for relapsed SCLC, such as standardizing the treatment for third-line chemotherapy. Topotecan alone was the first approved therapy for second-line treatment for relapsed SCLC. Amrubicin is a promising drug and a variety of trials evaluating its efficacy have been carried out. Amrubicin has shown superiority to topotecan in a Japanese population, but was not superior in a study of western patients. There are some controversial issues for relapsed SCLC, such as treatment for older patients, third-line chemotherapy and efficacy of molecular targeting therapy. This article reviews current standard treatment, recent clinical trials and other topics on relapsed SCLC. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1758-8340 -SN - 1758-8359 -DA - 2014 MAR -PY - 2014 -VL - 6 -IS - 2 -SP - 69 -EP - 82 -DO - 10.1177/1758834013517413 -AN - WOS:000335816900004 -AD - Aichi Med Univ, Dept Internal Med, Div Resp Med & Allergol, Sch Med, Aichi, Japan -AD - Dept Pulmonol, Nagakute, Aichi 4801195, Japan -AD - Kameda Med Ctr, Dept Pulmonol, Chiba, Japan -M2 - Dept Pulmonol -M2 - Kameda Med Ctr -Y2 - 2014-06-11 -ER - - -TY - JOUR -AU - Palomar-Abril, V -AU - Soria-Comes, T. -AU - Campos, S. T. -AU - Ureste, M. M. -AU - Bosch, V. G. -AU - Maiques, I. C. M. -TI - Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy -T2 - CLINICAL & TRANSLATIONAL ONCOLOGY -M3 - Article -AB - Purpose Locally advanced non-small cell lung cancer (LA-NSCLC) is frequently treated with chemoradiotherapy (CRT). Despite the efforts, long-term outcomes are poor, and novel therapies have been introduced to improve results. Biomarkers are needed to detect early treatment failure and plan future follow-up and therapies. Our aim is to evaluate the role of dynamics of neutrophil-to-lymphocyte ratio (NLR) in patients with locally advanced NSCLC treated with CRT. Methods We retrospectively reviewed patients diagnosed with LA-NSCLC receiving definitive CRT at our center from 2010 to 2015. Baseline and post-treatment NLR were collected from our center database. NLR was dichotomized (threshold = 4) and patients were divided into two groups based on the variation from baseline to post-treatment NLR. The prognostic role and association with response were examined with logistic regression and multivariate Cox regression model, respectively. Results Ninety-two patients were included. Our analysis shows that NLR after treatment is associated with response to treatment [OR in the multivariate analysis 4.94 (1.01-24.48); p value = 0.048]. Furthermore, NLR and ECOG are independent prognostic factors for progression-free survival (PFS) and overall survival (OS). Specifically, PFS was 25.79 months for the good prognosis group and 12.09 for the poor prognosis group [HR 2.98 (CI 95% = 1.74-5.10), p < 0.001]; and OS was 42.94 months and 18.86 months, respectively [HR 2.81 (CI 95% = 1.62-4.90), p < 0.001]. Conclusion Dynamics of NLR have a prognostic value in stage III NSCLC treated with definitive CRT. Pre- and post-CRT NLR should be evaluated in prospective clinical trials involving consolidation treatment with immunotherapy. -PU - SPRINGER INT PUBL AG -PI - CHAM -PA - GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND -SN - 1699-048X -SN - 1699-3055 -DA - 2020 DEC -PY - 2020 -VL - 22 -IS - 12 -SP - 2333 -EP - 2340 -DO - 10.1007/s12094-020-02396-6 -AN - WOS:000535163800001 -C6 - MAY 2020 -AD - Hosp Univ Doctor Peset, Dept Med Oncol, Valencia 46017, Spain -AD - Univ Politecn Valencia, Dept Appl Stat Operat Res & Qual, Valencia, Spain -AD - Univ Politecn Valencia, Ctr Qual & Change Management, Valencia, Spain -M2 - Hosp Univ Doctor Peset -Y2 - 2020-06-04 -ER - - -TY - JOUR -AU - Zhou, Qing -AU - Chen, Ming -AU - Wu, Gang -AU - Chang, Jian-Hua -AU - Jiang, Ou -AU - Cui, Jiu-Wei -AU - Han, Guang -AU - Lin, Qin -AU - Fang, Jian -AU - Chen, Gong-Yan -AU - Wu, Yi-Long -TI - GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Article -AB - Background: In China, platinum-based doublet chemotherapy is the standard treatment for patients who have unresectable stage III non-small cell lung cancer (NSCLC), administered with radiotherapy on either a concurrent or sequential basis. However, NSCLC patients who undergo this treatment can expect poor median progression-free survival (PFS) of around 8-10 months and a dismal 5-year overall survival (OS) rate of about 15%. In the recent PACIFIC trial, durvalumab was demonstrated to hold significant clinical benefit for patients with locally advanced/unresectable NSCLC who experienced no disease progression after definitive concurrent chemoradiotherapy (cCRT). CS1001 is the first full-length, fully human immunoglobin G4 (IgG4) monoclonal antibody (mAb) that targets programmed death ligand-1 (PD-L1) created through the OMT transgenic rat platform. The phase Ia/Ib study indicated CS1001 was well tolerated and exhibited anti-tumor potential with a range of tumors. GEMSTONE-301 is a phase III randomized, double-blind, study to explore the efficacy and safety of CS1001 compared with a placebo as consolidation therapy for stage III unresectable NSCLC patients.Methods: In this trial, eligible patients will be randomized to receive CS1001 1,200 mg or placebo, every 3 weeks (Q3W). The primary endpoint will be investigator-assessed PFS, based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The secondary endpoints will include OS, PFS assessment based on Blinded Independent Center Review (BICR), objective response rate (ORR), other efficacy measurements, safety, and tolerability.Discussion: This phase III trial will determine the efficacy and safety of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) NSCLC who did not have disease progression after prior concurrent/sequential chemoradiotherapy (cCRT or sCRT), and is the first phase III trial on an antiPD-L1 mAb initiated in China for this indication. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2020 OCT -PY - 2020 -VL - 9 -IS - 5 -SP - 2008 -EP - 2015 -DO - 10.21037/tlcr-20-608 -AN - WOS:000582799700030 -AD - South China Univ Technol, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China -AD - South China Univ Technol, Guangdong Acad Med Sci, Sch Med, Guangzhou, Peoples R China -AD - Zhejiang Canc Hosp, Hangzhou, Peoples R China -AD - Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China -AD - Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China -AD - Sichuan Med Univ, Peoples Hosp Neijiang 2, Neijiang, Peoples R China -AD - First Hosp Jilin Univ, Jilin, Jilin, Peoples R China -AD - Hubei Canc Hosp, Wuhan, Peoples R China -AD - Xiamen Univ, Affiliated Hosp 1, Canc Hosp, Xiamen, Peoples R China -AD - Beijing Canc Hosp, Beijing, Peoples R China -AD - Harbin Med Univ, Affiliated Hosp 3, Harbin, Peoples R China -M2 - First Hosp Jilin Univ -M2 - Hubei Canc Hosp -Y2 - 2020-11-11 -ER - - -TY - JOUR -AU - Yao, Yongfang -AU - Fareed, Rameesha -AU - Zafar, Aliya -AU - Saleem, Kalsoom -AU - Huang, Tao -AU - Duan, Yongtao -AU - Rehman, Masood Ur -TI - State-of-the-art combination treatment strategies for advanced stage non-small cell lung cancer -T2 - FRONTIERS IN ONCOLOGY -M3 - Review -AB - Non-small cell lung cancer (NSCLC) is the most abundant type of epithelial lung cancer being diagnosed after 40% of invasions of excrescence in pulmonary tissues. According to WHO, 30% of NSCLC patients can be cured if diagnosed and treated early. Mutations play an important role in advanced stage NSCLC treatment, which includes critical proteins necessary for cellular growth and replication. Restricting such mutations may improve survival in lung cancer patients. Newer technologies include endoscopic bronchial ultrasonography and esophageal ultrasonography. Currently, policymaking or decision-making for treatment regimens merely depends on the genomic alterations and mutations. DNA sequencing, methylation, protein, and fragmented DNA analysis do NSCLC screening. Achievement of these goals requires consideration of available therapeutics in current anticancer approaches for improving quality of life and treatment outcomes for NSCLC patient. The specific goals of this review are to discuss first-line and second-line therapies for advanced-stage NSCLC and molecularly targeted therapy including thoughtful discussion on precise role of treatment strategies in specific tumors. Also, concerned diagnostics, new clinical trial designs, and pursuing appropriate combinations of radiotherapy and/or chemotherapy with biological therapy for exceptional cases considering resistance mechanisms and palliative care will be discussed. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2022 AUG 1 -PY - 2022 -VL - 12 -C7 - 958505 -DO - 10.3389/fonc.2022.958505 -AN - WOS:000840830000001 -AD - Zhengzhou Univ, Childrens Hosp, Henan Prov Key Lab Childrens Genet & Metab Dis, Zhengzhou, Peoples R China -AD - Zhengzhou Univ, Sch Pharmaceut Sci, Key Lab Adv Drug Preparat Technol, Minist Educ, Zhengzhou, Peoples R China -AD - Zhengzhou Univ, Sch Pharmaceut Sci, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Peoples R China -AD - Riphah Int Univ, Riphah Inst Pharmaceut Sci, Islamabad, Pakistan -AD - Huanghe Sci & Technol Univ, Med Sch, Zhengzhou, Peoples R China -M2 - Riphah Int Univ -M2 - Huanghe Sci & Technol Univ -Y2 - 2022-08-24 -ER - - -TY - JOUR -AU - Wang, Fuli -AU - Xia, Teng -AU - Li, Zhiqiang -AU - Gao, Xuzhu -AU - Fang, Xinjian -TI - Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer -T2 - FRONTIERS IN ONCOLOGY -M3 - Review -AB - Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung cancer (NSCLC) with remarkable success. Compared to chemotherapy patients, the 5-year survival rate for immunotherapy patients is 3-fold higher, approximately 4%-5% versus 15%-16%, respectively. Immunotherapies include chimeric antigen receptor T-cell (CAR-T) therapy, tumor vaccines, immune checkpoint inhibitors, and so forth. Among them, immune checkpoint inhibitors are in the spotlight. Common immune checkpoint inhibitors (ICIs) currently in clinical use include programmed death receptor-1(PD-1)/programmed death ligand-1(PD-L1) and cytotoxic T lymphocyte-associated antigen 4(CTLA-4). This article focuses on monotherapy and combination therapy of CTLA-4 and PD-1/PD-L1 immune checkpoint inhibitors. In particular, the combination therapy of ICIs includes the combination of ICIs and chemotherapy, the combination therapy of dual ICIs, the combination of ICIs and anti-angiogenic drugs, the combination of ICIs and radiotherapy, and the combination of ICIs inhibitors and tumor vaccines and so forth. This article focuses on the combination therapy of ICIs with chemotherapy, the combination therapy of dual ICIs, and the combination therapy of ICIs with anti-angiogenic drugs. The efficacy and safety of ICIs as single agents in NSCLC have been demonstrated in many trials. However, ICIs plus chemotherapy regimens offer significant advantages in the treatment of NSCLC with little to no dramatic increase in toxicity, while combined dual ICIs significantly reduce the adverse effects (AEs) of chemotherapy. ICIs plus anti-angiogenic agents regimen improves anti-tumor activity and safety and is expected to be the new paradigm for the treatment of advanced NSCLC. Despite some limitations, these agents have achieved better overall survival rates. In this article, we review the current status and progress of research on ICIs in NSCLC in recent years, aiming to better guide the individualized treatment of NSCLC patients. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2023 SEP 1 -PY - 2023 -VL - 13 -C7 - 1213297 -DO - 10.3389/fonc.2023.1213297 -AN - WOS:001066468200001 -AD - Bengbu Med Coll, Lianyungang Clin Coll, Dept Oncol, Lianyungang, Peoples R China -AD - Nanjing Med Univ, Sir Run Run Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China -Y2 - 2023-10-06 -ER - - -TY - JOUR -AU - Mohanty, Sambit K. K. -AU - Mishra, Sourav K. K. -AU - Amin, Mahul B. B. -AU - Agaimy, Abbas -AU - Fuchs, Florian -TI - Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers -T2 - ADVANCES IN ANATOMIC PATHOLOGY -M3 - Review -AB - Until very recently, surgery, chemotherapy, and radiation therapy have been the mainstay of treatment in non-small cell carcinomas (NSCLCs). However, recent advances in molecular immunology have unveiled some of the complexity of the mechanisms regulating cellular immune responses and led to the successful targeting of immune checkpoints in attempts to enhance antitumor T-cell responses. Immune checkpoint molecules such as cytotoxic T-lymphocyte associated protein-4, programmed cell death protein-1, and programmed death ligand (PD-L) 1 have been shown to play central roles in evading cancer immunity. Thus, these molecules have been targeted by inhibitors for the management of cancers forming the basis of immunotherapy. Advanced NSCLC has been the paradigm for the benefits of immunotherapy in any cancer. Treatment decisions are made based on the expression of PD-L1 on the tumor cells and the presence or absence of driver mutations. Patients with high PD-L1 expression (= 50%) and no driver mutations are treated with single-agent immunotherapy whereas, for all other patients with a lower level of PD-L1 expression, a combination of chemotherapy and immunotherapy is preferred. Thus, PD-L1 blockers are the only immunotherapeutic agents approved in advanced NSCLC without any oncogenic driver mutations. PD-L1 immunohistochemistry, however, may not be the best biomarker in view of its dynamic nature in time and space, and the benefits may be seen regardless of PD -L1 expression. Each immunotherapy molecule is prescribed based on the levels of PD-L1 expression as assessed by a Food and Drug Administration-approved companion diagnostic assay. Other biomarkers that have been studied include tumor mutational burden, the T-effector signature, tumor-infiltrating lymphocytes, radiomic assays, inflammation index, presence or absence of immune-related adverse events and specific driver mutations, and gut as well as local microbiome. At the current time, none of these biomarkers are routinely used in the clinical decision-making process for immunotherapy in NSCLC. However, in individual cases, they can be useful adjuncts to conventional therapy. This review describes our current understanding of the role of biomarkers as predictors of response to immune checkpoint molecules. To begin with a brief on cancer immunology in general and in NSCLC, in particular, is discussed. In the end, recent advancements in laboratory techniques for refining biomarker assays are described. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1072-4109 -SN - 1533-4031 -DA - 2023 MAY -PY - 2023 -VL - 30 -IS - 3 -SP - 174 -EP - 194 -DO - 10.1097/PAP.0000000000000395 -AN - WOS:000967887400005 -AD - Adv Med Res Inst, Dept Pathol & Lab Med, Bhubaneswar, India -AD - CORE Diagnost, 406,Udyog Vihar 3, Gurgaon 122001, HR, India -AD - All India Inst Med Sci, Dept Med Oncol, Delhi, India -AD - Univ Tennessee, Dept Pathol & Lab Med, Hlth Sci Ctr, Memphis, TN USA -AD - Univ Tennessee, Dept Urol, Hlth Sci Ctr, Memphis, TN USA -AD - Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany -AD - Friedrich Alexander Univ Erlangen Nurnberg FAU, Erlangen Univ Hosp, Dept Internal Med 1, Erlangen, Germany -AD - Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany -AD - Adv Med Res Inst, 406,Udyog Vihar 3, Gurgaon 122001, HR, India -M2 - Adv Med Res Inst -M2 - CORE Diagnost -M2 - Adv Med Res Inst -Y2 - 2023-05-18 -ER - - -TY - JOUR -AU - Munoz-Unceta, Nerea -AU - Burgueno, Isabel -AU - Jimenez, Elizabeth -AU - Paz-Ares, Luis -TI - Durvalumab in NSCLC: latest evidence and clinical potential -T2 - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY -M3 - Review -AB - Advances in immunotherapy have led to radical improvements in outcomes, including overall survival, such as in non-small cell lung cancer (NSCLC) patients with metastatic disease treated with immune checkpoint inhibitors. More recently, promising results have been obtained in earlier disease settings, and combinations with other therapies are being actively investigated. Durvalumab, a monoclonal antibody directed against the programmed death ligand 1, has demonstrated significant activity in NSCLC, including increased progression-free survival rates after chemoradiation for unresectable stage III disease, with a favourable safety profile. Clinical trials, including phase III studies, are ongoing as monotherapy and in combination with chemotherapy, radiotherapy and other immunotherapies, such as the anti-cytotoxic T-lymphocyte antigen 4 drug tremelimumab, in diverse stages of the disease. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1758-8340 -SN - 1758-8359 -DA - 2018 OCT 11 -PY - 2018 -VL - 10 -DO - 10.1177/1758835918804151 -AN - WOS:000461929400001 -AD - Hosp Univ 12 Octubre, Serv Oncol Med, Ave Cordoba Km 5,4, Madrid 28041, Spain -AD - Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain -AD - Inst Invest I 12, Madrid, Spain -M2 - Inst Invest I 12 -Y2 - 2019-03-28 -ER - - -TY - JOUR -AU - Langberg, Christian Wilhelm -AU - Horndalsveen, Henrik -AU - Helland, Aslaug -AU - Haakensen, Vilde Drageset -TI - Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC -T2 - FRONTIERS IN ONCOLOGY -M3 - Article -AB - IntroductionThe introduction of consolidation immunotherapy after chemoradiotherapy has improved outcome for patients with locally advanced non-small cell lung cancer. However, not all patients receive this treatment. This study identifies factors associated with failure to start durvalumab as consolidation therapy with the aim of optimizing treatment, supportive care and prehabilitation to ensure that more patients complete the planned treatment. Materials and methodsPatients from two clinical trials and a named patient use program, were included in this study. All patients received platinum-doublet chemotherapy concomitant with radiotherapy to a total dose of 60-66 gray. Patient characteristics, cancer treatment, toxicity, performance status and laboratory data before and after chemoradiotherapy were recorded and patients who never started durvalumab were compared with those who did. ResultsA total of 101 patients were included, of which 83 started treatments with durvalumab after chemoradiotherapy. The 18 patients who did not start durvalumab had significantly higher lactate dehydrogenase at baseline and a worse performance status, cumulative toxicity and higher c-reactive protein after completed chemoradiotherapy. Data also suggest that pre-treatment diabetes and reduced hemoglobin and/or diffusion capacity of the lungs for carbon monoxide contribute to the risk of treatment abruption. ConclusionTreatment plan disruption rate was 18%. Systemic inflammation and performance status were associated with failure to receive durvalumab after chemoradiation. Further studies are needed to confirm findings and prospective trials should investigate whether prehabilitation and supportive treatment could help more patients finishing the planned treatment. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2023 JUL 5 -PY - 2023 -VL - 13 -C7 - 1217424 -DO - 10.3389/fonc.2023.1217424 -AN - WOS:001031274800001 -AD - Univ Oslo, Fac Med, Oslo, Norway -AD - Oslo Univ Hosp, Dept Oncol, Oslo, Norway -AD - Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway -AD - Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway -Y2 - 2023-08-02 -ER - - -TY - JOUR -AU - GOPAL, AJAY -TI - Radiolabeled Antibody Therapy of B-Cell Lymphoma -M3 - Awarded Grant -DA - 2008 -PY - 2008 -AN - GRANTS:10200568 -G1 - 0001; 5P01CA044991-21; 7620890; P01CA044991 -AD - FRED HUTCHINSON CANCER RESEARCH CENTER -Y2 - 2023-12-14 -ER - - -TY - JOUR -Z2 - 刘天池 -Z2 - 贾为国 -Z2 - 赵荣华 -Z2 - 崔龙 -AU - Liu Tianchi -AU - Jia Weiguo -AU - Zhao Ronghua -AU - Cui Long -TI - Immunotherapy for colorectal cancer: current status, challenges and solution -T2 - Chinese Journal of Cancer Biotherapy -M3 - Article -AB - Colorectal cancer (CRC) is the third most common malignancy and the fourth leading cause of cancer-related death all over the world. Traditional treatments, including chemotherapy, radiation therapy, surgery and targeted therapy, form the backbone of current treatment in various stages of CRC, but the efficacy in patients with recurrent or metastatic disease is extremely poor. Recently-developed immunotherapy is frequently used in various cancers with high malignancy, such as leukemia, melanoma and non-small-cell lung cancer, and achieves promising clinical outcomes. Immunotherapy has been also investigated in CRC, but the outcome is so disappointed in majority of patients, except the PD-1 inhibitor achieved excellent result in CRC with DNA mismatch repair system deficiency. In this review, the authors will mainly introduce the immunophenotype of different subtype of CRC and summarize current advances of clinical trials for CRC immunotherapy. The article will also discuss the reasons for the low efficacy of immunotherapeutic approaches in CRC and provide several potential directions for the future development of CRC immunotherapy. -SN - 1007-385X -DA - 2018 -PY - 2018 -VL - 25 -IS - 10 -SP - 967 -EP - 978 -C7 - 1007-385X(2018)25:10<967:JZCAMY>2.0.TX;2-M -AN - CSCD:6354312 -AD - Virogin Biotech Ltd., Vancouver, V6S 2L9, Canada -AD - 上海交通大学医学院附属新华医院肛肠外科, 上海 200092, 中国 -AD - Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China -M2 - Virogin Biotech Ltd. -M2 - 上海交通大学医学院附属新华医院肛肠外科 -M2 - Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine -Y2 - 2019-01-07 -ER - - -TY - JOUR -AU - Garassino, Marina C. -AU - Mazieres, Julien -AU - Reck, Martin -AU - Chouaid, Christos -AU - Bischoff, Helge -AU - Reinmuth, Niels -AU - Cove-Smith, Laura -AU - Mansy, Talal -AU - Cortinovis, Diego -AU - Migliorino, Maria R. -AU - Delmonte, Angelo -AU - Garcia Sanchez, Jose -AU - Chara Velarde, Luis Enrique -AU - Bernabe, Reyes -AU - Paz-Ares, Luis -AU - Perez, Ignacio Diaz -AU - Trunova, Nataliya -AU - Foroutanpour, Kayhan -AU - Faivre-Finn, Corinne -TI - Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial -T2 - JOURNAL OF THORACIC ONCOLOGY -M3 - Article -AB - Introduction: On the basis of the findings of the phase 3 PACIFIC trial (NCT02125461), durvalumab is standard of care for patients with stage III, unresectable NSCLC and no disease progression after concurrent chemoradiotherapy (cCRT). Many patients are considered unsuitable for cCRT owing to concerns with tolerability. The phase 2 PACIFIC-6 trial (NCT03693300) evaluates the safety and tolerability of durvalumab after sequential CRT (sCRT).Methods: Patients with stage III, unresectable NSCLC and no progression after platinum-based sCRT were enrolled to receive durvalumab (1500 mg intravenously) every 4 weeks for up to 24 months. The primary end point was the incidence of grade 3 or 4 adverse events possibly related to treatment occurring within 6 months. Secondary end points included investigator -assessed progression-free survival (PFS; Response Evaluation Criteria in Solid Tumors version 1.1) and overall survival.Results: Overall, 117 patients were enrolled (59.8% with performance status >0, 65.8% aged >65 y, and 37.6% with stage IIIA disease). Median treatment duration was 32.0 weeks; 37.6% of patients remained on treatment at data cutoff (July 15, 2021). Grade 3 or 4 AEs occurred in 18.8% of patients. Five patients had grade 3 or 4 possibly related adverse events within 6 months (incidence: 4.3%; 95% confidence interval: 1.4-9.7), including two pneumonitis cases. Two patients (1.7%) had grade 5 AEs of any cause. Survival data maturity was limited. Median PFS was 10.9 months (95% confidence interval: 7.3-15.6), and 12-month PFS and overall survival rates were 49.6% and 84.1%, respectively.Conclusions: Durvalumab after sCRT had a comparable safety profile with that observed with durvalumab after cCRT in PACIFIC and had encouraging preliminary efficacy in a frailer population. (c) 2022 International Association for the Study of Lung Can-cer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/). -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1556-0864 -SN - 1556-1380 -DA - 2022 DEC -PY - 2022 -VL - 17 -IS - 12 -SP - 1415 -EP - 1427 -DO - 10.1016/j.jtho.2022.07.1148 -AN - WOS:000892531300010 -C6 - NOV 2022 -AD - Fdn IRCCS Ist Nazl Tumori, Milan, Italy -AD - Univ Chicago, Dept Hematol Oncol, 5841 South Maryland Ave, Chicago, IL 60637 USA -AD - Univ Paul Sabatier, CHU Toulouse, Toulouse, France -AD - German Ctr Lung Res, Airway Res Ctr North, Lung Clin Grosshansdorf, Grosshansdorf, Germany -AD - Ctr Hosp Intercommunal Creteil, Serv Pneumol, Creteil, France -AD - Thoraxklin Heidelberg, Heidelberg, Germany -AD - German Ctr Lung Res, Asklepios Fachkliniken Munchen Gauting, Gauting, Germany -AD - Christie NHS Fdn Trust, Manchester, Lancs, England -AD - Manchester Univ Hosp Fdn Trust, Manchester, England -AD - South Tees Hosp NHS Fdn Trust, Middlesbrough, Cleveland, England -AD - San Gerardo Hosp, Oncol Unit, ASST Monza, Monza, Italy -AD - San Camillo Forlanini Hosp, Rome, Italy -AD - IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Meldola, Italy -AD - Hosp Arnau Vilanova, Fdn Fomento Invest Sanitaria & Biomed Comunidad V, Med Oncol Dept, Valencia, Spain -AD - Hosp Univ Guadalajara, Guadalajara, Spain -AD - Hosp Univ Virgen del Rocio, Seville, Spain -AD - Univ Complutense, CiberOnc, CNIO, Madrid, Spain -AD - Hosp Univ 12 Octubre, Madrid, Spain -AD - AstraZeneca, Gaithersburg, MD USA -AD - Univ Manchester, Manchester, Lancs, England -M2 - German Ctr Lung Res -M2 - German Ctr Lung Res -M2 - Manchester Univ Hosp Fdn Trust -M2 - South Tees Hosp NHS Fdn Trust -M2 - IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado -M2 - Hosp Arnau Vilanova -M2 - Hosp Univ Guadalajara -Y2 - 2022-12-30 -ER - - -TY - JOUR -AU - John V. Heymach; MINNA, JOHN D. -TI - Targeting Lung Cancer Vulnerabilities -M3 - Awarded Grant -AB - Overall SPORE Summary/AbstractTargeting Lung Cancer Vulnerabilities. The University of Texas SPORE in Lung Cancer represents a uniquecollaboration between the University of Texas Southwestern Medical Center (UTSW) and the University of TexasMD Anderson Cancer Center (MDACC), both of which have outstanding strengths in lung cancer translationaland clinical research. The overarching goal of the SPORE is to develop new therapeutic paradigms based onrecently identified “vulnerabilities” acquired during lung cancer pathogenesis, including a molecularunderstanding of lung cancers in individual patients, and using this information to “personalize” therapy for eachlung cancer patient. Thus, our strategy is to identify lung cancer “therapeutic quartets” which include: 1. aspecific vulnerability; 2. the mechanism of action thus defining therapeutic target(s) for the vulnerability; 3. adeliverable treatment for the target(s); and 4. tumor molecular biomarkers for the vulnerability predicting specifictherapies for each patient. The UT Lung Cancer SPORE builds on a 20-year productive history, incorporatingrecent advances made by our SPORE investigators and the rest of the lung cancer translational researchcommunity in the molecular and mechanistic understanding of tumor autonomous and microenvironmentchanges, acquired vulnerabilities, and important immuno-oncology effects. These advances include novelapproaches to identifying and molecularly classifying vulnerabilities in lung cancer metabolomic changes,cancers immunologically “inert” to PD1/PD-L1 checkpoint blockade, the lung cancer fibrotic stroma(microenvironment), and tumorigenesis-induced replication stress. Our contributions also include preclinicalhuman and mouse model systems for testing the different vulnerabilities, as well as large legacy molecular andclinically annotated preclinical model and clinical specimen datasets. The SPORE is composed of 4 projects,all of which have Human Endpoints: 1. Targeting metabolic vulnerabilities in lung cancer; 2. Targetingvulnerabilities in immunologically-inert lung cancer; 3. Targeting vulnerabilities in the fibrotic extracellular matrix(ECM) of lung cancers; and 4. Therapeutic targeting of oncogene-induced replication stress for tumor cell killingand anti-tumor immunity in small cell lung cancer (SCLC) (which includes a clinical trial targeting replicationstress combined with immune checkpoint inhibtion. There are three cores: A. Administrative (including patientadvocates); B. Molecular Pathology and Tissue Resources; and C. Data Sciences, as well as strongDevelopmental Research and Career Enhancement Programs (DRP, CEP). Our SPORE features leadinglung cancer multi-disciplinary clinical and laboratory scientists, a cadre of experienced patient advocates, andan outstanding publication record. Moving forward, this SPORE will provide information on newly identified lungcancer acquired vulnerabilities, biomarkers for personalizing individual patient therapy, and important preclinicaland information to facilitate clinical translation that has the possibility of changing the face of lung cancer therapy. -DA - 2022 -PY - 2022 -AN - GRANTS:17480018 -G1 - 10489252; 5P50CA070907-23; P50CA070907 -AD - UT SOUTHWESTERN MEDICAL CENTER -AD - UT SOUTHWESTERN MEDICAL CENTER -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - John V. Heymach; MINNA, JOHN D.; Jack Roth -TI - Targeting Lung Cancer Vulnerabilities -M3 - Awarded Grant -AB - Overall SPORE Summary/AbstractTargeting Lung Cancer Vulnerabilities. The University of Texas SPORE in Lung Cancer represents a uniquecollaboration between the University of Texas Southwestern Medical Center (UTSW) and the University of TexasMD Anderson Cancer Center (MDACC), both of which have outstanding strengths in lung cancer translationaland clinical research. The overarching goal of the SPORE is to develop new therapeutic paradigms based onrecently identified “vulnerabilities” acquired during lung cancer pathogenesis, including a molecularunderstanding of lung cancers in individual patients, and using this information to “personalize” therapy for eachlung cancer patient. Thus, our strategy is to identify lung cancer “therapeutic quartets” which include: 1. aspecific vulnerability; 2. the mechanism of action thus defining therapeutic target(s) for the vulnerability; 3. adeliverable treatment for the target(s); and 4. tumor molecular biomarkers for the vulnerability predicting specifictherapies for each patient. The UT Lung Cancer SPORE builds on a 20-year productive history, incorporatingrecent advances made by our SPORE investigators and the rest of the lung cancer translational researchcommunity in the molecular and mechanistic understanding of tumor autonomous and microenvironmentchanges, acquired vulnerabilities, and important immuno-oncology effects. These advances include novelapproaches to identifying and molecularly classifying vulnerabilities in lung cancer metabolomic changes,cancers immunologically “inert” to PD1/PD-L1 checkpoint blockade, the lung cancer fibrotic stroma(microenvironment), and tumorigenesis-induced replication stress. Our contributions also include preclinicalhuman and mouse model systems for testing the different vulnerabilities, as well as large legacy molecular andclinically annotated preclinical model and clinical specimen datasets. The SPORE is composed of 4 projects,all of which have Human Endpoints: 1. Targeting metabolic vulnerabilities in lung cancer; 2. Targetingvulnerabilities in immunologically-inert lung cancer; 3. Targeting vulnerabilities in the fibrotic extracellular matrix(ECM) of lung cancers; and 4. Therapeutic targeting of oncogene-induced replication stress for tumor cell killingand anti-tumor immunity in small cell lung cancer (SCLC) (which includes a clinical trial targeting replicationstress combined with immune checkpoint inhibtion. There are three cores: A. Administrative (including patientadvocates); B. Molecular Pathology and Tissue Resources; and C. Data Sciences, as well as strongDevelopmental Research and Career Enhancement Programs (DRP, CEP). Our SPORE features leadinglung cancer multi-disciplinary clinical and laboratory scientists, a cadre of experienced patient advocates, andan outstanding publication record. Moving forward, this SPORE will provide information on newly identified lungcancer acquired vulnerabilities, biomarkers for personalizing individual patient therapy, and important preclinicaland information to facilitate clinical translation that has the possibility of changing the face of lung cancer therapy. -DA - 2020 -PY - 2020 -AN - GRANTS:15043518 -G1 - 10023861; 2P50CA070907-21A1; P50CA070907 -AD - UT SOUTHWESTERN MEDICAL CENTER -AD - UT SOUTHWESTERN MEDICAL CENTER -AD - UT SOUTHWESTERN MEDICAL CENTER -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - John V. Heymach; MINNA, JOHN D.; Jack Roth -TI - Targeting Lung Cancer Vulnerabilities -M3 - Awarded Grant -AB - Overall SPORE Summary/AbstractTargeting Lung Cancer Vulnerabilities. The University of Texas SPORE in Lung Cancer represents a uniquecollaboration between the University of Texas Southwestern Medical Center (UTSW) and the University of TexasMD Anderson Cancer Center (MDACC), both of which have outstanding strengths in lung cancer translationaland clinical research. The overarching goal of the SPORE is to develop new therapeutic paradigms based onrecently identified “vulnerabilities” acquired during lung cancer pathogenesis, including a molecularunderstanding of lung cancers in individual patients, and using this information to “personalize” therapy for eachlung cancer patient. Thus, our strategy is to identify lung cancer “therapeutic quartets” which include: 1. aspecific vulnerability; 2. the mechanism of action thus defining therapeutic target(s) for the vulnerability; 3. adeliverable treatment for the target(s); and 4. tumor molecular biomarkers for the vulnerability predicting specifictherapies for each patient. The UT Lung Cancer SPORE builds on a 20-year productive history, incorporatingrecent advances made by our SPORE investigators and the rest of the lung cancer translational researchcommunity in the molecular and mechanistic understanding of tumor autonomous and microenvironmentchanges, acquired vulnerabilities, and important immuno-oncology effects. These advances include novelapproaches to identifying and molecularly classifying vulnerabilities in lung cancer metabolomic changes,cancers immunologically “inert” to PD1/PD-L1 checkpoint blockade, the lung cancer fibrotic stroma(microenvironment), and tumorigenesis-induced replication stress. Our contributions also include preclinicalhuman and mouse model systems for testing the different vulnerabilities, as well as large legacy molecular andclinically annotated preclinical model and clinical specimen datasets. The SPORE is composed of 4 projects,all of which have Human Endpoints: 1. Targeting metabolic vulnerabilities in lung cancer; 2. Targetingvulnerabilities in immunologically-inert lung cancer; 3. Targeting vulnerabilities in the fibrotic extracellular matrix(ECM) of lung cancers; and 4. Therapeutic targeting of oncogene-induced replication stress for tumor cell killingand anti-tumor immunity in small cell lung cancer (SCLC) (which includes a clinical trial targeting replicationstress combined with immune checkpoint inhibtion. There are three cores: A. Administrative (including patientadvocates); B. Molecular Pathology and Tissue Resources; and C. Data Sciences, as well as strongDevelopmental Research and Career Enhancement Programs (DRP, CEP). Our SPORE features leadinglung cancer multi-disciplinary clinical and laboratory scientists, a cadre of experienced patient advocates, andan outstanding publication record. Moving forward, this SPORE will provide information on newly identified lungcancer acquired vulnerabilities, biomarkers for personalizing individual patient therapy, and important preclinicaland information to facilitate clinical translation that has the possibility of changing the face of lung cancer therapy. -DA - 2021 -PY - 2021 -AN - GRANTS:17397239 -G1 - 10203838; 5P50CA070907-22; P50CA070907 -AD - UT SOUTHWESTERN MEDICAL CENTER -AD - UT SOUTHWESTERN MEDICAL CENTER -AD - UT SOUTHWESTERN MEDICAL CENTER -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - Tian, Lin -AU - Wang, Wei -AU - Yu, Bin -AU - Zhang, Guoxia -TI - Efficacy of dendritic cell-cytokine induced killer cells combined with concurrent chemoradiotherapy on locally advanced non-small cell lung cancer -T2 - JOURNAL OF BUON -M3 - Article -AB - Purpose: To explore the efficacy and safety of docetaxel/ cisplatin concurrent chemoradiotherapy (CCRT) combined with dendritic cell-cytokine induced killer cell (DC-CIK) immunotherapy in the treatment of locally advanced non-small cell lung cancer (LANSCLC).Methods: The clinical data of 142 LANSCLC patients treated in our hospital from March 2014 to March 2016 were retrospectively analyzed. 71 patients were treated with docetaxel/cisplatin CCRT (CCRT group), while the remaining 71 patients underwent CCRT combined with DC-CIK immunotherapy (DC-CIK group). The clinical data of all patients were collected, the short-term efficacy, the changes in serum immunological indexes and quality of life before and after treatment, and the incidence of adverse reactions were compared between the two groups, and the overall survival (OS) and progression-free survival (PFS) were recorded during the follow-up of patients.Results: After treatment, the level of cluster of differentiation 3(+) (CD3(+)) CD4(+) T lymphocytes, CD4/CD8 ratio and CD56(+) natural killer (NK) cell ratio significantly rose, while the level of CD3(+) CD8(+) T lymphocytes significantly declined in both groups compared with those before treatment. After treatment, the level of CD3(+) CD4(+) T lymphocytes, CD4/ CD8 ratio and CD56(+) NK cell ratio were obviously higher, while the level of CD3(+) CD8(+) T lymphocytes was obviously lower in DC-CIK group than those in CCRT group. At 12 months after treatment, both Karnofsky performance scale (KPS) score and quality of life (QOL) score in DC-CIK group were evidently higher than those in CCRT group. In CCRT group and DC-CIK group, 1-year OS was 74.6% and 83.1%, and 1-year PFS was 70.4% and 73.2%, respectively. 2-year OS was 45.1% and 57.7%, and 2-year PFS was 38.0% and 46.5%), respectively. 3-year OS was 26.8% and 40.8%, and 3-year PFS was 15.5% and 22.5%, respectively. It can be seen that both OS and PFS in DC-CIK group were remarkably superior to those in CCRT group.Conclusion: Docetaxel/cisplatin CCRT combined with DCCIK can significantly enhance the cellular immunity, improve the long-term survival rate and raise the quality of life of LANSCLC patients, with tolerable adverse reactions. -PU - IMPRIMATUR PUBLICATIONS -PI - ATHENS -PA - 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE -SN - 1107-0625 -SN - 2241-6293 -DA - 2020 SEP-OCT -PY - 2020 -VL - 25 -IS - 5 -SP - 2364 -EP - 2370 -AN - WOS:000612020000033 -AD - Changchun Univ Tradit Chinese Med, Affiliated Hosp, Dept Respirol, Changchun 130021, Peoples R China -AD - Changchun Univ Tradit Chinese Med, Affiliated Hosp, ICU, Changchun 130021, Peoples R China -AD - Changchun Univ Tradit Chinese Med, Affiliated Hosp, Dept Oncol Hematol, Changchun, Peoples R China -AD - Luohu Dist Chinese Med Hosp, Dept Oncol, 16 Xiantong Rd, Shenzhen 518000, Peoples R China -M2 - Luohu Dist Chinese Med Hosp -Y2 - 2021-02-16 -ER - - -TY - JOUR -AU - PEREZ, BRADFORD A. -TI - Finding Synergy with Radiation Therapy and Immunotherapy for Patients with Lung Cancer -M3 - Awarded Grant -AB - 7. PROJECT SUMMARY/ABSTRACTThe proposed career development training award will provide the candidate, Dr. Bradford Perez, with anexcellent opportunity to establish as an independent clinical/translational investigator. As part of his translationaleffort he seeks to characterize tumor infiltrating immune cells to understand mechanism of synergy withradiation and immunotherapy combinations with a specific interest and plan to further evaluate anti-41bbtherapy in conjunction with radiation therapy. An improved understanding of this mechanism is critical torobust and successful implementation of combined modality strategies in the clinic. The work proposed as partof this award application will also allow Dr. Perez to grow and establish independence as a clinical investigator.He currently serves as the principal investigator for an ongoing investigator initiated clinical trial for patients withextensive stage small cell lung cancer. With the support of a strong mentorship team, he was able to draft theprotocol and navigate the necessary regulatory infrastructure to enroll patients on this Phase I/II trial. Thehuman tissue samples (serial peripheral blood and tumor samples) collected as part of this ongoing trial will bethoroughly analyzed as part of Research Aim 2 to help understand the precise mechanism by which RTmodulates the immune system. Through an improved understanding, future clinical studies as proposed inResearch Aim 3 can be rationally designed to maximize the opportunity for synergy with radiation andimmunotherapy.The application includes a robust plan that highlights Dr. Perez's limitations in prior training with a didacticprogram that is specifically designed overcome knowledge gaps in the fields of cancer immunity/immunotherapyand early stage clinical trial design. In working to establish independence, the final training aim includesdedicated career development focus on grant writing and publications. This training will help Dr. Perez to masterthe necessary skills crucial to success as an independent investigator.Drs. Antonia, Conejo-Garcia and Schell will closely advise and oversee Dr. Perez's career development andrepresent a team of international experts in the field of cancer clinical and translational investigation. Theproposed training in this K08 NCI Mentored Clinical Scientist training grant for patient oriented research willallow Dr. Perez to transition to an independent clinical and translational researcher. -DA - 2020 -PY - 2020 -AN - GRANTS:15025646 -G1 - 5K08CA231454-02; 9939486; K08CA231454 -AD - H. LEE MOFFITT CANCER CTR & RES INST -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - O'Brien, MER -AU - Saini, A -AU - Smith, IE -AU - Webb, A -AU - Gregory, K -AU - Mendes, R -AU - Ryan, C -AU - Priest, K -AU - Bromelow, KV -AU - Palmer, RD -AU - Tuckwell, N -AU - Kennard, DA -AU - Souberbielle, BE -TI - A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma -T2 - BRITISH JOURNAL OF CANCER -M3 - Article -AB - Mycobacterial preparations have been used with limited success against cancer apart from superficial bladder cancer. Recently, a therapeutic vaccine derived from Mycobacterium vaccae has been given to patients with prostate cancer and melanoma indicating a possible beneficial effect on disease activity in such patients. We have recently initiated a series of randomized studies to test the feasibility and toxicity of combining a preparation of heat-killed Mycobacterium vaccae (designated SRL172) with a multidrug chemotherapy regimen to treat patients with inoperable non-small cell lung cancer (NSCLC) and mesothelioma. 28 evaluable patients with previously untreated symptomatic NSCLC and mesothelioma were randomized to receive either 3 weekly intravenous combination chemotherapy alone, or chemotherapy given with monthly intra-dermal injections of SRL172. Safety and tolerability were scored by common toxicity criteria and efficacy was evaluated by survival of patients and by tumour response assessed by CT scanning. The toxicity of chemotherapy was similar in the two groups. SRL172 caused mild inflammation at the injection site. In the group of patients randomized to receive chemotherapy combined with SRL172, there was a trend towards improved response rate (54% vs, 33%) with more patients in the combined arm receiving radical surgery and radiotherapy, improved median survival (9.7 months vs. 7.5 months) and improved 1 year survival (42% vs. 18%), SRL172 appeared to improve sleep (P = 0.08) and improved appetite (P = 0.01). There was no detectable change in serum cytokine levels for gamma-interferon and TNF-alpha before and after treatment. in patients with NSCLC and mesothelioma, there may be a beneficial interaction when chemotherapy is administered in combination with SRL172. Confirmation of this effect and further investigation is underway in a randomized phase III trial and in laboratory models. (C) 2000 Cancer Research Campaign. -PU - NATURE PUBLISHING GROUP -PI - LONDON -PA - MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 0007-0920 -DA - 2000 OCT -PY - 2000 -VL - 83 -IS - 7 -SP - 853 -EP - 857 -DO - 10.1054/bjoc.2000.1401 -AN - WOS:000089389600003 -AD - Royal Marsden Hosp NHS Trust, Sutton SM2 5PT, Surrey, England -AD - Kent Canc Ctr, Maidstone ME16 9QQ, Kent, England -AD - Kings Coll London, Dept Mol Med, London SE5 9NU, England -AD - UCL, Sch Med, Dept Bacteriol, London W1P 6DB, England -AD - SR Pharma, London WC1A 1DD, England -M2 - Kent Canc Ctr -M2 - SR Pharma -Y2 - 2000-10-01 -ER - - -TY - JOUR -AU - Li, Fenge -AU - Deng, Ligang -AU - Jackson, Kyle R. -AU - Talukder, Amjad H. -AU - Katailiha, Arjun S. -AU - Bradley, Sherille D. -AU - Zou, Qingwei -AU - Chen, Caixia -AU - Huo, Chong -AU - Chiu, Yulun -AU - Stair, Matthew -AU - Feng, Weihong -AU - Bagaev, Aleksander -AU - Kotlov, Nikita -AU - Svekolkin, Viktor -AU - Ataullakhanov, Ravshan -AU - Miheecheva, Natalia -AU - Frenkel, Felix -AU - Wang, Yaling -AU - Zhang, Minying -AU - Hawke, David -AU - Han, Ling -AU - Zhou, Shuo -AU - Zhang, Yan -AU - Wang, Zhenglu -AU - Decker, William K. -AU - Sonnemann, Heather M. -AU - Roszik, Jason -AU - Forget, Marie-Andree -AU - Davies, Michael A. -AU - Bernatchez, Chantale -AU - Yee, Cassian -AU - Bassett, Roland -AU - Hwu, Patrick -AU - Du, Xueming -AU - Lizee, Gregory -TI - Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations -T2 - JOURNAL FOR IMMUNOTHERAPY OF CANCER -M3 - Article -AB - Background Neoantigen (NeoAg) peptides displayed at the tumor cell surface by human leukocyte antigen molecules show exquisite tumor specificity and can elicit T cell mediated tumor rejection. However, few NeoAgs are predicted to be shared between patients, and none to date have demonstrated therapeutic value in the context of vaccination. Methods We report here a phase I trial of personalized NeoAg peptide vaccination (PPV) of 24 stage III/IV non-small cell lung cancer (NSCLC) patients who had previously progressed following multiple conventional therapies, including surgery, radiation, chemotherapy, and tyrosine kinase inhibitors (TKIs). Primary endpoints of the trial evaluated feasibility, tolerability, and safety of the personalized vaccination approach, and secondary trial endpoints assessed tumor-specific immune reactivity and clinical responses. Of the 16 patients with epidermal growth factor receptor (EGFR) mutations, nine continued TKI therapy concurrent with PPV and seven patients received PPV alone. Results Out of 29 patients enrolled in the trial, 24 were immunized with personalized NeoAg peptides. Aside from transient rash, fatigue and/or fever observed in three patients, no other treatment-related adverse events were observed. Median progression-free survival and overall survival of the 24 vaccinated patients were 6.0 and 8.9 months, respectively. Within 3-4 months following initiation of PPV, seven RECIST-based objective clinical responses including one complete response were observed. Notably, all seven clinical responders had EGFR-mutated tumors, including four patients that had continued TKI therapy concurrently with PPV. Immune monitoring showed that five of the seven responding patients demonstrated vaccine-induced T cell responses against EGFR NeoAg peptides. Furthermore, two highly shared EGFR mutations (L858R and T790M) were shown to be immunogenic in four of the responding patients, all of whom demonstrated increases in peripheral blood neoantigen-specific CD8+ T cell frequencies during the course of PPV. Conclusions These results show that personalized NeoAg vaccination is feasible and safe for advanced-stage NSCLC patients. The clinical and immune responses observed following PPV suggest that EGFR mutations constitute shared, immunogenic neoantigens with promising immunotherapeutic potential for large subsets of NSCLC patients. Furthermore, PPV with concurrent EGFR inhibitor therapy was well tolerated and may have contributed to the induction of PPV-induced T cell responses. -PU - BMJ PUBLISHING GROUP -PI - LONDON -PA - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND -SN - 2051-1426 -DA - 2021 -PY - 2021 -VL - 9 -IS - 7 -C7 - e002531 -DO - 10.1136/jitc-2021-002531 -AN - WOS:000691846500001 -AD - Univ Texas MD Anderson Canc Ctr, Dept Melanoma, Houston, TX 77030 USA -AD - Tianjin HengJia Biotechnol Dev Co Ltd, Tianjin, Peoples R China -AD - Mary Bird Perkins Canc Ctr, Baton Rouge, LA USA -AD - Tianjin Beichen Hosp, Dept Oncol, Tianjin, Peoples R China -AD - BostonGene Corp, Waltham, MA USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA -AD - Fujian Med Univ, Prov Clin Coll, Fuzhou, Fujian, Peoples R China -AD - Nankai Univ, State Key Lab Med Chem Biol, Tianjin, Peoples R China -AD - Tianjin First Cent Hosp, Biol Sample Resource Sharing Ctr, Tianjin, Peoples R China -AD - Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA -M2 - Tianjin HengJia Biotechnol Dev Co Ltd -M2 - Mary Bird Perkins Canc Ctr -M2 - Tianjin Beichen Hosp -M2 - BostonGene Corp -Y2 - 2021-09-08 -ER - - -TY - JOUR -AU - Yamanaka, Yuta -AU - Ota, Takayo -AU - Masuoka, Yutaka -AU - Takeyasu, Yuki -AU - Nakamura, Satoaki -AU - Terashima, Masaaki -AU - Yoshioka, Hiroshige -AU - Fukuoka, Masahiro -AU - Kurata, Takayasu -TI - Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer -T2 - CANCERS -M3 - Article -AB - Simple Summary Lung cancer remains a leading cause of death despite advancements in treatment. A recent phase III trial has shown that adding an immune checkpoint inhibitor (ICI) to standard chemoradiation therapy (CCRT) improves survival in patients with advanced lung cancer. A sub-analysis of the same study also showed that shortening the interval between CRT and ICI increased the clinical benefits. Therefore, a feasibility study of nivolumab plus CCRT was conducted in Japanese patients with unresectable locally advanced NSCLC. We enrolled 12 patients and examined 10 for dose-limiting toxicities (DLT). The treatment was considered feasible if DLT occurred in three or fewer of the ten evaluable patients, meeting the study criteria. The findings suggest that nivolumab combined with CCRT is a safe and promising treatment option for patients with previously untreated unresectable locally advanced NSCLC, potentially improving their chances of survival.Abstract Despite advancements in diagnosing and treating non-small cell lung cancer (NSCLC), the prognosis remains poor. Immune checkpoint inhibitors have shown promise in enhancing survival rates. Therefore, this study aimed to investigate the safety of nivolumab administration with concurrent chemoradiation therapy (CCRT) in patients with unresectable locally advanced NSCLC. Twelve patients with unresectable locally advanced NSCLC at Kansai Medical University Hospital and Izumi City General Medical Center were enrolled from May 2018 to September 2020. They received nivolumab (360 mg) tri-weekly twice, weekly carboplatin (AUC 2 min x mg/mL) and paclitaxel (40 mg/m2) for 6 weeks, and thoracic radiotherapy (60 Gy/30 fractions), followed by maintenance nivolumab therapy (360 mg, tri-weekly) for 6 months. The primary endpoint was incidence of dose-limiting toxicities (DLTs), and the secondary endpoints included safety, response rate, progression-free survival (PFS), overall survival (OS), 2-year survival rate, and treatment completion rate. Three patients completed the protocol. Nine discontinued due directly to interstitial pneumonia (three) and pneumonia (one). Ten patients (83.3%) experienced a grade 3 or higher event, of which three (25%) experienced a grade 4 or higher event, and of these, one (8.3%) experienced a grade 5 event. Three patients experienced DLTs. Concurrent nivolumab with CCRT was tolerated in unresectable locally advanced NSCLC, which offers potential treatment benefits. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2024 SEP -PY - 2024 -VL - 16 -IS - 18 -C7 - 3127 -DO - 10.3390/cancers16183127 -AN - WOS:001323305300001 -AD - Kansai Med Univ Hosp, Dept Thorac Oncol, 2-5-1 Shinmachi, Hirakata, Osaka 5731010, Japan -AD - Izumi City Gen Med Ctr, Med Oncol, 4-5-1 Wakechou, Izumishi, Osaka 5940073, Japan -AD - Izumi City Gen Med Ctr, Dept Radiol, 4-5-1 Wakechou, Izumishi, Osaka 5940073, Japan -AD - Kansai Med Univ Hosp, Dept Radiol, 2-5-1 Shinmachi, Hirakata, Osaka 5731010, Japan -M2 - Izumi City Gen Med Ctr -M2 - Izumi City Gen Med Ctr -Y2 - 2024-10-07 -ER - - -TY - JOUR -AU - Zhou, Qing -AU - Chen, Ming -AU - Jiang, Ou -AU - Pan, Yi -AU - Hu, Desheng -AU - Lin, Qin -AU - Wu, Gang -AU - Cui, Jiuwei -AU - Chang, Jianhua -AU - Cheng, Yufeng -AU - Huang, Cheng -AU - Liu, Anwen -AU - Yang, Nong -AU - Gong, Youling -AU - Zhu, Chuan -AU - Ma, Zhiyong -AU - Fang, Jian -AU - Chen, Gongyan -AU - Zhao, Jun -AU - Shi, Anhui -AU - Lin, Yingcheng -AU - Li, Guanghui -AU - Liu, Yunpeng -AU - Wang, Dong -AU - Wu, Rong -AU - Xu, Xinhua -AU - Shi, Jianhua -AU - Liu, Zhihua -AU - Cui, Na -AU - Wang, Jingru -AU - Wang, Qiang -AU - Zhang, Ran -AU - Yang, Jason -AU - Wu, Yi-Long -TI - Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial -T2 - LANCET ONCOLOGY -M3 - Article -AB - Background A substantial proportion of patients with unresectable stage III non-small-cell lung cancer (NSCLC) cannot either tolerate or access concurrent chemoradiotherapy, so sequential chemoradiotherapy is commonly used. We assessed the efficacy and safety of sugemalimab, an anti-PD-L1 antibody, in patients with stage III NSCLC whose disease had not progressed after concurrent or sequential chemoradiotherapy.Methods GEMSTONE-301 is a randomised, double-blind, placebo-controlled, phase 3 trial in patients with locally advanced, unresectable, stage III NSCLC, done at 50 hospitals or academic research centres in China. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 who had not progressed after concurrent or sequential chemoradiotherapy. We randomly assigned patients (2:1, using an interactive voice-web response system) to receive sugemalimab 1200 mg or matching placebo, intravenously every 3 weeks for up to 24 months. Stratification factors were ECOG performance status, previous chemoradiotherapy, and total radiotherapy dose. The investigators, trial coordination staff, patients, and study sponsor were masked to treatment allocation. The primary endpoint was progression-free survival as assessed by blinded independent central review (BICR) in the intention-to-treat population. Safety was assessed in all participants who received at least one dose of assigned study treatment. The study has completed enrolment and the results of a preplanned analysis of the primary endpoint are reported here. The trial is registered with ClinicalTrials.gov, NCT03728556.Findings Between Aug 30, 2018 and Dec 30, 2020, we screened 564 patients of whom 381 were eligible. Study treatment was received by all patients randomly assigned to sugemalimab (n=255) and to placebo (n=126). At data cutoff (March 8, 2021), median follow-up was 14.3 months (IQR 6.4-19-4) for patients in the sugemalimab group and 13.7 months (7.1-18-4) for patients in the placebo group. Progression-free survival assessed by BICR was significantly longer with sugemalimab than with placebo (median 9.0 months [95% CI 8.1-14.1] vs 5.8 months [9s% CI 4.2-6.6]; stratified hazard ratio 0.64 [95% CI 0-48-0.85], p=0-0026). Grade 3 or 4 treatment-related adverse events occurred in 22 (9%) of 255 patients in the sugemalimab group versus seven (6%) of 126 patients in the placebo group, the most common being pneumonitis or immune-mediated pneumonitis (seven 13%1 of 255 patients in the sugemalimab group vs one (<1%1 of 126 in the placebo group). Treatment-related serious adverse events occurred in 38 (15%) patients in the sugemalimab group and 12 (10%) in the placebo group. Treatment-related deaths were reported in four (2%) of 255 patients (pneumonia in two patients, pneumonia with immune-mediated pneumonitis in one patient, and acute hepatic failure in one patient) in the sugemalimab group and none in the placebo group.Interpretation Sugemalimab after definitive concurrent or sequential chemoradiotherapy could be an effective consolidation therapy for patients with stage III NSCLC whose disease has not progressed after sequential or concurrent chemoradiotherapy. Longer follow-up is needed to confirm this conclusion. Copyright (C) 2022 Elsevier Ltd. All rights reserved. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1470-2045 -SN - 1474-5488 -DA - 2022 FEB -PY - 2022 -VL - 23 -IS - 2 -SP - 209 -EP - 219 -DO - 10.1016/S1470-2045(21)00630-6 -AN - WOS:000751827100025 -C6 - JAN 2022 -AD - Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Insitute, Guangzhou 510080, Peoples R China -AD - Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China -AD - Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China -AD - Second Peoples Hosp Neijiang, Neijiang, Peoples R China -AD - Hubei Canc Hosp, Wuhan, Peoples R China -AD - Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China -AD - Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China -AD - First Hosp Jilin Univ, Changchun, Peoples R China -AD - Fudan Univ, Canc Ctr, Shenzhen, Peoples R China -AD - Chinese Acad Med Sci, Canc Hosp, Shenzhen, Peoples R China -AD - Shandong Univ, Qilu Hosp, Jinan, Peoples R China -AD - Fujian Med Univ, Fujian Prov Canc Hosp, Fuzhou, Peoples R China -AD - Nanchang Univ, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China -AD - Hunan Canc Hosp, Changsha, Peoples R China -AD - Sichuan Univ, West China Hosp, Chengdu, Peoples R China -AD - Chongqing Univ, Gorges Hosp 3, Chongqing, Peoples R China -AD - Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China -AD - Beijing Canc Hosp, Beijing, Peoples R China -AD - Harbin Med Univ, Canc Hosp, Harbin, Peoples R China -AD - Shantou Univ, Canc Hosp, Med Coll, Shantou, Peoples R China -AD - Army Med Univ, Xinqiao Hosp, Chongqing, Peoples R China -AD - China Med Univ, Hosp 1, Shenyang, Peoples R China -AD - Army Med Ctr PLA, Chongqing, Peoples R China -AD - China Med Univ, Shengjing Hosp, Shenyang, Peoples R China -AD - China Three Gorges Univ, Yichang Cent Peoples Hosp, Coll Clin Med Sci 1, Yichang, Peoples R China -AD - Linyi Canc Hosp, Linyi, Shandong, Peoples R China -AD - Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China -AD - CStone Pharmaceut Suzhou, Shanghai, Peoples R China -M2 - Second Peoples Hosp Neijiang -M2 - Hubei Canc Hosp -M2 - Hunan Canc Hosp -M2 - Army Med Ctr PLA -M2 - Linyi Canc Hosp -M2 - Jiangxi Canc Hosp -M2 - CStone Pharmaceut Suzhou -Y2 - 2022-02-17 -ER - - -TY - JOUR -AU - PEREZ, BRADFORD A. -TI - Finding Synergy with Radiation Therapy and Immunotherapy for Patients with Lung Cancer -M3 - Awarded Grant -AB - 7. PROJECT SUMMARY/ABSTRACTThe proposed career development training award will provide the candidate, Dr. Bradford Perez, with anexcellent opportunity to establish as an independent clinical/translational investigator. As part of his translationaleffort he seeks to characterize tumor infiltrating immune cells to understand mechanism of synergy withradiation and immunotherapy combinations with a specific interest and plan to further evaluate anti-41bbtherapy in conjunction with radiation therapy. An improved understanding of this mechanism is critical torobust and successful implementation of combined modality strategies in the clinic. The work proposed as partof this award application will also allow Dr. Perez to grow and establish independence as a clinical investigator.He currently serves as the principal investigator for an ongoing investigator initiated clinical trial for patients withextensive stage small cell lung cancer. With the support of a strong mentorship team, he was able to draft theprotocol and navigate the necessary regulatory infrastructure to enroll patients on this Phase I/II trial. Thehuman tissue samples (serial peripheral blood and tumor samples) collected as part of this ongoing trial will bethoroughly analyzed as part of Research Aim 2 to help understand the precise mechanism by which RTmodulates the immune system. Through an improved understanding, future clinical studies as proposed inResearch Aim 3 can be rationally designed to maximize the opportunity for synergy with radiation andimmunotherapy.The application includes a robust plan that highlights Dr. Perez's limitations in prior training with a didacticprogram that is specifically designed overcome knowledge gaps in the fields of cancer immunity/immunotherapyand early stage clinical trial design. In working to establish independence, the final training aim includesdedicated career development focus on grant writing and publications. This training will help Dr. Perez to masterthe necessary skills crucial to success as an independent investigator.Drs. Antonia, Conejo-Garcia and Schell will closely advise and oversee Dr. Perez's career development andrepresent a team of international experts in the field of cancer clinical and translational investigation. Theproposed training in this K08 NCI Mentored Clinical Scientist training grant for patient oriented research willallow Dr. Perez to transition to an independent clinical and translational researcher. -DA - 2019 -PY - 2019 -AN - GRANTS:14959020 -G1 - 1K08CA231454-01A1; 9743526; K08CA231454 -AD - H. LEE MOFFITT CANCER CTR & RES INST -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Duan, R. -AU - Kwan, M. -AU - Kordon, A. -AU - Hu, C. -AU - Vanjani, N. -AU - Thomas, T. O. -AU - Patel, J. D. -AU - Yadav, P. -AU - Abazeed, M. -AU - Gharzai, L. A. -TI - Stage IIIA Non-Small Cell Lung Cancer Treatment and Outcomes: A Single Institution Retrospective Analysis -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2032 -SP - E16 -EP - E16 -AN - WOS:001079706800031 -AD - Northwestern Univ, Feinberg Sch Med, Dept Radiat Oncol, Chicago, IL USA -AD - Northwestern Univ, Feinberg Sch Med, Lurie Canc Ctr, Chicago, IL USA -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - Spaas, Mathieu -AU - Sundahl, Nora -AU - Kruse, Vibeke -AU - Rottey, Sylvie -AU - De Maeseneer, Daan -AU - Duprez, Frederic -AU - Lievens, Yolande -AU - Surmont, Veerle -AU - Brochez, Lieve -AU - Reynders, Dries -AU - Danckaert, Willeke -AU - Goetghebeur, Els -AU - van den Begin, Robbe -AU - Van Gestel, Dirk -AU - Renard, Vincent -AU - Dirix, Piet -AU - Ost, Piet -TI - Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors The CHEERS Phase 2 Randomized Clinical Trial -T2 - JAMA ONCOLOGY -M3 - Article -AB - Importance Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and PD-1 ligand 1 have improved the outcome for many cancer types, the majority of patients fails to respond to ICI monotherapy. Hypofractionated radiotherapy has the potential to improve the therapeutic ratio of ICIs.Objective To assess the addition of radiotherapy to ICIs compared with ICI monotherapy in patients with advanced solid tumors.Design, Setting, and Participants This open-label, multicenter, randomized phase 2 trial was conducted in 5 Belgian hospitals and enrolled participants between March 2018 and October 2020. Patients 18 years or older with locally advanced or metastatic melanoma, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, or non-small cell lung carcinoma were eligible. A total of 99 patients were randomly assigned to either the control arm (n = 52) or the experimental arm (n = 47). Of those, 3 patients (1 in the control arm vs 2 in the experimental arm) withdrew consent and thus were not included in the analysis. Data analyses were performed between April 2022 and March 2023.Interventions Patients were randomized (1:1) to receive anti-PD-1/PD-1 ligand 1 ICIs alone as per standard of care (control arm) or combined with stereotactic body radiotherapy 3 x 8 gray to a maximum of 3 lesions prior to the second or third ICI cycle, depending on the frequency of administration (experimental arm). Randomization was stratified according to tumor histologic findings and disease burden (3 and fewer or more than 3 cancer lesions).Main Outcomes and Measures The primary end point was progression-free survival (PFS) as per immune Response Evaluation Criteria in Solid Tumors. Key secondary end points included overall survival (OS), objective response rate, local control rate, and toxic effects. Efficacy was assessed in the intention-to-treat population, while safety was evaluated in the as-treated population.Results Among 96 patients included in the analysis (mean age, 66 years; 76 [79%] female), 72 (75%) had more than 3 tumor lesions and 65 (68%) had received at least 1 previous line of systemic treatment at time of inclusion. Seven patients allocated to the experimental arm did not complete the study-prescribed radiotherapy course due to early disease progression (n = 5) or intercurrent illness (n = 2). With a median (range) follow-up of 12.5 (0.7-46.2) months, median PFS was 2.8 months in the control arm compared with 4.4 months in the experimental arm (hazard ratio, 0.95; 95% CI, 0.58-1.53; P = .82). Between the control and experimental arms, no improvement in median OS was observed (11.0 vs 14.3 months; hazard ratio, 0.82; 95% CI, 0.48-1.41; P = .47), and objective response rate was not statistically significantly different (22% vs 27%; P = .56), despite a local control rate of 75% in irradiated patients. Acute treatment-related toxic effects of any grade and grade 3 or higher occurred in 79% and 18% of patients in the control arm vs 78% and 18% in the experimental arm, respectively. No grade 5 adverse events occurred.Conclusions and Relevance This phase 2 randomized clinical trial demonstrated that while safe, adding subablative stereotactic radiotherapy of a limited number of metastatic lesions to ICI monotherapy failed to show improvement in PFS or OS. -PU - AMER MEDICAL ASSOC -PI - CHICAGO -PA - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA -SN - 2374-2437 -SN - 2374-2445 -DA - 2023 SEP -PY - 2023 -VL - 9 -IS - 9 -SP - 1205 -EP - 1213 -DO - 10.1001/jamaoncol.2023.2132 -AN - WOS:001025131600002 -C6 - JUL 2023 -AD - Univ Ghent, Ghent Univ Hosp, Dept Radiat Oncol, B-9000 Ghent, Belgium -AD - AZ Groeninge, Dept Radiat Oncol, Kortrijk, Belgium -AD - AZ Nikolaas, Dept Med Oncol, St Niklaas, Belgium -AD - Univ Ghent, Ghent Univ Hosp, Dept Med Oncol, Ghent, Belgium -AD - Dept Med Oncol, AZ Sint Lucas, Brugge, Belgium -AD - Univ Ghent, Ghent Univ Hosp, Dept Pulm Med, Ghent, Belgium -AD - Univ Ghent, Ghent Univ Hosp, Dept Dermatol, Ghent, Belgium -AD - Univ Ghent, Dept Appl Math Comp Sci & Stat, Ghent, Belgium -AD - Univ Ghent, Stat Gent CRESCENDO Consortium, Ghent, Belgium -AD - Univ Libre Bruxelles, Jules Bordet Inst, Dept Radiat Oncol, Brussels, Belgium -AD - AZ Sint Lucas, Dept Med Oncol, Ghent, Belgium -AD - Iridium Network, Dept Radiat Oncol, Antwerp, Belgium -M2 - AZ Groeninge -M2 - AZ Nikolaas -M2 - Dept Med Oncol -M2 - AZ Sint Lucas -M2 - Iridium Network -Y2 - 2023-08-01 -ER - - -TY - JOUR -AU - Cheng, Monica -AU - Jolly, Shruti -AU - Quarshie, William O. -AU - Kapadia, Nirav -AU - Vigneau, Fawn D. -AU - Kong, Feng-Ming (Spring) -TI - Modern Radiation Further Improves Survival in Non-Small Cell Lung Cancer: An Analysis of 288,670 Patients -T2 - JOURNAL OF CANCER -M3 - Article -AB - Background: Radiation therapy plays an increasingly important role in the treatment of patients with non-small-cell lung cancer (NSCLC). The purpose of the present study is to assess the survival outcomes of radiotherapy treatment compared to other treatment modalities and to determine the potential role of advanced technologies in radiotherapy on improving survival.Methods: We used cancer incidence and survival data from the Surveillance, Epidemiology, and End Results database linked to U.S. Census data to compare survival outcomes of 288,670 patients with stage I-IV NSCLC treated between 1999 and 2008. The primary endpoint was overall survival.Results: Among the 288,670 patients diagnosed with stage I-IV NSCLC, 92,374 (32%) patients received radiotherapy-almost double the number receiving surgery (51,961, 18%). Compared to other treatment groups and across all stages of NSCLC, patients treated with radiotherapy showed greater median and overall survival than patients without radiation treatment (p < 0.0001). Radiotherapy had effectively improved overall survival regardless of age, gender, and histological categorization. Radiotherapy treatment received during the recent time period 2004 - 2008 is correlated with enhanced survival compared to the earlier time period 1999 - 2003.Conclusion: Radiation therapy was correlated with increased overall survival for all patients with primary NSCLC across stages. Combined surgery and radiotherapy treatment also correlates with improved survival, signaling the value of bimodal or multimodal treatments. Population-based increases in overall survival were seen in the recent time period, suggesting the potential role of advanced radiotherapeutic technologies in enhancing survival outcomes for lung cancer patients. -PU - IVYSPRING INT PUBL -PI - LAKE HAVEN -PA - PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA -SN - 1837-9664 -DA - 2019 -PY - 2019 -VL - 10 -IS - 1 -SP - 168 -EP - 177 -DO - 10.7150/jca.26600 -AN - WOS:000453270100019 -AD - Indiana Univ Sch Med, Dept Radiat Oncol, Indianapolis, IN 46202 USA -AD - Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA -AD - Wayne State Univ, Metropolitan Detroit Canc Surveillance Syst, Surveillance Epidemiol & End Results SEER Program, Karmanos Canc Inst,Epidemiol Res Core,Sch Med, Detroit, MI USA -AD - Dartmouth Hitchcock Med Ctr, Dept Radiat Oncol, Lebanon, NH 03766 USA -AD - Case Western Reserve Univ, Seidman Comprehens Canc Ctr, Dept Radiat Oncol, Cleveland, OH 44106 USA -Y2 - 2019-01-01 -ER - - -TY - JOUR -AU - Wu, Yi-Long -AU - Park, Keunchil -AU - Soo, Ross A. -AU - Sun, Yan -AU - Tyroller, Karin -AU - Wages, David -AU - Ely, Guy -AU - Yang, James Chih-Hsin -AU - Mok, Tony -TI - INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer -T2 - BMC CANCER -M3 - Article -AB - Background: Previous research suggests the therapeutic cancer vaccine L-BLP25 potentially provides a survival benefit in patients with locally advanced unresectable stage III non-small cell lung carcinoma (NSCLC). These promising findings prompted the phase III study, INSPIRE, in patients of East-Asian ethnicity. East-Asian ethnicity is an independent favourable prognostic factor for survival in NSCLC. The favourable prognosis is most likely due to a higher incidence of EGFR mutations among this patient population.Methods/design: The primary objective of the INSPIRE study is to assess the treatment effect of L-BLP25 plus best supportive care (BSC), as compared to placebo plus BSC, on overall survival time in East-Asian patients with unresectable stage III NSCLC and either documented stable disease or an objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria following primary chemoradiotherapy. Those in the L-BLP25 arm will receive a single intravenous infusion of cyclophosphamide (300 mg/m(2)) 3 days before the first L-BLP25 vaccination, with a corresponding intravenous infusion of saline to be given in the control arm. A primary treatment phase of 8 subcutaneous vaccinations of L-BLP25 930 mu g or placebo at weekly intervals will be followed by a maintenance treatment phase of 6-weekly vaccinations continued until disease progression or discontinuation from the study.Discussion: The ongoing INSPIRE study is the first large study of a therapeutic cancer vaccine specifically in an East-Asian population. It evaluates the potential of maintenance therapy with L-BLP25 to prolong survival in East-Asian patients with stage III NSCLC where there are limited treatment options currently available. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 1471-2407 -DA - 2011 OCT 7 -PY - 2011 -VL - 11 -C7 - 430 -DO - 10.1186/1471-2407-11-430 -AN - WOS:000296278400001 -AD - Chinese Univ Hong Kong, Prince Wales Hosp, Sir YK Pau Canc Ctr, State Key Lab So China, Hong Kong, Hong Kong, Peoples R China -AD - Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China -AD - Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China -AD - Samsung Med Ctr, Seoul 135710, South Korea -AD - Natl Univ Singapore Hosp, Natl Univ Canc Inst Singapore NCIS, Singapore 117548, Singapore -AD - Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore -AD - Chinese Acad Med Sci, Canc Hosp & Inst, Hong Kong, Hong Kong, Peoples R China -AD - Merck KGaA, Darmstadt, Germany -AD - Natl Taiwan Univ Hosp, Dept Oncol, Taipei 100, Taiwan -Y2 - 2011-10-07 -ER - - -TY - JOUR -AU - Huang, Chih-Yang -AU - Ju, Da-Tong -AU - Chang, Chih-Fen -AU - Muralidhar Reddy, P -AU - Velmurugan, Bharath Kumar -TI - A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. -T2 - BioMedicine -M3 - Journal Article -AB - Lung cancer is the leading cause of cancer deaths worldwide, and this makes it an attractive disease to review and possibly improve therapeutic treatment options. Surgery, radiation, chemotherapy, targeted treatments, and immunotherapy separate or in combination are commonly used to treat lung cancer. However, these treatment types may cause different side effects, and chemotherapy-based regimens appear to have reached a therapeutic plateau. Hence, effective, better-tolerated treatments are needed to address and hopefully overcome this conundrum. Recent advances have enabled biologists to better investigate the potential use of natural compounds for the treatment or control of various cancerous diseases. For the past 30 years, natural compounds have been the pillar of chemotherapy. However, only a few compounds have been tested in cancerous patients and only partial evidence is available regarding their clinical effectiveness. Herein, we review the research on using current chemotherapy drugs and natural compounds (Wortmannin and Roscovitine, Cordyceps militaris, Resveratrol, OSU03013, Myricetin, Berberine, Antroquinonol) and the beneficial effects they have on various types of cancers including non-small cell lung cancer. Based on this literature review, we propose the use of these compounds along with chemotherapy drugs in patients with advanced and/or refractory solid tumours. -SN - 2211-8020 -DA - 2017 Dec (Epub 2017 Nov 13) -PY - 2017 -VL - 7 -IS - 4 -SP - 23 -EP - 23 -DO - 10.1051/bmdcn/2017070423 -AN - MEDLINE:29130448 -AD - Graduate Institute of Basic Medical Science, China Medical University, Taichung 404, Taiwan - Graduate Institute of Chinese Medical Science, China Medical University, Taichung 404, Taiwan - Department of Biological Science and Technology, Asia University, Taichung 413, Taiwan. -AD - Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan. -AD - Department of Internal Medicine, Division of Cardiology, Armed Forces Taichung General Hospital, Taichung 406, Taiwan. -AD - Department of Chemistry, Nizam College, Osmania University, Hyderabad-500001, India. -AD - Faculty of Applied Sciences, Ton Duc Thang University, Tan Phong Ward, District 7, 700000 Ho Chi Minh City, Vietnam. -Y2 - 2018-01-08 -ER - - -TY - JOUR -AU - Dumoulin, Daphne W. -AU - Dingemans, Anne-Marie C. -AU - Aerts, Joachim G. J., V -AU - Remon, Jordi -AU - De Ruysscher, Dirk K. M. -AU - Hendriks, Lizza E. L. -TI - Immunotherapy in small cell lung cancer: one step at a time: a narrative review -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Chemotherapy with or without radiotherapy has been the standard of care for many years for patients with small cell lung cancer (SCLC). Despite exceptionally high responses (up to 80%) with chemotherapy, the majority of patients relapse rapidly within weeks to months after treatment completion. Therefore, new and better treatment options are necessary. Recently, synergistic activity has been reported for the addition of immune checkpoint inhibitors (ICI) to standard platinum-based chemotherapy in the therapeutic strategy of advanced SCLC. For the first time after several decades, a significant survival improvement was achieved for this population. However, the overwhelming majority of patients do not respond to ICI, or relapse rapidly. There is need for better knowledge about the biology, histopathologic features, and molecular pathways of SCLC. This can probably help to identify the optimal predictive biomarkers, which are warranted to develop an individual therapeutic strategy including the rational use of a combination of immunotherapeutic agents. Here, we provide an overview of the rationale for and clinical results of the completed and ongoing trials using different strategies of immunotherapy in SCLC. In addition, opportunities for further improvement of therapies will be discussed, including the addition of radiotherapy, co-stimulatory antibodies, and other immune modifying agents. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2021 JUN -PY - 2021 -VL - 10 -IS - 6 -SP - 2970 -EP - 2987 -DO - 10.21037/tlcr-20-630 -AN - WOS:000670783900039 -AD - Erasmus MC Canc Inst, Dept Pulm Med, Rotterdam, Netherlands -AD - Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Resp Med, Maastricht, Netherlands -AD - HM Hosp, Hosp HM Delfos, Ctr Integral Oncol Clara Campal Barcelona CIOCCB, Dept Med Oncol, Barcelona, Spain -AD - Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Radiat Oncol,MAASTRO Clin, Maastricht, Netherlands -M2 - HM Hosp -Y2 - 2021-07-28 -ER - - -TY - JOUR -AU - Liao, Zhongxing -AU - Wu, Lirong -AU - Xu, Ting -AU - Gandhi, Saumil -AU - Lin, Steven H. -AU - Jing, Wang -AU - Quynh-Nhu Nguyen -AU - Chen, Aileen -AU - Chang, Joe -AU - Altan, Mehmet -AU - Tsao, Anne -AU - Nurieva, Roza -AU - Sheshadri, Ajay -AU - Welsh, James -AU - Lee, Percy -TI - Pulmonary Adverse Events After Real World Adjuvant Immune Checkpoint Inhibitor (ICI) Therapy and Its Impact on Survival for Locally Advanced Non-Small Cell Lung Cancer -T2 - AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS -M3 - Meeting Abstract -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0277-3732 -SN - 1537-453X -DA - 2021 OCT -PY - 2021 -VL - 44 -IS - 10 -MA - P118 -SP - S105 -EP - S106 -AN - WOS:000701779700170 -AD - Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA -AD - Jiangsu Canc Hosp, Nanjing, Peoples R China -AD - UT MD Anderson Canc Ctr, Houston, TX USA -AD - Shandong Canc Hosp, Jinan, Shandong, Peoples R China -AD - Univ Texas MD Anderson Canc Ctr, Welsh Lab, Houston, TX 77030 USA -Y2 - 2021-10-10 -ER - - -TY - JOUR -AU - Tredaniel, J. -AU - Barlesi, F. -AU - Le Pechoux, C. -AU - Lerouge, D. -AU - Pichon, E. -AU - Le Moulec, S. -AU - Moreau, L. -AU - Friard, S. -AU - Westeel, V. -AU - Petit, L. -AU - Carre, O. -AU - Guichard, F. -AU - Raffy, O. -AU - Villa, J. -AU - Prevost, A. -AU - Langlais, A. -AU - Morin, F. -AU - Wislez, M. -AU - Giraud, P. -AU - Zalcman, G. -AU - Mornex, F. -AU - French Cooperat Thoracic Intergrp IFCT, for the French Cooperative Thoracic Intergroup (IFCT) -TI - Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer -T2 - CANCER RADIOTHERAPIE -M3 - Article -AB - Purpose. - Roughly 20% of patients with non-small-cell lung cancer exhibit locally advanced, unresectable, stage III disease. Concurrent platinum-based chemoradiotherapy is the backbone treatment, which is followed by maintenance immunotherapy, yet with poor long-term prognosis. This phase II trial (IFCT-0803) sought to evaluate whether adding cetuximab to cisplatin and pemetrexed chemoradiotherapy would improve its efficacy in these patients. Materials and methods. - Eligible patients received weekly cetuximab (loading dose 400 mg/m2 day 1; subsequent weekly 250 mg/m2 doses until two weeks postradiotherapy). Chemotherapy comprised cis-platin (75 mg/m2) and pemetrexed (500 mg/m2), both delivered on day 1 of a 21-day cycle of maximally four. Irradiation with maximally 66 Gy started on day 22. Disease control rate at week 16 was the primary endpoint. Results. - One hundred and six patients were included (99 eligible patients). Compliance exceeded 95% for day 1 of chemotherapy cycles 1 to 4, with 76% patients receiving the 12 planned cetuximab doses. Maximal grade 3 toxicity occurred in 63% patients, and maximal grade 4 in 9.6%. The primary endpoint involving the first 95 eligible patients comprised two (2.1%) complete responses, 57 (60.0%) partial responses, and 27 (28.4%) stable diseases. This 90.5% disease control rate (95% confidence interval [95% CI]: 84.6%-96.4%) was achieved at week 16. After median 63.0-month follow-up, one-year and two-year survival rates were 75.8% and 59.5%. Median overall survival was 35.8 months (95% CI: 23.5-NR), and median progression -free survival 14.4 months (95% CI: 11.2-18.8), with one-year and two-year progression-free survival rates of 57.6% and 34.3%. Conclusion. - These survival rates compare favourably with published data, thus justifying further deve-lopment of cetuximab-based induction chemoradiotherapy.(c) 2022 Les Auteurs. Publie par Elsevier Masson SAS au nom de Societe franc , aise de radiotherapie oncologique (SFRO). Cet article est publie en Open Access sous licence CC BY-NC-ND (http:// creativecommons.org/licenses/by-nc-nd/4.0/). -PU - ELSEVIER -PI - BRIDGEWATER -PA - 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA -SN - 1278-3218 -SN - 1769-6658 -DA - 2022 SEP -PY - 2022 -VL - 26 -IS - 5 -SP - 670 -EP - 677 -DO - 10.1016/j.canrad.2021.12.005 -AN - WOS:000842964400004 -C6 - AUG 2022 -AD - Hop St Joseph, Dept Pneumol, F-75014 Paris, France -AD - Ctr Hosp Univ Marseille, Multidisciplinary Oncol & Therapeut Innovat Dept, F-13000 Marseille, France -AD - Gustave Roussy, Dept Radiat Oncol, F-94805 Villejuif, France -AD - Ctr Francois Baclesse, Dept Radiat Oncol, F-14000 Caen, France -AD - Ctr Hosp Univ Tours, Dept Pneumol, F-37000 Tours, France -AD - Inst Bergonie, Dept Pneumol, F-33000 Bordeaux, France -AD - Hop Louis Pasteur, Dept Pneumol, F-68024 Suresnes, France -AD - Hop Foch, Dept Pneumol, F-92150 Suresnes, France -AD - Ctr Hosp Univ Besanc, Dept Pneumol, F-25000 Paris, France -AD - Ctr Hosp Univ Lyon, Dept Radiat Oncol, F-69000 Lyon, France -AD - Clin Europe, Dept Pneumol, F-80090 Amiens, France -AD - Polyclin, Dept Oncol, F-33000 Bordeaux, France -AD - Ctr Hosp Univ Grenoble, Dept Pneumol, F-38000 Grenoble, France -AD - Hop Chartres, Dept Pneumol, F-28000 Chartres, France -AD - Ctr Lutte Canc Jean Godinot, Dept Pneumol, F-51100 Reims, France -AD - Intergrp Francophone Cancerol Thorac, F-75000 Paris, France -AD - Hop Cochin, Dept Pneumol, F-75014 Paris, France -AD - Hop Europeen Georges Pompidou, Dept Radiat Oncol, F-75015 Paris, France -AD - Ctr Hosp Univ Caen, Dept pneumol, F-14000 Caen, France -M2 - Hop St Joseph -M2 - Ctr Hosp Univ Tours -M2 - Hop Louis Pasteur -M2 - Ctr Hosp Univ Besanc -M2 - Clin Europe -M2 - Polyclin -M2 - Hop Chartres -M2 - Ctr Lutte Canc Jean Godinot -M2 - Intergrp Francophone Cancerol Thorac -Y2 - 2022-08-31 -ER - - -TY - JOUR -AU - Benzekry, Sebastien -AU - Karlsen, Melanie -AU - Bigarre, Celestin -AU - El Kaoutari, Abdessamad -AU - Gomes, Bruno -AU - Stern, Martin -AU - Neubert, Ales -AU - Bruno, Rene -AU - Mercier, Francois -AU - Vatakuti, Suresh -AU - Curle, Peter -AU - Jamois, Candice -TI - Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre- and on-Treatment Prognostic Biomarkers -T2 - CLINICAL PHARMACOLOGY & THERAPEUTICS -M3 - Article -AB - Existing survival prediction models rely only on baseline or tumor kinetics data and lack machine learning integration. We introduce a novel kinetics-machine learning (kML) model that integrates baseline markers, tumor kinetics, and four on-treatment simple blood markers (albumin, C-reactive protein, lactate dehydrogenase, and neutrophils). Developed for immune-checkpoint inhibition (ICI) in non-small cell lung cancer on three phase II trials (533 patients), kML was validated on the two arms of a phase III trial (ICI and chemotherapy, 377 and 354 patients). It outperformed the current state-of-the-art for individual predictions with a test set C-index of 0.790, 12-months survival accuracy of 78.7% and hazard ratio of 25.2 (95% CI: 10.4-61.3, P < 0.0001) to identify long-term survivors. Critically, kML predicted the success of the phase III trial using only 25 weeks of on-study data (predicted HR = 0.814 (0.64-0.994) vs. final study HR = 0.778 (0.65-0.931)). Modeling on-treatment blood markers combined with predictive machine learning constitutes a valuable approach to support personalized medicine and drug development. The code is publicly available at at https:// gitlab.inria.fr/benzekry/nlml_ onco. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 0009-9236 -SN - 1532-6535 -DA - 2024 OCT -PY - 2024 -VL - 116 -IS - 4 -SP - 1110 -EP - 1120 -DO - 10.1002/cpt.3371 -AN - WOS:001271488200001 -C6 - JUL 2024 -AD - Aix Marseille Univ, Ctr Inria Univ Cote Azur, Inserm UMR1068, Canc Res Ctr Marseille,COMPutat Pharmacol & Clin O, Marseille, France -AD - Roche Innovat Ctr Basel, Early Dev Oncol, Pharm Res & Early Dev, Basel, Switzerland -AD - Roche Innovat Ctr Zurich, Early Dev Oncol, Pharm Res & Early Dev, Zurich, Switzerland -AD - Roche Innovat Ctr Basel, Pharm Res & Early Dev, Data & Analyt, Basel, Switzerland -AD - Genentech Res & Early Dev, Clin Pharmacol, Modeling & Simulat, Marseille, France -AD - Roche Innovat Ctr Basel, Modeling & Simulat, Clin Pharmacol, Genentech Res & Early Dev, Basel, Switzerland -AD - Roche Innovat Ctr Basel, Pharm Res & Early Dev, Predict Modeling & Data Analyt, Basel, Switzerland -AD - Inovigate, Basel, Switzerland -AD - Roche Innovat Ctr Basel, Pharm Res & Early Dev, Translat PKPD & Clin Pharmacol, Basel, Switzerland -M2 - Genentech Res & Early Dev -M2 - Inovigate -Y2 - 2024-07-26 -ER - - -TY - JOUR -AU - Zhao, Ye -AU - Feng, Haiming -AU - Tian, Jinhui -AU - Li, Bin -AU - Wang, Cheng -AU - Ge, Long -AU - Wang, Jian kai -AU - Yang, Kehu -AU - Yu, Qin -TI - Consolidation treatments after chemoradiotherapy in patients with locally advanced inoperable non-small cell lung cancer: a systematic review and network meta-analysis protocol -T2 - BMJ OPEN -M3 - Review -AB - Introduction Concurrent chemoradiotherapy (CCRT) is the standard of care for inoperable locally advanced non-small cell lung cancer. To further improve prognosis, the use of consolidation treatments after CCRT has been explored extensively. Although durvalumab is the only consolidation treatment recommended by national clinical practice guidelines, there have been many studies exploring the effectiveness of other agents. However, until now, no studies have compared all agents systematically, and no studies have provided evidence for the optimal combination of different CCRTs and consolidation treatments regimens. This systematic review will evaluate the comparative clinical efficacy of consolidation therapies after CCRT as well as various combinations of CCRTs and consolidation therapies. Methods and analysis PubMed, the Cochrane Controlled Register of Trials (CENTRAL), EMBASE and ClinicalTrials.gov will be searched for relevant information. The estimated end date for the search will be 3 February 2022. Each stage of the review, including the study section, data extraction and risk of bias and quality of evidence assessments, will be performed in duplicate. We will include randomised controlled trials that included participants who received CCRT and consolidation treatment in at least one treatment arm. The primary endpoints will be overall survival and progression-free survival. Tumour response, health-related quality of life, disease-free survival and treatment-related toxicity will be presented as secondary outcomes. Both traditional meta-analysis and network meta-analysis (NMA) with the Bayesian approach will be conducted. Subgroup analyses and meta-regression will be completed to investigate heterogeneity, and sensitivity analyses will be conducted to assess the robustness of the findings. Ethics and dissemination Ethical approval and patient consent are not required as this study is a meta-analysis based on published studies. The results of this study will be submitted to a peer-reviewed journal for publication. In case of any changes in the protocol, protocol amendments will be updated in PROSPERO and explanations of these modifications will be described in the final report of this review. The results of this systematic review and NMA will be published in a peer-reviewed journal. PROSPERO registration number CRD42021239433. -PU - BMJ PUBLISHING GROUP -PI - LONDON -PA - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND -SN - 2044-6055 -DA - 2022 APR -PY - 2022 -VL - 12 -IS - 4 -C7 - e060900 -DO - 10.1136/bmjopen-2022-060900 -AN - WOS:000783232500018 -AD - Lanzhou Univ, Clin Med Coll 1, Lanzhou, Gansu, Peoples R China -AD - Lanzhou Univ, Affiliated Hosp 2, Dept Thorac Surg, Lanzhou, Gansu, Peoples R China -AD - Lanzhou Univ, Evidence Based Med Ctr, Lanzhou, Gansu, Peoples R China -AD - Gansu Prov Peoples Hosp, Dept Radiotherapy, Lanzhou, Gansu, Peoples R China -M2 - Gansu Prov Peoples Hosp -Y2 - 2022-04-27 -ER - - -TY - JOUR -AU - SCHLOM, JEFFREY -TI - Strategies for Cancer Immunotherapy Clinical Trials -M3 - Awarded Grant -AB - Recent accomplishments include the following: BINTRAFUSP ALFA, A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF-BETA AND PD- L1, IN PATIENTS WITH HUMAN PAPILLOMAVIRUS-ASSOCIATED MALIGNANCIES. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of transforming growth factor (TGF)-betaRII (a TGF-beta "trap") fused to a human IgG1 mAb blocking programmed cell death ligand 1. This is the largest analysis of patients with advanced, pretreated human papillomavirus (HPV)-associated malignancies treated with bintrafusp alfa. In these phase 1 and phase 2 trials, patients with advanced, pretreated, checkpoint inhibitor- naive HPV- associated cancers received bintrafusp alfa intravenously every 2 weeks until progressive disease, unacceptable toxicity, or withdrawal. Primary endpoint was best overall response per Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1; other endpoints included safety. The confirmed objective response rate per RECIST V.1.1 in the checkpoint inhibitor-naive, full-analysis population was approximately 30% to 40% (including some complete responses); eight patients had stable disease (disease control rate, 44%). In addition, three patients experienced a delayed partial response after initial disease progression, for a total clinical response rate of approximately 35% (95% CI, 23.6% to 49.1%). Approximately 83%of patients experienced treatment-related adverse events, which were grade 3/4 in 16 patients. No treatment-related deaths occurred. Bintrafusp alfa showed clinical activity and manageable safety and is a promising treatment in HPV-associated cancers. These findings support further investigation of immunotherapy in patients with advanced HPV-associated cancers. In addition, staff in the translational compoent of the CIO were involved in the planning, review, and analyses of the followig completed clinical study publications: [] First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. Strauss...Schlom, Donahue, Tsai...Gulley. J Immunother Cancer, 2023. [] Flutamide with or without PROSTVAC in non-metastatic castration resistant (MO) prostate cancer. Madan...Donahue...Karzai...Strauss...Schlom, Gulley. Oncologist, 2023. [] Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer. Sievers...Redman, Soon-Shiong, Schlom, Gulley, Allen. Cancer Cell, 2023. [] Avelumab in men with metastatic castration-resistant prostate cancer, enriched for patients treated previously with a therapeutic cancer vaccine. Madan, Redman, Karzai...Schlom, Gulley. J Immunother, 2023. [] Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12. Toney, Gatti-Mays, Tschernia, Strauss, Gulley, Schlom, Donahue. Int Immunopharm, 2023. [] A phase 1 single arm study of bi-weekly NHS-IL12 in patients with metastatic solid tumors. Gatti-Mays, Tschernia, Strauss, Madan, Karzai, Bilusic, Redman... Floudas, Toney, Donahue, Jochems...Schlom, Gulley. The Oncologist, 2023. [] Phase 1 trial of CV301 in combination with anti-PD-1 therapy in non-squamous non-small cell lung cancer. Rajan...Donahue, Schlom, Gulley. Int J Cancer, 2023. [] Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa. Tsai, Strauss, Toney, Jochems, Gulley, Donahue, Schlom. J Immunother Cancer, 2022. [] A randomized phase II trial of mFOLFOX6 and bevacizumab alone or with combination immunotherapy with AdCEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer. Redman, Tsai...Donahue... Gatti-Mays...Jochems...Schlom, Gulley, Strauss. The Oncologist, 2022. Ongoing clinical studies include: [] A Pilot Study of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based Chemotherapy n=24 (Rajan) [] Combination Immunotherapy trial in mCRPC. Phase II. (Madan) [] QuEST: A Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (Gulley) [] A Phase I Study of TGF-beta trap (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary Malignancies (Apolo, Niglio) [] Phase I/II of NHS-IL12 Monotherapy in Advanced Kaposi Sarcoma (Yarchoan /Ramaswami) [] A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects with Thymoma and Thymic Carcinoma (Rajan) [] Chemoimmunotherapy of Prostate Cancer mCRPC and mCSPC (Madan) [] BEST: Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients with Advanced Cancer (Strauss) [] PRGN-2012 in RRP (Norberg) [] PECAN: A Phase I/II study of PD-L1 t-haNK cells plus Immunotherapy in Subjects with Advanced Cancer (Redman) [] SBRT + NHS-IL12 in localized Prostate Cancer (Madan) [] Phase II Study Evaluating the Efficacy of M9241 in Combination with Hepatic Artery Infusion Pump Therapy (HAIP) for Subjects with Metastatic Colorectal Cancer and Intrahepatic Cholangiocarcinoma (Hernandez) [] ConQueST: To determine the Role of N-803 Alone or in Combination with Brachyury Vaccine or M7824 in Response Among Patients with CRPC. (Gulley) [] A Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma (Rajan) [] A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective TCR Activation-Fusion Protein, in Subjects with Unresectable Locally Adv or Met Cancers that are Tumor Antigen-Rich or Have Limited Response to Immune Checkpoint Inhibition (START-001) (Gulley) [] A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccine (Tri-Ad5) and Il-15 Superagonist N-803 in Lynch Syndrome (Szabo). -DA - 2023 -PY - 2023 -AN - GRANTS:17767127 -G1 - 10926015; 1ZIABC010425-24; ZIABC010425 -AD - BASIC SCIENCES -M2 - BASIC SCIENCES -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - John V. Heymach; MINNA, JOHN D. -TI - Targeting Lung Cancer Vulnerabilities -M3 - Awarded Grant -AB - Overall SPORE Summary/AbstractTargeting Lung Cancer Vulnerabilities. The University of Texas SPORE in Lung Cancer represents a uniquecollaboration between the University of Texas Southwestern Medical Center (UTSW) and the University of TexasMD Anderson Cancer Center (MDACC), both of which have outstanding strengths in lung cancer translationaland clinical research. The overarching goal of the SPORE is to develop new therapeutic paradigms based onrecently identified “vulnerabilities” acquired during lung cancer pathogenesis, including a molecularunderstanding of lung cancers in individual patients, and using this information to “personalize” therapy for eachlung cancer patient. Thus, our strategy is to identify lung cancer “therapeutic quartets” which include: 1. aspecific vulnerability; 2. the mechanism of action thus defining therapeutic target(s) for the vulnerability; 3. adeliverable treatment for the target(s); and 4. tumor molecular biomarkers for the vulnerability predicting specifictherapies for each patient. The UT Lung Cancer SPORE builds on a 20-year productive history, incorporatingrecent advances made by our SPORE investigators and the rest of the lung cancer translational researchcommunity in the molecular and mechanistic understanding of tumor autonomous and microenvironmentchanges, acquired vulnerabilities, and important immuno-oncology effects. These advances include novelapproaches to identifying and molecularly classifying vulnerabilities in lung cancer metabolomic changes,cancers immunologically “inert” to PD1/PD-L1 checkpoint blockade, the lung cancer fibrotic stroma(microenvironment), and tumorigenesis-induced replication stress. Our contributions also include preclinicalhuman and mouse model systems for testing the different vulnerabilities, as well as large legacy molecular andclinically annotated preclinical model and clinical specimen datasets. The SPORE is composed of 4 projects,all of which have Human Endpoints: 1. Targeting metabolic vulnerabilities in lung cancer; 2. Targetingvulnerabilities in immunologically-inert lung cancer; 3. Targeting vulnerabilities in the fibrotic extracellular matrix(ECM) of lung cancers; and 4. Therapeutic targeting of oncogene-induced replication stress for tumor cell killingand anti-tumor immunity in small cell lung cancer (SCLC) (which includes a clinical trial targeting replicationstress combined with immune checkpoint inhibtion. There are three cores: A. Administrative (including patientadvocates); B. Molecular Pathology and Tissue Resources; and C. Data Sciences, as well as strongDevelopmental Research and Career Enhancement Programs (DRP, CEP). Our SPORE features leadinglung cancer multi-disciplinary clinical and laboratory scientists, a cadre of experienced patient advocates, andan outstanding publication record. Moving forward, this SPORE will provide information on newly identified lungcancer acquired vulnerabilities, biomarkers for personalizing individual patient therapy, and important preclinicaland information to facilitate clinical translation that has the possibility of changing the face of lung cancer therapy. -DA - 2023 -PY - 2023 -AN - GRANTS:17763593 -G1 - 10845884; 3P50CA070907-24S1; P50CA070907 -AD - UT SOUTHWESTERN MEDICAL CENTER -AD - UT SOUTHWESTERN MEDICAL CENTER -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - John V. Heymach; MINNA, JOHN D. -TI - Targeting Lung Cancer Vulnerabilities -M3 - Awarded Grant -AB - Overall SPORE Summary/AbstractTargeting Lung Cancer Vulnerabilities. The University of Texas SPORE in Lung Cancer represents a uniquecollaboration between the University of Texas Southwestern Medical Center (UTSW) and the University of TexasMD Anderson Cancer Center (MDACC), both of which have outstanding strengths in lung cancer translationaland clinical research. The overarching goal of the SPORE is to develop new therapeutic paradigms based onrecently identified “vulnerabilities” acquired during lung cancer pathogenesis, including a molecularunderstanding of lung cancers in individual patients, and using this information to “personalize” therapy for eachlung cancer patient. Thus, our strategy is to identify lung cancer “therapeutic quartets” which include: 1. aspecific vulnerability; 2. the mechanism of action thus defining therapeutic target(s) for the vulnerability; 3. adeliverable treatment for the target(s); and 4. tumor molecular biomarkers for the vulnerability predicting specifictherapies for each patient. The UT Lung Cancer SPORE builds on a 20-year productive history, incorporatingrecent advances made by our SPORE investigators and the rest of the lung cancer translational researchcommunity in the molecular and mechanistic understanding of tumor autonomous and microenvironmentchanges, acquired vulnerabilities, and important immuno-oncology effects. These advances include novelapproaches to identifying and molecularly classifying vulnerabilities in lung cancer metabolomic changes,cancers immunologically “inert” to PD1/PD-L1 checkpoint blockade, the lung cancer fibrotic stroma(microenvironment), and tumorigenesis-induced replication stress. Our contributions also include preclinicalhuman and mouse model systems for testing the different vulnerabilities, as well as large legacy molecular andclinically annotated preclinical model and clinical specimen datasets. The SPORE is composed of 4 projects,all of which have Human Endpoints: 1. Targeting metabolic vulnerabilities in lung cancer; 2. Targetingvulnerabilities in immunologically-inert lung cancer; 3. Targeting vulnerabilities in the fibrotic extracellular matrix(ECM) of lung cancers; and 4. Therapeutic targeting of oncogene-induced replication stress for tumor cell killingand anti-tumor immunity in small cell lung cancer (SCLC) (which includes a clinical trial targeting replicationstress combined with immune checkpoint inhibtion. There are three cores: A. Administrative (including patientadvocates); B. Molecular Pathology and Tissue Resources; and C. Data Sciences, as well as strongDevelopmental Research and Career Enhancement Programs (DRP, CEP). Our SPORE features leadinglung cancer multi-disciplinary clinical and laboratory scientists, a cadre of experienced patient advocates, andan outstanding publication record. Moving forward, this SPORE will provide information on newly identified lungcancer acquired vulnerabilities, biomarkers for personalizing individual patient therapy, and important preclinicaland information to facilitate clinical translation that has the possibility of changing the face of lung cancer therapy. -DA - 2023 -PY - 2023 -AN - GRANTS:17753385 -G1 - 10701005; 5P50CA070907-24; P50CA070907 -AD - UT SOUTHWESTERN MEDICAL CENTER -AD - UT SOUTHWESTERN MEDICAL CENTER -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - VONDERHEIDE, ROBERT H -TI - Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients -M3 - Awarded Grant -AB - Project Narrative New approved immune checkpoint therapies have been clinically revolutionary, but not all patients respond and others relapse after initial response. Based on extensive pre-clinical and clinical preliminary data, we will perform two immediate clinical trials combining agents that block CTLA-4 (ipilimumab or tremelimumab) or PD-1/PD-L1 (nivolumab or durvalumab) with hypofractionated radiotherapy. A comprehensive plan for immune assessment will determine the immunological mechanisms and resistance of our approach. 1 -DA - 2018 -PY - 2018 -AN - GRANTS:11157983 -G1 - 5P01CA210944-02; 9531302; P01CA210944 -AD - UNIVERSITY OF PENNSYLVANIA -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Zhao, Shen -AU - Jiang, Wei -AU - Yang, Nong -AU - Liu, Li -AU - Yu, Yan -AU - Wang, Qiming -AU - Zhao, Yuanyuan -AU - Yang, Yunpeng -AU - Ma, Shuxiang -AU - Yu, Qitao -AU - Zhang, Li -AU - Huang, Yan -TI - Intracranial response pattern, tolerability and biomarkers associated with brain metastases in non-small cell lung cancer treated by tislelizumab plus chemotherapy -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Article -AB - Background: Programmed cell death protein-1/programmed cell death protein-ligand 1 (PD-1/PD-L1) inhibitor and chemotherapy are the standard treatment for advanced non-small cell lung cancer (NSCLC) without sensitizing mutations. However, patients with untreated, symptomatic or recently-irradiated brain metastases (BMs) are mostly excluded from immunochemotherapy trials. This study aims to evaluate the intracranial response pattern, tolerability and biomarkers of tislelizumab plus chemotherapy in NSCLC with untreated, symptomatic or recently-irradiated BM. Methods: This multicenter, single-arm, phase 2 trial enrolled patients with treatment-na & iuml;ve, brainmetastasized NSCLC. BM could be untreated or irradiated. Symptomatic or recently-irradiated BMs that were deemed clinically stable were allowed. Patients received tislelizumab (200 mg) plus pemetrexed (500 mg/m2) and carboplatin (AUC =5) on day 1 every 3 weeks for 4 cycles, followed by maintenance with tislelizumab plus pemetrexed. Primary endpoint was 1-year progression-free survival (PFS) rate. Secondary endpoints included intracranial efficacy and tolerability. PD-L1 expression, tumor mutational burden (TMB) and genomic alterations were evaluated as potential biomarkers. Results: A total of 36 patients were enrolled, 19.2% had prior brain radiotherapy, 8.3% had symptomatic BMs that required corticosteroids <= 10 mg/d or antiepileptics. Confirmed systemic and intracranial ORR (iORR) was 43.8% and 46.7%, respectively. One-year systematic PFS rate and One-year iPFS rate was 36.8% and 55.8%, respectively. About 41.7% patients had neurological adverse events, 90% patients had concordant intracranial-extracranial responses. No intracranial pseudoprogression or hyperprogression occurred. Patients with prior brain radiation trended towards higher systemic (83.3% vs. 34.6%) and iORR (75.0% vs. 42.3%). Similar intracranial efficacy was observed in tumors with different PD-L1 and TMB levels, while alterations in cytokine receptors pathway predicted higher iORR (P=0.081), prolonged Conclusions: Untreated or irradiated BMs in NSCLC follows a conventional response and progression pattern under immunochemotherapy with altered cytokine receptors pathway being a potential biomarker for systemic and intracranial outcomes. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2024 FEB 29 -PY - 2024 -VL - 13 -IS - 2 -DO - 10.21037/tlcr-23-687 -AN - WOS:001223155800010 -AD - Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Med Oncol, State Key Lab Oncol South China,Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Peoples R China -AD - Guangxi Med Univ, Dept Oncol, Canc Hosp, Nanning, Peoples R China -AD - Hunan Canc Hosp, Dept Med Oncol, Changsha, Peoples R China -AD - Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China -AD - Harbin Med Univ, Dept Oncol, Canc Hosp, Harbin, Heilongjiang, Peoples R China -AD - Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China -M2 - Hunan Canc Hosp -Y2 - 2024-06-09 -ER - - -TY - JOUR -AU - HAIAN FU; RAMALINGAM, SURESH S -TI - Emory University Lung Cancer SPORE -M3 - Awarded Grant -AB - OVERVIEW SUMMARY/ABSTRACTLung cancer is the leading cause of cancer-related deaths, with more than 1.6 million deaths/year globally. It isoften diagnosed at an advanced stage and is associated with poor outcomes for the majority of patients. Thisapplication for a lung cancer SPORE award from Emory University brings together an outstanding and multi-disciplinary team of oncologists, immunologists, drug discovery experts, and translational researchers dedicatedto lung cancer research to address critical questions that will improve the outcome for patients with this lethaldisease. Our proposed program will have significant impact in two crucial areas of lung cancer management:enhancing the efficacy of immunotherapy and overcoming treatment resistance through the development ofnovel molecularly targeted agents. Through strong teamwork carried out by this highly collaborative team ofdedicated investigators, and building on exciting data published in leading journals by our group since ourprevious SPORE application, this revised submission aims to achieve substantial improvements in themanagement of patients with non-small cell lung cancer (NSCLC), through three overall Specific Aims: Aim 1:To evaluate stem-like T cells and improve efficacy of checkpoint inhibitors in NSCLC (Project 1); Aim 2:To target MERTK to improve outcomes for EGFR-mutated NSCLC (Project 2); and Aim 3: To target Baxsignaling to overcome treatment resistance in NSCLC (Project 3). The Emory Lung Cancer SPORE programwill be supported by close interaction with the Administrative Core (Core 1), Pathology Core (Core 2) and theBiostatistics and Biomedical Informatics Core (Core 3), and will conduct Career Enhancement andDevelopmental Research Programs (CEP and DRP). The SPORE program will benefit from regular advice andrecommendations from External and Internal Advisory Board members regarding its progress and direction. Ourprogram will receive strong institutional support including modern research space, excellent shared resources,and a significant level of matching funds (totaling $2.25M) from the Winship Cancer Institute of Emory University(an NCI-designated Comprehensive Cancer Center), Emory University Woodruff Health Sciences Center, EmoryHealthcare System, Emory School of Medicine, and the Department of Hematology and Medical Oncology.Through team-driven innovative research efforts in immunotherapies and molecularly targeted therapeutics, weare confident that this SPORE program, in collaboration with other lung cancer SPORE sites, will have a majorpositive impact on the management of lung cancer. -DA - 2019 -PY - 2019 -AN - GRANTS:14949164 -G1 - 1P50CA217691-01A1; 9633845; P50CA217691 -AD - EMORY UNIVERSITY -AD - EMORY UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Falchero, Lionel -AU - Guisier, Florian -AU - Darrason, Marie -AU - Boyer, Arnaud -AU - Dayen, Charles -AU - Cousin, Sophie -AU - Merle, Patrick -AU - Lamy, Regine -AU - Madroszyk, Anne -AU - Otto, Josiane -AU - Tomasini, Pascale -AU - Assoun, Sandra -AU - Canellas, Anthony -AU - Gervais, Radj -AU - Hureaux, Jose -AU - Le Treut, Jacques -AU - Leleu, Olivier -AU - Naltet, Charles -AU - Tiercin, Marie -AU - Van Hulst, Sylvie -AU - Missy, Pascale -AU - Morin, Franck -AU - Westeel, Virginie -AU - Girard, Nicolas -TI - Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study -T2 - LUNG CANCER -M3 - Article -AB - Background: Small cell lung cancer (SCLC) has a tendency towards recurrence and limited survival. Standard-of -care in 1st-line is platinum-etoposide chemotherapy plus atezolizumab or durvalumab, based on land-mark clinical trials.Methods: IFCT-1905 CLINATEZO is a nationwide, non-interventional, retrospective study of patients with extensive-SCLC receiving atezolizumab plus chemotherapy as part of French Early Access Program. Objectives were to analyse effectiveness, safety and subsequent treatments.Results: The population analyzed included 518 patients who received atezolizumab in 65 participating centers. There were 66.2% male, mean age was 65.7 years; 89.1% had a performance status (PS) 0/1 and 26.6% brain metastases. Almost all (95.9%) were smokers. Fifty-five (10.6%) received at least 1 previous treatment. Median number of atezolizumab injections was 7.0 (range [1.0-48.0]) for a median duration of 4.9 months (95% CI 4.5-5.1). Atezolizumab was continued beyond progression in 122 patients (23.6%) for a median duration of 1.9 months (95% CI: [1.4-2.3]). Best objective response was complete and partial in 19 (3.9%) and 378 (77.1%) patients. Stable disease was observed in 50 patients (10.2%). Median follow-up was 30.8 months (95% CI: [29.9-31.5]). Median overall survival (OS), 12-, 24-month OS rates were 11.3 months (95% CI: [10.1-12.4]), 46.7% (95% CI [42.3-50.9]) and 21.2% (95% CI [17.7-24.8]). Median real-world progression-free survival, 6-, 12-month rates were 5.2 months (95% CI [5.0-5.4]), 37.5% (95% CI [33.3-41.7]) and 15.2% (95% CI [12.2-18.6]). For patients with PS 0/1, median OS was 12.2 months (95% CI [11.0-13.5]). For patients with previous treatment, median OS was 14.9 months (95% CI [10.1-21.5]). Three-hundred-and-twenty-six patients (66.4%) received subsequent treatment and 27 (5.2%) were still under atezolizumab at date of last news.Conclusions: IFCT-1905 CLINATEZO shows reproductibility, in real-life, of IMpower-133 survival outcomes, possibly attributed to selection of patients fit for this regimen, adoption of pragmatic approaches, including concurrent radiotherapy and treatment beyond progression. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2023 NOV -PY - 2023 -VL - 185 -C7 - 107379 -DO - 10.1016/j.lungcan.2023.107379 -AN - WOS:001085467000001 -C6 - SEP 2023 -AD - Hop Nord Ouest, Serv Pneumol & Cancerol Thorac, Villefranche, France -AD - Univ Rouen Normandie, LITIS Lab, QuantIF Team, EA4108, Rouen, France -AD - CHU Rouen, Dept Pneumol Thorac Oncol & Resp Intens Care, Inserm, CIC CRB 1404, Rouen, France -AD - Ctr Hosp Lyon Sud, HCL, URCC Sect Essais Clin, Pierre Berard, France -AD - Hop St Joseph, Serv Pneumol, Marseille, France -AD - Clin Europe, Serv Pneumol, Amiens, France -AD - Inst Bergonie, Dept Oncol Med, Bordeaux, France -AD - CHU Clermont Ferrand, Hop Gabriel Montpied, Hop Jour, Serv Oncol Thorac, Clermont Ferrand, France -AD - Hop Scorff, CHBS, Oncol Med, Lorient, France -AD - Inst Paoli Calmettes, Dept Oncol Med, Marseille, France -AD - Ctr Antoine Lacassagne, Oncol, Nice, France -AD - Ctr Antoine Lacassagne, Nice, France -AD - Hop Nord Marseille, AP HM, Serv Oncol Multidisciplinaire & Franceat Rapeut, Marseille, France -AD - Hop Bichat Claude Bernard, AP HP, Serv Pneumol, Paris, France -AD - Hop Tenon, AP HP, Serv Pneumol, Paris, France -AD - Ctr Francois Baclesse, Serv Pneumolgie, Caen, France -AD - CHU Angers, Serv Pneumol, Angers, France -AD - Hop Europeen, Serv Pneumol, Marseille, France -AD - Ctr Hosp, Serv Pneumol, Abbeville, France -AD - Grp Hosp ParisFrance Joseph, Serv Pneumol Oncol, Paris, France -AD - Ctr Hosp, Federat Pneumol, St Malo, France -AD - CHU Nimes, Serv Cancerol, Nimes, France -AD - IFCT, Unite Rech Clin, Paris, France -AD - CHU Besancon, Serv Pneumol, Hop Minjoz, Besancon, France -AD - Inst Curie, Inst Thorax Curie Montsouris, Paris, France -AD - Univ Versailles St Quentin, Paris Saclay Univ, Versailles, France -M2 - Hop Nord Ouest -M2 - Hop St Joseph -M2 - Clin Europe -M2 - Hop Scorff -M2 - Hop Europeen -M2 - Ctr Hosp -M2 - Grp Hosp ParisFrance Joseph -M2 - Ctr Hosp -M2 - IFCT -Y2 - 2023-11-03 -ER - - -TY - JOUR -AU - Palmero, Ramon -AU - Vilarino, Noelia -AU - Navarro-Martin, Arturo -AU - Nadal, Ernest -TI - Induction treatment in patients with stage III non-small cell lung cancer -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Stage III non-small cell lung cancer (NSCLC) comprises a highly heterogeneous group of patients defined according to the extent and localization of disease. Patients with discrete N2 involvement identified preoperatively with resectable disease are candidates for multimodal therapy either with definitive chemoradiation therapy, induction chemotherapy, or chemoradiotherapy (CTRT) followed by surgery. Neoadjuvant chemotherapy has yielded comparable survival benefit to adjuvant chemotherapy in patients with stage II-III disease and may allow for downstaging the tumor or the lymph nodes, an earlier delivery of systemic treatment, and better compliance to systemic therapy. The use of immune checkpoint inhibitors (ICIs) as induction therapy shows encouraging activity and a favorable safety profile in patients with resectable early stage or locally advanced NSCLC. An unprecedented rate of pathological response and downstaging has been reported in single-arm clinical trials, especially when immunotherapy is combined with neoadjuvant chemotherapy. Ongoing randomized phase II/III clinical trials assessing the efficacy and safety of induction with immunotherapy plus chemotherapy have the potential to establish this therapeutic approach as a novel standard of care. These trials aim to validate pathological response as a surrogate marker of survival benefit and to demonstrate that this therapeutic strategy can improve the cure rate in patients with stage II-III NSCLC. -PU - AME PUBL CO -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2021 JAN -PY - 2021 -VL - 10 -IS - 1 -SP - 539 -EP - 554 -DO - 10.21037/tlcr-20-420 -AN - WOS:000616118200029 -AD - Catalan Inst Oncol, Dept Med Oncol, Barcelona, Spain -AD - Bellvitge Biomed Res Inst IDIBELL, Oncobell Program, Clin Res Solid Tumors CReST Grp, Barcelona, Spain -AD - Catalan Inst Oncol, Dept Radiat Oncol, Barcelona, Spain -Y2 - 2021-03-16 -ER - - -TY - BOOK -AU - Galecki, S. -AU - Kysiak, M. -AU - Kozlowska, E. -AU - Wilk, A.M. -AU - Suwinski, R. -AU - Swierniak, A. -ED - Strumillo, P. -ED - Klepaczko, A. -ED - Strzelecki, M. -ED - Bociaga, D. -TI - Assessing the Prognosis of Patients with Metastatic or Recurrent Non-small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy -T2 - The Latest Developments and Challenges in Biomedical Engineering: Proceedings of the 23rd Polish Conference on Biocybernetics and Biomedical Engineering. Lecture Notes in Networks and Systems (746) -M3 - Conference Paper -CP - Polish Conference on Biocybernetics and Biomedical Engineering -CL - Lodz, Poland -AB - Locally advanced non-small cell lung cancer (NSCLC) is characterized by poor prognosis and is the leading cause of cancer-related deaths worldwide. The main problem in NSCLC is treatment resistance and a high potential for progression and metastasis, which results in low survival rates for patients. Immunotherapy (IO) alone or combined with chemotherapy and targeted therapies, while dedicated to selective subgroups of patients, replaced traditional cytotoxic therapies (radiotherapy or chemotherapy) in advanced stages of disease. Therefore, it's important to search for new features that may help predict the effectiveness of currently available therapies. The paper presents preliminary results of exploratory data and survival analyses (Kaplan-Meier survival curves, uni- and multivariate Cox proportional hazards models), indicating potential factors that may help stratify the group of patients to select the appropriate treatment. -SN - 978-3-031-38430-1 -DA - 2024 -PY - 2024 -SP - 175 -EP - 86 -DO - 10.1007/978-3-031-38430-1_14 -AN - INSPEC:24439175 -AD - Dept. of Syst. Biol. & Eng., Silesian Univ. of Technol., Gliwice, Poland -AD - Maria Sklodowska-Curie Nat. Res. Inst. of Oncology, Gliwice, Poland -AD - Inst. of Electron., Lodz Univ. of Technol., Lodz, Poland -Y2 - 2024-02-02 -ER - - -TY - JOUR -AU - HAIAN FU; RAMALINGAM, SURESH S -TI - Emory University Lung Cancer SPORE -M3 - Awarded Grant -AB - OVERVIEW SUMMARY/ABSTRACTLung cancer is the leading cause of cancer-related deaths, with more than 1.6 million deaths/year globally. It isoften diagnosed at an advanced stage and is associated with poor outcomes for the majority of patients. Thisapplication for a lung cancer SPORE award from Emory University brings together an outstanding and multi-disciplinary team of oncologists, immunologists, drug discovery experts, and translational researchers dedicatedto lung cancer research to address critical questions that will improve the outcome for patients with this lethaldisease. Our proposed program will have significant impact in two crucial areas of lung cancer management:enhancing the efficacy of immunotherapy and overcoming treatment resistance through the development ofnovel molecularly targeted agents. Through strong teamwork carried out by this highly collaborative team ofdedicated investigators, and building on exciting data published in leading journals by our group since ourprevious SPORE application, this revised submission aims to achieve substantial improvements in themanagement of patients with non-small cell lung cancer (NSCLC), through three overall Specific Aims: Aim 1:To evaluate stem-like T cells and improve efficacy of checkpoint inhibitors in NSCLC (Project 1); Aim 2:To target MERTK to improve outcomes for EGFR-mutated NSCLC (Project 2); and Aim 3: To target Baxsignaling to overcome treatment resistance in NSCLC (Project 3). The Emory Lung Cancer SPORE programwill be supported by close interaction with the Administrative Core (Core 1), Pathology Core (Core 2) and theBiostatistics and Biomedical Informatics Core (Core 3), and will conduct Career Enhancement andDevelopmental Research Programs (CEP and DRP). The SPORE program will benefit from regular advice andrecommendations from External and Internal Advisory Board members regarding its progress and direction. Ourprogram will receive strong institutional support including modern research space, excellent shared resources,and a significant level of matching funds (totaling $2.25M) from the Winship Cancer Institute of Emory University(an NCI-designated Comprehensive Cancer Center), Emory University Woodruff Health Sciences Center, EmoryHealthcare System, Emory School of Medicine, and the Department of Hematology and Medical Oncology.Through team-driven innovative research efforts in immunotherapies and molecularly targeted therapeutics, weare confident that this SPORE program, in collaboration with other lung cancer SPORE sites, will have a majorpositive impact on the management of lung cancer. -DA - 2022 -PY - 2022 -AN - GRANTS:17470051 -G1 - 10459437; 5P50CA217691-04; P50CA217691 -AD - EMORY UNIVERSITY -AD - EMORY UNIVERSITY -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - HAIAN FU; RAMALINGAM, SURESH S -TI - Emory University Lung Cancer SPORE -M3 - Awarded Grant -AB - OVERVIEW SUMMARY/ABSTRACTLung cancer is the leading cause of cancer-related deaths, with more than 1.6 million deaths/year globally. It isoften diagnosed at an advanced stage and is associated with poor outcomes for the majority of patients. Thisapplication for a lung cancer SPORE award from Emory University brings together an outstanding and multi-disciplinary team of oncologists, immunologists, drug discovery experts, and translational researchers dedicatedto lung cancer research to address critical questions that will improve the outcome for patients with this lethaldisease. Our proposed program will have significant impact in two crucial areas of lung cancer management:enhancing the efficacy of immunotherapy and overcoming treatment resistance through the development ofnovel molecularly targeted agents. Through strong teamwork carried out by this highly collaborative team ofdedicated investigators, and building on exciting data published in leading journals by our group since ourprevious SPORE application, this revised submission aims to achieve substantial improvements in themanagement of patients with non-small cell lung cancer (NSCLC), through three overall Specific Aims: Aim 1:To evaluate stem-like T cells and improve efficacy of checkpoint inhibitors in NSCLC (Project 1); Aim 2:To target MERTK to improve outcomes for EGFR-mutated NSCLC (Project 2); and Aim 3: To target Baxsignaling to overcome treatment resistance in NSCLC (Project 3). The Emory Lung Cancer SPORE programwill be supported by close interaction with the Administrative Core (Core 1), Pathology Core (Core 2) and theBiostatistics and Biomedical Informatics Core (Core 3), and will conduct Career Enhancement andDevelopmental Research Programs (CEP and DRP). The SPORE program will benefit from regular advice andrecommendations from External and Internal Advisory Board members regarding its progress and direction. Ourprogram will receive strong institutional support including modern research space, excellent shared resources,and a significant level of matching funds (totaling $2.25M) from the Winship Cancer Institute of Emory University(an NCI-designated Comprehensive Cancer Center), Emory University Woodruff Health Sciences Center, EmoryHealthcare System, Emory School of Medicine, and the Department of Hematology and Medical Oncology.Through team-driven innovative research efforts in immunotherapies and molecularly targeted therapeutics, weare confident that this SPORE program, in collaboration with other lung cancer SPORE sites, will have a majorpositive impact on the management of lung cancer. -DA - 2023 -PY - 2023 -AN - GRANTS:17747435 -G1 - 10685410; 5P50CA217691-05; P50CA217691 -AD - EMORY UNIVERSITY -AD - EMORY UNIVERSITY -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - HAIAN FU; RAMALINGAM, SURESH S -TI - Emory University Lung Cancer SPORE -M3 - Awarded Grant -AB - OVERVIEW SUMMARY/ABSTRACTLung cancer is the leading cause of cancer-related deaths, with more than 1.6 million deaths/year globally. It isoften diagnosed at an advanced stage and is associated with poor outcomes for the majority of patients. Thisapplication for a lung cancer SPORE award from Emory University brings together an outstanding and multi-disciplinary team of oncologists, immunologists, drug discovery experts, and translational researchers dedicatedto lung cancer research to address critical questions that will improve the outcome for patients with this lethaldisease. Our proposed program will have significant impact in two crucial areas of lung cancer management:enhancing the efficacy of immunotherapy and overcoming treatment resistance through the development ofnovel molecularly targeted agents. Through strong teamwork carried out by this highly collaborative team ofdedicated investigators, and building on exciting data published in leading journals by our group since ourprevious SPORE application, this revised submission aims to achieve substantial improvements in themanagement of patients with non-small cell lung cancer (NSCLC), through three overall Specific Aims: Aim 1:To evaluate stem-like T cells and improve efficacy of checkpoint inhibitors in NSCLC (Project 1); Aim 2:To target MERTK to improve outcomes for EGFR-mutated NSCLC (Project 2); and Aim 3: To target Baxsignaling to overcome treatment resistance in NSCLC (Project 3). The Emory Lung Cancer SPORE programwill be supported by close interaction with the Administrative Core (Core 1), Pathology Core (Core 2) and theBiostatistics and Biomedical Informatics Core (Core 3), and will conduct Career Enhancement andDevelopmental Research Programs (CEP and DRP). The SPORE program will benefit from regular advice andrecommendations from External and Internal Advisory Board members regarding its progress and direction. Ourprogram will receive strong institutional support including modern research space, excellent shared resources,and a significant level of matching funds (totaling $2.25M) from the Winship Cancer Institute of Emory University(an NCI-designated Comprehensive Cancer Center), Emory University Woodruff Health Sciences Center, EmoryHealthcare System, Emory School of Medicine, and the Department of Hematology and Medical Oncology.Through team-driven innovative research efforts in immunotherapies and molecularly targeted therapeutics, weare confident that this SPORE program, in collaboration with other lung cancer SPORE sites, will have a majorpositive impact on the management of lung cancer. -DA - 2021 -PY - 2021 -AN - GRANTS:17399249 -G1 - 10210194; 5P50CA217691-03; P50CA217691 -AD - EMORY UNIVERSITY -AD - EMORY UNIVERSITY -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - Ospina, Aylen Vanessa -AU - Nadal, Sergio Bolufer -AU - de la Cruz, Jose Luis Campo-Canaveral -AU - Larriba, Jose Luis Gonzalez -AU - Vidueira, Ivan Macia -AU - Sureda, Bartomeu Massuti -AU - Nadal, Ernest -AU - Trancho, Florentino Hernando -AU - Kindelan, Antonio Alvarez -AU - Morillo, Edel Del Barco -AU - Caro, Reyes Bernabe -AU - Barrera, Joaquim Bosch -AU - de Juan, Virginia Calvo -AU - Rubio, Joaquin Casal -AU - de Castro, Javier -AU - Ramos, Angel Cilleruelo -AU - Dols, Manuel Cobo -AU - Gomez, Manuel Domine -AU - Almanzar, Santiago Figueroa -AU - Campelo, Rosario Garcia -AU - Molla, Amelia Insa -AU - Sarceda, Jose Ramon Jarabo -AU - Maestre, Unai Jimenez -AU - Castro, Rafael Lopez -AU - Majem, Margarita -AU - Martinez-Marti, Alex -AU - Tellez, Elisabeth Martinez -AU - Lorente, David Sanchez -AU - Provencio, Mariano -TI - Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP -T2 - CLINICAL & TRANSLATIONAL ONCOLOGY -M3 - Review -M3 - Early Access -AB - Introduction Recent advances in the treatment of locally advanced NSCLC have led to changes in the standard of care for this disease. For the selection of the best approach strategy for each patient, it is necessary the homogenization of diagnostic and therapeutic interventions, as well as the promotion of the evaluation of patients by a multidisciplinary oncology team.Objective Development of an expert consensus document with suggestions for the approach and treatment of locally advanced NSCLC leaded by Spanish Lung Cancer Group GECP.Methods Between March and July 2023, a panel of 28 experts was formed. Using a mixed technique (Delphi/nominal group) under the guidance of a coordinating group, consensus was reached in 4 phases: 1. Literature review and definition of discussion topics 2. First round of voting 3. Communicating the results and second round of voting 4. Definition of conclusions in nominal group meeting. Responses were consolidated using medians and interquartile ranges. The threshold for agreement was defined as 85% of the votes.Results New and controversial situations regarding the diagnosis and management of locally advanced NSCLC were analyzed and reconciled based on evidence and clinical experience. Discussion issues included: molecular diagnosis and biomarkers, radiologic and surgical diagnosis, mediastinal staging, role of the multidisciplinary thoracic committee, neoadjuvant treatment indications, evaluation of response to neoadjuvant treatment, postoperative evaluation, and follow-up.Conclusions Consensus clinical suggestions were generated on the most relevant scenarios such as diagnosis, staging and treatment of locally advanced lung cancer, which will serve to support decision-making in daily practice. -PU - SPRINGER INT PUBL AG -PI - CHAM -PA - GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND -SN - 1699-048X -SN - 1699-3055 -DA - 2024 MAR 26 -PY - 2024 -DO - 10.1007/s12094-024-03382-y -AN - WOS:001191066300001 -C6 - MAR 2024 -AD - Hosp Univ Puerta de Hierro, Oncol Dept, C Manuel de Falla,1, Madrid 28222, Spain -AD - Univ Autonoma Madrid, Med, C Manuel de Falla,1, Madrid 28222, Spain -AD - Hosp Gen Univ Dr Balmis de Alicante, Alicante, Spain -AD - Hosp Univ Puerta de Hierro Majadahonda, Madrid, Spain -AD - Hosp Clin San Carlos, Madrid, Spain -AD - Hosp Univ Bellvitge, L Hosp de Llobregat, Barcelona, Spain -AD - Hosp Univ Dr Balmis Alicante, Alicante, Spain -AD - ICO Bellvitge, Hosp Barcelona, Barcelona, Spain -AD - Hosp Reina Sofia, Cordoba, Spain -AD - Hosp Univ Salamanca, Salamanca, Spain -AD - Hosp Virgen Del Rocio, Seville, Spain -AD - Hosp Univ Dr Josep Trueta, ICO, Girona, Spain -AD - Hosp Univ Alvaro Cunqueiro, Vigo, Spain -AD - Hosp Univ La Paz, Madrid, Spain -AD - Hosp Clin Univ Valladolid, Valladolid, Spain -AD - Hosp Reg Univ Malaga, Malaga, Spain -AD - Hosp Univ Fdn Jimenez Diaz, Madrid, Spain -AD - Hosp Clin Univ Valencia, Valencia, Spain -AD - Hosp Univ A Coruna, La Coruna, Spain -AD - Hosp Univ Cruces, Baracaldo, Bizkaia, Spain -AD - Hosp St Pau i St Creu, Barcelona, Spain -AD - Hosp Univ Vall Dhebron, Barcelona, Spain -AD - Hosp Clin Barcelona, Barcelona, Spain -AD - Univ Autonoma Madrid, Ciudad Univ Cantoblanco, Madrid 28049, Spain -M2 - Hosp Gen Univ Dr Balmis de Alicante -M2 - Hosp Univ Dr Balmis Alicante -M2 - ICO Bellvitge -M2 - Hosp Univ Alvaro Cunqueiro -M2 - Hosp Reg Univ Malaga -M2 - Hosp Univ Fdn Jimenez Diaz -M2 - Hosp St Pau i St Creu -Y2 - 2024-04-03 -ER - - -TY - JOUR -AU - Oronsky, Bryan -AU - Caroen, Scott -AU - Zeman, Karen -AU - Quinn, Mary -AU - Brzezniak, Christina -AU - Scicinski, Jan -AU - Cabrales, Pedro -AU - Reid, Tony R -AU - Trepel, Jane B -AU - Abrouk, Nacer D -AU - Larson, Christopher -AU - Oronsky, Arnold -AU - Lybeck, Harry E -AU - Day, Regina M -AU - Carter, Corey A -TI - A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001. -T2 - Clinical Medicine Insights. Oncology -M3 - Case Reports -AB - As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse than other types of lung cancer, and many other tumor types, given a response rate of less than 10% and an overall survival of less than six months. It was broadly classified into three groups based on the initial response to cisplatin/etoposide therapy, platinum-refractory, platinum-resistant, and platinum-sensitive, extensive stage SCLC inevitably relapses, at which point the only standard options are to rechallenge with the first-line chemotherapeutic regimen in the case of sensitive disease or to start the topoisomerase I inhibitor, topotecan. Sensitive disease is defined by a response to the first-line therapy and a treatment-free interval of at least 90 days, while the definitions of refractory and resistant disease, respectively, are nonresponse to the first-line treatment or relapse within 90 days. As an important predictor of response to the second-line treatment, the clinical cutoff of three months (or two months in some cases) for resistant and sensitive disease, which along with performance status prognostically separates patients into high- and low-risk categories, dictates subsequent management. This case report presents a resistant SCLC patient enrolled on a Phase II clinical trial called QUADRUPLE THREAT (formerly TRIPLE THREAT; NCT02489903) who responded to reintroduced platinum doublets after sequential priming with the resistance-reversing epi-immunotherapeutic agent, RRx-001. In the QUADRUPLE THREAT clinical trial, both during priming with RRx-001 and during sequential treatment with platinum doublets, the patient maintained a good quality of life and performance status. -SN - 1179-5549 -DA - 2016 -PY - 2016 -VL - 10 -SP - 105 -EP - 108 -AN - MEDLINE:27840583 -AD - EpicentRx, Mountain View, CA, USA. -AD - Walter Reed Military Medical Center, Bethesda, MD, USA. -AD - Department of Bioengineering, UCSD, La Jolla, CA, USA. -AD - Moores Cancer Center, UCSD, La Jolla, CA, USA. -AD - Center for Cancer Research National Cancer Institute, Bethesda, MD, USA. -AD - Innovexe, Palo Alto, CA, USA. -AD - InterWest Partners, Menlo Park, CA, USA. -AD - University of Helsinki, Helsinki, Finland. -AD - Uniformed Services University of the Health Sciences, Bethesda, MD, USA. -Y2 - 2016-12-01 -ER - - -TY - JOUR -AU - HAIAN FU; RAMALINGAM, SURESH S -TI - Emory University Lung Cancer SPORE -M3 - Awarded Grant -AB - OVERVIEW SUMMARY/ABSTRACTLung cancer is the leading cause of cancer-related deaths, with more than 1.6 million deaths/year globally. It isoften diagnosed at an advanced stage and is associated with poor outcomes for the majority of patients. Thisapplication for a lung cancer SPORE award from Emory University brings together an outstanding and multi-disciplinary team of oncologists, immunologists, drug discovery experts, and translational researchers dedicatedto lung cancer research to address critical questions that will improve the outcome for patients with this lethaldisease. Our proposed program will have significant impact in two crucial areas of lung cancer management:enhancing the efficacy of immunotherapy and overcoming treatment resistance through the development ofnovel molecularly targeted agents. Through strong teamwork carried out by this highly collaborative team ofdedicated investigators, and building on exciting data published in leading journals by our group since ourprevious SPORE application, this revised submission aims to achieve substantial improvements in themanagement of patients with non-small cell lung cancer (NSCLC), through three overall Specific Aims: Aim 1:To evaluate stem-like T cells and improve efficacy of checkpoint inhibitors in NSCLC (Project 1); Aim 2:To target MERTK to improve outcomes for EGFR-mutated NSCLC (Project 2); and Aim 3: To target Baxsignaling to overcome treatment resistance in NSCLC (Project 3). The Emory Lung Cancer SPORE programwill be supported by close interaction with the Administrative Core (Core 1), Pathology Core (Core 2) and theBiostatistics and Biomedical Informatics Core (Core 3), and will conduct Career Enhancement andDevelopmental Research Programs (CEP and DRP). The SPORE program will benefit from regular advice andrecommendations from External and Internal Advisory Board members regarding its progress and direction. Ourprogram will receive strong institutional support including modern research space, excellent shared resources,and a significant level of matching funds (totaling $2.25M) from the Winship Cancer Institute of Emory University(an NCI-designated Comprehensive Cancer Center), Emory University Woodruff Health Sciences Center, EmoryHealthcare System, Emory School of Medicine, and the Department of Hematology and Medical Oncology.Through team-driven innovative research efforts in immunotherapies and molecularly targeted therapeutics, weare confident that this SPORE program, in collaboration with other lung cancer SPORE sites, will have a majorpositive impact on the management of lung cancer. -DA - 2020 -PY - 2020 -AN - GRANTS:15042613 -G1 - 5P50CA217691-02; 9975749; P50CA217691 -AD - EMORY UNIVERSITY -AD - EMORY UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Jabbour, Salma K. -AU - Berman, Abigail T. -AU - Simone, Charles B., II -TI - Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - For patients with inoperable stage II-III non-small cell lung cancer (NSCLC), the backbone of curative intent therapy is concurrent chemoradiotherapy (CRT). As checkpoint inhibitors have shown clinical benefit in the setting of metastatic NSCLC, additional study is necessary to understand their role in patients receiving CRT. When integrating immunotherapy with radiotherapy (RT) for cure, clinicians will need to consider synergy, timing, doses, and safety among the combination of therapies. This article seeks to review data evaluating interactions, temporal sequencing, fractionation, and overlapping toxicity profiles of thoracic chemoradiation and immunotherapy. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2017 APR -PY - 2017 -VL - 6 -IS - 2 -SP - 113 -EP - 118 -DO - 10.21037/tlcr.2017.04.02 -AN - WOS:000403489800002 -AD - Rutgers State Univ, Rutgers Robert Wood Johnson Med Sch, Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA -AD - Hosp Univ Penn, Dept Radiat Oncol, Perelman Sch Med, 3400 Spruce St, Philadelphia, PA 19104 USA -AD - Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA -Y2 - 2017-04-01 -ER - - -TY - JOUR -AU - Markovic, Filip -AU - Nikolic, Nikola -AU - Colic, Nikola -AU - Savic, Milan -AU - Stjepanovic, Mihailo -TI - Pathological complete response after primary tumor surgery following chemoimmunotherapy and stereotactic radiosurgery of initially metastatic non- small-cell lung cancer -T2 - SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO -M3 - Article -AB - Introduction Surgery of the primary tumor following extended course of chemoimmunotherapy has only recently been recognized as a feasible and safe option for selected groups of patients with initially unresectable non-small cell lung cancer. Case outline Here we report a case of a 49-year-old female patient, who never smoked, that was diagnosed with metastatic non-small cell lung cancer. Lesions were evident in both lungs and the brain. She underwent stereotactic radiosurgery for brain metastases and combination therapy of chemotherapy, atezolizumab and bevacizumab. Response to therapy was both remarkable and durable. Ten cycles into treatment, magnetic resonance imaging of the brain revealed no metastatic lesions. Positron emission tomography / computed tomography revealed a single lesion in the right upper lobe 22 x 23 mm in diameter. The patient underwent a right upper lobectomy. Pathohistological evaluation of the specimen revealed complete pathologic response. The patient recovered from surgery and continued chemoimmunotherapy. Four months post-surgery she is disease free and of excellent performance status. Conclusion Primary tumor surgery following extensive chemoimmunotherapy regiment is feasible and could be considered as a treatment option. Further research is warranted to define a patient population that stands to benefit the most from this modality. -PU - SRPSKO LEKARSKO DRUSTVO -PI - BEOGRAD -PA - UREDNISTVO CASOPISA SRPSKI ARHIV, UL DZORDZA VASINGTONA 19, BEOGRAD, 11000, SERBIA -SN - 0370-8179 -DA - 2024 MAY-JUN -PY - 2024 -VL - 152 -IS - 5-6 -SP - 297 -EP - 300 -DO - 10.2298/SARH240129031M -AN - WOS:001293770800001 -AD - Univ Clin Ctr Serbia, Clin Pulmonol, Dr Koste Todorovica 26, Belgrade 11000, Serbia -AD - Univ Clin Ctr Serbia, Ctr Radiol & Magnet Resonance Imaging, Belgrade, Serbia -AD - Univ Clin Ctr Serbia, Clin Thorac Surg, Belgrade, Serbia -AD - Univ Belgrade, Fac Med, Belgrade, Serbia -Y2 - 2024-08-23 -ER - - -TY - JOUR -AU - Zhao, Liang -AU - Chen, Haojun -AU - Guo, Zhide -AU - Fu, Kaili -AU - Yao, Lanling -AU - Fu, Li -AU - Guo, Weixi -AU - Wen, Xuejun -AU - Jacobson, Orit -AU - Zhang, Xianzhong -AU - Sun, Long -AU - Wu, Hua -AU - Lin, Qin -AU - Chen, Xiaoyuan -TI - Targeted Radionuclide Therapy in Patient-Derived Xenografts Using 177Lu-EB-RGD -T2 - MOLECULAR CANCER THERAPEUTICS -M3 - Article -AB - Currently, most patients with non-small cell lung cancer (NSCLC) are diagnosed in advanced stages with a poor fiveyear survival rate. Therefore, intensive research aimed at finding novel therapeutic strategies has been ongoing; experimental models that reliably emulate NSCLC disease are greatly needed to predict responses to novel therapeutics. Therefore, we developed patient-derived xenograft (PDX) models of NSCLC, which we then used to evaluate the therapeutic efficacy of Lu-177-EB-RGD, a peptide-based radiopharmaceutical with improved pharmacokinetics that targets integrin alpha(v)beta(3). In this study, three different groups of NSCLC-PDXs were successfully established, all of which maintained the same IHC and genetic characteristics of the human primary tumor. The two NSCLCPDX groups with intense and low expression of integrin avb3 ( denoted as PDX alpha v beta+ and PDX alpha v beta 3- ) were chosen as the experimental models to evaluate the in vivo biological behavior of Lu-177-EB-RGD. In SPECT imaging and biodistribution studies, Lu-177-EB-RGD showed significantly higher accumulation in PDX alpha v beta+ and PDX alpha v beta 3-. models than its corresponding monomer Lu-177-RGD. A single dose of 18.5 MBq Lu-177-EB-RGD was enough to completely eradicate the tumors in PDX alpha v beta+, with no sign of tumor recurrence during the observation period. Such treatment was also efficacious in PDX alpha v beta 3-: a single dose of 29.6 MBq Lu-177-EB-RGD led to a significant delay in tumor growth as compared with that in the control or Lu-177-RGD group. The preclinical data from the use of this model suggest that Lu-177-EB-RGD may be an effective treatment option for NSCLC and should be further evaluated in human trials. -PU - AMER ASSOC CANCER RESEARCH -PI - PHILADELPHIA -PA - 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA -SN - 1535-7163 -SN - 1538-8514 -DA - 2020 OCT 1 -PY - 2020 -VL - 19 -IS - 10 -SP - 2034 -EP - 2043 -DO - 10.1158/1535-7163.MCT-19-1098 -AN - WOS:000587913700008 -AD - Xiamen Univ, Xiamen Canc Ctr, Dept Radiat Oncol, Affiliated Hosp 1, Xiamen 361003, Peoples R China -AD - Xiamen Univ, Xiamen Canc Ctr, Dept Nucl Med, Affiliated Hosp 1, Xiamen 361003, Peoples R China -AD - Xiamen Univ, Xiamen Canc Ctr, Minnan PET Ctr, Affiliated Hosp 1, Xiamen 361003, Peoples R China -AD - Xiamen Univ, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen, Peoples R China -AD - Xiamen Univ, Ctr Mol Imaging & Translat Med, Sch Publ Hlth, Xiamen, Peoples R China -AD - Xiamen Univ, Xiamen Canc Hosp, Dept Pathol, Affiliated Hosp 1, Xiamen, Peoples R China -AD - Xiamen Univ, Xiamen Canc Ctr, Dept Thorac Surg, Affiliated Hosp 1, Xiamen, Fujian, Peoples R China -AD - NIBIB, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20814 USA -Y2 - 2020-11-27 -ER - - -TY - JOUR -AU - Kumar, Arvind -AU - Srinivasan, Deepti -AU - Potter, Alexandra L. -AU - Mathey-Andrews, Camille -AU - Lanuti, Michael -AU - Martin, Linda W. -AU - Yang, Chi-Fu Jeffrey -TI - Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non - small cell lung cancer -T2 - JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY -M3 - Article -AB - Objective: Despite the growing relevance of immunotherapy for non - small cell lung cancer (NSCLC), there is limited consensus on the optimal treatment strategy for locally advanced NSCLC. This study evaluated the overall survival of patients with stage III -N2 NSCLC undergoing induction chemoimmunotherapy with surgery (CT/IO + Surgery) and de fi nitive concurrent chemoradiation followed by immunotherapy (cCRT + IO). Methods: Patients with cT1-3, N2, M0 NSCLC in the National Cancer Database (2013 to 2019) were included and strati fi ed by treatment regimen: CT/IO + Surgery or cCRT + IO. Overall survival was evaluated using Kaplan -Meier analysis, Cox proportional hazards modeling, and propensity score matching on 10 prognostic variables. Results: Of the 3382 patients who met the study eligibility criteria, 3289 (97.3 % ) received cCRT + IO and 93 (2.8 % ) received CT/IO + Surgery. The 3 -year overall survival of the entire cohort was 58.2 % (95 % CI, 56.2 % to 60.1 % ). Multivariableadjusted Cox proportional hazards modeling demonstrated better survival after CT/IO + Surgery than after cCRT + IO (hazard ratio [HR], 0.52; 95 % con fi dence interval [CI], 0.32 to 0.84; P = .007). In a 3:1 variable ratio propensity scorematched analysis of 223 patients who received cCRT + IO and 76 patients who received CT/IO + Surgery, 3 -year overall survival was 63.2 % (95 % CI, 55.9 % to 70.2 % ) after cCRT + IO and 77.2 % (95 % CI, 64.6 % to 85.7 % ) after CT/IO + Surgery ( P = .029). Conclusions: In this national analysis, multimodal treatment including immunotherapy was associated with a 3 -year overall survival rate of 58.2 % for all patients with stage III -N2 NSCLC and 77.2 % for patients who underwent chemoimmunotherapy followed by surgery. These results should be considered hypothesisgenerating and demonstrate the importance of developing a randomized trial to evaluate the role of surgery versus chemoradiation for locally advanced NSCLC in the modern immunotherapy era. (J Thorac Cardiovasc Surg 2024;167:1895-905) -PU - MOSBY-ELSEVIER -PI - NEW YORK -PA - 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA -SN - 0022-5223 -SN - 1097-685X -DA - 2024 JUN -PY - 2024 -VL - 167 -IS - 6 -DO - 10.1016/j.jtcvs.2023.09.029 -AN - WOS:001241774600001 -C6 - MAY 2024 -AD - Icahn Sch Med Mt Sinai, New York, NY 10029 USA -AD - Massachusetts Gen Hosp, Dept Surg, Div Thorac Surg, 55 Fruit St, Boston, MA 02114 USA -AD - Univ Virginia, Dept Surg, Div Thorac & Cardiovasc Surg, Charlottesville, VA USA -Y2 - 2024-06-16 -ER - - -TY - JOUR -AU - Sunil Krishnan; LIN, STEVEN HSESHENG -TI - Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches -M3 - Awarded Grant -AB - A major barrier to improving cure rates in locally advanced cancers is our inability to make progress beyond whatchemoradiation (CRT) can currently deliver. Combination strategies using molecular targeted therapies with CRThold promise for improving outcomes further. While many drugs could enhance the effects of radiation alone, wehave discovered that the effects are quite unpredictable when drugs are combined with chemotherapy andradiotherapy. The successful translation of adding molecular targeted agents to CRT would require anunderstanding of the molecular pathways that enable the cancer cell to survive under conditions of CRT.Inhibiting these pathways with molecular targeted drugs will be synergistic with CRT in the cancer-specificcontext. Using a set of molecular targeted drugs from the CTEP portfolio as an initial starting point, we willinvestigate two hard-to-treat cancer types treated with CRT, non-small cell lung cancer (NSCLC) and pancreaticductal adenocarcinoma (PDAC). We will identify drugs that could synergize with radiation and CRT using a highthroughput clonogenic survival screen that we have developed on validated cancer lines and then test the mostclinically promising combinations of agents to multiple cell lines with varying genetic backgrounds, first in vitroand then further validated using 2 in vivo models: a panel of patient-derived xenografts (PDXs) and orthotopictumor models using syngeneic tumors, all done in combination with clinically-relevant chemotherapies. Thepharmacokinetic and pharmacodynamic properties of these drugs with chemotherapy in animals and tumors willbe assessed in order to determine the optimal sequencing approach with conventionally fractionatedradiotherapy. Since we have discovered that chemotherapy significantly alters the response of cancer cells toradiation and targeted drugs, we will also evaluate the molecular mechanisms that explain the response to CRT,and identify potential factors that may influence this response using 4 major approaches. In the first more classicapproach, we will assess DNA damage repair pathways and reactive oxygen species generation when targetedagents are combined with radiation or CRT. Second, we will use reverse phase protein arrays (RPPA) to assessthe functional proteome to determine pathways that may be altered with molecular targeted drugs in the settingof RT or CRT. In the third approach, we will use Stable Isotope Labeling with Amino Acids (SILAC) to assessglobal proteomic and phosphoproteomic changes that occur with radiation and CRT treatment, and how thesepathways could be altered with specific molecular targeted therapies. Lastly, we will use Imaging MassSpectrometry to analyze drug distribution within the various tumor models and assess how thepharmacodynamic heterogeneity impacts CRT responsiveness. Our proposal will not only identify the mostpromising drugs that could best be combined with CRT in NSCLC and PDAC, but we will have identifiedmolecular and tumor factors that confer drug resistance which will enable future development of novel targetedstrategies to enhance CRT or appropriately select patient for personalized therapy. Our approach will generatethe high quality preclinical data and novel insights to fulfill the overall FOA objective, which is “to accelerate thepace at which combined modality treatments with greater efficacy are identified and incorporated into standardpractices for treatments”. -DA - 2020 -PY - 2020 -AN - GRANTS:15025974 -G1 - 5U01CA216468-04; 9999948; U01CA216468 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - DENKO, NICHOLAS C.; Zihai Li; Terence Marques Williams -TI - Diversity Supplement R01CA262388: Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism -M3 - Awarded Grant -AB - PROJECT SUMMARY: Many groups are investigating why some lung cancer patients respond well to radio- andimmuno-therapies and some do not. One variable is tumor hypoxia, and many groups have shown it cansignificantly inhibit the effectiveness to these therapeutic modalities. Clinical studies have identified hypoxia asan independent prognostic indicator of poor patient outcomes, but even though this connection has been knownfor decades, no FDA-approved intervention exists to clinically overcome hypoxia. Some investigators have triedto deliver more oxygen to the tumor, but this approach remains constrained due to the poorly formed tumorvasculature. We have taken an innovative approach and asked if we can reduce demand for, rather than increasesupply of, oxygen to reduce hypoxia. We have found that the FDA-approved vasorelaxant papaverine (PPV) hasan off- target ability to inhibit mitochondrial complex 1, and reduce oxygen consumption rapidly, in low micromolarconcentrations in every cell line tested in vitro. We have also shown that PPV can enhance the effectiveness ofradiation and immune checkpoint blockade (ICB) in preclinical models of lung and other cancers, withoutsensitizing well-oxygenated normal tissue. Reducing hypoxia reverses immune privilege, decreases terminally-exhausted T cells, and increases progenitors that are responsive to PD-1 blockade. We have more recentlydeveloped new derivatives of PPV that have lost their vasorelaxant capability and increased their duration ofaction so that they can be improved immuno-sensitizers. We now propose to test the hypothesis that PPV caneffectively enhance the radio- and immuno-therapeutic treatment of preclinical models of lung cancer, and thatit is feasible to add PPV to standard of care therapy for advanced non-small cell lung cancer (NSCLC). We haveexamined TCGA databases and found that lung cancer driver mutations in the KEAP1/NRF2 pathway lead tohigh levels of mitochondrial gene expression that can cause elevated oxygen metabolism contributing to hypoxia.In Aim 1, we will investigate the effects of oncogenic NRF2 activation human and murine cells and model tumorsto determine the dependence of these cells on mitochondrial function, how increased oxygen metabolismcontributes to tumor hypoxia, and if therapy-refractory tumors are sensitized by PPV or its derivatives. In Aim 2,we will examine the effect of tumor hypoxia on the migration and activation of T-cells in model tumors and howthe immune infiltrate changes after reduction of hypoxia with PPV or its derivatives. Finally, in Aim 3 we willperform a phase 1 clinical trial to determine if the addition of PPV is feasible for patients receiving standard ofcare chemoradiation followed by immunotherapy for advanced NSCLC. We will look for effectiveness in changingtumor oxygenation using paired blood level oxygen determination (BOLD) MRIs, and for changes in immunepopulations of peripheral blood mononuclear cells. These studies will let us know if, and how, to use PPV or itsnovel derivatives in future clinical trials for the treatment of NSCLC. -DA - 2022 -PY - 2022 -AN - GRANTS:17486756 -G1 - 10595436; 3R01CA262388-02S1; R01CA262388 -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - DENKO, NICHOLAS C.; Zihai Li; Terence Marques Williams -TI - Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism -M3 - Awarded Grant -AB - PROJECT SUMMARYMany groups are investigating why some lung cancer patients respond well to radio- and immuno-therapies andsome do not. One variable is tumor hypoxia, and many groups have shown it can significantly inhibit theeffectiveness to these therapeutic modalities. Clinical studies have identified hypoxia as an independentprognostic indicator of poor patient outcomes, but even though this connection has been known for decades, noFDA-approved intervention exists to clinically overcome hypoxia. Some investigators have tried to deliver moreoxygen to the tumor, but this approach remains constrained due to the poorly formed tumor vasculature. Wehave taken an innovative approach and asked if we can reduce demand for, rather than increase supply of,oxygen to reduce hypoxia. We have found that the FDA-approved vasorelaxant papaverine (PPV) has an off-target ability to inhibit mitochondrial complex 1, and reduce oxygen consumption rapidly, in low micromolarconcentrations in every cell line tested in vitro. We have also shown that PPV can enhance the effectiveness ofradiation and immune checkpoint blockade (ICB) in preclinical models of lung and other cancers, withoutsensitizing well-oxygenated normal tissue. Reducing hypoxia reverses immune privilege, decreases terminally-exhausted T cells, and increases progenitors that are responsive to PD-1 blockade. We have more recentlydeveloped new derivatives of PPV that have lost their vasorelaxant capability and increased their duration ofaction so that they can be improved immuno-sensitizers. We now propose to test the hypothesis that PPV caneffectively enhance the radio- and immuno-therapeutic treatment of preclinical models of lung cancer, and thatit is feasible to add PPV to standard of care therapy for advanced non-small cell lung cancer (NSCLC). We haveexamined TCGA databases and found that lung cancer driver mutations in the KEAP1/NRF2 pathway lead tohigh levels of mitochondrial gene expression that can cause elevated oxygen metabolism contributing to hypoxia.In Aim 1, we will investigate the effects of oncogenic NRF2 activation human and murine cells and model tumorsto determine the dependence of these cells on mitochondrial function, how increased oxygen metabolismcontributes to tumor hypoxia, and if therapy-refractory tumors are sensitized by PPV or its derivatives. In Aim 2,we will examine the effect of tumor hypoxia on the migration and activation of T-cells in model tumors and howthe immune infiltrate changes after reduction of hypoxia with PPV or its derivatives. Finally, in Aim 3 we willperform a phase 1 clinical trial to determine if the addition of PPV is feasible for patients receiving standard ofcare chemoradiation followed by immunotherapy for advanced NSCLC. We will look for effectiveness in changingtumor oxygenation using paired blood level oxygen determination (BOLD) MRIs, and for changes in immunepopulations of peripheral blood mononuclear cells. These studies will let us know if, and how, to use PPV or itsnovel derivatives in future clinical trials for the treatment of NSCLC. -DA - 2022 -PY - 2022 -AN - GRANTS:17481558 -G1 - 10492487; 5R01CA262388-02; R01CA262388 -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - DENKO, NICHOLAS C.; Zihai Li; Terence Marques Williams -TI - Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism -M3 - Awarded Grant -AB - PROJECT SUMMARYMany groups are investigating why some lung cancer patients respond well to radio- and immuno-therapies andsome do not. One variable is tumor hypoxia, and many groups have shown it can significantly inhibit theeffectiveness to these therapeutic modalities. Clinical studies have identified hypoxia as an independentprognostic indicator of poor patient outcomes, but even though this connection has been known for decades, noFDA-approved intervention exists to clinically overcome hypoxia. Some investigators have tried to deliver moreoxygen to the tumor, but this approach remains constrained due to the poorly formed tumor vasculature. Wehave taken an innovative approach and asked if we can reduce demand for, rather than increase supply of,oxygen to reduce hypoxia. We have found that the FDA-approved vasorelaxant papaverine (PPV) has an off-target ability to inhibit mitochondrial complex 1, and reduce oxygen consumption rapidly, in low micromolarconcentrations in every cell line tested in vitro. We have also shown that PPV can enhance the effectiveness ofradiation and immune checkpoint blockade (ICB) in preclinical models of lung and other cancers, withoutsensitizing well-oxygenated normal tissue. Reducing hypoxia reverses immune privilege, decreases terminally-exhausted T cells, and increases progenitors that are responsive to PD-1 blockade. We have more recentlydeveloped new derivatives of PPV that have lost their vasorelaxant capability and increased their duration ofaction so that they can be improved immuno-sensitizers. We now propose to test the hypothesis that PPV caneffectively enhance the radio- and immuno-therapeutic treatment of preclinical models of lung cancer, and thatit is feasible to add PPV to standard of care therapy for advanced non-small cell lung cancer (NSCLC). We haveexamined TCGA databases and found that lung cancer driver mutations in the KEAP1/NRF2 pathway lead tohigh levels of mitochondrial gene expression that can cause elevated oxygen metabolism contributing to hypoxia.In Aim 1, we will investigate the effects of oncogenic NRF2 activation human and murine cells and model tumorsto determine the dependence of these cells on mitochondrial function, how increased oxygen metabolismcontributes to tumor hypoxia, and if therapy-refractory tumors are sensitized by PPV or its derivatives. In Aim 2,we will examine the effect of tumor hypoxia on the migration and activation of T-cells in model tumors and howthe immune infiltrate changes after reduction of hypoxia with PPV or its derivatives. Finally, in Aim 3 we willperform a phase 1 clinical trial to determine if the addition of PPV is feasible for patients receiving standard ofcare chemoradiation followed by immunotherapy for advanced NSCLC. We will look for effectiveness in changingtumor oxygenation using paired blood level oxygen determination (BOLD) MRIs, and for changes in immunepopulations of peripheral blood mononuclear cells. These studies will let us know if, and how, to use PPV or itsnovel derivatives in future clinical trials for the treatment of NSCLC. -DA - 2021 -PY - 2021 -AN - GRANTS:15594313 -G1 - 10275968; 1R01CA262388-01; R01CA262388 -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - YANNELLI, JOHN R. -TI - Evaluation of T Cell Response to Cisplatin Resistant NSCLC -M3 - Awarded Grant -AB - PUBLIC HEALTH RELEVANCE: Prognosis of advanced stage NSCLC is grim. While some oncologists advocate therapeutic nihilism for advanced NSCLC based on excessive drug toxicity and universally poor outcomes, chemotherapy can reduce symptoms, improve quality of life and result in small improvement in survival when compared to best supportive care. This application describes Proof of Principle studies for the improvement of an already proven cellular vaccine for NSCLC. -DA - 2015 -PY - 2015 -AN - GRANTS:10559061 -G1 - 5R03CA172954-02; 8788695; R03CA172954 -AD - UNIVERSITY OF KENTUCKY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - HAMMERMAN, PETER S; HEYMACH, JOHN V (contact) -TI - Therapeutic approaches for LKB1-deficient non-small cell lung cancer -M3 - Awarded Grant -AB - PUBLIC HEALTH RELEVANCE: Therapeutic advances have been made in the treatment of subpopulations of non-small cell lung cancer (NSCLC) patients who harbor specific genomic alterations (e.g. EGFR mutation and ALK ROS gene rearrangements) which can be targeted with small molecule kinase inhibitors; however, the serine/threonine kinase STK11 (LKB1) is the second most commonly altered tumor suppressors in NSCLC, with genomic loss or inactivating mutations occurring in 20-30% of lung adenocarcinoma and there are currently no treatment strategies tailored for LKB1-deficient NSCLC. The PIs have developed preliminary data showing that in human tumor specimens and in Genetically Engineered Mouse Models of NSCLC with Lkb1 deletion that loss of LKB1 is associated with higher stage of disease at presentation, increased metastasis and poor overall prognosis as well as unique biological characteristics. This proposal will deeply characterize the distinct biology of LKB1- deficient NSCLCs with a focus on the immune microenvironment as a means to develop novel therapeutic approaches for patients with LKB1-deficient NSCLCs. -DA - 2016 -PY - 2016 -AN - GRANTS:12108571 -G1 - 1R01CA205150-01; 9082508; R01CA205150 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Zheng, Hao-Ran -AU - Jiang, Ai-Min -AU - Gao, Huan -AU - Liu, Na -AU - Zheng, Xiao-Qiang -AU - Fu, Xiao -AU - Zhang, Rui -AU - Ruan, Zhi-Ping -AU - Tian, Tao -AU - Liang, Xuan -AU - Yao, Yu -TI - The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study -T2 - CANCER MANAGEMENT AND RESEARCH -M3 - Article -AB - Purpose: Anlotinib, an antiangiogenic multi-target tyrosine kinase inhibitor (TKI), has shown favorable anticancer efficacy and acceptable safety in treating extensive-stage small cell lung cancer (ES-SCLC) in some clinical studies. This research aimed to explore the real-world efficacy and safety of anlotinib in ES-SCLC.Methods: Pathologically confirmed ES-SCLC patients receiving anlotinib were enrolled for this retrospective study. The primary endpoint of this study was progression-free survival (PFS), and secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions.Results: In total, 202 patients were included in this study. The median PFS of all patients was 4.8 months [95% confidence interval (CI): 3.9-5.7], and the median OS was 7.6 months (95% CI 6.5-8.7). Respectively, the overall ORR and DCR were 30.2% and 87.1%. The univariate and multivariate Cox regression analyses revealed that patients with Eastern Cooperative Oncology Group Performance Status (ECOG PS) <= 1, plus chemotherapy or immunotherapy, plus radiotherapy, and post-medication hypertension might have longer PFS and OS. The PFS and OS were significantly prolonged in combination group than that in monotherapy group [PFS 6.0 vs 3.6 months, hazards ratio (HR)=0.49, 95% CI 0.34-0.70, P < 0.001; OS 9.2 vs 4.8 months, HR = 0.48, 95% CI 0.32-0.72, P < 0.001]. The main treatment-related adverse reactions were generally tolerated. The incidence of adverse reactions in combination group was higher than that in monotherapy group (75.0% vs 52.6%, P = 0.001). The most common adverse reaction was hypertension, followed by hand-foot syndrome and fatigue, regardless of monotherapy or combination group.Conclusion: Anlotinib is effective and well tolerated in patients with ES-SCLC in the real-world. The clinical efficacy of anlotinib combined with chemotherapy or immunotherapy is better than that of monotherapy. Further investigations are needed for prospective studies with larger sample size. -PU - DOVE MEDICAL PRESS LTD -PI - ALBANY -PA - PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND -SN - 1179-1322 -DA - 2022 -PY - 2022 -VL - 14 -SP - 2273 -EP - 2287 -DO - 10.2147/CMAR.S364125 -AN - WOS:000835376900001 -AD - Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian, Shaanxi, Peoples R China -AD - Xian 3 Hosp, Dept Med Oncol, Xian, Shaanxi, Peoples R China -AD - Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, 277 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China -M2 - Xian 3 Hosp -Y2 - 2022-08-10 -ER - - -TY - JOUR -AU - YEUNG, AW -AU - PANG, YK -AU - TSANG, YC -AU - WONG, SW -AU - LEUNG, JS -TI - SHORT-DURATION INVITRO INTERLEUKIN-2-ACTIVATED MONONUCLEAR-CELLS FOR ADVANCED CANCER - A HONG-KONG BIOTHERAPY PILOT-STUDY TRIAL -T2 - CANCER -M3 - Article -AB - Background. In vitro studies have demonstrated that a brief exposure of peripherally collected mononuclear cells to high-dose human recombinant interleukin-2 (rIL-2) will generate a population of pulsed lymphokine-activated killer (LAK) cells. These cells have similar cytotoxicity against natural killer cells and resistant and sensitive target cells as compared with the standard LAK cells incubated for 3-7 days with rIL-2. Therefore, the authors conducted a pilot study to investigate the activity of pulsed LAK cells in patients with advanced cancer.Methods. Nineteen patients were enrolled in a pilot study, and pulsed LAK cell treatment was administered two times per week for 4 weeks, followed by similar cycles if patients remained free of disease progression and unacceptable toxic effects.Results. Toxic effects consisted mainly of fever, chills, nausea, and dizziness but were self-limiting and mild. Most cycles were administered on an outpatient basis. There were six partial responses (31%), occurring in two of three patients with renal cell carcinoma, two of four with hepatocellular carcinoma, one of seven with non-small cell lung carcinoma, and one of one with ovarian carcinoma. Two minimal responses were seen in one case each of melanoma and carcinoma of colon. Nine other patients had disease stabilization for 16 weeks, and two additional patients had disease progression. Pheno-typing of peripheral mononuclear cells showed increases in CD56 and CD25 populations with no in vivo rIL-2 being administered after treatment with pulsed LAK cells.Conclusions. The relative ease in generating pulsed LAK cells and the associated mild toxic effects enable prolonged stimulation of the effector cells of the patients against sensitive tumor targets, with a response rate comparable to those of high-dose rIL-2 and LAK cell treatment. Therefore, it may be a theoretically ideal adjuvant for patients with renal cell carcinoma, melanoma, and hepatoma and other applicable patients after bone marrow transplantation. The initial high response rate in patients with late-stage renal cell carcinoma and hepatocellular carcinoma indicates the need for additional confirmation. -PU - WILEY-LISS -PI - NEW YORK -PA - DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 -SN - 0008-543X -DA - 1993 JUN 1 -PY - 1993 -VL - 71 -IS - 11 -SP - 3633 -EP - 3639 -DO - 10.1002/1097-0142(19930601)71:11<3633::AID-CNCR2820711127>3.0.CO;2-C -AN - WOS:A1993LE41900026 -Y2 - 1993-06-01 -ER - - -TY - JOUR -AU - Yu, Baodan -AU - Wang, Junli -AU - He, Chen -AU - Wang, Wei -AU - Tang, Jianli -AU - Zheng, Runhui -AU - Zhou, Chengzhi -AU - Zhang, Huanhuan -AU - Fu, Zhiping -AU - Li, Qiasheng -AU - Xu, Jun -TI - Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer -T2 - EXPERIMENTAL AND THERAPEUTIC MEDICINE -M3 - Article -AB - Previous studies have reported that regulatory T cells (Tregs), which are physiologically engaged in the maintenance of immunological self-tolerance, have a critical role in the regulation of the antitumor immune response. Targeting Tregs has the potential to augment cancer vaccine approaches. The current study therefore aimed to evaluate the role of cytokine-induced killer (CIK) cell infusion in modulating Tregs in patients with non-small cell lung cancer (NSCLC). A total of 15 patients with advanced NSCLC were treated by an infusion of CIK cells derived from autologous peripheral blood mononuclear cells (PBMCs). By using flow cytometry and liquid chip analysis, subsets of T cells and natural killer (NK) cells in peripheral blood, and plasma cytokine profiles in the treated patients, were analyzed at 2 and 4 weeks after CIK cell infusion. Cytotoxicity of PBMCs (n=15) and NK cells (n=6) isolated from NSCLC patients was evaluated before and after CIK cell therapy. Progression-free survival (PFS) and overall survival (OS) were also assessed. Analysis of the immune cell populations before and after treatment showed a significant increase in NK cells (P<0.05) concomitant with a significant decrease in Tregs (P<0.01) at 2 weeks post-infusion of CIK cells compared with the baseline. NK group 2D receptor (NKG2D) expression on NK cells was also significantly increased at 2 weeks post-infusion compared with the baseline (P<0.05). There was a positive correlation between NKG2D expression and the infusion number of CIK cells (P<0.05). When evaluated at 2 weeks after CIK cell therapy, the cytotoxicity of PBMCs and isolated NK cells was significantly increased compared with the baseline (P<0.01 and P<0.05). Correspondingly, plasma cytokine profiles showed significant enhancement of the following antitumor cytokines: Interferon (IFN)-gamma (P<0.05), IFN-gamma-inducible protein 10 (P<0.01), tumor necrosis factor-alpha (P<0.001), granulocyte-macrophage colony-stimulating factor (P<0.01), monocyte chemotactic protein-3 (P<0.01) and interleukin-21 (P<0.05) at 2 weeks post-infusion, compared with the baseline. At the same time, the expression of transforming growth factor-beta 1, which is primarily produced by Tregs, was significantly decreased compared with the baseline (P<0.05). Median PFS and OS in the CIK cell treatment group were significantly increased compared with the control group (PFS, 9.98 vs. 5.44 months, P=0.038; OS, 24.17 vs. 20.19 months, P=0.048). No severe side-effects were observed during the treatment period. In conclusion, CIK cell therapy was able to suppress. Tregs and enhance the antitumor immunity of NK cells in advanced NSCLC patients. Therefore, CIK cell treatment may improve PFS and OS in patients with advanced NSCLC. CIK cell infusion may have therapeutic value for patients with advanced NSCLC, as a treatment that can be combined with chemotherapy and radiotherapy. -PU - SPANDIDOS PUBL LTD -PI - ATHENS -PA - POB 18179, ATHENS, 116 10, GREECE -SN - 1792-0981 -SN - 1792-1015 -DA - 2017 JUL -PY - 2017 -VL - 14 -IS - 1 -SP - 831 -EP - 840 -DO - 10.3892/etm.2017.4562 -AN - WOS:000405645500054 -AD - Guangzhou Med Univ, Affiliated Hosp 1, Dept Clin Lab, Guangzhou 510120, Guangdong, Peoples R China -AD - Southern Med Univ, Shenzhen Hosp, Dept Respirat, Shenzhen 518100, Guangdong, Peoples R China -AD - Southern Med Univ, Dept Resp Med, Affiliated Shenzhen Baoan Hosp, Shenzhen 518101, Guangdong, Peoples R China -AD - Inner Mongolia Med Univ, Affiliated Hosp, Dept Med Oncol, Hohhot 010050, Inner Mongolia, Peoples R China -AD - Guangzhou Med Univ, Guangzhou Inst Resp Dis, Affiliated Hosp 1, State Key Lab Resp Dis, 1 Kangda Rd, Guangzhou 510000, Guangdong, Peoples R China -AD - Guangzhou Med Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou 510120, Guangdong, Peoples R China -AD - Yangtze Univ, Clin Med Coll 2, Jingzhou Cent Hosp, Dept Resp Med, Jingzhou 434020, Hubei, Peoples R China -Y2 - 2017-08-03 -ER - - -TY - JOUR -AU - Faehling, Martin -AU - Schumann, Christian -AU - Christopoulos, Petros -AU - Hoffknecht, Petra -AU - Alt, Juergen -AU - Horn, Marlitt -AU - Eisenmann, Stephan -AU - Schlenska-Lange, Anke -AU - Schuett, Philipp -AU - Steger, Felix -AU - Brueckl, Wolfgang M. -AU - Christoph, Daniel C. -TI - Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP) -T2 - LUNG CANCER -M3 - Article -AB - Background: Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy and safety.Methods: Data from 56 centres were analysed for adverse events (AE), progression-free survival (PFS), overall survival (OS).Results: 126 patients actually received at least 1 cycle durvalumab. Compared to the PACIFIC trial, the EAP population had more advanced stage and included "oligometastatic" stage IV patients and patients with autoimmune disease. PFS (20.1 months) and OS (not reached) were similar in the EAP and the PACIFIC trial. 42.9 % completed 12 months of durvalumab without deaths during FU. Stage IV patients (n = 7) had encouraging OS (not reached at 27 months). Autoimmune disease did not affect survival. PFS and OS were similar in PD-L1-negative patients (n = 32) and PD-L1-positive patients (n = 79).Conclusions: Survival in the EAP was comparable to the PACIFIC trial. Selected stage IV patients and patients with autoimmune disease may benefit from durvalumab consolidation and should be included in future immuno-oncological trials. PD-L1 did not predict survival challenging the exclusion of PD-L1-negative patients from durvalumab consolidation. In summary, durvalumab consolidation is safe and effective in a European real-world setting. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2020 DEC -PY - 2020 -VL - 150 -SP - 114 -EP - 122 -DO - 10.1016/j.lungcan.2020.10.006 -AN - WOS:000598669200001 -AD - Klinikum Esslingen, Klin Kardiol & Pneumol, D-73730 Esslingen, Germany -AD - Klinikum Kempten, Klin Pneumol Thoraxonkol Schlaf & Beatmungsmed, D-87439 Kempten, Germany -AD - Thoraxklin Heidelberg, D-69126 Heidelberg, Germany -AD - Franziskus Hosp Harderberg, Klin Thoraxonkol & Palliat Stat, D-49124 Georgsmarienhutte, Germany -AD - Johannes Gutenberg Univ Mainz, Med Klin & Poliklin 3, D-55131 Mainz, Germany -AD - LungenClin Grosshansdorf, Grosshansdorf, Germany -AD - Univ Klinikum Halle Saale, Univ & Poliklin Innere Med Gastroenterol & Pneumo, D-06120 Halle, Germany -AD - Krankenhaus Barmherzige Bruder Regensburg, Klin Onkol & Hamatol, D-93049 Regensburg, Germany -AD - Onkolog Gemeinschaftspraxis, Gutersloh, Germany -AD - Univ Klinikum Regensburg, Klin & Poliklin Strahlentherapie, D-93053 Regensburg, Germany -AD - Klinikum Nurnberg Nord, Klin Innere Med 3, D-90419 Nurnberg, Germany -AD - Evang Kliniken Essen Mitte, Klin Internist Onkol & Amatol Integrierter Pallia, D-45136 Essen, Germany -M2 - Klinikum Esslingen -M2 - Klinikum Kempten -M2 - Franziskus Hosp Harderberg -M2 - Krankenhaus Barmherzige Bruder Regensburg -M2 - Onkolog Gemeinschaftspraxis -M2 - Evang Kliniken Essen Mitte -Y2 - 2021-01-12 -ER - - -TY - JOUR -AU - FORASTIERE, ARLENE ANN -TI - Eastern Cooperative Oncology Group -M3 - Awarded Grant -DA - 2008 -PY - 2008 -AN - GRANTS:10521274 -G1 - 5U10CA016116-35; 7425432; U10CA016116 -AD - JOHNS HOPKINS UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Sunil Krishnan; LIN, STEVEN HSESHENG -TI - Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches -M3 - Awarded Grant -AB - A major barrier to improving cure rates in locally advanced cancers is our inability to make progress beyond whatchemoradiation (CRT) can currently deliver. Combination strategies using molecular targeted therapies with CRThold promise for improving outcomes further. While many drugs could enhance the effects of radiation alone, wehave discovered that the effects are quite unpredictable when drugs are combined with chemotherapy andradiotherapy. The successful translation of adding molecular targeted agents to CRT would require anunderstanding of the molecular pathways that enable the cancer cell to survive under conditions of CRT.Inhibiting these pathways with molecular targeted drugs will be synergistic with CRT in the cancer-specificcontext. Using a set of molecular targeted drugs from the CTEP portfolio as an initial starting point, we willinvestigate two hard-to-treat cancer types treated with CRT, non-small cell lung cancer (NSCLC) and pancreaticductal adenocarcinoma (PDAC). We will identify drugs that could synergize with radiation and CRT using a highthroughput clonogenic survival screen that we have developed on validated cancer lines and then test the mostclinically promising combinations of agents to multiple cell lines with varying genetic backgrounds, first in vitroand then further validated using 2 in vivo models: a panel of patient-derived xenografts (PDXs) and orthotopictumor models using syngeneic tumors, all done in combination with clinically-relevant chemotherapies. Thepharmacokinetic and pharmacodynamic properties of these drugs with chemotherapy in animals and tumors willbe assessed in order to determine the optimal sequencing approach with conventionally fractionatedradiotherapy. Since we have discovered that chemotherapy significantly alters the response of cancer cells toradiation and targeted drugs, we will also evaluate the molecular mechanisms that explain the response to CRT,and identify potential factors that may influence this response using 4 major approaches. In the first more classicapproach, we will assess DNA damage repair pathways and reactive oxygen species generation when targetedagents are combined with radiation or CRT. Second, we will use reverse phase protein arrays (RPPA) to assessthe functional proteome to determine pathways that may be altered with molecular targeted drugs in the settingof RT or CRT. In the third approach, we will use Stable Isotope Labeling with Amino Acids (SILAC) to assessglobal proteomic and phosphoproteomic changes that occur with radiation and CRT treatment, and how thesepathways could be altered with specific molecular targeted therapies. Lastly, we will use Imaging MassSpectrometry to analyze drug distribution within the various tumor models and assess how thepharmacodynamic heterogeneity impacts CRT responsiveness. Our proposal will not only identify the mostpromising drugs that could best be combined with CRT in NSCLC and PDAC, but we will have identifiedmolecular and tumor factors that confer drug resistance which will enable future development of novel targetedstrategies to enhance CRT or appropriately select patient for personalized therapy. Our approach will generatethe high quality preclinical data and novel insights to fulfill the overall FOA objective, which is “to accelerate thepace at which combined modality treatments with greater efficacy are identified and incorporated into standardpractices for treatments”. -DA - 2019 -PY - 2019 -AN - GRANTS:15049329 -G1 - 5U01CA216468-03; 9749046; U01CA216468 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Spicer, Jonathan D -AU - Cascone, Tina -AU - Wynes, Murry W -AU - Ahn, Myung-Ju -AU - Dacic, Sanja -AU - Felip, Enriqueta -AU - Forde, Patrick M -AU - Higgins, Kristin A -AU - Kris, Mark G -AU - Mitsudomi, Tetsuya -AU - Provencio, Mariano -AU - Senan, Suresh -AU - Solomon, Benjamin J -AU - Tsao, Ming Sound -AU - Tsuboi, Masahiro -AU - Wakelee, Heather A -AU - Wu, Yi-Long -AU - Chih-Hsin Yang, James -AU - Zhou, Caicun -AU - Harpole, David H -AU - Kelly, Karen L -TI - Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer. -T2 - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer -M3 - Journal Article -M3 - Review -AB - Advances in the multidisciplinary care of early stage resectable NSCLC (rNSCLC) are emerging at an unprecedented pace. Numerous phase 3 trials produced results that have transformed patient outcomes for the better, yet these findings also require important modifications to the patient treatment journey trajectory and reorganization of care pathways. Perhaps, most notably, the need for multispecialty collaboration for this patient population has never been greater. These rapid advances have inevitably left us with important gaps in knowledge for which definitive answers will only become available in several years. To this end, the International Association for the Study of Lung Cancer commissioned a diverse multidisciplinary international expert panel to evaluate the current landscape and provide diagnostic, staging, and therapeutic recommendations for patients with rNSCLC, with particular emphasis on patients with American Joint Committee on Cancer-Union for International Cancer Control TNM eighth edition stages II and III disease. Using a team-based approach, we generated 19 recommendations, of which all but one achieved greater than 85% consensus among panel members. A public voting process was initiated, which successfully validated and provided qualitative nuance to our recommendations. Highlights include the following: (1) the critical importance of a multidisciplinary approach to the evaluation of patients with rNSCLC driven by shared clinical decision-making of a multispecialty team of expert providers; (2) biomarker testing for rNSCLC; (3) a preference for neoadjuvant chemoimmunotherapy for stage III rNSCLC; (4) equipoise regarding the optimal management of patients with stage II between upfront surgery followed by adjuvant therapy and neoadjuvant or perioperative strategies; and (5) the robust preference for adjuvant targeted therapy for patients with rNSCLC and sensitizing EGFR and ALK tumor alterations. Our primary goals were to provide practical recommendations sensitive to the global differences in biology and resources for patients with rNSCLC and to provide expert consensus guidance tailored to the individualized patient needs, goals, and preferences in their cancer care journey as these are areas where physicians must make daily clinical decisions in the absence of definitive data. These recommendations will continue to evolve as the treatment landscape for rNSCLC expands and more knowledge is acquired on the best therapeutic approach in specific patient and disease subgroups. -SN - 1556-1380 -DA - 2024 Oct (Epub 2024 Jun 18) -PY - 2024 -VL - 19 -IS - 10 -SP - 1373 -EP - 1414 -DO - 10.1016/j.jtho.2024.06.010 -AN - MEDLINE:38901648 -AD - Division of Thoracic Surgery and Upper GI Surgery, Department of Surgery, McGill University Health Centre, Montreal, Quebec, Canada. -AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. -AD - Scientific Affairs, International Association for the Study of Lung Cancer, Denver, Colorado. -AD - Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Republic of Korea. -AD - Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. -AD - Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain. -AD - The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. -AD - Department of Radiation Oncology, Emory University, Winship Cancer Institute, Atlanta, Georgia. -AD - Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. -AD - Izumi City General Hospital, Izumi, Osaka, Japan; Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan. -AD - Medical Oncology Department, Puerta de Hierro University Teaching Hospital, Majadahonda, Spain. -AD - Cancer Center Amsterdam, Department of Radiation Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. -AD - Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. -AD - Department of Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. -AD - Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan. -AD - Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California; Stanford Cancer Institute, Stanford, California. -AD - Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. -AD - Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan. -AD - Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, People's Republic of China. -AD - Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina. -AD - Scientific Affairs, International Association for the Study of Lung Cancer, Denver, Colorado. Electronic address: Karen.Kelly@iaslc.org. -Y2 - 2024-06-22 -ER - - -TY - JOUR -AU - Mohamed, Shehab -AU - Bertolaccini, Luca -AU - Casiraghi, Monica -AU - Petrella, Francesco -AU - Galetta, Domenico -AU - Guarize, Juliana -AU - de Marinis, Filippo -AU - Spaggiari, Lorenzo -TI - Predictors, surrogate, and patient-reported outcomes in immunotherapy and salvage surgery for unresectable lung cancer: a single-center retrospective study -T2 - UPDATES IN SURGERY -M3 - Article -AB - Medical treatment has changed drastically in recent years, especially for advanced stages of non-small-cell lung cancer (NSCLC), for which the development of immunotherapy and molecular targeted therapy significantly increased survival and quality of life. This single-center retrospective study aimed to analyze the outcome predictors, the surrogate outcomes, and the patient-reported outcomes after neoadjuvant immunotherapy for initially unresectable NSCLC. Patients affected by an initially unresectable NSCLC and identified between March 2014 and December 2021 who received immunotherapy alone or in combination with platinum-based chemotherapy and/or radiotherapy were collected. Overall survival (OS) and disease-free survival (DFS) were estimated according to the Kaplan-Meier method. Patient-reported outcomes were recorded using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life (QoL) Group questionnaire-Lung Cancer 29 Module to compare differences in symptoms and QoL at two different times, 30 days and 1 year after surgery. Surgical, pathological records, and patient-reported outcomes (at 30 days and 1 year after surgery) were reviewed. Complete pathological remission was achieved in 7 patients (36.8%) and major pathological remission in 3 patients (15.7%). The median overall survival in the study group is 19 months (range: 2-57.4). Of 19 patients, 16 (84.2%) are alive to date, of which 2 (10.5%) have a local recurrence. At 30 days from surgery, the main symptoms reported by EORTC Module were coughing, shortness of breath, the side effect of treatment, fear of progression, and surgery-related problems. Induction immunotherapy with or without chemotherapy can be considered for unresectable locally advanced NSCLC, and after the downstaging, the possibility of surgery could be re-evaluated in a multidisciplinary setting with high rates of R0 resection. In this selected and highly motivated group of patients, the QoL and symptoms after salvage surgeries are acceptable and even better than those reported in the literature. -PU - SPRINGER-VERLAG ITALIA SRL -PI - MILAN -PA - VIA DECEMBRIO, 28, MILAN, 20137, ITALY -SN - 2038-131X -SN - 2038-3312 -DA - 2023 DEC -PY - 2023 -VL - 75 -IS - 8 -SP - 2355 -EP - 2363 -DO - 10.1007/s13304-023-01644-y -AN - WOS:001062724700001 -C6 - SEP 2023 -AD - European Inst Oncol IRCCS, Dept Thorac Surg, IEO, Milan, Italy -AD - European Inst Oncol IRCCS, Unit Intervent Pneumol, IEO, Milan, Italy -AD - European Inst Oncol IRCCS, Dept Thorac Oncol, IEO, Milan, Italy -AD - Univ Milan, Dept Oncol & Hematooncol, Milan, Italy -AD - European Inst Oncol IRCCS, Div Thorac Surg, IEO, Via Ripamonti 435, I-20141 Milan, Italy -Y2 - 2023-11-11 -ER - - -TY - JOUR -AU - Qin, Jian -AU - Yi, Shouhui -AU - Zhou, Hanjing -AU - Zeng, Chuan -AU - Zou, Minghua -AU - Zeng, Xuan -AU - Yang, Zhenzhou -AU - Huang, Yusheng -TI - Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis -T2 - FRONTIERS IN IMMUNOLOGY -M3 - Article -AB - AimTo compare the efficacy and safety of radiotherapy in combination with immunotherapy after achieving disease control from the first-line combination therapy of platinum-based chemotherapy and immunotherapy for advanced lung squamous cell carcinoma (LUSC). MethodsThis study retrospectively evaluated the patients with advanced LUSC treated with the combination of radiotherapy with immunotherapy and chemotherapy (ICRT group, n = 52) or immunotherapy and chemotherapy (ICT group, n = 63) as the first-line treatment from April 2018 to April 2022. Using propensity score matching (PSM), 50 pairs were created, while the confounders and bias were controlled. The objective response rate (ORR), duration of overall response (DOR), progression-free survival (PFS), overall survival (OS), and adverse events were analyzed in the two groups. The PFS and OS were re-analyzed separately for patients treated with thoracic radiotherapy. ResultsAfter PSM, the median PFS (12.23 vs. 7.43 months; P <0.001) and median OS (19.7 vs. 12.9 months; P <0.001) were significantly longer in the ICRT group than those in the ICT group. Both the PFS and OS rates were also significantly higher in the ICRT group than those in the ICT group, except for the OS rates in the 6th and 12th months. The mDOR of the ICRT group patients (17.10 vs. 8.27 months; P <0.001) was significantly higher than that of the ICT group patients. The median PFS, median OS, and local control rate were significantly longer in the thoracic radiotherapy group than in the control group. Radiation pneumonia was the most common adverse effect after radiotherapy; however, no treatment-related deaths occurred. The Cox regression analysis showed that ECOG scores 0-1, presence of necrosis in the tumor, radiotherapy, and optimal efficacy better than the stable disease (SD) were independent factors, affecting the PFS, while the patients with recurrent post-operative, pre-treatment NLR, radiotherapy, and optimal efficacy better than SD were the independent factors, affecting the OS. ConclusionsThe combination of radiotherapy with systematic immunotherapy and chemotherapy for the advanced LUSC was effective with tolerable adverse effects. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1664-3224 -DA - 2023 MAY 16 -PY - 2023 -VL - 14 -C7 - 1138025 -DO - 10.3389/fimmu.2023.1138025 -AN - WOS:000996214700001 -AD - Chongqing Med Univ, Affiliated Hosp 2, Dept Oncol, Chongqing, Peoples R China -AD - Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing, Peoples R China -Y2 - 2023-06-08 -ER - - -TY - JOUR -AU - Zhu, Jianwei -AU - Li, Rui -AU - Tiselius, Eva -AU - Roudi, Raheleh -AU - Teghararian, Olivia -AU - Suo, Chen -AU - Song, Huan -TI - Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent -T2 - COCHRANE DATABASE OF SYSTEMATIC REVIEWS -M3 - Review -AB - BackgroundNon-small cell lung cancer (NSCLC) is the most common lung cancer, accounting for approximately 80% to 85% of all cases. For patients with localised NSCLC (stages I to III), it has been speculated that immunotherapy may be helpful for reducing postoperative recurrence rates, or improving the clinical outcomes of current treatment for unresectable tumours. While several new agents have now entered phase III clinical trials, we felt a systematic review was needed to address the question of the effectiveness and safety of immunotherapy in patients with stages I to III NSCLC.ObjectivesTo evaluate the effectiveness and safety of immunotherapy (excluding checkpoint inhibitors) in patients with localised NSCLC (stages I to III) who received surgery or radiotherapy with curative intent.Search methodsWe searched the following databases (from inception to 20 January 2017): CENTRAL, MEDLINE, Embase, and CINAHL, and five trial registers. We also manually checked abstracts or reports from relevant conference proceedings and the reference lists of included trials.Selection criteriaWe searched for randomised controlled trials (RCTs) in adults (>= 18 years) with histologically-confirmed early-stage (stages I to III) NSCLC after surgical resection, and those with unresectable locally advanced stage III NSCLC who had received radiotherapy with curative intent. For patients who had received primary surgical treatment, postoperative radiotherapy or chemoradiotherapy was allowed if it was used for both experimental and control groups.Data collection and analysisTwo review authors independently selected eligible trials, assessed risk of bias, and extracted data. We used survival analysis to pool time-to-event data, expressing the intervention effect as a hazard ratio (HR). We calculated risk ratios (RR) for dichotomous data, and mean differences for continuous data, with 95% confidence intervals (CI). Due to clinical heterogeneity (immunotherapeutic agents with different underlying mechanisms), we used random-effects models for our meta-analyses.Main resultsWe identified nine eligible trials that randomised 4940 participants, who had received surgical resection or curative radiotherapy, to either an immunotherapy group or a control group. Included immunological interventions were active immunotherapy (i.e. Bacillus Calmette-Guerin (BCG)), adoptive cell transfer (i.e. transfer factor (TF), tumour-infiltrating lymphocytes (TIL), dendritic cell-cytokine induced killer (DC-CIK), and antigen-specific cancer vaccines (melanoma-associated antigen 3 (MAGE-A3) and L-BLP25). Except for one small trial, which provided insufficient information for risk assessment, we assessed five studies at high risk of bias for at least one of the seven biases studied; we considered the risk of bias in the other three trials to be low. We included data from seven of the nine trials in the meta-analyses (4695 participants). We pooled data from 3693 participants from the three high quality RCTs to evaluate overall survival (OS) and progression-free survival (PFS). We found a small, but not statistically significant, improvement in OS (HR 0.94, 95% CI 0.83 to 1.06; P = 0.35), and PFS (HR 0.93, 95% CI 0.81 to 1.07; P = 0.19; high-quality evidence). The addition of immunotherapy resulted in a small, but not statistically significant, increased risk of having any adverse event (RR 1.15, 95% CI 0.97 to 1.37; P = 0.11, three trials, 3955 evaluated participants, moderate-quality evidence), or severe adverse events (RR 1.10, 95% CI 0.88 to 1.39; four trials, 4362 evaluated participants; low-quality evidence).We analysed data from six studies for one-, two-, and three-year survival rates (4265 participants), and from six studies for five-year survival rates (4234 participants). We observed no clear between-group differences (low-quality evidence for one-and two-year survival rates, and moderate-quality evidence for three-and five-year survival rate).No trial reported the overall response rates; only one trial provided health-related quality of life results.Authors' conclusionsThe current literature does not provide evidence that suggests a survival benefit from adding immunotherapy (excluding checkpoint inhibitors) to conventional curative surgery or radiotherapy, for patients with localisedNSCLC (stages I to III). The addition of vaccine-based immunotherapy might increase the risk of adverse events. Several ongoing trials with immune checkpoints inhibitors (PD-1/PD-L1) might bring new insights for role of immunotherapy for patients with stages I to III NSCLC. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1469-493X -SN - 1361-6137 -DA - 2017 -PY - 2017 -IS - 12 -C7 - CD011300 -DO - 10.1002/14651858.CD011300.pub2 -AN - WOS:000419102200014 -AD - Shandong Univ, Dept Orthopaed, Shandong Prov Hosp, Jinan, Shandong, Peoples R China -AD - Sichuan Univ, West China Hosp, Canc Ctr, Thorac Oncol, Chengdu, Sichuan, Peoples R China -AD - Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China -AD - Karolinska Inst, Stockholm, Sweden -AD - Iran Univ Med Sci, Oncopathol Res Ctr, Tehran, Iran -AD - Fudan Univ, Sch Life Sci, Collaborat Innovat Ctr Genet & Dev, Shanghai, Peoples R China -AD - Univ Iceland, Ctr Publ Hlth Sci, Fac Med, Reykjavik, Iceland -AD - Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden -Y2 - 2017-01-01 -ER - - -TY - JOUR -AU - Shen, Changxian -AU - He, Yuqi -AU - Chen, Qiang -AU - Feng, Haihua -AU - Williams, Terence M. -AU - Lu, Yuanzhi -AU - He, Zhengfu -TI - Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy -T2 - ANNALS OF TRANSLATIONAL MEDICINE -M3 - Review -AB - Objective: To summarize the roles of AKT-mTOR signaling in the regulation of the DNA damage response and PD-L1 expression in cancer cells, and propose a novel strategy of targeting AKT-mTOR signaling in combination with radioimmunotherapy in the era of cancer immunotherapyBackground: Immunotherapy has greatly improved the clinical outcomes of many cancer patients and has changed the landscape of cancer patient management. However, only a small subgroup of cancer patients (similar to 20-30%) benefit from immune checkpoint blockade-based immunotherapy. The current challenge is to find biomarkers to predict the response of patients to immunotherapy and strategies to sensitize patients to immunotherapy.Methods: Search and review the literature which were published in PUBMED from 2000-2021 with the key words mTOR, AKT, drug resistance, DNA damage response, immunotherapy, PD-L1, DNA repair, radioimmunotherapy.Conclusions: More than 50% of cancer patients receive radiotherapy during their course of treatment. Radiotherapy has been shown to reduce the growth of locally irradiated tumors as well as metastatic non irradiated tumors (abscopal effects) by affecting systemic immunity. Consistently, immunotherapy has been demonstrated to enhance radiotherapy with more than one hundred clinical trials of radiation in combination with immunotherapy (radioimmunotherapy) across cancer types. Nevertheless, current available data have shown limited efficacy of trials testing radioimmunotherapy. AKT-mTOR signaling is a major tumor growth-promoting pathway and is upregulated in most cancers. AKT-mTOR signaling is activated by growth factors as well as genotoxic stresses including radiotherapy. Importantly, recent advances have shown that AKT-mTOR is one of the main signaling pathways that regulate DNA damage repair as well as PD-L1 levels in cancers. These recent advances clearly suggest a novel cancer therapy strategy by targeting AKTmTOR signaling in combination with radioimmunotherapy. -PU - AME PUBL CO -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2305-5839 -SN - 2305-5847 -DA - 2021 OCT -PY - 2021 -VL - 9 -IS - 20 -DO - 10.21037/atm-21-4544 -AN - WOS:000710740200001 -C6 - SEP 2021 -AD - City Hope Natl Med Ctr, Beckman Res Inst, Dept Radiat Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA -AD - Monash Univ, Monash Sch Med, Clayton, Vic 3800, Australia -AD - Jinan Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Peoples R China -AD - Jinan Univ, Affiliated Hosp 1, Dept Clin Pathol, 13 Huangpu W Ave, Guangzhou 510630, Peoples R China -AD - Zhejiang Univ, Sir Run Run Shaw Hosp, Coll Med, Dept Thorac Surg, East 3 Qingchun Rd, Hangzhou 310016, Peoples R China -Y2 - 2021-09-27 -ER - - -TY - JOUR -AU - Sentana-Lledo, Daniel -AU - Viray, Hollis -AU - Piper-Vallillo, Andrew J. -AU - Widick, Page -AU - Rangachari, Deepa -AU - Wilson, Jennifer L. -AU - Gangadharan, Sidharta P. -AU - Aronovitz, Joseph A. -AU - Berman, Stuart M. -AU - VanderLaan, Paul A. -AU - Costa, Daniel B. -TI - Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer -T2 - LUNG CANCER -M3 - Article -AB - Objectives: Neoadjuvant therapy prior to surgical resection for locally advanced lung cancer has evolved to incorporate systemic cytotoxic chemotherapy +/-immunotherapy +/-radiotherapy. The role of neoadjuvant precision therapies remains understudied. Materials and Methods: We report cases with major and complete pathologic responses to off-label neoadjuvant alectinib. Results: A case with stage IIIA (cT1b cN2 cM0) EML4-ALK variant 3a/b lung adenocarcinoma received 6 weeks of alectinib followed by R0 left upper lobectomy with complete pathological response (ypT0 ypN0). Another case with stage IIIA (cT3 cN2 cM0) EML4-ALK variant 2 received 12 weeks of alectinib followed by R0 right middle lobectomy with a major pathologic response (ypT1a ypN0) but systemic recurrence 12 months post-operatively. Conclusion: Ongoing clinical trials are evaluating the role of both neoadjuvant and adjuvant ALK-directed therapy. Our cases support the completion of ongoing trials (ALINA: NCT03456076 and ALNEO: NCT05015010), and highlight the ability of second generation ALK inhibitors to induce major and complete pathologic responses in the neoadjuvant setting plus the likely role of long-term adjuvant kinase inhibitor therapy to prevent radiographic/clinical recurrence. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2022 OCT -PY - 2022 -VL - 172 -SP - 124 -EP - 126 -DO - 10.1016/j.lungcan.2022.08.014 -AN - WOS:000858535300001 -C6 - SEP 2022 -AD - Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Med Oncol, Boston, MA USA -AD - Lahey Hosp & Med Ctr, Dept Med, Div Hematol Oncol, Burlington, MA USA -AD - Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Surg, Div Thorac Surg, Boston, MA USA -AD - Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA USA -AD - Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA USA -AD - Beth Israel Deaconess Med Ctr, Div Med Oncol, 330 Brookline Ave, Boston, MA 02215 USA -Y2 - 2022-09-30 -ER - - -TY - JOUR -AU - Knapp, Brendan J. -AU - Devarakonda, Siddhartha -AU - Govindan, Ramaswamy -TI - Bone metastases in non-small cell lung cancer: a narrative review -T2 - JOURNAL OF THORACIC DISEASE -M3 - Review -AB - Background and Objective: Bone metastases are common in patients with non-small cell lung cancer (NSCLC) and remain a significant source of morbidity, mortality, and diminished quality of life, despite the considerable progress made in the overall management of patients with metastatic NSCLC over the last decade. Understanding the molecular pathogenesis of bone metastases is critical to improving survival, preserving function, and managing symptoms in this patient population. The objective of our review is to provide a comprehensive review of the pathophysiology, clinical presentation, management, and factors predicting the development and prognosis of patients with NSCLC with bone metastases. Methods: An online electronic search was performed on PubMed and Google Scholar of all English language literature using combinations of the following keywords: bone metastases, non-small cell lung cancer, pathophysiology, skeletal related events, response to therapy, predictive factors, and immunotherapy. Bibliographies of identified papers were reviewed for additional articles of interest. Observational cohort, retrospective studies, randomized controlled trials (RCTs), meta-analyses, and review articles were examined for this review. Key Content and Findings: Bone metastases in lung cancer patients remain a common occurrence, impacting morbidity, mortality, and quality of life. Patients with skeletal related events (SREs) have worse prognosis. There is data supporting use of bisphosphonates and/or denosumab, and these should be considered in all patients with bone metastases. Novel studies comparing the genomic alterations of skeletal metastases and primary tumors are needed. As therapy for patients with advanced disease evolves, more studies are needed to evaluate the interplay between immunotherapy and bone metastases, and in determining the response to treatment in bone. Conclusions: Predicting development and progression of bone metastases could allow earlier and targeted therapy in patients with bone metastases. Predicting and evaluating response to conventional chemotherapy and immune checkpoint inhibitors in NSCLC patients with bone metastases remains an unmet need and merits further study. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2022 MAY -PY - 2022 -VL - 14 -IS - 5 -SP - 1696 -EP - + -DO - 10.21037/jtd-21-1502 -AN - WOS:000785994500001 -C6 - MAR 2022 -AD - Washington Univ, Sch Med, Dept Med, Div Gen Med, St Louis, MO 63110 USA -AD - Washington Univ, Sch Med, Dept Med, Div Oncol, 660 South Euclid Ave, St Louis, MO 63110 USA -Y2 - 2022-04-29 -ER - - -TY - JOUR -AU - DENKO, NICHOLAS C.; Zihai Li; Terence Marques Williams -TI - Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism -M3 - Awarded Grant -AB - PROJECT SUMMARYMany groups are investigating why some lung cancer patients respond well to radio- and immuno-therapies andsome do not. One variable is tumor hypoxia, and many groups have shown it can significantly inhibit theeffectiveness to these therapeutic modalities. Clinical studies have identified hypoxia as an independentprognostic indicator of poor patient outcomes, but even though this connection has been known for decades, noFDA-approved intervention exists to clinically overcome hypoxia. Some investigators have tried to deliver moreoxygen to the tumor, but this approach remains constrained due to the poorly formed tumor vasculature. Wehave taken an innovative approach and asked if we can reduce demand for, rather than increase supply of,oxygen to reduce hypoxia. We have found that the FDA-approved vasorelaxant papaverine (PPV) has an off-target ability to inhibit mitochondrial complex 1, and reduce oxygen consumption rapidly, in low micromolarconcentrations in every cell line tested in vitro. We have also shown that PPV can enhance the effectiveness ofradiation and immune checkpoint blockade (ICB) in preclinical models of lung and other cancers, withoutsensitizing well-oxygenated normal tissue. Reducing hypoxia reverses immune privilege, decreases terminally-exhausted T cells, and increases progenitors that are responsive to PD-1 blockade. We have more recentlydeveloped new derivatives of PPV that have lost their vasorelaxant capability and increased their duration ofaction so that they can be improved immuno-sensitizers. We now propose to test the hypothesis that PPV caneffectively enhance the radio- and immuno-therapeutic treatment of preclinical models of lung cancer, and thatit is feasible to add PPV to standard of care therapy for advanced non-small cell lung cancer (NSCLC). We haveexamined TCGA databases and found that lung cancer driver mutations in the KEAP1/NRF2 pathway lead tohigh levels of mitochondrial gene expression that can cause elevated oxygen metabolism contributing to hypoxia.In Aim 1, we will investigate the effects of oncogenic NRF2 activation human and murine cells and model tumorsto determine the dependence of these cells on mitochondrial function, how increased oxygen metabolismcontributes to tumor hypoxia, and if therapy-refractory tumors are sensitized by PPV or its derivatives. In Aim 2,we will examine the effect of tumor hypoxia on the migration and activation of T-cells in model tumors and howthe immune infiltrate changes after reduction of hypoxia with PPV or its derivatives. Finally, in Aim 3 we willperform a phase 1 clinical trial to determine if the addition of PPV is feasible for patients receiving standard ofcare chemoradiation followed by immunotherapy for advanced NSCLC. We will look for effectiveness in changingtumor oxygenation using paired blood level oxygen determination (BOLD) MRIs, and for changes in immunepopulations of peripheral blood mononuclear cells. These studies will let us know if, and how, to use PPV or itsnovel derivatives in future clinical trials for the treatment of NSCLC. -DA - 2023 -PY - 2023 -AN - GRANTS:17758597 -G1 - 10737837; 3R01CA262388-03S1; R01CA262388 -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - DENKO, NICHOLAS C.; Zihai Li; Terence Marques Williams -TI - Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism -M3 - Awarded Grant -AB - PROJECT SUMMARYMany groups are investigating why some lung cancer patients respond well to radio- and immuno-therapies andsome do not. One variable is tumor hypoxia, and many groups have shown it can significantly inhibit theeffectiveness to these therapeutic modalities. Clinical studies have identified hypoxia as an independentprognostic indicator of poor patient outcomes, but even though this connection has been known for decades, noFDA-approved intervention exists to clinically overcome hypoxia. Some investigators have tried to deliver moreoxygen to the tumor, but this approach remains constrained due to the poorly formed tumor vasculature. Wehave taken an innovative approach and asked if we can reduce demand for, rather than increase supply of,oxygen to reduce hypoxia. We have found that the FDA-approved vasorelaxant papaverine (PPV) has an off-target ability to inhibit mitochondrial complex 1, and reduce oxygen consumption rapidly, in low micromolarconcentrations in every cell line tested in vitro. We have also shown that PPV can enhance the effectiveness ofradiation and immune checkpoint blockade (ICB) in preclinical models of lung and other cancers, withoutsensitizing well-oxygenated normal tissue. Reducing hypoxia reverses immune privilege, decreases terminally-exhausted T cells, and increases progenitors that are responsive to PD-1 blockade. We have more recentlydeveloped new derivatives of PPV that have lost their vasorelaxant capability and increased their duration ofaction so that they can be improved immuno-sensitizers. We now propose to test the hypothesis that PPV caneffectively enhance the radio- and immuno-therapeutic treatment of preclinical models of lung cancer, and thatit is feasible to add PPV to standard of care therapy for advanced non-small cell lung cancer (NSCLC). We haveexamined TCGA databases and found that lung cancer driver mutations in the KEAP1/NRF2 pathway lead tohigh levels of mitochondrial gene expression that can cause elevated oxygen metabolism contributing to hypoxia.In Aim 1, we will investigate the effects of oncogenic NRF2 activation human and murine cells and model tumorsto determine the dependence of these cells on mitochondrial function, how increased oxygen metabolismcontributes to tumor hypoxia, and if therapy-refractory tumors are sensitized by PPV or its derivatives. In Aim 2,we will examine the effect of tumor hypoxia on the migration and activation of T-cells in model tumors and howthe immune infiltrate changes after reduction of hypoxia with PPV or its derivatives. Finally, in Aim 3 we willperform a phase 1 clinical trial to determine if the addition of PPV is feasible for patients receiving standard ofcare chemoradiation followed by immunotherapy for advanced NSCLC. We will look for effectiveness in changingtumor oxygenation using paired blood level oxygen determination (BOLD) MRIs, and for changes in immunepopulations of peripheral blood mononuclear cells. These studies will let us know if, and how, to use PPV or itsnovel derivatives in future clinical trials for the treatment of NSCLC. -DA - 2023 -PY - 2023 -AN - GRANTS:17754398 -G1 - 10704677; 5R01CA262388-03; R01CA262388 -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - Lazar-Poniatowska, Malgorzata -AU - Bandura, Artur -AU - Dziadziuszko, Rafal -AU - Jassem, Jacek -TI - Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review) -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Concurrent chemoradiotherapy (CHRT) remains the therapeutic standard for locally advanced inoperable non-small-cell lung cancer (NSCLC). The median overall survival (OS) with this approach is in the range of 20?30 months, with five-year survival of approximately 30%. These outcomes have recently been further improved by supplementing CHRT with maintenance durvalumab, a monoclonal anti-PD-L1 agent. The progress in treatment outcomes of locally advanced NSCLC before the era of immunotherapy has been achieved mainly by virtue of developments in diagnostics and radiotherapy techniques. Routine implementation of endoscopic and endobronchial ultrasonography for mediastinal lymph nodes assessment, positron emission tomography/computed tomography and magnetic resonance imaging of the brain allows for more accurate staging of NSCLC and for optimizing treatment strategy. Thorough staging and respiratory motion control allows for higher conformity of radiotherapy and reduction of radiotherapy related toxicity. Dose escalation with prolonged overall treatment time does not improve treatment outcomes of CHRT. In consequence, 60 Gy in 2 Gy fractions or equivalent biological dose remains the standard dose for definitive CHRT in locally advanced NSCLC. However, owing to increased toxicity of CHRT, this option may not be applicable in a proportion of elderly or frail patients. This article summarizes recent developments in curative CHRT for inoperable stage III NSCLC, and presents perspectives for further improvements of this strategy -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2021 APR -PY - 2021 -VL - 10 -IS - 4 -SP - 2018 -EP - 2031 -DO - 10.21037/tlcr-20-704 -AN - WOS:000646137600018 -AD - Med Univ Gdansk, Dept Oncol & Radiotherapy, 17 Smoluchowskiego St, PL-80214 Gdansk, Poland -Y2 - 2021-06-01 -ER - - -TY - JOUR -AU - DORSEY, JAY FITZGERALD; KAO, GARY D (contact) -TI - Circulating Tumor Cells Analyses and Molecular Profiling for Patients Receiving Radiation Therapy -M3 - Awarded Grant -AB - Project Narrative This application proposes to study a new method of identifying and analyzing circulating tumor cells (CTCs) in patients with non-small cell lung cancer and melanoma, which is based on an approach superior to currently available CTC assays. This form of ?liquid biopsy? will allow more accurate monitoring of each patient's cancer during and following treatment with no additional discomfort or risk. The information gained from analyzing CTCs could guide the choice of treatment that is the most effective and personalized yet harbors the least side-effects for many patients in a way that has not been previously possible. -DA - 2016 -PY - 2016 -AN - GRANTS:10400673 -G1 - 1R01CA201071-01A1; 9176002; R01CA201071 -AD - UNIVERSITY OF PENNSYLVANIA -AD - UNIVERSITY OF PENNSYLVANIA -Y2 - 2023-12-14 -ER - - -TY - JOUR -Z2 - 蒋日成(综述) -Z2 - 李凯(审校) -AU - Jiang Richeng -AU - Li Kai -TI - Advances in immunotherapy for small cell lung cancer -T2 - Chinese Journal of Clinical Oncology -M3 - Review -AB - Small cell lung cancer (SCLC), which accounts for about 15% of lung cancer cases, is an aggressive disease characterized by rapid growth and early widespread metastasis. Despite sensitive to chemotherapy and radiotherapy, SCLC is vulnerable to get resistant and has high recurrence rates. Therefore, novel therapies are desperately needed to improve treatment efficacy and increase overall survival. A complex molecular biological alteration of SCLC accounts for its pathogenesis and chemo-resistance. With the understanding of SCLC biologic behavior and improvement of detection technique, immunotherapy may be a viable therapeutic approach and bring breakthrough to the treatment of patients with SCLC. In this review, we will discuss the rationale for immunotherapy and recent clinical trials of immunotherapeutic agents for SCLC. -SN - 1000-8179 -DA - 2016 -PY - 2016 -VL - 43 -IS - 24 -SP - 1106 -EP - 1111 -C7 - 1000-8179(2016)43:24<1106:XXBFAM>2.0.TX;2-V -AN - CSCD:5892120 -AD - 天津医科大学肿瘤医院肺部肿瘤内科,国家肿瘤临床医学研究中心, 天津市恶性肿瘤临床医学研究中心,天津市肺癌诊治中心, 天津市肿瘤防治重点实验室, 天津 300060, 中国 -AD - Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China -M2 - 天津医科大学肿瘤医院肺部肿瘤内科,国家肿瘤临床医学研究中心, 天津市恶性肿瘤临床医学研究中心,天津市肺癌诊治中心 -M2 - Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Tianjin Key Laboratory of Cancer Prevention and Therapy -Y2 - 2017-03-23 -ER - - -TY - JOUR -AU - Koo, Taeryool -AU - Kim, In Ah -TI - Radiotherapy and immune checkpoint blockades: a snapshot in 2016. -T2 - Radiation oncology journal -M3 - Review -M3 - Journal Article -AB - Immune checkpoint blockades including monoclonal antibodies (mAbs) of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) have been emerged as a promising anticancer therapy. Several immune checkpoint blockades have been approved by US Food and Drug Administration (FDA), and have shown notable success in clinical trials for patients with advanced melanoma and non-small cell lung cancer. Radiotherapy is a promising combination partner of immune checkpoint blockades due to its potent pro-immune effect. This review will cover the current issue and the future perspectives for combined with radiotherapy and immune checkpoint blockades based upon the available preclinical and clinical data. -SN - 2234-1900 -DA - 2016 Dec (Epub 2016 Dec 28) -PY - 2016 -VL - 34 -IS - 4 -SP - 250 -EP - 259 -DO - 10.3857/roj.2016.02033 -AN - MEDLINE:28030901 -AD - Department of Radiation Oncology, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea. -AD - Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea. -Y2 - 2017-03-02 -ER - - -TY - CPAPER -AU - Alexander, A -AU - Obodnikov, MD -A1 - EDITRICE COMPOSITORI -TI - Endobronchial chemo-immunotherapy (ECIT): A new and effective method in treatment of advanced stage III non-resectable lung cancer -T2 - 2ND INTERNATIONAL CONGRESS OF THORAX SURGERY -M3 - Proceedings Paper -CP - 2nd International Congress of Thorax Surgery -CL - BOLOGNA, ITALY -AB - To evaluate the role of endobronchial chemo - immunotherapy (ECIT) we studied 68 patients with Stage III non - resectable lung cancer (LC) from February 1990 to March 1997: 13 patients had Stage IIIA, 55 patients - Stage IIIB, 27 patients - small - cell lung cancer (SCLC) and 41 patient - non - small cell lung cancer (NSCLC). All the patients were broken into two chemoradiotherapy (CRT) treatment arms: the control group - combination cisplatin - based chemotherapy (cyclophosphamide + vincristinum + doxonrbicin + methotrexatum + cisplatin) given together with sequential or concurrent radiation therapy (RT), and the study group - the same CRT regimen plus endobronchial administration of chemotherapeutic agents via a microtracheostomy catheter. A split - course of RT was delivered as a conventional daily fractionation schedule with 2Gy/fraction 5 times/week/30Gy repeated with a 4-week interruption up to a total dose of 60Gy. Objective partial tumor regression after 2 courses of CT and 60 Gy RT was noted in: NSCLC - in 13 (48%) of 27 patients in study group and in 4 (29%) of 14 patient in control group; SCLC - in 12 (80%) of 15 patients in study group and in 7 (58%) of 12 patients in control g-roup: one complete response was observed in each group (7% and 8%, respectively). A median survival in patients with NSCLC was 20,9 month in study group vs 12,3 month in control group, and 14,4 month in study group vs 8,7 month in control group in SCLC. Thus the adjunction of ECIT to CRT in patients with non - resectable Stage IIIA lung cancer contributes towards objective tumor regression and increases a median survival time. -PU - EDITRICE COMPOSITORI -PI - BOLOGNA -PA - VIA STALINGRADO 97/2, 40128 BOLOGNA, ITALY -SN - 88-7794-149-9 -DA - 1998 -PY - 1998 -SP - 259 -EP - 263 -AN - WOS:000075684100068 -AD - Kiev Med Acad Postgrad Educ, Dept Pulmonol, Kiev, Ukraine -Y2 - 1998-01-01 -ER - - -TY - JOUR -AU - DORSEY, JAY FITZGERALD; KAO, GARY D (contact) -TI - Circulating Tumor Cells Analyses and Molecular Profiling for Patients Receiving Radiation Therapy -M3 - Awarded Grant -AB - Project Narrative This application proposes to study a new method of identifying and analyzing circulating tumor cells (CTCs) in patients with non-small cell lung cancer and melanoma, which is based on an approach superior to currently available CTC assays. This form of ?liquid biopsy? will allow more accurate monitoring of each patient's cancer during and following treatment with no additional discomfort or risk. The information gained from analyzing CTCs could guide the choice of treatment that is the most effective and personalized yet harbors the least side-effects for many patients in a way that has not been previously possible. -DA - 2017 -PY - 2017 -AN - GRANTS:10877916 -G1 - 5R01CA201071-02; 9304112; R01CA201071 -AD - UNIVERSITY OF PENNSYLVANIA -AD - UNIVERSITY OF PENNSYLVANIA -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - HEYMACH, JOHN V. -TI - 10 Lung Cancer -M3 - Awarded Grant -AB - PROJECT SUMMARY/ABSTRACTThe Lung Cancer Program (LCP) includes 70 members (34 primary, 35 associate, 1 adjunct) from 19departments. The program is led by Dr. John Heymach, an expert in biomarker-driven clinical trials andtherapeutic targeting who oversees the program; Dr. Jack Roth, a surgeon-scientist and co-PI of the Universityof Texas Lung SPORE; and Dr. Lauren Byers, who leads the program's clinical research efforts and mentoringof trainees, fellows, and junior faculty. The major scientific goal of the LCP is to develop more effective andpersonalized approaches for the treatment of lung cancer. To achieve this goal, the program has 3 specific aimsthat focus on 3 themes: 1) lung cancer signaling and therapeutic targets; 2) targeting the immune system andmicroenvironment; and 3) the multimodal treatment of localized and advanced lung cancer. The annual directpeer-reviewed funding totals $5.7M, including an NCI Lung Cancer SPORE, a Stand Up 2 Cancer Dream TeamAward, and 3 CPRIT Multi-Investigator Research Awards. Of the total funding, $3.4M (60%) is from NCI grants.Since the last competitive renewal, total annual peer-reviewed direct-cost funding has increased by 93%. Sincethe last submission, the program has published 999 papers: 550 (55%) intra-programmatic collaborations, 355(36%) inter-programmatic collaborations, and 607 (61%) external collaborations. Forty-four percent of thepublications appeared in journals with an IF >5, and 15% appeared in journals with an IF >10, including Science,N Engl J Med, Proc Natl Acad Sci USA, Cancer Discov, and Lancet Oncol. During the last grant period, programmembers had leadership roles in standard-of-care–changing studies, including the AURA3 study (establishingosimertinib for EGFR T790M–mutant NSCLC) and a study demonstrating the benefit of local consolidativetherapy for patients with oligometastatic NSCLC. Our previous findings identifying novel targets in small cell lungcancer (SCLC) have been validated in subsequent clinical studies. Members also identified 3 subsets of KRAS-mutant NSCLC based on co-occurring genomic alterations that exhibit distinct biology, patterns of immune-system engagement, and therapeutic vulnerabilities. Finally, they identified a role for epithelial-to-mesenchymaltransition in regulating tumor immunosuppression via an miR200/ZEB1/PD-L1 axis, playing a central role inpromoting NSCLC metastasis. In upcoming years, members will build on these findings to identify newapproaches to target subsets of lung cancer, with a focus on SCLC and KRAS-mutant NSCLC; investigatestrategies for enhancing antitumor immunity and mechanisms of immunotherapy resistance; and developmultidisciplinary paradigms integrating immunotherapy and targeted agents as an approach to improve thesurvival of lung cancer patients. -DA - 2020 -PY - 2020 -AN - GRANTS:15552046 -G1 - 5726; 5P30CA016672-44; 9997826; P30CA016672 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - DORSEY, JAY FITZGERALD; KAO, GARY D (contact) -TI - Circulating Tumor Cells Analyses and Molecular Profiling for Patients Receiving Radiation Therapy -M3 - Awarded Grant -AB - Project Narrative This application proposes to study a new method of identifying and analyzing circulating tumor cells (CTCs) in patients with non-small cell lung cancer and melanoma, which is based on an approach superior to currently available CTC assays. This form of ?liquid biopsy? will allow more accurate monitoring of each patient's cancer during and following treatment with no additional discomfort or risk. The information gained from analyzing CTCs could guide the choice of treatment that is the most effective and personalized yet harbors the least side-effects for many patients in a way that has not been previously possible. -DA - 2018 -PY - 2018 -AN - GRANTS:10993372 -G1 - 5R01CA201071-03; 9533494; R01CA201071 -AD - UNIVERSITY OF PENNSYLVANIA -AD - UNIVERSITY OF PENNSYLVANIA -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Sunil Krishnan; LIN, STEVEN HSESHENG -TI - Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches -M3 - Awarded Grant -AB - A major barrier to improving cure rates in locally advanced cancers is our inability to make progress beyond whatchemoradiation (CRT) can currently deliver. Combination strategies using molecular targeted therapies with CRThold promise for improving outcomes further. While many drugs could enhance the effects of radiation alone, wehave discovered that the effects are quite unpredictable when drugs are combined with chemotherapy andradiotherapy. The successful translation of adding molecular targeted agents to CRT would require anunderstanding of the molecular pathways that enable the cancer cell to survive under conditions of CRT.Inhibiting these pathways with molecular targeted drugs will be synergistic with CRT in the cancer-specificcontext. Using a set of molecular targeted drugs from the CTEP portfolio as an initial starting point, we willinvestigate two hard-to-treat cancer types treated with CRT, non-small cell lung cancer (NSCLC) and pancreaticductal adenocarcinoma (PDAC). We will identify drugs that could synergize with radiation and CRT using a highthroughput clonogenic survival screen that we have developed on validated cancer lines and then test the mostclinically promising combinations of agents to multiple cell lines with varying genetic backgrounds, first in vitroand then further validated using 2 in vivo models: a panel of patient-derived xenografts (PDXs) and orthotopictumor models using syngeneic tumors, all done in combination with clinically-relevant chemotherapies. Thepharmacokinetic and pharmacodynamic properties of these drugs with chemotherapy in animals and tumors willbe assessed in order to determine the optimal sequencing approach with conventionally fractionatedradiotherapy. Since we have discovered that chemotherapy significantly alters the response of cancer cells toradiation and targeted drugs, we will also evaluate the molecular mechanisms that explain the response to CRT,and identify potential factors that may influence this response using 4 major approaches. In the first more classicapproach, we will assess DNA damage repair pathways and reactive oxygen species generation when targetedagents are combined with radiation or CRT. Second, we will use reverse phase protein arrays (RPPA) to assessthe functional proteome to determine pathways that may be altered with molecular targeted drugs in the settingof RT or CRT. In the third approach, we will use Stable Isotope Labeling with Amino Acids (SILAC) to assessglobal proteomic and phosphoproteomic changes that occur with radiation and CRT treatment, and how thesepathways could be altered with specific molecular targeted therapies. Lastly, we will use Imaging MassSpectrometry to analyze drug distribution within the various tumor models and assess how thepharmacodynamic heterogeneity impacts CRT responsiveness. Our proposal will not only identify the mostpromising drugs that could best be combined with CRT in NSCLC and PDAC, but we will have identifiedmolecular and tumor factors that confer drug resistance which will enable future development of novel targetedstrategies to enhance CRT or appropriately select patient for personalized therapy. Our approach will generatethe high quality preclinical data and novel insights to fulfill the overall FOA objective, which is “to accelerate thepace at which combined modality treatments with greater efficacy are identified and incorporated into standardpractices for treatments”. -DA - 2021 -PY - 2021 -AN - GRANTS:17403863 -G1 - 10223893; 5U01CA216468-05; U01CA216468 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - Venur, Vyshak A. -AU - Ahluwalia, Manmeet S. -TI - Novel therapeutic agents in the management of brain metastases -T2 - CURRENT OPINION IN ONCOLOGY -M3 - Review -AB - Purpose of reviewThis review aims to highlight the novel therapeutic agents in the management of brain metastases which are in various stages of clinical development. We review the results from recent clinical trials, publications and presentations at recent national and international conferences.Recent findingsSeveral new systemic treatment options for brain metastases are in early or advanced clinical trials. These drugs have good intracranial and extracranial activities. As lung cancer, breast cancer, and melanoma are the three most common causes of brain metastases, most agents in clinical development are focused on these tumor types. Several of these therapies are small molecule tyrosine kinase inhibitors or monoclonal antibodies against the tyrosine kinase receptors. Another exciting development in brain metastases management is the use of immunotherapy agents. The anti-CTLA-4 and\or anti-PD-1 antibodies have shown promising intracranial activity in melanoma and nonsmall cell lung cancer patients with brain metastases.SummaryContemporary clinical trials have shown encouraging intracranial activity of newer tyrosine kinase inhibitors, monoclonal antibodies against tyrosine kinase receptors and immunotherapy agents in select group of patients with brain metastases. Further studies are needed to develop therapeutic strategies, in order to improve survival in patients with brain metastases. -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 1040-8746 -SN - 1531-703X -DA - 2017 SEP -PY - 2017 -VL - 29 -IS - 5 -SP - 395 -EP - 399 -DO - 10.1097/CCO.0000000000000393 -AN - WOS:000407838800012 -AD - Univ Iowa Hosp & Clin, Div Hematol & Oncol, Dept Internal Med, Iowa City, IA USA -AD - Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA -AD - Cleveland Clin, Burkhardt Brain Tumor & Neurooncol Ctr, Cleveland, OH 44195 USA -Y2 - 2017-08-30 -ER - - -TY - JOUR -AU - Lim, Jeong Uk -AU - Lee, Eunyoung -AU - Lee, Sang-Yun -AU - Cho, Hyeong Jun -AU - Ahn, Dong Hyuck -AU - Hwang, Yongki -AU - Choi, Joon Young -AU - Yeo, Chang Dong -AU - Park, Chan Kwon -AU - Kim, Seung Joon -TI - Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Background and Objective: Immune checkpoint inhibitors (ICI) were a major clinical advancement that provided an opportunity to improve the prognosis of patients with non-small cell lung cancer (NSCLC). However, PD-L1 expression does not sufficiently predict ICI efficacy in NSCLC patients. In recent studies, the tumor immune microenvironment (TIME) was shown to have a central role in lung cancer progression and to affect clinical outcome of patients diagnosed with lung cancer. As development of new therapeutic targets to overcome ICI resistance is a priority, understanding the TIME is important. Recently, a series of studies was conducted to target each component of TIME to improve efficacy of cancer treatment. In this review, important features related to TIME, its heterogeneity and current trends in treatment targeting the component of TIME are discussed. Methods: PubMed and PMC were searched from January 1st, 2012 to August 16th, 2022 using the following key words: "NSCLC", "Tumor microenvironment", "Immune", "Metastasis" and "Heterogeneity" Key Content and Findings: Heterogeneity in the TIME can be either spatial or temporal. Subsequent to heterogeneous changes in the TIME, treatment of lung cancer can be more challenging because drug resistance is more likely to occur. In terms of the TIME, the main concept for increasing the chance of successful NSCLC treatment is to activate immune responses against tumor cells and inhibit immunosuppressive activities. In addition, relevant research is focused on normalizing an otherwise aberrant TIME in NSCLC patients. Potential therapeutic targets include immune cells, cytokine interactions, and non-immune cells such as fibroblasts or vessels. Conclusions: In management of lung cancer, understanding TIME and its heterogeneity is significant to treatment outcomes. Ongoing trials including various treatment modalities such as radiotherapy, cytotoxic chemotherapy, and anti-angiogenic treatment and regimens inhibiting other immunoinhibitory molecules are promising. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2023 APR -PY - 2023 -VL - 12 -IS - 4 -SP - 857 -EP - 876 -DO - 10.21037/tlcr-22-633 -AN - WOS:000954815600001 -C6 - MAR 2023 -AD - Catholic Univ Korea, Yeouido St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm Allergy & Crit Care Med, Seoul, South Korea -AD - Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm, Seoul, South Korea -AD - Catholic Univ Korea, Postech Catholic Biomed Engn Inst, Coll Med, Songeui Multiplex Hall, Seoul, South Korea -AD - Gachon Univ, Dept Biomed Engn, Seongnam, South Korea -AD - Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm & Crit Care Med, Seoul, South Korea -AD - Catholic Univ Korea, Eunpyeong St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm Crit Care & Sleep Med, Seoul, South Korea -AD - Catholic Univ Korea, Eunpyeong St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm Crit Care & Sleep Med, 1021 Tongil Ro, Seoul 03312, South Korea -Y2 - 2023-04-07 -ER - - -TY - JOUR -AU - Pluzanski, Adam -AU - Piorek, Aleksandra -TI - Advancements in non-small cell lung cancer treatment: from early to advanced stages -T2 - ONCOLOGY IN CLINICAL PRACTICE -M3 - Review -M3 - Early Access -AB - Over the past years, tremendous progress has been made in the treatment available for non-small cell lung cancer patients (NSCLC), both in the early and advanced stages of the disease. In early-stage NSCLC, perioperative immunotherapy is emerging as a promising approach. Several studies in preoperative chemoimmunotherapy showed a significant increase in the rate of complete pathologic response and prolonged event-free survival in resectable NSCLC patients. Similarly, atezolizumab and osimertinib are the standard of care in some patients after complete resection in EGFR-mutated or programmed cell death ligand 1 (PD-L1) high-expressing tumors. In locally advanced disease, durvalumab consolidation therapy following chemoradiotherapy improved progression-free survival (PFS) and overall survival (OS) in unresectable NSCLC while other immunotherapies in combination with chemotherapy showed promising results. In advanced NSCLC, novel immunotherapies or immunoconjugates such as trastuzumab deruxtecan are also demonstrating efficacy. Furthermore, molecularly targeted therapy targeting KRAS, , EGFR, , and other genetic aberrations, guided by next-generation sequencing, offers new treatment options. However, challenges remain, including patient selection, sequencing, and reimbursement. This article reviews the latest treatments for patients with NSCLC in the early and advanced stages of the disease. -PU - VIA MEDICA -PI - GDANSK -PA - UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND -SN - 2450-1654 -SN - 2450-6478 -DA - 2024 JUN 24 -PY - 2024 -DO - 10.5603/ocp.100477 -AN - WOS:001268759600001 -C6 - JUN 2024 -AD - Maria Sklodowska Curie Natl Res Inst Oncol, Lung Canc & Chest Tumors Dept, Ul Roentgena 5, PL-02781 Warsaw, Poland -M2 - Maria Sklodowska Curie Natl Res Inst Oncol -Y2 - 2024-07-22 -ER - - -TY - JOUR -AU - HEYMACH, JOHN V. -TI - 10 Lung Cancer -M3 - Awarded Grant -AB - PROJECT SUMMARY/ABSTRACTThe Lung Cancer Program (LCP) includes 70 members (34 primary, 35 associate, 1 adjunct) from 19departments. The program is led by Dr. John Heymach, an expert in biomarker-driven clinical trials andtherapeutic targeting who oversees the program; Dr. Jack Roth, a surgeon-scientist and co-PI of the Universityof Texas Lung SPORE; and Dr. Lauren Byers, who leads the program's clinical research efforts and mentoringof trainees, fellows, and junior faculty. The major scientific goal of the LCP is to develop more effective andpersonalized approaches for the treatment of lung cancer. To achieve this goal, the program has 3 specific aimsthat focus on 3 themes: 1) lung cancer signaling and therapeutic targets; 2) targeting the immune system andmicroenvironment; and 3) the multimodal treatment of localized and advanced lung cancer. The annual directpeer-reviewed funding totals $5.7M, including an NCI Lung Cancer SPORE, a Stand Up 2 Cancer Dream TeamAward, and 3 CPRIT Multi-Investigator Research Awards. Of the total funding, $3.4M (60%) is from NCI grants.Since the last competitive renewal, total annual peer-reviewed direct-cost funding has increased by 93%. Sincethe last submission, the program has published 999 papers: 550 (55%) intra-programmatic collaborations, 355(36%) inter-programmatic collaborations, and 607 (61%) external collaborations. Forty-four percent of thepublications appeared in journals with an IF >5, and 15% appeared in journals with an IF >10, including Science,N Engl J Med, Proc Natl Acad Sci USA, Cancer Discov, and Lancet Oncol. During the last grant period, programmembers had leadership roles in standard-of-care–changing studies, including the AURA3 study (establishingosimertinib for EGFR T790M–mutant NSCLC) and a study demonstrating the benefit of local consolidativetherapy for patients with oligometastatic NSCLC. Our previous findings identifying novel targets in small cell lungcancer (SCLC) have been validated in subsequent clinical studies. Members also identified 3 subsets of KRAS-mutant NSCLC based on co-occurring genomic alterations that exhibit distinct biology, patterns of immune-system engagement, and therapeutic vulnerabilities. Finally, they identified a role for epithelial-to-mesenchymaltransition in regulating tumor immunosuppression via an miR200/ZEB1/PD-L1 axis, playing a central role inpromoting NSCLC metastasis. In upcoming years, members will build on these findings to identify newapproaches to target subsets of lung cancer, with a focus on SCLC and KRAS-mutant NSCLC; investigatestrategies for enhancing antitumor immunity and mechanisms of immunotherapy resistance; and developmultidisciplinary paradigms integrating immunotherapy and targeted agents as an approach to improve thesurvival of lung cancer patients. -DA - 2019 -PY - 2019 -AN - GRANTS:14963060 -G1 - 2P30CA016672-43; 9794679; P30CA016672 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Jazieh, Khalid -AU - Khorrami, Mohammadhadi -AU - Saad, Anas -AU - Gad, Mohamed -AU - Gupta, Amit -AU - Patil, Pradnya -AU - Viswanathan, Vidya Sankar -AU - Rajiah, Prabhakar -AU - Nock, Charles J. -AU - Gilkey, Michael -AU - Fu, Pingfu -AU - Pennell, Nathan A. -AU - Madabhushi, Anant -TI - Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab -T2 - JOURNAL FOR IMMUNOTHERAPY OF CANCER -M3 - Article -AB - Background The landmark study of durvalumab as consolidation therapy in NSCLC patients (PACIFIC trial) demonstrated significantly longer progression-free survival (PFS) in patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) treated with durvalumab (immunotherapy, IO) therapy after chemoradiotherapy (CRT). In clinical practice in the USA, durvalumab continues to be used in patients across all levels of programmed cell death ligand-1 (PD-L1) expression. While immune therapies have shown promise in several cancers, some patients either do not respond to the therapy or have cancer recurrence after an initial response. It is not clear so far who will benefit of this therapy or what the mechanisms behind treatment failure are. Methods A total of 133 patients with unresectable stage III NSCLC who underwent durvalumab after CRT or CRT alone were included. Patients treated with durvalumab IO after CRT were randomly split into training (D1=59) and test (D2=59) sets and the remaining 15 patients treated with CRT alone were grouped in D3. Radiomic textural patterns from within and around the target nodules were extracted. A radiomic risk score (RRS) was built and was used to predict PFS and overall survival (OS). Patients were divided into high-risk and low-risk groups based on median RRS. Results RRS was found to be significantly associated with PFS in D1 (HR=2.67, 95% CI 1.85 to 4.13, p<0.05, C-index=0.78) and D2 (HR=2.56, 95% CI 1.63 to 4, p<0.05, C-index=0.73). Similarly, RRS was associated with OS in D1 (HR=1.89, 95% CI 1.3 to 2.75, p<0.05, C-index=0.67) and D2 (HR=2.14, 95% CI 1.28 to 3.6, p<0.05, C-index=0.69), respectively. RRS was found to be significantly associated with PFS in high PD-L1 (HR=3.01, 95% CI 1.41 to 6.45, p=0.0044) and low PD-L1 (HR=2.74, 95% CI 1.8 to 4.14, p=1.77e-06) groups. Moreover, RRS was not significantly associated with OS in the high PD-L1 group (HR=2.08, 95% CI 0.98 to 4.4, p=0.054) but was significantly associated with OS in the low PD-L1 group (HR=1.61, 95% CI 1.14 to 2.28, p=0.0062). In addition, RRS was significantly associated with PFS (HR=2.77, 95% CI 1.17 to 6.52, p=0.019, C-index=0.77) and OS (HR=2.62, 95% CI 1.25 to 5.51, p=0.01, C-index=0.77) in D3, respectively. Conclusions Tumor radiomics of pretreatment CT images from patients with stage III unresectable NSCLC were prognostic of PFS and OS to CRT followed by durvalumab IO and CRT alone. -PU - BMJ PUBLISHING GROUP -PI - LONDON -PA - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND -SN - 2051-1426 -DA - 2022 MAR -PY - 2022 -VL - 10 -IS - 3 -C7 - e003778 -DO - 10.1136/jitc-2021-003778 -AN - WOS:000766740800005 -AD - Cleveland Clin, Dept Internal Med, Cleveland, OH 44106 USA -AD - Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA -AD - Cleveland Clin, Heart & Vasc Inst, Cleveland, OH 44106 USA -AD - Univ Hosp Cleveland Med Ctr, Dept Radiol, Cleveland, OH USA -AD - Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA -AD - Mayo Clin, Dept Radiol, Rochester, MN USA -AD - Louis Stokes Cleveland VA Med Ctr Mental Hlth Ser, Cleveland, OH 44106 USA -AD - Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA -Y2 - 2022-03-22 -ER - - -TY - JOUR -AU - HEYMACH, JOHN V. -TI - 10 Lung Cancer -M3 - Awarded Grant -AB - PROJECT SUMMARY/ABSTRACTThe Lung Cancer Program (LCP) includes 70 members (34 primary, 35 associate, 1 adjunct) from 19departments. The program is led by Dr. John Heymach, an expert in biomarker-driven clinical trials andtherapeutic targeting who oversees the program; Dr. Jack Roth, a surgeon-scientist and co-PI of the Universityof Texas Lung SPORE; and Dr. Lauren Byers, who leads the program's clinical research efforts and mentoringof trainees, fellows, and junior faculty. The major scientific goal of the LCP is to develop more effective andpersonalized approaches for the treatment of lung cancer. To achieve this goal, the program has 3 specific aimsthat focus on 3 themes: 1) lung cancer signaling and therapeutic targets; 2) targeting the immune system andmicroenvironment; and 3) the multimodal treatment of localized and advanced lung cancer. The annual directpeer-reviewed funding totals $5.7M, including an NCI Lung Cancer SPORE, a Stand Up 2 Cancer Dream TeamAward, and 3 CPRIT Multi-Investigator Research Awards. Of the total funding, $3.4M (60%) is from NCI grants.Since the last competitive renewal, total annual peer-reviewed direct-cost funding has increased by 93%. Sincethe last submission, the program has published 999 papers: 550 (55%) intra-programmatic collaborations, 355(36%) inter-programmatic collaborations, and 607 (61%) external collaborations. Forty-four percent of thepublications appeared in journals with an IF >5, and 15% appeared in journals with an IF >10, including Science,N Engl J Med, Proc Natl Acad Sci USA, Cancer Discov, and Lancet Oncol. During the last grant period, programmembers had leadership roles in standard-of-care–changing studies, including the AURA3 study (establishingosimertinib for EGFR T790M–mutant NSCLC) and a study demonstrating the benefit of local consolidativetherapy for patients with oligometastatic NSCLC. Our previous findings identifying novel targets in small cell lungcancer (SCLC) have been validated in subsequent clinical studies. Members also identified 3 subsets of KRAS-mutant NSCLC based on co-occurring genomic alterations that exhibit distinct biology, patterns of immune-system engagement, and therapeutic vulnerabilities. Finally, they identified a role for epithelial-to-mesenchymaltransition in regulating tumor immunosuppression via an miR200/ZEB1/PD-L1 axis, playing a central role inpromoting NSCLC metastasis. In upcoming years, members will build on these findings to identify newapproaches to target subsets of lung cancer, with a focus on SCLC and KRAS-mutant NSCLC; investigatestrategies for enhancing antitumor immunity and mechanisms of immunotherapy resistance; and developmultidisciplinary paradigms integrating immunotherapy and targeted agents as an approach to improve thesurvival of lung cancer patients. -DA - 2019 -PY - 2019 -AN - GRANTS:15015125 -G1 - 3P30CA016672-43S1; 9997878; P30CA016672 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Ortega-Franco, Ana -AU - Calvo, Virginia -AU - Franco, Fabio -AU - Provencio, Mariano -AU - Califano, Raffaele -TI - Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Prognosis of early stage non-small cell lung cancer (eNSCLC) is poor even when treated radically with surgery and (neo)adjuvant chemotherapy (Cht). The discovery of tyrosine kinase inhibitors (TKIs) for oncogene addicted NSCLC and immune checkpoint inhibitors (ICIs) have revolutionised the therapeutic paradigm and improved survival of advanced NSCLC. The unprecedented impact of these drugs has shifted the focus of investigation to early stage disease aiming at improving cure. In this context, several single arm phase II studies evaluating neoadjuvant ICI alone or in combination with platinum-based Cht have shown encouraging rates of pathological response which have spurred several ongoing randomized trials with (neo)adjuvant ICI. More recently, ADAURA study evaluating adjuvant osimertinib demonstrated a profound reduction of the risk of recurrence in patients with stage I (>4 cm)-IIIA eNSCLC harbouring EGFR sensitizing mutations. ICIs and TKIs represent a true revolution in the treatment of eNSCLC call to challenge the current standard of care. However, questions regarding drug resistance, recurrence patterns, biomarker identification, optimal treatment duration and sequencing need be answered to effectively integrate new drugs in the rapidly evolving therapeutic landscape of NSCLC. In this review we critically review new developments and future perspectives of TKIs and ICI as (neo)adjuvant strategies for eNSCLC. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2020 DEC -PY - 2020 -VL - 9 -IS - 6 -SP - 2656 -EP - 2673 -DO - 10.21037/tlcr-20-546 -AN - WOS:000606333500003 -AD - Christie NHS Fdn Trust, Dept Med Oncol, 550 Wilmslow Rd, Manchester M20 4BX, Lancs, England -AD - Hosp Univ Puerta de Hierro, Dept Med Oncol, Madrid, Spain -AD - Manchester Univ NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England -AD - Univ Manchester, Div Canc Sci, Manchester, Lancs, England -M2 - Manchester Univ NHS Fdn Trust -Y2 - 2021-02-09 -ER - - -TY - JOUR -AU - Andraos, T. Y. -AU - Halmos, B. -AU - Cheng, H. -AU - Huntzinger, C. -AU - Shirvani, S. -AU - Ohri, N. -TI - Does Disease Burden on PET Predict Outcomes for Advanced NSCLC Patients Treated With First-Line Immunotherapy? -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 2883 -SP - E428 -EP - E428 -AN - WOS:000715803800879 -AD - Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10467 USA -AD - Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA -AD - Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA -AD - RefleXion Med Inc, Hayward, CA USA -M2 - RefleXion Med Inc -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Qin, Wenru -AU - Yang, Linlin -AU - Fan, Bingjie -AU - Zou, Bing -AU - Duan, Yanan -AU - Li, Butuo -AU - Wang, Linlin -TI - Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer -T2 - FRONTIERS IN IMMUNOLOGY -M3 - Article -AB - IntroductionRecent developments in immune checkpoint inhibitors (ICIs) have improved the treatment outcomes of esophageal cancer (EC); however, it may initiate immune-related adverse events (irAEs) in some patients. The ICIs' therapeutic efficacy is associated with irAEs in patients with non-small cell lung cancer or renal cell carcinoma, although this association is unknown in EC. The purpose of this study was to explore the association between irAEs and the efficacy of programmed death 1 (PD-1) inhibitors in EC patients. Patients and methodsThis study included patients with advanced EC treated with PD-1 inhibitors. The patients were divided into two groups according to the occurrence of irAEs. Afterward, the efficacy was compared between the irAE-negative and irAE-positive groups, and we analyzed the predictive factors of irAEs and survival. ResultsOverall, 295 patients were included in this study. Baseline characteristics were balanced in the irAE-negative and irAE-positive groups. In total, 143 (48.47%) patients experienced irAEs. The most frequent irAEs were anemia (49, 16.61%), hyperthyroidism (45, 15.25%), and pneumonitis (44, 14.92%). In total, 33 (11.19%) patients had grade >= 3 irAEs and pneumonitis have 15 (5.08%). No grade 5 adverse events were observed. A total of 52 (17.63%) and 91 (30.85%) patients had single and multiple irAEs, respectively. Compared with patients without irAEs, those with irAEs had significantly higher objective response rate (ORR) (37.76% vs. 25.00%, p = 0.018) and disease control rate (DCR) (92.31% vs. 83.55%, p = 0.022). Univariate Cox analyses indicated the significant association between irAEs and improved median progression-free survival (PFS) (10.27 vs. 6.2 months, p < 0.001) and overall survival (OS) (15.4 vs. 9.2 months, p < 0.001). In multivariate analyses, irAEs were independently associated with longer PFS (p = 0.011) and OS (p = 0.002). Moreover, multivariate analysis revealed that cycles > 8, radiation, as well as antiangiogenic therapy were strongly associated with irAEs development (p < 0.001, p = 0.002, and p = 0.025, respectively). ConclusionIn advanced EC, patients with irAEs showed markedly better efficacy in ORR, DCR, PFS, and OS compared with patients without irAEs. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 1664-3224 -DA - 2022 SEP 28 -PY - 2022 -VL - 13 -C7 - 931429 -DO - 10.3389/fimmu.2022.931429 -AN - WOS:000868507100001 -AD - Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncology, Jinan, Peoples R China -AD - Shandong First Med Univ, Dept Oncol, Jinan, Peoples R China -Y2 - 2022-10-22 -ER - - -TY - JOUR -AU - Sun, Chao -AU - Wang, Xu -AU - Xu, Yinghui -AU - Shao, Guoguang -AU - Chen, Xi -AU - Liu, Yunpeng -AU - Zhang, Peng -AU - Lin, Xingyu -AU - Ma, Xiaobo -AU - Qiu, Shi -AU - He, Hua -AU - Yang, Zhiguang -AU - Ma, Kewei -TI - Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial -T2 - ECLINICALMEDICINE -M3 - Article -AB - Background Some locally advanced (IIIA/IIIB) non -small cell lung cancers (NSCLCs) might have surgical options available. However, information regarding the effectiveness of neoadjuvant immunotherapy for potentially resectable IIIA/IIIB NSCLC is limited. The intent of this investigation was to offer a more favourable alternative to the standard approach of chemoradiotherapy (concurrent or sequential chemoradiotherapy) followed by immunotherapy for potentially resectable stage III NSCLC. Methods This prospective, single -arm, phase 2 clinical trial (NCT04326153) enrolled treatment -naive patients with 'potentially resectable' IIIA/IIIB NSCLC who were deemed unsuitable for complete (R0) resection upon initial diagnosis. The study period was between March 20, 2020, and August 20, 2021. Patients underwent neoadjuvant chemoimmunotherapy (sintilimab combined with nab-paclitaxel and carboplatin) for two to three cycles prior to surgical resection of the lung carcinoma and systematic nodal dissection within 30-45 days. The primary endpoint was the 2 -year disease -free survival (DFS) rate, with secondary endpoints encompassing major pathological response (MPR) rate, pathological complete response (pCR) rate, overall survival, objective response rate (ORR), downstaging rate, and adverse events (AEs). Tumour immune cell infiltrates, identified via immunohistochemistry, were assessed as biomarkers at baseline and after surgery. Findings Among 30 patients who received neoadjuvant chemoimmunotherapy, 20 underwent complete resection. The disease control rate was 96.7% (95% CI: 90.3%-99.99%), with an ORR of 55% (95% CI: 37.2%-72.8%) and a downstaging rate of 80% (95% CI: 65.7%-94.3%). In the subgroup of 20 patients who underwent surgery, the MPR rate was 65% (95% CI: 43.3%-82.9%), and the pCR rate was 40% (95% CI: 21.2%-46.3%). The 2 -year DFS rate in the surgical group was 75% (95% CI 56%-94%). Notably, the MPR group demonstrated significantly prolonged DFS compared with the non-MPR group (p = 0.00024). A significant increase in pretreatment CD8 expression correlated with improved DFS (p = 0.00019). Three patients (10%) experienced grade 3 or higher immune -related AEs-one case of grade 3 elevated myocardial enzymes, one case of grade 3 interstitial pneumonia, and one case of grade 5 bronchopleural fistula. Interpretation Neoadjuvant immunotherapy markedly enhanced the rate of pathological response and 2 -year DFS in patients with potentially resectable IIIA/IIIB NSCLC. Overexpression of CD8 before treatment (H score >= 3) may serve as a potential predictive biomarker for DFS. Consequently, the treatment landscape for potentially resectable IIIA/ IIIB NSCLC could undergo changes. Funding This study did not receive any financial support. Copyright (c) 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 2589-5370 -DA - 2024 FEB -PY - 2024 -VL - 68 -C7 - 102422 -DO - 10.1016/j.eclinm.2024.102422 -AN - WOS:001167947400001 -AD - First Hosp Jilin Univ, Canc Ctr, 1 Xinmin St, Changchun 130021, Jilin, Peoples R China -AD - First Hosp Jilin Univ, Thorac Surg Dept, 1 Xinmin St, Changchun 130021, Jilin, Peoples R China -AD - First Hosp Jilin Univ, Pathol Dept, Changchun 130021, Jilin, Peoples R China -Y2 - 2024-03-08 -ER - - -TY - JOUR -AU - Hu, Tao -AU - Li, Li -AU - Cui, Jinfeng -AU - Song, Xiaoyu -AU - Zhu, He -AU - Hou, Zhi Wei -AU - Yuan, Shuanghu -TI - Effects of antibiotics on immunotherapy in patients with metastatic nonsmall cell lung cancer. -T2 - European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) -M3 - Journal Article -AB - To investigate the effects of antibiotic exposure on the prognosis of patients with advanced metastatic non-small cell lung cancer (m-NSCLC) who received immune checkpoint inhibitors (ICIs). This study retrospectively included 199 patients diagnosed with m-NSCLC in Shandong Cancer Hospital and Institute from December 2017 to October 2021, all patients received ICIs for the first time. The basic clinical characteristics of patients before the first treatment of ICIs, whether antibiotics were used during treatment, progression-free survival (PFS), and overall survival (OS) were collected. The survival among different groups was compared by the Kaplan-Meier method. The median follow-up time of m-NSCLC patients was 33.79months, mPFS was 11.67months, and mOS was 21.55months. Univariate analysis showed that antibiotic use, radiotherapy, and targeted drug resistance influenced PFS and OS (P < 0.05). Multivariate analysis showed that antibiotic use, radiotherapy, and targeted resistance remained independent factors of PFS, and targeted resistance was an independent factor of OS (P < 0.05). Subgroup analysis found that antibiotic use within 30days before and after immunotherapy could decrease the PFS and OS (P < 0.05). Kaplan-Meier analysis showed that patients without radiotherapy had shorter PFS (mPFS, 12.89 vs. 8.13months; P = 0.0258) and OS (mOS, 26.94 vs. 16.43months; P = 0.0465). The mPFS (16.17 vs. 9.19months; P = 0.0151) and mOS (27.27 vs. 18.65months; P = 0.0437) of patients in the antibiotic group were shorter. Patients in the targeted drug-resistant group had shorter PFS (mPFS, 40.66 vs. 7.77months, P < 0.001) and OS (mOS, 41.98 vs. 16.89months, P < 0.001) compared with patients who did not receive targeted treatment. Antibiotics and radiation therapy are associated with the prognosis of m-NSCLC who are newly treated with ICIs. Effectively reducing antibiotic use in 1month before and after ICIs treatment may help improve the immunotherapy efficacy of patients with m-NSCLC. -SN - 1473-5709 -DA - 2024 Sep 20 (Epub 2024 Sep 20) -PY - 2024 -DO - 10.1097/CEJ.0000000000000912 -AN - MEDLINE:39302841 -AD - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences. -AD - Center for Medical Integration and Practice, Shandong University, Jinan. -AD - Division of Life Sciences and Medicine, Department of Radiation Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China. -AD - Department of Radiation Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui, China. -Y2 - 2024-09-23 -ER - - -TY - JOUR -Z2 - 吴丽(综述) -Z2 - 王永生(审校) -AU - Wu Li -AU - Wang Yongsheng -TI - Progress in Vaccines Against Non-small Cell Lung Cancer -T2 - Cancer Research on Prevention and Treatment -M3 - Review -AB - In recent years, the total 5-year survival rate of the patients with non-small cell lung cancer (NSCLC) remains unsatisfactory, though there are some recent advances in the survival rate of the patients with NSCLC because of the advances in surgery, irradiation, chemotherapy and targeted therapy. The immunotherapy which utilizes the immune system to control, kill and eradicate cancer cell is a viable treatment approach for cancer. Recent advances in our understanding of cancer immunology and molecular biology resulted in the development of non-antigen specific immunotherapy, for example, monoclonal antibodies targeting immune checkpoints on the T-cell lymphocyte. Not only non-antigen specific immunotherapy, but also the antigen specific immunotherapy or vaccination have made great progress. This makes them become promising therapeutic agents. Herein, we review the recent progress and advances of tumor vaccine from randomized controlled trials. -SN - 1000-8578 -DA - 2016 -PY - 2016 -VL - 43 -IS - 8 -SP - 721 -EP - 727 -C7 - 1000-8578(2016)43:8<721:NDYMZL>2.0.TX;2-# -AN - CSCD:5774047 -AD - 四川大学华西医院肿瘤中心胸部肿瘤科, 成都, 四川 610041, 中国 -AD - Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China -M2 - 四川大学华西医院肿瘤中心胸部肿瘤科 -M2 - Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University -Y2 - 2016-11-17 -ER - - -TY - JOUR -AU - Wang, DaQuan -AU - Liu, SongRan -AU - Fu, Jia -AU - Zhang, PengXin -AU - Zheng, ShiYang -AU - Qiu, Bo -AU - Liu, Hui -AU - Ye, YongQuan -AU - Guo, JinYu -AU - Zhou, Yin -AU - Jiang, HaiHang -AU - Yin, ShaoHan -AU - He, HaoQiang -AU - Xie, ChuanMiao -AU - Liu, Hui -TI - Correlation of Ktrans derived from dynamic contrast-enhanced MRI with treatment response and survival in locally advanced NSCLC patients undergoing induction immunochemotherapy and concurrent chemoradiotherapy -T2 - JOURNAL FOR IMMUNOTHERAPY OF CANCER -M3 - Article -AB - Purpose This study aimed to investigate the prognostic significance of pretreatment dynamic contrast-enhanced (DCE)-MRI parameters concerning tumor response following induction immunochemotherapy and survival outcomes in patients with locally advanced non-small cell lung cancer (NSCLC) who underwent immunotherapy-based multimodal treatments. Material and methods Unresectable stage III NSCLC patients treated by induction immunochemotherapy, concurrent chemoradiotherapy (CCRT) with or without consolidative immunotherapy from two prospective clinical trials were screened. Using the two-compartment Extend Tofts model, the parameters including K-trans, K-ep, V-e, and V-p were calculated from DCE-MRI data. The apparent diffusion coefficient was calculated from diffusion-weighted-MRI data. The receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to assess the predictive performance of MRI parameters. The Cox regression model was used for univariate and multivariate analysis. Results 111 unresectable stage III NSCLC patients were enrolled. Patients received two cycles of induction immunochemotherapy and CCRT, with or without consolidative immunotherapy. With the median follow-up of 22.3 months, the median progression-free survival (PFS) and overall survival (OS) were 16.3 and 23.8 months. The multivariate analysis suggested that Eastern Cooperative Oncology Group score, TNM stage and the response to induction immunochemotherapy were significantly related to both PFS and OS. After induction immunochemotherapy, 67 patients (59.8%) achieved complete response or partial response and 44 patients (40.2%) had stable disease or progressive disease. The K-trans of primary lung tumor before induction immunochemotherapy yielded the best performance in predicting the treatment response, with an AUC of 0.800. Patients were categorized into two groups: high-K-trans group (n=67, K-trans > 164.3x10(-3)/min) and low-K-trans group (n=44, K-trans <= 164.3x10(-3)/min) based on the ROC analysis. The high-K-trans group had a significantly higher objective response rate than the low-K-trans group (85.1% (57/67) vs 22.7% (10/44), p<0.001). The high-K-trans group also presented better PFS (median: 21.1 vs 11.3 months, p=0.002) and OS (median: 34.3 vs 15.6 months, p=0.035) than the low-K-trans group. Conclusions Pretreatment K-trans value emerged as a significant predictor of the early response to induction immunochemotherapy and survival outcomes in unresectable stage III NSCLC patients who underwent immunotherapy-based multimodal treatments. Elevated K-trans values correlated positively with enhanced treatment response, leading to extended PFS and OS durations. -PU - BMJ PUBLISHING GROUP -PI - LONDON -PA - BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND -SN - 2051-1426 -DA - 2024 JUN -PY - 2024 -VL - 12 -IS - 6 -C7 - e008574 -DO - 10.1136/jitc-2023-008574 -AN - WOS:001259858100005 -AD - Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Guangdong Prov Clin Res Ctr Canc, Dept Radiat Oncol,Canc Ctr,State Key Lab Oncol So, Guangzhou, Guangdong, Peoples R China -AD - Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Guangdong Prov Clin Res Ctr Canc, Dept Pathol,Canc Ctr,State Key Lab Oncol South Ch, Guangzhou, Guangdong, Peoples R China -AD - United Imaging Healthcare, Shanghai, Peoples R China -AD - United Imaging Healthcare Amer, Houston, TX USA -AD - SuZhou TongDiao Co, Suzhou, Peoples R China -AD - Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Dept Radiol,Canc, Guangzhou, Guangdong, Peoples R China -M2 - United Imaging Healthcare -M2 - United Imaging Healthcare Amer -M2 - SuZhou TongDiao Co -Y2 - 2024-07-14 -ER - - -TY - JOUR -AU - Sandler, Jason E. -AU - D'Aiello, Angelica -AU - Halmos, Balazs -TI - Changes in store for early-stage non-small cell lung cancer -T2 - JOURNAL OF THORACIC DISEASE -M3 - Review -AB - The management of advanced non-small cell lung cancer (NSCLC) has been revolutionized in recent years with the introduction of biomarker-targeted molecular therapies and immune checkpoint inhibitors. In contrast, since adjuvant chemotherapy was first established twenty years ago as the standard of care, little has changed for resected early-stage (IB-IIIA) patients for whom the potential for cure is greatest. In this manuscript we will review recently presented data as well as ongoing/planned studies in this arena. So far, investigative efforts have yielded mixed results regarding the use of tyrosine kinase inhibitors (TKIs) in early-stage NSCLC, though a series of now better planned, biomarker-driven ongoing phase III trials may be more informative. Several innovative immunotherapy studies have already shown promising results principally in the neoadjuvant setting with a large number of pivotal neo-adjuvant and adjuvant trials now in progress. Given the more robust design and biomarker-focused approach of the new generation of studies, significant advances in the optimal curative treatment of early stage NSCLC are anticipated. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2019 MAY -PY - 2019 -VL - 11 -IS - 5 -SP - 2117 -EP - 2125 -DO - 10.21037/jtd.2019.05.34 -AN - WOS:000469979100048 -AD - Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA -AD - Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA -Y2 - 2019-06-18 -ER - - -TY - JOUR -AU - Mainguene, Juliette -AU - Basse, Clemence -AU - Girard, Philippe -AU - Beaucaire-Danel, Sophie -AU - Cao, Kim -AU - Brian, Emmanuel -AU - Grigoroiu, Madalina -AU - Gossot, Dominique -AU - Luporsi, Marie -AU - Perrot, Loic -AU - Vieira, Thibault -AU - Caliandro, Raffaele -AU - Daniel, Catherine -AU - Seguin-Givelet, Agathe -AU - Girard, Nicolas -TI - Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board -T2 - LUNG CANCER -M3 - Article -AB - Background: Stage IIIA/B-N2 is a very heterogeneous group of patients and accounts for one third of NSCLC at diagnosis. The best treatment strategy is established at a Multidisciplinary Tumor Board (MTB): surgical resection with neoadjuvant or adjuvant therapy versus definitive chemoradiation with immune checkpoint inhibitors consolidation. Despite the crucial role of MTBs in this complex setting, limited data is available regarding its performances and the reproducibility of the decision-making.Methods: Using a large cohort of IIIA/B-N2 NSCLC patients, we described patient's characteristics and treatment strategies established at the initial MTB: with a "surgical strategy" group, for potentially resectable disease, and a "medical strategy" group for non-resectable patients. A third group consisted of patients who were not eligible for surgery after neoadjuvant treatment and switched from the surgical to the medical strategy. We randomly selected 30 cases (10 in each of the 3 groups) for a blinded re-discussion at a fictive MTB and analyzed the reproducibility and factors associated with treatment decision.Results: Ninety-seven IIIA/B-N2 NSCLC patients were enrolled between June 2017 and December 2019. The initial MTB opted for a medical or a surgical strategy in 44% and 56% of patients respectively. We identified histology, tumor size and localization, extent of lymph node involvement and the presence of bulky mediastinal nodes as key decision-making factors. Thirteen patients were not eligible for surgical resection after neoadjuvant therapy and switched for a medical strategy. Overall concordance between the initial decision and the re discussion was 70%. The kappa correlation coefficient was 0.43. Concordance was higher for patients with limited mediastinal node invasion. Survival did not appear to be impacted by conflicting decisions.Conclusions: Reproducibility of treatment decision-making for stage IIIA/B-N2 NSCLC patients at a MTB is moderate but does not impact survival. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2022 JAN -PY - 2022 -VL - 163 -SP - 51 -EP - 58 -DO - 10.1016/j.lungcan.2021.12.004 -AN - WOS:000788216700008 -AD - Inst Curie, Thorax Inst Curie Montsouris, Thorac Oncol Serv, Paris, France -AD - Univ Paris, Paris, France -AD - Inst Mutualiste Montsouris, Thorax Inst Curie Montsouris, Resp Med Dept, Paris, France -AD - Inst Curie, Radiat Oncol Dept, Paris, France -AD - Inst Mutualiste Montsouris, Thorax Inst Curie Montsouris, Thorac Surg Dept, Paris, France -AD - Inst Curie, Nucl Med Serv, Paris, France -AD - UVSQ, Paris Saclay Campus, Versailles, France -Y2 - 2022-05-18 -ER - - -TY - JOUR -AU - Franchino, Federica -AU - Ruda, Roberta -AU - Soffietti, Riccardo -TI - Mechanisms and Therapy for Cancer Metastasis to the Brain -T2 - FRONTIERS IN ONCOLOGY -M3 - Review -AB - Advances in chemotherapy and targeted therapies have improved survival in cancer patients with an increase of the incidence of newly diagnosed brain metastases (BMs). Intracranial metastases are symptomatic in 60-70% of patients. Magnetic resonance imaging (MRI) with gadolinium is more sensitive than computed tomography and advanced neuroimaging techniques have been increasingly used in the detection, treatment planning, and follow-up of BM. Apart from the morphological analysis, the most effective tool for characterizing BM is immunohistochemistry. Molecular alterations not always reflect those of the primary tumor. More sophisticated methods of tumor analysis detecting circulating biomarkers in fluids (liquid biopsy), including circulating DNA, circulating tumor cells, and extracellular vesicles, containing tumor DNA and macromolecules (microRNA), have shown promise regarding tumor treatment response and progression. The choice of therapeutic approaches is guided by prognostic scores (Recursive Partitioning Analysis and diagnostic-specific Graded Prognostic Assessment-DS-GPA). The survival benefit of surgical resection seems limited to the subgroup of patients with controlled systemic disease and good performance status. Leptomeningeal disease (LMD) can be a complication, especially in posterior fossa metastases undergoing a "piecemeal" resection. Radiosurgery of the resection cavity may offer comparable survival and local control as postoperative whole-brain radiotherapy (WBRT). WBRT alone is now the treatment of choice only for patients with single or multiple BMs not amenable to surgery or radiosurgery, or with poor prognostic factors. To reduce the neurocognitive sequelae of WBRT intensity modulated radiotherapy with hippocampal sparing, and pharmacological approaches (memantine and donepezil) have been investigated. In the last decade, a multitude of molecular abnormalities have been discovered. Approximately 33% of patients with non-small cell lung cancer (NSCLC) tumors and epidermal growth factor receptor mutations develop BMs, which are targetable with different generations of tyrosine kinase inhibitors (TKIs: gefitinib, erlotinib, afatinib, icotinib, and osimertinib). Other "druggable" alterations seen in up to 5% of NSCLC patients are the rearrangements of the "anaplastic lymphoma kinase" gene TKI (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib). In human epidermal growth factor receptor 2-positive, breast cancer targeted therapies have been widely used (trastuzumab, trastuzumab-emtansine, lapatinib-capecitabine, and neratinib). Novel targeted and immunotherapeutic agents have also revolutionized the systemic management of melanoma (ipilimumab, nivolumab, pembrolizumab, and BRAF inhibitors dabrafenib and vemurafenib). -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2018 MAY 24 -PY - 2018 -VL - 8 -C7 - 161 -DO - 10.3389/fonc.2018.00161 -AN - WOS:000432922100001 -AD - Univ & City Hlth & Sci Hosp, Dept Neurooncol, Turin, Italy -Y2 - 2018-12-28 -ER - - -TY - JOUR -AU - SCHRUMP, DAVID -TI - Epigenetic Therapy for Thoracic Malignancies -M3 - Awarded Grant -AB - Our published studies pertaining to more than 100 patients with lung and esophageal cancers and pleural mesotheliomas, or pulmonary metastases from non-thoracic malignancies have clearly demonstrated that Decitabine and romidepsin alone or in combination can modulate gene expression in thoracic malignancies and induce immune responses against these neoplasms. Our goal has always been to couple epigenetic priming regimens with adoptive immunotherapy for thoracic malignancies. Presently, poor biodistribution and systemic toxicities prevent optimal, chronic administration of epigenetic agents necessary to reprogram thoracic malignancies. To overcome these limitations, we formulated DAC and tetrahydrouridine (a potent, non-toxic inhibitor of CDA) for oral administration in collaboration with the Cleveland Clinic. A phase I/II study of oral DAC/THU and pembrolizumab for patients with inoperable NSCLC, esophageal cancers, or malignant pleural mesotheliomas is currently underway. Virtually all patients have exhibited evidence of systemic epigenetic reprogramming, and impressive, near complete and durable (1 yr) responses have been observed in several patients. To further optimize epigenetic priming of pulmonary malignancies for immune checkpoint blockade while decreasing potential systemic toxicities, we have recently initiated preclinical studies to examine the pharmacokinetics and potential efficacy of azacytidine administered by aerosolization techniques. A phase I/II clinical protocol trial to examine the toxicities and potential efficacy of AZA administered via inhalation techniques in combination with M7824, a dual immune checkpoint inhibitor-TGF-beta trap in patients with locally advanced pulmonary metastases was approved by NIH IRB only to be closed due to a company decision not to further develop M7824. This trial was intended to establish the paradigm for evaluation of a series of aerosolized epigenetic agents alone or in combination with adoptive immunotherapy for the treatment of locally advanced pulmonary malignancies. No similar efforts are currently underway elsewhere in the world. The trial will be reinitiated once we have commitment from a pharmaceutical company for a replacement immune checkpoint inhibitor. Additionally, we have tentative commitment from AstraZeneca to conduct an inhaled AZA trial in combination with Durvalumab in patients with operable early-stage NSCLC. This protocol is being prepared for scientific review. Whereas cancer-testis antigens are expressed in a variety of human malignancies, immune responses to these proteins are uncommon in thoracic oncology patients due to low level, heterogeneous antigen expression, deficient antigen processing/presentation, and local as well as systemic immunosuppression. Our published studies from cell lines and patient biopsies have demonstrated that thoracic malignancies exhibit diverse patterns of CTA expression and heterogeneous responses to epigenetic regimens that up-regulate CTAs. A strategy to overcome these limitations is to immunize patients against a panel of CTAs that potentially can be up-regulated by systemic administration of chromatin remodeling agents. To address this issue, we conducted a phase 2.5 First-in-Human trial to ascertain if a tumor lysate vaccine can induce broad immunity to CTA and determine if metronomic oral cyclophosphamide and celecoxib (cy/cel) enhances vaccine-induced immune responses. The primary endpoint was serologic response to purified CTA 1 month after the 6th vaccination. Exploratory objectives included analysis of serologic reactivity to carbohydrate antigens and assessment of peripheral immune subsets before and after vaccine therapy. All patients exhibited local and systemic inflammatory responses lasting 72-96 hours following vaccinations. There were no dose limiting treatment related toxicities in 21 patients accrued to the trial. 14 patients (67%) completed all six vaccinations. 8 patients (57%) exhibited serologic responses to NY-ESO-1. Additional reactivities were observed against GAGE7, XAGE, and MAGE-C2. Reactivities against tumor-associated carbohydrate antigens were uncommon. Vaccine therapy decreased percent Tregs (p=0.067*), PD-1 expression on Tregs (p=0.023*), and PD-L1 expression on CD14+ monocytes (p=0.0089*), classical monocytes (p=0.0159*), and intermediate monocytes (p= 0.0031*). Cy/cel did not impact immune responses or vaccine-induced alterations in peripheral immune subsets. Laboratory metrics of response did not appear to correlate with patient survival. Results of this positive trial have recently been published and support further vaccination efforts in patients with thoracic malignancies. Two phase two trials one using the lysate vaccine in combination with the IL-15 superagonist N-803 as post-operative adjuvant therapy in lung cancer patients, and the other using the lysate in combination with entinostat and nivolumab in esophageal cancer patients post chemo-radiation +/- surgery are undergoing FDA and IRB approval at this time and are expected to be open for patient accrual in Autumn of 2022. -DA - 2022 -PY - 2022 -AN - GRANTS:17493112 -G1 - 10703002; 1ZIASC010093-26; ZIASC010093 -AD - DIVISION OF CLINICAL SCIENCES - NCI -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - Socola, Francisco -AU - Scherfenberg, Naomi -AU - Raez, Luis E -TI - Therapeutic vaccines in non-small cell lung cancer. -T2 - ImmunoTargets and therapy -M3 - Journal Article -M3 - Review -AB - Non-small cell lung cancer (NSCLC) unfortunately carries a very poor prognosis. Patients usually do not become symptomatic, and therefore do not seek treatment, until the cancer is advanced and it is too late to employ curative treatment options. New therapeutic options are urgently needed for NSCLC, because even current targeted therapies cure very few patients. Active immunotherapy is an option that is gaining more attention. A delicate and complex interplay exists between the tumor and the immune system. Solid tumors utilize a variety of mechanisms to evade immune detection. However, if the immune system can be stimulated to recognize the tumor as foreign, tumor cells can be specifically eliminated with little systemic toxicity. A number of vaccines designed to boost immunity against NSCLC are currently undergoing investigation in phase III clinical trials. Belagenpumatucel-L, an allogeneic cell vaccine that decreases transforming growth factor (TGF-beta) in the tumor microenvironment, releases the immune suppression caused by the tumor and it has shown efficacy in a wide array of patients with advanced NSCLC. Melanoma-associated antigen A3 (MAGE-A3), an antigen-based vaccine, has shown promising results in MAGE-A3(+) NSCLC patients who have undergone complete surgical resection. L-BLP25 and TG4010 are both antigenic vaccines that target the Mucin-1 protein (MUC-1), a proto-oncogene that is commonly mutated in solid tumors. CIMAVax is a recombinant human epidermal growth factor (EGF) vaccine that induces anti-EGF antibody production and prevents EGF from binding to its receptor. These vaccines may significantly improve survival and quality of life for patients with an otherwise dismal NSCLC prognosis. This review is intended to give an overview of the current data and the most promising studies of active immunotherapy for NSCLC. -SN - 2253-1556 -DA - 2013 -PY - 2013 -VL - 2 -SP - 115 -EP - 24 -DO - 10.2147/ITT.S30813 -AN - MEDLINE:27471692 -AD - Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Leonard M Miller School of Medicine, Miami, Florida, USA. -AD - University of Miami Leonard M Miller School of Medicine, Miami, Florida, USA. -AD - Thoracic Oncology Program, Memorial Cancer Institute, Memorial Health Care System, Pembroke Pines, Florida, USA. -Y2 - 2013-01-01 -ER - - -TY - JOUR -AU - Tsukita, Yoko -AU - Tozuka, Takehiro -AU - Kushiro, Kohei -AU - Hosokawa, Shinobu -AU - Sumi, Toshiyuki -AU - Uematsu, Mao -AU - Honjo, Osamu -AU - Yamaguchi, Ou -AU - Asao, Tetsuhiko -AU - Sugisaka, Jun -AU - Saito, Go -AU - Shiihara, Jun -AU - Morita, Ryo -AU - Katakura, Seigo -AU - Yasuda, Takehiro -AU - Hisakane, Kakeru -AU - Miyauchi, Eisaku -AU - Morita, Satoshi -AU - Kobayashi, Kunihiko -AU - Asahina, Hajime -TI - Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer -T2 - JAMA ONCOLOGY -M3 - Article -AB - IMPORTANCE Immune checkpoint inhibitor (ICI) plus chemotherapy combination treatment (ICI-chemotherapy) is now a standard treatment for non-small cell lung cancer (NSCLC) without targetable oncogene alterations, but there are few data on ICI-chemotherapy for patients 75 years and older. OBJECTIVE To inform the choice of first-line drugs in clinical practice and assess the safety and efficacy of ICI-chemotherapy combination treatment in older adult patients with previously untreated advanced NSCLC. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study included 58 centers in Japan. The cohort consisted of patients 75 years and older with clinical stage IIIB, IIIC, IV, postoperative or radiotherapy recurrent NSCLC. Patients started first-line systemic therapy between December 2018 and March 2021. Those receiving first-line molecular targeted drugs were excluded. The data were analyzed from February 2022 to October 2022. EXPOSURES Systemic therapy. MAIN OUTCOMES AND MEASURES The main outcomes were overall survival (OS), progression-free survival (PFS), and safety. RESULTS A total of 1245 patients (median [range] age, 78 [75-95] years; 967 [78%] male) with NSCLC were included in the cohort. Programmed death ligand-1 (PD-L1) expression of less than 1% occurred in 268 tumors (22%); 1% to 49% in 387 tumors (31%); 50% and higher in 410 tumors (33%), and unknown expression in 180 tumors (14%). Median OS was 20.0 (95% CI, 17.1-23.6) months for the 354 patients receiving ICI-chemotherapy (28%); 19.8 (95% CI, 16.5-23.8) months for the 425 patients receiving ICI alone (34%); 12.8 (95% CI, 10.7-15.6) months for the 311 patients receiving platinum-doublet chemotherapy (25%); and 9.5 (95% CI, 7.4-13.4) months for the 155 patients receiving single-agent chemotherapy (12%). After propensity score matching, no differences in OS and PFS were found between the patients receiving ICI-chemotherapy vs ICI alone. Each group consisted of 118 patients. For PD-L1 expression of 1% and higher the OS hazard ratio (HR) was 0.98 (95% CI, 0.67-1.42; P = .90), and the PFS HR was 0.92 (95% CI, 0.67-1.25; P = .59). Significance was also not reached when separately analyzed for lower or higher PD-L1 expression (1%-49% or >= 50%). However, grade 3 or higher immune-related adverse events occurred in 86 patients (24.3%) treated with ICI-chemotherapy and 76 (17.9%) with ICI alone (P = .03). CONCLUSIONS AND RELEVANCE In this study, ICI-chemotherapy combination treatment did not improve survival and increased the incidence of grade 3 and higher immune-related adverse events compared with ICI alone in patients 75 years and older. Based on these results, ICI alone may be recommended for older adult patients with PD-L1-positive NSCLC. -PU - AMER MEDICAL ASSOC -PI - CHICAGO -PA - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA -SN - 2374-2437 -SN - 2374-2445 -DA - 2024 APR -PY - 2024 -VL - 10 -IS - 4 -SP - 439 -EP - 447 -DO - 10.1001/jamaoncol.2023.6277 -AN - WOS:001181324700002 -C6 - APR 2024 -AD - Hokkaido Univ, Dept Resp Med, Grad Sch Med, North 15,West 7,Kita Ku, Sapporo 0608638, Japan -AD - Tohoku Univ, Grad Sch Med, Dept Resp Med, Sendai, Japan -AD - Nippon Med Sch, Dept Pulm Med & Oncol, Grad Sch Med, Tokyo, Japan -AD - Niigata Univ, Grad Sch Med & Dent Sci, Dept Resp Med & Infect Dis, Niigata, Japan -AD - Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan -AD - Hakodate Goryoukaku Hosp, Dept Resp Med, Hakodate, Japan -AD - Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan -AD - Sapporo Minami Sanjo Hosp, Dept Resp Med, Sapporo, Japan -AD - Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka, Saitama, Japan -AD - Juntendo Univ, Grad Sch Med, Dept Resp Med, Tokyo, Japan -AD - Sendai Kousei Hosp, Dept Pulm Med, Sendai, Japan -AD - Chiba Univ, Grad Sch Med, Dept Respirol, Chiba, Japan -AD - Jichi Med Univ, Saitama Med Ctr, Dept Resp Med, Saitama, Japan -AD - Akita Kousei Med Ctr, Dept Resp Med, Akita, Japan -AD - Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Japan -AD - Yokosuka Kyosai Hosp, Dept Resp Med, Yokosuka, Japan -AD - Nippon Med Sch, Tamanagayama Hosp, Dept Pulm Med & Med Oncol, Tokyo, Japan -AD - Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan -M2 - Japanese Red Cross Okayama Hosp -M2 - Hakodate Goryoukaku Hosp -M2 - Sapporo Minami Sanjo Hosp -M2 - Akita Kousei Med Ctr -M2 - Yokosuka Kyosai Hosp -Y2 - 2024-03-26 -ER - - -TY - JOUR -AU - Ohri, N. -AU - Jolly, S. -AU - Cooper, B.T. -AU - Kabarriti, R. -AU - Iii, W.R.B. -AU - Klein, J. -AU - Viswanathan, S. -AU - Kaufman, R. -AU - Shum, E. -AU - Sabari, J.K. -AU - Cheng, H. -AU - Gucalp, R. -AU - Castellucci, E. -AU - Qin, A. -AU - Gadgeel, S.M. -AU - Halmos, B. -TI - The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT) -T2 - International Journal of Radiation Oncology, Biology, Physics -M3 - Journal Paper -AB - Purpose/Objective(s) Standard therapy for unresectable locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiotherapy (chemoRT), which is usually followed by adjuvant durvalumab. We performed a prospective trial testing sequential pembrolizumab and risk-adapted radiotherapy without chemotherapy for biomarker-selected LA-NSCLC patients.Materials/Methods Patients with AJCC version 8 stage III NSCLC or unresectable stage II NSCLC and ECOG performance status 0-1 were eligible for this trial. Subjects with PD-L1 tumor proportion score (TPS) ≥ 50% received three cycles of induction pembrolizumab (200 mg, every 21 days), underwent restaging FDG-PET/CT, received risk-adapted thoracic radiotherapy (55 Gy delivered to tumors or lymph nodes with metabolic tumor volume exceeding 20 cc and 48 Gy delivered to smaller lesions, all in 20 daily fractions), and then received up to 13 cycles of additional pembrolizumab. Subjects with PD-L1 TPS < 50% received concurrent chemoRT, and adjuvant durvalumab was recommended for patients without disease progression. The primary study endpoint was one-year progression-free survival (PFS) for subjects treated with pembrolizumab and radiotherapy (pembroRT), which we hypothesized would exceed 65%. Other study endpoints included 1-year overall survival (OS) and rates of clinician-scored (CTCAE v. 4.03) and patient-reported (PRO-CTCAE) adverse events observed over one year.Results Twenty-five subjects with PD-L1 TPS ≥ 50% and 12 subjects with PD-L1 TPS < 50% from three institutions were enrolled between August 2018 and November 2021. Median age was 70. Twenty-four subjects had stage II-IIIA disease, and 13 had stage IIIB-IIIC disease. Except for PD-L1 TPS, subject characteristics did not differ significantly across treatment groups. Ten out of the 12 subjects with ChemoRT received adjuvant durvalumab, and one received adjuvant osimertinib for EGFR mutation. The median follow-up duration is 15 months. Compared to patients treated with chemoRT, treatment with pembroRT has yielded numerically higher 1-year PFS (72% v. 46%, log rank p=0.232) and OS (91% v. 73%, log rank p=0.213) rates. Similar rates of grade 3 physician-scored adverse events have been observed with pembroRT (24%) and chemoRT (25%). Less severe patient-reported adverse events occurred with pembroRT compared to chemoRT (See Table).Conclusion Treatment with pembrolizumab and risk-adapted radiotherapy without chemotherapy is a promising approach for LA-NSCLC patients with PD-L1 TPS ≥ 50%. In addition to yielding high disease control rates, this strategy appears to reduce patient-reported adverse events compared to standard chemoRT and adjuvant therapy. All rights reserved Elsevier. -SN - 1879-355X -DA - 2022 -PY - 2022 -SP - S31 -EP - S31 -DO - 10.1016/j.ijrobp.2022.07.385 -AN - INSPEC:22845769 -AD - Dept. of Radiat. Oncology, Coll. of Med., Baghdad, NY, USA -AD - Univ. of Michigan, Ann Arbor, MI, USA -AD - Sch. of Med., New York Univ., New York, NY, USA -AD - Montefiore Med. Center, Coll. of Med., Baghdad, NY, USA -AD - Cancer Inst., Health Syst., Detroit, MI, USA -Y2 - 2023-04-13 -ER - - -TY - JOUR -AU - Kumar, Chaitanya -AU - Bagga, Jasmine -AU - Chiliveru, Srikanth -AU - Kohli, Sakshi -AU - Bharadwaj, Asmi -AU - Jain, Minish -AU - Inamdar, Shriram -AU - Sharan, Bandana -TI - Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN® in combination with chemotherapy -T2 - FUTURE SCIENCE OA -M3 - Article -AB - Of the most prevalent solid tumors with advanced disease, prostate and ovarian cancer and non-small cell lung carcinoma have the fewest therapeutic options. Herein, we report the case of a 63-year-old male with metastatic prostate adenocarcinoma showing substantial remission post-administration of personalized dendritic cell-based vaccine APCEDEN (R) in combination with chemotherapeutic drug Mitoxantrone. Therapeutic response displayed an interesting clinical correlation validated by PET scan images showing decreased fluorodeoxyglucose (FDG) avidity in the prostate gland, reduced skeletal metastases further established by the drop in serum Prostate Specific Antigen (PSA) levels and expression of immune assessment markers (IFN-gamma, Tregs, neutrophil lymphocyte ratio and platelet lymphocyte ratio). This case demonstrates the potential efficacy of dendritic cell immunotherapy, showing a potent antitumor activity by enhancing the host immune responses, and improving quality of life.Lay abstract: Prostate adenocarcinoma is the most common cancer and second leading cause of cancer-related death inmen. Advanced cancers have very few therapeutic options. Understanding of the immune system has led to the development of novel personalized vaccines as an emerging and efficient treatment modality for cancer. This case study describes the substantial remission of advanced prostate cancer after receiving the personalized dendritic cell therapy APCEDEN in combination with the chemotherapy drug mitoxantrone, even after the patient's previous failed treatment history of standard hormonal, chemoand radiotherapy regimens. This case stands as an interesting example of combination therapy for cancer benefiting the patient. -PU - FUTURE SCI LTD -PI - LONDON -PA - UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND -SN - 2056-5623 -DA - 2019 DEC -PY - 2019 -VL - 5 -IS - 10 -C7 - FSO435 -DO - 10.2144/fsoa-2019-0086 -AN - WOS:000508465100004 -AD - APAC Biotech Pvt Ltd, R&D, Gurgaon, India -AD - Ruby Hall Clin, Med Oncol, Pune, Maharashtra, India -AD - Xylem Clin Res Pvt Ltd, Pune, Maharashtra, India -M2 - APAC Biotech Pvt Ltd -M2 - Ruby Hall Clin -M2 - Xylem Clin Res Pvt Ltd -Y2 - 2020-01-30 -ER - - -TY - JOUR -Z2 - 李淑芬(综述) -Z2 - 佟仲生(审校) -AU - LI Shufen -AU - TONG Zhongsheng -TI - Advances in Endostatin Therapy for Non-small Cell Lung Cancer -T2 - Chinese Journal of Clinical Oncology -M3 - Review -AB - Angioge.nesis, growth, invasion and metastasis of cancer involve a multi-factorial process. Tumor growth and metastasis depend on tumor angiogenesis. Antiangiogenesis is a new strategy for cancer therapy. Endostatin is a recently discovered endogenous inhibitor of angiegenesis. In vivo and in vitro experiments have shown that Endostatin can specifically target endothelial cells, inhibiting proliferation and migration and inducing apoptosis. The antitumor mechanism of Endostatin and its signal transduction pathway are not yet thoroughly elucidated. Endostatin level is related to tumor condition and is considered a prognostic indicator. En- dostatin can enhance the antitumor effect of chemotherapy, radiotherapy and immunotherapy and decrease their adverse effects. In the past Several years, there have been many reports on Endostatin therapy for non-small cell lung cancer. We review the progress of the research on the structure of Endostatin and its mechanism, as well as its use in preclinical and clinical trials for treatment of non-small cell lung cancer. -SN - 1000-8179 -DA - 2008 -PY - 2008 -VL - 35 -IS - 18 -SP - 1076 -EP - 1079 -C7 - 1000-8179(2008)35:18<1076:XGNPYS>2.0.TX;2-# -AN - CSCD:3392321 -AD - 天津医科大学附属肿瘤医院肿瘤内科, 天津市肿瘤防治重点实验室, 天津 300060, 中国 -AD - Department of Medical Oncology, Cancer Institute and Hospital of Tianjin Medical University, Tianjin 300060, China -M2 - 天津医科大学附属肿瘤医院肿瘤内科 -M2 - Department of Medical Oncology, Cancer Institute and Hospital of Tianjin Medical University -Y2 - 2008-01-01 -ER - - -TY - JOUR -AU - Dias e Silva, Douglas -AU - Mambetsariev, Isa -AU - Fricke, Jeremy -AU - Babikian, Razmig -AU - Dingal, Shaira Therese -AU - Mazdisnian, Farhad -AU - Badie, Behnam -AU - Arvanitis, Leonidas -AU - Afkhami, Michelle -AU - Villalona-Calero, Miguel -AU - Salgia, Ravi -TI - A novel HLA-DQB2::MET gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case report -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Article -AB - Background: MET rearrangements are infrequently observed in non -small cell lung cancer (NSCLC). Advanced genomic detection techniques have unveiled such infrequent genomic variations, particularly MET fusions in approximately 0.5% of NSCLC patients. Tyrosine kinase inhibitors (TKIs) have revolutionized the standard of care in lung cancer and more recently a second generation MET TKI tepotinib received Food and Drug Administration (FDA) approval for MET exon 14 alterations in metastatic NSCLC. Despite this, the therapeutic landscape for MET -rearranged NSCLC patients remains significantly unexplored. The aim of our report is to detail a unique case of a patient with metastatic lung adenocarcinoma with a novel HLADQB2::MET fusion detected by next -generation sequencing (NGS) following previous treatment resistance. Case Description: A 73 -year -old female was initially started on carboplatin, pemetrexed and pembrolizumab with maintenance, but eventually had progression in the left upper lobe (LUL). Upon progression she was enrolled in a clinical trial of a monoclonal antibody with or without a PD -1 inhibitor, but brain metastasis progression was eventually detected by magnetic resonance imaging (MRI) requiring stereotactic radiosurgery (SRS) and a craniotomy. The trial drug was eventually discontinued due to progression and toxicity and NGS on bronchoscopy tissue revealed HLA-DQB2::MET fusion. The patient was initiated on tepotinib and continues with clinical and radiological stable disease for over 12 months. The patient's response to a MET inhibitor, tepotinib, underscores the potential efficacy of selective MET inhibitors for individuals with previously unexplored MET fusions. Conclusions: The positive response to tepotinib of a patient with NSCLC harboring a novel METFusion underscores the importance of the use of comprehensive next -generational sequencing -based panels and highlights the necessity for additional research and clinical exploration of selective MET inhibitors for managing NSCLC with MET rearrangements. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2024 MAY 31 -PY - 2024 -VL - 13 -IS - 5 -DO - 10.21037/tlcr-24-34 -AN - WOS:001263252300011 -AD - City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, 1500 East Duarte Rd, Duarte, CA 91010 USA -AD - Hosp Israelita Albert Einstein, Dept Med Oncol, Sao Paulo, Brazil -AD - City Hope Natl Med Ctr, Dept Med, Duarte, CA USA -AD - City Hope Natl Med Ctr, Dept Surg, Duarte, CA USA -AD - Dept Pathol, City Hope, Duarte, CA USA -Y2 - 2024-07-14 -ER - - -TY - JOUR -AU - Sardaro, Angela -AU - McDonald, Fiona -AU - Bardoscia, Lilia -AU - Lavrenkov, Konstantin -AU - Singh, Shalini -AU - Ashley, Sue -AU - Traish, Daphne -AU - Ferrari, Cristina -AU - Meattini, Icro -AU - Asabella, Artor Niccoli -AU - Brada, Michael -TI - Dyspnea in Patients Receiving Radical Radiotherapy for Non-Small Cell Lung Cancer: A Prospective Study -T2 - FRONTIERS IN ONCOLOGY -M3 - Article -AB - Background and Purpose: Dyspnea is an important symptomatic endpoint for assessment of radiation-induced lung injury (RILI) following radical radiotherapy in locally advanced disease, which remains the mainstay of treatment at the time of significant advances in therapy including combination treatments with immunotherapy and chemotherapy and the use of local ablative radiotherapy techniques. We investigated the relationship between dose-volume parameters and subjective changes in dyspnea as a measure of RILI and the relationship to spirometry.Material and Methods: Eighty patients receiving radical radiotherapy for non-small cell lung cancer were prospectively assessed for dyspnea using two patient-completed tools: EORTC QLQ-LC13 dyspnea quality of life assessment and dyspnea visual analogue scale (VAS). Global quality of life, spirometry and radiation pneumonitis grade were also assessed. Comparisons were made with lung dose-volume parameters.Results: The median survival of the cohort was 26 months. In the evaluable group of 59 patients there were positive correlations between lung dose-volume parameters and a change in dyspnea quality of life scale at 3 months (V-30 p=0.017; V-40 p=0.026; V-50 p=0.049; mean lung dose p=0.05), and a change in dyspnea VAS at 6 months (V-30 p=0.05; V-40 p=0.026; V-50 p=0.028) after radiotherapy. Lung dose-volume parameters predicted a 10% increase in dyspnea quality of life score at 3 months (V-40; p=0.041, V-50; p=0.037) and dyspnea VAS score at 6 months (V-40; p=0.027) post-treatment.Conclusions: Worsening of dyspnea is an important symptom of RILI. We demonstrate a relationship between lung dose-volume parameters and a 10% worsening of subjective dyspnea scores. Our findings support the use of subjective dyspnea tools in future studies on radiation-induced lung toxicity, particularly at doses below conventional lung radiation tolerance limits. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2020 DEC 23 -PY - 2020 -VL - 10 -C7 - 594590 -DO - 10.3389/fonc.2020.594590 -AN - WOS:000605955800001 -AD - Royal Marsden NHS Fdn Trust, Lung Res Unit, Sutton, Surrey, England -AD - Univ Bari Aldo Moro, Interdisciplinary Dept Med, Nucl Med Unit, Bari, Italy -AD - Univ Bari Aldo Moro, Sect Radiol & Radiat Oncol, Bari, Italy -AD - Inst Canc Res, Acad Radiotherapy Unit, Sutton, Surrey, England -AD - Azienda USL IRCCS Reggio Emilia, Dept Oncol & Adv Technol, Radiat Therapy Unit, Reggio Emilia, Italy -AD - Ben Gurion Univ Negev, Dept Oncol, Soroka Univ Med Ctr, Fac Hlth Sci, Beer Sheva, Israel -AD - Sanjay Gandhi Post Grad Inst Med Sci SGPGIMS, Dept Radiotherapy, Lucknow, Uttar Pradesh, India -AD - Univ Florence, Azienda Osped Univ Careggi, Dept Biomed Expt & Clin Sci, Radiat Oncol Unit,Oncol Dept, Florence, Italy -AD - Univ Liverpool, Dept Radiat Oncol, Wirral, Merseyside, England -AD - Clatterbridge Canc Ctr NHS Fdn Trust, Wirral, Merseyside, England -M2 - Azienda USL IRCCS Reggio Emilia -M2 - Clatterbridge Canc Ctr NHS Fdn Trust -Y2 - 2021-01-25 -ER - - -TY - CPAPER -AU - Alilou, Mehdi -AU - Vaidya, Pranjal -AU - Khorrami, Mohammadhadi -AU - Zagouras, Alexia -AU - Patil, Pradnya -AU - Bera, Kaustav -AU - Fu, Pingfu -AU - Velcheti, Vamsidhar -AU - Madabhushi, Anant -ED - Mori, K -ED - Hahn, HK -TI - Quantitative vessel tortuosity radiomics on baseline non-contrast lung CT predict response to immunotherapy and are prognostic of overall survival -T2 - MEDICAL IMAGING 2019: COMPUTER-AIDED DIAGNOSIS -M3 - Proceedings Paper -CP - Conference on Medical Imaging - Computer-Aided Diagnosis -CL - San Diego, CA -AB - Recently immune-checkpoint inhibitors have demonstrated promising clinical efficacy in patients with advanced non-small cell lung cancer (NSCLC). However, the response rates to immune checkpoint blockade drugs remain modest (45% in the front line setting and 20% in the second line setting). Consequently, there is an unmet need to develop accurate, validated biomarkers to predict which NSCLC patients will benefit from immunotherapy. While there has been recent interest in evaluating the role of texture and shape patterns of the nodule on CT scans to predict response to checkpoint inhibitors for NSCLC, our group has shown that nodule vessel morphology might also play a role in determining tumor aggressiveness and behavior. In this work we present a new approach using quantitative vessel tortuosity (QVT) radiomics, to predict response to checkpoint inhibitors and overall survival for patients with NSCLC treated with Nivolumab (a PD1 inhibitor) on a retrospective data set of 111 patients (D-1) including 56 responders and 45 non-responders. Patients who did not receive Nivolumab after 2 cycles due to a lack of response or progression as per Response Evaluation Criteria in Solid Tumors (RECIST) were classified as non-responders, patients who had radiological response or stable disease as per RECIST were classified as responders. On D-1, in conjunction with a linear discriminant analysis (LDA) classifier the QVT features were able to predict response to immunotherapy with an AUC of 0.73 +/- 0.04. Kaplan Meier analysis showed significant difference of overall survival between patients with low risk and high risk defined by the radiomics classifier (p-value = 0.004, HR= 2.29, 95% CI= 1.35 - 3.87). -PU - SPIE-INT SOC OPTICAL ENGINEERING -PI - BELLINGHAM -PA - 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA -SN - 0277-786X -SN - 1996-756X -SN - 978-1-5106-2548-8 -DA - 2019 -PY - 2019 -VL - 10950 -C7 - UNSP 109501F -DO - 10.1117/12.2513648 -AN - WOS:000491309500050 -AD - Case Western Reserve Univ, Cleveland, OH 44106 USA -AD - Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA -AD - Louis Stokes Cleveland Vet Adm Med Ctr, Cleveland, OH USA -AD - NYU Langone, New York, NY USA -Y2 - 2019-11-22 -ER - - -TY - JOUR -AU - Tanzawa, Shigeru -AU - Ushijima, Sunao -AU - Shibata, Kazuhiko -AU - Shibayama, Takuo -AU - Bessho, Akihiro -AU - Kaira, Kyoichi -AU - Misumi, Toshihiro -AU - Shiraishi, Kenshiro -AU - Matsutani, Noriyuki -AU - Tanaka, Hisashi -AU - Inaba, Megumi -AU - Haruyama, Terunobu -AU - Nakamura, Junya -AU - Kishikawa, Takayuki -AU - Nakashima, Masanao -AU - Iwasa, Keiichi -AU - Fujiwara, Keiichi -AU - Kohyama, Tadashi -AU - Kuyama, Shoichi -AU - Miyazawa, Naoki -AU - Nakamura, Tomomi -AU - Miyawaki, Hiroshi -AU - Ishida, Hiroo -AU - Oda, Naohiro -AU - Ishikawa, Nobuhisa -AU - Morinaga, Ryotaro -AU - Kusaka, Kei -AU - Fujimoto, Nobukazu -AU - Yokoyama, Toshihide -AU - Gemba, Kenichi -AU - Tsuda, Takeshi -AU - Nakagawa, Hideyuki -AU - Ono, Hirotaka -AU - Shimizu, Tetsuo -AU - Nakamura, Morio -AU - Kusumoto, Sojiro -AU - Hayashi, Ryuji -AU - Shirasaki, Hiroki -AU - Ochi, Nobuaki -AU - Aoe, Keisuke -AU - Kanaji, Nobuhiro -AU - Kashiwabara, Kosuke -AU - Inoue, Hiroshi -AU - Seki, Nobuhiko -TI - A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study) -T2 - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY -M3 - Article -AB - Background: Based on the results of the PACIFIC study, chemoradiotherapy followed by 1-year consolidation therapy with durvalumab was established as the standard of care for unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC). However, some topics not foreseen in that design can be explored, including progression-free survival (PFS) and overall survival (OS) after the start of chemoradiotherapy, the proportion of patients who proceeded to consolidation therapy with durvalumab, and the optimal chemotherapeutic regimens. In Japan, the combination regimen of S-1 + cisplatin (SP), for which the results of multiple clinical studies have suggested a good balance of efficacy and tolerability, is frequently selected in clinical settings. However, the efficacy and safety of consolidation therapy with durvalumab following this SP regimen have not been evaluated. We therefore planned a multicenter, prospective, single-arm, phase II study.Methods: In treatment-naive LA-NSCLC, two cycles of combination chemotherapy with S-1 (80-120 mg/body, Days 1-14) + cisplatin (60 mg/m(2), Day 1) will be administered at an interval of 4 weeks, with concurrent thoracic radiotherapy (60 Gy). Responders will then receive durvalumab every 2 weeks for up to 1 year. The primary endpoint is 1-year PFS rate.Discussion: Compared with the conventional standard regimen in Japan, the SP regimen is expected to be associated with lower incidences of pneumonitis, esophagitis, and febrile neutropenia, which complicate the initiation of consolidation therapy with durvalumab, and have higher antitumor efficacy during chemoradiotherapy. Therefore, SP-based chemoradiotherapy is expected to be successfully followed by consolidation therapy with durvalumab in more patients, resulting in prolonged PFS and OS. Toxicity and efficacy results of the SP regimen in this study will also provide information important to the future establishment of the concurrent combination of chemoradiotherapy and durvalumab.Trial registration: Japan Registry of Clinical Trials, jRCTs031190127, registered 1 November 2019, https://jrct.niph.go.jp/latest-detail/jRCTs031190127 -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1758-8340 -SN - 1758-8359 -DA - 2021 FEB -PY - 2021 -VL - 13 -C7 - 1758835921998588 -DO - 10.1177/1758835921998588 -AN - WOS:000625060100001 -AD - Teikyo Univ, Div Med Oncol, Dept Internal Med, Sch Med,Itabashi Ku, 2-11-1 Kaga, Tokyo 1738606, Japan -AD - Teikyo Univ, Div Med Oncol, Dept Internal Med, Sch Med, Itabashi City, Tokyo, Japan -AD - Kumamoto City Hosp, Dept Med Oncol, Kumamoto, Kumamoto, Japan -AD - Kouseiren Takaoka Hosp, Dept Med Oncol, Takaoka, Toyama, Japan -AD - Natl Hosp Org Okayama Med Ctr, Dept Resp Med, Okayama, Okayama, Japan -AD - Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Okayama, Japan -AD - Saitama Med Univ, Dept Resp Med, Int Med Ctr, Hidaka City, Saitama, Japan -AD - Yokohama City Univ, Dept Biostat, Sch Med, Yokohama, Kanagawa, Japan -AD - Teikyo Univ, Dept Radiol, Sch Med, Itabashi City, Tokyo, Japan -AD - Teikyo Univ, Dept Surg, Mizonokuchi Hosp, Kawasaki, Kanagawa, Japan -AD - Hirosaki Univ, Dept Resp Med, Grad Sch Med, Hirosaki, Aomori, Japan -AD - Kumamoto City Hosp, Dept Resp Med, Kumamoto, Kumamoto, Japan -AD - Ehime Prefectural Cent Hosp, Dept Resp Med, Matsuyama, Ehime, Japan -AD - Tochigi Canc Ctr, Div Thorac Oncol, Dept Med Oncol, Utsunomiya, Tochigi, Japan -AD - Shin Yurigaoka Gen Hosp, Dept Resp Med, Kawasaki, Kanagawa, Japan -AD - Teikyo Univ, Dept Internal Med, Mizonokuchi Hosp, Kawasaki, Kanagawa, Japan -AD - Natl Hosp Org Iwakuni Clin Ctr, Dept Resp Med, Iwakuni City, Yamaguchi, Japan -AD - Saiseikai Yokohamashi Nanbu Hosp, Dept Resp Med, Yokohama, Kanagawa, Japan -AD - Saga Univ, Div Hematol Resp Med & Oncol, Dept Internal Med, Fac Med, Saga, Saga, Japan -AD - Kagawa Prefectural Cent Hosp, Dept Resp Med, Takamatsu, Kagawa, Japan -AD - Showa Univ, Dept Internal Med, Northern Yokohama Hosp, Yokohama, Kanagawa, Japan -AD - Fukuyama City Hosp, Dept Internal Med, Fukuyama, Hiroshima, Japan -AD - Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Hiroshima, Japan -AD - Oita Prefectural Hosp, Dept Thorac Med Oncol, Oita, Oita, Japan -AD - Natl Hosp Org Tokyo Natl Hosp, Ctr Pulm Dis, Kiyose, Tokyo, Japan -AD - Okayama Rosai Hosp, Dept Med Oncol, Okayama, Okayama, Japan -AD - Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan -AD - Chugoku Cent Hosp, Dept Resp Med, Fukuyama, Hiroshima, Japan -AD - Toyama Prefectural Cent Hosp, Dept Resp Med, Toyama, Toyama, Japan -AD - Hirosaki Hosp, Natl Hosp Org, Dept Resp Med, Hirosaki, Aomori, Japan -AD - Tsuboi Hosp, Dept Resp Med, Koriyama, Fukushima, Japan -AD - Nihon Univ, Div Resp Med, Dept Internal Med, Sch Med, Itabashi City, Tokyo, Japan -AD - Tokyo Saiseikai Cent Hosp, Dept Pulm Med, Minato City, Tokyo, Japan -AD - Showa Univ, Div Allergol & Resp Med, Sch Med, Shinagawa City, Tokyo, Japan -AD - Toyama Univ Hosp, Clin Oncol, Toyama, Toyama, Japan -AD - Fukui Ken Saiseikai Hosp, Dept Resp Med, Fukui, Fukui, Japan -AD - Kawasaki Med Sch, Gen Internal Med 4, Okayama, Okayama, Japan -AD - Natl Hosp Org Yamaguchi Ube Med Ctr, Dept Med Oncol, Ube, Yamaguchi, Japan -AD - Kagawa Univ, Div Hematol Rheumatol & Resp Med, Dept Internal Med, Fac Med, Takamatsu, Kagawa, Japan -AD - Kumamoto Reg Med Ctr, Dept Resp Med, Kumamoto, Kumamoto, Japan -AD - Karatsu Red Cross Hosp, Dept Internal Med, Karatsu, Saga, Japan -M2 - Kumamoto City Hosp -M2 - Kouseiren Takaoka Hosp -M2 - Natl Hosp Org Okayama Med Ctr -M2 - Japanese Red Cross Okayama Hosp -M2 - Kumamoto City Hosp -M2 - Ehime Prefectural Cent Hosp -M2 - Shin Yurigaoka Gen Hosp -M2 - Natl Hosp Org Iwakuni Clin Ctr -M2 - Saiseikai Yokohamashi Nanbu Hosp -M2 - Kagawa Prefectural Cent Hosp -M2 - Fukuyama City Hosp -M2 - Hiroshima Prefectural Hosp -M2 - Oita Prefectural Hosp -M2 - Natl Hosp Org Tokyo Natl Hosp -M2 - Okayama Rosai Hosp -M2 - Chugoku Cent Hosp -M2 - Toyama Prefectural Cent Hosp -M2 - Hirosaki Hosp -M2 - Tsuboi Hosp -M2 - Fukui Ken Saiseikai Hosp -M2 - Natl Hosp Org Yamaguchi Ube Med Ctr -M2 - Kumamoto Reg Med Ctr -M2 - Karatsu Red Cross Hosp -Y2 - 2021-03-14 -ER - - -TY - JOUR -AU - Metro, Giulio -AU - Addeo, Alfredo -AU - Signorelli, Diego -AU - Gili, Alessio -AU - Economopoulou, Panagiota -AU - Roila, Fausto -AU - Banna, Giuseppe -AU - De Toma, Alessandro -AU - Cobo, Juliana Rey -AU - Camerini, Andrea -AU - Christopoulou, Athina -AU - Lo Russo, Giuseppe -AU - Banini, Marco -AU - Galetta, Domenico -AU - Jimenez, Beatriz -AU - Collazo-Lorduy, Ana -AU - Calles, Antonio -AU - Baxevanos, Panagiotis -AU - Linardou, Helena -AU - Kosmidis, Paris -AU - Garassino, Marina C. -AU - Mountzios, Giannis -TI - Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort -T2 - JOURNAL OF THORACIC DISEASE -M3 - Article -AB - Background: In this real-world multicenter study we addressed the activity of post-progression anticancer treatments after first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC) patients with PD-L1 >= 50%.Methods: Clinico-pathological data of PD-L1 >= 50% advanced NSCLCs who failed first-line pembrolizumab were collected in 14 Oncologic Centers from different European countries. Types of subsequent anticancer treatment and outcomes on salvage chemotherapy or pembrolizumab beyond progression with or without the addition of local ablative therapies were reported.Results: Out of 173 patients, 100 had progressed on pembrolizumab, of which 60 patients (60%) met eligibility criteria and were treated with either salvage chemotherapy (42/60, 70%) or pembrolizumab beyond progression (18/60, 30%). Overall, median age was 66 years, 63.3% were male, 60.0% had a performance status of 0-1, 88.3% were smokers and 61.7% had adenocarcinoma histology. In patients evaluable for response, objective response rate to salvage chemotherapy was 41.9%, with no significant difference according to the type of regimen (42.9% for platinum-based and 40.0% for single-agent chemotherapy). Median progression-free survival (PFS) to salvage chemotherapy was 4.5 months. Among patients treated with pembrolizumab beyond progression, 13 out of 18 patients (72.2%) had progressive disease in <= 2 organ sites, of whom 9 (69.2%) were managed with the addition of local ablative therapies consisting of radiation at progressive lesion(s). No significant difference was noted in terms of post-progression survival between the salvage chemotherapy and the pembrolizumab beyond progression groups of patients (6.9 versus 8.1 months, respectively, P=0.08).Conclusions: In PD-L1 >= 50% advanced NSCLCs who progress on first-line pembrolizumab, salvage chemotherapy is associated with a remarkable anticancer activity, while select patients may benefit from continuation of pembrolizumab beyond progression, with the possible addition of local ablative radiotherapy in oligoprogressive cases. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2019 DEC -PY - 2019 -VL - 11 -IS - 12 -SP - 4972 -EP - 4981 -DO - 10.21037/jtd.2019.12.23 -AN - WOS:000505050300007 -AD - Azienda Osped Perugia, Santa Maria Misericordia Hosp, Med Oncol, Via Dottori 1, I-06156 Perugia, Italy -AD - Geneva Univ Hosp, Dept Oncol, Geneva, Switzerland -AD - Fdn IRCCS, Med Oncol Dept, Ist Nazl Tumori Milano, Milan, Italy -AD - Univ Perugia, Dept Expt Med, Publ Hlth Sect, Perugia, Italy -AD - Attikon Univ Hosp, Oncol Dept, Athens, Greece -AD - Osped Cannizzaro, Med Oncol, Catania, Italy -AD - Osped Versilia, UOC Oncol, Lido Di Camaiore, LU, Italy -AD - Agios Andreas Gen Hosp Patras, Med Oncol, Patras, Greece -AD - IRCCS Ist Tumori Giovanni Paolo II, Med Thorac Oncol Unit, Bari, Italy -AD - Hosp Univ HM Sanchinarro, Med Oncol, Madrid, Spain -AD - Hosp Gen Univ Gregorio Maranon, Div Med Oncol, Madrid, Spain -AD - St Savvas Anticanc Hosp, Dept Med Oncol 2, Athens, Greece -AD - Metropolitan Hosp, Dept Med Oncol 1, Athens, Greece -AD - Hygeia Hosp, Dept Med Oncol 2, Athens, Greece -AD - Henry Dunant Hosp Ctr, Dept Med Oncol 2, Athens, Greece -M2 - Osped Cannizzaro -M2 - Agios Andreas Gen Hosp Patras -M2 - Hosp Univ HM Sanchinarro -M2 - St Savvas Anticanc Hosp -M2 - Metropolitan Hosp -Y2 - 2020-01-14 -ER - - -TY - JOUR -AU - OLIVER, TRUDY GALE -TI - Mechanisms of Arginine Deprivation in Small Cell Lung Cancer -M3 - Awarded Grant -AB - Project SummarySmall cell lung cancer (SCLC) is a highly aggressive neuroendocrine lung tumor responsible for over 30,000deaths each year in the US. SCLC has a two-year survival rate of ~6% with no approved targeted therapiesbeyond the recent approval of immunotherapy. SCLC is initially highly responsive to chemotherapy, but rapidlydevelops resistance leading to mortality in ~12 months. A major unmet need for SCLC treatment is theidentification of new therapeutic targets and treatment strategies. SCLC has historically been treated as a singledisease without patient stratification. SCLC is driven by distinct MYC family members (MYCL or MYC), whichare notoriously difficult to drug. We and others showed that MYC and MYCL-driven SCLC have distinct molecularphenotypes with unique vulnerabilities to targeted therapies. We performed unbiased metabolite profiling onMYC versus MYCL-driven subtypes of SCLC and found that they are metabolically distinct. Using human celllines, genetically-engineered mouse models (GEMMs), and human patient-derived xenografts (PDX), we foundthat MYC-driven SCLC is uniquely dependent on the amino acid arginine. Arginine depletion with pegylatedarginine deiminase (ADI-PEG20) is the most effective drug we have tested in >25 drug combinations in GEMMs.Consistently, MYC-driven SCLC has reduced ASS1 expression, the enzyme required to synthesize arginine. Inpreliminary data, we discovered that MYC-driven tumor cells treated with ADI-PEG20 undergo autophagy andferroptosis. After dramatic initial responses, tumors eventually relapse with re-expression of ASS1 and metabolicreprogramming with changes in one-carbon, polyamine, and ferroptosis-related pathways. We hypothesize thatarginine deprivation in MYC-driven SCLC promotes autophagy and death by ferroptosis, and that inhibition offerroptosis will improve the efficacy of ADI-PEG20. We also hypothesize that during ADI-PEG20 resistance, re-expression of ASS1 leads to metabolic reprogramming that can be blocked by targeting new metabolic pathways.To test these hypotheses, our objectives are: 1) Determine the function of autophagy and ferroptosis in responseto arginine deprivation in SCLC. 2) Determine mechanisms of resistance to ADI-PEG20 and test newcombination strategies to increase the efficacy of ADI-PEG20 treatment. This approach is innovative becausewe will employ our immune-competent GEMM of MYC-driven SCLC and new human PDX that recapitulate keyfeatures of the human disease. We will integrate state-of-the-art technologies in metabolite profiling and singlecell RNA-seq to understand the mechanisms of resistance to arginine deprivation in vivo. This research issignificant because arginine deprivation is being tested in numerous clinical trials in various cancer types andwe are currently designing new clinical trials for ADI-PEG20 in SCLC. A better understanding of the functions ofarginine deprivation may improve treatment of MYC-driven cancers and lead to more effective combinationtreatment strategies. -DA - 2023 -PY - 2023 -AN - GRANTS:17753651 -G1 - 10701855; 5R01CA251147-03; R01CA251147 -AD - DUKE UNIVERSITY -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - Ciammella, Patrizia -AU - Cozzi, Salvatore -AU - Borghetti, Paolo -AU - Galaverni, Marco -AU - Nardone, Valerio -AU - Ruggieri, Maria Paola -AU - Sepulcri, Matteo -AU - Scotti, Vieri -AU - Bruni, Alessio -AU - Zanelli, Francesca -AU - Piro, Roberto -AU - Tagliavini, Elena -AU - Botti, Andrea -AU - Iori, Federico -AU - Ali, Emanuele -AU - Bennati, Chiara -AU - Tiseo, Marcello -TI - Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis -T2 - FRONTIERS IN ONCOLOGY -M3 - Article -AB - Background Chemoradiation therapy (CRT) is the treatment of choice for locally advanced non-small cell lung cancer (LA-NSCLC). Several clinical trials that combine programmed cell death 1 (PD1) axis inhibitors with radiotherapy are in development for patients with LA-NSCLC. However, the effect of CRT on tumor cells programmed cell death ligand-1 (PD-L1) expression is unknown.Methods In this multicentric retrospective study, we analyzed paired NSCLC specimens that had been obtained pre- and post-CRT. PD-L1 expression on tumor cells was studied by immunohistochemistry. The purpose of this study was to evaluate the feasibility, risk of complications, and clinical relevance of performing re-biopsy after CRT in patients with PD-L1 negative LA-NSCLC.Results Overall, 31 patients from 6 centers with PD-L1 negative LA-NSCLC were analyzed. The percentage of tumor cells with PD-L1 expression significantly increased between pre- and post-CRT specimens in 14 patients (45%). Nine patients had unchanged PD-L1 expression after CRT, in five patients the rebiopsy material was insufficient for PD-L1 analysis and in two patients no tumor cells at rebiopsy were found. The post-rebiopsy complication rate was very low (6%). All patients with positive PD-L1 re-biopsy received Durvalumab maintenance after CRT, except one patient who had a long hospitalization for tuberculosis reactivation. Median PFS of patients with unchanged or increased PD-L1 expression was 10 and 16.9 months, respectively.Conclusion CRT administration can induce PD-L1 expression in a considerable fraction of PD-L1 negative patients at baseline, allowing them receiving the maintenance Durvalumab in Europe. Hence, after a definitive CRT, PD-L1 redetermination should be considered in patients with LA-NSCLC PD-L1 negative, to have a better selection of maintenance Durvalumab candidates. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2024 JAN 31 -PY - 2024 -VL - 14 -C7 - 1325249 -DO - 10.3389/fonc.2024.1325249 -AN - WOS:001161256700001 -AD - Azienda USL IRCCS Reggio Emilia, Radiat Oncol Unit, Reggio Emilia, Italy -AD - Ctr Leon Berard, Radiat Oncol Dept, Lyon, France -AD - Univ Brescia, Dipartimento Radioterapia Oncol, Brescia, Italy -AD - ASST Spedali Civili Brescia, Brescia, Italy -AD - Univ Hosp Parma, Radiat Oncol Unit, Parma, Italy -AD - Univ Campania L Vanvitelli, Dipartimento Med Precis, Naples, Italy -AD - Veneto Inst Oncol IOV IRCCS, Radiat Oncol Unit, Padua, Italy -AD - Azienda Osped Univ Careggi, Oncol Dept, Florence, Italy -AD - Univ Hosp Modena, Dept Oncol & Hematol, Radiat Therapy Unit, Modena, Italy -AD - Azienda Unita Sanit Locale IRCCS Reggio Emilia, Oncol Unit, Reggio Emilia, Italy -AD - Azienda Unita Sanit Locale IRCCS Reggio Emilia, Pulmonol Unit, Reggio Emilia, Italy -AD - Azienda USL IRCCS Reggio Emilia, Pathol Unit, Reggio Emilia, Italy -AD - Azienda USL IRCCS Reggio Emilia, Med Phys Unit, Reggio Emilia, Italy -AD - Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Clin & Expt Med PhD Program, Modena, Italy -AD - S Maria delle Croci Hosp, Dept Hematol Onco, Ravenna, Italy -AD - Univ Parma, Dept Med & Surg, Parma, Italy -M2 - Azienda USL IRCCS Reggio Emilia -M2 - Azienda Unita Sanit Locale IRCCS Reggio Emilia -M2 - Azienda Unita Sanit Locale IRCCS Reggio Emilia -M2 - Azienda USL IRCCS Reggio Emilia -M2 - Azienda USL IRCCS Reggio Emilia -M2 - S Maria delle Croci Hosp -Y2 - 2024-02-24 -ER - - -TY - JOUR -AU - Almuradova, Elvina -AU - Menekse, Serkan -TI - Survival outcomes and prognostic nutritional index in very elderly small-cell lung cancer patients: importance of active treatment and nutritional support -T2 - AGING MALE -M3 - Article -AB - Background: Small-cell lung cancer (SCLC) is a highly aggressive tumor with a high metastatic potential, particularly affecting current or former heavy smokers. Treatment typically involves chemotherapy, often combined with radiotherapy, and immunotherapy for extensive disease. Prophylactic cranial irradiation is recommended to reduce brain metastases. Elderly SCLC patients face unique challenges due to frailty and comorbidities, leading to increased risks of treatment-related toxicity and malnutrition. The prognostic nutritional index (PNI), a composite marker of nutritional and immune status, has shown promise in predicting outcomes in various malignancies. However, the optimal treatment approach for very elderly SCLC patients remains unclear, as they are often excluded from clinical trials.Aims: This study aimed to evaluate the survival outcomes of SCLC patients aged 75 years or older and their correlation with PNI.Study design Retrospective cohort study.Methods: The study retrospectively analyzed data from 71 SCLC patients aged =75 years, focusing on age, gender, smoking status, chronic diseases, performance status, clinical stage, treatment modality, and pretreatment PNI. Survival estimates were calculated using the Kaplan-Meier method, and multivariate Cox regression analysis was performed to identify independent predictors of overall survival (OS).Results: The results demonstrated that 26.8% of very elderly SCLC patients received no active treatment, resulting in a significantly shorter median survival time of 1.3 months. In contrast, patients who underwent aggressive treatment, such as palliative chemotherapy or chemotherapy plus radiotherapy, had significantly longer median survival times. Multivariate analysis revealed that receiving chemotherapy plus radiotherapy was associated with a significant survival benefit compared to no treatment. Furthermore, low PNI (=40) was independently associated with decreased OS.Conclusion: This study highlights the importance of active treatment and nutritional support in improving survival outcomes for very elderly SCLC patients. The findings suggest that low PNI and lack of oncological treatment are associated with worse survival outcomes. Therefore, integrating nutritional assessment, interventions, and appropriate treatment strategies are crucial in managing lung cancer patients. Larger, multicenter studies are needed to validate these findings and explore potential interventions to optimize nutritional status and improve outcomes for elderly patients with SCLC. -PU - TAYLOR & FRANCIS LTD -PI - ABINGDON -PA - 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND -SN - 1368-5538 -SN - 1473-0790 -DA - 2023 DEC 31 -PY - 2023 -VL - 26 -IS - 1 -C7 - 2251573 -DO - 10.1080/13685538.2023.2251573 -AN - WOS:001057362100001 -AD - Ege Univ, Fac Med, Dept Med Oncol, Izmir, Turkiye -AD - Manisa City Hosp, Dept Nucl Med, Manisa, Turkiye -M2 - Manisa City Hosp -Y2 - 2023-09-08 -ER - - -TY - JOUR -AU - OLIVER, TRUDY GALE -TI - Mechanisms of Arginine Deprivation in Small Cell Lung Cancer -M3 - Awarded Grant -AB - Project SummarySmall cell lung cancer (SCLC) is a highly aggressive neuroendocrine lung tumor responsible for over 30,000deaths each year in the US. SCLC has a two-year survival rate of ~6% with no approved targeted therapiesbeyond the recent approval of immunotherapy. SCLC is initially highly responsive to chemotherapy, but rapidlydevelops resistance leading to mortality in ~12 months. A major unmet need for SCLC treatment is theidentification of new therapeutic targets and treatment strategies. SCLC has historically been treated as a singledisease without patient stratification. SCLC is driven by distinct MYC family members (MYCL or MYC), whichare notoriously difficult to drug. We and others showed that MYC and MYCL-driven SCLC have distinct molecularphenotypes with unique vulnerabilities to targeted therapies. We performed unbiased metabolite profiling onMYC versus MYCL-driven subtypes of SCLC and found that they are metabolically distinct. Using human celllines, genetically-engineered mouse models (GEMMs), and human patient-derived xenografts (PDX), we foundthat MYC-driven SCLC is uniquely dependent on the amino acid arginine. Arginine depletion with pegylatedarginine deiminase (ADI-PEG20) is the most effective drug we have tested in >25 drug combinations in GEMMs.Consistently, MYC-driven SCLC has reduced ASS1 expression, the enzyme required to synthesize arginine. Inpreliminary data, we discovered that MYC-driven tumor cells treated with ADI-PEG20 undergo autophagy andferroptosis. After dramatic initial responses, tumors eventually relapse with re-expression of ASS1 and metabolicreprogramming with changes in one-carbon, polyamine, and ferroptosis-related pathways. We hypothesize thatarginine deprivation in MYC-driven SCLC promotes autophagy and death by ferroptosis, and that inhibition offerroptosis will improve the efficacy of ADI-PEG20. We also hypothesize that during ADI-PEG20 resistance, re-expression of ASS1 leads to metabolic reprogramming that can be blocked by targeting new metabolic pathways.To test these hypotheses, our objectives are: 1) Determine the function of autophagy and ferroptosis in responseto arginine deprivation in SCLC. 2) Determine mechanisms of resistance to ADI-PEG20 and test newcombination strategies to increase the efficacy of ADI-PEG20 treatment. This approach is innovative becausewe will employ our immune-competent GEMM of MYC-driven SCLC and new human PDX that recapitulate keyfeatures of the human disease. We will integrate state-of-the-art technologies in metabolite profiling and singlecell RNA-seq to understand the mechanisms of resistance to arginine deprivation in vivo. This research issignificant because arginine deprivation is being tested in numerous clinical trials in various cancer types andwe are currently designing new clinical trials for ADI-PEG20 in SCLC. A better understanding of the functions ofarginine deprivation may improve treatment of MYC-driven cancers and lead to more effective combinationtreatment strategies. -DA - 2021 -PY - 2021 -AN - GRANTS:15587480 -G1 - 10295695; 1R01CA251147-01A1; R01CA251147 -AD - UNIVERSITY OF UTAH -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - OLIVER, TRUDY GALE -TI - Mechanisms of Arginine Deprivation in Small Cell Lung Cancer -M3 - Awarded Grant -AB - Project SummarySmall cell lung cancer (SCLC) is a highly aggressive neuroendocrine lung tumor responsible for over 30,000deaths each year in the US. SCLC has a two-year survival rate of ~6% with no approved targeted therapiesbeyond the recent approval of immunotherapy. SCLC is initially highly responsive to chemotherapy, but rapidlydevelops resistance leading to mortality in ~12 months. A major unmet need for SCLC treatment is theidentification of new therapeutic targets and treatment strategies. SCLC has historically been treated as a singledisease without patient stratification. SCLC is driven by distinct MYC family members (MYCL or MYC), whichare notoriously difficult to drug. We and others showed that MYC and MYCL-driven SCLC have distinct molecularphenotypes with unique vulnerabilities to targeted therapies. We performed unbiased metabolite profiling onMYC versus MYCL-driven subtypes of SCLC and found that they are metabolically distinct. Using human celllines, genetically-engineered mouse models (GEMMs), and human patient-derived xenografts (PDX), we foundthat MYC-driven SCLC is uniquely dependent on the amino acid arginine. Arginine depletion with pegylatedarginine deiminase (ADI-PEG20) is the most effective drug we have tested in >25 drug combinations in GEMMs.Consistently, MYC-driven SCLC has reduced ASS1 expression, the enzyme required to synthesize arginine. Inpreliminary data, we discovered that MYC-driven tumor cells treated with ADI-PEG20 undergo autophagy andferroptosis. After dramatic initial responses, tumors eventually relapse with re-expression of ASS1 and metabolicreprogramming with changes in one-carbon, polyamine, and ferroptosis-related pathways. We hypothesize thatarginine deprivation in MYC-driven SCLC promotes autophagy and death by ferroptosis, and that inhibition offerroptosis will improve the efficacy of ADI-PEG20. We also hypothesize that during ADI-PEG20 resistance, re-expression of ASS1 leads to metabolic reprogramming that can be blocked by targeting new metabolic pathways.To test these hypotheses, our objectives are: 1) Determine the function of autophagy and ferroptosis in responseto arginine deprivation in SCLC. 2) Determine mechanisms of resistance to ADI-PEG20 and test newcombination strategies to increase the efficacy of ADI-PEG20 treatment. This approach is innovative becausewe will employ our immune-competent GEMM of MYC-driven SCLC and new human PDX that recapitulate keyfeatures of the human disease. We will integrate state-of-the-art technologies in metabolite profiling and singlecell RNA-seq to understand the mechanisms of resistance to arginine deprivation in vivo. This research issignificant because arginine deprivation is being tested in numerous clinical trials in various cancer types andwe are currently designing new clinical trials for ADI-PEG20 in SCLC. A better understanding of the functions ofarginine deprivation may improve treatment of MYC-driven cancers and lead to more effective combinationtreatment strategies. -DA - 2022 -PY - 2022 -AN - GRANTS:16273949 -G1 - 10642432; 7R01CA251147-02; R01CA251147 -AD - DUKE UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Desai, Aakash -AU - Lovly, Christine M. -TI - Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Background and Objective: Anaplastic lymphoma kinase (ALK) rearrangements are detected in 3-7% of advanced non-small cell lung cancer (NSCLC). There are currently 5 U.S Food and Drug Administration (FDA)-approved ALK tyrosine kinase inhibitors (TKIs) for the treatment of patients with ALK-positive lung cancer in the advanced/metastatic disease setting. Despite these advances, most patients with ALK-positive lung cancer who are treated with ALK TKI therapy ultimately experience disease progression due to various mechanisms of drug resistance. In this review, we discuss strategies to address acquired therapeutic resistance to ALK inhibition, novel agents and combinatorial strategies in development for both on and off-target resistance, and some emerging approaches to prolong response to ALK inhibitors.Methods: We performed a search of peer-reviewed literature in the English language, conference abstracts, and trial registrations from the MEDLINE (Ovid), Embase (Elsevier), and CENTRAL (Cochrane Library) databases and major international oncology meetings up to August 2022. We then screened for studies describing interventions to overcome ALK resistance based on review of each title and abstract. Key Content and Findings: For patients with oligo-progression, treatment may include maintaining the same systemic treatment beyond progression while adding local therapies to progressing lesions. Strategies to combat ALK TKI resistance mediated by on-target resistance mechanisms include 4th generation TKIs (TPX-0131, NVL-655) and Proteolysis-targeting chimeras (PROTACs) currently in development. While for those patients who develop tumor progression due to off-target (ALK independent) resistance, options may include combination therapies targeting ALK and other downstream or parallel pathways, novel antibody drug conjugates, or combinations of ALK inhibitors with chemotherapy and immunotherapy. Lastly, other potential strategies being explored in the clinic include circulating tumor DNA (ctDNA) surveillance to monitor for molecular mediators of drug resistance prior to frank progression on imaging studies and utilization of ALK TKIs in the adjuvant and neoadjuvant settings.Conclusions: Strategies to overcome resistance to currently available ALK inhibitors are urgently needed. Given the variety of resistance mechanisms, tailormade approaches are required for disease control. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2023 MAR -PY - 2023 -VL - 12 -IS - 3 -SP - 615 -EP - 628 -DO - 10.21037/tlcr-22-708 -AN - WOS:000961884600001 -C6 - MAR 2023 -AD - Mayo Clin, Div Med Oncol, Rochester, MN USA -AD - Vanderbilt Univ, Dept Med, Div Hematol Oncol, Med Ctr, Nashville, TN USA -AD - Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN USA -AD - 2220 Pierce Ave South,777 PRB, Nashville, TN 37232 USA -Y2 - 2024-03-02 -ER - - -TY - JOUR -AU - Tanzawa, Shigeru -AU - Makiguchi, Tomonori -AU - Tasaka, Sadatomo -AU - Inaba, Megumi -AU - Ochiai, Ryosuke -AU - Nakamura, Junya -AU - Inoue, Koji -AU - Kishikawa, Takayuki -AU - Nakashima, Masanao -AU - Fujiwara, Keiichi -AU - Kohyama, Tadashi -AU - Ishida, Hiroo -AU - Kuyama, Shoichi -AU - Miyazawa, Naoki -AU - Nakamura, Tomomi -AU - Miyawaki, Hiroshi -AU - Oda, Naohiro -AU - Ishikawa, Nobuhisa -AU - Morinaga, Ryotaro -AU - Kusaka, Kei -AU - Miyamoto, Yosuke -AU - Yokoyama, Toshihide -AU - Matsumoto, Chiaki -AU - Tsuda, Takeshi -AU - Ushijima, Sunao -AU - Shibata, Kazuhiko -AU - Shibayama, Takuo -AU - Bessho, Akihiro -AU - Kaira, Kyoichi -AU - Misumi, Toshihiro -AU - Shiraishi, Kenshiro -AU - Matsutani, Noriyuki -AU - Seki, Nobuhiko -TI - Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study) -T2 - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY -M3 - Article -AB - Background: The standard of care for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC trial. Disease progression and pneumonitis were reported as the main reasons to preclude the initiation of durvalumab in multiple retrospective studies. However, the transition rate and the reasons for failure to proceed to consolidation therapy with durvalumab after CRT were not evaluated prospectively. Although phase II studies in Japan have shown high efficacy and tolerability of CRT with cisplatin + S-1 (SP), no prospective study using durvalumab after SP-based CRT has yet been reported. We therefore conducted a phase II study to verify the efficacy and safety of durvalumab following SP-based CRT. In this interim analysis, we report the transition rate and the reasons for its failure.Methods: In treatment-naive LA-NSCLC, cisplatin (60 mg/m(2), day 1) and S-1 (80-120 mg/body, days 1-14) were administered with two 4-week cycles with concurrent thoracic radiotherapy (60 Gy) followed by durvalumab every 2 weeks for up to 12 months. The primary endpoint was 12 month progression-free survival rate.Results: Fifty-nine patients were enrolled, of whom 86.4% (51/59) proceeded to durvalumab. All of them initiated durvalumab within 42 days after CRT [median 18 days (range: 3-38)], including 27.5% (14/51) in <14 days. Common reasons for failure to proceed to durvalumab were disease progression (2/59, 3.4%) and adverse events (6/59, 10.2%). Among the latter cases, four resumed treatment and proceeded to durvalumab within 42 days on off-protocol. The objective response rate and the disease control rate were 62.7% and 93.2%, respectively. The incidences of >= grade 3 pneumonitis, febrile neutropenia, and esophagitis were 0%, 8.5%, and 3.4%, respectively.Conclusion: Regarding durvalumab after CRT, this interim analysis of the SAMURAI study clarified the high transition rate, early introduction, and reasons for failure to proceed to consolidation therapy, which were not determined in the PACIFIC trial. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1758-8340 -SN - 1758-8359 -DA - 2022 JUL -PY - 2022 -VL - 14 -C7 - 17588359221116603 -DO - 10.1177/17588359221116603 -AN - WOS:000835671100001 -AD - Teikyo Univ, Sch Med, Dept Internal Med, Div Med Oncol,Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan -AD - Hirosaki Univ, Grad Sch Med, Dept Resp Med, Hirosaki, Aomori, Japan -AD - Kumamoto City Hosp, Dept Resp Med, Kumamoto, Kumamoto, Japan -AD - Ehime Prefectural Cent Hosp, Dept Resp Med, Matsuyama, Ehime, Japan -AD - Tochigi Canc Ctr, Dept Resp Med, Utsunomiya, Tochigi, Japan -AD - Shin Yurigaoka Gen Hosp, Dept Resp Med, Kawasaki, Kanagawa, Japan -AD - Natl Hosp Org Okayama Med Ctr, Dept Resp Med, Okayama, Okayama, Japan -AD - Teikyo Univ, Mizonokuchi Hosp, Dept Internal Med, Kawasaki, Kanagawa, Japan -AD - Showa Univ, Northern Yokohama Hosp, Dept Internal Med, Yokohama, Kanagawa, Japan -AD - Natl Hosp Org Iwakuni Clin Ctr, Dept Resp Med, Yamaguchi, Japan -AD - Saiseikai Yokohamashi Nanbu Hosp, Dept Resp Med, Yokohama, Kanagawa, Japan -AD - Saga Univ, Fac Med, Dept Internal Med, Div Hematol Resp Med & Oncol, Saga, Saga, Japan -AD - Kagawa Prefectural Cent Hosp, Dept Resp Med, Takamatsu, Kagawa, Japan -AD - Fukuyama City Hosp, Dept Internal Med, Fukuyama, Hiroshima, Japan -AD - Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Hiroshima, Japan -AD - Oita Prefectural Hosp, Dept Thorac Med Oncol, Oita, Oita, Japan -AD - Natl Hosp Org Tokyo Natl Hosp, Ctr Pulm Dis, Tokyo, Japan -AD - Okayama Rosai Hosp, Dept Med Oncol, Okayama, Okayama, Japan -AD - Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan -AD - Chugoku Cent Hosp, Dept Resp Med, Fukuyama, Hiroshima, Japan -AD - Toyama Prefectural Cent Hosp, Dept Resp Med, Toyama, Toyama, Japan -AD - Kumamoto Kenhoku Hosp, Dept Med Oncol, Kumamoto, Japan -AD - Kouseiren Takaoka Hosp, Dept Med Oncol, Takaoka, Toyama, Japan -AD - Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Okayama, Japan -AD - Saitama Med Univ, Int Med Ctr, Dept Resp Med, Saitama, Japan -AD - Yokohama City Univ, Sch Med, Dept Biostat, Yokohama, Kanagawa, Japan -AD - Teikyo Univ, Sch Med, Dept Radiol, Itabashi Ku, Tokyo, Japan -AD - Teikyo Univ, Mizonokuchi Hosp, Dept Surg, Kawasaki, Kanagawa, Japan -M2 - Kumamoto City Hosp -M2 - Ehime Prefectural Cent Hosp -M2 - Shin Yurigaoka Gen Hosp -M2 - Natl Hosp Org Okayama Med Ctr -M2 - Natl Hosp Org Iwakuni Clin Ctr -M2 - Saiseikai Yokohamashi Nanbu Hosp -M2 - Kagawa Prefectural Cent Hosp -M2 - Fukuyama City Hosp -M2 - Hiroshima Prefectural Hosp -M2 - Oita Prefectural Hosp -M2 - Natl Hosp Org Tokyo Natl Hosp -M2 - Okayama Rosai Hosp -M2 - Chugoku Cent Hosp -M2 - Toyama Prefectural Cent Hosp -M2 - Kumamoto Kenhoku Hosp -M2 - Kouseiren Takaoka Hosp -M2 - Japanese Red Cross Okayama Hosp -Y2 - 2022-08-12 -ER - - -TY - JOUR -AU - Zhao, Guangyin -AU - Zhang, Hongyu -AU - Xu, Fengkai -AU - Lu, Chunlai -AU - Zhu, Qiaoliang -AU - Grossi, Francesco -AU - Divisi, Duilio -AU - Ma, Teng -AU - Gu, Jie -AU - Ge, Di -TI - Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Article -AB - Background: Pembrolizumab has been shown to be effective and safe in improving the survival of patients with advanced non-small-cell lung cancer (NSCLC). However, the effectiveness and safty of pembrolizumab in the induction treatment of patients with potential resectable clinical stage III NSCLC remains undetermined.Methods: A total of 25 patients who received neoadjuvant pembrolizumab plus chemotherapy for preoperative stage III NSCLC between August 2020 and November 2021 in Zhongshan Hospital were retrospectively evaluated, and 21 of them were followed by pulmonary resection. The neoadjuvant treatment was as follows: intravenous pembrolizumab (200 mg) on day 1, carboplatin [target area under the curve (AUC) 5 mg/mL] or cisplatin (75 mg/m(2)) on day 1, and pemetrexed ( 500 mg/m(2) for adenocarcinoma) or nabpaclitaxel (260 mg/m(2) for other subtypes) on day 1 of every 21-day cycle up to two or three cycles.Results: The mean age of all 25 patients was 65 years, of whom 22 were men and 3 were women. Seventeen were diagnosed before treatment as clinical stage IIIA, seven as IIIB, and one as IIB. All received neoadjuvant immunotherapy plus chemotherapy. Following induction therapy, 21 patients with stable disease or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) underwent surgical resection without delay. Among the patients who underwent operation, major pathological response (MPR) was achieved in 13 patients, including 6 (28.6%) patients achieved a complete pathological response (CPR). Two patients with partial radiologic remission refused operative treatment, one had progressive disease (PD), and another developed a grade immune pneumonia and could not tolerate surgery. However, none of the adverse events caused surgery delays or deaths.Conclusions: Neoadjuvant pembrolizumab plus chemotherapy could be considered reliable for clinical stage III NSCLC, but needs to be validated with more robust clinical trials. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2023 JAN -PY - 2023 -VL - 12 -IS - 1 -SP - 141 -EP - 149 -DO - 10.21037/tlcr-22-871 -AN - WOS:000915020600001 -C6 - JAN 2023 -AD - Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, Shanghai 200032, Peoples R China -AD - Univ Insubria, ASST Sette Laghi, Dept Med & Surg, Med Oncol Unit, Varese, Italy -AD - Univ Aquila, Giuseppe Mazzini Hosp Teramo, Dept Life Hlth & Environm Sci, Thorac Surg Unit, Teramo, Italy -Y2 - 2023-02-08 -ER - - -TY - JOUR -AU - Edwards, Donna M -AU - Schonewolf, Caitlin A -AU - Rice, John D -AU - Schipper, Matthew -AU - Haken, Randall K Ten -AU - Matuszak, Martha -AU - Balter, James -AU - Jarema, David -AU - Arenberg, Douglas A -AU - Piert, Morand -AU - Qin, Angel -AU - Kalemkerian, Gregory P -AU - Schneider, Bryan J -AU - Ramnath, Nithya -AU - Chapman, Christina H -AU - Elliott, David A -AU - Lawrence, Theodore S -AU - Hearn, Jason -AU - Hayman, James A -AU - Jolly, Shruti -TI - Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer. -T2 - International journal of radiation oncology, biology, physics -M3 - Journal Article -AB - PURPOSE: Local failure rates after treatment for locally advanced non-small cell lung cancer (NSCLC) remain high. Efforts to improve local control with a uniform dose escalation or dose escalation to midtreatment positron emission tomography (PET)-avid residual disease have been limited by heightened toxicity. This trial aimed to refine response-based adaptive radiation therapy (RT) and minimize toxicity by incorporating fluorodeoxyglucose-PET (FDG-PET) and ventilation-perfusion single-photon emission computed tomography (SPECT) imaging midtreatment.METHODS AND MATERIALS: A total of 47 patients with stage IIA to III unresectable NSCLC were prospectively enrolled in this single-institution trial (NCT02492867). Patients received concurrent chemoradiation therapy with personalized response-based adaptive RT over 30 fractions incorporating ventilation-perfusion single-photon emission computed tomography and FDG-PET. The first 21 fractions (46.2 Gy at 2.2 Gy/fraction) were delivered to the tumor while minimizing the dose to the SPECT-defined functional lung. The plan was then adapted for the final 9 fractions (2.2-3.8 Gy/fraction) up to a total of 80.4 Gy, based on the midtreatment FDG-PET tumor response to escalate the dose to the residual tumor while minimizing the dose to the SPECT-defined functional lung. Nonprogressing patients received consolidative carboplatin, paclitaxel, or durvalumab. The primary endpoint of the study was ≥ grade 2 lung and esophageal toxicities. Secondary endpoints included time to local progression, tumor response, and overall survival.RESULTS: At 1 year posttreatment, the rates of grade 2 and grade 3 pneumonitis were 21.3% and 2.1%, respectively, with no difference in pneumonitis rates among patients who received and did not receive adjuvant durvalumab (P = .74). Although there were no grade 3 esophageal-related toxicities, 66.0% of patients experienced grade 2 esophagitis. The 1- and 2-year local control rates were 94.5% (95% CI, 87.4%-100%) and 87.5% (95% CI, 76.7%-100%), respectively. Overall survival was 82.8% (95% CI, 72.6%-94.4%) at 1 year and 62.3% (95% CI, 49.6%-78.3%) at 2 years.CONCLUSIONS: Response-based adaptive dose-escalation accounting for tumor change and normal tissue function during treatment provided excellent local control, comparable toxicity to standard chemoradiation therapy, and did not increase toxicity with adjuvant immunotherapy. -SN - 1879-355X -DA - 2024 Jul 04 (Epub 2024 Jul 04) -PY - 2024 -DO - 10.1016/j.ijrobp.2024.06.018 -AN - MEDLINE:38971385 -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. -AD - Department of Biostatistics, University of Michigan, Ann Arbor, Michigan. -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Biostatistics, University of Michigan, Ann Arbor, Michigan. -AD - Department of Medicine, Pulmonology, University of Michigan, Ann Arbor, Michigan. -AD - Department of Radiology, University of Michigan, Ann Arbor, Michigan. -AD - Department of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, Michigan. -AD - Department of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, Michigan; Section of Hematology Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan. -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan; Department of Radiation Oncology, Baylor College of Medicine, Houston, Texas. -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan. -AD - Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Electronic address: shrutij@med.umich.edu. -Y2 - 2024-07-08 -ER - - -TY - JOUR -AU - Tufman, Amanda -AU - Neumann, Jens -AU - Manapov, Farkhad -AU - Sellmer, Laura -AU - Jung, Andreas -AU - Kauffmann-Guerrero, Diego -AU - Kahnert, Kathrin -AU - Mertsch, Pontus -AU - Borgmeier, Astrid -AU - Semrau, Sabine -AU - Rittmeyer, Achim -AU - Ulm, Bernhard -AU - Ulm, Kurt -AU - Flentje, Michael -AU - Fietkau, Rainer -AU - Huber, Rudolf Maria -TI - Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT) -T2 - LUNG CANCER -M3 - Article -AB - Objectives: Immune checkpoint inhibition after radiochemotherapy (RTCT) has become a new standard of care for locally advanced non-small cell lung cancer with programmed death-ligand 1 (PD-L1) expression. However, little is known about the prognostic role of immune response markers in this setting. We analysed PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in tumour biopsies from the multicenter German Intergroup Lung Trial (GILT), which previously randomised patients with stage III NSCLC to RTCT with or without consolidation chemotherapy. Materials and methods: We retrospectively analyzed tumour biopsies from patients treated in the GILT trial. PD-L1 expression was analysed using the Ventana SP263 assay and TiL score (low, intermediate, high) and pattern (excluded, inflamed, desert) were assessed. The primary endpoint of the biomarker analysis was PFS in patients with PD-L1 > 1% vs. PD-L1 < 1% NSCLC. Secondary endpoints explored the prognostic relevance of additional PD-L1 expression levels and TiL score and pattern. Results: Biopsies were available from 92 patients treated with RTCT. Patients with available tumor tissue did not differ significantly from the whole study population. PD-L1 scores from 78 samples were available for analysis. There was no difference in PFS in the PD-L1 < 1% vs. PD-L1 > 1% subgroups. TiL score was available in 66 patients. Patients with high TiL score showed favourable overall survival compared to the low TiL subgroup. This trend was most pronounced in those patients treated with consolidative chemotherapy. Conclusion: In this analysis, PD-L1 expression did not correlate with PFS following RTCT. However, patients with TiLs > 10% were found to have longer overall survival, especially for those patients treated with consolidation chemotherapy after the end of RTCT. Further analyses to explore the prognostic and predictive relevance of TiLs in the context of consolidative checkpoint inhibition with durvalumab are required. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2021 OCT -PY - 2021 -VL - 160 -SP - 17 -EP - 27 -DO - 10.1016/j.lungcan.2021.07.008 -AN - WOS:000702866700003 -C6 - AUG 2021 -AD - Ludwig Maximilians Univ Munchen, Dept Internal Med 5, Thorac Oncol Ctr Munich, Ziemssenstr 1, D-80336 Munich, Germany -AD - German Ctr Lung Res DZL, Comprehens Pneumol Ctr Munich CPC M, Max Lebsche Pl 31, D-81377 Munich, Germany -AD - Ludwig Maximilians Univ Munchen, Inst Pathol, Fac Med, Thalkirchner Str 36, D-80337 Munich, Germany -AD - Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Univ Hosp, Marchioninistr 15, D-81377 Munich, Germany -AD - Univ Hosp Erlangen, Dept Radiat Oncol, Univ Str 27, D-91054 Erlangen, Germany -AD - Lung Clin Immenhausen, Dept Pneumol, Robert Koch Str 3, D-34376 Immenhausen, Germany -AD - Tech Univ Munich, Inst Med Informat Stat & Epidemiol, Ismaninger Str 22, D-81675 Munich, Germany -AD - Univ Hosp Wurzburg, Dept Radiat Oncol, Josef Schneider Str 2, D-97080 Wurzburg, Germany -AD - Tech Univ Munich, Sch Med, Dept Anaesthesiol & Intens Care Med, Munich, Germany -M2 - German Ctr Lung Res DZL -M2 - Lung Clin Immenhausen -Y2 - 2021-10-14 -ER - - -TY - JOUR -AU - Zhang, Yao -AU - Zhang, Lincheng -AU - Cao, Shuhui -AU - Wang, Yue -AU - Ling, Xuxinyi -AU - Zhou, Yan -AU - Zhong, Hua -TI - A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer -T2 - CANCER MEDICINE -M3 - Article -AB - Objective: Immunotherapy extensively treats advanced non-small-cell lung cancer (NSCLC). Although immunotherapy is generally better tolerated than chemotherapy, it can cause multiple immune-related adverse events (irAEs) involving multiple organs. Checkpoint inhibitor-related pneumonitis (CIP) is a relatively uncommon irAE that, in severe cases, can be fatal. Potential risk factors for the occurrence of CIP are currently poorly understood. This study sought to develop a novel scoring system for predicting the risk of CIP based on a nomogram model.Methods: We retrospectively collected advanced NSCLC patients who received immunotherapy at our institution between January 1, 2018, and December 30, 2021. All patients who met the criteria were randomly divided into the training set and testing set (in a ratio of 7:3), and cases fulfilling the CIP diagnostic criteria were screened. The patients' baseline clinical characteristics, laboratory tests, imaging, and treatment information were extracted from the electronic medical records. The risk factors associated with the occurrence of CIP were identified based on the results of logistic regression analysis on the training set, and a nomogram prediction model was developed. The discrimination and prediction accuracy of the model was evaluated using the receiver operating characteristic (ROC) curve, the concordance index (C-index), and the calibration curve. Decision curve analysis (DCA) was used to evaluate the clinical applicability of the model.Results: The training set comprised 526 (CIP: 42 cases), and the testing set comprised 226 (CIP: 18 cases) patients, respectively. In the training set, the final multivariate regression analysis revealed that age (p = 0.014; odds ratio [OR] = 1.056; 95% Confidence Interval [CI] =1.011-1.102), Eastern Cooperative Oncology Group performance status (p = 0.002; OR = 6.170; 95% CI = 1.943-19.590), history of prior radiotherapy (p < 0.001; OR = 4.005; 95% CI = 1.920-8.355), baseline white blood cell count (WBC) (p < 0.001; OR = 1.604; 95% CI = 1.250-2.059), and baseline absolute lymphocyte count (ALC) (p = 0.034; OR = 0.288; 95% CI = 0.091-0.909) were identified as independent risk factors for the occurrence of CIP. A prediction nomogram model was developed based on these five parameters. The area under the ROC curve and C-index of the prediction model in the training set and testing set were 0.787 (95% CI: 0.716-0.857) and 0.874 (95% CI: 0.792-0.957), respectively. The calibration curves are in good agreement. The DCA curves indicate that the model has good clinical utility.Conclusion: We developed a nomogram model that proved to be a good assistant tool for predicting the risk of CIP in advanced NSCLC. This model has the potential power to help clinicians in making treatment decisions. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2045-7634 -DA - 2023 AUG -PY - 2023 -VL - 12 -IS - 15 -SP - 15998 -EP - 16010 -DO - 10.1002/cam4.6244 -AN - WOS:001020963100001 -C6 - JUL 2023 -AD - Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Resp & Crit Care Med, Sch Med, Shanghai, Peoples R China -AD - Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Resp & Crit Care Med, Sch Med, Huaihai West Rd 241, Shanghai 200030, Peoples R China -Y2 - 2023-07-13 -ER - - -TY - JOUR -AU - Chu, Ngoc-Quynh -AU - Tan, Kay See -AU - Dycoco, Joe -AU - Adusumilli, Prasad S -AU - Bains, Manjit S -AU - Bott, Matthew J -AU - Downey, Robert J -AU - Gray, Katherine D -AU - Huang, James -AU - Isbell, James M -AU - Molena, Daniela -AU - Sihag, Smita -AU - Rocco, Gaetano -AU - Jones, David R -AU - Park, Bernard J -AU - Rusch, Valerie W -TI - Determinants of successful minimally invasive surgery for resectable non-small cell lung cancer after neoadjuvant therapy. -T2 - The Journal of thoracic and cardiovascular surgery -M3 - Journal Article -AB - OBJECTIVE: Minimally invasive surgery (MIS) (video-assisted thoracoscopic surgery and robot-assisted thoracoscopic surgery) for pulmonary resection is standard in early-stage non-small cell lung cancer because it is associated with better perioperative outcomes than thoracotomy. MIS for resection of more advanced non-small cell lung cancer (Stages IB-IIIB) treated with neoadjuvant therapy has been utilized. However, the determinants of success are not well defined.METHODS: A single institution retrospective review of a prospectively maintained database was conducted, querying for patients with clinical Stage IB through IIIB non-small cell lung cancer who had resection after neoadjuvant systemic therapy without radiation from 2013 to 2022. Patients were grouped by surgical approach; that is, open versus MIS. Successful MIS was defined by no conversion, R0 resection, and no major (grade 3 or greater) morbidity. Analyses by intent-to-treat assessed outcomes by Wilcoxon rank-sum test and Fisher exact test. (Multivariable regression analysis identified variables that contributed to successful MIS resection.) RESULTS: Of 627 eligible patients, 360 (57%) had open and 267 (43%) had MIS procedures. Most patients (79.1%) received neoadjuvant platinum-based chemotherapy, and 21.9% were treated with immunotherapy or targeted therapy alone or combined with chemotherapy. Among MIS resections, 179 (67%) were performed by video-assisted thoracoscopic surgery and 88 (33%) by robot-assisted thoracoscopic surgery. The conversion rate was 16% (n=43). Successful MIS resection was achieved in 77% of patients. Multivariable regression analysis showed that pretreatment clinical N stage was a significant determinant of success, but not pretreatment clinical T stage or type of neoadjuvant therapy.CONCLUSIONS: Following neoadjuvant systemic therapy for clinical stage IB or IIIB non-small cell lung cancer, MIS resection can be successfully accomplished and should be considered in appropriate patients. Presence of pretreatment nodal disease is associated with higher odds of conversion, major morbidity, and incomplete resection. -SN - 1097-685X -DA - 2024 Aug 20 (Epub 2024 Aug 20) -PY - 2024 -DO - 10.1016/j.jtcvs.2024.08.012 -AN - MEDLINE:39168279 -AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. -AD - Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. -AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: ruschv@mskcc.org. -Y2 - 2024-08-23 -ER - - -TY - JOUR -AU - Zhang, Yuanyuan -AU - Iyengar, Puneeth -AU - Montalvo, Steven -AU - Westover, Kenneth D -AU - Rashdan, Sawsan -AU - Donthireddy, Kavitha -AU - Kim, James -AU - Dowell, Jonathan E -AU - Drapkin, Benjamin -AU - Bhalla, Sheena -AU - Chukwuma, Christian -AU - Nadeem, Urooba -AU - Ahn, Chul -AU - Timmerman, Robert D -AU - Gerber, David E -TI - Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief Report. -T2 - International journal of radiation oncology, biology, physics -M3 - Journal Article -AB - PURPOSE: Consolidative durvalumab, an anti-programmed death ligand 1 (PDL1) immune checkpoint inhibitor, administered after concurrent chemoradiation improves outcomes of patients with locally advanced non-small cell lung cancer (NSCLC) without substantially increasing toxicities. We studied a chemotherapy-free regimen of thoracic radiation therapy (RT) with concurrent and consolidative durvalumab.METHODS AND MATERIALS: This single-arm phase 2 trial enrolled patients with stage III NSCLC (regardless of tumor PDL1 expression), Eastern Cooperative Oncology Group (ECOG) performance status 0-1, adequate pulmonary function, and RT fields meeting standard organ constraints. Participants received 2 cycles of durvalumab (1500 mg every 4 weeks) concurrently with thoracic RT (60 Gy in 30 fractions), followed by up to 13 cycles of consolidative durvalumab.RESULTS: After 10 patients were enrolled, the trial was closed because of poor clinical outcomes. With a median follow-up of 12 months, 5 patients had disease progression and 8 patients died. Six patients experienced 15 treatment-related, grade ≥3 events, including 1 grade 4 acute kidney injury during consolidation and 2 fatal pulmonary events. One fatal pulmonary event occurred during the concurrent phase in an active smoker; the other occurred after the first cycle of consolidative durvalumab. The primary endpoint of progression-free survival at 12 months was 20% (50% for PDL1≥1% vs 0% for PDL1 unavailable or <1%). Median overall survival was not reached, 10.5 months, and 7 months, for PDL1 ≥1%, <1%, and unavailable, respectively.CONCLUSIONS: In PDL1 unselected stage III NSCLC, thoracic RT plus concurrent and consolidative durvalumab is associated with high-grade toxicity and early disease progression. -SN - 1879-355X -DA - 2024 Aug 13 (Epub 2024 Aug 13) -PY - 2024 -DO - 10.1016/j.ijrobp.2024.07.2333 -AN - MEDLINE:39147210 -AD - Departments of Radiation Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: yuanyuan.zhang@utsouthwestern.edu. -AD - Departments of Radiation Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas. -AD - Division of Hematology-Oncology, Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas. -AD - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas. -AD - Peter O'Donnell, Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas. -AD - Division of Hematology-Oncology, Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; Peter O'Donnell, Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas. -Y2 - 2024-08-17 -ER - - -TY - PAT -AU - INBAL B -AU - MANDABI A -AU - PENROSE S D -AU - SIMHAEV ISCHAKOV L -AU - ALROY I -AU - WASSERMANN R -AU - SHEINBERGER Y -AU - WANG Y -AU - LI H -AU - WILLMS L -AU - SADLER S A -AU - CHU S -TI - New substituted 2-phenyl-5,6,7,8,8a,9-hexahydro-4aH-imidazo(1,2-a)indole-7-carboxamide compounds are cellular Myelocytomatosis messenger RNA translation modulators used for treating, suppressing, reducing severity and risk inhibiting cancer -AB - - NOVELTY - Substituted 2-phenyl-5,6,7,8,8a,9-hexahydro-4aH-imidazo[1,2-a]indole-7-carboxamide compounds (I) are new. - USE - (I) are useful: for treating, suppressing, reducing the severity, reducing risk of developing or inhibiting cancer in a subject; and suppressing, reducing or inhibiting tumor growth in a subject, where the cancer is breast cancer, ovarian carcinoma, acute myeloid leukemia, chronic myelogenous leukemia, Hodgkin's and Burkitt's lymphoma, diffuse large Bcell lymphoma, prostate cancer, colon cancer, gastric cancer, primary central nervous system lymphoma, glioblastoma, medulloblastoma, melanoma, non-small cell lung carcinoma, germinal center-derived lymphomas, esophageal squamous cell carcinoma, osteosarcoma, bladder cancer, pancreatic cancer, lung adenocarcinoma, BRAF V600E thyroid cancer, choroid plexus carcinoma, colitis-associated cancer, epithelial ovarian cancer, colorectal cancer, pancreatic cancer, uterine cancer, early cancer, advanced cancer, invasive cancer, metastatic cancer and/or drug resistant cancer, the subject has been previously treated with chemotherapy, immunotherapy, radiotherapy, biological therapy and/or surgical intervention (all claimed). - ADVANTAGE - None given. - DETAILED DESCRIPTION - Substituted 2-phenyl-5,6,7,8,8a,9-hexahydro-4aH-imidazo[1,2-a]indole-7-carboxamide compounds of formula (I) and their salts, stereoisomers, tautomers, hydrates, N-oxides, reverse amide analogs, prodrugs, isotopic variant (e.g. deuterated analog), proteolysis targeting chimera (PROTAC) or product are new.ring W1=aromatic or non-aromatic ring; eitherX2, X3, and X4=CH, C(R) or N (e.g. C(CH ), C(O-CH -cyclopropyl), C(O-CH -methylcyclobutyl), C(O-CH -3-methyloxetane), C(NH-CH -cyclopropyl), C(isopropoxy), C(O-CH(CH )-CH -O-CH ), C(CH CH ), C-iPr, C-CH -cyclopropyl, C(OCH ), C(OCH CH ), C(O-(CH ) -O-CH , C(OCHF ), C(Cl), C(C(O)CH ), C(O-CH CH -O-CH ) or C(OH)) ((if ring W1 is aromatic); eitherX15=C (if ring W1 is aromatic); orX2, X3, and X4=CH , CH(R), C(R) , NH, N(R), O, S, S=O or SO (e.g. CH ) (if ring W1 is non-aromatic); orX15=CH, C(R) or N (e.g. CH or N) (if ring W1 is non-aromatic);X5-X9=N or C; eitherR7', R7'', R7, R7''', and R7''''=absent (if either one of X5, X6, X7, X8 and X9 is N); eitherX10=N, CH, C(R), or C=O; eitherX11=N (e.g. C(CH -OH), C(CH -CH -OH), C(NH-CH -cyclopropyl), C(COOH), C(CH ), C(cyclopropyl) or C(isopropoxy)) (if X10 is C=O); orX11=N or C; orX10=C=O (if X11 is N);ring W1a=aromatic or non-aromatic ring; eitherX12=S, SO , O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N or C(R)=N (e.g. N-CH -COOH, N-CH -CH -OH, N-CH , N-CH CH , N-iPr, N-cyclopropyl or N-CH -cyclopropyl) (if ring W1a is aromatic); orX12=CH=CH, CH=CH(R), C(R)=CH, OCH , SCH , CH=N, C(R)=N, N=CH or N=C(R) (if ring W1a is non-aromatic); orat least one of X2, X3, and X4=C(R) (if both ring W1 and ring W1a are aromatic); orX11=N (if both ring W1 and ring W1a are aromatic); orX12=not S (if both ring W1 and ring W1a are aromatic); eitherR5=H or 1-5C linear or branched alkyl (e.g. methyl); orR6=H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R10 (e.g. CH -O-CH , (CH ) -O-CH (CH ) -O-CH , (CH ) -O-CH(CH ) ), R8-S-R10 (e.g. (CH ) -S-(CH ) CH ), R8-NHC(O)-R10, -O-R8- R10, R8-(optionally substituted 3-8C cycloalkyl) (e.g. CH -cyclopropyl, CH -cyclobutanol, CH -difluorocyclopropyl, CH -methylcyclopropyl, CH -dimethylamino-cyclohexyl, (CH ) -cyclopentanole, CH -cyclohexanol), R8-(optionally substituted saturated, unsaturated or aromatic, single, fused or spiro 3-10 membered heterocyclic ring) (e.g. (CH ) -piperidine, (CH ) -4-fluoro-piperidine, (CH ) -pyran, (CH ) -pyrrazole, (CH ) -imidazole, CH -tetrahydrofurane, CH -dioxane, CH -oxetane, CH -piperidine, CH -triazole, CH -1-oxa-8-azaspiro[4.5]decane, (CH ) -diazabicyclo[2.2.1]heptane, CH -methyl-THF, CH -ethyl-piperidine, CH -oxa-azaspirodecane, (CH ) -dimethylpyrazole, CH - -oxo-methylpyrrolidine, CH -methyl-azetidine, CH -azaspiroheptane), CF , CD , OCD , CN, NO , -CH CN, -R8CN, NH , NHR, N(R) , NH(R10), N(R10)(R11), R8-N(R10)(R11) (e.g. (CH ) -NH , (CH ) -N(CH CH ) , (CH ) -N(CH(CH ) ) , (CH ) -piperidine, (CH ) -4-fluoro-piperidine, (CH ) -4-cyano- piperidine, (CH ) -NH(CH ), (CH ) -NH-CH-3, (CH ) -NH-CH CH , (CH ) -N(CH CH ) , (CH ) -NH , (CH ) -N(CH CH )(CH CF )), R9-R8-N(R10)(R11) (e.g. (CH ) -C(O)-piperidine), B(OH) , -OC(O)CF , -OCH Ph, NHC(O)-R10, NHCO-N(R10)(R11), COOH, -C(O)Ph, C(O)O-R10, R8-C(O)-R10, C(O)H, C(O)- R10 (e.g., C(O)CH ), 1-5C linear or branched C(O)-haloalkyl, -C(O)NH , C(O)NHR, C(O)N(R10)(R11), SO R, SO N(R10)(R11), CH(CF )(NH-R10), 3-8 cyclic haloalkyl, 1-5C linear or branched alkyl (e.g. CH(CH )CH OCH , CH(CH )CH NH , CH(CH )C(O)N(CH ) , CH -CH(OH)Ph, (CH ) N(H)CH CH , CH(CH )(CH ) OH, CH(CH OH)(CH CH ), (CH ) -OCH , (CH ) -OCH , (CH ) -OCH(CH ) , CH(CH OH)(CH CH(CH ) ), CH CH(CH )(OCH ), CH CH(N(CH ) )(CH CH ), benzyl, methyl, ethyl, CH -OCH -CH -O-CH , CH(CH )C(O)N(CH ) ), 1-5C linear or branched alkenyl, 1-5C linear or branched, 1-5C linear or branched 3-8C cyclic alkoxy (e.g. methoxy, O-(CH )2-O-CH ) (at least one methylene group (CH ) in the alkoxy is replaced with O, 1-5C linear or branched thioalkoxy, 1-5C linear or branched haloalkoxy, 1-5C linear or branched alkoxyalkyl, optionally substituted 3-8C cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(optionally substituted 3-8C cycloalkyl), optionally substituted 3-8 membered heterocyclic ring (e.g. piperidine, 1-methyl-piperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3.3]heptane, imidazole, trifluoromethyl-oxetane, hydroxy-etrahydrofurane, azepan-2-one or azabicyclohexane), optionally substituted aryl, optionally substituted R8-aryl (e.g. benzyl), optionally substituted benzyl; orR6R5=optionally substituted 5-8 membered heterocyclic ring e.g. azepane, piperazine or 2-(piperazin-1-yl)acetamide; orR6=substituted amine moieties of formulae (R12R13N-CH -(CH ) -CH -) (II) or (III); andm=0 or 1.Provided that: Full definitions are given in the DEFINITIONS (Full Definitions) Field. INDEPENDENT CLAIMs are also included for:(1) modulating c-MYC mRNA translation, or regulating c-MYC mRNA transcription in a cell, comprising contacting (I) with a cell to modulate c-MYC mRNA translation, or regulating c-MYC mRNA transcription in the cell. -SN - WO2024010761-A1 -AN - DIIDW:202405659Y -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - Zhu, Xianmin -AU - Dong, Shuang -AU - Tang, Jing -AU - Xie, Rong -AU - Wu, Huijing -AU - Hofman, Paul -AU - Mrugala, Maciej M. -AU - Hu, Sheng -TI - Lung cancer with brain metastases remaining in continuous complete remission due to pembrolizumab and temozolomide: a case report -T2 - ANNALS OF TRANSLATIONAL MEDICINE -M3 - Article -AB - Background: Immunotherapy has been shown to improve the overall survival (OS) in patients with advanced or metastatic non-small cell lung cancer ( NSCLC) without driver gene mutations. However, monotherapy with immunotherapy alone or combined with chemotherapy in NSCLC patients with untreated brain metastases (BM) is still under debate. Data regarding treatment of BM with immunotherapy and temozolomide (TMZ) in patients with NSCLC is rare.Case Presentation: A 60-year-old male due to cough and expectoration presented in our hospital. Chest computed tomography (CT), brain magnetic resonance imaging (MRI) and immunohistochemistry of a mediastinal lymph node biopsy were administered, he was diagnosed with stage IIIB lung adenocarcinoma. Without driver gene mutations, he was treated with platinum-based chemotherapy because he refused to accept concurrent radiation therapy (RT). Heavy cough companied with hemoptysis and chest CT scan both revealed progressive disease (PD) after 6 cycles of chemotherapy. Immunotherapy was consequently considered, while two metastatic lesions in the brain were confirmed after combined treatment of pembrolizumab with docetaxel. TMZ was administered in combination with pembrolizumab (200 mg, day 1). A new metastasis in the right occipital lobe was detected on a scan 1 month later, though the other 2 lesions continued to shrink. The treatment was continued, MRI and CT scans suggested complete response (CR) was achieved for both the BM and lung lesions after 3 cycles. Consolidation therapy with TMZ and pembrolizumab ( 100 mg) per month was considered for another 7 months. Maintenance monotherapy with pembrolizumab (100 mg) was selected because of his stable CR status. At 59 months since diagnosis, the patient remains alive, with CR for both the primary lesions and BM. The patient experienced slight numbness on each side of his feet. There was no occurrence of adverse effects greater than grade 3.Conclusions: The data indicates that immunotherapy combined with TMZ for untreated BM in NSCLC patients maybe an efficient and safe decision making therapeutic choice. Despite the encouraging efficacy of the combination, it is an isolated case and the speculation of synergism need to be proved in further pharmacokinetic/pharmacodynamic studies even in large randomized controlled trials. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2305-5839 -SN - 2305-5847 -DA - 2022 SEP -PY - 2022 -VL - 10 -IS - 17 -DO - 10.21037/atm-22-4208 -AN - WOS:000886931900005 -AD - Huazhong Univ Sci & Technol, Hubei Canc Hosp, Dept Med Oncol, Tongji Med Coll, Wuhan, Peoples R China -AD - Univ Cote Azur, Pasteur Hosp, Lab Clin & Expt Pathol, FHU OncoAge,CHU Nice, BB-0033-00025, Nice, France -AD - Mayo Clin, Dept Neurol & Oncol, Comprehens Neuro Oncol Program, Canc Ctr, Phoenix, AZ USA -Y2 - 2022-12-02 -ER - - -TY - JOUR -AU - Nardone, Valerio -AU - Belfiore, Maria Paola -AU - De Chiara, Marco -AU - De Marco, Giuseppina -AU - Patane, Vittorio -AU - Balestrucci, Giovanni -AU - Buono, Mauro -AU - Salvarezza, Maria -AU - Di Guida, Gaetano -AU - D'Angiolella, Domenico -AU - Grassi, Roberta -AU - D'Onofrio, Ida -AU - Cimmino, Giovanni -AU - Della Corte, Carminia Maria -AU - Gambardella, Antonio -AU - Morgillo, Floriana -AU - Ciardiello, Fortunato -AU - Reginelli, Alfonso -AU - Cappabianca, Salvatore -TI - CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial -T2 - DIAGNOSTICS -M3 - Article -AB - Background: Non-small-cell lung cancer (NSCLC) is a common, steady growing lung tumour that is often discovered when a surgical approach is forbidden. For locally advanced inoperable NSCLC, the clinical approach consists of a combination of chemotherapy and radiotherapy, eventually followed by adjuvant immunotherapy, a treatment that is useful but may cause several mild and severe adverse effect. Chest radiotherapy, specifically, may affect the heart and coronary artery, impairing heart function and causing pathologic changes in myocardial tissues. The aim of this study is to evaluate the damage coming from these therapies with the aid of cardiac imaging. Methods: This is a single-centre, prospective clinical trial. Patients with NSCLC who are enrolled will undergo computed tomography (CT) and magnetic resonance imaging (MRI) before chemotherapy 3 months, 6 months, and 9-12 months after the treatment. We expect to enrol 30 patients in 2 years. Conclusions: Our clinical trial will be an opportunity not only to highlight the timing and the radiation dose needed for pathological cardiac tissue changes to happen but will also provide useful data to set new follow-up schedules and strategies, keeping in mind that, more often than not, patients affected by NSCLC may present other heart- and lung-related pathological conditions. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2075-4418 -DA - 2023 MAY 12 -PY - 2023 -VL - 13 -IS - 10 -C7 - 1717 -DO - 10.3390/diagnostics13101717 -AN - WOS:000997835400001 -AD - Univ Campania L Vanvitelli, Dept Precis Med, I-80138 Naples, Italy -AD - ASL Napoli Ctr 1, Osped Mare, Radiotherapy Unit, I-80138 Naples, Italy -AD - Univ Campania L Vanvitelli, Dept Translat Med Sci, I-80138 Naples, Italy -M2 - ASL Napoli Ctr 1 -Y2 - 2023-06-15 -ER - - -TY - JOUR -AU - Steindl, Ariane -AU - Berghoff, Anna Sophie -TI - Brain metastases: new systemic treatment approaches -T2 - MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY -M3 - Review -AB - Background Brain metastases (BM) still present a clinical challenge in oncology. Treatment of BM was mainly based on local approaches including neurosurgery and radiation. However, the fraction of patients with asymptomatic BM has risen over the last decade. Recent clinical trials on immune- and targeted therapies showed promising intracranial responses-especially in neurological asymptomatic status. Therefore, systemic treatment presents an emerging therapy approach specifically in patients with asymptomatic BM. Methods The present review highlights the recent advances in systemic therapeutic and preventive approaches in BM focusing on the main BM causing tumors: non-small cell lung cancer (NSCLC), melanoma and breast cancer. Results Remarkable intracranial efficacies were presented for several next-generation tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors, especially in asymptomatic BM patients. In NSCLC, osimertinib and afatinib presented intracranial response rates over 80%. Osimertinib showed even a potential for primary BM prevention. Considerable intracranial response rates were observed for the combination of dabrafenib and trametinib in BRAF mutated melanoma BM. Combined ipilimumab and nivolumab treatment in asymptomatic melanoma BM even presented with similar intra- and extracranial response rates. In breast cancer, HER2-targeted TKIs like lapatinib in combination with chemotherapy, or trastuzumab deruxtecan monotherapy presented also notable intracranial response rates. Conclusion New developments in targeted and immune-modulating therapies have postulated high intracranial efficacies in patients with BM from different solid tumors. However, more BM-specific studies and BM-specific endpoints in registration trials are warranted to underscore the role of systemic treatment in patients with BM. -PU - SPRINGER WIEN -PI - WIEN -PA - SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA -SN - 1865-5041 -SN - 1865-5076 -DA - 2021 JUN -PY - 2021 -VL - 14 -IS - 2 -SP - 198 -EP - 203 -DO - 10.1007/s12254-021-00709-1 -AN - WOS:000652929700001 -C6 - MAY 2021 -AD - Med Univ Vienna, Dept Med 1, Div Oncol, Waehringer Guertel 18-20, A-1090 Vienna, Austria -Y2 - 2021-05-28 -ER - - -TY - JOUR -AU - Lee, H.-Y. -TI - Current options for the treatment of advanced or metastatic NSCLC -T2 - Proceedings of SPIE -M3 - Conference Paper -M3 - Journal Paper -CP - Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022) -CL - Oxford, UK -AB - Non-small cell lung cancer (NSCLC) remains the predominate cause of cancer-related death worldwide. The estimate in the last decade indicates that for patients with metastatic NSCLC, the overall 5-year survival rate is only 7%. It is worthy that molecular target therapies or immunotherapy enable patients with metastatic lung cancer to prolong overall survival and associated with less frequent adverse events. However, chemotherapy alone, such as docetaxel, is correlated with limited efficacy and inevitable toxicity. Although cytotoxic chemotherapy still plays a vital role in cancer interventions, the biomarker-directed therapies that target the molecular alterations or programmed cell death 1 (PD-L1) and programmed cell ligand 1 (PD-1) pathways have substituted for chemotherapy as the standard first-line or second-line therapies for nearly half of patients with advanced NSCLC. An identifiable biomarker that predicts the efficacy of immune checkpoint blockades and tyrosine kinase inhibitors (TKIs) is necessary to determine the patients who most probably benefit from immunotherapy. Evaluating the PD-L1 expression level and workable molecular alterations may be the best prediction indicator for efficacy in NSCLC. This review summarizes the effectiveness in current clinical trials guiding the patients with NSCLC using checkpoint blockades and TKIs as first-line treatment, evaluating the survival efficacy of PD-L1 expression level in selected patients treated with checkpoint blockades. Sixty-three articles about clinical trials of immunotherapy for NSCLC were identified from PubMed. All included articles were published from January 1, 2007, to January 30, 2021, and divided into different PD-L1 expression levels to analyze survival. -SN - 1996-756X -DA - 2023 -PY - 2023 -SP - 126111Q (9 pp.) -EP - 126111Q (9 pp.) -DO - 10.1117/12.2669366 -AN - INSPEC:23252444 -AD - Nanchang Univ., Nanchang, China -Y2 - 2023-06-24 -ER - - -TY - JOUR -Z2 - 李若楠 -Z2 - 陈小科 -Z2 - 许元元 -Z2 - 谭强 -AU - Li Ruonan -AU - Chen Xiaoke -AU - Xu Yuanyuan -AU - Tan Qiang -TI - Advances in postoperative adjuvant targeted therapy for patients with stage ⅠB-ⅢA non-small cell lung cancer -T2 - Journal of Shanghai Jiaotong University .Medical Science -M3 - Review -AB - As the cancer with the highest mortality rate in the world, the treatment of lung cancer has always been a difficult problem for a wide range of patients and physicians alike. Based on the degree of differentiation, morphological features and biological characteristics, lung cancer can be divided into small cell lung cancer and non-small cell lung cancer (NSCLC). The incidence of NSCLC accounts for 80% - 85%. Clinically, the treatment options of NSCLC include surgery, chemotherapy, radiotherapy, targeted drug therapy, immunotherapy, etc. For the patients with stage ⅠB-ⅢA NSCLC, in addition to the first choice of surgical treatment, postoperative adjuvant therapy is applied to reduce tumor recurrence and metastasis. Studies have shown that targeted drugs are efficient and safe in the adjuvant therapy for NSCLC patients, and the most attention has been given to agents that target mutations in the epidermal growth factor receptor (EGFR) gene, such as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). At present, three generations of EGFR TKIs have been approved for clinical use. Among them, the first generation EGFR-TKIs are dominant in the research and application of adjuvant therapy. For example, erlotinib and gefitinib can prolong the disease-free survival (DFS) and overall survival (OS) of patients after surgery, and icotinib has been approved for postoperative adjuvant therapy in China because of its obvious improvement of patients' DFS. Compared with the placebo, the third generation EGFR-TKIs drug osimertinib demonstrated a more significant DFS advantage in the ADAURA trial, decreased tumor recurrence in central nervous system and brought greater benefits in DFS to patients previously treated with standard chemotherapy regime. Osimertinib or chemotherapy combined with osimertinib has therefore become the standard of care for the patients with postoperative adjuvant therapy of stage ⅠB - ⅢA NSCLC. As the third generation EGFR-TKIs new drugs, the clinical trials of almonertinib and furmonertinib for postoperative adjuvant therapy are also underway. This article systematically summarizes the structure of EGFR, the types and detection methods of EGFR gene mutations, introduces the treatment strategies of clinical use of EGFR-TKIs, and discusses the problems that may be encountered in the clinical use of EGFR-TKIs. -SN - 1674-8115 -DA - 2022 -PY - 2022 -VL - 42 -IS - 11 -SP - 1612 -EP - 1619 -C7 - 1674-8115(2022)42:11<1612:BAQFXX>2.0.TX;2-H -AN - CSCD:7374909 -AD - 上海交通大学医学院附属胸科医院肿瘤科, 上海 200230, 中国 -AD - Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200230, China -M2 - 上海交通大学医学院附属胸科医院肿瘤科 -M2 - Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine -Y2 - 2023-04-28 -ER - - -TY - JOUR -Z2 - 虞思来 -Z2 - 倪建佼 -Z2 - 朱正飞 -AU - Yu Silai -AU - Ni Jianjiao -AU - Zhu Zhengfei -TI - Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy:status and prospects -T2 - China Oncology -M3 - Review -AB - The PACIFIC trial uncovered a new era of immunotherapy in the multi-disciplinary treatment of unresectable locally advanced non-small cell lung cancer (LA-NSCLC),but also proposed a new question of how to further optimize radiotherapy and chemotherapy,in order to maximize synergistic effects with immunotherapy.The treatment progress of unresectable LANSCLC was reviewed in the context of immunotherapy.Updated data of the PACIFIC trial along with the research progress among special populations,especially for elderly patients,programmed death ligand-1 (PD-L1) expression negative and epidermal growth factor receptor (EGFR) gene mutant were summarized.Meanwhile,the optimal sequence of radiotherapy,chemotherapy and immunotherapy,the technical advancement and implementation of radiotherapy,including dose fractionation,target delineation and ray selection,were discussed,as well as its application prospect in the era of immunotherapy. -SN - 1007-3639 -DA - 2022 -PY - 2022 -VL - 32 -IS - 6 -SP - 487 -EP - 498 -C7 - 1007-3639(2022)32:6<487:MYZLSD>2.0.TX;2-7 -AN - CSCD:7277640 -AD - 复旦大学上海医学院基础医学院, 上海 200032, 中国 -AD - 复旦大学附属肿瘤医院放射治疗中心,复旦大学上海医学院肿瘤学系, 上海 200032, 中国 -AD - 复旦大学附属肿瘤医院放射治疗中心,复旦大学上海医学院肿瘤学系;;复旦大学胸部肿瘤研究所, ;;, ;;, 上海;;上海 200032;;200032, 中国 -AD - School of Basic Medical Sciences,Shanghai Medical College,Fudan University, Shanghai 200032, China -AD - Department of Radiation Oncology,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University, Shanghai 200032, China -AD - Department of Radiation Oncology,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University;;Institute of Thoracic Oncology,Fudan University, ;;, ;;, Shanghai;;Shanghai 200032;;200032 -M2 - 复旦大学上海医学院基础医学院 -M2 - 复旦大学附属肿瘤医院放射治疗中心,复旦大学上海医学院肿瘤学系 -M2 - 复旦大学附属肿瘤医院放射治疗中心,复旦大学上海医学院肿瘤学系;;复旦大学胸部肿瘤研究所 -M2 - School of Basic Medical Sciences,Shanghai Medical College,Fudan University -M2 - Department of Radiation Oncology,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University -M2 - Department of Radiation Oncology,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University;;Institute of Thoracic Oncology,Fudan University -Y2 - 2022-11-07 -ER - - -TY - JOUR -AU - Matiello, Juliana -AU - Dal Pra, Alan -AU - Zardo, Laise -AU - Silva, Ricardo -AU - Berton, Danilo C. -TI - Impacts of post-radiotherapy lymphocyte count on progression-free and overall survival in patients with stageIIIlung cancer -T2 - THORACIC CANCER -M3 - Article -AB - Background We evaluated the impact of thoracic radiation in patients with non-small cell lung cancer (NSCLC), considering the depletion of total lymphocytes, use or not of chemotherapy, and radiation doses in healthy lung tissue. Methods Patients with stage III NSCLC, ECOG 0 to 2, receiving radiotherapy with or without chemotherapy were prospectively evaluated. All patients should be treated with three-dimensional radiotherapy and received biologically effective doses (BED10 alpha/beta 10) of 48 to 80 Gy. Peripheral blood lymphocyte total counts were measured at the start of radiotherapy and at 2, 6 and 12 months after radiotherapy. Along with lymphocytes, PTV and doses of 5 Gy and 20 Gy in healthy lung tissue were also evaluated as potential factors influencing overall survival (OS) and progression-free survival (PFS). Results A total of 46 patients were prospectively evaluated from April 2016 to August 2019, with a median follow-up of 13 months (interquartile range, 1-39 months). The median of OS of all cohort was 22,8 months (IC 95% 17,6-28,1) and the median PFS was 19,5 months (IC 95%: 14,7-24,2). Most patients received concurrent or neoadjuvant chemotherapy (43; 93.4%). No patient received adjuvant immunotherapy. The lower the lymphocyte loss at 6 months after radiotherapy (every 100 lymphocytes/mcL), the greater the chance of PFS (HR, 0.44; 95%CI, 0.25-0.77;P = 0.004) and OS (HR, 0.83; 95%CI, 0.70-0.98;P = 0.025;P = 0.025). BED was a protective factor for both PFS (HR, 0.52; 95%CI 0.33-0.83;P = 0.0006) and OS (HR, 0.73; 95%CI 0.54-0.97;P = 0.029). Conclusions Our results suggest that lymphocyte depletion after radiotherapy reduces tumor control and survival in patients with stage III lung cancer. Radiation doses equal or higher than 60 Gy (BED(10)72 Gy) improve PFS and OS, but they negatively affect lymphocyte counts for months, which reduces survival and the potential of immunotherapy. Key pointsSignificant findings of the study Thoracic irradiation for locally advanced lung cancer depletes T lymphocytes for months. Patients whose lymphocyte loss is lower have better overall survival and progression-free survival. What this study adds It is necessary to protect the lymphocyte population, as well as other organs at risk. New forms of irradiation for large fields are needed. Furthermore, could immunotherapy before chemo-radiotherapy, with a greater number of lymphocytes, bring an even better result? -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1759-7706 -SN - 1759-7714 -DA - 2020 NOV -PY - 2020 -VL - 11 -IS - 11 -SP - 3139 -EP - 3144 -DO - 10.1111/1759-7714.13621 -AN - WOS:000571327900001 -C6 - SEP 2020 -AD - Santa Casa Porto Alegre, Dept Radiat Oncol, Porto Alegre, RS, Brazil -AD - UHlth Radiat Oncol, Dept Radiat Oncol, Miami, FL USA -AD - Univ Fed Rio Grande do Sul, Dept Pneumol Sci, Porto Alegre, RS, Brazil -M2 - Santa Casa Porto Alegre -M2 - UHlth Radiat Oncol -Y2 - 2020-10-01 -ER - - -TY - JOUR -AU - Li, Fei -AU - Landis, Mark -TI - Application of PET to the Diagnosis, Staging, and Treatment of Locally Advanced Non-small Cell Lung Cancer -T2 - CURRENT MEDICAL IMAGING -M3 - Review -AB - The strength of positron emission tomography (PET) lies in the application of its underlying technological and molecular biology advancements to clinical practice and pharmacological development. Currently, PET is used to identify malignant pulmonary nodules, evaluate mediastinal disease, detect distant metastasis, assess response to therapy, and identify novel oncologic drug targets. Over the last decade, PET has also increasingly influenced the management of locally advanced nonsmall cell lung cancer (NSCLC) by directing chemoradiation and surgical treatment. Although the majority of clinical trials and practice have used 2-18F-fluoro-2-deoxy-D-glucose (FDG) as the radiopharmaceutical agent for evaluating NSCLC, novel radiolabeled tracers, radiopharmaceutical agents, and targeted immunotherapy drugs are actively being investigated to improve the treatment of NSCLC. This review focuses on the utility of PET for diagnosing malignant pulmonary nodules, staging the extent of disease, and evaluating immuno-oncology therapies in locally advanced NSCLC. -PU - BENTHAM SCIENCE PUBL LTD -PI - SHARJAH -PA - EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES -SN - 1573-4056 -SN - 1875-6603 -DA - 2015 -PY - 2015 -VL - 11 -IS - 2 -SP - 91 -EP - 98 -DO - 10.2174/157340561102150624144437 -AN - WOS:000356886100005 -AD - Univ Toronto, Dept Med Imaging, Toronto, ON, Canada -AD - Western Univ, Victoria Hosp, London Hlth Sci Ctr, Dept Med Imaging, London, ON, Canada -Y2 - 2015-07-15 -ER - - -TY - JOUR -AU - Yang, Zhang-Ru -AU - Liu, Mi-Na -AU - Yu, Jia-Hua -AU - Yang, Yun-Hai -AU - Chen, Tian-Xiang -AU - Han, Yu-Chen -AU - Zhu, Lei -AU - Zhao, Ji-Kai -AU - Fu, Xiao-Long -AU - Cai, Xu-Wei -TI - Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. The expected 5-year survival of stage III NSCLC ranges from 13% to 36% for stage III. Due to the heterogeneity and poor efficacy of stage III patients, there is great controversy on how to optimize the therapy strategy. Immunotherapy is providing better clinical efficacy to more NSCLC patients, and is rapidly extending its range of care from advanced stage to locally advanced stage and early stage NSCLC. Due to the patient's strong treatment intention, drug availability, and a few encouraging results from clinical trials (NADIM, NCT02716038, etc.), the authors observed a case of stage III NSCLC that achieved complete remission after receiving neoadjuvant chemotherapy combined with immunotherapy. In view of such a satisfactory result in neoadjuvant therapy, this article discusses how comprehensive treatment for stage III NSCLC patients may be conducted and the manner in which various therapeutic techniques can be mastered in the era of immunotherapy. Immunotherapy has opened the exploratory space for finding resolutions to numerous challenges of treating stage III NSCLC. Further clinical studies and exploration of personalized treatment, guided by imaging data, and clinical and pathological biomarkers are imperative for the benefit of these patients. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2020 OCT -PY - 2020 -VL - 9 -IS - 5 -SP - 2059 -EP - 2073 -DO - 10.21037/tlcr-20-896 -AN - WOS:000582799700036 -AD - Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Radiat Oncol, 241 West Huaihai Rd, Shanghai 200030, Peoples R China -AD - Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China -AD - Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pathol, Shanghai, Peoples R China -Y2 - 2020-11-11 -ER - - -TY - JOUR -AU - Shi, Yue -AU - Ji, Min -AU - Jiang, Yingying -AU - Yin, Rong -AU - Wang, Zihan -AU - Li, Hang -AU - Wang, Shuaiyu -AU - He, Kang -AU - Ma, Yuxin -AU - Wang, Zhitong -AU - Lu, Jianwei -AU - Shi, Meiqi -AU - Shen, Bo -AU - Zhou, Guoren -AU - Leong, Tracy L. -AU - Wang, Xiaohua -AU - Chen, Cheng -AU - Feng, Jifeng -TI - A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Article -AB - Background: Anlotinib is a new multi-target tyrosine kinase inhibitor (TKI) and has been shown to have antitumor effects and synergistic antitumor effects with immunotherapy only in animal studies and in the 2nd-line treatment in small clinical trials. A real-world study with large sample to compare the efficacy and safety of anlotinib plus immune checkpoint inhibitors (ICIs) with ICIs alone in the multiline treatment of advanced non-small cell lung cancer (NSCLC) was urgently needed. Methods: The data of 535 advanced NSCLC patients were collected from January 1, 2018, to December 31, 2021. The patients were divided into 2 groups: (I) ICI monotherapy (230 patients); (II) ICI + anlotinib (305 patients). After propensity-score matching (PSM) to reduce the effects of biases and confounding variables, the progression-free survival time (PFS), occurrence of adverse events, disease control rate (DCR), and objective response rate (ORR) of the 2 groups were compared. The effects of clinical factors, including age, gender, gene mutations, tumor proportion score, metastases, and combined radiotherapy, were also analyzed. Results: After PSM, the baseline clinical characteristics were well balanced and the 2 group had a good comparability. Patients in the ICI + anlotinib group had significantly longer median PFS in both the 2nd-line treatment (7.73 vs. 4.70 months; P=0.003) and 3rd-line treatment (5.90 vs. 3.37 months; P=0.020), but the difference lacked statistical significance in the 1st-line treatment (8.40 vs. 5.20 months; P=0.229). The overall median PFS of patients in the ICI + anlotinib group was also much longer than that of patients in the ICI monotherapy group (6.37 vs. 3.90 months; P<0.001). The ICI + anlotinib group also tended to have a higher DCR, a higher ORR, and a higher probability of severe adverse drug reactions during the treatment than the ICI monotherapy group, but the differences were not statistically significant. Combining ICI + anlotinib could improve the outcomes of patients with bone metastasis. Conclusions: Anlotinib + ICI therapy could have greater efficacy in the treatment of advanced NSCLC patients than ICI monotherapy. The probability of adverse events might increase in the combined treatment, but could be controlled. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2022 JUN -PY - 2022 -VL - 11 -IS - 6 -SP - 1051 -EP - 1068 -DO - 10.21037/tlcr-22-350 -AN - WOS:000813488700001 -C6 - JUN 2022 -AD - Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Canc Hosp, Dept Oncol,Jiangsu Inst Canc Res, Nanjing, Peoples R China -AD - Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Canc Hosp, Dept Radiotherapy,Jiangsu Inst Canc Res, Nanjing, Peoples R China -AD - Nanjing Med Univ, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Dept Thorac Surg,Affiliated Canc Hosp, Nanjing, Peoples R China -AD - Nantong Univ, Sch Life Sci, Nantong, Peoples R China -AD - Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA -AD - UCL, UCL Sch Pharm, London, England -AD - Nanjing Med Univ, Dept Radiotherapy, Nanjing, Peoples R China -AD - Austin Hosp, Dept Resp Med, Heidelberg, Vic, Australia -Y2 - 2022-06-26 -ER - - -TY - JOUR -Z2 - 程森森 -Z2 - 马原 -Z2 - 宋宝(综述) -Z2 - 刘杰(审校) -AU - Cheng Sensen -AU - Ma Yuan -AU - Song Bao -AU - Liu Jie -TI - Advances and challenges in immunotherapy for non- small cell lung cancer -T2 - Chinese Journal of Clinical Oncology -M3 - Review -AB - Lung cancer is the leading cause of cancer-related deaths, with high morbidity and mortality, as well as poor prognosis in China and worldwide. Despite the recent advances in surgery, irradiation, chemotherapy, and targeted therapy, the curative effect of non-small cell lung cancer (NSCLC) in advanced cancer patients is unsatisfactory, and the five-year survival rate of patients remains low. Immunotherapeutic approaches, such as checkpoint inhibitors, active vaccination, and adoptive vaccination, have been given increasing attention for the treatment of patients with NSCLC. Results of phase I clinical trials show a higher remission rate, and the outcomes of phases II and III clinical trials are under exploration. This review provides an overview of the latest advances and challenges in immunotherapy for NSCLC. -SN - 1000-8179 -DA - 2015 -PY - 2015 -VL - 42 -IS - 20 -SP - 1031 -EP - 1036 -C7 - 1000-8179(2015)42:20<1031:FXXBFA>2.0.TX;2-9 -AN - CSCD:5580175 -AD - 山东省肿瘤医院内三科, 济南, 山东 250117, 中国 -AD - 山东省肿瘤医院基础实验室, 山东省肿瘤医院基础实验室 -AD - Third Department of Medical Oncology, Shandong Cancer Hospital, Shandong Academy of Medical Sciences, Ji'nan, Shandong 250117, China -AD - Basic Laboratory, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Ji'nan, Shandong China -M2 - 山东省肿瘤医院内三科 -M2 - 山东省肿瘤医院基础实验室 -M2 - Third Department of Medical Oncology, Shandong Cancer Hospital, Shandong Academy of Medical Sciences -M2 - Basic Laboratory, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences -Y2 - 2016-02-11 -ER - - -TY - JOUR -AU - Goldman, Jonathan W. -AU - Waterhouse, David M. -AU - George, Ben -AU - O'Dwyer, Peter J. -AU - Bhore, Rafia -AU - Banerjee, Sibabrata -AU - Lyons, Larry -AU - Louis, Chrystal U. -AU - Ong, Teng Jin -AU - Kelly, Karen -TI - Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer -T2 - FRONTIERS IN ONCOLOGY -M3 - Article -AB - Introduction: Multicenter, phase I study of concurrent and delayed nivolumab plus nab-paclitaxel/carboplatin in advanced non-small cell lung cancer (NSCLC). Methods: Chemotherapy-naive patients with advanced NSCLC (ineligible for potentially curative radiation or surgery) received nab-paclitaxel 100 mg/m(2) (days 1, 8, 15) and carboplatin area under the curve 6 (day 1) intravenously every 21 days (first 4 cycles); nivolumab 5 mg/kg was administered intravenously (day 15) beginning in cycle 1 (concurrent) or cycle 3 (delayed) in separate cohorts and continued beyond the 4 chemotherapy cycles. The primary objective was to assess safety. Secondary objectives were to assess tolerability and explore antitumor activity. Results: All 32 patients received chemotherapy; 20 of 22 and 6 of 10 patients also received concurrent or delayed nivolumab, respectively. No dose-limiting toxicities were reported in the concurrent cohort; 1 dose-limiting toxicity was reported in the delayed cohort. In the concurrent cohort, 20 patients (91%) had >= 1 grade 3/4 treatment-emergent adverse event (TEAE), and 7 (32%) discontinued treatment due to TEAEs. In the delayed cohort, all patients had >= 1 grade 3/4 TEAE, and 2 (20%) discontinued due to TEAEs. The median progression-free and overall survival, respectively, were 10.5 and 29.3 months in the concurrent cohort and 4.1 and 8.2 months in the delayed cohort. Conclusions: The safety profile of the combination was consistent with that of individual agents and generally similar in the 2 cohorts. Efficacy outcomes in the concurrent cohort, but not in the delayed cohort, were encouraging and support the rationale for concurrent administration of nivolumab with nab-paclitaxel/carboplatin for the treatment of advanced NSCLC. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2019 NOV 26 -PY - 2019 -VL - 9 -C7 - 1256 -DO - 10.3389/fonc.2019.01256 -AN - WOS:000501848000001 -AD - Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA -AD - Oncol Hematol Care, Cincinnati, OH USA -AD - Froedtert, Milwaukee, WI USA -AD - Med Coll Wisconsin, Milwaukee, WI 53226 USA -AD - Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA -AD - Celgene Corp, Summit, NJ USA -AD - Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA -M2 - Froedtert -Y2 - 2019-12-19 -ER - - -TY - JOUR -AU - Bolonaki, Irini -AU - Kotsakis, Athanassios -AU - Papadimitraki, Elsa -AU - Aggouraki, Despoina -AU - Konsolakis, George -AU - Vagia, Aphrodite -AU - Christophylakis, Charalambos -AU - Nikoloudi, Irini -AU - Magganas, Elefterios -AU - Galanis, Athanassios -AU - Cordopatis, Paul -AU - Kosmatopoulos, Kostas -AU - Georgoulias, Vassilis -AU - Mavroudis, Dimitris -TI - Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide -T2 - JOURNAL OF CLINICAL ONCOLOGY -M3 - Article -AB - PurposeTo evaluate the immunological and clinical response as well as the safety of the optimized peptide telomerase reverse transcriptase p572Y (TERT572Y) presented by HLA-A*0201 in patients with advanced non-small-cell lung cancer (NSCLC).Patients and MethodsTwenty-two patients with advanced NSCLC and residual (n = 8) or progressive disease (PD; n = 14) following chemotherapy and/or radiotherapy received two subcutaneous injections of the optimized TERT572Y peptide followed by four injections of the native TERT572 peptide administered every 3 weeks. Peptide-specific immune responses were monitored by enzyme-linked immunosorbent spot assay and/or TERT572Y pentamer staining.ResultsTwelve (54.5%) of 22 patients completed the vaccination program. Toxicity consisted primarily of local skin reactions. TERT572-specific CD8(+) cells were detected in 16 (76.2%) of 21 patients after the second vaccination, and 10 (90.9%) of 11 patients after the sixth vaccination. Stable disease (SD) occurred in eight (36.4%) of 22 vaccinated patients, with three (13.6%) having had PD before entering the study. The median duration of SD was 11.2 months. After a median follow-up of 10.0 months, patients with early developed immunological response ( n = 16) had a significantly longer time to progression and overall survival (OS) than nonresponders (n = 5; log-rank tests P = .046 and P = .012, respectively). The estimated median OS was 30.0 months ( range, 2.8 to 40.0 months) and 4.1 months (range, 2.4 to 10.9 months) for responders and nonresponders, respectively.ConclusionTERT572Y peptide vaccine is well tolerated and effective in eliciting a specific T cell immunity. Immunological response is associated with prolonged survival. These results are encouraging and warrant further evaluation in a randomized study. -PU - AMER SOC CLINICAL ONCOLOGY -PI - ALEXANDRIA -PA - 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA -SN - 0732-183X -DA - 2007 JUL 1 -PY - 2007 -VL - 25 -IS - 19 -SP - 2727 -EP - 2734 -DO - 10.1200/JCO.2006.10.3465 -AN - WOS:000247862000017 -AD - Univ Gen Hosp Herakl, Dept Med Oncol, Iraklion 71110, Greece -AD - Univ Gen Hosp Herakl, Dept Transfus Med, Iraklion 71110, Greece -AD - Univ Gen Hosp Herakl, Dept Radiol, Iraklion 71110, Greece -AD - Univ Crete, Lab Tumor Biol, Sch Med, Iraklion, Greece -AD - Iaso Gen Hosp, Athens, Greece -AD - Univ Patras, Dept Pharm, Patras, Greece -AD - Genopole, Vaxon Biotech, Evry, France -M2 - Iaso Gen Hosp -Y2 - 2007-07-01 -ER - - -TY - JOUR -AU - Zhao, Yuhua -AU - Yu, Limeng -AU - Wang, Lili -AU - Wu, Yingxi -AU - Chen, Haiyang -AU - Wang, Qiming -AU - Wu, Yufeng -TI - The Riddle of the Sphinx: Progress in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer -T2 - CLINICAL MEDICINE INSIGHTS-ONCOLOGY -M3 - Article -AB - Leptomeningeal metastasis (LM) is a serious complication of advanced non-small cell lung cancer (NSCLC), and the incidence of LM has been increasing yearly in recent times. There is no consensus on the best treatment modality for LM, which underscores a difficult problem in the management of advanced NSCLC patients. The existing treatments include molecular targeted therapy, systemic chemotherapy, local radiotherapy, antivascular tumor therapy, intrathecal chemotherapy, and immunotherapy, but their efficacy is not satisfactory. In this article, we briefly describe the clinical manifestations, diagnosis, and treatment of NSCLC-LM and discuss progress regarding evaluation of the efficacy of LM treatment to better provide a necessary reference for clinical practice and clinical trial evaluation. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1179-5549 -DA - 2023 -PY - 2023 -VL - 17 -DO - 10.1177/11795549231205206 -AN - WOS:001096010700001 -AD - Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China -AD - Henan Canc Hosp, Zhengzhou 450008, Peoples R China -Y2 - 2023-12-27 -ER - - -TY - JOUR -AU - Seban, Romain-David -AU - Assie, Jean-Baptiste -AU - Giroux-Leprieur, Etienne -AU - Massiani, Marie-Ange -AU - Soussan, Michael -AU - Bonardel, Gerald -AU - Chouaid, Christos -AU - Playe, Margot -AU - Goldfarb, Lucas -AU - Duchemann, Boris -AU - Mezquita, Laura -AU - Girard, Nicolas -AU - Champion, Laurence -TI - Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab -T2 - CANCERS -M3 - Article -AB - Background: We aimed to assess the clinical utility of a previously published score combining the total metabolic tumor volume (TMTV) on baseline FDG-PET/CT and pretreatment derived from the neutrophils to lymphocytes ratio (dNLR) for prognostication in NSCLC patients undergoing first-line immunotherapy (IT).Methods: In this multicenter retrospective study, 63 advanced NSCLC patients with a PD-L1 tumor proportion score (TPS) >= 50%, who underwent FDG-PET/CT before first-line IT, treated from January 2017 to September 2019, were enrolled. Associations between this score and the progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and overall response rate (ORR) were evaluated.Results: The median (m) PFS and mOS were 7.7 (95% CI 4.9-10.6) and 12.1 (8.6-15.6) months, respectively, and DCR and ORR were 65% and 58%, respectively. mOS was 17.9 months (14.6 not reached) for the good group versus 13.8 (95%CI 8.4-18.9) and 6.6 (CI 2.0-11.2) months for the intermediate and poor groups, respectively. mPFS was 15.1 (95%CI 12.1-20.0) months for the good group versus 5.2 (1.9-8.5) and 1.9 (95%CI 1.3-2.5) months for the intermediate and poor groups, respectively. The poor prognosis group was associated with DCR and ORR (p< 0.05).Conclusions: The metabolic score combining TMTV on the baseline FDG-PET/CT scan and pretreatment dNLR was associated with the survival and response in a cohort of advanced NSCLC patients with >= 50% PD-L1 receiving frontline IT. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 2072-6694 -DA - 2020 AUG -PY - 2020 -VL - 12 -IS - 8 -C7 - 2234 -DO - 10.3390/cancers12082234 -AN - WOS:000578978500001 -AD - Inst Curie, Dept Nucl Med, F-92210 St Cloud, France -AD - Paris Est Univ, Dept Pneumol, Ctr Hosp Intercommunal Creteil, Inserm U955,UPEC,IMRB,Equipe CEpiA, F-94010 Creteil, France -AD - Sorbonne Univ, Ctr Rech Cordeliers, Functionnal Genom Solid Tumors Lab, INSERM, F-75006 Paris, France -AD - Hop Ambroise Pare, AP HP, Dept Resp Dis & Thorac Oncol, F-92100 Boulogne Billancourt, France -AD - Inst Curie, Dept Med Oncol, F-92210 St Cloud, France -AD - Paris 13 Univ, Hop Avicenne, AP HP, Dept Nucl Med, F-93000 Bobigny, France -AD - Ctr Cardiol Nord, Dept Nucl Med, F-93200 St Denis, France -AD - Paris 13 Univ, Hop Avicenne, AP HP, Dept Med Oncol, F-93000 Bobigny, France -AD - IDIBAPS, Dept Med Oncol, Hosp Clin, Lab Translat Genom & Target Therapeut Solid Tumor, Barcelona 08036, Spain -AD - Inst Curie, Inst Thorax Curie Montsouris, F-75006 Paris, France -M2 - Ctr Cardiol Nord -Y2 - 2020-10-27 -ER - - -TY - JOUR -AU - Tanaka, Hisashi -AU - Tanzawa, Shigeru -AU - Misumi, Toshihiro -AU - Makiguchi, Tomonori -AU - Inaba, Megumi -AU - Honda, Takeshi -AU - Nakamura, Junya -AU - Inoue, Koji -AU - Kishikawa, Takayuki -AU - Nakashima, Masanao -AU - Fujiwara, Keiichi -AU - Kohyama, Tadashi -AU - Ishida, Hiroo -AU - Kuyama, Shoichi -AU - Miyazawa, Naoki -AU - Nakamura, Tomomi -AU - Miyawaki, Hiroshi -AU - Oda, Naohiro -AU - Ishikawa, Nobuhisa -AU - Morinaga, Ryotaro -AU - Kusaka, Kei -AU - Fujimoto, Nobukazu -AU - Fukuda, Yasushi -AU - Yasugi, Masayuki -AU - Tsuda, Takeshi -AU - Ushijima, Sunao -AU - Shibata, Kazuhiko -AU - Shibayama, Takuo -AU - Bessho, Akihiro -AU - Kaira, Kyoichi -AU - Shiraishi, Kenshiro -AU - Matsutani, Noriyuki -AU - Seki, Nobuhiko -TI - A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis -T2 - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY -M3 - Article -AB - Background: The standard of care for unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC study. Although multiple Japanese phase II studies have shown high efficacy and tolerability of CRT with cisplatin plus S-1 (SP), no prospective study using durvalumab after SP-based CRT has been reported.Objectives: We conducted a multicenter phase II study of this approach, the interim analysis of which showed a high transition rate to durvalumab consolidation therapy. Here, we report the primary analysis results.Design: In treatment-naive LA-NSCLC, cisplatin (60 mg/m(2), day 1) and S-1 (80-120 mg/body, days 1-14) were administered with two 4-week cycles with concurrent thoracic radiotherapy (60 Gy) followed by durvalumab (10 mg/kg) every 2 weeks for up to 1 year.Methods: The primary endpoint was 1-year progression-free survival (PFS). The expected 1-year PFS and its lower limit of the 80% confidence interval (CI) were set as 63% and 47%, respectively, based on the results of TORG1018 study.Results: In all, 59 patients were enrolled, with 51 (86.4%) proceeding to durvalumab. The objective response rate throughout the study was 72.9% (95% CI: 59.7-83.6%). After median follow-up of 21.9 months, neither median PFS nor OS was reached. The 1-year PFS was 72.5% (80% CI: 64.2-79.2%, 95% CI: 59.1-82.2%), while the 1-year overall survival was 91.5% (95% CI: 80.8-96.4%). No grade 5 adverse events were observed throughout the study. The most common adverse event during the consolidation phase was pneumonitis (any grade, 78.4%; grade > 3, 2.0%). Eventually, 52.5% of patients completed 1-year durvalumab consolidation therapy from CRT initiation.Conclusion: This study of durvalumab after SP-based CRT met its primary endpoint and found a 1-year PFS of 73% from CRT initiation. This study provides the first prospective data on the prognosis and tolerability of durvalumab consolidation from the initiation of CRT. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1758-8340 -SN - 1758-8359 -DA - 2022 -PY - 2022 -VL - 14 -C7 - 17588359221142786 -DO - 10.1177/17588359221142786 -AN - WOS:000928022800001 -AD - Hirosaki Univ, Grad Sch Med, Dept Resp Med, Hirosaki, Aomori, Japan -AD - Teikyo Univ, Sch Med, Dept Internal Med, Div Med Oncol, Itabashi Ku, Tokyo, Japan -AD - Yokohama City Univ, Sch Med, Dept Biostat, Yokohama, Kanagawa, Japan -AD - Kumamoto City Hosp, Dept Resp Med, Kumamoto, Japan -AD - Teikyo Univ, Sch Med, Dept Internal Med, Div Med Oncol, Itabashi Ku, Tokyo, Japan -AD - Ehime Prefectural Cent Hosp, Dept Resp Med, Matsuyama, Ehime, Japan -AD - Tochigi Canc Ctr, Dept Resp Med, Utsunomiya, Tochigi, Japan -AD - Shin Yurigaoka Gen Hosp, Dept Resp Med, Kawasaki, Kanagawa, Japan -AD - Natl Hosp Org Okayama Med Ctr, Dept Resp Med, Okayama, Japan -AD - Teikyo Univ Hosp, Dept Internal Med, Kawasaki, Kanagawa, Japan -AD - Showa Univ, Northern Yokohama Hosp, Dept Internal Med, Yokohama, Kanagawa, Japan -AD - Natl Hosp Org, Iwakuni Clin Ctr, Dept Resp Med, Iwakuni, Japan -AD - Saiseikai Yokohamashi Nanbu Hosp, Dept Resp Med, Yokohama, Kanagawa, Japan -AD - Saga Univ, Fac Med, Dept Internal Med, Div Hematol Resp Med & Oncol, Saga, Saga, Japan -AD - Kagawa Prefectural Cent Hosp, Dept Resp Med, Takamatsu, Kagawa, Japan -AD - Fukuyama City Hosp, Dept Internal Med, Hiroshima, Japan -AD - Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Hiroshima, Japan -AD - Oita Prefectural Hosp, Dept Thorac Med Oncol, Oita, Oita, Japan -AD - Natl Hosp Org Tokyo Natl Hosp, Ctr Pulm Dis, Kiyose, Tokyo, Japan -AD - Okayama Rosai Hosp, Dept Med Oncol, Okayama, Okayama, Japan -AD - Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan -AD - Chugoku Cent Hosp, Dept Resp Med, Hiroshima, Japan -AD - Toyama Prefectural Cent Hosp, Dept Resp Med, Toyama, Toyama, Japan -AD - Kumamoto Kenhoku Hosp, Dept Med Oncol, Tamana, Kumamoto, Japan -AD - Kouseiren Takaoka Hosp, Dept Med Oncol, Takaoka, Toyama, Japan -AD - Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Okayama, Japan -AD - Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka, Saitama, Japan -AD - Teikyo Univ, Sch Med, Dept Radiol, Itabashi Ku, Tokyo, Japan -AD - Teikyo Univ, Sch Med, Dept Internal Med, Div Med Oncol, 2-11-1 Kaga,Itabashi Ku, Tokyo 1738605, Japan -AD - Teikyo Univ Hosp, Dept Surg, Kawasaki, Kanagawa, Japan -M2 - Kumamoto City Hosp -M2 - Ehime Prefectural Cent Hosp -M2 - Shin Yurigaoka Gen Hosp -M2 - Natl Hosp Org Okayama Med Ctr -M2 - Natl Hosp Org -M2 - Saiseikai Yokohamashi Nanbu Hosp -M2 - Kagawa Prefectural Cent Hosp -M2 - Fukuyama City Hosp -M2 - Hiroshima Prefectural Hosp -M2 - Oita Prefectural Hosp -M2 - Natl Hosp Org Tokyo Natl Hosp -M2 - Okayama Rosai Hosp -M2 - Chugoku Cent Hosp -M2 - Toyama Prefectural Cent Hosp -M2 - Kumamoto Kenhoku Hosp -M2 - Kouseiren Takaoka Hosp -M2 - Japanese Red Cross Okayama Hosp -Y2 - 2023-02-24 -ER - - -TY - JOUR -AU - RAMSEY, MATTHEW ROBERT -TI - Identification of Epigenetic Regulators Mediating Resistance to FGFR Inhibition in Squamous Cell Carcinoma -M3 - Awarded Grant -AB - PROJECT SUMMARY/ABSTRACTSquamous Cell Carcinoma (SCC) is a common cancer that develops in stratified epithelial tissues such as theepidermis, the oral cavity, and the lungs. Standard treatments for patients with un-resectable SCC, whichinclude radiation, cis-platin, 5-fluorouracil, and paclitaxel, are only modestly effective, resulting in approximately45,000 deaths every year. While there has been some progress in the development of target therapies, suchas EGFR inhibition, these treatments have not shown the efficacy seen in other tumors such as lungAdenocarcinoma. Recent advances in immunotherapy have shown great promise in treating SCC, even atadvanced stage, but like many other tumor types only a minority of SCC patients respond to immunotherapy.In addition, the risk of cutaneous SCC is greatly increased in immunosuppressed transplant recipients, who arepoor candidates for immunotherapy. This project aims to identify novel therapeutic targets that mediateresistance to FGFR inhibition in SCC. We will employ an orthotopic transplant model system that is driven bygenetic alterations commonly found in human SCC tumors. A drop-out screen using a CRISPR/Cas9 librarywill be performed in vivo using orthotopic tumors. Hits will be validated using in vitro and in vivo SCC modelsystems employing either shRNA or CRISPR/Cas9-based target gene knockdown, as well as availableantibody-based or small molecule inhibitors. In addition, we will validate the expression of potential targetshuman SCC tumors by Tissue Microarray, which will help to identify clinical characteristics of patients that maybenefit from this therapeutic strategy. There are many drugs that are FDA-approved or in clinical trials thathave not been tested for cooperation with FGFR inhibition, and thus this un-biased approach is likely touncover unexpected vulnerabilities that can be rapidly translated into treatments for SCC patients. -DA - 2020 -PY - 2020 -AN - GRANTS:14967681 -G1 - 5R21CA226099-02; 9870895; R21CA226099 -AD - BRIGHAM AND WOMEN'S HOSPITAL -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - RAMSEY, MATTHEW ROBERT -TI - Identification of Epigenetic Regulators Mediating Resistance to FGFR Inhibition in Squamous Cell Carcinoma -M3 - Awarded Grant -AB - PROJECT SUMMARY/ABSTRACTSquamous Cell Carcinoma (SCC) is a common cancer that develops in stratified epithelial tissues such as theepidermis, the oral cavity, and the lungs. Standard treatments for patients with un-resectable SCC, whichinclude radiation, cis-platin, 5-fluorouracil, and paclitaxel, are only modestly effective, resulting in approximately45,000 deaths every year. While there has been some progress in the development of target therapies, suchas EGFR inhibition, these treatments have not shown the efficacy seen in other tumors such as lungAdenocarcinoma. Recent advances in immunotherapy have shown great promise in treating SCC, even atadvanced stage, but like many other tumor types only a minority of SCC patients respond to immunotherapy.In addition, the risk of cutaneous SCC is greatly increased in immunosuppressed transplant recipients, who arepoor candidates for immunotherapy. This project aims to identify novel therapeutic targets that mediateresistance to FGFR inhibition in SCC. We will employ an orthotopic transplant model system that is driven bygenetic alterations commonly found in human SCC tumors. A drop-out screen using a CRISPR/Cas9 librarywill be performed in vivo using orthotopic tumors. Hits will be validated using in vitro and in vivo SCC modelsystems employing either shRNA or CRISPR/Cas9-based target gene knockdown, as well as availableantibody-based or small molecule inhibitors. In addition, we will validate the expression of potential targetshuman SCC tumors by Tissue Microarray, which will help to identify clinical characteristics of patients that maybenefit from this therapeutic strategy. There are many drugs that are FDA-approved or in clinical trials thathave not been tested for cooperation with FGFR inhibition, and thus this un-biased approach is likely touncover unexpected vulnerabilities that can be rapidly translated into treatments for SCC patients. -DA - 2019 -PY - 2019 -AN - GRANTS:10587842 -G1 - 1R21CA226099-01A1; 9728268; R21CA226099 -AD - BRIGHAM AND WOMEN'S HOSPITAL -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - KHERADMAND, FARRAH ; ANITA L SABICHI -TI - Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC -M3 - Awarded Grant -AB - This application seeks to conduct a phase Ib proof-of-concept clinical trial at the Houston VA Lung PrecisionOncology Program (LPOP) to determine if intratumor injections with pooled human immunoglobulins (IVIG) plusan immune adjuvant are safe. Patients with stage IV non-small cell lung cancer (NSCLC) who receive immunecheckpoint inhibitors (ICIs) show treatment resistance. Solid tumors fail to establish in unrelated hosts becauseof the host’s antibodies that deposit immune complexes and activate local antigen-presenting cells (APCs) in thetumor. Further, established tumors from related donors injected with alloantibodies plus an adjuvant, poly-IC, apotent TLR-3 agonist, abrogated the original tumors and their distant metastasis in mice. In a single phase I study,patients with solid tumors refractory to ICIs tolerated multiple intratumoral (IT) and intramuscular (IM) injectionswith a stabilized form of poly-IC, such as poly-ICLC, (Hiltonol®; Oncovir Inc, USA). However, whether IVIGintratumor injections can cause immune complex formation and, combined with TLR-3 agonists, can enhanceICIs in patients with advanced non-small cell lung cancer (NSCLC), remains unknown. Our preliminary dataindicate that IVIG (Hizentra®) binds to antigens found in human NSCLC, indicating that like the preclinical models,intratumor injection with IVIG could induce immune complexes, inducing antitumor responses. We will test ouroverarching hypothesis that IT injection of IVIG + poly-ICLC and IM injection of poly-ICLC to boost APCs, aresafe and can activate antitumor immunity in patients with advanced NSCLC with the following Specific Aims:Specific Aim 1: To determine the safety and maximum tolerated dose of intratumor injection of animmune adjuvant plus alloantibodies in veterans with advanced NSCLC. Hypothesis: a combination ofintratumor (IT) injections of IVIG + poly-ICLC, and IM injections of poly-ICLC are safe in patients with advanced-stage NSCLC. We plan to conduct a first-in-human phase Ib single-center study at the Lung Precision OncologyProgram (LPOP) MEDVAMC site titled: Harnessing Allo-Immunity To Enhance Immune Checkpoint Inhibitors inAdvanced NSCLC (HAITEN-ICI). The study objective will be to evaluate the safety of, and maximum tolerateddose (MTD) of IT injections of a peripherally accessible metastatic site with IVIG + poly-ICLC followed by IMpoly-ICLC in veterans with stage IV NSCLC (N=16) who are eligible to receive systemic ICIs monotherapy. Theprimary endpoint includes assessment of an MTD dose for IT injection of IVIG + poly-ICLC, and IM injection ofpoly-ICLC given in combination with ICI in the same cohort. Specific Aim 2: To determine the progression-free survival in response to immune adjuvant plus alloantibodies in veterans with advanced NSCLC.Hypothesis: compared to standard of care (SOC), poly-ICLC + IVIG improve progression-free survival in patientswith advanced NSCLC receiving ICI. If our proof-of-concept pilot study conducted as part of Aim 1 shows nosafety concerns, and we identify MTD, we will proceed with a phase II multi-center randomized clinical trial todetermine the safety and progression-free survival (PFS) in veterans with advanced NSCLC treated withintertumoral IVIG + poly-ICLC, compared to SOC. Specific Aim 3: To explore immune responses in pre-andpost-intratumor treatment with IVIG + poly-ICLC in Phase Ib & II cohorts. Hypothesis: intratumor injectionsusing IVIG + poly-ICLC activates adaptive immune responses in advanced NSCLC patients. We will examinepre-, mid-and post-treatment systemic immune activation in comparison with baseline in patients enrolled in pilotphase Ib and if safe, in phase II study. We will compare pre- and post-therapy immune responses using state-of-the-art technologies for locoregional tumors. The proposed two-stage clinical trial is a novel approach todetermine if inducing tumor-specific immune responses can enhance systemic ICI treatment and improve clinicaloutcomes for veterans with advanced NSCLC. Therefore, a combined treatment with an immune adjuvant suchas poly-ICLC, plus IVIG could provide a novel approach to overcoming the tumor-suppressive microenvironment. -DA - 2024 -PY - 2024 -AN - GRANTS:17672463 -G1 - 10806202; 1I01CX002636-01A1; I01CX002636 -AD - MICHAEL E DEBAKEY VA MEDICAL CENTER -AD - MICHAEL E DEBAKEY VA MEDICAL CENTER -Y2 - 2024-05-12 -ER - - -TY - JOUR -AU - Larimer, Benjamin M. -AU - Wehrenberg-Klee, Eric -AU - Caraballo, Alexander -AU - Mahmood, Umar -TI - Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy -T2 - JOURNAL OF NUCLEAR MEDICINE -M3 - Article -AB - Immune checkpoint inhibitors have made rapid advances, resulting in multiple Food and Drug Administration-approved therapeutics that have markedly improved survival. However, these benefits are limited to a minority subpopulation that achieves a response. Predicting which patients are most likely to benefit would be valuable for individual therapy optimization. T-cell markers such as CD3 by examining active recruitment of the T cells responsible for cancer-cell death represent a more direct approach to monitoring tumor immune response than pretreatment biopsy or genetic screening. This approach could be especially effective as numerous different therapeutic strategies emerge, decreasing the need for drug-specific biomarkers and instead focusing on T-cell infiltration, which has been previously correlated with treatment response. Methods: A CD3 PET imaging agent targeting T cells was synthesized to test the role of such imaging as a predictive marker. The Zr-89-p-isothiocyanatobenzyldeferoxamine-CD3 PET probe was assessed in a murine tumor xenograft model of anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) immunotherapy of colon cancer. Results: Imaging on day 14 revealed 2 distinct groups of mice stratified by PET signal intensity. Although there was no significant difference in tumor volume on the day of imaging, in the high-uptake group subsequent measurements revealed significantly smaller tumors than in either the low-uptake group or the untreated controls. In contrast, there was no significant difference in the size of tumors between the low-uptake and untreated control mice. Conclusion: These findings indicate that high CD3 PET uptake in the anti-CTLA-4-treated mice correlated with subsequent reduced tumor volume and was a predictive biomarker of response. -PU - SOC NUCLEAR MEDICINE INC -PI - RESTON -PA - 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA -SN - 0161-5505 -SN - 1535-5667 -DA - 2016 OCT -PY - 2016 -VL - 57 -IS - 10 -SP - 1607 -EP - 1611 -DO - 10.2967/jnumed.116.173930 -AN - WOS:000384961900027 -AD - Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA -Y2 - 2016-11-02 -ER - - -TY - JOUR -Z2 - 吴寅飞 -Z2 - 周娟 -Z2 - 叶伶云 -Z2 - 苏春霞 -AU - Wu Yinfei -AU - Zhou Juan -AU - Ye Lingyun -AU - Su Chunxia -TI - Progress in immune microenvironment and immunotherapy of driver gene negative advanced non-small cell lung cancer patients with brain metastases -T2 - Chinese Journal of Clinical Oncology -M3 - Review -AB - Distant metastases are inevitable in patients with advanced non-small cell lung cancer (NSCLC),and the brain is one of the most common site of metastasis.Patients who suffer brain metastases (BM) may have headaches,blurred vision,hemiplegia,limb numbness,and other symptoms.Quality of life is severely impacted for these patients.Previous studies have shown that prognosis for patients with BM is usually very poor,and natural median survival time is only about 3 months.Traditional treatment strategies for driver-gene negative NSCLC patients with BM include local intervention surgery,radiotherapy,and systemic chemotherapy.New generation targeted drugs can be used for patients with gene mutations such as EGFR,ALK,and ROS1.However,the efficacy of both approaches has not been optimized in patients with BM.Immunotherapy based on immune checkpoint inhibitors (ICIs) has brought new hope to patients with advanced NSCLC.A large number of randomized clinical trials have shown that the application of ICIs on melanoma and NSCLC patients with BM can produce amazing anti-tumor effects compared with chemotherapy.Studies have confirmed that the vasculature in BM is significantly different from normal cerebral vasculature.BM also establish a unique tumor microenvironment,and unique immune cell components and functions.The characteristics of immune cells infiltrating metastases are different from those infiltrating primary lesions.In addition,several retrospective studies have found that either immune-monotherapy or combined immunotherapy is effective in lung cancer patients with BM.Research into predictive biomarkers for assessing the efficacy of immunotherapy is hampered by the difficulty of obtaining brain tissue samples.In addition to programmed cell death ligand-1 (PD-L1) expression in tumor cells,tumor mutation burden (TMB) may be a potential biomarker to predict the efficacy of immunotherapy.This review focuses on tumor microenvironment of NSCLC metastases,and surveys progress in ICI therapies,to provide a reference for the treatment of NSCLC patients with BM. -SN - 1000-8179 -DA - 2021 -PY - 2021 -VL - 48 -IS - 24 -SP - 1253 -EP - 1258 -C7 - 1000-8179(2021)48:24<1253:QDJYYX>2.0.TX;2-9 -AN - CSCD:7160505 -AD - 同济大学附属上海市肺科医院肿瘤科, 上海 200433, 中国 -AD - Department of Oncology,Shanghai Pulmonary Hospital,Tongji University, Shanghai 200433, China -M2 - 同济大学附属上海市肺科医院肿瘤科 -M2 - Department of Oncology,Shanghai Pulmonary Hospital,Tongji University -Y2 - 2022-05-27 -ER - - -TY - JOUR -AU - Hamada, Akira -AU - Soh, Junichi -AU - Mitsudomi, Tetsuya -TI - Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Review -AB - Definitive chemoradiotherapy (CRT) has been a standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC). However, locoregional recurrence occurs in about 30% of patients after definitive CRT. Recently, the addition of durvalumab as maintenance therapy has shown to improve the outcome of these patients. However, locoregional recurrence will still remain. "Salvage surgery" has been performed to achieve local control in clinical practice, although its clinical significance is unclear. In this review, we define salvage surgery as lung resection for local control of the tumor which was not planned initially, after failure or insufficient treatment effect of the initial CRT for locally advanced cancer and evaluated nine studies to gain some insights on its role in the treatment of lung cancer. The time from radiotherapy (RT) to salvage surgery varied considerably (range, 3 to 282 weeks). Salvage surgery was performed for persistent disease (47%) and locoregional recurrence (52%). Lobectomy (63%) and mediastinal lymph node dissections (90%) were the most common procedures. However, the rate of pneumonectomy was higher in salvage surgery (28%) compared to that in lung resection in general. The median morbidity was 41% (range, 15% to 62%) and the mortality was 4% (range, 0 to 11%) which appeared acceptable. The median recurrence-free survival and overall survival (OS) after salvage surgery ranged from 10 to 22 months and 13 to 76 months, respectively. Favorable prognostic factors of salvage surgery were longer period from RT to salvage surgery and radiological downstaging. The pathological response was also prognostic, although this information cannot be obtained preoperatively. We conclude that salvage surgery can be considered especially for those with late local recurrence or those with the metabolic response. Given the condition where phase III trials are difficult, the accumulation of real-world evidence in a prospective fashion will be necessary. -PU - AME PUBL CO -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2021 JAN -PY - 2021 -VL - 10 -IS - 1 -SP - 555 -EP - 562 -DO - 10.21037/tlcr-20-453 -AN - WOS:000616118200030 -AD - Kindai Univ, Fac Med, Dept Surg, Div Thorac Surg, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan -Y2 - 2021-03-16 -ER - - -TY - JOUR -AU - GAN, BOYI ; ALBERT KOONG -TI - Acquired Resistance to Therapy and Iron (ARTI) Center -M3 - Awarded Grant -AB - Overall SummaryApproximately 50% of cancer patients are treated with radiation therapy (RT), but local recurrence can still occureven with the use of advanced RT techniques. This local recurrence, which commonly develops in 30-50% ofcancer cases, is exacerbated by the acquisition of RT resistance. This RT resistance is especially true forpatients with locally advanced thoracic cancers, such as lung and esophageal cancers. RT can lead to an iron-dependent cell death modality, called ferroptosis, but whether ferroptosis resistance occurs within tumors givingrise to acquired RT resistance is not known and is the central theme of the proposed Acquired Resistance toTherapy and Iron (ARTI) Center. The overarching goals of the ARTI Center are: 1) to bridge the basic sciencemechanisms of ferroptosis in acquired resistance with translational research in preclinical models and humanpatient samples; 2) to identify cohorts of patients who are at greatest risk to develop acquired RT resistance;and 3) to investigate the ability of novel therapeutic agents to re-sensitize lung and esophageal cancer cells toradiation by inducing ferroptosis. The ARTI Center comprises two basic/mechanistic projects (Project 1 andProject 2), one preclinical/translational project (Project 3), and one shared resource core (Molecular ImagingCore [MIC]). Project 1 will focus on elucidating whether ferroptosis evasion is a key driver in acquired RTresistance using radioresistant lung cancer and esophageal cancer cell lines and xenograft models that will beused in Project 2. Project 2 will test the hypothesis that hypoxia, a long-recognized driver of tumorradioresistance, suppresses ferroptosis induction during RT and contributes to RT-induced acquired resistanceto ferroptosis. Furthermore, expression of hypoxia-related genes and other targets of acquired RT resistance willbe analyzed by single-cell sequencing in Project 3. Project 3 investigates changes in immune cells in the tumormicroenvironment of humanized tumor models derived from chemoradiation therapy-responsive or -non-responsive esophageal adenocarcinoma patients. These ferroptosis-mediated immunologic changes in thetumor microenvironment may serve as prognostic biomarkers for identifying tumors that may acquire RTresistance and predicting cancer patient outcomes, which could, in the future, be modulated by the ferroptosis-inducing agents tested in Projects 1 and 2. Projects 1, 2, and 3 will be supported by the MIC that utilizesbioluminescence imaging to monitor tumor growth, positron emission tomography (PET) tracers to monitorcystine transporter activity and to identify hypoxic regions within tumors, as well as novel, redox-tuned PETtracers for identifying activated innate immune cells. The ARTI Center will develop an Administrative Core foreffective communication and collaboration between the ARTI Center Project and Core Leaders and Co-Leaderswith National Cancer Institute (NCI) of Acquired Resistance to Therapy Network (ARTNet) program staff as wellas other ARTNet centers to synergize ARTI Center-related activities. -DA - 2023 -PY - 2023 -AN - GRANTS:17755523 -G1 - 10707117; 5U54CA274220-02; U54CA274220 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - GAN, BOYI ; Steven Hsesheng Lin; Spencer Rae Rosario -TI - Administrative Supplement: Metabolic Alterations Associated with Acquired Resistance to Ferroptosis in Esophageal Cancer -M3 - Awarded Grant -AB - Overall SummaryApproximately 50% of cancer patients are treated with radiation therapy (RT), but local recurrence can still occureven with the use of advanced RT techniques. This local recurrence, which commonly develops in 30-50% ofcancer cases, is exacerbated by the acquisition of RT resistance. This RT resistance is especially true forpatients with locally advanced thoracic cancers, such as lung and esophageal cancers. RT can lead to an iron-dependent cell death modality, called ferroptosis, but whether ferroptosis resistance occurs within tumors givingrise to acquired RT resistance is not known and is the central theme of the proposed Acquired Resistance toTherapy and Iron (ARTI) Center. The overarching goals of the ARTI Center are: 1) to bridge the basic sciencemechanisms of ferroptosis in acquired resistance with translational research in preclinical models and humanpatient samples; 2) to identify cohorts of patients who are at greatest risk to develop acquired RT resistance;and 3) to investigate the ability of novel therapeutic agents to re-sensitize lung and esophageal cancer cells toradiation by inducing ferroptosis. The ARTI Center comprises two basic/mechanistic projects (Project 1 andProject 2), one preclinical/translational project (Project 3), and one shared resource core (Molecular ImagingCore [MIC]). Project 1 will focus on elucidating whether ferroptosis evasion is a key driver in acquired RTresistance using radioresistant lung cancer and esophageal cancer cell lines and xenograft models that will beused in Project 2. Project 2 will test the hypothesis that hypoxia, a long-recognized driver of tumorradioresistance, suppresses ferroptosis induction during RT and contributes to RT-induced acquired resistanceto ferroptosis. Furthermore, expression of hypoxia-related genes and other targets of acquired RT resistance willbe analyzed by single-cell sequencing in Project 3. Project 3 investigates changes in immune cells in the tumormicroenvironment of humanized tumor models derived from chemoradiation therapy-responsive or -non-responsive esophageal adenocarcinoma patients. These ferroptosis-mediated immunologic changes in thetumor microenvironment may serve as prognostic biomarkers for identifying tumors that may acquire RTresistance and predicting cancer patient outcomes, which could, in the future, be modulated by the ferroptosis-inducing agents tested in Projects 1 and 2. Projects 1, 2, and 3 will be supported by the MIC that utilizesbioluminescence imaging to monitor tumor growth, positron emission tomography (PET) tracers to monitorcystine transporter activity and to identify hypoxic regions within tumors, as well as novel, redox-tuned PETtracers for identifying activated innate immune cells. The ARTI Center will develop an Administrative Core foreffective communication and collaboration between the ARTI Center Project and Core Leaders and Co-Leaderswith National Cancer Institute (NCI) of Acquired Resistance to Therapy Network (ARTNet) program staff as wellas other ARTNet centers to synergize ARTI Center-related activities. -DA - 2023 -PY - 2023 -AN - GRANTS:17762745 -G1 - 10830901; 3U54CA274220-02S1; U54CA274220 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - BACHOVCHIN, WILLIAM W; JONES, BARRY (contact) -TI - A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma -M3 - Awarded Grant -AB - PUBLIC HEALTH RELEVANCE: Metastatic melanoma is a lethal skin cancer with response rates to chemotherapy of only 5-20%, and although immunotherapy (Proleukin and Yervoy) provides an alternative option that can produce durable responses and long-term survival, as currently used, immunotherapy only provides a benefit in a small proportion of patients. A newer targeted agent, vemurafenib (PLX4032), is a B-Raf kinase inhibitor that can produce remarkable responses in melanoma harboring the BRAFV600E mutation, but following the initial response, drug resistance allows the recurrence of aggressive malignant disease after only a few months. This proposal will test the feasibility of using a small molecule immunotherapeutic agent to activate a tumor-specific immune response that can suppress the recurrence of disease after the initial regression of melanoma lesions in response to PLX4032. -DA - 2014 -PY - 2014 -AN - GRANTS:11929734 -G1 - 3R41CA174008-01A1S1; 8835639; R41CA174008 -AD - ARISAPH PHARMACEUTICALS, INC. -AD - ARISAPH PHARMACEUTICALS, INC. -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - BACHOVCHIN, WILLIAM W; JONES, BARRY (contact) -TI - A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma -M3 - Awarded Grant -AB - PUBLIC HEALTH RELEVANCE: Metastatic melanoma is a lethal skin cancer with response rates to chemotherapy of only 5-20%, and although immunotherapy (Proleukin and Yervoy) provides an alternative option that can produce durable responses and long-term survival, as currently used, immunotherapy only provides a benefit in a small proportion of patients. A newer targeted agent, vemurafenib (PLX4032), is a B-Raf kinase inhibitor that can produce remarkable responses in melanoma harboring the BRAFV600E mutation, but following the initial response, drug resistance allows the recurrence of aggressive malignant disease after only a few months. This proposal will test the feasibility of using a small molecule immunotherapeutic agent to activate a tumor-specific immune response that can suppress the recurrence of disease after the initial regression of melanoma lesions in response to PLX4032. -DA - 2013 -PY - 2013 -AN - GRANTS:10307924 -G1 - 1R41CA174008-01A1; 8521751; R41CA174008 -AD - ARISAPH PHARMACEUTICALS, INC. -AD - ARISAPH PHARMACEUTICALS, INC. -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - GAN, BOYI ; ALBERT KOONG -TI - Acquired Resistance to Therapy and Iron (ARTI) Center -M3 - Awarded Grant -AB - Overall SummaryApproximately 50% of cancer patients are treated with radiation therapy (RT), but local recurrence can still occureven with the use of advanced RT techniques. This local recurrence, which commonly develops in 30-50% ofcancer cases, is exacerbated by the acquisition of RT resistance. This RT resistance is especially true forpatients with locally advanced thoracic cancers, such as lung and esophageal cancers. RT can lead to an iron-dependent cell death modality, called ferroptosis, but whether ferroptosis resistance occurs within tumors givingrise to acquired RT resistance is not known and is the central theme of the proposed Acquired Resistance toTherapy and Iron (ARTI) Center. The overarching goals of the ARTI Center are: 1) to bridge the basic sciencemechanisms of ferroptosis in acquired resistance with translational research in preclinical models and humanpatient samples; 2) to identify cohorts of patients who are at greatest risk to develop acquired RT resistance;and 3) to investigate the ability of novel therapeutic agents to re-sensitize lung and esophageal cancer cells toradiation by inducing ferroptosis. The ARTI Center comprises two basic/mechanistic projects (Project 1 andProject 2), one preclinical/translational project (Project 3), and one shared resource core (Molecular ImagingCore [MIC]). Project 1 will focus on elucidating whether ferroptosis evasion is a key driver in acquired RTresistance using radioresistant lung cancer and esophageal cancer cell lines and xenograft models that will beused in Project 2. Project 2 will test the hypothesis that hypoxia, a long-recognized driver of tumorradioresistance, suppresses ferroptosis induction during RT and contributes to RT-induced acquired resistanceto ferroptosis. Furthermore, expression of hypoxia-related genes and other targets of acquired RT resistance willbe analyzed by single-cell sequencing in Project 3. Project 3 investigates changes in immune cells in the tumormicroenvironment of humanized tumor models derived from chemoradiation therapy-responsive or -non-responsive esophageal adenocarcinoma patients. These ferroptosis-mediated immunologic changes in thetumor microenvironment may serve as prognostic biomarkers for identifying tumors that may acquire RTresistance and predicting cancer patient outcomes, which could, in the future, be modulated by the ferroptosis-inducing agents tested in Projects 1 and 2. Projects 1, 2, and 3 will be supported by the MIC that utilizesbioluminescence imaging to monitor tumor growth, positron emission tomography (PET) tracers to monitorcystine transporter activity and to identify hypoxic regions within tumors, as well as novel, redox-tuned PETtracers for identifying activated innate immune cells. The ARTI Center will develop an Administrative Core foreffective communication and collaboration between the ARTI Center Project and Core Leaders and Co-Leaderswith National Cancer Institute (NCI) of Acquired Resistance to Therapy Network (ARTNet) program staff as wellas other ARTNet centers to synergize ARTI Center-related activities. -DA - 2022 -PY - 2022 -AN - GRANTS:16277050 -G1 - 10517140; 1U54CA274220-01; U54CA274220 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - PALENA, CLAUDIA -TI - Novel Targets for Immunotherapy -M3 - Awarded Grant -AB - Our laboratory has identified and characterized the T-box transcription factor brachyury as a driver of cancer plasticity and tumor resistance to various therapeutics. We have shown that brachyury is expressed in various types of carcinomas, including lung, triple negative breast, colon, small cell lung carcinomas, germ cell tumors (both embryonal and seminomas), and the rare tumor type chordoma. In collaboration with the private sector, we have now developed three brachyury-targeting cancer vaccine platforms, which are currently undergoing clinical evaluation, including (1) a yeast-brachyury vaccine; (2) an adenovirus-brachyury vaccine; and (3) a poxviral vector-based vaccine expressing the transgenes for brachyury and three human costimulatory molecules (B7-1, ICAM-1, and LFA-3, designated TRICOM). Recently, a Phase I trial of a Modified Vaccine Ankara (MVA) priming vaccine followed by a fowlpox virus boosting vaccine encoding brachyury and TRICOM has been completed in patients with advanced solid tumors. The results of this trial showed the development of brachyury-specific T cells and T cells against the "cascade antigens" CEA and MUC1 in the majority of patients, in the absence of toxicities. Similarly, a Phase I trial of a multi-targeted recombinant Adenovirus 5-based vaccine encoding brachyury, CEA and MUC1 was completed, demonstrating the generation of T-cell responses against all three antigens in the majority of patients, without any evidence of antigenic competition or toxicity. The study of brachyury as a tumor-associated antigen and its role as a driver of cancer plasticity led our laboratory to demonstrate that carcinoma cells bearing mesenchymal features may also be resistant to the cytotoxic effect of immune effector cells. These observations led us to investigate novel therapeutic modalities that could modify the phenotype of a tumor from mesenchymal to epithelial, in an attempt to improve the tumor's susceptibility to immune attack. As multiple tumor extrinsic factors, including cytokines, chemokines and growth factors, could induce EMT or plasticity in cancer cells, we are investigating whether blockade of such factors may revert the phenotype and resistance of the tumor. Our laboratory has shown that the chemokine IL-8 promotes the acquisition of mesenchymal features, stem-cell like properties, resistance to therapies, and the recruitment of immune-suppressive cells to the tumor site. Previous studies conducted in our laboratory with a clinical-grade monoclonal antibody that neutralizes IL-8 (HuMax-IL8), showed that blockade of IL-8 can (1) revert tumor plasticity in models of triple negative breast cancer, both in vitro and in vivo; (2) significantly decrease the recruitment of granulocytic myeloid-derived suppressor cells (G-MDSCs) at the tumor site; and (3) enhance the susceptibility of breast cancer cells to immune-mediated lysis with NK and antigen-specific T cells in vitro. Recently, a Phase I clinical study has been completed at the NIH Clinical Center on the use of HuMax-IL8 in patients with metastatic or unresectable locally advanced solid tumors, showing safety and reductions in IL-8 levels in serum at all doses evaluated. One of the tumor types with a high degree of infiltration with G-MDSCs is head and neck carcinoma (HNSCC), a tumor type where IL-8 has also been shown to be relevant to the biology of the disease. In collaboration with Dr. C. Allen (NIDCD), we have evaluated the potential effect of IL-8 signaling blockade via inhibition with a small molecule inhibitor of IL-8 receptors, CXCR1 and CXCR2, in models of HNSCC. The results of these studies demonstrated that inhibition of CXCR1/2 can decrease tumor accumulation of G-MDSCs and enhance the efficacy of PD-1 axis immune checkpoint blockade and adoptive cell transfer of engineered T cells or NK cells. In addition to IL-8, transforming growth factor beta (TGF-beta) is a master regulator of tumor plasticity, in addition to mediating tumor immune suppression. In an attempt to overcome tumor escape mechanisms mediated by these two cytokines, we recently investigated the combined use of a CXCR1/2 inhibitor and a bifunctional agent that simultaneously blocks programmed death ligand 1 (PD-L1) and 'traps' soluble TGF-beta (bintrafusp alfa). We showed that simultaneous inhibition of CXCR1/2, TGF-beta, and PD-L1 signaling synergizes to reduce mesenchymal tumor features in murine models of breast and lung cancer, and to markedly enhance the expression of tumor epithelial markers while reducing infiltration with suppressive G-MDSCs, significantly enhancing T-cell infiltration and activation in tumors, and leading to improved anti-tumor activity. These studies highlight the potential benefit of combined blockade of CXCR1/2 and TGF-beta signaling for modulation of tumor plasticity and potential enhancement of tumor responses to PD-L1 blockade. Additional studies are being conducted in our laboratory to evaluate the use of IL-8 neutralizing antibodies or the small molecule inhibitor of CXCR1/2 in combination with various immunotherapeutic agents including checkpoint inhibitor antibodies, vaccines and other modulatory agents. -DA - 2020 -PY - 2020 -AN - GRANTS:15556962 -G1 - 10262732; 1ZICBC010937-13; ZICBC010937 -AD - DIVISION OF BASIC SCIENCES - NCI -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Fuorivia, Valeria -AU - Attili, Ilaria -AU - Corvaja, Carla -AU - Asnaghi, Riccardo -AU - Schianca, Ambra Carnevale -AU - Aliaga, Pamela Trillo -AU - Del Signore, Ester -AU - Spitaleri, Gianluca -AU - Passaro, Antonio -AU - de Marinis, Filippo -TI - Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario -T2 - CURRENT ONCOLOGY -M3 - Review -AB - The ever-growing knowledge regarding NSCLC molecular biology has brought innovative therapies into clinical practice; however, the treatment situation in the non-metastatic setting is rapidly evolving. Indeed, immunotherapy-based perioperative treatments are currently considered the standard of care for patients with resectable NSCLC in the absence of EGFR mutations or ALK gene rearrangements. Recently, data have been presented on the use of tyrosine kinase inhibitors (TKIs) in the adjuvant and locally advanced setting for patients with NSCLC harboring such driver gene alterations. The aim of the current work is to review the available evidence on the use of targeted treatments in the non-metastatic setting, together with a summary of the ongoing trials designed for actionable gene alterations other than EGFR and ALK. To date, 3-year adjuvant osimertinib treatment has been demonstrated to improve DFS and OS and to reduce CNS recurrence in resected EGFR-mutated NSCLC in stage IB-IIIA (TNM 7th edition). The use of osimertinib after chemo-radiation in stage III unresectable EGFR-mutated NSCLC showed the relevant PFS improvement. In the ALK-positive setting, 2-year alectinib treatment was shown to clearly improve DFS compared to adjuvant standard chemotherapy in resected NSCLC with stage IB (>= 4 cm)-IIIA (TNM 7th edition). Several trials are ongoing to establish the optimal adjuvant TKI treatment duration, as well as neoadjuvant TKI strategies in EGFR- and ALK-positive disease, and (neo)adjuvant targeted treatments in patients with actionable gene alterations other than EGFR or ALK. In conclusion, our review depicts how the current treatment scenario is expected to rapidly change in the context of non-metastatic NSCLC with actionable gene alterations, hence appropriate molecular testing from the early stages has become crucial to establish the most adequate approaches both in the perioperative and the locally advanced disease. -PU - MDPI -PI - BASEL -PA - ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND -SN - 1198-0052 -SN - 1718-7729 -DA - 2024 SEP -PY - 2024 -VL - 31 -IS - 9 -SP - 5121 -EP - 5139 -DO - 10.3390/curroncol31090379 -AN - WOS:001323302700001 -AD - European Inst Oncol IRCCS, Div Thorac Oncol, I-20141 Milan, Italy -AD - Univ Milan, Dept Oncol & Hematooncol, I-20122 Milan, Italy -Y2 - 2024-10-07 -ER - - -TY - JOUR -AU - LETTERIO, JOHN JAMES -TI - Developmental Therapeutics Research Program -M3 - Awarded Grant -AB - DEVELOPMENTAL THERAPEUTICS (DT) RESEARCH PROGRAMPROJECT SUMMARY/ABSTRACTThe Developmental Therapeutics (DT) Research Program develops and evaluates novel therapeutics andcombinations that: 1) overcome drug resistance of cancer cells mediated by a spectrum of genetic andepigenetic mechanisms; 2) inhibit growth and drug-resistant pathways of cancer; and 3) utilize novel immunecheckpoint therapeutics to increase the proportion of cancer patients who benefit. The overall approach of theDT Program is to leverage the creativity and expertise of basic scientists in the Case Comprehensive CancerCenter (Case CCC) Programs by analyzing new agents for specific validated molecular targets and newtherapeutic compounds for preclinical and clinical validation in early-phase clinical trials. DT members guidetheir development, and convey clinical samples back to laboratory investigators to drive further discovery. Thisbidirectional interchange enables DT's continued role as a major convener of new therapeutic concepts for theCenter’s Programs. The program is organized around 3 scientific aims: (1) Interrogate cancer pathways todevelop new efficacious therapeutics; (2) Implement early-phase clinical trials around novel pathway targets,new agents and combinatorial approaches; and (3) Implement early-phase trials around novel approaches tocancer immunotherapies, to widen their activity spectra. These aims reflect major working groups andinitiatives that coalesces program members with other cancer center investigators through inter-programmaticcollaborations that result in preclinical and clinical research efforts, grants, and trial protocols. Extensive use ofan array of shared resources, in particular Translational, Cytometry, Imaging, Proteomics, and Drug Discoveryfacilitate all aspects of member discoveries.Under the leadership of Yogen Saunthararajah (Co-Leader) and John Letterio (Co-Leader) the DT Programhas 52 members including 18 full, 5 associate and 29 clinical members representing 21 different departmentsacross the consortium. Members are funded by a total of $12.5M in research grant funding (annual directcosts), of which $5.1M is peer-reviewed and $2.9M is NCI-funded. Between 2012 and 2016, DT programmembers published 1,012 publications. Cancer and program related publications included 35% inter-programmatic, 25% intra-programmatic, 14% inter- and intra-programmatic and 10% that involvedcollaborations with another Cancer Center. This highly effective Program has made major practice-changingcontributions benefiting cancer patients. Examples include: discoveries of first-in-class compounds(SMARCA5 inhibitor, PP2A activator, malate dehydrogenase inhibitor, base excision repair target withmethoxyamine); discoveries targeting EGFR resistance, inhibition of uracil glycosylase and the inhibition of theBH4 domain of Bcl-2; analysis into the genetic markers of resistance to radiation; and identification of severalsmall cell lung cancer genetic subsets.! -DA - 2022 -PY - 2022 -AN - GRANTS:17446006 -G1 - 10380717; 5P30CA043703-32; 8085; P30CA043703 -AD - CASE WESTERN RESERVE UNIVERSITY -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - LETTERIO, JOHN JAMES -TI - Developmental Therapeutics Research Program -M3 - Awarded Grant -AB - DEVELOPMENTAL THERAPEUTICS (DT) RESEARCH PROGRAMPROJECT SUMMARY/ABSTRACTThe Developmental Therapeutics (DT) Research Program develops and evaluates novel therapeutics andcombinations that: 1) overcome drug resistance of cancer cells mediated by a spectrum of genetic andepigenetic mechanisms; 2) inhibit growth and drug-resistant pathways of cancer; and 3) utilize novel immunecheckpoint therapeutics to increase the proportion of cancer patients who benefit. The overall approach of theDT Program is to leverage the creativity and expertise of basic scientists in the Case Comprehensive CancerCenter (Case CCC) Programs by analyzing new agents for specific validated molecular targets and newtherapeutic compounds for preclinical and clinical validation in early-phase clinical trials. DT members guidetheir development, and convey clinical samples back to laboratory investigators to drive further discovery. Thisbidirectional interchange enables DT's continued role as a major convener of new therapeutic concepts for theCenter’s Programs. The program is organized around 3 scientific aims: (1) Interrogate cancer pathways todevelop new efficacious therapeutics; (2) Implement early-phase clinical trials around novel pathway targets,new agents and combinatorial approaches; and (3) Implement early-phase trials around novel approaches tocancer immunotherapies, to widen their activity spectra. These aims reflect major working groups andinitiatives that coalesces program members with other cancer center investigators through inter-programmaticcollaborations that result in preclinical and clinical research efforts, grants, and trial protocols. Extensive use ofan array of shared resources, in particular Translational, Cytometry, Imaging, Proteomics, and Drug Discoveryfacilitate all aspects of member discoveries.Under the leadership of Yogen Saunthararajah (Co-Leader) and John Letterio (Co-Leader) the DT Programhas 52 members including 18 full, 5 associate and 29 clinical members representing 21 different departmentsacross the consortium. Members are funded by a total of $12.5M in research grant funding (annual directcosts), of which $5.1M is peer-reviewed and $2.9M is NCI-funded. Between 2012 and 2016, DT programmembers published 1,012 publications. Cancer and program related publications included 35% inter-programmatic, 25% intra-programmatic, 14% inter- and intra-programmatic and 10% that involvedcollaborations with another Cancer Center. This highly effective Program has made major practice-changingcontributions benefiting cancer patients. Examples include: discoveries of first-in-class compounds(SMARCA5 inhibitor, PP2A activator, malate dehydrogenase inhibitor, base excision repair target withmethoxyamine); discoveries targeting EGFR resistance, inhibition of uracil glycosylase and the inhibition of theBH4 domain of Bcl-2; analysis into the genetic markers of resistance to radiation; and identification of severalsmall cell lung cancer genetic subsets.! -DA - 2023 -PY - 2023 -AN - GRANTS:17760171 -G1 - 10784825; 4P30CA043703-33; 9178; P30CA043703 -AD - CASE WESTERN RESERVE UNIVERSITY -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - LETTERIO, JOHN JAMES -TI - Developmental Therapeutics Research Program -M3 - Awarded Grant -AB - DEVELOPMENTAL THERAPEUTICS (DT) RESEARCH PROGRAMPROJECT SUMMARY/ABSTRACTThe Developmental Therapeutics (DT) Research Program develops and evaluates novel therapeutics andcombinations that: 1) overcome drug resistance of cancer cells mediated by a spectrum of genetic andepigenetic mechanisms; 2) inhibit growth and drug-resistant pathways of cancer; and 3) utilize novel immunecheckpoint therapeutics to increase the proportion of cancer patients who benefit. The overall approach of theDT Program is to leverage the creativity and expertise of basic scientists in the Case Comprehensive CancerCenter (Case CCC) Programs by analyzing new agents for specific validated molecular targets and newtherapeutic compounds for preclinical and clinical validation in early-phase clinical trials. DT members guidetheir development, and convey clinical samples back to laboratory investigators to drive further discovery. Thisbidirectional interchange enables DT's continued role as a major convener of new therapeutic concepts for theCenter’s Programs. The program is organized around 3 scientific aims: (1) Interrogate cancer pathways todevelop new efficacious therapeutics; (2) Implement early-phase clinical trials around novel pathway targets,new agents and combinatorial approaches; and (3) Implement early-phase trials around novel approaches tocancer immunotherapies, to widen their activity spectra. These aims reflect major working groups andinitiatives that coalesces program members with other cancer center investigators through inter-programmaticcollaborations that result in preclinical and clinical research efforts, grants, and trial protocols. Extensive use ofan array of shared resources, in particular Translational, Cytometry, Imaging, Proteomics, and Drug Discoveryfacilitate all aspects of member discoveries.Under the leadership of Yogen Saunthararajah (Co-Leader) and John Letterio (Co-Leader) the DT Programhas 52 members including 18 full, 5 associate and 29 clinical members representing 21 different departmentsacross the consortium. Members are funded by a total of $12.5M in research grant funding (annual directcosts), of which $5.1M is peer-reviewed and $2.9M is NCI-funded. Between 2012 and 2016, DT programmembers published 1,012 publications. Cancer and program related publications included 35% inter-programmatic, 25% intra-programmatic, 14% inter- and intra-programmatic and 10% that involvedcollaborations with another Cancer Center. This highly effective Program has made major practice-changingcontributions benefiting cancer patients. Examples include: discoveries of first-in-class compounds(SMARCA5 inhibitor, PP2A activator, malate dehydrogenase inhibitor, base excision repair target withmethoxyamine); discoveries targeting EGFR resistance, inhibition of uracil glycosylase and the inhibition of theBH4 domain of Bcl-2; analysis into the genetic markers of resistance to radiation; and identification of severalsmall cell lung cancer genetic subsets.! -DA - 2021 -PY - 2021 -AN - GRANTS:17380948 -G1 - 10135953; 5P30CA043703-31; 8085; P30CA043703 -AD - CASE WESTERN RESERVE UNIVERSITY -Y2 - 2024-03-01 -ER - - -TY - JOUR -AU - LETTERIO, JOHN JAMES -TI - Developmental Therapeutics Research Program -M3 - Awarded Grant -AB - DEVELOPMENTAL THERAPEUTICS (DT) RESEARCH PROGRAMPROJECT SUMMARY/ABSTRACTThe Developmental Therapeutics (DT) Research Program develops and evaluates novel therapeutics andcombinations that: 1) overcome drug resistance of cancer cells mediated by a spectrum of genetic andepigenetic mechanisms; 2) inhibit growth and drug-resistant pathways of cancer; and 3) utilize novel immunecheckpoint therapeutics to increase the proportion of cancer patients who benefit. The overall approach of theDT Program is to leverage the creativity and expertise of basic scientists in the Case Comprehensive CancerCenter (Case CCC) Programs by analyzing new agents for specific validated molecular targets and newtherapeutic compounds for preclinical and clinical validation in early-phase clinical trials. DT members guidetheir development, and convey clinical samples back to laboratory investigators to drive further discovery. Thisbidirectional interchange enables DT's continued role as a major convener of new therapeutic concepts for theCenter’s Programs. The program is organized around 3 scientific aims: (1) Interrogate cancer pathways todevelop new efficacious therapeutics; (2) Implement early-phase clinical trials around novel pathway targets,new agents and combinatorial approaches; and (3) Implement early-phase trials around novel approaches tocancer immunotherapies, to widen their activity spectra. These aims reflect major working groups andinitiatives that coalesces program members with other cancer center investigators through inter-programmaticcollaborations that result in preclinical and clinical research efforts, grants, and trial protocols. Extensive use ofan array of shared resources, in particular Translational, Cytometry, Imaging, Proteomics, and Drug Discoveryfacilitate all aspects of member discoveries.Under the leadership of Yogen Saunthararajah (Co-Leader) and John Letterio (Co-Leader) the DT Programhas 52 members including 18 full, 5 associate and 29 clinical members representing 21 different departmentsacross the consortium. Members are funded by a total of $12.5M in research grant funding (annual directcosts), of which $5.1M is peer-reviewed and $2.9M is NCI-funded. Between 2012 and 2016, DT programmembers published 1,012 publications. Cancer and program related publications included 35% inter-programmatic, 25% intra-programmatic, 14% inter- and intra-programmatic and 10% that involvedcollaborations with another Cancer Center. This highly effective Program has made major practice-changingcontributions benefiting cancer patients. Examples include: discoveries of first-in-class compounds(SMARCA5 inhibitor, PP2A activator, malate dehydrogenase inhibitor, base excision repair target withmethoxyamine); discoveries targeting EGFR resistance, inhibition of uracil glycosylase and the inhibition of theBH4 domain of Bcl-2; analysis into the genetic markers of resistance to radiation; and identification of severalsmall cell lung cancer genetic subsets.! -DA - 2020 -PY - 2020 -AN - GRANTS:15039176 -G1 - 5P30CA043703-30; 9904162; P30CA043703 -AD - CASE WESTERN RESERVE UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - LETTERIO, JOHN JAMES -TI - Developmental Therapeutics Research Program -M3 - Awarded Grant -AB - DEVELOPMENTAL THERAPEUTICS (DT) RESEARCH PROGRAMPROJECT SUMMARY/ABSTRACTThe Developmental Therapeutics (DT) Research Program develops and evaluates novel therapeutics andcombinations that: 1) overcome drug resistance of cancer cells mediated by a spectrum of genetic andepigenetic mechanisms; 2) inhibit growth and drug-resistant pathways of cancer; and 3) utilize novel immunecheckpoint therapeutics to increase the proportion of cancer patients who benefit. The overall approach of theDT Program is to leverage the creativity and expertise of basic scientists in the Case Comprehensive CancerCenter (Case CCC) Programs by analyzing new agents for specific validated molecular targets and newtherapeutic compounds for preclinical and clinical validation in early-phase clinical trials. DT members guidetheir development, and convey clinical samples back to laboratory investigators to drive further discovery. Thisbidirectional interchange enables DT's continued role as a major convener of new therapeutic concepts for theCenter’s Programs. The program is organized around 3 scientific aims: (1) Interrogate cancer pathways todevelop new efficacious therapeutics; (2) Implement early-phase clinical trials around novel pathway targets,new agents and combinatorial approaches; and (3) Implement early-phase trials around novel approaches tocancer immunotherapies, to widen their activity spectra. These aims reflect major working groups andinitiatives that coalesces program members with other cancer center investigators through inter-programmaticcollaborations that result in preclinical and clinical research efforts, grants, and trial protocols. Extensive use ofan array of shared resources, in particular Translational, Cytometry, Imaging, Proteomics, and Drug Discoveryfacilitate all aspects of member discoveries.Under the leadership of Yogen Saunthararajah (Co-Leader) and John Letterio (Co-Leader) the DT Programhas 52 members including 18 full, 5 associate and 29 clinical members representing 21 different departmentsacross the consortium. Members are funded by a total of $12.5M in research grant funding (annual directcosts), of which $5.1M is peer-reviewed and $2.9M is NCI-funded. Between 2012 and 2016, DT programmembers published 1,012 publications. Cancer and program related publications included 35% inter-programmatic, 25% intra-programmatic, 14% inter- and intra-programmatic and 10% that involvedcollaborations with another Cancer Center. This highly effective Program has made major practice-changingcontributions benefiting cancer patients. Examples include: discoveries of first-in-class compounds(SMARCA5 inhibitor, PP2A activator, malate dehydrogenase inhibitor, base excision repair target withmethoxyamine); discoveries targeting EGFR resistance, inhibition of uracil glycosylase and the inhibition of theBH4 domain of Bcl-2; analysis into the genetic markers of resistance to radiation; and identification of severalsmall cell lung cancer genetic subsets.! -DA - 2019 -PY - 2019 -AN - GRANTS:10139585 -G1 - 5P30CA043703-29; 9696794; P30CA043703 -AD - CASE WESTERN RESERVE UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Verleger, Katharina -AU - Penrod, John R. -AU - Daumont, Melinda Manley -AU - Solem, Caitlyn -AU - Luo, Linlin -AU - Macahilig, Cynthia -AU - Hertel, Nadine -TI - Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe -T2 - CLINICOECONOMICS AND OUTCOMES RESEARCH -M3 - Article -AB - Purpose: Advanced non-small-cell lung cancer (aNSCLC; stage IIIB/IV) presents a substantial clinical burden to society; reliable estimates of its economic burden are lacking. Therefore, this study aimed to quantify real-world health care resource utilization (HCRU) and costs of patients with squamous (SQ) and non-SQ (NSQ) aNSCLC who received two or more lines of treatment (2L+) in Europe, and to describe cost-predictors.Methods: The LENS (Leading the Evaluation of Non-squamous and Squamous NSCLC) retrospective chart review study collected data from 2L+ patients with aNSCLC diagnosed between 07/2009 and 08/2011 (wave 1) or 07/2010 and 09/2012 (wave 2) in France, Germany, Italy, Spain, England, the Netherlands, and Sweden. Patients were followed from diagnosis through most recent visit/death. A weighted average of countryspecific unit costs (2018 Euro) was applied to systemic anti-cancer therapy usage and HCRU (hospital/emergency department visit, surgery, radiotherapy, ancillary care, biomarker testing) to determine the total cost from aNSCLC diagnosis to death. Generalized linear models (gamma distribution, log link) were used to assess clinical and demographic predictors.Results: Of 973 2L+ aNSCLC patients, median overall survival (OS) was 1.5 years from advanced diagnosis (range: 0.2-5.3; median OS: 1.4 [SQ], 1.6 [NSQ]), 79.0% died during follow-up. Weighted mean total per-patient costs were (sic)21,273, ranging from (sic)17,761 (England) to (sic)30,854 (Sweden), and (sic)15,446 (SQ) to (sic)26,477 (NSQ). Systemic drug costs comprised 77.4% of total costs. Insurance status, presence of epidermal growth factor receptor (EGFR) mutation, SQ histology, age, alcohol abuse, and year of diagnosis were significant predictors for lower total costs per patient-month, Eastern Cooperative Oncology Group performance status (ECOG PS) >= 1 and country for higher costs.Conclusion: In the era pre-immunotherapy, HCRU and costs were substantial in aNSCLC 2L+ patients, with most of the costs accrued prior to start of 2L. NSQ patients incurred significantly higher total costs than SQ patients in all participating countries. -PU - DOVE MEDICAL PRESS LTD -PI - ALBANY -PA - PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND -SN - 1178-6981 -DA - 2020 -PY - 2020 -VL - 12 -SP - 23 -EP - 33 -DO - 10.2147/CEOR.S223760 -AN - WOS:000512006000001 -AD - Pharmerit Int, Krausenstr 8, D-10117 Berlin, Germany -AD - Bristol Myers Squibb, Princeton, NJ USA -AD - Bristol Myers Squibb, Braine Lalleud, Belgium -AD - Pharmerit Int, Bethesda, MD USA -AD - Med Data Analyt, Parsippany, NJ USA -AD - Bristol Myers Squibb, Uxbridge, Middx, England -M2 - Pharmerit Int -M2 - Med Data Analyt -Y2 - 2020-02-20 -ER - - -TY - JOUR -AU - Xue, W J -AU - Bi, N -AU - Yang, L -AU - Wang, X -AU - Dong, J Y -AU - Zhang, T -AU - Wu, L F -AU - Wang, L H -TI - [Expression and prognostic value of programmed cell death ligand 1 in patients with locally advanced and non-EGFR-mutated non-small cell lung cancer receiving concurrent chemoradiotherapy]. -T2 - Zhonghua yi xue za zhi -M3 - Journal Article -AB - Objective: To explore the expression of programmed cell death ligand 1 (PD-L1) in patients with locally advanced and non-EGFR-mutated non-small cell lung cancer (LA-NSCLC) undergoing concurrent chemoradiotherapy (cCRT) and its association with clinical outcome of patients. Methods: The basic clinical information of 19 patients with unresectable, non-EGFR mutated LA-NSCLC receiving radical cCRT in Cancer Hospital Chinese Academy of Medical Sciences from January 2016 to December 2017 was retrospectively analyzed. The rabbit monoclonal antibody SP263 was used for immunohistochemical analysis to detect the expression of PD-L1 in LA-NSCLC tissues and the tumor proportion score (TPS) equal to or greater than 1% was defined as PD-L1 positive. The associations between PD-L1 ≥1% and PD-L1 ≥25% with the clinical characteristics and clinical outcome of LA-NSCLC patients were evaluated respectively. Results: Among 19 LA-NSCLC patients, 13 had PD-L1 positive expression, and 4 had PD-L1 expression greater than or equal to 25%. No significant difference was observed between patients with PD-L1 positive and negative expressions regarding the distribution of age, smoking history, pathological classification, and TNM staging (P>0.05). A total of 15 patients could be evaluated for therapeutic effect, including 7 patients with partial response (PR), 7 patients with stable disease (SD), and 1 patient with progressive disease (PD). In the group with PD-L1 expression<1%, 3 patients were in objective response, and 4 patients were in disease control. In the group with PD-L1 expression ≥1%, 4 patients were in objective response, and 10 patients were in disease control. When the PD-L1 expression was less than 25%, 6 patients gained the objective response, and 11 patients gained the disease control. When the PD-L1 expression was greater than or equal to 25%, 1 patient gained the objective response, and 3 patients gained the disease control. The median overall survival (OS) was 35 (95%CI: 12.7-57.3) months for patients with PD-L1 ≥1% and 40 (95%CI: not reaching the end point) months for patients with PD-L1<1% (P=0.284). Patients with PD-L1 ≥25% had a median survival time of 12 (95%CI:0.0-34.5) months, and patients with PD-L1<25% had a median survival time of 40 (95%CI: 27.4-52.6) months (P=0.241). Conclusions: The prognosis of LA-NSCLC patients with PD-L1 positive and no-EGFR mutation receiving concurrent chemoradiation has a trend of poor prognosis. A larger sample size study is warranted to explore the prognostic value of PD-L1 expression in inoperable LA-NSCLC patients and to further explore the effect of immunotherapy on patients with different PD-L1 expression levels. -AB - 目的: 探讨程序性细胞死亡配体1(PD-L1)在同步放化疗非表皮生长因子受体(EGFR)突变局部晚期非小细胞肺癌(NSCLC)中的表达及其与患者预后的关系。 方法: 回顾性分析中国医学科学院肿瘤医院放疗科2016年1月至2017年12月收治的根治性同步放化疗非EGFR突变局部晚期不可手术的19例NSCLC患者的临床资料。采用免疫组化方法以兔单克隆抗体SP263检测PD-L1在NSCLC组织中的表达,以肿瘤阳性细胞比例≥1%为PD-L1阳性表达,分别分析PD-L1表达≥1%和≥25%与NSCLC患者临床特征和预后的关系。 结果: 19例NSCLC患者中,PD-L1阳性表达13例,其中PD-L1表达≥25%者4例。PD-L1表达≥1%和PD-L1表达<1%组年龄、吸烟史、病理类型和TNM分期差异均无统计学意义(均P>0.05)。15例患者可进行疗效评价,其中部分缓解(PR)7例,疾病稳定(SD)7例,疾病进展(PD)1例。PD-L1表达<1%组患者客观缓解3例,疾病控制4例;PD-L1表达≥1%组患者客观缓解4例,疾病控制10例。PD-L1表达<25%组患者客观缓解6例,疾病控制11例;PD-L1表达≥25%组患者客观缓解1例,疾病控制3例。PD-L1表达≥1%组患者的中位生存时间为35个月(95%CI:12.7~57.3个月),PD-L1表达<1%组患者的中位生存时间为40个月(95%CI未达终点),差异无统计学意义(P=0.284);PD-L1≥25%组患者的中位生存时间为12个月(95%CI:0.0~34.5个月),PD-L1<25%组患者的中位生存时间为40个月(95%CI:27.4~52.6个月),差异无统计学意义(P=0.241)。 结论: PD-L1阳性接受同步放化疗非EGFR突变局部晚期NSCLC患者的预后有不良趋势,有必要扩大样本量探索PD-L1在局部晚期不可手术NSCLC患者中的预后意义,并探讨免疫治疗对不同PD-L1表达水平患者的疗效。. -SN - 0376-2491 -DA - 2022 Feb 15 -PY - 2022 -VL - 102 -IS - 6 -SP - 406 -EP - 411 -DO - 10.3760/cma.j.cn112137-20211002-02207 -AN - MEDLINE:35144339 -AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. -AD - Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. -AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China. -Y2 - 2022-02-14 -ER - - -TY - JOUR -AU - Zhang, Qianru -AU - Wang, Ruo -AU - Xu, Lu -TI - Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review -T2 - TRANSLATIONAL CANCER RESEARCH -M3 - Review -AB - Background and Objective: Mutations located in epidermal growth factor receptor (EGFR) tyrosine kinase domains have been described as the 'Achilles heel' of non-small cell lung cancer (NSCLC) and can be targeted by epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). However, the clinical benefits of EGFR-TKIs are limited, and drug resistance inevitably occurs in NSCLC patients after long-term exposure to certain drugs. EGFR-TKI combination therapies, including combined targeted therapy, radiotherapy, chemotherapy, and immunotherapy, have shown promise in addressing this issue. This literature review analyzed the rationale and controversies of clinical research related to various EGFR-TKI combination therapies.Methods: The PubMed database was searched to retrieve articles published from January 1, 2001 to April 15, 2023 using the following Medical Subject Headings (MeSH) terms: "EGFR-mutated non-small cell lung cancer" and "clinical trial". Google Scholar was also reviewed to retrieve additional articles. The search was limited to articles published in English.Key Content and Findings: In this review, we summarized EGFR-TKI combination therapies, including combined targeted therapy, radiotherapy, chemotherapy, and immunotherapy, most of which have shown efficacy and safety in patients with EGFR-mutated NSCLC. A number of clinical studies with large sample sizes have analyzed the activity and toxicity of combined therapies and explored potential and well-tolerated treatment options.Conclusions: EGFR mutations have been detected in many NSCLC patients and can be targeted by EGFR-TKIs. However, drug resistance after long-term exposure remains a significant challenge for this type of treatment. Most clinical trials have shown that the combination of EGFR-TKIs and targeted therapy, chemotherapy, radiotherapy or immunotherapy is efficacious and safe in the treatment of EGFR-mutated NSCLC. It should be noted that in some instances, serious adverse events have led to the termination of trials. However, EGFR-TKI combination therapy is indeed an effective approach for the treatment of patients with EGFR-mutated NSCLC and deserves further development. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-676X -SN - 2219-6803 -DA - 2023 DEC -PY - 2023 -VL - 12 -IS - 12 -SP - 3764 -EP - 3778 -DO - 10.21037/tcr-23-956 -AN - WOS:001111038900001 -C6 - NOV 2023 -AD - Shanghai Jiao Tong Univ, Sch Med, Dept Pharmacol & Chem Biol, Shanghai, Peoples R China -AD - Shanghai Jiao Tong Univ, Sch Med, Dept Pharmacol & Chem Biol, 227 Chongqing South Rd,Ruijin Second Rd St, Shanghai 200025, Peoples R China -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Bi, Z K -AU - Xu, Y -AU - Guo, L -AU - Zhang, W J -AU - You, Y T -AU - Li, J W -AU - Zhao, C L -AU - Shan, Y F -AU - Xia, T T -AU - Li, Y F -AU - Xu, Z -AU - Fan, Y -AU - Bai, L -TI - [Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease]. -T2 - Zhonghua yi xue za zhi -M3 - English Abstract -M3 - Journal Article -AB - Objective: To investigate the impact of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD). Methods: A retrospective cohort study was performed to include 178 patients with Ⅲ-Ⅳ NSCLC complicated with COPD who received at least 2 times of immunotherapy in Xinqiao Hospital of the Army Medical University from January 2019 to August 2021. Baseline peripheral blood inflammatory indicators such as interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha) were collected within 2 weeks before the first treatment, with the last one being on or before February 7, 2022. X-tile software was used to determine the optimal cut-off value of peripheral blood inflammatory indicators. The Cox multivariate regression models were used to analyze the factors affecting progression free survival (PFS) and overall survival (OS). Results: Among the 178 patients, there were 174 males (97.8%) and 4 females (2.2%); the age ranged from 42 to 86 (64.3±8.3) years old.There were 30 cases (16.9%) of immunotherapy monotherapy, 114 cases (64.0%) of immunotherapy combined with chemotherapy, 21 cases (11.8%) of immunotherapy combined with antivascular therapy, and 13 cases (7.3%) of immunotherapy combined with radiotherapy. The median follow-up period was 14.5 months (95%CI: 13.6-15.3 months). The objective response rate (ORR) and disease control rate (DCR) were 44.9% (80/178) and 90.4% (161/178) for the whole group, the median PFS was 14.6 months (95%CI: 11.6-17.6 months), and the median OS was 25.7 months (95%CI: 18.0-33.4 months). The results of Cox multivariate analysis showed that IL-6>9.9 ng/L (HR=5.885, 95%CI: 2.558-13.543, P<0.01), TNF-alpha>8.8 ng/L (HR=3.213, 95%CI: 1.468-7.032, P=0.003), IL-8>202 ng/L (HR=2.614, 95%CI: 1.054-6.482, P=0.038), systemic immune inflammatory index (SII)>2 003.95 (HR=2.976, 95%CI: 1.647-5.379, P<0.001) were risk factors for PFS, and advanced lung cancer inflammation index (ALI)>171.15 was protective factor for PFS (HR=0.545, 95%CI: 0.344-0.863, P=0.010). IL-6>9.9 ng/L(HR=6.124, 95%CI: 1.950-19.228, P<0.002), lactate dehydrogenase (LDH)>190.7 U/L (HR=2.776, 95%CI: 1.020-7.556, P=0.046), SII>2 003.95 (HR=4.521, 95%CI: 2.241-9.120, P<0.001) were risk factors for OS, and ALI>171.15 was a protective factor for OS (HR=0.434, 95%CI: 0.243-0.778, P=0.005). Conclusion: Baseline high levels of IL-6, TNF-alpha, IL-8, SII, LDH, and low levels of ALI are risk factors for poor prognosis in patients with advanced NSCLC-COPD receiving immunotherapy. -AB - 目的: 探讨外周血炎症指标对晚期非小细胞肺癌合并慢性阻塞性肺疾病(NSCLC-COPD)患者免疫治疗疗效的影响。 方法: 回顾性分析2019年1月至2021年8月在陆军军医大学新桥医院接受至少2次免疫治疗的178例Ⅲ、Ⅳ期NSCLC-COPD患者资料,收集治疗前2周内白细胞介素6(IL-6)、IL-8、肿瘤坏死因子alpha(TNF-alpha)等基线血液检测指标。随访截至2022年2月7日。应用X-tile软件确定外周血炎症指标的cut-off值,采用多因素Cox回归模型分析无进展生存时间(PFS)和总生存时间(OS)的影响因素。 结果: 178例患者中,男174例(97.8%),女4例(2.2%);年龄42~86(64.3±8.3)岁;免疫单药治疗30例(16.9%),免疫联合化疗治疗114例(64.0%),免疫联合抗血管治疗21例(11.8%),免疫联合放疗13例(7.3%)。中位随访时间为14.5个月(95%CI:13.6~15.3个月)。客观缓解率(ORR)为44.9%(80/178),疾病控制率(DCR)为90.4%(161/178),中位PFS为14.6个月(95%CI:11.6~17.6个月),中位OS为25.7个月(95%CI:18.0~33.4个月)。多因素Cox风险模型分析结果显示,IL-6>9.9 ng/L(HR=5.885,95%CI:2.558~13.543,P<0.01)、TNF-alpha>8.8 ng/L(HR=3.213,95%CI:1.468~7.032,P=0.003)、IL-8>202 ng/L(HR=2.614,95%CI:1.054~6.482,P=0.038)、全身免疫炎症指数(SII)>2 003.95(HR=2.976,95%CI:1.647~5.379,P<0.001)是PFS的危险因素,晚期肺癌炎症指数(ALI)>171.15是PFS的保护因素(HR=0.545,95%CI:0.344~0.863,P=0.010);IL-6>9.9 ng/L(HR=6.124,95%CI:1.950~19.228,P<0.002)、乳酸脱氢酶(LDH)>190.7 U/L(HR=2.776,95%CI:1.020~7.556,P=0.046)、SII>2 003.95(HR=4.521,95%CI:2.241~9.120,P<0.001)是OS的危险因素,ALI>171.15是OS的保护因素(HR=0.434,95%CI:0.243~0.778,P=0.005)。 结论: 基线高水平IL-6、TNF-alpha、IL-8、SII、LDH和低水平ALI是接受免疫治疗晚期NSCLC-COPD患者预后不良的危险因素。. -SN - 0376-2491 -DA - 2024 May 14 -PY - 2024 -VL - 104 -IS - 18 -SP - 1601 -EP - 1609 -DO - 10.3760/cma.j.cn112137-20231130-01247 -AN - MEDLINE:38742347 -AD - Department of Respiratory and Critical Care Medicine, Xinqiao Hospital, Army Medical University, Chongqing 400037, China. -AD - Department of Oncology, Army Specialty Medical Center, Army Medical University, Chongqing 400010, China. -AD - Department of Epidemiology, Faculty of Military Preventive Medicine, Army Medical University, Chongqing 400037, China. -Y2 - 2024-05-16 -ER - - -TY - JOUR -AU - Akkad, Neha -AU - Thomas, Theodore S. -AU - Luo, Suhong -AU - Knoche, Eric -AU - Sanfilippo, Kristen M. -AU - Keller, Jesse W. -TI - A real-world study of pneumonitis in non-small cell lung cancer patients receiving durvalumab following concurrent chemoradiation -T2 - JOURNAL OF THORACIC DISEASE -M3 - Article -AB - Background: Locally advanced non-small cell lung cancer (LA-NSCLC) treated with the programmed death-ligand 1 inhibitor durvalumab has been associated with significant rates of pneumonitis, which has led to higher rates of discontinuation of therapy in real-world populations. Thus far there has been no consensus in the literature on the impact of pneumonitis on survival. Methods: This is a retrospective cohort study of veterans receiving durvalumab between 12/5/2017 and 4/15/2020. Participants were identified using VINCI data services. Patients were followed through 9/14/2021. Development of clinical pneumonitis was assessed through review of documentation and graded using CTCAE 4.0 criteria. Univariate logistic regression analysis evaluated for associations between body mass index (BMI), age, race, co-morbidity index, chemotherapy regimen, chronic obstructive pulmonary disease (COPD) severity, and development of clinical pneumonitis. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier methods. Cox proportional hazards models were utilized to evaluate the association between risk of death at 1 and 2 years and candidate predictor variables.Results: A total of 284 patients were included in this study. Sixty-one patients developed clinically significant pneumonitis, 7 patients developed grade 5 pneumonitis (death from pneumonitis). The median OS in patients that developed pneumonitis was 27.8 vs. 36.9 months in patients that did not develop pneumonitis (P=0.22). BMI was found to be a clinical predictor of pneumonitis (P=0.04). COPD severity, race, age at durvalumab start date, chemotherapy regimen, and Romano comorbidity index were not significant predictors of pneumonitis. Cox proportional hazards analysis failed to demonstrate an association between the development of pneumonitis and risk of death in this population.Conclusions: The incidence of clinically significant pneumonitis is higher than noted in the PACIFIC trial in this cohort, however this high rate of pneumonitis does not have an impact on OS or PFS. Obesity was found to be a significant predictor of pneumonitis in this patient population. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2023 DEC -PY - 2023 -VL - 15 -IS - 12 -SP - 6427 -EP - 6435 -DO - 10.21037/jtd-22-1604 -AN - WOS:001110577400001 -C6 - NOV 2023 -AD - Washington Univ, Sch Med, Barnes Jewish Hosp, St Louis, MO USA -AD - St Louis Vet Hlth Adm Med Ctr Res Serv, St Louis, MO USA -AD - Washington Univ, Barnes Jewish Hosp, Internal Med Resident, Sch Med, 4901 Forest Pk Ave,Floor 2,Suite 241, St Louis, MO 63108 USA -Y2 - 2023-12-17 -ER - - -TY - JOUR -AU - Viani, Gustavo Arruda -AU - Gouveia, Andre Guimaraes -AU - Moraes, Fabio Ynoe -TI - Sequential or concomitant chemotherapy with hypofractionated radiotherapy for locally advanced non-small cell lung cancer: a meta-analysis of randomized trials -T2 - JOURNAL OF THORACIC DISEASE -M3 - Article -AB - Background: For patients with locally advanced non-small cell lung cancer (NSCLC), the standard treatment is concurrent or sequential chemotherapy with radiotherapy. Most treatment schedules use radiotherapy with conventional fractionation; however, the application of hypofractionated radiotherapy (HYPO-RT) regimens is rising. A meta-analysis was performed to assess the efficacy and safety of chemotherapy combined with HYPO-RT and indirectly compare with the outcomes from previous studies employing concomitant conventional radiotherapy (CONV-RT). Methods: Randomized controlled trials (RCTs) were identified on the electronic database sources through June 2020. Following the PRISMA guidelines, a meta-analysis was performed to assess if there were significant differences in the overall mortality (OM), local failure (LF), and disease progression (DP), comparing HYPO-RT-C vs. sequential chemotherapy followed HYPO-RT (HYPO-RT-S). To establish an indirect comparison with the current standard treatment, we calculate the risk ratio (RR) of the OM from RCTs using conventional chemoradiation, concurrent (CONV-RT-C), and sequential (CONV-RT-S), and compared with HYPO-RT. A P-value <0.05 was considered significant. Results: Two RCTs with a total of 288 patients were included. The RR for the OM, DP and LF at 3 year comparing HYPO-RT-C vs. HYPO-RT-S were 1.09 (95% CI: 0.96-1.28, P=0.17), 1.06 (95% CI: 0.82-1.23, P=0.610), and 1.06 (95% CI: 0.86-1.29, P=0.490), respectively. The late grade 3 pneumonitis and esophagitis had no significant difference between HYPO-RT groups. In the indirect comparison of RCTs using CONV-RT, the RR for the OM at 3 years was 1.03 (95% CI: 0.96-1.10, P=0.36) with no significant difference for the HYPO-RT arms 1.09 (95% CI: 0.96-1.28, P=0.17). Discussion: HYPO-RT given with chemotherapy provides satisfactory OM, LF, and DP in locally advanced NSCLC with similar rates to the CONV-RT. These findings support HYPO-RT inclusion in future clinical trials as an experimental arm in addition to the incorporation of new strategies, such as immunotherapy. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2021 NOV -PY - 2021 -VL - 13 -IS - 11 -SP - 6272 -EP - 6282 -DO - 10.21037/jtd-21-573 -AN - WOS:000720855800001 -C6 - JUL 2021 -AD - Univ Sao Paulo FMRP USP, Ribeirao Preto Med Sch, Dept Med Imagings Hematol & Oncol, Sao Paulo, Brazil -AD - Amer Ctr Oncol Integrad, Radiat Oncol Dept, Rio De Janeiro, Brazil -AD - Queens Univ, Kingston Gen Hosp, Dept Oncol, Div Radiat Oncol, Kingston, ON, Canada -M2 - Amer Ctr Oncol Integrad -Y2 - 2021-11-27 -ER - - -TY - JOUR -AU - SIGALOV, ALEXANDER B -TI - First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer -M3 - Awarded Grant -AB - Project Summary/AbstractCarcinoma of the pancreas, or pancreatic cancer (PC), is the third leading cause of cancer-related death inthe US. Despite recent advances in the current treatments that include surgery, radiation therapy, chemo-and immunotherapy, the 5-year survival rate is as low as 9%. The long-term goal of this project is todevelop a first-in-class, efficient and well tolerable therapy for PC to be used standalone or with standardchemo- and/or immune checkpoint blockade (ICB) treatments as induction and/or maintenance therapy. In PC patients, overexpression of TREM-1 correlates with poor survival, implicating TREM-1 as a newtarget. Current TREM-1 blockers all attempt to block binding of uncertain ligand(s) to TREM-1. To reducerisk of failure in the clinic, we developed a ligand-independent TREM-1 inhibitory peptide GF9 that can beformulated into macrophage-specific lipopeptide complexes (LPC) to improve its half-life and targeting. In Phase I, we showed that: 1) In suppressing tumor growth and improving survival, TREM-1 blockadeusing GF9-LPC in PC xenografts is as effective as a standard chemo: gemcitabine (GEM)+nab-paclitaxel(PTX) combo, and 2) addition of GF9-LPC to GEM+nab-PTX sensitizes the tumor to chemo and triplessurvival rate of mice. Mechanistically, in PC xenografts, GF9-LPC reduces tumor-associated macrophage(TAM) infiltration and serum level of CSF1. As shown by others, in mice with hepatocellular carcinoma,blocking TREM-1+ TAMs by GF9 reverses immunosuppression and overcomes anti-PDL1 resistance. The goal of this project is to further develop GF9 therapy for PC to be used as an induction/maintenancetherapy alone or with first-line standard chemo treatments (GEM+nab-PTX) and/or ICB (anti-PD1/PDL1). Phase II aims are to: 1) generate and test rationally designed manufacturing friendly GF9 sequence-based formulations with favorable pharmacokinetic profile and high efficacy in vivo and select the lead(sub-aim – develop an assay to analyze GF9 in blood in PK studies), 2) test the lead in combination withGEM+nab-PTX in xenograft and syngeneic mouse models of PC, 3) test the lead in combination with anti-PD1/PDL1 in syngeneic mouse models of PC, and 4) test the lead in the non-clinical toxicology studies.Histology/IHC studies will be performed to analyze intratumoral macrophage infiltration as well asangiogenesis, tumor cell proliferation and death. Cytokines including CSF-1 will be analyzed. Follow-up Phase IIb will include other administration and combination (eg, radiation+GF9; anti-CSF-1R+GF9) regimen, TOX, ADME, CMC and other IND-enabling studies. Final manufacturing friendly product willrepresent safe and stable PC therapy. Its anticipated safety is supported by good tolerability of SignaBlok'sGF9 sequence-based formulations by long term-treated healthy, cancer and arthritic mice. Prototypes ofSignaBlok's LPC were safe and well tolerated in clinical trials. TREM-1 blockade using peptide LR12 bySignaBlok's top competitor (Inotrem, France) was safe and well tolerated in healthy and septic subjects. -DA - 2020 -PY - 2020 -AN - GRANTS:14996458 -G1 - 10024061; 5R44CA217400-03; R44CA217400 -AD - SIGNABLOK, INC. -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - SIGALOV, ALEXANDER B -TI - First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer -M3 - Awarded Grant -AB - Project Summary/AbstractCarcinoma of the pancreas, or pancreatic cancer (PC), is the third leading cause of cancer-related death inthe US. Despite recent advances in the current treatments that include surgery, radiation therapy, chemo-and immunotherapy, the 5-year survival rate is as low as 9%. The long-term goal of this project is todevelop a first-in-class, efficient and well tolerable therapy for PC to be used standalone or with standardchemo- and/or immune checkpoint blockade (ICB) treatments as induction and/or maintenance therapy. In PC patients, overexpression of TREM-1 correlates with poor survival, implicating TREM-1 as a newtarget. Current TREM-1 blockers all attempt to block binding of uncertain ligand(s) to TREM-1. To reducerisk of failure in the clinic, we developed a ligand-independent TREM-1 inhibitory peptide GF9 that can beformulated into macrophage-specific lipopeptide complexes (LPC) to improve its half-life and targeting. In Phase I, we showed that: 1) In suppressing tumor growth and improving survival, TREM-1 blockadeusing GF9-LPC in PC xenografts is as effective as a standard chemo: gemcitabine (GEM)+nab-paclitaxel(PTX) combo, and 2) addition of GF9-LPC to GEM+nab-PTX sensitizes the tumor to chemo and triplessurvival rate of mice. Mechanistically, in PC xenografts, GF9-LPC reduces tumor-associated macrophage(TAM) infiltration and serum level of CSF1. As shown by others, in mice with hepatocellular carcinoma,blocking TREM-1+ TAMs by GF9 reverses immunosuppression and overcomes anti-PDL1 resistance. The goal of this project is to further develop GF9 therapy for PC to be used as an induction/maintenancetherapy alone or with first-line standard chemo treatments (GEM+nab-PTX) and/or ICB (anti-PD1/PDL1). Phase II aims are to: 1) generate and test rationally designed manufacturing friendly GF9 sequence-based formulations with favorable pharmacokinetic profile and high efficacy in vivo and select the lead(sub-aim – develop an assay to analyze GF9 in blood in PK studies), 2) test the lead in combination withGEM+nab-PTX in xenograft and syngeneic mouse models of PC, 3) test the lead in combination with anti-PD1/PDL1 in syngeneic mouse models of PC, and 4) test the lead in the non-clinical toxicology studies.Histology/IHC studies will be performed to analyze intratumoral macrophage infiltration as well asangiogenesis, tumor cell proliferation and death. Cytokines including CSF-1 will be analyzed. Follow-up Phase IIb will include other administration and combination (eg, radiation+GF9; anti-CSF-1R+GF9) regimen, TOX, ADME, CMC and other IND-enabling studies. Final manufacturing friendly product willrepresent safe and stable PC therapy. Its anticipated safety is supported by good tolerability of SignaBlok'sGF9 sequence-based formulations by long term-treated healthy, cancer and arthritic mice. Prototypes ofSignaBlok's LPC were safe and well tolerated in clinical trials. TREM-1 blockade using peptide LR12 bySignaBlok's top competitor (Inotrem, France) was safe and well tolerated in healthy and septic subjects. -DA - 2019 -PY - 2019 -AN - GRANTS:15046422 -G1 - 2R44CA217400-02; 9902597; R44CA217400 -AD - SIGNABLOK, INC. -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Yang, Lexie Zidanyue -AU - He, Qihua -AU - Zhang, Jianrong -AU - Ganti, Apar Kishor -AU - Stinchcombe, Thomas E. -AU - Pang, Herbert -AU - Wang, Xiaofei -TI - Characteristics of toxicity occurrence patterns in concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced non-small-cell lung cancer: a pooled analysis based on individual patient data of CALGB/Alliance trials -T2 - TRANSLATIONAL CANCER RESEARCH -M3 - Article -M3 - Early Access -AB - Background: For patients with locally advanced non-small-cell lung cancer (NSCLC), concurrent chemoradiotherapy is the foundational treatment strategy. Adding induction chemotherapy did not achieve a superior efficacy but increased the burden from toxicity. Accordingly, we retrospectively investigated the toxicity patterns through pooling individual patient data of the Cancer and Leukemia Group B (CALGB)/ Alliance trials.Methods: We included a total of 637 patients with unresectable stage III NSCLC who received induction chemotherapy with a platinum doublet and concurrent chemoradiotherapy and experienced at least one adverse event (AE) in CALGB 9130, 9431, 9534, 30105, 30106 and 39801 trials. The following toxicity occurrence patterns were evaluated: top 10 most frequent AEs, AE distribution by grade, rate of treatment discontinuation due to AEs, associations of AE occurrence with patient characteristics and treatment phase, the time to the first grade >_3 AE occurrence and its associations with patient characteristics and treatment phase.Results: The occurrence of AEs was the main reason accounting for treatment discontinuation (60 of 637 among all patients; 18 of 112 patients who experienced the induction phase only; 42 of 525 patients who experienced both phases). All patients experienced a total of 11,786 AEs (grade >_3: 1,049 of 5,538 in induction phase, 1,382 of 6,248 in concurrent phase). Lymphocytes and white blood count were of top 3 grade >_3 AEs that patients experienced the most in the either phase. Multivariable analysis found AE occurrence was associated with age >_65 {any grade: odds ratio (OR) =1.44 [95% confidence interval (CI): 1.12-1.86]} and the concurrent phase [grade >_3: OR =1.86 (95% CI: 1.41-2.47); any grade: OR =1.47 (95% CI: 1.19-1.81)]. Patients in the concurrent phase were more likely and earlier to develop grade >_3 AEs than those in the induction phase [hazard ratio (HR) =4.37 (95% CI: 2.52-7.59)].Conclusions: The report provides a better understanding regarding the toxicity occurrence patterns in concurrent chemoradiotherapy after induction chemotherapy. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-676X -SN - 2219-6803 -DA - 2022 AUG 25 -PY - 2022 -DO - 10.21037/tcr-22-2006 -AN - WOS:000856258900001 -C6 - AUG 2022 -AD - Duke Univ, Dept Biostat & Bioinformat, Sch Med, 2424 Erwin Rd, Durham, NC 27705 USA -AD - Guangzhou Med Univ, China State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis, Dept Oncol,Affiliated Hosp 1, Guangzhou, Peoples R China -AD - Washington Univ, Brown Sch, St Louis, MO 63110 USA -AD - Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne Med Sch, Melbourne, Vic, Australia -AD - Univ Melbourne, Fac Med Dent & Hlth Sci, Ctr Canc Res, Melbourne, Vic, Australia -AD - Victorian Comprehens Canc Ctr, 305 Grattan St, Melbourne, Vic 3000, Australia -AD - VA Nebraska Western Iowa Healthcare Syst, Dept Internal Med, Omaha, NE USA -AD - Univ Nebraska Med Ctr, Omaha, NE USA -AD - Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA -AD - Duke Univ, Alliance Stat & Data Management Ctr, Durham, NC USA -Y2 - 2023-02-05 -ER - - -TY - JOUR -AU - Chen, Hailong -AU - Yan, Weiwei -AU - Xu, Dechang -AU - Wang, Qi -AU - Yu, Ying -AU - Huang, Jing -AU - Zhou, Qian -AU - Xiao, Wei -AU - Lukanovic, David -AU - Barra, Fabio -AU - Izzotti, Alberto -AU - Jiang, Feizhou -TI - A postoperative tumor-specific death prediction model for patients with endometrial cancer: a retrospective study -T2 - TRANSLATIONAL CANCER RESEARCH -M3 - Article -AB - Background: Endometrial cancer (EC) is an epithelial malignancy occurring in the endometrium, with a 5-year mortality rate of above 10%. However, there is currently a lack of studies exploring the potential of a predictive model of tumor-specific death after surgery in these patients. Methods: From January 2015 to December 2017, data related to 482 patients with EC admitted to the Dushu Lake Hospital Affiliated to Soochow University were analyzed. Patients were divided into death (n=62) and survival (n=420) groups according to whether tumor-specific death occurred at 5 years postoperatively or not. The clinical characteristics of the two groups were compared, and the risk factors for tumorspecific death in patients with EC 5 years after surgery were investigated by logistics regression analysis. A nomogram prediction model was established according to the relevant risk factors. Results: Tumor size, Ki-67 positive rate, Federation International of Gynecology and Obstetrics (FIGO) stage, and the rate of vascular tumor thrombus between the two groups (P<0.05) were found to be the statistically significant factors. Positive Ki-67, tumor size >3.35 cm, stage III, and vascular tumor thrombus were factors that influenced the tumor-specific death at 5 years after surgery (P<0.05). The predictive model obtained an area under the receiver operating characteristic (ROC) curves in the training and verification sets of 0.847 [95% confidence interval (CI): 0.779-0.916] and 0.886 (95% CI: 0.803-0.969), respectively. Conclusions: The nomogram prediction model, which was established in this study, was proved to be valuable in predicting tumor-specific death 5 years after the surgery in patients with EC. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-676X -SN - 2219-6803 -DA - 2024 FEB -PY - 2024 -VL - 13 -IS - 2 -SP - 1083 -EP - 1090 -DO - 10.21037/tcr-23-1959 -AN - WOS:001223651500001 -AD - Ganzhou Canc Hosp, Dept Gynecomatol, Ganzhou, Peoples R China -AD - First Peoples Hosp Jiangxia Dist Wuhan City, Dept Obstet & Gynecol, Wuhan, Peoples R China -AD - Ganzhou Peoples Hosp, Dept Vasc Hernia Surg, Ganzhou, Peoples R China -AD - Univ Ljubljana, Med Ctr, Div Gynecol & Obstet, Ljubljana, Slovenia -AD - PO Osped Tigullio ASL4, Unit Obstet & Gynecol, Metropolitan Area Genoa, Genoa, Italy -AD - Univ Genoa, Dept Hlth Sci DISSAL, Genoa, Italy -AD - IRCCS Osped Policlin San Martino, Unit Mutagenesis & Canc Prevent, Genoa, Italy -AD - Univ Genoa, Dept Expt Med DIMES, Genoa, Italy -AD - Soochow Univ, Dushu Lake Hosp, Dept Obstet & Gynecol, 9 Chongwen Rd,Suzhou Ind Pk, Suzhou 215100, Peoples R China -M2 - Ganzhou Canc Hosp -M2 - First Peoples Hosp Jiangxia Dist Wuhan City -M2 - Ganzhou Peoples Hosp -M2 - PO Osped Tigullio ASL4 -M2 - IRCCS Osped Policlin San Martino -Y2 - 2024-05-23 -ER - - -TY - JOUR -AU - Dong, Zhong-Yi -AU - Wei, Wei -AU - Ruan, Yingchen -AU - Bai, Xue -AU - Li, Qisheng -TI - A phase II exploratory trial of adebrelimab in combination with chemotherapy and concurrent radiotherapy as a first-line treatment for oligo-metastatic extensive-stage small-cell lung cancer -T2 - JOURNAL OF CLINICAL ONCOLOGY -M3 - Meeting Abstract -CP - Special Clinical Science Symposia -CL - ELECTR NETWORK -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0732-183X -SN - 1527-7755 -DA - 2024 JUN 1 -PY - 2024 -VL - 42 -IS - 16 -MA - TPS8131 -AN - WOS:001275557406371 -AD - Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Guangdong Provi, Peoples R China -AD - Hubei Univ Arts & Sci, XiangYang Cent Hosp, Dept Oncol, Xiangyang, Peoples R China -AD - Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China -Y2 - 2024-08-18 -ER - - -TY - JOUR -AU - Xuzhang, Wendi -AU - Huang, Huayan -AU - Yu, Yongfeng -AU - Shen, Lan -AU - Li, Ziming -AU - Lu, Shun -TI - Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC -T2 - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY -M3 - Article -AB - Background:Oligoprogressive disease is recognized as the overall umbrella term; however, a small number of progressions on imaging can represent different clinical scenarios. This study aims to explore the optimal treatment strategy after immunotherapy (IO) resistance in advanced non-small-cell lung cancer (NSCLC), especially in personalized therapies for patients with different oligoprogressive patterns. Methods:Based on European Society for Radiotherapy and Oncology/European Organization for Research and Treatment of Cancer consensus, metastatic NSCLC patients with cancer progression after IO resistance were divided into four patterns, repeat oligoprogression (REO, oligoprogression with a history of oligometastatic disease), induced oligoprogression (INO, oligoprogression with a history of polymetastatic disease), de-novo polyprogression (DNP, polyprogression with a history of oligometastatic disease), and repeat polyprogression (REP, polyprogression with a history of polymetastatic disease). Patients with advanced NSCLC who received programmed cell death-1/programmed cell death ligand-1 inhibitors between January 2016 and July 2021 at Shanghai Chest Hospital were identified. The progression patterns and next-line progression-free survival (nPFS), overall survival (OS) were investigated stratified by treatment strategies. nPFS and OS were calculated using the Kaplan-Meier method. Results:A total of 500 metastatic NSCLC patients were included. Among 401 patients developed progression, 36.2% (145/401) developed oligoprogression and 63.8% (256/401) developed polyprogression. Specifically, 26.9% (108/401) patients had REO, 9.2% (37/401) patients had INO, 27.4% (110/401) patients had DNP, and 36.4% (146/401) patients had REP, respectively. The patients with REO who received local ablative therapy (LAT) had significant longer median nPFS and OS compared with no LAT group (6.8 versus 3.3 months; p = 0.0135; OS, not reached versus 24.5 months; p = 0.0337). By contrast, there were no nPFS and OS differences in INO patients who received LAT compared with no LAT group (nPFS, 3.6 versus 5.3 months; p = 0.3540; OS, 36.6 versus 45.4 months; p = 0.8659). But in INO patients, there were significant longer median nPFS and OS using IO maintenance by contrast with IO halt treatment (nPFS, 6.1 versus 4.1 months; p = 0.0264; OS, 45.4 versus 32.3 months; p = 0.0348). Conclusions:LAT (radiation or surgery) is more important for patients with REO while IO maintenance plays a more dominant role in patients with INO. -PU - SAGE PUBLICATIONS LTD -PI - LONDON -PA - 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND -SN - 1758-8340 -SN - 1758-8359 -DA - 2023 -PY - 2023 -VL - 15 -C7 - 17588359231156387 -DO - 10.1177/17588359231156387 -AN - WOS:000943178600001 -AD - Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Tumor Clin Med Ctr, Sch Med, West Huaihai Rd 241, Shanghai 200030, Peoples R China -Y2 - 2023-03-18 -ER - - -TY - JOUR -AU - Jayadevappa, Ravishankar -AU - Chhatre, Sumedha -AU - Soukiasian, Harmik J. -AU - Murgu, Septimiu -TI - Outcomes of patients with advanced non-small cell lung cancer and airway obstruction treated with photodynamic therapy and non-photodynamic therapy ablation modalities -T2 - JOURNAL OF THORACIC DISEASE -M3 - Article -AB - Background: Non-small cell lung cancer (NSCLC) patients with central airway obstruction (CAO) may have better survival on systemic therapy if the airway patency is successfully restored by bronchoscopic interventions. It remains unclear which therapeutic bronchoscopic modality [laser, stenting, external beam radiation, brachytherapy and photodynamic therapy (PDT)] used for restoring airway patency positively affects outcomes in these patients. We analyzed the effectiveness of PDT in terms of mortality, and time to subsequent treatments in patients with stage III and IV NSCLC.Methods: Study used Surveillance, Epidemiology, and End Results (SEER) Medicare linked data. We categorized NSCLC patients diagnosed between 2000 and 2011 and with stage III and IV, into three treatment groups: PDT + radiation +/- chemotherapy, non-PDT ablation therapy + radiation +/- chemotherapy, and radiation + chemotherapy. We analyzed all-cause and cause-specific mortality using Cox proportional hazard models with an inverse probability weighted propensity score adjustment. Time to subsequent treatment was analyzed using GLM model.Results: For the PDT group, hazard for all-cause and cause-specific mortality was comparable to the radiation + chemotherapy group (HR =1.03, 95% CI: 0.73-1.45; and HR =1.04, 95% CI: 0.71-1.51, respectively). The non-PDT ablation group had higher hazard for all-cause (HR =1.22, 95% CI: 1.13-1.33) and cause-specific mortality (HR =1.10, 95% CI: 1.01-1.20), compared to the radiation + chemotherapy group. The PDT group had longer time to follow-up treatment, compared to non-PDT ablation group.Conclusions: In our exploratory study of stage III and IV NSCLC patients with CAO, addition of PDT demonstrated hazard of mortality comparable to radiation + chemotherapy group. However, addition of non-PDT ablation showed higher mortality compared to the radiation + chemotherapy group. Future studies should investigate the efficacy and effectiveness of multimodal therapy including radiation, chemo, immunotherapy and bronchoscopic interventions. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2019 OCT -PY - 2019 -VL - 11 -IS - 10 -SP - 4389 -EP - 4399 -DO - 10.21037/jtd.2019.04.60 -AN - WOS:000493819500050 -AD - Univ Penn, Dept Med, 3615 Chestnut St,R,224, Philadelphia, PA 19104 USA -AD - Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA -AD - Univ Penn, Div Urol, Dept Surg, Sch Med, Philadelphia, PA 19104 USA -AD - Univ Penn, Abramson Canc Ctr, Sch Med, Philadelphia, PA 19104 USA -AD - Corporal Michael J Crescenz VAMC, Philadelphia, PA USA -AD - Univ Penn, Dept Psychiat, Sch Med, Philadelphia, PA 19104 USA -AD - Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA -AD - Univ Chicago Med, Chicago, IL USA -M2 - Corporal Michael J Crescenz VAMC -M2 - Univ Chicago Med -Y2 - 2019-11-18 -ER - - -TY - JOUR -AU - Camacho Sosa, Kirenia -AU - Alonso Lemus, Lisandry -AU - Ramírez Rodríguez, Doralys -AU - Carreño Rolando, Ihosvannys E -AU - Mendoza Jorge, Erasmo -AU - García Soto, Jesús -T2 - Revista Médica Electrónica -M3 - research-article -PU - CENTRO PROVINCIAL DE INFORMACIÓN DE CIENCIAS MÉDICAS. MATANZAS -SN - 1684-1824 -DA - 2021 02 -PY - 2021 -VL - 43 -IS - 1 -SP - 2795 -EP - 2807 -AN - SCIELO:S1684-18242021000102795 -AD - Hospital Universitario Clínico Quirúrgico Comandante “Faustino Pérez Hernández, Cuba -M2 - Hospital Universitario Clínico Quirúrgico Comandante “Faustino Pérez Hernández -Y2 - 2021-09-12 -ER - - -TY - JOUR -AU - Douillard, JY -AU - Chatal, JF -TI - Monoclonal antibodies and their fragments in cancer treatment -T2 - BULLETIN DU CANCER -M3 - Article -AB - During the last 15 years, various antibodies specific for antigens associated with determined types of cancer have been used therapeutically, including some in unlabeled forms as immune effectors. The results of clinical studies have been unpromising for patients with colorectal cancer at the advanced metastatic stage but much more favorable in terms of increased survival for the adjuvant situations of residual microscopic disease. Antibodies have also been used as carriers for cytotoxic substances, but with rather disappointing clinical results when they were labeled with toxins or antimitotic agents. The results have been variable for labeling with radionuclides (mainly iodine-131), sometimes proving quite favorable for refractory forms of non-hodgkin's lymphomas or acute leukemias. In this last indication, radioimmunotherapy has been associated with chemotherapy to enhance action before a bone-marrow graft. However, the clinical results have been disappointing in the treatment of solid tumors, showing responses only in the case of small targets. In the future, treatment with antibodies will focus on microscopic tumors, in association with other therapeutic modalities especially, chemotherapy and biotherapy. -PU - JOHN LIBBEY EUROTEXT LTD -PI - MONTROUGE -PA - 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE -SN - 0007-4551 -SN - 1769-6917 -DA - 1998 NOV -PY - 1998 -VL - 85 -IS - 11 -SP - 951 -EP - 959 -AN - WOS:000077558100009 -AD - Ctr Rene Gauducheau, Site Hosp Nord Nantes St Herblain, F-44805 St Herblain, France -Y2 - 1998-11-01 -ER - - -TY - JOUR -AU - Akamatsu, Hiroaki -AU - Murakami, Haruyasu -AU - Harada, Hideyuki -AU - Shimizu, Junichi -AU - Hayashi, Hidetoshi -AU - Daga, Haruko -AU - Hasegawa, Yoshikazu -AU - Kim, Young Hak -AU - Kato, Terufumi -AU - Tokunaga, Shoji -AU - Nishimura, Yasumasa -AU - Yamamoto, Nobuyuki -AU - Nakagawa, Kazuhiko -TI - Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L -T2 - JOURNAL OF THORACIC ONCOLOGY -M3 - Article -M3 - Proceedings Paper -CP - Virtual Conference of the European-Society-for-Medical-Oncology (ESMO) -CL - ELECTR NETWORK -AB - Introduction: About 10% of patients with locally advanced NSCLC (LA-NSCLC) harbor EGFR mutation and recent reports suggested the declined benefit with an immune checkpoint inhibitor in this population. The attempt that introduces EGFR tyrosine kinase inhibitor into the treatment of LA-NSCLC with EGFR mutation has been warranted.Methods: Chemotherapy-naive patients with unresectable LA-NSCLC with sensitive EGFR mutation (exon 19 deletion or exon 21 L858R point mutation) were enrolled. Patients were treated with gefitinib (250 mg/d for 2 y) plus concurrent thoracic radiotherapy (64 Gy/32 fractions). The primary end point was progression-free survival (PFS) at 2 years (trial identifier, UMIN000008366).Results: Between August 2012 and November 2017, a total of 28 patients were enrolled and 27 were eligible. The median age was 67 years (range: 45-74); never/current or former smoker in 15/12 patients, respectively; Eastern Cooperative Oncology Group performance status of 0/1 in 19/8; EGFR exon 19 deletion/exon 21 L858R in 13/14; and c-stage IIIA/IIIB in 14/13. The PFS rate at 2 years by independent review was 29.6% (one-sided 95% confidence interval [CI]: 17.6%-). The overall response rate was 81.5% (95% CI: 63.3%91.3%), median PFS was 18.6 months (95% CI: 12.0-24.5 mo), and median overall survival was 61.1 months (95% CI: 38.1 mo-not reached). Approximately half of the patients exhibited solitary brain metastasis as their first site of relapse. Adverse events greater than or equal to grade 3 were fatigue, skin reaction, and appetite loss (3.7% each).Conclusions: This prospective study revealed the tolerability and the possible efficacy of gefitinib plus concurrent thoracic radiotherapy in patients with LA-NSCLC having EGFR mutation. (C) 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 1556-0864 -SN - 1556-1380 -DA - 2021 OCT -PY - 2021 -VL - 16 -IS - 10 -SP - 1745 -EP - 1752 -DO - 10.1016/j.jtho.2021.05.019 -AN - WOS:000797195300004 -AD - Shizuoka Canc Ctr, Dept Thorac Oncol, Shizuoka, Japan -AD - Wakayama Med Univ, Intemal Med 3, 811-1 Kimiidera, Wakayama 6418509, Japan -AD - Shizuoka Canc Ctr, Dept Radiat Oncol, 1007 Shimonagakubo, Nagaizumi, Shizuoka, Japan -AD - Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan -AD - Kindai Univ, Dept Med Oncol, Fac Med, Osakasayama, Japan -AD - Osaka City Gen Hosp, Dept Med Oncol, Osaka, Japan -AD - Izumi City Gen Hosp, Dept Med Oncol, Izumi, Japan -AD - Kyoto Univ, Dept Resp Med, Kyoto, Japan -AD - Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan -AD - Kyushu Univ Hosp, Med Informat Ctr, Fukuoka, Japan -AD - Kindai Univ, Dept Radiat Oncol, Fac Med, Osakasayama, Japan -M2 - Kindai Univ -M2 - Izumi City Gen Hosp -M2 - Kindai Univ -Y2 - 2022-05-31 -ER - - -TY - JOUR -AU - LETTERIO, JOHN JAMES -TI - Developmental Therapeutics Research Program -M3 - Awarded Grant -DA - 2018 -PY - 2018 -AN - GRANTS:10710681 -G1 - 2P30CA043703-28; 9488775; P30CA043703 -AD - CASE WESTERN RESERVE UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - LETTERIO, JOHN JAMES -TI - Developmental Therapeutics Research Program -M3 - Awarded Grant -DA - 2018 -PY - 2018 -AN - GRANTS:10755654 -G1 - 3P30CA043703-28S1; 9759069; P30CA043703 -AD - CASE WESTERN RESERVE UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Desage, Anne-Laure -AU - Tissot, Claire -AU - Bayle-Bleuez, Sophie -AU - Muron, Thierry -AU - Deygas, Nadine -AU - Grangeon-Vincent, Valerie -AU - Monange, Brigitte -AU - Torche, Fatah -AU - Vercherin, Paul -AU - Kaczmarek, David -AU - Tiffet, Olivier -AU - Forest, Fabien -AU - Vergnon, Jean-Michel -AU - Bouleftour, Wafa -AU - Fournel, Pierre -TI - Adjuvant chemotherapy for completely resected IIA-IIIA non-small cell lung cancer: compliance to guidelines, safety and efficacy in real-life practice -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Article -AB - Background: Since randomised clinical trials demonstrated a survival benefit of adjuvant chemotherapy (AC) following curative-intent lung surgery, AC has been implemented as a standard therapeutic strategy for patients with a completely resected IIA-IIIA non-small cell lung cancer (NSCLC). Regarding the moderate benefit of AC and the lack of literature on AC use in real-life practice, we aimed to evaluate compliance to guidelines, AC safety and efficacy in a less selected population. Methods: Between January 2009 and December 2014, we retrospectively analysed 210 patients with theoretical indication of AC following curative-intent lung surgery for a completely resected IIA-IIIA NSCLC. The primary objective of this retrospective study was to evaluate compliance to AC guidelines. Secondary objectives included safety and efficacy of AC in real-life practice. Results: Among 210 patients with a theoretical indication of AC, chemotherapy administration was validated in multidisciplinary team (MDT) for 62.4% of them and 117 patients (55.7%) finally received AC. Patient's clinical conditions were the main reasons advanced in MDT for no respect to AC guidelines. Most of the patients received cisplatin-vinorelbine (86.3%) and AC was initiated within 8 weeks following lung surgery for 73.5% of patients. One-half of patients who received AC experienced side effects leading to either dose-intensity modification or treatment interruption. In real-life practice, AC was found to provide a survival benefit over surgery alone. Factors related to daily-life practice such as delayed AC initiation or incomplete AC planned dose received were not associated with an inferior survival. Conclusions: Although AC use might differ from guidelines in real-life practice, this retrospective study highlights that AC can be used safely and remains efficient among a less selected population. In the context of immunotherapy and targeted therapies development in peri-operative treatment strategies, the place of AC has to be precised in the future. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2022 DEC -PY - 2022 -VL - 11 -IS - 12 -SP - 2418 -EP - 2437 -DO - 10.21037/tlcr-22-345 -AN - WOS:000905054600001 -C6 - OCT 2022 -AD - Univ Hosp St Etienne, Dept Pulmonol & Thorac Oncol, North Hosp, St Etienne, France -AD - Private Loire Hosp HPL, Oncol Dept, St Etienne, France -AD - Univ Hosp St Etienne, Dept Med Oncol, North Hosp, St Etienne, France -AD - Gier Hosp, Dept Pulmonol, St Chamond, France -AD - Roanne Hosp, Dept Pulmonol, Roanne, France -AD - Emile Roux Hosp, Dept Med Oncol, Le Puy En Velay, France -AD - Univ Hosp St Etienne, Publ Hlth & Med Informat Dept, North Hosp, St Etienne, France -AD - Private Loire Hosp HPL, Thorac & Digest Surg Dept, St Etienne, France -AD - Univ Hosp St Etienne, Dept Thorac Surg, North Hosp, St Etienne, France -AD - Univ Hosp St Etienne, Pathol Dept, North Hosp, St Etienne, France -M2 - Private Loire Hosp HPL -M2 - Gier Hosp -M2 - Roanne Hosp -M2 - Emile Roux Hosp -M2 - Private Loire Hosp HPL -Y2 - 2023-01-21 -ER - - -TY - JOUR -AU - Waninger, J. J. -AU - Bryant, A. K. -AU - Sankar, K. -AU - Ramnath, N. -AU - Green, M. -TI - Efficiency Effectiveness Gap of Durvalumab in Locally Advanced Non-Small Cell Lung Cancer -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) -CL - ELECTR NETWORK -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2022 NOV 1 -PY - 2022 -VL - 114 -IS - 3 -MA - 2883 -SP - E395 -EP - E396 -AN - WOS:000892639301210 -AD - Univ Michigan, Sch Med, Ann Arbor, MI USA -AD - Vet Affairs Ann Arbor Hlth Syst, Dept Radiat Oncol, Ann Arbor, MI USA -AD - Univ Michigan, Dept Hematol & Oncol, Ann Arbor, MI 48109 USA -AD - Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA -Y2 - 2023-03-09 -ER - - -TY - JOUR -Z2 - 郑雅文 -Z2 - 李润美 -Z2 - 魏枫 -Z2 - 刘亮 -Z2 - 张新伟 -Z2 - 任秀宝 -AU - Zheng Yawen -AU - Li Runmei -AU - Wei Feng -AU - Liu Liang -AU - Zhang Xinwei -AU - Ren Xiubao -TI - A Meta-analysis of adoptive immunotherapy combined with chemo /radio therapy in the treatment of non-small cell lung cancer -T2 - Chinese Journal of Cancer Biotherapy -M3 - Article -AB - Objective: To systematically assess the therapeutic effectiveness of adoptive immunotherapy combined with chemo /radio therapy compared with chemo /radio therapy alone in non-small cell lung cancer (NSCLC) patients. Methods: A systematic search of Pubmed,Medline,EMBASE,Cochrane Library,CNKI and VIP database from January 1995 to September 2012 was performed to identify the eligible randomized controlled trials (RCTs) and non-randomized concurrent controlled trails (NRCCTs). The improper documents were excluded. The soft-ware Revman5. 0 was used for data synthesis. Results: A total of 10 studies involving 1 326 patients were identified. The result of Meta-analyses showed that adoptive immunotherapy combined with radio /chemo therapy improved the 2-year progression-free survival (PFS) (OR = 2. 20,95%CI: 1. 44 - 3. 36,P = 0. 0003) and 2-year overall survival (OR = 2. 69,95% CI: 1. 92 - 3. 78,P < 0. 00001). Both early-stage and advanced NSCLC patients benefited from adoptive immunotherapy (OR = 3. 24[1. 65 - 6. 35]; OR = 2. 86[1. 37 - 5. 98]). The adverse events were self limiting,including fever,chill,nausea,and fatigue. No severe toxicity was observed. Conclusion: Adoptive immunotherapy combined with chemo /radio therapy can decrease the risk of recurrence and improve the overall survival of NSCLC patients; early-stage patients receiving adoptive immunotherapy may benefit more. -SN - 1007-385X -DA - 2013 -PY - 2013 -VL - 20 -IS - 4 -SP - 461 -EP - 467 -C7 - 1007-385X(2013)20:4<461:GJMYZL>2.0.TX;2-N -AN - CSCD:4908450 -AD - 天津医科大学附属肿瘤医院生物治疗科, 天津市肿瘤免疫与生物治疗重点实验室, 天津 300060, 中国 -AD - Key Laboratory of Cancer Immunology and Biotherapy of Tianjin,Department of Biotherapy,Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China -M2 - 天津医科大学附属肿瘤医院生物治疗科 -M2 - Key Laboratory of Cancer Immunology and Biotherapy of Tianjin,Department of Biotherapy,Tianjin Medical University Cancer Institute and Hospital -Y2 - 2013-11-14 -ER - - -TY - JOUR -AU - Hao, D Q -AU - Li, L Q -AU - Li, M C -AU - Gong, L L -TI - [Advances in immunotherapy of extranodal NK/T cell lymphoma]. -T2 - Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery -M3 - Journal Article -AB - Extranodal NK/T-cell lymphoma (ENKTCL) is a relatively rare group of highly aggressive non-Hodgkin's lymphoma (NHL). The disease has rapid clinical progress, high degree of malignancy and poor prognosis. Traditional chemoradiotherapy regimens have not shown good efficacy. In recent years, the immunotherapy of tumors has developed rapidly. At present, it has shown strong therapeutic activity in the treatment of various solid tumors such as non-small cell lung cancer, prostate cancer, melanoma and kidney cancer. Multiple tumor immunotherapy drugs have been approved by the US Food and Drug Administration (FDA) for clinical use. This article reviews recent novel immunotherapeutic regimens of ENKTCL, hoping to change the treatment modality of this malignant disease. -AB - 结外NK/T细胞淋巴瘤(ENKTCL)是一组比较少见的高度侵袭性的非霍奇金淋巴瘤。该病临床进展迅速、恶性程度高、预后较差,传统的放化疗方案并没有显示出良好的疗效。近几年来,肿瘤的免疫治疗迅猛发展,目前已在多种实体肿瘤如非小细胞肺癌、前列腺癌、黑色素瘤、肾癌的治疗中展示出了强大的治疗活性,多个肿瘤免疫治疗药物已经获得美国食品药品监督管理局批准上市并应用于临床。本文综述了近年来ENKTCL的新型免疫治疗方案,希望能够改变这种恶性疾病的治疗模式。. -SN - 1673-0860 -DA - 2019 Dec 07 -PY - 2019 -VL - 54 -IS - 12 -SP - 949 -EP - 953 -DO - 10.3760/cma.j.issn.1673-0860.2019.12.015 -AN - MEDLINE:31887826 -AD - Shandong First Medical University (Shandong Academy of Medical Sciences), Taian 271000, China. -AD - Liaocheng People's Hospital, Otorhinolaryngology Head and Neck Surgery, Liaocheng 252000, China. -Y2 - 2020-01-03 -ER - - -TY - JOUR -AU - Guo, Jiao -AU - Zhao, Wei -AU - Xiao, Xinyu -AU - Liu, Shanshan -AU - Liu, Liang -AU - Zhang, La -AU - Li, Lu -AU - Li, Zhenghang -AU - Li, Zhi -AU - Xu, Mengxia -AU - Peng, Qiling -AU - Wang, Jianwei -AU - Wei, Yuxian -AU - Jiang, Ning -TI - Reprogramming exosomes for immunity-remodeled photodynamic therapy against non-small cell lung cancer -T2 - BIOACTIVE MATERIALS -M3 - Article -AB - Traditional treatments against advanced non-small cell lung cancer (NSCLC) with high morbidity and mortality continue to be dissatisfactory. Given this situation, there is an urgent requirement for alternative modalities that provide lower invasiveness, superior clinical effectiveness, and minimal adverse effects. The combination of photodynamic therapy (PDT) and immunotherapy gradually become a promising approach for high-grade malignant NSCLC. Nevertheless, owing to the absence of precise drug delivery techniques as well as the hypoxic and immunosuppressive characteristics of the tumor microenvironment (TME), the efficacy of this combination therapy approach is less than ideal. In this study, we construct a novel nanoplatform that indocyanine green (ICG), a photosensitizer, loads into hollow manganese dioxide (MnO2) nanospheres (NPs) (ICG@MnO2), and then encapsulated in PD-L1 monoclonal antibodies (anti-PD-L1) reprogrammed exosomes (named ICG@MnO2@Exo-anti-PD-L1), to effectively modulate the TME to oppose NSCLC by the synergy of PDT and immunotherapy modalities. The ICG@MnO2@Exo-anti-PD-L1 NPs are precisely delivered to the tumor sites by targeting specially PD-L1 highly expressed cancer cells to controllably release anti-PD-L1 in the acidic TME, thereby activating T cell response. Subsequently, upon endocytic uptake by cancer cells, MnO2 catalyzes the conversion of H2O2 to O2, thereby alleviating tumor hypoxia. Meanwhile, ICG further utilizes O2 to produce singlet oxygen (1O2) to kill tumor cells under 808 nm near-infrared (NIR) irradiation. Furthermore, a high level of intratumoral H2O2 reduces MnO2 to Mn2+, which remodels the immune microenvironment by polarizing macrophages from M2 to M1, further driving T cells. Taken together, the current study suggests that the ICG@MnO2@Exo-anti-PDL1 NPs could act as a novel drug delivery platform for achieving multimodal therapy in treating NSCLC. -PU - KEAI PUBLISHING LTD -PI - BEIJING -PA - 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG DISTRICT 100009, PEOPLES R CHINA -SN - 2452-199X -DA - 2024 SEP -PY - 2024 -VL - 39 -SP - 206 -EP - 223 -DO - 10.1016/j.bioactmat.2024.05.030 -AN - WOS:001249406100001 -AD - Chongqing Med Univ, Sch Basic Med Sci, Chongqing 400016, Peoples R China -AD - Chongqing Med Univ, Affiliated Hosp 2, Dept Plast & Maxillofacial Surg, Chongqing 400016, Peoples R China -AD - Chongqing Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Chongqing 400016, Peoples R China -AD - Chongqing Med Univ, Affiliated Hosp 1, Dept Breast & Thyroid Surg, Chongqing 400016, Peoples R China -AD - Tradit Chinese Med Hosp Bijie City, Bijie 551700, Guizhou, Peoples R China -AD - Bijie Municipal Hlth Bur, Bijie 551700, Guizhou, Peoples R China -AD - Guizhou Med Univ, Hlth Management Ctr, Affiliated Hosp, Guiyang, Peoples R China -AD - Chongqing Med Univ, Sch Basic Med Sci, Dept Pathol, Chongqing 400016, Peoples R China -AD - Chongqing Med Univ, Mol Med Diagnost & Testing Ctr, Chongqing 400016, Peoples R China -AD - Chongqing Med Univ, Affiliated Hosp 1, Dept Pathol, Chongqing 400016, Peoples R China -M2 - Tradit Chinese Med Hosp Bijie City -M2 - Bijie Municipal Hlth Bur -Y2 - 2024-06-24 -ER - - -TY - JOUR -AU - PALENA, CLAUDIA -TI - Novel Targets for Immunotherapy -M3 - Awarded Grant -AB - Our laboratory has previously identified the embryonic transcription factor transcription as a tumor antigen and a driver of cancer plasticity and tumor resistance to various therapeutics. Brachyury is expressed in various types of cancer, including lung cancer, triple negative breast cancer, small cell lung carcinomas, germ cell tumors, and the rare tumor type chordoma, while being almost undetectable in the majority of adult normal tissues. A phase I clinical study of a modified vaccinia Ankara (MVA) priming followed by a fowlpox virus boosting, each encoding for brachyury and three costimulatory molecules has been completed in patients with advanced solid tumors. The vaccine was well-tolerated and induced immune responses to brachyury and the "cascade antigens" carcinoembryonic antigen (CEA) and mucin-1 (MUC1) in the majority of patients, with some evidence of clinical benefit. A phase I clinical trial of a multi-targeted recombinant adenovirus 5-based vaccine targeting brachyury, CEA and MUC1 was also completed, demonstrating the generation of CD4+ and/or CD8+ T-cell responses against all three antigens in the majority of patients, without any evidence of antigenic competition or toxicity. Similarly, an adenovirus vaccine platform using adenovirus 5 vectors targeting prostate-specific antigen (PSA), brachyury, and MUC1 was evaluated in patients with metastatic castration prostate cancer (mCRPC). The vaccine was tolerable and safe, elicited multifunctional T-cell responses to all three antigens, and showed evidence of clinical activity. The study of brachyury as a tumor antigen and its role as a driver of cancer plasticity led us to investigate and demonstrate a link between the acquisition of mesenchymal features by carcinoma cells and mechanisms of resistance to lysis by immune effector cells. Following these observations, we investigated approaches to improve tumor susceptibility to immune attack via modulation of tumor phenotype. We previously showed that one of the drivers of tumor EMT is the chemokine IL-8 which also promotes the recruitment of immunosuppressive cells to the tumor site, particularly the migration of granulocytic myeloid suppressor cells (G-MDSCs). One of the tumor types with a high degree of infiltration with G-MDSCs is head and neck carcinoma (HNSCC), also characterized by high expression of IL-8. In collaboration with Dr. C. Allen (NIDCD), the benefit of blocking IL-8 signaling in HNSCC models via inhibition of the IL-8 receptors, CXCR1 and CXCR2, was shown in combination with NK-cell mediated immunotherapy. In addition to IL-8, transforming growth factor beta (TGF-beta) is a master regulator of tumor plasticity. We recently showed that the combined use of a CXCR1/2 inhibitor with a bifunctional agent that simultaneously blocks PD-L1 and 'traps' soluble TGF-beta at the site of the tumor, termed bintrafusp alfa, results in more effective anti-tumor control, compared to each monotherapy. We showed that simultaneous inhibition of CXCR1/2, TGF-beta, and PD-L1 signaling synergizes to reduce mesenchymal tumor features in murine models of breast and lung cancer, and to markedly enhance the expression of tumor epithelial markers while reducing infiltration with suppressive G-MDSCs, enhancing tumor infiltration and activation of T-cells, and leading to improved anti-tumor activity. The addition of vaccine to the combination of bintrafusp alfa and CXCR1/2 inhibition was subsequently shown to induce greater tumor infiltration with T cells highly positive for markers of proliferation and cytotoxicity, and to restructure the tumor microenvironment with reduced Tregs and CD11b+Ly6G+ myeloid cells. Altogether, these results provide the rationale for the use of strategies that simultaneously block IL-8 signaling, neutralize TGF-beta in the tumor microenvironment, inhibit PD-L1, and activate tumor-specific immunity via the use of cancer vaccines. -DA - 2021 -PY - 2021 -AN - GRANTS:17427296 -G1 - 10487216; 1ZICBC010937-14; ZICBC010937 -AD - DIVISION OF BASIC SCIENCES - NCI -Y2 - 2024-03-05 -ER - - -TY - BOOK -AU - Deem, Jennifer Dezet -Z2 - -TI - Real World Treatment Patterns and Outcomes Among Patients With Early Non-Small Cell Lung Cancer -M3 - Dissertation/Thesis -SN - 9798384098355 -DA - 2024 -PY - 2024 -AN - PQDT:91907123 -AD - University of Washington, Pharmacy, Washington, United States -M2 - University of Washington -ER - - -TY - JOUR -AU - CHEN, LIEPING -TI - Project 1: Siglec15 as a new target for lung cancer immunotherapy -M3 - Awarded Grant -AB - PROJECT SUMMARYThe inability of tumor infiltrating lymphocytes (TILs) to target and kill tumor cells is a major hurdle in treatingmany malignancies. New treatment strategies that block immune inhibitory mechanisms, such as antibodiesthat block the interaction of programmed death-1 (PD-1) with its ligand, B7 homolog 1 (B7-H1, also known asPD-L1), have shown promising efficacy in the clinic. Termed checkpoint inhibitor therapy, these drugs havebeen approved for many indications, including melanoma, Hodgkin lymphoma and lung cancer, and areincreasingly being used in combination or in conjunction with other cancer therapies, such as chemotherapyand radiation. Although checkpoint inhibitor treatments have resulted in durable clinical responses in a largeproportion of cases, many patients present with tumor types that do not respond to treatment. For instance,~26% of NSCLC cases, which are negative for B7-H1/PD-L1 and positive for TILs, have been shown to beresistant to anti-PD-1/B7-H1(PD-L1) (anti-PD) therapy. This type of NSCLC, denoted as Type III, is suspectedto harbor a mechanism of immune inhibition distinct from other NSCLC types, which has been found to bedriven, at least in part, by sialic acid binding immunoglobulin-like lectin 15 (siglec-15). Siglec-15 expression ismutually exclusive from B7-H1/PD-L1 expression in NSCLC cohorts and has been shown to inhibit T cellproliferation and effector function. Blocking of siglec-15 using anti-siglec-15 (S15) monoclonal antibody (mAb)is therapeutic in mouse models and human cell culture systems and results in amplified T cell responses.Based on these findings, a phase I/II, dose escalation, safety and tolerability clinical trial for S15 mAbtreatment in patients with advanced or metastatic solid tumors is on-going. Although preliminary studies havegenerated promising results with regard to the potential efficacy of S15 mAb in the clinic, the mechanism ofS15-mediated immune suppression remains unknown. Furthermore, to enhance and improve treatmentresponse rates, more work must be done to identify pertinent biomarkers for S15 mAb therapy and modes thatmodulate S15 expression. Finally, developing combination strategies that alter the tumor microenvironment(TME), such that conversion of the tumor Type is achieved, is imperative for successful targeting and killing oftumor by immune cells and in attaining increased patient response rates to available checkpoint inhibitortherapies. A newly generated immune PDX (iPDX) mouse model, which uses patient-derived tumor tissue torecapitulate and manipulate immune cell responses in the TME, will be utilized to investigate these topicsspecifically in the NSCLC setting. A proposed investigator-initiated phase II clinical trial in patients with S15+advanced NSCLC who have progressed on PD-1 axis inhibitor therapy will evaluate S15 mAb efficacy andsupport biomarker validation studies. Strategies to combine S15 mAb with other agents, such as anti-FGL1and anti-4-1BB/CD137, to improve therapeutic effect will also be explored. Taken together, the studiesproposed here will improve our understanding of the NSCLC TME and enhance therapeutic approaches. -DA - 2022 -PY - 2022 -AN - GRANTS:17478171 -G1 - 10479800; 5P50CA196530-08; 8102; P50CA196530 -AD - YALE UNIVERSITY -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - RIMM, DAVID L -TI - Project 1: Siglec15 as a new target for lung cancer immunotherapy -M3 - Awarded Grant -AB - PROJECT SUMMARYThe inability of tumor infiltrating lymphocytes (TILs) to target and kill tumor cells is a major hurdle in treatingmany malignancies. New treatment strategies that block immune inhibitory mechanisms, such as antibodiesthat block the interaction of programmed death-1 (PD-1) with its ligand, B7 homolog 1 (B7-H1, also known asPD-L1), have shown promising efficacy in the clinic. Termed checkpoint inhibitor therapy, these drugs havebeen approved for many indications, including melanoma, Hodgkin lymphoma and lung cancer, and areincreasingly being used in combination or in conjunction with other cancer therapies, such as chemotherapyand radiation. Although checkpoint inhibitor treatments have resulted in durable clinical responses in a largeproportion of cases, many patients present with tumor types that do not respond to treatment. For instance,~26% of NSCLC cases, which are negative for B7-H1/PD-L1 and positive for TILs, have been shown to beresistant to anti-PD-1/B7-H1(PD-L1) (anti-PD) therapy. This type of NSCLC, denoted as Type III, is suspectedto harbor a mechanism of immune inhibition distinct from other NSCLC types, which has been found to bedriven, at least in part, by sialic acid binding immunoglobulin-like lectin 15 (siglec-15). Siglec-15 expression ismutually exclusive from B7-H1/PD-L1 expression in NSCLC cohorts and has been shown to inhibit T cellproliferation and effector function. Blocking of siglec-15 using anti-siglec-15 (S15) monoclonal antibody (mAb)is therapeutic in mouse models and human cell culture systems and results in amplified T cell responses.Based on these findings, a phase I/II, dose escalation, safety and tolerability clinical trial for S15 mAbtreatment in patients with advanced or metastatic solid tumors is on-going. Although preliminary studies havegenerated promising results with regard to the potential efficacy of S15 mAb in the clinic, the mechanism ofS15-mediated immune suppression remains unknown. Furthermore, to enhance and improve treatmentresponse rates, more work must be done to identify pertinent biomarkers for S15 mAb therapy and modes thatmodulate S15 expression. Finally, developing combination strategies that alter the tumor microenvironment(TME), such that conversion of the tumor Type is achieved, is imperative for successful targeting and killing oftumor by immune cells and in attaining increased patient response rates to available checkpoint inhibitortherapies. A newly generated immune PDX (iPDX) mouse model, which uses patient-derived tumor tissue torecapitulate and manipulate immune cell responses in the TME, will be utilized to investigate these topicsspecifically in the NSCLC setting. A proposed investigator-initiated phase II clinical trial in patients with S15+advanced NSCLC who have progressed on PD-1 axis inhibitor therapy will evaluate S15 mAb efficacy andsupport biomarker validation studies. Strategies to combine S15 mAb with other agents, such as anti-FGL1and anti-4-1BB/CD137, to improve therapeutic effect will also be explored. Taken together, the studiesproposed here will improve our understanding of the NSCLC TME and enhance therapeutic approaches. -DA - 2023 -PY - 2023 -AN - GRANTS:17749688 -G1 - 10690060; 5P50CA196530-09; 6574; P50CA196530 -AD - YALE UNIVERSITY -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - CHEN, LIEPING -TI - Project 1: Siglec15 as a new target for lung cancer immunotherapy -M3 - Awarded Grant -AB - PROJECT SUMMARYThe inability of tumor infiltrating lymphocytes (TILs) to target and kill tumor cells is a major hurdle in treatingmany malignancies. New treatment strategies that block immune inhibitory mechanisms, such as antibodiesthat block the interaction of programmed death-1 (PD-1) with its ligand, B7 homolog 1 (B7-H1, also known asPD-L1), have shown promising efficacy in the clinic. Termed checkpoint inhibitor therapy, these drugs havebeen approved for many indications, including melanoma, Hodgkin lymphoma and lung cancer, and areincreasingly being used in combination or in conjunction with other cancer therapies, such as chemotherapyand radiation. Although checkpoint inhibitor treatments have resulted in durable clinical responses in a largeproportion of cases, many patients present with tumor types that do not respond to treatment. For instance,~26% of NSCLC cases, which are negative for B7-H1/PD-L1 and positive for TILs, have been shown to beresistant to anti-PD-1/B7-H1(PD-L1) (anti-PD) therapy. This type of NSCLC, denoted as Type III, is suspectedto harbor a mechanism of immune inhibition distinct from other NSCLC types, which has been found to bedriven, at least in part, by sialic acid binding immunoglobulin-like lectin 15 (siglec-15). Siglec-15 expression ismutually exclusive from B7-H1/PD-L1 expression in NSCLC cohorts and has been shown to inhibit T cellproliferation and effector function. Blocking of siglec-15 using anti-siglec-15 (S15) monoclonal antibody (mAb)is therapeutic in mouse models and human cell culture systems and results in amplified T cell responses.Based on these findings, a phase I/II, dose escalation, safety and tolerability clinical trial for S15 mAbtreatment in patients with advanced or metastatic solid tumors is on-going. Although preliminary studies havegenerated promising results with regard to the potential efficacy of S15 mAb in the clinic, the mechanism ofS15-mediated immune suppression remains unknown. Furthermore, to enhance and improve treatmentresponse rates, more work must be done to identify pertinent biomarkers for S15 mAb therapy and modes thatmodulate S15 expression. Finally, developing combination strategies that alter the tumor microenvironment(TME), such that conversion of the tumor Type is achieved, is imperative for successful targeting and killing oftumor by immune cells and in attaining increased patient response rates to available checkpoint inhibitortherapies. A newly generated immune PDX (iPDX) mouse model, which uses patient-derived tumor tissue torecapitulate and manipulate immune cell responses in the TME, will be utilized to investigate these topicsspecifically in the NSCLC setting. A proposed investigator-initiated phase II clinical trial in patients with S15+advanced NSCLC who have progressed on PD-1 axis inhibitor therapy will evaluate S15 mAb efficacy andsupport biomarker validation studies. Strategies to combine S15 mAb with other agents, such as anti-FGL1and anti-4-1BB/CD137, to improve therapeutic effect will also be explored. Taken together, the studiesproposed here will improve our understanding of the NSCLC TME and enhance therapeutic approaches. -DA - 2021 -PY - 2021 -AN - GRANTS:17397255 -G1 - 10203854; 5P50CA196530-07; 8102; P50CA196530 -AD - YALE UNIVERSITY -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - CHEN, LIEPING -TI - Project 1: Siglec15 as a new target for lung cancer immunotherapy -M3 - Awarded Grant -AB - PROJECT SUMMARYThe inability of tumor infiltrating lymphocytes (TILs) to target and kill tumor cells is a major hurdle in treatingmany malignancies. New treatment strategies that block immune inhibitory mechanisms, such as antibodiesthat block the interaction of programmed death-1 (PD-1) with its ligand, B7 homolog 1 (B7-H1, also known asPD-L1), have shown promising efficacy in the clinic. Termed checkpoint inhibitor therapy, these drugs havebeen approved for many indications, including melanoma, Hodgkin lymphoma and lung cancer, and areincreasingly being used in combination or in conjunction with other cancer therapies, such as chemotherapyand radiation. Although checkpoint inhibitor treatments have resulted in durable clinical responses in a largeproportion of cases, many patients present with tumor types that do not respond to treatment. For instance,~26% of NSCLC cases, which are negative for B7-H1/PD-L1 and positive for TILs, have been shown to beresistant to anti-PD-1/B7-H1(PD-L1) (anti-PD) therapy. This type of NSCLC, denoted as Type III, is suspectedto harbor a mechanism of immune inhibition distinct from other NSCLC types, which has been found to bedriven, at least in part, by sialic acid binding immunoglobulin-like lectin 15 (siglec-15). Siglec-15 expression ismutually exclusive from B7-H1/PD-L1 expression in NSCLC cohorts and has been shown to inhibit T cellproliferation and effector function. Blocking of siglec-15 using anti-siglec-15 (S15) monoclonal antibody (mAb)is therapeutic in mouse models and human cell culture systems and results in amplified T cell responses.Based on these findings, a phase I/II, dose escalation, safety and tolerability clinical trial for S15 mAbtreatment in patients with advanced or metastatic solid tumors is on-going. Although preliminary studies havegenerated promising results with regard to the potential efficacy of S15 mAb in the clinic, the mechanism ofS15-mediated immune suppression remains unknown. Furthermore, to enhance and improve treatmentresponse rates, more work must be done to identify pertinent biomarkers for S15 mAb therapy and modes thatmodulate S15 expression. Finally, developing combination strategies that alter the tumor microenvironment(TME), such that conversion of the tumor Type is achieved, is imperative for successful targeting and killing oftumor by immune cells and in attaining increased patient response rates to available checkpoint inhibitortherapies. A newly generated immune PDX (iPDX) mouse model, which uses patient-derived tumor tissue torecapitulate and manipulate immune cell responses in the TME, will be utilized to investigate these topicsspecifically in the NSCLC setting. A proposed investigator-initiated phase II clinical trial in patients with S15+advanced NSCLC who have progressed on PD-1 axis inhibitor therapy will evaluate S15 mAb efficacy andsupport biomarker validation studies. Strategies to combine S15 mAb with other agents, such as anti-FGL1and anti-4-1BB/CD137, to improve therapeutic effect will also be explored. Taken together, the studiesproposed here will improve our understanding of the NSCLC TME and enhance therapeutic approaches. -DA - 2020 -PY - 2020 -AN - GRANTS:15559091 -G1 - 2P50CA196530-06; 8102; 9854323; P50CA196530 -AD - YALE UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - MELLMAN, IRA S -TI - Research Programs-Immunology and Immunotherapy -M3 - Awarded Grant -DA - 2008 -PY - 2008 -AN - GRANTS:11649921 -G1 - 0003; 5P30CA016359-30; 7673426; P30CA016359 -AD - YALE UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Wang, Lili -AU - He, Zhen -AU - Yang, Sen -AU - Tang, Hong -AU - Wu, Yufeng -AU - Li, Shaomei -AU - Han, Baohui -AU - Li, Kai -AU - Zhang, Li -AU - Shi, Jianhua -AU - Wang, Zhehai -AU - Cheng, Ying -AU - He, Jianxing -AU - Shi, Yuankai -AU - Chen, Weiqiang -AU - Luo, Yi -AU - Wu, Lin -AU - Wang, Xiuwen -AU - Nan, Kejun -AU - Jin, Faguang -AU - Dong, Jian -AU - Li, Baolan -AU - Sun, Yan -AU - Wang, Qiming -TI - The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial -T2 - TRANSLATIONAL LUNG CANCER RESEARCH -M3 - Article -AB - Background: Lung cancer remains one of the deadliest cancers worldwide. The ALTER0303 trial revealed that anlotinib might be used as a third-line or further treatment in non-small cell lung cancer (NSCLC) patients. Meanwhile, the impact of previous therapy strategies on the efficiency of anlotinib still remains unknown.Methods: The subgroup of patients in ALTER0303 were analyzed by using Kaplan-Meier estimates, Pearson chi(2), or Fisher's exact test.Results: There was no statistical significance on progression-free survival (PFS) and overall survival (OS) among patients in different previous antiangiogenic treatments groups. Patients in the chest radiotherapy (CRT) group had longer median PFS than the non-CRT group (5.93 vs. 4.63 m, P=0.027). Regardless of what kind of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) and chemotherapy regimens were used previously, all patients gained longer PFS in the anlotinib group, while only patients treated with vinorelbine/platinum in the EGFR wild type group, pemetrexed/platinum, vinorelbine/platinum, and gefitinib in the EGFR mutation group, and EGFR TKI used as the first line group could benefit from anlotinib on OS. When the OS was calculated from the time of diagnosis to the death, anlotinib could have increased median OS about 6 months (33.8 vs. 27.8 m, P<0.001) compared to the placebo with a hazard ratio (HR) (95% CI): 0.77 (0.60, 1.00).Conclusions: This study indicated that previous bevacizumab or endostatin treatments had no impact on the efficiency of anlotinib. Patients with CRT history benefited more from anlotinib on PFS. EGFR TKI and chemotherapy treatment history had more impact on OS than PFS in patients treated with anlotinib compared to placebo. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2218-6751 -SN - 2226-4477 -DA - 2019 OCT -PY - 2019 -VL - 8 -IS - 5 -SP - 575 -EP - + -DO - 10.21037/tlcr.2019.09.21 -AN - WOS:000493742600002 -AD - Zhengzhou Univ, Canc Hosp, Oncol Dept, Zhengzhou 450008, Henan, Peoples R China -AD - Henan Canc Hosp, Oncol Dept, Zhengzhou 450008, Henan, Peoples R China -AD - Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Med, Shanghai 200030, Peoples R China -AD - Tianjin Med Univ Canc Hosp, Dept Thorac Oncol, Tianjin 300060, Peoples R China -AD - Peking Union Med Coll Hosp, Dept Resp Dis, Beijing 100032, Peoples R China -AD - Linyi Canc Hosp, Dept Oncol, Linyi 276001, Shandong, Peoples R China -AD - Shandong Canc Hosp, Dept Internal Med Oncol, Jinan 250117, Shandong, Peoples R China -AD - Jilin Canc Hosp, Dept Thorac Oncol, Changchun 130012, Jilin, Peoples R China -AD - Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Guangzhou 510120, Guangdong, Peoples R China -AD - Chinese Acad Med Sci, Canc Hosp, Beijing 100021, Peoples R China -AD - Lanzhou Mil Gen Hosp, Dept Pulm Med, Lanzhou 730050, Gansu, Peoples R China -AD - Hunan Canc Hosp, Dept Med Oncol, Changsha 410006, Hunan, Peoples R China -AD - Shandong Univ, Qilu Hosp, Dept Chemotherapy, Jinan 250012, Shandong, Peoples R China -AD - Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Oncol, Xian 710061, Shaanxi, Peoples R China -AD - Tang Du Hosp, Dept Resp Dis, Xian 710038, Shaanxi, Peoples R China -AD - Yunnan Canc Hosp, Dept Med Oncol 1, Kunming 650118, Yunnan, Peoples R China -AD - Capital Med Univ, Dept Gen Med, Beijing Chest Hosp, Beijing 101149, Peoples R China -M2 - Linyi Canc Hosp -M2 - Jilin Canc Hosp -M2 - Lanzhou Mil Gen Hosp -M2 - Hunan Canc Hosp -M2 - Yunnan Canc Hosp -Y2 - 2019-11-18 -ER - - -TY - JOUR -AU - BEKAII-SAAB, TANIOS; CARSON, WILLIAM E.; KAUMAYA, PRAVIN T.P (contact) -TI - Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors -M3 - Awarded Grant -AB - Project NarrativeThe proposed clinical trial and research program has as its goal to define the basic knowledgerequired for engineering the human immune system to recognize and destroy deadly forms ofcancer. Both preclinical animal and human clinical studies with a HER-2 peptide vaccinepoint to the possibility of controlling cancer. This project will be to continue to determinewhether better peptide vaccines can be engineered to produce cancer-killing antibodies withhigh efficacy. Scientific advances from this project will have a significant public health impactfor cancer. The advantage of active immunotherapy with safe and non toxic natural syntheticpeptides over passive immunotherapy with mAbs such as trastuzumab (Herceptin) is afundamental aspect of this work. -DA - 2010 -PY - 2010 -AN - GRANTS:10890536 -G1 - 5R21CA135608-02; 7920871; R21CA135608 -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - BEKAII-SAAB, TANIOS; CARSON, WILLIAM E.; KAUMAYA, PRAVIN T.P (contact) -TI - Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors -M3 - Awarded Grant -AB - Project NarrativeThe proposed clinical trial and research program has as its goal to define the basic knowledgerequired for engineering the human immune system to recognize and destroy deadly forms ofcancer. Both preclinical animal and human clinical studies with a HER-2 peptide vaccinepoint to the possibility of controlling cancer. This project will be to continue to determinewhether better peptide vaccines can be engineered to produce cancer-killing antibodies withhigh efficacy. Scientific advances from this project will have a significant public health impactfor cancer. The advantage of active immunotherapy with safe and non toxic natural syntheticpeptides over passive immunotherapy with mAbs such as trastuzumab (Herceptin) is afundamental aspect of this work. -DA - 2009 -PY - 2009 -AN - GRANTS:10525000 -G1 - 1R21CA135608-01A2; 7737662; R21CA135608 -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -AD - OHIO STATE UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Tozuka, Takehiro -AU - Minegishi, Yuji -AU - Yamaguchi, Ou -AU - Watanabe, Kana -AU - Toi, Yukihiro -AU - Saito, Ryota -AU - Nagai, Yoshiaki -AU - Tamura, Yosuke -AU - Shoji, Tetsuaki -AU - Odagiri, Haruka -AU - Ebi, Noriyuki -AU - Sakai, Kosuke -AU - Kanaji, Nobuhiro -AU - Izumi, Makoto -AU - Soda, Sayo -AU - Watanabe, Satoshi -AU - Morita, Satoshi -AU - Kobayashi, Kunihiko -AU - Seike, Mashiro -TI - Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060 -T2 - JTO CLINICAL AND RESEARCH REPORTS -M3 - Article -AB - Introduction: Immune checkpoint inhibitor (ICI) -based treatment has become standard treatment for patients with advanced NSCLC. We aimed to determine the survival bene fit of upfront radiotherapy for brain metastases (BMs) in patients with NSCLC who received ICI alone (ICI-alone) or with chemotherapy (ICI-chemo). Methods: This study included consecutive patients with NSCLC having BMs who received ICI alone or ICI-chemo at 50 institutes between February 2017 and September 2021. The presence of BMs was con firmed by imaging before treatment. Treatment outcomes were compared between patients who did and did not receive upfront radiotherapy for BMs. Potential confounding factors were adjusted between the groups through inverse probability treatment weighting (IPTW) analysis and overlap weighting (OW) analysis with propensity scores. Results: Patients were grouped as ICI-alone cohort, 224 patients (upfront-radiotherapy group, 135 patients; noradiotherapy group, 89 patients) and ICI-chemo cohort, 367 patients (upfront-radiotherapy group, 212 patients; noradiotherapy group, 155 patients). In the ICI-alone cohort, the overall survival of the upfront -radiotherapy group was significantly longer than that of the no -radiotherapy group (IPTW-adjusted hazards ratio [HR] = 0.45 [95% confidence interval [CI]: 0.29-0.72], OW -adjusted HR = 0.52 [95% CI: 0.35-0.77]). In contrast, in the ICI-chemo cohort, the OS of the upfront -radiotherapy group was not significantly different from that of the no -radiotherapy group (IPTWadjusted HR = 1.02 [95% CI: 0.70-1.48], OW -adjusted HR = 0.93 [95% CI: 0.65-1.33]). Conclusions: Upfront radiotherapy for BMs was associated with longer overall survival in patients with NSCLC who received ICI alone; however, it did not exhibit survival benefits in the patients who received ICI-chemo. Copyright (c) 2024 by the International Association for the Study of Lung Cancer. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/). -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 2666-3643 -DA - 2024 APR -PY - 2024 -VL - 5 -IS - 4 -C7 - 100655 -DO - 10.1016/j.jtocrr.2024.100655 -AN - WOS:001222903200001 -AD - Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, 1-1-5 Sendagi,Bunkyo Ku, Tokyo 1138603, Japan -AD - Mitsui Mem Hosp, Dept Resp Med, Tokyo, Japan -AD - Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka, Saitama, Japan -AD - Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan -AD - Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan -AD - Tohoku Univ, Grad Sch Med, Dept Resp Med, Sendai, Japan -AD - Jichi Med Univ, Saitama Med Ctr, Dept Resp Med, Saitama, Japan -AD - Osaka Med & Pharmaceut Univ Hosp, Dept Resp Med & Thorac Oncol, Osaka, Japan -AD - Hokkaido Univ, Fac Med, Dept Resp Med, Sapporo, Hokkaido, Japan -AD - Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan -AD - Hirosaki Univ, Grad Sch Med, Dept Resp Med, Hirosaki, Japan -AD - Fukuoka Univ Hosp, Dept Resp Med, Fukuoka, Japan -AD - Saitama Med Univ, Saitama Med Ctr, Dept Pulm Med, Saitama, Japan -AD - Kagawa Univ, Fac Med, Div Hematol Rheumatol & Resp Med, Dept Internal Med, Takamatsu, Kagawa, Japan -AD - Yokosuka Kyosai Hosp, Dept Pathol, Yokosuka, Kanagawa, Japan -AD - Dokkyo Med Univ, Sch Med, Dept Pulm & Clin Immunol, Mibu, Tochigi, Japan -AD - Niigata Univ, Grad Sch Med & Dent Sci, Dept Resp Med & Infect Dis, Niigata, Japan -AD - Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan -M2 - Osaka Med & Pharmaceut Univ Hosp -M2 - Yokosuka Kyosai Hosp -Y2 - 2024-05-23 -ER - - -TY - JOUR -AU - JAY FITZGERALD DORSEY; KAO, GARY D -TI - Circulating Tumor Cells Analyses and Molecular Profiling for Patients Receiving Radiation Therapy -M3 - Awarded Grant -AB - Circulating Tumor Cells Analyses and Molecular Profiling for Patients ReceivingRadiation TherapyABSTRACTWe propose to develop a circulating tumor cell (CTC) assay with unique features and efficacysuperior to currently available CTC assays. CTC assays have attracted intense recent attentionbecause of the potential to serially interrogate the biology of solid tumors with minimal risk. Theresulting information obtained, including genetic information predicting response to targetedtherapy, may inform the clinical management of patients receiving radiation therapy (RT), thus“personalizing treatment” in ways previously unachievable. We propose to study non-small celllung cancer (NSCLC) and melanoma, two solid tumors of strategic importance and for which wehave protocols rapidly accruing patients. These disease sites represent high priority for RTtreatment in our investigational clinical trials and represent examples of respectively, epithelialand non-epithelial tumors. We have achieved preliminary data that suggests our approachsuccessfully detects CTCs in patients for whom the current FDA-approved CTC assay isineffective. Key questions regarding CTC analyses remain, the answers to which would informhow best to incorporate these assays into standard radiation oncology practice. Thesequestions include: (1) Can CTCs be detected in a range of solid tumors undergoing radiationtherapy (RT) or other forms of treatment? (2) Do CTC counts give lead-time notice of diseaserecurrence or progression? (3) Can the genetic background of the identified CTCs beelucidated and does it change over time and after treatment? We will employ a CTC detectionmethod that relies on the elevated telomerase activity in almost all tumors, a hallmark of cancer,which is impervious to limitations posed by the lack of surface expression of tumor markers. InSpecific Aim 1 we will track CTC counts in patients with a range of presentations of localizedNSCLC undergoing RT to test whether CTC analysis can give lead time notice of tumorrecurrence. Aim 2 will test whether CTC analysis is effective in melanoma patients undergoingtreatment, including radiation and immunotherapy. For Aim 3, we will test whether the geneticprofile of CTCs changes after treatment, including DNA mutations that predict for response tobiologically targeted agents. Our successful accomplishment of these scientific aims willilluminate the potential usefulness of CTC assays for a wide range of patients receiving RT andother anticancer treatment. -DA - 2020 -PY - 2020 -AN - GRANTS:15056225 -G1 - 5R01CA201071-05; 9981676; R01CA201071 -AD - UNIVERSITY OF PENNSYLVANIA -AD - UNIVERSITY OF PENNSYLVANIA -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - NEEL, BENJAMIN G.; Kwok Kin Wong -TI - Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer -M3 - Awarded Grant -AB - Despite recent advances in targeted and immune-therapies, there is an urgent need for new therapeuticapproaches for metastatic non-small cell lung cancer (NSCLC). SH2 domain-containing phosphatase-2(SHP2), encoded by PTPN11, is a key “positive” signaling component, required for RAS/ERK MAP kinaseactivation by receptor tyrosine kinases (RTKs) and cytokine receptors, as well as by oncogenic amplified RTKsand protein-tyrosine kinase (PTK) fusion proteins. Recently, potent, orally available, highly specific SHP2inhibitors were developed. These agents inhibit amplified RTK/PTK-fusion-driven cells/tumors and are inPhase I clinical trials. Our results suggest that SHP2-inhibitors (SHP2-Is) could have a much broader role incancer therapy. SHP2-Is block adaptive resistance to MEK inhibitors (MEK-Is) in KRAS-mutant and -WT cells,acting upstream of guanine nucleotide exchange factors (SOS1/2). Consequently, SHP2-Is have single agentefficacy against “cycling” KRAS mutants (e.g., KRASG12C), which retain intrinsic GTPase activity. Supported byextensive Preliminary Data, we hypothesize that SHP2-Is will also enhance the efficacy of newly developedKRASG12C (G12C) inhibitors in G12C-mutant NSCLC, the effects of MEK-Is in Osimertinib (Osi)-resistantEGFR- mutant NSCLC, and the effects of Osi in Osi-sensitive EGFR-mutant NSCLC. SHP2 also binds immunecheckpoint receptors, including PD1, might inhibit immune receptor signaling, and has complex effects onmyeloid cells and other cells in the tumor microenvironment (TME). These pleiotropic actions position SHP2at the nexus of targeted and immune therapies. This MPI application joins experts in SHP2 action (NEEL) andNSCLC translational biology (WONG) to clarify the utility of SHP2-Is as NSCLC therapeutics. We will: (1) testcombinations of SHP2-Is with covalent RASG12C inhibitors, MEK-Is, and EGFR-inhibitors in KRAS- andEGFR-mutant NSCLC GEMMs; (2) clarify cell-autonomous and non-autonomous effects of these combinationsusing state-of-the art immune assays, drug-resistant tumor cells, immune cell depletion and new, inducibleSHP2-I-resistant GEMMs; and (3) analyze recurrent tumors and perform CRISPR/Cas9 screens to identify thelandscape of resistance to these agents. -DA - 2023 -PY - 2023 -AN - GRANTS:17705058 -G1 - 10531929; 5R01CA248896-03; R01CA248896 -AD - NEW YORK UNIVERSITY SCHOOL OF MEDICINE -AD - NEW YORK UNIVERSITY SCHOOL OF MEDICINE -Y2 - 2024-07-23 -ER - - -TY - JOUR -AU - NEEL, BENJAMIN G.; Kwok Kin Wong -TI - Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer -M3 - Awarded Grant -AB - Despite recent advances in targeted and immune-therapies, there is an urgent need for new therapeuticapproaches for metastatic non-small cell lung cancer (NSCLC). SH2 domain-containing phosphatase-2(SHP2), encoded by PTPN11, is a key “positive” signaling component, required for RAS/ERK MAP kinaseactivation by receptor tyrosine kinases (RTKs) and cytokine receptors, as well as by oncogenic amplified RTKsand protein-tyrosine kinase (PTK) fusion proteins. Recently, potent, orally available, highly specific SHP2inhibitors were developed. These agents inhibit amplified RTK/PTK-fusion-driven cells/tumors and are inPhase I clinical trials. Our results suggest that SHP2-inhibitors (SHP2-Is) could have a much broader role incancer therapy. SHP2-Is block adaptive resistance to MEK inhibitors (MEK-Is) in KRAS-mutant and -WT cells,acting upstream of guanine nucleotide exchange factors (SOS1/2). Consequently, SHP2-Is have single agentefficacy against “cycling” KRAS mutants (e.g., KRASG12C), which retain intrinsic GTPase activity. Supported byextensive Preliminary Data, we hypothesize that SHP2-Is will also enhance the efficacy of newly developedKRASG12C (G12C) inhibitors in G12C-mutant NSCLC, the effects of MEK-Is in Osimertinib (Osi)-resistantEGFR- mutant NSCLC, and the effects of Osi in Osi-sensitive EGFR-mutant NSCLC. SHP2 also binds immunecheckpoint receptors, including PD1, might inhibit immune receptor signaling, and has complex effects onmyeloid cells and other cells in the tumor microenvironment (TME). These pleiotropic actions position SHP2at the nexus of targeted and immune therapies. This MPI application joins experts in SHP2 action (NEEL) andNSCLC translational biology (WONG) to clarify the utility of SHP2-Is as NSCLC therapeutics. We will: (1) testcombinations of SHP2-Is with covalent RASG12C inhibitors, MEK-Is, and EGFR-inhibitors in KRAS- andEGFR-mutant NSCLC GEMMs; (2) clarify cell-autonomous and non-autonomous effects of these combinationsusing state-of-the art immune assays, drug-resistant tumor cells, immune cell depletion and new, inducibleSHP2-I-resistant GEMMs; and (3) analyze recurrent tumors and perform CRISPR/Cas9 screens to identify thelandscape of resistance to these agents. -DA - 2022 -PY - 2022 -AN - GRANTS:17432400 -G1 - 10316237; 5R01CA248896-02; R01CA248896 -AD - NEW YORK UNIVERSITY SCHOOL OF MEDICINE -AD - NEW YORK UNIVERSITY SCHOOL OF MEDICINE -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - NEEL, BENJAMIN G.; Kwok Kin Wong -TI - Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer -M3 - Awarded Grant -AB - Despite recent advances in targeted and immune-therapies, there is an urgent need for new therapeuticapproaches for metastatic non-small cell lung cancer (NSCLC). SH2 domain-containing phosphatase-2(SHP2), encoded by PTPN11, is a key “positive” signaling component, required for RAS/ERK MAP kinaseactivation by receptor tyrosine kinases (RTKs) and cytokine receptors, as well as by oncogenic amplified RTKsand protein-tyrosine kinase (PTK) fusion proteins. Recently, potent, orally available, highly specific SHP2inhibitors were developed. These agents inhibit amplified RTK/PTK-fusion-driven cells/tumors and are inPhase I clinical trials. Our results suggest that SHP2-inhibitors (SHP2-Is) could have a much broader role incancer therapy. SHP2-Is block adaptive resistance to MEK inhibitors (MEK-Is) in KRAS-mutant and -WT cells,acting upstream of guanine nucleotide exchange factors (SOS1/2). Consequently, SHP2-Is have single agentefficacy against “cycling” KRAS mutants (e.g., KRASG12C), which retain intrinsic GTPase activity. Supported byextensive Preliminary Data, we hypothesize that SHP2-Is will also enhance the efficacy of newly developedKRASG12C (G12C) inhibitors in G12C-mutant NSCLC, the effects of MEK-Is in Osimertinib (Osi)-resistantEGFR- mutant NSCLC, and the effects of Osi in Osi-sensitive EGFR-mutant NSCLC. SHP2 also binds immunecheckpoint receptors, including PD1, might inhibit immune receptor signaling, and has complex effects onmyeloid cells and other cells in the tumor microenvironment (TME). These pleiotropic actions position SHP2at the nexus of targeted and immune therapies. This MPI application joins experts in SHP2 action (NEEL) andNSCLC translational biology (WONG) to clarify the utility of SHP2-Is as NSCLC therapeutics. We will: (1) testcombinations of SHP2-Is with covalent RASG12C inhibitors, MEK-Is, and EGFR-inhibitors in KRAS- andEGFR-mutant NSCLC GEMMs; (2) clarify cell-autonomous and non-autonomous effects of these combinationsusing state-of-the art immune assays, drug-resistant tumor cells, immune cell depletion and new, inducibleSHP2-I-resistant GEMMs; and (3) analyze recurrent tumors and perform CRISPR/Cas9 screens to identify thelandscape of resistance to these agents. -DA - 2021 -PY - 2021 -AN - GRANTS:17376878 -G1 - 10120971; 1R01CA248896-01A1; R01CA248896 -AD - NEW YORK UNIVERSITY SCHOOL OF MEDICINE -AD - NEW YORK UNIVERSITY SCHOOL OF MEDICINE -Y2 - 2024-03-01 -ER - - -TY - JOUR -AU - Shang, Shijie -AU - Wang, Ruiyang -AU - Wang, Fei -AU - Wu, Meng -AU - Chen, Dawei -AU - Yu, Jinming -TI - Treatment Patterns for Patients With Unresected Stage III NSCLC: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database -T2 - FRONTIERS IN ONCOLOGY -M3 - Article -AB - BackgroundRecently, immunotherapy (IO) has shown striking survival improvement in unresectable stage III non-small cell lung cancer (NSCLC). However, the role of chemo-radiotherapy (CRT) for improvement in outcomes should not be disregarded. This study aimed to compare the treatment patterns and illustrate the impact of radiotherapy on the cancer-specific survival (CSS) and overall survival (OS) of patients with unresected locally advanced stage III NSCLC. MethodsWe retrospectively analyzed the data of patients with stage III NSCLC patients who did not undergo surgery from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database between 2001 and 2016, and three continuous years were regarded as one unit. Using the Kaplan-Meier method, we identified the CSS and OS. Then, a linear regression model was graphed to analyze the correlation between median survival of CSS or OS and calendar years in the radiotherapy alone, chemotherapy alone, and CRT groups. ResultsA total of 20986 patients were included in this study. In the overall cohort, CSS and OS improved consistently. To explore the reason for the improved survival, patients were divided into three different cohorts: radiotherapy alone, chemotherapy alone, and CRT. From 2001 to 2015, the median CSS improved persistently, 7, 8, 8, 9, and 11 months in the radiotherapy alone group and 12, 13, 15, 17, 19 months in the CRT group, but improvement in outcomes was less consistent in the chemotherapy alone group (10, 9, 11, 12, 12 months). To better visualize the correlation between CSS and calendar year, linear regression was performed, yielding r(2) = 0.8032, P = 0.0395 for the radiotherapy alone group; r(2) = 0.7206, P = 0.0689 for the chemotherapy alone group; and r(2) = 0.9878, P = 0.0006 for the CRT group. Similar findings were observed in the OS data. In addition to this, we also analyzed different pathological types and also obtained the same results. ConclusionsThe survival of patients with unresectable stage III NSCLC has improved substantially, and the most pronounced and consistent improvements were observed in the CRT group. In addition to IO, radiotherapy played an essential role in the treatment of unresectable stage III NSCLC in the past years and should be considered in the design of clinical trials. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2022 JUN 17 -PY - 2022 -VL - 12 -C7 - 874022 -DO - 10.3389/fonc.2022.874022 -AN - WOS:000820468100001 -AD - Shandong Univ Canc Ctr, Dept Radiat Oncol, Jinan, Peoples R China -AD - Shandong First Med Univ, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China -AD - Shandong First Med Univ, Shandong Canc Hosp & Inst, Shandong Prov Key Lab Radiat Oncol, Jinan, Peoples R China -AD - Shandong Canc Hosp & Inst, Shandong Acad Med Sci, Dept Radiat Oncol, Jinan, Peoples R China -AD - Shandong Canc Hosp & Inst, Shandong Acad Med Sci, Shandong Prov Key Lab Radiat Oncol, Jinan, Peoples R China -AD - Shandong Canc Hosp & Inst, Shandong Acad Med Sci, Shandong Prov Key Lab Radiat Oncol, Jinan, Peoples R China -M2 - Shandong Univ Canc Ctr -Y2 - 2022-07-13 -ER - - -TY - JOUR -AU - JAY FITZGERALD DORSEY; KAO, GARY D -TI - Circulating Tumor Cells Analyses and Molecular Profiling for Patients Receiving Radiation Therapy -M3 - Awarded Grant -AB - Circulating Tumor Cells Analyses and Molecular Profiling for Patients ReceivingRadiation TherapyABSTRACTWe propose to develop a circulating tumor cell (CTC) assay with unique features and efficacysuperior to currently available CTC assays. CTC assays have attracted intense recent attentionbecause of the potential to serially interrogate the biology of solid tumors with minimal risk. Theresulting information obtained, including genetic information predicting response to targetedtherapy, may inform the clinical management of patients receiving radiation therapy (RT), thus“personalizing treatment” in ways previously unachievable. We propose to study non-small celllung cancer (NSCLC) and melanoma, two solid tumors of strategic importance and for which wehave protocols rapidly accruing patients. These disease sites represent high priority for RTtreatment in our investigational clinical trials and represent examples of respectively, epithelialand non-epithelial tumors. We have achieved preliminary data that suggests our approachsuccessfully detects CTCs in patients for whom the current FDA-approved CTC assay isineffective. Key questions regarding CTC analyses remain, the answers to which would informhow best to incorporate these assays into standard radiation oncology practice. Thesequestions include: (1) Can CTCs be detected in a range of solid tumors undergoing radiationtherapy (RT) or other forms of treatment? (2) Do CTC counts give lead-time notice of diseaserecurrence or progression? (3) Can the genetic background of the identified CTCs beelucidated and does it change over time and after treatment? We will employ a CTC detectionmethod that relies on the elevated telomerase activity in almost all tumors, a hallmark of cancer,which is impervious to limitations posed by the lack of surface expression of tumor markers. InSpecific Aim 1 we will track CTC counts in patients with a range of presentations of localizedNSCLC undergoing RT to test whether CTC analysis can give lead time notice of tumorrecurrence. Aim 2 will test whether CTC analysis is effective in melanoma patients undergoingtreatment, including radiation and immunotherapy. For Aim 3, we will test whether the geneticprofile of CTCs changes after treatment, including DNA mutations that predict for response tobiologically targeted agents. Our successful accomplishment of these scientific aims willilluminate the potential usefulness of CTC assays for a wide range of patients receiving RT andother anticancer treatment. -DA - 2019 -PY - 2019 -AN - GRANTS:14960221 -G1 - 5R01CA201071-04; 9743767; R01CA201071 -AD - UNIVERSITY OF PENNSYLVANIA -AD - UNIVERSITY OF PENNSYLVANIA -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Elegbede, Anifat A. -AU - Gibson, Amanda J. -AU - Fung, Andrea S. -AU - Cheung, Winson Y. -AU - Dean, Michelle L. -AU - Bebb, Gwyn -AU - Pabani, Aliyah -TI - A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada -T2 - JTO CLINICAL AND RESEARCH REPORTS -M3 - Article -AB - Introduction: The real-world data evaluating treatment outcomes of atezolizumab plus carboplatin-etoposide chemotherapy (atezolizumab) for extensive-stage SCLC (ESCLC) are lacking. Our objective was to evaluate real -world outcomes of ESCLC treated with atezolizumab.Methods: A retrospective analysis of provincial patients with ESCLC who started first-line (1L) systemic treatment was conducted. We primarily evaluated the progression -free survival (PFS) and overall survival (OS) outcomes in association with atezolizumab compared with platinum-etoposide chemotherapy (chemotherapy) while adjusting for relevant demographic and clinical factors. Adverse events (AEs) during 1L were evaluated.Results: A total of 67 patients were identified. Of the 34 patients who received atezolizumab, 24% had Eastern Cooperative Oncology Group performance status greater than or equal to 2, approximately 50% were more than or equal to 65 years, 21% received cisplatin-etoposide chemotherapy before atezolizumab, and 12% had thoracic radiation (tRT). Within the atezolizumab versus chemo-therapy group, the median PFS equals to 6.0 versus 4.3 months (p = 0.03) whereas OS = 12.8 versus 7.1 months (p = 0.01). Relative to chemotherapy, the hazard ratio (95% confidence interval) for PFS was 0.53 (0.28-1.02) and OS was 0.42 (0.20-0.88) with atezolizumab. tRT compared with no tRT receipt correlated with reduced death risk (hazard ratio [95% confidence interval] = 0.33 [0.13- 0.88]). AE-related treatment withdrawal with atezolizumab was 32% and 15% with chemotherapy (p = 0.02). Within the tRT subgroup, 25% versus 20% in atezolizumab versus chemotherapy group, respectively, discontinued 1L owing to AE. lConclusions: This is the first real-world study revealing comparable survival with that in the IMpower133 trial. Treatment discontinuation from AEs was higher with ate-zolizumab among Canadian patients with ESCLC. Our data suggest safe use of tRT and chemoimmunotherapy, but its efficacy for ESCLC warrants further study.(c) 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 2666-3643 -DA - 2021 DEC -PY - 2021 -VL - 2 -IS - 12 -C7 - 100249 -DO - 10.1016/j.jtocrr.2021.100249 -AN - WOS:001137351800007 -AD - Univ Calgary, Dept Oncol, Calgary, AB, Canada -AD - Alberta Hlth Serv, Tom Baker Canc Ctr, Calgary, AB, Canada -AD - Kingston Hlth Sci Ctr, Canc Ctr Southeastern Ontario, Kingston, ON, Canada -AD - Tom Baker Canc Clin, 1331 29th St Northwest, Calgary, AB T2N 4N2, Canada -M2 - Kingston Hlth Sci Ctr -Y2 - 2021-12-01 -ER - - -TY - JOUR -AU - Dunlop, Will -AU - van Keep, Marjolijn -AU - Elroy, Peter -AU - Perez, Ignacio Diaz -AU - Ouwens, Mario J. N. M. -AU - Sarbajna, Tina -AU - Zhang, Yiduo -AU - Greystoke, Alastair -TI - Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective -T2 - PHARMACOECONOMICS-OPEN -M3 - Article -AB - Background In the phase III PACIFIC study, durvalumab improved survival versus placebo in patients with unresectable stage III non-small-cell lung cancer (NSCLC) whose disease had not progressed after platinum-based concurrent chemoradiotherapy. The appraisal by the UK's National Institute for Health and Care Excellence (NICE) included a cost-effectiveness analysis based on an early data readout from PACIFIC [March 2018 data cut-off (DCO); median follow- up duration 25.2 months; range 0.2-43.1]. Uncertainties regarding long-term survival outcomes with durvalumab led to some challenges in estimating the cost effectiveness of this therapy.Objective Here, we validate the survival extrapolations used in the original company base-case analysis by benchmarking them against updated survival data from the 4-year follow-up analysis of PACIFIC (i.e. approximately 4 years after the last patient was randomised; March 2020 DCO; median follow-up duration 34.2 months; range 0.2-64.9). Moreover, we update the original analysis with these more mature survival data to examine the consistency of key economic outputs with the original analysis.Methods The original analysis used a semi-Markov (state-transition) approach and was based on patients whose tumours expressed programmed cell death-ligand 1 on = 1% of cells (to reflect the European licence for durvalumab). We benchmarked the survival extrapolations used in the original company base- case analysis against survival data from the 4-year follow-up of PACIFIC and updated the cost-effectiveness analysis with these more mature survival data. Early deaths avoided by the adoption of durvalumab into the UK Cancer Drugs Fund (CDF) in March 2019 were estimated using the 4- year follow-up survival data and an assumed uptake of 125 patients/year (lower estimate) and 367 patients/year (higher estimate).Results The original company base-case analysis had a good visual fit with the observed overall survival (OS) distribution for the durvalumab arm and accurately predicted the 48-month OS rate (predicted 55%; observed 55%); by comparison, the fit was less precise for the placebo arm, for which the analysis underestimated the 48-month OS rate (predicted 32%; observed 38%). In the updated company base-case analysis, durvalumab yielded 2.51 incremental quality-adjusted life-years (QALYs) (- 0.43 vs. the original company base-case analysis), corresponding to an incremental cost-effectiveness ratio of pound 22,665/QALY (+ pound 3298 vs. the original analysis), which falls within the upper bound of NICE's willingness-to-pay threshold (30,000 pound/QALY gained). We estimate that between 31 and 91 early patient deaths may have been avoided by the adoption of durvalumab into the CDF.Conclusions These findings reinforce the patient benefit observed with durvalumab in unresectable stage III NSCLC, support the routine use and cost effectiveness of this therapy, and demonstrate how appropriate modelling can inform the early adoption of therapies by payers to achieve patient benefit.Plain Language SummaryBased on the results of a clinical trial, the European Medicines Agency approved durvalumab for the treatment of adults with a specific type of advanced lung cancer whose tumours cannot be removed surgically and whose disease has not progressed after chemotherapy and radiotherapy. The UK's National Institute for Health and Care Excellence (NICE) invites companies to submit cost-effectiveness analyses to help with decision making about adopting new therapies. The company included an analysis based on early trial data that suggested durvalumab was cost effective compared with other previous treatments. As patients in the study at the time of the initial submission to NICE were only followed for approximately 2 years, the long-term survival benefit that could be achieved with durvalumab was uncertain. Therefore, NICE recommended durvalumab for use within the Cancer Drugs Fund (CDF) to allow patients to access the drug while more data were being collected. Here, we demonstrate that the original cost-effectiveness model accurately predicted the rates of long-term survival for patients receiving durvalumab and that durvalumab remains a cost-effective use of healthcare resources based on recently published data from the trial (which added approximately 2 further years of follow-up). Moreover, we estimate that adopting durvalumab into the CDF may have avoided 31-91 early patient deaths from lung cancer. These findings support NICE's early decision to make durvalumab available within the CDF and the adoption of durvalumab for routine use within the UK national health service. -PU - SPRINGER INT PUBL AG -PI - CHAM -PA - GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND -SN - 2509-4262 -SN - 2509-4254 -DA - 2022 MAR -PY - 2022 -VL - 6 -IS - 2 -SP - 241 -EP - 252 -DO - 10.1007/s41669-021-00301-7 -AN - WOS:000696422400001 -C6 - SEP 2021 -AD - Cambridge Biomed Campus, AstraZeneca Global Hlth Econ & Payer Evidence Onc, 1 Francis Crick Ave, Cambridge CB2 0AA, England -AD - BresMed Netherlands, Utrecht, Netherlands -AD - AstraZeneca, Gaithersburg, MD USA -AD - AstraZeneca, Gothenburg, Sweden -AD - Newcastle Upon Tyne Hosp NHS Fdn Trust, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England -M2 - Cambridge Biomed Campus -M2 - BresMed Netherlands -Y2 - 2021-09-23 -ER - - -TY - JOUR -AU - Cooke, S. -AU - De Ruysscher, D. -AU - Reymen, B. -AU - Lambrecht, M. -AU - Persson, G. Fredberg -AU - Faivre-Finn, C. -AU - Dieleman, E. M. -AU - Van Diessen, J. -AU - Sikorska, K. -AU - Lalezari, F. -AU - Sonke, J. J. -AU - Belderbos, J. -TI - Sites of First Progression in the Randomized PET-Boost Trial for Patients With Locally Advanced NSCLC -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2021 NOV 1 -PY - 2021 -VL - 111 -IS - 3 -MA - 177 -SP - S91 -EP - S91 -AN - WOS:000715803801518 -AD - Netherlands Canc Inst NKI AVL, Amsterdam, Netherlands -AD - Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Maastro Clin, Maastricht, Netherlands -AD - Univ Leuven, KU Leuven, Leuven, Belgium -AD - Univ Hosp Leuven, Gasthuisberg, Belgium -AD - Rigshosp Univ Copenhagen, Copenhagen, Denmark -AD - Univ Copenhagen, Herlev Hosp, Herlev, Denmark -AD - Christie NHS Fdn Trust, Manchester, Lancs, England -AD - Univ Manchester, Manchester, Lancs, England -AD - Amsterdam UMC, Locat AMC, Amsterdam, Netherlands -Y2 - 2021-11-24 -ER - - -TY - JOUR -AU - Tao, Lei -AU - Zhou, Yue -AU - Luo, Yuan -AU - Qiu, Jiahao -AU - Xiao, Yuzhou -AU - Zou, Jiao -AU - Zhang, Yu -AU - Liu, Xingchen -AU - Yang, Xinyu -AU - Gou, Kun -AU - Xu, Jing -AU - Guan, Xinqi -AU - Cen, Xiaobo -AU - Zhao, Yinglan -TI - Epigenetic regulation in cancer therapy: From mechanisms to clinical advances -T2 - MEDCOMM-ONCOLOGY -M3 - Review -AB - Epigenetic regulation refers to the alteration of gene expression independent of changes in DNA sequence. It involves chemical modifications such as DNA methylation, histone methylation, and histone acetylation, which are regulated by a coordinated interplay of various regulators to ensure precise spatial and temporal regulation of gene expression. Epigenetic aberrations are commonly observed in cancer and are considered as hallmarks of cancer. In recent years, small molecules targeting specific epigenetic regulators have been developed and are demonstrating promising therapeutic potential in preclinical and clinical trials for cancer treatment. In this review, we summarize the essential regulatory mechanisms and dysfunctions of epigenetic regulators involved in DNA methylation, histone methylation, and histone acetylation during tumor development and progression. Moreover, we discuss the current advances and challenges in cancer epigenetic therapy that target these mechanisms in both hematologic malignancies and solid tumors. Finally, we discuss the potential of combining epigenetic drugs with other therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, as a promising approach for cancer treatment. Overall, we aim to enhance the understanding of epigenetic regulation in cancer therapy and explore targeted therapeutic strategies based on these mechanisms, to ultimately advance cancer therapy and improve patient prognosis.Epigenetic regulation involves chemical modifications including DNA methylation, histone methylation, and histone acetylation, which are governed by a coordinated interplay of various regulators. In cancer, epigenetic aberrations are commonly observed and considered as a hallmark of cancer. Small molecules have been developed to target specific epigenetic regulators and reverse the epigenetic reprogramming occurring in cancer. image -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2769-6448 -DA - 2024 MAR -PY - 2024 -VL - 3 -IS - 1 -C7 - e59 -DO - 10.1002/mog2.59 -AN - WOS:001328267400003 -AD - Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu 610041, Peoples R China -AD - Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Peoples R China -AD - Sichuan Univ, West China Hosp, Natl Chengdu Ctr Safety Evaluat Drugs, Chengdu, Peoples R China -AD - Sichuan Univ, West China Sch Pharm, Dept Pharmacol, Chengdu, Peoples R China -AD - Tibet Univ, Dept Med, Lhasa, Peoples R China -Y2 - 2024-10-12 -ER - - -TY - JOUR -AU - Kawachi, Hayato -AU - Tamiya, Motohiro -AU - Oya, Yuko -AU - Saito, Go -AU - Taniguchi, Yoshihiko -AU - Matsumoto, Hirotaka -AU - Sato, Yuki -AU - Otsuki, Taiichiro -AU - Suzuki, Hidekazu -AU - Fukuda, Yasushi -AU - Tanaka, Satoshi -AU - Tsukita, Yoko -AU - Uchida, Junji -AU - Sakata, Yoshihiko -AU - Nakatani, Yuki -AU - Shibaki, Ryota -AU - Arai, Daisuke -AU - Okada, Asuka -AU - Hara, Satoshi -AU - Takayama, Koichi -AU - Nishino, Kazumi -TI - Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005). -T2 - Clinical lung cancer -M3 - Journal Article -AB - BACKGROUND: The optimal subsequent treatment strategy for locally advanced non-small cell lung cancer (LA-NSCLC) after chemoradiotherapy (CRT) and consolidative durvalumab therapy remains unknown. We aimed to determine the optimal subsequent treatment strategy for this clinical population.MATERIALS AND METHODS: We retrospectively enrolled 523 consecutive patients with LA-NSCLC treated with CRT and analyzed the treatment outcomes of subsequent therapy after progression following CRT and consolidative durvalumab therapy. Patients who received tyrosine kinase inhibitors as subsequent therapy were excluded.RESULTS: Out of 122 patients who received subsequent chemotherapy, 55% underwent platinum-based, 25% non-platinum-based, and 20% immune checkpoint inhibitor (ICI)-containing therapies. In the platinum-based group, patients with a durvalumab-progression-free survival (Dur-PFS) ≥ 1 year had a significantly longer median subsequent therapy-PFS (SubTx-PFS) than those with Dur-PFS < 1 year (13.2 months vs. 4.7 months; hazard ratio, 0.45; 95% confidence interval, 0.21-0.97; P = .04). Furthermore, among patients receiving non-platinum-based chemotherapy, the median SubTx-PFS was longer in the combined with angiogenesis inhibitor group than in the without group, although the difference was not statistically significant. No significant difference of SubTx-PFS was observed between the reason for durvalumab discontinuation and the outcomes of ICI-containing therapy.CONCLUSION: In clinical practice, platinum-based chemotherapy rechallenge is frequently employed following progression subsequent to CRT and consolidative durvalumab therapy for LA-NSCLC. Optimal treatment strategies may consider Dur-PFS and angiogenesis inhibitor feasibility. Further research is warranted to identify clinical biomarkers that can help identify patients who would benefit from ICI rechallenge. -SN - 1938-0690 -DA - 2024 Jul 25 (Epub 2024 Jul 25) -PY - 2024 -DO - 10.1016/j.cllc.2024.07.014 -AN - MEDLINE:39138106 -AD - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan. Electronic address: kwhat@koto.kpu-m.ac.jp. -AD - Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan. -AD - Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan. -AD - Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. -AD - Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Sakai, Osaka, Japan. -AD - Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan. -AD - Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan. -AD - Department of Respiratory Medicine and Hematology, School of Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan. -AD - Department of Thoracic Oncology, Osaka Habikino Medical Center, Habikino, Osaka, Japan. -AD - Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Okayama, Japan. -AD - Department of Respiratory Medicine, Osaka General Medical Center, Osaka, Osaka, Japan. -AD - Department of Respiratory Medicine, Tohoku University Hospital, Sendai, Miyagi, Japan. -AD - Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan. -AD - Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Kumamoto, Japan. -AD - Department of Medical Oncology, Osaka City General Hospital, Osaka, Osaka, Japan. -AD - Internal Medicine III, Wakayama Medical University, Wakayama, Wakayama, Japan. -AD - Department of Internal Medicine, Saiseikai Utsunomiya Hospital, Utsunomiya, Tochigi, Japan. -AD - Department of Respiratory Medicine, Saiseikai Suita Hospital, Suita, Osaka, Japan. -AD - Department of Respiratory Medicine, Itami City Hospital, Itami, Japan. -AD - Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan. -Y2 - 2024-08-16 -ER - - -TY - JOUR -AU - van Zyp, Noelle van der Voort -AU - Hashimzadah, Masoma -AU - Kouwenhoven, Erik -AU - Liskamp, Carmen -AU - Gadellaa-van Hooijdonk, Christa -AU - Pouw, Ellen -AU - Belderbos, Jose -AU - Maas, Klaartje -AU - van de Vaart, Paul -AU - Mast, Mirjam -TI - Excessive esophageal toxicity in patients with locally advanced non-small cell lung cancer treated with concurrent hypofractionated chemoradiotherapy and 3-weekly platinum doublet chemotherapy -T2 - CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY -M3 - Article -AB - Introduction: Concurrent chemoradiation followed by immunotherapy is the standard of care for patients with stage III non-small cell lung cancer (NSCLC). Prior to the introduction of adjuvant immunotherapy, we treated patients with stage III NSCLC with concurrent platinum doublet chemotherapy and 66 Gy in 24 fractions. We determined the toxicity of this treatment.Methods: A retrospective observational study was performed in a cohort of patients with stage III NSCLC, <70 years old, and WHO performance score 0-1. Patients were treated with concurrent platinum doublet chemotherapy and 66 Gy in 24 fractions. All patients were staged with a PET-scan and brain MRI-scan. Toxicity was scored using the common criteria for adverse events (CTCAE v4.03).Results: Between 2012 and 2017, 41 patients were treated with mildly hypofractionated radiotherapy and platinum doublet chemotherapy. The median follow-up was 4.7 years. The median age was 57 and 58% of patients were male. The majority of patients had stage IIIB disease (68%). The median total Gross Tumor Volume (GTV) was 104 cc (range: 15-367 cc). The median lymph node GTV was 59 cc (10-341 cc). Five patients died: four due to an esophagus perforation or fistula, and one due to pulmonary bleeding. Grade >= 3 esophageal toxicity occurred in 16 patients. Five patients had late grade >= 3 esophageal toxicity (12%). The median overall survival was 19 months.Conclusion: Toxicity was unexpectedly high in patients with stage III NSCLC (WHO 0-1) after concurrent platinum doublet chemotherapy and 66 Gy in 24 fractions. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 2405-6308 -DA - 2022 SEP -PY - 2022 -VL - 36 -SP - 70 -EP - 76 -DO - 10.1016/j.ctro.2022.07.002 -AN - WOS:000825037200001 -C6 - JUL 2022 -AD - Haaglanden Med Ctr, Dept Radiat Oncol, Leidschendam, Netherlands -AD - Haaglanden Med Ctr, Dept Med Phys, Leidschendam, Netherlands -AD - Groene Hart, Dept Pulmonol, Gouda, Netherlands -AD - NKI, Dept Radiat Oncol, Leidschendam, Netherlands -AD - Haaglanden Med Ctr, Dept Pulmonol, Leidschendam, Netherlands -M2 - Groene Hart -Y2 - 2022-07-21 -ER - - -TY - JOUR -AU - Sasaki, Y. M. -AU - Xu, T. -AU - Koutroumpakis, S. -AU - Sheshadri, A. -AU - Deswal, A. -AU - Nguyen, Q. N. -AU - Gandhi, S. -AU - Cascone, T. -AU - Le, X. -AU - Allan, M. -AU - Chen, A. B. -AU - Liao, Z. -TI - Comorbidities and Their Impact on Treatment Tolerance and Outcome in Elderly NSCLC Patients Treated with Concurrent Chemoradiation Using Proton or Photon Followed by Immunotherapy -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - 65th ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-RADIATION-ONCOLOGY (ASTRO) -CL - San Diego, CA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2023 OCT 1 -PY - 2023 -VL - 117 -IS - 2 -MA - 2119 -SP - E54 -EP - E55 -AN - WOS:001079706800113 -AD - Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA -AD - Univ Texas MD Anderson Canc Ctr, Houston, TX USA -AD - Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA -Y2 - 2023-12-10 -ER - - -TY - JOUR -AU - CARBONE, DAVID P. -TI - Project 05: Translational Therapeutics (TT) -M3 - Awarded Grant -AB - PROJECT SUMMARY – TRANSLATIONAL THERAPEUTICS (TT)The Translational Therapeutics (TT) Program at The Ohio State University Comprehensive Cancer Center(OSUCCC), co-led by David Carbone, MD, PhD, Blake Peterson, PhD, and Elaine Mardis, PhD, unites anoutstanding team of 79 basic, translational and/or clinical researchers from 18 departments within The OhioState University (OSU) Colleges of Medicine, Pharmacy, and Veterinary Medicine and Nationwide Children’sHospital (NCH). The goal of the TT program is to translate advances in solid tumor molecular biology andpromising preclinical studies into innovative clinical trials to improve the state of the art in the diagnosis andtreatment of solid tumors. Solid tumors are by far the major causes of cancer death in our catchment area (thestate of Ohio), dominated by diseases of special interest in this program, including lung, breast, colorectal, headand neck, thyroid, and gynecologic cancers. As a result of existing expertise and collaborative scientific efforts,as well as focused recruitments across a spectrum of disciplines, the TT program exhibits strength in basic andtranslational research in lung cancer, gastrointestinal malignancies, breast cancer, sarcoma, and glioblastoma,as well as newly enhanced capabilities in drug development. The Specific Aims of the TT program are to: 1)identify and therapeutically target alterations in solid tumor proliferation and survival signaling pathways; 2)identify tumor-host interactions and target them via small molecule and immunotherapeutic approaches; and 3)develop and improve upon approaches for determining prognosis, selecting appropriate therapies, andevaluating the response to treatment. During the current funding cycle, the TT Program successfully recruited28 solid tumor clinicians, basic scientists, and physician-scientists. In addition, TT investigators produced 1130peer-reviewed publications; 178 of these were published in high impact (≥10) journals, 16% resulted from intra-programmatic collaborations, and 31% from inter-programmatic collaborations; 74% were multi-institutional; atotal of 86% were collaborative publications. TT members collaborated on programmatic grant submissions andwere awarded one NCI P01, two U01s, and two UG1s, as well as two T32 training grants. The TT Program has$9.2M in current annual direct costs from peer-reviewed grants, $6.6M (71%) of which is from the NCI. The TTProgram is well-integrated with the clinical teams via participation in the multidisciplinary Disease SpecificResearch Groups (DSRG) and organizes Pan-Disease Investigator-Initiated Trial meetings to catalyzeinteractions between DSRGs. As such, there were 4,070 accruals to interventional clinical trials during the lastfunding cycle, of which 3,351 (82%) were therapeutic, including 1,144 (28%) investigator-initiated trials. Futuredirections focused on the OSUCCC research priorities and cancers relevant to our catchment area and growthin cellular and checkpoint inhibitor research (adult and pediatric), immunogenomics, tumor resistance and tumorheterogeneity and small molecule drug development. -DA - 2022 -PY - 2022 -AN - GRANTS:17436135 -G1 - 10333281; 5446; 5P30CA016058-46; P30CA016058 -AD - OHIO STATE UNIVERSITY -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - Xu, Sheng -AU - Li, Yuan-Ming -AU - Bie, Zhi-Xin -AU - Li, Xiao-Guang -TI - Drug-eluting beads bronchial arterial chemoembolization/ bronchial arterial infusion chemotherapy with and without PD-1 blockade for advanced non-small cell lung cancer: a comparative single-center cohort study -T2 - QUANTITATIVE IMAGING IN MEDICINE AND SURGERY -M3 - Article -AB - Background: Drug-eluting beads bronchial arterial chemoembolization (DEB-BACE)/bronchial artery infusion chemotherapy (BAI) have been investigated as treatment options for advanced non-small cell lung cancer (NSCLC), especially for those patients who develop refractoriness to or are intolerant to systemic chemotherapy. This retrospective study aimed to compare the outcomes of DEB- BACE/BAI with and without programmed cell death protein 1 (PD-1) blockade for advanced NSCLC, and to investigate the effectiveness and safety of combination regimens.Methods: This retrospective cohort study included advanced NSCLC patients who were intolerant to or were resistant to systemic chemotherapy, radiotherapy, or molecular targeted therapy and underwent DEBBACE/BAI between October 2016 and October 2021 in Beijing Hospital, National Center of Gerontology. A total of 84 advanced NSCLC patients (DEB-BACE/BAI + PD-1 blockade group: group A, n=27; DEBBACE/BAI: group B, n=57) were enrolled finally. The embolic agent CalliSpheres (100-300, 300-500, or 500-700 mu m) loaded with gemcitabine (800 mg) was administered during the DEB-BACE procedure. The adverse events (AEs) and outcomes were compared. Of these, the median progression-free survival (PFS) and overall survival (OS) were compared via Kaplan-Meier (KM) methods. Univariate and multivariate Cox regression analyses were used to investigate the predictors of PFS and OS.Results: KM methods showed that group A had longer median PFS (12.0 vs. 3.0 months, P<0.001) and OS (27.0 vs. 8.0 months, P<0.001) than group B. The predictors of PFS for DEB- BACE/BAI included tumor diameter (P=0.013), immunotherapy (P<0.001), and DEB-BACE/BAI cycles (P=0.012), whereas the predictors of OS included tumor diameter (P=0.021), extrapulmonary metastases (P=0.041), immunotherapy (P<0.001), and DEB-BACE/BAI cycles (P=0.020). The incidence rates of overall AEs in groups A and B were 40.7% (11/27) and 36.8% (21/57), respectively, and no significant difference was found (P=0.731). Group A had an incidence rate of 11.1% for grade 3 immunotherapy-related AEs (irAEs). There were no incidences of ectopic embolization or spinal artery injury.Conclusions: Compared with DEB-BACE/BAI, PD-1 blockade plus DEB-BACE/BAI could improve the prognosis for advanced NSCLC despite the associated risk of grade 3 irAEs. The combination regimens are promising and safe approaches for advanced NSCLC. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2223-4292 -SN - 2223-4306 -DA - 2023 SEP -PY - 2023 -VL - 13 -IS - 9 -SP - 6241 -EP - 6256 -DO - 10.21037/qims-23-287 -AN - WOS:001115321900014 -AD - Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Dept Minimally Invas Tumor Therapies Ctr,Natl Ctr, 1 Hua Rd, Beijing 100730, Peoples R China -AD - Chinese Acad Med Sci, Peking Union Med Coll, Grad Sch, 9 Dongdansantiao St, Beijing 100730, Peoples R China -Y2 - 2023-12-25 -ER - - -TY - JOUR -AU - CARBONE, DAVID P. -TI - Project 05: Translational Therapeutics (TT) -M3 - Awarded Grant -AB - PROJECT SUMMARY – TRANSLATIONAL THERAPEUTICS (TT)The Translational Therapeutics (TT) Program at The Ohio State University Comprehensive Cancer Center(OSUCCC), co-led by David Carbone, MD, PhD, Blake Peterson, PhD, and Elaine Mardis, PhD, unites anoutstanding team of 79 basic, translational and/or clinical researchers from 18 departments within The OhioState University (OSU) Colleges of Medicine, Pharmacy, and Veterinary Medicine and Nationwide Children’sHospital (NCH). The goal of the TT program is to translate advances in solid tumor molecular biology andpromising preclinical studies into innovative clinical trials to improve the state of the art in the diagnosis andtreatment of solid tumors. Solid tumors are by far the major causes of cancer death in our catchment area (thestate of Ohio), dominated by diseases of special interest in this program, including lung, breast, colorectal, headand neck, thyroid, and gynecologic cancers. As a result of existing expertise and collaborative scientific efforts,as well as focused recruitments across a spectrum of disciplines, the TT program exhibits strength in basic andtranslational research in lung cancer, gastrointestinal malignancies, breast cancer, sarcoma, and glioblastoma,as well as newly enhanced capabilities in drug development. The Specific Aims of the TT program are to: 1)identify and therapeutically target alterations in solid tumor proliferation and survival signaling pathways; 2)identify tumor-host interactions and target them via small molecule and immunotherapeutic approaches; and 3)develop and improve upon approaches for determining prognosis, selecting appropriate therapies, andevaluating the response to treatment. During the current funding cycle, the TT Program successfully recruited28 solid tumor clinicians, basic scientists, and physician-scientists. In addition, TT investigators produced 1130peer-reviewed publications; 178 of these were published in high impact (≥10) journals, 16% resulted from intra-programmatic collaborations, and 31% from inter-programmatic collaborations; 74% were multi-institutional; atotal of 86% were collaborative publications. TT members collaborated on programmatic grant submissions andwere awarded one NCI P01, two U01s, and two UG1s, as well as two T32 training grants. The TT Program has$9.2M in current annual direct costs from peer-reviewed grants, $6.6M (71%) of which is from the NCI. The TTProgram is well-integrated with the clinical teams via participation in the multidisciplinary Disease SpecificResearch Groups (DSRG) and organizes Pan-Disease Investigator-Initiated Trial meetings to catalyzeinteractions between DSRGs. As such, there were 4,070 accruals to interventional clinical trials during the lastfunding cycle, of which 3,351 (82%) were therapeutic, including 1,144 (28%) investigator-initiated trials. Futuredirections focused on the OSUCCC research priorities and cancers relevant to our catchment area and growthin cellular and checkpoint inhibitor research (adult and pediatric), immunogenomics, tumor resistance and tumorheterogeneity and small molecule drug development. -DA - 2021 -PY - 2021 -AN - GRANTS:17371496 -G1 - 10089997; 2P30CA016058-45; 5446; P30CA016058 -AD - OHIO STATE UNIVERSITY -Y2 - 2024-03-01 -ER - - -TY - JOUR -AU - CARBONE, DAVID P. -TI - Project 05: Translational Therapeutics (TT) -M3 - Awarded Grant -AB - PROJECT SUMMARY – TRANSLATIONAL THERAPEUTICS (TT)The Translational Therapeutics (TT) Program at The Ohio State University Comprehensive Cancer Center(OSUCCC), co-led by David Carbone, MD, PhD, Blake Peterson, PhD, and Elaine Mardis, PhD, unites anoutstanding team of 79 basic, translational and/or clinical researchers from 18 departments within The OhioState University (OSU) Colleges of Medicine, Pharmacy, and Veterinary Medicine and Nationwide Children’sHospital (NCH). The goal of the TT program is to translate advances in solid tumor molecular biology andpromising preclinical studies into innovative clinical trials to improve the state of the art in the diagnosis andtreatment of solid tumors. Solid tumors are by far the major causes of cancer death in our catchment area (thestate of Ohio), dominated by diseases of special interest in this program, including lung, breast, colorectal, headand neck, thyroid, and gynecologic cancers. As a result of existing expertise and collaborative scientific efforts,as well as focused recruitments across a spectrum of disciplines, the TT program exhibits strength in basic andtranslational research in lung cancer, gastrointestinal malignancies, breast cancer, sarcoma, and glioblastoma,as well as newly enhanced capabilities in drug development. The Specific Aims of the TT program are to: 1)identify and therapeutically target alterations in solid tumor proliferation and survival signaling pathways; 2)identify tumor-host interactions and target them via small molecule and immunotherapeutic approaches; and 3)develop and improve upon approaches for determining prognosis, selecting appropriate therapies, andevaluating the response to treatment. During the current funding cycle, the TT Program successfully recruited28 solid tumor clinicians, basic scientists, and physician-scientists. In addition, TT investigators produced 1130peer-reviewed publications; 178 of these were published in high impact (≥10) journals, 16% resulted from intra-programmatic collaborations, and 31% from inter-programmatic collaborations; 74% were multi-institutional; atotal of 86% were collaborative publications. TT members collaborated on programmatic grant submissions andwere awarded one NCI P01, two U01s, and two UG1s, as well as two T32 training grants. The TT Program has$9.2M in current annual direct costs from peer-reviewed grants, $6.6M (71%) of which is from the NCI. The TTProgram is well-integrated with the clinical teams via participation in the multidisciplinary Disease SpecificResearch Groups (DSRG) and organizes Pan-Disease Investigator-Initiated Trial meetings to catalyzeinteractions between DSRGs. As such, there were 4,070 accruals to interventional clinical trials during the lastfunding cycle, of which 3,351 (82%) were therapeutic, including 1,144 (28%) investigator-initiated trials. Futuredirections focused on the OSUCCC research priorities and cancers relevant to our catchment area and growthin cellular and checkpoint inhibitor research (adult and pediatric), immunogenomics, tumor resistance and tumorheterogeneity and small molecule drug development. -DA - 2023 -PY - 2023 -AN - GRANTS:17709546 -G1 - 10553318; 5446; 5P30CA016058-47; P30CA016058 -AD - OHIO STATE UNIVERSITY -Y2 - 2024-07-23 -ER - - -TY - JOUR -AU - Kotsakis, Athanasios -AU - Papadimitraki, Elisavet -AU - Vetsika, Eleni Kyriaki -AU - Aggouraki, Despoina -AU - Dermitzaki, Eleftheria Kleio -AU - Hatzidaki, Dora -AU - Kentepozidis, Nikolaos -AU - Mavroudis, Dimitris -AU - Georgoulias, Vassilis -TI - A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide -T2 - LUNG CANCER -M3 - Article -AB - Objectives: The immunological and clinical responses of patients with NSCLC treated, in the context of an expanded action program, with the cryptic hTERT-targeting Vx-001 vaccine are presented.Materials and methods: Forty-six HLA-A*0201-positive patients with advanced NSCLC and residual (n = 27) or progressive (n = 19) disease following front-line treatment received two subcutaneous injections of the optimized TERT572Y peptide followed by four injections of the native TERT572 peptide, every 3 weeks. Peptide-specific immune responses were monitored by enzyme-linked immunosorbent spot assay at baseline, and after the 2nd and the 6th vaccinations. Thirty-eight HLA-A*0201-positive matched patients were used as historical controls.Results: Twenty-three patients (50%) completed the vaccination protocol and 87% received at least two administrations. Twelve patients (26%) without disease progression after the 6th vaccination received boost vaccinations. Three (7%) patients achieved a partial response and 13 (28%) disease stabilization. The disease control rate was significantly higher in patients with non-squamous histology compared to those with squamous-cell histology [n = 14 (45%) versus n = 2 (13%); p = 0.03]. The median progression-free survival (PFS) and overall survival (OS) was 3.8 (range, 0.7-99.4) and 19.8 months (range, 0.7-99.4), respectively. Patients who developed immune response had a numerically higher PFS compared to those who failed to mount any (6.7 versus 2.7 months; p = 0.090). However, the median OS for the immune-responders was significantly prolonged compared to non-responders (40.0 versus 9.2 months, respectively; p = 0.02). Toxicity was 5,000 patients. Aim 2: We will test how specimen-related pre-analytical variables affect the assay usinga wide variety of fresh, frozen, and formalin fixed tissue types and sizes. Aim 3: Once we have defined optimal patient-specific and specimen-related procedures, we will validate our multiplex assay in a prospective cohort of immunotherapypatients at MSKCC.Significance: This project will yield abundant data about the pre-analytical variables that influence a PD-L1 multipleximmunohistochemistry assay. These data will inform optimal specimen acquisition and handling and strategies foravoiding or mitigating inaccurate assay results. Innovation: This will be the first study to systematically explore bothpatient context factors and specimen pre-analytics in multiplexed immunohistochemical testing for immuno-oncology.Our close collaboration with commercial test developers as part of our research team will accelerate the translation ofour scientific findings into optimized assays for the direct benefit of patients. -DA - 2023 -PY - 2023 -AN - GRANTS:17349552 -G1 - 10907058; 7U01CA263986-02; U01CA263986 -AD - BETH ISRAEL DEACONESS MEDICAL CENTER -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - ROEHRL, MICHAEL H. A. -TI - Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology Patients -M3 - Awarded Grant -AB - Project Summary/AbstractTherapies against immunologic checkpoint proteins, such as PD-L1, have revolutionized the treatment of multiplemalignancies, such as malignant melanoma, lung cancer, bladder cancer, or gastroesophageal cancer. All of thesetherapies depend on predictive biomarker assays for PD-L1 protein expression in tumor tissue to identify patients whowill most likely respond. PD-L1 assays face two significant challenges: (i) they often need to be performed on small tissuebiopsies where tumor tissue is limited and (ii) the threshold for positivity by immunohistochemistry (1%) is very small,highlighting crucial dependence on utmost precision and pre-analytical sample validity.To address the issue of small and limited samples in biopsies, we have developed a chromogenic multiplexedimmunohistochemical assay that combines PD-L1 assessment with tissue and cell type-specific markers to provide acombined diagnostic and predictive assay on a single histologic slide. To move multiplexed assays around PD-L1 into theclinic, there exists an important knowledge gap: what are the patient-specific factors and specimen-related pre-analyticalvariables that can influence the readout of PD-L1 positivity? Very limited knowledge is available about these variables.Importantly, because the PD-L1 positivity threshold is so low and requires the reliable separation of two very smallnumbers (<1% vs. ≥1%), even minute pre-analytical variabilities would be expected to have significant negative impact onassay validity. In that respect, PD-L1 testing in tissue is particularly in need of extensive characterization and control ofpre-analytical variability, even more so than other assays whose cut-off points lie in more favorable ranges.Our proposal is based on the hypothesis that both patient-specific factors (such as molecular features of the cancer,current immune status, prior drug therapy, etc.) and specimen-related factors (such as timing of biopsy, size of tissue,ischemic time, fixation protocol, etc.) can significantly influence subsequent biomarker measurements. We furtherhypothesize that solid knowledge about these influences will allow controlling for and mitigating patient-specific andspecimen-related effects and will lead to more accurate and valid biomarker assessment. Aim 1: We will create a cohortto test the influence of patient-specific context factors. We will make use of our extensive immuno-oncology databaseand biobank of >5,000 patients. Aim 2: We will test how specimen-related pre-analytical variables affect the assay usinga wide variety of fresh, frozen, and formalin fixed tissue types and sizes. Aim 3: Once we have defined optimal patient-specific and specimen-related procedures, we will validate our multiplex assay in a prospective cohort of immunotherapypatients at MSKCC.Significance: This project will yield abundant data about the pre-analytical variables that influence a PD-L1 multipleximmunohistochemistry assay. These data will inform optimal specimen acquisition and handling and strategies foravoiding or mitigating inaccurate assay results. Innovation: This will be the first study to systematically explore bothpatient context factors and specimen pre-analytics in multiplexed immunohistochemical testing for immuno-oncology.Our close collaboration with commercial test developers as part of our research team will accelerate the translation ofour scientific findings into optimized assays for the direct benefit of patients. -DA - 2022 -PY - 2022 -AN - GRANTS:16274290 -G1 - 10451186; 1U01CA263986-01A1; U01CA263986 -AD - SLOAN-KETTERING INST CAN RESEARCH -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - KIMURA Hideki -AA - YUSA Toshikazu; BABA Masayuki; SHIBA Mitsutoshi; FUJISAWA Takehiko; YAMAGUCHI Yutaka -TI - Immunotherapy of lung cancer using biotechnological methods. -M3 - Awarded Grant -AB - A controlled, randomized study has been conducted to assess the efficacy of adoptive immunotherapy with Interleukin 2(IL2)and lymphokine activated killer cells(LAK cells)combined with chemotherapy or radiotherapy for advanced non-small cell lung cancer(NSCLC)patients. Out of 403 NSCLC patients who received resection of primary tumors from Jan. 1985 to Dec. 1990 in our hospital, a total of 106 patients with relatively curative and non-curative resection, were entered into a randomized controlled trial of postoperative adjuvant immunotherapy. The former group(n=36)was divided into three groups ; a)Chemotherapy(CDDP+VDS)group(n=13), b)Chemoimmunotherapy(CDDP+VDS+IL2+LAK cells)group(n=12), and c)control group(n=ll). The latter(noncurative)group(n=68)was randomized into d)immunotherapy(chemo/radiotherapy+IL2+LAK cells)group(n=33)and e)control(chemo/radiotherapy alone)group(n=35).The overall 4 year survival rates of immunotherapy(b+d)and control(a+c+e)groups were 52.4% and 28.3% respectively and the difference was significant(p<0.01)with generalized Wilcoxon test. In the relative curative group, the 4 year survival rates of a), b), and c)groups were 34.2%, 70.9% and 34.1% respectively. In the non-curative group, those of d)and e)groups were 43.1% and 29.3%(p<0.05). From this study, it it suggested that adoptive immunotherapy with IL2 and LAK cells is effective as a postoperative adjuvant immunotherapy for advanced NSCLC patients. -DA - 1989 -PY - 1989 -AN - GRANTS:14109699 -G1 - 01480338 -AD - Chiba University -Y2 - 2023-12-08 -ER - - -TY - JOUR -AU - Godoy, Luis A. -AU - Chen, Joy -AU - Ma, Weijie -AU - Lally, Jag -AU - Toomey, Kyra A. -AU - Rajappa, Prabhu -AU - Sheridan, Roya -AU - Mahajan, Shirish -AU - Stollenwerk, Nicholas -AU - Phan, Chinh T. -AU - Cheng, Danny -AU - Knebel, Robert J. -AU - Li, Tianhong -TI - Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives -T2 - BIOMARKER RESEARCH -M3 - Review -AB - Over the past decade, targeted therapy for oncogene-driven NSCLC and immune checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved the survival and quality of life for patients with unresectable NSCLC. Increasingly, these biomarker-guided systemic therapies given before or after surgery have been used in patients with early-stage NSCLC. In March 2022, the US FDA granted the approval of neoadjuvant nivolumab and chemotherapy for patients with stage IB-IIIA NSCLC. Several phase II/III trials are evaluating the clinical efficacy of various neoadjuvant immune checkpoint inhibitor combinations for non-oncogene-driven NSCLC and neoadjuvant molecular targeted therapies for oncogene-driven NSCLC, respectively. However, clinical application of precision neoadjuvant treatment requires a paradigm shift in the biomarker testing and multidisciplinary collaboration at the diagnosis of early-stage NSCLC. In this comprehensive review, we summarize the current diagnosis and treatment landscape, recent advances, new challenges in biomarker testing and endpoint selections, practical considerations for a timely multidisciplinary collaboration at diagnosis, and perspectives in emerging neoadjuvant precision systemic therapy for patients with resectable, early-stage NSCLC. These biomarker-guided neoadjuvant therapies hold the promise to improve surgical and pathological outcomes, reduce systemic recurrences, guide postoperative therapy, and improve cure rates in patients with resectable NSCLC. -PU - BMC -PI - LONDON -PA - CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND -SN - 2050-7771 -DA - 2023 JAN 18 -PY - 2023 -VL - 11 -IS - 1 -C7 - 7 -DO - 10.1186/s40364-022-00444-7 -AN - WOS:000913281900001 -AD - Univ Calif Davis, Dept Surg, Div Thorac Surg, Sch Med, Sacramento, CA USA -AD - Univ Calif Davis, Sch Med, Sacramento, CA USA -AD - Univ Calif Davis, Comprehens Canc Ctr, Dept Internal Med, Div Hematol Oncol,Sch Med, Sacramento, CA 95817 USA -AD - Vet Affairs Northern Calif Hlth Care Syst, Med Serv Hematol & Oncol, Mather, CA USA -AD - Univ Calif Davis, Sch Med, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Sacramento, CA USA -AD - Vet Affairs Northern Calif Hlth Care Syst, Med Serv, Pulmonol, Mather, CA USA -AD - Vet Affairs Northern Calif Hlth Care Syst, Dept Radiol, Intervent Radiol, Mather, CA USA -M2 - Vet Affairs Northern Calif Hlth Care Syst -M2 - Vet Affairs Northern Calif Hlth Care Syst -M2 - Vet Affairs Northern Calif Hlth Care Syst -Y2 - 2023-02-06 -ER - - -TY - JOUR -AU - Jabbour, Salma K. -AU - Lee, Ki Hyeong -AU - Frost, Nikolaj -AU - Breder, Valeriy -AU - Kowalski, Dariusz M. -AU - Pollock, Theodore -AU - Levchenko, Evgeny -AU - Reguart, Noemi -AU - Martinez-Marti, Alex -AU - Houghton, Baerin -AU - Paoli, Jean-Baptiste -AU - Safina, Sufia -AU - Park, Keunchil -AU - Komiya, Takefumi -AU - Sanford, Amy -AU - Boolell, Vishal -AU - Liu, Hong -AU - Samkari, Ayman -AU - Keller, Steven M. -AU - Reck, Martin -TI - Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer The Phase 2 KEYNOTE-799 Nonrandomized Trial -T2 - JAMA ONCOLOGY -M3 - Article -AB - IMPORTANCE Administration of pembrolizumab plus concurrent chemoradiation therapy (cCRT) may provide treatment benefit to patients with locally advanced, stage III non-small cell lung cancer (NSCLC).OBJECTIVE To evaluate treatment outcomes and safety of pembrolizumab plus cCRT in stage III NSCLC.DESIGN, SETTING, AND PARTICIPANTS The phase 2, nonrandomized, 2-cohort, open-label KEYNOTE-799 study enrolled patients between November 5, 2018, and July 31, 2020, from 52 academic facilities and community-based institutions across 10 countries. As of October 28, 2020, median (range) follow-up was 18.5 (13.6-23.8) months in cohort A and 13.7 (2.9-23.5) months in cohort B. Of 301 patients screened, 216 eligible patients with previously untreated, unresectable, and pathologically/radiologically confirmed stage IIIA/IIIB/IIIC NSCLC with measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) were enrolled.INTERVENTIONS Patients in cohort A (squamous/nonsquamous) received 1 cycle (3 weeks) of carboplatin (area under the curve [AUC] 6mg/mL/min), paclitaxel (200mg/m(2)), and pembrolizumab (200mg), followed by carboplatin (AUC 2mg/mL/min) and paclitaxel (45 mg/m2) once weekly for 6 weeks and 2 cycles of pembrolizumab plus standard thoracic radiotherapy. Patients in cohort B (nonsquamous) received 3 cycles of cisplatin (75mg/m(2)), pemetrexed (500mg/m(2)), and pembrolizumab (200mg) every 3 weeks and thoracic radiotherapy in cycles 2 and 3. Patients received 14 additional cycles of pembrolizumab.MAIN OUTCOMES AND MEASURES Coprimary end pointswere objective response rate per RECIST v1.1 by blinded independent central review and incidence of grade 3 to 5 pneumonitis.RESULTS A total of 112 patients received treatment in cohort A ( 76 men [67.9%]; median [range] age, 66.0 [46-90] years; 66 patients [58.9%] with programmed cell death ligand 1 [PD-L1] tumor proportion score >= 1%) and 102 patients received treatment in cohort B (62 men [60.8%]; median [range] age, 64.0 [35-81] years; 40 patients [39.2%] with PD-L1 tumor proportion score >= 1%). Objective response rate was 70.5%(79 of 112; 95% CI, 61.2%-78.8%) in cohort A and 70.6%(72 of 102; 95% CI, 60.7%-79.2%) in cohort B. Median duration of response was not reached, but 79.7% and 75.6%, respectively, had response duration of 12 months or longer. Grade 3 or higher pneumonitis occurred in 9 of 112 patients (8.0%) in cohort A and 7 of 102 (6.9%) in cohort B. Grade 3 to 5 treatment-related adverse events occurred in 72 of 112 (64.3%) and 51 of 102 (50.0%) patients, respectively.CONCLUSIONS AND RELEVANCE The findings of this phase 2, nonrandomized, 2-cohort study suggest promising antitumor activity of pembrolizumab plus cCRT and manageable safety in patients with previously untreated, locally advanced, stage III NSCLC. -PU - AMER MEDICAL ASSOC -PI - CHICAGO -PA - 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA -SN - 2374-2437 -SN - 2374-2445 -DA - 2021 SEP -PY - 2021 -VL - 7 -IS - 9 -SP - 1351 -EP - 1359 -DO - 10.1001/jamaoncol.2021.2301 -AN - WOS:000657799300001 -C6 - JUN 2021 -AD - Rutgers State Univ, Rutgers RobertWood Johnson Med Sch, Rutgers Canc Inst New Jersey, Dept Radiat Oncol, 195 Little Albany St, New Brunswick, NJ 08903 USA -AD - Chungbuk Natl Univ, Coll Med, Chungbuk Natl Univ Hosp, Cheongju, South Korea -AD - Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany -AD - Free Univ Berlin, Berlin, Germany -AD - Humboldt Univ, Berlin, Germany -AD - Berlin Inst Hlth, Berlin, Germany -AD - NN Blokhin Russian Canc Res Ctr, Moscow, Russia -AD - Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland -AD - Northeastern Hlth Syst, Tahlequah, OK USA -AD - NN Petrov Natl Med Res Ctr Oncol, St Petersburg, Russia -AD - Hosp Clin Barcelona, IDIBAPS, Dept Med Oncol, Thorac Oncol Unit, Barcelona, Spain -AD - Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Barcelona, Spain -AD - Port Macquarie Base Hosp, Mid North Coast Canc Inst, Port Macquarie, NSW, Australia -AD - Clin Clairval, Radiotherapie, Marseille, France -AD - Republican Dispensary Tatarstan Minist Healthcare, Med Oncol, Kazan, Russia -AD - Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea -AD - Parkview Canc Inst, Hematol Med Oncol, Ft Wayne, IN USA -AD - Sanford Hlth, Sioux Falls, SD USA -AD - Ballarat Hlth Serv, Ballarat, Vic, Australia -AD - Merck & Co Inc, Kenilworth, NJ USA -AD - German Ctr Lung Res, Airway Res Ctr North, LungenClin, Grosshansdorf, Germany -M2 - Maria Sklodowska Curie Natl Res Inst Oncol -M2 - Northeastern Hlth Syst -M2 - NN Petrov Natl Med Res Ctr Oncol -M2 - Clin Clairval -M2 - Republican Dispensary Tatarstan Minist Healthcare -M2 - Parkview Canc Inst -Y2 - 2021-06-10 -ER - - -TY - JOUR -AU - Filosso, Pier Luigi -AU - Guerrera, Francesco -AU - Lausi, Paolo Olivo -AU - Ruffini, Enrico -TI - Locally advanced non-small cell lung cancer treatment: another step forward -T2 - JOURNAL OF THORACIC DISEASE -M3 - Editorial Material -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2017 DEC -PY - 2017 -VL - 9 -IS - 12 -SP - 4908 -EP - 4911 -DO - 10.21037/jtd.2017.11.103 -AN - WOS:000419323400058 -AD - Univ Torino, Dept Surg Sci, Turin, Italy -Y2 - 2017-12-01 -ER - - -TY - JOUR -AU - Wang, Daquan -AU - Mo, Yiwen -AU - Liu, Fangjie -AU - Zheng, Shiyang -AU - Liu, Hui -AU - Li, Hongdi -AU - Guo, Jinyu -AU - Fan, Wei -AU - Qiu, Bo -AU - Zhang, Xu -AU - Liu, Hui -TI - Repeated dynamic [18F]FDG PET/CT imaging using a high-sensitivity PET/CT scanner for assessing non-small cell lung cancer patients undergoing induction immuno-chemotherapy followed by hypo-fractionated chemoradiotherapy and consolidative immunotherapy: report from a prospective observational study (GASTO-1067) -T2 - EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING -M3 - Article -M3 - Early Access -AB - Objective The study aims to investigate the role of dynamic [18F]FDG PET/CT imaging by high-sensitivity PET/CT scanner for assessing patients with locally advanced non-small cell lung cancer (LA-NSCLC) who undergo induction immuno-chemotherapy, followed by concurrent hypo-fractionated chemoradiotherapy (hypo-CCRT) and consolidative immunotherapy. Methods Patients with unresectable LA-NSCLC are prospectively recruited. Dynamic [18F]FDG PET/CT scans are conducted at four timepoints: before treatment (Baseline), after induction immuno-chemotherapy (Post-IC), during hypo-CCRT (Mid-hypo-CCRT) and after hypo-CCRT (Post-hypo-CCRT). The primary lung tumors (PTs) are manually delineated, and the metabolic features, including the Patlak-Ki (Ki), maximum SUV (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) have been evaluated. The expressions of CD3, CD8, CD68, CD163, CD34 and Ki67 in primary lung tumors at baseline are assayed by immunohistochemistry. The levels of blood lymphocytes at four timepoints are analyzed with flow cytometry. Results Fifteen LA-NSCLC patients are enrolled between December 2020 and December 2022. Baseline Ki of primary tumor yields the highest AUC values of 0.722 and 0.796 for predicting disease progression and patient death, respectively. Patients are classified into the High FDG Ki group (n = 8, Ki > 2.779 ml/min/100 g) and the Low FDG Ki group (n = 7, Ki <= 2.779 ml/min/100 g). The High FDG Ki group presents better progression-free survival (P = 0.01) and overall survival (P = 0.025). The High FDG Ki group exhibits more significant reductions in Ki after hypo-CCRT compared to the Low FDG Ki group. Patients with a reduction in Ki > 73.1% exhibit better progression-free survival than those with a reduction <= 73.1% in Ki (median: not reached vs. 7.33 months, P = 0.12). The levels of CD3(+) T cells (P = 0.003), CD8(+) T cells (P = 0.002), CD68(+) macrophages (P = 0.071) and CD163(+) macrophages (P = 0.012) in primary tumor tissues are higher in the High FDG Ki group. The High FDG Ki group has higher CD3(+)CD8(+) lymphocytes in blood at baseline (P = 0.108), post-IC (P = 0.023) and post-hypo-CCRT (P = 0.041) than the Low FDG Ki group. Conclusions The metabolic features in the High FDG Ki group significantly decrease during the treatment, particularly after induction immuno-chemotherapy. The Ki value of primary tumor shows significant relationship with the treatment response and survival in LA-NSCLC patients by the combined immuno-chemoradiotherapy regimen. -PU - SPRINGER -PI - NEW YORK -PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES -SN - 1619-7070 -SN - 1619-7089 -DA - 2024 JUL 2 -PY - 2024 -DO - 10.1007/s00259-024-06819-2 -AN - WOS:001261235000002 -C6 - JUL 2024 -AD - Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Collaborat Innovat Ctr Canc Med,Canc Ctr, Dept Radiat Oncol,State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China -AD - Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Nucl Med,Canc Ctr,State Key Lab Oncol South C, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China -AD - United Imaging Healthcare, Shanghai, Peoples R China -M2 - United Imaging Healthcare -Y2 - 2024-07-10 -ER - - -TY - JOUR -AU - Hata, Akito -AU - Ninomaru, Taira -AU - Okada, Hideaki -AU - Kogure, Yoshihito -AU - Oki, Masahide -AU - Katakami, Nobuyuki -AU - Kijima, Takashi -AU - Yokoyama, Toshihide -AU - Matsumoto, Hirotaka -AU - Sato, Yuki -AU - Kato, Terufumi -AU - Sugawara, Shunichi -AU - Sawada, Takeshi -AU - Yoshimura, Kenichi -AU - Seto, Takashi -AU - Yamamoto, Nobuyuki -AU - Nakagawa, Kazuhiko -TI - Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P plus C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): An early report analyzing depth of response from multicenter single arm phase II study (Evolution trial: WJOG11819L). -T2 - JOURNAL OF CLINICAL ONCOLOGY -M3 - Meeting Abstract -CP - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -CL - Chicago, IL -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0732-183X -SN - 1527-7755 -DA - 2023 JUN 1 -PY - 2023 -VL - 41 -IS - 16 -MA - 8544 -AN - WOS:001053772003620 -AD - Kobe Minimally Invas Canc Ctr, Kobe, Hyogo, Japan -AD - Natl Hosp Org Nagoya Med Ctr, Nagoya, Aichi, Japan -AD - Takarazuka City Hosp, Takarazuka, Hyogo, Japan -AD - Hyogo Med Univ, Nishinomiya, Hyogo, Japan -AD - Kurashiki Cent Hosp, Kurashiki, Okayama, Japan -AD - Hyogo Prefectural Amagasaki Gen Med Ctr, Amagasaki, Hyogo, Japan -AD - Kobe City Med Ctr, Gen Hosp, Kobe, Hyogo, Japan -AD - Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan -AD - Sendai Kousei Hosp, Sendai, Miyagi, Japan -AD - Kyoto Univ Hosp, Kyoto, Japan -AD - Hiroshima Univ Hosp, Hiroshima, Japan -AD - Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan -AD - Wakayama Med Univ, Internal Med 3, Wakayama, Japan -AD - Kindai Univ, Fac Med, Osakasayama, Japan -M2 - Kobe Minimally Invas Canc Ctr -M2 - Takarazuka City Hosp -M2 - Hyogo Prefectural Amagasaki Gen Med Ctr -M2 - Kindai Univ -Y2 - 2023-09-28 -ER - - -TY - JOUR -AU - Cappuzzo, F. -AU - Castro Junior, G. -AU - Kang, J. H. -AU - Wu, Y. L. -AU - Brustugun, O. T. -AU - Cheema, P. K. -AU - Owonikoko, T. K. -AU - Longin, A. S. -AU - Duan, J. -AU - Caparica, R. -AU - Loong, H. H. F. -AU - Chan, E. -TI - KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - Multidisciplinary Thoracic Cancers Symposium -CL - New Orleans, LA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2024 JAN -PY - 2024 -VL - 118 -IS - 1 -MA - 2013 -SP - E14 -EP - E14 -AN - WOS:001129462100025 -AD - AUSL Romagna, Hematol Dept, Ravenna, Italy -AD - Univ Sao Paulo, Sao Paulo, SP, Brazil -AD - Catholic Univ Korea, Dept Internal Med, Seoul, South Korea -AD - Guangdong Lung Canc Inst, Guangzhou, Peoples R China -AD - Vestre Viken HF, Dramen Hosp, Sect Oncol, Drammen, Norway -AD - Univ Oslo, Fac Med, Oslo, Norway -AD - William Osler Hlth Syst, Brampton, ON, Canada -AD - UPMC Hillman Canc Ctr, Pittsburgh, PA USA -AD - Novartis Pharmaceut, Paris, France -AD - Novartis Pharmaceut, E Hanover, NJ USA -AD - Novartis Pharmaceut, Basel, Switzerland -AD - Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China -M2 - Guangdong Lung Canc Inst -M2 - Vestre Viken HF -M2 - William Osler Hlth Syst -M2 - UPMC Hillman Canc Ctr -Y2 - 2024-01-18 -ER - - -TY - JOUR -AU - Xu, Sheng -AU - Bie, Zhi-Xin -AU - Li, Yuan-Ming -AU - Li, Bin -AU - Kong, Fan-Lei -AU - Peng, Jin-Zhao -AU - Li, Xiao-Guang -TI - Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study -T2 - FRONTIERS IN ONCOLOGY -M3 - Article -AB - PurposeTo compare the outcomes of drug-eluting bead bronchial arterial chemoembolization (DEB-BACE) with and without microwave ablation (MWA) for the treatment of advanced and standard treatment-refractory/ineligible non-small cell lung cancer (ASTRI-NSCLC). Materials and MethodsA total of 77 ASTRI-NSCLC patients who received DEB-BACE combined with MWA (group A; n = 28) or DEB-BACE alone (group B; n = 49) were included. Clinical outcomes were compared between groups A and B. Kaplan-Meier methods were used to compare the median progression-free survival (PFS) or overall survival (OS) between the two groups. Univariate and multivariate Cox proportional hazards analyses were used to investigate the predictors of OS for ASTRI-NSCLC treated with DEB-BACE. ResultsNo severe adverse event was found in both groups. Pneumothorax was the predominant MWA-related complication in group A, with an incidence rate of 32.1% (9/28). Meanwhile, no significant difference was found in DEB-BACE-related complications between groups A and B. The overall disease control rate (DCR) was 61.0% (47/77), with a significantly higher DCR in group A (85.7% vs. 46.9%, P = 0.002). The median PFS in groups A and B was 7.0 and 4.0 months, respectively, with a significant difference (P = 0.037). The median OS in groups A and B was both 8.0 months, with no significant difference (P = 0.318). The 6-month PFS and OS rates in groups A and B were 75.0% and 78.6%, 22.4% and 59.2%, respectively, while the 12-month PFS and OS rates in groups A and B were 17.9% and 28.6%, 14.3% and 22.4%, respectively. Of these, a significantly higher 6-month PFS rate was found in group A (75.0% vs. 22.4%; P < 0.001). The cycles of DEB-BACE/bronchial artery infusion chemotherapy [hazard ratio (HR): 0.363; 95% confidence interval (CI): 0.202-0.655; P = 0.001] and postoperative immunotherapy (HR: 0.219; 95% CI: 0.085-0.561; P = 0.002) were identified as the predictors of OS in ASTRI-NSCLC treated with DEB-BACE. ConclusionMWA sequentially combined with DEB-BACE was superior to DEB-BACE alone in the local control of ASTRI-NSCLC. Although the combination therapy reveals a trend of prolonging the OS, long-term prognosis warrants an investigation with a longer follow-up. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2022 MAR 15 -PY - 2022 -VL - 12 -C7 - 851830 -DO - 10.3389/fonc.2022.851830 -AN - WOS:000778673000001 -AD - Beijing Hosp, Inst Geriatr Med, Chinese Acad Med Sci,Natl Ctr Gerontol, Dept Minimally Invas Tumor Therapies Ctr, Beijing, Peoples R China -AD - Chinese Acad Med Sci, Grad Sch Peking Union Med Coll, Beijing, Peoples R China -Y2 - 2022-04-24 -ER - - -TY - JOUR -AU - Mitchell, Paul -AU - Siva, Shankar -AU - Kok, Peey Sei -AU - O'Byrne, Ken -AU - Yeung, Annie -AU - Livingstone, Ann -AU - Donoghoe, Mark -AU - Yip, Sonia -AU - Stockier, Martin R. -TI - NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy. -T2 - JOURNAL OF CLINICAL ONCOLOGY -M3 - Meeting Abstract -CP - 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO) -CL - Chicago, IL -PU - AMER SOC CLINICAL ONCOLOGY -PI - ALEXANDRIA -PA - 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA -SN - 0732-183X -SN - 1527-7755 -DA - 2017 MAY 20 -PY - 2017 -VL - 35 -MA - 9097 -DO - 10.1200/JCO.2017.35.15_suppl.9097 -AN - WOS:000411932202155 -AD - Austin Hlth, Austin, Australia -AD - Sunshine Hosp, Radiat Therapy Ctr, Melbourne, Australia -AD - Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia -AD - Princess Alexandra Hosp, Brisbane, Qld, Australia -AD - Queensland Univ Technol, Brisbane, Qld, Australia -AD - Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia -AD - Sydney Catalyst Translat Canc Res Ctr, Sydney, NSW, Australia -M2 - Austin Hlth -M2 - Sydney Catalyst Translat Canc Res Ctr -Y2 - 2017-11-23 -ER - - -TY - JOUR -AU - Demircan, Volkan -AU - Acar, Elif -AU - Senturk, Ertuorul -AU - Guzel, Cagar -AU - Eroglu Arkoc, Nazan -AU - Akyurek, Nalan -AU - Ozturk, Furkan -AU - Dincbas, Fazilet -AU - Akmansu, Muge -TI - Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer -T2 - TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY -M3 - Article -AB - OBJECTIVEThe discovery of PD-L1 receptors triggered a great interest in immunotherapeutics for the management of locally advanced non-small-cell lung cancer (NSCLC). The efficacy of immunotherapeutics for overall survival (OS) in locally advanced NSCLC has been proven in several clinical trials. However, no data exist for the relationship between radiotherapy (RT) response and programmed death-ligand (PD-L1) receptor positivity in the literature. In this regard, we aimed to investigate the predictor value of PD-L1 receptors for RT response.METHODSEighty patients who were diagnosed as having locally advanced NSCLC were selected from among patients in whom PD-L1 status was assessed in the Gazi University pathology laboratory. The relationship between PD-L1 and progression-free survival (PFS), OS, metastasis-free survival (MFS), RT response, and RT doses was evaluated using Kaplan-Meier and Cox regression analysis. Chi-square and t-tests were used for descriptive statistics.RESULTSThe median follow-up was 16.1 months. The mean age was 61.1 years. PD-L1 positivity was detected in 34 patients. One year and 2-year OS and PFS ratios were found as 87%, 54% and 65%, 30%, respectively. The median OS and PFS were 26.8 and 15.1 months, respectively. There was no statistically significant difference between PD-L1 receptor status and OS and PFS (p=0.736 and p=0.372, respectively). In the PD-L1 positive subgroup analysis for OS, doses higher than 60 Gy (n=28, mean dose 64.6 +/- 1.53) were found superior to the 60 Gy dose (n=6) (p=0.034). The median MFS was 33 months.CONCLUSIONPD-L1 status did not seem to be a predictor for RT response. However, despite the low number of patients in the 60 Gy group, our study showed that dose-escalation could improve survival in PD-L1 positive locally advanced NSCLC. -PU - KARE PUBL -PI - ISTANBUL -PA - Goztepe Mah. Fahrettin Kerim Gokay Caddesi. No: 200/A D:2 Cemenzar - Kadkoy, ISTANBUL, Turkiye -SN - 1300-7467 -DA - 2022 -PY - 2022 -VL - 37 -IS - 3 -SP - 227 -EP - 238 -DO - 10.5505/tjo.2022.3523 -AN - WOS:000809631700001 -C6 - JUN 2022 -AD - Mehmet Akif Inan Training & Res Hosp, Dept Radiat Oncol, Sanliurfa, Turkey -AD - Gazi Univ, Dept Pathol, Fac Med, Ankara, Turkey -AD - Gazi Univ, Dept Radiat Oncol, Fac Med, Ankara, Turkey -AD - Ataturk Chest Dis & Chest Surg Training & Res Hos, Dept Radiat Oncol, Ankara, Turkey -AD - Ankara Bilkent City Hosp, Dept Radiat Oncol, Ankara, Turkey -AD - Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Radiat Oncol, Istanbul, Turkey -M2 - Ankara Bilkent City Hosp -Y2 - 2022-06-03 -ER - - -TY - JOUR -AU - Mitchell, Paul -AU - Siva, Shankar -AU - Mersiades, Antony -AU - O'Byrne, Ken -AU - Chinchen, Sarah -AU - Brown, Chris -AU - Yip, Sonia -AU - Stockler, Martin R. -TI - NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy (SABR) in advanced non-small cell lung cancer (NSCLC), progressing after first- or second-line chemotherapy -T2 - ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY -M3 - Meeting Abstract -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 1743-7555 -SN - 1743-7563 -DA - 2018 NOV -PY - 2018 -VL - 14 -MA - 424 -SP - 201 -EP - 201 -AN - WOS:000449544200353 -AD - Austin Hosp, Dept Med Oncol, Melbourne, Vic, Australia -AD - Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia -AD - Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia -AD - Princess Alexandra Hosp, Dept Med Oncol, Brisbane, Qld, Australia -Y2 - 2018-11-22 -ER - - -TY - JOUR -AU - Naidoo, Jarushka -AU - Vansteenkiste, Johan F. -AU - Faivre-Finn, Corinne -AU - Ozguroglu, Mustafa -AU - Murakami, Shuji -AU - Hui, Rina -AU - Quantin, Xavier -AU - Broadhurst, Helen -AU - Newton, Michael -AU - Thiyagarajah, Piruntha -AU - Antonia, Scott J. -TI - Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial -T2 - LUNG CANCER -M3 - Article -AB - Introduction: Immune-mediated adverse events (imAEs), including all-cause immune-mediated pneumonitis, were reported in approximately 25% of patients in the placebo-controlled, phase III PACIFIC trial of durvalumab monotherapy (for up to 12 months) in patients with unresectable, stage III NSCLC and no disease progression after concurrent chemoradiotherapy; only 3.4% of patients experienced grade 3/4 imAEs. With broad application of the PACIFIC regimen (consolidation durvalumab after chemoradiotherapy), now standard-of-care in this setting, there is a need to better characterize the occurrence of imAEs with this regimen.Methods: We performed descriptive, post-hoc, exploratory analyses to characterize the occurrence of imAEs (pneumonitis and non-pneumonitis) in PACIFIC in terms of: incidence, severity, and timing; clinical management and outcomes; and associations between the occurrence of imAEs and (1) all-cause AEs and (2) baseline patient, disease, and treatment characteristics.Results: Any-grade immune-mediated pneumonitis (9.4%) and non-pneumonitis imAEs (10.7%) occurred infrequently and were more common with durvalumab versus placebo. Grade 3/4 immune-mediated pneumonitis (1.9%) and non-pneumonitis imAEs (1.7%) were uncommon with durvalumab, as were fatal imAEs (0.8%; all pneumonitis). The most common non-pneumonitis imAEs with durvalumab were thyroid disorders, dermatitis/ rash, and diarrhea/colitis. Dermatitis/rash had the shortest time to onset (from durvalumab initiation), followed by pneumonitis; dermatitis/rash had the longest time to resolution, followed by thyroid disorders. Most patients with immune-mediated pneumonitis (78.4%) and non-pneumonitis imAEs (56.3%) had these events occur <= 3 months after initiating durvalumab. ImAEs were well managed with administration of systemic corticosteroids, administration of endocrine replacement therapy, and interruption/discontinuation of durvalumab. Time elapsed from completion of prior radiotherapy to trial randomization (< 14 vs. >= 14 days) did not impact either incidence or severity of imAEs. Durvalumab had a manageable safety profile broadly irrespective of whether patients experienced imAEs.Conclusion: The risk of imAEs should not deter use of the PACIFIC regimen in eligible patients, as these events are generally well managed through appropriate clinical intervention. -PU - ELSEVIER IRELAND LTD -PI - CLARE -PA - ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND -SN - 0169-5002 -SN - 1872-8332 -DA - 2022 APR -PY - 2022 -VL - 166 -SP - 84 -EP - 93 -DO - 10.1016/j.lungcan.2022.02.003 -AN - WOS:000791997800011 -C6 - MAR 2022 -AD - Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA -AD - Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA -AD - RCSI Univ Hlth Sci, Beaumont Hosp Dublin, Dublin, Ireland -AD - Katholieke Univ Leuven, Univ Hosp, Leuven, Belgium -AD - Univ Manchester, Manchester, Lancs, England -AD - Christie NHS Fdn Trust, Manchester, Lancs, England -AD - Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Istanbul, Turkey -AD - Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan -AD - Westmead Hosp, Sydney, NSW, Australia -AD - Univ Sydney, Sydney, NSW, Australia -AD - Montpellier Univ, ICM Val dAurelle, Montpellier, France -AD - Montpellier Univ, IRCM, U1194, Montpellier, France -AD - Plus Project Ltd, Alderley Pk, Macclesfield, Cheshire, England -AD - AstraZeneca, Gaithersburg, MD USA -AD - AstraZeneca, Cambridge, England -AD - H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA -M2 - RCSI Univ Hlth Sci -M2 - Plus Project Ltd -M2 - AstraZeneca -Y2 - 2022-05-26 -ER - - -TY - JOUR -AU - LARRIEU, AJ -AU - JAMIESON, WRE -AU - NELEMS, JMB -AU - FOWLER, R -AU - YAMAMOTO, B -AU - LERICHE, J -AU - MURRAY, N -TI - CARCINOMA OF THE LUNG IN PATIENTS UNDER 40 YEARS OF AGE -T2 - AMERICAN JOURNAL OF SURGERY -M3 - Article -PU - CAHNERS PUBL CO -PI - NEW YORK -PA - 249 WEST 17 STREET, NEW YORK, NY 10011 -SN - 0002-9610 -DA - 1985 -PY - 1985 -VL - 149 -IS - 5 -SP - 602 -EP - 605 -DO - 10.1016/S0002-9610(85)80135-5 -AN - WOS:A1985AHK1800008 -AD - UNIV BRITISH COLUMBIA,CANC CONTROL AGCY BRITISH COLUMBIA,VANCOUVER V6T 1W5,BC,CANADA -Y2 - 1985-01-01 -ER - - -TY - JOUR -AU - Jabbour, Salma K. -AU - Park, Keunchil -AU - Cohn, Dosinda -AU - Liu, Hong -AU - Keller, Steven M. -AU - Kowalski, Dariusz M. -TI - Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage Ill non small-cell lung cancer (NSCLC): KEYNOTE-799. -T2 - JOURNAL OF CLINICAL ONCOLOGY -M3 - Meeting Abstract -CP - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -CL - Chicago, IL -PU - AMER SOC CLINICAL ONCOLOGY -PI - ALEXANDRIA -PA - 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA -SN - 0732-183X -SN - 1527-7755 -DA - 2019 MAY 20 -PY - 2019 -VL - 37 -IS - 15 -MA - TPS8575 -AN - WOS:000487345803455 -AD - Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA -AD - Rutgers State Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ USA -AD - Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea -AD - Merck & Co Inc, Kenilworth, NJ USA -AD - Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland -Y2 - 2019-10-09 -ER - - -TY - JOUR -AU - van der Weijst, Lotte -AU - Surmont, Veerle -AU - Schrauwen, Wim -AU - Lievens, Yolande -TI - Real Life Data on Patient-Reported Outcomes and Neuro-Cognitive Functioning of Lung Cancer Patients: The PRO-Long Study -T2 - FRONTIERS IN ONCOLOGY -M3 - Article -AB - Introduction This report investigates the impact of systemic treatments (chemotherapy or immunotherapy) with(out) loco-regional radiotherapy, on HRQoL, toxicity and neurocognitive functioning (NCF) in locally advanced and metastatic non-small cell lung cancer patients enrolled in the PRO-Long study. Materials and Methods Data on patient-reported HRQoL and fourteen toxicities was collected, while NCF was tested, up to one-year post-treatment. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30. Lung cancer, treatment and neuro-psychological related toxicities were scored with the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events. NCF was evaluated with six neurocognitive tests. Mixed model analyses were conducted to determine statistical significance (p = .01). Meaningful clinical important differences (MCIDs) were applied for changes in HRQoL and NCF data, while toxicities were compared to baseline values. Results In total, 50 patients were enrolled. Overall HRQoL (p = .357) nor its domains (physical, p = .643; role, p = .069; emotional, p = .254; cognitive, p = 494; social, p = .735) changed significantly over time. Meaningful improvements in overall HRQoL were seen in 22, 38 and 39% and deteriorations in 22, 5 and 28% of patients at 2-3, 6 and 12 months respectively post-treatment. Overall toxicity (p = .007), lack of appetite (p = .001), nausea (p = .004) and dysphagia (p = .000) significantly decreased over time. Treatment caused acute toxicity, such as dyspnoea (45%) and memory problems (42%), but also alleviated pre-existing symptoms, including lack of appetite (32%), anxiety (29%) and depression (28%) at 2/3 months. The NCF domains of visual memory (p = .000) and cognitive processing speed (p = .000) showed significant improvements over time. In terms of MCIDs, at 2-3 months (18%) and 6 months (15%), verbal memory was particularly impacted; at 12 months, visual memory (18%) and executive function (18%) deteriorated primarily. Conclusion The results suggest that therapy has no significant negative impact on overall HRQoL, its domains, and NCF. About one-third of patients reported a meaningful improved HRQoL at 1 year post-treatment. Treatment caused toxicity, but also alleviated pre-existing symptoms. -PU - FRONTIERS MEDIA SA -PI - LAUSANNE -PA - AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND -SN - 2234-943X -DA - 2021 JUN 17 -PY - 2021 -VL - 11 -C7 - 685605 -DO - 10.3389/fonc.2021.685605 -AN - WOS:000668622600001 -AD - Ghent Univ Hosp, Dept Radiat Oncol, Ghent, Belgium -AD - Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium -AD - Ghent Univ Hosp, Dept Med Psychol, Ghent, Belgium -Y2 - 2021-07-13 -ER - - -TY - JOUR -AU - Bassiri, Kayleigh -AU - Cairns, Linda -AU - McVie, Gordon -AU - Seckl, Michael -TI - Highlights from the ecancer Future Horizons in Lung Cancer conference, 1-2 September 2016: Focusing on the future of treatment for NSCLC and SCLC. -T2 - Ecancermedicalscience -M3 - Journal Article -AB - The 'Future Horizons in Lung Cancer' meeting was designed to bring leading scientists together alongside clinicians to discuss the most recent advances in lung cancer pathophysiology and treatment. The aim was to take those attending the event on a journey through decades of lung cancer research and understanding, with topics spanning from screening and surgical care to "omics" approaches for drug target and biomarker discovery. There were also several talks describing the role of radiotherapy in lung cancer and advancements in imaging techniques, aiding surgeons in their attempts to resect early lesions. Current standards of care were both challenged and celebrated, while new and innovative immunotherapies also came into the spotlight. The meeting, held over two days, attracted a high calibre of speakers and delegates from across the globe. There were 10 sessions in total focusing on the latest therapeutic advances and predictions for the future of lung cancer treatment. Highlights included a key note lecture from Dr Frances Shepherd packing 40 years of lung cancer research into a 40-minute presentation. Heated debates were had regarding the validity of maintenance therapy and immune checkpoint inhibitors that have taken the research community by storm. The latest developments in imaging, surgery, systemic and radiotherapy were presented over 10 sessions of exciting, innovative and stimulating presentations, leaving the audience lively yet pensive. -SN - 1754-6605 -DA - 2017 -PY - 2017 -VL - 11 -SP - 729 -EP - 729 -DO - 10.3332/ecancer.2017.729 -AN - MEDLINE:28386299 -AD - KB James Complete Academic Services, Plymouth, UK. -AD - Istituto Europeo di Oncologia, via Ripamonti 435 Milano, Italy. -AD - Cancer Studies, Kings College London, UK. -AD - Faculty of Medicine, Department of Surgery and Cancer, Imperial College London, SW7 2AZ. -Y2 - 2017-04-13 -ER - - -TY - JOUR -AU - Hata, Akito -AU - Ninomaru, Taira -AU - Okada, Hideaki -AU - Kogure, Yoshihito -AU - Oki, Masahide -AU - Katakami, Nobuyuki -AU - Kijima, Takashi -AU - Yokoyama, Toshihide -AU - Matsumoto, Hirotaka -AU - Sato, Yuki -AU - Kato, Terufumi -AU - Sugawara, Shunichi -AU - Sawada, Takeshi -AU - Yoshimura, Kenichi -AU - Seto, Takashi -AU - Nakagawa, Kazuhiko -AU - Okamoto, Isamu -AU - Yamamoto, Nobuyuki -TI - Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P plus C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): Primary analysis from multicenter single arm phase II study (Evolution trial; WJOG11819L). -T2 - JOURNAL OF CLINICAL ONCOLOGY -M3 - Meeting Abstract -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0732-183X -SN - 1527-7755 -DA - 2024 JUN 10 -PY - 2024 -VL - 42 -IS - 17_SUPPL -SP - LBA8050 -EP - LBA8050 -DO - 10.1200/JCO.2024.42.17_suppl.LBA8050 -AN - WOS:001244441000057 -AD - Kobe Minimally Invas Canc Ctr, Kobe, Hyogo, Japan -AD - Natl Hosp Org Nagoya Med Ctr, Nagoya, Japan -AD - NHO Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan -AD - Takarazuka City Hosp, Takarazuka, Japan -AD - Hyogo Med Univ, Nishinomiya, Hyogo, Japan -AD - Kurashiki Cent Hosp, Kurashiki, Japan -AD - Hyogo Prefectural Amagasaki Gen Med Ctr, Amagasaki, Hyogo, Japan -AD - Kobe City Med Ctr Gen Hosp, Kobe, Japan -AD - Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Japan -AD - Sendai Kousei Hosp, Sendai, Miyagi, Japan -AD - Kyoto Univ Hosp, Kyoto, Japan -AD - Hiroshima Univ Hosp, Hiroshima, Japan -AD - Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Fukuoka, Japan -AD - Kindai Univ Hosp, Canc Ctr, Osaka, Japan -AD - Kyushu Univ, Grad Sch Med Sci, Dept Resp Med, Fukuoka, Japan -AD - Wakayama Med Univ, Wakayama, Japan -M2 - Kobe Minimally Invas Canc Ctr -M2 - Takarazuka City Hosp -M2 - Hyogo Prefectural Amagasaki Gen Med Ctr -M2 - Kindai Univ Hosp -Y2 - 2024-09-23 -ER - - -TY - JOUR -AU - MURPHY, WILLIAM JOSEPH -TI - Radio-immunotherapy to Target Cancer Stem Cells in Solid Tumor Malignancies -M3 - Awarded Grant -AB -  DESCRIPTION (provided by applicant): Cancer stem cells (CSCs) or tumor-initiating cells are a small subset of malignant cells which are resistant to chemotherapy and radiotherapy (RT) and are able to repopulate a tumor after cytotoxic treatment. It is these quiescent cells which can seed cancer relapse and metastasis, even in cases of apparent complete response to treatment. Immunotherapy offers a tremendous advantage over cytotoxic therapies to target CSCs because immune effector cells do not require targets to be actively proliferating. Therefore, immune-mediated killing appears to be an attractive candidate for targeting CSCs following the depletion of non-CSCs. Natural killer (NK) cells are cytotoxic lymphocytes which play a major role in eliminating transformed cells. NK cells not only attack hematologic malignancies and circulating solid tumor cells, but they also appear to have the unique ability to spontaneously recognize and reject allogeneic hematopoietic stem cells. Our laboratory has extensive preliminary data demonstrating that ex vivo activated NK cells can preferentially target CSCs in multiple experimental models, including tumor cell lines, primary tumor samples, and xenograft mouse models. In parallel, we have observed that RT and chemotherapy enrich for CSCs due to preferential targeting of non-CSCs by cytotoxic therapy. In addition, we have shown that RT sensitizes tumor cells, especially CSCs, to NK cell attack and recruitment. The central hypothesis of this proposal is that the combination of RT and NK immunotherapy will be more effective than standard anti-proliferative therapy or immunotherapy alone because we will be able to simultaneously target both non-CSCs and CSCs. To test this hypothesis, we propose the following 3 Specific Aims: The first specific aim will determine the mechanism by which NK cells recognize and kill CSCs. This aim will also examine the effects of RT on the sensitization of the CSC to NK killing. Specific Aim 1: To demonstrate that activated NK cells recognize and preferentially attack CSC populations compared with non-CSC in breast, pancreatic, and sarcoma malignancies. We hypothesize that RT debulking of non-CSCs will augment the ability of NK cells to destroy the CSC population resulting in the greatest anti-tumor effects. Our second specific aim will test the efficacy of combination of NK and local RT against xenograft tumor models including both orthotopic breast, pancreatic, and sarcomas and patient-derived xenografts. Specific Aim 2: To demonstrate that RT will improve NK immunotherapy by decreasing tumor bulk, enriching CSCs, sensitizing CSCs to NK attack, and recruiting NK cells to the tumor site. Our third specific aim will utilize the world-class UC Davis Veterinary Cancer Center to establish a clinical trial in canine companion animals. This trial will involve the use o autologous NK cells from canine sarcoma patients in combination with palliative RT or chemotherapy directed towards either primary or metastatic tumors. Specific Aim 3: To demonstrate that NK cell radio-immunotherapy will show local and systemic anti-tumor effects targeting CSCs and non-CSCS with minimal toxicities in canine patients. The aims of this research will elucidate the role of adoptive NK immunotherapy to target CSCs with the goal of translation to meaningful clinical benefit for patients with solid cancers. -DA - 2019 -PY - 2019 -AN - GRANTS:10527106 -G1 - 5R01CA189209-05; 9652812; R01CA189209 -AD - UNIVERSITY OF CALIFORNIA AT DAVIS -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - GERSON, STANTON L. -TI - Leadership, Planning, and Evaluation -M3 - Awarded Grant -AB - LEADERSHIP, PLANNING AND EVALUATIONPROJECT SUMMARY/ABSTRACTAs a consortium cancer center, Case Comprehensive Cancer Center (Case CCC) prioritizes frequent inter-institutional engagement regarding the activities, investments, priorities, and initiatives of the Center asarticulated in the strategic plan. All planning and evaluation efforts reflect the Center’s mission: to applyscientific discoveries in human cancers to improve lives through cancer prevention, detection,treatment, cure, and survivorship. The Specific Aims of leadership, planning and evaluation are to: 1. Maintain a Cancer Center leadership and internal and external advisory committee structure that promotes dynamic assessment, review, planning, and implementation of collaborative and transdisciplinary research across the Center. 2. Involve the entire Center membership and its consortium institutions in periodic assessment of priorities and opportunities to advance the goals of the Center, and to develop and maintain a strategic plan in alignment with the Center mission.As the Center’s director, Stan Gerson prioritizes a coordinated effort in strategic planning and evaluation forthe Center. This impacts the direction of scientific programs, recruitments, investments, expansion andcreation of new shared resources and new initiatives, and clinical translation. All scientific research programsdeveloped a future directions priority list that has been reviewed by the Center’s advisory committees,coordinated and endorsed by the Center’s Executive Committee (EC), and approved by consortium institutionleaders. These specific priorities are codified in the updated strategic plan. -DA - 2020 -PY - 2020 -AN - GRANTS:14974184 -G1 - 5P30CA043703-30; 9904167; P30CA043703 -AD - CASE WESTERN RESERVE UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - JOHNSON, FRANCES L -TI - Receptor-targeted radionuclide therapy combined with immunotherapies to improve metastatic melanoma tumor response. -M3 - Awarded Grant -AB - Melanoma incidence is rising faster than any other cancer. Surgery can be curative at early stages, butmetastatic melanoma is typically fatal. Responses to new targeted and immunotherapies can be remarkable inselect cases, but low response rates, acquired resistance, and severe adverse side effects (particularly forcombination immunotherapies) limit long-term quality of life for these patients. Thus, despite what is rightlyseen as a revolution in advanced-stage melanoma treatment, the overall response rate to all therapies remainsdismally near 50% and the 5-year survival is <25%. Despite these shortcomings, there is a clear and growingmarket for advanced melanoma drugs (2016 global revenues $4Bln; expected CAGR 15%). Further, receptor-targeted radionuclide therapies are emerging as valuable products in oncology. Two recent acquisitions bylarge pharma: Algeta by Bayer in 2014 ($2.9Bln); and Advanced Accelerator Applications by Novartis in 2017($3.9Bln) highlight this value. Viewpoint identified an initial indication for its MCR1-targeted radionuclidetherapy of progressive stage 4 metastatic melanoma (potential global annual revenues $600Mln). However,emerging evidence suggests a synergistic role for ionizing radiation (IR) combined with immunotherapy topromote immunogenic cancer cell death. Current external beam IR relies on an abscopal effect because IRdelivered in this way can only be directed to individual lesions. Because of known intertumoral heterogeneity ofmelanoma, the advantage of systemic MC1R-RT is precise deposition of radiation in all metastatic lesions,which has the potential to improve the repertoire of neoantigens presented to the immune system. Thus, thereis a critical need to determine the feasibility of safely combining immunotherapies with MC1R-RT for metastaticmelanoma. Proof-of-concept study results support the hypothesis that this combination can expand ourindication to a front-line therapy. The State of Iowa will match $50k upon award for this project.BUSINESS RATIONALE: Success in combining MC1R-RT with immunotherapy to safely improve rates ofoverall and complete response for malignant melanoma potentially expands our indication to a frontlinecombination therapy for all metastatic melanoma patients, which would significantly increase our valuation.AIM 1: Determine the feasibility of safely combining MC1R-RT (90Y) with immunotherapies to improvetumor response rates and survival in two immune-competent mouse melanoma models.IMPACT and SIGNIFICANCE: Successful completion of this Aim will establish the feasibility of safelycombining Viewpoint’s proprietary MCR1-targeted radionuclide therapy with immunotherapies for malignantmelanoma. This work if successful will also establish a robust biochemical and immunological rationale forfurther development of MC1R-RT in clinical trials designed to overcome low response rates, acquiredresistance, and serious side effects that limit current malignant melanoma therapies. -DA - 2019 -PY - 2019 -AN - GRANTS:11356462 -G1 - 1R43CA232954-01A1; 9769465; R43CA232954 -AD - VIEWPOINT MOLECULAR TARGETING, INC. -M2 - VIEWPOINT MOLECULAR TARGETING, INC. -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - GERSON, STANTON L. -TI - Leadership, Planning, and Evaluation -M3 - Awarded Grant -AB - LEADERSHIP, PLANNING AND EVALUATIONPROJECT SUMMARY/ABSTRACTAs a consortium cancer center, Case Comprehensive Cancer Center (Case CCC) prioritizes frequent inter-institutional engagement regarding the activities, investments, priorities, and initiatives of the Center asarticulated in the strategic plan. All planning and evaluation efforts reflect the Center’s mission: to applyscientific discoveries in human cancers to improve lives through cancer prevention, detection,treatment, cure, and survivorship. The Specific Aims of leadership, planning and evaluation are to: 1. Maintain a Cancer Center leadership and internal and external advisory committee structure that promotes dynamic assessment, review, planning, and implementation of collaborative and transdisciplinary research across the Center. 2. Involve the entire Center membership and its consortium institutions in periodic assessment of priorities and opportunities to advance the goals of the Center, and to develop and maintain a strategic plan in alignment with the Center mission.As the Center’s director, Stan Gerson prioritizes a coordinated effort in strategic planning and evaluation forthe Center. This impacts the direction of scientific programs, recruitments, investments, expansion andcreation of new shared resources and new initiatives, and clinical translation. All scientific research programsdeveloped a future directions priority list that has been reviewed by the Center’s advisory committees,coordinated and endorsed by the Center’s Executive Committee (EC), and approved by consortium institutionleaders. These specific priorities are codified in the updated strategic plan. -DA - 2022 -PY - 2022 -AN - GRANTS:17446008 -G1 - 10380720; 5P30CA043703-32; 8088; P30CA043703 -AD - CASE WESTERN RESERVE UNIVERSITY -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - GERSON, STANTON L. -TI - Leadership, Planning, and Evaluation -M3 - Awarded Grant -AB - LEADERSHIP, PLANNING AND EVALUATIONPROJECT SUMMARY/ABSTRACTAs a consortium cancer center, Case Comprehensive Cancer Center (Case CCC) prioritizes frequent inter-institutional engagement regarding the activities, investments, priorities, and initiatives of the Center asarticulated in the strategic plan. All planning and evaluation efforts reflect the Center’s mission: to applyscientific discoveries in human cancers to improve lives through cancer prevention, detection,treatment, cure, and survivorship. The Specific Aims of leadership, planning and evaluation are to: 1. Maintain a Cancer Center leadership and internal and external advisory committee structure that promotes dynamic assessment, review, planning, and implementation of collaborative and transdisciplinary research across the Center. 2. Involve the entire Center membership and its consortium institutions in periodic assessment of priorities and opportunities to advance the goals of the Center, and to develop and maintain a strategic plan in alignment with the Center mission.As the Center’s director, Stan Gerson prioritizes a coordinated effort in strategic planning and evaluation forthe Center. This impacts the direction of scientific programs, recruitments, investments, expansion andcreation of new shared resources and new initiatives, and clinical translation. All scientific research programsdeveloped a future directions priority list that has been reviewed by the Center’s advisory committees,coordinated and endorsed by the Center’s Executive Committee (EC), and approved by consortium institutionleaders. These specific priorities are codified in the updated strategic plan. -DA - 2021 -PY - 2021 -AN - GRANTS:17380954 -G1 - 10135958; 5P30CA043703-31; 8088; P30CA043703 -AD - CASE WESTERN RESERVE UNIVERSITY -Y2 - 2024-03-01 -ER - - -TY - JOUR -AU - SCHWARTZ, GARY K -TI - Leadership, Planning, and Evaluation -M3 - Awarded Grant -AB - LEADERSHIP, PLANNING AND EVALUATIONPROJECT SUMMARY/ABSTRACTAs a consortium cancer center, Case Comprehensive Cancer Center (Case CCC) prioritizes frequent inter-institutional engagement regarding the activities, investments, priorities, and initiatives of the Center asarticulated in the strategic plan. All planning and evaluation efforts reflect the Center’s mission: to applyscientific discoveries in human cancers to improve lives through cancer prevention, detection,treatment, cure, and survivorship. The Specific Aims of leadership, planning and evaluation are to: 1. Maintain a Cancer Center leadership and internal and external advisory committee structure that promotes dynamic assessment, review, planning, and implementation of collaborative and transdisciplinary research across the Center. 2. Involve the entire Center membership and its consortium institutions in periodic assessment of priorities and opportunities to advance the goals of the Center, and to develop and maintain a strategic plan in alignment with the Center mission.As the Center’s director, Stan Gerson prioritizes a coordinated effort in strategic planning and evaluation forthe Center. This impacts the direction of scientific programs, recruitments, investments, expansion andcreation of new shared resources and new initiatives, and clinical translation. All scientific research programsdeveloped a future directions priority list that has been reviewed by the Center’s advisory committees,coordinated and endorsed by the Center’s Executive Committee (EC), and approved by consortium institutionleaders. These specific priorities are codified in the updated strategic plan. -DA - 2023 -PY - 2023 -AN - GRANTS:17760174 -G1 - 10784828; 4P30CA043703-33; 9181; P30CA043703 -AD - CASE WESTERN RESERVE UNIVERSITY -Y2 - 2024-07-25 -ER - - -TY - JOUR -AU - Wu, Ranpu -AU - Yuan, Bingxiao -AU - Li, Chuling -AU - Wang, Zimu -AU - Song, Yong -AU - Liu, Hongbing -TI - A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers -T2 - JOURNAL OF THORACIC DISEASE -M3 - Review -AB - Human epidermal growth factor receptor 2 (HER2), as a receptor tyrosine kinase of EGF receptor family, whose mutation is often associated with even if less frequency but poor prognosis and shorter survival in pulmonary malignant tumor. HER2 status include mutation, overexpression, amplification and also some rare genotypes, detected by next generation sequencing (NGS), immunohistochemistry (IHC), and also fluorescence in situ hybridization (FISH). Different genotypes represent different therapeutic targets and indicate different clinical prognosis concluded by previous studies. Unfortunately, no standard guidelines for first-line treatment are widely recognized, and current therapeutic schedules include chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Especially for patients with advanced metastasis, chemotherapy is based as a systemic therapy using studies of breast cancer or EGFR-positive lung adenocarcinoma as a template. Studies already explored treatment including EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and afatinib, and also trastuzumab and its conjugation like HER2-targeted antibody drug conjugate trastuzumab emtansine (T-DM1) and conjugate trastuzumab deruxtecan (T-DXd). Also, he researches explored combination therapy with chemotherapy and TKIs or monoclonal antibodies. This review describes commonly used therapies for HER2-positive/HER2-overexpression patients and general relationship between genotypes of HER2, drug selection and final prognosis in order to provide suggestions for future diagnosis and treatment. -PU - AME PUBLISHING COMPANY -PI - SHATIN -PA - FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA -SN - 2072-1439 -SN - 2077-6624 -DA - 2021 JUN -PY - 2021 -VL - 13 -IS - 6 -SP - 3708 -EP - 3720 -DO - 10.21037/jtd-20-3265 -AN - WOS:000667652200003 -AD - Southeast Univ Med, Jinling Hosp, Dept Resp & Crit Care Med, Nanjing, Peoples R China -AD - Nanjing Med Univ, Sch Med, Affiliated Jinling Hosp, Dept Resp & Crit Care Med, Nanjing, Peoples R China -AD - Nanjing Univ, Sch Med, Dept Resp Med, Jinling Hosp, Nanjing, Peoples R China -M2 - Southeast Univ Med -Y2 - 2021-07-14 -ER - - -TY - JOUR -AU - Bonomi, Philip -AU - Moudgalya, Hita -AU - Gomez, Sandra L. -AU - Shah, Palmi -AU - Basu, Sanjib -AU - Batus, Marta -AU - Martinka, Levi B. -AU - Abdelkader, Ahmed -AU - Tzameli, Iphigenia -AU - Cobain, Sonia -AU - Collins, Susie -AU - Keliher, Edmund J. -AU - Breen, Danna M. -AU - Calle, Roberto A. -AU - Fidler, Mary Jo -AU - Borgia, Jeffrey A. -TI - Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy -T2 - JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE -M3 - Article -M3 - Early Access -AB - Background: The primary objective of this study was to assess the frequency of body composition increases and their relationships to changes in body weight in two cohorts of real world, treatment-na & iuml;ve, advanced non-small cell lung cancer (NSCLC) patients. One cohort received the current standard of care (CSOC), which consisted of immunotherapy and newer chemotherapy regimens, and the other cohort was treated with the former standard of care (FSOC), consisting only of older platinum-containing regimens. Methods: CSOC (n = 106) and FSOC (n = 88) cohorts of advanced NSCLC patients were included in this study. Weights were collected at each clinical visit, and body composition analysis from routine chest computed tomography via automated segmentation software assessed at baseline and at 6 and 12 weeks. Standard statistical methods were used to calculate relationships between changes in weight and in body composition. Results: The CSOC cohort contained 106 stage IV NSCLC patients treated between 16/12/2014 and 22/10/2020 while the FSOC cohort contained 88 stage III/IV NSCLC patients treated between 16/6/2006 and 18/11/2014. While each cohort exhibited decreases in median weight, body mass index (BMI), mean skeletal muscle index (SMI) and subcutaneous adipose tissue index (SATI) at the 6 and 12 week time points, a subset of patients experienced increases in these parameters. Using a threshold of >= 2.5% increase for weight, BMI, SMI, and SATI at the 12 week time point, both cohorts showed similar (20.5% and 27.3%) increases in these parameters. With a cut point of >= 5% increase at 12 weeks follow-up, 8.0% to 25.0% of the patients gained >= 5% in weight, BMI, SMI and SATI. Comparing these results in each cohort showed no significant differences. Pearson coefficients for weight change related to changes in SMI and SATI at 6 and 12 weeks ranged from 0.31 to 0.58 with all P values <0.02. Pearson coefficients for weight change at 12 weeks related to changes in VATI and IMATI ranged from 0.26 to 0.47 with all P values <0.05. Comparison of Pearson coefficients for each cohort showed no significant differences. Conclusions: Although decreases in median weight, BMI, SMI and SATI were observed in both cohorts, similar percentage of patients in each cohort experienced increases in these parameters. These findings, plus the positive correlations between longitudinal measurements of weight, muscle mass and adipose tissue, indicate that weight gain in these patients involves increases in both muscle mass and adipose tissue. Upon validation, these findings could have implications for clinical trial design and for translational research in cancer cachexia. -PU - WILEY -PI - HOBOKEN -PA - 111 RIVER ST, HOBOKEN 07030-5774, NJ USA -SN - 2190-5991 -SN - 2190-6009 -DA - 2024 SEP 17 -PY - 2024 -DO - 10.1002/jcsm.13534 -AN - WOS:001314758900001 -C6 - SEP 2024 -AD - Rush Univ, Div Hematol Oncol, Med Ctr, Chicago, IL 60612 USA -AD - Rush Univ, Med Ctr, Dept Anat & Cell Biol, Chicago, IL 60612 USA -AD - Rush Univ, Med Ctr, Dept Clin Nutr, Chicago, IL USA -AD - Rush Univ, Med Ctr, Dept Radiol, Chicago, IL USA -AD - Univ Illinois, Sch Publ Hlth, Biostat, Chicago, IL USA -AD - Pfizer Inc, Internal Med Res Unit, Cambridge, MA USA -AD - Pfizer R&D UK Ltd, Global Biometr & Data Management, Sandwich, England -AD - Pfizer Inc, Early Clin Dev, Cambridge, MA USA -AD - Rush Univ, Med Ctr, Dept Pathol, Chicago, IL USA -Y2 - 2024-09-23 -ER - - -TY - JOUR -AU - Chen, Yuanbin -AU - Paz-Ares, Luis -AU - Reinmuth, Niels -AU - Garassino, Marina Chiara -AU - Statsenko, Galina -AU - Hochmair, Maximilian J. -AU - Oezgueroglu, Mustafa -AU - Verderame, Francesco -AU - Havel, Libor -AU - Losonczy, Gyoergy -AU - Conev, Nikolay, V -AU - Hotta, Katsuyuki -AU - Ji, Jun Ho -AU - Spencer, Stuart -AU - Dalvi, Tapashi -AU - Jiang, Haiyi -AU - Goldman, Jonathan W. -TI - Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report -T2 - JTO CLINICAL AND RESEARCH REPORTS -M3 - Article -AB - Introduction: In the phase 3 study involving the use of durvalumab with or without tremelimumab in combination with platinum-based chemotherapy in untreated extensive -stage SCLC (CASPIAN study), first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone (p = 0.0047). We report exploratory subgroup analyses of treatment patterns and outcomes according to the presence of baseline brain or central nervous system metastases.Methods: Patients (WHO performance status 0 or 1), including those with asymptomatic or treated-and-stable brain metastases, were randomized to four cycles of dur-valumab plus EP followed by maintenance durvalumab until progression or up to six cycles of EP and optional prophy-lactic cranial irradiation. Prespecified analyses of OS and progression-free survival (PFS) in subgroups with or without brain metastases used unstratified-Cox proportional hazards models. The data cutoff was on January 27, 2020.Results: At baseline, 28 out of 268 patients (10.4%) in the durvalumab plus EP arm and 27 out of 269 patients (10.0%) in the EP arm had known brain metastases, of whom 3 of 28 (10.7%) and 4 of 27 (14.8%) had previous brain radio-therapy, respectively. Durvalumab plus EP (versus EP alone) prolonged OS (hazard ratio, 95% confidence interval) in patients with (0.79, 0.44-1.41) or without (0.76, 0.62-0.92) brain metastases, with similar PFS results (0.73, 0.42-1.29 and 0.80, 0.66-0.97, respectively). Among patients without brain metastases, similar proportions in each arm developed new brain lesions as part of their first progression (8.8% and 9.5%), although 8.3% in the EP arm received prophy-lactic cranial irradiation. Similar proportions in each arm received subsequent brain radiotherapy (20.5% and 21.2%), although more common in patients with than without baseline brain metastases (45.5% and 18.0%).Conclusions: The OS and PFS benefit with first-line durvalumab plus EP were maintained irrespective of the presence of brain metastases, further supporting its standard-of-care use.(c) 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/). -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 2666-3643 -DA - 2023 JUN -PY - 2023 -VL - 3 -IS - 6 -C7 - 100330 -DO - 10.1016/j.jtocrr.2022.100330 -AN - WOS:001137472400009 -AD - Canc & Hematol Ctr Western Michigan, Grand Rapids, MI USA -AD - Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain -AD - Asklepios Lung Clin, Dept Thorac Oncol, Gauting, Germany -AD - Fdn Ist Ricovero, Cura Carattere Scienti IRCCS Ist Nazl Tumori f, Milan, Italy -AD - Univ Chicago, Sect Hematol Oncol, Chicago, IL USA -AD - Omsk Reg Canc Ctr, Omsk, Russia -AD - Krankenhaus Nord, Dept Resp & Crit Care Med, Karl Landsteiner Inst Lung Res & Pulm Oncol, Vienna, Austria -AD - Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Dept Internal Med, Div Med Oncol, Istanbul, Turkiye -AD - Azienda Ospedaliera AO Ospedali Riuniti Presidio, Palermo, Italy -AD - Charles Univ Prague, Thomayer Hosp, Fac Med 1, Dept Pneumol, Prague, Czech Republic -AD - Semmelweis Univ, Dept Pulmonol, Budapest, Hungary -AD - UMHAT St Marina, Clin Med Oncol, Varna, Bulgaria -AD - Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan -AD - Sungkyunkwan Univ, Samsung Changwon Hosp, Sch Med, Dept Internal Med, Changwon Si, South Korea -AD - AstraZeneca, Cambridge, England -AD - AstraZeneca, Gaithersburg, MD USA -AD - Univ Calif Angeles UCLA, David Geffen Sch Med, Los Angeles, CA USA -AD - Canc & Hematol Ctr Western Michigan PC, Lemmen Holton Canc Pavil, 145 Michigan St NE,Suite 3100, Grand Rapids, MI 49503 USA -M2 - Canc & Hematol Ctr Western Michigan -M2 - Asklepios Lung Clin -M2 - Fdn Ist Ricovero -M2 - Omsk Reg Canc Ctr -M2 - Krankenhaus Nord -M2 - Azienda Ospedaliera AO Ospedali Riuniti Presidio -M2 - AstraZeneca -M2 - Canc & Hematol Ctr Western Michigan PC -Y2 - 2024-01-19 -ER - - -TY - PAT -AU - PARK J Y -AU - YU Y -AU - KIM C M -AU - KONG S -AU - PARK K H -TI - New isolated set of probes capable of detecting panel of biomarkers comprising at least two biomarkers comprising e.g. ankyrin repeat domain, ankyrin repeat domain pseudogene, B-box and SPRY domain used for treating cancer -AB - - NOVELTY - Isolated set of probes capable of detecting a panel of biomarkers comprising at least two biomarkers comprising e.g.(a) ankyrin repeat domain 36 (ANKRD36), ankyrin repeat domain 36B pseudogene 2 (ANKRD36BP2), B-box and SPRY domain containing (BSPRY), chromosome 12 open reading frame 65 (C12orf65), chromosome 2 open reading frame 49 (C2orf49), chromosome 1 open reading frame 198 (Clorfl98), coiled-coil domain containing 114 (CCDC114), claudin 4 (CLDN4), CUE domain containing 1 (CUEDC1), outer dynein arm docking complex subunit 1 (ODAD1), cell growth regulator with EF-hand domain 1 (CGREF1), DEP domain containing 7 (DEPDC7), is new. - USE - The isolated set of probes or kits is useful for: predicting a disease prognosis and/or a treatment outcome for a subject diagnosed with cancer; and predicting a disease prognosis and/or a treatment outcome for a subject diagnosed with triple negative breast cancer (TNBC), where the cancer is breast cancer, the breast cancer is triple-negative breast cancer (TNBC), the TNBC is early-stage TNBC, and the subject is high risk, and further comprises an advanced, strengthened, or standard form of treatment for TNBC comprising surgery and/or administering chemotherapeutic agents, radiotherapy, immunotherapeutic agents, and/or any novel therapeutics (all claimed); and treating cancer. No biological data given. - ADVANTAGE - The isolated set of probes: provides accurately predict prognosis and response to treatment; and capable of detecting the biomarkers. - DETAILED DESCRIPTION - The isolated set of probes comprising at least two biomarkers comprising (a) ankyrin repeat domain 36 (ANKRD36), ankyrin repeat domain 36B pseudogene 2 (ANKRD36BP2), B-box and SPRY domain containing (BSPRY), chromosome 12 open reading frame 65 (C12orf65), chromosome 2 open reading frame 49 (C2orf49), chromosome 1 open reading frame 198 (Clorfl98), coiled-coil domain containing 114 (CCDC114), claudin 4 (CLDN4), CUE domain containing 1 (CUEDC1), outer dynein arm docking complex subunit 1 (ODAD1), cell growth regulator with EF-hand domain 1 (CGREF1), DEP domain containing 7 (DEPDC7), doublecortin like kinase 2 (DCLK2), diacylglycerol kinase (DGKH), disco interacting protein 2 homolog B (DIP2B), disrupted-in-schizophrenia 1 (DISCI), epithelial membrane protein 1 (EMP1), ERH mRNA splicing and mitosis factor (ERH), growth arrest and DNA damage inducible β (GADD45B), glutaminase (GLS), grainyhead like transcription factor 1 (GRHL1), glycophorin C (GYPC), H2A histone family member X (H2AFX), HRas proto-oncogene (HRAS), intracellular adhesion molecule 1 (ICAM1), interphotoreceptor matrix proteoglycan 2 (IMPG2), potassium voltagegated channel subfamily C member 3 (KCNC3), kruppel like factor 6 (KLF6), kruppel like factor 7 (KLF7), keratin 17 (KRT17), LON peptidase N-terminal domain and RING finger protein 2 (LONRF2), LPS responsive beige-like anchor protein (LRBA), leucine rich repeat, Ig-like and transmembrane domains 3 (LRIT3), leucine rich repeat containing 37B (LRRC37B), LSM11, U7 small nuclear RNA associated (LSM11), lysosomal trafficking regulator (LYST), metastasis associated lung adenocarcinoma transcript 1 (MALAT1), mini chromosome maintenance complex component 3 associated protein antisense RNA 1 (MCM3AP AS1), MIC AL like 2 (MICALL2), MHC class I polypeptide-related sequence B (MICB), metallothionein 2A (MT2A), myelin expression factor 2 (MYEF2), NEDD4 binding protein 3 (N4BP3), neuroblastoma breakpoint family member 20 (NBPF20), NADH: Ubiquinone Oxidoreductase Core Subunit V2 (NDUFV2), neurogenic locus notch homolog protein 2 (NOTCH2), NADPH oxidase activator 1 (NOXA1), natriuretic peptide receptor 3 (NPR3), nuclear receptor subfamily 6 group A member 1 (NR6A1), P21 (RAC1) activated kinase 3 (PAK3), pantothenate kinase 3 (PANK3), par-6 family cell polarity regulator β (PARD6B), peroxisomal biogenesis factor 1 (PEX1), piggyBac transposable element derived 4 (PGBD4), praja ring finger ubiquitin ligase 1 (PJA1), pleckstrin homology and FYVE domain containing 1 (PLEKHF1), purine nucleoside phosphorylase (PNP), protein tyrosine phosphatase receptor type A (PTPRA), protein phosphatase, Mg2+/Mn2+ dependent IK (PPM1K), prickle planar cell polarity protein 1 (PRICKLEI), protein kinase AMP-activated non-catalytic subunit β 2 (PRKAB2), PYD and CARD domain containing (PYCARD), RAS p21 protein activator 1 (RASA1), RASD family member 2 (RASD2), RAS guanyl releasing protein 1 (RASGRP1), rhophilin RHO GTPase binding protein 2 (RHPN2), Rab interacting lysosomal protein like 2 (RILPL2), roundabout guidance receptor 1 (R0B01), RAR related orphan receptor A (RORA), Stromal cell derived factor 4 (SDF4), SERTA domain containing 4 (SERTAD4), shisa family member 5 (SHISA5), signal induced proliferation associated 1 like 2 (SIPA1L2), solute carrier family 22 member 20 (SLC22A20P), solute carrier family 24 member 3 (SLC24A3), solute carrier family 2 member 12 (SLC2A12), solute carrier family 39 member 10 (SLC39A10), solute carrier family 25 member 40 (SLC25A40), solute carrier family 43 member 1 (SLC43A1), solute carrier family 45 member 4 (SLC45A4), solute carrier family 6 member 20 (SLC6A20), spectrin β , erthrocytic (SPTB), stromal antigen 3-like 3 (STAG3L3), sushi domain containing 3 (SUSD3), TATA-Box binding protein associated factor 10 (TAF10), t-complex-associated testis expressed 3 (TCTE3), transmembrane channel like 7 (TMC7), transmembrane and coiled-coil domain family 2 (TMCC2), transcriptional repressor GATA binding 1 (TRPS1), tubulin tyrosine ligase like 4 (TTLL4), tRNA-γ W synthesizing protein 5 (TYW5), ubiquitin conjugating enzyme E2 W (UBE2W), WD repeat, sterile α motif and U-box domain containing 1 (WDSUB1), N-protein N-terminal glutamine amidohydrolase (WDYHV1), amino-terminal glutamine amidase 1 (NTAQ1), zinc finger BED-type containing 6 (ZBED6), zinc finger and BTB domain containing 46 (ZBTB46), zinc finger CCCH-type containing 13 (ZC3H13), zinc fingers and homeoboxes 2 (ZHX2), zinc finger protein 217 (ZNF217), zinc finger protein 233 (ZNF233), zinc finger protein 248 (ZNF248), zinc finger protein 469 (ZNF469), and zinc finger protein 785 (ZNF785). INDEPENDENT CLAIMs are also included for:predicting a disease prognosis and/or a treatment outcome for a subject diagnosed with cancer comprising (a1) obtaining a sample from the subject, (b) contacting the sample with the isolated set of probes to detect a panel of biomarkers in the sample, and (c) analyzing a pattern of the panel of biomarkers to determine a risk score for the subject; anda kit for predicting a disease prognosis and/or a treatment outcome for a subject diagnosed with triple negative breast cancer (TNBC) comprising (a) as per se, and (b1) instructions for use. -SN - WO2024100556-A1 -AN - DIIDW:202450677C -Y2 - 2024-06-09 -ER - - -TY - JOUR -AU - LASSOUED, WIEM -TI - Tumor Immune MicroEnvironment Facility -M3 - Awarded Grant -AB - The microenvironment consists not only of tumor cells but also of physiological tissues which include the stroma with fibroblasts, blood vessels and white blood cells, especially T lymphocytes and macrophages, whose precursors are monocytes deriving from the myeloid lineage. Some tumors have a rich T lymphocyte infiltration. Innate immunity cells such as macrophages, granulocytes and immature myeloid cells from which monocytes or macrophages derive are also found in different densities. To study the evolvement of TIME and the interaction between tumor cells and other immune cells we developed and validated mainly 3 different panels of biomarkers to immuno-stain Formalin fixed paraffin embedded tumor tissue sections using immunofluorescence and opal technique. Each one of these panels included 7 markers. Panel 1 included: CD4, CD8, FOXP3, PDL1, Ki67, CK and Dapi. we use panel1 to phenotypically identify T lymphocytes and their subgroups: T helpers, Cytotoxic T cell, T regulators. Panel 2 included: CD68, CD163, CD56, CD4, CD8 and Dapi. We use panel 2 to identify macrophages and both subtypes, M1 and M2 and their interactions with CD4+ cells and CD8+ cells. Panel 3 included CD11b, CD68, CD14, CD15, CK, HLA-DR and DAPI. We use panel 3 to identify Myeloid derived suppressor cells MDSCs and both subtypes monocyte M-MDSC and Poly-morpho-nuclear PMN-MDSC. Applications and results: Immunotherapy, as a single agent, provides benefit to a small subset of PC patients, which is thought to be partially due to its known cold tumor immune microenvironment (TIME).. Prostvac is a therapeutic cancer vaccine engineered to activate an immune response against prostate-specific Antigen (PSA). Prostvac alone could induce systemic immune response by increasing immune-cell infiltrates in and around the tumor. In our study published in JITC 2020, 27 prostate cancer patients were enrolled in a an open-label, phase II study of neoadjuvant Prostvac vaccine. We evaluated increases in CD4 and CD8 T-cell infiltrates in Radical Prostatectomy (RP) tissue vs baseline biopsies, using our panel 1. We found that for non-compartmentalized analysis (NCA) and compartmentalized analysis (CA), tumor CD4 T-cell infiltrates were significantly increased in postvaccination RP specimens compared with baseline biopsies by NCA . By CA, an increase in both CD4 T-cell infiltrates at the tumor infiltrative margin and in CD8 T-cell infiltrates at the tumor were noted in postvaccination RP specimens compared with baseline biopsies. In a complimentary study, we explored the effect of Prostvac in combination with nivolumab in TIME of prostate cancer. We treated locally advanced prostate cancer patients (n=6) undergoing RP with neoadjuvant Prostvac in combination with nivolumab. Dynamic changes in TIME before and after treatment were studied using multiplex immunofluorescence (Opal Method). FFPE sections from matched pre-treated prostate biopsies and post-treated RP samples were stained with our validated T cell panel1. Combination immunotherapy significantly increased CD4+ T cells and CD8+ T cells densities in the invasive margin, intratumoral and the benign compartments. 5/6 and 4/6 patients showed more than 2Xincrease of CD4 and CD8 T cells in the TIME, respectively, in at least one of the three compartments, showing more effect that Prostvac alone. Increased proliferative indices in CD4+ and CD8+ T cells were also seen after treatment. Tregs were present in low frequencies in TIME (maximum of 12 cells/mm2) with no significant changes. Moreover, a significant drop in tumor cell Ki67 after treatment) suggests that the combination may control tumor growth. The combination of Neoadjuvant Prostvac and nivolumab was associated with increased immune cell infiltration in a cohort of early prostate cancer patients. More patients (10) will be enrolled in this combination study to confirm our finding and that the combined therapy has more benefit than the vaccine alone The Division of Cancer Prevention, NCI sponsored a study of Prostvac vs. Placebo in the active surveillance setting in prostate cancer. In this multicenter study, 154 patients with indolent localized prostate cancer who elected to go on active surveillance, were randomized 2:1 to receive vaccine vs. empty vector placebo. The primary endpoint of the study is immune infiltrate in vaccinated patients vs. placebo patients. We have other ongoing studies that involves clinical trials using bintrafusp alpha on patients with metastatic or locally advanced solid tumors. Expression of both TGF-Beta and PDL1 has been linked with poor prognosis in patients with cancer. Two agents targeting the PD1 / PDL1 pathway have been recently approved by the FDA with impressive duration of responses. Unfortunately, only a fraction of patients develops these responses. M7824 has been shown to have improved activity compared with the parent anti-PDL1 antibody (avelumab), which is now in phase III clinical testing. Bintrafusp alfa (M7824) is a bifunctional fusion protein that targets TGF Beta and PDL1. We have great interest to look at the changes happening in TIME after treatment with bintrafusp alfa. First, we looked at the changes of macrophages densities in non-small lung cancer cohort, and we found that for patients that had progressive disease there was an increase in M2 macrophages and a decrease in M1 macrophages. M1 densities increased in patients that has stable disease, along with T helpers and Cytotoxic T cells. M2 densities decreased in these patients after treatment. The presence of MDSCs in these tumors and their dynamic change is still under investigation. We are investigation the changes in TIME in patients with other cancer types and treated with bintrafusp alfa under protocols 15-C0179 and 18-C0056.We are requesting more tumor samples to have a high number of paired samples with matched pre and post treated samples. in a collaboration with the group of engineers at the Frederick national labs and the Brigham and women's hospital Harvard medical school, we are looking at TIME from spatial distribution angle. We are using our paired samples from patients treated with Bintrafusp alfa to develop a platform that leverage state-of-the-art image analysis techniques to better understand Whole Slide Images (WSI). Multiplex immunofluorescence (MxIF) images are few to 10s of channels that measure the expression of various markers (e.g., CD4, PD-L1, etc.) and therefore are an order of magnitude larger than H&E images. The use of artificial deep neural networks to automatically extract embedded features or patterns helps overcome challenges in traditional MxIF analysis and potentially enables high-level information beyond SA of images. We aim to build on advances in WSI analysis that enable cell-cell interactions to be represented as a graph that can be used as input to dimensionality reduction techniques like autoencoders. Working with a smaller dimension space allows us to use unsupervised clustering and form new groups of the Regions of Interest (ROIs) extracted from the WSI. These groups can suggest new hypotheses that explain the reasons behind the effectiveness of the drug. We will augment and test weakly supervised learning techniques where a single label is provided per WSI to predict the clinical outcome. We will use multiple-instance learning where ROIs with mixed positive and negative signals collectively predict the label of the WSI. Finally, we will utilize recent deep learning techniques like attention to identify important ROIs in the WSIs in making the clinical prediction. This study will push the frontiers of TIME analysis to better understand drug effects and prescribe new promising treatments for patients with cancer. -DA - 2021 -PY - 2021 -AN - GRANTS:17427352 -G1 - 10487272; 1ZICBC012029-01; ZICBC012029 -AD - DIVISION OF BASIC SCIENCES - NCI -Y2 - 2024-06-01 -ER - - -TY - JOUR -AU - Bernard S Black; JOHN RICHARD MEURER; SHAKER, REZA NONE -TI - Clinical and Translational Science Award -M3 - Awarded Grant -AB - PROJECT SUMMARY/ABSTRACT for Randomized COVID-19 Testing in Vulnerable Communities and Risk Tool CreationThe broad objective of this project is first to perform community-engaged research using randomized COVID-19 testsamong vulnerable populations in Milwaukee County, Wisconsin, and then to use innovative empirical methods tomeasure infection rates and progression risk, if infected, from symptomatic infection, to hospitalization, ICU admission,and death. This project is part of the NIH RADx-UP initiative to transform health through research and discovery inCOVID testing among underserved populations. The 2-year project has three specific aims. Aim 1: Use randomized COVIDantibody testing of more than 23,000 persons to measure the population proportion infected with COVID and how thisproportion varies over time and with patient health and demographic characteristics. Twelve partner primary care healthcenters and 150 churches will support community engagement to achieve target enrollments for low-income, minority andelderly populations. These populations will be oversampled to obtain more precise estimates for these high-risk groups. Aim2: Use extensive data linkages to health care data, virus testing data, and mortality records to estimate infection rates andprogression risks as a multivariate function of patient and community characteristics. A web-based risk assessment tool inEnglish and Spanish will be created to allow individuals, families, and health care professionals to assess individual progressionrisk and household transmission risk and to advise individuals on risk mitigation. This risk assessment tool will be informed bythe Milwaukee data and will be of value nationwide. Aim 3: When COVID vaccines become available, the risk assessment toolwill be used to inform the prioritization of vaccination of higher risk individuals. Established trusting relationships withprimary care health centers and churches that serve vulnerable populations, social media outreach, community interestin COVID antibody test results, and easily accessed web-based consents, surveys, and risk assessment tools, as well asCommunity Advisory Board and focus groups input, will foster successful participation in this project. Random samplingmethods will be used to estimate the population proportion infected as a function of demographic and healthcharacteristics accounting for the potential for COVID virus testing, antibody testing, or both, to result in false negativetest results. Population-representative estimates will be adjusted to account for oversampling of elderly, minority, andlow-income populations, and for differences in response rates to the testing offers. To estimate progression risk, thetested population will be used to create a “synthetic” Milwaukee. This synthetic Milwaukee information will becombined with data on deceased patients and hospitalized patients to estimate progression risks. Core empiricalmethods innovations include: 1) estimating the proportion of persons who are antibody negative, and either were notvirus tested or were virus negative, as a function of personal and community characteristics, in order to develop a morecomplete measure of the infection rate; 2) using the tested subsample to create a synthetic Milwaukee which can becombined with actual data on hospitalized and deceased patients to estimate progression risks, and using multipleimputation methods to correctly estimate the uncertainty in defining the synthetic Milwaukee. -DA - 2021 -PY - 2021 -AN - GRANTS:17425662 -G1 - 10478410; 3UL1TR001436-07S1; UL1TR001436 -AD - MEDICAL COLLEGE OF WISCONSIN -AD - MEDICAL COLLEGE OF WISCONSIN -AD - MEDICAL COLLEGE OF WISCONSIN -Y2 - 2024-03-05 -ER - - -TY - BOOK -AU - Pimentel, Beatriz Tarrafa Ameal Figo -Z2 - -TI - Study of Circulating and Exosomal Levels of VEGF and Ang-2 mRNA in Lung Cancer -M3 - Dissertation/Thesis -SN - 9798383254820 -DA - 2018 -PY - 2018 -AN - PQDT:91356370 -AD - Universidade do Porto (Portugal), Portugal -M2 - Universidade do Porto (Portugal) -ER - - -TY - JOUR -AU - Lindsay, C. -AU - Veluswamy, R. -AU - Castro Junior, G. -AU - Tan, D. Y. H. -AU - Caparica, R. -AU - Glaser, S. -AU - Malhotra, S. -AU - Felip, E. -AU - Chan, E. -TI - A Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC with PD-L1 Expression <1% or PD-L1 Expression ≥1% and an STK11 Co-Mutation -T2 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS -M3 - Meeting Abstract -CP - Multidisciplinary Thoracic Cancers Symposium -CL - New Orleans, LA -PU - ELSEVIER SCIENCE INC -PI - NEW YORK -PA - STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA -SN - 0360-3016 -SN - 1879-355X -DA - 2024 JAN -PY - 2024 -VL - 118 -IS - 1 -MA - 2012 -SP - E13 -EP - E14 -AN - WOS:001129462100024 -AD - Univ Manchester, Div Canc Sci, Manchester, Lancs, England -AD - Christie NHS Fdn Trust, Manchester, Lancs, England -AD - Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA -AD - Inst Canc Estado de Sao Paulo ICESP, Sao Paulo, SP, Brazil -AD - Natl Canc Ctr Singapore, Singapore, Singapore -AD - Novartis Pharma AG, Basel, Switzerland -AD - Novartis Pharmaceut, E Hanover, NJ USA -AD - Vall Hebron Inst Oncol, Barcelona, Spain -M2 - Inst Canc Estado de Sao Paulo ICESP -Y2 - 2024-01-18 -ER - - -TY - JOUR -AU - GOMEZ-MANZANO, CANDELARIA -TI - Pilot Project 1: Combination of Viroimmunotherapy and Microbiota Modulation to Treat Gastric Cancer -M3 - Awarded Grant -AB - PILOT PROJECT 1: COMBINATION OF VIROIMMUNOTHERAPY AND MICROBIOTA MODULATION TOTREAT GASTRIC CANCERPROJECT SUMMARY/ABSTRACTGastric cancer is the third leading cause of cancer-related mortality, with a 5-year survival rate ofapproximately 20%. The incidence and mortality rates of gastric cancer in the U.S. are of high concern,especially among non-white populations. Hispanic, black non-Hispanic, and Asian/Pacific Islander populationshave a 40-50% higher risk of gastric cancer than white people, and African Americans are nearly twice as likelyto die of stomach cancer. Virotherapy, as a special case of immunotherapy, is showing promising results forsolid tumors in clinical trials. We developed an oncolytic adenovirus, Delta-24-RGD, which was clinically testedin a first-in-human phase I clinical trial in patients with recurrent glioblastoma. Clinical trials and preclinicalstudies showed that the intratumoral injection of Delta-24-RGD triggered an anti-tumor immune response thatinduced complete tumor regression in a small but significant percentage of patients. These clinical dataemphasize the need to develop strategies that will significantly increase the percentage of solid tumors likegastric cancer sensitive to virotherapy. Recent studies showed that the intestinal microbiota influence theefficacy of immunotherapy. These clinical data have been supported by rigorously controlled experimentsusing gnotobiotic mouse models colonized with one or more specific bacteria, which showed that certainmicrobial biomarkers were associated with modulating and enhancing anti-tumor therapies, such as improvingefficacy of immunotherapy. These data suggest that therapeutic interventions aimed at altering the gutmicrobiome may influence the final clinical outcome. Here, we hypothesize that oncolytic adenoviruses willexert an effective anti-cancer effect in gastric cancer, and that the host gut microbiome plays an important rolein modulating the virus-driven anti-tumor response. To test this hypothesis, we propose the following aims:Aim 1. Characterize the anticancer-potency elicited by armed oncolytic adenovirus in gastric cancer. We willutilize the Delta-24-RGD platform of replication-competent, tumor-selective adenoviruses, and the nextgeneration of Delta-24-RGD armed with the immunomodulator OX40L, Delta-24-RGDOX. Aim 2. Examine therole of gut microbial communities in modulating the efficacy of the viroimmunotherapy. We will assess the anti-cancer effect of the oncolytic therapy in relation to different bacterial signatures. This project should yield newinformation about the potential use of oncolytic adenoviruses as therapy for gastric cancer and will openavenues to include intestinal microbiota as a potential treatment modifier, by maximizing the synergy betweenlaboratories at the University of Puerto Rico (UPR) and M.D. Anderson Cancer Center (MDACC). Our pilotproject is aligned with the Infection-Driven Malignancies Program for Advancing Careers andTranslational Sciences (IMPACT), in that it will allow us to generate preliminary data with potential to betranslated into a full project to address a public health problem among the Hispanic population. -DA - 2021 -PY - 2021 -AN - GRANTS:17412138 -G1 - 10249301; 5U54CA096300-18; 6472; U54CA096300 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - GOMEZ-MANZANO, CANDELARIA -TI - Pilot Project 1: Combination of Viroimmunotherapy and Microbiota Modulation to Treat Gastric Cancer -M3 - Awarded Grant -AB - PILOT PROJECT 1: COMBINATION OF VIROIMMUNOTHERAPY AND MICROBIOTA MODULATION TOTREAT GASTRIC CANCERPROJECT SUMMARY/ABSTRACTGastric cancer is the third leading cause of cancer-related mortality, with a 5-year survival rate ofapproximately 20%. The incidence and mortality rates of gastric cancer in the U.S. are of high concern,especially among non-white populations. Hispanic, black non-Hispanic, and Asian/Pacific Islander populationshave a 40-50% higher risk of gastric cancer than white people, and African Americans are nearly twice as likelyto die of stomach cancer. Virotherapy, as a special case of immunotherapy, is showing promising results forsolid tumors in clinical trials. We developed an oncolytic adenovirus, Delta-24-RGD, which was clinically testedin a first-in-human phase I clinical trial in patients with recurrent glioblastoma. Clinical trials and preclinicalstudies showed that the intratumoral injection of Delta-24-RGD triggered an anti-tumor immune response thatinduced complete tumor regression in a small but significant percentage of patients. These clinical dataemphasize the need to develop strategies that will significantly increase the percentage of solid tumors likegastric cancer sensitive to virotherapy. Recent studies showed that the intestinal microbiota influence theefficacy of immunotherapy. These clinical data have been supported by rigorously controlled experimentsusing gnotobiotic mouse models colonized with one or more specific bacteria, which showed that certainmicrobial biomarkers were associated with modulating and enhancing anti-tumor therapies, such as improvingefficacy of immunotherapy. These data suggest that therapeutic interventions aimed at altering the gutmicrobiome may influence the final clinical outcome. Here, we hypothesize that oncolytic adenoviruses willexert an effective anti-cancer effect in gastric cancer, and that the host gut microbiome plays an important rolein modulating the virus-driven anti-tumor response. To test this hypothesis, we propose the following aims:Aim 1. Characterize the anticancer-potency elicited by armed oncolytic adenovirus in gastric cancer. We willutilize the Delta-24-RGD platform of replication-competent, tumor-selective adenoviruses, and the nextgeneration of Delta-24-RGD armed with the immunomodulator OX40L, Delta-24-RGDOX. Aim 2. Examine therole of gut microbial communities in modulating the efficacy of the viroimmunotherapy. We will assess the anti-cancer effect of the oncolytic therapy in relation to different bacterial signatures. This project should yield newinformation about the potential use of oncolytic adenoviruses as therapy for gastric cancer and will openavenues to include intestinal microbiota as a potential treatment modifier, by maximizing the synergy betweenlaboratories at the University of Puerto Rico (UPR) and M.D. Anderson Cancer Center (MDACC). Our pilotproject is aligned with the Infection-Driven Malignancies Program for Advancing Careers andTranslational Sciences (IMPACT), in that it will allow us to generate preliminary data with potential to betranslated into a full project to address a public health problem among the Hispanic population. -DA - 2020 -PY - 2020 -AN - GRANTS:15011530 -G1 - 10020950; 5U54CA096300-17; 6472; U54CA096300 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - ZHANG, HUANG-GE -TI - BLR&D RESEARCH CAREER SCIENTIST AWARD APPLICATION -M3 - Awarded Grant -AB - My research work largely explores the underlying physiologic questions regarding tiny vesicles calledexosomes. These exosomes are released from many different types of cells or food-derived exosome-likenanoparticles and I am investigating in VA patients the promising role of exosomes as therapeutic vehicles indelivering treatment for a diverse but specific group of medical conditions, i.e.,obesity/diabetes, Nonalcoholicfatty liver disease (NASH), and cancer. There is a substantial population of veterans who are obese and/orhave cancer. Obesity and cancer pose special burdens on veterans who depend on VA care. Obesitycontributes to over 300,000 deaths per year and increases the risk of NASH, type 2 diabetes, and severalcancers including colon, prostate, and kidney. Since receiving my initial Research Career Scientist award, myresearch group has published more than 50 manuscripts on this subject. Collectively, our findings supportcontinued funding of my team to investigate the following 3 aims: (1) Tumor exosomes play a role in: (a)immunosuppression through induction of myeloid-derived suppressor cells, inhibition of dendritic celldifferentiation, and inhibition of activation of NK cell immunotherapy; (b) by sorting suppressor miRNAs fromtumor cells into exosomes based on the oncogenic major vault protein (MVP), tumors grow faster (NatureCommunications. 2017 Feb 17;8:14448, Nature communications. 2015;6:6956); and (c) more recently, wediscovered a novel nanoparticle (Oncotarget. 2016 May 12). Unlike other EVs, this extracellular nanovesicle(named HG-NV, HG-NV stands for HomoGenous nanovesicle as well as for Huang-Ge- nanovesicle) releasedfrom both mouse and human breast tumor cells is enriched with RNAs. Tumor-derived HG-NVs are morepotent in promoting tumor progression than exosomes. Molecules predominantly present in breast tumor HG-NVs have been identified and characterized. This discovery may have implications in advancing bothmicrovesicle biology research and clinical management including potential useas a biomarker, (2). Exosomesreleased from non-tumor cells play a role in: (a) adipose tissue exosome-like vesicles mediating activation ofmacrophage-induced insulin resistance (Diabetes. 2009 Nov;58(11):2498-505); (b) we also found thatintestinal mucus-derived exosomes mediate activation of Wnt/β-catenin signaling and play a role in inductionof liver NKT cell anergy (Hepatology, 2013 57(3):1250-61); and (c) intestinal mucus‐derived exosomes carryprostaglandin E2 and suppress activation of liver NKT cells (J Immunol, 2013, 190(7):3579-89); (3). Exosome-like nanoparticles from edible plants have an effect and therapeutic application on mammalian cells: (a) weused mouse models to show that interspecies communication between plant and mouse gut host cells throughedible plant derived exosome‐like nanoparticles by inducing expression of genes for anti-inflammationcytokines, antioxidation, and activation of Wnt signaling, which are crucial for maintaining intestinalhomeostasis. This finding not only opens up a new avenue for investigating ELNs as a means to protect againstthe development of liver related diseases such as alcohol induced liver damage, but sheds light on studyingthe cellular and molecular mechanisms underlying inter-species communication in the liver via edible plant-derived nanoparticles; (b) targeted drug/therapeutic miRNAs (Nature Communications. 2013;4:1867) deliveryto intestinal macrophages, brain microglia cells (Molecular therapy: 2015, Volume 24, Issue 1, p96–105) andinflammatory tumor sites (Cancer Research, 2015;75:2520-9) by grapefruit ELN is possible; (c) Broccoli-Derived Nanoparticle Inhibits Mouse Colitis by Activating Dendritic Cell AMP-Activated Protein Kinase(Molecular Therapy. 2017, in press); and (d) Grape exosome-like nanoparticles induce intestinal stem cellsand protect mice from DSS-induced colitis (Molecular Therapy. 2013 Jul;21(7):1345-57). -DA - 2018 -PY - 2018 -AN - GRANTS:13113257 -G1 - 1042530; 1IK6BX004199-01 -AD - LOUISVILLE VA MEDICAL MEDICAL CENTER -M2 - LOUISVILLE VA MEDICAL MEDICAL CENTER -Y2 - 2023-12-08 -ER - - -TY - JOUR -AU - ZHANG, HUANG-GE -TI - BLR&D Research Career Scientist Award application -M3 - Awarded Grant -AB - My research work largely explores the underlying physiologic questions regarding tiny vesicles calledexosomes. These exosomes are released from many different types of cells or food-derived exosome-likenanoparticles and I am investigating in VA patients the promising role of exosomes as therapeutic vehicles indelivering treatment for a diverse but specific group of medical conditions, i.e.,obesity/diabetes, Nonalcoholicfatty liver disease (NASH), and cancer. There is a substantial population of veterans who are obese and/orhave cancer. Obesity and cancer pose special burdens on veterans who depend on VA care. Obesitycontributes to over 300,000 deaths per year and increases the risk of NASH, type 2 diabetes, and severalcancers including colon, prostate, and kidney. Since receiving my initial Research Career Scientist award, myresearch group has published more than 50 manuscripts on this subject. Collectively, our findings supportcontinued funding of my team to investigate the following 3 aims: (1) Tumor exosomes play a role in: (a)immunosuppression through induction of myeloid-derived suppressor cells, inhibition of dendritic celldifferentiation, and inhibition of activation of NK cell immunotherapy; (b) by sorting suppressor miRNAs fromtumor cells into exosomes based on the oncogenic major vault protein (MVP), tumors grow faster (NatureCommunications. 2017 Feb 17;8:14448, Nature communications. 2015;6:6956); and (c) more recently, wediscovered a novel nanoparticle (Oncotarget. 2016 May 12). Unlike other EVs, this extracellular nanovesicle(named HG-NV, HG-NV stands for HomoGenous nanovesicle as well as for Huang-Ge- nanovesicle) releasedfrom both mouse and human breast tumor cells is enriched with RNAs. Tumor-derived HG-NVs are morepotent in promoting tumor progression than exosomes. Molecules predominantly present in breast tumor HG-NVs have been identified and characterized. This discovery may have implications in advancing bothmicrovesicle biology research and clinical management including potential useas a biomarker, (2). Exosomesreleased from non-tumor cells play a role in: (a) adipose tissue exosome-like vesicles mediating activation ofmacrophage-induced insulin resistance (Diabetes. 2009 Nov;58(11):2498-505); (b) we also found thatintestinal mucus-derived exosomes mediate activation of Wnt/β-catenin signaling and play a role in inductionof liver NKT cell anergy (Hepatology, 2013 57(3):1250-61); and (c) intestinal mucus‐derived exosomes carryprostaglandin E2 and suppress activation of liver NKT cells (J Immunol, 2013, 190(7):3579-89); (3). Exosome-like nanoparticles from edible plants have an effect and therapeutic application on mammalian cells: (a) weused mouse models to show that interspecies communication between plant and mouse gut host cells throughedible plant derived exosome‐like nanoparticles by inducing expression of genes for anti-inflammationcytokines, antioxidation, and activation of Wnt signaling, which are crucial for maintaining intestinalhomeostasis. This finding not only opens up a new avenue for investigating ELNs as a means to protect againstthe development of liver related diseases such as alcohol induced liver damage, but sheds light on studyingthe cellular and molecular mechanisms underlying inter-species communication in the liver via edible plant-derived nanoparticles; (b) targeted drug/therapeutic miRNAs (Nature Communications. 2013;4:1867) deliveryto intestinal macrophages, brain microglia cells (Molecular therapy: 2015, Volume 24, Issue 1, p96–105) andinflammatory tumor sites (Cancer Research, 2015;75:2520-9) by grapefruit ELN is possible; (c) Broccoli-Derived Nanoparticle Inhibits Mouse Colitis by Activating Dendritic Cell AMP-Activated Protein Kinase(Molecular Therapy. 2017, in press); and (d) Grape exosome-like nanoparticles induce intestinal stem cellsand protect mice from DSS-induced colitis (Molecular Therapy. 2013 Jul;21(7):1345-57). -DA - 2021 -PY - 2021 -AN - GRANTS:17415703 -G1 - 10265394; 5IK6BX004199-04; IK6BX004199 -AD - LOUISVILLE VA MEDICAL MEDICAL CENTER -M2 - LOUISVILLE VA MEDICAL MEDICAL CENTER -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - ZHANG, HUANG-GE -TI - BLR&D RESEARCH CAREER SCIENTIST AWARD APPLICATION -M3 - Awarded Grant -AB - My research work largely explores the underlying physiologic questions regarding tiny vesicles calledexosomes. These exosomes are released from many different types of cells or food-derived exosome-likenanoparticles and I am investigating in VA patients the promising role of exosomes as therapeutic vehicles indelivering treatment for a diverse but specific group of medical conditions, i.e.,obesity/diabetes, Nonalcoholicfatty liver disease (NASH), and cancer. There is a substantial population of veterans who are obese and/orhave cancer. Obesity and cancer pose special burdens on veterans who depend on VA care. Obesitycontributes to over 300,000 deaths per year and increases the risk of NASH, type 2 diabetes, and severalcancers including colon, prostate, and kidney. Since receiving my initial Research Career Scientist award, myresearch group has published more than 50 manuscripts on this subject. Collectively, our findings supportcontinued funding of my team to investigate the following 3 aims: (1) Tumor exosomes play a role in: (a)immunosuppression through induction of myeloid-derived suppressor cells, inhibition of dendritic celldifferentiation, and inhibition of activation of NK cell immunotherapy; (b) by sorting suppressor miRNAs fromtumor cells into exosomes based on the oncogenic major vault protein (MVP), tumors grow faster (NatureCommunications. 2017 Feb 17;8:14448, Nature communications. 2015;6:6956); and (c) more recently, wediscovered a novel nanoparticle (Oncotarget. 2016 May 12). Unlike other EVs, this extracellular nanovesicle(named HG-NV, HG-NV stands for HomoGenous nanovesicle as well as for Huang-Ge- nanovesicle) releasedfrom both mouse and human breast tumor cells is enriched with RNAs. Tumor-derived HG-NVs are morepotent in promoting tumor progression than exosomes. Molecules predominantly present in breast tumor HG-NVs have been identified and characterized. This discovery may have implications in advancing bothmicrovesicle biology research and clinical management including potential useas a biomarker, (2). Exosomesreleased from non-tumor cells play a role in: (a) adipose tissue exosome-like vesicles mediating activation ofmacrophage-induced insulin resistance (Diabetes. 2009 Nov;58(11):2498-505); (b) we also found thatintestinal mucus-derived exosomes mediate activation of Wnt/β-catenin signaling and play a role in inductionof liver NKT cell anergy (Hepatology, 2013 57(3):1250-61); and (c) intestinal mucus‐derived exosomes carryprostaglandin E2 and suppress activation of liver NKT cells (J Immunol, 2013, 190(7):3579-89); (3). Exosome-like nanoparticles from edible plants have an effect and therapeutic application on mammalian cells: (a) weused mouse models to show that interspecies communication between plant and mouse gut host cells throughedible plant derived exosome‐like nanoparticles by inducing expression of genes for anti-inflammationcytokines, antioxidation, and activation of Wnt signaling, which are crucial for maintaining intestinalhomeostasis. This finding not only opens up a new avenue for investigating ELNs as a means to protect againstthe development of liver related diseases such as alcohol induced liver damage, but sheds light on studyingthe cellular and molecular mechanisms underlying inter-species communication in the liver via edible plant-derived nanoparticles; (b) targeted drug/therapeutic miRNAs (Nature Communications. 2013;4:1867) deliveryto intestinal macrophages, brain microglia cells (Molecular therapy: 2015, Volume 24, Issue 1, p96–105) andinflammatory tumor sites (Cancer Research, 2015;75:2520-9) by grapefruit ELN is possible; (c) Broccoli-Derived Nanoparticle Inhibits Mouse Colitis by Activating Dendritic Cell AMP-Activated Protein Kinase(Molecular Therapy. 2017, in press); and (d) Grape exosome-like nanoparticles induce intestinal stem cellsand protect mice from DSS-induced colitis (Molecular Therapy. 2013 Jul;21(7):1345-57). -DA - 2018 -PY - 2018 -AN - GRANTS:15209536 -G1 - 1142853; 5IK6BX004199-02 -AD - LOUISVILLE VA MEDICAL MEDICAL CENTER -M2 - LOUISVILLE VA MEDICAL MEDICAL CENTER -Y2 - 2023-12-08 -ER - - -TY - JOUR -AU - ZHANG, HUANG-GE -TI - BLR&D Research Career Scientist Award application -M3 - Awarded Grant -AB - My research work largely explores the underlying physiologic questions regarding tiny vesicles calledexosomes. These exosomes are released from many different types of cells or food-derived exosome-likenanoparticles and I am investigating in VA patients the promising role of exosomes as therapeutic vehicles indelivering treatment for a diverse but specific group of medical conditions, i.e.,obesity/diabetes, Nonalcoholicfatty liver disease (NASH), and cancer. There is a substantial population of veterans who are obese and/orhave cancer. Obesity and cancer pose special burdens on veterans who depend on VA care. Obesitycontributes to over 300,000 deaths per year and increases the risk of NASH, type 2 diabetes, and severalcancers including colon, prostate, and kidney. Since receiving my initial Research Career Scientist award, myresearch group has published more than 50 manuscripts on this subject. Collectively, our findings supportcontinued funding of my team to investigate the following 3 aims: (1) Tumor exosomes play a role in: (a)immunosuppression through induction of myeloid-derived suppressor cells, inhibition of dendritic celldifferentiation, and inhibition of activation of NK cell immunotherapy; (b) by sorting suppressor miRNAs fromtumor cells into exosomes based on the oncogenic major vault protein (MVP), tumors grow faster (NatureCommunications. 2017 Feb 17;8:14448, Nature communications. 2015;6:6956); and (c) more recently, wediscovered a novel nanoparticle (Oncotarget. 2016 May 12). Unlike other EVs, this extracellular nanovesicle(named HG-NV, HG-NV stands for HomoGenous nanovesicle as well as for Huang-Ge- nanovesicle) releasedfrom both mouse and human breast tumor cells is enriched with RNAs. Tumor-derived HG-NVs are morepotent in promoting tumor progression than exosomes. Molecules predominantly present in breast tumor HG-NVs have been identified and characterized. This discovery may have implications in advancing bothmicrovesicle biology research and clinical management including potential useas a biomarker, (2). Exosomesreleased from non-tumor cells play a role in: (a) adipose tissue exosome-like vesicles mediating activation ofmacrophage-induced insulin resistance (Diabetes. 2009 Nov;58(11):2498-505); (b) we also found thatintestinal mucus-derived exosomes mediate activation of Wnt/β-catenin signaling and play a role in inductionof liver NKT cell anergy (Hepatology, 2013 57(3):1250-61); and (c) intestinal mucus‐derived exosomes carryprostaglandin E2 and suppress activation of liver NKT cells (J Immunol, 2013, 190(7):3579-89); (3). Exosome-like nanoparticles from edible plants have an effect and therapeutic application on mammalian cells: (a) weused mouse models to show that interspecies communication between plant and mouse gut host cells throughedible plant derived exosome‐like nanoparticles by inducing expression of genes for anti-inflammationcytokines, antioxidation, and activation of Wnt signaling, which are crucial for maintaining intestinalhomeostasis. This finding not only opens up a new avenue for investigating ELNs as a means to protect againstthe development of liver related diseases such as alcohol induced liver damage, but sheds light on studyingthe cellular and molecular mechanisms underlying inter-species communication in the liver via edible plant-derived nanoparticles; (b) targeted drug/therapeutic miRNAs (Nature Communications. 2013;4:1867) deliveryto intestinal macrophages, brain microglia cells (Molecular therapy: 2015, Volume 24, Issue 1, p96–105) andinflammatory tumor sites (Cancer Research, 2015;75:2520-9) by grapefruit ELN is possible; (c) Broccoli-Derived Nanoparticle Inhibits Mouse Colitis by Activating Dendritic Cell AMP-Activated Protein Kinase(Molecular Therapy. 2017, in press); and (d) Grape exosome-like nanoparticles induce intestinal stem cellsand protect mice from DSS-induced colitis (Molecular Therapy. 2013 Jul;21(7):1345-57). -DA - 2020 -PY - 2020 -AN - GRANTS:14974573 -G1 - 5IK6BX004199-03; 9899084; IK6BX004199 -AD - LOUISVILLE VA MEDICAL MEDICAL CENTER -M2 - LOUISVILLE VA MEDICAL MEDICAL CENTER -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - ZHANG, HUANG-GE -TI - BLR&D Research Career Scientist Award application -M3 - Awarded Grant -AB - My research work largely explores the underlying physiologic questions regarding tiny vesicles calledexosomes. These exosomes are released from many different types of cells or food-derived exosome-likenanoparticles and I am investigating in VA patients the promising role of exosomes as therapeutic vehicles indelivering treatment for a diverse but specific group of medical conditions, i.e.,obesity/diabetes, Nonalcoholicfatty liver disease (NASH), and cancer. There is a substantial population of veterans who are obese and/orhave cancer. Obesity and cancer pose special burdens on veterans who depend on VA care. Obesitycontributes to over 300,000 deaths per year and increases the risk of NASH, type 2 diabetes, and severalcancers including colon, prostate, and kidney. Since receiving my initial Research Career Scientist award, myresearch group has published more than 50 manuscripts on this subject. Collectively, our findings supportcontinued funding of my team to investigate the following 3 aims: (1) Tumor exosomes play a role in: (a)immunosuppression through induction of myeloid-derived suppressor cells, inhibition of dendritic celldifferentiation, and inhibition of activation of NK cell immunotherapy; (b) by sorting suppressor miRNAs fromtumor cells into exosomes based on the oncogenic major vault protein (MVP), tumors grow faster (NatureCommunications. 2017 Feb 17;8:14448, Nature communications. 2015;6:6956); and (c) more recently, wediscovered a novel nanoparticle (Oncotarget. 2016 May 12). Unlike other EVs, this extracellular nanovesicle(named HG-NV, HG-NV stands for HomoGenous nanovesicle as well as for Huang-Ge- nanovesicle) releasedfrom both mouse and human breast tumor cells is enriched with RNAs. Tumor-derived HG-NVs are morepotent in promoting tumor progression than exosomes. Molecules predominantly present in breast tumor HG-NVs have been identified and characterized. This discovery may have implications in advancing bothmicrovesicle biology research and clinical management including potential useas a biomarker, (2). Exosomesreleased from non-tumor cells play a role in: (a) adipose tissue exosome-like vesicles mediating activation ofmacrophage-induced insulin resistance (Diabetes. 2009 Nov;58(11):2498-505); (b) we also found thatintestinal mucus-derived exosomes mediate activation of Wnt/β-catenin signaling and play a role in inductionof liver NKT cell anergy (Hepatology, 2013 57(3):1250-61); and (c) intestinal mucus‐derived exosomes carryprostaglandin E2 and suppress activation of liver NKT cells (J Immunol, 2013, 190(7):3579-89); (3). Exosome-like nanoparticles from edible plants have an effect and therapeutic application on mammalian cells: (a) weused mouse models to show that interspecies communication between plant and mouse gut host cells throughedible plant derived exosome‐like nanoparticles by inducing expression of genes for anti-inflammationcytokines, antioxidation, and activation of Wnt signaling, which are crucial for maintaining intestinalhomeostasis. This finding not only opens up a new avenue for investigating ELNs as a means to protect againstthe development of liver related diseases such as alcohol induced liver damage, but sheds light on studyingthe cellular and molecular mechanisms underlying inter-species communication in the liver via edible plant-derived nanoparticles; (b) targeted drug/therapeutic miRNAs (Nature Communications. 2013;4:1867) deliveryto intestinal macrophages, brain microglia cells (Molecular therapy: 2015, Volume 24, Issue 1, p96–105) andinflammatory tumor sites (Cancer Research, 2015;75:2520-9) by grapefruit ELN is possible; (c) Broccoli-Derived Nanoparticle Inhibits Mouse Colitis by Activating Dendritic Cell AMP-Activated Protein Kinase(Molecular Therapy. 2017, in press); and (d) Grape exosome-like nanoparticles induce intestinal stem cellsand protect mice from DSS-induced colitis (Molecular Therapy. 2013 Jul;21(7):1345-57). -DA - 2022 -PY - 2022 -AN - GRANTS:17467213 -G1 - 10454206; 5IK6BX004199-05; IK6BX004199 -AD - LOUISVILLE VA MEDICAL MEDICAL CENTER -M2 - LOUISVILLE VA MEDICAL MEDICAL CENTER -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - ZHANG, HUANG-GE -TI - BLR&D Research Career Scientist Award application -M3 - Awarded Grant -AB - My research work largely explores the underlying physiologic questions regarding tiny vesicles calledexosomes. These exosomes are released from many different types of cells or food-derived exosome-likenanoparticles and I am investigating in VA patients the promising role of exosomes as therapeutic vehicles indelivering treatment for a diverse but specific group of medical conditions, i.e.,obesity/diabetes, Nonalcoholicfatty liver disease (NASH), and cancer. There is a substantial population of veterans who are obese and/orhave cancer. Obesity and cancer pose special burdens on veterans who depend on VA care. Obesitycontributes to over 300,000 deaths per year and increases the risk of NASH, type 2 diabetes, and severalcancers including colon, prostate, and kidney. Since receiving my initial Research Career Scientist award, myresearch group has published more than 50 manuscripts on this subject. Collectively, our findings supportcontinued funding of my team to investigate the following 3 aims: (1) Tumor exosomes play a role in: (a)immunosuppression through induction of myeloid-derived suppressor cells, inhibition of dendritic celldifferentiation, and inhibition of activation of NK cell immunotherapy; (b) by sorting suppressor miRNAs fromtumor cells into exosomes based on the oncogenic major vault protein (MVP), tumors grow faster (NatureCommunications. 2017 Feb 17;8:14448, Nature communications. 2015;6:6956); and (c) more recently, wediscovered a novel nanoparticle (Oncotarget. 2016 May 12). Unlike other EVs, this extracellular nanovesicle(named HG-NV, HG-NV stands for HomoGenous nanovesicle as well as for Huang-Ge- nanovesicle) releasedfrom both mouse and human breast tumor cells is enriched with RNAs. Tumor-derived HG-NVs are morepotent in promoting tumor progression than exosomes. Molecules predominantly present in breast tumor HG-NVs have been identified and characterized. This discovery may have implications in advancing bothmicrovesicle biology research and clinical management including potential useas a biomarker, (2). Exosomesreleased from non-tumor cells play a role in: (a) adipose tissue exosome-like vesicles mediating activation ofmacrophage-induced insulin resistance (Diabetes. 2009 Nov;58(11):2498-505); (b) we also found thatintestinal mucus-derived exosomes mediate activation of Wnt/β-catenin signaling and play a role in inductionof liver NKT cell anergy (Hepatology, 2013 57(3):1250-61); and (c) intestinal mucus‐derived exosomes carryprostaglandin E2 and suppress activation of liver NKT cells (J Immunol, 2013, 190(7):3579-89); (3). Exosome-like nanoparticles from edible plants have an effect and therapeutic application on mammalian cells: (a) weused mouse models to show that interspecies communication between plant and mouse gut host cells throughedible plant derived exosome‐like nanoparticles by inducing expression of genes for anti-inflammationcytokines, antioxidation, and activation of Wnt signaling, which are crucial for maintaining intestinalhomeostasis. This finding not only opens up a new avenue for investigating ELNs as a means to protect againstthe development of liver related diseases such as alcohol induced liver damage, but sheds light on studyingthe cellular and molecular mechanisms underlying inter-species communication in the liver via edible plant-derived nanoparticles; (b) targeted drug/therapeutic miRNAs (Nature Communications. 2013;4:1867) deliveryto intestinal macrophages, brain microglia cells (Molecular therapy: 2015, Volume 24, Issue 1, p96–105) andinflammatory tumor sites (Cancer Research, 2015;75:2520-9) by grapefruit ELN is possible; (c) Broccoli-Derived Nanoparticle Inhibits Mouse Colitis by Activating Dendritic Cell AMP-Activated Protein Kinase(Molecular Therapy. 2017, in press); and (d) Grape exosome-like nanoparticles induce intestinal stem cellsand protect mice from DSS-induced colitis (Molecular Therapy. 2013 Jul;21(7):1345-57). -DA - 2019 -PY - 2019 -AN - GRANTS:11406645 -G1 - 5IK6BX004199-02; 9678201; IK6BX004199 -AD - LOUISVILLE VA MEDICAL MEDICAL CENTER -M2 - LOUISVILLE VA MEDICAL MEDICAL CENTER -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - CARRENO, BEATRIZ M.; CARL H. JUNE; Gerald P Linette -TI - Next generation T cell therapies for mutant KRAS solid tumors -M3 - Awarded Grant -AB - Project SummaryThis proposal “Next generation T cell therapies for KRAS mutated solid tumors” was developed in response toRFA-CA-22-028 and to fulfill the Cancer Adoptive Cellular Therapy Network (Can-ACT) objectives. The focus ofour proposal is targeting mutant KRAS, a clonal driver oncoprotein, by the early-stage clinical testing ofTCR1020, a T cell receptor specific for mKRAS G12V restricted to HLA-A*11:01. If successful, this novel-state-of-the-art Adoptive Cell Therapy (ACT) could be available to ~5,000 new solid tumor patients per year in the US.Advances in gene editing together with new insights related to mechanisms of T cell exhaustion provide thescientific basis for development of the next generation T cell therapies in solid tumors. Our central hypothesisis that targeting mutant KRAS through the action of TCR1020-T cells, engineered to overcome cell intrinsicmechanisms of exhaustion and counteract a cell extrinsic myeloid checkpoint to overcome TME resistance, willpromote durable tumor regression in solid tumors. There are three hypothesis-driven specific Aims in thisproposal. In Aim 1, we will develop genetically modified T cells expressing TCR1020 targeting mKRASG12V/HLA-A*11:01 to overcome extrinsic and intrinsic mechanisms of resistance. In Aim 2, we plan to evaluateTCR1020-T CD4+ cells to improve the persistence and potency of mKRAS specific CD8+ effector cells. In Aim3, the safety and clinical activity of engineered TCR1020-T cell products will be determined in a dose escalationmulti-site phase 1 study. We have assembled an exceptional group of investigators with an extensive trackrecord of collaboration and productivity with expertise in human immunology, immuno-oncology, cell therapy, Tcell engineering and gene editing. Additionally, experts in molecular pathology and biomarker discovery willcontribute to cutting-edge correlative studies to aid in biomarker development and TME characterization todelineate potential mechanisms of response and resistance. The Center for Cellular Immunotherapies (CCI) atthe University of Pennsylvania has extensive expertise in the development of ACT therapies producing morethan 2,500 cell products for administration to adult and pediatric patients. CCI has a long track record oftechnology transfer related to cell therapies to both large pharmaceutical companies (Novartis, Kymriah) andbiotechnology companies over the past decade. As a multi-site trial application, an important programmaticcomponent of our proposal is to leverage NCI resources thru utilization of the Immune Cell Network (ICN) Coreat FNLCR to manufacture, test, release and distribute the engineered TCR1020-T cell products. In summary,our proposal incorporates multiple scientific and technological innovations that targets a recurrent clonal driveroncoprotein with engineered T cells modified to resist T cell exhaustion and overcome the immunosuppressiveTME. -DA - 2023 -PY - 2023 -AN - GRANTS:17350697 -G1 - 10731929; 1UG3CA283652-01; UG3CA283652 -AD - UNIVERSITY OF PENNSYLVANIA -AD - UNIVERSITY OF PENNSYLVANIA -AD - UNIVERSITY OF PENNSYLVANIA -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - WENDER, PAUL ANTHONY -TI - Synthetic Studies Related to Cancer Research/Treatment -M3 - Awarded Grant -AB -  DESCRIPTION (provided by applicant): This renewal involves integrated and interdependent synthetic, mechanistic, structural, biochemical mode of action, computer modeling, collaborative and preclinical studies directed at the design, synthesis and advancement of fundamentally new and unique therapeutic leads and strategies directed at unsolved global human health problems: the eradication of HIV/AIDS, the treatment of Alzheimer's disease, and small molecule enhanced cancer immunotherapy. HIV is one of the most catastrophic pandemics to confront mankind. Current antiretroviral therapy (ART) addresses the active virus, allowing one to live with AIDS, but with cost, compliance, resistance and chronic chemo exposure challenges. ART is not curative. Reservoir cells incorporating genomically encoded provirus episodically resupply the active virus. Elimination of these reservoir cells if done with ART is thus one of the most promising strategies to eradicate HIV/AIDS. Modulation of protein kinase C (PKC) represents one of the best strategies to eliminate reservoir cells. PKC modulators are also implicated in cancer (in clinical trials), Alzheimer's disease (in clinical trials), and many other unmet therapeutic needs. The lead PKC modulator, bryostatin 1, is now in the clinic for AIDS eradication, Alzheimer's disease and cancer. It supply is nearly, if not, exhausted. A plan is provided to address the supply problem through the scalable synthesis of bryostatin 1. At the same time, plans are proposed to use combined experimental (REDOR and DNP solid state NMR) and computational approaches to produce the first structural and dynamic analysis of PKC-bryostatin analog complexes in a membrane environment. This first-of-its-kind integrated synthesis/solid state NMR/computational approach will allow us to understand at a molecular level the binding of current PKC modulators to the PKC regulatory domain. That information will then inform the design of new PKC modulators. Our current bryostatin analogs (bryologs) are superior to bryostatin in all studies conducted thus far including binding, cell, animal and ex viv studies on primary cells from patients. Our newest bryologs exhibit unprecedented PKC selectivities. These and new analogs will be advanced through a comprehensive series of assays conducted by us and our collaborators. The resulting bryologs represent preclinical leads proving thus far to be superior to bryostatin and because of their simplified structure are significantly more synthetically accessible than bryostatin. -DA - 2020 -PY - 2020 -AN - GRANTS:14974057 -G1 - 5R01CA031845-40; 9953951; R01CA031845 -AD - STANFORD UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - GODOY-VITORINO, FILIPA -TI - Pilot Project 1: Combination of Viroimmunotherapy and Microbiota Modulation to Treat Gastric Cancer -M3 - Awarded Grant -AB - PILOT PROJECT 1: COMBINATION OF VIROIMMUNOTHERAPY AND MICROBIOTA MODULATION TOTREAT GASTRIC CANCERPROJECT SUMMARY/ABSTRACTGastric cancer is the third leading cause of cancer-related mortality, with a 5-year survival rate ofapproximately 20%. The incidence and mortality rates of gastric cancer in the U.S. are of high concern,especially among non-white populations. Hispanic, black non-Hispanic, and Asian/Pacific Islander populationshave a 40-50% higher risk of gastric cancer than white people, and African Americans are nearly twice as likelyto die of stomach cancer. Virotherapy, as a special case of immunotherapy, is showing promising results forsolid tumors in clinical trials. We developed an oncolytic adenovirus, Delta-24-RGD, which was clinically testedin a first-in-human phase I clinical trial in patients with recurrent glioblastoma. Clinical trials and preclinicalstudies showed that the intratumoral injection of Delta-24-RGD triggered an anti-tumor immune response thatinduced complete tumor regression in a small but significant percentage of patients. These clinical dataemphasize the need to develop strategies that will significantly increase the percentage of solid tumors likegastric cancer sensitive to virotherapy. Recent studies showed that the intestinal microbiota influence theefficacy of immunotherapy. These clinical data have been supported by rigorously controlled experimentsusing gnotobiotic mouse models colonized with one or more specific bacteria, which showed that certainmicrobial biomarkers were associated with modulating and enhancing anti-tumor therapies, such as improvingefficacy of immunotherapy. These data suggest that therapeutic interventions aimed at altering the gutmicrobiome may influence the final clinical outcome. Here, we hypothesize that oncolytic adenoviruses willexert an effective anti-cancer effect in gastric cancer, and that the host gut microbiome plays an important rolein modulating the virus-driven anti-tumor response. To test this hypothesis, we propose the following aims:Aim 1. Characterize the anticancer-potency elicited by armed oncolytic adenovirus in gastric cancer. We willutilize the Delta-24-RGD platform of replication-competent, tumor-selective adenoviruses, and the nextgeneration of Delta-24-RGD armed with the immunomodulator OX40L, Delta-24-RGDOX. Aim 2. Examine therole of gut microbial communities in modulating the efficacy of the viroimmunotherapy. We will assess the anti-cancer effect of the oncolytic therapy in relation to different bacterial signatures. This project should yield newinformation about the potential use of oncolytic adenoviruses as therapy for gastric cancer and will openavenues to include intestinal microbiota as a potential treatment modifier, by maximizing the synergy betweenlaboratories at the University of Puerto Rico (UPR) and M.D. Anderson Cancer Center (MDACC). Our pilotproject is aligned with the Infection-Driven Malignancies Program for Advancing Careers andTranslational Sciences (IMPACT), in that it will allow us to generate preliminary data with potential to betranslated into a full project to address a public health problem among the Hispanic population. -DA - 2020 -PY - 2020 -AN - GRANTS:15049897 -G1 - 10247768; 3U54CA096297-17S1; 6434; U54CA096297 -AD - UNIVERSITY OF PUERTO RICO MED SCIENCES -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - GODOY-VITORINO, FILIPA -TI - Pilot Project 1: Combination of Viroimmunotherapy and Microbiota Modulation to Treat Gastric Cancer -M3 - Awarded Grant -AB - PILOT PROJECT 1: COMBINATION OF VIROIMMUNOTHERAPY AND MICROBIOTA MODULATION TOTREAT GASTRIC CANCERPROJECT SUMMARY/ABSTRACTGastric cancer is the third leading cause of cancer-related mortality, with a 5-year survival rate ofapproximately 20%. The incidence and mortality rates of gastric cancer in the U.S. are of high concern,especially among non-white populations. Hispanic, black non-Hispanic, and Asian/Pacific Islander populationshave a 40-50% higher risk of gastric cancer than white people, and African Americans are nearly twice as likelyto die of stomach cancer. Virotherapy, as a special case of immunotherapy, is showing promising results forsolid tumors in clinical trials. We developed an oncolytic adenovirus, Delta-24-RGD, which was clinically testedin a first-in-human phase I clinical trial in patients with recurrent glioblastoma. Clinical trials and preclinicalstudies showed that the intratumoral injection of Delta-24-RGD triggered an anti-tumor immune response thatinduced complete tumor regression in a small but significant percentage of patients. These clinical dataemphasize the need to develop strategies that will significantly increase the percentage of solid tumors likegastric cancer sensitive to virotherapy. Recent studies showed that the intestinal microbiota influence theefficacy of immunotherapy. These clinical data have been supported by rigorously controlled experimentsusing gnotobiotic mouse models colonized with one or more specific bacteria, which showed that certainmicrobial biomarkers were associated with modulating and enhancing anti-tumor therapies, such as improvingefficacy of immunotherapy. These data suggest that therapeutic interventions aimed at altering the gutmicrobiome may influence the final clinical outcome. Here, we hypothesize that oncolytic adenoviruses willexert an effective anti-cancer effect in gastric cancer, and that the host gut microbiome plays an important rolein modulating the virus-driven anti-tumor response. To test this hypothesis, we propose the following aims:Aim 1. Characterize the anticancer-potency elicited by armed oncolytic adenovirus in gastric cancer. We willutilize the Delta-24-RGD platform of replication-competent, tumor-selective adenoviruses, and the nextgeneration of Delta-24-RGD armed with the immunomodulator OX40L, Delta-24-RGDOX. Aim 2. Examine therole of gut microbial communities in modulating the efficacy of the viroimmunotherapy. We will assess the anti-cancer effect of the oncolytic therapy in relation to different bacterial signatures. This project should yield newinformation about the potential use of oncolytic adenoviruses as therapy for gastric cancer and will openavenues to include intestinal microbiota as a potential treatment modifier, by maximizing the synergy betweenlaboratories at the University of Puerto Rico (UPR) and M.D. Anderson Cancer Center (MDACC). Our pilotproject is aligned with the Infection-Driven Malignancies Program for Advancing Careers andTranslational Sciences (IMPACT), in that it will allow us to generate preliminary data with potential to betranslated into a full project to address a public health problem among the Hispanic population. -DA - 2021 -PY - 2021 -AN - GRANTS:17411564 -G1 - 10247755; 5U54CA096297-18; 6434; U54CA096297 -AD - UNIVERSITY OF PUERTO RICO MED SCIENCES -Y2 - 2024-03-05 -ER - - -TY - JOUR -AU - GODOY-VITORINO, FILIPA -TI - Pilot Project 1: Combination of Viroimmunotherapy and Microbiota Modulation to Treat Gastric Cancer -M3 - Awarded Grant -AB - PILOT PROJECT 1: COMBINATION OF VIROIMMUNOTHERAPY AND MICROBIOTA MODULATION TOTREAT GASTRIC CANCERPROJECT SUMMARY/ABSTRACTGastric cancer is the third leading cause of cancer-related mortality, with a 5-year survival rate ofapproximately 20%. The incidence and mortality rates of gastric cancer in the U.S. are of high concern,especially among non-white populations. Hispanic, black non-Hispanic, and Asian/Pacific Islander populationshave a 40-50% higher risk of gastric cancer than white people, and African Americans are nearly twice as likelyto die of stomach cancer. Virotherapy, as a special case of immunotherapy, is showing promising results forsolid tumors in clinical trials. We developed an oncolytic adenovirus, Delta-24-RGD, which was clinically testedin a first-in-human phase I clinical trial in patients with recurrent glioblastoma. Clinical trials and preclinicalstudies showed that the intratumoral injection of Delta-24-RGD triggered an anti-tumor immune response thatinduced complete tumor regression in a small but significant percentage of patients. These clinical dataemphasize the need to develop strategies that will significantly increase the percentage of solid tumors likegastric cancer sensitive to virotherapy. Recent studies showed that the intestinal microbiota influence theefficacy of immunotherapy. These clinical data have been supported by rigorously controlled experimentsusing gnotobiotic mouse models colonized with one or more specific bacteria, which showed that certainmicrobial biomarkers were associated with modulating and enhancing anti-tumor therapies, such as improvingefficacy of immunotherapy. These data suggest that therapeutic interventions aimed at altering the gutmicrobiome may influence the final clinical outcome. Here, we hypothesize that oncolytic adenoviruses willexert an effective anti-cancer effect in gastric cancer, and that the host gut microbiome plays an important rolein modulating the virus-driven anti-tumor response. To test this hypothesis, we propose the following aims:Aim 1. Characterize the anticancer-potency elicited by armed oncolytic adenovirus in gastric cancer. We willutilize the Delta-24-RGD platform of replication-competent, tumor-selective adenoviruses, and the nextgeneration of Delta-24-RGD armed with the immunomodulator OX40L, Delta-24-RGDOX. Aim 2. Examine therole of gut microbial communities in modulating the efficacy of the viroimmunotherapy. We will assess the anti-cancer effect of the oncolytic therapy in relation to different bacterial signatures. This project should yield newinformation about the potential use of oncolytic adenoviruses as therapy for gastric cancer and will openavenues to include intestinal microbiota as a potential treatment modifier, by maximizing the synergy betweenlaboratories at the University of Puerto Rico (UPR) and M.D. Anderson Cancer Center (MDACC). Our pilotproject is aligned with the Infection-Driven Malignancies Program for Advancing Careers andTranslational Sciences (IMPACT), in that it will allow us to generate preliminary data with potential to betranslated into a full project to address a public health problem among the Hispanic population. -DA - 2020 -PY - 2020 -AN - GRANTS:15041517 -G1 - 10021569; 5U54CA096297-17; 6434; U54CA096297 -AD - UNIVERSITY OF PUERTO RICO MED SCIENCES -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - WENDER, PAUL ANTHONY -TI - Synthetic Studies Related to Cancer Research/Treatment -M3 - Awarded Grant -AB -  DESCRIPTION (provided by applicant): This renewal involves integrated and interdependent synthetic, mechanistic, structural, biochemical mode of action, computer modeling, collaborative and preclinical studies directed at the design, synthesis and advancement of fundamentally new and unique therapeutic leads and strategies directed at unsolved global human health problems: the eradication of HIV/AIDS, the treatment of Alzheimer's disease, and small molecule enhanced cancer immunotherapy. HIV is one of the most catastrophic pandemics to confront mankind. Current antiretroviral therapy (ART) addresses the active virus, allowing one to live with AIDS, but with cost, compliance, resistance and chronic chemo exposure challenges. ART is not curative. Reservoir cells incorporating genomically encoded provirus episodically resupply the active virus. Elimination of these reservoir cells if done with ART is thus one of the most promising strategies to eradicate HIV/AIDS. Modulation of protein kinase C (PKC) represents one of the best strategies to eliminate reservoir cells. PKC modulators are also implicated in cancer (in clinical trials), Alzheimer's disease (in clinical trials), and many other unmet therapeutic needs. The lead PKC modulator, bryostatin 1, is now in the clinic for AIDS eradication, Alzheimer's disease and cancer. It supply is nearly, if not, exhausted. A plan is provided to address the supply problem through the scalable synthesis of bryostatin 1. At the same time, plans are proposed to use combined experimental (REDOR and DNP solid state NMR) and computational approaches to produce the first structural and dynamic analysis of PKC-bryostatin analog complexes in a membrane environment. This first-of-its-kind integrated synthesis/solid state NMR/computational approach will allow us to understand at a molecular level the binding of current PKC modulators to the PKC regulatory domain. That information will then inform the design of new PKC modulators. Our current bryostatin analogs (bryologs) are superior to bryostatin in all studies conducted thus far including binding, cell, animal and ex viv studies on primary cells from patients. Our newest bryologs exhibit unprecedented PKC selectivities. These and new analogs will be advanced through a comprehensive series of assays conducted by us and our collaborators. The resulting bryologs represent preclinical leads proving thus far to be superior to bryostatin and because of their simplified structure are significantly more synthetically accessible than bryostatin. -DA - 2019 -PY - 2019 -AN - GRANTS:10161817 -G1 - 5R01CA031845-39; 9706630; R01CA031845 -AD - STANFORD UNIVERSITY -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Zhou, Lin -AU - Sun, Jianguo -AU - Xie, Conghua -AU - Gong, Youling -AU - Huang, Meijuan -AU - Yuan, Zhiyong -AU - Wu, Lin -AU - Wang, Hui -AU - Bi, Nan -AU - Xu Yaping -AU - Zhu, Jiang -AU - Zhang, Yan -AU - Fan, Min -AU - Zou, Bingwen -AU - Yu, Min -AU - Na, Feifei -AU - Xiu, Weigang -AU - Zhang, Xuanwei -AU - Xue, Jianxin -AU - Lu, You -A1 - MATCH Study Grp -TI - Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC : Interim analysis of Phase II MATCH trial. -T2 - JOURNAL OF CLINICAL ONCOLOGY -M3 - Meeting Abstract -CP - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -CL - ELECTR NETWORK -PU - LIPPINCOTT WILLIAMS & WILKINS -PI - PHILADELPHIA -PA - TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA -SN - 0732-183X -SN - 1527-7755 -DA - 2022 JUN 1 -PY - 2022 -VL - 40 -IS - 16 -MA - e20611 -AN - WOS:000863680304243 -AD - Sichuan Univ, West China Hosp, Dept Thorac Oncol, Canc Ctr, Chengdu, Peoples R China -AD - Army Med Univ, Xinqiao Hosp, Canc Inst, Chongqing, Peoples R China -AD - Wuhan Univ, Zhongnan Hosp, Wuhan, Peoples R China -AD - Sichuan Univ, Dept Thorac Oncol, Canc Ctr, West China Hosp, Chengdu, Peoples R China -AD - Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China -AD - Cent South Univ, Xiangya Sch Med, Dept Thorac Med, Hunan Canc Hosp,Affiliated Canc Hosp, Changsha, Peoples R China -AD - Cent South Univ, Hunan Canc Hosp, Changsha, Peoples R China -AD - Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China -AD - Natl Canc Center, Canc Hosp, Natl Clin Res Ctr Canc, Beijing, Peoples R China -AD - Shenzhen Hosp, Beijing, Peoples R China -AD - Shanghai Pulm Hosp, Shanghai, Peoples R China -AD - Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China -AD - Sichuan Univ, Dept Thorac Oncol, Canc Ctr, West China Hosp, Chengdu, Peoples R China -AD - Sichuan Univ, Dept Thorac Oncol, Ctr Canc, West China Hosp, Sichuan, Peoples R China -AD - Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Sichuan, Peoples R China -M2 - Shenzhen Hosp -M2 - Shanghai Pulm Hosp -Y2 - 2022-11-02 -ER - - -TY - JOUR -AU - GOMEZ-MANZANO, CANDELARIA -TI - Pilot Project 1: Combination of Viroimmunotherapy and Microbiota Modulation to Treat Gastric Cancer -M3 - Awarded Grant -AB - PILOT PROJECT 1: COMBINATION OF VIROIMMUNOTHERAPY AND MICROBIOTA MODULATION TOTREAT GASTRIC CANCERPROJECT SUMMARY/ABSTRACTGastric cancer is the third leading cause of cancer-related mortality, with a 5-year survival rate ofapproximately 20%. The incidence and mortality rates of gastric cancer in the U.S. are of high concern,especially among non-white populations. Hispanic, black non-Hispanic, and Asian/Pacific Islander populationshave a 40-50% higher risk of gastric cancer than white people, and African Americans are nearly twice as likelyto die of stomach cancer. Virotherapy, as a special case of immunotherapy, is showing promising results forsolid tumors in clinical trials. We developed an oncolytic adenovirus, Delta-24-RGD, which was clinically testedin a first-in-human phase I clinical trial in patients with recurrent glioblastoma. Clinical trials and preclinicalstudies showed that the intratumoral injection of Delta-24-RGD triggered an anti-tumor immune response thatinduced complete tumor regression in a small but significant percentage of patients. These clinical dataemphasize the need to develop strategies that will significantly increase the percentage of solid tumors likegastric cancer sensitive to virotherapy. Recent studies showed that the intestinal microbiota influence theefficacy of immunotherapy. These clinical data have been supported by rigorously controlled experimentsusing gnotobiotic mouse models colonized with one or more specific bacteria, which showed that certainmicrobial biomarkers were associated with modulating and enhancing anti-tumor therapies, such as improvingefficacy of immunotherapy. These data suggest that therapeutic interventions aimed at altering the gutmicrobiome may influence the final clinical outcome. Here, we hypothesize that oncolytic adenoviruses willexert an effective anti-cancer effect in gastric cancer, and that the host gut microbiome plays an important rolein modulating the virus-driven anti-tumor response. To test this hypothesis, we propose the following aims:Aim 1. Characterize the anticancer-potency elicited by armed oncolytic adenovirus in gastric cancer. We willutilize the Delta-24-RGD platform of replication-competent, tumor-selective adenoviruses, and the nextgeneration of Delta-24-RGD armed with the immunomodulator OX40L, Delta-24-RGDOX. Aim 2. Examine therole of gut microbial communities in modulating the efficacy of the viroimmunotherapy. We will assess the anti-cancer effect of the oncolytic therapy in relation to different bacterial signatures. This project should yield newinformation about the potential use of oncolytic adenoviruses as therapy for gastric cancer and will openavenues to include intestinal microbiota as a potential treatment modifier, by maximizing the synergy betweenlaboratories at the University of Puerto Rico (UPR) and M.D. Anderson Cancer Center (MDACC). Our pilotproject is aligned with the Infection-Driven Malignancies Program for Advancing Careers andTranslational Sciences (IMPACT), in that it will allow us to generate preliminary data with potential to betranslated into a full project to address a public health problem among the Hispanic population. -DA - 2019 -PY - 2019 -AN - GRANTS:15050069 -G1 - 2U54CA096300-16; 9848149; U54CA096300 -AD - UNIVERSITY OF TX MD ANDERSON CAN CTR -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - GODOY-VITORINO, FILIPA -TI - Pilot Project 1: Combination of Viroimmunotherapy and Microbiota Modulation to Treat Gastric Cancer -M3 - Awarded Grant -AB - PILOT PROJECT 1: COMBINATION OF VIROIMMUNOTHERAPY AND MICROBIOTA MODULATION TOTREAT GASTRIC CANCERPROJECT SUMMARY/ABSTRACTGastric cancer is the third leading cause of cancer-related mortality, with a 5-year survival rate ofapproximately 20%. The incidence and mortality rates of gastric cancer in the U.S. are of high concern,especially among non-white populations. Hispanic, black non-Hispanic, and Asian/Pacific Islander populationshave a 40-50% higher risk of gastric cancer than white people, and African Americans are nearly twice as likelyto die of stomach cancer. Virotherapy, as a special case of immunotherapy, is showing promising results forsolid tumors in clinical trials. We developed an oncolytic adenovirus, Delta-24-RGD, which was clinically testedin a first-in-human phase I clinical trial in patients with recurrent glioblastoma. Clinical trials and preclinicalstudies showed that the intratumoral injection of Delta-24-RGD triggered an anti-tumor immune response thatinduced complete tumor regression in a small but significant percentage of patients. These clinical dataemphasize the need to develop strategies that will significantly increase the percentage of solid tumors likegastric cancer sensitive to virotherapy. Recent studies showed that the intestinal microbiota influence theefficacy of immunotherapy. These clinical data have been supported by rigorously controlled experimentsusing gnotobiotic mouse models colonized with one or more specific bacteria, which showed that certainmicrobial biomarkers were associated with modulating and enhancing anti-tumor therapies, such as improvingefficacy of immunotherapy. These data suggest that therapeutic interventions aimed at altering the gutmicrobiome may influence the final clinical outcome. Here, we hypothesize that oncolytic adenoviruses willexert an effective anti-cancer effect in gastric cancer, and that the host gut microbiome plays an important rolein modulating the virus-driven anti-tumor response. To test this hypothesis, we propose the following aims:Aim 1. Characterize the anticancer-potency elicited by armed oncolytic adenovirus in gastric cancer. We willutilize the Delta-24-RGD platform of replication-competent, tumor-selective adenoviruses, and the nextgeneration of Delta-24-RGD armed with the immunomodulator OX40L, Delta-24-RGDOX. Aim 2. Examine therole of gut microbial communities in modulating the efficacy of the viroimmunotherapy. We will assess the anti-cancer effect of the oncolytic therapy in relation to different bacterial signatures. This project should yield newinformation about the potential use of oncolytic adenoviruses as therapy for gastric cancer and will openavenues to include intestinal microbiota as a potential treatment modifier, by maximizing the synergy betweenlaboratories at the University of Puerto Rico (UPR) and M.D. Anderson Cancer Center (MDACC). Our pilotproject is aligned with the Infection-Driven Malignancies Program for Advancing Careers andTranslational Sciences (IMPACT), in that it will allow us to generate preliminary data with potential to betranslated into a full project to address a public health problem among the Hispanic population. -DA - 2019 -PY - 2019 -AN - GRANTS:14973203 -G1 - 2U54CA096297-16; 9848097; U54CA096297 -AD - UNIVERSITY OF PUERTO RICO MED SCIENCES -Y2 - 2023-12-14 -ER - - -TY - JOUR -AU - Odetola, Oluwatobi -AU - Adekola, Kehinde -AU - Moreira, Jonathan -AU - Karmali, Reem -AU - Ma, Shuo -AU - Carson, Kenneth R. -AU - Mehta, Jayesh -AU - Winter, Jane N. -AU - Gordon, Leo I. -AU - Lin, Adam Yuh -TI - Engraftment Syndrome Incidence after Immune Checkpoint Inhibitor Therapy in Pts with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Single Institutional Review -T2 - BLOOD -M3 - Meeting Abstract -CP - 65th Annual Meeting of the American-Society-of-Hematology (ASH) -CL - San Diego, CA -PU - ELSEVIER -PI - AMSTERDAM -PA - RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS -SN - 0006-4971 -SN - 1528-0020 -DA - 2023 NOV 2 -PY - 2023 -VL - 142 -DO - 10.1182/blood-2023-185289 -AN - WOS:001159900807133 -C6 - NOV 2023 -AD - Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Maywood, IL USA -AD - Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA -AD - Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA -AD - Northwestern Univ, Chicago, IL USA -AD - Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA -AD - Northwestern Univ, Dept Med, Div Hematol Oncol, Chicago, IL USA -Y2 - 2024-03-04 -ER - - diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/webofscience 1112.txt" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/webofscience 1112.txt" deleted file mode 100644 index 35c17b4..0000000 --- "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/webofscience 1112.txt" +++ /dev/null @@ -1,81 +0,0 @@ -# Web of Science 检索策略 (v0.1) - -# 数据库: 所有数据库 - -# 权限: - -- WOS: 1900 to 2024 -- CSCD: 1989 to 2024 -- DIIDW: 1966 to 2024 -- GRANTS: 1953 to 2024 -- INSPEC: 1969 to 2024 -- KJD: 1980 to 2024 -- MEDLINE: 1950 to 2024 -- PPRN: 1991 to 2024 -- PQDT: 1637 to 2024 -- SCIELO: 2002 to 2024 - - -# 检索: - -1: TS=(extensive stage OR extensive disease OR extensive OR advanced) 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 13:55:01 GMT+0800 (中国标准时间) 检索结果: 4974674 - -2: TS=(Small Cell Lung Carcinoma OR Carcinoma, Small Cell Lung OR Oat Cell Carcinoma of Lung OR Oat Cell Lung Cancer OR Small Cell Lung Cancer OR Small Cell Cancer of the Lung OR SCLC) 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 13:55:38 GMT+0800 (中国标准时间) 检索结果: 279540 - -3: TS=((small cell OR oat cell ) AND (Lung Neoplasm OR Pulmonary Neoplasm OR Lung Cancer OR Pulmonary Cancer OR Cancer of the Lung)) 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 13:56:44 GMT+0800 (中国标准时间) 检索结果: 279977 - -4: (#1 AND (#2 OR #3)) OR TS=(ES-SCLC ) 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 13:57:40 GMT+0800 (中国标准时间) 检索结果: 56228 - -5: TS=( Drug Therap* OR Chemotherap* OR Pharmacotherap* OR Therap*, Drug) 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 13:58:55 GMT+0800 (中国标准时间) 检索结果: 7905176 - -6: TS=("Antineoplastic Agent*" OR "Antitumor Agent*" OR "Anticancer Agent*" OR "Antineoplastic Drug*" OR "Antitumor Drug*" OR "Cancer Chemotherapy Agent*" OR "Antineoplastic*" OR "Chemotherapeutic Anticancer Agent*" OR "Cancer Chemotherapy Drug*") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 13:59:15 GMT+0800 (中国标准时间) 检索结果: 1215497 - -7: TS=("Cisplatin" OR "cis-Diamminedichloroplatinum" OR "cis Diamminedichloroplatinum" OR "cis-Diamminedichloroplatinum(II)" OR "cis-Dichlorodiammineplatinum(II)" OR "cis-Platinum" OR "Dichlorodiammineplatinum" OR "Platinum Diamminodichloride" OR "Diamminodichloride, Platinum" OR "Biocisplatinum" OR "Platidiam" OR "Platino" OR "Platinol" OR "NSC-119875") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 13:59:30 GMT+0800 (中国标准时间) 检索结果: 177526 - -8: TS=( "Carboplatin" OR "CBDCA" OR "cis-Diammine(cyclobutanedicarboxylato)platinum II" OR "Paraplatin" OR "Paraplatine" OR "NSC-241240" OR "NSC241240" OR "NSC 241240" OR "JM-8" OR "JM8" OR "JM 8" OR "Blastocarb" OR "Carbotec" OR "Carbosin" OR "Ercar" OR "Nealorin" OR "Neocarbo" OR "Platinwas" OR "Ribocarbo" OR "Carboplat") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 13:59:45 GMT+0800 (中国标准时间) 检索结果: 44421 - -9: TS=( "Oxaliplatin" OR "1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II)" OR "L-OHP" OR "Cpd" OR "Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1)" OR "Oxalato-(1,2-cyclohexanediamine)platinum II" OR "Oxaliplatin, (SP-4-2-(1R-trans))-isomer" OR "Oxaliplatine" OR "1,2-Diaminocyclohexane Platinum Oxalate" OR "1,2 Diaminocyclohexane Platinum Oxalate" OR "Platinum(II)-1,2-cyclohexanediamine Oxalate" OR "Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II)" OR "ACT 078" OR "ACT-078" OR "ACT078" OR "Oxaliplatin, (SP-4-3-(cis))-isomer" OR "Eloxatine") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:00:01 GMT+0800 (中国标准时间) 检索结果: 430310 - -10: TS=("Lobaplatin" OR "1,2-diaminomethylcyclobutane-platinum(II) lactate" OR "D 19466" OR "D-19466") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:00:20 GMT+0800 (中国标准时间) 检索结果: 483 - -11: TS=("Etoposide" OR "Demethyl Epipodophyllotoxin Ethylidine Glucoside" OR "Eposide" OR "Vepesid" OR "Etoposide, alpha-D-Glucopyranosyl Isomer" OR "alpha-D-Glucopyranosyl Isomer Etoposide" OR "Etoposide, alpha D Glucopyranosyl Isomer" OR "Etoposide, (5S)-Isomer" OR "Etoposide, (5a alpha)-Isomer" OR "Etoposide, (5a alpha,9 alpha)-Isomer" OR "NSC-141540" OR "NSC141540" OR "NSC 141540" OR "VP 16-213" OR "VP 16213" OR "VP 16 213" OR "VP-16" OR "VP16" OR "VP 16" OR "Celltop" OR "Eposin" OR "Toposar" OR "Etoposide Teva" OR "Teva, Etoposide" OR "Eto-GRY" OR "Eto GRY" OR "Etoposide Pierre Fabre" OR "Etoposido Ferrer Farma" OR "Etopos" OR "Exitop" OR "Lastet" OR "Onkoposid" OR "Riboposid" OR "Vépéside-Sandoz" OR "Vépéside Sandoz" OR "Etomedac") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:00:44 GMT+0800 (中国标准时间) 检索结果: 56362 - -12: #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:00:59 GMT+0800 (中国标准时间) 检索结果: 8466146 - -13: TS=(immunotherap* OR chemoimmunotherap*) 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:01:17 GMT+0800 (中国标准时间) 检索结果: 370621 - -14: (TS=(immunotherap* OR chemoimmunotherap*)) AND TS=("Immune Checkpoint Inhibitors" OR "Checkpoint Inhibitors, Immune" OR "Immune Checkpoint Blockers" OR "Checkpoint Blockers, Immune" OR "Immune Checkpoint Inhibitor" OR "Checkpoint Inhibitor, Immune" OR "CTLA-4 Inhibitors" OR "CTLA 4 Inhibitors" OR "Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors" OR "Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors" OR "Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor" OR "Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor" OR "CTLA-4 Inhibitor" OR "CTLA 4 Inhibitor" OR "PD-1 Inhibitors" OR "PD 1 Inhibitors" OR "Programmed Cell Death Protein 1 Inhibitor" OR "Programmed Cell Death Protein 1 Inhibitors" OR "PD-1 Inhibitor" OR "Inhibitor, PD-1" OR "PD 1 Inhibitor" OR "Immune Checkpoint Blockade" OR "Checkpoint Blockade, Immune" OR "Immune Checkpoint Inhibition" OR "Checkpoint Inhibition, Immune" OR "PD-L1 Inhibitors" OR "PD L1 Inhibitors" OR "Programmed Death-Ligand 1 Inhibitors" OR "Programmed Death Ligand 1 Inhibitors" OR "PD-L1 Inhibitor" OR "PD L1 Inhibitor" OR "PD-1-PD-L1 Blockade" OR "Blockade, PD-1-PD-L1" OR "PD 1 PD L1 Blockade") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:01:32 GMT+0800 (中国标准时间) 检索结果: 39963 - -15: TS=("Nivolumab" OR "MDX-1106" OR "MDX1106" OR "MDX 1106" OR "Opdivo" OR "BMS-936558" OR "BMS936558" OR "BMS 936558" OR "ONO-4538" OR "ONO4538" OR "ONO 4538") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:01:49 GMT+0800 (中国标准时间) 检索结果: 30006 - -16: TS=("Ipilimumab" OR "Anti-CTLA-4 MAb Ipilimumab" OR "Anti CTLA 4 MAb Ipilimumab" OR "Ipilimumab, Anti-CTLA-4 MAb" OR "MDX 010" OR "MDX-010" OR "MDX010" OR "MDX-CTLA-4" OR "MDX CTLA 4" OR "Yervoy") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:02:02 GMT+0800 (中国标准时间) 检索结果: 16996 - -17: TS=("camrelizumab" OR "SHR-1210" OR "SHR 1210" OR "carrelizumab") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:02:16 GMT+0800 (中国标准时间) 检索结果: 1468 - -18: TS=("atezolizumab" OR "immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MDPL3280a heavy chain), disulfide with human monoclonal MDPL3280a kappa-chain, dimer" OR "anti-PDL1" OR "MPDL3280A" OR "MPDL-3280A" OR "Tecentriq" OR "RG7446" OR "RG-7446") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:02:28 GMT+0800 (中国标准时间) 检索结果: 9409 - -19: TS=("pembrolizumab" OR "MK-3475" OR "Keytruda" OR "lambrolizumab" OR "SCH-900475") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:02:45 GMT+0800 (中国标准时间) 检索结果: 26347 - -20: TS=("pidilizumab" OR "CT-011" OR "CT 011") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:02:58 GMT+0800 (中国标准时间) 检索结果: 150 - -21: TS=("avelumab" OR "MSB0010718C" OR "MSB-0010718C" OR "bavencio" OR "MSB0010682" OR "MSB-0010682") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:03:14 GMT+0800 (中国标准时间) 检索结果: 2347 - -22: TS=("durvalumab" OR "MEDI4736" OR "MEDI-4736" OR "Imfinzi") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:03:28 GMT+0800 (中国标准时间) 检索结果: 4538 - -23: TS=("tislelizumab" OR "BGB-A317") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:03:46 GMT+0800 (中国标准时间) 检索结果: 944 - -24: TS=("toripalimab") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:03:58 GMT+0800 (中国标准时间) 检索结果: 749 - -25: TS=("Serplulimab") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:04:07 GMT+0800 (中国标准时间) 检索结果: 97 - -26: TS=("Adebrelimab") 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:04:18 GMT+0800 (中国标准时间) 检索结果: 38 - -27: #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:04:44 GMT+0800 (中国标准时间) 检索结果: 407592 - -28: TS=( Radiotherapy OR Radiation Therapy OR Targeted Radiotherap* OR Targeted Radiation Therap* OR radiation OR irradiation OR radio-chemotherapy OR chemoradiotherapy OR radiation treatment OR 3D Conformal Radiation Therapy OR 3D-CRT OR Intensity-Modulated Radiation Therapy OR IMRT OR Image-Guided Radiation Therapy OR IGRT OR Stereotactic Radiation Therapy OR SRT OR Stereotactic Radiosurgery OR SRS OR Stereotactic Body Radiation Therapy OR SBRT OR Volumetric Modulated Arc Therapy OR VMAT OR Adaptive Radiation Therapy OR ART) 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:05:04 GMT+0800 (中国标准时间) 检索结果: 9366807 - -29: #4 AND #12 AND #27 AND #28 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:05:28 GMT+0800 (中国标准时间) 检索结果: 1743 - -30: TS=(randomized controlled trial OR randomi?ed OR placebo OR randomly OR trial OR group) 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:06:48 GMT+0800 (中国标准时间) 检索结果: 17771666 - -31: #29 AND #30 版本: WOS.IC,WOS.CCR,WOS.SCI,WOS.AHCI,WOS.ESCI,WOS.ISTP,WOS.SSCI,CSCD.CSCD,DIIDW.CDerwent,DIIDW.EDerwent,DIIDW.MDerwent,GRANTS.GRANTS,INSPEC.INSPEC,KJD.KJD,MEDLINE.MEDLINE,PQDT.PQDT,SCIELO.SCIELO 运行日期: Fri Oct 18 2024 14:07:20 GMT+0800 (中国标准时间) 检索结果: 1112 diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/\345\274\225\346\226\207\346\243\200\347\264\242/Crestsecondaryanalysispaper2017 Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy A secondary analysis of the Phase III CREST trial.pdf" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/\345\274\225\346\226\207\346\243\200\347\264\242/Crestsecondaryanalysispaper2017 Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy A secondary analysis of the Phase III CREST trial.pdf" deleted file mode 100644 index 0767f43..0000000 Binary files "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/\345\274\225\346\226\207\346\243\200\347\264\242/Crestsecondaryanalysispaper2017 Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy A secondary analysis of the Phase III CREST trial.pdf" and /dev/null differ diff --git "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/\345\274\225\346\226\207\346\243\200\347\264\242/Use of thoracic radiotherapy for extensive stage small-cell lung cancer a phase 3 randomised controlled trial.pdf" "b/meta/\346\226\207\347\214\256\346\243\200\347\264\242/\345\274\225\346\226\207\346\243\200\347\264\242/Use of thoracic radiotherapy for extensive stage small-cell lung cancer a phase 3 randomised controlled trial.pdf" deleted file mode 100644 index 5d06366..0000000 Binary files "a/meta/\346\226\207\347\214\256\346\243\200\347\264\242/\345\274\225\346\226\207\346\243\200\347\264\242/Use of thoracic radiotherapy for extensive stage small-cell lung cancer a phase 3 randomised controlled trial.pdf" and /dev/null differ diff --git "a/meta/\346\226\260\345\273\272\346\226\207\346\234\254\346\226\207\346\241\243.txt" "b/meta/\346\226\260\345\273\272\346\226\207\346\234\254\346\226\207\346\241\243.txt" deleted file mode 100644 index beffb9b..0000000 --- "a/meta/\346\226\260\345\273\272\346\226\207\346\234\254\346\226\207\346\241\243.txt" +++ /dev/null @@ -1 +0,0 @@ -Background: The role of PCI and TRT in ES-SCLC is controversial. We performed a systematic review of all comparative studies to investigate the benefits and harms of PCI and TRT in ES-SCLC. Methods: We searched MEDLINE, CENTRAL from date of inception and various conference proceedings from 2009 to November 2014 for eligible studies. The primary outcome is overall survival (OS). Secondary outcomes include progression-free survival (PFS), freedom from brain metastasis and toxicity. The Cochrane risk of bias instrument was used to assess the risk of methodological bias and the Grading of Recommendations Assessment Development and Evaluation (GRADE) approach was used to assess the quality of evidence. Hazard ratios (HR), confidence intervals (CI), p values (p) was estimated with random effects models using Revman 5.3. Results: We found 2 randomized controlled trials (RCTs) and 3 non-RCTs, including 2192 patients comparing PCI versus no PCI; 4 RCTs and 1 non-RCT including 782 patients comparing TRT versus no TRT. The risk of methodological bias was low for 2 RCTs evaluating PCI and 2 RCTs evaluating TRT. Meta-analysis of these low risk bias RCTs showed that PCI decreased the risk of brain metastasis development (HR 0.43, 95% CI 0.30 to 0.60, p < 0.001, high quality evidence) but did not improve OS (HR 0.95, 95% CI 0.48 to 1.91, p = 0.89) or PFS (HR 0.91, 95% CI 0.63 to 1.32, p = 0.62) (moderate quality of evidence). There was high quality evidence that TRT improved OS (HR 0.82, 95%CI 0.69 to 0.97, p = 0.02) and PFS (HR 0.76, 95%CI 0.64 to 0.89, p < 0.001). The incidence of grade 3-4 toxicities of PCI and TRT ranged from 1 to 20%. Conclusions: There was high quality evidence that PCI reduced the risk of brain metastasis development and TRT improved survival in ES- SCLC. Toxicity rates were variable and are probably related to dose and treated volume effects. \ No newline at end of file